NATIONAL INSTITUTES OF HEALTH

CUMULATED INDEX MEDICUS

1997

VOLUME 38 BOOK 2

SUBJECT INDEX
A–Ars

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health

NATIONAL LIBRARY OF MEDICINE
8600 Rockville Pike
Bethesda, MD 20894
NIH Publication Number: 98-259

ISSN: 0090-1423

Cumulated Index Medicus

© All or portions of this publication are protected against copying or other reproduction outside of the United States in accordance with the provisions of Article II of the Universal Copyright Convention.

National Library of Medicine Cataloging in Publication

Cumulated Index medicus.
Vol. 1 (Jan.-Dec. 1960)-
--Chicago : American Medical Association ; Washington, D.C. : Supt. of Docs., U.S. G.P.O. [distributor], 1961-
v.

Vols. for 1971-1978 issued as DHEW publication ; no. (NIH) 72-259, etc.; for 1979- as NIH publication ; no. 80-259, etc.
Annual cumulation of the monthly issues of Index medicus.
Continues: Quarterly cumulative Index medicus.
Issues for 1967- include Bibliography of medical reviews.
Vols. for 1965- issued by the National Library of Medicine.

1. Bibliography of Medicine 2. Medicine - indexes I. American Medical Association II. National Library of Medicine (U.S.). III. Bibliography of medical reviews IV. Index medicus V. Series: DHEW publication ; no. (NIH) 72-259, etc. VI. Series: NIH publication ; no. 80-259, etc.

ISSN 0090-1423 = Cumulated Index medicus.

ZW 1 I384

This book is printed on acid-free paper for permanence.

Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through September 30, 1998.

For sale by the U.S. Government Printing Office
Superintendent of Documents, Mail Stop: SSOP, Washington, DC 20402-9328
ISBN 0-16-049542-3

CUMULATED INDEX MEDICUS 1997

CONTENTS

BOOK 1

Preface v
Index Medicus Citation Format vii
Introduction viii
Materials Indexed viii
The Indexing Operation viii
Subject Headings viii
Subject Heading Changes ix
Arrangement ix
Subject Section ix
Author Section xi
Bibliography of Medical Reviews xi
Access to Articles Cited xii
Interlibrary Loan Policy xii
Other Resources xiv
National Network of Libraries of Medicine xiv
International MEDLARS/MEDLINE Centers xv

MEDICAL SUBJECT HEADINGS (Contents) I-3
Medical Subject Headings 1

JOURNALS INDEXED Abbreviation Listing 1429
Full Title Listing 1529

BOOK 2 Subject Index **A-Ars** 1609

BOOK 3 Subject Index **Art-Cas** 3447

BOOK 4 Subject Index **Cat-De** 5280

BOOK 5 Subject Index **Df-Fil** 7174

BOOK 6 Subject Index **Fim-His** 9065

BOOK 7 Subject Index **Hit-Lh** 10920

BOOK 8 Subject Index **Li-Mu** 12782

BOOK 9 Subject Index **Mv-Pep** 14625

BOOK 10 Subject Index **Per-Rea** 16435

BOOK 11 Subject Index **Reb-St** 18189

BOOK 12 Subject Index **Su-Z** 20080

BOOK 13 Author Index **A-Dif** 21921

BOOK 14 Author Index **Dig-Jeq** 23938

BOOK 15 Author Index **Jer-Mor** 25951

BOOK 16 Author Index **Mos-She** 27971

BOOK 17 Author Index **Shf-Z** 29991

BOOK 18 Bibliography of Medical Reviews **A-H** 1

BOOK 19 Bibliography of Medical Reviews **I-Z** 1177

SUBJECT SECTION

A-23187 see **CALCIMYCIN**

A FIBERS see **NERVE FIBERS, MYELINATED**

ABATE see **TEMEFOS**

ABATTOIRS

Effect of the method of killing, interval between killing and neck cutting and blood vessels cut on blood loss in broilers. Raj AB, et al. **Br Poult Sci** 1997 May;38(2):190–4

Bruising and biochemical measures of stress, dehydration and injury determined at slaughter in sheep transported from farms or markets. Jarvis AM, et al. **Br Vet J** 1996 Nov; 152(6):719–22

A survey to investigate potential dehydration in slaughtered broiler chickens. Knowles TG, et al. **Br Vet J** 1995 May; 152(3):307–14

Bovine spongiform encephalopathy [letter; comment] Mallek D. **Can Med Assoc J** 1997 Feb 15;156(4):481, 484. Comment on: Can Med Assoc J 1996 Sep 1;155(5):529–36.

Sero-epidemiology and perception of human brucellosis in Calabar, Nigeria [letter] Useh MF, et al. **Cent Afr J Med** 1996 Jun;42(6):184–5

Q fever vaccination in Queensland abattoirs. Bell M, et al. **Commun Dis Intell** 1997 Feb 6;21(3):29–31

Prevalence of Helicobacter-like organisms in porcine gastric mucosa: a study of swine slaughtered in Italy. Grasso GM, et al. **Comp Immunol Microbiol Infect Dis** 1996 Jun; 19(3):213–7

Campylobacter incidence on a chicken farm and the spread of Campylobacter during the slaughter process. Berndtson E, et al. **Int J Food Microbiol** 1996 Sep;32(1–2):35–47

Hazard identification in swine slaughter with respect to foodborne bacteria. Borch E, et al. **Int J Food Microbiol** 1996 Jun;30(1–2):9–25 (56 ref.)

Pathogenic micro-organisms in slaughterhouse sludge—a survey. Fransen NG, et al. **Int J Food Microbiol** 1996 Dec; 33(2–3):245–56

Investigation of an outbreak of human salmonellosis caused by Salmonella enterica ssp. enterica serovar Infantis by use of pulsed field gel electrophoresis. Wegener HC, et al. **Int J Food Microbiol** 1996 Sep;32(1–2):125–31

Attitudes of veterinarians to a standardized slaughter-monitoring program for pigs. Davies PR, et al. **J Am Vet Med Assoc** 1996 Jul 1;209(1):123–6

Effect of halothane genotype, breed, feed withdrawal, and lairage on pork quality of belgian slaughter pigs. De Smet SM, et al. **J Anim Sci** 1996 Aug;74(8):1854–63

Microbiological contamination of ovine carcasses associated with the presence of wool and faecal material. Biss ME, et al. **J Appl Bacteriol** 1996 Dec;81(6):594–600

Listeria monocytogenes in poultry and poultry products: epidemiological investigations in seven Danish abattoirs. Ojeniyi B, et al. **J Appl Bacteriol** 1996 Apr;80(4):395–401

Sero-prevalence of brucellosis among abattoir personnel of Delhi. Kumar P, et al. **J Commun Dis** 1997 Jun;29(2):131–7

Escherichia coli O157 in abattoirs [letter] Pennington TH. **Lancet** 1997 Jun 28;349(9069):1918

Cutaneous infection in meatworkers. Lillington T, et al. **Occup Med (Oxf)** 1997 May;47(4):197–202

Utilization of fermented flocculated poultry sludge as a feed constituent for pigs. Fransen NG, et al. **Poult Sci** 1995 Dec; 74(12):1948–60

Supplementation of broiler diets with all-rac-alpha- or a mixture of natural source RRR-alpha-,gamma-,delta-tocopheryl acetate. 1. effect on vitamin E status of broilers in vivo and at slaughter. Jakobsen K, et al. **Poult Sci** 1995 Dec;74(12):1984–94

The effect of evisceration on visible contamination and the microbiological profile of fresh broiler chicken carcasses using the Nu-Tech Evisceration System or the conventional Streamlined Inspection System. Russell SM, et al. **Poult Sci** 1997 May;76(5):780–4

Effects of stunning duration on quality characteristics of early deboned chicken fillets. Young LL, et al. **Poult Sci** 1997 Jul;76(7):1052–5

Changes in the release of amino acid neurotransmitters in the brains of calves and sheep after head-only electrical stunning and throat cutting. Cook CJ, et al. **Res Vet Sci** 1996 May;60(3):255–61

Ovine psoroptic otoacariasis: an abattoir survey. Bates PG. **Vet Rec** 1996 Sep 7;139(10):235–6

BSE: compensation and reporting [letter] Broberg JO. **Vet Rec** 1996 Jun 8;138(23):575

Presentation of clean livestock for slaughter [letter] Mullen PA. **Vet Rec** 1997 Jun 14;140(24):634

[Serologic screening of certain zoonoses in the abattoir personnel in Djibouti] Chantal J, et al. **Bull Soc Pathol Exot** 1996;89(5):353–7 (Eng. Abstr.) **(Fre)**

[Experiences during training of a group for tasting bovine meat at an industrial refrigerated abattoir in Venezuela] Huerta-Leidenz N, et al. **Arch Latinoam Nutr** 1996 Mar; 46(1):47–53 (Eng. Abstr.) **(Spa)**

ECONOMICS

Effect of vaccination against Aujeszky's disease compared with test and slaughter programme: epidemiological and economical evaluations. Willeberg P, et al. **Acta Vet Scand Suppl** 1996;90:25–51

LEGISLATION & JURISPRUDENCE

Government proposes precautionary controls on ovine offals [news] **Vet Rec** 1996 Aug 3;139(5):102

STANDARDS

Microbiological contamination of carcasses related to hygiene practice and facilities on slaughtering lines. Rahkio M, et al. **Acta Vet Scand** 1996;37(3):219–28

Description of cellulitis lesions and associations between cellulitis and other categories of condemnation. Elfadil AA, et al. **Avian Dis** 1996 Jul-Sep;40(3):690–8

Carcase and meat quality in broilers either killed with a gas mixture or stunned with an electric current under commercial processing conditions. Raj AB, et al. **Br Poult Sci** 1997 May;38(2):169–74

Canadian beef quality audit. Van Donkersgoed J, et al. **Can Vet J** 1997 Apr;38(4):217–25

Factors that impede animal movement at slaughter plants. Grandin T. **J Am Vet Med Assoc** 1996 Aug 15;209(4):757–9

HACCP system simplified [news] Reed CA, et al. **J Am Vet Med Assoc** 1997 Jul 1;211(1):16

Slaughter plant location, USDA quality grade, external fat thickness, and aging time effects on sensory characteristics of beef loin strip steak. Miller MF, et al. **J Anim Sci** 1997 Mar;75(3):662–7

Relevance of abattoir hygiene assessment to microbial contamination of British beef carcases. Hudson WR, et al. **Vet Rec** 1996 Dec 14;139(24):587–9

[Alternatives to presently established forms of animal body removal— tolerated, intended and feared?] Kamphues J. **DTW Dtsch Tierarztl Wochenschr** 1997 Jul;104(7):257–60 (Eng. Abstr.) **(Ger)**

ABBREVIATED INJURY SCALE

The Abbreviated Injury Scale. A valuable tool for forensic documentation of trauma. Friedman Z, et al. **Am J Forensic Med Pathol** 1996 Sep;17(3):233–8

Abbreviated Injury Scale does not reflect the added morbidity of multiple lower extremity fractures [letter; comment] Garthe EA. **J Trauma** 1996 Nov;41(5):930–1. Comment on: J Trauma 1996 Jun;40(6):951–4; discussion 954–5.

Internal fixation in pelvic fractures and primary repairs of associated genitourinary disruptions: a team approach [letter; comment] McKee MD. **J Trauma** 1997 May; 42(5):981. Comment on: J Trauma 1996 May;40(5):784–90.

Abbreviated injury scale does not reflect the added morbidity of multiple lower extremity fractures [letter; comment] [see comments] McKee MD. **J Trauma** 1997 Feb;42(2):347–8. Comment on: J Trauma 1996 Jun;40(6):951–4; discussion 954–5. Comment in: J Trauma 1997 Jul;43(1):173–4.

Statistical analysis in Abbreviated Injury Scale does not reflect the added morbidity of multiple lower extremity fractures (J. Trauma 1996; 40; 951) [letter; comment] Wright SW. **J Trauma** 1997 Jul;43(1):173–4. Comment on: J Trauma 1996 Jun;40(6):951–4; discussion 954–5. Comment on: J Trauma 1997 Feb;42(2):347–8.

Sorting variables for each case: a new algorithm to calculate injury severity score (ISS) using SPSS-PC. Linn S. **Stat Med** 1996 Apr 15-May 15;15(7-9):933–7

ABBREVIATIONS

Borderline mnemonic [letter] Senger HL. **Am J Psychiatry** 1997 Sep;154(9):1321

P-R-A-C-T-I-C-A-L: a step-by-step model for conducting the consultation in general practice. Larsen JH, et al. **Fam Pract** 1997 Aug;14(4):295–301

Adaptive Morse-coded single-switch communication system for the disabled. Luo CH, et al. **Int J Biomed Comput** 1996 Apr;41(2):99–106

Mnemonics usage and cognitive decline in age-associated memory impairment. Small GW, et al. **Int Psychogeriatr** 1997 Mar;9(1):47–56

The meaning of the acronym MULTIFIT [letter; comment] Cheng TO. **J Cardiovasc Nurs** 1997 Jan;11(2):ix. Comment on: J Cardiovasc Nurs 1996 Oct;11(1):76–87.

POEMs, DOEs, and PROSE [letter; comment] Merenstein JH. **J Fam Pract** 1996 Nov;43(5):432. Comment on: J Fam Pract 1994 May;38(5):505–13. Comment on: J Fam Pract 1994 Nov;39(5):489–99.

Acronymia [letter] Reiswig J. **J Fam Pract** 1996 Nov; 43(5):431–2

[Eponyms and acronyms (editorial)] Wackenheim A. **Ann Radiol (Paris)** 1996;39(3):109–10 **(Fre)**

[Systematics of osteodensitometric methods and acronyms] Felsenberg D, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Oct;165(4):398–402 (14 ref.) (Eng. Abstr.) **(Ger)**

ABC TRANSPORTERS

Biophysical aspects of P-glycoprotein-mediated multidrug resistance. Wadkins RM, et al. **Int Rev Cytol** 1997; 171:121–65 (124 ref.)

Expansion of natural (NK1+) T cells that express alpha beta T cell receptors in transporters associated with antigen presentation-1 null and thymus leukemia antigen positive mice. Joyce S, et al. **J Exp Med** 1996 Oct 1;184(4):1579–84

Complete inventory of the yeast ABC proteins. Decottignies A, et al. **Nat Genet** 1997 Feb;15(2):137–45

[Multidrug resistance protein (MRP)] Abe T, et al. **Nippon Rinsho** 1997 May;55(5):1077–82 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Multidrug resistance of cancer cells mediated by ABC superfamily transporters] Ueda K. **Nippon Rinsho** 1997 May;55(5):1024–9 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Role of transporters in the detoxification of xenobiotics: recent advances in the study of cMOAT/MRP] Suzuki H, et al. **Tanpakushitsu Kakusan Koso** 1997 Jun; 42(8):1273–84 (83 ref.) **(Jpn)**

[Molecular mechanisms for drug transport by MDR1/P-glycoprotein] Ueda K. **Tanpakushitsu Kakusan Koso** 1997 Jun;42(8):1263–72 (45 ref.) **(Jpn)**

ANALYSIS

The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Nooter K, et al. **Br J Cancer** 1997;76(4):486–93

Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Withoff S, et al. **Br J Cancer** 1996 Dec; 74(12):1869–76

Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Gollapudi S, et al. **Cancer Chemother Pharmacol** 1997;40(2):150–8

Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Sugawara I, et al. **Cancer Lett** 1997 Jan 15;112(1):23–31

Differential abundance of glutamate transporter subtypes in amyotrophic lateral sclerosis (ALS)-vulnerable versus ALS-resistant brain stem motor cell groups. Medina L, et al. **Exp Neurol** 1996 Dec;142(2):287–95

The TAP complex influences allorecognition of class II MHC molecules. Carmichael P, et al. **Hum Immunol** 1996 Sep 15;50(1):70–7

Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Endo K, et al. **Int J Cancer** 1996 Nov 4;68(3):372–7

Brain glutamate transporter proteins form homomultimers. Haugeto O, et al. **J Biol Chem** 1996 Nov 1;271(44):27715–22

Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia. Den Boer ML, et al. **Leukemia** 1997 Jul; 11(7):1078–85

Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source and disease status. Filipits M, et al. **Leukemia** 1997 Jul; 11(7):1073–7

Selection of phage-displayed peptides mimicking an extracellular epitope of human MDR1-P-glycoprotein. Poloni F, et al. **Physiol Chem Phys Med NMR** 1995; 27(4):271–80

ANTAGONISTS & INHIBITORS

Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Vanhoefer U, et al. **Biochem Pharmacol** 1997 Mar 21; 53(6):801–9

Structure of the viral TAP-inhibitor ICP47 induced by membrane association. Beinert D, et al. **Biochemistry** 1997 Apr 15;36(15):4694–700

The rational design of TAP inhibitors using peptide substrate modifications and peptidomimetics. Grommé M, et al. **Eur J Immunol** 1997 Apr;27(4):898–904

The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Ahn K, et al. **Immunity** 1997 May;6(5):613–21

New beta-hydroxyaspartate derivatives are competitive blockers for the bovine glutamate/aspartate transporter. Lebrun B, et al. **J Biol Chem** 1997 Aug 15;272(33):20336–9

MgADP antagonism to Mg2+-independent ATP binding of the sulfonylurea receptor SUR1. Ueda K, et al. **J Biol Chem** 1997 Sep 12;272(37):22983–6

The active site of ICP47, a herpes simplex virus-encoded inhibitor of the major histocompatibility complex (MHC)-encoded peptide transporter associated with antigen processing (TAP), maps to the NH2-terminal 35 residues. Galocha B, et al. **J Exp Med** 1997 May 5;

185(9):1565–72

Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Sumizawa T, et al. **Mol Pharmacol** 1997 Mar;51(3):399–405

BIOSYNTHESIS

Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Nooter K, et al. **Ann Oncol** 1996 Jan;7(1):75–81

Fetal exposure to interferon-gamma leads to induction of antigen-presenting molecules and leukocyte recruitment. Lee MS, et al. **Autoimmunity** 1997;25(3):147–55

Expression of c-fos precedes MDR3 in vincristine and adriamycin selected multidrug resistant murine erythroleukemia cells. Bhushan A, et al.
Biochem Biophys Res Commun 1996 Sep 24;226(3):819–21

Identification of the transporter for the M-factor mating pheromone in fission yeast. Davey J, et al.
Biochem Soc Trans 1997 May;25(2):224S

Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. Izquierdo MA, et al. **Br J Cancer** 1996 Dec;74(12):1961–7

Altered kinetics of Tap-1 gene expression in macrophages following stimulation with both IFN-gamma and LPS. Cramer LA, et al. **Cell Immunol** 1997 May 25;178(1):53–61

Interferon-gamma rescues HLA class Ia cell surface expression in term villous trophoblast cells by inducing synthesis of TAP proteins. Rodriguez AM, et al.
Eur J Immunol 1997 Jan;27(1):45–54

Differential developmental expression of the two rat brain glutamate transporter proteins GLAST and GLT. Ullensvang K, et al. **Eur J Neurosci** 1997 Aug;9(8):1646–55

Expression of a glutamate transporter cDNA in human pancreatic islets. Manfras BJ, et al.
Exp Clin Endocrinol Diabetes 1995;103 Suppl 2:95–8

Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion. Barrand MA, et al. **Gen Pharmacol** 1997 May;28(5):639–45 (44 ref.)

Expression of high-affinity neuronal and glial glutamate transporters in the rat optic nerve. Choi I, et al. **Glia** 1997 Jul;20(3):184–92

Widespread expression of a new putative hormone extrusion pump: NG-TRA transporter protein in human and rat tissue. Ristow M, et al. **Horm Metab Res** 1996 Mar; 28(3):138–41

External glycopeptide binding to MHC class-I in relation to expression of TAP transporters, beta 2-microglobulin and to pH. Abdel-Motal UM, et al. **Immunol Lett** 1996 Dec 1;54(1):31–5

TAP off--tumors on. Seliger B, et al. **Immunol Today** 1997 Jun;18(6):292–9 (96 ref.)

Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas. Kubo H, et al.
Int J Cancer 1996 Dec 20;69(6):488–94

Multiple Pdr1p/Pdr3p binding sites are essential for normal expression of the ATP binding cassette transporter protein-encoding gene PDR5. Katzmann DJ, et al.
J Biol Chem 1996 Sep 20;271(38):23049–54

Interferon-gamma rapidly increases peptide transporter (TAP) subunit expression and peptide transport capacity in endothelial cells. Ma W, et al. **J Biol Chem** 1997 Jun 27;272(26):16585–90

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. Maeurer MJ, et al. **J Clin Invest** 1996 Oct 1; 98(7):1633–41

Overexpression of mdr2 gene by peroxisome proliferators in the mouse liver. Miranda S, et al. **J Hepatol** 1997 Jun; 26(6):1331–9

Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. Salazar-Onfray F, et al. **J Immunol** 1997 Oct 1;159(7):3195–202

Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP. Stein U, et al.
J Natl Cancer Inst 1997 Jun 4;89(11):807–13

Neuronal regulation of glutamate transporter subtype expression in astrocytes. Swanson RA, et al. **J Neurosci** 1997 Feb 1;17(3):932–40

Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer [see comments] Nakagawa M, et al. **J Urol** 1997 Apr; 157(4):1260–4; discussion 1264–5. Comment in: J Urol 1997 Apr;157(4):1266–7.

Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. Arai Y, et al. **Leuk Res** 1997 Apr; 21(4):313–9

Dynamic changes in expression of glutamate transporter mRNAs in developing brain. Shibata T, et al.
Neuroreport 1996 Feb 29;7(3):705–9

Expression of glial glutamate transporters GLT-1 and GLAST is unchanged in the hippocampus in fully kindled rats. Akbar MT, et al. **Neuroscience** 1997 May;78(2):351–9

Expression and characterization of the multidrug resistance-associated protein in insect cells infected with a recombinant baculovirus. Sun H, et al. **Oncol Res** 1996; 8(7–8):287–93

ALDP expression in fetal cells and its application in prenatal diagnosis of X-linked adrenoleukodystrophy. Ruiz M, et al. **Prenat Diagn** 1997 Jul;17(7):651–6

CHEMISTRY

An S. cerevisiae peroxisomal transporter, orthologous to the human adrenoleukodystrophy protein, appears to be a heterodimer of two half ABC transporters: Pxa1p and Pxa2p. Shani N, et al. **Ann N Y Acad Sci** 1996 Dec 27; 804:770–2

Topology of ATP-binding domain of adrenoleukodystrophy gene product in peroxisomes. Contreras M, et al.
Arch Biochem Biophys 1996 Oct 15;334(2):369–79

Primary structure of human PMP69, a putative peroxisomal ABC-transporter. Holzinger A, et al.
Biochem Biophys Res Commun 1997 Aug 8;237(1):152–7

Identification of the transporter for the M-factor mating pheromone in fission yeast. Davey J, et al.
Biochem Soc Trans 1997 May;25(2):224S

Structure/function relationships in glutamate transporters. Kanner BI. **Biochem Soc Trans** 1996 Aug;24(3):843–6 (28 ref.)

The photoreceptor rim protein is an ABC transporter encoded by the gene for recessive Stargardt's disease (ABCR). Azarian SM, et al. **FEBS Lett** 1997 Jun 9; 409(2):247–52

Membrane topology distinguishes a subfamily of the ATP-binding cassette (ABC) transporters. Tusnády GE, et al. **FEBS Lett** 1997 Jan 27;402(1):1–3 (27 ref.)

Distribution of a sub-class of bacterial ABC polar amino acid transporter and identification of an N-terminal region involved in solute specificity. Walshaw DL, et al.
FEBS Lett 1997 Sep 8;414(2):397–401

Topological studies of the membrane component of the OleC ABC transporter involved in oleandomycin resistance in Streptomyces antibioticus. Olano C, et al.
FEMS Microbiol Lett 1996 Oct 1;143(2–3):133–9

Amide metabolism: a putative ABC transporter in Rhodococcus sp. R312. Chebrou H, et al. **Gene** 1996 Dec 5;182(1–2):215–8

Use of phoA and lacZ fusions to study the membrane topology of ProW, a component of the osmoregulated ProU transport system of Escherichia coli. Haardt M, et al. **J Bacteriol** 1996 Sep;178(18):5370–81

Membrane topology of the ATP-binding cassette transporter associated with antigen presentation (Tap1) expressed in Escherichia coli. Gileadi U, et al. **J Biol Chem** 1997 Apr 25;272(17):11103–8

Membrane topology of the C-terminal half of the neuronal, glial, and bacterial glutamate transporter family. Slotboom DJ, et al. **J Biol Chem** 1996 Dec 6;271(49):31317–21

Multiple regions of the transporter associated with antigen processing (TAP) contribute to its peptide binding site. Nijenhuis M, et al. **J Immunol** 1996 Dec 15;157(12):5467–77

Sequence requirements for membrane assembly of polytopic membrane proteins: molecular dissection of the membrane insertion process and topogenesis of the human MDR3 P-glycoprotein. Zhang JT. **Mol Biol Cell** 1996 Nov; 7(11):1709–21

DRUG EFFECTS

Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Draper MP, et al.
Br J Cancer 1997;75(6):810–5

Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? [letter] Lallemand JY, et al. **Lancet** 1997 Sep 6; 350(9079):711–2

Arachidonic acid inhibits 3H-glutamate uptake with different potencies in rodent central nervous system regions expressing different transporter subtypes. Manzoni C, et al. **Pharmacol Res** 1997 Feb;35(2):149–51

ATP-binding cassette proteins as targets for drug discovery. Demolombe S, et al. **Trends Pharmacol Sci** 1996 Aug; 17(8):273–5 (32 ref.)

GENETICS

X-linked adrenoleukodystrophy. Aubourg P, et al.
Ann N Y Acad Sci 1996 Dec 27;804:461–76 (75 ref.)

Mutational analysis of an X-linked adrenoleukodystrophy (ALD) patient with detectable ALD protein. Jorge P, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:756–9

The glial glutamate transporter complementary DNA in patients with amyotrophic lateral sclerosis. Meyer T, et al. **Ann Neurol** 1996 Sep;40(3):456–9

Polymorphisms of the TAP1 and TAP2 transporter genes in Japanese SLE. Takeuchi F, et al. **Ann Rheum Dis** 1996 Dec;55(12):924–6

Specificities of human TAP alleles for HLA-B27 binding peptides. Kuipers JG, et al. **Arthritis Rheum** 1996 Nov; 39(11):1892–5

Association of a new allele of the TAP2 gene, TAP2*Bky2 (Val577), with susceptibility to Sjögren's syndrome. Kumagai S, et al. **Arthritis Rheum** 1997 Sep;40(9):1685–92

Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature region. Bakos E, et al. **Biochem J** 1997 May 1;323 (Pt 3):777–83

Induction of pgp3 expression and reversion of the multidrug resistance phenotype in 9-OH-ellipticine-resistant Chinese hamster lung fibroblasts transfected with the MYC oncogene. Delaporte C, et al. **Biochem Pharmacol** 1997 Jan 10;53(1):59–66

Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Lautier D, et al.
Biochem Pharmacol 1996 Oct 11;52(7):967–77 (97 ref.)

Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Rappa G, et al.
Biochem Pharmacol 1997 Sep 15;54(6):649–55

Molecular cloning and characterization of the ABC transporter expressed in Trachea (ATET) gene from Drosophila melanogaster. Kuwana H, et al.
Biochim Biophys Acta 1996 Nov 11;1309(1–2):47–52

Mechanically regulated expression of a neural glutamate transporter in bone: a role for excitatory amino acids as osteotropic agents? Mason DJ, et al. **Bone** 1997 Mar; 20(3):199–205

The anthracycline resistance-associated (ara) gene, a novel gene associated with multidrug resistance in a human leukaemia cell line. Longhurst TJ, et al. **Br J Cancer** 1996 Nov;74(9):1331–5

Cloning and expression of a neuronal rat brain glutamate transporter. Bjørås M, et al. **Brain Res Mol Brain Res** 1996 Feb;36(1):163–8

Expression of three glutamate transporter subtype mRNAs in human brain regions and peripheral tissues. Nakayama T, et al. **Brain Res Mol Brain Res** 1996 Feb;36(1):189–92

Multidrug resistance: molecular mechanisms and clinical relevance. Ling V. **Cancer Chemother Pharmacol** 1997;40 Suppl:S3–8 (36 ref.)

Chemoprotection of normal tissues by transfer of drug resistance genes. Rafferty JA, et al.
Cancer Metastasis Rev 1996 Sep;15(3):365–83 (110 ref.)

Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Alpan RS, et al. **Cancer Res** 1996 Oct 1;56(19):4358–61

Identification of a new P-glycoprotein-like ATP-binding cassette transporter gene that is overexpressed during hepatocarcinogenesis. Furuya KN, et al. **Cancer Res** 1997 Sep 1;57(17):3708–16

Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Lorico A, et al. **Cancer Res** 1996 Dec 1;56(23):5351–5

Localization of sequences that influence basal and cell type-specific activity of the murine mdr2 promoter. Yang CP, et al. **Cell Growth Differ** 1996 Sep;7(9):1227–37

Association of TAP1 and TAP2 with systemic sclerosis in Japanese. Takeuchi F, et al. **Clin Exp Rheumatol** 1996 Sep-Oct;14(5):513–21

Two novel missense mutations in the ATP-binding domain of the adrenoleukodystrophy gene: immunoblotting and immunocytological study of two patients. Imamura A, et al. **Clin Genet** 1997 May;51(5):322–5

Sequence comparison of yeast ATP-binding cassette proteins. Michaelis S, et al.
Cold Spring Harb Symp Quant Biol 1995;60:291–307 (89 ref.)

Photoreceptor rim protein: partial sequences of cDNA show a high degree of similarity to ABC transporters. Thomson JL, et al. **Curr Eye Res** 1997 Jul;16(7):741–5

yAP-1- and yAP-2-mediated, heat shock-induced transcriptional activation of the multidrug resistance ABC transporter genes in Saccharomyces cerevisiae. Miyahara K, et al. **Curr Genet** 1996 Jan;29(2):103–5

The unusual inheritance of multidrug-resistance factors in Saccharomyces. Shallom JM, et al. **Curr Genet** 1996 Aug; 30(3):212–7

Susceptibility to type 1 diabetes in the Senegalese population is linked to HLA-DQ and not TAP and LMP genes. Chauffert M, et al. **Diabetes Care** 1997 Aug;20(8):1299–303

Organisation and functions of class II genes and molecules. Beck S, et al. **DNA Seq** 1996;7(1):21–3

Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. Grondin K, et al.
EMBO J 1997 Jun 2;16(11):3057–65

Tap gene associations in UK caucasoids. Donn RP, et al.
Eur J Immunogenet 1994 Jun;21(3):159–67

HLA class II region genes and susceptibility to dermatitis herpetiformis: DPB1 and TAP2 associations are secondary to those of the DQ subregion. Hall MA, et al.
Eur J Immunogenet 1996 Aug;23(4):285–96

Polymorphisms of TAP1 and TAP2 genes in German patients with type 1 diabetes mellitus. Rau H, et al.
Eur J Immunogenet 1997 Jun;24(3):229–36

An improved method for the detection of peptide-induced upregulation of HLA-A2 molecules on TAP-deficient T2 cells. Regner M, et al. **Exp Clin Immunogenet** 1996; 13(1):30–5

Hepatic canalicular membrane 4: expression of the multidrug resistance genes in the liver. Silverman JA, et al.
FASEB J 1997 Apr;11(5):308–13 (55 ref.)

Fenofibrate differently alters expression of genes encoding ATP-binding transporter proteins of the peroxisomal membrane. Albet S, et al. **FEBS Lett** 1997 Apr 1; 405(3):394–7

The photoreceptor rim protein is an ABC transporter encoded by the gene for recessive Stargardt's disease (ABCR). Azarian SM, et al. **FEBS Lett** 1997 Jun 9; 409(2):247–52

Identification of a second Mycobacterium tuberculosis gene cluster encoding proteins of an ABC phosphate transporter. Braibant M, et al. **FEBS Lett** 1996 Sep 30;394(2):206–12

Functional expression of the rat liver canalicular isoform of the multidrug resistance-associated protein. Madon J, et al. **FEBS Lett** 1997 Apr 7;406(1-2):75-8

The MHC-encoded TAP1/LMP2 bidirectional promoter is down-regulated in highly oncogenic adenovirus type 12 transformed cells. Proffitt JA, et al. **FEBS Lett** 1997 Jan 3;400(2):141-4

Differential expression of genes coding for ABC transporters after treatment of Arabidopsis thaliana with xenobiotics. Tommasini R, et al. **FEBS Lett** 1997 Jul 14;411(2-3):206-10

Expression of a pepT homologue from Bacillus subtilis. Schrögel O, et al. **FEMS Microbiol Lett** 1996 Dec 15; 145(3):341-8

Is the CvaA protein, encoded within the colicin V export gene cvaA, required for colicin V transport? Skvirsky RC, et al. **FEMS Microbiol Lett** 1996 May 1;138(2-3):201-6

A putative ABC-transport operon of Mycobacterium smegmatis. Barsom EK, et al. **Gene** 1997 Jan 31; 185(1):127-32

A Mycobacterium tuberculosis gene cluster encoding proteins of a phosphate transporter homologous to the Escherichia coli Pst system. Braibant M, et al. **Gene** 1996 Oct 17;176(1-2):171-6

Isolation and characterization of a mammalian homolog of the Drosophila white gene. Croop JM, et al. **Gene** 1997 Jan 31;185(1):77-85

ABC transporters in Archaea: two genes encoding homologs of the nucleotide-binding components in the methanogen Methanosarcina mazei S-6. Jovell RJ, et al. **Gene** 1996 Oct 3;174(2):281-4

Characterisation of the pvdE gene which is required for pyoverdine synthesis in Pseudomonas aeruginosa. McMorran BJ, et al. **Gene** 1996 Oct 17;176(1-2):55-9

The Bacillus subtilis chromosome region near 78 degrees contains the genes encoding a new two-component system, three ABC transporters and a lipase. Yamamoto H, et al. **Gene** 1996 Nov 28;181(1-2):147-51

The cloning of a human ABC gene (ABC3) mapping to chromosome 16p13.3. Connors TD, et al. **Genomics** 1997 Jan 15;39(2):231-4

Structure and location of the murine adrenoleukodystrophy gene. Kennedy MA, et al. **Genomics** 1996 Mar 15; 32(3):395-400

Isolation and chromosomal mapping of a novel ATP-binding cassette transporter conserved in mouse and human. Savary S, et al. **Genomics** 1997 Apr 15;41(2):275-8

Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes. Kauffmann HM, et al. **Hepatology** 1997 Oct; 26(4):980-5

TAP-polymorphisms in juvenile onset psoriasis and psoriatic arthritis. Höhler T, et al. **Hum Immunol** 1996 Nov; 51(1):49-54

Genetic polymorphisms of the major histocompatibility complex-encoded antigen-processing genes TAP and LMP in sarcoidosis. Ishihara M, et al. **Hum Immunol** 1996 Feb; 45(2):105-110

Transporter associated with antigen-processing-1 (TAP1) alleles in Gorilla gorilla: diversification of the locus postspeciation. Laud PR, et al. **Hum Immunol** 1996 Oct; 50(2):91-102

Evaluation of TAP1 polymorphisms with insulin dependent diabetes mellitus in Finnish diabetic patients. The Childhood Diabetes in Finland (DiMe) Study Group. Ma L, et al. **Hum Immunol** 1997 Apr 1;53(2):159-66

Genetic susceptibility and anti-human platelet antigen 5b alloimmunization role of HLA class II and TAP genes. Semana G, et al. **Hum Immunol** 1996 Apr;46(2):114-9

Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Allikmets R, et al. **Hum Mol Genet** 1996 Oct;5(10):1649-55

Identification of two new nonsense mutations (Q311X and W326X) in Exon 2 of the adrenoleukodystrophy (ALD) gene. Barceló A, et al. **Hum Mutat** 1996;8(3):286-7

A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Hengel H, et al. **Immunity** 1997 May;6(5):623-32

Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8+ T cells in IRF-1-/- mice. White LC, et al. **Immunity** 1996 Oct;5(4):365-76

A new human transporter associated with antigen processing alleles encodes a large C-terminal protein domain. Cesari MM, et al. **Immunogenetics** 1997;45(4):280-1

Transport-associated proteins in Atlantic salmon (Salmo salar). Grimholt U. **Immunogenetics** 1997;46(3):213-21

Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines. Singal DP, et al. **Immunol Lett** 1996 May;50(3):149-54

TAP1 and TAP2 genes in nickel allergy. Silvennoinen-Kassinen S, et al. **Int Arch Allergy Immunol** 1997 Sep;114(1):94-6

Polymorphism in transporter antigen peptides gene (TAP1) associated with atopy in Tunisians. Ismaïl A, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):216-23

Are HLA-DR or TAP genes genetic markers of severity in ulcerative colitis? Heresbach D, et al. **J Autoimmun** 1996 Dec;9(6):777-84

The temperature-sensitive growth and survival phenotypes of Escherichia coli cydDC and cydAB strains are due to deficiencies in cytochrome bd and are corrected by exogenous catalase and reducing agents. Goldman BS, et al. **J Bacteriol** 1996 Nov;178(21):6348-51

The ggtA gene encodes a subunit of the transport system for the osmoprotective compound glucosylglycerol in Synechocystis sp. strain PCC 6803. Hagemann M, et al. **J Bacteriol** 1997 Feb;179(3):714-20

Helicobacter pylori ABC transporter: effect of allelic exchange mutagenesis on urease activity. Hendricks JK, et al. **J Bacteriol** 1997 Sep;179(18):5892-902

Characterization of in-frame proteins encoded by cvaA, an essential gene in the colicin V secretion system: CvaA* stabilizes CvaA to enhance secretion. Hwang J, et al. **J Bacteriol** 1997 Feb;179(3):689-96

The Agrobacterium tumefaciens virulence gene chvE is part of a putative ABC-type sugar transport operon. Kemner JM, et al. **J Bacteriol** 1997 Apr;179(7):2452-8

Isolation and characterization of Enterobacter cloacae mutants which are defective in chemotaxis toward inorganic phosphate. Kusaka K, et al. **J Bacteriol** 1997 Oct; 179(19):6192-5

Requirement for genes with homology to ABC transport systems for attachment and virulence of Agrobacterium tumefaciens. Matthysse AG, et al. **J Bacteriol** 1996 Sep; 178(17):5302-8

Identification and functional characterization of an ABC transport system involved in polysaccharide export of A-band lipopolysaccharide in Pseudomonas aeruginosa. Rocchetta HL, et al. **J Bacteriol** 1997 Aug;179(15):4713-24

The stationary-phase-exit defect of cydC (surB) mutants is due to the lack of a functional terminal cytochrome oxidase. Siegele DA, et al. **J Bacteriol** 1996 Nov;178(21):6091-6

Localized frameshift mutation generates selective, high-frequency phase variation of a surface lipoprotein encoded by a mycoplasma ABC transporter operon. Theiss P, et al. **J Bacteriol** 1997 Jun;179(12):4013-22

Open reading frame 3 of the barotolerant bacterium strain DSS12 is complementary with cydD in Escherichia coli: cydD functions are required for cell stability at high pressure. Kato C, et al. **J Biochem (Tokyo)** 1996 Aug; 120(2):301-5

Manganese transport in the cyanobacterium Synechocystis sp. PCC 6803. Bartsevich VV, et al. **J Biol Chem** 1996 Oct 18;271(42):26057-61

Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone. Oda Y, et al. **J Cancer Res Clin Oncol** 1997;123(4):237-9

Semiquantitation of intrahepatic MDR3 mRNA levels by reverse transcription/competitive polymerase chain reaction. Dumoulin FL, et al. **J Hepatol** 1997 Apr; 26(4):852-6

Absence of functional relevance of human transporter associated with antigen processing polymorphism for peptide selection. Daniel S, et al. **J Immunol** 1997 Sep 1; 159(5):2350-7

Allelic variation in the mouse Tap-1 and Tap-2 transporter genes. Marusina K, et al. **J Immunol** 1997 Jun 1; 158(11):5251-6

Reduced expression of Tap1 and Lmp2 antigen-processing genes in the nonobese diabetic (NOD) mouse due to a mutation in their shared bidirectional promoter. Yan G, et al. **J Immunol** 1997 Sep 15;159(6):3068-80

ALDP expression in fibroblasts of patients with X-linked adrenoleukodystrophy. Kemp S, et al. **J Inherit Metab Dis** 1996;19(5):667-74

Spread of measles virus through axonal pathways into limbic structures in the brain of TAP1 -/- mice. Urbanska EM, et al. **J Med Virol** 1997 Aug;52(4):362-9

Novel missense and frameshift mutations in the adrenoleukodystrophy gene. Ueyama H, et al. **Jpn J Hum Genet** 1996 Dec;41(4):407-11

The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Kuss BJ, et al. **Leuk Lymphoma** 1996 Feb;20(5-6):357-64 (34 ref.)

Identification of genes in Rhizobium leguminosarum bv. trifolii whose products are homologues to a family of ATP-binding proteins. Król J, et al. **Microbiology** 1997 Apr;143 (Pt 4):1389-94

The Paracoccus denitrificans ccmA, B and C genes: cloning and sequencing, and analysis of the potential of their products to form a haem or apo- c-type cytochrome transporter. Page MD, et al. **Microbiology** 1997 Feb;143 (Pt 2):563-76

Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Sanglard D, et al. **Microbiology** 1997 Feb;143 (Pt 2):405-16

An operon from Lactobacillus helveticus composed of a proline iminopeptidase gene (pepI) and two genes coding for putative members of the ABC transporter family of proteins. Varmanen P, et al. **Microbiology** 1996 Dec;142 (Pt 12):3459-68

Characterization of a prolinase gene and its product and an adjacent ABC transporter gene from Lactobacillus helveticus. Varmanen P, et al. **Microbiology** 1996 Apr;142 (Pt 4):809-16

Cloning and sequence analysis of a novel member of the ATP-binding cassette (ABC) protein gene family from Plasmodium falciparum. Bozdech Z, et al. **Mol Biochem Parasitol** 1996 Oct 18;81(1):41-51

Molecular characterization of a P-glycoprotein-related tcpgp2 gene in Trypanosoma cruzi. Dallagiovanna B, et al. **Mol Biochem Parasitol** 1996 Jan;75(2):145-57

Cloning and characterization of cDNAs encoding putative glutamate transporters from Caenorhabditis elegans and Onchocerca volvulus. Radice AD, et al. **Mol Biochem Parasitol** 1996 Sep;80(1):41-53

Identification of a novel TAP2 allele in a Colombian black population: gene conversion, ancestral intermediate or convergent change? [letter] Carrington M, et al. **Mol Biol Evol** 1997 Aug;14(8):892-4

Mutations in STS1 suppress the defect in 3' mRNA processing caused by the rna15-2 mutation in Saccharomyces cerevisiae. Amrani N, et al. **Mol Gen Genet** 1996 Oct 16;252(5):552-62

The Schizosaccharomyces pombe mam1 gene encodes an ABC transporter mediating secretion of M-factor. Christensen PU, et al. **Mol Gen Genet** 1997 Jun; 255(2):226-36

Multidrug resistance in Aspergillus nidulans involves novel ATP-binding cassette transporters. Del Sorbo G, et al. **Mol Gen Genet** 1997 Apr 28;254(4):417-26

A two-gene ABC-type transport system that extrudes Na+ in Bacillus subtilis is induced by ethanol or protonophore. Cheng J, et al. **Mol Microbiol** 1997 Mar;23(6):1107-20

Protein secretion by heterologous bacterial ABC-transporters: the C-terminus secretion signal of the secreted protein confers high recognition specificity. Duong F, et al. **Mol Microbiol** 1996 Aug;21(3):459-70

Localization of OccR-activated and TraR-activated promoters that express two ABC-type permeases and the traR gene of Ti plasmid pTiR10. Fuqua C, et al. **Mol Microbiol** 1996 Jun;20(6):1199-210

The ATP-binding cassette multidrug transporter Snq2 of Saccharomyces cerevisiae: a novel target for the transcription factors Pdr1 and Pdr3. Mahé Y, et al. **Mol Microbiol** 1996 Apr;20(1):109-17

Mutational analysis and properties of the msbA gene of Escherichia coli, coding for an essential ABC family transporter. Polissi A, et al. **Mol Microbiol** 1996 Jun; 20(6):1221-33

Double-glycine-type leader peptides direct secretion of bacteriocins by ABC transporters: colicin V secretion in Lactococcus lactis. van Belkum MJ, et al. **Mol Microbiol** 1997 Mar;23(6):1293-301

The general L-amino acid permease of Rhizobium leguminosarum is an ABC uptake system that also influences efflux of solutes. Walshaw DL, et al. **Mol Microbiol** 1996 Sep;21(6):1239-52

A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy [see comments] Allikmets R, et al. **Nat Genet** 1997 Mar;15(3):236-46. Comment in: Nat Genet 1997 Mar;15(3):224-5.

A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Allikmets R. **Nat Genet** 1997 Sep;17(1):122

Widening the view [news; comment] Meitinger T. **Nat Genet** 1997 Mar;15(3):224-5. Comment on: Nat Genet 1997 Mar;15(3):236-46. Comment on: Nat Genet 1997 Mar;15(3):247-51.

Genomic organization of the human excitatory amino acid transporter gene GLT-1. Meyer T, et al. **Neuroreport** 1997 Feb 10;8(3):775-7

Decreased glutamate transporter (GLT-1) expression in frontal cortex of rats with acute liver failure. Knecht K, et al. **Neurosci Lett** 1997 Jul 4;229(3):201-3

Analysis of the heterogeneous transcripts of the highly edited orf206 in tomato mitochondria. Shikanai T, et al. **Plant Cell Physiol** 1996 Jul;37(5):692-6

Cloning and functional characterization of a subunit of the transporter associated with antigen processing. Li S, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8708-13

AtMRP1 gene of Arabidopsis encodes a glutathione S-conjugate pump: isolation and functional definition of a plant ATP-binding cassette transporter gene. Lu YP, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8243-8

Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter MDR1. van Veen HW, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10668-72

Molecular and structural features of the proton-coupled oligopeptide transporter superfamily. Fei YJ, et al. **Prog Nucleic Acid Res Mol Biol** 1998;58:239-61 (57 ref.)

Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration [see comments] Allikmets R, et al. **Science** 1997 Sep 19;277(5333):1805-7 . Comment in: Science 1997 Sep 19;277(5333):1765-6.

Gene found for the fading eyesight of old age [news; comment] Pennisi E. **Science** 1997 Sep 19;277(5333):1765-6 . Comment on: Science 1997 Sep 19;277(5333):1805-7.

TAP polymorphisms in Swedish myasthenia gravis patients. Hjelmström P, et al. **Tissue Antigens** 1997 Feb;49(2):176-9

Analysis of allelic variation of the TAP2 gene in sarcoidosis. Ishihara M, et al. **Tissue Antigens** 1997 Feb;49(2):107-10

Allelic variations in the TAP2 and LMP2 genes in Behçet's disease. Ishihara M, et al. **Tissue Antigens** 1996 Mar; 47(3):249-52

The human leukocyte antigen TAP2 gene defines the centromeric limit of melanoma susceptibility on chromosome 6p. Lee JE, et al. **Tissue Antigens** 1996 Feb; 47(2):117-21

Genetic heterogeneity between type Ia and type II insulin-dependent diabetes mellitus: HLA class II and TA. gene analysis. Maugendre D, et al. **Tissue Antigens** 1996 Nov;48(5):540-8

Transporter associated with antigen-processing (TAP) genes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis. Rajalingam R, et al. **Tissue Antigens** 1997 Feb; 49(2):168–72

Polymorphisms of TAP1 and TAP2 genes in Graves' disease. Rau H, et al. **Tissue Antigens** 1997 Jan;49(1):16–22

Human TAP1 polymorphisms detected by denaturing gradient gel electrophoresis. Shi L, et al. **Tissue Antigens** 1997 Apr;49(4):421–6

Polymorphism of TAP1 and TAP2 in Japanese patients with rheumatoid arthritis. Takeuchi F, et al. **Tissue Antigens** 1997 Mar;49(3 Pt 1):280–2

Polymorphisms of the TAP2 gene may influence antibody response to live measles vaccine virus. Hayney MS, et al. **Vaccine** 1997 Jan;15(1):3–6

Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours. Oda Y, et al. **Virchows Arch** 1997 Feb;430(2):99–105

Sequence analysis of a 33.2 kb segment from the left arm of yeast chromosome XV reveals eight known genes and ten new open reading frames including homologues of ABC transporters, inositol phosphatases and human expressed sequence tags. Tzermia M, et al. **Yeast** 1997 May; 13(6):583–9

Sequence analysis of a near-subtelomeric 35.4 kb DNA segment on the right arm of chromosome VII from Saccharomyces cerevisiae carrying the MAL1 locus reveals 15 complete open reading frames, including ZUO1, BGL2 and BIO2 genes and an ABC transporter gene. Volckaert G, et al. **Yeast** 1997 Mar 15;13(3):251–9

IMMUNOLOGY

Increased class Ib antigen display on TAP-2 mutant cells by a mitochondrial function inhibitor. Hermel E, et al. **Cell Immunol** 1997 Jul 10;179(1):10–5

Requirements for HLA-B*2705-binding peptides with special regard to the transporter associated with antigen processing (TAP). Kuipers JG, et al. **Clin Exp Rheumatol** 1996 Sep-Oct;14(5):523–9

Point mutations in the alpha 2 domain of HLA-A2.1 define a functionally relevant interaction with TAP. Lewis JW, et al. **Curr Biol** 1996 Jul 1;6(7):873–83

Major histocompatibility complex class I presentation of ovalbumin peptide 257–264 from exogenous sources: protein context influences the degree of TAP-independent presentation. Wick MJ, et al. **Eur J Immunol** 1996 Nov; 26(11):2790–9

The TAP complex influences allorecognition of class II MHC molecules. Carmichael P, et al. **Hum Immunol** 1996 Sep 15;50(1):70–7

Genetic polymorphisms of the major histocompatibility complex-encoded antigen-processing genes TAP and LMP in sarcoidosis. Ishihara M, et al. **Hum Immunol** 1996 Feb; 45(2):105–110

Are transporter associated with antigen processing (TAP) and tapasin class I MHC chaperones? Solheim JC, et al. **J Immunol** 1997 Jan 15;158(2):541–3

Presentation of an influenza nucleoprotein epitope incorporated into the H-2Db signal sequence requires the transporter-associated with antigen presentation. Uger RA, et al. **J Immunol** 1997 Jan 15;158(2):685–92

Binding and transport of melanoma-specific antigenic peptides by the transporter associated with antigen processing. Chang SA, et al. **Mol Immunol** 1996 Oct; 33(15):1165–9

Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Hicklin DJ, et al. **Tissue Antigens** 1996 Jul; 48(1):38–46

ISOLATION & PURIFICATION

Characterization of an ATP-binding cassette transporter in Cryptosporidium parvum. Perkins ME, et al. **Mol Biochem Parasitol** 1997 Jul;87(1):117–22

The proteins encoded by the rbs operon of Escherichia coli: I. Overproduction, purification, characterization, and functional analysis of RbsA. Barroga CF, et al. **Protein Sci** 1996 Jun;5(6):1093–9

The proteins encoded by the rbs operon of Escherichia coli: II. Use of chimeric protein constructs to isolate and characterize RbsC. Zaitseva J, et al. **Protein Sci** 1996 Jun; 5(6):1100–7

METABOLISM

The function of the multidrug resistance proteins (MRP and cMRP) in drug conjugate transport and hepatobiliary excretion. Keppler D, et al. **Adv Enzyme Regul** 1996; 36:17–29

Heterogeneity and functional properties of subtypes of sodium-dependent glutamate transporters in the mammalian central nervous system. Robinson MB, et al. **Adv Pharmacol** 1997;37:69–115 (210 ref.)

Glutamate transport and not cellular content modulates paracellular permeability in LLC-PK1-F+ cells. Welbourne TC, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):E367–70

Increased glutamate transporter (GLT-1) immunoreactivity in the rat striatum after repeated intermittent administration of methamphetamine. Nishino N, et al. **Ann N Y Acad Sci** 1996 Oct 31;801:310–4

Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Masliah E, et al. **Ann Neurol** 1996 Nov;40(5):759–66

Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Germann UA, et al. **Anticancer Drugs** 1997 Feb;8(2):141–55

Topology of ATP-binding domain of adrenoleukodystrophy gene product in peroxisomes. Contreras M, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):369–79

Effect of ATP binding cassette/multidrug resistance proteins on ATP efflux of Saccharomyces cerevisiae. Boyum R, et al. **Biochem Biophys Res Commun** 1997 Jan 3;230(1):22–6

Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells. Chen ZS, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):586–90

Molecular cloning of a cDNA for the glutamate transporter of the nematode Caenorhabditis elegans. Kawano T, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):415–20

Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Kobayashi T, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):631–6

Evaluation of clinical and environmental anti-estrogens with human estrogen receptor expressed in Saccharomyces cerevisiae: a novel role for ABC-cassette transporters in mediating anti-estrogenic activity. Tran DQ, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):669–74

Interaction between ATP, oleandomycin and the OleB ATP-binding cassette transporter of Streptomyces antibioticus involved in oleandomycin secretion. Buche A, et al. **Biochem J** 1997 Jan 1;321 (Pt 1):139–44

Structure/function relationships in glutamate transporters. Kanner BI. **Biochem Soc Trans** 1996 Aug;24(3):843–6 (28 ref.)

Novel peptide-binding proteins and peptide transport in normal and TAP-deficient microsomes. Marusina K, et al. **Biochemistry** 1997 Jan 28;36(4):856–63

Structure and in vitro substrate specificity of the murine multidrug resistance-associated protein. Paul S, et al. **Biochemistry** 1996 Oct 22;35(42):13647–55

ATP-dependent transport of lipophilic cytotoxic drugs by membrane vesicles prepared from MRP-overexpressing HL60/ADR cells. Paul S, et al. **Biochemistry** 1996 Nov 5;35(44):14003–11

Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Heijn M, et al. **Biochim Biophys Acta** 1997 May 22;1326(1):12–22

Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas. Fillpits M, et al. **Br J Cancer** 1997;75(2):208–12

Assessment of intracellular TAP-1 and TAP-2 in conjunction with surface MHC class I in plasma cells from patients with multiple myeloma. Crucian BE, et al. **Br J Haematol** 1997 Aug;98(2):426–32

P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. Michieli M, et al. **Br J Haematol** 1997 Feb;96(2):356–65

Expression of mdr1 and mrp in the normal B-cell homologue of B-cell chronic lymphocytic leukaemia. Wall DM, et al. **Br J Haematol** 1997 Mar;96(4):697–707

Rat C6 and human astrocytic tumor cells express a neuronal type of glutamate transporter. Palos TP, et al. **Brain Res Mol Brain Res** 1996 Apr;37(1-2):297–303

Non P-glycoprotein novel proteins involved in human cancer multidrug resistance. Baggetto LG. **Bull Cancer** 1997 Apr; 84(4):385–90 (57 ref.)

The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Miller DW, et al. **Cancer Lett** 1996 Oct 22;107(2):301–6

Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Chan HS, et al. **Cancer Res** 1997 Jun 15; 57(12):2325–30

Differential expression of three glutamate transporter subtypes in the rat retina. Rauen T, et al. **Cell Tissue Res** 1996 Dec;286(3):325–36

ATP transport and ABC proteins. Guidotti G. **Chem Biol** 1996 Sep;3(9):703–6 (26 ref.)

Changing the transport of a cell. Prasad R. **Crit Rev Biotechnol** 1997;17(2):171–83 (37 ref.)

Rehearsing the ABCs. Protein translocation. Cleves AE, et al. **Curr Biol** 1996 Mar 1;6(3):276–8 (28 ref.)

Family of neutral and acidic amino acid transporters: molecular biology, physiology and medical implications. Kanai Y. **Curr Opin Cell Biol** 1997 Aug;9(4):565–72 (62 ref.)

The linker region of the ABC-transporter Ste6 mediates ubiquitination and fast turnover of the protein. Kölling R, et al. **EMBO J** 1997 May 1;16(9):2251–61

Protein secretion in gram-negative bacteria: assembly of the three components of ABC protein-mediated exporters is ordered and promoted by substrate binding. Létoffé S, et al. **EMBO J** 1996 Nov 1;15(21):5804–11

Subunit interactions in ABC transporters: a conserved sequence in hydrophobic membrane proteins of periplasmic permeases defines an important site of interaction with the ATPase subunits. Mourez M, et al. **EMBO J** 1997 Jun 2; 16(11):3066–77

Active efflux of the free acid form of the fluorescent dye 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein in multidrug-resistance-protein-overexpressing murine and human leukemia cells. Draper MP, et al. **Eur J Biochem** 1997 Jan 15;243(1-2):219–24

Neuronal and glial glutamate transporters possess an SH-based redox regulatory mechanism. Trotti D, et al. **Eur J Neurosci** 1997 Jun;9(6):1236–43

Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Seliger B, et al. **Exp Hematol** 1997 Jul;25(7):608–14

Schistosoma mansoni: L-glutamate-induced contractions in isolated muscle fibers; evidence for a glutamate transporter. Miller CL, et al. **Exp Parasitol** 1996 Dec;84(3):410–9

Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. Hooijberg JH, et al. **FEBS Lett** 1997 Aug 18;413(2):344–8

Aureobasidin A, an antifungal cyclic depsipeptide antibiotic, is a substrate for both human MDR1 and MDR2/P-glycoproteins. Kino K, et al. **FEBS Lett** 1996 Dec 9;399(1-2):29–32

The involvement of the Saccharomyces cerevisiae multidrug resistance transporters Pdr5p and Snq2p in cation resistance. Miyahara K, et al. **FEBS Lett** 1996 Dec 16; 399(3):317–20

Mutational analysis eliminates Glu64 and Glu94 as candidates for 'catalytic carboxylate' in the bacterial ATP-binding-cassette protein MalK. Stein A, et al. **FEBS Lett** 1997 Aug 18;413(2):211–4

Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). Taguchi Y, et al. **FEBS Lett** 1997 Jan 13;401(1):11–4

Characterization of the ATPase activity of the N-terminal nucleotide binding domain of an ABC transporter involved in oleandomycin secretion by Streptomyces antibioticus. Aparicio G, et al. **FEMS Microbiol Lett** 1996 Aug 1, 141(2-3):157–62

Is the CvaA protein, encoded within the colicin V export gene cvaA, required for colicin V transport? Skvirsky RC, et al. **FEMS Microbiol Lett** 1996 May 1;138(2-3):201–6

Evidence for an ATP-dependent bile acid transport protein other than the canalicular liver ecto-ATPase in rats. Luther TT, et al. **Gastroenterology** 1997 Jul;113(1):249–54

The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Trauner M, et al. **Gastroenterology** 1997 Jul;113(1):255–64

Protein secretion by Gram-negative bacterial ABC exporters--a review. Binet R, et al. **Gene** 1997 Jun 11; 192(1):7–11 (31 ref.)

The glial glutamate transporter in hyperammonemia and hepatic encephalopathy: relation to energy metabolism and glutamatergic neurotransmission. Norenberg MD, et al. **Glia** 1997 Sep;21(1):124–33

Glutamate transport and metabolism in astrocytes. Sonnewald U, et al. **Glia** 1997 Sep;21(1):56–63

Polysialic acid export in Escherichia coli K1: the role of KpsT, the ATP-binding component of an ABC transporter, in chain translocation. Bliss JM, et al. **Glycobiology** 1996 Jun;6(4):445–52

Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Sadasivan B, et al. **Immunity** 1996 Aug;5(2):103–14

Peptide selection for presentation by HLA class I: a role for the human transporter associated with antigen processing? van Endert PM. **Immunol Res** 1996; 15(4):265–79 (34 ref.)

TAP off--tumors on. Seliger B, et al. **Immunol Today** 1997 Jun;18(6):292–9 (96 ref.)

Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. Berger W, et al. **Int J Cancer** 1997 Mar 28;71(1):108–15

Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. Perez-Soler R, et al. **Int J Cancer** 1997 Mar 28;71(1):35–41

Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Thor Straten P, et al. **Int J Cancer** 1997 Mar 4;70(5):582–6

Lipase secretion by bacterial hybrid ATP-binding cassette exporters: molecular recognition of the LipBCD, PrtDEF, and HasDEF exporters. Akatsuka H, et al. **J Bacteriol** 1997 Aug;179(15):4754–60

Evidence that KpsT, the ATP-binding component of an ATP-binding cassette transporter, is exposed to the periplasm and associates with polymer during translocation of the polysialic acid capsule of Escherichia coli K1. Bliss JM, et al. **J Bacteriol** 1997 Feb;179(4):1400–3

Use of heme reporters for studies of cytochrome biosynthesis and heme transport. Goldman BS, et al. **J Bacteriol** 1996 Nov;178(21):6338–47

Expression and characterization of DrrA and DrrB proteins of Streptomyces peucetius in Escherichia coli: DrrA is an ATP binding protein. Kaur P. **J Bacteriol** 1997 Feb; 179(3):569–75

Identification and functional characterization of an ABC transport system involved in polysaccharide export of A-band lipopolysaccharide in Pseudomonas aeruginosa. Rocchetta HL, et al. **J Bacteriol** 1997 Aug;179(15):4713–24

Functional and physical interactions between partial molecules of STE6, a yeast ATP-binding cassette protein. Berkower C, et al. **J Biol Chem** 1996 Sep 20; 271(38):22983–9

Brain glutamate transporter proteins form homomultimers. Haugeto O, et al. **J Biol Chem** 1996 Nov 1;271(44):27715–22

Membrane topology of the multidrug resistance protein (MRP). A study of glycosylation–site mutants reveals an extracytosolic NH2 terminus. Hipfner DR, et al. **J Biol Chem** 1997 Sep 19;272(38):23623–30

The 220–kDa rim protein of retinal rod outer segments is a member of the ABC transporter superfamily. Illing M, et al. **J Biol Chem** 1997 Apr 11;272(15):10303–10

Mutation of an amino acid residue influencing potassium coupling in the glutamate transporter GLT–1 induces obligate exchange. Kavanaugh MP, et al. **J Biol Chem** 1997 Jan 17;272(3):1703–8

Anticancer drugs, ionophoric peptides, and steroids as substrates of the yeast multidrug transporter Pdr5p. Kolaczkowski M, et al. **J Biol Chem** 1996 Dec 6; 271(49):31543–8

Characterization of the adenosine triphosphatase activity of the periplasmic histidine permease, a traffic ATPase (ABC transporter). Liu CE, et al. **J Biol Chem** 1997 Aug 29; 272(35):21883–91

The ATP binding cassette transporters Pdr5 and Snq2 of Saccharomyces cerevisiae can mediate transport of steroids in vivo. Mahé Y, et al. **J Biol Chem** 1996 Oct 11; 271(41):25167–72

A yeast ATP–binding cassette–type protein mediating ATP–dependent bile acid transport. Ortiz DF, et al. **J Biol Chem** 1997 Jun 13;272(24):15358–65

Hepatocellular ATP–binding cassette protein expression enhances ATP release and autocrine regulation of cell volume. Roman RM, et al. **J Biol Chem** 1997 Aug 29; 272(35):21970–6

Processing of colicin V–1, a secretable marker protein of a bacterial ATP binding cassette export system, requires membrane integrity, energy, and cytosolic factors. Zhong X, et al. **J Biol Chem** 1996 Nov 8;271(45):28057–63

Prominence of beta 2–microglobulin, class I heavy chain conformation, and tapasin in the interactions of class I heavy chain with calreticulin and the transporter associated with antigen processing. Solheim JC, et al. **J Immunol** 1997 Mar 1;158(5):2236–41

Molecular and immunological analysis of an ABC transporter complex required for cytochrome c biogenesis. Goldman BS, et al. **J Mol Biol** 1997 May 16;268(4):724–38

Elevated venous glutamate levels in (pre)catabolic conditions result at least partly from a decreased glutamate transport activity. Hack V, et al. **J Mol Med** 1996 Jun;74(6):337–43

Alterations in glutamate transporter protein levels in kindling–induced epilepsy. Miller HP, et al. **J Neurochem** 1997 Apr;68(4):1564–70

Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. Li S, et al. **J Neuropathol Exp Neurol** 1997 Aug;56(8):901–11

Glutamate–gated chloride channel with glutamate–transporter–like properties in cone photoreceptors of the tiger salamander. Picaud SA, et al. **J Neurophysiol** 1995 Oct;74(4):1760–71

Quantitative analysis of binding protein–mediated ABC transport systems. Bohl E, et al. **J Theor Biol** 1997 May 7;186(1):65–74

Peptide transporter (TAP–1 and TAP–2)–independent endogenous processing of Epstein–Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T–lymphocyte control of EBV–associated malignancies. Khanna R, et al. **J Virol** 1996 Aug;70(8):5357–62

Substrate binding sites of glutamate transporters and structurally related neutral amino acid transporters. Kanai Y. **Jpn J Physiol** 1997;47 Suppl 1:S55–6

Multidrug resistance in recurrent breast cancer [letter] Nooter K, et al. **Lancet** 1997 Jun 28; 349(9069):1885–6

Multidrug resistance in leukemias and its reversal. Malayeri R, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):451–8 (89 ref.)

Sequence requirements for membrane assembly of polytopic membrane proteins: molecular dissection of the membrane insertion process and topogenesis of the human MDR3 P–glycoprotein. Zhang JT. **Mol Biol Cell** 1996 Nov; 7(11):1709–21

The Schizosaccharomyces pombe mam1 gene encodes an ABC transporter mediating secretion of M–factor. Christensen PU, et al. **Mol Gen Genet** 1997 Jun; 255(2):226–36

Genetically probing the regions of ribose–binding protein involved in permease interaction. Eym Y, et al. **Mol Microbiol** 1996 Aug;21(4):695–702

A TonB–like protein and a novel membrane protein containing an ATP–binding cassette function together in exotoxin secretion. Howard SP, et al. **Mol Microbiol** 1996 Nov;22(4):595–604

An oligopeptide permease responsible for the import of an extracellular signal governing aerial mycelium formation in Streptomyces coelicolor. Nodwell JR, et al. **Mol Microbiol** 1996 Dec;22(5):881–93

A putative helical domain in the MalK subunit of the ATP–binding–cassette transport system for maltose of Salmonella typhimurium (MalFGK2) is crucial for interaction with MalF and MalG. A study using the LacK protein of Agrobacterium radiobacter as a tool. Wilken S, et al. **Mol Microbiol** 1996 Nov;22(4):655–66

ATP–dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Loe DW, et al. **Mol Pharmacol** 1997 Jun;51(6):1034–41

Flux coupling in a neuronal glutamate transporter. Zerangue N, et al. **Nature** 1996 Oct 17;383(6601):634–7

Expression of the adrenoleukodystrophy protein in the human and mouse central nervous system. Fouquet F, et al. **Neurobiol Dis** 1997;3(4):271–85

Protease inhibitors suppress the degradation of mutant adrenoleukodystrophy proteins but do not correct impairment of very long chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. Yamada T, et al. **Neurochem Res** 1997 Mar;22(3):233–7

ALS–linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1–containing inclusions. Bruijn LI, et al. **Neuron** 1997 Feb;18(2):327–38

EAAT4 is a post–synaptic glutamate transporter at Purkinje cell synapses. Yamada K, et al. **Neuroreport** 1996 Aug 12; 7(12):2013–7

Autoradiographic studies indicate regional variations in the characteristics of L–glutamate transporters in the rat brain. Killinger S, et al. **Neurosci Lett** 1996 Sep 27;216(2):101–4

Immunocytochemical localization of the high–affinity glutamate transporter, EAAC1, in the retina of representative vertebrate species. Schultz K, et al. **Neurosci Lett** 1996 Jun 28;211(3):191–4

Changes in expression and distribution of the glutamate transporter EAAT4 in developing mouse Purkinje cells. Yamada K, et al. **Neurosci Res** 1997 Mar;27(3):191–8

Hypotonicity–induced anion fluxes in cells expressing the multidrug–resistance–associated protein, MRP. Hainsworth AH, et al. **Pflugers Arch** 1996 Jun;432(2):234–40

Effect of charge on oligopeptide transporter–mediated permeation of cyclic dipeptides across Caco–2 cell monolayers. Tamura K, et al. **Pharm Res** 1996 Nov; 13(11):1752–4

Arachidonic acid inhibits 3H–glutamate uptake with different potencies in rodent central nervous system regions expressing different transporter subtypes. Manzoni C, et al. **Pharmacol Res** 1997 Feb;35(2):149–51

A Saccharomyces cerevisiae homolog of the human adrenoleukodystrophy transporter is a heterodimer of two half ATP–binding cassette transporters. Shani N, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11901–6

Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. Uebel S, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):8976–81

Deglucosylation of N–linked glycans is an important step in the dissociation of calreticulin–class I–TAP complexes. van Leeuwen JE, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13997–4001

Association of spindle assembly checkpoint component XMAD2 with unattached kinetochores. Chen RH, et al. **Science** 1996 Oct 11;274(5285):242–6

A critical role for tapasin in the assembly and function of multimeric MHC class I–TAP complexes. Ortmann B, et al. **Science** 1997 Aug 29;277(5330):1306–9

Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT–1. Tanaka K, et al. **Science** 1997 Jun 13;276(5319):1699–702

PHARMACOKINETICS

ABC1, an ATP binding cassette transporter required for phagocytosis of apoptotic cells, generates a regulated anion flux after expression in Xenopus laevis oocytes. Becq F, et al. **J Biol Chem** 1997 Jan 31;272(5):2695–9

PHARMACOLOGY

The ER–luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Ahn K, et al. **Immunity** 1997 May;6(5):613–21

A glutamate–elicited chloride current with transporter–like properties in rod photoreceptors of the tiger salamander. Grant GB, et al. **Vis Neurosci** 1996 Jan–Feb;13(1):135–44

PHYSIOLOGY

Transporter associated with antigen processing. Elliott T. **Adv Immunol** 1997;65:47–109 (215 ref.)

An S. cerevisiae peroxisomal transporter, orthologous to the human adrenoleukodystrophy protein, appears to be a heterodimer of two half ABC transporters: Pxa1p and Pxa2p. Shani N, et al. **Ann N Y Acad Sci** 1996 Dec 27; 804:770–2

Functional interactions between synthetic alkyl phospholipids and the ABC transporters P–glycoprotein, Ste–6, MRP, and Pgh 1. Ruetz S, et al. **Biochemistry** 1997 Jul 1;36(26):8180–8

Multidrug resistance associated with overexpression of MRP. Cole SP, et al. **Cancer Treat Res** 1996;87:39–62 (97 ref.)

MDR1 P–glycoprotein is a lipid translocase of broad specificity, while MDR3 P–glycoprotein specifically translocates phosphatidylcholine. van Helvoort A, et al. **Cell** 1996 Nov 1;87(3):507–17

The ABCs of ATP–sensitive potassium channels: more pieces of the puzzle. Bryan J, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):553–9 (44 ref.)

Intracellular location, complex formation, and function of the transporter associated with antigen processing in yeast. Urlinger S, et al. **Eur J Biochem** 1997 Apr 15;245(2):266–72

TAP–dependent major histocompatibility complex class I presentation of soluble proteins using listeriolysin. Darji A, et al. **Eur J Immunol** 1997 Jun;27(6):1353–9

The endoplasmic reticulum–resident stress protein gp96 binds peptides translocated by TAP. Lammert E, et al. **Eur J Immunol** 1997 Apr;27(4):923–7

Constitutive macropinocytosis allows TAP–dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow–derived dendritic cells. Norbury CC, et al. **Eur J Immunol** 1997 Jan;27(1):280–8

Major histocompatibility complex class I presentation of ovalbumin peptide 257–264 from exogenous sources: protein context influences the degree of TAP–independent presentation. Wick MJ, et al. **Eur J Immunol** 1996 Nov; 26(11):2790–9

Hepatic canalicular membrane 1: The role of mdr2 P–glycoprotein in hepatobiliary lipid transport. Elferink RP, et al. **FASEB J** 1997 Jan;11(1):19–28 (59 ref.)

Transmembrane translocation of phosphatidylcholines and biliary lipid secretion: evidence for "flippases" in the canalicular plasma membrane [published erratum appears in Hepatology 1997 Feb;25(2):505] Fuchs M, et al. **Hepatology** 1996 Dec;24(6):1546–8

ABC1, an ATP binding cassette transporter required for phagocytosis of apoptotic cells, generates a regulated anion flux after expression in Xenopus laevis oocytes. Becq F, et al. **J Biol Chem** 1997 Jan 31;272(5):2695–9

Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P–glycoprotein or MRP overexpression. Lee JS, et al. **J Cell Biochem** 1997 Jun 15;65(4):513–26

Role of the ABC transporter Ste6 in cell fusion during yeast conjugation. Elia L, et al. **J Cell Biol** 1996 Nov; 135(3):741–51

The role of glutamate transporters in glutamate homeostasis in the brain. Takahashi M, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):401–9 (51 ref.)

Influences of transporter associated with antigen processing (TAP) on the repertoire of peptides associated with the endoplasmic reticulum–resident stress protein gp96. Arnold D, et al. **J Exp Med** 1997 Aug 4;186(3):461–6

Role of multidrug resistance protein (MRP) in glutathione S–conjugate transport in mammalian cells. Müller M, et al. **J Hepatol** 1996;24 Suppl 1:100–8 (123 ref.)

The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)–dependent and TAP–independent peptide epitopes by class I molecules. Bai A, et al. **J Immunol** 1997 Sep 1;159(5):2139–46

Human peptide transporter deficiency: importance of HLA–B in the presentation of TAP–independent EBV antigens. de la Salle H, et al. **J Immunol** 1997 May 15; 158(10):4555–63

Leukotriene C4 secretion from normal murine mast cells by a probenecid–sensitive and multidrug resistance–associated protein–independent mechanism. Nguyen T, et al. **J Immunol** 1997 May 15;158(10):4916–20

Down–regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL–10. Salazar–Onfray F, et al. **J Immunol** 1997 Oct 1;159(7):3195–202

Spread of measles virus through axonal pathways into limbic structures in the brain of TAP1 –/– mice. Urbanska EM, et al. **J Med Virol** 1997 Aug;52(4):362–9

Multidrug resistance–associated protein (MRP) in haematological malignancies. Nooter K, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):381–7 (34 ref.)

A novel a–factor–related peptide of Saccharomyces cerevisiae that exits the cell by a Ste6p–independent mechanism. Chen P, et al. **Mol Biol Cell** 1997 Jul; 8(7):1273–91

Pharmacological characterization of the murine and human orthologs of multidrug–resistance protein in transfected human embryonic kidney cells. Stride BD, et al. **Mol Pharmacol** 1997 Sep;52(3):344–53

Discrete cellular and subcellular localization of glutamine synthetase and the glutamate transporter GLAST in the rat vestibular end organ. Takumi Y, et al. **Neuroscience** 1997 Aug;79(4):1137–44

Functional analysis of the nucleotide binding domains of the multidrug resistance protein (MRP). Zhu Q, et al. **Oncol Res** 1997;9(5):229–36

The Dr1/DRAP1 heterodimer is a global repressor of transcription in vivo. Kim S, et al. **Proc Natl Acad Sci U S A** 1997 Feb 4;94(3):820–5

Hepatocellular transport: role of ATP–binding cassette proteins. Lomri N, et al. **Semin Liver Dis** 1996 May; 16(2):201–10 (112 ref.)

Secretion of organic anions by hepatocytes: involvement of homologues of the multidrug resistance protein. Müller M, et al. **Semin Liver Dis** 1996 May;16(2):211–20 (137 ref.)

[Glutamate transporter and neuronal cell death] Kawakami H, et al. **Rinsho Shinkeigaku** 1996 Dec;36(12):1316–7 (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Discrete cellular and subcellular localization of glutamine synthetase and the glutamate transporter GLAST in the rat vestibular end organ. Takumi Y, et al. **Neuroscience** 1997 Aug;79(4):1137–44

ABDOMEN

Use of abdominal compression as an aid to CT–guided

retroperitoneal biopsies [letter] de Kerviler E, et al. **AJR Am J Roentgenol** 1996 Nov;167(5):1346–7

Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice. Abate N, et al. **Am J Clin Nutr** 1997 Feb;65(2):403–8

Re: "Sex-specific associations of magnetic resonance imaging-derived intra-abdominal and subcutaneous fat areas with conventional anthropometric indices: the Atherosclerosis in Communities Study" [letter; comment] Kahn HS. **Am J Epidemiol** 1997 Jan 1;145(1):83–4. Comment on: Am J Epidemiol 1996 Aug 15;144(4):335–45.

Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Chang DC, et al. **Am J Surg** 1997 Sep;174(3):284–90

Antimicrobial therapy for intraabdominal infection. Nathens AB, et al. **Am J Surg** 1996 Dec;172(6A):1S–6S (27 ref.)

Pancreas graft loss caused by intra-abdominal infection. A risk factor for a subsequent pancreas retransplantation. Benedetti E, et al. **Arch Surg** 1996 Oct;131(10):1054–60

Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group. Christou NV, et al. **Arch Surg** 1996 Nov;131(11):1193–201

The relation between fetal abdominal circumference and birthweight: findings in 3512 pregnancies. Smith GC, et al. **Br J Obstet Gynaecol** 1997 Feb;104(2):186–90

The abdominal compartment syndrome. Nathens AB, et al. **Can J Surg** 1997 Aug;40(4):254–8 (23 ref.)

Late presentation of an intra-abdominal foreign body [see comments] Quantz MA, et al. **Can J Surg** 1997 Aug; 40(4):305–7. Comment in: Can J Surg 1997 Aug;40(4):249–50.

Leave no stone unturned [editorial; comment] Stoller JL. **Can J Surg** 1997 Aug;40(4):249–50. Comment on: Can J Surg 1997 Aug;40(4):300–4. Comment on: Can J Surg 1997 Aug;40(4):305–7.

Percutaneous retrieval of a retained Jackson-Pratt drain fragment. Namyslowski J, et al. **Cardiovasc Intervent Radiol** 1996 Nov-Dec;19(6):446–8

The association of cardiovascular disease risk factors with abdominal obesity in Canada. Canadian Heart Health Surveys Research Group. Reeder BA, et al. **CMAJ** 1997 Jul 1;157 Suppl 1:S39–45

Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease? Kissebah AH. **Diabetes Res Clin Pract** 1996 Feb;30 Suppl:25–30 (37 ref.)

Isolate abdominal bronchogenic cyst: a case report. Cetinkurşun S, et al. **Eur J Pediatr Surg** 1997 Apr; 7(2):103–5 (12 ref.)

Duration of antibiotic treatment in surgical infections of the abdomen. Introduction—the different ways to reach consensus. Lorenz W, et al. **Eur J Surg Suppl** 1996;(576):5–8

Antibiotics for prophylaxis and treatment of intra-abdominal infections. Michalopoulos A, et al. **Hepatogastroenterology** 1997 Jul-Aug;44(16):947–58 (76 ref.)

Surgical treatment of severe intra-abdominal infection. van Goor H. **Hepatogastroenterology** 1997 Jul-Aug; 44(16):975–81 (90 ref.)

Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. Hube F, et al. **Horm Metab Res** 1996 Dec;28(12):690–3

Intra-abdominal adipose tissue, physical activity and cardiovascular risk in pre- and post-menopausal women. Hunter GR, et al. **Int J Obes Relat Metab Disord** 1996 Sep;20(9):860–5

Insulin and glucagon responses to adrenaline infusion in abdominal obese men. Mauriège P, et al. **Int J Obes Relat Metab Disord** 1996 Jul;20(7):668–76

The reallocation of body fat toward the abdomen persists to very old age, while body mass index declines after middle age in Chinese. Teh BH, et al. **Int J Obes Relat Metab Disord** 1996 Jul;20(7):683–7

Intra-abdominal adipose tissue cut-points related to elevated cardiovascular risk in women. Williams MJ, et al. **Int J Obes Relat Metab Disord** 1996 Jul;20(7):613–7

Simulation of ultrasonic pulse propagation through the abdominal wall. Mast TD, et al. **J Acoust Soc Am** 1997 Aug;102(2 Pt 1):1177–90

Comparison of the enzyme activities between the thickest and the thinnest parts of the abdominal pannus. Cazes L, et al. **J Am Coll Nutr** 1997 Aug;16(4):341–5

Abdominal fat determines growth hormone-binding protein levels in healthy nonobese adults. Fisker S, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):123–8

Epidemiology and clinical presentation of abdominal tuberculosis—a retrospective study. Sircar S, et al. **J Indian Med Assoc** 1996 Sep;94(9):342–4

The subcutaneous spleen: a new model for percutaneous access to the portal venous system. Brandt ML, et al. **J Invest Surg** 1996 May-Jun;9(3):161–6

Fast MR imaging techniques: impact in the abdomen. Mitchell DG. **J Magn Reson Imaging** 1996 Sep-Oct; 6(5):812–21 (87 ref.)

Rational antibiotic therapy for intra-abdominal infections. Quinn JP. **Lancet** 1997 Feb 22;349(9051):517–8

Frequency of extra-cardiac activity and its effect on 99Tcm-MIBI cardiac SPET interpretation. Rehm PK, et al. **Nucl Med Commun** 1996 Oct;17(10):851–6

Controversies in abdominal imaging. Morrison SC. **Pediatr Clin North Am** 1997 Jun;44(3):555–74 (70 ref.)

Bilateral abdominal aplasia cutis congenita associated with atrial septal defect: a case report. Tekinalp G, et al. **Pediatr Dermatol** 1997 Mar-Apr;14(2):117–9

Extraperitoneal abdominopelvic inflammatory pseudotumor: report of four cases. Jimenez JM, et al. **Pediatr Radiol** 1997 Feb;27(2):170–4

Intra-abdominal manifestations of AIDS. Redvanly RD, et al. **Radiol Clin North Am** 1997 Sep;35(5):1083–125 (148 ref.)

Effect of the rate of gadopentetate dimeglumine administration on abdominal vascular and soft-tissue MR imaging enhancement patterns. Strouse PJ, et al. **Radiology** 1996 Dec;201(3):809–16

Sex differences in cardiovascular risk factors independent of abdominal fat distribution. Nilsson P, et al. **Scand J Prim Health Care** 1996 Sep;14(3):177–83

Clinics in diagnostic imaging (19). Acute respiratory distress syndrome (ARDS) secondary to intra-abdominal sepsis [published erratum appears in Singapore Med J 1997 Feb;38(2):53] Ho ET, et al. **Singapore Med J** 1996 Dec; 37(6):653–7

The abdominal drain. A convenient port for second-look laparoscopy. Nassar AH, et al. **Surg Endosc** 1996 Nov; 10(11):1114–5

Umbilical sinus tract with gallstone extrusion after laparoscopic cholecystectomy. Pohl D, et al. **Surg Endosc** 1997 Aug;11(8):846–7

The effects of sterile or infected bile and dropped gallstones in abdominal adhesions and abscess formation. Soybir GR, et al. **Surg Endosc** 1997 Jul;11(7):711–3

Abdominal imaging in the diagnosis of portal hypertension. Das K, et al. **Trop Gastroenterol** 1997 Jan-Mar;18(1):7–12 (26 ref.)

Bilateral perinephric urinomas. Thibault G, et al. **Urology** 1997 Jul;50(1):120

[A case of heterotopic abdominal echinococcosis] Genchev G, et al. **Khirurgiia (Sofiia)** 1996;49(5):37–8 **(Bul)**

[Abdominopelvic actinomycosis. Apropos of 2 clinical cases] Kron C, et al. **Chirurgie** 1996;121(5):346–8; discussion 349 (Eng. Abstr.) **(Fre)**

[Abdomen, digestive tract] Pradel J, et al. **J Radiol** 1997 Mar; 78(3 Suppl):23–6 **(Fre)**

[Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study] Tonelli F. **Minerva Chir** 1997 Mar;52(3):317–26 (Eng. Abstr.) **(Ita)**

[Abdominal compartment syndrome] Solheim K. **Tidsskr Nor Laegeforen** 1996 Nov 10;116(27):3209–10 **(Nor)**

[A case of a foreign body—surgical linen left in the abdominal cavity 25 years earlier] Emerich J, et al. **Ginekol Pol** 1996 May;67(5):274–6 (Eng. Abstr.) **(Pol)**

[The study of drug resistance in aerobic and anaerobic bacterial flora to selected antibacterial drugs] Michalska W, et al. **Med Dosw Mikrobiol** 1996;48(1-2):61–70 (Eng. Abstr.) **(Pol)**

[Severe multiple trauma in a victim during the 3d trimester of pregnancy with traumatic delivery into the abdominal cavity] Baramiia NN, et al. **Klin Khir** 1996;(6):47–8 **(Rus)**

[Treatment of intra-abdominal hydatidosis with albendazole (letter)] Martínez G, et al. **Gastroenterol Hepatol** 1996 Dec; 19(10):542–3 **(Spa)**

[Intra-abdominal and surgical wound infections in liver transplant recipients] Lumbreras Bermejo C, et al. **Rev Clin Esp** 1995 Oct;195 Spec No:14–8 **(Spa)**

[Prolonged stay of intrauterine spiral in the abdominal cavity] Baev OO, et al. **Klin Khir** 1996;(8):52 **(Ukr)**

[Manual therapy of the abdomen and its effect on the homeostatic system of the human body] Miahkov IH, et al. **Lik Sprava** 1996 Oct-Dec;(10-12):129–31 **(Ukr)**

ABNORMALITIES

Failure to detect connexin43 mutations in 38 cases of sporadic and familial heterotaxy. Gebbia M, et al. **Circulation** 1996 Oct 15;94(8):1909–12

Effects of estrogenic hormones on early development of Xenopus laevis. Nishimura N, et al. **J Exp Zool** 1997 Jul 1;278(4):221–33

ANATOMY & HISTOLOGY

The abdominal diameter index and sudden coronary death in men. Kahn HS, et al. **Am J Cardiol** 1996 Oct 15; 78(8):961–4

Abdominal SPECT/MRI fusion applied to the study of splenic and hepatic uptake of radiolabeled thrombocytes and colloids. Pohjonen HK, et al. **Ann Nucl Med** 1996 Nov; 10(4):409–17

Geometric and inertial data of the trunk in adult males. Erdmann WS. **J Biomech** 1997 Jul;30(7):679–88

A revised anatomical model of the abdominal musculature for torso flexion efforts. McGill SM. **J Biomech** 1996 Jul; 29(7):973–7

Abdominal fat distribution and insulin levels only partially explain adverse cardiovascular risk profile in Asian Indians. Hodge AM, et al. **J Cardiovasc Risk** 1996 Jun;3(3):263–70

Long-term testosterone administration increases visceral fat in female to male transsexuals. Elbers JM, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2044–7

Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated GH secretion in healthy adults. Vahl N, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2209–15

Implementation of a reduced field-of-view method for dynamic MR imaging using navigator echoes. Kyriakos WE, et al. **J Magn Reson Imaging** 1997 Mar-Apr; 7(2):376–81

Recent technical advances in MR imaging of the abdomen. Riederer SJ. **J Magn Reson Imaging** 1996 Sep-Oct; 6(5):822–32 (59 ref.)

Abdominal circumference contributes to absence of wasting in Brazilian children. César JA, et al. **J Nutr** 1996 Nov; 126(11):2752–6

Breathhold imaging of the upper abdomen using a circular polarized-array coil: comparison with standard body coil imaging. Gauger J, et al. **MAGMA** 1996 Jun;4(2):93–104

RARE spiral T2-weighted imaging. Block W, et al. **Magn Reson Med** 1997 Apr;37(4):582–90

Calming the newborn tummy. Mott-Smith M. **Nurse Pract** 1997 Feb;22(2):162

Laparoscopic abdominal anatomy of foals positioned in dorsal recumbency. Bouré L, et al. **Vet Surg** 1997 Jan-Feb; 26(1):1–6

[Measure of abdominal cavity volumes by gynecologic laparoscopy] Jambon AC, et al. **Contracept Fertil Sex** 1997 May;25(5):VI–XII **(Fre)**

BLOOD SUPPLY

Spiral CT angiography of the abdomen and pelvis: interventional applications. Brink JA. **Abdom Imaging** 1997 Jul-Aug;22(4):365–72 (26 ref.)

Spiral CT angiography of the abdomen. Prokop M, et al. **Abdom Imaging** 1997 Mar-Apr;22(2):143–53

Effect of iomeprol on renal function immediately after abdominal angiography. Murakami R, et al. **Acta Radiol** 1996 Nov;37(6):962–5

Peripancreatic veins on thin-section (3 mm) helical CT. Ibukuro K, et al. **AJR Am J Roentgenol** 1996 Oct; 167(4):1003–8

Reflex vascular responses to abdominal venous distension in the anesthetized dog. Doe CP, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1049–56

Spatiotemporal aspects of sympathetic C-fiber afferent activity in pressor reflex during abdominal ischemia. Pan HL, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1928–36

Anatomical study of the abdominal arterial system in soricids (Insectivora, Mammalia): functional and phylogenetic implications. López-Fuster MJ, et al. **Anat Rec** 1997 May; 248(1):142–7

Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Summers LK, et al. **Clin Sci (Colch)** 1996 Dec;91(6):679–83

Cigarette smoking, abdominal blood flow and abdominal diseases [editorial; comment] Bolondi L, et al. **J Gastroenterol Hepatol** 1996 Nov;11(11):995–6. Comment on: J Gastroenterol Hepatol 1996 Nov;11(11):997–1000.

MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. Anzai Y, et al. **J Magn Reson Imaging** 1997 Jan-Feb;7(1):209–14

Abdominal phase-contrast MR angiography: breath-hold versus non-breath-hold techniques. Hara AK, et al. **J Magn Reson Imaging** 1996 Jan-Feb;6(1):94–8

Abdominal vascular injuries. Carrillo EH, et al. **J Trauma** 1997 Jul;43(1):164–71 (66 ref.)

Contrast-enhanced abdominal MR angiography: optimization of imaging delay time by automating the detection of contrast material arrival in the aorta. Prince MR, et al. **Radiology** 1997 Apr;203(1):109–14

Low-dose hypertonic saline (NaCl 8.0%) treatment of uncontrolled abdominal hemorrhage: effects on arterial versus venous injury. Elgjo GI, et al. **Shock** 1996 Jan; 5(1):52–8

Color-coded Doppler sonography in the diagnosis of abdominal masses. Fiechtner H, et al. **Urol Int** 1996; 56(3):184–7

A review of sonographic identification of abdominal blood vessels and juxtavascular organs. Spaulding KA. **Vet Radiol Ultrasound** 1997 Jan-Feb;38(1):4–23 (18 ref.)

[MR angiography: abdominal veins] Arlart IP. **Radiologe** 1997 Jul;37(7):554–65 (48 ref.) (Eng. Abstr.) **(Ger)**

[Gadolinium-enhanced magnetic resonance angiography of abdominal blood vessels] Stehling MK, et al. **Radiologe** 1997 Jul;37(7):539–46 (Eng. Abstr.) **(Ger)**

[A successful case of infrarenal abdominal aortic replacement against acute abdominal organ failures and ischemia of bilateral lower limbs following the operation of DeBakey IIIb-type dissecting aneurysm] Gu K, et al. **Kyobu Geka** 1996 Dec;49(13):1100–3 (Eng. Abstr.) **(Jpn)**

[Standardization of use of 4-F size catheter for selective transcatheter angiography and intervention of abdomen] Kiyosue H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jan;56(1):32–6 (Eng. Abstr.) **(Jpn)**

EMBRYOLOGY

Fetal abdominal protuberance ratio throughout pregnancy. Morales-Roselló J, et al. **Arch Gynecol Obstet** 1996; 259(1):13–7

Refined fetal abdominal growth assessment in normal pregnancy: Part I. Abdominal anteroposterior diameter. Yu CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Mar;

59(3):164–70

INJURIES see ABDOMINAL INJURIES

INNERVATION

Spatiotemporal aspects of sympathetic C-fiber afferent activity in pressor reflex during abdominal ischemia. Pan HL, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1928–36

Effect of feedback from peripheral movements on neuron activity in the aplysia abdominal ganglion. Höpp HP, et al. **Eur J Neurosci** 1996 Sep;8(9):1865–72

Anatomy and targets of Dorsal Unpaired Median neurones in the Terminal Abdominal Ganglion of the male cockroach Periplaneta americana L. Sinakevitch IG, et al. **J Comp Neurol** 1996 Mar 25;367(1):147–63

Estimation of the size and directional output of functional groups of interneurons underlying abdominal positioning behaviors in crayfish. Brewer LD, et al. **J Exp Zool** 1997 Jun 15;278(3):119–32

Effects of area postrema lesion and abdominal vagotomy on interleukin-1 beta-induced norepinephrine release in the hypothalamic paraventricular nucleus region in the rat. Ishizuka Y, et al. **Neurosci Lett** 1997 Feb 14;223(1):57–60

Effects of talipexole on emesis-related changes in abdominal afferent vagal activity and ileal serotonin metabolism in rats. Minami M, et al.
Res Commun Mol Pathol Pharmacol 1997 Jan;95(1):67–82

MICROBIOLOGY

Microbiology of intraabdominal infection and contamination. Condon RE. **Eur J Surg Suppl** 1996;(576):9–12

A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. Angerås MH, et al.
Scand J Infect Dis 1996;28(5):513–8

Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group. Brismar B, et al.
Scand J Infect Dis 1996;28(5):507–12

Superoxide radical scavenging prevents cellular calcium dysregulation during intraabdominal sepsis. Rose S, et al. **Shock** 1997 Apr;7(4):263–8

Bacterial culturing of ventral median celiotomies for prediction of postoperative incisional complications in horses. Ingle-Fehr JE, et al. **Vet Surg** 1997 Jan–Feb; 26(1):7–13

PARASITOLOGY

Ectopic locations of Taenia saginata asiatica cysticerci in the abdominal cavity of domestic pig and monkey. Chung WC, et al. **J Parasitol** 1996 Dec;82(6):1032–4

Diagnostic exercise: abdominal parasites in a spider monkey. Baker DG, et al. **Lab Anim Sci** 1996 Jun;46(3):338–40 (11 ref.)

PATHOLOGY

Abdominal and pelvic applications of opposed-phase MR imaging. Earls JP, et al. **AJR Am J Roentgenol** 1997 Oct; 169(4):1071–7

Perfusion-weighted MR imaging in the upper abdomen: preliminary clinical experience in 61 patients. Ichikawa T, et al. **AJR Am J Roentgenol** 1997 Oct;169(4):1061–6

Optimization of sequences for MRI of the abdomen and pelvis. Lomas DJ. **Clin Radiol** 1997 Jun;52(6):412–28 (78 ref.)

Abdominal dissemination of malignant cells with hysteroscopy. Egarter C, et al. **Gynecol Oncol** 1996 Oct; 63(1):143–4

Nodular intra-abdominal panniculitis: an accompaniment of colorectal carcinoma and diverticular disease. Bak M. **Histopathology** 1996 Jul;29(1):21–7

Intra-abdominal fat, lipid metabolism and insulin resistance in coronary artery disease. Kawamoto T, et al.
Hypertens Res 1996 Jun;19 Suppl 1:S69–74

Simple method for necropsy dissection of the abdominal organs after abdominal surgery. Culora GA, et al.
J Clin Pathol 1996 Sep;49(9):776–9

Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. Sugerman H, et al. **J Intern Med** 1997 Jan;241(1):71–9

HASTE MR imaging: description of technique and preliminary results in the abdomen. Semelka RC, et al. **J Magn Reson Imaging** 1996 Jul–Aug;6(4):698–9

Blind-ending ureteral duplication: cause of asymptomatic abdominal mass. Klein FA, et al. **J Pediatr Surg** 1997 Apr; 32(4):654–5

Diagnostic exercise: abdominal distension and icterus in a spontaneous dwarf rat. Hamlen HJ, et al. **Lab Anim Sci** 1996 Oct;46(5):561–4

High-density oral barium sulfate in abdominal MRI: efficacy and tolerance in a clinical setting. Burton SS, et al.
Magn Reson Imaging 1997;15(2):147–53

Line scan diffusion imaging. Gudbjartsson H, et al.
Magn Reson Med 1996 Oct;36(4):509–19

Errors and pitfalls in diagnostic cytology of abdominal organs. Silverman JF. **Monogr Pathol** 1997;(39):147–70 (107 ref.)

Effect of high sucrose feeding on fat accumulation in the male Wistar rat. Toida S, et al. **Obes Res** 1996 Nov; 4(6):561–8

Fast MR imaging of abdomen: application of the QD body coil and low refocusing flip angle. Nitatori T, et al.
Radiat Med 1995 Nov–Dec;13(6):285–9

Invasive cytology of internal organs. Cytology of the thorax and abdomen. Burkhard MJ, et al.
Vet Clin North Am Small Anim Pract 1996 Sep; 26(5):1203–22 (28 ref.)

Abdominal distension in a cat [letter] Hibbert S. **Vet Rec** 1997 Jul 12;141(2):56

Abdominal distension in a cat [letter] Walsh G. **Vet Rec** 1997 Aug 16;141(7):180

Abdominal distension in a cat [letter] Yates D, et al.
Vet Rec 1997 Jul 5;141(1):27

[Effect of diagnostic imaging on pre-mortem diagnostic reliability] Schölmerich J, et al. **Med Klin** 1997 Jul 15; 92(7):394–400 (Eng. Abstr.) **(Ger)**

[Relation between the abdominal sagittal diameter, fat tissue distribution and metabolic complications] Stokić E, et al. **Med Pregl** 1996;49(9–10):365–8 (Eng. Abstr.) **(Scr)**

PHYSIOLOGY

Waist percentiles: a simple test for atherogenic disease? Zannolli R, et al. **Acta Paediatr** 1996 Nov;85(11):1368–9

Effect of intra-abdominally induced pressure on the urethral pressure profiles of healthy and incontinent bitches. Theus R, et al. **Am J Vet Res** 1997 May;58(5):555–9

Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Jacquet P, et al. **Anticancer Drugs** 1996 Jul; 7(5):596–603

Electrical activity recorded from abdominal surface before and after gastric surgery in man. Riezzo G, et al.
Arch Physiol Biochem 1996;104(1):50–6

Contribution of abdomen and legs to central blood volume expansion in humans during immersion. Johansen LB, et al. **J Appl Physiol** 1997 Sep;83(3):695–9

Segmentally distributed metamorphic changes in neural circuits controlling abdominal bending in the hawk moth Manduca sexta. Lemon WC, et al. **J Comp Physiol [A]** 1997 Jun;180(6):597–610

Elevated intra-abdominal pressure increases plasma renin activity and aldosterone levels. Bloomfield GL, et al.
J Trauma 1997 Jun;42(6):997–1004; discussion 1004–5

TmDOTP5–: a substance for NMR temperature measurements in vivo. Zuo CS, et al. **Magn Reson Med** 1996 Dec;36(6):955–9

Influence of thoracoabdominal pattern of breathing on respiratory resistance. Gallego J, et al. **Respir Physiol** 1997 May;108(2):143–52

[Intraoperative continuous epidural block influences postoperative changes in breathing pattern and thoracoabdominal movement associated with upper abdominal surgery] Mitsuhashi S, et al. **Masui** 1996 Jul; 45(7):813–7 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Abdominal compartment syndrome: case reports and implications for management in critically ill patients. Williams M, et al. **Am Surg** 1997 Jun;63(6):555–8

Changes in the resistive and reactive components of abdominal impedance during the 1–21 day post-mortem periods in rats. Querido D, et al. **Forensic Sci Int** 1997 Mar 14;85(3):163–75

The abdominal compartment syndrome: the physiological and clinical consequences of elevated intra-abdominal pressure [letter; comment] Hopgood P, et al.
J Am Coll Surg 1996 Oct;183(4):420–2. Comment on: J Am Coll Surg 1995 Jun;180(6):745–53.

The abdominal compartment syndrome: the physiological and clinical consequences of elevated intra-abdominal pressure [letter; comment] MacDonnell SP, et al.
J Am Coll Surg 1996 Oct;183(4):419–20. Comment on: J Am Coll Surg 1995 Jun;180(6):745–53.

The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. Jones EM, et al.
J Antimicrob Chemother 1997 Jul;40(1):121–4

Transmission of pressure within the abdomen. Tzelepis GE, et al. **J Appl Physiol** 1996 Sep;81(3):1111–4

Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. Sugerman H, et al. **J Intern Med** 1997 Jan;241(1):71–9

Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri. Sugerman HJ, et al. **Neurology** 1997 Aug;49(2):507–11

Abdominal compartment syndrome. The Nashville experience. Eddy V, et al. **Surg Clin North Am** 1997 Aug; 77(4):801–12 (22 ref.)

Intra-abdominal hypertension and the abdominal compartment syndrome. Ivatury RR, et al.
Surg Clin North Am 1997 Aug;77(4):783–800 (51 ref.)

Intraabdominal pressure and gastric intramucosal pH: is there an association? Sugrue M, et al. **World J Surg** 1996 Oct; 20(8):988–91

RADIATION EFFECTS

Is there a place for whole abdominal radiotherapy in the management of ovarian cancer? Morton GC, et al.
Ann Acad Med Singapore 1996 May;25(3):429–36 (68 ref.)

A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy [see comments] Franzén L, et al. **Ann Oncol** 1996 Aug; 7(6):587–92. Comment in: Ann Oncol 1996 Aug;7(6):553–4.

Reactions of the gastric wall following IORT +/- ERT to the upper abdomen in rabbits. Grab J, et al.
Front Radiat Ther Oncol 1997;31:47–50

Neutrophils generate oxygen free radicals in rat mesenteric microcirculation after abdominal irradiation. Panés J, et al. **Gastroenterology** 1996 Oct;111(4):981–9

Respiration-induced motion of the kidneys in whole abdominal radiotherapy: implications for treatment planning and late toxicity. Ahmad NR, et al.
Radiother Oncol 1997 Jan;42(1):87–90

[Plastic surgery defect coverage in the area of the pelvis and trunk] Germann G, et al. **Chirurg** 1997 May; 68(5):469–76 (26 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Cause of satisfaction of search effects in contrast studies of the abdomen. Berbaum KS, et al. **Acad Radiol** 1996 Oct; 3(10):815–26

Abdominal CT findings when the superior vena cava, brachiocephalic vein, or subclavian vein is obstructed. Bashist B, et al. **AJR Am J Roentgenol** 1996 Dec; 167(6):1457–63

Continent urinary diversion procedures: radiographic appearances and potential complications. Keogan MT, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):173–8

The subperitoneal space of the abdomen and pelvis: planes of continuity. Oliphant M, et al. **AJR Am J Roentgenol** 1996 Dec;167(6):1433–9

Quality assurance for abdominal CT: a rapid, computer-assisted technique. Pomerantz SM, et al.
AJR Am J Roentgenol 1996 Nov;167(5):1141–5

Appearance of oxidized cellulose (Surgicel) on abdominal radiographs [letter] van Gelderen F, et al.
AJR Am J Roentgenol 1996 Dec;167(6):1593

An intraoperative method of localizing a missing piece of a broken laparoscopic instrument. Ostrzenski A.
Am J Obstet Gynecol 1997 Mar;176(3):726–7

Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Thakore JH, et al. **Biol Psychiatry** 1997 Jun 1;41(11):1140–2

Imaging routines for the esophagus, small bowel, abdomen, and liver in six Norwegian hospitals from 1975 to 1993. Gudmundsen TE, et al. **Clin Imaging** 1996 Oct–Dec; 20(4):256–61

Helical/spiral computed body tomography. Brink JA, et al. **Clin Radiol** 1997 Jul;52(7):489–503 (102 ref.)

Clinical utility of abdominal CT scanning in patients with HIV disease. Sansom H, et al. **Clin Radiol** 1997 Sep; 52(9):698–703

Abdominal computed tomography in systemic lupus erythematosus. Si-Hoe CK, et al. **Clin Radiol** 1997 Apr; 52(4):284–9

Helical CT of the abdomen after pancreaticoduodenectomy: usefulness for detecting postoperative complications. Furukawa H, et al. **Hepatogastroenterology** 1997 May–Jun; 44(15):849–55

Incidental adrenal mass hampers the diagnosis of an extra-adrenal phaeochromocytoma. Jeck T, et al.
Horm Res 1996;46(6):282–3

Relationship of metabolic variables to abdominal adiposity measured by different anthropometric measurements and dual-energy X-ray absorptiometry in obese middle-aged women. Rissanen P, et al.
Int J Obes Relat Metab Disord 1997 May;21(5):367–71

Subhepatic migration of a hip prosthesis. Muñoz Vives JM, et al. **J Bone Joint Surg Br** 1996 Jan;78(1):152–3

The infraconal compartment: a multidirectional pathway for spread of disease between the extraperitoneal abdomen and pelvis. Beaulieu CF, et al. **J Comput Assist Tomogr** 1997 Mar–Apr;21(2):223–8

Interpretation of abdominal CT: analysis of errors and their causes. Bechtold RE, et al. **J Comput Assist Tomogr** 1997 Sep–Oct;21(5):681–5

CT in searching for abscess after abdominal or pelvic surgery in patients with neoplasia: do abdomen and pelvis both need to be scanned? Krumenacker JH, et al.
J Comput Assist Tomogr 1997 Jul–Aug;21(4):652–5

Spontaneous rectus sheath hematoma during treatment of pulmonary embolism with warfarin: report of a case. Chi TW, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Oct;12(10):601–4

The sun should not rise or set on a patient with mechanical obstruction [letter; comment] Miller JM. **Md Med J** 1997 Jan;46(1):10–1. Comment on: Md Med J 1996 Jul;45(7):558–60.

A survey of pentobarbital sedation for children undergoing abdominal CT scans after oral contrast medium. Sanderson PM. **Paediatr Anaesth** 1997;7(4):309–15

A "wandering liver" in an infant [letter] al-Ali F, et al.
Pediatr Radiol 1997 Mar;27(3):287

Bili-beads. Czyz C. **Radiol Technol** 1997 Mar–Apr;68(4):354

Systemic mastocytosis: CT and US features of abdominal manifestations. Avila NA, et al. **Radiology** 1997 Feb; 202(2):367–72

Unenhanced helical CT versus plain abdominal radiography: a dissenting opinion [comment] Baker SR. **Radiology** 1997 Oct;205(1):45–7. Comment on: Radiology 1997 Oct;205(1):43–5.

Enlarged abdominal lymph nodes in end-stage cirrhosis:

CT–histopathologic correlation in 507 patients. Dodd GD 3rd, et al. **Radiology** 1997 Apr;203(1):127–30

Abdomen after a Puestow procedure: postoperative CT appearance, complications, and potential pitfalls. Freed KS, et al. **Radiology** 1997 Jun;203(3):790–4

Communications of the pelvic extraperitoneal spaces and their relation to the abdominal extraperitoneal spaces: helical CT cadaver study with pelvic extraperitoneal injections. Mastromatteo JF, et al. **Radiology** 1997 Feb; 202(2):523–30

Upper gastrointestinal tract and abdomen: water as an orally administered contrast agent for helical CT. Winter TC, et al. **Radiology** 1996 Nov;201(2):365–70

Abdominal computed tomography of intensive care unit patients. Jacobs JE, et al. **Semin Roentgenol** 1997 Apr; 32(2):128–41

The abdomen in the intensive care unit. Miller WT Sr. **Semin Roentgenol** 1997 Apr;32(2):122–7

Helical computed tomography for abdominal imaging. Krasny RM, et al. **World J Surg** 1996 Feb;20(2):248–52

[Value of plain abdominal radiography for evaluating the patency of LGM caval filters] Trogrlic S, et al. **J Radiol** 1996 Nov;77(11):1135–9 (Eng. Abstr.) **(Fre)**

[Castleman lymphoma: isolated abdominal involvement with an 8–year course in a child] Strunk H, et al. **Aktuelle Radiol** 1997 Jul;7(4):193–6 (Eng. Abstr.) **(Ger)**

[The computed tomographic determination of intra–abdominal fat volume by single–layer measurement] Jacobi V, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):115–9 (Eng. Abstr.) **(Ger)**

[Radiation exposure in abdominal radiography with digital luminescence radiography and conventional screen–film system: an experimental animal study] Seifert H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Oct;165(4):386–91 (Eng. Abstr.) **(Ger)**

[Diagnostic imaging of "body packers"] Ichikawa K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Feb; 57(3):89–93 (Eng. Abstr.) **(Jpn)**

[A basic study on gastric emptying test using barium grains and effect of drugs on gastric emptying in rats] Sakurai T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb; 93(2):75–82 (Eng. Abstr.) **(Jpn)**

[Percutaneous drainage of abdominal fluid collections guided by computer tomography] Lincender L, et al. **Med Arh** 1996;50(1–2):31–3 (Eng. Abstr.) **(Scr)**

[Obesity and distribution of body fat. Correlation between anthropometric and tomographic data on areas at the abdominal level] Lara Fernández A, et al. **Rev Clin Esp** 1996 Jul;196(7):437–45 (41 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Abdominal SPECT/MRI fusion applied to the study of splenic and hepatic uptake of radiolabeled thrombocytes and colloids. Pohjonen HK, et al. **Ann Nucl Med** 1996 Nov; 10(4):409–17

False–positive radioiodine uptake in the abdomen and the pelvis: radioiodine retention in the kidneys and review of the literature. Bakheet SM, et al. **Clin Nucl Med** 1996 Dec; 21(12):932–7 (25 ref.)

Incidental massive Ga–67 uptake in the thorax and abdomen for the diagnosis of lumbar osteomyelitis. Finn N, et al. **Clin Nucl Med** 1997 Jun;22(6):417–8

Ga–67 scintigraphy in pediatric patients. Comparison of extended SPECT of the chest and abdomen with planar imaging. Tan TX, et al. **Clin Nucl Med** 1996 Sep; 21(9):717–9

SURGERY

Is closed diagnostic peritoneal lavage contraindicated in patients with previous abdominal surgery? Moore GP, et al. **Acad Emerg Med** 1997 Apr;4(4):287–90

The effects of warming intravenous fluids on intraoperative hypothermia and postoperative shivering during prolonged abdominal surgery. Camus Y, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):779–82

Epidural analgesia following upper abdominal surgery: United Kingdom practice. Cook TM, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 1):18–24

Decrease in plasma volume from intra–abdominal trauma in rats is prevented by H1 but not by H2 histaminergic blockade. Larmark M, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):112–8

Neuroendocrine response to mid and upper abdominal surgery [letter; comment] Richardson J, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):433–4. Comment on: Acta Anaesthesiol Scand 1996 Jul;40(6):691–6.

Laparoscopic cholecystectomy following abdominal surgery of the lower part of abdomen. Perko Z, et al. **Acta Med Croatica** 1996;50(3):145–6

Effect of continued electroacupuncture on induction of interleukin–2 production of spleen lymphocytes from the injured rats. Cheng XD, et al. **Acupunct Electrother Res** 1997;22(1):1–8

Gastroesophageal reflux following male abdominoplasty. Gilliland MD, et al. **Aesthetic Plast Surg** 1996 Nov–Dec; 20(6):527–8

Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part II. Resnick J, et al. **Am J Gastroenterol** 1997 Jun;92(6):934–40 (69 ref.)

Vaginal versus abdominal reconstructive surgery for the treatment of pelvic support defects: a prospective randomized study with long–term outcome evaluation. Benson JT, et al. **Am J Obstet Gynecol** 1996 Dec; 175(6):1418–21; discussion 1421–2

Prevention of postoperative adhesions by an antibody to vascular permeability factor/vascular endothelial growth factor in a murine model. Saltzman AK, et al. **Am J Obstet Gynecol** 1996 May;174(5):1502–6

Neuronal pathways involved in abdominal surgery–induced gastric ileus in rats. Barquist E, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):R888–94

Abdominal surgery–induced inhibition of gastric emptying is mediated in part by interleukin–1 beta. Coimbra CR, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):R556–60

Risk factors for bleeding in major abdominal surgery using heparin thromboprophylaxis. Cohen AT, et al. **Am J Surg** 1997 Jul;174(1):1–5

Lower extremity iatrogenic nerve injury due to compression during intraabdominal surgery. Dillavou ED, et al. **Am J Surg** 1997 Jun;173(6):504–8

Is incidental prophylactic oophorectomy an acceptable means to reduce the incidence of ovarian cancer? Rozario D, et al. **Am J Surg** 1997 Jun;173(6):495–8

National audit of anaesthesia for major abdominal surgery. Rigg JR, et al. **Anaesth Intensive Care** 1997 Jun;25(3):282–5

Staged abdominal repair in critical illness. Torrie J, et al. **Anaesth Intensive Care** 1996 Jun;24(3):368–74

Remifentanil for major abdominal surgery [letter] Evans TN, et al. **Anaesthesia** 1997 Jun;52(6):606

A comparison of remifentanil and alfentanil in patients undergoing major abdominal surgery [see comments] Schüttler J, et al. **Anaesthesia** 1997 Apr;52(4):307–17. Comment in: Anaesthesia 1997 Apr;52(4):291–3.

Preemptive ketamine decreases postoperative narcotic requirements in patients undergoing abdominal surgery. Fu ES, et al. **Anesth Analg** 1997 May;84(5):1086–90

Transcutaneous cranial electrical stimulation (Limoge's currents) decreases early buprenorphine analgesic requirements after abdominal surgery. Mignon A, et al. **Anesth Analg** 1996 Oct;83(4):771–5

Metabolic pattern and lipid oxidation during abdominal surgery: midazolam versus propofol. Pestaña D, et al. **Anesth Analg** 1996 Oct;83(4):837–43

Reduced postoperative analgesic demand after inhaled anesthesia in comparison to combined epidural–inhaled anesthesia in patients undergoing abdominal surgery. Rockemann MG, et al. **Anesth Analg** 1997 Mar;84(3):600–5

Rectus turnover flaps for the reconstruction of large midline abdominal wall defects. DeFranzo AJ, et al. **Ann Plast Surg** 1996 Jul;37(1):18–23

Z–plasty practice for the beginner [letter] Gürünlüoğlu R, et al. **Ann Plast Surg** 1997 Aug;39(2):218

Effect of electrosurgical technique on wound healing and early complication rate following abdominal dermolipectomy. Kuzon WM Jr, et al. **Ann Plast Surg** 1996 Sep;37(3):245–50

Myocardial perfusion scintigraphy in patients undergoing major non–vascular abdominal surgery. Mumtaz H, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5):420–5

The low transverse Pfannenstiel incision and the prevalence of incisional hernia and nerve entrapment. Luijendijk RW, et al. **Ann Surg** 1997 Apr;225(4):365–9

Recovery of gastrointestinal tract motility and myoelectric activity change after abdominal surgery. Hotokezaka M, et al. **Arch Surg** 1997 Apr;132(4):410–7

Prevention of abdominal compartment syndrome by absorbable mesh prosthesis closure. Mayberry JC, et al. **Arch Surg** 1997 Sep;132(9):957–61; discussion 961–2

Impact of minimally invasive surgery in children. Lugo–Vicente HL. **Bol Asoc Med P R** 1997 Jan–Mar; 89(1–3):25–30 (43 ref.)

Respiratory mechanics after abdominal surgery measured with continuous analysis of pressure, flow and volume signals. Nimmo AF, et al. **Br J Anaesth** 1996 Sep; 77(3):317–26

Randomized trial of blunt–tipped versus cutting needles to reduce glove puncture during mass closure of the abdomen. Hartley JE, et al. **Br J Surg** 1996 Aug;83(8):1156–7

Corticotropin–releasing factor and systemic capsaicin–sensitive afferents are involved in abdominal surgery–induced Fos expression in the paraventricular nucleus of the hypothalamus. Bonaz B, et al. **Brain Res** 1997 Feb 14;748(1–2):12–20

Lower transversal laparotomy has no appreciable effect on respiratory mechanics in guinea pigs. Santos MA, et al. **Braz J Med Biol Res** 1996 Jan;29(1):53–9

Bupivacaine decreases epidural meperidine requirements after abdominal surgery. St–Onge S, et al. **Can J Anaesth** 1997 Apr;44(4):360–6

Combined spinal and epidural anaesthesia for major abdominal surgery in infants. Williams RK, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):511–4

Predictors of postoperative pulmonary complications following abdominal surgery. Brooks–Brunn JA. **Chest** 1997 Mar;111(3):564–71

Contouring the hip and the abdomen. Baroudi R, et al. **Clin Plast Surg** 1996 Oct;23(4):551–72; discussion 572–3

Endoscopic abdominoplasty and endoscopically assisted miniabdominoplasty. Eaves FF 3rd, et al. **Clin Plast Surg** 1996 Oct;23(4):599–616; discussion 617

Body contouring. Introduction. Grazer FM. **Clin Plast Surg** 1996 Oct;23(4):511–28

Comparison of laparoscopic imaging systems and conditions using a knot–tying task. Tendick F, et al. **Comput Aided Surg** 1997;2(1):24–33

Abdominoperineal excision of the rectum––an endangered operation. Norman Nigro Lectureship. Heald RJ, et al. **Dis Colon Rectum** 1997 Jul;40(7):747–51

Postoperative perineal hernia. So JB, et al. **Dis Colon Rectum** 1997 Aug;40(8):954–7

The effect of low dose heparin therapy on complication and survival rates in horses following exploratory celiotomy. Young DR, et al. **Equine Vet J Suppl** 1989 Jun;(7):91–3

Comparison of tramadol with morphine for post–operative pain following abdominal surgery [letter; comment] Stubhaug A. **Eur J Anaesthesiol** 1996 Jul;13(4):416–8. Comment on: Eur J Anaesthesiol 1995 May;12(3):265–71.

Strangulated iatrogenic diaphragmatic hernia: a late diagnosed complication. Axon PR, et al. **Eur J Cardiothorac Surg** 1995;9(11):664–6

Leucocyte scintigraphy or computed tomography for the febrile post–operative patient? Bearcroft PW, et al. **Eur J Radiol** 1996 Sep;23(2):126–9

Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. The Fragmin Multicentre Study Group. Flordal PA, et al. **Eur J Surg** 1996 Oct;162(10):783–9

Double gloving as self protection in abdominal surgery. Jensen SL, et al. **Eur J Surg** 1997 Mar;163(3):163–7

Duration of postoperative pneumoperitoneum. Nielsen KT, et al. **Eur J Surg** 1997 Jul;163(7):501–3

To dress or not to dress surgical wounds? Patients' attitudes to wound care after major abdominal operations. Persson M, et al. **Eur J Surg** 1995 Nov;161(11):791–3; discussion 794

The clinical significance of adhesions: focus on intestinal obstruction. Ellis H. **Eur J Surg Suppl** 1997;(577):5–9 (29 ref.)

Mechanisms of adhesion development and effects on wound healing. Holmdahl L. **Eur J Surg Suppl** 1997;(579):7–9 (11 ref.)

Cost implications of adhesions as highlighted in a European study. Jeekel H. **Eur J Surg Suppl** 1997;(579):43–5

Upper abdominal surgery: does a lung function test exist to predict early severe postoperative respiratory complications? Barisione G, et al. **Eur Respir J** 1997 Jun; 10(6):1301–8

Use of medroxyprogesterone acetate in the prevention of postoperative adhesions. Montanino–Oliva M, et al. **Fertil Steril** 1996 Mar;65(3):650–4

Three coins in a nutrition fountain. Koretz RL. **Gastroenterology** 1997 Jan;112(1):307–9

Extensive lymph node clearance for cancer of the esophagus or cardia: merits and limits in reference to 5–year absolute survival. Collard JM, et al. **Hepatogastroenterology** 1995 Sep–Oct;42(5):619–27

Myths and antimyths [letter] Benhamou G. **Int Surg** 1995 Jul–Sep;80(3):291–2

Iatrogenic injuries to ureter, bladder and urethra during abdominal and pelvic operations. Polat O, et al. **Int Urol Nephrol** 1997;29(1):13–8

Is repeat laparotomy of value in patients with suspected intra–abdominal sepsis in the intensive care unit? McCrory C, et al. **Ir J Med Sci** 1997 Apr–Jun;166(2):88–91

Extraumbilical insertion of the operative laparoscope in patients with extensive intraabdominal adhesions. Chang FH, et al. **J Am Assoc Gynecol Laparosc** 1995 May; 2(3):335–7

Factors related to the use of early postoperative enteral feeding in thoracic and abdominal surgery patients in the United States. Beier B, et al. **J Am Diet Assoc** 1997 Mar; 97(3):293–5

Risk factors for wound infection following celiotomy in horses. Honnas CM, et al. **J Am Vet Med Assoc** 1997 Jan 1;210(1):78–81

Comparison of epidural morphine and oxycodone for pain after abdominal surgery. Backlund M, et al. **J Clin Anesth** 1997 Feb;9(1):30–5

Elevated plasma levels of interleukin–6, interleukin–8, and granulocyte colony–stimulating factor during and after major abdominal surgery. Kato M, et al. **J Clin Anesth** 1997 Jun;9(4):293–8

Heart rate, heart rate variability, and blood pressure during perioperative stressor events in abdominal surgery. Schubert A, et al. **J Clin Anesth** 1997 Feb;9(1):52–60

Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction–based assay: demonstration of reduced expression after elective surgery. Hermansson M, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):421–8

Efficacy of tenoxicam on intra–abdominal adhesion prevention in a rat model. Yilmazlar T, et al. **J Int Med Res** 1996 Jul–Aug;24(4):352–7

Proximity injury by the ultrasonically activated scalpel during dissection. Kadesky KM, et al. **J Pediatr Surg** 1997 Jun;32(6):878–9

Separation of thoraco–omphalopagus conjoined twins with complex hepato–biliary anatomy. Spitz L, et al. **J Pediatr Surg** 1997 May;32(5):787–9

ASA status and age predict adverse events after abdominal surgery. Hall JC, et al. **J Qual Clin Pract** 1996 Jun; 16(2):103–8

Emergency abdominal surgery in the elderly. McIntyre R,

et al. **J R Coll Surg Edinb** 1997 Jun;42(3):173–8

Nonendoscopic antegrade percutaneous gastrostomy: the effect of preplacement gastric insufflation on tube position and intra-abdominal anatomy. Clary EM, et al. **J Vet Intern Med** 1996 Jan–Feb;10(1):15–20

Prophylactic administration of ondansetron in emergency intraabdominal operations. Ulusoy HO, et al. **Middle East J Anesthesiol** 1997 Feb;14(1):45–58

Prophylactic administration of ondansetron in emergency intraabdominal operations. Ulusoy HO, et al. **Middle East J Anesthesiol** 1996 Jun;13(5):513–26

Gut rest versus early feeding after elective abdominal surgery [editorial] Eagon JC, et al. **Nutrition** 1997 Feb;13(2):155–6

Uterine leiomyoma particle growing in an abdominal-wall incision after laparoscopic retrieval. Ostrzenski A. **Obstet Gynecol** 1997 May;89(5 Pt 2):853–4

Use of a tourniquet in panniculus resection. Daw JL, et al. **Plast Reconstr Surg** 1997 Jun;99(7):2082–4

Local anaesthesia for major general surgical procedures. A review of 116 cases over 12 years. Dennison A, et al. **Postgrad Med J** 1996 Feb;72(844):105–8

Effect of type of anesthesia and lower-abdominal laparotomy in mice on the cytokine response to acute stress. Fu ES, et al. **Reg Anesth** 1996 Sep–Oct;21(5):470–3

The effect of spinal versus general anesthesia on postoperative pain and analgesic requirements in patients undergoing lower abdominal surgery [see comments] Wang JJ, et al. **Reg Anesth** 1996 Jul–Aug;21(4):281–6. Comment in: Reg Anesth 1996 Jul–Aug;21(4):277–80.

Effect of octreotide on postoperative intraperitoneal adhesions in rats. Lai HS, et al. **Scand J Gastroenterol** 1996 Jul;31(7):678–81

Reoperation. Planned and unplanned. Hirshberg A, et al. **Surg Clin North Am** 1997 Aug;77(4):897–907 (14 ref.)

Laparoscopic-assisted abdominoperineal resection in the prone position. An alternative technique. Koerner K, et al. **Surg Endosc** 1997 Jun;11(6):684–6

Early experience with laparoscopic abdominoperineal resection. Wu JS, et al. **Surg Endosc** 1997 May;11(5):449–55

Sling retraction of the falciform ligament to ameliorate exposure in laparoscopic upper abdominal surgery. Hashmonai M, et al. **Surg Laparosc Endosc** 1996 Feb; 6(1):71–2

Abdominoperineal resection: laparoscopic versus conventional. Ramos JR, et al. **Surg Laparosc Endosc** 1997 Apr;7(2):148–52

Reconstruction of the abdomen and perineum in cancer surgery. Fix RJ, et al. **Surg Oncol Clin N Am** 1997 Jan; 6(1):115–32 (11 ref.)

A comparison of epidural saline, morphine, and bupivacaine for pain relief after abdominal surgery in goats. Hendrickson DA, et al. **Vet Surg** 1996 Jan–Feb;25(1):83–7

Bacterial culturing of ventral median celiotomies for prediction of postoperative incisional complications in horses. Ingle-Fehr JE, et al. **Vet Surg** 1997 Jan–Feb; 26(1):7–13

[Total intravenous anesthesia (TIVA) with propofol/ketamine as an alternative for patients at risk in abdominal surgery] Vankov I, et al. **Khirurgiia (Sofiia)** 1996; 49(4):17–9 (Eng. Abstr.) **(Bul)**

[Iatrogenic lesions of the ureter in women] Hanuš T, et al. **Rozhl Chir** 1997 Jun;76(6):302–5 (Eng. Abstr.) **(Cze)**

[Measurement of gastric mucosal pH by tonometry in major abdominal surgery] Leclerc J, et al. **Ann Fr Anesth Reanim** 1996;15(7):1022–7 (Eng. Abstr.) **(Fre)**

[Prevention of respiratory complications after abdominal surgery] Rezaiguia S, et al. **Ann Fr Anesth Reanim** 1996; 15(5):623–46 (119 ref.) (Eng. Abstr.) **(Fre)**

["Mini-invasive" surgery of the abdomen in 1996] Steichen FM. **Chirurgie** 1997;122(2):94–7 (Eng. Abstr.) **(Fre)**

[Comparison of sufentanil–propofol–anesthesia with fentanyl–propofol in major abdominal surgery] Kietzmann D, et al. **Anaesthesist** 1996 Dec;45(12):1151–7 (Eng. Abstr.) **(Ger)**

[The Vollmer hook—a new abdominal retractor] Herzog U, et al. **Chirurg** 1997 Jul;68(7):742–3 (Eng. Abstr.) **(Ger)**

[Risk factors, preoperative delay and mortality in surgical gerontologic interventions] Steinau G, et al. **Langenbecks Arch Chir** 1996;381(4):228–31 (Eng. Abstr.) **(Ger)**

[Improved outcome by preoperative administration of methylprednisolone before large abdominal surgery interventions—a prospective double-blind study] Fu ZX, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997; 114:663–6 (Eng. Abstr.) **(Ger)**

[Abdominal surgery in the elderly—a retrospective analysis over 11 years] Krenz D, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:515–8 (Eng. Abstr.) **(Ger)**

[Technology: training centers—a new method for learning surgery in visceral surgery] Troidl H. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:727–41 (Eng. Abstr.) **(Ger)**

[Abdominal interventions in advanced age: risk factors and fatal outcome] Steinau G, et al. **Leber Magen Darm** 1996 Jan;26(1):27–31 (Eng. Abstr.) **(Ger)**

[Cost increase due to incorrect antibiotic prophylaxis in visceral, thoracic and vascular surgery] Zengaffinen R, et al. **Swiss Surg** 1997;3(3):125–8 (Eng. Abstr.) **(Ger)**

[Significance of special reimbursement and case sums in visceral surgery] Bauer H. **Zentralbl Chir** 1997;122(1):2–8 (Eng. Abstr.) **(Ger)**

[Practical and theoretical aspects of cost–benefit relations in viscerosynthesis] Fuchs KH, et al. **Zentralbl Chir** 1997; 122(1):9–13 (Eng. Abstr.) **(Ger)**

[The risk of needle-stick-injuries during abdominal closure] Meyer D, et al. **Zentralbl Chir** 1996;121(1):30–4 (Eng. Abstr.) **(Ger)**

[Quality assurance and cost benefit analysis of viscerosynthesis (editorial)] Thiede A, et al. **Zentralbl Chir** 1997;122(1):1 **(Ger)**

[Use of new elastomeric pumps and PCA in postoperative pain control in thoraco-abdominal surgery] Testa G, et al. **Ann Ital Chir** 1996 Mar–Apr;67(2):257–63 (Eng. Abstr.) **(Ita)**

[Postoperative intra-abdominal adhesions: prevention and treatment] Enrico S, et al. **Minerva Chir** 1996 Apr; 51(4):223–6 (Eng. Abstr.) **(Ita)**

[Emergency abdominal surgery in the aged] Monaco A, et al. **Minerva Chir** 1996 Dec;51(12):1043–7 (Eng. Abstr.) **(Ita)**

[The effect of low-dose prostaglandin E1 on intra- and post-operative renal function] Hayashida M, et al. **Masui** 1997 Apr;46(4):464–70 (Eng. Abstr.) **(Jpn)**

[Does the difference in anesthetic methods influence postoperative nitrogen balance?] Kim C. **Masui** 1996 Feb; 45(2):215–22 (Eng. Abstr.) **(Jpn)**

[Somatosensory evoked potentials (SEPs) as an intraoperative monitor in lower abdominal surgery during lumbar epidural anesthesia] Dong WY, et al. **Nippon Ika Daigaku Zasshi** 1997 Jun;64(3):264–7 **(Jpn)**

[Preoperative identification of ischemic heart disease in patients with surgical diseases of the abdominal cavity] Korsunskiĭ SB, et al. **Anesteziol Reanimatol** 1997 Jan–Feb; (1):27–8 (Eng. Abstr.) **(Rus)**

[Exchange plasmapheresis in surgical diseases of abdominal cavity organs] Vatazin AV. **Anesteziol Reanimatol** 1997 May–Jun;(3):83–7 (92 ref.) **(Rus)**

[The use of the transabdominal approach in a patient with wounds of the heart, diaphragm, phrenic vein and liver] Boĭko VV, et al. **Klin Khir** 1996;(7):50–1 **(Rus)**

[The performance of simultaneous operations in a combination of gallstones with other organic diseases of the abdominal cavity] Bragin VV, et al. **Klin Khir** 1995; (3):11–3 **(Rus)**

[Clinical bases of dynamics of adaptative reaction in children in the development of acute inflammation in the abdominal cavity. Possibilities of the concept "abdominal stress" in surgery] Moskalenko VZ, et al. **Klin Khir** 1996;(4):38–41 **(Rus)**

[A rare combination of stomach cancer and a foreign body of the abdominal cavity] Munasypov FR, et al. **Klin Khir** 1995;(1):48 **(Rus)**

[A cyst of the abdominal cavity] Raĭchuk IE, et al. **Klin Khir** 1995;(1):50 **(Rus)**

[The risk and prevention of deep venous thrombosis of the lower extremities in abdominal surgery] Baeshko AA, et al. **Vestn Khir Im I I Grek** 1996;155(3):34–9 (Eng. Abstr.) **(Rus)**

[Disseminated coccidioidomycosis of the abdominal cavity] Korneev EL, et al. **Vestn Khir Im I I Grek** 1997;156(3):75–6 **(Rus)**

[Analgesics in the postoperative period of abdominal interventions. The Study Group on Postoperative Analgesia of the Spanish Society of Clinical Pharmacology] Aguilera C, et al. **Med Clin (Barc)** 1997 Feb 1;108(4):136–40 (Eng. Abstr.) **(Spa)**

[Intraoperative monitoring of gastric intramucosal pH] Concha M, et al. **Rev Med Chil** 1996 Aug;124(8):918–22 (Eng. Abstr.) **(Spa)**

[Risk factors for the occurrence of postoperative suppurative-septic complications in abdominal surgery] Ohonovs'kyĭ VK. **Klin Khir** 1995;(1):33–5 (44 ref.) **(Ukr)**

ULTRASONOGRAPHY

The role of invasive sonography in the differential diagnosis and treatment of intraabdominal fluid collections. Regöly-Mérei J, et al. **Acta Chir Hung** 1995–96; 35(3–4):185–99

Determination of chorionicity in twin gestations by high-frequency abdominal ultrasonography: counting the layers of the dividing membrane. Vayssière CF, et al. **Am J Obstet Gynecol** 1996 Dec;175(6):1529–33

Refined fetal abdominal growth assessment in normal pregnancy: Part I. Abdominal anteroposterior diameter. Yu CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Mar; 59(3):164–70

Simethicone coated cellulose as an oral contrast agent for ultrasound of the upper abdomen. Harisinghani MG, et al. **Clin Radiol** 1997 Mar;52(3):224–6

Ultrasound of the abdomen in endurance athletes. Gabriel H, et al. **Eur J Appl Physiol** 1996;73(1–2):191–3

Transverse cerebellar diameter and transverse cerebellar diameter/ abdominal circumference index for assessing fetal growth. Dilmen G, et al. **Fetal Diagn Ther** 1996 Jan–Feb; 11(1):50–6

Ultrasonographic intra-abdominal depth and its relation to haemostatic factors in healthy males. Targher G, et al. **Int J Obes Relat Metab Disord** 1996 Sep;20(9):882–5

Harmonic amplitude distribution in a wideband ultrasonic wavefront after propagation through human abdominal wall and breast specimens. Liu DL, et al. **J Acoust Soc Am** 1997 Feb;101(2):1172–83

What is your diagnosis? Ruptured bladder with uroperitoneum. Worth LT, et al. **J Am Vet Med Assoc** 1997 Jun 1;210(11):1601–2

Abdominal ultrasound findings of disseminated tuberculosis in AIDS. Monill-Serra JM, et al. **J Clin Ultrasound** 1997 Jan;25(1):1–6

Opportunistic screening for abdominal aortic aneurysm. Derbyshire ND, et al. **J Med Screen** 1994 Oct;1(4):220–2 "Opportunistic" screening [editorial] Law M. **J Med Screen** 1994 Oct;1(4):208

Could we diagnose active schistosomiasis in children by abdominal sonography? [letter] Abdel-Ghaffar Y, et al. **J Trop Pediatr** 1996 Dec;42(6):374–5

Abdominal sonography in asymptomatic executives: prevalence of pathologic findings, potential benefits, and problems. Spouge AR, et al. **J Ultrasound Med** 1996 Nov; 15(11):763–7; quiz 769–70

Abdominal ultrasound findings during and after treatment of childhood acute lymphoblastic leukemia. Ojala AE, et al. **Med Pediatr Oncol** 1997 Oct;29(4):266–71

Ménétrier's disease evaluated serially by abdominal ultrasonography. Takaya J, et al. **Pediatr Radiol** 1997 Feb; 27(2):178–80

Systemic mastocytosis: CT and US features of abdominal manifestations. Avila NA, et al. **Radiology** 1997 Feb; 202(2):367–72

Diagnostic methods in dyspepsia: the usefulness of upper abdominal ultrasound and gastroscopy. Heikkinen MT, et al. **Scand J Prim Health Care** 1997 Jun;15(2):82–6

Incorporating sonographic cheek-to-cheek diameter, biparietal diameter and abdominal circumference improves weight estimation in the macrosomic fetus. Abramowicz JS, et al. **Ultrasound Obstet Gynecol** 1997 Jun;9(6):409–13

[Intraoperative abdominal echography] Dimitrov G, et al. **Khirurgiia (Sofiia)** 1996;49(2):43–6 (Eng. Abstr.) **(Bul)**

[Ultrasonography of changes in the retroperitoneal vessels and perivascular spaces during retroviral infection: preliminary results] N'gbesso RD, et al. **Sante** 1997 Jan–Feb;7(1):25–31 (Eng. Abstr.) **(Fre)**

[Ultrasound "screening examination" of the abdomen: of value or senseless?] Mostbeck GH. **Ultraschall Med** 1996 Aug; 17(4):175–8 (Eng. Abstr.) **(Ger)**

[Diagnostic imaging of "body packers"] Ichikawa K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Feb; 57(3):89–93 (Eng. Abstr.) **(Jpn)**

[Progress and clinical usefulness of color Doppler method in diagnosing abdominal diseases] Tomiyama T, et al. **Nippon Rinsho** 1996 Sep;54(9):2561–73 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Therapeutic interventions under ultrasonic control in diseases of the abdominal cavity organs] Briskin BS, et al. **Khirurgiia (Mosk)** 1996;(6):17–22 (Eng. Abstr.) **(Rus)**

ABDOMEN, ACUTE

Emergency laparoscopic procedures. Ravintharan T. **Ann Acad Med Singapore** 1996 Sep;25(5):687–93 (65 ref.)

Acute abdominal pain: a medical emergency in older patients. Abi-Hanna P, et al. **Geriatrics** 1997 Jul;52(7):72–4

[Acute abdomen in the third trimester] Mecacci F, et al. **Minerva Ginecol** 1996 Nov;48(11):497–9 (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

[Hepatic veno-occlusive disease—simulating acute abdomen in chemotherapy of Wilms' tumors] Tröbs RB, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:1112–4 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Acute abdomen. Special considerations for the neurologically and immunologically impaired child. Bensard DD, et al. **Semin Pediatr Surg** 1997 May;6(2):92–9

DIAGNOSIS

Evaluation acute abdominal pain in the emergency department. View of the emergency physician. Askenasi R, et al. **Acta Gastroenterol Belg** 1996 Apr–Jun;59(2):133

Effect of health care system factors on test ordering. Scholer SJ, et al. **Arch Pediatr Adolesc Med** 1996 Nov; 150(11):1154–9

Avoiding premature closure in sequential diagnosis. McSherry D. **Artif Intell Med** 1997 Jul;10(3):269–83

Diagnostic laparoscopy: indication and benefit. Yu SY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Mar; 59(3):158–63

Pyomyositis—a differential diagnosis in the acute abdomen. Mangell P, et al. **Eur J Surg** 1997 Jul;163(7):553–5 (11 ref.)

Giant duodenal hematoma in hemophilia A. Benjamin B, et al. **Indian Pediatr** 1996 May;33(5):411–4

An unusual presentation of intestinal lymphangiectasia. Jameson JS, et al. **Int J Colorectal Dis** 1996;11(4):198–9

Pulmonary embolism presenting as an acute surgical abdomen. Smith DC. **J Emerg Med** 1996 Nov–Dec; 14(6):715–7

Does this patient have appendicitis? [see comments] Wagner JM, et al. **JAMA** 1996 Nov 20;276(19):1589–94. Comment in: JAMA 1997 Feb 26;277(8):625; discussion 626–7. Comment in: JAMA 1997 Feb 26;277(8):625–6; discussion 626–7. Comment in: JAMA 1997 Feb 26;277(8):626;

discussion 626–7.
Chilaiditi's syndrome presenting as acute abdomen. Hisham AN, et al. **Med J Malaysia** 1995 Sep;50(3):281–3
Primary care diagnosis of acute abdominal pain. Stone R. **Nurse Pract** 1996 Dec;21(12 Pt 1):19–20, 23–30, 35–9; quiz 40–1 (18 ref.)
Sepsis, septic shock, acute abdomen? The ability of cardiac disease to mimic other medical illness. Mahle WT, et al. **Pediatr Emerg Care** 1996 Aug;12(4):317–24
Interventional radiology in the acute pediatric abdomen. Hoffer FA. **Radiol Clin North Am** 1997 Jul;35(4):977–87 (35 ref.)
Computer-assisted diagnosis in gastroenterology. Malchow-Møller A, et al. **Scand J Gastroenterol Suppl** 1996;216:225–33 (63 ref.)
Acute abdomen. Laboratory evaluation and imaging. Schwartz MZ, et al. **Semin Pediatr Surg** 1997 May; 6(2):65–73
Ruptured phaeochromocytoma—a rare differential diagnosis of acute abdomen. Ong KL, et al. **Singapore Med J** 1996 Feb;37(1):113–4
The efficacy of laparoscopic surgery in the diagnosis and treatment of peritonitis. Experience with 107 cases in Mexico City. Cueto J, et al. **Surg Endosc** 1997 Apr; 11(4):366–70
The acute abdomen in the pregnant patient. Is there a role for laparoscopy? Gurbuz AT, et al. **Surg Endosc** 1997 Feb; 11(2):98–102 (33 ref.)
[Intra-abdominal torsion of the testis with seminoma (see comments)] Andreasen DA, et al. **Ugeskr Laeger** 1997 Mar 31;159(14):2103–4 (Eng. Abstr.). Comment in: Ugeskr Laeger 1997 Jun 30;159(27):4281–2. **(Dan)**
[Acute intestinal obstruction in an elderly patient] Linthoudt H, et al. **Tijdschr Gerontol Geriatr** 1996 Dec;27(6):255–7 (Eng. Abstr.) **(Dut)**
[How I explore... an afebrile difficult infant] Bourguignon JP. **Rev Med Liege** 1996 Nov;51(11):726–8 **(Fre)**
[The dynamics of stress inducers, of lipid peroxidation indices and of the antioxidant system components in children with acute surgical diseases of the abdominal cavity organs] Moskalenko VZ, et al. **Klin Khir** 1996;(7):29–32 **(Rus)**
[The main trends in the hospitalization of patients with a diagnosis of "acute abdomen"] Red'ko AA, et al. **Vestn Khir Im I I Grek** 1996;155(6):94–5 **(Rus)**
[It takes more than to count weeks—pregnancy symptoms may be misinterpreted] **Lakartidningen** 1997 Sep 3; 94(36):3062 **(Swe)**
[Acute abdomen with unclear diagnosis justifies rectal palpation (letter; comment)] Farnebo LO, et al. **Lakartidningen** 1996 Sep 25;93(39):3347. Comment on: Lakartidningen 1995 Feb 22;92(8):727–8. **(Swe)**
[Warning signals in acute abdominal disorders. Lactate is the best marker of mesenteric ischemia] Lange H, et al. **Lakartidningen** 1997 May 14;94(20):1893–6 (Eng. Abstr.) **(Swe)**
[A case report: abdominal pain of TBC was misjudged as urethritis] Wittesjö B, et al. **Lakartidningen** 1997 May 7; 94(19):1814–6 **(Swe)**

DRUG THERAPY

Intravenous morphine for early pain relief in patients with acute abdominal pain [see comments] Pace S, et al. **Acad Emerg Med** 1996 Dec;3(12):1086–92. Comment in: Acad Emerg Med 1996 Dec;3(12):1081–2.
Challenging dogma—analgesia in abdominal pain [editorial; comment] Yealy DM, et al. **Acad Emerg Med** 1996 Dec; 3(12):1081–2. Comment on: Acad Emerg Med 1996 Dec;3(12):1086–92.

EPIDEMIOLOGY

Acute abdomen requiring emergency surgery in renal allograft recipients during a single center cohort follow-up. Gutiérrez de la Barrera M, et al. **Transplant Proc** 1996 Dec; 28(6):3333–4
[The hospitalization of patients with acute surgical diseases of the abdominal organs] Kharisova IM, et al. **Probl Sotsialnoi Gig Istor Med** 1997 Mar-Apr;(2):32–3 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Spontaneous rupture of a vesicourachal diverticulum manifesting as acute abdominal pain. Lewis JB, et al. **Acad Emerg Med** 1996 Dec;3(12):1140–3
Ruptured ectopic pregnancy with undetectable beta-hCG levels coexisting with acute appendicitis. Bozoklu S, et al. **Acta Obstet Gynecol Scand** 1997 Feb;76(2):181–2
Using CT to evaluate the acute abdomen: spectrum of urinary pathology. Johnson GL, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):273–6
Perforated duodenal ulcer presenting with shock in a child. Moon D, et al. **Am J Emerg Med** 1997 Mar;15(2):167–9
Jejunal diverticulitis [letter; comment] Anand A, et al. **Am J Gastroenterol** 1996 Oct;91(10):2251–2. Comment on: Am J Gastroenterol 1996 Feb;91(2):393–4.
Acute abdomen in systemic lupus erythematosus: the importance of early laparotomy. Medina F, et al. **Am J Med** 1997 Aug;103(2):100–5
Acute abdominal pain in adults. Miettinen P, et al. **Ann Chir Gynaecol** 1996;85(1):5–9
Acute abdominal pain and vomiting in a 10-year-old girl. Gupta R, et al. **Ann Emerg Med** 1997 Sep;30(3):322–8
Acute abdomen due to endometriosis as a diagnostic and therapeutic challenge in the treatment of acute myelocytic leukemia. Karthaus M, et al. **Ann Hematol** 1997 Jan; 74(1):29–31
Perforated duodenal ulcer-an unusual and often forgotten cause of an acute abdomen in pregnancy. Goh JT, et al. **Aust N Z J Obstet Gynaecol** 1995 Nov;35(4):433–4
A rare cause of an acute abdomen in late pregnancy. Simpson I, et al. **Aust N Z J Obstet Gynaecol** 1995 Nov;35(4):435–6
Acute abdomen from a femoral venous catheter. Moriarty KP, et al. **Clin Pediatr (Phila)** 1997 Mar;36(3):175–6
Torsion of an appendix epiploica: a nonsurgical cause of acute abdomen [letter] Pavone E, et al. **Dig Dis Sci** 1997 Apr; 42(4):851–2
Another inflammatory bile duct polyp [letter; comment] Moulis H. **Endoscopy** 1996 Mar;28(3):330. Comment on: Endoscopy 1994 Feb;26(2):271.
Pseudomembranous colitis presenting as an acute abdomen. Reihnér E, et al. **Eur J Surg** 1996 Jul;162(7):579–81
Acute abdomen following dermoid cyst rupture during transvaginal ultrasonographically guided retrieval of oocytes. Coccia ME, et al. **Hum Reprod** 1996 Sep; 11(9):1897–9
Carcinoid tumor presenting as acute abdomen due to hemoperitoneum. Rungta U, et al. **Indian J Gastroenterol** 1995 Oct;14(4):147–8
Mesenteric venous thrombosis due to coagulation deficiencies - a case report [published erratum appears in Int Angiol 1996 Mar;15(1):following 85] Papalambros E, et al. **Int Angiol** 1995 Sep;14(3):236–8
Clostridium difficile colitis presenting as an acute abdomen: case report and review of the literature. Muehlhausen VL, et al. **J Fam Pract** 1997 Jan;44(1):97–100 (26 ref.)
The management of acute abdominal pain in children [see comments] Simpson ET, et al. **J Paediatr Child Health** 1996 Apr;32(2):110–2. Comment in: J Paediatr Child Health 1996 Oct;32(5):469. Comment in: J Paediatr Child Health 1996 Dec;32(6):546.
Spontaneous rupture of choledochal cyst: an unusual cause of acute abdomen in children. Karnak I, et al. **J Pediatr Surg** 1997 May;32(5):736–8
Abdominal pain in infants and children. Moir CR. **Mayo Clin Proc** 1996 Oct;71(10):984–9, quiz 989 (11 ref.)
The acute abdomen in spinal cord injury individuals. Bar-On Z, et al. **Paraplegia** 1995 Dec;33(12):704–6
Pediatric abdominal surgical emergencies. Pollack ES. **Pediatr Ann** 1996 Aug;25(8):448–57
Hypothyroidism presenting as acute abdomen. Kumar N, et al. **Postgrad Med J** 1997 Jun;73(860):373–4
Acute abdomen after total hip replacement. Nashi M, et al. **Postgrad Med J** 1997 Jun;73(860):351–3
Pulmonary embolism presenting as acute abdominal pain. von Pohle WR. **Respiration** 1996;63(5):318–20 (11 ref.)
Inguinal hernia incarceration as a form of intestinal tuberculosis. Faccin M, et al. **Rev Paul Med** 1996 Jan-Feb; 114(1):1097–9
Severe candida cystitis with perforation of the urinary bladder. Aanestad O, et al. **Scand J Urol Nephrol** 1997 Jun; 31(3):311–2
Acute abdomen. Outcomes. Madonna MB, et al. **Semin Pediatr Surg** 1997 May;6(2):105–11 (42 ref.)
Acute abdomen. The physical examination. Molenaar JC. **Semin Pediatr Surg** 1997 May;6(2):62–4
Acute abdomen. The teenage girl. Mollitt DL, et al. **Semin Pediatr Surg** 1997 May;6(2):100–4
Acute abdomen. Laboratory evaluation and imaging. Schwartz MZ, et al. **Semin Pediatr Surg** 1997 May; 6(2):65–73
Acute abdomen. The history. Spitz L, et al. **Semin Pediatr Surg** 1997 May;6(2):58–61
Ruptured phaeochromocytoma—a rare differential diagnosis of acute abdomen. Ong KL, et al. **Singapore Med J** 1996 Feb;37(1):113–4
Lupus peritonitis mimicking acute surgical abdomen in a patient with systemic lupus erythematosus: report of a case. Wakiyama S, et al. **Surg Today** 1996;26(9):715–8
Ruptured uterus presenting as a rapidly growing cystic mass in the epigastrium. Meguid T, et al. **Trop Doct** 1997 Jul; 27(3):186
[Abdominal emergencies and Von Recklinghausen neurofibromatosis (letter)] Dewailly A, et al. **Gastroenterol Clin Biol** 1997;21(3):227–8 **(Fre)**
[Clinical case of the month. Acute mesenteric venous thrombosis treated in a conservative manner] Kolh PH, et al. **Rev Med Liege** 1996 Dec;51(12):744–8 **(Fre)**
[Meckel lithiasis. A rare complication of a Meckel's diverticulum] Esslinger P, et al. **Dtsch Med Wochenschr** 1997 Jan 3;122(1-2):18–20 (Eng. Abstr.) **(Ger)**
[Acute epigastric pain after travel to the tropics. Emergency admission of a 28-year-old stewardess] Steimann R, et al. **Fortschr Med** 1996 Dec 20;114(35-36):488–91 (Eng. Abstr.) **(Ger)**
[Intestinal emergencies in newborn infants] Brzezinska R. **Radiologe** 1997 Jun;37(6):432–8 (25 ref.) (Eng. Abstr.) **(Ger)**
[Acute abdomen with palpable resistance in the pelvis and painful kidney region.Acute retroperitoneal hemorrhage from angiomyolipoma kidney in tuberous sclerosis (Bourneville-Pringle disease)] Hünerbein R, et al. **Radiologe** 1997 Apr;37(4):333–5 **(Ger)**
[Volvulus in childhood] Peitz HG. **Radiologe** 1997 Jun; 37(6):439–45 (30 ref.) (Eng. Abstr.) **(Ger)**
[Invagination] Rohrschneider W. **Radiologe** 1997 Jun; 37(6):446–53 (45 ref.) (Eng. Abstr.) **(Ger)**
[Acute abdomen with left-sided lower abdominal pain. Acute mesenterial ischemia with infarct of the small intestine in mesenteric vein s thrombosis and hepatic vein thrombosis] Schäfer C. **Radiologe** 1997 Mar;37(3):251–4 **(Ger)**
[Gynecologic origin of acute abdomen in childhood] Schmitz-Stolbrink A. **Radiologe** 1997 Jun;37(6):459–63 (27 ref.) (Eng. Abstr.) **(Ger)**
[Acute abdomen in childhood and adolescence (editorial)] Tröger J. **Radiologe** 1997 Jun;37(6):425 **(Ger)**
[Acute abdomen and cystic space-occupying lesion in mid abdomen] Mouton W, et al. **Schweiz Med Wochenschr** 1996 Dec 7;126(49):2152 **(Ger)**
[Acute abdominal pain--internist's viewpoint] Criblez D. **Schweiz Rundsch Med Prax** 1997 Feb 4;86(6):203–8 (Eng. Abstr.) **(Ger)**
[Necrotizing vasculitis of the appendix and cecum in systemic lupus erythematosus] Schmidt WA, et al. **Z Rheumatol** 1996 Jul-Aug;55(4):267–71 (Eng. Abstr.) **(Ger)**
[Spontaneous intraperitoneal perforation of the urinary bladder--a rare cause of acute abdomen. 2 case reports] Steinert M, et al. **Zentralbl Chir** 1997;122(4):301–3; discussion 303–4 (Eng. Abstr.) **(Ger)**
[Aneurysms of the iliac artery in fibromuscular dysplasia as differential diagnostic consideration in acute lower abdominal pain] Tsatalpas P, et al. **Zentralbl Chir** 1997; 122(5):413–7 (Eng. Abstr.) **(Ger)**
[Acute abdomen caused by the rupture of a solitary non-parasitic cyst of the liver] Morano C, et al. **Minerva Chir** 1996 Sep;51(9):713–6 (Eng. Abstr.) **(Ita)**
[Primary omental torsion in children: report of 2 cases and review of the literature] Pesce C, et al. **Pediatr Med Chir** 1996 Jul-Aug;18(4):403–5 (16 ref.) (Eng. Abstr.) **(Ita)**
[Pheochromocytoma with hemorrhagic necrosis and rupture with symptoms of acute abdomen and shock] Chlebus M, et al. **Pol Arch Med Wewn** 1996 Jul;96(1):58–61 (Eng. Abstr.) **(Pol)**
[Acute abdomen of urologic origin] Estrada Saiz RV, et al. **Actas Urol Esp** 1996 Jul-Aug;20(7):662–3 (Eng. Abstr.) **(Spa)**
[Hemoperitoneum as the first manifestation of ileal leiomyoma (letter)] Hallal H, et al. **An Med Interna** 1996 Aug;13(8):409–10 **(Spa)**
[Acute abdomen and pulmonary nodules in a kidney transplant recipient] Peset V, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):501–2 **(Spa)**
[Acute abdomen caused by thrombosis of the portal and superior mesenteric veins in a splenectomized hematologic patient] Acea Nebril B, et al. **Gastroenterol Hepatol** 1997 Jun-Jul;20(6):299–302 (Eng. Abstr.) **(Spa)**
[Acute abdomen in a 36-year-old woman with systemic lupus erythematous of 12 year duration (clinical conference)] Veny A, et al. **Med Clin (Barc)** 1996 Nov 23;107(18):711–6 **(Spa)**
[Anisakidosis of the colon as a cause of acute abdomen] Louredo Méndez A, et al. **Rev Esp Enferm Dig** 1997 May; 89(5):403–6 (Eng. Abstr.) **(Spa)**
[Acute abdomen caused by jejunal perforation as a clinical presentation of MEN-1 syndrome] Uriarte C, et al. **Rev Esp Enferm Dig** 1996 Apr;88(4):289–91 (Eng. Abstr.) **(Spa)**
[Acute abdomen due to mesenteric vasculitis as a presentation form of systemic lupus erythematosus] Palma S, et al. **Rev Med Chil** 1996 Jan;124(1):89–93 (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Acute abdomen due to anthrax. Tekin A, et al. **Br J Surg** 1997 Jun;84(6):813
[Aerobic and anaerobic bacterial flora in acute abdominal illnesses] Michalska W, et al. **Med Dosw Mikrobiol** 1995; 47(3-4):197–202 (Eng. Abstr.) **(Pol)**

PARASITOLOGY

Eustrongylidiasis--a parasitic infection acquired by eating live minnows. Narr LL, et al. **J Am Osteopath Assoc** 1996 Jul;96(7):400–2
[Liver abscess caused by Ascaris lumbricoides. Memorandum about hepatic changes in adopted children from developing countries] Sandholm E. **Lakartidningen** 1997 Jul 9; 94(28-29):2553–4 **(Swe)**

PHYSIOPATHOLOGY

A proposed relationship between increased intra-abdominal, intrathoracic, and intracranial pressure. Bloomfield GL, et al. **Crit Care Med** 1997 Mar;25(3):496–503

RADIOGRAPHY

Emergency computed tomography of the acute abdomen. Why? When and how to do it? Regent D, et al. **Acta Gastroenterol Belg** 1996 Apr-Jun;59(2):137–9
CT imaging of immunocompromised children with acute abdominal symptoms. Donnelly LF. **AJR Am J Roentgenol** 1996 Oct;167(4):909–13
Using CT to evaluate the acute abdomen: spectrum of urinary pathology. Johnson GL, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):273–6
Impact of CT on diagnosis and management of acute abdomen in patients initially treated without surgery.

Siewert B, et al. **AJR Am J Roentgenol** 1997 Jan; 168(1):173–8

CT evaluation of the acute abdomen: bowel pathology spectrum of disease. Johnson GL, et al. **Crit Rev Diagn Imaging** 1996 Aug;37(3):163–90 (8 ref.)

Unenhanced helical CT versus plain abdominal radiography: a dissenting opinion [comment] Baker SR. **Radiology** 1997 Oct;205(1):45–7. Comment on: Radiology 1997 Oct;205(1):43–5.

Unenhanced helical CT for evaluating acute abdominal pain: a little more cost, a lot more information [see comments] Mindelzun RE, et al. **Radiology** 1997 Oct;205(1):43–5. Comment in: Radiology 1997 Oct;205(1):45–7.

[Present possibilities and the role of imaging methods in the diagnosis of acute abdomen, particularly ileus] Válek V, et al. **Rozhl Chir** 1997 May;76(5):258–61 (Eng. Abstr.) **(Cze)**

[Value of abdominal CT in surgical intensive care patients] Rieger J, et al. **Rontgenpraxis** 1996 Sep;49(9):239–43 **(Ger)**

[Use of ultravist to examine the gastrointestinal tract in patients with emergency abdominal pathology] Beresneva EA, et al. **Vestn Rentgenol Radiol** 1997 May–Jun;(3):51–2 (Eng. Abstr.) **(Rus)**

SURGERY

Surgical management of diverticulitis. A two year retrospective study. Pattyn P, et al. **Acta Gastroenterol Belg** 1996 Apr–Jun;59(2):155–8

Acute abdomen in systemic lupus erythematosus: the importance of early laparotomy. Medina F, et al. **Am J Med** 1997 Aug;103(2):100–5

The outcome of elderly patients after operation for acute abdomen. Miettinen P, et al. **Ann Chir Gynaecol** 1996; 85(1):11–5

Emergency laparoscopy in a patient with severe asthma. Arrowsmith JE, et al. **Br J Hosp Med** 1996 May 1–14; 55(9):593

Measuring surgical performance in acute abdominal pain: some reflections from international studies. de Dombal FT, et al. **Eur J Surg** 1997 May;163(5):323–9

Emergency surgery in colorectal cancer. Lucisano E, et al. **J Chemother** 1997 Apr;9(2):142–3

Emergency abdominal surgery in the elderly. McIntyre R, et al. **J R Coll Surg Edinb** 1997 Jun;42(3):173–8

Pediatric abdominal surgical emergencies. Pollack ES. **Pediatr Ann** 1996 Aug;25(8):448–57

Acute abdomen. When to operate immediately and when to observe. Gauderer MW. **Semin Pediatr Surg** 1997 May; 6(2):74–80

Acute abdomen. The role of laparoscopy. Lobe TE. **Semin Pediatr Surg** 1997 May;6(2):81–7

The efficacy of laparoscopic surgery in the diagnosis and treatment of peritonitis. Experience with 107 cases in Mexico City. Cueto J, et al. **Surg Endosc** 1997 Apr; 11(4):366–70

The acute abdomen in the pregnant patient. Is there a role for laparoscopy? Gurbuz AT, et al. **Surg Endosc** 1997 Feb; 11(2):98–102 (33 ref.)

Acute abdomen requiring emergency surgery in renal allograft recipients during a single center cohort follow-up. Gutiérrez de la Barrera M, et al. **Transplant Proc** 1996 Dec; 28(6):3333–4

[How to approach an acute surgical abdomen in Africa?] Vicq P, et al. **Med Trop (Mars)** 1996;56(2):131–6 (4 ref.) **(Fre)**

[Incarcerated diaphragmatic hernia as a sequela of iatrogenic diaphragmatic defect. 2 case reports] Peterli R, et al. **Chirurg** 1996 Oct;67(10):1050–2 (Eng. Abstr.) **(Ger)**

[Acute abdominal pain. Surgeon's viewpoint] Largiadèr J. **Schweiz Rundsch Med Prax** 1997 Feb 4;86(6):209–13 (Eng. Abstr.) **(Ger)**

[Aneurysms of the splanchnic arteries] Masciariello S, et al. **Minerva Chir** 1997 Jan–Feb;52(1–2):45–52 (Eng. Abstr.) **(Ita)**

[Abdominal surgical emergencies in patients with acquired immunodeficiency syndrome] Steinman M, et al. **Rev Assoc Med Bras** 1996 Jan–Mar;42(1):19–24 (Eng. Abstr.) **(Por)**

[Role of laparocentesis in emergency surgery] Antoniuk SM, et al. **Klin Khir** 1996;(6):14–6 **(Rus)**

[An analysis of the treatment indices of patients with acute surgical diseases of the abdominal organs in Saint-Petersburg over 50 years (1946–1996)] Borisov AE, et al. **Vestn Khir Im I I Grek** 1997;156(3):35–9 (Eng. Abstr.) **(Rus)**

THERAPY

Deep assessment of machine learning techniques using patient treatment in acute abdominal pain in children. Blazadonakis M, et al. **Artif Intell Med** 1996 Nov;8(6):527–42

ULTRASONOGRAPHY

Acute abdomen. Is ultrasonography useful, essential or unnecessary? Brisbois D, et al. **Acta Gastroenterol Belg** 1996 Apr–Jun;59(2):134–6

Sonography and the acute abdomen: practical considerations. Puylaert JB, et al. **AJR Am J Roentgenol** 1997 Jan; 168(1):179–86

[Appendicitis in childhood] Hahn H, et al. **Radiologe** 1997 Jun;37(6):454–8 (Eng. Abstr.) **(Ger)**

[Vaginal ultrasound in perityphlitic abscess] Hönigl W, et al. **Ultraschall Med** 1997 Feb;18(1):39–41 (Eng. Abstr.) **(Ger)**

VETERINARY

Liver torsion and associated bacterial peritonitis in a dog. McConkey S, et al. **Can Vet J** 1997 Jul;38(7):438–9

ABDOMINAL ABSCESS

Degos' disease: radiological and immunological aspects. Yoshikawa H, et al. **Acta Neurol Scand** 1996 Nov; 94(5):353–6

[Atypical abdominal abscesses] Beláček J, et al. **Rozhl Chir** 1996 Nov;75(11):528–31 (Eng. Abstr.) **(Slo)**

BLOOD

The influence of surgery on cytokines in patients with intra-abdominal sepsis. Hammond JM, et al. **Anaesth Intensive Care** 1996 Aug;24(4):430–4

COMPLICATIONS

Recurrent muscle abscesses in a patient with HIV infection: beware the Baron von Munchausen [letter] Wolf LE, et al. **AIDS** 1996 Jun;10(6):685–7

Pelvic inflammatory pseudotumor with central infectious abscess: a case report. Han CP, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Nov;58(5):374–9

Cavernous sinus thrombosis secondary to abdominal wall abscess. Jinbayashi H, et al. **Ophthalmologica** 1997; 211(5):308–11

Inflammatory pseudotumor of the liver associated with extrahepatic infection. White JE, et al. **South Med J** 1997 Jan;90(1):23–9 (48 ref.)

DIAGNOSIS

Intraabdominal abscesses: image-guided diagnosis and therapy. Montgomery RS, et al. **Clin Infect Dis** 1996 Jul; 23(1):28–36 (60 ref.)

Five cases of extraoral infection associated with Eikenella corrodens [letter] Nebreda T, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):254–6

Splenic abscess with Clostridium novyi bacteraemia and sepsis. Vleminckx WG, et al. **Eur J Gastroenterol Hepatol** 1997 Mar;9(3):303–5

Pyomyositis—a differential diagnosis in the acute abdomen. Mangell P, et al. **Eur J Surg** 1997 Jul;163(7):553–5 (11 ref.)

Retroperitoneal fungal abscess presenting as superior mesenteric artery syndrome. Siddiqui MN, et al. **Postgrad Med J** 1996 Jul;72(849):433–4

"Splenic abscess in a HIV patient". Swamy TK, et al. **Trop Gastroenterol** 1995 Jul–Sep;16(3):29–31

Splenic abscesses and abdominal tuberculosis in patients with AIDS. Reichel C, et al. **Z Gastroenterol** 1996 Aug; 34(8):494–6

DRUG THERAPY

In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Thadepalli H, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):583–6

Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Thauvin-Eliopoulos C, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1053–7

Trial of electrolyzed strong acid aqueous solution lavage in the treatment of peritonitis and intraperitoneal abscess. Inoue Y, et al. **Artif Organs** 1997 Jan;21(1):28–31

Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. Wilson SE. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S197–206

Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Falagas ME, et al. **Eur J Clin Microbiol Infect Dis** 1996 Dec; 15(12):913–21

[Piperacillin/tazobactam in the treatment of abdominal sepsis in patients with peritonitis] Gel'fand BR, et al. **Antibiot Khimioter** 1997;42(2):17–20 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Primary repair of 58 consecutive penetrating injuries of the colon: should colostomy be abandoned? Jacobson LE, et al. **Am Surg** 1997 Feb;63(2):170–7

Predictors of outcome in patients with postoperative intra-abdominal infection. Grunau G, et al. **Eur J Surg** 1996 Aug;162(8):619–25

ETIOLOGY

Intra-abdominal abscess and tumor-enteric fistula formation: an unusual complication of chemotherapy for advanced testicular choriocarcinoma [letter] Stein ME, et al. **Ann Oncol** 1996 Jul;7(5):536–7

Major acute inflammatory complications of diverticular disease of the colon: planning of surgical management. Tucci G, et al. **Hepatogastroenterology** 1996 Jul–Aug; 43(10):839–45

Abdominal wall sinus: a late complication of gallstone spillage during laparoscopic cholecystectomy. Graham MD, et al. **HPB Surg** 1997;10(3):163–4

Comment on the article by Leuken et al (2(3)269–272, 1995) [letter] Wright BD. **J Am Assoc Gynecol Laparosc** 1995 Nov;3(1):121–2

Pelvic abscess following laparoscopic appendectomy [letter] Frizelle FA, et al. **Surg Endosc** 1996 Sep;10(9):947–8 (30 ref.)

The effects of sterile or infected bile and dropped gallstones in abdominal adhesions and abscess formation. Soybir GR, et al. **Surg Endosc** 1997 Jul;11(7):711–3

Is it necessary to retrieve dropped gallstones during laparoscopic cholecystectomy? Zorluoğlu A, et al. **Surg Endosc** 1997 Jan;11(1):64–6

Clinical manifestations of lost gallstones after laparoscopic cholecystectomy: a case report with review of the literature. Läuffer JM, et al. **Surg Laparosc Endosc** 1997 Apr;7(2):103–12 (69 ref.)

Abscesses caused by "dropped" stones after laparoscopic cholecystectomy for cholelithiasis: a report of three cases. Hashimoto M, et al. **Surg Today** 1997;27(4):364–7

[A pelvic and abdominal wall abscess secondary to a perianal abscess (letter)] Acea Nebril B, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):69–70 **(Spa)**

IMMUNOLOGY

Age-dependent susceptibility to intraabdominal abscess formation. Lally KP, et al. **J Pediatr Surg** 1996 Feb; 31(2):301–3

MICROBIOLOGY

Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Thauvin-Eliopoulos C, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1053–7

Hepatosplenic abscesses due to Brucella melitensis: report of a case involving a child and review of the literature. Vallejo JG, et al. **Clin Infect Dis** 1996 Mar;22(3):485–9 (22 ref.)

Five cases of extraoral infection associated with Eikenella corrodens [letter] Nebreda T, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):254–6

Actinomycosis of the large bowel: unusual presentations and their surgical treatment. Dayan K, et al. **Eur J Surg** 1996 Aug;162(8):657–60

Animal models for intra-abdominal infection. Sayek I. **Hepatogastroenterology** 1997 Jul–Aug;44(16):923–6 (22 ref.)

[Abdominal actinomycosis. Two cases from a department of surgery] Aaseby J, et al. **Ugeskr Laeger** 1997 Jul 14; 159(29):4534–5 (Eng. Abstr.) **(Dan)**

[Acute systemic nocardiosis. Renal abscess] Valbuena Alvarez R, et al. **Arch Esp Urol** 1996 Jun;49(5):529–31 (Eng. Abstr.) **(Spa)**

PATHOLOGY

Lung microvessel injury from peritoneal abscesses and gram-negative bacteremia. Jones R, et al. **Microvasc Res** 1996 Jul;52(1):84–100

[Broad actinomyces abscess in pelvic cavity and abdominal wall—a case report] Terada Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Oct;48(10):904–6 **(Jpn)**

PREVENTION & CONTROL

[The pathophysiology and treatment of severe intra-abdominal abscess] Shinagawa N. **Nippon Geka Gakkai Zasshi** 1996 Dec;97(12):1048–53 (5 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Leucocyte scintigraphy or computed tomography for the febrile post-operative patient? Bearcroft PW, et al. **Eur J Radiol** 1996 Sep;23(2):126–9

CT in searching for abscess after abdominal or pelvic surgery in patients with neoplasia: do abdomen and pelvis both need to be scanned? Krumenacker JH, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):652–5

Abdominal actinomycosis: barium enema and computed tomography findings. Uchiyama N, et al. **J Gastroenterol** 1997 Feb;32(1):89–94

An unusual presentation of tuberculosis. Dean G, et al. **Trop Doct** 1997 Jul;27(3):185–6

[Prognostic value of early CT examination for evaluating duration and complications in acute pancreatitis] Tarasów E, et al. **Pol Merkuriusz Lek** 1997 Jan;2(7):26–7 (Eng. Abstr.) **(Pol)**

SURGERY

Postoperative intraabdominal abscesses: percutaneous versus surgical treatment. Bufalari A, et al. **Acta Chir Belg** 1996 Sep–Oct;96(5):197–200

Percutaneous drainage of intra-abdominal abscesses in Crohn's disease: short and long-term outcome. Sahai A, et al. **Am J Gastroenterol** 1997 Feb;92(2):275–8

The influence of surgery on cytokines in patients with intra-abdominal sepsis. Hammond JM, et al. **Anaesth Intensive Care** 1996 Aug;24(4):430–4

ABDOMINAL ABSCESS

Use of laparoscopic trocar for percutaneous introduction of drains into intra-abdominal abscess [letter; comment] Demartines N, et al. **Br J Surg** 1996 Dec;83(12):1799. Comment on: **Br J Surg** 1996 May;83(5):670–1.

Percutaneous drainage of intra-abdominal abscesses using large lumen tubes under computed tomographic control. Voros D, et al. **Eur J Surg** 1996 Nov;162(11):895–8

Percutaneous drainage of enteric-related abscesses. Fulcher AS, et al. **Gastroenterologist** 1996 Dec;4(4):276–85 (36 ref.)

Major acute inflammatory complications of diverticular disease of the colon: planning of surgical management. Tucci G, et al. **Hepatogastroenterology** 1996 Jul–Aug; 43(10):839–45

[Asymmetric hypertrophic cardiomyopathy in a septic patient—intraoperative preliminary diagnosis with transesophageal echocardiography] Greim CA, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jul; 32(7):463–5 (Eng. Abstr.) **(Ger)**

[Late abscess after laparoscopic cholecystectomy caused by lost gallstones] Zarras K, et al. **Chirurg** 1996 Oct; 67(10):1047–9 (Eng. Abstr.) **(Ger)**

THERAPY

The role of invasive sonography in the differential diagnosis and treatment of intraabdominal fluid collections. Regöly-Mérei J, et al. **Acta Chir Hung** 1995–96; 35(3–4):185–99

Re: Fallopian tube communication after percutaneous abdominal abscess drainage [letter] Herskowitz MM, et al. **Cardiovasc Intervent Radiol** 1997 Sep–Oct;20(5):409

Intraabdominal abscesses: image-guided diagnosis and therapy. Montgomery RS, et al. **Clin Infect Dis** 1996 Jul; 23(1):28–36 (60 ref.)

Neonatal adrenal abscesses. Steffens J, et al. **Eur Urol** 1997; 31(3):347–9

Combined transrectal sonographic and fluoroscopic guidance for deep pelvic abscess drainage. Kastan DJ, et al. **J Ultrasound Med** 1996 Mar;15(3):235–9

[Abdominal abscesses: their treatment and the study of prognostic factors] Giangreco L, et al. **Minerva Chir** 1997 Apr;52(4):369–76 (Eng. Abstr.) **(Ita)**

[CT-guided drainage of intra-abdominal abscess] Manenti A, et al. **Minerva Chir** 1996 Oct;51(10):809–12 (Eng. Abstr.) **(Ita)**

[Clinical course of prostatic abscess treated with transperineal drainage] Ruiz de la Roja JC, et al. **Actas Urol Esp** 1996 Jul–Aug;20(7):672–5 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

The role of invasive sonography in the differential diagnosis and treatment of intraabdominal fluid collections. Regöly-Mérei J, et al. **Acta Chir Hung** 1995–96; 35(3–4):185–99

Sclerosing peritonitis with gross peritoneal calcification and abdominal wall abscess secondary to bowel perforation: ultrasonographic appearance. Verbanck JJ, et al. **J Clin Ultrasound** 1997 Mar–Apr;25(3):136–40

Combined transrectal sonographic and fluoroscopic guidance for deep pelvic abscess drainage. Kastan DJ, et al. **J Ultrasound Med** 1996 Mar;15(3):235–9

[Endosonography control of percutaneous paracoccygeal drainage of deep pelvic abscesses after rectum resection] Truong S, et al. **Chirurg** 1997 Jun;68(6):633–7 (Eng. Abstr.) **(Ger)**

[Vaginal ultrasound in perityphlitic abscess] Hönigl W, et al. **Ultraschall Med** 1997 Feb;18(1):39–41 (Eng. Abstr.) **(Ger)**

[The ultrasonic study method in the diagnosis and treatment of abscesses and inflammatory infiltrates of the abdominal cavity] Kuznetsov NM, et al. **Voen Med Zh** 1997 Feb; 318(2):35–7 **(Rus)**

ABDOMINAL CRAMPS see **COLIC**

ABDOMINAL DECOMPRESSION see **LOWER BODY NEGATIVE PRESSURE**

ABDOMINAL INJURIES

Disruption of cholecystoenteric fistula induced by minor blunt trauma. Nadu A, et al. **J Trauma** 1996 Nov; 41(5):914–5

[Closed abdominal injuries] Massaia Lamberti G, et al. **Minerva Chir** 1997 Mar;52(3):235–41 (Eng. Abstr.) **(Ita)**

[Severe multiple trauma in a victim during the 3d trimester of pregnancy with traumatic delivery into the abdominal cavity] Baramiia NN, et al. **Klin Khir** 1996;(6):47–8 **(Rus)**

[Gunshot injury of the aorta] Guch OO, et al. **Klin Khir** 1996; (5):53–4 **(Ukr)**

COMPLICATIONS

Kleibauer-Betke test for pregnant trauma patients [letter; comment] Johnson KH. **Am Fam Physician** 1997 Feb 15; 55(3):781–2. Comment on: Am Fam Physician 1996 Mar;53(4):1269–74.

Randomized blinded study of aprotinin infusion for liver crush injuries in the pig model. Thomae KR, et al. **Am Surg** 1997 Feb;63(2):113–20

Air embolism following abdominal stab-wound [letter] Southern DA, et al. **Anaesth Intensive Care** 1996 Oct; 24(5):623

Benign hepatic portal venous gas following blunt abdominal trauma. Dill-Macky MJ. **Australas Radiol** 1997 May; 41(2):166–8

Delayed rupture of the spleen and streptokinase therapy. Nam R, et al. **Can J Surg** 1996 Apr;39(2):151–4

Appendicitis after blunt abdominal trauma: cause or coincidence? Ciftci AO, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):350–3 (26 ref.)

Posttraumatic intestinal stenosis: radiographic and sonographic appearance. Loberant N, et al. **Eur Radiol** 1997;7(4):524–6

Complete transection of the left hepatic duct due to blunt abdominal trauma. Miyakawa S, et al. **Hepatogastroenterology** 1996 Sep–Oct;43(11):1395–8

Delayed presentation of porta hepatis injury following blunt abdominal trauma. Lau LL, et al. **HPB Surg** 1997; 10(4):249–52

Endoscopic management of perforation of right hepatic duct following non-surgical abdominal trauma. Sharma BC, et al. **HPB Surg** 1997;10(4):245–7

Stomach jolt—a possible mechanism for gastrosplenic injury in blunt abdominal trauma. Garg P, et al. **Indian J Gastroenterol** 1996 Oct;15(4):153

Traumatic asphyxia in children. Sarihan H, et al. **J Cardiovasc Surg (Torino)** 1997 Feb;38(1):93–5

Bullet embolus to the right pulmonary artery after abdominal gunshot wound with "piggyback bullet". Panichabhongse V, et al. **J Med Assoc Thai** 1996 Oct;79(10):676–9

Splanchnic artery pseudo-aneurysms secondary to blunt abdominal trauma in children. Gow KW, et al. **J Pediatr Surg** 1996 Jun;31(6):812–5

Pitfalls of nonoperative management of blunt abdominal trauma in children in Korea. Yoo SY, et al. **J Pediatr Surg** 1996 Feb;31(2):263–6

Post-traumatic small bowel obstruction. Allen JC. **J R Army Med Corps** 1994 Feb;140(1):47–8

Biliary-pleural fistula presenting as a massive pleural effusion after thoracoabdominal penetrating trauma. Bamberger PK, et al. **J Trauma** 1997 Jul;43(1):162–3

Conservative treatment of a traumatic tear of the left hepatic duct: case report. Eid A, et al. **J Trauma** 1996 Nov; 41(5):912–3

Traumatic pneumatosis cystoides intestinalis with portal venous air embolism. Kelly BS Jr, et al. **J Trauma** 1997 Jan;42(1):112–4

Traumatic uterine prolapse. Mukalian GG. **J Trauma** 1997 Mar;42(3):553–4

A simple stenting method for management of hepatic ductal injury secondary to blunt abdominal trauma: two case reports. Sakamoto Y, et al. **J Trauma** 1997 Jun;42(6):1165–8

Hypotension after blunt abdominal trauma: the role of emergent abdominal sonography in surgical triage. Wherrett LJ, et al. **J Trauma** 1996 Nov;41(5):815–20

Renal colic following a gunshot wound to the abdomen: the birdshot calculus. Harrington TG, et al. **J Urol** 1997 Apr; 157(4):1351–2

Stricture of the duodenum and jejunum in an abused child. Shah P, et al. **Pediatr Radiol** 1997 Mar;27(3):281–3

Post-traumatic costochondritis caused by Candida albicans. Aetiology, diagnosis and treatment. Heckenkamp J, et al. **Scand Cardiovasc J** 1997;31(3):165–7 (12 ref.)

Delayed manifestation of aortic stenosis after blunt abdominal trauma: report of a case. Shindo S, et al. **Surg Today** 1997; 27(1):76–9

[Post-traumatic splenic pseudocyst in a child and surgical treatment] Kirchmannová L, et al. **Rozhl Chir** 1996 Jun; 75(6):313–5 (Eng. Abstr.) **(Cze)**

[Post-traumatic hematoma of the duodenum. A case in a young child] Boulos L, et al. **J Radiol** 1997 Jan;78(1):61–4 (Eng. Abstr.) **(Fre)**

[Traumatic rupture of duodenal diverticulum. Report of a case and literature review] Souza Júnior A de L, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Nov–Dec; 51(6):247–9 (29 ref.) (Eng. Abstr.) **(Por)**

[Tissue embolism of the pulmonary arteries in a gunshot wound of the chest and abdomen] Sakharov GIu, et al. **Sud Med Ekspert** 1997 Jul–Sep;40(3):43 **(Rus)**

DIAGNOSIS

Is closed diagnostic peritoneal lavage contraindicated in patients with previous abdominal surgery? Moore GP, et al. **Acad Emerg Med** 1997 Apr;4(4):287–90

Incremental analysis of diagnostic peritoneal lavage fluid in adult abdominal trauma. Sullivan KR, et al. **Am J Emerg Med** 1997 May;15(3):277–9

The role of laparoscopy in blunt abdominal trauma. Leppäniemi AK, et al. **Ann Med** 1996 Dec;28(6):483–9 (52 ref.)

Evaluation of diagnostic peritoneal lavage in stable patients with gunshot wounds to the abdomen. Kelemen JJ 3rd, et al. **Arch Surg** 1997 Aug;132(8):909–13

Blunt injury of the small intestine and mesentery—the trauma surgeon's Achilles heel? Bloom AI, et al. **Eur J Emerg Med** 1996 Jun;3(2):85–91

The value of physical examination in the diagnosis of patients with blunt abdominal trauma: a retrospective study. Schurink GW, et al. **Injury** 1997 May;28(4):261–5

Superman play and pediatric blunt abdominal trauma. Machi JM, et al. **J Emerg Med** 1996 May–Jun;14(3):327–30

Laparoscopy for triage of penetrating trauma: the decision to explore. Ditmars ML, et al. **J Laparoendosc Surg** 1996 Oct;6(5):285–91

Diagnostic laparoscopy for dog bite wounds to the abdomen [letter] Namias N, et al. **J Laparoendosc Surg** 1996 Dec; 6(6):435–6

The use of laparoscopy in the management of seat belt trauma in children. VanderKolk WE, et al. **J Laparoendosc Surg** 1996 Mar;6 Suppl 1:S45–9

Can ultrasonography replace computed tomography in the initial assessment of children with blunt abdominal trauma? [see comments] Katz S, et al. **J Pediatr Surg** 1996 May; 31(5):649–51. Comment in: J Pediatr Surg 1997 Feb;32(2):382–3.

Diagnosis of injuries after stab wounds to the back and flank. Boyle EM Jr, et al. **J Trauma** 1997 Feb;42(2):260–5

A method of determining peritoneal penetration in gunshot wounds to the abdomen. Nagy KK, et al. **J Trauma** 1997 Aug;43(2):242–5; discussion 245–6

Isolated avulsion of the middle colic artery with colonic infarction after blunt abdominal trauma. Patel S, et al. **J Trauma** 1997 Jul;43(1):137–9

Diagnostic and therapeutic laparoscopy for penetrating abdominal trauma: a multicenter experience. Zantut LF, et al. **J Trauma** 1997 May;42(5):825–9; discussion 829–31

Vomiting and anuria after bicycle accident. Swischuk LE. **Pediatr Emerg Care** 1996 Apr;12(2):137–9

Laparoscopic diagnosis of blunt abdominal trauma in children. Hasegawa T, et al. **Pediatr Surg Int** 1997 Feb; 12(2–3):132–6

Cost analysis of diagnostic laparoscopy vs laparotomy in the evaluation of penetrating abdominal trauma. Marks JM, et al. **Surg Endosc** 1997 Mar;11(3):272–6

[Blunt abdominal trauma with lesion of the abdominal aorta—a case report] Leiser A, et al. **Swiss Surg** 1997; 3(4):181–4 (Eng. Abstr.) **(Ger)**

[The value of diagnostic peritoneal lavage in emergency situations] Rhiner R, et al. **Swiss Surg** 1997;3(2):85–91 (Eng. Abstr.) **(Ger)**

[Value of diagnostic laparoscopy in abdominal trauma] Röthlin M, et al. **Unfallchirurg** 1997 Jul;100(7):595–600 (60 ref.) **(Ger)**

[The role of diagnostic laparoscopy in treatment of penetrating injuries of the lower thoracic wall and anterior abdominal wall] Ertekin C, et al. **Zentralbl Chir** 1997; 122(7):535–7 (Eng. Abstr.) **(Ger)**

[Role of laparoscopy in abdominal traumas: a case report] Amendolara M, et al. **G Chir** 1997 Mar;18(3):111–4 (Eng. Abstr.) **(Ita)**

[Diagnostic laparoscopy in abdominal injuries] Gruppel' GG, et al. **Khirurgiia (Mosk)** 1997;(6):26–8 (Eng. Abstr.) **(Rus)**

[Problems in the diagnosis and surgical care of thoracoabdominal wounds] Korolev MP, et al. **Vestn Khir Im I I Grek** 1997;156(1):83–6 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Duration of antibiotic treatment in surgical infections of the abdomen. Penetrating abdominal trauma. Hirshberg A, et al. **Eur J Surg Suppl** 1996;(576):56–7; discussion 57–8

Duration of antibiotic treatment in surgical infections of the abdomen. Blunt abdominal trauma. Melcher GA, et al. **Eur J Surg Suppl** 1996;(576):59–60

Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury. Fabian TC, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):951–7

ECONOMICS

Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury. Fabian TC, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):951–7

EPIDEMIOLOGY

A nationwide analysis of laparoscopic complications. Härkki-Sirén P, et al. **Obstet Gynecol** 1997 Jan;89(1):108–12

Air bags alone compared with the combination of mechanical restraints and air bags: implications for the emergency evaluation of crash victims. Sutyak JP, et al. **South Med J** 1997 Sep;90(9):915–9

[Combined trauma—an analysis of a 10-year period] Radenovski D, et al. **Khirurgiia (Sofiia)** 1996;49(2):30–8 (Eng. Abstr.) **(Bul)**

[Traumatic lesions of the thoracic and abdominal organs in childhood] Trifonov G, et al. **Khirurgiia (Sofiia)** 1996; 49(3):18–23 (Eng. Abstr.) **(Bul)**

ETIOLOGY

Multiple impalement with survival. Vaslef SN, et al. **Am J Emerg Med** 1997 Jan;15(1):70–2

Handlebar injuries in children: patterns and prevention. Clarnette TD, et al. **Aust N Z J Surg** 1997 Jun;67(6):338–9

Urethral injury in girls with fractured pelvis following blunt abdominal trauma. Ahmed S, et al. **Br J Urol** 1996 Sep; 78(3):450–3

Air-powered guns: too much firepower to be a toy. Bond SJ, et al. **J Trauma** 1996 Oct;41(4):674–8

Diagnosis of injuries after stab wounds to the back and flank. Boyle EM Jr, et al. **J Trauma** 1997 Feb;42(2):260–5

HISTORY

The adoption of laparotomy for the treatment of penetrating abdominal wounds in war. Bamberger PK. **Mil Med** 1996 Apr;161(4):189–96

MORTALITY

Severely injured patients in the intensive care unit: a critical analysis of outcome and unexpected deaths identified by the TRISS methodology. Coimbra R, et al. **Int Surg** 1996 Jan–Mar;81(1):102–6

NURSING

Laparoscopic applications for abdominal trauma injuries. Pilcher CJ, et al. **AORN J** 1996 Sep;64(3):366–75

PATHOLOGY

Portal vein embolization following shotgun–pellet injuries to the abdomen. Yates TE, et al.
Am J Forensic Med Pathol 1996 Jun;17(2):151–4

Intrapancreatic avulsion of common bile duct after blunt abdominal trauma. Chow LW, et al. **Eur J Surg** 1996 Jun; 162(6):519–21

Laceration of the liver with delayed massive intra–abdominal hemorrhage: a case report of child abuse. Aoki Y, et al. **Nippon Hoigaku Zasshi** 1997 Feb;51(1):44–7

[Marks on clothing and skin in absolutely and relatively close distance gunshots with fright weapons] Nadjem H, et al. **Arch Kriminol** 1996 May–Jun;197(5–6):175–84 (Eng. Abstr.) **(Ger)**

[Isolated trauma of the pancreas and splenic artery] Bastuev NV, et al. **Sud Med Ekspert** 1997 Jan–Mar;40(1):48–9 (Eng. Abstr.) **(Rus)**

[The diagnosis of the types of automobile–caused trauma by the nature of the injuries to the internal abdominal organs] Solokhin AA, et al. **Sud Med Ekspert** 1996 Jul–Sep; 39(3):9–13 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Intestinal injury mechanisms after blunt abdominal impact. Cripps NP, et al. **Ann R Coll Surg Engl** 1997 Mar; 79(2):115–20

Traumatic pneumatosis cystoides intestinalis with portal venous air embolism. Kelly BS Jr, et al. **J Trauma** 1997 Jan;42(1):112–4

[The characteristics of changes in the hemodynamics and respiratory function of children with severe closed abdominal trauma] Tsareva M, et al. **Khirurgiia (Sofiia)** 1996;49(3):24–9 (Eng. Abstr.) **(Bul)**

[Abdominal gunshot wounds. Ballistic data and practical management] Vicq P, et al. **Cah Anesthesiol** 1996; 44(4):327–33 (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Handlebar injuries in children: patterns and prevention. Clarnette TD, et al. **Aust N Z J Surg** 1997 Jun;67(6):338–9

[Open laparoscopy for prevention of puncture injuries] Köckerling F, et al. **Chirurg** 1996 Feb;67(2):183–7 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Aspiration after administration of oral contrast material in children undergoing abdominal CT for trauma. Lim–Dunham JE, et al. **AJR Am J Roentgenol** 1997 Oct; 169(4):1015–8

Blunt abdominal trauma in children: impact of CT on operative and nonoperative management. Ruess L, et al. **AJR Am J Roentgenol** 1997 Oct;169(4):1011–4

The role of "one–shot" intravenous pyelogram in evaluation of penetrating abdominal trauma. Patel VG, et al.
Am Surg 1997 Apr;63(4):350–3

Effect of oral contrast administration for abdominal computed tomography in the evaluation of acute blunt trauma. Tsang BD, et al. **Ann Emerg Med** 1997 Jul; 30(1):7–13

A review of computerized tomography in blunt abdominal trauma at Christchurch Hospital. Bohmer RD, et al.
Australas Radiol 1997 Feb;41(1):16–9

Comparison of computed tomography and ultrasonographic imaging in the assessment of blunt abdominal trauma in children. Richardson MC, et al. **Br J Surg** 1997 Aug; 84(8):1144–6

Spiral computed tomography with three–dimensional reconstructions for severe blunt abdominal traumas: a useful complementary tool? Michel LA, et al.
Eur J Emerg Med 1997 Jun;4(2):87–93

Traumatic pancreatic duct rupture in a child diagnosed by endoscopic retrograde pancreatography. Hirata K, et al. **Eur J Pediatr Surg** 1997 Feb;7(1):48–9

The use of air weapons in attempted suicide. Campbell–Hewson G, et al. **Injury** 1997 Mar;28(2):153–8 (31 ref.)

Computed tomography and blunt abdominal injury: patient selection based on examination, haematocrit and haematuria. Richards JR, et al. **Injury** 1997 Apr;28(3):181–5

Blunt abdominal trauma. Degryse H, et al.
J Belge Radiol 1996 Dec;79(6):266

Pediatric blunt abdominal trauma: role of computed tomography vascular blush. Cox CS Jr, et al.
J Pediatr Surg 1997 Aug;32(8):1196–200

A review of computed tomography in the diagnosis of intestinal and mesenteric injury in pediatric blunt abdominal trauma. Graham JS, et al. **J Pediatr Surg** 1996 Jun; 31(6):754–6

Traumatic perforation of duodenal diverticulum. Poostizadeh A, et al. **J Trauma** 1997 Aug;43(2):370–1

Blunt abdominal trauma [letter; comment] Ratcliffe J.
Pediatr Radiol 1996 Nov;26(11):830. Comment on: Pediatr Radiol 1995;25(5):321–5. Comment on: Pediatr Radiol 1995;25(5):326–8. Comment on: Pediatr Radiol 1995;25(5):329–31.

Abdominal trauma: use of oral contrast material for CT is safe. Federle MP, et al. **Radiology** 1997 Oct;205(1):91–3

Choledochal cyst misinterpreted as a biloma after a blunt abdominal trauma. Vanlangenhove P, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Nov;165(5):496–8 (10 ref.)

Abdominal computed tomography scan as a screening tool in blunt trauma. Brasel KJ, et al. **Surgery** 1996 Oct; 120(4):780–3; discussion 783–4

[Spiral computerized tomography diagnosis of abdominal seat belt injuries in children] Klöppel R, et al.
Aktuelle Radiol 1997 Jan;7(1):19–22 (Eng. Abstr.) **(Ger)**

[Use of 3–D multi–tissue reconstruction of CT studies of the abdomen] Hünerbein R, et al. **Rontgenpraxis** 1996 Jul; 49(7):169–72 **(Ger)**

[Emergency computed tomography in closed trauma of the chest and abdomen] Abakumov MM, et al.
Vestn Khir Im I I Grek 1997;156(2):63–8 (Eng. Abstr.) **(Rus)**

[Possibilities of general x–ray studies in the diagnosis of wounds of the diaphragm] Beresneva ZA, et al.
Vestn Rentgenol Radiol 1996 May–Jun;(3):18–24 (Eng. Abstr.) **(Rus)**

SURGERY

Enterostomal complications: are emergently created enterostomas at greater risk? Del Pino A, et al.
Am Surg 1997 Jul;63(7):653–6

Use of ultrasound to determine need for laparotomy in trauma patients. Porter RS, et al. **Ann Emerg Med** 1997 Mar; 29(3):323–30

Abdominal wounds in war. Coupland R. **Br J Surg** 1996 Nov;83(11):1505–11 (57 ref.)

Penetrating trauma to the abdominal vessels. Khoury G, et al. **Cardiovasc Surg** 1996 Jun;4(3):405–7

Hepatic venous injury; a case report of atriocaval shunt by a centrifugal pump. Taga S, et al.
Hepatogastroenterology 1997 Jul–Aug;44(16):1219–21

Transection of common bile duct following blunt injury to abdomen. Krishnamurthy B, et al.
Indian J Gastroenterol 1997 Jul;16(3):109–10

Pancreatoduodenectomy in abdominal trauma: a viable alternative. Verma GR, et al. **Indian J Gastroenterol** 1997 Jan;16(1):26–7

Blunt trauma abdomen: a study of 63 cases. Gupta S, et al.
Indian J Med Sci 1996 Aug;50(8):272–6

Diagnostic laparoscopy and laparoscopic transdiaphragmatic pericardial window in a patient with an epigastric stab wound: a case report. Porter JM. **J Laparoendosc Surg** 1996 Feb;6(1):51–4

Pediatric blunt abdominal trauma: role of computed tomography vascular blush. Cox CS Jr, et al.
J Pediatr Surg 1997 Aug;32(8):1196–200

Diaphragmatic rupture. Mathews JA, et al.
J Tenn Med Assoc 1996 Apr;89(4):117–9

Diagnostic and therapeutic laparoscopy for penetrating abdominal trauma: a multicenter experience. Zantut LF, et al. **J Trauma** 1997 May;42(5):825–9; discussion 829–31

Damage control for abdominal trauma. Hirshberg A, et al.
Surg Clin North Am 1997 Aug;77(4):813–20 (16 ref.)

Autotransfusion with laparoscopically salvaged blood in trauma: report on 21 cases. Zantut LF, et al.
Surg Laparosc Endosc 1996 Feb;6(1):46–8

Management of penetrating abdominal injuries. McFarlane M. **West Indian Med J** 1995 Dec;44(4):140–2

[Injuries of organs in the abdominal and retroperitoneal cavities] Michek J, et al. **Rozhl Chir** 1996 May;75(5):266–8 (Eng. Abstr.) **(Cze)**

[Duodenopancreatic injuries. Apropos of 30 cases] Errougani A, et al. **J Chir (Paris)** 1997 May;134(1):9–13 (Eng. Abstr.) **(Fre)**

[Impalement injury of the colon, iliac vein and sacrum—a rare combination in penetrating abdominal trauma. A case report] Funke M, et al. **Chirurg** 1996 Nov;67(11):1184–7 (27 ref.) (Eng. Abstr.) **(Ger)**

[Injuries to the pancreas] Jacobi T, et al. **Chirurg** 1997 Jun; 68(6):624–9 (Eng. Abstr.) **(Ger)**

[Diaphragmatic injuries—classification, diagnosis and therapy] Steinau G, et al. **Chirurg** 1997 May;68(5):509–12 (18 ref.) (Eng. Abstr.) **(Ger)**

[Aspects relevant for abdominal surgery of attempted suicide] Nagel E, et al. **Langenbecks Arch Chir** 1997;382(1):29–32 (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of diaphragmatic rupture after blunt thoracic and abdominal trauma] Ruf G, et al.
Zentralbl Chir 1996;121(1):24–9 (Eng. Abstr.) **(Ger)**

[Long term results of spleen trauma treatment] Afendulov SA, et al. **Khirurgiia (Mosk)** 1997;(5):49–51 (Eng. Abstr.) **(Rus)**

[Role of laparocentesis in emergency surgery] Antoniuk SM, et al. **Klin Khir** 1996;(6):14–6 **(Rus)**

[The surgical procedure in left–sided thoracoabdominal knife wounds] Abakumov MM, et al.
Vestn Khir Im I I Grek 1997;156(1):86–90 (Eng. Abstr.) **(Rus)**

[The successful resuscitation and treatment of a female patient with a thoracicoabdominal wound and multiple injuries to the organs at a branch hospital] Abrosimov IP, et al.
Vestn Khir Im I I Grek 1996;155(5):90 **(Rus)**

[Gunshot wounds of the abdomen] Alisov PG, et al.
Vestn Khir Im I I Grek 1995;154(4–6):48–53 (Eng. Abstr.) **(Rus)**

[Emergency pancreaticoduodenal resection in closed abdominal trauma] Dolgushin NE, et al.
Vestn Khir Im I I Grek 1996;155(2):58–9 (17 ref.) **(Rus)**

[The immediate results of treating gunshot injuries to the liver in penetrating abdominal wounds (based on data from a military garrison hospital)] Guseinov BN.
Vestn Khir Im I I Grek 1996;155(6):64–5 (Eng. Abstr.) **(Rus)**

[An unusual penetrating wound of the abdomen by a tree trunk] Tufanov SA. **Vestn Khir Im I I Grek** 1996;155(2):57 **(Rus)**

[Problems of the surgical approach in splenic injury] Urakcheev ShK, et al. **Vestn Khir Im I I Grek** 1996; 155(6):66–8 (Eng. Abstr.) **(Rus)**

[Advantages of laparatomy in the treatment of closed injuries of the abdomen and retroperitoneal space] Tomusiak TL.
Klin Khir 1996;(6):11–2 **(Ukr)**

THERAPY

Blunt abdominal trauma and severe pelvic rupture. What to do? Hötker U, et al. **Acta Chir Belg** 1997 Apr;97(2):65–8 (16 ref.)

How many antibiotics are necessary to treat abdominal trauma victims? Sims EH, et al. **Am Surg** 1997 Jun; 63(6):525–35

Autotransfusion utilization in abdominal trauma. Smith LA, et al. **Am Surg** 1997 Jan;63(1):47–9

Treatment of chronic, nonhealing abdominal wound in a liquid environment. Eriksson E, et al. **Ann Plast Surg** 1996 Jan;36(1):80–3

Selective nonoperative management of gunshot wounds of the anterior abdomen. Demetriades D, et al. **Arch Surg** 1997 Feb;132(2):178–83

Blunt abdominal trauma. A review of 637 patients. Ball SK, et al. **J Miss State Med Assoc** 1996 Feb;37(2):465–8

Predicting life–threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. Cosgriff N, et al. **J Trauma** 1997 May; 42(5):857–61; discussion 861–2

Selective nonoperative management of abdominal stab wounds: prospective, randomized study. Leppäniemi AK, et al. **World J Surg** 1996 Oct;20(8):1101–5; discussion 1105–6

[Closed traumas of the abdomen: nonsurgical treatment] Di Lauro G, et al. **Minerva Chir** 1997 Jun;52(6):747–51 (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Emergency physician use of ultrasonography in blunt abdominal trauma. Ingeman JE, et al. **Acad Emerg Med** 1996 Oct;3(10):931–7

Sonographic examination of abdominal trauma by senior surgical residents. Kern SJ, et al. **Am Surg** 1997 Aug; 63(8):669–74

The role of ultrasonography in blunt abdominal trauma: a prospective study. McElveen TS, et al. **Am Surg** 1997 Feb; 63(2):184–8

Ultrasound in the evaluation and management of blunt abdominal trauma. Nordenholz KE, et al.
Ann Emerg Med 1997 Mar;29(3):357–66 (51 ref.)

Use of ultrasound to determine need for laparotomy in trauma patients. Porter RS, et al. **Ann Emerg Med** 1997 Mar; 29(3):323–30

Comparison of computed tomography and ultrasonographic imaging in the assessment of blunt abdominal trauma in children. Richardson MC, et al. **Br J Surg** 1997 Aug; 84(8):1144–6

Hepatic trauma in children: long–term follow–up. Farron F, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):347–9

Role of ultrasonography in blunt abdominal trauma: a prospective study. Abu–Zidan FM, et al. **Eur J Surg** 1996 May;162(5):361–5 (19 ref.)

Blunt abdominal injuries. Diagnostic peritoneal lavage, ultrasonography and computed tomography scanning [letter; comment] Abu–Zidan F. **Injury** 1996 Nov;27(9):677 . Comment on: Injury 1996 Mar;27(2):117–24.

Sonography is an effective and accurate tool for the initial evaluation of children following blunt trauma [letter] Akgür FM, et al. **J Pediatr Surg** 1997 Feb;32(2):384

Posttraumatic peritoneal fluid: is it a reliable indicator of intraabdominal injury in children? [letter; comment] Akgür FM, et al. **J Pediatr Surg** 1996 Sep;31(9):1332. Comment on: J Pediatr Surg 1995 Dec;30(12):1644–8.

Sonography is an effective and accurate tool for the initial evaluation of children following blunt trauma [letter; comment] Taylor GA. **J Pediatr Surg** 1997 Feb;32(2):382–3 . Comment on: J Pediatr Surg 1996 May;31(5):649–51.

Prospective study investigating routine usage of ultrasonography as the initial diagnostic modality for the evaluation of children sustaining blunt abdominal trauma.

ABDOMINAL INJURIES

Akgür FM, et al. **J Trauma** 1997 Apr;42(4):626–8

Ultrasound based key clinical pathway reduces the use of hospital resources for the evaluation of blunt abdominal trauma. Branney SW, et al. **J Trauma** 1997 Jun; 42(6):1086–90

Abdominal injuries without hemoperitoneum: a potential limitation of focused abdominal sonography for trauma (FAST). Chiu WC, et al. **J Trauma** 1997 Apr;42(4):617–23; discussion 623–5

Ultrasound evaluation of blunt abdominal trauma: program implementation, initial experience, and learning curve. Thomas B, et al. **J Trauma** 1997 Mar;42(3):384–8; discussion 388–90

Hypotension after blunt abdominal trauma: the role of emergent abdominal sonography in surgical triage. Wherrett LJ, et al. **J Trauma** 1996 Nov;41(5):815–20

The evaluation of blunt abdominal trauma: the evolving role of ultrasound. Givre S, et al. **Mt Sinai J Med** 1997 Sep–Oct; 64(4–5):311–5 (23 ref.)

Blunt abdominal trauma [letter; comment] Ratcliffe J. **Pediatr Radiol** 1996 Nov;26(11):830. Comment on: Pediatr Radiol 1995;25(5):321–5. Comment on: Pediatr Radiol 1995;25(5):326–8. Comment on: Pediatr Radiol 1995;25(5):329–31.

[Ultrasound in diagnosis of traumatic intra-abdominal lesions. Value in primary diagnosis in the shock unit] Partik B, et al. **Ultraschall Med** 1997 Feb;18(1):35–8 (Eng. Abstr.) **(Ger)**

ABDOMINAL MUSCLES

Abdominal wall tumor seeding at sonographically guided needle-core aspiration biopsy of hepatocellular carcinoma [letter] Kanematsu M, et al. **AJR Am J Roentgenol** 1997 Oct;169(4):1198–9

Endometriosis in abdominal scars: a diagnostic pitfall. Wolf Y, et al. **Am Surg** 1996 Dec;62(12):1042–4

Retained gallstones: a pain in the back. Draganic BD, et al. **Aust N Z J Surg** 1997 Sep;67(9):662–4

Bamboo skewer perforation of the bowel: computed tomography appearances. Peh WC, et al. **Australas Radiol** 1997 Aug;41(3):308–10

Wound metastases following laparoscopic and open surgery for abdominal cancer in a rat model. Mathew G, et al. **Br J Surg** 1996 Aug;83(8):1087–90

Abdominal wall metastases after surgical resection of an immature teratoma of the ovary. Swartjes JM, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jul;74(1):41–3

Laparoscopic hepatic resection: a new and safe procedure by abdominal wall lifting method. Watanabe Y, et al. **Hepatogastroenterology** 1997 Jan–Feb;44(13):143–7

Abdominal wall sinus: a late complication of gallstone spillage during laparoscopic cholecystectomy. Graham MD, et al. **HPB Surg** 1997;10(3):163–4

Anterior abdominal wall adhesions after laparotomy or laparoscopy. Levrant SG, et al. **J Am Assoc Gynecol Laparosc** 1997 May;4(3):353–6

Difficult to insert the accessory cannula and sheath into the lower abdomen when performing laparoscopy under local anesthesia [letter] Nagel TC, et al. **J Am Assoc Gynecol Laparosc** 1996 May;3(3):482–3

Hypotonic abdominal muscle in stroke patients [letter; comment] Panturin E. **Physiother Res Int** 1996;1(4):269. Comment on: Physiother Res Int 1996;1(1):30–40.

Fishing-rod-type abdominal wall lifter for gasless laparoscopic surgery. Nakamura H, et al. **Surg Endosc** 1996 Sep;10(9):944–6

[Abdominal pseudo-eventration disclosing Lyme disease (letter)] Roche C, et al. **Ann Med Interne (Paris)** 1997; 148(2):188–90 **(Fre)**

[Pseudotumoral abdominal cysto-steato-necrosis: an unusual etiology] Jouini S, et al. **Ann Radiol (Paris)** 1996;39(3):111–4 (Eng. Abstr.) **(Fre)**

[Abdominal wall prostheses. Biomechanic and histological study] Rath AM, et al. **Chirurgie** 1996;121(4):253–65 (Eng. Abstr.) **(Fre)**

[Multi-truncular nerve compression by hematoma of the pyramidal muscle during anticoagulant therapy (letter)] Bouscarat F, et al. **Presse Med** 1997 Mar 8;26(7):320 **(Fre)**

[Abdominal wall metastasis of pancreatic adenocarcinoma following laparoscopy] Iuppa A, et al. **Ann Ital Chir** 1996 Mar–Apr;67(2):265–9; discussion 269–70 (Eng. Abstr.) **(Ita)**

[A case of the tuberculous abscess in the abdominal wall] Saika A, et al. **Kansenshogaku Zasshi** 1997 Jun;71(6):540–4 (Eng. Abstr.) **(Jpn)**

[Repair of the wounded and resected kidney surface by the flap of musculus obliques externus abdominus (experimental study)] Makhovskii VZ, et al. **Khirurgiia (Mosk)** 1996; (5):48–51 (Eng. Abstr.) **(Rus)**

[Abscess of the abdominal wall as a form of presentation of Crohn's disease (letter)] Guilarte López-Mañas J, et al. **Rev Esp Enferm Dig** 1996 Jul;88(7):521–2 **(Spa)**

[Primary actinomycosis of the abdominal wall (letter)] Soler Dorda G, et al. **Rev Esp Enferm Dig** 1997 Mar;89(3):228–9 **(Spa)**

ABNORMALITIES

Umbilical cord agenesis in limb body wall defect. Craven CM, et al. **Am J Med Genet** 1997 Jul 11;71(1):97–105

Superior mesenteric artery Doppler velocimetry and ultrasonographic assessment of fetal bowel in gastroschisis: a prospective longitudinal study. Abuhamad AZ, et al. **Am J Obstet Gynecol** 1997 May;176(5):985–90

Prenatal diagnosis and perinatal aspects of abdominal wall defects. Chen CP, et al. **Am J Perinatol** 1996 Aug; 13(6):355–61

The survivors of gastroschisis. Davies BW, et al. **Arch Dis Child** 1997 Aug;77(2):158–60

Congenital anterior abdominal wall defects. Rate of abdominal wall defects is higher in Scotland than England and Wales [letter; comment] [see comments] Chalmers J, et al. **BMJ** 1997 Feb 1;314(7077):371–2. Comment on: BMJ 1996 Oct 12;313(7062):903–6. Comment in: BMJ 1997 Apr 26;314(7089):1278.

Congenital anterior abdominal wall defects [editorial; comment] Chitty L, et al. **BMJ** 1996 Oct 12; 313(7062):891–2. Comment on: BMJ 1996 Oct 12;313(7062):903–6.

Congenital anterior abdominal wall defects. Authors' figures for Northern region are underestimates [letter; comment] [see comments] Dillon E, et al. **BMJ** 1997 Feb 1; 314(7077):372. Comment on: BMJ 1996 Oct 12;313(7062):903–6. Comment in: BMJ 1997 Apr 26;314(7089):1278.

Congenital anterior abdominal wall defects. A national congenital malformations register is needed [letter; comment] [see comments] Luck C, et al. **BMJ** 1997 Feb 1;314(7077):371. Comment on: BMJ 1996 Oct 12;313(7062):903–6. Comment in: BMJ 1997 Apr 26;314(7089):1278.

Congenital anterior abdominal wall defects. Gastroschisis has a good prognosis [letter; comment] [see comments] Stringer MD, et al. **BMJ** 1997 Feb 1;314(7077):372–3. Comment on: BMJ 1996 Oct 12;313(7062):903–6. Comment in: BMJ 1997 Apr 26;314(7089):1278.

Congenital anterior abdominal wall defects in England and Wales 1987–93: retrospective analysis of OPCS data [see comments] Tan KH, et al. **BMJ** 1996 Oct 12; 313(7062):903–6. Comment in: BMJ 1996 Oct 12;313(7062):891–2. Comment in: BMJ 1997 Feb 1;314(7077):371. Comment in: BMJ 1997 Feb 1;314(7077):371–2. Comment in: BMJ 1997 Feb 1;314(7077):372. Comment in: BMJ 1997 Feb 1;314(7077):372–3.

Small bowel injury in gastroschisis: relation to fetal presentation. Bagley JS, et al. **Br J Obstet Gynaecol** 1996 Oct;103(10):1047–8

Maternal serum alpha-fetoprotein in fetal neural tube and abdominal wall defects at 10 to 14 weeks of gestation. Sebire NJ, et al. **Br J Obstet Gynaecol** 1997 Jul; 104(7):849–51

Chylous ascites associated with gastroschisis. Solans CV, et al. **Clin Pediatr (Phila)** 1996 Aug;35(8):415–6

Genetic factors in the aetiology of gastroschisis: a case report. Reece A, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jun;73(2):127–8

The fate of undescended testes in patients with gastroschisis. Levard G, et al. **Eur J Pediatr Surg** 1997 Jun;7(3):163–5

Unusual cloacal exstrophy in a male neonate with a normal penis and urethra. Sarin YK. **Indian Pediatr** 1996 Jan; 33(1):60–3

The role of antepartum surveillance in the management of gastroschisis. Adair CD, et al. **Int J Gynaecol Obstet** 1996 Feb;52(2):141–4

Extensive facial hemangioma associated with cardiac and abdominal anomalies. Patel SD, et al. **J Am Acad Dermatol** 1997 Apr;36(4):636–8

Gastroschisis with rare congenital anomalies. Chakrabarti AK, et al. **J Indian Med Assoc** 1995 May;93(5):211

Rising incidence of gastroschisis in teenage pregnancies. Nichols CR, et al. **J Matern Fetal Med** 1997 Jul–Aug; 6(4):225–9

Gastroschisis: 13 years' experience at RCH Melbourne. Tawil KA, et al. **J Paediatr Child Health** 1995 Dec;31(6):553–6

Gastroschisis complicated by midgut atresia and closure of the defect in utero. Bhatia AM, et al. **J Pediatr Surg** 1996 Sep;31(9):1288–9

Adverse outcome after prenatal diagnosis of gastroschisis: the role of fetal monitoring. Burge DM, et al. **J Pediatr Surg** 1997 Mar;32(3):441–4 (18 ref.)

Gastrointestinal myoelectric activity in a child with gastroschisis and ileal atresia. Cheng G, et al. **J Pediatr Surg** 1997 Jun;32(6):923–7

Epigastric cleft: a previously unreported entity. Ciftci AO, et al. **J Pediatr Surg** 1997 Aug;32(8):1247–9

Temporary impairment of lung function in infants with anterior abdominal wall defects who have undergone surgery. Dimitriou G, et al. **J Pediatr Surg** 1996 May; 31(5):670–2

Serial transabdominal amnioinfusion in the management of gastroschisis with severe oligohydramnios. Dommergues M, et al. **J Pediatr Surg** 1996 Sep;31(9):1297–9

Prenatal diagnosis of abdominal wall defects and their prognosis. Kamata S, et al. **J Pediatr Surg** 1996 Feb; 31(2):267–71

Effect of prokinetic agents on ileal contractility in a rabbit model of gastroschisis. Langer JC, et al. **J Pediatr Surg** 1997 Apr;32(4):605–8

Silo formation without suturing in gastroschisis: use of Steridrape for delayed repair. Lee SC, et al. **J Pediatr Surg** 1997 Jan;32(1):66–8

End-tidal carbon dioxide for monitoring primary closure of gastroschisis. Puffinbarger NK, et al. **J Pediatr Surg** 1996 Feb;31(2):280–2

Congenital spigelian hernia with cryptorchidism. Silberstein PA, et al. **J Pediatr Surg** 1996 Sep;31(9):1208–10

Umbilical preservation in gastroschisis. Uceda J. **J Pediatr Surg** 1996 Oct;31(10):1367–8

Modified Boerema technique for the closure of congenital abdominal wall defects to prevent incisional herniation and infection. Yamataka A, et al. **J Pediatr Surg** 1997 May; 32(5):708–9

Submucosal collagen in experimental gastroschisis. Srinathan SK, et al. **J Surg Res** 1996 Sep;65(1):25–30

Enterocytic gene expression is altered in experimental gastroschisis. Srinathan SK, et al. **J Surg Res** 1997 Feb 15;68(1):1–6

Growth retardation in fetuses with gastroschisis. Raynor BD, et al. **J Ultrasound Med** 1997 Jan;16(1):13–6

Genetic analysis of the cause of gastroschisis in the HLG mouse strain. Hillebrandt S, et al. **Mutat Res** 1996 Nov 11;372(1):43–51

Association of congenital muscular dystrophy with hypoplasia of the lateral abdominal wall musculature and hypoplasia of the external genitalia. Leyten QH, et al. **Neuropediatrics** 1996 Apr;27(2):108–10

Prenatal ultrasonographic findings associated with short bowel syndrome in two fetuses with gastroschisis. McMahon MJ, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):676–8

Gastroschisis: are prenatal ultrasonographic findings useful for assessing the prognosis? Brun M, et al. **Pediatr Radiol** 1996 Oct;26(10):723–6

Gastroschisis: a radiological and clinical review. Ramsden WH, et al. **Pediatr Radiol** 1997 Feb;27(2):166–9

Gastroschisis: can the morbidity be avoided? Blakelock RT, et al. **Pediatr Surg Int** 1997 Apr;12(4):276–82

Small-bowel continuity: a crucial factor in determining survival in gastroschisis. Cusick E, et al. **Pediatr Surg Int** 1997;12(1):34–7

Cantrell's pentalogy. Report of four cases and their management. Fernández MS, et al. **Pediatr Surg Int** 1997 Jul;12(5–6):428–31 (20 ref.)

Prenatal diagnosis of fetal abdominal wall defects: a retrospective analysis of 44 cases. Heydanus R, et al. **Prenat Diagn** 1996 May;16(5):411–7

Concordant body stalk anomaly in monozygotic twinning--early embryo cleavage disorder. Shih JC, et al. **Prenat Diagn** 1996 May;16(5):467–70

Prenatal diagnosis and management of abdominal wall defects. Dykes EH. **Semin Pediatr Surg** 1996 May;5(2):90–4 (17 ref.)

Gastroschisis and omphalocele. Langer JC. **Semin Pediatr Surg** 1996 May;5(2):124–8 (53 ref.)

Embryonic development of the ventral body wall and its congenital malformations. Vermeij-Keers C, et al. **Semin Pediatr Surg** 1996 May;5(2):82–9 (25 ref.)

Maternal medications and environmental exposures as risk factors for gastroschisis. Torfs CP, et al. **Teratology** 1996 Aug;54(2):84–92

Three-dimensional ultrasound is useful in diagnosing the fetus with abdominal wall defect [letter] Matsumi H, et al. **Ultrasound Obstet Gynecol** 1996 Nov;8(5):356–8 (13 ref.)

[Epidemiology of gastroschisis in China] Zhu J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jul;31(7):397–400 (Eng. Abstr.) **(Chi)**

[Effect of the mode of delivery on the newborn infant with gastroschisis. With data from the Styrian Malformation Register] Häusler MC, et al. **Gynakol Geburtshilfliche Rundsch** 1997;37(1):25–9 (Eng. Abstr.) **(Ger)**

[Limb-body wall malformation complex: an unusual developmental abnormality of the abdominal wall. Case report, clinicopathological and etiological implications (see comments)] Cserni G, et al. **Orv Hetil** 1997 Apr 13; 138(15):931–7 (26 ref.) (Eng. Abstr.). Comment in: Orv Hetil 1997 Aug 24;138(34):2157. **(Hun)**

[Medical-historical contribution to the literature on a rare developmental anomaly of the abdominal wall (letter; comment)] Kiss L. **Orv Hetil** 1997 Aug 24;138(34):2157. Comment on: Orv Hetil 1997 Apr 13;931–7. **(Hun)**

[Ectopia cordis and Cantrell's pentalogy: personal experience and considerations on the surgical treatment] Pampaloni A, et al. **Pediatr Med Chir** 1997 Jan–Feb;19(1):59–64 (Eng. Abstr.) **(Ita)**

[Changes of respiratory system compliance by closure of congenital abdominal wall defects and postoperative complications] Takeuchi M, et al. **Masui** 1996 Jun; 45(6):731–4 (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

The abdominal subcutaneous tissue: computed tomographic, magnetic resonance, and anatomical observations. Johnson D, et al. **Clin Anat** 1996;9(1):19–24

The in vivo biodynamic properties of the intact equine linea alba. Kirker-Head CA, et al. **Equine Vet J Suppl** 1989 Jun; (7):98–106

Applied anatomy of the cremasteric muscle and fascia. Redman JF. **J Urol** 1996 Oct;156(4):1337–40

Re: Applied anatomy of the cremasteric muscle and fascia [letter] Shafik A. **J Urol** 1997 Sep;158(3 Pt 1):889

Laparoscopic cholecystectomy in patients with cardiac disease: hemodynamic advantage of the abdominal wall retraction method. Uchikoshi F, et al.

Surg Laparosc Endosc 1997 Jun;7(3):196–201

The abdominal linea alba: an anatomo–radiologic and biomechanical study. Rath AM, et al. **Surg Radiol Anat** 1996;18(4):281–8

BLOOD SUPPLY

Oxygen saturation and pH changes in cremaster microvessels of the rat. Kobayashi H, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):H1453–61

Anesthetics alter relative contributions of NO and EDHF in rat cremaster muscle microcirculation. Loeb AL, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H618–27

Ischemic gastric ulcer after coronary bypass using the right gastroepiploic artery. Schroeyers P, et al. **Ann Thorac Surg** 1997 May;63(5):1470–2

Assessment of ischemia and reperfusion injury. Urbaniak JR, et al. **Clin Orthop** 1997 Jan;(334):30–6

Arterial bypass graft spasm: an examination of the role of high flow demands and endothelial function in the porcine GEA. Montgomery WD, et al. **Eur J Cardiothorac Surg** 1996;10(1):12–9

Gastroepiploic artery graft in 400 patients. Suma H, et al. **Eur J Cardiothorac Surg** 1996;10(1):6–10; discussion 11

The effects of two levels of vasomotor tone at physiologic suffusate PO2 on acetylcholine– and sodium nitroprusside–induced relaxation of cremaster third–order arterioles in 5–hour ischemia–reperfusion control rats. Borsch DM, et al. **Int J Microcirc Clin Exp** 1997 May–Jun; 17(3):113–22

Repair of laparoscopic injury to abdominal wall arteries complicated by cutaneous necrosis. Spitzer M, et al. **J Am Assoc Gynecol Laparosc** 1996 May;3(3):449–52

Coronary artery bypass grafting with both internal thoracic arteries and the right gastroepiploic artery. Nishida H, et al. **J Cardiovasc Surg (Torino)** 1996 Oct;37(5):471–4

Laparoscopic transillumination for the location of anterior abdominal wall blood vessels. Quint EH, et al. **J Laparoendosc Surg** 1996 Jun;6(3):167–9

Neural responses of rat abdominal skin artery. Shimamura K, et al. **J Smooth Muscle Res** 1995 Dec;31(6):397–9

Enzymatic isolation and characterization of single vascular smooth muscle cells from cremasteric arterioles. Jackson WF, et al. **Microcirculation** 1996 Sep;3(3):313–28

The effect of the delay phenomenon on the vascularity of rabbit abdominal cutaneous island flaps. Cederna PS, et al. **Plast Reconstr Surg** 1997 Jan;99(1):183–93

The vascular anatomy of the inner anterior abdominal wall with special reference to the transversus and rectus abdominis musculoperitoneal (TRAMP) composite flap for vaginal reconstruction. Konerding MA, et al. **Plast Reconstr Surg** 1997 Mar;99(3):705–10; discussion 711–2

The role of the venous system in the abdominal flap of the rat. Miles DA, et al. **Plast Reconstr Surg** 1997 Jun; 99(7):2030–3

An animal model for teaching subfacial ligation of perforator veins to treat venous stasis ulcers. Kolata RJ. **Surg Laparosc Endosc** 1997 Aug;7(4):316–9

Myoperitoneal microvascular free flaps in dogs: an anatomical study and a clinical case report. Degner DA, et al. **Vet Surg** 1996 Nov–Dec;25(6):463–70

EMBRYOLOGY

Paraumbilical intestinal remnant, closed abdominal wall, and midgut loss in a neonate. Anveden–Hertzberg L, et al. **J Pediatr Surg** 1996 Jun;31(6):862–3

Embryonic development of the ventral body wall and its congenital malformations. Vermeij–Keers C, et al. **Semin Pediatr Surg** 1996 May;5(2):82–9 (25 ref.)

IMMUNOLOGY

A novel method for induction and detection of anaphylactic reaction using the mouse abdominal wall (AW method). Kataoka H, et al. **Biol Pharm Bull** 1997 Jun;20(6):714–6

INJURIES

Contralateral rectus abdominis muscle flap coverage for the management of a complicated groin defect [letter] Aygit AC, et al. **Ann Plast Surg** 1997 Mar;38(3):307–8

INNERVATION

An anatomical analysis of the relationships between the intercostal nerves and the thoracic and abdominal muscles in man. II. Detailed analysis of innervation of the three lateral abdominal muscles. Sakamoto H, et al. **Acta Anat (Basel)** 1996;156(2):143–50

Microanatomy of the structures contributing to abdominal cutaneous nerve entrapment syndrome. Applegate WV, et al. **J Am Board Fam Pract** 1997 Sep–Oct;10(5):329–32

Belly dystonia induced by levodopa and biperiden in a case of suspected multiple–system atrophy. Shan DE, et al. **Mov Disord** 1996 Jul;11(4):455–7

Functional role of ventral respiratory group expiratory neurons during vocalization. Katada A, et al. **Neurosci Res** 1996 Nov;26(3):225–33

The rectus sheath block in paediatric anaesthesia: new indications for an old technique? Ferguson S, et al. **Paediatr Anaesth** 1996;6(6):463–6

METABOLISM

Production and manipulation of elevated temperatures in pig abdomen with a three–electrode capacitive heating device. Nussbaum GH, et al. **Int J Hyperthermia** 1996 May–Jun; 12(3):421–30

PATHOLOGY

Giant hemangioma in infant. A case presentation and literature review. Malamou–Mitsi VD, et al. **Arch Anat Cytol Pathol** 1996;44(4):199–201 (14 ref.)

Laparoscopic cholecystectomy: incidental carcinoma of the gallbladder with abdominal wall and axillary node metastasis. Johnson RC, et al. **HPB Surg** 1997;10(3):169–71

The relationship of different power settings and fiber geometries to thermal tissue damage created by the superpulse Nd:YAG laser. Shirk GJ, et al. **J Am Assoc Gynecol Laparosc** 1994 Aug;1(4 Pt 1):389–93

Angiosarcoma which developed on the abdominal wall: report of a case. Funaki M, et al. **J Dermatol** 1997 May; 24(5):342–4 (6 ref.)

Lumbar lordosis and pelvic inclination of asymptomatic adults [see comments] Youdas JW, et al. **Phys Ther** 1996 Oct;76(10):1066–81. Comment in: Phys Ther 1997 Apr;77(4):439–40.

PHYSIOLOGY

Use of manipulation to treat low back pain [letter] Fisher RM. **Am Fam Physician** 1997 Sep 1;56(3):744; discussion 744, 747

Muscle activity in upper and lower rectus abdominus during abdominal exercises. Sarti MA, et al. **Arch Phys Med Rehabil** 1996 Dec;77(12):1293–7

Inflammatory reaction dependence on implant localization in rat soft tissue models. Rosengren A, et al. **Biomaterials** 1997 Jul;18(14):979–87

The in vivo biodynamic properties of the intact equine linea alba. Kirker–Head CA, et al. **Equine Vet J Suppl** 1989 Jun; (7):98–106

Ultrasonographic evaluation of the healing of ventral midline abdominal incisions in the horse. Wilson DA, et al. **Equine Vet J Suppl** 1989 Jun;(7):107–10

Abdominal and hip flexor muscle activation during various training exercises. Andersson EA, et al. **Eur J Appl Physiol** 1997;75(2):115–23

Differential respiratory activity of four abdominal muscles in humans. Abe T, et al. **J Appl Physiol** 1996 Apr; 80(4):1379–89

Contractions of specific abdominal muscles in postural tasks are affected by respiratory maneuvers. Hodges PW, et al. **J Appl Physiol** 1997 Sep;83(3):753–60

Abdominal muscle fatigue after maximal ventilation in humans. Kyroussis D, et al. **J Appl Physiol** 1996 Oct; 81(4):1477–83

Effect of hypoxia on abdominal motor unit activities in spontaneously breathing cats. Mateika JH, et al. **J Appl Physiol** 1996 Dec;81(6):2428–35

Chest wall muscle cross talk in canine costal diaphragm electromyogram. Sinderby C, et al. **J Appl Physiol** 1996 Nov;81(5):2312–27

A neural network model for simulation of torso muscle coordination. Nussbaum MA, et al. **J Biomech** 1997 Mar; 30(3):251–8

Distributed moment histogram: a neurophysiology based method of agonist and antagonist trunk muscle activity prediction. Raschke U, et al. **J Biomech** 1996 Dec; 29(12):1587–96

Support for a linear length–tension relation of the torso extensor muscles: an investigation of the length and velocity EMG–force relationships. Raschke U, et al. **J Biomech** 1996 Dec;29(12):1597–604

Low back loads over a variety of abdominal exercises: searching for the safest abdominal challenge. Axler CT, et al. **Med Sci Sports Exerc** 1997 Jun;29(6):804–11

Effect of abdominal vibroacoustic stimulation on sound and acceleration levels at the head of the fetal sheep. Abrams RM, et al. **Obstet Gynecol** 1997 Aug;90(2):216–20

Influence of sleep states on laryngeal and abdominal muscle response to upper airway occlusion in lambs. Kianicka I, et al. **Pediatr Res** 1997 Jun;41(6):862–71

Contraction of the abdominal muscles associated with movement of the lower limb. Hodges PW, et al. **Phys Ther** 1997 Feb;77(2):132–42; discussion 142–4

Abdominal–wall recovery following TRAM flap: a functional outcome study. Kind GM, et al. **Plast Reconstr Surg** 1997 Feb;99(2):417–28

Estimation of loads and stresses in abdominal muscles during slow lifts. Thomson KD. **Proc Inst Mech Eng [H]** 1997; 211(3):271–4

Insertional action of the abdominal muscles in rabbits and dogs. D'Angelo E, et al. **Respir Physiol** 1996 Jul; 104(2–3):147–57

Vibration of the abdominal segment in pregnant sheep. Abrams RM, et al. **Semin Perinatol** 1996 Feb;20(1):30–7 (27 ref.)

Effects of respiratory muscle training and electrical stimulation of abdominal muscles on respiratory capabilities in tetraplegic patients. Zupan A, et al. **Spinal Cord** 1997 Aug;35(8):540–5

An electromyographic study of unresisted trunk rotation with normal velocity among healthy subjects. Kumar S, et al. **Spine** 1996 Jul 1;21(13):1500–12

An electromyographic comparison of abdominal muscle synergies during curl and double straight leg lowering exercises with control of the pelvic position. Shields RK, et al. **Spine** 1997 Aug 15;22(16):1873–9

Abdominal muscle recruitment and PEEPi during bronchoconstriction in chronic obstructive pulmonary disease. Gorini M, et al. **Thorax** 1997 Apr;52(4):355–61

PHYSIOPATHOLOGY

Bone scan in strenuous abdominal muscular exercise. Rimkus DS, et al. **Clin Nucl Med** 1996 Aug;21(8):648

Accurate measurement of intrinsic positive end–expiratory pressure: how to detect and correct for expiratory muscle activity [see comments] Zakynthinos SG, et al. **Eur Respir J** 1997 Mar;10(3):522–9. Comment in: Eur Respir J 1997 Mar;10(3):516–8.

Evaluation of the relationship between laboratory and clinical tests of transversus abdominis function [see comments] Hodges P, et al. **Physiother Res Int** 1996;1(1):30–40. Comment in: Physiother Res Int 1996;1(4):269.

[Abdominal respiratory muscle activity in patients with stable chronic obstructive pulmonary disease] Ortega Ruiz F, et al. **Arch Bronconeumol** 1996 Jan;32(1):23–8 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Genetic analysis of the cause of gastroschisis in the HLG mouse strain. Hillebrandt S, et al. **Mutat Res** 1996 Nov 11;372(1):43–51

Hyperbaric oxygen an adjunctive treatment for delayed radiation injuries of the abdomen and pelvis. Feldmeier JJ, et al. **Undersea Hyperb Med** 1996 Dec;23(4):205–13

RADIOGRAPHY

Ectopic cranium: postoperative abdominal wall skull fragments [letter] Marlow TJ, et al. **AJR Am J Roentgenol** 1997 Oct;169(4):1201

RADIONUCLIDE IMAGING

Optimized sampling and parameter estimation for quantification in whole body PET. Ho–Shon K, et al. **IEEE Trans Biomed Eng** 1996 Oct;43(10):1021–8

SURGERY

Comparison of prosthetic materials used for abdominal wall defects or hernias (an experimental study). Sahin M, et al. **Acta Chir Hung** 1995–96;35(3–4):291–5

Deep planed torso–abdominoplasty combined with buttocks pexy. Gonzalez M, et al. **Aesthetic Plast Surg** 1997 Jul–Aug; 21(4):245–53

Breast reconstruction by expansion and advancement of the upper abdominal flap. Leal PR, et al. **Aesthetic Plast Surg** 1997 May–Jun;21(3):175–9

Should diastasis recti be corrected? Nahas FX, et al. **Aesthetic Plast Surg** 1997 Jul–Aug;21(4):285–9

Creation of a neoabdominal wall to facilitate emergency placement of a terminal ileostomy in a morbidly obese patient. Meguid MM, et al. **Am J Surg** 1997 Apr; 173(4):298–300

Circumferential torsoplasty. Carwell GR, et al. **Ann Plast Surg** 1997 Mar;38(3):213–6

An evaluation of fascial staples (a new technique) in wide fascial plication during reconstructive abdominoplasty. Jansen DA, et al. **Ann Plast Surg** 1996 Feb;36(2):171–5

A method of reconstructing a natural–looking umbilicus in abdominoplasty. Massiha H, et al. **Ann Plast Surg** 1997 Mar; 38(3):228–31

Tumescent mini abdominoplasty. Nguyen TT, et al. **Ann Plast Surg** 1997 Mar;38(3):209–12

Small intestinal perforation and peritonitis after abdominal suction lipoplasty. Ovrebø KK, et al. **Ann Plast Surg** 1997 Jun;38(6):642–4

Sequelae in the abdominal wall after pedicled or free TRAM flap surgery. Suominen S, et al. **Ann Plast Surg** 1996 Jun; 36(6):629–36

Experimental assay of a Dual Mesh polytetrafluoroethylene prosthesis (non–porous on one side) in the repair of abdominal wall defects. Bellón JM, et al. **Biomaterials** 1996 Dec;17(24):2367–72

Improvement of the tissue integration of a new modified polytetrafluoroethylene prosthesis: Mycro Mesh. Bellón JM, et al. **Biomaterials** 1996 Jul;17(13):1265–71

Cardiorespiratory changes during gynaecological laparoscopy by abdominal wall elevation: comparison with carbon dioxide pneumoperitoneum. Casati A, et al. **Br J Anaesth** 1997 Jan;78(1):51–4

The fate of the oblique abdominal muscles after free TRAM flap surgery. Blondeel N, et al. **Br J Plast Surg** 1997 Jul; 50(5):315–21

Abdominoplasty in multiparous women with severe musculoaponeurotic laxity. al–Qattan MM. **Br J Plast Surg** 1997 Sep;50(6):450–5

Successful use of size–mismatched liver allografts in children by delayed primary closure of abdominal wall [letter; comment] Drake D. **Br J Surg** 1997 May;84(5):729. Comment on: Br J Surg 1996 Nov;83(11):1530–1.

Ultrasonographic evaluation of the healing of ventral midline abdominal incisions in the horse. Wilson DA, et al. **Equine Vet J Suppl** 1989 Jun;(7):107–10

The behavior of different types of polytetrafluoroethylene

(PTFE) prostheses in the reparative scarring process of abdominal wall defects. Buján J, et al.
Histol Histopathol 1997 Jul;12(3):683–90

Experimentally contaminated reabsorbable meshes: their evolution in abdominal wall defects. López Villalta GC, et al. **Int Surg** 1995 Jul–Sep;80(3):223–6

Comparison of visual and tactile localization of the trocar tip during abdominal entry. Kaali SG, et al.
J Am Assoc Gynecol Laparosc 1994 Nov;2(1):75–7

A simplified method of open laparoscopic entry and abdominal wall adhesiolysis. Pelosi MA 3rd, et al.
J Am Assoc Gynecol Laparosc 1995 Nov;3(1):91–8

Lower extremity salvage after radical resection of malignant tumors in the groin and lower abdominal wall. Reece GP, et al. **J Am Coll Surg** 1997 Sep;185(3):260–7

A preliminary report on the use of relon mesh in the repair of eventrations with large parietal defects. An experimental study in rats. Birbilis T, et al. **J Int Med Res** 1997 May–Jun; 25(3):135–40

End–tidal carbon dioxide for monitoring primary closure of gastroschisis. Puffinbarger NK, et al. **J Pediatr Surg** 1996 Feb;31(2):280–2

Transdiaphragmatic pressure gradients and the lower esophageal sphincter after tight abdominal wall plication in the rat. Qi B, et al. **J Pediatr Surg** 1996 Dec; 31(12):1666–9

Microsurgical reconstruction of chest– and abdominal–wall defects associated with intraperitoneal vessels. Sekido M, et al. **J Reconstr Microsurg** 1996 Oct;12(7):425–30

The tensor fascia lata free flap in abdominal–wall reconstruction. Williams JK, et al.
J Reconstr Microsurg 1997 Feb;13(2):83–90; discussion 90–1

Improving the efficiency, ease, and efficacy of endoscopic abdominoplasty. Ferraro FJ, et al. **Plast Reconstr Surg** 1997 Mar;99(3):895–8

Massive abdominal–wall hernia reconstruction with expanded external/internal oblique and transversalis musculofascia. Jacobsen WM, et al. **Plast Reconstr Surg** 1997 Aug;100(2):326–35

Abdominal–wall recovery following TRAM flap: a functional outcome study. Kind GM, et al.
Plast Reconstr Surg 1997 Feb;99(2):417–28

A simple technique to determine the future location of the umbilicus in abdominoplasty. Kurul S, et al.
Plast Reconstr Surg 1997 Sep;100(3):753–4

Managing the umbilicus during abdominoplasty [letter; comment] Lim TC, et al. **Plast Reconstr Surg** 1996 Nov; 98(6):1113. Comment on: Plast Reconstr Surg 1996 Jan;97(1):227–32.

Endoscopic balloon–assisted abdominoplasty [letter] O'Brien JJ, et al. **Plast Reconstr Surg** 1997 Apr;99(5):1462–3

Free tensor fasciae latae flap reconstruction of defects of the chest and abdominal wall: selection of recipient vessels. Penington AJ, et al.
Scand J Plast Reconstr Surg Hand Surg 1996 Dec; 30(4):299–305

Acute wound failure. Carlson MA. **Surg Clin North Am** 1997 Jun;77(3):607–36 (200 ref.)

Laparoscopic cholecystectomy using abdominal wall retraction. Hemodynamics and gas exchange, a comparison with conventional pneumoperitoneum. Meijer DW, et al. **Surg Endosc** 1997 Jun;11(6):645–9

Laparoscopic–assisted colon surgery by abdominal wall lifting with newly developed lifting bars. Nisii H, et al. **Surg Endosc** 1997 Jul;11(7):754–7

Laparoscopic surgery by abdominal wall lifting using original lifting bars. Nishii H, et al. **Surg Laparosc Endosc** 1997 Apr;7(2):124–8

Use of laparoscopic instrumentation to quickly stretch the abdominal wall in repair of giant inguinal hernias [letter] Myers B. **Surgery** 1997 Apr;121(4):477

Repair of complex giant or recurrent ventral hernias by using tension–free intraparietal prosthetic mesh (Stoppa technique): lessons learned from our initial experience (fifty patients). Temudom T, et al. **Surgery** 1996 Oct; 120(4):738–43; discussion 743–4

Commercial polyester fabric repair of abdominal hernias and defects. Shoukry M, et al. **Vet Rec** 1997 Jun 7;140(23):606–7

[Abdominal parietoscopy. Technique and indications. Preliminary results: 7 cases] Champault G. **Ann Chir** 1996; 50(6):445–8 (Eng. Abstr.) **(Fre)**

[Dynamic and functional abdominal wall stabilization, reconstruction of extensive abdominal wall defects] Harpf C, et al. **Chirurg** 1997 May;68(5):488–92 (10 ref.) (Eng. Abstr.) **(Ger)**

[Full–thickness abdominal wall closure of laparoscopic trocar incision sites: a new, simplified technique] Schwegler I, et al. **Chirurg** 1996 Jul;67(7):748–51 (Eng. Abstr.) **(Ger)**

[Changes in abdominal wall mechanics after mesh implantation. Experimental changes in mesh stability] Klinge U, et al. **Langenbecks Arch Chir** 1996;381(6):323–32 (Eng. Abstr.) **(Ger)**

[Morphologic correlation of functional abdominal wall mechanics after mesh implantation] Klosterhalfen B, et al. **Langenbecks Arch Chir** 1997;382(2):87–94 (Eng. Abstr.) **(Ger)**

[Therapy of upper gastrointestinal fistulas with simultaneous abdominal wall defects] Leppert R, et al. **Zentralbl Chir** 1996;121 Suppl:82–3 **(Ger)**

[Our experience with Spigelio's hernia] Gesuelli GC, et al. **Ann Ital Chir** 1996 Jul–Aug;67(4):527–30; discussion 531 (19 ref.) (Eng. Abstr.) **(Ita)**

[Plastic surgery of the abdominal wall in laparocele in a patient with previous kidney transplant] Cervelli V, et al. **Minerva Chir** 1997 Jun;52(6):817–21 (Eng. Abstr.) **(Ita)**

[Changes of respiratory system compliance by closure of congenital abdominal wall defects and postoperative complications] Takeuchi M, et al. **Masui** 1996 Jun; 45(6):731–4 (Eng. Abstr.) **(Jpn)**

[Primary abdominal parietorrhaphy and the cure of eventrations with the relon monofilament suture (N.I. 2402/76)] Constantinoiu S, et al. **Chirurgia (Bucur)** 1997 Mar–Apr;92(2):115–9 (Eng. Abstr.) **(Rum)**

[Plastic repair of the anterior abdominal wall in bladder exstrophy] Gel'dt VG, et al. **Urol Nefrol (Mosk)** 1997 May–Jun;(3):34–6 (Eng. Abstr.) **(Rus)**

[Operations in inguinal hernia from the preperitoneal approach with explant prosthesis of the abdominal wall] Sedov VM, et al. **Vestn Khir Im I I Grek** 1996;155(2):33–4 (Eng. Abstr.) **(Rus)**

[Preperitoneal plastic repair of the anterior abdominal wall in inguinal hernias] Tarbaev SD, et al.
Vestn Khir Im I I Grek 1996;155(4):101–3 (41 ref.) **(Rus)**

[Bovine pericardium prostheses (letter; comment)] Gutiérrez Samperio C. **Rev Invest Clin** 1996 May–Jun;48(3):245–6. Comment on: Rev Invest Clin 1995 Nov–Dec;47(6):439–46. **(Spa)**

[Repair of thoracoabdominal wall defects in dogs using a bovine pericardium bioprosthesis (see comments) (published erratum appears in Rev Invest Clin 1996 May–Jun;48(3):245–6)] Santillán–Doherty P, et al.
Rev Invest Clin 1995 Nov–Dec;47(6):439–46 (Eng. Abstr.) . Comment in: Rev Invest Clin 1996 May–Jun;48(3):245–6. **(Spa)**

TRANSPLANTATION

Use of a pedicled rectus abdominis muscle flap sling in the treatment of complicated stress urinary incontinence. Wall LL, et al. **Am J Obstet Gynecol** 1996 Dec;175(6):1460–4; discussion 1464–6

The use of the Rectus abdominis muscle to suspend the bladder in the treatment of uretero–vaginal fistulae. Krolikowski A, et al. **Cent Afr J Med** 1996 Sep; 42(9):269–70

Free rectus abdominis musculocutaneous flap for head and neck reconstruction. Nishimoto S, et al.
J Reconstr Microsurg 1997 Apr;13(3):171–5

Physical therapy implications following the TRAM procedure. Monteiro M. **Phys Ther** 1997 Jul;77(7):765–70 (20 ref.)

Absence of hernia after removal of Gore–Tex [letter; comment] Halls MJ. **Plast Reconstr Surg** 1997 Jan;99(1):270 . Comment on: Plast Reconstr Surg 1996 Jun;97(7):1436–40; discussion 1441–2.

The external oblique muscle free flap. Kuzbari R, et al.
Plast Reconstr Surg 1997 Apr;99(5):1338–45

The rectus abdominis myocutaneous flap combined with vascularized costal cartilages in reconstructive craniofacial surgery. Yamamoto Y, et al. **Plast Reconstr Surg** 1997 Aug; 100(2):439–44; discussion 445–6

ULTRASONOGRAPHY

Sonographic features of abdominal wall endometriosis [letter] Wolf C, et al. **AJR Am J Roentgenol** 1997 Sep;169(3):916–7

Prediction of fetal macrosomia using sonographically measured abdominal subcutaneous tissue thickness. Petrikovsky BM, et al. **J Clin Ultrasound** 1997 Sep; 25(7):378–82

Spigelian hernia: diagnosis by high–resolution real–time sonography. Mufid MM, et al. **J Ultrasound Med** 1997 Mar; 16(3):183–7

Three–dimensional ultrasound is useful in diagnosing the fetus with abdominal wall defect [letter] Matsumi H, et al. **Ultrasound Obstet Gynecol** 1996 Nov;8(5):356–8 (13 ref.)

ABDOMINAL NEOPLASMS

Peripheral neuroepithelioma developing in the abdominal cavity. Kelessis NG, et al. **Anticancer Res** 1996 Sep–Oct; 16(5B):3193–5

Extra–adrenal pheochromocytoma. Vázquez Quintana E, et al. **Bol Asoc Med P R** 1995 Oct–Dec;87(10–12):171–3

Solitary extramedullary plasmacytoma. Mazzone A, et al. **Recenti Prog Med** 1997 Jul–Aug;88(7–8):325–7

Intraabdominal desmoplastic small round cell tumour in an 11–year–old boy. Ariffin H, et al. **Singapore Med J** 1997 Apr;38(4):169–71

[Incidentally discovered masses: diagnostic and therapeutic features] Viti M, et al. **Minerva Chir** 1996 Jun;51(6):471–4 (Eng. Abstr.) **(Ita)**

BLOOD

Relationship between circulating secretory immunoglobulin A levels and portal blood cytokine levels during major abdominal surgery. Fujita T, et al. **Arch Surg** 1997 Feb; 132(2):124–7

COMPLICATIONS

Self–expanding metallic stents as palliative treatment of malignant gastroduodenal stenosis. de Baere T, et al.
AJR Am J Roentgenol 1997 Oct;169(4):1079–83

Hemorrhage from abdominal non–Hodgkin's lymphoma treated successfully by emergency transcatheter arterial embolization. Suzumiya J, et al. **Am J Hematol** 1996 Jul; 52(3):201–4

Inguinal cord lipoma. Fawcett AN, et al. **Br J Surg** 1997 Aug;84(8):1169

Mechanisms of tumor–induced hypoglycemia with intraabdominal hemangiopericytoma. Chung J, et al.
J Clin Endocrinol Metab 1996 Mar;81(3):919–25

CT in searching for abscess after abdominal or pelvic surgery in patients with neoplasia: do abdomen and pelvis both need to be scanned? Krumenacker JH, et al.
J Comput Assist Tomogr 1997 Jul–Aug;21(4):652–5

Obstructive jaundice, an unusual initial manifestation of intraabdominal non–Hodgkin's lymphoma in children: complications of percutaneous transhepatic cholangial drainage. Watanabe Y, et al. **J Pediatr Surg** 1997 Apr; 32(4):650–3

Analgesic effect of subarachnoid neostigmine in two patients with cancer pain. Klamt JG, et al. **Pain** 1996 Aug; 66(2–3):389–91

Malignancy–associated membranoproliferative glomerulonephritis. Rahman RC, et al. **Pediatr Nephrol** 1997 Apr;11(2):208–9

Intestinal obstruction in an adolescent female. Kumar A, et al. **Postgrad Med J** 1996 May;72(847):307–8

[Malignant neoplasms and intestinal obstruction in children 3 to 15 years old] Trifonov G, et al. **Khirurgiia (Sofiia)** 1996;49(3):33–6 (Eng. Abstr.) **(Bul)**

CONGENITAL

Rapid growth of a fetal abdominal mass: a case report of congenital neuroblastoma. Shen MR, et al.
J Clin Ultrasound 1997 Jan;25(1):39–42 (11 ref.)

DIAGNOSIS

The value of hyoscine butylbromide in abdominal MR imaging with and without oral magnetic particles. Laniado M, et al. **Abdom Imaging** 1997 Jul–Aug;22(4):381–8

A case of Kabuki make–up syndrome with EBV + Burkitt's lymphoma. Ijichi O, et al. **Acta Paediatr Jpn** 1996 Feb; 38(1):66–8

Laparoscopy in the management of gastric adenocarcinoma. Burke EC, et al. **Ann Surg** 1997 Mar;225(3):262–7 (9 ref.)

Bilateral intraabdominal ganglioneuroblastoma in an adult. Mehta N, et al. **Br J Radiol** 1997 Jan;70:96–8

Sister Joseph's nodule. Leow CK, et al. **Can J Surg** 1997 Jun;40(3):167

Diagnostic laparoscopy: indication and benefit. Yu SY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Mar; 59(3):158–63

Intra–abdominal cystic lymphangiomas in children. Roumen RM, et al. **Eur J Surg** 1996 Oct;162(10):831–6

Differential diagnosis of malignant tumours in the abdominal cavity of rats after intraperitoneal injection of crocidolite or benzo[a]pyrene. Friemann J, et al.
Exp Toxicol Pathol 1996 Jan;48(1):13–7

Association of a fetus in fetu and two teratomas: US and MRI. Hanquinet S, et al. **Pediatr Radiol** 1997 Apr; 27(4):336–8

Infradiaphragmatic extralobar pulmonary sequestration masquerading as an intra–abdominal, suprarenal mass. Gross E, et al. **Pediatr Surg Int** 1997 Sep;12(7):529–31

Self–induced vomiting as a presentation of abdominal mass. Vaughn BL, et al. **Pediatrics** 1997 May;99(5):731–3

An intra–abdominal tumour. Rehm A, et al.
Postgrad Med J 1997 Jun;73(860):353–5

Desmoplastic small round cell tumor. Leuschner I, et al.
Semin Diagn Pathol 1996 Aug;13(3):204–12 (46 ref.)

Leiomyomatosis peritonealis disseminata occurring in a postmenopausal woman: report of a case. Komatsu M, et al. **Surg Today** 1996;26(9):700–3

[Severe complications in diagnostic laparoscopy. 9 years experience in 747 examinations] Adamek HE, et al.
Med Klin 1996 Nov 15;91(11):694–7 (Eng. Abstr.) **(Ger)**

[Possibilities of abdominal tumor volumetry] Helmberger H, et al. **Rontgenpraxis** 1997 Jan;50(1):11–7 (55 ref.) **(Ger)**

[Tumor in the abdomen?] Schuler G, et al.
Schweiz Med Wochenschr 1997 Jun 7;127(23):1007 **(Ger)**

[Use of videolaparoscopy in the diagnosis and treatment of patients with abdominal neoplasms] Ukhanov AP.
Vopr Onkol 1996;42(4):56–8 **(Rus)**

[Correlation of cytologic and pathohistologic findings in ultrasonically–guided thin–needle biopsy of abdominal and retroperitoneal organs] Bokun R, et al. **Vojnosanit Pregl** 1997 May–Jun;54(3):223–6 (Eng. Abstr.) **(Scr)**

DRUG THERAPY

Apparent stimulation of thrombopoesis with interleukin–3 (IL–3) in chemotherapy induced myelosuppression. Schweiger C, et al. **Biofactors** 1995–96;5(2):73–4

Radiotherapy after chemotherapy for metastatic seminoma––a diminishing role. MRC Testicular Tumour Working Party. Duchesne GM, et al. **Eur J Cancer** 1997 May;33(6):829–35

Treatment results in children and adolescents with loco–regional recurrences of abdominal germ cell tumors (GCTs): a pilot–study with PEI chemotherapy and regional deep hyperthermia (RHT) in comparison to a matched cohort. Wessalowski R, et al. **Klin Padiatr** 1997 Jul–Aug; 209(4):250–6

EPIDEMIOLOGY

Malignant abdominal tumors in children. Rai AT, et al. **JPMA J Pak Med Assoc** 1996 Aug;46(8):168–71

GENETICS

Cytogenetic and immunohistochemical analysis of an adult anaplastic neuroblastoma. Cowan JM, et al. **Am J Surg Pathol** 1997 Aug;21(8):957–63

Molecular analysis of the secretory phospholipase A2 gene, a candidate of Mom1 gene, in neuroblastomas. Kawamata N, et al. **Cancer Lett** 1997 Jan 1;111(1–2):71–5

Immunohistochemical detection of the Wilms' tumour gene WT1 in desmoplastic small round cell tumour. Charles AK, et al. **Histopathology** 1997 Apr;30(4):312–4

Genetic analysis of a sarcoma accidentally transplanted from a patient to a surgeon. Gärtner HV, et al. **N Engl J Med** 1996 Nov 14;335(20):1494–6

Intra-abdominal polyphenotypic tumor. Thorner P. **Pediatr Pathol Lab Med** 1996 Jan–Feb;16(1):161–9

[A case of ectopic familial pheochromocytoma] Nakada J, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Aug; 87(8):1060–3 (11 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Antineuronal antibody in a patient with neuroblastoma and opsoclonus–myoclonus–ataxia: a case report. Salmaggi A, et al. **Tumori** 1997 May–Jun;83(3):709–11

PATHOLOGY

Laparoscopic ultrasonography for abdominal tumor staging: technical aspects and imaging findings. van Delden OM, et al. **Abdom Imaging** 1997 Mar–Apr;22(2):125–31

Small round cell tumors of the abdomen and thorax. Role of fine needle aspiration cytologic features in the diagnosis and differential diagnosis. Das DK, et al. **Acta Cytol** 1997 Jul–Aug;41(4):1035–47

Correlation between the grade of tumoral invasion and pain relief in patients with celiac ganglia block. Akhan O, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1565–7

Malignant hemangioendothelioma: a case of sudden unexpected death in infancy. Perrot LJ. **Am J Forensic Med Pathol** 1997 Mar;18(1):96–9

Metastatic liposarcoma to the orbit. Fezza J, et al. **Am J Ophthalmol** 1997 Feb;123(2):271–2

Florid soft-tissue decidual reaction: a potential mimic of neoplasia. Bégin LR. **Am J Surg Pathol** 1997 Mar; 21(3):348–53

Granular cell tumor of uncertain malignant potential. Menaker GM, et al. **Ann Plast Surg** 1997 Jun;38(6):658–60

Intra-abdominal desmoplastic small cell tumors: report of two cases. Liau CT, et al. **Anticancer Drugs** 1996 Feb; 7(2):228–32

Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies. van Noesel MM, et al. **Cancer** 1997 Sep 1;80(5):834–43 (63 ref.)

Patterns of spread of recurrent intraabdominal sarcoma. Sugarbaker TA, et al. **Cancer Treat Res** 1996;82:65–77

Malignant cells revealed in fine needle punctures of lymph nodes and tumours by electronmicroscopical methods. Hulinska D, et al. **Cent Eur J Public Health** 1995 Nov; 3(4):195–8

Widespread intraabdominal carcinoid tumor presenting as an umbilical metastasis: diagnosis by fine-needle aspiration [letter] Grunewald B, et al. **Diagn Cytopathol** 1996 Dec; 15(5):457–8

Hyaline matrix material in high-grade endometrial stromal sarcoma diagnosed by fine-needle aspiration: case report. Liu K, et al. **Diagn Cytopathol** 1997 Feb;16(2):151–5

Chest wall resection and reconstruction for metastatic basal cell carcinoma. Cunnick GH, et al. **Eur J Surg Oncol** 1997 Apr;23(2):189–90

Differential diagnosis of malignant tumours in the abdominal cavity of rats after intraperitoneal injection of crocidolite or benzo[a]pyrene. Friemann J, et al. **Exp Toxicol Pathol** 1996 Jan;48(1):13–7

Staging of abdominal cancer by local anesthesia outpatient laparoscopy. Sand J, et al. **Hepatogastroenterology** 1996 Nov–Dec;43(12):1685–8

Dedifferentiated myxoid liposarcoma: a clinicopathological study suggesting a closer relationship between myxoid and well-differentiated liposarcoma. Mentzel T, et al. **Histopathology** 1997 May;30(5):457–63

An intra-abdominal small round cell neoplasm with features of primitive neuroectodermal and desmoplastic round cell tumor and a EWS/FLI-1 fusion transcript. Katz RL, et al. **Hum Pathol** 1997 Apr;28(4):502–9

Case report of intramuscular myxoma with review of literature. Calton N, et al. **Indian J Pathol Microbiol** 1996 Oct;39(4):299–301 (9 ref.)

Triphasic nephroblastoma in a horse. Jardine JE, et al. **J Comp Pathol** 1996 Feb;114(2):193–8

Angiosarcoma which developed on the abdominal wall: report of a case. Funaki M, et al. **J Dermatol** 1997 May; 24(5):342–4 (6 ref.)

Fine needle aspiration of intra-abdominal masses for cytodiagnosis. Khan AA, et al. **J Indian Med Assoc** 1996 May;94(5):167–8, 194

Primary extrarenal Wilms' tumor in the inguinal canal: case report and review of the literature. Arkovitz MS, et al. **J Pediatr Surg** 1996 Jul;31(7):957–9 (15 ref.)

Abdominal wall implantation of an endocervical-like mucinous borderline tumor. Measham C, et al. **Mod Pathol** 1996 Apr;9(4):381–5

Images in clinical medicine. Sister Joseph's node in non-Hodgkin's lymphoma. Nagao K, et al. **N Engl J Med** 1996 Nov 21;335(21):1569

Postmenopausal intra-abdominal desmoplastic small cell tumor. Fukunaga M, et al. **Pathol Int** 1996 Apr;46(4):281–5

Endometrioid adenoma (polypoid endometriosis) of the omentum maius. Grouls V, et al. **Pathol Res Pract** 1995 Oct;191(10):1049–52

Intra-abdominal polyphenotypic tumor. Thorner P. **Pediatr Pathol Lab Med** 1996 Jan–Feb;16(1):161–9

Stage IVN neuroblastoma: MRI diagnosis of left supraclavicular "Virchow's" nodal spread. Abramson SJ, et al. **Pediatr Radiol** 1996 Oct;26(10):717–9

Desmoplastic small round cell tumor. Leuschner I, et al. **Semin Diagn Pathol** 1996 Aug;13(3):204–12 (46 ref.)

Clear cell tumors of the alimentary tract and abdominal cavity. Ritter JH, et al. **Semin Diagn Pathol** 1997 Aug; 14(3):213–9 (42 ref.)

Intraabdominal lymphangiosarcoma in a Fischer-344 rat. Takahashi K, et al. **Toxicol Pathol** 1997 Jul–Aug; 25(4):403–6

Umbilical polyp originating from urachal remnants. Oğuzkurt P, et al. **Turk J Pediatr** 1996 Jul–Sep;38(3):371–4

[Value of cytologic studies in staging solid tumors. Report of a Workshop 11 December 1995 in Erlangen] Schmidt O, et al. **Chirurg** 1997 Jan;68(1):90–3 **(Ger)**

[Current TNM classification. 4. Residual tumor—classification. Commissioned by the German Speaking TNM Committee] Hermanek P, et al. **Zentralbl Chir** 1997;122(1):52–5 **(Ger)**

[CT-guided core needle biopsy of abdominal, pelvic and retroperitoneal masses] Sklair-Levy M, et al. **Harefuah** 1997 Mar 2;132(5):318–23, 382 (Eng. Abstr.) **(Heb)**

[Cancer of the sebaceous gland and precancerous Pinkus fibroepithelioma of the anterior abdominal wall] Samoĭlov MV, et al. **Arkh Patol** 1997 Jan–Feb;59(1):57–9 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

[Ultrasound "screening examination" of the abdomen: of value or senseless?] Mostbeck GH. **Ultraschall Med** 1996 Aug; 17(4):175–8 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Clinical utility of abdominal CT scanning in patients with HIV disease. Sansom H, et al. **Clin Radiol** 1997 Sep; 52(9):698–703

An 8-year-old girl with an abdominal mass.Pica. Yogev Y, et al. **Eur J Pediatr** 1997 Mar;156(3):243–4

Radiology quiz #13. Lymphoma. Francis RA. **Mo Med** 1997 Jul;94(7):321–2

Images in clinical medicine. Sister Joseph's node in carcinoma of the cecum. Moll S. **N Engl J Med** 1996 Nov 21; 335(21):1568

Intravenous urography revisited in the age of ultrasound and computerized tomography: diagnostic yield in cases of renal colic, suspected pelvic and abdominal malignancies, suspected renal mass, and acute pyelonephritis. Andresen R, et al. **Urol Int** 1997;58(4):221–6

[Malignant desmoplastic tumor with divergent differentiation] Strunk H, et al. **Aktuelle Radiol** 1996 Jan; 6(1):35–7 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Radioimmunoguided surgery benefits for recurrent colorectal cancer [see comments] Schneebaum S, et al. **Ann Surg Oncol** 1997 Jul–Aug;4(5):371–6. Comment in: Ann Surg Oncol 1997 Jul–Aug;4(5):369–70.

Single photon emission computerized tomography increases the sensitivity of indium-111-pentetreotide scintigraphy in detecting abdominal carcinoids. Schillaci O, et al. **Anticancer Res** 1997 May–Jun;17(3B):1753–6

DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Otte A, et al. **Eur J Nucl Med** 1997 Jul;24(7):792–5

Diagnostic imaging in abdominal neuroblastoma: is there a complementary role of MIBG-scintigraphy and ultrasonography? Petjak M, et al. **Eur J Pediatr** 1997 Aug; 156(8):610–5

Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. Leisure GP, et al. **J Nucl Med Technol** 1997 Jun;25(2):115–9

Intraoperative search for neuroblastoma by MIBG and radioguided surgery with the gamma detector. Heij HA, et al. **Med Pediatr Oncol** 1997 Mar;28(3):171–4

Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. Kim CK, et al. **Nucl Med Commun** 1996 Oct;17(10):890–4

Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma. Claudiani F, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):21–4

Upper clavicular and cardiac meta-[123I]iodobenzylguanidine uptake in children. Lumbroso J, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):17–20

PET scans of abdominal malignancy. Blahd WH, et al. **World J Surg** 1996 Feb;20(2):245–7

RADIOTHERAPY

Intraoperative electron irradiation in the management of pediatric malignancies. Schomberg PJ, et al. **Cancer** 1997 Jun 1;79(11):2251–6

Radiotherapy after chemotherapy for metastatic seminoma—a diminishing role. MRC Testicular Tumour Working Party. Duchesne GM, et al. **Eur J Cancer** 1997 May;33(6):829–35

DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Otte A, et al. **Eur J Nucl Med** 1997 Jul;24(7):792–5

Quality assurance in radiotherapy of neoplasms of the upper abdomen. Cellini N, et al. **Rays** 1996 Oct–Dec;21(4):634–40 **(Eng, Ita)**

Hyperbaric oxygen an adjunctive treatment for delayed radiation injuries of the abdomen and pelvis. Feldmeier JJ, et al. **Undersea Hyperb Med** 1996 Dec;23(4):205–13

SECONDARY

Abdominal metastases of infiltrating lobular breast carcinoma: CT and fluoroscopic imaging findings. Kidney DD, et al. **Abdom Imaging** 1997 Mar–Apr;22(2):156–9

Sister Mary Joseph's nodule: cytopathologic analysis of four cases [letter] Hoda RS, et al. **Acta Cytol** 1997 Sep–Oct; 41(5):1634–6

Analysis of interobserver and intraobserver variability in CT tumor measurements. Hopper KD, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):851–4

Impact of gas(less) laparoscopy and laparotomy on peritoneal tumor growth and abdominal wall metastases. Bouvy ND, et al. **Ann Surg** 1996 Dec;224(6):694–700; discussion 700–1

Laparoscopy in the management of gastric adenocarcinoma. Burke EC, et al. **Ann Surg** 1997 Mar;225(3):262–7 (9 ref.)

Radiotherapy after chemotherapy for metastatic seminoma—a diminishing role. MRC Testicular Tumour Working Party. Duchesne GM, et al. **Eur J Cancer** 1997 May;33(6):829–35

Umbilical port metastasis from gallbladder carcinoma after laparoscopic cholecystectomy. Karayiannakis AJ, et al. **Eur J Surg Oncol** 1997 Apr;23(2):186–7

Metastatic breast carcinoma to the abdomen and pelvis. Abu-Rustum NR, et al. **Gynecol Oncol** 1997 Jul;66(1):41–4

Intra-abdominal spread of malignant cells following hysteroscopy [letter] Bettocchi S, et al. **Gynecol Oncol** 1997 Jul;66(1):165–6

The approach to the patient with single and multiple liver metastases, pulmonary metastases, and intra-abdominal metastases from colorectal carcinoma. VanderMeer TJ, et al. **Hematol Oncol Clin North Am** 1997 Aug;11(4):759–77 (78 ref.)

Unsuspected carcinoma of the gall bladder: case report of trocar-site metastasis following laparoscopic cholecystectomy. Principe A, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):990–3

Images in clinical medicine. Sister Joseph's node in carcinoma of the cecum. Moll S. **N Engl J Med** 1996 Nov 21; 335(21):1568

Images in clinical medicine. Sister Joseph's node in non-Hodgkin's lymphoma. Nagao K, et al. **N Engl J Med** 1996 Nov 21;335(21):1569

Metastasis of an intracranial germinoma through a ventriculoperitoneal shunt: recurrence as a yolk-sac tumor. Back MR, et al. **Pediatr Surg Int** 1997;12(1):24–7

Portsite and intraabdominal metastases of unsuspected gallbladder carcinoma after laparoscopic cholecystectomy: report of a case. Shibata N, et al. **Surg Today** 1996; 26(12):1014–6

Adult-type granulosa cell tumor, presenting as extraovarian metastases: ultrastructural diagnosis. Drachenberg CB, et al. **Ultrastruct Pathol** 1996 May–Jun;20(3):231–9

Malignant mesenchymoma arising from the prostate in Gardner's syndrome. Ohta S, et al. **Urol Int** 1996; 56(4):256–8

[An umbilical nodule to be considered religiously] Gigon M, et al. **Ann Pathol** 1997 Mar;17(1):59–60 **(Fre)**

[Tumor disseminate in site following laparoscopic cholecystectomy] Shibata N, et al. **Nippon Geka Gakkai Zasshi** 1997 Apr;98(4):462–5 (25 ref.) **(Jpn)**

SURGERY

Radioimmunoguided surgery benefits for recurrent colorectal cancer [see comments] Schneebaum S, et al. **Ann Surg Oncol** 1997 Jul–Aug;4(5):371–6. Comment in: Ann Surg Oncol 1997 Jul–Aug;4(5):369–70.

Relationship between circulating secretory immunoglobulin A levels and portal blood cytokine levels during major abdominal surgery. Fujita T, et al. **Arch Surg** 1997 Feb; 132(2):124–7

Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. **Br J Surg** 1997 Aug;84(8):1099–103

Wound metastases following laparoscopic and open surgery for abdominal cancer in a rat model. Mathew G, et al. **Br J Surg** 1996 Aug;83(8):1087–90

Cancer cell seeding during abdominal surgery: experimental studies. Zoetmulder FA. **Cancer Treat Res** 1996;82:155–61

Metastatic breast carcinoma to the abdomen and pelvis. Abu-Rustum NR, et al. **Gynecol Oncol** 1997 Jul;66(1):41–4

ABDOMINAL NEOPLASMS

Abdominal cystic lymphangioma in children: benign lesions that can have a proliferative course. Steyaert H, et al. **J Pediatr Surg** 1996 May;31(5):677–80

Intraoperative search for neuroblastoma by MIBG and radioguided surgery with the gamma detector. Heij HA, et al. **Med Pediatr Oncol** 1997 Mar;28(3):171–4

Laparoscopic surgery in the rat. Beneficial effect on body weight and tumor take [letter] Watson DI, et al. **Surg Endosc** 1997 Feb;11(2):165–6

Questionability of the benefits of routine laparotomy as the surgical approach for pheochromocytomas and abdominal paragangliomas. Pattou FN, et al. **Surgery** 1996 Dec; 120(6):1006–11; discussion 1012

[Intra-abdominal schwannoma. Diagnosis and surgical therapy] Dette K, et al. **Chirurg** 1997 Feb;68(2):159–67 (Eng. Abstr.) **(Ger)**

[Plastic surgery defect coverage in the area of the pelvis and trunk] Germann G, et al. **Chirurg** 1997 May; 68(5):469–76 (26 ref.) (Eng. Abstr.) **(Ger)**

[Prolonged intensive care stay after abdominal surgery interventions with special reference to quality of life, occupational rehabilitation and economics] Neipp M, et al. **Chirurg** 1997 Apr;68(4):410–5 (Eng. Abstr.) **(Ger)**

[Laparoscopy in diagnosis and therapy of advanced abdominal malignancies] Müller G, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:568–70 (Eng. Abstr.) **(Ger)**

[Results of operative therapy in sequential liver and lung metastasis] Piltz S, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:225–8 (Eng. Abstr.) **(Ger)**

[Abdominal liposarcomas--surgical therapy principles] Schmidbauer U, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:232–3 **(Ger)**

[Indications and results of surgically treated, with temporary vena cava filter managed patients] Zwaan M, et al. **Zentralbl Chir** 1996;121(12):1063–8 (Eng. Abstr.) **(Ger)**

[Neuro-fibro-liposarcoma healed by partial surgical intervention complicated by post-transfusional shock] Kuś H, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):346–7 **(Pol)**

[Use of videolaparoscopy in the diagnosis and treatment of patients with abdominal neoplasms] Ukhanov AP. **Vopr Onkol** 1996;42(4):56–8 **(Rus)**

THERAPY

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. Punt CJ, et al. **Br J Cancer** 1997;76(2):266–9

Recurrent intraabdominal cancer, causing intestinal obstruction: Washington Hospital Center experience with 42 patients managed by surgery and intraperitoneal chemotherapy. Averbach AM, et al. **Cancer Treat Res** 1996; 81:133–47

The approach to the patient with single and multiple liver metastases, pulmonary metastases, and intra-abdominal metastases from colorectal carcinoma. VanderMeer TJ, et al. **Hematol Oncol Clin North Am** 1997 Aug;11(4):759–77 (78 ref.)

ULTRASONOGRAPHY

Diagnostic imaging in abdominal neuroblastoma: is there a complementary role of MIBG-scintigraphy and ultrasonography? Petjak M, et al. **Eur J Pediatr** 1997 Aug; 156(8):610–5

Sonographic patterns in extranodal abdominal lymphomas. Görg C, et al. **Eur Radiol** 1996;6(6):855–64

Prenatal ultrasonographic findings of intra-abdominal cystic lymphangioma: a case report. Devesa R, et al. **J Clin Ultrasound** 1997 Jul-Aug;25(6):330–2

Rapid growth of a fetal abdominal mass: a case report of congenital neuroblastoma. Shen MR, et al. **J Clin Ultrasound** 1997 Jan;25(1):39–42 (11 ref.)

Abdominal lymphangioma in a preterm infant. Salvador A, et al. **J Perinatol** 1996 Jul-Aug;16(4):305–8 (9 ref.)

Transcutaneous abdominal ultrasonography in the staging of lung cancer. Bakke PS, et al. **Thorax** 1997 Mar;52(3):276–80

Color-coded Doppler sonography in the diagnosis of abdominal masses. Fiechtner H, et al. **Urol Int** 1996; 56(3):184–7

[Ultrasound manifestations of abdominal lymphomas. An overview] Görg C, et al. **Ultraschall Med** 1996 Aug; 17(4):179–84 (13 ref.) (Eng. Abstr.) **(Ger)**

[Progress and clinical usefulness of color Doppler method in diagnosing abdominal diseases] Tomiyama T, et al. **Nippon Rinsho** 1996 Sep;54(9):2561–73 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Sonography in the diagnosis of lesions of abdominal lymph nodes, liver and spleen in malignant lymphoma] Semenov II. **Vopr Onkol** 1997;43(2):198–201 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Adult-type granulosa cell tumor, presenting as extraovarian metastases: ultrastructural diagnosis. Drachenberg CB, et al. **Ultrastruct Pathol** 1996 May-Jun;20(3):231–9

VETERINARY

Triphasic nephroblastoma in a horse. Jardine JE, et al. **J Comp Pathol** 1996 Feb;114(2):193–8

Intraabdominal lymphangiosarcoma in a Fischer-344 rat. Takahashi K, et al. **Toxicol Pathol** 1997 Jul-Aug; 25(4):403–6

VIROLOGY

Epstein-Barr virus (EBV)-associated smooth-muscle tumor arising in a post-transplant patient treated successfully for two PT-EBV-associated large-cell lymphomas. Case report. Kingma DW, et al. **Am J Surg Pathol** 1996 Dec; 20(12):1511–9

ABDOMINAL PAIN

see related

COLIC

Acute appendicitis: the myths of migratory pain and gradual onset of symptoms [letter] Wigder HN, et al. **Am J Emerg Med** 1997 Jan;15(1):111–2

Chronic functional abdominal pain. Drossman DA. **Am J Gastroenterol** 1996 Nov;91(11):2270–81 (96 ref.)

Adolescents with psychosomatic problems. Brown RT. **Compr Ther** 1996 Dec;22(12):810–6 (30 ref.)

Common problems in pediatric gastroenterology. Squires RH Jr. **Compr Ther** 1996 Dec;22(12):767–75 (61 ref.)

Recurrent abdominal pain and irritable bowel syndrome in children. Hyams JS. **J Pediatr Gastroenterol Nutr** 1997;25 Suppl 1:S16–7

[A 36-year-old male with abdominal pain during 19 years and mass in the right iliac fossa (clinical conference)] Pedro-Botet J, et al. **Med Clin (Barc)** 1996 Nov 9; 107(16):628–35 **(Spa)**

CHEMICALLY INDUCED

Abdominal pain, leg weakness, and alopecia in a teenage boy. Fred HL, et al. **Hosp Pract (Off Ed)** 1997 Apr 15; 32(4):69–70

COMPLICATIONS

Dietary fibre and the occurrence of gut symptoms in cystic fibrosis. Gavin J, et al. **Arch Dis Child** 1997 Jan;76(1):35–7

Helicobacter pylori gastritis in a child with sickle cell anemia and recurrent abdominal pain. Kennedy L, et al. **J Pediatr Hematol Oncol** 1997 Mar-Apr;19(2):163–4

Abdominal pain and psychosis [letter] Aronson ME. **J R Soc Med** 1997 Jul;90(7):414

DIAGNOSIS

Recurrent abdominal pain. Dire DJ. **Acad Emerg Med** 1996 Oct;3(10):952, 957–9

Recurrent abdominal pain and Helicobacter pylori: a comment [letter; comment] Radke M. **Acta Paediatr** 1997 Jun;86(6):671–3. Comment on: Acta Paediatr 1996 Aug;85(8):961–4.

Trichuris trichiura infection, abdominal pain, and colonoscopy [letter; comment] Raj SM. **Am J Gastroenterol** 1997 Apr;92(4):719–20. Comment on: Am J Gastroenterol 1996 Jan;91(1):161–2.

Evaluation of automatic knowledge acquisition techniques in the diagnosis of acute abdominal pain. Acute Abdominal Pain Study Group. Ohmann C, et al. **Artif Intell Med** 1996 Feb;8(1):23–36

One-year prognosis of abdominal complaints in general practice: a prospective study of patients in whom no organic cause is found. Muris JW, et al. **Br J Gen Pract** 1996 Dec;46(413):715–9

Diagnostic laparoscopy: indication and benefit. Yu SY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Mar; 59(3):158–63

Abdominal pain in the elderly: use of temperature and laboratory testing to screen for surgical disease. Parker JS, et al. **Fam Med** 1996 Mar;28(3):193–7

A young man with fever, chills, and abdominal pain. De Masi R, et al. **Hosp Pract (Off Ed)** 1997 Mar 15;32(3):51–2

Evaluation of plasma serotonin concentration in acute appendicitis. Kalra U, et al. **Indian J Gastroenterol** 1997 Jan;16(1):18–9

Prognosis of elderly patients with non-specific abdominal pain. Smyth E, et al. **J Accid Emerg Med** 1996 Jan; 13(1):44–5

Symptom-specific use of upper gastrointestinal endoscopy in human immunodeficiency virus-infected patients yields high dividends. Bashir RM, et al. **J Clin Gastroenterol** 1996 Dec;23(4):292–8

Imaging findings in patients with-right lower quadrant pain: alternative diagnoses to appendicitis. Jain KA, et al. **J Comput Assist Tomogr** 1997 Sep-Oct;21(5):693–8 (8 ref.)

Acute abdominal pain in children [letter; comment] Cockington RA. **J Paediatr Child Health** 1996 Dec; 32(6):546. Comment on: J Paediatr Child Health 1996 Apr;32(2):110–2.

The management of acute abdominal pain in children [letter; comment] Mawdsley JA, et al. **J Paediatr Child Health** 1996 Oct;32(5):469. Comment on: J Paediatr Child Health 1996 Apr;32(2):110–2.

Laparoscopy for diagnosis and treatment of recurrent abdominal pain in children. Stylianos S, et al. **J Pediatr Surg** 1996 Aug;31(8):1158–60

Imaging children with acute right lower quadrant pain. Sivit CJ. **Pediatr Clin North Am** 1997 Jun;44(3):575–89 (42 ref.)

A strategy for abdominal pain. Waterston T. **Practitioner** 1997 Jun;241(1575):316–8, 320 (3 ref.)

Papillary cystic tumor of the pancreas in children. Yang YJ, et al. **Scand J Gastroenterol** 1996 Dec;31(12):1223–7 (18 ref.)

Diagnosis and treatment of right upper quadrant abdominal pain. Dill JE. **Va Med Q** 1996 Winter;123(1):27–9

50th annual J. Shelton Horsley Lecture. Gains and losses in the modern diagnosis of abdominal pain. McGuire HH Jr. **Va Med Q** 1997 Winter;124(1):14–7

[Emergency medicine for the practitioner: abdominal pain] Fresard F, et al. **Rev Med Suisse Romande** 1997 Apr; 117(4):281–4 **(Fre)**

[Diarrhea and abdominal discomfort of 4 months' evolution in a 60-year-old woman] Gómez Anta I, et al. **Rev Clin Esp** 1997 Jan;197(1):63–4 **(Spa)**

DRUG THERAPY

Power error [letter] Weinberger M, et al. **Acad Emerg Med** 1997 Aug;4(8):838–9

The relative risks [letter] Williams ER, et al. **Acad Emerg Med** 1997 Aug;4(8):838–9

Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Schütze K, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):387–94

Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral kappa-opioid receptors. Langlois A, et al. **Eur J Pharmacol** 1997 Apr 18;324(2–3):211–7

[Abdominal syndromes and analgesia] Camus-Kerebel C, et al. **Cah Anesthesiol** 1996;44(4):335–9 (Eng. Abstr.) **(Fre)**

[Caustic proctitis after lavage: an African cause of rectal hemorrhage (letter)] Iboudo D, et al. **Med Trop (Mars)** 1996;56(2):204–5 **(Fre)**

[Eradication of Helicobacter pylori and chronic abdominal pain (editorial)] Madrazo de la Garza JA. **Rev Gastroenterol Mex** 1996 Oct-Dec;61(4):398–9 **(Spa)**

[Eradication of Helicobacter pylori in patients with recurrent abdominal pain using a triple drug treatment] Ramírez Mayans J, et al. **Rev Gastroenterol Mex** 1996 Oct-Dec; 61(4):310–3 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Familial hyperamylasaemia. Cuckow PM, et al. **Gut** 1997 May;40(5):689–90

Macrolipasaemia in a patient with pancreas divisum and acute abdominal pain: a case report. Selberg O, et al. **Scand J Clin Lab Invest** 1997 Aug;57(5):435–43

EPIDEMIOLOGY

Experience of recurrent abdominal pain: evaluation based on the Eland scale [letter] Guariso G, et al. **J Pain Symptom Manage** 1997 Sep;14(3):133–4

Clinical outcomes of children with acute abdominal pain. Scholer SJ, et al. **Pediatrics** 1996 Oct;98(4 Pt 1):680–5

Prevalence of pain combinations and overall pain: a study of headache, stomach pain and back pain among school-children. Kristjánsdóttir G. **Scand J Soc Med** 1997 Mar;25(1):58–63

ETIOLOGY

Ileocolic intussusception secondary to a lipoma in an adult [letter] Bui DQ, et al. **Acad Emerg Med** 1997 Jul;4(7):758–60

Diagnosis of midgut volvulus in an adult with the aid of key radiologic findings [letter] Vergara EC, et al. **Acad Emerg Med** 1997 Jul;4(7):756–8

Evaluation acute abdominal pain in the emergency department. View of the emergency physician. Askenasi R, et al. **Acta Gastroenterol Belg** 1996 Apr-Jun;59(2):133

Recurrent abdominal pain and Helicobacter pylori in a community-based sample of London children [see comments] O'Donohoe JM, et al. **Acta Paediatr** 1996 Aug; 85(8):961–4. Comment in: Acta Paediatr 1997 Jun;86(6):671–3.

Pregnant adolescents in the emergency department: diagnosed and not diagnosed. Causey AL, et al. **Am J Emerg Med** 1997 Mar;15(2):125–9

Atypical presentation of Henoch-Schoenlein purpura in two children. Sharieff GQ, et al. **Am J Emerg Med** 1997 Jul; 15(4):375–7

Intestinal endometriosis as a cause of chronic abdominal pain leading to intestinal obstruction. Gómez-Rubio M, et al. **Am J Gastroenterol** 1997 Mar;92(3):525–6

Diabetic thoracic polyradiculopathy: ten patients with abdominal pain. Longstreth GF. **Am J Gastroenterol** 1997 Mar;92(3):502–5

Sclerosing mesenteritis: an unusual cause of abdominal pain in an HIV-positive patient. Venkataramani A, et al. **Am J Gastroenterol** 1997 Jun;92(6):1059–60

The role of laparoscopy in chronic and recurrent abdominal pain. Miller K, et al. **Am J Surg** 1996 Oct;172(4):353–6; discussion 356–7

Serum amylase and lipase in the evaluation of acute abdominal pain. Chase CW, et al. **Am Surg** 1996 Dec; 62(12):1028–33

Can serum interleukin-6 levels predict the outcome of patients with right iliac fossa pain? [see comments] Goodwin AT, et al. **Ann R Coll Surg Engl** 1997 Mar; 79(2):130–3. Comment in: Ann R Coll Surg Engl 1997 Jul;79(4):310–1.

Long-term review of coeliac axis compression syndrome.

Holland AJ, et al. **Ann R Coll Surg Engl** 1996 Sep; 78(5):470–2

Radiological case of the month. Incarcerated umbilical hernia. Simon HK. **Arch Pediatr Adolesc Med** 1997 May; 151(5):519–20

Diversion colitis: a cause of abdominal discomfort in spinal cord injury patients with colostomy. Lai JM, et al. **Arch Phys Med Rehabil** 1997 Jun;78(6):670–1

Phlegmonous enteritis: an unusual cause of abdominal pain. Mooney WW, et al. **Australas Radiol** 1997 May;41(2):173–5

Pneumonia presenting with acute abdominal pain in children. Ravichandran D, et al. **Br J Surg** 1996 Dec;83(12):1707–8

Radiology for the surgeon. Case 13. Giant cavernous hemangioma of the liver. Mott BD, et al. **Can J Surg** 1997 Feb;40(1):13, 66–7

Abdominal pain and massive intravascular hemolysis in a 47–year–old man. Pun KC, et al. **Chest** 1996 Nov; 110(5):1353–5

Abdominal pain, heart murmur, and lung infiltrates in a 40–year–old man. Schultz M, et al. **Chest** 1997 Feb; 111(2):498–500

Nongynecologic causes of unexplained lower abdominal pain in adolescent girls. Cavanaugh RM Jr. **Clin Pediatr (Phila)** 1996 Jul;35(7):337–41

Evaluation of the erythrocyte sedimentation rate in children presenting with limp, fever, or abdominal pain. Huttenlocher A, et al. **Clin Pediatr (Phila)** 1997 Jun; 36(6):339–44

Celiac disease as a frequent cause of abdominal symptoms in children with insulin–dependent diabetes mellitus [letter; comment] Madácsy L, et al. **Clin Pediatr (Phila)** 1997 Mar; 36(3):185–6. Comment on: Clin Pediatr (Phila) 1996 Jul;35(7):343–7.

Cases of the month: three children with abdominal complaints. Kolho KL, et al. **Eur J Pediatr** 1997 Jan; 156(1):75–6

Dyslipidaemia in a boy with recurrent abdominal pain, hypersalivation and decreased lipoprotein lipase activity. Matern D, et al. **Eur J Pediatr** 1996 Aug;155(8):660–4

Additional value of biochemical tests in suspected acute appendicitis. Hallan S, et al. **Eur J Surg** 1997 Jul; 163(7):533–8

Bronchogenic cyst: a rare cause of a retroperitoneal mass. Menke H, et al. **Eur J Surg** 1997 Apr;163(4):311–4 (14 ref.)

Audit of the outcome of peptic ulcer disease diagnosed 10 to 20 years previously. Malliwah JA, et al. **Gut** 1996 Jun; 38(6):812–5

Abdominal discomfort in a man with sprue. Fred HL, et al. **Hosp Pract (Off Ed)** 1997 Jan 15;32(1):132–4

A woman with abdominal pain and a history of thromboses. Matfin G, et al. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):21–2

Recurrent pain abdomen due to biliary calculus [letter] Jha BB. **Indian Pediatr** 1997 Mar;34(3):258

Slipping rib syndrome: an overlooked cause of chest and abdominal pain. Lum–Hee N, et al. **Int J Clin Pract** 1997 Jun;51(4):252–3

Gastrointestinal malignant melanoma. Woollons A, et al. **Int J Dermatol** 1997 Feb;36(2):129–31

Primary gastro–oesophageal reflux disease and irritable oesophagus syndrome as causes of recurrent abdominal pain in children. Corrado G, et al. **Ital J Gastroenterol** 1996 Oct–Nov;28(8):462–9

Laparoscopic diagnosis and treatment of an infarcted epiploic appendage. Silva PD, et al. **J Am Assoc Gynecol Laparosc** 1996 Feb;3(2):325–7

Microanatomy of the structures contributing to abdominal cutaneous nerve entrapment syndrome. Applegate WV, et al. **J Am Board Fam Pract** 1997 Sep–Oct;10(5):329–32

Radiological case of the month. Gallstone ileus. Hays D, et al. **J Ark Med Soc** 1997 Jul;94(2):89–90

Splenic infarct presenting as acute abdominal pain in an older patient. Beeson MS. **J Emerg Med** 1996 May–Jun; 14(3):319–22

Intermittent abdominal pain in a middle–aged man. Brown DF, et al. **J Emerg Med** 1997 Jul–Aug;15(4):517–22

The relationship between abdominal pain regions and specific diseases: an epidemiologic approach to clinical practice. Yamamoto W, et al. **J Epidemiol** 1997 Mar;7(1):27–32

Severe abdominal pain and thrombocytopenia––typical symptoms of occult jejunal diverticulum perforation? Klee FE, et al. **J Gastroenterol** 1997 Apr;32(2):246–50 (62 ref.)

Chronic upper abdominal pain due to duodenal ulcer and other structural and functional causes: its localization and nocturnal occurrence. Kang JY, et al. **J Gastroenterol Hepatol** 1996 Jun;11(6):515–9

First clinical judgment by primary care physicians distinguishes well between nonorganic and organic causes of abdominal or chest pain [see comments] Martina B, et al. **J Gen Intern Med** 1997 Aug;12(8):459–65. Comment in: J Gen Intern Med 1997 Aug;12(8):509–10.

Radiology case of the month. Evaluation of right lower quadrant pain. Acute appendicitis. Lobrano ME, et al. **J La State Med Soc** 1996 Aug;148(8):335–6

Radiology case of the month. Calcified mass and indistinct retroperitoneal landmarks on abdominal radiograph. Ruptured abdominal aortic aneurysm. Romano CC, et al. **J La State Med Soc** 1997 Aug;149(8):267–8

Upper gastrointestinal endoscopy in children with recurrent abdominal pain. Aanpreung P, et al. **J Med Assoc Thai** 1997 Jan;80(1):22–5

Management quandary. Quint EH. **J Pediatr Adolesc Gynecol** 1997 May;10(2):101–2

A causal link between recurrent abdominal pain and migraine [letter; comment] Mavromichalis I. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):365–6. Comment on: J Pediatr Gastroenterol Nutr 1995 Feb;20(2):209–14.

Slipping rib syndrome in childhood. Mooney DP, et al. **J Pediatr Surg** 1997 Jul;32(7):1081–2

Acute abdominal pain in children: an analysis of admissions over a three year period. Holland A, et al. **J Qual Clin Pract** 1996 Sep;16(3):151–5

Zieve's syndrome a potential surgical pitfall? Pilcher CR, et al. **J R Army Med Corps** 1996 Jun;142(2):84

Incidence of recurrent bladder cancer in patients requiring admission for abdominal pain long after cystectomy. Phillips JL, et al. **J Surg Oncol** 1996 Nov;63(3):191–4

Epigastric pain unrelieved by omeprazole. Weber L. **J Tenn Med Assoc** 1996 Mar;89(3):84–5

Does non–dysenteric intestinal amoebiasis exist? Anand AC, et al. **Lancet** 1997 Jan 11;349(9045):89–92

Persisting abdominal pain in an 11–year–old without an appendix. Nassimbeni G, et al. **Lancet** 1997 Mar 29; 349(9056):920

Referral of patients with pain from pancreatic cancer for neurolytic celiac plexus block. Brown DL, et al. **Mayo Clin Proc** 1997 Sep;72(9):831–4

3–year–old boy with cystic fibrosis and abdominal pain. Fallick JS, et al. **Mayo Clin Proc** 1997 Jul;72(7):679–82

64–year–old woman with chronic epigastric pain. Miller AL, et al. **Mayo Clin Proc** 1997 Jan;72(1):73–6

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 24–1997. A six–year–old boy with bouts of abdominal pain, vomiting, and a left–sided abdominal mass [clinical conference] **N Engl J Med** 1997 Jul 31;337(5):329–36

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 8–1997. A 65–year–old man with recurrent abdominal pain for five years [clinical conference] **N Engl J Med** 1997 Mar 13;336(11):786–93

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6–1997. A 69–year–old man with a complex medical history and severe abdominal pain [clinical conference] **N Engl J Med** 1997 Feb 20; 336(8):567–73

Abdominal pain in New Zealand general practice. Frear D, et al. **N Z Med J** 1997 Sep 12;110(1051):333–4

Severe upper abdominal pain due to a large hepatocellular adenoma. Reijnierse JE, et al. **Neth J Med** 1997 Jul; 51(1):46–50

Coital injury presenting in a 13 year old as abdominal pain and vaginal bleeding. Bhagat M. **Pediatr Emerg Care** 1996 Oct;12(5):354–5

Chronic abdominal pain and Helicobacter pylori. Adams RM. **Pediatr Infect Dis J** 1997 May;16(5):534–5

Hepatosplenic cat–scratch disease and abdominal pain. Dunn MW, et al. **Pediatr Infect Dis J** 1997 Mar;16(3):269–72

Recurrent abdominal pain: an update. Boyle JT. **Pediatr Rev** 1997 Sep;18(9):310–20; quiz 321

Index of suspicion. Case 3. Diagnosis: intussusception. Falaki NN. **Pediatr Rev** 1997 May;18(5):175, 177–8

Abdominal pain associated with cranial nerve palsy and peripheral neuropathy. Dawson LK, et al. **Postgrad Med J** 1997 May;73(859):305–6

Abdominal pain in a young girl. Handa R, et al. **Postgrad Med J** 1996 Feb;72(844):123–5

Diagnosing the causes of abdominal pain in children. Bell R. **Practitioner** 1996 Oct;240(1567):598, 601–2, 604 (3 ref.)

Iron deficiency anemia, backache, and abdominal pain attacks during sexual intercourse in a 42–year–old woman. Mulari S, et al. **Scand J Gastroenterol** 1996 Jun;31(6):622–3

Mesenteric tumor emboli manifested as recurrent abdominal pain. Duckworth C, et al. **South Med J** 1997 Apr; 90(4):419–22

An unusual complication of diabetes mellitus: the zebra that became a horse. Nicol KK, et al. **South Med J** 1997 Jan; 90(1):83–5

Abdominal fat tissue necrosis as a cause of acute abdominal pain. Laparoscopic diagnosis and therapy. Aronsky D, et al. **Surg Endosc** 1997 Jul;11(7):737–40

Laparoscopy for chronic abdominal pain. Klingensmith ME, et al. **Surg Endosc** 1996 Nov;10(11):1085–7

Hypotensive reactions to white cell–reduced plasma in a patient undergoing angiotensin–converting enzyme inhibitor therapy [see comments] Fried MR, et al. **Transfusion** 1996 Oct;36(10):900–3. Comment in: Transfusion 1996 Oct;36(10):852–3.

Adrenal myelolipoma with abdominal pain. Kobayashi T, et al. **Urol Int** 1997;58(4):254–6 (9 ref.)

[Chronic torsion of an ectopic spleen in the differential diagnosis of abdominal pain in a child. Case report] Machart M, et al. **Rozhl Chir** 1996 Oct;75(10):480–1 (Eng. Abstr.) **(Cze)**

[Anemia, abdominal pain and fatigue––lead can still be found] Laine O, et al. **Duodecim** 1995;111(12):1107–10 **(Fin)**

[Diagnostic laparoscopy in persistent and chronic abdominal pain] Renteria SC, et al. **Arch Gynecol Obstet** 1996;259 Suppl 1:S47–53 **(Fre)**

[Abdominal pain syndrome disclosing acute eosinophilic pneumonia (letter)] Elcadi T, et al. **Presse Med** 1997 Mar 22;26(9):416 **(Fre)**

[Abdominal pains and ascite in hemorrhagic fever with renal syndrome (letter)] Tiberghien F, et al. **Presse Med** 1997 May 24;26(17):809 **(Fre)**

[Abdominal pain of uncertain origin––value of laparoscopy. "If in doubt, carry it out"] Bruch HP, et al. **Chirurg** 1997 Jan;68(1):12–6 (Eng. Abstr.) **(Ger)**

[Recurrent abdominal pain] Alsalameh S, et al. **Med Klin** 1997 Aug 15;92(8):471 **(Ger)**

[A case from practice (361). Acute pancreatitis in AIDS. idiopathic. In microscopic gallstones. (Cotrimoxazole–induced). (In cryptosporidiosis)] Bassetti S. **Schweiz Rundsch Med Prax** 1996 Nov 12;85(46):1493–4 **(Ger)**

[Acute abdominal pain––internist's viewpoint] Criblez D. **Schweiz Rundsch Med Prax** 1997 Feb 4;86(6):203–8 (Eng. Abstr.) **(Ger)**

[Helicobacter pylori infection as a cause of recurrent abdominal pain in children] Cinquetti M, et al. **Pediatr Med Chir** 1997 Jan–Feb;19(1):17–21 (Eng. Abstr.) **(Ita)**

[Intrauterine pregnancy complicated by coexisting ectopic pregnancy] Jaszczyński P, et al. **Ginekol Pol** 1996 Jun; 67(6):317–9 (Eng. Abstr.) **(Pol)**

[Pain syndrome in gastroenterological practice: potentialities of evaluation] Rutgaizer IM, et al. **Klin Med (Mosk)** 1996; 74(4):45–8 (Eng. Abstr.) **(Rus)**

[Mesenteric panniculitis in the differential diagnosis of abdominal pain] de la Peña Fernández A, et al. **Rev Esp Enferm Dig** 1996 Jul;88(7):505–8 (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Symptomatology of Helicobacter pylori infection in children. Blecker U, et al. **Acta Paediatr** 1996 Oct;85(10):1156–8

Relation between Helicobacter pylori infection and gastrointestinal symptoms and syndromes. Rosenstock S, et al. **Gut** 1997 Aug;41(2):169–76

Endoscopic, histologic and microbiologic evaluation of upper abdominal pain with special reference to Helicobacter pylori infection [see comments] Kumar M, et al. **Indian Pediatr** 1996 Nov;33(11):905–9. Comment in: Indian Pediatr 1996 Nov;33(11):899–903.

Helicobacter pylori is not associated with nonspecific abdominal pain in children. Yoshida NR, et al. **J Pediatr Surg** 1996 Jun;31(6):747–9

PARASITOLOGY

Case in point. Small bowel giardiasis. Ansari A, et al. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):74

PATHOLOGY

[Eosinophilic gastroenteritis associated with rheumatoid arthritis. Its presentation as acute abdominal pain (letter)] Medina Pérez M, et al. **Rev Esp Enferm Dig** 1997 Feb; 89(2):143–4 **(Spa)**

PHYSIOPATHOLOGY

Involvement of the dorsal paratrigeminal nucleus in visceral pain–related phenomena. Bon K, et al. **C R Acad Sci III** 1997 Jul;320(7):533–9

Long–lasting functional abdominal pain and duodenal ulcer are associated with stress, vulnerability and symptoms of psychological stress. A controlled study including healthy and patient controls. Jørgensen LS, et al. **Dan Med Bull** 1996 Sep;43(4):359–63

Chronic upper abdominal pain due to duodenal ulcer and other structural and functional causes: its localization and nocturnal occurrence. Kang JY, et al. **J Gastroenterol Hepatol** 1996 Jun;11(6):515–9

Recurrent abdominal pain: an update. Boyle JT. **Pediatr Rev** 1997 Sep;18(9):310–20; quiz 321

PREVENTION & CONTROL

Correlation between the grade of tumoral invasion and pain relief in patients with celiac ganglia block. Akhan O, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1565–7

Epidural morphine plus ketamine for upper abdominal surgery: improved analgesia from preincisional versus postincisional administration. Choe H, et al. **Anesth Analg** 1997 Mar;84(3):560–3

New endoscopic treatment for chronic pancreatitis, using contrast media containing ulinastatin and prednisolone. Ohwada M, et al. **J Gastroenterol** 1997 Apr;32(2):216–21

PSYCHOLOGY

Recurrent abdominal pain in children: a review of psychological factors and treatment. Scharff L. **Clin Psychol Rev** 1997;17(2):145–66 (132 ref.)

Long–lasting functional abdominal pain and duodenal ulcer are associated with stress, vulnerability and symptoms of psychological stress. A controlled study including healthy and patient controls. Jørgensen LS, et al. **Dan Med Bull** 1996 Sep;43(4):359–63

Wheelchair use: a physical sign in gastroenterological practice [see comments] Chiotakakou–Faliakou E, et al. **J R Soc Med** 1996 Sep;89(9):490–2. Comment in: J R Soc Med 1997 Jan;90(1):59–60.

Abdominal pain of psychotic origin. Khan Z, et al. **J R Soc Med** 1997 Apr;90(4):221–2

Wheelchairs as a sign of functional abdominal pain [letter; comment] Kumar D. **J R Soc Med** 1997 Jan;90(1):59–60 . Comment on: J R Soc Med 1996 Sep;89(9):490–2.

ABDOMINAL PAIN

[Clinical and psychological characterization of children and adolescents with recurrent abdominal pain] Guiraldes E, et al. **Rev Med Chil** 1995 Nov;123(11):1341–8 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Elderly man with unusual symptoms. Nemcek A Jr. **J Vasc Interv Radiol** 1996 Jul–Aug;7(4):542–3

SURGERY

Measuring surgical performance in acute abdominal pain: some reflections from international studies. de Dombal FT, et al. **Eur J Surg** 1997 May;163(5):323–9

Unilateral left–sided thoracoscopic sympathectomy for visceral pain control: a pilot study. Lönroth H, et al. **Eur J Surg** 1997 Feb;163(2):97–100

Abdominal pain in the elderly: use of temperature and laboratory testing to screen for surgical disease. Parker JS, et al. **Fam Med** 1996 Mar;28(3):193–7

Laparoscopy for diagnosis and treatment of recurrent abdominal pain in children. Stylianos S, et al. **J Pediatr Surg** 1996 Aug;31(8):1158–60

Thoracoscopic thoracic splanchnicectomy for chronic pancreatitis with intractable abdominal pain. Kusano T, et al. **Surg Laparosc Endosc** 1997 Jun;7(3):213–8

[Acute abdominal pain. Surgeon's viewpoint] Largiadèr J. **Schweiz Rundsch Med Prax** 1997 Feb 4;86(6):209–13 (Eng. Abstr.) **(Ger)**

THERAPY

Deep assessment of machine learning techniques using patient treatment in acute abdominal pain in children. Blazadonakis M, et al. **Artif Intell Med** 1996 Nov;8(6):527–42

Recurrent abdominal pain in children: a review of psychological factors and treatment. Scharff L. **Clin Psychol Rev** 1997;17(2):145–66 (132 ref.)

Celiac plexus block as treatment for refractory pain related to sclerosing cholangitis in AIDS patients. Coliazos J, et al. **J Clin Gastroenterol** 1996 Jul;23(1):47–9

Referral of patients with pain from pancreatic cancer for neurolytic celiac plexus block. Brown DL, et al. **Mayo Clin Proc** 1997 Sep;72(9):831–4

Abdominal pain in New Zealand general practice. Frear D, et al. **N Z Med J** 1997 Sep 12;110(1051):333–4

Diagnosis and treatment of right upper quadrant abdominal pain. Dill JE. **Va Med Q** 1996 Winter;123(1):27–9

ULTRASONOGRAPHY

Emergency department ultrasound: impact on ED stay times [letter] Schlager D, et al. **Am J Emerg Med** 1997 Mar; 15(2):216–7

Upper abdominal ultrasound. Gibson RN. **Aust Fam Physician** 1997 Feb;26(2):153–4

Intra–abdominal ectopic thyroid presenting as a pancreatic tumour. Seelig MH, et al. **Eur J Surg** 1997 Jul;163(7):549–51 (18 ref.)

[Imaging methods, especially ultrasound in lower abdominal pain] Tercanli S. **Arch Gynecol Obstet** 1996;259 Suppl 1:S54–60 (23 ref.) **(Ger)**

VETERINARY

A dog with acute abdominal pain. Allworth M. **Aust Vet J** 1996 Aug;74(2):112–3

A comparison of N–butylscopolammonium bromide and butorphanol tartrate for analgesia using a balloon model of abdominal pain in ponies. Boatwright CE, et al. **Can J Vet Res** 1996 Jan;60(1):65–8

Hyperammonaemia associated with encephalopathy and abdominal pain without evidence of liver disease in four mature horses [see comments] Peek SF, et al. **Equine Vet J** 1997 Jan;29(1):70–4. Comment in: Equine Vet J 1997 Jan;29(1):1–2.

Use of diagnostic ultrasonography in horses with signs of acute abdominal pain. Klohnen A, et al. **J Am Vet Med Assoc** 1996 Nov 1;209(9):1597–601

Medical management of a full–thickness tear of the retroperitoneal portion of the rectum in a horse with hyperadrenocorticism. Mazan MR. **J Am Vet Med Assoc** 1997 Mar 1;210(5):665–7

ABDOMINAL WALL see **ABDOMINAL MUSCLES**

ABDUCENS NERVE

Recurrent abducens nerve palsy caused by dolichoectasia of the cavernous internal carotid artery. Blumenthal EZ, et al. **Am J Ophthalmol** 1997 Aug;124(2):255–7

Eye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir. Openshaw H, et al. **Bone Marrow Transplant** 1997 Mar;19(5):503–5

Bilateral traumatic abducens nerve paralysis with cervical spine flexion injury. Uzan M, et al. **Eur Spine J** 1996; 5(4):275–7

Middle ear infection and sixth nerve palsy. Homer JJ, et al. **J Laryngol Otol** 1996 Sep;110(9):872–4

Unilateral abducens nerve palsy: a presenting sign of sphenoid sinus mucocoeles. Muneer A, et al. **J Laryngol Otol** 1997 Jul;111(7):644–6

Painful bilateral abducens nerve palsy associated with anti–neutrophil cytoplasmic autoantibodies [letter] Sanjo N, et al. **J Neurol** 1996 Aug;243(8):612–3

Antibiotic treatment for giant–cell arteritis? Fontana PE, et al. **Lancet** 1996 Dec 14;348(9042):1630

Trochlear and abducens nerve neurinomas accompanied by a cerebellopontine angle meningioma––case report. Beppu T, et al. **Neurol Med Chir (Tokyo)** 1997 May;37(5):416–21

Clival chordoma presenting as acute esotropia due to bilateral abducens palsy. Harada T, et al. **Ophthalmologica** 1997; 211(2):109–11

Neurogenic diplopia: paralysis of cranial nerves III, IV, and VI. Sowka J. **Optom Clin** 1996;5(3–4):53–76 (46 ref.)

[Orbital neurinoma presenting orbital apex syndrome] Anegawa S, et al. **No Shinkei Geka** 1997 May;25(5):473–7 (Eng. Abstr.) **(Jpn)**

[Skull base metastasis from renal cell carcinoma presenting as abducens nerve paresis: report of two cases] Sagoh M, et al. **No Shinkei Geka** 1996 Sep;24(9):829–33 (Eng. Abstr.) **(Jpn)**

[Abducens palsy] Taguchi Y, et al. **No To Shinkei** 1997 Jun; 49(6):568–9 **(Jpn)**

[A case report of alternating abducens hemiplegia with special reference to the supranuclear pathway to the facial nucleus] Horiuchi I, et al. **Rinsho Shinkeigaku** 1997 Apr; 37(4):334–7 (Eng. Abstr.) **(Jpn)**

[Abducent nerve palsy as the only symptom of intracavernous carotid aneurysm in a child] Oleszczyńska–Prost E, et al. **Klin Oczna** 1996;98(6):451–4 (Eng. Abstr.) **(Pol)**

ANATOMY & HISTOLOGY

Abnormality of the labyrinthine artery and its topographical relation to the abducent nerve. Melling M, et al. **Acta Anat (Basel)** 1996;156(2):151–4 (38 ref.)

Immunohistochemical study of neurons in the rat abducens nucleus that project to the flocculus. Rodella L, et al. **J Anat** 1996 Jun;188 (Pt 3):727–31

CYTOLOGY

Cytoarchitecture of the abducens nucleus of man: a Nissl and Golgi study. Bianchi R, et al. **Acta Anat (Basel)** 1996; 157(3):210–6

INJURIES

Spontaneous recovery rate in traumatic sixth–nerve palsy. Mutyala S, et al. **Am J Ophthalmol** 1996 Dec;122(6):898–9

Sixth cranial nerve palsy following closed head injury in a child. Hollis GJ. **J Accid Emerg Med** 1997 May;14(3):172–5

Bilateral traumatic abducens palsy as a complication of a frontal–nasal–orbital–ethmoidal fracture. Celiköz B, et al. **J Oral Maxillofac Surg** 1996 Dec;54(12):1471–4

PATHOLOGY

Anatomic relationship of the oculomotor nuclear complex and medial longitudinal fasciculus in the midbrain. Miller MJ, et al. **AJNR Am J Neuroradiol** 1997 Jan;18(1):111–3

The ocular motor nerves. Miller NR. **Curr Opin Neurol** 1996 Feb;9(1):21–5 (43 ref.)

Ocular motor consequences of damage to the abducens nucleus area in humans. Müri RM, et al. **J Neuroophthalmol** 1996 Sep;16(3):191–5

Results of surgery for paralytic esotropia due to abducens palsy. Maruo T, et al. **Jpn J Ophthalmol** 1996;40(2):229–34

Abducens neuropathy detected by three–dimensional magnetic resonance imaging using a multiplanar reconstruction technique with gadolinium–DTPA enhancement. Yamaguchi K, et al. **Jpn J Ophthalmol** 1997 Jan–Feb;41(1):59–61

Abducens nerve neurinoma––case report. Ichimi K, et al. **Neurol Med Chir (Tokyo)** 1997 Feb;37(2):197–200

Cranial nerves III, IV, and VI. Laine FJ. **Top Magn Reson Imaging** 1996 Apr;8(2):111–30 (61 ref.)

PHYSIOLOGY

Pressor response elicited by nose–up vestibular stimulation in cats. Woodring SF, et al. **Exp Brain Res** 1997 Jan; 113(1):165–8

Inhibitory input to pause neurons from pontine burst neuron area in the cat. Kamogawa H, et al. **Neurosci Lett** 1996 Jan 26;203(3):163–6

Electron microscopic serial analysis of GABA presynaptic terminals on the axon hillock and initial segment of labeled abducens motoneurons in the rat. Lahjouji F, et al. **Neurosci Res** 1997 Feb;27(2):143–53

PHYSIOPATHOLOGY

Pontine lesion of the abducens fasciculus producing so–called posterior internuclear ophthalmoplegia. Oliveri RL, et al. **Eur Neurol** 1997;37(1):67–9

[Spontaneous intracranial hypotension and sixth cranial nerve paralysis] Alvarez Sabín J. **Neurologia** 1996 Nov;11(9):358 **(Spa)**

SURGERY

Large sixth nerve neuroma involving the prepontine region: case report. Okada Y, et al. **Neurosurgery** 1997 Mar; 40(3):608–10

Full functional recovery after surgical repair of transected abducens nerve: case report. Sawamura Y, et al. **Neurosurgery** 1997 Mar;40(3):605–7; discussion 607–8

ABELSON LEUKEMIA VIRUS

GENETICS

Immunosuppression by metastatic lymphoma derived altered retroviral gp70 molecule. Hao W, et al. **Leukemia** 1997 Apr;11 Suppl 3:202–5

Characterization of mouse cellular deoxyribonucleic acid homologous to Abelson murine leukemia virus–specific sequences. Dale B, et al. **Mol Cell Biol** 1981 Aug; 1(8):731–42

ABERRANT TISSUE see **CHORISTOMA**

ABETALIPOPROTEINEMIA

BLOOD

Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in abetalipoproteinemia. Du EZ, et al. **J Lipid Res** 1996 Jun;37(6):1309–15

PHYSIOPATHOLOGY

Effect of decreased plasma low–density lipoprotein levels on adrenal and testicular function in man. Arem R, et al. **Clin Biochem** 1997 Jul;30(5):419–24

ABH BLOOD GROUP see **ABO BLOOD–GROUP SYSTEM**

ABILITY see **APTITUDE**

ABL GENES see **GENES, ABL**

ABL ONCOGENE PROTEINS see **ONCOGENE PROTEINS V–ABL**

ABL PROTO–ONCOGENE PROTEINS see **PROTO–ONCOGENE PROTEINS C–ABL**

ABLATION, TRANSVENOUS ELECTRIC see **CATHETER ABLATION**

ABNORMAL FIBRINOGENS see **FIBRINOGENS, ABNORMAL**

ABNORMALITIES

Genetics and epidemiology, congenital anomalies and cancer [editorial] Friedman JM. **Am J Hum Genet** 1997 Mar; 60(3):469–73

The quality of data reported on birth certificates [letter; comment] Kirby RS. **Am J Public Health** 1997 Feb; 87(2):301. Comment on: Am J Public Health 1996 May;86(5):731–4.

Congenital malformations. Gadow EC, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):412–6 (32 ref.)

Prospective follow–up study of 877 children born after intracytoplasmic sperm injection (ICSI), with ejaculated epididymal and testicular spermatozoa and after replacement of cryopreserved embryos obtained after ICSI. Bonduelle M, et al. **Hum Reprod** 1996 Dec;11 Suppl 4:131–55; discussion 156–9

Registration of congenital anomalies in ART populations: pitfalls. Simpson JL. **Hum Reprod** 1996 Dec;11 Suppl 4:81–8 (19 ref.)

Report on the activities of the ESHRE Task Force on intracytoplasmic sperm injection. European Society of Human Reproduction and Embryology. Tarlatzis BC. **Hum Reprod** 1996 Dec;11 Suppl 4:160–85; discussion 186

Minor physical anomalies: modifiers of environmental risks for psychiatric impairment? Pine DS, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Mar; 36(3):395–403

Midtrimester pregnancy termination for fetal malformations. Use of intravaginal prostaglandin E2. Hagar DL, et al. **J Reprod Med** 1997 Aug;42(8):497–500

US studies fail to find link between Gulf War and birth defects [news] Veggeberg S. **Mol Med Today** 1996 Jan; 2(1):3

Cesarean delivery for fetal malformations. Kuller JA, et al. **Obstet Gynecol Surv** 1996 Jun;51(6):371–5 (28 ref.)

Fumes from the spleen. **Paediatr Perinat Epidemiol** 1997 Jan; 11(1):21–4

New Approaches for Assessing the Etiology and Risks of Developmental Abnormalities from Chemical Exposure. Symposium proceedings. December 11–12, 1995. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):261–463

A teratologist to extinction [letter] Kalter H. **Teratology** 1996 Apr;53(4):224–5

Public drinking water contamination and birthweight, prematurity, fetal deaths, and birth defects. Bove FJ. **Toxicol Ind Health** 1996 Mar–Apr;12(2):255–66

[Severe fetal damage as maternal indication for pregnancy termination within the scope of section 218 StGB and its revision in German jurisprudence 1975/1995] Hiersche HD. **Z Geburtshilfe Neonatol** 1996 Nov–Dec;200(6):236–40 **(Ger)**

BLOOD

Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry

Study. Giampietro PF, et al. **Am J Med Genet** 1997 Jan 10;68(1):58–61

[From happy to worrisome expectation? Various ethical problems concerning the triple test (letter; comment)] Beekhuis JR, et al. **Ned Tijdschr Geneeskd** 1997 Jan 4; 141(1):62–3. Comment on: Ned Tijdschr Geneeskd 1996 Oct 12;140(41):2024–5. **(Dut)**

CHEMICALLY INDUCED see ABNORMALITIES, DRUG–INDUCED

CLASSIFICATION

Epidemiological analysis of the schisis association in the Spanish registry of congenital malformations. Martínez–Frías ML, et al. **Am J Med Genet** 1997 May 2; 70(1):16–23

The Dutch Uniform Multicenter Registration system for genetic disorders and malformation syndromes. Zwamborn–Hanssen AM, et al. **Am J Med Genet** 1997 Jun 27;70(4):444–7

A classification scheme for malformations of cortical development. Barkovich AJ, et al. **Neuropediatrics** 1996 Apr;27(2):59–63 (53 ref.)

DIAGNOSIS

Postmortem fetal MR imaging: comparison with findings at autopsy. Woodward PJ, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):41–6

Informative morphogenetic variants in patients with schizophrenia and alcohol–dependent patients: beyond the Waldrop Scale. Trixler M, et al. **Am J Psychiatry** 1997 May;154(5):691–3

Preimplantation diagnosis is likely to increase in The Netherlands [news] Sheldon T. **BMJ** 1997 May 17; 314(7092):1435

Congenital abnormalities in twins: selective termination. Stewart KS, et al. **Curr Opin Obstet Gynecol** 1997 Apr; 9(2):136–9 (13 ref.)

Antenatal genetic counselling: implications for population screening. Stock A, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):109–12 (13 ref.)

Overview of screening techniques. Recent advances in prenatal diagnosis for aneuploidy. Chard T. **Early Hum Dev** 1996 Dec 30;47 Suppl:S3–4 (0 ref.)

Prenatal diagnosis in Belgium. Vamos E, et al. **Eur J Hum Genet** 1997;5 Suppl 1:7–13

The origin of genetic defects in the human and their detection in the preimplantation embryo. Delhanty JD, et al. **Hum Reprod Update** 1995 May;1(3):201–15 (59 ref.)

Early fetal growth delay: is it really predictive of congenital anomalies in infants of diabetic women? Reece EA, et al. **J Matern Fetal Med** 1997 May–Jun;6(3):168–73

Flexion and extension cervical MRI in a pediatric population. Weng MS, et al. **J Pediatr Orthop** 1996 May–Jun; 16(3):359–63

Molecular zygosity studies aid in the management of discordant multiple gestations. Norton ME, et al. **J Perinatol** 1997 May–Jun;17(3):202–7

Embryoscopy and early prenatal diagnosis. Reece EA. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):111–21 (24 ref.)

Results of 12 years' combined maternal serum alpha–fetoprotein screening and ultrasound fetal monitoring for prenatal detection of fetal malformations in Havana City, Cuba. Rodríguez L, et al. **Prenat Diagn** 1997 Apr;17(4):301–4

Impact of the detection and prevention of developmental abnormalities in human studies. Holmes LB. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):267–9 (19 ref.)

[The preimplantation diagnosis of genetic defects] Delimitreva SM, et al. **Akush Ginekol (Sofiia)** 1996; 35(4):25–7 (41 ref.) **(Bul)**

[Prenatal diagnosis: methods—indications—risks] Kienholz–Only C. **Fortschr Med** 1997 Jul 10;115(19):24–7 (12 ref.) (Eng. Abstr.) **(Ger)**

[Changes in prenatal diagnosis. Hope for many couples—ethical problems unavoidable] Strobel E. **Fortschr Med** 1997 Jul 10;115(19):23 (12 ref.) **(Ger)**

[Telecommunication—a medium for improving prenatal diagnosis and gynecologic ultrasound diagnosis? Initial experiences] Sohn C, et al. **Zentralbl Gynakol** 1997; 119(4):177–80 (Eng. Abstr.) **(Ger)**

ECONOMICS

[A cost–benefit evaluation of prenatal diagnosis performed at a referral center with a population with a genetic or abnormality risk] Tomé T, et al. **Acta Med Port** 1997 Feb–Mar;10(2–3):167–72 (Eng. Abstr.) **(Por)**

EMBRYOLOGY

Zinc deficiency and abnormal fetal development: assessment of maternal or fetal zinc status [letter] Bloxam DL, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1078

Placental causes of fetal malformation. Craven C, et al. **Clin Obstet Gynecol** 1996 Sep;39(3):588–606 (34 ref.)

EPIDEMIOLOGY

Congenital anomalies and childhood cancer in Great Britain. Narod SA, et al. **Am J Hum Genet** 1997 Mar;60(3):474–85

Are omphalocele and neural tube defects related congenital anomalies?: Data from 21 registries in Europe (EUROCAT). Calzolari E, et al. **Am J Med Genet** 1997 Oct 3;72(1):79–84

Use of record linkage between a statewide genetics service and a Birth Defects/Congenital Malformations Register to determine use of genetic counselling services. Halliday J, et al. **Am J Med Genet** 1997 Oct 3;72(1):3–10

Major congenital malformations in Down syndrome. Källén B, et al. **Am J Med Genet** 1996 Oct 16;65(2):160–6

Classifying sex biased congenital anomalies. Lubinsky MS. **Am J Med Genet** 1997 Mar 31;69(3):225–8

Primary developmental field. III: Clinical and epidemiological study of blastogenetic anomalies and their relationship to different MCA patterns. Martínez–Frías ML, et al. **Am J Med Genet** 1997 May 2;70(1):11–5

Epidemiological analysis of the schisis association in the Spanish registry of congenital malformations. Martínez–Frías ML, et al. **Am J Med Genet** 1997 May 2; 70(1):16–23

Correlation between drug exposure and major malformations [letter; comment] Martínez–Frías ML, et al. **Am J Med Genet** 1997 May 2;70(1):99–101. Comment on: Am J Med Genet 1996 May 3;63(1):268–76.

Vitamin A and birth defects. Mills JL, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):31–6

Recommendations for improving national data on congenital anomalies are being implemented [letter; comment] Alberman E, et al. **BMJ** 1997 Apr 26;314(7089):1278. Comment on: BMJ 1997 Feb 1;314(7077):371. Comment on: BMJ 1997 Feb 1;314(7077):371–2. Comment on: BMJ 1997 Feb 1;314(7077):372. Comment on: BMJ 1997 Feb 1;314(7077):372–3.

Minor physical anomalies and their relationship to the aetiology of schizophrenia [editorial] [see comments] Murphy KC, et al. **Br J Psychiatry** 1996 Feb;168(2):139–42 (29 ref.). Comment in: Br J Psychiatry 1996 Jun;168(6):789–90.

Incidence of congenital malformations in Tokyo Metropolitan Hospitals, 1979–1993. Kato K, et al. **Brain Dev** 1996 May–Jun;18(3):230–3

Temporal trends in Canadian birth defects birth prevalences, 1979–1993. Johnson KC, et al. **Can J Public Health** 1997 May–Jun;88(3):169–76

Environmental epidemiology at the Medical Birth Registry of Norway; strengths and limitations. Lie RT. **Cent Eur J Public Health** 1997 Jun;5(2):57–9 (6 ref.)

Using the Hungarian Birth Defects Registry for surveillance, research and intervention. Siffel C, et al. **Cent Eur J Public Health** 1997 Jun;5(2):79–81

Disturbed development of the preimplantation embryo in the insulin–dependent diabetic BB/E rat. Lea RG, et al. **Diabetes** 1996 Nov;45(11):1463–70

Immunostimulation increases the resistance of mouse embryos to the teratogenic effect of diabetes mellitus. Torchinsky A, et al. **Diabetologia** 1997 Jun;40(6):635–40

Heterogeneous rates for birth defects in Latin America: hints on causality. Lopez–Camelo JS, et al. **Genet Epidemiol** 1996;13(5):469–81

Incidence of birth defects after artificial insemination with frozen donor spermatozoa: a collaborative study of the French CECOS Federation on 11,535 pregnancies. Thepot F, et al. **Hum Reprod** 1996 Oct;11(10):2319–23

The incidence of congenital malformations in a Turkish population. Himmetoglu O, et al. **Int J Gynaecol Obstet** 1996 Nov;55(2):117–21

Short– and long–range complications in offspring of diabetic mothers. Weintrob N, et al. **J Diabetes Complications** 1996 Sep–Oct;10(5):294–301 (72 ref.)

Epidemiological pitfalls using Medicaid data in reproductive health research. Grisso JA, et al. **J Matern Fetal Med** 1997 Jul–Aug;6(4):230–6

Factors associated with congenital malformations in Thailand. Suwatanaviroj A, et al. **J Med Assoc Thai** 1996 Sep;79(9):545–9

Major anomalies in consecutive births in south of Beirut. A preliminary report about incidence and pattern. Bittar Z. **J Med Liban** 1995;43(2):62–7

Frequency of consanguinity and its effect on congenital malformation—a hospital based study. Hashmi MA. **JPMA J Pak Med Assoc** 1997 Mar;47(3):75–8

Congenital abnormalities and indicators of germinal mutations in the vicinity of the Paks nuclear plant, Hungary. Siffel C, et al. **Mutagenesis** 1996 May; 11(3):299–303

The risk of birth defects among children of Persian Gulf War veterans. Cowan DN, et al. **N Engl J Med** 1997 Jun 5;336(23):1650–6

Birth defects among children of Persian Gulf War veterans [letter] Doyle P, et al. **N Engl J Med** 1997 Oct 16; 337(16):1175–6

Congenital malformations and maternal occupation: a registry based case–control study. Bianchi F, et al. **Occup Environ Med** 1997 Apr;54(4):223–8

Congenital malformations in newborns of women with established and gestational diabetes in Washington State, 1984–91 [see comments] Janssen PA, et al. **Paediatr Perinat Epidemiol** 1996 Jan;10(1):52–63. Comment in: Paediatr Perinat Epidemiol 1996 Oct;10(4):469–76.

Diabetes and congenital malformations [letter; comment] Kirby RS. **Paediatr Perinat Epidemiol** 1996 Oct; 10(4):469–76. Comment on: Paediatr Perinat Epidemiol 1996 Jan;10(1):52–63.

Risk of recurrence of birth defects in Washington State. Mueller BA, et al. **Paediatr Perinat Epidemiol** 1997 Jan;11 Suppl 1:107–18

Case–control study on maternal residential proximity to high voltage power lines and congenital anomalies in France. Robert E, et al. **Paediatr Perinat Epidemiol** 1996 Jan; 10(1):32–8

Congenital malformations in the vicinity of a smelter in Northern Sweden, 1973–1990. Wulff M, et al. **Paediatr Perinat Epidemiol** 1996 Jan;10(1):22–31

The influence of the experience of the investigator on the rate of sonographic diagnosis of fetal malformations in Vienna. Bernaschek G, et al. **Prenat Diagn** 1996 Sep; 16(9):807–11

Surveillance of developmental disabilities with an emphasis on special studies. Boyle CA. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):271–4

Assessment of reproductive disorders and birth defects in communities near hazardous chemical sites. I. Birth defects and developmental disorders [see comments] Savitz DA, et al. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):223–30. Comment in: Reprod Toxicol 1997 Mar–Jun;11(2–3):221–2.

Incorporating molecular genetic variation and environmental exposures into epidemiologic studies of congenital anomalies. Shaw GM, et al. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):275–80

The spatial relationship between infant mortality and birth defect rates in a U.S. city. Rushton G, et al. **Stat Med** 1996 Sep 15–30;15(17–18):1907–19

Exploratory spatial analysis of birth defect rates in an urban population. Rushton G, et al. **Stat Med** 1996 Apr 15–May 15;15(7–9):717–26

First 25 years of the Hungarian congenital abnormality registry. Czeizel AE. **Teratology** 1997 May;55(5):299–305

A study of level of lesion, associated malformations and sib occurrence risks in spina bifida. Hunter AG, et al. **Teratology** 1996 Nov;54(5):213–8

Commentary: contributions of epidemiology to the study of birth defects in humans. Khoury MJ. **Teratology** 1995 Oct; 52(4):186–9

Letter from the editor [comment] Sadler TW. **Teratology** 1995 Oct;52(4):185. Comment on: Teratology 1995 Oct;52(4):186–9.

[Why the incidence of congenital and hereditary disorders usually is zero] Cornel MC, et al. **Ned Tijdschr Geneeskd** 1997 Jan 25;141(4):180–2 (Eng. Abstr.) **(Dut)**

[Is an ultrasound screening program in pregnancy justified?] Holzgreve W. **Arch Gynecol Obstet** 1996;259 Suppl 1:S118–27 (30 ref.) **(Ger)**

[An epidemiological study of malformations in infants delivered from diabetic mothers] Tanabe M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Feb;48(2):103–10 (Eng. Abstr.) **(Jpn)**

[Frequency of birth defects in newborns in four regions of Poland] Sitarek K, et al. **Med Pr** 1997;48(1):25–34 (Eng. Abstr.) **(Pol)**

[Congenital developmental defects negatively affecting the viability of children of Kursk region: prevalence, pattern, trends] Ivanov VP, et al. **Arkh Patol** 1997 Mar–Apr; 59(2):46–8 (Eng. Abstr.) **(Rus)**

[One approach to comparison of the distribution of the prevalence of congenital defects in populations] Volkov IK, et al. **Dokl Akad Nauk** 1996 Sep;350(2):281–3 **(Rus)**

[Neonatal pathology in town neighboring a major chemical plant] Krinitsyn NV, et al. **Med Tr Prom Ekol** 1997;(6):41–5 **(Rus)**

[Eleven years of registration of congenital anomalies in Croatia associated with the EUROCAT international project] Ligutić I, et al. **Lijec Vjesn** 1997 Feb;119(2):47–53 (Eng. Abstr.) **(Scr)**

[Etiologic distribution of children with congenital defects] Martínez Frías ML, et al. **An Esp Pediatr** 1996 Dec; 45(6):635–8 (Eng. Abstr.) **(Spa)**

[Birth defects. A public health problem in Mexico] Jurado–García E, et al. **Gac Med Mex** 1996 Mar–Apr; 132(2):141–82 (38 ref.) **(Spa)**

ETHNOLOGY

Birth defects and parental consanguinity in Norway [published erratum appears in Am J Epidemiol 1997 May 15;145(10):957] Stoltenberg C, et al. **Am J Epidemiol** 1997 Mar 1;145(5):439–48

Midline congenital anomalies: the estimated occurrence among American Indian and Alaska Native infants. Coddington DA, et al. **Clin Genet** 1996 Aug;50(2):74–7

Excess of congenital abnormalities in French–Canadian children with neuroblastoma: a case series study from Montréal. Foulkes WD, et al. **Med Pediatr Oncol** 1997 Oct; 29(4):272–9

ETIOLOGY

Zinc deficiency and abnormal fetal development: assessment of maternal or fetal zinc status [letter] Bloxam DL, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1078

Ionising radiation: are orthopaedic surgeons' offspring at risk? Zadeh HG, et al. **Ann R Coll Surg Engl** 1997 May; 79(3):214–20

Interactions of radiofrequency radiation–induced hyperthermia and 2–methoxyethanol teratogenicity in rats. Nelson BK, et al. **Bioelectromagnetics** 1997;18(5):349–59

Behavioral teratogenesis: an extension to the teratogenesis of functions [editorial] Auroux M. **Biol Neonate** 1997; 71(3):137–47 (92 ref.)

Embryonic abnormality caused by male pheromonal effect in pregnancy block in mice. Chung HJ, et al. **Biol Reprod** 1997 Aug;57(2):312–9

In vivo evidence for the existence of a threshold for hyperglycemia–induced major fetal malformations: relevance to the etiology of diabetic teratogenesis. Torchinsky A, et al. **Early Pregnancy** 1997 Mar;3(1):27–33

Minor congenital anomalies, major congenital malformations and development in children conceived from cryopreserved embryos. Sutcliffe AG, et al. **Hum Reprod** 1995 Dec;10(12):3332–7

Hyperthermia, teratogenesis and the heat shock response in mammalian embryos in culture. Edwards MJ, et al. **Int J Dev Biol** 1997 Apr;41(2):345–58 (93 ref.)

Congenital absence of the vas deferens: a mild form of cystic fibrosis. Patrizio P, et al. **Mol Med Today** 1996 Jan; 2(1):24–31 (40 ref.)

Assessment of reproductive disorders and birth defects in communities near hazardous chemical sites: introduction [comment] Amler RW. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):221–2. Comment on: Reprod Toxicol 1997 Mar–Jun;11(2–3):223–30. Comment on: Reprod Toxicol 1997 Mar–Jun;11(2–3):231–42. Comment on: Reprod Toxicol 1997 Mar–Jun;11(2–3):243–59.

Molecular and cellular mechanisms of early mammalian development: an overview of NIEHS/EPA Developmental Toxicity Workshops. Bishop JB, et al. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):285–91

Introduction to the symposium. Kimmel CA. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):261–3

Teratogenic and lethal effects of long–term hyperthermia and hypothermia in the chick embryo. Peterka M, et al. **Reprod Toxicol** 1996 Jul–Aug;10(4):327–32

Weighing the risks and the benefits: a call for the empirical assessment of perceived teratogenic risk. Polifka JE, et al. **Reprod Toxicol** 1997 Jul–Aug;11(4):633–40

NIEHS/EPA Workshops. Growth and differentiation factors. Sadler TW, et al. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):331–7

Congenital abnormalities and pregestational diabetes mellitus in pregnancy. Chia YT, et al. **Singapore Med J** 1996 Aug; 37(4):380–3

Absence of correlation between transient cranial hemorrhages and congenital malformations following neural crest ablation in chicks. Gale TF, et al. **Teratology** 1996 May;53(5):318–25

[Changes in the amniotic fluid volume in fetal structural anomalies] Khaïdar A, et al. **Akush Ginekol (Sofiia)** 1997; 36(1):18–21 (20 ref.) **(Bul)**

[Follow–up of a cohort of 422 children aged from 6 to 13 and conceived by in vitro fertilization] Olivennes F, et al. **Contracept Fertil Sex** 1997 May;25(5):XIII–XVIII **(Fre)**

[Metabolic compensation and malformations in pregnancy complicated by diabetes] Matti P, et al. **Minerva Ginecol** 1997 Mar;49(3):73–6 (Eng. Abstr.) **(Ita)**

[Zinc, pregnancy and the fetus] Solé D, et al. **Rev Assoc Med Bras** 1996 Jan–Mar;42(1):31–8 (106 ref.) **(Por)**

[Etiologic distribution of children with congenital defects] Martínez Frías ML, et al. **An Esp Pediatr** 1996 Dec; 45(6):635–8 (Eng. Abstr.) **(Spa)**

GENETICS

A mother and daughter with agenesis of the corpus callosum. Fuchigami T, et al. **Acta Paediatr Jpn** 1996 Feb;38(1):52–6 (21 ref.)

Major congenital malformations in Down syndrome. Källén B, et al. **Am J Med Genet** 1996 Oct 16;65(2):160–6

Risk of phenotypic abnormalities in paracentric inversion carriers [letter; comment] Warburton D, et al. **Am J Med Genet** 1997 Mar 17;69(2):219. Comment on: Am J Med Genet 1995 Jan 16;55(2):171–87.

Analysing human developmental abnormalities. Winter RM. **Bioessays** 1996 Dec;18(12):965–71 (52 ref.)

Current status of the human malformation map. Carey JC, et al. **Birth Defects Orig Artic Ser** 1996;30(1):13–34 (149 ref.)

Limb anomalies from evolutionary, developmental, and genetic perspectives. Opitz JM. **Birth Defects Orig Artic Ser** 1996;30(1):35–77 (161 ref.)

Minor physical and factual anomalies [letter; comment] Murray RM. **Br J Psychiatry** 1996 Jun;168(6):789–90. Comment on: Br J Psychiatry 1996 Feb;168(2):139–42.

Haploinsufficient phenotypes in Bmp4 heterozygous null mice and modification by mutations in Gli3 and Alx4. Dunn NR, et al. **Dev Biol** 1997 Aug 15;188(2):235–47

Cellular analysis of limb development in the mouse mutant hypodactyly. Robertson KE, et al. **Dev Genet** 1996; 19(1):9–25

Defects of urogenital development in mice lacking Emx2. Miyamoto N, et al. **Development** 1997 May;124(9):1653–64

Homeobox genes: molecular link between congenital anomalies and cancer. Anbazhagan R, et al. **Eur J Cancer** 1997 Apr;33(4):635–7

Positional candidate genes for congenital chloride diarrhea suggested by high–resolution physical mapping in chromosome region 7q31. Höglund P, et al. **Genome Res** 1996 Mar;6(3):202–10

Chromosome 18q22.2–>qter deletion and a congenital anomaly syndrome with multiple vertebral segmentation defects. Dowton SB, et al. **J Med Genet** 1997 May; 34(5):414–7

An autosomal dominant syndrome of renal and anogenital malformations with syndactyly. Green AJ, et al. **J Med Genet** 1996 Jul;33(7):594–6

Diagnosis of genetic defects by chromosomal analysis. Ghani F, et al. **JPMA J Pak Med Assoc** 1995 Nov;45(11):295–6

Frequency of consanguinity and its effect on congenital malformation—a hospital based study. Hashmi MA. **JPMA J Pak Med Assoc** 1997 Mar;47(3):75–8

Orientation of the Hoxa complex and placement of the Hd locus distal to Hoxa2 on mouse chromosome 6. Innis JW, et al. **Mamm Genome** 1996 Mar;7(3):216–7

Cytogenetics in obstetrics and gynecology. Mark HF, et al. **Med Health R I** 1996 Feb;79(2):55–7 (25 ref.)

Mutations in the cystic fibrosis gene in men with congenital bilateral absence of the vas deferens. De Braekeleer M, et al. **Mol Hum Reprod** 1996 Sep;2(9):669–77 (124 ref.)

Genomic imprinting abnormalities: a new potential risk of assisted reproduction. Tesarik J, et al. **Mol Hum Reprod** 1996 May;2(5):295–8 (28 ref.)

Congenital abnormalities and indicators of germinal mutations in the vicinity of the Paks nuclear plant, Hungary. Siffel C, et al. **Mutagenesis** 1996 May; 11(3):299–303

Nonhomologous Robertsonian translocations form predominantly during female meiosis [letter] Page SL, et al. **Nat Genet** 1997 Mar;15(3):231–2

Genetics of human kidney malformations. Winyard P, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):976–8 (10 ref.)

Dysmorphology in the next millennium: history of medical genetics. Van Allen MI. **Pediatr Ann** 1997 Sep;26(9):540–5

Severe fetal malformations associated with trisomy 16 confined to the placenta. Sánchez JM, et al. **Prenat Diagn** 1997 Aug;17(8):777–9

Incorporating molecular genetic variation and environmental exposures into epidemiologic studies of congenital anomalies. Shaw GM, et al. **Reprod Toxicol** 1997 Mar–Jun; 11(2–3):275–80

NIEHS/EPA Workshops. Genomic imprinting. Stewart CL, et al. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):309–16

Presence of dermatoglyphic ridge dissociation in a schizotypy–affected subject in a pair of discordant MZ twins [letter] Fañanás L, et al. **Schizophr Res** 1996 Aug 23;21(2):125–7

Minor physical anomalies in psychoses: associations with clinical and putative aetiological variables. McGrath JJ, et al. **Schizophr Res** 1995 Dec;18(1):9–20

Eleven chromosomal integration sites of a human endogenous retrovirus (HERV 4–1) map close to known loci of thirteen hereditary malformation syndromes. Taruscio DA, et al. **Teratology** 1996 Aug;54(2):108–10 (21 ref.)

[Malformations of the midline. A case–control study] Guala A, et al. **Pediatr Med Chir** 1997 Mar–Apr;19(2):117–9 (Eng. Abstr.) **(Ita)**

[Population–demographic structure in the Kurskaya district. Isolation by distance] Ivanov VP, et al. **Genetika** 1997 Mar; 33(3):381–6 (Eng. Abstr.) **(Rus)**

HISTORY

McKeown, Record, and the epidemiology of malformations. Leck I. **Paediatr Perinat Epidemiol** 1996 Jan;10(1):2–16

[Explanations of the development of abnormalities in physiological and medical manuscripts in ancient times] Bien CG. **Sudhoffs Arch Z Wissenschaftsgesch Beih** 1997; (38):1–212 **(Ger)**

METABOLISM

Contribution of LFA–1 and Mac–1 to CD18–dependent neutrophil emigration in a neonatal rabbit model. Graf JM, et al. **J Appl Physiol** 1996 Jun;80(6):1984–92

Mechanisms of amino acid supply to the rat conceptus in normal and abnormal development. Beckman DA. **Reprod Toxicol** 1997 Jul–Aug;11(4):595–9

MORTALITY

[Potentially avoidable perinatal deaths in Denmark and Sweden 1991] Langhoff–Roos J, et al. **Ugeskr Laeger** 1997 Sep 1;159(36):5378–82 (Eng. Abstr.) **(Dan)**

PATHOLOGY

A bibliography covering the use of metacarpophalangeal pattern profile analysis in bone dysplasias, congenital malformation syndromes, and other disorders. Poznanski AK, et al. **Pediatr Radiol** 1997 May;27(5):358–65

PHYSIOPATHOLOGY

Visual–perceptual and phonological factors in the acquisition of literacy among children with congenital developmental coordination disorder. Fletcher–Flinn C, et al. **Dev Med Child Neurol** 1997 Mar;39(3):158–66

Growth as a manifestation of teratogenesis: lessons from human fetal pathology. Barr M Jr. **Reprod Toxicol** 1997 Jul–Aug;11(4):583–7

PREVENTION & CONTROL

Prevention of diabetic embryopathy in offspring of diabetic rats with use of a cocktail of deficient substrates and an antioxidant. Reece EA, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):790–7; discussion 797–8

Folic acid and the prevention of birth defects. Butterworth CE Jr, et al. **Annu Rev Nutr** 1996;16:73–97 (91 ref.)

MRCOG. Screening for fetal abnormalities. Smith NC. **Br J Hosp Med** 1996 Jun 5–18;55(11):679–82 (15 ref.)

Preconception genetic counseling. Hogge JS, et al. **Clin Obstet Gynecol** 1996 Dec;39(4):751–62 (23 ref.)

Pregnant diabetic rats fed the antioxidant butylated hydroxytoluene show decreased occurrence of malformations in offspring. Eriksson UJ, et al. **Diabetes** 1996 Nov;45(11):1497–502

Teratogenic effects of diabetes mellitus in the rat. Prevention by vitamin E. Viana M, et al. **Diabetologia** 1996 Sep; 39(9):1041–6

Screening for toxoplasmosis in pregnancy: what is the evidence of reducing a health problem? Eskild A, et al. **J Med Screen** 1996;3(4):188–94 (76 ref.)

Can terathanasia explain the protective effect of folic–acid supplementation on birth defects? Hook EB, et al. **Lancet** 1997 Aug 16;350(9076):513–5 (20 ref.)

Cost–effectiveness of strategies used in the evaluation of pregnancies complicated by elevated maternal serum alpha–fetoprotein levels [see comments] Nadel AS, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):660–5. Comment in: Obstet Gynecol 1997 Aug;90(2):317–8.

Prenatal diagnosis using fetal cells from the maternal circulation. Lamvu G, et al. **Obstet Gynecol Surv** 1997 Jul; 52(7):433–7 (21 ref.)

Teratology Society Consensus Statement on use of folic acid to reduce the risk of birth defects. Holmes L, et al. **Teratology** 1997 Jun;55(6):381 (3 ref.)

[Pregnancy ultrasound screening in relation to the new health insurance regulation] Biedermann K. **Arch Gynecol Obstet** 1996;259 Suppl 1:S128–36 **(Ger)**

[Periconceptional multivitamin administration result in reduction of congenital abnormalities: adequate evidence for formulating national recommendations for Germany?] Hort A, et al. **Gesundheitswesen** 1997 Apr;59(4):248–51 (20 ref.) (Eng. Abstr.) **(Ger)**

[Reliability of ultrasound pregnancy screening] Müller RJ, et al. **Ultraschall Med** 1996 Aug;17(4):163–6 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Adult sensory capacities as a function of birth risk factors. Harland RE, et al. **J Clin Exp Neuropsychol** 1996 Jun; 18(3):394–405

Decision–making in the critically ill neonate: cultural background v individual life experiences. Hammerman C, et al. **J Med Ethics** 1997 Jun;23(3):164–9

Infanticide of defective newborns: an old midwife's story. Hontela S, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1275–8

Counseling prenatal diagnosis patients: the role of the social worker. Fertel PE, et al. **Soc Work Health Care** 1997; 24(3–4):47–63 (28 ref.)

Comparison of long–term psychological responses of women after pregnancy termination due to fetal anomalies and after perinatal loss [see comments] Salvesen KA, et al. **Ultrasound Obstet Gynecol** 1997 Feb;9(2):80–5. Comment in: Ultrasound Obstet Gynecol 1997 Feb;9(2):76–9.

RADIOGRAPHY

Diagnosis of fetal anomalies by three–dimensional imaging using helical computed tomography. Sohda S, et al. **Prenat Diagn** 1997 Jul;17(7):670–4

RADIONUCLIDE IMAGING

Incidence and clinical significance of linear defects ascribed to interrenuncular septa on 99Tcm–DMSA SPET. Tsukamoto E, et al. **Nucl Med Commun** 1997 Jan;18(1):53–6

SURGERY

Applied embryology in pediatric surgery. Kluth D, et al. **Eur J Pediatr Surg** 1997 Aug;7(4):196–203 (52 ref.)

Relevance of performing a 'sepsis screen' in a surgical neonate. Kataria R, et al. **Indian Pediatr** 1997 Mar; 34(3):238–41

Ethical resource allocation and the quest for normalcy: is pediatric reconstructive surgery justified? de Chalain TM. **Plast Reconstr Surg** 1997 Apr;99(4):1184–91

[Advantages and limits of primary final correction of congenital abnormalities] Waldschmidt J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:1024–8 (Eng. Abstr.) **(Ger)**

[Acute kidney failure in newborn infants with congenital abnormalities] Balagin VM, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):61–2 **(Rus)**

THERAPY

Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Hassan M, et al. **Bone Marrow Transplant** 1996 Nov;18(5):843–50

Late selective termination of fetal abnormalities in twin pregnancies: a multicentre report. Lipitz S, et al. **Br J Obstet Gynaecol** 1996 Dec;103(12):1212–6

Staff attitudes towards continuation of life–support in newborns with major congenital anomalies. Hazebroek FW, et al. **Eur J Pediatr** 1996 Sep;155(9):783–6

FIGO News. Report of the FIGO Committee for the Study

of Ethical Aspects of Human Reproduction. International Federation of Gynecologists and Obstetrics [news] Schenker JG. **Int J Gynaecol Obstet** 1997 Jun;57(3):333–7

Manslaughter or a legitimate parental decision? The Messenger case [letter; comment] Buchanan ME. **J Perinatol** 1996 Jul–Aug;16(4):321–2. Comment on: J Perinatol 1996 Jan–Feb;16(1):60–4.

Use of the Wagner apparatus to lengthen the antebrachium of a growing dog. Hay CW, et al. **J Small Anim Pract** 1996 Nov;37(11):543–8

Neural grafting as a tool for the study and reversal of neurobehavioral birth defects. Yanai J, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):673–81

ULTRASONOGRAPHY

The antenatal diagnosis of fetal abnormalities: a 10 year audit of influencing factors. Dillon E, et al. **Br J Radiol** 1997 Apr;70:341–6

Antenatal diagnosis of aberrant umbilical vessels. Aoki S, et al. **Gynecol Obstet Invest** 1997;43(4):232–5

Evaluation of routine ultrasound in the prenatal diagnosis of structural anomalies of the fetus. Ashe RG, et al. **Ir Med J** 1996 Sep–Oct;89(5):180–2

Diagnosis of congenital malformations using two-dimensional and three-dimensional ultrasonography. Chan L, et al. **Obstet Gynecol Clin North Am** 1997 Mar; 24(1):49–69 (25 ref.)

Ultrasound detection of fetal abnormalities. Abramowicz JS, et al. **Pediatr Ann** 1996 Apr;25(4):228–38 (29 ref.)

The influence of the experience of the investigator on the rate of sonographic diagnosis of fetal malformations in Vienna. Bernaschek G, et al. **Prenat Diagn** 1996 Sep; 16(9):807–11

Screening for fetal anomalies in the 12th week of pregnancy by transvaginal sonography in an unselected population. Hernádi L, et al. **Prenat Diagn** 1997 Aug;17(8):753–9

The sonographic finding of persistent umbilical cord cystic masses is associated with lethal aneuploidy and/or congenital anomalies. Smith GN, et al. **Prenat Diagn** 1996 Dec;16(12):1141–7 (17 ref.)

Early sonographic diagnosis of fetal midline disruption syndromes. Zimmer EZ, et al. **Prenat Diagn** 1996 Jan; 16(1):65–9

The influence of prenatal ultrasound on the prevalence of congenital anomalies at birth. Zimmer EZ, et al. **Prenat Diagn** 1997 Jul;17(7):623–8

Incidence of chromosomal abnormalities in 153 pregnancies with ultrasound detected fetal abnormalities. Chew S, et al. **Singapore Med J** 1996 Dec;37(6):595–7

Fetal dysmorphology [editorial] Donnenfeld AE. **Ultrasound Obstet Gynecol** 1997 Feb;9(2):73–5

An unusual late presentation of hematocolpos diagnosed by sonography [letter] Flam F, et al. **Ultrasound Obstet Gynecol** 1997 May;9(5):353

False-positive diagnosis of fetal face malformation due to brow compression in early labor [letter] Giacomello F, et al. **Ultrasound Obstet Gynecol** 1997 May;9(5):354–5

Cost-effectiveness of one-stage ultrasound screening in pregnancy: a report from the Helsinki ultrasound trial [see comments] Leivo T, et al. **Ultrasound Obstet Gynecol** 1996 May;7(5):309–14. Comment in: Ultrasound Obstet Gynecol 1996 May;7(5):307–8.

[Transabdominal chorionic villi and placental biopsy: rapid karyotyping in the 1st-3rd trimester of pregnancy] Hitschold T, et al. **Ultraschall Med** 1997 Jun;18(3):134–8 (Eng. Abstr.) **(Ger)**

[Ultrasonic screening of neonates] Jójárt G, et al. **Orv Hetil** 1996 Mar 24;137(12):623–7 (50 ref.) (Eng. Abstr.) **(Hun)**

[Embryo-fetal ultrasonographic diagnosis in the early pregnancy using transvaginal echography] Guariglia L, et al. **Minerva Ginecol** 1997 Mar;49(3):95–108 (61 ref.) (Eng. Abstr.) **(Ita)**

[Ultrasonographic diagnosis of polyhydramnios and its association with congenital malformations] Romero Gutierrez G, et al. **Ginecol Obstet Mex** 1996 Jan;64:1–5 (Eng. Abstr.) **(Spa)**

VETERINARY

Birth rate and mortality rate of infants with congenital malformations of the limbs in the Awajishima free-ranging group of Japanese monkeys (Macaca fuscata). Nakamichi M, et al. **Am J Primatol** 1997;42(3):225–34

Surgical correction of anorectal atresia and rectovaginal fistula in an alpaca cria. Carraro DB, et al. **Aust Vet J** 1996 Nov;74(5):352–4

Ammonia in ruminal and abomasal contents of cows with abomasal displacement. Geishauser T, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Nov;103(11):465–8

The relationship between abnormalities detected in live lambs on farms and those detected at post mortem meat inspection. Green LE, et al. **Epidemiol Infect** 1997 Jun; 118(3):267–73

Use of the Wagner apparatus to lengthen the antebrachium of a growing dog. Hay CW, et al. **J Small Anim Pract** 1996 Nov;37(11):543–8

Management of antebrachial deformity and shortening secondary to a synostosis in a dog. Langley-Hobbs SJ, et al. **J Small Anim Pract** 1996 Aug;37(8):359–63

Dietary 1,25-dihydroxycholecalciferol has variable effects on the incidences of leg abnormalities, plasma vitamin D metabolites, and vitamin D receptors in chickens divergently selected for tibial dyschondroplasia. Mitchell RD, et al. **Poult Sci** 1997 Feb;76(2):338–45

The effects of ultraviolet light and cholecalciferol and its metabolites on the development of leg abnormalities in chickens genetically selected for a high and low incidence of tibial dyschondroplasia. Mitchell RD, et al. **Poult Sci** 1997 Feb;76(2):346–54

Persistent cloaca and caudal spinal agenesis in calves: three cases. Dean CE, et al. **Vet Pathol** 1996 Nov;33(6):711–2

Persistent oropharyngeal membrane in a Hereford calf. Smoak IW, et al. **Vet Pathol** 1996 Jan;33(1):80–2

VIROLOGY

Proliferation and teratogenicity of Aino virus in chick embryos. Kitano Y, et al. **Microbiol Immunol** 1996; 40(1):85–8

The elusive search for fetal infection. Changing the gold standards. Weiner CP. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):19–32 (67 ref.)

Eleven chromosomal integration sites of a human endogenous retrovirus (HERV 4–1) map close to known loci of thirteen hereditary malformation syndromes. Taruscio DA, et al. **Teratology** 1996 Aug;54(2):108–10 (21 ref.)

ABNORMALITIES, DRUG-INDUCED

see related

TERATOGENS

Dose-related growth deficits in LS but not SS mice prenatally exposed to alcohol. Gilliam DM, et al. **Alcohol** 1996 Jan–Feb;13(1):47–51

Effect of acute ethanol and cocaine administration on gestation days 14–17 in mice. Salo AL, et al. **Alcohol** 1996 Jul–Aug;13(4):369–75

Morphologic changes in offspring of female mice exposed to ethanol before conception. Soltes BA, et al. **Am J Obstet Gynecol** 1996 Nov;175(5):1158–62

Comparison of effects of albendazole sulfoxide on in vitro produced bovine embryos and rat embryos. Piscopo SE, et al. **Am J Vet Res** 1997 Sep;58(9):1038–42

Effect of the day of administration on the developmental toxicity of tributyltin chloride in rats. Ema M, et al. **Arch Environ Contam Toxicol** 1997 Jul;33(1):90–6

Interactions of radiofrequency radiation-induced hyperthermia and 2-methoxyethanol teratogenicity in rats. Nelson BK, et al. **Bioelectromagnetics** 1997;18(5):349–59

Congenital anomalies and fluconazole [news] Wray CM. **Can Med Assoc J** 1997 Jan 1;156(1):91, 95–6 **(Eng, Fre)**

Polydactyly and fetal hydantoin syndrome: an additional component of the syndrome? Yalçinkaya C, et al. **Clin Genet** 1997 May;51(5):343–5

Fetal abnormalities and use of substances sold in 'herbal remedies' shops [letter] Lana-Moliner F, et al. **Drug Saf** 1996 Jan;14(1):68

Reproductive and developmental effects of disinfection by-products in drinking water. Reif JS, et al. **Environ Health Perspect** 1996 Oct;104(10):1056–61 (26 ref.)

Histological analysis of limb defects induced in developing limb buds of NMRI mouse embryos after oral administration of 3-3-dimethyl-1-phenyltriazene (DMPT) to their mother on day 10 of gestation. Milaire J, et al. **Eur J Morphol** 1995 Nov;33(5):491–508

Embryotoxicity/teratogenicity study with isomaltulose (Palatinose) in rats. Lina BA, et al. **Food Chem Toxicol** 1997 Mar–Apr;35(3–4):309–14

Developmental toxicity of concanavalin A in rats: association with restricted migration of neural crest cells. Nishida A, et al. **Food Chem Toxicol** 1996 Aug;34(8):701–8

Developmental toxicity study of mangafodipir trisodium injection (MnDPDP) in New Zealand white rabbits. Blazak WF, et al. **Fundam Appl Toxicol** 1996 Sep;33(1):11–5

Acute, subchronic, and developmental toxicity and genotoxicity of 1,1,1-trifluoroethane (HFC-143a). Brock WJ, et al. **Fundam Appl Toxicol** 1996 Jun;31(2):200–9

Factors affecting the extent of fetal fragility induced by histamine H1 antagonists. Sturman G, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S53–4

A review of the contribution of whole embryo culture to the determination of hazard and risk in teratogenicity testing. Webster WS, et al. **Int J Dev Biol** 1997 Apr; 41(2):329–35 (68 ref.)

Correlation of in vitro anti-proliferative potential with in vivo teratogenicity in a series of valproate analogues. Courage-Maguire C, et al. **Int J Dev Neurosci** 1997 Feb; 15(1):37–43

Antileprosy drugs, pregnancy and fetal outcome [letter] Bhargava P, et al. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4):457–8

Lamotrigine and pregnancy [letter] Quattrini A, et al. **Ital J Neurol Sci** 1996 Dec;17(6):441

Developmental effects of di-n-butyl phthalate after a single administration in rats. Ema M, et al. **J Appl Toxicol** 1997 Jul–Aug;17(4):223–9

Effects of estrogenic hormones on early development of Xenopus laevis. Nishimura N, et al. **J Exp Zool** 1997 Jul 1;278(4):221–33

Developmental toxicity of clarified slurry oil, syntower bottoms, and distillate aromatic extract administered as a single oral dose to pregnant rats. Feuston MH, et al. **J Toxicol Environ Health** 1996 Sep;49(1):45–66

Effect of ethylene thiourea on cultured rat embryos in the presence of hepatic microsomal fraction. Iwase T, et al. **J Vet Med Sci** 1997 Jan;59(1):59–61

Prenatal cocaine and/or nicotine exposure in rats: preliminary findings on long-term cognitive outcome and genital development at birth. Cutler AR, et al. **Neurotoxicol Teratol** 1996 Nov–Dec;18(6):635–43

Teratogenicity of fluconazole [letter; comment] Krcmery V Jr, et al. **Pediatr Infect Dis J** 1996 Sep;15(9):841. Comment on: Pediatr Infect Dis J 1992 Dec;11(12):1062–4.

The teratogenicity of N(omega)-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, in rats. Fantel AG, et al. **Reprod Toxicol** 1997 Sep–Oct; 11(5):709–17

Developmental toxicity of chlorpropham in mice. Tanaka T, et al. **Reprod Toxicol** 1997 Sep–Oct;11(5):697–701

Teratogenicity of methanol following a single oral dose in Long-Evans rats. Youssef AF, et al. **Reprod Toxicol** 1997 Jul–Aug;11(4):503–10

Embryotoxicity induced by alkylating agents: 10. Analysis of the combined teratogenic effects of methylnitrosourea and ethylmethanesulfonate in mice. Platzek T, et al. **Teratog Carcinog Mutagen** 1995;15(4):201–14

Effect of oral Sulfenamide TS administration on prenatal development in rats. Sitarek K, et al. **Teratog Carcinog Mutagen** 1996;16(1):1–6

Teratogenic effects of selenium compounds on cultured postimplantation rat embryos. Usami M, et al. **Teratog Carcinog Mutagen** 1996;16(1):27–36

Teratogenic effects of vigabatrin in TO mouse fetuses. Abdulrazzaq YM, et al. **Teratology** 1997 Mar;55(3):165–76

Phenytoin causes phalangeal hypoplasia in the rabbit fetus at clinically relevant free plasma concentrations. Danielsson BR, et al. **Teratology** 1995 Nov;52(5):252–9

Severe limb defects and craniofacial anomalies in a fetus conceived during acitretin therapy. de Die-Smulders CE, et al. **Teratology** 1995 Oct;52(4):215–9

Hydroxamic acid: a potential human teratogen that could be recommended to treat ureaplasma. Holmes LB. **Teratology** 1996 Apr;53(4):227–9

Teratogen update: polychlorinated biphenyls. Jacobson JL, et al. **Teratology** 1997 May;55(5):338–47 (91 ref.)

Is there a cocaine syndrome? Dysmorphic and anthropometric assessment of infants exposed to cocaine. Little BB, et al. **Teratology** 1996 Sep;54(3):145–9

Mathematical analysis for teratogenic sensitivity. Luecke RH, et al. **Teratology** 1997 Jun;55(6):373–80

Comparison of two approaches to analyzing correlated binary data in developmental toxicity studies. Ten Have TR, et al. **Teratology** 1995 Nov;52(5):267–76

Teratogen update: smoking and reproductive outcomes. Werler MM. **Teratology** 1997 Jun;55(6):382–8 (101 ref.)

All-trans-retinoic acid in maternal plasma and teratogenicity in rats and rabbits. Tembe EA, et al. **Toxicol Appl Pharmacol** 1996 Dec;141(2):456–72

Canadian health databases relevant to Great Lakes Basin research. Johnson KC. **Toxicol Ind Health** 1996 May–Aug; 12(3–4):551–5

Chromium induced teratogenicity in female rat. Kanojia RK, et al. **Toxicol Lett** 1996 Dec 31;89(3):207–13

Male-mediated F1 effects in mice exposed to 1,3-butadiene. Anderson D, et al. **Toxicology** 1996 Oct 28;113(1–3):120–7

[Teratogenicity study of magnesium chloride hexahydrate in rats] Usami M, et al. **Eisei Shikenjo Hokoku** 1996; (114):16–20 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (III)—Teratological study in rabbits by oral administration] Shinomiya M, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:619–41 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (II)—Teratological study in rats by oral administration] Yukiyama S, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:603–18 (Eng. Abstr.) **(Jpn)**

[Health risks from medicinal herbs (letter) (see comments)] Lana Moliner F, et al. **Med Clin (Barc)** 1996 Nov 30; 107(19):756–7. Comment in: Med Clin (Barc) 1997 Jun 21;109(4):159. **(Spa)**

DIAGNOSIS

Use of biometric embryonic growth parameters as indicator of exposure to a teratogen. Amwayi PJ, et al. **East Afr Med J** 1997 Jan;74(1):6–11

Comparison of magnetic resonance imaging and transvaginal ultrasonography with hysterosalpingography in the evaluation of women exposed to diethylstilbestrol. Kipersztok S, et al. **J Reprod Med** 1996 May;41(5):347–51

DRUG THERAPY

Serine-enhanced restoration of 2-methoxyethanol-induced dysmorphogenesis in the rat embryo and near-term fetus. Sleet RB, et al. **Toxicol Appl Pharmacol** 1997 Aug; 145(2):415–24

EMBRYOLOGY

Expression of Fgf-3 in relation to hindbrain segmentation, otic pit position and pharyngeal arch morphology in normal and retinoic acid-exposed mouse embryos. Mahmood R, et al. **Anat Embryol (Berl)** 1996 Jul;194(1):13–22

Behavioral teratogenesis: an extension to the teratogenesis of functions [editorial] Auroux M. **Biol Neonate** 1997;

71(3):137-47 (92 ref.)
Assessment of fetal well-being in methadone-maintained pregnancies: abnormal nonstress tests. Anyaegbunam A, et al. **Gynecol Obstet Invest** 1997;43(1):25-8
Supernumerary lumbar rib: manifestation of basic alteration in embryonic development of ribs. Branch S, et al. **J Appl Toxicol** 1996 Mar-Apr;16(2):115-9
Stereoselective dysmorphogenicity of the enantiomers of the valproic acid analogue 2-N-propyl-4-pentynoic acid (4-yn-VPA): cross-species evaluation in whole embryo culture. Andrews JE, et al. **Teratology** 1997 May; 55(5):314-8

EPIDEMIOLOGY

Correlation between drug exposure and major malformations [letter; comment] Martínez-Frías ML, et al. **Am J Med Genet** 1997 May 2;70(1):99-101. Comment on: Am J Med Genet 1996 May 3;63(1):268-76.
Using the Hungarian Birth Defects Registry for surveillance, research and intervention. Siffel C, et al. **Cent Eur J Public Health** 1997 Jun;5(2):79-81
Cisapride use during human pregnancy: a prospective, controlled multicenter study. Bailey B, et al. **Dig Dis Sci** 1997 Sep;42(9):1848-52
Congenital malformation and maternal occupational exposure to glycol ethers. Occupational Exposure and Congenital Malformations Working Group [see comments] Cordier S, et al. **Epidemiology** 1997 Jul;8(4):355-63. Comment in: Epidemiology 1997 Jul;8(4):340-1.
Reproductive disorders among hairdressers. Kersemaekers WM, et al. **Epidemiology** 1997 Jul;8(4):396-401
Birth defects among offspring of Norwegian farmers, 1967-1991. Kristensen P, et al. **Epidemiology** 1997 Sep; 8(5):537-44
Safety of first trimester exposure to H2 blockers. Lagace E. **J Fam Pract** 1996 Oct;43(4):342-3
Teratologic evaluation of 178 infants born to mothers who attempted suicide by drugs during pregnancy. Czeizel AE, et al. **Obstet Gynecol** 1997 Aug;90(2):195-201
Anticonvulsants and congenital malformations. Jick SS, et al. **Pharmacotherapy** 1997 May-Jun;17(3):561-4
Reproductive effects of paternal exposure to chlorophenate wood preservatives in the sawmill industry [see comments] Dimich-Ward H, et al. **Scand J Work Environ Health** 1996 Aug;22(4):267-73. Comment in: Scand J Work Environ Health 1997 Feb;23(1):69.
Thalidomide, a current teratogen in South America. Castilla EE, et al. **Teratology** 1996 Dec;54(6):273-7
An outbreak of thiram poisoning on Spanish poultry farms. Guitart R, et al. **Vet Hum Toxicol** 1996 Aug;38(4):287-8

ETIOLOGY

Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. White A, et al. **Acta Paediatr Suppl** 1997 Jun;421:86-8
Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Seto A, et al. **Am J Perinatol** 1997 Mar;14(3):119-24
Assessment of cerebral hemispheric symmetry in hatchling chickens exposed in ovo to polychlorinated biphenyl congeners. Lipsitz L, et al. **Arch Environ Contam Toxicol** 1997 May;32(4):399-406
Birth defects and childhood cancer in offspring of survivors of childhood cancer. Green DM, et al. **Arch Pediatr Adolesc Med** 1997 Apr;151(4):379-83
Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Buckley LM, et al. **Arthritis Rheum** 1997 May;40(5):971-3
Toxicity to transferred rat embryos after aspirin treatment during preimplantation stage in vivo. Lou YJ, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jan;17(1):52-4
Holoprosencephaly in a fetus with maternal medication of sulfasalazine in early gestation. A case report. Koyama N, et al. **Clin Exp Obstet Gynecol** 1996;23(3):136-40
Fluconazole-induced congenital anomalies in three infants. Pursley TJ, et al. **Clin Infect Dis** 1996 Feb;22(2):336-40
Reproductive toxicity of di-n-butylphthalate in a continuous breeding protocol in Sprague-Dawley rats. Wine RN, et al. **Environ Health Perspect** 1997 Jan;105(1):102-7
Congenital malformation and maternal occupational exposure to glycol ethers. Occupational Exposure and Congenital Malformations Working Group [see comments] Cordier S, et al. **Epidemiology** 1997 Jul;8(4):355-63. Comment in: Epidemiology 1997 Jul;8(4):340-1.
Phenytoin-induced teratogenesis: a molecular basis for the observed developmental delay during neurulation. Bennett GD, et al. **Epilepsia** 1997 Apr;38(4):415-23
Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Kondo T, et al. **Epilepsia** 1996 Dec;37(12):1242-4
Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Schaefer C, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Nov; 69(2):83-9
Teratogenic effects of chlormetine hydrochloride in rats. Anasiewicz A. **Folia Morphol (Warsz)** 1996;55(4):197-9
Reproductive risks of cocaine. Rizk B, et al. **Hum Reprod Update** 1996 Jan-Feb;2(1):43-55 (119 ref.)
The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Moody GA, et al. **Int J Colorectal Dis** 1997;12(4):220-4
Teratogenic effects of cytochalasin B on 9.5 day rat embryos. Mirapeix RM, et al. **Int J Dev Biol** 1996;Suppl 1:289S-290S
A risk assessment of topical tretinoin as a potential human developmental toxin based on animal and comparative human data. Johnson EM. **J Am Acad Dermatol** 1997 Mar; 36(3 Pt 2):S86-90
Interactions of radiofrequency radiation on 2-methoxyethanol teratogenicity in rats. Nelson BK, et al. **J Appl Toxicol** 1997 Jan-Feb;17(1):31-9
Uterine contraction in the development of Möbius syndrome. Graf WD, et al. **J Child Neurol** 1997 Apr;12(3):225-7
Paternal exposures and the question of birth defects. Poynor DH, et al. **J Fla Med Assoc** 1997 Jun-Jul;84(5):323-6 (38 ref.)
Effects of 3,3',4,4'-tetrachlorobiphenyl, 2,3,3',4,4'-pentachlorobiphenyl, and 3,3',4,4',5-pentachlorobiphenyl on the developing chicken embryo when injected prior to incubation. Powell DC, et al. **J Toxicol Environ Health** 1996 Oct 25;49(3):319-38
A woman with a balanced autosomal translocation who received chemotherapy while pregnant. Kim WY, et al. **Med Health R I** 1996 Nov;79(11):396-9
Possible adverse fetal effect of insulin lispro [letter] Diamond T, et al. **N Engl J Med** 1997 Oct 2;337(14):1009; discussion 1010
Developmental neurotoxicity of PCBs in humans: what do we know and where do we go from here? [see comments] Schantz SL. **Neurotoxicol Teratol** 1996 May-Jun; 18(3):217-27; discussion 229-76 (73 ref.). Comment in: Neurotoxicol Teratol 1997 Jan-Feb;19(1):1-5.
The teratogenicity of the drugs of abuse: a symposium. **NIDA Res Monogr** 1994;140:51-4
Teratogenic study of doxycycline. Czeizel AE, et al. **Obstet Gynecol** 1997 Apr;89(4):524-8
Effects of first-trimester fluoxetine exposure on the newborn. Goldstein DJ, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):713-8
Visual anomalies in young children exposed to cocaine. Block SS, et al. **Optom Vis Sci** 1997 Jan;74(1):28-36
Development of a rat model of toluene-abuse embryopathy. Gospe SM Jr, et al. **Pediatr Res** 1996 Jul;40(1):82-7
Teratology study of erythritol in rabbits. Shimizu M, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 2):S247-53
Embryotoxicity and teratogenicity study with erythritol in rats. Smits-van Prooije AE, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 2):S232-6
Influence of dietary folic acid on the developmental toxicity of methanol and the frequency of chromosomal breakage in the CD-1 mouse. Fu SS, et al. **Reprod Toxicol** 1996 Nov-Dec;10(6):455-63
New approaches for assessing the etiology and risks of developmental abnormalities from chemical exposure. Goldman LR. **Reprod Toxicol** 1997 Mar-Jun; 11(2-3):443-51 (62 ref.)
Recent advances in mathematical modeling of developmental abnormalities using mechanistic information. Kavlock RJ. **Reprod Toxicol** 1997 Mar-Jun;11(2-3):423-34 (86 ref.)
The developmental toxicity of the H1 histamine antagonists. Lione A, et al. **Reprod Toxicol** 1996 Jul-Aug;10(4):247-55 (97 ref.)
Lysosomes and teratogenesis: from hypothesis to dogma and back. Lloyd JB. **Reprod Toxicol** 1997 Jul-Aug;11(4):589-94
The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). McElhatton PR, et al. **Reprod Toxicol** 1996 Jul-Aug;10(4):285-94
Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy [see comments] Manson JM, et al. **Reprod Toxicol** 1996 Nov-Dec;10(6):439-46. Comment in: Reprod Toxicol 1997 Jul-Aug;11(4):641-2.
Pharmacokinetics, pharmacodynamics, and prediction of developmental abnormalities. O'Flaherty EJ. **Reprod Toxicol** 1997 Mar-Jun;11(2-3):413-6 (28 ref.)
Carpal and tarsal bone development is highly sensitive to three antiproliferative teratogens in mice. Rahman ME, et al. **Reprod Toxicol** 1996 Nov-Dec;10(6):485-9
Pregnancy outcome after treatment with the ergot derivative, cabergoline. Robert E, et al. **Reprod Toxicol** 1996 Jul-Aug; 10(4):333-7
Cardiovascular alterations in rat fetuses exposed to calcium channel blockers. Scott WJ Jr, et al. **Reprod Toxicol** 1997 Mar-Jun;11(2-3):207-14
Arsenic-induced neural tube defects in mice: alterations in cell cycle gene expression. Wlodarczyk BJ, et al. **Reprod Toxicol** 1996 Nov-Dec;10(6):447-54
Vitamin A, birth defects and multivitamin preparations [letter] Presbury D. **S Afr Med J** 1997 Jan;87(1):73
Exposure of embryonic cells to alcohol: contrasting effects during preimplantation and postimplantation development. Armant DR, et al. **Semin Perinatol** 1996 Apr;20(2):127-39 (115 ref.)
Teratogenic potential of cocaine. Buehler BA, et al. **Semin Perinatol** 1996 Apr;20(2):93-8 (38 ref.)
Psychotropics. Goldaber KG. **Semin Perinatol** 1997 Apr; 21(2):154-9 (44 ref.)
Vitamin A and its congeners. Monga M. **Semin Perinatol** 1997 Apr;21(2):135-42 (64 ref.)
Evaluation of the developmental toxicity of 4-bromobenzene using frog embryo teratogenesis assay--Xenopus: possible mechanisms of action. Fort DJ, et al. **Teratog Carcinog Mutagen** 1996;16(6):307-15
Effects of the antiepileptic drug valproic acid on the development of the axolotl (Ambystoma mexicanum): histological investigations. Krätke R, et al. **Teratog Carcinog Mutagen** 1996;16(3):149-67
Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Menegola E, et al. **Teratog Carcinog Mutagen** 1996;16(2):97-108
Male-mediated teratogenesis: spectrum of congenital malformations in the offspring of A/J male mice treated with ethylnitrosourea. Nagao T, et al. **Teratog Carcinog Mutagen** 1996;16(6):301-5
Dose-response relationship of teratogenicity and prenatal-toxic risk estimation of 6-mercaptopurine riboside in mice. Platzek T, et al. **Teratog Carcinog Mutagen** 1996; 16(3):169-81
Cyclophosphamide-induced teratogenesis in ICR mice: the role of apoptosis. Torchinsky A, et al. **Teratog Carcinog Mutagen** 1995;15(4):179-90
Developmental and dysmorphogenic effects of glufosinate ammonium on mouse embryos in culture. Watanabe T, et al. **Teratog Carcinog Mutagen** 1996;16(6):287-92
Retinoic acid-induced embryopathy of the mouse inner ear. Frenz DA, et al. **Teratology** 1996 May;53(5):292-303
Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta). Prahalada S, et al. **Teratology** 1997 Feb; 55(2):119-31
Maternal medications and environmental exposures as risk factors for gastroschisis. Torfs CP, et al. **Teratology** 1996 Aug;54(2):84-92
Mechanism of teratogenic action of thalidomide [letter] Vaisman B. **Teratology** 1996 May;53(5):283-4 (17 ref.)
RARalpha-mediated teratogenicity in mice is potentiated by an RXR agonist and reduced by an RAR antagonist: dissection of retinoid receptor-induced pathways. Elmazar MM, et al. **Toxicol Appl Pharmacol** 1997 Sep;146(1):21-8
Early life stage toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in zebrafish (Danio rerio). Henry TR, et al. **Toxicol Appl Pharmacol** 1997 Jan; 142(1):56-68
Fetal malformations in an epileptic pregnant woman treated with carbamazepine. Ceci O, et al. **Zentralbl Gynakol** 1996; 118(3):169-71
[Is lithium a teratogen?] Kučera V. **Cas Lek Cesk** 1996 Nov 20;135(22):726-8 (20 ref.) (Eng. Abstr.) **(Cze)**
["Massimo Crepet" study award] Manno M, et al. **Med Lav** 1996 Jul-Aug;87(4):362-3 **(Ita)**
[Toxic effects of fluorine compounds on the the fetus and their effect on the course of pregnancy] Chlubek D, et al. **Ginekol Pol** 1996 Aug;67(8):414-8 (21 ref.) (Eng. Abstr.) **(Pol)**
[Emryopathy due to isotretinoine. A case history of one observation] Balliu Badía PR, et al. **An Esp Pediatr** 1997 Apr;46(4):397-8 **(Spa)**
[The use of several drugs and their risks in pregnancy] Vázquez-Benítez E. **Gac Med Mex** 1996 Sep-Oct; 132(5):541-3 **(Spa)**
[Cleft lip and palate associated with meclozine] Lastra-Lastra A, et al. **Ginecol Obstet Mex** 1996 Nov;64:485 **(Spa)**

GENETICS

Human germinal mutagenic effects in relation to intentional and accidental exposure to toxic agents. Czeizel AE. **Environ Health Perspect** 1996 May;104 Suppl 3:615-7
Genome scan for teratogen-induced clefting susceptibility loci in the mouse: evidence of both allelic and locus heterogeneity distinguishing cleft lip and cleft palate. Diehl SR, et al. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):5231-6
Valproic acid-induced somite teratogenesis in the chick embryo: relationship with Pax-1 gene expression. Barnes GL Jr, et al. **Teratology** 1996 Aug;54(2):93-102
Effect of multifactorial genetic liability to exencephaly on the teratogenic effect of valproic acid in mice. Hall JL, et al. **Teratology** 1997 May;55(5):306-13
Retinoic acid teratogenicity in rat congenic and recombinant inbred strains with malformation syndrome. Bilá V, et al. **Transplant Proc** 1997 May;29(3):1707-8

METABOLISM

Alterations in Msx 1 and Msx 2 expression correlate with inhibition of outgrowth of chick facial primordia induced by retinoic acid. Brown JM, et al. **Anat Embryol (Berl)** 1997 Feb;195(2):203-7
Teratogen-induced eye defects mediated by p53-dependent apoptosis [published erratum appears in Curr Biol 1996 Jun 1;6(6):753] Wubah JA, et al. **Curr Biol** 1996 Jan 1;6(1):60-9
Valproate-induced limb malformations in mice associated with reduction of intracellular pH. Scott WJ Jr, et al. **Reprod Toxicol** 1997 Jul-Aug;11(4):483-93
Never-ending tales of the mode of the teratogenic action of thalidomide [comment] Neubert D. **Teratog Carcinog Mutagen** 1997;17(1):i-ii (11 ref.). Comment on: Teratog Carcinog Mutagen 1997 ;17(1):1-5.
Comparison of nicotinic receptor binding and biotransformation of coniine in the rat and chick. Forsyth CS, et al. **Toxicol Lett** 1996 Dec 31;89(3):175-83

PATHOLOGY

Acute treatment of paternal alcohol exposure produces malformations in offspring. Bielawski DM, et al. **Alcohol** 1997 Jul–Aug;14(4):397–401

Demonstration of congenital anomalies in the joints of the forelimbs and hindlimbs caused by several pharmacological agents. Erdoğan D, et al. **Anat Histol Embryol** 1996 Dec; 25(4):263–7

Evaluation of the developmental toxicity of methacrylonitrile in Sprague–Dawley rats and New Zealand white rabbits. George JD, et al. **Fundam Appl Toxicol** 1996 Dec; 34(2):249–59

Developmental toxicity of PCB 126 (3,3',4,4',5–pentachlorobiphenyl) in nestling American kestrels (Falco sparverius). Hoffman DJ, et al. **Fundam Appl Toxicol** 1996 Dec;34(2):188–200

Inhalation teratology and reproduction studies with 1,1–dichloro–2,2,2–trifluoroethane (HCFC–123). Malinverno G, et al. **Fundam Appl Toxicol** 1996 Dec; 34(2):276–87

The developmental toxicity of boric acid in rabbits. Price CJ, et al. **Fundam Appl Toxicol** 1996 Dec;34(2):176–87

Developmental toxicity of inhaled ethylene oxide in rats following short–duration exposure. Saillenfait AM, et al. **Fundam Appl Toxicol** 1996 Dec;34(2):223–7

LiCl–induced malformations of the eyes and the rostral CNS in Xenopus laevis. Reichenbach A, et al. **J Hirnforsch** 1997; 38(1):35–45

Congenital renal tubular dysplasia and skull ossification defects similar to teratogenic effects of angiotensin converting enzyme (ACE) inhibitors. Kumar D, et al. **J Med Genet** 1997 Jul;34(7):541–5

Neuronal heterotopias in the developing cerebral cortex produced by neurotrophin–4. Brunstrom JE, et al. **Neuron** 1997 Mar;18(3):505–17

Methanol causes posteriorization of cervical vertebrae in mice. Connelly LE, et al. **Teratology** 1997 Feb;55(2):138–44

PREVENTION & CONTROL

Cleft beak induced by hydrocortisone in the chick is prevented by increased cell division after experimental reduction of amniotic fluid. Peterka M, et al. **Anat Embryol (Berl)** 1997 Apr;195(4):387–91

Potential subversion of pregnancy prevention program in the managed care setting [letter; comment] Wilkin JK. **Arch Dermatol** 1997 Feb;133(2):243–4. Comment on: Arch Dermatol 1996 Sep;132(9):1013–5.

Application of thiamine in preventing malformations, specifically cleft alveolus and palate, during the intrauterine development of rats. Bienengräber V, et al. **Cleft Palate Craniofac J** 1997 Jul;34(4):318–24

Influence of maternal nicotine exposure on neonatal rat lung structure: protective effect of ascorbic acid. Maritz GS, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jun;117(2):159–65

Prevention of etretinate–induced craniofacial malformations by vitamin B6 in the rat. Jacobsson C, et al. **Eur J Oral Sci** 1996 Oct–Dec;104(5–6):583–8

Inhibition of 3,3',4,4',5–pentachlorobiphenyl–induced chicken embryotoxicity by 2,2',4,4',5,5'–hexachlorobiphenyl. Zhao F, et al. **Fundam Appl Toxicol** 1997 Jan;35(1):1–8

Valproate–induced developmental modifications maybe partially prevented by coadministration of folinic acid and S–adenosylmethionine. Ubeda N, et al. **Int J Dev Biol** 1996; Suppl 1:291S–292S

ACOG educational bulletin. Teratology. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 Apr;57(1):81–8

Alcohol and other Drug–Related Birth Defects Awareness Week--May 11–17, 1997. **MMWR Morb Mortal Wkly Rep** 1997 Apr 25;46(16):345

Maternal and fetal implications of anticonvulsive therapy during pregnancy. Eller DP, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):523–34 (46 ref.)

Advances in understanding mechanisms of toxicity and implications for risk assessment. Daston GP. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):389–96 (48 ref.)

Old paths retrodden. Peters PW, et al. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):457–60

The care of pregnant women with epilepsy--a survey of obstetricians in Scotland. Russell AJ, et al. **Seizure** 1996 Dec;5(4):271–7

Developmental effects of magnetic field (50 Hz) in combination with ionizing radiation and chemical teratogens. Pafková H, et al. **Toxicol Lett** 1996 Nov; 88(1–3):313–6

SURGERY

[Hysteroscopic metroplasty for uterine enlargement: a treatment for diethylbestrol–exposed and hypoplastic uteri] Garbin O, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(1):41–6 (Eng. Abstr.) **(Fre)**

VETERINARY

Microphthalmia, brachygnathia superior, and palatocheiloschisis in a foal associated with griseofulvin administration to the mare during early pregnancy. Schutte JG, et al. **Vet Q** 1997 Jun;19(2):58–60

ABNORMALITIES, MULTIPLE

Holt–Oram syndrome with malformations of renal and cerebral arteries. Koutlas ED, et al. **Acta Cardiol** 1996; 51(4):373–6

CHARGE association with congenital glaucoma due to maldevelopment of the anterior chamber angle. Katai N, et al. **Acta Ophthalmol Scand** 1997 Jun;75(3):322–4

Unilateral hypoplasia of the calcaneus associated with other abnormalities. A new entity? Theodorou SD, et al. **Acta Orthop Belg** 1996 Sep;62(3):165–7

Pyruvate dehydrogenase complex deficiency with multiple minor anomalies. Saijo H, et al. **Acta Paediatr Jpn** 1997 Apr;39(2):230–2

Anaesthetic considerations in exomphalos repair: a report of 2 cases. Amata AO. **Afr J Med Med Sci** 1995 Dec; 24(4):403–6

Hemangiomas of the head, neck, and chest with associated vascular and brain anomalies: a complex neurocutaneous syndrome. Pascual–Castroviejo I, et al. **AJNR Am J Neuroradiol** 1996 Mar;17(3):461–71

Absent right superior vena cava in visceroatrial situs solitus. Bartram U, et al. **Am J Cardiol** 1997 Jul 15;80(2):175–83 (95 ref.)

Clinicopathologic findings in congenital aneurysms of the great vessels. Adès LC, et al. **Am J Med Genet** 1996 Dec 18;66(3):289–99 (37 ref.)

Unusual complex of ventral midline anomalies: a multiple congenital anomalies/mental retardation syndrome. Bohring A, et al. **Am J Med Genet** 1996 Dec 30;66(4):453–6

Clinical and roentgenographic findings in a patient with primordial microcephalic dwarfism type Caroline Crachami. Boscherini B, et al. **Am J Med Genet** 1996 Dec 18;66(3):269–72

A new Seckel–like syndrome of primordial dwarfism [see comments] Buebel MS, et al. **Am J Med Genet** 1996 Aug 23;64(3):447–52. Comment in: Am J Med Genet 1997 Jun 27;70(4):454.

Distichiasis–lymphedema syndrome: tetralogy of Fallot, chylothorax, and neonatal death. Chen E, et al. **Am J Med Genet** 1996 Dec 18;66(3):273–5

Large congenital follicular ovarian cyst in a girl with Kabuki syndrome [letter] Devriendt K, et al. **Am J Med Genet** 1996 Oct 2;65(1):90–91

Possibly new multiple congenital anomaly syndrome: cranio–fronto–nasal dysplasia with Poland anomaly. Erdoğan B, et al. **Am J Med Genet** 1996 Oct 28;65(3):222–5

Microphthalmia, marked short stature, hearing loss, and developmental delay: extension of the phenotype of GOMBO syndrome? Farrell SA. **Am J Med Genet** 1997 Oct 3;72(1):18–23

Hypoplastic thymus and T–cell reduction in EECUT syndrome. Frick H, et al. **Am J Med Genet** 1997 Mar 3; 69(1):65–8

Velo–facio–skeletal syndrome versus Aarskog syndrome [letter; comment] Fryns JP, et al. **Am J Med Genet** 1996 Sep 6;64(4):604. Comment on: Am J Med Genet 1995 Jul 31;58(1):8–12.

Previously apparently undescribed syndrome: shallow orbits, ptosis, coloboma, trigonocephaly, gyral malformations, and mental and growth retardation [letter; comment] Fryns JP. **Am J Med Genet** 1996 Aug 23;64(3):521–2. Comment on: Am J Med Genet 1995 Jul 3;57(3):403–9.

COACH syndrome: report of two brothers with congenital hepatic fibrosis, cerebellar vermis hypoplasia, oligophrenia, ataxia, and mental retardation. Gentile M, et al. **Am J Med Genet** 1996 Aug 23;64(3):514–20

Congenital pulmonary lymphangiectasia and other anomalies in a child: provisionally unique syndrome? Gilewski MK, et al. **Am J Med Genet** 1996 Dec 30;66(4):438–40

The floating harbor syndrome with cardiac septal defect. Lazebnik N, et al. **Am J Med Genet** 1996 Dec 18; 66(3):300–2 (23 ref.)

Hypothesis: septo–optic dysplasia is a vascular disruption sequence. Lubinsky MS. **Am J Med Genet** 1997 Mar 31; 69(3):235–6

VACTERL–hydrocephaly, DK–phocomelia, and cerebro–cardio–radio–reno–rectal community. Lurie IW, et al. **Am J Med Genet** 1997 May 16;70(2):144–9 (50 ref.)

Greig cephalopolysyndactyly syndrome with dysgenesis of the corpus callosum in a Bedouin family. Marafie MJ, et al. **Am J Med Genet** 1996 Dec 18;66(3):261–4

Multiple vertebral segmentation defects and rib anomalies [letter; comment] Martínez–Frías ML. **Am J Med Genet** 1996 Dec 2;66(1):91. Comment on: Am J Med Genet 1996 Feb 2;61(4):310–9.

Sperm acrosome defects in a patient with Aarskog–Scott syndrome. Meschede D, et al. **Am J Med Genet** 1996 Dec 18;66(3):340–2

Heterogeneity in adducted thumbs sequence. Moldavsky M, et al. **Am J Med Genet** 1997 May 16;70(2):114–7 (13 ref.)

Cerebello–trigeminal–dermal dysplasia (Gómez–López–Hernández syndrome): description of three new cases and review. Muñoz R MV, et al. **Am J Med Genet** 1997 Oct 3;72(1):34–9 (8 ref.)

New MCA/MR syndrome with generalized hypotonia, congenital hydronephrosis, and characteristic face. Okamoto N, et al. **Am J Med Genet** 1997 Jan 31;68(3):347–9

Probable Opitz trigonocephaly C syndrome with medulloblastoma. Omran H, et al. **Am J Med Genet** 1997 Apr 14;69(4):395–9

Skeletal and cardiac malformations with thrombocytopenia: a new syndrome? Rupps R, et al. **Am J Med Genet** 1996 Aug 23;64(3):497–500

GAPO syndrome in Türkiye [letter; comment] Sayli BS, et al. **Am J Med Genet** 1996 Oct 28;65(3):252–3. Comment on: Am J Med Genet 1995 Jul 31;58(1):87–90.

Not a new Seckel–like syndrome but ear–patella–short stature syndrome [letter; comment] Teebi AS, et al. **Am J Med Genet** 1997 Jun 27;70(4):454. Comment on: Am J Med Genet 1996 Aug 23;64(3):447–52.

Elejalde syndrome: a case report. Thornton CM, et al. **Am J Med Genet** 1997 Apr 14;69(4):406–8 (4 ref.)

Fibrotic eye muscles, Axenfeld anomaly, flat face, and mild developmental retardation: a new example of the Chitty syndrome. Van Daele SG, et al. **Am J Med Genet** 1996 Oct 28;65(3):205–8

Coloboma, mental retardation, hypogonadism, and obesity: critical review of the so–called Biemond syndrome type 2, updated nosology, and delineation of three "new" syndromes. Verloes A, et al. **Am J Med Genet** 1997 Apr 14;69(4):370–9

Goldenhar complex: a further case with uncommon associated anomalies. Zelante L, et al. **Am J Med Genet** 1997 Apr 14;69(4):418–21

Surgical correction of incomplete cryptophthalmos in Fraser syndrome. Dibben K, et al. **Am J Ophthalmol** 1997 Jul; 124(1):107–9

Laryngotracheal stenosis in a case of Pena–Shokier syndrome. Billings KR, et al. **Am J Otolaryngol** 1997 May–Jun;18(3):226–8

Isolated right subclavian artery, interrupted aortic arch, and ventricular septal defect. Mulay AV, et al. **Ann Thorac Surg** 1997 Apr;63(4):1163–5

Clinicopathologic findings in the Bannayan–Riley–Ruvalcaba syndrome. Fargnoli MC, et al. **Arch Dermatol** 1996 Oct; 132(10):1214–8

Recurrent meningitis in a case of congenital anterior sacral meningocele and agenesis of sacral and coccygeal vertebrae. Funayama CA, et al. **Arq Neuropsiquiatr** 1995 Dec;53(4):799–801

Sacrococcygeal teratoma and anorectal malformation. Ng WT, et al. **Aust N Z J Surg** 1997 Apr;67(4):218–20 (28 ref.)

Ectopic respiratory epithelium associated with multiple malformations. Mahler V, et al. **Br J Dermatol** 1997 Jun; 136(6):933–4

Giant hemifacial angioma and PHACE syndrome [letter] Quecedo E, et al. **Br J Dermatol** 1997 Apr;136(4):649–50

Prediction and course of grief four years after perinatal loss due to congenital anomalies: a follow–up study. Hunfeld JA, et al. **Br J Med Psychol** 1997 Mar;70 (Pt 1):85–91

Role of ocular involvement in the prediction of visual development and clinical prognosis in Aicardi syndrome. Menezes AV, et al. **Br J Ophthalmol** 1996 Sep;80(9):805–11

Retinal detachment in identical twins with Stickler syndrome type 1. Watanabe Y, et al. **Br J Ophthalmol** 1996 Nov; 80(11):976–81

Velocardiofacial syndrome with facial and pinna asymmetries. Tabith Júnior A, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1445–7

Holoprosencephaly and cerebellar hypoplasia in a neonate with multiple congenital malformations [letter] de Silva MV, et al. **Ceylon Med J** 1997 Jun;42(2):108–9

Scoliosis in Escobar syndrome (multiple pterygium syndrome). Description of two cases. Di Gennaro GL, et al. **Chir Organi Mov** 1996 Jul–Sep;81(3):317–23 **(Eng, Ita)**

Robinow syndrome: report of one case. Wang LY, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1997 May–Jun;38(3):235–8

Fine–Lubinsky syndrome: a fourth patient with brachycephaly, deafness, cataract, microstomia and mental retardation. Aymé S, et al. **Clin Dysmorphol** 1996 Jan; 5(1):55–60

A syndrome of brachyphalangy, polydactyly and absent tibiae. Baraitser M, et al. **Clin Dysmorphol** 1997 Apr; 6(2):111–21

Unusual type of brachydactyly associated with intraventricular septal defect and deafness: a new condition? Camera G, et al. **Clin Dysmorphol** 1997 Jan; 6(1):31–3

New syndrome or severe expression of Gordon syndrome? A case report. Courtens W, et al. **Clin Dysmorphol** 1997 Jan;6(1):39–44

Antley–Bixler syndrome: case report and review of the literature. Crisponi G, et al. **Clin Dysmorphol** 1997 Jan; 6(1):61–8

Filippi syndrome with mild learning difficulties. Fryer A. **Clin Dysmorphol** 1996 Jan;5(1):35–9

A boy with a cleft lip and palate, tritubercular incisors, and finger anomaly. Hennekam RC, et al. **Clin Dysmorphol** 1996 Oct;5(4):303–5

The cardio–facio–cutaneous (CFC) syndrome--two possible new cases and review of the literature. Krajewska–Walasek M, et al. **Clin Dysmorphol** 1996 Jan;5(1):65–72

Cranio–oculo–fronto–nasal malformation: a new MCA condition? Lopes VL, et al. **Clin Dysmorphol** 1997 Jan; 6(1):25–9

Bonneau syndrome: a further case report [letter] Rajab A. **Clin Dysmorphol** 1997 Jan;6(1):85–8

ABNORMALITIES, MULTIPLE

Ectrodactyly of lower limbs, congenital heart defect and characteristic facies in four unrelated Dutch patients: a new association. Van Den Ende JJ, et al. **Clin Dysmorphol** 1996 Jan;5(1):1–7

A new form of mandibulofacial dysostosis with macroblepharon and macrostomia. Verloes A, et al. **Clin Dysmorphol** 1997 Jan;6(1):21–4

Keipert syndrome in two brothers from Turkey. Balci S, et al. **Clin Genet** 1996 Oct;50(4):223–8

Duodenal web in the syndrome of osteopathia striata with cranial sclerosis [letter] Bar–Oz B, et al. **Clin Genet** 1996 Jun;49(6):329–30

Oto–facio–osseous–gonadal syndrome: a new form of syndromic deafness? da–Silva EO, et al. **Clin Genet** 1997 Jul;52(1):51–5

Nosology of fetal hypokinesia sequence based on CNS abnormalities: is there an Aase–Smith syndrome? David A, et al. **Clin Genet** 1996 Oct;50(4):251–4

Distinct facial appearance with nasal hypoplasia, constipation, severe mental retardation and hypotonia in two unrelated young males. Fryns JP, et al. **Clin Genet** 1996 Oct;50(4):212–6

Prenatal growth retardation, microphthalmos/iris coloboma, cloudy cornea, urogenital anomalies and microcephaly. A possible new sublethal syndrome. Fryns JP, et al. **Clin Genet** 1997 Mar;51(3):164–6

Desbuquois syndrome in an Arab Bedouin family. al–Gazeli LI, et al. **Clin Genet** 1996 Oct;50(4):255–9 (13 ref.)

A new multiple malformation syndrome of Müllerian dysgenesis and conductive hearing loss with facial hypoplasia, bilateral forearm deformity, brachydactyly, spinal stenosis and scoliosis. Kumar D, et al. **Clin Genet** 1997 Jul;52(1):30–6

Congenital heart defect and conductive hypoacusia in a patient with the KBG syndrome [letter] Rivera–Vega MR, et al. **Clin Genet** 1996 Oct;50(4):278–9

Further evidence for a syndrome of "apple peel" intestinal atresia, ocular anomalies and microcephaly. Slee J, et al. **Clin Genet** 1996 Oct;50(4):260–2

Developmental aspects in apple peel intestinal atresia–ocular anomalies–microcephaly syndrome [letter] Strømme P, et al. **Clin Genet** 1997 Aug;52(2):133

Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes. Esterly NB. **Curr Probl Pediatr** 1996 Jan;26(1):3–39 (272 ref.)

The Marshall–Smith syndrome: a review of the laryngeal complications. Cullen A, et al. **Eur J Pediatr** 1997 Jun; 156(6):463–4

Arthrogryposis, renal tubular dysfunction, cholestasis, ichthyosis syndrome (ARCI) [letter; comment] Franceschini P, et al. **Eur J Pediatr** 1997 Jan;156(1):78. Comment on: Eur J Pediatr 1995 Oct;154(10):835–9.

Congenital microgastria, growth hormone deficiency and diabetes insipidus. Hernáiz Driever P, et al. **Eur J Pediatr** 1997 Jan;156(1):37–40

Leprechaunism/Donohue syndrome/insulin receptor gene mutations: a syndrome delineation story from clinicopathological description to molecular understanding. Kosztolányi G. **Eur J Pediatr** 1997 Apr;156(4):253–5 (17 ref.)

Renal–hepatic–pancreatic dysplasia: an autosomal recessive disorder with renal and hepatic failure. Neuhaus TJ, et al. **Eur J Pediatr** 1996 Sep;155(9):791–5

Growth hormone therapy in Silver Russell syndrome: 5 years experience of the Australian and New Zealand Growth database (OZGROW). Rakover Y, et al. **Eur J Pediatr** 1996 Oct;155(10):851–7

Case report. Microcephalic osteodysplastic primordial dwarfism type II: a child with unusual symptoms and clinical course. Spranger S, et al. **Eur J Pediatr** 1996 Sep; 155(9):796–9

Congenital bilateral agenesis of diaphragm: report of a case. Wang SM, et al. **Eur J Pediatr** 1997 Jul;156(7):572–4 (9 ref.)

Lung involvement in the multisystem syndrome CHARGE association. Sporik R, et al. **Eur Respir J** 1997 Jun; 10(6):1354–5

FIGO committee for the study of ethical aspects of human reproduction. Ethical aspects in the management of the severely malformed fetus. International Federation of Gynecology and Obstetrics. Schenker JG. **Ginekol Pol** 1996 Nov;67(11):585–6

A note on the Nuer. Bouchard LD. **Hastings Cent Rep** 1996 Jan–Feb;26(1):15–6

Incomplete pancreas divisum coexistent with anomalous union of pancreaticobiliary duct—report of a Chinese patient. Lin CC, et al. **Hepatogastroenterology** 1996 Nov–Dec;43(12):1650–2

Congenital alacrima in a patient with G (Opitz Frias) syndrome. Dundar M, et al. **Hum Genet** 1996 Apr; 97(4):540–2

Ablepharon macrostomia syndrome with associated cutis laxa: possible localization to 18q. Pellegrino JE, et al. **Hum Genet** 1996 Apr;97(4):532–6

Unusual congenital limb anomalies. Agarwal RP, et al. **Indian Pediatr** 1996 Jan;33(1):58–60

Unusual cloacal exstrophy in a male neonate with a normal penis and urethra. Sarin YK. **Indian Pediatr** 1996 Jan; 33(1):60–3

Congenital microgastria. Sarin YK, et al. **Indian Pediatr** 1997 Feb;34(2):157–8

Esophageal atresia and tracheo–esophageal fistula with right pulmonary agenesis. Sarin YK. **Indian Pediatr** 1996 Jul; 33(7):595–7

Asymmetry of the labia minora, uterus didelphys, unilateral imperforate vagina and other müllerian anomalies. Ruiz–Parra A, et al. **Int J Gynaecol Obstet** 1997 Sep; 58(3):329–30

Vestibular areflexia as a cause of delayed motor skill development in children with the CHARGE association. Admiraal RJ, et al. **Int J Pediatr Otorhinolaryngol** 1997 Apr 11;39(3):205–22

Hypoplasia of the epiglottis: case report and review. Benjamin B, et al. **Int J Pediatr Otorhinolaryngol** 1996 Dec 5;38(1):65–9

Systematized inflammatory epidermal nevus with symmetrical involvement: an unusual case of CHILD syndrome? Fink–Puches R, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 2):823–6

Extensive facial hemangioma associated with cardiac and abdominal anomalies. Patel SD, et al. **J Am Acad Dermatol** 1997 Apr;36(4):636–8

Small ureterocele–like Gartner's duct cyst associated with ipsilateral renal dysgenesis: report of two cases. Sheih CP, et al. **J Clin Ultrasound** 1996 Nov–Dec;24(9):533–5

Maxillomandibular deformity in association with Poland anomaly. Ahmed MS, et al. **J Craniomaxillofac Surg** 1997 Jun;25(3):158–61

p50–NF–kappaB complexes partially compensate for the absence of RelB: severely increased pathology in p50(–/–)relB(–/–) double–knockout mice. Weih F, et al. **J Exp Med** 1997 Apr 7;185(7):1359–70

Cantrell's syndrome in an infant. Chen LJ, et al. **J Formos Med Assoc** 1997 Apr;96(4):288–90

CATCH 22: deletion of locus 22q11 in velocardiofacial syndrome, DiGeorge anomaly, and nonsyndromic conotruncal defects. Hou JW, et al. **J Formos Med Assoc** 1997 Jun;96(6):419–23

Aortic root replacement for annuloaortic ectasia in Shprintzen–Goldberg syndrome: a case report. Fukunaga S, et al. **J Heart Valve Dis** 1997 Mar;6(2):181–3 (11 ref.)

Gastroschisis with rare congenital anomalies. Chakrabarti AK, et al. **J Indian Med Assoc** 1995 May;93(5):211

Distal ureteral atresia with giant hydro–ureter and xanthogranulomatous pyelonephritis. Saha SC, et al. **J Indian Med Assoc** 1995 May;93(5):212

Communication, social–emotional development and parenting stress in Cornelia–de–Lange syndrome. Sarimski K. **J Intellect Disabil Res** 1997 Feb;41 (Pt 1):70–5

Congenital aglossia with situs inversus totalis—a case report. Jang GY, et al. **J Korean Med Sci** 1997 Feb;12(1):55–7

Conductive deafness in aglossia. Higashi K, et al. **J Laryngol Otol** 1996 Nov;110(11):1057–9

Cebocephaly, alobar holoprosencephaly, spina bifida, and sirenomelia in a stillbirth. Chen CP, et al. **J Med Genet** 1997 Mar;34(3):252–5

Chromosome 18q22.2—>qter deletion and a congenital anomaly syndrome with multiple vertebral segmentation defects. Dowton SB, et al. **J Med Genet** 1997 May; 34(5):414–7

Femoral hypoplasia–unusual facies syndrome with bifid hallux, absent tibia, and macrophallus: a report of a Bedouin baby. Sabry MA, et al. **J Med Genet** 1996 Feb;33(2):165–7 (9 ref.)

Further evidence for preaxial hallucal polydactyly as a marker of diabetic embryopathy. Slee J, et al. **J Med Genet** 1997 Mar;34(3):261–3

Hemifacial atrophy: a neurocutaneous disorder with coup de sabre deformity, telangiectatic naevus, aneurysmatic malformation of the internal carotid artery and crossed hemiatrophy [letter] Strenge H, et al. **J Neurol** 1996 Sep; 243(9):658–60

Rieger syndrome: a case report. Dimitrakopoulos J, et al. **J Oral Maxillofac Surg** 1997 May;55(5):517–21

Humero–spinal dysostosis: report of the fourth case with emphasis on generalized skeletal involvement, abnormal craniofacial features, and mitral valve thickening. Hall BD. **J Pediatr Orthop B** 1997 Jan;6(1):11–4 (3 ref.)

Challenging the embryogenesis of cloacal exstrophy. Bruch SW, et al. **J Pediatr Surg** 1996 Jun;31(6):768–70

Cystic lung lesions with systemic arterial blood supply: a hybrid of congenital cystic adenomatoid malformation and bronchopulmonary sequestration. Cass DL, et al. **J Pediatr Surg** 1997 Jul;32(7):986–90

Epigastric cleft: a previously unreported entity. Ciftci AO, et al. **J Pediatr Surg** 1997 Aug;32(8):1247–9

Megacystis microcolon intestinal hypoperistalsis syndrome: evidence of a primary myocellular defect of contractile fiber synthesis. Ciftci AO, et al. **J Pediatr Surg** 1996 Dec; 31(12):1706–11

Management of the gastrointestinal tract and nutrition in patients with cloacal exstrophy. Davidoff AM, et al. **J Pediatr Surg** 1996 Jun;31(6):771–3

Hirschsprung's disease, imperforate anus, and Down's syndrome: a case report. Flageole H, et al. **J Pediatr Surg** 1996 Jun;31(6):759–60

Familial combined duodenal and jejunal atresia. Gross E, et al. **J Pediatr Surg** 1996 Nov;31(11):1573

Prenatal diagnosis of abdominal wall defects and their prognosis. Kamata S, et al. **J Pediatr Surg** 1996 Feb; 31(2):267–71

The tethered spinal cord in patients with anorectal malformations. Levitt MA, et al. **J Pediatr Surg** 1997 Mar; 32(3):462–8

Cloacal duplication. Salman AB. **J Pediatr Surg** 1996 Nov; 31(11):1587–8

Disorders in foregut diverticulization: congenital hepaticoesophageal fistula in a baby with laryngotracheoesophageal cleft. Webber EM, et al. **J Pediatr Surg** 1997 Apr;32(4):609–11

Special imaging casebook. Meckel–Gruber syndrome. Herman TE, et al. **J Perinatol** 1996 Mar–Apr;16(2 Pt 1):144–6

Special imaging casebook. Walker–Warburg syndrome. Herman TE, et al. **J Perinatol** 1997 May–Jun;17(3):250–1

Adenocarcinoma in a duplicated bladder. Brandes SB, et al. **J Surg Oncol** 1997 Aug;65(4):280–3

Associated anomalies in patients with undescended testes. Cheng W, et al. **J Trop Pediatr** 1996 Aug;42(4):204–6

Association of epididymal anomalies with patent processus vaginalis in hernia, hydrocele and cryptorchidism. Barthold JS, et al. **J Urol** 1996 Dec;156(6):2054–6

Complete bladder duplication with exstrophy of 1 moiety in a male infant. Fouda–Neel K, et al. **J Urol** 1996 Oct; 156(4):1468

Penis and bladder agenesis in a living male neonate. Kaefer M, et al. **J Urol** 1997 Apr;157(4):1439–40 (6 ref.)

Inverted Y ureteral duplication with a large ureterocele and draining a bifid renal pelvis in a man. Mourad MS. **J Urol** 1997 Apr;157(4):1353

Enteric type adenocarcinoma of the upper tract urothelium associated with ectopic ureter and renal dysplasia: an oncological rationale for complete extirpation of this aberrant developmental anomaly. Rao DS, et al. **J Urol** 1996 Oct;156(4):1272–4

Role of the antegrade continence enema in the management of the most debilitating childhood recto–urogenital anomalies. Sheldon CA, et al. **J Urol** 1997 Sep;158(3 Pt 2):1277–9; discussion 1279–80

Urolithiasis in the exstrophy–epispadias complex. Silver RI, et al. **J Urol** 1997 Sep;158(3 Pt 2):1322–6 (20 ref.)

Malformation and stenosis of the cricoid cartilage in association with Larsen's syndrome. Hoeve HJ, et al. **Laryngoscope** 1997 Jun;107(6):792–4

Complete absence of the pericardium with bronchogenic cyst. Ruchman RB, et al. **N J Med** 1996 Aug;93(8):27–9

A child with nephrotic syndrome and with focal and segmental glomerulosclerosis: do we have to care about associated malformations? Ehrich JH, et al. **Nephrol Dial Transplant** 1996 Oct;11(10):2096–8 (29 ref.)

Agenesis of corpus callosum, hypertrophic pyloric stenosis and Hirschsprung disease: coincidence or common etiology? Sayed M, et al. **Neuropediatrics** 1996 Aug; 27(4):204–6

Duplicate cervix and vagina associated with infertility, endometriosis, and chronic pelvic pain. Keltz MD, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):701–3

Anaesthesia for Hecht Beals syndrome [letter] Geva D, et al. **Paediatr Anaesth** 1997;7(2):178–9

Accessory nipples and associated conditions [letter] Lewis EJ, et al. **Pediatr Dermatol** 1997 Jul–Aug;14(4):333–4

Zunich neuroectodermal syndrome: migratory ichthyosiform dermatosis, colobomas, and other abnormalities. Tinschert S, et al. **Pediatr Dermatol** 1996 Sep–Oct;13(5):363–71

Freeman Sheldon syndrome: severe upper airway obstruction requiring neonatal tracheostomy. Robinson PJ. **Pediatr Pulmonol** 1997 Jun;23(6):457–9 (5 ref.)

A "wandering liver" in an infant [letter] al–Ali F, et al. **Pediatr Radiol** 1997 Mar;27(3):287

Medical genetics for the practitioner. Toomey KE. **Pediatr Rev** 1996 May;17(5):163–74 (10 ref.)

Agenesis of the urinary bladder with cutaneous ectopic ureteric orifice and multiple birth defects. Bhagwat AD, et al. **Pediatr Surg Int** 1997;12(1):63–5

Imperforate anus (anal agenesis) with rectal and sigmoid atresias in a newborn. Ein SH. **Pediatr Surg Int** 1997 Jul; 12(5–6):449–51

Cantrell's pentalogy. Report of four cases and their management. Fernández MS, et al. **Pediatr Surg Int** 1997 Jul;12(5–6):428–31 (20 ref.)

Unilateral intermittent occlusion of a bicornuate uterus in association with ipsilateral renal agenesis and vena cava inferior duplication. Vergauwen S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 May;166(5):457–9

Isolation of the left subclavian artery in tetralogy of Fallot and bronchial anomalies. Kalis NN, et al. **S Afr Med J** 1997 Feb;87 Suppl 1:C25–8

Ectrodactyly, ectodermal dysplasia, and cleft lip syndrome. Case report. Seno H, et al. **Scand J Plast Reconstr Surg Hand Surg** 1996 Sep; 30(3):227–30 (22 ref.)

Cloacal exstrophy. Molenaar JC. **Semin Pediatr Surg** 1996 May;5(2):133–5 (10 ref.)

Scoliosis and congenital anomalies associated with Klippel–Feil syndrome types I–III. Thomsen MN, et al. **Spine** 1997 Feb 15;22(4):396–401

Minor malformations and physical measurements in autism: data from Nova Scotia. Rodier PM, et al. **Teratology** 1997 May;55(5):319–25

A case of tetralogy of Fallot with pulmonary atresia and restrictive perimembranous ventricular septal defect. van Meurs–van Woezik H, et al. **Thorac Cardiovasc Surg** 1997 Feb;45(1):46–7

A report of 27 cases of congenital short colon with an imperforate anus: so–called 'pouch colon syndrome'.

Budhiraja S, et al. **Trop Doct** 1997 Oct;27(4):217–20

Tricho–rhino–phalangeal syndrome type I. Eroğlu Y, et al. **Turk J Pediatr** 1996 Oct–Dec;38(4):537–42

Spondylocostal dysplasia and cardiac anomalies in one dizygotic twin. Ozkinay F, et al. **Turk J Pediatr** 1996 Jul–Sep;38(3):381–4

The megacystis–microcolon–intestinal hypoperistalsis syndrome: report of a case and review of the literature. Yigit S, et al. **Turk J Pediatr** 1996 Jan–Mar;38(1):137–41

Type II ureteral triplication associated with ectopic ureter. Engelstein D, et al. **Urology** 1996 Nov;48(5):786–8 (9 ref.)

Horseshoe kidney with a retrocaval ureter. Grossfeld GD, et al. **Urology** 1997 Jan;49(1):119–22

Ureteral duplication with lower pole ectopia to the vas: a case report of an exception to the Weigert–Meyer law. Slaughenhoupt BL, et al. **Urology** 1997 Feb;49(2):269–71 (3 ref.)

[Congenital diverticula of the ureter] Machmouchi M, et al. **J Med Liban** 1996;44(4):227–9 (8 ref.) (Eng. Abstr.) **(Fre)**

[A rare combination of partial trisomy 9 with pulmonary atresia] Nekarda T, et al. **Klin Padiatr** 1997 May–Jun; 209(3):127–9 (Eng. Abstr.) **(Ger)**

[Presentation of a case of sclerocornea with bilateral microphthalmos and auricular malformations] Guffanti A. **Minerva Oftalmol** 1967 Jul–Aug;9(4):149–52 (15 ref.) (Eng. Abstr.) **(Ita)**

[A case of lingual agenesis] Carinci F, et al. **Minerva Stomatol** 1996 Jul–Aug;45(7–8):359–62 (Eng. Abstr.) **(Ita)**

[A case of hemifacial oculo–oral anomalies] Carinci F, et al. **Minerva Stomatol** 1996 Jun;45(6):281–3 (Eng. Abstr.) **(Ita)**

[Renal agenesis associated with homolateral ovarian dysplasia. A case report] De Caro L, et al. **Pediatr Med Chir** 1997 Mar–Apr;19(2):137–9 (Eng. Abstr.) **(Ita)**

[Ectopia cordis and Cantrell's pentalogy: personal experience and considerations on the surgical treatment] Pampaloni A, et al. **Pediatr Med Chir** 1997 Jan–Feb;19(1):59–64 (Eng. Abstr.) **(Ita)**

[Sacro–coccygeal agenesis with central nervous system malformations: embryogenetic features of a case] Manfrè L, et al. **Radiol Med (Torino)** 1996 Oct;92(4):479–82 (19 ref.) **(Ita)**

[Currarino triad : a case report] Miyake S, et al. **No Shinkei Geka** 1996 Feb;24(2):189–93 (Eng. Abstr.) **(Jpn)**

[A case of multiple cerebral arteriovenous malformations treated by gamma knife radiosurgery] Yahara K, et al. **No Shinkei Geka** 1995 Dec;23(12):1121–5 (Eng. Abstr.) **(Jpn)**

[Polysplenia syndrome] Abukawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):328–30 (15 ref.) **(Jpn)**

[Seckel's syndrome] Ichihara T. **Ryoikibetsu Shokogun Shirizu** 1996;(15):524–6 (18 ref.) **(Jpn)**

[Costello syndrome] Ishikiriyama S. **Ryoikibetsu Shokogun Shirizu** 1996;(15):258–60 (15 ref.) **(Jpn)**

[Townes–Brocks syndrome] Ishikiriyama S. **Ryoikibetsu Shokogun Shirizu** 1996;(15):305–6 (8 ref.) **(Jpn)**

[VATER association (VACTERL association)] Masuno M. **Ryoikibetsu Shokogun Shirizu** 1996;(15):309–10 (20 ref.) **(Jpn)**

[Holt–Oram syndrome] Matsuoka R. **Ryoikibetsu Shokogun Shirizu** 1996;(15):267–70 (13 ref.) **(Jpn)**

[CATCH22 syndrome] Miyamoto T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):205–7 (9 ref.) **(Jpn)**

[Kabuki make–up syndrome] Miyoshi O, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):317–9 (10 ref.) **(Jpn)**

[Mohr–Claussen syndrome] Nakano M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):281–3 (10 ref.) **(Jpn)**

[Shprintzen syndrome] Nishikawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):300–1 (9 ref.) **(Jpn)**

[Asplenia syndrome (Ivemark syndrome)] Ohashi H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):334–6 (25 ref.) **(Jpn)**

[Marchesani syndrome] Ohyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):373–5 (11 ref.) **(Jpn)**

[Smith–Magenis syndrome] Teraoka M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):224–6 (14 ref.) **(Jpn)**

[WAGR syndrome] Teraoka M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):227–8 (14 ref.) **(Jpn)**

[Renal retinal dysplasia] Tomosugi N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):381–4 (20 ref.) **(Jpn)**

[LEOPARD syndrome] Tsukahara M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):278–80 (17 ref.) **(Jpn)**

[CHARGE association] Tsukahara M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):247–9 (20 ref.) **(Jpn)**

[Miller–Dieker syndrome] Yokoyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):217–9 (10 ref.) **(Jpn)**

[Meckel syndrome] Yoshida K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):406–9 (3 ref.) **(Jpn)**

[Microcephaly with chromosomal instability and immunodeficiency—Nijmegen syndrome] Chrzanowska KH. **Pediatr Pol** 1996 Mar;71(3):223–34 (44 ref.) (Eng. Abstr.) **(Pol)**

[Tetralogy of Fallot associated with left atrial isomerism] Ferrin LM, et al. **Arq Bras Cardiol** 1996 Oct;67(4):249–53 (Eng. Abstr.) **(Por)**

[2 of the multiple congenital defects of urogenital organs in girls] Karpenko VS. **Klin Khir** 1996;(8):47–8 **(Rus)**

[Soto's syndrome (cerebral gigantism)] Jović NS, et al. **Srp Arh Celok Lek** 1996 Jan–Feb;124(1–2):37–40 (Eng. Abstr.) **(Scc)**

[The Cohen syndrome] Dumić M, et al. **Lijec Vjesn** 1996 Sep;118(9):202–4 (Eng. Abstr.) **(Scr)**

[Emryopathy due to isotretinoine. A case history of one observation] Balliu Badia PR, et al. **An Esp Pediatr** 1997 Apr;46(4):397–8 **(Spa)**

[Miller–Dieker syndrome and endocrine changes in twins] Noguera Moya A, et al. **An Esp Pediatr** 1996 Sep; 45(3):299–301 **(Spa)**

[Partial agenesis of the sacrum and microcephaly: an uncommon association] Ruiz Moreno JA, et al. **An Esp Pediatr** 1997 Jun;46(6):607–10 (18 ref.) **(Spa)**

[Blind ureter ending in ejaculatory duct. Report of a case] Castellanos González L, et al. **Arch Esp Urol** 1996 Oct; 49(8):864–7 (Eng. Abstr.) **(Spa)**

[A case of twin death with a co–twin of the acardius acephalus type] Alaniz–Sánchez A, et al. **Ginecol Obstet Mex** 1996 Oct;64:467–70 (Eng. Abstr.) **(Spa)**

[Caudal appendix in sequential defects of amniotic rupture. A case report] Bustamante–Sarabia J, et al. **Ginecol Obstet Mex** 1997 Mar;65:114–7 (Eng. Abstr.) **(Spa)**

[Weaver syndrome. 1st case reported in Venezuela] Sánchez O, et al. **Invest Clin** 1997 Mar;38(1):9–24 (29 ref.) (Eng. Abstr.) **(Spa)**

[Influence of coronary anatomy on the anatomic repair of transposition of great arteries] Girona Comas J, et al. **Rev Esp Cardiol** 1996 Jun;49(6):451–6 (Eng. Abstr.) **(Spa)**

[Congenital stenosis of pulmonary veins in the adult] Rumoroso JR, et al. **Rev Esp Cardiol** 1996 Sep; 49(9):697–700 (Eng. Abstr.) **(Spa)**

BLOOD

Absence of serum alanine aminotransferase activity in a neonate. Delanghe J, et al. **Clin Chem** 1997 Sep; 43(9):1665–7

CHEMICALLY INDUCED

Fetal valproate embryopathy in twins: genetic modification of the response to a teratogen. Hockey A, et al. **Birth Defects Orig Artic Ser** 1996;30(1):401–5

Congenital anomalies and fluconazole [news] Wray CM. **Can Med Assoc J** 1997 Jan 1;156(1):91, 95–6 **(Eng, Fre)**

Polydactyly and fetal hydantoin syndrome: an additional component of the syndrome? Yalçinkaya C, et al. **Clin Genet** 1997 May;51(5):343–5

Developmental toxicity evaluation of methyl tertiary–butyl ether (MTBE) by inhalation in mice and rabbits. Bevan C, et al. **J Appl Toxicol** 1997 May;17 Suppl 1:S21–9

Effects induced by feeding organochlorine–contaminated carp from Saginaw Bay, Lake Huron, to laying White Leghorn hens. II. Embryotoxic and teratogenic effects. Summer CL, et al. **J Toxicol Environ Health** 1996 Nov; 49(4):409–38

CLASSIFICATION

Geleophysic dysplasia vs. Myhre syndrome [letter; comment] Figuera LE. **Am J Med Genet** 1996 Nov 11;65(4):361–2. Comment on: Am J Med Genet 1995 Sep 11;58(3):217–21.

Macrocephaly–cutis marmorata telangiectatica congenita: a distinct disorder with developmental delay and connective tissue abnormalities. Moore CA, et al. **Am J Med Genet** 1997 May 2;70(1):67–73

VACTERL association, epidemiologic definition and delineation. Rittler M, et al. **Am J Med Genet** 1996 Jun 28;63(4):529–36

Severe limb abnormalities: Nievergelt or new syndrome? Vasil M, et al. **Am J Med Genet** 1997 May 2;70(1):48–51

Tibioperoneal diaphyseal toxopachyosteosis or Weismann–Netter–Stuhl syndrome: difficulties encountered in classifying this syndrome and differentiation from rickets. Nores JM, et al. **Clin Exp Rheumatol** 1997 Jan–Feb; 15(1):105–9 (49 ref.)

Tri–amelia and phocomelia with multiple malformations resembling Roberts syndrome in a fetus: is it a variant or a new syndrome? Song SY, et al. **Clin Genet** 1996 Dec; 50(6):502–4

Longitudinal failure of upper–limb formation. Manske PR. **Instr Course Lect** 1997;46:83–110 (95 ref.)

Noncardiac malformations at major congenital heart defects. Pradat P. **Pediatr Cardiol** 1997 Jan–Feb;18(1):11–8

DIAGNOSIS

A case of Kabuki make–up syndrome with EBV + Burkitt's lymphoma. Ijichi O, et al. **Acta Paediatr Jpn** 1996 Feb; 38(1):66–8

Aventriculy: a new entity? Garfinkle WB. **AJNR Am J Neuroradiol** 1996 Oct;17(9):1649–50

Cyclopia: craniofacial appearance on MR and three–dimensional CT. Liu DP, et al. **AJNR Am J Neuroradiol** 1997 Mar;18(3):543–6

MR evaluation of right pulmonary agenesis and vascular airway compression in pediatric patients. Newman B, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):55–8

Postmortem fetal MR imaging: comparison with findings at autopsy. Woodward PJ, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):41–6

Diagnosis and management of agenesis of the right lung and left pulmonary artery sling. Pu WT, et al. **Am J Cardiol** 1996 Sep 15;78(6):723–7

De novo trisomy 16p. Carrasco Juan JL, et al. **Am J Med Genet** 1997 Jan 20;68(2):219–21

Hardikar syndrome: a new syndrome with cleft lip/palate, pigmentary retinopathy and cholestasis. Cools F, et al. **Am J Med Genet** 1997 Sep 5;71(4):472–4

Tetra–amelia and splenogonadal fusion in Roberts syndrome. de Ravel TJ, et al. **Am J Med Genet** 1997 Jan 20;68(2):185–9

Limb–pelvis hypoplasia/aplasia: a discrete entity in the fibuloulnar developmental field complex. Genuardi M, et al. **Am J Med Genet** 1997 Jan 20;68(2):190–4

The Pointer syndrome: a new syndrome with skeletal abnormalities, camptodactyly, facial anomalies, and feeding difficulties. Huq AH, et al. **Am J Med Genet** 1997 Jan 20; 68(2):225–30

Limb anomalies in DiGeorge and CHARGE syndromes. Prasad C, et al. **Am J Med Genet** 1997 Jan 20;68(2):179–83

Interstitial deletion of chromosome 1q [del(1)(q24q25.3)] identified by fluorescence in situ hybridization and gene dosage analysis of apolipoprotein A–II, coagulation factor V, and antithrombin III. Takano T, et al. **Am J Med Genet** 1997 Jan 20;68(2):207–10

Dubowitz syndrome in a boy without developmental delay: further evidence for phenotypic variability. Wallerstein R, et al. **Am J Med Genet** 1997 Jan 20;68(2):216–8

Salivary gland disorders and heredity. Wiedemann HR. **Am J Med Genet** 1997 Jan 20;68(2):222–4

Diagnostic problems in a case with mucometrocolpos, polydactyly, congenital heart disease, and skeletal dysplasia. Yapar EG, et al. **Am J Med Genet** 1996 Dec 18;66(3):343–6

Perinatal features of omphalocele–exstrophy–imperforate anus–spinal defects (OEIS complex) associated with large meningomyeloceles and severe limb defects. Chen CP, et al. **Am J Perinatol** 1997 May;14(5):275–9

Oculomotor nerve and muscle abnormalities in congenital fibrosis of the extraocular muscles. Engle EC, et al. **Ann Neurol** 1997 Mar;41(3):314–25

Diagnosis and management of left main stem bronchus compression. Goldman SA, et al. **Ann Otol Rhinol Laryngol** 1997 Jun;106(6):461–5

Diagnosing congenital heart defects using the Fallot computational model. Reed NE, et al. **Artif Intell Med** 1997 May;10(1):25–40

CHARGE syndrome: review of literature and report of case. Coloboma, Heart disease, Atresia of choanae, Retarded mental development, Genital hypoplasia, Ear abnormalities–deafness. Grimm SE 3rd, et al. **ASDC J Dent Child** 1997 May–Jun;64(3):218–21, 228 (15 ref.)

Rhombencephalosynapsis associated with hand anomalies. Aydingöz U, et al. **Br J Radiol** 1997 Jul;70(835):764–6

Ocular manifestations in Delleman syndrome (Oculocerebrocutaneous syndrome, OCC–syndrome) and encephalocraniocutaneous lipomatosis (ECCL). Report of three cases. Narbay G, et al. **Bull Soc Belge Ophtalmol** 1996;261:65–70

Cutis marmorata telangiectatica congenita with cerebral and ophthalmic anomalies: report of one case. Mu SC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1997 Jan–Feb;38(1):65–8

Polysyndactyly and trigonocephaly with partial agenesis of corpus callosum: an example of the variable clinical spectrum of the Acrocallosal syndrome? [letter] Fryns JP, et al. **Clin Dysmorphol** 1997 Jul;6(3):285–6

Bardet–Biedl syndrome: delayed diagnosis in a child with Hirschsprung disease [letter] Işlek I, et al. **Clin Dysmorphol** 1996 Jul;5(3):271–3 (7 ref.)

Focal dermal hypoplasia (Goltz syndrome) presenting as a severe fetal malformation syndrome. Patel JS, et al. **Clin Dysmorphol** 1997 Jul;6(3):267–72

Hypertrichosis, coarse face, brachydactyly, obesity and mental retardation. Pavone L, et al. **Clin Dysmorphol** 1996 Jul;5(3):223–9

Oculo–auriculo–vertebral spectrum and the CHARGE association: clinical evidence for a common pathogenetic mechanism. Van Meter TD, et al. **Clin Dysmorphol** 1996 Jul;5(3):187–96

Exclusion of Treacher Collins Franceschetti syndrome in a subject with tetralogy of Fallot and cryptorchidism. Bruni L, et al. **Clin Genet** 1996 Aug;50(2):89–92

Osteopenia, abnormal dentition, hydrops fetalis and communicating hydrocephalus: unusual early clinical signs in Coffin–Lowry syndrome [letter; comment] Fryns JP.

Clin Genet 1996 Aug;50(2):112. Comment on: Clin Genet 1995 Oct;48(4):217–20.

Cardio-facio-cutaneous (CFC) syndrome--a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome. Wieczorek D, et al. **Clin Genet** 1997 Jul;52(1):37–46 (57 ref.)

Early fatal course in three brothers with FG syndrome. Sorge G, et al. **Clin Pediatr (Phila)** 1996 Jul;35(7):365–7

Kabuki make-up (Niikawa-Kuroki) syndrome: cognitive abilities and autistic features. Ho HH, et al. **Dev Med Child Neurol** 1997 Jul;39(7):487–90

Annular pancreas accompanied by an ectopic pancreas in the adult: a case report. Nakajima H, et al. **Endoscopy** 1995 Nov;27(9):713

Search for 22q11 deletion in non-syndromic conotruncal cardiac defects [letter; comment] Digilio MC, et al. **Eur J Pediatr** 1996 Jul;155(7):619–20. Comment on: Eur J Pediatr 1995 Nov;154(11):878–81.

Additional congenital defects in anorectal malformations. Hassink EA, et al. **Eur J Pediatr** 1996 Jun;155(6):477–82

Occult spinal dysraphism--the common combination of lesions and the clinical manifestations in 50 patients. Sattar MT, et al. **Eur J Pediatr Surg** 1996 Dec;6 Suppl 1:10–4

The Floating-Harbor syndrome: report of another patient and differential diagnosis with Shprintzen syndrome. Smeets E, et al. **Genet Couns** 1996;7(2):143–6

Morgagni hernia in a neonate with ventricular septal defect. Budhiraja S, et al. **Indian J Gastroenterol** 1997 Jul; 16(3):111–2

Mediastinal enterogenic cyst presenting as paraplegia--a case report. Mam MK, et al. **Indian J Med Sci** 1996 Sep; 50(9):337–9

Otolaryngologic manifestations of Kabuki syndrome. Peterson-Falzone SJ, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jan 3;38(3):227–36

Congenital ectopic vas deferens inserting into the bladder with ipsilateral renal agenesis. Delakas D, et al. **Int Urol Nephrol** 1996;28(5):701–7 (13 ref.)

Extensive pure venous malformations in the upper or lower limb: a review of 27 cases. Enjolras O, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):219–25

Lissencephaly with pontocerebellar hypoplasia. al Shawan SA, et al. **J Child Neurol** 1996 May;11(3):241–4

Multiple nodular lesions seen in a patient with neurocutaneous melanosis. Sasaki Y, et al. **J Dermatol** 1996 Nov;23(11):828–31 (11 ref.)

Infantile hypertrophic pyloric stenosis after surgery for esophageal atresia with tracheoesophageal fistula. Wang JN, et al. **J Formos Med Assoc** 1996 Aug;95(8):642–3

Should the 3C (craniocerebellocardiac) syndrome be included in the spectrum of velocardiofacial syndrome and DiGeorge sequence? [letter; comment] Butler MG, et al. **J Med Genet** 1996 Aug;33(8):719–20. Comment on: J Med Genet 1995 Jul;32(7):561–3.

Carbohydrate deficient glycoprotein (CDG) syndrome type I. Jaeken J, et al. **J Med Genet** 1997 Jan;34(1):73–6

Mayer-Rokitansky-Kuster-Hauser syndrome diagnosed by magnetic resonance imaging in a 15-year-old girl. Russ PD, et al. **J Pediatr Adolesc Gynecol** 1997 May;10(2):89–92

Neonatal fellowship. McKusick-Kaufman syndrome with legal complications of hydrometrocolpos and congenital endometriosis. Arcellana RC, et al. **J Perinatol** 1996 May-Jun;16(3 Pt 1):220–3

Special imaging casebook. Cerebrocostomandibular syndrome with hypoxic myocardiopathy and encephalopathy. Herman TE, et al. **J Perinatol** 1996 Nov-Dec;16(6):504–6

Special imaging casebook. Trisomy 13 and occult dysraphism with tethered cord. Herman TE, et al. **J Perinatol** 1997 Mar-Apr;17(2):172–4

Accessory scrotum and anorectal malformation associated with "pseudo" prune belly in a neonate. Shoshany G, et al. **J Perinatol** 1996 May-Jun;16(3 Pt 1):224–6 (25 ref.)

Redefining the genital abnormality in the Robinow syndrome. -004 Wilcox DT, et al. **J Urol** 1997 Jun; 157(6):2312–4

Chilaiditi's syndrome presenting as acute abdomen. Hisham AN, et al. **Med J Malaysia** 1995 Sep;50(3):281–3

Hemimegalencephaly associated with somatic hemihypertrophy and a malformation of the feet: case report. Calzolari F, et al. **Neuroradiology** 1996 May; 38(4):367–70

Dysgenesis of the corpus callosum and associated telencephalic anomalies: MRI. Utsunomiya H, et al. **Neuroradiology** 1997 Apr;39(4):302–10

The clinical, neuroradiographic, and endocrinologic profile of patients with bilateral optic nerve hypoplasia. Siatkowski RM, et al. **Ophthalmology** 1997 Mar;104(3):493–6

Syndromic forms of hydrometrocolpos [letter; comment] Fryns JP. **Prenat Diagn** 1997 Jan;17(1):87. Comment on: Prenat Diagn 1996 Jun;16(6):572–6.

The use of interphase FISH for prenatal diagnosis of Pallister-Killian syndrome. Mowery-Rushton PA, et al. **Prenat Diagn** 1997 Mar;17(3):255–65

Prenatal diagnosis of a tetraploid fetus. Teyssier M, et al. **Prenat Diagn** 1997 May;17(5):474–8 (21 ref.)

Gallbladder abnormalities associated with hypoplasia of the right lobe of the liver. Kakitsubata Y, et al. **Radiat Med** 1997 Mar-Apr;15(2):71–4

Fetal anomaly, the Internet and the 'informed' patient: a dangerous combination [letter; comment] Challis DE, et al. **Ultrasound Obstet Gynecol** 1996 Jul;8(1):68. Comment on: Ultrasound Obstet Gynecol 1996 Feb;7(2):89–91.

[The CHARGE association (see comments)] Finel E, et al. **Arch Pediatr** 1996 Oct;3(10):1020–5 (Eng. Abstr.). Comment in: Arch Pediatr 1997 Jun;4(6):583–4. **(Fre)**

[CHARGE association: new associated anomalies (letter; comment)] Haddad J, et al. **Arch Pediatr** 1997 Jun; 4(6):583–4. Comment on: Arch Pediatr 1996 Oct;3(10):1020–5. **(Fre)**

[Aicardi syndrome and acquired retinal detachment] Kleiner A, et al. **Klin Monatsbl Augenheilkd** 1997 Feb;210(2):116–8 (Eng. Abstr.) **(Ger)**

[Septo-optic dysplasia (de Morsier syndrome)] Liptai Z, et al. **Orv Hetil** 1996 Aug 4;137(31):1705–9 (Eng. Abstr.) **(Hun)**

[The persistent müllerian duct syndrome with transverse testicular ectopia. A hypothesis on the role of müllerian inhibiting factor in the process of testicular migration] Asero L, et al. **Pediatr Med Chir** 1997 May-Jun;19(3):223–5 (14 ref.) (Eng. Abstr.) **(Ita)**

[A case of pena-shokeir syndrome without response to vibratory acoustic stimulation] Kadowaki K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Apr; 48(4):289–92 **(Jpn)**

[A case of preduodenal portal vein diagnosed concomitantly with malrotation of the intestine] Kito Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug;94(8):538–42 (10 ref.) **(Jpn)**

[Evaluation of the diagnostic usefulness for ultrasonographic and echocardiographic lethal markers in fetal pulmonary hypoplasia. Analysis of 11 cases] Kieszek S, et al. **Ginekol Pol** 1996 Jul;67(7):346–51 (Eng. Abstr.) **(Pol)**

[Clinical examinations in Usher's syndrome] Lubiński W, et al. **Klin Oczna** 1996 Jan;98(1):55–8 (Eng. Abstr.) **(Pol)**

[Aicardi's syndrome: agenesis of the corpus callosum, infantile flexor spasms and macular dystrophy] Badalian LO, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(5):87–90 (13 ref.) **(Rus)**

[The Robinow syndrome: a report of a family with autosomal dominant transmission] Díaz López MT, et al. **An Esp Pediatr** 1996 May;44(5):520–3 (15 ref.) **(Spa)**

[The McKusick-Kaufman syndrome: a report of 5 new cases, including a male] Paredes Esteban RM, et al. **An Esp Pediatr** 1996 May;44(5):493–5 (17 ref.) **(Spa)**

EMBRYOLOGY

Congenital scalp defect, distal limb reduction anomalies, right spastic hemiplegia and hypoplasia of the left arteria cerebri media. Further evidence that interruption of early embryonic blood supply may result in Adams-Oliver (plus) syndrome. Fryns JP, et al. **Clin Genet** 1996 Dec;50(6):505–9

The use of interphase FISH for prenatal diagnosis of Pallister-Killian syndrome. Mowery-Rushton PA, et al. **Prenat Diagn** 1997 Mar;17(3):255–65

ENZYMOLOGY

Craniofacial anomalies and malformations in respiratory chain deficiency. Cormier-Daire V, et al. **Am J Med Genet** 1996 Dec 30;66(4):457–63

Glycerol kinase deficiency in two brothers with and without clinical manifestations. Blomquist HK, et al. **Clin Genet** 1996 Nov;50(5):375–9

Dihydropyrimidinase deficiency, a progressive neurological disorder? Putman CW, et al. **Neuropediatrics** 1997 Apr; 28(2):106–10

EPIDEMIOLOGY

Body proportions and early neonatal morbidity in small-for-gestational-age infants of successive births. Vik T, et al. **Acta Obstet Gynecol Scand Suppl** 1997;165:76–81

The spectrum of congenital anomalies of the VATER association: an international study. Botto LD, et al. **Am J Med Genet** 1997 Jul 11;71(1):8–15

Are blastogenetic anomalies sporadic? Martínez-Frías ML, et al. **Am J Med Genet** 1997 Feb 11;68(4):381–5

VACTERL association, epidemiologic definition and delineation. Rittler M, et al. **Am J Med Genet** 1996 Jun 28;63(4):529–36

CHARGE association looking at the future--the voice of a family support group. Blake KD, et al. **Child Care Health Dev** 1993 Nov-Dec;19(6):395–409

The prevalence of Usher syndrome and other retinal dystrophy-hearing impairment associations. Rosenberg T, et al. **Clin Genet** 1997 May;51(5):314–21

Urinary tract abnormalities (UTA) and associated malformations: data of the Emilia-Romagna Registry. IMER Group. Emilia-Romagna Registry on Congenital Malformations. Cocchi G, et al. **Eur J Epidemiol** 1996 Oct; 12(5):493–7

Genital malformations and coexistent urinary tract or spinal anomalies in patients with imperforate anus. Metts JC 3rd, et al. **J Urol** 1997 Sep;158(3 Pt 2):1298–300

Epidemiology of choanal atresia with special reference to the CHARGE association. Harris J, et al. **Pediatrics** 1997 Mar;99(3):363–7

Associated malformations in infants with cleft lip and palate: a prospective, population-based study. Milerad J, et al. **Pediatrics** 1997 Aug;100(2 Pt 1):180–6

[Fetal diaphragmatic hernia. Concomitant anomalies] Ruseva R, et al. **Akush Ginekol (Sofiia)** 1997;36(1):7–9 (Eng. Abstr.) **(Bul)**

[Morphologic analysis of congenital central nervous system malformations in children from the first of life dying in the years 1986–1990] Sobaniec-Lotowska M, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):334–6 (Eng. Abstr.) **(Pol)**

ETIOLOGY

More on the Noonan-CFC controversy [editorial; comment] Neri G, et al. **Am J Med Genet** 1996 Oct 16;65(2):100. Comment on: Am J Med Genet 1996 Oct 16;65(2):97–9.

Midtrimester genetic amniocentesis of a twin gestation complicated by immediate severe fetal bradycardia with subsequent associated fetal anomalies. Sherer DM, et al. **Am J Perinatol** 1996 Aug;13(6):347–50

Growth retardation, alopecia, pseudoanodontia, and optic atrophy (GAPO syndrome) with congenital glaucoma. Mullaney PB, et al. **Arch Ophthalmol** 1997 Jul;115(7):940–1

Charge association in a neonate exposed in utero to carbon monoxide. Courtens W, et al. **Birth Defects Orig Artic Ser** 1996;30(1):407–12

The child with a cephalocele: etiology, neuroimaging, and outcome. Martínez-Lage JF, et al. **Childs Nerv Syst** 1996 Sep;12(9):540–50

Three infants of diabetic mothers with malformations of left-right asymmetry--further evidence for the aetiological role of diabetes in this malformation spectrum. Slavotinek A, et al. **Clin Dysmorphol** 1996 Jul;5(3):241–7

Hypothesis: patient with possible disturbance in programmed cell death [letter] Hennekam RC, et al. **Eur J Hum Genet** 1995;3(6):374–7

Goldenhar syndrome with multiple additional anomalies. Jaison SG, et al. **Indian J Ophthalmol** 1996 Mar;44(1):42–4

Congenital dislocation of the hip in extrauterine pregnancy [see comments] Uglow MG, et al. **J Bone Joint Surg Br** 1996 Sep;78(5):751–3 (17 ref.). Comment in: J Bone Joint Surg Br 1997 Mar;79(2):343.

Kenny syndrome: case report and literature review. Tsai CE, et al. **J Formos Med Assoc** 1996 Oct;95(10):793–7

Transient bradycardia in a mouse model for the oromandibulofacial limb hypogenesis syndrome following chorionic villus sampling. Chang HH, et al. **J Hand Surg [Br]** 1997 Apr;22(2):243–9

Multiple congenital contractures. Vanpaemel L, et al. **J Pediatr Orthop B** 1997 Jul;6(3):172–8

Urologic abnormalities in Menkes' kinky hair disease: report of three cases. Oshio T, et al. **J Pediatr Surg** 1997 May; 32(5):782–4

A woman with a balanced autosomal translocation who received chemotherapy while pregnant. Kim WY, et al. **Med Health R I** 1996 Nov;79(11):396–9

Fetal akinesia sequence caused by nemaline myopathy. Lammens M, et al. **Neuropediatrics** 1997 Apr;28(2):116–9

Etretinate-induced malformation of the first two branchial arches: differential staining and microdissection study of embryonic cartilage. Jacobsson C, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 May-Jun; 59(3):147–54

Common clinical manifestations of maternal diabetes in newborn infants: implications for the practicing pediatrician. Rosenn B, et al. **Pediatr Ann** 1996 Apr; 25(4):215–22 (46 ref.)

Concordant body stalk anomaly in monozygotic twinning--early embryo cleavage disorder. Shih JC, et al. **Prenat Diagn** 1996 May;16(5):467–70

Influence of genetic and maternal diabetes in the pathogenesis of visceroatrial heterotaxy in mice. Morishima M, et al. **Teratology** 1996 Oct;54(4):183–90

GENETICS

Noonan syndrome and its related disorders. Fukushima Y. **Acta Paediatr Jpn** 1996 Feb;38(1):102–4 (6 ref.)

Assignment of the mulibrey nanism gene to 17q by linkage and linkage-disequilibrium analysis. Avela K, et al. **Am J Hum Genet** 1997 Apr;60(4):896–902

Molecular analysis of velo-cardio-facial syndrome patients with psychiatric disorders. Carlson C, et al. **Am J Hum Genet** 1997 Apr;60(4):851–9

A submicroscopic deletion in Xq26 associated with familial situs ambiguus. Ferrero GB, et al. **Am J Hum Genet** 1997 Aug;61(2):395–401

The DiGeorge syndrome minimal critical region contains a goosecoid-like (GSCL) homeobox gene that is expressed early in human development. Gottlieb S, et al. **Am J Hum Genet** 1997 May;60(5):1194–201

A variant of Freeman-Sheldon syndrome maps to 11p15.5-pter. Krakowiak PA, et al. **Am J Hum Genet** 1997 Feb;60(2):426–32

Possible narrowed assignment of the loci of monosomy 21-associated microcephaly and intrauterine growth retardation to a 1.2-Mb segment at 21q22.2 [letter; comment] Matsumoto N, et al. **Am J Hum Genet** 1997 Apr; 60(4):997–9. Comment on: Am J Hum Genet 1995 Jul;57(1):62–71.

Genetic mapping using microcell-mediated chromosome transfer suggests a locus for Nijmegen breakage syndrome at chromosome 8q21–24. Matsuura S, et al. **Am J Hum Genet** 1997 Jun;60(6):1487–94

Further delineation of renal-coloboma syndrome in patients with extreme variability of phenotype and identical PAX2 mutations. Schimmenti LA, et al. **Am J Hum Genet** 1997 Apr;60(4):869–78

Is there an abnormal phenotype associated with maternal

isodisomy for chromosome 2 in the presence of two isochromosomes? [letter] Shaffer LG, et al. **Am J Hum Genet** 1997 Aug;61(2):461–2

Chromosome 1p36 deletions: the clinical phenotype and molecular characterization of a common newly delineated syndrome. Shapira SK, et al. **Am J Hum Genet** 1997 Sep; 61(3):642–50

Molecular characterization of patients with 18q23 deletions. Strathdee G, et al. **Am J Hum Genet** 1997 Apr;60(4):860–8

Molecular analysis of deletion (17)(p11.2p11.2) in a family segregating a 17p paracentric inversion: implications for carriers of paracentric inversions. Yang SP, et al. **Am J Hum Genet** 1997 May;60(5):1184–93

Delimiting the Wolf–Hirschhorn syndrome critical region to 750 kilobase pairs. Altherr MR, et al. **Am J Med Genet** 1997 Jul 11;71(1):47–53

Expansion of the phenotype in Hennekam syndrome: a case with new manifestations. Angle B, et al. **Am J Med Genet** 1997 Aug 8;71(2):211–4

Say syndrome: a new case with cystic renal dysplasia in discordant monozygotic twins. Ashton–Prolla P, et al. **Am J Med Genet** 1997 Jun 27;70(4):353–6

Clinical analysis of a large kindred with the Pallister ulnar–mammary syndrome. Bamshad M, et al. **Am J Med Genet** 1996 Nov 11;65(4):325–31

Two sibs with partial trisomy 2q. Barnicoat AJ, et al. **Am J Med Genet** 1997 May 16;70(2):166–70

Monosomy 1p36.31–33–>pter due to a paternal reciprocal translocation: prognostic significance of FISH analysis. Blennow E, et al. **Am J Med Genet** 1996 Oct 2;65(1):60–7 (30 ref.)

Variant of Coffin–Siris syndrome or previously undescribed syndrome? Braun–Quentin C, et al. **Am J Med Genet** 1996 Sep 6;64(4):568–72

Two patients with duplication of 17p11.2: the reciprocal of the Smith–Magenis syndrome deletion? Brown A, et al. **Am J Med Genet** 1996 May 17;63(2):373–7

Delineation of a clinical syndrome caused by mosaic trisomy 15. Bühler EM, et al. **Am J Med Genet** 1996 Mar 15; 62(2):109–12

De novo trisomy 16p. Carrasco Juan JL, et al. **Am J Med Genet** 1997 Jan 20;68(2):219–21

Maternal balanced translocation leading to partial duplication of 4q and partial deletion of 1p in a son: cytogenetic and FISH studies using band–specific painting probes generated by chromosome microdissection. Chen Z, et al. **Am J Med Genet** 1997 Aug 8;71(2):160–6

Bilateral sensorineural deafness and hydrocephalus due to foramen of Monro obstruction in sibs: a newly described autosomal recessive disorder. Chudley AE, et al. **Am J Med Genet** 1997 Jan 31;68(3):350–6

Pitt–Rogers–Danks syndrome: the result of a 4p microdeletion. Clemens M, et al. **Am J Med Genet** 1996 Dec 2;66(1):95–100

Prezygotic origin of the isochromosome 12p in Pallister–Killian syndrome. Cormier–Daire V, et al. **Am J Med Genet** 1997 Mar 17;69(2):166–8

Lymphoproliferative disorders in Sotos syndrome: observation of two cases. Corsello G, et al. **Am J Med Genet** 1996 Sep 6;64(4):588–93

Paternal uniparental disomy for chromosome 14: a case report and review. Cotter PD, et al. **Am J Med Genet** 1997 May 2;70(1):74–9 (27 ref.)

Interstitial deletion 2q33.3–q34 in a boy with a phenotype resembling the Seckel syndrome. Courtens W, et al. **Am J Med Genet** 1997 Sep 5;71(4):479–85 (52 ref.)

Toriello–Carey syndrome: evidence for X–linked inheritance. Czarnecki P, et al. **Am J Med Genet** 1996 Nov 11; 65(4):291–4

Autosomal recessive lateralization and midline defects: blastogenesis recessive 1. Debrus S, et al. **Am J Med Genet** 1997 Feb 11;68(4):401–4

11Q duplication in a patient with Pitt–Rogers–Danks phenotype [letter] de Die–Smulders CE, et al. **Am J Med Genet** 1996 Dec 2;66(1):116–7

Blastogenesis dominant 1: a sequence with midline anomalies and heterotaxy. de Meeus A, et al. **Am J Med Genet** 1997 Feb 11;68(4):405–8

Pitt–Rogers–Danks syndrome and Wolf–Hirschhorn syndrome [editorial] Donnai D. **Am J Med Genet** 1996 Dec 2;66(1):101–3

Supernumerary ring chromosome 17 identified by fluorescent in situ hybridization. Fagan K, et al. **Am J Med Genet** 1997 Apr 14;69(4):352–5

Liability, thresholds, malformations, and syndromes [editorial; comment] Fraser FC. **Am J Med Genet** 1996 Dec 2;66(1):75–6. Comment on: Am J Med Genet 1996 Dec 2;66(1):72–4.

Asplenia syndrome in a child with a balanced reciprocal translocation of chromosomes 11 and 20 [46,XX,t(11;20)(q13.1;q13.13)]. Freeman SB, et al. **Am J Med Genet** 1996 Feb 2;61(4):340–4

Congenital hypertrichosis, osteochondrodysplasia, and cardiomegaly: further delineation of a new genetic syndrome. Garcia–Cruz D, et al. **Am J Med Genet** 1997 Mar 17;69(2):138–51

Gene localisation for Sutherland–Haan syndrome (SHS:MIM 309470) [letter; comment] Gedeon A, et al. **Am J Med Genet** 1996 Jul 12;64(1):78–9. Comment on: Am J Med Genet 1988 May–Jun;30(1–2):493–508.

Arthrogryposis multiplex congenita, craniofacial, and ophthalmological abnormalities and normal intelligence: a new syndrome? al–Ghamdi MA, et al. **Am J Med Genet** 1997 Sep 5;71(4):401–5

Fragile X syndrome in two siblings with major congenital malformations. Giampietro PF, et al. **Am J Med Genet** 1996 May 17;63(2):396–400

A complex chromosome rearrangement with at least five breakpoints studied by fluorescence in situ hybridization. Gibson LH, et al. **Am J Med Genet** 1997 Feb 11; 68(4):417–20

Prune–belly syndrome and other anomalies in a stillborn fetus with a ring X chromosome lacking XIST. Guillén DR, et al. **Am J Med Genet** 1997 May 2;70(1):32–6

Leiomyoma of uterus in a patient with ring chromosome 12: case presentation and literature review. Hajianpour MJ, et al. **Am J Med Genet** 1996 May 17;63(2):335–9 (12 ref.)

PCR and FISH analysis of a ring Y chromosome. Henegariu O, et al. **Am J Med Genet** 1997 Mar 17;69(2):171–6

Type III tracheal agenesis with familial tetralogy of Fallot and absent pulmonary valve syndrome. Hirt–Armon K, et al. **Am J Med Genet** 1996 Nov 11;65(4):266–8

Abnormalities of the heart and great arteries in first trimester chromosomally abnormal fetuses. Hyett J, et al. **Am J Med Genet** 1997 Mar 17;69(2):207–16

Possible new autosomal recessive syndrome of lymphedema, hydroceles, atrial septal defect, and characteristic facial changes. Irons MB, et al. **Am J Med Genet** 1996 Dec 2; 66(1):69–71

Unbalanced 15;22 translocation in a patient with manifestations of DiGeorge and velocardiofacial syndrome. Jaquez M, et al. **Am J Med Genet** 1997 May 2;70(1):6–10

Mosaicism for del(17)(p11.2p11.2) underlying the Smith–Magenis syndrome. Juyal RC, et al. **Am J Med Genet** 1996 Dec 11;66(2):193–6

Cystic kidneys associated with connective tissue disorders. Kaplan BS, et al. **Am J Med Genet** 1997 Mar 17;69(2):133–7

De novo balanced translocation (6;18)(q21;q21.3 or q22) [corrected] in a patient with heterotaxia [published erratum appears in Am J Med Genet 1997 May 2;70(1):104] Kato R, et al. **Am J Med Genet** 1996 Dec 11;66(2):184–6

XX–agonadism in a fetus with multiple dysraphic lesions: a new syndrome. Kennerknecht I, et al. **Am J Med Genet** 1997 Jun 27;70(4):413–4

The brain finger protein gene (ZNF179), a member of the RING finger family, maps within the Smith–Magenis syndrome region at 17p11.2. Kimura T, et al. **Am J Med Genet** 1997 Mar 31;69(3):320–4

Pattern of malformations in the axial skeleton in human trisomy 13 fetuses. Kjaer I, et al. **Am J Med Genet** 1997 Jun 27;70(4):421–6

Paracentric inversion involving the long arm of chromosome 9 resulting in deletion of abl gene. Kleyman SM, et al. **Am J Med Genet** 1997 Feb 11;68(4):409–11

Ritscher–Schinzel (3C) syndrome: documentation of the phenotype. Kosaki K, et al. **Am J Med Genet** 1997 Feb 11;68(4):421–7 (16 ref.)

Familial aplasia/hypoplasia of pelvis, femur, fibula, and ulna with abnormal digits in an inbred Pakistani Muslim family: a possible new autosomal recessive disorder with overlapping manifestations of the syndromes of Fuhrmann, Al–Awadi, and Raas–Rothschild. Kumar D, et al. **Am J Med Genet** 1997 May 16;70(2):107–13

Opitz GBBB syndrome and the 22q11.2 deletion [letter] Lacassie Y, et al. **Am J Med Genet** 1996 Mar 29;62(3):318

Linkage studies suggest a possible locus for bipolar disorder near the velo–cardio–facial syndrome region on chromosome 22. Lachman HM, et al. **Am J Med Genet** 1997 Apr 18;74(2):121–8

Association of codon 108/158 catechol–O–methyltransferase gene polymorphism with the psychiatric manifestations of velo–cardio–facial syndrome. Lachman HM, et al. **Am J Med Genet** 1996 Sep 20;67(5):468–72

Non–mosaic tetrasomy 9p in a liveborn infant with multiple congenital anomalies: case report and comparison with trisomy 9p. Leichtman LG, et al. **Am J Med Genet** 1996 Jun 14;63(3):434–7

Kabuki syndrome is not caused by a microdeletion in the DiGeorge/velocardiofacial chromosomal region within 22q 11.2. Li M, et al. **Am J Med Genet** 1996 Oct 16; 65(2):101–3

Frequency of associated anomalies in congenital hypoplasia of depressor anguli oris muscle: a study of 50 patients. Lin DS, et al. **Am J Med Genet** 1997 Aug 8;71(2):215–8

Cytogenetic abnormalities in two new patients with Pitt–Rogers–Danks phenotype. Lindeman–Kusse MC, et al. **Am J Med Genet** 1996 Dec 2;66(1):104–12

Velo–cardio–facial and partial DiGeorge phenotype in a child with interstitial deletion at 10p13—implications for cytogenetics and molecular biology. Lipson A, et al. **Am J Med Genet** 1996 Nov 11;65(4):304–8

Proximal partial 5p trisomy resulting from a maternal (19;5) insertion. Lorda–Sánchez I, et al. **Am J Med Genet** 1997 Feb 11;68(4):476–80 (28 ref.)

Tetrasomy 5p mosaicism due to an extra i(5p) in a severely affected girl. Lorda–Sánchez I, et al. **Am J Med Genet** 1997 Feb 11;68(4):481–4 (5 ref.)

Retinitis pigmentosa in a young man with Noonan syndrome: further evidence that Noonan syndrome (NS) and the cardio–facio–cutaneous syndrome (CFC) are variable manifestations of the same entity? [see comments] Lorenzetti ME, et al. **Am J Med Genet** 1996 Oct 16; 65(2):97–9 (17 ref.). Comment in: Am J Med Genet 1996 Oct 16;65(2):100.

"Shifted" threshold may explain diversity of cardiovascular malformations in multiple congenital abnormalities syndromes: 3C (Ritscher–Schinzel) syndrome as an example [see comments] Lurie IW, et al. **Am J Med Genet** 1996 Dec 2;66(1):72–4. Comment in: Am J Med Genet 1996 Dec 2;66(1):75–6.

EEC syndrome and genitourinary anomalies: an update. Maas SM, et al. **Am J Med Genet** 1996 Jun 14;63(3):472–8 (24 ref.)

Autosomal dominant "Opitz" GBBB syndrome due to a 22q11.2 deletion [letter; comment] McDonald–McGinn DM, et al. **Am J Med Genet** 1996 Aug 23;64(3):525–6. Comment on: Am J Med Genet 1996 Aug 23;64(3):523–4.

Ring chromosome X in a child with manifestations of Kabuki syndrome. McGinniss MJ, et al. **Am J Med Genet** 1997 May 2;70(1):37–42 (34 ref.)

Familial recurrence of tracheoesophageal fistula and associated malformations. McMullen KP, et al. **Am J Med Genet** 1996 Jun 28;63(4):525–8

Apparently balanced t(1;7)(q21.3;q34) in an infant with Coffin–Siris syndrome. McPherson EW, et al. **Am J Med Genet** 1997 Sep 5;71(4):430–3

Refined localization of the Prieto–syndrome locus [letter] Martínez F, et al. **Am J Med Genet** 1996 Jul 12;64(1):82

Are blastogenetic anomalies sporadic? Martínez–Frías ML, et al. **Am J Med Genet** 1997 Feb 11;68(4):381–5

Hydrometrocolpos as a neonatal manifestation of the Bardet–Biedl syndrome [letter; comment] Mehrotra N, et al. **Am J Med Genet** 1997 Mar 17;69(2):220. Comment on: Am J Med Genet 1995 Jan 30;55(3):276–8.

Ectodermal dysplasia, Rapp–Hodgkin type in a mother and severe ectrodactyly–ectodermal dysplasia–clefting syndrome (EEC) in her child. Moerman P, et al. **Am J Med Genet** 1996 Jun 14;63(3):479–81

De novo interstitial tandem duplication of chromosome 4(q21–q28). Navarro EG, et al. **Am J Med Genet** 1996 Mar 29;62(3):297–9 (12 ref.)

A new observation of two cases of acrofacial dysostosis type Genée–Wiedemann in a family—remarks on the mode of inheritance: report on two sibs. Neumann L, et al. **Am J Med Genet** 1996 Sep 6;64(4):556–62

Interstitial deletion of 2q associated with craniosynostosis, ocular coloboma, and limb abnormalities: cytogenetic and molecular investigation. Nixon J, et al. **Am J Med Genet** 1997 Jun 13;70(3):324–7

The Wolf–Hirschhorn syndrome in adulthood: evaluation of a 24–year–old man with a rec(4) chromosome. Ogle R, et al. **Am J Med Genet** 1996 Oct 16;65(2):124–7

Premature aging syndrome with osteosarcoma, cataracts, diabetes mellitus, osteoporosis, erythroid macrocytosis, severe growth and developmental deficiency. Okamoto N, et al. **Am J Med Genet** 1997 Mar 17;69(2):169–70

Developmental profile in a patient with monosomy 10q and dup(17p) associated with a peripheral neuropathy. Pellegrino JE, et al. **Am J Med Genet** 1996 Feb 2; 61(4):377–81

Clinical and molecular analysis in Joubert syndrome. Pellegrino JE, et al. **Am J Med Genet** 1997 Oct 3; 72(1):59–62

New progeroid disorder. Penttinen M, et al. **Am J Med Genet** 1997 Mar 17;69(2):182–7

Chromosome instability with bleomycin and X–ray hypersensitivity in a boy with Nijmegen breakage syndrome. Pérez–Vera P, et al. **Am J Med Genet** 1997 May 2;70(1):24–7

Follow–up of a familial translocation t(10;16) with an unusual segregation pattern. Resta RG, et al. **Am J Med Genet** 1996 May 17;63(2):363–5

Severe mental retardation and macroorchidism without mutation in the FMR1 gene. Reyniers E, et al. **Am J Med Genet** 1996 Aug 9;64(2):408–12 (26 ref.)

Unique mosaicism of tetraploidy and trisomy 8: clinical, cytogenetic, and molecular findings in a live–born infant. Roberts HE, et al. **Am J Med Genet** 1996 Mar 29; 62(3):243–6

Opitz G/BBB syndrome: clinical comparisons of families linked to Xp22 and 22q, and a review of the literature. Robin NH, et al. **Am J Med Genet** 1996 Mar 29; 62(3):305–17

Monosomy 6q1: syndrome delineation. Romie SS, et al. **Am J Med Genet** 1996 Mar 15;62(2):105–8

Loss of the N–myc oncogene in a patient with a small interstitial deletion of the short arm of chromosome 2. Saal HM, et al. **Am J Med Genet** 1996 Dec 30;66(4):373–7 (17 ref.)

Patients with geleophysic dysplasia are not always geleophysic. Santolaya JM, et al. **Am J Med Genet** 1997 Oct 3;72(1):85–90 (12 ref.)

Partial trisomy 17q22–qter and partial monosomy Xq27–qter in a girl with a de novo unbalanced translocation due to a postzygotic error: case report and review of the literature on partial trisomy 17qter. Sarri C, et al. **Am J Med Genet** 1997 May 2;70(1):87–94 (46 ref.)

Sub–band deletion of 7q36.3 in a patient with ring chromosome 7: association with holoprosencephaly. Sawyer JR, et al. **Am J Med Genet** 1996 Oct 16;65(2):113–6

The neuroimaging findings in Sotos syndrome. Schaefer GB, et al. **Am J Med Genet** 1997 Feb 11;68(4):462–5

Interstitial deletion 5p accompanied by dicentric ring formation of the deleted segment resulting in trisomy 5p13–cen. Schuffenhauer S, et al. **Am J Med Genet** 1996 Oct 2;65(1):56–9

ABNORMALITIES, MULTIPLE

Molecular and cytogenetic characterization of a recurrent unbalanced translocation (4;21)(p16.3;q22.1): relevance to the Wolf-Hirschhorn and Down syndrome critical regions. Sebastio G, et al. **Am J Med Genet** 1996 May 17; 63(2):366–72

Partial 9p monosomy in a girl with a tdic(9p23;13p11) translocation, minor anomalies, obesity, and mental retardation. Serra A, et al. **Am J Med Genet** 1997 Aug 8;71(2):139–43

The Marshall syndrome: report of a new family and review of the literature. Shanske AL, et al. **Am J Med Genet** 1997 May 2;70(1):52–7 (16 ref.)

Evidence for genetic anticipation in the oculodentodigital syndrome. Shapiro RE, et al. **Am J Med Genet** 1997 Jul 11;71(1):36–41

Trichorrhexis nodosa and lip pits in autosomal dominant ectodermal dysplasia--central nervous system malformation syndrome. Silengo M, et al. **Am J Med Genet** 1997 Aug 8;71(2):226–8

Inheritance of Niikawa-Kuroki (Kabuki makeup) syndrome [letter; comment] Silengo M, et al. **Am J Med Genet** 1996 Dec 18;66(3):368. Comment on: Am J Med Genet 1996 Jan 2;61(1):92–3.

Familial patent ductus arteriosus: a further case of CHAR syndrome. Slavotinek A, et al. **Am J Med Genet** 1997 Aug 8;71(2):229–32

Severe clinical phenotype due to an interstitial deletion of the short arm of chromosome 1: a brief review. Stockton DW, et al. **Am J Med Genet** 1997 Aug 8;71(2):189–93

Kenny-Caffey syndrome in six Bedouin sibships: autosomal recessive inheritance is confirmed. Tahseen K, et al. **Am J Med Genet** 1997 Mar 17;69(2):126–32

Interstitial deletion of chromosome 1q [del(1)(q24q25.3)] identified by fluorescence in situ hybridization and gene dosage analysis of apolipoprotein A-II, coagulation factor V, and antithrombin III. Takano T, et al. **Am J Med Genet** 1997 Jan 20;68(2):207–10

An apparently acentric marker chromosome originating from 9p with a functional centromere without detectable alpha and beta satellite sequences. Vance GH, et al. **Am J Med Genet** 1997 Sep 5;71(4):436–42 (38 ref.)

Mosaic tetrasomy 15q25-->qter in a newborn infant with multiple anomalies [published erratum appears in Am J Med Genet 1996 Aug 23;64(3):528] Van den Enden A, et al. **Am J Med Genet** 1996 Jun 14;63(3):482–5

Oto- spondylo-megaepiphyseal dysplasia (OSMED): clinical description of three patients homozygous for a missense mutation in the COL11A2 gene. van Steensel MA, et al. **Am J Med Genet** 1997 Jun 13;70(3):315–23

Dubowitz syndrome in a boy without developmental delay: further evidence for phenotypic variability. Wallerstein R, et al. **Am J Med Genet** 1997 Jan 20;68(2):216–8

A patient with interstitial deletion of the short arm of chromosome 3 (pter-->p21.2::p12-->qter) and a CHARGE-like phenotype. Wieczorek D, et al. **Am J Med Genet** 1997 Apr 14;69(4):413–7

Salivary gland disorders and heredity. Wiedemann HR. **Am J Med Genet** 1997 Jan 20;68(2):222–4

Patterson-Stevenson-Fontaine syndrome: 30-year follow-up and clinical details of a further affected case [letter] Wilkie AO, et al. **Am J Med Genet** 1997 Apr 14;69(4):433–4

Diaphragmatic and multiple midline defects [letter; comment] Winter RM. **Am J Med Genet** 1996 May 17;63(2):411. Comment on: Am J Med Genet 1994 Oct 15;53(1):33–8.

Weill-Marchesani syndrome--possible linkage of the autosomal dominant form to 15q21.1. Wirtz MK, et al. **Am J Med Genet** 1996 Oct 2;65(1):68–75

New X-linked mental retardation syndrome with the gene mapped tentatively in Xp22.3. Wittwer B, et al. **Am J Med Genet** 1996 Jul 12;64(1):42–9

Is the autosomal dominant Optiz GBBB syndrome part of the DiGeorge/velocardiofacial syndrome with deletions of chromosome area 22q11.2? [letter; comment] [see comments] Wulfsberg EA. **Am J Med Genet** 1996 Aug 23;64(3):523–4. Comment on: Am J Med Genet 1995 Oct 23;59(1):103–13. Comment in: Am J Med Genet 1996 Aug 23;64(3):525–6.

Cryptic pericentric inversion of chromosome 17 detected by fluorescence in situ hybridization study in familial Miller-Dieker syndrome [letter] Yokoyama Y, et al. **Am J Med Genet** 1997 Aug 8;71(2):236–7

From Pitt-Rogers-Danks syndrome to Wolf-Hirschhorn syndrome and back? Zollino M, et al. **Am J Med Genet** 1996 Dec 2;66(1):113–5

Hypothalamic-hypophyseal dysgenesis as a neuroimaging correlate of pituitary hormone deficiency in anophthalmia. Brodsky MC, et al. **Am J Ophthalmol** 1996 Nov; 122(5):747–8

Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder? Papolos DF, et al. **Am J Psychiatry** 1996 Dec; 153(12):1541–7

Identification of a cat eye syndrome using DNA sequence dosage analysis. Bulle F, et al. **Ann Genet** 1996;39(3):139–43

Interstitial deletion 6q16.2q22.2 in a child with ectrodactyly. Correa-Cerro L, et al. **Ann Genet** 1996;39(2):105–9

Agenesis of corpus callosum and anophthalmia in the asplenia syndrome. A recognisable association? Devriendt K, et al. **Ann Genet** 1997;40(1):14–7

Malformative syndrome with trigonocephaly, shallow orbits, ptosis, growth and mental retardation. De novo autosomal reciprocal t(9;13)(Q32;Q22) in a male patient. Fryns JP, et al. **Ann Genet** 1996;39(1):51–3

Partial trisomy 10q: further delineation of the clinical manifestations involving the segment 10q23-->10q24. Halpern GJ, et al. **Ann Genet** 1996;39(3):181–3

Mosaic trisomy 14 with hepatic involvement. Iglesias A, et al. **Ann Genet** 1997;40(2):104–8

Collaborative study of mosaic tetrasomy 12p or Pallister-Killian syndrome (nineteen fetuses or children). Mathieu M, et al. **Ann Genet** 1997;40(1):45–54

Trisomy for the distal segment of the short arm of chromosome 17 in a boy with mild mental retardation and some dysmorphic features. Mégarbané A, et al. **Ann Genet** 1997;40(1):55–9

Further delineation of 7p trisomy. Case report and review of literature. Pallotta R, et al. **Ann Genet** 1996;39(3):152–8 (26 ref.)

Characterization of a derivative chromosome 17 by fish-technique. Ramesh KH, et al. **Ann Genet** 1996; 39(3):177–80

De novo direct duplication 7p (p11.2-->pter) in an Arab child with MCA/MR syndrome: trisomy 7p a delineated syndrome? Redha MA, et al. **Ann Genet** 1996;39(1):5–9 (18 ref.)

Further arguments for non-fortuitous association of Potter sequence with XYY males. Rudnik-Schöneborn S, et al. **Ann Genet** 1996;39(1):43–6 (12 ref.)

A study on limb reduction defects in six European regions [published erratum appears in Ann Genet 1996;39(4):204] Stoll C, et al. **Ann Genet** 1996;39(2):99–104

Facial asymmetry, cardio-vascular anomalies and adducted thumbs as unusual symptoms in Dubowitz syndrome? Vogels A, et al. **Ann Genet** 1996;39(1):31–4 (23 ref.)

Jadassohn's sebaceous nevus and aphalangia [letter] Midón J, et al. **Ann Plast Surg** 1997 Apr;38(4):438–9

Analysing human developmental abnormalities. Winter RM. **Bioessays** 1996 Dec;18(12):965–71 (52 ref.)

Mapping of an X-linked gene for ventral midline defects (the TAS gene). Carmi R, et al. **Birth Defects Orig Artic Ser** 1996;30(1):179–87

Postmortem findings in three triploid fetuses. de Ravel TJ, et al. **Birth Defects Orig Artic Ser** 1996;30(1):341–52

Malformation syndromes with kidney dysplasia. Genuardi M, et al. **Birth Defects Orig Artic Ser** 1996;30(1):379–95

Fetal valproate embryopathy in twins: genetic modification of the response to a teratogen. Hockey A, et al. **Birth Defects Orig Artic Ser** 1996;30(1):401–5

Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Huang ZF, et al. **Blood** 1997 Aug 1;90(3):944–51

Effects of shaker-1 mutations on myosin-VIIa protein and mRNA expression. Hasson T, et al. **Cell Motil Cytoskeleton** 1997;37(2):127–38

The cardio-facio-cutaneous syndrome: a long-term follow-up of two patients, with special reference to the neurological features. Sabatino G, et al. **Childs Nerv Syst** 1997 Apr;13(4):238–41

Failure to detect connexin43 mutations in 38 cases of sporadic and familial heterotaxy. Gebbia M, et al. **Circulation** 1996 Oct 15;94(8):1909–12

New autosomal recessive syndrome of mental retardation, coarse face, microcephaly, epilepsy and skeletal abnormalities. Battaglia A, et al. **Clin Dysmorphol** 1996 Jan; 5(1):41–7

Deletion (13)(q22) with multiple congenital anomalies, hydranencephaly and penoscrotal transposition. Gershoni-Baruch R, et al. **Clin Dysmorphol** 1996 Oct; 5(4):289–94

The autosomal dominant syndrome with congenital stapes ankylosis, broad thumbs and hyperopia. Hilhorst-Hofstee Y, et al. **Clin Dysmorphol** 1997 Jul;6(3):195–203

Absent nails, kinesogenic choreoathetosis, epilepsy and developmental delay--a new autosomal dominant disorder? Lynch SA, et al. **Clin Dysmorphol** 1997 Apr;6(2):133–8

Ptosis, down-slanting palpebral fissures, hypertelorism, seizures and mental retardation: a possible new MCA/MR syndrome. Mégarbané A, et al. **Clin Dysmorphol** 1997 Jul; 6(3):239–44

Yunis-Varon syndrome: the first case of German origin. Rabe H, et al. **Clin Dysmorphol** 1996 Jul;5(3):217–22

Non-haematological traits associated with congenital dyserythropoietic anaemia type 1: a new entity emerging. Sabry MA, et al. **Clin Dysmorphol** 1997 Jul;6(3):205–12

Two male siblings with cavum septum pellucidum, cavum vergae, macrocephaly, seizures and mental retardation. A new hereditary syndrome? Sánchez O, et al. **Clin Dysmorphol** 1997 Apr;6(2):129–32

Phenotypic diversity in the Smith-Lemli-Opitz syndrome. Seller MJ, et al. **Clin Dysmorphol** 1997 Jan;6(1):69–73

Fronto-facio-nasal dysplasia. Suthers G, et al. **Clin Dysmorphol** 1997 Jul;6(3):245–9 (10 ref.)

New autosomal recessive multiple congenital abnormalities/mental retardation syndrome with craniofacial dysmorphism absent corpus callosum, iris colobomas and connective tissue dysplasia. Temtamy SA, et al. **Clin Dysmorphol** 1996 Jul;5(3):231–40 (31 ref.)

Exclusion of the p75 neurotrophin receptor gene as a candidate gene for Meckel syndrome. Wartiovaara K, et al. **Clin Dysmorphol** 1997 Jul;6(3):213–7

Pterygia associated with otomandibular anomalies: a new autosomal recessive condition? Williams DK, et al. **Clin Dysmorphol** 1997 Apr;6(2):123–8

Trisomy 13/trisomy 18 mosaicism in an infant. Abe K, et al. **Clin Genet** 1996 Nov;50(5):300–3

Two brothers with multiple congenital anomalies and mental retardation due to disomy (X)(q12-->q13.3) inherited from the mother. Apacik C, et al. **Clin Genet** 1996 Aug; 50(2):63–73 (23 ref.)

Silver-Russell syndrome and exclusion of uniparental disomy. Ayala-Madrigal ML, et al. **Clin Genet** 1996 Dec; 50(6):494–7

De novo duplication of 7pter-->p21.2 and deletion of 9pter-->p23.5: clinical and cytogenetic diagnosis. Back E, et al. **Clin Genet** 1997 Jan;51(1):56–60 (1 ref.)

Chromosome deletion 17p11.2 (Smith-Magenis syndrome) in seven new patients, four of whom had been referred for fragile-X investigation. Behjati F, et al. **Clin Genet** 1997 Jan;51(1):71–4

Partial trisomy 10 mosaicism with cutaneous manifestations: report of a case and review of the literature. Boon C, et al. **Clin Genet** 1996 Nov;50(5):417–21 (16 ref.)

Chromosome 22q11 deletion and other chromosome aberrations in cases with cleft palate, congenital heart defects and/or mental disability. A survey based on the Danish Facial Cleft Register. Brøndum-Nielsen K, et al. **Clin Genet** 1996 Sep;50(3):116–20

Mild phenotypic manifestations of terminal deletion of the long arm of chromosome 4: clinical description of a new patient. Caliebe A, et al. **Clin Genet** 1997 Aug;52(2):116–9 (8 ref.)

A mild form of Roberts/SC phocomelia syndrome with asymmetrical reduction of the upper limbs. Concolino D, et al. **Clin Genet** 1996 May;49(5):274–6

Extending the overlap of three congenital overgrowth syndromes. Coppin B, et al. **Clin Genet** 1997 Jun; 51(6):375–8

Terminal deletion of the long arm of chromosome 4 in a mother and two sons. Descartes M, et al. **Clin Genet** 1996 Dec;50(6):538–40 (2 ref.)

Submicroscopic deletion in chromosome 22q11 in trizygous triplet siblings and their father. Clinical variability of 22q11 deletion. Devriendt K, et al. **Clin Genet** 1997 Apr; 51(4):246–9

An autosomal recessive adducted thumb-club foot syndrome observed in Turkish cousins. Dundar M, et al. **Clin Genet** 1997 Jan;51(1):61–4

Deletion of the long arm of chromosome 6: two new patients and literature review. Evers LJ, et al. **Clin Genet** 1996 Sep; 50(3):138–44

Lissencephaly associated with cerebellar hypoplasia and myoclonic epilepsy in a Bedouin kindred: a new syndrome? Farah S, et al. **Clin Genet** 1997 May;51(5):326–30

De novo direct tandem duplication of a small segment of the short arm of chromosome 7 (p21.22-->22.1). Franz HB, et al. **Clin Genet** 1996 Nov;50(5):426–9

De novo balanced 5;21 translocation in a child with acrobrachycephaly, ventriculomegaly, pulmonary stenosis, ectopic anus and mental retardation. Hordnes K, et al. **Clin Genet** 1995 Dec;48(6):321–3

Trisomy 1 mosaicism only detected on a direct chromosome preparation in a neonate. Howard PJ, et al. **Clin Genet** 1995 Dec;48(6):313–6

Partial deletion of 18p and partial duplication of 18q caused by a paternal pericentric inversion. Israëls T, et al. **Clin Genet** 1996 Dec;50(6):520–4 (17 ref.)

De novo direct duplication 3 (p25-->pter): a previously undescribed chromosomal aberration. Kotzot D, et al. **Clin Genet** 1996 Aug;50(2):96–8

Polycystic kidney disease, biliary dysgenesis in a patient with Larsen's syndrome. Kurtoglu S, et al. **Clin Genet** 1997 Jun; 51(6):408–11

CFC syndrome: report of familial cases [letter] Lecora M, et al. **Clin Genet** 1996 Dec;50(6):558–9

Antley-Bixler syndrome [letter; comment] Mattina T, et al. **Clin Genet** 1996 Oct;50(4):277. Comment on: Clin Genet 1995 Jan;47(1):53–5.

Microcephaly and intracranial calcification: two new cases [letter] Monastiri K, et al. **Clin Genet** 1997 Feb;51(2):142–3

Agenesis of the corpus callosum in Schinzel-Giedion syndrome associated with 47,XXY karyotype. Ozkinay FF, et al. **Clin Genet** 1996 Sep;50(3):145–8

Cerebral defects confirm midline developmental field disturbances in supernumerary der(22), t(11;22) syndrome. Pallotta R, et al. **Clin Genet** 1996 Nov;50(5):411–6 (15 ref.)

A new syndrome with cardiac malformation, cleft lip-palate, microcephaly and digital anomalies? Perçin EF, et al. **Clin Genet** 1995 Nov;48(5):264–7

On two patients with and without the classical Wolf-Hirschhorn syndrome (WHS) sharing the same chromosome 4p16.3 specific probe deletion: evidence of a contiguous gene deletion syndrome. Petit P, et al. **Clin Genet** 1996 Jul;50(1):19–22

Unusual segregation of t(11;22) resulting from crossing-over followed by 3:1 disjunction at meiosis I. Petković I, et al. **Clin Genet** 1996 Dec;50(6):515–9

Size of 22q deletions in four previously reported patients with conotruncal anomaly face syndrome. Pierpont JW, et al. **Clin Genet** 1996 Dec;50(6):545–7

Unbalanced karyotype, dup 14(q13-q22), in a mother and her two children. Pot ML, et al. **Clin Genet** 1996 Nov; 50(5):398–402

Reciprocal translocation 4;11 with both adjacent-1 segregants viable within a family. Rogers JC, et al. **Clin Genet** 1997 Apr;51(4):250–6

Clinical variability of tetrasomy 12p. Schaefer GB, et al. **Clin Genet** 1997 Feb;51(2):102–8

Discordant monozygotic twins with the Schimmelpenning–Feuerstein–Mims syndrome. Schworm HD, et al. **Clin Genet** 1996 Nov;50(5):393–7

Pearson marrow pancreas syndrome: a molecular study and clinical management. Seneca S, et al. **Clin Genet** 1997 May; 51(5):338–42

Wolcott–Rallison syndrome associated with congenital malformations and a mosaic deletion 15q 11–12. Stewart FJ, et al. **Clin Genet** 1996 Mar;49(3):152–5

A new autosomal recessive syndrome of pachygyria. Straussberg R, et al. **Clin Genet** 1996 Dec;50(6):498–501

Increased paternal age in CHARGE association. Tellier AL, et al. **Clin Genet** 1996 Dec;50(6):548–50

Moving towards a syndrome: a review of 20 cases and a new case of non–mosaic tetrasomy 9p with long–term survival. Tonk VS. **Clin Genet** 1997 Jul;52(1):23–9 (26 ref.)

Parental origin and mechanisms of formation of three cases of 12p tetrasomy. Turleau C, et al. **Clin Genet** 1996 Jul; 50(1):41–6

Jumping translocation in a phenotypically normal female. von Ballestrem CL, et al. **Clin Genet** 1996 Mar;49(3):156–9

Multiple congenital malformations in an infant prenatally diagnosed with mosaicism for dup(lq) and del(Xq). Wells SR, et al. **Clin Genet** 1996 Apr;49(4):216–9 (10 ref.)

Terminal 2q deletion—a recognizable syndrome [letter; comment] Wenger SL, et al. **Clin Genet** 1997 Apr;51(4):290 . Comment on: Clin Genet 1995 Sep;48(3):134–9.

Sex reversal in a child with the karyotype 46,XY, dup (1) (p22.3p32.3). Wieacker P, et al. **Clin Genet** 1996 May; 49(5):271–3

Cell cycle checkpoints and DNA repair in Nijmegen breakage syndrome. Sullivan KE, et al. **Clin Immunol Immunopathol** 1997 Jan;82(1):43–8

Chromosomes 22q11 deletion syndrome: an update and review for the primary pediatrician. Thomas JA, et al. **Clin Pediatr (Phila)** 1997 May;36(5):253–66 (73 ref.)

Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence. Weeda G, et al. **Curr Biol** 1997 Jun 1; 7(6):427–39

Characterization of a de novo unbalanced chromosome rearrangement by comparative genomic hybridization and fluorescence in situ hybridization. Levy B, et al. **Cytogenet Cell Genet** 1997;76(1–2):68–71

Trichorhinophalangeal syndrome type III. Itin PH, et al. **Dermatology** 1996;193(4):349–52 (13 ref.)

Targeted mutation in beta1,4–galactosyltransferase leads to pituitary insufficiency and neonatal lethality. Lu Q, et al. **Dev Biol** 1997 Jan 15;181(2):257–67

Multigenic control of the localization of the zone of polarizing activity in limb morphogenesis in the mouse. Masuya H, et al. **Dev Biol** 1997 Feb 1;182(1):42–51

Ectopic expression of Fgf–4 in chimeric mouse embryos induces the expression of early markers of limb development in the lateral ridge. Abud HE, et al. **Dev Genet** 1996;19(1):51–65

Paternal transmission of the mouse Thp mutation is lethal in some genetic backgrounds. Rogers I, et al. **Dev Genet** 1997;20(1):23–8

Targeted disruption of the Hoxb–2 locus in mice interferes with expression of Hoxb–1 and Hoxb–4. Barrow JR, et al. **Development** 1996 Dec;122(12):3817–28

Genetic evidence that the retinoid signal is transduced by heterodimeric RXR/RAR functional units during mouse development. Kastner P, et al. **Development** 1997 Jan; 124(2):313–26

TGFbeta2 knockout mice have multiple developmental defects that are non–overlapping with other TGFbeta knockout phenotypes. Sanford LP, et al. **Development** 1997 Jul;124(13):2659–70

Maternal origin of inv dup(15) chromosomes in infantile autism. Martinsson T, et al. **Eur Child Adolesc Psychiatry** 1996 Dec;5(4):185–92

Uniparental disomy in cartilage–hair hypoplasia. Sulisalo T, et al. **Eur J Hum Genet** 1997 Jan–Feb;5(1):35–42

An Xp22.1–p22.2 YAC contig encompassing the disease loci for RS, KFSD, CLS, HYP and RP15: refined localization of RS. Van de Vosse E, et al. **Eur J Hum Genet** 1996; 4(2):101–4

Ocular abnormalities in transgenic mice harboring mutations in the type II collagen gene. Ihanamäki T, et al. **Eur J Ophthalmol** 1996 Oct–Dec;6(4):427–35

A case of Duane's retraction syndrome with multiple congenital malformations. Kadayifçilar S, et al. **Eur J Ophthalmol** 1997 Apr–Jun;7(2):193–5

Severe feeding problems and congenital laryngostenosis in a patient with 3q23 deletion. Chandler KE, et al. **Eur J Pediatr** 1997 Aug;156(8):636–8

BMP7 null mutation in mice: developmental defects in skeleton, kidney, and eye. Jena N, et al. **Exp Cell Res** 1997 Jan 10;230(1):28–37

On the phenotypic overlap between "severe" oto–palato digital type II syndrome and Larsen syndrome. Variable manifestation of a single autosomal dominant gene. Alembik Y, et al. **Genet Couns** 1997;8(2):133–7

A collaborative approach to the diagnosis of a lethal short limb skeletal dysplasia. Carvalho L, et al. **Genet Couns** 1997; 8(2):139–43

Partial trisomy 15q: report of a patient and literature review. Chandler K, et al. **Genet Couns** 1997;8(2):91–7 (25 ref.)

Polyhydramnios and paroxysmal atrial tachycardia as first clinical signs in Costello syndrome [letter] Fryns JP, et al. **Genet Couns** 1996;7(3):237–9

The oculo–dento–digital syndrome: male–to–male transmission and variable expression in a family. Ioan DM, et al. **Genet Couns** 1997;8(2):87–90

Caudal developmental field defect with female pseudohermaphroditism and VACTERL anomalies. Lukusa T, et al. **Genet Couns** 1996;7(3):207–12

Brachytelephalangy with mental retardation, peculiar face and short stature in two sibs. A new MCA/MR syndrome? Mégarbané A, et al. **Genet Couns** 1997;8(2):127–32

Short stature, mental retardation and multiple dysmorphisms in two unrelated females: one or two different syndromes or none? Pfeiffer RA, et al. **Genet Couns** 1996;7(3):213–7

Brachydactyly and short stature in a mother and her daughter with a fragile site at 16q22. Stoll C, et al. **Genet Couns** 1997;8(2):115–20

Deafness and Mondini dysplasia in Kabuki (Niikawa–Kuroki) syndrome. Report of a case and review of the literature. Toutain A, et al. **Genet Couns** 1997;8(2):99–105 (40 ref.)

Fountain syndrome: further delineation of the clinical syndrome and follow–up data. Van Buggenhout GJ, et al. **Genet Couns** 1996;7(3):177–86

Kabuki syndrome in son and low grade mosaic 45,X/46,XX in mother. Van Hagen JM, et al. **Genet Couns** 1996; 7(3):201–6 (16 ref.)

A unique genomic sequence in the Wolf–Hirschhorn syndrome [WHS] region of humans is conserved in the great apes. Tarzami ST, et al. **Genetica** 1996 Oct; 98(2):217–9

14–3–3 epsilon has no homology to LIS1 and lies telomeric to it on chromosome 17p13.3 outside the Miller–Dieker syndrome chromosome region. Chong SS, et al. **Genome Res** 1996 Aug;6(8):735–41

A region of mouse chromosome 16 is syntenic to the DiGeorge, velocardiofacial syndrome minimal critical region [published erratum appears in Genome Res 1997 Apr;7(4):399] Galili N, et al. **Genome Res** 1997 Jan; 7(1):17–26

Long–range mapping and construction of a YAC contig within the cat eye syndrome critical region. McDermid HE, et al. **Genome Res** 1996 Dec;6(12):1149–59

Linkage mapping in 29 Bardet–Biedl syndrome families confirms loci in chromosomal regions 11q13, 15q22.3–q23, and 16q21. Bruford EA, et al. **Genomics** 1997 Apr 1; 41(1):93–9

Detection of a megabase deletion in a patient with branchio–oto–renal syndrome (BOR) and tricho–rhino–phalangeal syndrome (TRPS): implications for mapping and cloning the BOR gene. Gu JZ, et al. **Genomics** 1996 Jan 15;31(2):201–6

The genomic structure of the gene defective in Usher syndrome type Ib (MYO7A). Kelley PM, et al. **Genomics** 1997 Feb 15;40(1):73–9

Identification of a new human catenin gene family member (ARVCF) from the region deleted in velo–cardio–facial syndrome. Sirotkin H, et al. **Genomics** 1997 Apr 1; 41(1):75–83

Identification, characterization, and precise mapping of a human gene encoding a novel membrane–spanning protein from the 22q11 region deleted in velo–cardio–facial syndrome. Sirotkin H, et al. **Genomics** 1997 Jun 1; 42(2):245–51

Spherophakia, nanophthalmia, hypoplastic ciliary body and glaucoma in brachydactyly–associated syndromes. Dietlein TS, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug; 234 Suppl 1:S187–92

Trisomy 8 and urogenital malformation in the ACI–rat. Kneidl M, et al. **Hereditas** 1995;123(2):97–101

Apolipoprotein E polymorphism in a French Canadian population of northeastern Quebec: allele frequencies and effects on blood lipid and lipoprotein levels. Robitaille N, et al. **Hum Biol** 1996 Jun;68(3):357–70

Molecular studies in 37 Silver–Russell syndrome patients: frequency and etiology of uniparental disomy. Eggermann T, et al. **Hum Genet** 1997 Sep;100(3–4):415–9

Comparative genomic hybridization reveals a partial de novo trisomy 6q23–qter in an infant with congenital malformations: delineation of the phenotype. Erdel M, et al. **Hum Genet** 1997 May;99(5):596–601

Evidence that skewed X inactivation is not needed for the phenotypic expression of Aicardi syndrome. Hoag HM, et al. **Hum Genet** 1997 Sep;100(3–4):459–64

Nance–Horan syndrome: linkage analysis in 4 families refines localization in Xp22.31–p22.13 region. Toutain A, et al. **Hum Genet** 1997 Feb;99(2):256–61

Quantification by flow cytometry of chromosome–17 deletions in Smith–Magenis syndrome patients. Trask BJ, et al. **Hum Genet** 1996 Dec;98(6):710–8

Congenital anomalies in infants with congenital hypothyroidism: is it a coincidental or an associated finding? Al–Jurayyan NA, et al. **Hum Hered** 1997 Jan–Feb; 47(1):33–7

Progress in the autosomal segmental aneusomy syndromes (SASs): single or multi–locus disorders? Budarf ML, et al. **Hum Mol Genet** 1997;6(10):1657–65 (121 ref.)

A revision of the lissencephaly and Miller–Dieker syndrome critical regions in chromosome 17p13.3. Chong SS, et al. **Hum Mol Genet** 1997 Feb;6(2):147–55

Homozygosity mapping at Alström syndrome to chromosome 2p. Collin GB, et al. **Hum Mol Genet** 1997 Feb;6(2):213–9

Localization of a gene for oculodentodigital syndrome to human chromosome 6q22–q24. Gladwin A, et al. **Hum Mol Genet** 1997 Jan;6(1):123–7

A transcription map of the DiGeorge and velo–cardio–facial syndrome minimal critical region on 22q11. Gong W, et al. **Hum Mol Genet** 1996 Jun;5(6):789–800

Disruption of the clathrin heavy chain–like gene (CLTCL) associated with features of DGS/VCFS: a balanced (21;22)(p12;q11) translocation. Holmes SE, et al. **Hum Mol Genet** 1997 Mar;6(3):357–67

Point mutations and an intragenic deletion in LIS1, the lissencephaly causative gene in isolated lissencephaly sequence and Miller–Dieker syndrome. Lo Nigro C, et al. **Hum Mol Genet** 1997 Feb;6(2):157–64

A gene which causes severe ocular alterations and occipital encephalocele (Knobloch syndrome) is mapped to 21q22.3. Sertié AL, et al. **Hum Mol Genet** 1996 Jun;5(6):843–7

Isolation of a new clathrin heavy chain gene with muscle–specific expression from the region commonly deleted in velo–cardio–facial syndrome. Sirotkin H, et al. **Hum Mol Genet** 1996 May;5(5):617–24

A transcript map of the newly defined 165 kb Wolf–Hirschhorn syndrome critical region. Wright TJ, et al. **Hum Mol Genet** 1997 Feb;6(2):317–24

Neurofibromatosis type I gene mutation in a patient with features of LEOPARD syndrome. Wu R, et al. **Hum Mutat** 1996;8(1):51–6

Genetic evidence that formins function within the nucleus. Chan DC, et al. **J Biol Chem** 1996 Sep 20;271(38):23472–7

Association of hyperprolinaemia type I and heparin cofactor II deficiency with CATCH 22 syndrome: evidence for a contiguous gene syndrome locating the proline oxidase gene. Jaeken J, et al. **J Inherit Metab Dis** 1996;19(3):275–7

A report of a child with a deletion (9)(q34.3): a recognisable phenotype? Ayyash H, et al. **J Med Genet** 1997 Jul; 34(7):610–2 (4 ref.)

Monozygotic twins discordant for Aicardi syndrome. Costa T, et al. **J Med Genet** 1997 Aug;34(8):688–91

Der(22)t(11;22) resulting from a paternal de novo translocation, adjacent 1 segregation, and maternal heterodisomy of chromosome 22. Dawson AJ, et al. **J Med Genet** 1996 Nov;33(11):952–6

A maternally transmitted lethal neonatal progeroid syndrome with prominent genitourinary and gastrointestinal features. Delatycki MB, et al. **J Med Genet** 1997 Jun;34(6):520–4

Precise localisation of 3p25 breakpoints in four patients with the 3p–syndrome. Drumheller T, et al. **J Med Genet** 1996 Oct;33(10):842–7

Neurogenic chronic idiopathic intestinal pseudo–obstruction, patent ductus arteriosus, and thrombocytopenia segregating as an X linked recessive disorder. FitzPatrick DR, et al. **J Med Genet** 1997 Aug;34(8):666–9

Monozygotic twins with 22q11 deletion and discordant phenotypes [letter] Fryer A. **J Med Genet** 1996 Feb; 33(2):173

Evidence for a fourth locus in Usher syndrome type I. Gerber S, et al. **J Med Genet** 1996 Jan;33(1):77–9

Lethal femoral–facial syndrome: a case with unusual manifestations. Gillerot Y, et al. **J Med Genet** 1997 Jun; 34(6):518–9

Five novel mutations in the L1CAM gene in families with X linked hydrocephalus. Gu SM, et al. **J Med Genet** 1996 Feb;33(2):103–6

Amelia, dextrocardia, asplenia, and congenital short bowel in deleted ring chromosome 4. Hou JW, et al. **J Med Genet** 1996 Oct;33(10):879–81

Split hand/split foot malformation, deafness, and mental retardation with a complex cytogenetic rearrangement involving 7q21.3. Ignatius J, et al. **J Med Genet** 1996 Jun; 33(6):507–10

Linkage mapping and phenotypic analysis of autosomal dominant Pallister–Hall syndrome. Kang S, et al. **J Med Genet** 1997 Jun;34(6):441–6

Pitt–Rogers–Danks syndrome and Wolf–Hirschhorn syndrome are caused by a deletion in the same region on chromosome 4p 16.3. Kant SG, et al. **J Med Genet** 1997 Jul;34(7):569–72

X linked hydrocephalus and MASA syndrome. Kenwrick S, et al. **J Med Genet** 1996 Jan;33(1):59–65 (77 ref.)

Miller–Dieker syndrome resulting from rearrangement of a familial chromosome 17 inversion detected by fluorescence in situ hybridisation. Kingston HM, et al. **J Med Genet** 1996 Jan;33(1):69–72

Fine mapping of the dyskeratosis congenita locus in Xq28. Knight SW, et al. **J Med Genet** 1996 Dec;33(12):993–5

Large scale deletions in the GPC3 gene may account for a minority of cases of Simpson–Golabi–Behmel syndrome. Lindsay S, et al. **J Med Genet** 1997 Jun;34(6):480–3

On the genetics of hypodontia and microdontia: synergism or allelism of major genes in a family with six affected members. Lyngstadaas SP, et al. **J Med Genet** 1996 Feb; 33(2):137–42

Currarino triad with a terminal deletion 7q35–>qter. Masuno M, et al. **J Med Genet** 1996 Oct;33(10):877–8

Delineation of 14q32.3 deletion syndrome. Ortigas AP, et al. **J Med Genet** 1997 Jun;34(6):515–7 (18 ref.)

Genetic heterogeneity of Usher syndrome type II in a Dutch population. Pieke–Dahl S, et al. **J Med Genet** 1996 Sep; 33(9):753–7

Jacobsen syndrome: report of a patient with severe eye anomalies, growth hormone deficiency, and

hypothyroidism associated with deletion 11 (q23q25) and review of 52 cases. Pivnick EK, et al. **J Med Genet** 1996 Sep;33(9):772–8 (61 ref.)

Maternal uniparental disomy 7 in Silver–Russell syndrome. Preece MA, et al. **J Med Genet** 1997 Jan;34(1):6–9

Two sibs with Wolf–Hirschhorn and DiGeorge deletions resulting from an unbalanced chromosome rearrangement, 45,XX/XY, der(4)t(4;22) (p16.3;q11.2) mat,–22. Reddy KS, et al. **J Med Genet** 1996 Oct;33(10):852–5

Interstitial deletion, del(4)(q12q21.1), owing to de novo unbalanced translocation in a 2 year old girl: further evidence that the piebald trait maps to proximal 4q12. Schinzel A, et al. **J Med Genet** 1997 Aug;34(8):692–5

Detection of a familial cryptic translocation by fluorescent in situ hybridisation. Smith DP, et al. **J Med Genet** 1996 Jan;33(1):84

Mosaicism for trisomy 3q arising from an unbalanced, de novo t(3;15). Stallings R, et al. **J Med Genet** 1997 Jun; 34(6):512–4

Fried syndrome is a distinct X linked mental retardation syndrome mapping to Xp22. Strain L, et al. **J Med Genet** 1997 Jul;34(7):535–40

Intelligence and psychosocial adjustment in velocardiofacial syndrome: a study of 37 children and adolescents with VCFS. Swillen A, et al. **J Med Genet** 1997 Jun;34(6):453–8

A duplication of distal Xp associated with hypogonadotrophic hypogonadism, hypoplastic external genitalia, mental retardation, and multiple congenital abnormalities. Telvi L, et al. **J Med Genet** 1996 Sep; 33(9):767–71

Nijmegen breakage syndrome. van der Burgt I, et al. **J Med Genet** 1996 Feb;33(2):153–6 (25 ref.)

Mirror hands and feet [letter] van Steensel MA. **J Med Genet** 1997 Aug;34(8):701–2

Lack of evidence for connexin 43 gene mutations in human autosomal recessive lateralization defects. Debrus S, et al. **J Mol Cell Cardiol** 1997 May;29(5):1423–31

De novo terminal deletion of chromosome 7 [46,XX,del(7)(q35)] Lo BH, et al. **J Paediatr Child Health** 1996 Aug;32(4):347–9

Ivemark syndrome with asplenia in siblings. Cesko I, et al. **J Pediatr** 1997 May;130(5):822–4

Standing on the ground at Kitty Hawk [editorial; comment] Goldberg MJ. **J Pediatr Orthop** 1996 Nov–Dec;16(6):701–3 . Comment on: J Pediatr Orthop 1996 Nov–Dec;16(6):704–18. Comment on: J Pediatr Orthop 1996 Nov–Dec;16(6):719–22. Comment on: J Pediatr Orthop 1996 Nov–Dec;16(6):723–6. Comment on: J Pediatr Orthop 1996 Nov–Dec;16(6):727–30. Comment on: J Pediatr Orthop 1996 Nov–Dec;16(6):731–3.

Genetics casebook. Pallister–Killian sindrome. Smulian J, et al. **J Perinatol** 1996 Sep–Oct;16(5):406–12 (13 ref.)

Identification of a subtle chromosomal translocation in a family with recurrent miscarriages and a child with multiple congenital anomalies. A case report. Shaffer LG, et al. **J Reprod Med** 1996 May;41(5):367–71

The role of a single formin isoform in the limb and renal phenotypes of limb deformity. Wynshaw–Boris A, et al. **Mol Med** 1997 Jun;3(6):372–84

Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin–like growth factor I gene [see comments] Woods KA, et al. **N Engl J Med** 1996 Oct 31;335(18):1363–7. Comment in: N Engl J Med 1996 Oct 31;335(18):1389–91.

Mutations in human TBX3 alter limb, apocrine and genital development in ulnar–mammary syndrome. Bamshad M, et al. **Nat Genet** 1997 Jul;16(3):311–5

Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt–Oram syndrome [published erratum appears in Nat Genet 1997 Apr;15(4):411] Basson CT, et al. **Nat Genet** 1997 Jan;15(1):30–5

A novel X–linked gene, DDP, shows mutations in families with deafness (DFN–1), dystonia, mental deficiency and blindness. Jin H, et al. **Nat Genet** 1996 Oct;14(2):177–80

GLI3 frameshift mutations cause autosomal dominant Pallister–Hall syndrome. Kang S, et al. **Nat Genet** 1997 Mar;15(3):266–8

Holt–Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family. Li QY, et al. **Nat Genet** 1997 Jan;15(1):21–9

Mutation of HOXA13 in hand–foot–genital syndrome [see comments] Mortlock DP, et al. **Nat Genet** 1997 Feb; 15(2):179–80. Comment in: Nat Genet 1997 Feb;15(2):117–8.

Cloning and characterization of a novel bicoid–related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Semina EV, et al. **Nat Genet** 1996 Dec; 14(4):392–9

Mutations in the kinase Rsk–2 associated with Coffin–Lowry syndrome. Trivier E, et al. **Nature** 1996 Dec 12; 384(6609):567–70

Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome. Zhang P, et al. **Nature** 1997 May 8; 387(6629):151–8

CRASH syndrome: mutations in L1CAM correlate with severity of the disease. Yamasaki M, et al. **Neuropediatrics** 1997 Jun;28(3):175–8

The ocular phenotype of the Bardet–Biedl syndrome. Comparison to non–syndromic retinitis pigmentosa. Iannaccone A, et al. **Ophthalmic Genet** 1997 Mar; 18(1):13–26

Corneal coloboma, aphakia and retinal neovascularization with anterior segment dysgenesis (Peters' anomaly). Gunderson CA, et al. **Ophthalmologica** 1996;210(6):361–6

Smith–Magenis syndrome [letter; comment] Finucane BM, et al. **Ophthalmology** 1997 May;104(5):732–3. Comment on: Ophthalmology 1996 Jul;103(7):1084–91.

Bifid epiglottis and polydactyly: a new genetic syndrome. McClay JE, et al. **Otolaryngol Head Neck Surg** 1997 Jan; 116(1):129–33

Multiple hepatoblastomas associated with trisomy 18 in a 3–year–old girl. Teraguchi M, et al. **Pediatr Hematol Oncol** 1997 Sep–Oct;14(5):463–7

Bilateral internal carotid artery agenesis in a child with psychomotor developmental delay. Yokochi K, et al. **Pediatr Neurol** 1996 Jul;15(1):76–8

A male fetus with aqueductal stenosis and four accessory spleens. A case report with a tentative genetic explanation. Catala M, et al. **Pediatr Neurosurg** 1996 Jul;25(1):36–40

Molecular analysis of the insulin receptor gene for prenatal diagnosis of leprechaunism in two families. Desbois–Mouthon C, et al. **Prenat Diagn** 1997 Jul; 17(7):657–63

Monosomy X and omphalocele [letter] Govaerts LC, et al. **Prenat Diagn** 1997 Mar;17(3):282

Prenatal and postnatal investigation of a case with Miller–Dieker syndrome due to a familial cryptic translocation t(17;20) (p13.3;q13.3) detected by fluorescence in situ hybridization. van Zelderen–Bhola SL, et al. **Prenat Diagn** 1997 Feb;17(2):173–9

The mouse Pax2(1Neu) mutation is identical to a human PAX2 mutation in a family with renal–coloboma syndrome and results in developmental defects of the brain, ear, eye, and kidney. Favor J, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13870–5

Congenital anomalies in relatives of schizophrenic probands may indicate a retinoid pathology. Goodman AB. **Schizophr Res** 1996 May;19(2–3):163–70

HOX gene links limb, genital defects [news] Dickman S. **Science** 1997 Mar 14;275(5306):1568

Forebrain overgrowth (fog): a new mutation in the mouse affecting neural tube development. Harris BS, et al. **Teratology** 1997 Apr;55(4):231–40

Congenital isolation of the subclavian artery in adults [letter; comment] Reynolds JL. **Tex Heart Inst J** 1997;24(2):146–7 . Comment on: Tex Heart Inst J 1997;24(1):58–61; discussion 61–3.

Retinoic acid teratogenicity in rat congenic and recombinant inbred strains with malformation syndrome. Bílá V, et al. **Transplant Proc** 1997 May;29(3):1707–8

[Smith–Magenis syndrome] Lacombe D, et al. **Arch Pediatr** 1997 May;4(5):438–42 (Eng. Abstr.) **(Fre)**

[Special anesthesiological aspects in patients with Niikawa–Kuroki ("Kabuki Make–Up") syndrome] Wappler F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Mar; 32(3):197–200 (Eng. Abstr.) **(Ger)**

[Prassad syndrome––case report] Sayali E, et al. **Wien Med Wochenschr** 1996;146(12):261–3 (Eng. Abstr.) **(Ger)**

["CHARGE" association] Barak A, et al. **Harefuah** 1997 Feb 16;132(4):254–8, 311 (Eng. Abstr.) **(Heb)**

[PEHO syndrome (progressive encephalopathy, edema, hypsarrhythmia. optic atrophy)] Hollódy K, et al. **Orv Hetil** 1997 Feb 16;138(7):425–8 (7 ref.) (Eng. Abstr.) **(Hun)**

[Cryptorchidism with didymo–epididymal dissociation and Robinow's syndrome: 2 case reports] Fabbro MA, et al. **Pediatr Med Chir** 1997 Mar–Apr;19(2):121–4 (Eng. Abstr.) **(Ita)**

[Partial trisomy of chromosome 13––diagnosis confirmed with the FISH in situ hybridization technique] Obersztyn E, et al. **Pediatr Pol** 1996 Mar;71(3):247–52 (Eng. Abstr.) **(Pol)**

[Marker chromosomes as a product of familial translocation (11;22) identified with molecular cytogenetic methods] Stankiewicz P, et al. **Pediatr Pol** 1996 Mar;71(3):241–5 (Eng. Abstr.) **(Pol)**

[Molecular–genetic characteristics of the deleted region of chromosome 8q24.1 in Langer–Giedion and tricho–rhino–phalangeal type I syndromes] Nemtsova MV, et al. **Genetika** 1996 Jul;32(7):978–84 (Eng. Abstr.) **(Rus)**

[Translocation (2:4)(46 XY, t (2,4) q31–33; q35) associated with Evans' syndrome in a patient with mental retardation and Aarskog–like phenotype] Cañabate Reche F, et al. **An Esp Pediatr** 1997 May;46(5):499–502 **(Spa)**

[High risk for psychosis in velo–cardio–facial sydnrome. Description of symptoms and a case report] Jönsson S, et al. **Lakartidningen** 1997 Jan 29;94(5):329–31 **(Swe)**

HISTORY

Earliest evidence for arthrogryposis multiplex congenita or Larsen syndrome? Anderson T. **Am J Med Genet** 1997 Aug 8;71(2):127–9

METABOLISM

Localization of type II collagen mRNA isoforms in the developing eyes of normal and transgenic mice with a mutation in type II collagen gene. Savontaus M, et al. **Invest Ophthalmol Vis Sci** 1997 Apr;38(5):930–42

PATHOLOGY

Hydrolethalus: a midline malformation syndrome with optic nerve coloboma and hypoplasia. Kivelä T, et al. **Acta Neuropathol (Berl)** 1996;91(5):511–8

Camptomelic dysplasia: report of one case. Tsao PN, et al. **Acta Paediatr Sin** 1996 Sep–Oct;37(5):381–3

Aortic outflow obstruction in visceral heterotaxy: a study based on twenty postmortem cases. Van Praagh S, et al. **Am Heart J** 1997 May;133(5):558–69

Anophthalmia, intracerebral cysts, and cleft lip/palate: expansion of the phenotype in oculocerebrocutaneous syndrome? Angle B, et al. **Am J Med Genet** 1997 Jan 10; 68(1):39–42

Macrocephaly, facial abnormalities, disproportionate tall stature, and mental retardation––a sib observation. Bakker HD, et al. **Am J Med Genet** 1997 Jun 13;70(3):312–4

Omphalocele in Miller–Dieker syndrome: expanding the phenotype. Chitayat D, et al. **Am J Med Genet** 1997 Mar 31;69(3):293–8

Family with branchial arch anomalies, hearing loss, ear and commissural lip pits, and rib anomalies. A new autosomal recessive condition: branchio–oto–costal syndrome? Clementi M, et al. **Am J Med Genet** 1997 Jan 10;68(1):91–3

Microcephaly with agenesis of corticospinal tracts and arthrogryposis, hypospadias, single umbilical artery, hypertelorism, and renal and adrenal hypoplasia––previously undescribed syndrome. Coad JE, et al. **Am J Med Genet** 1997 Sep 5;71(4):458–62

VACTERL with hydrocephalus in twins due to Fanconi anemia (FA): mutation in the FAC gene. Cox PM, et al. **Am J Med Genet** 1997 Jan 10;68(1):86–90

The atrioventricular canal defect is the congenital heart disease connecting short rib–polydactyly and oral–facial–digital syndromes [letter; comment] Digilio MC, et al. **Am J Med Genet** 1997 Jan 10;68(1):110–2. Comment on: Am J Med Genet 1994 Nov 20;59(3):365–8.

Syndrome of microcephaly, facial and hand abnormalities, tracheoesophageal fistula, duodenal atresia, and developmental delay. Feingold M, et al. **Am J Med Genet** 1997 Mar 31;69(3):245–9

Ectodermal dysplasia, cleft lip/palate, and severe cutaneous and osseous syndactyly in a mentally retarded girl: a new multiple malformation syndrome. Freihofer HP, et al. **Am J Med Genet** 1997 Jun 13;70(3):211–5

Lethal multiple pterygium syndrome: suggestion for a consistent pathological workup and review of reported cases. Froster UG, et al. **Am J Med Genet** 1997 Jan 10; 68(1):82–5

Major central nervous system malformation in "micromelic dwarfism with cone epiphyses, metaphyseal dysplasia and vertebral segmentation defects" [letter] Fryns JP. **Am J Med Genet** 1997 Jan 10;68(1):109

Severe facial clefting, limbic dermoid, hypoplasia of the corpus callosum, and multiple skin appendages: severe frontofacionasal "dysplasia" or newly recognised syndrome? al–Gazali LI, et al. **Am J Med Genet** 1996 May 17; 63(2):346–7

Lateral meningocele syndrome: three new patients and review of the literature. Gripp KW, et al. **Am J Med Genet** 1997 Jun 13;70(3):229–39 (11 ref.)

Shprintzen–Goldberg syndrome with osteopenia and progressive hydrocephalus [letter] Hassed S, et al. **Am J Med Genet** 1997 Jun 27;70(4):450–3

Fetal alcohol syndrome: craniofacial and central nervous system manifestations. Johnson VP, et al. **Am J Med Genet** 1996 Feb 2;61(4):329–39

Zimmer phocomelia: delineation by principal coordinate analysis. Kosaki K, et al. **Am J Med Genet** 1996 Dec 2; 66(1):55–9

Elastic fiber degeneration in Costello syndrome. Mori M, et al. **Am J Med Genet** 1996 Feb 2;61(4):304–9

Hirschsprung disease, postaxial polydactyly, and atrial septal defect. Nowaczyk MJ, et al. **Am J Med Genet** 1997 Jan 10;68(1):74–5

Single aberrant umbilical artery in a fetus with severe caudal defects: sirenomelia or caudal dysgenesis. Perez–Aytes A, et al. **Am J Med Genet** 1997 Apr 14;69(4):409–12

The neuroimaging findings in Sotos syndrome. Schaefer GB, et al. **Am J Med Genet** 1997 Feb 11;68(4):462–5

Toriello–Carey syndrome [letter] Till M, et al. **Am J Med Genet** 1997 Jun 13;70(3):332

Six patients with oral–facial–digital syndrome IV: the case for heterogeneity. Toriello HV, et al. **Am J Med Genet** 1997 Mar 31;69(3):250–60

Extended survival in a new case of ter Haar syndrome: further delineation of the syndrome. Wallerstein R, et al. **Am J Med Genet** 1997 Jun 13;70(3):267–72

Cerebellar and brainstem "atrophy" in a patient with Kabuki make–up syndrome [letter] Yano S, et al. **Am J Med Genet** 1997 Sep 5;71(4):486–7

Limb body wall complex: analysis of eight fetuses. Cusí V, et al. **Birth Defects Orig Artic Ser** 1996;30(1):165–70

Postmortem findings in three triploid fetuses. de Ravel TJ, et al. **Birth Defects Orig Artic Ser** 1996;30(1):341–52

Amniotic bands and the EEC syndrome. Guion–Almeida ML, et al. **Birth Defects Orig Artic Ser** 1996;30(1):171–7

Pentalogy of Cantrell: detection through fetal board registry and fetal pathology. Kousseff BG, et al. **Birth Defects Orig Artic Ser** 1996;30(1):189–202

Limb body wall complex: craniofacial defects as a distinctive factor. Russo R, et al. **Birth Defects Orig Artic Ser** 1996; 30(1):157–64 (21 ref.)

Focal facial dermal dysplasia: report of a case with associated cardiac defects. Tay YK, et al. **Br J Dermatol** 1996 Oct; 135(4):607–8

A novel pattern of oculocerebral malformation. Clark BJ, et al. **Br J Ophthalmol** 1997 Jun;81(6):470–5

From the WWW Dysmorphology Discussion Board. Bijlsma E, et al. **Clin Dysmorphol** 1997 Apr;6(2):189–90

Meckel syndrome and Dandy Walker malformation. Al-Gazali LI, et al. **Clin Dysmorphol** 1996 Jan;5(1):73–6

Townes-Brocks syndrome presenting as end stage renal failure. Newman WG, et al. **Clin Dysmorphol** 1997 Jan; 6(1):57–60

Oculo-facio-cardio-dental (OFCD) syndrome [letter] Obwegeser HL, et al. **Clin Dysmorphol** 1997 Jul;6(3):281–3

A new lethal chondrodysplasia with platyspondyly, long bone angulation and mixed bone density. Seller MJ, et al. **Clin Dysmorphol** 1996 Jul;5(3):213–5

Isolated aplasia of the anterior pituitary gland with unusual associations. Sultan Z, et al. **Clin Dysmorphol** 1996 Oct; 5(4):347–50

Heminasal aplasia: a case report and review of the literature of the last 25 years. van Kempen AA, et al. **Clin Dysmorphol** 1997 Apr;6(2):147–52 (32 ref.)

Polyarticular pigmented villonodular synovitis associated with multiple congenital anomalies. A case of Noonan-like/multiple giant cell lesion syndrome. Minisola G, et al. **Clin Exp Rheumatol** 1996 Mar–Apr;14(2):207–10

Report of a new case of axial mesodermal dysplasia complex. Bini R, et al. **Clin Genet** 1996 Nov;50(5):407–10

Ohdo syndrome: report on a Brazilian girl with additional findings. da Silva Lopes VL, et al. **Clin Genet** 1997 Apr; 51(4):268–70

Craniofacial morphology of the tricho-dento-osseous syndrome. Kula K, et al. **Clin Genet** 1996 Dec;50(6):446–54

GAPO syndrome: first Egyptian case with ultrastructural changes in the gingiva. Meguid NA, et al. **Clin Genet** 1997 Aug;52(2):110–5

Histopathology and molecular cytogenetics of a corneal opacity associated with the trisomy 8 mosaic syndrome (46,XY/47,XY, +8). Scott JA, et al. **Cornea** 1997 Jan; 16(1):35–41

Cerebellar hypoplasia in a patient with velo-cardio-facial syndrome. Devriendt K, et al. **Dev Med Child Neurol** 1996 Oct;38(10):949–53

Adrenal glands in anencephaly. Bocian-Sobkowska J, et al. **Folia Morphol (Warsz)** 1996;55(4):214–6

Three siblings with Walker-Warburg Syndrome. Bornemann A, et al. **Gen Diagn Pathol** 1996 May;141(5-6):371–5

"Cutis tricolor": congenital hyper- and hypopigmented macules associated with a sporadic multisystem birth defect: an unusual example of twin spotting? Happle R, et al. **J Med Genet** 1997 Aug;34(8):676–8

Congenital renal tubular dysplasia and skull ossification defects similar to teratogenic effects of angiotensin converting enzyme (ACE) inhibitors. Kumar D, et al. **J Med Genet** 1997 Jul;34(7):541–5

Anal anomalies: an uncommon feature of velocardiofacial (Shprintzen) syndrome? Worthington S, et al. **J Med Genet** 1997 Jan;34(1):79–82

Congenital aphakia: a clinicopathologic report of three cases. Johnson BL, et al. **J Pediatr Ophthalmol Strabismus** 1997 Jan-Feb;34(1):35–9

Dicephalus dipus dibrachius: an unusual case of conjoined twins. Groner JI, et al. **J Pediatr Surg** 1996 Dec; 31(12):1698–700

Oral-facial-digital syndrome type 1 is another dominant polycystic kidney disease: clinical, radiological and histopathological features of a new kindred. Feather SA, et al. **Nephrol Dial Transplant** 1997 Jul;12(7):1354–61

Odontodysplasia, gingival manifestations, and accompanying abnormalities. Fanibunda KB, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jan;81(1):84–8

Clinical and radiographic features of the lacrimo-auriculo-dento-digital syndrome. Murdoch-Kinch CA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jun;81(6):727–35

Linear sebaceous nevus syndrome: report of a patient with unusual associated abnormalities. Palazzi P, et al. **Pediatr Dermatol** 1996 Jan-Feb;13(1):22–4 (16 ref.)

Pena-Shokeir phenotype associated with bilateral opercular polymicrogyria. Hevner RF, et al. **Pediatr Neurol** 1996 Nov;15(4):348–51

Neu-Laxova syndrome: pathological evaluation of a fetus and review of the literature. King JA, et al. **Pediatr Pathol Lab Med** 1995 Jan-Feb;15(1):57–79 (38 ref.)

Prenatal diagnosis of ectrodactyly: the 'lobster claw' anomaly. Leung KY, et al. **Ultrasound Obstet Gynecol** 1995 Dec;6(6):443–6 (16 ref.)

[Iniencephaly: description of a case] Zatterale A, et al. **Pathologica** 1995 Dec;87(6):726–8 (Eng. Abstr.) **(Ita)**

[Pathological study of the kidney and the lung in patients with Potter sequence] Shimada K, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 Jul;88(7):664–9 (Eng. Abstr.) **(Jpn)**

[Temporal bone pathology in neonates with severe visceral anomalies] Koyama S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Aug;99(8):1079–84 (Eng. Abstr.) **(Jpn)**

[Morphologic analysis of congenital central nervous system malformations in children from the first of life dying in the years 1986–1990] Sobaniec-Lotowska M, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):334–6 (Eng. Abstr.) **(Pol)**

[Septo-optic dysplasia: report of 6 patients studied with MR and discussion on its pathogenesis] Ramos Fernández JM, et al. **An Esp Pediatr** 1996 Dec;45(6):614–8 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Hepatic dysfunction in two sibs with Alström syndrome: case report and review of the literature. Awazu M, et al. **Am J Med Genet** 1997 Mar 3;69(1):13–6 (6 ref.)

Costello syndrome: update on the original cases and commentary. [letter] Costello JM. **Am J Med Genet** 1996 Mar 15;62(2):199–201

Acrocallosal syndrome in an Algerian boy born to consanguineous parents: review of the literature and further delineation of the syndrome. Courtens W, et al. **Am J Med Genet** 1997 Mar 3;69(1):17–22

Mulvihill-Smith progeria-like syndrome: a further report with delineation of phenotype, immunologic deficits, and novel observation of fibroblast abnormalities. de Silva DC, et al. **Am J Med Genet** 1997 Mar 3;69(1):56–64 (12 ref.)

VACTERL with hydrocephalus and branchial arch defects: prenatal, clinical, and autopsy findings in two brothers. Froster UG, et al. **Am J Med Genet** 1996 Mar 15; 62(2):169–72

Neurologic anomalies of Perrault syndrome. Gottschalk ME, et al. **Am J Med Genet** 1996 Nov 11;65(4):274–6 (10 ref.)

Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2). Greenberg F, et al. **Am J Med Genet** 1996 Mar 29;62(3):247–54

Apparently new syndrome of congenital cataracts, sensorineural deafness, Down syndrome-like facial appearance, short stature, and mental retardation [see comments] Gripp KW, et al. **Am J Med Genet** 1996 Feb 2;61(4):382–6. Comment in: Am J Med Genet 1997 Jun 13;70(3):333–5.

Extending the spectrum of distal arthrogryposis. Gripp KW, et al. **Am J Med Genet** 1996 Nov 11;65(4):286–90

Further case of Galloway-Mowat syndrome of abnormal gyral patterns and glomerulopathy [letter] Kingo AR, et al. **Am J Med Genet** 1997 Apr 14;69(4):431

Cardio-facio-cutaneous (CFC) syndrome: report of an adult without mental retardation. Manoukian S, et al. **Am J Med Genet** 1996 May 17;63(2):382–5

Novel findings in a patient with Weaver or a Weaver-like syndrome. Scarano G, et al. **Am J Med Genet** 1996 May 17;63(2):378–81

Facio-oculo-acoustico-renal (FOAR) syndrome: case report and review. Schowalter DB, et al. **Am J Med Genet** 1997 Mar 3;69(1):45–9; discussion 44 (7 ref.)

Thomas syndrome: potter sequence with cleft lip/palate and cardiac anomalies. Zlotogora J, et al. **Am J Med Genet** 1996 Mar 29;62(3):224–6

Olfactory loss in Usher syndrome: another sensory deficit? [letter] Zrada SE, et al. **Am J Med Genet** 1996 Sep 6; 64(4):602–3

Visual function in velocardiofacial syndrome. Kok LL, et al. **Aust N Z J Ophthalmol** 1996 May;24(2 Suppl):53–5

Two more diagnostic signs in the Floating-Harbor syndrome. Ala-Mello S, et al. **Clin Dysmorphol** 1996 Jan;5(1):85–8

Short stature, moderate mental retardation, hyperactivity, facial dysmorphism, skeletal abnormalities, and exaggerated ketosis: a new syndrome. Boneh A, et al. **Clin Genet** 1996 Nov;50(5):403–6

Cohen syndrome: the clinical symptoms and stigmata at a young age. Fryns JP, et al. **Clin Genet** 1996 May; 49(5):237–41

Biliary malformation with renal tubular insufficiency in two male infants: third family report. Papadia F, et al. **Clin Genet** 1996 May;49(5):267–70

Branchio-oto (BO) syndrome and oculo-auriculo-vertebral phenotype: overlapping clinical findings in a child from a BO family. Sensi A, et al. **Clin Genet** 1996 Jun;49(6):300–2

Neuroradiology and clinical aspects of Usher syndrome. Tamayo ML, et al. **Clin Genet** 1996 Sep;50(3):126–32

Shwachman syndrome: exocrine pancreatic dysfunction and variable phenotypic expression. Mack DR, et al. **Gastroenterology** 1996 Dec;111(6):1593–602

Linear and whorled nevoid hypermelanosis in a boy with mental retardation and congenital defects. Schepis C, et al. **Int J Dermatol** 1996 Sep;35(9):654–5 (10 ref.)

Megalocornea-mental retardation syndrome: report of a new case. Barišić I, et al. **J Med Genet** 1996 Oct;33(10):882–3

Two sisters with a syndrome of ocular, skeletal, and abdominal abnormalities (OSA syndrome). Mingarelli R, et al. **J Med Genet** 1996 Oct;33(10):884–6

Long-term renal function in the posterior urethral valves, unilateral reflux and renal dysplasia syndrome. Cuckow PM, et al. **J Urol** 1997 Sep;158(3 Pt 2):1004–7

Malpuech facial clefting syndrome in a Japanese boy with cardiac defects. Chinen Y, et al. **Jpn J Hum Genet** 1995 Dec;40(4):335–8

The first neurophysiological evidence for cognitive brain dysfunctions in children with CATCH. Cheour M, et al. **Neuroreport** 1997 May 6;8(7):1785–7

Computerized analysis of behavior in fetuses with congenital abnormalities. Vindla S, et al. **Ultrasound Obstet Gynecol** 1997 May;9(5):302–9

PREVENTION & CONTROL

Ontario Maternal Serum Screening Program: practices, knowledge and opinions of health care providers [see comments] Carroll JC, et al. **Can Med Assoc J** 1997 Mar 15;156(6):775–84. Comment in: Can Med Assoc J 1997 Mar 15;156(6):805–6.

Screening for fetal anomalies: old habits, new challenges [editorial; comment] Evans JA. **Can Med Assoc J** 1997 Mar 15;156(6):805–6. Comment on: Can Med Assoc J 1997 Mar 15;156(6):775–84.

Binge drinking during pregnancy: who are the women at risk? [editorial; comment] Nanson JL. **Can Med Assoc J** 1997 Mar 15;156(6):807–8. Comment on: Can Med Assoc J 1997 Mar 15;156(6):789–94.

PSYCHOLOGY

Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Lachman HM, et al. **Am J Med Genet** 1996 Sep 20;67(5):468–72

Carolyn's feet. Resta RG. **Am J Med Genet** 1997 Oct 3; 72(1):1–2

Total anonychia congenita and microcephaly with normal intelligence: a new autosomal-recessive syndrome? Teebi AS, et al. **Am J Med Genet** 1996 Dec 18;66(3):257–60

Brief report: cognitive and behavioral profiles in persons with Smith-Magenis syndrome. Dykens EM, et al. **J Autism Dev Disord** 1997 Apr;27(2):203–11

Intelligence and psychosocial adjustment in velocardiofacial syndrome: a study of 37 children and adolescents with VCFS. Swillen A, et al. **J Med Genet** 1997 Jun;34(6):453–8

Do couples grieve differently following infant loss? Hunfeld JA, et al. **Psychol Rep** 1996 Oct;79(2):407–10

RADIOGRAPHY

A case of Menkes' syndrome associated with deafness and inferior cerebellar vermian hypoplasia [letter] Aynaci FM, et al. **Acta Paediatr** 1997 Jan;86(1):121–3

Coffin-Siris syndrome: a case of an extremely low birthweight infant with severe kyphoscoliosis. Suzumura H, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):537–40 (5 ref.)

Another "new" form, the palagonia type of acrofacial dysostosis in a Sicilian family. Sorge G, et al. **Am J Med Genet** 1997 Apr 14;69(4):388–94

Simultaneous discovery of bilateral intralobar and extralobar pulmonary sequestrations. Jeanfaivre T, et al. **Ann Thorac Surg** 1997 Apr;63(4):1171–3

Anomalous inferior vena cava associated with horseshoe kidneys. Smith TR, et al. **Clin Imaging** 1996 Oct-Dec; 20(4):276–8

Duodenal atresia and situs inversus: case report. Kiguli-Malwadde E, et al. **East Afr Med J** 1996 Nov; 73(11):769–70

Acrocallosal syndrome: a case report. Bonatz E, et al. **J Hand Surg [Am]** 1997 May;22(3):492–4

Lunatomalacia associated with congenital shortening of the ulna in Langer-Giedion syndrome: a case report. Schuind FA, et al. **J Hand Surg [Am]** 1997 May;22(3):404–7

A case of double outlet left ventricle--a rare congenital heart disease. Guha S, et al. **J Indian Med Assoc** 1996 Mar; 94(3):117–8

A horseshoe adrenal gland in an infant with asplenia. Shafaie FF, et al. **Pediatr Radiol** 1997 Jul;27(7):591–3

Normal modiolus: CT appearance in patients with a large vestibular aqueduct. Lemmerling MM, et al. **Radiology** 1997 Jul;204(1):213–9

[Congenital anotia with hemifacial atrophy (a report of 12 cases)] Yang Z, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 Mar;12(2):119–21 (Eng. Abstr.) **(Chi)**

[Congenital stenosis of the nasal piriform aperture] Merkle E, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Sep;165(3):298–9 **(Ger)**

[The FF complex: a rare congenital malformation] Smilari P, et al. **Pediatr Med Chir** 1997 May-Jun;19(3):215–7 (9 ref.) **(Ita)**

[Scimitar sign in a partially anomalous pulmonary venous drainage] Carrión Valero F, et al. **An Med Interna** 1997 Feb;14(2):86–8 (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Bone scintigraphy of caudal regression syndrome. Nguyen BD, et al. **Clin Nucl Med** 1996 Oct;21(10):802–4

SURGERY

Operative mortality and frequency of coexistent anomalies in interruption of the aortic arch. Powell CB, et al. **Am J Cardiol** 1997 Apr 15;79(8):1147–8

Diagnosis and management of agenesis of the right lung and left pulmonary artery sling. Pu WT, et al. **Am J Cardiol** 1996 Sep 15;78(6):723–7

Laryngeal atresia in the newborn: surgical implications. Hicks BA, et al. **Am J Perinatol** 1996 Oct;13(7):409–11

Nasal dysplasia. de Blécourt RA, et al. **Ann Plast Surg** 1996 Dec;37(6):633–7

One-stage repair of truncus arteriosus, CAVC, and TAPVC. Conte S, et al. **Ann Thorac Surg** 1997 Jun;63(6):1781–3

Tessier 30 median mandibular cleft: case report and literature review. Armstrong AP, et al. **Br J Plast Surg** 1996 Dec;

49(8):536–8 (11 ref.)
Poland's syndrome and vascular malformations. Beer GM, et al. **Br J Plast Surg** 1996 Oct;49(7):482–4
Objective evaluation of the Tajima secondary cleft lip nose correction. Coghlan BA, et al. **Br J Plast Surg** 1996 Oct; 49(7):457–61
Congenital midline palatomandibular bony fusion with a mandibular cleft and a bifid tongue. Rao S, et al. **Br J Plast Surg** 1997 Feb;50(2):139–41
Supernumerary nostrils associated with cleft lip and palate [letter] Umeda T, et al. **Br J Plast Surg** 1996 Oct; 49(7):499–500
Successful early separation of a premature xipho–omphalopagus conjoined twins: a case report. Lai HS, et al. **Can J Surg** 1997 Apr;40(2):139, 141–2 (7 ref.)
Spinal intradural neuroepithelial cyst associated with multiple congenital anomalies in a child. Ceviz A, et al. **Childs Nerv Syst** 1996 Dec;12(12):781–4
Atrioventricular septal defect and tetralogy of Fallot: a 15–year experience. Delius RE, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):171–6
Repair of anomalous connection of the left coronary artery to the pulmonary artery using native aortic and pulmonary tissue flaps. van Son JA, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):322–4
Acute aortic outflow obstruction by diminution of bulboventricular foramen size after volume unloading in univentricular physiology. Van Son JA, et al. **Eur J Cardiothorac Surg** 1996;10(9):809–11
The fate of undescended testes in patients with gastroschisis. Levard G, et al. **Eur J Pediatr Surg** 1997 Jun;7(3):163–5
Laparoscopic–ultrasonographic combined technique for the creation of a neovagina in Mayer–Rokitansky–Kuster–Hauser syndrome. Busacca M, et al. **Fertil Steril** 1996 Dec;66(6):1039–41
Laparoscopic extirpation of an aplastic ectopic uterus in a patient with Mayer–Rokitansky–Küster–Hauser syndrome. Malik E, et al. **Hum Reprod** 1997 Jun;12(6):1298–9
Longitudinal failure of upper–limb formation. Manske PR. **Instr Course Lect** 1997;46:83–110 (95 ref.)
A case of Turner's syndrome associated with partial anomalous pulmonary venous return complicated by dissecting aortic aneurysm and aortic regurgitation. Shiroma K, et al. **J Cardiovasc Surg (Torino)** 1997 Jun; 38(3):257–9
Individualized repair of the left atrioventricular valve in spectrum of atrioventricular septal defect. Tláskal T, et al. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):233–9
Concomitant syndactyly and polydactyly in a pediatric foot. Adler J, et al. **J Foot Ankle Surg** 1997 Mar–Apr;36(2):151–4
Pentalogy of Cantrell corrected by one–stage repair. Chen Y, et al. **J Formos Med Assoc** 1996 Jul;95(7):555–7
Limb ring constriction. Mutsuddi M, et al. **J Indian Med Assoc** 1996 Feb;94(2):82
Segmental spinal dysgenesis: early neurologic deterioration and treatment. Flynn JM, et al. **J Pediatr Orthop** 1997 Jan–Feb;17(1):100–4
A unique presentation of atypical complete duplication of terminal ileum, colon, rectum, and urinary bladder. Gopal SC, et al. **J Pediatr Surg** 1997 Aug;32(8):1250–1
Type IV laryngotracheoesophageal clefts: surgical management for long–term survival. Simpson BB, et al. **J Pediatr Surg** 1996 Aug;31(8):1128–33
Pericardial patch augmentation of restrictive innominate vein and division of left superior vena cava in unroofed coronary sinus syndrome. van Son JA, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):132–4
The genetic male with absent penis and urethrorectal communication: experience with 5 patients. Hendren WH. **J Urol** 1997 Apr;157(4):1469–74
Management of ectopic ureters: experience with the upper tract approach. Plaire JC, et al. **J Urol** 1997 Sep;158(3 Pt 2):1245–7 (11 ref.)
Reconstruction of the high urogenital sinus: early perineal prone approach without division of the rectum. Rink RC, et al. **J Urol** 1997 Sep;158(3 Pt 2):1293–7
Double uterus, blind hemivagina, and ipsilateral renal agenesis: 36 cases and long–term follow–up. Candiani GB, et al. **Obstet Gynecol** 1997 Jul;90(1):26–32
Association of ambiguous genitalia with VATER anomalies [letter] Ozbey H, et al. **Pediatr Surg Int** 1997 Feb; 12(2–3):230
Cardiopulmonary bypass venous cannulation challenges in a paediatric patient with complex congenital heart disease: a case report. Manzer R, et al. **Perfusion** 1997 May; 12(3):203–6
Ivemark syndrome. A case with successful surgical intervention. Tkebuchava T, et al. **Scand Cardiovasc J** 1997; 31(3):173–5 (8 ref.)
Congenital multiple intestinal atresia successfully treated with multiple anastomoses in a premature neonate: report of a case. Hasegawa T, et al. **Surg Today** 1996;26(10):849–51 (17 ref.)
A rare case of mixed type total anomalous pulmonary venous connection and its surgical treatment. Sarioğlu T, et al. **Thorac Cardiovasc Surg** 1997 Jun;45(3):152–4
[Vesico–amniotic shunt–therapy in fetal obstructive uropathy] Nguyen TH, et al. **Ugeskr Laeger** 1996 Sep 23; 158(39):5463–4 (Eng. Abstr.) **(Dan)**
[Aortopulmonary window: influence of associated cardiovascular lesions on surgical management] Elami A, et al. **Harefuah** 1996 Jul;131(1–2):1–3, 72 (Eng. Abstr.) **(Heb)**
[Successful management of malum perforans resulting from spina bifida (see comments)] Somogyi T, et al. **Orv Hetil** 1997 Mar 2;138(9):547–50 (Eng. Abstr.). Comment in: Orv Hetil 1997 Jul 13;138(28):1833. **(Hun)**
[Difficult tracheal intubation and abnormal response to thiopental in a patient with arthrogryposis multiplex congenita] Kimura F, et al. **Masui** 1996 Aug;45(8):1022–5 (Eng. Abstr.) **(Jpn)**
[Conjoined twins—diagnostic and therapeutic strategies] Szymula J, et al. **Ginekol Pol** 1996 Jul;67(7):370–3 (Eng. Abstr.) **(Pol)**
[A modified method for the surgical treatment of patients with maxillary retro– and micrognathism] Bezrukov VM, et al. **Stomatologiia (Mosk)** 1996;75(2):49–51 (Eng. Abstr.) **(Rus)**
[First experience with the surgical treatment of young infants with congenital pathology of the locomotor system] Baindurashvili AG, et al. **Vestn Khir Im I I Grek** 1996; 155(4):41–4 (Eng. Abstr.) **(Rus)**
[Surgery of the elongated styloid syndrome] Miyar V, et al. **An Otorrinolaringol Ibero Am** 1997;24(3):303–9 (Eng. Abstr.) **(Spa)**
[Surgical treatment of Fallot's tetralogy with hyperplasia or agenesis of the conal septum] Cordovilla Zurdo G, et al. **Rev Esp Cardiol** 1997 Apr;50(4):262–7 (Eng. Abstr.) **(Spa)**

THERAPY

Use of Palmaz stents to palliate pulmonary atresia with ventricular septal defect and stenotic aortopulmonary collaterals. Vance MS. **Cathet Cardiovasc Diagn** 1997 Apr; 40(4):387–9
Multiple congenital synostosis of the upper limb associated with ulnar hypoplasia and cleft hand. A case report. Sahoo MM, et al. **Int Orthop** 1996;20(2):117–8
Multiple congenital contractures. Vanpaemel L, et al. **J Pediatr Orthop B** 1997 Jul;6(3):172–8
[Single umbilical artery. Management] Riethmuller D, et al. **Contracept Fertil Sex** 1997 Jan;25(1):I–III **(Fre)**
[The Pallister–Hall syndrome—a rare case and an example of the differentiated approach to the treatment of hormonally inactive hypothalamic hamartomas] Ozerov SS, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1997 Jan–Mar;(1):40–2 (6 ref.) **(Rus)**

ULTRASONOGRAPHY

Cleft lip and palate associated with malformation of the central nervous system: a prospective neurosonographic study. Shen EY, et al. **Acta Paediatr Sin** 1996 Jan–Feb; 37(1):39–44
Prenatal diagnosis and perinatal aspects of abdominal wall defects. Chen CP, et al. **Am J Perinatol** 1996 Aug; 13(6):355–61
Ultrasonic demonstration of ectopic urethral ureter in duplex kidney: report of two cases. Cheng SW, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1997 Mar–Apr;38(2):149–51
Meckel–Gruber syndrome concomitant with Dandy–Walker malformation: prenatal sonographic diagnosis in two cases. Yapar EG, et al. **Clin Dysmorphol** 1996 Oct;5(4):357–62
Cystic dysplasia of the testis with ipsilateral renal agenesis. A case report and review of the literature. Bonnet JP, et al. **Eur J Pediatr Surg** 1997 Feb;7(1):57–9
Antenatal diagnosis of Grebe syndrome in a twin pregnancy by ultrasound. Kulkarni ML, et al. **Indian Pediatr** 1995 Sep; 32(9):1007–11 (7 ref.)
Ultrasonographic detection of single umbilical artery: a simple marker of fetal anomaly. Sener T, et al. **Int J Gynaecol Obstet** 1997 Aug;58(2):217–21
Prenatal diagnosis with ultrasound of anomalous course of the umbilical vein and its relationship to fetal outcome. Kinare AS, et al. **J Clin Ultrasound** 1996 Sep;24(7):333–8
Bilateral ureteral atresia. Madjar S, et al. **J Perinatol** 1997 Mar–Apr;17(2):166–7
Congenital bladder perforation and urinary ascites caused by posterior urethral valves: a case report. Sahdev S, et al. **J Perinatol** 1997 Mar–Apr;17(2):164–5
MURCS association: ultrasonographic findings and pathologic correlation. Fernandez CO, et al. **J Ultrasound Med** 1996 Dec;15(12):867–70
Antenatal sonographic detection of cerebral white matter necrosis. Hill LM. **J Ultrasound Med** 1997 May; 16(5):377–80
A case of fetal decapitation. Shipp TD, et al. **J Ultrasound Med** 1996 Jul;15(7):535–7
Prenatal sonographic features of Russell–Silver syndrome. Wax JR, et al. **J Ultrasound Med** 1996 Mar;15(3):253–5
Prenatal ultrasound abnormalities in a patient with generalized neurofibromatosis type 1. Drouin V, et al. **Neuropediatrics** 1997 Apr;28(2):120–1
Beta haemolytic streptococcal infection does not cause right diaphragmatic eventration. Jain M, et al. **Pediatr Surg Int** 1997 Feb;12(2–3):188–9
Diagnostic echographic findings in cryptophthalmos syndrome (Fraser syndrome). Fryns JP, et al. **Prenat Diagn** 1997 Jun;17(6):582–4
Prenatal and postnatal investigation of a case with Miller–Dieker syndrome due to a familial cryptic translocation t(17;20) (p13.3;q13.3) detected by fluorescence in situ hybridization. van Zelderen–Bhola SL, et al. **Prenat Diagn** 1997 Feb;17(2):173–9
Giant megalo–ureter and duplex kidney in an asymptomatic adult. Balén EM, et al. **Scand J Urol Nephrol** 1997 Aug; 31(4):413–6
Nonimmune fetal hydrops: diagnosis and obstetrical management. Jones DC. **Semin Perinatol** 1995 Dec; 19(6):447–61
Early sonographic diagnosis of Jarcho–Levin syndrome: a prospective screening program in one family. Eliyahu S, et al. **Ultrasound Obstet Gynecol** 1997 May;9(5):314–8
Cerebro–costo–mandibular syndrome: early sonographic prenatal diagnosis. Ibba RM, et al. **Ultrasound Obstet Gynecol** 1997 Aug;10(2):142–4
[Single umbilical artery. Management] Riethmuller D, et al. **Contracept Fertil Sex** 1997 Jan;25(1):I–III **(Fre)**
[Meckel syndrome. Update on a recurrent case] Calmelet P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997; 26(4):435–41 (35 ref.) (Eng. Abstr.) **(Fre)**
[Congenital adenomatoid cystic malformation of the lung and renal polycystosis. A fetal case report and review of the literature] Jamet F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):193–6 (11 ref.) (Eng. Abstr.) **(Fre)**
[Anomalies of umbilical vein in the fetus. A case report and review of the literature] Tordjeman N, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):495–9 (18 ref.) (Eng. Abstr.) **(Fre)**
[Limb–body wall malformation complex: an unusual developmental abnormality of the abdominal wall. Case report, clinicopathological and etiological implications (see comments)] Cserni G, et al. **Orv Hetil** 1997 Apr 13; 138(15):931–7 (26 ref.) (Eng. Abstr.). Comment in: Orv Hetil 1997 Aug 24;138(34):2157. **(Hun)**
[Conjoined twins—diagnostic and therapeutic strategies] Szymula J, et al. **Ginekol Pol** 1996 Jul;67(7):370–3 (Eng. Abstr.) **(Pol)**

VETERINARY

Ovine fetal malformations induced by in utero inoculation with Main Drain, San Angelo, and LaCrosse viruses. Edwards JF, et al. **Am J Trop Med Hyg** 1997 Feb; 56(2):171–6
What is your diagnosis? Retinal dysplasia with concurrent developmental skeletal abnormalities in a Labrador retriever. Cook JL, et al. **J Am Vet Med Assoc** 1997 Feb 1;210(3):329–30
Characterization and mapping of the mouse NDP (Norrie disease) locus (Ndp). Battinelli EM, et al. **Mamm Genome** 1996 Feb;7(2):93–7
A dicephalic goat with other defects. Ramadan RO. **Zentralbl Veterinarmed A** 1996 Aug;43(6):337–43

VIROLOGY

Detection of varicella–zoster virus in congenital varicella syndrome: a case report. Sauerbrei A, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):687–9

ABNORMALITIES, RADIATION–INDUCED

Ten years after Chernobyl. Rytömaa T. **Ann Med** 1996 Apr; 28(2):83–7 (48 ref.)
The effect of pulsed and sinusoidal magnetic fields on the morphology of developing chick embryos. Farrell JM, et al. **Bioelectromagnetics** 1997;18(6):431–8
Leukaemia near La Hague nuclear plant. Deformed insects have been found near nuclear plants [letter; comment] Hesse–Honegger C. **BMJ** 1997 May 24;314(7093):1554–5. Comment on: BMJ 1997 Jan 11;314(7074):101–6.
Heritable malformations in the progeny of the male medaka (Oryzias latipes) irradiated with X–rays. Ishikawa Y, et al. **Mutat Res** 1997 Mar 17;389(2–3):149–55
The embryonic and fetal effects in ICR mice irradiated in the various stages of the preimplantation period. Gu Y, et al. **Radiat Res** 1997 Jun;147(6):735–40

EMBRYOLOGY

Malformations after radiation exposure of preimplantation stages. Streffer C, et al. **Int J Dev Biol** 1996 Feb; 40(1):355–60

EPIDEMIOLOGY

Birth prevalence of congenital malformations in Bavaria, Germany, after the Chernobyl accident. Irl C, et al. **Eur J Epidemiol** 1995 Dec;11(6):621–5
Chernobyl, low–dose radiation, and trisomy 21: possibly something to worry about. von Mühlendahl KE, et al. **Eur J Pediatr** 1996 Jul;155(7):612–4

ETIOLOGY

Radiation exposure and the pregnant patient. Berlin L. **AJR Am J Roentgenol** 1996 Dec;167(6):1377–9

GENETICS

Genetic analysis of the cause of gastroschisis in the HLG mouse strain. Hillebrandt S, et al. **Mutat Res** 1996 Nov 11;372(1):43–51
A genetic characterization of differences in the sensitivity to radiation–induced malformation frequencies in the mouse strains Heiligenberger, C57BI, and Heiligenberger

x C57Bl. Muller WU, et al. **Radiat Environ Biophys** 1996 Feb;35(1):37–40

PREVENTION & CONTROL

Radiotherapy for Hodgkin's disease in pregnancy (editorial) [letter; comment] Leung JT, et al. **Australas Radiol** 1997 Feb;41(1):84–5. Comment on: Australas Radiol 1996 May;40(2):101–3.

ABO BLOOD-GROUP SYSTEM

Schistosomiasis infection in relation to the ABO blood groups among school children in Zimbabwe. Ndamba J, et al. **Acta Trop** 1997 May 30;65(3):181–90

Helicobacter pylori infection and blood groups [letter; comment] Carneiro F, et al. **Am J Gastroenterol** 1996 Dec; 91(12):2646–7. Comment on: Am J Gastroenterol 1996 Jan;91(1):101–4.

Characterization of coffea canephora alpha-D-galactosidase blood group B activity. Phillips R, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1996 Sep; 24(5):489–502

ABO incompatible renal transplantation: a chance to re-examine? Mackie FE, et al. **Aust N Z J Med** 1996 Dec; 26(6):824–6

Blood group B glycosphingolipids in alpha-galactosidase deficiency (Fabry disease): influence of secretor status. Ledvinová J, et al. **Biochim Biophys Acta** 1997 Apr 1; 1345(2):180–7

Intravenous immune globulin in neonatal ABO isoimmunization: factors associated with clinical efficacy. Hammerman C, et al. **Biol Neonate** 1996;70(2):69–74

ABO blood groups and salivary gland tumors (Alabama, United States). Pinkston JA, et al. **Cancer Causes Control** 1996 Nov;7(6):572–4

Blood groups Lewis(b) and ABH expression in gastric mucosa: lack of inter-relation with Helicobacter pylori colonisation and occurrence of gastric MALT lymphoma. Oberhuber G, et al. **Gut** 1997 Jul;41(1):37–42

Massive delayed hemolysis following peripheral blood stem cell transplantation with minor ABO incompatibility. Laurencet FM, et al. **Hematol Cell Ther** 1997 Jun; 39(3):159–62

Simultaneous expression of keratan sulphate epitope (a sulphated poly-N-acetyllactosamine) and blood group ABH antigens in papillary carcinomas of the human thyroid gland. Ito N, et al. **Histochem J** 1996 Sep;28(9):613–23

Distribution of three genetic markers and malaria in other backward castes of Kheda district, Gujarat. Pant CS, et al. **Indian J Malariol** 1997 Mar;34(1):42–6

Modification of blood group A expression in human pancreatic tumor cell lines by inhibitors of N-glycan processing. Schaffert C, et al. **Int J Pancreatol** 1997 Feb; 21(1):21–9

Purification and characterization of blood group A-degrading isoforms of alpha-N-acetylgalactosaminidase from Ruminococcus torques strain IX-70. Hoskins LC, et al. **J Biol Chem** 1997 Mar 21;272(12):7932–9

Expression of human H-type alpha1,2-fucosyltransferase encoding for blood group H(O) antigen in Chinese hamster ovary cells. Evidence for preferential fucosylation and truncation of polylactosamine sequences. Prieto PA, et al. **J Biol Chem** 1997 Jan 24;272(4):2089–97

Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype. Chaim W, et al. **J Infect Dis** 1997 Sep;176(3):828–30

ABO blood groups in relation to the infection rate of dermatophytosis. Balajee SA, et al. **Mycoses** 1996 Nov-Dec;39(11-12):475–8

Blood-type and age affect human plasma levels of histidine-rich glycoprotein in a large population. Drasin T, et al. **Thromb Res** 1996 Nov 1;84(3):179–88

Presence of glycosyltransferase inhibitors in the sera of patients with long-term surviving ABO incompatible (A2 to O) kidney grafts. Rydberg L, et al. **Transfus Med** 1991 Sep;1(3):177–82

Detection of acquired B antigen by monoclonal anti-B blood grouping reagents [letter] Case J, et al. **Transfusion** 1997 Jan;37(1):105

Detection of acquired B antigen by monoclonal anti-B blood grouping reagents [letter] Cummings E, et al. **Transfusion** 1997 Jan;37(1):105–6

Detection of acquired B antigen by monoclonal anti-B blood grouping reagents [letter] Epstein JS. **Transfusion** 1997 Jan; 37(1):103–5

Detection of acquired B antigen by monoclonal anti-B blood grouping reagents [letter] Scott ML, et al. **Transfusion** 1997 Jan;37(1):103

Removal of ABO-incompatible red cells from lymphocytapheresis and granulocytapheresis components before transfusion. Wuest DL, et al. **Transfusion** 1997 Feb; 37(2):144–9

Cross-matching in liver transplantation. Donaldson PT, et al. **Transplantation** 1997 Mar 27;63(6):789–94 (65 ref.)

Relationship between ABO blood group and levels of Gal alpha,3Galactose-reactive human immunoglobulin G. McMorrow IM, et al. **Transplantation** 1997 Aug 15; 64(3):546–9

[A case of renal transplantation from an ABO-incompatible donor successfully pretreated with double filtration plasmapheresis] Hirano Y, et al. **Hinyokika Kiyo** 1996 Nov; 42(11):887–90 (Eng. Abstr.) **(Jpn)**

[A puerperal woman received massive ABO-incompatible blood transfusion: a case report rescued by exchange transfusion therapy] Fujiki Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jul;48(7):533–6 **(Jpn)**

ANALYSIS

Lewis, secretor, and ABO phenotypes, and sulfomucin expression in gastric intestinal metaplasia. Torrado J, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Apr;6(4):287–9

Ultrastructural localization of blood group antigens in human salivary glands. Cossu M, et al. **Eur J Morphol** 1996 Aug; 34(3):191–5

Change in blood group phenotype. Balachandran V, et al. **J Indian Med Assoc** 1996 Apr;94(4):151, 153

An explanation and the clinical significance of the failure of microcolumn tests to detect weak ABO and other antibodies. Phillips P, et al. **Transfus Med** 1997 Mar; 7(1):47–53

Evidence for an expression of blood group A antigen on platelet glycoproteins IV and V. Stockelberg D, et al. **Transfus Med** 1996 Sep;6(3):243–8

Citrate-dependent auto-antibody causing error in blood grouping. Joshi SR. **Vox Sang** 1997;72(4):229–32

[Subcellular localization of blood group substances ABH in human gastrointestinal tracts] Li R, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Feb; 18(1):49–53 (Eng. Abstr.) **(Chi)**

[Suitability of monoclonal reagents in determination of ABO blood group of newborn infants] Strobel E. **Infusionsther Transfusionsmed** 1996 Jun;23(3):138–42 (Eng. Abstr.) **(Ger)**

[The detection of ABO system antigens in bone, nail and tooth fragments] Gurtovaia SV, et al. **Sud Med Ekspert** 1996 Oct-Dec;39(4):23–5 (Eng. Abstr.) **(Rus)**

[Natural antibodies to the ABO(H)-system antigens in the blood serum of chickens (a preliminary report)] Kolokolova GP, et al. **Sud Med Ekspert** 1996 Jul-Sep;39(3):32–4 (Eng. Abstr.) **(Rus)**

[The complex detection of AB(O)-system antigens and of keratin polymorphism in the forensic medical study of hair] Kukhar'kov IuV, et al. **Sud Med Ekspert** 1997 Jan-Mar; 40(1):31–3 (Eng. Abstr.) **(Rus)**

[The determination of the group classification of sperm by the ABO system by means of the immunofluorescence reaction in a quantitative modification] Sidorov VL, et al. **Sud Med Ekspert** 1996 Oct-Dec;39(4):47–8 (Eng. Abstr.) **(Rus)**

[The group specificity of the sweat and fat excretions from the skin of the hands] Smetanina NI, et al. **Sud Med Ekspert** 1996 Jul-Sep;39(3):35–6 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Biosynthesis of a blood group H1 antigen by alpha 1, 2-fucosyltransferase in PC12 cells. Kojima H, et al. **Glycoconj J** 1996 Jun;13(3):445–52

Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts. Minato H, et al. **Histopathology** 1996 May; 28(5):411–9

BLOOD

ABO blood group and Achilles tendon rupture. Leppilahti J, et al. **Ann Chir Gynaecol** 1996;85(4):369–71

The activity of a blood type B specific exoglycosidase from Glycine max. Hobbs L, et al. **Clin Chim Acta** 1996 Mar 29;247(1-2):7–21

The Oka blood group antigen is a marker for the M6 leukocyte activation antigen, the human homolog of OX-47 antigen, basigin and neurothelin, an immunoglobulin superfamily molecule that is widely expressed in human cells and tissues. Spring FA, et al. **Eur J Immunol** 1997 Apr;27(4):891–7

ABO, Rh and Kell frequency distribution in a sample population of Terni province, Italy. Cassetti M, et al. **Hum Hered** 1996 Jul-Aug;46(4):205–10

Leukocyte phenotypic changes in an in vitro model of ABO hemolytic transfusion reaction. Udani M, et al. **Transfusion** 1997 Sep;37(9):904–9

[The level of alcohol and titre of A and B group substances of the ABO system in blood samples infected by some strains of Escherichia coli] Kurzejamska-Parafiniuk M. **Ann Acad Med Stetin** 1996;42:85–104 (Eng. Abstr.) **(Pol)**

[The role of genetically determined blood system markers in the development of humoral immunity disorders in those who worked in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Pavliuk RP, et al. **Lik Sprava** 1996 Jul-Sep;(7-9):44–7 (Eng. Abstr.) **(Ukr)**

CHEMISTRY

Hemagglutinins in fungus extracts and their blood group specificity. Furukawa K, et al. **Exp Clin Immunogenet** 1995; 12(4):223–31

Structural characterization of blood group A glycosphingolipids recognized by the antibody 3G9-A. Briggs JB, et al. **Glycoconj J** 1996 Jun;13(3):487–94

Microscale analysis of glycosphingolipids by TLC blotting/secondary ion mass spectrometry: a novel blood group A-active glycosphingolipid and changes in glycosphingolipid expression in rat mammary tumour cells with different metastatic potentials. Kasama T, et al. **Glycoconj J** 1996 Jun;13(3):461–9

CLASSIFICATION

A unique and sensitive ELISA technique for typing ABH antigens in bloodstains using UEA-I lectin—the removal of detergent with a Sephadex G-25 mini-column improves sensitivity [retracted by Kimura K, Matsubara K. In: J Forensic Sci 1996 Nov;41(6):1085] Matsubara K, et al. **J Forensic Sci** 1996 Jan;41(1):35–9

GENETICS

Blood type AB in the feline AB blood group system. Griot-Wenk ME, et al. **Am J Vet Res** 1996 Oct; 57(10):1438–42

Racial heterogeneity of DNA polymorphisms linked to the A and the O alleles of the ABO blood group gene. Zago MA, et al. **Ann Hum Genet** 1996 Jan;60 (Pt 1):67–72

Missense mutation of FUT1 and deletion of FUT2 are responsible for Indian Bombay phenotype of ABO blood group system. Koda Y, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):21–5

Molecular analysis of the O alleles at the blood group ABO locus in populations of different ethnic origin reveals novel crossing-over events and point mutations. Olsson ML, et al. **Biochem Biophys Res Commun** 1997 May 29; 234(3):779–82

Molecular genetic analysis of variant phenotypes of the ABO blood group system. Ogasawara K, et al. **Blood** 1996 Oct 1;88(7):2732–7

Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility. Mehta J, et al. **Bone Marrow Transplant** 1996 Jul;18(1):151–6

Lack of association between ABO blood groups and Rh factor and the tendency to develop mycetoma [letter] Fahal AH, et al. **East Afr Med J** 1996 Nov;73(11):771

ABO genotyping by mutagenically separated polymerase chain reaction. Lee JC, et al. **Forensic Sci Int** 1996 Oct 25;82(3):227–32

Distribution of AB0 and Lewis blood groups in Greece. Kremastinou J, et al. **Gene Geogr** 1996 Dec;10(3):201–5

Geographic variation analysis of the ABO and RH systems in Turkey. Onde S, et al. **Gene Geogr** 1995 Dec;9(3):211–20

The distribution of the ABO and Rhesus blood groups (phenotype and allele frequencies) in the populations of Cyprus. Poumpouridou A, et al. **Gene Geogr** 1995 Dec; 9(3):197–205

Gene differentiation at the AB0, MN and Rhesus loci among Albanians and their relation with other Balkanic populations. Susanne C, et al. **Gene Geogr** 1996 Apr; 10(1):31–6

ABO genotyping in Italian blood donors. Villa A, et al. **Haematologica** 1996 Nov-Dec;81(6):492–6

A de novo recombination in the ABO blood group gene and evidence for the occurence of recombination products. Suzuki K, et al. **Hum Genet** 1997 Apr;99(4):454–61

Amplified product length polymorphism (APLP): a novel strategy for genotyping the ABO blood group. Watanabe G, et al. **Hum Genet** 1997 Jan;99(1):34–7

A rapid and reliable PCR method for genotyping the ABO blood group. II: A2 and O2 alleles. O'Keefe DS, et al. **Hum Mutat** 1996;8(4):358–61

Frequencies of the blood groups ABO, Rhesus, D category VI, Kell, and of clinically relevant high-frequency antigens in south-western Germany. Wagner FF, et al. **Infusionsther Transfusionsmed** 1995 Oct;22(5):285–90

Genotyping of the ABO blood group system: analysis of nucleotide position 802 by PCR-RFLP and the distribution of ABO genotypes in a German population. Nishimukai H, et al. **Int J Legal Med** 1996;109(2):90–3

ABO genotyping following a single PCR amplification. Akane A, et al. **J Forensic Sci** 1996 Mar;41(2):272–4

A simplified amplification procedure for two regions of the glycosyl transferase (ABO blood group) gene. Herrin G Jr. **J Forensic Sci** 1996 Jan;41(1):138–41

A PCR-based strategy for ABO genotype determination. Ladd C, et al. **J Forensic Sci** 1996 Jan;41(1):134–7

ABO genotyping of suspects from sperm DNA isolated from postcoital samples in sex crimes. Sasaki M, et al. **J Forensic Sci** 1996 Mar;41(2):275–8

Rapid and clear detection of ABO genotypes by simultaneous PCR-RFLP method. Tun Z, et al. **J Forensic Sci** 1996 Nov;41(6):1027–30

The extension coat color locus and the loci for blood group O and tyrosine aminotransferase are on pig chromosome 6. Mariani P, et al. **J Hered** 1996 Jul-Aug;87(4):272–6

Evolution of primate ABO blood group genes and their homologous genes. Saitou N, et al. **Mol Biol Evol** 1997 Apr;14(4):399–411

Genotyping of ABO blood group system by PCR and RFLP on mummies discovered at Taklamakan desert in 1912. Lin Z, et al. **Nippon Hoigaku Zasshi** 1996 Oct;50(5):336–42

ABO genotyping by PCR-direct sequencing. Nata M, et al. **Nippon Hoigaku Zasshi** 1997 Feb;51(1):1–5

Rapid detection of the cisAB allele consisting of a chimera of normal A and B alleles by PCR-RFLPs. Fukumori Y, et al. **Transfus Med** 1996 Dec;6(4):337–44

ABO BLOOD-GROUP SYSTEM

Absence of the G871A mutation in A3 blood donors from Brazil [letter] Barjas-Castro ML, et al. **Transfusion** 1997 May;37(5):564

Frequent occurrence of a variant O1 gene at the blood group ABO locus. Olsson ML, et al. **Vox Sang** 1996;70(1):26-30

Evidence for a new type of O allele at the ABO locus, due to a combination of the A2 nucleotide deletion and the Ael nucleotide insertion. Olsson ML, et al. **Vox Sang** 1996; 71(2):113-7

Two missense mutations of H type alpha(1,2)fucosyltransferase gene (FUT1) responsible for para-Bombay phenotype [published erratum appears in Vox Sang 1997;72(3):147] Wang B, et al. **Vox Sang** 1997; 72(1):31-5

Heterogeneity of the human H blood group alpha(1,2)fucosyltransferase gene among para-Bombay individuals. Yu LC, et al. **Vox Sang** 1997;72(1):36-40

Spatial autocorrelation analysis reveals that A, B and O allele frequency surfaces on the Indian subcontinent are highly fractured. Mukherjee BN, et al. **Z Morphol Anthropol** 1995 Dec;81(1):33-9

[Application of stochastical analysis to maternity testing without putative mother] Nata M, et al. **Nippon Hoigaku Zasshi** 1997 Feb;51(1):6-10 (Eng. Abstr.) **(Jpn)**

[Personal identification using DNA polymorphism--the identification of forensic biological materials] Shiono H. **Nippon Hoigaku Zasshi** 1996 Oct;50(5):320-30 (Eng. Abstr.) **(Jpn)**

[DNA analysis of a case of so-called blood group chimerism] Tsuji A, et al. **Nippon Hoigaku Zasshi** 1996 Feb;50(1):17-22 (Eng. Abstr.) **(Jpn)**

[Direct determination of ABO and cisAB blood group genotypes using polymerase chain reaction amplification of specific alleles (PASA)--method] Hosoi E. **Rinsho Byori** 1996 Aug;44(8):783-90 (Eng. Abstr.) **(Jpn)**

[Genetic analyses of the ABO blood groups and application of the clinical laboratories] Hosoi E. **Rinsho Byori** 1997 Feb;45(2):148-56 (Eng. Abstr.) **(Jpn)**

[Blood genotyping of patients with ABO-group transformations in hematologic disorders] Iwasaki M, et al. **Rinsho Ketsueki** 1996 Feb;37(2):116-22 (Eng. Abstr.) **(Jpn)**

[Retrospective estimation of the frequency of heterozygous beta-thalassemia in the Crimean Tartar population. Formulation of the problem. Estimation of the gametic contribution to a mixed population from frequencies of the ABO blood group genes] Asanov AIu, et al. **Genetika** 1996 Dec;32(12):1683-6 (Eng. Abstr.) **(Rus)**

[Genetic markers of the ABO blood system in pulmonary sarcoidosis patients of different ethnic origin] Volkova KI, et al. **Klin Med (Mosk)** 1996;74(8):44-6 (Eng. Abstr.) **(Rus)**

HISTORY

Early observations about the ABO blood groups. Widmann FK. **Transfusion** 1997 Jun;37(6):665-7

IMMUNOLOGY

Effect of medium composition on hybridoma growth and antibody production. Hencsey Z, et al. **Acta Microbiol Immunol Hung** 1996;43(4):359-70

Fetal ascites associated with ABO incompatibility: case report and review of the literature. Stiller RJ, et al. **Am J Obstet Gynecol** 1996 Nov;175(5):1371-2

ABH and related histo-blood group antigens in normal & malignant human endometrium in relation to genetic and hormonal factors. Skovlund VR. **APMIS Suppl** 1997; 69:1-33

ABO blood group incompatibility in liver transplantation: a single-centre experience. Chui AK, et al. **Aust N Z J Surg** 1997 May;67(5):275-8

Kinetics and locus of failure of receptor-ligand-mediated adhesion between latex spheres. I. Protein-carbohydrate bond. Tees DF, et al. **Biophys J** 1996 Aug;71(2):1102-14

Early and fatal immune haemolysis after so-called 'minor' ABO-incompatible peripheral blood stem cell allotransplantation. Oziel-Taieb S, et al. **Bone Marrow Transplant** 1997 Jun;19(11):1155-6

Lectins and antibodies against blood-group antigens as tools for studying the cellular source of glycoproteins in human bronchial fluid: a comparison of morphological and biochemical observations. Bals R, et al. **Cell Tissue Res** 1996 Dec;286(3):457-65

Failure to detect potent anti-H in Parabombay patients with the gel system [letter] Cheng G, et al. **Clin Lab Haematol** 1996 Mar;18(1):63-4

P1 blood group phenotype, secretor status in patients with urinary tract infections. Lichodziejewska-Niemierko M, et al. **Clin Nephrol** 1995 Dec;44(6):376-9

ABO antigen blood-group compatibility in corneal transplantation. Borderie VM, et al. **Cornea** 1997 Jan; 16(1):1-6

The Helicobacter pylori seroprevalence in blood donors related to Lewis (a,b) histo-blood group phenotype. Klaamas K, et al. **Eur J Gastroenterol Hepatol** 1997 Apr; 9(4):367-70

Fungal anti-A agglutinins with different affinities for subgroups A1 and A2 red cells. Ying R, et al. **Exp Clin Immunogenet** 1995;12(4):232-7

Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Gal alpha 1-3Gal), blood group H determinant and N-glycolylneuraminic acid. Bouhours D, et al. **Glycoconj J** 1996 Dec;13(6):947-53

Ethnic differences in the expression of blood group antigens in the salivary gland secretory cells from German and Japanese non-secretor individuals. Tanegashima A, et al. **Glycoconj J** 1996 Aug;13(4):537-45

Aberrant glycosylation based on the neo-expression of poly-N-acetyllactosamine structures in squamous cell carcinomas of the head and neck. Yokota M, et al. **Histochem J** 1997 Jul;29(7):555-62

The development of ABO isohemagglutinins in Taiwanese. Liu YJ, et al. **Hum Hered** 1996 Jul-Aug;46(4):181-4

Apheresis therapy for prolonged red cell aplasia after major ABO-mismatched bone marrow transplantation. Ohta S, et al. **Intern Med** 1997 Jul;36(7):487-91

Severe hemolysis caused by graft-derived anti-B production after lung transplantation. Taaning E, et al. **J Heart Lung Transplant** 1996 Aug;15(8):850-1

ABO system of blood groups in people and their resistance to certain infectious diseases (prognosis). Skripal' IG. **Mikrobiol Z** 1996 Mar-Apr;58(2):102-8 (11 ref.)

Monoclonal antibody against an amniotic protein carrying ABH blood group epitopes and its forensic application. Nagae M, et al. **Tohoku J Exp Med** 1995 Dec;177(4):353-64

Coordinator's report: ABH and other glycoconjugates--serology. Beck ML. **Transfus Clin Biol** 1997;4(1):13-6

Report on section 2A antibodies: ABH and other glycoconjugates--serology. Beck ML, et al. **Transfus Clin Biol** 1997;4(1):29-34

Report on section 2A antibodies: ABH and other glycoconjugates--serology. Harrison D, et al. **Transfus Clin Biol** 1997;4(1):23-7

Report of section 2A serology: anti-A, anti-B and anti-A,B reagents. Hartman KP, et al. **Transfus Clin Biol** 1997; 4(1):19-22

Report on section 2A antibodies: ABH and other glycoconjugates--serology. Janus G, et al. **Transfus Clin Biol** 1997;4(1):35-40

Immunohistological analysis of antibodies against ABH and other glycoconjugates in normal human pyloric and duodenal mucosae. Le Pendu J, et al. **Transfus Clin Biol** 1997;4(1):41-6

Specificity of monoclonal antibodies against ABH and related structures tested by ELISA with synthetic glycoconjugates. Rieben R, et al. **Transfus Clin Biol** 1997; 4(1):47-54

Report on section 2A antibodies: ABH and other glycoconjugates--serology. Williams M, et al. **Transfus Clin Biol** 1997;4(1):17-8

Mechanism of cryoprecipitation of anti-blood group B murine monoclonal antibodies. Judson PA, et al. **Transfus Med** 1991 Jun;1(2):97-102

The acquired-B phenomenon. Judd WJ, et al. **Transfus Med Rev** 1996 Apr;10(2):111-7 (43 ref.)

Serologic characteristics of H-deficient phenotypes among Chinese in Hong Kong. Mak KH, et al. **Transfusion** 1996 Nov-Dec;36(11-12):994-9

Successful management of hemolysis in ABO-nonidentical orthotopic liver transplantation by steroid therapy: a case report. Auwerda JJ, et al. **Transpl Int** 1996;9(5):509-12

Pure red cell aplasia after major ABO-incompatible bone marrow transplantation: two case reports of treatment with recombinant human erythropoietin. Fujisawa S, et al. **Transpl Int** 1996;9(5):506-8

Weak expression of blood type B antigen in kidney tissue and successful B-incompatible kidney transplantation without special treatments. Koyama I, et al. **Transpl Int** 1996;9 Suppl 1:S25-7

Interaction of platelet fc and complement receptors with circulating immune complexes involving the AB0 system. Heal JM, et al. **Vox Sang** 1996;71(4):205-11

Severe ABO hemolytic disease of newborn is infrequent among Hong Kong Chinese [letter] Wong HF, et al. **Vox Sang** 1996;70(1):45

[Temporary changes and permanent changes in the erythrocyte blood-group antigens in malignant hemopathies] Hafner V, et al. **Rom J Intern Med** 1996 Jul-Dec;34(3-4):183-8 (Eng. Abstr.) **(Fre)**

[Immuno-hemolytic transfusion reactions. III. Report of 61 cases] Le Pennec PY, et al. **Transfus Clin Biol** 1996; 3(3):157-65 (Eng. Abstr.) **(Fre)**

[Rapid onset of hemolytic anemia after allogeneic bone marrow transplantation from an unrelated ABO major mismatched donor] Watanabe H, et al. **Rinsho Ketsueki** 1997 Jan;38(1):14-20 (Eng. Abstr.) **(Jpn)**

[Immunogenetic aspects of pathogenesis, prognosis and treatment of the main forms of chronic pancreatitis] Gubergrits NB, et al. **Klin Med (Mosk)** 1996;74(7):26-8 (Eng. Abstr.) **(Rus)**

[The detection of the Glm(1) antigen by the indirect immunofluorescence reaction in a quantitative modification] Sidorov VL, et al. **Sud Med Ekspert** 1997 Jan-Mar;40(1):33-4 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Direct extraction of A and B blood group antigens from human red cells by liposomes. Suzuki K, et al. **Transfusion** 1996 Nov-Dec;36(11-12):966-8

METABOLISM

Cloning, sequence, and expression of a blood group B active recombinant alpha-D-galactosidase from pinto bean (Phaseolus vulgaris). Davis MO, et al. **Biochem Mol Biol Int** 1997 Jul;42(3):453-67

Serum bactericidal activity in a secondary school population following an outbreak of meningococcal disease: effects of carriage and secretor status. Zorgani AA, et al. **FEMS Immunol Med Microbiol** 1996 Jun;14(2-3):73-81

PHYSIOLOGY

Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility: approach with A and B gene transfection. Ichikawa D, et al. **Cancer Res** 1997 Aug 1;57(15):3092-6

Serum lipids, ABO blood group and sickle cell trait. Njoku OU, et al. **Indian J Physiol Pharmacol** 1996 Apr;40(2):171-4

Role of ABO and Lewis blood group antigens in donor-recipient compatibility of corneal transplantation rejection. Roy R, et al. **Ophthalmology** 1997 Mar; 104(3):508-12

[The significance of blood group-related antigen A in a pancreatic cell line (PGHAM-1) in hamsters. With special reference to cell proliferation] Inoue M, et al. **Nippon Ika Daigaku Zasshi** 1997 Feb;64(1):30-8 (Eng. Abstr.) **(Jpn)**

ABO FACTORS see **ABO BLOOD-GROUP SYSTEM**

ABOMASUM

Gravel obstruction in the abomasum or duodenum of two cows. Cebra CK, et al. **J Am Vet Med Assoc** 1996 Oct 1;209(7):1294-6

Effects of left displaced abomasum on test day milk yields of Holstein cows. Detilleux JC, et al. **J Dairy Sci** 1997 Jan;80(1):121-6

Abomasal infusion of cis or trans fatty acid isomers and energy metabolism of lactating dairy cows. Romo GA, et al. **J Dairy Sci** 1996 Nov;79(11):2005-15

Excretion of purine derivatives by Holstein cows abomasally infused with incremental amounts of purines. Vagnoni DB, et al. **J Dairy Sci** 1997 Aug;80(8):1695-702

Fat/protein ratio in first DHI test milk as test for displaced abomasum in dairy cows. Geishauser T, et al. **Zentralbl Veterinarmed A** 1997 Jul;44(5):265-70

[Occurrence of abomasal displacement in cattle in Hesse] Geishauser T, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Apr;103(4):142-4 (Eng. Abstr.) **(Ger)**

[Abomasal ulcers in calves: clinical investigations and experiences] Dirksen G, et al. **Tierarztl Prax** 1997 Jul; 25(4):318-28 (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Decreased serum apolipoprotein B-100 and A-I concentrations in cows with ketosis and left displacement of the abomasum. Oikawa S, et al. **Am J Vet Res** 1997 Feb;58(2):121-5

Ammonia in ruminal and abomasal contents of cows with abomasal displacement. Geishauser T, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Nov;103(11):465-8

Serum apolipoprotein B-100 concentrations in healthy and diseased cattle. Itoh H, et al. **J Vet Med Sci** 1997 Jul; 59(7):587-91

Duodeno-abomasal reflux in cows with abomasal displacement. Geishauser T, et al. **Zentralbl Veterinarmed A** 1996 Sep;43(7):445-50

Plasma and liver alpha-tocopherol in dairy cows with left abomasal displacement and fatty liver. Mudron P, et al. **Zentralbl Veterinarmed A** 1997 Apr;44(2):91-7

[Percutaneous fixation--or "doubling" the left-sidedness--and righting of the displaced abomasum in milk cows] Nottebrock A, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug;104(8):295-7 (Eng. Abstr.) **(Ger)**

ANATOMY & HISTOLOGY

[The abomasum and its relative position] Stoffel MH. **Schweiz Arch Tierheilkd** 1996;138(7):337-41 (0 ref.) (Eng. Abstr.) **(Ger)**

CYTOLOGY

Oxyntic cell differentiation during physiological cell renewal in abomasal mucosa of adult cattle. Kressin M. **Anat Embryol (Berl)** 1996 Mar;193(3):259-69

[The differentiation of the surface mucous-cell line in the abomasum of the adult cow] Kressin M, et al. **Anat Histol Embryol** 1996 Sep;25(3):177-86 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Abomasal infusion of glucose and fat--effect on digestion, production, and ovarian and uterine functions of cows. Oldick BS, et al. **J Dairy Sci** 1997 Jul;80(7):1315-28

IMMUNOLOGY

Sequential cellular and humoral responses in the abomasal mucosa and blood of Romney sheep dosed with Trichostrongylus axei. Pfeffer A, et al. **Int J Parasitol** 1996 Jul;26(7):765-73

Isolation and phenotypic characterization of abomasal mucosal lymphocytes in the course of a primary Ostertagia ostertagi infection in calves. Almería S, et al. **Vet Immunol Immunopathol** 1997 Jun;57(1–2):87–98

METABOLISM

Infection of sheep with adult and larval Ostertagia circumcincta: effects on abomasal pH and serum gastrin and pepsinogen. Lawton DE, et al. **Int J Parasitol** 1996 Oct;26(10):1063–74

Glucose and norepinephrine challenges during abomasal infusion of cis or trans octadecenoates in Holstein cows. Gaynor PJ, et al. **J Dairy Sci** 1996 Sep;79(9):1590–5

MICROBIOLOGY

Abomasal bloat associated with Sarcina-like bacteria in goat kids. DeBey BM, et al. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1468–9

PARASITOLOGY

A new host record of Camelostrongylus mentulatus (Nematoda; Trichostrongyloidea) from abomasum of a giraffe at a zoo in Japan. Fukumoto S, et al. **J Vet Med Sci** 1996 Dec;58(12):1223–5

Abomasal nematodes in goats from the subtropical island of Grand Canary (Spain). Molina JM, et al. **Vet Res** 1997 May–Jun;28(3):259–70

PATHOLOGY

Mucinous adenocarcinoma in the abomasum of a cow. Ritchey JW, et al. **Vet Pathol** 1996 Jul;33(4):454–6

PHYSIOLOGY

Ammonia in ruminal and abomasal contents of cows with abomasal displacement. Geishauser T, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Nov;103(11):465–8

Radionuclide imaging of abomasal emptying in sheep. Nicholson T, et al. **Res Vet Sci** 1997 Jan–Feb;62(1):26–9

[Motor, digestive and secretory processes of the forestomach and the abomasum--a short review] Wolffram S. **Schweiz Arch Tierheilkd** 1996;138(7):343–50 (6 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Abomasal disorders in dairy cattle [letter] Cammack J. **Vet Rec** 1997 Jul 12;141(2):55

Duodeno-abomasal reflux in cows with abomasal displacement. Geishauser T, et al. **Zentralbl Veterinarmed A** 1996 Sep;43(7):445–50

RADIONUCLIDE IMAGING

Radionuclide imaging of abomasal emptying in sheep. Nicholson T, et al. **Res Vet Sci** 1997 Jan–Feb;62(1):26–9

SECRETION

Effects of adult and larval Haemonchus contortus on abomasal secretion. Simpson HV, et al. **Int J Parasitol** 1997 Jul;27(7):825–31

SURGERY

Post surgical convalescence of dairy cows with left abomasal displacement in relation to fatty liver. Rehage J, et al. **Schweiz Arch Tierheilkd** 1996;138(7):361–8

[Percutaneous fixation--or "doubling" the left-sidedness--and righting of the displaced abomasum in milk cows] Nottebrock A, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug;104(8):295–7 (Eng. Abstr.) **(Ger)**

[The surgical treatment of left-sided abomasal displacement in the cow: a literature review] Steiner A. **Schweiz Arch Tierheilkd** 1996;138(7):353–60 (16 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Ultrasonographic examination of the abomasum of 50 cows. Braun U, et al. **Vet Rec** 1997 Jan 25;140(4):93–8

Percutaneous ultrasound-guided abomasocentesis in cows. Braun U, et al. **Vet Rec** 1997 Jun 7;140(23):599–602

ABORIGINES

see related

AUSTRALOID RACE

Persistent growth faltering among aboriginal infants and young children in north-west Australia: a retrospective study from 1969 to 1993. Rousham EK, et al. **Acta Paediatr** 1997 Jan;86(1):46–50

Fc epsilon R1-beta polymorphism and total serum IgE levels in endemically parasitized Australian aborigines. Palmer LJ, et al. **Am J Hum Genet** 1997 Jul;61(1):182–8

Dopamine D2 receptor gene and alcoholism among four aboriginal groups and Han in Taiwan. Chen WJ, et al. **Am J Med Genet** 1997 Apr 18;74(2):129–36

Analysis of the probability of multiple taxa in a combined sample of Swartkrans and Kromdraai dental material. Fuller K. **Am J Phys Anthropol** 1996 Nov;101(3):429–39

Patterns of persistent otitis media in the first year of life in aboriginal and non-aboriginal infants. Boswell JB, et al. **Ann Otol Rhinol Laryngol** 1996 Nov;105(11):893–900

Gout is on the increase in New Zealand. Klemp P, et al. **Ann Rheum Dis** 1997 Jan;56(1):22–6

Plasma lipids and apolipoproteins in a population of Orang Asli ('aborigines') from West Malaysia. Candlish JK, et al. **Atherosclerosis** 1997 Feb 28;129(1):49–51

Palatal rugae patterns in Australian aborigines and Caucasians. Kapali S, et al. **Aust Dent J** 1997 Apr; 42(2):129–33

Aboriginal health in the peel region of Western Australia. Hamdorf M, et al. **Aust Fam Physician** 1996 Sep;25(9 Suppl 2):S81–5

Why do(n't) aboriginal women have Pap smears? [letter] Mak D. **Aust Fam Physician** 1997 Jun;26(6):763

ABO incompatible renal transplantation: a chance to re-examine? Mackie FE, et al. **Aust N Z J Med** 1996 Dec; 26(6):824–6

Community acquired pneumonia in north eastern Australia--a hospital based study of aboriginal and non-aboriginal patients. Thompson JE. **Aust N Z J Med** 1997 Feb;27(1):59–61

Anti-streptokinase antibodies and streptokinase resistance in an Aboriginal population in northern Australia. Urdahl KB, et al. **Aust N Z J Med** 1996 Feb;26(1):49–53

Low aboriginal birth-weight--prematurity or intrauterine growth restriction? [see comments] Humphrey MD. **Aust N Z J Obstet Gynaecol** 1996 May;36(2):126–8. Comment in: Aust N Z J Obstet Gynaecol 1997 Feb;37(1):131–2.

Low aboriginal birth-weight--prematurity or intrauterine growth restriction, Humphrey MD. Aust NZ J Obstet and Gynaecol 1996; 36: 126–128 [letter; comment] Sayers S, et al. **Aust N Z J Obstet Gynaecol** 1997 Feb;37(1):131–2 . Comment on: Aust N Z J Obstet Gynaecol 1996 May;36(2):126–8.

Mobile retinal photography. A means of screening for diabetic retinopathy in aboriginal communities. Karagiannis A, et al. **Aust N Z J Ophthalmol** 1996 Nov;24(4):333–7

Visual acuity in an Australian aboriginal population. Stocks NP, et al. **Aust N Z J Ophthalmol** 1997 May;25(2):125–31

Presentation of early otitis media in 'Top End' Aboriginal infants. Boswell J. **Aust N Z J Public Health** 1997 Feb; 21(1):100–2

Aboriginal drug and alcohol use: recent developments and trends [editorial] Brady M. **Aust N Z J Public Health** 1997 Feb;21(1):3–4

Effect of gestational age misclassification on the pattern of low birthweight in Aborigines. Coory M. **Aust N Z J Public Health** 1997 Feb;21(1):84–8

Towards guidelines for survey research in remote Aboriginal communities [see comments] Donovan RJ, et al. **Aust N Z J Public Health** 1997 Feb;21(1):89–95. Comment in: Aust N Z J Public Health 1997 Feb;21(1):96–7.

The use of tobacco, alcohol and other drugs by young Aboriginal people in Albany, Western Australia. Gray D, et al. **Aust N Z J Public Health** 1997 Feb;21(1):71–6

Pneumococcal vaccination: an important strategy to prevent pneumonia in Aboriginal and Torres Strait Island adults [see comments] Hanna JN, et al. **Aust N Z J Public Health** 1997 Jun;21(3):281–5. Comment in: Aust N Z J Public Health 1997 Jun;21(3):243–4.

A health profile of adults in a Northern Territory aboriginal community, with an emphasis on preventable morbidities [see comments] Hoy WE, et al. **Aust N Z J Public Health** 1997 Apr;21(2):121–6. Comment in: Aust N Z J Public Health 1997 Jun;21(3):343–4.

Equity in health care: some conceptual and practical issues. Jan S, et al. **Aust N Z J Public Health** 1996 Feb;20(1):9–11

The effect of retail store managers on aboriginal diet in remote communities. Lee A, et al. **Aust N Z J Public Health** 1996 Apr;20(2):212–4

Models for horizontal equity in resource allocation in aboriginal health. McDermott R, et al. **Aust N Z J Public Health** 1996 Feb;20(1):13–5

Has access to hospital improved for Aborigines in the northern territory? McDermott RA, et al. **Aust N Z J Public Health** 1996 Dec;20(6):589–93

Treatment of renal disease among aboriginal people [letter; comment] McLaren B. **Aust N Z J Public Health** 1996 Apr;20(2):217–8. Comment on: Aust J Public Health 1995 Dec;19(6):603–9.

Effects and sustainability of a cervical screening program in remote Aboriginal Australia. Mak D, et al. **Aust N Z J Public Health** 1997 Feb;21(1):67–70

Internal markets and Aboriginal health [letter] Markey P. **Aust N Z J Public Health** 1997 Jun;21(3):343

Commentary: don't forget the plumber: research in remote Aboriginal communities [comment] Miller P, et al. **Aust N Z J Public Health** 1997 Feb;21(1):96–7. Comment on: Aust N Z J Public Health 1997 Feb;21(1):89–95.

Resource allocation and aboriginal health. Mooney G. **Aust N Z J Public Health** 1996 Feb;20(1):9

Funding aboriginal health care: the case for a new initiative [editorial; comment] Mooney G. **Aust N Z J Public Health** 1996 Dec;20(6):564–5. Comment on: Aust N Z J Public Health 1996 Dec;20(6):661–4.

Hepatitis B immunisation rates among infants in ethnic groups with high prevalences of hepatitis B surface antigen carriers. Oman KM, et al. **Aust N Z J Public Health** 1997 Jun;21(3):293–6

Equitable provision of health services to aboriginal and Torres Strait Islander people of Queensland. Runciman C, et al. **Aust N Z J Public Health** 1996 Feb;20(1):15–7

Aboriginal health workers [letter; comment] Saint-Yves IF. **Aust N Z J Public Health** 1996 Aug;20(4):440–1. Comment on: Aust N Z J Public Health 1996 Jun;20(3):227–9.

Funding for community control of indigenous health services. Scrimgeour D. **Aust N Z J Public Health** 1996 Feb; 20(1):17–8

Trends in the prevalence of trachoma, South Australia, 1976 to 1990. Stocks NP, et al. **Aust N Z J Public Health** 1996 Aug;20(4):375–81

Respiratory signs in Aboriginal communities [letter; comment] Thompson J. **Aust N Z J Public Health** 1997 Jun;21(3):343–4. Comment on: Aust N Z J Public Health 1997 Apr;21(2):121–6.

Aboriginal health workers [letter; comment] Thompson JF. **Aust N Z J Public Health** 1996 Aug;20(4):441. Comment on: Aust N Z J Public Health 1996 Jun;20(3):227–9.

Public health implications of pneumococcal disease in indigenous Australians [editorial; comment] Torzillo PJ. **Aust N Z J Public Health** 1997 Jun;21(3):243–4 (13 ref.) . Comment on: Aust N Z J Public Health 1997 Jun;21(3):281–5.

Aboriginal self-determination, education and health: towards a radical change in attitudes to education. Tsey K. **Aust N Z J Public Health** 1997 Feb;21(1):77–83

The funder-purchaser-provider model and aboriginal health care provision [see comments] Tsey K, et al. **Aust N Z J Public Health** 1996 Dec;20(6):661–4. Comment in: Aust N Z J Public Health 1996 Dec;20(6):564–5.

Variations in health care expenditure in the Alice Springs Rural District in 1993–94. Warchivker I. **Aust N Z J Public Health** 1996 Feb;20(1):11–3

Tinea due to Trichophyton violaceum in Victoria, Australia. Maslen MM, et al. **Australas J Dermatol** 1997 Aug; 38(3):124–8 (21 ref.)

Dental caries among Australian Aboriginal, non-Aboriginal Australian-born, and overseas-born children. Davies MJ, et al. **Bull World Health Organ** 1997;75(3):197–203

Sugar group not part of CDA [letter] Brazeau L. **Can Fam Physician** 1997 May;43:845–6

Survey of Montreal's Aboriginal population's knowledge, attitudes and behaviour regarding HIV/AIDS. DuBois MJ, et al. **Can J Public Health** 1996 Jan–Feb;87(1):37–9

The Feather of Hope Aboriginal AIDS Prevention Society: a community approach to HIV/AIDS prevention. Mill JE, et al. **Can J Public Health** 1996 Jul–Aug;87(4):268–71

The visiting lectureship on aboriginal health: an educational initiative at the University of Toronto. Shah CP, et al. **Can J Public Health** 1996 Jul–Aug;87(4):272–4

Using participatory action research to understand the meanings aboriginal Canadians attribute to the rising incidence of diabetes. Boston P, et al. **Chronic Dis Can** 1997;18(1):5–12

Meningococcal disease in Australia; looking at the past, thinking of the future. Patel M. **Commun Dis Intell** 1997 Aug 21;21(17):233–6

Dental health of aboriginal pre-school children in Brisbane, Australia. Seow WK, et al. **Community Dent Oral Epidemiol** 1996 Jun;24(3):187–90

Abnormal glucose tolerance and other coronary heart disease risk factors in an isolated aboriginal community in central Australia. Gault A, et al. **Diabetes Care** 1996 Nov; 19(11):1269–73

An analysis of sudden infant death syndrome in aboriginal infants. Alessandri LM, et al. **Early Hum Dev** 1996 Jul 19; 45(3):235–44

Antigenic epitope mapping of the M24 protein of Streptococcus pyogenes: implications for serodiagnosis of rheumatic fever. Norton RE, et al. **FEMS Immunol Med Microbiol** 1996 Dec 31; 16(3–4):267–71

Heart disease and associated risk factors among Hawaiians: culturally responsive strategies. Mokuau N, et al. **Health Soc Work** 1995 Feb;20(1):46–51 (20 ref.)

Dermatoglyphics in Araucanian Indians from Patagonia and multivariate comparisons with other Argentinian aboriginal populations. Demarchi DA, et al. **Hum Biol** 1997 Apr; 69(2):227–39

Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians. Hegele RA, et al. **Hypertension** 1997 May;29(5):1073–7

Does gestational age misclassification explain the difference in birthweights for Australian aborigines and whites? Coory M. **Int J Epidemiol** 1996 Oct;25(5):980–8

Hospitalization of aboriginal and non-aboriginal patients for respiratory tract diseases in Western Australia, 1988–1993. Williams P, et al. **Int J Epidemiol** 1997 Aug;26(4):797–805

Cultural safety in nursing: the New Zealand experience. Papps E, et al. **Int J Qual Health Care** 1996 Oct;8(5):491–7 (23 ref.)

Decreased insulin-like growth factor I receptor expression and function in immortalized African Pygmy T cells. Hattori Y, et al. **J Clin Endocrinol Metab** 1996 Jun; 81(6):2257–63

Genetic variation of intestinal fatty acid-binding protein associated with variation in body mass in aboriginal Canadians. Hegele RA, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4334–7

Characteristics of malignant lymphoma in eastern Taiwan: comparison between aborigines and nonaborigines. Kao RH, et al. **J Formos Med Assoc** 1997 Mar;96(3):179–84

Why do aboriginal newborns weigh less? Determinants of birthweight for gestation. Blair E.

ABORIGINES

J Paediatr Child Health 1996 Dec;32(6):498–503

Skin sores in Aboriginal children [letter] Carapetis JR, et al. **J Paediatr Child Health** 1995 Dec;31(6):563

The social and educational outcome of a cohort of rural children in relation to the racial and socio–economic groupings of their parents [see comments] Cox JW. **J Paediatr Child Health** 1996 Apr;32(2):99–102. Comment in: J Paediatr Child Health 1997 Apr;33(2):174; discussion 175–6. Comment in: J Paediatr Child Health 1997 Apr;33(2):175–6.

Nasal inflammation and chronic ear disease in Australian Aboriginal children. Gibson PG, et al. **J Paediatr Child Health** 1996 Apr;32(2):143–7

Paediatric urolithiasis in a remote Australian aboriginal community. Williams WM, et al. **J Paediatr Child Health** 1996 Aug;32(4):344–6

The growth of children for two generations at an Australian aboriginal community. Alsop–Shields L. **J Pediatr Nurs** 1996 Dec;11(6):402–8

Health/ill–health transition in less privileged populations: what does the future hold? Walker AR, et al. **J R Coll Physicians Lond** 1997 Jul–Aug;31(4):392–5 (61 ref.)

High prevalence of gout and related risk factors in Taiwan's Aborigines. Chang SJ, et al. **J Rheumatol** 1997 Jul; 24(7):1364–9

The prevalence of hookworm infection, iron deficiency and anaemia in an aboriginal community in north–west Australia. Hopkins RM, et al. **Med J Aust** 1997 Mar 3; 166(5):241–4

Could parasitic infections protect aboriginal children against asthma and allergies? [letter] Prociv P. **Med J Aust** 1997 Apr 7;166(7):391–2

Urinary diagnosis of gonorrhoea and Chlamydia in men in remote aboriginal communities [see comments] Skov SJ, et al. **Med J Aust** 1997 May 5;166(9):468–71. Comment in: Med J Aust 1997 May 5;166(9):456–7.

Malnutrition and microcephaly in Australian aboriginal children. Skull SA, et al. **Med J Aust** 1997 Apr 21; 166(8):412–4

Premature mortality in aboriginal adults in the Northern Territory, 1979–1991 [letter; comment] Wilson GC. **Med J Aust** 1997 Mar 3;166(5):278–9. Comment on: Med J Aust 1996 Sep 16;165(6):309–12.

Death and dying in Australia—some medico–legal problems for legislators. MacFarlane PJ. **Med Law** 1997;16(1):179–86

A place for cultural safety beyond nursing education? Kearns RA. **N Z Med J** 1997 Feb 14;110(1037):23–4

Balancing human exposure, risk and reality: questions raised by the Canadian aboriginal methylmercury program. Wheatley B, et al. **Neurotoxicology** 1996 Spring;17(1):241–9

Sudden infant death syndrome in Australian aboriginal and non–aboriginal infants: an analytical comparison. Alessandri LM, et al. **Paediatr Perinat Epidemiol** 1996 Jul; 10(3):309–18

Success of a scabies control program in an Australian aboriginal community. Carapetis JR, et al. **Pediatr Infect Dis J** 1997 May;16(5):494–9

Sarcoidosis in an Australian aborigine and a Torres Strait Islander. MacGinley RJ, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1997 Mar;14(1):83–5

"Painting a Leonardo with finger paint": medical practitioners communicating about death with aboriginal people. Weeramanthri T. **Soc Sci Med** 1997 Oct;45(7):1005–15

Streptococcal impetigo among aboriginal children in Malaysia. Norazah A, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):803–4

Diagnosis of scrub typhus in Malaysian aborigines using nested polymerase chain reaction. Tay ST, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):580–3

Molecular analysis of HLA–B in the Malaysian aborigines. Hirayama K, et al. **Tissue Antigens** 1996 Dec;48(6):692–7

A novel DRB1 allele (DRB1*0815) defined in an Australian Aborigine. Trejaut J, et al. **Tissue Antigens** 1997 May; 49(5):529–31

Alloimmune neonatal neutropenia in Australian aboriginals: an unrecognized disorder? Rodwell RL, et al. **Transfus Med** 1991 Mar;1(1):63–7

HIV risk behaviors become survival techniques for aboriginal women. Mill JE. **West J Nurs Res** 1997 Aug;19(4):466–89

The transition of Australian aboriginal diet and nutritional health. Lee A. **World Rev Nutr Diet** 1996;79:1–52 (340 ref.)

[Features of hormonal status in aborigines of Northeast Russia as a function of the level of hypoxic resistance] Batosh TP, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):5–9 **(Rus)**

[Regulation of metabolic pathways in various groups of aboriginal populations of the European North (as exemplified by the thyroliberin test)] Bolko ER, et al. **Fiziol Cheloveka** 1997 Jul–Aug;23(4):95–7 **(Rus)**

[The characteristics of the blood lipid composition in northern Selkups and in the immigrant population of northern Siberia and the problems of miscegenation] Maslennikov AB, et al. **Ter Arkh** 1997;69(1):26–9 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Heterochronic quantitative microevolution: dental divergence in aboriginal Americans. Shields ED, et al. **Am J Phys Anthropol** 1996 Jul;100(3):355–65

EDUCATION

The social and educational outcome of a cohort of rural children in relation to the racial and socioeconomic groupings of their parents [letter; comment] McDermott R, et al. **J Paediatr Child Health** 1997 Apr;33(2):175–6. Comment on: J Paediatr Child Health 1996 Apr;32(2):99–102.

Missing values ignored [letter; comment] Sayers S, et al. **J Paediatr Child Health** 1997 Apr;33(2):174; discussion 174–5. Comment on: J Paediatr Child Health 1996 Apr;32(2):99–102.

Social and educational outcome of rural children [letter; comment] Stanley F. **J Paediatr Child Health** 1997 Apr; 33(2):174; discussion 175–6. Comment on: J Paediatr Child Health 1996 Apr;32(2):99–102.

GENETICS

Limb–girdle muscular dystrophy and Miyoshi myopathy in an aboriginal Canadian kindred map to LGMD2B and segregate with the same haplotype. Weiler T, et al. **Am J Hum Genet** 1996 Oct;59(4):872–8

Lack of association between TaqI A1 allele of dopamine D2 receptor gene and alcohol–use disorders in atayal natives of Taiwan. Chen CH, et al. **Am J Med Genet** 1996 Sep 20;67(5):488–90

Geographic clustering of human Y–chromosome haplotypes. Ruiz Linares A, et al. **Ann Hum Genet** 1996 Sep;60 (Pt 5):401–8

Genotype associations among seven apolipoprotein B polymorphisms in a population of Orang Asli of western Malaysia. Gajra B, et al. **Hum Biol** 1997 Oct;69(5):629–40

High frequency of the apolipoprotein E *4 allele in African pygmies and most of the African populations in sub–Saharan Africa. Zekraoui L, et al. **Hum Biol** 1997 Aug; 69(4):575–81

Lack of founding Amerindian mitochondrial DNA lineages in extinct aborigines from Tierra del Fuego–Patagonia. Lalueza C, et al. **Hum Mol Genet** 1997 Jan;6(1):41–6

Machado–Joseph disease in east Arnhem Land, Australia: chromosome 14q32.1 expanded repeat confirmed in four families. Burt T, et al. **Neurology** 1996 Apr;46(4):1118–22

[The "Indian deletion" in the hypervariable segment II of mitochondrial DNA is absent in representatives of the native population of Northeastern Asia] Derenko MV, et al. **Genetika** 1996 Jun;32(6):854–5 (Eng. Abstr.) **(Rus)**

[The gene pool of native inhabitants of the Samburg tundra] Osipova LP, et al. **Genetika** 1996 Jun;32(6):830–6 (Eng. Abstr.) **(Rus)**

[Genetic–demographic analysis of the population of native inhabitants of the Samburg tundra] Posukh OL, et al. **Genetika** 1996 Jun;32(6):822–9 (Eng. Abstr.) **(Rus)**

HISTORY

Traditional remedies of the Yukon–Kuskokwim Delta (1842–1844). Fortuine R. **Alaska Med** 1996 Jul–Sep; 38(3):110

PSYCHOLOGY

Gender, race and poverty: bringing the sociopolitical into psychotherapy. Krawitz R, et al. **Aust N Z J Psychiatry** 1997 Aug;31(4):474–9 (30 ref.)

The problem of dementia in Australian aboriginal and Torres Strait Islander communities: an overview. Pollitt PA. **Int J Geriatr Psychiatry** 1997 Feb;12(2):155–63 (75 ref.)

Differences in sexual risk–taking behavior with state of inebriation in an aboriginal population in Ontario, Canada. Myers T, et al. **J Stud Alcohol** 1997 May;58(3):312–22

Race, combat, and PTSD in a community sample of New Zealand Vietnam War veterans. MacDonald C, et al. **J Trauma Stress** 1997 Jan;10(1):117–24

Euthanasia and the potential adverse effects for Northern Territory aborigines. Collins JJ, et al. **Lancet** 1997 Jun 28; 349(9069):1907–8

The importance of social and cultural effects of mercury on aboriginal peoples. Wheatley MA. **Neurotoxicology** 1996 Spring;17(1):251–6

Cultural linkage: treating Maori with alcohol and drug problems in dedicated Maori treatment programs. Sellman JD, et al. **Subst Use Misuse** 1997 Mar;32(4):415–24

STATISTICS & NUMERICAL DATA

Spondyloarthropathies in circumpolar populations: II. Characterization of the populations. Boyer GS, et al. **Arctic Med Res** 1996 Oct;55(4):195–203

Spondyloarthropathies in circumpolar populations: I. Design and methods of United States and Russian studies. Lawrence RC, et al. **Arctic Med Res** 1996 Oct;55(4):187–94

Important statistics missing [letter; comment] DuBois MJ. **Can Fam Physician** 1996 Dec;42:2341–2, 2344. Comment on: Can Fam Physician 1996 Sep;42:1734–40.

Suicide among Manitoba's aboriginal people, 1988 to 1994. Malchy B, et al. **Can Med Assoc J** 1997 Apr 15; 156(8):1133–8

Aboriginal physician use in Canada: location, orientation and identity. Newbold KB. **Health Econ** 1997 Mar–Apr; 6(2):197–207

Recent fertility and mortality trends among aboriginal and nonaboriginal populations of central Siberia. Leonard WR, et al. **Hum Biol** 1997 Jun;69(3):403–17

Premature mortality in aboriginal adults in the Northern Territory, 1979–1991 [see comments] Cunningham J, et al. **Med J Aust** 1996 Sep 16;165(6):309–12. Comment in: Med J Aust 1997 Mar 3;166(5):278–9.

Aboriginal suicide in British Columbia. Lester D. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1202

Seroprevalence of Sarcoptes scabiei var canis antibodies among aborigines in peninsular Malaysia. Normaznah Y, et al. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):53–6

[An epidemiological study of sacroiliitis among the native inhabitants of Chukotka] Erdes Sh, et al. **Ter Arkh** 1997; 69(5):50–4 (Eng. Abstr.) **(Rus)**

[The effect of socioeconomic status on the prevalence of biliary tract diseases in the Evens and Evenki] Sedov KR, et al. **Ter Arkh** 1993;65(2):42–4 (Eng. Abstr.) **(Rus)**

ABORTIFACIENT AGENTS

see related

OXYTOCICS

Medical abortion is not just a medical issue [editorial; comment] Orr RD, et al. **Am Fam Physician** 1997 Aug; 56(2):351, 355–6. Comment on: Am Fam Physician 1997 Aug;56(2):533–8.

Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone–misoprostol versus surgical abortion. Winikoff B, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):431–7

Successful methotrexate treatment of a viable pregnancy within a thin uterine scar. Ravhon A, et al. **Br J Obstet Gynaecol** 1997 May;104(5):628–9

Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: a randomised comparative trial. Ho PC, et al. **Contraception** 1996 May;53(5):281–3

Choosing between surgical abortions and medical abortions induced with methotrexate and misoprostol. Wiebe ER. **Contraception** 1997 Feb;55(2):67–71

The pill is not an abortive agent [editorial] Eskes TK. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72(1):1–2

Second trimester pregnancy termination including fetal death: comparison of five different methods. Yapar EG, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Nov; 69(2):97–102

The use of methotrexate and arterial embolization to avoid surgery in a case of cervical pregnancy. Cosin JA, et al. **Fertil Steril** 1997 Jun;67(6):1169–71

Controversies and problems in the current management of tubal pregnancy. Maymon R, et al. **Hum Reprod Update** 1996 Nov–Dec;2(6):541–51 (82 ref.)

Experience and acceptability of medical abortion with mifepristone and misoprostol among U.S. women. Beckman LJ, et al. **Womens Health Issues** 1997 Jul–Aug;7(4):253–62

ADMINISTRATION & DOSAGE

Medical options for early pregnancy termination [see comments] Gold M, et al. **Am Fam Physician** 1997 Aug; 56(2):533–8 (16 ref.). Comment in: Am Fam Physician 1997 Aug;56(2):351, 355–6.

Oral methotrexate and vaginal misoprostol for early abortion. Creinin MD. **Contraception** 1996 Jul;54(1):15–8

Methotrexate and misoprostol for early abortion: a multicenter trial. Acceptability. Creinin MD, et al. **Contraception** 1996 Jul;54(1):19–22

[The termination of pregnancy in the second trimester with rivanol] Vlasova D, et al. **Akush Ginekol (Sofiia)** 1996; 35(1–2):16–7 (Eng. Abstr.) **(Bul)**

ADVERSE EFFECTS

The toxic and abortifacient effects of ponderosa pine. Stegelmeier BL, et al. **Vet Pathol** 1996 Jan;33(1):22–8

ANALYSIS

The toxic and abortifacient effects of ponderosa pine. Stegelmeier BL, et al. **Vet Pathol** 1996 Jan;33(1):22–8

PHARMACOLOGY

Termination of early pregnancy in the rat by a single dose of human menopausal gonadotropin. Espey LL, et al. **Early Pregnancy** 1997 Mar;3(1):23–6

Comparison of labor induction with misoprostol vs. oxytocin/prostaglandin E2 in term pregnancy. Kadanali S, et al. **Int J Gynaecol Obstet** 1996 Nov;55(2):99–104

POISONING

Toxic ingestions in pregnancy: abortifacient use in a case series of pregnant overdose patients. Perrone J, et al. **Acad Emerg Med** 1997 Mar;4(3):206–9

ABORTIFACIENT AGENTS, NONSTEROIDAL

Midtrimester termination of complicated pregnancy with oral misoprostol. Batioğlu S, et al. **Adv Contracept** 1997 Mar; 13(1):55–61

Oral misoprostol use in early complicated pregnancy. Haberal A, et al. **Adv Contracept** 1996 Jun;12(2):139–43

Induced termination of pregnancy by purified extracts of Azadirachta Indica (Neem): mechanisms involved. Talwar GP, et al. **Am J Reprod Immunol** 1997 Jun;37(6):485–91

Intrafetal prostaglandin F2alpha administration for uterine evacuation in a case of intrauterine death. Christodoulou CN, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Feb; 64(2):227–9

Termination of 2nd and 3rd trimester pregnancies with mifepristone and misoprostol. Jannet D, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec 27; 70(2):159–63

Methotrexate and misoprostol for early abortion [see comments] Schaff EA, et al. **Fam Med** 1996 Mar; 28(3):198–203. Comment in: Fam Med 1996 Jul–Aug;28(7):464.

Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. Schaff EA, et al. **J Fam Pract** 1997 Apr;44(4):353–60

Abortion procedure [letter] Schneider AP 2nd. **J Fam Pract** 1997 Sep;45(3):193; discussion 194

[Intravaginal misoprostol before induced abortion in nulliparous women] Schaub B, et al. **Contracept Fertil Sex** 1996 Jan;24(1):67–71 (Eng. Abstr.) **(Fre)**

[Use of sulprostone in the medical evacuation of uterine contents] Paulo AS, et al. **Acta Med Port** 1996 Apr–Jun; 9(4–6):157–61 (Eng. Abstr.) **(Por)**

ADMINISTRATION & DOSAGE

Medically induced abortion in a woman with a large myomatous uterus. Creinin MD. **Am J Obstet Gynecol** 1996 Nov;175(5):1379–80

Effect of the rate of progesterone decline at luteolysis on the ovulatory follicles and subsequent estrous cycle length in ewes. Wiley TM, et al. **Anim Reprod Sci** 1997 Mar; 46(1–2):79–87

A randomized trial of 2 regimens for the administration of vaginal prostaglandins (gemeprost) for the induction of midtrimester abortion. Armatage RJ, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):296–9

Prolonged induction to delivery time in termination of pregnancy using 16, 16–dimethyl–PGE1–methyl ester (gemeprost) for fetuses with a neural tube defect or hydrocephalus. Nesbitt D, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):300–3

Termination of early human pregnancy with either 50 mg or 200 mg single oral dose of mifepristone (RU486) in combination with either 0.5 mg or 1.0 mg vaginal gemeprost. Prasad RN, et al. **Aust N Z J Obstet Gynaecol** 1996 Feb;36(1):20–3

Oral versus vaginal misoprostol for cervical priming [letter; comment] Barik S, et al. **Br J Obstet Gynaecol** 1997 May; 104(5):644. Comment on: Br J Obstet Gynaecol 1996 Nov;103(11):1117–9.

A randomised comparison of oral and vaginal misoprostol for cervical priming before suction termination of pregnancy [see comments] Lawrie A, et al. **Br J Obstet Gynaecol** 1996 Nov;103(11):1117–9. Comment in: Br J Obstet Gynaecol 1997 May;104(5):644.

Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomised study. Ngai SW, et al. **Br J Obstet Gynaecol** 1996 Nov; 103(11):1120–3

Unsuccessful treatment of missed abortion with a combination of an antiprogesterone and a prostaglandin E1 analogue. Nielsen S, et al. **Br J Obstet Gynaecol** 1997 Sep;104(9):1094–6

The use of misoprostol for termination of early pregnancy. Carbonell JL, et al. **Contraception** 1997 Mar;55(3):165–8

A randomised study of two doses of gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. Thong KJ, et al. **Contraception** 1996 Aug;54(2):97–100

Abortion induced with methotrexate and misoprostol: a comparison of various protocols. Wiebe ER. **Contraception** 1997 Mar;55(3):159–63

A comparative trial of labor induction with misoprostol versus oxytocin. Escudero F, et al. **Int J Gynaecol Obstet** 1997 May;57(2):139–43

A comparative study of the efficacy and safety of synthetic prostaglandin E2 derivative and 15–methyl prostaglandin F2 alpha in the termination of midtrimester pregnancy. Biswas A, et al. **J Indian Med Assoc** 1996 Aug;94(8):292–3

Termination of second–trimester pregnancy with intracervicovaginal misoprostol. Srisomboon J, et al. **J Med Assoc Thai** 1997 Apr;80(4):242–6

Misoprostol for medical evacuation of early pregnancy failure. Creinin MD, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):768–72

Absorption kinetics of misoprostol with oral or vaginal administration. Zieman M, et al. **Obstet Gynecol** 1997 Jul; 90(1):88–92

[A phase III multicentre study on medical termination of early pregnancy with two regimens of mifepristone followed by PG05] Sang G, et al. **Chung Hua I Hsueh Tsa Chih** 1996 May;76(5):325–30 (Eng. Abstr.) **(Chi)**

[Pathophysiologic principles and clinical effects of local drug therapy of tubal pregnancies] Klein M, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(3):133–7 (Eng. Abstr.) **(Ger)**

[Current method for pregnancy termination with prostaglandins in the 2nd and 3rd trimester] Winkler M, et al. **Z Geburtshilfe Neonatol** 1997 Mar–Apr;201(2):39–43 **(Ger)**

CHEMISTRY

Amino acid sequences and ribosome–inactivating activities of karasurin–B and karasurin–C. Kondo T, et al. **Biol Pharm Bull** 1996 Nov;19(11):1485–9

ISOLATION & PURIFICATION

Novel saponins hainaneosides A and B isolated from Marsdenia hainanensis. Ma B, et al. **J Nat Prod** 1997 Feb; 60(2):134–8

PHARMACOKINETICS

Absorption kinetics of misoprostol with oral or vaginal administration. Zieman M, et al. **Obstet Gynecol** 1997 Jul; 90(1):88–92

PHARMACOLOGY

The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study––final results. **Contraception** 1997 Jan;55(1):1–5

Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Creinin MD, et al. **Contraception** 1996 Jun;53(6):321–7

Purified neem (Azadirachta indica) seed extracts (Praneem) abrogate pregnancy in primates. Mukherjee S, et al. **Contraception** 1996 Jun;53(6):375–8

Exogenous prostaglandin F2 alpha stimulates utero–ovarian release of prostaglandin F2 alpha in sheep: a possible component of the luteolytic mechanism of action of exogenous prostaglandin F2 alpha. Wade DE, et al. **Domest Anim Endocrinol** 1996 Sep;13(5):383–98

Structure/function relationship study of Tyr14 and Arg22 in trichosanthin, a ribosome–inactivating protein. Shaw PC, et al. **Eur J Biochem** 1997 Apr 15;245(2):423–7

Anabolic effects of prostaglandins in cultured fetal rat calvariae: structure–activity relations and signal transduction pathway. Woodiel FN, et al. **J Bone Miner Res** 1996 Sep;11(9):1249–55

Methotrexate. A single agent for early abortion. Schaff EA, et al. **J Reprod Med** 1997 Jan;42(1):56–60

Modulation of noradrenaline release in rat isolated stomach by prostanoids, but not by histaminergic mechanisms. Racké K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec;352(6):631–9

POISONING

Pennyroyal metabolites in human poisoning [letter; comment] Carmichael PG. **Ann Intern Med** 1997 Feb 1;126(3):250–1 . Comment on: Ann Intern Med 1996 Apr 15;124(8):726–34.

Acute intravaginal misoprostol toxicity with fetal demise. Austin J, et al. **J Emerg Med** 1997 Jan–Feb;15(1):61–4

THERAPEUTIC USE

A medical approach to management of spontaneous abortion using misoprostol. Extending misoprostol treatment to a maximum of 48 hours can further improve evacuation of retained products of conception in spontaneous abortion. Chung T, et al. **Acta Obstet Gynecol Scand** 1997 Mar; 76(3):248–51

Combined chemotherapy in the medical management of tubal pregnancy. Anandakumar C, et al. **Aust N Z J Obstet Gynaecol** 1995 Nov;35(4):437–40

Nitric oxide donors induce ripening of the human uterine cervix: a randomised controlled trial. Thomson AJ, et al. **Br J Obstet Gynaecol** 1997 Sep;104(9):1054–7

Misoprostol in the management of missed abortion. Herabutya Y, et al. **Int J Gynaecol Obstet** 1997 Mar; 56(3):263–6

ABORTIFACIENT AGENTS, STEROIDAL

Boycott threat forces French company to abandon RU486 [news] Dorozynski A. **BMJ** 1997 Apr 19;314(7088):1150

Impact of the introduction of new medical methods on therapeutic abortions at the Royal Infirmary of Edinburgh [see comments] Cameron ST, et al. **Br J Obstet Gynaecol** 1996 Dec;103(12):1222–9. Comment in: Br J Obstet Gynaecol 1997 Jul;104(7):871.

Clinical pharmacokinetics of mifepristone. Heikinheimo O. **Clin Pharmacokinet** 1997 Jul;33(1):7–17

Effects of two antiprogestins on early pregnancy in the long–tailed macaque (Macaca fascicularis). Tarantal AF, et al. **Contraception** 1996 Aug;54(2):107–15

Termination of 2nd and 3rd trimester pregnancies with mifepristone and misoprostol. Jannet D, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec 27; 70(2):159–63

Knowledge and perceptions of medical abortion among potential users. Harvey SM, et al. **Fam Plann Perspect** 1995 Sep–Oct;27(5):203–7

Abortion procedure [letter] Casner P. **J Fam Pract** 1997 Sep; 45(3):193–4

Abortion procedure [letter] Gehred GA. **J Fam Pract** 1997 Sep;45(3):194

Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. Schaff EA, et al. **J Fam Pract** 1997 Apr;44(4):353–60

Abortion procedure [letter] Schneider AP 2nd. **J Fam Pract** 1997 Sep;45(3):193; discussion 194

Pregnancy interruption using mifepristone (RU–486). A new choice for women in the USA. Mackenzie SJ, et al. **J Nurse Midwifery** 1997 Mar–Apr;42(2):86–90 (32 ref.)

Mifepristone (RU486) and abortion [editorial; comment] Henshaw RC. **Med J Aust** 1997 Sep 15;167(6):292–3. Comment on: Med J Aust 1997 Sep 15;167(6):316–7.

Women's satisfaction with medical abortion with RU486 [see comments] Mamers PM, et al. **Med J Aust** 1997 Sep 15; 167(6):316–7. Comment in: Med J Aust 1997 Sep 15;167(6):292–3.

Medical abortion in early pregnancy: a review of the evidence. Grimes DA. **Obstet Gynecol** 1997 May;89(5 Pt 1):790–6 (55 ref.)

ADMINISTRATION & DOSAGE

Termination of early human pregnancy with either 50 mg or 200 mg single oral dose of mifepristone (RU486) in combination with either 0.5 mg or 1.0 mg vaginal gemeprost. Prasad RN, et al. **Aust N Z J Obstet Gynaecol** 1996 Feb;36(1):20–3

Unsuccessful treatment of missed abortion with a combination of an antiprogesterone and a prostaglandin E1 analogue. Nielsen S, et al. **Br J Obstet Gynaecol** 1997 Sep;104(9):1094–6

Effect of single–dose, early luteal phase administration of mifepristone (RU486) on implantation stage endometrium in the rhesus monkey. Ghosh D, et al. **Hum Reprod** 1996 Sep;11(9):2026–35

Plasma protein changes induced by two orally administered androgen derivatives. Rannevik G, et al. **Scand J Clin Lab Invest** 1996 Apr;56(2):161–6

[A phase III multicentre study on medical termination of early pregnancy with two regimens of mifepristone followed by PG05] Sang G, et al. **Chung Hua I Hsueh Tsa Chih** 1996 May;76(5):325–30 (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

Pharmacokinetics of mifepristone after low oral doses. Kekkonen R, et al. **Contraception** 1996 Oct;54(4):229–34

PHARMACOLOGY

The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study––final results. **Contraception** 1997 Jan;55(1):1–5

Tamoxifen and RU39411 synergize with mifepristone to produce preimplantation pregnancy loss by increasing embryo transport (rat). Kaplan–Kraicer R, et al. **Contraception** 1996 Jun;53(6):367–73

Anti–implantation activity of luteal phase mifepristone administration is not mimicked by prostaglandin synthesis inhibitor or prostaglandin analogue in the rhesus monkey. Nayak NR, et al. **Contraception** 1997 Feb;55(2):103–14

Medical abortion. Bardin CW, et al. **Curr Ther Endocrinol Metab** 1997;6:305–11 (6 ref.)

Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation. Cameron ST, et al. **Fertil Steril** 1997 Jun; 67(6):1046–53

THERAPEUTIC USE

RU486 (mifepristone): mechanisms of action and clinical uses. Cadepond F, et al. **Annu Rev Med** 1997;48:129–56 (179 ref.)

[Tumor necrosis factor and induced labor] Rongières–Bertrand C, et al. **Contracept Fertil Sex** 1997 Jan;25(1):51–7 (Eng. Abstr.) **(Fre)**

ABORTION

see related

ABORTIFACIENT AGENTS

Rapid diagnosis of intrauterine pregnancy by smear cytology [letter] Strengell L, et al. **Acta Cytol** 1997 May–Jun; 41(3):942–4

Untreated celiac disease with bad outcome of three pregnancies followed by a fourth normal pregnancy after two years of gluten–free diet [letter] De Sandre G, et al. **Am J Gastroenterol** 1996 Dec;91(12):2653

Parental decisions to terminate/continue following abnormal cytogenetic prenatal diagnosis: "what" is still more important than "when". Evans MI, et al. **Am J Med Genet** 1996 Feb 2;61(4):353–5

Lethal multiple pterygium syndrome: suggestion for a consistent pathological workup and review of reported cases. Froster UG, et al. **Am J Med Genet** 1997 Jan 10; 68(1):82–5

Pharmacists should not participate in abortion or assisted suicide [editorial] Wagner BK. **Ann Pharmacother** 1996 Oct; 30(10):1192–6

The contribution of the pathologist after a perinatal loss: what we should be telling the parents. Khong TY. **Aust N Z J Obstet Gynaecol** 1996 Feb;36(1):15–17

Re: Delayed interval delivery and multiple pregnancy––use of cervical suture [letter; comment] Wilkinson C, et al. **Aust N Z J Obstet Gynaecol** 1996 May;36(2):223–4.

Comment on: Aust N Z J Obstet Gynaecol 1995 Aug;35(3):280–2.

The selective miscarriage of Down's syndrome from 10 weeks of pregnancy [letter] Macintosh MC, et al. **Br J Obstet Gynaecol** 1996 Nov;103(11):1172–3

The risk of breast cancer following spontaneous or induced abortion [published erratum appears in Cancer Causes Control 1997 Mar;8(2):260] Wingo PA, et al. **Cancer Causes Control** 1997 Jan;8(1):93–108 (96 ref.)

Evaluation and management of recurrent spontaneous abortion. Daya S. **Curr Opin Obstet Gynecol** 1996 Jun; 8(3):188–92 (22 ref.)

Conservative treatment after miscarriage of one fetus in multifetal pregnancies. Report of three cases and review of the literature. Antsaklis A, et al. **Fetal Diagn Ther** 1996 Nov–Dec;11(6):366–72

Comparative study of hemopoietic precursors from fetal and adult bone marrow: utilization of stem cells derived from miscarriages. Michejda M, et al. **Fetal Diagn Ther** 1996 Nov–Dec;11(6):373–82

Correlation between karyotype and ultrasound findings in patients with failed early pregnancy. Goldstein SR, et al. **Ultrasound Obstet Gynecol** 1996 Nov;8(5):314–7

BLOOD

Circulating maternal corticotropin–releasing hormone and gonadotropin–releasing hormone in normal and abnormal pregnancies. Sorem KA, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):912–6

Low serum M–CSF levels are associated with unexplained recurrent abortion. Katano K, et al. **Am J Reprod Immunol** 1997 Jul;38(1):1–5

First trimester pregnancy: ultrasound and biochemical evaluation. Daly S, et al. **Br J Hosp Med** 1996 Sep 4–17; 56(5):225–7 (20 ref.)

Coenzyme Q10 in pregnancy. Noia G, et al. **Fetal Diagn Ther** 1996 Jul–Aug;11(4):264–70

Association of early beta–human chorionic gonadotrophin values with pregnancy wastage and multiple implantation in a donor oocyte programme. Legro RS, et al. **Hum Reprod** 1995 Dec;10(12):3293–6

Placental isoferritin as a marker of early abortion in pregnancies induced by in vitro fertilization. Fisch B, et al. **Placenta** 1996 May;17(4):247–51

[Is it always necessary to give anti–D gamma–globulins in the case of spontaneous miscarriage in Rhesus–negative patients?] Salvat J, et al. **Contracept Fertil Sex** 1997 Apr; 25(4):V–IX (27 ref.) **(Fre)**

CHEMICALLY INDUCED

Study of the embryotoxic effects of an extract of rosemary (Rosmarinus officinalis L.). Lemonica IP, et al. **Braz J Med Biol Res** 1996 Feb;29(2):223–7

Cisapride use during human pregnancy: a prospective, controlled multicenter study. Bailey B, et al. **Dig Dis Sci** 1997 Sep;42(9):1848–52

Maternal caffeine consumption and spontaneous abortion: a prospective cohort study. Dlugosz L, et al. **Epidemiology** 1996 May;7(3):250–5

Ethylene oxide exposure may increase the risk of spontaneous abortion, preterm birth, and postterm birth [see comments] Rowland AS, et al. **Epidemiology** 1996 Jul;7(4):363–8. Comment in: Epidemiology 1997 Jul;8(4):465–6.

Camphor ingestion for abortion (case report). Rabl W, et al. **Forensic Sci Int** 1997 Sep 19;89(1–2):137–40

Risk of spontaneous abortion and maternal exposure to organic solvents in the shoe industry. Agnesi R, et al. **Int Arch Occup Environ Health** 1997;69(5):311–6

Oral anticoagulants and fetal loss [letter; comment] Brown SA, et al. **Lancet** 1996 Dec 21–28;348(9043):1734. Comment on: Lancet 1996 Oct 5;348(9032):913–6.

Can terathanasia explain the protective effect of folic–acid supplementation on birth defects? Hook EB, et al. **Lancet** 1997 Aug 16;350(9076):513–5 (20 ref.)

Levodopa in pregnancy [letter; comment] Nomoto M, et al. **Mov Disord** 1997 Mar;12(2):261. Comment on: Mov Disord 1995 Jan;10(1):115.

Risk of spontaneous abortion in women occupationally exposed to anaesthetic gases: a meta–analysis. Boivin JF. **Occup Environ Med** 1997 Aug;54(8):541–8

COMPLICATIONS

Does induced or spontaneous abortion affect the risk of breast cancer? Michels KB, et al. **Epidemiology** 1996 Sep; 7(5):521–8 (79 ref.)

Thyroiditis after pregnancy loss. Marqusee E, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2455–7

Abortion, breast cancer, and impact factors—in this number and the last [editorial; comment] Donnan S. **J Epidemiol Community Health** 1996 Dec;50(6):605. Comment on: J Epidemiol Community Health 1996 Oct;50(5):481–96.

First–trimester spontaneous abortions and the incidence of human immunodeficiency virus seropositivity. Bakas C, et al. **J Reprod Med** 1996 Jan;41(1):15–8

Obstetric outcome in antiphospholipid syndrome. Granger KA, et al. **Lupus** 1997;6(6):509–13

[Risks of diagnostic errors in pathology research of post–abortion herpetic endometritis: limitations of immunohistochemistry in situ hybridization] Sando Z, et al. **Ann Pathol** 1996 Sep;16(4):279–81 (Eng. Abstr.) **(Fre)**

[Ectopic pregnancy recurrence: role of gynecologic, obstetric, contraceptive and smoking history] Saada M, et al. **Contracept Fertil Sex** 1997 Jun;25(6):457–62 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The managed care of early pregnancy problems. Draycott T, et al. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):262–6 (32 ref.)

Characterization of Escherichia coli serotype O12:K1:H7 isolates from an immunocompetent carrier with a history of spontaneous abortion and septicemia. Blum–Oehler G, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb;16(2):153–5

Case report: mixed germ cell tumour of the ovary presenting as a missed abortion. Vergote IB, et al. **Eur J Gynaecol Oncol** 1996;17(6):518–9

The prognostic value of serum estradiol, progesterone, testosterone and free testosterone levels in detecting early abortions. Aksoy S, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jul;67(1):5–8

The value of hysteroscopic evaluation in patients with preclinical in–vitro fertilization abortions. Dicker D, et al. **Hum Reprod** 1996 Apr;11(4):730–1

The role of a single free beta–human chorionic gonadotrophin measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability. al–Sebai MA, et al. **Hum Reprod** 1996 Apr;11(4):881–8

DRUG THERAPY

A medical approach to management of spontaneous abortion using misoprostol. Extending misoprostol treatment to a maximum of 48 hours can further improve evacuation of retained products of conception in spontaneous abortion. Chung T, et al. **Acta Obstet Gynecol Scand** 1997 Mar; 76(3):248–51

ECONOMICS

The costs of treating miscarriage: a comparison of medical and surgical management. Hughes J, et al. **Br J Obstet Gynaecol** 1996 Dec;103(12):1217–21

Using conjoint analysis to assess women's preferences for miscarriage management. Ryan M, et al. **Health Econ** 1997 May–Jun;6(3):261–73

EMBRYOLOGY

Hand malformations in the aborted embryo: an important source of genetic information. Ramsing M, et al. **Birth Defects Orig Artic Ser** 1996;30(1):79–94

EPIDEMIOLOGY

Impaired glucose tolerance during pregnancy is associated with increased fetal mortality in preceding sibs. Aberg A, et al. **Acta Obstet Gynecol Scand** 1997 Mar;76(3):212–7

Tree–based, two–stage risk factor analysis for spontaneous abortion. Zhang H, et al. **Am J Epidemiol** 1996 Nov 15; 144(10):989–96

Are blastogenetic anomalies sporadic? Martínez–Frías ML, et al. **Am J Med Genet** 1997 Feb 11;68(4):381–5

Evaluating alternative exposure indices in epidemiologic studies on extremely low–frequency magnetic fields. Juutilainen J, et al. **Bioelectromagnetics** 1996;17(2):138–43

Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. Everett C. **BMJ** 1997 Jul 5;315(7099):32–4

Incomplete pregnancies and risk of ovarian cancer (Washington, United States). Chen MT, et al. **Cancer Causes Control** 1996 Jul;7(4):415–20

Similar pregnancy and spontaneous abortion rates after treatment with low–dose human menopausal gonadotropin versus pure follicle stimulating hormone in women with luteal phase defects. Check JH, et al. **Clin Exp Obstet Gynecol** 1997;24(1):5–7

Caffeinated beverages, decaffeinated coffee, and spontaneous abortion. Fenster L, et al. **Epidemiology** 1997 Sep; 8(5):515–23

A prospective study of work–related physical exertion and spontaneous abortion. Fenster L, et al. **Epidemiology** 1997 Jan;8(1):66–74

Does an abortion increase the risk of intrapartum infection in the following pregnancy? Mühlemann K, et al. **Epidemiology** 1996 Mar;7(2):194–8

Moderate maternal alcohol consumption and risk of spontaneous abortion. Windham GC, et al. **Epidemiology** 1997 Sep;8(5):509–14

Differences between spontaneous and induced abortions as risk factors for breast cancer. Zhang J. **Epidemiology** 1996 May;7(3):316–8

Deliveries, abortion and HIV–1 infection in Rome, 1989–1994. The Lazio AIDS Collaborative Group. Abeni DD, et al. **Eur J Epidemiol** 1997 Jun;13(4):373–8

Estimates of human fertility and pregnancy loss. Zinaman MJ, et al. **Fertil Steril** 1996 Mar;65(3):503–9

Percutaneous umbilical blood sampling: indication changes and procedure loss rate in a nine years' experience. Buscaglia M, et al. **Fetal Diagn Ther** 1996 Mar–Apr; 11(2):106–13

Spontaneous abortion pattern in an isolated Mediterranean population: La Alta Alpujarra Oriental (southeast Spain). Luna F, et al. **Hum Biol** 1997 Jun;69(3):345–56

A prospective study of early pregnancy loss. Ellish NJ, et al. **Hum Reprod** 1996 Feb;11(2):406–12

Are spontaneous abortion rates useful in monitoring reproductive hazards? [letter] James WH. **Hum Reprod** 1996 Oct;11(10):2333–5

Trend of spontaneous abortions in Italy 1980–91 [letter] Parazzini F, et al. **Hum Reprod** 1996 Apr;11(4):914

Obstetric outcome of 904 pregnancies after intracytoplasmic sperm injection. Wisanto A, et al. **Hum Reprod** 1996 Dec; 11 Suppl 4:121–9; discussion 130

The repeatability of self–reported exposure after miscarriage. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Farrow A, et al. **Int J Epidemiol** 1996 Aug;25(4):797–806

Sociobiological risk factors for spontaneous abortion in Malaysia. Tan NH, et al. **J Obstet Gynaecol** 1995 Aug; 21(4):313–8

Self–reported stress and reproductive health of female lawyers. Schenker MB, et al. **J Occup Environ Med** 1997 Jun;39(6):556–68

Epidemiology of hysterectomy in the United States: demographic and reproductive factors in a nationally representative sample. Brett KM, et al. **J Womens Health** 1997 Jun;6(3):309–16

Tetanus toxoid and spontaneous abortions: is there epidemiological evidence of an association? [letter] Catindig N, et al. **Lancet** 1996 Oct 19;348(9034):1098–9

Reproductive and developmental effects of occupational pesticide exposure: the epidemiologic evidence. Sever LE, et al. **Occup Med** 1997 Apr–Jun;12(2):305–25 (101 ref.)

Onchocerciasis and reproductive health in Ecuador. Guderian RH, et al. **Trans R Soc Trop Med Hyg** 1997 May–Jun;91(3):315–7

[Perinatal mortality in Denmark. An analysis of development assessed in connection with medically induced abortion during the period 1980–1993] Helweg–Larsen K, et al. **Ugeskr Laeger** 1996 Dec 9;158(50):7216–22 (Eng. Abstr.) **(Dan)**

ETHNOLOGY

Generational differences in perinatal health among the Mexican American population: findings from HHANES 1982–84. Guendelman S, et al. **Am J Public Health** 1990 Dec;80 Suppl:61–5

The narrative of AIDS among the Tonga of Zambia. Mogensen HO. **Soc Sci Med** 1997 Feb;44(4):431–9

ETIOLOGY

Rapid diagnosis of intrauterine pregnancy by smear cytology [letter] Strengell L, et al. **Acta Cytol** 1997 May–Jun; 41(3):942–4

Retrospective study of couples with a history of recurrent spontaneous abortion. Maione S, et al. **Acta Eur Fertil** 1995 May–Jun;26(3):95–100

Maternal alcohol consumption and spontaneous abortion. Abel EL. **Alcohol Alcohol** 1997 May–Jun;32(3):211–9 (45 ref.)

Exposure to video display terminals and risk of spontaneous abortion. Grasso P, et al. **Am J Ind Med** 1997 Oct; 32(4):403–7

Elevated amniotic fluid interleukin–6 levels at genetic amniocentesis predict subsequent pregnancy loss. Wenstrom KD, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):830–3

Teratogenic IgG from sera of women with spontaneous abortions seem to induce anomalies and yolk sac damage in rat embryos. A possible method to detect abortions of immunologic origin. Abir R, et al. **Am J Reprod Immunol** 1996 Feb;35(2):93–101

Spermatozoal DNA flow cytometry and recurrent miscarriage. Drudy L, et al. **Arch Androl** 1996 Nov–Dec; 37(3):143–7

Evaluating alternative exposure indices in epidemiologic studies on extremely low–frequency magnetic fields. Juutilainen J, et al. **Bioelectromagnetics** 1996;17(2):138–43

History of maternal fetal loss and increased risk of childhood acute leukemia at an early age. A report from the Childrens Cancer Group. Yeazel MW, et al. **Cancer** 1995 Apr 1; 75(7):1718–27

Hypothesis on a casual link between EMF and an evolutionary class of cancer and spontaneous abortion. Cooper WG. **Cancer Biochem Biophys** 1996 Apr; 15(3):151–70 (57 ref.)

Recurrent second trimester miscarriage. Flint S, et al. **Curr Opin Obstet Gynecol** 1996 Dec;8(6):449–53 (45 ref.)

Demographic characteristics, socioeconomic profile and contraceptive behaviour in patients with abortion at Jimma Hospital, Ethiopia. Abdella A. **East Afr Med J** 1996 Oct; 73(10):660–4

Induced abortion as a risk factor for subsequent fetal loss. Infante–Rivard C, et al. **Epidemiology** 1996 Sep;7(5):540–2

Evidence that oligoasthenozoospermia may be an etiologic factor for spontaneous abortion after in vitro fertilization–embryo transfer. Kiefer D, et al. **Fertil Steril** 1997 Sep;68(3):545–8

Incidence of spontaneous abortion in clomiphene pregnancies. Dickey RP, et al. **Hum Reprod** 1996 Dec; 11(12):2623–8

The roles of oligomenorrhoea and fetal chromosomal abnormalities in spontaneous abortions. Hasegawa I, et al. **Hum Reprod** 1996 Oct;11(10):2304–5

Further evidence that infection is an infrequent cause of first

trimester spontaneous abortion. Simpson JL, et al. **Hum Reprod** 1996 Sep;11(9):2058–60

Increased fetal loss in women with heritable thrombophilia [see comments] Preston FE, et al. **Lancet** 1996 Oct 5; 348(9032):913–6. Comment in: Lancet 1996 Dec 21–28;348(9043):1734. Comment in: Lancet 1996 Dec 21–28;348(9043):1734–5. Comment in: Lancet 1996 Dec 21–28;348(9043):1735.

Oral anticoagulants and fetal loss [letter; comment] Rintelen C, et al. **Lancet** 1996 Dec 21–28;348(9043):1735. Comment on: Lancet 1996 Oct 5;348(9032):913–6.

Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. Sundberg K, et al. **Lancet** 1997 Sep 6;350(9079):697–703

Spontaneous abortions possibly related to ingestion of nitrate-contaminated well water—LaGrange County, Indiana, 1991–1994. **MMWR Morb Mortal Wkly Rep** 1996 Jul 5;45(26):569–72

The relationship between maternal nutritional status and spontaneous abortion. Neela J, et al. **Natl Med J India** 1997 Jan–Feb;10(1):15–6

Seminars in perinatology. Gallagher PG. **Semin Perinatol** 1995 Dec;19(6):435–6

[Obstetrical complications of antiphospholipid syndrome] Weber JC. **Rev Med Interne** 1997;18(3):240–9 (88 ref.) (Eng. Abstr.) **(Fre)**

[Immunopathology of early abortion: current status] Guzmán Sánchez A, et al. **Ginecol Obstet Mex** 1997 Jun;65:262–5 (30 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

DNA ploidy of ectopic pregnancy and first trimester spontaneous abortion investigated by flow cytometry. Erel CT, et al. **Acta Obstet Gynecol Scand** 1996 Nov; 75(10):881–5

Normal phenotype with maternal isodisomy in a female with two isochromosomes: i(2p) and i(2q). Bernasconi F, et al. **Am J Hum Genet** 1996 Nov;59(5):1114–8

Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Dizon-Townson DS, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):402–5

A 13-year cytogenetic study of spontaneous abortion: clinical applications of testing. Ford JH, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):314–8

Two different pregnancy outcomes of trisomic zygote rescue through postzygotic mitotic error. Kalousek DK. **Birth Defects Orig Artic Ser** 1996;30(1):295–9 (12 ref.)

Hand malformations in the aborted embryo: an important source of genetic information. Ramsing M, et al. **Birth Defects Orig Artic Ser** 1996;30(1):79–94

Cytogenetic and morphologic findings in chorionic villi from spontaneous abortions. Silvestre E, et al. **Birth Defects Orig Artic Ser** 1996;30(1):353–7

A review of the genetics of recurrent pregnancy loss. Trott EA, et al. **Del Med J** 1996 Oct;68(10):495–8 (22 ref.)

Conflicting findings in the association of maternal HLA-DR homozygosity and fetal loss [letter; comment] Hoff C, et al. **Dis Markers** 1996 Aug;13(1):65–8. Comment on: Dis Markers 1995 Mar;12(2):123–5.

Spontaneous abortion pattern in an isolated Mediterranean population: La Alta Alpujarra Oriental (southeast Spain). Luna F, et al. **Hum Biol** 1997 Jun;69(3):345–56

Direct assessment of triploid cells in mosaic human fetuses by fluorescence in-situ hybridization. Horiuchi I, et al. **Mol Hum Reprod** 1997 May;3(5):445–50

Microsatellite instability in aborted embryos [letter] Kiaris H, et al. **Mol Hum Reprod** 1996 Jan;2(1):72–4

Partial mole and triploidy: screening patients with first-trimester spontaneous abortion. Jauniaux E, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):616–9

Determination of reliable histological features associated with early triploidy using DNA image cytometry. Lorenzato M, et al. **Pathol Res Pract** 1995 Dec;191(12):1179–85

Lack of correlation between conceptual karyotype and maternal response to placentation. Khong TY, et al. **Reprod Fertil Dev** 1997;9(2):271–4

[Chromosome aberrations in the etiology of abortions after infertility treatment using IVF and ET] Mardešič T, et al. **Ceska Gynekol** 1996 Jun;61(3):142–3 (Eng. Abstr.) **(Cze)**

[Correlation of the histological and cytogenetic pictures in placental tissue from early abortion. Does immunohistochemistry have a role?] Martinazzi S, et al. **Pathologica** 1996 Aug;88(4):275–85 (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Early spontaneous abortions and fetal thymic abnormalities in maternal-to-fetal HIV infection. Shearer WT, et al. **Acta Paediatr Suppl** 1997 Jun;421:60–4 (25 ref.)

Teratogenic IgG from sera of women with spontaneous abortions seem to induce anomalies and yolk sac damage in rat embryos. A possible method to detect abortions of immunologic origin. Abir R, et al. **Am J Reprod Immunol** 1996 Feb;35(2):93–101

Regulation of abortion by gamma delta T cells. Arck PC, et al. **Am J Reprod Immunol** 1997 Jan;37(1):87–93

The emerging role of IL-10 in pregnancy [published erratum appears in Am J Reprod Immunol 1996 Aug;36(2):127] Chaouat G, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):325–9

Expression of an immunomodulatory protein known as progesterone induced blocking factor (PIBF) does not correlate with first trimester spontaneous abortions in progesterone supplemented women. Check JH, et al. **Am J Reprod Immunol** 1997 Apr;37(4):330–4

Psycho-neuro-cytokine/endocrine pathways in immunoregulation during pregnancy. Clark DA, et al. **Am J Reprod Immunol** 1996 Apr;35(4):330–7 (71 ref.)

Stress triggered abortions are associated with alterations of granulated cells into the decidua. Markert UR, et al. **Am J Reprod Immunol** 1997 Jan;37(1):94–100

Immunodystrophism, T cells, cytokines, and pregnancy failure. Raghupathy R, et al. **Am J Reprod Immunol** 1996 Apr;35(4):291–6 (58 ref.)

Maternal anti-placental cell-mediated reactivity and spontaneous abortions. Raghupathy R. **Am J Reprod Immunol** 1997 Jun;37(6):478–84 (62 ref.)

The presence of anti-beta 2-glycoprotein I and anti-prothrombin antibodies and their correlations with venous and arterial thrombosis. Horbach DA, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:42–3

Inhibition of immunoprotective CD8+ T cells as a basis for stress-triggered substance P-mediated abortion in mice. Arck PC, et al. **Cell Immunol** 1996 Aug 1;171(2):226–30

Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Marzi M, et al. **Clin Exp Immunol** 1996 Oct;106(1):127–33

Prospective study showing that antisperm antibodies are not associated with pregnancy losses. Simpson JL, et al. **Fertil Steril** 1996 Jul;66(1):36–42

Activation status of T and NK cells in the endometrium throughout menstrual cycle and normal and abnormal early pregnancy. Ho HN, et al. **Hum Immunol** 1996 Sep 1; 49(2):130–6

Antiphospholipid antibodies in women undergoing in-vitro fertilization [letter; comment] Rai R, et al. **Hum Reprod** 1997 Jan;12(1):197–8. Comment on: Hum Reprod 1996 Jun;11(6):1185–9.

Immunohistochemical evidence for increased numbers of 'classic' CD57+ natural killer cells in the endometrium of women suffering spontaneous early pregnancy loss. Vassiliadou N, et al. **Hum Reprod** 1996 Jul;11(7):1569–74

Anticardiolipin, but not the 16/6 Id anti-DNA antibody induces pregnancy failure. Sthoeger ZM, et al. **Immunol Lett** 1996 Jan;49(1–2):117–22

Seroprevalence of antibodies to Toxoplasma gondii, with particular reference to obstetric history of patients in Rawalpindi-Islamabad, Pakistan. Pal RA, et al. **JPMA J Pak Med Assoc** 1996 Mar;46(3):56–8

Autoantibodies and pregnancy loss [editorial; comment] Cowchock S. **N Engl J Med** 1997 Jul 17;337(3):197–8. Comment on: N Engl J Med 1997 Jul 17;337(3):148–50. Comment on: N Engl J Med 1997 Jul 17;337(3):154–60.

Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism [see comments] Rand JH, et al. **N Engl J Med** 1997 Jul 17; 337(3):154–60. Comment in: N Engl J Med 1997 Jul 17;337(3):197–8.

Pregnancy loss and autoantibodies against phospholipid-binding proteins. Falcón CR, et al. **Obstet Gynecol** 1997 Jun;89(6):975–80

METABOLISM

Successful pregnancy outcome after first-trimester spontaneous abortion and selective removal of one placenta from a twin pregnancy. Laifer SA, et al. **J Assist Reprod Genet** 1996 Mar;13(3):275–6

Decreased type IV collagen expression by human decidual tissues in spontaneous abortion. Iwahashi M, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2925–9

MICROBIOLOGY

Zoonotic and viral infection in fetal loss after 12 weeks. Sanghi A, et al. **Br J Obstet Gynaecol** 1997 Aug; 104(8):942–5

Characterization of Escherichia coli serotype O12:K1:H7 isolates from an immunocompetent carrier with a history of spontaneous abortion and septicemia. Blum-Oehler G, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb;16(2):153–5

PATHOLOGY

Decidual and placental histologic findings in patients experiencing spontaneous abortions in relation to pregnancy order. Kohut KG, et al. **Am J Reprod Immunol** 1997 Mar;37(3):257–61

Proliferation kinetics of chorionic villi in chromosomally normal and abnormal spontaneous abortions analyzed by premature chromosome condensation and northern blot. Miller K, et al. **Ann Genet** 1996;39(3):159–67

Cytogenetic and morphologic findings in chorionic villi from spontaneous abortions. Silvestre E, et al. **Birth Defects Orig Artic Ser** 1996;30(1):353–7

A clinical, histopathological and flow cytometric study of 149 complete moles, 146 partial moles and 107 non-molar hydropic abortions. Paradinas FJ, et al. **Histopathology** 1996 Feb;28(2):101–10

Determination of reliable histological features associated with early triploidy using DNA image cytometry. Lorenzato M, et al. **Pathol Res Pract** 1995 Dec;191(12):1179–85

[Correlation of the histological and cytogenetic pictures in placental tissue from early abortion. Does immunohistochemistry have a role?] Martinazzi S, et al. **Pathologica** 1996 Aug;88(4):275–85 (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

The emerging role of IL-10 in pregnancy [published erratum appears in Am J Reprod Immunol 1996 Aug;36(2):127] Chaouat G, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):325–9

Expression of an immunomodulatory protein known as progesterone induced blocking factor (PIBF) does not correlate with first trimester spontaneous abortions in progesterone supplemented women. Check JH, et al. **Am J Reprod Immunol** 1997 Apr;37(4):330–4

The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production. Szekeres-Bartho J, et al. **Am J Reprod Immunol** 1996 Apr;35(4):348–51

Efficacy of low dose prednisone plus aspirin in preventing spontaneous abortions and/or fetal deaths due to antiphospholipid antibodies: results of a pilot study [letter] Mazzucconi MG, et al. **Autoimmunity** 1996;24(2):123–5

Using a logistic model to identify women with first-trimester spontaneous abortion suitable for expectant management [see comments] Nielsen S, et al. **Br J Obstet Gynaecol** 1996 Dec;103(12):1230–5. Comment in: Br J Obstet Gynaecol 1997 Jun;104(6):755–6.

The antiabortive effect of progesterone-induced blocking factor in mice is manifested by modulating NK activity. Szekeres-Bartho J, et al. **Cell Immunol** 1997 May 1; 177(2):194–9

Treatment of polycystic ovary patients undergoing IVF. Barri PN, et al. **J Assist Reprod Genet** 1997 Jan;14(1):10–2 (17 ref.)

PSYCHOLOGY

Patterns of grief reaction after pregnancy loss. Lin SX, et al. **Am J Orthopsychiatry** 1996 Apr;66(2):262–71

The psychological sequelae of miscarriage: a critical review of the literature. Frost M, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):54–62 (123 ref.)

The grief response in the partners of women who miscarry. Johnson MP, et al. **Br J Med Psychol** 1996 Dec;69 (Pt 4):313–27

Bereavement, grieving and psychological morbidity after first trimester spontaneous abortion: comparing expectant management with surgical evacuation. Nielsen S, et al. **Hum Reprod** 1996 Aug;11(8):1767–70

Psychiatric morbidity following miscarriage: a prevalence study of Chinese women in Hong Kong. Lee DT, et al. **J Affect Disord** 1997 Mar;43(1):63–8

Pregnancy following miscarriage: course of grief and some determining factors. Cuisinier M, et al. **J Psychosom Obstet Gynaecol** 1996 Sep;17(3):168–74

Similarities and differences in couples' grief reactions following a miscarriage: results from a longitudinal study. Beutel M, et al. **J Psychosom Res** 1996 Mar;40(3):245–53

Miscarriage as a traumatic event: a review of the literature and new implications for intervention. Lee C, et al. **J Psychosom Res** 1996 Mar;40(3):235–44 (60 ref.)

Major depressive disorder following miscarriage [letter; comment] Lynch DJ, et al. **JAMA** 1997 May 21; 277(19):1517. Comment on: JAMA 1997 Feb 5;277(5):383–8.

Major depressive disorder in the 6 months after miscarriage [see comments] Neugebauer R, et al. **JAMA** 1997 Feb 5; 277(5):383–8. Comment in: JAMA 1997 May 21;277(19):1517.

Quality of life and anxiety in pregnancies after late pregnancy loss: a case-control study. Hunfeld JA, et al. **Prenat Diagn** 1996 Sep;16(9):783–90

Mothers' trait anxiety and adaptation to an infant born subsequent to the loss of a late pregnancy. Agterberg G, et al. **Psychol Rep** 1997 Feb;80(1):216–8

Screening psychiatric morbidity after miscarriage: application of the 30-item General Health Questionnaire and the Edinburgh Postnatal Depression Scale. Lee DT, et al. **Psychosom Med** 1997 Mar–Apr;59(2):207–10

Perinatal loss: considerations in social work practice. Mahan CK, et al. **Soc Work Health Care** 1997;24(3–4):141–52 (17 ref.)

Comparison of long-term psychological responses of women after pregnancy termination due to fetal anomalies and after perinatal loss [see comments] Salvesen KA, et al. **Ultrasound Obstet Gynecol** 1997 Feb;9(2):80–5. Comment in: Ultrasound Obstet Gynecol 1997 Feb;9(2):76–9.

Ectopic pregnancy loss during fertility management. Schaper AM, et al. **West J Nurs Res** 1996 Oct;18(5):503–17

SURGERY

Bereavement, grieving and psychological morbidity after first trimester spontaneous abortion: comparing expectant management with surgical evacuation. Nielsen S, et al. **Hum Reprod** 1996 Aug;11(8):1767–70

THERAPY

Using a logistic model to identify women with first-trimester spontaneous abortion suitable for expectant management [letter; comment] Tincello DG, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):755–6. Comment on: Br J Obstet Gynaecol 1996 Dec;103(12):1230–5.

The managed care of early pregnancy problems. Draycott

T, et al. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):262–6 (32 ref.)

A randomised trial evaluating pain and bleeding after a first trimester miscarriage treated surgically or medically. Johnson N, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Apr;72(2):213–5

The management of first trimester miscarriage by general practitioners in Ireland. Prendiville W, et al. **Ir J Med Sci** 1997 Jan–Mar;166(1):3–6

The management of failed first trimester pregnancy [editorial] [see comments] Daly S, et al. **Ir Med J** 1997 Mar;90(2):52 . Comment in: Ir Med J 1997 Apr–May;90(3):116.

Failed first trimester pregnancy in perspective [letter; comment] Impey L, et al. **Ir Med J** 1997 Apr–May; 90(3):116. Comment on: Ir Med J 1997 Mar;90(2):52.

Fertility after a randomised trial of spontaneous abortion managed by surgical evacuation or expectant treatment [letter] Blohm F, et al. **Lancet** 1997 Apr 5;349(9057):995

ULTRASONOGRAPHY

First trimester pregnancy: ultrasound and biochemical evaluation. Daly S, et al. **Br J Hosp Med** 1996 Sep 4–17; 56(5):225–7 (20 ref.)

Comparison of ultrasonographic findings in spontaneous abortions with normal and abnormal karyotypes. Coulam CB, et al. **Hum Reprod** 1997 Apr;12(4):823–6

First-trimester detection of amniotic sac in relation to miscarriage. Ikegawa A. **J Obstet Gynaecol Res** 1997 Jun; 23(3):283–8

VETERINARY see ABORTION, VETERINARY

VIROLOGY

Human papillomavirus is more prevalent in first trimester spontaneously aborted products of conception compared to elective specimens. Hermonat PL, et al. **Virus Genes** 1997;14(1):13–7

[Cytomegalovirus infection in women of reproductive age with an at-risk obstetrical history] Cheshik SG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov–Dec; (6):47–9 (Eng. Abstr.) **(Rus)**

ABORTION APPLICANTS

[Induced abortion in Greenland] Bjerregaard P, et al. **Ugeskr Laeger** 1996 Oct 21;158(43):6085–9 (Eng. Abstr.) **(Dan)**

[Occurrence of bacterial vaginosis among abortion seekers] Bjørnerem A, et al. **Tidsskr Nor Laegeforen** 1997 Apr 10; 117(9):1282–4 (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

Mandatory parental involvement in minors' abortions: effects of the laws in Minnesota, Missouri, and Indiana. Ellertson C. **Am J Public Health** 1997 Aug;87(8):1367–74

PSYCHOLOGY

Women's satisfaction with medical abortion with RU486 [see comments] Mamers PM, et al. **Med J Aust** 1997 Sep 15; 167(6):316–7. Comment in: Med J Aust 1997 Sep 15;167(6):292–3.

Physicians should relinquish reproductive control to patients [letter] Hodgson JE. **Minn Med** 1996 Dec;79(12):6–7

Hats off to Dr. Struve's ideas for approaching unwanted pregnancy [letter] Howard TE. **Minn Med** 1996 Dec; 79(12):6

Physicians should respect and support their patients' decisions [letter] Lyon FA. **Minn Med** 1996 Dec;79(12):7, 42–3

[Induced abortions in relation to the use of contraceptive agents (see comments)] Andreasen EE, et al. **Ugeskr Laeger** 1996 Oct 14;158(42):5928–32 (Eng. Abstr.) . Comment in: Ugeskr Laeger 1997 Jan 6;159(2):189–90. Comment in: Ugeskr Laeger 1997 Feb 10;159(7):966–8. **(Dan)**

[Use of contraception and reasons for choosing abortion among abortion applicants] Hansen SK, et al. **Ugeskr Laeger** 1996 Oct 7;158(41):5773–6 (Eng. Abstr.) **(Dan)**

ABORTION, CRIMINAL

Camphor ingestion for abortion (case report). Rabl W, et al. **Forensic Sci Int** 1997 Sep 19;89(1–2):137–40

Abortion as a public health problem in Zambia. Sims P. **J Public Health Med** 1996 Jun;18(2):232–3

Unwanted pregnancy: it's existing solutions from the perspective of young adults in Bangkok and the abortion law. Prajayayothin P, et al. **Med Law** 1996;15(2):365–73

Improving the medical care and counseling of postabortion patients in Egypt. Huntington D, et al. **Stud Fam Plann** 1995 Nov–Dec;26(6):350–62

ETHNOLOGY

Women's hidden transcripts about abortion in Brazil. Nations MK, et al. **Soc Sci Med** 1997 Jun;44(12):1833–45

LEGISLATION & JURISPRUDENCE

Procreative freedom: a legal and moral challenge. Petersen K. **Med Law** 1996;15(3):433–40

Estimation of fetal age by histological study of kidney. Kumar KU, et al. **Med Sci Law** 1996 Jul;36(3):226–30

STATISTICS & NUMERICAL DATA

[Determinants of induced abortion among poor women admitted to hospitals in a locality of northeastern Brazil] Fonseca W, et al. **Rev Saude Publica** 1996 Feb;30(1):13–8 (Eng. Abstr.) **(Por)**

ABORTION, EUGENIC

Study of side-effects of Cu-T as intra-uterine contraceptive device in post medical termination of pregnancy and interval cases. Das CR, et al. **J Indian Med Assoc** 1995 Oct;93(10):375–6

Ethical and legal issues regarding selective abortion of fetuses with Down syndrome. Glover NM, et al. **Ment Retard** 1996 Aug;34(4):207–14 (42 ref.)

Prenatal sexing of human fetuses and selective abortion [editorial; comment] Hsi BL, et al. **Prenat Diagn** 1997 Jan; 17(1):1–3. Comment on: Prenat Diagn 1997 Jan;17(1):77–80.

[Severe fetal damage as maternal indication for pregnancy termination within the scope of section 218 StGB and its revision in German jurisprudence 1975/1995] Hiersche HD. **Z Geburtshilfe Neonatol** 1996 Nov–Dec;200(6):236–40 **(Ger)**

[Section 218 (editorial)] Ratzel R. **Z Geburtshilfe Neonatol** 1996 Jul–Aug;200(4):131 **(Ger)**

METHODS

[Current method for pregnancy termination with prostaglandins in the 2nd and 3rd trimester] Winkler M, et al. **Z Geburtshilfe Neonatol** 1997 Mar–Apr;201(2):39–43 **(Ger)**

PSYCHOLOGY

Early prenatal diagnosis of cleft lip and its potential impact on the number of babies with cleft lip [letter] Goodacre TE. **Br J Oral Maxillofac Surg** 1997 Aug;35(4):296

Early prenatal diagnosis of cleft lip and the potential impact on the number of babies with cleft lip [letter] Winstanley RP. **Br J Oral Maxillofac Surg** 1997 Aug;35(4):296

ABORTION, HABITUAL

The outcome of in vitro fertilization in unexplained habitual aborters concurrent with secondary infertility. Raziel A, et al. **Fertil Steril** 1997 Jan;67(1):88–92

Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Clifford K, et al. **Hum Reprod** 1997 Feb;12(2):387–9

[Habitual abortion. A review of etiology, diagnosis and treatment with emphasis on immunonological factors] Christiansen OB, et al. **Ugeskr Laeger** 1997 Aug 4; 159(32):4841–5 (40 ref.) (Eng. Abstr.) **(Dan)**

[Repeat spontaneous abortions] Hédon B, et al. **Contracept Fertil Sex** 1997 Feb;25(2):XVII–XXI (0 ref.) **(Fre)**

[Recurrent spontaneous abortions] Bjereke S, et al. **Tidsskr Nor Laegeforen** 1997 Apr 10;117(9):1278–82 (38 ref.) (Eng. Abstr.) **(Nor)**

BLOOD

Low serum M-CSF levels are associated with unexplained recurrent abortion. Katano K, et al. **Am J Reprod Immunol** 1997 Jul;38(1):1–5

Serum concentrations of human chorionic gonadotrophin and immunoreactive inhibin in early pregnancy and recurrent miscarriage: a longitudinal study. France JT, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):325–30

Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Goddijn-Wessel TA, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 May;66(1):23–9

Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Branch DW, et al. **Obstet Gynecol** 1997 Apr; 89(4):549–55

Presence of FV Leiden and MTHFR mutation in a patient with complicated pregnancies [letter] Grandone E, et al. **Thromb Haemost** 1997 May;77(5):1036–7

Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Gris JC, et al. **Thromb Haemost** 1997 Jun; 77(6):1096–103

COMPLICATIONS

Association of bacterial vaginosis with a history of second trimester miscarriage. Llahi-Camp JM, et al. **Hum Reprod** 1996 Jul;11(7):1575–8

[Reccurent abortions: unpublished syndrome suggesting the explanation of fetal death] Netter AP, et al. **C R Acad Sci III** 1996 Jul;319(7):637–8 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Current clinical options for diagnosis and treatment of recurrent spontaneous abortion. Clinical Guidelines Recommendation Committee for Diagnosis and Treatment of Recurrent Spontaneous Abortion. Coulam CB, et al. **Am J Reprod Immunol** 1997 Aug;38(2):57–74

Controversies in diagnosis and management of recurrent spontaneous abortion [editorial] Coulam CB, et al. **Am J Reprod Immunol** 1997 Apr;37(4):279–82 (25 ref.)

DRUG THERAPY

Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin. Marzusch K, et al. **Acta Obstet Gynecol Scand** 1996 Nov;75(10):922–6

Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Kutteh WH. **Am J Obstet Gynecol** 1996 May;174(5):1584–9

A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Kutteh WH, et al. **Am J Reprod Immunol** 1996 Apr;35(4):402–7

Treatment for patients with recurrent abortion with positive antiphospholipid antibodies using a traditional Chinese herbal medicine. Takakuwa K, et al. **J Perinat Med** 1996; 24(5):489–94

ETIOLOGY

Retrospective study of couples with a history of recurrent spontaneous abortion. Maione S, et al. **Acta Eur Fertil** 1995 May–Jun;26(3):95–100

Enhanced expression of cytokines may play a fundamental role in the mechanisms of immunologically mediated recurrent spontaneous abortion. Shaarawy M, et al. **Acta Obstet Gynecol Scand** 1997 Mar;76(3):205–11

Teratogenic IgG from sera of women with spontaneous abortions seem to induce anomalies and yolk sac damage in rat embryos. A possible method to detect abortions of immunologic origin. Abir R, et al. **Am J Reprod Immunol** 1996 Feb;35(2):93–101

Implication of abnormal human trophoblast karyotype for the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. The Recurrent Miscarriage Immunotherapy Trialists Group [editorial] Clark DA, et al. **Am J Reprod Immunol** 1996 May;35(5):495–8 (28 ref.)

Antiphospholipid antibodies and recurrent pregnancy loss. Rote NS. **Am J Reprod Immunol** 1996 Apr;35(4):394–401 (63 ref.)

Impact of age on reproductive outcome in women with recurrent spontaneous abortions and infertility of immune etiology. Ruiz AM, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):408–14

Embryotoxicity as a marker for recurrent pregnancy loss. Sargent IL, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):383–7 (13 ref.)

Thrombophilia and fetal loss. Brenner B, et al. **Blood Rev** 1997 Jun;11(2):72–9 (82 ref.)

Antiphospholipid (Hughes') syndrome [editorial; comment] Khamashta MA, et al. **BMJ** 1997 Jan 25;314(7076):244. Comment on: BMJ 1997 Jan 25;314(7076):253–7.

Activated protein C resistance can be associated with recurrent fetal loss. Brenner B, et al. **Br J Haematol** 1997 Jun;97(3):551–4

Recurrent miscarriages as an indication for percutaneous tricuspid valvuloplasty during pregnancy. Gamra H, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):283–6

Antiphospholipid antibodies, infertility and recurrent miscarriage. Rai R, et al. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):279–82

Evaluating müllerian anomalies as a cause of recurrent pregnancy loss. Nguyen L, et al. **Del Med J** 1997 Apr; 69(4):209–12

The hypo-osmotic swelling test in recurrent miscarriage. Buckett WM, et al. **Fertil Steril** 1997 Sep;68(3):506–9

Frequency of factors associated with habitual abortion in 197 couples. Stephenson MD. **Fertil Steril** 1996 Jul;66(1):24–9

Chromosome analysis of aborted conceptuses of recurrent aborters positive for anticardiolipin antibody. Takakuwa K, et al. **Fertil Steril** 1997 Jul;68(1):54–8

High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Rai RS, et al. **Hum Reprod** 1995 Dec; 10(12):3301–4

Familial thrombophilia—the scientific rationale for thrombophylaxis in recurrent pregnancy loss? Younis JS, et al. **Hum Reprod** 1997 Jul;12(7):1389–90

Reproductive failure due to spontaneous abortion and recurrent miscarriage. Bulletti C, et al. **Hum Reprod Update** 1996 Mar–Apr;2(2):118–36 (209 ref.)

A fresh look at the causes and treatments of recurrent miscarriage, especially its immunological aspects. Christiansen OB. **Hum Reprod Update** 1996 Jul–Aug; 2(4):271–93 (198 ref.)

Autoantibody screening for infertility: explaining the unexplained? Hatasaka HH, et al. **J Reprod Immunol** 1997 Sep;34(2):137–53 (30 ref.)

Criteria for antiphospholipid syndrome: early pregnancy loss, fetal loss, or recurrent pregnancy loss? Branch DW, et al. **Lupus** 1996 Oct;5(5):409–13 (31 ref.)

The syndrome of thrombosis, thrombocytopenia, and recurrent spontaneous abortions associated with antiphospholipid antibodies: Hughes syndrome. Gharavi AE, et al. **Lupus** 1996 Oct;5(5):343–4

GENETICS

HLA sharing and history of miscarriage among women with rheumatoid arthritis [letter; comment] Brennan P. **Am J Hum Genet** 1997 Mar;60(3):738–40. Comment on: Am J Hum Genet 1995 Jun;56(6):1456–67.

Familial skewed X inactivation: a molecular trait associated with high spontaneous-abortion rate maps to Xq28. Pegoraro E, et al. **Am J Hum Genet** 1997 Jul;61(1):160–70

Indications for examination of spontaneous abortion specimens: a different perspective [letter; comment] Hunter A. **Am J Obstet Gynecol** 1996 Aug;175(2):508–9. Comment on: Am J Obstet Gynecol 1995 Nov;173(5):1364–8.

Maternal HLA class II alleles predispose to pregnancy losses in Danish women with recurrent spontaneous abortions and their female relatives. Christiansen OB, et al. **Am J Reprod Immunol** 1996 Mar;35(3):239–44

Analyses of HLA–DQ alleles in recurrent spontaneous abortion (RSA) couples. Wagenknecht DR, et al. **Am J Reprod Immunol** 1997 Jan;37(1):1–6

A cytogenetic study of 514 Chinese couples with recurrent spontaneous abortion. Tsui KM, et al. **Chin Med J (Engl)** 1996 Aug;109(8):635–8

A history of miscarriages and mild prognathism as possible mode of presentation of mosaic trisomy 18 in women. Satge D, et al. **Clin Genet** 1996 Dec;50(6):470–3 (22 ref.)

Xenobiotic metabolism genes and the risk of recurrent spontaneous abortion. Hirvonen A, et al. **Epidemiology** 1996 Mar;7(2):206–8

Frequency of factors associated with habitual abortion in 197 couples. Stephenson MD. **Fertil Steril** 1996 Jul;66(1):24–9

Pericentric inversion of chromosome 7 associated with recurrent abortion [letter] Imai A, et al. **Int J Gynaecol Obstet** 1996 Feb;52(2):187–8

Recurrent abortion associated with 1qh+. Imai A, et al. **J Med** 1995;26(5–6):343–5

Increased frequency of HLA–DR4 allele in women with unexplained recurrent spontaneous abortions, detected by the method of PCR–SSP. Sasaki T, et al. **J Reprod Immunol** 1997 Feb;32(3):273–9

Identification of a subtle chromosomal translocation in a family with recurrent miscarriages and a child with multiple congenital anomalies. A case report. Shaffer LG, et al. **J Reprod Med** 1996 May;41(5):367–71

Genetic risk factor for unexplained recurrent early pregnancy loss [letter] Nelen WL, et al. **Lancet** 1997 Sep 20; 350(9081):861

Chromosome abnormalities associated with recurrent abortion. Imai A, et al. **Res Commun Mol Pathol Pharmacol** 1996 Dec;94(3):323–6

Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Grandone E, et al. **Thromb Haemost** 1997 May;77(5):822–4

[Cytogenetic research in couples with recurrent spontaneous gestational losses] Ceballos-Quintal JM, et al. **Ginecol Obstet Mex** 1996 Nov;64:503–7 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Antiphospholipid antibody–associated recurrent pregnancy loss: treatment with heparin and low–dose aspirin is superior to low–dose aspirin alone. Kutteh WH. **Am J Obstet Gynecol** 1996 May;174(5):1584–9

Teratogenic IgG from sera of women with spontaneous abortions seem to induce anomalies and yolk sac damage in rat embryos. A possible method to detect abortions of immunologic origin. Abir R, et al. **Am J Reprod Immunol** 1996 Feb;35(2):93–101

Immunophenotypic profiles of peripheral blood lymphocytes in women with recurrent pregnancy losses and in infertile women with multiple failed in vitro fertilization cycles. Beer AE, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):376–82

Maternal HLA class II alleles predispose to pregnancy losses in Danish women with recurrent spontaneous abortions and their female relatives. Christiansen OB, et al. **Am J Reprod Immunol** 1996 Mar;35(3):239–44

Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials. Coulam CB, et al. **Am J Reprod Immunol** 1996 Apr;35(4):352–9 (67 ref.)

The use of intravenous immunoglobulin in recurrent pregnancy loss associated with combined alloimmune and autoimmune abnormalities. Kiprov DD, et al. **Am J Reprod Immunol** 1996 Oct;36(4):228–34

A clinical trial for the treatment of antiphospholipid antibody–associated recurrent pregnancy loss with lower dose heparin and aspirin. Kutteh WH, et al. **Am J Reprod Immunol** 1996 Apr;35(4):402–7

Antiphospholipid antibodies and recurrent pregnancy loss. Rote NS. **Am J Reprod Immunol** 1996 Apr;35(4):394–401 (63 ref.)

Laboratory evaluation of women experiencing reproductive failure. Roussev RG, et al. **Am J Reprod Immunol** 1996 Apr;35(4):415–20

Impact of age on reproductive outcome in women with recurrent spontaneous abortions and infertility of immune etiology. Ruiz AM, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):408–14

Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion. Ruiz JE, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):370–5

Embryotoxicity as a marker for recurrent pregnancy loss. Sargent IL, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):383–7 (13 ref.)

Influence of histocompatibility antigens in recurrent spontaneous abortion couples and on their reproductive performances [see comments] Sbracia M, et al. **Am J Reprod Immunol** 1996 Feb;35(2):85–92. Comment in: Am J Reprod Immunol 1997 Feb;37(2):213–4.

Analyses of HLA–DQ alleles in recurrent spontaneous abortion (RSA) couples. Wagenknecht DR, et al. **Am J Reprod Immunol** 1997 Jan;37(1):1–6

Hemocoagulative pathology and immunological recurrent abortion. Borrelli AL, et al. **Clin Exp Obstet Gynecol** 1997; 24(1):39–40

The immunopathology of recurrent abortion. Unander AM. **Curr Top Microbiol Immunol** 1997;222:189–203 (104 ref.)

Clinical and immunological condition of newborns of mothers treated for recurrent spontaneous abortions with paternal lymphocytes immunization. Malinowski A, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 May;73(1):55–61

Antibodies to beta 2–glycoprotein I and prothrombin in habitual abortion. Ailus K, et al. **Fertil Steril** 1996 Dec; 66(6):937–41

Antiphospholipid antibodies and human reproductive failure. Balasch J, et al. **Hum Reprod** 1996 Oct;11(10):2310–5

Allogenic leukocyte immunization after five or more miscarriages. Recurrent Miscarriage Immunotherapy Trialists Group. Carp HJ, et al. **Hum Reprod** 1997 Feb; 12(2):250–5

Anti–cardiolipin antibodies in sexual partners of recurrent aborters. Panton JA, et al. **Hum Reprod** 1997 Mar; 12(3):464–7

High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Rai RS, et al. **Hum Reprod** 1995 Dec; 10(12):3301–4

Low–dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Tulppala M, et al. **Hum Reprod** 1997 Jul; 12(7):1567–72

A fresh look at the causes and treatments of recurrent miscarriage, especially its immunological aspects. Christiansen OB. **Hum Reprod Update** 1996 Jul–Aug; 2(4):271–93 (198 ref.)

Treatment for patients with recurrent abortion with positive antiphospholipid antibodies using a traditional Chinese herbal medicine. Takakuwa K, et al. **J Perinat Med** 1996; 24(5):489–94

Increased frequency of HLA–DR4 allele in women with unexplained recurrent spontaneous abortions, detected by the method of PCR–SSP. Sasaki T, et al. **J Reprod Immunol** 1997 Feb;32(3):273–9

Anti beta 2glycoprotein I antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: prevalence and clinical significance. Ogasawara M, et al. **Lupus** 1996 Dec; 5(6):587–92

Immunological tolerance of the fetal allograft: efficacy of immunotherapy and IL–4 and TNF alpha serum levels in recurrent abortion. Deneys V, et al. **Transplant Proc** 1997 Aug;29(5):2467–9

CD36 autoantibodies and thrombotic diathesis, thrombocytopenia and repeated early fetal losses. Borzini P, et al. **Vox Sang** 1997;73(1):46–8

[Autoimmune habitual abortion] Nouza K, et al. **Ceska Gynekol** 1996 Oct;61(5):310–6 **(Cze)**

[Embryotoxic factors and recurrent spontaneous abortions] Yao J, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997; 26(3):304–8 (Eng. Abstr.) **(Fre)**

[Analysis of immunoglobulin classes of five anti–phospholipid antibodies in sera from patients with SLE, ITP and recurrent fetal abortion by enzyme linked immunosorbent assay] Hayashi S, et al. **Rinsho Byori** 1996 Feb;44(2):169–75 (Eng. Abstr.) **(Jpn)**

[Changes in the spectrum of antibodies to membrane phospholipids in women with habitual abortion] Ponomareva IV, et al. **Biull Eksp Biol Med** 1997 Mar; 123(3):312–5 **(Rus)**

[Immunopathology of early abortion: current status] Guzmán Sánchez A, et al. **Ginecol Obstet Mex** 1997 Jun;65:262–5 (30 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

MUC1 as a cell surface and secretory component of endometrial epithelium: reduced levels in recurrent miscarriage. Aplin JD, et al. **Am J Reprod Immunol** 1996 Mar;35(3):261–6 (47 ref.)

Deficient syncytiotrophoblast tumour necrosis factor–alpha characterizes failing first trimester pregnancies in a subgroup of recurrent miscarriage patients. Lea RG, et al. **Hum Reprod** 1997 Jun;12(6):1313–20

PHYSIOPATHOLOGY

Enhanced expression of cytokines may play a fundamental role in the mechanisms of immunologically mediated recurrent spontaneous abortion. Shaarawy M, et al. **Acta Obstet Gynecol Scand** 1997 Mar;76(3):205–11

Cytokines and immuno–endocrine factors in recurrent miscarriage. Lim KJ, et al. **Hum Reprod Update** 1996 Nov–Dec;2(6):469–81 (152 ref.)

PREVENTION & CONTROL

Intravenous immunoglobulin in women with five or more abortions. Carp HJ, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):360–2

The use of intravenous immunoglobulin in recurrent pregnancy loss associated with combined alloimmune and autoimmune abnormalities. Kiprov DD, et al. **Am J Reprod Immunol** 1996 Oct;36(4):228–34

Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion. Ruiz JE, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):370–5

Treatment of pregnant women with recurrent miscarriage associated with phospholipid antibodies. General prognosis is favourable in untreated women [letter; comment] Christiansen OB. **BMJ** 1997 Aug 9;315(7104):372; discussion 373. Comment on: BMJ 1997 Jan 25;314(7076):253–7.

Treatment of pregnant women with recurrent miscarriage associated with phospholipid antibodies. No cytogenetic data were reported [letter; comment] Kingdom J, et al. **BMJ** 1997 Aug 9;315(7104):372. Comment on: BMJ 1997 Jan 25;314(7076):253–7.

Treatment of pregnant women with recurrent miscarriage associated with phospholipid antibodies. During pregnancy, heparin should be stopped during labour and then restarted soon after delivery [letter; comment] Piette JC, et al. **BMJ** 1997 Aug 9;315(7104):372–3; discussion 373 . Comment on: BMJ 1997 Jan 25;314(7076):253–7.

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) [see comments] Rai R, et al. **BMJ** 1997 Jan 25;314(7076):253–7. Comment in: BMJ 1997 Jan 25;314(7076):244. Comment in: BMJ 1997 Aug 9;315(7104):372. Comment in: BMJ 1997 Aug 9;315(7104):372; discussion 373. Comment in: BMJ 1997 Aug 9;315(7104):372–3; discussion 373.

Low–dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Tulppala M, et al. **Hum Reprod** 1997 Jul; 12(7):1567–72

Effect of intravenous immunoglobulin G on natural killer cell cytotoxicity in vitro in women with recurrent spontaneous abortion. Ruiz JE, et al. **J Reprod Immunol** 1996 Aug;31(1–2):125–41

Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss [see comments] Laskin CA, et al. **N Engl J Med** 1997 Jul 17;337(3):148–53. Comment in: N Engl J Med 1997 Jul 17;337(3):197–8.

Immunization with WBC induces monocyte suppression activity in vitro. Gafter U, et al. **Transplant Proc** 1997 Sep; 29(6):2649–50

Immunization with WBC suppresses T cells and NK activity in vitro. Gafter U, et al. **Transplant Proc** 1997 Sep; 29(6):2703–5

THERAPY

Intravenous immunoglobulin in women with five or more abortions. Carp HJ, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):360–2

Enhancement of the expression of progesterone receptor on progesterone–treated lymphocytes after immunotherapy in unexplained recurrent spontaneous abortion. Chiu L, et al. **Am J Reprod Immunol** 1996 Jun;35(6):552–7

Implication of abnormal human trophoblast karyotype for the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. The Recurrent Miscarriage Immunotherapy Trialists Group [editorial] Clark DA, et al. **Am J Reprod Immunol** 1996 May;35(5):495–8 (28 ref.)

Controversies in diagnosis and management of recurrent spontaneous abortion [editorial] Coulam CB, et al. **Am J Reprod Immunol** 1997 Apr;37(4):279–82 (25 ref.)

Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials. Coulam CB, et al. **Am J Reprod Immunol** 1996 Apr;35(4):352–9 (67 ref.)

Current clinical options for diagnosis and treatment of recurrent spontaneous abortion. Clinical Guidelines Recommendation Committee for Diagnosis and Treatment of Recurrent Spontaneous Abortion. Coulam CB, et al. **Am J Reprod Immunol** 1997 Aug;38(2):57–74

Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Kwak JY, et al. **Am J Reprod Immunol** 1996 Apr;35(4):363–9

In–vitro fertilization treatment for unexplained recurrent abortion: a pilot study [see comments] Balasch J, et al. **Hum Reprod** 1996 Jul;11(7):1579–82. Comment in: Hum Reprod 1997 Feb;12(2):397–8.

The ETEP protocol for recurrent miscarriage [letter] Carp HJ, et al. **Hum Reprod** 1996 Apr;11(4):912–3

Intravenous immunoglobulin treatment of pregnant patients with unexplained recurrent abortions. Raziel A, et al. **Hum Reprod** 1996 Apr;11(4):711–5 (64 ref.)

IVF and embryo transfer—a therapeutic approach for unexplained recurrent miscarriages [letter; comment] Raziel A, et al. **Hum Reprod** 1997 Feb;12(2):397–8. Comment on: Hum Reprod 1996 Jul;11(7):1579–82.

Oocyte donation in women with recurrent pregnancy loss.

ABORTION, HABITUAL

Remohí J, et al. **Hum Reprod** 1996 Sep;11(9):2048–51
Immunotherapy with husband's leukocytes to primary habitual aborters and autoantibodies in their sera. Takesako S, et al. **J Obstet Gynaecol Res** 1997 Feb;23(1):51–7
Effect of intravenous immunoglobulin G on natural killer cell cytotoxicity in vitro in women with recurrent spontaneous abortion. Ruiz JE, et al.
J Reprod Immunol 1996 Aug;31(1–2):125–41
The use of allogeneic leukocytes or i.v. IgG for the treatment of patients with recurrent spontaneous abortions. Clark DA, et al. **Transfus Med Rev** 1997 Apr;11(2):85–94 (50 ref.)
[Immunotherapy of primary habitual abortion] Lin Q, et al.
Chung Hua Fu Chan Ko Tsa Chih 1996 Jun;31(6):351–2 (Eng. Abstr.) **(Chi)**
[Treatment of habitual abortion (editorial)] Bagger PV.
Ugeskr Laeger 1997 Aug 4;159(32):4835 **(Dan)**
[Treatment of adrenal diseases using transplantation of cultured adrenal tissue from newborn piglets] Egorov IuI, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):389–91 **(Rus)**

ULTRASONOGRAPHY

Sonohysterography for screening in recurrent pregnancy loss. Keltz MD, et al. **Fertil Steril** 1997 Apr;67(4):670–4
Role of Doppler ultrasonography in the prediction of pregnancy outcome in women with recurrent spontaneous abortion. Frates MC, et al. **J Ultrasound Med** 1996 Aug; 15(8):557–62

ABORTION, ILLEGAL see **ABORTION, CRIMINAL**

ABORTION, INCOMPLETE

COMPLICATIONS

Intrauterine retention of fetal bone. Chan NS.
Aust N Z J Obstet Gynaecol 1996 Aug;36(3):368–71

ECONOMICS

An analysis of the cost of incomplete abortion to the public health sector in South Africa—1994. Kay BJ, et al.
S Afr Med J 1997 Apr;87(4):442–7

EPIDEMIOLOGY

Biosocial profile of women with incomplete abortions in Ga-Rankuwa Hospital, Medunsa, RSA. Adu SA.
Cent Afr J Med 1996 Jul;42(7):198–202
The epidemiology of incomplete abortion in South Africa. National Incomplete Abortion Reference Group [see comments] Rees H, et al. **S Afr Med J** 1997 Apr;87(4):432–7 . Comment in: S Afr Med J 1997 Apr;87(4):417–8.

ETIOLOGY

[Early diagnosis of congenital and acquired intrauterine causes of abortion by post-abortion hysteroscopy] Römer T, et al. **Geburtshilfe Frauenheilkd** 1996 Oct;56(10):542–5 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Biosocial profile of women with incomplete abortions in Ga-Rankuwa Hospital, Medunsa, RSA. Adu SA.
Cent Afr J Med 1996 Jul;42(7):198–202

SURGERY

Managing residual trophoblastic tissue. Hysteroscopy for directing curettage. Goldenberg M, et al.
J Reprod Med 1997 Jan;42(1):26–8
Improving care for patients undergoing curettage for incomplete abortion [editorial] de Jonge ET, et al.
S Afr Med J 1996 Sep;86(9 Suppl):1173–4
The impact of the manual vacuum aspiration (MVA) technique on health care services at Queen Elizabeth Central Teaching Hospital, Blantyre, Malawi. Leme VM, et al. **S Afr Med J** 1997 Feb;87(2 Suppl):218–22, 224

THERAPY

Randomised trial of expectant versus surgical management of spontaneous miscarriage. Chipchase J, et al.
Br J Obstet Gynaecol 1997 Jul;104(7):840–1
Management of incomplete abortion with manual vacuum aspiration in comparison to sharp metallic curette in an Ethiopian setting. Lukman HY, et al. **East Afr Med J** 1996 Sep;73(9):598–603
Management of incomplete abortions at South African public hospitals. National Incomplete Abortion Study Reference Group. Fawcus S, et al. **S Afr Med J** 1997 Apr;87(4):438–42
[Manual intrauterine aspiration in the treatment of incomplete abortion] Lara Ricalde R, et al. **Ginecol Obstet Mex** 1997 Mar;65:101–6 (Eng. Abstr.) **(Spa)**

ABORTION, INDUCED

Comparison of ethacridine lactate and prostaglandin E2 in second trimester medical abortion. Inan I, et al.
Acta Obstet Gynecol Scand 1997 Aug;76(7):680–3
New technologies permit safe abortion at less than six weeks' gestation and provide timely detection of ectopic gestation. Edwards J, et al. **Am J Obstet Gynecol** 1997 May; 176(5):1101–6
Blood loss during suction termination of pregnancy with two different anaesthetic techniques. Kumarasinghe N, et al.
Anaesth Intensive Care 1997 Feb;25(1):48–50
Abortion and the internist [letter; comment] Simcic KJ.
Ann Intern Med 1997 Mar 1;126(5):411. Comment on: Ann Intern Med 1996 Aug 1;125(3):213–20.
Comment: abortion and assisted suicide [letter] Clark TL.
Ann Pharmacother 1997 Mar;31(3):375
Terminations of pregnancy for exposure to oral retinoids in South Australia, 1985–1993. Chan A, et al.
Aust N Z J Obstet Gynaecol 1995 Nov;35(4):422–6
Prolonged induction to delivery time in termination of pregnancy using 16, 16-dimethyl-PGE1-methyl ester (gemeprost) for fetuses with a neural tube defect or hydrocephalus. Nesbitt D, et al.
Aust N Z J Obstet Gynaecol 1996 Aug;36(3):300–3
Boycott threat forces French company to abandon RU486 [news] Dorozynski A. **BMJ** 1997 Apr 19;314(7088):1150
Evidence to be given to the public must be presented accurately and fairly [letter; comment] Irving HC. **BMJ** 1997 Mar 15;314(7083):831. Comment on: BMJ 1996 Nov 16;313(7067):1251–3.
Do fetuses feel pain? Surgical terminations of pregnancy take place under general anaesthesia [letter; comment] Savage W. **BMJ** 1997 Apr 19;314(7088):1201. Comment on: BMJ 1997 Jan 25;314(7076):302–3. Comment on: BMJ 1997 Jan 25;314(7076):303.
Blood loss during first trimester termination of pregnancy: comparison of two anaesthetic techniques. Hall JE, et al.
Br J Anaesth 1997 Feb;78(2):172–4
Oral versus vaginal misoprostol for cervical priming [letter; comment] Barik S, et al. **Br J Obstet Gynaecol** 1997 May; 104(5):644. Comment on: Br J Obstet Gynaecol 1996 Nov;103(11):1117–9.
Late termination of pregnancy in North Holland [see comments] Bosma JM, et al. **Br J Obstet Gynaecol** 1997 Apr;104(4):478–87. Comment in: Br J Obstet Gynaecol 1997 Apr;104(4):398–400.
Management of twin pregnancies with fetal trisomies. Sebire NJ, et al. **Br J Obstet Gynaecol** 1997 Feb;104(2):220–2
Some final responses to Dr. Waugh [letter; comment] Adams PV. **Can Med Assoc J** 1997 Jun 1;156(11):1529. Comment on: Can Med Assoc J 1997 Feb 1;156(3):408.
Some final responses to Dr. Waugh [letter; comment] Cuddy TJ. **Can Med Assoc J** 1997 Jun 1;156(11):1529. Comment on: Can Med Assoc J 1997 Feb 1;156(3):408.
Abortion and our changing society [see comments] Waugh D. **Can Med Assoc J** 1997 Feb 1;156(3):408. Comment in: Can Med Assoc J 1997 Jun 1;156(11):1529. Comment in: Can Med Assoc J 1997 Jun 1;156(11):1529–30.
Incomplete pregnancies and risk of ovarian cancer (Washington, United States). Chen MT, et al.
Cancer Causes Control 1996 Jul;7(4):415–20
The risk of breast cancer following spontaneous or induced abortion [published erratum appears in Cancer Causes Control 1997 Mar;8(2):260] Wingo PA, et al.
Cancer Causes Control 1997 Jan;8(1):93–108 (96 ref.)
Methotrexate and misoprostol for early abortion: a multicenter trial. Acceptability. Creinin MD, et al.
Contraception 1996 Jul;54(1):19–22
Oral methotrexate and vaginal misoprostol for early abortion. Creinin MD. **Contraception** 1996 Jul;54(1):15–8
Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: a randomised comparative trial. Ho PC, et al. **Contraception** 1996 May;53(5):281–3
Effects of two antiprogestins on early pregnancy in the long-tailed macaque (Macaca fascicularis). Tarantal AF, et al. **Contraception** 1996 Aug;54(2):107–15
A randomised study of two doses of gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. Thong KJ, et al.
Contraception 1996 Aug;54(2):97–100
Analysis of failure in medical abortion. Winikoff B, et al.
Contraception 1996 Dec;54(6):323–7
Termination of second trimester pregnancy with gemeprost and misoprostol: a randomized double-blind placebo-controlled trial. Wong KS, et al. **Contraception** 1996 Jul;54(1):23–5
Medical abortion. Bardin CW, et al.
Curr Ther Endocrinol Metab 1997;6:305–11 (6 ref.)
Reducing pain of first trimester abortion under local anaesthesia. Donati S, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Dec 27;70(2):145–9
Termination of 2nd and 3rd trimester pregnancies with mifepristone and misoprostol. Jannet D, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Dec 27; 70(2):159–63
Research on abortion is objectionable [letter; comment] Foley EC. **Fam Med** 1996 Jul-Aug;28(7):464. Comment on: Fam Med 1996 Mar;28(3):198–203.
Abortion article hits a nerve with readers [letter; comment] O'Handley JG. **Fam Med** 1996 Sep;28(8):535. Comment on: Fam Med 1996 Apr;28(4):245–8.
Abortion article hits a nerve with readers [letter; comment] Piacentini M. **Fam Med** 1996 Sep;28(8):535–6. Comment on: Fam Med 1996 Apr;28(4):245–8. Comment on: Fam Med 1996 Apr;28(4):287–8.
Sentinel surveillance of Chlamydia trachomatis infection in women terminating pregnancy. Skjeldestad FE, et al.
Genitourin Med 1997 Feb;73(1):29–32
Information needs among Italian abortion patients. Bengtsson Agostino M. **Gynecol Obstet Invest** 1997;43(2):84–8
Attitudes of Mexican physicians toward induced abortion. Casanueva E, et al. **Int J Gynaecol Obstet** 1997 Jan; 56(1):47–52
Illegal abortion: consequences for women's health and the health care system. Faúndes A, et al.
Int J Gynaecol Obstet 1997 Jul;58(1):77–83
Abortion and contraceptive practices in eastern Europe. Kovács L. **Int J Gynaecol Obstet** 1997 Jul;58(1):69–75
Comparison of 0.5% and 1.0% lidocaine for abortions. Wiebe ER, et al. **Int J Gynaecol Obstet** 1996 Oct;55(1):71–2
Pharmacists' beliefs about abortion and RU-486. Giannetti V. **J Am Pharm Assoc (Wash)** 1996 Dec;NS36(12):698–703
Abortion procedure [letter] Casner P. **J Fam Pract** 1997 Sep; 45(3):193–4
Abortion procedure [letter] Fletcher JL Jr. **J Fam Pract** 1997 Sep;45(3):193; discussion 194
Abortion procedure [letter] Gehred GA. **J Fam Pract** 1997 Sep;45(3):194
Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. Schaff EA, et al. **J Fam Pract** 1997 Apr;44(4):353–60
Abortion procedure [letter] Schneider AP 2nd.
J Fam Pract 1997 Sep;45(3):193; discussion 194
Nurse-midwives' attitudes toward abortion performance and related procedures [letter] Glenn PS.
J Nurse Midwifery 1996 Jan-Feb;41(1):55–6
A case of uterine choriocarcinoma with spontaneous rupture twenty-three years following the antecedent pregnancy. Okamoto T, et al. **J Obstet Gynaecol Res** 1997 Apr; 23(2):189–95
Pain during early abortion. Borgatta L, et al.
J Reprod Med 1997 May;42(5):287–93
Sonohysterography for detection of a retained laminaria fragment. Bussey LA, et al. **J Ultrasound Med** 1996 Mar; 15(3):249–51
Abortion beliefs [letter; comment] Allen JC. **Lancet** 1996 Oct 5;348(9032):962. Comment on: Lancet 1996 Aug 17;348(9025):478; discussion 478–9.
Mifepristone (RU486) and abortion [editorial; comment] Henshaw RC. **Med J Aust** 1997 Sep 15;167(6):292–3. Comment on: Med J Aust 1997 Sep 15;167(6):316–7.
Women's satisfaction with medical abortion with RU486 [see comments] Mamers PM, et al. **Med J Aust** 1997 Sep 15; 167(6):316–7. Comment in: Med J Aust 1997 Sep 15;167(6):292–3.
Unwanted pregnancy: it's existing solutions from the perspective of young adults in Bangkok and the Abortion Law. Prajayyothin P, et al. **Med Law** 1996;15(3):519–27
The consultation. Struve JK. **Minn Med** 1996 Aug;79(8):12–3
Should abortion training be a requirement of obstetrics and gynecology residencies? Bowes WA. **N C Med J** 1996 Mar-Apr;57(2):108–11
Should legislatures practice medicine? [letter] Perry AM.
N Engl J Med 1997 Oct 23;337(17):1240; discussion 1241
Medicine on the margins: perspectives of abortion operating surgeons in southern New Zealand. Haslett L, et al.
N Z Med J 1997 Jul 11;110(1047):256–8
Referral for abortion [letter] [see comments] Sparrow M.
N Z Med J 1996 Sep 13;109(1029):346. Comment in: N Z Med J 1997 Jan 24;110(1036):18.
Abortion foe blamed for research head upset in Australia [news] Pockley P. **Nature** 1997 Feb 27;385(6619):758
High failure rate of postmortem karyotyping after termination for fetal abnormality. Kyle PM, et al.
Obstet Gynecol 1996 Nov;88(5):859–62
Ethical conflicts in regulating the start of life. Hemminki E, et al. **Perspect Biol Med** 1997 Summer;40(4):586–91
FIGO Committee for the Study of Ethical Aspects of Human Reproduction: Ethical aspects in the management of the severely deformed fetus. **S Afr Med J** 1997 Feb;87(2 Suppl):229
Backstreet abortion in South Africa [editorial; comment] Jewkes RK, et al. **S Afr Med J** 1997 Apr;87(4):417–8. Comment on: S Afr Med J 1997 Apr;87(4):432–7.
Fetal anomaly, the Internet and the 'informed' patient: a dangerous combination [letter; comment] Challis DE, et al. **Ultrasound Obstet Gynecol** 1996 Jul;8(1):68. Comment on: Ultrasound Obstet Gynecol 1996 Feb;7(2):89–91.
[A phase III multicentre study on medical termination of early pregnancy with two regimens of mifepristone followed by PG05] Sang G, et al.
Chung Hua I Hsueh Tsa Chih 1996 May;76(5):325–30 (Eng. Abstr.) **(Chi)**
[Induced abortions in relation to the use of contraceptive agents (see comments)] Andreasen EE, et al.
Ugeskr Laeger 1996 Oct 14;158(42):5928–32 (Eng. Abstr.) . Comment in: Ugeskr Laeger 1997 Jan 6;159(2):189–90. Comment in: Ugeskr Laeger 1997 Feb 10;159(7):966–8. **(Dan)**
[Induced abortion in Greenland] Bjerregaard P, et al.
Ugeskr Laeger 1996 Oct 21;158(43):6085–9 (Eng. Abstr.) **(Dan)**
[Induced abortions in relation to the use of contraceptive agents (letter; comment)] Knudsen LB. **Ugeskr Laeger** 1997 Feb 10;159(7):966–8. Comment on: Ugeskr Laeger 1996 Oct 14;158(42):5928–32. **(Dan)**
[Errors of the not-known? (letter; comment)] Leth K.
Ugeskr Laeger 1997 Jan 6;159(2):189–90. Comment on: Ugeskr Laeger 1996 Oct 14;158(42):5928–32. **(Dan)**
[Voluntary pregnancy termination in adolescence in the Vaud canton] Narring F, et al. **Rev Med Suisse Romande** 1997

Jan;117(1):47–53 **(Fre)**

[Public child killing (letter)] Hackelöer BJ. **Dtsch Med Wochenschr** 1997 Feb 7;122(6):175 **(Ger)**

[Pregnancy termination in fetal abnormalities] Müller P, et al. **Schweiz Med Wochenschr** 1997 Jan 18;127(3):73–8 (Eng. Abstr.) **(Ger)**

[Is there justification for destroying viable fetuses for medical indications?] Schenker JG. **Harefuah** 1996 Aug; 131(3–4):101–3 (11 ref.) **(Heb)**

[Contraception and voluntary termination of pregnancy. Survey of a sample of 500 women] Bastianelli C, et al. **Minerva Ginecol** 1996 Sep;48(9):359–63 (Eng. Abstr.) **(Ita)**

[Occurrence of bacterial vaginosis among abortion seekers] Bjørnerem A, et al. **Tidsskr Nor Laegeforen** 1997 Apr 10; 117(9):1282–4 (Eng. Abstr.) **(Nor)**

[Use of sulprostone in the medical evacuation of uterine contents] Paulo AS, et al. **Acta Med Port** 1996 Apr–Jun; 9(4–6):157–61 (Eng. Abstr.) **(Por)**

[Abortion. Some considerations] Márquez–Piñero R. **Gac Med Mex** 1997 May–Jun;133(3):267–71 **(Spa)**

[Ecology and abortion: opinions and fallacies (letter; comment)] Segura A, et al. **Med Clin (Barc)** 1996 Oct 26; 107(14):558–9. Comment on: Med Clin (Barc) 1995 Nov 11;105(16):617–8. **(Spa)**

[Proposal on an abortion registry with social security number. The scientists want to create a basis for epidemiological studies] Orn P. **Lakartidningen** 1997 Apr 9;94(15):1342 **(Swe)**

ADVERSE EFFECTS

Multiple induced abortions as risk factor for ectopic pregnancy. A prospective study. Skjeldestad FE, et al. **Acta Obstet Gynecol Scand** 1997 Aug;76(7):691–6

Evaluation of induced abortion as a risk factor for ectopic pregnancy. A case–control study. Skjeldestad FE, et al. **Acta Obstet Gynecol Scand** 1997 Feb;76(2):151–8

Midtrimester pregnancy termination [letter; comment] Baxi LV. **Am J Obstet Gynecol** 1997 Apr;176(4):952–3. Comment on: Am J Obstet Gynecol 1996 Oct;175(4 Pt 1):889–92.

Complications of midtrimester pregnancy termination: the effect of prior cesarean delivery [see comments] Chapman SJ, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):889–92. Comment in: Am J Obstet Gynecol 1997 Apr;176(4):952–3.

Iatrogenic secondary infertility caused by residual intrauterine fetal bone after midtrimester abortion. Moon HS, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):369–70

Fatal myocardial infarction resulting from coronary artery septic embolism after abortion: unusual cause and complication of endocarditis. Caraballo V. **Ann Emerg Med** 1997 Jan;29(1):175–7

The use of intraoperative ultrasound in the management of a perforated uterus with retained products of conception. Kohlenberg CF, et al. **Aust N Z J Obstet Gynaecol** 1996 Nov;36(4):482–4

Ureterouterine fistula as a complication of an elective abortion. Lodh U, et al. **Aust N Z J Obstet Gynaecol** 1996 Feb;36(1):94–5

Overdose and termination of pregnancy: an important association? [see comments] Houston H, et al. **Br J Gen Pract** 1996 Dec;46(413):737–8. Comment in: Br J Gen Pract 1997 Mar;47(416):184.

A follow–up study of first trimester induced abortions at hospitals and family planning clinics in Sichuan province, China. Luo L, et al. **Contraception** 1996 May;53(5):267–73

Induced abortion as a risk factor for subsequent fetal loss. Infante–Rivard C, et al. **Epidemiology** 1996 Sep;7(5):540–2

Does induced or spontaneous abortion affect the risk of breast cancer? Michels KB, et al. **Epidemiology** 1996 Sep; 7(5):521–8 (79 ref.)

Accurate diagnosis of postabortal placental remnant by sonohysterography and color Doppler sonographic studies. Tal J, et al. **Gynecol Obstet Invest** 1997;43(2):131–4

Induced abortion and the risk of non–Hodgkin's lymphoma [letter] Frisch M, et al. **Int J Cancer** 1997 Mar 28; 71(1):127–8

Induced abortion as an independent risk factor for breast cancer: a comprehensive review and meta–analysis [see comments] Brind J, et al. **J Epidemiol Community Health** 1996 Oct;50(5):481–96. Comment in: J Epidemiol Community Health 1996 Dec;50(6):605.

Re: Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch case–control study [letter; comment] Brind J, et al. **J Natl Cancer Inst** 1997 Apr 16;89(8):588–90. Comment on: J Natl Cancer Inst 1996 Dec 4;88(23):1698–700. Comment on: J Natl Cancer Inst 1996 Dec 4;88(23):1759–64.

Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch case–control study [see comments] Rookus MA, et al. **J Natl Cancer Inst** 1996 Dec 4;88(23):1759–64. Comment in: J Natl Cancer Inst 1996 Dec 4;88(23):1698–700. Comment in: J Natl Cancer Inst 1997 Apr 16;89(8):588–90.

Induced abortion, bias, and breast cancer: why epidemiology hasn't reached its limit [editorial; comment] [see comments] Weed DL, et al. **J Natl Cancer Inst** 1996 Dec 4; 88(23):1698–700. Comment on: J Natl Cancer Inst 1996 Dec 4;88(23):1759–64. Comment in: J Natl Cancer Inst 1997 Apr 16;89(8):588–90.

Pyomyoma after uterine instrumentation. A case report. Tobias DH, et al. **J Reprod Med** 1996 May;41(5):375–8

Induced abortion and the risk of breast cancer [letter; comment] Brind J, et al. **N Engl J Med** 1997 Jun 19; 336(25):1834; discussion 1835. Comment on: N Engl J Med 1997 Jan 9;336(2):81–5.

Abortion, breast cancer, and epidemiology [editorial; comment] Hartge P. **N Engl J Med** 1997 Jan 9;336(2):127–8. Comment on: N Engl J Med 1997 Jan 9;336(2):81–5.

Induced abortion and the risk of breast cancer [see comments] Melbye M, et al. **N Engl J Med** 1997 Jan 9;336(2):81–5. Comment in: N Engl J Med 1997 Jan 9;336(2):127–8. Comment in: N Engl J Med 1997 Jun 19;336(25):1834; discussion 1835. Comment in: ACP J Club 1997 Jul–Aug;127(1):18.

Induced abortion and the risk of breast cancer [letter; comment] Senghas RE, et al. **N Engl J Med** 1997 Jun 19; 336(25):1834; discussion 1835. Comment on: N Engl J Med 1997 Jan 9;336(2):81–5.

The relation between induced abortion and ectopic pregnancy. Atrash HK, et al. **Obstet Gynecol** 1997 Apr; 89(4):512–8

Breast cancer risk: protective effect of an early first full–term pregnancy versus increased risk of induced abortion. Canty L. **Oncol Nurs Forum** 1997 Jul;24(6):1025–31 (60 ref.)

[A permanent magnetic field in the combined treatment of acute endometritis after an artificial abortion] Strugatskiĭ VM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Nov–Dec;(6):21–4 (Eng. Abstr.) **(Rus)**

HISTORY

Receptions of the Hippocratic Oath in the Renaissance: the prohibition of abortion as a case study in reception. Rütten T. **J Hist Med Allied Sci** 1996 Oct;51(4):456–83

METHODS

Midtrimester termination of complicated pregnancy with oral misoprostol. Batioğlu S, et al. **Adv Contracept** 1997 Mar; 13(1):55–61

Medical options for early pregnancy termination [see comments] Gold M, et al. **Am Fam Physician** 1997 Aug; 56(2):533–8 (16 ref.). Comment in: Am Fam Physician 1997 Aug;56(2):351, 355–6.

Medical abortion is not just a medical issue [editorial; comment] Orr RD, et al. **Am Fam Physician** 1997 Aug; 56(2):351, 355–6. Comment on: Am Fam Physician 1997 Aug;56(2):533–8.

Medically induced abortion in a woman with a large myomatous uterus. Creinin MD. **Am J Obstet Gynecol** 1996 Nov;175(5):1379–80

Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone–misoprostol versus surgical abortion. Winikoff B, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):431–7

Induced termination of pregnancy by purified extracts of Azadirachta Indica (Neem): mechanisms involved. Talwar GP, et al. **Am J Reprod Immunol** 1997 Jun;37(6):485–91

A randomized trial of 2 regimens for the administration of vaginal prostaglandins (gemeprost) for the induction of midtrimester abortion. Armatage RJ, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):296–9

Termination of early human pregnancy with either 50 mg or 200 mg single oral dose of mifepristone (RU486) in combination with either 0.5 mg or 1.0 mg vaginal gemeprost. Prasad RN, et al. **Aust N Z J Obstet Gynaecol** 1996 Feb;36(1):20–3

A randomised comparison of oral and vaginal misoprostol for cervical priming before suction termination of pregnancy [see comments] Lawrie A, et al. **Br J Obstet Gynaecol** 1996 Nov;103(11):1117–9. Comment in: Br J Obstet Gynaecol 1997 May;104(5):644.

Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomised study. Ngai SW, et al. **Br J Obstet Gynaecol** 1996 Nov; 103(11):1120–3

Successful methotrexate treatment of a viable pregnancy within a thin uterine scar. Ravhon A, et al. **Br J Obstet Gynaecol** 1997 May;104(5):628–9

Nitric oxide donors induce ripening of the human uterine cervix: a randomised controlled trial. Thomson AJ, et al. **Br J Obstet Gynaecol** 1997 Sep;104(9):1054–7

Pregnancy and neoplasm are two outstanding examples of natural tolerance to homograft [letter] Bhattacharya N. **Clin Exp Obstet Gynecol** 1996;23(4):272–5

The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study--final results. **Contraception** 1997 Jan;55(1):1–5

The use of misoprostol for termination of early pregnancy. Carbonell JL, et al. **Contraception** 1997 Mar;55(3):165–8

Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Creinin MD, et al. **Contraception** 1996 Jun;53(6):321–7

Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat. Dao B, et al. **Contraception** 1997 Jan;55(1):35–40

Choosing between surgical abortions and medical abortions induced with methotrexate and misoprostol. Wiebe ER. **Contraception** 1997 Feb;55(2):67–71

Abortion induced with methotrexate and misoprostol: a comparison of various protocols. Wiebe ER. **Contraception** 1997 Mar;55(3):159–63

Intrafetal prostaglandin F2alpha administration for uterine evacuation in a case of intrauterine death. Christodoulou CN, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Feb; 64(2):227–9

Second trimester pregnancy termination including fetal death: comparison of five different methods. Yapar EG, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Nov; 69(2):97–102

Methotrexate and misoprostol for early abortion [see comments] Schaff EA, et al. **Fam Med** 1996 Mar; 28(3):198–203. Comment in: Fam Med 1996 Jul–Aug;28(7):464.

Knowledge and perceptions of medical abortion among potential users. Harvey SM, et al. **Fam Plann Perspect** 1995 Sep–Oct;27(5):203–7

Plant immunomodulators for termination of unwanted pregnancy and for contraception and reproductive health. Talwar GP, et al. **Immunol Cell Biol** 1997 Apr;75(2):190–2

Evidence for the promoting role of the intra–uterine kinin release in the development of late hypertonic saline–induced abortion. Makevnina LG, et al. **Immunopharmacology** 1996 Jun;33(1–3):133–6

A comparative study of the efficacy and safety of synthetic prostaglandin E2 derivative and 15–methyl prostaglandin F2 alpha in the termination of midtrimester pregnancy. Biswas A, et al. **J Indian Med Assoc** 1996 Aug;94(8):292–3

Termination of second–trimester pregnancy with intracervicovaginal misoprostol. Srisomboon J, et al. **J Med Assoc Thai** 1997 Apr;80(4):242–6

Pregnancy interruption using mifepristone (RU–486). A new choice for women in the USA. Mackenzie SJ, et al. **J Nurse Midwifery** 1997 Mar–Apr;42(2):86–90 (32 ref.)

Midtrimester pregnancy termination for fetal malformations. Use of intravaginal prostaglandin E2. Hagar DL, et al. **J Reprod Med** 1997 Aug;42(8):497–500

Methotrexate. A single agent for early abortion. Schaff EA, et al. **J Reprod Med** 1997 Jan;42(1):56–60

Medical abortion in early pregnancy: a review of the evidence. Grimes DA. **Obstet Gynecol** 1997 May;89(5 Pt 1):790–6 (55 ref.)

Induction of second trimester non–viable pregnancies by intrauterine infusions through a vaginally placed Foley catheter. Tomlinson AJ. **Trop Doct** 1997 Apr;27(2):91–3

[The termination of pregnancy in the second trimester with rivanol] Vlasova D, et al. **Akush Ginekol (Sofiia)** 1996; 35(1–2):16–7 (Eng. Abstr.) **(Bul)**

[Intravaginal misoprostol before induced abortion in nulliparous women] Schaub B, et al. **Contracept Fertil Sex** 1996 Jan;24(1):67–71 (Eng. Abstr.) **(Fre)**

MORTALITY

Induced abortion—a global health problem. Odlind V. **Acta Obstet Gynecol Scand Suppl** 1997;164:43–5

PSYCHOLOGY

Suicides after pregnancy. Study did not show association between induced abortion and suicide [letter; comment] Mitchison S. **BMJ** 1997 Mar 22;314(7084):902; discussion 902–3. Comment on: BMJ 1996 Dec 7;313(7070):1431–4.

Medical abortion or vacuum aspiration? Two year follow up of a patient preference trial. Howie FL, et al. **Br J Obstet Gynaecol** 1997 Jul;104(7):829–33

Attitudes towards termination for fetal abnormality: comparisons in three European countries. Drake H, et al. **Clin Genet** 1996 Mar;49(3):134–40

Demographic characteristics, socioeconomic profile and contraceptive behaviour in patients with abortion at Jimma Hospital, Ethiopia. Abdella A. **East Afr Med J** 1996 Oct; 73(10):660–4

Early predictors of nonmarital first pregnancy and abortion. Udry JR, et al. **Fam Plann Perspect** 1996 May–Jun; 28(3):113–6

Conceptions and misconceptions. Decisions about pregnancy. Stotland NL. **Gen Hosp Psychiatry** 1996 Jul;18(4):238–43 (11 ref.)

Late psychological sequelae of abortion: questions from a primary care perspective. Butler C. **J Fam Pract** 1996 Oct; 43(4):396–401

Mixed messages: implications of social conflict and social support within close relationships for adjustment to a stressful life event. Major B, et al. **J Pers Soc Psychol** 1997 Jun;72(6):1349–63

Assessment of satisfaction with induced abortion procedure. Guilbert E, et al. **J Psychol** 1997 Mar;131(2):157–66

The abortion decision: fantasy processes. Allanson S, et al. **J Psychosom Obstet Gynaecol** 1996 Sep;17(3):158–67

Clinical implications of respect for autonomy in the psychiatric treatment of pregnant patients with depression. Coverdale JH, et al. **Psychiatr Serv** 1997 Feb;48(2):209–12

Comparison of long–term psychological responses of women after pregnancy termination due to fetal anomalies and after perinatal loss [see comments] Salvesen KA, et al. **Ultrasound Obstet Gynecol** 1997 Feb;9(2):80–5. Comment in: Ultrasound Obstet Gynecol 1997 Feb;9(2):76–9.

[Psychological consequences of induced abortion] Schleiss L, et al. **Ugeskr Laeger** 1997 Jun 2;159(23):3603–6 (Eng. Abstr.) **(Dan)**

[Psychological and social characteristics of women having

repeated induced abortions. A French study in three centers] Garel M, et al. **Contracept Fertil Sex** 1996 Jan; 24(1):72–7 (Eng. Abstr.) **(Fre)**

[Couple treatment following abortion in prenatal diagnosis. An interdisciplinary and interprofessional cooperation] Buchegger P. **Schweiz Med Wochenschr** 1997 Jan 18; 127(3):69–72 (Eng. Abstr.) **(Ger)**

STANDARDS

Abortion after 24 weeks [comment] Paintin D.
Br J Obstet Gynaecol 1997 Apr;104(4):398–400. Comment on: Br J Obstet Gynaecol 1997 Apr;104(4):478–87.

STATISTICS & NUMERICAL DATA

Abortion in the framework of family planning in Estonia. Karro H. **Acta Obstet Gynecol Scand Suppl** 1997;164:46–50

Induced abortions in Denmark. Knudsen LB.
Acta Obstet Gynecol Scand Suppl 1997;164:54–9

Pregnancy termination—situation in Finland. Mandelin MA.
Acta Obstet Gynecol Scand Suppl 1997;164:51–3

Abortions in Malmö—problems and prevention. Söderberg H. **Acta Obstet Gynecol Scand Suppl** 1997;164:60–2

Termination of pregnancy in New South Wales, 1990. Adelson PL, et al. **Aust N Z J Public Health** 1996 Feb; 20(1):64–8

Overdose and termination of pregnancy [letter; comment] Gbolade BA. **Br J Gen Pract** 1997 Mar;47(416):184. Comment on: Br J Gen Pract 1996 Dec;46(413):737–8.

Ensuring access to abortion in an era of cutbacks [editorial] Powell MG. **Can Med Assoc J** 1997 Jun 1;156(11):1545–7

Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives. Skjeldestad FE. **Contraception** 1997 Jan;55(1):11–4

Choosing between surgical abortions and medical abortions induced with methotrexate and misoprostol. Wiebe ER. **Contraception** 1997 Feb;55(2):67–71

The impact of state-level restrictions on abortion. Meier KJ, et al. **Demography** 1996 Aug;33(3):307–12

Demographic characteristics, socioeconomic profile and contraceptive behaviour in patients with abortion at Jimma Hospital, Ethiopia. Abdella A. **East Afr Med J** 1996 Oct; 73(10):660–4

Does an abortion increase the risk of intrapartum infection in the following pregnancy? Mühlemann K, et al.
Epidemiology 1996 Mar;7(2):194–8

Livebirths and induced abortions in Italy after the Chernobyl accident [letter] Spinelli A, et al. **Epidemiology** 1996 Nov; 7(6):653–4

Differences between spontaneous and induced abortions as risk factors for breast cancer. Zhang J. **Epidemiology** 1996 May;7(3):316–8

Deliveries, abortion and HIV-1 infection in Rome, 1989–1994. The Lazio AIDS Collaborative Group. Abeni DD, et al. **Eur J Epidemiol** 1997 Jun;13(4):373–8

Induced abortion in Italy: levels, trends and characteristics. Bettarini SS, et al. **Fam Plann Perspect** 1996 Nov–Dec; 28(6):267–71, 277 (19 ref.)

Teenage abortion and pregnancy statistics by state, 1992. Henshaw SK. **Fam Plann Perspect** 1997 May–Jun; 29(3):115–22

A medical record linkage analysis of abortion underreporting. Udry JR, et al. **Fam Plann Perspect** 1996 Sep–Oct; 28(5):228–31

Declining induced abortion rate in Finland: data quality of the Finnish abortion register. Gissler M, et al.
Int J Epidemiol 1996 Apr;25(2):376–80

Family planning in Russia. Savelyeva GM, et al.
Int J Gynaecol Obstet 1997 Jul;58(1):51–7

Chromosomal analysis in 894 induced abortuses from women of advanced maternal age in relation to gestational weeks and fetal sex ratio. Hoshi N, et al.
J Obstet Gynaecol Res 1997 Feb;23(1):1–7

Knowledge and use of emergency contraception among women seeking termination of pregnancy in New South Wales [letter] Weisberg E, et al. **Med J Aust** 1997 Mar 17;166(6):336

Traditions and reproductive technology in an urbanizing north Indian village. Khanna SK. **Soc Sci Med** 1997 Jan; 44(2):171–80

New estimates of induced abortion in Russia. Entwisle B, et al. **Stud Fam Plann** 1997 Mar;28(1):14–23

Survey questions for the measurement of induced abortion. Huntington D, et al. **Stud Fam Plann** 1996 May–Jun; 27(3):155–61

The road not taken—another perspective [letter] Baumgartner F. **West J Med** 1997 Jan;166(1):69

[Repeat induced abortions in France: analysis of statistic bulletins] Kaminski M, et al. **Contracept Fertil Sex** 1997 Feb;25(2):152–8 (Eng. Abstr.) **(Fre)**

[Pregnancy interruption in Switzerland 1942–1996] Dondénaz M, et al. **Schweiz Rundsch Med Prax** 1997 Feb 25;86(9):340–7 (Eng. Abstr.) **(Ger)**

[Pregnancy interruption in group 1 hospitals in 1996 (letter)] Nilsen ST, et al. **Tidsskr Nor Laegeforen** 1997 Feb 10; 117(4):558 **(Nor)**

[Determinants of induced abortion among poor women admitted to hospitals in a locality of northeastern Brazil] Fonseca W, et al. **Rev Saude Publica** 1996 Feb;30(1):13–8 (Eng. Abstr.) **(Por)**

[Dynamics of abortion in various regions of Russian Federation] Katkova IP, et al.
Probl Sotsialnoi Gig Istor Med 1996 Jan–Feb;(1):9–16 (Eng. Abstr.) **(Rus)**

[Recommendations are missing: the part of medical abortions varies between hospitals] Orn P. **Lakartidningen** 1997 Apr 9;94(15):1347 **(Swe)**

TRENDS

Induced abortions and childbirths: trends in Estonia, Latvia, Lithuania, Russia, Belarussia and the Ukraine during 1970 to 1994. Mogilevkina I, et al.
Acta Obstet Gynecol Scand 1996 Nov;75(10):908–11

Some final responses to Dr. Waugh [letter; comment] Harris JD. **Can Med Assoc J** 1997 Jun 1;156(11):1529–30. Comment on: Can Med Assoc J 1997 Feb 1;156(3):408.

Contraceptive practices of women requesting termination of pregnancy: a study from China. Cheng Y, et al.
Contraception 1997 Jan;55(1):15–7

Declining induced abortion rate in Finland: data quality of the Finnish abortion register. Gissler M, et al.
Int J Epidemiol 1996 Apr;25(2):376–80

[Negative reports on oral contraceptives—increased number of interrupted pregnancies (see comments)] Nilsen ST, et al. **Tidsskr Nor Laegeforen** 1996 Nov 30;116(29):3486–8 (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1997 Feb 10;117(4):558–9. **(Nor)**

VETERINARY

Use of transvaginal ultrasound-guided puncture for elimination of equine pregnancies. Squires EL.
Vet Clin North Am Equine Pract 1996 Apr;12(1):161–8 (19 ref.)

ABORTION, LEGAL

Reduced prevalence of cervical Chlamydia infection among women requesting termination. Jónsdóttir K, et al.
Acta Obstet Gynecol Scand 1997 May;76(5):438–41

Physician-assisted suicide and abortion [letter] Dobscha SK.
Am J Psychiatry 1997 Aug;154(8):1173–4

Mandatory parental involvement in minors' abortions: effects of the laws in Minnesota, Missouri, and Indiana. Ellertson C. **Am J Public Health** 1997 Aug;87(8):1367–74

Legalising abortion: it's time [editorial] Richters J.
Aust N Z J Public Health 1996 Feb;20(1):3–4

Importance of accurate assessment of fetomaternal haemorrhage after late abortions. Bromilow I, et al.
BMJ 1996 Nov 9;313(7066):1200–1

Terminations of pregnancy, not unplanned deliveries, increased as result of pill scare [letter] Child TJ, et al.
BMJ 1996 Oct 19;313(7063):1005

Setback for French antiabortionists [news] Dorozynski A.
BMJ 1996 Dec 7;313(7070):1425

Selective abortion. Doctors who perform abortions for social reasons are social technicians [letter; comment] Gardner G. **BMJ** 1996 Oct 19;313(7063):1004. Comment on: BMJ 1996 Aug 17;313(7054):373–4.

Selective abortion. Dead fetuses might have to be registered as stillbirths [letter; comment] [see comments] Heys RF. **BMJ** 1996 Oct 19;313(7063):1004. Comment on: BMJ 1996 Aug 17;313(7054):373–4. Comment in: BMJ 1997 Feb 8;314(7078):441–2. Comment in: BMJ 1997 Feb 8;314(7078):442.

US senate likely to ban controversial abortion procedure [news] Macready N. **BMJ** 1997 May 24;314(7093):1504

American Medical Association backs amended abortion bill [news] Macready N. **BMJ** 1997 May 31;314(7094):1572

Abortion must not be advocated as preventive solution to unwanted pregnancy [letter] Ross S. **BMJ** 1997 May 31; 314(7094):1623–4

Legal abortions save women's lives [letter] Savage W, et al.
BMJ 1997 May 31;314(7094):1623

South Africa plans to liberalise abortion law [news] Sidley P. **BMJ** 1996 Oct 26;313(7064):1034

The BMJ's Nuremberg issue. Abortion and euthanasia evoke thoughts of Nazi Germany [letter] Thomson HJ. **BMJ** 1997 Feb 8;314(7078):439

Whose life is it anyway? Goodman NW. **Br J Hosp Med** 1996 Sep 4–17;56(5):240

The moral status of fetuses in Russia. Tichtchenko P, et al.
Camb Q Healthc Ethics 1997 Winter;6(1):31–8

Medical abortion: ethics, laws and religious points of view, A study by the 1994–1995 Ethics and Morals Committee of the ISPN. Hirsch JF, et al. **Childs Nerv Syst** 1996 Sep; 12(9):507–14

The impact of state-level restrictions on abortion. Meier KJ, et al. **Demography** 1996 Aug;33(3):307–12

Abortion article hits a nerve with readers [letter; comment] Robinson R. **Fam Med** 1996 Sep;28(8):536. Comment on: Fam Med 1996 Apr;28(4):245–8.

The measurement of public opinion on abortion: the effects of survey design. Bumpass LL. **Fam Plann Perspect** 1997 Jul–Aug;29(4):177–80

State actions on reproductive health issues in 1996. Sollom T. **Fam Plann Perspect** 1997 Jan–Feb;29(1):35–40 (4 ref.)

People to people visit [news] Putnam CE.
Hastings Cent Rep 1996 Jan–Feb;26(1):47

Religious discrimination in the selection of medical students: a case study. Gunn AE, et al. **Issues Law Med** 1996 Spring; 11(4):363–78

Response to medicine and abortion issue [letter] Hoffman M, et al. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):9, 18

Social reform and violence: the case of the American prohibitionists. Hamm RF. **J Clin Pharm Ther** 1996 Jun; 21(3):131–3

Selective reduction of pregnancy: a legal analysis. Hall A.
J Med Ethics 1996 Oct;22(5):304–8

Bodies, rights and abortion. McLachlan HV.
J Med Ethics 1997 Jun;23(3):176–80

Privacy and autonomy: from Warren and Brandeis to Roe and Cruzan. Halper T. **J Med Philos** 1996 Apr;21(2):121–35

Abortion as a public health problem in Zambia. Sims P.
J Public Health Med 1996 Jun;18(2):232–3

Abortion Law in Bavaria [letter] Wisser J. **Lancet** 1996 Oct 5;348(9032):962–3

The hole of the pit [letter] Tibbs GJ. **Med J Aust** 1997 Apr 7;166(7):392

Unwanted pregnancy: it's existing solutions from the perspective of young adults in Bangkok and the abortion law. Prajayayothin P, et al. **Med Law** 1996;15(2):365–73

A need for options [letter] Dorsen PJ. **Minn Med** 1996 Dec; 79(12):43

MSNJ's expert panel on late-term abortion. Medical Society of New Jersey. Caggiano AP Jr, et al. **N J Med** 1997 Aug; 94(8):25–8 (0 ref.)

Referral for abortion [letter; comment] O'Neill P.
N Z Med J 1997 Jan 24;110(1036):18. Comment on: N Z Med J 1996 Sep 13;109(1029):346.

Ethical issues in perinatology. Anon.. **Natl Med J India** 1996 Jan–Feb;9(1):32–7

Parents' consent for a minors' abortion [letter; comment] Beiser HR. **Pharos** 1996 Summer;59(3):47. Comment on: Pharos 1996 Winter;59(1):2–6.

Parents' consent for minors' abortion [letter; comment] Cook IH. **Pharos** 1996 Summer;59(3):47. Comment on: Pharos 1996 Winter;59(1):2–6.

Parents' consent for a minor's abortion [letter; comment] Fanning GL. **Pharos** 1996 Summer;59(3):46–7. Comment on: Pharos 1996 Winter;59(1):2–6.

Minor's abortion: is the requirement for parental consent ethically justified? [see comments] Yussman SM. **Pharos** 1996 Winter;59(1):2–6. Comment in: Pharos 1996 Summer;59(3):46–7. Comment in: Pharos 1996 Summer;59(3):47.

Opinions on the abortion legislature [news] Cronjé HS.
S Afr Med J 1996 Sep;86(9 Suppl):1170

Abortion legislation [letter] [see comments] Hardy W, et al.
S Afr Med J 1996 Nov;86(11):1433. Comment in: S Afr Med J 1997 Jan;87(1):74–5.

Abortion legislation [letter] Horsfall CG, et al.
S Afr Med J 1996 Nov;86(11):1433–4

Abortion on demand [letter; comment] van der Merwe TL, et al. **S Afr Med J** 1997 Jan;87(1):74–5. Comment on: S Afr Med J 1996 Nov;86(11):1433.

Abortion objectors—rights and responsibilities [letter] Ward H. **S Afr Med J** 1997 Jul;87(7):910

Successful transvaginal ultrasound-guided puncture and injection of a cervical pregnancy in a patient with simultaneous intrauterine pregnancy and a history of a previous cervical pregnancy. Monteagudo A, et al.
Ultrasound Obstet Gynecol 1996 Dec;8(6):381–6

Reader questions Dr Ulmer's statement on AB 441 [letter] Sullivan PJ. **Wis Med J** 1996 Aug;95(8):536

[Sexual activity, contraception and abortions among teenagers in Bulgaria] Sirakov M, et al.
Akush Ginekol (Sofiia) 1996;35(4):12–4 (Eng. Abstr.) **(Bul)**

[Therapeutic abortions: basis and ethical foundations] Barjot P, et al. **Contracept Fertil Sex** 1997 Jan;25(1):37–45 (23 ref.) (Eng. Abstr.) **(Fre)**

[Knowledge and behavior of pregnant women towards HIV infection and its screening] Rey D, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(1):57–63 (Eng. Abstr.) **(Fre)**

[Pregnancy interruption in Switzerland 1942–1996] Dondénaz M, et al. **Schweiz Rundsch Med Prax** 1997 Feb 25;86(9):340–7 (Eng. Abstr.) **(Ger)**

[Severe fetal damage as maternal indication for pregnancy termination within the scope of section 218 StGB and its revision in German jurisprudence 1975/1995] Hiersche HD. **Z Geburtshilfe Neonatol** 1996 Nov–Dec;200(6):236–40 **(Ger)**

[Section 218 (editorial)] Ratzel R.
Z Geburtshilfe Neonatol 1996 Jul–Aug;200(4):131 **(Ger)**

[The clinical experiences of abortions on demand in a group of 221 adolescents] Ciolli P, et al. **Minerva Ginecol** 1996 Dec;48(12):527–32 (Eng. Abstr.) **(Ita)**

[Ending life by medical means. Do attitudes of physicians differ from those of the population?] Førde R, et al.
Tidsskr Nor Laegeforen 1997 Mar 20;117(8):1135–7 (Eng. Abstr.) **(Nor)**

[Euthanasia, abortion, ethics, religion and medicine (letter)] Molvaer OI. **Tidsskr Nor Laegeforen** 1996 Oct 20; 116(25):3047 **(Nor)**

[The National Ethics Committee should change its name (letter)] Kjellmer I. **Lakartidningen** 1997 Mar 5;94(10):813 **(Swe)**

[Abortion registry—don't! (letter)] Mandahl A.
Lakartidningen 1997 May 28;94(22):2070 **(Swe)**

[When does the fetus become a child according to the law? The national ethics committee wants to keep the 28th week of pregnancy as a limit] Orn P. **Lakartidningen** 1997 Jan

22;94(4):198 **(Swe)**

ADVERSE EFFECTS

Repeat abortion: a comparative study. Törnbom M, et al. **J Psychosom Obstet Gynaecol** 1996 Dec;17(4):208–14

ECONOMICS

Sex, lies, and health insurance: employer-provided health insurance coverage of abortion and infertility services and the ADA. Millsap D. **Am J Law Med** 1996;22(1):51–84 (309 ref.)

The effects of economic conditions and access to reproductive health services on state abortion rates and birthrates. Matthews S, et al. **Fam Plann Perspect** 1997 Mar–Apr;29(2):52–60

METHODS

Experience and acceptability of medical abortion with mifepristone and misoprostol among U.S. women. Beckman LJ, et al. **Womens Health Issues** 1997 Jul–Aug;7(4):253–62

PSYCHOLOGY

Normatology: a review and commentary with reference to abortion and physician-assisted suicide. Brodie HK, et al. **Am J Psychiatry** 1997 Jun;154(6 Suppl):13–9 (42 ref.)

Abortion patients in 1994–1995: characteristics and contraceptive use. Henshaw SK, et al. **Fam Plann Perspect** 1996 Jul–Aug;28(4):140–7, 158

Repeat abortion: a comparative study. Törnbom M, et al. **J Psychosom Obstet Gynaecol** 1996 Dec;17(4):208–14

Politicizing abortion: personal morality and professional responsibility of residents training in the United States. Lazarus ES. **Soc Sci Med** 1997 May;44(9):1417–25

Experience and acceptability of medical abortion with mifepristone and misoprostol among U.S. women. Beckman LJ, et al. **Womens Health Issues** 1997 Jul–Aug;7(4):253–62

STANDARDS

FIGO committee for the study of ethical aspects of human reproduction. Ethical aspects in the management of the severely malformed fetus. International Federation of Gynecology and Obstetrics. Schenker JG. **Ginekol Pol** 1996 Nov;67(11):585–6

STATISTICS & NUMERICAL DATA

The recent pill scare and number of legal abortions in Norway [letter] Iversen OE, et al. **Acta Obstet Gynecol Scand** 1996 Aug;75(7):690–1

Abortion patients in 1994–1995: characteristics and contraceptive use. Henshaw SK, et al. **Fam Plann Perspect** 1996 Jul–Aug;28(4):140–7, 158

Repeat abortions in Canada, 1975–1993. Millar WJ, et al. **Fam Plann Perspect** 1997 Jan–Feb;29(1):20–4

From the Centers for Disease Control and Prevention. Abortion surveillance: preliminary data—United States, 1994. **JAMA** 1997 Jan 22–29;277(4):284

Abortion surveillance—United States, 1993 and 1994. Koonin LM, et al. **MMWR CDC Surveill Summ** 1997 Aug 8; 46(4):37–98

Abortion surveillance: preliminary data—United States, 1994. **MMWR Morb Mortal Wkly Rep** 1997 Jan 3; 45(51–52):1123–7

Trends in abortion 1990–1995. Filakti H. **Popul Trends** 1997 Spring;(87):11–9

Lessons from the Dutch abortion experience. David HP, et al. **Stud Fam Plann** 1996 Nov–Dec;27(6):341–3

[Reporting of induced abortions in 1994. A comparison between the data in the Registry of Legally Induced Abortions and the National Patient Registry] Krebs L, et al. **Ugeskr Laeger** 1997 Mar 10;159(11):1607–11 (Eng. Abstr.) **(Dan)**

TRENDS

Roe v. Wade and the euthanasia debate. Bopp J Jr, et al. **Issues Law Med** 1997 Spring;12(4):343–54

Trends in abortion 1990–1995. Filakti H. **Popul Trends** 1997 Spring;(87):11–9

UTILIZATION

The impact of Mississippi's mandatory delay law on abortions and births. Joyce T, et al. **JAMA** 1997 Aug 27;278(8):653–8

The role of access in explaining state abortion rates. Gober P. **Soc Sci Med** 1997 Apr;44(7):1003–16

ABORTION, MISSED

COMPLICATIONS

Iatrogenic secondary infertility caused by residual intrauterine fetal bone after midtrimester abortion. Moon HS, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):369–70

DRUG THERAPY

Unsuccessful treatment of missed abortion with a combination of an antiprogesterone and a prostaglandin E1 analogue. Nielsen S, et al. **Br J Obstet Gynaecol** 1997 Sep;104(9):1094–6

Misoprostol for medical evacuation of early pregnancy failure. Creinin MD, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):768–72

EPIDEMIOLOGY

The prevalence and consequences of missed abortion in twin pregnancies at 10 to 14 weeks of gestation. Sebire NJ, et al. **Br J Obstet Gynaecol** 1997 Jul;104(7):847–8

ETIOLOGY

[Early diagnosis of congenital and acquired intrauterine causes of abortion by post-abortion hysteroscopy] Römer T, et al. **Geburtshilfe Frauenheilkd** 1996 Oct;56(10):542–5 (Eng. Abstr.) **(Ger)**

METABOLISM

Perforin-expressing lymphocytes in peripheral blood and decidua of human first-trimester pathological pregnancies. Gulan G, et al. **Am J Reprod Immunol** 1997 Jul;38(1):9–18

PHYSIOPATHOLOGY

Transvaginal color Doppler assessment of the uteroplacental circulation in normal and abnormal pregnancies in the first trimester [letter] Dilmen G, et al. **Int J Gynaecol Obstet** 1996 Mar;52(3):285–6

PSYCHOLOGY

Missed abortion versus delayed miscarriage [letter] Hutchon DJ. **Br J Obstet Gynaecol** 1997 Jun;104(6):753

THERAPY

Misoprostol in the management of missed abortion. Herabutya Y, et al. **Int J Gynaecol Obstet** 1997 Mar; 56(3):263–6

VETERINARY

Postpartum mummification of a co-twin fetus in a Cameroon dwarf goat doe. Tutt CL. **Vet Rec** 1997 Mar 1; 140(9):229–31

ABORTION ON DEMAND see **ABORTION, LEGAL**

ABORTION SEEKERS see **ABORTION APPLICANTS**

ABORTION, SEPTIC

COMPLICATIONS

Fluconazole in Candida albicans sepsis during pregnancy: case report and review of the literature. Wiesinger EC, et al. **Infection** 1996 May–Jun;24(3):263–6

[Surfactant administration and laterally independent positive pressure ventilation in acute lung failure and atelectasis after septic abortion. Case report] Hoheisel G, et al. **Pneumologie** 1997 Mar;51(3):270–3 (Eng. Abstr.) **(Ger)**

VETERINARY

Bovine abortion caused by Listeria ivanovii. Gill PA, et al. **Aust Vet J** 1997 Mar;75(3):214

Comparison of five tests for the detection of antibodies against chlamydial (enzootic) abortion of ewes. Jones GE, et al. **Vet Rec** 1997 Aug 16;141(7):164–8

[Detection methods for Salmonella abortus ovis and examinations in sheep flocks in northern Baden-Württemberg] Sting R, et al. **Zentralbl Veterinarmed [B]** 1997 Apr;44(2):87–98 (Eng. Abstr.) **(Ger)**

ABORTION, SPONTANEOUS see **ABORTION**

ABORTION, THERAPEUTIC

Oral misoprostol use in early complicated pregnancy. Haberal A, et al. **Adv Contracept** 1996 Jun;12(2):139–43

A paternally derived inverted duplication of 7q with evidence of a telomeric deletion. Stetten G, et al. **Am J Med Genet** 1997 Jan 10;68(1):76–81

Therapeutic abortions due to severe morning sickness. Unacceptable combination. Mazzota P, et al. **Can Fam Physician** 1997 Jun;43:1055–7

Amniotic fluid embolism causing severe left ventricular dysfunction and death: case report and review of the literature. Dib N, et al. **Cathet Cardiovasc Diagn** 1996 Oct; 39(2):177–80 (9 ref.)

Management of patients with intrauterine fetal death. Visentin L, et al. **Clin Exp Obstet Gynecol** 1996;23(4):263–7

Low resistance Doppler waveforms with retained products of conception: potential for diagnostic confusion with gestational trophoblastic disease. Keogan MT, et al. **Eur J Radiol** 1995 Dec 15;21(2):109–11

Response to medicine and abortion issue [letter] Castle MA. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):9

Reversal of intractable acute severe asthma by first-trimester termination of pregnancy. Shanies HM, et al. **J Asthma** 1997;34(2):169–72

Intraamniotic prostaglandin F2 alpha for pregnancy termination in the second and early third trimesters of pregnancy. Lipitz S, et al. **J Reprod Med** 1997 Apr; 42(4):235–8

Mid-pregnancy genetic terminations of pregnancy--postnatal assessment and management. Christianson AL, et al. **S Afr Med J** 1995 Oct;85(10 Suppl):1084–7

Pregnancy after renal transplantation: impact on graft function. Barrou B, et al. **Transplant Proc** 1996 Oct; 28(5):2835

[Therapeutic abortions: basis and ethical foundations] Barjot P, et al. **Contracept Fertil Sex** 1997 Jan;25(1):37–45 (23 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Small balloon catheters in the induction of labour in mid-trimester pregnancy. Li ZX. **Trop Doct** 1996 Oct; 26(4):171–2

METHODS

Impact of the introduction of new medical methods on therapeutic abortions at the Royal Infirmary of Edinburgh [see comments] Cameron ST, et al. **Br J Obstet Gynaecol** 1996 Dec;103(12):1222–9. Comment in: Br J Obstet Gynaecol 1997 Jul;104(7):871.

Impact of new methods on therapeutic abortion at the Royal Infirmary of Edinburgh [letter; comment] Stewart P, et al. **Br J Obstet Gynaecol** 1997 Jul;104(7):871. Comment on: Br J Obstet Gynaecol 1996 Dec;103(12):1222–9.

[Trends in therapeutic abortion management from 1986 to 1994] Zimbris L, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(1):76–84 (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

The influence of prenatal ultrasound on the prevalence of congenital anomalies at birth. Zimmer EZ, et al. **Prenat Diagn** 1997 Jul;17(7):623–8

[Perinatal mortality in Denmark. An analysis of development assessed in connection with medically induced abortion during the period 1980–1993] Helweg-Larsen K, et al. **Ugeskr Laeger** 1996 Dec 9;158(50):7216–22 (Eng. Abstr.) **(Dan)**

TRENDS

[Trends in therapeutic abortion management from 1986 to 1994] Zimbris L, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(1):76–84 (Eng. Abstr.) **(Fre)**

ABORTION, THREATENED

Fetal growth and perinatal outcome of pregnancies continuing after threatened abortion. Das AG, et al. **Aust N Z J Obstet Gynaecol** 1996 May;36(2):135–9

BLOOD

Serum placental protein 14 (PP14) levels in patients with threatened abortion. Tomczak S, et al. **Arch Gynecol Obstet** 1996;258(4):165–9

Coenzyme Q10 in pregnancy. Noia G, et al. **Fetal Diagn Ther** 1996 Jul–Aug;11(4):264–70

[Magnesium and calcium level in blood serum of pregnant women with pregnancy threatening miscarriage] Roszyk A. **Ginekol Pol** 1996 Dec;67(12):607–11 (Eng. Abstr.) **(Pol)**

[Lipid metabolism in women with threatened abortion] Smolarczyk R, et al. **Ginekol Pol** 1996 Oct;67(10):481–7 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

The role of a single free beta-human chorionic gonadotrophin measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability. al-Sebai MA, et al. **Hum Reprod** 1996 Apr;11(4):881–8

GENETICS

[The Standard 'Threatened) Miscarriage' of the Dutch Society of Family Physicians (letter)] Niermeijer MF, et al. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):115–6 **(Dut)**

METABOLISM

[Calcium-phosphorus-magnesium homeostasis in women with threatened abortion] Smolarczyk R, et al. **Ginekol Pol** 1997 Jan;68(1):11–6 (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Pregnancy outcome of threatened abortion with demonstrable fetal cardiac activity: a cohort study. Tongsong T, et al. **J Obstet Gynaecol** 1995 Aug;21(4):331–5

PREVENTION & CONTROL

[The Standard 'Threatened) Miscarriage' of the Dutch Society of Family Physicians (letter; comment)] Braken JB. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):114–5. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1935–9. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1939–40. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1956–9. **(Dut)**

[The Standard 'Threatened) Miscarriage' of the Dutch Society of Family Physicians (letter; comment)] van der

ABORTION, THREATENED

Horst HE, et al. **Ned Tijdschr Geneeskd** 1997 Jan 11; 141(2):118–9. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1956–9. **(Dut)**

PSYCHOLOGY

[The Standard 'Threatened) Miscarriage' of the Dutch Society of Family Physicians (letter; comment)] de Kleine MJ, et al. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):116–7 . Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1935–9. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1939–40. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1956–9. **(Dut)**

THERAPY

[The guideline 'Threatened) abortion' from the Dutch Society of Family hysicians: too little connection to clinical practice (comment) (see comments)] Essed GG. **Ned Tijdschr Geneeskd** 1996 Sep 28;140(39):1939–40. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1956–9. Comment in: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):114–5. Comment in: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):116–7. **(Dut)**

[Cause for referral by family physicians and obstetricians in Amsterdam in (threatened) miscarriage as reflected in the guideline 'Threatened) abortion' of the Dutch Society for Family Physicians (see comments)] Fleuren MA, et al. **Ned Tijdschr Geneeskd** 1996 Sep 28;140(39):1956–9 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1935–9. Comment in: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1939–40. Comment in: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):114–5. Comment in: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):116–7. Comment in: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):117–8. Comment in: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):118–9. **(Dut)**

[The guideline '(threatened) abortion' of the Dutch Society of Family Physicians; too little compliance (comment) (see comments)] Flikweert S. **Ned Tijdschr Geneeskd** 1996 Sep 28;140(39):1935–9. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1956–9. Comment in: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):114–5. Comment in: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):116–7. Comment in: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):117–8. **(Dut)**

ULTRASONOGRAPHY

Effects of transvaginal sonography on pregnant patients' perceptions of care in the ED [letter] Krubel R, et al. **Am J Emerg Med** 1996 Mar;14(2):232–3

Predictive value of ultrasound in threatened miscarriage [letter] Everett CB. **Br J Gen Pract** 1996 Dec;46(413):756

Early pregnancy bleeding [letter; comment] Smith LF. **Br J Gen Pract** 1996 Jul;46(408):437–8. Comment on: Br J Gen Pract 1996 Jan;46(402):7–9.

[The Standard 'Threatened) Miscarriage of the Dutch Society of Family Physicians (letter)] Braken JB. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2): 14 **(Dut)**

[The Standard 'Threatened) Miscarriage of the Dutch Society of Family Physicians (letter; comment)] Zwart S. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):117–8. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1935–9. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1956–9. **(Dut)**

ABORTION, VETERINARY

Effect of progesterone on prostaglandin F2 alpha secretion and outcome of pregnancy during cloprostenol-induced abortion in mares. Daels PF, et al. **Am J Vet Res** 1996 Sep;57(9):1331–7

Studies on the early phase of the pathogenesis of ovine enzootic abortion in the non-pregnant ewe [see comments] Amin JD, et al. **Br Vet J** 1995 Mar-Apr;151(2):141–55. Comment in: Br Vet J 1995 Mar-Apr;151(2):115–8.

Failure of endometrial cup development in the donkey-in-horse model of equine abortion. Enders AC, et al. **J Anat** 1996 Jun;188 (Pt 3):575–89

Investigation of the selenium status of aborted calves with cardiac failure and myocardial necrosis. Orr JP, et al. **J Vet Diagn Invest** 1997 Apr;9(2):172–9

Demonstration of infectious bovine rhinotracheitis virus antigen by immunoperoxidase method in tissues of aborted bovine fetuses preserved for 25 years in paraffin blocks. Ogino H, et al. **J Vet Med Sci** 1996 May;58(5):459–60

Biochemical changes in the equine capsule following prostaglandin-induced pregnancy failure. Chu JW, et al. **Mol Reprod Dev** 1997 Mar;46(3):286–95

Use of transvaginal ultrasound-guided puncture for elimination of equine pregnancies. Squires EL. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):161–8 (19 ref.)

Arrangements for bovine abortion investigations [letter] McKeating FJ. **Vet Rec** 1997 Jun 21;140(25):663–4

Direct detection of equine herpesvirus DNA in tissues of aborted equine fetuses. Ishiyama T, et al. **Zentralbl Veterinarmed [B]** 1996 Dec;43(10):639–42

[Listeriosis in a rabbitry] Peters M, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Nov;103(11):460–2 (Eng. Abstr.) **(Ger)**

[Neospora caninum causes abortions in a cattle herd in North Rhine Westphalia] Schares G, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Jun;104(6):208–12 (Eng. Abstr.) **(Ger)**

[The "other" parvovirus: first description of the minute virus of canines (Canine parvovirus type 1) in Germany] Truyen U, et al. **Tierarztl Prax** 1996 Oct;24(5):511–3 (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Bromocriptine-induced blockade of pregnancy affects sleep patterns in rats. Zhang SQ, et al. **Neuroimmunomodulation** 1996 Jul-Aug;3(4):219–26

DIAGNOSIS

Serological diagnosis of ovine enzootic abortion by comparative inclusion immunofluorescence assay, recombinant lipopolysaccharide enzyme-linked immunosorbent assay, and complement fixation test. Griffiths PC, et al. **J Clin Microbiol** 1996 Jun;34(6):1512–8

Comparison of five tests for the detection of antibodies against chlamydial (enzootic) abortion of ewes. Jones GE, et al. **Vet Rec** 1997 Aug 16;141(7):164–8

EPIDEMIOLOGY

Neospora caninum antibodies in cows during pregnancy as a predictor of congenital infection and abortion. Paré J, et al. **J Parasitol** 1997 Feb;83(1):82–7

Dairy cattle abortion in California: evaluation of diagnostic laboratory data. Jamaluddin AA, et al. **J Vet Diagn Invest** 1996 Apr;8(2):210–8

A 12-year retrospective study of equine abortion in Michigan. Tengelsen LA, et al. **J Vet Diagn Invest** 1997 Jul;9(3):303–6

Epidemiology of bovine abortions in Israeli dairy herds. Markusfeld-Nir O. **Prev Vet Med** 1997 Aug;31(3–4):245–55

Chlamydial disease--more than just abortion [editorial; comment] Jones GE. **Vet J** 1997 May;153(3):249–51 (18 ref.). Comment on: Vet J 1997 May;153(3):307–11.

[Significance of causes of infectious abortion in sheep flocks in northern Baden-Württemberg with special reference to Chlamydia psittaci] Sting R, et al. **Berl Munch Tierarztl Wochenschr** 1997 Jan;110(1):5–11 (Eng. Abstr.) **(Ger)**

[Detection of antibodies against Neospora caninum in cows on Hessian farms with abortion and fertility problems] Conraths FJ, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jun;103(6):221–4 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Soluble receptors neutralizing TNF-alpha and IL-1 block stress-triggered murine abortion. Arck PC, et al. **Am J Reprod Immunol** 1997 Mar;37(3):262–6

Evaluation of fetal infection and abortion in pregnant ponies experimentally infected with Ehrlichia risticii. Long MT, et al. **Am J Vet Res** 1995 Oct;56(10):1307–16

Diagnosis of equine herpesvirus 1 abortion using polymerase chain reaction. Mackie JT, et al. **Aust Vet J** 1996 Nov; 74(5):390–1

Leptospiral abortion in horses following a flooding incident. Kinde H, et al. **Equine Vet J** 1996 Jul;28(4):327–30

Experimental pathological studies on mechanism of abortion caused by equine arteritis virus. Wada R. **Jpn J Vet Res** 1996 Aug;44(2):133–5

The pregnancy that doesn't stay—lessons from 25 years of observation [editorial; comment] Allen GP. **Vet J** 1997 May;153(3):239–44 (28 ref.). Comment on: Vet J 1997 May;153(3):253–68.

Fetal microscopic lesions in porcine reproductive and respiratory syndrome virus-induced abortion. Rossow KD, et al. **Vet Pathol** 1996 Jan;33(1):95–9

Stillbirth/perinatal weak calf syndrome: serological examination for evidence of Neospora caninum infection. Graham DA, et al. **Vet Rec** 1996 Nov 23;139(21):523–4

GENETICS

Chromosomal aneuploidy associated with spontaneous abortions and neonatal losses in cattle. Schmutz SM, et al. **J Vet Diagn Invest** 1996 Jan;8(1):91–5

IMMUNOLOGY

Decidua-associated suppressor cells in abortion-prone DBA/2-mated CBA/J mice that release bioactive transforming growth factor beta2-related immunosuppressive molecules express a bone marrow-derived natural suppressor cell marker and gamma delta T-cell receptor. Clark DA, et al. **Biol Reprod** 1997 May;56(5):1351–60

Serological response over time to recombinant Neospora caninum antigens in cattle after a neosporosis-induced abortion. Jenkins MC, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):270–4

MICROBIOLOGY

Abortion and placentitis in pregnant bison (Bison bison) induced by the vaccine candidate, Brucella abortus strain RB51. Palmer MV, et al. **Am J Vet Res** 1996 Nov; 57(11):1604–7

Diagnosis of ovine enzootic abortion, using a competitive ELISA based on monoclonal antibodies against variable segments 1 and 2 of the major outer membrane protein of Chlamydia psittaci serotype 1. Salti-Montesanto V, et al. **Am J Vet Res** 1997 Mar;58(3):228–35

An outbreak of abortion in mares associated with Salmonella abortusequi infection. Madić J, et al. **Equine Vet J** 1997 May;29(3):230–3

Abortion in a heifer associated with the intra-uterine transmission of Cowdria ruminantium-like organisms following heartwater vaccination. van Halderen A, et al. **J S Afr Vet Assoc** 1996 Sep;67(3):158–60

Mycobacterium avium complex abortion in a mare. Hélie P, et al. **J Vet Diagn Invest** 1996 Apr;8(2):257–8

Caprine abortion following exposure to Mycoplasma capricolum subsp. capricolum. Rodriguez JL, et al. **J Vet Diagn Invest** 1996 Oct;8(4):492–4

Phenotypic and ribosomal RNA characterization of Arcobacter species isolated from porcine aborted fetuses. Schroeder-Tucker L, et al. **J Vet Diagn Invest** 1996 Apr; 8(2):186–95

Herd-based diagnosis of Neospora caninum-induced endemic and epidemic abortion in cows and evidence for congenital and postnatal transmission. Thurmond MC, et al. **J Vet Diagn Invest** 1997 Jan;9(1):44–9

Detection of Chlamydia psittaci in enteric subclinical infections in adult sheep, through cell culture isolation. Escalante-Ochoa C, et al. **Rev Latinoam Microbiol** 1996 Jan-Mar;38(1):17–23

Diversity among abortion strains of Chlamydia psittaci demonstrated by inclusion morphology, polypeptide profiles and monoclonal antibodies. Vretou E, et al. **Vet Microbiol** 1996 Aug;51(3–4):275–89

Fusobacterium necrophorum abortion in a cow. Otter A. **Vet Rec** 1996 Sep 28;139(13):318–9

Neospora and bovine abortion [letter] Otter A. **Vet Rec** 1997 Mar 1;140(9):239

[Significance of causes of infectious abortion in sheep flocks in northern Baden-Württemberg with special reference to Chlamydia psittaci] Sting R, et al. **Berl Munch Tierarztl Wochenschr** 1997 Jan;110(1):5–11 (Eng. Abstr.) **(Ger)**

PARASITOLOGY

Evidence suggesting a point source exposure in an outbreak of bovine abortion due to neosporosis. McAllister MM, et al. **J Vet Diagn Invest** 1996 Jul;8(3):355–7

Bovine fetal neosporosis: a comparison of epizootic and sporadic abortion cases and different age classes with regard to lesion severity and immunohistochemical identification of organisms in brain, heart, and liver. Wouda W, et al. **J Vet Diagn Invest** 1997 Apr;9(2):180–5

Results of a survey to determine whether Neospora is a significant cause of ovine abortion in England and Wales. Otter A, et al. **Vet Rec** 1997 Feb 15;140(7):175–7

PATHOLOGY

Cardio-histopathological observations on aborted equine fetuses infected with equid herpesvirus 1 (EHV-1). Machida N, et al. **J Comp Pathol** 1997 May;116(4):379–85

A comparison of equid herpesvirus-1 (EHV-1) vascular lesions in the early versus late pregnant equine uterus. Smith KC, et al. **J Comp Pathol** 1996 Apr;114(3):231–47

PREVENTION & CONTROL

Soiuble receptors neutralizing TNF-alpha and IL-1 block stress-triggered murine abortion. Arck PC, et al. **Am J Reprod Immunol** 1997 Mar;37(3):262–6

Effects of age at vaccination on efficacy of Brucella abortus strain RB51 to protect cattle against brucellosis. Cheville NF, et al. **Am J Vet Res** 1996 Aug;57(8):1153–6

Effects of oral or intravenous inoculation with Brucella abortus strain RB51 vaccine in beagles. Palmer MV, et al. **Am J Vet Res** 1997 Aug;58(8):851–6

The pathogenesis of ED71, a defined deletion mutant of equine herpesvirus-1, in a murine intranasal infection model for equine abortion. Fitzmaurice T, et al. **J Gen Virol** 1997 Sep;78 (Pt 9):2167–9

Use of a live chlamydial vaccine to prevent ovine enzootic abortion. Chalmers WS, et al. **Vet Rec** 1997 Jul 19; 141(3):63–7

VIROLOGY

Abortion and death in pregnant bitches associated with a canine vaccine contaminated with bluetongue virus. Levings RL, et al. **Dev Biol Stand** 1996;88:219–20

Multiple abortions associated with caprine herpesvirus infection in a goat herd. Williams NM, et al. **J Am Vet Med Assoc** 1997 Jul 1;211(1):89–91

Restriction endonuclease analysis of equine herpesvirus-1 isolates recovered in Ontario, 1986-1992, from aborted, stillborn, and neonatal foals. Nagy E, et al. **J Vet Diagn Invest** 1997 Apr;9(2):143–8

Herpesviral abortion in domestic animals [see comments] Smith KC. **Vet J** 1997 May;153(3):253–68 (191 ref.). Comment in: Vet J 1997 May;153(3):239–44.

ABREACTION

Magical realism: a cultural intervention for traumatized Hispanic children. De Rios MD. **Cult Divers Ment Health** 1997;3(3):159–70

ABRIN

CHEMISTRY

A- and B-subunit variant distribution in the holoprotein variants of protein toxin abrin: variants of abrins I and III have constant toxic A subunits and variant lectin B subunits. Hegde R, et al. **Arch Biochem Biophys** 1997 Aug 1;344(1):75–84

Probing the domain structure of abrin-a by tryptic digestion. Lin SH, et al. **Eur J Biochem** 1996 Sep 15;240(3):564–9

TOXICITY

Establishment and characterization of an abrin-resistant cell line. Ko JL, et al. **Cell Biol Toxicol** 1997 Feb;13(2):75–81

Morphology of ricin and abrin exposed endothelial cells is consistent with apoptotic cell death. Hughes JN, et al. **Hum Exp Toxicol** 1996 May;15(5):443–51

ABRUPTIO PLACENTAE

BLOOD

Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Goddijn-Wessel TA, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 May;66(1):23–9

Activity alterations of chosen parameters of cord blood hemostasis in newborns from complicated pregnancies with premature ablation of placenta. Bielecki M, et al. **Rocz Akad Med Bialymst** 1996;41(2):374–80

'Never say die'—survival of a woman with massive abruptio placentae and a haemoglobin concentration of 0.6 g/dl [letter] Janowski K, et al. **S Afr Med J** 1996 Sep;86(9 Suppl):1207

COMPLICATIONS

Outcome of abruptio placentae in normotensive and hypertensive patients in Aga Khan University Hospital, Pakistan. Munim S, et al. **J Obstet Gynaecol Res** 1997 Jun; 23(3):267–71

Placental abruption and spontaneous rupture of renal angiomyolipoma in a pregnant woman with tuberous sclerosis. Forsnes EV, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):725

DIAGNOSIS

Spontaneous rectus sheath hematoma during pregnancy mimicking abruptio placenta. Ramirez MM, et al. **Am J Perinatol** 1997 Jul;14(6):321–3

Maternal serum alpha-fetoprotein in placental abruption associated with preterm labor. Bartha JL, et al. **Int J Gynaecol Obstet** 1997 Mar;56(3):231–6

[Partial premature abruptio placentae] Krauss T. **Z Geburtshilfe Neonatol** 1997 Mar-Apr;201(2):71–2 **(Ger)**

EPIDEMIOLOGY

The paradoxical effect of smoking in preeclamptic pregnancies: smoking reduces the incidence but increases the rates of perinatal mortality, abruptio placentae, and intrauterine growth restriction. Cnattingius S, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):156–61

ETIOLOGY

Maternal cigarette smoking as a risk factor for placental abruption, placenta previa, and uterine bleeding in pregnancy. Ananth CV, et al. **Am J Epidemiol** 1996 Nov 1;144(9):881–9

Maternal age modifies the effect of maternal smoking on intrauterine growth retardation but not on late fetal death and placental abruption. Cnattingius S. **Am J Epidemiol** 1997 Feb 15;145(4):319–23

Long-term effects of cesarean sections: ectopic pregnancies and placental problems [see comments] Hemminki E, et al. **Am J Obstet Gynecol** 1996 May;174(5):1569–74. Comment in: Am J Obstet Gynecol 1997 Jan;176(1 Pt 1):254–5.

Influence of hypertensive disorders and cigarette smoking on placental abruption and uterine bleeding during pregnancy. Ananth CV, et al. **Br J Obstet Gynaecol** 1997 May;104(5):572–8

Placental abruption after insertion of catheter tip intrauterine pressure transducers: a report of four cases. Handwerker SM, et al. **J Reprod Med** 1995 Dec;40(12):845–9

Oral anticoagulants and fetal loss [letter; comment] Pajor A, et al. **Lancet** 1996 Dec 21-28;348(9043):1734–5. Comment on: Lancet 1996 Oct 5;348(9032):913–6.

Effect of maternal age and parity on the risk of uteroplacental bleeding disorders in pregnancy. Ananth CV, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):511–6

Etiologic determinants of abruptio placentae. Kramer MS, et al. **Obstet Gynecol** 1997 Feb;89(2):221–6

The association of cigarette smoking with placenta previa and abruptio placentae. Andres RL. **Semin Perinatol** 1996 Apr;20(2):154–9 (43 ref.)

[Premature placental separation] Winkler M, et al. **Z Geburtshilfe Neonatol** 1997 Jan-Feb;201(1):34–7 **(Ger)**

PHYSIOPATHOLOGY

[Features of uterine contractile function in intrauterine fetal death] Zaĭtsev LM, et al. **Patol Fiziol Eksp Ter** 1997 Jan-Mar;(1):38–40 (Eng. Abstr.) **(Rus)**

SURGERY

'Never say die'—survival of a woman with massive abruptio placentae and a haemoglobin concentration of 0.6 g/dl [letter] Janowski K, et al. **S Afr Med J** 1996 Sep;86(9 Suppl):1207

[Cesarean section or not in solutio placentae and signs of fetal distress? (letter)] Molendijk IW, et al. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):120 **(Dut)**

[Cesarean section or not in solutio placentae and signs of fetal distress? (letter; comment)] Umans-Eckenhausen MA. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):119–20. Comment on: Ned Tijdschr Geneeskd 1996 Oct 5;140(40):1973–5. **(Dut)**

THERAPY

[Cesarean section or not in placental loosening and signs of fetal distress? (see comments)] Go AT, et al. **Ned Tijdschr Geneeskd** 1996 Oct 5;140(40):1973–5. Comment in: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):119–20. **(Dut)**

ABSCESS

see related

EMPYEMA

Splenic abscesses from 1987 to 1995. Ooi LL, et al. **Am J Surg** 1997 Jul;174(1):87–93 (95 ref.)

Central nervous system abscesses due to Coccidioides species. Bañuelos AF, et al. **Clin Infect Dis** 1996 Feb;22(2):240–50 (26 ref.)

Adrenal insufficiency, recurrent bacteremia, and disseminated abscesses caused by Nocardia asteroides in a patient with acquired immunodeficiency syndrome. Arabi Y, et al. **Diagn Microbiol Infect Dis** 1996 Jan;24(1):47–51

Brodie's abscess of the ilium and fifth lumbar vertebra. case reports. Lindsetmo RO, et al. **Eur J Surg** 1995 Dec; 161(12):928–30

Focal intracranial infections. Heilpern KL, et al. **Infect Dis Clin North Am** 1996 Dec;10(4):879–98 (77 ref.)

Tubercular splenic abscesses in a patient with AIDS. Dubey SG, et al. **J Assoc Physicians India** 1996 Aug;44(8):575–7

Tubo-ovarian abscess caused by multidrug resistant Bacteroides gracilis. Yu WL, et al. **J Formos Med Assoc** 1997 Jun;96(6):457–60

The resonant shoulder; gas abscess of the deltoid bursa. Bowditch MG, et al. **J Shoulder Elbow Surg** 1997 Jan-Feb; 6(1):70–1

Two unusual nerve abscesses—lepromatous leprosy and pure neural leprosy: case reports. Kumar GR, et al. **Lepr Rev** 1996 Sep;67(3):217–21

Neurologic complications of lumbar epidural analgesia: spinal and paraspinal abscess. Bertol V, et al. **Neurology** 1997 Jun; 48(6):1732–3

Management of deep neck infection. Nicklaus PJ, et al. **Pediatr Clin North Am** 1996 Dec;43(6):1277–96 (28 ref.)

[A rare case of primary abdominal actinomycosis] Lazzaretti MG, et al. **Minerva Chir** 1996 Sep;51(9):707–11 (Eng. Abstr.) **(Ita)**

[A case of the tuberculous abscess in the abdominal wall] Saika A, et al. **Kansenshogaku Zasshi** 1997 Jun;71(6):540–4 (Eng. Abstr.) **(Jpn)**

[Intrapericardial abscess, pericardial abscess] Yuasa N. **Ryoikibetsu Shokogun Shirizu** 1996;(13):546–9 (22 ref.) **(Jpn)**

[Splenic abscess. Diagnosis and treatment] Rerbakken G, et al. **Tidsskr Nor Laegeforen** 1997 May 20;117(13):1908–10 (35 ref.) (Eng. Abstr.) **(Nor)**

[Debatable questions of surgical tactics in appendiceal infiltrates and periappendiceal abscess] Aliev SA. **Khirurgiia (Mosk)** 1997;(4):48–54 (Eng. Abstr.) **(Rus)**

[Bilateral abscess of cavernous bodies] Fernández Goméz JM, et al. **Actas Urol Esp** 1997 Jan;21(1):75–7 (Eng. Abstr.) **(Spa)**

[Abscess of the tongue] Condado MA, et al. **An Otorrinolaringol Ibero Am** 1997;24(3):219–25 (Eng. Abstr.) **(Spa)**

[Cesarean scar abscess caused by Staphylococcus lugdunensis (letter)] Uriel JA, et al. **Enferm Infecc Microbiol Clin** 1996 Dec;14(10):631–2 **(Spa)**

[Epidural and rhomboid muscle abscess (letter; comment)] Pinar Sedeño G, et al. **Neurologia** 1997 Jun-Jul;12(6):265–6 . Comment on: Neurologia 1996 Aug-Sep;11(7):268–71. **(Spa)**

BLOOD

Serum testosterone, DHEAS, and prolactin levels in patients with a Bartholin's abscess. Lurie S, et al. **Arch Gynecol Obstet** 1997;259(4):167–8

COMPLICATIONS

Clinical pearls. Headache and eye pain. Melanson SW, et al. **Acad Emerg Med** 1996 Sep;3(9):879–80, 892–4

Septic symphysial disruption presenting as severe symphysiolysis in pregnancy. Magnúsdóttir R, et al. **Acta Obstet Gynecol Scand** 1996 Aug;75(7):681–2

Immune response to anaerobic bacteria in patients with peritonsillar cellulitis and abscess. Brook I, et al. **Acta Otolaryngol (Stockh)** 1996 Nov;116(6):888–91

Back pain in the older patient. Baumgartner E, et al. **Ann Rheum Dis** 1996 Sep;55(9):600–2

Conversion disorder presenting in a patient with an implantable morphine pump and an epidural abscess resulting in paraplegia. Shell MG, et al. **Arch Phys Med Rehabil** 1997 Feb;78(2):226–9

Gastroenteritis causing critical limb ischaemia. Mamode N, et al. **Br J Clin Pract** 1996 Oct-Nov;50(7):410

Isolated subcutaneous candidal abscess and HIV disease [letter] Manfredi R, et al. **Br J Dermatol** 1997 Apr; 136(4):647–9

Case report: abscess of the adductor muscles of the thigh—an unusual complication of Crohn's disease. Denton ER, et al. **Br J Radiol** 1996 Sep;69(825):865–6

Metastatic choroidal abscess due to Pseudomonas aeruginosa in patients with cystic fibrosis. Detering K, et al. **Clin Infect Dis** 1997 Mar;24(3):525–6

A case of infective endocarditis complicated with anterior mitral valve leaflet abscess [letter] Kumbasar SD, et al. **Eur Heart J** 1997 Jul;18(7):1194–5

Peripheral nerve abscess in leprosy: report of twenty cases. Kumar P, et al. **Indian J Lepr** 1997 Apr-Jun;69(2):143–7

An unusual case of ischio rectal abscess presenting as acute urinary retention. Lennon GM, et al. **Ir J Med Sci** 1997 Jan-Mar;166(1):26–7

Multiple Salmonella typhi subcutaneous abscesses in a sickle cell anaemia patient. Sarma PS, et al. **J Assoc Physicians India** 1996 Aug;44(8):563–4

Spleenic abscess in a case of chronic myeloid leukemia. Somalwar AM, et al. **J Assoc Physicians India** 1996 Oct; 44(10):721–2

Gastrointestinal autonomic nerve tumor with giant abscess. A case report and literature review. Honda K, et al. **J Clin Gastroenterol** 1997 Jun;24(4):280–5 (12 ref.)

Pituitary apoplexy secondary to an underlying abscess. Kingdon CC, et al. **J Infect** 1996 Jul;33(1):53–5

Pyomyositis and osteomyelitis in a patient with radiating pain in the leg [letter] Kampman MT, et al. **J Neurol** 1997 Jun; 244(6):398–401

Recurrent appendicitis after initial conservative management of appendiceal abscess. Price MR, et al. **J Pediatr Surg** 1996 Feb;31(2):291–4

Enterocutaneous fistula [letter] Fry DR. **J R Soc Med** 1997 Aug;90(8):471

A young woman with a sore throat, septicaemia, and respiratory failure. Vohra A, et al. **Lancet** 1997 Sep 27; 350(9082):928

Spinal abscess with cord compression complicating infected subclavian cannula. Nawaz M, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):842

Polymicrobial soft tissue abscesses in patients with cyanotic congenital heart disease. Rodgers GL, et al. **Pediatr Infect Dis J** 1996 Nov;15(11):1046–8

Hepatosplenic abscess caused by Curvularia boedijn in a patient with acute monocytic leukemia. Shigemori M, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1128–9 (11 ref.)

Adrenobronchial fistula complicating a neonatal adrenal abscess: treatment by percutaneous aspiration and antibiotics. Pointe HD, et al. **Pediatr Radiol** 1997 Feb; 27(2):184–5

Isolated H-type recto-vaginal fistula associated with a vulval abscess. White DW, et al. **Pediatr Radiol** 1997 Jul; 27(7):586–7

Ruptured splenic abscess as cause of pneumoperitoneum. Puhakka KB, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):273–4 (6 ref.)

Surgical treatment of infective endocarditis complicated by annular infection and cerebral infarction. Sugimoto T, et al. **Surg Today** 1996;26(9):679–82

Spontaneous vocal cord paresis and return to normocalcemia: an unusual presentation of parathyroid adenoma with concomitant abscess. Angelos P, et al. **Surgery** 1997 Jun; 121(6):704–7

Tuberculous skeletal muscle involvement in acute leukemia: report on two cases. del Giglio A, et al. **Tumori** 1997 Mar-Apr;83(2):618–20

[An abscess may be hiding another] Bataillon V, et al. **Ann Biol Clin (Paris)** 1997 Jan-Feb;55(1):41–2 **(Fre)**

[A rare complication of renal lithiasis: peritonitis and splenic abscess caused by rupture of pyonephrosis] Hendaoui MS, et al. **J Urol (Paris)** 1996;102(3):130–3 (Eng. Abstr.) **(Fre)**

[Hypophyseal abscess disclosed by panhypopituitarism (letter)] Bauduceau B, et al. **Presse Med** 1997 Feb 15; 26(4):163 **(Fre)**

[Aortic valve abscess with perforation in the right atrium] Zuber M, et al. **Schweiz Med Wochenschr** 1996 Nov 2; 126(44):1900 **(Ger)**

[Tuberculous pancreatic abscess in a case of miliary lung tuberculosis] Meneghello A, et al. **Radiol Med (Torino)** 1997 Mar;93(3):308–10 **(Ita)**

[Valve replacement concomitant with anulus reconstruction] Sawazaki M, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):617–20 (Eng. Abstr.) **(Jpn)**

[Computed tomographic findings in septic pulmonary emboli secondary to renal abscess] Matsumoto H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Aug; 34(8):937–42 (Eng. Abstr.) **(Jpn)**

[Tracheotomy complicates disease in patients with mediastinitis of oropharyngeal origin (letter; comment)] Hernández-Cosido L, et al. **Arch Bronconeumol** 1997 Jun;

33(6):315–6. Comment on: Arch Bronconeumol 1996 Oct;32(8):394–6. **(Spa)**

[A pelvic and abdominal wall abscess secondary to a perianal abscess (letter)] Acea Nebril B, et al.
Rev Esp Enferm Dig 1997 Jan;89(1):69–70 **(Spa)**

DIAGNOSIS

Tophaceous gout of the lumbar spine mimicking an epidural abscess: MR features. Bonaldi VM, et al.
AJNR Am J Neuroradiol 1996 Nov–Dec;17(10):1949–52

Candida splenic abscess in the absence of obvious immunodeficiency. Kapur A, et al. **Am J Gastroenterol** 1997 Mar;92(3):509–12 (29 ref.)

Diabetes and neck pain [letter; comment] [published erratum appears in Ann Emerg Med 1997 Feb;29(2):310] Weiner T. **Ann Emerg Med** 1996 Dec;28(6):731. Comment on: Ann Emerg Med 1996 Jun;27(6):777–80.

A chronic organized masseter abscess causing trismus resolved by hemi-masseter myotomy. Nishimura T, et al.
Auris Nasus Larynx 1996;23:140–2

Abscess in the non-lactating breast: radiodiagnostic aspects [published erratum appears in Australas Radiol 1997 Feb;41(1):90] Muttarak M. **Australas Radiol** 1996 Aug; 40(3):223–5

Salmonella braenderup sacroiliac osteomyelitis in a nonsickle cell patient: case report. Hunt BK, et al.
Bull Hosp Jt Dis 1996;55(2):86–7 (9 ref.)

Aortic root abscess with fistula formation. Hwang SW, et al. **Chest** 1997 May;111(5):1436–8

Sphenoid abcess mimicking giant cell temporal arteritis [letter] Goupille P, et al. **Clin Exp Rheumatol** 1996 Sep–Oct; 14(5):579–80

Intramedullary abscess of the spinal cord in a patient with a right-to-left shunt: case report. David C, et al.
Clin Infect Dis 1997 Jan;24(1):89–90

Salmonella parotitis with abscess formation in a patient with human immunodeficiency virus infection. Knee TS, et al. **Clin Infect Dis** 1997 May;24(5):1009–10

Parapharyngeal lymphangioma mimicking a peritonsillar abscess. Mra Z, et al. **Ear Nose Throat J** 1996 Dec; 75(12):790–2

A case of infective endocarditis complicated with anterior mitral valve leaflet abscess [letter] Kumbasar SD, et al. **Eur Heart J** 1997 Jun;18(6):1035–6

Staphylococcus lugdunensis as a cause of abscesses in the perineal area. Ortiz de la Tabla V, et al.
Eur J Clin Microbiol Infect Dis 1996 May;15(5):405–7

MR monitoring of a medically treated spinal cord abscess presumptively due to Listeria monocytogenes. Duprez TP, et al. **Eur Neurol** 1997;37(4):249–51

Pyogenic infectious spondylitis: clinical, laboratory and MRI features. Kapeller P, et al. **Eur Neurol** 1997;38(2):94–8

Prostatic abscesses in sub-Saharan Africa: a hospital-based experience from Cameroon. Angwafo FF 3rd, et al.
Eur Urol 1996;30(1):28–33

Bilateral secondary renal neoplasm mimicking renal abscesses. de La Taille A, et al. **Eur Urol** 1997;31(2):249–50

Spinal epidural abscess: the nurse's role in early detection and intervention. Hoppe B. **Heart Lung** 1996 Nov–Dec; 25(6):463–6 (34 ref.)

Orbital myocysticercosis presenting as subconjunctival abscess. Grover AK, et al. **Indian J Ophthalmol** 1996 Dec; 44(4):229–31

Diagnostic evaluation of myocardial abscesses. A new look at an old problem. Chakrabarti J. **Int J Cardiol** 1995 Dec; 52(3):189–96 (45 ref.)

Spinal epidural abscess associated with epidural anesthesia: gadolinium-enhanced magnetic resonance imaging and its usefulness in diagnosis and treatment. Higuchi T, et al.
Intern Med 1996 Nov;35(11):902–4

A case of muscle abscess presenting to an accident and emergency department. Howell MA, et al.
J Accid Emerg Med 1997 May;14(3):180–2 (22 ref.)

Diagnosing protracted submasseteric abscess: the role of computed tomography. Mandel L. **J Am Dent Assoc** 1996 Nov;127(11):1646–50

Pituitary abscess: CT and MRI findings. Hwang SL, et al.
J Formos Med Assoc 1996 Mar;95(3):267–9

Management of a deep space infection of the neck in a patient with Glanzmann's thrombasthenia. Kirita T, et al.
J Oral Maxillofac Surg 1997 Aug;55(8):882–5 (9 ref.)

Deep-neck space abscesses. el-Sayed Y, et al.
J Otolaryngol 1996 Aug;25(4):227–33

Tuboovarian abscess in the adolescent. Huang A, et al.
J Pediatr Adolesc Gynecol 1997 May;10(2):73–7

Diverticulitis mimicking a tuboovarian abscess. Report of a case in a young woman. Naliboff JA, et al.
J Reprod Med 1996 Dec;41(12):921–3

Pyomyositis: clinical features and predisposing conditions. Patel SR, et al. **J Rheumatol** 1997 Sep;24(9):1734–8 (61 ref.)

Paravertebral inflammation mistaken for neoplasm or abscess by MRI. Klekamp JW, et al. **J South Orthop Assoc** 1997 Summer;6(2):81–7

Spinal epidural abscess--a case report. Chang CZ, et al.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1997 Jul; 13(7):457–61

Tropical pyomyositis in a temperate climate: a case report. Simmers TA, et al. **Neth J Med** 1996 Aug;49(2):86–9

Multiple hepatosplenic tuberculous abscesses in an eight-year-old boy. Kohli V, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):178–9

Tropical pyomyositis: imaging findings and a review of the literature. Pretorius ES, et al. **Skeletal Radiol** 1996 Aug; 25(6):576–9 (15 ref.)

Lemierre syndrome. Barker J, et al. **South Med J** 1996 Oct; 89(10):1021–3

Perforated cecal adenocarcinoma presenting as a thigh abscess. Mann GN, et al. **South Med J** 1997 Sep; 90(9):949–51 (7 ref.)

Intramedullary tuberculous abscess: a case report. Hanci M, et al. **Spine** 1996 Mar 15;21(6):766–9

Spinal osteomyelitis presenting with a life-threatening pleural empyema. Jari S, et al. **Spine** 1996 Dec 1;21(23):2806–8

Epidural spinal infection. Variability of clinical and magnetic resonance imaging findings. Küker W, et al. **Spine** 1997 Mar 1;22(5):544–50; discussion 551

Mediastinal tuberculous lymphadenitis diagnosed and treated by thoracoscopy. Suzuki T, et al.
Thorac Cardiovasc Surg 1997 Jun;45(3):140–2

Spinal epidural abscess in a liver transplant recipient. Wszolek ZK, et al. **Transplant Proc** 1996 Oct;28(5):2978–9

Renal cortical abscess in a gravid female: US and MRI documentation. Barzilai M, et al. **Urol Int** 1996;56(1):41–3

[A case of genital actinomycosis--the diagnostic difficulties] Tsankova M, et al. **Akush Ginekol (Sofiia)** 1996;35(4):38–40 **(Bul)**

[Clinical judgment and decision making in clinical practice. A patient with fever and neck pain (clinical conference) (see comments)] Gans RO, et al.
Ned Tijdschr Geneeskd 1996 Oct 26;140(43):2122–7. Comment in: Ned Tijdschr Geneeskd 1996 Dec 21;140(51):2588. **(Dut)**

[Clinical judgement and decision making in clinical practice. A patient with fever and neck pain (letter; comment)] van der Meer JW, et al. **Ned Tijdschr Geneeskd** 1996 Dec 21; 140(51):2588. Comment on: Ned Tijdschr Geneeskd 1996 Oct 26;140(43):2122–7. **(Dut)**

[Value of MRI with injection of gadolinium in the diagnosis of mitral ring abscess. Apropos of a case] Furber A, et al. **Arch Mal Coeur Vaiss** 1997 Mar;90(3):399–404 (Eng. Abstr.) **(Fre)**

[Clinical and radiological aspects of tuberculous splenic abscesses. Presentation of 3 cases] Abitbol V, et al.
Gastroenterol Clin Biol 1996;20(6–7):597–600 (20 ref.) (Eng. Abstr.) **(Fre)**

[Intradural extramedullary tuberculous abscess. Apropos of a case] Achouri M, et al. **Neurochirurgie** 1996;42(6):306–8 (Eng. Abstr.) **(Fre)**

[Pulmonary and musculo-cutaneous thigh actinomycosis] Falchero L, et al. **Rev Mal Respir** 1997 Apr;14(2):141–3 (Eng. Abstr.) **(Fre)**

[Diagnosis and therapy of splenic abscess exemplified by 3 unusual cases] Riediger H, et al. **Rontgenpraxis** 1997 Aug; 50(8):233–7 **(Ger)**

[Anorectal abscess and fistula] De Lorenzi D.
Ther Umsch 1997 Apr;54(4):197–201 (Eng. Abstr.) **(Ger)**

[Case report of primary chronic osteomyelitis] Windolf J, et al. **Unfallchirurgie** 1997 Feb;23(1):23–9 (Eng. Abstr.) **(Ger)**

[A case of tubercular liver and splenic abscesses] Miyagi H, et al. **Kansenshogaku Zasshi** 1996 Oct;70(10):1116–21 (Eng. Abstr.) **(Jpn)**

[Primary pituitary abscess: a case report] Sugimoto S, et al.
No Shinkei Geka 1996 Apr;24(4):343–6 (Eng. Abstr.) **(Jpn)**

[A case of acute cervical epidural abscess] Kimura T, et al.
No To Shinkei 1997 Apr;49(4):359–63 (Eng. Abstr.) **(Jpn)**

[Spinal epidural empyemas] Evangelista T, et al.
Acta Med Port 1995 Nov;8(11):643–7 (Eng. Abstr.) **(Por)**

[The atypical and chronic course of suppurative inflammatory diseases of the maxillofacial area and the diagnostic and treatment methods] Fomichev EV, et al.
Stomatologiia (Mosk) 1996;Spec No:85–6 **(Rus)**

[The clinico-immunological diagnosis, prognosis and treatment follow-up in odontogenic abscesses, phlegmons and lymphadenitis] Kazimirskiĭ VA, et al.
Stomatologiia (Mosk) 1996;Spec No:60 **(Rus)**

[Tuberculous pancreatic abscess: differential diagnosis and favorable response to medical treatment] Boadas J, et al.
Gastroenterol Hepatol 1996 Mar;19(3):156–8 (Eng. Abstr.) **(Spa)**

[Male with fever and behavioral disorders] García-Lechuz Moya JM, et al. **Rev Clin Esp** 1997 Feb;197(2):133–4 **(Spa)**

DIET THERAPY

Red pepper effect [letter] Brooks MH, et al.
Br J Gen Pract 1996 Dec;46(413):759

DRUG THERAPY

Rifampicin and isoniazid in the treatment of leprous nerve abscesses. Husain S, et al. **Acta Leprol** 1997;10(3):147–50

Efficacies of ofloxacin, rifampin, and clindamycin in treatment of Staphylococcus aureus abscesses and correlation with results of an in vitro assay of intracellular bacterial killing. Bamberger DM, et al.
Antimicrob Agents Chemother 1997 May;41(5):1178–81

Acute dentoalveolar infections: an investigation of the duration of antibiotic therapy. Martin MV, et al.
Br Dent J 1997 Aug 23;183(4):135–7

Cutaneous tuberculous abscess: a management problem. Harris A, et al. **Br J Dermatol** 1996 Sep;135(3):457–9

Conservative management of infective mastitis and breast abscesses after ultrasonographic assessment. O'Hara RJ, et al. **Br J Surg** 1996 Oct;83(10):1413–4

Outcome of medical treatment of bacterial abscesses without therapeutic drainage: review of cases reported in the literature [see comments] Bamberger DM.
Clin Infect Dis 1996 Sep;23(3):592–603 (166 ref.). Comment in: Clin Infect Dis 1996 Sep;23(3):604–7.

Medical resolution of proven and putative bacterial abscesses without surgical drainage [editorial; comment] Lerner PI.
Clin Infect Dis 1996 Sep;23(3):604–7. Comment on: Clin Infect Dis 1996 Sep;23(3):592–603.

Duration of antibiotic treatment in surgical infections of the abdomen. Pancreatic infections. Frileux P, et al.
Eur J Surg Suppl 1996;(576):53–5

Evaluation of interleukin-1 receptor antagonist (IL-1RA) and tumor necrosis factor binding protein (TNF-BP) in a rodent abscess model of host resistance. Colagiovanni DB, et al. **Immunopharmacol Immunotoxicol** 1996 Aug; 18(3):397–419

Development of quinolone resistance in salmonella: failure to prevent splenic abscess [letter] Boswell TC, et al.
J Infect 1997 Jan;34(1):86–7

Spinal epidural abscess: evaluation of factors influencing outcome. Khanna RK, et al. **Neurosurgery** 1996 Nov; 39(5):958–64

Selection of multiple resistance in Salmonella enteritidis during treatment with ciprofloxacin. Pers C, et al.
Scand J Infect Dis 1996;28(5):529–31

[Outcome of cardiac valve ring abscesses after medical treatment: attempt to identify criteria of favorable prognosis] Tribouilloy C, et al. **Presse Med** 1996 Sep 28; 25(28):1276–80 (Eng. Abstr.) **(Fre)**

[Chemo-extirpation of Bartholin cysts and abscesses] Maral I, et al. **Zentralbl Gynakol** 1996;118(3):172–3 **(Ger)**

EPIDEMIOLOGY

Nerve abscess in children and adults leprosy patients: analysis of 145 cases and review of the literature. Salafia A, et al.
Acta Leprol 1996;10(1):45–50 (40 ref.)

Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction. Villanueva A, et al. **Clin Infect Dis** 1997 Jun;24(6):1147–53

Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users [see comments] Spijkerman IJ, et al.
J Clin Epidemiol 1996 Oct;49(10):1149–54. Comment in: J Clin Epidemiol 1997 Jun;50(6):745.

[Postoperative complications of anterior and middle skull base surgery] Tokutomi T, et al. **No Shinkei Geka** 1997 Jan;25(1):29–34 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Extradural abscess complicating lumbar extradural anaesthesia and analgesia in an obstetric patient. Kindler C, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):858–61

MR of multiple intraspinal abscesses associated with congenital dermal sinus. Dev R, et al.
AJNR Am J Neuroradiol 1997 Apr;18(4):742–3

Atypical presentations of epidural abscess in intravenous drug abusers. Prendergast H, et al. **Am J Emerg Med** 1997 Mar; 15(2):158–60

Orbital complications of pediatric sinusitis: treatment of periorbital abscess. Mann W, et al. **Am J Rhinol** 1997 Mar–Apr;11(2):149–53

Epidural abscess following epidural steroid and local anaesthetic injection. Knight JW, et al. **Anaesthesia** 1997 Jun;52(6):576–8

An epidural abscess due to resistant Staphylococcus aureus following epidural catheterisation. Yuste M, et al.
Anaesthesia 1997 Feb;52(2):163–5

Successful treatment of epidural abscess with a percutaneously introduced 4-French catheter for drainage. Hori K, et al. **Anesth Analg** 1997 Jun;84(6):1384–6

Epidural abscess in a one-year-old boy after continuous epidural analgesia. Larsson BA, et al. **Anesth Analg** 1997 Jun;84(6):1245–7

Skin abscess with lumbar epidural catheterization in infants: is it dangerous? Report of two cases. Meunier JF, et al.
Anesth Analg 1997 Jun;84(6):1248–9

Delayed abscess formation in the wrist due to an unusual retained foreign body--a case report. Liew YM, et al.
Ann Acad Med Singapore 1995 Nov;24(6):867–8

A case of secondary Sjögren's syndrome with a swollen thigh. Deodhar AA, et al. **Ann Rheum Dis** 1997 Mar; 56(3):162–4

The princess and the pea. An unusual complication after a laparoscopic cholecystectomy. Pharr ME, et al.
Arch Fam Med 1997 Mar–Apr;6(2):188–9 (10 ref.)

Fourth branchial sinus causing recurrent cervical abscess. Burstin PP, et al. **Aust N Z J Surg** 1997 Feb–Mar; 67(2–3):119–22

Renal Salmonella enteritidis abscess in a patient with severe aplastic anemia after allogeneic stem cell transplantation. Hashino S, et al. **Bone Marrow Transplant** 1996 Oct; 18(4):807–8

Conservative management of extradural abscess complicating

spinal–extradural anaesthesia for caesarean section. Dysart RH, et al. **Br J Anaesth** 1997 May;78(5):591–3

Perianal sepsis in children. Nix P, et al. **Br J Surg** 1997 Jun; 84(6):819–21

Unusual presentations of pericolic abscess following nephrectomy. Hines J, et al. **Br J Urol** 1996 Dec; 78(6):955–6

Epidural abscess after combined spinal–epidural block [see comments] Schröter J, et al. **Can J Anaesth** 1997 Mar; 44(3):300–4. Comment in: Can J Anaesth 1997 Mar;44(3):235–8.

Infection after central neuraxial block [editorial; comment] Smedstad KG. **Can J Anaesth** 1997 Mar;44(3):235–8. Comment on: Can J Anaesth 1997 Mar;44(3):300–4. **(Eng, Fre)**

Orbital abscess secondary to acute dacryocystitis. Warrak E, et al. **Can J Ophthalmol** 1996 Jun;31(4):201–2

Pericolic abscess due to Streptococcus pyogenes: report of a case that clinically mimicked acute cholecystitis. Procop GW, et al. **Clin Infect Dis** 1996 Jul;23(1):182–3

Perianal abscess in Crohn's disease. Makowiec F, et al. **Dis Colon Rectum** 1997 Apr;40(4):443–50

Iatrogenic spinal epidural abscesses: early diagnosis essential for good outcome. Lindner A, et al. **Eur J Med Res** 1997 May 28;2(5):201–5

Splenic abscess associated with osteomyelitis. Yelon JA, et al. **Eur J Surg** 1996 Nov;162(11):913–4

Spinal epidural abscess: an unusual cause of sciatica. Kotilainen E, et al. **Eur Spine J** 1996;5(3):201–3

Intracranial epidural abscess: late complication of allograft cranioplasty. Morioka T, et al. **Fukuoka Igaku Zasshi** 1996 Feb;87(2):57–9

Periurethral abscess: complication of UTI. Mylonakis E, et al. **Geriatrics** 1997 Aug;52(8):86–8 (18 ref.)

"Gallstone hip" and other sequelae of retained gallstones. Chin PT, et al. **HPB Surg** 1997;10(3):165–8

Severe pancreatitis as first symptom of mumps complicated with pseudocyst and abscess of pancreas. Šušković T, et al. **Infection** 1997 Jan–Feb;25(1):39–40

Fistulae and abscesses in symptomatic perianal Crohn's disease. Solomon MJ. **Int J Colorectal Dis** 1996;11(5):222–6

Periurethral abscess caused by a nonvenereological ulcer at the glans penis. Jungwirth A, et al. **Int Urol Nephrol** 1996; 28(5):713–5

A clustering of epidural abscesses in chronic hemodialysis patients: risks of salvaging access catheters in cases of infection. Kovalik EC, et al. **J Am Soc Nephrol** 1996 Oct; 7(10):2264–7

Long term complication of button gastrostomy tube. Hellstern PA, et al. **J Ark Med Soc** 1996 Nov;93(6):269–70

Suture reaction following skin closure with subcuticular polydioxanone in total knee arthroplasty. Casha JN, et al. **J Arthroplasty** 1996 Oct;11(7):859–61

Late manifestation of pelvic abscess following oocyte retrieval, for in vitro fertilization, in patients with severe endometriosis and ovarian endometriomata. Younis JS, et al. **J Assist Reprod Genet** 1997 Jul;14(6):343–6

Delayed remote abscess formation after spillage of infected gallstone during laparoscopic cholecystectomy: CT and US findings. Van Hover P, et al. **J Belge Radiol** 1997 Feb; 80(1):9–10

Musculoskeletal complications of varicella. Schreck P, et al. **J Bone Joint Surg Am** 1996 Nov;78(11):1713–9

Peri-urethral abscess--a rare presentation of urethral carcinoma. Singla SL, et al. **J Indian Med Assoc** 1997 Mar; 95(3):90

Luc's abscess--a rare complication of middle-ear infection. Knappe MV, et al. **J Laryngol Otol** 1997 May;111(5):461–4 (8 ref.)

Squamous cell carcinoma of the pharynx and larynx presenting as a neck abscess or cellulitis. Lee WC, et al. **J Laryngol Otol** 1996 Sep;110(9):893–5

Parapharyngeal abscess: a rare complication of elective tonsillectomy. McEwan JA, et al. **J Laryngol Otol** 1997 Jun;111(6):578–9

Post-traumatic intracranial epidural Aspergillus fumigatus abscess. Letscher V, et al. **J Med Vet Mycol** 1997 Jul–Aug; 35(4):279–82

Submasseteric abscess caused by a dentigerous cyst mimicking a parotitis: report of two cases. Mandel L. **J Oral Maxillofac Surg** 1997 Sep;55(9):996–9 (17 ref.)

Acute thyroid abscess in infancy as a complication of pharyngeal fistula. el-Naggar M, et al. **J Otolaryngol** 1997 Apr;26(2):136–8

Abscess formation around a hydroxyapatite-coated implant placed into the extraction socket with autogenous bone graft. A histological study using light microscopy, image processing, and confocal laser scanning microscopy. Takeshita F, et al. **J Periodontol** 1997 Mar;68(3):299–305

Sterile abscess formation following plague vaccination. Smith AL, et al. **J R Army Med Corps** 1997 Jun;143(2):116–7

'Gossypiboma': an unusual cause of perinephric abscess. Bhat HS, et al. **J R Coll Surg Edinb** 1997 Aug;42(4):277–8

Orbital subperiosteal abscess as a complication of acute orbital cellulitis [letter; comment] Callanan V, et al. **J R Coll Surg Edinb** 1997 Feb;42(1):62–3. Comment on: J R Coll Surg Edinb 1995 Aug;40(4):246–7.

Posttraumatic retroperitoneal rupture of the right colon simulating a retroperitoneal hematoma. Duruisseau O, et al. **J Trauma** 1997 Apr;42(4):741–2

Closed blunt chest trauma causing mediastinal abscess. Gregory MW, et al. **J Trauma** 1996 Nov;41(5):899–901

Acute appendicitis presenting as a perinephric abscess. Bologna RA, et al. **J Urol** 1996 Nov;156(5):1758

From the Centers for Disease Control and Prevention. Infection with Mycobacterium abscessus associated with intramuscular injection of adrenal cortex extract--Colorado and Wyoming, 1995–1996. **JAMA** 1996 Oct 9;276(14):1130

Ulnar abscess: 4 months after release from control with paucibacillary-multidrug therapy. Darius EJ, et al. **Lepr Rev** 1997 Jun;68(2):173–4

Renal abscess: an illustrative case and review of the literature. Rinder MR. **Md Med J** 1996 Oct;45(10):839–43 (27 ref.)

Pyoderma gangrenosum and spinal epidural abscess after subcutaneous administration of recombinant human erythropoietin. Park CW, et al. **Nephrol Dial Transplant** 1997 Jul;12(7):1506–8

Congenital cholesteatoma with spontaneous epidural abscess, sinus thrombosis and cutaneous fistula. Gök A, et al. **Neurosurg Rev** 1996;19(3):189–91

Acute dacryocystitis: an unusual cause of life-threatening orbital intraconal abscess with frozen globe. Mauriello JA Jr, et al. **Ophthal Plast Reconstr Surg** 1996 Dec;12(4):294–5

Abscessed hydroxyapatite orbital implants [letter; comment] Soparkar CN, et al. **Ophthalmology** 1997 Jul;104(7):1059. Comment on: Ophthalmology 1996 Nov;103(11):1784–7.

Immunosuppression and systemic lupus erythematosus predisposing to laryngeal abscess. McNellis EL, et al. **Otolaryngol Head Neck Surg** 1997 Jan;116(1):107–9

Nontuberculous mycobacterial infection of the frontal sinus in a child. Weiss RL, et al. **Otolaryngol Head Neck Surg** 1997 Jan;116(1):110–2

Hepatosplenic cat-scratch disease and abdominal pain. Dunn MW, et al. **Pediatr Infect Dis J** 1997 Mar;16(3):269–72

Vertebral osteomyelitis in an infant presenting with a posterior mediastinal mass. Merriman TE, et al. **Pediatr Surg Int** 1997 Sep;12(7):541–3

Splenic abscess associated with pancreatic cancer: report of a case [letter] Nano J, et al. **Surgery** 1997 Feb;121(2):237–8

[Rare ocular complications in patients with acute necrotizing pancreatitis] Hejcmanová D, et al. **Cesk Slov Oftalmol** 1997 May;53(2):71–5 (Eng. Abstr.) **(Cze)**

[Pelvic actinomycosis abscess and intrauterine device] Ko-Kivok-Yun P, et al. **Contracept Fertil Sex** 1997 Mar; 25(3):239–41 (Eng. Abstr.) **(Fre)**

[Infectious complications after peridural obstetric anesthesia] Marsaudon E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):159–62 (20 ref.) (Eng. Abstr.) **(Fre)**

[Cold abscess of the forehead with intracranial extension disclosing tuberculous osteitis of the skull (letter)] Granier F, et al. **Presse Med** 1997 Mar 29;26(10):467 **(Fre)**

[Epidural abscess with Staphylococcus aureus meningitis and septicemia following saccoradiculography (letter)] Parola P, et al. **Presse Med** 1996 Oct 26;25(32):1561 **(Fre)**

[Sweet's syndrome and aseptic abscess of the spleen] Quilichini R, et al. **Rev Med Interne** 1996;17(12):1029–31 (15 ref.) (Eng. Abstr.) **(Fre)**

[Retroperitoneal abscess from odontogenic infection. Clinical case] Pelizzo G, et al. **Minerva Chir** 1997 Jan–Feb; 52(1–2):129–30 (Eng. Abstr.) **(Ita)**

[A case of retroperitoneal abscess and disseminated intravascular coagulation as a complication of upper ureteral rupture caused by ureteral calculus] Igawa T, et al. **Hinyokika Kiyo** 1996 Jul;42(7):525–8 (Eng. Abstr.) **(Jpn)**

[Peritonsillar and neck abscess with septicemia during interferon therapy in a patient with chronic hepatitis C] Shirahama M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Apr;94(4):295–9 **(Jpn)**

[Mitral ring abscess] Kato I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):399–402 (20 ref.) **(Jpn)**

[Perivalvular abscess] Kondo T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):425–7 (20 ref.) **(Jpn)**

[Appendiceal abscess in the third gestational trimester of pregnancy, complications pre and postoperatively] Cyrkowicz A, et al. **Przegl Lek** 1996;53(12):877–8 (Eng. Abstr.) **(Pol)**

[A rare complication of leiomyoma of the colon] Korymasov EA, et al. **Vestn Khir Im I I Grek** 1995;154(4–6):46 **(Rus)**

[Acute appendicitis complicated by destruction of the large intestine and septic shock] Kulibaba DM, et al. **Vestn Khir Im I I Grek** 1997;156(2):117–8 **(Rus)**

[Retropharyngeal abscess for foreign body complicated by mediastinitis and pericarditis] Grijalba Uche M, et al. **An Otorrinolaringol Ibero Am** 1996;23(6):577–87 (Eng. Abstr.) **(Spa)**

[Tuberculous prostatic abscess in acquired immunodeficiency syndrome] Galbis Sanjuan F, et al. **Arch Esp Urol** 1997 May;50(4):393–5 (Eng. Abstr.) **(Spa)**

[Tuberculous abscess of the pancreas as initial manifestation of AIDS (letter)] Molina M, et al. **Gastroenterol Hepatol** 1997 Mar;20(3):165–6 **(Spa)**

[Dorsal subdural spinal abscess after epidural anesthesia] Barón M, et al. **Neurologia** 1997 Jun-Jul;12(6):262–4 (Eng. Abstr.) **(Spa)**

[Epidural abscess: a complication of the use of corticoids in the treatment for back pain] de Andrés J, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):164–5 **(Spa)**

[A retroperitoneal abscess after endoscopic sphincterotomy: a severe and infrequent complication] Fernández Pérez FJ, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):139–41 (11 ref.) (Eng. Abstr.) **(Spa)**

[Abscess of the abdominal wall as a form of presentation of Crohn's disease (letter)] Guilarte López-Mañas J, et al. **Rev Esp Enferm Dig** 1996 Jul;88(7):521–2 **(Spa)**

[Iatrogenic abscesses of the cavity of the lesser pelvis of urologic origin] Priima OB, et al. **Klin Khir** 1996;(8):49–50 **(Ukr)**

IMMUNOLOGY

Immune response to anaerobic bacteria in patients with peritonsillar cellulitis and abscess. Brook I, et al. **Acta Otolaryngol (Stockh)** 1996 Nov;116(6):888–91

A case of lymphocutaneous nocardiosis with a review of lymphocutaneous nocardiosis reported in Japan [see comments] Ye Z, et al. **J Dermatol** 1996 Feb;23(2):120–4 (29 ref.). Comment in: J Dermatol 1997 Jan;24(1):68.

METABOLISM

Pharmacokinetics and pharmacodynamics of ceftizoxime in abscess fluid [letter] Guglielmo BJ, et al. **J Antimicrob Chemother** 1997 Mar;39(3):437–8

Accumulation of some small molecular weight complexes of 99mTc in experimental abscesses. Ercan MT, et al. **Nucl Med Biol** 1994 Feb;21(2):143–9

MICROBIOLOGY

Infective endocarditis and occult splenic abscess caused by Brucella melitensis infection: a case report and review of the literature. Saadeh AM, et al. **Acta Cardiol** 1996; 51(3):279–85 (32 ref.)

Epidural abscess: case report and review of the literature. Colle I, et al. **Acta Clin Belg** 1996;51(6):412–6

Experimental model for Porphyromonas gingivalis infection in animals. Eke PI, et al. **Afr J Med Med Sci** 1996 Mar; 25(1):31–9

Pyomyositis without predisposing factors [letter; comment] Nolan JT. **Am Fam Physician** 1997 Apr;55(5):1579. Comment on: Am Fam Physician 1996 Aug;54(2):565–9.

Metastatic abscess formation of the pelvis. Bauze AJ, et al. **Aust N Z J Surg** 1997 Sep;67(9):668–9

Infection with Mycobacterium avium-intracellulare with abscess, ulceration and fistula formation. Hide M, et al. **Br J Dermatol** 1997 Jan;136(1):121–3

Splenic abscess: a rare sequel to renal abscess caused by staghorn calculi. Yeh JT, et al. **Br J Urol** 1997 Sep; 80(3):504–5

Lung abscess caused by Legionella micdadei. Johnson KM, et al. **Chest** 1997 Jan;111(1):252–3

Actinomycotic splenic abscesses presenting with arthritis. Quintero-Del-Rio AI, et al. **Clin Exp Rheumatol** 1997 Jul-Aug;15(4):445–8 (13 ref.)

Torulopsis (Candida) glabrata: a new pathogen found in spinal epidural abscess. Bonomo RA, et al. **Clin Infect Dis** 1996 Mar;22(3):588–9

Microbiological analysis of pancreatic abscess. Brook I, et al. **Clin Infect Dis** 1996 Feb;22(2):384–5

Intramedullary abscess of the spinal cord in a patient with a right-to-left shunt: case report. David C, et al. **Clin Infect Dis** 1997 Jan;24(1):89–90

Testicular abscess due to Streptococcus pneumoniae in an infant with human immunodeficiency virus infection. Dobroszycki J, et al. **Clin Infect Dis** 1997 Jan;24(1):84–5

Cutaneous and muscular abscesses secondary to Actinomyces meyeri pneumonia. Liaudet L, et al. **Clin Infect Dis** 1996 Jan;22(1):185–6 (9 ref.)

Muscle abscess due to Aspergillus fumigatus in a patient with AIDS. Mylonakis E, et al. **Clin Infect Dis** 1996 Dec; 23(6):1323–4

Peritonitis due to a ruptured splenic abscess. Pera M, et al. **Clin Infect Dis** 1996 Aug;23(2):399–400

Isolation of presumptive Streptobacillus moniliformis from abscesses associated with the female genital tract. Pins MR, et al. **Clin Infect Dis** 1996 Mar;22(3):471–6

First report of a strain of Brucella melitensis that was widely sensitive to brucellaphages isolated in the United Arab Emirates. Worsley B, et al. **Clin Infect Dis** 1996 Jan; 22(1):190–1

Lumbar facet joint infection associated with epidural and paraspinal abscess. Baltz MS, et al. **Clin Orthop** 1997 Jun; (339):109–12

Virulence of Staphylococcus epidermidis in a mouse model: significance of extracellular slime. Deighton MA, et al. **Epidemiol Infect** 1996 Oct;117(2):267–80

Iatrogenic spinal infection following epidural anaesthesia: case report. Dunn LT, et al. **Eur Spine J** 1996;5(6):418–20

Endophthalmitis after Lasiodiplodia theobromae corneal abscess. Borderie VM, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Apr;235(4):259–61

Acute tongue abscess: report of two cases. Jungell P, et al. **Int J Oral Maxillofac Surg** 1996 Aug;25(4):308–10

Pediatric deep space neck infections: the Medical College of Wisconsin experience. Flanary VA, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jan 3;38(3):263–71

Myopathy and spontaneous Pasteurella pneumotropica-induced abscess formation in an HIV-1 transgenic mouse model. Dickie P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Oct 1;13(2):101–16

Subungual abscess: a bacterial infection of the nail bed.

Fleming TE, et al. **J Am Acad Dermatol** 1997 Sep;37(3 Pt 1):486–7

Ovarian abscess during pregnancy mimicking a leiomyoma of the uterus: a complication of transvaginal ultrasound-guided oocyte aspiration. Zweemer RP, et al. **J Assist Reprod Genet** 1996 Jan;13(1):81–5

Isolation of Mycoplasma hominis from a brain abscess. Zheng X, et al. **J Clin Microbiol** 1997 Apr;35(4):992–4

Breast abscess caused by Brucella melitensis. Al Abdely HM, et al. **J Infect** 1996 Nov;33(3):219–20

Lateral neck abscess caused by Streptococcus bovis in a patient with undiagnosed colon cancer. Goumas PD, et al. **J Laryngol Otol** 1997 Jul;111(7):666–8

A rare case of Salmonella neck abscess. Ray J, et al. **J Laryngol Otol** 1997 May;111(5):489–90 (4 ref.)

Lasiodiplodia theobromae isolated from a subcutaneous abscess in a Cambodian immigrant to Australia. Maslen MM, et al. **J Med Vet Mycol** 1996 Jul–Aug;34(4):279–83

Abscessed hydroxyapatite orbital implants. A report of two cases [see comments] Jordan DR, et al. **Ophthalmology** 1996 Nov;103(11):1784–7. Comment in: Ophthalmology 1997 Jul;104(7):1059.

Sternal abscess due to Bartonella (Rochalimaea) henselae in a renal transplant patient. Bruckert F, et al. **Skeletal Radiol** 1997 Jul;26(7):431–3

Tuberculous skeletal muscle involvement in acute leukemia: report on two cases. del Giglio A, et al. **Tumori** 1997 Mar–Apr;83(2):618–20

[Streptococcus milleri subacute spinal cord abscess. Apropos of a case] Lahdou JB, et al. **Neurochirurgie** 1996;42(2):100–4 (Eng. Abstr.) **(Fre)**

[The importance of microbiological study in the therapy of odontogenic abscesses. A report of a clinical case] Bux P, et al. **Minerva Stomatol** 1996 May;45(5):227–30 (10 ref.) (Eng. Abstr.) **(Ita)**

[The connection between the duration of the course of postinjection abscesses and the biological characteristics of the causative microorganisms] Kurlaev PP, et al. **Vestn Khir Im I I Grek** 1996;155(6):54–6 (Eng. Abstr.) **(Rus)**

[The role of the persistent characteristics of a causative agent in determining the protracted course of a suppurative-inflammatory course Deriabin DB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May–Jun;(3):74–7 (Eng. Abstr.) **(Rus)**

[[Brucellar orchiepididymitis with abscess] González Sánchez FJ, et al. **Arch Esp Urol** 1997 Apr;50(3):289–92 (14 ref.) (Eng. Abstr.) **(Spa)**

[Corneal crystalline image in patient with keratoplasty] Villuendas MC, et al. **Enferm Infecc Microbiol Clin** 1996 Nov;14(9):565–6 **(Spa)**

[Purulent abscess myocarditis with fatal outcome, caused by Streptococcus agalactiae (letter)] Abad C. **Med Clin (Barc)** 1996 Jan 27;106(3):119 **(Spa)**

[Prosthetic endocarditis and splenic abscess caused by Clostridium clostridiformis] Robles P, et al. **Rev Esp Cardiol** 1997 May;50(5):360–2 (Eng. Abstr.) **(Spa)**

PARASITOLOGY

[Perianal abscess caused by Enterobius vermicularis (letter)] López-Vélez R, et al. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):228 **(Spa)**

PATHOLOGY

Tumour presenting as a retrosternal abscess following median sternotomy. Martin IR, et al. **Br J Clin Pract** 1997 Apr–May;51(3):185

Listeria spinal cord abscess—clinical and MRI findings. Chu JY, et al. **Can J Neurol Sci** 1996 Aug;23(3):220–3

Candida abscess of the thyroid in a patient with acute lymphocytic leukemia. Daʼas N, et al. **Eur J Med Res** 1997 Aug 28;2(8):365–6

Spinal abscess. Louvel JP, et al. **J Belge Radiol** 1996 Dec; 79(6):271

MRI detection of epidural spinal abscesses at noncontiguous sites. Pfister HW, et al. **J Neurol** 1996 Apr;243(4):315–7

Breast abscesses in Nigeria: lactational versus non-lactational [letter; comment] Cotton MH. **J R Coll Surg Edinb** 1997 Feb;42(1):61. Comment on: J R Coll Surg Edinb 1995 Feb;40(1):25–7.

Phaeohyphomycosis due to Alternaria spp. and Phaeosclera dematioides: a histopathological study. Pec J, et al. **Mycoses** 1996 May–Jun;39(5–6):217–21

Suppurative lesions without prominent epithelioid cell response in abscess-forming granulomatous lymphadenitis. Kojima M, et al. **Pathol Res Pract** 1995 Nov; 191(11):1072–77

Perianal abscess and fistula in ano in infancy and childhood: a clinicopathological study. al-Salem AH, et al. **Pediatr Pathol Lab Med** 1996 Sep–Oct;16(5):755–64

[Does heparin modify the course of chronic abscess-forming peritonitis in the animal model?] Woltmann A, et al. **Langenbecks Arch Chir** 1997;382(2):107–10 (Eng. Abstr.) **(Ger)**

[An autopsy case of an extensive epidural spinal abscess demonstrating necrotizing poliomyelopathy] Yamashita M, et al. **No To Shinkei** 1996 Sep;48(9):839–44 (Eng. Abstr.) **(Jpn)**

[Neonatal suprarenal abscess: a diagnosis to be taken into account] Sanz Villa N, et al. **Cir Pediatr** 1997 Jan;10(1):42–3 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Immediate tonsillectomy for peritonsillar abscess. Fujimoto M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:252–5

Mastoid abscess: underlying disease and management. al-Serhani AM. **Am J Otol** 1996 Sep;17(5):694–6

Paradoxical subcutaneous tuberculous abscess. Valdez LM, et al. **Clin Infect Dis** 1997 Apr;24(4):734

Management of medial subperiosteal abscess of the orbit in children—a 5 year experience. Pereira KD, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jan 3;38(3):247–54

[Retropharyngeal abscess for foreign body complicated by mediastinitis and pericarditis] Grijalba Uche M, et al. **An Otorrinolaringol Ibero Am** 1996;23(6):577–87 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Human skin flora as a potential source of epidural abscess. Sato S, et al. **Anesthesiology** 1996 Dec;85(6):1276–82

Evaluation of interleukin-1 receptor antagonist (IL-1RA) and tumor necrosis factor binding protein (TNF-BP) in a rodent abscess model of host resistance. Colagiovanni DB, et al. **Immunopharmacol Immunotoxicol** 1996 Aug; 18(3):397–419

PSYCHOLOGY

Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Kozak W, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R621–30

[Artificially induced suppurative diseases] Svetukhin AM, et al. **Khirurgiia (Mosk)** 1996;(6):69–72 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Leiomyosarcoma of the larynx presenting as a laryngopyocele. Helmberger RC, et al. **AJNR Am J Neuroradiol** 1996 Jun–Jul;17(6):1112–4

Percutaneous CT-guided aspiration of deep neck abscesses. Poe LB, et al. **AJNR Am J Neuroradiol** 1996 Aug; 17(7):1359–63

Branchial pouch sinus tract from the piriform fossa causing acute suppurative thyroiditis, neck abscess, or both: CT appearance and the use of air as a contrast agent. Bar-Ziv J, et al. **AJR Am J Roentgenol** 1996 Dec;167(6):1569–72

Pyomyositis of the calf muscles mimicking distal deep venous thrombosis: a case report. Wang KC, et al. **Am J Orthop** 1997 May;26(5):358–9

Radiological case of the month. Subperiosteal abscess of the mastoid. Balwally AN, et al. **Arch Pediatr Adolesc Med** 1997 Feb;151(2):201–2

The radiology of melioidosis. Chong VF, et al. **Australas Radiol** 1996 Aug;40(3):244–9 (14 ref.)

Pituitary abscess: a series of six cases. Jain KC, et al. **Br J Neurosurg** 1997 Apr;11(2):139–43 (15 ref.)

Case in point. Perinephric abscess. Fred HL, et al. **Hosp Pract (Off Ed)** 1997 Jun 15;32(6):40

Quantitative analysis of the plain radiographic appearance of Brodie's abscess. Lopes TD, et al. **Invest Radiol** 1997 Jan;32(1):51–8

Odontogenic versus nonodontogenic deep neck space infections: CT manifestations. Kim HJ, et al. **J Comput Assist Tomogr** 1997 Mar–Apr;21(2):202–8

CT in searching for abscess after abdominal or pelvic surgery in patients with neoplasia: do abdomen and pelvis both need to be scanned? Krumenacker JH, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):652–5

Idiopathic bilateral anterior mediastinal abscesses. Fields JM, et al. **Pediatr Radiol** 1997 Jul;27(7):596–7

[Actinomycotic tubo-ovarian abscess. Contribution of pelvic angioscanner] Bazot M, et al. **J Radiol** 1997 Jul;78(7):513–6 (Eng. Abstr.) **(Fre)**

[Computed tomographic findings in septic pulmonary emboli secondary to renal abscess] Matsumoto H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Aug; 34(8):937–42 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

FDG-PET in infectious lesions: The detection and assessment of lesion activity. Ichiya Y, et al. **Ann Nucl Med** 1996 May;10(2):185–91

Extrarenal accumulation of Tc-99m DTPA in a gluteal abscess. Prakash R. **Clin Nucl Med** 1997 May;22(5):324–5

Tc-99m MDP uptake in Staphylococcus aureus paraspinal abscess. Value of bone SPECT and reprojectional display in preoperative guidance. Turoglu T, et al. **Clin Nucl Med** 1997 May;22(5):335–6

Retention of technetium-99m in infectious foci in rats after release from technetium-99m labelled human non-specific polyclonal immunoglobulin G: a dual-label study with hydrazinonicotinamido and iminothiolano immunoglobulin. Claessens RA, et al. **Eur J Nucl Med** 1996 Nov; 23(11):1536–9

Different behaviour of radioiodinated human recombinant interleukin-1 and its receptor antagonist in an animal model of infection. van der Laken CJ, et al. **Eur J Nucl Med** 1996 Nov;23(11):1531–5

Optimization of technetium-99m-labeled PEG liposomes to image focal infection: effects of particle size and circulation time. Boerman OC, et al. **J Nucl Med** 1997 Mar; 38(3):489–93

Rapid imaging of experimental infection with technetium-99m-DTPA after anti-DTPA monoclonal antibody priming. Kranenborg MH, et al. **J Nucl Med** 1997 Jun;38(6):901–6

Technetium-99m-labeled chemotactic peptides in acute infection and sterile inflammation [see comments] van der Laken CJ, et al. **J Nucl Med** 1997 Aug;38(8):1310–5. Comment in: J Nucl Med 1997 Aug;38(8):1322–6.

SURGERY

Spinal epidural abscess--review of 10 cases. Tacconi L, et al. **Acta Neurochir (Wien)** 1996;138(5):520–3 (17 ref.)

Immediate tonsillectomy for peritonsillar abscess. Fujimoto M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:252–5

Percutaneous CT-guided aspiration of deep neck abscesses. Poe LB, et al. **AJNR Am J Neuroradiol** 1996 Aug; 17(7):1359–63

Transantral evacuation of an orbital abscess following a molar tooth extraction. Bizakis JG, et al. **Am J Otolaryngol** 1997 Jul–Aug;18(4):277–9

Orbital complications of pediatric sinusitis: treatment of periorbital abscess. Mann W, et al. **Am J Rhinol** 1997 Mar–Apr;11(2):149–53

Outcome after incision and drainage with fistulotomy for ischiorectal abscess. Cox SW, et al. **Am Surg** 1997 Aug; 63(8):686–9

Successful treatment of epidural abscess with a percutaneously introduced 4-French catheter for drainage. Hori K, et al. **Anesth Analg** 1997 Jun;84(6):1384–6

Incision and drainage of cutaneous abscesses is not associated with bacteremia in afebrile adults. Bobrow BJ, et al. **Ann Emerg Med** 1997 Mar;29(3):404–8

Squamous cell carcinoma in perineal inflammatory disease. Gur E, et al. **Ann Plast Surg** 1997 Jun;38(6):653–7

Provision of a day case abscess service. Loftus IM, et al. **Ann R Coll Surg Engl** 1997 Jul;79(4):289–90

Minimal endoscopic approach to subperiosteal orbital abscess. Froehlich P, et al. **Arch Otolaryngol Head Neck Surg** 1997 Mar;123(3):280–2

Conversion disorder presenting in a patient with an implantable morphine pump and an epidural abscess resulting in paraplegia. Shell MG, et al. **Arch Phys Med Rehabil** 1997 Feb;78(2):226–9

Open versus closed surgical treatment of abscesses: a controlled clinical trial. Abraham N, et al. **Aust N Z J Surg** 1997 Apr;67(4):173–6

Pitfalls in the management of preauricular sinuses. Currie AR, et al. **Br J Surg** 1996 Dec;83(12):1722–4

Endoscopic sinus surgery for the treatment of frontoethmoidal mucocele complicated with orbital abscess: a case report. Chen TM, et al. **Chang Keng I Hsueh** 1997 Mar;20(1):39–43

Anorectal abscesses: need for accurate anatomical localization of the disease. Nomikos IN. **Clin Anat** 1997; 10(4):239–44

Fistulotomy in the management of acute anorectal sepsis [letter] Grace R. **Dis Colon Rectum** 1997 Sep;40(9):1130–1

Prospective randomized trial of drainage alone vs. drainage and fistulotomy for acute perianal abscesses with proven internal opening. Tang CL, et al. **Dis Colon Rectum** 1996 Dec;39(12):1415–7

Surgical treatment of acute endocarditis of the aortic valve with paravalvular abscess: considerations justifying the use of mechanical replacement devices. Bauernschmitt R, et al. **Eur J Cardiothorac Surg** 1996;10(9):741–7

Laparoscopic management of adnexal abscesses: consequences for fertility. Raiga J, et al. **Fertil Steril** 1996 Nov;66(5):712–7

Endoscopic transrectal drainage of a diverticular abscess. Baron TH, et al. **Gastrointest Endosc** 1997 Jan;45(1):84–7

Percutaneous abscess drainage in gynecologic cancer patients. Ramondetta LM, et al. **Gynecol Oncol** 1996 Sep; 62(3):366–9

Wide reconstruction of the anterior cranial base with bipedicled galeopericranial flap. Terashi H, et al. **Head Neck** 1996 May–Jun;18(3):292–4

Management of medial subperiosteal abscess of the orbit in children—a 5 year experience. Pereira KD, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jan 3;38(3):247–54

The natural history of the neglected felon. Watson PA, et al. **Iowa Orthop J** 1996;16:164–6

Surgical management of aortic root abscess. David TE. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):262–6; discussion 266–9

Partial thyroidectomy and selective neck dissection in the management of pyriform sinus fistulae. Elahi MM, et al. **J Otolaryngol** 1997 Feb;26(1):57–63

Saline injection into the perirectal space to assist transgluteal drainage of deep pelvic abscesses. Shah H, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):119–21

Spinal epidural abscess: evaluation of factors influencing outcome. Khanna RK, et al. **Neurosurgery** 1996 Nov; 39(5):958–64

Vitrectomy for endogenous Klebsiella pneumoniae endophthalmitis with massive subretinal abscess. Yarng SS, et al. **Ophthalmic Surg Lasers** 1997 Feb;28(2):147–50

Subareolar breast abscesses [letter; comment] Schein M. **Surgery** 1996 Nov;120(5):902–3. Comment on: Surgery 1995 Oct;118(4):775–82.

Mediastinal tuberculous lymphadenitis diagnosed and treated by thoracoscopy. Suzuki T, et al. **Thorac Cardiovasc Surg** 1997 Jun;45(3):140–2

[Percutaneous drainage of a presacral and spinal extra-dural abscess complicating Crohn's disease] Cassagnou M, et al. **Gastroenterol Clin Biol** 1996;20(8-9):689-92 (13 ref.) (Eng. Abstr.) **(Fre)**

[Percutaneous ultrasound controlled drainage of large splenic abscesses] Schäberle W, et al. **Chirurg** 1997 Jul;68(7):744-8 (29 ref.) (Eng. Abstr.) **(Ger)**

[Paranephritic abscess. Local late complication after laparoscopic cholecystectomy] Sichardt G, et al. **Chirurg** 1996 Jul;67(7):754-6 (Eng. Abstr.) **(Ger)**

[Anesthesia and analgesia in intravenous drug dependent patients with injection abscesses of the upper extremity. Case report] Ebert B, et al. **Handchir Mikrochir Plast Chir** 1997 Jan;29(1):38-41 (Eng. Abstr.) **(Ger)**

[Management of hematoma of the nasal septum and abscesses of the nasal septum] Kastenbauer ER. **Laryngorhinootologie** 1997 Jan;76(1):A1-5 **(Ger)**

[Closure of infected problem wounds by soft tissue traction] Schmid A, et al. **Zentralbl Chir** 1996;121 Suppl:85-6 **(Ger)**

[The role of surgery in the treatment of appendicular abscesses] Zarba Meli E, et al. **Minerva Chir** 1997 May; 52(5):577-81 (Eng. Abstr.) **(Ita)**

[A case of urachal abscess resected electively after successful drainage from umbilicus] Ito K, et al. **Hinyokika Kiyo** 1997 May;43(5):367-9 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of aortic valve endocarditis associated with aortic root aneurysm and abscess] Kamata S, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):612-6 (Eng. Abstr.) **(Jpn)**

[Valve replacement concomitant with anulus reconstruction] Sawazaki M, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):617-20 (Eng. Abstr.) **(Jpn)**

[A case of DVR with Nicks's procedure for active infective endocarditis with periannular abscess] Bonkohara Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):174-80 (Eng. Abstr.) **(Jpn)**

[Acute right-sided paranephritis complicated by abscess of the recto-bladder recess] Tomusiak TL, et al. **Klin Khir** 1996;(8):49 **(Rus)**

[Simultaneous treatment of an anal abscess and fistula] Vrzgula A, et al. **Rozhl Chir** 1996 Apr;75(4):219-21 (Eng. Abstr.) **(Slo)**

THERAPY

Postoperative highcervical quadriplegia after transoral biopsy of a paravertebral tuberculous abscess with epidural extension: complete resolution after decompressive laminectomy and high-dose methylprednisolone. Knutti O, et al. **Acta Neurochir (Wien)** 1997;139(2):158-9

Emphysematous pyelonephritis or renal abscess? [letter; comment] Loftus WK. **AJR Am J Roentgenol** 1996 Nov; 167(5):1341-2. Comment on: AJR Am J Roentgenol 1995 Jun;164(6):1554-5.

Percutaneous radiologic drainage of pancreatic abscesses. vanSonnenberg E, et al. **AJR Am J Roentgenol** 1997 Apr; 168(4):979-84

Spontaneous healing of pancreatic abscess after fistulization to the duodenal bulb. Kawachi S, et al. **Am J Med Sci** 1997 Jul;314(1):44-6

Transvaginal ultrasound-guided aspiration in the treatment and follow-up of tubo-ovarian abscess: a report of two cases. Hsu YL, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Sep;56(3):211-4

Technical report: perirectal abscess drainage--a simple modification in technique using a vascular sheath. D'Costa H, et al. **Clin Radiol** 1997 Jun;52(6):469-71

Computed tomography-guided percutaneous abscess drainage in intestinal disease: factors associated with outcome. Bernini A, et al. **Dis Colon Rectum** 1997 Sep; 40(9):1009-13

Endoscopic treatment of fistulas and abscesses in pancreatitis: three case reports. Schoefl R, et al. **Endoscopy** 1996 Nov; 28(9):776-9

Percutaneous sump drainage of pancreatic abscess. Soonawalla ZF, et al. **Indian J Gastroenterol** 1996 Jul; 15(3):99-100

Characterization and management of deep neck infections. Sakaguchi M, et al. **Int J Oral Maxillofac Surg** 1997 Apr; 26(2):131-4

The management of infectious and noninfectious anorectal complications in patients with leukemia. North JH Jr, et al. **J Am Coll Surg** 1996 Oct;183(4):322-8

Recurrent sacro-iliac joint abscess. Eskander MB, et al. **J R Army Med Corps** 1994 Jun;140(2):95-6 (7 ref.)

Transrectal and transvaginal abscess drainage. Hovsepian DM. **J Vasc Interv Radiol** 1997 Jul-Aug;8(4):501-15 (39 ref.)

Transrectal drainage of deep pelvic abscesses in children using a combined transrectal sonographic and fluoroscopic guidance. Chung T, et al. **Pediatr Radiol** 1996 Dec; 26(12):874-8

Percutaneous drainage of subperiosteal abscess: a potential treatment for osteomyelitis. Hoffer FA, et al. **Pediatr Radiol** 1996 Dec;26(12):879-81

Abscess aspiration in a bush hospital in Botswana. Kennedy I. **Trop Doct** 1997 Oct;27(4):237-9

Interventional and surgical treatment of pancreatic abscess. Mithöfer K, et al. **World J Surg** 1997 Feb;21(2):162-8 (62 ref.)

[A case of ovarian abscess aspirated under transvaginal ultrasonography followed by local administration of antibiotics] Serikawa T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Sep;48(9):841-4 **(Jpn)**

[Antiseptics in the combined treatment of patients with perimaxillary abscesses and phlegmons] Biberman IaM, et al. **Stomatologiia (Mosk)** 1996;75(6):25-7 (Eng. Abstr.) **(Rus)**

[The use of lasers and a plasma surgical unit in the combined treatment of patients with inflammatory diseases of the maxillofacial area] Shargorodskiĭ AG, et al. **Stomatologiia (Mosk)** 1996;Spec No:40-1 **(Rus)**

[The local treatment of suppurative wounds of the maxillofacial area] Starodubtsev VS, et al. **Stomatologiia (Mosk)** 1996;Spec No:78-9 **(Rus)**

TRANSMISSION

[Paravertebral abscess with secondary meningomyelitis after infiltration therapy. A brief case report] Ohlmann D, et al. **Wien Klin Wochenschr** 1996;108(14):442-3 **(Ger)**

ULTRASONOGRAPHY

Pyomyositis without predisposing factors [letter; comment] Nolan JT. **Am Fam Physician** 1997 Apr;55(5):1579. Comment on: Am Fam Physician 1996 Aug;54(2):565-9.

Postoperative mitral valve abscess. A case report. Pamidi S, et al. **Angiology** 1997 Aug;48(8):749-52

Sterile, caseous mitral valve "abscess" mimicking infective endocarditis. Gilbert HM, et al. **Clin Infect Dis** 1997 May; 24(5):1015-6

Ultrasonography in the evaluation of neck abscesses in children. Quraishi MS, et al. **Clin Otolaryngol** 1997 Feb; 22(1):30-3

Pericardial abscess due to transdiaphragmatic perforation of the pyogenic liver abscess [letter] Cho MC, et al. **Eur Heart J** 1996 Oct;17(10):1602-3

Cardiac aspergillosis: importance of transesophageal echocardiography [letter] Blanc-Jouvan M, et al. **Intensive Care Med** 1996 Dec;22(12):1462

Recognition of tubo-ovarian abscess in adolescents with pelvic inflammatory disease. Slap GB, et al. **J Adolesc Health** 1996 Jun;18(6):397-403

Bartholin gland abscess: sonographic findings. Abulafia O, et al. **J Clin Ultrasound** 1997 Jan;25(1):47-9

Sonographically guided aspiration: an alternative therapy for tubo-ovarian abscess [see comments] Caspi B, et al. **Ultrasound Obstet Gynecol** 1996 Jun;7(6):439-42. Comment in: Ultrasound Obstet Gynecol 1996 Jun;7(6):398-400.

Regarding the best approach to the pyosalpinx [comment] Parsons AK. **Ultrasound Obstet Gynecol** 1996 Jun; 7(6):398-400 (20 ref.). Comment on: Ultrasound Obstet Gynecol 1996 Jun;7(6):435-8. Comment on: Ultrasound Obstet Gynecol 1996 Jun;7(6):439-42.

Early ultrasound-guided transvaginal drainage of tubo-ovarian abscesses: a randomized study [see comments] Perez-Medina T, et al. **Ultrasound Obstet Gynecol** 1996 Jun;7(6):435-8. Comment in: Ultrasound Obstet Gynecol 1996 Jun;7(6):398-400.

[Echographic features in the diagnosis of renal abscess] Beleggia F, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):171-3 (Eng. Abstr.) **(Ita)**

[Infrequent application of intraoperative ultrasonography in urology] Trombetta C, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):31-6 (Eng. Abstr.) **(Ita)**

[Transanal ultrasonography in the study of fistulas of perianal abscess] Piccinini EE, et al. **Minerva Chir** 1996 Sep; 51(9):653-9 (Eng. Abstr.) **(Ita)**

VETERINARY

The influence of tail biting on performance of fattening pigs. Wallgren P, et al. **Acta Vet Scand** 1996;37(4):453-60

Corynebacterium pseudotuberculosis infection in horses: 538 cases (1982-1993). Aleman M, et al. **J Am Vet Med Assoc** 1996 Aug 15;209(4):804-9

What is your diagnosis? Chronic retrobulbar abscess in a horse. Hubert J, et al. **J Am Vet Med Assoc** 1996 Nov 15;209(10):1703-4

Anorectal lymphadenopathy causing colic, perirectal abscesses, or both in five young horses. Magee AA, et al. **J Am Vet Med Assoc** 1997 Mar 15;210(6):804-7

Actinobacillus lignieresi infection in camels on the Sokoto plains, Nigeria. Daneji AI, et al. **Trop Anim Health Prod** 1996 Nov;28(4):315-6

Dermatophilosis and abscessation of lymph nodes in a group of tick-infested horses in Uganda. Shannon D. **Trop Anim Health Prod** 1997 May;29(2):102-4

Incidence, location and interrelationships between the sites of abscesses recorded in pigs at a bacon factory in Northern Ireland. Huey RJ. **Vet Rec** 1996 May 25;138(21):511-4

Influence of diet on the occurrence of intraepithelial microabscesses and foreign bodies in the ruminal mucosa of reindeer calves (Rangifer tarandus tarandus). Josefsen TD, et al. **Zentralbl Veterinarmed A** 1997 Jul;44(5):249-57

A new pathogenic Staphylococcus aureus type in commercial rabbits. Devriese LA, et al. **Zentralbl Veterinarmed [B]** 1996 Jul;43(5):313-5

ABSCESS, ABDOMINAL see **ABDOMINAL ABSCESS**

ABSCESS, AMEBIC, HEPATIC see **LIVER ABSCESS, AMEBIC**

ABSCESS, CEREBRAL see **BRAIN ABSCESS**

ABSCESS, HEPATIC see **LIVER ABSCESS**

ABSCESS, HEPATIC, AMEBIC see **LIVER ABSCESS, AMEBIC**

ABSCESS, INTRA-ABDOMINAL see **ABDOMINAL ABSCESS**

ABSCESS, LIVER, AMEBIC see **LIVER ABSCESS, AMEBIC**

ABSCESS, PERIAPICAL see **PERIAPICAL ABSCESS**

ABSCESS, PERIODONTAL see **PERIODONTAL ABSCESS**

ABSCESS, PERITONSILLAR see **PERITONSILLAR ABSCESS**

ABSCESS, PSOAS see **PSOAS ABSCESS**

ABSCESS, PULMONARY see **LUNG ABSCESS**

ABSCESS, RETROPHARYNGEAL see **RETROPHARYNGEAL ABSCESS**

ABSCESS, SUBDURAL see **EMPYEMA, SUBDURAL**

ABSCESS, SUBPHRENIC see **SUBPHRENIC ABSCESS**

ABSCISIC ACID

Microviscosity of cucumber (Cucumis sativus L.) fruit protoplast membranes is altered by triacontanol and abscisic acid. Shripathi V, et al. **Biochim Biophys Acta** 1997 Jan 31;1323(2):263-71

GENETICS

Isolation and characterization of abscisic acid-deficient Arabidopsis mutants at two new loci. Léon-Kloosterziel KM, et al. **Plant J** 1996 Oct;10(4):655-61

IMMUNOLOGY

Unusual discrimination against carrier protein antibodies during partial purification of hapten-protein polyclonal antibodies to plant stress hormones. Manju RV, et al. **Indian J Exp Biol** 1995 Jan;33(1):1-5

METABOLISM

Immunogold localization and quantification of cellular and subcellular abscisic acid, prior to and during drought stress. van Rensburg L, et al. **Biotech Histochem** 1996 Jan; 71(1):38-43

Seed-specific immunomodulation of abscisic acid activity induces a developmental switch. Phillips J, et al. **EMBO J** 1997 Aug 1;16(15):4489-96

Purification and identification of ABA-binding proteins and antibody preparation. Wan Y, et al. **J Mol Recognit** 1996 Sep-Dec;9(5-6):722-7

Isolation of a novel class of bZIP transcription factors that interact with ABA-responsive and embryo-specification elements in the Dc3 promoter using a modified yeast one-hybrid system. Kim SY, et al. **Plant J** 1997 Jun; 11(6):1237-51

QTL analysis to study the association between leaf size and abscisic acid accumulation in droughted rice leaves and comparisons across cereals. Quarrie SA, et al. **Plant Mol Biol** 1997 Sep;35(1-2):155-65 (45 ref.)

Convergence of the abscisic acid, CO2, and extracellular calcium signal transduction pathways in stomatal guard cells. Webb AA, et al. **Plant Physiol** 1997 Aug; 114(4):1557-60

PHARMACOLOGY

In vivo phosphorylation of phosphoenolpyruvate carboxylase in guard cells of Vicia faba L. is enhanced by fusicoccin and suppressed by abscisic acid. Du Z, et al. **Arch Biochem Biophys** 1997 Jan 15;337(2):345-50

Protein phosphatase activity of abscisic acid insensitive 1 (ABI1) protein from Arabidopsis thaliana. Bertauche N, et al. **Eur J Biochem** 1996 Oct 1;241(1):193-200

A group 3 LEA cDNA of rice, responsive to abscisic acid, but not to jasmonic acid, shows variety-specific differences in salt stress response. Moons A, et al. **Gene** 1997 Jun 3; 191(2):197-204

Effects of internal K+ and ABA on the voltage- and time-dependence of the outward K(+)-rectifier in Vicia guard cells. Lemtiri-Chlieh F. **J Membr Biol** 1996 Sep; 153(2):105-16

Abscisic acid-independent and abscisic acid-dependent regulation of proline biosynthesis following cold and osmotic stresses in Arabidopsis thaliana. Savouré A, et al. **Mol Gen Genet** 1997 Mar 18;254(1):104-9

Differential abscisic acid regulation of guard cell slow anion channels in Arabidopsis wild-type and abi1 and abi2 mutants. Pei ZM, et al. **Plant Cell** 1997 Mar;9(3):409-23

Effects of abscisic acid and cytoplasmic pH on potassium and chloride efflux in Arabidopsis thaliana seedlings.

Beffagna N, et al. **Plant Cell Physiol** 1997 May;38(5):503–10
A major jasmonate-inducible protein of sweet potato, ipomoelin, is an ABA-independent wound-inducible protein. Imanishi S, et al. **Plant Cell Physiol** 1997 Jun; 38(6):643–52
Accumulation of 19-kDa plasma membrane polypeptide during induction of freezing tolerance in wheat suspension-cultured cells by abscisic acid. Koike M, et al. **Plant Cell Physiol** 1997 Jun;38(6):707–16
Regulatory elements in vivo in the promoter of the abscisic acid responsive gene rab17 from maize. Busk PK, et al. **Plant J** 1997 Jun;11(6):1285–95
Abscisic acid and jasmonic acid activate wound-inducible genes in potato through separate, organ-specific signal transduction pathways. Dammann C, et al. **Plant J** 1997 Apr;11(4):773–82
Alteration of anion channel kinetics in wild-type and abi1-1 transgenic Nicotiana benthamiana guard cells by abscisic acid. Grabov A, et al. **Plant J** 1997 Jul;12(1):203–13
Nitrogen and hormonal responsiveness of the 22 kDa alpha-zein and b-32 genes in maize endosperm is displayed in the absence of the transcriptional regulator Opaque-2. Müller M, et al. **Plant J** 1997 Aug;12(2):281–91
A rice bZIP protein, designated OSBZ8, is rapidly induced by abscisic acid. Nakagawa H, et al. **Plant J** 1996 Feb; 9(2):217–27
Interactions between the ABI1 and the ectopically expressed ABI3 genes in controlling abscisic acid responses in Arabidopsis vegetative tissues. Parcy F, et al. **Plant J** 1997 Apr;11(4):693–702
The Arabidopsis homeobox gene ATHB-7 is induced by water deficit and by abscisic acid. Söderman E, et al. **Plant J** 1996 Aug;10(2):375–81
The isolation of a novel metallothionein-related cDNA expressed in somatic and zygotic embryos of Douglas-fir: regulation by ABA, osmoticum, and metal ions. Chatthai M, et al. **Plant Mol Biol** 1997 May;34(2):243–54
A family of novel myb-related genes from the resurrection plant Craterostigma plantagineum are specifically expressed in callus and roots in response to ABA or desiccation. Iturriaga G, et al. **Plant Mol Biol** 1996 Nov;32(4):707–16
Identification and expression of water stress- and abscisic acid-regulated genes in a drought-tolerant sunflower genotype. Ouvrard O, et al. **Plant Mol Biol** 1996 Jul; 31(4):819–29
Tissue-specific activation of the osmotin gene by ABA, C2H4 and NaCl involves the same promoter region. Raghothama KG, et al. **Plant Mol Biol** 1997 Jun; 34(3):393–402
Changes in abundance of an abscisic acid-responsive, early cysteine-labeled metallothionein transcript during pollen embryogenesis in bread wheat (Triticum aestivum). Reynolds TL, et al. **Plant Mol Biol** 1996 Dec;32(5):823–9
Apoptosis in barley aleurone during germination and its inhibition by abscisic acid. Wang M, et al. **Plant Mol Biol** 1996 Dec;32(6):1125–34
Phytohormone-regulated beta-amylase gene expression in rice. Wang SM, et al. **Plant Mol Biol** 1996 Aug;31(5):975–82
Identification of a receptor-like protein kinase gene rapidly induced by abscisic acid, dehydration, high salt, and cold treatments in Arabidopsis thaliana. Hong SW, et al. **Plant Physiol** 1997 Apr;113(4):1203–12
The rab16B promoter of rice contains two distinct abscisic acid-responsive elements. Ono A, et al. **Plant Physiol** 1996 Oct;112(2):483–91
Regulation of acyltransferase activity in immature maize embryos by abscisic acid and the osmotic environment. Pacheco-Moisés F, et al. **Plant Physiol** 1997 Jul; 114(3):1095–101

PHYSIOLOGY

The Arabidopsis ABSCISIC ACID-INSENSITIVE2 (ABI2) and ABI1 genes encode homologous protein phosphatases 2C involved in abscisic acid signal transduction. Leung J, et al. **Plant Cell** 1997 May; 9(5):759–71
Genetic analysis of abscisic acid signal transduction. Merlot S, et al. **Plant Physiol** 1997 Jul;114(3):751–7 (46 ref.)

ABSENCE SEIZURES see **EPILEPSY, ABSENCE**

ABSENTEEISM

Inability to work after surgical removal of mandibular third molars. Berge TI. **Acta Odontol Scand** 1997 Jan;55(1):64–9
Workplace organizational correlates of lost-time accident rates in manufacturing. Shannon HS, et al. **Am J Ind Med** 1996 Mar;29(3):258–68 (17 ref.)
School refusal and truancy. Berg I. **Arch Dis Child** 1997 Feb; 76(2):90–1
Absenteeism in the workforce, Klang Valley, Malaysia--preliminary report. Indran SK, et al. **Asia Pac J Public Health** 1995;8(2):109–13
ABC of work related disorders. Absence from work. Briner RB. **BMJ** 1996 Oct 5;313(7061):874–7 (0 ref.)
Injury consequences from participation in professional rugby league: a preliminary investigation. Meir RA, et al. **Br J Sports Med** 1997 Jun;31(2):132–4
Early predictors of outcome. Nordin M, et al. **Bull Hosp Jt Dis** 1996;55(4):204–6
The physician's role in helping patients return to work after an illness or injury. Canadian Medical Association [see comments] **Can Med Assoc J** 1997 Mar 1;156(5):680A–680F . Comment in: Can Med Assoc J 1997 May 15;156(10):1382. **(Eng, Fre)**
Helping patients return to work. Kazimirski JC. **Can Med Assoc J** 1997 Mar 1;156(5):680–1 **(Eng, Fre)**
Predicting factors for absenteeism in patients with major depressive disorders. Souêtre E, et al. **Eur J Epidemiol** 1997 Jan;13(1):87–93
Scheduled hand washing in an elementary school population. Master D, et al. **Fam Med** 1997 May;29(5):336–9
Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort. Michel P, et al. **Headache** 1997 Feb;37(2):71–8
Labour productivity effects of prescribed medicines for chronically ill workers. Rizzo JA, et al. **Health Econ** 1996 May-Jun;5(3):249–65
System for analysing sickness absenteeism in Poland. Indulski JA, et al. **Int J Occup Med Environ Health** 1997; 10(2):159–65
Female sickness absenteeism in Poland. Indulski JA, et al. **Int J Occup Med Environ Health** 1996;9(3):219–25
Burnout, self- and supervisor-rated job performance, and absenteeism among nurses. Parker PA, et al. **J Behav Med** 1995 Dec;18(6):581–99
Quality of life and panic-related work disability in subjects with infrequent panic and panic disorder. Katerndahl DA, et al. **J Clin Psychiatry** 1997 Apr;58(4):153–8
Cost-effectiveness of the influenza vaccine in a healthy, working-age population. Campbell DS, et al. **J Occup Environ Med** 1997 May;39(5):408–14
Cigarette smoking at hire as a predictor of employment outcome. Ryan J, et al. **J Occup Environ Med** 1996 Sep; 38(9):928–33
Illness absence at an oil refinery and petrochemical plant. Tsai SP, et al. **J Occup Environ Med** 1997 May;39(5):455–62
Long-term outcomes in blunt trauma: who goes back to work? Brenneman FD, et al. **J Trauma** 1997 May; 42(5):778–81
A biocultural perspective on health and household economy in southern Peru [see comments] Leatherman TL. **Med Anthropol Q** 1996 Dec;10(4):476–95. Comment in: Med Anthropol Q 1996 Dec;10(4):451–4. Comment in: Med Anthropol Q 1996 Dec;10(4):516–9. Comment in: Med Anthropol Q 1996 Dec;10(4):519–22.
The efficacy and effectiveness of process consultation in improving staff morale and absenteeism. Weir R, et al. **Med Care** 1997 Apr;35(4):334–53
Relapse and short sickness absence for back pain in the six months after return to work. Infante-Rivard C, et al. **Occup Environ Med** 1997 May;54(5):328–34
The role of the human spirit in recovery from injury. Miller M. **Occup Health Saf** 1994 Oct;63(10):167–70, 193
Sickness absence following a campaign of vaccination against influenza in the workplace. Leighton L, et al. **Occup Med (Oxf)** 1996 Apr;46(2):146–50
The impact of psychiatric disorders on work loss days. Kessler RC, et al. **Psychol Med** 1997 Jul;27(4):861–73
Social support and psychiatric sickness absence: a prospective study of British civil servants. Stansfeld SA, et al. **Psychol Med** 1997 Jan;27(1):35–48
Hostility and registered sickness absences: a prospective study of municipal employees. Vahtera J, et al. **Psychol Med** 1997 May;27(3):693–701
Absence due to illness among toddlers in day-care centres in relation to child group structure. Sennerstam RB. **Public Health** 1997 Mar;111(2):85–8
Musculoskeletal pain: concepts of disease, illness, and sickness certification in health professionals in Norway. Haldorsen EM, et al. **Scand J Rheumatol** 1996;25(4):224–32
Sex differences in sickness absence in relation to parental status. Akerlind I, et al. **Scand J Soc Med** 1996 Mar; 24(1):27–35
Impact of pregnancy on gender differences in sickness absence. Alexanderson K, et al. **Scand J Soc Med** 1996 Sep;24(3):169–76
Short-term and long-term sick-leave in Sweden: relationships with social circumstances, working conditions and gender. Blank N, et al. **Scand J Soc Med** 1995 Dec; 23(4):265–72
Effect of intestinal helminthiasis on school attendance by early primary schoolchildren. Raj SM, et al. **Trans R Soc Trop Med Hyg** 1997 Mar-Apr;91(2):131–2
Impact of guineaworm disease on agricultural productivity in Owo local government area, Ondo state. Adewale B, et al. **West Afr J Med** 1997 May-Jun;16(2):75–9
[The role of health care in occupational disability (letter; comment)] Jong GD. **Ned Tijdschr Geneeskd** 1996 Dec 7;140(49):2477. Comment on: Ned Tijdschr Geneeskd 1996 Oct 5;140(40):1982–6. **(Dut)**
[Cancer incidence among active male workers at Electricite de France-Gaz de France] Chevalier A, et al. **Rev Epidemiol Sante Publique** 1996 Jan;44(1):25–36 (Eng. Abstr.) **(Fre)**
[Work disability work in the first year of chronic polyarthritis. A comparison with members of the legal health health insurance] Mau W, et al. **Z Rheumatol** 1997 Jan-Feb;56(1):1–7 (Eng. Abstr.) **(Ger)**
[Temporary work disability in Poland--analysis of morbidity causes in the years 1985-1994] Szubert Z, et al. **Med Pr** 1995;46(6):595–602 (Eng. Abstr.) **(Pol)**
[Selected diseases of the spine and spinal cord as a cause of work disability] Szubert Z, et al. **Med Pr** 1996; 47(6):597–604 (Eng. Abstr.) **(Pol)**
[A health-promoting approach to the study of morbidity with temporary loss of work capacity among oil workers in western Siberia] Ovcharov EA. **Probl Sotsialnoi Gig Istor Med** 1996 Nov-Dec;(6):16–9 (Eng. Abstr.) **(Rus)**
[Profiles of the duration of temporary work incapacity in a health district and its comparison with some proposed standards] Ugalde Díez M, et al. **Gac Sanit** 1996 Nov-Dec; 10(57):293–8 (Eng. Abstr.) **(Spa)**
[The need for new regulations on the issuing of documents on temporary work disability] Shevchenko SI, et al. **Lik Sprava** 1996 Jan-Feb;(1-2):183–5 **(Ukr)**

ABSORBABLE CELLULOSE see **CELLULOSE, OXIDIZED**

ABSORPTIOMETRY, DUAL-ENERGY X-RAY see **DENSITOMETRY, X-RAY**

ABSORPTIOMETRY, PHOTON

Vertebral and metacarpal morphometry as indicators of nutritional improvement. Revilla M, et al. **Clin Rheumatol** 1997 May;16(3):279–83
Bone densitometry: patients receiving prolonged steroid therapy. Erlichman M, et al. **Health Technol Assess** 1996 Sep;(9):i–vi, 1–31 (198 ref.)
Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Silverman SL, et al. **Obstet Gynecol** 1997 Mar;89(3):321–5
Contribution of calcaneal ultrasonic assessment to the evaluation of postmenopausal and glucocorticoid-induced osteoporosis. Blanckaert F, et al. **Rev Rhum Engl Ed** 1997 May;64(5):305–13
[X-ray and radionuclide methods in the diagnosis of osteoporosis] Shiraliev OK, et al. **Vestn Rentgenol Radiol** 1996 Nov-Dec;(6):51–4 (46 ref.) **(Rus)**
[Evaluation of bone mass in hip fractures measuring lumbar spine and contralateral hip with bone densitometry] Muñoz A, et al. **Rev Med Chil** 1995 Sep;123(9):1122–8 (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Comparative calibration without a gold standard. Lu Y, et al. **Stat Med** 1997 Aug 30;16(16):1889–905

METHODS

Bone densitometry of the forearm: comparison of single-photon and dual-energy X-ray absorptiometry. Eckert P, et al. **Bone** 1996 Jun;18(6):575–9
Correlation of bone density to strength and physical activity in young men with a low or moderate level of physical activity. Nordström P, et al. **Calcif Tissue Int** 1997 Apr; 60(4):332–7
The skeletal calcium/phosphorus ratio: a new in vivo method of determination. Fountos G, et al. **Med Phys** 1997 Aug; 24(8):1303–10
Theoretical analysis of error propagation in triple-energy absorptiometry: application to measurement of lead in bone in vivo. Mourtada FA, et al. **Med Phys** 1997 Jun; 24(6):925–7
Interpretation of bone densitometry. Genant HK. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):20S–25S (81 ref.)

STANDARDS

Comparison between broad-band ultrasound attenuation of the calcaneum and total body bone mineral density in children. Mughal MZ, et al. **Acta Paediatr** 1996 Jun; 85(6):663–5
Bone mineral changes during tibial fracture healing. Cattermole HC, et al. **Clin Orthop** 1997 Jun;(339):190–6
The contribution of bone densitometry to the diagnosis and treatment of osteoporosis. Coupland CA, et al. **Public Health** 1997 May;111(3):191–4

STATISTICS & NUMERICAL DATA

Comparative calibration without a gold standard. Lu Y, et al. **Stat Med** 1997 Aug 30;16(16):1889–905

VETERINARY

Ultrasonic transmission velocity and single photon absorptiometric measurement of metacarpal bone strength: an in vitro study in the horse. McCarhey RN, et al. **Equine Vet J Suppl** 1988 Sep;(6):80–7

ABSORPTION

Tmax: an unconfounded metric for rate of absorption in single dose bioequivalence studies. Basson RP, et al. **Pharm Res** 1996 Feb;13(2):324–8

ABSORPTION, INTESTINAL see **INTESTINAL ABSORPTION**

ABSORPTION, SKIN see **SKIN ABSORPTION**

ABSTINENCE SYNDROME, NEONATAL see

NEONATAL ABSTINENCE SYNDROME

ABSTRACTING AND INDEXING

Dual publication of surgical abstracts is acceptable [letter; comment] Earnshaw JJ, et al. **BMJ** 1997 Jun 28; 314(7098):1903–4. Comment on: **BMJ** 1997 Feb 1;314(7077):346–7.

Mapping the literature of respiratory therapy. Burnham JF. **Bull Med Libr Assoc** 1997 Jul;85(3):293–6

Mapping the literature of radiologic technology. Burnham JF. **Bull Med Libr Assoc** 1997 Jul;85(3):289–92

Population groups: indexing, coverage, and retrieval effectiveness of ethnically related health care issues in health sciences databases. Efthimiadis EN, et al. **Bull Med Libr Assoc** 1996 Jul;84(3):386–96

Where should the pharmacy researcher look first? Comparing International Pharmaceutical Abstracts and MEDLINE. Fishman DL, et al. **Bull Med Libr Assoc** 1996 Jul; 84(3):402–8

Clinical extracts of biomedical literature for patient-centered problem solving. Florance V. **Bull Med Libr Assoc** 1996 Jul;84(3):375–85

A role in cyberspace for prospective indexing [letter] Schell CL. **Bull Med Libr Assoc** 1996 Jul;84(3):437

Mapping the literature of allied health: project overview. Schloman BF. **Bull Med Libr Assoc** 1997 Jul;85(3):271–7

Mapping the literature of health education. Schloman BF. **Bull Med Libr Assoc** 1997 Jul;85(3):278–83

Mapping the literature of speech-language pathology. Slater LG. **Bull Med Libr Assoc** 1997 Jul;85(3):297–302

Mapping the literature of physical therapy. Wakiji EM. **Bull Med Libr Assoc** 1997 Jul;85(3):284–8

Active index for content-based medical image retrieval. Chang SK. **Comput Med Imaging Graph** 1996 Jul–Aug; 20(4):219–29

Medical image collection indexing: shape-based retrieval using KD-trees. Robinson GP, et al. **Comput Med Imaging Graph** 1996 Jul–Aug;20(4):209–17

An overview of statistical methods for the classification and retrieval of patient events. Chute CG, et al. **Methods Inf Med** 1995 Mar;34(1–2):104–10

Abstract values [letter; comment] Goodman NW. **Nature** 1996 Nov 14;384(6605):106. Comment on: Nature 1996 Sep 5;383(6595):20.

Beyond the language barrier [letter] [see comments] Sanberg PR, et al. **Nature** 1996 Dec 19–26;384(6610):608. Comment in: Nature 1997 Jan 30;385(6615):385. Comment in: Nature 1997 Feb 27;385(6619):764.

Computer indexing of journal references [letter] Harris NR. **Plast Reconstr Surg** 1997 Jun;99(7):2120

[Value of automated medical indexing of an image database and a digital radiological library] Duvauferrier R, et al. **J Radiol** 1997 Jun;78(6):425–32 (Eng. Abstr.) **(Fre)**

METHODS

Use of data abstraction methods to simplify monitoring. Russ TA. **Artif Intell Med** 1995 Dec;7(6):497–514

More informative abstracts revisited. Haynes RB, et al. **Cleft Palate Craniofac J** 1996 Jan;33(1):1–9 (41 ref.)

Free-text fields change the meaning of coded data. Hogan WR, et al. **Proc AMIA Annu Fall Symp** 1996;:517–21

An evaluation of statistical approaches to MEDLINE indexing. Yang Y. **Proc AMIA Annu Fall Symp** 1996; :358–62

STANDARDS

Quality assessment of pharmacoeconomic abstracts of original research articles in selected journals. Trakas K, et al. **Ann Pharmacother** 1997 Apr;31(4):423–8

A critical evaluation of free paper abstracts accepted for the 1996 RACS Annual Scientific Congress. Usatoff V, et al. **Aust N Z J Surg** 1997 Jan;67(1):45–6

How to read a paper. The Medline database. Greenhalgh T. **BMJ** 1997 Jul 19;315(7101):180–3 (4 ref.)

International Classification of Diseases, 9th Revision, Clinical Modification codes in discharge abstracts are poor measures of complication occurrence in medical inpatients. Geraci JM, et al. **Med Care** 1997 Jun;35(6):589–602

STATISTICS & NUMERICAL DATA

Randomised controlled trials [letter] Phillips R, et al. **Arch Dis Child** 1997 Jul;77(1):93–4

Identifying a core set of medical informatics serials: an analysis using the MEDLINE database. Sittig DF. **Bull Med Libr Assoc** 1996 Apr;84(2):200–4

Parapsychology and the neurosciences: a computer-based content analysis of abstracts in the database "MEDLINE" from 1975 to 1995. Fassbender P. **Percept Mot Skills** 1997 Apr;84(2):452–4

ABUSE OF HEALTH SERVICES see **HEALTH SERVICES MISUSE**

ABUSE REPORTING see **MANDATORY REPORTING**

ABUSED WOMEN see **BATTERED WOMEN**

ABUTMENTS, DENTAL see **DENTAL ABUTMENTS**

ACACIA

Nitrogen metabolism of sheep and goats consuming Acacia brevispica and Sesbania sesban. Woodward A, et al. **J Anim Sci** 1997 Apr;75(4):1130–9

CHEMISTRY

Saponins with antifilarial activity from Acacia auriculiformis. Mahato SB. **Adv Exp Med Biol** 1996;404:173–84

Acacia concinna saponins. I. Structures of prosapogenols, concinnosides A–F, isolated from the alkaline hydrolysate of the highly polar saponin fraction. Abul Gafur M, et al. **Chem Pharm Bull (Tokyo)** 1997 Apr;45(4):620–5

The antiplatelet aggregatory activity of Acacia nilotica is due to blockade of calcium influx through membrane calcium channels. Shah BH, et al. **Gen Pharmacol** 1997 Aug;29(2):251–5

Cestocidal activity of Acacia auriculiformis. Ghosh NK, et al. **J Helminthol** 1996 Jun;70(2):171–2

ACACIA GUM see **GUM ARABIC**

ACADEMIC MEDICAL CENTERS

Three medical schools' responses to the HIV/AIDS epidemic and the effect on students' knowledge and attitudes. Anderson DG, et al. **Acad Med** 1997 Feb;72(2):144–6

Improving America's health status through a more diverse physician workforce. Cohen JJ. **Acad Med** 1997 Feb; 72(2):130

A comparison of specialty choices, residency training, and practice locations of early-decision and regular-admission graduates. Elam CL, et al. **Acad Med** 1997 Feb;72(2):140–3

Institutional challenges posed by faculty development. Evans CH. **Acad Med** 1997 Jun;72(6):477–80

Recruiting and retaining volunteer community preceptors. Foley R, et al. **Acad Med** 1996 May;71(5):460–3

Tapping the power of information: an orientation for academic medical centers. Gewertz BL, et al. **Acad Med** 1997 Aug;72(8):677–81

Restrictive covenants in internal medicine training program contracts. Grossman RS. **Acad Med** 1997 May;72(5):403–4

What Americans say about the nation's medical schools and teaching hospitals. McInturff WD, et al. **Acad Med** 1997 Feb;72(2):132–3

The emperor's new clothes: the OSCE reassessed [see comments] Mavis BE, et al. **Acad Med** 1996 May; 71(5):447–53. Comment in: Acad Med 1996 Nov;71(11):1137; discussion 1138. Comment in: Acad Med 1996 Nov;71(11):1137–8.

Introduction—improving the transformation of data into knowledge [comment] Moy E, et al. **Acad Med** 1996 Oct; 71(10):1114–5. Comment on: Acad Med 1996 Oct;71(10):1116–22.

The Federal Demonstration Partnership, phase III: a cooperative venture between federal agencies and participating institutions. Siegel BE. **Acad Med** 1997 May; 72(5):374–5

Choosing an academic career. Halpern EJ. **Acad Radiol** 1997 Aug;4(8):612–5

The effects of a practice guideline on endoscopic sinus surgery at an academic center. Stewart MG, et al. **Am J Rhinol** 1997 Mar–Apr;11(2):161–5

Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Steinberg DM, et al. **Am J Surg Pathol** 1997 May; 21(5):566–76

Academic anaesthetists [letter; comment] Forrest AL. **Anaesthesia** 1997 May;52(5):502. Comment on: Anaesthesia 1997 Jan;52(1):1–2.

Academic anaesthetists [letter; comment] Snowdon SL. **Anaesthesia** 1997 May;52(5):501–2. Comment on: Anaesthesia 1997 Jan;52(1):1–2.

The interface of academic and community practice in medical and graduate medical education. Holt GR. **Arch Otolaryngol Head Neck Surg** 1996 Oct;122(10):1041–4

Development of an academic productivity scale for departments of physical medicine and rehabilitation. Kaplan PE, et al. **Arch Phys Med Rehabil** 1997 Sep; 78(9):938–41

One approach to care for patients infected with human immunodeficiency virus in an academic medical center. Jacobs JL, et al. **Bull N Y Acad Med** 1996 Winter; 73(2):301–13

Academic cardiology division in the era of managed care. A paradigm for survival [see comments] Feldman AM, et al. **Circulation** 1997 Feb 4;95(3):740–4 (25 ref.). Comment in: Circulation 1997 Feb 4;95(3):545. Comment in: Circulation 1997 Feb 4;95(3):546–7.

Report from the University of Toronto Department of Medicine Ad Hoc Committee on career development of clinician scientists. Siminovitch K. **Clin Invest Med** 1997 Aug;20(4):265–7

Causes of death among mental patients at Muhimbili Medical Centre, Dar es Salaam. Ndosi NK, et al. **East Afr Med J** 1997 Feb;74(2):82–4

Old attitudes in a new world [editorial] Saultz JW. **Fam Med** 1996 Nov–Dec;28(10):739–40

Phase three of academic family medicine. Scherger JE. **Fam Med** 1997 Jun;29(6):439–40

Accessing HIV-infected research subjects: the need for collaboration. Regan-Kubinski MJ, et al. **J Assoc Nurses AIDS Care** 1997 Mar–Apr;8(2):83–6

Perspectives from the academic health center. Bulger RJ. **J Dent Educ** 1996 Nov;60(11):886–8

Patient-centered care in an academic health center: faculty perspective. Cobb DS. **J Dent Educ** 1996 Dec; 60(12):955–60

The provider-patient relationship in academic health centers: the movement toward patient-centered care. Gerbert B, et al. **J Dent Educ** 1996 Dec;60(12):961–6

Patient-centered care in an academic health center: an administrator's perspective. Kalkwarf KL. **J Dent Educ** 1996 Dec;60(12):951–4

What does patient-centered care mean in an academic health center? An introduction. Logan HL. **J Dent Educ** 1996 Dec;60(12):943–4

What does patient-centered care mean in an academic health center? A conclusion. Logan HL. **J Dent Educ** 1996 Dec; 60(12):967–8

Health care relationships: instruments for effective patient-focused care in the academic health center. Tresolini CP. **J Dent Educ** 1996 Dec;60(12):945–50

Factors influencing medical students' choice of academic medicine as a career. Donnelly MB, et al. **J Ky Med Assoc** 1996 May;94(5):186–90

Challenges and opportunities in establishing a Latino health research center in a majority academic institution. Giachello AL. **J Med Syst** 1996 Oct;20(5):351–76 (14 ref.)

Lessons learned during the INSURRECT project (INteractive SURgical Teaching at REmote CeNtres). Hobsley M, et al. **J Telemed Telecare** 1997;3 Suppl 1:38–40

The merger of New York University and Mount Sinai Medical Centers: students voice their opinions. Batouli AR, et al. **JAMA** 1996 Dec 4;276(21):1772

Academic medical center mergers [editorial] Lin JH. **JAMA** 1996 Dec 4;276(21):1768

Center for genetic research on scleroderma [news] Skolnick AA. **JAMA** 1997 Oct 15;278(15):1224

A research culture that asks too much [editorial] [see comments] **Lancet** 1997 Feb 22;349(9051):515. Comment in: Lancet 1997 Apr 12;349(9058):1104–5. Comment in: Lancet 1997 Apr 12;349(9058):1105.

Academic institutions and primary care. Malik T. **Lancet** 1996 Oct 12;348(9033):1004–5

The Medical Skills Centre at the University of Calgary Medical School. Wilson DB, et al. **Med Educ** 1997 Jan; 31(1):45–8

The department of neurosurgery, Kyoto University School of Medicine. Kikuchi H. **Neurosurgery** 1996 Mar; 38(3):558–62

Advanced dietetic training in nutrition support and metabolism: the University of Pennsylvania Medical Center experience. Coffey A, et al. **Nutrition** 1996 Nov–Dec; 12(11–12):836–8

Quality assessment and quality improvement of optometric care and services in a hospital and medical center environment. Newcomb RD. **Optom Vis Sci** 1996 May; 73(5):318–20

Pharmaceutical formulary for the primary care optometrist in a hospital and medical center. Townsend JC. **Optom Vis Sci** 1996 May;73(5):328–33

Staff functions and administrative responsibilities of the professional optometrist in a hospital and medical center environment. Williams PA. **Optom Vis Sci** 1996 May; 73(5):338–40

Position statement on limited private practice by the Academic Doctors' Group of the MASA [editorial] van der Merwe WL. **S Afr Med J** 1996 Aug;86(8):941–2

Continuous innovation in health [editorial] [see comments] Shine KI. **Science** 1997 Jan 3;275(5296):9. Comment in: Science 1997 Mar 28;275(5308):1863–4.

Parathyroidectomy in Maryland: effects of an endocrine center. Chen H, et al. **Surgery** 1996 Dec;120(6):948–52; discussion 952–3

Ten-year experience of phototherapy in Yonsei Medical Center. Park SH, et al. **Yonsei Med J** 1996 Dec;37(6):392–6

[Intra- and extramural workshop for care, teaching, and research] Reijneveld SA, et al. **Ned Tijdschr Geneeskd** 1997 Mar 8;141(10):484–7 (Eng. Abstr.) **(Dut)**

[University medicine in Silicon Valley] Bogen B. **Tidsskr Nor Laegeforen** 1997 Apr 30;117(11):1641–2 **(Nor)**

[Birth defects. A public health problem in Mexico] Jurado-Garcia E, et al. **Gac Med Mex** 1996 Mar–Apr; 132(2):141–82 (38 ref.) **(Spa)**

[Centro Universitario de Atencion del Adolescente (C.U.A.A.). Catedra e Pediatria y Neonatologia. Universidad Nacional de Cordoba (editorial)] Zamar R, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53 Suppl:5–6 **(Spa)**

CLASSIFICATION

University of Minnesota—also "bimodal"? [letter; comment] Michael AF, et al. **Acad Med** 1997 Feb;72(2):87. Comment on: Acad Med 1996 Sep;71(9):941–9.

ECONOMICS

Academic medicine meets managed care: a high-impact collision. Carey RM, et al. **Acad Med** 1996 Aug; 71(8):839–45

Financing academic medicine: strengthening the tangled strands before they snap. Cohen JJ. **Acad Med** 1997 Jun;

72(6):520
An economist's view of the future financing of AHCs [letter] Ginzberg E. **Acad Med** 1997 May;72(5):318–9
Effects of the growth of managed care on academic medical centers and graduate medical education. Gold MR. **Acad Med** 1996 Aug;71(8):828–38
The future of medical schools and teaching hospitals in the era of managed care [see comments] Pardes H. **Acad Med** 1997 Feb;72(2):97–102. Comment in: Acad Med 1997 Jun;72(6):470.
Changes in academic emergency departments in response to market-driven health care reform. Simon HK, et al. **Acad Med** 1997 May;72(5):404
"Managed education": an approach to funding medical education. Watson RT. **Acad Med** 1997 Feb;72(2):92–3
A public policy agenda for academic medicine. Knapp RM. **Am J Surg** 1997 Jan;173(1):65–8; discussion 69
Impact of managed care on the economics of laboratory operation in an academic medical center. Benge H, et al. **Arch Pathol Lab Med** 1997 Jul;121(7):689–94
Academic health centers and managed care [editorial] Deckers PJ. **Conn Med** 1996 May;60(5):299–300
Academic health centers in competitive markets. Reuter J, et al. **Health Aff (Millwood)** 1997 Jul–Aug;16(4):242–52
Education ... "social mission" costs incurred by academic medical centers [news] **Hosp Health Netw** 1997 Jul 5; 71(13):18
Half empty or half full, it will be a smaller glass [editorial] Detmer DE. **Inquiry** 1997 Spring;34(1):8–10
Academic medicine--rearranging deck chairs on the Titanic [editorial] Parmley WW. **J Am Coll Cardiol** 1997 Aug; 30(2):592–3
From "piety to platitudes to pork" to what? The changing politics of health workforce policy: a view from university-based academic health centers [comment] Bulger RJ. **J Health Polit Policy Law** 1996 Winter; 21(4):845–8; discussion 869–71. Comment on: J Health Polit Policy Law 1996 Winter;21(4):825–44.
Federal report on academic research funding [news] Marwick C. **JAMA** 1997 Sep 17;278(11):886–7
Listening in on the Duke University Private Sector Conference. Iglehart JK. **N Engl J Med** 1997 Jun 19; 336(25):1827–31
More on compensation for teaching [letter] Korn D, et al. **N Engl J Med** 1996 Nov 14;335(20):1537–8
Insurance levy could fund medical centres [news] Wadman M. **Nature** 1997 Jan 30;385(6615):375
Medical centre repays 'overbilled' $15.5m [news] Wadman M. **Nature** 1997 Apr 17;386(6626):637
Academic centers and change in health care reimbursement [editorial] Schafermeyer RM. **Pediatr Emerg Care** 1996 Jun; 12(3):155

HISTORY

Medical universities and academic health centers: lessons of history. Evans HH, et al. **Acad Med** 1996 Nov; 71(11):1141–3
Goodbye to all that: centennial cycles in academic medicine. Maulitz RC. **Acad Med** 1996 Aug;71(8):898–902
The history of otolaryngology in Canada: the University of British Columbia. Baxter JD. **J Otolaryngol** 1997 Apr; 26(2):143–6
A perspective on the history of the academic health center. Johns ME. **Laryngoscope** 1996 Sep;106(9 Pt 1):1059–62
The summer of 1982 [editorial] Khuri RN. **Middle East J Anesthesiol** 1996 Jun;13(5):451–8
The awakening. 1985 [classical article] Reece R. **Minn Med** 1996 Mar;79(3):10–4
The development of neurological surgery at the Salpétrière Hospital. Philippon JH. **Neurosurgery** 1996 May; 38(5):1016–21; discussion 1021–2
The Neurosurgical Clinic at the Ludwig-Maximilians University in Munich. Reulen HJ, et al. **Neurosurgery** 1996 Dec;39(6):1224–31
The origin of the Plastic Surgery Program at Columbia-Presbyterian Medical Center. McLaughlin MJ. **Plast Reconstr Surg** 1997 Feb;99(2):576–82
Thomas Ferrar, MB, LRCSI (1797–1837): the absentee professor of surgery at the Royal Belfast Academical Institution. Froggatt P. **Ulster Med J** 1996 Nov; 65(2):152–61
[In difficult times, courageously... (History of the Semmelweis Medical University Library)] Vasas L. **Orv Hetil** 1996 Aug 11;137(32):1763–5 **(Hun)**
[Outline of the history of the Medical Sciences and Ophthalmology University in Wrocław] Niżankowska MH. **Klin Oczna** 1996 Jan;98(1):69–72 **(Pol)**
[The Central Research Institute of Tuberculosis of the Russian Academy of Medical Sciences is 75 years old] **Probl Tuberk** 1996;(6):2–6 **(Rus)**

MANPOWER

Social work in the academic medical center: advanced training--a necessity. Berkman B, et al. **Soc Work Health Care** 1996;24(1-2):115–35

ORGANIZATION & ADMINISTRATION

Changing structure to improve function: one academic health center's experience. Alexander B, et al. **Acad Med** 1997 Apr;72(4):259–68
Pew catalyzes education partnerships with managed care organizations. Cohen JJ. **Acad Med** 1997 May;72(5):372
How successfully can academic faculty practices compete in developing managed care markets? Culbertson RA. **Acad Med** 1996 Aug;71(8):858–70
Bowling alone: implications for academic medicine. Evans CH. **Acad Med** 1997 Mar;72(3):163–5
Managing conflicting expectations to better achieve our division's goals [letter] Fargason CA Jr, et al. **Acad Med** 1996 Aug;71(8):816
Linking health services research to education at an academic health center. Hayes RP, et al. **Acad Med** 1996 Sep; 71(9):957–62
Changes in medical education: the community perspective. Hensel WA, et al. **Acad Med** 1996 May;71(5):441–6
The need for comprehensive data on educational affiliations between academic health centers and managed care organizations. Karp S, et al. **Acad Med** 1997 May; 72(5):341–6
Fostering the health of communities: a unifying mission for the University of New Mexico Health Sciences Center. Kaufman A, et al. **Acad Med** 1996 May;71(5):432–40
Rejecting conventional wisdom: how academic medical centers can regain their leadership positions. Krauss K, et al. **Acad Med** 1997 Jul;72(7):571–5
A successful academic-community partnership to improve the public's health. Maurana CA, et al. **Acad Med** 1996 May;71(5):425–31
Managed care, ethics, and academic health centers: maximizing potential, minimizing drawbacks. Morreim EH. **Acad Med** 1997 May;72(5):332–40 (141 ref.)
A promising process for creating an AHC-managed care organization alliance for research and care. Myers RE, et al. **Acad Med** 1997 May;72(5):321–2
Implementing a comprehensive approach to managing faculty roles, rewards, and development in an era of change. Nieman LZ, et al. **Acad Med** 1997 Jun; 72(6):496–504
The Tufts partnership for managed care education. Phillips RR, et al. **Acad Med** 1997 May;72(5):347–56
The impact of managed care on research: the changing face of medicine. Skirboll LR. **Acad Med** 1997 Sep;72(9):778–9
An academic health center-community partnership: the Morgantown Health Right free clinic. Smego RA Jr, et al. **Acad Med** 1996 Jun;71(6):613–21
A blueprint for building an AMC-HMO teaching affiliation. Thomas PA, et al. **Acad Med** 1996 Jun;71(6):577–9
Academic radiology in a networked environment. Seltzer SE, et al. **Acad Radiol** 1996 Oct;3(10):865–72
Restructuring the academic health center for the twenty-first century. Schwartz MA. **Am J Health Syst Pharm** 1997 Aug 1;54(15):1711–5
Risks and opportunities to AHC/VAMC affiliations. Olson P. **Am J Med** 1997 Sep;103(3):173–84
Strategic planning for academic health centers. Weitekamp MR, et al. **Am J Med** 1996 Sep;101(3):309–15
Using quality and cost for employee incentives in a reengineered hospital setting. Nash IS, et al. **Am J Med Qual** 1997 Summer;12(2):130–4
Restructuring academic departments of surgery at university medical centers. Ariyan S. **Am J Surg** 1997 Apr; 173(4):351–7
The department without walls. Acceptability, cost, and utilization of interactive video technology. Crump WJ, et al. **Arch Fam Med** 1997 May-Jun;6(3):273–8
Development of postgraduate centres in the UK [editorial] Paice E. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1-2):6–7
Anatomy departments and anatomy education: reflections and myths [see comments] Jones DG. **Clin Anat** 1997; 10(1):34–40 (2 ref.). Comment in: Clin Anat 1997;10(1):60.
Anatomy into the next millennium: quo vadis, or simply where to? Satyapal KS, et al. **Clin Anat** 1997;10(1):41–3; discussion 44–6 (8 ref.)
The application of management principles to academic medicine. Walker PM. **Clin Invest Med** 1997 Apr; 20(2):127–30
Clinical practice in academic medical center departments of family medicine. The Association of Departments of Family Medicine Task Force on Clinical Practice in US family medicine departments in academic medical centers. **Fam Med** 1997 Jan;29(1):15–20
Mergers. So much for collegiality. Serb C. **Hosp Health Netw** 1997 Jul 5;71(13):42, 44
The evolving health care system: the Medical University of South Carolina. Greenberg RS. **J Allied Health** 1997 Winter;26(1):13–6
Mergers and re-engineering--possible implications for allied health students (the Minnesota Story). Karni KR. **J Allied Health** 1997 Winter;26(1):35–40
Organizational factors that influence information technology diffusion in academic health sciences centers. Ash J. **J Am Med Inform Assoc** 1997 Mar-Apr;4(2):102–11
Evaluating IAIMS at Yale: information access. Grajek SE, et al. **J Am Med Inform Assoc** 1997 Mar-Apr;4(2):138–49
Cancer education--summation: how academic health centers can continue as an academic entity in a managed care environment. Mirand EA. **J Cancer Educ** 1997 Spring; 12(1):32–3
Institutional change. Experiences in two departments. Humphrey HJ, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S79–82
How a community-academic partnership serves as a force for change in health care and health professions education. Maurana CA, et al. **J Health Care Poor Underserved** 1997 Feb;8(1):5–17
H. Richard Nesson, MD [interview] Nesson HR. **J Investig Med** 1997 Feb;45(2):14–9
Herbert Pardes, MD [interview] Pardes H. **J Investig Med** 1997 Apr;45(4):132–8
Departments of internal medicine: upright or supine? Weber KT. **J Lab Clin Med** 1997 Mar;129(3):273–80
Challenges facing academic health centers and major teaching hospitals. Shine KI. **J Nurs Adm** 1997 Apr; 27(4):21–6
Preventing worker injuries. Mason K. **J Nurs Care Qual** 1996 Dec;11(2):5, 7
Community nursing centers: models of nurse managed care. Henry JK. **J Obstet Gynecol Neonatal Nurs** 1997 Mar-Apr; 26(2):224–8
The merger of Stanford's and UCSF's clinical enterprises: impact on education. Bauer EA, et al. **JAMA** 1996 Dec 4;276(21):1770–1
Managing the interface between medical schools, hospitals, and clinical research. Gallin JI, et al. **JAMA** 1997 Feb 26; 277(8):651–4
Correspondence Re: Healy JC, Darcy TP, Sims KL: The role of clinical pathology in academic pathology departments. Mod Pathol 9:603, 1996 [letter; comment] Bender BL. **Mod Pathol** 1996 Nov;9(11):1090–1. Comment on: Mod Pathol 1996 Jun;9(6):603–5.
The role of clinical pathology in academic pathology departments [editorial] [see comments] Healy JC, et al. **Mod Pathol** 1996 Jun;9(6):603–5. Comment in: Mod Pathol 1996 Nov;9(11):1090–1.
The folly of teaching-hospital mergers [see comments] Andreopoulos S. **N Engl J Med** 1997 Jan 2;336(1):61–4. Comment in: N Engl J Med 1997 Jun 12;336(24):1762; discussion 1763. Comment in: N Engl J Med 1997 Jun 12;336(24):1762–3.
The folly of teaching-hospital mergers [letter; comment] Bauer EA. **N Engl J Med** 1997 Jun 12;336(24):1762–3. Comment on: N Engl J Med 1997 Jan 2;336(1):61–4.
The folly of teaching-hospital mergers [letter; comment] Speck WT. **N Engl J Med** 1997 Jun 12;336(24):1762; discussion 1763. Comment on: N Engl J Med 1997 Jan 2;336(1):61–4.
Effects of the rapid expansion of managed care on academic medical centers [editorial] Sibai BM. **Obstet Gynecol Surv** 1996 Nov;51(11):639–40
Consolidation of academic health centers: a solution to manpower, financial problems? [editorial] D'Ambrosia R. **Orthopedics** 1996 Oct;19(10):847
The future of plastic surgery in academic medical centers: making the case for autonomous departments of plastic surgery [editorial] Rohrich RJ, et al. **Plast Reconstr Surg** 1997 Sep;100(3):761–3
Is there a crisis in academic medicine in South Africa? [editorial] Lochner JV. **S Afr Med J** 1997 Jul;87(7):873–4

STANDARDS

Emergency medicine: a status report [editorial; comment] Bowles LT. **Acad Emerg Med** 1997 Jul;4(7):647–8. Comment on: Acad Emerg Med 1997 Jul;4(7):746–51.
Changing clinicians' behaviors in an academic medical center: does institutional commitment to total quality management matter? Wyszewianski L, et al. **Am J Med Qual** 1997 Spring;12(1):3–10
I've been where it's gone, so I know what I got ... An American Fulbright Lecturer in Albania, 1994–1995. Hardison WG. **Ann Intern Med** 1996 Nov 15;125(10):835–8
Quality management in an academic integrated delivery system: the case of the University of Pennsylvania Health System. Shulkin DJ. **Int J Qual Health Care** 1997 Jun; 9(3):171–6
Benchmarking patient satisfaction at academic health centers. Drachman DA. **Jt Comm J Qual Improv** 1996 May; 22(5):359–67
Building excellence in an academic medical center. Holzberg HA. **N J Med** 1996 Oct;93(10):59–61
Ethical concerns for the optometrist in a hospital and medical center environment. Fingeret M, et al. **Optom Vis Sci** 1996 May;73(5):323–4
Accreditation of optometric care and services in a hospital and medical center environment. Gruning C. **Optom Vis Sci** 1996 May;73(5):312–4
HMOs and academic medicine: are they both deaf to patients? [letter; comment] Cotler MP. **West J Med** 1997 Feb; 166(2):156. Comment on: West J Med 1996 Oct;165(4):241–4.

STATISTICS & NUMERICAL DATA

The volume and mix of inpatient services provided by academic medical centers [see comments] Moy E, et al. **Acad Med** 1996 Oct;71(10):1116–22. Comment in: Acad Med 1996 Oct;71(10):1114–5.
Academic medical centers and the care of underserved populations. Moy E, et al. **Acad Med** 1996 Dec; 71(12):1370–7
Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals [see comments] Albers GW, et al. **Arch Intern Med** 1996 Nov 11;156(20):2311–6 . Comment in: Arch Intern Med 1997 Jul 14;157(13):1505.
An obstetric and neonatal study on unplanned deliveries before arrival at hospital. Di Benedetto MR, et al.

Clin Exp Obstet Gynecol 1996;23(2):108–11
Quality watch ... academic health centers [news] **Hosp Health Netw** 1997 May 20;71(10):16
Thirty years of transplantation: 2000 kidney transplants at the University of Florida. Howard RJ, et al. **J Fla Med Assoc** 1997 Jun–Jul;84(5):327–31

TRENDS

Changing status of academic emergency medicine (1991–1996). Task Force on the Development Emergency Medicine [see comments] Gallagher EJ, et al. **Acad Emerg Med** 1997 Jul;4(7):746–51. Comment in: Acad Emerg Med 1997 Jul;4(7):647–8.
News from the future: health care summit caps decade of transformation, 1996–2005. Aschenbrener CA. **Acad Med** 1996 Aug;71(8):823–7
Whither academic values during the transition from academic medical centers to integrated health delivery systems? Blake DA. **Acad Med** 1996 Aug;71(8):818–9
Finishing the bridge to diversity. Cohen JJ. **Acad Med** 1997 Feb;72(2):103–9
Managed care and medical education: hard cases and hard choices. Friedman E. **Acad Med** 1997 May;72(5):325–31
Forum on the future of academic medicine: Session II—Finances and culture. Iglehart J. **Acad Med** 1997 Sep; 72(9):754–9
Reengineering academic medical centers: reengineering academic values? Korn D. **Acad Med** 1996 Oct; 71(10):1033–43
The future of medical schools and teaching hospitals in the era of managed care [see comments] Pardes H. **Acad Med** 1997 Feb;72(2):97–102. Comment in: Acad Med 1997 Jun;72(6):470.
How the university medical center survived by going "back to the future" [editorial] Solomon SS, et al. **Am J Med Sci** 1997 Jul;314(1):1–2
Academic anaesthetists—an endangered species? [editorial] [see comments] Feldman S. **Anaesthesia** 1997 Jan;52(1):1–2 . Comment in: Anaesthesia 1997 May;52(5):501–2. Comment in: Anaesthesia 1997 May;52(5):502.
Academic health centers in an era of managed care. Biles B, et al. **Bull N Y Acad Med** 1996 Winter;73(2 Suppl):484–9
Whither academic health centers? A commentary. Wilson DE. **J Assoc Acad Minor Phys** 1996;7(2):56–61
Presidential Address to the American Society for Clinical Investigation, Washington, DC, May 4, 1996. Is there room left for academics in academic medicine? Swain JL. **J Clin Invest** 1996 Sep 1;98(5):1071–3
Academic medicine: building on the strengths of the past as we approach a cloudy future. Bennett JC, et al. **J Lab Clin Med** 1996 Jul;128(1):12–8 (9 ref.)
Development of leadership within the university and beyond: challenges to faculty and their development. Klauer Triolo P, et al. **J Prof Nurs** 1997 May–Jun;13(3):149–53
Managed care's role in shaping the physician job market. Goodman L. **JAMA** 1997 Jan 1;277(1):72
The Columbia–Cornell Alliance: a strategic response to a changing health care environment. Pardes H, et al. **JAMA** 1996 Dec 4;276(21):1769, 1771
A lofty mission. Gorrill D. **Minn Med** 1996 Mar;79(3):16–24
Issues and problems relating to reporting relations in a medical center and comprehensive health care environment. Cohen A. **Optom Vis Sci** 1996 May; 73(5):321–2
Academic affiliations and the role of the professional school in a comprehensive medical center environment. Holsinger J Jr. **Optom Vis Sci** 1996 May;73(5):309–11
Dual roles of academic health care centers for the future: medical education and applied managed care research? [editorial] Holt GR. **Otolaryngol Head Neck Surg** 1997 Feb; 116(2):141–5

UTILIZATION

Radiological, laboratory, and other diagnostic procedures ordered by professional staff optometrists in a hospital and medical center environment. Terry JE. **Optom Vis Sci** 1996 May;73(5):334–7

ACADEMIES AND INSTITUTES

The first Summer Research Institute in Geriatric Psychiatry. Halpain MC, et al. **Am J Geriatr Psychiatry** 1997 Summer; 5(3):238–46
Mothers at risk of alloimmunization to the Rh (D) antigen and availability of gamma-globulin at the Mexican Institute of Social Security. Zavala C, et al. **Arch Med Res** 1996 Autumn;27(3):373–6
Consulting about priorities for the NHMRC National Breast Cancer Centre: how good is the nominal group technique. Redman S, et al. **Aust N Z J Public Health** 1997 Jun; 21(3):250–6
The role of the National Institute of Public Health in the field of infections with natural focality. Rosický B, et al. **Cent Eur J Public Health** 1996 May;4(2):123–6
Environmental specimen banking of nationwide biomonitoring samples in Finland. Kubin E, et al. **Chemosphere** 1997 May;34(9–10):1939–44 (10 ref.)
Specimen banking at National Institute for Environmental Studies, Japan. Morita M, et al. **Chemosphere** 1997 May; 34(9–10):1907–19
Developments in biotechnological research in Austria. Kubicek CP. **Crit Rev Biotechnol** 1996;16(3):217–55 (234 ref.)
The European Molecular Biology Laboratory. **Curr Biol** 1996 Mar 1;6(3):224–5
Dental mythology and the Institute of Medicine report [editorial] Barnett ML. **J Dent Res** 1997 Sep;76(9):1524–5
Academic medicine in the 21st century: lessons from the dinosaurs. Catanese VM. **J Investig Med** 1997 Aug; 45(6):362–5
Academy of hospice physicians' position statement on access to hospice and palliative care. Byock IR, et al. **J Pain Symptom Manage** 1996 Feb;11(2):69–70
UK academy of medicine [letter; comment] Macara AW. **Lancet** 1996 Oct 19;348(9034):1108. Comment on: Lancet 1996 Sep 14;348(9029):700.
Institut de Génétique et Biologie Moléculaire et Cellulaire: IGBMC. Chambon P, et al. **Mol Med** 1996 May;2(3):283–4
Weizmann Institute of Science. Groner Y. **Mol Med** 1997 Jan;3(1):2–4
The Walter and Eliza Hall Institute of Medical Research. Nossal GJ. **Mol Med** 1996 Mar;2(2):165–8
Educational excellence from AMNJ. Heitzmann C. **N J Med** 1997 Jul;94(7):51–2
The Howard Hughes Medical Institute and science in Central Europe, the Baltics and the former Soviet Union. Choppin PW. **Nat Med** 1997 Sep;3(9):949–50
Montagnier to set up an AIDS research centre in New York [news] **Nature** 1997 May 1;387(6628):10
Human genome centre receives a leg-up [news] **Nature** 1997 Jan 23;385(6614):283
Ho joins Montagnier in AIDS centres project [news] **Nature** 1997 May 22;387(6631):330
EMBO panel gives biology in Finland a pat on the back...as privatization windfall fills research coffers [news] Abbott A. **Nature** 1997 Feb 20;385(6618):666
Karolinska Institute disowns work of cancer researcher [news] Butler D. **Nature** 1997 Aug 28;388(6645):816
CNRS returns fire on ethics review panel [news] Butler D. **Nature** 1997 Jul 10;388(6638):110
EMBO fellows go home [letter] Gannon F, et al. **Nature** 1997 Jul 31;388(6641):416
Human origins centre pulls up roots in move to Arizona [news] Lehrman S. **Nature** 1997 Apr 24;386(6627):750
NSF urged to increase plant genome sequencing effort [news] Macilwain C. **Nature** 1997 Jul 24;388(6640):312
Hughes confirms its faith in excellence [news] Macilwain C. **Nature** 1997 May 15;387(6630):223
Approaches to AIDS research [letter] Desrosiers RC. **Science** 1997 Jan 3;275(5296):13
Hughes network expands by a big leap [news] Marshall E. **Science** 1997 May 23;276(5316):1189
Labs form biomedical network [news] Normile D. **Science** 1997 Jun 27;276(5321):1964
Korean institute ponders role in global eradication efforts [news] Normile D. **Science** 1996 Dec 6;274(5293):1607
New institute seen as brains behind big boost in spending [news] Normile D. **Science** 1997 Mar 14;275(5306):1562–3
Merck gives researchers knockout deal [news] Pennisi E. **Science** 1997 Apr 25;276(5312):527
Whitehead, three firms splice a deal [news] Roush W. **Science** 1997 May 9;276(5314):891
NIH, Hopkins team up on genotyping [news] Stone R. **Science** 1997 Jan 10;275(5297):153
[The training of health personnel by the Marchoux Institute in Bamako from 1979 to 1995] Tiendrébéogo A, et al. **Acta Leprol** 1996;10(1):37–43 (Eng. Abstr.) **(Fre)**
[Information on the Federation of national academies of medicine of the European Union] Sicard A, et al. **Bull Acad Natl Med** 1996 May;180(5):1105–8 **(Fre)**
[Bibliography of publications of scientific workers from the Pomeranian Medical Academy for the year 1994] Dawidowicz M. **Ann Acad Med Stetin** 1996;42:277–404 **(Pol)**
[First meeting of the "Ecology and Health" section of the Russian Ecologic Academy] Agadzhanian NA, et al. **Med Tr Prom Ekol** 1996;(5):44–5 **(Rus)**
[Experience and prospective activities of the Department of Occupational Medicine at the St. Petersburg Medical Academy of Postgraduate Education] Retnev VM. **Med Tr Prom Ekol** 1997;(1):23–5 (Eng. Abstr.) **(Rus)**
[Far East research center "Ecology and Occupational Medicine" of the Russian Academy of Medical Sciences] Yakimova LD. **Med Tr Prom Ekol** 1996;(5):40–1 **(Rus)**
[The development of social hygiene science and the contribution of the N. A, Semashko Research Institute of Social Hygiene, Economics and Public Health Management in this field of medicine] Ovcharov VK. **Probl Sotsialnoi Gig Istor Med** 1995 Jan–Feb;(1):8–21 **(Rus)**
[Current problems of aviation medicine (the 60th anniversary of the State Research Institute of Aviation and Space Medicine)] Stupakov GP. **Vestn Ross Akad Med Nauk** 1996;(7):3–9 (Eng. Abstr.) **(Rus)**
[The N. N. Burdenko Institute of Neurosurgery of the Russian Academy of Medical Sciences: its scientific and practical activities today] Iartsev VV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Apr–Jun; (2):36–9 **(Rus)**
[International perspective of the role of the INTA in nutrition] Cordano A. **Arch Latinoam Nutr** 1994 Dec;44(4 Suppl 2):63S–66S **(Spa)**
[The role of the Academia Nacional de Medicina in the field of continuing medical education] Campillo-Serrano C, et al. **Gac Med Mex** 1997 Jan–Feb;133(1):13–24 **(Spa)**
[Speech on behalf of the new academicians] García-de la Torre I. **Gac Med Mex** 1996 Sep–Oct;132(5):467–9 **(Spa)**
[The management of biologically infectious residues in a health institution: the Salvador Zubirán National Institute of Nutrition] Jiménez-Corona ME, et al. **Gac Med Mex** 1997 Jan–Feb;133(1):53–6 **(Spa)**
[Speech welcoming new academicians] Vilar-Puig P. **Gac Med Mex** 1996 Sep–Oct;132(5):463–5 **(Spa)**

HISTORY

Cornelius G. Dyke and the Neurological Institute of New York: the foundations of American neuroradiology. Kieffer SA. **AJNR Am J Neuroradiol** 1997 May;18(5):801–9
Biomedical research in Quebec: the history of the Fonds de la recherche en santé du Québec. Genest J. **Can Med Assoc J** 1996 Sep 15;155(6):639–44
Conference on the occasion of the National Institute of Public Health in Prague jubilee. **Cent Eur J Public Health** 1996 May;4(2):149–52
Jubilee. National Institute of Public Health, Prague. Tichacek B. **Cent Eur J Public Health** 1995 Nov;3(4):183–5
The Strangeways Research Laboratory: archives in the contemporary medical archives centre. Hall LA. **Med Hist** 1996 Apr;40(2):231–8
The Calcutta School of Tropical Medicine: institutionalizing medical research in the periphery. Power H. **Med Hist** 1996 Apr;40(2):197–214
Capital, profession and medical technology: the electro-therapeutic institutes and the Royal College of Physicians, 1888–1922. Ueyama T. **Med Hist** 1997 Apr; 41(2):150–81
The Medical Research Council, laboratory of molecular biology. Perutz MF. **Mol Med** 1996 Nov;2(6):659–62
The Skirball Institute of Biomolecular Medicine: an infant among giants. Philipson L. **Mol Med** 1997 Jun;3(6):353–5
The Carnegie Institution of Washington, Department of Embryology. Spradling AC. **Mol Med** 1997 Jul;3(7):417–9
Neurosurgery at the Montreal Neurological Institute and McGill University Hospitals. Feindel W. **Neurosurgery** 1996 Oct;39(4):830–9
The Burdenko Neurosurgery Institute: past, present, future. Konovalov AN, et al. **Neurosurgery** 1997 Jan;40(1):178–85
Department of Neurosurgery, Karolinska Institute: 60 years. Lindquist C, et al. **Neurosurgery** 1996 Nov;39(5):1016–21
[ENT department on the 50th anniversary of the Academy of Medicine in Gdansk] Jordan J, et al. **Otolaryngol Pol** 1995;49(6):606–13 **(Pol)**
[Twenty years of work at the Clinic for Lung Diseases of the Institute for Tuberculosis and Lung Diseases (1976–1996] Zieliński J. **Pneumonol Alergol Pol** 1996; 64(9–10):539–43 **(Pol)**
[Seventy-five years since foundation of the Pathology chair at Omsk Medical Academy] Kosterina LD, et al. **Arkh Patol** 1997 May–Jun;59(3):72–4 **(Rus)**
[Role of the Department of Hygiene of Children and Adolescents of the I.M. Sechenov Moscow Medical Academy in training medical personnel and the development of hygiene science (on the 70th anniversary of the foundation of the Department)] Kuchma VR. **Gig Sanit** 1997 Jan–Feb;(1):40–3 **(Rus)**
[150 years since the foundation of the university clinic at the I.M. Sechenov Moscow Medical Academy] **Klin Med (Mosk)** 1996;74(3):2–5 **(Rus)**
[The history of the first joint scientific and practical measures of the Ukrainian Institute of Physician Advanced Training and of the public health institutions of Sumy Province] Chernobrov IV. **Lik Sprava** 1997 Mar–Apr;(2):143–6 **(Rus)**
[The 60th anniversary of the All-Union Research Institute of Medical Instrument Making] **Med Tekh** 1996 Jan–Feb; (1):3–4 **(Rus)**
[Fruitful union of science and pedagogy (70th anniversary of the Occupational Hygiene Department of the I.M. Sechenov Moscow Medical Academy)] Kirillov VF. **Med Tr Prom Ekol** 1996;(10):1–3 **(Rus)**
[The Omsk Institute of Epidemiology and Microbiology in 1941–1945] Iastrebov VK. **Probl Sotsialnoi Gig Istor Med** 1996 Sep–Oct;(5):48–9 **(Rus)**
[The founding of the Russian Academy of Medical Sciences] Lisitsin IuP, et al. **Probl Sotsialnoi Gig Istor Med** 1994 May–Jun;(3):45–7 **(Rus)**
[The history of the opening of the clinical institutes of Moscow University] Stochik AM, et al. **Probl Sotsialnoi Gig Istor Med** 1997 Mar–Apr;(2):47–9 **(Rus)**
[A centennial of the ORL clinic of the I.M. Sechenov Moscow Medical Academy] Ovchinnikov IuM. **Vestn Otorinolaringol** 1996 May–Jun;(3):3–11 **(Rus)**
[Acute sensorineural hearing loss (data of the otorhinolaryngologic clinic of the I.M. Sechenov Moscow Medical Academy)] Ovchinnikov IuM, et al. **Vestn Otorinolaringol** 1996 May–Jun;(3):12–8 (Eng. Abstr.) **(Rus)**
[75th anniversary of the Kharkov Research Institute of Medical Radiology] Pilipenko NI, et al. **Vestn Rentgenol Radiol** 1996 Nov–Dec;(6):55–7 **(Rus)**
[V. V. Strel'tsov: founder of the Institute and father of our country's aerospace medicine] Agadzhanian NA.

Vestn Ross Akad Med Nauk 1996;(7):10–5 (Eng. Abstr.) **(Rus)**

[History of Russian medical primatology] Dzhikidze EK. **Vestn Ross Akad Med Nauk** 1996;(10):40–7 **(Rus)**

[I.P. Pavlov at the Imperial Institute of Experimental Medicine and his contribution to digestive physiology] Lange KA, et al. **Vestn Ross Akad Med Nauk** 1996;(1):11–6 (Eng. Abstr.) **(Rus)**

[The flagship of aerospace medicine (on the 55th anniversary of the Central Military Research Aviation Hospital of the Ministry of Defense of the Russian Federation)] Kokhan VE. **Voen Med Zh** 1997 Apr;318(4):63–6 **(Rus)**

[The 75th anniversary of the Tomsk Research Institute of Health Resort Medicine and Physiotherapy] Levitskiĭ EF, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 May–Jun; (3):54–5 **(Rus)**

[The 60th anniversary of the Azerbaijan Research Institute of Medical Rehabilitation and Natural Therapeutic Factors] Musaev AV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Mar–Apr; (2):45–8 **(Rus)**

[Issues in the organization of cancer control conducted by the Oncology Research Institute Prof. N.N.Petrov] Merabishvili VM, et al. **Vopr Onkol** 1997;43(1):130–5 **(Rus)**

[The 70th anniversary of the N.N.Petrov Institute of Oncology] Napalkov NP. **Vopr Onkol** 1997;43(1):7–14 **(Rus)**

[The 70th anniversary of the Khabarovsk Research Institute of Epidemiology and Microbiology] Kolganov AV. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul–Aug; (4):123–4 **(Rus)**

[The A. L. Polenov Russian Neurosurgical Research Institute (on the 70th anniversary of its founding)] Bersnev VP, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct–Dec; (4):41–3 **(Rus)**

[The Laboratory of Pathological Anatomy of the A. L. Polenov Russian Neurosurgical Research Institute. The results of research over 20 years (1976–1996)] Medvedev IuA. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct–Dec; (4):43–5 **(Rus)**

[A short essay on the history of the A. D. Romodanov Institute of Neurosurgery of the Academy of Medical Sciences of Ukraine] Zozulia IuA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1997 Jan–Mar; (1):42–6 **(Rus)**

[The 45th anniversary of the Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences] Simonov PV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 May–Jun; 46(3):636–7 **(Rus)**

[The development of research into higher nervous activity at the I. P. Pavlov Institute of Physiology of the Russian Academy of Sciences over the past 70 years] Suvorov NF. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Sep–Oct; 46(5):819–30 **(Rus)**

[Tenth anniversary of chapter Falcon's: notes for the history of the Venezuelan Association for the Advancement of Science (AsoVAC)] Conde JE. **Acta Cient Venez** 1994; 45(3):178–85 (Eng. Abstr.) **(Spa)**

[The origin of scientific academies] de Micheli A. **Arch Inst Cardiol Mex** 1997 Jan–Feb;67(1):67–72 **(Spa)**

[The "Ignacio Chávez" Magisterial Lecture. The National Academy of Medicine 180 years after its foundation. In the final millenium and before the future] Cárdenas Loaeza M. **Gac Med Mex** 1994 Jul–Aug;130(4):305–9 **(Spa)**

[The Rafael Lucio Hall in National Academy of Medicine] García-Procel E. **Gac Med Mex** 1996 Mar–Apr; 132(2):113–4 **(Spa)**

[The Kiev Research Institute of Epidemiology and Infectious Diseases (on the centenary of its founding)] **Lik Sprava** 1997 Mar–Apr;(2):146–7 **(Ukr)**

ORGANIZATION & ADMINISTRATION

Restructuring of NCIC research programs National Cancer Institute of Canada, Toronto, Ontario. **Can J Oncol** 1995 Mar;5(1):307–13

Charting the NCIC's future: stakeholder support for identified options. Ashbury FD, et al. **Can J Oncol** 1995 Mar;5(1):314–27

Issues for interpreting external stakeholder feedback on restructuring NCIC's research programs. Ashbury FD, et al. **Can J Oncol** 1995 Mar;5(1):328–37

Restructuring: meeting the challenges [news] Beatty JD. **Can J Oncol** 1995 Mar;5(1):VII–IX

Science among the Saguaros [news] Barrett JR. **Environ Health Perspect** 1997 May;105(5):478–80

The birth of the RCMI Clinical Research Center is a joint venture of the University of Hawaii and Kapiolani Health. Trockman C, et al. **Hawaii Med J** 1997 Apr;56(4):93–5

Challenges and opportunities in establishing a Latino health research center in a majority academic institution. Giachello AL. **J Med Syst** 1996 Oct;20(5):351–76 (14 ref.)

Dedicated research institute keeps Wyeth–Ayerst focused on women's health. Levy RI. **J Womens Health** 1997 Feb; 6(1):45–7

The Queensland Institute of Medical Research. Excellence from the interplay of medicine and science. Powell LW. **Med J Aust** 1996 Dec 2–16;165(11–12):645–8

The Howard Hughes Medical Institute. Choppin PW. **Mol Med** 1996 Jan;2(1):1–3

HGS–TIGR splits, opportunity knocks [editorial] **Nat Biotechnol** 1997 Aug;15(8):693

Academic–industry research relationships in genetics: a field apart. Blumenthal D, et al. **Nat Genet** 1997 May;16(1):104–8

New DFG head vows to back Germany's young scientists—and genetics research [news] Abbott A. **Nature** 1997 Aug 7;388(6642):507

Events at Jena institute [letter; comment] Diekmann S. **Nature** 1997 Jun 12;387(6634):648–9. Comment on: Nature 1997 Feb 27;385(6619):761.

Culture clash tarnishes the image of star laboratory [news] [see comments] Schiermeier Q. **Nature** 1997 Feb 27; 385(6619):761. Comment in: Nature 1997 Jun 12;387(6634):648–9.

AIDS pioneer to set up centre in SA [news] van der Linde I. **S Afr Med J** 1997 Jun;87(6):695–6

Montagnier to head New York center [news] Balter M. **Science** 1997 May 2;276(5313):672

[Assessment of strategies of science and technology management: a case study] Pereira JC, et al. **Rev Saude Publica** 1995 Aug;29(4):308–17 (Eng. Abstr.) **(Por)**

[Experience with integration of research institutes if the Russian Academy of Medical Sciences with the departments if higher educational establishments of the IM Sechenov is an effective type of teaching and research intensification] Paltsev MA, et al. **Vestn Ross Akad Med Nauk** 1997;(3):54–8 (0 ref.) **(Rus)**

[The Instituto Navarro de Salud Laboral: an experience in collaboration between health and occupational jurisdictions] Gallo Fernández M. **Rev Esp Salud Publica** 1996 Jul–Aug;70(4):431–6 (Eng. Abstr.) **(Spa)**

[Occupational health in the Autonomous Community of the Basque Country. OSALAN–Instituto Vasco de Seguridad y Salud Laborales] Martínez Castillo A, et al. **Rev Esp Salud Publica** 1996 Jul–Aug;70(4):437–44 (Eng. Abstr.) **(Spa)**

STANDARDS

Anticoagulant therapy monitoring with international normalized ratio at US academic health centers. Yim JM, et al. **Ann Pharmacother** 1996 Dec;30(12):1390–5

Consensus radiation protection practices for academic research institutions. Schiager KJ, et al. **Health Phys** 1996 Dec;71(6):960–5

A lesson on preparedness [editorial] **Nature** 1997 Jun 19; 387(6635):743

TRENDS

National Institute of Public Health, Prague, Czech Republic, in 1995–2000. Kriz J. **Cent Eur J Public Health** 1995 Nov; 3(4):186–8

Forty years at the pitface in the Walter and Eliza Hall Institute of Medical Research. Metcalf D. **Med J Aust** 1996 Dec 2–16;165(11–12):652–5

The Garvan Institute of Medical Research. Setting the agenda for medical research into the 21st century. Shine J. **Med J Aust** 1996 Dec 2–16;165(11–12):649–51

ACANTHAMOEBA

Cutaneous infections due to Acanthamoeba in patients with acquired immunodeficiency syndrome. Chandrasekar PH, et al. **Arch Intern Med** 1997 Mar 10;157(5):569–72

Coexistent Acanthamoeba keratitis and herpetic keratitis. Mathers WD, et al. **Arch Ophthalmol** 1997 Jun;115(6):714–8

Binding of Acanthamoeba to hydrogel contact lenses. Gorlin AI, et al. **Curr Eye Res** 1996 Feb;15(2):151–5

Acanthamoeba infection. Wortman PD. **Int J Dermatol** 1996 Jan;35(1):48–51 (31 ref.)

Free living amoebae as opportunistic parasites in immunocompromised hosts. el-Fakahany AF, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):515–27

Cutaneous lesions due to Acanthamoeba sp in a patient with AIDS. Deluol AM, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):130S–131S

Non-acanthamoeba amoebic keratitis [letter] Hay J, et al. **J Infect** 1997 Jan;34(1):89–91

Granulomatous amebic encephalitis caused by acanthamoeba. Sell JJ, et al. **Neuroradiology** 1997 Jun;39(6):434–6

CHEMISTRY

Two-state thermal unfolding of a long dimeric coiled-coil: the Acanthamoeba myosin II rod. Zolkiewski M, et al. **Biochemistry** 1997 Jun 24;36(25):7876–83

Structure, subunit topology, and actin-binding activity of the Arp2/3 complex from Acanthamoeba. Mullins RD, et al. **J Cell Biol** 1997 Jan 27;136(2):331–43

Biochemical and molecular characterization of a strain KA/S2 of Acanthamoeba castellanii isolated from Korean soil. Chung DI, et al. **Korean J Parasitol** 1996 Mar; 34(1):79–85

Crystal structure of the actin-binding protein actophorin from Acanthamoeba [letter] Leonard SA, et al. **Nat Struct Biol** 1997 May;4(5):369–73

CLASSIFICATION

Species identification and molecular characterization of Acanthamoeba isolated from contact lens paraphernalia. Lee SM, et al. **Korean J Ophthalmol** 1997 Jun;11(1):39–50

Close relatedness of Acanthamoeba pustulosa with Acanthamoeba palestinensis based on isoenzyme profiles and rDNA PCR-RFLP patterns. Kim YH, et al. **Korean J Parasitol** 1996 Dec;34(4):259–66

Identification of two genetic markers that distinguish pathogenic and nonpathogenic strains of Acanthamoeba spp. Howe DK, et al. **Parasitol Res** 1997;83(4):345–8

CYTOLOGY

Flow cytometric determination of endocytosis of viable labelled Legionella pneumophila by Acanthamoeba palestinensis. Harf C, et al. **Cytometry** 1997 Mar 1; 27(3):269–74

DRUG EFFECTS

In vitro amoebicidal activity of propamidine and pentamidine isethionate against Acanthamoeba species and toxicity to corneal tissues. Alizadeh H, et al. **Cornea** 1997 Jan; 16(1):94–100

Effects of polyhexamethylene biguanide and chlorhexidine on four species of Acanthamoeba in vitro. Tirado-Angel J, et al. **Curr Eye Res** 1996 Feb;15(2):225–8

Aspects of the mechanisms of action of biguanides on trophozoites and cysts of Acanthamoeba castellanii. Khunkitti W, et al. **J Appl Microbiol** 1997 Jan;82(1):107–14

In vitro drug susceptibility of Acanthamoeba castellani to chloroquine, ivermectin and fungizon. Rain AN, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):319–24

ENZYMOLOGY

Immunological identification of the alternative oxidase of Acanthamoeba castellanii mitochondria. Jarmuszkiewicz W, et al. **FEBS Lett** 1997 Jul 7;411(1):110–4

The catalytic domain of Acanthamoeba myosin I heavy chain kinase. I. Identification and characterization following tryptic cleavage of the native enzyme. Brzeska H, et al. **J Biol Chem** 1996 Oct 25;271(43):27049–55

The catalytic domain of acanthamoeba myosin I heavy chain kinase. II. Expression of active catalytic domain and sequence homology to p21-activated kinase (PAK). Brzeska H, et al. **J Biol Chem** 1996 Oct 25;271(43):27056–62

p21-activated kinase has substrate specificity similar to Acanthamoeba myosin I heavy chain kinase and activates Acanthamoeba myosin I. Brzeska H, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1092–5

GENETICS

Nucleotide sequence and developmental expression of Acanthamoeba S-adenosylmethionine synthetase gene. Ahn KS, et al. **Biochim Biophys Acta** 1997 Mar 20; 1351(1–2):223–30

An Acanthamoeba polyubiquitin gene and application of its promoter to the establishment of a transient transfection system. Hu Q, et al. **Biochim Biophys Acta** 1997 Mar 20; 1351(1–2):126–36

Stable transfection of Acanthamoeba. Yin J, et al. **Can J Microbiol** 1997 Mar;43(3):239–44

Subgenus systematics of Acanthamoeba: four nuclear 18S rDNA sequence types. Gast RJ, et al. **J Eukaryot Microbiol** 1996 Nov–Dec;43(6):498–504

PCR and RFLP variation of conserved region of small subunit ribosomal DNA among Acanthamoeba isolates assigned to either A. castellanii or A. polyphaga. Kong HH, et al. **Korean J Parasitol** 1996 Jun;34(2):127–34

Restriction endonuclease analysis of mitochondrial DNA of Acanthamoeba sp. YM-4 (Korean isolate). Shin HJ, et al. **Korean J Parasitol** 1997 Jun;35(2):119–25

GROWTH & DEVELOPMENT

Differences in isoenzyme patterns of axenically and monoxenically grown Acanthamoeba and Hartmannella. Weekers PH, et al. **Antonie Van Leeuwenhoek** 1997 Mar; 71(3):231–7

Axenic mass cultivation of the free-living soil amoeba, Acanthamoeba castellanii in a laboratory fermentor. Weekers PH, et al. **Antonie Van Leeuwenhoek** 1996 May; 69(4):317–22

Static uniform magnetic fields and amoebae. Berk SG, et al. **Bioelectromagnetics** 1997;18(1):81–4

ISOLATION & PURIFICATION

Techniques for isolating thermotolerant and pathogenic freeliving amebae. John DT, et al. **Folia Parasitol (Praha)** 1996;43(4):267–71

Comparison of axenic and monoxenic media for isolation of Acanthamoeba. Penland RL, et al. **J Clin Microbiol** 1997 Apr;35(4):915–22

Prevalence of pathogenic Acanthamoeba (Protozoa:Amoebidae) in the atmosphere of the city of San Luis Potosi, Mexico. Rodriguez-Zaragoza S, et al. **Toxicol Ind Health** 1997 Jul–Aug;13(4):519–26

METABOLISM

Differences in isoenzyme patterns of axenically and monoxenically grown Acanthamoeba and Hartmannella. Weekers PH, et al. **Antonie Van Leeuwenhoek** 1997 Mar; 71(3):231–7

Local accumulation of alpha-spectrin-related protein under

plasma membrane during capping and phagocytosis in Acanthamoeba. Kwiatkowska K, et al. **Cell Motil Cytoskeleton** 1997;36(3):253–65

Effect of time and washing on the adhesion of Acanthamoeba to extended wear disposable hydrogel contact lenses. Ramachandran L, et al. **CLAO J** 1997 Apr;23(2):113–6

Acanthamoebae bind to rabbit corneal epithelium in vitro. Panjwani N, et al. **Invest Ophthalmol Vis Sci** 1997 Aug; 38(9):1858–64

Biosynthesis of prostaglandins in pathogenic and nonpathogenic strains of Acanthamoeba spp. Hadas E, et al. **Parasitol Res** 1997;83(3):296–9

MICROBIOLOGY

Obligate intracellular bacterial parasites of acanthamoebae related to Chlamydia spp. Amann R, et al. **Appl Environ Microbiol** 1997 Jan;63(1):115–21

Infection of Acanthamoeba castellanii by Chlamydia pneumoniae. Essig A, et al. **Appl Environ Microbiol** 1997 Apr;63(4):1396–9

Multiplication of different Legionella species in Mono Mac 6 cells and in Acanthamoeba castellanii. Neumeister B, et al. **Appl Environ Microbiol** 1997 Apr;63(4):1219–24

Resuscitation of viable but nonculturable Legionella pneumophila Philadelphia JR32 by Acanthamoeba castellanii. Steinert M, et al. **Appl Environ Microbiol** 1997 May;63(5):2047–53

Chlamydia-like obligate parasite of free-living amoebae [letter] Birtles RJ, et al. **Lancet** 1997 Mar 29; 349(9056):925–6

Phylogenetic diversity of intra-amoebal legionellae as revealed by 16S rRNA gene sequence comparison. Birtles RJ, et al. **Microbiology** 1996 Dec;142 (Pt 12):3525–30

Isolation of an Acanthamoeba strain with intracellular Burkholderia pickettii infection. Michel R, et al. **Zentralbl Bakteriol** 1997 Apr;285(4):541–57

[Bacterial endosymbiosis within the cytoplasm of Acanthamoeba lugdunensis isolated from a contact lens storage case] Chung DI, et al. **Korean J Parasitol** 1997 Jun;35(2):127–33 (Eng. Abstr.) **(Kor)**

PATHOGENICITY

Pathogenesis of Acanthamoeba keratitis: carbohydrate-mediated host-parasite interactions. Yang Z, et al. **Infect Immun** 1997 Feb;65(2):439–45

The possibility of congenital infection with Acanthamoeba culbertsoni. Awadalla HN, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):601–8

Identification of two genetic markers that distinguish pathogenic and nonpathogenic strains of Acanthamoeba spp. Howe DK, et al. **Parasitol Res** 1997;83(4):345–8

PHYSIOLOGY

Phagocytosis occurs in Acanthamoeba castellanii after electroporation. Dybowska U, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Sep;42(6):881–8

Participation of 125 kDa tyrosine-phosphorylated protein in phagocytosis of Acanthamoeba cells. Krawczyńska W, et al. **Folia Histochem Cytobiol** 1996;34 Suppl 1:11–2

The effectiveness of soft contact lens disinfection systems against Acanthamoeba on the lens surface. Liedel KK, et al. **J Am Optom Assoc** 1996 Mar;67(3):135–42

Osmolarity is an independent trigger of Acanthamoeba castellanii differentiation. Cordingley JS, et al. **J Cell Biochem** 1996 May;61(2):167–71

In vitro destruction of nerve cell cultures by Acanthamoeba spp.: a transmission and scanning electron microscopy study. Pettit DA, et al. **J Parasitol** 1996 Oct;82(5):769–77

Species identification and molecular characterization of Acanthamoeba isolated from contact lens paraphernalia. Lee SM, et al. **Korean J Ophthalmol** 1997 Jun;11(1):39–50

Effect of patient wear and extent of protein deposition on adsorption of Acanthamoeba to five types of hydrogel contact lenses. Simmons PA, et al. **Optom Vis Sci** 1996 Jun;73(6):362–8

ACANTHAMOEBA KERATITIS

Contact lenses, disinfectants, and Acanthamoeba keratitis. Ahearn DG, et al. **Adv Appl Microbiol** 1997;43:35–56 (95 ref.)

Acanthamoeba keratitis. Ishibashi Y. **Ophthalmologica** 1997; 211 Suppl 1:39–44 (25 ref.)

DIAGNOSIS

Acanthamoeba keratitis with granulomatous reaction involving the stroma and anterior chamber. Mietz H, et al. **Arch Ophthalmol** 1997 Feb;115(2):259–63

Acanthamoeba keratitis. Contact lens and noncontact lens characteristics. Chynn EW, et al. **Ophthalmology** 1995 Sep; 102(9):1369–73

Decreased corneal sensation as an initial feature of Acanthamoeba keratitis. Perry HD, et al. **Ophthalmology** 1995 Oct;102(10):1565–8

[Therapy refractory keratitis. Contact lens-induced keratitis caused by Acanthamoeba palestinensis] Faudel F, et al. **Ophthalmologe** 1997 Jun;94(6):448–9 **(Ger)**

DRUG THERAPY

Should we be using polyhexamethylene biguanide to treat Acanthamoeba keratitis? [editorial] Kumar B, et al. **Aust N Z J Ophthalmol** 1997 May;25(2):94–5

Acanthamoeba keratitis: risk factors and outcome [letter; comment] Hay J, et al. **Br J Ophthalmol** 1996 Aug;80(8):773 . Comment on: Br J Ophthalmol 1995 Dec;79(12):1078–82.

Acanthamoeba keratitis: first recorded case from a Palestinian patient with trachoma [letter] Pyott A, et al. **Br J Ophthalmol** 1996 Sep;80(9):849

The role of topical corticosteroids in the management of Acanthamoeba keratitis. Park DH, et al. **Cornea** 1997 May; 16(3):277–83

Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine. Seal D, et al. **Eye** 1996;10 (Pt 4):413–21

Outcome of acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. Duguid IG, et al. **Ophthalmology** 1997 Oct;104(10):1587–92

EPIDEMIOLOGY

Acanthamoeba keratitis in the south of Sweden. Skarin A, et al. **Acta Ophthalmol Scand** 1996 Dec;74(6):593–7

ETIOLOGY

Acanthamoeba infection after radial keratotomy. Friedman RF, et al. **Am J Ophthalmol** 1997 Mar;123(3):409–10

Acanthamoeba keratitis: is water exposure a true risk factor? Chynn EW, et al. **CLAO J** 1997 Jan;23(1):55–6

The use of epidemiological techniques to assess risk: the epidemiology of microbial keratitis. Dart JK. **Eye** 1995;9 (Pt 6):679–83

Pathogenesis of Acanthamoeba keratitis: carbohydrate-mediated host-parasite interactions. Yang Z, et al. **Infect Immun** 1997 Feb;65(2):439–45

Incidence of acanthamoeba keratitis associated with contact lens wear [letter] Morlet N, et al. **Lancet** 1997 Aug 9; 350(9075):414

PARASITOLOGY

Pathogenesis of Acanthamoeba keratitis: carbohydrate-mediated host-parasite interactions. Yang Z, et al. **Infect Immun** 1997 Feb;65(2):439–45

PREVENTION & CONTROL

Acanthamoeba keratitis, contact lenses, and the potential health implications of global marketing [letter; comment] Hay J, et al. **Trans R Soc Trop Med Hyg** 1996 May-Jun; 90(3):331. Comment on: Trans R Soc Trop Med Hyg 1995 Nov-Dec;89(6):652.

SURGERY

[Therapy of advanced amoeba keratitis with keratoplasty à chaud and adjuvant cryotherapy] Klüppel M, et al. **Ophthalmologe** 1997 Feb;94(2):99–103 (Eng. Abstr.) **(Ger)**

ACANTHOCEPHALA

ANATOMY & HISTOLOGY

Koronacantha mexicana n. gen., n. sp. (Acanthocephala: Illiosentidae) from marine fishes in Chamela Bay, Jalisco, Mexico. Monks S, et al. **J Parasitol** 1996 Oct;82(5):788–92

Syncytial organization of acanthors of Polymorphus minutus (Palaeacanthocephala), Neoechinorhynchus rutili (Eoacanthocephala), and Moniliformis moniliformis (Archiacanthocephala) (Acanthocephala). Albrecht H, et al. **Parasitol Res** 1997;83(4):326–38

CHEMISTRY

Intestinal fish parasites as heavy metal bioindicators: a comparison between Acanthocephalus lucii (Palaeacanthocephala) and the zebra mussel, Dreissena polymorpha. Sures B, et al. **Bull Environ Contam Toxicol** 1997 Jul;59(1):14–21

CLASSIFICATION

Molecular evidence for Acanthocephala as a subtaxon of Rotifera. Garey JR, et al. **J Mol Evol** 1996 Sep;43(3):287–92

Sphaerechinorhynchus ophiograndis n. sp. (Acanthocephala:Plagiorhynchidae:Sphaerechinorhynchinae), described from the intestine of a king cobra, Ophiophagus hannah. Bolette DP. **J Parasitol** 1997 Apr; 83(2):272–5

Koronacantha pectinaria n. comb. (Acanthocephala: Illiosentidae) from Microlepidotus brevipinnis (Haemulidae) and redescription of Tegorhynchus brevis. Monks S, et al. **J Parasitol** 1997 Jun;83(3):485–94

Koronacantha mexicana n. gen., n. sp. (Acanthocephala: Illiosentidae) from marine fishes in Chamela Bay, Jalisco, Mexico. Monks S, et al. **J Parasitol** 1996 Oct;82(5):788–92

CYTOLOGY

The establishment of embryonic axial properties in the nemertean, Cerebratulus lacteus. Henry JQ, et al. **Dev Biol** 1996 Dec 15;180(2):713–21

EMBRYOLOGY

The establishment of embryonic axial properties in the nemertean, Cerebratulus lacteus. Henry JQ, et al. **Dev Biol** 1996 Dec 15;180(2):713–21

GENETICS

Molecular evidence for Acanthocephala as a subtaxon of Rotifera. Garey JR, et al. **J Mol Evol** 1996 Sep;43(3):287–92

GROWTH & DEVELOPMENT

Seasonal occurrence and maturation of Neoechinorhynchus rutili (Acanthocephala) in barbel, Barbus barbus (Pisces), of the Jihlava River, Czech Republic. Moravec F, et al. **Parasite** 1994 Sep;1(3):271–8

ISOLATION & PURIFICATION

Colonization and establishment of Pomphorhynchus laevis (Acanthocephala) in an isolated English river. Kennedy CR. **J Helminthol** 1996 Mar;70(1):27–31

First record of Pachysentis canicola (Acanthocephala:Oligacanthorhynchida) and the occurrence of Mesocestoides sp. tetrathyridia (Cestoidea:Cyclophyllidea) in the western diamondback rattlesnake, Crotalus atrox (Serpentes:Viperidae). Bolette DP. **J Parasitol** 1997 Aug;83(4):751–2

Helminths of Anolis acutus (Sauria: Polychrotidae) from St. Croix, U.S. Virgin Islands. Goldberg SR, et al. **J Parasitol** 1997 Jun;83(3):530–1

Acanthocephala of the bald eagle (Haliaeetus leucocephalus) in North America. Richardson DJ, et al. **J Parasitol** 1997 Jun;83(3):540–1

PHYSIOLOGY

Comparison of Leptorhynchoides thecatus (Acanthocephala) recruitment into green sunfish and largemouth bass populations. Olson PD, et al. **J Parasitol** 1996 Oct; 82(5):702–6

Copulation and sexual congress of Leptorhynchoides thecatus (Acanthocephala). Richardson DJ, et al. **J Parasitol** 1997 Jun;83(3):542–3

ACANTHOCHEILONEMA see **DIPETALONEMA**

ACANTHOCHEILONEMIASIS see **DIPETALONEMA INFECTIONS**

ACANTHOCYTES

CT and MR findings of neuroacanthocytosis. Okamoto K, et al. **J Comput Assist Tomogr** 1997 Mar-Apr;21(2):221–2

Acanthocytosis, retinitis pigmentosa, pallidal degeneration. Report of two cases without serum lipid abnormalities. Malandrini A, et al. **J Neurol Sci** 1996 Sep 1; 140(1-2):129–31

Acanthocytosis and spinocerebellar degeneration: a new association? Tsai CH, et al. **Mov Disord** 1997 May; 12(3):456–9

PATHOLOGY

Analysis of the McLeod syndrome gene in three patients with neuroacanthocytosis. Shizuka M, et al. **J Neurol Sci** 1997 Sep 10;150(2):133–5

Neuro-acanthocytosis--a rare cause of chorea. Nielsen SM, et al. **S Afr Med J** 1997 Jul;87(7):897–8

Liver alcoholic cirrhosis and spur-cell (acanthocytic) anaemia. A study of erythrocyte ghost composition and fluidity. Arienti G, et al. **Scand J Gastroenterol** 1995 Dec; 30(12):1204–9

ACANTHOLYSIS

[Transient acantholytic dermatosis (Grover disease)] Maghraoui S, et al. **Ann Dermatol Venereol** 1995; 122(11-12):801–6 (41 ref.) **(Fre)**

CHEMICALLY INDUCED

Transient acantholytic dermatosis (Grover's disease) in a patient with progressive systemic sclerosis treated with D-penicillamine [letter] Zvulunov A, et al. **Int J Dermatol** 1997 Jun;36(6):476–7

COMPLICATIONS

Pityriasis rubra pilaris and focal acantholytic dyskeratosis. Cowen P, et al. **Australas J Dermatol** 1997 Feb;38(1):40–1 (5 ref.)

Acantholytic dermatosis in chronic renal failure. Chua SH, et al. **Int J Dermatol** 1997 Mar;36(3):200–2

Multiple cutaneous malignancies in a patient with pityriasis rubra pilaris and focal acantholytic dyskeratosis. Tannenbaum CB, et al. **J Am Acad Dermatol** 1996 Nov; 35(5 Pt 1):781–2

ENZYMOLOGY

Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus. Penneys NS. **Br J Dermatol** 1996 Oct; 135(4):592–4

ETIOLOGY

Are acantholysis and transglutaminase inhibition related

ACANTHOLYSIS

phenomena? Esposito C, et al. **Dermatology** 1996; 193(3):221–5

PATHOLOGY

Viral warts in a patient with Darier's disease show acantholytic dyskeratosis. Jacyk WK, et al. **Am J Dermatopathol** 1997 Feb;19(1):87–8

Verruciform xanthoma of the penis with acantholytic cells. Requena L, et al. **Clin Exp Dermatol** 1995 Nov;20(6):504–8

Desmosomal dissolution in Grover's disease, Hailey–Hailey's disease and Darier's disease. Hashimoto K, et al. **J Cutan Pathol** 1995 Dec;22(6):488–501

Sudoriferous acrosyringeal acantholytic disease. A subset of Grover's disease. Hashimoto K, et al. **J Cutan Pathol** 1996 Apr;23(2):151–64

Pityriasis rubra pilaris with acantholysis. Howe K, et al. **J Cutan Pathol** 1996 Jun;23(3):270–4

Neutrophilic spongiosis in pemphigus herpetiformis. Huhn KM, et al. **J Cutan Pathol** 1996 Jun;23(3):264–9

Involvement of the adherens junction–actin filament system in acantholytic dyskeratosis of Hailey–Hailey disease. A histological, ultrastructural, and histochemical study of lesional and non-lesional skin. Metze D, et al. **J Cutan Pathol** 1996 Jun;23(3):211–22

PHYSIOPATHOLOGY

Gaining more insight into the pathomechanisms of thiol-induced acantholysis. Wolf R, et al. **Med Hypotheses** 1997 Feb;48(2):107–10 (23 ref.)

VETERINARY

Dominantly inherited epidermal acantholysis in dogs, simulating human benign familial chronic pemphigus (Hailey–Hailey disease). Sueki H, et al. **Br J Dermatol** 1997 Feb;136(2):190–6

Langerhans cells in the development of skin cancer: a qualitative and quantitative comparison of cell markers in normal, acanthotic and neoplastic ovine skin. Townsend WL, et al. **Pathology** 1997 Feb;29(1):42–50

ACANTHOLYSIS BULLOSA see **EPIDERMOLYSIS BULLOSA**

ACANTHOSIS NIGRICANS

Successful treatment of hirsutism in HAIR-AN syndrome using flutamide, spironolactone, and birth control therapy. Zemtsov A, et al. **Arch Dermatol** 1997 Apr;133(4):431–3

Absence of acanthosis nigricans in a patient with the type B syndrome of insulin resistance and preexisting diabetes [see comments] Stolarczyk R, et al. **Diabetes Care** 1996 Aug;19(8):885–6. Comment in: Diabetes Care 1997 Jun;20(6):1045.

COMPLICATIONS

Generalised acanthosis nigricans with vitiligo. Blume-Peytavi U, et al. **Acta Derm Venereol** 1996 Sep; 76(5):377–80

A case of severe hyperandrogenism, acanthosis nigricans and over diabetes: the use of non-invasive methods for diagnosis, pathogenesis and management. Grisaru D, et al. **Gynecol Endocrinol** 1996 Oct;10(5):337–41

Malignant acanthosis nigricans and tripe palms in a patient with endometrial adenocarcinoma—a case report and review of literature. Gorisek B, et al. **Gynecol Oncol** 1997 Jun;65(3):539–42 (17 ref.)

Acanthosis nigricans associated with hepatolenticular degeneration. Thaipisuttikul Y. **J Dermatol** 1997 Jun; 24(6):395–400

Hyperinsulinemia and acanthosis Nigricans in African Americans. Stuart CA, et al. **J Natl Med Assoc** 1997 Aug; 89(8):523–7

Acanthosis nigricans associated with longstanding dermatomyositis [letter] Tuna Castro MA, et al. **J Rheumatol** 1996 Aug;23(8):1487–8

Crouzon disease with acanthosis nigricans and melanocytic nevi. Gines E, et al. **Pediatr Dermatol** 1996 Jan–Feb; 13(1):18–21 (16 ref.)

DIAGNOSIS

Terra firma-forme dermatosis. O'Brien TJ, et al. **Australas J Dermatol** 1997 Aug;38(3):163–4

Brown patches, skin tags on axilla. Are this patient's velvety plaques related to his obesity and diabetes? Levine N. **Geriatrics** 1996 Oct;51(10):27

[Will acanthosis nigricans be a new cutaneous manifestation of human immunodeficiency virus infection?] Maltez F, et al. **Acta Med Port** 1997 Jun–Jul;10(6–7):493–5 (Eng. Abstr.) **(Por)**

DRUG THERAPY

Effect of metformin on glucose disposal and hyperinsulinaemia in a 14-year-old boy with acanthosis nigricans. Lee PJ, et al. **Horm Res** 1997;48(2):88–92

ETIOLOGY

Is hyperinsulinemia the cause of acanthosis nigricans in the type B syndrome of insulin resistance? [letter; comment] Eriksson JW. **Diabetes Care** 1997 Jun;20(6):1045. Comment on: Diabetes Care 1996 Aug;19(8):885–6.

Transforming growth factor-alpha (TGF alpha)-producing gastric carcinoma with acanthosis nigricans: an endocrine effect of TGF alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. Koyama S, et al. **J Gastroenterol** 1997 Feb; 32(1):71–7

Case report: acanthosis nigricans in association with primary biliary cirrhosis: resolution after liver transplantation. Pham TH, et al. **J Gastroenterol Hepatol** 1996 Nov;11(11):1021–3

Systemic lupus erythematosus with acanthosis nigricans, hyperpigmentation, and insulin receptor antibody. Baird JS, et al. **Lupus** 1997;6(3):275–8

GENETICS

Familial acanthosis nigricans. Dhar S, et al. **Int J Dermatol** 1996 Feb;35(2):126–7

A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans. Wilkes D, et al. **J Med Genet** 1996 Sep; 33(9):744–8

PATHOLOGY

Role of mast cell and stem cell factor in hyperpigmented mycosis fungoides [letter] Yamamoto T, et al. **Blood** 1997 Aug 1;90(3):1338–40

Brown patches, skin tags on axilla. Are this patient's velvety plaques related to his obesity and diabetes? Levine N. **Geriatrics** 1996 Oct;51(10):27

PHYSIOPATHOLOGY

Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans. Lunetta M, et al. **J Endocrinol Invest** 1996 Nov;19(10):699–703

ACARI

MICROBIOLOGY

Mould-devouring mites differ in guanine excretion from dust-eating Acari, a possible error source in mite allergen exposure studies. Kort HS, et al. **Clin Exp Allergy** 1997 Aug;27(8):921–5

PHYSIOLOGY

Survival and reproductive output of Chironomus tentans (Diptera: Chironomidae) in response to parasitism by larval Unionicola foili (Acari: Unionicolidae). Weiberg M, et al. **J Parasitol** 1997 Feb;83(1):173–5

ACARIASIS see **MITE INFESTATIONS**

ACARUS see **MITES**

ACCELERATED IDIOVENTRICULAR RHYTHM

[Idioventricular rhythm] Shirayama T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):315–7 (7 ref.) **(Jpn)**

[Accelerated idioventricular rhythm] Shirayama T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):458–60 (9 ref.) **(Jpn)**

ACCELERATION

Theoretical considerations concerning the effect of relativistic velocities on the rate of biological processes. Heneine IF. **Aviat Space Environ Med** 1997 Jun; 68(6):538–41

+Gz acceleration affects the trace minerals zinc, copper, and chromium in serum and urine of humans. Kikukawa A, et al. **Aviat Space Environ Med** 1996 Dec;67(12):1166–9

Human subject research at Armstrong Laboratory, 1973–93: medical and musculoskeletal disqualifications. Morris CE, et al. **Aviat Space Environ Med** 1997 May;68(5):378–83

Alcohol and workload as factors affecting the detection of angular acceleration. Mughni WN, et al. **Aviat Space Environ Med** 1996 Dec;67(12):1148–51

Differences between syncope resulting from rapid onset acceleration and orthostatic stress. Self DA, et al. **Aviat Space Environ Med** 1996 Jun;67(6):547–54

The human vertical vestibulo-ocular reflex during combined linear and angular acceleration with near-target fixation. Viirre ES, et al. **Exp Brain Res** 1996 Nov;112(2):313–24

The retention of balance: an exploratory study into the limits of acceleration the human body can withstand without losing equilibrium. de Graaf B, et al. **Hum Factors** 1997 Mar;39(1):111–8

A triaxial accelerometer and portable data processing unit for the assessment of daily physical activity. Bouten CV, et al. **IEEE Trans Biomed Eng** 1997 Mar;44(3):136–47

Assessment of fracture healing in the tibia using the impulse response method. Nakatsuchi Y, et al. **J Orthop Trauma** 1996;10(1):50–62

Three-dimensional baselines for perceived self-motion during acceleration and deceleration in a centrifuge. Holly JE. **J Vestib Res** 1997 Jan–Feb;7(1):45–61

Effects of placement and orientation of body-fixed accelerometers on the assessment of energy expenditure during walking. Bouten CV, et al. **Med Biol Eng Comput** 1997 Jan;35(1):50–6

The efficient range of velocities for inducing depth perception by motion parallax. Hayashibe K. **Percept Mot Skills** 1996 Oct;83(2):659–74

A useful method for measuring daily physical activity by a three-direction monitor. Sugimoto A, et al. **Scand J Rehabil Med** 1997 Mar;29(1):37–42

[Prediction of tolerance of longitudinal linear head-to-tail accelerations of short duration (up to 5 seconds)] Mazurin IuV, et al. **Aviakosm Ekolog Med** 1997;31(3):10–4 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

An overview of the physiological effects of sustained high +Gz forces on human being. Fong KL, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):94–103 (61 ref.)

Female acceleration tolerance: effects of menstrual state and physical condition. Heaps CL, et al. **Aviat Space Environ Med** 1997 Jun;68(6):525–30

Comparison of acceleration subjects to other populations: spinal anomaly distribution. Popper SE, et al. **Aviat Space Environ Med** 1997 May;68(5):426–31

Total and regional cerebral blood flow during recovery from G-LOC. Werchan PM, et al. **Aviat Space Environ Med** 1996 Aug;67(8):751–8

Perception of direction of visual motion. I. Influence of angular body acceleration and tilt. Loose R, et al. **Behav Brain Res** 1996 Nov;81(1–2):141–6

Perception of direction of visual motion. II. Influence of linear body acceleration. Probst T, et al. **Behav Brain Res** 1996 Nov;81(1–2):147–54

Perceptual responses to linear acceleration after spaceflight: human neurovestibular studies on SLS-2. Merfeld DM, et al. **J Appl Physiol** 1996 Jul;81(1):58–68

Effect of acceleration stress on salivary cortisol and plasma cortisol and testosterone levels in cadet pilots. Obmiński Z, et al. **J Physiol Pharmacol** 1997 Jun;48(2):193–200

[Biodynamic response to the windblast in expulsions with an ejection seat: the pathogenetic mechanism, analysis and prevention of lesions due to aerodynamic wind pressure] Rotondo G. **Riv Med Aeronaut Spaz** 1975 Apr–Sep; 38(2–3):209–34 (Eng. Abstr.) **(Ita)**

[Study of human orientation with respect to vertical under effect of lateral and combined longitudinal–lateral accelerations] Bukhtiiarov IV, et al. **Aviakosm Ekolog Med** 1996;30(1):16–21 (Eng. Abstr.) **(Rus)**

ACCELOGRAPHY see **KINETOCARDIOGRAPHY**

ACCEPTABILITY OF HEALTH CARE see **PATIENT ACCEPTANCE OF HEALTH CARE**

ACCESS TO HEALTH CARE see **HEALTH SERVICES ACCESSIBILITY**

ACCESSIBILITY OF HEALTH SERVICES see **HEALTH SERVICES ACCESSIBILITY**

ACCESSORY CELLS, IMMUNOLOGIC see **ANTIGEN-PRESENTING CELLS**

ACCESSORY NERVE

Asystole from tetanic stimulation of the accessory nerve. Scott PV. **Anaesthesia** 1996 Dec;51(12):1148–50

Accessory nerve palsy and serratus palsy. Vastamäki M. **Ann Chir Gynaecol** 1996;85(2):167–71 (14 ref.)

Spinal accessory nerve palsy due to neurovascular compression. Report of a case diagnosed by magnetic resonance imaging and magnetic resonance angiography. Lunardi P, et al. **Neurosurg Rev** 1996;19(3):175–8

ANATOMY & HISTOLOGY

Morphometric investigations of the connections between the posterior C-1 root and the accessory nerve in the human cranial cervical region. Schneider U, et al. **Acta Anat (Basel)** 1996;156(2):118–22

Distribution of motoneurons supplying feline neck muscles taking origin from the shoulder girdle. Liinamaa TL, et al. **J Comp Neurol** 1997 Jan 13;377(2):298–312

Spinal accessory nerve in a trapezius-splitting surgical approach. Jobe CM, et al. **J Shoulder Elbow Surg** 1996 May–Jun;5(3):206–8

Magnetic resonance imaging of cranial nerves IX, X, XI, and XII. Castillo M, et al. **Top Magn Reson Imaging** 1996 Jun;8(3):180–6

INJURIES

Iatrogenic accessory nerve injury [letter; comment] Almeyda JS, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5):479. Comment on: Ann R Coll Surg Engl 1996 Mar;78(2):146–50.

Iatrogenic accessory nerve injury [letter] Norman JE. **Ann R Coll Surg Engl** 1997 Jul;79(4):307–8

The posterior triangle and the painful shoulder: spinal accessory nerve injury. Williams WW, et al. **Ann R Coll Surg Engl** 1996 Nov;78(6):521–5

Delayed primary repair of a kyrogenic spinal accessory nerve

injury: a case report. Jensen KL, et al. **Clin Orthop** 1997 Mar;(336):116–21
Spinal accessory nerve injury: a complication of carotid endarterectomy. Yagnik PM, et al. **Muscle Nerve** 1996 Jul; 19(7):907–9 (18 ref.)

PATHOLOGY

Motor innervation of the trapezius muscle: a histochemical study. Karuman PM, et al. **Head Neck** 1996 May–Jun; 18(3):254–8
Radiologic manifestation of spinal accessory neurinoma: a case report. Ohkawa M, et al. **Radiat Med** 1996 Sep–Oct; 14(5):269–73 (16 ref.)

PHYSIOPATHOLOGY

Bilateral myoclonus of the trapezius muscles after distal lesion of an accessory nerve. Glocker FX, et al. **Mov Disord** 1996 Sep;11(5):571–5
[Spinal accessory nerve and lymphatic neck dissection] Pinsolle V, et al. **Rev Stomatol Chir Maxillofac** 1997 Sep; 98(3):138–42 (Eng. Abstr.) **(Fre)**

SURGERY

Accessory nerve damages and impaired shoulder movements after neck dissections. Miyata K, et al.
Am J Otolaryngol 1997 May–Jun;18(3):197–201
Ultrastructural changes in the nerve fiber population of anastomosed vagal and spinal accessory nerves in the sheep. Delorme P, et al. **Anat Rec** 1997 May;248(1):129–36
The posterior triangle and the painful shoulder: spinal accessory nerve injury. Williams WW, et al.
Ann R Coll Surg Engl 1996 Nov;78(6):521–5
Extirpation of a jugular foramen schwannoma via the transcervical–transmandibular approach. Saydam L, et al. **Eur Arch Otorhinolaryngol** 1997;254(2):110–2
Spinal accessory neurotization for restoration of elbow flexion in avulsion injuries of the brachial plexus. Songcharoen P, et al. **J Hand Surg [Am]** 1996 May; 21(3):387–90
Experimental study on donor nerves for brachial plexus injury: comparison between the spinal accessory nerve and the intercostal nerve. Hattori Y, et al.
Plast Reconstr Surg 1997 Sep;100(4):900–6
[Experimental study of hypoglossal facial anastomosis and accessory–facial anastomosis in guinea pigs] Horiuchi J. **Nippon Jibiinkoka Gakkai Kaiho** 1997 Mar;100(3):299–306 (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Ultrastructural changes in the nerve fiber population of anastomosed vagal and spinal accessory nerves in the sheep. Delorme P, et al. **Anat Rec** 1997 May;248(1):129–36

ACCESSORY OLFACTORY BULB see **OLFACTORY BULB**

ACCIDENT INSURANCE see **INSURANCE, ACCIDENT**

ACCIDENT PREVENTION

see related
PROTECTIVE DEVICES

The role of the emergency department in creating a safe America [editorial; comment] Waxweiler RJ.
Acad Emerg Med 1997 Aug;4(8):761–3. Comment on: Acad Emerg Med 1997 Aug;4(8):764–71. Comment on: Acad Emerg Med 1997 Aug;4(8):772–5.
Risk of injury per hour of exposure to consumer products. Hayward G. **Accid Anal Prev** 1996 Jan;28(1):115–21
Supervision in childhood injury cases: a reliable taxonomy. Wills KE, et al. **Accid Anal Prev** 1997 Jan;29(1):133–7
A community prevention trial to reduce alcohol-involved accidental injury and death: overview. Holder HD, et al. **Addiction** 1997 Jun;92 Suppl 2:S155–71
Media advocacy in community prevention: news as a means to advance policy change. Holder HD, et al. **Addiction** 1997 Jun;92 Suppl 2:S189–99
Summing up: lessons from a comprehensive community prevention trial. Holder HD, et al. **Addiction** 1997 Jun;92 Suppl 2:S293–301
Community mobilization: evaluation of an environmental approach to local action. Treno AJ, et al. **Addiction** 1997 Jun;92 Suppl 2:S173–87
Modifying the environment: a community–based injury–reduction program for elderly residents. Plautz B, et al. **Am J Prev Med** 1996 Jul–Aug;12(4 Suppl):33–8
The role of emergency medical services in primary injury prevention. Consensus workshop. Arlington, Virginia, August 25–26, 1995. Garrison HG, et al.
Ann Emerg Med 1997 Jul;30(1):84–91 (11 ref.)
Qualitative research methods in interventions in injury. Roberts H. **Arch Dis Child** 1997 Jun;76(6):487–9
Accidental injury: risk and preventative interventions. van Weeghel I, et al. **Arch Dis Child** 1997 Jul;77(1):28–31
Effects of rear–wheel camber on wheelchair stability. Trudel G, et al. **Arch Phys Med Rehabil** 1997 Jan;78(1):78–81
Nonfatal firearm misuse: licence status of perpetrators and legality of the firearms. Gardiner J, et al.
Aust N Z J Public Health 1996 Oct;20(5):479–82
Collision avoidance: a helicopter simulator study. Kruk R, et al. **Aviat Space Environ Med** 1996 Feb;67(2):111–14
Childhood injury prevention: time for tougher measures [editorial; comment] [see comments] Pless IB.
Can Med Assoc J 1996 Nov 15;155(10):1429–31. Comment on: Can Med Assoc J 1996 Nov 15;155(10):1417–9. Comment in: Can Med Assoc J 1997 Feb 15;156(4):479–80. Comment in: Can Med Assoc J 1997 Feb 15;156(4):480–1.
'Accident proneness': statistical and practical significance [comment] Langley JD. **Inj Prev** 1997 Jun;3(2):80–1. Comment on: Inj Prev 1997 Jun;3(2):135–43. Comment on: Inj Prev 1997 Jun;3(2):144–5.
Is saying NO to 'accident proneness' throwing the baby out with the bathwater? [comment] Wright P. **Inj Prev** 1997 Jun;3(2):79–80. Comment on: Inj Prev 1997 Jun;3(2):135–43. Comment on: Inj Prev 1997 Jun;3(2):144–5.
Road humps: accident prevention or hazard? Bowrey D, et al. **J Accid Emerg Med** 1996 Jul;13(4):288–9
Emergency medicine at a large rock festival [see comments] Hewitt S, et al. **J Accid Emerg Med** 1996 Jan;13(1):26–7 . Comment in: J Accid Emerg Med 1996 Jul;13(4):303.
Childhood burns in camping and outdoor cooking accidents: a focus for prevention. Sheridan RL, et al.
J Burn Care Rehabil 1997 Jul–Aug;18(4):369–71
Propane gas dangers and strategies for prevention of injuries. Smoot EC 3rd, et al. **J Burn Care Rehabil** 1996 May–Jun; 17(3):273–9
A randomized trial of a consultation service to reduce falls in nursing homes [see comments] Ray WA, et al.
JAMA 1997 Aug 20;278(7):557–62. Comment in: JAMA 1997 Aug 20;278(7):595–6.
Preventing falls in the nursing home [editorial; comment] Rubenstein LZ. **JAMA** 1997 Aug 20;278(7):595–6. Comment on: JAMA 1997 Aug 20;278(7):557–62.
Injury prevention. First of two parts. Rivara FP, et al.
N Engl J Med 1997 Aug 21;337(8):543–8 (70 ref.)
Injury prevention. Second of two parts. Rivara FP, et al.
N Engl J Med 1997 Aug 28;337(9):613–8 (145 ref.)
Successful health and safety management. Doidge JP.
Perfusion 1997 Jul;12(4):217–20
Injuries in developing countries: policy response needed now. Zwi AB, et al. **Trans R Soc Trop Med Hyg** 1996 Nov–Dec; 90(6):593–5 (9 ref.)
An analysis of skiing injuries in West Virginia. Metz MM, et al. **W V Med J** 1997 Mar–Apr;93(2):68–71
[Prevention of accidents in children and adolescents (editorial)] Lévêque B. **Arch Pediatr** 1996 Sep;3(9):845–6 **(Fre)**

ACCIDENT PRONENESS

Correlations between traffic, occupational, sports, and home accidents. Salminen S, et al. **Accid Anal Prev** 1997 Jan; 29(1):33–6
Are there injury–prone children? A critical review of the literature. Wazana A. **Can J Psychiatry** 1997 Aug; 42(6):602–10 (40 ref.)
'Accident proneness': statistical and practical significance [comment] Langley JD. **Inj Prev** 1997 Jun;3(2):80–1. Comment on: Inj Prev 1997 Jun;3(2):135–43. Comment on: Inj Prev 1997 Jun;3(2):144–5.
Personality characteristics of the child accident repeater. 1967 [classical article] [see comments] Manheimer DI, et al. **Inj Prev** 1997 Jun;3(2):135–43. Comment in: Inj Prev 1997 Jun;3(2):79–80. Comment in: Inj Prev 1997 Jun;3(2):80–1.
Behavioral antecedents of accidental injuries in early childhood: a study of twins. 1971 [classical article] [see comments] Matheny AP Jr, et al. **Inj Prev** 1997 Jun; 3(2):144–5. Comment in: Inj Prev 1997 Jun;3(2):79–80.
Is saying NO to 'accident proneness' throwing the baby out with the bathwater? [comment] Wright P. **Inj Prev** 1997 Jun;3(2):79–80. Comment on: Inj Prev 1997 Jun;3(2):135–43. Comment on: Inj Prev 1997 Jun;3(2):144–5.
Parent–reported injury–associated behaviors and life events among injured, ill, and well preschool children. Bernardo LM. **J Pediatr Nurs** 1996 Apr;11(2):100–10
Psychopathologic risk factors for intentional and nonintentional injury. Poole GV, et al. **J Trauma** 1997 Apr; 42(4):711–5
Using the Downton index to predict those prone to falls in stroke rehabilitation. Nyberg L, et al. **Stroke** 1996 Oct; 27(10):1821–4

ACCIDENTAL FALLS

The effects of shopping cart design and prior behavioral history on children's standing in cart seats. Harrell WA. **Accid Anal Prev** 1996 May;28(3):385–9
Fear of falling and restriction of mobility in elderly fallers. Vellas BJ, et al. **Age Ageing** 1997 May;26(3):189–93
Reasons for poor detection of frequent falls in elderly people by general practitioners. Vetter NJ, et al.
Aging (Milano) 1995 Dec;7(6):430–2
A mediastinal hematoma after a fall. Earls JP, et al.
AJR Am J Roentgenol 1997 Sep;169(3):659
Diagnosis of pulmonary contusions and a bronchial laceration after a fall. Song JK, et al. **AJR Am J Roentgenol** 1996 Dec;167(6):1510
Case–control study of exposure to medication and the risk of injurious falls requiring hospitalization among nursing home residents. Mustard CA, et al. **Am J Epidemiol** 1997 Apr 15;145(8):738–45
Age–related factors in the pathogenesis of senile (Type II) femoral neck fractures. Boonen S, et al. **Am J Orthop** 1996 Mar;25(3):198–204 (107 ref.)
Traumatic hip dislocation during childhood. A case report and review of the literature [see comments] Petrie SG, et al. **Am J Orthop** 1996 Sep;25(9):645–9 (25 ref.). Comment in: Am J Orthop 1997 Feb;26(2):73, 76.
Progressive scapulothoracic subluxation after fracture of the clavicle. Uhl RL, et al. **Am J Orthop** 1996 Sep;25(9):637–8; discussion 638–9
Do wrist guards protect against fractures? Lewis LM, et al.
Ann Emerg Med 1997 Jun;29(6):766–9
Pediatric cervical spine injury sustained in falls from low heights. Schwartz GR, et al. **Ann Emerg Med** 1997 Sep; 30(3):249–52
Head injury—abuse or accident? Wilkins B.
Arch Dis Child 1997 May;76(5):393–6; discussion 396–7 (58 ref.)
Fracture of the femoral head without associated hip dislocation following low–energy trauma. A report of two cases. Mody BS, et al. **Arch Orthop Trauma Surg** 1996; 115(5):300–2
Fear of falling revisited. Hill KD, et al.
Arch Phys Med Rehabil 1996 Oct;77(10):1025–9
Medications and fractures [letter; comment] Byrne A.
Aust Fam Physician 1997 Apr;26(4):475. Comment on: Aust Fam Physician 1997 Feb;26(2):115–21.
The consequences of osteoporosis in the elderly [see comments] Mykyta LJ. **Aust Fam Physician** 1997 Feb; 26(2):115–21 (26 ref.). Comment in: Aust Fam Physician 1997 Apr;26(4):475.
Carotid dissection causing stroke in a child with migraine [see comments] Ganesan V, et al. **BMJ** 1997 Jan 25; 314(7076):291–2. Comment in: BMJ 1997 Jan 25;314(7076):243.
Controlled trial of weight bearing exercise in older women in relation to bone density and falls [see comments] McMurdo ME, et al. **BMJ** 1997 Feb 22;314(7080):569. Comment in: BMJ 1997 Jun 28;314(7098):1907–8.
Impact direction from a fall influences the failure load of the proximal femur as much as age–related bone loss. Pinilla TP, et al. **Calcif Tissue Int** 1996 Apr;58(4):231–5
Postural control in the older adult. Maki BE, et al.
Clin Geriatr Med 1996 Nov;12(4):635–58 (78 ref.)
Case report: post–traumatic thoracolumbar pseudomeningocoele—an unusual cause of upper lumbar pain. Johnson DB, et al. **Clin Radiol** 1997 Sep;52(9):715–7
The effect of load carrying and floor contaminants on slip and fall parameters. Myung R, et al. **Ergonomics** 1997 Feb; 40(2):235–46
Selections from current literature: falls in the elderly. Trilling JS, et al. **Fam Pract** 1995 Dec;12(4):482–5 (17 ref.)
An evaluation of risk factors for in–patient falls in acute and rehabilitation elderly care wards. Gluck T, et al.
Gerontology 1996;42(2):104–7
Simple physiological and clinical tests for the accurate prediction of falling in older people. Lord SR, et al.
Gerontology 1996;42(4):199–203
Relationship between falls and stride length variability in senile dementia of the Alzheimer type. Nakamura T, et al. **Gerontology** 1996;42(2):108–13
Physical parameters of free fall in a child. Hajivassiliou CA, et al. **Injury** 1996 Dec;27(10):739–41
Multiple impalement injury—a remarkable survival. O'Leary ST, et al. **Injury** 1996 Oct;27(8):589–90
Vertical deceleration injuries: a comparative study of the injury patterns of 101 patients after accidental and intentional high falls. Richter D, et al. **Injury** 1996 Nov; 27(9):655–9
Biepicondylar fracture dislocation of a child's elbow. Taylor GR, et al. **Injury** 1997 Jan;28(1):71–2
The diagnostic management of suspected scaphoid fracture. Tiel–van Buul MM, et al. **Injury** 1997 Jan;28(1):1–8 (63 ref.)
Falling, hoarding and hiding, eating disturbances, and sexual disinhibition. Brännström B. **Int Psychogeriatr** 1996;8 Suppl 3:419–22
Missed cervical spine injury following barflying. Taylor M, et al. **J Accid Emerg Med** 1996 May;13(3):222–3
Rising from the floor in older adults. Alexander NB, et al. **J Am Geriatr Soc** 1997 May;45(5):564–9
Chronic medical conditions and risk of fall injury events at home in older adults. Herndon JG, et al.
J Am Geriatr Soc 1997 Jun;45(6):739–43
One–leg balance is an important predictor of injurious falls in older persons. Vellas BJ, et al. **J Am Geriatr Soc** 1997 Jun;45(6):735–8
Measures of paraspinal muscle performance do not predict initial trunk kinematics after tripping. Grabiner MD, et al. **J Biomech** 1996 Jun;29(6):735–44
Hip impact velocities and body configurations for voluntary falls from standing height. van den Kroonenberg AJ, et al. **J Biomech** 1996 Jun;29(6):807–11
Altered mental status in an anticoagulated patient [clinical conference] Nadel ES, et al. **J Emerg Med** 1997 Jan–Feb; 15(1):95–8
Risk factors, falls, and fracture of the distal forearm in Manchester, UK. O'Neill TW, et al.
J Epidemiol Community Health 1996 Jun;50(3):288–92
Concomitant medial facet and dome fractures of the talus.

Storm M, et al. **J Foot Ankle Surg** 1996 Jul–Aug; 35(4):331–4 (12 ref.)

The effect of strength and endurance training on gait, balance, fall risk, and health services use in community–living older adults. Buchner DM, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):M218–24

Balance and skeletal alignment in a group of elderly female fallers and nonfallers. O'Brien K, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):B221–6

Differences in muscle endurance and recovery between fallers and nonfallers, and between young and older women. Schwendner KI, et al. **J Gerontol A Biol Sci Med Sci** 1997 May;52(3):M155–60

The effects of two types of cognitive tasks on postural stability in older adults with and without a history of falls. Shumway–Cook A, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):M232–40

Age differences in using a rapid step to regain balance during a forward fall. Thelen DG, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):M8–13

An assessment of falls in elderly men and women. Woolley SM, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar; 52(2):M80–7

Penetrating oral foreign body presenting as an aural polyp. Law S, et al. **J Laryngol Otol** 1997 Aug;111(8):749–51

Head injuries due to falls caused by seizures: a group at high risk for traumatic intracranial hematomas. Zwimpfer TJ, et al. **J Neurosurg** 1997 Mar;86(3):433–7

Reimplantation of the totally extruded talus. Brewster NT, et al. **J Orthop Trauma** 1997 Jan;11(1):42–5

Ulnar nerve laceration in a closed both bone forearm fracture. Torpey BM, et al. **J Orthop Trauma** 1996;10(2):131–4 (12 ref.)

The physical basis of severity of torso injury owing to falls in childhood [letter] Gimmon Z. **J Pediatr Surg** 1996 Feb; 31(2):327

Head injuries in infants caused by falls from surfaces while restrained in car seats. Dixon JJ, et al. **J R Soc Med** 1997 Jun;90(6):335–6

Head extension and age–dependent posturographic instability in normal subjects. Jackson RT, et al. **J Rehabil Res Dev** 1996 Feb;33(1):1–5

Wheelchair rider injuries: causes and consequences for wheelchair design and selection [letter; comment] Marshall S. **J Rehabil Res Dev** 1997 Apr;34(2):vi. Comment on: J Rehabil Res Dev 1997 Jan;34(1);58–71.

The obstacle course: a tool for the assessment of functional balance and mobility in the elderly. Means KM. **J Rehabil Res Dev** 1996 Oct;33(4):413–29

The effects of the severe snowstorm of 1996 in the New England community [letter] Lalikos JF, et al. **J Trauma** 1997 Feb;42(2):348

Diagnosis and management of acute aortic valvular disruption secondary to rapid–deceleration trauma. Munshi IA, et al. **J Trauma** 1996 Dec;41(6):1047–50

An 85–year–old woman with a history of falls, 1 year later [comment] Delbanco TL, et al. **JAMA** 1997 Mar 26; 277(12):996. Comment on: JAMA 1996 Jul 3;276(1):59–66.

An 85–year–old women with a history of falls [letter; comment] Landau WM. **JAMA** 1996 Nov 6;276(17):1383; discussion 1383–4. Comment on: JAMA 1996 Jul 3;276(1):59–66.

An 85–year–old women with a history of falls [letter; comment] Wong EH. **JAMA** 1996 Nov 6;276(17):1383; discussion 1383–4. Comment on: JAMA 1996 Jul 3;276(1):59–66.

Falling again [see comments] Johnston S, et al. **Lancet** 1997 Jan 4;349(9044):26. Comment in: Lancet 1997 Feb 22;349(9051):575–6.

"Stops walking when talking" as a predictor of falls in elderly people [letter] [see comments] Lundin–Olsson L, et al. **Lancet** 1997 Mar 1;349(9052):617. Comment in: Lancet 1997 Apr 19;349(9059):1180.

An unfortunate consequence of being tickled. Nance J, et al. **Lancet** 1997 Apr 19;349(9059):1142

Falls in elderly people [letter; comment] Nisipeanu P, et al. **Lancet** 1997 Apr 19;349(9059):1180. Comment on: Lancet 1997 Mar 1;349(9052):617.

Primary cutaneous cryptococcosis following trauma of the right forearm. Bohne T, et al. **Mycoses** 1996 Nov–Dec; 39(11–12):457–9

Radiographic progression to dorsal intercalated segment instability. Wolfe SW, et al. **Orthopedics** 1996 Aug; 19(8):691–5

Cardiovascular syncope is the most common cause of drop attacks in the elderly. Dey AB, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):818–9

Fatal extradural hemorrhage following a fall from a baby bouncer. Claydon SM. **Pediatr Emerg Care** 1996 Dec; 12(6):432–4

Accidental anorectal impalement in children. Jona JZ. **Pediatr Emerg Care** 1997 Feb;13(1):40–3

Infant walker injuries persist in Canada after sales have ceased. Morrison CD, et al. **Pediatr Emerg Care** 1996 Jun; 12(3):180–2

Single rope tree swing injuries among children. Albanese CT, et al. **Pediatrics** 1997 Apr;99(4):548–50

Use of the "fast evaluation of mobility, balance, and fear" in elderly community dwellers: validity and reliability. Di Fabio RP, et al. **Phys Ther** 1997 Sep;77(9):904–17

Berg balance test [letter; comment] Stevenson T. **Phys Ther** 1996 Oct;76(10):1124, 1126. Comment on: Phys Ther 1996 Jun;76(6):576–83; discussion 584–5.

Severe pulmonary dysfunction following acute respiratory distress syndrome. Smith HR, et al. **Postgrad Med J** 1996 Sep;72(851):555–6

Multidisciplinary conservative management in classical Volkmann's contracture: a case report. Reinders MF, et al. **Prosthet Orthot Int** 1996 Dec;20(3):199–202

Drop attacks in the elderly revisited [editorial] Dey AB, et al. **QJM** 1997 Jan;90(1):1–3

Pain due to bone insufficiency as a symptom heralding femoral neck fracture. Maugars Y, et al. **Rev Rhum Engl Ed** 1996 Jan;63(1):30–5

Falls and hip fracture. A reasonable basis for possibilities for prevention? Some preliminary data from the MEDOS study Mediterranean Osteoporosis Study. Allander E, et al. **Scand J Rheumatol Suppl** 1996;103:49–52; discussion 53

Differential diagnosis of electrocardiographic changes in altered mental state. Ooi SB. **Singapore Med J** 1995 Oct; 36(5):549, 571–2

Using the Downton index to predict those prone to falls in stroke rehabilitation. Nyberg L, et al. **Stroke** 1996 Oct; 27(10):1821–4

Fall prediction index for patients in stroke rehabilitation. Nyberg L, et al. **Stroke** 1997 Apr;28(4):716–21

Risk factors for falls of hospitalized stroke patients. Tutuarima JA, et al. **Stroke** 1997 Feb;28(2):297–301

[Prevention with hip protectors. Biomechanical aspects in falls and hip fractures] Lauritzen JB. **Nord Med** 1996 Dec; 111(10):340–3 (15 ref.) (Eng. Abstr.) **(Dan)**

[Benzodiazepine administration increases accidental fall–induced femoral fractures!] Klipstein A. **Schweiz Rundsch Med Prax** 1997 Jul 2;86(27–28):1120–1 **(Ger)**

[Dens fracture and multiple fracture of the thoracic spine after fall from great height. Diagnostic standard] Weisskopf M, et al. **Unfallchirurg** 1996 Jul;99(7):520–4 (Eng. Abstr.) **(Ger)**

[Comment on D. Moskopp and H. Wassmann: Subarachnoid hemorrhage from cerebral artery aneurysm subsequent to a fall: external or internal etiology? (letter)] Bratzke H. **Versicherungsmedizin** 1997 Feb 1;49(1):30 **(Ger)**

[Comment on D. Moskopp and H. Wassmann: Subarachnoid hemorrhage from cerebral artery aneurysm subsequent to a fall: external or internal etiology? (letter)] in der Schmitten J. **Versicherungsmedizin** 1997 Feb 1;49(1):30–1 **(Ger)**

[Comment on D. Moskopp and H. Wassmann: Subarachnoid hemorrhage from cerebral artery aneurysm subsequent to a fall: external or internal etiology? (letter) (published erratum appears in Versicherungsmedizin 1997 Apr 1;49(2):60)] Marx HH. **Versicherungsmedizin** 1997 Feb 1; 49(1):30; discussion 31 **(Ger)**

[Subarachnoid hemorrhage from cerebral artery aneurysm within the context of a fall: external or internal etiology?] Moskopp D, et al. **Versicherungsmedizin** 1996 Aug 1; 48(4):134–7 (Eng. Abstr.) **(Ger)**

[Benzodiazepines and falls in the elderly] Shats V, et al. **Harefuah** 1996 Oct;131(7–8):279–82 **(Heb)**

[An examination of two reporting methods of falls among the elderly living in the community] Haga H, et al. **Nippon Koshu Eisei Zasshi** 1996 Nov;43(11):983–8 (Eng. Abstr.) **(Jpn)**

[Neck injuries in children] Muratov ID. **Khirurgiia (Mosk)** 1996;(4):76 **(Rus)**

[The use of a method of sequential mathematical analysis for the differential diagnosis of trauma from a fall from a height and of trauma due to the collision of a moving automobile with a pedestrian by the chest injuries] Solokhin AA, et al. **Sud Med Ekspert** 1997 Apr–Jun;40(2):32–6 (Eng. Abstr.) **(Rus)**

[A foreign body of the parapharyngeal space] Tselishchev VA. **Vestn Otorinolaringol** 1997;(1):60 **(Rus)**

[Late reopening of patent ductus arteriosus after complete closure with the Rashkind prosthesis. Possible traumatic origin] Alcibar J, et al. **Rev Esp Cardiol** 1997 Feb; 50(2):133–6 (Eng. Abstr.) **(Spa)**

MORTALITY

Fatal occupational falls in the U.S. construction industry, 1980–1989. Cattledge GH, et al. **Accid Anal Prev** 1996 Sep; 28(5):647–54

Fatal head injuries in ground–level falls. Hartshorne NJ, et al. **Am J Forensic Med Pathol** 1997 Sep;18(3):258–64

[Trauma in elderly patients] Markgraf E, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:453–6 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

REM sleep behaviour disorder: a treatable cause of falls in elderly people. Morfis L, et al. **Age Ageing** 1997 Jan; 26(1):43–4

A comparison of the effects of three types of endurance training on balance and other fall risk factors in older adults. Buchner DM, et al. **Aging (Milano)** 1997 Feb–Apr; 9(1–2):112–9

Rehabilitation of elderly fallers: pilot study of a low to moderate intensity exercise program. Means KM, et al. **Arch Phys Med Rehabil** 1996 Oct;77(10):1030–6

The STEPS Project: participatory action research to reduce falls in public places among seniors and persons with disabilities. Gallagher EM, et al. **Can J Public Health** 1997 Mar–Apr;88(2):129–33 (24 ref.)

Role of the environment in falls prevention. Connell BR. **Clin Geriatr Med** 1996 Nov;12(4):859–80 (47 ref.)

A multifactorial approach to reducing injurious falls. King MB, et al. **Clin Geriatr Med** 1996 Nov;12(4):745–59 (67 ref.)

Medications and falls. Causation, correlation, and prevention. Monane M, et al. **Clin Geriatr Med** 1996 Nov;12(4):847–58 (67 ref.)

Falls and fall prevention in the nursing home. Rubenstein LZ, et al. **Clin Geriatr Med** 1996 Nov;12(4):881–902 (86 ref.)

Clinical overview of instability in the elderly. Studenski S, et al. **Clin Geriatr Med** 1996 Nov;12(4):679–88 (16 ref.)

Effects of hormone replacement therapy on muscle performance and balance in post–menopausal women. Armstrong AL, et al. **Clin Sci (Colch)** 1996 Dec; 91(6):685–90

Instability in the older adult. Rigler SK. **Compr Ther** 1996 May;22(5):297–303 (20 ref.)

Hip fractures. Epidemiology, risk factors, falls, energy absorption, hip protectors, and prevention. Lauritzen JB. **Dan Med Bull** 1997 Apr;44(2):155–68

Patients who fall: how to predict and prevent injuries. Tibbitts GM. **Geriatrics** 1996 Sep;51(9):24–8, 31 (19 ref.)

The risks associated with HVAC drip pans. **Health Devices** 1996 Jan;25(1):43

Dynamics of human flight on skis: improvements in safety and fairness in ski jumping. Müller W, et al. **J Biomech** 1996 Aug;29(8):1061–8

The Harstad injury prevention study: community based prevention of fall–fractures in the elderly evaluated by means of a hospital based injury recording system in Norway. Ytterstad B. **J Epidemiol Community Health** 1996 Oct;50(5):551–8

Static and dynamic balance responses in persons with bilateral knee osteoarthritis. Wegener L, et al. **J Orthop Sports Phys Ther** 1997 Jan;25(1):13–8 (50 ref.)

Falls may be preventable [letter] Stolinsky DC. **J Trauma** 1997 Sep;43(3):562

A randomized trial of a consultation service to reduce falls in nursing homes [see comments] Ray WA, et al. **JAMA** 1997 Aug 20;278(7):557–62. Comment in: JAMA 1997 Aug 20;278(7):595–6.

Preventing falls in the nursing home [editorial; comment] Rubenstein LZ. **JAMA** 1997 Aug 20;278(7):595–6. Comment on: JAMA 1997 Aug 20;278(7):557–62.

Preventing injurious falls. Sattin RW. **Lancet** 1997 Jan 18; 349(9046):150

Preventing falls in the elderly at home: a community–based program [letter; comment] Cameron I, et al. **Med J Aust** 1996 Oct 21;165(8):459–60. Comment on: Med J Aust 1996 May 6;164(9):530–2.

The impact of a dedicated "syncope and falls" clinic on pacing practice in northeastern England. Dey AB, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):815–7

How effective are brakes on infant walkers? Ridenour MV. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):1051–7

The effect of multidimensional exercises on balance, mobility, and fall risk in community–dwelling older adults. Shumway–Cook A, et al. **Phys Ther** 1997 Jan;77(1):46–57

Social status, life changes, housing conditions, health, functional abilities and life–style as risk factors for recurrent falls among the home–dwelling elderly. Luukinen H, et al. **Public Health** 1996 Mar;110(2):115–8

Prevention of falls in patients with osteoporosis. Grisso JA. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):75S–77S

A community intervention program targeting the elderly in Stockholm county. Hökby A, et al. **Scand J Rheumatol Suppl** 1996;103:115–8; discussion 119–22

STATISTICS & NUMERICAL DATA

Slipping on ice and snow—elderly women and young men are typical victims. Björnstig U, et al. **Accid Anal Prev** 1997 Mar;29(2):211–5

Nonfatal occupational fall injuries in the West Virginia construction industry. Cattledge GH, et al. **Accid Anal Prev** 1996 Sep;28(5):655–63

Spontaneous hip fractures, 44/872 in a prospective study. Parker MJ, et al. **Acta Orthop Scand** 1997 Aug;68(4):325–6

Falls presenting to the accident and emergency department: types of presentation and risk factor profile. Davies AJ, et al. **Age Ageing** 1996 Sep;25(5):362–6

Sensori–motor function, gait patterns and falls in community–dwelling women. Lord SR, et al. **Age Ageing** 1996 Jul;25(4):292–9

New evidence on benzodiazepine use and falls: the time factor. Neutel CI, et al. **Age Ageing** 1996 Jul;25(4):273–8

Environmental hazards and hip fractures. Parker MJ, et al. **Age Ageing** 1996 Jul;25(4):322–5

Falls in construction: injury rates for OSHA–inspected employers before and after citation for violating the Washington State Fall Protection Standard. Nelson NA, et al. **Am J Ind Med** 1997 Mar;31(3):296–302

Pattern of fall and bone mineral density measurement in hip fractures. Goh JC, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):820–3

Physical activity, functional limitations, and the risk of fall–related fractures in community–dwelling elderly. Stevens JA, et al. **Ann Epidemiol** 1997 Jan;7(1):54–61

Fall risk assessment tool. MacAvoy S, et al. **Appl Nurs Res** 1996 Nov;9(4):213–8

Environmental and behavioral circumstances associated with falls at home among healthy elderly individuals. Atlanta FICSIT Group. Connell BR, et al. **Arch Phys Med Rehabil** 1997 Feb;78(2):179–86

More evidence linking benzodiazepines and falls. Grad R. **Can Fam Physician** 1997 Aug;43:1367–8

Medications and falls. Causation, correlation, and prevention. Monane M, et al. **Clin Geriatr Med** 1996 Nov;12(4):847–58 (67 ref.)

Patients who fall: how to predict and prevent injuries. Tibbitts GM. **Geriatrics** 1996 Sep;51(9):24–8, 31 (19 ref.)

Characteristics of falls in 70 year olds in Jerusalem. Dresner-Pollak R, et al. **Isr J Med Sci** 1996 Aug; 32(8):625–8

Association of postprandial hypotension with incidence of falls, syncope, coronary events, stroke, and total mortality at 29-month follow-up in 499 older nursing home residents. Aronow WS, et al. **J Am Geriatr Soc** 1997 Sep;45(9):1051–3

Gait changes in older adults: predictors of falls or indicators of fear? Maki BE. **J Am Geriatr Soc** 1997 Mar;45(3):313–20

Circumstances of falls resulting in hip fractures among older people. Norton R, et al. **J Am Geriatr Soc** 1997 Sep; 45(9):1108–12

Long latency ankle responses to dynamic perturbation in older fallers and non-fallers. Smith BN, et al. **J Am Geriatr Soc** 1996 Dec;44(12):1447–54

Incidence rates of falls among Japanese men and women living in Hawaii. Davis JW, et al. **J Clin Epidemiol** 1997 May;50(5):589–94

Potential adverse outcomes of psychotropic and narcotic drug use in Canadian seniors. Ebly EM, et al. **J Clin Epidemiol** 1997 Jul;50(7):857–63

Spinal cord injuries in Louisiana due to falls from deer stands, 1985–1994. Lawrence DW, et al. **J La State Med Soc** 1996 Feb;148(2):77–9

Falls in the elderly. Abyad A. **J Med Liban** 1995;43(4):194–9 (25 ref.)

Occupational fatalities among older workers in the United States: 1980–1991. Kisner SM, et al. **J Occup Environ Med** 1997 Aug;39(8):715–21

A study of maxillofacial injuries in the elderly resulting from falls. Chew DJ, et al. **J Oral Rehabil** 1996 Jul;23(7):505–9

Wheelchair rider injuries: causes and consequences for wheelchair design and selection [see comments] Gaal RP, et al. **J Rehabil Res Dev** 1997 Jan;34(1):58–71. Comment in: J Rehabil Res Dev 1997 Apr;34(2):vi.

Non-syncopal falls in the elderly in relation to home environments. Northridge ME, et al. **Osteoporos Int** 1996; 6(3):249–55

Prevalence of cardioinhibitory carotid sinus hypersensitivity in patients 50 years or over presenting to the accident and emergency department with "unexplained" or "recurrent" falls. Richardson DA, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):820–3

Predicting the probability for falls in community-dwelling older adults. Shumway-Cook A, et al. **Phys Ther** 1997 Aug; 77(8):812–9

Incidence of falls in three different types of geriatric care. A Swedish prospective study. Nyberg L, et al. **Scand J Soc Med** 1997 Mar;25(1):8–13

The use of sedative/hypnotic medication and its correlation with falling down in the hospital. Mendelson WB. **Sleep** 1996 Nov;19(9):698–701

Adverse reactions to sedative/hypnotics: three years' experience. Mendelson WB, et al. **Sleep** 1996 Nov; 19(9):702–6

[Risk for falls in the elderly. Role of activities of daily living and of the subjective assessment of health status. A case-control study] Gialloreti LE, et al. **Recenti Prog Med** 1996 Sep;87(9):405–11 (Eng. Abstr.) **(Ita)**

[Circumstances and factors related to falls in the institutionalized elderly] Niino N, et al. **Nippon Ronen Igakkai Zasshi** 1996 Jan;33(1):12–6 (Eng. Abstr.) **(Jpn)**

[The prevalence of and factors associated with falls in older persons living in the community] Méndez Rubio JI, et al. **Med Clin (Barc)** 1997 Feb 1;108(4):128–32 (Eng. Abstr.) **(Spa)**

ACCIDENTS

Fatigue and transport. Proceedings of the 2nd International Conference on Fatigue in Transportation. Fremantle, Australia, 1996. **Accid Anal Prev** 1997 Jul;29(4):407–553

Alcohol use and a safe environment. Holder HD. **Addiction** 1997 Mar;92 Suppl 1:S117–20

Concerned Americans for responsible driving (CARD): a personal narrative. Suroff SE. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:81–3

Fatal railway injuries in Cape Town, South Africa. Lerer LB, et al. **Am J Forensic Med Pathol** 1997 Jun;18(2):144–7

Forces, moments, and accelerations acting on an unrestrained dummy during simulations of three wheelchair accidents. Sosner J, et al. **Am J Phys Med Rehabil** 1997 Jul-Aug; 76(4):304–10

Prevention of flash fires during facial surgery performed under local anesthesia. Howard BK, et al. **Ann Otol Rhinol Laryngol** 1997 Mar;106(3):248–51

Minor head injury. Beattie TF. **Arch Dis Child** 1997 Jul; 77(1):82–5 (34 ref.)

Timing of paediatric deaths after trauma. Wyatt JP, et al. **BMJ** 1997 Mar 22;314(7084):868

Meningitis due to Mycobacterium bovis BCG—reactivation or accidental intrathecal inoculation? [letter; comment] Talbot EA, et al. **Clin Infect Dis** 1996 Dec;23(6):1335–6. Comment on: Clin Infect Dis 1996 May;22(5):870–1.

Philosophy and the accident. Campbell R. **Clio Med** 1997; 41:17–34

Accidents in history: an introduction. Cooter R, et al. **Clio Med** 1997;41:1–16

The moment of the accident: culture, militarism and modernity in late-Victorian Britain. Cooter R. **Clio Med** 1997;41:107–57

Accidents in the eighteenth century. Porter R. **Clio Med** 1997;41:90–106

Fatal unintentional child injuries in Denmark. Jorgensen IM. **Dan Med Bull** 1996 Feb;43(1):92–6

Escalator injuries in Genevan children: a report of 6 cases. Quinodoz P, et al. **Eur J Pediatr Surg** 1996 Aug;6(4):225–7

Accidental strangulation in a rickshaw [see comments] Kohli A, et al. **Forensic Sci Int** 1996 Mar 5;78(1):7–11. Comment in: Forensic Sci Int 1996 Sep 30;82(2):191–2.

Injuries from hovercraft racing. Cattermole HR. **Injury** 1997 Jan;28(1):25–7 (0 ref.)

Traumatic asphyxia: an indicator of potentially severe injury in trauma. Dunne JR, et al. **Injury** 1996 Dec;27(10):746–9 (29 ref.)

Injuries sustained during major evacuation of the high-speed catamaran St Malo off Jersey. Lockey D, et al. **Injury** 1997 Apr;28(3):187–90

Drug history taking and the identification of drug related problems in an accident and emergency department. Akwagyriam I, et al. **J Accid Emerg Med** 1996 May; 13(3):166–8

Childhood accidents [letter; comment] [see comments] Carley SD, et al. **J Accid Emerg Med** 1997 Jan;14(1):58–9. Comment on: J Accid Emerg Med 1996 May;13(3):196–7. Comment in: J Accid Emerg Med 1997 May;14(3):199–200.

Stress hormones in accident patients studied before admission to hospital. Hetz W, et al. **J Accid Emerg Med** 1996 Jul; 13(4):243–7

Are schools safer for children than public places? [see comments] Maitra AK, et al. **J Accid Emerg Med** 1996 May;13(3):196–7. Comment in: J Accid Emerg Med 1997 Jan;14(1):58–9. Comment in: J Accid Emerg Med 1997 May;14(3):199–200.

Accidental death due to inhalation of butane [letter] Winek CL, et al. **J Anal Toxicol** 1997 Jul-Aug;21(4):323

Injuries involving off-road cycling. Rivara FP, et al. **J Fam Pract** 1997 May;44(5):481–5

Acute hepatitis C transmitted by needlestick accident despite short duration interferon treatment. Nakano Y, et al. **J Gastroenterol Hepatol** 1995 Sep-Oct;10(5):609–11

Suction injuries in children leading to acute compartment syndrome of the interosseous muscles of the hand: case reports. Shin AY, et al. **J Hand Surg [Am]** 1996 Jul; 21(4):675–8

Psychological well-being and ratings of psychiatric symptoms in bereaved Israeli adolescents: differential effect of war-versus accident-related bereavement. Bachar E, et al. **J Nerv Ment Dis** 1997 Jun;185(6):402–6

Humerus shaft fractures in young children: accident or abuse? Shaw BA, et al. **J Pediatr Orthop** 1997 May-Jun; 17(3):293–7

Diagnosis and management of diving accidents. Smith DJ. **Med Sci Sports Exerc** 1996 May;28(5):587–90

Hunting-associated injuries and wearing "hunter" orange clothing—New York, 1989–1995. **MMWR Morb Mortal Wkly Rep** 1996 Oct 18;45(41):884–7

Severe accidental hypothermia: pathophysiology and therapeutic options for hospitals without cardiopulmonary bypass equipment. Schrijver G, et al. **Neth J Med** 1996 Oct;49(4):167–76 (36 ref.)

Severe accidental hypothermia: rewarming with CVVHD. van der Maten J, et al. **Neth J Med** 1996 Oct;49(4):160–3

Physicians' work in emergency response. Couturier AJ, et al. **Occup Health Saf** 1997 Feb;66(2):46–8, 50–2

The relationship between symptoms of post-traumatic stress disorder and pain, affective disturbance and disability among patients with accident and non-accident related pain. Geisser ME, et al. **Pain** 1996 Aug;66(2–3):207–14

Effects of type of symptom onset on psychological distress and disability in fibromyalgia syndrome patients. Turk DC, et al. **Pain** 1996 Dec;68(2–3):423–30

Roller coasters: let the rider beware. Holtzman DK, et al. **Pediatr Emerg Care** 1997 Jun;13(3):218–20

[Complex biomedical studies of the body under conditions of extreme marine factors] Sachanska T. **Probl Khig** 1996; 21:67–73 (Eng. Abstr.) **(Bul)**

[Monitoring after electrical accident (letter; comment)] Böger M. **Dtsch Med Wochenschr** 1997 Mar 7;122(10):315. Comment on: Dtsch Med Wochenschr 1996 Aug 16;121(33):1032. **(Ger)**

[Differential diagnosis of circulatory failure in hypothermic avalanche victims: retrospective analysis of 32 avalanche accidents] Locher T, et al. **Schweiz Rundsch Med Prax** 1996 Oct 8;85(41):1275–82 (Eng. Abstr.) **(Ger)**

[Expert assessment of railroad accidents at the beginning of the industrial age—a medical historical excursion with reference to current circumstances] Hausotter W. **Versicherungsmedizin** 1996 Aug 1;48(4):138–42 (Eng. Abstr.) **(Ger)**

[The analysis of frequency, causes and consequences of accidents on children's playgrounds] Kosmala M. **Pediatr Pol** 1996 Feb;71(2):143–52 (44 ref.) (Eng. Abstr.) **(Pol)**

[Morphologic analysis of congenital central nervous system malformations in children from the first of life dying in the years 1986–1990] Sobaniec-Lotowska M, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):334–6 (Eng. Abstr.) **(Pol)**

[Present-day medical preventive requirements for accident cleaning-up in transporting of chemical cargo] Krivulia SL, et al. **Gig Sanit** 1996 Sep-Oct;(5):33–5 **(Rus)**

[Tropical snakes as a risk of accidents even in Sweden. Four cases from the Norrbotten] Holmen C. **Lakartidningen** 1996 Nov 27;93(48):4409–11 **(Swe)**

[Medical efforts during the Estonian ship wreck] Kulling P, et al. **Lakartidningen** 1997 Mar 26;94(13):1189–91 **(Swe)**

CLASSIFICATION

Accidents: the remnants of a modern classificatory system. Green J. **Clio Med** 1997;41:35–58

ECONOMICS

People who cause accidents should pay for victims' care [news] Dyer C. **BMJ** 1997 Jan 4;314(7073):10

LEGISLATION & JURISPRUDENCE

Explaining "pain and suffering" awards: the role of injury characteristics and fault attributions. Wissler RL, et al. **Law Hum Behav** 1997 Apr;21(2):181–207

[Forensic medical implications of vascular injuries and accidents related to the practice of conventional vascular surgery] Natali J. **J Mal Vasc** 1996 Nov;21(4):216–9 (Eng. Abstr.) **(Fre)**

[Forensic medical implications of vascular injuries and accidents related to the practice of conventional general surgery] Natali J. **J Mal Vasc** 1996 Nov;21(4):220–2 (Eng. Abstr.) **(Fre)**

[Suicide or fatal accident in fantasy play?] Nadjem H, et al. **Arch Kriminol** 1997 Mar-Apr;199(3–4):97–102 (Eng. Abstr.) **(Ger)**

[Identification of unknown cadavers in forensic medicine practice] Riepert T, et al. **Arch Kriminol** 1996 Jul-Aug; 198(1–2):23–30 (Eng. Abstr.) **(Ger)**

[An extended case of autoerotic accident] Schumann M, et al. **Arch Kriminol** 1997 Jan-Feb;199(1–2):27–31 (Eng. Abstr.) **(Ger)**

[Differentiation of hunting accident and suicide with rifles] Karger B. **Versicherungsmedizin** 1996 Feb 1;48(1):11–5 (24 ref.) (Eng. Abstr.) **(Ger)**

[Gunshot wounds—homicide, suicide or accident?] Schyma P, et al. **Versicherungsmedizin** 1997 Aug 1;49(4):112–7 (Eng. Abstr.) **(Ger)**

[Comment on B. Madea and P. Schmidt: Fatal post-traumatic alcohol delirium—right to compensation in private accident insurance (letter)] Wehking E. **Versicherungsmedizin** 1997 Aug 1;49(4):136–7 **(Ger)**

[Legal definition of the accident concept in social accident insurance] Ernestus RI, et al. **Zentralbl Neurochir** 1996; 57(4):206–8 (Eng. Abstr.) **(Ger)**

MORTALITY

Accidental fatal drug overdoses in New York City: 1990–1992. Tardiff K, et al. **Am J Drug Alcohol Abuse** 1996 May;22(2):135–46

Criminality and morbidity in young victims of firearm injuries. A follow-up study. Bergman B, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:334–5

Reducing accident death rates in children and young adults: the contribution of hospital care. Steering Committee of the Major Trauma Outcome Study Group. Roberts I, et al. **BMJ** 1996 Nov 16;313(7067):1239–41

An analysis of unnatural deaths between 1990 and 1994 in A-Lein, Taiwan. Wang CS, et al. **Injury** 1997 Apr; 28(3):203–8

Prehospital deaths in the Yorkshire Health Region. Limb D, et al. **J Accid Emerg Med** 1996 Jul;13(4):248–50

Deaths among railroad trespassers. The role of alcohol in fatal injuries. Pelletier A. **JAMA** 1997 Apr 2;277(13):1064–6

Accidental death and the shift to daylight savings time. Coren S. **Percept Mot Skills** 1996 Dec;83(3 Pt 1):921–2

Epidemiology of childhood injuries in Reykjavík 1974–1991. Stefánsdóttir A, et al. **Scand J Prim Health Care** 1997 Mar; 15(1):30–4

Unintentional injury death rates for Texas children drop, while intentional injury death rates rise [news] Zane DF, et al. **Tex Med** 1997 Jan;93(1):22–3

[Accident-related mortality in 5- to 9-year-old children] Syrovátka A, et al. **Cas Lek Cesk** 1996 Dec 18; 135(24):786–8 (Eng. Abstr.) **(Cze)**

[Comment on O. Huth: Incidence of accidents in various age groups (letter)] Effert S. **Versicherungsmedizin** 1997 Aug 1;49(4):135–6 **(Ger)**

PREVENTION & CONTROL see ACCIDENT PREVENTION

PSYCHOLOGY

Understanding nurses' communication with patients in accident & emergency departments using a symbolic interactionist perspective. Byrne G, et al. **J Adv Nurs** 1997

ACCIDENTS

Jul;26(1):93–100
MMPI–2 profiles in traumatic and non–traumatic spinal cord injured patients. Fow NR, et al. **J Clin Psychol** 1996 Sep; 52(5):573–9
Perception of physical pain in accident and suicide attempt patients: self–preservation vs self–destruction. Orbach I, et al. **J Psychiatr Res** 1996 Jul–Aug;30(4):307–20
Psychological sequelae of mountain accidents: a preliminary study. Peck DF, et al. **J Psychosom Res** 1996 Jul; 41(1):55–63
Serious on–the–track accidents experienced by train drivers: psychological reactions and long–term health effects. Vatshelle A, et al. **J Psychosom Res** 1997 Jan;42(1):43–52

STATISTICS & NUMERICAL DATA

Injury in West Virginia: a statewide survey. Williams JM, et al. **Acad Emerg Med** 1996 Oct;3(10):911–6
An epidemiological study of bicycle–related injuries. Eilert–Petersson E, et al. **Accid Anal Prev** 1997 May; 29(3):363–72
A multiple discriminant analysis of vessel accidents. Le Blanc LA, et al. **Accid Anal Prev** 1996 Jul;28(4):501–10
Motor vehicle crashes and drivers with DAT. Carr DB. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:38–41
Child–resistant prescription packaging shown to save lives [news] **Am J Health Syst Pharm** 1996 Jul 15;53(14):1654, 1661
Injuries and the risk of disability in teenagers and young adults. Barker M, et al. **Arch Dis Child** 1996 Aug; 75(2):156–8
Epidemiology of shopping cart–related injuries to children [letter; comment] Harrell WA.
Arch Pediatr Adolesc Med 1997 Jan;151(1):105–6. Comment on: Arch Pediatr Adolesc Med 1995 Nov;149(11):1207–10.
Agent and nature of childhood injury and initial care provided at the community level in Ibadan, Nigeria. Edet EE. **Cent Afr J Med** 1996 Dec;42(12):347–9
Non–fatal injuries and the use of psychoactive drugs among young adults in Spain. Regidor E, et al.
Drug Alcohol Depend 1996 Mar;40(3):249–59
A retrospective analysis of ingestion of caustic substances by children. Ten–year statistics in Galicia. Bautista Casasnovas A, et al. **Eur J Pediatr** 1997 May;156(5):410–4 (30 ref.)
Causes and consequences of trauma in Swedish county 1989–1992. Holmdahl L, et al. **Eur J Surg** 1997 Feb; 163(2):83–92
School accidents to children: time to act. Maitra A.
J Accid Emerg Med 1997 Jul;14(4):240–2
Nonfatal injuries in adolescents: United States, 1988. Fraser JJ Jr. **J Adolesc Health** 1996 Sep;19(3):166–70
ATV–related central nervous system injuries in Louisiana. Gibbs L, et al. **J La State Med Soc** 1997 Aug;149(8):276–8
Train injuries in children. Blazar PE, et al.
J Orthop Trauma 1997 Feb–Mar;11(2):126–9
Studies of risks associated with technological development in Nigeria [see comments] Ezenwa AO.
J R Soc Health 1996 Dec;116(6):376–80. Comment in: J R Soc Health 1997 Jun;117(3):194.
From the Centers for Disease Control and Prevention. Injuries and deaths associated with use of snowmobiles––Maine, 1991–1996. **JAMA** 1997 Feb 19; 277(7):526–7
Personal watercraft–related injuries. A growing public health concern. Branche CM, et al. **JAMA** 1997 Aug 27; 278(8):663–5
Injuries and deaths associated with use of snowmobiles––Maine, 1991–1996.
MMWR Morb Mortal Wkly Rep 1997 Jan 10;46(1):1–4
[Accidents in children. Retrospective epidemiological study of 1671 cases collected at the Hotel–Dieu of Beirut] Gerbaka B, et al. **J Med Liban** 1996;44(4):209–13 (Eng. Abstr.) **(Fre)**
[Accidents of the elderly] Kazár G, et al. **Orv Hetil** 1996 Jun 9;137(23):1245–9 (Eng. Abstr.) **(Hun)**
[Accidents in school. Epidemiological presentation] Astulfoni A, et al. **Minerva Pediatr** 1995 Dec;47(12):527–31 (Eng. Abstr.) **(Ita)**
[Accidents in the ocular area in children. An epidemiologic study and the medicosocial implications] Spineanu L, et al. **Oftalmologia** 1997;41(1):28–33 (Eng. Abstr.) **(Rum)**
[A survey of registered traumas at the Mora hospital. Hospital size does not determine achievement] Bjernheld H, et al. **Lakartidningen** 1996 Nov 27;93(48):4412–4 **(Swe)**

ACCIDENTS, AVIATION

Pharmacist's role in rescue efforts after plane crash in Indian Ocean [letter] Berod T, et al. **Am J Health Syst Pharm** 1997 May 1;54(9):1110
A correlative investigation of simulated occupant motion and accident report in a helicopter crash. Beale DG, et al.
Aviat Space Environ Med 1996 Jan;67(1):23–9
Liferaft evacuation from a ditched helicopter: dry shod vs. swim away method. Brooks CJ, et al.
Aviat Space Environ Med 1997 Jan;68(1):35–40
Helicopter door and window jettison mechanisms for underwater escape: ergonomic confusion! Brooks CJ, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):844–57
Aircraft fires, smoke toxicity, and survival. Chaturvedi AK, et al. **Aviat Space Environ Med** 1996 Mar;67(3):275–8 (18 ref.)
Role of metabolites in aviation forensic toxicology. Chaturvedi AK, et al. **Aviat Space Environ Med** 1997 Mar; 68(3):230–3 (30 ref.)
Collision avoidance: a helicopter simulator study. Kruk R, et al. **Aviat Space Environ Med** 1996 Feb;67(2):111–14
U.S. naval aviation mishaps, 1977–92: differences between single– and dual–piloted aircraft. Shappell SA, et al.
Aviat Space Environ Med 1996 Jan;67(1):65–9
Evaluation of trauma care in a developing country highlighted by a major aircraft accident. Agalar F, et al. **Eur J Emerg Med** 1997 Jun;4(2):97–102
Atlanto–axial dislocation without fracture: case report of an ejection injury. Boos N, et al. **J Bone Joint Surg Br** 1997 Mar;79(2):204–5 (8 ref.)
Helicopter main rotor blade injury to the head with survival. Gibbons JR, et al. **J R Army Med Corps** 1997 Jun; 143(2):122–3
Of airships, space shuttles, and biological products. Beale J. **J R Soc Med** 1997 Mar;90(3):166–9
Stress reactions in disaster victims following the Bijlmermeer plane crash. Carlier IV, et al. **J Trauma Stress** 1997 Apr; 10(2):329–35
Degloving injury from a helicopter rotor strike. Nelson JM, et al. **Mil Med** 1995 Dec;160(12):644–5
Anesthesia during a mass–casualty disaster: the Army's experience at Fort Bragg, North Carolina, March 23, 1994. Phillips WJ, et al. **Mil Med** 1997 Jun;162(6):371–3
Flight 800. Mobilized by disaster. Clark LB.
N Y State Dent J 1996 Nov;62(9):57–9
Flight 800. In the wake of tragedy. Friedman BK, et al.
N Y State Dent J 1996 Nov;62(9):60–1
They were there. Stoll MG. **N Y State Dent J** 1996 Nov; 62(9):54–7
[The organization of helicopter emergency services for the rescue of aircraft crash victims in the topical forest] Lemaire M. **Med Trop (Mars)** 1997;57(1):91–5 (Eng. Abstr.) **(Fre)**
[Vertebral lesions due to being expelled with an ejection seat. The mechanism, diagnosis and prevention results and means] Rotondo G. **Riv Med Aeronaut Spaz** 1975 Jan–Mar; 38(1):62–77 concl (Eng. Abstr.) **(Ita)**
[The Thule accident in 1968] Glattre E.
Tidsskr Nor Laegeforen 1996 Sep 10;116(21):2539–40 **(Nor)**
[Health effects of plutonium pollution––assessment after the Thule disaster in 1968] Lund E. **Tidsskr Nor Laegeforen** 1996 Sep 10;116(21):2588–90 (Eng. Abstr.) **(Nor)**
[Identification of bodies in mass disasters. The aircraft on Svalbard] Olaisen B. **Tidsskr Nor Laegeforen** 1997 Mar 20; 117(8):1069–70 **(Nor)**

CLASSIFICATION

Role of medical factors in 1000 fatal aviation accidents: case note study. Cullen SA, et al. **BMJ** 1997 May 31; 314(7094):1592

LEGISLATION & JURISPRUDENCE

Incorrect identification of a military pilot with international implications. Cecchi R, et al. **Int J Legal Med** 1997; 110(3):167–9

MORTALITY

Injury patterns in aviation–related fatalities. Implications for preventive strategies. Li G, et al.
Am J Forensic Med Pathol 1997 Sep;18(3):265–70
Population–based description of aircraft accident mortality, U.S. military, 1980–90. Ungs TJ.
Aviat Space Environ Med 1996 Jan;67(1):70–3
Fatal light aircraft accidents in Ontario: a five year study. Shkrum MJ, et al. **J Forensic Sci** 1996 Mar;41(2):252–63
Work–related aviation fatalities––Alaska, 1990–1994.
MMWR Morb Mortal Wkly Rep 1997 Jun 6;46(22):496–8
Application of full–scale fire tests to characterize and improve the aircraft postcrash fire environment. Sarkos CP. **Toxicology** 1996 Dec 31;115(1–3):79–87 (16 ref.)
Fractional effective dose model for post–crash aircraft survivability. Speitel LC. **Toxicology** 1996 Dec 31; 115(1–3):167–77 (30 ref.)
The management of aircraft passenger survival in fire. Trimble EJ. **Toxicology** 1996 Dec 31;115(1–3):41–61 (25 ref.)

PREVENTION & CONTROL

Crew resource management: a simulator study comparing fixed versus formed aircrews. Barker JM, et al.
Aviat Space Environ Med 1996 Jan;67(1):3–7
Performance of color–dependent air traffic control tasks as a function of color vision deficiency. Mertens HW, et al.
Aviat Space Environ Med 1996 Oct;67(10):919–27
Policy improvements for prevention of alcohol misuse by airline pilots. McFadden KL. **Hum Factors** 1997 Mar; 39(1):1–8
[Training with a simulator––experiences in space flight] Müller M. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:533–6 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Alcohol and aviation. Cook CC. **Addiction** 1997 May; 92(5):539–55 (101 ref.)
Sources of situation awareness errors in aviation. Jones DG, et al. **Aviat Space Environ Med** 1996 Jun;67(6):507–12
Lessons learned from providing disaster counseling after TWA flight 800. Cohen NL. **Psychiatr Serv** 1997 Apr; 48(4):461–2
Computer modelling of human behaviour in aircraft fire accidents. Galea ER, et al. **Toxicology** 1996 Dec 31; 115(1–3):63–78 (34 ref.)
Behavioural impairment in smoke environments. Purser D. **Toxicology** 1996 Dec 31;115(1–3):25–40 (17 ref.)

STATISTICS & NUMERICAL DATA

Crashes of instructional flights. Baker SP, et al.
Aviat Space Environ Med 1996 Feb;67(2):105–10
F–16 Class A mishaps in the U.S. Air Force, 1975–93. Knapp CJ, et al. **Aviat Space Environ Med** 1996 Aug;67(8):777–83
Injuries in military parachuting: a prospective study of 4499 jumps. Ekeland A. **Injury** 1997 Apr;28(3):219–22
Fatal air transport accidents involving athletic teams from the United States. Murphy GK. **J Forensic Sci** 1997 Jan; 42(1):74–8 (14 ref.)

ACCIDENTS, HOME

Mushroom poisoning in children: report of an accident. Lee CL, et al. **Acta Paediatr Sin** 1996 Mar–Apr;37(2):133–4
An unusual death due to screwdriver impalement: A case report. Evans RJ, et al. **Am J Forensic Med Pathol** 1996 Mar;17(1):70–2
Vancomycin–resistant Enterococcus in the Singapore National Burns Centre: a case report. Ang SW, et al.
Ann Acad Med Singapore 1996 Mar;25(2):270–2
Severe burns resulting from an exploding teat on a bottle of infant formula milk heated in a microwave oven. Dixon JJ, et al. **Burns** 1997 May;23(3):268–9
Pneumomediastinum, pneumothorax and subcutaneous emphysema with kerosene oil. Sharma A, et al.
Indian J Chest Dis Allied Sci 1996 Jul–Sep;38(3):211–3
Accidental poisoning in children. Singh A, et al.
Indian Pediatr 1996 Jan;33(1):39–41
Fatal accidental ingestion of carbon tetrachloride: a postmortem distribution study. Tombolini A, et al.
J Forensic Sci 1996 Jan;41(1):166–8
Head injuries in infants caused by falls from surfaces while restrained in car seats. Dixon JJ, et al. **J R Soc Med** 1997 Jun;90(6):335–6
Pediatric hand injuries due to exercise bicycles. Lehrer MS, et al. **J Trauma** 1997 Jul;43(1):100–2
Lawn mower injury resulting in Chopart amputation in a young child [see comments] Rougraff BT, et al.
Orthopedics 1996 Aug;19(8):689–91. Comment in: Orthopedics 1997 May;20(5):388.
The nontoxic ingestion. Wasserman GS. **Pediatr Ann** 1996 Jan;25(1):39–46
Infections complicating lawn mower injuries in children. Gaglani MJ, et al. **Pediatr Infect Dis J** 1996 May; 15(5):452–5 (22 ref.)
Automatic garage door openers: hazard for children. Kriel RL, et al. **Pediatrics** 1996 Oct;98(4 Pt 1):770–3
An unusual lawn mower injury. Logar M, et al.
Unfallchirurg 1996 Feb;99(2):152–3
[The dangerous kitchen] MacIntyre BH. **Ugeskr Laeger** 1997 Jul 14;159(29):4533 (Eng. Abstr.) **(Dan)**
[Scalds in children caused by water from toppled electrical kettles. Mechanisms, costs and preventive measures] Sheller JP, et al. **Ugeskr Laeger** 1996 Dec 9;158(50):7233–6 (Eng. Abstr.) **(Dan)**
[Severity of ingestion of caustic substance in children] Lamireau T, et al. **Arch Pediatr** 1997 Jun;4(6):529–34 (Eng. Abstr.) **(Fre)**
[Accidents caused by gas equipment and carbon monoxide poisoning in dwellings of the Lombardy region in the period October 1955–April 1996] Carreri V, et al.
Ann Ig 1996 Sep–Oct;8(5):579–91 (Eng. Abstr.) **(Ita)**

LEGISLATION & JURISPRUDENCE

[Gunshot into the eye] Schyma C, et al. **Arch Kriminol** 1996 May–Jun;197(5–6):155–64 (Eng. Abstr.) **(Ger)**

MORTALITY

State gun safe storage laws and child mortality due to firearms. Cummings P, et al. **JAMA** 1997 Oct 1; 278(13):1084–6
Pediatric window–cord strangulations in the United States, 1981–1995. Rauchschwalbe R, et al. **JAMA** 1997 Jun 4; 277(21):1696–8

PREVENTION & CONTROL

Modifying the environment: a community–based injury–reduction program for elderly residents. Plautz B, et al. **Am J Prev Med** 1996 Jul–Aug;12(4 Suppl):33–8
Accidental injury: risk and preventative interventions. van Weeghel I, et al. **Arch Dis Child** 1997 Jul;77(1):28–31
Environmental and behavioral circumstances associated with falls at home among healthy elderly individuals. Atlanta FICSIT Group. Connell BR, et al.
Arch Phys Med Rehabil 1997 Feb;78(2):179–86
Housewives as home safety managers: the changing perception of the home as a place of hazard and risk, 1870–1940. Tarr JA, et al. **Clio Med** 1997;41:196–233
Health beliefs and social influence in home safety practices

of mothers with preschool children. Russell KM, et al. **Image J Nurs Sch** 1996 Spring;28(1):59–64

Evaluation of a community based childhood injury prevention program. Bablouzian L, et al. **Inj Prev** 1997 Mar;3(1):14–6

Socioeconomic status and the prevention of child home injuries: a survey of parents of preschool children [see comments] Evans SA, et al. **Inj Prev** 1997 Mar;3(1):29–34 . Comment in: Inj Prev 1997 Mar;3(1):5–6. Comment in: Inj Prev 1997 Mar;3(1):7–8.

Threats to measurement validity in self reported data can be overcome [comment] Mickalide A. **Inj Prev** 1997 Mar; 3(1):7–8. Comment on: Inj Prev 1997 Mar;3(1):29–34.

A controlled evaluation of a community injury prevention project in two Greek islands. Petridou E, et al. **Int J Epidemiol** 1997 Feb;26(1):173–9

Identifying homes with inadequate smoke detector protection from residential fires in Pennsylvania. Forjuoh SN, et al. **J Burn Care Rehabil** 1997 Jan–Feb;18(1 Pt 1):86–91

Grease burns of the hand: preventable injuries. Bill TJ, et al. **J Emerg Med** 1996 May–Jun;14(3):351–5

Lower extremity lawn-mower injuries in children. Farley FA, et al. **J Pediatr Orthop** 1996 Sep–Oct;16(5):669–72

Pediatric window-cord strangulations [letter] Bishai DM. **JAMA** 1997 Oct 8;278(14):1152

Preventing falls in the elderly at home: a community-based program [letter; comment] Cameron I, et al. **Med J Aust** 1996 Oct 21;165(8):459–60. Comment on: Med J Aust 1996 May 6;164(9):530–2.

Age appropriateness and safety of electric outlet protectors for children. Ridenour MV. **Percept Mot Skills** 1997 Apr; 84(2):387–92

A review of successful transport and home injury interventions to guide developing countries. Forjuoh SN, et al. **Soc Sci Med** 1996 Dec;43(11):1551–60 (90 ref.)

Firearms prevalence and storage practices in Wisconsin households. Chatterjee BF, et al. **Wis Med J** 1996 May; 95(5):286–91

PSYCHOLOGY

You can't believe all that you're told: the issue of unvalidated questionnaires [comment] Scott I. **Inj Prev** 1997 Mar; 3(1):5–6. Comment on: Inj Prev 1997 Mar;3(1):29–34.

STATISTICS & NUMERICAL DATA

Risk of injury per hour of exposure to consumer products. Hayward G. **Accid Anal Prev** 1996 Jan;28(1):115–21

Risk factors for injuries among the elderly in Greece. Petridou E, et al. **Accid Anal Prev** 1996 May;28(3):333–8

Correlations between traffic, occupational, sports, and home accidents. Salminen S, et al. **Accid Anal Prev** 1997 Jan; 29(1):33–6

The beefburger injury: a retrospective survey. Jigjinni VS, et al. **BMJ** 1997 Sep 6;315(7108):580

The kerosene tragedy of 1994, an unusual epidemic of burns: epidemiological aspects and management of patients. Gupta M, et al. **Burns** 1996 Feb;22(1):3–9

Epidemiological survey of childhood burn injuries in France. Mercier C, et al. **Burns** 1996 Feb;22(1):29–34

Home accidents in Sri Lanka—multicentre study. Aloysius DJ, et al. **Ceylon Med J** 1996 Dec;41(4):151–4

Infant walker use, injuries, and motor development. Thein MM, et al. **Inj Prev** 1997 Mar;3(1):63–6

Childhood accidents at home. Laffoy M. **Ir Med J** 1997 Jan–Feb;90(1):26–7

Extremity lawn-mower injuries in children: report by the Research Committee of the Pediatric Orthopaedic Society of North America. Loder RT, et al. **J Pediatr Orthop** 1997 May–Jun;17(3):360–9

The characteristics and outcomes for patients presenting with unintentional domestic injuries to general practice. McLeod D, et al. **N Z Med J** 1996 Dec 13;109(1035):456–9

[The incidence and distribution of accidents with biological fluids among health personnel and the general population] Imaz Iglesia I, et al. **Gac Sanit** 1996 Nov–Dec;10(57):274–81 (Eng. Abstr.) **(Spa)**

[Burns are frequent among immigrant children] Svensson H, et al. **Lakartidningen** 1996 Oct 30;93(44):3905–6 **(Swe)**

ACCIDENTS, INDUSTRIAL see **ACCIDENTS, OCCUPATIONAL**

ACCIDENTS, NUCLEAR see **ACCIDENTS, RADIATION**

ACCIDENTS, NUCLEAR REACTOR see **ACCIDENTS, RADIATION**

ACCIDENTS, OCCUPATIONAL

The age-related risk of occupational accidents: the case of Swedish iron-ore miners. Laflamme L, et al. **Accid Anal Prev** 1996 May;28(3):349–57

Accidental firearm fatality involving a hand-crafted pen gun. Case report. Hartshorne NJ, et al. **Am J Forensic Med Pathol** 1997 Mar;18(1):92–5

Acute radiodermatitis from accidental overexposure to X-rays. Soleo L, et al. **Am J Ind Med** 1996 Aug; 30(2):207–11

An on-site job evaluation performed via activity analysis. Canelón MF, et al. **Am J Occup Ther** 1997 Feb;51(2):144–53

Determining injury at work on the California death certificate. Peek-Asa C, et al. **Am J Public Health** 1997 Jun;87(6):998–1002

Life-threatening airway obstruction from nitrous oxide induced frostbite of the oral cavity. Svartling N, et al. **Anaesth Intensive Care** 1996 Dec;24(6):717–20

Awake fibreoptic intubation in the semi-prone position following facial trauma. Neal MR, et al. **Anaesthesia** 1996 Nov;51(11):1053–4

Fatality due to acute fluoride poisoning following dermal contact with hydrofluoric acid in a palynology laboratory. Muriale L, et al. **Ann Occup Hyg** 1996 Dec;40(6):705–10

Vinblastine toxicity to the ocular surface. Chowers I, et al. **Anticancer Drugs** 1996 Sep;7(7):805–8

Surgical treatment of a macular hole secondary to accidental laser burn [letter] Ciulla TA, et al. **Arch Ophthalmol** 1997 Jul;115(7):929–30

Autopsy risk and acquisition of human immunodeficiency virus infection: a case report and reappraisal. Johnson MD, et al. **Arch Pathol Lab Med** 1997 Jan;121(1):64–6

Intralenticular metallic foreign body. Lee LR, et al. **Aust N Z J Ophthalmol** 1996 Nov;24(4):361–3

Narratives of risk in occupational health and safety: why the 'good' boss blames his tradesman and the 'good' tradesman blames his tools [see comments] Holmes N, et al. **Aust N Z J Public Health** 1997 Feb;21(1):11–6. Comment in: Aust N Z J Public Health 1997 Feb;21(1):9–10.

At work and play in a hazardous environment: injuries aboard a deployed U.S. Navy aircraft carrier. Krentz MJ, et al. **Aviat Space Environ Med** 1997 Jan;68(1):51–5

Respiratory morbidity 10 years after the Union Carbide gas leak at Bhopal: a cross sectional survey. The International Medical Commission on Bhopal [see comments] Cullinan P, et al. **BMJ** 1997 Feb 1;314(7077):338–42. Comment in: BMJ 1997 Feb 1;314(7077):342. Comment in: BMJ 1997 Feb 1;314(7077):343.

Commentary: industry can damage your health [comment] Garner P. **BMJ** 1997 Feb 1;314(7077):342. Comment on: BMJ 1997 Feb 1;314(7077):338–42.

Commentary: assessing the effects of environmental pollution when people know that they have been exposed [comment] Mayon-White RT. **BMJ** 1997 Feb 1;314(7077):343. Comment on: BMJ 1997 Feb 1;314(7077):338–42.

An unusual corneal injury [letter] Newsom RS, et al. **Br J Ophthalmol** 1996 Dec;80(12):1112–3

Cement-related burns. Morley SE, et al. **Burns** 1996 Dec; 22(8):646–7

Hyperbaric oxygen therapy [letter] Wallach SG, et al. **Burns** 1996 Aug;22(5):425

The lessons of Bhopal [toxic] MIC gas disaster scope for expanding global biomonitoring and environmental specimen banking. Sriramachari S, et al. **Chemosphere** 1997 May;34(9–10):2237–50

Working environments: an ecological approach to industrial health and safety. McEvoy AF. **Clio Med** 1997;41:59–89

The effect of load carrying and floor contaminants on slip and fall parameters. Myung R, et al. **Ergonomics** 1997 Feb; 40(2):235–46

Late consequences of accidental exposure to inhaled irritants: RADS and the Bhopal disaster [editorial; comment] Nemery B. **Eur Respir J** 1996 Oct;9(10):1973–6. Comment on: Eur Respir J 1996 Oct;9(10):1977–82.

Relationship between lung inflammation, changes in lung function and severity of exposure in victims of the Bhopal tragedy [see comments] Vijayan VK, et al. **Eur Respir J** 1996 Oct;9(10):1977–82. Comment in: Eur Respir J 1996 Oct;9(10):1973–6.

Usefulness of elastica-van Gieson stain for the pathomorphological diagnosis of a cutaneous electric mark—a fatal electrocution case during arc welding. Imamura T, et al. **Fukuoka Igaku Zasshi** 1997 Feb; 88(2):23–6

Electrical injury on removal of implantable defibrillator after death. Ghosh D, et al. **Heart** 1997 May;77(5):484–5

Ocular injury with xylene—a report of two cases. Ansari EA. **Hum Exp Toxicol** 1997 May;16(5):273–5

Replantation of four severed limbs in one patient. Pei GX, et al. **Injury** 1997 Jan;28(1):73–6

Dose-dependent elimination kinetics for mercury in urine: observations in subjects with brief but high-level exposure. Barregård L, et al. **Int Arch Occup Environ Health** 1996; 68(5):345–8

Nail gun injury: a barbed problem. Armstrong AP, et al. **J Accid Emerg Med** 1996 May;13(3):210

Protecting the public's health & investigating the potential for exposure: the BPS Chemical Company fire & explosion in West Helena. **J Ark Med Soc** 1997 Aug;94(3):125–6

Formic acid inhalation injury: a case report. Yelon JA, et al. **J Burn Care Rehabil** 1996 May–Jun;17(3):241–2

Industrial high-voltage electrical burn of the skull, a preventable injury. Wright HR, et al. **J Emerg Med** 1997 May–Jun;15(3):345–9

Colorectal injury by compressed air—a report of 2 cases. Suh HH, et al. **J Korean Med Sci** 1996 Apr;11(2):179–82

Percutaneous injuries during oral and maxillofacial surgery procedures. Carlton JE, et al. **J Oral Maxillofac Surg** 1997 Jun;55(6):553–6; discussion 556–7

Open anterior dislocation of the shoulder. Gregory PR Jr, et al. **J Orthop Trauma** 1996;10(2):128–30

Helicopter main rotor blade injury to the head with survival. Gibbons JR, et al. **J R Army Med Corps** 1997 Jun; 143(2):122–3

Autopenetrating hernia: a novel form of traumatic abdominal wall hernia—case report and review of the literature. Ganchi PA, et al. **J Trauma** 1996 Dec;41(6):1064–6 (31 ref.)

Acute lung injury after phosgene inhalation. Lim SC, et al. **Korean J Intern Med** 1996 Jan;11(1):87–92 (18 ref.)

Concentrations of dioxin 20 years after Seveso [letter] Landi MT, et al. **Lancet** 1997 Jun 21;349(9068):1811

A prospective study of hepatitis C virus infection after needlestick accidents. Arai Y, et al. **Liver** 1996 Oct; 16(5):331–4

The workplace athlete. Rozmaryn LM. **Md Med J** 1996 Aug; 45(8):647–54 (32 ref.)

Violence and work injury. A revealing look at turbulent times. Wheeler AH, et al. **N C Med J** 1996 Jan–Feb; 57(1):31–5

Long term morbidity in survivors of the 1984 Bhopal gas leak. Cullinan P, et al. **Natl Med J India** 1996 Jan–Feb; 9(1):5–10

A study of cognitive functions in methyl-iso-cyanate victims one year after bhopal accident. Misra UK, et al. **Neurotoxicology** 1997;18(2):381–6

Cause specific mortality and cancer incidence among employees exposed to 2,3,7,8-TCDD after a 1953 reactor accident. Ott MG, et al. **Occup Environ Med** 1996 Sep; 53(9):606–12

A deluge can save the eyes. Champagne R. **Occup Health Saf** 1994 Oct;63(10):69–72, 74

Prompt diagnosis, treatment critical in workplace burn emergency response. Scully T, et al. **Occup Health Saf** 1994 Mar;63(3):80–1

Emergency response to environmental toxic incidents: the role of the occupational physician. McCunney RJ. **Occup Med (Oxf)** 1996 Dec;46(6):397–401

Work-related accidents of ophthalmologic interest in Italy during 1986–1991. Cruciani F, et al. **Ophthalmologica** 1997; 211(4):251–5

Projectile metallic foreign bodies in the orbit: a retrospective study of epidemiologic factors, management, and outcomes. Finkelstein M, et al. **Ophthalmology** 1997 Jan;104(1):96–103

Ocular nail gun injuries. Lee BL, et al. **Ophthalmology** 1996 Sep;103(9):1453–7

The role of managed care in work-related injuries. Shor MJ, et al. **Orthop Clin North Am** 1996 Oct;27(4):711–21

Penetrating injury of the vertebral artery caused by a nail gun: preoperative embolization. Kaji T, et al. **Radiat Med** 1996 Mar–Apr;14(2):99–101

Long-term lung sequelae following accidental chlorine gas exposure. Schönhofer B, et al. **Respiration** 1996;63(3):155–9

Ammonia gassing deaths—a report on two cases. Chao TC, et al. **Singapore Med J** 1996 Apr;37(2):147–9 (11 ref.)

Clinics in diagnostic imaging (12). Iatrogenic pneumothorax. Irwin MG, et al. **Singapore Med J** 1996 Apr;37(2):212–5

Simultaneous open dislocations of the interphalangeal and metacarpo-phalangeal joints in a thumb—a case report. Lee JC, et al. **Singapore Med J** 1996 Jun;37(3):318–9 (7 ref.)

[Causality in insurance medicine] Heliövaara M, et al. **Duodecim** 1995;111(17):1688–93 **(Fin)**

[Degenerative diseases and trauma] Myllynen P. **Duodecim** 1995;111(17):1694–6 **(Fin)**

[Orthopedic indemnity for chronic low back pain. The experience of Division des Accidents du Travail du Service Médical de la Région Ile-de-France] Laburthe-Tolra Y, et al. **Chirurgie** 1996;121(8):601–7; discussion 607–8 (Eng. Abstr.) **(Fre)**

[Measures to take after exposure to blood (letter)] Rabaud C, et al. **Presse Med** 1997 May 17;26(16):769 **(Fre)**

[After accidental exposure to blood. What should be done?] Vayssettes JC, et al. **Presse Med** 1997 Apr 5;26(11):517–9 (25 ref.) **(Fre)**

[Myocardial infarct and rhabdomyolysis after a high-voltage accident with successful resuscitation] Franzius C, et al. **Dtsch Med Wochenschr** 1997 Mar 27;122(13):400–6 (22 ref.) (Eng. Abstr.) **(Ger)**

[Rehabilitation of hand injured co-workers from the occupational medicine viewpoint (exemplified by a chassis and montage automobile industry] Harwerth A. **Handchir Mikrochir Plast Chir** 1997 Jul;29(4):218–21 (Eng. Abstr.) **(Ger)**

[Burns risk caused by the interaction of NIR at radiofrequency and metal structures at a building site] Valoti E, et al. **G Ital Med Lav Ergon** 1996 Jan–May; 18(1–3):57–61 (Eng. Abstr.) **(Ita)**

[NO2 inhalation in two smokers and two non-smokers] Shimatsu Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Oct; 34(10):1145–9 (Eng. Abstr.) **(Jpn)**

[Case of toluene poisoning associated with acute kidney failure] Kadomitsu M, et al. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):120–1 **(Jpn)**

[A study of industrial poisoning from official reports of accident investigations] Katoh K, et al. **Sangyo Eiseigaku Zasshi** 1996 Jul;38(4):156–7 **(Jpn)**

[Amplified chemical disasters: a challenge for public health] de Freitas CM, et al. **Rev Saude Publica** 1995 Dec; 29(6):503–14 (75 ref.) (Eng. Abstr.) **(Por)**

[Chemical accidents and organization of medical services] Musiïchuk IuI. **Med Tr Prom Ekol** 1997;(6):27–30 (Eng. Abstr.) **(Rus)**

[The function of the hypothalamo-hypophyseal-adrenal system in participants in the cleanup of the aftereffects of the accident at the Chernobyl Atomic Electric Power

Station who have a neurocirculatory dystonia syndrome] Kovalenko AN, et al. **Ter Arkh** 1993;65(2):58–62 **(Rus)**

[An unusual penetrating wound of the abdomen by a tree trunk] Tufanov SA. **Vestn Khir Im I I Grek** 1996;155(2):57 **(Rus)**

[Traumatic asphyxia and continuous venovenous hemofiltration. Report of a case] Casas ML, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):30–2 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Conceptual and definitional issues in occupational injury epidemiology. Hagberg M, et al. **Am J Ind Med** 1997 Aug; 32(2):106–15

ECONOMICS

The occupational disease and injury compensatory system in the Czech Republic. Hrnčíř E, et al. **Am J Ind Med** 1997 Apr;31(4):381–4

Occupational injury and illness in the United States. Estimates of costs, morbidity, and mortality. Leigh JP, et al. **Arch Intern Med** 1997 Jul 28;157(14):1557–68

A comparison of results of arthroscopic-assisted anterior cruciate ligament reconstruction between workers' compensation and noncompensation patients. Noyes FR, et al. **Arthroscopy** 1997 Aug;13(4):474–84

Workplace injuries and the role of insurance: claims costs, outcomes, and incentives. Durbin D. **Clin Orthop** 1997 Mar; (336):18–32

The Work Rehabilitation Impact Quotient: a tool to assess the effectiveness of early rehabilitation of injured workers. Caradoc-Davies T, et al. **Disabil Rehabil** 1996 Dec; 18(12):613–8

The value of in-house physical therapy. Grayzel EF, et al. **J Occup Environ Med** 1997 Apr;39(4):344–6

Occupational disease and injury and state compensation. Brooks A. **J R Soc Health** 1997 Apr;117(2):123–6

Characteristics and cost of staff injuries in a forensic hospital. Hillbrand M, et al. **Psychiatr Serv** 1996 Oct;47(10):1123–5

LEGISLATION & JURISPRUDENCE

No-fault liability—twenty years experience in New Zealand. Lewis A. **Med Law** 1996;15(3):425–8

The law of workplace violence. Mathiason GG, et al. **Occup Med** 1996 Apr-Jun;11(2):315–34 (96 ref.)

Assessment of disability under the Social Security Industrial Injuries Benefit Scheme. Brooks A, et al. **Occup Med (Oxf)** 1997 Feb;47(2):112–6

[Labor union medical treatment guidelines—new quality criteria after adoption of SGB VII] Förster B. **Chirurg** 1997 May;68(5):Suppl 132–3 **(Ger)**

[Return to work after occupational accidents and occupational diseases] Mehrhoff F. **Rehabilitation (Stuttg)** 1997 May;36(2):84–91 (Eng. Abstr.) **(Ger)**

[Death at the work site] Betz P, et al. **Versicherungsmedizin** 1996 Feb 1;48(1):2–4 (Eng. Abstr.) **(Ger)**

[Drugs and occupational accident] Bratzke H, et al. **Versicherungsmedizin** 1996 Feb 1;48(1):4–6 (Eng. Abstr.) **(Ger)**

[Traumatic splenic rupture—fatal increase in thrombocytes after splenectomy] Schulz F, et al. **Versicherungsmedizin** 1997 Apr 1;49(2):56–8 (Eng. Abstr.) **(Ger)**

[The indemnification of accidents in itinere in the military medicolegal field] Rotondo G. **Riv Med Aeronaut Spaz** 1975 Apr-Sep;38(2-3):317–26 (Eng. Abstr.) **(Ita)**

MORTALITY

Fatal occupational falls in the U.S. construction industry, 1980–1989. Cattledge GH, et al. **Accid Anal Prev** 1996 Sep; 28(5):647–54

Farm-related injury mortality in New Mexico, 1980–91. Crandall CS, et al. **Accid Anal Prev** 1997 Mar;29(2):257–61

Years of potential life lost and lost future productivity due to occupational fatalities—Alaska, 1990–1994. Klatt ML, et al. **Alaska Med** 1995 Oct-Dec;37(4):123–5

Commercial logging fatalities in Ontario, 1986–1991. West R, et al. **Am J Forensic Med Pathol** 1996 Dec;17(4):299–304

Working lifetime risk of occupational fatal injury. Fosbroke DE, et al. **Am J Ind Med** 1997 Apr;31(4):459–67

Mortality among a cohort of electric utility workers, 1960–1991. Kelsh MA, et al. **Am J Ind Med** 1997 May; 31(5):534–44

Traumatic occupational fatalities in the U.S. and Australian construction industries. Ore T, et al. **Am J Ind Med** 1996 Aug;30(2):202–6

Fatalities in the construction industry in the United States, 1992 and 1993. Pollack ES, et al. **Am J Ind Med** 1996 Sep; 30(3):325–30

Fatal agricultural injuries in North Carolina by race and occupation, 1977–1991. Richardson D, et al. **Am J Ind Med** 1997 Apr;31(4):452–8

A cohort mortality study of construction workers. Sun J, et al. **Am J Ind Med** 1997 Jul;32(1):35–41

Suicides, homicides, and accidental death: a comparative risk assessment of police officers and municipal workers. Violanti JM, et al. **Am J Ind Med** 1996 Jul;30(1):99–104

Trends in fatal occupational injuries and industrial restructuring in North Carolina in the 1980s. Richardson D, et al. **Am J Public Health** 1997 Jun;87(6):1041–3

Population-based description of aircraft accident mortality, U.S. military, 1980–90. Ungs TJ. **Aviat Space Environ Med** 1996 Jan;67(1):70–3

Influence of occupational accidents and deaths related to lifestyle on mortality among merchant seafarers. Hansen HL, et al. **Int J Epidemiol** 1996 Dec;25(6):1237–43

Occupational fatalities in Kentucky—1994. Struttmann TW, et al. **J Ky Med Assoc** 1996 Sep;94(9):395–400

An epidemiological study of roadway fatalities related to farm vehicles: United States, 1988 to 1993. Gerberich SG, et al. **J Occup Environ Med** 1996 Nov;38(11):1135–40

Occupational fatalities caused by contact with overhead power lines in the construction industry. Janicak CA. **J Occup Environ Med** 1997 Apr;39(4):328–32

Electrical fatalities among U.S. construction workers. Ore T, et al. **J Occup Environ Med** 1996 Jun;38(6):587–92

Machinery-related occupational fatalities in the United States, 1980 to 1989. Pratt SG, et al. **J Occup Environ Med** 1996 Jan;38(1):70–6

Five years of work-related injuries and fatalities in Minnesota. Agriculture: a high-risk industry. Brown M, et al. **Minn Med** 1997 Aug;80(8):29–32

Work-related aviation fatalities—Alaska, 1990–1994. **MMWR Morb Mortal Wkly Rep** 1997 Jun 6;46(22):496–8

Suffocations in grain bins—Minnesota, 1992–1995. **MMWR Morb Mortal Wkly Rep** 1996 Oct 4;45(39):837–41

Skid-steer loader-related fatalities in the workplace—United States, 1992–1995. **MMWR Morb Mortal Wkly Rep** 1996 Jul 26;45(29):624–8

A nested case-control study of fatal work related injuries among Brazilian steel workers. Barreto SM, et al. **Occup Environ Med** 1997 Aug;54(8):599–604

Highway fatalities: leading cause of work-related deaths. Personick M, et al. **Stat Bull Metrop Insur Co** 1997 Apr-Jun;78(2):19–25

University of Wisconsin agricultural safety and health activities. Purschwitz M. **Wis Med J** 1997 Aug;96(8):25–9

[Occupation and illness] Schaefer H. **Gesundheitswesen** 1996 Aug-Sep;58(8–9):442–6 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Prospects for technological countermeasures against driver fatigue. Brown ID. **Accid Anal Prev** 1997 Jul;29(4):525–31

The influence of sustained attention on railway accidents. Edkins GD, et al. **Accid Anal Prev** 1997 Jul;29(4):533–9

Balancing work and rest to combat driver fatigue: an investigation of two-up driving in Australia. Feyer AM, et al. **Accid Anal Prev** 1997 Jul;29(4):541–53

Fatigue, workload and adaptive driver systems. Hancock PA, et al. **Accid Anal Prev** 1997 Jul;29(4):495–506

Should people taking opioids for medical reasons be allowed to work and drive? [editorial] Zacny JP. **Addiction** 1996 Nov;91(11):1581–4 (16 ref.)

The Safe Teen Work Project: a study to reduce cutting injuries among young and inexperienced workers. Banco L, et al. **Am J Ind Med** 1997 May;31(5):619–22

Designing prevention-oriented software for workplace health and safety. Maizlish N. **Am J Ind Med** 1997 Jan; 31(1):64–74

Program to Reduce Exposure by Surveillance System (PRESS) in Taiwan: experiences of closing the surveillance gap [letter; comment] Wu TN, et al. **Am J Ind Med** 1997 Apr;31(4):479–80. Comment on: Am J Ind Med 1996 Feb;29(2):223–4.

Design and conduct of occupational injury intervention studies: a review of evaluation strategies. Zwerling C, et al. **Am J Ind Med** 1997 Aug;32(2):164–79 (105 ref.)

Device-specific sharps injury and usage rates: an analysis by hospital department. Patel N, et al. **Am J Infect Control** 1997 Apr;25(2):77–84

Influence of blunt needles on surgical glove perforation and safety for the surgeon. Mingoli A, et al. **Am J Surg** 1996 Nov;172(5):512–6; discussion 516–7

U.S. naval aviation mishaps, 1977–92: differences between single- and dual-piloted aircraft. Shappell SA, et al. **Aviat Space Environ Med** 1996 Jan;67(1):65–9

Some aspects of the safety of high speed catamarans. Grainger R. **Bull Inst Marit Trop Med Gdynia** 1996; 47(1–4):61–6

A comparison of risk assessment of single and combination manual handling tasks: 1. maximum acceptable weight measures [published erratum appears in Ergonomics 1997 Jun;40(6):656] Straker LM, et al. **Ergonomics** 1996 Jan; 39(1):128–40

Tipping of Bird VIP ventilators. **Health Devices** 1996 Aug; 25(8):311

The risk of explosions when handling liquid nitrogen in Delasco glass-bottle thermos-type Cryo-Tainers. **Health Devices** 1997 Apr;26(4):177–9

Randomized prospective study of the impact of three needleless intravenous systems on needlestick injury rates. L'Ecuyer PB, et al. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):803–8

Assigned versus participative goal setting and response generalization: managing injury control among professional pizza deliverers. Ludwig TD, et al. **J Appl Psychol** 1997 Apr;82(2):253–61

Steam press hand burns: a serious burn injury. Woods JA, et al. **J Emerg Med** 1996 May-Jun;14(3):357–60

Preventive medicine and health promotion are overdue in the agricultural workplace. Schenker MB. **J Public Health Policy** 1996;17(3):275–305 (95 ref.)

From the Centers for Disease Control and Prevention. Use of rollover protective structures--Iowa, Kentucky, New York, and Ohio, 1992–1997. **JAMA** 1997 Oct 8; 278(14):1144–5

From the Centers for Disease Control and Prevention. Evaluation of safety devices for preventing percutaneous injuries among health-care workers during phlebotomy procedures--Minneapolis-St Paul, New York City, and San Francisco, 1993–1995. **JAMA** 1997 Feb 12; 277(6):449–50

From the Centers for Disease Control and Prevention. Evaluation of blunt suture needles in preventing percutaneous injuries among health-care workers during gynecologic surgical procedures--New York City, March 1993–June 1994. **JAMA** 1997 Feb 12;277(6):451–2

Evaluation of safety devices for preventing percutaneous injuries among health-care workers during phlebotomy procedures—Minneapolis-St. Paul, New York City, and San Francisco, 1993–1995. **MMWR Morb Mortal Wkly Rep** 1997 Jan 17;46(2):21–5

Evaluation of blunt suture needles in preventing percutaneous injuries among health-care workers during gynecologic surgical procedures--New York City, March 1993–June 1994. **MMWR Morb Mortal Wkly Rep** 1997 Jan 17; 46(2):25–9

Use of rollover protective structures -- Iowa, Kentucky, and Ohio, 1992–1997. **MMWR Morb Mortal Wkly Rep** 1997 Sep 12;46(36):842–5

Stemming the tide of work-related illness and injury [letter] Dineen JR. **N C Med J** 1996 May-Jun;57(3):128–9

The interlink needleless intravenous system did not reduce the number of needlestick injuries in Christchurch hospital operating theatres. MacPherson J. **N Z Med J** 1996 Oct 11;109(1031):387–8

Class distinctions. Those who don't distinguish their flammable liquids' flashpoint classes, storage specifications and compliance codes can wind up trying to extinguish a blaze. Buric A. **Occup Health Saf** 1994 Nov;63(11):42–4, 50

Eyewear lenses change shape, tint for protection in wide variety of jobs. Campbell SL. **Occup Health Saf** 1994 Feb; 63(2):52–4

Waste away. Campbell SL. **Occup Health Saf** 1994 Oct; 63(10):160–4, 166

Managing the MSDS mess. Helmrich DM. **Occup Health Saf** 1996 Mar;65(3):47–8

Chipping and grinding away at vision protection. Johnson LF. **Occup Health Saf** 1996 Mar;65(3):56

Educating workers on the need for a firm, safe footing. Johnson LF. **Occup Health Saf** 1997 Jul;66(7):20–7, 36 (0 ref.)

The missing letter in TQM. Quality principles are tailor-made for safety. Jonas P. **Occup Health Saf** 1996 Mar;65(3):18–9

Study options on respiratory protection before permitting confined space entry. Matranga B, et al. **Occup Health Saf** 1994 May;63(5):64–7, 72

In plane view: blind spots and visual limits. Miller BC. **Occup Health Saf** 1994 May;63(5):98–102

Alarming readings. Rekus J. **Occup Health Saf** 1994 Oct; 63(10):59–62, 64, 66–7

Detecting invisible risks. Rekus JF. **Occup Health Saf** 1994 May;63(5):46–8, 50, 52, passim

Ready for the road. Schmitt D. **Occup Health Saf** 1996 Mar; 65(3):51–4

Tools for developing a workplace violence prevention program. Askari E. **Occup Med** 1996 Apr-Jun;11(2):363–74 (5 ref.)

Organizational factors in workplace violence: developing effective programs to reduce workplace violence. Baron SA. **Occup Med** 1996 Apr-Jun;11(2):335–48 (11 ref.)

Policies for developing workplace violence prevention strategies. Cabral R. **Occup Med** 1996 Apr-Jun; 11(2):303–14 (32 ref.)

Improving workplace security. D'Addario FJ. **Occup Med** 1996 Apr-Jun;11(2):349–61 (15 ref.)

Retail employees as a group at risk for violence. Erickson RJ. **Occup Med** 1996 Apr-Jun;11(2):269–76 (21 ref.)

Surveillance and investigation of homicides at work: California fatality assessment and control evaluation program. Harrison R, et al. **Occup Med** 1996 Apr-Jun; 11(2):243–55 (56 ref.)

State and local regulatory approaches to preventing workplace violence. Howard J. **Occup Med** 1996 Apr-Jun; 11(2):293–301 (20 ref.)

Health care workers and workplace violence. Simonowitz JA. **Occup Med** 1996 Apr-Jun;11(2):277–91 (43 ref.)

The perceptions of line and senior managers in relation to occupational health issues. Falconer L, et al. **Occup Med (Oxf)** 1996 Apr;46(2):151–6

New safety skin hooks. Brooks JG, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):135–6

OSHA guidelines aim at reducing violence in health care settings [news] **Psychiatr Serv** 1996 Aug;47(8):891–2

Major chemical accidents in industrializing countries: the socio-political amplification of risk. de Souza Porto MF, et al. **Risk Anal** 1996 Feb;16(1):19–29

Occupational health [editorial; comment] Roche DA. **Trop Doct** 1996 Jul;26(3):98–9. Comment on: Trop Doct 1996 Jul;26(3):102–4.

Farm injuries don't just involve farmers [editorial] Purschwitz MA. **Wis Med J** 1997 Aug;96(8):9

[Revision of the brochure "Hygiene, Accident Prevention and First Aid" and "Recommendations for HIV-Post-Exposure Preventive Management] Juhl K, et al. **Chirurg** 1997 Mar;68(3):suppl 86-7 **(Ger)**

[Health promotion in the work environment--old and new challenges for public health] Hacker W, et al. **Gesundheitswesen** 1996 Sep;58 Suppl 2:152-4 (Eng. Abstr.) **(Ger)**

[The risk of needle-stick-injuries during abdominal closure] Meyer D, et al. **Zentralbl Chir** 1996;121(1):30-4 (Eng. Abstr.) **(Ger)**

[The social hygiene problems in preventing military job-related traumatism] Ian'shin LA. **Voen Med Zh** 1997 Feb;318(2):50-3 **(Rus)**

PSYCHOLOGY

Risk perception following exposure to a job-related electrocution accident: the mediating role of perceived control. Greening L. **Acta Psychol (Amst)** 1997 Apr; 95(3):267-77

I. Do chronic pain patients' perceptions about their preinjury jobs determine their intent to return to the same type of job post-pain facility treatment? Fishbain DA, et al. **Clin J Pain** 1995 Dec;11(4):267-78

II. Do chronic pain patients' perceptions about their preinjury jobs differ as a function of worker compensation and non-worker compensation status? Rosomoff HL, et al. **Clin J Pain** 1995 Dec;11(4):279-86

The role of the human spirit in recovery from injury. Miller M. **Occup Health Saf** 1994 Oct;63(10):167-70, 193

Electromyography and chronic pain: do current electromyographic diagnostic techniques discriminate against injured female workers? Biedermann HJ, et al. **Percept Mot Skills** 1996 Aug;83(1):28-30

Psychological testing variables as predictors of return to work by chronic pain patients. Robbins RA, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1317-8

Predicting accidents at work with measures of locus of control and job hazards. Janicak CA. **Psychol Rep** 1996 Feb;78(1):115-21

Explaining disablement in modern times: hand-injured workers' accounts of their injuries in Hong Kong. Cheng YH. **Soc Sci Med** 1997 Sep;45(5):739-50

STATISTICS & NUMERICAL DATA

Work-related injuries in a rural emergency department population. Williams JM, et al. **Acad Emerg Med** 1997 Apr; 4(4):277-81

The impact of major transformations of a production process on age-related accident risks: a study of an iron-ore mine. Blank VL, et al. **Accid Anal Prev** 1996 Sep;28(5):627-36

Nonfatal occupational fall injuries in the West Virginia construction industry. Cattledge GH, et al. **Accid Anal Prev** 1996 Sep;28(5):655-63

Motor vehicle accidents, fatigue and optimism bias in taxi drivers. Dalziel JR, et al. **Accid Anal Prev** 1997 Jul; 29(4):489-94

Black times: temporal determinants of transport safety. Folkard S. **Accid Anal Prev** 1997 Jul;29(4):417-30 (25 ref.)

Medical conditions and the severity of commercial motor vehicle drivers' road accidents. Laberge-Nadeau C, et al. **Accid Anal Prev** 1996 Jan;28(1):43-51

Medications as risk factors for farm injury. Pickett W, et al. **Accid Anal Prev** 1996 Jul;28(4):453-62

Correlations between traffic, occupational, sports, and home accidents. Salminen S, et al. **Accid Anal Prev** 1997 Jan; 29(1):33-6

Alcohol and occupational injuries among older workers. Zwerling C, et al. **Accid Anal Prev** 1996 May;28(3):371-6

Work-related injuries to Massachusetts teens, 1987-1990. Brooks DR, et al. **Am J Ind Med** 1996 Feb;29(2):153-60

Advancing epidemiologic studies of occupational injury--approaches and future directions. Burdorf A, et al. **Am J Ind Med** 1997 Aug;32(2):180-3

Follow-back study of oldest workers with emergency department-treated injuries. Castillo D, et al. **Am J Ind Med** 1997 May;31(5):609-18

Methodological challenges to the study of occupational injury--an international epidemiology workshop. Courtney TK, et al. **Am J Ind Med** 1997 Aug;32(2):103-5 (15 ref.)

Working lifetime risk of occupational fatal injury. Fosbroke DE, et al. **Am J Ind Med** 1997 Apr;31(4):459-67

Occupational injuries and medication use. Gilmore TM, et al. **Am J Ind Med** 1996 Aug;30(2):234-9

Design factors in epidemiologic cohort studies of work-related low back injury or pain. Kraus JF, et al. **Am J Ind Med** 1997 Aug;32(2):153-63 (50 ref.)

Age-related accident risks: longitudinal study of Swedish iron ore miners. Laflamme L, et al. **Am J Ind Med** 1996 Oct;30(4):479-87

Alternative approaches to analytical designs in occupational injury epidemiology. Mittleman MA, et al. **Am J Ind Med** 1997 Aug;32(2):129-41 (58 ref.)

Injury and illness in the American workplace: a comparison of data sources. Murphy PL, et al. **Am J Ind Med** 1996 Aug;30(2):130-41

Falls in construction: injury rates for OSHA-inspected employers before and after citation for violating the Washington State Fall Protection Standard. Nelson NA, et al. **Am J Ind Med** 1997 Mar;31(3):296-302

Machinery-related fatalities in the construction industry. Pratt SG, et al. **Am J Ind Med** 1997 Jul;32(1):42-50

Acute work injuries among electric utility linemen. Sahl JD, et al. **Am J Ind Med** 1997 Feb;31(2):223-32

Workplace organizational correlates of lost-time accident rates in manufacturing. Shannon HS, et al. **Am J Ind Med** 1996 Mar;29(3):258-68 (17 ref.)

Three perspectives on work-related injury surveillance systems. Sorock GS, et al. **Am J Ind Med** 1997 Aug; 32(2):116-28

Epidemiologic study of occupational injuries among foreign and native workers in Taiwan. Wu TN, et al. **Am J Ind Med** 1997 May;31(5):623-30

Influence of blunt needles on surgical glove perforation and safety for the surgeon. Mingoli A, et al. **Am J Surg** 1996 Nov;172(5):512-6; discussion 516-7

Occupational injuries among adolescents in Dunedin, New Zealand, 1990-1993. Dufort VM, et al. **Ann Emerg Med** 1997 Sep;30(3):266-73

Occupational injury and illness in the United States. Estimates of costs, morbidity, and mortality. Leigh JP, et al. **Arch Intern Med** 1997 Jul 28;157(14):1557-68

Occupational injuries among fishermen. Jensen OC, et al. **Bull Inst Marit Trop Med Gdynia** 1996;47(1-4):11-8

Mortality in Danish fishermen. Jensen OC. **Bull Inst Marit Trop Med Gdynia** 1996;47(1-4):5-10

Non-tractor, agricultural machinery injuries in Ontario. Hartling L, et al. **Can J Public Health** 1997 Jan-Feb; 88(1):32-5

Using Labour Force Survey and census data to generate denominators for occupational injury rates: an application and expansion of Haggar-Guénette's method. Rael EG, et al. **Chronic Dis Can** 1996;17(3-4):87-91

The true rates of injury among workers in New Zealand: comparing 1986 and 1991. Caradoc-Davies T, et al. **Disabil Rehabil** 1997 Jul;19(7):285-92

Acute work injuries among electric utility meter readers. Sahl JD, et al. **Epidemiology** 1997 May;8(3):287-92

Human resources. Home is where the harm is [news] **Hosp Health Netw** 1997 May 20;71(10):22

National survey on accidental low back pain in workplace. Kuwashima A, et al. **Ind Health** 1997 Apr;35(2):187-93

Injury, death, and the deregulation fetish: the politics of occupational safety regulation in U.K. manufacturing industries. Tombs S. **Int J Health Serv** 1996;26(2):309-29 (73 ref.)

Accidental exposures to blood and body fluids among health care workers in dental teaching clinics: a prospective study. Ramos-Gomez F, et al. **J Am Dent Assoc** 1997 Sep; 128(9):1253-61

Predisposing factors to industrial hand injuries in Saudi Arabia. al Zahrani S, et al. **J Hand Surg [Br]** 1997 Feb; 22(1):131-2

Pattern of injuries in a hydro-electric project. Malhotra P, et al. **J Indian Med Assoc** 1995 May;93(5):171-2

Tool-related injuries among amateur and professional woodworkers. Becker TM, et al. **J Occup Environ Med** 1996 Oct;38(10):1032-5

Recording, notification, compilation, and classification of statistics of occupational accidents and diseases: the Thai experience. Choi BC. **J Occup Environ Med** 1996 Nov; 38(11):1151-60

Patterns and risk factors for sprains and strain in Ontario, Canada 1990: an analysis of the Workplace Health and Safety Agency data base. Choi BC, et al. **J Occup Environ Med** 1996 Apr;38(4):379-89

Epidemiology of hazardous materials responses by Massachusetts district HAZMAT teams. Kales SN, et al. **J Occup Environ Med** 1996 Apr;38(4):394-400

Occupational fatalities among older workers in the United States: 1980-1991. Kisner SM, et al. **J Occup Environ Med** 1997 Aug;39(8):715-21

Comparison of disability behavior after different sites and types of injury in a workers' compensation population. Menard MR. **J Occup Environ Med** 1996 Nov; 38(11):1161-70

Occupational disease surveillance using disability insurance at an automotive stamping and assembly complex. Park RM, et al. **J Occup Environ Med** 1996 Nov;38(11):1111-23

Occupational injuries among urban recyclers. Rendleman N, et al. **J Occup Environ Med** 1997 Jul;39(7):672-5

Glove failure: an occupational hazard of surgeons in a developing country. Gunasekera PC, et al. **J R Coll Surg Edinb** 1997 Apr;42(2):95-7

Accidental injuries associated with nonhuman primate exposure at two regional primate research centers (USA): 1988-1993. bin Zakaria M, et al. **Lab Anim Sci** 1996 Jun; 46(3):298-304

Reporting occupational illnesses and injuries in North Carolina. An update for physicians. Jones B, et al. **N C Med J** 1997 Sep-Oct;58(5):350-3

Needle stick injuries in country general practice. Lum D, et al. **N Z Med J** 1997 Apr 11;110(1041):122-5

Industrial accidents are related to relative body weight: the Israeli CORDIS study. Froom P, et al. **Occup Environ Med** 1996 Dec;53(12):832-5

Accidents related to manure in eastern Switzerland: an epidemiological study. Knoblauch A, et al. **Occup Environ Med** 1996 Sep;53(9):577-82

Epidemiology of violence and theft in the workplace. Bachman R. **Occup Med** 1996 Apr-Jun;11(2):237-41 (9 ref.)

Public employees as a group at risk for violence. Barab J. **Occup Med** 1996 Apr-Jun;11(2):257-67 (34 ref.)

Workplace homicide: industries and occupations at high risk. Jenkins EL. **Occup Med** 1996 Apr-Jun;11(2):219-25 (15 ref.)

Epidemiology of violent injury in the workplace. Kraus JF, et al. **Occup Med** 1996 Apr-Jun;11(2):201-17 (42 ref.)

Workplace violence: an analysis of bureau of labor statistics data. Toscano G. **Occup Med** 1996 Apr-Jun;11(2):227-35

Ocular trauma in an iron forging industry in the eastern province, Saudi Arabia. Ballal SG. **Occup Med (Oxf)** 1997 Feb;47(2):77-80

Occupational injuries in the Finnish furniture industry. Aaltonen MV. **Scand J Work Environ Health** 1996 Jun; 22(3):197-203

Injuries related to logging: epidemiology, etiology and implications for prevention. Williams JM, et al. **W V Med J** 1996 Nov-Dec;92(6):320-3

[An analysis of 148 outpatient treated occupational accidents] Nicaeus T, et al. **Klin Monatsbl Augenheilkd** 1996 Oct; 209(4):A7-11 (Eng. Abstr.) **(Ger)**

[Occupational injuries and prolonged sick listings during the period 1989-93] Lien L, et al. **Tidsskr Nor Laegeforen** 1997 May 10;117(12):1774-8 (Eng. Abstr.) **(Nor)**

[Serious childhood accidents involving tractors] Rodríguez Núñez A, et al. **An Esp Pediatr** 1996 May;44(5):461-3 (Eng. Abstr.) **(Spa)**

[The incidence and distribution of accidents with biological fluids among health personnel and the general population] Imaz Iglesia I, et al. **Gac Sanit** 1996 Nov-Dec;10(57):274-81 (Eng. Abstr.) **(Spa)**

ACCIDENTS, RADIATION

see related
RADIATION INJURIES

Cytologic characteristics of pediatric thyroid carcinoma around Chernobyl, Republic of Belarus [letter] Ito M, et al. **Acta Cytol** 1997 Sep-Oct;41(5):1642-4

Thyroid ultrasound findings 7 years after the Chernobyl accident. A comparative epidemiological study in the Bryansk region of Russia. Kumpusalo L, et al. **Acta Radiol** 1996 Nov;37(6):904-9

Osteogenic sarcoma of the maxillary alveolus occurring five years following the Chernobyl nuclear accident. Harvey RT, et al. **Am J Otolaryngol** 1996 May-Jun;17(3):210-4

Morphometry and densitometry of alveolar macrophage cytoplasmic particles in Chernobyl, Ukraine, liquidators. Charpin C, et al. **Anal Quant Cytol Histol** 1997 Feb; 19(1):37-44

Sperm angiotensin-converting enzyme activity in Chernobyl victims and patients with chronic prostatitis. Sakharov IYu, et al. **Andrologia** 1996 Sep-Oct;28(5):259-60

Ten years after Chernobyl. Rytömaa T. **Ann Med** 1996 Apr; 28(2):83-7 (48 ref.)

Chernobyl: after ten years, consequences are showing up [news] **Ann Oncol** 1996 Jul;7(5):430

Fibrosarcoma of the thyroid in a man exposed to fallout from the Chernobyl accident. Sichel JY, et al. **Ann Otol Rhinol Laryngol** 1996 Oct;105(10):832-4

129I and 36Cl concentrations in lichens collected in 1990 from three regions around Chernobyl. Chant LA, et al. **Appl Radiat Isot** 1996 Sep-Oct;47(9-10):933-7

Criticality accident dosimetry with ESR spectroscopy. d'Errico F, et al. **Appl Radiat Isot** 1996 Nov-Dec; 47(11-12):1335-9

Gamma-ray dose assessment after the 1994 radiation accident in Kiisa (Estonia): preliminary results. Hütt G, et al. **Appl Radiat Isot** 1996 Nov-Dec;47(11-12):1329-34

ESR dosimetry of a deceased radiation worker. Ikeya M, et al. **Appl Radiat Isot** 1996 Nov-Dec;47(11-12):1341-4

Radiation dosimetry of an accidental overexposure using EPR spectrometry and imaging of human bone. Schauer DA, et al. **Appl Radiat Isot** 1996 Nov-Dec; 47(11-12):1345-50

EPR-based dosimetry of large dimensional radiation fields (Chernobyl experience and new approaches). Usatyi AF, et al. **Appl Radiat Isot** 1996 Nov-Dec;47(11-12):1351-6

Radiation lentigo. A distinct cutaneous lesion after accidental radiation exposure. Peter RU, et al. **Arch Dermatol** 1997 Feb;133(2):209-11

Hematological malignancies in the Republic of Belarus after the Chernobyl accident. Ivanov E, et al. **Bull Soc Sci Med Grand Duche Luxemb** 1996;133(2):41-5

Hematopoiesis research in aplastic anaemia induced by accidental protracted radiation. Socié G, et al. **C R Acad Sci III** 1996 Aug;319(8):711-6

Absence of G(s)alpha gene mutations in childhood thyroid tumors after Chernobyl in contrast to sporadic adult thyroid neoplasia. Waldmann V, et al. **Cancer Res** 1997 Jun 15;57(12):2358-61

Analysis of blood lymphocyte subsets in children living on territory that received high amounts of fallout from Chernobyl accident. Chernyshov VP, et al. **Clin Immunol Immunopathol** 1997 Aug;84(2):122-8

131I dose-dependent thyroid autoimmune disorders in children living around Chernobyl. Vykhovanets EV, et al. **Clin Immunol Immunopathol** 1997 Sep;84(3):251-9

Childhood cancer 10 years after the Chernobyl accident. Schwenn MR, et al. **Curr Opin Pediatr** 1997 Feb;9(1):51-4 (26 ref.)

Childhood thyroid cancer following the Chernobyl accident: a status report [published erratum appears in Endocrinol Metab Clin North Am 1996 Jun;25(2):xi] Becker DV, et

al. **Endocrinol Metab Clin North Am** 1996 Mar; 25(1):197–211 (55 ref.)
External radiation and thyroid neoplasia. Sarne D, et al. **Endocrinol Metab Clin North Am** 1996 Mar;25(1):181–95 (48 ref.)
Revisiting Three Mile Island [news] **Environ Health Perspect** 1997 Jan;105(1):22–3
Radiation exposure and cancer: a simpler view of Three Mile Island [letter] Berg GG. **Environ Health Perspect** 1997 Jun; 105(6):566
Epidemiology of accidental radiation exposures. Cardis E. **Environ Health Perspect** 1996 May;104 Suppl 3:643–9 (64 ref.)
Comments on "A reevaluation of cancer incidence near the Three Mile Island nuclear plant" [letter; comment] [see comments] Hatch M, et al. **Environ Health Perspect** 1997 Jan;105(1):12. Comment on: Environ Health Perspect 1997 Jan;105(1):52–7. Comment in: Environ Health Perspect 1997 Mar;105(3):266–8.
Consequences of the 1979 Three Mile Island accident continued: further comment [letter] Susser M. **Environ Health Perspect** 1997 Jun;105(6):566–70
A reevaluation of cancer incidence near the Three Mile Island nuclear plant: the collision of evidence and assumptions [see comments] Wing S, et al. **Environ Health Perspect** 1997 Jan;105(1):52–7. Comment in: Environ Health Perspect 1997 Jan;105(1):12.
Reply to comments on "A reevaluation of cancer incidence near the Three Mile Island" [letter; comment] Wing S, et al. **Environ Health Perspect** 1997 Mar;105(3):266–8. Comment on: Environ Health Perspect 1997 Jan;105(1):12.
Increased hprt mutant frequencies in Brazilian children accidentally exposed to ionizing radiation. Saddi V, et al. **Environ Mol Mutagen** 1996;28(3):267–75
Livebirths and induced abortions in Italy after the Chernobyl accident [letter] Spinelli A, et al. **Epidemiology** 1996 Nov; 7(6):653–4
Radiation and thyroid cancer. Pinchera A, et al. **Eur J Cancer Prev** 1996 Oct;5(5):386–8
Serum dipeptidyl peptidase IV activities in Czernobyl zone inhabitants exposed to the power-station catastrophe [letter] Sedo A, et al. **Eur J Clin Chem Clin Biochem** 1996 May;34(5):447–8
Birth prevalence of congenital malformations in Bavaria, Germany, after the Chernobyl accident. Irl C, et al. **Eur J Epidemiol** 1995 Dec;11(6):621–5
Chernobyl, low-dose radiation, and trisomy 21: possibly something to worry about. von Mühlendahl KE, et al. **Eur J Pediatr** 1996 Jul;155(7):612–4
Optimization of health protection of the public following a major nuclear accident: interaction between radiation protection and social and psychological factors. Allen PT, et al. **Health Phys** 1996 Nov;71(5):763–5
Long term radiocesium contamination of fruit trees following the Chernobyl accident. Antonopoulos-Domis M, et al. **Health Phys** 1996 Dec;71(6):910–4
Radiocesium contamination in a submediterranean semi-natural ecosystem following the Chernobyl accident: measurements and models. Antonopoulos-Domis M, et al. **Health Phys** 1997 Feb;72(2):243–55
Accidental radiation injury to the hand: anatomical and physiological considerations. Berger ME, et al. **Health Phys** 1997 Mar;72(3):343–8
Early dose assessment following severe radiation accidents. Goans RE, et al. **Health Phys** 1997 Apr;72(4):513–8
One decade after Chernobyl: summing up the consequences. Kaul A, et al. **Health Phys** 1996 Nov;71(5):634–40
Plutonium releases from the 1957 fire at Rocky Flats. Mongan TR, et al. **Health Phys** 1996 Oct;71(4):510–21
Plutonium release from the 903 pad at Rocky Flats. Mongan TR, et al. **Health Phys** 1996 Oct;71(4):522–31
Predictive and retrospective dose assessment [letter] Müller H, et al. **Health Phys** 1996 Nov;71(5):798–9
Modeling the washoff of 90Sr and 137Cs from an experimental plot established in the vicinity of the Chernobyl reactor. Nair SK, et al. **Health Phys** 1996 Dec; 71(6):896–909
Modeling the resuspension of radionuclides in Ukrainian regions impacted by Chernobyl fallout. Nair SK, et al. **Health Phys** 1997 Jan;72(1):77–85
Establishing protective long term measures after severe nuclear accidents using multiple criteria. Papazoglou IA, et al. **Health Phys** 1997 May;72(5):676–90; appendix 690–2
Collective biodosimetry as a dosimetric "gold standard": a study of three radiation accidents. Pass B, et al. **Health Phys** 1997 Mar;72(3):390–6
Applications of a self-collimating BGO detector system to radiological emergency response. Pernick A, et al. **Health Phys** 1997 Jan;72(1):136–40
Adaptation of ECOSYS-87 to Hong Kong environmental conditions. Poon CB, et al. **Health Phys** 1997 Jun; 72(6):856–64
ECOSYS-87: model calculations of the activity in cattle meat related to deposition time and feeding regimes after a nuclear fallout. Riesen TK, et al. **Health Phys** 1996 Dec; 71(6):863–9
Issues in establishing an aerosol radiological baseline for the waste isolation pilot plant near Carlsbad, New Mexico. Rodgers JC, et al. **Health Phys** 1997 Feb;72(2):300–8
137Cs urinary excretion by northwestern Italians ten years after the Chernobyl accident. Ropolo R, et al. **Health Phys** 1997 Sep;73(3):498–501
An analysis of time-dependence for Chernobyl fallout in Italy. Salvadori G, et al. **Health Phys** 1997 Jan;72(1):60–76
Reconstruction of doses and deposition in the western trace from the Chernobyl accident. Sikkeland T, et al. **Health Phys** 1997 May;72(5):750–8
Towards a generalized model for the primary and secondary contamination of lakes by Chernobyl-derived radiocesium. Smith JT, et al. **Health Phys** 1997 Jun;72(6):880–92
Incidence of neoplasms in ages 0–19 y in parts of Sweden with high 137Cs fallout after the Chernobyl accident. Tondel M, et al. **Health Phys** 1996 Dec;71(6):947–50
Survey of the 137Cs contamination in Belgium by in-situ gamma spectrometry, a decade after the Chernobyl accident. Uyttenhove J, et al. **Health Phys** 1997 Oct; 73(4):644–6
129I, 131I and 127I in animal thyroids after the Chernobyl nuclear accident. VanMiddlesworth L, et al. **Health Phys** 1997 Oct;73(4):647–50
The consequences of the Chernobyl accident one decade after the disaster. Jankowski J. **Int J Occup Med Environ Health** 1996;9(4):365–74 (18 ref.)
Chromosome translocations in thyroid tissues from Belarussian children exposed to radioiodine from the Chernobyl accident, measured by FISH-painting. Lehmann L, et al. **Int J Radiat Biol** 1996 Nov;70(5):513–6
Biodosimetry after accidental radiation exposure by conventional chromosome analysis and FISH. Lindholm C, et al. **Int J Radiat Biol** 1996 Dec;70(6):647–56
Unstable and stable chromosomal aberrations in lymphocytes of people exposed to Chernobyl fallout in Bryansk, Russia. Salomaa S, et al. **Int J Radiat Biol** 1997 Jan;71(1):51–9
Retrospective biodosimetry of Chernobyl clean-up workers using chromosome painting and conventional chromosome analysis. Snigiryova G, et al. **Int J Radiat Biol** 1997 Feb; 71(2):119–27
Determination of long-life radiocesiums Cs-134 and Cs-137 in food by gamma-ray spectrometry: summary of collaborative study. Beljaars PR, et al. **J AOAC Int** 1997 May-Jun;80(3):545–8
Thyroid cancer and the Chernobyl accident. Are long-term and long distance side effects of fall-out radiation greater than estimated? [letter; comment] Cetta F, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):2015–7. Comment on: J Clin Endocrinol Metab 1996 Jan;81(1):6–8. Comment on: J Clin Endocrinol Metab 1996 Jan;81(1);9–14.
Thyroid pathology in residents of the Kiev region, Ukraine, during pre- and post-Chernobyl periods. Avetisian IL, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):233–7
Latent thyroid pathology in residents of Kiev, Ukraine. Avetisian IL, et al. **J Environ Pathol Toxicol Oncol** 1996; 15(2–4):239–43
Chernobyl: 10 years later [news] [published erratum appears in J Nucl Med 1997 Feb;38(2):19N] Mettler FH Jr, et al. **J Nucl Med** 1996 Dec;37(12):24N, 26N–27N
An evaluation of the use of bronchopulmonary lavage in the treatment of plutonium oxide inhalation. Dean MR. **J R Nav Med Serv** 1997;82(3):188–96 (27 ref.)
Case control study of neuroblastoma in west-Germany after the Chernobyl accident. Michaelis J, et al. **Klin Padiatr** 1996 Jul-Aug;208(4):172–8
Going to Extremes. Feldman MK. **Minn Med** 1997 Jan; 80(1):8–10
Chromosome analysis of peripheral lymphocytes from persons exposed to radioactive fallout in Norway from the Chernobyl accident. Brøgger A, et al. **Mutat Res** 1996 Dec 12;361(2–3):73–9
Radiation risk estimation in human populations: lessons from the radiological accident in Brazil. da Cruz AD, et al. **Mutat Res** 1997 Feb 3;373(2):207–14
Oxidative stress-related clastogenic factors in plasma from Chernobyl liquidators: protective effects of antioxidant plant phenols, vitamins and oligoelements. Emerit I, et al. **Mutat Res** 1997 Jul 3;377(2):239–46
Infant leukaemia after the Chernobyl accident [letter; comment] Michaelis J, et al. **Nature** 1997 May 15; 387(6630):246. Comment on: Nature 1996 Jul 25;382(6589):352–3.
Vertical migration of Chernobyl-derived radiocesium in Bavarian grassland soils. Schimmack W, et al. **Naturwissenschaften** 1997 May;84(5):204–7
Electrophysiological characterization of the functional state of the brain in mental disturbances in workers involved in the clean-up following the Chernobyl atomic energy station accident. Vyatleva OA, et al. **Neurosci Behav Physiol** 1997 Mar-Apr;27(2):166–72
The International Chernobyl Project Technical Report: assessment of radiological consequences and evaluation of protective measures. Report by an International Advisory Committee. Mann WB. **Nucl Med Biol** 1994 Jan;21(1):3–7 (7 ref.)
Effects of acute exposure to ultrahigh radiofrequency radiation on three antenna engineers. Schilling CJ. **Occup Environ Med** 1997 Apr;54(4):281–4
Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. Fugazzola L, et al. **Oncogene** 1996 Sep 5;13(5):1093–7
A new form of RET rearrangement in thyroid carcinomas of children after the Chernobyl reactor accident. Klugbauer S, et al. **Oncogene** 1996 Sep 5;13(5):1099–1102
137Cs mobility in soils and its long-term effect on the external radiation exposure. Bunzl K, et al. **Radiat Environ Biophys** 1997 Feb;36(1):31–7
Thyroid dose reconstruction for the population of Belarus after the Chernobyl accident. Drozdovitch VV, et al. **Radiat Environ Biophys** 1997 Feb;36(1):17–23
Estimation of 131I thyroid doses for the evacuees from Pripjat. Goulko GM, et al. **Radiat Environ Biophys** 1996 May;35(2):81–7
Perinatal mortality in Bavaria, Germany, after the Chernobyl reactor accident. Grosche B, et al. **Radiat Environ Biophys** 1997 Jun;36(2):129–36
Childhood leukemia in Belarus before and after the Chernobyl accident. Ivanov EP, et al. **Radiat Environ Biophys** 1996 May;35(2):75–80
Leukaemia and thyroid cancer in emergency workers of the Chernobyl accident: estimation of radiation risks (1986–1995). Ivanov VK, et al. **Radiat Environ Biophys** 1997 Feb;36(1):9–16
Ten years ago the Unit 4 of the reactor station Chernobyl exploded, and 200 tons of burning graphite spread their deadly content of fission products [editorial] Kellerer AM. **Radiat Environ Biophys** 1996 May;35(2):63–4
Perinatal mortality in Germany following the Chernobyl accident. Körblein A, et al. **Radiat Environ Biophys** 1997 Feb;36(1):3–7
PARATI--a dynamic model for radiological assessments in urban areas. Part I. Modelling of urban areas, their contamination and radiation fields. Rochedo ER, et al. **Radiat Environ Biophys** 1996 Nov;35(4):243–61 (87 ref.)
A response to "Perinatal mortality in Germany following the Chernobyl accident" [letter] Rossi HH. **Radiat Environ Biophys** 1997 Jun;36(2):137
Scientific recommendations for the reconstruction of radiation doses due to the reactor accident at Chernobyl. Voigt G, et al. **Radiat Environ Biophys** 1996 Feb;35(1):1–9
Biodosimetry of Chernobyl cleanup workers from Estonia and Latvia using the glycophorin A in vivo somatic cell mutation assay. Bigbee WL, et al. **Radiat Res** 1997 Feb; 147(2):215–24
Down syndrome clusters in Germany after the Chernobyl accident. Burkart W, et al. **Radiat Res** 1997 Mar; 147(3):321–8
Thyroid nodularity and cancer among Chernobyl cleanup workers from Estonia. Inskip PD, et al. **Radiat Res** 1997 Feb;147(2):225–35
Issues in the comparison of risk estimates for the population in the Techa River region and atomic bomb survivors. Kossenko MM, et al. **Radiat Res** 1997 Jul;148(1):54–63
The Estonian study of Chernobyl cleanup workers: II. Incidence of cancer and mortality. Rahu M, et al. **Radiat Res** 1997 May;147(5):653–7
The Estonian study of Chernobyl cleanup workers: I. Design and questionnaire data. Tekkel M, et al. **Radiat Res** 1997 May;147(5):641–52
Remedial policies in radiologically-contaminated forests: environmental consequences and risk assessment. Linkov I, et al. **Risk Anal** 1997 Feb;17(1):67–75
Influence of environmental factors on development of Bialystok newborns born in 1987. Litwiejko-Pietryńczak E. **Rocz Akad Med Bialymst** 1996;41(2):457–62
Lungs exposed to nuclear catastrophe: one-year therapeutic programme in Chernobyl liquidators group. Chuchalin AG, et al. **Schweiz Med Wochenschr** 1997 Feb 1;127(5):165–9
Ten years of the Chernobyl era. Shcherbak YM. **Sci Am** 1996 Apr;274(4):44–9
Long-term decline of radiocesium concentration in seafood from the Ligurian sea (northern Italy) after Chernobyl. Gallelli G, et al. **Sci Total Environ** 1997 Mar 20; 196(2):163–70
The sunken nuclear submarine Komsomolets and its effects on the environment. Høibråten S, et al. **Sci Total Environ** 1997 Aug 25;202(1–3):67–78
Mobility of Chernobyl-derived 137Cs in a peatbog system within the catchment of the Pripyat River, Belarus [published erratum appears in Sci Total Environ 1996 Dec 13;193(1):75] Kudelsky AV, et al. **Sci Total Environ** 1996 Oct 11;188(2–3):101–13
Dynamics of 137Cs in the forests of the 30-km zone around the Chernobyl nuclear power plant. Mamikhin SV, et al. **Sci Total Environ** 1997 Jan 30;193(3):169–77
Perturbation in the 240Pu/239Pu global fallout ratio in local sediments following the nuclear accidents at Thule (Greenland) and Palomares (Spain). Mitchell PI, et al. **Sci Total Environ** 1997 Aug 25;202(1–3):147–53
Transfer of radiocaesium in sensitive agricultural environments after the Chernobyl fallout in Sweden. I. County of Gavleborg. Rosen K, et al. **Sci Total Environ** 1996 Apr 5;182(1–3):117–33
Transfer of radiocaesium in sensitive agricultural environments after the Chernobyl fallout in Sweden. II. Marginal and semi-natural areas in the county of Jamtland. Rosen K. **Sci Total Environ** 1996 Apr 5;182(1–3):135–45
The impact of chronic radioactive stress on the immuno-physiological condition of small mammals. Tsiperson VP, et al. **Sci Total Environ** 1997 Sep 6; 203(2):105–13
Instrumental neutron activation analysis of essential and toxic elements in child and adolescent diets in the Chernobyl disaster territories of the Kaluga Region. Zaichick V, et al. **Sci Total Environ** 1996 Dec 9;192(3):269–74
France distributes iodine near reactors [news] Balter M. **Science** 1997 Mar 28;275(5308):1871–2
Lessons from Chernobyl: the event, the aftermath fallout:

radioactive, political, social. Robbins J. **Thyroid** 1997 Apr; 7(2):189–92 (30 ref.)

Sonographic determination of cutaneous and subcutaneous fibrosis after accidental exposure to ionising radiation in the course of the Chernobyl nuclear power plant accident. Gottlöber P, et al. **Ultrasound Med Biol** 1997;23(1):9–13

Health effects of radiological accidents [news] **World Health Forum** 1996;17(2):206–8

The health consequences of the Chernobyl accident and other radiological events. Introduction. **World Health Stat Q** 1996;49(1):2–3

Health consequences of the Chernobyl Accident. Summary report. Fact sheet. **World Health Stat Q** 1996;49(1):72

Epidemiological survey of the medical consequences of the Chernobyl accident in Ukraine. Buzunov VA, et al. **World Health Stat Q** 1996;49(1):4–6

The Chernobyl accident and radiation risks: dynamics of epidemiological rates (morbidity, disability and death rates) according to the data in the national registry. Ivanov VK, et al. **World Health Stat Q** 1996;49(1):22–8

Health conditions among workers who participated in the cleanup of the Chernobyl accident. Kamarli Z, et al. **World Health Stat Q** 1996;49(1):29–31

Radiation effects on the population of Belarus after the Chernobyl accident and the prediction of stochastic effects. Kenigsberg JE, et al. **World Health Stat Q** 1996;49(1):58–61

Internal exposure of the staff involved in the cleanup after the accident at the Chernobyl nuclear power plant in 1986. Kutkov VA, et al. **World Health Stat Q** 1996;49(1):62–6

Dosimetric support of the International Programme on the Health Effects of the Chernobyl Accident (IPHECA) pilot project: main results and problems. Likhtarev IA, et al. **World Health Stat Q** 1996;49(1):40–51

Main scientific results of the WHO International Programme on the Health Effects of the Chernobyl Accident (IPHECA). Souchkevitch GN. **World Health Stat Q** 1996; 49(3–4):209–12

[Protection of the thyroid in children and fetuses in case of nuclear accident] Vernis M, et al. **Arch Pediatr** 1997 May; 4(5):473–9 (29 ref.) (Eng. Abstr.) **(Fre)**

[Chernobyl 26 April 1986: 10 years later (editorial)] Dicato M. **Bull Soc Sci Med Grand Duche Luxemb** 1996; 133(2):39–40 **(Fre)**

[The Thule accident in 1968] Glattre E. **Tidsskr Nor Laegeforen** 1996 Sep 10;116(21):2539–40 **(Nor)**

[Health effects of plutonium pollution—assessment after the Thule disaster in 1968] Lund E. **Tidsskr Nor Laegeforen** 1996 Sep 10;116(21):2588–90 (Eng. Abstr.) **(Nor)**

[One decade after Chernobyl: sequelae of the accident and urgent problems of radiation pathology (editorial)] Lushnikov EF. **Arkh Patol** 1997 Jul–Aug;59(4):42–6 (Eng. Abstr.) **(Rus)**

[Effect of radiation on the functional status of neuronal chromatin in mice exposed in the region of the Chernobyl atomic power plant] Mustafin AG, et al. **Biull Eksp Biol Med** 1996 May;121(5):555–8 **(Rus)**

[Radioactive contamination of "Red forest" burial waters in the area nearest the Chernobyl nuclear power plant] Kopeĭkin VA. **Dokl Akad Nauk** 1996 Dec;351(5):709–11 **(Rus)**

[Accumulation of radionuclides in wood of live trees in areas closest to the Chernobyl nuclear power plant] Kopeĭkin VA. **Dokl Akad Nauk** 1996 Dec;351(6):841–3 **(Rus)**

[Strategy of survival of animal populations during radioactive pollution] Krivolutskiĭ DA. **Dokl Akad Nauk** 1996 Aug; 349(4):568–70 **(Rus)**

[Psychophysiologic functions of the clean-up crew 6 years after the accident at the Chernobyl power plant] Makarenko NV, et al. **Fiziol Cheloveka** 1996 Jul–Aug; 22(4):79–85 **(Rus)**

[Economic assessment of damage caused to population's health by radiation pollution of the environment] Bushueva GA, et al. **Gig Sanit** 1996 Jul–Aug;(4):42–5 **(Rus)**

[Environmental radiation pollution and internal irradiation of children] Mikhalev VP, et al. **Gig Sanit** 1996 Jul–Aug; (4):32–5 **(Rus)**

[Health evaluation of radioactive pollution of the environment] Mikhalev VP, et al. **Gig Sanit** 1997 May–Jun; (3):36–41 **(Rus)**

[Comparative study of adaptation of school children from regions with radiation pollution and from Moscow to conditions of rest at Artek, a health center] Rybakov VP, et al. **Gig Sanit** 1996 Nov–Dec;(6):35–6 **(Rus)**

[Radionuclides in the benthofauna in the region of the location of the Komsomolets atomic submarine (the Norwegian Sea)] Kuznetsov AP, et al. **Izv Akad Nauk Ser Biol** 1996 Jul–Aug;(4):467–71 (Eng. Abstr.) **(Rus)**

[The morphological characteristics of craniocerebral and cerebrospinal hernias in children after the accident at the Chernobyl Atomic Electric Power Station] Brodskaia IA, et al. **Klin Khir** 1994;(12):20–3 (Eng. Abstr.) **(Rus)**

[Chernobyl accident 10 years after (a retrospective study of clinical events and medical measures in the treatment of sequelae)] Gus'kova AK. **Klin Med (Mosk)** 1996;74(3):5–8 **(Rus)**

[Hypophyseal and sex hormones in Chernobyl' emergency team members with neurocirculatory dystonia] Kovalenko AN. **Klin Med (Mosk)** 1996;74(4):68–9 **(Rus)**

[Cardiac contractile function in the participants of the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station who are ill with hypertension] Ignatova OA, et al. **Lik Sprava** 1997 Mar–Apr;(2):114–6 (Eng. Abstr.) **(Rus)**

[Immune system function in the participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Ivanitskaia NF, et al. **Lik Sprava** 1996 Mar–Apr;(3–4):31–3 (Eng. Abstr.) **(Rus)**

[The dynamics of the internal radiation activity in schoolchildren living in contaminated regions of Zhitomir Province 7 years after the accident at the Chernobyl Atomic Electric Power Station[Nabukhotnyĭ TK, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):16–8 **(Rus)**

[The moisture-releasing function of the lungs in persons who were exposed to moderate doses of ionizing radiation after the accident at the Chernobyl Atomic Electric Power Station] Protsiuk RH, et al. **Lik Sprava** 1996 Jul–Sep; (7–9):37–40 (Eng. Abstr.) **(Rus)**

[The clinico-hematological characteristics of the participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Station with stable deviations in blood analyses] Radchuk ZV. **Lik Sprava** 1997 Jan–Feb; (1):14–7 (Eng. Abstr.) **(Rus)**

[The characteristics of the immunity status of people with arterial hypertension who took part in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Semidotskaia ZhD, et al. **Lik Sprava** 1996 Mar–Apr;(3–4):27–30 (Eng. Abstr.) **(Rus)**

[The medical ecological consequences of the Chernobyl catastrophe] Serdiuk AM. **Lik Sprava** 1997 Jan–Feb;(1):3–9 **(Rus)**

[The effect of long-acting radiation on the diversity of heterotrophic bacteria in the soils of a 10-kilometer area around the Chernobyl Atomic Electric Power Station] Romanovskaia VA, et al. **Mikrobiol Z** 1996 Sep–Oct; 58(5):3–12 (Eng. Abstr.) **(Rus)**

[The antagonistic properties of bacteria isolated from the digestive tract of female mink housed in the area of the Chernobyl Atomic Electric Power Station] Sudenko VI, et al. **Mikrobiol Z** 1996 Nov–Dec;58(6):38–44 (Eng. Abstr.) **(Rus)**

[The status of the gastric and duodenal mucosa, biopsied from those who worked in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station, in an organotypic tissue culture] Nikiforov AM, et al. **Morfologiia** 1996;110(6):100–5 (Eng. Abstr.) **(Rus)**

[The characteristics of the prenatal morphogenesis of human lungs-in the area of the action of the radiation factors after the accident at the Chernobyl Atomic Electric Power Station] Romanova LK, et al. **Ontogenez** 1997 Jan–Feb; 28(1):41–8 (Eng. Abstr.) **(Rus)**

[A decade after Chernobyl: the results of research on radioecology] Aleksakhin RM. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):451–9 (54 ref.) (Eng. Abstr.) **(Rus)**

[Atmospheric contamination by 137Cs during forest fires in the Chernobyl area] Azarov SI. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):506–15 (Eng. Abstr.) **(Rus)**

[Modelling of the biological availability of 137Cs in soils subjected to contamination after the accident at the Chernobyl Atomic Electric Power Station] Fesenko SV, et al. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):479–87 (Eng. Abstr.) **(Rus)**

[Changes in the immune system of the victims of the action of the factors in the accident at the Chernobyl Atomic Electric Power Station. Their manifestations, nature and the possible sequelae] Iarilin AA, et al. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):587–600 (60 ref.) (Eng. Abstr.) **(Rus)**

[Computerization of the research into radionuclide dynamics in the forest ecosystems contaminated as a result of the Chernobyl accident (1986–1995)] Mamikhin SV, et al. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):516–23 (Eng. Abstr.) **(Rus)**

[The need to account for beta radiation in determining the total radiation exposure of those working in cleanup] Osanov DP, et al. **Radiats Biol Radioecol** 1996 Jul–Aug; 36(4):641–50 (Eng. Abstr.) **(Rus)**

[Genomic instability after exposure to radiation at low doses (in the 10-kilometer zone of the accident at the Chernobyl Atomic Electric Power Station and under laboratory conditions)] Pelevina II, et al. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):546–60 (Eng. Abstr.) **(Rus)**

[Exposure levels of persons involved in cleaning-up after the Chernobyl AES accident and included in the Russian State Medical and Dosimetric Registry (letter)] Pitkevich VA, et al. **Radiats Biol Radioecol** 1996 Sep–Oct; 36(5):747–57 (Eng. Abstr.) **(Rus)**

[The aftereffects of the accident at the Chernobyl Atomic Electric Power Station for hydrobionts (1986–1996)] Polikarpov GG, et al. **Radiats Biol Radioecol** 1996 Jul–Aug; 36(4):460–8 (Eng. Abstr.) **(Rus)**

[The probable sequelae of thyroid damage from radioactive iodine during the Chernobyl accident] Poverennyĭ AM, et al. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):632–40 (Eng. Abstr.) **(Rus)**

[Radiation-induced changes in the cellular chromatin of cereal plants cultivated in the area of the Chernobyl Atomic Electric Power Station] Reshetnikov VN, et al. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):567–72 (Eng. Abstr.) **(Rus)**

[The biogeochemistry of the radionuclides of the Chernobyl release in the forest ecosystems of the European portion of the CIS] Shcheglov AI, et al. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):469–78 (Eng. Abstr.) **(Rus)**

[The genetic sequelae for plant populations of radioactive environmental pollution in connection with the Chernobyl accident] Shevchenko VA, et al. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):531–45 (Eng. Abstr.) **(Rus)**

[The build up of absorbed doses in the critical organs of cereal grains in a contaminated area after the accident at the Chernobyl Atomic Electric Power Station] Spirin EV. **Radiats Biol Radioecol** 1997 May–Jun;37(3):445–52 (Eng. Abstr.) **(Rus)**

[A comparative evaluation of the content of T-lymphocyte subpopulations, alpha 1-thymosin and autoantibodies to epithelial thymic cells in the personnel in the 30-kilometer control zone of the accident at the Chernobyl Atomic Electric Power Station] Titova LD, et al. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):601–9 (Eng. Abstr.) **(Rus)**

[An analysis of the genetic sequelae of the contamination of winter rye crops by the radioactive fallout from the Chernobyl Atomic Electric Power Station] Ziablitskaia EIa, et al. **Radiats Biol Radioecol** 1996 Jul–Aug; 36(4):498–505 (Eng. Abstr.) **(Rus)**

[The assessment of the stomatological status of children living in radionuclide-contaminated areas] Mel'nichenko EM, et al. **Stomatologiia (Mosk)** 1996;75(2):59–61 (Eng. Abstr.) **(Rus)**

[The morphometric and immunohistochemical indices of the gastric and duodenal mucosa in the dynamic treatment of erosive gastroduodenitis in those who worked in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station in the follow-up period] Dement'eva OIu, et al. **Ter Arkh** 1997;69(2):18–22 (Eng. Abstr.) **(Rus)**

[Characteristics of the gastric and duodenal mucosa in participants in the cleanup of the sequelae of the accident at the Chernobyl Atomic Electric Power Station] Loginov AS, et al. **Ter Arkh** 1995;67(12):39–43 (Eng. Abstr.) **(Rus)**

[The clinico-hematological indices of the participants in the cleanup of the aftermath of the Chernobyl accident] Pivnik AV, et al. **Ter Arkh** 1996;68(7):73–7 (Eng. Abstr.) **(Rus)**

[Multiaberrant cells in the participants of the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Rivkind NB, et al. **Ter Arkh** 1996;68(7):77–9 **(Rus)**

[Erythron system function in adults subjected to radiation exposure as a result of the Chernobyl accident] Bil'ko NM, et al. **Tsitol Genet** 1996 Jul–Aug;30(4):55–62 (Eng. Abstr.) **(Rus)**

[The adaptation of natural plant populations to chronic irradiation due to the accident at the Chernobyl Atomic Electric Power Station] Dmitrieva SA. **Tsitol Genet** 1996 Jul–Aug;30(4):3–8 (Eng. Abstr.) **(Rus)**

[The heterogeneity of the cytogenetic variability in the bone marrow cells of laboratory and wild rodents in the exclusion zone of the Chernobyl Atomic Electric Power Station] Glazko TT, et al. **Tsitol Genet** 1996 Jul–Aug; 30(4):25–34 (Eng. Abstr.) **(Rus)**

[The dynamics of the allele variants of biochemical markers in generations of cattle in the exclusion zone of the Chernobyl Atomic Electric Power Station] Glazko VI, et al. **Tsitol Genet** 1996 Jul–Aug;30(4):49–55 (Eng. Abstr.) **(Rus)**

[The results of the cytogenetic monitoring of the species of angiosperm plants growing in the area of the radionuclide contamination after the accident at the Chernobyl Atomic Electric Power Station] Kordium EL, et al. **Tsitol Genet** 1997 May–Jun;31(3):39–46 (Eng. Abstr.) **(Rus)**

[The genetic effects in the somatic cells of persons working under chronic irradiation of different intensities after the accident at the Chernobyl Atomic Electric Power Station] Pilinskaia MA, et al. **Tsitol Genet** 1996 Mar–Apr; 30(2):17–25 (Eng. Abstr.) **(Rus)**

[The genetic monitoring of the house mouse population from areas contaminated by radionuclides as a result of the accident at the Chernobyl Atomic Electric Power Station] Pomerantseva MD, et al. **Tsitol Genet** 1996 Jul–Aug; 30(4):42–8 (Eng. Abstr.) **(Rus)**

[Biochemical changes in the brain of the root vole (Microtus oeconomus) from a 30-kilometer zone around the Chernobyl Atomic Electric Power Station] Kudiasheva AG, et al. **Ukr Biokhim Zh** 1996 Mar–Apr;68(2):87–93 (Eng. Abstr.) **(Rus)**

[Immunological studies on cataracts under conditions of exposure to low-dose radiation] Shubik VM, et al. **Vestn Oftalmol** 1996 Sep–Oct;112(4):21–3 (Eng. Abstr.) **(Rus)**

[The genetic sequelae of the Chelyabinsk and Chernobyl radioactive contaminations] Bochkov NP, et al. **Vestn Ross Akad Med Nauk** 1996;(6):64–72 (Eng. Abstr.) **(Rus)**

[Implementation of international scientific and technological projects in the study of consequences of the Chernobyl AES accident] Kniazhev VA. **Vestn Ross Akad Med Nauk** 1996;(12):56–8 (Eng. Abstr.) **(Rus)**

[Evaluation of technogenic radiation exposures from ecological and physiological points of view] Matiukhin VA, et al. **Vestn Ross Akad Med Nauk** 1997;(4):49–52 (Eng. Abstr.) **(Rus)**

ACCIDENTS, RADIATION

[Changes in lymphocyte cytochemical markers in radiation-exposed patients under mountain conditions] Taradiĭ NN, et al. **Vestn Ross Akad Med Nauk** 1997;(5):33–7 (Eng. Abstr.) **(Rus)**

[The results of medical and dosimetric research on the population and on those who worked in cleanup subjected to radiation exposure as a result of the Chernobyl catastrophe] Tsyb AF, et al. **Vestn Ross Akad Med Nauk** 1996;(6):58–64 (Eng. Abstr.) **(Rus)**

[Possibility of correction of the hormonal state of girls by hypoxic training] Zakusilo MP. **Vestn Ross Akad Med Nauk** 1997;(5):38–41 (Eng. Abstr.) **(Rus)**

[The All-Russia Disaster Medical Service in the organization of the cleanup of the aftermath of radiation accidents] Avetisov GM, et al. **Voen Med Zh** 1996 Jun;317(6):47–56 **(Rus)**

[The experience of the medical service of the Armed Forces in the cleanup of the aftereffects of the accident at the Chernobyl Atomic Electric Power Station] Chizh IM. **Voen Med Zh** 1996 Jun;317(6):4–15, 80 (Eng. Abstr.) **(Rus)**

[The basic trends in improving the dispensary care for servicemen subjected to irradiation as a result of radiation accidents] Nikiforov AM, et al. **Voen Med Zh** 1996 Jun; 317(6):37–42 **(Rus)**

[The health indices of those working in the cleanup during accident recovery operations] Shantyr' II, et al. **Voen Med Zh** 1996 Jun;317(6):42–6, 80 (Eng. Abstr.) **(Rus)**

[The clinical aspects of the aftermath of the accident (based on data from the Military Medical Academy)] Shevchenko IuL. **Voen Med Zh** 1996 Jun;317(6):16–21, 80 (Eng. Abstr.) **(Rus)**

[The nature of the changes in the immunity of the women who worked in the cleanup of the sequelae of the accident at the Chernobyl Atomic Electric Power Station and were evacuated from the radioactively contaminated area] Tsvelev IuV, et al. **Voen Med Zh** 1997 Jan;318(1):38–42, 80 (Eng. Abstr.) **(Rus)**

[The sequelae and problems of the Chernobyl catastrophe] Tsyb AF, et al. **Voen Med Zh** 1997 Jan;318(1):34–7 **(Rus)**

[The prevention and pharmacological correction of body functional disorders from exposure to the extreme factors of large-scale radiation accidents] Ziliaev EG, et al. **Voen Med Zh** 1996 Jun;317(6):31–6, 80 (Eng. Abstr.) **(Rus)**

[The use of sapropels in osteoarthritis in participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Ivanova TG, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 May-Jun; (3):23–5 **(Rus)**

[The evaluation of the physical work capacity of participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station during their rehabilitation at a health resort] Kazets AI, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 May-Jun; (3):46–7 **(Rus)**

[Nondrug methods for the rehabilitation of participants in the cleanup of the aftermath of accident at the Chernobyl Atomic Electric Power Station who have neurocirculatory dystonia and hypertension] Kniazeva TA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 May-Jun; (3):10–2 (Eng. Abstr.) **(Rus)**

[The use of sodium chloride baths in children with a heart lesion subjected to long-term exposure to low radiation doses] Poberskaia VA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Jan-Feb;(1):4–7 (Eng. Abstr.) **(Rus)**

[The dynamics of the immunological indices of children from regions around Chernobyl during health-resort treatment] Shvedunova LN, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Sep-Oct;(5):37–9 **(Rus)**

[Dietary fibers as radiation protectors] Dudkin MS, et al. **Vopr Pitan** 1997;(2):12–4 (Eng. Abstr.) **(Rus)**

[The effect of vitamin- and beta-carotene-enriched products on the vitamin A allowance and the concentration of different carotenoids of the blood serum in victims of the accident at the Chernobyl Atomic Electric Power Station] Iakushina LM, et al. **Vopr Pitan** 1996;(1):12–5 (Eng. Abstr.) **(Rus)**

[Nutrition and health status of schoolchildren in Brianskaia region, residing in territories polluted by radionuclides] Kon' IIa, et al. **Vopr Pitan** 1996;(2):17–21 (Eng. Abstr.) **(Rus)**

[Vitamin status of the population from regions suffering from the accident at the Chernobyl power plant, and its correction with multivitamins "Duovit" and "Undevit" and multivitamin premix 730/4 of the firm "Roche"] Spirichev VB, et al. **Vopr Pitan** 1997;(3):11–6 (Eng. Abstr.) **(Rus)**

[Evaluation of the immune and interferon status of children infected with herpes simplex virus and living in areas with increased radiation background] Alimbarova LM, et al. **Vopr Virusol** 1997 Jan-Feb;42(1):36–41 (Eng. Abstr.) **(Rus)**

[The late sequelae of radiation exposure on the nervous system] Kholodova NB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(5):29–33 (Eng. Abstr.) **(Rus)**

[Mental disorders in the participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Panchenko OA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(5):34–7 (Eng. Abstr.) **(Rus)**

[The electrophysiological characteristics of brain function in mental disorders in participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Viatleva OA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(3):41–6 (Eng. Abstr.) **(Rus)**

[The characteristics of the late reaction of the human brain to radiation exposure: the EEG and neuropsychological study (the sequelae of the accident at the Chernobyl Atomic Electric Power Station)] Zhavoronkova LA, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jul-Aug; 46(4):699–711 (Eng. Abstr.) **(Rus)**

[Dynamics of ultrastructural morphology of the nucleolar apparatus in bovine preimplantation embryos collected in an area of chronic irradiation] Pivko J, et al. **Vet Med (Praha)** 1997 Feb;42(2):33–8 (Eng. Abstr.) **(Slo)**

[A comprehensive hygienic assessment of the prevalence of cerebrovascular diseases among the population of Kiev Province before and after the accident at the Chernobyl Atomic Electric Power Station] Bardov VH, et al. **Lik Sprava** 1996 Oct-Dec;(10–12):51–2 (Eng. Abstr.) **(Ukr)**

[The results of the medical examination of forestry industry workers in an area under intensified radioecological control] Bebeshko VH, et al. **Lik Sprava** 1996 Oct-Dec; (10–12):48–50 (Eng. Abstr.) **(Ukr)**

[The immune status characteristics and kidney function in persons exposed to the effect of ionizing radiation] Danylash MM, et al. **Lik Sprava** 1996 Jan-Feb;(1–2):18–20 **(Ukr)**

[The clinico-hemodynamic and psychological characteristics of the course of hypertension in those who cleaned up the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Korolenko SS, et al. **Lik Sprava** 1997 Jan-Feb;(1):10–4 (Eng. Abstr.) **(Ukr)**

[The transformation of psoriasis into mycosis fungoides in a person who worked to cleanup the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Liashenko IN, et al. **Lik Sprava** 1995 Sep-Dec;(9–12):29–31 **(Ukr)**

[The role of genetically determined blood system markers in the development of humoral immunity disorders in those who worked in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Pavliuk RP, et al. **Lik Sprava** 1996 Jul-Sep;(7–9):44–7 (Eng. Abstr.) **(Ukr)**

[The characteristics of cerebrovascular disorders in persons exposed to the effect of ionizing radiation as a result of the accident at the Chernobyl Atomic Electric Power Station] Zozulia IS, et al. **Lik Sprava** 1995 Mar-Apr; (3–4):26–9 (Eng. Abstr.) **(Ukr)**

[Disorders in the synchronism of homologous chromosome condensation in women with a predisposed familial anamnesis] Baryliak IR, et al. **Tsitol Genet** 1996 Jul-Aug; 30(4):63–9 (Eng. Abstr.) **(Ukr)**

[Genetic or ecogenetic consequences of the Chernobyl accident? (facts and hypotheses)] Buzhiievs'ka TI, et al. **Tsitol Genet** 1996 Jul-Aug;30(4):86–96 (Eng. Abstr.) **(Ukr)**

[The cytomorphological characteristics of the epithelial layer of the gastric and duodenal mucosa in those who worked in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Dehtiar'ova LV, et al. **Tsitol Genet** 1996 Sep-Oct;30(5):11–6 (Eng. Abstr.) **(Ukr)**

[The molecular mechanisms of the somatic effects of irradiation recorded in plants from the 10-km area around the Chernobyl Atomic Electric Power Station] Sosrochyns'kyĭ BV, et al. **Tsitol Genet** 1996 Jul-Aug; 30(4):15–9 (Eng. Abstr.) **(Ukr)**

LEGISLATION & JURISPRUDENCE

[Legal guarantees of radiation safety for Russian population] Mel'nikova LS, et al. **Med Tr Prom Ekol** 1996;(9):5–7 **(Rus)**

MORTALITY

[Oncoepidemiologic situation in the Kaluga region of the Russian Federation ten years after the Chernobyl accident] Ivanov VK, et al. **Vopr Onkol** 1997;43(2):143–50 (Eng. Abstr.) **(Rus)**

[Mortality indices for hemoblastoses in Rivno Province before and after the accident at the Chernobyl Atomic Electric Power Station] Vyhovs'ka IaI, et al. **Lik Sprava** 1995 Mar-Apr;(3–4):23–5 (Eng. Abstr.) **(Ukr)**

PREVENTION & CONTROL

Today's problems of Chernobyl. Baryakhtar VG. **Eur J Cancer Prev** 1996 Oct;5(5):385–6

NRC regulation of DOE nuclear safety: an observation and some questions concerning radiation doses [letter] Sims CS. **Health Phys** 1997 May;72(5):798

PSYCHOLOGY

[Low doses of irradiation and psychoemotional stress] Legeza VI, et al. **Voen Med Zh** 1996 Jun;317(6):62–4 **(Rus)**

[The psychological sequelae of the accident] Novikov VS, et al. **Voen Med Zh** 1996 Jun;317(6):57–62, 80 (Eng. Abstr.) **(Rus)**

ACCIDENTS, TRAFFIC

see related
AIR BAGS
SEAT BELTS

Cervical seat belt sign after motor vehicle collision [letter] Riviello RJ, et al. **Acad Emerg Med** 1997 Apr;4(4):335–7

Gender patterns in minor head and neck injuries: an analysis of casualty register data. Bring G, et al. **Accid Anal Prev** 1996 May;28(3):359–69

Methodological issues in testing the hypothesis of risk compensation. Dulisse B. **Accid Anal Prev** 1997 May; 29(3):285–92

Antilock brakes and risk of front and rear impact in two-vehicle crashes. Evans L, et al. **Accid Anal Prev** 1996 May;28(3):315–23

Two-vehicle side impact crashes: the relationship of vehicle and crash characteristics to injury severity. Farmer CM, et al. **Accid Anal Prev** 1997 May;29(3):399–406

Protection of the side of the head. Gilchrist A, et al. **Accid Anal Prev** 1996 Jul;28(4):525–35

Motor-vehicle crash-injury risk factors among American Indians. Grossman DC, et al. **Accid Anal Prev** 1997 May; 29(3):313–9

Exposure and risk factors among elderly drivers: a case-control study. Lefrançois R, et al. **Accid Anal Prev** 1997 May;29(3):267–75

Effects of retroreflector positioning on nighttime recognition of pedestrians. Luoma J, et al. **Accid Anal Prev** 1996 May; 28(3):377–83

A comprehensive methodology for the fitting of predictive accident models. Maher MJ, et al. **Accid Anal Prev** 1996 May;28(3):281–96

The effects of paved shoulders on accidents on rural highways. Ogden KW. **Accid Anal Prev** 1997 May; 29(3):353–62

Foot-ankle injuries: influence of crash location, seating position and age. Parenteau CS, et al. **Accid Anal Prev** 1996 Sep;28(5):607–17

Modelling of conspicuity-related motorcycle accidents in Seremban and Shah Alam, Malaysia. Radin UR, et al. **Accid Anal Prev** 1996 May;28(3):325–32

What surviving drivers learn from a fatal road accident. Rajalin S, et al. **Accid Anal Prev** 1997 May;29(3):277–83

Supervision in childhood injury cases: a reliable taxonomy. Wills KE, et al. **Accid Anal Prev** 1997 Jan;29(1):133–7

Minimizing inter city transportation risk--a matter of perspective. Wulff P. **Accid Anal Prev** 1996 May; 28(3):409–13

Motor vehicle accident during the second or third trimester of pregnancy. Aitokallio-Tallberg A, et al. **Acta Obstet Gynecol Scand** 1997 Apr;76(4):313–7 (32 ref.)

Psychosocial impact of bereavement after suicide and fatal traffic accident: a comparative two-country study. Cleiren MP, et al. **Acta Psychiatr Scand** 1996 Jul;94(1):37–44

Photograph documentation of motor vehicle damage by EMTs at the scene: a prospective multicenter study in the United States. Hunt RC, et al. **Am J Emerg Med** 1997 May; 15(3):233–9

Vehicular accidents and cardiac concussion. A traumatic connection. Michalodimitrakis EN, et al. **Am J Forensic Med Pathol** 1997 Sep;18(3):282–4

Complete transection of the trunk of passengers in car accidents. Nadjem H, et al. **Am J Forensic Med Pathol** 1996 Jun;17(2):167–71

Carboxyhemoglobin levels in a series of automobile fires. Death due to crash or fire? Wirthwein DP, et al. **Am J Forensic Med Pathol** 1996 Jun;17(2):117–23

Automobile crash simulation with the first pregnant crash test dummy. Pearlman MD, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):977–81

Transient alteration in fetal biophysical profile immediately following fetomaternal hemorrhage sustained during motor vehicle accident. Sherer DM, et al. **Am J Perinatol** 1997 Apr;14(4):187–9

Motor vehicle rollover and static stability: an exposure study. Robertson LS, et al. **Am J Public Health** 1997 May; 87(5):839–41

The acute stress response following motor vehicle accidents and its relation to PTSD. McFarlane AC, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:437–41

Craniofacial injuries resulting from taxicab accidents in New York City. Talmor M, et al. **Ann Plast Surg** 1996 Jan; 36(1):1–6

Childhood absence epilepsy and accidents [letter] Deonna T. **Arch Neurol** 1997 Sep;54(9):1063

Simulated car crashes and crash predictors in drivers with Alzheimer disease. Rizzo M, et al. **Arch Neurol** 1997 May; 54(5):545–51

Firearm versus motor vehicle related spinal cord injury: preinjury factors, injury characteristics, and initial outcome comparisons among ethnically diverse groups. Waters RL, et al. **Arch Phys Med Rehabil** 1997 Feb;78(2):150–5

The effect of payer status on utilization of hospital resources in trauma care. Rhee PM, et al. **Arch Surg** 1997 Apr;

132(4):399–404

Efficacy of arthroscopic surgery and midlaser treatments for chronic temporomandibular joint articular disc derangement following motor vehicle accident [see comments] McNamara DC, et al. **Aust Dent J** 1996 Dec; 41(6):377–87. Comment in: Aust Dent J 1997 Feb;42(1):67.

A randomised controlled trial of psychological debriefing for victims of road traffic accidents. Hobbs M, et al. **BMJ** 1996 Dec 7;313(7070):1438–9

Ruptured diaphragm: the latent phase. Huggon AM, et al. **Br J Clin Pract** 1996 Oct–Nov;50(7):408–9

Type A behaviour pattern and traffic accidents. Magnavita N, et al. **Br J Med Psychol** 1997 Mar;70 (Pt 1):103–7

Corneoscleral laceration associated with passenger-side airbag inflation [letter] Bhavsar AR, et al. **Br J Ophthalmol** 1997 Jun;81(6):514–5

Retrograde intramedullary nailing of the femur using a tibial nail—the adjunctive use of an existing implant: a case report. Rodgers WB, et al. **Bull Hosp Jt Dis** 1996; 55(2):78–80

Children's exposure to traffic and risk of pedestrian injury in an urban setting. Rao R, et al. **Bull N Y Acad Med** 1997 Summer;74(1):65–80

Case report: retinal tear as a consequence of air bag inflation. Dubinsky I, et al. **Can Fam Physician** 1997 Sep;43:1576–7

Lunate and perilunate dislocation. Su CJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Nov; 58(5):348–54

Thoracic outlet syndrome after motor vehicle accidents in a Canadian pain clinic population. Mailis A, et al. **Clin J Pain** 1995 Dec;11(4):316–24

Stroke and automobile accidents. Finelli PF, et al. **Conn Med** 1996 Mar;60(3):145–7

Single road traffic deaths—accidents or suicide? [letter; comment] Etzersdorfer E. **Crisis** 1995;16(4):188–91. Comment on: Crisis 1995;16(2):85–9.

The wreck of Amtrak's Sunset Limited: news coverage of a mass transport disaster. Garner AC, et al. **Disasters** 1997 Mar;21(1):4–19

Traumatic retinal angiopathy and seat belts: pathogenesis of whiplash injury [letter; comment] Liguori G, et al. **Eye** 1997;11 (Pt 1):139–40. Comment on: Eye 1994;8 (Pt 6):615–7.

Foot and ankle severity scale (FASS). Manoli A 2nd, et al. **Foot Ankle Int** 1997 Sep;18(9):598–602

Development of an upper extremity FES system for individuals with C4 tetraplegia. Smith BT, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):264–70 (26 ref.)

Cervical spinal injuries caused by collision of cars with camels. al-Sebai MW, et al. **Injury** 1997 Apr;28(3):191–4

Gastric rupture from blunt abdominal injury. Dharap SB, et al. **Injury** 1996 Dec;27(10):753–4

Risk factors for 'whiplash' in drivers: a cohort study of rear-end traffic crashes. Dolinis. **Injury** 1997 Apr; 28(3):173–9

Avulsion of the lesser tuberosity with intra-articular injury of the glenohumeral joint. Leslie A, et al. **Injury** 1996 Dec; 27(10):742–5

Traumatic intervertebral incarceration of ileum: a unique lap belt injury. Patterson R, et al. **Injury** 1996 Oct;27(8):596–8

Pelvic ring diastasis and pseudo-diastasis in motorcycle pillion passengers. Price N, et al. **Injury** 1996 Jul; 27(6):441–4

Injury of the cervical spine associated with carotid and vertebral artery occlusion: case report and literature review. Schippinger G, et al. **Injury** 1997 May;28(4):315–8 (24 ref.)

An unusual mechanism of airbag injury. Walter DP, et al. **Injury** 1996 Sep;27(7):523–4

Motor vehicle crashes, pregnancy loss and preterm labor [see comments] Pearlman MD. **Int J Gynaecol Obstet** 1997 May; 57(2):127–32 (17 ref.). Comment in: Int J Gynaecol Obstet 1997 May;57(2):123.

Incidental neck symptoms in high energy trauma victims. Khan H, et al. **Ir Med J** 1997 Jun–Jul;90(4):143

An unusual cause of rib fracture following a road traffic accident. Daniels RJ, et al. **J Accid Emerg Med** 1997 Mar; 14(2):113–4

A case of maternal pelvic trauma following a road traffic accident, associated with fetal intracranial haemorrhage. Matthews G, et al. **J Accid Emerg Med** 1997 Mar; 14(2):115–7

An investigation into the effects of British Summer Time on road traffic accident casualties in Cheshire. Whittaker JD. **J Accid Emerg Med** 1996 May;13(3):189–92

Seven-year follow-up of child survivors of a bus-train collision. Tyano S, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Mar;35(3):365–73

Motor vehicle accidents and TMDS: assessing the relationship. Burgess JA, et al. **J Am Dent Assoc** 1996 Dec; 127(12):1767–72; quiz 1785

Carpal tunnel syndrome and motor vehicle accidents. Ames EL. **J Am Osteopath Assoc** 1996 Apr;96(4):223–6

The confirmation of volatiles by solid-phase microextraction and GC-MS in the investigation of two traffic fatalities. Brewer WE, et al. **J Anal Toxicol** 1997 Jul–Aug; 21(4):286–90

Hampson, D: facial injury: a review of biomechanical studies and test procedures for facial injury assessment [letter] Yoganandan N, et al. **J Biomech** 1996 Jul;29(7):985–6

Injury severity assessment for car occupants in frontal impacts, using disability scaling. Norin H, et al. **J Clin Epidemiol** 1997 Jan;50(1):95–103

Psychophysiology of posttraumatic stress disorder related to motor vehicle accidents: replication and extension. Blanchard EB, et al. **J Consult Clin Psychol** 1996 Aug; 64(4):742–51

Facial nerve paresis involving passenger airbag deployment: a case report. Bedell JR, et al. **J Emerg Med** 1997 Jul–Aug; 15(4):475–6

Traffic fatality related to the use of methylenedioxymethamphetamine. Crifasi J, et al. **J Forensic Sci** 1996 Nov;41(6):1082–4

Self-report versus state records for identifying crashes among older drivers. Marottoli RA, et al. **J Gerontol A Biol Sci Med Sci** 1997 May;52(3):M184–7

Medical risk factors amongst drivers in single-car accidents. Gislason T, et al. **J Intern Med** 1997 Mar;241(3):213–9

An unusual cause of facial pain. de Carpentier JP, et al. **J Laryngol Otol** 1996 Aug;110(8):796–8

Glass in the frontal sinus: report of three cases. Onerci M, et al. **J Laryngol Otol** 1997 Feb;111(2):156–8 (3 ref.)

Spondyloptotic fracture of the cervical spine in a pregnant, anemic Jehovah's Witness: technical and ethical considerations. Case report. Feigenbaum F, et al. **J Neurosurg** 1997 Sep;87(3):458–63

Effects of a hydrochloric acid spill on neurobehavioral and pulmonary function. Kilburn KH. **J Occup Environ Med** 1996 Oct;38(10):1018–25

Femoral nerve palsy associated with an associated posterior wall transverse acetabular fracture. Hardy SL. **J Orthop Trauma** 1997 Jan;11(1):40–2 (6 ref.)

Open total talus dislocation: case report and review of the literature. Palomo-Traver JM, et al. **J Orthop Trauma** 1997 Jan;11(1):45–9 (19 ref.)

Avulsion of the patellar ligament with combined fracture luxation of the proximal tibial epiphysis: case report and review of the literature. Perez Carro L. **J Orthop Trauma** 1996;10(5):355–8 (8 ref.)

Irreducible fracture dislocation of the knee. Pugh KJ, et al. **J Orthop Trauma** 1996;10(5):359–62 (25 ref.)

Irreducible open intertrochanteric hip fracture secondary to entrapment of the sciatic nerve in a child. Wiss DA, et al. **J Orthop Trauma** 1997 Jan;11(1):38–40 (10 ref.)

Pelvic and bladder trauma: a case report and subject review. Wright DG, et al. **J Orthop Trauma** 1996;10(5):351–4 (28 ref.)

Personality profile among symptomatic and recovered patients with neck sprain injury, measured by MCMI-I acutely and 6 months after car accidents. Borchgrevink GE, et al. **J Psychosom Res** 1997 Apr;42(4):357–67

Moving car-tire injuries of the foot: reconstruction with microvascular free flaps. Nuzumlali E, et al. **J Reconstr Microsurg** 1996 Jul;12(5):297–302

Seat-belt use and relation to neurologic injury in motor vehicle crashes. Sasso RC, et al. **J Spinal Disord** 1997 Aug; 10(4):325–8

Identification of the motor vehicle accident victim who abuses alcohol: an opportunity to reduce trauma. Mancino M, et al. **J Stud Alcohol** 1996 Nov;57(6):652–8

Posttraumatic retroperitoneal rupture of the right colon simulating a retroperitoneal hematoma. Duruisseau O, et al. **J Trauma** 1997 Apr;42(4):741–2

Pedestrian pelvic fractures: 5-year experience of a major urban trauma center. Eastridge BJ, et al. **J Trauma** 1997 Apr;42(4):695–700

Experimentally induced upper facial third fractures in unembalmed human cadaver heads. Hudson JW, et al. **J Trauma** 1997 Apr;42(4):705–10

Perimortem intracranial orogastric tube insertion in a pediatric trauma patient with a basilar skull fracture. Junsanto T, et al. **J Trauma** 1997 Apr;42(4):746–7

Lateral impact motor vehicle collisions: significant cause of blunt traumatic rupture of the thoracic aorta. Katyal D, et al. **J Trauma** 1997 May;42(5):769–72

Injury pattern and severity in lateral motor vehicle collisions: a Canadian experience. McLellan BA, et al. **J Trauma** 1996 Oct;41(4):708–13

Aspiration of shattered windshield glass after blind nasotracheal intubation in a motor vehicle crash. Madhere S, et al. **J Trauma** 1997 Aug;43(2):353–6

Traumatic carotid artery dissection of restrained driver and thoracic aorta transection of unrestrained passenger in a motor vehicle accident: case report. Mason DP, et al. **J Trauma** 1997 Sep;43(3):537–40

Blunt injury of the abdominal aorta: a review. Roth SM, et al. **J Trauma** 1997 Apr;42(4):748–55 (63 ref.)

Prediction of remission of acute posttraumatic stress disorder in motor vehicle accident victims. Blanchard EB, et al. **J Trauma Stress** 1997 Apr;10(2):215–34

Thoracic aortography in a motor vehicle accident victim [see comments] Redman HC. **J Vasc Interv Radiol** 1997 Mar–Apr;8(2):226–7. Comment in: J Vasc Interv Radiol 1997 Jul–Aug;8(4):720.

Benzodiazepine use and the risk of motor vehicle crash in the elderly [see comments] Hemmelgarn B, et al. **JAMA** 1997 Jul 2;278(1):27–31. Comment in: JAMA 1997 Jul 2;278(1):66–7.

Safety and mobility of the older driver: a research challenge [editorial; comment] Ray WA. **JAMA** 1997 Jul 2; 278(1):66–7. Comment on: JAMA 1997 Jul 2;278(1):27–31.

Alcohol-impaired driving: the family's tragedy and the public's health [letter; comment] Robberstad MK. **JAMA** 1997 Apr 23–30;277(16):1279–80; discussion 1280. Comment on: JAMA 1997 Jan 8;277(2):122–5.

Alcohol-impaired driving: the family's tragedy and the public's health [letter; comment] Templeton B. **JAMA** 1997 Apr 23–30;277(16):1279; discussion 1280. Comment on: JAMA 1997 Jan 8;277(2):122–5.

Dementia and driving: screening, assessment, and advice [see comments] O'Neill D. **Lancet** 1996 Oct 26;348(9035):1114 . Comment in: Lancet 1996 Dec 7;348(9041):1591–2.

Medical evaluation in road injury claims [letter] [see comments] Tomberg C, et al. **Lancet** 1997 Feb 22; 349(9051):577–8. Comment in: Lancet 1997 Apr 19;349(9059):1179.

Machine learning of motor vehicle accident categories from narrative data. Lehto MR, et al. **Methods Inf Med** 1996 Dec;35(4–5):309–16

Cautions about car telephones and collisions [editorial; comment] Maclure M, et al. **N Engl J Med** 1997 Feb 13; 336(7):501–2. Comment on: N Engl J Med 1997 Feb 13;336(7):453–8.

Cellular telephones and traffic accidents [letter; comment] Paltiel O. **N Engl J Med** 1997 Jul 10;337(2):127–8. Comment on: N Engl J Med 1997 Feb 13;336(7):453–8.

Association between cellular-telephone calls and motor vehicle collisions [see comments] Redelmeier DA, et al. **N Engl J Med** 1997 Feb 13;336(7):453–8. Comment in: N Engl J Med 1997 Feb 13;336(7):501–2. Comment in: N Engl J Med 1997 Jul 10;337(2):127; discussion 128–9. Comment in: N Engl J Med 1997 Jul 10;337(2):127–8.

PIP 21-day rule adds to physicians' burdens. Sanders DL, et al. **N J Med** 1997 Aug;94(8):53–6

MRI of car occupants with whiplash injury. Voyvodic F, et al. **Neuroradiology** 1997 Jan;39(1):35–40

An unexpected fetal outcome following a severe maternal motor vehicle accident. Anquist KW, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):656–9

Airbag deployment following a motor vehicle accident in pregnancy. Sims CJ, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):726

Lethal airbag injury in an infant. Hollands CM, et al. **Pediatr Emerg Care** 1996 Jun;12(3):201–2

Wide mediastinum after motor vehicle accident. Swischuk LE. **Pediatr Emerg Care** 1996 Oct;12(5):382–4

Motor vehicle accident: closed head injury. Swischuk LE. **Pediatr Emerg Care** 1996 Aug;12(4):305–7

Speed and acceleration as measures of driving style in young male drivers. Lajunen T, et al. **Percept Mot Skills** 1997 Aug;85(1):3–16

Profound accidental hypothermia in the deep South: clinical experience. Tyndal CM Jr, et al. **Perfusion** 1996 Jan; 11(1):57–60

Psychiatry in trauma care [letter; comment] Ayonrinde OA. **Postgrad Med J** 1997 Mar;73(857):190. Comment on: Postgrad Med J 1996 Oct;72(852):587–93.

An unusual cause of orthopnoea. Donohoe P, et al. **Postgrad Med J** 1996 Jul;72(849):439–45

Seat belt-induced intestinal perforation. Codina Barreras A, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):94–100 **(Eng, Spa)**

Age and gender differences in perceived accident likelihood and driver competences. Glendon AI, et al. **Risk Anal** 1996 Dec;16(6):755–62

Mania following left hemisphere injury. Lim LC. **Singapore Med J** 1996 Aug;37(4):448–50 (18 ref.)

Effect of sleep deprivation on driving safety in housestaff. Marcus CL, et al. **Sleep** 1996 Dec;19(10):763–6

Air bags alone compared with the combination of mechanical restraints and air bags: implications for the emergency evaluation of crash victims. Sutyak JP, et al. **South Med J** 1997 Sep;90(9):915–9

Large radiolucent tracheal foreign body found by CT scan caused dyspnea: an admonition on flexible fiberscopic foreign body removal. Ikeda M, et al. **Surg Endosc** 1996 Feb;10(2):164–5

Unilateral hypertranslucency of the left hemithorax due to aneurysm of the thoracic aorta. Loukides S, et al. **Thorax** 1997 Mar;52(3):299–300

Jeep door handle injury. Singla SL, et al. **Trop Doct** 1997 Jul;27(3):175

Automobile crashes and sleep. Findley LJ, et al. **Va Med Q** 1996 Fall;123(4):258–9

[Roller skating injuries] Houshian S, et al. **Ugeskr Laeger** 1997 Jun 2;159(23):3580–2 (Eng. Abstr.) **(Dan)**

[Traumatic tricuspid valve insufficiency] Jensen SS, et al. **Ugeskr Laeger** 1997 Aug 4;159(32):4857–8 (Eng. Abstr.) **(Dan)**

[Roller skating accidents. A dangerous game on the road (editorial)] Juhl M. **Ugeskr Laeger** 1997 Jun 2;159(23):3555 **(Dan)**

[Occupational accidents in road traffic] Lings S, et al. **Ugeskr Laeger** 1997 Jan 20;159(4):426–30 (Eng. Abstr.) **(Dan)**

[Fatal traffic accidents in Denmark. Survival time and factors of importance for the prehospital phase] Madsen FQ, et al. **Ugeskr Laeger** 1996 Sep 23;158(39):5432–7 (Eng. Abstr.) **(Dan)**

[Fatal traffic accidents in Denmark. Prehospital changes in consciousness and loss of life-years due to traffic accidents] Madsen FQ, et al. **Ugeskr Laeger** 1996 Sep 23; 158(39):5428–31 (Eng. Abstr.) **(Dan)**

[Use of cellular telephones and automobile driving] Olsen J. **Ugeskr Laeger** 1997 May 5;159(19):2881 **(Dan)**

[Fatal traffic accidents in Denmark (editorial)] Reich H.

Ugeskr Laeger 1996 Sep 23;158(39):5416 **(Dan)**
[Urinary screening of drugs of abuse among drivers involved in road accidents] Pélissier AL, et al. **Ann Biol Clin (Paris)** 1996;54(10–11):365–71 (Eng. Abstr.) **(Fre)**
[Disruption of the pubic symphysis with overriding impacted symphysis. Apropos of a case] Catonné Y, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(5):458–61 (Eng. Abstr.) **(Fre)**
[Spiral computerized tomography diagnosis of abdominal seat belt injuries in children] Klöppel R, et al. **Aktuelle Radiol** 1997 Jan;7(1):19–22 (Eng. Abstr.) **(Ger)**
[Traffic accidents from the social medicine viewpoint—a medical history connection with present time] Hausotter W. **Swiss Surg** 1997;3(4):142–8 (Eng. Abstr.) **(Ger)**
[Biomechanics and injury prevention in road traffic] Walz E. **Ther Umsch** 1997 May;54(5):238–41 (Eng. Abstr.) **(Ger)**
[Automobile head supports—adjustment possibilities and utilization. Results of a field study] Jerosch J, et al. **Unfallchirurg** 1997 Jul;100(7):561–7 (Eng. Abstr.) **(Ger)**
[Road traffic accidents—a public health issue (editorial)] Ishay R. **Harefuah** 1997 Jun 15;132(12):847–8 **(Heb)**
[Falling asleep at the wheel: chronicle of a predicatable accident (editorial)] Lavie P. **Harefuah** 1997 Apr 15; 132(8):552–3 **(Heb)**
[Patterns of injuries and preventive measures for motorcycle accidents] Soffer D, et al. **Harefuah** 1997 Mar 16; 132(6):436–8, 447 (Eng. Abstr.) **(Heb)**
[Effects of seat belt legislation on injuries of traffic accidents] Campello C, et al. **Epidemiol Prev** 1996 Oct–Dec; 20(4):313–7 (Eng. Abstr.) **(Ita)**
[A case of death due to mitral regurgitation caused by traumatic mitral valve injury] Iwasaki Y, et al. **Nippon Hoigaku Zasshi** 1996 Jun;50(3):178–81 (Eng. Abstr.) **(Jpn)**
[An autopsy case of pulmonary thromboembolism: a delayed complication of a victim by traffic accident] Yamazaki M, et al. **Nippon Hoigaku Zasshi** 1997 Feb;51(1):48–55 (Eng. Abstr.) **(Jpn)**
[Traumatic transection of the descending thoracic aorta with free open rupture in left pleural cavity—a case report] Kamohara K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):783–6 (Eng. Abstr.) **(Jpn)**
[Internal carotid artery occlusion related to seat belt shoulder strap: report of two cases] Watanabe Y, et al. **Rinsho Shinkeigaku** 1996 May;36(5):670–4 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Safety equipment and automobile accidents] Lereim I. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2436 **(Nor)**
[Air bags influence the pattern of injury in severe thoracic trauma] Pillgram-Larsen J, et al. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2437–9 (Eng. Abstr.) **(Nor)**
[Prehospital care for the victims in road traffic accidents] Levenets VN, et al. **Klin Khir** 1995;(1):25–7 **(Rus)**
[Eye injuries on highways of Kabardino-Balkar] Aidarova EM, et al. **Med Tr Prom Ekol** 1996;(8):33–4 **(Rus)**
[Ophthalmologic causes of traffic accidents] Chernysheva SG, et al. **Med Tr Prom Ekol** 1996;(8):23–6 (Eng. Abstr.) **(Rus)**
[The 14th World Congress of International Association of traffic medicine (August 20–23, 1995, Singapore)] El'garova LV. **Med Tr Prom Ekol** 1996;(8):41–2 **(Rus)**
[Role of drivers' epilepsy in traffic accidents] Sabanchiev Slu, et al. **Med Tr Prom Ekol** 1996;(8):15–6 (Eng. Abstr.) **(Rus)**
[Traffic medicine: experience and unresolved problems] Vaisman AI, et al. **Med Tr Prom Ekol** 1996;(8):29–31 **(Rus)**
[The use of a method of sequential mathematical analysis for the differential diagnosis of trauma from a fall from a height and of trauma due to the collision of a moving automobile with a pedestrian by the chest injuries] Solokhin AA, et al. **Sud Med Ekspert** 1997 Apr–Jun;40(2):32–6 (Eng. Abstr.) **(Rus)**
[The diagnosis of the types of automobile-caused trauma by the nature of the injuries to the internal abdominal organs] Solokhin AA, et al. **Sud Med Ekspert** 1996 Jul–Sep; 39(3):9–13 (Eng. Abstr.) **(Rus)**
[Massive hemorrhage caused by musculoskeletal trauma in the dorsal region (letter)] Güemes M, et al. **Rev Esp Anestesiol Reanim** 1996 Jun–Jul;43(6):228–9 **(Spa)**
[The Ersta hospital's help during the Estonia disaster must not be forgotten (letter)] Berglund L. **Lakartidningen** 1997 May 28;94(22):2069–70 **(Swe)**
[Accidents, suicide or cry for help? 173 fatal cases on the railroads during 1990–95] Frisk M. **Lakartidningen** 1997 Mar 12;94(11):973–4, 979–80 **(Swe)**
[Air crash on Svalbard. An effective disaster planning at a Norwegian hospital] Ivert T, et al. **Lakartidningen** 1997 Feb 12;94(7):508–9 **(Swe)**
[An intensive rehabilitation helped. A new life for a patient with severe cranial injuries] Londos E, et al. **Lakartidningen** 1996 Oct 23;93(43):3791–2 **(Swe)**

ECONOMICS

United States passenger-vehicle crashes by crash geometry: direct costs and other losses. Miller T, et al. **Accid Anal Prev** 1997 May;29(3):343–52
National Highway Traffic Safety Administration (NHTSA) notes. The economic cost of motor vehicle crashes, 1994 [published erratum appears in Ann Emerg Med 1997 Feb;29(2):310] **Ann Emerg Med** 1996 Dec;28(6):711–2
Coverage of public reimbursement scheme for traffic accident victims in Thailand. Suriyawongpaisal P, et al. **J Med Assoc Thai** 1997 Jun;80(6):391–5
Temporomandibular disorders, headaches, and neck pain after motor vehicle accidents: a pilot investigation of persistence and litigation effects. Kolbinson DA, et al. **J Prosthet Dent** 1997 Jan;77(1):46–53
The care and cost of snowmobile-related injuries. Farley DR, et al. **Minn Med** 1996 Dec;79(12):21–5

LEGISLATION & JURISPRUDENCE

Estimating blood alcohol level from observable signs. McKnight AJ, et al. **Accid Anal Prev** 1997 Mar; 29(2):247–55
Head injuries and bicycle helmet laws. Robinson DL. **Accid Anal Prev** 1996 Jul;28(4):463–75
Drink-driving US style [news] **Addiction** 1996 Aug; 91(8):1239–40
Estimates of injury impairment after acute traumatic injury in motorcycle crashes before and after passage of a mandatory helmet use law. Peek-Asa C, et al. **Ann Emerg Med** 1997 May;29(5):630–6
An impaired judicial system [letter; comment] Workman S. **CMAJ** 1997 Jun 15;156(12):1698. Comment on: Can Med Assoc J 1997 Mar 15;156(6):889–90.
MADD Massachusetts versus Senator Burke: a media advocacy case study. DeJong W. **Health Educ Q** 1996 Aug; 23(3):318–29
Crash helmets in Bali, Indonesia [letter] Chapman S. **Inj Prev** 1997 Mar;3(1):70
Illusory safeguards: legitimizing distortion in recall with guidelines for forensic hypnosis—two case reports. Karlin RA. **Int J Clin Exp Hypn** 1997 Jan;45(1):18–40
Cellular telephones and traffic accidents [letter; comment] Cohen PJ. **N Engl J Med** 1997 Jul 10;337(2):127; discussion 128–9. Comment on: N Engl J Med 1997 Feb 13;336(7):453–8.
Hypoglycemia as a mitigating factor in vehicular accidents. Piotrowski C. **Percept Mot Skills** 1997 Jun;84(3 Pt 2):1241–2
[Whiplash injuries] Huittinen VM. **Duodecim** 1995; 111(17):1700–3 **(Fin)**
[Compensation of handicap in statutory accident insurance and traffic insurance] Torstila I. **Duodecim** 1995; 111(17):1722–3 **(Fin)**
[Alcohol and energy drink—can combined consumption of both beverages modify automobile driving fitness?] Riesselmann B, et al. **Blutalkohol** 1996 Jul;33(4):201–8 (Eng. Abstr.) **(Ger)**
[Alcohol at the wheel—medical psychological expert assessment. Laboratory data and abstinence—prognosis—responsibilities of the family physician] Müller-Wickop J, et al. **Fortschr Med** 1996 Oct 20;114(29):374–6 (4 ref.) **(Ger)**
[Intoxication or psychosis? Expert assessment of a crime] Schröter A. **Psychiatr Prax** 1997 Jan;24(1):43–4 **(Ger)**
[Aspects of medical expert assessment of sleep-waking disorders] Mayer G. **Wien Med Wochenschr** 1996; 146(13–14):391–5 (24 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

Estimating the exposure and fatal crash rates of suspended/revoked and unlicensed drivers in California. DeYoung DJ, et al. **Accid Anal Prev** 1997 Jan;29(1):17–23
Fatal pedestrian accidents in France: a typological analysis. Fontaine H, et al. **Accid Anal Prev** 1997 May;29(3):303–12
Trams—a risk factor for pedestrians. Hedelin A, et al. **Accid Anal Prev** 1996 Nov;28(6):733–8
Exploring the male–female discrepancy in death rates from bicycling injury: the decomposition method. Li G, et al. **Accid Anal Prev** 1996 Jul;28(4):537–40
Alcohol use among pedestrians and the odds of surviving an injury: evidence from Florida law enforcement data. Miles-Doan R. **Accid Anal Prev** 1996 Jan;28(1):23–31
Impact modelling studies for a three-wheeled scooter taxi. Mohan D, et al. **Accid Anal Prev** 1997 Mar;29(2):161–70
Role of disease in initiating the crashes of fatally injured drivers. Sjögren H, et al. **Accid Anal Prev** 1996 May; 28(3):307–14
Age-period-cohort analysis of motor vehicle mortality in Taiwan, 1974–1992. Tsauo JY, et al. **Accid Anal Prev** 1996 Sep;28(5):619–26
A comparative analysis of alcohol in fatal and nonfatal bicycling injuries. Li G, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1553–9
Alcohol, central nervous system injury, and time to death in fatal motor vehicle crashes. Zink BJ, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1518–22
Motor-vehicle crash fatalities among American Indians and non-Indians in Arizona, 1979 through 1988. Campos-Outcalt D, et al. **Am J Public Health** 1997 Feb; 87(2):282–5
Injuries to bicyclists in Wuhan, People's Republic of China. Li G, et al. **Am J Public Health** 1997 Jun;87(6):1049–52
Vehicle crash mortality in the Kimberley region, 1990 to 1994: the role of open-load-space passengers in utility trucks. Garrow SC. **Aust N Z J Public Health** 1997 Jun; 21(3):341–2
Management deficiencies and death preventability in 120 Victorian road fatalities (1993–1994). The Consultative Committee on Road Traffic Fatalities in Victoria. McDermott FT, et al. **Aust N Z J Surg** 1997 Sep; 67(9):611–8
The pattern of injury in fatal pedal cycle accidents and the possible benefits of cycle helmets. Kennedy A. **Br J Sports Med** 1996 Jun;30(2):130–3
The current situation of road traffic trauma. Wang Z. **Chin Med J (Engl)** 1996 Jan;109(1):24–7 (9 ref.)
Differentiation of visibility and alcohol as contributors to twilight road fatalities. Owens DA, et al. **Hum Factors** 1996 Dec;38(4):680–9
Some host factors and seasonal variations in the fatal road traffic accidents occurring in eastern suburban Calcutta. Majumder B, et al. **Indian J Public Health** 1996 Apr–Jun; 40(2):46–9
Risk of death from motor-vehicle injury in Brazilian steelworkers: a nested case-control study. Barreto SM, et al. **Int J Epidemiol** 1997 Aug;26(4):814–21
Alcohol availability and motor vehicle fatalities. Kelleher KJ, et al. **J Adolesc Health** 1996 Nov;19(5):325–30
Alcohol availability and motor vehicle fatalities [letter] Tonkin RS. **J Adolesc Health** 1997 Aug;21(2):74–5
An epidemiological study of roadway fatalities related to farm vehicles: United States, 1988 to 1993. Gerberich SG, et al. **J Occup Environ Med** 1996 Nov;38(11):1135–40
Alcohol-related measures as factors in traffic fatalities. Mann RE, et al. **J Stud Alcohol** 1996 Nov;57(6):646–51
Alcohol use, driver, and crash characteristics among injured motorcycle drivers. Peek-Asa C, et al. **J Trauma** 1996 Dec; 41(6):989–93
Geographic variations in mortality from motor vehicle crashes in Taiwan. Yang CY, et al. **J Trauma** 1997 Jul; 43(1):74–7
From the Centers for Disease Control and Prevention. Update: fatal air bag-related injuries to children—United States, 1993–1996 [published erratum appears in JAMA 1997 Feb 5;277(5):372] **JAMA** 1997 Jan 1;277(1):11–2
Alzheimer's disease and apolipoprotein E epsilon 4 allele in older drivers who died in automobile accidents [letter] Johansson K, et al. **Lancet** 1997 Apr 19;349(9059):1143–4
Global burden of disease [letter; comment] Roberts I. **Lancet** 1997 Jul 12;350(9071):144. Comment on: Lancet 1997 May 3;349(9061):1263. Comment on: Lancet 1997 May 3;349(9061):1498–504.
Alcohol involvement in motor vehicle fatalities, 1995. Buechner JS, et al. **Med Health R I** 1997 Jul;80(7):232–3
Vehicle-related fatalities among Swedish conscripts. Bylund PO, et al. **Mil Med** 1997 Jun;162(6):412–5
Involvement by young drivers in fatal motor-vehicle crashes—United States, 1988–1995. **MMWR Morb Mortal Wkly Rep** 1996 Dec 6; 45(48):1049–53
Alcohol involvement in fatal motor-vehicle crashes—United States, 1994–1995. **MMWR Morb Mortal Wkly Rep** 1996 Dec 6;45(48):1060, 1067
Update: fatal air bag-related injuries to children—United States, 1993–1996 [published erratum appears in MMWR Morb Mortal Wkly Rep 1997 Jan 17;46(2):40] **MMWR Morb Mortal Wkly Rep** 1996 Dec 13; 45(49):1073–6
Class differences and traffic deaths. Krus DJ, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 1):1005–6
The role of heavy drinking in the risk of traffic fatalities. Kennedy BP, et al. **Risk Anal** 1996 Aug;16(4):565–9
The effect of epilepsy on road traffic accidents and casualties. Bener A, et al. **Seizure** 1996 Sep;5(3):215–9
Highway fatalities: leading cause of work-related deaths. Personick M, et al. **Stat Bull Metrop Insur Co** 1997 Apr–Jun;78(2):19–25
Firearms continue to be the leading cause of injury mortality in Texas. Zane DF, et al. **Tex Med** 1996 May;92(5):54
Motor vehicle crashes and maternal mortality in New Mexico: the significance of seat belt use. Schiff M, et al. **West J Med** 1997 Jul;167(1):19–22
[An epidemiological analysis on the relationship between motorization and traffic mortality in China] Chi GB, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Feb; 17(1):25–8 (Eng. Abstr.) **(Chi)**
[Bicycle accidents. A retrospective study 1986–1991] Reinhardt G, et al. **Versicherungsmedizin** 1996 Feb 1; 48(1):15–7 (Eng. Abstr.) **(Ger)**
[Report on medico-legal data from the mass-investigation performed by the Medico-Legal Society of Japan (XIV). Autopsy cases of traffic accidents in Japan (1990–1994). Planning and Development Committee of The Medico-Legal Society of Japan] **Nippon Hoigaku Zasshi** 1997 Apr;51(2):120–6 (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

The view from Washington: an emergency physician in NHTSA's court. Martinez R. **Acad Emerg Med** 1997 Apr; 4(4):313–22
Further aspects of the British index of secondary car safety. Broughton J. **Accid Anal Prev** 1996 Nov;28(6):791–8
Prospects for technological countermeasures against driver fatigue. Brown ID. **Accid Anal Prev** 1997 Jul;29(4):525–31
Are lower legal blood alcohol limits and a combination of sanctions desirable in reducing drunken driver-involved traffic fatalities and traffic accidents? Deshapriya EB, et al. **Accid Anal Prev** 1996 Nov;28(6):721–31 (37 ref.)

A comparison of two direct-observation methods for measuring daytime safety belt use. Eby DW, et al. **Accid Anal Prev** 1996 May;28(3):403–7

The influence of sustained attention on railway accidents. Edkins GD, et al. **Accid Anal Prev** 1997 Jul;29(4):533–9

A meta-analysis of studies concerning the safety effects of daytime running lights on cars. Elvik R. **Accid Anal Prev** 1996 Nov;28(6):685–94

Evaluations of road accident blackspot treatment: a case of the Iron Law of Evaluation Studies? Elvik R. **Accid Anal Prev** 1997 Mar;29(2):191–9

Does prior knowledge of safety effect help to predict how effective a measure will be? Elvik R. **Accid Anal Prev** 1996 May;28(3):339–47

Safety-belt effectiveness: the influence of crash severity and selective recruitment. Evans L. **Accid Anal Prev** 1996 Jul; 28(4):423–33

The effect of time headway feedback on following behaviour. Fairclough SH, et al. **Accid Anal Prev** 1997 May; 29(3):387–97

Balancing work and rest to combat driver fatigue: an investigation of two-up driving in Australia. Feyer AM, et al. **Accid Anal Prev** 1997 Jul;29(4):541–53

Advertising wearout in the Transport Accident Commission road safety campaigns. Fry TR. **Accid Anal Prev** 1996 Jan; 28(1):123–9

The evaluation of road-rail crossing safety with limited accident statistics. Gitelman V, et al. **Accid Anal Prev** 1997 Mar;29(2):171–9

Effects of signalisation on four-arm urban junction safety. Golias JC. **Accid Anal Prev** 1997 Mar;29(2):181–90

Road safety improvement in large companies. An experimental comparison of different measures. Gregersen NP, et al. **Accid Anal Prev** 1996 May;28(3):297–306

Evaluation of California's commercial driver license program. Hagge RA, et al. **Accid Anal Prev** 1996 Sep; 28(5):547–59

Fatigue, workload and adaptive driver systems. Hancock PA, et al. **Accid Anal Prev** 1997 Jul;29(4):495–506

Speed limitation and motorway casualties: a time series count data regression approach. Johansson P. **Accid Anal Prev** 1996 Jan;28(1):73–87

Age, gender and the effectiveness of high-threat letters: an analysis of Oregon's driver improvement advisory letters. Jones B. **Accid Anal Prev** 1997 Mar;29(2):225–34

Conflicting goals of skid training. Katila A, et al. **Accid Anal Prev** 1996 Nov;28(6):785–9

Accident prevention versus recidivism prevention courses for repeat traffic offenders. McKnight AJ, et al. **Accid Anal Prev** 1997 Jan;29(1):25–31

The use of feedback signs to increase observed daytime seat belt use in two cities in North Carolina. Malenfant L, et al. **Accid Anal Prev** 1996 Nov;28(6):771–7

Evaluation of an alternative traffic light change anticipation system. Newton C, et al. **Accid Anal Prev** 1997 Mar; 29(2):201–9

Adaptation to the driver as part of a driver monitoring and warning system. Onken R, et al. **Accid Anal Prev** 1997 Jul; 29(4):507–13

Head injuries and bicycle helmet laws. Robinson DL. **Accid Anal Prev** 1996 Jul;28(4):463–75

Impact of the Illinois child passenger protection act: a retrospective look. Rock SM. **Accid Anal Prev** 1996 Jul; 28(4):487–92 (14 ref.)

Comment on Williams and Farmer's evaluation of daytime running lights [comment] Theeuwes J, et al. **Accid Anal Prev** 1996 Nov;28(6):799–800. Comment on: Accid Anal Prev 1996 Jul;28(4):541–42.

The effectiveness of side marker lamps: an experimental study. Theeuwes J, et al. **Accid Anal Prev** 1997 Mar; 29(2):235–45

Increased police enforcement: effects on speed. Vaa T. **Accid Anal Prev** 1997 May;29(3):373–85

Headrest position during normal driving: implication to neck injury risk in rear crashes. Viano DC, et al. **Accid Anal Prev** 1996 Nov;28(6):665–74

What do Israeli Jewish and Arab adolescents know about drinking and driving? Weiss S. **Accid Anal Prev** 1996 Nov; 28(6):765–9

Comment on Theeuwes and Riemersma's revisit of daytime running lights [see comments] Williams AF, et al. **Accid Anal Prev** 1996 Jul;28(4):541–42. Comment in: Accid Anal Prev 1996 Nov;28(6):799–800.

Drinking and driving prevention in the community: program planning and implementation. Voas RB. **Addiction** 1997 Jun;92 Suppl 2:S201–19

The effect of drinking and driving interventions on alcohol-involved traffic crashes within a comprehensive community trial. Voas RB, et al. **Addiction** 1997 Jun;92 Suppl 2:S221–36

Should people taking opioids for medical reasons be allowed to work and drive? [editorial] Zacny JP. **Addiction** 1996 Nov;91(11):1581–4 (16 ref.)

The driver's role in automobile safety [letter; comment] Fisher L. **Am J Public Health** 1997 May;87(5):871–2. Comment on: Am J Public Health 1996 Jun;86(6):784–6.

National Highway Traffic Safety Administration (NHTSA) notes. New Technologies from NHTSA. **Ann Emerg Med** 1997 Jun;29(6):812–3

National Highway Traffic Safety Administration: vehicle weight and safety [see comments] **Ann Emerg Med** 1997 Aug;30(2):224–5. Comment in: Ann Emerg Med 1997 Aug;30(2):225–6.

NHTSA Crash-Injury Research and Engineering Network. **Ann Emerg Med** 1996 Oct;28(4):450–1; discussion 451–2

Helmets work best [editorial; comment] Graitcer PL. **Ann Emerg Med** 1997 May;29(5):643–4 (10 ref.). Comment on: Ann Emerg Med 1997 May;29(5):625–9.

Building a smarter car: visions of the future at NHTSA. Jolly BT. **Ann Emerg Med** 1997 Jun;29(6):813–4

Bigger is better, but not for everyone. NHTSA. National Highway Traffic Safety Administration [comment] Jolly BT. **Ann Emerg Med** 1997 Aug;30(2):225–6. Comment on: Ann Emerg Med 1997 Aug;30(2):224–5.

Rider training, reasons for riding, and the social context of riding among young on-road motorcyclists in New Zealand. Reeder AI, et al. **Aust N Z J Public Health** 1996 Aug;20(4):369–74

Childhood pedestrian injuries: what can changes to the road environment achieve? Stevenson M. **Aust N Z J Public Health** 1997 Feb;21(1):33–7

Management deficiencies and death preventability in 120 Victorian road fatalities (1993–1994). The Consultative Committee on Road Traffic Fatalities in Victoria. McDermott FT, et al. **Aust N Z J Surg** 1997 Sep; 67(9):611–8

Counseling to reduce road injuries and deaths. Johnson D. **Can Fam Physician** 1996 Nov;42:2154–8

Secondary safety of car adaptations for disabled motorists. Turner-Stokes L, et al. **Disabil Rehabil** 1996 Jun; 18(6):317–27 (1 ref.)

Alarm effectiveness in driver-centred collision-warning systems. Parasuraman R, et al. **Ergonomics** 1997 Mar; 40(3):390–9

Choice of time-headway in car-following and the role of time-to-collision information in braking. Van Winsum W, et al. **Ergonomics** 1996 Apr;39(4):579–92

Risk of traffic accidents in patients with sleep-disordered breathing: reduction with nasal CPAP. Cassel W, et al. **Eur Respir J** 1996 Dec;9(12):2606–11

Comprehensive drug screening in blood for detecting abused drugs or drugs potentially hazardous for traffic safety. Lillsunde P, et al. **Forensic Sci Int** 1996 Feb 9;77(3):191–210

Human factors field evaluation of automotive headway maintenance/collision warning devices. Dingus TA, et al. **Hum Factors** 1997 Jun;39(2):216–29

Automotive HUDs: the overlooked safety issues. Tufano DR. **Hum Factors** 1997 Jun;39(2):303–11

High levels of incorrect use of car seat belts and child restraints in Fife—an important and under-recognised road safety issue. Campbell H, et al. **Inj Prev** 1997 Mar; 3(1):17–22

Crash helmets in Bali, Indonesia [letter] Chapman S. **Inj Prev** 1997 Mar;3(1):70

The safety of older pedestrians at signal-controlled crossings. Harrell WA. **Int J Aging Hum Dev** 1996;42(1):65–79

And then there were 12 [editorial] Classé JG. **J Am Optom Assoc** 1996 Jul;67(7):373–4

Assigned versus participative goal setting and response generalization: managing injury control among professional pizza deliverers. Ludwig TD, et al. **J Appl Psychol** 1997 Apr;82(2):253–61

Prevalence and effectiveness of self-regulatory techniques used to avoid drunk driving. Brown SL. **J Behav Med** 1997 Feb;20(1):55–66

A parametric study of a side airbag system to meet deflection based criteria. Håland Y, et al. **J Biomech Eng** 1996 Aug; 118(3):412–9

Everyday murder [letter] Davis GJ. **J Ky Med Assoc** 1997 Jun;95(6):246

Too many MVAs [editorial] [see comments] McIntyre RV. **J Okla State Med Assoc** 1996 Aug;89(8):263. Comment in: J Okla State Med Assoc 1996 Oct;89(10):379.

Patterns and correlates of supervision in child pedestrian injury. The Kids 'N' Cars Research Team. Wills KE, et al. **J Pediatr Psychol** 1997 Feb;22(1):89–104

Wake-up call aimed at drowsy drivers: message is 'drive alert, arrive alive' [news] Lamberg L. **JAMA** 1996 Oct 16;276(15):1209–10

Conducting truck drivers' physical exams. The high prevalence of sleep apnea. Asp DS. **Minn Med** 1997 Jan; 80(1):29–30

Injury prevention. First of two parts. Rivara FP, et al. **N Engl J Med** 1997 Aug 21;337(8):543–8 (70 ref.)

Ready for the road. Schmitt D. **Occup Health Saf** 1996 Mar; 65(3):51–4

Road characteristics and bicycle accidents. Nyberg P, et al. **Scand J Soc Med** 1996 Dec;24(4):293–301

A review of successful transport and home injury interventions to guide developing countries. Forjuoh SN, et al. **Soc Sci Med** 1996 Dec;43(11):1551–60 (90 ref.)

The Republic of Yemen. Nasher AA, et al. **Trop Doct** 1996 Jul;26(3):137–8

At risk drivers: are physicians required to report? [letter] Hansotia P. **Wis Med J** 1997 May;96(5):7

[Problems in traffic medicine in hospital and everyday practice: able to drive?] Hauri-Bionda R, et al. **Ther Umsch** 1997 May;54(5):255–62 (Eng. Abstr.) **(Ger)**

[Physicians and the battle against road accidents (editorial)] Shoenfeld Y, et al. **Harefuah** 1997 Feb 2;132(3):183–4 **(Heb)**

[Vision defects in two age groups of drivers who caused road accidents] Toczolowski J, et al. **Klin Oczna** 1996 Mar; 98(3):221–4 (Eng. Abstr.) **(Pol)**

[Prevention of arterial hypertension in automobile transport workers and ways of reducing traffic accidents] Inarokova AM. **Med Tr Prom Ekol** 1996;(8):6–10 (Eng. Abstr.) **(Rus)**

[Prevention of traffic accidents involving children] Uvizheva MKh, et al. **Med Tr Prom Ekol** 1996;(8):31–3 **(Rus)**

[Significance of psychological personality testing of motor vehicle drivers in the traffic safety system] Zhurtova MM, et al. **Med Tr Prom Ekol** 1996;(8):19–20 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Attitudes and road accident risk. Assum T. **Accid Anal Prev** 1997 Mar;29(2):153–9

Behavioural feedback to risk variation ensues from unsatisfied appetency. Dussault C. **Accid Anal Prev** 1996 Jul; 28(4):477–86 (20 ref.)

Age and experience in motorcycling safety. Rutter DR, et al. **Accid Anal Prev** 1996 Jan;28(1):15–21

Psychosocial sequelae of motor vehicle collisions: a follow-up study. Vingilis E, et al. **Accid Anal Prev** 1996 Sep;28(5):637–45

Antecedents and consequences of acute stress disorder among motor vehicle accident victims. Barton KA, et al. **Behav Res Ther** 1996 Oct;34(10):805–13

One-year prospective follow-up of motor vehicle accident victims. Blanchard EB, et al. **Behav Res Ther** 1996 Oct; 34(10):775–86

The private practice psychologist and manual-based treatments: post-traumatic stress disorder secondary to motor vehicle accidents [see comments] Hickling EJ, et al. **Behav Res Ther** 1997 Mar;35(3):191–203. Comment in: Behav Res Ther 1997 Mar;35(3):205–10.

Treatment manuals in clinical practice [comment] Wilson GT. **Behav Res Ther** 1997 Mar;35(3):205–10. Comment on: Behav Res Ther 1997 Mar;35(3):191–203.

Post-traumatic stress reactions in children: gender differences in the incidence of trauma reactions at two years and examination of factors influencing adjustment. Curle CE, et al. **Br J Clin Psychol** 1996 May;35 (Pt 2):297–309

Attitudes towards emotional expression and post-traumatic stress in survivors of the Herald of Free Enterprise disaster. Joseph S, et al. **Br J Clin Psychol** 1997 Feb;36 (Pt 1):133–8

Early psychological reactions in a group of individuals with pre-existing and enduring mental health difficulties following a major coach accident. Chubb HL, et al. **Br J Psychiatry** 1996 Oct;169(4):430–3

Psychological sequelae of road traffic accidents: an inadequately addressed problem [editorial] Di Gallo A, et al. **Br J Psychiatry** 1996 Oct;169(4):405–7

Road traffic accidents: early psychological consequences in children and adolescents. Di Gallo A, et al. **Br J Psychiatry** 1997 Apr;170:358–62

The spectrum of emotional distress and personality changes after minor head injury incurred in a motor vehicle accident. Parker RS. **Brain Inj** 1996 Apr;10(4):287–302

Posttraumatic stress disorder and motor vehicle accidents: a multidisciplinary overview [see comments] Kuch K, et al. **Can J Psychiatry** 1996 Sep;41(7):429–34 (69 ref.). Comment in: Can J Psychiatry 1997 Mar;42(2):210.

Re: Posttraumatic stress disorder and motor vehicle accidents [letter; comment] Solursh LP, et al. **Can J Psychiatry** 1997 Mar;42(2):210. Comment on: Can J Psychiatry 1996 Sep;41(7):429–34.

Re: Posttraumatic stress disorder and motor vehicle accidents [letter; comment] Tyndel M, et al. **Can J Psychiatry** 1997 Mar;42(2):210. Comment on: Can J Psychiatry 1996 Sep;41(7):429–34.

Magical realism: a cultural intervention for traumatized Hispanic children. De Rios MD. **Cult Divers Ment Health** 1997;3(3):159–70

A prospective examination of delayed onset PTSD secondary to motor vehicle accidents. Buckley TC, et al. **J Abnorm Psychol** 1996 Nov;105(4):617–25

Acute and chronic distress and posttraumatic stress disorder as a function of responsibility for serious motor vehicle accidents. Delahanty DL, et al. **J Consult Clin Psychol** 1997 Aug;65(4):560–7

Long-term outcome of trauma in adults: the psychological impact of a fatal bus accident. Winje D. **J Consult Clin Psychol** 1996 Oct;64(5):1037–43

The five-factor model, conscientiousness, and driving accident involvement. Arthur W Jr, et al. **J Pers** 1996 Sep; 64(3):593–618

Voluntary and professional disaster-workers: similarities and differences in reactions. Dyregrov A, et al. **J Trauma Stress** 1996 Jul;9(3):541–55

Children's selective coping after a bus disaster: confronting behavior and perceived support. Milgram N, et al. **J Trauma Stress** 1996 Oct;9(4):687–702

Parental bereavement after suicide and accident: a comparative study. Séguin M, et al. **Suicide Life Threat Behav** 1995 Winter;25(4):489–92

STATISTICS & NUMERICAL DATA

Alcohol abuse/dependence in motor vehicle crash victims presenting to the emergency department. Maio RF, et al. **Acad Emerg Med** 1997 Apr;4(4):256–62

Tractor-trailer crashes in Indiana: a case-control study of the role of truck configuration. Braver ER, et al. **Accid Anal Prev** 1997 Jan;29(1):79–96

ACCIDENTS, TRAFFIC

The British index for comparing the accident record of car models. Broughton J. **Accid Anal Prev** 1996 Jan;28(1):101–9
The theoretical basis for comparing the accident record of car models. Broughton J. **Accid Anal Prev** 1996 Jan; 28(1):89–99
A new method for predicting crashworthiness. Council FM, et al. **Accid Anal Prev** 1997 Jan;29(1):109–23
Motor vehicle accidents, fatigue and optimism bias in taxi drivers. Dalziel JR, et al. **Accid Anal Prev** 1997 Jul; 29(4):489–94
Driver fatigue in the city. Fell DL, et al. **Accid Anal Prev** 1997 Jul;29(4):463–9
Black times: temporal determinants of transport safety. Folkard S. **Accid Anal Prev** 1997 Jul;29(4):417–30 (25 ref.)
The validity of police assessment of driver intoxication in motor vehicle crashes leading to hospitalization. Grossman DC, et al. **Accid Anal Prev** 1996 Jul;28(4):435–42
Welfare consequences of injuries due to traffic accidents. Haukeland JV. **Accid Anal Prev** 1996 Jan;28(1):63–72
A review of crash data analysis in a defect and recall investigation of the general motors C/K pickup trucks. Hubele NF, et al. **Accid Anal Prev** 1996 Jan;28(1):33–42
Speed limitation and motorway casualties: a time series count data regression approach. Johansson P. **Accid Anal Prev** 1996 Jan;28(1):73–87
Medical conditions and the severity of commercial motor vehicle drivers' road accidents. Laberge-Nadeau C, et al. **Accid Anal Prev** 1996 Jan;28(1):43–51
Taxi drivers' accidents: how binocular vision problems are related to their rate and severity in terms of the number of victims. Maag U, et al. **Accid Anal Prev** 1997 Mar; 29(2):217–24
The scope and nature of the drowsy driving problem in New York State. McCartt AT, et al. **Accid Anal Prev** 1996 Jul; 28(4):511–17
Light vehicle occupant ejections--a comprehensive investigation. Malliaris AC, et al. **Accid Anal Prev** 1996 Jan;28(1):1–14 (9 ref.)
Sleepiness and driving: the experience of U.K. car drivers. Maycock G. **Accid Anal Prev** 1997 Jul;29(4):453–62
Accident prediction models for roads with minor junctions. Mountain L, et al. **Accid Anal Prev** 1996 Nov;28(6):695–707
Predicting the severity of motor vehicle accident injuries using models of ordered multiple choice. O'Donnell CJ, et al. **Accid Anal Prev** 1996 Nov;28(6):739–53
Influences of the physical parameters on the risk to neck injuries in low impact speed rear-end collisions. Ono K, et al. **Accid Anal Prev** 1996 Jul;28(4):493–9
Injuries sustained by motorcycle riders in the approaching turn crash configuration. Peek-Asa C, et al. **Accid Anal Prev** 1996 Sep;28(5):561–9
Impact of the Illinois child passenger protection act: a retrospective look. Rock SM. **Accid Anal Prev** 1996 Jul; 28(4):487–92 (14 ref.)
Age and experience in motorcycling safety. Rutter DR, et al. **Accid Anal Prev** 1996 Jan;28(1):15–21
Correlations between traffic, occupational, sports, and home accidents. Salminen S, et al. **Accid Anal Prev** 1997 Jan; 29(1):33–6
Statistical analysis of accident severity on rural freeways. Shankar V, et al. **Accid Anal Prev** 1996 May;28(3):391–401
Alcohol-related predictors of adolescent driving: gender differences in crashes and offenses. Shope JT, et al. **Accid Anal Prev** 1996 Nov;28(6):755–64
Does license disqualification reduce reoffence rates? Siskind V. **Accid Anal Prev** 1996 Jul;28(4):519–24
Alcohol use among injured sets of drivers and passengers. Soderstrom CA, et al. **Accid Anal Prev** 1996 Jan;28(1):111–4
Motor vehicle crashes in roadway construction workzones: an analysis using narrative text from insurance claims. Sorock GS, et al. **Accid Anal Prev** 1996 Jan;28(1):131–8
Quasi-induced exposure: methodology and insight. Stamatiadis N, et al. **Accid Anal Prev** 1997 Jan;29(1):37–52
Safety and the car size effect: a fundamental explanation. Wood DP. **Accid Anal Prev** 1997 Mar;29(2):139–51
Drinking and driving: drinking patterns and drinking problems. Gruenewald PJ, et al. **Addiction** 1996 Nov; 91(11):1637–49
Validity of self-reported criminal offences and traffic violations in screening of driving-while-intoxicated offenders. Chang I, et al. **Alcohol Alcohol** 1996 Nov; 31(6):583–90
Recidivism among drunken and drugged drivers in Norway. Christophersen AS, et al. **Alcohol Alcohol** 1996 Nov; 31(6):609–11
Assessing alcohol problems in female DWI offenders. Parks KA, et al. **Alcohol Clin Exp Res** 1996 May;20(3):434–9
Motor vehicle crashes, restraint use, and severity of injury in children in Nevada. Niemcryk SJ, et al. **Am J Prev Med** 1997 Mar-Apr;13(2):109–14
Mistaken assertions on reducing motor vehicle injury [comment] Robertson LS. **Am J Public Health** 1997 Feb; 87(2):295–6. Comment on: Am J Public Health 1996 Jun;86(6):784–6.
Natural disease and alcohol intoxication amongst drivers of motor vehicles in Singapore from 1989 to 1993: a study of 140 necropsies. Lau G. **Ann Acad Med Singapore** 1996 Jul;25(4):516–21
Helmets work best [editorial; comment] Graitcer PL. **Ann Emerg Med** 1997 May;29(5):643–4 (10 ref.). Comment on: Ann Emerg Med 1997 May;29(5):625–9.
Walking to school and traffic exposure in Australian children. Carlin JB, et al. **Aust N Z J Public Health** 1997 Jun; 21(3):286–92
Childhood pedestrian injuries: what can changes to the road environment achieve? Stevenson M. **Aust N Z J Public Health** 1997 Feb;21(1):33–7
Head injuries from bicycle accidents. Zentner J, et al. **Clin Neurol Neurosurg** 1996 Nov;98(4):281–5
War on the roads: traffic accidents and social tension in Britain, 1939–45. Luckin B. **Clio Med** 1997;41:234–54
Social patterns of road accidents to children: some characteristics of vulnerable families. Backett EM, et al. **Inj Prev** 1997 Mar;3(1):57–62
Statistical commentary. Platt RW. **Inj Prev** 1997 Jun; 3(2):87–8
Can a physician recognize an older driver with increased crash risk potential? Johansson K, et al. **J Am Geriatr Soc** 1996 Oct;44(10):1198–204
A case-control study of childhood pedestrian injuries in Perth, Western Australia. Stevenson M, et al. **J Epidemiol Community Health** 1996 Jun;50(3):280–7
Aetiological factors contributing to road traffic accidents in Riyadh City, Saudi Arabia. Nofal FH, et al. **J R Soc Health** 1996 Oct;116(5):304–11
Airbag protection versus compartment intrusion effect determines the pattern of injuries in multiple trauma motor vehicle crashes. Loo GT, et al. **J Trauma** 1996 Dec; 41(6):935–51
Alcohol use, driver, and crash characteristics among injured motorcycle drivers. Peek-Asa C, et al. **J Trauma** 1996 Dec; 41(6):989–93
School bus-related deaths and injuries in New South Wales [letter; comment] Black BP. **Med J Aust** 1997 Jan 20; 166(2):107; discussion 107–8. Comment on: Med J Aust 1996 Aug 5;165(3):134–7.
School bus-related deaths and injuries in New South Wales [letter; comment] Watson DA. **Med J Aust** 1997 Jan 20; 166(2):107; discussion 107–8. Comment on: Med J Aust 1996 Aug 5;165(3):134–7.
Epileptic drivers--a study of 1,089 patients. Beaussart M, et al. **Med Law** 1997;16(2):295–306
Cellular telephones and traffic accidents [letter; comment] Quinlan KP. **N Engl J Med** 1997 Jul 10;337(2):127; discussion 128. Comment on: N Engl J Med 1997 Feb 13;336(7):453–8.
The role of the physical and traffic environment in child pedestrian injuries. Agran PF, et al. **Pediatrics** 1996 Dec; 98(6 Pt 1):1096–103
Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Barkley RA, et al. **Pediatrics** 1996 Dec;98(6 Pt 1):1089–95
Chronic drinking, binge drinking and drunk driving. Duncan DF. **Psychol Rep** 1997 Apr;80(2):681–2
Seasonal variation and weather effects on road traffic accidents in Riyadh city. Nofal FH, et al. **Public Health** 1997 Jan;111(1):51–5
National health insurance consumption and chronic symptoms following mild neck sprain injuries in car collisions. Borchgrevink GE, et al. **Scand J Soc Med** 1996 Dec;24(4):264–71
Road traffic injuries in developing countries: a comprehensive review of epidemiological studies. Odero W, et al. **Trop Med Int Health** 1997 May;2(5):445–60
Sleep, sleep disorders and motor vehicle crashes. Hansotia P. **Wis Med J** 1997 May;96(5):42–7
Nonfatal motor vehicle crash injuries: Wisconsin's experience with linked data systems. Karlson TA, et al. **Wis Med J** 1996 May;95(5):301–4
[Traffic accidents as a couse for emergency hospitalization] Lindner UK. **Anaesthesist** 1996 Nov;45(11):1108–10 **(Ger)**
[Alcohol, street drugs and therapeutic drugs in street traffic] Schöch H. **Fortschr Med** 1997 Mar 10;115(7):39–42 (Eng. Abstr.) **(Ger)**
[Motorcycle accidents in street traffic. An analysis of 86 cases] Wick M, et al. **Unfallchirurg** 1997 Feb;100(2):140–5 (Eng. Abstr.) **(Ger)**
[Accident incidence at various ages] Huth O. **Versicherungsmedizin** 1997 Apr 1;49(2):36–40 (Eng. Abstr.) **(Ger)**
[Risk of accident due to hypersomnia: relevance for sleep medicine] Cassel W, et al. **Wien Med Wochenschr** 1996; 146(13–14):337–9 (16 ref.) (Eng. Abstr.) **(Ger)**
[Driving performance and auto accidents in patients with sleep apnea] Findley LJ. **Wien Med Wochenschr** 1996; 146(13–14):335–6 (16 ref.) (Eng. Abstr.) **(Ger)**
[Motor vehicle accidents and eye injuries] Pikkel J, et al. **Harefuah** 1997 Jan 1;132(1):16–8, 72, 71 (Eng. Abstr.) **(Heb)**
[Perforating eye injuries caused by motor vehicle accidents: cases assisted during the year 1994] Sampaio MW, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Mar-Apr; 51(2):69–71 (Eng. Abstr.) **(Por)**
[Traffic accidents in Kabardino-Balkar: prophylactic ways] El'garov AA. **Med Tr Prom Ekol** 1996;(8):1–4 **(Rus)**
[Traffic accidents and sleep apnea (editorial)] Jiménez Gómez A, et al. **Arch Bronconeumol** 1997 Jan;33(1):4–5 **(Spa)**
[Traffic accidents in the Spanish population: analysis from an emergency department (letter; comment)] Tomás S, et al. **Med Clin (Barc)** 1996 Oct 26;107(14):557. Comment on: Med Clin (Barc) 1995 Nov 11;105(16):601–4. **(Spa)**

TRENDS

Estimates of injury impairment after acute traumatic injury in motorcycle crashes before and after passage of a mandatory helmet use law. Peek-Asa C, et al. **Ann Emerg Med** 1997 May;29(5):630–6

ACCLIMATION see **ACCLIMATIZATION**

ACCLIMATIZATION

Changes in the apical surface of chloride cells following acclimation of lampreys to seawater. Bartels H, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):R125–33
Brown fat thermogenesis and cardiac rate regulation during cold challenge in infant rats. Blumberg MS, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1308–13
Enzyme adaptation along a heterothermic tissue: the visceral retia mirabilia of the bluefin tuna. Fudge DS, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1834–40
Thermal modulation of channel catfish intestinal dimensions, BBM fluidity, and glucose transport. Houpe KL, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R1037–43
Ca2+ uptake by cardiac sarcoplasmic reticulum at low temperature in rat and ground squirrel. Liu B, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1121–7
Effect of chronic cold exposure on Na-dependent D-glucose transport along small intestine in ducklings. Thomas V, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1429–38
A comparison of the metabolic cost of protein synthesis in stenothermal and eurythermal isopod crustaceans. Whiteley NM, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1295–303
Muscle biopsy as a tool for assessing muscular adaptation to training in horses. Rivero JL. **Am J Vet Res** 1996 Oct; 57(10):1412–6
Relation of sympathetic activation to ventilation in man at 4300 m altitude. Asano K, et al. **Aviat Space Environ Med** 1997 Feb;68(2):104–10
Increased histidine preference during specific alteration of rhythm of environmental temperature stress in rats. Kondoh T, et al. **Behav Neurosci** 1996 Oct;110(5):1187–92
Differential scanning calorimetry and CD spectrometry of acclimation temperature-associated types of carp light meromyosin. Nakaya M, et al. **Biochemistry** 1997 Jul 29; 36(30):9179–84
Heat acclimatisation and rehydration strategy. Maughan R. **Br J Sports Med** 1997 Mar;31(1):77
Effect of prewarming in the cold season on thermoregulatory responses during exercise. Torii M, et al. **Br J Sports Med** 1996 Jun;30(2):102–11
Chronic congestive heart failure elicits adaptations of endurance exercise in diaphragmatic muscle. Tikunov B, et al. **Circulation** 1997 Feb 18;95(4):910–6
Skeletal muscle resting metabolism in cold-acclimated rats: effect of age, noradrenaline and hyperosmolarity. Cox JP, et al. **Clin Exp Pharmacol Physiol** 1997 Jun;24(6):403–7
Physiological responses in nonheat acclimated horses performing treadmill exercise in cool (20 degrees C/40% RH), hot dry (30 degrees C/40% RH) and hot humid (30 degrees C/80% RH) conditions. Marlin DJ, et al. **Equine Vet J Suppl** 1996 Jul;(22):70–84
Plasma arginine vasopressin, atrial natriuretic peptide and brain natriuretic peptide responses to long-term field training in the heat: effects of fluid ingestion and acclimatization. Mudambo KS, et al. **Eur J Appl Physiol** 1997;75(3):219–25
Effects of long-term acclimatization in lowlanders migrating to high altitude: comparison with high altitude residents. Niu W, et al. **Eur J Appl Physiol** 1995;71(6):543–8
Effects of high altitude acclimatization on heart rate variability in resting humans. Perini R, et al. **Eur J Appl Physiol** 1996;73(6):521–8
Hypothermic general cold adaptation induced by local cold acclimation. Savourey G, et al. **Eur J Appl Physiol** 1996; 73(3–4):237–44
Change in heat loss as a part of adaptation to repeated cold exposures in adult and aged male C57BL/6J mice. Shefer VI, et al. **Exp Gerontol** 1997 May-Jun;32(3):325–32
Can the intestine adapt to a changing environment? [editorial; comment] Thompson JS. **Gastroenterology** 1997 Oct; 113(4):1402–5 (32 ref.). Comment on: Gastroenterology 1997 Oct;113(4):1074–81.
Characterization of adrenoceptor types and subtypes in American bullfrogs acclimated to warm or cold temperature. Herman CA, et al. **Gen Comp Endocrinol** 1996 Nov;104(2):168–78
Eicosanoid synthesis by purified thrombocytes and erythrocytes from warm- and cold-acclimated American bullfrogs (Rana catesbeiana). Wang X, et al. **Gen Comp Endocrinol** 1997 Apr;106(1):138–44
Desiccation survival and water contents of entomopathogenic nematodes, Steinernema spp. (Rhabditida:Steinernematidae). Patel MN, et al. **Int J Parasitol** 1997 Jan;27(1):61–70
Exercise performance of Tibetan and Han adolescents at altitudes of 3,417 and 4,300 m. Chen QH, et al. **J Appl Physiol** 1997 Aug;83(2):661–7
Clinical observations on tropical men during their sojourn over the Arctic region. Bandopadhyay P, et al. **J Assoc Physicians India** 1996 Apr;44(4):248–51
Heat-induced longevity extension in Drosophila. I. Heat treatment, mortality, and thermotolerance. Khazaeli AA, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):B48–52

Maximal sweating rate in humans. Torii M. **J Hum Ergol (Tokyo)** 1995 Dec;24(2):137–52 (85 ref.)

Stress and sensitization in children: a controlled prospective psychophysiological study of children exposed to international relocation. Anderzén I, et al. **J Psychosom Res** 1997 Sep;43(3):259–69

Setting heat stress limits for acclimatised soldiers exercising in heat. Bricknell MC. **J R Army Med Corps** 1997 Feb; 143(1):44–8

Fatty acid profiles of phospholipids in brown adipose tissue from rats during cold acclimation and repetitive intermittent immobilization: with special reference to docosahexaenoic acid. Ohno T, et al. **Jpn J Physiol** 1996 Jun;46(3):265–70

Electrophysiological evidence of an increase in cold tolerance of cardiac muscles in mice after energy restriction. Wada Y, et al. **Mech Ageing Dev** 1997 Jul; 97(1):35–43

Acclimatization, preconditioning and heat shock proteins. Steinmann CM, et al. **Med Hypotheses** 1996 Oct; 47(4):257–60

Antioxidant systems and anoxia tolerance in a freshwater turtle Trachemys scripta elegans. Willmore WG, et al. **Mol Cell Biochem** 1997 May;170(1–2):177–85

Effects of prolonged exposure to and physical training in hypobaric conditions on skeletal muscle morphology and metabolic enzymes in rats. Perhonen M, et al. **Pflugers Arch** 1996 May;432(1):50–8

Ecophysiological adaptations to dry thermal environments measured in two unrestrained Namibian scorpions, Parabuthus villosus (Buthidae) and Opisthophthalmus flavescens (Scorpionidae). Bridges CR, et al. **Physiol Zool** 1997 Mar–Apr;70(2):244–56

Freezing impairment of male reproductive behaviors of the freeze-tolerant wood frog, Rana sylvatica. Costanzo JP, et al. **Physiol Zool** 1997 Mar–Apr;70(2):158–66

Seasonal adjustment of solar heat gain independent of coat coloration in a desert mammal. Walsberg GE, et al. **Physiol Zool** 1997 Mar–Apr;70(2):150–7

Transformation of Arabidopsis thaliana with the codA gene for choline oxidase; accumulation of glycinebetaine and enhanced tolerance to salt and cold stress. Hayashi H, et al. **Plant J** 1997 Jul;12(1):133–42

Identification of a receptor-like protein kinase gene rapidly induced by abscisic acid, dehydration, high salt, and cold treatments in Arabidopsis thaliana. Hong SW, et al. **Plant Physiol** 1997 Apr;113(4):1203–12

Interactions of physical training and heat acclimation. The thermophysiology of exercising in a hot climate. Aoyagi Y, et al. **Sports Med** 1997 Mar;23(3):173–210 (311 ref.)

Altitude training for improvements in sea level performance. Is the scientific evidence of benefit? Wolski LA, et al. **Sports Med** 1996 Oct;22(4):251–63

[Evaluation of the effect of global changes to the environment and climate on the qualitative potential of a population] Krut'ko VN. **Fiziol Cheloveka** 1997 Jan–Feb; 23(1):81–7 **(Rus)**

[Sex differences in the structure of the laterality distribution in schoolchildren from Tuva] Leutin VP, et al. **Fiziol Cheloveka** 1997 Mar–Apr;23(2):132–7 **(Rus)**

[Stress-induced hemodynamic changes in shepherds during migration and winter stay in the mountains] Bekbolotova AK, et al. **Patol Fiziol Eksp Ter** 1997 Jul–Sep;(3):15–8 **(Rus)**

[Protein and RNA synthesis in larvae of the yellow mealworm beetle (Tenebrio molitor) during cooling and cold acclimatization] Gulevskiĭ AK, et al. **Ukr Biokhim Zh** 1996 Jan–Feb;68(1):88–91 (Eng. Abstr.) **(Rus)**

[Changes in glycolipid level in the brain of rats with different resistance to hypoxia during acclimation to cold] Kozulina LE, et al. **Vopr Med Khim** 1996 Apr–Jun;42(2):141–3 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Effects of continuous intracarotid infusion of dopamine during long-term hypoxia in awake goats. Janssen PL, et al. **Adv Exp Med Biol** 1996;410:383–6

Influence of vanadium on acclimatization of humans to high altitude. Rawal SB, et al. **Int J Biometeorol** 1997 Apr; 40(2):95–8

GENETICS

Cold shock proteins and cold acclimation proteins in the psychrotrophic bacterium Pseudomonas putida Q5 and its transconjugant. Gumley AW, et al. **Can J Microbiol** 1996 Aug;42(8):798–803

Gene expression during cold acclimation in strawberry. NDong C, et al. **Plant Cell Physiol** 1997 Jul;38(7):863–70

PHYSIOLOGY

An evaluation of the role of skin temperature during heat adaptation. Regan JM, et al. **Acta Physiol Scand** 1996 Dec; 158(4):365–75

Capillary geometry in the soleus muscle of rats cold-acclimatized for 68 generations. Suzuki J, et al. **Acta Physiol Scand** 1997 Jul;160(3):243–50

The role of carotid body CO2 during ventilatory acclimatization to hypoxia in the goat. Dwinell MR, et al. **Adv Exp Med Biol** 1996;410:387–90

Carbon monoxide excretion, not oxygen secretion? Torrance RW. **Adv Exp Med Biol** 1996;410:335–9 (11 ref.)

Early functional and biochemical adaptations to low-frequency stimulation of rabbit fast-twitch muscle. Hicks A, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C297–305

Role of nitrosyl factors in the hemodynamic adjustments to heat stress in the rat. Kregel KC, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1537–43

Specific adaptations in muscle and adipose tissue in response to chronic systemic glucose oversupply in rats. Laybutt DR, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E1–9

Induction of cardiac natriuretic peptide gene expression in rats trained in hypobaric hypoxic conditions. Perhonen M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R344–52

Discrete thalamic lesions attenuate winter adaptations and increase body weight. Purvis CC, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R226–35

Structural and biochemical analyses of cardiac ventricular enlargement in cold-acclimated striped bass. Rodnick KJ, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R252–8

Glutathione systems and anoxia tolerance in turtles. Willmore WG, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R219–25

The effect of selective and nonselective opioids on body temperature in cold-acclimated rats. Weinberg R, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:702–4

Induction of thermotolerance in chickens by temperature conditioning: heat shock protein expression. Yahav S, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:628–36

Physiological responses of women during exercise under dry-heat condition in winter and summer. Keatisuwan W, et al. **Appl Human Sci** 1996 Jul;15(4):169–76

Respiratory changes during initial days of acclimatization to increasing altitudes. Basu CK, et al. **Aviat Space Environ Med** 1996 Jan;67(1):40–5

Differential regulation of the expression of alpha1-adrenergic receptor subtype genes in brown adipose tissue. Kikuchi-Utsumi K, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):417–24

The sensation of respiration in men experiencing high-altitude chronic hypoxia. Noël-Jorand MC, et al. **Biol Psychol** 1996 Mar 8;43(1):1–12

Physiological implications of altitude training for endurance performance at sea level: a review. Bailey DM, et al. **Br J Sports Med** 1997 Sep;31(3):183–90 (111 ref.)

Acclimation to three different hot climates with equivalent wet bulb globe temperatures. Griefahn B. **Ergonomics** 1997 Feb;40(2):223–34

Thermal responses and physiological strain in men wearing impermeable and semipermeable protective clothing in the cold. Rissanen S, et al. **Ergonomics** 1997 Feb;40(2):141–50

The effects of two types of clothing on seasonal heat tolerance. Li X, et al. **Eur J Appl Physiol** 1996;72(4):287–91

Hypothermic general cold adaptation induced by local cold acclimation. Savourey G, et al. **Eur J Appl Physiol** 1996; 73(3–4):237–44

Lung diffusion capacity, oxygen uptake, cardiac output and oxygen transport during exercise before and after an himalayan expedition. Steinacker JM, et al. **Eur J Appl Physiol** 1996;74(1–2):187–93

Increased growth of brown adipose tissue but its decreased lysosomal enzyme activity in heat-acclimatized, insulin-treated rats. Ohno H, et al. **Horm Metab Res** 1996 Aug;28(8):397–9

Metabolic responses during initial days of altitude acclimatization in the eastern Himalayas. Basu CK, et al. **Int J Biometeorol** 1996 Sep;39(3):133–8

Changes in cold tolerance due to a 14-day stay in the Canadian Arctic. Livingstone SD, et al. **Int J Biometeorol** 1996 Nov;39(4):182–6

Muscle tissue adaptations of high-altitude natives to training in chronic hypoxia or acute normoxia. Desplanches D, et al. **J Appl Physiol** 1996 Nov;81(5):1946–51

Peak blood lactate and blood lactate vs. workload during acclimatization to 5,050 m and in deacclimatization. Grassi B, et al. **J Appl Physiol** 1996 Feb;80(2):685–92

Shift working in the Chilean Andes (> 3,600 m) and its influence on erythropoietin and the low-pressure system. Gunga HC, et al. **J Appl Physiol** 1996 Aug;81(2):846–52

Distinct scattering in basal values of oxygen consumption [letter; comment] Heller H, et al. **J Appl Physiol** 1996 Aug; 81(2):1035–6. Comment on: J Appl Physiol 1995 Aug;79(2):487–92.

Evidence against an increase in capillary permeability in subjects exposed to high altitude. Kleger GR, et al. **J Appl Physiol** 1996 Nov;81(5):1917–23

Alveolar Pco2 and Po2 of high-altitude natives living at sea level. León-Velarde F, et al. **J Appl Physiol** 1996 Oct; 81(4):1605–9

"Living high-training low": effect of moderate-altitude acclimatization with low-altitude training on performance. Levine BD, et al. **J Appl Physiol** 1997 Jul;83(1):102–12

Acclimatization to 4,300-m altitude decreases reliance on fat as a substrate. Roberts AC, et al. **J Appl Physiol** 1996 Oct; 81(4):1762–71

Altitude acclimatization and blood volume: effects of exogenous erythrocyte volume expansion. Sawka MN, et al. **J Appl Physiol** 1996 Aug;81(2):636–42

Heat acclimation: cardiovascular response to hot/dry and hot/wet heat loads in rats. Moran D, et al. **J Basic Clin Physiol Pharmacol** 1996;7(4):375–87

Lower activation energy for sliding of F-actin on a less thermostable isoform of carp myosin. Chaen S, et al. **J Biochem (Tokyo)** 1996 Oct;120(4):788–91

Changes of biological reducing activity in rat brain following closed head injury: a cyclic voltammetry study in normal and heat-acclimated rats. Beit-Yannai E, et al. **J Cereb Blood Flow Metab** 1997 Mar;17(3):273–9

Acute and chronic effects of temperature, and of nutritional state, on ion homeostasis and energy metabolism in teleost hepatocytes. Krumschnabel G, et al. **J Comp Physiol [B]** 1997 May;167(4):280–6

Summer acclimatization in the short-tailed field vole, Microtus agrestis. McDevitt RM, et al. **J Comp Physiol [B]** 1996;166(4):286–93

Increased calcium current in carotid body glomus cells following in vivo acclimatization to chronic hypoxia. Hempleman SC. **J Neurophysiol** 1996 Sep;76(3):1880–6

Human acclimation to work in warm and humid environments. Kubica R, et al. **J Physiol Pharmacol** 1996 Sep;47(3):515–24

Changes in plasma electrolytes during acclimatization at high altitude. Khan DA, et al. **JPMA J Pak Med Assoc** 1996 Jun;46(6):128–31

Effects of cold acclimation and central opioid processes on thermoregulation in rats. Wilson JR, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):317–25

Sympathetic outflow to interscapular brown adipose tissue in cold acclimated mice. Kirov SA, et al. **Physiol Behav** 1996 Feb;59(2):231–5

Cold acclimation-associated changes in brown adipose tissue do not necessarily indicate an increase of nonshivering thermogenesis in C57BL/6J mice. Talan MI, et al. **Physiol Behav** 1996 Nov;60(5):1285–9

Seasonal variations in the temperature acclimation response of the channel catfish, Ictalurus punctatus. Seddon WL, et al. **Physiol Zool** 1997 Jan–Feb;70(1):33–44

Differential accumulation of two glycine-rich proteins during cold-acclimation alfalfa. Ferullo JM, et al. **Plant Mol Biol** 1997 Mar;33(4):625–33

Role of beta-adrenergic and cholinergic systems in acclimatization to hypoxia in the rat. Clancy RL, et al. **Respir Physiol** 1997 Jan;107(1):75–84

Smaller alveolar-arterial O2 gradients in Tibetan than Han residents of Lhasa (3658 m). Zhuang J, et al. **Respir Physiol** 1996 Jan;103(1):75–82

Perspectives of plant cold tolerance: physiology and molecular responses. Kaye C, et al. **Sci Prog** 1995;78 (Pt 4):271–99 (174 ref.)

Thermotolerance attenuates ischemia-reperfusion induced renal injury and increased expression of ICAM-1. Stokes KY, et al. **Transplantation** 1996 Oct 27;62(8):1143–9

[Altitude sickness] Bielenberg J. **Med Monatsschr Pharm** 1996 Aug;19(8):232–4 (7 ref.) **(Ger)**

[Periodic breathing at high altitude relation to acclimatization and acute mountain sickness] Sugie T. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec; 33(12):1355–60 (Eng. Abstr.) **(Jpn)**

[Patterns of metabolic reorganization in man in the Far North] Boĭko ER. **Fiziol Cheloveka** 1996 Jul–Aug; 22(4):122–9 **(Rus)**

[Effect of acclimatization to cold on the hypoxic sensitivity of the respiratory center] Krivoshchekov SG, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):51–6 **(Rus)**

ACCOMMODATION, OCULAR

Partially accommodative esotropia: should you overcorrect and cut the plus? [letter; comment] Wright KW. **Arch Ophthalmol** 1996 Nov;114(11):1429–31. Comment on: Arch Ophthalmol 1995 Dec;113(12):1530–4.

A study on visual characteristics of binocular 3-D images. Cho A, et al. **Ergonomics** 1996 Nov;39(11):1285–93

Surmised state of accommodation to stereoscopic three-dimensional images with binocular disparity. Iwasaki T, et al. **Ergonomics** 1996 Nov;39(11):1268–72

Accommodation, convergence, pupil diameter and eye blinks at a CRT display flickering near fusion limit. Jaschinski W, et al. **Ergonomics** 1996 Jan;39(1):152–64

Effects on visual functions during tasks of object handling in virtual environment with a head mounted display. Kawara T, et al. **Ergonomics** 1996 Nov;39(11):1370–80

Visual accommodation and subject performance during a stereographic object task using liquid crystal shutters. Miyao M, et al. **Ergonomics** 1996 Nov;39(11):1294–309

Influence on visual function by a stereoscopic TV programme with binocular liquid crystal shutter and Hi-Vision TV display. Oohira A, et al. **Ergonomics** 1996 Nov;39(11):1310–4

Integration of a sensory component into the accommodation model reveals differences between emmetropia and late-onset myopia. Jiang BC. **Invest Ophthalmol Vis Sci** 1997 Jul;38(8):1511–6

Accommodative and binocular vision disorders associated with video display terminals: diagnosis and management issues. Scheiman M. **J Am Optom Assoc** 1996 Sep; 67(9):531–9 (20 ref.)

Accommodative intraocular lens: a challenge for future development [editorial] Assia EI. **J Cataract Refract Surg** 1997 May;23(4):458–60

Apparent accommodation and depth of field in pseudophakia. Elder MJ, et al. **J Cataract Refract Surg** 1996 Jun; 22(5):615–9

Visual acuity and accommodation in infants and young children with Down's syndrome. Woodhouse JM, et al. **J Intellect Disabil Res** 1996 Feb;40 (Pt 1):49–55

The effect of accommodative hysteresis on apparent stationarity. Fisher K, et al. **Ophthalmic Physiol Opt** 1997 Mar;17(2):112–21

Accommodative response in children and young adults using dynamic retinoscopy. Leat SJ, et al. **Ophthalmic Physiol Opt** 1996 Sep;16(5):375–84

Reduced accommodation in children with cerebral palsy. Leat SJ. **Ophthalmic Physiol Opt** 1996 Sep;16(5):385–90

An integrated system for measuring static and dynamic accommodation with a Canon Autoref R-1 refractometer. Wetzel PA, et al. **Ophthalmic Physiol Opt** 1996 Nov; 16(6):520–7

Age-related changes in the accommodation mechanism. Beers AP, et al. **Optom Vis Sci** 1996 Apr;73(4):235–42

Local changes in eye growth induced by imposed local refractive error despite active accommodation. Diether S, et al. **Vision Res** 1997 Mar;37(6):659–68

[Accommodation in pseudophakic eyes with monofocal posterior chamber intraocular lens] Yang Y, et al. **Chung Hua Yen Ko Tsa Chih** 1996 Mar;32(2):98–100 (Eng. Abstr.) **(Chi)**

[Posterior iris bowing after accommodation—elucidation of the etiology of pigment dispersion syndrome] Ueda J, et al. **Nippon Ganka Gakkai Zasshi** 1997 Feb;101(2):187–91 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Levocabastine eye drops do not affect accommodative capacity in volunteers and intraocular pressure in glaucoma patients. Wolf S, et al. **Eur J Ophthalmol** 1995 Oct–Dec; 5(4):225–9

Dose-response study of dapiprazole HCl in the reversal of mydriasis induced by 2.5% phenylephrine. Hogan TS, et al. **J Ocul Pharmacol Ther** 1997 Aug;13(4):297–302

[Effects of topical application of adrenergic agents on refraction and accommodation] Otsuka N, et al. **Nippon Ganka Gakkai Zasshi** 1997 May;101(5):400–6 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Is myopia related to amplitude of accommodation? Fong DS. **Am J Ophthalmol** 1997 Mar;123(3):416–8

In vivo increase of the human lens equatorial diameter during accommodation. Schachar RA, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R670–6

Effects of overlay symbology in night vision goggles on accommodation and attention shift. Schor CM, et al. **Aviat Space Environ Med** 1996 Nov;67(11):1039–47

Frequency characteristics of accommodation in a patient with agenesis of the posterior vermis and normal subjects. Ohtsuka K, et al. **Br J Ophthalmol** 1997 Jun;81(6):476–80

Analysis of accommodation function with ultrasonography. Beers AP, et al. **Doc Ophthalmol** 1996–97;92(1):1–10

Anticipatory locomotor adjustments for accommodating versus avoiding level changes in humans. McFadyen BJ, et al. **Exp Brain Res** 1997 May;114(3):500–6

Retinal projections to the accommodation-related area in the rostral superior colliculus of the cat. Ohtsuka K, et al. **Exp Brain Res** 1997 Jan;113(1):169–73

Behavior of luminance neurons in the pretectal olivary nucleus during the pupillary near response. Zhang H, et al. **Exp Brain Res** 1996 Nov;112(1):158–62

Quantitative analysis of the accommodative convergence to accommodation ratio: linear and nonlinear static models. Hung GK. **IEEE Trans Biomed Eng** 1997 Apr;44(4):306–16

Accommodation and presbyopia in the human eye. Changes in the anterior segment and crystalline lens with focus. Koretz JF, et al. **Invest Ophthalmol Vis Sci** 1997 Mar; 38(3):569–78

Visual results of progressive multifocal posterior chamber intraocular lens implantation. Bleckmann H, et al. **J Cataract Refract Surg** 1996 Oct;22(8):1102–7

Experience with an accommodating IOL [letter] Cumming JS, et al. **J Cataract Refract Surg** 1996 Oct;22(8):1001

Accommodation and pupilloconstriction areas in the cat midbrain. Konno S, et al. **Jpn J Ophthalmol** 1997 Jan–Feb; 41(1):43–8

Accommodation responses to flickering stimuli. Chauhan K, et al. **Ophthalmic Physiol Opt** 1996 Sep;16(5):391–408

Changes in ocular dimensions and refraction with accommodation. Garner LF, et al. **Ophthalmic Physiol Opt** 1997 Jan;17(1):12–7

Characteristics of dynamic accommodation responses: comparison between the dominant and non-dominant eyes. Ibi K. **Ophthalmic Physiol Opt** 1997 Jan;17(1):44–54

Repeatability of clinical measurements of the amplitude of accommodation. Rosenfield M, et al. **Ophthalmic Physiol Opt** 1996 May;16(3):247–9

Microfluctuations of steady-state accommodation measured with ultrasonography. van der Heijde GL, et al. **Ophthalmic Physiol Opt** 1996 May;16(3):216–21

Amount of defocus is not used as an error signal in the control system of accommodation dynamics. Yamada T, et al. **Ophthalmic Physiol Opt** 1997 Jan;17(1):55–60

Surgery for esotropia with a high accommodative convergence/accommodation ratio: effects on accommodative vergence and binocularity. Arnoldi KA, et al. **Ophthalmic Surg Lasers** 1996 May;27(5):342–8

Progressive increase in the quantity of deviation in congenital esotropia. Ing MR. **Ophthalmic Surg Lasers** 1996 Jul; 27(7):612–7

Subjective depth-of-focus of the eye. Atchison DA, et al. **Optom Vis Sci** 1997 Jul;74(7):511–20

Irlen lenses do not improve accommodative accuracy at near [see comments] Ciuffreda KJ, et al. **Optom Vis Sci** 1997 May;74(5):298–302. Comment in: Optom Vis Sci 1997 May;74(5):239–40.

Changes in equivalent and gradient refractive index of the crystalline lens with accommodation. Garner LF, et al. **Optom Vis Sci** 1997 Feb;74(2):114–9

Accommodation to stationary and moving targets. Kruger PB, et al. **Optom Vis Sci** 1997 Jul;74(7):505–10

Comparison of clinical techniques to assess the near accommodative response. Rosenfield M, et al. **Optom Vis Sci** 1996 Jun;73(6):382–8

Hard contact lenses alter accommodative gain but do not prevent refractive adaptation in chicks. Schmid KL, et al. **Optom Vis Sci** 1997 Jan;74(1):20–7

Refractive variation under accommodative demand: curvital and scaled torsional variances and covariance across the meridians of the eye [see comments] van Gool RD, et al. **Optom Vis Sci** 1997 Jun;74(6):445–51. Comment in: Optom Vis Sci 1997 Jun;74(6):339–41.

A history of studies of visual accommodation in birds [published erratum appears in Q Rev Biol 1997 Jun;72(2):134] Glasser A, et al. **Q Rev Biol** 1996 Dec; 71(4):475–509

Sympathetic overactivity of intraocular muscles evaluated by accommodation in patients with hyperthyroidism. Noh JY, et al. **Thyroid** 1996 Aug;6(4):289–93

The naturally occurring accommodative response of the oscar, Astronotus ocellatus, to visual stimuli. Andison ME, et al. **Vision Res** 1996 Oct;36(19):3021–7

The development of accommodation. Currie DC, et al. **Vision Res** 1997 Jun;37(11):1525–33

Accommodation in binocular contour rivalry. Flitcroft DI, et al. **Vision Res** 1997 Jan;37(1):121–5

[Microfluctuations in accommodation] Menozzi M, et al. **Klin Monatsbl Augenheilkd** 1997 May;210(5):325–6 (Eng. Abstr.) **(Ger)**

[Bilateral congenital mydriasis with accommodation failure] Gräf M. **Ophthalmologe** 1996 Aug;93(4):377–9 (Eng. Abstr.) **(Ger)**

[Detection of resting state of accommodation by accommodative microfluctuation] Kajita M, et al. **Nippon Ganka Gakkai Zasshi** 1997 May;101(5):413–6 (Eng. Abstr.) **(Jpn)**

[Selected problems with ocular accommodation in children and youth] Kubatko-Zielińska A, et al. **Klin Oczna** 1996; 98(6):459–61 (4 ref.) (Eng. Abstr.) **(Pol)**

[A new method for accommodation training] Belozerov AE, et al. **Vestn Oftalmol** 1997 Mar-Apr;113(2):25–8 (Eng. Abstr.) **(Rus)**

[Ophthalmophysiological features of applying soft contact lenses to correct myopia in pilots] Ovechkin IG, et al. **Vestn Oftalmol** 1997 May-Jun;113(3):20–3 (Eng. Abstr.) **(Rus)**

[Early age-specific changes in the accommodation volume] Rosenblium IZ, et al. **Vestn Oftalmol** 1996 Sep-Oct; 112(4):16–8 (Eng. Abstr.) **(Rus)**

[Biomechanical characteristics of interactions between the drainage and accommodation regulatory systems of the eye in health and in contusion sens subluxation] Volkov VV, et al. **Vestn Oftalmol** 1997 May-Jun;113(3):5–7 (21 ref.) (Eng. Abstr.) **(Rus)**

ACCOUNTABLE HEALTH PLANS see **MANAGED COMPETITION**

ACCOUNTING

Use and abuse of the medical loss ratio to measure health plan performance. Robinson JC. **Health Aff (Millwood)** 1997 Jul-Aug;16(4):176–87

500 FBI agents. Glaser D. **Iowa Med** 1996 Mar;86(3):110–2

Desktop system for accounting, audit, and research in A&E. Taylor CJ, et al. **J Accid Emerg Med** 1997 Mar;14(2):92–7

Billing for CRNP services. Olmstead DL, et al. **Pa Med** 1996 Dec;99(12):26–9

An examination of the relationship between accountants' scores on field independence and use of and attitude toward computers. Mills TY. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):715–20

HISTORY

Edward Jenner's 1794 accompt-book for the pocket or desk. Kirkup J. **Med Hist** 1996 Oct;40(4):487–98

METHODS

Activity-based costing for hospitals. Udpa S. **Health Care Manage Rev** 1996 Summer;21(3):83–96

National health accounts in developing countries: appropriate methods and recent applications. Berman PA. **Health Econ** 1997 Jan-Feb;6(1):11–30 (52 ref.)

Bridging the gap between finance and clinical operations with activity-based cost management. Storfjell JL, et al. **J Nurs Adm** 1996 Dec;26(12):12–7

ACCOUNTS PAYABLE AND RECEIVABLE

Finance ... Catholic hospitals take a more conservative approach to collecting what's due them [news] **Hosp Health Netw** 1997 Jul 5;71(13):12

ACCREDITATION

see related
CERTIFICATION
LICENSURE

The objectives of medical education: reflections in the accreditation looking glass. Kassebaum DG, et al. **Acad Med** 1997 Jul;72(7):648–56

Reducing the number of radiology residents: antitrust and action by the Accreditation Council for Graduate Medical Education. Smith JJ, et al. **Acad Radiol** 1996 Sep;3(9):766–9

Accredited laboratories. **Am Ind Hyg Assoc J** 1996 Apr; 57(4):401–12

ELPAT Program report: background and current status (October 1996). Esche CA, et al. **Am Ind Hyg Assoc J** 1997 Jan;58(1):59–63

Accreditation: the Australian experience. White GH. **Ann Clin Biochem** 1996 Jul;33 (Pt 4):273–83

Accreditation and the use of outcomes-oriented information systems. Wilkerson DL. **Arch Phys Med Rehabil** 1997 Aug; 78(8 Suppl 4):S31–5

Accreditation: the key to your future! Possible benefits from accreditation. Bollen M. **Aust Fam Physician** 1996 Oct; 25(10):1523–5

Application of primary health care standards to a developing community health group: a rural case history. Sheehan M, et al. **Aust N Z J Public Health** 1996 Apr;20(2):201–9

Safety in acupuncture. Rigorous accreditation schedule for acupuncture already exists [letter; comment] Baldwin of Bewdley E. **BMJ** 1997 Aug 16;315(7105):429–30. Comment on: BMJ 1997 May 10;314(7091):1362.

The Joint Commission on Accreditation of Healthcare Organizations' Indicator Measurement System. Health care outcomes database. McGreevey C, et al. **Comput Nurs** 1997 Mar-Apr;15(2 Suppl):S87–94

Physicians ... when doctors claim that they're "accredited" [news] **Hosp Health Netw** 1997 Jul 5;71(13):15

Quality watch. Physician, accredit thyself [news] **Hosp Health Netw** 1997 Jun 20;71(12):19

Accreditation. One thumb down for reviewers. Edlin M. **Hosp Health Netw** 1997 Aug 20;71(16):49–50

Patients first and always [editorial] Meskin LH. **J Am Dent Assoc** 1997 Feb;128(2):138, 140

Certification of osteopathic physicians. Glatz L, et al. **J Am Osteopath Assoc** 1996 Nov;96(11):675–8

Dental curriculum and accreditation--means, ends, and the continuum. Chambers DW. **J Dent Educ** 1996 Oct; 60(10):816–20

The application of computers to accreditation. Eisner J. **J Dent Educ** 1997 Jun;61(6):493–500

From chaos to excellence: preparing for a successful Joint Commission survey. Snyder R, et al. **J Nurs Adm** 1997 Jul-Aug;27(7–8):10–3

ACNM accredited and preaccredited nurse-midwifery and midwifery education programs. Program information. Slattery LE, et al. **J Nurse Midwifery** 1996 Jul-Aug; 41(4):305–21

The JCAHO medical staff standards. Impact on clinical privileges for nurse-midwives. Williams DR, et al. **J Nurse Midwifery** 1996 Jan-Feb;41(1):43–6

Accreditation: who's counting? Oehlert WH, et al. **J Okla State Med Assoc** 1997 Feb;90(2):48–53

Education. Creating meaningful accreditation practices for the next millennium. Bartels JE. **J Prof Nurs** 1997 May-Jun;13(3):140

Acceptance of spinal cord medicine as a subspecialty by the Accreditation Council of Graduate Medical Education (ACGME) [editorial] DeLisa JA, et al. **J Spinal Cord Med** 1996 Jul;19(3):175

Assessment and accreditation of Mexican medical schools. Cordova JA, et al. **Med Educ** 1996 Sep;30(5):319–21

Interview with Joseph W. Sokolowski, Jr, MD [interview by Bill Berlin] Sokolowski JW Jr. **N J Med** 1997 Feb; 94(2):23–5

The accreditation process for advanced education programs in pediatric dentistry: a look from the inside out. Vann WF Jr. **Pediatr Dent** 1997 May;19(3):203–6

Accreditation of residency training in the US. Armbruster JS. **Postgrad Med J** 1996 Jul;72(849):391–4 (0 ref.)

Selection criteria for APA-accredited internships stratified by type of site and competitiveness. Lopez SJ, et al. **Psychol Rep** 1997 Apr;80(2):639–42

Components of laboratory accreditation. Royal PD. **Qual Assur** 1995 Dec;4(4):274–82

Managing change--a continuum. Buck BA. **Radiol Technol** 1996 Jan-Feb;67(3):257–8

Opportunities for specialized accreditation. Bugg N. **Radiol Technol** 1997 Jan-Feb;68(3):253–4

What makes a toxicologist? [editorial] Hesse-Callaway S. **Regul Toxicol Pharmacol** 1996 Dec;24(3):195–6

[Guidelines of the American Thoracic Society/American Lung Association for education in pneumology and in pneumology and intensive care medicine. Accreditation Council for Graduate Medical Education (ACGME)] Wagner TOF, et al. **Pneumologie** 1996 Mar;50(3):231–6 **(Ger)**

[The accreditation of medical laboratories (the position of the experts of the European Confederation of Laboratory Medicine)] Balakhovskiĭ IS. **Klin Lab Diagn** 1997 Feb;

(2):46–50 **(Rus)**
[Experience with the accreditation of clinical diagnostic laboratories in Voronezh Province] Burmakova LM. **Klin Lab Diagn** 1996 Nov–Dec;(6):42–3 **(Rus)**
[Experience with the accreditation and certification of laboratories in the Czech Republic] Jabor A. **Klin Lab Diagn** 1996 Nov–Dec;(6):45–8 **(Rus)**
[Accreditation and assessment of quality of medical institutions] Ovcharov VK. **Probl Sotsialnoi Gig Istor Med** 1995 Jul–Aug;(4):25–35 **(Rus)**
[The accreditation and certification of specialists in dentistry] Kuklin GS, et al. **Stomatologiia (Mosk)** 1997;76(1):69–70 **(Rus)**
[Accreditation of the surgical service in the ambulatory component as a factor in raising the quality of its activities] Vinnik LF, et al. **Vestn Khir Im I I Grek** 1997;156(2):122–5 **(Rus)**
[It's time to join efforts in favor of the accreditation in infectious diseases (letter; comment)] Muñoz Sanz A. **Med Clin (Barc)** 1997 Jun 14;109(3):115. Comment on: Med Clin (Barc) 1995 Oct 28;105(14):534–6. Comment on: Med Clin (Barc) 1996 Sep 28;107(10):399. **(Spa)**
[It's time to join efforts in favor of the accreditation in infectious diseases (letter; comment)] Pahissa Berga A. **Med Clin (Barc)** 1997 Jun 14;109(3):115; discussion 115–6 . Comment on: Med Clin (Barc) 1996 Sep 28;107(10):399. **(Spa)**
[Accreditation may be a false quality label (letter)] Carlström K. **Lakartidningen** 1997 Aug 6;94(32–33):2714–5 **(Swe)**
[Accredited laboratory? Worthless information in a scientific article] Carlström K. **Lakartidningen** 1997 Jun 11; 94(24):2251–2 **(Swe)**
[Research laboratories can also be accredited (letter)] Jonsson R. **Lakartidningen** 1997 Jul 9;94(28–29):2532 **(Swe)**
[There are all reasons to choose an accredited laboratory (letter)] Kallner A. **Lakartidningen** 1997 Jul 9; 94(28–29):2531–2 **(Swe)**
[Accreditation of a laboratory involves quality requirements (letter)] Simonsson P. **Lakartidningen** 1997 Jul 9; 94(28–29):2532 **(Swe)**

HISTORY

The College of American Pathologists, 1946–1996: laboratory accreditation. Hamlin WB, et al. **Arch Pathol Lab Med** 1997 Jul;121(7):745–53
History of osteopathic medical education accreditation. Ward WD, et al. **J Am Osteopath Assoc** 1996 Nov;96(11):651–2

LEGISLATION & JURISPRUDENCE

National accreditation is important to any poison control center [news] **J Okla State Med Assoc** 1997 Mar; 90(3):116–7
Training and education in forensic psychiatry. Heisel D. **New Dir Ment Health Serv** 1996 Spring;(69):73–9
[Inspection of medical specialists from a legal perspective] Lombarts MJ, et al. **Ned Tijdschr Geneeskd** 1996 Sep 7; 140(36):1824–7 **(Dut)**

ORGANIZATION & ADMINISTRATION

The meaning and application of medical accreditation standards. Kassebaum DG, et al. **Acad Med** 1997 Sep; 72(9):808–18 (11 ref.)
The Australian Quality Assurance and Continuing Education Program as a model for the reaccreditation of general practitioners in the United Kingdom. Salisbury C. **Br J Gen Pract** 1997 May;47(418):319–22
Accreditation programs for hospitals: funding and operation. Bohigas L, et al. **Int J Qual Health Care** 1996 Dec; 8(6):583–9
Managed care and melting moments [editorial] Palmer RH. **Int J Qual Health Care** 1996 Aug;8(4):317–9 (15 ref.)
Community Health Accreditation Program and Joint Commission announce cooperative agreement. **J Nurs Adm** 1996 Dec;26(12):4
Accreditation under siege [editorial] Tanner CA. **J Nurs Educ** 1996 Sep;35(6):243–4
Facts you may not know--and opinions you may not have considered--about the AIUM's voluntary accreditation program [letter] Arger PH. **J Ultrasound Med** 1996 Aug; 15(8):611–2
The two cultures and the health care revolution. Commerce and professionalism in medical care [see comments] McArthur JH, et al. **JAMA** 1997 Mar 26;277(12):985–9. Comment in: JAMA 1997 Mar 26;277(12):1004–5. Comment in: JAMA 1997 Jul 2;278(1):20; discussion 21–2. Comment in: JAMA 1997 Jul 2;278(1):21–2.
Environmental monitoring programs vs Good Laboratory Practice (GLP) programs: differences and similarities. Bentley RE. **Qual Assur** 1995 Dec;4(4):283–7

STANDARDS

American Society of Cytopathology Laboratory Accreditation Program. Gupta PK, et al. **Arch Pathol Lab Med** 1997 Mar;121(3):260–3 (25 ref.)
The College of American Pathologists, 1946–1996: laboratory accreditation. Hamlin WB, et al. **Arch Pathol Lab Med** 1997 Jul;121(7):745–53
Cytopathology laboratory improvement programs of the College of American Pathologists: Laboratory Accreditation Program (CAP LAP) and Performance Improvement Program in Cervicovaginal Cytology (CAP PAP). Nielsen ML. **Arch Pathol Lab Med** 1997 Mar; 121(3):256–9 (26 ref.)
The performance of doctors. I: Professionalism and self regulation in a changing world. Irvine D. **BMJ** 1997 May 24;314(7093):1540–2 (21 ref.)
ESHRE guidelines for training, accreditation and monitoring in gynaecological endoscopy. European Society for Human Reproduction and Embryology. Committee of Special Interest Group on Reproductive Surgery. Chapron C, et al. **Hum Reprod** 1997 Apr;12(4):867–8
JCAHO deadline for indicator measurements [news] **Infect Control Hosp Epidemiol** 1997 Apr;18(4):292
Establishing thresholds for adverse patient outcomes. Ansari MZ, et al. **Int J Qual Health Care** 1996 Jun;8(3):223–30
Accreditation and ISO: international convergence on health care standards ISQua position paper--October 1996. Shaw CD. **Int J Qual Health Care** 1997 Feb;9(1):11–3
Accreditation of optometric care and services in a hospital and medical center environment. Gruning C. **Optom Vis Sci** 1996 May;73(5):312–4
[Quality assurance, certification, accreditation, development toward a European harmonization] **Ann Biol Clin (Paris)** 1997 May–Jun;55(3):244–51 **(Fre)**

TRENDS

Recent developments in accreditation. Scrivens E. **Int J Qual Health Care** 1995 Dec;7(4):427–33
New sextant coordinates for physician offices under managed care. Magel JS. **J Health Care Finance** 1996 Winter; 23(2):83–5

ACCULTURATION

Acculturative stress among Amerasian refugees: gender and racial differences. Nwadiora E, et al. **Adolescence** 1996 Summer;31(122):477–87
Homicide rates among Native American children: the status integration hypothesis. Young TJ, et al. **Adolescence** 1997 Spring;32(125):57–9
Serum lipids and modernization in coastal and highland Papua New Guinea. Hodge AM, et al. **Am J Epidemiol** 1996 Dec 15;144(12):1129–42
Acculturation and prevalence of diabetes among Japanese–American men in Hawaii. Huang B, et al. **Am J Epidemiol** 1996 Oct 1;144(7):674–81
Acculturation and marijuana and cocaine use: findings from HHANES 1982–84. Amaro H, et al. **Am J Public Health** 1990 Dec;80 Suppl:54–60
Acculturation and alcohol consumption in the Mexican American population of the southwestern United States: findings from HHANES 1982–84. Markides KS, et al. **Am J Public Health** 1990 Dec;80 Suppl:42–6
Health risk behaviors of Hispanics in the United States: findings from HHANES, 1982–84. Marks G, et al. **Am J Public Health** 1990 Dec;80 Suppl:20–6
Acculturation, access to care, and use of preventive services by Hispanics: findings from HHANES 1982–84. Solis JM, et al. **Am J Public Health** 1990 Dec;80 Suppl:11–9
Prenatal health behaviors and psychosocial risk factors in pregnant women of Mexican origin: the role of acculturation. Zambrana RE, et al. **Am J Public Health** 1997 Jun;87(6):1022–6
Psychological well-being of Cambodian women in resettlement. Catolico O. **ANS Adv Nurs Sci** 1997 Jun; 19(4):75–84 (52 ref.)
Emotional health of Indonesian adoptees living in Australian families. Goldney RD, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):534–9
Acculturation and its effects on self-esteem among immigrant Latina women. Flaskerud JH, et al. **Behav Med** 1996 Fall; 22(3):123–33
Culturally sensitive integration of supportive and cognitive behavioral therapy in the treatment of a bicultural dysthymic patient. Elligan D. **Cult Divers Ment Health** 1997;3(3):207–13
The effects of acculturative stress on incarcerated Alaska Native and non-Native men. Glass MH, et al. **Cult Divers Ment Health** 1997;3(3):175–91
Brief symptom inventory scores of Asian, Asian-American, and European-American college students. Iwamasa GY, et al. **Cult Divers Ment Health** 1995;1(2):149–57
Diabetes in Japanese-Brazilians--influence of the acculturation process. Franco LJ. **Diabetes Res Clin Pract** 1996 Oct;34 Suppl:S51–7
Religious attendance and psychological well-being in Mexican Americans: a panel analysis of three-generations data. Levin JS, et al. **Gerontologist** 1996 Aug;36(4):454–63
The impact of the Wellness Guide/Guía on Hispanic women's well-being-related knowledge, efficacy beliefs, and behaviors: the mediating role of acculturation. Bell RA, et al. **Health Educ Behav** 1997 Jun;24(3):326–43
Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hollenberg NK, et al. **Hypertension** 1997 Jan;29(1 Pt 2):171–6
Acculturation, socioeconomic status, and obesity in Mexican Americans, Cuban Americans, and Puerto Ricans. Khan LK, et al. **Int J Obes Relat Metab Disord** 1997 Feb; 21(2):91–6
Acculturative stress, depression, and suicidal ideation among immigrant and second-generation Latino adolescents. Hovey JD, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Sep;35(9):1183–92
Acculturation and cigarette smoking among African American adults. Klonoff EA, et al. **J Behav Med** 1996 Oct;19(5):501–14
Coping with a new society: the unique psychosocial problems of immigrant youth. James DC. **J Sch Health** 1997 Mar; 67(3):98–102
Acculturation mode, identity variation, and psychosocial adjustment. Damji T, et al. **J Soc Psychol** 1996 Aug; 136(4):493–500
Crossing new bridges: the process of adaptation and psychological distress of Russian immigrants in Israel. Baider L, et al. **Psychiatry** 1996 Summer;59(2):175–83
Cultural distance and its relationship to psychological adjustment of international exchange students. Furukawa T. **Psychiatry Clin Neurosci** 1997 Jun;51(3):87–91
"Put yourself in the skin of the child," she said. Goldstein J, et al. **Psychoanal Study Child** 1996;51:46–55
Affective Bicultural and Global-Human Identity Scales for Mexican-American adolescents. Der-Karabetian A, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):1027–39
Validation of an acculturation measure for Hispanic adolescents. Epstein JA, et al. **Psychol Rep** 1996 Dec;79(3 Pt 1):1075–9
Family life satisfaction, age, length of residency: predicting alcohol and cigarette use among Korean adolescents in Australia. Hong SM, et al. **Psychol Rep** 1996 Feb; 78(1):187–93
Cross-cultural adjustment of Chinese students in Japan. Jou YH, et al. **Psychol Rep** 1996 Apr;78(2):435–44
Acculturation and MMPI-2 scale scores of Mexican American substance abuse patients. Lessenger LH. **Psychol Rep** 1997 Jun;80(3 Pt 2):1181–2
Major trade routes and the "silk road". Chapoutot-Remadi M. **Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):509–11
Psychosocial factors in blood pressure variation: a comparative study of young Samoans. Hanna JM. **Soc Biol** 1996 Fall–Winter;43(3–4):169–90
Resettlement: a cultural and psychological crisis. Hulewat P. **Soc Work** 1996 Mar;41(2):129–35
The influence of acculturation on attitudes toward alcohol and alcohol use within the Punjabi community: an exploratory analysis. Weber TR. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1715–32
Suicidality among acculturating Mexican Americans: current knowledge and directions for research. Hovey JD, et al. **Suicide Life Threat Behav** 1997 Spring;27(1):92–103
[Evaluation of certain personality trains in Czech emigrants. (The problem of so-called "debohemization")] Krizek GO. **Ceska Slov Psychiatr** 1996 Feb;92(1):57–60 (Eng. Abstr.) **(Cze)**

ACE INHIBITORS see **ANGIOTENSIN-CONVERTING ENZYME INHIBITORS**

ACEBUTOLOL

PHARMACOKINETICS

Pharmacokinetics of acebutolol enantiomers after intravenous administration of racemate in a rat model: a dosing range comparison. Mostafavi SA, et al. **Biopharm Drug Dispos** 1997 Jul;18(5):397–408
Pharmacokinetics and multiple peaking of acebutolol enantiomers in rats. Piquette-Miller M, et al. **Biopharm Drug Dispos** 1997 Aug;18(6):543–56

PHARMACOLOGY

[Doppler echocardiography in assessing the effect of the beta 1-selective adrenoblocker acebutolol on left-ventricular diastolic filling in hypertension patients] Alekhin MN, et al. **Ter Arkh** 1997;69(4):15–8 **(Rus)**

POISONING

Acebutolol overdose treated with hemodialysis and extracorporeal membrane oxygenation. Rooney M, et al. **J Clin Pharmacol** 1996 Aug;36(8):760–3

THERAPEUTIC USE

Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. The APSI Investigators. Acebutolol et Prévention Secondaire de l'Infarctus. Cucherat M, et al. **Am J Cardiol** 1997 Mar 1;79(5):587–9
Effectiveness of digitalis with or without acebutolol in preventing atrial arrhythmias after coronary artery surgery. Kowey PR, et al. **Am J Cardiol** 1997 Apr 15;79(8):1114–7
Effects of long-term antihypertensive therapy on physical fitness of men with mild hypertension. Tomiyama H, et al. **Hypertens Res** 1997 Jun;20(2):105–11
Long-term prevention of atrial fibrillation after coronary artery surgery. Yilmaz AT, et al. **Panminerva Med** 1997 Jun;39(2):103–5

ACECAINIDE

ANALYSIS

Direct determination of procainamide and N-acetylprocainamide by capillary zone electrophoresis in

ACECAINIDE

pharmaceutical formulations and urine. Vargas G, et al. **J Chromatogr A** 1997 Jun 6;772(1–2):271–6

PHARMACOKINETICS

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part I. Procainamide and its active metabolite–N–acetylprocainamide. Orszulak–Michalak D. **Acta Pol Pharm** 1995 Mar–Apr;52(2):141–6

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part II. N–acetylprocainamide. Orszulak–Michalak D. **Acta Pol Pharm** 1995 Mar–Apr; 52(2):147–51

Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization. Yang BB, et al. **J Clin Pharmacol** 1996 Jul;36(7):623–33

URINE

Comparison of fluorescence polarization immunoassay with liquid chromatography for quantification of procainamide and N–acetylprocainamide in urine. Tisdale JE, et al. **Ther Drug Monit** 1996 Dec;18(6):693–7

ACEMETHADONE see **METHADYL ACETATE**

ACENAPHTHENES

CHEMICAL SYNTHESIS

Acenaphthenequinone thiosemicarbazone and its transition metal complexes: synthesis, structure, and biological activity. Rodriguez–Argüelles MC, et al. **J Inorg Biochem** 1997 Apr;66(1):7–17

PHARMACOLOGY

Regulation of hepatic CYP1A isozymes by piperonyl butoxide and acenaphthylene in the mouse. Ryu DY, et al. **Chem Biol Interact** 1997 Jun 6;105(1):53–63

Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon–responsive receptor knock–out mouse liver. Ryu DY, et al. **Mol Pharmacol** 1996 Sep;50(3):443–6

ACENOCOUMARIN see **ACENOCOUMAROL**

ACENOCOUMAROL

ADMINISTRATION & DOSAGE

Ticlopidine antagonizes acenocoumarol treatment [letter] Salar A, et al. **Thromb Haemost** 1997 Jan;77(1):223–4

ADVERSE EFFECTS

[Liver injury caused by coumarin anticoagulants: experience of the IKS (Intercanton Monitoring Station) and the SANZ (Swiss Center for Drug Monitoring)] Ciorciaro C, et al. **Schweiz Med Wochenschr** 1996 Dec 7;126(49):2109–13 (Eng. Abstr.) **(Ger)**

[Hemorrhagic complications and thrombotic phenomena in oral anticoagulation of elderly patients] Selva O'Callaghan A, et al. **Rev Clin Esp** 1997 May;197(5):323–8 (Eng. Abstr.) **(Spa)**

[Spinal epidural hematoma in anticoagulated patient. Letter] Rodríguez J, et al. **Rev Neurol** 1997 Feb;25(138):308–9 **(Spa)**

METABOLISM

Probable interaction between cetirizine and acenocoumarol [letter] Berod T, et al. **Ann Pharmacother** 1997 Jan;31(1):122

PHARMACOKINETICS

Stereoselective interaction between piroxicam and acenocoumarol. Bonnabry P, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):525–30

PHARMACOLOGY

Anticoagulants and thyroid [letter] Agarwal A. **J Assoc Physicians India** 1995 Jan;43(1):70

[Plausible pharmacologic interaction between fosinopril and acenocoumarol (letter)] de Tomás ME, et al. **Med Clin (Barc)** 1997 May 17;108(19):757 **(Spa)**

THERAPEUTIC USE

Interaction between clarithromycin and oral anticoagulants [letter] Grau E, et al. **Ann Pharmacother** 1996 Dec; 30(12):1495–6

Evolution of blood coagulation and fibrinolysis parameters after abrupt versus gradual withdrawal of acenocoumarol in patients with venous thromboembolism: a double–blind randomized study. Tardy B, et al. **Br J Haematol** 1997 Jan;96(1):174–8

ACEPROMAZINE

ADMINISTRATION & DOSAGE

Chemical immobilisation of giraffe to facilitate short procedures. Vogelnest L, et al. **Aust Vet J** 1997 Mar; 75(3):180–2

ADVERSE EFFECTS

Rare, idiosyncratic reaction to acepromazine in dogs. Meyer EK. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1114–5

PHARMACOLOGY

Physiologic effects of anesthesia induced and maintained by intravenous administration of a climazolam–ketamine combination in ponies premedicated with acepromazine and xylazine. Bettschart–Wolfensberger R, et al. **Am J Vet Res** 1996 Oct;57(10):1472–7

Effects of acepromazine and buprenorphine on measured indices of the signal–averaged electrocardiogram in healthy dogs. Kushner LI, et al. **Am J Vet Res** 1996 Oct; 57(10):1511–4

Effects of acepromazine maleate and phenoxybenzamine on urethral pressure profiles of anesthetized, healthy, sexually intact male cats. Marks SL, et al. **Am J Vet Res** 1996 Oct; 57(10):1497–500

Effects of three sedative protocols on glomerular filtration rate in clinically normal dogs. Newell SM, et al. **Am J Vet Res** 1997 May;58(5):446–50

The suppression of formalin–induced fos expression by different anesthetic agents in the infant rat. Yi DK, et al. **Dev Psychobiol** 1996 Sep;29(6):497–506

Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. Correia D, et al. **Res Vet Sci** 1996 May; 60(3):213–7

Assessment of orocaecal transit time in cats by the breath hydrogen method: the effects of sedation and a comparison of definitions. Sparkes AH, et al. **Res Vet Sci** 1996 May; 60(3):243–6

ACETABULARIA

CHEMISTRY

The primary structure of the Cl(–)–translocating ATPase, b subunit of Acetabularia acetabulum, which belongs to the F–type ATPase family. Moritani C, et al. **Arch Biochem Biophys** 1997 Mar 1;339(1):115–24

METABOLISM

Decreasing period–length of the endogenous circadian rhythm of oxygen evolution in Acetabularia and its possible relation to aging. von Lindern L, et al. **Chronobiol Int** 1996 Nov;13(5):341–7

ACETABULUM

Chondrosarcoma secondary to synovial chondromatosis. Report of two cases and a review of the literature. Wuisman PI, et al. **Arch Orthop Trauma Surg** 1997;116(5):307–11 (20 ref.)

Wear of the epiphysis–acetabulum in total hip arthroplasty: a review of the literature. Affatato S, et al. **Chir Organi Mov** 1996 Apr–Jun;81(2):119–28 (22 ref.) **(Eng, Ita)**

Observations on the initial stability of acetabular components in total hip arthroplasty. An experimental study. Pitto RP, et al. **Chir Organi Mov** 1996 Apr–Jun;81(2):107–18 **(Eng, Ita)**

Bone cement penetration of the acetabulum in total hip replacement. An experimental study. Heller KD, et al. **Int Orthop** 1996;20(5):315–20

Relationship between polyethylene wear, pelvic osteolysis, and clinical symptomatology in patients with cementless acetabular components. A framework for decision making. Hozack WJ, et al. **J Arthroplasty** 1996 Oct;11(7):769–72

Reamed surface topography and component seating in press–fit cementless acetabular fixation. Kim YS, et al. **J Arthroplasty** 1995 Nov;10 Suppl:S14–21

Effect of cementless acetabular cup geometry on strain distribution and press–fit stability. Ries MD, et al. **J Arthroplasty** 1997 Feb;12(2):207–12

Fracture of an acetabular component inserted without cement. A case report. Trousdale RT, et al. **J Bone Joint Surg Am** 1997 Jun;79(6):901–5

Acetabular cup migration: prediction of aseptic loosening [letter; comment] Freeman MA. **J Bone Joint Surg Br** 1997 Mar;79(2):342–3. Comment on: J Bone Joint Surg Br 1995 Nov;77(6):853–61.

Aspergillus osteomyelitis after heart–lung transplantation. Taillandier J, et al. **J Heart Lung Transplant** 1997 Apr; 16(4):436–8

Migration of press–fit cups fixed with poly–L–lactic acid or titanium screws: a randomized study using radiostereometry. Thanner J, et al. **J Orthop Res** 1996 Nov; 14(6):895–900

Intra–articular osteoid osteoma of the acetabulum in a 6 year old. Miller SJ, et al. **Orthopedics** 1997 Jul;20(7):654–5

Clear–cell chondrosarcoma with elevated alkaline phosphatase, mistaken for osteosarcoma on biopsy. Brien EW, et al. **Skeletal Radiol** 1996 Nov;25(8):770–4

[Osteochondritis dissecans of the acetabulum] Werther K, et al. **Ugeskr Laeger** 1997 May 26;159(22):3417–8 (Eng. Abstr.) **(Dan)**

[Malignant hemangiopericytoma of the pelvis: treatment using internal hemipelvectomy] Heymans O, et al. **Acta Orthop Belg** 1997 Mar;63(1):40–2 (Eng. Abstr.) **(Fre)**

[Uretero–acetabular fistula: report of a case] Villamizar J, et al. **Prog Urol** 1996 Dec;6(6):950–4 (Eng. Abstr.) **(Fre)**

[Ceramic acetabulum components for hip endoprostheses. 2: Evaluating design and safety] Willmann G, et al. **Biomed Tech (Berl)** 1996 Oct;41(10):284–90 (Eng. Abstr.) **(Ger)**

[Labrum lesions and acetabular dysplasia in adults] Pitto RP, et al. **Z Orthop Ihre Grenzgeb** 1996 Sep–Oct;134(5):452–6 (27 ref.) (Eng. Abstr.) **(Ger)**

[Vesico–acetabular fistula occurring 10 years after total hip replacement] Hamano S, et al. **Hinyokika Kiyo** 1996 Oct; 42(10):743–5 (6 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

What is your diagnosis? Proximal femoral aplasia of the left femoral head and neck and hypoplasia of the left acetabulum in a dog. Godbold JC Jr, et al. **J Am Vet Med Assoc** 1996 Sep 15;209(6):1069–70

Protrusio acetabuli: its occurrence in the completely expressed Marfan syndrome and its musculoskeletal component and a procedure to arrest the course of protrusion in the growing pelvis [see comments] Steel HH. **J Pediatr Orthop** 1996 Nov–Dec;16(6):704–18 (100 ref.). Comment in: J Pediatr Orthop 1996 Nov–Dec;16(6):701–3.

Morphology of the acetabulum in hip dislocations caused by cerebral palsy. Brunner R, et al. **J Pediatr Orthop B** 1997 Jul;6(3):207–11

Pemberton's pericapsular osteotomy for the treatment of acetabular dysplasia. Szepesi K, et al. **J Pediatr Orthop B** 1996 Fall;5(4):252–8

ANATOMY & HISTOLOGY

Structure, strain and function of the transverse acetabular ligament. Löhe F, et al. **Acta Anat (Basel)** 1996; 157(4):315–23

Impacted graft incorporation after cemented acetabular revision. Histological evaluation in 8 patients. Buma P, et al. **Acta Orthop Scand** 1996 Dec;67(6):536–40

MR imaging of the acetabular labrum: variations in 200 asymptomatic hips. Lecouvet FE, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):1025–8

Anatomic basis of lag screw placement in the anterior column of the acetabulum. Ebraheim NA, et al. **Clin Orthop** 1997 Jun;(339):200–5

The supra–acetabular line [letter; comment] Stoker DJ. **Skeletal Radiol** 1997 Mar;26(3):199. Comment on: Skeletal Radiol 1996 Aug;25(6):525–9.

Acetabular anatomy and the relationship with pelvic vascular structures. Implications in hip surgery. Feugier P, et al. **Surg Radiol Anat** 1997;19(2):85–90

Dynamic anatomy of the acetabulum: an experimental approach and surgical implications. Lazennec JY, et al. **Surg Radiol Anat** 1997;19(1):23–30

BLOOD SUPPLY

A study of the arterial supply of the human acetabulum using a corrosion casting method. Itokazu M, et al. **Clin Anat** 1997;10(2):77–81

INJURIES

Total effective radiation dose from spiral CT and conventional radiography of the pelvis with regard to fracture classification. Jurik AG, et al. **Acta Radiol** 1996 Sep;37(5):651–4

The effect of knee immobilization on degree of hip flexion: a clinical correlation with posterior wall acetabular fractures. Alexander RD, et al. **Am J Orthop** 1997 May; 26(5):345–7

Sliding osteotomy of the greater trochanter. Ebraheim NA, et al. **Am J Orthop** 1997 Mar;26(3):212–5

Direct complications of trochanteric osteotomy in open reduction and internal fixation of acetabular fractures. Heck BE, et al. **Am J Orthop** 1997 Feb;26(2):124–8

Fractures of posterior wall of acetabulum. Chiu FY, et al. **Arch Orthop Trauma Surg** 1996;115(5):273–5

Surgically treated acetabular fractures in adult patients. Nooraie H, et al. **Arch Orthop Trauma Surg** 1996; 115(3–4):227–30

Labral lesions: an elusive source of hip pain case reports and literature review. Byrd JW. **Arthroscopy** 1996 Oct; 12(5):603–12 (19 ref.)

The acetabular labral tear: an arthroscopic classification. Lage LA, et al. **Arthroscopy** 1996 Jun;12(3):269–72

Acetabular labrum tear in a 15–year–old male: diagnosis with correlative imaging. Kelley B, et al. **Australas Radiol** 1997 May;41(2):157–9

Supra–acetabular insufficiency fractures: role of fluoride treatment and vitamin D deficiency? [letter] Chary–Valckenaere I, et al. **Br J Rheumatol** 1997 May; 36(5):603–5

Acetabular fractures [letter; comment] Limb D.
Br J Sports Med 1996 Jun;30(2):185. Comment on: Br J Sports Med 1995 Sep;29(3):205–6.
Major pelvic injuries in equestrian sports. O'Farrell DA, et al. **Br J Sports Med** 1997 Sep;31(3):249–51
Traumatic lesions of the acetabular triradiate cartilage (presentation of four cases and considerations on treatment). Valdiserri L, et al. **Chir Organi Mov** 1996 Sep–Dec;81(4):361–7 **(Eng, Ita)**
Anatomic basis of lag screw placement in the anterior column of the acetabulum. Ebraheim NA, et al. **Clin Orthop** 1997 Jun;(339):200–5
Biomechanics of the hip joint and the effects of fracture of the acetabulum. Olson SA, et al. **Clin Orthop** 1997 Jun; (339):92–104 (26 ref.)
Evaluation of hip stability after simulated transverse acetabular fractures. Thomas KA, et al. **Clin Orthop** 1997 Jul;(340):244–56
Bilateral acetabular fracture as a result of epileptic seizure: a report of two cases. Granhed HP, et al. **Injury** 1997 Jan; 28(1):65–8
Surgical management of fractures of the acetabulum: the Sheffield experience 1976–1994. Hull JB, et al. **Injury** 1997 Jan;28(1):35–40
Self–compressive osteotomy of the greater trochanter. Naito M, et al. **Int Orthop** 1997;21(2):119–21
Use of anchor sutures to repair labral avulsions of the hip: a brief report. Weigel DP, et al. **Iowa Orthop J** 1997; 17:141–3
A case of maternal pelvic trauma following a road traffic accident, associated with fetal intracranial haemorrhage. Matthews G, et al. **J Accid Emerg Med** 1997 Mar; 14(2):115–7
Entrapment of the bladder in an acetabular fracture. A case report. McKee MD, et al. **J Bone Joint Surg Am** 1997 Jan; 79(1):113–7
Fractures of the acetabulum: accuracy of reduction and clinical results in patients managed operatively within three weeks after the injury. Matta JM.
J Bone Joint Surg Am 1996 Nov;78(11):1632–45
Femoral nerve palsy associated with an associated posterior wall transverse acetabular fracture. Hardy SL.
J Orthop Trauma 1997 Jan;11(1):40–2 (6 ref.)
Intraoperative monitoring of motor pathways during operative fixation of acute acetabular fractures. Helfet DL, et al. **J Orthop Trauma** 1997 Jan;11(1):2–6
The goal of acetabular fracture surgery [letter] Matta JM. **J Orthop Trauma** 1996;10(8):586
Incidence of sciatic nerve injury in operatively treated acetabular fractures without somatosensory evoked potential monitoring. Middlebrooks ES, et al.
J Orthop Trauma 1997 Jul;11(5):327–9
Three–view radiographic assessment of heterotopic ossification after acetabular fracture surgery. Moed BR, et al. **J Orthop Trauma** 1996;10(2):93–8
The detection and management of proximal deep venous thrombosis in patients with acute acetabular fractures: a follow–up report. Montgomery KD, et al.
J Orthop Trauma 1997 Jul;11(5):330–6
The effect of variable size posterior wall acetabular fractures on contact characteristics of the hip joint. Olson SA, et al. **J Orthop Trauma** 1996;10(6):395–402
Triradiate cartilage fracture associated with a transepiphyseal separation of the femoral head: a case report. Pina–Medina A, et al. **J Orthop Trauma** 1996;10(8):575–7
Diagnosis and management of closed internal degloving injuries associated with pelvic and acetabular fractures: the Morel–Lavallée lesion. Hak DJ, et al. **J Trauma** 1997 Jun; 42(6):1046–51
Postrenal anuria in pelvic or acetabular injury: a report of three cases. Hötker U, et al. **J Trauma** 1996 Nov; 41(5):916–9
Surgical approaches to the acetabulum. Jimenez ML, et al. **Orthop Clin North Am** 1997 Jul;28(3):419–34 (8 ref.)
Total hip replacement after acetabular fracture. Jimenez ML, et al. **Orthop Clin North Am** 1997 Jul;28(3):435–46 (26 ref.)
Acetabular fractures. Perry DC, et al.
Orthop Clin North Am 1997 Jul;28(3):405–17 (27 ref.)
Pelvic and acetabular trauma. Hunter JC, et al.
Radiol Clin North Am 1997 May;35(3):559–90 (55 ref.)
A new case of insufficiency fracture in a patient with tabes dorsalis. Marc V, et al. **Rev Rhum Engl Ed** 1997 Apr; 64(4):271–3
Acetabular fractures due to bone insufficiency. Two case–reports. Timsit MA, et al. **Rev Rhum Engl Ed** 1996 May;63(5):364–6
Results of screw/wire/polymethylmethacrylate composite fixation for acetabular fracture repair in 14 dogs. Lewis DD, et al. **Vet Surg** 1997 May–Jun;26(3):223–34
[Gluteal posterior approach for surgery of the acetabulum] Perves A, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(7):639–42 (Eng. Abstr.) **(Fre)**
[Acetabular and pelvic fractures in multiple trauma] Euler E, et al. **Orthopade** 1997 Apr;26(4):354–9 (Eng. Abstr.) **(Ger)**
[Acetabular fractures in elderly persons. Primary endoprosthetic treatment] Hoellen IP, et al. **Orthopade** 1997 Apr;26(4):348–53 (Eng. Abstr.) **(Ger)**
[Indication, technique and complications in the surgical treatment of acetabular fractures] Kuner EH. **Orthopade** 1997 Apr;26(4):327–35 (Eng. Abstr.) **(Ger)**
[Rehabilitation following hip fractures] Maurer F, et al. **Orthopade** 1997 Apr;26(4):368–74 (Eng. Abstr.) **(Ger)**
[Approach–related results following acetabular fractures] Mayr E, et al. **Orthopade** 1997 Apr;26(4):384–93 (Eng. Abstr.) **(Ger)**
[Long–term results and late complications following acetabular fractures] Schlickewei W, et al. **Orthopade** 1997 Apr;26(4):375–83 (17 ref.) (Eng. Abstr.) **(Ger)**
[Hip dislocations and hip fractures—acetabular fractures. Indication, technique and results of conservative treatment] Weise K, et al. **Orthopade** 1997 Apr;26(4):336–47 (Eng. Abstr.) **(Ger)**
[The pelvic digital image data bank. Experiences after 18 months in clinical practice] Pohlemann T, et al.
Unfallchirurg 1996 Aug;99(8):587–94 (Eng. Abstr.) **(Ger)**
[Preparation and technique for surgical treatment of 225 acetabulum fractures. 2 year results of 175 cases] Rommens PM, et al. **Unfallchirurg** 1997 May;100(5):338–48 (Eng. Abstr.) **(Ger)**
[Bilateral acetabulum fractures of the anterior column and vertebral body fracture after alcohol–induced seizure] Rommens PM, et al. **Unfallchirurg** 1996 Sep;99(9):704–7 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Re: Acetabular rim pathology secondary to congenital hip dysplasia in the adult. A radiographic study [letter] Klaue K. **Chir Organi Mov** 1997 Jan–Mar;82(1):VII–VIII **(Eng, Ita)**
Postmortem analysis of bone growth into porous–coated acetabular components. Bloebaum RD, et al.
J Bone Joint Surg Am 1997 Jul;79(7):1013–22
Innominate osteotomy in adolescents and adults who have acetabular dysplasia. McCarthy JJ, et al.
J Bone Joint Surg Am 1996 Oct;78(10):1455–61
Evaluation of the acetabular labrum by MR arthrography [published erratum appears in J Bone Joint Surg Br 1997 Jul;79(4):693] Leunig M, et al. **J Bone Joint Surg Br** 1997 Mar;79(2):230–4
Acetabular osteolysis and migration in bipolar arthroplasty of the hip: five– to 13–year follow–up study. Nakata K, et al. **J Bone Joint Surg Br** 1997 Mar;79(2):258–64
Hydroxyapatite in revision of total hip replacements with massive acetabular defects: 4– to 10–year clinical results. Oonishi H, et al. **J Bone Joint Surg Br** 1997 Jan;79(1):87–92
Location of acetabular deficiency and associated hip dislocation in neuromuscular hip dysplasia: three–dimensional computed tomographic analysis. Kim HT, et al. **J Pediatr Orthop** 1997 Mar–Apr;17(2):143–51
Hip joint acetabular dysplasia [editorial] Wedge JH.
J Pediatr Orthop 1997 Mar–Apr;17(2):141–2
Osteoarthritis of the hip and acetabular dysplasia in Nigerian men. Ali–Gombe A, et al. **J Rheumatol** 1996 Mar; 23(3):512–5
Pustulotic arthro–osteitis associated with acetabular cartilage lesion in pustulotic arthropathy—implication of bone marrow. Seki K, et al. **J Rheumatol** 1997 May;24(5):971–3
Wear in retrieved Charnley acetabular sockets[see comments] Hall RM, et al. **Proc Inst Mech Eng [H]** 1996; 210(3):197–207. Comment in: Proc Inst Mech Eng [H] 1996 ;210(3):137–40.
Intraosseous ganglion communicating with soft tissue counterpart. Abe O, et al. **Radiat Med** 1997 Mar–Apr; 15(2):125–7
MR imaging of supra–acetabular insufficiency fractures. Otte MT, et al. **Skeletal Radiol** 1997 May;26(5):279–83
Magnetic resonance imaging of labral cysts of the hip. Schnarkowski P, et al. **Skeletal Radiol** 1996 Nov; 25(8):733–7
[Murata–Chiba (MC) support ring for acetabular defect in rheumatoid hip] Suzuki M, et al. **Ryumachi** 1996 Jun; 36(3):574–9 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Acetabular strains produced by oversized press fit cups. Ries MD, et al. **Clin Orthop** 1997 Jan;(334):276–81
Statically equivalent load and support conditions produce different hip joint contact pressures and periacetabular strains. Bay BK, et al. **J Biomech** 1997 Feb;30(2):193–6
Experimental study of periacetabular deformations before and after implantation of hip prostheses. Massin P, et al. **J Biomech** 1996 Jan;29(1):53–61
Pelvic muscle and acetabular contact forces during gait. Pedersen DR, et al. **J Biomech** 1997 Sep;30(9):959–65
Subchondral plate thickness reflects tensile stress in the primate acetabulum. Dewire P, et al. **J Orthop Res** 1996 Sep;14(5):838–41
The ability of various acetabular components to resist protrusio migration. Benjamin J, et al. **Orthopedics** 1997 Apr;20(4):307–10
Wear of ultra–high molecular weight polyethylene acetabular cups in a physiological hip joint simulator in the anatomical position using bovine serum as a lubricant. Bigsby RJ, et al. **Proc Inst Mech Eng [H]** 1997;211(3):265–9
[Contact surface and pressure load at implant–bone interface in press–fit cups compared to natural hip joints] Widmer KH, et al. **Orthopade** 1997 Feb;26(2):181–9 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Incidence of late bead shedding from uncemented porous coated cups. A radiographic evaluation. von Knoch M, et al. **Clin Orthop** 1997 Sep;(342):99–105
Factors affecting socket fixation after cemented revision. Raut VV, et al. **Int Orthop** 1997;21(2):83–6
Radiographic assessment of acetabular prosthesis anteversion: an experimental study. O'Mahony PB, et al.
Ir J Med Sci 1996 Jan–Mar;165(1):10–6
Use of acetabular models in planning complex acetabular reconstructions. John JF, et al. **J Arthroplasty** 1995 Oct; 10(5):661–6
Progression of radiolucent lines adjacent to the acetabular component and factors influencing migration after Charnley low–friction total hip arthroplasty.
García–Cimbrelo E, et al. **J Bone Joint Surg Am** 1997 Sep; 79(9):1373–80
Variability in the assessment of acetabular index. Kay RM, et al. **J Pediatr Orthop** 1997 Mar–Apr;17(2):170–3
Three–dimensional computer analysis of complex acetabular insufficiency. Roach JW, et al. **J Pediatr Orthop** 1997 Mar–Apr;17(2):158–64
The predictive value of the development of the acetabular teardrop figure in developmental dysplasia of the hip. Smith JT, et al. **J Pediatr Orthop** 1997 Mar–Apr;17(2):165–9
Measurement of acetabular index intraobserver and interobserver variation. Spatz DK, et al.
J Pediatr Orthop 1997 Mar–Apr;17(2):174–5
Morphology of the acetabulum in hip dislocations caused by cerebral palsy. Brunner R, et al.
J Pediatr Orthop B 1997 Jul;6(3):207–11
Absence or interruption of the supra–acetabular line: a subtle plain film indicator of hip pathology [see comments] Major NM, et al. **Skeletal Radiol** 1996 Aug;25(6):525–9. Comment in: Skeletal Radiol 1997 Mar;26(3):199.
Observer variation in the detection of acetabular bone deficiencies. Wenz JF, et al. **Skeletal Radiol** 1997 May; 26(5):272–8
[Fatigue rupture of a Harris–Galante shell in contact with an autograft of the femur head. Analysis of bone, mechanical and metallurgical factors] Migaud H, et al.
Acta Orthop Belg 1996 Sep;62(3):168–72 (Eng. Abstr.) **(Fre)**
[Radiologic evaluation of acetabular defects on acetabular loosening of hip alloarthroplasty] Jerosch J, et al.
Unfallchirurg 1996 Oct;99(10):727–33 (Eng. Abstr.) **(Ger)**
[Paraproctic fistula in acetabulum loosening after implantation of a total hip endoprosthesis. A rare complication] Loggen B, et al. **Unfallchirurg** 1997 May; 100(5):402–5 (Eng. Abstr.) **(Ger)**
[Normal values of some parameters of the acetabulum and proximal femur in radiographic images]
Wierusz–Kozłowska M, et al.
Chir Narzadow Ruchu Ortop Pol 1996;61(3):259–64 (Eng. Abstr.) **(Pol)**

SURGERY

Reconstruction in metastatic destruction of the acetabulum. Support rings and arthroplasty in 12 patients. Stark A, et al. **Acta Orthop Scand** 1996 Oct;67(5):435–8
Contemporary trends in orthopaedics of the hip joint. 3. Steel's triple pelvic osteotomy in the treatment of arthritis of the hip joint in dysplasia of the acetabulum. Rejholec M. **Acta Univ Carol [Med] (Praha)** 1992;38(1–4):35–47
Long–term follow–up results of rotational acetabular osteotomy in painful dysplastic hips: efficacy in delaying the onset of osteoarthritis. Takatori Y, et al.
Am J Orthop 1996 Mar;25(3):222–5
The ceramic cup type Lindenhof. Results 10–14 years after implantation. Gierse H, et al. **Arch Orthop Trauma Surg** 1996;115(3–4):167–70
Surgically treated acetabular fractures in adult patients. Nooraie H, et al. **Arch Orthop Trauma Surg** 1996; 115(3–4):227–30
Results of the Müller acetabular reinforcement ring in revision arthroplasty. Stöckl B, et al.
Arch Orthop Trauma Surg 1997;116(1–2):55–9
Rotational acetabular osteotomies: a rabbit model. Yasunaga Y, et al. **Arch Orthop Trauma Surg** 1997;116(1–2):74–6
Results after femoral and innominate osteotomy in Legg–Calvé–Perthes disease. Moberg A, et al.
Clin Orthop 1997 Jan;(334):257–64
Acetabular and femoral fixation 15 years after cemented total hip surgery. Mulroy WF, et al. **Clin Orthop** 1997 Apr; (337):118–28
Limb salvage in periacetabular sarcomas: review of 21 consecutive cases. Windhager R, et al. **Clin Orthop** 1996 Oct;(331):265–76 (33 ref.)
Combined acetabuloplasty and varus derotation osteotomy in congenital dislocation of the hip. Long–term results. Hess T, et al. **Int Orthop** 1996;20(6):350–6
Bone–graft augmentation for acetabular deficiencies in total hip arthroplasty. Results of long–term follow–up evaluation. Lee BP, et al. **J Arthroplasty** 1997 Aug; 12(5):503–10
A technique of revision of failed acetabular components leaving the femoral component in situ. Neil MJ, et al.
J Arthroplasty 1996 Jun;11(4):482–3
Appositional bone bridging of primary gaps in the dome area of uncemented, porous acetabular components. Onsten I. **J Arthroplasty** 1995 Oct;10(5):702–6
Acetabular revision using a bone–ingrowth total hip component in patients who have acetabular bone stock deficiency. Woolson ST, et al. **J Arthroplasty** 1996 Sep;

11(6):661–7
Pemberton pelvic osteotomy and varus rotational osteotomy in the treatment of acetabular dysplasia in patients who have static encephalopathy. Gordon JE, et al. **J Bone Joint Surg Am** 1996 Dec;78(12):1863–71
Revision of the acetabular component of a total hip arthroplasty with cement in young patients without rheumatoid arthritis. Raut VV, et al. **J Bone Joint Surg Am** 1996 Dec;78(12):1853–6
Bulk structural autogenous grafts and allografts for reconstruction of the acetabulum in total hip arthroplasty. Sixteen-year-average follow-up. Shinar AA, et al. **J Bone Joint Surg Am** 1997 Feb;79(2):159–68
Triple osteotomy of the pelvis for acetabular dysplasia: results at 8 to 15 years. de Kleuver M, et al. **J Bone Joint Surg Br** 1997 Mar;79(2):225–9
Rotational acetabular osteotomy for severe dysplasia of the hip [letter; comment] Hartofilakidis G, et al. **J Bone Joint Surg Br** 1997 May;79(3):510. Comment on: J Bone Joint Surg Br 1996 Nov;78(6):871–7.
Early deterioration after modified rotational acetabular osteotomy for the dysplastic hip. Matsui M, et al. **J Bone Joint Surg Br** 1997 Mar;79(2):220–4
Rotational acetabular osteotomy for severe dysplasia of the hip with a false acetabulum [see comments] Shindo H, et al. **J Bone Joint Surg Br** 1996 Nov;78(6):871–7. Comment in: J Bone Joint Surg Br 1997 May;79(3):510.
Triple innominate osteotomy and rotational acetabular osteotomy in the treatment of congenital hip dysplasia. Huang SC, et al. **J Formos Med Assoc** 1997 Feb;96(2):91–7
The goal of acetabular fracture surgery [letter] Matta JM. **J Orthop Trauma** 1996;10(8):586
Pemberton's pericapsular osteotomy for the treatment of acetabular dysplasia. Szepesi K, et al. **J Pediatr Orthop B** 1996 Fall;5(4):252–8
Concerns with cementless modular acetabular components. Barrack RL. **Orthopedics** 1996 Sep;19(9):741–3
Survivorship analysis of acetabular revision in medial, lateral, and global primary osteoarthritis. Bissacotti JF, et al. **Orthopedics** 1995 Dec;18(12):1145–50
Acetabular revision options. Christie MJ, et al. **Orthopedics** 1997 Sep;20(9):804–7
Pelvic osteolysis associated with an uncemented acetabular component in total hip arthroplasty. Kavanagh BF, et al. **Orthopedics** 1996 Feb;19(2):159–63
Cemented Charnley acetabular failures. Ritter MA. **Orthopedics** 1996 Sep;19(9):739–40
Placement of screws in the uncemented acetabulum: anatomic analysis of the danger zone. Xu R, et al. **Orthopedics** 1997 Aug;20(8):699–702
Results of screw/wire/polymethylmethacrylate composite fixation for acetabular fracture repair in 14 dogs. Lewis DD, et al. **Vet Surg** 1997 May–Jun;26(3):223–34
[Enlargement plasty of the acetabulum by vascularized iliac crest cartilage transfer in children] Clément JL, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(7):636–42 (Eng. Abstr.) **(Fre)**
[Design considerations for improving the acetabular cup of the ESKA hip endoprosthesis by using the ceramic/ceramic wear couple] Quack G, et al. **Biomed Tech (Berl)** 1996 Sep;41(9):253–9 (0 ref.) (Eng. Abstr.) **(Ger)**
[Acetabuloplasty] Ekkernkamp M, et al. **Orthopade** 1997 Jan; 26(1):75–80 (Eng. Abstr.) **(Ger)**
[Indication, technique and complications in the surgical treatment of acetabular fractures] Kuner EH. **Orthopade** 1997 Apr;26(4):327–35 (Eng. Abstr.) **(Ger)**
[Approach-related results following acetabular fractures] Mayr E, et al. **Orthopade** 1997 Apr;26(4):384–93 (Eng. Abstr.) **(Ger)**
[Rotational acetabular osteotomy—long-term results] Ninomiya S. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jan; 70(1):7–16 **(Jpn)**
[Murata–Chiba (MC) support ring for acetabular defect in rheumatoid hip] Suzuki M, et al. **Ryumachi** 1996 Jun; 36(3):574–9 (Eng. Abstr.) **(Jpn)**
[Use of bone grafts in acetabular wall deficit reconstruction during total hip replacement] Gaździk T. **Chir Narzadow Ruchu Ortop Pol** 1997;62(2):123–9 (Eng. Abstr.) **(Pol)**
[Reconstruction of the acetabular roof in cemented total hip replacement] Król R. **Chir Narzadow Ruchu Ortop Pol** 1996;61(4):371–7 (Eng. Abstr.) **(Pol)**

TRANSPLANTATION

Cementless revision of total hip arthroplasty using the anatomic porous replacement revision prosthesis. Buoncristiani AM, et al. **J Arthroplasty** 1997 Jun; 12(4):403–15

ULTRASONOGRAPHY

Acetabular notch. Portinaro NM, et al. **J Pediatr Orthop B** 1997 Jan;6(1):48–51
[Gray scale histographic analysis of the acetabular cartilage for quantifying hip ultrasound images] Merk H, et al. **Ultraschall Med** 1997 Apr;18(2):62–6 (Eng. Abstr.) **(Ger)**

ACETALDEHYDE

Formation and determination of aldehyde-addition products of tryptophan. Meyer K, et al. **Adv Exp Med Biol** 1996; 398:711–7

ANALOGS & DERIVATIVES

Inhibition of feeding responses by the molluscicide, metaldehyde. McCrohan CR, et al. **Acta Biol Hung** 1995; 46(2–4):241–5
Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Brüggemann SK, et al. **Cancer Res** 1997 Jul 1;57(13):2676–80
Mutagenicity of vinyl chloride and its reactive metabolites, chloroethylene oxide and chloroacetaldehyde, in a metabolically competent human B-lymphoblastoid line. Chiang SY, et al. **Carcinogenesis** 1997 Jan;18(1):31–6
A 13C NMR study of 2-(13)C-chloroacetaldehyde, a metabolite of ifosfamide and cyclophosphamide, in the isolated perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac metabolism. Loqueviel C, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jul; 43(5):773–82
Oxidative metabolism of 1-(2-chloroethyl)-3-alkyl-3-(methylcarbamoyl)triazenes: formation of chloroacetaldehyde and relevance to biological activity. Rouzer CA, et al. **Chem Res Toxicol** 1996 Jan–Feb; 9(1):172–8
Reaction of trifluoroacetaldehyde with amino acids, nucleotides, lipid nucleophiles, and their analogs. Yin H, et al. **Chem Res Toxicol** 1996 Jan–Feb;9(1):140–6
Generation of glycolaldehyde from guinea pig airway epithelial monolayers exposed to nitrogen dioxide and its effects on sodium pump activity. Robison TW, et al. **Environ Health Perspect** 1996 Aug;104(8):852–6
Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. Springate JE. **J Appl Toxicol** 1997 Jan–Feb;17(1):75–9
p-Hydroxyphenylacetaldehyde, the major product of L-tyrosine oxidation by the myeloperoxidase-H2O2-chloride system of phagocytes, covalently modifies epsilon-amino groups of protein lysine residues. Hazen SL, et al. **J Biol Chem** 1997 Jul 4; 272(27):16990–8
Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. Anderson MM, et al. **J Clin Invest** 1997 Feb 1;99(3):424–32
Effects of reactive oxygen species (ROS) modulators, TEMPOL and catalase, on methoxyacetaldehyde (MALD)-induced chromosome aberrations in Chinese hamster ovary (CHO)-AS52 cells. Ratanavalachai TC, et al. **Mutat Res** 1996 Oct 25;357(1–2):25–33
Phenobarbital-type P-450 inducers protect rats against metaldehyde toxicity. Tardieu D, et al. **Vet Hum Toxicol** 1996 Dec;38(6):454–6

ANALYSIS

Monitoring and modelling of exposure to ethanol in hairdressing salons. van Muiswinkel WJ, et al. **Ann Occup Hyg** 1997 Apr;41(2):235–47
Determination of acetaldehyde in biological samples by gas chromatography with electron-capture detection. Ohata H, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6; 693(2):297–305

BLOOD

Aldehyde dehydrogenase-mediated metabolism of acetaldehyde and mafosfamide in blood of healthy subjects and patients with malignant lymphoma. Metzenthin M, et al. **Adv Exp Med Biol** 1997;414:147–53
A possible acetaldehyde-mediated cardioprotective mechanism [letter] Wickramasinghe SN, et al. **Alcohol Alcohol** 1996 May;31(3):309–11
Estrogen-related acetaldehyde elevation in women during alcohol intoxication. Eriksson CJ, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1192–5
Inhibitory mechanism of intestinal ethanol absorption induced by high acetaldehyde concentrations: effect of intestinal blood flow and substance specificity. Kinoshita H, et al. **Alcohol Clin Exp Res** 1996 May;20(3):510–3
Alcohol metabolism in Asian-American men with genetic polymorphisms of aldehyde dehydrogenase [see comments] Wall TL, et al. **Ann Intern Med** 1997 Sep 1;127(5):376–9. Comment in: Ann Intern Med 1997 Sep 1;127(5):401–3.
Elevated levels of hemoglobin-associated acetaldehyde related to alcohol drinking in the atypical genotype of low Km aldehyde dehydrogenase. Takeshita T, et al. **Cancer Res** 1997 Apr 1;57(7):1241–3
An accurate, automated, simultaneous gas chromatographic headspace measurement of whole blood ethanol and acetaldehyde for human in vivo studies. McCarver-May DG, et al. **J Anal Toxicol** 1997 Mar–Apr;21(2):134–41
Voluntary alcohol drinking and acetaldehyde metabolism in F2 hybrid crosses of AA and ANA rat lines. Koivisto T, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):441–6

CHEMISTRY

The separation of hemoglobin-acetaldehyde adducts by cation exchange chromatography: a brief history. Itälä L, et al. **Alcohol Alcohol Suppl** 1994;2:509–13 (38 ref.)
Studies on the usefulness of acetaldehyde-modified proteins and associated antibodies as markers of alcohol abuse. Worrall S, et al. **Alcohol Alcohol Suppl** 1994;2:503–7
Rat hepatic microsomal aldehyde dehydrogenase. Identification of 3- and 4-substituted aromatic aldehydes as substrates of the enzyme. Martini R, et al. **Chem Res Toxicol** 1996 Jan–Feb;9(1):268–76
Addition of acetaldehyde to the N-terminus of a recombinant Schistosoma mansoni glutathione S-transferase upon high-level expression in Saccharomyces cerevisiae. Roecklin D, et al. **Eur J Biochem** 1997 May 1;245(3):589–99
Structural characterisation of acetaldehyde adducts formed by a synthetic peptide mimicking the N-terminus of the hemoglobin beta-chain under reducing and nonreducing conditions. Sillanaukee P, et al. **Eur J Biochem** 1996 Aug 15;240(1):30–6
Spectrophotometric determination of salbutamol sulphate using chlorinated quinones in the presence or absence of acetaldehyde. Bakry RS, et al. **J Pharm Biomed Anal** 1996 Jan;14(3):357–62

IMMUNOLOGY

Relationship between alcohol intake and immunoglobulin a immunoreactivity with acetaldehyde-modified bovine serum albumin. Worrall S, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):836–40

METABOLISM

Aldehyde dehydrogenase activity and acetate production by aerobic bacteria representing the normal flora of human large intestine. Nosova T, et al. **Alcohol Alcohol** 1996 Nov; 31(6):555–64
Aldehyde dehydrogenase and acetaldehyde metabolism. Weiner H, et al. **Alcohol Alcohol Suppl** 1994;2:141–5 (27 ref.)
Antipyrine and aminopyrine induce acetaldehyde accumulation from ethanol in isolated hepatocytes. Efthivoulou MA, et al. **Alcohol Clin Exp Res** 1997 Apr; 21(2):267–74
Co-metabolism of ethanol, ethanol-derived acetaldehyde, and 4-hydroxynonenal in isolated rat hepatocytes. Hartley DP, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):298–304
Increased acetaldehyde production by mouthwashings from patients with oral cavity, laryngeal, or pharyngeal cancer. Jokelainen K, et al. **Alcohol Clin Exp Res** 1996 Oct; 20(7):1206–10
In vitro alcohol dehydrogenase-mediated acetaldehyde production by aerobic bacteria representing the normal colonic flora in man. Jokelainen K, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):967–72
The formation and measurement of DNA neuroadduction in alcoholism. Case report. Steinberg JJ, et al. **Am J Forensic Med Pathol** 1997 Mar;18(1):84–91
High intracolonic acetaldehyde values produced by a bacteriocolonic pathway for ethanol oxidation in piglets. Jokelainen K, et al. **Gut** 1996 Jul;39(1):100–4
Acetaldehyde-modified and 4-hydroxynonenal-modified proteins in the livers of rats with alcoholic liver disease. Li CJ, et al. **Hepatology** 1997 Sep;26(3):650–7
Long-term ethanol administration alters the degradation of acetaldehyde adducts by liver endothelial cells. Thiele GM, et al. **Hepatology** 1996 Sep;24(3):643–8
Oxidation of circulating proteins in alcoholics: role of acetaldehyde and xanthine oxidase. Grattagliano I, et al. **J Hepatol** 1996 Jul;25(1):28–36
Cellular and subcellular localization of acetaldehyde-protein adducts in liver biopsies from alcoholic patients. Paradis V, et al. **J Histochem Cytochem** 1996 Sep;44(9):1051–7
Binding of acetaldehyde to rat gastric mucosa during ethanol oxidation. Salmela KS, et al. **J Lab Clin Med** 1997 Jun; 129(6):627–33
Acetaldehyde as well as ethanol is metabolized by human CYP2E1. Kunitoh S, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):527–32

PHARMACOKINETICS

Ethanol and acetaldehyde metabolism: past, present, and future. Kitson KE. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):82A–92A
Mitochondrial ALDH polymorphism affects ethanol-derived acetate disposition in Wistar rats. Matsumoto H, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):284A–288A
Differences in the serum levels of acetaldehyde and cytotoxic acetaldehyde-albumin complexes after the consumption of red and white wine: in vitro effects of flavonoids, vitamin E, and other dietary antioxidants on cytotoxic complexes. Wickramasinghe SN, et al. **Alcohol Clin Exp Res** 1996 Aug; 20(5):799–803
Uptake of acetaldehyde vapor and aldehyde dehydrogenase levels in the upper respiratory tracts of the mouse, rat, hamster, and guinea pig. Morris JB. **Fundam Appl Toxicol** 1997 Jan;35(1):91–100
A detoxication route for acetaldehyde: metabolism of diacetyl, acetoin, and 2,3-butanediol in liver homogenate and perfused liver of rats. Otsuka M, et al. **J Biochem (Tokyo)** 1996 Feb;119(2):246–51
[The dynamics of 14C-ethanol and 14C-acetaldehyde distribution in rat testes] Bozhko HKh, et al. **Fiziol Zh** 1996; 42(1–2):104–9 (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

Coagulation protein function. III. Effect of acetaldehyde upon the activation of prothrombin. Brecher A, et al. **Alcohol** 1996 Sep-Oct;13(5):423-9

Coagulation protein function. IV. Effect of acetaldehyde upon factor X and factor Xa, the proteins at the gateway to the common coagulation pathway. Brecher AS, et al. **Alcohol** 1996 Nov-Dec;13(6):539-45

A hypothesis linking hypoglycemia, hyperuricemia, lactic acidemia, and reduced gluconeogenesis in alcoholics to inactivation of glucose-6-phosphatase activity by acetaldehyde. Brecher AS, et al. **Alcohol** 1996 Nov-Dec; 13(6):553-7

Acetaldehyde-induced growth inhibition in cultured rat astroglial cells. Holownia A, et al. **Alcohol** 1996 Jan-Feb; 13(1):93-7

Effect of acetaldehyde generated from ethanol by ADH-transfected CHO cells on their membrane fatty acid profiles [published erratum appears in Alcohol 1997 Mar-Apr;14(2):203] Meskar A, et al. **Alcohol** 1996 Nov-Dec;13(6):611-6

Stable acetaldehyde adducts: structural characterization of acetaldehyde adducts of human hemoglobin N-terminal beta-globin chain peptides. Braun KP, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):40-3

Effect of acetaldehyde on Sp1 binding and activation of the mouse alpha 2(I) collagen promoter. Miao K, et al. **Arch Biochem Biophys** 1997 May 1;341(1):140-52

Blockage of N-myristoylation of HIV-1 gag induces the production of impotent progeny virus. Furuishi K, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):504-11

Mitochondrial NADH dehydrogenase activity and ability to tolerate acetaldehyde determine faster ethanol production in Saccharomyces cerevisiae. Shankar CS, et al. **Biochem Mol Biol Int** 1996 Sep;40(1):145-50

Prenatal exposure to alcohol in adult rats: relationships between sleep and memory deficits, and effects of glucose administration on memory. Stone WS, et al. **Brain Res** 1996 Dec 2;742(1-2):98-106

Influences of changes in calcium concentrations, cocaine and clonidine on the cardiac effect of acetaldehyde in rat isolated atria. Martínez JL, et al. **Gen Pharmacol** 1997 Aug; 29(2):281-4

Serum IgA, IgG, and IgM antibodies directed against acetaldehyde-derived epitopes: relationship to liver disease severity and alcohol consumption. Viitala K, et al. **Hepatology** 1997 Jun;25(6):1418-24

Inhibitory effect of indomethacin on tachyphylaxis in response to acetaldehyde-induced bronchoconstriction in patients with asthma. Fujimura M, et al. **J Allergy Clin Immunol** 1997 May;99(5):620-3

Suppression of splenic natural killer cell activity in a mouse model for binge drinking. I. Direct effects of ethanol and its major metabolites are not primarily responsible for decreased natural killer cell activity. Wu WJ, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1325-30

Interaction of aldehydes with glyoxalase I and the status of several aldehyde metabolizing enzymes of Ehrlich ascites carcinoma cells. Biswas S, et al. **Mol Cell Biochem** 1996 Dec 6;165(1):9-16

Acetaldehyde-induced changes in monoamine and amino acid extracellular microdialysate content of the nucleus accumbens. Ward RJ, et al. **Neuropharmacology** 1997 Feb; 36(2):225-32

The inhibition of xanthine oxidase by acetaldehyde in aqueous solution. Aversa ML, et al. **Physiol Chem Phys Med NMR** 1996;28(3):153-62

Acetaldehyde inhibits current through voltage-dependent calcium channels. Morales JA, et al. **Toxicol Appl Pharmacol** 1997 Mar;143(1):70-4

TOXICITY

Sensory irritation to mixtures of formaldehyde, acrolein, and acetaldehyde in rats. Cassee FR, et al. **Arch Toxicol** 1996; 70(6):329-37

Age-related metabolic effects of acetaldehyde on rats with reference to detoxification enzymes and sulfhydryl groups. Devi GU, et al. **Biomed Environ Sci** 1996 Dec;9(4):380-5

Effect of acetaldehyde on oxidoreductases in tissues of rats at different ages. Devi GU, et al. **Biomed Environ Sci** 1996 Dec;9(4):430-6

Mutagenic activity of incense smoke in comparison to formaldehyde and acetaldehyde in Salmonella typhimurium TA102. Chang HL, et al. **Bull Environ Contam Toxicol** 1997 Mar;58(3):394-401

Detection of DNA adducts of acetaldehyde in peripheral white blood cells of alcohol abusers. Fang JL, et al. **Carcinogenesis** 1997 Apr;18(4):627-32

A parallelogram approach for safety evaluation of ingested acetaldehyde. Morris JB, et al. **Regul Toxicol Pharmacol** 1996 Dec;24(3):251-63 (69 ref.)

Comparative study of the damage produced by acute ethanol and acetaldehyde treatment in a human fetal hepatic cell line. Olivares IP, et al. **Toxicology** 1997 Jun 27; 120(2):133-44

ACETALS

CHEMICAL SYNTHESIS

Interglycosidic acetals. Part 3. Synthesis and structure determination of cyclic monobenzylidene acetals of cyclodextrin derivatives bridging between two contiguous D-glucopyranosyl residues. Sakairi N, et al. **Carbohydr Res** 1996 Sep 23;291:53-62

CHEMISTRY

One-step esterification of benzoylecgonine with dimethylformamide-dipropylacetal or dimethylformamide-diisopropylacetal in the presence of pyridine. Paul BD, et al. **J Anal Toxicol** 1996 Oct; 20(6):506-8

ISOLATION & PURIFICATION

Antibacterial neoclerodane diterpenoids from Ajuga lupulina. Chen H, et al. **J Nat Prod** 1996 Jul;59(7):668-70

METABOLISM

The reaction of the soybean cotyledon mitochondrial cyanide-resistant oxidase with sulfhydryl reagents suggests that alpha-keto acid activation involves the formation of a thiohemiacetal. Umbach AL, et al. **J Biol Chem** 1996 Oct 4;271(40):25019-26

PHARMACOLOGY

Blockage of N-myristoylation of HIV-1 gag induces the production of impotent progeny virus. Furuishi K, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):504-11

ACETAMIDES

ADMINISTRATION & DOSAGE

Inhibition of nonselective cation channels reduces focal ischemic injury of rat brain. Hoehn-Berlage M, et al. **J Cereb Blood Flow Metab** 1997 May;17(5):534-42

A controlled trial of remacemide hydrochloride in Huntington's disease. Kieburtz K, et al. **Mov Disord** 1996 May;11(3):273-7

ADVERSE EFFECTS

Cancer incidence among alachlor manufacturing workers. Leet T, et al. **Am J Ind Med** 1996 Sep;30(3):300-6

Contact allergy to chloroacetamide. Taran JM, et al. **Australas J Dermatol** 1997 May;38(2):95-6

Evaluation of mortality and cancer incidence among alachlor manufacturing workers. Acquavella JF, et al. **Environ Health Perspect** 1996 Jul;104(7):728-33

ANALYSIS

Cross-reactivity analysis using a four-parameter model applied to environmental immunoassays. Fare TL, et al. **Bull Environ Contam Toxicol** 1996 Sep;57(3):367-74

Time-related analysis of alachlor concentrations in Florida wells. Simons AP, et al. **Bull Environ Contam Toxicol** 1997 Jun;58(6):934-8

Rapid method for analysis of chloroacetanilide and chloronitrophenoxyaniline herbicides by gas chromatography. Dhouib M, et al. **Cent Eur J Public Health** 1996;4 Suppl:51-2

CHEMICAL SYNTHESIS

(E)-(methyloxyimino)acetamides as analogues of neuroleptic benzamides: synthesis and D2-dopaminergic binding affinity. Lapucci A, et al. **Farmaco** 1996 Jan;51(1):33-9

Heterocyclic amides: inhibitors of acyl-CoA:cholesterol O-acyl transferase with hypocholesterolemic activity in several species and antiatherosclerotic activity in the rabbit. White AD, et al. **J Med Chem** 1996 Sep 27;39(20):3908-19

CHEMISTRY

The anticonvulsant activities of functionalized N-benzyl 2-acetamidoacetamides. The importance of the 2-acetamido substituent. Choi D, et al. **Bioorg Med Chem** 1996 Dec;4(12):2105-14

Hydrophobic chromatography of the HL-60 cellular fraction co-binding with hexamethylene bisacetamide. Xie D, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):359-63

METABOLISM

Effect of subsurface drains on runoff losses of metolachlor and trifluralin from Mississippi River alluvial soil. Southwick LM, et al. **Arch Environ Contam Toxicol** 1997 Jan;32(1):106-9

The desglycinyl metabolite of remacemide hydrochloride is neuroprotective in cultured rat cortical neurons. Black MA, et al. **J Neurochem** 1996 Mar;66(3):989-95

Irreversible binding of N-methyl-N-[(1S)-1-(4-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl-3,4 -dichlorophenylacetamide to the cloned rat kappa opioid receptor. Chen C, et al. **Life Sci** 1997;61(8):787-94

PHARMACOKINETICS

Mutual interaction between remacemide hydrochloride and carbamazepine: two drugs with active metabolites. Leach JP, et al. **Epilepsia** 1996 Nov;37(11):1100-6

Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients. Leach JP, et al. **Seizure** 1997 Jun;6(3):179-84

PHARMACOLOGY

Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis. Cajochen C, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1189-96

Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Kräuchi K, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1178-88

Effect of lipoxygenase inhibition on mucous glycoprotein secretion from chinchilla middle ear epithelial cells in vitro. Lin J, et al. **Ann Otol Rhinol Laryngol** 1996 Nov; 105(11):916-21

In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Eliopoulos GM, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1745-7

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Jones RN, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):720-6

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Jorgensen JH, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):465-7

In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Kaatz GW, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):799-801

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Mulazimoglu L, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2428-30

Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells. Okamoto M, et al. **Antiviral Res** 1996 Jun;31(1-2):69-77

The anticonvulsant activities of functionalized N-benzyl 2-acetamidoacetamides. The importance of the 2-acetamido substituent. Choi D, et al. **Bioorg Med Chem** 1996 Dec;4(12):2105-14

Inhibition of a store-operated Ca2+ entry pathway in human endothelial cells by the isoquinoline derivative LOE 908. Encabo A, et al. **Br J Pharmacol** 1996 Oct;119(4):702-6

The antidopaminergic action of S-20098 is mediated by benzodiazepine/GABA(A) receptors in the striatum. Tenn CC, et al. **Brain Res** 1997 May 9;756(1-2):293-6

Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells. Richon VM, et al. **Cancer Res** 1997 Jul 1;57(13):2789-98

High frequency oscillations in the activity of phosphotyrosine phosphatase in murine erythroleukaemic cells: action of insulin and hexamethylene bisacetamide. Ferreira GM, et al. **Cell Biol Int** 1996 Sep;20(9):599-605

Changes in E2F DNA-binding activity during induced erythroid differentiation. Richon VM, et al. **Cell Growth Differ** 1996 Jan;7(1):31-42

Differentiating agent, hexamethylene bisacetamide, inhibits neointimal formation after vascular injury. Ishikawa S, et al. **Coron Artery Dis** 1997 Jan;8(1):28-32

Genotoxicity of humic acid in cultured human lymphocytes and its interaction with the herbicides alachlor and maleic hydrazide. Ribas G, et al. **Environ Mol Mutagen** 1997; 29(3):272-6

Remacemide HCl and its metabolite, FPL 12495AA, limit action potential firing frequency and block NMDA responses of mouse spinal cord neurons in cell culture. Wamil AW, et al. **Epilepsy Res** 1996 Feb;23(1):1-14

Induced differentiation of cancer cells: second generation potent hybrid polar compounds target cell cycle regulators. Marks PA, et al. **Eur J Cancer Prev** 1996 Dec;5 Suppl 2:75-7

The effect of the desglycinyl metabolite of remacemide on cortical wedges prepared from DBA/2 mice. Hu RQ, et al. **Eur J Pharmacol** 1995 Dec 20;287(3):251-6

Stimulation of mucin biosynthesis in rat gastric mucosa by FRG-8813 and its structural analogs. Ichikawa T, et al. **Eur J Pharmacol** 1996 Feb 15;297(1-2):87-92

Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Sanger DJ, et al. **Eur J Pharmacol** 1996 Oct 10;313(1-2):35-42

Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Ying SW, et al. **Eur J Pharmacol** 1996 Jan 18;296(1):33-42

Preparation and local anaesthetic activity of N-[2-(tert-amino)ethyl]- and N-(lupinyl)-benzotriazol-1/2-ylacetamides. Vazzana I, et al. **Farmaco** 1997 Mar;52(3):131-9

Renal protection by a dual ETA/ETB endothelin antagonist, L-754,142, after aortic cross-clamping in the dog. Krause SM, et al. **J Am Soc Nephrol** 1997 Jul;8(7):1061-71

Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists. Tasker AS, et al. **J Med Chem** 1997 Jan 31;40(3):322-30

Plasma cholesterol reducing effect of FR129169, a novel acyl-CoA:cholesterol acyltransferase inhibitor, in the rat. Sakuma Y, et al. **Jpn J Pharmacol** 1996 Jan;70(1):35-41

Oncogenic RAS genes impair erythroid differentiation of erythroleukaemia cells. Zaker F, et al. **Leuk Res** 1997 Jul;

21(7):635–40

A guinea pig ileum preparation devoid of functional kappa receptors: a new in vitro pharmacologic assay for mu–opioid ligands. Schwartz RW, et al. **Life Sci** 1997; 60(15):PL235–9

The neurokinin–1 receptor antagonist LY306,740 blocks nociception–induced increases in dorsal horn neurokinin–1 receptor gene expression. McCarson KE, et al. **Mol Pharmacol** 1996 Nov;50(5):1189–99

A microdialysis study of glycinamide, glycine and other amino acid neurotransmitters in rat frontal cortex and hippocampus after the administration of milacemide, a glycine pro–drug. Doheny MH, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jul; 354(2):157–63

Electrophysiological effects of the anticonvulsant remacemide hydrochloride and its metabolite ARL 12495AA on rat CA1 hippocampal neurons in vitro. Norris SK, et al. **Neuropharmacology** 1997 Jul;36(7):951–9

Entrainment of circadian rhythms by S–20098, a melatonin agonist, is dose and plasma concentration dependent. Martinet L, et al. **Pharmacol Biochem Behav** 1996 Aug; 54(4):713–8

Induced differentiation, the cell cycle, and the treatment of cancer. Rifkind RA, et al. **Pharmacol Ther** 1996; 69(2):97–102 (59 ref.)

An analysis of dimethylsulfoxide–induced action potential block: a comparative study of DMSO and other aliphatic water soluble solutes. Larsen J, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):296–314

[Human mucoepidermoid carcinoma MEC–1 cells induced differentiation by HMBA] Chen Y, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1996 Jan; 31(1):28–30 (Eng. Abstr.) **(Chi)**

[Hexamethylene bisacetamide (HMBA) prevents the loss of porcine thyroid monolayer cells to thyrotropin sensitivity] Amphoux–Fazekas T, et al. **C R Acad Sci III** 1997 Jan; 320(1):1–11 (Eng. Abstr.) **(Fre)**

[Recent progress in development of psychotropic drugs (5)—Hypnotics] Ohta T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Oct; 16(5):161–70 (40 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

In vivo activities of U–100592 and U–100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Ford CW, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1508–13

Mutual interaction between remacemide hydrochloride and phenytoin. Leach JP, et al. **Epilepsy Res** 1997 Jan; 26(2):381–8

Hexamethylene bisacetamide as a chemopreventive agent in hamster cheek pouch tumorigenesis. Yura Y, et al. **Eur J Cancer B Oral Oncol** 1996 Jul;32B(4):246–50

Remacemide hydrochloride: a novel antiepileptic agent. Davies JA. **Gen Pharmacol** 1997 Apr;28(4):499–502 (31 ref.)

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine–containing regimens for patients with HIV–1 infection: the CAESAR trial [see comments] **Lancet** 1997 May 17;349(9063):1413–21. Comment in: Lancet 1997 May 17;349(9063):1408–9.

[Effect of a novel antiulcer drug, lafutidine, on experimental chronic gastritis in rats] Onodera S, et al. **Nippon Yakurigaku Zasshi** 1997 Jan;109(1):31–40 (Eng. Abstr.) **(Jpn)**

[The participation of the central and peripheral kappa–opiate receptors in the mechanism of the anti–arrhythmia action of benzeneacetamide derivatives] Maslov LN, et al. **Eksp Klin Farmakol** 1996 Nov–Dec;59(6):20–2 (Eng. Abstr.) **(Rus)**

TOXICITY

Observation of hepatotoxic effects of 2–n–pentylaminoacetamide (Milacemide) in rat liver by a combined in vivo/in vitro approach. Rogiers V, et al. **Arch Toxicol** 1997;71(5):271–82

Effect of river and wetland sediments on toxicity of metolachlor. Karuppiah M, et al. **Ecotoxicol Environ Saf** 1997 Mar;36(2):180–2

Differentiating agents modulate topoisomerase I activity in U–937 promonocytic cells. Shayo CC, et al. **Eur J Pharmacol** 1997 Apr 11;324(1):129–33

Subchronic, developmental, and genetic toxicology studies with the ethane sulfonate metabolite of alachlor. Heydens WF, et al. **Fundam Appl Toxicol** 1996 Oct;33(2):173–81

Mode of action of thyroid tumor formation in the male Long–Evans rat administered high doses of alachlor. Wilson AG, et al. **Fundam Appl Toxicol** 1996 Sep; 33(1):16–23

Genotoxicity of the herbicides alachlor and maleic hydrazide in cultured human lymphocytes. Ribas G, et al. **Mutagenesis** 1996 May;11(3):221–7

Hypersegmented megakaryocytes and megakaryocytes with multiple separate nuclei in dogs treated with PNU–100592, an oxazolidinone antibiotic. Lund JE, et al. **Toxicol Pathol** 1997 Jul–Aug;25(4):339–43

URINE

Identification of a major human urinary metabolite of metolachlor by LC–MS/MS. Driskell WJ, et al. **Bull Environ Contam Toxicol** 1997 Jun;58(6):929–33

2–ACETAMIDOFLUORENE see **2–ACETYLAMINOFLUORENE**

4–ACETAMIDO–4'–ISOTHIOCYANATOSTILBENE–2,2'–DISULFONIC ACID see **SITS**

ACETAMIDOPHENOL see **ACETAMINOPHEN**

ACETAMINOPHEN

Paracetamol use, availability, and knowledge of toxicity among British and American adolescents. Gilbertson RJ, et al. **Arch Dis Child** 1996 Sep;75(3):194–8

Genes encoding the acetaminophen and selenium binding proteins map to mouse chromosome 3. Navarro CL, et al. **Mamm Genome** 1996 Dec;7(12):919–20

The enhanced effect of parenteral nutrition on hepatotoxicity [see comments] Denno R, et al. **Nutrition** 1996 Jan; 12(1):30–5. Comment in: Nutrition 1996 Jan;12(1):54–5.

Risk factors between analgesic use and chronic nephropathy in Thailand. Kantachuvesiri S, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):350–5

[Study of authorized chronic medication in a basic health area (letter; comment)] Formento Tirado JA. **Aten Primaria** 1996 Sep 30;18(5):271. Comment on: Aten Primaria 1996 Mar 15;17(4):251–6. **(Spa)**

ADMINISTRATION & DOSAGE

Analgesic efficacy of paracetamol in children using tonsillectomy as a pain model. Anderson B, et al. **Anaesth Intensive Care** 1996 Dec;24(6):669–73

A comparison of oral ketorolac and hydrocodone–acetaminophen for analgesia after ambulatory surgery: arthroscopy versus laparoscopic tubal ligation. White PF, et al. **Anesth Analg** 1997 Jul;85(1):37–43

Tylenol Extended Relief overdose. Cetaruk EW, et al. **Ann Emerg Med** 1997 Jul;30(1):104–8

Paracetamol–codeine combinations versus paracetamol alone. Actual size of increase needs to be measured [letter; comment] Collins S, et al. **BMJ** 1996 Nov 9;313(7066):1209 . Comment on: BMJ 1996 Aug 10;313(7053):321–5.

Paracetamol–codeine combinations versus paracetamol alone [letter; comment] Li Wan Po A, et al. **BMJ** 1996 Nov 9; 313(7066):1209. Comment on: BMJ 1996 Aug 10;313(7053):321–5.

Paracetamol–codeine combinations versus paracetamol alone. Intention to treat approach is not popular [letter; comment] Skoglund LA. **BMJ** 1996 Nov 9;313(7066):1209. Comment on: BMJ 1996 Aug 10;313(7053):321–5.

Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Muir N, et al. **Curr Med Res Opin** 1997; 13(9):491–500

Preoperative hypnotic techniques reduce consumption of analgesics after surgical removal of third mandibular molars: a brief communication. Enqvist B, et al. **Int J Clin Exp Hypn** 1997 Apr;45(2):102–8

Assessment of nurses' judgement for analgesic requirements of postoperative children. Rømsing J. **J Clin Pharm Ther** 1996 Jun;21(3):159–63

Dissolution testing of soft shell capsules–acetaminophen and nifedipine. Bottom CB, et al. **J Pharm Sci** 1997 Sep; 86(9):1057–61

Acetaminophen or ketorolac for post myringotomy pain in children? A prospective, double–blinded comparison. Bean–Lijewski JD, et al. **Paediatr Anaesth** 1997;7(2):131–7

Plasma concentration profiles after pre–operative rectal administration of a solution of paracetamol in children. Kollöffel WJ, et al. **Pharm World Sci** 1996 Jun;18(3):105–8

Protective effect of acetaminophen against acute gastric mucosal lesions induced by ischemia–reperfusion in the rat. Nakamoto K, et al. **Pharmacology** 1997 Apr;54(4):203–10

[Combination preparations of codeine and paracetamol] Ostergaard HT, et al. **Ugeskr Laeger** 1997 Sep 15; 159(38):5685–6 **(Dan)**

[Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type] Göbel H, et al. **Nervenarzt** 1996 Aug;67(8):672–81 (Eng. Abstr.) **(Ger)**

[Comment on the contribution: "Usefulness of fixed analgesic combinations exemplified by thomapyrin" (letter; comment)] Hörl WH. **Wien Klin Wochenschr** 1997 Apr 11; 109(7):255–6. Comment on: Wien Klin Wochenschr 1996;108(8):219–33. **(Ger)**

ADVERSE EFFECTS

Acetaminophen–induced hepatotoxicity: predisposing factors and treatments. Makin AJ, et al. **Adv Intern Med** 1997; 42:453–83 (143 ref.)

Postoperative acute liver failure after therapeutic paracetamol administration. Gould TH, et al. **Anaesth Intensive Care** 1997 Apr;25(2):153–5

Acetaminophen anaphylaxis with aspirin and sodium salicylate sensitivity: a case report. Schwarz N, et al. **Ann Allergy Asthma Immunol** 1996 Dec;77(6):473–4

Agranulocytosis, plasmacytosis, and thrombocytosis followed by a leukemoid reaction due to acute acetaminophen toxicity. Gürsoy M, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):762–5

Correlation between the severity of acute hepatic necrosis induced by acetaminophen and serum aminotransferase levels in fasted and sucrose–fed rats. Hessel G, et al. **Braz J Med Biol Res** 1996 Jun;29(6):793–6

Paracetamol–induced pancreatitis and fulminant hepatitis in a hemodialysis patient. Farrell J, et al. **Clin Nephrol** 1997 Aug;48(2):132–3

The complex interaction between ethanol and acetaminophen. Slattery JT, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):241–6 (49 ref.)

Acute generalized exanthematous pustulosis induced by paracetamol. A case with severe hemodynamic disturbances. De Coninck AL, et al. **Dermatology** 1996; 193(4):338–41 (35 ref.)

Acetaminophen and renal and bladder cancer. Derby LE, et al. **Epidemiology** 1996 Jul;7(4):358–62

Fixed drug eruption induced by acetaminophen in a 12–year–old girl [letter] Kawada A, et al. **Int J Dermatol** 1996 Feb;35(2):148–9

Prevalence of cross–sensitivity with acetaminophen and other nonsteroidal antiinflammatory drugs in asthmatic patients [letter; comment] Kalyoncu AF, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):713–4. Comment on: J Allergy Clin Immunol 1995 Oct;96(4):480–5.

Acetaminophen–induced urticaria and tolerance of ibuprofen in an eight–year–old child. Ownby DR. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):151–2

Paracetamol–induced acute liver failure: prevention and management. O'Grady JG. **J Hepatol** 1997;26 Suppl 1:41–6 (45 ref.)

Paracetamol–induced cholestatic and granulomatous liver injuries. Lindgren A, et al. **J Intern Med** 1997 May; 241(5):435–9

Fixed exanthema due to paracetamol. Gómez Martínez M, et al. **J Investig Allergol Clin Immunol** 1996 Mar–Apr; 6(2):131–2

Acetaminophen use in children: more is not better [editorial; comment] [published erratum appears in J Pediatr 1997 Apr;130(4):682] Heubi JE, et al. **J Pediatr** 1997 Feb; 130(2):175–7 (17 ref.). Comment on: J Pediatr 1997 Feb;130(2):300–4.

Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity [see comments] Rivera–Penera T, et al. **J Pediatr** 1997 Feb;130(2):300–4. Comment in: J Pediatr 1997 Feb;130(2):175–7.

Biochemical basis for deficient paracetamol glucuronidation in cats: an interspecies comparison of enzyme constraint in liver microsomes. Court MH, et al. **J Pharm Pharmacol** 1997 Apr;49(4):446–9

Ibuprofen and paracetamol: relative safety in non–prescription dosages. Rainsford KD, et al. **J Pharm Pharmacol** 1997 Apr;49(4):345–76 (234 ref.)

Rhabdomyolysis with acute renal failure and disseminated intravascular coagulation: association with acetaminophen and ethanol. Riggs JE, et al. **Mil Med** 1996 Nov; 161(11):708–9

Pediatric subacute acetaminophen toxicity. Dunlevy TM, et al. **Otolaryngol Head Neck Surg** 1997 Jan;116(1):134–6

Acute pancreatitis induced by codeine–acetaminophen association: a case report with positive rechallenge [letter] Hastier P, et al. **Pancreas** 1996 Oct;13(3):324–6

Hepatic necrosis masquerading as trauma. Anderson B, et al. **Pediatr Radiol** 1997 Jan;27(1):82–3

Relationship between upper gastrointestinal bleeding and non steroidal anti–inflammatory drugs in children. Li Voti G, et al. **Pediatr Surg Int** 1997 Apr;12(4):264–5

Acetaminophen–related acute renal failure without fulminant liver failure. Eguia L, et al. **Pharmacotherapy** 1997 Mar–Apr;17(2):363–70

Environmental hazard assessment of pharmaceuticals. Henschel KP, et al. **Regul Toxicol Pharmacol** 1997 Jun; 25(3):220–5

Paracetamol overdose in pregnancy analysis of the outcomes of 300 cases referred to the Teratology Information Service. McElhatton PR, et al. **Reprod Toxicol** 1997 Jan–Feb;11(1):85–94

[Anaphylactic or anaphylactoid reactions to paracetamol. Report of 3 cases] Sabbah A, et al. **Allerg Immunol (Paris)** 1997 Mar;29(3):60–2 (Eng. Abstr.) **(Fre)**

[Nephrotoxicity of analgesic combination preparations (letter; comment)] Schwarz A. **Wien Klin Wochenschr** 1997 Apr 11;109(7):247–8; discussion 249–54. Comment on: Wien Klin Wochenschr 1996;108(8):219–33. **(Ger)**

[Drug–induced pneumonitis associated PABRON–GOLD] Nomura M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Jan;35(1):72–6 (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

Acetaminophen glucuronidation accurately reflects gluconeogenesis in fasted dogs. Schwenk WF, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E529–34

Isobolographic analysis of interactions between intravenous morphine, propacetamol, and diclofenac in carrageenin–injected rats. Fletcher D, et al. **Anesthesiology** 1997 Aug;87(2):317–26

Biopharmaceutical studies on drug/conjugated–metabolite interactions. III. Effect of acetaminophen sulfate and its positional isomers on the pharmacokinetics of acetaminophen in rats. Nakayama T, et al. **Biol Pharm Bull** 1997 May;20(5):522–9

Postoperative analgesia with i.v. propacetamol and ketoprofen combination after disc surgery. Fletcher D, et

al. **Can J Anaesth** 1997 May;44(5 Pt 1):479–85

Airborne contact dermatitis from propacetamol.
Mathelier-Fusade P, et al. **Contact Dermatitis** 1997 May; 36(5):267–8

Occupational contact dermatitis from propacetamol.
Szczurko C, et al. **Contact Dermatitis** 1996 Nov; 35(5):299–301

Synthesis, physical properties, toxicological studies and bioavailability of L-pyroglutamic and L-glutamic acid esters of paracetamol as potentially useful prodrugs.
Bousquet E, et al. **J Pharm Pharmacol** 1996 May; 48(5):479–85

Comparative pharmacokinetics of paracetamol (acetaminophen) and its sulphate and glucuronide metabolites in desert camels and goats.
Ali BH, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):238–44

Rat liver microsomal cytochrome P450-dependent oxidation of 3,5-disubstituted analogues of paracetamol.
Bessems JG, et al. **Xenobiotica** 1996 Jun;26(6):647–66

ANALYSIS

Rapid screening of marketed paracetamol tablets: use of thin-layer chromatography and a semiquantitative spot test.
Roy J, et al. **Bull World Health Organ** 1997;75(1):19–22

Development and validation of a high-performance liquid chromatography method for the determination of cold relief ingredients in chewing gum.
Gasco-Lopez AI, et al. **J Chromatogr A** 1997 Jul 18;775(1–2):179–85

Simultaneous assay of phenylpropanolamine hydrochloride, caffeine, paracetamol, glycerylguaiacolate and chlorpheniramine maleate in Silabat tablet using HPLC with diode array detection.
Indrayanto G, et al. **J Pharm Biomed Anal** 1995 Nov;13(12):1555–59

Determination of paracetamol in pure form and in dosage forms using N,N-dibromo dimethylhydantoin.
Kumar KG, et al. **J Pharm Biomed Anal** 1997 Jul;15(11):1725–8

Simultaneous determination of acetaminophen, dipyrone and caffeine in pharmaceutical preparations by the absorbance ratio technique.
Doğan HN. **Pharmazie** 1996 Oct; 51(10):773–4

ANTAGONISTS & INHIBITORS

Protective effect of S-(1,2-dicarboxyethyl)glutathione, an intrinsic tripeptide in liver, heart and lens, and its esters on acetaminophen-induced hepatotoxicity in rats.
Sakaue T, et al. **Biol Pharm Bull** 1996 Sep;19(9):1216–9

Effects of fructose-induced hypertriglyceridemia on hepatorenal toxicity of acetaminophen in rats.
Ishida K, et al. **Exp Toxicol Pathol** 1995 Dec;47(6):509–16

Tropisetron inhibits the antinociceptive effect of intrathecally administered paracetamol and serotonin.
Alloui A, et al. **Fundam Clin Pharmacol** 1996;10(4):406–7

Protection by clofibrate against acetaminophen hepatotoxicity in male CD-1 mice is associated with an early increase in biliary concentration of acetaminophen-glutathione adducts.
Manautou JE, et al. **Toxicol Appl Pharmacol** 1996 Sep;140(1):30–8

BLOOD

Advantage of high-surface-area charcoal for gastrointestinal decontamination in a human acetaminophen ingestion model [see comments]
Roberts JR, et al. **Acad Emerg Med** 1997 Mar;4(3):167–74. Comment in: Acad Emerg Med 1997 Mar;4(3):161. Comment in: Acad Emerg Med 1997 Mar;4(3):162–3.

Acetaminophen plasma level after oral administration in liver cirrhotic patients suffering from schistosomal infection.
el-Azab G, et al. **Int J Clin Pharmacol Ther** 1996 Jul; 34(7):299–303

Quantitation of acetaminophen and salicylic acid in plasma using capillary electrophoresis without sample pretreatment. Improvement of precision.
Kunkel A, et al. **J Chromatogr A** 1997 Apr 18;768(1):125–33

The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate.
Bartoli A, et al. **Ther Drug Monit** 1996 Oct;18(5):586–91

CHEMISTRY

Characterization of acetaminophen: molecular microanalysis with Raman microprobe spectroscopy.
Pestaner JP, et al. **J Forensic Sci** 1996 Nov;41(6):1060–3

Examination of the compaction properties of a 1:1 acetaminophen:microcrystalline cellulose mixture using precompression and main compression.
Akande OF, et al. **J Pharm Sci** 1997 Aug;86(8):900–7

Dissolution testing of soft shell capsules-acetaminophen and nifedipine.
Bottom CB, et al. **J Pharm Sci** 1997 Sep; 86(9):1057–61

An investigation into the melting behavior of binary mixes and solid dispersions of paracetamol and PEG 4000.
Lloyd GR, et al. **J Pharm Sci** 1997 Sep;86(9):991–6

Topochemistry of the initial stages of the dissolution of single crystals of acetaminophen.
Vasil'chenko MA, et al. **J Pharm Sci** 1996 Sep;85(9):929–34

DIAGNOSTIC USE

[Gastric emptying test (acetaminophen method)]
Hasebe T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:135–8 (6 ref.) **(Jpn)**

METABOLISM

Combined HPLC, NMR spectroscopy, and ion-trap mass spectrometry with application to the detection and characterization of xenobiotic and endogenous metabolites in human urine.
Shockcor JP, et al. **Anal Chem** 1996 Dec 15;68(24):4431–5

Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes.
Court MH, et al. **Biochem Pharmacol** 1997 Apr 4;53(7):1041–7

Studies comparing the kinetics of cysteine conjugation and protein binding of acetaminophen by hepatic microsomes from male mice.
Zhou L, et al. **Biochim Biophys Acta** 1997 Apr 17;1335(1–2):153–60

Glutamate dehydrogenase covalently binds to a reactive metabolite of acetaminophen.
Halmes NC, et al. **Chem Res Toxicol** 1996 Mar;9(2):541–6

Acetaminophen binds to mouse hepatic and renal DNA at human therapeutic doses.
Rogers LK, et al. **Chem Res Toxicol** 1997 Apr;10(4):470–6

The covalent binding of [14C]acetaminophen to mouse hepatic microsomal proteins: the specific binding to calreticulin and the two forms of the thiol:protein disulfide oxidoreductases.
Zhou L, et al. **Chem Res Toxicol** 1996 Oct-Nov;9(7):1176–82

Metabolism and toxicity of 4-hydroxyphenylacetone in rat liver slices: comparison with acetaminophen.
Thompson DC, et al. **Drug Metab Dispos** 1996 Aug;24(8):866–71

Paracetamol metabolism in two ethnically different Spanish populations.
Esteban A, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jul-Sep;21(3):233–9

Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat.
Yeung JH, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct-Dec; 20(4):287–92

Sex- and age-dependent acetaminophen hepato- and nephrotoxicity in Sprague-Dawley rats: role of tissue accumulation, nonprotein sulfhydryl depletion, and covalent binding.
Tarloff JB, et al. **Fundam Appl Toxicol** 1996 Mar;30(1):13–22

Relative binding of acetaminophen, lidocaine, phenobarbital, phenytoin, quinidine, and theophylline to human tissues in vitro.
Bailey DN. **J Anal Toxicol** 1997 Jan-Feb;21(1):1–4

Effect of gelation conditions and dissolution media on the release of paracetamol from alginate gel beads.
Aslani P, et al. **J Microencapsul** 1996 Sep-Oct;13(5):601–14

Acetaminophen metabolism and cytotoxicity in PC12 cells transfected with cytochrome P4502E1 [see comments]
Holownia A, et al. **J Mol Med** 1997 Jul;75(7):522–7. Comment in: J Mol Med 1997 Jul;75(7):465–6.

Covalent binding of acetaminophen to N-10-formyltetrahydrofolate dehydrogenase in mice.
Pumford NR, et al. **J Pharmacol Exp Ther** 1997 Jan; 280(1):501–5

Catalysis of the cysteine conjugation and protein binding of acetaminophen by microsomes from a human lymphoblast line transfected with the cDNAs of various forms of human cytochrome P450.
Zhou L, et al. **J Pharmacol Exp Ther** 1997 May;281(2):785–90

Role of glutathione conjugation in protection of weanling rat liver against acetaminophen-induced hepatotoxicity.
Allameh A, et al. **Mech Ageing Dev** 1997 Apr;95(1–2):71–9

Abnormalities in the metabolism of acetaminophen in patients infected with the human immunodeficiency virus (HIV).
Esteban A, et al. **Methods Find Exp Clin Pharmacol** 1997 Mar;19(2):129–32

Regulation of sulphation and glutathion conjugation of acetaminophen in isolated rat hepatocytes.
Dalhoff K. **Pharmacol Toxicol** 1996;78 Suppl 1:1–24 (173 ref.)

Metabolic changes of acetaminophen after intravenous administration to rats pretreated with a hepatoprotective agent, YH-439.
Cho E, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jan;91(1):3–16

Identification of a 54-kDa mitochondrial acetaminophen-binding protein as aldehyde dehydrogenase.
Landin JS, et al. **Toxicol Appl Pharmacol** 1996 Nov;141(1):299–307

Comparison of covalent binding of acetaminophen and the regioisomer 3'-hydroxyacetanilide to mouse liver protein.
Matthews AM, et al. **Toxicol Lett** 1997 Jan 15;90(1):77–82

Rat liver microsomal cytochrome P450-dependent oxidation of 3,5-disubstituted analogues of paracetamol.
Bessems JG, et al. **Xenobiotica** 1996 Jun;26(6):647–66

PHARMACOKINETICS

The acetaminophen nomogram: will it withstand the test of the extended relief formulation? [editorial; comment]
Burkhart KK. **Acad Emerg Med** 1996 Aug;3(8):738–9. Comment on: Acad Emerg Med 1996 Aug;3(8):740–4.

A pharmacokinetic comparison of acetaminophen products (Tylenol Extended Relief vs regular Tylenol) [see comments]
Douglas DR, et al. **Acad Emerg Med** 1996 Aug; 3(8):740–4. Comment in: Acad Emerg Med 1996 Aug;3(8):738–9.

Twenty-four-hour pharmacokinetics of rectal acetaminophen in children: an old drug with new recommendations.
Birmingham PK, et al. **Anesthesiology** 1997 Aug;87(2):244–52

Comparison between Sprague-Dawley and Wistar rats as an experimental model of pharmacokinetic alterations induced by spinal cord injury.
García-López P, et al. **Arch Med Res** 1996 Winter;27(4):453–7

Effect of guaiazulene on some cytochrome P450 activities. Implication in the metabolic activation and hepatotoxicity of paracetamol.
Kourounakis AP, et al. **Arch Pharm (Weinheim)** 1997 Jan-Feb;330(1–2):7–11

Biopharmaceutical studies on drug/conjugated-metabolite interactions. III. Effect of acetaminophen sulfate and its positional isomers on the pharmacokinetics of acetaminophen in rats.
Nakayama T, et al. **Biol Pharm Bull** 1997 May;20(5):522–9

Pharmacokinetics of acetaminophen sulfate after oral administration in rats: analysis of plasma profiles exhibiting a non-linear second peak.
Sawamoto T, et al. **Biol Pharm Bull** 1996 Jan;19(1):77–82

Oral paracetamol bioavailability in rats subjected to experimental spinal cord injury.
García-López P, et al. **Biopharm Drug Dispos** 1997 Apr;18(3):203–11

Paracetamol and its metabolites in saliva and plasma in chronic dialysis patients.
Lee HS, et al. **Br J Clin Pharmacol** 1996 Jan;41(1):41–7

Impaired absorption of paracetamol in vegetarians.
Prescott LF, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):237–40

Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers.
Chen L, et al. **Clin Pharmacol Ther** 1996 Dec; 60(6):651–60

Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid.
Chien JY, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):24–34

The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin.
Sarich T, et al. **Clin Pharmacol Ther** 1997 Jul;62(1):21–8

Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets.
Muir N, et al. **Curr Med Res Opin** 1997; 13(9):491–500

Paracetamol (acetominophen) sulphoconjugation in man: no correlation with tyramine sulphoconjugation.
Hannah P, et al. **Drug Metabol Drug Interact** 1996;13(2):119–28

Human metabolism of paracetamol (acetaminophen) at different dose levels.
Steventon GB, et al. **Drug Metabol Drug Interact** 1996;13(2):111–7

Single-dose pharmacokinetics of paracetamol and its conjugates in Chinese non-insulin-dependent diabetic patients with renal impairment.
Chan MT, et al. **Eur J Clin Pharmacol** 1997;52(4):285–8

Bioavailability study of paracetamol tablets in saliva and urine.
Retaco P, et al. **Eur J Drug Metab Pharmacokinet** 1996 Oct-Dec; 21(4):295–300

A model of gastric emptying using paracetamol absorption in intensive care patients [see comments]
Tarling MM, et al. **Intensive Care Med** 1997 Mar;23(3):256–60. Comment in: Intensive Care Med 1997 Mar;23(3):243–5.

Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats.
Jang SH, et al. **J Pharm Sci** 1994 Jun;83(6):810–4

Comparative pharmacokinetics of paracetamol (acetaminophen) and its sulphate and glucuronide metabolites in desert camels and goats.
Ali BH, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):238–44

Plasma concentration profiles after pre-operative rectal administration of a solution of paracetamol in children.
Kollöffel WJ, et al. **Pharm World Sci** 1996 Jun;18(3):105–8

Rectal administration of paracetamol: a comparison of a solution and suppositories in adult volunteers.
Kollöffel WJ, et al. **Pharm World Sci** 1996 Jan;18(1):26–9

Alteration in the biliary and urinary excretion of acetaminophen metabolites by nephrotoxicants in rats.
Seo KW, et al. **Res Commun Mol Pathol Pharmacol** 1997 Mar; 95(3):305–17

Acetaminophen absorption test as a marker of small bowel transplant rejection.
Miyauchi T, et al. **Transplantation** 1997 Apr 27;63(8):1179–82

[The relative bioavailability of paracetamol in suppositories in comparison to tablets]
Blume H, et al. **Arzneimittelforschung** 1996 Oct;46(10):975–80 (Eng. Abstr.) **(Ger)**

[An experimental study of the pharmacokinetics of a new pediatric drug form--Paravit tablets]
Shapovalova VA. **Eksp Klin Farmakol** 1996 Nov-Dec;59(6):29–30 (Eng. Abstr.) **(Rus)**

[Paracetamol pharmacokinetics in the blood plasma of sexually immature rabbits with the use of the new Paravit preparation]
Shapovalova VO. **Fiziol Zh** 1995 Sep-Dec; 41(5–6):57–60 (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

The effect of acetaminophen, ibuprofen, and misoprostol on prostaglandin E2 synthesis and the degree and rate of orthodontic tooth movement.
Kehoe MJ, et al. **Angle Orthod** 1996;66(5):339–49

The effect of acetaminophen on tooth movement in rabbits.
Roche JJ, et al. **Angle Orthod** 1997;67(3):231–6

Long-term tolerability of nimesulide and acetaminophen in nonsteroidal antiinflammatory drug-intolerant patients.
Quaratino D, et al. **Ann Allergy Asthma Immunol** 1997 Jul;

79(1):47–50
Paracetamol counteracts docosahexaenoic acid–induced growth inhibition of A–427 lung carcinoma cells and enhances tumor cell proliferation in vitro. Schønberg SA, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2443–8
Effect of acetylsalicylic acid, paracetamol, caffeine and a combination of these substances on the renal prostaglandin E2, 6–keto–prostaglandin F1 alpha, water, creatinine and electrolyte excretion of the rat. Engelhardt G. **Arzneimittelforschung** 1996 May;46(5):509–12
Effects of acetylsalicylic acid, paracetamol and caffeine and a combination of these substances on kidney glutathione levels. Engelhardt G, et al. **Arzneimittelforschung** 1996 May;46(5):513–8
The thermal potentiation of acetaminophen–inhibited PMN oxidative metabolism in vitro. Shalabi EA, et al. **Biopharm Drug Dispos** 1996 Aug;17(6):501–9
The dose–related effects of paracetamol on hyperalgesia and nociception in the rat. Bianchi M, et al. **Br J Pharmacol** 1996 Jan;117(1):130–2
The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Pini LA, et al. **Eur J Pharmacol** 1996 Jul 11;308(1):31–40
Calcium–dependent DNA damage and adenosine 3',5'–cyclic monophosphate–independent glycogen phosphorylase activation in an in vitro model of acetaminophen–induced liver injury. Salas VM, et al. **Hepatology** 1997 Jun; 25(6):1432–8
Acetaminophen, N–acetyl–benzo–quinoneimine, and apoptosis [comment] Luft FC. **J Mol Med** 1997 Jul; 75(7):465–6 (8 ref.). Comment on: J Mol Med 1997 Jul;75(7):522–7.
Opioid and opioid–like drug effects on whole–gut transit measured by scintigraphy. Maurer AH, et al. **J Nucl Med** 1996 May;37(5):818–22
Acetaminophen cytotoxicity in mouse eye: mitochondria in anterior tissues are the primary target. Zhao C, et al. **J Ocul Pharmacol Ther** 1997 Jun;13(3):269–76
Nitric oxide and acetaminophen–mediated oxidative injury: modulation of interleukin–1–induced nitric oxide synthesis in cultured rat hepatocytes. Kuo PC, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):1072–83
Naloxone–reversible antinociception by paracetamol in the rat. Pini LA, et al. **J Pharmacol Exp Ther** 1997 Feb; 280(2):934–40
Protection of acetaminophen–induced hepatocellular apoptosis and necrosis by cholesteryl hemisuccinate pretreatment. Ray SD, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1470–83
Acetaminophen–derived activation of liver microsomal glutathione S–transferase of rats. Yonamine M, et al. **Jpn J Pharmacol** 1996 Oct;72(2):175–81
Changes in formalin–evoked spinal Fos expression and nociceptive behaviour after oral administration of Bufferin A (aspirin) and L–5409709 (ibuprofen + caffeine + paracetamol). Carrive P, et al. **Pain** 1997 Apr; 70(2–3):253–66
Changes in protein turnover and resting energy expenditure after treatment of malaria in Gambian children. Berclaz PY, et al. **Pediatr Res** 1996 Mar;39(3):401–9
Potentiation of acetaminophen hepatotoxicity by acute physical exercise in rats. Yoon MY, et al. **Res Commun Mol Pathol Pharmacol** 1997 Apr;96(1):35–44
[Effect of paracetamol on the microsomal oxidation, oxidative phosphorylation and liver mitochondria swelling in rats of various ages] Padalko VI, et al. **Ukr Biokhim Zh** 1996 Nov–Dec;68(6):92–8 (Eng. Abstr.) **(Rus)**
[The physiological properties of the action of a new analgesic and antipyretic preparation] Shapovalova VO, et al. **Fiziol Zh** 1997;43(1–2):117–21 (Eng. Abstr.) **(Ukr)**

POISONING

The acetaminophen nomogram: will it withstand the test of the extended relief formulation? [editorial; comment] Burkhart KK. **Acad Emerg Med** 1996 Aug;3(8):738–9. Comment on: Acad Emerg Med 1996 Aug;3(8):740–4.
Late increase in acetaminophen concentration after overdose of Tylenol Extended Relief. Bizovi KE, et al. **Ann Emerg Med** 1996 Nov;28(5):549–51
Tylenol Extended Relief overdose. Cetaruk EW, et al. **Ann Emerg Med** 1997 Jul;30(1):104–8
Use of the Rumack–Matthew nomogram in cases of extended–release acetaminophen toxicity [letter] Vassallo S, et al. **Ann Intern Med** 1996 Dec 1;125(11):940
Adverse reactions to N–acetylcysteine in Inuit to paracetamol (acetaminophen) overdose. Nielsen PT, et al. **Arctic Med Res** 1996 Oct;55(4):204–5
Reducing paracetamol overdoses [editorial] [see comments] Fagan E, et al. **BMJ** 1996 Dec 7;313(7070):1417–8. Comment in: BMJ 1997 Mar 8;314(7082):750–1. Comment in: BMJ 1997 Mar 8;314(7082):751.
Should methionine be added to every paracetamol tablet? Jones AL, et al. **BMJ** 1997 Aug 2;315(7103):301–4
Reducing paracetamol overdoses. Proposals will have negative effects [letter; comment] O'Connell S. **BMJ** 1997 Mar 8;314(7082):751. Comment on: BMJ 1996 Dec 7;313(7070):1417–8.
Reducing paracetamol overdoses. Paracetamol is wrongly blamed [letter; comment] Pounder D, et al. **BMJ** 1997 Mar 8;314(7082):751. Comment on: BMJ 1996 Dec 7;313(7070):1417–8.
Reducing paracetamol overdoses. Methionine should be included in all paracetamol preparations [letter; comment] Spender Q. **BMJ** 1997 Mar 8;314(7082):751. Comment on: BMJ 1996 Dec 7;313(7070):1417–8.
Reducing paracetamol overdoses. Provide hurdles to overdosing [letter; comment] [see comments] Taylor SJ. **BMJ** 1997 Mar 8;314(7082):750–1. Comment on: BMJ 1996 Dec 7;313(7070):1417–8. Comment in: BMJ 1997 Jul 26;315(7102):255.
Public should know of efficacy of early hospital treatment of paracetamol overdose [letter; comment] Wannan G, et al. **BMJ** 1997 Jul 26;315(7102):255. Comment on: BMJ 1997 Mar 8;314(7082):750–1.
Acute psychosis associated with acetaminophen overdose [letter] Servis M, et al. **Gen Hosp Psychiatry** 1997 Mar; 19(2):149–50
N–acetylcysteine (NAC)––a safe antidote in paracetamol poisoning? [letter; comment] Casey PB, et al. **Ir Med J** 1997 Jan–Feb;90(1):38. Comment on: Ir Med J 1996 Sep–Oct;89(5):156, 158.
Paracetamol poisoning: the action line and the timing of acetylcysteine therapy [editorial] [see comments] Delanty N, et al. **Ir Med J** 1996 Sep–Oct;89(5):156, 158 (20 ref.) . Comment in: Ir Med J 1997 Jan–Feb;90(1):38.
Acetylcysteine in paracetamol poisoning––no drug is a safe drug! [letter] McKiernan J, et al. **Ir Med J** 1996 Nov–Dec; 89(6):213
Status epilepticus following intravenous N–acetylcysteine therapy. Hershkovitz E, et al. **Isr J Med Sci** 1996 Nov; 32(11):1102–4
Paracetamol overdose [letter; comment] Whittaker J. **J Accid Emerg Med** 1996 Jul;13(4):301–2. Comment on: J Accid Emerg Med 1996 Jan;13(1):46–8.
Refining the level for anticipated hepatotoxicity in acetaminophen poisoning. Brandwene EL, et al. **J Emerg Med** 1996 Nov–Dec;14(6):691–5
Use of paracetamol for suicide and non–fatal poisoning in the UK and France: are restrictions on availability justified? Gunnell D, et al. **J Epidemiol Community Health** 1997 Apr; 51(2):175–9
Site to site variability of postmortem drug concentrations in liver and lung. Pounder DJ, et al. **J Forensic Sci** 1996 Nov;41(6):927–32
Expression of liver–specific functions in rat hepatocytes following sublethal and lethal acetaminophen poisoning. Tygstrup N, et al. **J Hepatol** 1996 Aug;25(2):183–90
Paracetamol hepatotoxicity: how to prevent. O'Grady JG. **J R Soc Med** 1997 Jul;90(7):368–70 (12 ref.)
Acetaminophen poisoning in late pregnancy. A case report. Wang PH, et al. **J Reprod Med** 1997 Jun;42(6):367–71
Safety packaging of acetaminophen combination preparations and severity of adult poisoning [letter] Chan TY. **J Toxicol Clin Toxicol** 1996;34(6):747–9
Heart donation after fatal acetaminophen poisoning [letter] Hantson P, et al. **J Toxicol Clin Toxicol** 1997;35(3):325–6
Placental transfer of N–acetylcysteine following human maternal acetaminophen toxicity. Horowitz RS, et al. **J Toxicol Clin Toxicol** 1997;35(5):447–51
Hemolysis after acetaminophen overdose in a patient with glucose–6–phosphate dehydrogenase deficiency. Wright RO, et al. **J Toxicol Clin Toxicol** 1996;34(6):731–4 (16 ref.)
Transplantation in patients with paracetamol–induced fulminant hepatic failure [letter] Gow PJ, et al. **Lancet** 1997 Mar 1;349(9052):651–2
Enhanced hepatotoxicity of acetaminophen in the alcoholic patient. Two case reports and a review of the literature. Johnston SC, et al. **Medicine (Baltimore)** 1997 May; 76(3):185–91 (40 ref.)
Acetaminophen toxicity in an urban county hospital. Schiødt FV, et al. **N Engl J Med** 1997 Oct 16;337(16):1112–7
Acute hepatic failure related to chronic acetaminophen intoxication. Luria JW, et al. **Pediatr Emerg Care** 1996 Aug; 12(4):291–3 (13 ref.)
Poisoning with acetaminophen "jello" [letter] Nasir AK, et al. **Pediatrics** 1997 Apr;99(4):652–3
Self–poisoning and the general hospital [editorial] Hawton K. **QJM** 1996 Dec;89(12):879–80
Unusual complications of paracetamol poisoning. Jones AL, et al. **QJM** 1997 Mar;90(3):161–8 (148 ref.)
Classification, etiology, and considerations of outcome in acute liver failure. Williams R. **Semin Liver Dis** 1996 Nov; 16(4):343–8 (39 ref.)
Factors responsible for continuing morbidity after paracetamol poisoning in Chinese patients in Hong Kong. Chan TY, et al. **Singapore Med J** 1996 Jun;37(3):275–7
Treatment of acetaminophen–induced fulminant hepatic failure with a bioartificial liver. Watanabe FD, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):487–8
The epidemiology of acetaminophen (paracetamol) poisoning in Hong Kong. Chan TY. **Vet Hum Toxicol** 1996 Dec; 38(6):443–4
Outpatient N–acetylcysteine treatment for acetaminophen poisoning: an ethical dilemma or a new financial mandate? Dean BS, et al. **Vet Hum Toxicol** 1996 Jun;38(3):222–4
[Recommendations for treatment of paracetamol poisoning. Danish Medical Society, Study of the Liver] Clemmesen JO, et al. **Ugeskr Laeger** 1996 Nov 25;158(48):6892–5 (20 ref.) (Eng. Abstr.) **(Dan)**
[Gc–globulin in paracetamol poisoning] Schiødt FV, et al. **Ugeskr Laeger** 1996 Nov 11;158(46):6609–12 (Eng. Abstr.) **(Dan)**
[Acetaminophen poisoning] Washio M. **Fukuoka Igaku Zasshi** 1997 Mar;88(3):41–3 (4 ref.) **(Jpn)**
[Anaphylactic reaction to N–acetylcysteine after poisoning with paracetamol] Stavem K. **Tidsskr Nor Laegeforen** 1997 May 30;117(14):2038–9 (Eng. Abstr.) **(Nor)**

SUPPLY & DISTRIBUTION

Restrictions on paracetamol planned [news] Wise J. **BMJ** 1996 Nov 30;313(7069):1352

THERAPEUTIC USE

Paracetamol. D'Arcy PF. **Adverse Drug React Toxicol Rev** 1997 Mar;16(1):9–14 (14 ref.)
The efficacy of tepid sponge bathing to reduce fever in young children. Sharber J. **Am J Emerg Med** 1997 Mar; 15(2):188–92
A prospective comparison of transnasal butorphanol and acetaminophen with codeine for the relief of acute musculoskeletal pain [letter] Wolford R, et al. **Am J Emerg Med** 1997 Jan;15(1):101–3
Comparison of the efficacy of paracetamol versus paracetamol, codeine and promethazine (Painstop) for premedication and analgesia for myringotomy in children. Ragg P, et al. **Anaesth Intensive Care** 1997 Feb;25(1):29–32
Restless legs syndrome [letter; comment] Hindmarsh JT. **Arch Intern Med** 1996 Nov 11;156(20):2390. Comment on: Arch Intern Med 1996 Feb 12;156(3):243–8.
Managing measles. Giving paracetamol for fever is unnecessary [letter; comment] Havinga WH. **BMJ** 1997 Jun 7;314(7095):1692; discussion 1692–3. Comment on: BMJ 1997 Feb 1;314(7077):316–7.
Morphine consumption in patients receiving rectal paracetamol and diclofenac alone and in combination. Montgomery JE, et al. **Br J Anaesth** 1996 Oct;77(4):445–7
The efficacy of ketoprofen and paracetamol (acetaminophen) in postoperative pain after third molar surgery. Seymour RA, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):581–5
Bromfenac sodium, acetaminophen/oxycodone, ibuprofen, and placebo for relief of postoperative pain. Johnson GH, et al. **Clin Ther** 1997 May–Jun;19(3):507–19
Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever. Autret E, et al. **Eur J Clin Pharmacol** 1997;51(5):367–71
A randomized, double–blind, multicentre controlled trial of ibuprofen versus acetaminophen and placebo for symptoms of acute otitis media in children. Bertin L, et al. **Fundam Clin Pharmacol** 1996;10(4):387–92
Ketoprofen versus paracetamol in the treatment of acute migraine. Karabetsos A, et al. **Headache** 1997 Jan; 37(1):12–4
Comparison of the analgesic effects of diflunisal and paracetamol in the treatment of postoperative dental pain. Selçuk E, et al. **Int J Clin Pharmacol Res** 1996; 16(2–3):57–65
Acetaminophen–induced urticaria and tolerance of ibuprofen in an eight–year–old child. Ownby DR. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):151–2
Assessment of nurses' judgement for analgesic requirements of postoperative children. Rømsing J. **J Clin Pharm Ther** 1996 Jun;21(3):159–63
Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain––a meta–analysis. Zhang WY, et al. **J Clin Pharm Ther** 1996 Aug;21(4):261–82
Nonprescription ibuprofen and acetaminophen in the treatment of tension–type headache. Schachtel BP, et al. **J Clin Pharmacol** 1996 Dec;36(12):1120–5
Analgesic efficacy of controlled–release oxycodone in postoperative pain. Sunshine A, et al. **J Clin Pharmacol** 1996 Jul;36(7):595–603
Acetaminophen in the management of background pain in children post–burn. Meyer WJ 3rd, et al. **J Pain Symptom Manage** 1997 Jan;13(1):50–5
Ibuprofen and/or acetaminophen: what price for "euthermia"? [letter] Block S. **J Pediatr** 1997 Aug;131(2):332–3
Ibuprofen and/or acetaminophen: what price for "euthermia"? [letter] Melis R. **J Pediatr** 1997 Aug;131(2):332; discussion 333
Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Brandts CH, et al. **Lancet** 1997 Sep 6;350(9079):704–9
Paracetamol prescribing habits in a children's hospital. Anderson B, et al. **N Z Med J** 1996 Oct 11;109(1031):376–8
Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double–blind, randomized, placebo–controlled, crossover study. Hämäläinen ML, et al. **Neurology** 1997 Jan;48(1):103–7
Comparison of postoperative emesis, recovery profile, and analgesia in pediatric strabismus repair. Rectal acetaminophen versus intravenous fentanyl–droperidol. Padda GS, et al. **Ophthalmology** 1997 Mar;104(3):419–24
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient. St. Charles CS, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):76–82
Paracetamol with and without codeine in acute pain: a quantitative systematic review. Moore A, et al. **Pain** 1997 Apr;70(2–3):193–201 (18 ref.)
Antipyretic effect of parenteral paracetamol (propacetamol) in pediatric oncologic patients: a randomized trial. Reymond D, et al. **Pediatr Hematol Oncol** 1997 Jan–Feb; 14(1):51–7
Varicella and necrotizing fasciitis [letter; comment] Rosefsky

JB. **Pediatr Infect Dis J** 1996 Jun;15(6):556–7. Comment on: Pediatr Infect Dis J 1995 Jul;14(7):588–94.

Floctafenin versus acetaminophen for pain control in patients with osteoarthritis in the lower limbs. Franco–Belgian Task Force. Lequesne M, et al. **Rev Rhum Engl Ed** 1997 May; 64(5):327–33

[Comparative trial of lysine acetylsalicylate and paracetamol on pain in daily medical practice] Cabane J, et al. **Presse Med** 1996 Oct 12;25(30):1367–71 (Eng. Abstr.) **(Fre)**

[Analgesic effect and clinical tolerability of the combination of paracetamol 500 mg and caffeine 50 mg versus paracetamol 400 mg and dextropropoxyphene 30 mg in back pain] Kuntz D, et al. **Presse Med** 1996 Sep 7; 25(25):1171–4 (Eng. Abstr.) **(Fre)**

[Paracetamol—the safe analgesic] Gleiter CH. **Internist (Berl)** 1997 Jul;38(7):707–11; discussion 712 (31 ref.) **(Ger)**

[Caffetin in the treatment of neck pain and lumbago–sciatica] Vornovskaia OV, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(4):48–9 (Eng. Abstr.) **(Rus)**

[Comparative, randomized, parallel clinical study of the effectiveness and safety of aceclofenac vs. paracetamol in the treatment of viral pharyngoamygdalitis] Conti M. **Acta Otorrinolaringol Esp** 1997 Mar;48(2):133–7 (Eng. Abstr.) **(Spa)**

TOXICITY

Immunochemical detection of drug–protein adducts in acetaminophen hepatotoxicity. Hinson JA, et al. **Adv Exp Med Biol** 1996;387:47–55

Acetaminophen predisposes to renal and hepatic injury from compound A in the fasting rat. Laster MJ, et al. **Anesth Analg** 1997 Jan;84(1):169–72

Protection of ethanol–mediated acetaminophen hepatotoxicity by triacetyloleandomycin, a specific inhibitor of CYP3A. Kostrubsky VE, et al. **Ann Clin Lab Sci** 1997 Jan–Feb;27(1):57–62

Effect of guaiazulene on some cytochrome P450 activities. Implication in the metabolic activation and hepatotoxicity of paracetamol. Kourounakis AP, et al. **Arch Pharm (Weinheim)** 1997 Jan–Feb;330(1–2):7–11

Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid, paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys. Lehmann H, et al. **Arzneimittelforschung** 1996 Sep;46(9):895–905

Sinusoidal endothelial cells as a target for acetaminophen toxicity. Direct action versus requirement for hepatocyte activation in different mouse strains. DeLeve LD, et al. **Biochem Pharmacol** 1997 May 9;53(9):1339–45

Effect of acetaminophen administration on hepatic glutathione compartmentation and mitochondrial energy metabolism in the rat. Vendemiale G, et al. **Biochem Pharmacol** 1996 Oct 25;52(8):1147–54

Increased resistance to acetaminophen–induced hepatotoxicity in retrovirus–infected mice. Chow HH, et al. **Biopharm Drug Dispos** 1996 Nov;17(8):661–74

Acetaminophen–induced hepatotoxicity. Analysis of total covalent binding vs. specific binding to cysteine. Matthews AM, et al. **Drug Metab Dispos** 1996 Nov;24(11):1192–6

Metabolism and toxicity of 4–hydroxyphenylacetone in rat liver slices: comparison with acetaminophen. Thompson DC, et al. **Drug Metab Dispos** 1996 Aug;24(8):866–71

Selective protein arylation and acetaminophen–induced hepatotoxicity. Cohen SD, et al. **Drug Metab Rev** 1997 Feb–May;29(1–2):59–77 (111 ref.)

Reproductive toxicology. Acetaminophen. **Environ Health Perspect** 1997 Feb;105 Suppl 1:267–8

Histocytological study on the possible mechanism of acetaminophen cataractogenesis in mouse eye. Zhao C, et al. **Exp Mol Pathol** 1995 Oct;63(2):118–28

Effects of acetaminophen on the ultrastructure of isolated rat hepatocytes. Fujimura H, et al. **Exp Toxicol Pathol** 1995 Nov;47(5):345–51

Effects of fructose–induced hypertriglyceridemia on hepatorenal toxicity of acetaminophen in rats. II. Role of enhancement of fructose metabolism and overproduction of triglyceride in the liver and kidney on hepatorenal toxicity of acetaminophen. Ishida K, et al. **Exp Toxicol Pathol** 1997 Feb;49(1–2):39–46

Effects of fructose–induced hypertriglyceridemia on hepatorenal toxicity of acetaminophen in rats. Ishida K, et al. **Exp Toxicol Pathol** 1995 Dec;47(6):509–16

Protective effects of diallyl sulfide on acetaminophen–induced toxicities. Hu JJ, et al. **Food Chem Toxicol** 1996 Oct;34(10):963–9

Protein arylation precedes acetaminophen toxicity in a dynamic organ slice culture of mouse kidney. Hoivik DJ, et al. **Fundam Appl Toxicol** 1996 Nov;34(1):99–104

Sex– and age–dependent acetaminophen hepato– and nephrotoxicity in Sprague–Dawley rats: role of tissue accumulation, nonprotein sulfhydryl depletion, and covalent binding. Tarloff JB, et al. **Fundam Appl Toxicol** 1996 Mar;30(1):13–22

Selective protective effect of an extract from Fumaria parviflora on paracetamol–induced hepatotoxicity. Gilani AH, et al. **Gen Pharmacol** 1996 Sep;27(6):979–83

Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells. Nicod L, et al. **Hum Exp Toxicol** 1997 Jan;16(1):28–34

Respiratory functions in kidney mitochondria following paracetamol administration to young–adult & old rats. Satav JG, et al. **Indian J Med Res** 1997 Mar;105:131–5

Interaction of ciprofloxacin with diclofenac and paracetamol in relation to it's epileptogenic effect. Shrivastava MP, et al. **Indian J Physiol Pharmacol** 1997 Apr;41(2):164–6

Protective effect of diallyl sulfone against acetaminophen–induced hepatotoxicity in mice. Lin MC, et al. **J Biochem Toxicol** 1996;11(1):11–20

Protection against acetaminophen–induced hepatotoxicity by L–CySSME and its N–acetyl and ethyl ester derivatives. Nagasawa HT, et al. **J Biochem Toxicol** 1996;11(6):289–95

Hepatoprotective activity of Apium graveolens and Hygrophila auriculata against paracetamol and thioacetamide intoxication in rats. Singh A, et al. **J Ethnopharmacol** 1995 Dec 15;49(3):119–26

Expression of liver functions following sub–lethal and non–lethal doses of allyl alcohol and acetaminophen in the rat. Tygstrup N, et al. **J Hepatol** 1997 Jul;27(1):156–62

Acetaminophen–induced hepatotoxicity is associated with early changes in NF–kB and NF–IL6 DNA binding activity. Blazka ME, et al. **J Inflamm** 1995–96;47(3):138–50

Acetaminophen metabolism and cytotoxicity in PC12 cells transfected with cytochrome P4502E1 [see comments] Holownia A, et al. **J Mol Med** 1997 Jul;75(7):522–7. Comment in: J Mol Med 1997 Jul;75(7):465–6.

Role of macrophages in acetaminophen (paracetamol)–induced hepatotoxicity. Goldin RD, et al. **J Pathol** 1996 Aug;179(4):432–5

Is activation of lysosomal enzymes responsible for paracetamol–induced hepatotoxicity and nephrotoxicity? Khandkar MA, et al. **J Pharm Pharmacol** 1996 Apr; 48(4):437–40

Differential heat shock protein induction by acetaminophen and a nonhepatotoxic regioisomer, 3'–hydroxyacetanilide, in mouse liver. Salminen WF Jr, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1533–40

Nephrotoxicity of acetaminophen in male Wistar rats: role of hepatically derived metabolites. Trumper L, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):548–54

Role of glutathione conjugation in protection of weanling rat liver against acetaminophen–induced hepatotoxicity. Allameh A, et al. **Mech Ageing Dev** 1997 Apr;95(1–2):71–9

Increased basal expression of hepatic Cyp1a1 and Cyp1a2 genes in inbred mice selected for susceptibility to acetaminophen–induced hepatotoxicity. Casley WL, et al. **Pharmacogenetics** 1997 Aug;7(4):283–93

Paracetamol–induced spindle disturbances in V79 cells with and without expression of human CYP1A2. Jensen KG, et al. **Pharmacol Toxicol** 1996 Apr;78(4):224–8

Acetaminophen–induced hepatotoxicity is associated with early changes in AP–1 DNA binding activity. Blazka ME, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jun; 92(3):259–73

Effect of Taxol on cytochrome P450 3A and acetaminophen toxicity in cultured rat hepatocytes: comparison to dexamethasone. Kostrubsky VE, et al. **Toxicol Appl Pharmacol** 1997 Jan;142(1):79–86

Role of CYP3A in ethanol–mediated increases in acetaminophen hepatotoxicity. Kostrubsky VE, et al. **Toxicol Appl Pharmacol** 1997 Apr;143(2):315–23

Effects of phenethyl isothiocyanate on acetaminophen metabolism and hepatotoxicity in mice. Li Y, et al. **Toxicol Appl Pharmacol** 1997 Jun;144(2):306–14

Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine. Fariss MW, et al. **Toxicol Lett** 1997 Feb 7;90(2–3):133–44

Histopathology of acetaminophen–induced liver changes: role of interleukin 1 alpha and tumor necrosis factor alpha. Blazka ME, et al. **Toxicol Pathol** 1996 Mar–Apr;24(2):181–9

Influence of acetaminophen treatment and hydrogen peroxide treatment on the release of a CINC–related protein and TNF–alpha from rat hepatocyte cultures. Horbach M, et al. **Toxicology** 1997 Aug 15;121(2):117–26

Inhibition of DNA synthesis by paracetamol in different tissues of the rat in vivo. Lister CF, et al. **Toxicology** 1997 Jan 15;116(1–3):49–57

Cimetidine enhances the hepatoprotective action of N–acetylcysteine in mice treated with toxic doses of paracetamol. Al–Mustafa ZH, et al. **Toxicology** 1997 Sep 5;121(3):223–8

URINE

On–line liquid chromatography coupled with high field NMR and mass spectrometry (LC–NMR–MS): a new technique for drug metabolite structure elucidation. Burton KI, et al. **J Pharm Biomed Anal** 1997 Aug;15(12):1903–12

NMR and HPLC–NMR spectroscopic studies of futile deacetylation in paracetamol metabolites in rat and man. Nicholls AW, et al. **J Pharm Biomed Anal** 1997 Apr; 15(7):901–10

ACETANILIDES

CHEMICAL SYNTHESIS

Evaluation of some acylamide derivatives as potential hypoglycemic agents. Srivastava V, et al. **Boll Chim Farm** 1996 Jul–Aug;135(7):452–7

CHEMISTRY

Oxygen transport through methacrylate–based hydrogels with potential biological capability. Compañ V, et al. **Biomaterials** 1996 Jun;17(12):1243–9

NP–101A, antifungal antibiotic from Streptomyces aurantiogriseus NPO–101. Phay N, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):703–5

METABOLISM

Sorption of herbicides butachlor, thiobencarb, and chlomethoxyfen in soils. Chiang HC, et al. **Bull Environ Contam Toxicol** 1997 May;58(5):758–63

Comparison of covalent binding of acetaminophen and the regioisomer 3'–hydroxyacetanilide to mouse liver protein. Matthews AM, et al. **Toxicol Lett** 1997 Jan 15;90(1):77–82

PHARMACOLOGY

Effect of substituted bromoacetanilides on cytosolic aldehyde dehydrogenase. Euston SE, et al. **Adv Exp Med Biol** 1997; 414:233–41

ACAT inhibitor HL–004 accelerates the regression of hypercholesterolemia in stroke–prone spontaneously hypertensive rats (SHRSP): stimulation of bile acid production by HL–004. Murakami S, et al. **Atherosclerosis** 1997 Aug;133(1):97–104

Butachlor impact on protein, free amino acid and glutamine contents, and on activity levels of aminotransferases, glutamate dehydrogenase and glutamine synthetase in the fresh water snail, Pila globosa (Swainson). Rajyalakshmi T, et al. **Biochem Mol Biol Int** 1996 Aug;39(5):949–60

Effect of the ACAT inhibitor, HL–004, on cholesterol metabolism in macrophages. Murakami S, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 Sep;42(6):865–72

NP–101A, antifungal antibiotic from Streptomyces aurantiogriseus NPO–101. Phay N, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):703–5

Interactions of Escherichia coli UmuD with activated RecA analyzed by cross–linking UmuD monocysteine derivatives. Lee MH, et al. **J Bacteriol** 1996 Dec; 178(24):7285–94

TOXICITY

Action of the herbicide butachlor on cholinesterases in the freshwater snail Pila globosa (Swainson). Rajyalakshmi T, et al. **Drug Chem Toxicol** 1996 Nov;19(4):325–31

ACETATE–COA LIGASE

GENETICS

Involvement of iclR and rpoS in the induction of acs, the gene for acetyl coenzyme A synthetase of Escherichia coli K–12. Shin S, et al. **FEMS Microbiol Lett** 1997 Jan 1; 146(1):103–8

METABOLISM

The Saccharomyces cerevisiae acetyl–coenzyme A synthetase encoded by the ACS1 gene, but not the ACS2–encoded enzyme, is subject to glucose catabolite inactivation. de Jong–Gubbels P, et al. **FEMS Microbiol Lett** 1997 Aug 1;153(1):75–81

The two acetyl–coenzyme A synthetases of Saccharomyces cerevisiae differ with respect to kinetic properties and transcriptional regulation. van den Berg MA, et al. **J Biol Chem** 1996 Nov 15;271(46):28953–9

ACETATE–FREE BIOFILTRATION see **HEMODIAFILTRATION**

ACETATE KINASE

METABOLISM

The acetate kinase of Clostridum acetobutylicum strain P262. Diez–Gonzalez F, et al. **Arch Microbiol** 1996 Dec; 166(6):418–20

ACETATE THIOKINASE see **ACETATE–COA LIGASE**

ACETATES

Sensitive in situ hybridization with catalyzed reporter deposition, streptavidin–Nanogold, and silver acetate autometallography: detection of single–copy human papillomavirus. Zehbe I, et al. **Am J Pathol** 1997 May; 150(5):1553–61

Substitution of carbonate by acetate buffer for IgG coating in sandwich ELISA. Cuvelier A, et al. **J Immunoassay** 1996 Nov;17(4):371–82

Comparison of a lactate–versus acetate–based hemofiltration replacement fluid in patients with acute renal failure. Morgera S, et al. **Ren Fail** 1997 Jan;19(1):155–64

ADMINISTRATION & DOSAGE

Effects of a 2.5–mg silver acetate lozenge on initial and long–term smoking cessation. Hymowitz N, et al. **Prev Med** 1996 Sep–Oct;25(5):537–46

Hyperammonemia inhibits platelet aggregation in rats. Shinya H, et al. **Thromb Res** 1996 Jan 15;81(2):195–201

ACETATES

ADVERSE EFFECTS

Occupational allergic contact dermatitis from BAC-esterchloride (beta-phenylethyl-dibutylacetic acid-ethylester-ammonium chloride). Straube M, et al. **Contact Dermatitis** 1996 Aug;35(2):103-4

ANALYSIS

Practical capillary electrophoresis method for the quantitation of the acetate counter-ion in a novel antifungal lipopeptide. Zhou L, et al. **J Chromatogr A** 1997 Feb 28; 763(1-2):279-84

ANTAGONISTS & INHIBITORS

Proximity of acetate, manganese, and exchangeable deuterons to tyrosine YZ. in acetate-inhibited photosystem II membranes: implications for the direct involvement of YZ. in water-splitting. Force DA, et al. **Biochemistry** 1997 Oct 7;36(40):12062-70

BLOOD

L-carnitine and acetyl-L-carnitine status during hemodialysis with acetate in humans: a kinetic analysis [see comments] Jackson JM, et al. **Am J Clin Nutr** 1996 Dec; 64(6):922-7. Comment in: Am J Clin Nutr 1996 Dec;64(6):976-7.

Serum acetate:propionate ratio is related to serum cholesterol in men but not women. Wolever TM, et al. **J Nutr** 1996 Nov;126(11):2790-7

Determination of montelukast (MK-0476) and its S-enantiomer in human plasma by stereoselective high-performance liquid chromatography with column-switching. Liu L, et al. **J Pharm Biomed Anal** 1997 Feb;15(5):631-8

CHEMICAL SYNTHESIS

Synthesis and semisynthesis of alpha-D-mannopyranosyl-(1-->2)-alpha-D-mannopyranose octaacetate. Szurmai Z, et al. **Carbohydr Res** 1996 Dec 24;296:279-84

Synthesis of carbon-11- and fluorine-18-labeled 1-methyl-4-piperidyl-4'-fluorobenzoate and their biodistribution in mice. Bormans G, et al. **Nucl Med Biol** 1996 May;23(4):513-7

Synthesis of [1-11C], [2-11C], [1-11C](2H3) and [2-11C](2H3)acetate for in vivo studies of myocardium using PET. Kihlberg T, et al. **Nucl Med Biol** 1994 Nov; 21(8):1067-72

CHEMISTRY

2-Methyl-3-oxo-4-phenyl-2,3-dihydrofuran-2-yl acetate: a fluorogenic reagent for detection and analysis of primary amines. Chen P, et al. **Anal Chem** 1997 Jul 15; 69(14):2806-11

Neural network classification and quantification of organic vapors based on fluorescence data from a fiber-optic sensor array. Sutter JM, et al. **Anal Chem** 1997 Mar 1;69(5):856-62

Mechanism for the stabilization in vivo of the aziridine precursor --(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride by serum proteins. Louw A, et al. **Biochem Pharmacol** 1997 Jan 24;53(2):189-97

Construction of a single-chain Fv from an antibody which catalyses a Diels Alder cycloaddition. Brooks L, et al. **Biochem Soc Trans** 1996 May;24(2):313S

Covalent complexes between serum albumin and 7-hydroxycoumarin-4-acetic acid: synthesis and applications in the spectrophotometric detection of long-chain fatty acids. Demant EJ. **Biochim Biophys Acta** 1996 Nov 11;1304(1):43-55

Immunochemical assay for recognition of 2-S-glutathionyl acetate, a glutathione conjugate derived from 1,1-dichloroethylene-epoxide. Forkert PG, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1422-30

Prebiotic chemistry. Where smokers rule [comment] Crabtree RH. **Science** 1997 Apr 11;276(5310):222. Comment on: Science 1997 Apr 11;276(5310):245-7.

DIAGNOSTIC USE

Noninvasive assessment of myocardial viability by positron emission tomography with 11C acetate in patients with old myocardial infarction. Usefulness of low-dose dobutamine infusion. Hata T, et al. **Circulation** 1996 Oct 15; 94(8):1834-41

Assessment of myocardial viability by use of 11C-acetate and positron emission tomography. Threshold criteria of reversible dysfunction. Wolpers HG, et al. **Circulation** 1997 Mar 18;95(6):1417-24

Imaging of the pancreas and related diseases with PET carbon-11-acetate. Shreve PD, et al. **J Nucl Med** 1997 Aug;38(8):1305-10

A kinetic model for cardiac PET with [1-carbon-11]-acetate. van den Hoff J, et al. **J Nucl Med** 1996 Mar;37(3):521-9

[13C-acetate breath test for the measurement of gastric emptying rates] Urita Y, et al. **Kaku Igaku** 1996 Oct; 33(10):1083-90 (Eng. Abstr.) **(Jpn)**

METABOLISM

Aldehyde dehydrogenase activity and acetate production by aerobic bacteria representing the normal flora of human large intestine. Nosova T, et al. **Alcohol Alcohol** 1996 Nov; 31(6):555-64

Kinetic aspects of acetate metabolism in healthy humans using [1-13C] acetate. Pouteau E, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E58-64

Growth promotion of Mycobacterium avium-M. intracellulare complex by enterobacterial acetate. Gomez-Flores R, et al. **Am J Trop Med Hyg** 1996 Dec; 55(6):610-6

Reduction of aerobic acetate production by Escherichia coli. Farmer WR, et al. **Appl Environ Microbiol** 1997 Aug; 63(8):3205-10

Attempts to induce reductive acetogenesis into a sheep rumen. Immig I, et al. **Arch Tierernahr** 1996;49(4):363-70

Proximity of acetate, manganese, and exchangeable deuterons to tyrosine YZ. in acetate-inhibited photosystem II membranes: implications for the direct involvement of YZ. in water-splitting. Force DA, et al. **Biochemistry** 1997 Oct 7;36(40):12062-70

Acetyl-CoA hydrolase involved in acetate utilization in Saccharomyces cerevisiae. Lee FJ, et al. **Biochim Biophys Acta** 1996 Sep 13;1297(1):105-9

Evidence to suggest that extracellular acetate is accumulated by rat hippocampal cholinergic nerve terminals for acetylcholine formation and release. Carroll PT. **Brain Res** 1997 Apr 4;753(1):47-55

Assimilation of oxalate, acetate, and CO2 by Oxalobacter formigenes. Cornick NA, et al. **Can J Microbiol** 1996 Nov; 42(11):1081-6

Metabolism of acetate in rat brain neurons, astrocytes and cocultures: metabolic interactions between neurons and glia cells, monitored by NMR spectroscopy. Brand A, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jul;43(5):645-57

Gastric emptying in soldiers during and after field exercise in the heat measured with the [13C]acetate breath test method. Mudambo KS, et al. **Eur J Appl Physiol** 1997; 75(2):109-14

Clostridium ultunense sp. nov., a mesophilic bacterium oxidizing acetate in syntrophic association with a hydrogenotrophic methanogenic bacterium. Schnurer A, et al. **Int J Syst Bacteriol** 1996 Oct;46(4):1145-52

Oxidation of lactate and acetate in rat skeletal muscle: analysis by 13C-nuclear magnetic resonance spectroscopy. Bertocci LA, et al. **J Appl Physiol** 1997 Jul;83(1):32-9

A novel alternate anaplerotic pathway to the glyoxylate cycle in streptomycetes. Han L, et al. **J Bacteriol** 1997 Aug; 179(16):5157-64

Stable isotope model for assessing production of short chain fatty acids from colon-derived sugar: application in pigs. Kien CL, et al. **J Nutr** 1996 Dec;126(12):3069-76

Oxidation of acetate in rabbit skeletal muscle: detection by 13C NMR spectroscopy in vivo. Szczepaniak L, et al. **Magn Reson Med** 1996 Sep;36(3):451-7

Detection of 13C-labeled metabolites in the in vivo canine heart by B1 insensitive heteronuclear coherent polarization transfer and comparison of signal enhancement with NOE. Wei H, et al. **Magn Reson Med** 1997 Mar;37(3):327-30

The acetate regulatory gene facB of Aspergillus nidulans encodes a Zn(II)2Cys6 transcriptional activator. Todd RB, et al. **Mol Gen Genet** 1997 May 20;254(5):495-504

DNA flexibility of the UP element is a major determinant for transcriptional activation at the Escherichia coli acetate promoter. Nègre D, et al. **Nucleic Acids Res** 1997 Feb 15; 25(4):713-8

PHARMACOKINETICS

Superiority of C-11 acetate compared with F-18 fluorodeoxyglucose in predicting myocardial functional recovery by positron emission tomography in patients with acute myocardial infarction. Rubin PJ, et al. **Am J Cardiol** 1996 Dec 1;78(11):1230-5

L-carnitine and acetyl-L-carnitine status during hemodialysis with acetate in humans: a kinetic analysis [see comments] Jackson JM, et al. **Am J Clin Nutr** 1996 Dec; 64(6):922-7. Comment in: Am J Clin Nutr 1996 Dec;64(6):976-7.

Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. Lave T, et al. **J Pharm Pharmacol** 1996 Jun; 48(6):573-7

Synthesis of carbon-11- and fluorine-18-labeled 1-methyl-4-piperidyl-4'-fluorobenzoate and their biodistribution in mice. Bormans G, et al. **Nucl Med Biol** 1996 May;23(4):513-7

PHARMACOLOGY

Hypertonic acetate-alpha alpha hemoglobin for small volume resuscitation of hemorrhagic shock. Poli de Figueiredo LF, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1997 Jan-Mar;25(1-2):61-73

Effect of ammonia on motor function in adult rats. Jayakumar AR, et al. **Brain Res Bull** 1997;43(3):275-8

Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. De Lepeleire I, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):83-92

Effects of concanavalin A and phorbol myristate acetate on glutamine metabolism and proliferation of porcine intestinal intraepithelial lymphocytes. Wu G. **Comp Biochem Physiol A Physiol** 1996 Aug;114(4):363-8

Ammonium acetate challenge in experimental chronic hepatic encephalopathy induces a transient increase of brain 5-HT release in vivo. Bergqvist PB, et al. **Eur Neuropsychopharmacol** 1996 Nov;6(4):317-22

Growth of Escherichia coli in acetate as a sole carbon source is inhibited by ankyrin-like repeats present in the 2',5'-linked oligoadenylate-dependent human RNase L enzyme. Diaz-Guerra M, et al. **FEMS Microbiol Lett** 1997 Apr 1;149(1):107-13

Effects of carbonylcyanide-m-chlorophenylhydrazone (CCCP) and acetate on Escherichia coli O157:H7 and K-12: uncoupling versus anion accumulation. Diez-Gonzalez F, et al. **FEMS Microbiol Lett** 1997 Jun 1;151(1):71-6

Mutants of Saccharomyces cerevisiae with defects in acetate metabolism: isolation and characterization of Acn- mutants. McCammon MT. **Genetics** 1996 Sep;144(1):57-69

Influence of acetate and bicarbonate hemodialysis on the plasma erythropoietin concentration in patients with chronic renal failure. Więcek A, et al. **Int J Artif Organs** 1997 Feb;20(2):108-11

Insertional inactivation of dsbA produces sensitivity to cadmium and zinc in Escherichia coli. Rensing C, et al. **J Bacteriol** 1997 Apr;179(8):2769-71

Suppression of splenic natural killer cell activity in a mouse model for binge drinking. I. Direct effects of ethanol and its major metabolites are not primarily responsible for decreased natural killer cell activity. Wu WJ, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1325-30

Effects of acetate on energy metabolism and function in the isolated perfused rat heart. Jacob AD, et al. **Kidney Int** 1997 Sep;52(3):755-60

Regulation of alpha 2A-adrenergic receptor expression in the human colon carcinoma cell line HT29: SCFA-induced enterocytic differentiation results in an inhibition of alpha 2C10 gene transcription. Devedjian JC, et al. **Proc Assoc Am Physicians** 1996 Jul;108(4):334-44

[3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding. Seiler SM, et al. **Prostaglandins** 1997 Jan;53(1):21-35

The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function. Wise H. **Prostaglandins Leukot Essent Fatty Acids** 1996 May; 54(5):351-60

[The levels of adenine nucleotides and hypoxanthine in blood of patients on long-term hemodialysis using dialysis fluid containing acetate or bicarbonate] Bułło B, et al. **Przegl Lek** 1997;54(1):3-5 (Eng. Abstr.) **(Pol)**

[The effect of Kaviner and the smear layer on dentin permeability of permanent teeth in children] Tadmiščija H, et al. **Med Arh** 1996;50(1-2):49-52 (Eng. Abstr.) **(Scr)**

THERAPEUTIC USE

Ethyl propionate is more effective and less cytotoxic than methyl tert-butyl ether for topical gallstone dissolution. Zakko SF, et al. **Gastroenterology** 1997 Jul;113(1):232-7

Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. Reiss TF, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):528-34

Dentine hypersensitivity and the placebo response. A comparison of the effect of strontium acetate, potassium nitrate and fluoride toothpastes. West NX, et al. **J Clin Periodontol** 1997 Apr;24(4):209-15

Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Reiss TF, et al. **Thorax** 1997 Jan;52(1):45-8

TOXICITY

Oxidative DNA base damage and its repair in kidneys and livers of nickel(II)-treated male F344 rats. Kasprzak KS, et al. **Carcinogenesis** 1997 Feb;18(2):271-7

A comparison of the acute behavioral effects of inhaled amyl, ethyl, and butyl acetate in mice. Bowen SE, et al. **Fundam Appl Toxicol** 1997 Feb;35(2):189-96

Ethyl propionate is more effective and less cytotoxic than methyl tert-butyl ether for topical gallstone dissolution. Zakko SF, et al. **Gastroenterology** 1997 Jul;113(1):232-7

Sertoli cells in culture and mRNA differential display provide a sensitive early warning assay system to detect changes induced by xenobiotics. Syed V, et al. **J Androl** 1997 May-Jun;18(3):264-73

Ontogenic profile of brain lipids following perinatal exposure to cadmium. Gupta A, et al. **J Appl Toxicol** 1996 May-Jun; 16(3):227-33

Effects of ethanol and acetate on adenosine production in rat hippocampal slices. Fredholm BB, et al. **Pharmacol Toxicol** 1996 Sep;79(3):120-3

Acute lung injury induced by a commercial leather conditioner. Hubbs AF, et al. **Toxicol Appl Pharmacol** 1997 Mar;143(1):37-46

Oxidative stress-mediated neurotoxicity of cadmium. Kumar R, et al. **Toxicol Lett** 1996 Dec;89(1):65-9

[Effects of cadmium acetate and ionizing radiation on rat alveolar macrophages] Shopova VL, et al. **Gig Sanit** 1997 Jan-Feb;(1):37-9 **(Rus)**

URINE

Dermal absorption of vaporous and liquid 2-methoxyethanol and 2-ethoxyethanol in volunteers. Kežić S, et al. **Occup Environ Med** 1997 Jan;54(1):38-43

ACETAZINE see **ACEPROMAZINE**

ACETAZOLAMIDE

ADMINISTRATION & DOSAGE

Comparison of topical timolol gel to oral acetazolamide in the prophylaxis of viscoelastic-induced ocular hypertension after penetrating keratoplasty. Kanellopoulos AJ, et al. **Cornea** 1997 Jan;16(1):12-5

[Postoperative course of intraocular pressure after uncomplicated cataract operation with and without acetazolamide] Gareis O, et al. **Ophthalmologe** 1996 Feb; 93(1):45-8 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Taste disturbance with acetazolamide [letter] Martínez-Mir I, et al. **Ann Pharmacother** 1997 Mar;31(3):373

Prevalence of chronic hypokalaemia amongst elderly patients using acetazolamide and diuretics [letter; comment] Barnes EA, et al. **Eye** 1996;10 (Pt 5):648-9. Comment on: Eye 1995;9 (Pt 3):381-2.

Growth suppression in children receiving acetazolamide with antiepileptic drugs. Futagi Y, et al. **Pediatr Neurol** 1996 Nov;15(4):323-6

ANALYSIS

Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Allen LV Jr, et al. **Am J Health Syst Pharm** 1996 Aug 15;53(16):1944-9

CHEMISTRY

The polymorphic drug substances of the European pharmacopoeia. Part 9. Physicochemical properties and crystal structure of acetazolamide crystal forms. Griesser UJ, et al. **J Pharm Sci** 1997 Mar;86(3):352-8

DIAGNOSTIC USE

Comparison of changes in cerebral blood flow and cerebral oxygen saturation measured by near infrared spectroscopy (NIRS) after acetazolamide. Holzschuh M, et al. **Acta Neurochir (Wien)** 1997;139(1):58-62

Cerebral vascular reactivity assessed with acetazolamide single photon emission computer tomography scans before and after carotid endarterectomy. Cikrit DF, et al. **Am J Surg** 1997 Aug;174(2):193-7

Cerebral blood flow reserve in patients with syndrome X. Brunelli C, et al. **Coron Artery Dis** 1996 Aug;7(8):587-90

Cerebellar vascular response to acetazolamide in crossed cerebellar diaschisis: a comparison of 99mTc-HMPAO single-photon emission tomography with 15O-H2O positron emission tomography. Kuwabara Y, et al. **Eur J Nucl Med** 1996 Jun;23(6):683-9

Acetazolamide affects performance on the Nagel II anomaloscope. Leys MJ, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234 Suppl 1:S193-7

Acetazolamide testing of cerebral vasodilator capacity provokes "vascular" but not tension headaches. Shirai T, et al. **Headache** 1996 Nov-Dec;36(10):589-94

Cerebral blood flow and cerebrovascular response to acetazolamide in patients with chronic alcoholism. Oishi M, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul; 63(1):100-2

One-day protocol for cerebral perfusion reserve with acetazolamide. Hattori N, et al. **J Nucl Med** 1996 Dec; 37(12):2057-61

Vasoreactive effect of acetazolamide as a function of time with sequential PET 15O-water measurement. Hayashida K, et al. **Nucl Med Commun** 1996 Dec;17(12):1047-51

Cerebrovascular reserve capacity in patients with occlusive cerebrovascular disease: assessment with dynamic susceptibility contrast-enhanced MR imaging and the acetazolamide stimulation test. Gückel FJ, et al. **Radiology** 1996 Nov;201(2):405-12

[Cerebrovascular reactivity in insulin dependent diabetes mellitus studied by an acetazolamide test] Fülesdi B, et al. **Orv Hetil** 1996 Sep 29;137(39):2137-40 (Eng. Abstr.) **(Hun)**

[Noninvasive regional cerebral blood flow measurements at pre- and post-acetazolamide test using 99mTc-ECD] Matsuda H, et al. **Kaku Igaku** 1996 Jul;33(7):759-66 (Eng. Abstr.) **(Jpn)**

[Quantitative evaluation of response at acetazolamide test using 99mTc-ECD SPECT; a trial of production of the response map] Oyama T, et al. **Kaku Igaku** 1997 Jun; 34(6):389-97 (Eng. Abstr.) **(Jpn)**

[Regional cerebral blood flow measurements at pre- and post-Diamox test using split dose 99mTc-ECD SPECT: comparison with 133Xe inhalation method and linearization correction] Sogabe I. **Kaku Igaku** 1997 Jan;34(1):35-44 (Eng. Abstr.) **(Jpn)**

[Noninvasive quantitative measurements of regional cerebral blood flow using technetium-99m-L, L-ECD SPECT activated with acetazolamide] Takeuchi R, et al. **Kaku Igaku** 1996 Nov;33(11):1213-20 (Eng. Abstr.) **(Jpn)**

[Acetazolamide reactivity on SPECT correlates with PET parameters] Hirano T, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1581 **(Jpn)**

PHARMACOLOGY

Assessment of whole-brain vasodilatory capacity with acetazolamide challenge at 1.5 T using dynamic contrast imaging with frequency-shifted burst. Petrella JR, et al. **AJNR Am J Neuroradiol** 1997 Jun-Jul;18(6):1153-61

Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Maus TL, et al. **Arch Ophthalmol** 1997 Jan;115(1):45-9

Video-imaging micro-fluorometric assessment of luminal chloride/bicarbonate exchange activity in Madin-Darby canine kidney cells: influence of cell density, 4,4'-diisothiocyano-2,2'-disulfonic stilbene and acetazolamide. Ebner S, et al. **Biol Chem Hoppe Seyler** 1996 May;377(5):275-81

Effect of acetazolamide on cerebral blood flow and tympanic temperature in healthy subjects and patients with subacute subarachnoid haemorrhage. Sugino F, et al. **Eur J Appl Physiol** 1997;75(3):252-5

Central chemoreception in the region of the ventral respiratory group in the rat. Nattie EE, et al. **J Appl Physiol** 1996 Nov;81(5):1987-95

Acetazolamide and CO2: acute effects on cerebral and retrobulbar hemodynamics. Harris A, et al. **J Glaucoma** 1996 Feb;5(1):39-45

Cerebral blood flow and cerebrovascular response to acetazolamide in patients with chronic alcoholism. Oishi M, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul; 63(1):100-2

Acetazolamide challenge and technetium-99m-ECD versus iodine-123-IMP SPECT in chronic occlusive cerebrovascular disease. Ohnishi T, et al. **J Nucl Med** 1997 Sep;38(9):1463-7

The effect of low-dose acetazolamide on the ventilatory CO2 response curve in the anaesthetized cat. Wagenaar M, et al. **J Physiol (Lond)** 1996 Aug 15;495 (Pt 1):227-37

Brain pH responses to acetazolamide and hypercapnia in cats. Kohshi K, et al. **Neurol Med Chir (Tokyo)** 1997 Apr; 37(4):313-8; discussion 318-9

Comparison of vasodilatory effect of carbon dioxide inhalation and intravenous acetazolamide on brain vasculature using positron emission tomography. Gambhir S, et al. **Neurol Res** 1997 Apr;19(2):139-44

Partial recovery of in vivo function by improved incubation conditions of isolated renal proximal tubule. II. Change of Na-HCO3 cotransport stoichiometry and of response to acetazolamide. Müller-Berger S, et al. **Pflugers Arch** 1997 Aug;434(4):383-91

Effect of acetazolamide and melittin on polarization of the frog gastric mucosa proton pump. Carrasquer G, et al. **Proc Soc Exp Biol Med** 1996 Dec;213(3):258-61

Dissociation of vasoreactivity to acetazolamide and hypercapnia. Comparative study in patients with chronic occlusive major cerebral artery disease. Kazumata K, et al. **Stroke** 1996 Nov;27(11):2052-8

Sex-related differences in acetazolamide-induced cerebral vasomotor reactivity: a statistical misinterpretation? [letter; comment] Nirkko AC, et al. **Stroke** 1996 Sep;27(9):1700. Comment on: Stroke 1996 Jan;27(1):56-8.

THERAPEUTIC USE

Acetazolamide responsiveness in familial hemiplegic migraine [letter] Athwal BS, et al. **Ann Neurol** 1996 Nov;40(5):820-1

Acetazolamide-responsive episodic ataxia in an Italian family refines gene mapping on chromosome 19p13. Calandriello L, et al. **Brain** 1997 May;120 (Pt 5):805-12

A treatment for tardive dyskinesia and some other extrapyramidal symptoms. Cowen MA, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):190-3

Acetazolamide therapy improves action myoclonus in Ramsay Hunt Syndrome. Baig SM. **J Neurol Sci** 1997 Jan; 145(1):123-4

Cerebral blood flow and clinical outcome in patients with thalamic hemorrhages: a comparison with putaminal hemorrhages. Tanaka A, et al. **J Neurol Sci** 1996 Dec; 144(1-2):191-7

Bilateral angle closure glaucoma in HIV infection. Zambarakji HJ, et al. **J R Soc Med** 1996 Oct;89(10):581-2

The electroencephalogram in acetazolamide-responsive periodic ataxia. Neufeld MY, et al. **Mov Disord** 1996 May; 11(3):283-8

EEG findings in acetazolamide-responsive hereditary paroxysmal ataxia. Van Bogaert P, et al. **Neurophysiol Clin** 1996;26(5):335-40

Acetazolamide treatment of CME in patients with uveitis [letter; comment] Flach A. **Ophthalmology** 1996 Nov; 103(11):1715-6; discussion 1716-7. Comment on: Ophthalmology 1996 Jul;103(7):1054-62; discussion 1062-3.

Acetazolamide treatment of CME in patients with uveitis [letter; comment] Rho D. **Ophthalmology** 1996 Nov; 103(11):1717; discussion 1717-8. Comment on: Ophthalmology 1996 Jul;103(7):1054-62; discussion 1062-3.

Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure. Rulo AH, et al. **Ophthalmology** 1997 Sep;104(9):1503-7

The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Hoyng PF, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S93-8 (43 ref.)

[Glaucoma. Current problems. Continuing education courses at the Ophthalmologic Clinic of the Eppendorf University Hospital, 9 December 1995] **Klin Monatsbl Augenheilkd** 1996 Feb;208(2 Suppl):1-4 **(Ger)**

[Positional impedance tests with acetazolamide: a clinical test for evaluating endolymphatic hydrops] Abramo A, et al. **Acta Otorhinolaryngol Ital** 1996 Oct;16(5):401-6 (Eng. Abstr.) **(Ita)**

[Efficacy of acetazolamide treatment of patients with hypercapnia and superimposed metabolic alkalosis] Prieto de Paula JM, et al. **Rev Clin Esp** 1997 Apr;197(4):237-40 (Eng. Abstr.) **(Spa)**

ACETIC ACID

Fixation with Carnoy's fluid reduces the number of chymase-positive mast cells: not all chymase-positive mast cells are also positive for tryptase. KleinJan A, et al. **Allergy** 1996 Sep;51(9):614-20

The influence of 2-propanol and acetone on oviposition rate and oviposition site preference for acetic acid and ethanol of Drosophila melanogaster. Eisses KT. **Behav Genet** 1997 May;27(3):171-80

Method for the purification of tissue DNA suitable for PCR after fixation with Bouin's fluid. Uses and limitations in microsatellite typing. Longy M, et al. **Diagn Mol Pathol** 1997 Jun;6(3):167-73

One- and two-dimensional histone separations in acidic gels: usefulness of methylene blue-driven photopolymerization. Rabilloud T, et al. **Electrophoresis** 1996 Jan;17(1):67-73

Role of polymorphonuclear leukocytes and oxygen-derived free radicals in chronic gastric lesion induced by acetic acid in rat. Motilva V, et al. **Gen Pharmacol** 1996 Apr; 27(3):545-50

The role of transient mucosal ischemia in acetic acid-induced colitis in the rat. Fabia R, et al. **J Surg Res** 1996 Jul 1; 63(2):406-12

[Differentiation of antinociceptive effects of mu, delta and kappa agonists using heat, chemical and mechanical nociception] Murakawa K, et al. **Masui** 1996 Aug; 45(8):937-42 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Can small hepatocellular carcinoma be cured by percutaneous acetic acid injection therapy? Fan ST. **HPB Surg** 1997;10(5):340-1

Effects of a 2.5-mg silver acetate lozenge on initial and long-term smoking cessation. Hymowitz N, et al. **Prev Med** 1996 Sep-Oct;25(5):537-46

[The disinfection of fish in the family Cyprinidae of Opisthorchis felineus Riv. metacercariae by the combined use of acetic acid and table salt] Zviagina VV, et al. **Med Parazitol (Mosk)** 1997 Jan-Mar;(1):9-12 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Ethanol metabolite acetic acid as causative agent for type-1 hypersensitivity-like reactions to alcoholic beverages [see comments] Boehncke WH, et al. **Clin Exp Allergy** 1996 Sep;26(9):1089-91. Comment in: Clin Exp Allergy 1997 Mar;27(3):343.

Chemical burn from acetic acid with deep ulceration. Kuniyuki S, et al. **Contact Dermatitis** 1997 Mar; 36(3):169-70

ANALOGS & DERIVATIVES see ACETIC ACIDS

ANALYSIS

Use of ion chromatography for monitoring microbial spoilage in the fruit juice industry. Trifirò A, et al. **J Chromatogr A** 1997 May 16;770(1-2):243-52

CHEMISTRY

Astringency of organic acids is related to pH. Lawless HT, et al. **Chem Senses** 1996 Aug;21(4):397-403

Activated acetic acid by carbon fixation on (Fe,Ni)S under primordial conditions [see comments] Huber C, et al. **Science** 1997 Apr 11;276(5310):245-7. Comment in: Science 1997 Apr 11;276(5310):222.

DIAGNOSTIC USE

Acetowhite staining in the detection of laryngeal disease. Soh KB, et al. **Clin Otolaryngol** 1996 Jun;21(3):252-5

METABOLISM

Production of acetic acid by Clostridium thermoaceticum. Cheryan M, et al. **Adv Appl Microbiol** 1997;43:1-33 (77 ref.)

A freshwater anaerobe coupling acetate oxidation to tetrachloroethylene dehalogenation. Krumholz LR, et al. **Appl Environ Microbiol** 1996 Nov;62(11):4108-13

Effect of 2-bromoethanesulfonic acid and Peptostreptococcus productus ATCC 35244 addition on stimulation of reductive acetogenesis in the ruminal ecosystem by selective inhibition of methanogenesis. Nollet

L, et al. **Appl Environ Microbiol** 1997 Jan;63(1):194–200

Isolation of O-demethylase, an ether-cleaving enzyme system of the homoacetogenic strain MC. Kaufmann F, et al. **Arch Microbiol** 1997 Aug;168(2):136–42

Acetogenic bacteria: what are the in situ consequences of their diverse metabolic versatilities? Drake HL, et al. **Biofactors** 1997;6(1):13–24 (46 ref.)

Enzymology of the fermentation of acetate to methane by Methanosarcina thermophila. Ferry JG. **Biofactors** 1997; 6(1):25–35 (43 ref.)

The ability of Escherichia coli O157:H7 to decrease its intracellular pH and resist the toxicity of acetic acid. Diez-Gonzalez F, et al. **Microbiology** 1997 Apr;143 (Pt 4):1175–80

Initial pH as a determining factor of glucose consumption and lactic and acetic acid production in oral streptococci. Concha ML, et al. **Microbios** 1996;87(353):207–16

Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Wallot M, et al. **Pediatr Nephrol** 1996 Oct;10(5):625–30

Activation of E350A mutant maltodextrin phosphorylase by exogenously added acetate. Drueckes P, et al. **Protein Eng** 1996 Aug;9(8):701–5

Acetogenic coccoid spore-forming bacteria isolated from the rumen. Rieu-Lesme F, et al. **Res Microbiol** 1996 Nov–Dec; 147(9):753–64

PHARMACOKINETICS

[The pharmacokinetics of D-lactate, L-lactate and acetate in humans] Hamada T, et al. **Masui** 1997 Feb;46(2):229–36 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Effects of dilute acetic acid on the cervical smear. Cronjé HS, et al. **Acta Cytol** 1997 Jul–Aug;41(4):1091–4

Delayed gastric emptying rate as a potential mechanism for lowered glycemia after eating sourdough bread: studies in humans and rats using test products with added organic acids or an organic salt. Liljeberg HG, et al. **Am J Clin Nutr** 1996 Dec;64(6):886–93

Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model. Mariadason JM, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):G705–12

Effect of organic acids in the prevention of aggregation on rapid refolding of proteins. Yang PW, et al. **Biochem Mol Biol Int** 1996 Feb;38(2):393–99

The effect of electron beam irradiation, combined with acetic acid, on the survival and recovery of Escherichia coli and Lactobacillus curvatus. Fielding LM, et al. **Int J Food Microbiol** 1997 Apr 15;35(3):259–65

Predictive models of the effect of temperature, pH and acetic and lactic acids on the growth of Listeria monocytogenes. George SM, et al. **Int J Food Microbiol** 1996 Sep; 32(1–2):73–90

A 16 kDa protein family overexpressed by Streptococcus thermophilus PB18 in acid environments. González-Márquez H, et al. **Microbiology** 1997 May;143 (Pt 5):1587–94

Effects of taste preexposure on aversion training to visual cues in chicks (Gallus domesticus). Franchina JJ. **Physiol Behav** 1997 Sep;62(3):611–5

Effects of acetic acid and hydrogen peroxide application during defeathering on the microbiological quality of broiler carcasses prior to evisceration. Dickens JA, et al. **Poult Sci** 1997 Apr;76(4):657–60

[Antibacterial actin of vinegar against food-borne pathogenic bacteria including Escherichia coli O157:H7 (Part 1). Examination of bacteriostatic and bactericidal activities] Entani E, et al. **Kansenshogaku Zasshi** 1997 May; 71(5):443–50 (Eng. Abstr.) **(Jpn)**

[Antibacterial actin of vinegar against food-borne pathogenic bacteria including Escherichia coli O157:H7 (Part 2). Effect of sodium chloride and temperature on bactericidal activity] Entani E, et al. **Kansenshogaku Zasshi** 1997 May; 71(5):451–8 (Eng. Abstr.) **(Jpn)**

[The physiological properties of the action of a new analgesic and antipyretic preparation] Shapovalova VO, et al. **Fiziol Zh** 1997;43(1–2):117–21 (Eng. Abstr.) **(Ukr)**

THERAPEUTIC USE

Treatment of hypervascular small hepatocellular carcinoma with ultrasound-guided percutaneous acetic acid injection: comparison with segmental transcatheter arterial embolization. Ohnishi K, et al. **Am J Gastroenterol** 1996 Dec;91(12):2574–9

Acetic acid iontophoresis and ultrasound for the treatment of calcifying tendinitis of the shoulder: a randomized control trial. Perron M, et al. **Arch Phys Med Rehabil** 1997 Apr;78(4):379–84

Treatment of nodular hepatocellular carcinoma larger than 3 cm with ultrasound-guided percutaneous acetic acid injection. Ohnishi K, et al. **Hepatology** 1996 Dec; 24(6):1379–85

Acetic acid treatment of pseudomonal postoperative wound infection [letter] Nagoba BS, et al. **J Hosp Infect** 1997 Jul; 36(3):243–4

[Usefulness of calcium acetate as a chelating of phosphorus in patients in hemodialysis with secondary hyperthyroidism] Torregrosa Prats JV, et al. **An Med Interna** 1995 Aug;12(8):377–81 (Eng. Abstr.) **(Spa)**

TOXICITY

Calcitonin gene-related peptide in viscerosensitive response to colorectal distension in rats. Plourde V, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):G191–6

URINE

Urinary alkoxyacetic acids and renal effects of exposure to ethylene glycol ethers. Laitinen J, et al. **Occup Environ Med** 1996 Sep;53(9):595–600

ACETIC ACID ESTERS see **ACETATES**

ACETIC ACIDS

A method for preparation of amino acid thiohydantoins from free amino acids activated by acetyl chloride for development of protein C-terminal sequencing. Mo B, et al. **Anal Biochem** 1997 Jul 1;249(2):207–11

ADMINISTRATION & DOSAGE

Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients. Janssen MJ, et al. **Nephrol Dial Transplant** 1995 Dec;10(12):2321–4

A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Bhaumik S, et al. **Seizure** 1997 Apr;6(2):127–33

ADVERSE EFFECTS

Stuttering caused by gabapentin [letter] Nissani M, et al. **Ann Intern Med** 1997 Mar 1;126(5):410

Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. Chudnow RS, et al. **Arch Neurol** 1997 Jul;54(7):910–2

Psychomotor agitation following gabapentin use in brain injury. Childers MK, et al. **Brain Inj** 1997 Jul;11(7):537–40

Incontinence during treatment with gabapentin. Gil-Nagel A, et al. **Neurology** 1997 May;48(5):1467–8

Changes in body weight with chronic, high-dose gabapentin therapy. DeToledo JC, et al. **Ther Drug Monit** 1997 Aug; 19(4):394–6

BLOOD

Determination of gabapentin in serum using solid-phase extraction and gas-liquid chromatography. Wolf CE, et al. **J Anal Toxicol** 1996 Oct;20(6):498–501

Determination of gabapentin in plasma by high-performance liquid chromatography. Forrest G, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):421–5

Contrasting nutrient effects on the plasma levels of an amino acid-like antiepileptic agent from jejunal administration in dogs. Stevenson CM, et al. **J Pharm Sci** 1997 Aug; 86(8):953–7

CHEMICAL SYNTHESIS

Synthesis of short polyoxyethylene-based heterobifunctional cross-linking reagents. Application to the coupling of peptides to liposomes. Frisch B, et al. **Bioconjug Chem** 1996 Mar–Apr;7(2):180–6

Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids. Kotani T, et al. **J Med Chem** 1997 Feb 28;40(5):684–94

CHEMISTRY

Interwoven hydrogen-bonding networks in benzene-1,3,5-triacetic acid. Fitzgerald LJ, et al. **Acta Crystallogr C** 1997 Jul 15;53 (Pt 7):967–9

Pterulinic acid and pterulone, two novel inhibitors of NADH:ubiquinone oxidoreductase (complex I) produced by a Pterula species. II. Physico-chemical properties and structure elucidation. Engler M, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):330–3

35Cl NOR and 19F NMR relaxation studies of CClF2 group dynamics in N(CH3)4H(ClF2CCOO)2. Zdanowska-Frączek M, et al. **Solid State Nucl Magn Reson** 1996 Apr;6(2):141–6

DIAGNOSTIC USE

Sensitivity of the acetic acid test [letter; comment] Cronjé HS, et al. **S Afr Med J** 1996 Jul;86(7):850. Comment on: S Afr Med J 1996 Apr;86(4):378.

ECONOMICS

A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy [see comments] Hughes D, et al. **Seizure** 1996 Jun; 5(2):89–95 (38 ref.). Comment in: Seizure 1996 Sep;5(3):247–8.

If comparisons can be odious, so can assumptions [letter; comment] Jackson D, et al. **Seizure** 1996 Sep;5(3):247–8. Comment on: Seizure 1996 Jun;5(2):89–95.

ISOLATION & PURIFICATION

Pterulinic acid and pterulone, two novel inhibitors of NADH:ubiquinone oxidoreductase (complex I) produced by a Pterula species. I. Production, isolation and biological activities. Engler M, et al. **J Antibiot (Tokyo)** 1997 Apr; 50(4):325–9

METABOLISM

Introduction of anaerobic dechlorinating bacteria into soil slurry microcosms and nested-PCR monitoring. el Fantroussi S, et al. **Appl Environ Microbiol** 1997 Feb; 63(2):806–11

Spermine modulation of specific [3H]-gabapentin binding to the detergent-solubilized porcine cerebral cortex alpha 2 delta calcium channel subunit. Dissanayake VU, et al. **Br J Pharmacol** 1997 Mar;120(5):833–40

Comparison of the uptake of [3H]-gabapentin with the uptake of L-[3H]-leucine into rat brain synaptosomes. Thurlow RJ, et al. **Br J Pharmacol** 1996 Jun;118(3):449–56

Comparison of the autoradiographic binding distribution of [3H]-gabapentin with excitatory amino acid receptor and amino acid uptake site distributions in rat brain. Thurlow RJ, et al. **Br J Pharmacol** 1996 Jun;118(3):457–65

Electrophysiological and ultrastructural events evoked by methacholine and intracellular photolysis of caged compounds in cultured ovine tracheal gland cells. Griffin A, et al. **Exp Physiol** 1996 Jan;81(1):27–43

PHARMACOKINETICS

Colonic absorption of antiepileptic agents. Stevenson CM, et al. **Epilepsia** 1997 Jan;38(1):63–7

Effect of a high-protein meal on gabapentin pharmacokinetics. Gidal BE, et al. **Epilepsy Res** 1996 Feb; 23(1):71–6

Kinetic properties of DM-nitrophen and calcium indicators: rapid transient response to flash photolysis. Escobar AL, et al. **Pflugers Arch** 1997 Sep;434(5):615–31

PHARMACOLOGY

Gabapentin. Bruni J. **Can J Neurol Sci** 1996 Nov;23(4):S10–2

Neurochemical actions of gabapentin in mouse brain. Leach JP, et al. **Epilepsy Res** 1997 Jun;27(3):175–80

The anticonvulsant gabapentin decreases firing rates of substantia nigra pars reticulata neurons. Bloms-Funke P, et al. **Eur J Pharmacol** 1996 Dec 5;316(2–3):211–8

2-Methoxyacetic acid (MAA)-induced spermatocyte apoptosis in human and rat testes: an in vitro comparison. Li LH, et al. **J Androl** 1996 Sep–Oct;17(5):538–49

Pterulinic acid and pterulone, two novel inhibitors of NADH:ubiquinone oxidoreductase (complex I) produced by a Pterula species. I. Production, isolation and biological activities. Engler M, et al. **J Antibiot (Tokyo)** 1997 Apr; 50(4):325–9

Montiporic acids A and B, cytotoxic and antimicrobial polyacetylene carboxylic acids from eggs of the scleractinian coral Montipora digitata. Fusetani N, et al. **J Nat Prod** 1996 Aug;59(8):796–7

A peroxidase gene promoter induced by phytopathogens and methyl jasmonate in transgenic plants. Curtis MD, et al. **Mol Plant Microbe Interact** 1997 Apr;10(3):326–38

Gabapentin interaction with felbamate. Hussein G, et al. **Neurology** 1996 Oct;47(4):1106

Gabapentin, ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation. Stanfa LC, et al. **Neuroreport** 1997 Feb 10;8(3):587–90

Spinal gabapentin is antinociceptive in the rat formalin test. Shimoyama N, et al. **Neurosci Lett** 1997 Jan 24;222(1):65–7

Methyl jasmonate induces an O-methyltransferase in barley. Lee JE, et al. **Plant Cell Physiol** 1997 Jul;38(7):851–62

Identification of a methyl jasmonate-responsive region in the promoter of a lipoxygenase 1 gene expressed in barley grain. Rouster J, et al. **Plant J** 1997 Mar;11(3):513–23

Differential expression of soybean cysteine proteinase inhibitor genes during development and in response to wounding and methyl jasmonate. Botella MA, et al. **Plant Physiol** 1996 Nov;112(3):1201–10

A gene encoding a chloroplast-targeted lipoxygenase in tomato leaves is transiently induced by wounding, systemin, and methyl jasmonate. Heitz T, et al. **Plant Physiol** 1997 Jul;114(3):1085–93

The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Singh L, et al. **Psychopharmacology (Berl)** 1996 Sep;127(1):1–9

Mechanisms of action of antiepileptic drugs. Davies JA. **Seizure** 1995 Dec;4(4):267–71 (28 ref.)

[The effect on central dopaminergic structures of various hydrazides of phosphorylated carbonic acids and diaziridines] Baĭchurina AZ, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):648–51 **(Rus)**

[Features of the antidepressive effect of O-beta-chloroethyl-para-N-dimethylaminophenylphosphinylacetic acid (amfazide)] Semina II, et al. **Biull Eksp Biol Med** 1996 May; 121(5):538–40 **(Rus)**

POISONING

Hemodialysis and hemoperfusion for treatment of valproic acid and gabapentin poisoning. Fernandez MC, et al. **Vet Hum Toxicol** 1996 Dec;38(6):438–43

THERAPEUTIC USE

Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Olson WL, et al. **Am J Med** 1997 Jan;102(1):60–6

Gabapentin in the treatment of bipolar disorder [letter] Schaffer CB, et al. **Am J Psychiatry** 1997 Feb;154(2):291–2

Treatment of acute mania with gabapentin [letter] Stanton SP, et al. **Am J Psychiatry** 1997 Feb;154(2):287
Erythromelalgia pain managed with gabapentin. McGraw T, et al. **Anesthesiology** 1997 Apr;86(4):988–90
A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. McElroy SL, et al. **Ann Clin Psychiatry** 1997 Jun;9(2):99–103
A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Averbuch-Heller L, et al. **Ann Neurol** 1997 Jun;41(6):818–25
Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis [see comments] Gurney ME, et al. **Ann Neurol** 1996 Feb; 39(2):147–57. Comment in: Ann Neurol 1996 Feb;39(2):145–6.
Use of gabapentin in pain management. Wetzel CH, et al. **Ann Pharmacother** 1997 Sep;31(9):1082–3 (8 ref.)
Reflex sympathetic dystrophy treated with gabapentin. Mellick GA, et al. **Arch Phys Med Rehabil** 1997 Jan; 78(1):98–105
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Mueller ME, et al. **Arch Phys Med Rehabil** 1997 May;78(5):521–4
Add-on gabapentin for refractory seizures in patients with brain tumours. Perry JR, et al. **Can J Neurol Sci** 1996 May; 23(2):128–31
Treatment of restless legs syndrome with gabapentin. Adler CH. **Clin Neuropharmacol** 1997 Apr;20(2):148–51
A review of the newer antiepileptic drugs and the ketogenic diet. Barron TF, et al. **Clin Pediatr (Phila)** 1997 Sep; 36(9):513–21 (61 ref.)
Gabapentin in generalized seizures. Chadwick D, et al. **Epilepsy Res** 1996 Nov;25(3):191–7
The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Hunter JC, et al. **Eur J Pharmacol** 1997 Apr 18;324(2–3):153–60
Seizure control: how to use the new antiepileptic drugs in older patients. Haider A, et al. **Geriatrics** 1996 Sep; 51(9):42–5 (16 ref.)
Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. Trudeau V, et al. **J Child Neurol** 1996 Nov;11(6):470–5
Gabapentin for behavioral agitation in Alzheimer's disease [letter] Regan WM, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):59–60
Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Leach JP, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):372–6
Gabapentin in bipolar disorder [letter] Ryback RS, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):301
Evaluation of gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain. Field MJ, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1242–6
Gabapentin and motor fluctuations in Parkinson's disease. Chaná P, et al. **Mov Disord** 1997 Jul;12(4):608
Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. Bergey GK, et al. **Neurology** 1997 Sep;49(3):739–45
Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Beydoun A, et al. **Neurology** 1997 Sep;49(3):746–52
Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Miller RG, et al. **Neurology** 1996 Dec;47(6):1383–8
Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin. Samkoff LM, et al. **Neurology** 1997 Jul;49(1):304–5
Gabapentin as a novel treatment for postherpetic neuralgia. Segal AZ, et al. **Neurology** 1996 Apr;46(4):1175–6
Gabapentin for idiopathic trigeminal neuralgia: report of two cases. Sist T, et al. **Neurology** 1997 May;48(5):1467
Effect of gabapentin (Neurontin) [corrected] on mood and well-being in patients with epilepsy [published erratum appears in Prog Neuropsychopharmacol Biol Psychiatry 1996 Aug;20(6):1081] Dimond KR, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Apr; 20(3):407–17
Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Hwang JH, et al. **Reg Anesth** 1997 May–Jun; 22(3):249–56
Mechanisms of action of antiepileptic drugs. Davies JA. **Seizure** 1995 Dec;4(4):267–71 (28 ref.)
A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy [see comments] Hughes D, et al. **Seizure** 1996 Jun; 5(2):89–95 (38 ref.). Comment in: Seizure 1996 Sep;5(3):247–8.
An audit of the new antiepileptic drugs in clinical neurological practice. McDonnell GV, et al. **Seizure** 1996 Jun;5(2):127–30
Management of restless legs syndrome with gabapentin (Neurontin) [letter] Mellick GA, et al. **Sleep** 1996 Apr; 19(3):224–6
Effectiveness of gabapentin in controlling spasticity: a quantitative study. Priebe MM, et al. **Spinal Cord** 1997 Mar; 35(3):171–5
[Gabapentine--advances in the management of epilepsy] **Nervenarzt** 1994 Nov;65(11 Suppl):1–8 **(Ger)**
[Gabapentin--a new anti-epileptic agent] **Nervenarzt** 1994 Jun;65(6 Suppl):1–8 **(Ger)**
[New antiepileptic drugs] Padró L, et al. **Rev Neurol** 1997 Feb;25(138):291–4 (26 ref.) **(Spa)**

TOXICITY

Reproductive toxicology. Ethoxyacetic acid. **Environ Health Perspect** 1997 Feb;105 Suppl 1:211–2
Reproductive toxicology. Methoxyacetic acid. **Environ Health Perspect** 1997 Feb;105 Suppl 1:227–8
Toxicity of methoxyacetic acid in cultured human luteal cells. Almekinder JL, et al. **Fundam Appl Toxicol** 1997 Aug; 38(2):191–4
Lipid peroxidation and formation of 8-hydroxydeoxyguanosine from acute doses of halogenated acetic acids. Austin EW, et al. **Fundam Appl Toxicol** 1996 May;31(1):77–82
Time-dependent autoimmune response of dichloroacetyl chloride in female MRL +/+ mice. Khan MF, et al. **Immunopharmacol Immunotoxicol** 1997 May;19(2):265–77
Histopathologic changes in the testes of rats exposed to dibromoacetic acid. Linder RE, et al. **Reprod Toxicol** 1997 Jan–Feb;11(1):47–56
Spermatotoxicity of dichloroacetic acid. Linder RE, et al. **Reprod Toxicol** 1997 Sep–Oct;11(5):681–8
Comparative effects of haloacetic acids in whole embryo culture. Hunter ES 3rd, et al. **Teratology** 1996 Aug; 54(2):57–64
Quantitative structure-activity relationships for the developmental toxicity of haloacetic acids in mammalian whole embryo culture. Richard AM, et al. **Teratology** 1996 Jun;53(6):352–60
Ovarian luteal cell toxicity of ethylene glycol monomethyl ether and methoxy acetic acid in vivo and in vitro. Davis BJ, et al. **Toxicol Appl Pharmacol** 1997 Feb;142(2):328–37
Protection against methoxyacetic-acid-induced spermatocyte apoptosis with calcium channel blockers in cultured rat seminiferous tubules: possible mechanisms. Li LH, et al. **Toxicol Appl Pharmacol** 1997 May;144(1):105–19

URINE

Direct characterization of drug glucuronide isomers in human urine by HPLC-NMR spectroscopy: application to the positional isomers of 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid glucuronide. Lenz EM, et al. **Anal Chem** 1996 Sep 1; 68(17):2832–7

ACETIC ANHYDRIDES

PHARMACOLOGY

Epitope mapping by differential chemical modification of antigens. Bosshard HR. **Methods Mol Biol** 1996;66:85–95

ACETOACETATES

ADMINISTRATION & DOSAGE

Synthesis and intravenous infusion into the rat of glyceryl bisacetoacetate, 1-acetoacetamido-2, 3-propane diol, and partially reduced glucosyl pentaacetoacetate. Birkhahn RH, et al. **Br J Nutr** 1997 Jul;78(1):155–72

BLOOD

Increased lactate/pyruvate ratio with normal beta-hydroxybutyrate/acetoacetate ratio and lack of oxygen supply dependency in a patient with fatal septic shock. Gallet D, et al. **Intensive Care Med** 1997 Jan; 23(1):114–6
[Ketone bodies in patients after partially liver resection] Skarżyńska E, et al. **Pol Merkuriusz Lek** 1996 Nov; 1(5):316–8 (Eng. Abstr.) **(Pol)**

METABOLISM

Quantitative analysis of acetoacetate metabolism in AS-30D hepatoma cells with 13C and 14C isotopic techniques. Holleran AL, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E945–51
Carbon dioxide catalysis of the reaction of peroxynitrite with ethyl acetoacetate: an example of aliphatic nitration by peroxynitrite. Uppu RM, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):764–9

PHARMACOLOGY

Effect of carbonic anhydrase inhibition and acetoacetate on anaplerotic pyruvate carboxylase activity in cultured rat astrocytes. Hazen SA, et al. **Dev Neurosci** 1997;19(2):162–71

TOXICITY

The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Jorquera R, et al. **Biochem Biophys Res Commun** 1997 Mar 6;232(1):42–8

ACETOACETYL COA THIOLASE see **ACETYL-COA ACETYLTRANSFERASE**

ACETOBACTER

CHEMISTRY

Characterization of microbial cellulose from a high-producing mutagenized Acetobacter pasteurianus strain. Bertocchi C, et al. **Biochim Biophys Acta** 1997 Aug 29;1336(2):211–7
Structure of the repeating oligosaccharide from the lipopolysaccharide of the nitrogen-fixing bacterium Acetobacter diazotrophicus strain PAL 5. Previato JO, et al. **Carbohydr Res** 1997 Mar 13;298(4):311–8

ENZYMOLOGY

Purification and properties of citrate synthase from Acetobacter europaeus. Sievers M, et al. **FEMS Microbiol Lett** 1997 Jan 1;146(1):53–8
Cloning and expression of AatII restriction-modification system in Escherichia coli. Nwankwo DO, et al. **Gene** 1997 Jan 31;185(1):105–9

GENETICS

Characterization of the genes encoding the three-component membrane-bound alcohol dehydrogenase from Gluconobacter suboxydans and their expression in Acetobacter pasteurianus. Kondo K, et al. **Appl Environ Microbiol** 1997 Mar;63(3):1131–8
Biochemical and genetic characterization of the acetaldehyde dehydrogenase complex from Acetobacter europaeus. Thurner C, et al. **Arch Microbiol** 1997 Aug;168(2):81–91
Sequence-specific DNA modification in Acetobacter xylinum. Petroni EA, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Jul;42(5):759–67
Genetic analysis of the acetan biosynthetic pathway in Acetobacter xylinum: nucleotide sequence analysis of the aceB, aceC, aceD and aceE genes. Griffin AM, et al. **DNA Seq** 1996;6(5):275–84
Identification, cloning and sequencing the aceA gene involved in acetan biosynthesis in Acetobacter xylinum. Griffin AM, et al. **FEMS Microbiol Lett** 1996 Mar 15; 137(1):115–21
Cloning of the aceF gene encoding the phosphomannose isomerase and GDP-mannose pyrophosphorylase activities involved in acetan biosynthesis in Acetobacter xylinum. Griffin AM, et al. **FEMS Microbiol Lett** 1997 Sep 15; 154(2):389–96
Cloning and expression of AatII restriction-modification system in Escherichia coli. Nwankwo DO, et al. **Gene** 1997 Jan 31;185(1):105–9
A new insertion sequence IS1452 from Acetobacter pasteurianus. Kondo K, et al. **Microbiology** 1997 Feb;143 (Pt 2):539–46

ISOLATION & PURIFICATION

Coffea arabica L., a new host plant for Acetobacter diazotrophicus, and isolation of other nitrogen-fixing acetobacteria. Jimenez-Salgado T, et al. **Appl Environ Microbiol** 1997 Sep;63(9):3676–83

METABOLISM

Identification, cloning and sequencing the aceA gene involved in acetan biosynthesis in Acetobacter xylinum. Griffin AM, et al. **FEMS Microbiol Lett** 1996 Mar 15; 137(1):115–21
Influence of substituent of direct dye having bisphenylenebis(azo) skeletal structure on structure of nascent cellulose produced by Acetobacter xylinum [I]: different influence of direct red 28, blue 1 and 15 on nascent structure. Kai A, et al. **Int J Biol Macromol** 1997 Jun; 20(3):221–31
Production of cellulose II by Acetobacter xylinum in the presence of 2,6-dichlorobenzonitrile. Yu X, et al. **Int J Biol Macromol** 1996 Aug;19(2):145–6

ACETOBACTERACEAE

GENETICS

Cloning of genes coding for L-sorbose and L-sorbosone dehydrogenases from Gluconobacter oxydans and microbial production of 2-keto-L-gulonate, a precursor of L-ascorbic acid, in a recombinant G. oxydans strain. Saito Y, et al. **Appl Environ Microbiol** 1997 Feb; 63(2):454–60
Transposon induced mutation in Gluconobacter oxydans with special reference to its direct-glucose oxidation metabolism. Gupta A, et al. **FEMS Microbiol Lett** 1997 Feb 15;147(2):181–8

METABOLISM

Oxygen diffusivity in calcium alginate gel beads containing Gluconobacter suboxydans. Mehmetoglu U, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1996 Mar; 24(2):91–106
Transposon induced mutation in Gluconobacter oxydans with special reference to its direct-glucose oxidation metabolism. Gupta A, et al. **FEMS Microbiol Lett** 1997 Feb 15;147(2):181–8

ACETOHEXAMIDE

ACETOHEXAMIDE

METABOLISM

Inhibitory effect of drugs with a ketone group on reduction of acetohexamide catalyzed by carbonyl reductase from rabbit kidney. Imamura Y, et al. **J Enzyme Inhib** 1997 Feb; 11(4):285–92

ACETOHYDROXY ACID REDUCTOISOMERASE see **2-ACETOLACTATE MUTASE**

ACETOHYDROXY ACID SYNTHASE see **ACETOLACTATE SYNTHASE**

ACETOHYDROXY ACID SYNTHETASE see **ACETOLACTATE SYNTHASE**

2-ACETOHYDROXY-3-KETOACID ISOMEROREDUCTASE see **2-ACETOLACTATE MUTASE**

ACETOIN

METABOLISM

A detoxication route for acetaldehyde: metabolism of diacetyl, acetoin, and 2,3-butanediol in liver homogenate and perfused liver of rats. Otsuka M, et al. **J Biochem (Tokyo)** 1996 Feb;119(2):246–51

Cloning and sequencing of a 40.6 kb segment in the 73 degrees-76 degrees region of the Bacillus subtilis chromosome containing genes for trehalose metabolism and acetoin utilization. Yamamoto H, et al. **Microbiology** 1996 Nov;142 (Pt 11):3057–65

ACETOIN DEHYDROGENASE

GENETICS

Identification and characterization of acoK, a regulatory gene of the Klebsiella pneumoniae acoABCD operon. Peng HL, et al. **J Bacteriol** 1997 Mar;179(5):1497–504

2-ACETOLACTATE MUTASE

GENETICS

Purification and characterization of a fusion protein of plant acetohydroxy acid synthase and acetohydroxy acid isomeroreductase. Dumas R, et al. **FEBS Lett** 1997 May 19;408(2):156–60

ACETOLACTATE SYNTHASE

CHEMISTRY

Homology modeling of the structure of bacterial acetohydroxy acid synthase and examination of the active site by site-directed mutagenesis. Ibdah M, et al. **Biochemistry** 1996 Dec 17;35(50):16282–91

GENETICS

Soluble overexpression in Escherichia coli, and purification and characterization of wild-type recombinant tobacco acetolactate synthase. Chang SI, et al. **Biochem Biophys Res Commun** 1997 May 29;234(3):549–53

Purification and characterization of a fusion protein of plant acetohydroxy acid synthase and acetohydroxy acid isomeroreductase. Dumas R, et al. **FEBS Lett** 1997 May 19;408(2):156–60

Cloning and phylogenetic analysis of the genes encoding acetohydroxyacid synthase from the archaeon Methanococcus aeolicus. Bowen TL, et al. **Gene** 1997 Mar 25;188(1):77–84

Identification of an acetolactate synthase small subunit gene in two eukaryotes. Duggleby RG. **Gene** 1997 May 6; 190(2):245–9

Cloning and sequencing of the ilvBNC gene cluster from Mycobacterium avium. Gusberti L, et al. **Gene** 1996 Oct 24;177(1-2):83–5

A human homolog of bacterial acetolactate synthase genes maps within the CADASIL critical region. Joutel A, et al. **Genomics** 1996 Dec 1;38(2):192–8

Rational molecular design and genetic engineering of herbicide resistant crops by structure modeling and site-directed mutagenesis of acetohydroxyacid synthase. Ott KH, et al. **J Mol Biol** 1996 Oct 25;263(2):359–68

Functional analysis of YCL09C: evidence for a role as the regulatory subunit of acetolactate synthase. Cullin C, et al. **Yeast** 1996 Dec;12(15):1511–8

METABOLISM

Homology modeling of the structure of bacterial acetohydroxy acid synthase and examination of the active site by site-directed mutagenesis. Ibdah M, et al. **Biochemistry** 1996 Dec 17;35(50):16282–91

Identification of an acetolactate synthase small subunit gene in two eukaryotes. Duggleby RG. **Gene** 1997 May 6; 190(2):245–9

Functional analysis of YCL09C: evidence for a role as the regulatory subunit of acetolactate synthase. Cullin C, et al. **Yeast** 1996 Dec;12(15):1511–8

ACETOLACTATE SYNTHETASE see **ACETOLACTATE SYNTHASE**

ACETONCHLOROFORM see **CHLOROBUTANOL**

ACETONE

Selective spectrophotometric determination of glucose and fructose in the presence of aldoses using phenol-acetone reagent and cerium(III) chloride. Gamian A, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(4):249–54

ADVERSE EFFECTS

Perceived odor, irritation, and health symptoms following short-term exposure to acetone. Dalton P, et al. **Am J Ind Med** 1997 May;31(5):558–69

Human barrier formation and reaction to irritation. Fartasch M. **Curr Probl Dermatol** 1995;23:95–103

Otoneurological study in workers exposed to styrene in the fiberglass industry. Calabrese G, et al. **Int Arch Occup Environ Health** 1996;68(4):219–23

The influence of cognitive bias on the perceived odor, irritation and health symptoms from chemical exposure. Dalton P, et al. **Int Arch Occup Environ Health** 1997; 69(6):407–17

Relationship between acetone exposure concentration and health effects in acetate fiber plant workers. Satoh T, et al. **Int Arch Occup Environ Health** 1996;68(3):147–53

ANALOGS & DERIVATIVES

New catalytic roles for serine esterases: a 19F-NMR study of the interaction of 3,3,3-trifluoro-2,2-dihydroxy-1-phenyl-1-propanone with chicken liver carboxylesterase. Bowles MR, et al. **Biochim Biophys Acta** 1996 Dec 5;1298(2):167–79

"Teflon-coated peptides": hexafluoroacetone trihydrate as a structure stabilizer for peptides. Rajan R, et al. **Biopolymers** 1997 Aug;42(2):125–8

Biotransformation of the aerosol propellant 1,1,1,2,3,3,3-heptafluoropropane (HFA-227): lack of protein binding of the metabolite hexafluoroacetone. Köster U, et al. **Drug Metab Dispos** 1996 Aug;24(8):906–10

Metabolism and toxicity of 4-hydroxyphenylacetone in rat liver slices: comparison with acetaminophen. Thompson DC, et al. **Drug Metab Dispos** 1996 Aug;24(8):866–71

ANALYSIS

Biological monitoring of styrene exposure and possible interference of acetone co-exposure. Marhuenda D, et al. **Int Arch Occup Environ Health** 1997;69(6):455–60

Detection of ketosis in dairy cows by analysis of exhaled breath. Dobbelaar P, et al. **Vet Q** 1996 Dec;18(4):151–2

Evaluation of bulk milk analyses of acetone, urea, and the fat-lactose-quotient as diagnostic aids in preventive veterinary medicine. Steen A, et al. **Zentralbl Veterinarmed A** 1996 Jul;43(5):261–9

BLOOD

Volatile organic compound testing of a population living near a hazardous waste site. Hamar GB, et al. **J Expo Anal Environ Epidemiol** 1996 Apr-Jun;6(2):247–55

Driving under the influence of acetone [letter] Jones AW. **J Toxicol Clin Toxicol** 1997;35(4):419–21

CHEMISTRY

Reclamation of acetone in plastination laboratories: a simple and inexpensive method. Grondin G, et al. **Acta Anat (Basel)** 1997;158(1):26–9

IMMUNOLOGY

The murine local lymph node assay: search for an alternative, more adequate, vehicle than acetone/olive oil (4:1). Montelius J, et al. **Contact Dermatitis** 1996 Jun;34(6):428–30

METABOLISM

Isolation and characterization of a new gram-negative, acetone-degrading, nitrate-reducing bacterium from soil, Paracoccus solventivorans sp. nov. Siller H, et al. **Int J Syst Bacteriol** 1996 Oct;46(4):1125–30

The genes for butanol and acetone formation in Clostridium acetobutylicum ATCC 824 reside on a large plasmid whose loss leads to degeneration of the strain. Cornillot E, et al. **J Bacteriol** 1997 Sep;179(17):5442–7

[Acetone metabolism: biochemistry, toxicology and clinical implications] Kalapos MP. **Orv Hetil** 1997 May 11; 138(19):1187–93 (57 ref.) (Eng. Abstr.) **(Hun)**

PHARMACOKINETICS

New ways to use biochemical indicators of alcohol abuse to regrant licences in a fairer manner after drunken driving in Germany. Iffland R. **Alcohol Alcohol** 1996 Nov; 31(6):619–20

Pharmacokinetics of and CYP1A induction by pyridine and acetone in the rat: interactions and effects of route of exposure. Scholl HR, et al. **Xenobiotica** 1997 Mar; 27(3):265–77

PHARMACOLOGY

The epidermal hyperplasia associated with repeated barrier disruption by acetone treatment or tape stripping cannot be attributed to increased water loss. Denda M, et al. **Arch Dermatol Res** 1996 May;288(5-6):230–8

Induction of cytochromes P450 1A, 2B and 2E in hamster tissues by acetone. Chen RM, et al. **Arch Toxicol** 1997; 71(8):489–95

The influence of 2-propanol and acetone on oviposition rate and oviposition site preference for acetic acid and ethanol of Drosophila melanogaster. Eisses KT. **Behav Genet** 1997 May;27(3):171–80

Effects of acetone on the capacity of o-xylene and toluene to induce several forms of cytochrome P450 in rat liver. Nedelcheva V. **Cent Eur J Public Health** 1996 May; 4(2):119–22

Modulation of the development of humoral immunity by topically applied acetone, ethanol, and 12-O-tetradecanoylphorbol-13-acetate. Singh KP, et al. **Fundam Appl Toxicol** 1996 Sep;33(1):129–39

Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes. Cotreau-Bibbo MM, et al. **J Pharm Sci** 1996 Nov;85(11):1180–5

Pharmacokinetics of and CYP1A induction by pyridine and acetone in the rat: interactions and effects of route of exposure. Scholl HR, et al. **Xenobiotica** 1997 Mar; 27(3):265–77

POISONING

Neurotoxicity associated with occupational exposure to acetone, methyl ethyl ketone, and cyclohexanone. Mitran E, et al. **Environ Res** 1997;73(1-2):181–8

TOXICITY

Gene expression and cellular sources of inducible nitric oxide synthase during tumor promotion. Robertson FM, et al. **Carcinogenesis** 1996 Sep;17(9):2053–9

Pattern of inhalation exposure: blood levels and acute subnarcotic effects of toluene and acetone in rats. Frantík E, et al. **Cent Eur J Public Health** 1996 Dec;4(4):226–32

Ketone potentiation of haloalkane-induced hepatotoxicity: CCl4 and ketone treatment on hepatic membrane integrity. Raymond P, et al. **J Toxicol Environ Health** 1996 Oct 25; 49(3):285–300

URINE

Acetone in urine as biological index of occupational exposure to isopropyl alcohol. Ghittori S, et al. **Ind Health** 1996; 34(4):409–14

Simultaneous determination of eight lipid peroxidation degradation products in urine of rats treated with carbon tetrachloride using gas chromatography with electron-capture detection. De Zwart LL, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):277–87

ACETONE BODIES see **KETONE BODIES**

ACETONITRILES

Estimating diffusion coefficients for alkylbenzenes and alkylphenones in aqueous mixtures with acetonitrile and methanol. Li J, et al. **Anal Chem** 1997 Jul 1;69(13):2550–3

CHEMISTRY

Acid-base behavior of quinolones in aqueous acetonitrile mixtures. Sanz-Nebot V, et al. **Acta Chem Scand** 1997 Sep; 51(9):896–903

Analysis of macrolide antibiotics by capillary electrophoresis. Flurer CL. **Electrophoresis** 1996 Feb;17(2):359–66

Peptide stacking by acetonitrile-salt mixtures for capillary zone electrophoresis. Shihabi ZK. **J Chromatogr A** 1996 Sep 13;744(1-2):231–40

METABOLISM

The biotransformation of t-butylacetonitrile and its boron-containing analogue trimethylamine-cyanoborane by Brevibacterium R312. Millais AJ, et al. **Arch Microbiol** 1997 Aug;168(2):164–8

Utilization of acetonitrile and other aliphatic nitriles by a Candida famata strain. Linardi VR, et al. **FEMS Microbiol Lett** 1996 Oct 15;144(1):67–71

PHARMACOKINETICS

Cyanide detoxification in rats exposed to acetonitrile and fed a low protein diet. Swenne I, et al. **Fundam Appl Toxicol** 1996 Jul;32(1):66–71

PHARMACOLOGY

Synthesis and antiparasitic activities of amidinic azolated derivatives. Danan A, et al. **Farmaco** 1997 Apr;52(4):227–9

3-Morpholino-sydnonimine-induced suppression of human neutrophil degranulation is not mediated by cyclic GMP, nitric oxide or peroxynitrite: inhibition of the increase in intracellular free calcium concentration by N-morpholino-iminoacetonitrile, a metabolite of 3-morpholino-sydnonimine. Kankaanranta H, et al. **Mol Pharmacol** 1997 May;51(5):882–8

POISONING

Delayed cyanide poisoning following acetonitrile ingestion. Mueller M, et al. **Postgrad Med J** 1997 May; 73(859):299-300

THERAPEUTIC USE

Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. Blanshard C, et al. **Int J STD AIDS** 1997 Feb;8(2):124-9

ACETOPHENETIDIN see **PHENACETIN**

ACETOPHENONES

ADVERSE EFFECTS

Allergic contact dermatitis from 3-(alpha-methoxy) methylenebenzofuran-2(3H)-one (MBF) and alpha-chloro-4-fluoroacetophenone (CFAP) in chemical process workers. Boffa MJ, et al. **Contact Dermatitis** 1996 Jun;34(6):434-5

ANALYSIS

Quantitative analysis of 2-aminoacetophenone in off-flavored wines by stable isotope dilution assay. Dollmann B, et al. **J AOAC Int** 1996 Mar-Apr;79(2):583-6

CHEMICAL SYNTHESIS

Slow reversible inhibitions of rabbit muscle aldolase with substrate analogues: synthesis, enzymatic kinetics and UV difference spectroscopy studies. Gefflaut T, et al. **Bioorg Med Chem** 1996 Dec;4(12):2043-54

CHEMISTRY

Estimating diffusion coefficients for alkylbenzenes and alkylphenones in aqueous mixtures with acetonitrile and methanol. Li J, et al. **Anal Chem** 1997 Jul 1;69(13):2550-3

Hydrogen bond formation as basis for radical scavenging activity: a structure-activity study of C-methylated dihydrochalcones from Myrica gale and structurally related acetophenones. Mathiesen L, et al. **Free Radic Biol Med** 1997;22(1-2):307-11

High-performance liquid chromatographic determination of cytosine-containing compounds by precolumn fluorescence derivatization with phenacyl bromide: application to antiviral nucleosides and nucleotides. Eisenberg EJ, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1-2):119-27

Use of 2,6-dihydroxyacetophenone for analysis of fragile peptides, disulphide bonding and small proteins by matrix-assisted laser desorption/ionization. Gorman JJ, et al. **Rapid Commun Mass Spectrom** 1996;10(5):529-36

ISOLATION & PURIFICATION

Isolation of paeonol from Arisaema erubescens. Ducki S, et al. **Planta Med** 1995 Dec;61(6):586-7

PHARMACOLOGY

Common structural requirements for peroxisome proliferation by tetrazole and carboxylic acid-containing compounds. Eacho PI, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:387-402

Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells. Okamoto M, et al. **Antiviral Res** 1996 Jun;31(1-2):69-77

Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Parmer TG, et al. **Cell Growth Differ** 1997 Mar;8(3):327-34

Differences in the acute actions of sGnRH and cGnRH-II on gonadotropin release in goldfish pituitary cells. Chang JP, et al. **Gen Comp Endocrinol** 1995 Dec;100(3):339-54

Fungicide and fungiostatic effects of xanthoxyline. Cechinel Filho V, et al. **J Ethnopharmacol** 1996 Sep;53(3):171-3

Role of phospholipase A2 enzymes in degradation of dipalmitoylphosphatidylcholine by granular pneumocytes. Fisher AB, et al. **J Lipid Res** 1996 May;37(5):1057-64

Effectiveness of thirteen vertebrate repellents as rodent trigeminal stimulants. Mason JR, et al. **Physiol Behav** 1996 Dec;60(6):1449-52

Partial characterization of glutathione S-transferases from wheat (Triticum spp.) and purification of a safener-induced glutathione S-transferase from Triticum tauschii. Riechers DE, et al. **Plant Physiol** 1997 Aug;114(4):1461-70

[Recent progresses in pharmacological and clinical studies of paeonol] Zhang LH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Mar; 16(3):187-90 (24 ref.) **(Chi)**

THERAPEUTIC USE

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial [see comments] **Lancet** 1997 May 17;349(9063):1413-21. Comment in: Lancet 1997 May 17;349(9063):1408-9.

ACETOPROMAZINE see **ACEPROMAZINE**

ACETOXYACETAMIDOFLUORENE see

ACETOXYACETYLAMINOFLUORENE

ACETOXYACETYLAMINOFLUORENE

Acetoxy-acetylaminofluorene-modified dGTP can be used to label oligonucleotides or DNA enzymatically. Auriol J, et al. **Mol Cell Probes** 1997 Apr;11(2):113-21

PHARMACOLOGY

The sensitivity of human fibroblasts to N-acetoxy-2-acetylaminofluorene is determined by the extent of transcription-coupled repair, and/or their capability to counteract RNA synthesis inhibition. van Oosterwijk MF, et al. **Nucleic Acids Res** 1996 Dec 1; 24(23):4653-9

ACETOXYFLUORENYLACETAMIDE see **ACETOXYACETYLAMINOFLUORENE**

ACETOXYPHENYLMERCURY see **PHENYLMERCURIC ACETATE**

ACETYL ACTIVATING ENZYME see **ACETATE-COA LIGASE**

N-ACETYL-BETA-D-GLUCOSAMINIDASE see **ACETYLGLUCOSAMINIDASE**

ACETYL CARNITINE see **ACETYLCARNITINE**

ACETYL COA see **ACETYL COENZYME A**

ACETYL-COA ACETYLTRANSFERASE

CHEMISTRY

A second isoform of 3-ketoacyl-CoA thiolase found in Caenorhabditis elegans, which is similar to sterol carrier protein x but lacks the sequence of sterol carrier protein 2. Bun-Ya M, et al. **Eur J Biochem** 1997 Apr 15; 245(2):252-9

Expression in Escherichia coli and refolding of the malonyl-/acetyltransferase domain of the multifunctional animal fatty acid synthase. Rangan VS, et al. **J Biol Chem** 1996 Dec 6;271(49):31749-55

GENETICS

Altered ovarian sterol carrier protein expression in the pregnant streptozotocin-treated diabetic rat. McLean MP, et al. **Biol Reprod** 1996 Jul;55(1):38-46

Assignment of the human cytosolic acetoacetyl-coenzyme A thiolase (ACAT2) gene to chromosome 6q25.3-q26. Masuno M, et al. **Genomics** 1996 Aug 15;36(1):217-8

Identification of three novel frameshift mutations (83delAT, 754insCT, and 435 + 1G to A) of mitochondrial acetoacetyl-coenzyme A thiolase gene in two Swiss patients with CRM-negative beta-ketothiolase deficiency. Fukao T, et al. **Hum Mutat** 1997;9(3):277-9

Respiration and low cAMP-dependent protein kinase activity are required for high-level expression of the peroxisomal thiolase gene in Saccharomyces cerevisiae. Igual JC, et al. **Mol Gen Genet** 1996 Sep 25;252(4):446-55

METABOLISM

Peb1p (Pas7p) is an intra-peroxisomal receptor for the N-terminal, type 2, peroxisomal targeting signal of thiolase. Zhang JW, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:654-5

Tissue-specific distribution of a peroxisomal 46-kDa protein related to the 58-kDa protein (sterol carrier protein x; sterol carrier protein 2/3-oxoacyl-CoA thiolase). Ossendorp BC, et al. **Arch Biochem Biophys** 1996 Oct 15; 334(2):251-60

Sterol carrier protein X (SCPx) is a peroxisomal branched-chain beta-ketothiolase specifically reacting with 3-oxo-pristanoyl-CoA: a new, unique role for SCPx in branched-chain fatty acid metabolism in peroxisomes. Wanders RJ, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):565-9

Immunotitration analysis of cytosolic acetoacetyl-coenzyme A thiolase activity in human fibroblasts. Fukao T, et al. **Pediatr Res** 1996 Jun;39(6):1055-8

Identification of a chloroplast coenzyme A-binding protein related to the peroxisomal thiolases. Yang LM, et al. **Plant Physiol** 1996 Dec;112(4):1641-7

ACETYL-COA ACYLASE see **ACETYL-COA HYDROLASE**

ACETYL COA ACYLTRANSFERASE

ANTAGONISTS & INHIBITORS

Sequestration of coenzyme A by the industrial surfactant, Toximul MP8. A possible role in the inhibition of fatty-acid beta-oxidation in a surfactant/influenza B virus mouse model for acute hepatic encephalopathy. Murphy MG, et al. **Biochim Biophys Acta** 1997 Jul 10;1361(1):103-13

CHEMISTRY

Importance of the gamma-carboxyl group of glutamate-462 of the large alpha-subunit for the catalytic function and the stability of the multienzyme complex of fatty acid oxidation from Escherichia coli. He XY, et al. **Biochemistry** 1997 Jan 7;36(1):261-8

A second isoform of 3-ketoacyl-CoA thiolase found in Caenorhabditis elegans, which is similar to sterol carrier protein x but lacks the sequence of sterol carrier protein 2. Bun-Ya M, et al. **Eur J Biochem** 1997 Apr 15; 245(2):252-9

DEFICIENCY

Metabolic studies in twin brothers with 2-methylacetoacetyl-CoA thiolase deficiency. Fontaine M, et al. **Clin Chim Acta** 1996 Nov 15;255(1):67-83

Mild form of beta-ketothiolase deficiency (mitochondrial acetoacetyl-CoA thiolase deficiency) in two Japanese siblings: identification of detectable residual activity and cross-reactive material in EB-transformed lymphocytes. Fukao T, et al. **Clin Genet** 1996 Oct;50(4):263-6

Identification of three novel frameshift mutations (83delAT, 754insCT, and 435 + 1G to A) of mitochondrial acetoacetyl-coenzyme A thiolase gene in two Swiss patients with CRM-negative beta-ketothiolase deficiency. Fukao T, et al. **Hum Mutat** 1997;9(3):277-9

beta-Ketothiolase (2-methylacetoacetyl-coenzyme A thiolase) deficiency: identification of two patients in Israel. Gibson KM, et al. **J Inherit Metab Dis** 1996;19(5):698-9

Molecular basis of Zellweger syndrome, beta-ketothiolase deficiency and mucopolysaccharidoses. Orii T. **Jpn J Hum Genet** 1997 Mar;42(1):1-11 (63 ref.)

GENETICS

Molecular basis of Zellweger syndrome, beta-ketothiolase deficiency and mucopolysaccharidoses. Orii T. **Jpn J Hum Genet** 1997 Mar;42(1):1-11 (63 ref.)

cDNA cloning and expression of a gene for 3-ketoacyl-CoA thiolase in pumpkin cotyledons. Kato A, et al. **Plant Mol Biol** 1996 Jul;31(4):843-52

METABOLISM

Competition between beta-ketothiolase and citrate synthase during poly(beta-hydroxybutyrate) synthesis in Methylobacterium rhodesianum. Mothes G, et al. **Arch Microbiol** 1996 Dec;166(6):405-10

The glyoxysomal 3-ketoacyl-CoA thiolase precursor from Brassica napus has enzymatic activity when synthesized in Escherichia coli. Olesen C, et al. **FEBS Lett** 1997 Jul 21;412(1):138-40

Characterization of the malonyl-/acetyltransacylase domain of the multifunctional animal fatty acid synthase by expression in Escherichia coli and refolding in vitro. Rangan VS, et al. **Protein Eng** 1997 May;10(5):561-6

ACETYL-COA CARBOXYLASE

Specific immobilization of firefly luciferase through a biotin carboxyl carrier protein domain. Wang CY, et al. **Anal Biochem** 1997 Mar 1;246(1):133-9

[Plant acetyl-CoA carboxylases: strategy for survival] Sasaki Y. **Seikagaku** 1996 May;68(5):335-44 (58 ref.) **(Jpn)**

ANALYSIS

Vanadate induces normolipidemia and a reduction in the levels of hepatic lipogenic enzymes in obese Zucker rat. Pugazhenthi S, et al. **Mol Cell Biochem** 1995 Dec 6-20; 153(1-2):211-5

ANTAGONISTS & INHIBITORS

Inhibition of animal acetyl-coenzyme A carboxylase by 2-(p-chlorophenoxy)-2-methylpropionic acid and 2-ethylhexanoic acid. Sumida K, et al. **Chemosphere** 1996 Dec;33(11):2201-7

BIOSYNTHESIS

Regulation of acetyl coenzyme-A carboxylase gene in a transgenic animal model. Ekhterae D, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):547-52

Regulation of lipogenic enzyme expression by glucose in liver and adipose tissue: is glucose 6-phosphate the signalling metabolite? Foufelle F, et al. **Biochem Soc Trans** 1996 May; 24(2):372-8 (43 ref.)

Regulation of acetyl CoA carboxylase gene expression in adipose tissue from lactating sheep. Travers MT, et al. **Biochem Soc Trans** 1996 May;24(2):223S

Long-chain fatty acids inhibit acetyl-CoA carboxylase gene expression in the pancreatic beta-cell line INS-1. Brun T, et al. **Diabetes** 1997 Mar;46(3):393-400

Human acetyl-CoA carboxylase 2. Molecular cloning, characterization, chromosomal mapping, and evidence for two isoforms. Abu-Elheiga L, et al. **J Biol Chem** 1997 Apr 18;272(16):10669-77

Cloning of human acetyl-CoA carboxylase-beta and its unique features. Ha J, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11466-70

[Rapid induction of hepatic acetyl-CoA carboxylase activity after estradiol benzoate injection in the quail] Pageaux JF, et al. **FEBS Lett** 1981 Nov 2;134(1):99-102 (Eng. Abstr.) **(Fre)**

ACETYL-COA CARBOXYLASE

CHEMISTRY

The pea chloroplast membrane-associated protein, IEP96, is a subunit of acetyl-CoA carboxylase. Shorrosh BS, et al. **Plant J** 1996 Aug;10(2):261-8

Cloning of human acetyl-CoA carboxylase-beta and its unique features. Ha J, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11466-70

DRUG EFFECTS

Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. Winder WW, et al. **J Appl Physiol** 1997 Jan;82(1):219-25

Lipoic acid reduces the activities of biotin-dependent carboxylases in rat liver. Zempleni J, et al. **J Nutr** 1997 Sep;127(9):1776-81

GENETICS

Regulation of mammalian acetyl-coenzyme A carboxylase. Kim KH. **Annu Rev Nutr** 1997;17:77-99 (107 ref.)

Triiodothyronine stimulates and glucagon inhibits transcription of the acetyl-CoA carboxylase gene in chick embryo hepatocytes: glucose and insulin amplify the effect of triiodothyronine. Hillgartner FB, et al. **Arch Biochem Biophys** 1997 Jan 15;337(2):159-68

Protein kinase CK2 down-regulates glucose-activated expression of the acetyl-CoA carboxylase gene. Zhang S, et al. **Arch Biochem Biophys** 1997 Feb 15;338(2):227-32

Regulation of acetyl coenzyme-A carboxylase gene in a transgenic animal model. Ekhterae D, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):547-52

Alterations in nutritional status regulate acetyl-CoA carboxylase expression in avian liver by a transcriptional mechanism. Hillgartner FB, et al. **Biochem J** 1996 Oct 1; 319 (Pt 1):263-8

Induction of a variant acetyl-CoA carboxylase mRNA in ovine mammary gland during lactation. Barber MC, et al. **Biochem Soc Trans** 1996 Aug;24(3):360S

Acetyl-CoA carboxylase gene expression in the developing mouse brain. Comparison with other genes involved in lipid biosynthesis. Garbay B, et al. **Brain Res Dev Brain Res** 1997 Feb 20;98(2):197-203

Assignment of acetyl-CoA carboxylase-beta (ACACB) to human chromosome band 12q24.1 by in situ hybridization. Ullrich CK, et al. **Cytogenet Cell Genet** 1997;77(3-4):176-7

Human acetyl-CoA carboxylase 2. Molecular cloning, characterization, chromosomal mapping, and evidence for two isoforms. Abu-Elheiga L, et al. **J Biol Chem** 1997 Apr 18;272(16):10669-77

A yeast acetyl coenzyme A carboxylase mutant links very-long-chain fatty acid synthesis to the structure and function of the nuclear membrane-pore complex. Schneiter R, et al. **Mol Cell Biol** 1996 Dec;16(12):7161-72

Structure of the CAC1 gene and in situ characterization of its expression. The Arabidopsis thaliana gene coding for the biotin-containing subunit of the plastidic acetyl-coenzyme A carboxylase. Ke J, et al. **Plant Physiol** 1997 Feb;113(2):357-65

Multi-functional acetyl-CoA carboxylase from Brassica napus is encoded by a multi-gene family: indication for plastidic localization of at least one isoform. Schulte W, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3465-70

METABOLISM

Electrical stimulation inactivates muscle acetyl-CoA carboxylase and increases AMP-activated protein kinase. Hutber CA, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):E262-6

Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Winder WW, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):E299-304

Studies on the intracellular localization of acetyl-CoA carboxylase. Geelen MJ, et al. **Biochem Biophys Res Commun** 1997 Apr 7;233(1):253-7

Acetyl-CoA carboxylase is essential for nutrient-induced insulin secretion. Zhang S, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):701-5

Kinetic studies on two isoforms of acetyl-CoA carboxylase from maize leaves. Herbert D, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):997-1006

Enzymatic diagnosis of holocarboxylase synthetase deficiency using apo-carboxyl carrier protein as a substrate. Suzuki Y, et al. **Clin Chim Acta** 1996 Jul 15;251(1):41-52

Targeting of the Arabidopsis homomeric acetyl-coenzyme A carboxylase to plastids of rapeseeds. Roesler K, et al. **Plant Physiol** 1997 Jan;113(1):75-81

Short-term regulation of acetyl CoA carboxylase in tissues of higher animals. Allred JB, et al. **Prog Lipid Res** 1996 Dec;35(4):371-85 (186 ref.)

PHYSIOLOGY

Contraction-induced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle. Vavvas D, et al. **J Biol Chem** 1997 May 16;272(20):13255-61

ACETYL-COA DEACYLASE see **ACETYL-COA HYDROLASE**

ACETYL-COA HYDROLASE

METABOLISM

Acetyl-CoA hydrolase involved in acetate utilization in Saccharomyces cerevisiae. Lee FJ, et al. **Biochim Biophys Acta** 1996 Sep 13;1297(1):105-9

Acetyl-CoA hydrolase activity and function in Ascaris suum muscle mitochondria. de Mata ZS, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Mar; 116(3):379-83

ACETYL COA SYNTHETASE see **ACETATE-COA LIGASE**

ACETYL COENZYME A

Synthesis, purification, and characterization of dicarboxylylmono-coenzyme A esters. Pourfarzam M, et al. **Methods Enzymol** 1997;279:240-54 (19 ref.)

ANALYSIS

Determination of acetyl-CoA enrichment in rat heart and skeletal muscle by 1H nuclear magnetic resonance analysis of glutamate in tissue extracts. Jones JG, et al. **Anal Biochem** 1997 Jul 1;249(2):201-6

CHEMISTRY

Acetyl-CoA enolization in citrate synthase: a quantum mechanical/molecular mechanical (QM/MM) study. Mulholland AJ, et al. **Proteins** 1997 Jan;27(1):9-25

METABOLISM

13C isotopomer model for estimation of anaplerotic substrate oxidation via acetyl-CoA. Jeffrey FM, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):E788-99

Evidence for acetyl coenzyme A and cinnamoyl coenzyme A in the anaerobic toluene mineralization pathway in Azoarcus tolulyticus Tol-4. Chee-Sanford JC, et al. **Appl Environ Microbiol** 1996 Mar;62(3):964-73

Changes in the size and composition of intracellular pools of nonesterified coenzyme A and coenzyme A thioesters in aerobic and facultatively anaerobic bacteria. Chohnan S, et al. **Appl Environ Microbiol** 1997 Feb;63(2):553-60

Ability of single-site mutants of citrate synthase to catalyze proton transfer from the methyl group of dethiaacetyl-coenzyme A, a non-thioester substrate analog. Kurz LC, et al. **Biochemistry** 1997 Apr 1;36(13):3981-90

Evidence that carbon monoxide is an obligatory intermediate in anaerobic acetyl-CoA synthesis. Menon S, et al. **Biochemistry** 1996 Sep 17;35(37):12119-25

Fatty alcohol synthesis accompanied with chain elongation in liver peroxisomes. Hayashi H, et al. **Biochim Biophys Acta** 1997 May 17;1346(1):38-44

Regulation of fatty acid oxidation by acetyl-CoA generated from glucose utilization in isolated myocytes. Abdel-aleem S, et al. **J Mol Cell Cardiol** 1996 May;28(5):825-33

PHYSIOLOGY

The phenylacetic acid uptake system of Aspergillus nidulans is under a creA-independent model of catabolic repression which seems to be mediated by acetyl-CoA. Fernández-Cañón JM, et al. **J Antibiot (Tokyo)** 1997 Jan; 50(1):45-52

ACETYL COENZYME A ACETYLTRANSFERASE see **ACETYL-COA ACETYLTRANSFERASE**

ACETYL COENZYME A ACYLTRANSFERASE see **ACETYL COA ACYLTRANSFERASE**

ACETYL COENZYME A CARBOXYLASE see **ACETYL-COA CARBOXYLASE**

ACETYL COENZYME A HYDROLASE see **ACETYL-COA HYDROLASE**

ACETYL GLYCERYL ETHER PHOSPHORYLCHOLINE see **PLATELET ACTIVATING FACTOR**

ACETYL HYDROPEROXIDE see **PERACETIC ACID**

2-ACETYLAMINOFLUORENE

ANALOGS & DERIVATIVES

Mechanisms of frameshift mutations: insight from aromatic amines. Hoffmann GR, et al. **Chem Res Toxicol** 1997 Apr; 10(4):347-59

Cellular strategies for accommodating replication-hindering adducts in DNA: control by the SOS response in Escherichia coli. Koffel-Schwartz N, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7805-10

IMMUNOLOGY

Modulation of DNA binding in vivo by specific humoral immunological response: a novel host factor in environmental carcinogenesis? Verdina A, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:679-82

METABOLISM

Cellular strategies for accommodating replication-hindering adducts in DNA: control by the SOS response in Escherichia coli. Koffel-Schwartz N, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7805-10

PHARMACOLOGY

Induction of O6-alkylguanine-DNA-alkyltransferase in the hepatocytes of rats following treatment with 2-acetylaminofluorene. Chinnasamy N, et al. **DNA Cell Biol** 1997 Apr;16(4):493-500

Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes. Kauffmann HM, et al. **Hepatology** 1997 Oct; 26(4):980-5

The dual role of 2-acetylaminofluorene in hepatocarcinogenesis: specific targets for initiation and promotion. Neumann HG, et al. **Mutat Res** 1997 May 12; 376(1-2):169-76

Induction of frameshift mutations at hotspot sequences by carcinogen adducts. Burnouf D, et al. **Recent Results Cancer Res** 1997;143:1-20 (42 ref.)

TOXICITY

2-Acetylaminofluorene-produced selective cytotoxic damage of a ductal compartment and its repair in the submandibular gland of rats. Danz M, et al. **Cell Tissue Res** 1997 May;288(2):371-9

Mechanisms of frameshift mutations: insight from aromatic amines. Hoffmann GR, et al. **Chem Res Toxicol** 1997 Apr; 10(4):347-59

Evaluation of the developmental toxicity of benzo[alpha]pyrene and 2-acetylaminofluorene using Xenopus: modes of biotransformation. Stover Group. Propst TL, et al. **Drug Chem Toxicol** 1997 Feb-May; 20(1-2):45-61

TUNEL--morituri te salutant. Quantitative in situ image analysis of apoptosis in well and poorly differentiated tumors from rat liver. Roberts RA. **Hum Exp Toxicol** 1996 May;15(5):457-8

Differential replication of a single N-2-acetylaminofluorene lesion in the leading or lagging strand DNA in a human cell extract. Veaute X, et al. **J Biol Chem** 1997 Jun 13; 272(24):15351-7

Molecular mechanisms of mutagenesis by aromatic amines and amides. Shibutani S, et al. **Mutat Res** 1997 May 12; 376(1-2):71-8

2-Acetylaminofluorene mechanistic data and risk assessment: DNA reactivity, enhanced cell proliferation and tumor initiation. Verna L, et al. **Pharmacol Ther** 1996; 71(1-2):83-105 (107 ref.)

Biological model of ED01 hepatocarcinogenesis. Travis CC, et al. **Toxicol Appl Pharmacol** 1996 Sep;140(1):19-29

Alterations in epidermal growth factor binding to hepatic membranes following dietary exposure of rats to known hepatocarcinogens. Ringer DP, et al. **Toxicol Lett** 1997 Mar 14;91(1):7-12

ACETYLASE see **ACETYLESTERASE**

ACETYLATION

[Determination of acetylation phenotype in the therapeutic monitoring of drugs] Evgen'ev MI, et al. **Klin Lab Diagn** 1996 Sep-Oct;(5):24-7 (Eng. Abstr.) **(Rus)**

ACETYLBENZOYLACONINE see **ACONITINE**

ACETYLCARNITINE

ANALOGS & DERIVATIVES

Acetyl-L-carnitine arginine amide prevents beta 25-35-induced neurotoxicity in cerebellar granule cells. Scorziello A, et al. **Neurochem Res** 1997 Mar;22(3):257-65

BLOOD

L-carnitine and acetyl-L-carnitine status during hemodialysis with acetate in humans: a kinetic analysis [see comments] Jackson JM, et al. **Am J Clin Nutr** 1996 Dec; 64(6):922-7. Comment in: Am J Clin Nutr 1996 Dec;64(6):976-7.

Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene. Longo A, et al. **J Chromatogr B Biomed Appl** 1996 Nov 15;686(2):129-39

DEFICIENCY

Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. Famularo G, et al. **AIDS** 1997 Feb;11(2):185-90

METABOLISM

The effect of respiratory chain impairment of beta-oxidation in rat heart mitochondria. Eaton S, et al. **Biochem J** 1996 Oct 15;319 (Pt 2):633-40

Synthesis of citrate from phosphoenolpyruvate and acetylcarnitine by mitochondria from rabbit, pigeon and

rat liver: implications for lipogenesis. Wiese TJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Aug; 114(4):417–22

Role of free L–carnitine and acetyl–L–carnitine in post–gonadal maturation of mammalian spermatozoa. Jeulin C, et al. **Hum Reprod Update** 1996 Mar–Apr;2(2):87–102 (119 ref.)

Carnitine metabolism in human muscle fiber types during submaximal dynamic exercise. Constantin–Teodosiu D, et al. **J Appl Physiol** 1996 Mar;80(3):1061–4

Acetyl–L–carnitine flux to lipids in cells estimated using isotopomer spectral analysis. Lligona–Trulla L, et al. **J Lipid Res** 1997 Jul;38(7):1454–62

PHARMACOKINETICS

L–carnitine and acetyl–L–carnitine status during hemodialysis with acetate in humans: a kinetic analysis [see comments] Jackson JM, et al. **Am J Clin Nutr** 1996 Dec; 64(6):922–7. Comment in: Am J Clin Nutr 1996 Dec;64(6):976–7.

High uptake of [2–11C]acetyl–L–carnitine into the brain: a PET study. Kuratsune H, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):488–93

PHARMACOLOGY

Acetylcarnitine modulation of the morphology of rat hippocampal synapses. Bertoni–Freddari C, et al. **Anal Quant Cytol Histol** 1996 Aug;18(4):275–8

Decompensation of hepatic and cerebral acyl–CoA metabolism in BALB/cByJ mice by chronic riboflavin deficiency: restoration by acetyl–L–carnitine. Rao KV, et al. **Can J Physiol Pharmacol** 1997 May;75(5):423–30

Acetylcholinesterase activity of synaptic plasma membranes during ageing: effect of L–acetylcarnitine. Gorini A, et al. **Dementia** 1996 May–Jun;7(3):147–54

Acetyl–L–carnitine effects on nerve conduction and glycemic regulation in experimental diabetes. Soneru IL, et al. **Endocr Res** 1997 Feb–May;23(1–2):27–36

Effect of acetyl–L–carnitine on hyperactivity and spatial memory deficits of rats exposed to neonatal anoxia. Dell'Anna E, et al. **Neurosci Lett** 1997 Feb 28;223(3):201–5

Progressive decrease of cerebral cytochrome C oxidase activity in sparse–fur mice: role of acetyl–L–carnitine in restoring the ammonia–induced cerebral energy depletion. Rao KV, et al. **Neurosci Lett** 1997 Mar 14;224(2):83–6

Effects of carnitine and its derivatives on gastric acid secretion in rats. Valoti M, et al. **Pharmacol Res** 1996 Nov–Dec;34(5–6):219–24

Protective actions of L–carnitine and acetyl–L–carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Virmani MA, et al. **Pharmacol Res** 1995 Dec; 32(6):383–9

THERAPEUTIC USE

Neuroprotective effects of acetyl–L–carnitine after stroke in rats. Lolic MM, et al. **Ann Emerg Med** 1997 Jun; 29(6):758–65

A 1–year multicenter placebo–controlled study of acetyl–L–carnitine in patients with Alzheimer's disease. Thal LJ, et al. **Neurology** 1996 Sep;47(3):705–11

URINE

Effect of carnitine administration on glycine metabolism in patients with isovaleric acidemia: significance of acetylcarnitine determination to estimate the proper carnitine dose. Itoh T, et al. **Tohoku J Exp Med** 1996 Jun; 179(2):101–9

ACETYLCHOLINE

see related
CHOLINERGIC AGENTS
RECEPTORS, CHOLINERGIC

Modulation of cholinergic locus expression by glucocorticoids and retinoic acid is cell–type specific. Berse B, et al. **FEBS Lett** 1997 Jun 30;410(2–3):175–9

NGF and BDNF increase the immunoreactivity of vesicular acetylcholine transporter in cultured neurons from the embryonic rat septum. Takei N, et al. **Neurosci Lett** 1997 May 2;226(3):207–9

ADMINISTRATION & DOSAGE

Insulin resistance caused by hepatic cholinergic interruption and reversed by acetylcholine administration. Xie H, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E587–92

Acetylcholine causes dose dependent increase in pulmonary flow in patients with chronic heart failure and elevated pulmonary vascular resistance. Kleber FX, et al. **Basic Res Cardiol** 1996 Sep–Oct;91(5):401–5

The cardiovascular response to medullary cholinergic and corticoid stimulation is calcium channel dependent in rats. Zhu DN, et al. **Blood Press** 1997 May;6(3):171–9

Ultrastructure of the tracheal epithelium in rabbits after acetylcholine administration. Konrádová V, et al. **Folia Biol (Praha)** 1996;42(5):261–6

Coronary segmental responses to acetylcholine in patients with hypercholesterolemia. Kato M, et al. **J Atheroscler Thromb** 1996;3(1):39–44

Intra–arterial nitrovasodilators do not increase cerebral blood flow in angiographically normal territories of arteriovenous malformation patients. Joshi S, et al. **Stroke** 1997 Jun; 28(6):1115–22

[The reactions of the cortical neurons to the microiontophoretic delivery of acetylcholine to their dendrites] Mednikova IuS, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Sep–Oct; 46(5):893–903 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Effects of acetylcholine and carbachol on bovine corneal endothelial cells in vitro. Yee RW, et al. **J Cataract Refract Surg** 1996 Jun;22(5):591–6

ANALYSIS

Sensitive and specific electrochemical sensors for charge–diffuse cations: use of lipophilic cyclodextrins and an enzyme relay for the determination of acetylcholine. Kataky R, et al. **Analyst** 1996 Dec;121(12):1829–34

Enzymic determinations with rotating bioreactors and continuous–flow–stopped–flow processing. Determination of choline esters in pharmaceuticals. López Ruiz B, et al. **Analyst** 1996 Nov;121(11):1695–8

Changes in the noradrenaline and acetylcholine content of three major salivary glands and in the salivation and protein component patterns of whole saliva in chronically isoprenaline–administered mice. Kawaguchi T, et al. **Arch Oral Biol** 1997 Mar;42(3):225–34

The clustered cell system is present before formation of the ACh patches in the intermediate gray layer of the cat superior colliculus. Banfro FT, et al. **Brain Res** 1996 Sep 16;733(2):273–83

Localization of choline acetyltransferase and acetylcholine in the chorion of early human pregnancy. Oda Y, et al. **Histochem Cell Biol** 1996 Feb;105(2):93–9

Microbore high–performance liquid chromatographic method for measuring acetylcholine in microdialysis samples: optimizing performance of platinum electrodes. Carter AJ, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):207–12

Detection of basal acetylcholine release in the microdialysis of rat frontal cortex by high–performance liquid chromatography using a horseradish peroxidase–osmium redox polymer electrode with pre–enzyme reactor. Kato T, et al. **J Chromatogr B Biomed Appl** 1996 Jun 28; 682(1):162–6

Determination of acetylcholine by on–line microdialysis coupled with pre– and post–microbore column enzyme reactors with electrochemical detection. Tsai TR, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):151–5

Quantification of acetylcholine in cell culture systems by semi–micro high–performance liquid chromatography and electrospray ionization mass spectrometry. Acevedo LD, et al. **J Mass Spectrom** 1996 Dec;31(12):1399–402

Direct intracerebral nerve growth factor gene transfer using a recombinant adenovirus: effect on basal forebrain cholinergic neurons during aging. Castel–Barthe MN, et al. **Neurobiol Dis** 1996 Feb;3(1):76–86

The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Giacobini E, et al. **Neuropharmacology** 1996 Feb;35(2):205–11

Acetylcholine detection by a modified HPLC–ED method improves the assessment of cholinergic function in the myenteric plexus of the guinea–pig colon. Giaroni C, et al. **Neurosci Lett** 1997 Aug 22;232(1):9–12

ANTAGONISTS & INHIBITORS

Involvement of calciseptine–sensitive calcium channels in the evoked acetylcholine release from electric organ synaptosomes. Tokumaru H, et al. **Biol Pharm Bull** 1997 Jun;20(6):641–5

Naloxone–insensitive inhibition of acetylcholine release from parasympathetic nerves innervating guinea–pig trachea by the novel opioid, nociceptin. Patel HJ, et al. **Br J Pharmacol** 1997 Mar;120(5):735–6

Endothelin–1 mediated inhibition of the acetylcholine–activated potassium current from rabbit isolated atrial cardiomyocytes. Spiers JP, et al. **Br J Pharmacol** 1996 Dec;119(7):1427–37

Galanin microinjected into the medial septum inhibits scopolamine–induced acetylcholine overflow in the rat ventral hippocampus. Robinson JK, et al. **Brain Res** 1996 Feb 12;709(1):81–7

Halothane inhibits endothelium–dependent relaxation elicited by acetylcholine in human isolated pulmonary arteries. Higueras J, et al. **Eur J Pharmacol** 1997 May 20; 326(2–3):175–81

Adenosine A1 receptors mediate hypoxia–induced inhibition of electrically evoked transmitter release from rat striatal slices. Jin S, et al. **Eur J Pharmacol** 1997 Jun 25; 329(2–3):107–13

Inhibitory effects of a fullerene derivative, dimalonic acid C60, on nitric oxide–induced relaxation of rabbit aorta. Satoh M, et al. **Eur J Pharmacol** 1997 May 30; 327(2–3):175–81

Effects of the phosphatase inhibitors calyculin A and okadaic acid on acetylcholine synthesis and content of rat hippocampal formation. Issa AM, et al. **J Neurochem** 1996 May;66(5):1924–32

Vesamicol, an inhibitor of acetylcholine vesicle packaging, increases synaptophysin phosphorylation in rat cortical synaptosomes. Asermely KE, et al. **Life Sci** 1996; 59(25–26):2113–28

Kindled seizures do not affect adenosinergic inhibition of DA or ACh release in rat accumbens or PFC. Engelbrecht AH, et al. **Pharmacol Biochem Behav** 1996 Nov; 55(3):315–21

[Endothelin–1 modulates acetylcholine–induces relaxation of isolated rat aorta] Grafov MA, et al. **Dokl Akad Nauk** 1996 Nov;351(1):128–30 **(Rus)**

BIOSYNTHESIS

Central acetylcholine synthesis and catabolism activities in the cuttlefish during aging. Bellanger C, et al. **Brain Res** 1997 Jul 11;762(1–2):219–22

Evidence to suggest that extracellular acetate is accumulated by rat hippocampal cholinergic nerve terminals for acetylcholine formation and release. Carroll PT. **Brain Res** 1997 Apr 4;753(1):47–55

Inhibitors of serine/threonine phosphatases increase membrane–bound choline acetyltransferase activity and enhance acetylcholine synthesis. Cooke LJ, et al. **Brain Res** 1997 Mar 21;751(2):232–8

Nontoxic amyloid beta peptide 1–42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer's disease. Hoshi M, et al. **J Biol Chem** 1997 Jan 24;272(4):2038–41

Cyclic AMP–mediated enhancement of high–affinity choline transport and acetylcholine synthesis in brain. Vogelsberg V, et al. **J Neurochem** 1997 Mar;68(3):1062–70

Localization and synthesis of acetylcholine in human leukemic T cell lines. Fujii T, et al. **J Neurosci Res** 1996 Apr 1;44(1):66–72

Effects of MF–268, a new cholinesterase inhibitor, on acetylcholine and biogenic amines in rat cortex. Zhu XD, et al. **J Neurosci Res** 1996 Jan 1;43(1):120–6

Non–neuronal acetylcholine, a signalling molecule synthezised by surface cells of rat and man. Klapproth H, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Apr; 355(4):515–23

Diurnal rhythms in ornithine decarboxylase activity and norepinephrine and acetylcholine synthesis and acetylcholine synthesis of rat submaxillary lymph nodes: effect of pinealectomy, superior cervical ganglionectomy and melatonin replacement. Cardinali DP, et al. **Neuroimmunomodulation** 1996 Mar–Jun;3(2–3):102–11

Amyloid beta–protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Pedersen WA, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8068–71

BLOOD

Architecture of the mammalian pituitary cholinergic system with observations on a putative blood acetylcholine sensor [published erratum appears in Histol Histopathol 1996 Jul;11(3):831] Caffe AR. **Histol Histopathol** 1996 Apr; 11(2):537–51 (64 ref.)

Maintenance of constant blood acetylcholine content before and after feeding in young chimpanzees. Fujii T, et al. **Neurosci Lett** 1997 May 9;227(1):21–4

Oral administration of KW–5092, a novel gastroprokinetic agent with acetylcholinesterase inhibitory and acetylcholine release enhancing activities, causes a dose–dependent increase in the blood acetylcholine content of beagle dogs. Yamada S, et al. **Neurosci Lett** 1997 Mar 28;225(1):25–8

Diethylcarbamazine: effect on lysosomal enzymes and acetylcholine in Wuchereria bancrofti infection. Bhattacharya C, et al. **Trop Med Int Health** 1997 Jul; 2(7):686–90

CEREBROSPINAL FLUID

Determination of acetylcholine concentration in cerebrospinal fluid of patients with neurologic diseases. Yamada H, et al. **Acta Neurol Scand** 1996 Jan;93(1):76–8

Analgesic doses of intrathecal but not intravenous clonidine increase acetylcholine in cerebrospinal fluid in humans. De Kock M, et al. **Anesth Analg** 1997 Apr;84(4):800–3

Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer–type dementia. Tohgi H, et al. **J Neural Transm** 1996;103(10):1211–20

CHEMISTRY

Conformational analysis of acetylcholine and related choline esters. Frydenvang K, et al. **Acta Crystallogr B** 1996 Feb 1;52 (Pt 1):184–93

Thyrotropin releasing hormone prevents abnormalities of cortical acetylcholine and monoamines in mice following head injury. Tanaka K, et al. **Regul Pept** 1997 Jun 18; 70(2–3):173–8

DEFICIENCY

Cholinergic deficits in aged rat spinal cord: restoration by GM1 ganglioside. Vogelsberg V, et al. **Brain Res** 1997 Jul 4;761(2):250–6

DIAGNOSTIC USE

Disparity between serotonin– and acetylcholine–provoked coronary artery spasm. Kanazawa K, et al. **Clin Cardiol**

1997 Feb;20(2):146–52

Endothelium-dependent vasodilatation is not selectively impaired in patients with chronic heart failure secondary to valvular heart disease and congenital heart disease [see comments] Nakamura M, et al. **Eur Heart J** 1996 Dec; 17(12):1875–81. Comment in: Eur Heart J 1996 Dec;17(12):1775–7.

Coronary vasomotor response to acetylcholine late after angioplasty. Nishijima H, et al. **Jpn Circ J** 1996 Oct; 60(10):789–96

The vascular function of the long-term coronary artery after Kawasaki disease--evaluation by intracoronary injection of acetylcholine. Yamakawa R. **Kurume Med J** 1997; 44(1):7–14

GENETICS

Culture density regulates both the cholinergic phenotype and the expression of the CNTF receptor in P19 neurons. Parnas D, et al. **J Mol Neurosci** 1997 Apr;8(2):115–30

HISTORY

Sir Henry Dale and autopharmacology: the role of acetylcholine in neurotransmission. Tansey T. **Clio Med** 1995;33:179–93

The Otto Loewi Lecture. Loewi's discovery and the XXI century. Karczmar AG. **Prog Brain Res** 1996;109:1–27, xvii (108 ref.)

IMMUNOLOGY

Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. Goin JC, et al. **FASEB J** 1997 Jan;11(1):77–83

METABOLISM

Extract of the marine alga Prymnesium patelliferum induces release of acetylcholine from cholinergic nerves in the rat bronchial smooth muscle. Meldahl AS, et al. **Acta Physiol Scand** 1996 Feb;156(2):99–107

Regulatory effect of danggui-shaoyao-san on central cholinergic nervous system dysfunction in mice. Itoh T, et al. **Am J Chin Med** 1996;24(3–4):205–17

Effects of chaihu-guizhi-ganjiang-tang on the levels of monoamines and their related substances, and acetylcholine in discrete brain regions of mice. Itoh T, et al. **Am J Chin Med** 1996;24(1):53–64

Acetylcholine receptor alpha-subunit isoforms are differentially expressed in thymuses from myasthenic patients. Andreetta F, et al. **Am J Pathol** 1997 Jan; 150(1):341–8

Acetylcholine in isolated airways of rat, guinea pig, and human: species differences in role of airway mucosa. Reinheimer T, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L722–8

Coactivation of resistance vessels and muscle fibers with acetylcholine release from motor nerves. Welsh DG, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H156–63

Potentiation of acetylcholine release from tracheal parasympathetic nerves by cAMP. Zhang XY, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L541–6

Origin and modulation of ACh release from rat airway cholinergic nerves. Zhu FX, et al. **Am J Physiol** 1997 Jan; 272(1 Pt 1):L8–14

Incubation with IgE increases cholinergic neurotransmission in human airways in vitro. Ichinose M, et al. **Am J Respir Crit Care Med** 1996 Nov;154(5):1272–6

Intrathecal alpha 2-adrenergic agonists stimulate acetylcholine and norepinephrine release from the spinal cord dorsal horn in sheep. An in vivo microdialysis study. Klimscha W, et al. **Anesthesiology** 1997 Jul;87(1):110–6

Inhibition of the vesicular release of neurotransmitters by stimulation of GABAB receptor. Taniyama K, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:496–9

Mediation of the depolarization-induced [Ca(2+)]i increase in rat sublingual acini by acetylcholine released from nerve terminals. Zhang GH, et al. **Arch Oral Biol** 1996 Jan; 41(1):85–90

The effect of the loss of molar teeth on spatial memory and acetylcholine release from the parietal cortex in aged rats. Kato T, et al. **Behav Brain Res** 1997 Feb;83(1–2):239–42

Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers. Sarter M, et al. **Behav Brain Res** 1997 Feb;83(1–2):7–14 (100 ref.)

Allosteric regulation of the binding of [3H]acetylcholine to m2 muscarinic receptors. Gnagey A, et al. **Biochem Pharmacol** 1996 Dec 13;52(11):1767–75

Agonist binding to the Torpedo acetylcholine receptor. 1. Complexities revealed by dissociation kinetics. Dunn SM, et al. **Biochemistry** 1997 Apr 1;36(13):3846–53

Synaptic transmission at visualized sympathetic boutons: stochastic interaction between acetylcholine and its receptors. Bennett MR, et al. **Biophys J** 1997 Apr; 72(4):1595–606

The choline-leakage hypothesis for the loss of acetylcholine in Alzheimer's disease. Ehrenstein G, et al. **Biophys J** 1997 Sep;73(3):1276–80

Changes in the elastic properties of cholinergic synaptic vesicles as measured by atomic force microscopy. Laney DE, et al. **Biophys J** 1997 Feb;72(2 Pt 1):806–13

A two-dimensional compartment model for the reaction-diffusion system of acetylcholine in the synaptic cleft at the neuromuscular junction. Naka T, et al. **Biosystems** 1997;41(1):17–27

Differential effects of ketamine and pentobarbitone on acetylcholine release from the rat hippocampus and striatum. Sato K, et al. **Br J Anaesth** 1996 Sep;77(3):381–4

Differential effects of the neuropeptide galanin on striatal acetylcholine release in anaesthetized and awake rats. Antoniou K, et al. **Br J Pharmacol** 1997 Jul;121(6):1180–6

Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Blandina P, et al. **Br J Pharmacol** 1996 Dec;119(8):1656–64

Different effects of reducing agents on omega-conotoxin GVIA inhibition of [3H]-acetylcholine release from rat cortical slices and guinea-pig myenteric plexus. Casali TA, et al. **Br J Pharmacol** 1997 Jan;120(1):88–92

Differential effects of nitric oxide donors on basal and electrically evoked release of acetylcholine from guinea-pig myenteric neurones. Hebeiss K, et al. **Br J Pharmacol** 1996 Aug;118(8):2073–8

Inhibition by nociceptin of the light-evoked release of ACh from retinal cholinergic neurones. Neal MJ, et al. **Br J Pharmacol** 1997 Apr;120(8):1399–400

Evidence for direct and indirect mechanisms in the potent modulatory action of interleukin-2 on the release of acetylcholine in rat hippocampal slices. Seto D, et al. **Br J Pharmacol** 1997 Mar;120(6):1151–7

Localization of endothelin ETB receptors on the myenteric plexus of guinea-pig ileum and the receptor-mediated release of acetylcholine. Yoshimura M, et al. **Br J Pharmacol** 1996 Jul;118(5):1171–6

Effects of novelty, pain and stress on hippocampal extracellular acetylcholine levels in male rats. Aloisi AM, et al. **Brain Res** 1997 Feb 14;748(1–2):219–26

Central acetylcholine synthesis and catabolism activities in the cuttlefish during aging. Bellanger C, et al. **Brain Res** 1997 Jul 11;762(1–2):219–22

Evidence to suggest that cytosolic acetylcholine in rat hippocampal nerve terminals is not directly transferred into synaptic vesicles for release. Carroll PT. **Brain Res** 1996 Jun 24;725(1):3–10

Downregulation of muscarinic- and 5-HT1B-mediated modulation of [3H]acetylcholine release in hippocampal slices of rats with fimbria-fornix lesions and intrahippocampal grafts of septal origin. Cassel JC, et al. **Brain Res** 1995 Dec 18;704(2):153–66

Galparan induces in vivo acetylcholine release in the frontal cortex. Consolo S, et al. **Brain Res** 1997 May 9; 756(1–2):174–8

A critical role for D1 receptors in the 5-HT1A-mediated facilitation of in vivo acetylcholine release in rat frontal cortex. Consolo S, et al. **Brain Res** 1996 Jan 29;707(2):320–3

Inhibition by the neurosteroid allopregnanolone of basal and stress-induced acetylcholine release in the brain of freely moving rats. Dazzi L, et al. **Brain Res** 1996 Feb 26; 710(1–2):275–80

Reduced evoked release of acetylcholine in the rodent neocortex following traumatic brain injury. Dixon CE, et al. **Brain Res** 1997 Feb 21;749(1):127–30

Demonstration of the facilitatory role of 8-OH-DPAT on cholinergic transmission in the rat hippocampus using in vivo microdialysis. Fujii T, et al. **Brain Res** 1997 Jul 4; 761(2):244–9

Effects of estrogen on potassium-stimulated acetylcholine release in the hippocampus and overlying cortex of adult rats. Gibbs RB, et al. **Brain Res** 1997 Feb 21;749(1):143–6

Comparative dopamine-acetylcholine interactions in the ventral and dorsal striatum of rabbit and rat brain. Guevara BH, et al. **Brain Res** 1996 Sep 9;733(1):105–7

L-DOPA induces concentration-dependent facilitation and inhibition of presynaptic acetylcholine release in the guinea-pig submucous plexus. Hirai K, et al. **Brain Res** 1996 Apr 29;718(1–2):105–11

The disruption of spatial cognition and changes in brain amino acid, monoamine and acetylcholine in rats with transient cerebral ischemia. Iwasaki K, et al. **Brain Res** 1996 Feb 19;709(2):163–72

Inhibition of potassium-stimulated acetylcholine release from rat brain cortical slices by two high-affinity analogs of vesamicol. Leão RM, et al. **Brain Res** 1995 Dec 12; 703(1–2):86–92

A D1 dopamine agonist stimulates acetylcholine release from dissociated striatal cholinergic neurons. Login IS, et al. **Brain Res** 1996 Jul 15;727(1–2):162–8

D2 dopamine receptor activation inhibits basal and forskolin-evoked acetylcholine release from dissociated striatal cholinergic interneurons. Login IS. **Brain Res** 1997 Feb 21;749(1):147–51

Adenylate cyclase in striatal cholinergic interneurons regulates acetylcholine release. Login IS, et al. **Brain Res** 1996 Oct 7;735(2):330–4

Atropine decreases drinking but not feeding and induces less hypothalamic acetylcholine release in diabetic rats. Murzi E, et al. **Brain Res** 1997 Mar 28;752(1–2):184–8

Enhanced acetylcholine release in the hippocampus and cortex during acquisition of an operant behavior. Orsetti M, et al. **Brain Res** 1996 Jun 10;724(1):89–96

Time-related effects of stress on cholinergic sensitivity. Pullia D, et al. **Brain Res** 1996 Dec 16;743(1–2):333–6

Enhancement of hippocampal acetylcholine release by the neurosteroid dehydroepiandrosterone sulfate: an in vivo microdialysis study. Rhodes ME, et al. **Brain Res** 1996 Sep 16;733(2):284–6

Reversal of a selective decrease in hippocampal acetylcholine release, but not of the persistence of kindling, after discontinuation of long-term pentylenetetrazol administration in rats. Serra M, et al. **Brain Res** 1997 Mar 14;751(1):175–9

Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors. Svensson AL, et al. **Brain Res** 1996 Jul 8;726(1–2):207–12

Immobilization stress-induced increase of hippocampal acetylcholine and of plasma epinephrine, norepinephrine and glucose in rats. Tajima T, et al. **Brain Res** 1996 May 13;720(1–2):155–8

Acetylcholine release from frontal cortex in the waking rat measured by microdialysis without acetylcholinesterase inhibitors: effects of diisopropylfluorophosphate. Testylier G, et al. **Brain Res** 1996 Nov 18;740(1–2):307–15

Injection of IgG 192-saporin into the medial septum produces cholinergic hypofunction and dose-dependent working memory deficits. Walsh TJ, et al. **Brain Res** 1996 Jul 8; 726(1–2):69–79

Regulation of dopamine D1 and D2 receptors on striatal acetylcholine release in rats. Ikarashi Y, et al. **Brain Res Bull** 1997;43(1):107–15

Effects of nicergoline on age-related decrements in radial maze performance and acetylcholine levels. McArthur RA, et al. **Brain Res Bull** 1997;43(3):305–11

Relations between acetylcholine release and electrophysiological characteristics of theta rhythm: a microdialysis study in the urethane-anesthetized rat hippocampus. Monmaur P, et al. **Brain Res Bull** 1997; 42(2):141–6

Blockade of N- and Q-type Ca2+ channels inhibit K(+)-evoked [3H]acetylcholine release in rat hippocampal slices. Saydoff JA, et al. **Brain Res Bull** 1996;40(4):283–6

Acetylcholine: oscillation of levels in mouse brain following electroshock. Stavinoha WB, et al. **Brain Res Bull** 1997; 43(1):47–52

Effects of M2 antagonists on in vivo hippocampal acetylcholine levels. Stillman MJ, et al. **Brain Res Bull** 1996;41(4):221–6

Differential distribution of the putative vesicular transporter for acetylcholine in the rat central nervous system. Roghani A, et al. **Brain Res Mol Brain Res** 1996 Dec 31; 43(1–2):65–76

Cellular toxicity of 2,4,5-trichlorophenoxyacetic acid: formation of 2,4,5-trichlorophenoxyacetylcholine. Sastry BV, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jun; 43(4):549–57

Acetylcholine release in the rostral ventrolateral medulla of spontaneously hypertensive rats. Kubo T, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S40–2

Nuclear magnetic resonance (NMR) analysis of ligand receptor interactions: the cholinergic system--a model. Fraenkel Y, et al. **Crit Rev Biochem Mol Biol** 1996; 31(4):273–301 (149 ref.)

The molecular biology of neuronal nicotinic acetylcholine receptors. Boyd RT. **Crit Rev Toxicol** 1997 May; 27(3):299–318 (164 ref.)

Electric field stimulation-induced guinea pig gallbladder contractions: role of calcium channels in acetylcholine release. Parkman HP, et al. **Dig Dis Sci** 1997 Sep; 42(9):1919–25

Perinatal exposure to methadone affects central cholinergic activity in the weanling rat. Robinson SE, et al. **Drug Alcohol Depend** 1996 Jun;41(2):119–26

Selective depletion of clear synaptic vesicles and enhanced quantal transmitter release at frog motor nerve endings produced by trachynilysin, a protein toxin isolated from stonefish (Synanceia trachynis) venom. Colasante C, et al. **Eur J Neurosci** 1996 Oct;8(10):2149–56

The cerebral cortex and parafascicular thalamic nucleus facilitate in vivo acetylcholine release in the rat striatum through distinct glutamate receptor subtypes. Consolo S, et al. **Eur J Neurosci** 1996 Dec;8(12):2702–10

Cocaine-induced increase in cortical acetylcholine release: interaction with the hypothalamo-pituitary-adrenal axis. Day JC, et al. **Eur J Neurosci** 1997 Jun;9(6):1130–6

Glutamatergic modulation of cortical acetylcholine release in the rat: a combined in vivo microdialysis, retrograde tracing and immunohistochemical study. Giovannini MG, et al. **Eur J Neurosci** 1997 Aug;9(8):1678–89

Zinc blocks acetylcholine release but not vesicle fusion at the Torpedo nerve-electroplate junction. Parducz A, et al. **Eur J Neurosci** 1997 Apr;9(4):732–8

In vitro effects of toxogonin, HI-6 and HLö-7 on the release of [3H]acetylcholine from peripheral cholinergic nerves in rat airway smooth muscle. Aas P. **Eur J Pharmacol** 1996 Apr 22;301(1–3):59–66

Spontaneous release of acetylcholine in striatum is preferentially regulated by inhibitory dopamine D2 receptors. DeBoer P, et al. **Eur J Pharmacol** 1996 Dec 19;317(2–3):257–62

Increased hippocampal acetylcholine release during a working memory task. Fadda F, et al. **Eur J Pharmacol** 1996 Jun 27;307(2):R1–2

Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. Gifford AN, et al. **Eur J Pharmacol** 1997 Apr 18;324(2–3):187–92

Effects of and interactions between antagonists for different

sites on the NMDA receptor complex on hippocampal and striatal acetylcholine efflux in vivo. Hutson PH, et al. **Eur J Pharmacol** 1996 Jan 4;295(1):45–52

Chronic morphine increases hippocampal acetylcholine release: possible relevance in drug dependence. Imperato A, et al. **Eur J Pharmacol** 1996 Apr 29;302(1–3):21–6

Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats. Scali C, et al. **Eur J Pharmacol** 1997 May 1;325(2–3):173–80

Cholinergic control of rabbit tracheal transepithelial potential difference in vivo. Tamaoki J, et al. **Eur Respir J** 1996 Aug;9(8):1632–6

Neocortical activation: modulation by multiple pathways acting on central cholinergic and serotonergic systems. Dringenberg HC, et al. **Exp Brain Res** 1997 Aug; 116(1):160–74

Synthesis and release of acetylcholine by the isolated perifused trout caudal neurosecretory system. Conlon JM, et al. **Gen Comp Endocrinol** 1996 Jul;103(1):36–40

Effect of dotarizine on K(+)-stimulated [3H]-serotonin and [3H]-acetylcholine release from rat hippocampus. Hadjiivanova C, et al. **Gen Pharmacol** 1997 Jan; 28(1):129–32

Effects of SM-9018, a novel 5-HT2 and D2 receptor antagonist, on electrically-evoked [3H]acetylcholine release from rat striatal slices. Ishida K, et al. **Gen Pharmacol** 1996 Oct;27(7):1203–7

Changes in brain neurotransmitters in hypothalamus related to feeding behavior in LEC rat. Darwita RR. **Hokkaido Igaku Zasshi** 1996 May;71(3):377–89

Nitric oxide enhancement of cholinergic amacrine activity by inhibition of glycine release. Neal M, et al. **Invest Ophthalmol Vis Sci** 1997 Jul;38(8):1634–9

Active transport of acetylcholine by the human vesicular acetylcholine transporter. Varoqui H, et al. **J Biol Chem** 1996 Nov 1;271(44):27229–32

Comparative ontogenic profile of cholinergic markers, including nicotinic and muscarinic receptors, in the rat brain. Aubert I, et al. **J Comp Neurol** 1996 May 20; 369(1):31–55

Effect of Hachimi-jio-gan on scopolamine-induced memory impairment and on acetylcholine content in rat brain. Hirokawa S, et al. **J Ethnopharmacol** 1996 Feb;50(2):77–84

Role of dopaminergic neuronal system in dizocilpine-induced acetylcholine release in the rat brain. Hasegawa M, et al. **J Neural Transm Gen Sect** 1996;103(6):651–60

Regional differences of the effect of sigma receptor ligands on the acetylcholine release in the rat brain. Kobayashi T, et al. **J Neural Transm Gen Sect** 1996;103(6):661–9

Evoked acetylcholine release expressed in neuroblastoma cells by transfection of mediatophore cDNA [published erratum appears in J Neurochem 1996 Jun;66(6):2632] Falk-Vairant J, et al. **J Neurochem** 1996 Mar;66(3):1322–5

Norepinephrine microinjections in the hypothalamic paraventricular nucleus increase extracellular dopamine and decrease acetylcholine in the nucleus accumbens: relevance to feeding reinforcement. Hajnal A, et al. **J Neurochem** 1997 Feb;68(2):667–74

Relations between the extracellular concentrations of choline and acetylcholine in rat striatum. Ikarashi Y, et al. **J Neurochem** 1997 Sep;69(3):1246–51

Dysfunction of cholinergic and dopaminergic neuronal systems in beta-amyloid protein--infused rats. Itoh A, et al. **J Neurochem** 1996 Mar;66(3):1113–7

Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo. Kurokawa M, et al. **J Neurochem** 1996 May;66(5):1882–8

Nicotinic autoreceptors mediating enhancement of acetylcholine release become operative in conditions of "impaired" cholinergic presynaptic function. Marchi M, et al. **J Neurochem** 1996 Nov;67(5):1974–81

Protein kinases are involved in prolonged acetylcholine release from rat hippocampus induced by thyrotropin-releasing hormone analogue NS-3. Oka M, et al. **J Neurochem** 1996 May;66(5):1889–93

Effect of pentylenetetrazole-induced kindling on acetylcholine release in the hippocampus of freely moving rats. Serra M, et al. **J Neurochem** 1997 Jan;68(1):313–8

Effects of colchicine application to preganglionic axons on choline acetyltransferase activity and acetylcholine content and release in the superior cervical ganglion. Tandon A, et al. **J Neurochem** 1996 Mar;66(3):1033–41

Acetylcholine release in the rat prefrontal cortex in vivo: modulation by alpha 2-adrenoceptor agonists and antagonists. Tellez S, et al. **J Neurochem** 1997 Feb; 68(2):778–85

Presynaptic A1 inhibitory/A2A facilitatory adenosine receptor activation balance depends on motor nerve stimulation paradigm at the rat hemidiaphragm. Correia-de-Sá P, et al. **J Neurophysiol** 1996 Dec; 76(6):3910–9

Transmitter packaging at frog neuromuscular junctions exposed to anticholinesterases; the role of second-stage acetylcholine loading. Naves LA, et al. **J Neurophysiol** 1996 Oct;76(4):2614–25

Trans-synaptic stimulation of cortical acetylcholine release after partial 192 IgG-saporin-induced loss of cortical cholinergic afferents. Fadel J, et al. **J Neurosci** 1996 Oct 15;16(20):6592–600

Effect of neostigmine on concentration and extraction fraction of acetylcholine using quantitative microdialysis. Vinson PN, et al. **J Neurosci Methods** 1997 Apr 25; 73(1):61–7

Cell lines expressing an acetylcholine release mechanism; correction of a release-deficient cell by mediatophore transfection. Falk-Vairant J, et al. **J Neurosci Res** 1996 Aug 1;45(3):195–201

Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. Dixon CE, et al. **J Neurotrauma** 1997 Mar;14(3):161–9

Striatal acetylcholine release correlates with behavioral sensitization in rats withdrawn from chronic amphetamine. Bickerdike MJ, et al. **J Pharmacol Exp Ther** 1997 Aug; 282(2):818–26

Influence of endothelin-1 on cholinergic nerve-mediated contractions and acetylcholine release in rat isolated tracheal smooth muscle. Knott PG, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1142–7

Positive feedback modulation of acetylcholine release from isolated rat superior cervical ganglion. Liang SD, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):650–5

How to express an effect mean as percentage of a control mean? Feuerstein TJ, et al. **J Pharmacol Toxicol Methods** 1997 Jun;37(4):187–90 (7 ref.)

Detection and modulation of acetylcholine release from neurites of rat basal forebrain cells in culture. Allen TG, et al. **J Physiol (Lond)** 1996 Apr 15;492 (Pt 2):453–66

Regulation of quantal secretion by neurotrophic factors at developing motoneurons in Xenopus cell cultures. Liou JC, et al. **J Physiol (Lond)** 1997 Aug 15;503 (Pt 1):129–39

NO decreases evoked quantal ACh release at a synapse of Aplysia by a mechanism independent of Ca2+ influx and protein kinase G. Mothet JP, et al. **J Physiol (Lond)** 1996 Jun 15;493 (Pt 3):769–84

Involvement of protein kinases in the upregulation of acetylcholine release at endplates of alpha-bungarotoxin-treated rats. Plomp JJ, et al. **J Physiol (Lond)** 1996 May 15;493 (Pt 1):175–86

Role of L- and N-type Ca2+ channels in muscarinic receptor-mediated facilitation of ACh and noradrenaline release in the rat urinary bladder. Somogyi GT, et al. **J Physiol (Lond)** 1997 Mar 15;499 (Pt 3):645–54

M1 muscarinic receptor-induced facilitation of ACh and noradrenaline release in the rat bladder is mediated by protein kinase C. Somogyi GT, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):245–54

Effect of TA-0910, a novel thyrotropin-releasing hormone analog, on in vivo acetylcholine release and turnover in rat brain. Kinoshita K, et al. **Jpn J Pharmacol** 1996 Jun; 71(2):139–45

Muscarinic autoinhibition and modulatory role of protein kinase C in acetylcholine release from the myenteric plexus of guinea pig ileum. Saitoh N, et al. **Jpn J Pharmacol** 1997 Jun;74(2):155–63

Effects of clobenpropit (VUF-9153), a histamine H3-receptor antagonist, on learning and memory, and on cholinergic and monoaminergic systems in mice. Miyazaki S, et al. **Life Sci** 1997;61(4):355–61

The effects of a long-term powdered diet on the amounts of two principal neurotransmitters in the major salivary glands and on stimulated salivary secretion in mice. Murai S, et al. **Methods Find Exp Clin Pharmacol** 1996 Sep; 18(7):459–63

Differences in acetylcholine but not choline in brain tissue fixed by freeze fixation or microwave heating. Shahed AR, et al. **Methods Find Exp Clin Pharmacol** 1996 Jul-Aug; 18(6):349–51

Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Jakubík J, et al. **Mol Pharmacol** 1997 Jul; 52(1):172–9

Single channel evidence for a cytoskeletal defect involving acetylcholine receptors and calcium influx in cultured dystrophic (mdx) myotubes. Carlson CG, et al. **Muscle Nerve** 1996 Sep;19(9):1116–26

alpha-Bungarotoxin, kappa-bungarotoxin, alpha-cobratoxin and erabutoxin-b do not affect [3H]acetylcholine release from the rat isolated left hemidiaphragm. Apel C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec; 352(6):646–52

Neurotransmitter release evoked by alpha-latrotoxin in the smooth muscle of the female pig urethra. Werkström V, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Aug; 356(2):151–8

Potassium, but not atropine-stimulated cortical acetylcholine efflux, is reduced in aged rats. Moore H, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):565–71

Effects of galanins pGAL1-29 and hGAL1-30 and their fragments on cholinergic neurons present in the nucleus of the vertical diagonal band. Farkas Z, et al. **Neurobiology (Bp)** 1996;4(1-2):105–7

Feeding and acetylcholine in the amygdala: microdialysis in freely moving rats. Hajnal A, et al. **Neurobiology (Bp)** 1996; 4(1-2):109–10

The role of human galanin (hGAL1-30), hGAL1-19 and hGAL17-30 in the release of acetylcholine in the striatum: a neuropharmacological study. Sebók L, et al. **Neurobiology (Bp)** 1996;4(3):237–9

Post-hypoxic recovery of acetylcholine release: different sensitivity of guinea pig neocortical and striatal slices. Badini I, et al. **Neurochem Int** 1996 Nov;29(5):477–85

Ca(2+)-dependent changes of acetylcholine release and IP3 mass in Torpedo cholinergic synaptosomes. Carrasco MA, et al. **Neurochem Int** 1997 Mar;30(3):321–7

Ca(2+)-dependent changes of acetylcholine release and IP3 mass in Torpedo cholinergic synaptosomes. Carrasco MA, et al. **Neurochem Int** 1996 Dec;29(6):637–43

Suppression of cholinergic activity via the dopamine D2 receptor in the rat striatum. Ikarashi Y, et al. **Neurochem Int** 1997 Feb;30(2):191–7

Glutamatergic regulation of [3H]acetylcholine release in striatal slices of normotensive and spontaneously hypertensive rats. Tsuda K, et al. **Neurochem Int** 1996 Sep; 29(3):231–7

The acetylcholine receptor ligand-gated channel as a molecular target of disease and therapeutic agents. Barrantes FJ. **Neurochem Res** 1997 Apr;22(4):391–400 (68 ref.)

Chronic administration of Oren-gedoku-to (TJ15) inhibits ischemia-induced changes in brain indoleamine metabolism and muscarinic receptor binding in the Mongolian gerbil. Kabuto H, et al. **Neurochem Res** 1997 Jan;22(1):33–6

Effect of subtype-specific Ca(2+)-antagonists and Ca(2+)-free media on the field stimulation-evoked release of ATP and [3H]acetylcholine from rat habenula slices. Sperlágh B, et al. **Neurochem Res** 1997 Aug;22(8):967–75

A microdialysis study of the effects of the nicotinic agonist RJR-2403 on cortical release of acetylcholine and biogenic amines. Summers KL, et al. **Neurochem Res** 1996 Oct; 21(10):1181–6

Pharmacological characterization of a nicotinic autoreceptor in rat hippocampal synaptosomes. Wilkie GI, et al. **Neurochem Res** 1996 Sep;21(9):1141–8

From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Nitsch RM. **Neurodegeneration** 1996 Dec;5(4):477–82 (44 ref.)

Expression of a putative vesicular acetylcholine transporter facilitates quantal transmitter packaging [see comments] Song H, et al. **Neuron** 1997 May;18(5):815–26. Comment in: Neuron 1997 May;18(5):683–6.

Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine efflux in morphine-dependent rats. Bristow LJ, et al. **Neuropharmacology** 1997 Feb; 36(2):241–50

5-HT1A receptor-mediated inhibition of acetylcholine release from guinea pig myenteric plexus: potential mechanisms. Dietrich C, et al. **Neuropharmacology** 1996 Apr;35(4):483–8

Polyamine FTX-3.3 and polyamine amide sFTX-3.3 inhibit presynaptic calcium currents and acetylcholine release at mouse motor nerve terminals. Fatehi M, et al. **Neuropharmacology** 1997 Feb;36(2):185–94

Effects of lobeline and dimethylphenylpiperazinium iodide (DMPP) on N-methyl-D-aspartate (NMDA)-evoked acetylcholine release in vitro: evidence for a lack of involvement of classical neuronal nicotinic acetylcholine receptors. Rao TS, et al. **Neuropharmacology** 1997 Jan; 36(1):39–50

Inhibition of acetylcholine release from presynaptic terminals of skate electric organ by calcium channel antagonists: a detailed pharmacological study. Richardson CM, et al. **Neuropharmacology** 1996;35(11):1537–46

Vesicular acetylcholine transport inhibitor suppresses REM sleep. Capece ML, et al. **Neuroreport** 1997 Jan 20;8(2):481–4

Carbachol inhibits basal and forskolin-evoked adult rat striatal acetylcholine release. Login IS. **Neuroreport** 1997 May 27;8(8):1863–6

Acetylcholine exocytosis in PC12 cells deficient in SNAP-25. Ray P, et al. **Neuroreport** 1997 Jul 7;8(9-10):2271–4

Pontine acetylcholine release is regulated by muscarinic autoreceptors. Roth MT, et al. **Neuroreport** 1996 Nov 25; 7(18):3069–72

Gangliosides enhance KCl-induced Ca2+ influx and acetylcholine release in brain synaptosomes. Tanaka Y, et al. **Neuroreport** 1997 Jul 7;8(9-10):2203–7

Release of cerebral acetylcholine increases during visually mediated behavior in monkeys. Tang Y, et al. **Neuroreport** 1996 Sep 2;7(13):2231–5

Acetylcholine in the hippocampus during the discrimination learning performance in a rat model of chronic cerebral ischaemia. Yamamuro Y, et al. **Neuroreport** 1996 Jul 29; 7(11):1837–40

Modulation of hippocampal acetylcholine release after fimbria-fornix lesions and septal transplantation in rats. Erb C, et al. **Neurosci Lett** 1997 Aug 1;231(1):5–8

Differences in the developmental expression of the vesicular acetylcholine transporter and choline acetyltransferase in the rat brain. Holler T, et al. **Neurosci Lett** 1996 Jul 12; 212(2):107–10

In vivo regulation of acetylcholine release via adenosine A1 receptor in rat cerebral cortex. Kurokawa M, et al. **Neurosci Lett** 1996 May 17;209(3):181–4

Attenuated stress response of hippocampal acetylcholine release and adrenocortical secretion in aged rats. Mizuno T, et al. **Neurosci Lett** 1997 Jan 24;222(1):49–52

An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. Papke RL, et al. **Neurosci Lett** 1996 Aug 9;213(3):201–4

Changes in dopamine and acetylcholine release in the rat lateral hypothalamus during deprivation-induced drinking. Puig de Parada M, et al. **Neurosci Lett** 1997 May 23; 227(3):153–6

Acetylcholine release from rat brain cortical slices evoked

by the fraction P4 of the venom of the spider Phoneutria nigriventer has Ca2+ and temperature independent components. Romano-Silva MA, et al. **Neurosci Lett** 1996 Nov 29;219(3):159-62

Evidence for active acetylcholine metabolism in human amniotic epithelial cells: applicable to intracerebral allografting for neurologic disease. Sakuragawa N, et al. **Neurosci Lett** 1997 Aug 22;232(1):53-6

Day-night rhythm of acetylcholine in the rat pineal gland. Wessler I, et al. **Neurosci Lett** 1997 Mar 21;224(3):173-6

Role of the parafascicular thalamic nucleus and N-methyl-D-aspartate transmission in the D1-dependent control of in vivo acetylcholine release in rat striatum. Consolo S, et al. **Neuroscience** 1996 Mar;71(1):157-65

Adenosine uptake and deamination regulate tonic A2a receptor facilitation of evoked [3H]acetylcholine release from the rat motor nerve terminals. Correia-de-Sá P, et al. **Neuroscience** 1996 Jul;73(1):85-92

Strain-dependent effects of dopamine agonists on acetylcholine release in the hippocampus: an in vivo study in mice. Imperato A, et al. **Neuroscience** 1996 Feb; 70(3):653-60

Changes in cortical acetylcholine release in the rat during day and night: differences between motor and sensory areas. Jiménez-Capdeville ME, et al. **Neuroscience** 1996 Mar;71(2):567-79

The structural localization of galanin, and its function in modulating acetylcholine release in the olfactory bulb of adult rat. Kasa P, et al. **Neuroscience** 1996 Jun;72(3):709-23

Inescapable stress enhances extracellular acetylcholine in the rat hippocampus and prefrontal cortex but not the nucleus accumbens or amygdala. Mark GP, et al. **Neuroscience** 1996 Oct;74(3):767-74

Effects of ventral hippocampal galanin on spatial learning and on in vivo acetylcholine release in the rat. Orgen SO, et al. **Neuroscience** 1996 Dec;75(4):1127-40

Quantal release of transmitter at a central synapse. Sastry BR, et al. **Neuroscience** 1996 Dec;75(4):987-92

Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats. Vannucchi MG, et al. **Neuroscience** 1997 Aug;79(3):837-46

Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo. Irie T, et al. **Nucl Med Biol** 1994 Aug;21(6):801-8

Reduced evoked release of acetylcholine in the rodent hippocampus following traumatic brain injury. Dixon CE, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):679-86

Acetylcholine, aging, and Alzheimer's disease. Muir JL. **Pharmacol Biochem Behav** 1997 Apr;56(4):687-96 (124 ref.)

5-HT3 serotonin hetero-receptors inhibit [3H]acethylcholine release in rat cortical synaptosomes. Crespi D, et al. **Pharmacol Res** 1997 Apr;35(4):351-4

The heterogeneity of vesicular acetylcholine storage in cholinergic nerve terminals. Prior C, et al. **Pharmacol Res** 1995 Dec;32(6):345-53 (46 ref.)

Acetylcholine release at motor endplates and autonomic neuroeffector junctions: a comparison. Wessler I. **Pharmacol Res** 1996 Feb;33(2):81-94 (156 ref.)

Hippocampal acetylcholine increases during eyeblink conditioning in the rabbit. Meyer JJ, et al. **Physiol Behav** 1996 Nov;60(5):1199-203

Opposite effects of nitric oxide on identified inhibitory and excitatory cholinergic synapses of Aplysia californica. Mothet JP, et al. **Physiol Res** 1996;45(3):177-83

Effects of trophic factors on the CNS cholinergic phenotype. Cuello AC. **Prog Brain Res** 1996;109:347-58 (59 ref.)

The VAChT/ChAT "cholinergic gene locus": new aspects of genetic and vesicular regulation of cholinergic function. Erickson JD, et al. **Prog Brain Res** 1996;109:69-82 (50 ref.)

Modulation of acetylcholine release by nitric oxide. Kilbinger H. **Prog Brain Res** 1996;109:219-24 (33 ref.)

Interactions of protons with the acetylcholine transporter of synaptic vesicles. Nguyen ML, et al. **Prog Brain Res** 1996; 109:97-103

Amyloid beta-peptides injection into the cholinergic nuclei: morphological, neurochemical and behavioral effects. Pepeu G, et al. **Prog Brain Res** 1996;109:273-82

Purinergic regulation of acetylcholine release. Ribeiro JA, et al. **Prog Brain Res** 1996;109:231-41 (41 ref.)

Acetylcholine releases of mesopontine PGO-on cells in the lateral geniculate nucleus in sleep-waking cycle and serotonergic regulation. Kodama T, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Oct; 20(7):1213-27

Chronic lithium attenuates dopamine D1-receptor mediated increases in acetylcholine release in rat frontal cortex. Acquas E, et al. **Psychopharmacology (Berl)** 1996 May; 125(2):162-7

Stimulation of cortical acetylcholine efflux by FG 7142 measured with repeated microdialysis sampling. Moore H, et al. **Synapse** 1995 Dec;21(4):324-31

Effect of Mg(2+)-ATP on acetylcholinesterase of Electrophorus electricus (L.). Nery da Matta A, et al. **Z Naturforsch [C]** 1996 Jan-Feb;51(1-2):65-9

[Regulation of muscarinic potassium channels] Thiebot H, et al. **C R Seances Soc Biol Fil** 1996;190(2-3):237-41 (13 ref.) (Eng. Abstr.) **(Fre)**

[NANC relaxation and potassium channel in rat colon and rectum] Kishi M, et al. **J Smooth Muscle Res** 1995 Dec; 31(6):462-5 **(Jpn)**

[Non-adrenergic-non-cholinergic relaxation and nitric oxide in the intestines of Hirschsprung disease] Watanabe H, et al. **J Smooth Muscle Res** 1995 Dec;31(6):467-70 **(Jpn)**

[Effects of carbamazepine and zonisamide on acetylcholine levels in rat striatum] Mizuno K. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Feb; 17(1):17-23 (Eng. Abstr.) **(Jpn)**

[New approach for the studies on Alzheimer's disease: a beta 1-42 and acetylcholine] Hoshi M. **Seikagaku** 1997 Mar; 69(3):181-7 (19 ref.) **(Jpn)**

[The effect of hypoxic hypoxia on energy metabolism in the liver mitochondria and the acetylcholine content of different tissues] Doliba MM, et al. **Fiziol Zh** 1996; 42(5-6):45-50 (Eng. Abstr.) **(Ukr)**

PHARMACOKINETICS

Heart rate variability, respiratory sinus arrhythmia, and mathematical modeling of acetylcholine pharmacokinetics/pharmacodynamics in sinus node neuroeffector junctions [letter] Dexter F. **Anesth Analg** 1997 Jun;84(6):1393

PHARMACOLOGY

Effects on skeletal muscle oxygenation and capillary blood flow by adenosine-, sodium nitroprusside- and acetylcholine-induced hypotension. Gustafsson U, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):832-7

Local actions of acetylcholine on vasomotor regulation in rat incisor pulp. Olgart L, et al. **Acta Physiol Scand** 1996 Dec;158(4):311-6

Contractile responses of rat duodenum caused by transmural nerve stimulation: interaction between tachykininergic and cholinergic mechanisms. Tolessa T, et al. **Acta Physiol Scand** 1996 Oct;158(2):135-42

Acetylcholine elevates intracellular Ca2+ via muscarinic and nicotinic receptors in rat carotid body type I cells. Dasso LL, et al. **Adv Exp Med Biol** 1996;410:239-44

Effect of acetylcholine on intracellular calcium of carotid body cells of adult cats. Shirahata M, et al. **Adv Exp Med Biol** 1996;410:257-60

Simultaneous measurements of cytosolic calcium ion and pH in cultured superior cervical ganglion cells of rat. Yoshizaki K, et al. **Adv Exp Med Biol** 1996;410:221-6

Variations of segmental endothelium-dependent and endothelium-independent vasomotor tone after cardiac transplantation (qualitative changes in endothelial function). Weis M, et al. **Am Heart J** 1997 Aug;134(2 Pt 1):306-15

Coronary segmental responses to acetylcholine and bradykinin in patients with atherosclerotic risk factors. Kato M, et al. **Am J Cardiol** 1997 Sep 15;80(6):751-5

Halothane reduces myofilament Ca2+ sensitivity during muscarinic receptor stimulation of airway smooth muscle. Akao M, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):L719-25

Role of intracellular alkalinization in inhibition of acetylcholine-induced relaxation by FMLP in rat aorta. Ando K, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2405-10

Cholesterol feeding does not alter renal hemodynamic response to acetylcholine and angiotensin II in rabbits. Carroll JF, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R940-7

Vasodilator responses to acetylcholine, bradykinin, and substance P are mediated by a TEA-sensitive mechanism. Champion HC, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R414-22

Effect of K(+)-channel blockers on ACh-induced hyperpolarization and relaxation in mesenteric arteries. Chen G, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2306-12

Release of nitric oxide and prostaglandin H2 to acetylcholine in skeletal muscle venules. Dörnyei G, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2541-6

Acetylcholine induces conducted vasodilation by nitric oxide-dependent and -independent mechanisms. Doyle MP, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1364-71

Acetylcholine- and flow-induced production and release of nitric oxide in arterial and venous endothelial cells. Fukaya Y, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H99-106

Regulation by acetylcholine of Ca2+ current in rabbit atrioventricular node cells. Habuchi Y, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2274-82

7-Nitroindazole attenuates vasodilation from cerebellar parallel fiber stimulation but not acetylcholine. Iadecola C, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):R914-9

Permissive and obligatory roles of NO in cerebrovascular responses to hypercapnia and acetylcholine. Iadecola C, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R990-1001

Meandering and unstable reentrant wave fronts induced by acetylcholine in isolated canine right atrium. Ikeda T, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H356-70

In situ visualization of bronchial submucosal glands and their secretory response to acetylcholine. Inglis SK, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):L203-10

Role of endogenous NO in modulating airway contraction mediated by muscarinic receptors during development. Jakupaj M, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):L531-6

Acetylcholine and caffeine activate Cl- and suppress K+ conductances in human bronchial smooth muscle. Janssen LJ. **Am J Physiol** 1996 May;270(5 Pt 1):L772-81

Halothane inhibits agonist-induced potentiation of rMLC phosphorylation in permeabilized airway smooth muscle. Jones KA, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):L80-5

ACh dilates pial arterioles in endothelial and neuronal NOS knockout mice by NO-dependent mechanisms. Meng W, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1145-50

Nitric oxide synthase does not participate in negative inotropic effect of acetylcholine in frog heart. Méry PF, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):H1178-88

Endothelial vasoconstrictor prostanoids modulate contractions to acetylcholine and ANG II in Ren-2 rats. Noll G, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H493-500

Nitric oxide inhibits ACh-induced intracellular calcium oscillations in porcine tracheal smooth muscle. Prakash YS, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):L588-96

Airway hyperreactivity produced by short-term exposure to hyperoxia in neonatal guinea pigs. Schulman SR, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):L1211-6

Possible nicotinic receptor-mediated modulation of synaptic transmission in nucleus of the solitary tract. Shiraki T, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R869-73

Prolactin enables normal development of ACh-stimulated current in cultured larval bullfrog skin. Takada M, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1059-63

Development of muscarinic potassium current in fetal and neonatal rat heart. Takano M, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1188-95

Muscarinic receptor stimulation modulates the effect of halothane on Mn2+ influx in airway smooth muscle. Warner DO, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C868-73

Acetylcholine via muscarinic receptors inhibits histamine release from human isolated bronchi. Reinheimer T, et al. **Am J Respir Crit Care Med** 1997 Aug;156(2 Pt 1):389-95

Muscarinic hyperresponsiveness of antigen-sensitized feline airway smooth muscle in vitro. Mitchell RW, et al. **Am J Vet Res** 1997 Jun;58(6):672-6

Heart rate variability, respiratory sinus arrhythmia, and mathematical modeling of acetylcholine pharmacokinetics/pharmacodynamics in sinus node neuroeffector junctions [letter] Dexter F. **Anesth Analg** 1997 Jun;84(6):1393

The effects of halothane pretreatment on manganese influx induced by muscarinic stimulation of airway smooth muscle. Warner DO, et al. **Anesth Analg** 1997 Jun; 84(6):1366-71

Distribution of systemically administered ampicillin, benzylpenicillin, and flucloxacillin in excisional wounds in diabetic and normal rats and effects of local topical vasodilator treatment. Cross SE, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1703-10

Comparative study on different responses of vascular and extravascular smooth muscles mounted inside the guinea-pig trachea: effects of ovalbumin sensitization. Guc MO, et al. **Arch Int Pharmacodyn Ther** 1996 Jan-Feb; 331(1):32-45

Effect of temperature on the contractile response of isolated rat small intestine to acetylcholine and KCl: calcium dependence. Sabeur G. **Arch Physiol Biochem** 1996; 104(2):220-8

The L-name-resistant component of acetylcholine-induced relaxation of the rat superior mesenteric arterial bed is innervation-dependent. Scott TM, et al. **Artery** 1994; 21(5):271-86

Structural differences in the ability of lysophospholipids to inhibit endothelium-dependent hyperpolarization by acetylcholine in rat mesenteric arteries. Fukao M, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):479-83

Membrane potential and cytosolic free calcium levels modulate acetylcholine-induced inositol phosphate production in insulin-secreting BTC3 cells. Gromada J, et al. **Biochim Biophys Acta** 1997 Jan 10;1310(1):145-8

Influence of OSW-1 [3 beta,16 beta,17 alpha-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1-->3)-(2-O-acetyl-alpha-L-arabinopyranoside)], a steroidal saponin, on endothelium dependent relaxation caused by acetylcholine in rat aorta. Honda H, et al. **Biol Pharm Bull** 1997 Apr;20(4):428-30

Flow regulates vasodilator responses to acetylcholine in the isolated canine mesenteric arterial bed. Nakahara T, et al. **Biol Pharm Bull** 1997 May;20(5):568-70

Comparison of cholinergic vasodilator responses to acetylcholine and methacholine in the human forearm. Bruning TA, et al. **Blood Press** 1996 Nov;5(6):333-41

An investigation into variability in microvascular skin blood flow and the responses to transdermal delivery of acetylcholine at different sites in the forearm and hand. Gardner-Medwin JM, et al. **Br J Clin Pharmacol** 1997 Apr; 43(4):391-7

Comparative effects of L-NOARG and L-NAME on basal blood flow and ACh-induced vasodilatation in rat diaphragmatic microcirculation. Chang HY, et al. **Br J Pharmacol** 1997 Jan;120(2):326-32

Evidence against a role of cytochrome P450-derived arachidonic acid metabolites in endothelium-dependent hyperpolarization by acetylcholine in rat isolated mesenteric artery. Fukao M, et al. **Br J Pharmacol** 1997 Feb;120(3):439-46

Sources of Ca2+ in relation to generation of acetylcholine-induced endothelium-dependent hyperpolarization in rat mesenteric artery. Fukao M, et al. **Br J Pharmacol** 1997 Apr;120(7):1328-34

Inhibition by endothelin-1 of cholinergic nerve-mediated

acetylcholine release and contraction in sheep isolated trachea. Henry PJ, et al. **Br J Pharmacol** 1996 Jun; 118(3):762–8

Mechanotransduction through the endothelial cytoskeleton: mediation of flow- but not agonist-induced EDRF release. Hutcheson IR, et al. **Br J Pharmacol** 1996 Jun;118(3):720–6

Central role of intracellular calcium stores in acute flow- and agonist-evoked endothelial nitric oxide release. Hutcheson IR, et al. **Br J Pharmacol** 1997 Sep; 122(1):117–25

Role of Ca(2+)-activated K+ channels in acetylcholine-induced dilatation of the basilar artery in vivo. Kitazono T, et al. **Br J Pharmacol** 1997 Jan; 120(1):102–6

The involvement of the endothelium in the relaxation of the leopard frog (Rana pipiens) aorta in response to acetylcholine. Knight GE, et al. **Br J Pharmacol** 1996 Jul; 118(6):1518–22

Comparison of the effects of hydroxocobalamin and oxyhaemoglobin on responses to NO, EDRF and the nitrergic transmitter. La M, et al. **Br J Pharmacol** 1996 Mar;117(5):805–10

Characterization of the anatomical structures involved in the contractile response of the rat lung periphery. Salerno FG, et al. **Br J Pharmacol** 1996 Jun;118(3):734–40

The effect of ovariectomy on depressed contractions to phenylephrine and KCl and increased relaxation to acetylcholine in isolated aortic rings of female compared to male rabbits. Sánchez A, et al. **Br J Pharmacol** 1996 Aug;118(8):2017–22

Development of cholinergic and inhibitory non-adrenergic non-cholinergic responses in the rat gastric funds. Smits GJ, et al. **Br J Pharmacol** 1996 Aug;118(8):1987–94

Role of Ca(2+)-activated K+ channel in epithelium-dependent relaxation of human bronchial smooth muscle. Tamaoki J, et al. **Br J Pharmacol** 1997 Jun;121(4):794–8

Acetylcholinesterase inhibitors block acetylcholine-evoked release of dopamine in rat striatum, in vivo. Dajas-Bailador F, et al. **Brain Res** 1996 May 25;722(1–2):12–8

A microiontophoretic study of acetylcholine effects in the inferior colliculus of horseshoe bats: implications for a modulatory role. Habbicht H, et al. **Brain Res** 1996 Jun 17;724(2):169–79

Modulatory action of dopamine on acetylcholine-responsive striatal and accumbal neurons in awake, unrestrained rats. Kiyatkin EA, et al. **Brain Res** 1996 Mar 25;713(1–2):70–8

Lead modulation of the neuronal nicotinic acetylcholine receptor in PC12 cells. Nagata K, et al. **Brain Res** 1997 Apr 18;754(1–2):21–7

Short-term depression and long-term enhancement of ACh-gated channel currents induced by linoleic and linolenic acid. Nishizaki T, et al. **Brain Res** 1997 Mar 21; 751(2):253–8

5-HT2 receptor regulation of acetylcholine release induced by dopaminergic stimulation in rat striatal slices. Ramírez MJ, et al. **Brain Res** 1997 May 16;757(1):17–23

Changes in the sensitivity of frontal cortical neurones to acetylcholine after unilateral lesion of the nucleus basalis with alpha-amino-3-OH-4-isoxozole propionic acid (AMPA): effects of basal forebrain transplants into neocortex. Abdulla FA, et al. **Brain Res Bull** 1997; 42(3):169–86

The effects of melatonin on vasopressin secretion in vivo: interactions with acetylcholine and prostaglandins. Bojanowska E, et al. **Brain Res Bull** 1997;42(6):457–61

Neuronal mechanisms mediating drug-induced cognition enhancement: cognitive activity as a necessary intervening variable. Sarter M, et al. **Brain Res Cogn Brain Res** 1996 Jun;3(3–4):329–43 (127 ref.)

Cholinergic stimulation increases thrombin activity and gene expression in cultured mouse muscle. Glazner GW, et al. **Brain Res Dev Brain Res** 1997 Apr 18;99(2):148–54

Action of acetylcholine on regional myocardial work and metabolism in vivo: association with cyclic GMP. Guo X, et al. **Can J Physiol Pharmacol** 1996 Jan;74(1):73–9

Cultured dog aortic endothelial cells release vasodilatory products in response to acetylcholine and adenosine. Woodley N, et al. **Can J Physiol Pharmacol** 1996 Aug; 74(8):949–56

Effects of acetylcholine on lung liquid production by in vitro lungs from fetal guinea pigs. Woods BA, et al. **Can J Physiol Pharmacol** 1996 Aug;74(8):918–27

Differential effect of nitric oxide synthase inhibitors on acetylcholine-induced relaxation of rat pulmonary and celiac artery rings. Yaghi A, et al. **Can J Physiol Pharmacol** 1997 Apr;75(4):279–86

Characteristics of coronary endothelial dysfunction in experimental diabetes. Koltai MZ, et al. **Cardiovasc Res** 1997 Apr;34(1):157–63

Effects of glycosylated hemoglobin on vascular responses in vitro. Oltman CL, et al. **Cardiovasc Res** 1997 Apr; 34(1):179–84

The amount of acetylcholine mobilisable Ca2+ in single smooth muscle cells measured with the exogenous cytoplasmic Ca2+ buffer, Indo-1. Ganitkevich VY. **Cell Calcium** 1996 Dec;20(6):483–92

Evidence for muscarinic 3 receptor mediated ion transport in HT29 cells studied by X-ray microanalysis. Zhang W, et al. **Cell Struct Funct** 1997 Jun;22(3):379–85

Effects of caffeine and acetylcholine on glucose-stimulated insulin release from islet transplants in mice. Shi CL. **Cell Transplant** 1997 Jan–Feb;6(1):33–7

Modulation of endothelium-dependent hyperpolarization and relaxation to acetylcholine in rat mesenteric artery by cytochrome P450 enzyme activity. Chen G, et al. **Circ Res** 1996 Oct;79(4):827–33

Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P. Quyyumi AA, et al. **Circulation** 1997 Jan 7; 95(1):104–10

Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. van der Zee R, et al. **Circulation** 1997 Feb 18;95(4):1030–7

Withdrawal of acetylcholine elicits Ca2+-induced delayed afterdepolarizations in cat atrial myocytes. Wang YG, et al. **Circulation** 1997 Aug 19;96(4):1275–81

Depressed endothelium-dependent relaxation responses to acetylcholine and histamine in isolated human epigastric arteries from pre-eclamptic women. Oguogho A, et al. **Clin Auton Res** 1996 Jun;6(3):153–5

The effect of anti-IL-4 monoclonal antibody, rapamycin and interferon-gamma on airway hyperreactivity to acetylcholine in mice. Nagai H, et al. **Clin Exp Allergy** 1997 Feb;27(2):218–24

Acetylcholine induces contraction in vergebral arteries from treated hypertensive patients. Charpie JR, et al. **Clin Exp Hypertens** 1996 Jan;18(1):87–99

Action of cholinesters on sensory nerve endings in skin and muscle. Carr RW, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):355–62 (81 ref.)

Possible involvement of muscarinic M1 and M3 receptor subtypes mediating vasodilation in isolated, perfused canine lingual arteries. Chiba S, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):839–43

Altered reactivity of the inferior vena cava to noradrenaline and acetylcholine following the blockade of EDRF-biosynthesis with NG-nitro-L-arginine methyl ester. Schwarzacher S, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul;23(6–7):490–2

Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide. Newby DE, et al. **Clin Sci (Colch)** 1997 Feb;92(2):133–8

The effects of disease severity and sex on coronary endothelium-dependent vasomotor function in an atherosclerotic primate model. Honoré EK, et al. **Coron Artery Dis** 1996 Aug;7(8):579–85

Differential effects of nitric oxide synthase modulation on porcine systemic and pulmonary circulation in vivo. Dahm P, et al. **Crit Care Med** 1997 Feb;25(2):280–5

Acetylcholine and the visual evoked potential. Peachey NS, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996; 46:161–4 (27 ref.)

Acetylcholine autoexcites the release of proopiomelanocortin-derived peptides from melanotrope cells of Xenopus laevis via an M1 muscarinic receptor. Van Strien FJ, et al. **Endocrinology** 1996 Oct;137(10):4298–307

Cholinergic responses in developing outer hair cells of the rat cochlea. Dulon D, et al. **Eur J Neurosci** 1996 Sep; 8(9):1945–52

Functional properties of neuronal nicotinic acetylcholine receptor channels expressed in transfected human cells. Ragozzino D, et al. **Eur J Neurosci** 1997 Mar;9(3):480–8

Differential effects of acetylcholine on neuronal activity and interactions in the auditory cortex of the guinea-pig. Shulz DE, et al. **Eur J Neurosci** 1997 Feb;9(2):396–409

Effect of nitric oxide synthase inhibition on the acetylcholine response in the perfused hind limb of rats. Brouwers-Ceiler DL, et al. **Eur J Pharmacol** 1996 Jun 20;307(1):65–8

Halothane counteracts acetylcholine-induced increase in Ca2+ sensitivity of the contractile apparatus in airway smooth muscle. Kai T, et al. **Eur J Pharmacol** 1996 Nov 21;315(3):313–8

Characteristics of vasodilatation induced by acetylcholine and platelet-activating factor in the rat mesenteric arterial bed. Kamata K, et al. **Eur J Pharmacol** 1996 Mar 7; 298(2):129–36

Apamin-sensitive K+ channels involved in the inhibition of acetylcholine-induced contractions in lamb coronary small arteries. Simonsen U, et al. **Eur J Pharmacol** 1997 Jun 25;329(2–3):153–63

Influence of age on cholinergic and inhibitory nonadrenergic noncholinergic responses in the rat ileum. Smits GJ, et al. **Eur J Pharmacol** 1996 May 6;303(1–2):79–86

Mast cell tryptase potentiates histamine-induced contraction in human sensitized bronchus. Johnson PR, et al. **Eur Respir J** 1997 Jan;10(1):38–43

Activation of muscarinic receptors modulates NMDA receptor-mediated responses in auditory cortex. Aramakis VB, et al. **Exp Brain Res** 1997 Mar;113(3):484–96

Effects of acetylcholine on a slow voltage-activated non-selective cation current mediated by non-nicotinic receptors on isolated Ascaris muscle bags. Martin RJ, et al. **Exp Physiol** 1996 Nov;81(6):909–25

Osmotic flow transients during acetylcholine stimulation in the perfused rat submandibular gland. Nakahari T, et al. **Exp Physiol** 1997 Jan;82(1):55–70

Acetylcholine-evoked potassium transport in the isolated guinea-pig pancreas. Rosado JA, et al. **Exp Physiol** 1997 Jan;82(1):149–59

Interactions between acetylcholine and substance P effects on lung mechanics in the rabbit. Delaunois A, et al. **Fundam Clin Pharmacol** 1996;10(3):278–88

Leukotrienes in acetylcholine-induced contraction of esophageal circular smooth muscle in experimental esophagitis. Kim N, et al. **Gastroenterology** 1997 May; 112(5):1548–58

Neuroendocrine effects on adrenal hormone secretion in carp (Cyprinus carpio). Gfell B, et al. **Gen Comp Endocrinol** 1997 Jun;106(3):310–9

Effects of deferoxamine and sympathectomy on endothelin-1-induced contraction and acetylcholine-induced relaxation following subarachnoid hemorrhage in carotid artery. Sarioğlu Y, et al. **Gen Pharmacol** 1997 Jan;28(1):145–51

The involvement of KCa, KATP and KV channels in vasorelaxing responses to acetylcholine in rat aortic rings. Satake N, et al. **Gen Pharmacol** 1997 Mar;28(3):453–7

Responsiveness of smooth muscle in the lower urinary tract of rabbits to various agonists. Sudoh K, et al. **Gen Pharmacol** 1997 Apr;28(4):629–31

Abnormal renal vascular reactivity to acetylcholine and nitroprusside in aging rats. Vargas F, et al. **Gen Pharmacol** 1997 Jan;28(1):133–7

Effects of acetylcholine, carbachol, and mannitol on rabbit corneal endothelial function as assessed by corneal deturgescence. Akiyama R, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Jun;235(6):384–7

Activation of ion channels by acetylcholine: two contrasting transduction pathways. Lester HA. **Harvey Lect** 1995–96; 91:79–98 (40 ref.)

Differences in cholinergic responses from outer hair cells of rat and guinea pig. Chen C, et al. **Hear Res** 1996 Sep 1;98(1–2):9–17

Effect of acetylcholine and GABA on the transfer function of electromotility in isolated outer hair cells. Sziklai I, et al. **Hear Res** 1996 May;95(1–2):87–99

Prejunctional regulation by endogenous and exogenous acetylcholine of adrenergic nerve function in isolated canine mesenteric arteries. Zhang JX, et al. **Hypertens Res** 1997 Jun;20(2):119–25

Use-dependent loss of acetylcholine- and bradykinin-mediated vasodilation after nitric oxide synthase inhibition. Evidence for preformed stores of nitric oxide-containing factors in vascular endothelial cells. Davisson RL, et al. **Hypertension** 1996 Sep;28(3):354–60

Endogenous estrogen and acetylcholine-induced vasodilation in normotensive women. Pinto S, et al. **Hypertension** 1997 Jan;29(1 Pt 2):268–73

Cyclooxygenase inhibition restrores nitric oxide activity in essential hypertension. Taddei S, et al. **Hypertension** 1997 Jan;29(1 Pt 2):274–9

Regulation of cholinomimetic action of pyrantel pamoate by calcium channels in Setaria cervi. Ganguly B, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):245–8

Increased constrictor response to acetylcholine of the isolated coronary arteries from patients with variant angina. Kugiyama K, et al. **Int J Cardiol** 1995 Dec;52(3):223–33

Increased basal tone and hyperresponsiveness to acetylcholine and ergonovine in spasm-related coronary arteries in patients with variant angina. Lee SJ, et al. **Int J Cardiol** 1996 Jul 26;55(2):117–26

Opposing actions of cholinergic agonist and trinitroglycerin on net vascular resistance in perfused rat heart. Lockwood TD. **Int J Cardiol** 1996 Nov 15;57(1):9–19

The effects of two levels of vasomotor tone at physiologic suffusate PO2 on acetylcholine- and sodium nitroprusside-induced relaxation of cremaster third-order arterioles in 5-hour ischemia-reperfusion control rats. Borsch DM, et al. **Int J Microcirc Clin Exp** 1997 May-Jun; 17(3):113–22

Eosinophilia-induced vascular and airway remodeling and hyperresponsiveness in rat lungs. Yoshikawa S, et al. **J Appl Physiol** 1996 Sep;81(3):1279–87

The central respiratory effects of acetylcholine vary with CSF pH. Burton MD, et al. **J Auton Nerv Syst** 1997 Jan 12;62(1–2):27–32

Acetylcholine-induced bronchoconstriction modified by noise exposure in normal but not in sensitized guinea-pigs. Nieri P, et al. **J Auton Pharmacol** 1996 Apr;16(2):55–62

Stimulation of cyclic ADP-ribose synthesis by acetylcholine and its role in catecholamine release in bovine adrenal chromaffin cells. Morita K, et al. **J Biol Chem** 1997 Aug 22;272(34):21002–9

Thapsigargin inhibits the response to acetylcholine and substance P but does not interfere with the responses to endothelium-independent agents. Amerini S, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):82–8

Endothelial dysfunction in the San Juan hypertensive rat: possible role of the nitric oxide synthase. Crespo MJ, et al. **J Cardiovasc Pharmacol** 1996 Jun;27(6):802–8

Impairment of coronary blood flow regulation by endothelium-derived nitric oxide in dogs with alloxan-induced diabetes. Matsunaga T, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):60–7

Cutaneous vasodilation to acetylcholine in patients with essential hypertension. Rossi M, et al. **J Cardiovasc Pharmacol** 1997 Mar;29(3):406–11

Measurement of adenylylcyclase activity in the AV nodal region of the canine heart: evidence for inhibition by adenosine and acetylcholine. Sugiyama A, et al. **J Cardiovasc Pharmacol** 1997 Jun;29(6):734–9

Loss of acetylcholine-induced relaxation by M3-receptor activation in mesenteric arteries of spontaneously hypertensive rats. Wu CC, et al.

J Cardiovasc Pharmacol 1997 Aug;30(2):245–52
Leptin constrains acetylcholine–induced insulin secretion from pancreatic islets of ob/ob mice. Chen NG, et al. **J Clin Invest** 1997 Sep 1;100(5):1174–9
A non–invasive vibrating calcium–selective electrode measures acetylcholine–induced calcium flux across the sarcolemma of a smooth muscle. Devlin CL, et al. **J Comp Physiol [B]** 1996;166(4):270–7
Octanoate increases cytosolic Ca2+ concentration and membrane conductance in ovine pancreatic acinar cells. Katoh K, et al. **J Comp Physiol [B]** 1996;166(6):369–74
Mutation in the M1 domain of the acetylcholine receptor alpha subunit decreases the rate of agonist dissociation. Wang HL, et al. **J Gen Physiol** 1997 Jun;109(6):757–66
Cholinergic short–term conditioning and activation of ATP–sensitive K+ current in cat atrial myocytes. Lipsius SL, et al. **J Mol Cell Cardiol** 1997 Mar;29(3):907–14
Hydroxyl radical—a mediator of acetylcholine–induced vascular relaxation. Prasad K, et al. **J Mol Cell Cardiol** 1996 Sep;28(9):2033–41
Acetylcholine modulates I(f) and IK(ACh) via different pathways in rabbit sino–atrial node cells. Renaudon B, et al. **J Mol Cell Cardiol** 1997 Mar;29(3):969–75
Multiple determinants of dihydro–beta–erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. Harvey SC, et al. **J Neurochem** 1996 Nov;67(5):1953–9
Acetylcholine stimulates growth hormone secretion in the neonatal rat pituitary. Pintér I, et al. **J Neuroendocrinol** 1996 Dec;8(12):935–9
Pharmacology of directionally selective ganglion cells in the rabbit retina. Kittila CA, et al. **J Neurophysiol** 1997 Feb; 77(2):675–89
Acetylcholine, outer hair cell electromotility, and the cochlear amplifier. Dallos P, et al. **J Neurosci** 1997 Mar 15;17(6):2212–26
Slow–channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor alpha subunit. Milone M, et al. **J Neurosci** 1997 Aug 1;17(15):5651–65
Activation of Fyn tyrosine kinase upon secretagogue stimulation of bovine chromaffin cells. Allen CM, et al. **J Neurosci Res** 1996 Jun 1;44(5):421–9
Nitric oxide donor sodium nitroprusside inhibits the acetylcholine–induced K+ current in identified Aplysia neurons. Sawada M, et al. **J Neurosci Res** 1996 Apr 1; 44(1):21–6
The sources of Ca2+ for muscarinic receptor–induced contraction in the rat ileum. Elorriaga M, et al. **J Pharm Pharmacol** 1996 Aug;48(8):817–9
Role of nitric oxide and Ca++–dependent K+ channels in mediating heterogeneous microvascular responses to acetylcholine in different vascular beds. Clark SG, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1473–9
Differentiation of muscarinic receptors mediating negative chronotropic and vasoconstrictor responses to acetylcholine in isolated rat hearts. Hoover DB, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1337–44
Signal transduction mechanism(s) involved in prostacyclin production elicited by acetylcholine in coronary endothelial cells of rabbit heart. Kan H, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):113–22
Lipopolysaccharide inhibits acetylcholine– and nitric oxide–mediated vasodilation in vivo. Peters TS, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):918–25
Intracellular Ca2+ changes and Ca2+–activated K+ channel activation induced by acetylcholine at the endplate of mouse skeletal muscle fibres. Allard B, et al. **J Physiol (Lond)** 1996 Jul 15;494 (Pt 2):337–49
Voltage dependence of mouse acetylcholine receptor gating: different charge movements in di–, mono– and unliganded receptors. Auerbach A, et al. **J Physiol (Lond)** 1996 Jul 1;494 (Pt 1):155–70
Acetylcholine activates two currents in guinea–pig outer hair cells. Evans MG. **J Physiol (Lond)** 1996 Mar 1;491 (Pt 2):563–78
Interactions between secretin and acetylcholine in the regulation of fluid secretion by isolated rat pancreatic ducts. Evans RL, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):265–73
Effects of acetylcholine on the Na(+)–K+ pump current in guinea–pig ventricular myocytes. Gao J, et al. **J Physiol (Lond)** 1997 Jun 15;501 (Pt 3):527–35
G protein–dependent inhibition of L–type Ca2+ currents by acetylcholine in mouse pancreatic B–cells. Gilon P, et al. **J Physiol (Lond)** 1997 Feb 15;499 (Pt 1):65–76
K+ channels which contribute to the acetylcholine–induced hyperpolarization in smooth muscle of the guinea–pig submucosal arteriole. Hashitani H, et al. **J Physiol (Lond)** 1997 Jun 1;501 (Pt 2):319–29
The effect of acetylcholine on finger capillary pressure and capillary flow in healthy volunteers. Morris SJ, et al. **J Physiol (Lond)** 1996 Jul 1;494 (Pt 1):307–13
Skin blood flow responses to the iontophoresis of acetylcholine and sodium nitroprusside in man: possible mechanisms. Morris SJ, et al. **J Physiol (Lond)** 1996 Oct 15;496 (Pt 2):531–42
Acetylcholine–induced K+ currents in smooth muscle cells of intact rat small arteries. Weidelt T, et al. **J Physiol (Lond)** 1997 May 1;500 (Pt 3):617–30
Rebound stimulation of the cAMP–regulated Cl– current by acetylcholine in guinea–pig ventricular myocytes. Zakharov SI, et al. **J Physiol (Lond)** 1997 Feb 15;499 (Pt 1):105–20
Basal responses of the L–type Ca2+ and hyperpolarization–activated currents to autonomic agonists in the rabbit sino–atrial node. Zaza A, et al. **J Physiol (Lond)** 1996 Mar 1;491 (Pt 2):347–55
Intracellular calcium release mediated by noradrenaline and acetylcholine in mammalian pineal cells. Marín A, et al. **J Pineal Res** 1996 Aug;21(1):15–28
Changes in cholinergic and purinergic neurotransmission in pathologic bladder of chronic spinal rabbit. Yokota T, et al. **J Urol** 1996 Nov;156(5):1862–6
Impairment of acetylcholine relaxations by malondialdehyde, a marker of lipid peroxidation. Rodríguez–Martínez MA, et al. **J Vasc Res** 1996 Nov–Dec;33(6):463–70
Potentiation of acetylcholine–induced responses in freshly isolated rabbit aortic endothelial cells. Wang X, et al. **J Vasc Res** 1996 Sep–Oct;33(5):414–24
Acetylcholine–induced relaxation of rat aorta is greatest during estrus in the sexual cycle. Honda H, et al. **Jpn J Pharmacol** 1997 May;74(1):113–5
Carbachol but not acetylcholine inhibits contraction by the protein kinase C–dependent and –independent pathways in the smooth muscle of guinea pig taenia caeci. Mitsui–Saito M, et al. **Jpn J Pharmacol** 1996 Sep;72(1):23–8
Endothelial prostanoids involved in the relaxation produced by acetylcholine in the human pulmonary artery. Zhang G, et al. **Jpn J Physiol** 1996 Oct;46(5):403–9
Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes. Birdsall NJ, et al. **Life Sci** 1997;60(13–14):1047–52 (29 ref.)
Accentuated antagonism in canine subendocardium is not altered by chronic exercise. Hamra M, et al. **Med Sci Sports Exerc** 1997 Aug;29(8):1013–20
Comparable effects of arteriolar and capillary stimuli on blood flow in rat skeletal muscle. Mitchell D, et al. **Microvasc Res** 1997 Jan;53(1):22–32
Rho family GTPases and neuronal growth cone remodelling: relationship between increased complexity induced by Cdc42Hs, Rac1, and acetylcholine and collapse induced by RhoA and lysophosphatidic acid. Kozma R, et al. **Mol Cell Biol** 1997 Mar;17(3):1201–11
Chemoattraction of sensory neuron growth cones by diffusible concentration gradients of acetylcholine. Kuffler DP. **Mol Chem Neuropathol** 1996 May–Aug; 28(1–3):199–208
"Orphan" alpha6 nicotinic AChR subunit can form a functional heteromeric acetylcholine receptor. Gerzanich V, et al. **Mol Pharmacol** 1997 Feb;51(2):320–7
Involvement of mitogen–activated protein kinase and translocation of cytosolic phospholipase A2 to the nuclear envelope in acetylcholine–induced prostacyclin synthesis in rabbit coronary endothelial cells. Kan H, et al. **Mol Pharmacol** 1996 Nov;50(5):1139–47
Differences in acetylcholine– and bradykinin–induced vasorelaxation of the mesenteric vascular bed in spontaneously hypertensive rats of different ages. Wirth KJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jun; 354(1):38–43
Signal transduction mechanism responsible for changes in axoplasmic transport caused by neurotransmitters. Takenaka T, et al. **Neurochem Res** 1996 May;21(5):553–6
Contribution of acetylcholine, vasoactive intestinal polypeptide and nitric oxide to CNS–evoked vagal gastric relaxation in the rat. Krowicki ZK, et al. **Neurogastroenterol Motil** 1996 Dec;8(4):307–17
Effects on iontophoretically applied acetylcholine on membrane potential and synaptic activity of bulbar respiratory neurones in decerebrate cats. Haji A, et al. **Neuropharmacology** 1996 Feb;35(2):195–203
Effects of chronic exposure to desipramine and mianserin on Ca2+ mobilization induced by noradrenaline, acetylcholine, and high K+ in rat frontocortical neurons. Shimizu M, et al. **Neuropsychobiology** 1996;33(2):66–70
Oleic acid enhances ACh receptor currents by activation of Ca2+/calmodulin–dependent protein kinase II. Nishizaki T, et al. **Neuroreport** 1997 Feb 10;8(3):597–601
Acetylcholine and carbachol prevent muscle depolarization in denervated rat diaphragm. Urazaev AK, et al. **Neuroreport** 1997 Jan 20;8(2):403–6
Electrical activity of isolated rabbit cerebral cortex after direct application of acetylcholine. Agladze NN, et al. **Neurosci Behav Physiol** 1996 Nov–Dec;26(6):500–6
Tetrahydroberberine inhibits acetylcholine–induced K+ current in acutely dissociated rat hippocampal CA1 pyramidal neurons. Wu J, et al. **Neurosci Lett** 1997 Jan 31;222(2):115–8
Sulfhydryl modification inhibits K+ (M) current with kinetics close to acetylcholine in rodent NG108–15 cells. Egorova A, et al. **Neurosci Res** 1997 Jan;27(1):35–44
Enhancement of quantal transmitter release and mediatophore expression by cyclic AMP in fibroblasts loaded with acetylcholine. Falk–Vairant J, et al. **Neuroscience** 1996 Nov;75(2):353–60
Arginine vasopressin release by acetylcholine or norepinephrine: region–specific and cytokine–specific regulation [published erratum appears in Neuroscience 1996 Jul;73(2):623] Raber J, et al. **Neuroscience** 1996 Apr; 71(3):747–59
Acetylcholine relaxation of renal artery and nitric oxide synthase activity of renal cortex increase with fetal and postnatal age. Thompson LP, et al. **Pediatr Res** 1996 Aug; 40(2):192–7
Effects of cholecystokinin agonists on striatal neurons are reduced by acetylcholine. Davidowa H, et al. **Peptides** 1997;18(4):541–5
Absence of acetylcholine– and ionomycin–activated Cl– currents in submandibular cells of early postnatal rats. Fatherazi S, et al. **Pflugers Arch** 1996 Nov–Dec; 433(1–2):116–22
Short pulses of acetylcholine stimulation induce cytosolic Ca2+ signals that are excluded from the nuclear region in pancreatic acinar cells. Gerasimenko OV, et al. **Pflugers Arch** 1996 Oct;432(6):1055–61
Cytoplasmic Ca2+ gradients evoked by acetylcholine and peptides in pancreatic acinar cells of the guinea–pig. Sjödin L, et al. **Pflugers Arch** 1997 Feb;433(4):397–402
Relaxation of rat resistance arteries by acetylcholine involves a dual mechanism: activation of K+ channels and formation of nitric oxide. Hansen PR, et al. **Pharmacol Toxicol** 1997 Jun;80(6):280–5
Histamine H1–receptor antagonists do not prevent the appearance of endothelium–dependent relaxation to acetylcholine in rat pulmonary artery. Kyselá S, et al. **Physiol Res** 1996;45(4):345–50
The unusual adrenergic–like excitatory action of acetylcholine on the ventricular cardiac muscle of the horned shark, Heterodontus portusjacksoni. Thompson AP, et al. **Physiol Zool** 1997 Mar–Apr;70(2):135–42
Neuronal nicotinic threonine–for–leucine 247 alpha7 mutant receptors show different gating kinetics when activated by acetylcholine or by the noncompetitive agonist 5–hydroxytryptamine. Palma E, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9915–9
Differential effects of acetylcholine and bradykinin on prostanoid release from the rat mesenteric bed: role of endothelium and of nitric oxide. Peredo HA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Apr; 56(4):253–8
Effect of modulating voltage–dependent calcium channels on cholecystokinin and acetylcholine–induced contractions of the guinea pig gallbladder. Parkman HP, et al. **Regul Pept** 1996 May 7;63(1):31–7
Differential responses of ovine intrapulmonary arteries and veins to acetylcholine. Toga H, et al. **Respir Physiol** 1996 Jul;104(2–3):197–204
The role of nitric oxide in the acetylcholine–induced relaxation of the feline internal anal sphincter, in vitro. Buntzen S, et al. **Scand J Gastroenterol** 1996 Dec; 31(12):1189–94
Endotoxin–induced inhibition of mesenteric vasodilator responses to acetylcholine, bradykinin, and post–occlusion hyperemia in anesthetized rats. Fatehi–Hassanabad Z, et al. **Shock** 1996 Nov;6(5):371–6
Selective impairment of response to acetylcholine after ischemia/reperfusion in mice. Rosenblum WI. **Stroke** 1997 Feb;28(2):448–51; discussion 451–2
Action of neurotransmitters: acetylcholine, adrenaline and serotonin on arterial thrombosis induced by a laser beam. Belougne E, et al. **Thromb Res** 1996 Nov 1;84(3):189–98
[Influence of bile salts on the motor response of isolated ileum to acetylcholine, in rats] Duval–Araujo I, et al. **Rev Assoc Med Bras** 1995 Sep–Oct;41(5):325–8 (Eng. Abstr.) **(Por)**
[The role of Na+/K+–ATPase in the presynaptic aftereffect of exogenous acetylcholine in rat diaphragm] Kubasov IV, et al. **Biull Eksp Biol Med** 1997 May;123(5):531–34 **(Rus)**
[Immunologic mechanisms for increasing radioresistance under the effect of cholinomimetics] Zabrodskiĭ PF. **Biull Eksp Biol Med** 1996 May;121(5):541–3 **(Rus)**
[The development of local nonexcitability in sinus node cells and other cells with diastolic depolarization in the right atrium of the rabbit under the action of acetylcholine] Vinogradova TM, et al. **Fiziol Zh Im I M Sechenova** 1996 Oct–Nov;82(10–11):1–19 (Eng. Abstr.) **(Rus)**
[Role of calcium ions in the mechanism of action of acetylcholine on energy metabolism in rat liver mitochondria] Vatamniuk MZ, et al. **Ukr Biokhim Zh** 1996 Sep–Oct;68(5):9–14 (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

The presynaptic component of a cholinergic mechanism in the carotid body chemotransduction of hypoxia in the cat. Fitzgerald RS, et al. **Adv Exp Med Biol** 1996;410:245–52
Local cholinergic mechanisms mediate nitric oxide–dependent flow–induced vasorelaxation in vitro. Martin CM, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):H442–6
Trefoil peptide expression and secretion is regulated by neuropeptides and acetylcholine. Ogata H, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):G348–54
Effects of cholinergic depletion on glutamic acid decarboxylase immunoreactivity in the somatosensory cortex of rats. Herron P, et al. **Anat Embryol (Berl)** 1997 Jul;196(1):27–38
Cholinergic stimulation of human microcytoma cell line H69. Fucile S, et al. **Biochem Biophys Res Commun** 1997 Jan 23;230(3):501–4
Human placental cholinergic system. Sastry BV. **Biochem Pharmacol** 1997 Jun 1;53(11):1577–86 (116 ref.)
Analysis of contributions of acetylcholine and tachykinins to neuro–neuronal transmission in motility reflexes in the guinea–pig ileum. Johnson PJ, et al. **Br J Pharmacol** 1996

Jun;118(4):973–83
A novel nicotinic–cholinergic role in behavioral sensitization to amphetamine–induced stereotypy in mice. Karler R, et al. **Brain Res** 1996 Jul 1;725(2):192–8
Amnesia induced in mice by centrally administered beta–amyloid peptides involves cholinergic dysfunction. Maurice T, et al. **Brain Res** 1996 Jan 15;706(2):181–93
Galanin gene expression declines with adulthood in the cholinergic fields of the horizontal diagonal band of male rats. Planas B, et al. **Brain Res** 1996 Jul 22;728(1):57–64
Acetylcholine: a neurotransmitter for learning and memory? Blokland A. **Brain Res Brain Res Rev** 1995 Nov; 21(3):285–300 (135 ref.)
Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Sarter M, et al. **Brain Res Brain Res Rev** 1997 Feb;23(1–2):28–46 (259 ref.)
Effects of MK–801 and pentobarbital on cholinergic terminal damage and delayed neuronal death in the ischemic gerbil hippocampus. Ishimaru H, et al. **Brain Res Bull** 1997; 43(1):81–5
Effects of systemic administration of 2–(4–phenyl–piperidino)–cyclohexanol (vesamicol) and an organophosphate DDVP on the cholinergic system in brain regions of rats. Kobayashi H, et al. **Brain Res Bull** 1997; 43(1):17–23
Changes in cholinergic neurons and failure in learning function after microsphere embolism–induced cerebral ischemia. Takagi N, et al. **Brain Res Bull** 1997;43(1):87–92
Hypothalamic cholinergic activity and 2–deoxyglucose–induced hyperglycemia. Takahashi A, et al. **Brain Res Bull** 1997;43(1):65–8
Neurogenesis of cholinoceptive neurons in the chick retina. Gardino PF, et al. **Brain Res Dev Brain Res** 1996 Sep 2; 95(2):205–12
192 IgG–saporin lesion of basal forebrain cholinergic neurons in neonatal rats. Pappas BA, et al. **Brain Res Dev Brain Res** 1996 Oct 23;96(1–2):52–61
Pontine cholinergic neurons show Fos–like immunoreactivity associated with cholinergically induced REM sleep. Shiromani PJ, et al. **Brain Res Mol Brain Res** 1996 May; 38(1):77–84
Intestinal phase of human antro–pyloro–duodenal motility: cholinergic and CCK–mediated regulation. Katschinski M, et al. **Eur J Clin Invest** 1996 Jul;26(7):574–83
Rectal response of cardiac origin in the cat: involvement of nitric oxide and acetylcholine. Koley J, et al. **Eur J Pharmacol** 1997 May 1;325(2–3):181–7
The role of brain acetylcholine in GABAA receptor antagonist–induced blood–pressure changes in rat. Tellioğlu T, et al. **Eur J Pharmacol** 1996 Dec 19; 317(2–3):301–7
Synergistic rise in Ca2+ produced by somatostatin and acetylcholine in ciliary body epithelial cells. Xia SL, et al. **Exp Eye Res** 1997 Apr;64(4):627–35
Selective immunolesions of hippocampal cholinergic input fail to impair spatial working memory. McMahan RW, et al. **Hippocampus** 1997;7(2):130–6
Prejunctional regulation by endogenous and exogenous acetylcholine of adrenergic nerve function in isolated canine mesenteric arteries. Zhang JX, et al. **Hypertens Res** 1997 Jun;20(2):119–25
Global effects of fluctuations in neural information processing. Liljenström H. **Int J Neural Syst** 1996 Sep; 7(4):497–505
Effect of brain acetylcholine depletion on bicuculline–induced cardiovascular and locomotor responses. Tellioğlu T, et al. **Int J Neurosci** 1997 Feb; 89(3–4):143–52
Further cholinergic aspects of carotid body chemotransduction of hypoxia in cats. Fitzgerald RS, et al. **J Appl Physiol** 1997 Mar;82(3):819–27
Physostigmine reversal of scopolamine–induced hypofrontality. Prohovnik I, et al. **J Cereb Blood Flow Metab** 1997 Feb;17(2):220–8
Acetylcholine innervation of sensory and motor neocortical areas in adult cat: a choline acetyltransferase immunohistochemical study. Avendaño C, et al. **J Chem Neuroanat** 1996 Aug;11(2):113–30
NGF prevents further atrophy of cholinergic cells of the nucleus basalis due to cortical infarction in adult post–hypothyroid rats but does not restore cell size compared to euthyroid [correction of euthroid] rats. Figueiredo BC, et al. **J Chem Neuroanat** 1996 Nov; 12(1):15–27
Sprouting adult CNS cholinergic axons express NILE and associate with astrocytic surfaces expressing neural cell adhesion molecule. Chalmers GR, et al. **J Comp Neurol** 1996 Jul 22;371(2):287–99
Extensive reinnervation of the hippocampus by embryonic basal forebrain cholinergic neurons grafted into the septum of neonatal rats with selective cholinergic lesions. Leanza G, et al. **J Comp Neurol** 1996 Sep 23;373(3):355–7
Genetic analysis of cholinergic nerve terminal function in invertebrates. Baylis HA, et al. **J Neurocytol** 1996 Dec; 25(12):747–62 (100 ref.)
Glycine current in rat septal cholinergic neuron in culture: monophasic positive modulation by Zn2+. Kumamoto E, et al. **J Neurophysiol** 1996 Jul;76(1):227–41
Progression of M–current inhibition after agonist removal. Villarroel A. **J Neurophysiol** 1996 Jan;75(1):518–21
Facilitation of N–type calcium current is dependent on the frequency of action potential–like depolarizations in dissociated cholinergic basal forebrain neurons of the guinea pig. Williams S, et al. **J Neurosci** 1997 Mar 1; 17(5):1625–32
Inhibition of nitroxidergic nerve function by neurogenic acetylcholine in monkey cerebral arteries. Toda N, et al. **J Physiol (Lond)** 1997 Jan 15;498 (Pt 2):453–61
Cholinergic control of the walking network in the crayfish Procambarus clarkii. Cattaert D, et al. **J Physiol Paris** 1995; 89(4–6):209–20
Nicotinic and muscarinic components in acetylcholine stimulation of porcine adrenal medullary cells. Nassar–Gentina V, et al. **Mol Cell Biochem** 1997 Apr; 169(1–2):107–13
Association of syntaxin with SNAP 25 and VAMP (synaptobrevin) in Torpedo synaptosomes. Shiff G, et al. **Neurochem Int** 1996 Dec;29(6):659–67
Cholinergic–nitrergic interactions in the guinea–pig gastric fundus. Milenov K, et al. **Neuropeptides** 1996 Aug; 30(4):365–71
Intact spatial learning following lesions of basal forebrain cholinergic neurons. Baxter MG, et al. **Neuroreport** 1996 May 31;7(8):1417–20
Persistence of CA1 hippocampal LTP after selective cholinergic denervation. Jouvenceau A, et al. **Neuroreport** 1996 Mar 22;7(4):948–52
The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. Wenk GL, et al. **Neuroreport** 1996 Jun 17;7(9):1453–6
Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Matsukawa M, et al. **Neurosci Lett** 1997 Jul 11;230(1):13–6
Rat fibroblast growth factor receptor–4 mRNA in the brain is preferentially expressed in cholinergic neurons in the medial habenular nucleus. Miyake A, et al. **Neurosci Lett** 1996 Jan 19;203(2):101–4
Effect of cholinergic activation by physostigmine on working memory failure caused in rats by pharmacological manipulation of hippocampal glutamatergic and 5–HTergic neurotransmission. Ohno M, et al. **Neurosci Lett** 1996 Oct 11;217(1):21–4
Effects of cholinergic depletion on experience–dependent plasticity in the cortex of the rat. Baskerville KA, et al. **Neuroscience** 1997 Oct;80(4):1159–69
Increased vulnerability of septal cholinergic neurons to partial loss of target neurons in aged rats. Cooper JD, et al. **Neuroscience** 1996 Nov;75(1):29–35
Cholinergic and GABAergic interneurons in the striatum. Kawaguchi Y, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):87–90
Evaluation of (–)[18F]fluoroethoxybenzovesamicol as a new PET tracer of cholinergic neurons of the heart. DeGrado TR, et al. **Nucl Med Biol** 1994 Feb;21(2):189–95
Cholinergic–androgenic interaction in the regulation of male sexual behavior in rats. Retana–Marquez S, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):373–8
Activity–related modulation of cholinergic transmission. Collier B. **Prog Brain Res** 1996;109:243–9 (41 ref.)
Cholinergic innervation and receptors in the cerebellum. Jaarsma D, et al. **Prog Brain Res** 1997;114:67–96 (113 ref.)
The Otto Loewi Lecture. Loewi's discovery and the XXI century. Karczmar AG. **Prog Brain Res** 1996;109:1–27, xvii (108 ref.)
Presynaptic interactions between acetylcholine and glycine in the human brain. Marchi M, et al. **Prog Brain Res** 1996; 109:225–9 (35 ref.)
The systems–level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. Mesulam MM. **Prog Brain Res** 1996; 109:285–97 (105 ref.)
The ascending basal forebrain cholinergic system. Page KJ, et al. **Prog Brain Res** 1996;107:513–22 (73 ref.)
Immunolesion by 192IgG–saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. Schliebs R, et al. **Prog Brain Res** 1996;109:253–64 (57 ref.)
Cholinergic control in the flocculus cerebellum of the rabbit. van der Steen J, et al. **Prog Brain Res** 1997;114:335–45 (52 ref.)
Role of sensory neuropeptides in PIV–3–infection–induced airway hyperresponsiveness in guinea pigs. Riedel F, et al. **Respiration** 1997;64(3):211–9
Ultrastructural evidence of adrenergic, as well as cholinergic, nerve varicosities in relation to the lamina propria of the human seminiferous tubules during childhood. Prince FP. **Tissue Cell** 1996 Oct;28(5):507–13
Contrast discrimination: a model and a hypothesis concerning the role of cholinergic modulation in contrast perception. Smith AT. **Vis Neurosci** 1996 Sep–Oct;13(5):873–84
[Waking mechanisms: multiple networks in the mesencephalic reticular formation] Jouvet M. **Arch Physiol Biochem** 1996 Oct;104(6):762–9 (26 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

The effect of non–depolarizing neuromuscular blocking agents on the release of acetylcholine from the right atrium of the guinea pig. Manabe N. **Acta Med Okayama** 1997 Feb;51(1):13–8
Release of acetylcholine from the in vitro cat carotid body. Fitzgerald RS, et al. **Adv Exp Med Biol** 1996;410:227–32
Release of acetylcholine from cultured cat and pig glomus cells. Shirahata M, et al. **Adv Exp Med Biol** 1996;410:233–7
Lambert–Eaton myasthenic syndrome: clinical diagnosis, immune–mediated mechanisms, and update on therapies. Sanders DB. **Ann Neurol** 1995 May;37 Suppl 1:S63–73 (58 ref.)
Aconitine, a main component of aconite, increases spontaneous acetylcholine release from the frontal cerebral cortex of freely moving rats. Kimura I, et al. **Biol Pharm Bull** 1996 Nov;19(11):1440–2
Effect of pilocarpine on striatal acetylcholine release in dopamine–depleted rats. Murakami Y, et al. **Biol Pharm Bull** 1997 Jan;20(1):88–90
Effects of ketamine and pentobarbitone on acetylcholine release from the rat frontal cortex in vivo. Kikuchi T, et al. **Br J Anaesth** 1997 Jul;79(1):128–30
Electrically–evoked dopamine and acetylcholine release from rat striatal slices perfused without magnesium: regulation by glutamate acting on NMDA receptors. Jin S, et al. **Br J Pharmacol** 1997 Aug;121(7):1269–76
Characterization of the muscarinic receptor subtype(s) mediating contraction of the guinea–pig lung strip and inhibition of acetylcholine release in the guinea–pig trachea with the selective muscarinic receptor antagonist tripitramine. Roffel AF, et al. **Br J Pharmacol** 1997 Sep; 122(1):133–41
Medial septal injection of naloxone elevates acetylcholine release in the hippocampus and induces behavioral seizures in rats. Mizuno T, et al. **Brain Res** 1996 Mar 25;713(1–2):1–7
Mechanisms controlling neuronal plasticity in somatosensory cortex. Dykes RW. **Can J Physiol Pharmacol** 1997 May; 75(5):535–45 (89 ref.)
Differential effects of an L–type Ca2+ channel antagonist on activity– and phosphorylation–enhanced release of acetylcholine at the neuromuscular junction of the frog in vitro [published erratum appears in Eur J Neurosci 1996 Jun;8(6):1315] Arenson MS, et al. **Eur J Neurosci** 1996 Mar; 8(3):437–45
Cyclosporin A affects functions concerning acetylcholine release of cholinergic Torpedo synaptosomes. Gaudry–Talarmain YM, et al. **Eur J Pharmacol** 1996 Feb 5;296(3):341–5
Mutual dependence of calcitonin–gene related peptide and acetylcholine release in neuromuscular preparations. Kimura I, et al. **Eur J Pharmacol** 1997 Jul 9;330(2–3):123–8
Epithelial modulation of cholinergic responses in rabbit trachea is partly due to neutral endopeptidase activity. Loenders B, et al. **Eur J Pharmacol** 1996 Jan 18; 296(1):89–96
Non–quantal acetylcholine release in the mouse diaphragm after phrenic nerve crush and during recovery. Nikolsky EE, et al. **Exp Physiol** 1996 May;81(3):341–8
GABAergic mechanism in histamine H3 receptor inhibition of K(+)–evoked release of acetylcholine from rat cortex in vivo. Giorgetti M, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S33–4
Modulation of acetylcholine release in the ventral striatum by histamine receptors. Prast H, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S37–8
Muscarinic autoinhibition of acetylcholine release in mouse atria is not transduced through cyclic AMP or protein kinase C. Dawson JJ, et al. **J Auton Pharmacol** 1996 Apr; 16(2):79–85
Impaired synaptic functions with aging as characterized by decreased calcium influx and acetylcholine release. Tanaka Y, et al. **J Neurosci Res** 1996 Jan 1;43(1):63–76
Nonstriatal dopamine D1 receptors regulate striatal acetylcholine release in vivo. Acquas E, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):360–8
Enhancement of acetylcholine release by SA4503, a novel sigma 1 receptor agonist, in the rat brain. Kobayashi T, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):106–13
Adenosine 3',5'–cyclic monophosphate–stimulated Ca++ efflux and acetylcholine release in ileal myenteric plexus are mediated by N–type Ca++ channels: inhibition by the kappa opioid receptor agonist. Kojima Y, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):403–9
Acetylcholine release and choline availability in rat hippocampus: effects of exogenous choline and nicotinamide. Köppen A, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1139–45
Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. Parada MA, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):582–8
Effects of tetrandrine on spontaneous and evoked release of acetylcholine at the mouse neuromuscular junction. Wiegand H, et al. **J Pharmacol Exp Ther** 1996 Nov; 279(2):891–901
Regulation of acetylcholine release by presynaptic nicotinic receptors at developing neuromuscular synapses. Fu WM, et al. **Mol Pharmacol** 1997 Mar;51(3):390–8
Opioid receptor–mediated control of acetylcholine release in human neocortex tissue. Feuerstein TJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):586–92
Modulation of cortical acetylcholine release by serotonin: the role of substance P interneurons. Feuerstein TJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):618–26
Adenosine A2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release. Jin S, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jan;

355(1):48–56
Differences in the prejunctional effects of methacholine and pilocarpine on the release of endogenous acetylcholine from guinea-pig trachea. ten Berge RE, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):606–11
Potentiation of spontaneous acetylcholine release from motor nerve terminals by glutamate in Xenopus tadpoles. Liou HC, et al. **Neuroscience** 1996 Nov;75(1):325–31
Chronic ethanol consumption in rats: correlation between memory performance and hippocampal acetylcholine release in vivo. Melis F, et al. **Neuroscience** 1996 Sep; 74(1):155–9
Roles of synaptotagmin C2 domains in neurotransmitter secretion and inositol high-polyphosphate binding at mammalian cholinergic synapses. Mochida S, et al. **Neuroscience** 1997 Apr;77(4):937–43
Epithelium-dependent inhibition of cholinergic transmission in rat isolated trachea by potassium channel openers. Fabiani ME, et al. **Pharmacol Res** 1996 Apr–May; 33(4–5):261–72
Histamine-evoked acetylcholine release in sensitized tracheal preparation. Barak N, et al. **Respir Physiol** 1997 May; 108(2):181–5
Excitatory prejunctional beta 2-adrenoceptor distribution within equine airway cholinergic nerves. Zhang XY, et al. **Respir Physiol** 1996 Oct;106(1):81–90

THERAPEUTIC USE

Acetylcholine reactivity in the pulmonary artery during cardiac surgery in patients with ischemic or valvular heart disease. Angdin M, et al. **J Cardiothorac Vasc Anesth** 1997 Jun;11(4):458–62

TOXICITY

Airway hyperresponsiveness to acetylcholine induced by aerosolized arachidonic acid metabolites in guinea-pigs. Sato T, et al. **Clin Exp Allergy** 1996 Aug;26(8):957–63
Acetylcholine response in guinea pig outer hair cells. I. Properties of the response. Nenov AP, et al. **Hear Res** 1996 Nov 1;101(1–2):132–48
Acetylcholine response in guinea pig outer hair cells. II. Activation of a small conductance Ca(2+)-activated K+ channel. Nenov AP, et al. **Hear Res** 1996 Nov 1; 101(1–2):149–72

ACETYLCHOLINE AGENTS see **CHOLINERGIC AGENTS**

ACETYLCHOLINE AGONISTS see **CHOLINERGIC AGONISTS**

ACETYLCHOLINE ANTAGONISTS see **CHOLINERGIC ANTAGONISTS**

ACETYLCHOLINE RECEPTORS see **RECEPTORS, CHOLINERGIC**

ACETYLCHOLINESTERASE

Characterization of human erythrocyte membrane-bound acetylcholinesterase inhibition by cisplatin at reversible phase. Kamal MA. **Anticancer Res** 1996 Nov–Dec; 16(6B):3725–30
Reversible inhibition of cholinesterases by opioids: possible pharmacological consequences. Galli A, et al. **J Pharm Pharmacol** 1996 Nov;48(11):1164–8
Detection of antibody classes and subpopulations in myasthenia gravis patients using a new nonradioactive enzyme immunoassay. Gotti C, et al. **Muscle Nerve** 1997 Jul;20(7):800–8
[Acetylcholinesterase from snake venoms] Cousin X, et al. **C R Seances Soc Biol Fil** 1997;191(3):381–400 (78 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Ultrastructural localization of acetylcholinesterase and choline acetyltransferase in oligodendrocytes, glioblasts and vascular endothelial cells in the external cuneate nucleus of the gerbil. Lan CT, et al. **Anat Embryol (Berl)** 1996 Aug;194(2):177–85
Acetylcholinesterase distribution in the central nervous system of the Megalobulimus oblongus (Gastropoda, Pulmonata). Zancan DM, et al. **Arch Anat Histol Embryol** 1993–94;75:75–86
Pregnancy-induced uterine neuronal degeneration in the rat. Haase EB, et al. **Cell Tissue Res** 1997 May;288(2):293–306
CNTF and LIF are not required for the target-directed acquisition of cholinergic and peptidergic properties by sympathetic neurons in vivo. Francis NJ, et al. **Dev Biol** 1997 Feb 1;182(1):76–87
A comparison of behavioural effects and morphological features of grafts rich in cholinergic neurons placed in two sites of the denervated rat hippocampus. Hofferer E, et al. **Exp Brain Res** 1996 Sep;111(2):187–207
Genetic variation in the morphology of the septo-hippocampal cholinergic and GABAergic systems in mice: II. Morpho-behavioral correlations. Schwegler H, et al. **Hippocampus** 1996;6(5):535–45
Expression of amyloid precursor protein mRNA isoforms in rat brain is differentially regulated during postnatal maturation and by cholinergic activity. Apelt J, et al. **Int J Dev Neurosci** 1997 Feb;15(1):95–112
Phenotypic characterisation of respecified visual cortex subsequent to prenatal enucleation in the monkey: development of acetylcholinesterase and cytochrome oxidase patterns. Dehay C, et al. **J Comp Neurol** 1996 Dec 16;376(3):386–402
Cultured basal forebrain cholinergic neurons in contact with cortical cells display synapses, enhanced morphological features, and decreased dependence on nerve growth factor. Ha DH, et al. **J Comp Neurol** 1996 Sep 23; 373(3):451–65
Immunolocalization of muscarinic acetylcholine subtype 2 receptors in rat cochlear nucleus. Yao W, et al. **J Comp Neurol** 1996 Sep 9;373(1):27–40
A simple enzyme histochemical method for the simultaneous demonstration of acetylcholinesterase and monoamine oxidase in fixed-frozen sections. Dunning DD, et al. **J Histochem Cytochem** 1997 Jun;45(6):895–902
Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Iyo M, et al. **Lancet** 1997 Jun 21;349(9068):1805–9
Colocalization of acetylcholinesterase and vasoactive intestinal peptide (VIP) in nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) positive neurons in the intralingual ganglia and perivascular nerve fibers around lingual arteries in the porcine, monkey and canine tongue. Yoshida K, et al. **Neurosci Lett** 1997 Feb 7;222(3):147–50
Alpha-fetoprotein and AChE in early amniocentesis [letter] Eiben B, et al. **Prenat Diagn** 1996 Jan;16(1):87–8
[sensorimotor differentiated reconstruction of peripheral nerves—a methods of intraoperative identification of motor fascicles] Girsch W, et al. **Handchir Mikrochir Plast Chir** 1996 Jul;28(4):181–6 (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS see CHOLINESTERASE INHIBITORS

BIOSYNTHESIS

Immature human megakaryocytes produce nuclear-associated acetylcholinesterase. Lev-Lehman E, et al. **Blood** 1997 May 15;89(10):3644–53
Cholinesterases precede "ON-OFF" channel dichotomy in the embryonic chick retina before onset of synaptogenesis. Layer PG, et al. **Cell Tissue Res** 1997 Jun;288(3):407–16
Amyloid precursor protein fragment and acetylcholinesterase increase with cell confluence and differentiation in a neuronal cell line. Bronfman FC, et al. **Exp Cell Res** 1996 Nov 25;229(1):93–9
Acetylcholinesterase regeneration in mouse CNS studied by a microphotometric method. Taglioni A, et al. **Int J Neurosci** 1996 Dec;88(3–4):175–84
Structure-activity relationships in platelet-activating factor (PAF). 8. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors: anti-acetylcholinesterase activity and comparative SAR. Le Texier L, et al. **J Lipid Mediat Cell Signal** 1996 May; 13(3):207–22
The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. Sberna G, et al. **J Neurochem** 1997 Sep;69(3):1177–84
A globular, not asymmetric, form of acetylcholinesterase is expressed in chick motor neurons: down-regulation toward maturity and after denervation. Tsim KW, et al. **J Neurochem** 1997 Feb;68(2):479–87
A possible role of transient AChE expression in the medial geniculate of developing rats. Okoyama S, et al. **Neuroreport** 1996 Apr 10;7(5):1067–71
Calcitonin gene-related peptide increases the expression of acetylcholinesterase in cultured chick myotubes. Choi RC, et al. **Neurosci Lett** 1996 Oct 18;217(2–3):165–8
Ciliary neurotrophic factor: regulation of acetylcholinesterase in skeletal muscle and distribution of messenger RNA encoding its receptor in synaptic versus extrasynaptic compartments. Boudreau-Larivière C, et al. **Neuroscience** 1996 Jul;73(2):613–22
Transient expression of acetylcholinesterase messenger RNA and enzyme activity in developing rat thalamus studied by quantitative histochemistry and in situ hybridization. Brimijoin S, et al. **Neuroscience** 1996 Mar;71(2):555–65
Application of the nonradioactive in situ hybridization for the localization of acetylcholinesterase mRNA in the central nervous system of the rat; comparison to the radioactive technique. Kreft S, et al. **Pflugers Arch** 1996; 431(6 Suppl 2):R309–10
Cholinergic drug resistance and impaired spatial learning in transgenic mice overexpressing human brain acetylcholinesterase. Andres C, et al. **Prog Brain Res** 1996; 109:265–72
Biosynthesis and integration of acetylcholinesterase in the cholinergic synapse. Massoulié J, et al. **Prog Brain Res** 1996;109:55–65 (69 ref.)
The influence of Pb2+ on expression of acetylcholinesterase and the acetylcholine receptor. Luo ZD, et al. **Toxicol Appl Pharmacol** 1997 Aug;145(2):237–45

BLOOD

Unacceptable "occupational" exposure to toxic agents among children in Ecuador. Harari R, et al. **Am J Ind Med** 1997 Sep;32(3):185–9
Reaction of ozone with enzymes of erythrocyte membranes. Mudd JB, et al. **Arch Biochem Biophys** 1996 Nov 1; 335(1):145–51
Acetylcholinesterase activity of normal and diabetic human erythrocyte membranes: the effect of oxidative agents. Krajewska E, et al. **Biochem Mol Biol Int** 1997 Jun; 42(1):203–10
Decrease in platelet, erythrocyte and lymphocyte acetylcholinesterase activities due to the presence of protease inhibitors in the storage buffer. Martín-Valmaseda EM, et al. **Biochem Mol Biol Int** 1997 Jan;41(1):83–91
Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase. Saxena A, et al. **Biochemistry** 1997 Jun 17;36(24):7481–9
Synthesis and 31P chemical shift identification of tripeptide active site models that represent human serum acetylcholinesterase covalently modified at serine by certain organophosphates. Thompson CM, et al. **Chem Res Toxicol** 1996 Dec;9(8):1325–32
Acetylcholinesterase inhibition in the crayfish Procambarus clarkii exposed to fenitrothion. Escartín E, et al. **Ecotoxicol Environ Saf** 1996 Jul;34(2):160–4
Effect of repeated treatment with pyridostigmine on acetylcholinesterase in mouse muscles. Lintern MC, et al. **Hum Exp Toxicol** 1997 Mar;16(3):158–65
Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues. Yu QS, et al. **J Med Chem** 1997 Aug 29; 40(18):2895–901
Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring. Yuknavage KL, et al. **J Toxicol Environ Health** 1997 May;51(1):35–55
Maintenance of constant blood acetylcholine content before and after feeding in young chimpanzees. Fujii T, et al. **Neurosci Lett** 1997 May 9;227(1):21–4
The preparation and kinetic analysis of multiple forms of human erythrocyte acetylcholinesterase. Kamal MA, et al. **Prep Biochem Biotechnol** 1996 May;26(2):105–19
Comparative kinetic analysis of cholinesterase methods in rat and human erythrocytes and plasma. Dass PD, et al. **Vet Hum Toxicol** 1997 Feb;39(1):11–7

CEREBROSPINAL FLUID

Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease [letter] Sáez-Valero J, et al. **Lancet** 1997 Sep 27;350(9082):929

CHEMISTRY

Differences in the localization of the postsynaptic nitric oxide synthase I and acetylcholinesterase suggest a heterogeneity of neuromuscular junctions in rat and mouse skeletal muscles. Grozdanovic Z, et al. **Acta Histochem** 1997 Mar; 99(1):47–53
Aging of somanyl-acetylcholinesterase adducts: facts and models [letter] Shafferman A, et al. **Biochem J** 1997 Jun 15;324 (Pt 3):996–8
Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase. Saxena A, et al. **Biochemistry** 1997 Jun 17;36(24):7481–9
Unique push-pull mechanism of dealkylation in soman-inhibited cholinesterases. Viragh C, et al. **Biochemistry** 1997 Jul 8;36(27):8243–52
Biochemical properties of acetyl- and butyrylcholinesterase in human meningioma. Sáez-Valero J, et al. **Biochim Biophys Acta** 1996 Dec 16;1317(3):210–8
Acetylcholinesterase: role of the enzyme's charge distribution in steering charged ligands toward the active site. Antosiewicz J, et al. **Biopolymers** 1996 Jul;39(1):85–94
Extracellular and asymmetric forms of acetylcholinesterase are expressed on cholinergic and noncholinergic terminal neuropil of the developing chick retina. Reiss Y, et al. **Cell Tissue Res** 1996 Oct;286(1):13–22
Acetylcholinesterase staining in human auditory and language cortices: regional variation of structural features. Hutsler JJ, et al. **Cereb Cortex** 1996 Mar-Apr;6(2):260–70
Biochemical and molecular characterization of acetylcholinesterase from the hagfish Myxine glutinosa. Sanders M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Sep; 115(1):97–109
Direct determination of the chemical composition of acetylcholinesterase phosphonylation products utilizing electrospray-ionization mass spectrometry. Barak R, et al. **FEBS Lett** 1997 May 5;407(3):347–52
Studies on a new series of THA analogues: effects of the aromatic residues that line the gorge of AChE. Pomponi M, et al. **FEBS Lett** 1997 Jun 9;409(2):155–60
Structural modifications of the omega loop in human acetylcholinesterase. Velan B, et al. **FEBS Lett** 1996 Oct 14;395(1):22–8
Quaternary associations of acetylcholinesterase. I. Oligomeric associations of T subunits with and without the

amino-terminal domain of the collagen tail. Bon S, et al. **J Biol Chem** 1997 Jan 31;272(5):3007-15

Quaternary associations of acetylcholinesterase. II. The polyproline attachment domain of the collagen tail. Bon S, et al. **J Biol Chem** 1997 Jan 31;272(5):3016-21

Hormone-sensitive lipase is structurally related to acetylcholinesterase, bile salt-stimulated lipase, and several fungal lipases. Building of a three-dimensional model for the catalytic domain of hormone-sensitive lipase. Contreras JA, et al. **J Biol Chem** 1996 Dec 6;271(49):31426-30

Electrostatic influence on the kinetics of ligand binding to acetylcholinesterase. Distinctions between active center ligands and fasciculin. Radić Z, et al. **J Biol Chem** 1997 Sep 12;272(37):23265-77

Thermodynamic investigation of camel retina acetylcholinesterase inhibition by cyclophosphamide. al-Jafari AA, et al. **J Enzyme Inhib** 1997 Feb;11(4):275-83

Distribution of acetylcholinesterase in the developing visual cortex of neonatally hemidecorticate rats. Vinette M, et al. **J Hirnforsch** 1996;37(1):91-101

A globular, not asymmetric, form of acetylcholinesterase is expressed in chick motor neurons: down-regulation toward maturity and after denervation. Tsim KW, et al. **J Neurochem** 1997 Feb;68(2):479-87

Molecular forms of acetyl- and butyrylcholinesterase in normal and dystrophic mouse brain. Moral-Naranjo MT, et al. **J Neurosci Res** 1996 Jan 15;43(2):224-34

Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Raves ML, et al. **Nat Struct Biol** 1997 Jan;4(1):57-63

Cholinoceptive neurons without acetylcholinesterase activity and enzyme-positive neurons without cholinergic synaptic innervation are present in the main olfactory bulb of adult rat. Kasa P, et al. **Neuroscience** 1996 Aug;73(3):831-44

Molecular forms of tegumental and muscle acetylcholinesterases of Schistosoma. Camacho M, et al. **Parasitology** 1996 Feb;112 (Pt 2):199-204

Allosteric effects of phenyltrimethylammonium and propidium on acetylcholinesterase active site. Stalc A, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R277-8

Two partially unfolded states of Torpedo californica acetylcholinesterase. Kreimer DI, et al. **Protein Sci** 1996 Sep;5(9):1852-64

Molecular mechanic study of nerve agent O-ethyl S-[2-(diisopropylamino)ethyl]methylphosphonothioate (VX) bound to the active site of Torpedo californica acetylcholinesterase. Albaret C, et al. **Proteins** 1997 Aug; 28(4):543-55

DEFICIENCY

Treatment of congenital endplate acetylcholinesterase deficiency by neuromuscular blockade. Breningstall GN, et al. **J Child Neurol** 1996 Jul;11(4):345-6

DRUG EFFECTS

Linkage of acetylcholinesterase insensitivity to methyl parathion resistance in Heliothis virescens. Gilbert RD, et al. **Biochem Genet** 1996 Aug;34(7-8):297-312

A self-consistent mechanism for dealkylation in soman-inhibited acetylcholinesterase [letter] Kovach IM, et al. **Biochem J** 1997 Jun 15;324 (Pt 3):995-6

Effect of sevin on kinetic parameters of camel retina acetylcholinesterase. Kamal MA. **Biochem Mol Biol Int** 1997 Jun;42(2):235-46

Decrease in platelet, erythrocyte and lymphocyte acetylcholinesterase activities due to the presence of protease inhibitors in the storage buffer. Martín-Valmaseda EM, et al. **Biochem Mol Biol Int** 1997 Jan;41(1):83-91

The interaction between methylene blue and the cholinergic system. Pfaffendorf M, et al. **Br J Pharmacol** 1997 Sep; 122(1):95-8

Malathion as a model for the enzymatic hydrolysis of the neurotoxic agent, VX. Hoskin FCG, et al. **Bull Environ Contam Toxicol** 1997 Jul;59(1):9-13

Toxic effects of sewage sludges on freshwater edible fish Cirrhina mrigala. Pereira L, et al. **Bull Environ Contam Toxicol** 1996 Mar;56(3):467-74

Action of the herbicide butachlor on cholinesterases in the freshwater snail Pila globosa (Swainson). Rajyalakshmi T, et al. **Drug Chem Toxicol** 1996 Nov;19(4):325-31

Inhibition of acetylcholine esterase and choline esterase by benzethonium chloride and avoidance of the benzethonium chloride carry-over inhibitory effect. Zaman Z, et al. **Eur J Clin Chem Clin Biochem** 1997 Aug;35(8):603-7

Studies on a new series of THA analogues: effects of the aromatic residues that line the gorge of AChE. Pomponi M, et al. **FEBS Lett** 1997 Jun 9;409(2):155-60

Effects of pyridostigmine on acetylcholinesterase in different muscles of the mouse. Lintern MC, et al. **Hum Exp Toxicol** 1997 Jan;16(1):18-24

2, 4-dichloro phenoxy acetic acid alters monoamine levels, acetylcholinesterase activity & operant learning in rats. Lakshmana MK, et al. **Indian J Med Res** 1996 Sep; 104:234-9

Kinetics of the inhibition of acetylcholinesterase from desert cobra (Walterinnesia aegyptia) venom by local anesthetics: procaine and tetracaine. al-Jafari AA, et al. **J Enzyme Inhib** 1996 Oct;11(2):123-34

Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. Cho SJ, et al. **J Med Chem** 1996 Dec 20;39(26):5064-71

The nature of the inhibition of camel retina acetylcholinesterase (EC 3.1.1.7) activity by tetrahydroaminoacridine. al-Jafari AA. **J Ocul Pharmacol Ther** 1996 Winter;12(4):503-14

Kinetics for camel (Camelus dromedarius) retina acetylcholinesterase inhibition by methotrexate in vitro. al-Jafari A, et al. **Jpn J Pharmacol** 1996 Sep;72(1):49-55

In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate. Kamal MA, et al. **Mol Cell Biochem** 1996 Jun 7;159(1):47-53

Kinetic analysis of the in vitro inhibition, aging, and reactivation of brain acetylcholinesterase from rat and channel catfish by paraoxon and chlorpyrifos-oxon. Carr RL, et al. **Toxicol Appl Pharmacol** 1996 Aug;139(2):365-73

The influence of Pb2+ on expression of acetylcholinesterase and the acetylcholine receptor. Luo ZD, et al. **Toxicol Appl Pharmacol** 1997 Aug;145(2):237-45

Inhibition of neurotoxic esterase in vitro by novel carbamates. Randall JC, et al. **Toxicol Appl Pharmacol** 1997 Mar; 143(1):173-8

The inhibitory effect of the neuromuscular blocking agent, gallamine triethiodide, on camel retina acetylcholinesterase activity. Al-Jafari AA. **Toxicol Lett** 1997 Jan 15; 90(1):45-51

[The inhibition of synaptic acetylcholinesterase by postsynaptic muscle relaxants] Danilov AF, et al. **Eksp Klin Farmakol** 1997 Jan-Feb;60(1):25-7 (Eng. Abstr.) **(Rus)**

GENETICS

Duplication of the Ace.1 locus in Culex pipiens mosquitoes from the Caribbean. Bourguet D, et al. **Biochem Genet** 1996 Oct;34(9-10):351-62

Sequence comparison of ACE-1, the gene encoding acetylcholinesterase of class A, in the two nematodes Caenorhabditis elegans and Caenorhabditis briggsae. Grauso M, et al. **DNA Seq** 1996;6(4):217-27

Transient expression of acetylcholinesterase messenger RNA and enzyme activity in developing rat thalamus studied by quantitative histochemistry and in situ hybridization. Brimijoin S, et al. **Neuroscience** 1996 Mar;71(2):555-65

Acetylcholinesterase-transgenic mice display embryonic modulations in spinal cord choline acetyltransferase and neurexin Ibeta gene expression followed by late-onset neuromotor deterioration. Andres C, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8173-8

Cholinergic drug resistance and impaired spatial learning in transgenic mice overexpressing human brain acetylcholinesterase. Andres C, et al. **Prog Brain Res** 1996; 109:265-72

Probing accessible sites for ribozymes on human acetylcholinesterase RNA. Birikh KR, et al. **RNA** 1997 Apr;3(4):429-37

IMMUNOLOGY

Autoimmunity and ALS: studies on antibodies to acetylcholinesterase in sera. Häggström B, et al. **Acta Neurol Scand** 1997 Feb;95(2):111-4

A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Reyes AE, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):652-5

Clinically insignificant (natural) autoantibodies against acetyl cholinesterase in the sera of patients with a variety of neurologic, muscular and autoimmune diseases. Lidar T, et al. **Immunol Lett** 1997 Feb;55(2):79-84

ISOLATION & PURIFICATION

Purification and characterization of acetylcholinesterase from desert cobra (Walterinnesia aegyptia) venom. Duhaiman AS, et al. **Biochimie** 1996;78(1):46-50

Computer aided data acquisition and analysis of acetlycholinesterase velocity sedimentation profiles. Ribarič S, et al. **Comput Methods Programs Biomed** 1996 Mar;49(2):149-56

Detection of an anatoxin-a(s)-like anticholinesterase in natural blooms and cultures of cyanobacteria/blue-green algae from Danish lakes and in the stomach contents of poisoned birds. Henriksen P, et al. **Toxicon** 1997 Jun; 35(6):901-13

[Purification of acetylcholinesterase from human erythrocytes using metal-chelate affinity chromatography] Il'ina AV, et al. **Prikl Biokhim Mikrobiol** 1996 Jul-Aug; 32(4):389-92 (Eng. Abstr.) **(Rus)**

METABOLISM

Acetylcholinesterase and choline uptake in striatum from rats with varying sleeping times. Chumakova OV, et al. **Alcohol Alcohol** 1996 Mar;31(2):217-20

Faint and positive amniotic fluid acetylcholinesterase with a normal sonogram. Brown CL, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1000-3

Fast and slow skeletal muscles express a common basic profile of acetylcholinesterase molecular forms. Boudreau-Larivière C, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):C68-76

Effects of protein-energy malnutrition on muscarinic receptor density and acetylcholinesterase activity in rat brain. Viana GS, et al. **Ann Nutr Metab** 1997;41(1):52-9

Interspecies variation of "B" esterases in birds: the influence of size and feeding habits. Fossi MC, et al. **Arch Environ Contam Toxicol** 1996 Nov;31(4):525-32

Influence of methyl parathion on gametogenic and acetylcholinesterase activity in the testis of whitethroated munia (Lonchura malabarica). Maitra SK, et al. **Arch Environ Contam Toxicol** 1996 Mar;30(3):384-9

Reactivation by various oximes of human erythrocyte acetylcholinesterase inhibited by different organophosphorus compounds. Worek F, et al. **Arch Toxicol** 1996;70(8):497-503

Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. Mimori Y, et al. **Behav Brain Res** 1997 Feb; 83(1-2):25-30

Chronic stimulation increases acetylcholinesterase activity in old Aplysia. Peretz B, et al. **Behav Brain Res** 1996 Oct; 80(1-2):203-10

Polycyclic aromatic hydrocarbons inhibit the activity of acetylcholinesterase purified from electric eel. Kang JJ, et al. **Biochem Biophys Res Commun** 1997 Sep 18; 238(2):367-9

A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Reyes AE, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):652-5

Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre. Shafferman A, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):833-40

Investigation of the effect of tetrahydroaminoacridine on turnover kinetics of camel (Camelus dromedarius) retina acetylcholinesterase. al-Jafari AA, et al. **Biochem Mol Biol Int** 1996 Aug;39(5):917-22

Investigation of the effect of anti-neoplastic drugs, cyclophosphamide, cisplatin and methotrexate on the turnover kinetics of human erythrocyte acetylcholinesterase. Kamal MA, et al. **Biochem Mol Biol Int** 1996 May;39(2):293-302

Mutant acetylcholinesterases as potential detoxification agents for organophosphate poisoning. Saxena A, et al. **Biochem Pharmacol** 1997 Jul 15;54(2):269-74

Unique push-pull mechanism of dealkylation in soman-inhibited cholinesterases. Viragh C, et al. **Biochemistry** 1997 Jul 8;36(27):8243-52

Acetylcholinesterases from Elapidae snake venoms: biochemical, immunological and enzymatic characterization. Frobert Y, et al. **Biochim Biophys Acta** 1997 May 23;1339(2):253-67

Kinetic characterization of all steps of the interaction between acetylcholinesterase and eserine. Stojan J, et al. **Biochim Biophys Acta** 1997 Jan 4;1337(1):75-84

Acetylcholinesterase: role of the enzyme's charge distribution in steering charged ligands toward the active site. Antosiewicz J, et al. **Biopolymers** 1996 Jul;39(1):85-94

A segmental map of architectonic subdivisions in the diencephalon of the frog Rana perezi: acetylcholinesterase-histochemical observations. Puelles L, et al. **Brain Behav Evol** 1996;47(6):279-310

Transient decrease of acetylcholinesterase in ventral horn neurons caudal to a low thoracic spinal cord hemisection in the adult rat. Nacimiento W, et al. **Brain Res** 1996 Apr 1;714(1-2):177-84

Two peptides derived from the nerve growth factor precursor enhance cholinergic enzyme activities in vivo. Clos J, et al. **Brain Res Dev Brain Res** 1997 Apr 18; 99(2):267-70

Acetylcholinesterase activity in juveniles of Daphnia magna Straus. Guilhermino L, et al. **Bull Environ Contam Toxicol** 1996 Dec;57(6):979-85

Use of acetylcholinesterase in Perna perna and Mytilus galloprovincialis as a biomarker of pollution in Agadir Marine Bay (South of Morocco). Najimi S, et al. **Bull Environ Contam Toxicol** 1997 Jun;58(6):901-8

Acetylcholinesterase activity of synaptic plasma membranes during ageing: effect of L-acetylcarnitine. Gorini A, et al. **Dementia** 1996 May-Jun;7(3):147-54

Schwann cells modify expression of acetylcholinesterase and butyrylcholinesterase at rat neuromuscular junctions. Chapron J, et al. **Eur J Neurosci** 1997 Feb;9(2):260-70

Acetylcholinesterase (ACE) staining shows the abnormal innervation of a pulled-through rectum in a case of repaired anorectal malformation. Shono T, et al. **Eur J Pediatr Surg** 1997 Aug;7(4):248-51

Direct determination of the chemical composition of acetylcholinesterase phosphonylation products utilizing electrospray-ionization mass spectrometry. Barak R, et al. **FEBS Lett** 1997 May 5;407(3):347-52

Cholinesterases from the common oyster (Crassostrea gigas). Evidence for the presence of a soluble acetylcholinesterase insensitive to organophosphate and carbamate inhibitors. Bocquene G, et al. **FEBS Lett** 1997 May 5;407(3):261-6

New substrates of acetylcholinesterase. Naveh M, et al. **FEBS Lett** 1981 Nov 2;134(1):53-6

Cholinesterase activity in pig airways and epithelial cells. Taisne C, et al. **Fundam Clin Pharmacol** 1997;11(3):201-5

Changes in cholinesterase activities after daunorubicin administration to rabbits. Geršl V, et al. **Hum Exp Toxicol** 1996 Oct;15(10):834-8

Changes in phospholipids and acetylcholinesterase during early phase of injury to spinal cord--an experimental study in rats. Cherian L, et al. **Indian J Physiol Pharmacol** 1996 Apr;40(2):134-8

ACETYLCHOLINESTERASE

Acetylcholinesterase histochemistry and functional characterization of the muscarinic receptor mediating the contraction of the bovine oesophageal groove. Barahona MV, et al. **J Auton Pharmacol** 1997 Apr;17(2):77–86

Maturational differences in chlorpyrifos–oxonase activity may contribute to age–related sensitivity to chlorpyrifos. Mortensen SR, et al. **J Biochem Toxicol** 1996;11(6):279–87

The effect of high and low dosages of paraoxon in beta–naphthoflavone–treated rats. Watson AM, et al. **J Biochem Toxicol** 1996;11(6):263–8

The mammalian gene of acetylcholinesterase–associated collagen. Krejci E, et al. **J Biol Chem** 1997 Sep 5; 272(36):22840–7

Electrostatic influence on the kinetics of ligand binding to acetylcholinesterase. Distinctions between active center ligands and fasciculin. Radić Z, et al. **J Biol Chem** 1997 Sep 12;272(37):23265–77

Transplantation of quail collagen–tailed acetylcholinesterase molecules onto the frog neuromuscular synapse. Rotundo RL, et al. **J Cell Biol** 1997 Jan 27;136(2):367–74

Evolution of morphological and histochemical changes in the adult cat cuneate nucleus following forelimb denervation. Avendaño C, et al. **J Comp Neurol** 1996 Jul 8;370(4):479–90

Distribution of choline acetyltransferase and acetylcholinesterase in vocal control nuclei of the budgerigar (Melopsittacus undulatus). Cookson KK, et al. **J Comp Neurol** 1996 May 27;369(2):220–35

An insensitive acetylcholinesterase in Culex pipiens (Diptera:Culicidae) from Portugal. Bourguet D, et al. **J Econ Entomol** 1996 Oct;89(5):1060–6

Kinetics of the inhibition of acetylcholinesterase from desert cobra (Walterinnesia aegyptia) venom by local anesthetics: procaine and tetracaine. al–Jafari AA, et al. **J Enzyme Inhib** 1996 Oct;11(2):123–34

Thermodynamic investigation of camel retina acetylcholinesterase inhibition by cyclophosphamide. al–Jafari AA, et al. **J Enzyme Inhib** 1997 Feb;11(4):275–83

Inhibitory action of the defensive discharge of the grasshopper, Poecilocerus pictus, on certain enzymes in the lizard, Calotes nemoricola. Sreenivasulu Y, et al. **J Enzyme Inhib** 1996 Oct;11(2):135–40

Two cholinesterase activities and genes are present in amphioxus. Sutherland D, et al. **J Exp Zool** 1997 Feb 15; 277(3):213–29

Synthesis and study of thiocarbonate derivatives of choline as potential inhibitors of acetylcholinesterase. Boyle NA, et al. **J Med Chem** 1997 Sep 12;40(19):3009–13

The simulated binding of (+/–)–2,3–dihydro–5,6–dimethoxy–2–[[1–(phenylmethyl)–4–piperidinyl]meth yl] –1H–inden–1–one hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and corresponding structure–activity analyses. Inoue A, et al. **J Med Chem** 1996 Oct 25; 39(22):4460–70

Existence of two acetylcholinesterases in the mosquito Culex pipiens (Diptera:Culicidae). Bourguet D, et al. **J Neurochem** 1996 Nov;67(5):2115–23

Acetylcholinesterase inhibitor treatment delays recovery from axotomy in cultured dorsal root ganglion neurons. Dupree JL, et al. **J Neurocytol** 1996 Aug;25(8):439–54

Glycine effects on glutamate–receptor elicited acetylcholinesterase release from slices and synaptosomes of the spinal ventral horn. Rodríguez–Ithurralde D, et al. **J Neurol Sci** 1996 Aug;139 Suppl:76–82

Reduced acetylcholinesterase (AChE) activity in adrenal medulla and loss of sympathetic preganglionic neurons in TrkA–deficient, but not TrkB–deficient, mice. Schober A, et al. **J Neurosci** 1997 Feb 1;17(3):891–903

Injection of dye into neurones in rat and human post–mortem brain, in combination with acetylcholinesterase histochemistry: permanent preparations. Loopuijt LD, et al. **J Neurosci Methods** 1997 Aug 22;75(2):161–9

Specific impulse patterns regulate acetylcholinesterase activity in skeletal muscles of rats and rabbits. Sketelj J, et al. **J Neurosci Res** 1997 Jan 1;47(1):49–57

Alteration of complex IV and acetylcholine–related enzymes in experimental spinal cord injury. Brambilla G, et al. **J Neurosurg Sci** 1996 Sep–Dec;40(3–4):213–9

Acetyl cholinesterase is expressed in the follicular dendritic cells of germinal centres: differences between normal and neoplastic follicles. Lampert IA, et al. **J Pathol** 1996 Oct; 180(2):169–74

Acetylcholinesterase activity changes in medial vestibular complex after hemilabyrinthectomy in the rat. Torte–Hoba MP, et al. **J Vestib Res** 1996 Mar–Apr;6(2):61–70

Interactions of oxime reactivators with diethylphosphoryl adducts of human acetylcholinesterase and its mutant derivatives. Grosfeld H, et al. **Mol Pharmacol** 1996 Sep; 50(3):639–49

Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta–peptide into Alzheimer's filaments [news] Inestrosa NC, et al. **Mol Psychiatry** 1996 Nov;1(5):359–61

Enhanced acetylcholinesterase in chronic subdural hematomas. Shiraishi K. **Nagoya J Med Sci** 1997 Mar; 60(1–2):43–8

Effect of hypocholinergic activity on the immunoreactivity of beta–amyloid precursor protein in the central nervous system. Kása P, et al. **Neurobiology (Bp)** 1996;4(1–2):119–21

Neuropathologic changes in the olfactory bulb in Alzheimer's disease. Kovács I, et al. **Neurobiology (Bp)** 1996; 4(1–2):123–6

The spontaneous release of acetylcholinesterase in rat substantia nigra is altered by local changes in extracellular levels of dopamine. Dally JJ, et al. **Neurochem Int** 1996 Dec;29(6):629–35

Systemic administration of defined extracts from Withania somnifera (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. Schliebs R, et al. **Neurochem Int** 1997 Feb; 30(2):181–90

Increased acetylcholinesterase activity in selected regions of rat brain after chronic (–)–deprenyl administration. Lakshmana MK, et al. **Neurochem Res** 1996 Oct; 21(10):1209–12

Differential release of acetylcholinesterase in vivo, from the guinea pig substantia nigra compared to the caudate putamen following dopamine depletion. Dally JJ, et al. **Neuropharmacology** 1996 May;35(5):579–87

The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Giacobini E, et al. **Neuropharmacology** 1996 Feb;35(2):205–11

Mouse G2–GPI AChE is processed as a membrane–bound ectoenzyme in transfected mouse sarcoma cells but is not a homophilic adhesion molecule. Guenneugues M, et al. **Neurosci Lett** 1996 May 24;210(1):17–20

Effects of nerve growth factor on acetylcholinesterase activity of the proximal stump of the transected sciatic nerve. Baykal S, et al. **Neurosurg Rev** 1997;20(2):124–7

Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo. Irie T, et al. **Nucl Med Biol** 1994 Aug;21(6):801–8

Comparison of neuropeptide Y, protein gene product 9.5, and acetylcholinesterase in the diagnosis of Hirschsprung's disease. Galvis DA, et al. **Pediatr Pathol Lab Med** 1997 May–Jun;17(3):413–25

Singlet oxygen–mediated inactivation of acetylcholinesterase: a comparison of purified enzyme in solution and enzyme bound to K562 leukemia cells. Deadwyler G, et al. **Photochem Photobiol** 1997 May;65(5):884–94

Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa. Park CH, et al. **Planta Med** 1996 Oct;62(5):405–9

Amyloid beta–protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Pedersen WA, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8068–71

Membrane–promoted unfolding of acetylcholinesterase: a possible mechanism for insertion into the lipid bilayer. Shin I, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):2848–52

Immunolesion by 192IgG–saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. Schliebs R, et al. **Prog Brain Res** 1996;109:253–64 (57 ref.)

Relative potencies of the four stereoisomers of isomalathion for inhibition of hen brain acetylcholinesterase and neurotoxic esterase in vitro. Jianmongkol S, et al. **Toxicol Appl Pharmacol** 1996 Aug;139(2):342–8

Effect of fasciculin on hydrolysis of neutral and choline esters by butyrylcholinesterase, cobra venom and chicken acetylcholinesterases. Durán R, et al. **Toxicon** 1996 Aug; 34(8):959–63

Characterization of acetylcholinesterase secreted by the trichostrongyle nematode parasites of ruminants. Mallet S, et al. **Vet Res** 1997 May–Jun;28(3):287–93

[Effect of Chinese herbal medicine of tonifying kidney on M–cholinergic receptor and acetylcholinesterase activity in dementia mimetic mice] Mo Q, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Feb; 16(2):99–101 (Eng. Abstr.) **(Chi)**

[Sexual features of acetylcholinesterase activity distribution in the dorsal vagal nucleus of newborn rats] Akmaev IG, et al. **Biull Eksp Biol Med** 1996 May;121(5):594–6 **(Rus)**

[AChE–positive neurons in the mammalian stellate ganglion] Nozdrachev AD, et al. **Fiziol Zh Im I M Sechenova** 1995 Oct;81(10):32–5 (Eng. Abstr.) **(Rus)**

[Diagnosis and surgical treatment of distal congenital intestinal aganglionosis in children] Iudin AA. **Khirurgiia (Mosk)** 1996;(4):40–2 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Involvement of the NMDA receptor in a non–cholinergic action of acetylcholinesterase in guinea–pig substantia nigra pars compacta neurons. Webb CP, et al. **Eur J Neurosci** 1996 Apr;8(4):837–41

Non–cholinergic, trophic action of recombinant acetylcholinesterase on mid–brain dopaminergic neurons. Holmes C, et al. **J Neurosci Res** 1997 Jul 15;49(2):207–18

Analysis of molecular forms and pharmacological properties of acetylcholinesterase in several mosquito species. Bourguet D, et al. **Neurochem Int** 1997 Jul;31(1):65–72

Acetylcholinesterase promotes regeneration of neurites in cultured adult neurons of Aplysia. Srivatsan M, et al. **Neuroscience** 1997 Apr;77(3):921–31

Comparison of the behavioural effects of infusion of carbachol and acetylcholinesterase into the rat substantia nigra. Hawkins CA, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):67–80

PHYSIOLOGY

Effect of acetylcholinesterase inhibition on behavior is age–dependent in freely moving Aplysia. Srivatsan M, et al. **Behav Brain Res** 1996 May;77(1–2):115–24

Manipulation of the cholinergic system. Geroldi C, et al. **Funct Neurol** 1997 May–Aug;12(3–4):187–91 (23 ref.)

Acetylcholinesterase activity as a marker of maturation of the basolateral complex of the amygdaloid body in the rat. Berdel B, et al. **Int J Dev Neurosci** 1996 Aug;14(5):543–9

Acetylcholinesterase promotes regeneration of neurites in cultured adult neurons of Aplysia. Srivatsan M, et al. **Neuroscience** 1997 Apr;77(3):921–31

SECRETION

Why do some nematode parasites of the alimentary tract secrete acetylcholinesterase? Lee DL. **Int J Parasitol** 1996 May;26(5):499–508 (91 ref.)

ACETYLCHOLINESTERASE INHIBITORS see **CHOLINESTERASE INHIBITORS**

ACETYLCYSTEINE

ADMINISTRATION & DOSAGE

Reduction of ischemia–reperfusion syndrome after abdominal aortic aneurysmectomy by N–acetylcysteine but not mannitol. Kretzschmar M, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):657–64

N–acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. Wiklund O, et al. **Atherosclerosis** 1996 Jan 5;119(1):99–106

N–acetylcysteine infusion in viral myocarditis: a case report. Rowbotham DS, et al. **Int J Cardiol** 1997 Aug 8;60(3):315–6

[Modification of ischemia–/ reperfusion damage after liver transplantation by N–acetylcysteine. Results of the Heidelberg pilot study] Thies JC, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:531–4 **(Ger)**

ADVERSE EFFECTS

Angioedema with oral N–acetylcysteine [letter] Mroz LS, et al. **Ann Emerg Med** 1997 Aug;30(2):240–1

Adverse reactions to N–acetylcysteine in Inuit to paracetamol (acetaminophen) overdose. Nielsen PT, et al. **Arctic Med Res** 1996 Oct;55(4):204–5

Status epilepticus following intravenous N–acetylcysteine therapy. Hershkovitz E, et al. **Isr J Med Sci** 1996 Nov; 32(11):1102–4

Dilution of intravenous N–acetylcysteine as a cause of hyponatremia. Sung L, et al. **Pediatrics** 1997 Sep;100(3 Pt 1):389–91

ANALOGS & DERIVATIVES

Urinary excretion of specific mercapturic acids in workers exposed to styrene. Ghittori S, et al. **Am J Ind Med** 1997 May;31(5):636–44

Urinary mercapturic acid diastereoisomers in rats subchronically exposed to styrene and ethanol. Coccini T, et al. **Arch Toxicol** 1996;70(11):736–41

Urinary excretion of N–acetyl–S–allyl–L–cysteine upon garlic consumption by human volunteers. de Rooij BM, et al. **Arch Toxicol** 1996;70(10):635–9

In vitro comparative assessment of the antioxidant activity of nacystelyn against three reactive oxygen species. Vanderbist F, et al. **Arzneimittelforschung** 1996 Aug; 46(8):783–8

Proteasome–dependent regulation of p21WAF1/CIP1 expression. Vilagosklonny MV, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):564–9

Lactacystin increases LDL receptor level on HepG2 cells. Miura H, et al. **Biochem Biophys Res Commun** 1996 Oct 23;227(3):684–7

Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A–like enzyme. Ostrowska H, et al. **Biochem Biophys Res Commun** 1997 May 29;234(3):729–32

On the mechanism of the inhibition of transducin function by farnesylcysteine analogs. Parish CA, et al. **Biochemistry** 1997 Mar 4;36(9):2686–93

Isolation and characterization of N–acetyl–S–[2–carboxy–1–(1 H–imidazol–4–yl) ethyl]–L–cysteine, a new metabolite of histidine, from normal human urine and its formation from S–[2–carboxy–1–(1 H–imidazol–4–yl) ethyl]–L–cysteine. Kinuta M, et al. **Biochim Biophys Acta** 1996 Oct 24; 1291(2):131–7

Apoptosis of Ewing's sarcoma cells is accompanied by accumulation of ubiquitinated proteins. Soldatenkov VA, et al. **Cancer Res** 1997 Sep 15;57(18):3881–5

Synthesis and characterization of m– and p–methylbenzyl–mercapturic acids derived from m– and p–xylenes. Tanaka M, et al. **Chemosphere** 1997 Jun; 34(12):2519–23

N–acetyl–S–(1,2,2–trichlorovinyl)–L–cysteine and 2,2,2–trichloroethanol: two novel metabolites of tetrachloroethene in humans after occupational exposure. Birner G, et al. **Drug Metab Dispos** 1996 Jan;24(1):41–8

Suitability of S–phenyl mercapturic acid and trans–trans–muconic acid as biomarkers for exposure to low concentrations of benzene. Boogaard PJ, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1151–7

The proteasome–specific inhibitor lactacystin blocks

presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Cerundolo V, et al. **Eur J Immunol** 1997 Jan;27(1):336–41

N–acetyl–S–(dichlorophenyl)cysteines as suitable biomarkers for the monitoring of occupational exposure to 1,2–dichlorobenzene. Zenser LP, et al. **Int Arch Occup Environ Health** 1997;69(4):252–4

Lactacystin and clasto–lactacystin beta–lactone modify multiple proteasome beta–subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. Craiu A, et al. **J Biol Chem** 1997 May 16;272(20):13437–45

Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. Dick LR, et al. **J Biol Chem** 1997 Jan 3;272(1):182–8

Identification and quantitative determination of 3–chloro–2–hydroxypropylmercapturic acid and alpha–chlorohydrin in urine of rats treated with epichlorohydrin. De Rooij BM, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25;685(2):241–50

Determination of urinary mercapturic acids of styrene in man by high–performance liquid chromatography with fluorescence detection. Maestri L, et al. **J Chromatogr B Biomed Appl** 1996 Dec 13;687(2):387–94

Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors. Fujita K, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):619–25

The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)–dependent and TAP–independent peptide epitopes by class I molecules. Bai A, et al. **J Immunol** 1997 Sep 1;159(5):2139–46

Chemopreventive effects of S–(N,N–diethyldithiocarbamoyl)–N–acetyl–L–cysteine against benzo[a]pyrene. Lee BH, et al. **Mutat Res** 1997 Jul 3;377(2):167–75

Transcriptional squelching by ectopic expression of E2F–1 and p53 is alleviated by proteasome inhibitors MG–132 and lactacystin. Magae J, et al. **Oncogene** 1997 Aug 14; 15(7):759–69

Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase. Dasgupta B, et al. **Pediatr Pulmonol** 1996 Sep;22(3):161–6

Side reaction of S–to–N acetamidomethyl shift during disulfide bond formation by iodine oxidation of S–acetamidomethyl–cysteine in a glutamine–containing peptide. Lamthanh H, et al. **Pept Res** 1995 Nov–Dec; 8(6):316–20

Disappearance and sex–dependent excretion of S–pentachlorophenyl–N–acetyl–L–cysteine in the rat. To–Figueras J, et al. **Pharmacol Toxicol** 1995 Dec; 77(6):412–3

A comparison of a new mucolytic N–acetylcysteine L–lysinate with N–acetylcysteine: airway epithelial function and mucus changes in dog. Tomkiewicz RP, et al. **Pulm Pharmacol** 1995 Dec;8(6):259–65

Nacystelyn, a novel lysine salt of N–acetylcysteine, to augment cellular antioxidant defence in vitro. Gillissen A, et al. **Respir Med** 1997 Mar;91(3):159–68

Biological monitoring of exposure to benzene in the production of benzene and in a cokery. Kivistö H, et al. **Sci Total Environ** 1997 Jun 20;199(1–2):49–63

Excretion of N–acetyl–S–(1–phenyl–2–hydroxyethyl)–cysteine and N–acetyl–S–(2–phenyl–2–hydroxyethyl)–cysteine in workers exposed to styrene. Maestri L, et al. **Sci Total Environ** 1997 Jun 20;199(1–2):13–22

Studies on the basis for the toxicity of acrolein mercapturates. Ramu K, et al. **Toxicol Appl Pharmacol** 1996 Oct; 140(2):487–98

[New perspectives of antioxidant therapy with thiols: nacystelyn] Gillissen A. **Pneumologie** 1996 Dec;50 Suppl 3:834–7 (31 ref.) **(Ger)**

ANALYSIS

Determination of glutathione, cysteine and N–acetylcysteine in rabbit eye tissues using high–performance liquid chromatography and post–column derivatization with 5,5'–dithiobis(2–nitrobenzoic acid). Nozal MJ, et al. **J Chromatogr A** 1997 Aug 22;778(1–2):347–53

High–performance liquid chromatography assay for N–acetylcysteine in biological samples following derivatization with N–(1–pyrenyl)maleimide. Ercal N, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25;685(2):329–34

BLOOD

Placental transfer of N–acetylcysteine following human maternal acetaminophen toxicity. Horowitz RS, et al. **J Toxicol Clin Toxicol** 1997;35(5):447–51

CHEMICAL SYNTHESIS

Synthesis and characterization of m– and p–methylbenzyl–mercapturic acids derived from m– and p–xylenes. Tanaka M, et al. **Chemosphere** 1997 Jun; 34(12):2519–23

Synthesis of N–acetylcysteine conjugates of catechol estrogens. Suzuki E, et al. **Steroids** 1996 May;61(5):296–301

CHEMISTRY

Stability of acetylcysteine in an extemporaneously compounded ophthalmic solution. Anaizi NH, et al. **Am J Health Syst Pharm** 1997 Mar 1;54(5):549–53

Sulfoxidation of mercapturic acids derived from tri– and tetrachloroethene by cytochromes P450 3A: a bioactivation reaction in addition to deacetylation and cysteine conjugate beta–lyase mediated cleavage. Werner M, et al. **Chem Res Toxicol** 1996 Jan–Feb;9(1):41–9

IMMUNOLOGY

N–acetylcysteine and alpha–tocopherol reverse the inflammatory response in activated rat Kupffer cells. Fox ES, et al. **J Immunol** 1997 Jun 1;158(11):5418–23

Albumin nitrosylated by activated macrophages possesses antiparasitic effects neutralized by anti–NO–acetylated–cysteine antibodies. Mnaimneh S, et al. **J Immunol** 1997 Jan 1;158(1):308–14

[Anaphylactic reaction to N–acetylcysteine after poisoning with paracetamol] Stavem K. **Tidsskr Nor Laegeforen** 1997 May 30;117(14):2038–9 (Eng. Abstr.) **(Nor)**

METABOLISM

MOAT4, a novel multispecific organic–anion transporter for glucuronides and mercapturates in mouse L1210 cells and human erythrocytes. Saxena M, et al. **Biochem J** 1996 Nov 15;320 (Pt 1):273–81

Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N–acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. Shen XM, et al. **Chem Res Toxicol** 1996 Oct–Nov; 9(7):1117–26

Synthesis, isolation and identification of glucuronides and mercapturic acids of a novel antiparasitic agent, licochalcone A. Nadelmann L, et al. **Xenobiotica** 1997 Jul; 27(7):667–80

PHARMACOLOGY

N–acetylcysteine: pharmacological considerations and experimental and clinical applications. Cotgreave IA. **Adv Pharmacol** 1997;38:205–27 (122 ref.)

N–acetyl–cysteine and L–2–oxothiazolidine–4–carboxylic acid enhance contact–dependent growth of HIV in resting peripheral blood mononuclear cells (PBMC) in vitro and increase recovery of HIV from human–PBMC SCID mice. Chen P, et al. **AIDS** 1997 Jan;11(1):33–41

Intracellular glutathione as a possible direct blocker of HIV type 1 reverse transcription. Kameoka M, et al. **AIDS Res Hum Retroviruses** 1996 Nov 20;12(17):1635–8

N–acetyl cysteine ameliorates ischemic renal failure. DiMari J, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):F292–8

Distinct mechanisms for N–acetylcysteine inhibition of cytokine–induced E–selectin and VCAM–1 expression. Faruqi RM, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H817–26

Cysteine S–conjugates activate transcription factor NF–kappa B in cultured renal epithelial cells. Otieno MA, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):F136–43

N–acetylcysteine does not protect against type II cell injury after prolonged exposure to hyperoxia in rats. van Klaveren RJ, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):L548–55

Scavenging effect of N–acetyl–L–cysteine against reactive oxygen species in human semen: a possible therapeutic modality for male factor infertility? Oeda T, et al. **Andrologia** 1997 May–Jun;29(3):125–31

N–acetylcysteine reduces methemoglobin in vitro. Wright RO, et al. **Ann Emerg Med** 1996 Nov;28(5):499–503

Effect of cysteine, N–acetyl–L–cysteine and glutathione on cytotoxic activity of antioxidants. Satoh K, et al. **Anticancer Res** 1997 May–Jun;17(3C):2175–9

N–acetylcysteine inhibits germination of conidia and growth of Aspergillus spp. and Fusarium spp. De Lucca AJ, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1274–6

Anti–hepatitis B virus activity of N–acetyl–L–cysteine (NAC): new aspects of a well–established drug. Weiss L, et al. **Antiviral Res** 1996 Aug;32(1):43–53

N–acetyl cysteine attenuates ethanol induced hypertension in rats. Vasdev S, et al. **Artery** 1995;21(6):312–6

Influence of acetylcysteine on aggravation of ischemic damage in ex vivo hearts of rats exposed to hyperbaric oxygen. Rossoni G, et al. **Arzneimittelforschung** 1997 Jun; 47(6):710–5

On the mechanism of the inhibition of transducin function by farnesylcysteine analogs. Parish CA, et al. **Biochemistry** 1997 Mar 4;36(9):2686–93

Antioxidant N–acetyl–cysteine increasing cell adhesion capability could facilitate the biocompatibility processes. Malorni W, et al. **Biomaterials** 1996 May;17(9):921–8

N–acetyl–L–cysteine exhibits antitumoral activity by increasing tumor necrosis factor alpha–dependent T–cell cytotoxicity. Delneste Y, et al. **Blood** 1997 Aug 1; 90(3):1124–32

Evidence for N–acetylcysteine–sensitive nitric oxide storage as dinitrosyl–iron complexes in lipopolysaccharide–treated rat aorta. Muller B, et al. **Br J Pharmacol** 1996 Nov; 119(6):1281–5

N–acetylcysteine protects against age–related increase in oxidized proteins in mouse synaptic mitochondria. Banaclocha MM, et al. **Brain Res** 1997 Jul 11; 762(1–2):256–8

Transforming growth factor beta 1–induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N–acetylcysteine and bcl–2. Lafon C, et al. **Cell Growth Differ** 1996 Aug;7(8):1095–104

The suppression of T cell function and NF(kappa)B expression by serine protease inhibitors is blocked by N–acetylcysteine. Breithaupt TB, et al. **Cell Immunol** 1996 Oct 10;173(1):124–30

Inhibition of N–nitrosodimethylamine demethylase in rat and human liver microsomes by isothiocyanates and their glutathione, L–cysteine, and N–acetyl–L–cysteine conjugates. Jiao D, et al. **Chem Res Toxicol** 1996 Sep; 9(6):932–8

The effect of N–acetylcysteine on the in vitro growth of normal rabbit middle ear fibroblasts. Ovesen T, et al. **Clin Otolaryngol** 1993 Oct;18(5):400–5

N–acetylcysteine attenuates endotoxin–induced leukocyte–endothelial cell adhesion and macromolecular leakage in vivo. Schmidt H, et al. **Crit Care Med** 1997 May; 25(5):858–63

N–acetyl–cysteine causes a late re–specification of the anteroposterior axis in the Xenopus embryo. Gatherer D, et al. **Dev Dyn** 1996 Apr;205(4):395–409

Teratogenic effect of diabetic serum is prevented by supplementation of superoxide dismutase and N–acetylcysteine in rat embryo culture. Wentzel P, et al. **Diabetologia** 1997 Jan;40(1):7–14

Glutathione and N–acetylcysteine reduce gastric mucosal blood flow in rats. Ovrebø KK, et al. **Dig Dis Sci** 1997 Aug;42(8):1765–74

Effects of the sulphydryl donor N–acetyl–L–cysteine on nerve conduction, perfusion, maturation and regeneration following freeze damage in diabetic rats. Love A, et al. **Eur J Clin Invest** 1996 Aug;26(8):698–706

Thiols prevent Fas (CD95)–mediated T cell apoptosis by down–regulating membrane Fas expression. Delneste Y, et al. **Eur J Immunol** 1996 Dec;26(12):2981–8

Improvement of hepatic microhemodynamics by N–acetylcysteine after warm ischemia. Koeppel TA, et al. **Eur Surg Res** 1996 Jul–Aug;28(4):270–7

Amelioration of hepatocellular integrity and inhibition of sinusoidal oxidative stress by N–acetylcysteine pretreatment in cold ischemia–reperfusion injury of rat liver. Nakano H, et al. **Eur Surg Res** 1996 Jul–Aug; 28(4):245–55

Prevention of dopamine–induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Offen D, et al. **Exp Neurol** 1996 Sep; 141(1):32–9

In vivo indices of oxidative stress in lead–exposed C57BL/6 mice are reduced by treatment with meso–2,3–dimercaptosuccinic acid or N–acetylcysteine. Ercal N, et al. **Free Radic Biol Med** 1996;21(2):157–61

Paraquat–induced formation of leukotriene B4 in rat lungs: modulation by N–acetylcysteine. Hoffer E, et al. **Free Radic Biol Med** 1997;22(3):567–72

Protection from acetaminophen–induced liver damage by the synergistic action of low doses of the poly(ADP–ribose) polymerase–inhibitor nicotinamide and the antioxidant N–acetylcysteine or the amino acid L–methionine. Kröger H, et al. **Gen Pharmacol** 1997 Feb;28(2):257–63

The effects of N–acetylcysteine and anti–intercellular adhesion molecule–1 monoclonal antibody against ischemia–reperfusion injury of the rat steatotic liver produced by a choline–methionine–deficient diet. Nakano H, et al. **Hepatology** 1997 Sep;26(3):670–8

Oral N–acetylcysteine protects against perfluoroisobutene toxicity in rats. Lailey AF. **Hum Exp Toxicol** 1997 Apr; 16(4):212–6

N–acetylcysteine does not influence the activity of endothelium–derived relaxing factor in vivo. Creager MA, et al. **Hypertension** 1997 Feb;29(2):668–72

Thiols decrease human IL–4 production and IL–4–induced immunoglobulin synthesis. Jeannin P, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):329–30

Induction of cytokines and ICAM–1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N–acetyl–L–cysteine and aspirin. Sakurada S, et al. **Int Immunol** 1996 Oct;8(10):1483–93

Synergism between N–acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models. De Flora S, et al. **Int J Cancer** 1996 Sep 17; 67(6):842–8

Chemopreventive efficacy of anethole trithione, N–acetyl–L–cysteine, miconazole and phenethylisothiocyanate in the DMBA–induced rat mammary cancer model. Lubet RA, et al. **Int J Cancer** 1997 Jul 3;72(1):95–101

Influence of N–acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. Pérez–Giraldo C, et al. **J Antimicrob Chemother** 1997 May;39(5):643–6

N–acetylcysteine administration alters the response to inspiratory loading in oxygen–supplemented rats. Supinski GS, et al. **J Appl Physiol** 1997 Apr;82(4):1119–25

N–Acetylcysteine potentiates nitroglycerin–induced reversal of platelet aggregation. Chirkov YY, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):375–80

Studies of vascular tolerance to nitroglycerin: effects of N–acetylcysteine, NG–monomethyl L–arginine, and endothelin–1. Lawson DL, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):418–24

Antioxidant enzyme status in biliary obstructed rats: effects

of N-acetylcysteine. Pastor A, et al. **J Hepatol** 1997 Aug; 27(2):363–70

Albumin nitrosylated by activated macrophages possesses antiparasitic effects neutralized by anti-NO-acetylated-cysteine antibodies. Mnaimneh S, et al. **J Immunol** 1997 Jan 1;158(1):308–14

N-acetyl-L-cysteine-induced up-regulation of HIV-1 gene expression in monocyte-derived macrophages correlates with increased NF-kappaB DNA binding activity. Nottet HS, et al. **J Leukoc Biol** 1997 Jan;61(1):33–9

Low plasma glutamine in combination with high glutamate levels indicate risk for loss of body cell mass in healthy individuals: the effect of N-acetyl-cysteine. Kinscherf R, et al. **J Mol Med** 1996 Jul;74(7):393–400

Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. Henderson JT, et al. **J Neurosci** 1996 Dec 1;16(23):7574–82

Inhibitory effects of N-acetylcysteine on superoxide anion generation in human polymorphonuclear leukocytes. Villagrasa V, et al. **J Pharm Pharmacol** 1997 May; 49(5):525–9

Suppression of UVB-induced c-fos and c-jun expression in human keratinocytes by N-acetylcysteine. Garmyn M, et al. **J Photochem Photobiol B** 1997 Jan;37(1–2):125–30

The antioxidative activity of the mucoregulatory agents: ambroxol, bromhexine and N-acetyl-L-cysteine. A pulse radiolysis study. Felix K, et al. **Life Sci** 1996;59(14):1141–7

Suppression of nitric oxide-induced apoptosis by N-acetyl-L-cysteine through modulation of glutathione, bcl-2, and bax protein levels. Ho YS, et al. **Mol Carcinog** 1997 Jun;19(2):101–13

The role of N-acetylcysteine as a putative radioprotective agent on X-ray-induced DNA damage as evaluated by alkaline single-cell gel electrophoresis. Abt G, et al. **Mutat Res** 1997 Jun 9;384(1):55–64

Protective effect of the antioxidant N-acetyl-L-cysteine in pneumococcal meningitis in the rat. Koedel U, et al. **Neurosci Lett** 1997 Mar 28;225(1):33–6

Development and in vitro evaluation of systems to protect peptide drugs from aminopeptidase N. Bernkop-Schnürch A, et al. **Pharm Res** 1997 Feb;14(2):181–5

The protective effect of N-acetylcysteine on UVB-induced immunosuppression by inhibition of the action of cis-urocanic acid. Hemelaar PJ, et al. **Photochem Photobiol** 1996 Mar;63(3):322–7

The effect of L-cysteine and N-acetylcysteine on porphyrin/heme biosynthetic pathway in cells treated with 5-aminolevulinic acid and exposed to radiation. He D, et al. **Photodermatol Photoimmunol Photomed** 1996 Oct; 12(5):194–9

A comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: airway epithelial function and mucus changes in dog. Tomkiewicz RP, et al. **Pulm Pharmacol** 1995 Dec;8(6):259–65

Oxidant scavenger function of ambroxol in vitro: a comparison with N-acetylcysteine. Gillissen A, et al. **Res Exp Med (Berl)** 1997;196(6):389–98

Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Gillissen A, et al. **Respir Med** 1997 Mar;91(3):159–68

Effects of 4-hydroxynonenal and N-acetyl-L-cysteine on Myc-induced apoptosis. Yildiz D, et al. **Toxicol Lett** 1996 Dec 31;89(3):215–21

Effect of thiols on cadmium-induced expression of metallothionein and other oxidant stress genes in rat lung epithelial cells. Gong Q, et al. **Toxicology** 1997 May 16; 119(3):179–91

Cimetidine enhances the hepatoprotective action of N-acetylcysteine in mice treated with toxic doses of paracetamol. Al-Mustafa ZH, et al. **Toxicology** 1997 Sep 5;121(3):223–8

Immunomodulatory and protective effects of N-acetylcysteine in mitogen-activated murine splenocytes in vitro. Omara FO, et al. **Toxicology** 1997 Jan 15; 116(1-3):219–26

Efficacy of N-acetylcysteine as a hepatoprotective agent in liver transplantation: an experimental study. Thies JC, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1326–7

Suppression of intestinal and hepatic cytochrome P4503A in murine Toxoplasma infection. Effects of N-acetylcysteine and N(G)-monomethyl-L-arginine on the hepatic suppression. Berg-Candolfi M, et al. **Xenobiotica** 1996 Apr;26(4):381–94

[Role of oxidants in adhesion molecule expression and cytokine production] Ishii Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:126–30 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Role of cysteine and glutathione in HIV infection and cancer cachexia: therapeutic intervention with N-acetylcysteine. Dröge W, et al. **Adv Pharmacol** 1997;38:581–600 (88 ref.)

N-acetylcysteine attenuates nitroglycerin tolerance in patients with angina pectoris and normal left ventricular function. Pizzulli L, et al. **Am J Cardiol** 1997 Jan 1; 79(1):28–33

Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine [letter] Redondo P, et al. **Br J Dermatol** 1997 Apr; 136(4):645–6

Lack of effect of daily N-acetylcysteine supplementation on mutagen sensitivity. Cloos J, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Nov;5(11):941–4

A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Bernard GR, et al. **Chest** 1997 Jul;112(1):164–72

N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction: safety and biochemical effects [letter; comment] Simon K, et al. **Circulation** 1996 Oct 1;94(7):1791 . Comment on: Circulation 1995 Nov 15;92(10):2855–62.

Infarct Size Limitation: acute N-acetylcysteine defense (ISLAND trial): preliminary analysis and report after the first 30 patients. Sochman J, et al. **Clin Cardiol** 1996 Feb; 19(2):94–100

Chronic sinusitis refractory to standard management in patients with humoral immunodeficiencies. Buehring I, et al. **Clin Exp Immunol** 1997 Sep;109(3):468–72

Abnormalities of antioxidant metabolism in a case of Friedreich's disease. Helveston W, et al. **Clin Neuropharmacol** 1996 Jun;19(3):271–5

N-acetylcysteine improves indocyanine green extraction and oxygen transport during hepatic dysfunction. Devlin J, et al. **Crit Care Med** 1997 Feb;25(2):236–42

Effect of N-acetylcysteine, an inhibitor of tumor necrosis factor, on irritant contact dermatitis in the human. Pasche-Koo F, et al. **Curr Probl Dermatol** 1995;23:198–206

Effect of N-acetylcysteine(NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. Akerlund B, et al. **Eur J Clin Pharmacol** 1996;50(6):457–61

Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. De Flora S, et al. **Eur Respir J** 1997 Jul;10(7):1535–41

Hepatotoxicity of N, N-dimethylformamide (DMF) in acute poisoning with the veterinary euthanasia drug T-61. Buylaert W, et al. **Hum Exp Toxicol** 1996 Aug;15(8):607–11

N-acetylcysteine pretreatment of cardiac surgery patients influences plasma neutrophil elastase and neutrophil influx in bronchoalveolar lavage fluid. De Backer WA, et al. **Intensive Care Med** 1996 Sep;22(9):900–8

N-acetylcysteine (NAC)--a safe antidote in paracetamol poisoning? [letter; comment] Casey PB, et al. **Ir Med J** 1997 Jan-Feb;90(1):38. Comment on: Ir Med J 1996 Sep-Oct;89(5):156, 158.

Paracetamol poisoning: the action line and the timing of acetylcysteine therapy [editorial] [see comments] Delanty N, et al. **Ir Med J** 1996 Sep-Oct;89(5):156, 158 (20 ref.) . Comment in: Ir Med J 1997 Jan-Feb;90(1):38.

Acetylcysteine in paracetamol poisoning--no drug is a safe drug! [letter] McKiernan J, et al. **Ir Med J** 1996 Nov-Dec; 89(6):213

Effects of Prussian blue and N-acetylcysteine on thallium toxicity in mice. Meggs WJ, et al. **J Toxicol Clin Toxicol** 1997;35(2):163–6

Prevention by 2-mercaptoethane sulfonate and N-acetylcysteine of renal oxidative damage in rats treated with ferric nitrilotriacetate. Umemura T, et al. **Jpn J Cancer Res** 1996 Sep;87(9):882–6

The protective role of zinc and N-acetylcysteine in modulating zidovudine induced hematopoietic toxicity. Gogu SR, et al. **Life Sci** 1996;59(16):1323–9

Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Hurd RW, et al. **Neurology** 1996 Nov; 47(5):1264–8

Glutathione deficiency is associated with impaired survival in HIV disease. Herzenberg LA, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1967–72

Chemoprevention of colorectal tumors: role of lactulose and of other agents. Ponz de Leon M, et al. **Scand J Gastroenterol Suppl** 1997;222:72–5

Outpatient N-acetylcysteine treatment for acetaminophen poisoning: an ethical dilemma or a new financial mandate? Dean BS, et al. **Vet Hum Toxicol** 1996 Jun;38(3):222–4

[Recommendations for treatment of paracetamol poisoning. Danish Medical Society, Study of the Liver] Clemmesen JO, et al. **Ugeskr Laeger** 1996 Nov 25;158(48):6892–5 (20 ref.) (Eng. Abstr.) **(Dan)**

[Acetylcysteine in children with lung disorders prescribed by one-third of family physicians: no support in the literature] Duijvestijn YC, et al. **Ned Tijdschr Geneeskd** 1997 Apr 26;141(17):826–30 (20 ref.) (Eng. Abstr.) **(Dut)**

[Acetylcysteine] Köhler D. **Dtsch Med Wochenschr** 1996 Dec 6;121(49):1550 **(Ger)**

[New therapy concepts in fibrosing lung diseases] Behr J. **Pneumologie** 1996 Sep;50(9):657–64 (87 ref.) **(Ger)**

[The effect of acetylcysteine and dipyroxime on the immune reactions in acute dichloroethane poisoning] Zabrodskii PF, et al. **Eksp Klin Farmakol** 1997 Jan-Feb;60(1):47–9 (Eng. Abstr.) **(Rus)**

TOXICITY

Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. Shen XM, et al. **Chem Res Toxicol** 1996 Oct-Nov; 9(7):1117–26

Effects of N-acetylcysteine on bacterial clearance. Koch T, et al. **Eur J Clin Invest** 1996 Oct;26(10):884–92

Studies on the basis for the toxicity of acrolein mercapturates. Ramu K, et al. **Toxicol Appl Pharmacol** 1996 Oct; 140(2):487–98

URINE

Biotransformation of trichloroethene: dose-dependent excretion of 2,2,2-trichloro-metabolites and mercapturic acids in rats and humans after inhalation. Bernauer U, et al. **Arch Toxicol** 1996;70(6):338–46

Urinary mercapturic acid diastereoisomers in rats subchronically exposed to styrene and ethanol. Coccini T, et al. **Arch Toxicol** 1996;70(11):736–41

Urinary excretion of N-acetyl-S-allyl-L-cysteine upon garlic consumption by human volunteers. de Rooij BM, et al. **Arch Toxicol** 1996;70(10):635–9

Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Thompson CD, et al. **Chem Res Toxicol** 1997 Apr; 10(4):457–62

Sensitive gas chromatographic method for determination of mercapturic acids in human urine. Einig T, et al. **J Chromatogr B Biomed Appl** 1996 Dec 13;687(2):379–85

Studies on the metabolic activation of disulfiram in rat. Evidence for electrophilic S-oxygenated metabolites as inhibitors of aldehyde dehydrogenase and precursors of urinary N-acetylcysteine conjugates. Hu P, et al. **J Pharmacol Exp Ther** 1997 May;281(2):611–7

ACETYLDIGOXINS

ANALYSIS

Extraction and quantitation of digoxin and acetyldigoxin from the Digitalis lanata leaf via near-supercritical methanol-modified carbon dioxide. Moore WN, et al. **J Nat Prod** 1996 Jul;59(7):690–3

ACETYLENE

ANALOGS & DERIVATIVES

"Vinylogs" and "acetylenylogs" of beta-adrenergic agents. Nudelman A, et al. **Arch Pharm (Weinheim)** 1996 Mar; 329(3):125–32

Biosynthesis of the acetylenic compounds in cultured cells of Asparagus officinalis from D- and 13C-labelled phenylalanines. Terada K, et al. **Biol Pharm Bull** 1996 May; 19(5):748–51

Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Foroozesh M, et al. **Chem Res Toxicol** 1997 Jan; 10(1):91–102

Triangulynes A–H and trangulynic acid, new cytotxic polyacetylenes from the marine sponge Pellina triangulata. Dai JR, et al. **J Nat Prod** 1996 Sep;59(9):860–5

Montiporic acids A and B, cytotoxic and antimicrobial polyacetylene carboxylic acids from eggs of the scleractinian coral Montipora digitata. Fusetani N, et al. **J Nat Prod** 1996 Aug;59(8):796–7

Dichloroacetylene: effects on the rat trigeminal nerve somatosensory evoked potential. Albee RR, et al. **Neurotoxicol Teratol** 1997 Jan-Feb;19(1):27–37

Solvophobically driven folding of nonbiological oligomers [see comments] Nelson JC, et al. **Science** 1997 Sep 19; 277(5333):1793–6. Comment in: Science 1997 Sep 19;277(5333):1764.

Polymer folds just like a protein [news; comment] Pennisi E. **Science** 1997 Sep 19;277(5333):1764. Comment on: Science 1997 Sep 19;277(5333):1793–6.

ANALYSIS

The non-invasive acetylene rebreathing method for estimation of cardiac output: influence of breath-by-breath variation. Hansen S, et al. **Clin Physiol** 1997 Mar; 17(2):193–202

Validation of the acetylene rebreathing method for measurement of cardiac output at rest and during high-intensity exercise. Liu Y, et al. **Clin Physiol** 1997 Mar; 17(2):171–82

Biological monitoring and risk assessment in occupational settings. Zober A, et al. **Int Arch Occup Environ Health** 1996;68(6):389–93

Detection of acetylene in the infrared spectrum of comet Hyakutake [see comments] Brooke TY, et al. **Nature** 1996 Oct 17;383(6601):606–8. Comment in: Nature 1996 Oct 17;383(6601):581–2.

Hyakutake's interstellar ices [news; comment] Mumma MJ. **Nature** 1996 Oct 17;383(6601):581–2. Comment on: Nature 1996 Oct 17;383(6601):606–8.

CHEMISTRY

Antimalarial activity of extracts and fractions from Bidens pilosa and other Bidens species (Asteraceae) correlated with the presence of acetylene and flavonoid compounds. Brandão MG, et al. **J Ethnopharmacol** 1997 Jul;57(2):131–8

Assay of the deuterium enrichment of water via acetylene. Previs SF, et al. **J Mass Spectrom** 1996 Jun;31(6):639–42

Organic synthesis in experimental impact shocks. McKay CP, et al. **Science** 1997 Apr 18;276(5311):390–2

Ab initio calculation of 1H and 13C NMR shielding constants in solid acetylene. Pecul M, et al. **Solid State Nucl Magn Reson** 1997 May;8(3):139–45

DIAGNOSTIC USE

Noninvasive measurement of cardiac output by an acetylene

uptake technique and simultaneous comparison with thermodilution in ICU patients. Sadeh JS, et al. **Chest** 1997 May;111(5):1295–300

METABOLISM

Improvement of lysine production by analog-sensitive and auxotroph mutants of the acetylene-utilizing bacterium Gordona bronchialis (Rhodococcus bronchialis). Kyriacou A, et al. **Appl Biochem Biotechnol** 1997 Jun;66(3):281–9

Acetylene degradation by new isolates of aerobic bacteria and comparison of acetylene hydratase enzymes. Rosner BM, et al. **FEMS Microbiol Lett** 1997 Mar 15;148(2):175–80

PHARMACOLOGY

Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Foroozesh M, et al. **Chem Res Toxicol** 1997 Jan; 10(1):91–102

Inhibition by iodoacetamide and acetylene of the H-D-exchange reaction catalyzed by Thiocapsa roseopersicina hydrogenase. Zorin NA, et al. **Eur J Biochem** 1996 Oct 15;241(2):675–81

ACETYLESTERASE

CHEMISTRY

The use of a novel recombinant heroin esterase in the development of an illicit drugs biosensor. Rathbone DA, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:90–6

Convenient chemoenzymatic synthesis of beta-purine-diphosphate sugars (GDP-fucose-analogues). Baisch G, et al. **Bioorg Med Chem** 1997 Feb;5(2):383–91

Characterization of crystals of Penicillium purpurogenum acetyl xylan esterase from high-resolution x-ray diffraction. Pangborn W, et al. **Proteins** 1996 Apr; 24(4):523–4

GENETICS

Molecular analysis of the Rhodococcus sp. strain H1 her gene and characterization of its product, a heroin esterase, expressed in Escherichia coli. Rathbone DA, et al. **Appl Environ Microbiol** 1997 May;63(5):2062–6

Cloning and sequence analysis of genes encoding xylanases and acetyl xylan esterase from Streptomyces thermoviolaceus OPC-520. Tsujibo H, et al. **Appl Environ Microbiol** 1997 Feb;63(2):661–4

ISOLATION & PURIFICATION

Purification and characterization of an acetyl xylan esterase produced by Streptomyces lividans. Dupont C, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):881–6

METABOLISM

Molecular analysis of the Rhodococcus sp. strain H1 her gene and characterization of its product, a heroin esterase, expressed in Escherichia coli. Rathbone DA, et al. **Appl Environ Microbiol** 1997 May;63(5):2062–6

Purification and characterization of an acetyl xylan esterase produced by Streptomyces lividans. Dupont C, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):881–6

Substrate specificity of acetylxylan esterase from Schizophyllum commune: mode of action on acetylated carbohydrates. Biely P, et al. **Biochim Biophys Acta** 1996 Dec 5;1298(2):209–22

Substrate specificity and mode of action of acetylxylan esterase from Streptomyces lividans. Biely P, et al. **FEBS Lett** 1996 Nov 4;396(2–3):257–60

Isolation, analysis, and expression of two genes from Thermoanaerobacterium sp. strain JW/SL YS485: a beta-xylosidase and a novel acetyl xylan esterase with cephalosporin C deacetylase activity. Lorenz WW, et al. **J Bacteriol** 1997 Sep;179(17):5436–41

Dithiothreitol tetraacetate S-acetyl esterase activity in different liver subcellular fractions and its potential role in the ester-mediated prevention of oxidative stress induced cell damage. de Mecca MM, et al. **Res Commun Mol Pathol Pharmacol** 1996 Nov;94(2):211–6

ACETYLFORMALDEHYDE see **PYRUVALDEHYDE**

ACETYLGALACTOSAMINE

Synthesis of N-acetylglucosaminyl- and N-acetylgalactosaminylceramides as cerebroside analogs and their anti-human immunodeficiency virus type 1 activities. Ikeda K, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb;45(2):402–5

ANALOGS & DERIVATIVES

Benzyl-alpha-GalNAc inhibits sialylation of O-glycosidic sugar chains on CD44 and enhances experimental metastatic capacity in B16BL6 melanoma cells. Nakano T, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3577–84

Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation. Delannoy P, et al. **Glycoconj J** 1996 Oct;13(5):717–26

Association of asialo-galactosyl beta 1-3N-acetylgalactosamine on the hinge with a conformational instability of Jacalin-reactive immunoglobulin A1 in immunoglobulin A nephropathy. Hiki Y, et al. **J Am Soc Nephrol** 1996 Jun;7(6):955–60

ANALYSIS

Blood group MN-dependent difference in degree of galactosylation of O-glycans of glycophorin A is restricted to the GalNAc residues located on amino acid residues 2–4 of the glycophorin polypeptide chain. Krotkiewski H, et al. **FEBS Lett** 1997 Apr 14;406(3):296–300

Spatial relationship of lectin-labelled extracellular matrix and glutamine synthetase-immunoreactive astrocytes in rat cortical forebrain regions. Derouiche A, et al. **J Anat** 1996 Oct;189 (Pt 2):363–72

Altered carbohydrate composition in colorectal adenomas and carcinomas: histochemical characterization of N-acetylgalactosamine, L-fucose, and o-acetylated sialic acid. Iwakawa K, et al. **J Gastroenterol** 1996 Feb; 31(1):24–32

CHEMISTRY

A spectroscopic study of the interaction of the VO2+ cation with the two components of chondroitin sulfate. Etcheverry SB, et al. **Biol Trace Elem Res** 1996 Feb; 51(2):169–76

Synthesis of a novel glycosaminoglycan pentasaccharide serine having an N-acetylgalactosamine residue alpha-linked to the core linkage tetrasaccharide. Neumann KW, et al. **Glycoconj J** 1996 Dec;13(6):933–6

Novel alphaGalNAc containing glycans on cytokeratins are recognized invitro by galectins with type II carbohydrate recognition domains. Goletz S, et al. **J Cell Sci** 1997 Jul; 110 (Pt 14):1585–96

IMMUNOLOGY

Structure and function of the galactose/N-acetyl D-galactosamine inhibitable adhesin of Entamoeba dispar. Mann BJ, et al. **Arch Med Res** 1997;28 Spec No:168–9

Expression of N-acetyl-D-galactosamine associated epitope in synovium: a potential marker of glycoprotein production. El-Gabalawy H, et al. **J Rheumatol** 1997 Jul; 24(7):1355–63

[Axonal Guillain-Barré syndrome associated with antibodies to GalNAc-GD1a and unidentified acidic glycolipids] Ono M, et al. **Rinsho Shinkeigaku** 1997 Feb;37(2):119–22 (Eng. Abstr.) **(Jpn)**

[Guillain-Barré syndrome with high titers of anti-GM2 and anti-GalNAc-GD1a antibody following cytomegalovirus hepatitis] Shimoya K, et al. **Rinsho Shinkeigaku** 1997 Feb; 37(2):106–10 (Eng. Abstr.) **(Jpn)**

[A case of chronic inflammatory demyelinating neuropathy associated with antibodies to gangliosides GM1 and GalNAc-GD1a] Tsukaguchi M, et al. **Rinsho Shinkeigaku** 1997 Mar;37(3):228–32 (Eng. Abstr.) **(Jpn)**

METABOLISM

Isolation and partial characterization of N-acetyl-D-galactosamine-binding lectins from Epiphragmophora trenquelleonis snail. Castagna L, et al. **J Biochem (Tokyo)** 1996 Feb;119(2):372–7

Mucopolysaccharidosis IVA: a comparative study of polymorphic DNA haplotypes in the Caucasian and Japanese populations. Rezvi GM, et al. **J Inherit Metab Dis** 1996;19(3):301–8

Expression of N-acetyl-D-galactosamine associated epitope in synovium: a potential marker of glycoprotein production. El-Gabalawy H, et al. **J Rheumatol** 1997 Jul; 24(7):1355–63

Novel phosphotransferase genes revealed by bacterial genome sequencing: a gene cluster encoding a putative N-acetylgalactosamine metabolic pathway in Escherichia coli. Reizer J, et al. **Microbiology** 1996 Feb;142 (Pt 2):231–50

Physical mapping and expression of gene families encoding the N-acetyl D-galactosamine adherence lectin of Entamoeba histolytica. Ramakrishnan G, et al. **Mol Microbiol** 1996 Jan;19(1):91–100

Nucleotide-sugar binding to ribosomes. Comparison of affinity and capacity of gastric mucosa and liver ribosomes to sugar-nucleotides. Paszkiewicz-Gadek A, et al. **Rocz Akad Med Bialymst** 1996;41(2):305–15

PHARMACOLOGY

Identification of a Gal/GalNAc lectin in the protozoan Hartmannella vermiformis as a potential receptor for attachment and invasion by the Legionnaires' disease bacterium. Venkataraman C, et al. **J Exp Med** 1997 Aug 18;186(4):537–47

Defining oligosaccharide specificity for initial sperm-zona pellucida adhesion in the mouse. Thaler CD, et al. **Mol Reprod Dev** 1996 Dec;45(4):535–46

N-ACETYLGALACTOSAMINYLTRANSFERASES

ANTAGONISTS & INHIBITORS

Identification of an endogenous inhibitor of the UDP-N-acetylgalactosamine: GM3, N-acetylgalactosaminyl transferase as apolipoprotein A1. Conde CB, et al. **Neurochem Res** 1997 Apr;22(4):483–90

BIOSYNTHESIS

In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line. Fredman P, et al. **Glycoconj J** 1996 Jun;13(3):391–9

CHEMISTRY

Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. Hansen JE, et al. **Biochem J** 1995 Jun 15;308 (Pt 3):801–13

Determination of the site-specific O-glycosylation pattern of the porcine submaxillary mucin tandem repeat glycopeptide. Model proposed for the polypeptide:galnac transferase peptide binding site. Gerken TA, et al. **J Biol Chem** 1997 Apr 11;272(15):9709–19

GENETICS

Cloning and expression of mouse UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-T3. Zara J, et al. **Biochem Biophys Res Commun** 1996 Nov 1;228(1):38–44

Cloning and sequence homology of a rat UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. Hagen FK, et al. **Glycoconj J** 1995 Dec;12(6):901–9

Cloning and expression of a porcine UDP-GalNAc: polypeptide N-acetylgalactosaminyl transferase. Yoshida A, et al. **Glycoconj J** 1995 Dec;12(6):824–828

A human UDP-GalNAc: polypeptide, N-acetylgalactosaminyltransferase type 1 gene is located at the chromosomal region 18q12.1. Takai S, et al. **Hum Genet** 1997 Mar;99(3):293–4

cDNA cloning and expression of a novel UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. Hagen FK, et al. **J Biol Chem** 1997 May 23;272(21):13843–8

Sequential interchange of four amino acids from blood group B to blood group A glycosylтransferase boosts catalytic activity and progressively modifies substrate recognition in human recombinant enzymes. Seto NOL, et al. **J Biol Chem** 1997 May 30;272(22):14133–8

Assignment of the human UDP-GalNAc:polypeptide, N-acetylgalactosaminyltransferase-type-2 gene to chromosomal region 1q42 by fluorescence in situ hybridization. Takai S, et al. **Jpn J Hum Genet** 1997 Mar; 42(1):237–40

Expression of beta 1-4 N-acetylgalactosaminyltransferase gene in the developing rat brain and retina: mRNA, protein immunoreactivity and enzyme activity. Daniotti JL, et al. **Neurochem Int** 1997 Jul;31(1):11–9

Expression cloning of Forssman glycolipid synthetase: a novel member of the histo-blood group ABO gene family. Haslam DB, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10697–702

IMMUNOLOGY

Increased sensitivity of gastric cancer cells to natural killer and lymphokine-activated killer cells by antisense suppression of N-acetylgalactosaminyltransferase. Adachi T, et al. **J Immunol** 1997 Sep 15;159(6):2645–51

METABOLISM

Artificial neural network model for predicting the specificity of GalNAc-transferase. Cai YD, et al. **Anal Biochem** 1996 Dec 15;243(2):284–5

Cloning and expression of mouse UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-T3. Zara J, et al. **Biochem Biophys Res Commun** 1996 Nov 1;228(1):38–44

Ganglioside biosynthetic gene expression in experimental mouse brain tumors. Ecsedy JA, et al. **Cancer Res** 1997 Apr 15;57(8):1580–3

O-Glycosylation and cellular differentiation in a subpopulation of mucin-secreting HT-29 cell line. Hennebicq-Reig S, et al. **Exp Cell Res** 1997 Aug 25; 235(1):100–7

A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases control the initiation of mucin-type O-linked glycosylation. Clausen H, et al. **Glycobiology** 1996 Sep;6(6):635–46

Differential expression of LacdiNAc sequences (GalNAc beta 1-4GlcNAc-R) in glycoproteins synthesized by Chinese hamster ovary and human 293 cells. Do KY, et al. **Glycobiology** 1997 Mar;7(2):183–94

Regulation of chondroitin sulfate biosynthesis by specific sulfation: acceptor specificity of serum beta-GalNAc transferase revealed by structurally defined oligosaccharides. Kitagawa H, et al. **Glycobiology** 1997 Jun; 7(4):531–7

N-ACETYLGALACTOSAMINYLTRANSFERASES

Complexity in O-linked oligosaccharide biosynthesis engendered by multiple polypeptide N-acetylgalactosaminyltransferases. Marth JD. **Glycobiology** 1996 Oct;6(7):701-5 (60 ref.)

Specificity of O-glycosylation by bovine colostrum UDP-GalNAc: polypeptide alpha-N-acetylgalactosaminyltransferase using synthetic glycopeptide substrates. Brockhausen I, et al. **Glycoconj J** 1996 Oct;13(5):849-56

A soluble form of Sda-beta 1,4-N-acetylgalactosaminyltransferase is released by differentiated human colon carcinoma CaCo-2 cells. Serafini-Cessi F, et al. **Glycoconj J** 1995 Dec;12(6):773-9

Beta1,4-N-acetylgalactosaminyltransferase (GM2 synthase) is released from Golgi membranes as a neuraminidase-sensitive, disulfide-bonded dimer by a cathepsin D-like protease. Jaskiewicz E, et al. **J Biol Chem** 1996 Oct 18;271(42):26395-403

Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3. Wandall HH, et al. **J Biol Chem** 1997 Sep 19;272(38):23503-14

Alpha-lactalbumin affects the acceptor specificity of Lymnaea stagnalis albumen gland UDP-GalNAc:GlcNAc beta-R beta 1-->4-N-acetylgalactosaminyltransferase: synthesis of GalNAc beta 1-->4Glc. Neeleman AP, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10111-6

PHYSIOLOGY

Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Takamiya K, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10662-7

RADIATION EFFECTS

Light exposure stimulates the activity of ganglioside glycosyltransferases of retina ganglion cells. Bussolino DF, et al. **Neurochem Int** 1997 Jul;31(1):105-11

ACETYLGLUCOSAMINE

Bisecting GlcNAc structures act as negative sorting signals for cell surface glycoproteins in forskolin-treated rat hepatoma cells. Sultan AS, et al. **J Biol Chem** 1997 Jan 31;272(5):2866-72

Identification of O-linked N-acetylglucosamine modification of ankyrinG isoforms targeted to nodes of Ranvier. Zhang X, et al. **J Biol Chem** 1996 Dec 6;271(49):31391-8

N-acetylglucosamine: a new osmotic solute in peritoneal dialysis solutions. Breborowicz A, et al. **Perit Dial Int** 1997; 17 Suppl 2:S80-3 (20 ref.)

ANALOGS & DERIVATIVES

Purification and characterization of guinea-pig liver microsomal deacetylase involved in the deacetylation of the O-glucoside of N-hydroxyacetanilide. Suzuki-Kurasaki M, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):155-61

Synthesis of allosamidin analogues. Blattner R, et al. **Carbohydr Res** 1996 Nov 20;294:29-39

Synthesis and characterization of a carbene-generating biotinylated N-acetylglucosamine for photoaffinity labeling of beta-(1-->4)-galactosyltransferase. Hatanka Y, et al. **Carbohydr Res** 1996 Nov 20;294:95-108

The synthesis of galactopyranosyl derivatives with beta-galactosidases of different origins. Yoon JH, et al. **Carbohydr Res** 1996 Oct 4;292:153-63

Two novel mutations in a Canadian family with aspartylglucosaminuria and early outcome post bone marrow transplantation. Laitinen A, et al. **Clin Genet** 1997 Mar;51(3):174-8

Voltage-dependent calcium channels and Gi regulatory protein mediate the human sperm acrosomal exocytosis induced by N-acetylglucosaminyl/mannosyl neoglycoproteins. Brandelli A, et al. **J Androl** 1996 Sep-Oct;17(5):522-9

Dansyl N-acetyl glucosamine as a precursor of fluorescent chitin: a method to detect fungal cell wall inhibitors. Carrano L, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):177-9

ANALYSIS

Peripheral alpha-linked N-acetylglucosamine on the carbohydrate moiety of mucin derived from mammalian gastric gland mucous cells: epitope recognized by a newly characterized monoclonal antibody. Ishihara K, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):409-16

Preparation of specific antiserum to 17 alpha-estradiol 17-N-acetylglucosaminide. Suzuki E, et al. **Biol Pharm Bull** 1996 Nov;19(11):1396-400

Fractionation and characterization of boar seminal plasma spermadhesion PSP-II glycoforms reveal the presence of uncommon N-acetylgalactosamine-containing N-linked oligosaccharides. Solis D, et al. **Glycoconj J** 1997 Feb; 14(2):275-80

Characterization of p92, karyopherin beta, co-purified with N-acetylglucosamine-bearing nucleoporins from rat liver nuclear envelopes. Makifuchi S, et al. **J Biochem (Tokyo)** 1996 Oct;120(4):716-24

BIOSYNTHESIS

Site of stimulation by mannosyl-P-dolichol of GlcNAc-lipid formation by microsomes of embryonic chick retina. Kean EL. **Glycoconj J** 1996 Aug;13(4):675-80

CHEMISTRY

Glycosylation beyond the Asn78-linked GlcNAc residue has a significant enhancing effect on the stability of the alpha subunit of human chorionic gonadotropin. van Zuylen CW, et al. **Biochem Biophys Res Commun** 1997 Mar 6; 232(1):117-20

Mimics of the sialyl Lewis X tetrasaccharide. Replacement of the N-acetylglucosamine sugar with simple C2-symmetric 1,2-diols. Prodger JC, et al. **Bioorg Med Chem** 1996 Jun;4(6):793-801

Isolation, characterization and inactivation of the mouse Mgat3 gene: the bisecting N-acetylglucosamine in asparagine-linked oligosaccharides appears dispensable for viability and reproduction. Priatel JJ, et al. **Glycobiology** 1997 Feb;7(1):45-56

Proton NMR study of triantennary complex type N-linked glycan chains: assignment of proton chemical shifts of the beta-Man residue in a basic unit of the triantennary glycan chain having a GlcNAc beta 1-->6 Man alpha 1-->6 Man beta-->sequence. Taguchi T, et al. **Glycobiology** 1997 Feb;7(1):31-6

Functional domains of bovine beta-1,4 galactosyltransferase. Boeggeman EE, et al. **Glycoconj J** 1995 Dec;12(6):865-78

Glycoproteins with N-acetylglucosamine and mannose residues in Chinese hamster metaphase chromosomes. Myllyharju J, et al. **Hereditas** 1996;124(3):251-9

The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. Arnold CS, et al. **J Biol Chem** 1996 Nov 15;271(46):28741-4

IMMUNOLOGY

Role of cell-associated N-acetyl-D-glucosamine specific haemagglutinin in the adhesion of Vibrio cholerae O1 to rabbit intestinal epithelial cells in vitro. Sasmal D, et al. **FEMS Immunol Med Microbiol** 1996 Feb;13(2):101-5

METABOLISM

Selective binding of N-acetylglucosamine to the chicken hepatic lectin. Burrows L, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):673-80

Characterization of a rat liver Golgi sulphotransferase responsible for the 6-O-sulphation of N-acetylglucosamine residues in beta-linkage to mannose: role in assembly of sialyl-galactosyl-N-acetylglucosamine 6-sulphate sequence of N-linked oligosaccharides. Spiro RG, et al. **Biochem J** 1996 Oct 1;319 (Pt 1):209-16

Affinity purification of N-acetylglucosamine specific lectins. Purification and partial charactersation of triticale lectin. Nadimpalli SK, et al. **Biochem Mol Biol Int** 1996 Apr; 38(5):1059-66

An in vivo approach for the identification of acceptor sites for O-glycosyltransferases: motifs for the addition of O-GlcNAc in Dictyostelium discoideum. Jung E, et al. **Biochemistry** 1997 Apr 1;36(13):4034-40

Post-partum flare in MRL-lpr/lpr mice is associated with a parallel increase of N-acetylglucosamine on serum IgG. Bond A, et al. **Br J Rheumatol** 1997 Feb;36(2):174-7

Transglycosylation of intact sialo complex-type oligosaccharides to the N-acetylglucosamine moieties of glycopeptides by Mucor hiemalis endo-beta-N-acetylglucosaminidase. Haneda K, et al. **Carbohydr Res** 1996 Oct 4;292:61-70

N-acetylglucosamine-dependent nuclear import of neoglycoproteins. Duverger E, et al. **Glycobiology** 1996 Jun;6(4):381-6

O-GlcNAcylation of key nuclear and cytoskeletal proteins: reciprocity with O-phosphorylation and putative roles in protein multimerization. Hart GW, et al. **Glycobiology** 1996 Oct;6(7):711-6 (120 ref.)

Targeting of active rat alpha 2,3-sialyltransferase to the yeast cell wall by the aid of the hsp 150 delta-carrier: toward synthesis of sLe(x)-decorated L-selectin ligands. Mattila P, et al. **Glycobiology** 1996 Dec;6(8):851-9

Evaluation of the early processing routes of N-linked oligosaccharides of glycoproteins through the characterization of Man8GlcNAc2 isomers: evidence that endomannosidase functions in vivo in the absence of a glucosidase blockade. Weng S, et al. **Glycobiology** 1996 Dec;6(8):861-8

Liposidomycin B inhibits in vitro formation of polyprenyl (pyro)phosphate N-acetylglucosamine, an intermediate in glycoconjugate biosynthesis [letter] Muroi M, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):103-4

A detailed lectin analysis of IgG glycosylation, demonstrating disease specific changes in terminal galactose and N-acetylglucosamine. Bond A, et al. **J Autoimmun** 1997 Feb;10(1):77-85

Mitotic arrest with nocodazole induces selective changes in the level of O-linked N-acetylglucosamine and accumulation of incompletely processed N-glycans on proteins from HT29 cells. Haltiwanger RS, et al. **J Biol Chem** 1997 Mar 28;272(13):8752-8

A subpopulation of estrogen receptors are modified by O-linked N-acetylglucosamine. Jiang MS, et al. **J Biol Chem** 1997 Jan 24;272(4):2421-8

Gene transfection-mediated overexpression of beta1,4-N-acetylglucosamine bisecting oligosaccharides in glioma cell line U373 MG inhibits epidermal growth factor receptor function. Rebbaa A, et al. **J Biol Chem** 1997 Apr 4;272(14):9275-9

The carbohydrate N-acetylglucosamine is involved in the guidance of neurites from chick ciliary ganglion neurons through the extracellular matrix of rat skeletal muscle fiber. Iglesias M, et al. **Neurosci Lett** 1996 Mar 29;207(2):81-4

A lectin from leaves of Neoregelia flandria recognizes D-glucose, D-mannose and N-acetyl D-glucosamine, differing from the mannose-specific lectins of other monocotyledonous plants. Yagi F, et al. **Plant Cell Physiol** 1996 Oct;37(7):1007-12

Nucleotide-sugar binding to ribosomes. Comparison of affinity and capacity of gastric mucosa and liver ribosomes to sugar-nucleotides. Paszkiewicz-Gadek A, et al. **Rocz Akad Med Bialymst** 1996;41(2):305-15

PHARMACOLOGY

Reassessment of the effect of glucagon and nucleotides on Candida albicans germ tube formation. Zelada A, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Jun;42(4):567-76

Defining oligosaccharide specificity for initial sperm-zona pellucida adhesion in the mouse. Thaler CD, et al. **Mol Reprod Dev** 1996 Dec;45(4):535-46

THERAPEUTIC USE

Pilot study of oral polymeric N-acetyl-D-glucosamine as a potential treatment for patients with osteoarthritis. Talent JM, et al. **Clin Ther** 1996 Nov-Dec;18(6):1184-90

URINE

The identification of novel steroid N-acetylglucosaminides in the urine of pregnant women. Meng LJ, et al. **J Steroid Biochem Mol Biol** 1996 Aug;58(5-6):585-98

ACETYLGLUCOSAMINIDASE

[Bacteriolytic enzymes produced by the staphylococci] Sugai M, et al. **Nippon Saikingaku Zasshi** 1997 Apr;52(2):461-73 (61 ref.) **(Jpn)**

ANALYSIS

Loading with oxidised low density lipoprotein alters endocytic and secretory activities of murine macrophages. Bolton EJ, et al. **Biochim Biophys Acta** 1997 Mar 27; 1356(1):12-22

Low molecular mass proteins and urinary enzymes in amniotic fluid of healthy pregnant women at progressive stages of gestation. Mussap M, et al. **Clin Biochem** 1996 Feb;29(1):51-6

Assessment of hepatic graft injury by graft effluent in rodents: N-acetyl-beta-glucosaminidase and type III procollagen peptide. Wakiyama S, et al. **Transpl Int** 1996;9(4):359-63

Milk N-acetyl-beta-D-glucosaminidase and serum albumin as indicators of subclinical mastitis in the camel. Abdurahman OA. **Zentralbl Veterinarmed A** 1995 Dec; 42(10):643-7

BLOOD

N-acetyl-beta-D-glucosaminidase as a marker of renal damage in hens. Forman MF, et al. **Poult Sci** 1996 Dec; 75(12):1563-8

CHEMISTRY

Structure-function studies on the chitinolytic enzymes of Serratia marcescens chitinase and chitobiase. Vorgias CE, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:190-2

Transfer of Man9GlcNAc to L-fucose by endo-beta-N-acetylglucosaminidase from Arthrobacter protophormiae. Fan JQ, et al. **Glycoconj J** 1996 Aug; 13(4):643-52

DRUG EFFECTS

The effect of erythritol on the stability of gamma-glutamyl transpeptidase and N-acetyl glucosaminidase in human urine. Loeb WF, et al. **Toxicol Pathol** 1997 May-Jun; 25(3):264-7

GENETICS

Molecular cloning and expression of the nag1 gene (N-acetyl-beta-D-glucosaminidase-encoding gene) from Trichoderma harzianum P1. Peterbauer CK, et al. **Curr Genet** 1996 Sep;30(4):325-31

Temperature-related expression of the vacuolar aspartic proteinase (APR1) gene and beta-N-acetylglucosaminidase (HEX1) gene during Candida albicans morphogenesis. Niimi M, et al. **FEMS Microbiol Lett** 1997 Mar 15; 148(2):247-54

Cloning and expression of the gene involved in Sanfilippo B syndrome (mucopolysaccharidosis III B). Weber B, et al. **Hum Mol Genet** 1996 Jun;5(6):771-7

Cloning, expression, and hormonal regulation of an insect beta-N-acetylglucosaminidase gene. Zen KC, et al. **Insect Biochem Mol Biol** 1996 May;26(5):435-44

Molecular cloning and characterization of a novel beta-N-acetyl-D-glucosaminidase from Vibrio furnissii. Chitlaru E, et al. **J Biol Chem** 1996 Dec 27;271(52):33433-9

ISOLATION & PURIFICATION

The chitin catabolic cascade in the marine bacterium Vibrio furnissii. Molecular cloning, isolation, and characterization of a periplasmic beta-N-acetylglucosaminidase. Keyhani NO, et al. **J Biol Chem** 1996 Dec 27;271(52):33425-32

METABOLISM

Porcine fibrinogen glycopeptides: substrates for detecting endo-beta-N-acetylglucosaminidases F2 and F3(1). Plummer TH Jr, et al. **Anal Biochem** 1996 Mar 1; 235(1):98-101

Viral infection. I. Regulation of protein synthesis during vaccinia viral infection of animal cells. Bose A, et al. **Arch Biochem Biophys** 1997 Jun 15;342(2):362-72

Viral infection. II. Hemin induces overexpression of p67 as it partially prevents appearance of an active p67-deglycosylase in baculovirus-infected insect cells. Saha D, et al. **Arch Biochem Biophys** 1997 Jun 15; 342(2):373-82

Kidney and urine enzyme activity in experimental gentamicin nephrotoxicity in the Sprague-Dawley rat. Brown D, et al. **Biochem Soc Trans** 1996 May;24(2):317S

Identification of hydrolase binding activities of the acrosomal matrix of hamster spermatozoa. NagDas SK, et al. **Biol Reprod** 1996 Dec;55(6):1405-14

Lysosomal enzymes in corneal storage media and corneal graft outcome. Wiffen SJ, et al. **Cornea** 1997 Mar; 16(2):169-76

Molecular cloning and expression of the nag1 gene (N-acetyl-beta-D-glucosaminidase-encoding gene) from Trichoderma harzianum P1. Peterbauer CK, et al. **Curr Genet** 1996 Sep;30(4):325-31

Changes in N-acetyl-beta-D-glucosaminidase binding system in rat liver during growth. Sosa MA, et al. **Mech Ageing Dev** 1996 Feb 24;86(2):75-81

Adhesiveness for extracellular matrices and lysosomal enzyme release from normal and beta 2 integrin-deficient bovine neutrophils. Nagahata H, et al. **Microbiol Immunol** 1996;40(10):783-6

The relationship between enzymuria and kidney enzyme activities in experimental gentamicin nephrotoxicity. Whiting PH, et al. **Ren Fail** 1996 Nov;18(6):899-909

Lysosomal enzyme activities in cultured retinal pigment epithelial and glial cells of RCS rat. Hu J, et al. **Yen Ko Hsueh Pao** 1996 Mar;12(1):20-7

SECRETION

Dexamethasone downregulates lysosomal secretion in mouse macrophages: involvement of signaling through protein kinase C. Gewert K, et al. **J Inflamm** 1995-96;47(3):115-25

URINE

Increased urinary excretion of N-acetyl-beta-D-glucosaminidase in patients affected with psoriasis [letter] Cecchi R, et al. **Acta Derm Venereol** 1996 Nov;76(6):492

Urinary N-acetyl-beta-D-glucosaminidase changes in relation to age, sex, race, and diastolic and systolic blood pressure in a young adult biracial population. The Bogalusa Heart Study. Agirbasli M, et al. **Am J Hypertens** 1996 Feb; 9(2):157-61

Comparison of urinary albumin, retinol-binding protein and N-acetyl beta-glucosaminidase as predictors of progression of low level albuminuria in diabetes. O'Brien SF, et al. **Ann Clin Biochem** 1997 Mar;34 (Pt 2):202-4

Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta-lactam antibiotics. Nix DE, et al. **Ann Pharmacother** 1997 Jun; 31(6):696-703

Indices of renal tubular function in perinatal asphyxia. Willis F, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Jul; 77(1):F57-60

Effects of cadmium and lead exposure on urinary N-acetyl-beta-D-glucosaminidase, beta 2-microglobulin and metallothionein of workers. Kawada T, et al. **Asia Pac J Public Health** 1995;8(2):91-4

Diuresis-dependent excretion of enzymes in rat urine. Obatomi DK, et al. **Biochem Soc Trans** 1997 Feb;25(1):67S

N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment. Wiland P, et al. **Br J Rheumatol** 1997 Jan;36(1):59-63

New sandwich ELISA for human urinary N-acetyl-beta-D-glucosaminidase isoenzyme B as a useful clinical test. Numata Y, et al. **Clin Chem** 1997 Apr; 43(4):569-74

Effect of antiorthostatic hypokinetic/hypodynamia on urinary endothelin-1 and N-acetyl-beta-D-glucosaminidase excretion in rats. Capodicasa E, et al. **Clin Chim Acta** 1997 Apr 4; 260(1):35-48

Origin and significance of urinary N-acetyl-beta, D-glucosaminidase (NAG) in renal patients with proteinuria. Costigan MG, et al. **Clin Chim Acta** 1996 Nov 29;255(2):133-44

Changes in the urinary excretion of creatinine, albumin and N-acetyl-beta-D-glucosaminidase with increasing age and maturity in healthy schoolchildren. Skinner AM, et al. **Eur J Pediatr** 1996 Jul;155(7):596-602

Enzymuria as early marker of interstitial nephritis. Neimark A, et al. **Int Urol Nephrol** 1997;29(2):137-40

Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced "hepatorenal syndrome". Fink JC, et al. **J Am Soc Nephrol** 1995 Dec; 6(6):1655-60

Analysis of urinary N-acetyl-beta-glucosaminidase by capillary zone electrophoresis. Friedberg M, et al. **J Chromatogr B Biomed Appl** 1997 Jul 18;695(1):187-91

Cyclosporine nephrotoxicity and rejection crisis: diagnosis by urinary enzyme excretion. Bornstein B, et al. **Nephron** 1996;72(3):402-6

Urinary N-acetyl-beta-D-glucosaminidase and beta 2-microglobulin excretion in primary nephrotic children. Calişkan S, et al. **Nephron** 1996;74(2):401-4

Urinary N-acetyl-beta-D-glucosaminidase activity in rabbits with experimental hypercalciuria. Türkmen M, et al. **Pediatr Nephrol** 1997 Aug;11(4):481-4

N-acetyl-beta-D-glucosaminidase as a marker of renal damage in hens. Forman MF, et al. **Poult Sci** 1996 Dec; 75(12):1563-8

In fetuses with isolated hydronephrosis, urinary beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase (NAG) have a limited role in the prediction of postnatal renal function. Tassis BM, et al. **Prenat Diagn** 1996 Dec; 16(12):1087-93

Hemodialysis exacerbates enzymuria in patients with acute renal failure: brief report. Fink JC, et al. **Ren Fail** 1996 Nov;18(6):947-50

Serum levels of IgG antibodies against Tamm-Horsfall protein and urinary excretion of NAG and alpha-1-microglobulin as possible markers for tubular damage in patients with a continent ileal reservoir for urinary diversion. Campanello M, et al. **Scand J Urol Nephrol** 1997 Jun;31(3):237-43

N-acetyl-beta-D-glucosaminidase excretion in calcium oxalate stone patients and its relation to the risk of stone formation. Winter P, et al. **Scand J Urol Nephrol** 1996 Dec; 30(6):439-43

The effect of erythritol on the stability of gamma-glutamyl transpeptidase and N-acetyl glucosaminidase in human urine. Loeb WF, et al. **Toxicol Pathol** 1997 May-Jun; 25(3):264-7

Tubular markers in children with insulin-dependent diabetes mellitus. Calişkan S, et al. **Turk J Pediatr** 1997 Apr-Jun; 39(2):213-8

N-acetyl-beta-D-glucosaminidase excretion in patients with unilateral renal agenesis or nephrectomy in childhood. Tekin N, et al. **Turk J Pediatr** 1996 Oct-Dec;38(4):485-90

[Clinical significance of changes of urinary enzymes in pregnancy induced hypertension] Tian G, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Aug;31(8):465-7 (Eng. Abstr.) **(Chi)**

[Evaluation of N-acetyl-beta glucosaminidase in upper and lower urinary tract infections in childhood. Clinical study of 168 children] Belli A, et al. **Minerva Pediatr** 1996 Nov; 48(11):503-7 (Eng. Abstr.) **(Ita)**

[Urinary excretion of ulinastatin and NAG after cardiopulmonary bypass] Yokono S, et al. **Masui** 1997 Mar; 46(3):388-92 (Eng. Abstr.) **(Jpn)**

[Urinary enzymes in insulin-dependent diabetes mellitus] Platonova LV, et al. **Vopr Med Khim** 1996 Jan-Mar; 42(1):70-6 (Eng. Abstr.) **(Rus)**

TRANS-N-ACETYLGLUCOSAMINOSYLASE see **CHITIN SYNTHASE**

N-ACETYLGLUCOSAMINYLTRANSFERASES

ANALYSIS

UDP-N-acetylglucosamine transferase and glutamine: fructose 6-phosphate amidotransferase activities in insulin-sensitive tissues. Yki-Järvinen H, et al. **Diabetologia** 1997 Jan;40(1):76-81

Preparation of antisera to recombinant, soluble N-acetylglucosaminyltransferase V and its visualization in situ. Chen L, et al. **Glycoconj J** 1995 Dec;12(6):813-23

ANTAGONISTS & INHIBITORS

New synthetic trisaccharide inhibitors for N-acetylglucosaminyltransferase-V. Lu PP, et al. **Bioorg Med Chem** 1996 Nov;4(11):2011-22

BIOSYNTHESIS

Pilot scale expression and purification of soluble protein A tagged beta 1,6N-acetylglucosaminyltransferase in CHO cells. Zeng S, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):653-8

Effects of dibutyryl cAMP and bromodeoxyuridine on expression of N-acetylglucosaminyltransferases III and V in GOTO neuroblastoma cells. Ihara Y, et al. **Glycoconj J** 1995 Dec;12(6):787-94

Induction of Rhizobium meliloti nodC gene by Alnus incana compounds. Małek W. **J Basic Microbiol** 1996;36(5):319-26

A point mutation causes mistargeting of Golgi GlcNAc-TV in the Lec4A Chinese hamster ovary glycosylation mutant. Weinstein J, et al. **J Biol Chem** 1996 Nov 1;271(44):27462-9

BLOOD

Alpha-fetoprotein-producing renal cell carcinoma with increased activity of N-acetylglucosaminyl-transferase III. Aoyagi Y, et al. **Nephron** 1996;74(2):409-14

CHEMISTRY

Synthetic substrate analogues for UDP-GlcNAc: Man alpha 1-3R beta 1-2-N-acetylglucosaminyltransferase I. Substrate specificity and inhibitors for the enzyme. Reck F, et al. **Glycoconj J** 1995 Dec;12(6):747-54

Hamster UDP-N-acetylglucosamine:dolichol-P N-acetylglucosamine-1-P transferase has multiple transmembrane spans and a critical cytosolic loop. Dan N, et al. **J Biol Chem** 1996 Nov 29;271(48):30717-24

O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. Lubas WA, et al. **J Biol Chem** 1997 Apr 4; 272(14):9316-24

A point mutation causes mistargeting of Golgi GlcNAc-TV in the Lec4A Chinese hamster ovary glycosylation mutant. Weinstein J, et al. **J Biol Chem** 1996 Nov 1;271(44):27462-9

Circular dichroic spectroscopy of N-acetylglucosaminyltransferase V and its substrate interactions. Zhang N, et al. **J Biol Chem** 1997 Feb 14; 272(7):4225-9

GENETICS

Mutations in the MGAT2 gene controlling complex N-glycan synthesis cause carbohydrate-deficient glycoprotein syndrome type II, an autosomal recessive disease with defective brain development. Tan J, et al. **Am J Hum Genet** 1996 Oct;59(4):810-7

Organization of the human beta-1,2-N-acetylglucosaminyltransferase I gene (MGAT1), which controls complex and hybrid N-glycan synthesis. Yip B, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):465-74

Isolation and characterization of a pseudogene related to human core 2 beta-1,6-N-acetylglucosaminyl-transferase. Bierhuizen MF, et al. **Glycoconj J** 1995 Dec;12(6):857-64

Recent progress in the molecular biology of the cloned N-acetylglucosaminyltransferases. Taniguchi N, et al. **Glycoconj J** 1995 Dec;12(6):733-8 (55 ref.)

Two glycosyltransferase genes, lgtF and rfaK, constitute the lipooligosaccharide ice (inner core extension) biosynthesis operon of Neisseria meningitidis. Kahler CM, et al. **J Bacteriol** 1996 Dec;178(23):6677-84

Deletion of two exons from the Lymnaea stagnalis beta1-->4-N-acetylglucosaminyltransferase gene elevates the kinetic efficiency of the encoded enzyme for both UDP-sugar donor and acceptor substrates. Bakker H, et al. **J Biol Chem** 1997 Jul 25;272(30):18580-5

Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene. Buckhaults P, et al. **J Biol Chem** 1997 Aug 1; 272(31):19575-81

Transcriptional regulation of the N-acetylglucosaminyltransferase V gene in human bile duct carcinoma cells (HuCC-T1) is mediated by Ets-1. Kang R, et al. **J Biol Chem** 1996 Oct 25;271(43):26706-12

Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. Kreppel LK, et al. **J Biol Chem** 1997 Apr 4;272(14):9308-15

Glycosylation defect in Lec1 Chinese hamster ovary mutant is due to a point mutation in N-acetylglucosaminyltransferase I gene. Puthalakath H, et al. **J Biol Chem** 1996 Nov 1;271(44):27818-22

The common nodABC genes of Rhizobium meliloti are host-range determinants. Roche P, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15305-10

[Sugar chain remodeling by N-acetylglucosaminyltransferase III gene and its significance as a coordinator of glycoprotein function] Ihara Y. **Seikagaku** 1997 Mar; 69(3):172-6 (14 ref.) **(Jpn)**

IMMUNOLOGY

Expression of a cytoplasmically epitope-tagged human Golgi glycosyltransferase in homologous cells results in mislocalization of multiple Golgi proteins. Yang W, et al. **Cell Biol Int** 1997 Apr;21(4):223-8

ISOLATION & PURIFICATION

Pilot scale expression and purification of soluble protein A tagged beta 1,6N-acetylglucosaminyltransferase in CHO cells. Zeng S, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):653-8

Expression of the large I antigen forming beta-1,6-N-acetylglucosaminyltransferase in various tissues of adult mice. Magnet AD, et al. **Glycobiology** 1997 Mar;7(2):285-95

Isolation, characterization and inactivation of the mouse Mgat3 gene: the bisecting N-acetylglucosamine in asparagine-linked oligosaccharides appears dispensable for viability and reproduction. Priatel JJ, et al. **Glycobiology** 1997 Feb;7(1):45-56

Purification and characterization of UDP-N-acetylglucosamine: alpha1,3-D-mannoside beta1,4-N-acetylglucosaminyltransferase (N-acetylglucosaminyltransferase-IV) from bovine small

intestine. Oguri S, et al. **J Biol Chem** 1997 Sep 5; 272(36):22721–7

METABOLISM

Activity of UDP-GlcNAc:GlcNAc beta 1—>6(GlcNAc beta 1—>2) Man alpha 1—>R[GlcNAc to Man] beta 1—>4N-acetylglucosaminyltransferase VI (GnT VI) from the ovaries of Oryzias latipes (Medaka fish). Taguchi T, et al. **Biochem Biophys Res Commun** 1997 Jan 23; 230(3):533–6

Significant downregulation of the major swine xenoantigen by N-acetylglucosaminyltransferase III gene transfection. Tanemura M, et al. **Biochem Biophys Res Commun** 1997 Jun 18;235(2):359–64

Expression of stable human O-glycan core 2 beta-1,6-N-acetylglucosaminyltransferase in Sf9 insect cells. Toki D, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):63–9

Effects of epidermal growth factor and insulin on the activity of N-acetylglucosaminyltransferase V. Wang Q, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):543–5

Association of lipid A disaccharide synthase with aerobic glycerol-3-phosphate dehydrogenase in extracts of Escherichia coli. Milla ME, et al. **Biochim Biophys Acta** 1996 Dec 13;1304(3):245–53

1H and 13C NMR analysis of the pentasaccharide Gal beta (1—>4)GlcNAc beta (1—>3)-[GlcNAc beta (1—>6)]Gal beta (1—>4)GlcNAc synthesized by the mid-chain beta-(1—>6)-D-N-acetylglucosaminyltransferase of rat serum. Maaheimo H, et al. **Carbohydr Res** 1997 Jan 2; 297(2):145–51

The beta 1,6-GlcNAc transferase activity present in hog gastric mucosal microsomes catalyses site-specific branch formation on a long polylactosamine backbone. Helin J, et al. **FEBS Lett** 1997 Aug 4;412(3):637–42

The substrate specificity of the snail Lymnaea stagnalis UDP-GlcNAc:GlcNAc beta-R beta 4-N-acetylglucosaminyltransferase reveals a novel variant pathway of complex-type oligosaccharide synthesis. Bakker H, et al. **Glycobiology** 1997 Jun;7(4):539–48

Modification of CD43 and other lymphocyte O-glycoproteins by core 2 N-acetylglucosaminyltransferase. Barran P, et al. **Glycobiology** 1997 Feb;7(1):129–36

Partial purification and substrate specificity of heparan sulfate alpha-N-acetylglucosaminyltransferase I: synthesis, NMR spectroscopic characterization and in vitro assays of two aryl tetrasaccharides. Fritz TA, et al. **Glycobiology** 1997 Jul;7(5):587–95

Enzymatic transfer of a beta1,6-linked N-acetylglucosamine to the alpha-galactose of globo-N-tetraose: in vitro synthesis of a novel hybrid pentasaccharide of lacto-globo type. Natunen J, et al. **Glycobiology** 1997 Jul;7(5):711–8

Remodeling of cell surface glycoproteins by N-acetylglucosaminyltransferase III gene transfection: modulation of metastatic potentials and down regulation of hepatitis B virus replication. Taniguchi N, et al. **Glycobiology** 1996 Oct;6(7):691–4 (25 ref.)

N-Acetylglucosaminyl transferase regulates the expression of the sulfoglucuronyl glycolipids in specific cell types in cerebellum during development. Chou DKH, et al. **J Biol Chem** 1996 Nov 15;271(46):28868–74

Overexpression of N-acetylglucosaminyltransferase III disrupts the tyrosine phosphorylation of Trk with resultant signaling dysfunction in PC12 cells treated with nerve growth factor. Ihara Y, et al. **J Biol Chem** 1997 Apr 11; 272(15):9629–34

Glycosylation defect in Lec1 Chinese hamster ovary mutant is due to a point mutation in N-acetylglucosaminyltransferase I gene. Puthalakath H, et al. **J Biol Chem** 1996 Nov 1;271(44):27818–22

Altered Golgi localization of core 2 beta-1,6-N-acetylglucosaminyltransferase leads to decreased synthesis of branched O-glycans. Skrincosky D, et al. **J Biol Chem** 1997 Sep 5;272(36):22695–702

Bisecting GlcNAc structures act as negative sorting signals for cell surface glycoproteins in forskolin-treated rat hepatoma cells. Sultan AS, et al. **J Biol Chem** 1997 Jan 31;272(5):2866–72

Changes in N-acetylglucosaminyltransferase III, IV and V in renal cell carcinoma. Zhu TY, et al. **J Cancer Res Clin Oncol** 1997;123(5):296–9

Partitioning of the Golgi apparatus during mitosis in living HeLa cells. Shima DT, et al. **J Cell Biol** 1997 Jun 16; 137(6):1211–28

The role of the membrane-spanning domain and stalk region of N-acetylglucosaminyltransferase I in retention, kin recognition and structural maintenance of the Golgi apparatus in HeLa cells. Nilsson T, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1975–89

Reduction of the major swine xenoantigen Gal alpha (1,3)Gal by transfection of N-acetylglucosaminyl transferase III (GnT-III) gene. Tanemura M, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):891–2

Suppression of the xenoantigen Gal alpha(1,3)Gal by N-acetylglucosaminyltransferase III (GnT-III) in transgenic mice. Tanemura M, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):895–6

PHYSIOLOGY

Organization of the human beta-1,2-N-acetylglucosaminyltransferase I gene (MGAT1), which controls complex and hybrid N-glycan synthesis. Yip B, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):465–74

Core2 beta-1,6-N-acetylglucosaminyltransferase enzyme activity is critical for P-selectin glycoprotein ligand-1 binding to P-selectin. Kumar R, et al. **Blood** 1996 Nov 15;88(10):3872–9

Regulation of N-acetylglucosaminyltransferase V by protein kinases. Ju TZ, et al. **Glycoconj J** 1995 Dec;12(6):767–72

Rhizobium nodulation protein NodC is an important determinant of chitin oligosaccharide chain length in Nod factor biosynthesis. Kamst E, et al. **J Bacteriol** 1997 Apr; 179(7):2103–8

Essential role for complex N-glycans in forming an organized layer of bronchial epithelium. Ioffe E, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):11041–6

[Sugar chain remodeling by N-acetylglucosaminyltransferase III gene and its significance as a coordinator of glycoprotein function] Ihara Y. **Seikagaku** 1997 Mar; 69(3):172–6 (14 ref.) **(Jpn)**

N-ACETYLLACTOSAMINE SYNTHASE

ANTAGONISTS & INHIBITORS

A chemoenzymatic synthesis of UDP-(2-deoxy-2-fluoro)-galactose and evaluation of its interaction with galactosyltransferase. Hayashi T, et al. **Bioorg Med Chem** 1997 Mar;5(3):497–500

A search for pyrophosphate mimics for the development of substrates and inhibitors of glycosyltransferases. Wang R, et al. **Bioorg Med Chem** 1997 Apr;5(4):661–72

BLOOD

Serum galactosyltransferase as a marker of disease activity in rheumatoid arthritis. Alavi A, et al. **Biochem Soc Trans** 1997 May;25(2):313S

CHEMISTRY

Functional domains of bovine beta-1,4 galactosyltransferase. Boeggeman EE, et al. **Glycoconj J** 1995 Dec;12(6):865–78

DEFICIENCY

Growth retardation and early death of beta-1,4-galactosyltransferase knockout mice with augmented proliferation and abnormal differentiation of epithelial cells. Asano M, et al. **EMBO J** 1997 Apr 15; 16(8):1850–7

GENETICS

Targeted mutation in beta1,4-galactosyltransferase leads to pituitary insufficiency and neonatal lethality. Lu Q, et al. **Dev Biol** 1997 Jan 15;181(2):257–67

Molecular cloning and characterization of beta-1,4-galactosyltransferase expressed in mouse testis. Uehara K, et al. **Eur J Biochem** 1997 Mar 15;244(3):706–12

Characterization and developmental regulation of avian corneal beta-1,4-galactosyltransferase mRNA. Cai CX, et al. **Exp Eye Res** 1996 Aug;63(2):193–200

The stability of lymphocytic beta 1,4-galactosyltransferase expression during pregnancy and lactation. Jeddi PA, et al. **Scand J Immunol** 1997 Feb;45(2):145–50

ISOLATION & PURIFICATION

Modification of the cytoplasmic domain affects the subcellular localization of Golgi glycosyl-transferases. Yang W, et al. **Eur J Cell Biol** 1996 Sep;71(1):53–61

METABOLISM

Effect of all-trans-retinoic acid and phorbol 12-myristate 13-acetate on the activity of human hepatocellular carcinoma cell-surface beta-1,4-galactosyltransferase. Zhou D, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):623–5

Sperm plasma membrane remodeling during spermiogenetic maturation in men: relationship among plasma membrane beta 1,4-galactosyltransferase, cytoplasmic creatine phosphokinase, and creatine phosphokinase isoform ratios. Huszar G, et al. **Biol Reprod** 1997 Apr;56(4):1020–4

Sperm from a variety of mammalian species express beta1,4-galactosyltransferase on their surface. Larson JL, et al. **Biol Reprod** 1997 Aug;57(2):442–53

Mammary gland morphogenesis is inhibited in transgenic mice that overexpress cell surface beta1,4-galactosyltransferase. Hathaway HJ, et al. **Development** 1996 Sep;122(9):2859–72

Distinct compartmentalization of TGN46 and beta 1,4-galactosyltransferase in HeLa cells. Prescott AR, et al. **Eur J Cell Biol** 1997 Mar;72(3):238–46

Human melanoma and Chinese hamster ovary cells galactosylate n-alkyl-beta-glucosides using UDP gal:GlcNAc beta 1,4 galactosyltransferase. Pörtner A, et al. **Glycobiology** 1996 Jan;6(1):7–13

GTP-bound forms of rab6 induce the redistribution of Golgi proteins into the endoplasmic reticulum. Martinez O, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1828–33

N-ACETYLLACTOSAMINE SYNTHETASE see

N-ACETYLLACTOSAMINE SYNTHASE

ACETYLMETHADOL see **METHADYL ACETATE**

ACETYLMETHYLCARBINOL see **ACETOIN**

N-ACETYLMURAMOYL-L-ALANINE AMIDASE

On the misuse of the term 'lysozyme' [letter] Garcïa E. **Mol Microbiol** 1996 Aug;21(4):885

[Bacteriolytic enzymes produced by the staphylococci] Sugai M, et al. **Nippon Saikingaku Zasshi** 1997 Apr;52(2):461–73 (61 ref.) **(Jpn)**

ANALYSIS

Application of autolysin and deoxyribonuclease profiles generated by renaturing SDS-PAGE in the comparison of selected Proteobacteria. Charnock C. **Arch Microbiol** 1997 Jun;167(6):356–62

Localization of germination-specific spore-lytic enzymes in Clostridium perfringens S40 spores detected by immunoelectron microscopy. Miyata S, et al. **FEMS Microbiol Lett** 1997 Jul 15;152(2):243–7

ANTAGONISTS & INHIBITORS

Inhibition of peptidoglycan hydrolase activity in vivo and in vitro by energy uncouplers in Escherichia coli. Rodionov DG, et al. **Microb Drug Resist** 1996 Spring; 2(1):131–4

BIOSYNTHESIS

Expression and intracellular localization of the human N-acetylmuramyl-L-alanine amidase, a bacterial cell wall-degrading enzyme. Hoijer MA, et al. **Blood** 1997 Aug 1;90(3):1246–54

CHEMISTRY

Structural characterization of the unligated and choline-bound forms of the major pneumococcal autolysin LytA amidase. Conformational transitions induced by temperature. Medrano FJ, et al. **J Biol Chem** 1996 Nov 15;271(46):29152–61

GENETICS

Sequencing and analysis of four new Enterobacter ampD Alleles. Ehrhardt AF, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1953–6

Allelic variation in Streptococcus pneumoniae autolysin (N-acetyl muramoyl-L-alanine amidase). Gillespie SH, et al. **Infect Immun** 1997 Sep;65(9):3936–8

Molecular cloning, sequencing, and expression of lytM, a unique autolytic gene of Staphylococcus aureus. Ramadurai L, et al. **J Bacteriol** 1997 Jun;179(11):3625–31

Cloning and expression of a gene encoding Moraxella sp. CK-1 autolysin. Ohn TB, et al. **Mol Cells** 1997 Jun 30; 7(3):367–73

ISOLATION & PURIFICATION

Subcellular localization of the major autolysin, ATL and its processed proteins in Staphylococcus aureus. Komatsuzawa H, et al. **Microbiol Immunol** 1997; 41(6):469–79

METABOLISM

Characterisation of the peptidoglycan hydrolases of Listeria monocytogenes EGD. McLaughlan AM, et al. **FEMS Microbiol Lett** 1997 Jul 1;152(1):149–54

Localized perforation of the cell wall by a major autolysin: atl gene products and the onset of penicillin-induced lysis of Staphylococcus aureus. Sugai M, et al. **J Bacteriol** 1997 May;179(9):2958–62

The Listeria monocytogenes-secreted p60 protein is an N-end rule substrate in the cytosol of infected cells. Implications for major histocompatibility complex class I antigen processing of bacterial proteins. Sijts AJ, et al. **J Biol Chem** 1997 Aug 1;272(31):19261–8

Molecular interplay of murein synthases and murein hydrolases in Escherichia coli. Höltje JV. **Microb Drug Resist** 1996 Spring;2(1):99–103 (43 ref.)

Peptidoglycan hydrolases of Bacillus subtilis 168. Smith TJ, et al. **Microb Drug Resist** 1996 Spring;2(1):113–8 (40 ref.)

Evidence for autolysin-mediated primary attachment of Staphylococcus epidermidis to a polystyrene surface. Heilmann C, et al. **Mol Microbiol** 1997 Jun;24(5):1013–24

PHYSIOLOGY

Bacterial walls, peptidoglycan hydrolases, autolysins, and autolysis. Shockman GD, et al. **Microb Drug Resist** 1996 Spring;2(1):95–8 (19 ref.)

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE

Bacterial products and the control of ingestive behavior: clinical implications. Langhans W. **Nutrition** 1996 May; 12(5):303–15 (110 ref.)

Fever and production of cytokines in response to repeated

injections of muramyl dipeptide in guinea-pigs. Roth J, et al. **Pflugers Arch** 1997 Sep;434(5):525–33

ADMINISTRATION & DOSAGE

Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines. Sarkar K, et al. **J Immunol** 1997 Jun 1; 158(11):5357–65

ANALOGS & DERIVATIVES

Location of N-acetylmuramyl-L-alanyl-D-glutamylmesodiaminopimelic acid, presumed signal molecule for beta-lactamase induction, in the bacterial cell. Dietz H, et al. **Antimicrob Agents Chemother** 1996 Sep; 40(9):2173–7

Effect of dimerization of the D-glucose analogue of muramyl dipeptide on stimulation of macrophage-like cells. Murata J, et al. **Carbohydr Res** 1997 Jan 2;297(2):127–33

Selective potentiation of cytokine expression in human whole blood by murabutide, a muramyl dipeptide analogue. Darcissac EC, et al. **Cytokine** 1996 Aug;8(8):658–66

Inflammatory cytokine production induced by an analogue of muramyl dipeptide MDP-Lys(L18) in rat macrophage cultures and dog synovial fluid. Sugawara T, et al. **Inflammation** 1996 Feb;20(1):43–56

The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production. Venkataprasad N, et al. **Int Arch Allergy Immunol** 1997 Sep;114(1):23–9

Combined modality radioprotection: enhancement of survival and hematopoietic recovery in gamma-irradiated mice by the joint use of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and indomethacin. Fedoročko P, et al. **Int J Immunopharmacol** 1996 May; 18(5):329–37

Distinctive immunomodulating properties and interactivity with model membranes and cells of two homologous muramyl dipeptide derivatives differing by their lipophilicity. Kalyuzhin OV, et al. **Int J Immunopharmacol** 1996 Nov;18(11):651–9

N-acetylglucosamine-containing muramyl peptides directly affect macrophages. Khaidukov SV, et al. **Int J Immunopharmacol** 1995 Nov;17(11):903–11

Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. Quan WD Jr, et al. **J Clin Oncol** 1997 May; 15(5):2103–10

Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide. Bahr GM, et al. **J Interferon Cytokine Res** 1996 Apr;16(4):297–306

Synthesis and immunostimulating properties of lipophilic ester and ether muramyl peptide derivatives. Merhi G, et al. **J Med Chem** 1996 Oct 25;39(22):4483–8

Preparation of influenza virosome vaccine with muramyldipeptide derivative B30-MDP. Ando S, et al. **J Microencapsul** 1997 Jan-Feb;14(1):79–90

Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus. Fukushima A, et al. **Vaccine** 1996 Apr; 14(6):485–91

The effect of Syntex adjuvant formulation (SAF-m) on humoral immunity to the influenza virus in the mouse. Hjorth RN, et al. **Vaccine** 1997 Apr;15(5):541–6

Romurtide, a synthetic muramyl dipeptide derivative, promotes megakaryocytopoiesis through stimulation of cytokine production in nonhuman primates with myelosuppression. Namba K, et al. **Vaccine** 1997 Mar; 15(4):405–13

Oral application of romurtide, a synthetic muramyl dipeptide derivative, stimulates nonspecific resistance to microbial infections and hematopoiesis in mice. Namba K, et al. **Vaccine** 1996 Aug;14(12):1149–53

Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model. Namba K, et al. **Vaccine** 1996 Oct;14(14):1322–6

The role of N-actylglucosaminyl-1,6 anhydro N-acetylmuramyl-L-alanyl-D-glutamyl-meso-diaminopimelic acid-D-alanine for the induction of beta-lactamase in Enterobacter cloacae. Dietz H, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):207–17

[JOMOL—immunostimulation and rejection of tumor cells?] Allewelt MC, et al. **Schweiz Rundsch Med Prax** 1997 May 14;86(20):856–60 (29 ref.) (Eng. Abstr.) **(Ger)**

[L-MTP-PE—a potential antineoplastic agent] Dzierzbicka K, et al. **Postepy Hig Med Dosw** 1997;51(2):227–36 (37 ref.) (Eng. Abstr.) **(Pol)**

[Effect of novel derivatives of muramyl dipeptide on the immune system] Kaliuzhin OV, et al. **Biull Eksp Biol Med** 1994 May;117(5):510–3 **(Rus)**

[The effect of hydrolipophilic balance of muramyl dipeptide derivatives on their interaction with biomembranes and incorporation into cells] Kaliuzhin OV, et al. **Biull Eksp Biol Med** 1996 Dec;122(12):658–61 **(Rus)**

[Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)] Ivanov VT, et al. **Klin Med (Mosk)** 1997; 75(3):11–5 (45 ref.) **(Rus)**

CHEMISTRY

[The effect of hydrolipophilic balance of muramyl dipeptide derivatives on their interaction with biomembranes and incorporation into cells] Kaliuzhin OV, et al. **Biull Eksp Biol Med** 1996 Dec;122(12):658–61 **(Rus)**

IMMUNOLOGY

Effect of dimerization of the D-glucose analogue of muramyl dipeptide on stimulation of macrophage-like cells. Murata J, et al. **Carbohydr Res** 1997 Jan 2;297(2):127–33

Micrococcus luteus cells and cell walls induce anaphylactoid reactions accompanied by early death and serum cytokines in mice primed with muramyl dipeptide. Monodane T, et al. **FEMS Immunol Med Microbiol** 1997 Jan;17(1):49–55

METABOLISM

Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes. Weidemann B, et al. **Infect Immun** 1997 Mar;65(3):858–64

Further evidence on the interaction of muramyl dipeptide with the serotonergic system. Slánský J, et al. **Int J Immunopharmacol** 1996 Jan;18(1):23–9

PHARMACOLOGY

Bacterial cell wall products increase monocyte HLA-DR and ICAM-1 without affecting lymphocyte CD18 expression. Heinzelmann M, et al. **Cell Immunol** 1997 Mar 15;176(2):127–34

Further evidence on the interaction of muramyl dipeptide with the serotonergic system. Slánský J, et al. **Int J Immunopharmacol** 1996 Jan;18(1):23–9

Oral administration of muramyl dipeptide into mice modulates cell proliferation, immunoglobulin synthesis and cytokine mRNA levels in gut associated lymphoid tissues. Zunić M, et al. **Int J Immunopharmacol** 1996 Feb; 18(2):155–62

Role of endogenous morphine in the attenuation of opiate withdrawal syndrome by N-acetylmuramyl-L-alanine-D-isoglutamine (MDP). Munjal ID, et al. **Neuropsychopharmacology** 1996 Jul; 15(1):99–103

Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro. Krivorutchenko YL, et al. **Vaccine** 1997 Aug-Sep; 15(12–13):1479–86

[Effect of novel derivatives of muramyl dipeptide on the immune system] Kaliuzhin OV, et al. **Biull Eksp Biol Med** 1994 May;117(5):510–3 **(Rus)**

[Dynamics of changes in macrophage activity, metabolic activity of the liver, and level of cortisol in murine serum when administering bacterial immunostimulants] Sibiriak SV, et al. **Biull Eksp Biol Med** 1996 Feb;121(2):177–80 **(Rus)**

[Differential effect of glucosaminylmuramyl dipeptide on the phenotype of melanoma sublines with different metastatic potential] Valiakina TI, et al. **Mol Biol (Mosk)** 1996 Nov-Dec;30(6):1394–401 **(Rus)**

[Effect of saponins from Hedera taurica Carr. and modified muramylpeptides on replication of human immunodeficiency virus in vitro] Krivorutchenko IuL, et al. **Vopr Virusol** 1997 Jan-Feb;42(1):34–6 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Enhancement by muramyl peptides of the protective response of interferon-alpha/beta against encephalomyocarditis virus infection. Pouillart PR, et al. **Int J Immunopharmacol** 1996 Mar;18(3):183–92

TOXICITY

Liposomal phosphatidylserine inhibits tumor cytotoxicity of liver macrophages induced by muramyl dipeptide and lipopolysaccharide. Daemen T, et al. **Biochim Biophys Acta** 1996 Dec 4;1285(2):219–28

Muramyl-dipeptide-induced fever in cats. Amini-Sereshki-Kormi L. **Pathobiology** 1996;64(5):279–83

N-ACETYLNEURAMINIC ACIDS see **SIALIC ACIDS**

ACETYLPROCAINAMIDE see **ACECAINIDE**

ACETYLPROMAZINE see **ACEPROMAZINE**

ACETYLSALICYLIC ACID see **ASPIRIN**

O-ACETYLSERINE SULFHYDRYLASE see **CYSTEINE SYNTHASE**

ACETYLSEROTONIN METHYLTRANSFERASE

BIOSYNTHESIS

Circadian regulation of hydroxyindole-O-methyltransferase mRNA in the chicken pineal gland in vivo and in vitro. Grève P, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):761–6

Hydroxyindole-O-methyltransferase in Y-79 cells: regulation by serum. Bernard M, et al. **Brain Res** 1996 Jul 15;727(1–2):118–24

Hydroxyindole-O-methyltransferase mRNA expression in a subpopulation of photoreceptors in the chicken retina. Wiechmann AF. **J Pineal Res** 1996 May;20(4):217–25

GENETICS

Circadian regulation of hydroxyindole-O-methyltransferase mRNA levels in rat pineal and retina. Gauer F, et al. **Brain Res** 1996 Oct 21;737(1–2):99–109

Hydroxyindole-O-methyltransferase in the chicken retina: immunocytochemical localization and daily rhythm of mRNA. Guerlotté J, et al. **Eur J Neurosci** 1996 Apr; 8(4):710–5

Evidence for tryptophan hydroxylase and hydroxy-indol-O-methyl-transferase mRNAs in human blood platelets. Champier J, et al. **Life Sci** 1997; 60(24):2191–7

METABOLISM

Hydroxyindole-O-methyltransferase in the chicken retina: immunocytochemical localization and daily rhythm of mRNA. Guerlotté J, et al. **Eur J Neurosci** 1996 Apr; 8(4):710–5

Hydroxyindole-O-methyltransferase activity assay using high-performance liquid chromatography with fluorometric detection: determination of melatonin enzymatically formed from N-acetylserotonin and S-adenosyl-L-methionine. Itoh MT, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):217–21

ACETYLTRANSFERASES

ANALYSIS

Microplate chromatography assay for acetyl-CoA: lysoplatelet-activating factor acetyltransferase. Kume K, et al. **Anal Biochem** 1997 Mar 1;246(1):118–22

Different distribution of dihydrolipoamide succinyltransferase, dihydrolipoamide acetyltransferase and ATP synthase beta-subunit in monkey brain. Takase C, et al. **In Vivo** 1996 Sep-Oct;10(5):495–501

Polyamine N-acetyltransferase in Leishmania amazonensis. Rojas-Chaves M, et al. **Parasitol Res** 1996;82(5):435–8

ANTAGONISTS & INHIBITORS

Synthesis and evaluation of a polyamine phosphinate and phosphonamidate as transition-state analogue inhibitors of spermidine/spermine-N1-acetyltransferase. Wu R, et al. **Bioorg Med Chem** 1996 Jun;4(6):825–36

Inhibition of lysoPAF acetyltransferase activity by flavonoids. Yanoshita R, et al. **Inflamm Res** 1996 Nov; 45(11):546–9

ZG-1494 alpha, a novel platelet-activating factor acetyltransferase inhibitor from Penicillium rubrum, isolation, structure elucidation andbiological activity. West RR, et al. **J Antibiot (Tokyo)** 1996 Oct;49(10):967–73

Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors. Daigle DM, et al. **J Biol Chem** 1997 Oct 3;272(40):24755–8

Dual inhibitory activities of tannins from Hamamelis virginiana and related polyphenols on 5-lipoxygenase and lyso-PAF: acetyl-CoA acetyltransferase. Hartisch C, et al. **Planta Med** 1997 Apr;63(2):106–10

BIOSYNTHESIS

Gossypol induces spermidine/spermine N1-acetyltransferase in canine prostate epithelial cells. Chang WY, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):383–8

cDNA cloning and expression of murine 1-acyl-sn-glycerol-3-phosphate acyltransferase. Kume K, et al. **Biochem Biophys Res Commun** 1997 Aug 28; 237(3):663–6

RT-PCR of fatty acid elongases. Kells AP, et al. **Biochem Soc Trans** 1997 Feb;25(1):20S

Polyamine acetylation and apoptosis. Lindsay GS, et al. **Biochem Soc Trans** 1996 May;24(2):229S

Neuronal nuclear acetyltransferases involved in the synthesis of platelet-activating factor are located in the nuclear envelope and show differential losses in activity. Baker RR, et al. **Biochim Biophys Acta** 1997 Apr 1;1345(2):197–206

Production of bleomycin N-acetyltransferase in Escherichia coli and Streptomyces verticillus. Matsuo H, et al. **FEMS Microbiol Lett** 1997 Aug 1;153(1):83–8

Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA-adduct levels and human cancer susceptibility. Badawi AF, et al. **Prog Clin Biol Res** 1996;395:109–40 (123 ref.)

BLOOD

Lyso-PAF acetyltransferase activity in neutrophils of patients during acute asthma and after recovery. Misso NL, et al. **Eur Respir J** 1996 Nov;9(11):2243–9

Inhibition of lysoPAF acetyltransferase activity by flavonoids. Yanoshita R, et al. **Inflamm Res** 1996 Nov; 45(11):546–9

CHEMISTRY

cDNA cloning and expression of murine 1-acyl-sn-glycerol-3-phosphate acyltransferase. Kume K, et al. **Biochem Biophys Res Commun** 1997 Aug 28; 237(3):663–6

Refolding and reconstitution studies on the transacetylase-protein X (E2/X) subcomplex of the mammalian pyruvate dehydrogenase complex: evidence for specific binding of the dihydrolipoamide dehydrogenase component to sites on reassembled E2. McCartney RG, et al. **Biochemistry** 1997 Jun 3;36(22):6819–26

The catalytic domain of dihydrolipoyl acetyltransferase from the pyruvate dehydrogenase multienzyme complex of Bacillus stearothermophilus. Expression, purification and reversible denaturation. Allen MD, et al. **FEBS Lett** 1997 Aug 18;413(2):339–43

Recognition of a surface loop of the lipoyl domain underlies substrate channelling in the pyruvate dehydrogenase multienzyme complex. Wallis NG, et al. **J Mol Biol** 1996 Nov 1;263(3):463–74

Crystallization and preliminary diffraction studies of NodL, a rhizobial O-acetyl-transferase involved in the host-specific nodulation of legume roots. Dunn SM, et al. **Protein Sci** 1996 Mar;5(3):538–41

GCN5-related histone N-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein. Neuwald AF, et al. **Trends Biochem Sci** 1997 May; 22(5):154–5

DEFICIENCY

Stabilization of pet operon plasmids and ethanol production in Escherichia coli strains lacking lactate dehydrogenase and pyruvate formate-lyase activities. Hespell RB, et al. **Appl Environ Microbiol** 1996 Dec;62(12):4594–7

DRUG EFFECTS

Sequence specific antisense oligonucleotide analog interference with spermidine/spermine N1-acetyltransferase gene expression. Fogel-Petrovic M, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2517–23

Structural basis for differential induction of spermidine/spermine N1-acetyltransferase activity by novel spermine analogs. Fogel-Petrovic M, et al. **Mol Pharmacol** 1997 Jul;52(1):69–74

GENETICS

N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Oyama T, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):577–81

Characterization of the chromosomal aminoglycoside 2'-N-acetyltransferase gene from Mycobacterium fortuitum. Ainsa JA, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2350–5

Characterization of the 6'-N-aminoglycoside acetyltransferase gene aac(6')-Il associated with a sulI-type integron. Hannecart-Pokorni E, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):314–8

An extracellular factor regulating expression of the chromosomal aminoglycoside 2'-N-acetyltransferase of Providencia stuartii. Rather PN, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1749–54

Effect of aeration and unsaturated fatty acids on expression of the Saccharomyces cerevisiae alcohol acetyltransferase gene. Fujii T, et al. **Appl Environ Microbiol** 1997 Mar; 63(3):910–5

Expression of the human spermidine/spermine N1-acetyltransferase in spermidine acetylation-deficient Escherichia coli. Ignatenko NA, et al. **Biochem J** 1996 Oct 15;319 (Pt 2):435–40

Effects of polyamines, polyamine analogs, and inhibitors of protein synthesis on spermidine-spermine N1-acetyltransferase gene expression. Fogel-Petrovic M, et al. **Biochemistry** 1996 Nov 12;35(45):14436–44

Cysteine biosynthesis in higher plants: a new member of the Arabidopsis thaliana serine acetyltransferase small gene-family obtained by functional complementation of an Escherichia coli cysteine auxotroph. Howarth JR, et al. **Biochim Biophys Acta** 1997 Feb 7;1350(2):123–7

Spermidine/spermine N1-acetyltransferase mRNA levels show marked and region-specific changes in the early phase after transient forebrain ischemia. Zoli M, et al. **Brain Res Mol Brain Res** 1996 May;38(1):122–34

Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Welfare MR, et al. **Carcinogenesis** 1997 Jul;18(7):1351–4

Serine acetyltransferase from Arabidopsis thaliana can functionally complement the cysteine requirement of a cysE mutant strain of Escherichia coli. Murillo M, et al. **Cell Mol Biol Res** 1995;41(5):425–33

mof, a putative acetyl transferase gene related to the Tip60 and MOZ human genes and to the SAS genes of yeast, is required for dosage compensation in Drosophila. Hilfiker A, et al. **EMBO J** 1997 Apr 15;16(8):2054–60

Molecular cloning of spermidine/spermine N1-acetyltransferase from the periimplantation porcine uterus by messenger ribonucleic acid differential display: temporal and conceptus-modulated gene expression. Green ML, et al. **Endocrinology** 1996 Dec;137(12):5447–55

Combinations of susceptible genotypes and individual responses to toxicants. Hirvonen A. **Environ Health Perspect** 1997 Jun;105 Suppl 4:755–8 (48 ref.)

Acetylation as an indicator of risk. Lang NP. **Environ Health Perspect** 1997 Jun;105 Suppl 4:763–6 (44 ref.)

The prevalence of gentamicin 2'-N-acetyltransferase in the Proteeae and its role in the O-acetylation of peptidoglycan. Clarke AJ, et al. **FEMS Microbiol Lett** 1996 Dec 1; 145(2):201–7

Identification of the serine acetyltransferase gene of Staphylococcus xylosus. Fiegler H, et al. **FEMS Microbiol Lett** 1997 Mar 15;148(2):181–7

Genomic structure and expression analyses of serine acetyltransferase gene in Citrullus vulgaris (watermelon). Saito K, et al. **Gene** 1997 Apr 11;189(1):57–63

PAT1, an evolutionarily conserved acetyltransferase homologue, is required for multiple steps in the cell cycle. Lin R, et al. **Genes Cells** 1996 Oct;1(10):923–42

Cloning, expression, and characterization of the Lactococcus lactis pfl gene, encoding pyruvate formate-lyase. Arnau J, et al. **J Bacteriol** 1997 Sep;179(18):5884–91

Homoserine O-acetyltransferase, involved in the Leptospira meyeri methionine biosynthetic pathway, is not feedback inhibited. Bourhy P, et al. **J Bacteriol** 1997 Jul; 179(13):4396–8

A possible role for acetylated intermediates in diaminopimelate and tabtoxinine-beta-lactam biosynthesis in Pseudomonas syringae pv. tabaci BR2.024. Liu L, et al. **J Bacteriol** 1997 Sep;179(18):5922–7

aarC, an essential gene involved in density-dependent regulation of the 2'-N-acetyltransferase in Providencia stuartii. Rather PN, et al. **J Bacteriol** 1997 Apr; 179(7):2267–73

Molecular characterization of the oafA locus responsible for acetylation of Salmonella typhimurium O-antigen: oafA is a member of a family of integral membrane trans-acylases. Slauch JM, et al. **J Bacteriol** 1996 Oct; 178(20):5904–9

Predominance of slow acetylators of N-acetyltransferase in a Hmong population residing in the United States. Straka RJ, et al. **J Clin Pharmacol** 1996 Aug;36(8):740–7

Vectors based on maize streak virus can replicate to high copy numbers in maize plants. Shen WH, et al. **J Gen Virol** 1995 Apr;76 (Pt 4):965–9

Cloning, sequencing, characterisation and implications for vaccine design of the novel dihydrolipoyl acetyltransferase of Neisseria meningitidis. Ala' Aldeen DA, et al. **J Med Microbiol** 1996 Dec;45(6):419–32

Overlapping promoters modulate Fnr- and ArcA-dependent anaerobic transcriptional activation of the focApfl operon in Escherichia coli. Kaiser M, et al. **Microbiology** 1997 Mar; 143 (Pt 3):775–83

Aminoglycoside 2'-N-acetyltransferase genes are universally present in mycobacteria: characterization of the aac(2')-Ic gene from Mycobacterium tuberculosis and the aac(2')-Id gene from Mycobacterium smegmatis. Ainsa JA, et al. **Mol Microbiol** 1997 Apr;24(2):431–41

Differential effect of acetyltransferase expression on the genotoxicity of heterocyclic amines in CHO cells. Wu RW, et al. **Mutat Res** 1997 Apr 24;390(1–2):93–103

Yeast SAS silencing genes and human genes associated with AML and HIV-1 Tat interactions are homologous with acetyltransferases. Reifnyder C, et al. **Nat Genet** 1997 May; 16(1):109

Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Golka K, et al. **Scand J Work Environ Health** 1996 Oct;22(5):332–8

Nucleotide sequences of alcohol acetyltransferase genes from lager brewing yeast, Saccharomyces carlsbergensis. Fujii T, et al. **Yeast** 1996 May;12(6):593–8

[Clinical relevance of acetylator phenotyping in 196 urothelial tumor patients] Schöps W, et al. **Urologe A** 1997 Jan;36(1):64–7 (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Overexpression and characterization of the chromosomal aminoglycoside 6'-N-acetyltransferase from Enterococcus faecium. Wright GD, et al. **Antimicrob Agents Chemother** 1997 May;41(5):956–60

METABOLISM

Acetylation of sphingosine by PAF-dependent transacetylase. Lee T. **Adv Exp Med Biol** 1996;416:113–9

Casein kinase 2 phosphorylates recombinant human spermidine/spermine N1-acetyltransferase on both serine and threonine residues. Bordin L, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):845–51

Determination of the primary target for isoniazid in mycobacterial mycolic acid biosynthesis with Mycobacterium aurum A+. Wheeler PR, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):451–7

Hydrogen peroxide induces the catabolism of polyamines in human breast cancer cells. Chopra S, et al. **Biochem Soc Trans** 1996 May;24(2):230S

Histones in transit: cytosolic histone complexes and diacetylation of H4 during nucleosome assembly in human cells. Chang L, et al. **Biochemistry** 1997 Jan 21;36(3):469–80

Aging and polyamine acetylation in rat kidney. Ferioli ME, et al. **Biochim Biophys Acta** 1996 Oct 7;1317(1):15–8

In vivo incorporation of lipoic acid enantiomers and homologues in the pyruvate dehydrogenase complex from Escherichia coli. Loeffelhardt S, et al. **Biochim Biophys Acta** 1996 Sep 13;1297(1):90–8

Re-investigation of glucose metabolism in Fibrobacter succinogenes, using NMR spectroscopy and enzymatic assays. Evidence for pentose phosphates phosphoketolase and pyruvate formate lyase activities. Matheron C, et al. **Biochim Biophys Acta** 1997 Jan 10;1355(1):50–60

Kinamycin acetyltransferase I from Streptomyces murayamaensis, an apparently large, membrane-associated enzyme. Gould SJ, et al. **Bioorg Med Chem** 1996 Jul; 4(7):987–94

Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine. Espin Jaime MT, et al. **Br J Urol** 1997 Jul;80(1):151–2

Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Chen H, et al. **Cell** 1997 Aug 8;90(3):569–80

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Gu W, et al. **Cell** 1997 Aug 22;90(4):595–606

The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Mizzen CA, et al. **Cell** 1996 Dec 27;87(7):1261–70

The transcriptional coactivators p300 and CBP are histone acetyltransferases. Ogryzko VV, et al. **Cell** 1996 Nov 29; 87(5):953–9

The major cytoplasmic histone acetyltransferase in yeast: links to chromatin replication and histone metabolism. Parthun MR, et al. **Cell** 1996 Oct 4;87(1):85–94

Histone acetylation and chromatin assembly: a single escort, multiple dances? Roth SY, et al. **Cell** 1996 Oct 4;87(1):5–8 (20 ref.)

Growth arrest- and polyamine-dependent expression of spermidine/spermine N1-acetyltransferase in human tumor cells. Ignatenko NA, et al. **Cell Growth Differ** 1996 Apr; 7(4):481–6

Measurement of phospholipase A2 and 1-alkylglycerophosphocholine acetyltransferase activities in stimulated alveolar macrophages by HPLC analysis of NBD-labeled ether lipids. Kleuser B, et al. **Chem Phys Lipids** 1996 Jan 25;79(1):29–37

Histone acetyltransferases in control. Wade PA, et al. **Curr Biol** 1997 Feb 1;7(2):R82–4 (13 ref.)

Nucleosome assembly: the CAF and the HAT. Kaufman PD. **Curr Opin Cell Biol** 1996 Jun;8(3):369–73 (41 ref.)

Histone acetyltransferase activity and interaction with ADA2 are critical for GCN5 function in vivo. Candau R, et al. **EMBO J** 1997 Feb 3;16(3):555–65

The catalytic domain of dihydrolipoyl acetyltransferase from the pyruvate dehydrogenase multienzyme complex of Bacillus stearothermophilus. Expression, purification and reversible denaturation. Allen MD, et al. **FEBS Lett** 1997 Aug 18;413(2):339–43

Involvement of histone hyperacetylation in triggering DNA fragmentation of rat thymocytes undergoing apoptosis. Lee E, et al. **FEBS Lett** 1996 Oct 21;395(2–3):183–7

The prevalence of gentamicin 2'-N-acetyltransferase in the Proteeae and its role in the O-acetylation of peptidoglycan. Clarke AJ, et al. **FEMS Microbiol Lett** 1996 Dec 1; 145(2):201–7

The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Miners JO, et al. **Gen Pharmacol** 1996 Mar;27(2):245–9 (34 ref.)

Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complex. Grant PA, et al. **Genes Dev** 1997 Jul 1;11(13):1640–50

Spermidine acetyltransferase in rat hepatocytes cultured at different oxygen tensions. Vargiu C, et al. **Hepatology** 1996 Oct;24(4):924–7

Mechanism of multiple aminoglycoside resistance of kasugamycin-producing Streptomyces kasugaensis MB273: involvement of two types of acetyltransferases in resistance to astromicin group antibiotics. Hotta K, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):682–8

pH modulation of aminoglycoside resistance in Staphylococcus epidermidis harbouring 6'-N-aminoglycoside acetyltransferase. Culebras E, et al. **J Antimicrob Chemother** 1996 May;37(5):881–9

A possible role for acetylated intermediates in diaminopimelate and tabtoxinine-beta-lactam biosynthesis in Pseudomonas syringae pv. tabaci BR2.024. Liu L, et al. **J Bacteriol** 1997 Sep;179(18):5922–7

Characterization of gentamicin 2'-N-acetyltransferase from Providencia stuartii: its use of peptidoglycan metabolites for acetylation of both aminoglycosides and peptidoglycan. Payie KG, et al. **J Bacteriol** 1997 Jul;179(13):4106–14

The role of platelet-activating factor-dependent transacetylase in the biosynthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by stimulated endothelial cells. Balestrieri ML, et al. **J Biol Chem** 1997 Jul 11;272(28):17431–7

Activated function of the pyruvate dehydrogenase phosphatase through Ca2+-facilitated binding to the inner lipoyl domain of the dihydrolipoyl acetyltransferase. Chen G, et al. **J Biol Chem** 1996 Nov 8;271(45):28064–70

ADR1 activation domains contact the histone acetyltransferase GCN5 and the core transcriptional factor TFIIB. Chiang YC, et al. **J Biol Chem** 1996 Dec 13; 271(50):32359–65

Proteasomal degradation of spermidine/spermine N1-acetyltransferase requires the carboxyl-terminal glutamic acid residues. Coleman CS, et al. **J Biol Chem** 1997 May 2;272(18):12164–9

Activation of polyamine catabolism profoundly alters tissue polyamine pools and affects hair growth and female fertility

in transgenic mice overexpressing spermidine/spermine N1-acetyltransferase. Pietilä M, et al. **J Biol Chem** 1997 Jul 25;272(30):18746-51

Interaction of the GTP-binding and GTPase-activating domains of ARD1 involves the effector region of the ADP-ribosylation factor domain. Vitale N, et al. **J Biol Chem** 1997 Feb 14;272(7):3897-904

Assembly and full functionality of recombinantly expressed dihydrolipoyl acetyltransferase component of the human pyruvate dehydrogenase complex. Yang D, et al. **J Biol Chem** 1997 Mar 7;272(10):6361-9

Enzymological and physiological consequences of restructuring the lipoyl domain content of the pyruvate dehydrogenase complex of Escherichia coli. Guest JR, et al. **Microbiology** 1997 Feb;143 (Pt 2):457-66

Uptake and incorporation of an epitope-tagged sialic acid donor into intact rat liver Golgi compartments. Functional localization of sialyltransferase overlaps with beta-galactosyltransferase but not with sialic acid O-acetyltransferase. Chammas R, et al. **Mol Biol Cell** 1996 Nov;7(11):1691-707

Histone acetyltransferase activity is conserved between yeast and human GCN5 and is required for complementation of growth and transcriptional activation. Wang L, et al. **Mol Cell Biol** 1997 Jan;17(1):519-27

The possible role of acetyltransferase in the induction of cytogenetic effects by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in cultured Chinese hamster cells. Otsuka C, et al. **Mutat Res** 1996 Nov 4;371(1-2):23-8

The CBP co-activator is a histone acetyltransferase. Bannister AJ, et al. **Nature** 1996 Dec 19-26;384(6610):641-3

Steroid receptor coactivator-1 is a histone acetyltransferase. Spencer TE, et al. **Nature** 1997 Sep 11;389(6647):194-8

CYP2D6, N-acetylation, and xanthine oxidase activity in cystic fibrosis. Bosso JA, et al. **Pharmacotherapy** 1996 Sep-Oct;16(5):749-53

Cysteine synthesis in plants: protein-protein interactions of serine acetyltransferase from Arabidopsis thaliana. Bogdanova N, et al. **Plant J** 1997 Feb;11(2):251-62

Very-long-chain fatty acid biosynthesis is controlled through the expression and specificity of the condensing enzyme. Millar AA, et al. **Plant J** 1997 Jul;12(1):121-31

Opening the way to gene activity [news] Pennisi E. **Science** 1997 Jan 10;275(5297):155-7

Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Rasmussen BB, et al. **Ther Drug Monit** 1996 Jun;18(3):254-62

Histone acetylation: a gateway to transcriptional activation. Sternglanz R. **Trends Biochem Sci** 1996 Oct;21(10):357-8

PHARMACOLOGY

Enzymatic method for inactivation of aminoglycosides during measurement of postantibiotic effect. den Hollander JG, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):488-90

Production of plant non-protein amino acids by recombinant enzymes of sequential biosynthetic reactions in bacteria. Saito K, et al. **Biol Pharm Bull** 1997 Jan;20(1):47-53

ACHALASIA, ESOPHAGEAL see **ESOPHAGEAL ACHALASIA**

ACHIEVEMENT

Predictive value of letters of recommendation vs questionnaires for emergency medicine resident performance. Schaider JJ, et al. **Acad Emerg Med** 1997 Aug;4(8):801-5

Achievement motivation and level of aspiration: adolescent Ethiopian immigrants in the Israeli education system. Horowitz TR, et al. **Adolescence** 1997 Spring; 32(125):169-80

Temperament-based learning styles as moderators of academic achievement. Horton CB, et al. **Adolescence** 1997 Spring;32(125):131-41

The role of parental involvement in youth sport participation and performance. Hoyle RH, et al. **Adolescence** 1997 Spring;32(125):233-43

Language arts achievement level, attitude survey format, and adolescents' attitudes towards reading. Smith LR, et al. **Adolescence** 1997 Summer;32(126):271-4

Agency, communion, and achievement motivation. Strage A. **Adolescence** 1997 Summer;32(126):299-312

Prenatal alcohol exposure and academic achievement at age six: a nonlinear fit. Goldschmidt L, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):763-70

Are these interviewees actually good role models? [letter] Weiss R. **Am J Cardiol** 1997 Aug 1;80(3):394

Family, peer, and neighborhood influences on academic achievement among African-American adolescents: one-year prospective effects. Gonzales NA, et al. **Am J Community Psychol** 1996 Jun;24(3):365-87

Academic achievement in individuals with infantile nephropathic cystinosis. Ballantyne AO, et al. **Am J Med Genet** 1997 Apr 18;74(2):157-61

Competency beliefs and occupational role behavior among adolescents: explication of the personal causation construct. Henry AD, et al. **Am J Occup Ther** 1997 Apr;51(4):267-76 (80 ref.)

Attachment, self-concept, and academic motivation in high-school students. Learner DG, et al. **Am J Orthopsychiatry** 1997 Jul;67(3):485-92

School performance and emotional problems in refugee children. Rousseau C, et al. **Am J Orthopsychiatry** 1996 Apr;66(2):239-51

Predicting academic performance of medical students: the first three years. Höschl C, et al. **Am J Psychiatry** 1997 Jun;154(6 Suppl):87-92

A threat in the air. How stereotypes shape intellectual identity and performance. Steele CM. **Am Psychol** 1997 Jun;52(6):613-29

Does the Graduate Record Examination predict meaningful success in the graduate training of psychologists? A case study. Sternberg RJ, et al. **Am Psychol** 1997 Jun; 52(6):630-41

Scholastic impairments among traumatized adolescents. Saigh PA, et al. **Behav Res Ther** 1997 May;35(5):429-36

Law school performance predicted by explanatory style. Satterfield JM, et al. **Behav Sci Law** 1997 Winter; 15(1):95-105

Pupils' self assessments of academic attainment at 7, 11 and 16 years: effects of sex and ethnic group. Blatchford P. **Br J Educ Psychol** 1997 Jun;67 (Pt 2):169-84

Effects of menstrual cycle moods and symptoms on academic performance: a study of senior secondary school students. Boyle GJ. **Br J Educ Psychol** 1997 Mar;67 (Pt 1):37-49

Changes in control beliefs in Portuguese primary school pupils as a consequence of the employment of self-assessment strategies. Fernandes M, et al. **Br J Educ Psychol** 1996 Sep;66 (Pt 3):301-13

Models of job-related stress and personal achievement among consultant doctors. Deary IJ, et al. **Br J Psychol** 1996 Feb; 87 (Pt 1):3-29

Timing of academic difficulties for neglected and nonmaltreated males and females. Kendall-Tackett K. **Child Abuse Negl** 1997 Sep;21(9):885-7

The effects of neglect on academic achievement and disciplinary problems: a developmental perspective. Kendall-Tackett KA, et al. **Child Abuse Negl** 1996 Mar; 20(3):161-9

The academic achievement of adolescents from immigrant families: the roles of family background, attitudes, and behavior. Fuligni AJ. **Child Dev** 1997 Apr;68(2):351-63

Parenting styles, adolescents' attributions, and educational outcomes in nine heterogeneous high schools. Glasgow KL, et al. **Child Dev** 1997 Jun;68(3):507-29

The relationship between parenting types and older adolescents' personality, academic achievement, adjustment, and substance use. Weiss LH, et al. **Child Dev** 1996 Oct;67(5):2101-14

Relation between academic achievement and social adjustment: evidence from Chinese children. Chen X, et al. **Dev Psychol** 1997 May;33(3):518-25

Children's attachment representations: longitudinal relations to school behavior and academic competency in middle childhood and adolescence. Jacobsen T, et al. **Dev Psychol** 1997 Jul;33(4):703-10

Regularities in the development of children's causality beliefs about school performance across six sociocultural contexts. Little TD, et al. **Dev Psychol** 1997 Jan;33(1):165-75

Incongruity between occupational interests and academic skills in drug abusing women. Silverman K, et al. **Drug Alcohol Depend** 1995 Dec;40(2):115-23

Academic achievement of successful candidates for tenure and promotion to associate professor. Zyzanski SJ, et al. **Fam Med** 1996 May;28(5):358-63

Achievement domain and life expectancies in Japanese civilization. Simonton DK. **Int J Aging Hum Dev** 1997; 44(2):103-14

Coping strategies, drinking motives, and stressful life events among middle adolescents: associations with emotional and behavioral problems and with academic functioning. Windle M, et al. **J Abnorm Psychol** 1996 Nov;105(4):551-60

Entry age, entry mode and academic performance on a Project 2000 common foundation programme. Houltram B. **J Adv Nurs** 1996 Jun;23(6):1089-97

Nonaffective seasonality [letter] Harrison SI. **J Am Acad Child Adolesc Psychiatry** 1997 Feb;36(2):163-4

Relationship of perceived competencies, perceived social support, and gender to substance use in young adolescents. Lifrak PD, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jul;36(7):933-40

Psychosocial adjustment and educational outcome in adolescents with a childhood diagnosis of attention deficit disorder. Wilson JM, et al. **J Am Acad Child Adolesc Psychiatry** 1996 May; 35(5):579-87

Superego aspects of intellectual achievement. Gray SH. **J Am Acad Psychoanal** 1996 Spring;24(1):15-27 (46 ref.)

Leadership in pursuit of profession excellence. Sharma PS. **J Am Coll Dent** 1995 Winter;62(4):5-7

Depression and academic impairment in college students. Heiligenstein E, et al. **J Am Coll Health** 1996 Sep; 45(2):59-64

Effects of response cards during lesson closure on the academic performance of secondary students in an earth science course. Cavanaugh RA, et al. **J Appl Behav Anal** 1996 Fall;29(3):403-6

Academic effects of providing peer support in general education classrooms on students without disabilities. Cushing LS, et al. **J Appl Behav Anal** 1997 Spring; 30(1):139-50; quiz 150-1

Reactions to cognitive ability tests: the relationships between race, test performance, face validity perceptions, and test-taking motivation. Chan D, et al. **J Appl Psychol** 1997 Apr;82(2):300-10

Managerial self-awareness in high-performing individuals in organizations. Church AH. **J Appl Psychol** 1997 Apr; 82(2):281-92

Academic success among students at risk for school failure. Finn JD, et al. **J Appl Psychol** 1997 Apr;82(2):221-34

Parenting style and adolescent depressive symptoms, smoking, and academic achievement: ethnic, gender, and SES differences. Radziszewska B, et al. **J Behav Med** 1996 Jun;19(3):289-305

The importance of intelligence in western societies. Brand CR. **J Biosoc Sci** 1996 Oct;28(4):387-404 (85 ref.)

How local is the impact of a specific learning difficulty on premature children's evaluation of their own competence? Jongmans M, et al. **J Child Psychol Psychiatry** 1996 Jul; 37(5):563-8

The genetics of children's oral reading performance. Reynolds CA, et al. **J Child Psychol Psychiatry** 1996 May; 37(4):425-34

Patterns of relatedness, depressive symptomatology, and perceived competence in maltreated children. Toth SL, et al. **J Consult Clin Psychol** 1996 Feb;64(1):32-41

Characteristics identified by deans as essential to success. Brundo GC, et al. **J Dent Educ** 1997 Jun;61(6):484-8

The role of self-esteem in typical and atypical changes in expectations. Abel MH. **J Gen Psychol** 1997 Jan; 124(1):113-27

The intergenerational costs of parental social stressors: academic and social difficulties in early adolescence for children of young mothers. Menaghan EG, et al. **J Health Soc Behav** 1997 Mar;38(1):72-86

The impact of nonacademic variables on performance at two medical schools. Webb CT, et al. **J Natl Med Assoc** 1997 Mar;89(3):173-80

Students' academic performance in nursing as a function of student and faculty learning style congruency. Joyce-Nagata B. **J Nurs Educ** 1996 Feb;35(2):69-73

Avoidance achievement motivation: a personal goals analysis. Elliot AJ, et al. **J Pers Soc Psychol** 1997 Jul;73(1):171-85

Student expectancies and academic self-concept as predictors of science achievement. House JD. **J Psychol** 1996 Nov; 130(6):679-81

Effects of achievement motivation and study habits on Nigerian secondary school students' academic performance. Jegede JO, et al. **J Psychol** 1997 Sep; 131(5):523-9

Factors associated with fourth grade health education scores on the Maine Educational Assessment. Stroble LP. **J Sch Health** 1997 Feb;67(2):56-61

Predicting academic problems in college from freshman alcohol involvement. Wood PK, et al. **J Stud Alcohol** 1997 Mar;58(2):200-10

Abductive machine learning for modeling and predicting the educational score in school health surveys. Abdel-Aal RE, et al. **Methods Inf Med** 1996 Sep;35(3):265-71

Social and educational resources for patients with Tourette syndrome. Packer LE. **Neurol Clin** 1997 May;15(2):457-73 (51 ref.)

Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. North KN, et al. **Neurology** 1997 Apr;48(4):1121-7 (57 ref.)

Academic performance is not a viable determinant of physical therapy students' burnout. Balogun JA, et al. **Percept Mot Skills** 1996 Aug;83(1):21-2

Consistency of physical therapy students' academic performance. Bohannon RW. **Percept Mot Skills** 1997 Jun; 84(3 Pt 1):1040-2

Relationship between Myers-Briggs Type Indicator and Gregorc Style Delineator. Harasym PH, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 2):1203-10

Dispositional optimism and coping with academic examinations. Lai JC, et al. **Percept Mot Skills** 1996 Aug; 83(1):23-7

Goal confidence and difficulty as predictors of goal attainment in junior high school cross-country runners. Lane AM, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):747-52

Performance time transformed by count as a determinant of difficulty in the Shotokan karate Heian kata set. Layton C, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):989-90

Correlations between mood scores and volleyball performance. Newby RW, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1153-4

Accomplishments during young adulthood of children originally diagnosed with minimal cerebral dysfunction: a ten-year follow-up study. Rogers PT, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):891-8

Achievement motivation and involvement in sport competitions. Thomassen TO, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1363-74

The good boy syndrome and malignant academic failure in early adolescence. Tyson RL. **Psychoanal Study Child** 1996; 51:386-408

Self-esteem moderator or mediator between perceived stress and expectancy of success. Abel MH. **Psychol Rep** 1996 Oct;79(2):635-41

Examination-related feedback, mood and helping: a correlational study. Feldt RC, et al. **Psychol Rep** 1997 Feb;

ACHIEVEMENT

80(1):239–42
Personality and educational choice of general versus vocational studies among 16- to 19-year-olds. Halvari H. **Psychol Rep** 1996 Jun;78(3 Pt 2):1379–88
Motivational and behavioral correlates of life satisfaction in an elderly sample. Jacob M, et al. **Psychol Rep** 1997 Jun; 80(3 Pt 1):811–8
Mathematics achievement and attitudes of senior secondary-school students in Transkei, South Africa. Kulubya MM, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):915–9
Scores on the Wechsler Intelligence Scale for Children–Third Edition and Woodcock–Johnson Tests of Achievement–Revised for a sample of children with emotional handicaps. Lavin C. **Psychol Rep** 1996 Dec;79(3 Pt 2):1291–5
Interrater reliability of the written expression subtest of the Peabody Individual Achievement Test–Revised: an adolescent and adult sample. Ouchi BY, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1239–47
Academic performance among children with sickle cell disease: setting minimum standards for comparison groups. Richard HW, et al. **Psychol Rep** 1997 Aug;81(1):27–34
Use of group hypnosis to improve college students' achievement. Schreiber EH. **Psychol Rep** 1997 Apr; 80(2):636–8
Black south African adolescents' attitudes about studying. Watson MB, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):861–2
General well-being and academic performance. Wheeler RJ, et al. **Psychol Rep** 1997 Apr;80(2):581–2
Social loafing and identifiability: the mediating role of achievement goal orientations. Swain A. **Res Q Exerc Sport** 1996 Sep;67(3):337–44
The therapeutic value of visual-perceptual training and its effect on scholastic achievement [letter] Schoeman OJ. **S Afr Med J** 1996 Aug;86(8):983
Negative labelling of individuals with first episode schizophrenia: the effect of premorbid functioning. Bean G, et al. **Schizophr Res** 1996 Nov 15;22(2):111–8
I was a success at everything—except suicide [see comments] Eilers GM. **Wis Med J** 1996 Apr;95(4):223–5. Comment in: Wis Med J 1996 Apr;95(4):226–7.
[School achievement and epilepsy] Palao A. **Rev Neurol** 1997 Aug;25(144):1202 **(Spa)**
[Factors to consider in the evaluation of intellectual achievement of an epileptic child] Pestana EM, et al. **Rev Neurol** 1997 Aug;25(144):1225–8 (51 ref.) (Eng. Abstr.) **(Spa)**
[Influence of epilepsy-related factors on scholastic achievement in an epileptic child] Pestana EM, et al. **Rev Neurol** 1997 Jan;25(137):44–7 (Eng. Abstr.) **(Spa)**
[Intellectual achievements of the epileptic child in primary school] Pestana EM, et al. **Rev Neurol** 1996 Dec; 24(136):1513–5 (Eng. Abstr.) **(Spa)**
[The psychophysiological functions of students with different achievements in flight training] Makarenko MV. **Fiziol Zh** 1995 Sep–Dec;41(5–6):3–11 (Eng. Abstr.) **(Ukr)**

ACHILLES TENDON

The conservative treatment of xanthoma of the Achilles tendon in patients affected with type IIA hypercholesterolemia. Valeo M, et al. **Chir Organi Mov** 1996 Jul–Sep;81(3):303–10 **(Eng, Ita)**
Achilles tendonitis: are corticosteroid injections useful or harmful? [see comments] Shrier I, et al. **Clin J Sport Med** 1996 Oct;6(4):245–50. Comment in: Clin J Sport Med 1996 Oct;6(4):218–9.
Chronic disorders of the Achilles tendon: results of conservative and surgical treatments. Johnston E, et al. **Foot Ankle Int** 1997 Sep;18(9):570–4
Nonoperative management of posterior tibial tendon dysfunction [letter; comment] Lynn MD. **Foot Ankle Int** 1997 Jul;18(7):457–8. Comment on: Foot Ankle Int 1996 Dec;17(12):736–41.
Ultrastructure of fibrocartilages at the insertion of the rat Achilles tendon. Rufai A, et al. **J Anat** 1996 Aug;189 (Pt 1):185–91
Achilles and suprapatellar tendinitis due to isotretinoin [letter] Hernández Rodríguez I, et al. **J Rheumatol** 1995 Oct;22(10):2009–10
Imaging in chronic achilles tendinopathy: a comparison of ultrasonography, magnetic resonance imaging and surgical findings in 27 histologically verified cases. Aström M, et al. **Skeletal Radiol** 1996 Oct;25(7):615–20

ANATOMY & HISTOLOGY

Achilles tendon insertion: an in vitro anatomic study. Chao W, et al. **Foot Ankle Int** 1997 Feb;18(2):81–4
Torsion of the human Achilles tendon. van Gils CC, et al. **J Foot Ankle Surg** 1996 Jan–Feb;35(1):41–8

BLOOD SUPPLY

Achilleo-calcaneal vascular network. Sanz-Hospital FJ, et al. **Foot Ankle Int** 1997 Aug;18(8):506–9

CHEMISTRY

A simplified method for the analysis of hydroxyproline in biological tissues. Reddy GK, et al. **Clin Biochem** 1996 Jun; 29(3):225–9

CYTOLOGY

The effect of ultrasound on collagen synthesis and fibroblast proliferation in vitro. Ramirez A, et al. **Med Sci Sports Exerc** 1997 Mar;29(3):326–32

DRUG EFFECTS

Achilles tendon rupture and fluoroquinolones use: report of two cases. de la Garza Estrada VA, et al. **Arch Med Res** 1997 Autumn;28(3):429–30
Effects of "in situ" vitamin E on fibroblast differentiation and on collagen fibril development in the regenerating tendon. González Santander R, et al. **Int J Dev Biol** 1996;Suppl 1:181S–182S

EMBRYOLOGY

The arterial vascularisation of the human calcaneus (Achilles) tendo during the prenatal development. Karcz MJ, et al. **Folia Morphol (Warsz)** 1996;55(4):306–8

INJURIES

Increasing incidence of Achilles tendon rupture. Möller A, et al. **Acta Orthop Scand** 1996 Oct;67(5):479–81
Postoperative MR imaging and ultrasonography of surgically repaired Achilles tendon ruptures. Karjalainen PT, et al. **Acta Radiol** 1996 Sep;37(5):639–46
C-reactive protein levels determine the severity of soft-tissue injuries. Pritchett JW. **Am J Orthop** 1996 Nov; 25(11):759–61
Augmented repair of Achilles tendon ruptures. Fernández-Fairén M, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):177–81
Magnetic resonance imaging during healing of surgically repaired Achilles tendon ruptures. Karjalainen PT, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):164–71
Achilles tendon rupture. A new technique for easy surgical repair and immediate movement of the ankle and foot. Motta P, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):172–6
End-to-end operative repair of Achilles tendon rupture. Soldatis JJ, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):90–5
ABO blood group and Achilles tendon rupture. Leppilahti J, et al. **Ann Chir Gynaecol** 1996;85(4):369–71
Pulmonary embolism after repair of a traumatic Achilles tendon rupture. Volpicello C. **AORN J** 1996 Oct; 64(4):599–601
Achilles tendon rupture and fluoroquinolones use: report of two cases. de la Garza Estrada VA, et al. **Arch Med Res** 1997 Autumn;28(3):429–30
Fracture of ossified Achilles tendon. Goyal S, et al. **Arch Orthop Trauma Surg** 1997;116(5):312–4
Clinical and sonographic evaluation of the risk of rupture in the Achilles tendon. Nehrer S, et al. **Arch Orthop Trauma Surg** 1997;116(1–2):14–8
Repair of neglected Achilles tendon ruptures: procedures and functional results. Us AK, et al. **Arch Orthop Trauma Surg** 1997;116(6–7):408–11
Sports medicine. Pain in the Achilles region. Brukner P. **Aust Fam Physician** 1997 Apr;26(4):463–5
Fibrillogenesis in tendon healing: an experimental study. Gigante A, et al. **Boll Soc Ital Biol Sper** 1996 Jul–Aug; 72(7–8):203–10
Clinical tests in sports medicine, Achilles tendon rupture [letter] Hackney RG. **Br J Sports Med** 1996 Dec;30(4):365
Clinical tests in sports medicine: more on Achilles tendon. Maffulli N. **Br J Sports Med** 1996 Sep;30(3):250
Achilles tendon rupture [letter; comment] Maffulli N. **Br J Sports Med** 1995 Dec;29(4):279–80. Comment on: Br J Sports Med 1995 Jun;29(2):121–5.
Percutaneous longitudinal tenotomy in chronic Achilles tendonitis. Testa V, et al. **Bull Hosp Jt Dis** 1996;54(4):241–4
Operative versus nonoperative treatment of acute Achilles tendon ruptures: a quantitative review. Lo IK, et al. **Clin J Sport Med** 1997 Jul;7(3):207–11
Percutaneous repair of Achilles tendon rupture. Immobilization versus functional postoperative treatment. Buchgraber A, et al. **Clin Orthop** 1997 Aug;(341):113–22
Achilles and peroneal tendon injuries in the athlete. An expert's perspective. Subotnick SI. **Clin Podiatr Med Surg** 1997 Jul;14(3):447–58 (25 ref.)
Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. McGarvey WC, et al. **Foot Ankle Int** 1996 Aug; 17(8):496–8 (25 ref.)
Kinematic and neuromuscular changes of the gait pattern after Achilles tendon rupture. Neumann D, et al. **Foot Ankle Int** 1997 Jun;18(6):339–41
Primary repair without augmentation for early neglected Achilles tendon ruptures in the recreational athlete. Porter DA, et al. **Foot Ankle Int** 1997 Sep;18(9):557–64
Modulation of tendon healing by nitric oxide. Murrell GA, et al. **Inflamm Res** 1997 Jan;46(1):19–27
An audit of the combined non-operative and orthotic management of ruptured tendo Achillis. Eames MH, et al. **Injury** 1997 May;28(4):289–92
The incidence of Achilles tendon rupture in Copenhagen. Levi N. **Injury** 1997 May;28(4):311–3
Isokinetic evaluation of calf muscle performance after Achilles rupture repair. Leppilahti J, et al. **Int J Sports Med** 1996 Nov;17(8):619–23
Repair of neglected Achilles tendon ruptures with a triceps surae muscle tendon advancement. Mendicino SS, et al. **J Foot Ankle Surg** 1996 Jan–Feb;35(1):13–8 (21 ref.)
What is the risk of Achilles tendon rupture with ciprofloxacin? [letter] Shinohara YT, et al. **J Rheumatol** 1997 Jan;24(1):238–9
Spontaneous bilateral Achilles tendon rupture associated with ciprofloxacin [letter] Poon CC, et al. **Med J Aust** 1997 Jun 16;166(12):665
Rat tendon morphologic and functional changes resulting from soft tissue mobilization. Davidson CJ, et al. **Med Sci Sports Exerc** 1997 Mar;29(3):313–9
Achilles tendon rupture due to ciprofloxacin [letter] Jagose JT, et al. **N Z Med J** 1996 Dec 13;109(1035):471–2
Conservative treatment of a partial Achilles tendon rupture with an intratendinous lesion. Nicolaisen T, et al. **Scand J Med Sci Sports** 1997 Jun;7(3):191–3
Bilateral Achilles tendon rupture: a report on two cases. Orava S, et al. **Scand J Med Sci Sports** 1996 Oct;6(5):309–12
[Bilateral Achilles tendon rupture in individuals with renal transplantation] Skovgaard D, et al. **Ugeskr Laeger** 1996 Dec 30;159(1):57–8 (Eng. Abstr.) **(Dan)**
[Current status of treatment of Achilles tendon ruptures. Results of a nationwide survey in Germany] Lill H, et al. **Chirurg** 1996 Nov;67(11):1160–5 (Eng. Abstr.) **(Ger)**
[A new score for comparing outcome of surgical management of Achilles tendon ruptures] Merkel M, et al. **Chirurg** 1996 Nov;67(11):1141–6 (Eng. Abstr.) **(Ger)**
[Possibilities and limits of functional conservative therapy of acute Achilles tendon ruptures] Richter J, et al. **Chirurg** 1997 May;68(5):517–24 (37 ref.) (Eng. Abstr.) **(Ger)**
[Value of ultrasound imaging of the Achilles tendon in traumatology] Grechenig W, et al. **Radiologe** 1997 Apr; 37(4):322–9 (Eng. Abstr.) **(Ger)**
[Ultrasonography of Achilles tendon lesions—an experimental study] Sell S, et al. **Ultraschall Med** 1997 Jun; 18(3):124–8 (Eng. Abstr.) **(Ger)**
[Conservative functional therapy of closed rupture of the Achilles tendon. Treatment approach and analysis of results] Reilmann H, et al. **Unfallchirurg** 1996 Aug; 99(8):576–80 (Eng. Abstr.) **(Ger)**
[Achilles tendon rupture. Surgical or non-surgical treatment] Helgeland J, et al. **Tidsskr Nor Laegeforen** 1997 May 10; 117(12):1763–6 (Eng. Abstr.) **(Nor)**
[An unexpected verdict by the HSAN in a case of Achilles tendon rupture (letter)] Ottosson L. **Lakartidningen** 1996 Dec 18;93(51–52):4712, 4715 **(Swe)**

PATHOLOGY

Tendon pathology in long-standing achillodynia. Biopsy findings in 40 patients. Movin T, et al. **Acta Orthop Scand** 1997 Apr;68(2):170–5
Lesions of the Achilles tendon. A sonographic, biomechanical and histological study. Sell S, et al. **Arch Orthop Trauma Surg** 1996;115(1):28–32
Pathology of the Achilles tendon in association with ciprofloxacin treatment. Movin T, et al. **Foot Ankle Int** 1997 May;18(5):297–9
Ultrasonography-guided percutaneous core biopsy in Achilles tendon disorder. Movin T, et al. **Scand J Med Sci Sports** 1997 Aug;7(4):244–8

PHYSIOLOGY

Age-related changes in biomechanical properties of the Achilles tendon in rabbits. Nakagawa Y, et al. **Eur J Appl Physiol** 1996;73(1–2):7–10
The monitoring of tendon tension with an implantable intratendon probe and its use in the control of neuroprostheses. Scott TR, et al. **IEEE Trans Rehabil Eng** 1997 Jun;5(2):233–5
Effects of "in situ" vitamin E on fibroblast differentiation and on collagen fibril development in the regenerating tendon. González Santander R, et al. **Int J Dev Biol** 1996;Suppl 1:181S–182S
Elongation mechanism of collagen fibrils and force-strain relations of tendon at each level of structural hierarchy. Sasaki N, et al. **J Biomech** 1996 Sep;29(9):1131–6
The influence of stretching and warm-up exercises on Achilles tendon reflex activity. Rosenbaum D, et al. **J Sports Sci** 1995 Dec;13(6):481–90

PHYSIOPATHOLOGY

Achilles and patellar tendinopathies in athletes: pathogenesis and surgical treatment. Benazzo F, et al. **Bull Hosp Jt Dis** 1996;54(4):236–40
[Asymmetrical body tilt induced by vibration of the Achilles tendon in patients with unilateral vestibular hypofunction] Saling M, et al. **Bratisl Lek Listy** 1997 Feb;98(2):97–101 (Eng. Abstr.) **(Slo)**
[Cerebrotendinous xanthomatosis: utility of nuclear magnetic resonance image in the follow-up and response to treatment] Cuende E, et al. **Rev Neurol** 1996 Dec; 24(136):1535–8 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

[Extracorporeal shock-wave therapy. Experimental basis, clinical application] Rompe JD, et al. **Orthopade** 1997 Mar; 26(3):215–28 (Eng. Abstr.) **(Ger)**

SURGERY

Chronic Achilles tendinitis and calf muscle strength.

Alfredson H, et al. **Am J Sports Med** 1996 Nov–Dec; 24(6):829–33

Augmented repair of Achilles tendon ruptures. Fernández–Fairén M, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):177–81

Magnetic resonance imaging during healing of surgically repaired Achilles tendon ruptures. Karjalainen PT, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):164–71

Achilles tendon rupture. A new technique for easy surgical repair and immediate movement of the ankle and foot. Motta P, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):172–6

End–to–end operative repair of Achilles tendon rupture. Soldatis JJ, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):90–5

Pulmonary embolism after repair of a traumatic Achilles tendon rupture. Volpicello C. **AORN J** 1996 Oct; 64(4):599–601

Achilles tendon rupture [letter; comment] Maffulli N. **Br J Sports Med** 1995 Dec;29(4):279–80. Comment on: Br J Sports Med 1995 Jun;29(2):121–5.

Percutaneous longitudinal tenotomy in chronic Achilles tendonitis. Testa V, et al. **Bull Hosp Jt Dis** 1996;54(4):241–4

V–Y advancement flaps in the reconstruction of skin defects of the Achilles tendon region: a report of two cases. Tang YW. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Dec; 58(6):453–8

Percutaneous repair of Achilles tendon rupture. Immobilization versus functional postoperative treatment. Buchgraber A, et al. **Clin Orthop** 1997 Aug;(341):113–22

Equinus deformity in cerebral palsy: recurrence after tendo Achillis lengthening. Sala DA, et al. **Dev Med Child Neurol** 1997 Jan;39(1):45–8

The strength of achilles tendon repair: an in vitro study of the biomechanical behavior in human cadaver tendons [letter] Esemenli T. **Foot Ankle Int** 1997 Apr;18(4):250

Primary repair without augmentation for early neglected Achilles tendon ruptures in the recreational athlete. Porter DA, et al. **Foot Ankle Int** 1997 Sep;18(9):557–64

Etiology, histopathology, and outcome of surgery in achillodynia. Rolf C, et al. **Foot Ankle Int** 1997 Sep; 18(9):565–9

Grand rounds: Haglund's deformity and retrocalcaneal, intratendinous spurring [see comments] Hanft JR, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):362–8. Comment in: J Foot Ankle Surg 1997 Jan–Feb;36(1):70.

An open, randomized study of ketoprofen in patients in surgery for Achilles or patellar tendinopathy. Rolf C, et al. **J Rheumatol** 1997 Aug;24(8):1595–8

Tendon repair by laser welding: a histologic and biomechanical comparison and suture repair with CO2 and argon lasers. Kilkelly FX, et al. **Lasers Surg Med** 1996; 19(4):487–91

Island adipofascial flap for resurfacing of the Achilles tendon. el–Khatib H. **Plast Reconstr Surg** 1996 Nov;98(6):1034–8

[Surgical treatment of ruptures of the Achilles tendon. Apropos of 42 cases treated by Bosworth's technique] Farizon F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1997;83(1):65–9 (Eng. Abstr.) **(Fre)**

TRANSPLANTATION

Chronic rupture of a patellar tendon: a technique for reconstruction with Achilles allograft. Falconiero RP, et al. **Arthroscopy** 1996 Oct;12(5):623–6

Contact pressure and tension in anterior cruciate ligament grafts subjected to roof impingement during passive extension. Goss BC, et al. **J Orthop Res** 1997 Mar; 15(2):263–8

ULTRASONOGRAPHY

Tendon xanthoma in familial hypercholesterolemia—a clinical and ultrasonographic study. Tan AP, et al. **Singapore Med J** 1997 Jan;38(1):37–40

[Differential diagnosis of diseases of the Achilles tendon. A clinico–sonographic concept] Kainberger F, et al. **Radiologe** 1996 Jan;36(1):38–46 (42 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound morphology of the Achilles tendon and differential diagnosis] Kainberger F, et al. **Ultraschall Med** 1996 Oct;17(5):212–7 (27 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon. Grant WP, et al. **J Foot Ankle Surg** 1997 Jul–Aug;36(4):272–8; discussion 330

ACHLORHYDRIA

CHEMICALLY INDUCED

Prolonged gastric acid suppression therapy: a significant risk factor for Listeria monocytogenes infection? [comment] Glupczynski Y. **Eur J Gastroenterol Hepatol** 1996 Nov; 8(11):1063–6 (19 ref.). Comment on: Eur J Gastroenterol Hepatol 1996 Nov;8(11):1071–4.

DIAGNOSIS

Bacteria in biopsies of human hypochlorhydric stomach: a scanning electron microscopy study. Brandi G, et al. **Ultrastruct Pathol** 1996 May–Jun;20(3):203–9

ETIOLOGY

Primary gastric lymphoma presenting with vitamin B12 deficiency and achlorhydria. Drake WM, et al. **Am J Gastroenterol** 1996 Dec;91(12):2605–6

Helicobacter pylori infection and chronic gastric acid hyposecretion. El–Omar EM, et al. **Gastroenterology** 1997 Jul;113(1):15–24

[Helicobacter pylori, achlorhydria and gastric atrophy: what kind of "ménage à trois"?] Bretagne JF, et al. **Gastroenterol Clin Biol** 1997;21(2):117–23 (108 ref.) **(Fre)**

MICROBIOLOGY

Bacteria in biopsies of human hypochlorhydric stomach: a scanning electron microscopy study. Brandi G, et al. **Ultrastruct Pathol** 1996 May–Jun;20(3):203–9

ACHOLEPLASMA

[Chromosome aberrations induced by mycoplasma infections in human peripheral blood lymphocytes] Chernova OA, et al. **Genetika** 1996 Jun;32(6):810–4 (Eng. Abstr.) **(Rus)**

METABOLISM

Comparative metabolism of Mesoplasma, Entomoplasma, Mycoplasma, and Acholeplasma. Pollack JD, et al. **Int J Syst Bacteriol** 1996 Oct;46(4):885–90

ACHOLEPLASMA LAIDLAWII

Pathologic responses of lambs to experimental inoculation with Acholeplasma laidlawii. de la Concha–Bermejillo A, et al. **J Vet Diagn Invest** 1996 Jan;8(1):115–8

CHEMISTRY

Cryo–TEM and NMR studies of a micelle–forming phosphoglucolipid from membranes of Acholeplasma laidlawii A and B. Danino D, et al. **Chem Phys Lipids** 1997 Jan 17;85(1):75–89

[The binding activity of diglucosyl diacylglyceride derived from membranes of Acholeplasma laidlawii PG8 to lymphoid cells] Ono S. **Kansenshogaku Zasshi** 1997 Jun; 71(6):534–9 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Antisignature oligonucleotides and their analogs as inhibitors of mollicutes–cofactors of HIV. Skrypal' IH, et al. **Mikrobiol Z** 1997 Mar–Apr;59(2):3–11

[The inhibition of translation in vivo in Mollicutes by thiophosphate analogs of oligodeoxyribonucleotides] Egorov OV, et al. **Mikrobiol Z** 1996 Jul–Aug;58(4):11–9 (Eng. Abstr.) **(Rus)**

[The validation of the possible use of monosugars and 6–azacytidine for the elimination of Mollicutes associated with HIV/AIDS from the human urogenital tract] Skrypal' IH, et al. **Mikrobiol Z** 1996 Sep–Oct;58(5):80–5 (Eng. Abstr.) **(Ukr)**

ENZYMOLOGY

Lipid dependence and basic kinetics of the purified 1,2–diacylglycerol 3–glucosyltransferase from membranes of Acholeplasma laidlawii. Karlsson OP, et al. **J Biol Chem** 1997 Jan 10;272(2):929–36

[The modification of the internucleotide relations of antisignature oligodeoxyribonucleotides as a means of increasing their resistance to nuclease cleavage in mollicute cells] Egorov OV. **Mikrobiol Z** 1997 Jan–Feb;59(1):31–6 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Production of a T–cell clone which reacts with membrane proteins of Acholeplasma laidlawii. Kuwano K, et al. **Microbiol Immunol** 1997;41(3):261–4

METABOLISM

Differential scanning calorimetric study of the interaction of cholesterol with the major lipids of the Acholeplasma laidlawii B membrane. McMullen TP, et al. **Biochemistry** 1996 Dec 24;35(51):16789–98

[The sorption of antisense oligodeoxyribonucleotides by Mycoplasma cells] Egorov OV, et al. **Mikrobiol Z** 1996 May–Jun;58(3):30–7 (Eng. Abstr.) **(Rus)**

[The binding and absorption by mollicute cells of antisignature analogs of oligodeoxyribonucleotides] Egorov OV, et al. **Mikrobiol Z** 1996 Nov–Dec;58(6):18–29 (Eng. Abstr.) **(Rus)**

ACHONDROPLASIA

Achondrogenesis type II (Langer–Saldino)—a case report. Swar MO, et al. **Afr J Med Med Sci** 1995 Sep;24(3):297–9

Epidural anesthesia for extracorporeal shock wave lithotripsy in an achondroplastic dwarf. Nguyen TT, et al. **Reg Anesth** 1997 Jan–Feb;22(1):102–4

[Achondroplasia—new research and future goals] Stoilov I, et al. **Mol Med (Sofia)** 1996;1(1):13–7 (28 ref.) **(Bul)**

BLOOD

Effects and serum levels of thrombopoietin in a case of chronic thrombocytopenia with achondroplasia. Ishiguro A, et al. **Int J Hematol** 1997 Jul;66(1):99–102

COMPLICATIONS

Urine leakage from the umbilicus in a child with achondroplasia and tetraplegia (due to cervical stenosis): a safety vent for the obstructed neuropathic bladder. Krishnan KR, et al. **Int Urol Nephrol** 1997;29(1):45–51

Case report: renal osteodystrophy in association with spinal stenosis in achondroplasia. Ong JS, et al. **Ir J Med Sci** 1996 Jul–Sep;165(3):155–6

Is management of anesthesia in achondroplastic dwarfs really a challenge? Monedero P, et al. **J Clin Anesth** 1997 May; 9(3):208–12

Lumbar gibbus in storage diseases and bone dysplasias. Levin TL, et al. **Pediatr Radiol** 1997 Apr;27(4):289–94

DIAGNOSIS

Hydrocephalus and chronically increased intracranial pressure in achondroplasia. Erdinçler P, et al. **Childs Nerv Syst** 1997 Jun;13(6):345–8 (15 ref.)

Early detection of neurological manifestations in achondroplasia. Ruiz–Garcia M, et al. **Childs Nerv Syst** 1997 Apr;13(4):208–13

Achondrogenesis type 1B. Superti–Furga A. **J Med Genet** 1996 Nov;33(11):957–61 (30 ref.)

DRUG THERAPY

Growth and growth hormone therapy in children with achondroplasia: a two–year experience. Stamoyannou L, et al. **Am J Med Genet** 1997 Oct 3;72(1):71–6

Human growth hormone treatment in prepubertal children with achondroplasia. Weber G, et al. **Am J Med Genet** 1996 Feb 2;61(4):396–400

Short–term recombinant human growth hormone treatment increases growth rate in achondroplasia. Shohat M, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4033–7

GENETICS

Achondroplasia in Sweden caused by the G1138A mutation in FGFR3. Alderborn A, et al. **Acta Paediatr** 1996 Dec; 85(12):1506–7

Common mutations in the gene encoding fibroblast growth factor receptor 3 account for achondroplasia, hypochondroplasia and thanatophoric dysplasia. Bonaventure J, et al. **Acta Paediatr Suppl** 1996 Oct;417:33–8

Mosaicism in pseudoachondroplasia. Ferguson HL, et al. **Am J Med Genet** 1997 Jun 13;70(3):287–91

Atypical achondroplasia [letter; comment] Gorlin RJ. **Am J Med Genet** 1997 May 16;70(2):202; discussion 203–5 . Comment on: Am J Med Genet 1995 Nov 20;59(3):393–5.

Dwarfism in Dexter cattle is not caused by the mutations in FGFR3 responsible for achondroplasia in humans. Usha AP, et al. **Anim Genet** 1997 Feb;28(1):55–7

Multiple epiphyseal dysplasia and pseudoachondroplasia due to novel mutations in the calmodulin–like repeats of cartilage oligomeric matrix protein. Susic S, et al. **Clin Genet** 1997 Apr;51(4):219–24

Fibroblast growth factor receptor 3 and the human chondrodysplasias. Horton WA. **Curr Opin Pediatr** 1997 Aug;9(4):437–42 (49 ref.)

A case of achondrogenesis type IA with an occipital encephalocele [see comments] Chen CP, et al. **Genet Couns** 1996;7(3):193–9. Comment in: Genet Couns 1997;8(1):45.

The Bmp8 gene is expressed in developing skeletal tissue and maps near the Achondroplasia locus on mouse chromosome 4. DiLeone RJ, et al. **Genomics** 1997 Feb 15; 40(1):196–8

Mutations causing achondroplasia and thanatophoric dysplasia alter bFGF–induced calcium signals in human diploid fibroblasts. Nguyen HB, et al. **Hum Mol Genet** 1997 May;6(5):681–8

Fibroblast growth factor receptor 3 (FGFR3) gene G1138A mutation in Chinese patients with achondroplasia. Wang TR, et al. **Hum Mutat** 1996;8(2):178–9

Achondrogenesis type 1B. Superti–Furga A. **J Med Genet** 1996 Nov;33(11):957–61 (30 ref.)

Predominance of the mutation at 1138 of the cDNA for the fibroblast growth factor receptor 3 in Japanese patients with achondroplasia. Tonoki H, et al. **Jpn J Hum Genet** 1995 Dec;40(4):347–9

Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand–dependent differentiation of PC12 cells. Thompson LM, et al. **Mol Cell Biol** 1997 Jul;17(7):4169–77

Ultrasound and molecular mid–trimester prenatal diagnosis of de novo achondroplasia. Mesoraca A, et al. **Prenat Diagn** 1996 Aug;16(8):764–8

[Association of achondroplasia to a mutation in the transmembrane domain of fibroblastic growth factor receptor 3 (FGFR3)] Rousseau F, et al. **Ann Endocrinol (Paris)** 1996;57(3):151–2 (6 ref.) **(Fre)**

[Mutations of FGFR3 gene cause 3 types of nanisms with variably severity: achondroplasia, thanatophoric nanism and hypochondroplasia] Rousseau F, et al. **Ann Endocrinol (Paris)** 1996;57(3):153 **(Fre)**

[A new mutation causes achondrodysplasia. A simple DNA

ACHONDROPLASIA

analysis confirms the diagnosis] Alderborn A, et al. **Lakartidningen** 1997 Jan 29;94(5):341–2, 347 **(Swe)**

METABOLISM

Analysis of cellular proteins in achondroplasia by two–dimensional electrophoresis. Yang RC. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Jan;12(1):1–6

Overnight growth hormone secretion in achondroplasia: deconvolution analysis, correlation with sleep state, and changes after treatment of obstructive sleep apnea. Waters KA, et al. **Pediatr Res** 1996 Mar;39(3):547–53

PATHOLOGY

Dementia pugilistica in an alcoholic achondroplastic dwarf. Williams DJ, et al. **Pathology** 1996 Jan;28(1):102–4

PHYSIOPATHOLOGY

Standard weight for height curves in achondroplasia. Hunter AG, et al. **Am J Med Genet** 1996 Mar 29;62(3):255–61

Biophysical bases for delayed and aberrant motor development in young children with achondroplasia. Fowler ES, et al. **J Dev Behav Pediatr** 1997 Jun; 18(3):143–50

Sleep and upper airway obstruction in children with achondroplasia. Zucconi M, et al. **J Pediatr** 1996 Nov; 129(5):743–9

RADIOGRAPHY

Atypical achondroplasia [letter; comment] Gorlin RJ. **Am J Med Genet** 1997 May 16;70(2):202; discussion 203–5 . Comment on: Am J Med Genet 1995 Nov 20;59(3):393–5.

Neurologic abnormalities in the skeletal dysplasias: a clinical and radiological perspective. Lachman RS. **Am J Med Genet** 1997 Mar 3;69(1):33–43 (103 ref.)

[Pseudoachondroplasia: a case report] Justa Roldán ML, et al. **An Esp Pediatr** 1997 May;46(5):490–2 **(Spa)**

SURGERY

Surgical management of cervicomedullary compression in achondroplasia. Yamada Y, et al. **Childs Nerv Syst** 1996 Dec;12(12):737–41

The surgical treatment of vertebral deformities in achondroplastic dwarfism. Parisini P, et al. **Chir Organi Mov** 1996 Apr–Jun;81(2):129–37 **(Eng, Ita)**

Limb lengthening in children with achondroplasia. Differences based on gender. Ganel A, et al. **Clin Orthop** 1996 Nov;(332):179–83

ULTRASONOGRAPHY

Ultrasound and molecular mid–trimester prenatal diagnosis of de novo achondroplasia. Mesoraca A, et al. **Prenat Diagn** 1996 Aug;16(8):764–8

Errors in the prenatal diagnosis of children with achondroplasia. Modaff P, et al. **Prenat Diagn** 1996 Jun; 16(6):525–30

ACHROMATIACEAE see **GRAM–NEGATIVE AEROBIC BACTERIA**

ACHROMATIUM see **GRAM–NEGATIVE AEROBIC BACTERIA**

ACHROMOBACTER see **ALCALIGENES**

ACHROMOBACTERIACEAE see **GRAM–NEGATIVE AEROBIC BACTERIA**

ACHYLIA GASTRICA see **ACHLORHYDRIA**

ACID ANHYDRIDE HYDROLASES

ANALYSIS

Suramin––a powerful inhibitor of neural ecto–diadenosine polyphosphate hydrolase. Mateo J, et al. **Br J Pharmacol** 1996 Sep;119(1):1–2

Nuclear cholesterol content and nucleoside triphosphatase activity are altered in the JCR:LA–cp corpulent rat. Czubryt MP, et al. **J Cell Biochem** 1996 Dec 1;63(3):349–57

ANTAGONISTS & INHIBITORS

Suramin––a powerful inhibitor of neural ecto–diadenosine polyphosphate hydrolase. Mateo J, et al. **Br J Pharmacol** 1996 Sep;119(1):1–2

CHEMISTRY

Human diadenosine 5',5"'–P1,P4–tetraphosphate pyrophosphohydrolase (Ap4A hydrolase) possesses a MutT motif. Thorne NM, et al. **Biochem Soc Trans** 1996 May; 24(2):209S

Structural and kinetic investigations on the 15–21 and 42–45 loops of muscle acylphosphatase: evidence for their involvement in enzyme catalysis and conformational stabilization. Taddei N, et al. **Biochemistry** 1997 Jun 10; 36(23):7217–24

Insights into acylphosphatase structure and catalytic mechanism. Stefani M, et al. **Cell Mol Life Sci** 1997 Feb; 53(2):141–51 (88 ref.)

A point mutation abolishes the helicase but not the nucleoside triphosphatase activity of hepatitis C virus NS3 protein. Heilek GM, et al. **J Virol** 1997 Aug;71(8):6264–6

Crystal structure of common type acylphosphatase from bovine testis. Thunnissen MM, et al. **Structure** 1997 Jan 15;5(1):69–79

DRUG EFFECTS

Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of a hepatitis C virus NS3–NS4A complex isolated from transfected COS cells. Morgenstern KA, et al. **J Virol** 1997 May;71(5):3767–75

GENETICS

Manipulation of independent synthesis and degradation of polyphosphate in Escherichia coli for investigation of phosphate secretion from the cell. Van Dien SJ, et al. **Appl Environ Microbiol** 1997 May;63(5):1689–95

Molecular cloning of diadenosine 5',5"'–P1,P4–tetraphosphate pyrophosphohydrolase (Ap4A hydrolase) from porcine small intestine: relationship to other enzymes of Ap4A catabolism. Hankin S, et al. **Biochem Soc Trans** 1996 Aug;24(3):418S

An RNA 5'–triphosphatase related to the protein tyrosine phosphatases. Takagi T, et al. **Cell** 1997 Jun 13;89(6):867–73

Molecular cloning of diadenosine tetraphosphatase from pig small intestinal mucosa and identification of sequence blocks common to diadenosine polyphosphate hydrolases and phosphorylases. Hankin S, et al. **Int J Biochem Cell Biol** 1997 Feb;29(2):317–23

A protein related to eucaryal and bacterial DNA–motor proteins in the hyperthermophilic archaeon Sulfolobus acidocaldarius. Elie C, et al. **J Mol Evol** 1997 Jul; 45(1):107–14

Expression, purification, and characterization of acylphosphatase muscular isoenzyme as fusion protein with glutathione S–transferase. Modesti A, et al. **Protein Expr Purif** 1995 Dec;6(6):799–805

ISOLATION & PURIFICATION

Diadenosine polyphosphate hydrolase from presynaptic plasma membranes of Torpedo electric organ. Mateo J, et al. **Biochem J** 1997 May 1;323 (Pt 3):677–84

Expression, purification, and characterization of acylphosphatase muscular isoenzyme as fusion protein with glutathione S–transferase. Modesti A, et al. **Protein Expr Purif** 1995 Dec;6(6):799–805

Diadenosine 5',5"'–P1,P4–tetraphosphate (Ap4A) hydrolase from tomato (Lycopersicon esculentum cv. Lukullus)––purification, biochemical properties and behaviour during stress. Feussner K, et al. **Z Naturforsch [C]** 1996 Jul–Aug;51(7–8):477–86

[Purification and characteristics of Saccharomyces cerevisiae cytosol polyphosphatase] Andreeva NA, et al. **Biokhimiia** 1996 Sep;61(9):1714–24 (Eng. Abstr.) **(Rus)**

METABOLISM

Differential migration of acylphosphatase isoenzymes from cytoplasm to nucleus during apoptotic cell death. Chiarugi P, et al. **Biochem Biophys Res Commun** 1997 Feb 24; 231(3):717–21

Alteration of free calcium levels and acylphosphatase muscular isoenzyme in cultured dystrophic skin fibroblasts. Degl'Innocenti D, et al. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):327–30

Characterization of a novel nucleolytic activity of acylphosphatases. Chiarugi P, et al. **Biochem Mol Biol Int** 1996 Sep;40(1):73–81

2',3'–dideoxynucleoside triphosphates (ddNTP) and di–2',3'–dideoxynucleoside tetraphosphates (ddNp4ddN) behave differently to the corresponding NTP and Np4N counterparts as substrates of firefly luciferase, dinucleoside tetraphosphatase and phosphodiesterases. Sillero MA, et al. **Biochim Biophys Acta** 1997 Mar 15;1334(2–3):191–9

The NTPase/helicase activities of Drosophila maleless, an essential factor in dosage compensation. Lee CG, et al. **EMBO J** 1997 May 15;16(10):2671–81

Oxidation of nuclear membrane cholesterol inhibits nucleoside triphosphatase activity. Ramjiawan B, et al. **Free Radic Biol Med** 1997;23(4):556–62

Strain differences in the distribution of NDP–ase labelled microglia in the normal rabbit retina. Humphrey MF, et al. **Glia** 1995 Dec;15(4):367–76

Characterization of the nucleoside triphosphate phosphohydrolase and helicase activities of the reovirus lambda1 protein. Bisaillon M, et al. **J Biol Chem** 1997 Jul 18;272(29):18298–303

Endopolyphosphatases for long chain inorganic polyphosphate in yeast and mammals. Kumble KD, et al. **J Biol Chem** 1996 Oct 25;271(43):27146–51

Guanosine tetra– and pentaphosphate promote accumulation of inorganic polyphosphate in Escherichia coli. Kuroda A, et al. **J Biol Chem** 1997 Aug 22;272(34):21240–3

C–terminal deletion of human tissue transglutaminase enhances magnesium–dependent GTP/ATPase activity. Lai TS, et al. **J Biol Chem** 1996 Dec 6;271(49):31191–5

Nuclear membrane cholesterol can modulate nuclear nucleoside triphosphatase activity. Ramjiawan B, et al. **J Cell Biochem** 1996 Dec 15;63(4):442–52

Polar tube formation and nucleoside diphosphatase activity in the microsporidian, Glugea stephani. Takvorian PM, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):102S–103S

Characterization of the NTPase activity of Japanese encephalitis virus NS3 protein. Kuo MD, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2077–84

Properties of Cys21–mutated muscle acylphosphatases. Modesti A, et al. **J Protein Chem** 1996 Jan;15(1):27–34

Vaccinia virions lacking the RNA helicase nucleoside triphosphate phosphohydrolase II are defective in early transcription. Gross CH, et al. **J Virol** 1996 Dec; 70(12):8549–57

Core protein mu2 is a second determinant of nucleoside triphosphatase activities by reovirus cores. Noble S, et al. **J Virol** 1997 Oct;71(10):7728–35

Alteration of acylphosphatase levels in familial Alzheimer's disease fibroblasts with presenilin gene mutations. Liguri G, et al. **Neurosci Lett** 1996 Jun 7;210(3):153–6

Viral and cellular enzymes involved in synthesis of mRNA cap structure. Bisaillon M, et al. **Virology** 1997 Sep 15; 236(1):1–7 (65 ref.)

Towards defining a minimal functional domain for NTPase and RNA helicase activities of the hepatitis C virus NS3 protein. Kim DW, et al. **Virus Res** 1997 May;49(1):17–25

Diadenosine 5',5"'–P1,P4–tetraphosphate (Ap4A) hydrolase from tomato (Lycopersicon esculentum cv. Lukullus)––purification, biochemical properties and behaviour during stress. Feussner K, et al. **Z Naturforsch [C]** 1996 Jul–Aug;51(7–8):477–86

[Characteristics of polyphosphatase activity of isolated mitochondria from Saccharomyces cerevisiae] Lichko LP, et al. **Biokhimiia** 1996 Sep;61(9):1664–71 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Acylphosphatase stimulates Ca2+ transport and Ca(2+)–dependent ATPase activity in cardiac sarcoplasmic reticulum. Fiorillo C, et al. **Biochem Mol Biol Int** 1996 May;39(2):387–94

ACID ASPIRATION SYNDROME see **PNEUMONIA, ASPIRATION**

ACID–BASE EQUILIBRIUM

see related
ACIDOSIS
ALKALOSIS
BUFFERS

[Base excess] vs [strong ion difference]. Which is more helpful? Schlichtig R. **Adv Exp Med Biol** 1997;411:91–5

[Base excess] and [strong ion difference] during O2–CO2 exchange. Schlichtig R. **Adv Exp Med Biol** 1997;411:97–102

The values cannot work [letter; comment] Paul RH. **Am J Obstet Gynecol** 1997 May;176(5):1117–8. Comment on: Am J Obstet Gynecol 1996 Nov;175(5):1383–5.

Umbilical cord blood gas analysis at delivery. Thorp JA, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):517–22 (27 ref.)

Acid–base changes alter Mg2+ uptake in mouse distal convoluted tubule cells. Dai LJ, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):F759–66

Metabolic acid–base influences on renal thiazide receptor density. Fanestil DD, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R2004–8

Effect of age on blood acid–base composition in adult humans: role of age–related renal functional decline. Frassetto LA, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):F1114–22

Acid/base transport in a model of the proximal tubule brush border: impact of carbonic anhydrase. Krahn TA, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):F344–55

Mechanism for changes in vasopressin during acute exposure at 3 atm abs air. Torii R, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R259–64

Cerebrospinal fluid acid–base status during normocapnia and acute hypercapnia in equine neonates. Geiser DR, et al. **Am J Vet Res** 1996 Oct;57(10):1483–7

Association between blood lactate and acid–base status and mortality in ventilated babies. Deshpande SA, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Jan;76(1):F15–20

Serum anion gap: reevaluation of normal values [letter] Elisaf MS, et al. **Br J Clin Pract** 1996 Oct–Nov;50(7):411

Acid–base balance in plasmatic, pericardial and peritoneal fluids in 2 species of amphibians. Dejours P, et al. **C R Acad Sci III** 1996 Aug;319(8):693–7

Osmolal gap in alcoholic ketoacidosis. Almaghamsi AM, et al. **Clin Nephrol** 1997 Jul;48(1):52–3

Flow cytometric calibration of intracellular pH measurements in viable cells using mixtures of weak acids and bases. Chow S, et al. **Cytometry** 1996 Aug 1;24(4):360–7

Prerace venous blood acid–base values in standardbred horses. Soma LR, et al. **Equine Vet J** 1996 Sep;28(5):390–6

Acid–base and electrolyte effects of shortening steeplechase in a three–day–event. Foreman JH, et al. **Equine Vet J Suppl** 1996 Jul;(22):85–90

Acid:base and serum biochemistry changes in horses competing at a modified 1 Star 3–day–event. Hinchcliff KW, et al. **Equine Vet J Suppl** 1995 Nov;(20):105–10

Effect of tris–(hydroxymethyl)–aminomethane on experimental focal cerebral ischemia. Nagao S, et al. **Exp Brain Res** 1996 Sep;111(1):51–6

Acid–base effects on colonic electrolyte transport revisited. Charney AN, et al. **Gastroenterology** 1996 Nov;

111(5):1358–68 (119 ref.)
Acid–base balance determination on ultrafiltrate in two–chamber technique hemodiafiltration (PFD). Ghezzi PM, et al. **Int J Artif Organs** 1995 Nov;18(11):726–30
ACOG technical bulleting. Umbilical artery blood acid–base analysis. Number 216—November 1995. (Replaces No. 127, April 1989). **Int J Gynaecol Obstet** 1996 Mar;52(3):305–10
Reliability of anion gap as an indicator of blood lactate in critically ill patients. Levraut J, et al. **Intensive Care Med** 1997 Apr;23(4):417–22
Time to reassess the term "base excess" for negative acid–base balance [letter] McGing PG, et al. **Intensive Care Med** 1997 Jul;23(7):797
Effect of racing on serum sodium and potassium concentrations and acid–base status of Alaskan sled dogs. Hinchcliff KW, et al. **J Am Vet Med Assoc** 1997 Jun 1; 210(11):1615–8
The relationship among dietary undetermined anion, acid–base balance, and nutrient metabolism in swine. Patience JF, et al. **J Anim Sci** 1997 Sep;75(9):2445–52
Acid–base regulation after maximal exercise testing in late gestation. Kemp JG, et al. **J Appl Physiol** 1997 Aug; 83(2):644–51
Respiration during acute hypoxia: angiotensin– and vasopressin–receptor blocks. Overgaard CB, et al. **J Appl Physiol** 1996 Mar;80(3):810–7
Acid–base balance [letter; comment] Settergren G, et al. **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):566–7. Comment on: J Cardiothorac Vasc Anesth 1995 Apr;9(2):215–8.
Acid–base regulation, alpha–stat, and the emperor's new clothes. Tallman RD Jr. **J Cardiothorac Vasc Anesth** 1997 May;11(3):282–8 (52 ref.)
Splanchnic buffering of metabolic acid during early endotoxemia. Kellum JA, et al. **J Crit Care** 1997 Mar; 12(1):7–12
Iliac vessel injury: operative physiology related to outcome. Cushman JG, et al. **J Trauma** 1997 Jun;42(6):1033–40
Effects of environmental heat and intake of tall fescue seed infested with Acremonium coenophialum on the acid–base status of young bulls. Wallace LL, et al. **J Vet Diagn Invest** 1996 Apr;8(2):233–7
Determinants and utility of the anion gap in predicting hyperlactatemia in cattle. Constable PD, et al. **J Vet Intern Med** 1997 Mar–Apr;11(2):71–9
Effect of acidotic challenges on local depolarizations evoked by N–methyl–D–aspartate in the rat striatum. Urenjak J, et al. **Life Sci** 1997;61(5):523–35
Changes in extracellular acid–base homeostasis in cerebral ischemia. Taylor DL, et al. **Neurochem Res** 1996 Sep; 21(9):1013–21
Diagnostic use of anion and osmolal gaps in pediatric emergency medicine. Chabali R. **Pediatr Emerg Care** 1997 Jun;13(3):204–10
Role of perfusate hydrogen ion activity in kallikrein release from isolated rat kidneys. Marin–Grez M. **Pflugers Arch** 1996 Jun;432(2):182–6
Respiratory, blood–gas transport, and acid–base response of Leptograpsus variegatus to long–term immersion and hyposaline exposure. Cooper AR, et al. **Physiol Zool** 1997 Mar–Apr;70(2):181–92
IgA myeloma associated with decreased anion gap and renal failure. Fang JT, et al. **Ren Fail** 1997 May;19(3):481–3
Effect of acute induced metabolic alkalosis on the acid/base responses to sprint exercise of six racing greyhounds. Holloway SA, et al. **Res Vet Sci** 1996 Nov;61(3):245–51
Erythropoietin and base excess levels in patients with chronic pulmonary diseases. Kobayashi H, et al. **Respir Physiol** 1997 Jan;107(1):37–45
A simple unified explanation of the red–ox and acid–base concepts. Macarulla JM. **Rev Esp Fisiol** 1996 Mar; 52(1):59–64 (2 ref.)
Comparison and assessment of blood gas related quantities including base excess, the gas exchange indices, and temperature corrected pH/PO2/PCO2, as defined in approved NCCLS standard C12–A, using a computer simulation of input variables. Degen BR, et al. **Scand J Clin Lab Invest Suppl** 1996;224:89–106
The need for protein containing quality control materials for blood pH and electrolyte analyzers. Maas B, et al. **Scand J Clin Lab Invest Suppl** 1996;224:179–86 (8 ref.)
Acid–base balance alterations in laparoscopic cholecystectomy. Gándara V, et al. **Surg Endosc** 1997 Jul; 11(7):707–10
The relationship between Apgar score and umbilical arterial blood gas values in newborns. Energin M, et al. **Turk J Pediatr** 1996 Oct–Dec;38(4):447–57
[Maturational quality, adaptation reactions and clinical–chemical blood values in automatically milk–fed bred milk calves] Steinhardt M, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Jan;104(1):3–8 (Eng. Abstr.) **(Ger)**
[Acid base changes and muscle relaxants] Ono K, et al. **Masui** 1996 Jan;45(1):2–14 (31 ref.) (Eng. Abstr.) **(Jpn)**
[The acid–base status of chronic alcoholics undergoing a bicycle ergometry test] Kyshko MM. **Lik Sprava** 1996 Mar–Apr;(3–4):87–8 **(Ukr)**

DRUG EFFECTS

Effects of chronic treatments with adrenal steroids on acid–base homeostasis in the rat. Igarreta MP, et al. **Acta Physiol Pharmacol Ther Latinoam** 1996;46(3):149–58
Cytotoxicity, pH, and glucose degradation products in four different brands of PD fluid. Wieslander A, et al. **Adv Perit Dial** 1996;12:57–60
A prospective randomized trial of two solutions for intrapartum amnioinfusion: effects on fetal electrolytes, osmolality, and acid–base status. Pressman EK, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):945–9
Acid–base, metabolic, and hemodynamic effects of sodium bicarbonate or tromethamine administration in anesthetized dogs with experimentally induced metabolic acidosis. Moon PF, et al. **Am J Vet Res** 1997 Jul;58(7):771–6
Cardiopulmonary and gastrointestinal motility effects of xylazine/ketamine–induced anesthesia in horses previously treated with glycopyrrolate. Singh S, et al. **Am J Vet Res** 1996 Dec;57(12):1762–70
An oral sodium citrate–citric acid non–particulate buffer in humans. Hauptfleisch JJ, et al. **Br J Anaesth** 1996 Nov; 77(5):642–4
Effects of sodium lactate on ventilation and acid–base balance in healthy humans. Tappy L, et al. **Clin Physiol** 1996 Jul; 16(4):393–401
Bicarbonate loading in the thoroughbred: dose, method of administration and acid–base changes. Greenhaff PL, et al. **Equine Vet J Suppl** 1990 Jun;(9):83–5
Effects of two different crystalloid cardioplegic solutions assessed by myocardial pH, tissue lactate content and energy metabolism. Bical OM, et al. **Eur J Cardiothorac Surg** 1996;10(6):417–21
Effects of S20787 on pHi–regulating mechanisms in isolated rat ventricular myocytes. Lagadic–Gossmann D, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):547–52
Diltiazem blocks the PH–induced excitation of rat nociceptors together with their mechanical and electrical excitability in vitro. Wegner H, et al. **J Neurophysiol** 1996 Jan;75(1):1–10
A comparison of the hemodynamic and ventilatory effects of abdominal insufflation with helium and carbon dioxide in young swine. Liem TK, et al. **J Pediatr Surg** 1996 Feb; 31(2):297–300
Effects of dopamine and adrenaline infusions in severe infection [letter; comment] Wyncoll DL, et al. **Lancet** 1996 Oct 19;348(9034):1099; discussion 1100. Comment on: Lancet 1996 Jul 27;348(9022):219–23.
Brain pH responses to acetazolamide and hypercapnia in cats. Kohshi K, et al. **Neurol Med Chir (Tokyo)** 1997 Apr; 37(4):313–8; discussion 318–9
[Effects of diuretic therapy on electrolyte and acid–base homeostasis] Mayer G. **Wien Med Wochenschr** 1996; 146(16):436–8 (8 ref.) (Eng. Abstr.) **(Ger)**
[Acid–base equilibrium in anesthesia with the Valium–Inoval combination] do Amaral RV, et al. **Rev Bras Anestesiol** 1968 Oct–Dec;18(4):462–71 (Eng. Abstr.) **(Por)**

GENETICS

Molecular mechanisms of acidosis–mediated damage. Siesjö BK, et al. **Acta Neurochir Suppl (Wien)** 1996;66:8–14 (66 ref.)

PHYSIOLOGY

Application of ZK 150 471, a fluorinated pH probe for 19F–magnetic resonance spectroscopy, to in vivo pH measurement after hyperthermic treatment of tumors in mice. Miyazawa T, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S363–4
Swelling, intracellular acidosis, and damage of glial cells. Staub F, et al. **Acta Neurochir Suppl (Wien)** 1996;66:56–62
Delayed hyperglycemia and intracellular acidosis during focal cerebral ischemia in cats. Dempsey RJ, et al. **Acta Neurochir (Wien)** 1996;138(6):745–51
Acid–base balance and O2 transport at high altitude. Samaja M, et al. **Acta Physiol Scand** 1997 Mar;159(3):249–56
Increased anion gap after liver transplantation. Kirschbaum B. **Am J Med Sci** 1997 Feb;313(2):107–10
The serum anion gap. Has the reference interval really fallen? Roberts WL, et al. **Arch Pathol Lab Med** 1997 Jun; 121(6):568–72
Acid–base regulation during hypothermia. a brief review. Hauge A, et al. **Arctic Med Res** 1995;54 Suppl 2:76–82 (19 ref.)
Acid–base state of cerebrospinal fluid during pregnancy and its effect on spread of spinal anaesthesia. Hirabayashi Y, et al. **Br J Anaesth** 1996 Sep;77(3):352–5
Interactions between body temperature regulation and blood acid–base status in anuran amphibians. Branco LG. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1191–6 (54 ref.)
Regulation of acid–base status in ectothermic vertebrates: the consequences for oxygen pressures in lung gas and arterial blood. Glass ML, et al. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1161–6
A physical–chemical analysis of the acid–base response to chronic obstructive pulmonary disease. Alfaro V, et al. **Can J Physiol Pharmacol** 1996 Nov;74(11):1229–35
Surgery of descending thoracic aortic aneurysms with centrifugal pump support. Biglioli P, et al. **Cardiovasc Surg** 1997 Feb;5(1):99–103
Gastric intramucosal pH and hepatic venous oximetry after cardiopulmonary bypass in valve replacement patients. Takahashi T, et al. **Cardiovasc Surg** 1996 Jun;4(3):308–10
Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Elliott SL, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):432–4
Acid–base chemistry of the blood—a general model. Rees SE, et al. **Comput Methods Programs Biomed** 1996 Oct; 51(1–2):107–19
Methodological and clinical studies of Doppler ultrasound indices and their relation to fetal haemoglobin concentration, acid–base status, and blood gas values. Legarth J. **Dan Med Bull** 1996 Dec;43(5):419–28 (45 ref.)
Interrenal function in larval Ambystoma tigrinum. IV. Acid–base balance and the renin–angiotensin system. Eskandari S, et al. **Gen Comp Endocrinol** 1997 Jan; 105(1):18–30
Factors influencing the acid–base changes in the air–pouch exudate following carrageenan induced inflammation in rats. Alfaro V, et al. **Inflamm Res** 1996 Aug;45(8):405–11
Xenopus oocyte maturation: cytoplasm alkalization is involved in germinal vesicle migration. Flament S, et al. **Int J Dev Biol** 1996 Apr;40(2):471–6
A simplified strong ion model for acid–base equilibria: application to horse plasma. Constable PD. **J Appl Physiol** 1997 Jul;83(1):297–311
Tissue–arterial PCO2 difference is a better marker of ischemia than intramural pH (pHi) or arterial pH–pHi difference. Schlichtig R, et al. **J Crit Care** 1996 Jun;11(2):51–6
Dietary mixtures of sodium bicarbonate, sodium chloride, and potassium chloride: effects on lactational performance, acid–base status, and mineral metabolism of Holstein cows. Sanchez WK, et al. **J Dairy Sci** 1997 Jun;80(6):1207–16
The key role of the H+ V–ATPase in acid–base balance and Na+ transport processes in frog skin. Ehrenfeld J, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):247–56 (78 ref.)
Regulation of intracellular pH in the hepatocyte. Mechanisms and physiological implications. Strazzabosco M, et al. **J Hepatol** 1996 May;24(5):631–44 (122 ref.)
Sprint training enhances ionic regulation during intense exercise in men. McKenna MJ, et al. **J Physiol (Lond)** 1997 Jun 15;501 (Pt 3):687–702
Alpha–stat acid–base regulation during cardiopulmonary bypass [letter; comment] Murkin JM. **J Thorac Cardiovasc Surg** 1997 Mar;113(3):619–20. Comment on: J Thorac Cardiovasc Surg 1996 Jun;111(6):1267–79.
Evaluation of blood acid–base balance after experimental administration of endotoxin in adult cow. Ohtsuka H, et al. **J Vet Med Sci** 1997 Jun;59(6):483–5
Venous–arterial PCO2 and pH gradients in acutely ill postsurgical patients. Brandi LS, et al. **Minerva Anestesiol** 1995 Sep;61(9):345–50
Anion gap: may the anions restricted to the intravascular space undergo modification in their valence? Kamel KS, et al. **Nephron** 1996;73(3):382–9
Astroglial acid–base dynamics in hyperglycemic and normoglycemic global ischemia. Lascola C, et al. **Neurosci Biobehav Rev** 1997 Mar;21(2):143–50 (58 ref.)
Brain tissue gases and pH during arteriovenous malformation resection. Hoffman WE, et al. **Neurosurgery** 1997 Feb; 40(2):294–300; discussion 300–1
Respiratory, acid–base, and metabolic responses of the Christmas Island blue crab, Cardisoma hirtipes (Dana), during simulated environmental conditions. Dela–Cruz J, et al. **Physiol Zool** 1997 Jan–Feb;70(1):100–15
Relation between blood pH and ionized calcium during acute metabolic alteration of the acid–base balance in vivo. Gaiter AM, et al. **Scand J Clin Lab Invest** 1997 Jul;57(4):317–23
The electrogenic Na/HCO3 cotransporter. Boron WF, et al. **Wien Klin Wochenschr** 1997 Jun 27;109(12–13):445–56 (70 ref.)
Mechanisms and regulation of H+ transport in distal tubule epithelial cells. Malnic G, et al. **Wien Klin Wochenschr** 1997 Jun 27;109(12–13):429–34
Modulation by fish oil diet of eicosanoid–induced anion secretion in the rat distal colon. Hug F, et al. **Z Ernahrungswiss** 1996 Dec;35(4):323–31
Intracellular pH–measurements in rat duodenal mucosa in vitro using confocal laserscan microscopy. Weinlich M, et al. **Z Gastroenterol** 1997 Apr;35(4):263–70
[Basic indicators characterizing the acid–base equilibrium in the body and its disorders (letter; comment)] Rosival V. **Vnitr Lek** 1996 Nov;42(11):801–2. Comment on: Vnitr Lek 1996 Mar;42(3):181–7. **(Cze)**
[Oxygen supply and acid–base status in extreme anemia] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):492–4 (30 ref.) **(Ger)**
[Laparoscopic cholecystectomy—effect of position changes and CO2 pneumoperitoneum on hemodynamic, respiratory and endocrinologic parameters] Berg K, et al. **Zentralbl Chir** 1997;122(5):395–404 (Eng. Abstr.) **(Ger)**
[Evaluation of fetal condition in pregnancy complicated by hypertension—biochemical assessment of amniotic fluid. III. Acid–base balance] Smolarczyk R, et al. **Ginekol Pol** 1996 Dec;67(12):603–6 (Eng. Abstr.) **(Pol)**
[Dynamics of blood pH during the menstrual cycle in women] Gerasimov IG, et al. **Fiziol Cheloveka** 1996 Sep–Oct;22(5):138–9 **(Rus)**

ACID–BASE IMBALANCE

The etiology of fetal acidosis as determined by umbilical cord acid–base. studies. Johnson JW, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):274–80; discussion 280–2

ACID-BASE IMBALANCE

Lactic acidosis associated with a deceptively normal anion gap. Schwartz-Goldstein BH, et al. **Heart Lung** 1996 Jan-Feb;25(1):79-80

Admission base deficit predicts transfusion requirements and risk of complications [see comments] Davis JW, et al. **J Trauma** 1996 Nov;41(5):769-74. Comment in: J Trauma 1997 Mar;42(3):571-3.

Acid-base disturbances in the rabbit during experimental hepatic parasitosis. Fernández E, et al. **Parasitol Res** 1996; 82(6):524-8

BLOOD

Blood acid-base changes during acute experimental inflammation in rats. Alfaro V, et al. **Can J Physiol Pharmacol** 1996 Mar;74(3):313-9

The effects of sodium bicarbonate and sodium citrate on 600 m running time of trained females. Tiryaki GR, et al. **J Sports Med Phys Fitness** 1995 Sep;35(3):194-8

Admission base deficit predicts transfusion requirements and risk of complications [letter; comment] Asimos AW, et al. **J Trauma** 1997 Mar;42(3):571-3. Comment on: J Trauma 1996 Nov;41(5):769-74.

CEREBROSPINAL FLUID

[Acid-base balance and electrolytes in cerebrospinal fluid of patients with bacterial and lymphocytic meningitis] Wiczkowski A, et al. **Przegl Lek** 1995;52(10):509-12 (Eng. Abstr.) **(Pol)**

CHEMICALLY INDUCED

Acute hypermagnesemia after laxative use. Qureshi T, et al. **Ann Emerg Med** 1996 Nov;28(5):552-5

[Disturbances of water-electrolyte and acid-base balance due to pharmacologic treatment of hypertension] Kokot F, et al. **Przegl Lek** 1996;53(9):693-6 (7 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

[Use of hydrocarbonate-containing salt mixtures in the correction of deadaptation processes] Verbitskii ON, et al. **Fiziol Cheloveka** 1996 Jan-Feb;22(1):116-22 **(Rus)**

ETIOLOGY

Acid accumulation during end-stage bradycardia in term fetuses: how long is too long? Gull I, et al. **Br J Obstet Gynaecol** 1996 Nov;103(11):1096-101

[Treatment of acid base alterations during liver transplantation (letter)] Díaz J, et al. **Med Clin (Barc)** 1997 Jan 11;108(1):36-7 **(Spa)**

METABOLISM

Acute mild hypothermia in awake unrestrained rats induces a mixed acid-base disorder. Alfaro V, et al. **J Appl Physiol** 1996 Jun;80(6):2143-50

[Basic indicators characterizing the acid-base equilibrium in the body and its disorders (letter; comment)] Rosival V. **Vnitr Lek** 1996 Nov;42(11):801-2. Comment on: Vnitr Lek 1996 Mar;42(3):181-7. **(Cze)**

[Molecular aspects of Na+/H+ exchange in the renal tubule: localization and adaptation to the acid-base state] Borensztein P, et al. **Nephrologie** 1996;17(7):377-81 (21 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Electrolyte and acid-base disturbances in the horse. Johnson PJ. **Vet Clin North Am Equine Pract** 1995 Dec; 11(3):491-514 (58 ref.)

Strong ion difference approach to acid-base imbalances with clinical applications to dogs and cats. Russell KE, et al. **Vet Clin North Am Small Anim Pract** 1996 Sep; 26(5):1185-201 (13 ref.)

ACID ETCHING, DENTAL

Comment on concentration and etching time of phosphoric acid [letter; comment] Carstensen W. **Am J Orthod Dentofacial Orthop** 1997 Jan;111(1):16A. Comment on: Am J Orthod Dentofacial Orthop 1996 Jul;110(1):15A-16A.

Evaluation of Scotchbond Multipurpose and maleic acid as alternative methods of bonding orthodontic brackets. Olsen ME, et al. **Am J Orthod Dentofacial Orthop** 1997 May; 111(5):498-501

Bond strength following the application of chlorhexidine on etched enamel. Damon PL, et al. **Angle Orthod** 1997; 67(3):169-72

The effects of soft drinks on etched and sealed enamel. Steffen JM. **Angle Orthod** 1996;66(6):449-56

The effects of pH on N-methacryloyl glycine primer on bond strength to acid-etched dentin. Nishiyama N, et al. **J Biomed Mater Res** 1996 Jul;31(3):379-84

Influence of enamel prophylaxis on wettability of three commercially available orthophosphoric acids. Osorio R, et al. **J Biomed Mater Res** 1996 Winter;33(4):269-74

A short- and long-term shear bond strength study using acids of varying dilutions on bovine dentine. Chan AR, et al. **J Dent** 1997 Mar;25(2):145-52

The application of ESEM in dental materials research. Cowan AJ, et al. **J Dent** 1996 Sep;24(5):375-7

Surface treatment of indirect resin composite surfaces before cementation. Hummel SK, et al. **J Prosthet Dent** 1997 Jun; 77(6):568-72

Enhanced permeability of acid-etched or ground dental enamel. Kuhar M, et al. **J Prosthet Dent** 1997 Jun; 77(6):578-82

[An original proposal of a new partially crystalline glass material for dental use. Structural notes on SEM and the microscopic effects of surface acid treatment] Ortolani V, et al. **Minerva Stomatol** 1996 Apr;45(4):129-34 (Eng. Abstr.) **(Ita)**

METHODS

Fluoridated etching on orthodontic bonding. Meng CL, et al. **Am J Orthod Dentofacial Orthop** 1997 Sep;112(3):259-62

Comparison of in vivo and in vitro demineralized dentin with phosphoric and maleic acid. Cagidiaco MC, et al. **ASDC J Dent Child** 1997 Jan-Feb;64(1):17-21

Microleakage of cervical restorations etched with a weak organic acid. Owens BM. **J Can Dent Assoc** 1997 Jun; 63(6):445-7

N-phenyliminodiacetic acid as an etchant/primer for dentin bonding. Schumacher GE, et al. **J Dent Res** 1997 Jan; 76(1):602-9

Smear removal and collagen exposure after non-surgical root planing followed by etching with an EDTA gel preparation. Blomlöf JP, et al. **J Periodontol** 1996 Sep; 67(9):841-5

Influence of enamel conditioning on bond strength of resin-modified glass ionomer restorative materials and polyacid-modified composites. Attin T, et al. **J Prosthet Dent** 1996 Jul;76(1):29-33

A pilot study of lactic acid as an enamel and dentin conditioner for dentin-bonding agent development. Ayad MF, et al. **J Prosthet Dent** 1996 Sep;76(3):254-9

Comparison of air abrasion versus acid etch sealant techniques: six-month retention. Kanellis MJ, et al. **Pediatr Dent** 1997 May-Jun;19(4):258-61

ACID MALTASE see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

ACID PHOSPHATASE

An acid phosphatase assay for quantifying the growth of adherent and nonadherent cells. Yang TT, et al. **Anal Biochem** 1996 Oct 1;241(1):103-8

ANALYSIS

Immunohistochemical demonstration of acid phosphatase isoenzyme 5 (tartrate-resistant) in paraffin sections of hairy cell leukemia and other hematologic disorders. Hoyer JD, et al. **Am J Clin Pathol** 1997 Sep;108(3):308-15

Bayesian evaluation of the modified zinc test and the acid phosphatase spot test for forensic semen investigation. Hooft PJ, et al. **Am J Forensic Med Pathol** 1997 Mar; 18(1):45-9

Continuous assay for acid phosphatase using phenyl phosphate. Luchter-Wasylewska E. **Anal Biochem** 1996 Oct 15;241(2):167-72

Simultaneous demonstration of alkaline and acid phosphatase activity in bone, at bone-implant interfaces and at the epiphyseal growth plate in plastic-embedded undemineralized tissues. Piattelli A, et al. **Biomaterials** 1997 Apr;18(7):545-9

Generation of CD1+RelB+ dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes. Akagawa KS, et al. **Blood** 1996 Nov 15;88(10):4029-39

Occurrence of enzymes of free radical metabolism suggests the possible cytotoxic capacity of the transitional epithelium of the human ureter. Schindelmeiser J, et al. **Cell Tissue Res** 1997 Feb;287(2):351-6

Localisation of acid phosphatase activity on the surface of bloodstream forms of Trypanosoma congolense. Tosomba OM, et al. **Exp Parasitol** 1996 Dec;84(3):429-38

Ultrastructural localization of activity of phosphatases by low temperature incubation of unfixed cryostat sections. Song JY, et al. **Histochem Cell Biol** 1996 Sep;106(3):351-5

Ultrastructural, enzyme-, lectin, and immunohistochemical studies of the erosion zone in rat tibiae. Nakamura H, et al. **J Bone Miner Res** 1996 Aug;11(8):1158-64

Ultrastructural localization of acid phosphatase in some bacteria, after treatment with Lubrol W1. Cherepova N, et al. **Microbios** 1996;88(357):199-204

Activity of aspartate aminotransferase and acid phosphatase in cryopreserved trout sperm. Glogowski J, et al. **Reprod Fertil Dev** 1996;8(8):1179-84

Polymorphism of erythrocyte acid phosphatase system (ACP, EC 3.1.3.2) in hemolysates and bloodstains. I. Evaluation of selected methods of ACP phenotyping. Skawrońska M, et al. **Rocz Akad Med Bialymst** 1995;40(2):276-85

Immunocytomorphopathological studies on the pathogenesis of rheumatoid arthritis. Ciobanu A, et al. **Rom J Morphol Embryol** 1996 Jan-Jun;42(1-2):13-32

Is seminal prostatic acid phosphatase a reliable marker for male infertility? Singh G, et al. **Singapore Med J** 1996 Dec; 37(6):598-9

Histochemical demonstration of acid phosphatase in a human retinal pigment epithelial cell line. Kigasawa K, et al. **Tokai J Exp Clin Med** 1995 May;20(1):31-5

[Characteristics of alkaline and acid phosphatase in Spirometra erinacei] Kwak KH, et al. **Korean J Parasitol** 1996 Mar;34(1):69-77 (Eng. Abstr.) **(Kor)**

ANTAGONISTS & INHIBITORS

Phosphatase inhibitors--III. Benzylaminophosphonic acids as potent inhibitors of human prostatic acid phosphatase. Beers SA, et al. **Bioorg Med Chem** 1996 Oct;4(10):1693-701

BIOSYNTHESIS

Recombinant human and mouse purple acid phosphatases: expression and characterization. Marshall K, et al. **Arch Biochem Biophys** 1997 Sep 15;345(2):230-6

Regulation of phosphatase synthesis in Saccharomyces cerevisiae--a review. Oshima Y, et al. **Gene** 1996 Nov 7; 179(1):171-7 (50 ref.)

Temperature dependent expression of an acid phosphatase by Bordetella bronchiseptica: role in intracellular survival. Chhatwal GS, et al. **Microb Pathog** 1997 May;22(5):257-64

BLOOD

Value of acid phosphatase in screening for carcinoma in patients with prostatism in Nigeria. Anyanwu SN. **East Afr Med J** 1996 Jul;73(7):457-8

Comparative clinical features of stage A1 and stage A2 prostate cancers. Is the concept of stage A changing from the current status? Kunimi K, et al. **Int Urol Nephrol** 1995; 27(5):575-85

Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate [see comments] Smith JA Jr, et al. **J Urol** 1997 Apr;157(4):1329-34. Comment in: J Urol 1997 Apr;157(4):1335-6.

The value of the ultrastructural pattern of myeloperoxidase (MPO), platelet peroxidase (PPO) and acid phosphatase in identification of blastic cell types during acute transformation of chronic myeloproliferative disorders (cMPD). Moldoveanu E, et al. **Rom J Morphol Embryol** 1996 Jul-Dec;42(3-4):179-91

Effects of androgen therapy on prostatic markers in hemodialyzed patients. Teruel JL, et al. **Scand J Urol Nephrol** 1996 Apr;30(2):129-31

[Cytochemical method of simultaneous determination of oxidation-reduction enzymes and acid phosphatase in blood lymphocytes] Bulygin GV, et al. **Klin Lab Diagn** 1997 Apr; (4):6-8 (Eng. Abstr.) **(Rus)**

CHEMISTRY

The effect of water content on the thermostability of solid-state proteins. Greco G Jr, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:108-14

Evidence for a conserved binding motif of the dinuclear metal site in mammalian and plant purple acid phosphatases: 1H NMR studies of the di-iron derivative of the Fe(III)Zn(II) enzyme from kidney bean. Battistuzzi G, et al. **Biochem J** 1997 May 1;323 (Pt 3):593-6

Comparative studies of rat recombinant purple acid phosphatase and bone tartrate-resistant acid phosphatase. Ek-Rylander B, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):305-11

Unfolding and inactivation of Penaeus penicillatus acid phosphatase during denaturation by guanidine hydrochloride. Chen SL, et al. **Biochem Mol Biol Int** 1997 Jul;42(3):517-26

Bovine kidney low molecular weight acid phosphatase: FMN-dependent kinetics. Granjeiro JM, et al. **Biochem Mol Biol Int** 1997 May;41(6):1201-8

Superactivity and phase-sensitivity of potato acid phosphatase entrapped in reverse micelles. Lalitha J, et al. **Biochem Mol Biol Int** 1996 Oct;40(3):571-8

The 102 kDa chicken liver acid phosphatase: dimeric structure, glycoprotein nature and immunological properties. Szalewicz A, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Jun; 117(2):293-8

Serial lectin affinity chromatography with concavalin A and wheat germ agglutinin demonstrates altered asparagine-linked sugar-chain structures of prostatic acid phosphatase in human prostate carcinoma. Yoshida KI, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1; 695(2):439-43

Crystal structure of phytase from Aspergillus ficuum at 2.5 A resolution [letter] Kostrewa D, et al. **Nat Struct Biol** 1997 Mar;4(3):185-90

Polymorphism of erythrocyte acid phosphatase system (ACP, EC 3.1.3.2) in hemolysates and bloodstains. II. comparison of ACP stability in dried bloodstains in relation to the temperature of storage and the type and character of substrate. Skawrońska M, et al. **Rocz Akad Med Bialymst** 1995;40(2):286-92

DEFICIENCY

Mice deficient in lysosomal acid phosphatase develop lysosomal storage in the kidney and central nervous system. Saftig P, et al. **J Biol Chem** 1997 Jul 25;272(30):18628-35

DRUG EFFECTS

Effect of vanadium compounds on acid phosphatase activity.

Vescina CM, et al. **Biol Trace Elem Res** 1996 Summer; 53(1-3):185-91

GENETICS

Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate-specific glandular kallikrein. Shan JD, et al. **Endocrinology** 1997 Sep;138(9):3764-70

Identification of the gene (aphA) encoding the class B acid phosphatase/phosphotransferase of Escherichia coli MG1655 and characterization of its product. Thaller MC, et al. **FEMS Microbiol Lett** 1997 Jan 15;146(2):191-8

ACP and PGM1 polymorphisms in a Chilean population. Campusano C, et al. **Gene Geogr** 1996 Dec;10(3):167-70

Caste variation of two placental phosphatases. Kumari SA, et al. **Gene Geogr** 1996 Aug;10(2):75-7

Low-molecular-weight acid phosphatase (ACP1), obesity, and blood lipid levels in subjects with non-insulin-dependent diabetes mellitus. Lucarini N, et al. **Hum Biol** 1997 Aug;69(4):509-15

Cathepsin G, acid phosphatase, and alpha 1-proteinase inhibitor messenger RNA levels in keratoconus corneas. Whitelock RB, et al. **Invest Ophthalmol Vis Sci** 1997 Feb; 38(2):529-34

Tartrate-resistant acid phosphatase: gene structure and function. Fleckenstein E, et al. **Leukemia** 1997 Jan; 11(1):10-3 (39 ref.)

Biochemical properties and excretion behavior of repressible acid phosphatases with altered subunit composition. Shnyreva MG, et al. **Microbiol Res** 1996 Aug; 151(3):291-300

The KIPHO5 gene encoding a repressible acid phosphatase in the yeast Kluyveromyces lactis: cloning, sequencing and transcriptional analysis of the gene, and purification and properties of the enzyme. Fermiñán E, et al. **Microbiology** 1997 Aug;143 (Pt 8):2615-25

The phytase subfamily of histidine acid phosphatases: isolation of genes for two novel phytases from the fungi Aspergillus terreus and Myceliophthora thermophila. Mitchell DB, et al. **Microbiology** 1997 Jan;143 (Pt 1):245-52

Gene cloning and cellular localization of a membrane-bound acid phosphatase of Leishmania mexicana. Wiese M, et al. **Mol Biochem Parasitol** 1996 Nov 25;82(2):153-65

Allozyme variation among six populations of the freshwater-snail Oncomelania hupensis in Zhejiang, China. Qian BZ, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):400-5

[Similarity of geographic distribution of frequencies of p(c) allele of erythrocyte acid phosphatase and BamHI-3/MspI-4 types of mitochondrial DNA in Caucasoid human populations] Maliarchuk BA. **Genetika** 1997 Mar;33(3):393-8 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Characterization of monoclonal antibodies specific to human tartrate-resistant acid phosphatase. Janckila AJ, et al. **Hybridoma** 1997 Apr;16(2):175-82

Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. Fong L, et al. **J Immunol** 1997 Oct 1;159(7):3113-7

ISOLATION & PURIFICATION

Purification and characterization of acid phosphatase from yellow lupin (Lupinus luteus) seeds. Olczak M, et al. **Biochim Biophys Acta** 1997 Aug 15;1341(1):14-25

Purification, characterisation and steady state kinetic properties of cytosolic pyruvate kinase free of phosphoenol pyruvate phosphatase activity from germinating mung beans (Vigna radiata L.) Ambasht PK, et al. **Indian J Biochem Biophys** 1996 Jun;33(3):184-94

Tartrate-resistant acid phosphatase from human bone: purification and development of an immunoassay. Halleen J, et al. **J Bone Miner Res** 1996 Oct;11(10):1444-52

Soybean root nodule acid phosphatase. Penheiter AR, et al. **Plant Physiol** 1997 Jun;114(2):597-604

METABOLISM

Acid phosphatase activity in the chick's inner ear. Kido T, et al. **Acta Otolaryngol (Stockh)** 1996 Jul;116(4):540-5

Protein-tyrosine phosphatase activity of Coxiella burnetii that inhibits human neutrophils. Li YP, et al. **Acta Virol** 1996 Nov-Dec;40(5-6):263-72

Membrane acid phosphatase (MAP) from Entamoeba histolytica. Anaya-Ruíz M, et al. **Arch Med Res** 1997;28 Spec No:182-3

Bovine kidney low molecular weight acid phosphatase: FMN-dependent kinetics. Granjeiro JM, et al. **Biochem Mol Biol Int** 1997 May;41(6):1201-8

Stability and activity of potato acid phosphatase in aqueous surfactant media. Lalitha J, et al. **Biochem Mol Biol Int** 1997 Apr;41(4):797-803

Superactivity and phase-sensitivity of potato acid phosphatase entrapped in reverse micelles. Lalitha J, et al. **Biochem Mol Biol Int** 1996 Oct;40(3):571-8

Zinc-ion-dependent acid phosphatase exhibits magnesium-ion-dependent myo-inositol-1-phosphatase activity. Fujimoto S, et al. **Biol Pharm Bull** 1996 Jun; 19(6):882-5

Generation of multinuclear tartrate-resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34+ progenitors [see comments] Pierelli L, et al. **Br J Haematol** 1997 Jan; 96(1):64-9. Comment in: Br J Haematol 1997 Jun;97(4):934-6.

Programmed cell death in the honey-bee (Apis mellifera L.) larvae midgut. Gregorc A, et al. **Cell Biol Int** 1997 Mar; 21(3):151-8

Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Hayman AR, et al. **Development** 1996 Oct;122(10):3151-62

Toxicology of cupric salts on honeybees. V. Gluconate and sulfate action on gut alkaline and acid phosphatases. Bounias M, et al. **Ecotoxicol Environ Saf** 1996 Oct; 35(1):67-76

In vivo and in vitro analysis of lysosomes and acid phosphatase activity in human chagasic placentas. Fretes RE, et al. **Exp Mol Pathol** 1995 Dec;63(3):153-60

Characterization of the amsI gene product as a low molecular weight acid phosphatase controlling exopolysaccharide synthesis of Erwinia amylovora. Bugert P, et al. **FEBS Lett** 1997 Jan 3;400(2):252-6

Identification of a protein-tyrosine phosphatase (SHP1) different from that associated with acid phosphatase in rat prostate. Valencia AM, et al. **FEBS Lett** 1997 Apr 7; 406(1-2):42-8

Influence of growth temperature on the acid phosphatase activity in the yeast Yarrowia lipolytica. Vasileva-Tonkova E, et al. **FEMS Microbiol Lett** 1996 Dec 1;145(2):267-71

Lysosomal acid phosphatase activity and progesterone secretion by porcine corpora lutea at various periods of the luteal phase. Gregoraszczuk EL, et al. **Folia Histochem Cytobiol** 1997;35(1):35-9

Purification and characterization of Kurloff cell sialoglycoproteins with acid phosphatase activity. Taouji S, et al. **Glycoconj J** 1996 Aug;13(4):653-62

Single cell enzyme activity and proliferation in the growth plate: effects of growth hormone. Gevers EF, et al. **J Bone Miner Res** 1996 Aug;11(8):1103-11

New aspects of endochondral ossification in the chick: chondrocyte apoptosis, bone formation by former chondrocytes, and acid phosphatase activity in the endochondral bone matrix. Roach HI. **J Bone Miner Res** 1997 May;12(5):795-805

Relationship of acid phosphatase activity to ultrastructural features in mice inoculated with Mycobacterium paratuberculosis. Tanaka S, et al. **J Comp Pathol** 1996 Jan; 114(1):81-91

Lysosomal enzyme activities in gallbladder mucosa of gallstone-free subjects and patients with gallstones. Sahlin S, et al. **J Hepatol** 1996 Dec;25(6):895-9

Acid phosphatase in the pathogenic and nonpathogenic hemoflagellates, Cryptobia spp., of fishes. Zuo X, et al. **J Parasitol** 1996 Dec;82(6):893-9

Localization and biochemical characterization of acid phosphatase isoforms in the olfactory system of adult rats. Krizbai I, et al. **Neuroscience** 1997 Feb;76(3):799-807

Non-conventional role of lysosomal acid phosphatase in olfactory receptor axons: co-localization with growth-associated phosphoprotein-43. Wolff JR, et al. **Neuroscience** 1997 Aug;79(3):887-91

Assessment of variability in some lysosomal and soluble enzyme activities in corneal epithelium from slaughterhouse bovine eyes. Doughty MJ. **Ophthalmic Res** 1996;28(3):141-6

Tartrate-resistant acid phosphate activity as osteoclastic marker: sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry. Ballanti P, et al. **Osteoporos Int** 1997; 7(1):39-43

Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8. Ljung G, et al. **Prostate** 1997 May 1;31(2):91-7

Evolution of cell-surface acid phosphatase of Burkholderia pseudomallei. Kondo E, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):592-9

Lysosomal enzyme activities in cultured retinal pigment epithelial and glial cells of RCS rat. Hu J, et al. **Yen Ko Hsueh Pao** 1996 Mar;12(1):20-7

[Prostate-specific antigen, acid phosphatases and rectal exploration in the diagnosis of prostatic cancer] Andersen BR, et al. **Ugeskr Laeger** 1997 Apr 21;159(17):2538-42 (Eng. Abstr.) **(Dan)**

[Localization and activity of some hydrolases in larvae of tapeworms Neogryporhynchus cheilancristrotus and Triaenophorus nodulosus parasitizing fish] Niemczuk W, et al. **Wiad Parazytol** 1996;42(4):415-20 (Eng. Abstr.) **(Pol)**

[Activation of proteinases and acid phosphatase in swine leukocytes infected with the swine classical plague virus] Iushchenko IuA, et al. **Mol Gen Mikrobiol Virusol** 1997; (3):20-4 (Eng. Abstr.) **(Rus)**

[Diagnostic value of studying salivary enzymes in leukemia patients] Volchkova VM, et al. **Vopr Med Khim** 1996 Jan-Mar;42(1):46-53 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Tartrate-resistant acid phosphatase: gene structure and function. Fleckenstein E, et al. **Leukemia** 1997 Jan; 11(1):10-3 (39 ref.)

SECRETION

Secreted Entamoeba histolytica acid phosphatase (SAP). Aguirre-García MM, et al. **Arch Med Res** 1997;28 Spec No:184-5

Effect of osmotic stress on the rate of release of acid phosphatase by Leishmania donovani promastigotes. Lawrence F, et al. **J Eukaryot Microbiol** 1997 May-Jun; 44(3):206-7

URINE

Some urinary enzymes in bilharziasis. el-Naggar MM, et al. **Int Urol Nephrol** 1996;28(2):167-73

ACID RAIN

Acid rain in Laos and Thailand. Halpern M. **Allerg Immunol (Paris)** 1996 Sep;28(7):248-53

ADVERSE EFFECTS

Acute exposure to realistic acid fog: effects on respiratory function and airway responsiveness in asthmatics. Leduc D, et al. **Environ Res** 1995 Nov;71(2):89-98

ACID SEROMUCOID see **OROSOMUCOID**

ACIDIC FIBROBLAST GROWTH FACTOR see **FIBROBLAST GROWTH FACTOR, ACIDIC**

ACIDIC PANCREATIC TRYPSIN INHIBITOR see **TRYPSIN INHIBITOR, KAZAL PANCREATIC**

ACIDOSIS

An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Jang A, et al. **Clin Exp Metastasis** 1997 Sep;15(5):469-83

Survival after cardiac arrest and severe acidosis (pH = 6.54) [letter] Fumeaux T, et al. **Intensive Care Med** 1997 May; 23(5):594 (4 ref.)

BLOOD

Impact of acidosis on nutritional status in chronic peritoneal dialysis patients. Dumler F, et al. **Adv Perit Dial** 1996; 12:307-10

Components of the blood acid-base disturbance that accompanies urethane anaesthesia in rats during normothermia and hypothermia. Alfaro V, et al. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):498-502

Vasopressin and catecholamine responses to 24-hour, steady-state hypoxemia in fetal goats. Sameshima H, et al. **J Matern Fetal Med** 1996 Sep-Oct;5(5):262-7

Effects of blood pH and blood lactate on growth hormone, prolactin, and gonadotropin release after acute exercise in male volunteers. Elias AN, et al. **Proc Soc Exp Biol Med** 1997 Feb;214(2):156-60

Relation between blood pH and ionized calcium during acute metabolic alteration of the acid-base balance in vivo. Gaiter AM, et al. **Scand J Clin Lab Invest** 1997 Jul;57(4):317-23

CHEMICALLY INDUCED

High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy [letter] Yeh KH, et al. **Br J Cancer** 1997; 75(3):464-5

Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery. Sathyanarayana MV, et al. **Indian J Gastroenterol** 1996 Jul;15(3):104

Sulthiame-associated mild compensated metabolic acidosis. Tröger U, et al. **Int J Clin Pharmacol Ther** 1996 Dec; 34(12):542-5

Intracisternal papaverine administration associated with acute onset of hyperthermia and metabolic acidosis in a craniotomy. McLoughlin AL. **J Neurosurg Anesthesiol** 1997 Jan;9(1):21-4

Effect of alcohol on the utility of base deficit in trauma. Davis JW, et al. **J Trauma** 1997 Sep;43(3):507-10

A chronic glue sniffer with hyperchloraemia metabolic acidosis, rhabdomyolysis, irreversible quadriplegia, central pontine myelinolysis, and hypothyroidism. Hong JJ, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1848-9

Propylene glycol: the safe diluent that continues to cause harm. Glover ML, et al. **Pharmacotherapy** 1996 Jul-Aug; 16(4):690-3

[Prescription of ammonium chloride: anecdotic but catastrophic (letter)] Le Roy F, et al. **Presse Med** 1997 Mar 29;26(10):465 **(Fre)**

COMPLICATIONS

The clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity. Alpern RJ, et al. **Am J Kidney Dis** 1997 Feb;29(2):291-302

Neonatal complications in newborns with an umbilical artery pH < 7.00. van den Berg PP, et al.

Am J Obstet Gynecol 1996 Nov;175(5):1152–7
Extramyocardial acidosis impairs cardiac resuscitability in isolated, perfused, rat hearts. Morimoto Y, et al. **Crit Care Med** 1996 Oct;24(10):1719–23
Myoglobinuric acute renal failure in the rat: a role for acidosis? Heyman SN, et al. **Exp Nephrol** 1997 May–Jun; 5(3):210–6
Base deficit after major trauma directly relates to neutrophil CD11b expression: a proposed mechanism of shock–induced organ injury [see comments] Botha AJ, et al. **Intensive Care Med** 1997 May;23(5):504–9. Comment in: Intensive Care Med 1997 May;23(5):487–8.
Does tissue acidosis in sepsis indicate tissue hypoperfusion? [editorial] Fink MP. **Intensive Care Med** 1996 Nov; 22(11):1144–6
Distal renal tubular acidosis associated with non–autoimmune hypothyroidism. Fang JT, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):1146–7
The search for the uremic toxin: the case for metabolic acidosis [see comments] Bailey JL, et al. **Wien Klin Wochenschr** 1997 Jan 17;109(1):7–12 (50 ref.). Comment in: Wien Klin Wochenschr 1997 Jan 17;109(1):1–2.
[How "toxic" is acidosis? (editorial; comment)] Druml W. **Wien Klin Wochenschr** 1997 Jan 17;109(1):1–2. Comment on: Wien Klin Wochenschr 1997 Jan 17;109(1):7–12. **(Ger)**

DIAGNOSIS

The magnitude of metabolic acidosis is dependent on differences in bicarbonate assays [see comments] Bray SH, et al. **Am J Kidney Dis** 1996 Nov;28(5):700–3. Comment in: Am J Kidney Dis 1997 Jun;29(6):983–4.
The predictive value of biophysical profiles and Doppler velocimetry for fetal acidosis in a low risk population. Kent N, et al. **Aust N Z J Obstet Gynaecol** 1996 May;36(2):140–5
Monitoring tissue oxygenation. The search for the grail [editorial; comment] Dantzker DR. **Chest** 1997 Jan; 111(1):12–4. Comment on: Chest 1997 Jan;111(1):174–9.
The DCO2 measured by gastric tonometry predicts survival in children receiving extracorporeal life support. Comparison with other hemodynamic and biochemical information. Royal Children's Hospital ECMO Nursing Team [see comments] Duke T, et al. **Chest** 1997 Jan; 111(1):174–9. Comment in: Chest 1997 Jan;111(1):12–4.
Neonatal presentation of Gordon syndrome. Gereda JE, et al. **J Pediatr** 1996 Oct;129(4):615–7
Intrapartum assessment of fetal well–being: a comparison of scalp stimulation with scalp blood pH sampling. Elimian A, et al. **Obstet Gynecol** 1997 Mar;89(3):373–6
Diagnostic use of anion and osmolal gaps in pediatric emergency medicine. Chabali R. **Pediatr Emerg Care** 1997 Jun;13(3):204–10
[Fetal heart rate and acidosis] Butterwegge M, et al. **Z Geburtshilfe Neonatol** 1997 Jan–Feb;201(1):30–3 **(Ger)**
[Newborn baby with extreme acidosis] Strózik K. **Pediatr Pol** 1996 Sep;71(9):817–8 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Correction of metabolic alkalosis by potassium chloride in ectopic adrenocorticotropic hormone syndrome. Islam M, et al. **Am J Kidney Dis** 1996 Oct;28(4):610–3
Tris–hydroxymethyl aminomethane and sodium bicarbonate to buffer metabolic acidosis in an isolated heart model. Sirieix D, et al. **Am J Respir Crit Care Med** 1997 Mar; 155(3):957–63
Plasma potassium response after tromethamine (THAM) or sodium bicarbonate in the acidotic rabbit. Waters JH, et al. **Anesth Analg** 1996 Oct;83(4):789–92
Does the administration of carbicarb lead acutely to back–titration of non–bicarbonate buffers? Kamel KS. **Clin Nephrol** 1996 Aug;46(2):112–6
Growth hormone action is blunted by acidosis in experimental uremia or acid load. Maniar S, et al. **Clin Nephrol** 1996 Jul;46(1):72–6
The acute reversal of a diet–induced metabolic acidosis does not restore endurance capacity during high–intensity exercise in man. Ball D, et al. **Eur J Appl Physiol** 1996; 73(1–2):105–12
Effect of tris–(hydroxymethyl)–aminomethane on experimental focal cerebral ischemia. Nagao S, et al. **Exp Brain Res** 1996 Sep;111(1):51–6
Use of erythropoietin, active vitamin D3 metabolites, and alkali agents in predialysis patients. Ismail N. **Semin Nephrol** 1997 Jul;17(4):270–84 (112 ref.)

ENZYMOLOGY

Expression of carbonic anhydrase IV mRNA in rabbit kidney: stimulation by metabolic acidosis. Winkler CA, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):F551–60
Sarco/endoplasmic reticulum Ca2+–ATPase isoforms: diverse responses to acidosis. Wolosker H, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):545–50
Chronic extracellular acidosis induces plasmalemmal vacuolar type H+ ATPase activity in osteoclasts. Nordström T, et al. **J Biol Chem** 1997 Mar 7; 272(10):6354–60

EPIDEMIOLOGY

Stress hormones and acid–base status in human fetuses at term delivery: the effect of delivery method. Posaci C, et al. **JPMA J Pak Med Assoc** 1996 Jun;46(6):123–6

ETIOLOGY

Alcoholic ketoacidosis presenting with extreme hypoglycemia. Marinella MA. **Am J Emerg Med** 1997 May; 15(3):280–1
Marked dilutional acidosis complicating management of right ventricular myocardial infarction. Jaber BL, et al. **Am J Kidney Dis** 1997 Oct;30(4):561–7
Enterovesical fistula presenting as life–threatening normal anion gap metabolic acidosis. Saxena R, et al. **Am J Kidney Dis** 1997 Jul;30(1):131–3
The etiology of fetal acidosis as determined by umbilical cord acid–base studies. Johnson JW, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):274–80; discussion 280–2
Dilutional acidosis: is it a real clinical entity? Mathes DD, et al. **Anesthesiology** 1997 Feb;86(2):501–3
Metabolic acidosis and fetal reserve. Low JA. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):211–24 (58 ref.)
Metabolic acidosis and nutrition in dialysis patients. Bergström J. **Blood Purif** 1995 Nov–Dec;13(6):361–7 (26 ref.)
Acidosis in end–stage renal failure [editorial] Leunissen KM. **Blood Purif** 1995 Nov–Dec;13(6):358–60
Maternal fever in term labour in relation to fetal tachycardia, cord artery acidaemia and neonatal infection. Herbst A, et al. **Br J Obstet Gynaecol** 1997 Mar;104(3):363–6
Contact lens induced corneal acidosis. Bonanno JA. **CLAO J** 1996 Jan;22(1):70–4 (25 ref.)
Acidosis in uremic patients. Bommer J, et al. **Clin Nephrol** 1996 Oct;46(4):280–5 (43 ref.)
Benign duodenocolic fistula. A case presenting with acidosis. Benn M, et al. **Dig Dis Sci** 1997 Feb;42(2):345–7
The acute reversal of a diet–induced metabolic acidosis does not restore endurance capacity during high–intensity exercise in man. Ball D, et al. **Eur J Appl Physiol** 1996; 73(1–2):105–12
Severe metabolic acidosis in the alcoholic: differential diagnosis and management. Höjer J. **Hum Exp Toxicol** 1996 Jun;15(6):482–8 (45 ref.)
Neurological disturbances and hyperdynamic shock in a patient with esophagocoloplasty. Campos L, et al. **Intensive Care Med** 1997 May;23(5):590–2
Intermittent hemodialysis in critically ill patients with multiple organ dysfunction syndrome is associated with intestinal intramucosal acidosis. Van der Schueren G, et al. **Intensive Care Med** 1996 Aug;22(8):747–51
Cystic fibrosis presenting with hypokalemia and metabolic alkalosis in a previously healthy adolescent. Bates CM, et al. **J Am Soc Nephrol** 1997 Feb;8(2):352–5
Acidosis and coma after hemodialysis. Taylor R, et al. **J Am Soc Nephrol** 1997 May;8(5):853–6
Splanchnic buffering of metabolic acid during early endotoxemia. Kellum JA, et al. **J Crit Care** 1997 Mar; 12(1):7–12
Endotoxin and transient hypoxia cause severe acidosis in the piglet. Groner JI. **J Pediatr Surg** 1997 Jul;32(7):1123–5; discussion 1126
Predicting life–threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. Cosgriff N, et al. **J Trauma** 1997 May; 42(5):857–61; discussion 861–2
An acid–base conundrum for a rainy afternoon. Luft FC. **Nephrol Dial Transplant** 1996 Aug;11(8):1653–5
Diagnostic use of anion and osmolal gaps in pediatric emergency medicine. Chabali R. **Pediatr Emerg Care** 1997 Jun;13(3):204–10
Acidosis in severe childhood malaria. English M, et al. **QJM** 1997 Apr;90(4):263–70
[Metabolic acidosis revealing cow's milk protein intolerance (letter)] Masson P, et al. **Arch Pediatr** 1996 Oct;3(10):1043–4 **(Fre)**
[Acidosis and hyperlactatemia in acute sodium valproate poisoning] Dumoulin A, et al. **Presse Med** 1997 Apr 12; 26(12):555–7 (Eng. Abstr.) **(Fre)**
[Acidosis in severe acute asthma] Lissac J. **Presse Med** 1996 Oct 19;25(31):1411–4 (21 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Acute metabolic acidosis inhibits the induction of osteoblastic egr–1 and type 1 collagen. Frick KK, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1450–6
Missense mutations in the human glutathione synthetase gene result in severe metabolic acidosis, 5–oxoprolinuria, hemolytic anemia and neurological dysfunction. Dahl N, et al. **Hum Mol Genet** 1997 Jul;6(7):1147–52
Chronic metabolic acidosis enhances NHE–3 protein abundance and transport activity in the rat thick ascending limb by increasing NHE–3 mRNA. Laghmani K, et al. **J Clin Invest** 1997 Jan 1;99(1):24–30
Two siblings with episodic ketoacidosis and decreased activity of succinyl–CoA:3–ketoacid CoA–transferase in cultured fibroblasts. Pretorius CJ, et al. **J Inherit Metab Dis** 1996;19(3):296–300

METABOLISM

Acidosis inhibits calcium accumulation in intrasynaptosomal mitochondria. Fedorovich SV, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(3):703
Intracellular acidosis potentiates carotid chemoreceptor responses to hypoxia in the absence of CO2–HCO3–. Iturriaga R. **Adv Exp Med Biol** 1996;410:211–6 (20 ref.)
Response of cortical oxygen and striatal extracellular dopamine to metabolic acidosis in newborn piglets. Tammela O, et al. **Adv Exp Med Biol** 1997;411:103–12
Excitotoxic neuron death, acidotic endangerment, and the paradox of acidotic protection. Sapolsky RM, et al. **Adv Neurol** 1996;71:237–44; discussion 244–5
Acidosis–related damage. Siesjö BK, et al. **Adv Neurol** 1996; 71:209–33; discussion 234–6 (148 ref.)
Influence of metabolic acidosis on nutrition. Mitch WE. **Am J Kidney Dis** 1997 May;29(5):xlvi–xlviii
Chronic metabolic acidosis increases NHE3 protein abundance in rat kidney. Ambühl PM, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):F917–25
Effect of chronic metabolic acidosis on thyroid hormone homeostasis in humans. Brünger M, et al. **Am J Physiol** 1997 May;272(5 Pt 2):F648–53
Effect of acidosis on control of respiration in skeletal muscle. Harkema SJ, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C491–500
Acidosis has no effect on the ATP cost of contraction in cat fast– and slow–twitch skeletal muscles. Harkema SJ, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C485–90
Acidosis induces hyperpermeability in Caco–2BBe cultured intestinal epithelial monolayers. Menconi MJ, et al. **Am J Physiol** 1997 May;272(5 Pt 1):G1007–21
Ovine fetal leucine kinetics and protein metabolism during acute metabolic acidosis. Milley JR. **Am J Physiol** 1997 Feb;272(2 Pt 1):E275–81
Effects of acidosis on phosphorylation of phospholamban and troponin I in rat cardiac muscle. Mundiña–Weilenmann C, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C107–14
Mechanisms of pHi recovery from NH4Cl–induced acidosis in anoxic isolated turtle heart: a 31P–NMR study. Shi H, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R6–15
Ca2+ sensitizer Org–30029 reverses acidosis– and BDM–induced contractile depression in canine myocardium. Watanabe A, et al. **Am J Physiol** 1996 Nov; 271(5 Pt 2):H1829–39
Intracellular acidosis activates c–Src. Yamaji Y, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C886–93
Wound hypoxia and acidosis limit neutrophil bacterial killing mechanisms. Allen DB, et al. **Arch Surg** 1997 Sep; 132(9):991–6
The adrenal secretion of catecholamines during systemic metabolic acidosis in fetal sheep. Cohn HE, et al. **Biol Neonate** 1997;72(2):125–32
Cellular mechanisms of catabolism activated by metabolic acidosis. Mitch WE. **Blood Purif** 1995 Nov–Dec; 13(6):368–74 (29 ref.)
Diminished myocardial function precedes tissue acidosis during coronary hypoperfusion. Shortt KG, et al. **Cardiology** 1997 Jan–Feb;88(1):14–8
Metabolic studies in twin brothers with 2–methylacetoacetyl–CoA thiolase deficiency. Fontaine M, et al. **Clin Chim Acta** 1996 Nov 15;255(1):67–83
Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Cuvier C, et al. **Clin Exp Metastasis** 1997 Jan;15(1):19–25
Does the administration of carbicarb lead acutely to back–titration of non–bicarbonate buffers? Kamel KS. **Clin Nephrol** 1996 Aug;46(2):112–6
Extracellular acidosis delays cell death against glucose–oxygen deprivation in neuroblastoma x glioma hybrid cells. Morimoto Y, et al. **Crit Care Med** 1997 May; 25(5):841–7
Intramucosal acidosis and systemic host responses in abdominal aortic aneurysm surgery. Soong CV, et al. **Crit Care Med** 1997 Sep;25(9):1472–9
Astrocyte glucose metabolism under normal and pathological conditions in vitro. Swanson RA, et al. **Dev Neurosci** 1996; 18(5–6):515–21
Astrocyte survival and HSP70 heat shock protein induction following heat shock and acidosis. Narasimhan P, et al. **Glia** 1996 Jun;17(2):147–59
Dilution acidosis: evidence for a role of intracellular pH in the control of ventilation. Kasserra CE, et al. **J Appl Physiol** 1996 May;80(5):1804–10
Role of NHE3 in mediating renal brush border Na+–H+ exchange. Adaptation to metabolic acidosis. Wu MS, et al. **J Biol Chem** 1996 Dec 20;271(51):32749–52
Chronic metabolic acidosis enhances NHE–3 protein abundance and transport activity in the rat thick ascending limb by increasing NHE–3 mRNA. Laghmani K, et al. **J Clin Invest** 1997 Jan 1;99(1):24–30
Metabolic acidosis stimulates H+ secretion in the rabbit outer medullary collecting duct (inner stripe) of the kidney. Tsuruoka S, et al. **J Clin Invest** 1997 Mar 15;99(6):1420–31
Splanchnic buffering of metabolic acid during early endotoxemia. Kellum JA, et al. **J Crit Care** 1997 Mar; 12(1):7–12
Developmental differences and regional similarities in the responses of rat cardiac skinned muscles to acidosis, inorganic phosphate and caffeine. Palmer S, et al. **J Mol Cell Cardiol** 1996 Apr;28(4):797–805
Brain tissue acidosis: effects on the extracellular concentration of N–acetylaspartate. Gotoh M, et al. **J Neurochem** 1997 Aug;69(2):655–61

Protective effects of extracellular acidosis and blockade of sodium/hydrogen ion exchange during recovery from metabolic inhibition in neuronal tissue culture. Vornov JJ, et al. **J Neurochem** 1996 Dec;67(6):2379–89

Mechanism of oxidative stress–induced intracellular acidosis in rat cerebellar astrocytes and C6 glioma cells. Tsai KL, et al. **J Physiol (Lond)** 1997 Jul 1;502 (Pt 1):161–74

Endothelial cell swelling and brain perfusion. Kempski O, et al. **J Trauma** 1997 May;42(5 Suppl):S38–40

Bone histomorphometric changes due to differences in calcium intake under metabolic acidosis in rats. Won JH, et al. **J Vet Med Sci** 1996 Jul;58(7):611–6

Inhibitory effects of glibenclamide and pertussis toxin on the attenuation of ischemia–induced myocardial acidosis following ischemic preconditioning in dogs. Miura K, et al. **Jpn Circ J** 1997 Aug;61(8):709–14

Effect of chronic metabolic acidosis on the growth hormone/IGF–1 endocrine axis: new cause of growth hormone insensitivity in humans. Brüngger M, et al. **Kidney Int** 1997 Jan;51(1):216–21

Regulation of AE1 anion exchanger and H(+)–ATPase in rat cortex by acute metabolic acidosis and alkalosis. Sabolić I, et al. **Kidney Int** 1997 Jan;51(1):125–37

Effect of acidotic challenges on local depolarizations evoked by N–methyl–D–aspartate in the rat striatum. Urenjak J, et al. **Life Sci** 1997;61(5):523–35

Dissociation between lactate accumulation and acidosis in middle cerebral artery–occluded rats assessed by 31P and 1H NMR metabolic images under a 2–T magnetic field. Morikawa S, et al. **Magn Reson Imaging** 1996; 14(10):1197–204

Renal effects of metabolic acidosis in the normal rat. Throssell D, et al. **Nephron** 1996;73(3):450–5

Acidosis of hippocampal neurones mediated by a plasmalemmal Ca2+/H+ pump. Trapp S, et al. **Neuroreport** 1996 Aug 12;7(12):2000–4

The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Harrison PJ, et al. **Neurosci Lett** 1995 Nov 24;200(3):151–4

Neuronal injury in experimental status epilepticus in the rat: role of acidosis. Sasahira M, et al. **Neurosci Lett** 1997 Mar 21;224(3):177–80

Effects of hypoxia and hypercapnia on contact lens–induced corneal acidosis. Rivera RK, et al. **Optom Vis Sci** 1996 Mar;73(3):178–83

Acidosis alters the phosphorylation of Ser16 and Thr17 of phospholamban in rat cardiac muscle. Hulme JT, et al. **Pflugers Arch** 1997 Aug;434(4):475–83

Role of oxidant stress and iron delocalization in acidosis–induced intestinal epithelial hyperpermeability. Gonzalez PK, et al. **Shock** 1997 Aug;8(2):108–14

Role of potassium channels in relaxations of isolated canine basilar arteries to acidosis. Kinoshita H, et al. **Stroke** 1997 Feb;28(2):433–7; discussion 437–8

PARASITOLOGY

Deep breathing in children with severe malaria: indicator of metabolic acidosis and poor outcome. English M, et al. **Am J Trop Med Hyg** 1996 Nov;55(5):521–4

PATHOLOGY

K depletion and NH4Cl acidosis increase apical insertion of studded membrane in type A intercalated cells. Narbaitz R, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):F649–56

Effect of the acidosis on the degenerating mesonephric vascular system of the chick embryos. Navarro M, et al. **Int J Dev Biol** 1996;Suppl 1:287S–288S

PHYSIOPATHOLOGY

Delayed hyperglycemia and intracellular acidosis during focal cerebral ischemia in cats. Dempsey RJ, et al. **Acta Neurochir (Wien)** 1996;138(6):745–51

Acidosis has no effect on the ATP cost of contraction in cat fast– and slow–twitch skeletal muscles. Harkema SJ, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C485–90

Temporary acidosis during reperfusion limits myocardial infarct size in dogs. Kitakaze M, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2071–8

Effect of oxidative stress and acidosis on diaphragm contractile function. Lawler JM, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R630–6

Cerebral oxygen delivery is reduced during the acidaemia associated with prolonged hypoxaemia in the immature ovine fetus. McCrabb GJ, et al. **Biol Neonate** 1997; 71(6):385–94

Normovolaemic haemodilution attenuates cardiac depression induced by sodium bicarbonate in canine metabolic acidosis. Tanaka M, et al. **Br J Anaesth** 1996 Sep; 77(3):408–12

Salutary and deleterious effects of acidity on an indirect measure of metabolic rate and ATP concentrations in CNS cultures. Trafton J, et al. **Brain Res** 1996 Aug 26; 731(1–2):122–31

Comparative inotropic effect of calcium, endothelin–1, and forskolin on ferret papillary muscles during acidosis. Ishiguro Y, et al. **Fundam Clin Pharmacol** 1997;11(3):215–20

Interactive effects of K+, acid, norepinephrine, and ischemia on the heart: implications for exercise. O'Neill M, et al. **J Appl Physiol** 1997 Apr;82(4):1046–52

Metabolic acidosis stimulates H+ secretion in the rabbit outer medullary collecting duct (inner stripe) of the kidney. Tsuruoka S, et al. **J Clin Invest** 1997 Mar 15;99(6):1420–31

Effect of acidosis on contraction, intracellular pH and calcium in the rabbit mesenteric small artery. Nakanishi T, et al. **J Mol Cell Cardiol** 1996 Aug;28(8):1715–26

Endothelin–A receptors mediate vascular smooth–muscle response to moderate acidosis in the canine tibial nutrient artery. Coessens BC, et al. **J Orthop Res** 1996 Sep; 14(5):818–22

Extracellular acidosis and chloride channel inhibitors act in the late phase of cellular injury to prevent death. Waters SL, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1012–7

Acidosis impairs rabbit trabecular smooth muscle contractility. Saenz de Tejada I, et al. **J Urol** 1997 Feb; 157(2):722–6

Hyperkalemic hyperchloremic metabolic acidosis: pathophysiologic insights. DuBose TD Jr. **Kidney Int** 1997 Feb;51(2):591–602 (76 ref.)

Growth hormone and insulin–like growth factor in non–uremic acidosis and uremic acidosis. Kuemmerle N, et al. **Kidney Int Suppl** 1997 Mar;58:S102–5 (39 ref.)

Pain due to tissue acidosis: a mechanism for inflammatory and ischemic myalgia? Issberner U, et al. **Neurosci Lett** 1996 Apr 26;208(3):191–4

Modulation of the delayed rectifier potassium channel gating in guinea–pig ventricular myocytes by intracellular acidification. Sato R, et al. **Nippon Ika Daigaku Zasshi** 1997 Feb;64(1):71–3

Inflammatory mediators potentiate pain induced by experimental tissue acidosis. Steen KH, et al. **Pain** 1996 Aug;66(2–3):163–70

Acidosis prevents growth hormone–induced growth in experimental uremia. Kleinknecht C, et al. **Pediatr Nephrol** 1996 Jun;10(3):256–60

Tissue acidosis in nociception and pain. Reeh PW, et al. **Prog Brain Res** 1996;113:143–51 (65 ref.)

[Metabolic alkalosis on the surface but metabolic acidosis in depth] Halperin ML, et al. **Nephrologie** 1997;18(1):11–6 (17 ref.) (Eng. Abstr.) **(Fre)**

[Effect of acidosis on membrane potential and calcium transport in rat brain synaptosomes] Fedorovich SV, et al. **Biofizika** 1997 Mar–Apr;42(2):412–6 (Eng. Abstr.) **(Rus)**

[Mechanism of development of the dead point and threshold of anaerobic metabolism in physical work of a dynamics character] Agadzhanian NA, et al. **Fiziol Cheloveka** 1996 Jan–Feb;22(1):98–103 **(Rus)**

PREVENTION & CONTROL

Randomised controlled trial of acetate in preterm neonates receiving parenteral nutrition. Peters O, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Jul;77(1):F12–5

Short–term inhibition of the Na–H exchanger limits acidosis and reduces ischemic injury in the rat heart. Schaefer S, et al. **Cardiovasc Res** 1997 May;34(2):329–36

Seromuscular colocystoplasty lined with urothelium protects dogs from acidosis during ammonium chloride loading. Denes ED, et al. **J Urol** 1997 Sep;158(3 Pt 2):1075–80

SURGERY

Thomas G. Orr Memorial Lecture. Staged laparotomy for the hypothermia, acidosis, and coagulopathy syndrome. Moore EE. **Am J Surg** 1996 Nov;172(5):405–10

THERAPY

Effects of increased red cell mass on subclinical tissue acidosis in hyaline membrane disease. La Gamma EF, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Sep;75(2):F87–93

How to achieve optimal correction of acidosis in end–stage renal failure patients. Zucchelli P, et al. **Blood Purif** 1995 Nov–Dec;13(6):375–84 (34 ref.)

Correcting acidosis in hemodialysis: effect on phosphate clearance and calcification risk. Harris DC, et al. **J Am Soc Nephrol** 1995 Dec;6(6):1607–12

Comparison of lactate and bicarbonate buffered haemofiltration fluids: use in critically ill patients. Thomas AN, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1212–7

[Controversies concerning the use of sodium bicarbonate in metabolic acidosis] Bogdanik T. **Przegl Lek** 1995; 52(10):513–7 (21 ref.) **(Pol)**

URINE

Diagnostic applications of chromatography and capillary electrophoresis. Jellum E, et al. **J Chromatogr B Biomed Appl** 1997 Feb 7;689(1):155–64

Calciuric response to an acute acid load in healthy subjects and hypercalciuric calcium stone formers. Houillier P, et al. **Kidney Int** 1996 Sep;50(3):987–97

Effect of metabolic alkalosis and metabolic acidosis on urinary kallikrein excretion of anaesthetized rats: evidence for a role of blood pH as regulator of renal kallikrein secretion. Marin–Grez M, et al. **Pflugers Arch** 1996 Jun; 432(2):202–6

[A molecular study of methylmalonic aciduria: structure–function correlations] Rosenblatt DS, et al. **Bull Acad Natl Med** 1996 Oct;180(7):1553–63; discussion 1563–4 (33 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Characteristics of fetal heart rate changes during the expulsive stage of bovine parturition in relation to fetal outcome. Jonker FH, et al. **Am J Vet Res** 1996 Sep; 57(9):1373–81

Acid–base, metabolic, and hemodynamic effects of sodium bicarbonate or tromethamine administration in anesthetized dogs with experimentally induced metabolic acidosis. Moon PF, et al. **Am J Vet Res** 1997 Jul;58(7):771–6

Acidosis effects on insulin response during glucose tolerance tests in Jersey cows. Bigner DR, et al. **J Dairy Sci** 1996 Dec;79(12):2182–8

Determinants and utility of the anion gap in predicting hyperlactatemia in cattle. Constable PD, et al. **J Vet Intern Med** 1997 Mar–Apr;11(2):71–9

Outbreak of acidosis in yearling bulls [letter] White DG, et al. **Vet Rec** 1995 Dec 23–30;137(26):675–6

Changes in the profile of liver enzymes in newborn calves induced by experimental, subclinical acidosis in pregnant cows and osmotic diarrhoea. Lechowski R. **Vet Res Commun** 1996;20(4):351–65

[Effects of orally administered substances on rumen fermentation patterns in cattle (in vitro). 7. Effect of dried yeast in chronic ruminal acidosis] Höltershinken M, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug;104(8):317–20 (Eng. Abstr.) **(Ger)**

[The effect of subclinical and acute ante partum acidosis in cows on the course of pregnancy with regard to the steroid hormone profile] Raś A, et al. **Tierarztl Prax** 1996 Aug; 24(4):347–52 (Eng. Abstr.) **(Ger)**

[Metabolic acidosis in calves with diarrhea and treatment with NaHCO3] Michna A, et al. **Vet Med (Praha)** 1996 Oct;41(10):305–10 (Eng. Abstr.) **(Slo)**

ACIDOSIS, DIABETIC see **DIABETIC KETOACIDOSIS**

ACIDOSIS, LACTIC

Type B lactic acidosis following cardiopulmonary bypass. Raper RF, et al. **Crit Care Med** 1997 Jan;25(1):46–51

Lactic acidosis in sepsis: a commentary [see comments] Gutierrez G, et al. **Intensive Care Med** 1996 Jan;22(1):6–16 (86 ref.). Comment in: Intensive Care Med 1996 Jan;22(1):3–5.

Effects of anoxia, acidosis and temperature on the contractile properties of turtle cardiac muscle strips. Shi H, et al. **J Exp Biol** 1997 Jul;200 (Pt 14):1965–73

The naming of a syndrome. Pearson HA. **J Pediatr Hematol Oncol** 1997 Jul–Aug;19(4):271–3

BLOOD

Agreement between peripheral venous and arterial lactate levels. Gallagher EJ, et al. **Ann Emerg Med** 1997 Apr; 29(4):479–83

Survival put to the acid test: extreme arterial blood acidosis (pH, 6.33) after near drowning. Opdahl H. **Crit Care Med** 1997 Aug;25(8):1431–6

Pulmonary lactate release in patients with sepsis and the adult respiratory distress syndrome. Brown SD, et al. **J Crit Care** 1996 Mar;11(1):2–8

Protection against cardiovascular collapse in an alcoholic patient with thiamine deficiency by concomitant alcoholic ketoacidosis. Bakker SJ, et al. **J Intern Med** 1997 Aug; 242(2):179–83

CHEMICALLY INDUCED

Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report [letter] Lenzo NP, et al. **AIDS** 1997 Aug;11(10):1294–6

Survival after metformin–associated lactic acidosis in peritoneal dialysis––dependent renal failure. Schmidt R, et al. **Am J Med** 1997 May;102(5):486–8

Metformin–induced lactic acidosis associated with acute renal failure. Safadi R, et al. **Am J Nephrol** 1996;16(6):520–2

Fatal phenformin–associated lactic acidosis [letter] Rosand J, et al. **Ann Intern Med** 1997 Jul 15;127(2):170

Metformin–associated nonketotic metabolic acidosis. Jurovich MR, et al. **Ann Pharmacother** 1997 Jan;31(1):53–5

Lactic acidosis and fatal myocardial failure due to clozapine. Koren W, et al. **Ann Pharmacother** 1997 Feb;31(2):168–70

A paradoxical effect of bronchodilators. Maury E, et al. **Chest** 1997 Jun;111(6):1766–7 (6 ref.)

Zidovudine–induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Sundar K, et al. **Crit Care Med** 1997 Aug;25(8):1425–30 (26 ref.)

Phenformin–associated lactic acidosis due to imported phenformin. Lu HC, et al. **Diabetes Care** 1996 Dec; 19(12):1449–50

Lactic acidosis associated with Glucophage use in a man with normal renal and hepatic function [letter] Pepper GM, et al. **Diabetes Care** 1997 Feb;20(2):232–3

Phenformin induced lactic acidosis [letter; comment] Meisheri YV. **J Assoc Physicians India** 1995 Feb;43(2):147 . Comment on: J Assoc Physicians India 1994 Aug;42(8):643–4.

Metabolic consequences of a sorbitol overdose during neurosurgery. Buijs EJ, et al. **J Neurosurg Anesthesiol** 1997 Jan;9(1):17–20

Type B lactic acidosis in an AIDS patient treated with zidovudine. Aggarwal A, et al. **Md Med J** 1996 Nov;

45(11):929–31
New contraindication to intravascular contrast material [letter; comment] Rasuli P, et al. **Radiology** 1996 Oct; 201(1):289–90. Comment on: Radiology 1995 Nov;197(2):545.
[Lactic acidosis induced by phenformin: a still forgotten iatrogenic complication] Vecchiarelli P, et al. **Minerva Anestesiol** 1995 Oct;61(10):415–20 (Eng. Abstr.) **(Ita)**
[Lactic acidosis and buformin (letter)] Blasco Navalpotro MA, et al. **Rev Clin Esp** 1996 Dec;196(12):880 **(Spa)**
[Antidiabetic biguanides and lactic acidosis] Rojas Hidalgo E. **Rev Clin Esp** 1997 Aug;197(8):568–73 (45 ref.) **(Spa)**

COMPLICATIONS

Severe complex I deficiency in a case of neonatal-onset lactic acidosis and fatal liver failure. Mazzella M, et al. **Acta Paediatr** 1997 Mar;86(3):326–9
Lactic acidosis secondary to severe anemia in a patient with paroxysmal nocturnal hemoglobinuria. Essex DW, et al. **Am J Hematol** 1997 Jun;55(2):110–1
An autopsy case of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) with a point mutation of mitochondrial DNA. Terauchi A, et al. **Brain Dev** 1996 May–Jun;18(3):224–9
Acute necrotizing pancreatitis, lactic acidosis and prolonged hypoglycemia in a hemodialysed patient--a logical but unfortunately fatal combination. Korzets A, et al. **Clin Nephrol** 1996 Jun;45(6):410–2
Serial imaging of bilateral striatal necrosis associated with acidaemia in adults. Kamei S, et al. **Neuroradiology** 1996 Jul;38(5):437–40
[Lactic acidosis shock. Report of a clinical case] Venturini E, et al. **Minerva Cardioangiol** 1996 Jul–Aug;44(7–8):365–7 (Eng. Abstr.) **(Ita)**

CONGENITAL

Clinical impact of peritoneal equilibration testing in treatment of congenital lactic acidosis by acute peritoneal dialysis. Aufricht C, et al. **Am J Perinatol** 1997 Mar;14(3):145–6
The treatment of congenital lactic acidoses. Morris AA, et al. **J Inherit Metab Dis** 1996;19(4):573–80 (44 ref.)

DIAGNOSIS

Monozygotic twins with MELAS-like syndrome lacking ragged red fibers and lactacidaemia. Melberg A, et al. **Acta Neurol Scand** 1996 Oct;94(4):233–41

DRUG THERAPY

Alkali therapy extends the period of survival during hypoxia: studies in rats. Halperin FA, et al. **Am J Physiol** 1996 Aug; 271(2 Pt 2):R381–7
The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. Krishna S, et al. **Br J Clin Pharmacol** 1996 Jan;41(1):29–34
Clinical and biochemical aspects of thiamine treatment for metabolic acidosis during total parenteral nutrition. Nakasaki H, et al. **Nutrition** 1997 Feb;13(2):110–7

ETIOLOGY

Two survival cases of alcoholic lactic acidosis complicated with diabetes mellitus and alcoholic liver disease. Ishii K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):387A–390A
Excess pyruvate and lactate production occurs in sepsis and is not caused by anaerobic glycolysis [letter; comment] Hunt TK. **Ann Surg** 1997 Jul;226(1):108–9. Comment on: Ann Surg 1996 Jul;224(1):97–102.
Fetal monitoring with lactate. Nordström L, et al. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):225–42 (93 ref.)
Why does lactic acidosis occur in acute lung injury? [editorial; comment] Effros RM, et al. **Chest** 1997 May; 111(5):1157–8. Comment on: Chest 1997 May;111(5):1301–5.
Survival put to the acid test: extreme arterial blood acidosis (pH 6.33) after near drowning. Opdahl H. **Crit Care Med** 1997 Aug;25(8):1431–6
Ruptured hepatoma presenting with peritonitis and acute lactic acidosis. Kelly J, et al. **Int J Clin Pract** 1997 Jun; 51(4):258–9
Pulmonary lactate release in patients with sepsis and the adult respiratory distress syndrome. Brown SD, et al. **J Crit Care** 1996 Mar;11(1):2–8
Mitochondrial electron transport chain defect presenting as hypoglycemia. Freckmann ML, et al. **J Pediatr** 1997 Mar; 130(3):431–6
From the Centers for Disease Control and Prevention. Lactic acidosis traced to thiamine deficiency related to nationwide shortage of multivitamins for total parenteral nutrition--United States, 1997 [published erratum appears in JAMA 1997 Aug 6;278(5):380] **JAMA** 1997 Jul 9; 278(2):109, 111
Lactic acidosis traced to thiamine deficiency related to nationwide shortage of multivitamins for total parenteral nutrition -- United States, 1997. **MMWR Morb Mortal Wkly Rep** 1997 Jun 13;46(23):523–8
Clinical and biochemical aspects of thiamine treatment for metabolic acidosis during total parenteral nutrition. Nakasaki H, et al. **Nutrition** 1997 Feb;13(2):110–7
Fatal lactic acidosis from imported phenformin--report of two cases. Yeoh KG, et al. **Singapore Med J** 1996 Oct; 37(5):482–4
[Lactic acidosis in alcoholic patients: to think of beriberi (letter; comment)] Schleinitz N, et al. **Presse Med** 1996 Nov 30;25(37):1848. Comment on: Presse Med 1996 Jun 8;25(20):924–8. **(Fre)**
[Splenic infarct, lactate acidosis, and pulmonary edema as manifestations of a pheochromocytoma] Bischof T, et al. **Schweiz Med Wochenschr** 1997 Feb 15;127(7):261–5 (Eng. Abstr.) **(Ger)**

GENETICS

Acute pancreatitis in an infant with lactic acidosis and a mutation at nucleotide 3243 in the mitochondrial DNA tRNALeu(UUR) gene. Kishnani PS, et al. **Eur J Pediatr** 1996 Oct;155(10):898–903
Severe lactic acidosis and neonatal death in Pearson syndrome. Muraki K, et al. **J Inherit Metab Dis** 1997 Mar; 20(1):43–8

METABOLISM

Fetal monitoring with lactate. Nordström L, et al. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):225–42 (93 ref.)
Kinetics and metabolism of chloral hydrate in children: identification of dichloroacetate as a metabolite. Henderson GN, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):695–8
Alterations in the ganglioside composition of rat cortical brain slices during experimental lactic acidosis: implications of an enzymatic process independent of the oxidative stress. Barrier L, et al. **Biochim Biophys Acta** 1997 Jul 19; 1336(1):15–22
Effect of continuous venovenous hemofiltration with dialysis on lactate clearance in critically ill patients [see comments] Levraut J, et al. **Crit Care Med** 1997 Jan;25(1):58–62. Comment in: Crit Care Med 1997 Jan;25(1):4–5.
Effect of extreme metabolic acidosis on oxygen delivery capacity of the blood--an in vitro investigation of changes in the oxyhemoglobin dissociation curve in blood with pH values of approximately 6.30. Refsum HE, et al. **Crit Care Med** 1997 Sep;25(9):1497–501
Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. Henderson GN, et al. **J Clin Pharmacol** 1997 May;37(5):416–25
The role of magnetic resonance spectroscopy in the investigation of lactic acidosis and inborn errors of energy metabolism. Gadian DG, et al. **J Inherit Metab Dis** 1996; 19(4):548–52 (21 ref.)
Metabolic intermediates in lactic acidosis: compounds, samples and interpretation. Poggi-Travert F, et al. **J Inherit Metab Dis** 1996;19(4):478–88 (28 ref.)
Effects of methylprednisolone on extracellular lactic acidosis and amino acids after severe compression injury of rat spinal cord. Farooque M, et al. **J Neurochem** 1996 Mar; 66(3):1125–30
D-lactic acidosis: turning sugar into acids in the gastrointestinal tract. Halperin ML, et al. **Kidney Int** 1996 Jan;49(1):1–8 (75 ref.)
Effect of hypoxia on glucose-modulated cerebral lactic acidosis, agonal glycolytic rates, and energy utilization. Corbett RJ, et al. **Pediatr Res** 1996 Mar;39(3):477–86
Familial cardiomyopathy with cataracts and lactic acidosis: a defect in complex I (NADH-dehydrogenase) of the mitochondria respiratory chain. Pitkanen S, et al. **Pediatr Res** 1996 Mar;39(3):513–21

MICROBIOLOGY

Role of bacteria in the pathogenesis of short bowel syndrome-associated D-lactic acidemia. Bongaerts GP, et al. **Microb Pathog** 1997 May;22(5):285–93

PATHOLOGY

Mechanism of cellular swelling induced by extracellular lactic acidosis in neuroblastoma-glioma hybrid (NG108-15) cells. Alojado ME, et al. **Anesth Analg** 1996 Nov; 83(5):1002–8
Morphological studies of skeletal muscle in lactic acidosis. Romero NB, et al. **J Inherit Metab Dis** 1996;19(4):528–34 (12 ref.)
Magnetic resonance imaging in lactic acidosis. van der Knaap MS, et al. **J Inherit Metab Dis** 1996;19(4):535–47 (51 ref.)

PHYSIOPATHOLOGY

Contribution of peripheral chemoreceptor drive in exercise hyperpnea in humans. Kobayashi T, et al. **Appl Human Sci** 1996 Nov;15(6):259–66
Lactic acidosis associated with a deceptively normal anion gap. Schwartz-Goldstein BH, et al. **Heart Lung** 1996 Jan-Feb;25(1):79–80
Lactic acidosis and other mitochondrial disorders. Stacpoole PW. **Metabolism** 1997 Mar;46(3):306–21 (220 ref.)
Hepatic and gastrointestinal oxygen and lactate metabolism during low cardiac output in lambs. Fahey JT, et al. **Pediatr Res** 1997 Jun;41(6):842–51

THERAPY

Continuous venovenous hemofiltration with dialysis and lactate clearance in critically ill patients [editorial; comment] Benjamin E. **Crit Care Med** 1997 Jan;25(1):4–5 . Comment on: Crit Care Med 1997 Jan;25(1):58–62.
The treatment of congenital lactic acidoses. Morris AA, et al. **J Inherit Metab Dis** 1996;19(4):573–80 (44 ref.)

VETERINARY

Bovine acidosis: implications on laminitis. Nocek JE. **J Dairy Sci** 1997 May;80(5):1005–28 (138 ref.)

ACIDOSIS, RENAL TUBULAR

[Renal tubular acidosis (RTA)] Igarashi T. **Nippon Rinsho** 1996 Mar;54(3):794–800 (19 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Renal tubular acidosis in pregnancy: case report and literature review. Hardardottir H, et al. **J Matern Fetal Med** 1997 Jan-Feb;6(1):16–20 (30 ref.)

CHEMICALLY INDUCED

5-Aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease. Hämling J, et al. **Digestion** 1997;58(3):304–7
Newborn renal tubular acidosis associated with prenatal maternal toluene sniffing. Erramousepe J, et al. **J Psychoactive Drugs** 1996 Apr–Jun;28(2):201–4
Reversible voltage-dependent distal renal tubular acidosis in a patient receiving standard doses of trimethoprim-sulphamethoxazole. Lin SH, et al. **Nephrol Dial Transplant** 1997 May;12(5):1031–3
[Type 4 renal tubular acidosis caused by spironolactone. A case report] Bruno CM, et al. **Minerva Med** 1997 Mar; 88(3):93–5 (Eng. Abstr.) **(Ita)**

CLASSIFICATION

A new classification for renal defects in net acid excretion. Kamel KS, et al. **Am J Kidney Dis** 1997 Jan;29(1):136–46 (52 ref.)
[Type IV renal tubular acidosis] Kiyama S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):632–6 (10 ref.) **(Jpn)**

COMPLICATIONS

Distal renal tubular acidosis and hypokalemic paralysis--genetic and precipitating factors [letter] Koul PA, et al. **J Assoc Physicians India** 1996 Oct;44(10):752–3
[A case of Sjogren syndrome with renal tubular acidosis, osteomalacia and pseudo-bone fracture] Haba T, et al. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):127–9 **(Jpn)**
[Primary distal renal tubular acidosis coexisting with malabsorption syndrome] Korth-Piotrowska H, et al. **Pol Merkuriusz Lek** 1996 Sep;1(3):200–3 (Eng. Abstr.) **(Pol)**

CONGENITAL

Siblings with congenital renal tubular acidosis and nerve deafness. Stoll C, et al. **Clin Genet** 1996 Oct;50(4):235–9 (29 ref.)

DIAGNOSIS

Detection of distal renal tubular acidosis by urinary blood PCO2 gradient in patients with rheumatoid arthritis [letter] Rosemffet MG, et al. **Clin Exp Rheumatol** 1996 May–Jun; 14(3):351–2
Broadsheet number 40: the diagnosis of renal tubular acidosis. Clague A, et al. **Pathology** 1997 Feb;29(1):34–40 (9 ref.)

DRUG THERAPY

Alkali therapy versus sodium chloride supplement in low birthweight infants with incipient late metabolic acidosis. Kalhoff H, et al. **Acta Paediatr** 1997 Jan;86(1):96–101

ENZYMOLOGY

Stimulation of apical H-K-ATPase in intercalated cells of cortical collecting duct with chronic metabolic acidosis. Silver RB, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):F539–47
Preservation of intercalated cell H(+)-ATPase in two patients with lupus nephritis and hyperkalemic distal renal tubular acidosis. Bastani B, et al. **J Am Soc Nephrol** 1997 Jul;8(7):1109–17

ETIOLOGY

Complications of childhood Sjögren syndrome. Kobayashi I, et al. **Eur J Pediatr** 1996 Oct;155(10):890–4
Hypokalemic periodic paralysis: an unusual cause. Thomas N, et al. **J Assoc Physicians India** 1996 Mar;44(3):207–8
Sjögren's syndrome presenting as hypokalemic paralysis due to distal renal tubular acidosis. Zimhony O, et al. **J Rheumatol** 1995 Dec;22(12):2366–8
New insights into the pathogenesis of distal renal tubular acidosis. Bastani B, et al. **Miner Electrolyte Metab** 1996; 22(5–6):396–409 (133 ref.)
Type IV renal tubular acidosis and uric acid nephrolithiasis in William's syndrome--an unusual mode of renal involvement. De Ferrari ME, et al.

Nephrol Dial Transplant 1997 Jul;12(7):1484–6
Secondary distal renal tubular acidosis in association with urological abnormalities [letter] Sharma RK, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):233
Evaluation of renal acidification in HIV-infected patients with hypergammaglobulinemia. Seux-Levieil ML, et al. **Nephron** 1997;75(2):196–200
[Hypokalemic quadriparesis disclosing distal tubular acidosis in primary Gougerot-Sjögren syndrome (letter)] Neau D, et al. **Rev Med Interne** 1996;17(12):1039–40 **(Fre)**

GENETICS

Siblings with congenital renal tubular acidosis and nerve deafness. Stoll C, et al. **Clin Genet** 1996 Oct;50(4):235–9 (29 ref.)

IMMUNOLOGY

Tubulointerstitial nephritis with renal tubular acidosis and asymptomatic primary biliary cirrhosis accompanied by antibody to a 52-kDa mitochondrial protein alone. Kodama T, et al. **Clin Nephrol** 1996 Jun;45(6):401–5

METABOLISM

Pseudohypoaldosteronism with normal blood pressure. Shoker A, et al. **Clin Nephrol** 1996 Aug;46(2):105–11
Endogenous endothelins mediate increased distal tubule acidification induced by dietary acid in rats. Wesson DE. **J Clin Invest** 1997 May 1;99(9):2203–11
Reversible voltage-dependent distal renal tubular acidosis in a patient receiving standard doses of trimethoprim-sulphamethoxazole. Lin SH, et al. **Nephrol Dial Transplant** 1997 May;12(5):1031–3
[Type III renal tubular acidosis] Nonoguchi H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):629–31 (5 ref.) **(Jpn)**
[Type II (proximal) renal tubular acidosis] Tashima Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):624–8 (9 ref.) **(Jpn)**

PATHOLOGY

From the WWW Dysmorphology Discussion Board. Bijlsma E, et al. **Clin Dysmorphol** 1997 Apr;6(2):189–90
Mitochondrial cytopathies and renal tubular acidosis [letter; comment] Pintos-Morell G. **Pediatr Nephrol** 1997 Jun; 11(3):386. Comment on: Pediatr Nephrol 1996 Jun;10(3):368–73.

PHYSIOPATHOLOGY

Metabolic acidosis in hemodialysis patients: a study of prevalence and factors affecting intradialytic bicarbonate gain. Sepandj F, et al. **Artif Organs** 1996 Sep;20(9):976–80
Renal tubular dysfunction in multiple acyl-CoA dehydrogenase deficiency. Morris AA, et al. **J Inherit Metab Dis** 1997 Aug;20(4):604–5
Glomerular filtration rate in primary Sjögren's syndrome with renal disease. Eriksson P, et al. **Scand J Urol Nephrol** 1996 Apr;30(2):121–7
[Type I renal tubular acidosis (type I RTA)] Nakayama H, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):621–3 (0 ref.) **(Jpn)**

RADIOGRAPHY

A novel neurological disorder with progressive CNS calcification, deafness, renal tubular acidosis, and microcytic anemia. Yoshimura M, et al. **Dev Med Child Neurol** 1997 Mar;39(3):198–201
Renal tubular acidosis. Holmes NM, et al. **Urology** 1997 Aug; 50(2):279

THERAPY

[Case of refractory renal tubular acidosis complicated by idiopathic thrombocytopenic purpura: efficacy of embolization of the right kidney and left nephrectomy] Gomi H, et al. **Nippon Naika Gakkai Zasshi** 1996 Aug 10; 85(8):1307–8 **(Jpn)**

ULTRASONOGRAPHY

[Hyperechogenicity of the renal medulla in children: clinico-echographic correlations] Sorino P, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):117–23 (Eng. Abstr.) **(Ita)**

URINE

The spectrum of endemic renal tubular acidosis in the northeast of Thailand. Vasuvattakul S, et al. **Nephron** 1996; 74(3):541–7
[Urinary acidification and rheumatoid arthritis] Tobli JE, et al. **Medicina (B Aires)** 1996;56(2):150–4 (Eng. Abstr.) **(Spa)**

ACIDOSIS, RESPIRATORY

COMPLICATIONS

Phrenic nerve palsies and persistent respiratory acidosis in a patient with diabetes mellitus. Fisher MA, et al. **Muscle Nerve** 1997 Jul;20(7):900–2

DIAGNOSIS

Acute metabolic acidosis in chronic alcoholism: ketoacidosis as differential diagnosis [letter] Fumeaux T, et al. **Intensive Care Med** 1996 Dec;22(12):1462–3
Methods for detecting local intestinal ischemic anaerobic metabolic acidosis by PCO2. Rozenfeld RA, et al. **J Appl Physiol** 1996 Oct;81(4):1834–42
[Heart rate accelerations in the fetus during fetal blood sampling sub partu] Tzanov G, et al. **Z Geburtshilfe Neonatol** 1997 Jan-Feb;201(1):6–10 (Eng. Abstr.) **(Ger)**
[Pre-pathologic-pathologic cardiotocographic pattern in second stage of labor. Analysis of the incidence of acidosis and recommendations for fetal blood gas analysis] Schlotter CM. **Zentralbl Gynakol** 1997;119(3):117–22 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Treatment of severe respiratory failure during status asthmaticus in children and adolescents using high flow oxygen and sodium bicarbonate. Mansmann HC Jr, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):69–73

ETIOLOGY

Hypercapnic respiratory acidosis precipitated by hypercaloric carbohydrate infusion in resolving septic acute respiratory distress syndrome: a case report. Jih KS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Nov; 58(5):359–65
Acute metabolic acidosis in chronic alcoholism: ketoacidosis as differential diagnosis [letter] Fumeaux T, et al. **Intensive Care Med** 1996 Dec;22(12):1462–3
Iatrogenic "respiratory acidosis" during laparoscopic preperitoneal hernia repair. Waisbren SJ, et al. **J Laparoendosc Surg** 1996 Jun;6(3):181–3

METABOLISM

Effect of acute respiratory acidosis on the limits of oxygen extraction during hemorrhage. Ward ME. **Anesthesiology** 1996 Oct;85(4):817–22
Effect of extreme metabolic acidosis on oxygen delivery capacity of the blood--an in vitro investigation of changes in the oxyhemoglobin dissociation curve in blood with pH values of approximately 6.30. Refsum HE, et al. **Crit Care Med** 1997 Sep;25(9):1497–501

PHYSIOPATHOLOGY

Effect of respiratory acidosis on body movements in the chronically instrumented fetal lamb. Bessho T, et al. **Acta Obstet Gynecol Scand** 1997 Mar;76(3):200–4
Effects of hypercapnia on steady state, phenylephrine-induced tension in isolated rings of rat pulmonary artery. Sweeney M, et al. **Adv Exp Med Biol** 1996;410:463–9
The effects of bupivacaine and ropivacaine on baroreflex sensitivity with or without respiratory acidosis and alkalosis in rats. Watanabe Y, et al. **Anesth Analg** 1997 Feb; 84(2):398–404
[Acid base changes and muscle relaxants] Ono K, et al. **Masui** 1996 Jan;45(1):2–14 (31 ref.) (Eng. Abstr.) **(Jpn)**

ACIDS

Impairment of the gastric hyperemic response to luminal acid in cirrhotic rats. Nishizaki Y, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):G71–8
Aspirin renders the oesophageal mucosa more permeable to acid and pepsin [letter; comment] Brewer NR, et al. **Eur J Gastroenterol Hepatol** 1997 Mar;9(3):315. Comment on: Eur J Gastroenterol Hepatol 1995 Nov;7(11):1065–72.

ADMINISTRATION & DOSAGE

Reduced bicarbonate secretion mediates increased distal tubule acidification induced by dietary acid. Wesson DE. **Am J Physiol** 1996 Sep;271(3 Pt 2):F670–8

ADVERSE EFFECTS

[Association between dental erosion and exposure to acids in a chemical factory] Goto H, et al. **Sangyo Eiseigaku Zasshi** 1996 Jul;38(4):165–71 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Validated capillary electrophoresis method for the analysis of a range of acidic drugs and excipients. Altria KD, et al. **J Pharm Biomed Anal** 1997 May;15(8):1091–101
Determination of acid values of fats and oils by flow injection analysis with electrochemical detection. Fuse T, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1515–9

ANTAGONISTS & INHIBITORS

Lessening dental erosive potential by product modification. Grenby TH. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 2)):221–8 (36 ref.)

BLOOD

Acidaemia enhances the inhibitory effect of hypoxia on fetal lung liquid secretion in sheep. Wallace MJ, et al. **Reprod Fertil Dev** 1996;8(3):327–33
[Search for correlations between parameters of the kinetics of acid hemolysis of erythrocytes and the functional state of the body] Golenda IL, et al. **Fiziol Cheloveka** 1996 Jul-Aug;22(4):130–6 **(Rus)**

CHEMISTRY

The application of various protic acids in the extraction of (1-->3)-beta-D-glucan from Saccharomyces cerevisiae. Müller A, et al. **Carbohydr Res** 1997 Apr 21;299(3):203–8
Acid-catalyzed reductive amination of aldoses with 8-aminopyrene-1,3,6-trisulfonate. Evangelista RA, et al. **Electrophoresis** 1996 Feb;17(2):347–51
General equation for calculating the dissociation constants of polyprotic acids and bases from measured retention factors in high-performance liquid chromatography. Jano I, et al. **J Chromatogr A** 1997 Feb 21;762(1–2):63–72

METABOLISM

Fixed acid uptake by visceral organs during early endotoxemia. Kellum JA, et al. **Adv Exp Med Biol** 1997; 411:275–9
Control of proximal tubule acidification by the endothelium of the peritubular capillaries. Amorena C, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R691–4
Recovery from NMDA-induced intracellular acidification is delayed and dependent on extracellular bicarbonate. Canzoniero LM, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):C593–9
Role of acidic Ca2+-independent phospholipase A2 in synthesis of lung dipalmitoyl phosphatidylcholine. Fisher AB, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):L238–43
Importance of vagus nerves in duodenal acid neutralization in anesthetized pigs. Glad H, et al. **Am J Physiol** 1997 Jan; 272(1 Pt 1):G154–60
NH4Cl activates AE2 anion exchanger in Xenopus oocytes at acidic pHi. Humphreys BD, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1232–40
Control of acid secretion in cultured gas gland cells of the European eel Anguilla anguilla. Pelster B, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):R578–84
Cholera and pertussis toxins increase acidification of endocytic vesicles without altering ion conductances. Van Dyke RW. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1123–33
H(+)-K(+)-ATPase mediates net acid secretion in rat terminal inner medullary collecting duct. Wall SM, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):F1037–44
NH+4 augments net acid secretion by a ouabain-sensitive mechanism in isolated perfused inner medullary collecting ducts. Wall SM. **Am J Physiol** 1996 Mar;270(3 Pt 2):F432–9
Potassium depletion and acid-base transporters in rat kidney: differential effect of hypophysectomy. Wang Z, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):F736–43
Reduced bicarbonate secretion mediates increased distal tubule acidification induced by dietary acid. Wesson DE. **Am J Physiol** 1996 Sep;271(3 Pt 2):F670–8
Roles of Ca2+ and PKC in regulation of acid/base transport in isolated proximal tubules. Yamada H, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):F1068–76
Intracellular acidification inhibits opposum kidney cell phosphate uptake. Yanagawa N, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1904–11
Clozapine-chlorpromazine allergic cross-reactivity in a psychotic patient with asymptomatic AIDS [letter] Quintana J, et al. **Biol Psychiatry** 1996 Dec 1;40(11):1185–6
Selective acid vulnerability of dopaminergic neurons and its recovery by brain-derived neurotrophic factor. Akaneya Y, et al. **Brain Res** 1995 Dec 18;704(2):175–83
Acid stress responses in enterobacteria. Bearson S, et al. **FEMS Microbiol Lett** 1997 Feb 15;147(2):173–80 (39 ref.)
Luminal acid increases apical cell membrane resistance in isolated Necturus antral mucosa. Mustonen H, et al. **Gastroenterology** 1997 Sep;113(3):875–83
Intracellular acidification of the leech giant glial cell evoked by glutamate and aspartate. Deitmer JW, et al. **Glia** 1997 Feb;19(2):111–22
Effect of an acute oral protein load on renal acidification in healthy humans and in patients with chronic renal failure. de Santo NG, et al. **J Am Soc Nephrol** 1997 May; 8(5):784–92
Multiple G-protein involvement in parathyroid hormone regulation of acid production by osteoclasts. May LG, et al. **J Cell Biochem** 1997 Jan;64(1):161–70
Fibrous-long spacing fiber formation by collagen and non-collagenous acidic components from calf skin. Tajima S. **J Dermatol Sci** 1996 Jun;12(2):104–9
Acidity is involved in the development of neuropathy caused by oxidized cellulose. Nagamatsu M, et al. **J Neurol Sci** 1997 Mar 10;146(2):97–102
A proton-gated cation channel involved in acid-sensing. Waldmann R, et al. **Nature** 1997 Mar 13;386(6621):173–7
Inhibition of lactate export by quercetin acidifies rat glial cells in vitro. Volk C, et al. **Neurosci Lett** 1997 Feb 21; 223(2):121–4

PHARMACOLOGY

Synergistic effect of acidification and hypoxia: in vivo 31P-NMR and respirometric study in fishes. van Ginneken V, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1746–52
Acid adaptation sensitizes Salmonella typhimurium to hypochlorous acid. Leyer GJ, et al.

ACIDS

Appl Environ Microbiol 1997 Feb;63(2):461–7

The mechanism of acidic pH–induced contraction in aortae from SHR and WKY rats enhanced by increasing blood pressure. Furukawa K, et al. **Br J Pharmacol** 1996 Jun; 118(3):485–92

An acid–treatment method for the enhanced detection of GDNF in biological samples. Okragly AJ, et al. **Exp Neurol** 1997 Jun;145(2 Pt 1):592–6

The role of fur in the acid tolerance response of Salmonella typhimurium is physiologically and genetically separable from its role in iron acquisition. Hall HK, et al. **J Bacteriol** 1996 Oct;178(19):5683–91

Identification of sigma S–dependent genes associated with the stationary–phase acid–resistance phenotype of Shigella flexneri. Waterman SR, et al. **Mol Microbiol** 1996 Sep; 21(5):925–40

Acid treatment of lymphocytes selectively decreases the expression of HLA class I antigens: a method to confirm that a positive clinical crossmatch test was due to class I antibodies. Sumitran–Karuppan S, et al. **Transpl Immunol** 1996 Jun;4(2):163–8

[Acid resistance of erythrocytes in workers of the Astrakhan gas processing plant] Balashov VI, et al. **Med Tr Prom Ekol** 1996;(11):38–40 **(Rus)**

THERAPEUTIC USE

Thermal effects of neutralization therapy and water dilution for acute alkali exposure in canines. Homan CS, et al. **Acad Emerg Med** 1997 Jan;4(1):27–32

Successful treatment of mediastinitis after cardiovascular surgery using electrolyzed strong acid aqueous solution. Hayashi H, et al. **Artif Organs** 1997 Jan;21(1):39–42

Treatment of infectious skin defects or ulcers with electrolyzed strong acid aqueous solution. Sekiya S, et al. **Artif Organs** 1997 Jan;21(1):32–8

TOXICITY

Soluble complement receptor type 1 inhibited the systemic organ injury caused by acid instillation into a lung. Nishizawa H, et al. **Anesthesiology** 1996 Nov;85(5):1120–8

Evaluation of mutagenic and cytotoxic effects of sodium fluoride on mammalian cells influenced by an acid environment. Slameňová D, et al. **Cell Biol Toxicol** 1996 Feb;12(1):11–7

Stability of hemagglutinating activity of extracellular and intracellular forms of Japanese encephalitis virus exposed to acidic pH. Nawa M. **Microbiol Immunol** 1996; 40(5):365–71

URINE

Distal urinary acidification from Homer Smith to the present. Gluck SL, et al. **Kidney Int** 1996 Jun;49(6):1660–4 (57 ref.)

Scales of urine acidification: apical membrane–associated particles in turtle bladder. Steinmetz PR, et al. **Kidney Int** 1996 Jun;49(6):1655–9 (15 ref.)

Renal acid excretion in early infancy. Manz F, et al. **Pediatr Nephrol** 1997 Apr;11(2):231–43 (102 ref.)

[Development of methods for gas chromatographic measurement of sugars and organic acids in the urine of patients with diabetes mellitus] Chepurnoĭ IP, et al. **Klin Lab Diagn** 1996 May–Jun;(3):48–50 **(Rus)**

ACIDULATED PHOSPHATE FLUORIDE

ADMINISTRATION & DOSAGE

Fluoride profiles in different sites of approximal surfaces of second primary molars after topical application of acidulated phosphate fluoride gel in vivo. Nishioka Y, et al. **Arch Oral Biol** 1995 Dec;40(12):1157–61

ACINETOBACTER

Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Bergogne–Bérézin E, et al. **Clin Microbiol Rev** 1996 Apr;9(2):148–65 (228 ref.)

CHEMISTRY

Structure of a surface polysaccharide from Acinetobacter baumannii O16. Haseley SR, et al. **Carbohydr Res** 1996 Oct 31;293(2):259–65

Structural studies of the O–antigenic polysaccharide of the lipopolysaccharide from Acinetobacter (DNA group 11) strain 94 containing 3–amino–3,6–dideoxy–D–galactose substituted by the previously unknown amide–linked L–2–acetoxypropionic acid or L–2–hydroxypropionic acid. Haseley SR, et al. **Eur J Biochem** 1997 Aug 1;247(3):815–9

Structural and serological characterisation of the O–antigenic polysaccharide of the lipopolysaccharide from Acinetobacter strain 90 belonging to DNA group 10. Haseley SR, et al. **Eur J Biochem** 1997 Apr 15;245(2):470–6

Structural and serological characterisation of the O–antigenic polysaccharide of the lipopolysaccharide from Acinetobacter junii strain 65. Haseley SR, et al. **Eur J Biochem** 1997 Apr 15;245(2):477–81

Structures of polymeric products isolated from the lipopolysaccharides of reference strains for Acinetobacter baumannii O23 and O12. Haseley SR, et al. **Eur J Biochem** 1997 Feb 15;244(1):147–54

Structural investigation of the lipopolysaccharide from Acinetobacter haemolyticus strain NCTC 10305 (ATCC 17906, DNA group 4). Vinogradov EV, et al. **Eur J Biochem** 1997 Jul 1;247(1):82–90

The structure of the carbohydrate backbone of the lipopolysaccharide from Acinetobacter strain ATCC 17905. Vinogradov EV, et al. **Eur J Biochem** 1997 Jan 15; 243(1–2):122–7

CLASSIFICATION

The species composition of oligotrophic bacterial communities of Lake Balaton—a numerical analysis. Tóth E. **Acta Microbiol Immunol Hung** 1996;43(4):333–8

Behaviour of Acinetobacter strains with normal human serum. Cervi BM, et al. **Cent Eur J Public Health** 1996 Sep;4(3):197–200

Verification of a PCR–based typing method for Acinetobacter baumannii in a pseudo–outbreak investigation. Cimolai N, et al. **Diagn Microbiol Infect Dis** 1997 Jun;28(2):61–4

Phylogenetic relationship of the twenty–one DNA groups of the genus Acinetobacter as revealed by 16S ribosomal DNA sequence analysis. Ibrahim A, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):837–41

Outbreak of septicaemia in neonates caused by Acinetobacter junii investigated by amplified ribosomal DNA restriction analysis (ARDRA) and four typing methods. Bernards AT, et al. **J Hosp Infect** 1997 Feb;35(2):129–40

The use of plasmid profile analysis and ribotyping for typing Acinetobacter baumannii isolates. García DC, et al. **J Hosp Infect** 1996 Oct;34(2):139–44

Investigation of the epidemiology of hospital isolates of Acinetobacter anitratus by two molecular methods. Ling JM, et al. **J Hosp Infect** 1996 Jan;32(1):29–38

Differentiation of Acinetobacter baumannii biotypes by amplification of 16S–23S rRNA intergenic spacer sequences. Garcia A, et al. **Microbios** 1996;88(356):159–67

Differentiation of seventeen genospecies of Acinetobacter by multiplex polymerase chain reaction and restriction fragment length polymorphism analysis. Nowak A, et al. **Mol Cell Probes** 1996 Dec;10(6):405–11

Use of interrepeat PCR fingerprinting to investigate an Acinetobacter baumannii outbreak in an intensive care unit. Debast SB, et al. **Scand J Infect Dis** 1996;28(6):577–81

Biotypes, serovars and antimicrobial resistance patterns of Acinetobacter baumannii clinical isolates. Oliveira MG, et al. **Zentralbl Bakteriol** 1996 Aug;284(4):550–8

Phenotypic and genotypic characterization of clinically recovered presumptive Acinetobacter baumannii isolates which failed to grow at 44 degrees C. Traub WH, et al. **Zentralbl Bakteriol** 1996 Sep;285(1):29–34

Clusters of nosocomial cross–infection due to Acinetobacter baumannii and genospecies 3: comparison of serotyping with macrorestriction analysis of genomic DNA with pulsed–field gel electrophoresis. Traub WH, et al. **Zentralbl Bakteriol** 1996 Jun;284(1):115–23

DRUG EFFECTS

Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time–kill studies. Bajaksouzian S, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1073–6

Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Joly–Guillou ML, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):345–51

Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Marques MB, et al. **Antimicrob Agents Chemother** 1997 May;41(5):881–5

Activities of beta–lactams against Acinetobacter genospecies as determined by agar dilution and E–test MIC methods. Visalli MA, et al. **Antimicrob Agents Chemother** 1997 Apr; 41(4):767–70

Use of macrorestriction analysis to demonstrate interhospital spread of multiresistant Acinetobacter baumannii in São Paulo, Brazil. Sader HS, et al. **Clin Infect Dis** 1996 Sep; 23(3):631–4

In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood. Chang SC, et al. **Diagn Microbiol Infect Dis** 1995 Nov;23(3):105–110

Antimicrobial susceptibility of clinical isolates of Acinetobacter baumannii. Shi ZY, et al. **Diagn Microbiol Infect Dis** 1996 Feb;24(2):81–5

The toxicity of substituted phenolic compounds to a detoxifying and an acetic acid bacterium. Loffhagen N, et al. **Ecotoxicol Environ Saf** 1997 Apr;36(3):269–74

Oxacillin–hydrolyzing beta–lactamase involved in resistance to imipenem in Acinetobacter baumannii. Hornstein M, et al. **FEMS Microbiol Lett** 1997 Aug 15;153(2):333–9

Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33–36 kDa outer membrane protein. Clark RB. **J Antimicrob Chemother** 1996 Aug;38(2):245–51

In–vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii [letter] Martinez–Martinez L, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1107–8

In–vitro susceptibilities of multiresistant strains of Acinetobacter baumannii to eight quinolones [letter] Pascual A, et al. **J Antimicrob Chemother** 1997 Jul; 40(1):140–2

Comparative susceptibility patterns of Acinetobacter isolated in different departments of a Kuwaiti hospital. Dobardzic R, et al. **J Chemother** 1995 Nov;7 Suppl 4:66–8

In vitro activity of ampicillin–sulbactam against clinical multiresistant Acinetobacter baumannii isolates. Gales AC, et al. **J Chemother** 1996 Dec;8(6):416–9

Aminoglycoside resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates in a Greek tertiary–care hospital. Platsouka E, et al. **J Chemother** 1995 Nov;7 Suppl 4:73–5

In vitro bactericidal effect of a beta–lactam + aminoglycoside combination against multiresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Roussel–Delvallez M, et al. **J Chemother** 1996 Oct;8(5):365–8

Secondary carriage with multi–resistant Acinetobacter baumannii and Klebsiella pneumoniae in an adult ICU population: relationship with nosocomial infections and mortality. Garrouste–Orgeas M, et al. **J Hosp Infect** 1996 Dec;34(4):279–89

Clinical importance and antibiotic resistance of Acinetobacter spp. Proceedings of a symposium held on 4–5 November 1996 at Eilat, Israel. Towner KJ. **J Med Microbiol** 1997 Sep;46(9):721–46

Establishment of a protocol for testing antimicrobial activity in southern African macroalgae. Vlachos V, et al. **Microbios** 1996;88(355):115–23

Susceptibilities to 23 antimicrobial agents and beta–lactamase production of blood culture isolates of Acinetobacter sp in Hong Kong. Ling JM, et al. **Scand J Infect Dis Suppl** 1996;101:21–5

[In vitro antibacterial activity of cefoperazone–sulbactam] Zhang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct; 34(10):676–9 (Eng. Abstr.) **(Chi)**

[Peracetic acid: alternative to the sterilization of bronchofibroscopes] Villate JI, et al. **Arch Bronconeumol** 1997 Mar;33(3):133–5 (Eng. Abstr.) **(Spa)**

[Bactericide activity of sulbactam before bacteria belonging to the Acinetobacter calcoaceticus–Acinetobacter baumannii complex] Villar HE, et al. **Enferm Infecc Microbiol Clin** 1996 Nov;14(9):524–7 (Eng. Abstr.) **(Spa)**

[Selection of resistance mutants and bacteriostatic and bactericidal activity of meropenem and imipenem against Acinetobacter spp.] Villar HE, et al. **Enferm Infecc Microbiol Clin** 1997 Mar;15(3):140–3 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Characterization of the chromosomal cephalosporinases produced by Acinetobacter lwoffii and Acinetobacter baumannii clinical isolates. Perilli M, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):715–9

Sequence analysis of the gene encoding a novel L–2,4–diaminobutyrate decarboxylase of Acinetobacter baumannii: similarity to the group II amino acid decarboxylases. Ikai H, et al. **Arch Microbiol** 1996 Aug; 166(2):128–31

Inhibition studies of S–adenosylhomocysteine hydrolase purified from Acinetobacter calcoaceticus ULA–501. Impagnatiello A, et al. **Biochimie** 1996;78(4):267–72

Characterisation of DNA gyrase and measurement of drug accumulation in clinical isolates of Acinetobacter baumannii resistant to fluoroquinolones. Moreau NJ, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1079–83

Dihydroxyacetone synthase from a methanol–utilizing carboxydobacterium, Acinetobacter sp. strain JC1 DSM 3803. Ro YT, et al. **J Bacteriol** 1997 Oct;179(19):6041–7

Purification and some properties of ribulose 1,5–bisphosphate carboxylases/oxygenases from Acinetobacter sp. strain JC1 and Hydrogenophaga pseudoflava. Kim EY, et al. **Mol Cells** 1997 Jun 30;7(3):380–8

[Novel site–specific endonuclease from Acinetobacter species M strain] Zelinskaia NV, et al. **Biokhimiia** 1996 Aug; 61(8):1471–82 (Eng. Abstr.) **(Rus)**

GENETICS

Characterization of the chromosomal cephalosporinases produced by Acinetobacter lwoffii and Acinetobacter baumannii clinical isolates. Perilli M, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):715–9

High resolution DNA fingerprinting of Acinetobacter outbreak strains. Janssen P, et al. **FEMS Microbiol Lett** 1996 Sep 1;142(2–3):191–4

Identification and characterization of an aadB gene cassette at a secondary site in a plasmid from Acinetobacter. Segal H, et al. **FEMS Microbiol Lett** 1997 Aug 15;153(2):321–6

Phylogenetic relationship of the twenty–one DNA groups of the genus Acinetobacter as revealed by 16S ribosomal DNA sequence analysis. Ibrahim A, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):837–41

Phylogenetic analysis of Acinetobacter strains based on the nucleotide sequences of gyrB genes and on the amino acid sequences of their products. Yamamoto S, et al. **Int J Syst Bacteriol** 1996 Apr;46(2):506–11

DNA amplification fingerprinting (DAF) applied to the investigation of Acinetobacter baumanii isolated from

intensive care unit patients. Sheehan C, et al. **Ir J Med Sci** 1996 Jan-Mar;165(1):44–8

Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. Vila J, et al. **J Antimicrob Chemother** 1997 Jun;39(6):757–62

benK encodes a hydrophobic permease-like protein involved in benzoate degradation by Acinetobacter sp. strain ADP1. Collier LS, et al. **J Bacteriol** 1997 Sep;179(18):5943–6

Identification and analysis of a gene encoding L-2,4-diaminobutyrate:2-ketoglutarate 4-aminotransferase involved in the 1,3-diaminopropane production pathway in Acinetobacter baumannii. Ikai H, et al. **J Bacteriol** 1997 Aug;179(16):5118–25

Cloning and characterization of two catA genes in Acinetobacter lwoffii K24. Kim SI, et al. **J Bacteriol** 1997 Aug;179(16):5226–31

Combining localized PCR mutagenesis and natural transformation in direct genetic analysis of a transcriptional regulator gene, pobR. Kok RG, et al. **J Bacteriol** 1997 Jul; 179(13):4270–6

Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. Dijkshoorn L, et al. **J Clin Microbiol** 1996 Jun; 34(6):1519–25

Investigation of the epidemiology of hospital isolates of Acinetobacter anitratus by two molecular methods. Ling JM, et al. **J Hosp Infect** 1996 Jan;32(1):29–38

Direct comparison of two commercially available computer programs for analysing DNA fingerprinting gels. Seward RJ, et al. **J Med Microbiol** 1997 Apr;46(4):314–20

Plasmid-encoded genes specifying aniline oxidation from Acinetobacter sp. strain YAA. Fujii T, et al. **Microbiology** 1997 Jan;143 (Pt 1):93–9

Directed introduction of DNA cleavage sites to produce a high-resolution genetic and physical map of the Acinetobacter sp. strain ADP1 (BD413UE) chromosome. Gralton EM, et al. **Microbiology** 1997 Apr;143 (Pt 4):1345–57

Purification and some properties of ribulose 1,5-bisphosphate carboxylases/oxygenases from Acinetobacter sp. strain JC1 and Hydrogenophaga pseudoflava. Kim EY, et al. **Mol Cells** 1997 Jun 30;7(3):380–8

System to study horizontal gene exchange among microorganisms without cultivation of recipients. Strätz M, et al. **Mol Microbiol** 1996 Oct;22(2):207–15

Macrorestriction analysis (PFGE) of serologically cross-reactive serovars of Acinetobacter baumannii and genospecies 3. Traub WH, et al. **Zentralbl Bakteriol** 1997 Feb;285(3):403–12

GROWTH & DEVELOPMENT

Usefulness of Leeds Acinetobacter Medium for recovery of Acinetobacter species from respiratory specimens collected in an intensive care unit [letter] Alados JC, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jun;16(6):474–6

Survival of Acinetobacter baumannii on dry surfaces. Wendt C, et al. **J Clin Microbiol** 1997 Jun;35(6):1394–7

IMMUNOLOGY

Structure of the O18 antigen from Acinetobacter baumannii. Haseley S, et al. **Carbohydr Res** 1997 Jun 20; 301(3–4):187–92

Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter haemolyticus strain ATCC 17906. Haseley SR, et al. **Eur J Biochem** 1997 Mar 15;244(3):761–6

Macrorestriction analysis (PFGE) of serologically cross-reactive serovars of Acinetobacter baumannii and genospecies 3. Traub WH, et al. **Zentralbl Bakteriol** 1997 Feb;285(3):403–12

[Cross-reactivity between Chlamydia psittaci and Acinetobacter in indirect immunofluorescence assays] Espinosa M, et al. **Rev Argent Microbiol** 1996 Jul-Sep; 28(3):143–6 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Epidemiological study of Acinetobacter species isolated from an intensive care unit. García-Arata MI, et al. **APMIS** 1997 Feb;105(2):131–8

Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Corbella X, et al. **Clin Infect Dis** 1996 Aug;23(2):329–34

Evaluation of the ability of a commercial system to identify Acinetobacter genomic species. Bernards AT, et al. **Eur J Clin Microbiol Infect Dis** 1996 Apr;15(4):303–8

Association of private isolation rooms with ventilator-associated Acinetobacter baumanii pneumonia in a surgical intensive-care unit. Mulin B, et al. **Infect Control Hosp Epidemiol** 1997 Jul;18(7):499–503

A pseudo-outbreak of respiratory infection with Acinetobacter species. Sule O, et al. **Infect Control Hosp Epidemiol** 1997 Jul;18(7):510–2

Acinetobacter species identification by using tRNA spacer fingerprinting. Ehrenstein B, et al. **J Clin Microbiol** 1996 Oct;34(10):2414–20

Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces. Jawad A, et al. **J Clin Microbiol** 1996 Dec;34(12):2881–7

The use of plasmid profile analysis and ribotyping for typing Acinetobacter baumannii isolates. García DC, et al. **J Hosp Infect** 1996 Oct;34(2):139–44

Acinetobacter species as a cause of catheter-related infections. Seifert H. **Zentralbl Bakteriol** 1995 Dec; 283(2):161–8 (34 ref.)

METABOLISM

Isolation and characterization of soil microorganisms capable of utilizing the herbicide diclofop-methyl as a sole source of carbon and energy. Smith-Greeier LL, et al. **Can J Microbiol** 1996 Mar;42(3):221–6

Characterisation of DNA gyrase and measurement of drug accumulation in clinical isolates of Acinetobacter baumannii resistant to fluoroquinolones. Moreau NJ, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1079–83

Acinetobacter radioresistens metabolizing aromatic compounds. 2. Biochemical and microbiological characterization of the strain. Pessione E, et al. **Microbios** 1997;89(359):105–17

Acinetobacter radioresistens metabolizing aromatic compounds. 1. Optimization of the operative conditions for phenol degradation. Pessione E, et al. **Microbios** 1996; 88(357):213–21

PATHOGENICITY

Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Fagon JY, et al. **Clin Infect Dis** 1996 Sep;23(3):538–42

PHYSIOLOGY

Cell surface properties of Acinetobacter baumannii. Kõljalg S, et al. **APMIS** 1996 Sep;104(9):659–65

Biofilm formation by Acinetobacter baumannii. Vidal R, et al. **Microbios** 1996;86(346):49–58

ULTRASTRUCTURE

A comparison of three staining methods in estimation of structures on the cell wall surface of Acinetobacter junii by using electron microscope. Grzanka A, et al. **Acta Microbiol Pol** 1996;45(3–4):233–9

ACINETOBACTER CALCOACETICUS

Holy water--a risk factor for hospital-acquired infection [see comments] Rees JC, et al. **J Hosp Infect** 1996 Jan;32(1):51–5 . Comment in: J Hosp Infect 1996 Aug;33(4):301. Comment in: J Hosp Infect 1996 Aug;33(4):302. Comment in: J Hosp Infect 1997 Jan;35(1):71–2.

CHEMISTRY

Bioengineering of emulsifier structure: emulsan analogs. Gorkovenko A, et al. **Can J Microbiol** 1997 Apr; 43(4):384–90

Structural and serological characterisation of the O-specific polysaccharide from lipopolysaccharide of Acinetobacter calcoaceticus strain 7 (DNA group 1). Vinogradov EV, et al. **Eur J Biochem** 1997 Jan 15;243(1–2):167–73

CLASSIFICATION

An apparent outbreak of infection with Acinetobacter calcoaceticus reconsidered after investigation by pyrolysis mass spectrometry. Freeman R, et al. **Zentralbl Bakteriol** 1997 Jan;285(2):234–44

DRUG EFFECTS

Changing trends in the antimicrobial susceptibility of clinical isolates of Acinetobacter baumannii. Sng LH, et al. **Ann Acad Med Singapore** 1996 Mar;25(2):179–83

Emergence of resistant isolates of Acinetobacter calcoaceticus- A. baumannii complex in a Spanish hospital over a five-year period. García-Arata MI, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jun;15(6):512–5

Antibiotic resistance pattern and R-plasmids of Acinetobacter calcoaceticus subsp. anitratus. De A, et al. **Indian J Pathol Microbiol** 1995 Apr;38(2):185–8

ENZYMOLOGY

Production, characterization, and reconstitution of recombinant quinoprotein glucose dehydrogenase (soluble type; EC 1.1.99.17) apoenzyme of Acinetobacter calcoaceticus. Olsthoorn AJ, et al. **Arch Biochem Biophys** 1996 Dec 1;336(1):42–8

Purification of a lipase from Acinetobacter calcoaceticus AAC323-1 by hydrophobic-interaction methods. Bompensieri S, et al. **Biotechnol Appl Biochem** 1996 Feb; 23 (Pt 1):77–81

Nucleotide sequence of a putative periplasmic Mn superoxide dismutase from Acinetobacter calcoaceticus ADP1. Geissdörfer W, et al. **Gene** 1997 Feb 28;186(2):305–8

GENETICS

Natural transformation and availability of transforming DNA to Acinetobacter calcoaceticus in soil microcosms. Nielsen KM, et al. **Appl Environ Microbiol** 1997 May;63(5):1945–52

Uptake and processing of DNA by Acinetobacter calcoaceticus--a review. Palmen R, et al. **Gene** 1997 Jun 11;192(1):179–90 (72 ref.)

Antibiotic resistance pattern and R-plasmids of Acinetobacter calcoaceticus subsp. anitratus. De A, et al. **Indian J Pathol Microbiol** 1995 Apr;38(2):185–8

Identification and characterization of xcpR encoding a subunit of the general secretory pathway necessary for dodecane degradation in Acinetobacter calcoaceticus ADP1. Parche S, et al. **J Bacteriol** 1997 Jul;179(14):4631–4

Isolation of mutants of Acinetobacter calcoaceticus deficient in wax ester synthesis and complementation of one mutation with a gene encoding a fatty acyl coenzyme A reductase. Reiser S, et al. **J Bacteriol** 1997 May;179(9):2969–75

Expression, inducer spectrum, domain structure, and function of MopR, the regulator of phenol degradation in Acinetobacter calcoaceticus NCIB8250. Schirmer F, et al. **J Bacteriol** 1997 Feb;179(4):1329–36

mucK, a gene in Acinetobacter calcoaceticus ADP1 (BD413), encodes the ability to grow on exogenous cis,cis-muconate as the sole carbon source. Williams PA, et al. **J Bacteriol** 1997 Sep;179(18):5935–42

The expression of the Acinetobacter calcoaceticus recA gene increases in response to DNA damage independently of RecA and of development of competence for natural transformation. Rauch PJ, et al. **Microbiology** 1996 Apr;142 (Pt 4):1025–32

METABOLISM

Incorporation of 2-hydroxyl fatty acids by Acinetobacter calcoaceticus RAG-1 to tailor emulsan structure. Zhang J, et al. **Int J Biol Macromol** 1997 Feb;20(1):9–21

Degradation of crude oil by Acinetobacter calcoaceticus and Alcaligenes odorans. Lal B, et al. **J Appl Bacteriol** 1996 Oct;81(4):355–62

Novel nuclear magnetic resonance spectroscopy methods demonstrate preferential carbon source utilization by Acinetobacter calcoaceticus. Gaines GL 3rd, et al. **J Bacteriol** 1996 Dec;178(23):6833–41

Identification and characterization of xcpR encoding a subunit of the general secretory pathway necessary for dodecane degradation in Acinetobacter calcoaceticus ADP1. Parche S, et al. **J Bacteriol** 1997 Jul;179(14):4631–4

Isolation of mutants of Acinetobacter calcoaceticus deficient in wax ester synthesis and complementation of one mutation with a gene encoding a fatty acyl coenzyme A reductase. Reiser S, et al. **J Bacteriol** 1997 May;179(9):2969–75

PHYSIOLOGY

Physiological factors affecting production of extracellular lipase (LipA) in Acinetobacter calcoaceticus BD413: fatty acid repression of lipA expression and degradation of LipA. Kok RG, et al. **J Bacteriol** 1996 Oct;178(20):6025–35

Chemicals and heat generate different protein patterns in Acinetobacter calcoaceticus. Benndorf D, et al. **J Basic Microbiol** 1997;37(3):167–74

ACINETOBACTER INFECTIONS

Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Bergogne-Bérézin E, et al. **Clin Microbiol Rev** 1996 Apr;9(2):148–65 (228 ref.)

Pharmacokinetics and bactericidal activity of a single daily dose of netilmicin in the treatment of CAPD-associated peritonitis. Anding K, et al. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):465–9

Clinical importance and antibiotic resistance of Acinetobacter spp. Proceedings of a symposium held on 4–5 November 1996 at Eilat, Israel. Towner KJ. **J Med Microbiol** 1997 Sep;46(9):721–46

BLOOD

In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood. Chang SC, et al. **Diagn Microbiol Infect Dis** 1995 Nov;23(3):105–110

COMPLICATIONS

Microbial keratitis in intensive care. Kirwan JF, et al. **BMJ** 1997 Feb 8;314(7078):433–4

Acinetobacter pericarditis with tamponade in a patient with systemic lupus erythematosus. Lam SM, et al. **Lupus** 1997; 6(5):480–3 (13 ref.)

DIAGNOSIS

Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Cisneros JM, et al. **Clin Infect Dis** 1996 Jun;22(6):1026–32

Acinetobacter species as a cause of catheter-related infections. Seifert H. **Zentralbl Bakteriol** 1995 Dec; 283(2):161–8 (34 ref.)

DRUG THERAPY

Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Joly-Guillou ML, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):345–51

Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Jiménez-Mejías ME, et al. **Clin Infect Dis** 1997 May;24(5):932–5

Investigation of a multiyear multiple critical care unit outbreak due to relatively drug-sensitive Acinetobacter baumannii: risk factors and attributable mortality. Kaul R,

et al. **J Infect Dis** 1996 Dec;174(6):1279–87

EPIDEMIOLOGY

Epidemiological study of Acinetobacter species isolated from an intensive care unit. García-Arata MI, et al. **APMIS** 1997 Feb;105(2):131–8

Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Cisneros JM, et al. **Clin Infect Dis** 1996 Jun;22(6):1026–32

Association of private isolation rooms with ventilator-associated Acinetobacter baumanii pneumonia in a surgical intensive-care unit. Mulin B, et al. **Infect Control Hosp Epidemiol** 1997 Jul;18(7):499–503

Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. Dijkshoorn L, et al. **J Clin Microbiol** 1996 Jun; 34(6):1519–25

Investigation of a multiyear multiple critical care unit outbreak due to relatively drug-sensitive Acinetobacter baumannii: risk factors and attributable mortality. Kaul R, et al. **J Infect Dis** 1996 Dec;174(6):1279–87

Outbreak of gentamicin-resistant Acinetobacter baumanii in an intensive care unit: clinical, epidemiological and microbiological features. Riley TV, et al. **Pathology** 1996 Nov;28(4):359–63

Use of interrepeat PCR fingerprinting to investigate an Acinetobacter baumannii outbreak in an intensive care unit. Debast SB, et al. **Scand J Infect Dis** 1996;28(6):577–81

An apparent outbreak of infection with Acinetobacter calcoaceticus reconsidered after investigation by pyrolysis mass spectrometry. Freeman R, et al. **Zentralbl Bakteriol** 1997 Jan;285(2):234–44

ETIOLOGY

A retrospective study of clinical characteristics of acinetobacter bacteremia. Ng TK, et al. **Scand J Infect Dis Suppl** 1996;101:26–32

MICROBIOLOGY

Epidemiological study of Acinetobacter species isolated from an intensive care unit. García-Arata MI, et al. **APMIS** 1997 Feb;105(2):131–8

Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Corbella X, et al. **Clin Infect Dis** 1996 Aug;23(2):329–34

Use of macrorestriction analysis to demonstrate interhospital spread of multiresistant Acinetobacter baumannii in São Paulo, Brazil. Sader HS, et al. **Clin Infect Dis** 1996 Sep; 23(3):631–4

Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. Dijkshoorn L, et al. **J Clin Microbiol** 1996 Jun; 34(6):1519–25

Outbreak of septicaemia in neonates caused by Acinetobacter junii investigated by amplified ribosomal DNA restriction analysis (ARDRA) and four typing methods. Bernards AT, et al. **J Hosp Infect** 1997 Feb;35(2):129–40

Investigation of the epidemiology of hospital isolates of Acinetobacter anitratus by two molecular methods. Ling JM, et al. **J Hosp Infect** 1996 Jan;32(1):29–38

Holy water—a risk factor for hospital-acquired infection [see comments] Rees JC, et al. **J Hosp Infect** 1996 Jan;32(1):51–5 . Comment in: J Hosp Infect 1996 Aug;33(4):301. Comment in: J Hosp Infect 1996 Aug;33(4):302. Comment in: J Hosp Infect 1997 Jan;35(1):71–2.

Differentiation of Acinetobacter baumannii biotypes by amplification of 16S–23S rRNA intergenic spacer sequences. Garcia A, et al. **Microbios** 1996;88(356):159–67

Biotypes, serovars and antimicrobial resistance patterns of Acinetobacter baumannii clinical isolates. Oliveira MG, et al. **Zentralbl Bakteriol** 1996 Aug;284(4):550–8

Clusters of nosocomial cross-infection due to Acinetobacter baumannii and genospecies 3: comparison of serotyping with macrorestriction analysis of genomic DNA with pulsed-field gel electrophoresis. Traub WH, et al. **Zentralbl Bakteriol** 1996 Jun;284(1):115–23

PREVENTION & CONTROL

An outbreak of multiresistant Acinetobacter baumanii in a university hospital in São Paulo, Brazil. Levin AS, et al. **Infect Control Hosp Epidemiol** 1996 Jun;17(6):366–8

TRANSMISSION

A pseudo-outbreak of respiratory infection with Acinetobacter species. Sule O, et al. **Infect Control Hosp Epidemiol** 1997 Jul;18(7):510–2

ACITRETIN

ADMINISTRATION & DOSAGE

Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA. Rajan GP, et al. **Arch Dermatol Res** 1996 Aug;288(9):543–8

ADVERSE EFFECTS

Skeletal changes after long-term therapy with synthetic retinoids [letter] Herrmann G, et al. **Br J Dermatol** 1997 Mar;136(3):469–70

Severe limb defects and craniofacial anomalies in a fetus conceived during acitretin therapy. de Die-Smulders CE, et al. **Teratology** 1995 Oct;52(4):215–9

METABOLISM

Concentration of etretinate in plasma and subcutaneous fat after long-term acitretin [letter] Maier H, et al. **Lancet** 1996 Oct 19;348(9034):1107

THERAPEUTIC USE

Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Buccheri L, et al. **Arch Dermatol** 1997 Jun;133(6):711–5

Etretinate may work where acitretin fails. Bleiker TO, et al. **Br J Dermatol** 1997 Mar;136(3):368–70

Exanthematous lichen planus in a child—response to acitretin [letter] Brockow K, et al. **Br J Dermatol** 1997 Feb; 136(2):287–9

Acrodermatitis continua of Hallopeau: response to combined treatment with acitretin and calcipotriol ointment. Kuijpers AL, et al. **Dermatology** 1996;192(4):357–9

Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis [letter] Kuijpers AL, et al. **Dermatology** 1997;194(1):88–90 (11 ref.)

Remission of lichen amyloidosus after treatment with acitretin [letter] Reider N, et al. **Dermatology** 1997; 194(3):309–11

13-CIS-ACITRETIN see **ACITRETIN**

ACLACINOMYCIN A see **ACLARUBICIN**

ACLARUBICIN

ADMINISTRATION & DOSAGE

[Randomized controlled study of very low-dose Ara-C versus low-dose aclarubicin for the treatment of myelodysplastic syndrome] Shibuya T, et al. **Rinsho Ketsueki** 1996 Sep;37(9):782–4 **(Jpn)**

ANALOGS & DERIVATIVES

New betaclamycin and aclarubicin analogs obtained by prolonged microbial conversion with an aclarubicin-negative mutant. Johdo O, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):669–75

A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in epithelial ovarian cancer. Tokuhashi Y, et al. **Oncology** 1997 Jul-Aug;54(4):281–6

PHARMACOLOGY

Enhanced functional capacity of the peritoneal macrophages as antigen presenting cells after aclacinomycin treatment in mice. Bravo-Cuellar A, et al. **Biomed Pharmacother** 1997;51(4):181–4

Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines. Lehne G, et al. **Br J Cancer** 1996 Dec;74(11):1719–29

Mechanisms in inhibitory action of aclarubicin on contractility of rat aorta. Wakabayashi I, et al. **J Pharm Pharmacol** 1995 Dec;47(12A):1025–8

TOXICITY

Toxicity and antiproliferative effect of aclacinomycin A on RPE cells in vitro. Schmidt JF, et al. **Curr Eye Res** 1996 Nov;15(11):1112–6

ACNE see **ACNE VULGARIS**

ACNE KELOID

PATHOLOGY

Acne keloidalis nuchae and tufted hair folliculitis. Luz Ramos M, et al. **Dermatology** 1997;194(1):71–3

ACNE ROSACEA

Ocular rosacea. Current concepts and therapy [editorial; comment] Kligman AM. **Arch Dermatol** 1997 Jan; 133(1):89–90. Comment on: Arch Dermatol 1997 Jan;133(1):49–54.

CLASSIFICATION

Rosacea: classification and treatment. Jansen T, et al. **J R Soc Med** 1997 Mar;90(3):144–50 (60 ref.)

COMPLICATIONS

Role of allergic contact dermatitis in rosacea. Corazza M, et al. **Contact Dermatitis** 1997 Jul;37(1):40–1

Postmenopausal female rosacea patients are more disposed to react with migraine [letter] Berg M, et al. **Dermatology** 1996;193(1):73–4

Rosacea. Knox CM, et al. **Int Ophthalmol Clin** 1997 Spring; 37(2):29–40 (27 ref.)

Association of Melkersson-Rosenthal syndrome with rosacea. Bose SK. **J Dermatol** 1996 Dec;23(12):902–4 (8 ref.)

DIAGNOSIS

Periorbital edema as an initial presentation of rosacea. Chen DM, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):346–8 (15 ref.)

Case report—ocular rosacea. Ng PH, et al. **Singapore Med J** 1996 Feb;37(1):111–2

[Pathogenesis and therapy of rosacea. 2: Differential diagnosis, therapy and follow-up] Jansen T, et al. **Fortschr Med** 1997 Jan 20;115(1–2):50–3 (8 ref.) **(Ger)**

DRUG THERAPY

Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline [see comments] Quarterman MJ, et al. **Arch Dermatol** 1997 Jan;133(1):49–54 . Comment in: Arch Dermatol 1997 Jan;133(1):89–90.

Rosacea: beyond first blush. Zuber TJ. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):188–9

The efficacy of topical metronidazole in the treatment of ocular rosacea. Barnhorst DA Jr, et al. **Ophthalmology** 1996 Nov;103(11):1880–3

[Gram-negative folliculitis. Complication of antibiotic therapy of acne vulgaris, 1: Disease picture and classification—special form: whirlpool dermatitis] Jansen T, et al. **Fortschr Med** 1997 Jan 30;115(3):37–8 **(Ger)**

[Dapsone in granulomatous rosacea] Krause MH, et al. **Hautarzt** 1997 Apr;48(4):246–8 (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Pathogenesis and therapy of rosacea. 1: Clinical picture—chief symptoms—pathogenesis] Jansen T, et al. **Fortschr Med** 1996 Dec 20;114(35–36):494–6 (8 ref.) **(Ger)**

[The clinico-morphofunctional status of the esophagogastroduodenal system in patients with acne rosacea: the etiological, pathogenetic and treatment aspects] Abrahamovych LIe. **Lik Sprava** 1996 Oct-Dec; (10–12):84–8 **(Ukr)**

PATHOLOGY

Overlap of sarcoidosis and rosacea. Simonart T, et al. **Dermatology** 1997;194(4):416–8

VIROLOGY

Eradication of Helicobacter pylori as the only successful treatment in rosacea [letter] Kolibášová K, et al. **Arch Dermatol** 1996 Nov;132(11):1393

ACNE VULGARIS

Acne. An overview of clinical research findings. Thiboutot DM. **Dermatol Clin** 1997 Jan;15(1):97–109 (35 ref.)

Development and validation of a quality of life instrument for cutaneous diseases. Anderson RT, et al. **J Am Acad Dermatol** 1997 Jul;37(1):41–50

Mild insulin resistance during oral glucose tolerance test (OGTT) in women with acne. Aizawa H, et al. **J Dermatol** 1996 Aug;23(8):526–9

Sebaceous gland, acne and related disorders—basic and clinical research, clinical entities and treatment. IV International Dermatology Symposium. Berlin, Germany, April 11–13, 1997. Abstracts. **J Invest Dermatol** 1997 Mar; 108(3):371–98

"Awaiting an eruption": predictors of acne vulgaris [editorial; comment] Hansen RC. **J Pediatr** 1997 Jan;130(1):5. Comment on: J Pediatr 1997 Jan;130(1):30–9.

Pathogenesis and treatment of acne in childhood. Jansen T, et al. **Pediatr Dermatol** 1997 Jan-Feb;14(1):17–21

Dispelling myths about acne. Landow K. **Postgrad Med** 1997 Aug;102(2):94–9, 103–4, 110–2 (33 ref.)

[SAPHO syndrome: common denominator for various bone and skin diseases] Jahangier ZN, et al. **Ned Tijdschr Geneeskd** 1997 Apr 19;141(16):764–9 (37 ref.) (Eng. Abstr.) **(Dut)**

BLOOD

Serum 3 alpha-androstanediol-glucuronide is decreased in nonhirsute women with acne vulgaris. Joura EA, et al. **Fertil Steril** 1996 Dec;66(6):1033–5

Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. Timpatanapong P, et al. **J Dermatol** 1997 Apr;24(4):223–9

CHEMICALLY INDUCED

Gymnasium acne [letter] Collins P, et al. **Clin Exp Dermatol** 1995 Nov;20(6):509

The changes of stratum corneum interstices and calcium distribution of follicular epithelium of experimentally induced comedones (EIC) by oleic acid. Choi EH, et al. **Exp Dermatol** 1997 Feb;6(1):29–35

Acne-like eruption caused by amineptine [letter] Farella V, et al. **Int J Dermatol** 1996 Dec;35(12):892–3

Chloracne in the 1990s. Rosas Vazquez E, et al. **Int J Dermatol** 1996 Sep;35(9):643–5 (11 ref.)

CLASSIFICATION

Roaccutane treatment guidelines: results of an international

survey. Cunliffe WJ, et al. **Dermatology** 1997;194(4):351–7
A comparison of current acne grading systems and proposal of a novel system. Doshi A, et al. **Int J Dermatol** 1997 Jun;36(6):416–8
Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study [see comments] Lucky AW, et al. **J Pediatr** 1997 Jan;130(1):30–9 . Comment in: J Pediatr 1997 Jan;130(1):5.

COMPLICATIONS

Osseous manifestations of SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome. Reith JD, et al. **Am J Surg Pathol** 1996 Nov;20(11):1368–77
Acne conglobata and Klinefelter's syndrome. Wollenberg A, et al. **Br J Dermatol** 1997 Mar;136(3):421–3
Subcorneal pustular dermatosis (Sneddon–Wilkinson syndrome): another cutaneous manifestation of SAPHO syndrome? [letter] Scarpa R, et al. **Br J Rheumatol** 1997 May;36(5):602–3
Pyoderma gangrenosum associated with acne conglobata. Velez A, et al. **Clin Exp Dermatol** 1995 Nov;20(6):496–8
The course of the SAPHO syndrome during pregnancy. Pons JC, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec 27;70(2):215–6
SAPHO syndrome and pyoderma gangrenosum: is it fortuitous? Claudepierre P, et al. **J Rheumatol** 1996 Feb; 23(2):400–2
SAPHO syndrome and pulmonary disease [letter; comment] Ravelli A, et al. **J Rheumatol** 1996 Aug;23(8):1482–3. Comment on: J Rheumatol 1995 Nov;22(11):2190–1.
Ectrodactyly, soft-tissue syndactyly, and nodulocystic acne: coincidence or association? Krunic AL, et al. **Pediatr Dermatol** 1997 Jan–Feb;14(1):31–5

CONGENITAL

Congenital nasal comedones--report of three cases. Piqué E, et al. **Clin Exp Dermatol** 1996 May;21(3):220–1 (6 ref.)

DIAGNOSIS

Why the "SAPHO" syndrome? [letter; comment] Dihlmann W, et al. **J Rheumatol** 1996 Jul;23(7):1308–10. Comment on: J Rheumatol 1995 Nov;22(11):2017–9.
SAPHO syndrome and spondyloarthropathy [letter; comment] Goupille P, et al. **J Rheumatol** 1996 Sep; 23(9):1667–8. Comment on: J Rheumatol 1995 Nov;22(11):2135–41.
Metastatic Crohn's disease: a case report. Cummins RE, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):25–8
Trichostasis spinulosa: a clinical simulant of acne open comedones. Harford RR, et al. **Pediatr Dermatol** 1996 Nov–Dec;13(6):490–2
[SAPHO syndrome. Case description of 3 patients with acne conglobata and osteoarticular symptoms] Gutzmer R, et al. **Hautarzt** 1997 Mar;48(3):186–90 (Eng. Abstr.) **(Ger)**
[Multifocal periostitis in the SAPHO syndrome in Fortschr. Röntgenstr. 164 (1996) 514–516 (Case Reports) (letter; comment)] Schilling F.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997 Jan;166(1):90–1; discussion 92–3. Comment on: Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Jun;164(6):514–6. **(Ger)**
[The SAPHO syndrome and ulcerative colitis (letter)] Sanjuán Portugal F, et al. **An Med Interna** 1997 Apr; 14(4):210–1 (9 ref.) **(Spa)**

DRUG THERAPY

Minocycline induces an increase in the number of excreting pilosebaceous follicles in acne vulgaris. A randomised study. Bodokh I, et al. **Acta Derm Venereol** 1997 Jul; 77(4):255–9
Pseudotumor cerebri induced by minocycline treatment for acne vulgaris [letter] Lewis PA, et al.
Acta Derm Venereol 1997 Jan;77(1):83
Azelaic acid therapy for acne [published erratum appears in Am Fam Physician 1997 Apr;55(5):1586] Mackrides PS, et al. **Am Fam Physician** 1996 Dec;54(8):2457–9 (09 ref.)
Intracranial hypertension and minocycline [letter] Shiri J, et al. **Ann Intern Med** 1997 Jul 15;127(2):168
The comparative efficacy of benzoyl peroxide 5%/erythromycin 3% gel and erythromycin 4%/zinc 1.2% solution in the treatment of acne vulgaris. Chu A, et al. **Br J Dermatol** 1997 Feb;136(2):235–8
Treatment of acne with intermittent isotretinoin. Goulden V, et al. **Br J Dermatol** 1997 Jul;137(1):106–8
Juvenile nodulocystic acne responding to systemic isotretinoin [letter] Horne HL, et al. **Br J Dermatol** 1997 May;136(5):796–7 (7 ref.)
How to ensure fetal safety when mothers use isotretinoin (Accutane). Koren G, et al. **Can Fam Physician** 1997 Feb; 43:216–9 (4 ref.)
Effects of detergents on acne. Solomon BA, et al.
Clin Dermatol 1996 Jan–Feb;14(1):95–9 (8 ref.)
Acne conglobata: treatment with isotretinoin, colchicine, and cyclosporin as compared with surgical intervention [letter] Jeong S, et al. **Clin Exp Dermatol** 1996 Nov;21(6):462–3
Acne and allergic contact dermatitis. Balato N, et al.
Contact Dermatitis 1996 Jan;34(1):68–9
An extremely effective treatment for serious inflammatory acne: an uncontrolled, unblinded, unstatistical office study. Kligman AM. **Cutis** 1997 Mar;59(3):109–10
Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Shenefelt PD. **Cutis** 1996 May;57(5):315–9
Antiandrogen and hormonal treatment of acne. Shaw JC. **Dermatol Clin** 1996 Oct;14(4):803–11 (51 ref.)
The effect of glycolic acid on the treatment of acne in Asian skin. Wang CM, et al. **Dermatol Surg** 1997 Jan;23(1):23–9
Roaccutane treatment guidelines: results of an international survey. Cunliffe WJ, et al. **Dermatology** 1997;194(4):351–7
Acute arthritis during isotretinoin treatment for acne conglobata [letter] De Francesco V, et al. **Dermatology** 1997;194(2):195
Oral 9–cis–retinoic acid versus 13–cis–retinoic acid in acne therapy. Ott F, et al. **Dermatology** 1996;193(2):124–6
Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Brogden RN, et al. **Drugs** 1997 Mar;53(3):511–9 (29 ref.)
Azithromycin for the treatment of acne [letter] Fernandez–Obregon AC. **Int J Dermatol** 1997 Mar; 36(3):239–40
Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Charoenvisal C, et al. **Int J Fertil Menopausal Stud** 1996 Jul–Aug;41(4):423–9
Current management of acne [editorial] O'Loughlin S.
Ir Med J 1997 Apr–May;90(3):92–3
Split–face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. Caron D, et al.
J Am Acad Dermatol 1997 Jun;36(6 Pt 2):S110–2
Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. Clucas A, et al.
J Am Acad Dermatol 1997 Jun;36(6 Pt 2):S116–8
The treatment of acne with topical retinoids: one man's opinions. Kligman AM. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 2):S92–5
Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. Miller YW, et al. **J Antimicrob Chemother** 1996 Nov;38(5):829–37
An ultrastructural study of the retention hyperkeratosis of experimentally induced comedones in rabbits: the effects of three comedolytics. Oh CW, et al. **J Dermatol** 1996 Mar; 23(3):169–80
Comparative efficacy of four Ayurvedic formulations in the treatment of acne vulgaris: a double–blind randomised placebo–controlled clinical evaluation. Paranjpe P, et al. **J Ethnopharmacol** 1995 Dec 15;49(3):127–32
The effect of silicol gel compared with placebo on papulopustular acne and sebum production. A double–blind study. Lassus A. **J Int Med Res** 1996 Jul–Aug;24(4):340–4
Sensitivity of Propionibacterium acnes isolated from acne patients: comparative study of antimicrobial agents. Nishijima S, et al. **J Int Med Res** 1996 Nov–Dec; 24(6):473–7
Acne. Munro CS. **J R Coll Physicians Lond** 1997 Jul–Aug; 31(4):360–3 (23 ref.)
Benefit–risk assessment of acne therapies [letter; comment] Bénéton N, et al. **Lancet** 1997 Apr 26;349(9060):1252. Comment on: Lancet 1997 Feb 8;349(9049):374.
Safety of minocycline for acne [comment] [see comments] Gottlieb A. **Lancet** 1997 Feb 8;349(9049):374. Comment on: Lancet 1997 Feb 8;349(9049):400. Comment in: Lancet 1997 Apr 26;349(9060):1251–2. Comment in: Lancet 1997 Apr 26;349(9060):1252.
Benefit–risk assessment of acne therapies [letter; comment] Seukeran DC, et al. **Lancet** 1997 Apr 26;349(9060):1251–2 . Comment on: Lancet 1997 Feb 8;349(9049):374.
Adapalene for acne. **Med Lett Drugs Ther** 1997 Feb 28; 39(995):19–20
Therapy for acne vulgaris. Leyden JJ. **N Engl J Med** 1997 Apr 17;336(16):1156–62 (54 ref.)
Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo–controlled trial. Redmond GP, et al. **Obstet Gynecol** 1997 Apr;89(4):615–22
Acne fulminans treated with isotretinoin and "pulse" corticosteroids. Allison MA, et al. **Pediatr Dermatol** 1997 Jan–Feb;14(1):39–42
Thalidomide and isotretinoin--why treat them differently? [editorial] Robert E. **Reprod Toxicol** 1996 Jan–Feb; 10(1):1–2
[Pharma Clinics. Drug of the month. Benzamycin, an up–date on topical treatment of acne] Piérard GE.
Rev Med Liege 1997 Feb;52(2):120–2 (21 ref.) **(Fre)**
[Pharma–clinics. How I treat... facial acne] Piérard GE.
Rev Med Liege 1996 May;51(5):327–31 (22 ref.) **(Fre)**
[Gram–negative folliculitis. Complication of antibiotic therapy of acne vulgaris, 1: Disease picture and classification--special form: whirlpool dermatitis] Jansen T, et al. **Fortschr Med** 1997 Jan 30;115(3):37–8 **(Ger)**
[Gram negative folliculitis. A complication of antibiotic therapy of acne vulgaris. 2: Diagnosis and differential diagnosis--therapy] Jansen T, et al. **Fortschr Med** 1997 Feb 10;115(4):42–4 **(Ger)**
[Topical Isotretinoin in acne therapy. Acne therapy also a question of medical compliance] **Hautarzt** 1994 May;45(5 Suppl [topische]):1–4 **(Ger)**
[Alpha–hydroxy acid treatment in acne therapy] Fratila A. **Hautarzt** 1996 Dec;47(12):937–8 **(Ger)**
[Minocycline in Acne--an autoimmune disease–like syndrome as a side effect] Jagusch W, et al. **Hautarzt** 1996 Dec;47(12):936 **(Ger)**
[Chlormadinone acetate alone as therapy (letter)] Zaun H. **Hautarzt** 1996 Jan;47(1):66 **(Ger)**
[Can be treated with isotretinoin patients with acne and Gilbert's syndrome? (letter)] Suárez Crespo JF, et al.
Rev Esp Enferm Dig 1996 Aug;88(8):584–5 **(Spa)**

EPIDEMIOLOGY

Descriptive epidemiology of acne vulgaris in the community. Stathakis V, et al. **Australas J Dermatol** 1997 Aug; 38(3):115–23 (55 ref.)

ETIOLOGY

Post–adolescent acne: a review of clinical features. Goulden V, et al. **Br J Dermatol** 1997 Jan;136(1):66–70
Hormonal profile of acne vulgaris: new aspects of the androgen–dependent cutaneous syndrome: syndrome X. Vignale R, et al. **Int J Dermatol** 1996 Feb;35(2):94–5
Acne inversa (pyodermia fistulans sinifica) and smoking [letter; comment] Bassukas ID, et al.
J Am Acad Dermatol 1997 Jun;36(6 Pt 1):1029. Comment on: J Am Acad Dermatol 1996 May;34(5 Pt 1):717–32; quiz 733–4.
Acne. Munro CS. **J R Coll Physicians Lond** 1997 Jul–Aug; 31(4):360–3 (23 ref.)

GENETICS

A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Lindor NM, et al. **Mayo Clin Proc** 1997 Jul; 72(7):611–5

IMMUNOLOGY

IgG subclasses specific to Staphylococcus epidermidis and Propionibacterium acnes in patients with acne vulgaris. Ashbee HR, et al. **Br J Dermatol** 1997 May;136(5):730–3

METABOLISM

Increased degradation of type I collagen in acne fulminans. Oikarinen A, et al. **Acta Derm Venereol** 1996 Mar; 76(2):123–5
Percutaneous absorption of salicylic acid after repeated (14–day) in vivo administration to normal, acnegenic or aged human skin. Davis DA, et al. **J Pharm Sci** 1997 Aug; 86(8):896–9
[Sex steroid–binding globulin, free serum testosterone, and androgen receptors in the skin during papulo–pustulosa and conglobate forms of acne vulgaris] Kushlinskiĭ NE, et al. **Biull Eksp Biol Med** 1997 Feb;123(2):188–91 **(Rus)**

MICROBIOLOGY

Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associated with mutations in 23S rRNA. Ross JI, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1162–5
Sensitivity of Propionibacterium acnes isolated from acne patients: comparative study of antimicrobial agents. Nishijima S, et al. **J Int Med Res** 1996 Nov–Dec; 24(6):473–7
Propionibacterium acnes isolated from sternal osteitis in a patient with SAPHO syndrome. Kotilainen P, et al.
J Rheumatol 1996 Jul;23(7):1302–4
[Bacterial flora of acne lesions in diagnostic material of the Microbiology and Immunology Department, Pomeranian Medical Academy (PAM) in Szczecin] Zaluga E, et al.
Med Dosw Mikrobiol 1996;48(1–2):55–9 (Eng. Abstr.) **(Pol)**

PATHOLOGY

Chronic diffuse sclerosing osteomyelitis of the mandible or mandibular location of S.A.P.H.O. syndrome.
García–Marín F, et al. **Acta Stomatol Belg** 1996 Jun; 93(2):65–71 (31 ref.)
Hair cortex comedo. Toshitani A, et al.
Am J Dermatopathol 1996 Jun;18(3):322–5
Chronic acneiform eruption with crateriform scars. Acne necrotica (varioliformis) (necrotizing lymphocytic folliculitis). Zirn JR, et al. **Arch Dermatol** 1996 Nov; 132(11):1367, 1370
An intra–oral comedo? [letter] [see comments] Colquhoun A. **Br Dent J** 1996 Feb 24;180(4):128. Comment in: Br Dent J 1996 Aug 10;181(3):89.
Critical comments on "Propionibacterium acnes in the cortex of patients with Alzheimer's disease" by H.H.Kornhuber (Eur Arch Psychiatry Clin Neurosci, 1996, 246:108–109) [letter; comment] Bauer J, et al.
Eur Arch Psychiatry Clin Neurosci 1996;246(4):224–6. Comment on: Eur Arch Psychiatry Clin Neurosci 1996;246(2):108–9.
Spontaneous comedones on the skin of hairless descendants of Mexican hairless dogs. Kimura T, et al. **Exp Anim** 1996 Oct;45(4):377–84
A multirater validation study to assess the reliability of acne lesion counting [see comments] Lucky AW, et al.
J Am Acad Dermatol 1996 Oct;35(4):559–65. Comment in: J Am Acad Dermatol 1997 Jul;37(1):138.
Acne lesion counts and global assessments [letter; comment] Rand S. **J Am Acad Dermatol** 1997 Jul;37(1):138. Comment on: J Am Acad Dermatol 1996 Oct;35(4):559–65.

ACNE VULGARIS

PHYSIOPATHOLOGY

Sebum excretion in hidradenitis suppurativa. Jemec GB, et al. **Dermatology** 1997;194(4):325–8

Seasonal variations in the severity of acne vulgaris. Gfesser M, et al. **Int J Dermatol** 1996 Feb;35(2):116–7

PSYCHOLOGY

The Acne Disability Index: usefulness confirmed. Oakley AM. **Australas J Dermatol** 1996 Feb;37(1):37–9

Psychological factors affecting self-excoriative behavior in women with mild-to-moderate facial acne vulgaris. Gupta MA, et al. **Psychosomatics** 1996 Mar–Apr;37(2):127–30

Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Girman CJ, et al. **Qual Life Res** 1996 Oct; 5(5):481–90

Questionnaire techniques in assessing acne handicap: reliability and validity study. Salek MS, et al. **Qual Life Res** 1996 Feb;5(1):131–8

RADIOGRAPHY

Spondylodiscitis in SAPHO syndrome. A series of eight cases. Toussirot E, et al. **Ann Rheum Dis** 1997 Jan; 56(1):52–8

RADIONUCLIDE IMAGING

[Why SAPHO? Why adequate scintigraphy in this syndrome? Comments on M. Steinberg et al.: Multifocal periostitis in the SAPHO syndrome. Fortschr. Röntgenstr. 164 (1996) 514–516 (letter; comment)] Dihlmann W. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):87–9; discussion 92–3. Comment on: Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Jun;164(6):514–6. **(Ger)**

RADIOTHERAPY

Radiation therapy for acne and delayed neoplasia [letter] Marinella MA. **Am Fam Physician** 1996 Dec;54(8):2369–70

SURGERY

Effects of dermabrasion on acne scarring. A review and a study of 25 cases. Aronsson A, et al. **Acta Derm Venereol** 1997 Jan;77(1):39–42

A critical appraisal of high-energy pulsed carbon dioxide laser facial resurfacing for acne scars. Apfelberg DB. **Ann Plast Surg** 1997 Feb;38(2):95–100

Ultrapulse carbon dioxide laser with CPG scanner for full-face resurfacing for rhytids, photoaging, and acne scars. Apfelberg DB. **Plast Reconstr Surg** 1997 Jun; 99(7):1817–25

[Acne inversa] Eckert P. **Zentralbl Chir** 1996;121 Suppl:65–7 **(Ger)**

THERAPY

Phototherapy of acne vulgaris with visible light. Sigurdsson V, et al. **Dermatology** 1997;194(3):256–60

Advances and perspectives in acne therapy. Jansen T, et al. **Eur J Med Res** 1997 Aug 28;2(8):321–34 (203 ref.)

[Treatment of acne] Fyrand O. **Tidsskr Nor Laegeforen** 1997 Aug 30;117(20):2985–7 (Eng. Abstr.) **(Nor)**

[Susceptibility to antibiotics of Staphylococcus aureus strains isolated from pus specimens obtained from patients referred for autovaccine therapy] Ekiel A, et al. **Med Dosw Mikrobiol** 1995;47(3–4):127–32 (Eng. Abstr.) **(Pol)**

VETERINARY

A refractory case of schnauzer comedo syndrome. Hannigan MM. **Can Vet J** 1997 Apr;38(4):238–9

ACNU see **NIMUSTINE**

ACOCANTHERIN see **OUABAIN**

ACOMYS see **MURIDAE**

ACONITASE see **ACONITATE HYDRATASE**

ACONITATE HYDRATASE

ANTAGONISTS & INHIBITORS

Inactivation of aconitase in yeast exposed to oxidative stress. Murakami K, et al. **Biochem Mol Biol Int** 1997 Mar; 41(3):481–6

CHEMISTRY

An EPR investigation of the products of the reaction of cytosolic and mitochondrial aconitases with nitric oxide. Kennedy MC, et al. **J Biol Chem** 1997 Aug 15; 272(33):20340–7

Regulation of anaerobic citrate metabolism in Klebsiella pneumoniae. Bott M, et al. **Mol Microbiol** 1995 Nov; 18(3):533–46

The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex. Lauble H, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13699–703

GENETICS

Synergistic activation of the hydratase but not the ApoA1 gene by gemfibrozil and retinoids. Mukherjee R, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:734–5

ACO1 expression in Saccharomyces cerevisiae is regulated by the HAP complex. Haviernik P, et al. **Folia Microbiol (Praha)** 1996;41(1):96–8

The Saccharomyces cerevisiae RTG2 gene is a regulator of aconitase expression under catabolite repression conditions. Vélot C, et al. **Genetics** 1996 Nov;144(3):893–903

The Bradyrhizobium japonicum aconitase gene (acnA) is important for free-living growth but not for an effective root nodule symbiosis [published erratum appears in J Bacteriol 1997 Mar;179(5):1836] Thöny-Meyer L, et al. **J Bacteriol** 1996 Nov;178(21):6166–72

Identification of a conserved and functional iron-responsive element in the 5'-untranslated region of mammalian mitochondrial aconitase. Kim HY, et al. **J Biol Chem** 1996 Sep 27;271(39):24226–30

The second aconitase (AcnB) of Escherichia coli. Bradbury AJ, et al. **Microbiology** 1996 Feb;142 (Pt 2):389–400

Construction and properties of aconitase mutants of Escherichia coli. Gruer MJ, et al. **Microbiology** 1997 Jun; 143 (Pt 6):1837–46

Regulation of anaerobic citrate metabolism in Klebsiella pneumoniae. Bott M, et al. **Mol Microbiol** 1995 Nov; 18(3):533–46

The aconitase family: three structural variations on a common theme. Gruer MJ, et al. **Trends Biochem Sci** 1997 Jan; 22(1):3–6 (20 ref.)

METABOLISM

"Free" iron in neonatal plasma activates aconitase: evidence for biologically reactive iron. Gutteridge JM, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):806–9

Superoxide-driven aconitase FE-S center cycling. Gardner PR. **Biosci Rep** 1997 Feb;17(1):33–42 (65 ref.)

Aconitase activity in rat liver. Konstantinova SG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):125–30

ACO1 expression in Saccharomyces cerevisiae is regulated by the HAP complex. Haviernik P, et al. **Folia Microbiol (Praha)** 1996;41(1):96–8

Nitric oxide sensitivity of the aconitases. Gardner PR, et al. **J Biol Chem** 1997 Oct 3;272(40):25071–6

Differences in the regulation of iron regulatory protein-1 (IRP-1) by extra- and intracellular oxidative stress. Pantopoulos K, et al. **J Biol Chem** 1997 Apr 11; 272(15):9802–8

Dietary iron intake modulates the activity of iron regulatory proteins and the abundance of ferritin and mitochondrial aconitase in rat liver. Chen OS, et al. **J Nutr** 1997 Feb; 127(2):238–48

Interplay between NO and [Fe-S] clusters: relevance to biological systems. Drapier JC. **Methods** 1997 Mar; 11(3):319–29

Aconitases: a class of metalloproteins highly sensitive to nitric oxide synthesis. Drapier JC, et al. **Methods Enzymol** 1996; 269:26–36 (53 ref.)

Measuring nitric oxide and superoxide: rate constants for aconitase reactivity. Hausladen A, et al. **Methods Enzymol** 1996;269:37–41 (19 ref.)

The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex. Lauble H, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13699–703

Testosterone and prolactin stimulation of mitochondrial aconitase in pig prostate epithelial cells. Costello LC, et al. **Urology** 1996 Oct;48(4):654–9

ACONITIC ACID

METABOLISM

Fermentation of trans-aconitate via citrate, oxaloacetate, and pyruvate by Acidaminococcus fermentans. Härtel U, et al. **Arch Microbiol** 1996 Nov;166(5):342–9

PHARMACOKINETICS

Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. Swart PJ, et al. **J Drug Target** 1996;4(2):109–16

ACONITINE

ADVERSE EFFECTS

Toxicity following accidental ingestion of Aconitum containing Chinese remedy. Kolev ST, et al. **Hum Exp Toxicol** 1996 Oct;15(10):839–42

ANALOGS & DERIVATIVES

Frequency-dependent inhibition of neuronal activity by lappaconitine in normal and epileptic hippocampal slices. Ameri A, et al. **Br J Pharmacol** 1996 Jun;118(3):577–84

Inhibition of neuronal activity in rat hippocampal slices by Aconitum alkaloids. Ameri A, et al. **Brain Res** 1996 Oct 28;738(1):154–7

Antiarrhythmic effects of an aconitine-like compound, TJN-505, on canine arrhythmia models. Arita J, et al. **Eur J Pharmacol** 1996 Dec 30;318(2–3):333–40

Nicotine cue: lack of effect of the alpha 7 nicotinic receptor antagonist methyllycaconitine. Brioni JD, et al. **Eur J Pharmacol** 1996 Apr 22;301(1–3):1–5

Nudicauline and elatine as potent norditerpenoid ligands at rat neuronal alpha-bungarotoxin binding sites: importance of the 2-(methylsuccinimido)benzoyl moiety for neuronal nicotinic acetylcholine receptor binding. Hardick DJ, et al. **J Med Chem** 1996 Nov 22;39(24):4860–6

An HPLC assay for the norditerpenoid alkaloid methyllycaconitine, a potent nicotinic acetylcholine receptor antagonist. Coates PA, et al. **J Pharm Biomed Anal** 1995 Nov;13(12):1541–44

Preliminary synthetic studies of methyllycaconitine, a potent nicotinic acetylcholine receptor antagonist: rapid syntheses of AE-bicyclic analogues. Coates PA, et al. **J Pharm Pharmacol** 1996 Feb;48(2):210–3

Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine. Palma E, et al. **J Physiol (Lond)** 1996 Feb 15;491 (Pt 1):151–61

Inhibition of rat hippocampal excitability by the plant alkaloid 3-acetylaconitine mediated by interaction with voltage-dependent sodium channels. Ameri A. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):273–80

Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (NAChR) ligands in the rat tail-flick assay. Rao TS, et al. **Neuropharmacology** 1996 Apr; 35(4):393–405

Neuronal nicotinic receptor operates slow Ca2+ mobilization at mouse muscle endplate. Tsuneki H, et al. **Neurosci Lett** 1997 Apr 11;225(3):185–8

BLOOD

Method for the simultaneous determination of Aconitum alkaloids and their hydrolysis products by gas chromatography-mass spectrometry in human serum. Ito K, et al. **Planta Med** 1997 Feb;63(1):75–9

CHEMISTRY

Selective demethylation of some aconitine-type norditerpenoid alkaloids. Joshi BS, et al. **J Nat Prod** 1997 May;60(5):439–43

METABOLISM

Calcium-dependent, sustained enhancement of excitability during washout of aconitine in rat hippocampal slices. Ameri A, et al. **Exp Brain Res** 1997 May;114(3):518–24

PHARMACOLOGY

Aconitine, a main component of aconite, increases spontaneous acetylcholine release from the frontal cerebral cortex of freely moving rats. Kimura I, et al. **Biol Pharm Bull** 1996 Nov;19(11):1440–2

Potentiation by higenamine of the aconitine-induced positive chronotropic effect in isolated right atria of mice: the effects of cholera toxin, forskolin and pertussis toxin. Kimura I, et al. **Biol Pharm Bull** 1996 Aug;19(8):1032–7

Inhibition of neuronal activity in rat hippocampal slices by Aconitum alkaloids. Ameri A, et al. **Brain Res** 1996 Oct 28;738(1):154–7

Aconitine inhibits epileptiform activity in rat hippocampal slices. Ameri A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jun; 354(1):80–5

Age-dependent differences in sensitivity to aconitine of rat hippocampal slices. Ameri A. **Neurosci Lett** 1996 Sep 20; 216(1):13–6

POISONING

A case of aconitine poisoning with analysis of aconitine alkaloids by GC/SIM. Yoshioka N, et al. **Forensic Sci Int** 1996 Aug 15;81(2–3):117–23

ACOUSTIC EVOKED BRAIN STEM POTENTIALS see **EVOKED POTENTIALS, AUDITORY, BRAIN STEM**

ACOUSTIC IMPEDANCE TESTS

An experimental technique for determining middle ear impedance. Blayney AW, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):201–4

Impedance audiometry in newborns of abnormal deliveries. Pliszczyńska-Brennenstuhl M, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1995;50:55–8

Multifrequency tympanometry in chinchillas. Margolis RH, et al. **Audiology** 1995 Sep–Oct;34(5):232–47

The effects on transient evoked otoacoustic emissions following changes in external auditory canal acoustic impedance. Stephen RO, et al. **Audiology** 1996 Jul–Aug; 35(4):180–93

Tympanometry and otoacoustic emissions in a cohort of special care neonates [published erratum appears in Br J Audiol 1996 Apr;30(2):152] Sutton GJ, et al. **Br J Audiol** 1996 Feb;30(1):9–17

Middle ear function in rheumatoid arthritis: a multiple frequency tympanometric study. Biasi D, et al. **Clin Exp Rheumatol** 1996 May–Jun;14(3):243–7

Immittance findings in school-aged children. Haapaniemi JJ. **Ear Hear** 1996 Feb;17(1):19–27

Aging effects in multifrequency tympanometry. Holte L. **Ear Hear** 1996 Feb;17(1):12–8

Maturation of the middle and external ears: acoustic power–based responses and reflectance tympanometry. Keefe DH, et al. **Ear Hear** 1996 Oct;17(5):361–73

The use of acoustic reflectometry in the study of middle ear effusion in children suffering from acute otits media, upper respiratory tract infection and in healthy children. Bollag U, et al. **Eur J Pediatr** 1996 Dec;155(12):1027–30

Acoustic input impedance of the stapes and cochlea in human temporal bones. Merchant SN, et al. **Hear Res** 1996 Aug; 97(1–2):30–45

Multifrequency tympanometry: effects of ear canal volume compensation on middle ear resonance. Hanks WD, et al. **J Am Acad Audiol** 1997 Feb;8(1):53–8

Multifrequency tympanometry and evoked otoacoustic emissions in neonates during the first 24 hours of life. McKinley AM, et al. **J Am Acad Audiol** 1997 Jun; 8(3):218–23

Tympanometric measures in older adults. Wiley TL, et al. **J Am Acad Audiol** 1996 Aug;7(4):260–8

Precision of tympanometric measurements. Gaihede M, et al. **J Speech Lang Hear Res** 1997 Feb;40(1):215–22

[Multifrequency impedance audiometry and study of occupational deafness: "Teflag", a new test] Camicas Vangout M, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996; 117(5):399–407 (Eng. Abstr.) **(Fre)**

[Positional impedance tests with acetazolamide: a clinical test for evaluating endolymphatic hydrops] Abramo A, et al. **Acta Otorhinolaryngol Ital** 1996 Oct;16(5):401–6 (Eng. Abstr.) **(Ita)**

[Impedance audiometry] Taiji H. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:469–72 (3 ref.) **(Jpn)**

[Impedance measurements of the middle ear volume with tympanic membrane perforation] Namysłowski G, et al. **Otolaryngol Pol** 1996;50(6):618–21 (Eng. Abstr.) **(Pol)**

[226 Hz and high frequency tympanometry in children with cleft lip and/or palate] Namysłowski G, et al. **Otolaryngol Pol** 1996;50(1):73–80 (Eng. Abstr.) **(Pol)**

INSTRUMENTATION

[A registration system for evaluating acusto–mechanical transmission of middle ear implants] Meister H, et al. **HNO** 1997 Feb;45(2):81–5 (Eng. Abstr.) **(Ger)**

METHODS

Tympanometric preconditioning of the tympanic membrane. Gaihede M. **Hear Res** 1996 Dec 1;102(1–2):28–34

Multiple–frequency tympanometry in children with otitis media with effusion. Kontrogianni A, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Mar–Apr; 58(2):78–81

Acoustic reflectometry: spectral analysis and the conductive hearing loss of otitis media. Combs JT, et al. **Pediatr Infect Dis J** 1996 Aug;15(8):683–6

[Multifrequency tympanometry in Meniere's disease: preliminary results] Bianchedi M, et al. **Acta Otorhinolaryngol Ital** 1996 Feb;16(1):1–5 (Eng. Abstr.) **(Ita)**

STANDARDS

Interexaminer reliability of otoscopic signs and tympanometric measures for older adults. Nondahl DM, et al. **J Am Acad Audiol** 1996 Aug;7(4):251–9

ACOUSTIC MACULAE

PATHOLOGY

Ultrastructural findings of the macula utriculi in a case of a petrous apex cholesteatoma: a comparison with findings in a patient with an acoustic neuroma. Adachi M, et al. **Eur Arch Otorhinolaryngol** 1997;254(5):255–8

ULTRASTRUCTURE

Morphological evidence for local microcircuits in rat vestibular maculae. Ross MD. **J Comp Neurol** 1997 Mar 17;379(3):333–46

ACOUSTIC NERVE

Choristomas of the seventh and eighth cranial nerves. Smith MM, et al. **AJNR Am J Neuroradiol** 1997 Feb;18(2):327–9

Primary peripheral T–cell lymphoma of the acoustic nerve. Taskin M, et al. **Otolaryngol Head Neck Surg** 1997 Jun; 116(6 Pt 1):674–7

[Clinical study in vertiginuous patients suspected of having neurovascular compression syndrome of the eighth cranial nerve] Noguchi Y, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1997 May;100(5):492–8 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Hearing preservation and tinnitus following removal of acoustic neurinomas] Kurokawa Y, et al. **No Shinkei Geka** 1996 Apr;24(4):329–34 (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Aplasia and hypoplasia of the vestibulocochlear nerve: diagnosis with MR imaging. Casselman JW, et al. **Radiology** 1997 Mar;202(3):773–81

ANATOMY & HISTOLOGY

Anatomy of the facial and vestibulocochlear nerves in the internal auditory canal. Rubinstein D, et al. **AJNR Am J Neuroradiol** 1996 Jun–Jul;17(6):1099–105

Distinct but overlapping populations of commissural and GABAergic neurons in the dorsal nucleus of the little skate, Raja erinacea. Duman CH, et al. **Brain Behav Evol** 1997; 49(2):99–109

On the role played by ontogenetic remodeling and functional transformation in the evolution of terrestrial hearing. Fritzsch B. **Brain Behav Evol** 1997 Jul;50(1):38–49 (75 ref.)

MR imaging of acoustic neuroma with high resolution fast spin echo T2–weighted sequence. Soulié D, et al. **Eur J Radiol** 1997 Jan;24(1):61–5

Intracellular labeling of auditory nerve fibers in guinea pig: central and peripheral projections. Tsuji J, et al. **J Comp Neurol** 1997 May 5;381(2):188–202

BLOOD SUPPLY

The vasculature of the peripheral portion of the human eighth cranial nerve. Matsunaga T, et al. **Hear Res** 1996 Nov 1; 101(1–2):119–31

P–glycoprotein expression in capillary endothelial cells of the 7th and 8th nerves of guinea pig in relation to blood–nerve barrier sites. Saito T, et al. **Neurosci Lett** 1997 Aug 22;232(1):41–4

CYTOLOGY

Voltage–gated ionic currents and their roles in timing coding in auditory neurons of the nucleus magnocellularis of the chick. Koyano K, et al. **Neurosci Res** 1996 Sep;26(1):29–45

DRUG EFFECTS

Neurotrophic factors as pharmacological agents for the treatment of injured auditory neurons. Van De Water TR, et al. **Ciba Found Symp** 1996;196:149–62; discussion 162–6 (38 ref.)

Effect of methimazole, an FMO substrate and competitive inhibitor, on the neurotoxicity of 3,3'-iminodipropionitrile in male rats. Nace CG, et al. **Fundam Appl Toxicol** 1997 Jun;37(2):131–40

Influence of urethane anesthesia on neural processing in the auditory cortex analogue of a songbird. Capsius B, et al. **Hear Res** 1996 Jul;96(1–2):59–70

Electrophysiological and morphological evaluation of the acute ototoxicity of sodium nitroprusside. Kong WJ, et al. **Hear Res** 1996 Sep 15;99(1–2):22–30

Effects of salicylate on neural activity in cat primary auditory cortex. Ochi K, et al. **Hear Res** 1996 May;95(1–2):63–76

Recovery of structure and function of inner ear afferent synapses following kainic acid excitotoxicity. Zheng XY, et al. **Hear Res** 1997 Mar;105(1–2):65–76

Neurotoxicity testing of a new bioactive bone cement. Murai N, et al. **Neurol Med Chir (Tokyo)** 1997 Feb;37(2):201–4

METABOLISM

The cochlear place–frequency map of the adult and developing Mongolian gerbil. Müller M. **Hear Res** 1996 May;94(1–2):148–56

PATHOLOGY

Nerve growth factor receptor expression in heterotransplanted vestibular schwannoma in athymic nude mice. Charabi S, et al. **Acta Otolaryngol (Stockh)** 1996 Jan; 116(1):59–63

Angiogenesis from the eighth cranial nerve to vestibular schwannomas. Matsunaga T, et al. **Acta Otolaryngol (Stockh)** 1996 Jan;116(1):52–8

Otoacoustic emissions recorded at high rates in patients with confirmed acoustic neuromas. Norman M, et al. **Am J Otol** 1996 Sep;17(5):763–72

A severe combined immunodeficient mouse model for the in vivo study of acoustic schwannoma. Kumazawa H, et al. **Am J Otolaryngol** 1996 Jul–Aug;17(4):228–32

Kangaroo rats exhibit spongiform degeneration of the central auditory system similar to that found in gerbils. McGinn MD, et al. **Hear Res** 1997 Feb;104(1–2):90–100

Patterns of degeneration in the human cochlear nerve. Zimmermann CE, et al. **Hear Res** 1995 Oct;90(1–2):192–201

MRI and brainstem auditory evoked potential evidence of eighth cranial nerve involvement in multiple sclerosis. Bergamaschi R, et al. **Neurology** 1997 Jan;48(1):270–2

Perineural spread of facial squamous cell carcinoma to the vestibulocochlear nerve. Murofushi T, et al. **Otolaryngol Head Neck Surg** 1997 Mar;116(3):392–4

Hemorrhage and abnormal veins in acoustic neurinoma: MR findings. Ishii K, et al. **Radiat Med** 1996 Mar–Apr; 14(2):65–9

The eighth cranial nerve. Enterline DS. **Top Magn Reson Imaging** 1996 Jun;8(3):164–79 (83 ref.)

[Incidence of normal hearing in acoustic neuroma] De Donato G, et al. **Acta Otorhinolaryngol Ital** 1995 Apr; 15(2):73–9 (Eng. Abstr.) **(Ita)**

[Deafness from leptomeningeal metastasis] Hernández–Ramos FJ, et al. **Neurologia** 1996 Nov;11(9):344 **(Spa)**

[Electric stimulation of the brain stem. Treatment of deaf persons with destroyed auditory nerve] Rask–Anderson H, et al. **Lakartidningen** 1996 Oct 2;93(40):3461–4 **(Swe)**

PHYSIOLOGY

Proposal of a new auditory nerve stimulation method for cochlear prosthesis. Miyoshi S, et al. **Artif Organs** 1996 Aug;20(8):941–6

Simulation of the electrically stimulated auditory nerve. Rattay F. **Artif Organs** 1997 Mar;21(3):213–5

Computer simulation of shared input among projection neurons in the dorsal cochlear nucleus. Davis KA, et al. **Biol Cybern** 1996 May;74(5):413–25

Modeling inhibition of type II units in the dorsal cochlear nucleus. Hancock KE, et al. **Biol Cybern** 1997 Jun; 76(6):419–28

Modeling stochastic spike train responses of neurons: an extended Wiener series analysis of pigeon auditory nerve fibers. Joeken S, et al. **Biol Cybern** 1997 Feb;76(2):153–62

Electrical stimulation of the auditory nerve: the coding of frequency, the perception of pitch and the development of cochlear implant speech processing strategies for profoundly deaf people. Clark GM. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):766–76 (78 ref.)

The auditory system in humans [see comments] Doyle JH. **Ear Nose Throat J** 1997 Mar;76(3):136–9. Comment in: Ear Nose Throat J 1997 Mar;76(3):122.

Different effects of noise and salicylate and their interactions on the guinea pig cochlea. Aoyagi M, et al. **Eur Arch Otorhinolaryngol** 1996;253(7):429–34

Age–related changes in the compound action potentials of the eighth nerve in guinea pigs. Nozawa I, et al. **Eur Arch Otorhinolaryngol** 1997;254(3):145–9

Pressor response elicited by nose–up vestibular stimulation in cats. Woodring SF, et al. **Exp Brain Res** 1997 Jan; 113(1):165–8

On lateral inhibition in the auditory system. Kral A, et al. **Gen Physiol Biophys** 1996 Apr;15(2):109–27

Suppression in auditory–nerve fibers of cats using low–side suppressors. II. Effect of spontaneous rates. Cai Y, et al. **Hear Res** 1996 Jul;96(1–2):113–25

Suppression in auditory–nerve fibers of cats using low–side suppressors. III. Model results. Cai Y, et al. **Hear Res** 1996 Jul;96(1–2):126–40

Long–term suppression of the responses of auditory nerve fibers to a characteristic–frequency tone by a low–frequency suppressor. Cai Y, et al. **Hear Res** 1996 Jul; 96(1–2):141–50

Temporal patterns of the responses of auditory–nerve fibers to low–frequency tones. Cai Y, et al. **Hear Res** 1996 Jul; 96(1–2):83–93

Suppression in auditory–nerve fibers of cats using low–side suppressors. I. Temporal aspects. Cai Y, et al. **Hear Res** 1996 Jul;96(1–2):94–112

Average spectrum of cochlear activity: a possible synchronized firing, its olivo–cochlear feedback and alterations under anesthesia. Cazals Y, et al. **Hear Res** 1996 Nov 1;101(1–2):81–92

Changes in CM and CAP with sedation and temperature in the guinea pig: facts and interpretation. Charlet de Sauvage R, et al. **Hear Res** 1996 Dec 1;102(1–2):15–27

Comparing octaves, frequency ranges, and cochlear–map curvature across species. Greenwood DD. **Hear Res** 1996 May;94(1–2):157–62 (13 ref.)

Auditory nerve neurophonic recorded from the round window of the Mongolian gerbil. Henry KR. **Hear Res** 1995 Oct;90(1–2):176–84

Auditory nerve neurophonic produced by the frequency difference of two simultaneously presented tones. Henry KR. **Hear Res** 1996 Sep 15;99(1–2):151–9

Tuning curves of the difference tone auditory nerve neurophonic. Henry KR. **Hear Res** 1996 Sep 15; 99(1–2):160–7

Auditory nerve neurophonic tuning curves produced by masking of round window responses. Henry KR. **Hear Res** 1997 Feb;104(1–2):167–76

Quantifying 2–factor phase relations in non–linear responses from low characteristic–frequency auditory–nerve fibers. Lin T, et al. **Hear Res** 1995 Oct;90(1–2):126–38 (37 ref.)

Acoustic and electric forward–masking of the auditory nerve compound action potential: evidence for linearity of electro–mechanical transduction. McAnally KI, et al. **Hear Res** 1997 Apr;106(1–2):137–45

Effects of chronic high–rate electrical stimulation on the cochlea and eighth nerve in the deafened guinea pig. Mitchell A, et al. **Hear Res** 1997 Mar;105(1–2):30–43

Development of activity patterns in auditory nerve fibres of pigeons. Richter CP, et al. **Hear Res** 1996 May; 95(1–2):77–86

Representation of acoustic signals in the eighth nerve of the Tokay gecko. II. Masking of pure tones with noise. Sams–Dodd F, et al. **Hear Res** 1996 Oct;100(1–2):131–42

Electrical stimulation of the auditory nerve. I. Correlation of physiological responses with cochlear status. Shepherd RK, et al. **Hear Res** 1997 Jun;108(1–2):112–44

Effects of selective inner hair cell loss on auditory nerve fiber threshold, tuning and spontaneous and driven discharge rate. Wang J, et al. **Hear Res** 1997 May; 107(1–2):67–82

Chronic electrical stimulation of the auditory nerve at high stimulus rates: a physiological and histopathological study. Xu J, et al. **Hear Res** 1997 Mar;105(1–2):1–29

Temporal encoding and transmitting of amplitude and frequency modulations in dorsal cochlear nucleus. Zhao HB, et al. **Hear Res** 1997 Apr;106(1–2):83–94

Excitation produced by Schroeder–phase complexes:

evidence for fast-acting compression in the auditory system. Carlyon RP, et al. **J Acoust Soc Am** 1997 Jun; 101(6):3636–47

Masking period patterns of Schroeder-phase complexes: effects of level, number of components, and phase of flanking components. Carlyon RP, et al. **J Acoust Soc Am** 1997 Jun;101(6):3648–57

Neural contributions to the perstimulus compound action potential: implications for measuring the growth of the auditory nerve spike count as a function of stimulus intensity. Doucet JR, et al. **J Acoust Soc Am** 1997 May; 101(5 Pt 1):2720–34

Medial efferent inhibition produces the largest equivalent attenuations at moderate to high sound levels in cat auditory-nerve fibers. Guinan JJ Jr, et al. **J Acoust Soc Am** 1996 Sep;100(3):1680–90

Measures of tuning and suppression in single-fiber and whole-nerve responses in young and quiet-aged gerbils. Hellstrom LI, et al. **J Acoust Soc Am** 1996 Nov; 100(5):3275–85

Fractal noise strength in auditory-nerve fiber recordings. Kelly OE, et al. **J Acoust Soc Am** 1996 Apr;99(4 Pt 1):2210–20

Activity of primary auditory neurons in the cochlear ganglion of the emu Dromaius novaehollandiae: spontaneous discharge, frequency tuning, and phase locking. Manley GA, et al. **J Acoust Soc Am** 1997 Mar; 101(3):1560–73

Spectral cues for sound localization in cats: a model for discharge rate representations in the auditory nerve. May BJ, et al. **J Acoust Soc Am** 1997 May;101(5 Pt 1):2705–19

Is loudness simply proportional to the auditory nerve spike count? Relkin EM, et al. **J Acoust Soc Am** 1997 May;101(5 Pt 1):2735–40

Auditory-nerve fiber responses to clicks in guinea pigs with a damaged cochlea. Versnel H, et al. **J Acoust Soc Am** 1997 Feb;101(2):993–1009

Directional masking of phase locking in the amphibian auditory nerve. Wang J, et al. **J Acoust Soc Am** 1996 Mar; 99(3):1611–20

Activity-related features of synapse morphology: a study of endbulbs of held. Ryugo DK, et al. **J Comp Neurol** 1996 Jan 29;365(1):141–58

Sound and vibration sensitivity of VIIIth nerve fibers in the grassfrog, Rana temporaria. Christensen-Dalsgaard J, et al. **J Comp Physiol [A]** 1996 Oct;179(4):437–45

Temporally patterned pulse trains affect directional sensitivity of inferior collicular neurons of the big brown bat, Eptesicus fuscus. Wu MI, et al. **J Comp Physiol [A]** 1996 Sep;179(3):385–93

A model of selective processing of auditory-nerve inputs by stellate cells of the antero-ventral cochlear nucleus. Lai YC, et al. **J Comput Neurosci** 1994 Aug;1(3):167–94 (43 ref.)

Differential distribution of potassium channels in acutely demyelinated, primary-auditory neurons in vitro. Davis RL. **J Neurophysiol** 1996 Jul;76(1):438–47

Frequency tuning and spontaneous activity in the auditory nerve and cochlear nucleus magnocellularis of the barn owl Tyto alba. Köppl C. **J Neurophysiol** 1997 Jan; 77(1):364–77

Responses of auditory nerve fibers of the unanesthetized decerebrate cat to click pairs as simulated echoes. Parham K, et al. **J Neurophysiol** 1996 Jul;76(1):17–29

Age-related loss of activity of auditory-nerve fibers. Schmiedt RA, et al. **J Neurophysiol** 1996 Oct; 76(4):2799–803

Eighth nerve activity regulates intracellular calcium concentration of avian cochlear nucleus neurons via a metabotropic glutamate receptor. Zirpel L, et al. **J Neurophysiol** 1996 Dec;76(6):4127–39

Phase locking to high frequencies in the auditory nerve and cochlear nucleus magnocellularis of the barn owl, Tyto alba. Köppl C. **J Neurosci** 1997 May 1;17(9):3312–21

Multi-unit recording from regenerated bullfrog eighth nerve using implantable silicon-substrate microelectrodes. Della Santina CC, et al. **J Neurosci Methods** 1997 Mar; 72(1):71–86

Implantation of the lateral cochlear wall for auditory nerve stimulation. Yueh B, et al. **Laryngoscope** 1997 Aug; 107(8):1037–42

NT-3 has a tropic effect on process outgrowth by postnatal auditory neurones in vitro. Malgrange B, et al. **Neuroreport** 1996 Nov 4;7(15-17):2495–9

Contribution of the eighth nerve and cranial nerve nuclei to the short-latency vestibular evoked potentials in cats. Li G, et al. **Otolaryngol Head Neck Surg** 1997 Feb; 116(2):181–8

A nonrandom dynamic component in the synaptic noise of a central neuron. Faure P, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6506–11

PHYSIOPATHOLOGY

Synaptic repair mechanisms responsible for functional recovery in various cochlear pathologies. Puel JL, et al. **Acta Otolaryngol (Stockh)** 1997 Mar;117(2):214–8

Vascular loops of the internal auditory canal: a diagnostic dilemma. Herzog JA, et al. **Am J Otol** 1997 Jan;18(1):26–31

MR imaged neurovascular relationships at the cerebellopontine angle. De Carpentier J, et al. **Clin Otolaryngol** 1996 Aug;21(4):312–6

Discharge properties of pigeon single auditory nerve fibers after recovery from severe acoustic trauma. Müller M, et al. **Int J Dev Neurosci** 1997 Jul;15(4–5):401–16

Study of brain stem auditory-evoked potentials (BAEPs) and visual-evoked potentials (VEPs) in leprosy. Kochar DK, et al. **Int J Lepr Other Mycobact Dis** 1997 Jun;65(2):157–65

Effects of acoustic trauma on the representation of the vowel /epsilon/ in cat auditory nerve fibers. Miller RL, et al. **J Acoust Soc Am** 1997 Jun;101(6):3602–16

MRI and brainstem auditory evoked potential evidence of eighth cranial nerve involvement in multiple sclerosis. Bergamaschi R, et al. **Neurology** 1997 Jan;48(1):270–2

Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Samii M, et al. **Neurosurgery** 1997 Apr;40(4):696–705; discussion 705–6

Auditory nerve disease of both ears revealed by auditory brainstem responses, electrocochleography and otoacoustic emissions. Kaga K, et al. **Scand Audiol** 1996;25(4):233–8

RADIATION EFFECTS

Dose and diameter relationships for facial, trigeminal, and acoustic neuropathies following acoustic neuroma radiosurgery. Flickinger JC, et al. **Radiother Oncol** 1996 Dec;41(3):215–9

SURGERY

Racial considerations in acoustic neuroma removal with hearing preservation via the retrosigmoid approach. Low WK, et al. **Acta Otolaryngol (Stockh)** 1995 Nov; 115(6):783–6

Elimination of tinnitus following hearing preservation surgery for acoustic neuromas. Catalano PJ, et al. **Am J Otol** 1996 May;17(3):443–5

Prevention of headache after retrosigmoid removal of acoustic tumors. Catalano PJ, et al. **Am J Otol** 1996 Nov; 17(6):904–8

Delayed facial palsy after acoustic neuroma resection: the role of viral reactivation. Gianoli GJ, et al. **Am J Otol** 1996 Jul;17(4):625–9

Delayed facial paralysis after acoustic neuroma surgery: factors influencing recovery. Megerian CA, et al. **Am J Otol** 1996 Jul;17(4):630–3

Monitoring auditory function during operations to remove acoustic tumors. Møller AR. **Am J Otol** 1996 May; 17(3):452–60

Direct cochlear nerve action potentials as an aid to hearing preservation in middle fossa acoustic neuroma resection. Roberson J, et al. **Am J Otol** 1996 Jul;17(4):653–7

Pain subsequent to resection of acoustic neuromas via suboccipital and translabyrinthine approaches. Ruckenstein MJ, et al. **Am J Otol** 1996 Jul;17(4):620–4

Results and complications from acoustic neuroma excision via middle cranial fossa approach. Weber PC, et al. **Am J Otol** 1996 Jul;17(4):669–75

Bilateral acoustic neuromas. Anand VT, et al. **Clin Otolaryngol** 1993 Oct;18(5):365–71 (12 ref.)

Suboccipital surgery for acoustic neuroma. Vanleeuwen JP, et al. **Clin Otolaryngol** 1996 Jun;21(3):244–51

Hypoglossal-facial nerve anastomosis after acoustic neuroma resection: influence of the time anastomosis on recovery of facial movement. Kunihiro T, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Jan-Feb; 58(1):32–5

[Report on 2nd International Conference of Neurosurgery of Acoustic Nerve and 2nd Congress of the Society of Skull Surgery] Pietruski J. **Otolaryngol Pol** 1996; 50(1):106–11 **(Pol)**

[Our experience in neuroma surgery] Ruiz-Fornells A, et al. **Acta Otorrinolaringol Esp** 1996 May-Jun;47(3):205–7 (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

Activity-related features of synapse morphology: a study of endbulbs of held. Ryugo DK, et al. **J Comp Neurol** 1996 Jan 29;365(1):141–58

VIROLOGY

Delayed facial palsy after acoustic neuroma resection: the role of viral reactivation. Gianoli GJ, et al. **Am J Otol** 1996 Jul;17(4):625–9

ACOUSTIC NERVE DISEASES

DIAGNOSIS

Auditory and vestibular system findings in patients with vertebrobasilar dolichoectasia. Passero S, et al. **Acta Neurol Scand** 1996 Jan;93(1):50–55

Application of parasagittal surface coil MRI to otoneurological diagnosis. Naito Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;528:85–90

MRI evidence of labyrinthine and eighth-nerve bundle involvement in mumps virus sudden deafness and vertigo. Comacchio F, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov-Dec; 58(6):295–7 (18 ref.)

The eighth cranial nerve. Enterline DS. **Top Magn Reson Imaging** 1996 Jun;8(3):164–79 (83 ref.)

ETIOLOGY

Dose and diameter relationships for facial, trigeminal, and acoustic neuropathies following acoustic neuroma radiosurgery. Flickinger JC, et al. **Radiother Oncol** 1996 Dec;41(3):215–9

PATHOLOGY

Epithelioid Schwannoma of the acoustic nerve. Benhaiem-Sigaux N, et al. **Clin Neuropathol** 1996 Jul-Aug; 15(4):231–3

[Morphological and clinical study of acoustic tumor with respect to enlargement of internal auditory canal: mechanism of bone destruction] Takada Y, et al. **No Shinkei Geka** 1996 Aug;24(8):739–42 (Eng. Abstr.) **(Jpn)**

VIROLOGY

Ramsay Hunt syndrome presenting as a cranial polyneuropathy. Asnis DS, et al. **Cutis** 1996 Jun;57(6):421–4

ACOUSTIC NEUROMA see **NEUROMA, ACOUSTIC**

ACOUSTIC STIMULATION

see related
EVOKED POTENTIALS, AUDITORY

Acute mechanical overstimulation of isolated outer hair cells causes changes in intracellular calcium levels without shape changes. Fridberger A, et al. **Acta Otolaryngol (Stockh)** 1996 Jan;116(1):17–24

Distortion product otoacoustic emission test of sensorineural hearing loss: performance regarding sensitivity, specificity and receiver operating characteristics. Kim DO, et al. **Acta Otolaryngol (Stockh)** 1996 Jan;116(1):3–11

Transient evoked otoacoustic emission with unexpectedly short latency. Kruglov AV, et al. **Acta Otolaryngol (Stockh)** 1997 Mar;117(2):174–8

Ipsilateral suppression of transient evoked otoacoustic emission: role of the medial olivocochlear system. Tavartkiladze GA, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):213–8

Otoacoustic emission amplification after inner hair cell damage. Wake M, et al. **Acta Otolaryngol (Stockh)** 1996 May;116(3):374–81

Otoacoustic emissions. Probst R, et al. **Adv Otorhinolaryngol** 1997;53:182–204 (55 ref.)

Functional MR of the primary auditory cortex: an analysis of pure tone activation and tone discrimination [see comments] Strainer JC, et al. **AJNR Am J Neuroradiol** 1997 Apr;18(4):601–10. Comment in: AJNR Am J Neuroradiol 1997 Apr;18(4):621–3.

Electrocortical and heart rate response during vibroacoustic stimulation in fetal sheep. Bauer R, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):66–71

Effect of leukotriene inhibitor on otoacoustic emissions in salicylate ototoxicity. Arruda J, et al. **Am J Otol** 1996 Sep; 17(5):787–92

Sound-evoked activity in primary afferent neurons of a mammalian vestibular system. McCue MP, et al. **Am J Otol** 1997 May;18(3):355–60

Normal evoked otoacoustic emissions with a profound hearing loss due to a juvenile pilocytic astrocytoma. Monroe JA, et al. **Am J Otol** 1996 Jul;17(4):639–42

Otoacoustic emissions recorded at high rates in patients with confirmed acoustic neuromas. Norman M, et al. **Am J Otol** 1996 Sep;17(5):763–72

Direct cochlear nerve action potentials as an aid to hearing preservation in middle fossa acoustic neuroma resection. Roberson J, et al. **Am J Otol** 1996 Jul;17(4):653–7

The effect of vibroacoustic stimulation on fetal heart rate parameters utilizing computer analysis. Barton JR, et al. **Am J Perinatol** 1997 Apr;14(4):229–32

Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Pietrini P, et al. **Am J Psychiatry** 1997 Aug;154(8):1063–9

Electrophysiologic changes in preterm neonates: auditory brain stem response and distortion product otoacoustic emissions. Quiñónez RE, et al. **Ann Otol Rhinol Laryngol** 1997 Sep;106(9):721–8

Otoacoustic emissions in preterm infants: indications for cochlear development? Brienesse P, et al. **Audiology** 1996 Nov-Dec;35(6):296–306

Identification of hearing loss using TEOAE descriptors: theoretical foundations and preliminary results. Hatzopoulos S, et al. **Audiology** 1995 Sep-Oct;34(5):248–59

Transient evoked otoacoustic emissions in infants: effects of gender, ear asymmetry and activity status. Kei J, et al. **Audiology** 1997 Mar-Apr;36(2):61–71

'Derived nonlinear' versus 'linear' click-evoked otoacoustic emissions. Ravazzani P, et al. **Audiology** 1996 Mar-Apr; 35(2):73–86

Click-rate induced facilitation of the acoustic reflex using constant number of pulses. Rawool VW. **Audiology** 1996 Jul-Aug;35(4):171–9

The effects on transient evoked otoacoustic emissions following changes in external auditory canal acoustic impedance. Stephen RO, et al. **Audiology** 1996 Jul-Aug; 35(4):180–93

Distortion product otoacoustic emissions: a normative study. Vinck BM, et al. **Audiology** 1996 Sep-Oct;35(5):231–45

2f1–f2 distortion product otoacoustic emission latency: changes with frequency and level of primaries. Wable J, et al. **Audiology** 1997 Mar–Apr;36(2):72–82

Effect of middle ear on otoacoustic emissions. Wada H, et al. **Audiology** 1995 Jul–Aug;34(4):161–76

Influence of acquisition parameters on the measurement of click evoked otoacoustic emissions in neonates in a hospital environment. Welch D, et al. **Audiology** 1996 May–Jun; 35(3):143–57

Monitoring of cisplatin ototoxicity by distortion–product otoacoustic emissions. Ozturan O, et al. **Auris Nasus Larynx** 1996;23:147–51

The inferior collicular potential in acoustic and electrical stimulation of the cochlea: an experimental study of guinea pig. Saito H, et al. **Auris Nasus Larynx** 1996;23:83–90

Neural networks simulating the frequency discrimination of hearing for non–stationary short tone stimuli. Kral A, et al. **Biol Cybern** 1996 Apr;74(4):365–6

Vibroacoustic stimulation with a complex signal: effect on behavioral state in fetal sheep. Abrams RM, et al. **Biol Neonate** 1996;70(3):155–64

Physiologic responses to loud tones in Israeli veterans of the 1973 Yom Kippur War. Orr SP, et al. **Biol Psychiatry** 1997 Feb 1;41(3):319–26

P300 from a single–stimulus paradigm: auditory intensity and tone frequency effects. Cass M, et al. **Biol Psychol** 1997 Jun 20;46(1):51–65

The effect of acoustic pulse intensity upon the electrically elicited blink reflex at positive and negative stimulus onset asynchronies. Schmolesky MT, et al. **Biol Psychol** 1996 Oct 31;44(2):69–84

Transient evoked otoacoustic emissions in occupational medicine as an auditory screening test for employment. Lucertini M, et al. **Br J Audiol** 1996 Apr;30(2):79–88

Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. Mulheran M, et al. **Br J Audiol** 1997 Feb; 31(1):5–9

Otoacoustic emission versus ABR screening: the effect of external and middle ear abnormalities in a group of SCBU neonates. El–Refaie A, et al. **Br J Audiol** 1996 Feb;30(1):3–8

Feasibility of acoustic distortion product testing in newborns. Sheppard SL, et al. **Br J Audiol** 1996 Aug;30(4):261–74

Tympanometry and otoacoustic emissions in a cohort of special care neonates [published erratum appears in Br J Audiol 1996 Apr;30(2):152] Sutton GJ, et al. **Br J Audiol** 1996 Feb;30(1):9–17

Human auditory cortex is activated by omissions of auditory stimuli. Raij T, et al. **Brain Res** 1997 Jan 16;745(1–2):134–43

Adaptive modeling of the unattended acoustic environment reflected in the mismatch negativity event–related potential. Winkler I, et al. **Brain Res** 1996 Dec 2; 742(1–2):239–52

Social isolation affects the pattern of cardiovascular responses to repetitive acoustic startle stimuli. Blanc J, et al. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):40–5

Augmented prenatal auditory stimulation alters postnatal perception, arousal, and survival in bobwhite quail chicks. Sleigh MJ, et al. **Dev Psychobiol** 1997 Apr;30(3):201–12

The development of cochlear frequency resolution in the human auditory system. Abdala C, et al. **Ear Hear** 1996 Oct;17(5):374–85

Noise–induced otoacoustic emission loss with or without hearing loss. Attias J, et al. **Ear Hear** 1995 Dec;16(6):612–8

The effect of low level acoustic stimulation on susceptibility to noise in blue– and brown–eyed young human subjects. Barrenas ML, et al. **Ear Hear** 1996 Feb;17(1):63–8

Comparison of distortion product otoacoustic emission (DPOAE) and auditory brain stem response (ABR) traveling wave delay measurements suggests frequency–specific synapse maturation. Eggermont JJ, et al. **Ear Hear** 1996 Oct;17(5):386–94

Transient evoked otoacoustic emissions recorder using maximum length sequences as a function of stimulus rate and level. Hine JE, et al. **Ear Hear** 1997 Apr;18(2):121–8

Reliability of transient–evoked otoacoustic emissions. Marshall L, et al. **Ear Hear** 1996 Jun;17(3):237–54

Time–windowing of click–evoked otoacoustic emissions to increase signal–to–noise ratio. Whitehead ML, et al. **Ear Hear** 1995 Dec;16(6):599–611

Saccadic eye movements to visual and auditory targets. Yao L, et al. **Exp Brain Res** 1997 Jun;115(1):25–34

Data preparation for transient evoked otoacoustic emissions. Pascher–Mankiewicz B, et al. **Folia Phoniatr Logop** 1996; 48(4):186–92

Sharp low– and high–frequency limits on musical chord recognition. Biasutti M. **Hear Res** 1997 Mar;105(1–2):77–84

Long–term suppression of the responses of auditory nerve fibers to a characteristic–frequency tone by a low–frequency suppressor. Cai Y, et al. **Hear Res** 1996 Jul; 96(1–2):141–50

Suppression in auditory–nerve fibers of cats using low–side suppressors. III. Model results. Cai Y, et al. **Hear Res** 1996 Jul;96(1–2):126–40

Suppression in auditory–nerve fibers of cats using low–side suppressors. II. Effect of spontaneous rates. Cai Y, et al. **Hear Res** 1996 Jul;96(1–2):113–25

Temporal patterns of the responses of auditory–nerve fibers to low–frequency tones. Cai Y, et al. **Hear Res** 1996 Jul; 96(1–2):83–93

Interaural time and level differences: integrated or separated processing? Schröger E. **Hear Res** 1996 Jul;96(1–2):191–8

Aurally aided visual search under virtual and free–field listening conditions. Perrott DR, et al. **Hum Factors** 1996 Dec;38(4):702–15

Maternal perception of sound–provoked fetal movement in the early intrapartum period. Chittacharoen A, et al. **Int J Gynaecol Obstet** 1997 Feb;56(2):129–33

Transient evoked otoacoustic emissions in nonsurgical ear. Ferber–Viart C, et al. **Int J Neurosci** 1996 Sep; 86(3–4):207–16

Profound hearing loss and presence of click–evoked otoacoustic emissions in the neonate: a report of two cases. Psarommatis IM, et al. **Int J Pediatr Otorhinolaryngol** 1997 Apr 11;39(3):237–43

Visual and auditory evoked phase resetting of the alpha EEG. Brandt ME. **Int J Psychophysiol** 1997 Jun;26(1–3):285–98

P300, stimulus intensity, modality, and probability. Polich J, et al. **Int J Psychophysiol** 1996 Aug–Sep;23(1–2):55–62

Distortion product otoacoustic emission (2f1–f2) amplitude as a function of f2/f1 frequency ratio and primary tone level separation in human adults and neonates. Abdala C. **J Acoust Soc Am** 1996 Dec;100(6):3726–40

The effect of sound intensity on f1–sweep and f2–sweep distortion product otoacoustic emissions phase delay estimates in human adults. Bowman DM, et al. **J Acoust Soc Am** 1997 Mar;101(3):1550–9

The effect of the evanescent wave upon acoustic measurements in the human ear canal. Brass D, et al. **J Acoust Soc Am** 1997 Apr;101(4):2164–75

The effect of noise exposure on the details of distortion product otoacoustic emissions in humans. Engdahl B, et al. **J Acoust Soc Am** 1996 Mar;99(3):1573–87

Absolute pitch and sex effect event–related potential activity for a melodic interval discrimination task. Hantz EC, et al. **J Acoust Soc Am** 1997 Jul;102(1):451–60

Effects of low–frequency underwater sound on hair cells of the inner ear and lateral line of the teleost fish Astronotus ocellatus. Hastings MC, et al. **J Acoust Soc Am** 1996 Mar; 99(3):1759–66

Frequency dependence of acoustic distortion products in a locally active model of the cochlea. Kanis LJ, et al. **J Acoust Soc Am** 1997 Mar;101(3):1527–31

Frequency tuning and acoustic enhancement of electrically evoked otoacoustic emissions in the guinea pig cochlea. Kirk DL, et al. **J Acoust Soc Am** 1996 Dec;100(6):3714–25

Development of distortion product emissions in the gerbil: "filter" response and signal delay. Mills DM, et al. **J Acoust Soc Am** 1997 Jan;101(1):395–411

Interpretation of distortion product otoacoustic emission measurements. I. Two stimulus tones. Mills DM. **J Acoust Soc Am** 1997 Jul;102(1):413–29

Multicomponent acoustic distortion product otoacoustic emission phase in humans. II. Implications for distortion product otoacoustic emissions generation. Moulin A, et al. **J Acoust Soc Am** 1996 Sep;100(3):1640–62

Multicomponent acoustic distortion product otoacoustic emission phase in humans. I. General characteristics. Moulin A, et al. **J Acoust Soc Am** 1996 Sep;100(3):1617–39

Relations between notched–noise suppressed TEOAE and the psychoacoustical critical bandwidth. Neumann J, et al. **J Acoust Soc Am** 1997 May;101(5 Pt 1):2778–88

Auditory–nerve fiber responses to clicks in guinea pigs with a damaged cochlea. Versnel H, et al. **J Acoust Soc Am** 1997 Feb;101(2):993–1009

Is the pressure difference between the oval and round windows the effective acoustic stimulus for the cochlea? Voss SE, et al. **J Acoust Soc Am** 1996 Sep;100(3):1602–16

Visualization of the onset of distortion–product otoacoustic emissions, and measurement of their latency. Whitehead ML, et al. **J Acoust Soc Am** 1996 Sep;100(3):1663–79

Effects of middle ear pressure on otoacoustic emission measures. Zhang M, et al. **J Acoust Soc Am** 1997 Aug;102(2 Pt 1):1032–7

Multifrequency tympanometry and evoked otoacoustic emissions in neonates during the first 24 hours of life. McKinley AM, et al. **J Am Acad Audiol** 1997 Jun; 8(3):218–23

Comparison of standard and abbreviated distortion product otoacoustic emissions procedures. Musiek FE, et al. **J Am Acad Audiol** 1996 Oct;7(5):370–4

Evidence against the influence of aging on distortion–product otoacoustic emissions. Strouse AL, et al. **J Am Acad Audiol** 1996 Oct;7(5):339–45

The long–term effects of auditory training on children with autism [see comments] Bettison S. **J Autism Dev Disord** 1996 Jun;26(3):361–74. Comment in: J Autism Dev Disord 1997 Jun;27(3):347–8.

Neuroendocrine and behavioral responses and brain pattern of c–fos induction associated with audiogenic stress. Campeau S, et al. **J Neuroendocrinol** 1997 Aug;9(8):577–88

Analysis of dynamic spectra in ferret primary auditory cortex. I. Characteristics of single–unit responses to moving ripple spectra. Kowalski N, et al. **J Neurophysiol** 1996 Nov; 76(5):3503–23

Analysis of dynamic spectra in ferret primary auditory cortex. II. Prediction of unit responses to arbitrary dynamic spectra. Kowalski N, et al. **J Neurophysiol** 1996 Nov; 76(5):3524–34

Audible in utero sound caused by the ultrasonic radiation force from a real–time scanner. Arulkumaran S, et al. **J Obstet Gynaecol Res** 1996 Dec;22(6):523–7

Distortion–product otoacoustic emissions and glycerol on the guinea pig hydropic ear. Magliulo G, et al. **J Otolaryngol** 1997 Jun;26(3):188–93

Acoustic stimulation in hypoxic–ischemic encephalopathy: heart rate analysis. Manera J, et al. **J Perinat Med** 1997; 25(1):89–95

The effect of condoms in sexually explicit narratives on male sexual arousal. Gaither GA, et al. **J Sex Marital Ther** 1996 Summer;22(2):103–9

Effect of 5,7–dihydroxytryptamine on audiogenic seizures in genetically epilepsy–prone rats. Statnick MA, et al. **Life Sci** 1996;59(21):1763–71

Improvement in laryngeal dystonia with background noise. Stojanovic M, et al. **Mov Disord** 1997 Mar;12(2):249–50

Age–related prefrontal alterations during auditory memory. Chao LL, et al. **Neurobiol Aging** 1997 Jan–Feb;18(1):87–95

Influence of the N–methyl–D–aspartate receptor antagonist DL–2–amino–5–phosphonovaleric acid on auditory filial imprinting in the domestic chick. Bock J, et al. **Neurobiol Learn Mem** 1996 Mar;65(2):177–88

Excitatory acoustic responses in the inferior colliculus of the rat are increased by GABAB receptor blockade. Vaughn MD, et al. **Neuropharmacology** 1996;35(12):1761–7

Electrophysiological responses from a temporal order continuum in the newborn infant. Simos PG, et al. **Neuropsychologia** 1997 Jan;35(1):89–98

Temporal window of integration revealed by MMN to sound omission. Yabe H, et al. **Neuroreport** 1997 May 27; 8(8):1971–4

Influence of various types of species–specific acoustic signals on the heart rate of mammals. Movchan VN. **Neurosci Behav Physiol** 1996 Jul–Aug;26(4):295–300

Acoustic modulation of electrically evoked distortion product otoacoustic emissions in gerbil cochlea. Ren T. **Neurosci Lett** 1996 Apr 5;207(3):167–70

Effect of abdominal vibroacoustic stimulation on sound and acceleration levels at the head of the fetal sheep. Abrams RM, et al. **Obstet Gynecol** 1997 Aug;90(2):216–20

Decreased expression of the c–Fos, but not Jun B, transcription factor in the auditory pathway of the rat after repetitive acoustic stimulation. Keilmann A, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Sep–Oct; 58(5):262–5

Possible confounding effects of strobe "clicks" on flash evoked potentials in rats. Herr DW, et al. **Physiol Behav** 1996 Feb;59(2):325–40

Lesions of the amygdala do not affect the enhancement of the acoustic startle response by background noise. Schanbacher A, et al. **Physiol Behav** 1996 Nov;60(5):1341–6

Influence of reference electrodes, stimulation characteristics and task paradigms on auditory P50. Chen CH, et al. **Psychiatry Clin Neurosci** 1997 Jun;51(3):139–43

Effect of cigarette smoking on prepulse inhibition of the acoustic startle reflex in healthy male smokers. Kumari V, et al. **Psychopharmacology (Berl)** 1996 Nov;128(1):54–60

Hearing thresholds in four–year–old children with weak or no transient–evoked otoacoustic emissions. Grenner J, et al. **Scand Audiol** 1997;26(2):107–11

Auditory nerve disease of both ears revealed by auditory brainstem responses, electrocochleography and otoacoustic emissions. Kaga K, et al. **Scand Audiol** 1996;25(4):233–8

Effects of the conditioning click on click–evoked otoacoustic emission. Kevanishvili Z, et al. **Scand Audiol** 1996; 25(3):161–6

Transient–evoked otoacoustic emissions. Helpful tool in the detection of pseudohypacusis. Kvaerner KJ, et al. **Scand Audiol** 1996;25(3):173–7

Transient–evoked otoacoustic emissions and contralateral suppression in patients with unilateral tinnitus. Lind O. **Scand Audiol** 1996;25(3):167–72

Auditory feedback regulation of perturbed stance in stroke patients. Petersen H, et al. **Scand J Rehabil Med** 1996 Dec; 28(4):217–23

Respiratory and electrocortical responses to acoustic stimulation. Carley DW, et al. **Sleep** 1996 Dec;19(10 Suppl):S189–92

Auditory awakening thresholds in sleepy and alert individuals. Rosenthal L, et al. **Sleep** 1996 May;19(4):290–5

[Experimental endolymphatic hydrops and distortion otoacoustic emission] Magliulo G, et al. **Acta Otorhinolaryngol Ital** 1996 Jun;16(3):261–6 (Eng. Abstr.) **(Ita)**

[Otoacoustic distortion products in adults with normal hearing] Simoncelli C, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2):80–6 (Eng. Abstr.) **(Ita)**

[Suppression of spontaneous AC potentials in guinea pig cochlea by external tones] Yoshida M, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Feb;99(2):327–32 (Eng. Abstr.) **(Jpn)**

[A case of pena–shokeir syndrome without response to vibratory acoustic stimulation] Kadowaki K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Apr; 48(4):289–92 **(Jpn)**

[Report of scientific workshop on the topic "Early identification of hearing disorders by otoemission. Florence, May 1–2, 1995] Jędrusik A. **Otolaryngol Pol** 1996; 50(1):112–5 **(Pol)**

[Molecular mechanisms of disrupting lipid metabolism of the skin under conditions of acute acoustic stress] Melkonian MM, et al. **Dokl Akad Nauk** 1996 Aug;349(6):826–8 **(Rus)**

[Dynamics of immune response to single exposure to low–frequency acoustic oscillations] Voblikov IV, et al. **Gig Sanit** 1996 Jul–Aug;(4):39–40 **(Rus)**

ACOUSTIC STIMULATION

[Acoustic stimulation of the upper urinary tract in the combined treatment of urolithiasis] Seregin SP, et al. **Urol Nefrol (Mosk)** 1997 Jan-Feb;(1):8-11 (Eng. Abstr.) **(Rus)**

[Experimental study of morphologic changes in ocular tissue structures after exposure to infrasound pneumomassage] Sidorenko EI, et al. **Vestn Oftalmol** 1996 Jul-Aug; 112(3):17-9 (Eng. Abstr.) **(Rus)**

[Activation of proto-oncogene c-fos in the auditory tract of rats stimulation with wide-band noise] Olucha FE, et al. **Acta Otorrinolaringol Esp** 1997 Mar;48(2):85-92 (Eng. Abstr.) **(Spa)**

[Application of the distortion products register in newborns. Preliminary results] Morant A, et al. **An Otorrinolaringol Ibero Am** 1996;23(6):597-604 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Quantitative measurements of eye movements in a patient with Tullio phenomenon. Rottach KG, et al. **J Vestib Res** 1996 Jul-Aug;6(4):255-9

METHODS

Auditory quality cues are more effective than auditory location cues in a R—no R (go—no go) differentiation: the extension of the rule to primitive mammals (American opossum, Didelphis virginiana). Stasiak M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(4):949-53

Tinnitus maskers in the treatment of tinnitus. The MICROTEK 321Q. Vierstraete K, et al. **Acta Otorhinolaryngol Belg** 1996;50(3):211-20

A randomized controlled trial of a new fetal acoustic stimulation test for fetal well-being. Marden D, et al. **Am J Obstet Gynecol** 1997 Jun;176(6):1386-8

Preattentive periodicity detection in auditory patterns as governed by time and intensity information. Schröger E, et al. **Brain Res Cogn Brain Res** 1996 Sep;4(2):145-8

P300, stimulus intensity, and modality. Covington JW, et al. **Electroencephalogr Clin Neurophysiol** 1996 Nov; 100(6):579-84

A developmental study of the effect of temporal order on the ERPs elicited by novel environmental sounds. Cycowicz YM, et al. **Electroencephalogr Clin Neurophysiol** 1997 Aug; 103(2):304-18

The effect of sleep onset on event related potentials with rapid rates of stimulus presentation. de Lugt DR, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jun; 98(6):484-92

P300, probability, and the three-tone paradigm. Katayama J, et al. **Electroencephalogr Clin Neurophysiol** 1996 Nov; 100(6):555-62

The mismatch negativity to frequency deviant stimuli during natural sleep. Loewy DH, et al. **Electroencephalogr Clin Neurophysiol** 1996 Jun; 98(6):493-501

Intracellular recordings in response to monaural and binaural stimulation of neurons in the inferior colliculus of the cat. Kuwada S, et al. **J Neurosci** 1997 Oct 1;17(19):7565-81

Fetal recoil during labor to evaluate fetal well-being when heart rate monitoring is not informative. Elliott JP, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):800-2

Primary care fetal assessment—low-cost fetal arousal testing. Hofmeyr GJ, et al. **S Afr Med J** 1997 Feb;87(2):171-2

[Comparative study of methods of active effects on human brain to reveal abilities of low level perception] Li AG. **Biofizika** 1997 May-Jun;42(3):711-7 (Eng. Abstr.) **(Rus)**

[Experience of clinical use infrasound pneumomassage in the treatment of progressive myopia in schoolchildren] Sidorenko EI, et al. **Vestn Oftalmol** 1997 May-Jun; 113(3):18-20 (Eng. Abstr.) **(Rus)**

ACOUSTIC TRAUMA see **HEARING LOSS, NOISE-INDUCED**

ACOUSTICS

see related
PSYCHOACOUSTICS
SPEECH ACOUSTICS

Acoustic rhinometry in the pre-operative assessment of adenoidectomy candidates. Fisher EW, et al. **Acta Otolaryngol (Stockh)** 1995 Nov;115(6):815-22

Limitations of acoustic rhinometry determined by a simple model. Hamilton JW, et al. **Acta Otolaryngol (Stockh)** 1995 Nov;115(6):811-4

Acoustic reflectometry and endotracheal intubation. Eckmann DM, et al. **Anesth Analg** 1996 Nov;83(5):1084-9

Application of an acoustic cry template to evaluate at-risk newborns: preliminary findings. Robb MP, et al. **Biol Neonate** 1997;71(2):131-6

Reductions in bone strength after fluoride treatment are not reflected in tissue-level acoustic measurements. Turner CH, et al. **Bone** 1996 Dec;19(6):603-7

Acoustic rhinometry: validation of volume changes following intra-nasal polypectomy. O'Flynn P. **Clin Otolaryngol** 1993 Oct;18(5):423-5

Acoustic rhinometry: do we need a standardized operating procedure? Tomkinson A, et al. **Clin Otolaryngol** 1996 Jun; 21(3):284-7

Acoustic emission and nondestructive evaluation of biomaterials and tissues. Kohn DH. **Crit Rev Biomed Eng** 1995;23(3-4):221-306 (338 ref.)

Exploration of pharyngeal swallowing by audiosignal recording. Boiron M, et al. **Dysphagia** 1997 Spring; 12(2):86-92

Clinical correlates of quantitative acoustic analysis in ataxic dysarthria. Chiu MJ, et al. **Eur Neurol** 1996;36(5):310-4

Effect of acoustical, visual and tactile echo on speech fluency of stutterers. Kuniszyk-Jóźkowiak W, et al. **Folia Phoniatr Logop** 1996;48(4):193-200

A system for enabling blind people to identify landmarks: the sound buoy. Blenkhorn P, et al. **IEEE Trans Rehabil Eng** 1997 Sep;5(3):276-8

Acoustical Society of America 131st meeting. Indianapolis, Indiana, 13-17 May 1996. Abstracts. **J Acoust Soc Am** 1996 Apr;99(4 Pt 2):2449-608

References to contemporary papers on acoustics. **J Acoust Soc Am** 1996 Aug;100(2 Pt 2):R1-535

3rd Joint meeting of the Acoustical Society of America and the Acoustical Society of Japan. Honolulu, Hawaii, 2-6 December 1996. Abstract. **J Acoust Soc Am** 1996 Oct;100(4 Pt 2):2563-864

NOISE-CON 97. National Conference on Noise Control Engineering. State College, Pennsylvania, 15-17 June 1997. Abstracts. **J Acoust Soc Am** 1997 May;101(5 Pt 2):3003-209

References to contemporary papers on acoustics. **J Acoust Soc Am** 1997 Aug;102(2 Pt 2):R1-612

Harvey Fletcher's role in the creation of communication acoustics. Allen JB. **J Acoust Soc Am** 1996 Apr;99(4 Pt 1):1825-39

Acoustic effects of the ATOC signal (75 Hz, 195 dB) on dolphins and whales. Au WW, et al. **J Acoust Soc Am** 1997 May;101(5 Pt 1):2973-7

Bioeffects of positive and negative acoustic pressures in vivo. Bailey MR, et al. **J Acoust Soc Am** 1996 Dec;100(6):3941-6

Error analysis in acoustic elastography. I. Displacement estimation. Bilgen M, et al. **J Acoust Soc Am** 1997 Feb; 101(2):1139-46

Error analysis in acoustic elastography. II. Strain estimation and SNR analysis. Bilgen M, et al. **J Acoust Soc Am** 1997 Feb;101(2):1147-54

Effect of static pressure on acoustic transmittance of Albunex microbubble suspensions. Brayman AA, et al. **J Acoust Soc Am** 1996 Apr;99(4 Pt 1):2403-8

Frequency dependence of acoustic backscatter from 5 to 65 MHz ($0.06 < ka < 4.0$) of polystyrene beads in agarose. Bridal SL, et al. **J Acoust Soc Am** 1996 Sep;100(3):1841-8

Two sources of acoustic distortion products from the human cochlea. Brown AM, et al. **J Acoust Soc Am** 1996 Nov; 100(5):3260-7

Bioacoustic behavior of African fishes (Mormyridae): potential cues for species and individual recognition in Pollimyrus. Crawford JD, et al. **J Acoust Soc Am** 1997 Aug;102(2 Pt 1):1200-12

Onboard acoustic recording from diving northern elephant seals. Fletcher S, et al. **J Acoust Soc Am** 1996 Oct;100(4 Pt 1):2531-9

Suppression of human acoustic distortion product: dual origin of 2f1-f2. Gaskill SA, et al. **J Acoust Soc Am** 1996 Nov; 100(5):3268-74

Signal processing techniques for acoustic measurement of sperm whale body lengths. Goold JC. **J Acoust Soc Am** 1996 Nov;100(5):3431-41

Analytical method for describing the paraxial region of finite amplitude sound beams. Hamilton MF, et al. **J Acoust Soc Am** 1997 Mar;101(3):1298-308

Acoustic basis for recognition of aspect-dependent three-dimensional targets by an echolocating bottlenose dolphin. Helweg DA, et al. **J Acoust Soc Am** 1996 Apr; 99(4 Pt 1):2409-20

Acoustic absorption due to proton transfer in solutions of proteins, peptides and amino acids at neutral pH. Holmes AK, et al. **J Acoust Soc Am** 1996 Sep;100(3):1865-77

Frequency dependence of acoustic distortion products in a locally active model of the cochlea. Kanis LJ, et al. **J Acoust Soc Am** 1997 Mar;101(3):1527-31

Wind-instrument reflection function measurements in the time domain. Keefe DH. **J Acoust Soc Am** 1996 Apr;99(4 Pt 1):2370-81

Some acoustical properties of the otic bones of a fin whale. Lees S, et al. **J Acoust Soc Am** 1996 Apr;99(4 Pt 1):2421-7

A physical model of sound diffraction and reflections in the human concha. Lopez-Poveda EA, et al. **J Acoust Soc Am** 1996 Nov;100(5):3248-59

Noninvasive temperature estimation in tissue via ultrasound echo-shifts. Part II. In vitro study. Maass-Moreno R, et al. **J Acoust Soc Am** 1996 Oct;100(4 Pt 1):2522-30

Measurement of pressure and assessment of cavitation for a 22.5-kHz intra-arterial angioplasty device. Makin IR, et al. **J Acoust Soc Am** 1996 Sep;100(3):1855-64

Multicomponent acoustic distortion product otoacoustic emission phase in humans. II. Implications for distortion product otoacoustic emissions generation. Moulin A, et al. **J Acoust Soc Am** 1996 Sep;100(3):1640-62

Room noise criteria—the S12.2-1995 standard raises serious technical and economic considerations. Pei HS. **J Acoust Soc Am** 1997 May;101(5 Pt 1):2418-20

In vitro and in vivo enhancement of sonodynamically active cavitation by second-harmonic superimposition. Umemura S, et al. **J Acoust Soc Am** 1997 Jan;101(1):569-77

Is the pressure difference between the oval and round windows the effective acoustic stimulus for the cochlea? Voss SE, et al. **J Acoust Soc Am** 1996 Sep;100(3):1602-16

Using acoustic radiation force as a concentration method for erythrocytes [letter] Yasuda K, et al. **J Acoust Soc Am** 1997 Jul;102(1):642-5

Inertial cavitation and associated acoustic emission produced during electrohydraulic shock wave lithotripsy. Zhong P, et al. **J Acoust Soc Am** 1997 May;101(5 Pt 1):2940-50

Dynamic temporal processing of nonspeech acoustic information by children with specific language impairment. Visto JC, et al. **J Speech Hear Res** 1996 Jun;39(3):510-7

Some fundamental studies on clinical measurement conditions in acoustic rhinometry. Sipilä J, et al. **Rhinology** 1996 Dec; 34(4):206-9

The effect of changes in ambient temperature on the reliability of acoustic rhinometry data. Tomkinson A, et al. **Rhinology** 1996 Jun;34(2):75-7

Variable density linear acoustic inverse problem. Moghaddam M, et al. **Ultrason Imaging** 1993 Jul; 15(3):255-66

Acoustic streaming: comparison of low-amplitude linear model with streaming velocities measured by 32-MHz Doppler. Nowicki A, et al. **Ultrasound Med Biol** 1997; 23(5):783-91

An optical trigger source for hydrophone-based ultrasound measurement systems: a feasibility study. Petley GW, et al. **Ultrasound Med Biol** 1997;23(5):755-60

[Characteristics of 2F2-F1 distorsion products in adults with normal hearing] Erminy M, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(6):321-7 (Eng. Abstr.) **(Fre)**

[Evoked otoacoustic emissions using clicks in detection of deafness in young children] Molini E, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(4):341-3 (Eng. Abstr.) **(Fre)**

[History of the tuning fork. I: Invention of the tuning fork, its course in music and natural sciences. Pictures from the history of otorhinolaryngology, presented by instruments from the collection of the Ingolstadt German Medical History Museum] Feldmann H. **Laryngorhinootologie** 1997 Feb;76(2):116-22 (Eng. Abstr.) **(Ger)**

[Acoustic rhinometry. A new method for objective assessment of the nasal airway dimensions] Djupesland P. **Tidsskr Nor Laegeforen** 1996 Oct 30;116(26):3111-4 (Eng. Abstr.) **(Nor)**

[Effects of low-frequency acoustic oscillations on immune response to repeated exposures] Voblikov IV, et al. **Gig Sanit** 1996 Sep-Oct;(5):30-2 **(Rus)**

[Direct effects of low-frequency acoustic oscillations on cell membranes] Svidovyĭ VI. **Med Tr Prom Ekol** 1996; (9):29-32 (Eng. Abstr.) **(Rus)**

[Acoustic reflexometry in newborn] Sequí Canet JM, et al. **An Esp Pediatr** 1997 Apr;46(4):414-5 **(Spa)**

INSTRUMENTATION

An introduction to computerised speech lab. Van Lierde K, et al. **Acta Otorhinolaryngol Belg** 1996;50(4):309-14

Study of an acoustic technique to detect cavitation produced by a tilting disc valve. Herman BA, et al. **J Heart Valve Dis** 1996 Jan;5(1):90-6

Evaluation of the nasal cavity by acoustic rhinometry in normal and allergic subjects. Corey JP, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):22-8

Electromagnetic hydrophone for pressure determination of shock wave pulses. Etienne J, et al. **Ultrasound Med Biol** 1997;23(5):747-54

ACOUSTICS, SPEECH see **SPEECH ACOUSTICS**

ACQUIRED IMMUNODEFICIENCY SYNDROME

see related
AIDS SERODIAGNOSIS
HIV SEROPOSITIVITY
HIV SEROPREVALENCE
LYMPHOMA, AIDS-RELATED

Three medical schools' responses to the HIV/AIDS epidemic and the effect on students' knowledge and attitudes. Anderson DG, et al. **Acad Med** 1997 Feb;72(2):144-6

An innovative AIDS elective [letter] Snell JE, et al. **Acad Med** 1997 Feb;72(2):90-1

Undergraduate education on HIV/AIDS [letter] Valenti WM, et al. **Acad Med** 1997 May;72(5):319

AIDS: biochemical prospectives. Ghourab G. **Adv Clin Chem** 1996;32:167-240 (40 ref.)

AIDS, drugs of abuse and the neuroimmune axis: introduction and perspectives. Friedman H. **Adv Exp Med Biol** 1996;402:1-3

One World. One Hope. Proceedings of the XI International Conference on AIDS. Vancouver, Canada, 7-12 July 1996. **AIDS** 1996 Dec;10 Suppl 3:S1-133

AIDS 1995. Social, cultural and political aspects: overview. Aggleton P, et al. **AIDS** 1995;9 Suppl A:S237-8

Similarity in language in "AIDS" article and "AJE" article [letter] Fordyce EJ. **AIDS** 1997 Jun;11(7):947

AIDS education programme in Colombian medical schools: training the teachers [letter] Garcia-Bernard R, et al. **AIDS** 1997 Mar 15;11(4):554-5

Bioethics and AIDS research in Uganda [letter] Loue S, et al. **AIDS** 1996 Jul;10(8):932-3

The IXth International Conference on AIDS and STD in

Africa. Boahene K. **AIDS Care** 1996 Oct;8(5):609–16

Supporting children in need through a community-based orphan visiting programme. Foster G, et al. **AIDS Care** 1996 Aug;8(4):389–403

AIDS and ophthalmology: a period of transition [editorial; comment] Jabs DA, et al. **Am J Ophthalmol** 1997 Aug; 124(2):227–33 (42 ref.). Comment on: Am J Ophthalmol 1997 Aug;124(2):141–57. Comment on: Am J Ophthalmol 1997 Aug;124(2):158–67. Comment on: Am J Ophthalmol 1997 Aug;124(2):168–80. Comment on: Am J Ophthalmol 1997 Aug;124(2):190–8. Comment on: Am J Ophthalmol 1997 Aug;124(2):199–205. Comment on: Am J Ophthalmol 1997 Aug;124(2):234–9.

Stabilizing the HIV/AIDS workforce: lessons from the New York City experience. Healton C, et al. **Am J Prev Med** 1996 Jul–Aug;12(4 Suppl):39–46

Nuclear medicine applications in immunosuppressed patients, "AIDS". Abdel-Dayem HM. **Ann Nucl Med** 1996 Nov; 10(4):369–73 (46 ref.)

Reshaping Italian AIDS research [news] Bindi R. **Ann Oncol** 1997 Jun;8(6):508–9

Mycobacterium avium infection in a patient with acquired immunodeficiency syndrome and a solid silicone buttock implant. Kaplan A, et al. **Ann Plast Surg** 1996 Oct; 37(4):411–4

Parental human immunodeficiency virus infection. New challenges for the pediatrician [editorial; comment] Chernoff RG, et al. **Arch Pediatr Adolesc Med** 1996 Oct; 150(10):1012–3. Comment on: Arch Pediatr Adolesc Med 1996 Oct;150(10):1015–20.

The psychological effects of parental human immunodeficiency virus infection on uninfected children [see comments] Forsyth BW, et al. **Arch Pediatr Adolesc Med** 1996 Oct;150(10):1015–20. Comment in: Arch Pediatr Adolesc Med 1996 Oct;150(10):1012–3.

GPs and the care of people with AIDS. Chaney R. **Aust Fam Physician** 1997 Jul;26(7):835–40

Australian HIV/AIDS legislation: a review for doctors. Magnusson RS. **Aust N Z J Med** 1996 Jun;26(3):396–406 (47 ref.)

GMC's guidance on HIV infection and AIDS is useful [letter] Aston I. **BMJ** 1996 Sep 21;313(7059):751–2

Dealing with patients with HIV infection. Few authors have the courage to stand up and be counted [letter] Daggett P. **BMJ** 1997 Jan 18;314(7075):221

EU makes a difference over AIDS [news] Watson R. **BMJ** 1997 Apr 5;314(7086):997

Who owns AIDS? [editorial] [see comments] Pinching AJ. **Br J Hosp Med** 1997 Mar 5–18;57(5):186–7. Comment in: Br J Hosp Med 1997 Mar 5–18;57(5):228.

The manifestation and management of staff countertransference on a pediatric AIDS team. Mayers AM, et al. **Bull Menninger Clin** 1996 Spring;60(2):206–18

Re: AIDS knowledge and sexual behaviour in patients with schizophrenia [letter; comment] Buckley PF, et al. **Can J Psychiatry** 1996 Nov;41(9):603. Comment on: Can J Psychiatry 1996 Jun;41(5):269–72.

HIV/AIDS—the new "great teacher" [editorial] Archibald CP. **Can J Public Health** 1997 Jan–Feb;88(1):11–3 **(Eng, Fre)**

Hope and caution: report from the XI International Conference on AIDS [comment] Berger PB. **Can Med Assoc J** 1996 Sep 15;155(6):717–21. Comment on: Can Med Assoc J 1996 Sep 15;155(6):712–3.

Powerful politics at the XI International Conference on AIDS [editorial; comment] Walters DJ. **Can Med Assoc J** 1996 Sep 15;155(6):712–3. Comment on: Can Med Assoc J 1996 Sep 15;155(6):717–21.

African American families and HIV/AIDS: caring for surviving children. Carten AJ, et al. **Child Welfare** 1997 Jan–Feb;76(1):107–25

HIV in children. Bye MR. **Clin Chest Med** 1996 Dec; 17(4):787–96 (132 ref.)

Aids: déjà vu in ancient Egypt? [letter] Ablin RJ. **Emerg Infect Dis** 1996 Jul–Sep;2(3):242

Human immunodeficiency virus-related morbidity and mortality in injection drug users: should the AIDS definition be changed yet again? [editorial; comment] Royce R. **Epidemiology** 1996 Nov;7(6):563–5. Comment on: Epidemiology 1996 Nov;7(6):566–70. Comment on: Epidemiology 1996 Nov;7(6):571–7.

Nutritional status and dietary intakes in human immunodeficiency virus (HIV)-infected outpatients in Abidjan, Côte D'Ivoire, 1995. Castetbon K, et al. **Eur J Clin Nutr** 1997 Feb;51(2):81–6

Genitourinary medicine and the Internet. No 2. Lau RK. **Genitourin Med** 1996 Oct;72(5):380–1

High alcohol intake and slow progression to AIDS [letter] Soriano V, et al. **Genitourin Med** 1996 Oct;72(5):382

Perception about AIDS among residents of a Calcutta slum. Poddar AK, et al. **Indian J Public Health** 1996 Jan–Mar; 40(1):4–9

Impact of the mass media on calls to the CDC National AIDS Hotline. Fan DP. **Int J Biomed Comput** 1996 Jun; 41(3):207–16

The Internet and medicine: related sites including HIV/AIDS [editorial] Brettle RP. **Int J STD AIDS** 1997 Feb;8(2):71–7 (4 ref.)

Clinical features of AIDS in the Edinburgh City Hospital cohort. Brettle RP, et al. **Int J STD AIDS** 1996 May–Jun; 7(3):190–6

A national survey to medical and dental schools to assess the level of undergraduate teaching and research about HIV/AIDS in the UK. Carter YH, et al. **Int J STD AIDS** 1997 Feb;8(2):88–94

STD/AIDS knowledge and risk behaviour among masseuses and bar hostesses in Singapore. Chan R, et al. **Int J STD AIDS** 1997 Jun;8(6):373–7

Feedback from the XIth International Conference on AIDS. Radcliffe KW, et al. **Int J STD AIDS** 1996 Nov–Dec; 7(7):521–4

The fight against AIDS. Shafrir E. **Isr J Med Sci** 1997 Jan; 33(1):80

National AIDS Malignancy Conference. Bethesda, Maryland, April 28–30, 1997. Abstracts. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 1;14(4):A1–54

AIDS policy in Japan: integration within structured paternalism. Yonemoto S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S17–21 (1 ref.)

Sixth and eighth graders and acquired immunodeficiency syndrome: the results of focus group analysis. Palmer DA, et al. **J Adolesc Health** 1996 Oct;19(4):297–302

Using factor analysis to explore nurses' fear of AIDS in the United States of America. Wang JF, et al. **J Adv Nurs** 1996 Aug;24(2):287–95

The surgeon's database for AIDS: a collective review. Flum DR, et al. **J Am Coll Surg** 1997 Apr;184(4):403–12 (64 ref.)

One World. One Hope. XI International Conference on AIDS. Porche DJ. **J Assoc Nurses AIDS Care** 1996 Sep–Oct;7(5):94–100

Experimental component analysis of a behavioral HIV-AIDS prevention intervention for inner-city women. Kalichman SC, et al. **J Consult Clin Psychol** 1996 Aug;64(4):687–93

Does child abuse influence subsequent sexual behaviour and risk of AIDS? [letter] Meledandri G, et al. **J Epidemiol Community Health** 1997 Feb;51(1):103

Patients with HIV/AIDS: physicians' knowledge, attitudes, and referral practices. Fournier PO, et al. **J Fam Pract** 1997 Jan;44(1):85–9

Aging in AIDS; AIDS and aging [editorial; comment] Justice AC, et al. **J Gen Intern Med** 1996 Oct;11(10):645–7. Comment on: J Gen Intern Med 1996 Oct;11(10):591–6.

AIDS orphans in Louisiana in the year 2000: the potential economic impact on the foster care system. Parsons S, et al. **J La State Med Soc** 1996 Sep;148(9):391–8

Nonhuman Primate Models for AIDS VIII. Proceedings of a meeting. Monterey, California, November 5–8, 1995. **J Med Primatol** 1996 Jun;25(3):147–250

Immune and hematopoietic parameters in HIV-1-infected chimpanzees during clinical progression toward AIDS. Villinger F, et al. **J Med Primatol** 1997 Feb–Apr; 26(1–2):11–8

HIV/AIDS in African Americans: role of the National Medical Association in diagnosis, treatment, and eradication. Morgan RC Jr. **J Natl Med Assoc** 1997 Jan; 89(1):14–8

Preferred sources of AIDS information, risk perceptions, and risk behaviors among inner-city community college students. Rich JA, et al. **J Natl Med Assoc** 1996 Feb; 88(2):87–93

Nutrition in pediatric HIV infection: setting the research agenda; Work group session report: technology transfer. Greene H, et al. **J Nutr** 1996 Oct;126(10 Suppl):2691S–2693S

Nutrition in pediatric HIV infection: setting the research agenda. Working group session report: setting the basic research agenda. Hirschfeld S. **J Nutr** 1996 Oct;126(10 Suppl):2680S

Nutrition in pediatric HIV infection: setting the research agenda. Keynote address. Paul W. **J Nutr** 1996 Oct;126(10 Suppl):2599S–2601S

Accepting our responsibility for treating AIDS patients [letter] Smail DB. **J Oral Maxillofac Surg** 1997 Feb; 55(2):204

Life expectancy in hospitalized patients with AIDS: prognostic factors on admission. Gerard L, et al. **J Palliat Care** 1996 Spring;12(1):26–30

"Alan". Jamieson SP. **J Palliat Care** 1997 Summer;13(2):43–4

Assessing children's conceptions of AIDS. Kistner J, et al. **J Pediatr Psychol** 1996 Apr;21(2):269–81

Impoverished women at risk for AIDS. Social support variables. Nyamathi A, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Nov;34(11):31–9

Nonresponse bias in a survey of Ontario dentists' infection control and attitudes concerning HIV. McCarthy GM, et al. **J Public Health Dent** 1997 Winter;57(1):59–62

Knowledge of New Zealand youth regarding sexuality and AIDS. Duncan D, et al. **J Sex Marital Ther** 1997 Spring; 23(1):47–51

Plague and AIDS in literature. Yom SS. **JAMA** 1997 Feb 5;277(5):437–8

Knowledge, attitude and practice survey of acquired immune deficiency syndrome (AIDS) among paramedicals in a tertiary care hospital in Pakistan. Siddiqi S, et al. **JPMA J Pak Med Assoc** 1995 Aug;45(8):200–2

HIV: the other dimension. Adler MW. **Lancet** 1997 Feb 15; 349(9050):498–500

World AIDS day aims to combat growing complacence [news] Ng D. **Lancet** 1996 Dec 7;348(9041):1578

Culture, media, and HIV/AIDS in Asia. Wolffers I. **Lancet** 1997 Jan 4;349(9044):52–4

A new retroviral AIDS-like disease and/or acute leukemia induced in mice by alloimmune stimuli. Ter-Grigorov V, et al. **Leukemia** 1997 Apr;11 Suppl 3:263–6

The XI AIDS conference and HIV-1 lymphopathy. Shields JW. **Lymphology** 1997 Sep;30(3):137–54 (70 ref.)

Medicine behind bars and other lessons from the AIDS epidemic. Flanigan T. **Med Health R I** 1997 Aug; 80(8):242–3

Research ethics and HIV/AIDS. Dickens M. **Med Law** 1997; 16(1):187–97

Report of the First Brazilian Symposium on Basic Research in HIV/AIDS. Galvão-Castro B, et al. **Mem Inst Oswaldo Cruz** 1996 May–Jun;91(3):329–34

A lesson in AIDS education. Kakarlapudi V. **Mo Med** 1997 Apr;94(4):163

Resources for HIV/AIDS on the Internet. Dewhurst S, et al. **Mol Med Today** 1996 Feb;2(2):52–7

Physician-assisted suicide and patients with human immunodeficiency virus disease [see comments] Slome LR, et al. **N Engl J Med** 1997 Feb 6;336(6):417–21. Comment in: N Engl J Med 1997 Jul 3;337(1):56.

Dental offices open to the public [news] **N Y State Dent J** 1996 Nov;62(9):67

Round two: dentist victorious in AIDS discrimination case. Plunkett LR. **N Y State Dent J** 1997 May;63(5):6–7

Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. D'Souza MP, et al. **Nat Med** 1996 Dec;2(12):1293–300 (79 ref.)

Montagnier to set up an AIDS research centre in New York [news] **Nature** 1997 May 1;387(6628):10

Time honours AIDS pioneer [news] **Nature** 1997 Jan 2; 385(6611):5

Ho joins Montagnier in AIDS centres project [news] **Nature** 1997 May 22;387(6631):330

AIDS researcher loses libel fight against French newspaper [news] **Nature** 1996 Nov 7;384(6604):10

White House names AIDS policy director [news] **Nature** 1997 Feb 20;385(6618):671

Blood lab boss jailed for neglect over HIV test [news] **Nature** 1997 Jun 26;387(6636):840

Priorities for AIDS research set out by US task force [news] **Nature** 1996 Dec 19–26;384(6610):606

Company heads plead guilty on AIDS charged [news] **Nature** 1997 Mar 27;386(6623):316

Miami AIDS researcher denies charges over billing irregularities [news] Dalton R. **Nature** 1997 Aug 21; 388(6644):704

Sandra Thurman named as new 'AIDS Czar' [news] Wadman M. **Nature** 1997 Apr 10;386(6625):533

US increases health funds but ducks AIDS allocation [news] Wadman M. **Nature** 1996 Oct 3;383(6599):373

AIDS activists meet to establish community-based standards for life insurance settlements [news] **Oncology (Huntingt)** 1996 May;10(5):712

Diagnostic imaging in pediatric AIDS. Haller JO, et al. **Pediatr Clin North Am** 1997 Jun;44(3):721–40 (64 ref.)

AIDS-related attitudes and risk behaviors: a survey of a random sample of California heterosexuals. Bastani R, et al. **Prev Med** 1996 Mar–Apr;25(2):105–17

Sequential use of neural networks for survival prediction in AIDS. Ohno-Machado L. **Proc AMIA Annu Fall Symp** 1996;:170–4

Tropical illness profiles: the psychology of illness perception in Malawi. MacLachlan M, et al. **Public Health** 1997 Jul; 111(4):211–3

New edition updates schools on AIDS policies [news] **Public Health Rep** 1996 Sep–Oct;111(5):389

Surveillance of HIV knowledge, attitudes, beliefs, and behaviors in the general population. Safran MA, et al. **Public Health Rep** 1996;111 Suppl 1:123–8

Is there a cure for AIDS? [news] Karim SS, et al. **S Afr Med J** 1996 Sep;86(9):1058, 1063

Drop secrecy around HIV/AIDS [news] van der Linde I. **S Afr Med J** 1997 Jan;87(1):12–3

Shift in global AIDS focus [news] van der Linde I. **S Afr Med J** 1997 Jun;87(6):693–4

Russia steps into AIDS research arena [news] **Science** 1997 Apr 4;276(5309):23

Montagnier to head New York center [news] Balter M. **Science** 1997 May 2;276(5313):672

Netherlands pulls top teams' funding [news] Balter M. **Science** 1997 Sep 19;277(5333):1757

AIDS research. Program funding, Italian style [news] Biggin S. **Science** 1997 Apr 11;276(5310):191

AIDS research chief bows out [news] Cohen J. **Science** 1997 Oct 10;278(5336):218

The reluctant man of the year [news] Cohen J. **Science** 1997 Jan 17;275(5298):298

AIDS: a justifiable share [news] Cohen J. **Science** 1997 Apr 18;276(5311):345

Approaches to AIDS research [letter] Desrosiers RC. **Science** 1997 Jan 3;275(5296):13

"Man of the Year" [letter; comment] Gorman C. **Science** 1997 Feb 21;275(5303):1049. Comment on: Science 1997 Jan 17;275(5298):298–9.

Singaporean beliefs about HIV and AIDS. Bishop GD. **Singapore Med J** 1996 Dec;37(6):617–21

Constructing a complex of contagion: the perceptions of AIDS among working prostitutes in Costa Rica. Downe PJ. **Soc Sci Med** 1997 May;44(10):1575–83

Themes from the frontlines: hospital social work with people with AIDS. Beckerman N, et al.

Soc Work Health Care 1996;23(4):75–89

Israeli professionals' knowledge and attitudes towards AIDS. Ben-Ari A. **Soc Work Health Care** 1996;22(4):35–52

The impact of a client's diagnosis of AIDS on social workers' clinical judgements: an experimental study. Knight C. **Soc Work Health Care** 1996;23(4):35–50

[A study on AIDS-related knowledge, attitude and behavior in servicemen in China] Hang G, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1996 Mar;30(2):94–7 (Eng. Abstr.) **(Chi)**

[Human immunodeficiency virus infection and AIDS in Aquitaine. 10 years' experience of a hospital information system, 1985–1995. Le Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA)] Marimoutou C, et al. **Presse Med** 1997 May 3–10;26(15):703–10 (Eng. Abstr.) **(Fre)**

[Lecture notes. Attention AIDS!] Taverne B. **Sante** 1996 Sep–Oct;6(5):328–9 **(Fre)**

[Epidemiology of AIDS—discrimination, ethics and social policy] Ishay R. **Harefuah** 1996 Nov 1;131(9):357–9 **(Heb)**

[Artificial insemination in the AIDS era] Paz G, et al. **Harefuah** 1996 Oct;131(7–8):252–4 (23 ref.) **(Heb)**

[Survey on knowledge about AIDS among high school and university students] Pellegrini MG, et al. **Ann Ig** 1997 Jan–Feb;9(1):81–7 **(Ita)**

[Changes in nurses' knowledge and attitudes regarding AIDS in Mie Prefecture, Japan] Hashizume E, et al. **Nippon Koshu Eisei Zasshi** 1995 Dec;42(12):1054–60 (Eng. Abstr.) **(Jpn)**

[Medical science of AIDS—perspective] Hinuma Y. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):613–9 (0 ref.) **(Jpn)**

[AIDS] Mimaya J. **Ryoikibetsu Shokogun Shirizu** 1996; (15):365–72 (13 ref.) **(Jpn)**

[AIDS study with a racist slant (letter) (see comments)] Adobor RD, et al. **Tidsskr Nor Laegeforen** 1996 Aug 30; 116(20):2495–6. Comment in: Tidsskr Nor Laegeforen 1996 Sep 10;116(21):2607–8. **(Nor)**

[Opinions on the rights of seropositive persons or AIDS patients and the conduct adopted towards them] Tuchendria E, et al. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan–Jun; 42(1–2):85–6 **(Rum)**

[3rd International Conference on AIDS, Cancer and Related Problems (22–26 May 1995) (news)] Kovaleva SI. **Probl Tuberk** 1996;(4):63 **(Rus)**

[Basic results of research on AIDS in 1995] Pokrovskii VI, et al. **Vopr Virusol** 1997 Jan–Feb;42(1):2–5 **(Rus)**

[Attitudes of nursing staff in Western Málaga to HIV/AIDS infection] Molina Cabrillana J, et al. **Aten Primaria** 1997 Jun 30;20(2):65–70 (Eng. Abstr.) **(Spa)**

[AIDS in Mexico and the world: a global view] Soberón-Acevedo G, et al. **Gac Med Mex** 1996;132 Suppl 1:1–138 **(Spa)**

[Comparison of knowledge and risk behavior regarding AIDS among HIV+ and HIV- inmates at the provincial prison of Granada] Carrasco Rodríguez P, et al. **Gac Sanit** 1996 May–Jun;10(54):104–9 (Eng. Abstr.) **(Spa)**

[Patients infected with HIV-1: why some speedsters and others marathon runners? (editorial; comment) (published erratum appears in Med Clin (Barc) 1996 Jul 6;107(6):230)] Gatell JM. **Med Clin (Barc)** 1996 Dec 7;107(20):776–8. Comment on: Med Clin (Barc) 1996 Dec 7;107(20):761–6. **(Spa)**

[Knowledge and opinions of physicians on acquired immunodeficiency syndrome] González López E. **Med Clin (Barc)** 1996 Nov 16;107(17):664–8 (85 ref.) **(Spa)**

[Women and AIDS (letter)] Ollé Goig JE. **Med Clin (Barc)** 1997 Mar 1;108(8):315 **(Spa)**

[Rapid and slow progression of the infection by the type 1 human immunodeficiency virus in a population of seropositive subjects in Madrid (see comments)] Soriano V, et al. **Med Clin (Barc)** 1996 Dec 7;107(20):761–6 (Eng. Abstr.). Comment in: Med Clin (Barc) 1996 Dec 7;107(20):776–8. **(Spa)**

[Aids and otoneuroophthalmological disease: introduction] Aragonés JM. **Rev Neurol** 1996 Dec;24(136):1562 **(Spa)**

[Response of the authors to the comments on "12 years of AIDS in Mexico" special issue (letter)] Bronfman M, et al. **Salud Publica Mex** 1996 Jul–Aug;38(4):223–4 **(Spa)**

[Management strategies in HIV/AIDS at the family level] Castro R, et al. **Salud Publica Mex** 1997 Jan–Feb; 39(1):32–43 (Eng. Abstr.) **(Spa)**

BLOOD

Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 1l beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. Bisset LR, et al. **AIDS** 1997 Mar 15;11(4):485–91

Serum chemokine levels in patients with non-progressing HIV infection. McKenzie SW, et al. **AIDS** 1996 Aug; 10(9):F29–33

Detection of the herpesvirus-like DNA sequences in matched specimens of semen and blood from patients with AIDS-related Kaposi's sarcoma by polymerase chain reaction in situ hybridization. Huang YQ, et al. **Am J Pathol** 1997 Jan;150(1):147–53

Aeroallergen-specific IgE changes in individuals with rapid human immunodeficiency virus disease progression. Goetz DW, et al. **Ann Allergy Asthma Immunol** 1997 Mar; 78(3):301–6

Recombinant human granulocyte colony-stimulating factor increases circulating CD34-postive cells in patients with AIDS. Nielsen SD, et al. **Ann Hematol** 1997 May; 74(5):215–20

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team [see comments] Hughes MD, et al. **Ann Intern Med** 1997 Jun 15;126(12):929–38. Comment in: Ann Intern Med 1997 Jun 15;126(12):983–5.

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection [see comments] Mellors JW, et al. **Ann Intern Med** 1997 Jun 15;126(12):946–54. Comment in: Ann Intern Med 1997 Jun 15;126(12):983–5.

Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS [see comments] O'Brien WA, et al. **Ann Intern Med** 1997 Jun 15;126(12):939–45. Comment in: Ann Intern Med 1997 Jun 15;126(12):983–5.

Long-term assessment of interferon responses in the HIV+ and AIDS patients. Piasecki E, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):345–52

Intrathecal reactivity for myelin components precedes development of neurological symptoms in AIDS patients. Silva AA, et al. **Arch Med Res** 1997 Autumn;28(3):391–6

HIV-1 virus infected T lymphocytes. The behaviour of purine metabolism. Carlucci F, et al. **Biochem Soc Trans** 1996 May;24(2):319S

Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy? [editorial] Mathé G, et al. **Biomed Pharmacother** 1996;50(10):473–9 (41 ref.)

A stochastic model for the analysis of bivariate longitudinal AIDS data. Sy JP, et al. **Biometrics** 1997 Jun;53(2):542–55

Immunological markers of disease progression in patients infected with the human immunodeficiency virus. Pascale JM, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):474–7

Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Liu Z, et al. **Cytometry** 1996 Mar 15;26(1):1–7

Clastogenic factors in plasma of HIV-1 infected patients activate HIV-1 replication in vitro: inhibition by superoxide dismutase. Edeas MA, et al. **Free Radic Biol Med** 1997;23(4):571–8

Cytokine patterns in adults with AIDS. Alonso K, et al. **Immunol Invest** 1997 Apr;26(3):341–50

Serum leptin levels in the acquired immunodeficiency syndrome. Grunfeld C, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4342–6

Effect of interferon alpha on high serum androgen concentrations in HIV positive men with Kaposi's sarcoma. Christeff N, et al. **J Clin Pathol** 1997 Apr;50(4):341–5

Decreased short-term production of tumor necrosis factor-alpha and interleukin-1beta in human immunodeficiency virus-seropositive subjects. Ullum H, et al. **J Infect Dis** 1997 Jun;175(6):1507–10

Generation of CD4+ and CD8+ T-cell clones from PBLs of HIV-1 infected subjects using herpesvirus saimiri. Saha K, et al. **Nat Med** 1996 Nov;2(11):1272–5

Zinc levels and infections in hospitalized patients with AIDS. Koch J, et al. **Nutrition** 1996 Jul–Aug;12(7–8):515–8

Serum zinc and protein levels: lack of a correlation in hospitalized patients with AIDS [see comments] Koch J, et al. **Nutrition** 1996 Jul–Aug;12(7–8):511–4. Comment in: Nutrition 1996 Jul–Aug;12(7–8):551–3.

Serum zinc and protein status in AIDS patients [editorial; comment] Odeh M. **Nutrition** 1996 Jul–Aug;12(7–8):551–3 . Comment on: Nutrition 1996 Jul–Aug;12(7–8):511–4.

Effect of L-carnitine treatment in vivo on apoptosis and ceramide generation in peripheral blood lymphocytes from AIDS patients. Cifone MG, et al. **Proc Assoc Am Physicians** 1997 Mar;109(2):146–53

Mechanism(S) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis. Ambrus JL, et al. **Res Commun Mol Pathol Pharmacol** 1997 Jun;96(3):255–65

Circulating cell adhesion molecules in HIV1-infected patients as indicator markers for AIDS progression. Galea P, et al. **Res Immunol** 1997 Feb;148(2):109–17 (36 ref.)

T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover. Wolthers KC, et al. **Science** 1996 Nov 29;274(5292):1543–7

Lack of correlation between the incidence of bloodborne AIDS and overall AIDS incidence in Western Europe. Dal Maso L, et al. **Transfusion** 1997 Feb;37(2):221–5

[Macrophages as production sites of HIV (news)] Schattenfroh S. **Dtsch Med Wochenschr** 1997 Sep 12; 122(37):A7 **(Ger)**

[Lipoprotein(a) levels in patients with human immunodeficiency virus infection (letter)] Martínez-Triguero ML, et al. **Med Clin (Barc)** 1996 Nov 9;107(16):637 **(Spa)**

[Clinical significance of detecting in peripheral blood giant endothelial cells infected by cytomegalovirus in patients with AIDS (letter)] Reina J, et al. **Med Clin (Barc)** 1996 Sep 7;107(7):277–8 **(Spa)**

[Measurement of HIV-RNA in blood is of great predictive value (letter)] Sönnerborg A. **Lakartidningen** 1997 Apr 23; 94(17):1589–90 **(Swe)**

CEREBROSPINAL FLUID

Elevated cerebrospinal fluid sulfatide concentrations as a sign of increased metabolic turnover of myelin in HIV type I infection. Gisslén M, et al. **AIDS Res Hum Retroviruses** 1996 Jan 20;12(2):149–55

Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS. Akula SK, et al. **Am J Med Sci** 1997 Apr;313(4):244–6

Intrathecal reactivity for myelin components precedes development of neurological symptoms in AIDS patients. Silva AA, et al. **Arch Med Res** 1997 Autumn;28(3):391–6

[Cerebrospinal fluid in 50 AIDS patients] Hinrichsen SL, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):227–31 (Eng. Abstr.) **(Por)**

[Adenosine deaminase in the cerebrospinal fluid of patients with acquired immunodeficiency syndrome] Machado LD, et al. **Arq Neuropsiquiatr** 1995 Dec;53(4):755–9 (Eng. Abstr.) **(Por)**

[Biochemical changes in cerebrospinal fluid associated with the neurotoxic action of HIV-1] Gómez Alcalde MS, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jul–Aug;24(4):209–18 (65 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Redefining AIDS: towards a modification of the current AIDS case definition. Albrecht H. **Clin Infect Dis** 1997 Jan;24(1):64–74 (128 ref.)

Reclassified AIDS cases in Italy 1990–95 [letter] Arcieri R, et al. **Lancet** 1996 Dec 21–28;348(9043):1741–2

COMPLICATIONS

Localized crusted scabies in a patient with acquired immunodeficiency syndrome [letter] Porras-Luque JI, et al. **Acta Derm Venereol** 1997 Jul;77(4):326–7

Varicella-zoster ventriculo-encephalitis and spinal cord infarction in a patient with AIDS. Kenyon LC, et al. **Acta Neuropathol (Berl)** 1996 Aug;92(2):202–5

Diagnosis of disseminated toxoplasmosis using a peripheral blood smear [letter] Albrecht H, et al. **AIDS** 1996 Jun; 10(7):799–800

Atovaquone is effective treatment for the symptoms of gastrointestinal microsporidiosis in HIV-1-infected patients. Anwar-Bruni DM, et al. **AIDS** 1996 Jun; 10(6):619–23

Acute retinal necrosis in the course of AIDS: study of 26 cases [see comments] Batisse D, et al. **AIDS** 1996 Jan; 10(1):55–60. Comment in: AIDS 1996 Sep;10(11):1300–1.

Oxandrolone in AIDS-wasting myopathy. Berger JR, et al. **AIDS** 1996 Dec;10(14):1657–62

Identification of Mycobacterium genavense in intestinal tissue from a parakeet using two polymerase chain reaction methods: are pets a reservoir of infection in AIDS patients? [letter] Boian M, et al. **AIDS** 1997 Feb;11(2):255–6

The association between cigarette smoking and selected HIV-related medical conditions. Conley LJ, et al. **AIDS** 1996 Sep;10(10):1121–6

A trial of testosterone therapy for HIV-associated weight loss. Coodley GO, et al. **AIDS** 1997 Sep;11(11):1347–52

Kaposi's sarcoma in women with AIDS. Cooley TP, et al. **AIDS** 1996 Sep;10(11):1221–5

Treatment of isosporiasis with combined albendazole and ornidazole in patients with AIDS [letter] Dionisio D, et al. **AIDS** 1996 Sep;10(11):1301–2

Oral methionine may improve neuropsychological function in patients with AIDS myelopathy: results of an open-label trial [letter] Dorfman D, et al. **AIDS** 1997 Jul;11(8):1066–7

Evidence of activity of vinorelbine in patients with previously treated AIDS-associated Kaposi's sarcoma [letter] Errante D, et al. **AIDS** 1996 Dec;10(14):1742–3

Lack of association of low testosterone with HIV-associated Kaposi's sarcoma [letter; comment] Falutz J. **AIDS** 1996 Jun;10(7):794–5. Comment on: AIDS 1995 Nov;9(11):1295–6.

The pp65 antigenaemia test as a predictor of cytomegalovirus-induced end-organ disease in patients with AIDS. Francisci D, et al. **AIDS** 1997 Sep; 11(11):1341–5

Chronic rhinosinusitis in patients with AIDS: potential role of microsporidia [letter] Franzen C, et al. **AIDS** 1996 Jun; 10(6):687–8

Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. Gaidano G, et al. **AIDS** 1996 Aug;10(9):941–9

Foscarnet-induced hypercalcaemia in AIDS [letter] Gayet S, et al. **AIDS** 1997 Jul;11(8):1068–70

Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. Girard PM, et al. **AIDS** 1996 Jun;10(7):753–7

Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. Gold J, et al. **AIDS** 1996 Jun;10(7):745–52

Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. Gradoni L, et al. **AIDS** 1996 Jun;10(7):785–91

Totally implantable venous access device infections in patients with AIDS [letter] Hellard M, et al. **AIDS** 1997 Apr;11(5):697–8

Antimony/interferon–gamma combination in the treatment of visceral leishmaniasis in AIDS [letter] Kaplanski G, et al. **AIDS** 1996 Sep;10(10):1172–4

Atovaquone as long–term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. Katlama C, et al. **AIDS** 1996 Sep;10(10):1107–12

Famciclovir in AIDS–related acute retinal necrosis [letter; comment] Klein JL, et al. **AIDS** 1996 Sep;10(11):1300–1. Comment on: AIDS 1996 Jan;10(1):55–60.

Malabsorption and wasting in AIDS patients with microsporidia and pathogen–negative diarrhea. Lambl BB, et al. **AIDS** 1996 Jun;10(7):739–44

Ocular and neurological complications of varicella zoster virus infection in a patient with AIDS [letter] Meenken C, et al. **AIDS** 1996 Sep;10(10):1174–5

Painful neuropathy of the lateral cutaneous nerve of the thigh in patients with AIDS: successful treatment by injection with bupivacaine and triamcinolone [letter] Myers KG, et al. **AIDS** 1996 Sep;10(11):1302–3

Physical disability in a cohort of persons with AIDS: data from the AIDS Time–Oriented Health Outcome Study. O'Dell MW, et al. **AIDS** 1996 Jun;10(6):667–73

Symptomatic leiomyoma of the adrenal gland in a woman with AIDS. Parola P, et al. **AIDS** 1996 Mar;10(3):340–1

Successful treatment of cytomegalovirus encephalitis in an AIDS patient using cidofovir [letter] Sadler M, et al. **AIDS** 1997 Aug;11(10):1293–4

Kaposi's sarcoma and non–Hodgkin's lymphomas in children and adolescents with AIDS. Serraino D, et al. **AIDS** 1996 Jun;10(6):643–7

High frequency of invasive cervical cancer among female injecting drug users with AIDS in Italy [letter] [see comments] Serraino D, et al. **AIDS** 1996 Aug;10(9):1041–2 . Comment in: AIDS 1997 May;11(6):820–1.

Completeness of reporting of AIDS associated with invasive cervical carcinoma [letter; comment] [see comments] Simon PA, et al. **AIDS** 1997 May;11(6):820–1. Comment on: AIDS 1996 Aug;10(9):1041–2. Comment in: AIDS 1997 May;11(6):821–2.

High prevalence of cutaneous viral infections in AIDS patients with Kaposi's sarcoma: insight into the role of human herpesvirus 8? [letter] Simonart T, et al. **AIDS** 1997 May;11(6):824–6

Molecular biology and epidemiology of Pneumocystis carinii infection in AIDS [editorial] Stringer JR, et al. **AIDS** 1996 Jun;10(6):561–71 (120 ref.)

Detection of intracellular p24–positive macrophages in gingival crevicular fluid from periodontal lesions of stage IV AIDS patients [letter] Suzuki T, et al. **AIDS** 1996 Jun; 10(7):804–5

Reactive haemophagocytic syndrome in AIDS [letter] Tiab M, et al. **AIDS** 1996 Jan;10(1):108–11

Human chorionic gonadotrophin in the treatment of HIV–related Kaposi's sarcoma [letter] Tirelli U, et al. **AIDS** 1997 Mar;11(3):387–8

Modulation of all–trans–retinoic acid administered on intermittent schedule by alpha–interferon 2a in a patient with AIDS–related Kaposi's sarcoma [letter] Toma S, et al. **AIDS** 1996 Aug;10(9):1049–50

Cutaneous reactions to trimethoprim–sulphametrole in AIDS patients treated for Pneumocystis carinii pneumonia. van der Ven AJ, et al. **AIDS** 1996 Mar;10(3):341–2

Serological and polymerase chain reaction–based analysis of aqueous humour samples in patients with AIDS and necrotizing retinitis. Verbraak FD, et al. **AIDS** 1996 Sep; 10(10):1091–9

Cytomegalovirus infection in the genital tract of HIV–seropositive women [letter] Wales NM, et al. **AIDS** 1996 Jun;10(7):802–3

Interleukin 6 and AIDS–associated Kaposi's sarcoma: a nested case control study within the Multicenter AIDS Cohort Study. Dourado I, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10;13(9):781–8

Choroid plexitis caused by cytomegalovirus in a patient with AIDS [letter] Guermazi A, et al. **AJNR Am J Neuroradiol** 1996 Aug;17(7):1398–9

Cerebrovascular complications of HIV in children. Shah SS, et al. **AJNR Am J Neuroradiol** 1996 Nov–Dec; 17(10):1913–7

AIDS–related airway disease. McGuinness G, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):67–77 (61 ref.)

Review article: the therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome. Wilcox CM, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):425–43 (186 ref.)

Pericardial tamponade from Kaposi's sarcoma: role of early pericardial window. Vijay V, et al. **Am Heart J** 1996 Oct; 132(4):897–9 (6 ref.)

Leishmaniasis and Kaposi's sarcoma in an HIV–infected patient [letter; comment] Abajo P, et al. **Am J Dermatopathol** 1997 Feb;19(1):101–3. Comment on: Am J Dermatopathol 1995 Apr;17(2):145–50.

Risk of Kaposi's sarcoma and oroanal sexual contact. Grulich AE, et al. **Am J Epidemiol** 1997 Apr 15;145(8):673–9

Immunosuppression may lead to progression of hepatitis C virus–associated liver disease in hemophiliacs coinfected with HIV. Rockstroh JK, et al. **Am J Gastroenterol** 1996 Dec;91(12):2563–8

Liposomal daunorubicin marketed for HIV–related Kaposi's sarcoma [news] **Am J Health Syst Pharm** 1996 Jul 1; 53(13):1500, 1505

Thalidomide heals HIV–related oral ulcers, but caution is required [news] **Am J Health Syst Pharm** 1997 Jul 1; 54(13):1485–6

Misprint of dosage interval for liposomal doxorubicin hydrochloride [letter] Subach RA, et al. **Am J Health Syst Pharm** 1996 Jul 15;53(14):1727

AIDS and pure red cell aplasia [letter; comment] Stricker RB, et al. **Am J Hematol** 1997 Mar;54(3):264. Comment on: Am J Hematol 1996 Feb;51(2):171.

AIDS–associated membranous nephropathy with advanced renal failure: response to prednisone. Mattana J, et al. **Am J Kidney Dis** 1997 Jul;30(1):116–9

Fever and renal failure in a 31–year–old male with AIDS [clinical conference] **Am J Med** 1997 Mar;102(3):310–5

HIV type–1–related transient neurologic deficits [letter] Bradley TP, et al. **Am J Med** 1997 Sep;103(3):250

Ursodeoxycholic acid in the treatment of AIDS–associated cholangiopathy [letter; comment] Castiella A, et al. **Am J Med** 1997 Aug;103(2):170–1. Comment on: Am J Med 1995 Dec;99(6):600–3.

Disparate prognosis of thrombotic microangiopathy in HIV–infected patients with and without AIDS. Gadallah MF, et al. **Am J Nephrol** 1996;16(5):446–50 (33 ref.)

Understanding the devastation of AIDS. Lisanti P, et al. **Am J Nurs** 1997 Jul;97(7):26–34; quiz 35 (22 ref.)

Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus–1. Hitti J, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):450–4

Aphthous vaginal ulceration in two women with acquired immunodeficiency syndrome. Schuman P, et al. **Am J Obstet Gynecol** 1996 May;174(5):1660–3

Metastatic anterior chamber non–Hodgkin lymphoma in a patient with acquired immunodeficiency syndrome. España–Gregori E, et al. **Am J Ophthalmol** 1997 Aug; 124(2):243–5

Acanthamoeba endophthalmitis in acquired immunodeficiency syndrome. Heffler KF, et al. **Am J Ophthalmol** 1996 Oct;122(4):584–6

Molluscum contagiosum eyelid lesions as the initial manifestation of acquired immunodeficiency syndrome. Leahey AB, et al. **Am J Ophthalmol** 1997 Aug;124(2):240–1

Chiasmal infarction and sudden blindness caused by mucormycosis in AIDS and diabetes mellitus. Lee BL, et al. **Am J Ophthalmol** 1996 Dec;122(6):895–6

Elevation of laser flare photometry in patients with cytomegalovirus retinitis and AIDS [see comments] Magone MT, et al. **Am J Ophthalmol** 1997 Aug; 124(2):190–8. Comment in: Am J Ophthalmol 1997 Aug;124(2):227–33.

Regression of cytomegalovirus retinitis associated with protease–inhibitor treatment in patients with AIDS [see comments] Reed JB, et al. **Am J Ophthalmol** 1997 Aug; 124(2):199–205. Comment in: Am J Ophthalmol 1997 Aug;124(2):227–33.

A polymerase chain reaction–based assay for diagnosing varicella–zoster virus retinitis in patients with acquired immunodeficiency syndrome. Short GA, et al. **Am J Ophthalmol** 1997 Feb;123(2):157–64

A case of primary laryngeal T–cell lymphoma in a patient with acquired immunodeficiency syndrome. Smith MS, et al. **Am J Otolaryngol** 1996 Sep–Oct;17(5):332–4

Pulmonary mechanical and immunologic dysfunction in a murine model of AIDS. Hartsfield CL, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):L699–706

EBV–associated anorectal lymphomas in patients with acquired immune deficiency syndrome. Ioachim HL, et al. **Am J Surg Pathol** 1997 Sep;21(9):997–1006 (56 ref.)

Short report: herpes–like DNA sequences in African–endemic and acquired immunodeficiency syndrome–associated Kaposi's sarcoma. Eto H, et al. **Am J Trop Med Hyg** 1996 Oct;55(4):405–6

Cholestasis in patients with acquired immunodeficiency syndrome: a surgeon's perspective. Liu KJ, et al. **Am Surg** 1997 Jun;63(6):519–24 (59 ref.)

AIDS–related bone marrow lesions––myelodysplastic features or predominant inflammatory–reactive changes (HIV–myelopathy)? A comparative morphometric study by immunohistochemistry with special emphasis on apoptosis and PCNA–labeling. Thiele J, et al. **Anal Cell Pathol** 1996 Aug;11(3):141–57

Abnormal lung cytokine synthesis by immunodeficient T cells in murine AIDS–associated interstitial pneumonitis. Cohen D, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:47–58

Accumulation of beta–amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities. Giometto B, et al. **Ann Neurol** 1997 Jul; 42(1):34–40

Peripheral neuropathy in human immunodeficiency virus–infected patients with the diffuse infiltrative lymphocytosis syndrome. Moulignier A, et al. **Ann Neurol** 1997 Apr;41(4):438–45

Interleukin–4 in the treatment of AIDS–related Kaposi's sarcoma. Tulpule A, et al. **Ann Oncol** 1997 Jan;8(1):79–83

Kaposi's sarcoma of the larynx. Schiff NF, et al. **Ann Otol Rhinol Laryngol** 1997 Jul;106(7 Pt 1):563–7 (18 ref.)

Hyperglycemia induced by megestrol acetate in a patient with AIDS. Gonzalez Del Valle L, et al. **Ann Pharmacother** 1996 Oct;30(10):1113–4

Hypersensitivity anaphylactoid reaction to pefloxacin in a patient with AIDS. al–Hedaithy MA, et al. **Ann Pharmacother** 1996 Jun;30(6):612–4

Overview of the management of AIDS–related Kaposi's sarcoma. Morris AK, et al. **Ann Pharmacother** 1996 Oct; 30(10):1150–63 (81 ref.)

The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Strang P. **Anticancer Res** 1997 Jan–Feb;17(1B):657–62 (36 ref.)

Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Barchiesi F, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1317–20

Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients. Dautzenberg B, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1722–5

Treatment of gastrointestinal cytomegalovirus infection with twice–daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. Dieterich DT, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1226–30

High incidence and aggressive growth of non–AIDS–defining cancers among AIDS patients in Oslo. Goplen AK, et al. **APMIS** 1996 Oct;104(10):729–33

Intraepidermal neutrophilic IgA dermatosis in a patient with advanced human immunodeficiency virus infection [letter] Muldrow ME, et al. **Arch Dermatol** 1997 May;133(5):667–8

Detection of herpesvirus–like DNA in HIV–associated and classical Kaposi's sarcoma. Simon M, et al. **Arch Dermatol Res** 1996 Jun;288(7):402–4

Multiple myeloma in young patients [letter; comment] Kaplon MK, et al. **Arch Intern Med** 1997 Feb 10;157(3):361 . Comment on: Arch Intern Med 1996 Jul 8;156(13):1463–8.

Carcinoid tumor in the appendix in a patient with acquired immunodeficiency syndrome [letter] Warner D, et al. **Arch Intern Med** 1997 Sep 22;157(17):2016

Nodal radiotherapy in refractory tuberculosis in an AIDS patient. Ruiz–Argüelles GJ, et al. **Arch Med Res** 1996 Spring;27(1):93–5

Tuberculous meningitis. Clinical characteristics and comparison with cryptococcal meningitis in patients with human immunodeficiency virus infection. Sánchez–Portocarrero J, et al. **Arch Neurol** 1996 Jul; 53(7):671–6

Acquired immunodeficiency syndrome and the eye [letter] Brein KR. **Arch Ophthalmol** 1997 Feb;115(2):292–3

Acquired trichomegaly associated with acquired immunodeficiency syndrome [letter] Graham DA, et al. **Arch Ophthalmol** 1997 Apr;115(4):557–8

Central nervous system Mycobacterium avium complex infection [letter; comment] Baksh FK, et al. **Arch Pathol Lab Med** 1996 Jul;120(7):614–5. Comment on: Arch Pathol Lab Med 1995 Sep;119(9):836–9.

Primary adrenal leiomyosarcoma in acquired immunodeficiency syndrome [letter; comment] Dugan MC. **Arch Pathol Lab Med** 1996 Sep;120(9):797–8. Comment on: Arch Pathol Lab Med 1995 Dec;119(12):1164–7.

Liaison psychiatry in an HIV/AIDS unit. Judd FK, et al. **Aust N Z J Psychiatry** 1997 Jun;31(3):391–7

Malignant tumors and AIDS. Nasti G, et al. **Biomed Pharmacother** 1997;51(6–7):243–51 (78 ref.)

Non–Hodgkin's lymphoma associated with the acquired immunodeficiency syndrome. Cáceres W. **Bol Asoc Med P R** 1995 Oct–Dec;87(10–12):158–61

Trends of Kaposi's sarcoma at AIDS diagnosis in Europe and the United States, 1987–94. Franceschi S, et al. **Br J Cancer** 1997;76(1):114–7

Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa. Sitas F, et al. **Br J Cancer** 1997;75(11):1704–7

DNA diploidy in AIDS–related and steroid–induced Kaposi's sarcoma [letter; comment] Simonart T, et al. **Br J Dermatol** 1997 May;136(5):804. Comment on: Br J Dermatol 1995 Apr;132(4):548–50.

Revisiting the psychological aspects of AIDS [letter; comment] Catalán J. **Br J Hosp Med** 1996 May 1–14; 55(9):594. Comment on: Br J Hosp Med 1996 Feb 21–Mar 5;55(4):158–9.

Retinal detachment in AIDS: long–term results after repair with silicone oil [see comments] Irvine AR, et al. **Br J Ophthalmol** 1997 Mar;81(3):180–3. Comment in: Br J Ophthalmol 1997 Mar;81(3):177–8.

Management of varicella zoster virus retinitis in AIDS. Moorthy RS, et al. **Br J Ophthalmol** 1997 Mar;81(3):189–94

CT appearances of intrathoracic Kaposi's sarcoma in patients with AIDS. Traill ZC, et al. **Br J Radiol** 1996 Dec; 69(828):1104–7

White matter disease and dementia. Rao SM. **Brain Cogn** 1996 Jul;31(2):250–68 (161 ref.)

Intracranial hypertension and cryptococcal meningitis in a girl with AIDS. Laverda AM, et al. **Brain Dev** 1996 Jul–Aug;18(4):330–1

Performance status and age as independent predictors of survival among AIDS patients with primary CNS lymphoma: a multivariate analysis of a multi–institutional experience. Corn BW, et al. **Cancer J Sci Am** 1997 Jan–Feb; 3(1):52–6

Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Goldman CK, et al.

Cancer Res 1997 Apr 15;57(8):1447–51

A man with AIDS experiences near–syncope. **Chest** 1997 Feb;111(2):501–2

Cytomegalovirus appendicitis in a patient with acquired immunodeficiency syndrome: a case report. Tarng YW, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Jul; 60(1):48–51

Pericardial effusion and AIDS [letter; comment] Blanchard DG. **Circulation** 1996 Nov 1;94(9):2312. Comment on: Circulation 1995 Dec 1;92(11):3229–34.

Pericardial effusion in AIDS [letter] Cegielski P, et al. **Circulation** 1997 Sep 16;96(6):2080–1

Overview of pulmonary complications. Rosen MJ. **Clin Chest Med** 1996 Dec;17(4):621–31 (79 ref.)

Cutaneous cryptococcosis and Kaposi's sarcoma occurring in the same lesions in a patient with the acquired immunodeficiency syndrome. Glassman SJ, et al. **Clin Exp Dermatol** 1995 Nov;20(6):480–6

HIV infection in a male patient with systemic lupus erythematosus. Cimmino MA, et al. **Clin Exp Rheumatol** 1996 May–Jun;14(3):317–20

Rhinocerebral mucormycosis in a patient with AIDS: a complication of diabetic ketoacidosis following pentamidine therapy. Abril V, et al. **Clin Infect Dis** 1996 Oct;23(4):845–6

Pulmonary gangrene secondary to pneumococcal pneumonia in a patient with AIDS. Collazos J, et al. **Clin Infect Dis** 1997 Feb;24(2):268–9

Serum cryptococcal antigen in patients with AIDS [editorial] Feldmesser M, et al. **Clin Infect Dis** 1996 Oct;23(4):827–30

Immunologically confirmed disseminated, asymptomatic Encephalitozoon cuniculi infection of the gastrointestinal tract in a patient with AIDS. Franzen C, et al. **Clin Infect Dis** 1995 Dec;21(6):1480–4

Herpes simplex esophagitis in patients with AIDS: report of 34 cases. The Cooperative Study Group on Herpetic Esophagitis in HIV Infection. Généreau T, et al. **Clin Infect Dis** 1996 Jun;22(6):926–31

Dementia and pancytopenia in a patient who died of AIDS within one year of primary human immunodeficiency virus infection [see comments] Holland DJ, et al. **Clin Infect Dis** 1996 Jun;22(6):1121–2. Comment in: Clin Infect Dis 1997 Feb;24(2):282–3.

Lactobacillemia in three patients with AIDS. Horwitch CA, et al. **Clin Infect Dis** 1995 Dec;21(6):1460–2

Bilateral staphylococcal axillary lymphadenitis in a man with AIDS. Kaur B, et al. **Clin Infect Dis** 1996 Oct;23(4):840–1

Disseminated Mycobacterium simiae infection in a patient with AIDS: clinical features and treatment. Koeck JL, et al. **Clin Infect Dis** 1996 Oct;23(4):832–3 (7 ref.)

Cutaneous miliary tuberculosis in the AIDS era: case report and review. Libraty DH, et al. **Clin Infect Dis** 1996 Oct; 23(4):706–10 (28 ref.)

Isolated detection of cryptococcal polysaccharide antigen in cerebrospinal fluid samples from patients with AIDS. Manfredi R, et al. **Clin Infect Dis** 1996 Oct;23(4):849–50

Cutaneous Mycobacterium avium complex infection at an intramuscular injection site in a patient with AIDS. Meadows JR, et al. **Clin Infect Dis** 1997 Jun;24(6):1273–4

Cerebral lesions in two patients with AIDS: the possible role of Mycobacterium kansasii [letter; comment] Monno L, et al. **Clin Infect Dis** 1996 Jun;22(6):1130–1. Comment on: Clin Infect Dis 1995 Jul;21(1):77–85.

Paracoccidioidomycosis and AIDS [letter; comment] Nishioka S de A. **Clin Infect Dis** 1996 Jun;22(6):1132–3. Comment on: Clin Infect Dis 1995 Nov;21(5):1275–81.

Polyarthritis caused by Leishmania in a patient with AIDS. Perelló–Roso A, et al. **Clin Infect Dis** 1996 Jun;22(6):1113–4

Acalculous cholecystitis and microsporidiosis in a patient with AIDS [letter; comment] Ramón–García G, et al. **Clin Infect Dis** 1996 Sep;23(3):664. Comment on: Clin Infect Dis 1996 Jan;22(1):195–6.

Dermonodular and visceral leishmaniasis due to Leishmania infantum with a new isoenzyme pattern: report of a case involving a patient with AIDS [see comments] Scaglia M, et al. **Clin Infect Dis** 1996 Feb;22(2):376–7. Comment in: Clin Infect Dis 1997 Jun;24(6):1283–4.

Photo quiz. AIDS cholangiography or AIDS sclerosing cholangitis. Singh N, et al. **Clin Infect Dis** 1996 Sep; 23(3):481, 623

Unusual pigmentation in patients with AIDS who are receiving rifabutin for bacteremia due to Mycobacterium avium/Mycobacterium intracellulare complex. Smith JF, et al. **Clin Infect Dis** 1995 Dec;21(6):1515–6

Noncandidal fungal peritonitis in patients with AIDS: report of three cases and review. Spindel SJ, et al. **Clin Infect Dis** 1997 Feb;24(2):279–80 (10 ref.)

Pulmonary cryptococcosis presenting as pneumothorax in a patient with AIDS. Torre D, et al. **Clin Infect Dis** 1995 Dec;21(6):1524–5

Pneumonia and bacteremia due to Mycobacterium celatum masquerading as Mycobacterium xenopi in patients with AIDS: an underdiagnosed problem? Zurawski CA, et al. **Clin Infect Dis** 1997 Feb;24(2):140–3

Kaposi's sarcoma in the cerebellum of a patient with AIDS. Büttner A, et al. **Clin Neuropathol** 1997 Jul–Aug; 16(4):185–9

Augmentation of leukocyte count with G–CSF in a patient with neutropenia before In–111 WBC scintigraphy. Lin S, et al. **Clin Nucl Med** 1996 Jul;21(7):544–6

What's new in AIDS related malignancies? A report from the XI International Conference on AIDS, Vancouver, 7–12 July 1996. Harrison M, et al. **Clin Oncol (R Coll Radiol)** 1996;8(5):336–7

Population pharmacokinetics and pharmacodynamics of pegylated–liposomal doxorubicin in patients with AIDS–related Kaposi's sarcoma. Amantea MA, et al. **Clin Pharmacol Ther** 1997 Mar;61(3):301–11

Adverse reactions to trimethoprim–sulfamethoxazole. Lee BL. **Clin Rev Allergy Immunol** 1996–97 Winter;14(4):451–5

Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Murray PA, et al. **Clin Ther** 1997 May–Jun;19(3):471–80

Prevalence of axis I disorders in an AIDS cohort: a cross–sectional, controlled study. Rabkin JG, et al. **Compr Psychiatry** 1997 May–Jun;38(3):146–54

Ocular flora of patients with AIDS compared with those of HIV–negative patients. Gritz DC, et al. **Cornea** 1997 Jul;16(4):400–5

Herpes zoster peripheral ulcerative keratitis in patients with the acquired immunodeficiency syndrome. Neves RA, et al. **Cornea** 1996 Sep;15(5):446–50

Acquired immunodeficiency syndrome and ocular calcification. Pecorella I, et al. **Cornea** 1996 May; 15(3):305–11

Presumed bilateral herpes zoster ophthalmicus in an AIDS patient: a case report. Yau TH, et al. **Cornea** 1996 Nov; 15(6):633–4

Adoptive CD8+ T–cell immunotherapy of AIDS patients with Kaposi's sarcoma. Pataca R, et al. **Crit Rev Oncog** 1995;6(3–6):179–234 (685 ref.)

Pleural disease in patients with AIDS. Hamm H, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):315–8 (22 ref.)

Rheumatic aspects of acquired immunodeficiency syndrome. Itescu S. **Curr Opin Rheumatol** 1996 Jul;8(4):346–53 (61 ref.)

Cardiovascular involvement in AIDS. Michaels AD, et al. **Curr Probl Cardiol** 1997 Mar;22(3):109–48 (213 ref.)

AIDS–associated cerebral toxoplasmosis: an update on diagnosis and treatment. Ammassari A, et al. **Curr Top Microbiol Immunol** 1996;219:209–22 (63 ref.)

Adrenal insufficiency, recurrent bacteremia, and disseminated abscesses caused by Nocardia asteroides in a patient with acquired immunodeficiency syndrome. Arabi Y, et al. **Diagn Microbiol Infect Dis** 1996 Jan;24(1):47–51

Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients. Barchiesi F, et al. **Diagn Microbiol Infect Dis** 1995 Nov;23(3):99–103

Persistent diarrhea caused by Isospora belli: therapeutic response to pyrimethamine and sulfadiazine. Ebrahimzadeh A, et al. **Diagn Microbiol Infect Dis** 1996 Oct;26(2):87–9

Case report: a rare case of chylous ascites from Mycobacterium avium intracellulare in a patient with AIDS: review of the literature. Rollhauser C, et al. **Dig Dis Sci** 1996 Dec;41(12):2499–501 (21 ref.)

Polyethylene glycol–liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS–related Kaposi's sarcoma. Coukell AJ, et al. **Drugs** 1997 Mar; 53(3):520–38 (68 ref.)

Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma. Voltchek IV, et al. **Drugs Exp Clin Res** 1996;22(3–5):283–6

Peripheral neuropathy in AIDS patients at Kenyatta National Hospital. Mbuya SO, et al. **East Afr Med J** 1996 Aug; 73(8):538–40

Epidemic zoster and AIDS [letter] Morens DM, et al. **Emerg Infect Dis** 1996 Oct–Dec;2(4):361–2

Pulmonary hypertension associated with thrombotic thrombocytopaenic purpura in AIDS patients [letter] Monsuez JJ, et al. **Eur Heart J** 1997 Jun;18(6):1036–7

Lactobacillus casei infection in an AIDS patient [letter] Abgrall S, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb; 16(2):180–2 (7 ref.)

Detection of Aspergillus DNA in bronchoalveolar lavage fluid of AIDS patients by the polymerase chain reaction [letter] Bart–Delabesse E, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):24–5

Clinical diagnosis of mycobacterial diseases versus autopsy findings in 350 patients with AIDS. d'Arminio Monforte A, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jun; 15(6):453–8

Detection and identification of Mycobacterium avium in the blood of AIDS patients by the polymerase chain reaction. De Francesco MA, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jul;15(7):551–5

Thrombotic microangiopathy related to infection in an HIV–positive patient [letter] Mayo J, et al. **Eur J Clin Microbiol Infect Dis** 1996 Mar;15(3):254–6 (14 ref.)

Pleural and peritoneal leishmaniasis in an AIDS patient. Muñoz–Rodríguez FJ, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):246–8

Use of specialised isolation media for recognition and identification of Candida dubliniensis isolates from HIV–infected patients. Schoofs A, et al. **Eur J Clin Microbiol Infect Dis** 1997 Apr;16(4):296–300

Systemic Penicillium marneffei infection in a German AIDS patient [letter] Sobottka I, et al. **Eur J Clin Microbiol Infect Dis** 1996 Mar;15(3):256–9

AIDS related neoplasms in Genoa, Italy. Gabutti G, et al. **Eur J Epidemiol** 1995 Dec;11(6):609–14

Unusual presentation of a tuberculous peritonitis in a patient with concomitant AIDS and liver cirrhosis. Turner L, et al. **Eur J Gastroenterol Hepatol** 1996 Oct;8(10):1021–2

Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. Ventura G, et al. **Eur J Gastroenterol Hepatol** 1997 Mar;9(3):307–10 (18 ref.)

Rapidly progressive squamous cell carcinoma of the cervix in a patient with acquired immunodeficiency syndrome: case report. Saccucci P, et al. **Eur J Gynaecol Oncol** 1996; 17(4):306–8

Substitution of testosterone in a HIV–1 positive patient with hypogonadism and Wasting–syndrome led to a reduced rate of apoptosis. Klein SA, et al. **Eur J Med Res** 1997 Jan; 2(1):30–2

Beta–human choriogonadotropin therapy and HIV–related Kaposi's sarcoma. Witzke O, et al. **Eur J Med Res** 1997 Apr 21;2(4):155–8

Treatment of clinically resistant cytomegalovirus retinitis in AIDS patients: combination of intravenous ganciclovir and intravitreal foscarnet. Pivetti–Pezzi P, et al. **Eur J Ophthalmol** 1995 Oct–Dec;5(4):199–203

CNS involvement in AIDS: spectrum of CT and MR findings. Thurnher MM, et al. **Eur Radiol** 1997;7(7):1091–7

The pancreas in AIDS. Cappell MS. **Gastroenterol Clin North Am** 1997 Jun;26(2):337–65 (267 ref.)

Diarrheal diseases associated with HIV infection. Lew EA, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):259–90 (189 ref.)

Gallbladder and biliary tract disease in AIDS. Nash JA, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):323–35 (40 ref.)

Oral and esophageal disorders. Noyer CM, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):241–57 (99 ref.)

Pancreatic ductal changes in HIV–infected patients. Barthet M, et al. **Gastrointest Endosc** 1997 Jan;45(1):59–63

Thalidomide treatment for idiopathic esophageal ulcers in patients with HIV. Bellomo A, et al. **Gastrointest Endosc** 1996 Dec;44(6):729–31

Biliary fistula in a patient with HIV cholangiopathy. Cacciarelli AG, et al. **Gastrointest Endosc** 1996 Sep; 44(3):345–8

Prospective evaluation of biopsy number for the diagnosis of viral esophagitis in patients with HIV infection and esophageal ulcer. Wilcox CM, et al. **Gastrointest Endosc** 1996 Nov;44(5):587–93

Pneumothorax in AIDS: case reviews and proposed clinical management. Asboe D, et al. **Genitourin Med** 1996 Aug; 72(4):258–60

Multidrug resistant tuberculosis: practical lesson for HIV units [letter; comment] Coker R. **Genitourin Med** 1997 Feb; 73(1):76–7. Comment on: Genitourin Med 1996 Oct;72(5):313–4.

The spectrum of eye disease in children with AIDS due to vertically transmitted HIV disease: clinical findings, virology and recommendations for surveillance. Hammond CJ, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Mar; 235(3):125–9

Investigation of chronic diarrhoea in acquired immunodeficiency syndrome. A prospective study of 155 patients. Blanshard C, et al. **Gut** 1996 Dec;39(96):824–32

A cervical teratoma with invasive squamous cell carcinoma in an HIV–infected patient: a case report. Bell MC, et al. **Gynecol Oncol** 1996 Mar;60(3):475–9

Invasive vulvar carcinoma in two women infected with human immunodeficiency virus. Wright TC, et al. **Gynecol Oncol** 1996 Mar;60(3):500–3

The epidemiology of AIDS––related neoplasms. Biggar RJ, et al. **Hematol Oncol Clin North Am** 1996 Oct; 10(5):997–1010 (78 ref.)

Clinical presentation and natural history of AIDS––related Kaposi's sarcoma. Dezube BJ. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1023–9 (31 ref.)

AIDS–related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approaches. Karp JE, et al. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1031–49 (132 ref.)

Chemotherapy of AIDS––related Kaposi's sarcoma. Lee FC, et al. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1051–68 (87 ref.)

Pathogenesis of AIDS––related Kaposi's sarcoma. Evidence of a viral etiology. Miles SA. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1011–21 (80 ref.)

Non–AIDS–defining cancers. Remick SC. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1203–13 (110 ref.)

The role of radiation therapy in the management of HIV–related Kaposi's sarcoma. Swift PS. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1069–80 (71 ref.)

Disseminated microsporidiosis in a patient with acquired immunodeficiency syndrome. Cowley GP, et al. **Histopathology** 1997 Apr;30(4):386–9

Bilateral movement disorder in a patient with AIDS. Andavolu MV. **Hosp Pract (Off Ed)** 1997 Jan 15; 32(1):175–6

NeuroAIDS: diagnosis and management. McArthur JC. **Hosp Pract (Off Ed)** 1997 Aug 15;32(8):73–4, 77–9, 84 passim

Depletion of stromal and intraepithelial antigen-presenting cells in cervical neoplasia in human immunodeficiency virus infection. Rosini S, et al. **Hum Pathol** 1996 Aug;27(8):834–8

Mathematical modelling of the spread of HIV/AIDS amongst injecting drug users. Greenhalgh D, et al. **IMA J Math Appl Med Biol** 1997 Mar;14(1):11–38 (42 ref.)

Gender differences in early suspicion of tuberculosis in hospitalized, high-risk patients during 4 epidemic years, 1987 to 1990. Cegielski JP, et al. **Infect Control Hosp Epidemiol** 1997 Apr;18(4):237–43

Respiratory cryptosporidiosis: case series and review of the literature. Clavel A, et al. **Infection** 1996 Sep–Oct; 24(5):341–6 (47 ref.)

Respiratory syncytial virus pneumonia in an AIDS patient. van der Ven AJ, et al. **Infection** 1996 Sep–Oct;24(5):375–7

Specific pattern of circulating endothelial adhesion molecules in HIV-associated Kaposi's sarcoma. Becker K, et al. **Int Arch Allergy Immunol** 1997 Aug;113(4):512–5

The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth. Murakami-Mori K, et al. **Int Immunol** 1996 Apr; 8(4):595–602

Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group [published erratum appears in Int J Cancer 1997 Mar 17;70(6):727] Biggar RJ, et al. **Int J Cancer** 1996 Dec 11;68(6):754–8

Expression of HHV-8 latency-associated T0.7 RNA in spindle cells and endothelial cells of AIDS-associated, classical and African Kaposi's sarcoma. Stürzl M, et al. **Int J Cancer** 1997 Jul 3;72(1):68–71

Reiter's syndrome-like pattern in AIDS-associated psoriasiform dermatitis. Romaní J, et al. **Int J Dermatol** 1996 Jul;35(7):484–8

Immunohistochemical analysis of procathepsin L and cathepsin B in cutaneous Kaposi's sarcoma. Thewes M, et al. **Int J Dermatol** 1997 Feb;36(2):100–3

Cervical intra-epithelial neoplasia in HIV-positive women and women with AIDS. Carreras R, et al. **Int J Gynaecol Obstet** 1997 Sep;58(3):325–6

AIDS in pregnancy among Indian tribal women. Kumar RM, et al. **Int J Gynaecol Obstet** 1997 Jan;56(1):59–60

Palliation of AIDS-related primary lymphoma of the brain: observations from a multi-institutional database. Corn BW, et al. **Int J Radiat Oncol Biol Phys** 1997 Jun 1;38(3):601–5

The radiological manifestations of the acquired immunodeficiency syndrome: Part 2. Banerjee AK. **Int J STD AIDS** 1996 Aug–Sep;7(5):310–4

Drug-induced oesophageal ulceration in a patient with acquired immunodeficiency syndrome. Craig JM, et al. **Int J STD AIDS** 1996 Aug–Sep;7(5):370–1

An evaluation of percutaneous endoscopic gastrostomy feeding in AIDS. Dowling S, et al. **Int J STD AIDS** 1996 Mar–Apr;7(2):106–9

The ocular complications of HIV and AIDS. Greenwood J, et al. **Int J STD AIDS** 1997 Jun;8(6):358–65; quiz 365–7 (38 ref.)

Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Heald AE, et al. **Int J STD AIDS** 1996 Aug–Sep;7(5):337–46

Lack of behavioural risk factors for squamous intraepithelial lesions (SIL) in HIV-infected women. Heard I, et al. **Int J STD AIDS** 1997 Jun;8(6):388–92

Clinical features, outcome and survival from cerebral toxoplasmosis in Edinburgh AIDS patients. Laing RB, et al. **Int J STD AIDS** 1996 Jul;7(4):258–64

Association of sexually transmitted diseases and infection with the human immunodeficiency virus: biological cofactors and markers of behavioural interventions. Quinn TC. **Int J STD AIDS** 1996;7 Suppl 2:17–24 (81 ref.)

Cerebral abscesses in a patient with AIDS caused by methicillin-resistant Staphylococcus aureus (MRSA). Smith NP, et al. **Int J STD AIDS** 1997 Jul;8(7):459–60

Management and treatment of Kaposi's sarcoma in AIDS. The Jefferiss Wing Therapeutics and Protocols Group. Tomlinson DR, et al. **Int J STD AIDS** 1996 Nov–Dec; 7(7):466–70 (10 ref.)

Central venous catheter infections in AIDS patients with cytomegalovirus. Ustianowski AP, et al. **Int J STD AIDS** 1996 Aug–Sep;7(5):372–3

Report of a case of aggressive cytomegalovirus retinitis in an infant with AIDS. Tejada P, et al. **Int Ophthalmol** 1996–97;20(6):333–7

Severe hypokalemia causing rhabdomyolysis and quadriplegia in a patient with AIDS [letter] Joly LM, et al. **Intensive Care Med** 1997 May;23(5):596–7

Clinical presentation of pulmonary tuberculosis associated with acquired immunodeficiency syndrome in metropolitan Tokyo. Kanazawa M, et al. **Intern Med** 1996 Dec; 35(12):946–52

Neurologic manifestations in human immunodeficiency virus infection/acquired immunodeficiency syndrome [editorial; comment] Kimura S. **Intern Med** 1997 Mar;36(3):160–1. Comment on: Intern Med 1997 Mar;36(3):175–8.

Intestinal microsporidiosis in Italian individuals with AIDS. Voglino MC, et al. **Ital J Gastroenterol** 1996 Sep; 28(7):381–6

A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. Bush CE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):23–6

Variant A human herpesvirus six as a cofactor in the pathogenesis of AIDS [letter] Carrigan DR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):97–8

Treatment of severe diarrhea caused by Cryptosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS. Greenberg PD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 1;13(4):348–54

Mycobacterial acute lumbosacral polyradiculopathy as the initial manifestation of AIDS [letter] Masjuan J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jun 1;15(2):175

AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study Group. Ragni MV, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):78–86

Coinfection of GB virus C with HIV-1 in Japan [letter] Shibayama T, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Aug 1;15(4):319–20

Influence of HIV disease on serum anti-HCV antibody titers: a study of intravenous drug users [letter] Sorbi D, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Nov 1;13(3):295–6

Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS. Sanwo M, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1112–5

Unusual Microsporum canis infections in adult HIV patients. Bournerias I, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 2):808–10

Papular mucinosis associated with AIDS: response to isotretinoin. Yen A, et al. **J Am Acad Dermatol** 1997 Jul; 37(1):127–8

Treatment of AIDS and HIV-related conditions--1997. Goldschmidt RH, et al. **J Am Board Fam Pract** 1997 Mar–Apr;10(2):144–67 (50 ref.)

Trimethoprim-sulfamethoxazole-induced sepsis-like syndrome in a patient with AIDS. O'Kane EB, et al. **J Am Board Fam Pract** 1996 Nov–Dec;9(6):448–50

Appendicitis in patients with acquired immunodeficiency syndrome. Flum DR, et al. **J Am Coll Surg** 1997 May; 184(5):481–6

Presumed ocular tuberculosis in an AIDS patient. Welton TH, et al. **J Am Optom Assoc** 1996 Jun;67(6):350–7

Herpesviruses and AIDS. Griffiths PD. **J Antimicrob Chemother** 1996 May;37 Suppl B:87–95 (48 ref.)

Malnutrition associated with HIV/AIDS. Part One: Definition and scope, epidemiology, and pathophysiology. Casey KM. **J Assoc Nurses AIDS Care** 1997 May–Jun; 8(3):24–32 (52 ref.)

Is it better to inhale? An examination of the medical use of marijuana controversy in the United States [editorial] Corless IB, et al. **J Assoc Nurses AIDS Care** 1997 May–Jun; 8(3):17–8

Visceral manifestation of AIDS. Lyonnet D, et al. **J Belge Radiol** 1996 Dec;79(6):272

Experience with adriamycin, bleomycin, vincristine (ABV) palliative chemotherapy in advanced AIDS-related Kaposi's sarcoma. Paparizos VA, et al. **J Chemother** 1996 Oct;8(5):403–6

Atypical mycobacterium infections in AIDS: clinical and microbiological features. Pasticci MB, et al. **J Chemother** 1995 Nov;7 Suppl 4:187–9

Post-dural puncture headache and epidural blood patch in an AIDS patient [letter] Parris WC. **J Clin Anesth** 1997 Feb;9(1):87–8

Symptom-specific use of upper gastrointestinal endoscopy in human immunodeficiency virus-infected patients yields high dividends. Bashir RM, et al. **J Clin Gastroenterol** 1996 Dec;23(4):292–8

Celiac plexus block as treatment for refractory pain related to sclerosing cholangitis in AIDS patients. Collazos J, et al. **J Clin Gastroenterol** 1996 Jul;23(1):47–9

Human immunodeficiency virus infection, the acquired immunodeficiency syndrome, and inflammatory bowel disease. Yoshida EM, et al. **J Clin Gastroenterol** 1996 Jul; 23(1):24–8

Human chorionic gonadotropin hormone prevents wasting syndrome and death in HIV-1 transgenic mice. De SK, et al. **J Clin Invest** 1997 Apr 1;99(7):1484–91

Low levels of LTB4 in cerebrospinal fluid of AIDS patients with cryptococcal meningitis. Froldi M, et al. **J Clin Lab Immunol** 1995;47(1):41–7

Mycobacterium malmoense bacteremia in two AIDS patients. Fakih M, et al. **J Clin Microbiol** 1996 Mar;34(3):731–3

Invasive amoebiasis in two patients with AIDS and cytomegalovirus colitis. Fätkenheuer G, et al. **J Clin Microbiol** 1997 Aug;35(8):2168–9

HEp-2 cell adherence patterns, serotyping, and DNA analysis of Escherichia coli isolates from eight patients with AIDS and chronic diarrhea. Polotsky Y, et al. **J Clin Microbiol** 1997 Aug;35(8):1952–8

AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. Krown SE, et al. **J Clin Oncol** 1997 Sep;15(9):3085–92

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. Northfelt DW, et al. **J Clin Oncol** 1997 Feb; 15(2):653–9

Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy. Schwartsmann G, et al. **J Clin Oncol** 1997 May;15(5):2118–24

AIDS-related Kaposi's sarcoma. van den Brink MR, et al. **J Clin Oncol** 1997 Mar;15(3):1283–4

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. Northfelt DW, et al. **J Clin Pharmacol** 1996 Jan;36(1):55–63

A pentamidine-treated acquired immunodeficiency syndrome patient associated with sudden onset diabetes mellitus and high tumor necrosis factor alpha level. Ubukata E, et al. **J Diabetes Complications** 1997 Jul–Aug;11(4):256–8

Identification of a new Nosema-like microsporidian associated with myositis in an AIDS patient. Cali A, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):108S

Clinical features of tuberculosis associated with HIV infection in Taiwan. Hsieh SM, et al. **J Formos Med Assoc** 1996 Dec;95(12):923–8

Etiology of lymphadenopathy in patients with AIDS in Taiwan. Hung CC, et al. **J Formos Med Assoc** 1996 Feb; 95(2):119–25

Hospital-acquired infections in patients with HIV/AIDS [letter] Rogues AM, et al. **J Hosp Infect** 1996 Dec; 34(4):333–6

Enhancement of gp130-mediated tyrosine phosphorylation of STAT3 and its DNA-binding activity in dexamethasone-treated AIDS-associated Kaposi's sarcoma cells: selective synergy between dexamethasone and gp130-related growth factors in Kaposi's sarcoma cell proliferation. Murakami-Mori K, et al. **J Immunol** 1997 Jun 1;158(11):5518–26

Renal invasive aspergilloma: unusual infection in AIDS. Fiteni I, et al. **J Infect** 1996 Jul;33(1):61–3

Rotavirus infection in AIDS-associated diarrhoea [letter] Mura MS, et al. **J Infect** 1996 Jul;33(1):66–7

A malignant astrocytoma in a patient with AIDS: a possible association between astrocytomas and HIV infection. Neal JW, et al. **J Infect** 1996 Nov;33(3):159–62 (24 ref.)

Human T cell lymphotropic virus type II and human immunodeficiency virus type 1 disease progression [letter; comment] Harrison LH, et al. **J Infect Dis** 1997 Jul; 176(1):308–9. Comment on: J Infect Dis 1996 Aug;174(2):309–17.

A role for apoptosis in the pathogenesis of AIDS-related idiopathic esophageal ulcers. Houghton JM, et al. **J Infect Dis** 1997 May;175(5):1216–9

The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men [see comments] Sabin CA, et al. **J Infect Dis** 1997 Jan;175(1):164–8. Comment in: J Infect Dis 1997 Aug;176(2):542–3.

Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. Shinkai M, et al. **J Infect Dis** 1997 Feb;175(2):302–8

Continuous infusion etoposide in advanced AIDS-related kaposi sarcoma. Remick SC, et al. **J Infus Chemother** 1996 Spring;6(2):92–6

Mass in the post nasal space and acquired immune deficiency syndrome. Drake-Lee A, et al. **J Laryngol Otol** 1996 Aug; 110(8):787–8

Laryngeal Kaposi's sarcoma in patients with AIDS. Mochloulis G, et al. **J Laryngol Otol** 1996 Nov; 110(11):1034–7

Differentiation of strains of Mycoplasma fermentans from various sources by pyrolysis mass spectrometry. Hannan PC, et al. **J Med Microbiol** 1997 Apr;46(4):348–53

Comparison of magnetic resonance imaging with neuropathological findings in the diagnosis of HIV and CMV associated CNS disease in AIDS. Miller RF, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):346–51

Intracranial hypertension and HIV associated meningoradiculitis. Prevett MC, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):407–9

HIV related vasculitic mononeuropathy multiplex: a role for IVIg? [letter] Schifitto G, et al. **J Neurol Neurosurg Psychiatry** 1997 Aug;63(2):255–6

AIDS-associated vacuolar myelopathy and tumor necrosis factor-alpha (TNF alpha). Tan SV, et al. **J Neurol Sci** 1996 Jun;138(1–2):134–44

Primary T-cell lymphoma of the brain in acquired immunodeficiency syndrome: case report. Bindal AK, et al. **J Neurooncol** 1997 Feb;31(3):267–71

The neuropathology of HIV-infected African children in Abidjan, Côte d'Ivoire. Bell JE, et al. **J Neuropathol Exp Neurol** 1997 Jun;56(6):686–92

Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. Berger JR, et al. **J Neurovirol** 1995 Mar;1(1):5–18 (107 ref.)

NeuroAIDS, current understanding and future directions. Black RJ, et al. **J Neurovirol** 1996 Aug;2(4):230–3

CMV-infected subependymoma in the fourth ventricle of an HIV-1 infected patient. Büttner A, et al. **J Neurovirol** 1996 Jun;2(3):191–4

Evaluation of sequential thallium and gallium scans of the chest in AIDS patients. Abdel-Dayem HM, et al. **J Nucl Med** 1996 Oct;37(10):1662–7

ACQUIRED IMMUNODEFICIENCY SYNDROME

Neurobehavioral manifestations of symptomatic HIV-1 disease in children: can nutritional factors play a role? Brouwers P, et al. **J Nutr** 1996 Oct;126(10 Suppl):2651S-2662S (66 ref.)

Autopsy findings in the tongues of 20 patients with AIDS. Leonard N, et al. **J Oral Pathol Med** 1997 May;26(5):244-7

Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Beal JE, et al. **J Pain Symptom Manage** 1997 Jul;14(1):7-14

Sustained-release morphine sulfate in the management of pain associated with acquired immune deficiency syndrome. Kaplan R, et al. **J Pain Symptom Manage** 1996 Sep; 12(3):150-60

The pharmacologic management of pain and discomfort in persons with AIDS near the end of life: use of opioid analgesia in the hospice setting. Kimball LR, et al. **J Pain Symptom Manage** 1996 Feb;11(2):88-94

Western blot and immunofluorescence analysis of a human isolate of Encephalitozoon cuniculi established in culture from the urine of a patient with AIDS. Croppo GP, et al. **J Parasitol** 1997 Feb;83(1):66-9

Combination chemotherapy in the treatment of Kaposi sarcoma in a child infected with human immunodeficiency virus [letter] Mastroianni A, et al. **J Pediatr** 1997 Apr; 130(4):675

Idiopathic esophageal ulcers in a child with AIDS. Narwal S, et al. **J Pediatr Gastroenterol Nutr** 1997 Feb;24(2):211-4

Endoscopic retrograde cholangiopancreatography in children with HIV infection. Yabut B, et al. **J Pediatr Gastroenterol Nutr** 1996 Dec;23(5):624-7

Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. Singh AN, et al. **J Psychosom Res** 1997 May;42(5):489-93

Development of acquired immune deficiency syndrome in a patient with systemic lupus erythematosus [letter; comment] Fernández-Miranda C, et al. **J Rheumatol** 1996 Jul;23(7):1308. Comment on: J Rheumatol 1995 Feb;22(2):347-50.

The co-occurrence of acute rheumatic fever and AIDS. Georgescu L, et al. **J Rheumatol** 1997 Feb;24(2):404-6

Arthritis associated with HIV infection in Zimbabwe. Stein CM, et al. **J Rheumatol** 1996 Mar;23(3):506-11

Thoracoscopy in acquired immunodeficiency syndrome. Flum DR, et al. **J Thorac Cardiovasc Surg** 1997 Sep; 114(3):361-6

Renal cavernous hemangioma in a patient with the acquired immunodeficiency syndrome. Moody JA, et al. **J Urol** 1996 Nov;156(5):1759-60

Antibody to hepatitis E virus in HIV-infected individuals and AIDS patients. Balayan MS, et al. **J Viral Hepat** 1997 Jul;4(4):279-83

Human herpesvirus 8 strain variability in clinical conditions other than Kaposi's sarcoma [letter] Luppi M, et al. **J Virol** 1997 Oct;71(10):8082-3

Involvement of vascular endothelial growth factor in Kaposi's sarcoma associated with acquired immunodeficiency syndrome. Sakurada S, et al. **Jpn J Cancer Res** 1996 Nov;87(11):1143-52

Clinical experience of esophageal ulcers and esophagitis in AIDS patients. Yang MT, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Nov; 12(11):624-9

HIV infection and neoplasia [letter; comment] Petry KU. **Lancet** 1996 Nov 9;348(9037):1317; discussion 1318. Comment on: Lancet 1996 Aug 31;348(9027):587-91.

HIV infection and neoplasia [letter; comment] Piras MA, et al. **Lancet** 1996 Nov 9;348(9037):1316-7; discussion 1318. Comment on: Lancet 1996 Aug 31;348(9027):587-91.

Finger clubbing as sign of HIV infection in children [letter; comment] Smyth A, et al. **Lancet** 1997 Feb 22; 349(9051):575. Comment on: Lancet 1997 Jan 4;349(9044):31.

HIV infection of CD8 cells [letter; comment] Tiran B, et al. **Lancet** 1996 Nov 30;348(9040):1527-8. Comment on: Lancet 1996 Sep 7;348(9028):649-54.

HIV infection and neoplasia. GICAT (Italian Cooperation Group on AIDS and Tumours) [letter; comment] Vaccher E, et al. **Lancet** 1996 Nov 9;348(9037):1317-8. Comment on: Lancet 1996 Aug 31;348(9027):587-91.

Expression of interleukin-6 receptors and NF-kappa B in AIDS-related Kaposi sarcoma cell strains. Bailer RT, et al. **Lymphology** 1997 Jun;30(2):63-76

Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Coyle TE. **Med Clin North Am** 1997 Mar; 81(2):449-70 (154 ref.)

Acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Biology and management. Krown SE. **Med Clin North Am** 1997 Mar;81(2):471-94 (170 ref.)

Invasive Aspergillus sinusitis in patients with human immunodeficiency virus infection. Report of 2 cases and review. Mylonakis E, et al. **Medicine (Baltimore)** 1997 Jul; 76(4):249-55 (18 ref.)

Ascites and the acquired immunodeficiency syndrome. Report of 54 cases. Saab S, et al. **Medicine (Baltimore)** 1996 May;75(3):131-41 (76 ref.)

Evaluation of enzyme-linked immunosorbent assay for the serodiagnosis of tuberculosis in patients with AIDS in Cuba. Montoro E, et al. **Mem Inst Oswaldo Cruz** 1996 Mar-Apr;91(2):191

Use of the 2,3-diacyl-trehalose and the purified protein derivative in the serodiagnosis of tuberculosis in AIDS. Saad MH, et al. **Mem Inst Oswaldo Cruz** 1996 Jan-Feb; 91(1):97-100

Emergence of a methicillin-resistant Staphylococcus aureus clone related to the Brazilian epidemic clone III::B:A causing invasive disease among AIDS patients in a Brazilian hospital. Teixeira LA, et al. **Microb Drug Resist** 1996 Winter;2(4):393-9

Renal changes in patients with acquired immunodeficiency syndrome: a post-mortem study on an unselected population in northwestern Italy. Monga G, et al. **Mod Pathol** 1997 Mar;10(3):159-67

Pulmonary malakoplakia in acquired immunodeficiency syndrome: an ultrastructural study of morphogenesis of Michaelis-Gutmann bodies. Yuoh G, et al. **Mod Pathol** 1996 May;9(5):476-83

Digestive leishmaniasis in acquired immunodeficiency syndrome: a light and electron microscopic study of two cases. Zimmer G, et al. **Mod Pathol** 1996 Oct;9(10):966-9

Gastrointestinal histoplasmosis in a patient with acquired immune deficiency syndrome. Raza J, et al. **Mt Sinai J Med** 1996 Mar;63(2):136-40

Guillain-Barré syndrome in immunocompromised patients: a report of three patients and review of the literature. Qureshi AI, et al. **Muscle Nerve** 1997 Aug;20(8):1002-7 (44 ref.)

Analysis of myopathy in a placebo-controlled zidovudine trial. Simpson DM, et al. **Muscle Nerve** 1997 Mar; 20(3):382-5

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 4-1997. A 37-year-old man with AIDS and wheezing refractory to bronchodilator medication [clinical conference] **N Engl J Med** 1997 Jan 30;336(5):357-64

Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma [see comments] Foreman KE, et al. **N Engl J Med** 1997 Jan 16;336(3):163-71. Comment in: N Engl J Med 1997 Jan 16;336(3):214-5. Comment in: N Engl J Med 1997 Jun 19;336(25):1837-9.

The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma [see comments] [published erratum appears in N Engl J Med 1997 Feb 27;336(9):670] Gill PS, et al. **N Engl J Med** 1996 Oct 24; 335(17):1261-9. Comment in: N Engl J Med 1996 Oct 24;335(17):1309-10. Comment in: N Engl J Med 1997 Apr 17;336(16):1187; discussion 1188-9.

Intralesional human chorionic gonadotropin for Kaposi's sarcoma [letter; comment] Grulich AE, et al. **N Engl J Med** 1997 Apr 17;336(16):1187-8; discussion 1188-9. Comment on: N Engl J Med 1996 Oct 24;335(17):1309-10.

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Jacobson JM, et al. **N Engl J Med** 1997 May 22;336(21):1487-93

Absence of herpesvirus in AIDS-associated smooth-muscle tumors [letter] Jenson HB, et al. **N Engl J Med** 1996 Nov 28;335(22):1690

Kaposi's sarcoma--what's human chorionic gonadotropin got to do with it? [editorial; comment] [see comments] Krown SE. **N Engl J Med** 1996 Oct 24;335(17):1309-10. Comment on: N Engl J Med 1996 Oct 24;335(17):1261-9. Comment in: N Engl J Med 1997 Apr 17;336(16):1187; discussion 1188-9. Comment in: N Engl J Med 1997 Apr 17;336(16):1187-8; discussion 1188-9.

Acute cortical necrosis in acquired immunodeficiency syndrome (AIDS). Hertig A, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):585-7

AIDS-associated renal tuberculosis. Marques LP, et al. **Nephron** 1996;74(4):701-4

Spinal cord lesions in patients with AIDS. Quencer RM, et al. **Neuroimaging Clin N Am** 1997 May;7(2):359-73 (14 ref.)

Diagnostic imaging of infections and neoplasms affecting the spine in patients with AIDS. Thurnher MM, et al. **Neuroimaging Clin N Am** 1997 May;7(2):341-57 (86 ref.)

Intracranial mass lesions in acquired immunodeficiency syndrome: using decision analysis to determine the effectiveness of stereotactic brain biopsy. Holloway RG, et al. **Neurology** 1996 Apr;46(4):1010-5

Brainstem CMV encephalitis in AIDS: clinical case and MRI features. Pierelli F, et al. **Neurology** 1997 Feb;48(2):529-30

Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Simpson DM, et al. **Neurology** 1996 Nov;47(5):1254-9

Steatorrhea: a common manifestation in patients with HIV/AIDS. Koch J, et al. **Nutrition** 1996 Jul-Aug; 12(7-8):507-10

Pathogenesis of AIDS--related Kaposi's sarcoma. Emmanoulides C, et al. **Oncology (Huntingt)** 1996 Mar; 10(3):335-41; discussion: 342-50 (55 ref.)

Clinical Trials Referral Resource. Clinical trials in AIDS related malignancies. Feigal EG, et al. **Oncology (Huntingt)** 1997 Mar;11(3):337-8, 341

Initial experience with an eight-month sustained-release intravitreal ganciclovir implant for the treatment of CMV retinitis associated with AIDS. Duker JS, et al. **Ophthalmic Surg Lasers** 1995 Sep-Oct;26(5):442-8

Evidence for breaches of the retinal vasculature in acquired immune deficiency syndrome angiopathy. A fluorescent microsphere study. Glasgow BJ. **Ophthalmology** 1997 May; 104(5):753-60

Neuro-ophthalmic manifestations of AIDS. Woods AD, et al. **Optom Clin** 1996;5(3-4):113-52 (198 ref.)

Bilateral parotid sialolithiasis in a patient with acquired immunodeficiency syndrome and immunoglobulin G multiple myeloma. Ottaviani F, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 May;83(5):552-4

AIDS and the eye. Eller AW, et al. **Pa Med** 1996 Mar;99 Suppl:88-93 (45 ref.)

Pain in ambulatory AIDS patients. I: Pain characteristics and medical correlates. Breitbart W, et al. **Pain** 1996 Dec; 68(2-3):315-21

The undertreatment of pain in ambulatory AIDS patients. Breitbart W, et al. **Pain** 1996 May-Jun;65(2-3):243-9

Pain in ambulatory AIDS patients. II: Impact of pain on psychological functioning and quality of life. Rosenfeld B, et al. **Pain** 1996 Dec;68(2-3):323-8

The isolation of Leishmania donovani MON-18, from an AIDS patient in Portugal: possible needle transmission. Campino L, et al. **Parasite** 1994 Dec;1(4):391-2

Selected P. falciparum specific immune responses are maintained in AIDS adults in Burkina Faso. Migot F, et al. **Parasite Immunol** 1996 Jul;18(7):333-9

Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome. Chan SP, et al. **Pediatr Infect Dis J** 1996 May;15(5):443-7

Clinical manifestations of human immunodeficiency virus infection in Haitian children. Jean SS, et al. **Pediatr Infect Dis J** 1997 Jun;16(6):600-6

Disseminated Mycobacterium avium complex presenting as hematochezia in an infant with rapidly progressive acquired immunodeficiency syndrome. Keller C, et al. **Pediatr Infect Dis J** 1996 Aug;15(8):713-5

Human immunodeficiency virus type 1 infection of the heart in three infants with acquired immunodeficiency syndrome and sudden death. Kovacs A, et al. **Pediatr Infect Dis J** 1996 Sep;15(9):819-24

Disseminated histoplasmosis in a human immunodeficiency virus-infected African child. Pillay T, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):417-8

Disseminated calcification with predominant muscle and cerebral involvement in a child with acquired immunodeficiency syndrome: a case report. Liu J, et al. **Pediatr Pathol Lab Med** 1997 Jul-Aug;17(4):593-600

A newly recognized cause of wheezing: AIDS-related bronchial leiomyomas. de Chadarévian JP, et al. **Pediatr Pulmonol** 1997 Aug;24(2):106-10

Leiomyosarcoma of the kidney in an HIV-infected child. Norton KI, et al. **Pediatr Radiol** 1997 Jun;27(6):557-8

Leiomyomas of the gallbladder and splenic calcifications in an HIV-infected child. Tomà P, et al. **Pediatr Radiol** 1997 Jan;27(1):92-4

Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS. Klepser ME, et al. **Pharmacotherapy** 1996 Jul-Aug;16(4):656-62

AIDS pathology: infections and neoplasms in 55 fatal AIDS cases. A postmortem study. Walewska-Zielecka B, et al. **Pol J Pathol** 1996;47(4):163-70

CD68+ cells of monocyte/macrophage lineage in the environment of AIDS-associated and classic-sporadic Kaposi sarcoma are singly or doubly infected with human herpesviruses 7 and 6B. Kempf W, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7600-5

Central venous catheter infections in AIDS patients receiving daily home therapy for cytomegalovirus disease. Casado JL, et al. **QJM** 1996 Sep;89(9):695-9

Thoracic disease in children with AIDS. Marks MJ, et al. **Radiographics** 1996 Nov;16(6):1349-62

Granulocyte-macrophage colony-stimulating factor mouthwashes improve radiation induced mucositis in AIDS patients [letter] de la Torre A, et al. **Radiother Oncol** 1997 May;43(2):229-30

The treatment of AIDS-related cytomegalovirus disease with ganciclovir and foscarnet association. Three case reports. Manfredi R, et al. **Recenti Prog Med** 1996 Nov;87(11):545-8

Liver toxoplasmosis and acquired immunodeficiency syndrome. Mastroianni A, et al. **Recenti Prog Med** 1996 Jul-Aug;87(7-8):353-5

Fluorescein angiography in the progressive outer retinal necrosis syndrome. Walton RC, et al. **Retina** 1996; 16(5):393-8

Histoplasmosis in the Muñiz Hospital of Buenos Aires. Bava AJ. **Rev Inst Med Trop Sao Paulo** 1995 Nov-Dec; 37(6):531-5

Mycobacterium avium complex (MAC) isolated from AIDS patients and the criteria required for its implication in disease. Hadad DJ, et al. **Rev Inst Med Trop Sao Paulo** 1995 Sep-Oct;37(5):375-83 (39 ref.)

Abdominal mycobacterial infection in acquired immunodeficiency syndrome patients. Guidugli RB, et al. **Rev Paul Med** 1995 May-Jun;113(3):895-902

Tuberculous erythema nodosum in patients with human immunodeficiency virus infection [letter] Narvaez J, et al. **Rev Rhum Engl Ed** 1996 May;63(5):377

Concomitant active Crohn's disease and the acquired immunodeficiency syndrome. Christ AD, et al. **Scand J Gastroenterol** 1996 Jul;31(7):733-5

Rhodococcus equi infection in HIV-positive subjects: a retrospective analysis of 24 cases. Arlotti M, et al. **Scand J Infect Dis** 1996;28(5):463-7

Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence

of faster progression to AIDS. Sinicco A, et al. **Scand J Infect Dis** 1997;29(2):111–5

Risk factors for genital ulcerations in Kenyan sex workers. The role of human immunodeficiency virus type 1 infection. Kaul R, et al. **Sex Transm Dis** 1997 Aug; 24(7):387–92

CMV colitis masquerading as colon cancer—an unusual presentation of acquired immunodeficiency syndrome. Chow PK, et al. **Singapore Med J** 1997 Jan;38(1):32–4

AIDS-related Kaposi sarcoma involving the tarsal bones. Nguyen C, et al. **Skeletal Radiol** 1996 Jan;25(1):100–2 (9 ref.)

Mycobacterium avium complex in AIDS: who, when, where, why and how? Pozniak AL, et al. **Soc Appl Bacteriol Symp Ser** 1996;25:40S–46S (45 ref.)

Idiopathic midesophageal stricture: a new cause of dysphagia in a patient with AIDS. Shapiro BD, et al. **South Med J** 1997 Jan;90(1):80–2

AIDS and cerebrovascular disease [letter; comment] Roquer J, et al. **Stroke** 1996 Sep;27(9):1694; discussion 1695–7. Comment on: Stroke 1996 Mar;27(3):538–43.

HIV-associated stroke: report of two unusual cases [letter; comment] Zunker P, et al. **Stroke** 1996 Sep;27(9):1694–6. Comment on: Stroke 1996 Mar;27(3):538–43.

Computerized tomography and magnetic resonance guided stereotactic brain biopsy in nonimmunocompromised and AIDS patients. Nicolato A, et al. **Surg Neurol** 1997 Sep; 48(3):267–76; discussion 276–7

Acute suppurative thyroiditis and necrosis of the thyroid gland: a rare endocrine manifestation of acquired immunodeficiency syndrome. Golshan MM, et al. **Surgery** 1997 May;121(5):593–6 (12 ref.)

The relationship between plasma microparticles, protein S and anticardiolipin antibodies in patients with human immunodeficiency virus infection. Gris JC, et al. **Thromb Haemost** 1996 Jul;76(1):38–45

Splenectomy in a patients with AIDS, generalized Mycobacterium genavense infection and severe pancytopenia [letter] Delpire P, et al. **Tuber Lung Dis** 1996 Dec;77(6):569–70

Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma. Schwartsmann G, et al. **Tumori** 1996 Jul–Aug;82(4):360–3

Disseminated blastomycosis and acquired immunodeficiency syndrome: a case report and ultrastructural study. Guccion JG, et al. **Ultrastruct Pathol** 1996 Sep–Oct;20(5):429–35

[AIDS-related eosinophilic folliculitis. Efficacy of high dose topical corticotherapy] Grange F, et al. **Ann Dermatol Venereol** 1996;123(8):456–9 (Eng. Abstr.) **(Fre)**

[Bullous manifestations of Kaposi disease associated with AIDS] Perrot JL, et al. **Ann Dermatol Venereol** 1995; 122(11–12):793–5 (Eng. Abstr.) **(Fre)**

[Portal thrombosis, mesenteric infarction and anticardiolipin antibodies in a patient with AIDS (letter)] Lamaury I, et al. **Ann Med Interne (Paris)** 1996;147(5):344–5 **(Fre)**

[Endoscopic diagnosis of a biliodigestive fistula of tuberculous origin revealing acquired immunodeficiency syndrome] Paupard T, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):1055–8 (Eng. Abstr.) **(Fre)**

[Splenic infarction in a HIV-infected patient. Apropos of a case and review of the literature] Aouad K, et al. **J Chir (Paris)** 1996;133(8):392–5 (19 ref.) (Eng. Abstr.) **(Fre)**

[Ophthalmologic manifestations observed in a pediatric HIV-seropositive population] Girard B, et al. **J Fr Ophtalmol** 1997;20(1):49–60 (31 ref.) (Eng. Abstr.) **(Fre)**

[Recent data on the epidemiology of non-Hodgkin lymphoma. Groupe d'Etudes des Lymphomes de l'Adulte (GELA) (editorial)] Bosly A, et al. **Pathol Biol (Paris)** 1997 Jun;45(6):449–52 (39 ref.) (Eng. Abstr.) **(Fre)**

[Porphyria cutanea tarda associated with HIV infection in absence of hepatitis C virus co-infection (letter)] Berard F, et al. **Presse Med** 1996 Oct 5;25(29):1349 **(Fre)**

[Is prognosis in AIDS patients different in cases of cardiac involvement? Prospective study of 34 patients (letter)] d'Ivernois C, et al. **Presse Med** 1997 May 3–10;26(15):714 **(Fre)**

[Vasculitis related to human immunodeficiency virus infection. Therapeutic approach in a patient (letter)] Ruel M, et al. **Presse Med** 1997 Jun 21;26(21):1002–3 **(Fre)**

[Primary pulmonary arterial hypertension: a rare manifestation of AIDS. Apropos of a case (letter)] Duché A, et al. **Rev Med Interne** 1996;17(9):774–5 **(Fre)**

[Ocular manifestations of AIDS. Personal observations and literature review] Massoud H, et al. **Rev Med Liege** 1997 Feb;52(2):98–100 (10 ref.) **(Fre)**

[The eye and AIDS: ophthalmological consultation for AIDS screening, 1-year retrospective study] Lendi B, et al. **Rev Med Suisse Romande** 1996 Jan;116(1):59–64 **(Fre)**

[Immunologic deficiency and pain] Stein C. **Anaesthesist** 1996 Nov;45(11):1001 **(Ger)**

[Pain syndromes in AIDS] Wesselmann U. **Anaesthesist** 1996 Nov;45(11):1004–14 (52 ref.) (Eng. Abstr.) **(Ger)**

[AIDS patients for pain therapy often have to rely on an opiate (news)] **Dtsch Med Wochenschr** 1996 Nov 15; 121(46):A45 **(Ger)**

[Management of atypical Mycobacterium infections in AIDS-patients] **Internist (Berl)** 1996 Apr;37(4 Suppl):1–8 **(Ger)**

[Current aspects of Kaposi sarcoma virus (news)] **Schweiz Rundsch Med Prax** 1996 Sep 17;85(38):1189 **(Ger)**

[A case from practice (361). Acute pancreatitis in AIDS. idiopathic. In microscopic gallstones. (Cotrimoxazole-induced). (In cryptosporidiosis)] Bassetti S. **Schweiz Rundsch Med Prax** 1996 Nov 12;85(46):1493–4 **(Ger)**

[Epidemiology of skin diseases in HIV-infected patients: a prospective cohort study] Schaub N, et al. **Schweiz Rundsch Med Prax** 1996 Sep 17;85(38):1162–6 (Eng. Abstr.) **(Ger)**

[Epidemiology and diagnosis of invasive fungal mold infections in immunosuppressed patients: results of a 3 year study at Leipzig University] Horn LC, et al. **Verh Dtsch Ges Pathol** 1996;80:337 **(Ger)**

[Ocular manifestations of acquired immune deficiency syndrome] Averbukh E, et al. **Harefuah** 1997 Apr 15; 132(8):559–62 (30 ref.) **(Heb)**

[A case of Kaposi sarcoma of the pharynx as a primary manifestation of the acquired immunodeficiency syndrome] Fusetti M, et al. **Acta Otorhinolaryngol Ital** 1996 Apr; 16(2):129–31 (Eng. Abstr.) **(Ita)**

[Non-Hodgkin's lymphoma with perianal localization in patients with acquired immunodeficiency syndrome: a case report] Bianchi C, et al. **Ann Ital Chir** 1996 Mar–Apr; 67(2):277–80 (Eng. Abstr.) **(Ita)**

[Imaging techniques in the assessment of thoracic and abdominal manifestations of AIDS] Gualdi GF, et al. **Clin Ter** 1996 Sep;147(9):457–64 (Eng. Abstr.) **(Ita)**

[Acute pancreatitis and AIDS] Gruttadauria G, et al. **Minerva Chir** 1997 Jun;52(6):835–8 (Eng. Abstr.) **(Ita)**

[Symptomatic efficacy of clotrimazole combined with surgery in the treatment of recurring anal and genital condylomatosis in seropositive and AIDS patients] Erenbourg L, et al. **Minerva Med** 1996 Sep;87(9):433–5 (Eng. Abstr.) **(Ita)**

[Clinico-diagnostic and odonto-stomatologic therapeutic problems in patients with HIV infection and AIDS] Spadari F, et al. **Minerva Stomatol** 1997 Jun;46(6):307–28 (100 ref.) (Eng. Abstr.) **(Ita)**

[Description of an unusual case of hepatic leishmaniasis in AIDS] Boscia D, et al. **Radiol Med (Torino)** 1997 May; 93(5):644–5 **(Ita)**

[Diagnostic imaging and therapeutic implications in lung infections in patients with HIV-1 infection] Carella E, et al. **Radiol Med (Torino)** 1997 May;93(5):532–8 (Eng. Abstr.) **(Ita)**

[AIDS in children: diagnostic imaging of pulmonary and abdominal lesions. Review of the literature and personal experience] Cecconi L, et al. **Radiol Med (Torino)** 1997 May;93(5):497–503 (16 ref.) **(Ita)**

[Unusual laryngeal location of cytomegalovirus in acquired immunodeficiency: radiologic imaging. Report of a case] D'Andrea F, et al. **Radiol Med (Torino)** 1996 Dec; 92(6):798–800 **(Ita)**

[Malignant neoplasms and AIDS. Review of the literature and critical considerations on a case of epidermoid carcinoma of the anus] Romito A, et al. **Recenti Prog Med** 1997 Jul–Aug;88(7–8):348–55 (48 ref.) (Eng. Abstr.) **(Ita)**

[Mechanism of neuronal damage in AIDS] Nagashima K. **Hokkaido Igaku Zasshi** 1997 Jan;72(1):37–41 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A case of AIDS with miliary tuberculosis] Sasaki Y, et al. **Kekkaku** 1996 Aug;71(8):473–6 (Eng. Abstr.) **(Jpn)**

[Pneumocystis carinii pneumonia associated with high levels of serum KL-6] Kawakami R, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34(12):1420–6 (Eng. Abstr.) **(Jpn)**

[Pulmonary Kaposi's sarcoma in a patient with the acquired immunodeficiency syndrome] Takechi A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Feb;35(2):231–5 (Eng. Abstr.) **(Jpn)**

[Sulfamethoxazole-trimethoprim-induced pneumonitis in a patient with hemophilia B who was infected with the human immunodeficiency virus] Yamagishi T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul;34(7):822–8 (Eng. Abstr.) **(Jpn)**

[Aids associated nervous system infections] Kishida S. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):725–30 (5 ref.) **(Jpn)**

[AIDS and tuberculosis] Tanaka K. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):129–34 (8 ref.) **(Jpn)**

[Tuberculosis of the lymph nodes with esophageal-cutaneous fistula in a patient with AIDS] Garlicki A, et al. **Pol Tyg Lek** 1996 Jun;51(23–26):344–6 (Eng. Abstr.) **(Pol)**

[Lyell's syndrome in an AIDS patient] Quintas S, et al. **Acta Med Port** 1997 Jun–Jul;10(6–7):509–16 (22 ref.) (Eng. Abstr.) **(Por)**

[Rheumatic heart disease and infective endocarditis in a patient with acquired immunodeficiency syndrome] Mesquita ET, et al. **Arq Bras Cardiol** 1996 Oct;67(4):255–7 (Eng. Abstr.) **(Por)**

[Tuberculous pericarditis as the initial manifestation of acquired immunodeficiency syndrome] Vianna Araujo D, et al. **Arq Bras Cardiol** 1995 Dec;65(6):497–500 (Eng. Abstr.) **(Por)**

[Neuropathogenesis of HIV infection] Araújo AD, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):335–45 (72 ref.) (Eng. Abstr.) **(Por)**

[Cerebral malaria and AIDS: case report] Hinrichsen SL, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):324–7 (Eng. Abstr.) **(Por)**

[Transverse myelitis as initial symptom of disseminated non-Hodgkin lymphoma and HIV-associated vacuolar myelopathy: case report] Moura LP, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):318–23 (Eng. Abstr.) **(Por)**

[Long-term survival in patient with acquired immunodeficiency syndrome and adenocarcinoma of the lung] Pereira JR, et al. **Rev Assoc Med Bras** 1996 Oct–Dec; 42(4):258–60 (Eng. Abstr.) **(Por)**

[Abdominal surgical emergencies in patients with acquired immunodeficiency syndrome] Steinman M, et al. **Rev Assoc Med Bras** 1996 Jan–Mar;42(1):19–24 (Eng. Abstr.) **(Por)**

[Pericarditis in a general hospital] Faintuch JJ, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Mar–Apr; 51(2):49–52 (Eng. Abstr.) **(Por)**

[Evaluation of the excess of cases of tuberculosis due to HIV/AIDS infection: a preliminary assay] Ruffino-Netto A. **Rev Saude Publica** 1995 Aug;29(4):279–82 (Eng. Abstr.) **(Por)**

[Persistent neutrophilic meningitis in a patient with the acquired immunodeficiency syndrome] Marinho SF, et al. **Rev Soc Bras Med Trop** 1997 May–Jun;30(3):241–5 (22 ref.) (Eng. Abstr.) **(Por)**

[Psoriasis in HIV positive patients] Silva-Vergara ML, et al. **Rev Soc Bras Med Trop** 1996 Nov–Dec;29(6):599–602 (Eng. Abstr.) **(Por)**

[Why hepatitis and AIDS? (editorial)] Jmelnitzky AC. **Acta Gastroenterol Latinoam** 1996;26(3):201–4 **(Spa)**

[Pyomyositis and AIDS (letter)] Gregorio Vila A, et al. **An Med Interna** 1996 Feb;13(2):97–8 **(Spa)**

[Practical considerations in the treatment of patients with AIDS and tuberculosis (letter; comment)] Sánchez Muñoz LA, et al. **Aten Primaria** 1996 Nov 30;18(9):527–8. Comment on: Aten Primaria 1996 Mar 31;17(5):307–8. **(Spa)**

[HIV infection and Lyell syndrome: a wake-up call concerning anti-inflammatory agents (letter)] de Luis DA, et al. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):231–2 **(Spa)**

[Salmonella septic arthritis in a hemophiliac with AIDS: aggressive treatment (letter)] Ferré R, et al. **Enferm Infecc Microbiol Clin** 1996 Nov;14(9):573–4 **(Spa)**

[Cerebral SPECT with thallium-201 in the differential diagnosis of focal cerebral lesions in patients with AIDS] Sanjaume M, et al. **Enferm Infecc Microbiol Clin** 1997 Jan; 15(1):28–31 (Eng. Abstr.) **(Spa)**

[Diagnosis of 4 cases of intestinal microsporidiosis in AIDS patients] Subirats M, et al. **Enferm Infecc Microbiol Clin** 1996 Nov;14(9):533–7 (Eng. Abstr.) **(Spa)**

[Pneumothorax in patients with AIDS and tuberculosis (letter)] Supervía A, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):278 **(Spa)**

[Secondary chemoprophylaxis in tuberculosis and AIDS (letter)] Ussetti P, et al. **Enferm Infecc Microbiol Clin** 1996 May;14(5):332 **(Spa)**

[Chronic eosinophilic pneumonia in AIDS (letter)] Fernández Rodríguez R, et al. **Med Clin (Barc)** 1996 Nov 2;107(15):599 (8 ref.) **(Spa)**

[Myositis caused by Pleistophora in a patient with AIDS] Grau A, et al. **Med Clin (Barc)** 1996 Dec 7;107(20):779–81 (23 ref.) (Eng. Abstr.) **(Spa)**

[Hafnia alvei bacteremia in an AIDS patient (letter)] Ibáñez Pérez de la Blanca MA, et al. **Med Clin (Barc)** 1997 May 17;108(19):757–8 **(Spa)**

[Granulocyte colony-stimulating factor in the treatment of neutropenia associated with HIV infection (letter; comment)] Moreno García M, et al. **Med Clin (Barc)** 1996 Jul 6;107(6):237–8. Comment on: Med Clin (Barc) 1994 May 21;102(19):747–50. Comment on: Med Clin (Barc) 1995 Feb 4;104(4):157. **(Spa)**

[Fever and abdominal pain in a patient with human immunodeficiency virus infection and Burkitt's lymphoma (clinical conference)] Ribas MA, et al. **Med Clin (Barc)** 1996 Dec 7;107(20):788–94 **(Spa)**

[Primary lung Kaposi sarcoma associated to AIDS in a heterosexual drug addict man] Troncoso AR, et al. **Medicina (B Aires)** 1996;56(4):397–402 (Eng. Abstr.) **(Spa)**

[Cerebrovascular disease as a form of presentation of HIV infection] Palomeras E, et al. **Neurologia** 1996 Nov; 11(9):346–9 (Eng. Abstr.) **(Spa)**

[Molecular characterization of HTLV-II from an intravenous drug addict with AIDS in Argentina] Biglione M, et al. **Rev Argent Microbiol** 1996 Jul–Sep;28(3):139–42 (Eng. Abstr.) **(Spa)**

[Cutaneous cryptococcosis in 2 patients with AIDS (letter)] Baraia-Etxaburu J, et al. **Rev Clin Esp** 1996 Jun; 196(6):412–3 **(Spa)**

[Hyperkeratotic lesions in a patient with AIDS] Fernández-Martín JI, et al. **Rev Clin Esp** 1996 Jan; 196(1):55–6 **(Spa)**

[Ulcerated esophageal lesions in a patient with AIDS. Herpes esophagitis] López-Cubero L, et al. **Rev Clin Esp** 1996 Jun; 196(6):403–4, 409 **(Spa)**

[Mental disorders in HIV-1 infection] Lozano Suárez M, et al. **Rev Clin Esp** 1996 Nov;196(11):774–84 (120 ref.) **(Spa)**

ACQUIRED IMMUNODEFICIENCY SYNDROME

[Skin lesions in epidemic Kaposi's sarcoma (AIDS): local control assessment and esthetic results of a schedule of superficial radiotherapy] Pinazo J, et al. **Rev Clin Esp** 1996 Dec;196(12):806–10 (Eng. Abstr.) **(Spa)**

[Diarrhea in patients with AIDS] Monés J, et al. **Rev Esp Enferm Dig** 1996 Apr;88(4):280–6 (30 ref.) **(Spa)**

[Kaposi's sarcoma of the bile ducts with cutaneous involvement in a patient with AIDS] Segarra P, et al. **Rev Esp Enferm Dig** 1996 Sep;88(9):637–9 (Eng. Abstr.) **(Spa)**

[Pathology of the retina in patients with AIDS] Adán-Civera A, et al. **Rev Neurol** 1996 Dec;24(136):1614–8 (17 ref.) (Eng. Abstr.) **(Spa)**

[Cytomegalovirus retinitis in a pediatric AIDS patient] Barrio J, et al. **Rev Neurol** 1997 Jul;25(143):1064–6 (Eng. Abstr.) **(Spa)**

[AIDS manifestations in otorhinolaryngology] Ciges M, et al. **Rev Neurol** 1996 Dec;24(136):1619–22 (24 ref.) (Eng. Abstr.) **(Spa)**

[Equilibrium and auditory disorders in patients affected by HIV-1] Domènech J, et al. **Rev Neurol** 1996 Dec; 24(136):1623–6 (22 ref.) (Eng. Abstr.) **(Spa)**

[Thrombosis of the superior longitudinal sinus in patients with AIDS. A review of the literature] Pedraza S, et al. **Rev Neurol** 1997 Feb;25(138):247–9 (16 ref.) (Eng. Abstr.) **(Spa)**

[Neurological complications caused by cytomegalovirus in patients with AIDS] Reñé R, et al. **Rev Neurol** 1996 Dec; 24(136):1590–6 (70 ref.) (Eng. Abstr.) **(Spa)**

[Visual and central oculomotor disorders in patients with acquired immunodeficiency syndrome] Roig C, et al. **Rev Neurol** 1996 Dec;24(136):1597–604 (Eng. Abstr.) **(Spa)**

[Perceptive deafness and AIDS] Sancho EM, et al. **Rev Neurol** 1997 Jun;25(142):887–90 (Eng. Abstr.) **(Spa)**

[Neuro-AIDS] Tellechea N, et al. **Rev Neurol** 1997 Jun; 25(142):903–5 (Eng. Abstr.) **(Spa)**

[Optic neuropathies and peripheral oculomotor disorders in patients with AIDS] Torras-Sanvicens J, et al. **Rev Neurol** 1996 Dec;24(136):1605–13 (44 ref.) (Eng. Abstr.) **(Spa)**

[Acute lymphoblastic leukemia with L1 morphology arising during treatment for ALL-L3 in a child with AIDS] Fernández-Teijeiro A, et al. **Sangre (Barc)** 1996 Jun; 41(3):245–8 (Eng. Abstr.) **(Spa)**

CONGENITAL

Viewing AIDS from a glycobiological perspective: potential linkages to the human fetoembryonic defence system hypothesis. Clark GF, et al. **Mol Hum Reprod** 1997 Jan; 3(1):5–13 (75 ref.)

DIAGNOSIS

The effect of the 1993 European revision of the AIDS case definition in Italy: implications for modelling the HIV epidemic. Pezzotti P, et al. **AIDS** 1997 Jan;11(1):95–9

Trends in age at AIDS diagnosis in Europe and the United States: evidence of pronounced "ageing' among injecting drug users. Zellweger U, et al. **AIDS** 1996 Aug; 10(9):1001–7

Predictors of follow-through on plans to be tested for HIV. Phillips KA, et al. **Am J Prev Med** 1997 May-Jun; 13(3):193–8

Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Lyketsos CG, et al. **Am J Psychiatry** 1996 Nov;153(11):1430–7

Update on issues for HIV management. Bradford D. **Aust Fam Physician** 1997 Jul;26(7):812–7

Kaposi's sarcoma. Clearlhan L. **Aust Fam Physician** 1996 Mar;25(3):428–9

A competing risks analysis of presenting AIDS diagnoses trends. Fusaro RE, et al. **Biometrics** 1996 Mar;52(1):211–25

Does HIV status influence the outcome of patients admitted to a surgical intensive care unit? A prospective double blind study [see comments] Bhagwanjee S, et al. **BMJ** 1997 Apr 12;314(7087):1077–81; discussion 1081–4. Comment in: BMJ 1997 May 17;314(7092):1477. Comment in: BMJ 1997 May 17;314(7092);1477–8. Comment in: BMJ 1997 May 17;314(7092);1479–80. Comment in: BMJ 1997 Jul 26;315(7102):248. Comment in: BMJ 1997 Jul 26;315(7102):250. Comment in: BMJ 1997 Jul 26;315(7102):251–2. Comment in: BMJ 1997 Jul 26;315(7102):252.

An approach to the validation of markers for use in AIDS clinical trials. Mildvan D, et al. **Clin Infect Dis** 1997 May; 24(5):764–74 (184 ref.)

Patterns of geographic mobility of persons with AIDS in Canada from time of AIDS index diagnosis to death. Hogg RS, et al. **Clin Invest Med** 1997 Apr;20(2):77–83

Retesting of sera for antibodies to HIV-1/HIV-2. **Commun Dis Rep CDR Wkly** 1996 May 3;6(18):153

Use of the in vitro induced antibody production test (IVIAP) to elucidate inconclusive status of HIV-1 infection. Bellei N, et al. **Diagn Microbiol Infect Dis** 1996 Jun;25(2):65–9

Cardiac tamponade as the first manifestation of AIDS [letter] Bennis A, et al. **Eur Heart J** 1996 Nov;17(11):1771–2

Systemic lupus erythematosus features in an AIDS patient: diagnostic problems in an African rural hospital [letter] Falaschi F, et al. **Genitourin Med** 1996 Dec;72(6):448–9

Breach in confidential AIDS patient information [news] **Infect Control Hosp Epidemiol** 1996 Dec;17(12):829–30

Improving the prognostic value of CD4+ count using IgA and clinical signs in HIV-seropositive i.v. drug users. Montella F, et al. **Infection** 1997 Mar-Apr;25(2):117–20

AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study Group. Ragni MV, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):78–86

Whole saliva dried on filter paper or diagnosis of HIV-1 infection by detection of antibody IgG to HIV-1 with ultrasensitive enzyme immunoassay using recombinant reverse transcriptase as antigen. Ishikawa S, et al. **J Clin Lab Anal** 1996;10(1):35–41

Detection of infection with human immunodeficiency virus type 1 before seroconversion: correlation with clinical symptoms and outcome. Phair JP, et al. **J Infect Dis** 1997 Apr;175(4):959–62

Effect of maternal CD4+ cell count, acquired immunodeficiency syndrome, and viral load on disease progression in infants with perinatally acquired human immunodeficiency virus type 1 infection. New York City Perinatal HIV Transmission Collaborative Study Group. Lambert G, et al. **J Pediatr** 1997 Jun;130(6):890–7

Assessing prognosis in infants infected with human immunodeficiency virus [editorial; comment] Novelli VM. **J Pediatr** 1996 Nov;129(5):623–5. Comment on: J Pediatr 1996 Nov;129(5):648–55.

Oral HIV test found to be highly accurate [news] **Lancet** 1997 Jan 25;349(9047):259

Objective evaluation of two markers of HIV-1 infection (p24 antigen concentration and CD4+ cell counts) by a self organizing neural network. Giacomini M, et al. **Med Inf (Lond)** 1996 Jul-Sep;21(3):215–28

Endocrine implications of human immunodeficiency virus infection. Hofbauer LC, et al. **Medicine (Baltimore)** 1996 Sep;75(5):262–78 (213 ref.)

Dried blood spots collected on filter paper: an international resource for the diagnosis and genetic characterization of human immunodeficiency virus type-1. Cassol SA, et al. **Mem Inst Oswaldo Cruz** 1996 May-Jun;91(3):351–8

The definition and staging of human immunodeficiency virus infection and acquired immunodeficiency syndrome appropriate for India, Madras, Tamil Nadu, 29-30 July 1995. **Natl Med J India** 1996 Jul-Aug;9(4):195–6

Hemolytic uremic syndrome as a presenting form of HIV infection. Badesha PS, et al. **Nephron** 1996;72(3):472–5 (39 ref.)

Cervical cancer as an AIDS-defining illness. Maiman M, et al. **Obstet Gynecol** 1997 Jan;89(1):76–80

New test may predict course of AIDS [news] **Oncology (Huntingt)** 1995 Jul;9(7):674

Salivary testing for human immunodeficiency virus type 1 infection in children born to infected mothers in Sao Paulo, Brazil. The Sao Paulo Collaborative Study for Vertical Transmission of HIV-1. Tess BH, et al. **Pediatr Infect Dis J** 1996 Sep;15(9):787–90

Interventional procedures in the AIDS patient. Klein JS, et al. **Radiol Clin North Am** 1997 Sep;35(5):1223–43 (79 ref.)

Estimating asymptomatic duration in cancer: the AIDS connection. Etzioni R, et al. **Stat Med** 1997 Mar 30; 16(6):627–44

Development of polymerase chain reaction diagnostic assays for the detection and quantitation of human immunodeficiency virus and hepatitis C virus genomes. Colucci G. **Transplant Proc** 1996 Oct;28(5):2929–30

Qualitative and quantitative NASBA for detection of human immunodeficiency virus type 1 and hepatitis C virus infection. Sillekens PT. **Transplant Proc** 1996 Oct; 28(5):2941–4

Cat scratch disease and acquired immunodeficiency disease: diagnosis by transmission electron microscopy. Guccion JG, et al. **Ultrastruct Pathol** 1996 May-Jun;20(3):195–202

[The AIDS patient, AIDS, the general practitioner] Piquard D. **Rev Med Brux** 1996 Sep;17(4):160–3 (Eng. Abstr.) **(Fre)**

[HIV infection and acquired immunodeficiency syndrome] Takamatsu J. **Rinsho Byori** 1997 May;45(5):409–14 (14 ref.) (Eng. Abstr.) **(Jpn)**

[European case definition of AIDS surveillance in children, revision in 1995] Szata W. **Przegl Epidemiol** 1996; 50(4):387–94 **(Pol)**

[Correlation of clinical and morphological diagnoses in 55 fatal AIDS cases] Walewska-Zielecka B. **Przegl Epidemiol** 1995;49(4):353–9 (Eng. Abstr.) **(Pol)**

[Initial evaluation of the diagnostic usefulness of tuberculin tests among the patients of the Center of Diagnosis and Treatment of AIDS] Zieliński A, et al. **Przegl Epidemiol** 1996;50(4):395–400 (Eng. Abstr.) **(Pol)**

[False-positive reactions in laboratory diagnosis of Lassa, Marburg, and Ebola viral hemorrhagic fevers and AIDS] Vladyko AS, et al. **Vopr Virusol** 1997 Mar-Apr;42(2):66–70 (Eng. Abstr.) **(Rus)**

[Tuberculous abscess of the pancreas as initial manifestation of AIDS (letter)] Molina M, et al. **Gastroenterol Hepatol** 1997 Mar;20(3):165–6 **(Spa)**

[Cerebrovascular disease as a form of presentation of HIV infection] Palomeras E, et al. **Neurologia** 1996 Nov; 11(9):346–9 (Eng. Abstr.) **(Spa)**

[Diagnosis by imaging of the brain affected by AIDS] Mercader-Sobrequés JM, et al. **Rev Neurol** 1996 Dec; 24(136):1577–89 (43 ref.) (Eng. Abstr.) **(Spa)**

DIET THERAPY

Nutrition support for children with HIV/AIDS [news] Heller LS, et al. **J Am Diet Assoc** 1997 May;97(5):473–4

DRUG THERAPY

Transfer of antivirals to skin Langerhans cells--a novel approach to anti-HIV treatment by "antiviral peplotion". Becker Y. **Acta Biochim Pol** 1996;43(1):175–81 (30 ref.)

Resistance to anti-human immunodeficiency virus therapeutic agents. Emini EA. **Adv Exp Med Biol** 1995; 390:187–95 (50 ref.)

Xerostomia: a symptom which acts like a disease [letter; comment] Harry TC. **Age Ageing** 1997 May;26(3):239. Comment on: Age Ageing 1996 Sep;25(5):409–12.

Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir [letter] Conant MA, et al. **AIDS** 1997 Aug;11(10):1300–1

A trial of testosterone therapy for HIV-associated weight loss. Coodley GO, et al. **AIDS** 1997 Sep;11(11):1347–52

Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. Famularo G, et al. **AIDS** 1997 Feb;11(2):185–90

Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. Girard PM, et al. **AIDS** 1996 Jun;10(7):753–7

Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. Gold J, et al. **AIDS** 1996 Jun;10(7):745–52

Severe reversible thrombocytopenia caused by recombinant human granulocyte colony-stimulating factor in an AIDS patient receiving chronic ganciclovir therapy [letter] Holtzer CD, et al. **AIDS** 1997 Sep;11(11):1403–5

Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor [letter] Murphy M, et al. **AIDS** 1997 Feb;11(2):261–2

Hypercalcemia in an AIDS patient treated with growth hormone. Sakoulas G, et al. **AIDS** 1997 Sep;11(11):1353–6

Short-term response to indinavir in patients with advanced HIV disease with prior heavy exposure to nucleoside analogues [letter] Soriano V, et al. **AIDS** 1997 Mar; 11(3):391–2

Molecular biology and the development of AIDS therapeutics. Trono D. **AIDS** 1996 Dec;10 Suppl 3:S53–9 (23 ref.)

Constraints on the sequence diversity of the protease of human immunodeficiency virus type 1: a guide for drug design. Kaplan AH. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):849–53 (50 ref.)

Quantitative analysis of the endogenous reverse transcriptase reactions of HIV type 1 variants with decreased susceptibility to azidothymidine and nevirapine. Krogstad P, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20; 12(11):977–83

Use of floxuridine to modulate the antiviral activity of zidovudine. Medina DJ, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):965–8 (7 ref.)

Inhibition of murine AIDS by reduced glutathione. Palamara AT, et al. **AIDS Res Hum Retroviruses** 1996 Sep 20; 12(14):1373–81

Perspective: research highlights at the Albert Einstein College of Medicine Center for AIDS research. Approaches to control drug resistance in HIV: the role of increased polymerase fidelity. Prasad VR, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):959–63 (54 ref.)

The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Whitfield RM, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):122–7

Defining homeopathic growth factors [letter; comment] Brewitt B. **Altern Ther Health Med** 1996 Nov;2(6):16–7. Comment on: Altern Ther Health Med 1996 Sep;2(5):80–9.

Nonnucleoside reverse transcriptase inhibitor marketed for AIDS therapy [news] **Am J Health Syst Pharm** 1996 Sep 15;53(18):2132–3

Federal panel backs early, aggressive HIV therapy [news] **Am J Health Syst Pharm** 1997 Aug 1;54(15):1681, 1685–7

New safety information emerges from postmarketing use of ritonavir [news] **Am J Health Syst Pharm** 1997 Jan 15; 54(2):126

New products and research bring guarded optimism, new questions about AIDS therapy [news] Miller JL. **Am J Health Syst Pharm** 1996 Sep 15;53(18):2129–30, 2132

Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS. Akula SK, et al. **Am J Med Sci** 1997 Apr;313(4):244–6

Recombinant human granulocyte colony-stimulating factor increases circulating CD34-postive cells in patients with AIDS. Nielsen SD, et al. **Ann Hematol** 1997 May; 74(5):215–20

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team [see comments] Hughes MD, et al. **Ann Intern Med** 1997 Jun 15;126(12):929–38. Comment in: Ann Intern Med 1997 Jun 15;126(12):983–5.

Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on

AIDS [see comments] O'Brien WA, et al. **Ann Intern Med** 1997 Jun 15;126(12):939–45. Comment in: Ann Intern Med 1997 Jun 15;126(12):983–5.

Bias in observational studies of treatment [letter; comment] Osmond DH, et al. **Ann Intern Med** 1996 Dec 1;125(11):941 . Comment on: Ann Intern Med 1996 Jun 1;124(11):999–1005.

The role of dehydroepiandrosterone in AIDS. Centurelli MA, et al. **Ann Pharmacother** 1997 May;31(5):639–42

Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Balfour HH Jr, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2721–6

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti–human immunodeficiency virus activity. Daluge SM, et al. **Antimicrob Agents Chemother** 1997 May; 41(5):1082–93

Protein binding of clindamycin in sera of patients with AIDS. Flaherty JF Jr, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1134–8

Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. Lee BL, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1231–6

Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. Li RC, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1566–70

Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Morse GD, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):169–74

Protease inhibitor approved for AIDS treatment. **AORN J** 1996 Sep;64(3):453

Human immunodeficiency virus type 1 protease inhibitors. McDonald CK, et al. **Arch Intern Med** 1997 May 12; 157(9):951–9 (86 ref.)

AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue. Mathé G, et al. **Biomed Pharmacother** 1996;50(5):220–7

South African research into AIDS "cure" severely criticised [news] Sidley P. **BMJ** 1997 Mar 15;314(7083):771

Patient access to experimental drugs and AIDS clinical trial designs: ethical issues. Schüklenk U, et al. **Camb Q Healthc Ethics** 1996 Summer;5(3):400–9

A live-virus "suicide" vaccine for human immunodeficiency virus. Kestler HW, et al. **Cleve Clin J Med** 1997 May; 64(5):269–74 (32 ref.)

Treatment of HIV infection and its complications. Polsky B. **Clin Chest Med** 1996 Dec;17(4):647–63 (68 ref.)

Rhinocerebral mucormycosis in a patient with AIDS: a complication of diabetic ketoacidosis following pentamidine therapy. Abril V, et al. **Clin Infect Dis** 1996 Oct;23(4):845–6

Uveitis following administration of the protease inhibitor indinavir to a patient with AIDS. Gariano RF, et al. **Clin Infect Dis** 1997 Mar;24(3):529

Desensitization to trimethoprim–sulfamethoxazole in patients infected with human immunodeficiency virus [letter] Quirino T, et al. **Clin Infect Dis** 1996 Feb;22(2):396

International expenditure projections for pharmacotherapeutic advances in the treatment of HIV/AIDS. Sclar DA, et al. **Clin Ther** 1997 Jan–Feb; 19(1):86–95; discussion 84–5

An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Sullivan SD, et al. **Clin Ther** 1996 May–Jun;18(3):546–58

Hundreds enrolled in canadian HIV trials [news] **CMAJ** 1997 Jun 15;156(12):1691

Zidovudine–induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Sundar K, et al. **Crit Care Med** 1997 Aug;25(8):1425–30 (26 ref.)

Polyethylene glycol–liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS–related Kaposi's sarcoma. Coukell AJ, et al. **Drugs** 1997 Mar; 53(3):520–38 (68 ref.)

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Moyle GJ. **Drugs** 1996 Aug;52(2):168–85

Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma. Voltchek IV, et al. **Drugs Exp Clin Res** 1996;22(3–5):283–6

HIV–1 viraemia changes in patients with and without syncytium–inducing phenotype treated with nucleoside analogues: a case–control study. Leal M, et al. **Eur J Clin Invest** 1996 Oct;26(10):923–8

Predictive value of HIV–1 RNA detection in plasma by branched DNA assay during long–term zidovudine therapy. Cotte L, et al. **Eur J Clin Microbiol Infect Dis** 1996 Aug;15(8):639–45

Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS–906 Study Group. d'Arminio Monforte A, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb;16(2):135–42

Influence of hydrogen peroxide on the in vitro infectivity of human immunodeficiency virus. Ranjbar S, et al. **Free Radic Biol Med** 1996;20(4):573–7

Thalidomide: a novel therapy for microsporidiosis. Sharpstone D, et al. **Gastroenterology** 1997 Jun; 112(6):1823–9

Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms. Ferrando SJ, et al. **Gen Hosp Psychiatry** 1997 Mar;19(2):89–97

Medicare/Medicaid ... the most promising treatment for AIDS [news] **Hosp Health Netw** 1997 Jul 20;71(14):19

The pathogenesis of AIDS: lessons learned from other medical conditions. Griffiths PD, et al. **Infect Agents Dis** 1996 Oct;5(4):231–9 (50 ref.)

Anterior uveitis associated with rifabutin medication in AIDS patients. Becker K, et al. **Infection** 1996 Jan–Feb;24(1):34–6

Inhibition of HIV–1 infectivity by low molecular weight heparin. Results of in vitro studies and a pilot clinical trial in patients with advanced AIDS. Howell AL, et al. **Int J Clin Lab Res** 1996;26(2):124–31

Allergic skin reaction to GCSF in a patient with AIDS. Sullivan AK, et al. **Int J STD AIDS** 1997 Feb;8(2):135–6

Effects of reverse transcriptase inhibitor therapy on the HIV–1 viral burden in semen. Gilliam BL, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 May 1;15(1):54–60

Use of protease inhibitors among persons with AIDS in Los Angeles County [letter] Sorvillo F, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jun 1;15(2):179–81

Clinical experience with stavudine as salvage therapy in patients with advanced HIV disease [letter] Wallace MR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep;13(1):96–7

Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS. Sanwo M, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1112–5

Drug updates [news] **J Am Pharm Assoc (Wash)** 1996 Jan; NS36(1):7–8

Polypharmacy and the treatment of HIV/AIDS. Bretzel R, et al. **J Am Pharm Assoc (Wash)** 1996 Dec; NS36(12):722a–722e

Penetration of dapsone into cerebrospinal fluid of patients with AIDS. Gatti G, et al. **J Antimicrob Chemother** 1997 Jul;40(1):113–5

Should complex medication regimens be prescribed to people with a low probability of compliance? Benedict S, et al. **J Assoc Nurses AIDS Care** 1997 May–Jun;8(3):90–1

Neuroimmunotherapy with low–dose subcutaneous interleukin–2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase–II study. Lissoni P, et al. **J Biol Regul Homeost Agents** 1995 Oct–Dec;9(4):155–8

Changes in body composition of human immunodeficiency virus–infected males receiving insulin–like growth factor I and growth hormone. Ellis KJ, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):3033–8

A randomized, placebo–controlled trial of combined insulin–like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection [published erratum appears in J Clin Endocrinol Metab 1996 Oct;81(10):3696] Lee PD, et al. **J Clin Endocrinol Metab** 1996 Aug; 81(8):2968–75

Adherence in AIDS clinical trials: a framework for clinical research and clinical care. Ickovics JR, et al. **J Clin Epidemiol** 1997 Apr;50(4):385–91 (58 ref.)

The eleventh international conference on AIDS: cautious celebration in Vancouver. Gibaldi M. **J Clin Pharmacol** 1997 Jan;37(1):20–4

Protease inhibitors and drug interactions—an alert [editorial] Shader RI, et al. **J Clin Psychopharmacol** 1996 Oct; 16(5):343–4

Carotenoids in cancer, mastalgia, and AIDS: prevention and treatment—an overview. Santamaria L, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):89–95 (46 ref.)

Treatment of late–state HIV infection. Millard PS. **J Fam Pract** 1997 Feb;44(2):132–4

Zidovudine adherence in persons with AIDS. The relation of patient beliefs about medication to self–termination of therapy. Smith MY, et al. **J Gen Intern Med** 1997 Apr; 12(4):216–23

Central venous line infections in AIDS. Moore DA, et al. **J Infect** 1997 Jan;34(1):35–40

Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine–treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team. Bakshi SS, et al. **J Infect Dis** 1997 May;175(5):1039–50

Monitoring responses to antiretroviral treatment in human immunodeficiency virus type 1 (HIV–1)–infected patients by serial lymph node aspiration. Bürgisser P, et al. **J Infect Dis** 1997 May;175(5):1202–5

High–dose nevirapine in previously untreated human immunodeficiency virus type 1–infected persons does not result in sustained suppression of viral replication. de Jong MD, et al. **J Infect Dis** 1997 Apr;175(4):966–70

Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine–zidovudine therapy in subjects with non–syncytium–inducing phenotype. Holodniy M, et al. **J Infect Dis** 1996 Oct;174(4):854–7

Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. Lafeuillade A, et al. **J Infect Dis** 1997 May; 175(5):1051–5

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1–infected children. Luzuriaga K, et al. **J Infect Dis** 1996 Oct;174(4):713–21

Changes in cellular virus load and zidovudine resistance of syncytium–inducing and non–syncytium–inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. van 't Wout AB, et al. **J Infect Dis** 1996 Oct;174(4):845–9

Zinc ejection as a new rationale for the use of cystamine and related disulfide–containing antiviral agents in the treatment of AIDS. McDonnell NB, et al. **J Med Chem** 1997 Jun 20;40(13):1969–76

Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. Aleixo LF, et al. **J Pediatr** 1997 Jun;130(6):906–14

Cyclosporine A–resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. Braaten D, et al. **J Virol** 1996 Aug;70(8):5170–6

Debating dual AIDS guidelines [news] Voelker R. **JAMA** 1997 Aug 27;278(8):613–4

Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis [letter] Whitcup SM, et al. **JAMA** 1997 May 21;277(19):1519–20

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine–containing regimens for patients with HIV–1 infection: the CAESAR trial [see comments] **Lancet** 1997 May 17;349(9063):1413–21. Comment in: Lancet 1997 May 17;349(9063):1408–9.

USA outlines standard of care for HIV/AIDS [news] Ault A. **Lancet** 1997 Jun 28;349(9069):1891

Severe hepatitis in three AIDS patients treated with indinavir [letter] Bräu N, et al. **Lancet** 1997 Mar 29;349(9056):924–5

New AIDS drugs affect US state assistance [news] Firshein J. **Lancet** 1997 Jul 19;350(9072):195

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [see comments] Jacobson MA, et al. **Lancet** 1997 May 17;349(9063):1443–5. Comment in: Lancet 1997 Aug 23;350(9077):588; discussion 590. Comment in: Lancet 1997 Aug 23;350(9077):588–9; discussion 590. Comment in: Lancet 1997 Aug 23;350(9077):589; discussion 590. Comment in: Lancet 1997 Aug 23;350(9077):589–90.

Antiretroviral drugs for AIDS. Lipsky JJ. **Lancet** 1996 Sep 21;348(9030):800–3 (45 ref.)

Inclusion of women in clinical trials of antiretroviral agents for HIV/AIDS during pregnancy [letter] Mangino JE, et al. **Lancet** 1997 Jul 12;350(9071):150

Clearance of HHV–8 from peripheral blood mononuclear cells with a protease inhibitor [letter] Rizzieri DA, et al. **Lancet** 1997 Mar 15;349(9054):775–6

US expert panel reaffirms benefit of perinatal zidovudine [news] Rowe PM. **Lancet** 1997 Jan 25;349(9047):258

No news is good news at Washington AIDS meeting [news] Schechter MT. **Lancet** 1997 Feb 1;349(9048):331

Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset. Fiala M, et al. **Lymphology** 1997 Sep;30(3):128–36

Type B lactic acidosis in an AIDS patient treated with zidovudine. Aggarwal A, et al. **Md Med J** 1996 Nov; 45(11):929–31

Cure or control of HIV/AIDS? Collins DO, et al. **Med Hypotheses** 1997 Jun;48(6):489–90

Zidovudine and human immunodeficiency virus–associated peripheral neuropathies: low intake in patients with mononeuropathy multiplex and no evidence for neurotoxicity. Lefaucheur JP, et al. **Muscle Nerve** 1997 Jan; 20(1):106–9

Analysis of myopathy in a placebo–controlled zidovudine trial. Simpson DM, et al. **Muscle Nerve** 1997 Mar; 20(3):382–5

AIDS researchers emphasize new drug combinations [news] Fox JL. **Nat Biotechnol** 1997 Mar;15(3):215

AIDS patients demand drugs as government hesitates [news] Jayaraman KS. **Nat Med** 1997 Sep;3(9):943

Opening an electronic pharmacy to the world [news] Steele FR. **Nat Med** 1996 Oct;2(10):1064

AIDS 'cure' researchers guilty of misconduct [news] **Nature** 1997 Jul 10;388(6638):112

Placebo use defended in Third World studies [news] **Nature** 1997 May 15;387(6630):225

AIDS 'cure' scientists go to top for funds [news] Cherry M. **Nature** 1997 Feb 6;385(6616):474

Evaluation of drug use and cost of hospital care for AIDS patients between 1990 and 1994. Peyron F, et al. **Pharm World Sci** 1997 Aug;19(4):202–7

Effect of L–carnitine treatment in vivo on apoptosis and ceramide generation in peripheral blood lymphocytes from AIDS patients. Cifone MG, et al. **Proc Assoc Am Physicians** 1997 Mar;109(2):146–53

Pre–existence and emergence of drug resistance in HIV–1 infection. Bonhoeffer S, et al. **Proc R Soc Lond B Biol Sci** 1997 May 22;264(1382):631–7

Update on antiretroviral therapy. Hicks CB. **Radiol Clin North Am** 1997 Sep;35(5):995–1005 (59 ref.)

The effect of AZT on dendritic cell number and provirus load in the peripheral blood of AIDS patients: a preliminary study. Patterson S, et al. **Res Virol** 1996 Mar–Jun;

147(2–3):109–14
Virodene—support misguided [letter] Folb PI, et al. **S Afr Med J** 1997 Apr;87(4):466
Virodene—support misguided [letter; comment] Kalk WJ, et al. **S Afr Med J** 1997 Jun;87(6):775–6. Comment on: S Afr Med J 1997 Mar;87(3):253.
Give Virodene and the Minister a break! [editorial] [see comments] Ncayiyana DJ. **S Afr Med J** 1997 Mar;87(3):253. Comment in: S Afr Med J 1997 Apr;87(4):468. Comment in: S Afr Med J 1997 Jun;87(6):775–6.
Treatment options for human immunodeficiency virus. Heins JR. **S D J Med** 1996 Feb;49(2):51–2
Antiretroviral therapy: a guide to the most important trials. Rutschmann O, et al. **Schweiz Med Wochenschr** 1997 Mar 15;127(11):436–43 (38 ref.)
Group brands AIDS trials unethical [news] **Science** 1997 Apr 25;276(5312):519
NCI plans attack on HIV resistance [news] **Science** 1997 May 2;276(5313):667
AIDS trials ethics questioned [news; comment] [see comments] Cohen J. **Science** 1997 Apr 25;276(5312):520–3. Comment on: Science 1997 Apr 25;276(5312):548–50. Comment in: Science 1997 Jun 6;276(5318):1482–4.
Advances painted in shades of gray at a D.C. conference [news] Cohen J. **Science** 1997 Jan 31;275(5300):615–6
The daunting challenge of keeping HIV suppressed [news] Cohen J. **Science** 1997 Jul 4;277(5322):32–3
The media's love affair with AIDS research: hope vs. hype [news] [see comments] Cohen J. **Science** 1997 Jan 17; 275(5298):298–9. Comment in: Science 1997 Feb 21;275(5303):1049.
HIV treatment strategies utilizing virologic and immunologic markers as criteria for changing treatments. Elashoff M, et al. **Stat Med** 1996 Nov 15–30;15(21–22):2425–43; discussion 2455–8
Use of observational data, including surveillance studies, for evaluating AIDS therapies. Gail MH. **Stat Med** 1996 Nov 15–30;15(21–22):2273–88 (39 ref.)
Long-term follow-up in AIDS clinical trials. Schoenfeld DA. **Stat Med** 1996 Nov 15–30;15(21–22):2359–66; discussion 2367–70
[Pain and treatment of pain in patients with AIDS] Frich LM, et al. **Ugeskr Laeger** 1996 Nov 11;158(46):6595–9 (Eng. Abstr.) **(Dan)**
[AIDS; new developments. IV. Changes in primary medical care due to new possibilities of treating HIV-infected patients] Wigersma L. **Ned Tijdschr Geneeskd** 1997 May 24;141(21):1051–4 (Eng. Abstr.) **(Dut)**
[Hyperkalemia and acute renal insufficiency during overdose of trimethoprim-sulfamethoxazole in a patient with AIDS (letter)] Giraud O, et al. **Ann Med Interne (Paris)** 1997; 148(2):185–6 **(Fre)**
[Sugar diabetes in AIDS patients treated with antiretroviral nucleoside analogs] Mauvais-Jarvis F, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:43–8 (29 ref.) **(Fre)**
[Anti-retrovirus agents in AIDS: therapeutic strategy and prospectives for the future] **Rev Med Interne** 1997; 18(2):100–5 (37 ref.) **(Fre)**
[AIDS: early treatment too seldom implemented (news)] **Dtsch Med Wochenschr** 1997 Aug 22;122(34–35):A27 **(Ger)**
[Nevirapine: a new principle of action against HIV (news)] **Dtsch Med Wochenschr** 1996 Dec 6;121(49):A48–9 **(Ger)**
[HIV: to administer protease inhibitors early (news)] **Dtsch Med Wochenschr** 1996 Dec 6;121(49):A49 **(Ger)**
[Rhabdomyolysis in antiretroviral therapy with Lamivudin] Mendila M, et al. **Dtsch Med Wochenschr** 1997 Aug 15; 122(33):1003–6 (Eng. Abstr.) **(Ger)**
[AIDS Congress in Munich: "On the road to the breakthrough" (news)] Schenk M. **Dtsch Med Wochenschr** 1996 Dec 6;121(49):A7 **(Ger)**
[Control of the AIDS virus. The protease inhibitor Saquinavir apparently controls the disease course significantly and decreases death rate (news)] **Fortschr Med** 1996 Dec 20;114(35–36):60–2 **(Ger)**
[AIDS therapy: cautious optimism (editorial)] Heinzl S. **Med Monatsschr Pharm** 1996 Aug;19(8):225 **(Ger)**
[The battle against AIDS in not yet won] **Pharm Unserer Zeit** 1997 Mar;26(2):103–4 **(Ger)**
[Nevirapine—the first non-nucleoside inhibitor of reverse transcriptase in the battle against AIDS] Wiese E. **Pharm Unserer Zeit** 1997 Mar;26(2):99–100 **(Ger)**
[New AIDS study confirms: triple combination therapy with the protease inhibitor indinavir lowers the risk of mortality by 50% (news)] **Schweiz Rundsch Med Prax** 1997 May 14; 86(20):860 **(Ger)**
[Current AIDS drugs (news)] **Schweiz Rundsch Med Prax** 1997 Feb 25;86(9):364–5 **(Ger)**
[Can HIV/AIDS be healed with new therapies? (editorial)] Battegay M. **Schweiz Rundsch Med Prax** 1997 May 28; 86(22):931–2 **(Ger)**
[Role of clinical pharmacology in the monitoring of therapy of HIV-infected subjects] Villani P, et al. **Clin Ter** 1996 Jun;147(6):279–93 (57 ref.) (Eng. Abstr.) **(Ita)**
[Anti-HIV chemotherapy targeted at host-cellular factors] Baba M. **Uirusu** 1996 Dec;46(2):155–60 (42 ref.) **(Jpn)**
[Orientations and present day possibilities for use of anti-HIV drugs] Amato Neto V, et al. **Rev Assoc Med Bras** 1996 Jan-Mar;42(1):16–8 **(Por)**
[Treatment of AIDS and associated diseases] Rytik PG. **Klin Med (Mosk)** 1997;75(1):5–10 (22 ref.) **(Rus)**
[Surface-active substances in the arsenal of agents against AIDS] Krivoshein IuS, et al. **Mikrobiol Z** 1997 Jan-Feb; 59(1):87–97 (69 ref.) (Eng. Abstr.) **(Rus)**
[The molecular bases of AIDS therapy] Benítez-Bribiesca L. **Gac Med Mex** 1997 Mar-Apr;133(2):151–3 (8 ref.) **(Spa)**
[A response to the letter of Dr. Guillermo J. Ruíz Argüelles published in No. 2, 1997 of Gaceta Médica de México (letter)] del Río Chiriboga C. **Gac Med Mex** 1997 May-Jun; 133(3):281 **(Spa)**
[Effect of treatment with nucleoside analogues in subjects with primary genotypic resistance to zidovudine (letter)] Leal M, et al. **Med Clin (Barc)** 1996 Nov 30;107(19):755 **(Spa)**
[Viral load and monitoring of antiretroviral treatment] Soriano V, et al. **Rev Clin Esp** 1996 Dec;196(12):872–7 (53 ref.) **(Spa)**
[Antiretroviral treatment. Present and future of the combinations] Gatell-Artigas JM. **Rev Neurol** 1996 Dec; 24(136):1627–31 (16 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

The socioeconomic impact of AIDS in sub-Saharan Africa. Chevallier E, et al. **AIDS** 1996;10 Suppl A:S205–11 (105 ref.)
Efficiency and rationality in the planning of health care for people with AIDS: an application of the balance of care approach. North-East Italian Group for Planning of AIDS Health Care. Tramarin A, et al. **AIDS** 1997 May; 11(6):809–16
Failure to implement U.S. needle-exchange program has cost many lives and dollars, study says [news] **Am J Health Syst Pharm** 1997 May 15;54(10):1149–50
AIDS therapy: hype or reality? [news] **Ann Oncol** 1996 Sep; 7(7):652
In back alleys near Vancouver's AIDS conference, the disease was gaining ground. Cairney R. **Can Med Assoc J** 1996 Oct 15;155(8):1160–3
International expenditure projections for pharmacotherapeutic advances in the treatment of HIV/AIDS. Sclar DA, et al. **Clin Ther** 1997 Jan-Feb; 19(1):86–95; discussion 84–5
An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Sullivan SD, et al. **Clin Ther** 1996 May-Jun;18(3):546–58
The HIV/AIDS grants economy in New York City, 1983–1992. Chambré SM. **Health Aff (Millwood)** 1996 Fall; 15(3):250–60
Medicare/Medicaid ... the most promising treatment for AIDS [news] **Hosp Health Netw** 1997 Jul 20;71(14):19
Survival and the use and costs of hospital services for London AIDS patients treated with AZT. Beck EJ, et al. **Int J STD AIDS** 1996 Nov-Dec;7(7):507–12
The cost of health care for HIV-positive patients. Brettle RP, et al. **Int J STD AIDS** 1997 Jan;8(1):50–3
Lifetime costs of HIV/AIDS medical care [letter; comment] Pinkerton SD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 1;14(4):380–2. Comment on: J Acquir Immune Defic Syndr Hum Retrovirol 1996 Aug 1;12(4):371–8. Comment on: J Acquir Immune Defic Syndr Hum Retrovirol 1996 Aug 1;12(4):413–20.
The impact of human immunodeficiency virus/AIDS. Bertozzi SM. **J Infect Dis** 1996 Oct;174 Suppl 2:S253–7
The mounting medical care cost for adult AIDS patients at the Faculty of Medicine, Siriraj Hospital: consideration for management. Suwanagool S, et al. **J Med Assoc Thai** 1997 Jul;80(7):431–9
The use and cost of hospital services by London AIDS patients with different AIDS defining conditions. Beck EJ, et al. **J Public Health Med** 1996 Dec;18(4):457–64
Economic consequences of HIV/AIDS in India. Pandav CS, et al. **Natl Med J India** 1997 Jan-Feb;10(1):27–30
AIDS activists issue safeguards for people with AIDS who sell their life insurance policies. **Oncology (Huntingt)** 1996 Jul;10(7):984, 987
Evaluation of drug use and cost of hospital care for AIDS patients between 1990 and 1994. Peyron F, et al. **Pharm World Sci** 1997 Aug;19(4):202–7
Migration of persons with AIDS—a search for support from elderly parents? Ellis M, et al. **Soc Sci Med** 1996 Oct; 43(7):1109–18
Medicaid eligibility policies for people with AIDS. Buchanan RJ. **Soc Work Health Care** 1996;23(2):15–41
An economic analysis of two models of hospital care for AIDS patients: implications for hospital discharge planning. Fahs MC, et al. **Soc Work Health Care** 1996;22(4):21–34
Pediatric AIDS at Mount Sinai Medical Center 1988–89: a study of costs and social severity. Muller C, et al. **Soc Work Health Care** 1996;22(4):1–20
[The costs of AIDS: the adequacy of hospitalization to improve efficacy (letter)] Gutiérrez Rodero F, et al. **Med Clin (Barc)** 1996 Oct 26;107(14):559 **(Spa)**

ENZYMOLOGY

Absence of the inducible form of nitric oxide synthase in the brains of patients with the acquired immunodeficiency syndrome. Bagasra O, et al. **J Neurovirol** 1997 Apr; 3(2):153–67

EPIDEMIOLOGY

STDs, AIDS and reproductive health. Johannisson E. **Adv Contracept** 1996 Dec;12(4):281–4 (0 ref.)
Change, co-option and the community sector. Altman D. **AIDS** 1995;9 Suppl A:S239–43 (28 ref.)
A review of national AIDS-related behavioral surveys. Catania JA, et al. **AIDS** 1996;10 Suppl A:S183–90 (33 ref.)
The socioeconomic impact of AIDS in sub-Saharan Africa. Chevallier E, et al. **AIDS** 1996;10 Suppl A:S205–11 (105 ref.)
Survival in a cohort of 1205 AIDS patients from Milan [letter; comment] d'Arminio Monforte A, et al. **AIDS** 1996 Jun; 10(7):798–9. Comment on: AIDS 1995 Dec;9(12):1351–6.
Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort. Dore GJ, et al. **AIDS** 1996 Oct; 10(12):1401–6
Reconstruction and prediction of the HIV/AIDS epidemic among adults in the European Union and in the low prevalence countries of central and eastern Europe. Downs AM, et al. **AIDS** 1997 Apr;11(5):649–62
Steady sexual relationship with an HIV-positive partner and the progression rate to AIDS [letter] Flateby G, et al. **AIDS** 1996 Dec;10(14):1749–51
HIV/AIDS surveillance in Colombia: regional differences in epidemic trends [letter] Garcia-Bernal R, et al. **AIDS** 1997 Aug;11(10):1297–8
Comparative impact assessment of AIDS: between doomsday and complacency [letter] Jager JC, et al. **AIDS** 1996 Feb; 10(2):238–40
HIV-1 and HIV-2 AIDS in African patients living in Paris [letter] Matheron S, et al. **AIDS** 1997 Jun;11(7):934–6
Global estimates and epidemiology of HIV-1 infections and AIDS: further heterogeneity in spread and impact. Mertens TE, et al. **AIDS** 1995;9 Suppl A:S259–72
Bridge populations in the spread of HIV/AIDS in Thailand. Morris M, et al. **AIDS** 1996 Sep;10(11):1265–71
AIDS at a university hospital in Bangkok, Thailand [letter] Ruxrungtham K, et al. **AIDS** 1996 Aug;10(9):1047–9
HIV/AIDS in New Zealand: an epidemic in decline? Sharples KJ, et al. **AIDS** 1996 Sep;10(11):1273–8
World Health Organization Global AIDS Statistics. **AIDS Care** 1996 Oct;8(5):619–23
WHO Global AIDS Statistics. **AIDS Care** 1996 Jun;8(3):381
WHO Global AIDS Statistics. **AIDS Care** 1996 Dec;8(6):719
World Health Organization Global AIDS Statistics. **AIDS Care** 1997 Apr;9(2):251–5
WHO global AIDS statistics. **AIDS Care** 1996 Aug;8(4):501
The orphan problem: experience of a sub-Saharan Africa rural population in the AIDS epidemic. Kamali A, et al. **AIDS Care** 1996 Oct;8(5):509–15
The epidemiology of HIV and AIDS in the United States. Ward JW, et al. **AIDS Clin Rev** 1997–98;:1–45 (157 ref.)
Characteristics of risk-taking behaviors, HIV and AIDS knowledge, and risk perception among young males in southwest China. Wu Z, et al. **AIDS Educ Prev** 1997 Apr; 9(2):147–60
In vivo and in vitro sequence diversity of the V3 env region of HIV type 1 from the Ivory Coast. Audoly G, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):1073–5
Evidence for HIV type 1 strains of U.S. intravenous drug users as founders of AIDS epidemic among intravenous drug users in northern Europe. Lukashov VV, et al. **AIDS Res Hum Retroviruses** 1996 Aug 10;12(12):1179–83
Spread of HIV type 1 in Slovakia remains limited and is restricted to subtype B. Zachar V, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):1069–71
CDC data on AIDS [news] **Am Fam Physician** 1997 May 1;55(6):2347–8
A new era in HIV care [editorial; comment] Soloway B. **Am Fam Physician** 1997 Jul;56(1):37, 40–2. Comment on: Am Fam Physician 1997 Jul;56(1):87–96.
Epidemiology of acquired immunodeficiency syndrome: advancing to an endemic era. Graham NM. **Am J Med** 1997 Apr 1;102(4A):2–8 (34 ref.)
Hemophilia and AIDS in married men: functioning of family members. Hemophilia PAC Project. Forehand R, et al. **Am J Orthopsychiatry** 1997 Jul;67(3):470–84
The AIDS epidemic among Spanish drug users: a birth cohort-associated phenomenon. Castilla J, et al. **Am J Public Health** 1997 May;87(5):770–4
AIDS—an update on the global dynamics [editorial] Stein Z, et al. **Am J Public Health** 1997 Jun;87(6):901–4
The lack of association of marijuana and other recreational drugs with progression to AIDS in the San Francisco Men's Health Study. Di Franco MJ, et al. **Ann Epidemiol** 1996 Jul;6(4):283–9
Syphilis and AIDS. Podwińska J. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):329–33 (46 ref.)
Demographic pattern of AIDS in Australia, 1991 to 1993. The National HIV Surveillance Committee. Li Y, et al. **Aust N Z J Public Health** 1996 Aug;20(4):421–5
AIDS, epidemics, and statistics. Brookmeyer R. **Biometrics** 1996 Sep;52(3):781–96 (42 ref.)
A competing risks analysis of presenting AIDS diagnoses trends. Fusaro RE, et al. **Biometrics** 1996 Mar;52(1):211–25
Epidemiology of Kaposi's sarcoma in the Nordic countries before the AIDS epidemic. Hjalgrim H, et al. **Br J Cancer** 1996 Nov;74(9):1499–502
AIDS in Africa: face the facts [letter; comment] Squire SB. **Br J Hosp Med** 1997 Apr 16–May 6;57(8):412. Comment

on: Br J Hosp Med 1996 Nov 6-19;56(9):442-3.
Articles on AIDS in major Japanese newspapers. Hayashi Y, et al. **Bull Tokyo Med Dent Univ** 1996 Dec;43(4):75-7
Seroprevalence of HIV infection in childbearing women in Nova Scotia. Johnston BL, et al. **Can J Public Health** 1997 Jan-Feb;88(1):27-31
Africa's emerging AIDS-orphans crisis. Baggaley RC, et al. **Can Med Assoc J** 1997 Mar 15;156(6):873-5
In back alleys near Vancouver's AIDS conference, the disease was gaining ground. Cairney R. **Can Med Assoc J** 1996 Oct 15;155(8):1160-3
Should prisons ease drug prohibition to help reduce disease spread? Kent H. **Can Med Assoc J** 1996 Nov 15; 155(10):1489-91
The first one hundred AIDS cases in Hong Kong. Lee SS, et al. **Chin Med J (Engl)** 1996 Jan;109(1):70-6
AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Alvar J, et al. **Clin Dermatol** 1996 Sep-Oct;14(5):541-6 (31 ref.)
Primary human immunodeficiency virus type 1 infection may vary in time, place, and person [letter; comment] Hudson CP, et al. **Clin Infect Dis** 1997 Feb;24(2):282-3. Comment on: Clin Infect Dis 1996 Jun;22(6):1121-2.
Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Maenza JR, et al. **Clin Infect Dis** 1997 Jan;24(1):28-34
Patterns of geographic mobility of persons with AIDS in Canada from time of AIDS index diagnosis to death. Hogg RS, et al. **Clin Invest Med** 1997 Apr;20(2):77-83
HIV and AIDS among the severely mentally ill: introduction to the special series. Carey MP, et al. **Clin Psychol Rev** 1997;17(3):241-5
Research on HIV, AIDS, and severe mental illness: recommendations from the NIMH National Conference. McKinnon K, et al. **Clin Psychol Rev** 1997;17(3):327-31
The changing global epidemiology of HIV infection and AIDS. Davison K, et al. **Commun Dis Rep CDR Rev** 1997 Aug 22;7(9):R134-6
An overview of the HIV and AIDS epidemic in the United Kingdom. Hughes G. **Commun Dis Rep CDR Rev** 1997 Aug 22;7(9):R121-2
The HIV epidemic in injecting drug users. Madden PB, et al. **Commun Dis Rep CDR Rev** 1997 Aug 22;7(9):R128-30
AIDS and HIV infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1997 Jun 27; 7(26):237-8
AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1996 Dec 20; 6(51):451-2
AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1997 Mar 28; 7(13):117-8
AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1997 Feb 28;7(9):83-4
Surveillance of HIV and AIDS in 1996. **Commun Dis Rep CDR Wkly** 1997 Jan 24;7(4):17
AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1997 Jan 24;7(4):29-32
AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1996 Aug 16; 6(33):291-2
AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1996 Jan 19;6(3):25-8
AIDS surveillance in the Americas. **Epidemiol Bull** 1997 Mar; 18(1):16
The UK register of HIV seroconverters: methods and analytical issues. UK register of HIV seroconverters (UKRHS) Steering Committee. **Epidemiol Infect** 1996 Oct; 117(2):305-12
Routinely reported sexually transmitted diseases presage the evolution of the AIDS epidemic. Petridou E, et al. **Epidemiology** 1997 Jul;8(4):449-52
A meta-analysis of estimates of the AIDS incubation distribution. Cooley PC, et al. **Eur J Epidemiol** 1996 Jun; 12(3):229-35
Absence of HIV-1 and HIV-2 infection in different populations from Alexandria, Egypt [letter] Renganathan E, et al. **Eur J Epidemiol** 1995 Dec;11(6):711-2
Estimating the size of the HIV epidemic among injecting drug users in Amsterdam. van Haastrecht HJ, et al. **Eur J Epidemiol** 1997 Apr;13(3):261-5
Global expansion of HIV infection and AIDS. Tarantola DJ, et al. **Hosp Pract (Off Ed)** 1996 Oct 15;31(10):63-6, 69, 72-3 passim
Effects of treatment and prevalence-dependent recruitment on the dynamics of a fatal disease. Velasco-Hernández JX, et al. **IMA J Math Appl Med Biol** 1996 Sep;13(3):175-92
Computing marginal expectations for large compartmentalized models with application to AIDS evolution in a prison system. Yakowitz S, et al. **IMA J Math Appl Med Biol** 1996 Dec;13(4):223-44
HIV-2 prevalence in Uttar Pradesh. Kulshreshtha R, et al. **Indian J Med Res** 1996 Mar;103:131-3
Evidence for high prevalence & rapid transmission of HIV among individuals attending STD clinics in Pune, India. Mehendale SM, et al. **Indian J Med Res** 1996 Dec; 104:327-35
Epidemiological features of acquired immunodeficiency syndrome in southern India. Srikanth P, et al. **Indian J Med Res** 1997 May;105:191-7
Differential characteristics of AIDS patients with a history of imprisonment. Caylà JA, et al. **Int J Epidemiol** 1995 Dec;24(6):1188-96
Lack of AIDS awareness in primary care physicians: another Third World disaster? [letter] Bambery P, et al. **Int J STD AIDS** 1996 Aug-Sep;7(5):379-80
Clinical features, outcome and survival from cerebral toxoplasmosis in Edinburgh AIDS patients. Laing RB, et al. **Int J STD AIDS** 1996 Jul;7(4):258-64
AIDS defining diseases in the UK: the impact of PCP prophylaxis and twelve years of change. Porter K, et al. **Int J STD AIDS** 1996 Jul;7(4):252-7
Nationwide survey of neurologic manifestations of acquired immunodeficiency syndrome in Japan [see comments] Nakagawa M, et al. **Intern Med** 1997 Mar;36(3):175-8. Comment in: Intern Med 1997 Mar;36(3):160-1.
The molecular epidemiology of HIV-1 among male sex workers in northern Thailand. Beyrer C, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Aug 1;15(4):304-7
Impact of the 1993 expanded AIDS surveillance case definition on reporting of persons without HIV risk information. Hammett TA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Mar 1;14(3):259-62
AIDS epidemic in San Francisco among men who report sex with men: successes and challenges of HIV prevention. Katz MH. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S38-46 (21 ref.)
Descriptive epidemiology of HIV/AIDS in Japan, 1985-1994. Kihara M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S3-12
Impact of laboratory-initiated reporting of CD4+ T lymphocytes on U.S. AIDS surveillance. Klevens RM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jan 1;14(1):56-60
Trends in heterosexually acquired AIDS in the United States, 1988 through 1995. Neal JJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 15;14(5):465-74
The association between youth, women, and acquired immunodeficiency syndrome. Shevitz A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 15;13(5):427-33
Arkansas HIV/AIDS report 1983-1996. **J Ark Med Soc** 1996 May;92(12):636-7
AIDS in the ICU [editorial; comment] Kapadia F. **J Assoc Physicians India** 1996 Jul;44(7):447-8. Comment on: J Assoc Physicians India 1996 Jul;44(7):454-6.
Expression of the alpha 5 beta 1 fibronectin receptor on T lymphocytes of patients with HIV-1 infection. Torre D, et al. **J Clin Pathol** 1996 Sep;49(9):733-6
Epidemiologic principles in studies of infectious disease outcomes: pediatric HIV as a model. Scott GS, et al. **J Commun Disord** 1997 Jul-Aug;30(4):303-22; quiz 322-4 (78 ref.)
Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type 1 infection in homosexual men. Veugelers PJ, et al. **J Infect Dis** 1997 Jul;176(1):112-7
HIV and AIDS in Africa. African policies in response to AIDS in relation to various national legal traditions. Alkas PH, et al. **J Leg Med** 1996 Dec;17(4):527-46
Sex-ratio patterns of AIDS patients in Thailand. Rerks-Ngarm S. **J Med Assoc Thai** 1997 Jan;80(1):34-46
State HIV/AIDS cases reach 2622 [news] **J Okla State Med Assoc** 1997 Feb;90(2):73
Assessing prognosis in infants infected with human immunodeficiency virus [editorial; comment] Novelli VM. **J Pediatr** 1996 Nov;129(5):623-5. Comment on: J Pediatr 1996 Nov;129(5):648-55.
Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups. Dittmar MT, et al. **J Virol** 1997 Oct; 71(10):8008-13
From the Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths, and prevalence--United States, 1996. **JAMA** 1997 Mar 19; 277(11):874-5
From the Centers for Disease Control and Prevention. AIDS among children--United States, 1996. **JAMA** 1996 Dec 11; 276(22):1791-2
From the Centers for Disease Control and Prevention. AIDS rates. **JAMA** 1997 May 21;277(19):1509-10
AIDS in women in the United States. Recent trends. Wortley PM, et al. **JAMA** 1997 Sep 17;278(11):911-6
Hemophilia and AIDS in Kansas [news] Mehrhof A, et al. **Kans Med** 1995 Winter;96(4):177
Loss to follow-up effect in investigations of HIV-1 incidence [letter; comment] Beyrer C, et al. **Lancet** 1997 Mar 1; 349(9052):649-50. Comment on: Lancet 1996 Nov 16;348(9038):1347-51.
Hanoi gears up for growing AIDS threat [news] Ivker R. **Lancet** 1996 Oct 26;348(9035):1162
AIDS epidemic in Kaliningrad [letter] Leinikki P. **Lancet** 1997 Jun 28;349(9069):1914-5
Will Egypt escape the AIDS epidemic? [news] Lenton C. **Lancet** 1997 Apr 5;349(9057):1005
Increase reported in UK HIV-1 infections in 1996 [news] Morris K. **Lancet** 1997 Feb 15;349(9050):479
HIV and AIDS in southeast Asia [letter; comment] Müller O, et al. **Lancet** 1997 Jul 26;350(9073):288. Comment on: Lancet 1997 May 17;349(9063):1451-2.
Risk of HIV-1 infection after human bites [letter] Tereskerz PM, et al. **Lancet** 1996 Nov 30;348(9040):1512
The HIV/AIDS epidemics among drug injectors: a study of contact structure through a mathematical model. Iannelli M, et al. **Math Biosci** 1997 Jan 1;139(1):25-58
The intrinsic rate of increase of HIV/AIDS: epidemiological and evolutionary implications. Levin BR, et al. **Math Biosci** 1996 Feb;132(1):69-96
Steady-state calculation of the risk of HIV infection from transfusion of screened blood from repeat donors. Satten GA. **Math Biosci** 1997 Apr 15;141(2):101-13
The epidemiology of HIV and AIDS. Current trends. Gourevitch MN. **Med Clin North Am** 1996 Nov; 80(6):1223-38 (51 ref.)
AIDS and minorities. Fisher AE, et al. **Med Health R I** 1996 Jul;79(7):264-5
Epidemiology of HIV and AIDS in the Asia-Pacific region. Dore GJ, et al. **Med J Aust** 1996 Nov 4;165(9):494-8 (37 ref.)
AIDS among children--United States, 1996. **MMWR Morb Mortal Wkly Rep** 1996 Nov 22; 45(46):1005-10
AIDS rates. **MMWR Morb Mortal Wkly Rep** 1996 Oct 25; 45(42):926-7
Update: trends in AIDS incidence, deaths, and prevalence--United States, 1996. **MMWR Morb Mortal Wkly Rep** 1997 Feb 28;46(8):165-73
AIDS rates. **MMWR Morb Mortal Wkly Rep** 1997 Sep 26; 46(38):903-4
Update: trends in AIDS incidence -- United States, 1996. **MMWR Morb Mortal Wkly Rep** 1997 Sep 19;46(37):861-7
AIDS rates. **MMWR Morb Mortal Wkly Rep** 1997 Apr 18; 46(15):333-4
National HIV case reporting for the United States. A defining moment in the history of the epidemic. Gostin LO, et al. **N Engl J Med** 1997 Oct 16;337(16):1162-7
Empirical evidence for the severe but localized impact of AIDS on population structure [see comments] Low-Beer D, et al. **Nat Med** 1997 May;3(5):553-7. Comment in: Nat Med 1997 May;3(5):473.
Seroepidemiological profile of 50 AIDS patients in Kerala [letter] Jose L, et al. **Natl Med J India** 1996 Nov-Dec; 9(6):299
AIDS in Europe 'stabilizes' [news] **Nature** 1996 Oct 31; 383(6603):755
Psychiatric comorbidity among hospitalized AIDS patients vs. non-AIDS patients referred for psychiatric consultation [see comments] Bialer PA, et al. **Psychosomatics** 1996 Sep-Oct;37(5):469-75. Comment in: Psychosomatics 1996 Sep-Oct;37(5):407-12.
The emergence of HIV/AIDS in Africa. De Cock KM. **Rev Epidemiol Sante Publique** 1996 Nov;44(6):511-8
Drug resistance of M. tuberculosis isolated from patients with HIV infection seen at an AIDS Reference Center in São Paulo, Brazil. Pinto WP, et al. **Rev Inst Med Trop Sao Paulo** 1996 Jan-Feb;38(1):15-21
Empirical decompositions of overall AIDS epidemics in local epidemics using generalized neural networks. Zaharia CN, et al. **Rom J Virol** 1995 Jan-Jun;46(1-2):57-68
Coping with the impact of the HIV epidemic--the Hlabisa-Liverpool HIV link [editorial] Gilks CF, et al. **S Afr Med J** 1996 Sep;86(9):1077-8
An eleven year follow-up of delayed-type hypersensitivity testing for the identification of HIV-1 infected patients at increased risk of developing AIDS. Karlsson A, et al. **Scand J Infect Dis** 1996;28(2):125-30
The HIV/AIDS epidemic: its evolutionary implications for human ecology with special reference to the immune system. Caldararo N. **Sci Total Environ** 1996 Nov 22; 191(3):245-69 (289 ref.)
Scourge of Africa [news] **Science** 1996 Nov 8;274(5289):923
Community participation in HIV prevention: problems and prospects for community-based strategies among female sex workers in Madras. Asthana S, et al. **Soc Sci Med** 1996 Jul;43(2):133-48
Refocusing the lens: epidemiologic transition theory, mortality differentials, and the AIDS pandemic. Gaylin DS, et al. **Soc Sci Med** 1997 Mar;44(5):609-21 (48 ref.)
The hierarchical diffusion of AIDS and violent crime among U.S. metropolitan regions: inner-city decay, stochastic resonance and reversal of the mortality transition. Wallace R, et al. **Soc Sci Med** 1997 Apr;44(7):935-47
Evidence of an increasing AIDS burden in rural America. Fordyce EJ, et al. **Stat Bull Metrop Insur Co** 1997 Apr-Jun; 78(2):2-9
Use of observational data, including surveillance studies, for evaluating AIDS therapies. Gail MH. **Stat Med** 1996 Nov 15-30;15(21-22):2273-88 (39 ref.)
Uses of the EM algorithm in the analysis of data on HIV/AIDS and other infectious diseases. Becker NG. **Stat Methods Med Res** 1997 Mar;6(1):24-37
The changing demographics of AIDS in Texas. **Tex Med** 1997 Jun;93(6):19
Lack of correlation between the incidence of bloodborne AIDS and overall AIDS incidence in Western Europe. Dal Maso L, et al. **Transfusion** 1997 Feb;37(2):221-5
The molecular epidemiology of human immunodeficiency virus type 1 in six cities in Britain and Ireland. Brown AJ, et al. **Virology** 1997 Aug 18;235(1):166-77
AIDS--1996 [editorial] Figueroa JP. **West Indian Med J** 1996 Dec;45(4):103-4

ACQUIRED IMMUNODEFICIENCY SYNDROME

Human immunodeficiency virus disease in California. Effects of the 1993 expanded case definition of the acquired immunodeficiency syndrome. Singleton JA, et al. **West J Med** 1996 Feb;164(2):122–9

Acquired immunodeficiency syndrome (AIDS)–data as at 30 June 1996. **Wkly Epidemiol Rec** 1996 Jul 5;71(27):205–6 **(Eng, Fre)**

HIV/AIDS: the global epidemic, December 1996. **Wkly Epidemiol Rec** 1997 Jan 24;72(4):17–21 **(Eng, Fre)**

Global AIDS surveillance. **Wkly Epidemiol Rec** 1997 Jul 4; 72(27):197–8 **(Eng, Fre)**

Women and AIDS in south and South-East Asia: the challenge and the response. Mboi N. **World Health Stat Q** 1996;49(2):94–105

[Development of HIV/AIDS in Sweden and Denmark. There is a difference! (letter; comment)] Christenson B, et al. **Ugeskr Laeger** 1997 Aug 4;159(32):4868–70. Comment on: Ugeskr Laeger 1997 Mar 3;159(10):1429–33. **(Dan)**

[AIDS in Sweden and Denmark (letter)] Milfeldt M. **Ugeskr Laeger** 1997 Sep 22;159(39):5811–2 **(Dan)**

[HIV/AIDS development in Denmark and Sweden (letter; comment)] Milfeldt M. **Ugeskr Laeger** 1997 Jun 16; 159(25):3977–8. Comment on: Ugeskr Laeger 1997 Mar 3;159(10):1429–33. **(Dan)**

[Status on the HIV/AIDS epidemic in Denmark by the end of 1995] Smith E. **Ugeskr Laeger** 1997 Jan 27;159(5):585–90 (Eng. Abstr.) **(Dan)**

[HIV/AIDS development in Denmark and Sweden. Are there differences? (see comments)] Smith E. **Ugeskr Laeger** 1997 Mar 3;159(10):1429–33 (Eng. Abstr.) . Comment in: Ugeskr Laeger 1997 Jun 16;159(25):3975–7. Comment in: Ugeskr Laeger 1997 Jun 16;159(25):3977–8. Comment in: Ugeskr Laeger 1997 Aug 4;159(32):4868–70. **(Dan)**

[AIDS epidemic in The Netherlands: current developments in transmission route, age and nationality] Termorshuizen F, et al. **Ned Tijdschr Geneeskd** 1997 Apr 26;141(17):830–5 (Eng. Abstr.) **(Dut)**

[AIDS and HIV infection in the Federal Islamic Republic of Comores (1988–1995)] Toyb M, et al. **Med Trop (Mars)** 1997;57(1):59–61 (Eng. Abstr.) **(Fre)**

[AIDS: one pandemic or many epidemics? (news)] Schenk M. **Dtsch Med Wochenschr** 1996 Dec 6;121(49):A7–8 **(Ger)**

[Aids] Brede HD. **Pharm Unserer Zeit** 1997 Mar;26(2):87 **(Ger)**

[The lung in AIDS] Lo Giudice V, et al. **Minerva Med** 1996 Jul–Aug;87(7–8):347–54 (40 ref.) (Eng. Abstr.) **(Ita)**

[Study on trends of reported numbers of HIV infected and AIDS cases based on the AIDS surveillance data until 1994] Hashimoto S, et al. **Nippon Koshu Eisei Zasshi** 1995 Dec;42(12):1091–96 **(Jpn)**

[Women and AIDS: Issues in development countries] Tamashiro H. **Nippon Koshu Eisei Zasshi** 1995 Dec; 42(12):1013–16 **(Jpn)**

[The AIDS-statement of the Health Services on HIV infections among Africans (letter; comment)] Alvik A, et al. **Tidsskr Nor Laegeforen** 1996 Sep 10;116(21):2607–8. Comment on: Tidsskr Nor Laegeforen 1996 Aug 30;116(20):2495–6. **(Nor)**

[AIDS and HIV infection in 1995] Szata W. **Przegl Epidemiol** 1997;51(1–2):167–75 **(Pol)**

[AIDS: the view from Africa] Pereira MH. **Acta Med Port** 1995 Nov;8(11):655–9 (Eng. Abstr.) **(Por)**

[AIDS in the Americas at the end of 1995] **Bol Oficina Sanit Panam** 1996 Jul;121(1):87–90 **(Por)**

[Bacterial infections in patients with acquired immunodeficiency syndrome (AIDS). Review of literature] Masukawa II, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Jan–Feb;51(1):26–33 (113 ref.) (Eng. Abstr.) **(Por)**

[The epidemiological considerations of the evolution of HIV/AIDS in Iaşi County in 1990–1995] Ivan A, et al. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan–Jun; 42(1–2):77–80 **(Rum)**

[AIDS as a social problem] Sidorenko GI, et al. **Gig Sanit** 1996 Sep–Oct;(5):40–2 **(Rus)**

[A delay in the care for HIV patients in an area with a low rate of AIDS (letter)] López-Gómez M, et al. **An Med Interna** 1997 Apr;14(4):214 **(Spa)**

[An epidemiological and social study of 127 patients with AIDS IN Aragon] Zalba B, et al. **Aten Primaria** 1997 Mar 15;19(4):159–64 (Eng. Abstr.) **(Spa)**

[Analysis of 1,187 consecutive cases of AIDS: variations and trends in time] Buira E, et al. **Enferm Infecc Microbiol Clin** 1996 May;14(5):290–5 (Eng. Abstr.) **(Spa)**

[Epidemic of AIDS in Mexico. Global analysis 1981–1996] Magis-Rodriguez C, et al. **Gac Med Mex** 1996 Sep–Oct; 132(5):545–50 **(Spa)**

[AIDS and women (letter; comment)] Noguer I, et al. **Med Clin (Barc)** 1997 May 10;108(18):717–9. Comment on: Med Clin (Barc) 1996 May 18;106(19):734–6. **(Spa)**

[Future scenarios of HIV-AIDS: from the "event" disease to diffuse chronicity. From the moral stigma to the central zones of social vulnerability] Conde Gutiérrez F. **Rev Esp Salud Publica** 1997 Jan–Feb;71(1):1–7 **(Spa)**

[Natural history of human immunodeficiency virus infection in a cohort of Chilean patients] Vial PA, et al. **Rev Med Chil** 1996 May;124(5):525–35 (Eng. Abstr.) **(Spa)**

[AIDS ravages in Africa (letter)] Andersson S. **Lakartidningen** 1997 Jan 29;94(5):318 **(Swe)**

[The AIDS pandemic in Africa. Only one out of three poor Africans will reach the age of 40--so why worry? (see comments)] Sihm H. **Lakartidningen** 1997 Feb 12; 94(7):547–8. Comment in: Long Term Care (Don Mills) 1997 Apr 2;94(14):1261. **(Swe)**

[The HIV tragedy in India: twelve million will probably be HIV-positive in the year of 2000. Mostly suffering are the vulnerable women] Svensson P. **Lakartidningen** 1997 Mar 5;94(10):801–4 **(Swe)**

ETHNOLOGY

HIV and AIDS, other sexually transmitted diseases, and tuberculosis in ethnic minorities in United Kingdom: is surveillance serving its purpose? [see comments] De Cock KM, et al. **BMJ** 1997 Jun 14;314(7096):1747–51. Comment in: BMJ 1997 Jun 14;314(7096):1703–4.

The narrative of AIDS among the Tonga of Zambia. Mogensen HO. **Soc Sci Med** 1997 Feb;44(4):431–9

Acquired immunodeficiency syndrome in Alabama: special concerns for black women. Holmes R, et al. **South Med J** 1997 Jul;90(7):697–701

[How to manage HIV seropositive or AIDS patients in rural Burkina Faso?] Taverne B. **Sante** 1997 May–Jun; 7(3):177–86 (16 ref.) (Eng. Abstr.) **(Fre)**

[AIDS and Islam] Ridanović Z. **Med Arh** 1997;51(1–2):45–6 (Eng. Abstr.) **(Scr)**

ETIOLOGY

Is AIDS a disease of poverty? Gillies P, et al. **AIDS Care** 1996 Jun;8(3):351–63 (40 ref.)

Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques. Joag SV, et al. **AIDS Res Hum Retroviruses** 1997 May 20; 13(8):635–45

Unscreened transfusion related human immunodeficiency virus type-I infection amongst Indian thalassemic children [letter] Kumar RM, et al. **Am J Hematol** 1996 Sep; 53(1):51–2

The protective effect of AIDS-related behavioral change among injection drug users: a cross-national study. WHO Multi-Centre Study of AIDS and Injecting Drug Use. Des Jarlais DC, et al. **Am J Public Health** 1996 Dec; 86(12):1780–5

Those who believe in alternative theories of AIDS have little room for manoeuvre [letter] Derbyshire SW. **BMJ** 1997 Feb 22;314(7080):607–8

Alternative theories about AIDS should not be dismissed out of hand [letter] Strohman R. **BMJ** 1996 Nov 2; 313(7065):1147–8

Chemokine receptors – the new frontier for AIDS research. Wells TN, et al. **Chem Biol** 1996 Aug;3(8):603–9 (35 ref.)

HIV causes AIDS: Koch's postulates fulfilled [editorial] O'Brien SJ, et al. **Curr Opin Immunol** 1996 Oct;8(5):613–8 (84 ref.)

Distinctions between adult and paediatric AIDS. **Immunol Today** 1997 Jul;18(7):310

Does AIDS emerge from a disequilibrium between two complementary groups of molecules that mimic MHC? Susal C, et al. **Immunol Today** 1996 Mar;17(3):114–9 (46 ref.)

The pathogenesis of AIDS: lessons learned from other medical conditions. Griffiths PD, et al. **Infect Agents Dis** 1996 Oct;5(4):231–9 (50 ref.)

Variant A human herpesvirus six as a cofactor in the pathogenesis of AIDS [letter] Carrigan DR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):97–8

Cross-sectional studies in AIDS pathogenesis: how far can they mislead us? Phillips AN, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Feb 1;14(2):153–7

The relative contributions of psychiatric symptoms and AIDS knowledge to HIV risk behaviors among people with severe mental illness. McKinnon K, et al. **J Clin Psychiatry** 1996 Nov;57(11):506–13

Nutrition in pediatric HIV infection: setting the research agenda. Nutrition and immune function: overview. Beisel WR. **J Nutr** 1996 Oct;126(10 Suppl):2611S–2615S (32 ref.)

The necessity of cofactors in the pathogenesis of AIDS: a mathematical model. Root-Bernstein RS, et al. **J Theor Biol** 1997 Jul 7;187(1):135–46

Re-assessing the virological approach to HIV pathogenesis: can it explain AIDS as an immunological disease? Whitaker RE. **J Theor Biol** 1997 Jul 7;187(1):45–56

Induction of interleukin-1 and glucocorticoid hormones by HIV promotes viral replication and links human chromosome 2 to AIDS pathogenesis: genetic mechanisms and therapeutic implications. Corley PA. **Med Hypotheses** 1997 May;48(5):415–21 (73 ref.)

Apoptosis: mechanisms and relation to AIDS. Famularo G, et al. **Med Hypotheses** 1997 May;48(5):423–9 (73 ref.)

Can we find a solution to the human immunodeficiency virus/acquired immune deficiency syndrome controversy? Is acquired immune deficiency syndrome the consequence of continuous excessive stressing of the body? Hässig A, et al. **Med Hypotheses** 1996 Apr;46(4):388–92 (31 ref.)

Dental and research transmission of acquired immune deficiency syndrome? Or, is there any evidence that human immunodeficiency virus is sufficient to cause acquired immune deficiency syndrome? Root-Bernstein RS. **Med Hypotheses** 1996 Aug;47(2):117–22

Polio vaccines and the origin of AIDS: an update [letter] Stricker RB, et al. **Med Hypotheses** 1997 Feb;48(2):193

A new transmissible AIDS-like disease in mice induced by alloimmune stimuli. Ter-Grigorov VS, et al. **Nat Med** 1997 Jan;3(1):37–41

Blood scandal and E. coli raise questions in Japan [news] Swinbanks D. **Nature** 1997 Jan 2;385(6611):9

The supplement to HIV-AIDS Surveillance project: an approach for monitoring HIV risk behaviors. Buehler JW, et al. **Public Health Rep** 1996;111 Suppl 1:133–7

Circulating cell adhesion molecules in HIV1-infected patients as indicator markers for AIDS progression. Galea P, et al. **Res Immunol** 1997 Feb;148(2):109–17 (36 ref.)

The impact of exposure group on the progression rate to acquired immunodeficiency syndrome. A comparison between intravenous drug users, homosexual men and heterosexually infected subjects. Eskild A, et al. **Scand J Infect Dis** 1997;29(2):103–9

Recent developments in theories of pathogenesis of AIDS [see comments] Antia R, et al. **Trends Microbiol** 1996 Jul; 4(7):282–5 (35 ref.). Comment in: Trends Microbiol 1996 Aug;4(8):299.

Recent developments in theories of pathogenesis of AIDS [letter; comment] Michie CA. **Trends Microbiol** 1996 Aug; 4(8):299. Comment on: Trends Microbiol 1996 Jul;4(7):282–5.

GENETICS

An HIV-1 infected long-term non-progressor (LTNP): molecular analysis of HIV-1 strains in the vpr and nef genes. Saksena NK, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):848–54

HIV-1 DNA in brains in AIDS and pre-AIDS: correlation with the stage of disease. An SF, et al. **Ann Neurol** 1996 Oct;40(4):611–7

The HIV-1 regulatory genes tat and rev as targets for gene therapy. Caputo A, et al. **Antibiot Chemother** 1996; 48:205–16

Genetic pharmacomodulation of nucleoside analogues and gene therapy for AIDS and cancer. Guettari N, et al. **Antibiot Chemother** 1996;48:198–204 (21 ref.)

TAR decoys and trans-dominant gag mutant for HIV-1 gene therapy. Lisziewicz J. **Antibiot Chemother** 1996;48:192–7 (17 ref.)

Apoptosis in AIDS. Genetic control and relevance for AIDS pathogenesis. Gougeon ML. **Biochem Soc Trans** 1996 Nov; 24(4):1055–8 (34 ref.)

Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Garred P, et al. **Lancet** 1997 Jan 25;349(9047):236–40

Dual effect of CCR5 delta 32 gene deletion in HIV-1-infected patients. Copenhagen AIDS Study Group [letter] Garred P, et al. **Lancet** 1997 Jun 28;349(9069):1884

CCR5-delta 32 gene deletion in HIV-1 infected patients [letter] Michael NL, et al. **Lancet** 1997 Sep 6; 350(9079):741–2

CKR-5 deletion heterozygotes progress slower to AIDS [news] Rowe PM. **Lancet** 1996 Oct 5;348(9032):947

CCR5-delta 32 gene deletion in HIV-1 infected patients [letter] Smith MW, et al. **Lancet** 1997 Sep 6;350(9079):741; discussion 742

Association of simian immunodeficiency virus Nef with cellular serine/threonine kinases is dispensable for the development of AIDS in rhesus macaques. Lang SM, et al. **Nat Med** 1997 Aug;3(8):860–5

Scientists confirm natural resistance to HIV-1 [news] **Oncology (Huntingt)** 1996 Dec;10(12):1879–80

In search of AIDS-resistance genes. O'Brien SJ, et al. **Sci Am** 1997 Sep;277(3):44–51

Ethics of AIDS study [letter; comment] Gomperts ED, et al. **Science** 1996 Dec 6;274(5293):1596. Comment on: Science 1996 Sep 27;273(5283):1797–8.

Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Smith MW, et al. **Science** 1997 Aug 15;277(5328):959–65

Molecular pathology of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Knowles DM. **Semin Diagn Pathol** 1997 Feb;14(1):67–82 (141 ref.)

HISTORY

10th anniversary of the National Reference Laboratory on AIDS in the Czech Republic. Bruckova M, et al. **Cent Eur J Public Health** 1995 Nov;3(4):202–4

AIDS and AAA in Egypt? [letter] Littman RJ, et al. **Emerg Infect Dis** 1996 Oct–Dec;2(4):363

1959 Manchester case of syndrome resembling AIDS [see comments] Hooper E, et al. **Lancet** 1996 Nov 16; 348(9038):1363–5. Comment in: Lancet 1997 Feb 1;349(9048):360.

The Manchester seaman [letter; comment] Stricker RB, et al. **Lancet** 1997 Feb 1;349(9048):360. Comment on: Lancet 1996 Nov 16;348(9038):1363–5.

IMMUNOLOGY

Proceedings of the symposium on AIDS, Drugs of Abuse and the Neuroimmune Axis. San Diego, California,

November 11–13, 1995. **Adv Exp Med Biol** 1996;402:1–234

HIV-peplotion vaccine. A novel approach to vaccination against AIDS by transepithelial transport of viral peptides and antigens to Langerhans cells for induction of cytolytic T cells by HLA class I and CD1 molecules for long term protection. Becker Y. **Adv Exp Med Biol** 1996;397:97–104 (22 ref.)

Changing paradigms for an HIV vaccine. Schultz AM. **Adv Exp Med Biol** 1996;397:79–90 (61 ref.)

RANTES, MIP and interleukin-16 in HIV infection [letter] Blazevic V, et al. **AIDS** 1996 Oct;10(12):1435–6

Enhanced expression of activation antigens HLA-DR and CD69 on gamma delta T cells but impaired interleukin-2-induced upregulation in HIV-1 infection [letter] Gröttrup-Wolfers E, et al. **AIDS** 1997 May; 11(6):838–9

Bone-marrow-derived dendritic cells and the pathogenesis of AIDS [editorial] Knight SC. **AIDS** 1996 Jul;10(8):807–17 (104 ref.)

AIDS in a long-term HIV-1-infected patient with a stable high CD4+ cell count and conserved CD4+CD45RO+ subpopulation [letter] Negri C, et al. **AIDS** 1996 Dec; 10(14):1737–8

Inflammatory cytokines and inhibitors in HIV infection: correlation between interleukin-1 receptor antagonist and weight loss. Rimaniol AC, et al. **AIDS** 1996 Oct; 10(12):1349–56

CD4 lymphocyte counts in HIV/AIDS patients with intercurrent illness [letter] Woolley I, et al. **AIDS** 1996 Jun; 10(6):680–1

Dependence of the hazard of AIDS on markers. Yong FH, et al. **AIDS** 1997 Feb;11(2):217–28

Monocytes in HIV type 1-infected individuals lose expression of costimulatory B7 molecules and acquire cytotoxic activity. Dudhane A, et al. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):885–92

AIDS patient monocytes target CD4 T cells for cellular conjugate formation and deletion through the membrane expression of HIV-1 envelope molecules. Dudhane A, et al. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):893–9

Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages. Lewin SR, et al. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):877–83

HIV type 1 coreceptors, neutralization serotypes, and vaccine development. Moore J, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10;13(9):733–6 (35 ref.)

Immunological correlates of disease severity in pediatric slow progressors with human immunodeficiency virus type 1 infection. Patarca R, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):1063–8

Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. Quesada-Rolander M, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):993–9

Alcohol and human immunodeficiency virus infection. Cook RT. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):210A–215A

Progression to acquired immunodeficiency syndrome is influenced by CD4 T-lymphocyte count and time since seroconversion. Begtrup K, et al. **Am J Epidemiol** 1997 Apr 1;145(7):629–35

Unscreened transfusion related human immunodeficiency virus type-I infection amongst Indian thalassemic children [letter] Kumar RM, et al. **Am J Hematol** 1996 Sep; 53(1):51–2

What is going to happen as far as cytokines in AIDS are concerned? [interview] Galanaud P, et al. **Ann Med Interne (Paris)** 1996;147(8):539–41

Host factors in the pathogenesis of HIV disease. Fauci AS. **Antibiot Chemother** 1996;48:4–12 (32 ref.)

Some novel approaches to the control of HIV and select aspects of HIV pathogenesis. Gallo RC. **Antibiot Chemother** 1996;48:188–91 (17 ref.)

A recombinant HIV-1 virus-like particle vaccine: from concepts to a field study. Wagner R, et al. **Antibiot Chemother** 1996;48:68–83 (42 ref.)

Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. Fletcher CV, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1571–4

Preserved neutrophil response to Candida albicans stimulation in AIDS patients with candida esophagitis. Jensen T, et al. **APMIS** 1996 Jul–Aug;104(7–8):591–7

Opsonophagocytosis and intracellular killing activity of neutrophils in patients with human immunodeficiency virus infection. Tachavanich K, et al. **Asian Pac J Allergy Immunol** 1996 Jun;14(1):49–56

Modulation of macrophage inflammatory protein-1alpha and its receptors in human B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma. Sharma V, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):576–81

NIDA technical review: nitrite inhalants. Haverkos HW, et al. **Biomed Pharmacother** 1996;50(5):228–30 (18 ref.)

Antigen/antibody content of circulating immune complexes in HIV-infected patients. Stanojevic M, et al. **Biomed Pharmacother** 1996;50(10):488–93

A stochastic model for the analysis of bivariate longitudinal AIDS data. Sy JP, et al. **Biometrics** 1997 Jun;53(2):542–55

Preliminary observations using HIV-specific transfer factor in AIDS. Pizza G, et al. **Biotherapy** 1996;9(1–3):41–7

Interleukin-15 triggers activation and growth of the CD8 T-cell pool in extravascular tissues of patients with acquired immunodeficiency syndrome. Agostini C, et al. **Blood** 1997 Aug 1;90(3):1115–23

Elevated serum level of Fas ligand correlates with the asymptomatic stage of human immunodeficiency virus infection [letter] Bahr GM, et al. **Blood** 1997 Jul 15; 90(2):896–8

Abnormal expression of the B-cell homing chemokine receptor BLR1 during the progression of acquired immunodeficiency syndrome. Förster R, et al. **Blood** 1997 Jul 15;90(2):520–5

Role of Fas ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication. Sloand EM, et al. **Blood** 1997 Feb 15;89(4):1357–63

Immunological markers of disease progression in patients infected with the human immunodeficiency virus. Pascale JM, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):474–7

Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients. Re MC, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):230–2

T cell receptor (TCR) BV gene repertoires and clonal expansions of CD4 cells in patients with HIV infections. Roglic M, et al. **Clin Exp Immunol** 1997 Jan;107(1):21–30

Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression. Roos MT, et al. **Clin Exp Immunol** 1996 Sep;105(3):409–15

Characterization of HIV-related periodontitis in AIDS patients: HIV-infected macrophage exudate in gingival crevicular fluid as a hallmark of distinctive etiology. Suzuki T, et al. **Clin Exp Immunol** 1997 May;108(2):254–9

Decreased skin reactivity to codeine in patients with the acquired immunodeficiency syndrome. Simonart Th, et al. **Clin Immunol Immunopathol** 1996 Oct;81(1):12–5

A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex. Gries JM, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):70–82

AIDS: decline and fall of immune surveillance? [see comments] Feinberg MB, et al. **Curr Biol** 1997 Mar 1; 7(3):R136–40 (10 ref.). Comment in: Curr Biol 1997 Jul 1;7(7):R403–5.

Immune surveillance and AIDS progression [letter; comment] Zinkernagel R, et al. **Curr Biol** 1997 Jul 1; 7(7):R403–5. Comment on: Curr Biol 1997 Mar 1;7(3):R136–40.

Evolution of leukocyte immunophenotyping as influenced by the HIV/AIDS pandemic: a short history of the development of gating strategies for CD4+ T-cell enumeration. Mandy FF, et al. **Cytometry** 1997 Aug 15; 30(4):157–65 (31 ref.)

The relationship between beta-2-microglobulin, CD4 lymphocyte count, AIDS and death in HIV-positive individuals. Mocroft A, et al. **Epidemiol Infect** 1997 Jun; 118(3):259–66

Modeling AIDS in a mouse. Mosier DE. **Hosp Pract (Off Ed)** 1996 Sep 15;31(9):41–8, 53–5, 59–60 (10 ref.)

Correlates of protection in HIV infection and the progression of HIV infection to AIDS. Clerici M, et al. **Immunol Lett** 1996 Jun;51(1–2):69–73

Cytotoxic T cells--protection from disease progression--protection from infection. Gotch F, et al. **Immunol Lett** 1996 Jun;51(1–2):125–8 (26 ref.)

Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. Scarlatti G, et al. **Immunol Lett** 1996 Jun;51(1–2):23–8

Immune correlates of protection from HIV infection and AIDS. Heeney JL, et al. **Immunol Today** 1997 Jan;18(1):4–8

In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. See DM, et al. **Immunopharmacology** 1997 Jan;35(3):229–35

Autoimmune phenomena and activation of the immune system in HIV infection [letter] Radkowski M, et al. **Infection** 1996 Jan–Feb;24(1):56

Antiviral activity of biological response modifiers in a murine model of AIDS. Requirement for augmentation of natural killer cell activity and synergy with oral AZT. Black PL, et al. **Int J Immunopharmacol** 1996 Nov;18(11):633–50

T cells from individuals in advanced stages of HIV-1 infection do not proliferate but express activation antigens in response to HIV-1-specific antigens. Caruso A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 May 1;15(1):61–9

Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion. Farzadegan H, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 15;13(5):448–55

An immunovirological study of central nervous system involvement during HIV-1 infection of chimpanzees. Grimaldi LM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):12–7

Associations of age, immunosuppression, and AIDS among homosexual men in the Tricontinental Seroconverter Study. Veugelers PJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 15;14(5):435–41

Correlation of skin disorders with CD4 lymphocyte counts in patients with HIV/AIDS. Goldstein B, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):262–4

Immunology of AIDS. Vijayalakshmi V, et al. **J Assoc Physicians India** 1995 Jan;43(1):54–7 (32 ref.)

Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study. Lissoni P, et al. **J Biol Regul Homeost Agents** 1995 Oct-Dec;9(4):155–8

Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group. Phillips AN, et al. **J Clin Epidemiol** 1996 Nov;49(11):1253–8

Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status. Jiang JD, et al. **J Clin Immunol** 1997 Mar;17(2):185–92

Cross-linking of Fas by antibodies to a peculiar domain of gp120 V3 loop can enhance T cell apoptosis in HIV-1-infected patients. Silvestris F, et al. **J Exp Med** 1996 Dec 1;184(6):2287–300

Predicting progression to AIDS. An evaluation of two approaches. Rabeneck L, et al. **J Gen Intern Med** 1996 Oct;11(10):622–4

HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. Baum LL, et al. **J Immunol** 1996 Sep 1;157(5):2168–73

Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. Tomiyama H, et al. **J Immunol** 1997 May 15; 158(10):5026–34

HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS. van der Burg SH, et al. **J Immunol** 1997 Oct 1;159(7):3648–54

Improvement of Herpesvirus saimiri T cell immortalization procedure to generate multiple CD4+ T-cell clones from peripheral blood lymphocytes of AIDS patients. Saha K, et al. **J Immunol Methods** 1997 Aug 7;206(1–2):21–3

Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. Janoff EN, et al. **J Infect Dis** 1997 Apr;175(4):975–8

Longitudinal analysis of CD4 T cell counts, T cell reactivity, and human immunodeficiency virus type 1 RNA levels in persons remaining AIDS-free despite CD4 cell counts <200 for >5 years. Keet IP, et al. **J Infect Dis** 1997 Sep; 176(3):665–71

Human immunodeficiency virus infection and AIDS in a person with negative serology. Montagnier L, et al. **J Infect Dis** 1997 Apr;175(4):955–9

Cytokines enhance neutrophils from human immunodeficiency virus-negative donors and AIDS patients to inhibit the growth of Mycobacterium avium in vitro. Newman GW, et al. **J Infect Dis** 1997 Apr; 175(4):891–900

Cytokine pattern in relation to disease progression in human immunodeficiency virus-infected children. Than S, et al. **J Infect Dis** 1997 Jan;175(1):47–56

The cell surface marker phenotype of macrophages from HIV-1-infected subjects reflects an IL-10-Enriched and IFN-gamma-deprived donor environment. Orlikowsky T, et al. **J Interferon Cytokine Res** 1996 Nov;16(11):957–62

Possible participation of polymorphonuclear cells stimulated by microbial immunomodulators in the dysregulated cytokine patterns of AIDS patients. Cassone A, et al. **J Leukoc Biol** 1997 Jul;62(1):60–6

Immune stimulation and HIV-1 viral replication. Wahl SM, et al. **J Leukoc Biol** 1997 Jul;62(1):67–71 (60 ref.)

In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. Boyer JD, et al. **J Med Primatol** 1996 Jun;25(3):242–50

Virologic, immunologic, and clinical follow-up of a couple infected by the human immunodeficiency virus type one, group O. Nkengasong JN, et al. **J Med Virol** 1997 Mar; 51(3):202–9

Prevalence of anti-vif antibodies in HIV-1 infected individuals assessed using recombinant baculovirus expressed vif protein. O'Neil C, et al. **J Med Virol** 1997 Mar;51(3):139–44

3rd Annual Symposium on AIDS, Drugs of Abuse and the Neuroimmune Axis. San Diego, CA, USA. November 9–11, 1995. Proceedings. **J Neuroimmunol** 1996 Sep; 69(1–2):1–62

Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. Björndal A, et al. **J Virol** 1997 Oct;71(10):7478–87

Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice. Gulizia RJ, et al. **J Virol** 1997 May;71(5):4161–4

Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. Moog C, et al. **J Virol** 1997 May;71(5):3734–41

Detection of HLA-DR associated with monocytotropic, primary, and plasma isolates of human immunodeficiency virus type 1. Saarloos MN, et al. **J Virol** 1997 Feb;

71(2):1640–3
Controversies: does the CD4+ cell count reflect clinical efficacy? [letter] Kinloch-de-Loës S, et al. **JAMA** 1996 Oct 16;276(15):1219; discussion 1919–20
Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya [see comments] Fowke KR, et al. **Lancet** 1996 Nov 16;348(9038):1347–51 . Comment in: Lancet 1997 Mar 1;349(9052):649–50.
Keep guard up against HIV-1-related lung infections, say experts [news] McCarthy M. **Lancet** 1997 May 31; 349(9065):1607
Antigenic diversity thresholds and hazard functions. May RM, et al. **Math Biosci** 1997 Jan 1;139(1):59–68
Acquired immune deficiency syndrome caused by hyperimmunity. Chigira M. **Med Hypotheses** 1996 Jun; 46(6):489–98 (139 ref.)
The eighth mystery of acquired immune deficiency syndrome and the 'Trojan horse' mechanism. Erlander SR. **Med Hypotheses** 1996 Jul;47(1):55–64
Immunological aspects of nitric oxide in HIV-1 infection. Torre D, et al. **Med Hypotheses** 1996 Nov;47(5):405–7 (37 ref.)
CD4+ and CD8+ T cell immune responses of immunocompetent and immunocompromised (AIDS) patients with American tegumentary leishmaniasis. Coutinho SG, et al. **Mem Inst Oswaldo Cruz** 1996 May–Jun; 91(3):381–4
Laboratory indicators for monitoring HIV disease. Pereira RS, et al. **Mem Inst Oswaldo Cruz** 1996 May–Jun; 91(3):359–62
Early progression of disease in HIV-infected infants with thymus dysfunction [published erratum appears in N Engl J Med 1997 Feb 20;336(8):595] Kourtis AP, et al. **N Engl J Med** 1996 Nov 7;335(19):1431–6
Trick and treat: toward peptide mimic vaccines [news; comment] Shikhman AR, et al. **Nat Biotechnol** 1997 Jun; 15(6):512–3. Comment on: Nat Biotechnol 1997 Jun;15(6):547–51.
Live-attenuated HIV vaccines: how safe is safe enough? [news; comment] Murphey-Corb M. **Nat Med** 1997 Jan; 3(1):17–8. Comment on: Nat Med 1997 Jan;3(1):32–6.
Vitamins and immunomodulation in AIDS. Liang B, et al. **Nutrition** 1996 Jan;12(1):1–7 (91 ref.)
New test may predict course of AIDS [news] **Oncology (Huntingt)** 1995 Jul;9(7):674
Scientists confirm natural resistance to HIV-1 [news] **Oncology (Huntingt)** 1996 Dec;10(12):1879–80
Selected P. falciparum specific immune responses are maintained in AIDS adults in Burkina Faso. Migot F, et al. **Parasite Immunol** 1996 Jul;18(7):333–9
Cytokines, viruses and macrophages: an interactive network. An immune dysregulation involving the members of the tumor necrosis factor (TNF) receptor superfamily could be critical in AIDS pathogenesis. Herbein G. **Pathol Biol (Paris)** 1997 Feb;45(2):115–25 (127 ref.)
Activation of the CD95 system increases with disease progression in human immunodeficiency virus type 1–infected children and adolescents. Böhler T, et al. **Pediatr Infect Dis J** 1997 Aug;16(8):754–9
CD95-induced apoptosis contributes to loss of primed/memory but not resting/naive T cells in children infected with human immunodeficiency virus type 1. Böhler T, et al. **Pediatr Res** 1997 Jun;41(6):878–85
Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Klenerman P, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15323–8
Is alcohol a cofactor of HIV and AIDS? Evidence from immunological and behavioral studies. Dingle GA, et al. **Psychol Bull** 1997 Jul;122(1):56–71 (125 ref.)
Role of IL12 in HIV disease/AIDS. Chougnet C, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):615–22 (54 ref.)
Lymphokine-activated cytotoxicity in peripheral blood mononuclear cells of severely immunocompromised HIV-infected patients. Forthal DN, et al. **Scand J Immunol** 1997 Jan;45(1):91–5
Predominance of detrimental humoral immune responses to HIV-1 in AIDS patients with CD4 lymphocyte counts less than 400/mm3. McDougall B, et al. **Scand J Immunol** 1997 Jan;45(1):103–11
An eleven year follow-up of delayed-type hypersensitivity testing for the identification of HIV-1 infected patients at increased risk of developing AIDS. Karlsson A, et al. **Scand J Infect Dis** 1996;28(2):125–30
A new way to resist AIDS? [news] Kaiser J. **Science** 1997 Feb 28;275(5304):1258
Arrest of in vitro T cell differentiation of normal bone marrow-derived CD34+ stem cells with thymic epithelial fragments from children with AIDS. Ruiz ME, et al. **Stem Cells** 1996 Sep;14(5):533–47
Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Abuaf N, et al. **Thromb Haemost** 1997 May;77(5):856–61
Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS patients. Zerhouni B, et al. **Thymus** 1997;24(3):147–56
Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection. de Martino M, et al. **Vaccine** 1997 Aug;15(11):1235–8
[The effect of herbal medicines on the immunodeficient animals by injecting cancer chemotherapeutic agent-special reference to age related recovery of the function] Li AL, et al. **Kansenshogaku Zasshi** 1996 Jul;70(7):717–26 (Eng. Abstr.) **(Jpn)**
[AIDS and tuberculosis (letter)] Iwasaki Y. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):777 **(Jpn)**
[Strategy to overcome AIDS by cell-mediated immunity] Suglmoto M, et al. **Nippon Saikingaku Zasshi** 1996 Feb; 51(2):559–69 (28 ref.) **(Jpn)**
[Presence of autoantibodies in patients infected with HIV] Radkowski M, et al. **Pol Merkuriusz Lek** 1996 Oct; 1(4):254–6 (Eng. Abstr.) **(Pol)**
[Immunologic fetal and neonatal immaturity: influence on the clinical course of HIV-1 infection in children] Ortigão-de-Sampaio MB, et al. **Rev Assoc Med Bras** 1997 Jan–Mar;43(1):29–34 (62 ref.) (Eng. Abstr.) **(Por)**
[Apoptosis. Its role in the immune system ontogeny and in HIV infection (letter; comment)] Perandones CE. **Medicina (B Aires)** 1996;56(1):110–1. Comment on: Medicina (B Aires) 1994;54(6):661–70. **(Spa)**
[Progression of viral infection in twins born from a mother infected with human immunodeficiency virus] Gaggero A, et al. **Rev Med Chil** 1995 Oct;123(10):1189–98 (Eng. Abstr.) **(Spa)**

METABOLISM

Production of plasminogen activator and plasminogen activator inhibitors by alveolar macrophages in control subjects and AIDS patients. Angelici E, et al. **AIDS** 1996 Mar;10(3):283–90
Nutritional status and survival in HIV-1 disease [letter; comment] Baum MK, et al. **AIDS** 1997 Apr;11(5):689–90 . Comment on: AIDS 1996 Sep;10(10):1057–65.
Lack of association of low testosterone with HIV-associated Kaposi's sarcoma [letter; comment] Falutz J. **AIDS** 1996 Jun;10(7):794–5. Comment on: AIDS 1995 Nov;9(11):1295–6.
Vitamin A depletion in HIV infection and AIDS [letter] Jolly PE, et al. **AIDS** 1996 Jan;10(1):114
Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. Kapembwa MS, et al. **AIDS** 1996 Nov;10(13):1509–14
Malabsorption and wasting in AIDS patients with microsporidia and pathogen-negative diarrhea. Lambl BB, et al. **AIDS** 1996 Jun;10(7):739–44
5-Hydroxytryptamine deficits in the caudate nucleus in AIDS [letter] Reynolds GP, et al. **AIDS** 1996 Sep; 10(11):1303–4
Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection. Clerici M, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):1053–61
Lipolytic sensitivity to catecholamines in patients with human immunodeficiency virus infection. Heijligenberg R, et al. **Am J Clin Nutr** 1997 Sep;66(3):633–8
Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. Dieterich DT, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1226–30
Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Heald AE, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1514–9
Porphyrin abnormalities in acquired immunodeficiency syndrome [see comments] O'Connor WJ, et al. **Arch Dermatol** 1996 Dec;132(12):1443–7. Comment in: Arch Dermatol 1996 Dec;132(12):1503–4.
Purine metabolism in HIV-1 virus-infected T lymphocyte population. Carlucci F, et al. **Biomed Pharmacother** 1996; 50(10):505–9
Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers. Sobhani I, et al. **Br J Clin Pharmacol** 1996 Feb;41(2):109–14
Distinct expressions of three cytokines by IL-1-stimulated astrocytes in vitro and in AIDS brain. Vitkovic L, et al. **Brain Behav Immun** 1995 Dec;9(4):378–88
Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level. Guo R, et al. **Chin Med J (Engl)** 1996 Dec;109(12):933–6
Activation of PAK by HIV and SIV Nef: importance for AIDS in rhesus macaques. Sawai ET, et al. **Curr Biol** 1996 Nov 1;6(11):1519–27
Inflammatory disease. **Curr Opin Neurol** 1996 Jun; 9(3):B65–76
Inflammation in AIDS and the role of the macrophage in brain pathology. Achim CL, et al. **Curr Opin Neurol** 1996 Jun;9(3):221–5 (52 ref.)
Longitudinal changes in body composition measured with a variety of methods in patients with AIDS. Paton NI, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Feb 1;14(2):119–27
Increased circulating levels of interleukin-6 in HIV-seropositive subjects [letter] Ullum H, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):93–4
Decreased fat and nitrogen losses in patients with AIDS receiving medium-chain-triglyceride-enriched formula vs those receiving long-chain-triglyceride-containing formula. Craig GB, et al. **J Am Diet Assoc** 1997 Jun; 97(6):605–11
Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome. Pitrak DL, et al. **J Clin Invest** 1996 Dec 15;98(12):2714–9
Expression of the alpha 5 beta 1 fibronectin receptor on T lymphocytes of patients with HIV-1 infection. Torre D, et al. **J Clin Pathol** 1996 Sep;49(9):733–6
Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. Northfelt DW, et al. **J Clin Pharmacol** 1996 Jan;36(1):55–63
Induction of inflammatory cytokines in placental monocytes of gravidae infected with the human immunodeficiency virus type 1. Reuben JM, et al. **J Interferon Cytokine Res** 1996 Nov;16(11):963–71
Abnormalities in the metabolism of acetaminophen in patients infected with the human immunodeficiency virus (HIV). Esteban A, et al. **Methods Find Exp Clin Pharmacol** 1997 Mar;19(2):129–32
Increased hepatic iron in the acquired immunodeficiency syndrome: an autopsy study. al-Khafaji B, et al. **Mod Pathol** 1997 May;10(5):474–80
Parvalbumin and calbindin D-28 k immunoreactivity in dorsal root ganglia in acquired immunodeficiency syndrome. Nagano I, et al. **Neuropathol Appl Neurobiol** 1996 Aug;22(4):293–301
Decreased absolute levels of ascorbic acid and unaltered vasoactive intestinal polypeptide receptor binding in the frontal cortex in acquired immunodeficiency syndrome. Everall IP, et al. **Neurosci Lett** 1997 Mar 14;224(2):119–22
Expression of latent membrane protein 1 in clinically isolated cases and animal models of AIDS-associated non-Hodgkin's lymphomas. Katano H, et al. **Pathol Int** 1996 Aug;46(8):568–74
Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. Shelton MJ, et al. **Pharmacotherapy** 1997 May–Jun;17(3):438–44
[Effect of L-lysine-alpha-oxidase on the synthesis of cell proteins, targets of autoimmune pathology in HIV infection] Berezov TT, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):36–8 **(Rus)**
[Oxygen free radicals and HIV infection. Can antioxidants be useful? (editorial)] Kilstein J, et al. **Medicina (B Aires)** 1996;56(1):105–7 **(Spa)**

MICROBIOLOGY

Adherence patterns of bacterial diarrheal agents in AIDS. Polotsky Y, et al. **Adv Exp Med Biol** 1997;412:367–71
Adherence of Candida albicans strains isolated from AIDS patients. Comparison with pathogenic yeasts isolated from patients without HIV infection. Pereiro M Jr, et al. **Br J Dermatol** 1997 Jul;137(1):76–80
Cutaneous miliary tuberculosis in the AIDS era: case report and review. Libraty DH, et al. **Clin Infect Dis** 1996 Oct; 23(4):706–10 (28 ref.)
Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Maenza JR, et al. **Clin Infect Dis** 1997 Jan;24(1):28–34
Lactobacillus casei infection in an AIDS patient [letter] Abgrall S, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb; 16(2):180–2 (7 ref.)
Radiologic features of Rhodococcus equi pneumonia in AIDS. Muntaner L, et al. **Eur J Radiol** 1997 Jan; 24(1):66–70
Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. Kelly SL, et al. **FEBS Lett** 1997 Jan 2;400(1):80–2
Rapid diagnosis of periodontal infections: findings in AIDS patients. Zambon JJ. **Immunol Invest** 1997 Jan–Feb; 26(1–2):55–65 (45 ref.)
Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method. Marone P, et al. **J Chemother** 1997 Aug;9(4):247–50
In vitro susceptibility of mycobacterial isolates from AIDS patients. Scavizzi A, et al. **J Chemother** 1995 Nov;7 Suppl 4:87–9
Evaluation of an extended blood culture protocol to isolate fastidious organisms from patients with AIDS. Dougherty MJ, et al. **J Clin Microbiol** 1996 Oct;34(10):2444–7
Rapid detection of Mycobacterium avium in stool samples from AIDS patients by immunomagnetic PCR. Li Z, et al. **J Clin Microbiol** 1996 Aug;34(8):1903–7
Isolation of an unusual mycobacterium from an AIDS patient. Tortoli E, et al. **J Clin Microbiol** 1996 Sep;34(9):2316–9
Helicobacter westmeadii sp. nov., a new species isolated from blood cultures of two AIDS patients. Trivett-Moore NL, et al. **J Clin Microbiol** 1997 May;35(5):1144–50
Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses. Liu SL, et al. **J Virol** 1997 Jun;71(6):4284–95
Evidence of nosocomial transmission of tuberculosis among AIDS patients by DNA fingerprinting. Garzelli C, et al. **New Microbiol** 1996 Oct;19(4):285–91
Nasopharyngeal pneumococcal colonization among Kenyan children: antibiotic resistance, strain types and associations with human immunodeficiency virus type 1 infection. Rusen ID, et al. **Pediatr Infect Dis J** 1997 Jul;16(7):656–62
Detection of Cryptococcus neoformans capsular polysaccharide antigen in asymptomatic HIV-infected patients. Negroni R, et al. **Rev Inst Med Trop Sao Paulo** 1995 Sep–Oct;37(5):385–9
[Features in human immunodeficiency virus type 1 in the neonatal period] Moliner Calderón E, et al. **An Esp Pediatr** 1996 Aug;45(2):172–76 (Eng. Abstr.) **(Spa)**

MORTALITY

Long-term survival in patients with advanced immunodeficiency. Chêne G, et al. **AIDS** 1997 Feb; 11(2):209–16

Survival of AIDS patients in an academic unit in Athens, Greece [letter; comment] Dimitrakopoulos A, et al. **AIDS** 1997 May;11(6):828–9. Comment on: AIDS 1996 Sep;10(10):1057–65.

Survival with AIDS in Ireland. Dunne MT, et al. **AIDS** 1997 Aug;11(10):1281–90

Mortality impact of AIDS in Abidjan, 1986–1992. Garenne ML, et al. **AIDS** 1996 Sep;10(11):1279–86

HIV/AIDS mortality in Canada: evidence of gender, regional and local area differentials. Hogg RS, et al. **AIDS** 1996 Jul;10(8):889–94

Impact of HIV/AIDS on life expectancy in the United States. Lai D, et al. **AIDS** 1997 Feb;11(2):203–7

Factors affecting survival in patients with the acquired immunodeficiency syndrome [editorial] [see comments] Mocroft A, et al. **AIDS** 1996 Sep;10(10):1057–65. Comment in: AIDS 1997 Apr;11(5):689–90. Comment in: AIDS 1997 May;11(6):828–9.

Low serum cholesterol and risk of death from AIDS [letter] Neaton JD, et al. **AIDS** 1997 Jun;11(7):929–30

The effect of the 1993 European revision of the AIDS case definition in Italy: implications for modelling the HIV epidemic. Pezzotti P, et al. **AIDS** 1997 Jan;11(1):95–9

United Kingdom AIDS survival in adults. Rogers PA, et al. **AIDS** 1996 Nov;10(13):1571–8

Cryptosporidiosis among patients infected with human immunodeficiency virus. Factors related to symptomatic infection and survival [see comments] Colford JM Jr, et al. **Am J Epidemiol** 1996 Nov 1;144(9):807–16. Comment in: Am J Epidemiol 1997 Aug 15;146(4):358–9.

Annotation: wanted--a simple and meaningful HIV staging system [comment] el-Sadr W, et al. **Am J Public Health** 1997 Apr;87(4):546–8. Comment on: Am J Public Health 1997 Apr;87(4):567–73.

The Boston AIDS Survival Score (BASS): a multidimensional AIDS severity instrument [see comments] Seage GR 3rd, et al. **Am J Public Health** 1997 Apr; 87(4):567–73. Comment in: Am J Public Health 1997 Apr;87(4):546–8.

The distribution of selenium and mortality owing to acquired immune deficiency syndrome in the continental United States. Cowgill UM. **Biol Trace Elem Res** 1997 Jan; 56(1):43–61

Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Mocroft A, et al. **BMJ** 1997 Feb 8;314(7078):409–13

Declining AIDS mortality in New York City. New York City Department of Health. Chiasson MA. **Bull N Y Acad Med** 1997 Summer;74(1):151–2

Increased survival of AIDS patients with heart disease within 10 years? [letter; comment] Monsuez JJ, et al. **Circulation** 1996 Nov 1;94(9):2312–3. Comment on: Circulation 1995 Dec 1;92(11):3229–34.

Survival of adults with AIDS in the United Kingdom. Rogers PA, et al. **Commun Dis Rep CDR Rev** 1997 Jun 27; 7(7):R93–100

HIV infection and AIDS in the United States. **Commun Dis Rep CDR Wkly** 1996 May 3;6(18):153, 156

AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1996 Feb 16;6(7):63–4

A comparison of Cox proportional hazards and artificial neural network models for medical prognosis. Ohno-Machado L. **Comput Biol Med** 1997 Jan;27(1):55–65

The relationship between beta-2-microglobulin, CD4 lymphocyte count, AIDS and death in HIV-positive individuals. Mocroft A, et al. **Epidemiol Infect** 1997 Jun; 118(3):259–66

Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion [see comments] Spijkerman IJ, et al. **Epidemiology** 1996 Nov;7(6):571–7. Comment in: Epidemiology 1996 Nov;7(6):563–5.

Survival after AIDS diagnosis in Tuscany (Italy), 1985–1992. Barchielli A, et al. **Eur J Epidemiol** 1997 Feb;13(2):125–32

Survival and treatment of AIDS patients 1984–1993 [letter; comment] Coker R, et al. **Genitourin Med** 1997 Apr; 73(2):148. Comment on: Genitourin Med 1997 Feb;73(1):44–8.

Survival and treatment of AIDS patients 1984–1993: experience of a smaller east London HIV centre [see comments] Hillman RJ, et al. **Genitourin Med** 1997 Feb; 73(1):44–8. Comment in: Genitourin Med 1997 Apr;73(2):148.

Public health. Orphaned by AIDS. Swan H. **Hosp Health Netw** 1997 Apr 5;71(7):88, 90

Premature mortality in Italy during the first decade of the AIDS epidemic: 1984–1993. Conti S, et al. **Int J Epidemiol** 1997 Aug;26(4):873–9

Mortality among drug users in the AIDS era. Goedert JJ, et al. **Int J Epidemiol** 1995 Dec;24(6):1204–10

Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Mocroft AJ, et al. **Int J Epidemiol** 1997 Apr;26(2):400–7

Reporting delays of deaths with AIDS in the United States. Bacchetti P. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 1;13(4):363–7

Autopsy patterns of disease among subgroups of an inner-city Bronx AIDS population. Markowitz GS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):48–54

Survival after AIDS-defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial Group. Pueyo S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 15;14(5):459–64

Number of AIDS deaths decline in US [news] **J Am Osteopath Assoc** 1997 Aug;97(8):444

Status versus ability in function [letter; comment] Fawcett J, et al. **J Clin Epidemiol** 1997 Apr;50(4):499. Comment on: J Clin Epidemiol 1996 Feb;49(2):193–201.

The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Mofenson LM, et al. **J Infect Dis** 1997 May; 175(5):1029–38

Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death. Sacktor NC, et al. **J Neurovirol** 1996 Dec;2(6):404–10

Impact of pregnancy on maternal AIDS. Kumar RM, et al. **J Reprod Med** 1997 Jul;42(7):429–34

Survival after AIDS diagnosis in South Carolina, 1982–1992. Scott WK, et al. **J S C Med Assoc** 1997 Jan;93(1):5–12

AIDS in a medical intensive care unit: immediate prognosis and long-term survival. Lazard T, et al. **JAMA** 1996 Oct 16;276(15):1240–5

Decline in deaths from AIDS due to new antiretrovirals [letter] Hogg RS, et al. **Lancet** 1997 May 3;349(9061):1294

HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Morgan D, et al. **Lancet** 1997 Jul 26; 350(9073):245–50

9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Poulsen AG, et al. **Lancet** 1997 Mar 29;349(9056):911–4

Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset. Fiala M, et al. **Lymphology** 1997 Sep;30(3):128–36

The epidemiology of HIV and AIDS. Current trends. Gourevitch MN. **Med Clin North Am** 1996 Nov; 80(6):1223–38 (51 ref.)

NYC reports sharp decline in AIDS deaths [news] **Minn Med** 1997 Mar;80(3):55

Patterns of morbidity and mortality in AIDS patients on Pneumocystis carinii prophylaxis who died during hospital admission: a report of 50 diseased patients. Hentzen BT, et al. **Neth J Med** 1996 Sep;49(3):101–5

Pneumocystis carinii pneumonia versus wasting syndrome among AIDS cases in Puerto Rico: a survival analysis. Mayor Becerra AM, et al. **P R Health Sci J** 1996 Dec; 15(4):257–60

Disease patterns and survival after acquired immunodeficiency syndrome diagnosis in human immunodeficiency virus-infected children. Morris CR, et al. **Pediatr Infect Dis J** 1996 Apr;15(4):321–8

Independent epidemics of heterosexual and homosexual HIV infection in South Africa--survival differences. Maartens G, et al. **QJM** 1997 Jul;90(7):449–54

Estimating coverage of a community-based home care programme. Drew RS, et al. **Trop Doct** 1997 Oct; 27(4):210–4

[Statistics--lying, but properly] Bias R. **Wien Med Wochenschr** 1997;147(3):72–4 **(Ger)**

[Long-term survival in patient with acquired immunodeficiency syndrome and adenocarcinoma of the lung] Pereira JR, et al. **Rev Assoc Med Bras** 1996 Oct-Dec; 42(4):258–60 (Eng. Abstr.) **(Por)**

[Impact of AIDS on admissions and mortality in an Internal Medicine Department (1990–1995)] del Río Fernández MC, et al. **Rev Clin Esp** 1997 Apr;197(4):225–31 (Eng. Abstr.) **(Spa)**

NURSING

Informal caregiving to persons with AIDS in the United States: caregiver burden among central cities residents eighteen to forty-nine years old. Turner HA, et al. **Am J Community Psychol** 1997 Feb;25(1):35–59

Document helps school nurses deal with HIV/AIDS. **Am J Nurs** 1997 Jan;97(1):73

RN support seen for assisted suicide [news] **Am J Nurs** 1996 Sep;96(9):12

Understanding the devastation of AIDS. Lisanti P, et al. **Am J Nurs** 1997 Jul;97(7):26–34; quiz 35 (22 ref.)

Nurse advocates needed [letter; comment] Stevens MT. **Am J Nurs** 1997 Mar;97(3):25. Comment on: Am J Nurs 1997 Jan;97(1):44–51; quiz 52.

Computer networks: new tools for nursing practice [editorial] Brennan PF. **Appl Nurs Res** 1996 Nov;9(4):159–60

Hospice at home--a new service for patients with advanced HIV/AIDS: a pilot evaluation of referrals and outcomes. Koffman J, et al. **Br J Gen Pract** 1996 Sep;46(410):539–40

Taking care: caregiving to persons with cancer and AIDS. Stetz KM, et al. **Cancer Nurs** 1997 Feb;20(1):12–22

Nurses' willingness to care for AIDS patients and spirituality, social support, and death anxiety. Sherman DW. **Image J Nurs Sch** 1996 Fall;28(3):205–13

Nursing: sustaining the circle of life in HIV/AIDS prevention and care [news] **Int Nurs Rev** 1996 Sep-Oct; 43(5):132

Effects of group discussion and guided patient care experience on nurses' attitudes towards care of patients with AIDS. Kemppainen JK, et al. **J Adv Nurs** 1996 Aug; 24(2):296–302

Neuroscience nurses' intentions to care for persons with HIV/AIDS. DiIorio C. **J Neurosci Nurs** 1997 Feb; 29(1):50–5

Effects of social support, stress, and level of illness on caregiving of children with AIDS. Hughes CB, et al. **J Pediatr Nurs** 1996 Dec;11(6):347–58

Caring for persons with AIDS in greater Minnesota. Chial H, et al. **Minn Med** 1997 Feb;80(2):43–5

Relationship between hardiness and risk of burnout in a sample of 92 nurses working in oncology and AIDS wards. Costantini A, et al. **Psychother Psychosom** 1997;66(2):78–82

PARASITOLOGY

Diagnosis of disseminated toxoplasmosis using a peripheral blood smear [letter] Albrecht H, et al. **AIDS** 1996 Jun; 10(7):799–800

Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. Gradoni L, et al. **AIDS** 1996 Jun;10(7):785–91

Fluorescence techniques for diagnosing intestinal microsporidiosis in stool, enteric fluid, and biopsy specimens from acquired immunodeficiency syndrome patients with chronic diarrhea. Conteas CN, et al. **Arch Pathol Lab Med** 1996 Sep;120(9):847–53

Respiratory cryptosporidiosis: case series and review of the literature. Clavel A, et al. **Infection** 1996 Sep-Oct; 24(5):341–6 (47 ref.)

Transmission and establishment of a persistent infection of Enterocytozoon bieneusi, derived from a human with AIDS, in simian immunodeficiency virus-infected rhesus monkeys. Tzipori S, et al. **J Infect Dis** 1997 Apr; 175(4):1016–20

PATHOLOGY

Vascular changes in the cerebral cortex in HIV-1 infection. II. An immunohistochemical and lectinhistochemical investigation. Büttner A, et al. **Acta Neuropathol (Berl)** 1996 Jul;92(1):35–41

Intestinal inflammation, ileal structure and function in HIV. Bjarnason I, et al. **AIDS** 1996 Oct;10(12):1385–91

No evidence of significant abortive HIV infection of the brain [letter; comment] Wiley CA, et al. **AIDS** 1997 Feb;11(2):252 . Comment on: AIDS 1997 Feb;11(2):251–2.

A multicenter proton magnetic resonance spectroscopy study of neurological complications of AIDS. Paley M, et al. **AIDS Res Hum Retroviruses** 1996 Feb 10;12(3):213–22

BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. Carbone A, et al. **Am J Pathol** 1997 Jan;150(1):155–65

Aortic endothelium in HIV-1 infection: chronic injury, activation, and increased leukocyte adherence. Zietz C, et al. **Am J Pathol** 1996 Dec;149(6):1887–98

Pneumocystis carinii and cytomegalovirus infections in severely ill, HIV-infected African infants. Jeena PM, et al. **Ann Trop Paediatr** 1996 Dec;16(4):361–8

Expansion of the cerebral ventricles and correlation with acquired immunodeficiency syndrome neuropathology in 232 patients. Gelman BB, et al. **Arch Pathol Lab Med** 1996 Sep;120(9):866–71

Coinfection with Giardia lamblia and Enterocytozoon bieneusi in a patient with acquired immunodeficiency syndrome and chronic diarrhea. Hewan-Lowe K, et al. **Arch Pathol Lab Med** 1997 Apr;121(4):417–22

Neuropathology of early HIV-1 infection. Gray F, et al. **Brain Pathol** 1996 Jan;6(1):1–15 (107 ref.)

Macrophages, multinucleated giant cells, and apoptosis in HIV+ patients and normal blood donors. Ruibal-Ares B, et al. **Clin Immunol Immunopathol** 1997 Feb;82(2):102–16

Changing patterns of infections in patients with AIDS: a study of 279 autopsies of prison inmates and nonincarcerated patients at a university hospital in eastern Texas, 1984–1993 [see comments] Lyon R, et al. **Clin Infect Dis** 1996 Aug;23(2):241–7. Comment in: Clin Infect Dis 1996 Aug;23(2):248–54.

Acquired immune deficiency syndrome (AIDS) and cerebral astrocytoma. Tacconi L, et al. **Clin Neurol Neurosurg** 1996 May;98(2):149–51

Symptomatic myopathies in HIV-1 infected patients untreated with antiretroviral agents--a clinico-pathological study of 30 consecutive patients. Masanés F, et al. **Clin Neuropathol** 1996 Jul-Aug; 15(4):221–5

Vascular changes in the cerebral cortex in HIV-1 infection: I. A morphometric investigation by light and electron microscopy. Weis S, et al. **Clin Neuropathol** 1996 Nov-Dec; 15(6):361–6

Oral pathology of acquired immunodeficiency syndrome and oro-facial Kaposi's sarcoma. Reichart PA. **Curr Top Pathol** 1996;90:97–123 (43 ref.)

Lectin activities of cytokines and growth factors: function and implications for pathology. Zanetta JP, et al. **Histol Histopathol** 1996 Oct;11(4):1101–8 (67 ref.)

Incidence of apoptosis in HIV-myelopathy, myelodysplastic syndromes and non-specific inflammatory lesions of the

bone marrow. Thiele J, et al. **Histopathology** 1997 Apr; 30(4):307–11

Incarceration and the acquired immunodeficiency syndrome: autopsy results in Texas prison inmates. Gelman BB, et al. **Hum Pathol** 1996 Dec;27(12):1282–7

Recombinant human granulocyte–macrophage colony–stimulating factor (rHuGM–CSF) in leukopenic patients with advanced HIV disease. Manfredi R, et al. **J Chemother** 1996 Jun;8(3):214–20

Changes in body composition of human immunodeficiency virus–infected males receiving insulin–like growth factor I and growth hormone. Ellis KJ, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):3033–8

A randomized, placebo–controlled trial of combined insulin–like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection [published erratum appears in J Clin Endocrinol Metab 1996 Oct;81(10):3696] Lee PD, et al. **J Clin Endocrinol Metab** 1996 Aug; 81(8):2968–75

The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV–1 infection. Aupeix K, et al. **J Clin Invest** 1997 Apr 1; 99(7):1546–54

Transendothelial migration of lymphocytes from HIV–1–infected donors: a mechanism for extravascular dissemination of HIV–1. Birdsall HH, et al. **J Immunol** 1997 Jun 15;158(12):5968–77

Pathology of acquired immunodeficiency syndrome. Min KW. **J Korean Med Sci** 1997 Jun;12(3):171–84 (87 ref.)

Correlation of MRI and neuropathology in AIDS. Everall IP, et al. **J Neurol Neurosurg Psychiatry** 1997 Jan; 62(1):92–5

Simple i.v. inoculation of HIV–1 to Thy/Liv SCID–hu mice induce reproducible HIV infection with narrowing of medulla in human thymic implant. Okamoto Y, et al. **J Vet Med Sci** 1997 Apr;59(4):259–63

Pathology of acquired immunodeficiency syndrome (AIDS) in children. Joshi VV. **Keio J Med** 1996 Dec;45(4):306–12 (36 ref.)

HIV infection and aging: mechanisms to explain the accelerated rate of progression in the older patient. Adler WH, et al. **Mech Ageing Dev** 1997 Jun;96(1–3):137–55

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36–1996. A 37–year–old man with AIDS, neurologic deterioration, and multiple hemorrhagic cerebral lesions [clinical conference] **N Engl J Med** 1996 Nov 21;335(21):1587–95

Postmortem MR imaging of the brains of patients with AIDS. Scatliff JH, et al. **Neuroimaging Clin N Am** 1997 May; 7(2):297–320

Herpes simplex virus type 1 encephalitis in acquired immunodeficiency syndrome. Chrétien F, et al. **Neuropathol Appl Neurobiol** 1996 Oct;22(5):394–404 (32 ref.)

The 'high–risk' neuropathological autopsy in AIDS and Creutzfeldt–Jakob disease: principles and practice. Ironside JW, et al. **Neuropathol Appl Neurobiol** 1996 Oct; 22(5):388–93 (31 ref.)

Expression of latent membrane protein 1 in clinically isolated cases and animal models of AIDS–associated non–Hodgkin's lymphomas. Katano H, et al. **Pathol Int** 1996 Aug;46(8):568–74

Intracellular protozoan infection in small intestinal biopsies of patients with AIDS. Light and electron microscopic evaluation. Boldorini R, et al. **Pathol Res Pract** 1996 Mar; 192(3):249–59

Bone marrow biopsy in 50 AIDS patients: a diagnostic approach. Ricci D, et al. **Pathologica** 1995 Dec;87(6):640–5 (40 ref.)

Gastrointestinal manifestations in pediatric AIDS. Kahn E. **Pediatr Pathol Lab Med** 1997 Mar–Apr;17(2):171–208 (127 ref.)

Disseminated calcification with predominant muscle and cerebral involvement in a child with acquired immunodeficiency syndrome: a case report. Liu J, et al. **Pediatr Pathol Lab Med** 1997 Jul–Aug;17(4):593–600

Meningocerebral lesions in children with iatrogenic AIDS. Bogdan FL, et al. **Rom J Morphol Embryol** 1996 Jan–Jun; 42(1–2):53–62

Molecular pathology of acquired immunodeficiency syndrome–related non–Hodgkin's lymphoma. Knowles DM. **Semin Diagn Pathol** 1997 Feb;14(1):67–82 (141 ref.)

Computerized tomography and magnetic resonance guided stereotactic brain biopsy in nonimmunocompromised and AIDS patients. Nicolato A, et al. **Surg Neurol** 1997 Sep; 48(3):267–76; discussion 276–7

Cat scratch disease and acquired immunodeficiency disease: diagnosis by transmission electron microscopy. Guccion JG, et al. **Ultrastruct Pathol** 1996 May–Jun;20(3):195–202

[Neurosyphilis with multiple gummas and AIDS. Report of a case] Maurage CA, et al. **Ann Pathol** 1997 Apr; 17(2):116–9 (Eng. Abstr.) **(Fre)**

[Neuronal apoptosis in the course of human immunodeficiency virus infection] Gray F, et al. **Bull Acad Natl Med** 1996 Nov;180(8):1855–67; discussion 1867–8 (Eng. Abstr.) **(Fre)**

[Experimental study of mechanisms of neuronal death in the course oh HIV infection] Vincent JD, et al. **Bull Acad Natl Med** 1997 Apr;181(4):713–24 (Eng. Abstr.) **(Fre)**

[Multiorgan changes in AIDS in a reported case] Rogowska–Szadkowska D, et al. **Pol Tyg Lek** 1996 Jun; 51(23–26):340–3 (Eng. Abstr.) **(Pol)**

[Pathology of the heart in AIDS. Study of 73 consecutive necropsies] Politi Okoshi M, et al. **Arq Bras Cardiol** 1996 Mar;66(3):129–33 (Eng. Abstr.) **(Por)**

[Rectal biopsies from HIV–infected patients] Matinez C, et al. **G E N** 1995 Oct–Dec;49(4):267–72 (Eng. Abstr.) **(Spa)**

[Diarrhea, hypotension, hyponatremia and hypernatruria in AIDS (clinical conference)] **Medicina (B Aires)** 1996; 56(1):63–72 **(Spa)**

[A case of Kaposi's sarcoma of the eye in an AIDS patient] Barshtein IuA, et al. **Lik Sprava** 1995 Mar–Apr;(3–4):172–4 (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

Drugs of abuse as possible co–factors in AIDS progression: summary of panel discussion. Friedman H. **Adv Exp Med Biol** 1996;402:225–8

Apoptosis in AIDS. Badley AD, et al. **Adv Pharmacol** 1997; 41:271–94 (154 ref.)

Tissue lesions in AIDS patients involve both the lymphoid and the nervous system. Chiodi F. **AIDS** 1995;9 Suppl A:S41–8 (104 ref.)

Spectrum of disease in Africans with AIDS in London. Del Amo J, et al. **AIDS** 1996 Nov;10(13):1563–9

Comparison of progression and non–progression in injecting drug users and homosexual men with documented dates of HIV–1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study. Prins M, et al. **AIDS** 1997 Apr;11(5):621–31

Association between serum vitamin A and E levels and HIV–1 disease progression. Tang AM, et al. **AIDS** 1997 Apr;11(5):613–20

Modelling the AIDS incubation time: evaluation of three right censoring strategies [letter] van Benthem BH, et al. **AIDS** 1997 May;11(6):834–5

Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis [see comments] Banker AS, et al. **Am J Ophthalmol** 1997 Aug;124(2):168–80. Comment in: Am J Ophthalmol 1997 Aug;124(2):227–33.

Human immunodeficiency virus and the brain. Glass JD, et al. **Annu Rev Neurosci** 1996;19:1–26 (149 ref.)

Co–infection with HIV–1/HTLV–II and the risk of progression to AIDS and death. The Oslo HIV Cohort Study Group. Eskild A, et al. **APMIS** 1996 Sep; 104(9):666–72

Homeostasis of chemokines, interferon production and lymphocyte subsets: implications for AIDS pathogenesis. Cho YY, et al. **Biomed Pharmacother** 1997;51(5):221–9

Researchers in cell motility and the cytoskeleton can play major roles in understanding AIDS. Soll DR. **Cell Motil Cytoskeleton** 1997;37(2):91–7 (69 ref.)

Assessment of right ventricle function and pulmonary artery circulation by cine–MRI in patients with AIDS. Casalino E, et al. **Chest** 1996 Nov;110(5):1243–7

Glucocorticoids and Th–1, Th–2 type cytokines in rheumatoid arthritis, osteoarthritis, asthma, atopic dermatitis and AIDS. Norbiato G, et al. **Clin Exp Rheumatol** 1997 May–Jun;15(3):315–23 (79 ref.)

Weight loss, the gut and the inflammatory response in aids patients. Stein TP, et al. **Cytokine** 1997 Feb;9(2):143–7

Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Sellmeyer DE, et al. **Endocr Rev** 1996 Oct;17(5):518–32 (187 ref.)

HEMOCO: a French prospective study of hemophiliacs infected by human immunodeficiency virus type 1 (HIV–1). Boufassa F, et al. **Hematol Cell Ther** 1996 Apr;38(2):193–8

Skeletal muscle mass: evaluation of neutron activation and dual–energy X–ray absorptiometry methods. Wang ZM, et al. **J Appl Physiol** 1996 Mar;80(3):824–31

Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. Heijligenberg R, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4028–32

Pain management for the AIDS patient. Lefkowitz M. **J Fla Med Assoc** 1996 Dec;83(10):701–4 (21 ref.)

Human immunodeficiency virus type 1 Rev– and Tat–specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. van Baalen CA, et al. **J Gen Virol** 1997 Aug;78 (Pt 8):1913–8

Enhanced HIV–1 activity in bone marrow can lead to myelopoietic suppression partially contributed by gag p24. Rameshwar P, et al. **J Immunol** 1996 Nov 1;157(9):4244–50

The dendritic cell in clinical immunology: the AIDS example. Steinman RM. **J Lab Clin Med** 1996 Dec; 128(6):531–5 (18 ref.)

NeuroAIDS, current understanding and future directions. Black RJ, et al. **J Neurovirol** 1996 Aug;2(4):230–3

Relationship of circulating CD4+ T–lymphocytes and p24 antigenemia to the risk of developing AIDS in HIV–infected subjects with oral hairy leukoplakia. Ravina A, et al. **J Oral Pathol Med** 1996 Mar;25(3):108–11

High levels of viremia in hu–PBL–NOD–scid mice with HIV–1 infection. Koyanagi Y, et al. **Leukemia** 1997 Apr; 11 Suppl 3:109–12

Analysis of a model for the pathogenesis of AIDS. Stilianakis NI, et al. **Math Biosci** 1997 Oct 1;145(1):27–46

Acquired immune deficiency syndrome: the glucocorticoid solution. Corley PA. **Med Hypotheses** 1996 Jul;47(1):49–54

Review of the impact on the activation of the human immunodeficiency virus type 1 of ultraviolet light. Duan Y, et al. **Med Hypotheses** 1996 Jul;47(1):11–4 (9 ref.)

The eighth mystery of acquired immune deficiency syndrome and the 'Trojan horse' mechanism. Erlander SR. **Med Hypotheses** 1996 Jul;47(1):55–64

The SCID–hu mouse: an in vivo model for HIV–1 infection in humans. Bonyhadi ML, et al. **Mol Med Today** 1997 Jun; 3(6):246–53 (51 ref.)

Neuropathogenesis of AIDS. Dewhurst S, et al. **Mol Med Today** 1996 Jan;2(1):16–23 (39 ref.)

Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Sardar AM, et al. **Neuroreport** 1996 Mar 22;7(4):910–2

Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection. Muñoz–Fernández MA, et al. **Pediatr Res** 1996 Oct; 40(4):597–602

Can repeated plasma donation by asymptomatic HIV–infected individuals delay the onset of AIDS? Bainbridge DR, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jul 29; 352(1355):763–70

Pediatric aspects of AIDS. Miller CR. **Radiol Clin North Am** 1997 Sep;35(5):1191–221 (59 ref.)

Models for the incubation of AIDS and variations according to age and period. Muñoz A, et al. **Stat Med** 1996 Nov 15–30;15(21–22):2459–73

[Diagnosis by imaging of the brain affected by AIDS] Mercader–Sobrequés JM, et al. **Rev Neurol** 1996 Dec; 24(136):1577–89 (43 ref.) (Eng. Abstr.) **(Spa)**

[Neurological complications caused by cytomegalovirus in patients with AIDS] Reñé R, et al. **Rev Neurol** 1996 Dec; 24(136):1590–6 (70 ref.) (Eng. Abstr.) **(Spa)**

[The virus of human immunodeficiency: virological characteristics, natural history and physiopathology of the nervous system infection] Vidal–Lampurdanés C, et al. **Rev Neurol** 1996 Dec;24(136):1563–8 (44 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

The long–term impact of AIDS–preventive interventions for delinquent and abused adolescents. Slonim–Nevo V, et al. **Adolescence** 1996 Summer;31(122):409–21

Non–human primate models for AIDS vaccines. Desrosiers RC. **AIDS** 1995;9 Suppl A:S137–41 (40 ref.)

Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study. Dorrucci M, et al. **AIDS** 1997 Mar 15;11(4):461–7

Behavioral interventions for reduction of sexually transmitted disease/HIV transmission among female commercial sex workers and clients in Bali, Indonesia. Ford K, et al. **AIDS** 1996 Feb;10(2):213–22

Hope for evidence–based HIV/AIDS prevention? Hart GJ. **AIDS** 1996 Mar;10(3):337–8

The acceptability of voluntary HIV antibody testing in the United States: a decade of lessons learned. Irwin KL, et al. **AIDS** 1996 Dec;10(14):1707–17 (103 ref.)

HIV seroincidence and correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe. Mbizvo MT, et al. **AIDS** 1996 Jul;10(8):895–901

Cost–effectiveness of HIV–prevention skills training for men who have sex with men. Pinkerton SD, et al. **AIDS** 1997 Mar;11(3):347–57

Reducing HIV incidence in developing countries with structural and environmental interventions. Sweat MD, et al. **AIDS** 1995;9 Suppl A:S251–7 (55 ref.)

Interventions among injecting drug users: do they work? van Ameijden EJ, et al. **AIDS** 1995;9 Suppl A:S75–84 (117 ref.)

AIDS–related beliefs, attitudes and intentions among Malawian students in three secondary schools. Bandawe CR, et al. **AIDS Care** 1996 Apr;8(2):223–32

Theatre in AIDS education––a controlled study. Elliott L, et al. **AIDS Care** 1996 Jun;8(3):321–40

Reflections on the 9th International Conference on AIDS Education–– Interventions in Multi–cultural Societies, Israel 25 November–1 December, 1995. Vowles D. **AIDS Care** 1996 Apr;8(2):241–2

Behavior change communication strategies. Aggleton P. **AIDS Educ Prev** 1997 Apr;9(2):111–23 (43 ref.)

AIDS knowledge, teaching comfort, and support for AIDS education among school teachers: a statewide survey. Boscarino JA, et al. **AIDS Educ Prev** 1996 Jun;8(3):267–77

Needs assessment for an urban native HIV and AIDS prevention program. Brassard P, et al. **AIDS Educ Prev** 1996 Aug;8(4):343–51

Risk contexts and risk behaviors in the Euregion Maas–Rhein: the Boule de Neige intervention for AIDS prevention among drug users. Franken IH, et al. **AIDS Educ Prev** 1997 Apr;9(2):161–80

HIV counseling for behavior change. Grinstead OA. **AIDS Educ Prev** 1997 Apr;9(2):125–32

It's like a regular part of gay life: repeat HIV antibody testing among gay and bisexual men. Kalichman SC, et al. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):41–51

Effects of AIDS counseling and risk reduction training on the chronic mentally ill. Katz RC, et al. **AIDS Educ Prev** 1996 Oct;8(5):457–63

An impact evaluation of project SNAPP: an AIDS and pregnancy prevention middle school program. Kirby D,

et al. **AIDS Educ Prev** 1997 Feb;9(1 Suppl):44–61
Children's AIDS-related knowledge and attitudes: variations by grade, race, gender, socioeconomic status, and size of community. Kistner J, et al. **AIDS Educ Prev** 1997 Jun; 9(3):285–98
Understanding why heterosexual adults do not practice safer sex: a comparison of two samples. Kusseling FS, et al. **AIDS Educ Prev** 1996 Jun;8(3):247–57
Organizing Asian Pacific Islanders in an urban community to reduce HIV risk: a case study. Loue S, et al. **AIDS Educ Prev** 1996 Oct;8(5):381–93
Evaluation of HIV/STD prevention, care and support: an update on WHO's approaches. Mertens TE, et al. **AIDS Educ Prev** 1997 Apr;9(2):133–45
Single Thai women's interpersonal communication and mass media reception on AIDS. Nishino Y, et al. **AIDS Educ Prev** 1997 Apr;9(2):181–200
Concepts, goals, and techniques of counseling: review and implications for HIV counseling and testing. Sikkema KJ, et al. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):14–26 (55 ref.)
Prevention implications of AIDS discourses among South African women. Strebel A. **AIDS Educ Prev** 1996 Aug; 8(4):352–74
Does parental involvement make a difference? The impact of parent interactive activities on students in a school-based AIDS prevention program. Weeks K, et al. **AIDS Educ Prev** 1997 Feb;9(1 Suppl):90–106
Retroviral vaccines: challenges for the developing world. Essex M. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):361–3 (26 ref.)
Perspective: research highlights at the Medical College of Wisconsin's Center for AIDS Intervention Research. Advances in HIV primary and secondary prevention. Kelly JA. **AIDS Res Hum Retroviruses** 1996 Oct 10;12(15):1393–5 (14 ref.)
Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. Myagkikh M, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):985–92
Further insights on the inhibition of HIV type 1 infection in vitro by CD4-modified synthetic peptides containing phenylalanine. Prieto I, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):1023–30
The long-term outcome of a personal network-oriented HIV prevention intervention for injection drug users: the SAFE Study. Latkin CA, et al. **Am J Community Psychol** 1996 Jun;24(3):341–64
PHS updates guidelines on chemoprophylaxis after occupational HIV exposure [news] **Am J Health Syst Pharm** 1996 Aug 1;53(15):1764–6
Policy statement on needle exchange programs. **Am J Psychiatry** 1996 Dec;153(12):1660
Increased condom use without other major changes in sexual behavior among the general population in Switzerland. Dubois-Arber F, et al. **Am J Public Health** 1997 Apr; 87(4):558–66
Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention. Holtgrave DR, et al. **Am J Public Health** 1996 Oct; 86(10):1442–5
Establishment of WHO-sponsored field sites for HIV vaccine evaluation in developing countries. Heyward WL, et al. **Antibiot Chemother** 1996;48:139–44
Strategies for the achievement of prophylactic vaccination against HIV. Hilleman MR. **Antibiot Chemother** 1996; 48:161–72 (54 ref.)
Combination strategies for vaccination against HIV. Plotkin SA. **Antibiot Chemother** 1996;48:145–6
Dimensions of AIDS knowledge and risky sexual practices: a study of northern Thai males. VanLandingham M, et al. **Arch Sex Behav** 1997 Jun;26(3):269–93
Evaluating AIDS-related social skills in Anglo and Latino adolescents. Focus on assessment. Blumberg EJ, et al. **Behav Modif** 1997 Jul;21(3):281–307
Lymphoproliferative response to synthetic V3 loop P18 peptide and HIV-1 envelope glycoprotein among individuals immunized with gp160 candidate vaccines. Moukrim Z, et al. **Biomed Pharmacother** 1996;50(10):494–9
HIV control in Cuba. Pérez Avila J, et al. **Biomed Pharmacother** 1996;50(5):216–9
Needlestick injuries [letter] Erridge PL. **Br Dent J** 1996 Oct 19;181(8):284
AIDS in Africa [editorial] [see comments] Gilks CF. **Br J Hosp Med** 1996 Nov 6–19;56(9):442–3. Comment in: Br J Hosp Med 1997 Apr 16–May 6;57(8):412.
Commentary on Joffe (1996) AIDS research and prevention: a social representation approach. Fife-Schaw C. **Br J Med Psychol** 1997 Mar;70 (Pt 1):65–73
Juxtaposing positivist and non-positivist approaches to social scientific AIDS research: reply to Fife-Schaw's commentary. Joffe H. **Br J Med Psychol** 1997 Mar;70 (Pt 1):75–83
AIDS research and prevention: a social representational approach. Joffe H. **Br J Med Psychol** 1996 Sep;69 (Pt 3):169–90
The limitations of trust in intimate relationships: constructions of trust and sexual risk taking. Willig C. **Br J Soc Psychol** 1997 Jun;36 (Pt 2):211–21
HIV/AIDS electronic information resources: a profile of potential users. Huber JT, et al. **Bull Med Libr Assoc** 1996 Oct;84(4):579–81
Baseline for the evaluation of an AIDS programme using prevention indicators: a case study in Ethiopia. Mehret M, et al. **Bull World Health Organ** 1996;74(5):509–16
Request for research proposals. Division of STD Prevention and Control, bureau of HIV/AIDS and STD, Laboratory Centre for Disease Control. **Can Commun Dis Rep** 1996 Oct 15;22(20):173–4 **(Eng, Fre)**
Survey of Montreal's Aboriginal population's knowledge, attitudes and behaviour regarding HIV/AIDS. DuBois MJ, et al. **Can J Public Health** 1996 Jan–Feb;87(1):37–9
Sexual health: are we targeting the right age groups? Sahai V, et al. **Can J Public Health** 1996 Jan–Feb;87(1):40–1
Prison AIDS project focuses on peer education [news] **Can Med Assoc J** 1997 May 1;156(9):1261
AIDS info available over phone, Internet [news] **Can Med Assoc J** 1996 Nov 15;155(10):1467
Costs and benefits of screening pregnant women for HIV [letter; comment] Bueckert H. **Can Med Assoc J** 1996 Nov 15;155(10):1387. Comment on: Can Med Assoc J 1996 Jul 1;155(1):53–4.
A live-virus "suicide" vaccine for human immunodeficiency virus. Kestler HW, et al. **Cleve Clin J Med** 1997 May; 64(5):269–74 (32 ref.)
HIV risk reduction interventions for persons with severe mental illness. Kelly JA. **Clin Psychol Rev** 1997; 17(3):293–309 (50 ref.)
So far so good for HIV vaccine [news] **CMAJ** 1997 Jun 15;156(12):1692
Don't abandon AIDS prevention, warns WHO [news] **CMAJ** 1997 Jul 15;157(2):129
World AIDS Day, 1 December 1996. **Commun Dis Rep CDR Wkly** 1996 Nov 29;6(48):417, 420
The politics of marginalization: the appropriation of AIDS prevention messages among injection drug users. Connors MM. **Cult Med Psychiatry** 1995 Dec;19(4):425–52
AIDS turnaround: first remedy the adverse effects of the condom policy [letter] Gjorgov AN. **Eur J Cancer Prev** 1997 Feb;6(1):96–9
Early evaluation results of a collaborative partnership. Everett W, et al. **Health Aff (Millwood)** 1996 Spring; 15(1):210–2
An HIV/AIDS prevention project for Mexican homosexual men: an empowerment approach. Zimmerman MA, et al. **Health Educ Behav** 1997 Apr;24(2):177–90
Evaluation of 37 AIDS prevention projects: successful approaches and barriers to program effectiveness. Janz NK, et al. **Health Educ Q** 1996 Feb;23(1):80–97
Planned development and evaluation of AIDS/STD education for secondary school students in The Netherlands: short-term effects. Schaalma HP, et al. **Health Educ Q** 1996 Nov;23(4):469–87
Correlates of protection in HIV infection and the progression of HIV infection to AIDS. Clerici M, et al. **Immunol Lett** 1996 Jun;51(1–2):69–73
Cytotoxic T cells--protection from disease progression--protection from infection. Gotch F, et al. **Immunol Lett** 1996 Jun;51(1–2):125–8 (26 ref.)
Hot fusion breakthrough for AIDS research. **Immunol Today** 1996 Jul;17(7):299
Immune correlates of protection from HIV infection and AIDS. Heeney JL, et al. **Immunol Today** 1997 Jan;18(1):4–8
Awareness of AIDS among school children in Haryana. Aggarwal AK, et al. **Indian J Public Health** 1996 Apr-Jun; 40(2):38–45
Using existing health care systems to respond to the AIDS epidemic: research and recommendations for Chile. Aiken LH, et al. **Int J Health Serv** 1997;27(1):177–99
Global priorities for HIV/AIDS intervention research. Aggleton P. **Int J STD AIDS** 1996;7 Suppl 2:13–6 (37 ref.)
Designing behavioural and social science to impact practice and policy in HIV prevention and care. The Executive Committee of the Center for AIDS Prevention Studies (CAPS). Coates TJ, et al. **Int J STD AIDS** 1996;7 Suppl 2:2–12 (97 ref.)
The evaluation of behavioural interventions for gay men: obstacles to evidence-based prevention. Hart GJ. **Int J STD AIDS** 1996;7 Suppl 2:25–9 (19 ref.)
AIDS in rural Africa: a paradigm for HIV-1 prevention [editorial] Hudson CP. **Int J STD AIDS** 1996 Jul; 7(4):236–43 (64 ref.)
HIV/AIDS: the twenty injunctions of London summary of the conference. Kirby MD. **Int J STD AIDS** 1996;7 Suppl 2:83–90
Reflections on the first decade of the HIV/AIDS pandemic: opportunities and priorities for international behavioural research and interventions. Krause RM. **Int J STD AIDS** 1996;7 Suppl 2:47–51 (14 ref.)
The AIDS pandemic: where are we now? [news] **Int Nurs Rev** 1997 Jul-Aug;44(4):100–1
Conquering AIDS: a long way to go [news] **Int Nurs Rev** 1997 May-Jun;44(3):66
Partners in AIDS Prevention: a U.S./Japan collaboration. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S1–80
Science, politics, and AIDS prevention policy. Bayer R. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S22–9 (20 ref.)
International HIV and AIDS prevention: Japan/United States collaboration. Umenai T, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S58–67 (6 ref.)
Effectiveness of the 40 adolescent AIDS-risk reduction interventions: a quantitative review. Kim N, et al. **J Adolesc Health** 1997 Mar;20(3):204–15
AIDS knowledge, concerns, and behavioral changes among inner-city high school students. Sikand A, et al. **J Adolesc Health** 1996 May;18(5):325–8
Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm? Koff WC, et al. **J Clin Immunol** 1996 May;16(3):127–33 (63 ref.)
Knowledge and attitudes of pregnant women regarding AIDS in a semi arid area of Rajasthan. Singh MB, et al. **J Commun Dis** 1997 Jun;29(2):139–44
Acquired immunodeficiency syndrome and suburban adolescents: knowledge, attitudes, behaviors and risks. Imperato AM. **J Community Health** 1996 Oct;21(5):329–47
Sources of AIDS information among low-risk and at-risk populations in five U.S. cities. AIDS Community Demonstration Projects. Wolitski RJ, et al. **J Community Health** 1996 Aug;21(4):293–310
Effect of an AIDS education program for older adults. Rose MA. **J Community Health Nurs** 1996;13(3):141–8
HIV risk reduction for incarcerated women: a comparison of brief interventions based on two theoretical models. St Lawrence J, et al. **J Consult Clin Psychol** 1997 Jun; 65(3):504–9
Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine. Igarashi T, et al. **J Gen Virol** 1997 May;78 (Pt 5):985–9
A citizens' AIDS Task Force: overcoming obstacles. Aiken JH. **J Homosex** 1997;32(3–4):145–67
AIDS and the new medical gaze: bio-politics, AIDS, and homosexuality. Dennis D. **J Homosex** 1997;32(3–4):169–84
The problem with making AIDS comfortable: federal policy making and the rhetoric of innocence. Donovan MC. **J Homosex** 1997;32(3–4):115–44
The social marketing of project ARIES: overcoming challenges in recruiting gay and bisexual males for HIV prevention counseling. Fisher DS, et al. **J Homosex** 1996; 31(1–2):177–202
The social construction of target populations and the transformation of prison-based AIDS policy: a descriptive case study. Hogan NL. **J Homosex** 1997;32(3–4):77–114
Truth and deception in AIDS information brochures. Jones A. **J Homosex** 1997;32(3–4):37–75
The impact of human immunodeficiency virus/AIDS. Bertozzi SM. **J Infect Dis** 1996 Oct;174 Suppl 2:S253–7
Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. Frenkel LM, et al. **J Infect Dis** 1997 Apr; 175(4):971–4
Mechanisms of protection induced by attenuated simian immunodeficiency virus. IV. Protection against challenge with virus grown in autologous simian cells. Almond N, et al. **J Med Primatol** 1997 Feb-Apr;26(1–2):34–43
Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees. Bagarazzi ML, et al. **J Med Primatol** 1997 Feb-Apr; 26(1–2):27–33
Teen sex, AIDS, and contraception: Part three [editorial] Dawson G. **J Natl Med Assoc** 1996 Dec;88(12):768–72
Risk behaviors, self-efficacy, and AIDS prevention among adolescents. Goh DS, et al. **J Psychol** 1996 Sep; 130(5):537–46
Visual coping scenarios to facilitate discussion of coping responses with impoverished women at risk for AIDS. Nyamathi A, et al. **J Psychosoc Nurs Ment Health Serv** 1997 Aug;35(8):17–23
AIDS among children--United States, 1996. Division of HIV/AIDS Prevention, CDC [corrected and republished article originally printed in J Sch Health 1997 Apr;67(4):141–3] **J Sch Health** 1997 May;67(5):175–7
Consensus statements from conference on AIDS/HIV infection and drug abuse treatment. **J Subst Abuse Treat** 1996 Sep–Oct;13(5):441 (0 ref.)
The Wheel Project. Women Helping to Empower and Enhance Lives. Ashery RS, et al. **J Subst Abuse Treat** 1997 Mar–Apr;14(2):113–21
Therapeutic communities: AIDS/HIV risk and harm reduction. De Leon G. **J Subst Abuse Treat** 1996 Sep–Oct; 13(5):411–20; discussion 439 (40 ref.)
HIV risk reduction and service delivery strategies in criminal justice settings. Inciardi JA. **J Subst Abuse Treat** 1996 Sep–Oct;13(5):421–8; discussion 439 (52 ref.)
Sexual partners of substance abuse clients: strategies for HIV/AIDS prevention. Wermuth L. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):505–9 (16 ref.)
Refugees and AIDS [news] Voelker R. **JAMA** 1997 May 14;277(18):1427
Havana. Assessing Cuba's approach to contain AIDS and HIV [news] Burr C. **Lancet** 1997 Aug 30;350(9078):647
HIV prevention in developed countries. Coates TJ, et al. **Lancet** 1996 Oct 26;348(9035):1143–8 (50 ref.)
Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Cohen MS, et al. **Lancet** 1997 Jun 28; 349(9069):1868–73
Prevention of HIV infection in developing countries [see comments] d'Cruz-Grote D. **Lancet** 1996 Oct 19; 348(9034):1071–4. Comment in: Lancet 1996 Dec

21-28;348(9043):1742. Comment in: Lancet 1996 Dec 21-28;348(9043):1742-3.
Human rights and the HIV paradox. Kirby M. **Lancet** 1996 Nov 2;348(9036):1217-8
Investigators study morning-after AIDS treatment [news] Macready N. **Lancet** 1997 Mar 15;349(9054):780
President Clinton wages public war against AIDS [news] Rovner J. **Lancet** 1997 Jan 4;349(9044):39
Reliability, validity, and composition of a subset of the Centers for Disease Control and Prevention acquired immunodeficiency syndrome knowledge questionnaire in a sample of homeless and impoverished adults. Leake B, et al. **Med Care** 1997 Aug;35(8):747-55
The beta 3-adrenoceptor: an advance in the understanding of obesity and insulin resistance [editorial] Donnelly R. **Med J Aust** 1996 Nov 18;165(10):537-8
Universal precautions and anaesthetists: time for a rethink? [comment] Kerridge RK. **Med J Aust** 1997 Feb 3; 166(3):142. Comment on: Med J Aust 1997 Feb 3;166(3):138-40.
Universal precautions and anaesthetists: personalising the message [comment] Phillips GD. **Med J Aust** 1997 Feb 3;166(3):141. Comment on: Med J Aust 1997 Feb 3;166(3):138-40.
Universal precautions: attitudes of Australian and New Zealand anaesthetists [see comments] Richards MJ, et al. **Med J Aust** 1997 Feb 3;166(3):138-40. Comment in: Med J Aust 1997 Feb 3;166(3):141. Comment in: Med J Aust 1997 Feb 3;166(3):142.
AIDS: safety, regulation and the law in procedures using blood and blood products. Craven BM, et al. **Med Sci Law** 1997 Jul;37(3):215-27
A nationwide effort to sistematically monitor HIV-1 diversity in Brazil: preliminary results. Brazilian Network for the HIV-1 Isolation and Characterization. Galvão-Castro B, et al. **Mem Inst Oswaldo Cruz** 1996 May-Jun;91(3):335-8
Evaluation of an HIV/AIDS education program for family-based foster care providers. Scotti JR, et al. **Ment Retard** 1996 Apr;34(2):75-82
Speakers Bureau continues to get more requests. Seely T. **Mich Med** 1996 Nov;95(11):34
Walk the walk, if you talk the talk [editorial] Thomas JR. **Mo Med** 1996 Oct;93(10):622-3
Prevention of mother-to-infant transmission of HIV-1. Melvin AJ, et al. **Mol Med Today** 1997 Jun;3(6):242-5 (27 ref.)
Aids prevention [letter] Gilson SB. **N Engl J Med** 1996 Oct 31;335(18):1398; discussion 1399
Aids prevention [letter; comment] Illingworth PM. **N Engl J Med** 1996 Oct 31;335(18):1398-9. Comment on: N Engl J Med 1996 Jun 6;334(23):1540-2.
Aids prevention [letter; comment] Johnson DP. **N Engl J Med** 1996 Oct 31;335(18):1398; discussion 1399 . Comment on: N Engl J Med 1996 Jun 6;334(23):1540-2.
Battling HIV on many fronts [editorial; comment] Steinbrook R. **N Engl J Med** 1997 Sep 11;337(11):779-81. Comment on: N Engl J Med 1997 Sep 11;337(11):725-33. Comment on: N Engl J Med 1997 Sep 11;337(11):734-9.
For want of clean needles: race and the spread of AIDS. Day D. **N J Med** 1997 Jun;94(6):53-5
Politicians hamper AIDS prevention, says panel [news] **Nature** 1997 Feb 20;385(6618):671
Workplace AIDS/HIV: are you immune? Oswald E. **Occup Health Saf** 1996 Apr;65(4):39-40
Beliefs and attitudes towards AIDS policies and educational programs among Japanese businesses. Muto T, et al. **Occup Med (Oxf)** 1996 Oct;46(5):356-60
Health department booklet targets young parents [news] **Pa Med** 1996 Feb;99(2):18
An HIV vaccine: breaking the paradigms. Fauci AS. **Proc Assoc Am Physicians** 1996 Jan;108(1):6-13 (47 ref.)
Sharing research findings with the communities studied: the case of the Women and AIDS Support Network Research Project in Zimbabwe. McCharen N, et al. **Promot Educ** 1996 Sep;3(3):33-7, 48
Reliability of a knowledge of AIDS scale a replication. Nicholas L, et al. **Psychol Rep** 1996 Oct;79(2):529-30
HIV/AIDS infection control enforcement: a comparison between Nigeria and the United States [see comments] Essien EJ, et al. **Public Health** 1997 Jul;111(4):205-9. Comment in: Public Health 1997 Jul;111(4):199.
CDC data systems collecting behavioral data on HIV counseling and testing. Anderson JE. **Public Health Rep** 1996;111 Suppl 1:129-32
Paraprofessional delivery of a theory based HIV prevention counseling intervention for women. Cabral RJ, et al. **Public Health Rep** 1996;111 Suppl 1:75-82
Integrating a theoretical framework with street outreach services: issues for successful training. Cheney R, et al. **Public Health Rep** 1996;111 Suppl 1:83-8
Development and use of role model stories in a community level HIV risk reduction intervention. Corby NH, et al. **Public Health Rep** 1996;111 Suppl 1:54-8
Bridging the gap between behavioral science and public health practice in HIV prevention [editorial] Curran JW. **Public Health Rep** 1996;111 Suppl 1:3-4
Behavioral science and public health: a necessary partnership for HIV prevention [editorial] Fishbein M, et al. **Public Health Rep** 1996;111 Suppl 1:5-10
A method to measure the costs of counseling for HIV prevention. Gorsky RD. **Public Health Rep** 1996;111 Suppl 1:115-22
Developing community networks to deliver HIV prevention interventions. Guenther-Grey C, et al. **Public Health Rep** 1996;111 Suppl 1:41-9
Using formative research to lay the foundation for community level HIV prevention efforts: an example from the AIDS Community Demonstration Projects. Higgins DL, et al. **Public Health Rep** 1996;111 Suppl 1:28-35
Methodological issues in evaluating HIV prevention community planning. Holtgrave DR, et al. **Public Health Rep** 1996;111 Suppl 1:108-14
Quality assurance of HIV prevention counseling in a multi-center randomized controlled trial. Project RESPECT Study Group. Kamb ML, et al. **Public Health Rep** 1996;111 Suppl 1:99-107
Adaptation of behavioral theory to CDC's HIV prevention research: experience at the Centers for Disease Control and Prevention [editorial] Leviton LC, et al. **Public Health Rep** 1996;111 Suppl 1:11-7 (45 ref.)
The use of theory based semistructured elicitation questionnaires: formative research for CDC's Prevention Marketing Initiative. Middlestadt SE, et al. **Public Health Rep** 1996;111 Suppl 1:18-27
A model of community mobilization for the prevention of HIV in women and infants. Prevention of HIV in Women and Infants Demonstration Projects. Person B, et al. **Public Health Rep** 1996;111 Suppl 1:89-98
The importance of behavioral science in HIV prevention [editorial] Satcher D. **Public Health Rep** 1996;111 Suppl 1:1-2
Measuring the adoption of consistent use of condoms using the stages of change model. AIDS Community Demonstration Projects. Schnell DJ, et al. **Public Health Rep** 1996;111 Suppl 1:59-68
Building a peer network for a community level HIV prevention program among injecting drug users in Denver. Simons PZ, et al. **Public Health Rep** 1996;111 Suppl 1:50-3
Defining the components of street outreach for HIV prevention: the contact and the encounter. Valentine J, et al. **Public Health Rep** 1996;111 Suppl 1:69-74 (27 ref.)
Prevention of transmission of AIDS to health care workers. **Rinsho Kyobu Geka** 1988 Apr;8(2):211-3
The 'impending' AIDS catastrophe! [letter] Caldwell RI. **S Afr Med J** 1997 May;87(5):614
AIDS pioneer to set up centre in SA [news] van der Linde I. **S Afr Med J** 1997 Jun;87(6):695-6
Rebel with a cause. van der Linde I. **S Afr Med J** 1997 Mar; 87(3):263-4
UNAIDS to weigh vaccine ethics [news] **Science** 1997 Sep 19;277(5333):1751
Novel campaign to test live HIV vaccine [news] Cohen J. **Science** 1997 Aug 22;277(5329):1035
Baltimore to head new vaccine panel [news] Cohen J. **Science** 1996 Dec 20;274(5295):2005
Curtailing the AIDS pandemic [letter] Mullins JI. **Science** 1997 Jun 27;276(5321):1955-7
Communicating with the people about HIV infection risk as a basis for planning interventions: lessons from the Kagera Region of Tanzania. Killewo J, et al. **Soc Sci Med** 1997 Jul;45(2):319-29
Modelling space-time HIV/AIDS dynamics: applications to disease control. Thomas R. **Soc Sci Med** 1996 Aug; 43(3):353-66
Training and supporting the telephone intake worker for an AIDS prevention counseling study. Conte CK, et al. **Soc Work** 1996 May;41(3):314-9
On evaluating mass media's impact [letter; comment] Valente TW. **Stud Fam Plann** 1997 Jun;28(2):170-2. Comment on: Stud Fam Plann 1996 Jul-Aug;27(4):188-203.
Evaluating the program effects of a radio drama about AIDS in Zambia [see comments] Yoder PS, et al. **Stud Fam Plann** 1996 Jul-Aug;27(4):188-203. Comment in: Stud Fam Plann 1997 Jun;28(2):170-2.
Religious crusade. School health is at center of battle for control of state's education system. Ortolon K. **Tex Med** 1996 Feb;92(2):30-3
The participation of African traditional healers in AIDS/STD prevention programmes. Green EC. **Trop Doct** 1997;27 Suppl 1:56-9
Umbanda healers as effective AIDS educators: case-control study in Brazilian urban slums (favelas). Nations MK, et al. **Trop Doct** 1997;27 Suppl 1:60-6
Do-it-yourself information notes for AIDS counselling in developing countries. Scrimgeour EM. **Trop Doct** 1997 Apr;27(2):82-4
[Is the prevention of HIV/AIDS in Denmark effective? (editorial)] Fouchard JR. **Ugeskr Laeger** 1997 Mar 3; 159(10):1406 **(Dan)**
[Is the prevention of HIV/AIDS in Denmark efficient (letter; comment)] Zachariae H. **Ugeskr Laeger** 1997 Jun 16; 159(25):3975-7. Comment on: Ugeskr Laeger 1997 Mar 3;159(10):1429-33. **(Dan)**
[AIDS; new developments. I. HIV tests: time for a more active policy] Coutinho RA. **Ned Tijdschr Geneeskd** 1997 May 24;141(21):1034-6 (Eng. Abstr.) **(Dut)**
[AIDS: communication, information and prevention] Küss R, et al. **Bull Acad Natl Med** 1996 Jun-Jul;180(6):1203-12 **(Fre)**
[AIDS and health personnel in Ivory Coast] Diarra J, et al. **Med Trop (Mars)** 1996;56(3):259-63 (Eng. Abstr.) **(Fre)**
[10 years' research in the social sciences on AIDS in Burkina Faso. Elements for prevention] Desclaux A. **Sante** 1997 Mar-Apr;7(2):127-34 (Eng. Abstr.) **(Fre)**
[One world in hope?] Esmel D, et al. **Sante** 1997 Mar-Apr; 7(2):143-4 **(Fre)**
[Revision of the brochure "Hygiene, Accident Prevention and First Aid" and "Recommendations for HIV-Post-Exposure Preventive Management] Juhl K, et al. **Chirurg** 1997 Mar;68(3):suppl 86-7 **(Ger)**
[Prevention and responsible personal behavior remain effective weapons against AIDS (news)] **Pharm Unserer Zeit** 1997 Jan;26(1):45 **(Ger)**
[Stride for stride with AIDS vaccination (news)] Eibl I. **Pharm Unserer Zeit** 1996 Jul;25(4):211 **(Ger)**
[Recent topics on AIDS research-- study of AIDS viruses and the application for development of prevention and therapeutic methods of AIDS] Honda M. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):606-7 (0 ref.) **(Jpn)**
[Personal opinion on "the problem of women and AIDS in developing countries" (letter)] Furuse Y. **Nippon Koshu Eisei Zasshi** 1996 Jul;43(7):586-7 **(Jpn)**
[The effect of the AIDS campaign on case numbers of male urethritis] Kojima H. **Nippon Koshu Eisei Zasshi** 1996 Jul; 43(7):545-50 (Eng. Abstr.) **(Jpn)**
[AIDS seminar for personnel managers in japanese companies--application of health belief model and health norm model] Tanaka H. **Nippon Koshu Eisei Zasshi** 1996 Jun;43(6):479-85 **(Jpn)**
[Strength and will: theoretical and methodological issues from the standpoint of risk in epidemiology and HIV/AIDS prevention] Castiel LD. **Rev Saude Publica** 1996 Feb;30(1):91-100 (40 ref.) (Eng. Abstr.) **(Por)**
[The impact of an AIDS hotline service on pupils and students] Duma OO. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan-Jun; 42(1-2):81-3 **(Rum)**
[Is there a hope in fight against AIDS? (news)] Sverdlov ED. **Bioorg Khim** 1997 Feb;23(2):159-60 **(Rus)**
[The results of the realization of the Federal Special Program for 1993-1995 on Preventing the Spread of AIDS Diseases in the Russian Federation (Anti-AIDS)] Iasinskiĭ AA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 May-Jun; (3):45-8 **(Rus)**
[Secondary prevention of AIDS] Domínguez Carmona M. **An R Acad Nac Med (Madr)** 1996;113(2):371-410; discussion 411-2 **(Spa)**
[HIV infection and AIDS in Spanish prisons: an impossible challenge for public health? (editorial)] Caylà JA. **Gac Sanit** 1996 May-Jun;10(54):101-3 **(Spa)**
[Prison environment, HIV/AIDS and health promotion (letter)] Paredes J, et al. **Gac Sanit** 1997 Jan-Feb;11(1):45-7 **(Spa)**
[Primary prevention actions in AIDS and sexually transmitted diseases in adolescents] Barrón de Carbonetti M, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53 Suppl:55-63 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Reassessing medical students' willingness to treat HIV-infected patients. Carter D, et al. **Acad Med** 1996 Nov;71(11):1250-2
Searching for the Magic Johnson effect: AIDS, adolescents, and celebrity disclosure. Brown BR Jr, et al. **Adolescence** 1996 Summer;31(122):253-64
Knowledge, attitudes and perception of AIDS in rural Senegal: relationship to sexual behaviour and behaviour change. Lagarde E, et al. **AIDS** 1996 Mar;10(3):327-34
Changes in male sexual behaviour in response to the AIDS epidemic: evidence from a cohort study in urban Tanzania. Ng'weshemi JZ, et al. **AIDS** 1996 Oct;10(12):1415-20
The impact of illness disclosure and custody plans on adolescents whose parents live with AIDS. Rotheram-Borus MJ, et al. **AIDS** 1997 Jul 15;11(9):1159-64
Self-reported risk factors for AIDS among homeless youth. Johnson TP, et al. **AIDS Educ Prev** 1996 Aug;8(4):308-22
Single Thai women's interpersonal communication and mass media reception on AIDS. Nishino Y, et al. **AIDS Educ Prev** 1997 Apr;9(2):181-200
Attitudes about AIDS education and condom availability among parents of high school students in New York City: a focus group approach. Rafferty Y, et al. **AIDS Educ Prev** 1997 Feb;9(1):14-30
AIDS-relevant condom use by gay and bisexual men: the role of person variables and the interpersonal situation. Sacco WP, et al. **AIDS Educ Prev** 1996 Oct;8(5):430-43
Children's understanding of the symptoms of AIDS. Shoemaker MR, et al. **AIDS Educ Prev** 1996 Oct; 8(5):403-14
Coping with AIDS. A longitudinal study. Brook JS, et al. **Am J Addict** 1997 Winter;6(1):11-20
Visions of those who left too soon. Wiener L, et al. **Am J Nurs** 1996 Sep;96(9):57-61
Multicultural identity and gay men in the era of AIDS. Paradis BA. **Am J Orthopsychiatry** 1997 Apr;67(2):300-7
Comparison of emotional distress in men with acquired immunodeficiency syndrome and in men with cancer. Sarna L, et al. **Appl Nurs Res** 1996 Nov;9(4):209-12
Liaison psychiatry in an HIV/AIDS unit. Judd FK, et al. **Aust N Z J Psychiatry** 1997 Jun;31(3):391-7
Revisiting the psychological aspects of AIDS [letter; comment] O'Dea E. **Br J Hosp Med** 1996 May 1-14; 55(9):594. Comment on: Br J Hosp Med 1996 Feb 21-Mar 5;55(4):158-9.

An atypical case of parasuicide or 'bradysuicide' [letter] Maniam T. **Br J Psychiatry** 1996 Dec;169(6):795–6

New perspectives in clinical practice. Introduction. Menninger WW. **Bull Menninger Clin** 1997 Spring; 61(2):143–5

AIDS knowledge and high-risk behaviour in the chronic mentally ill [see comments] Chuang HT, et al. **Can J Psychiatry** 1996 Jun;41(5):269–72. Comment in: Can J Psychiatry 1996 Nov;41(9):603.

Depression in the medically ill: management considerations. Evans DL, et al. **Depress Anxiety** 1996–97;4(4):199–208 (110 ref.)

Rethinking perceived risk and health behavior: a critical review of HIV prevention research. Kowalewski MR, et al. **Health Educ Behav** 1997 Jun;24(3):313–25 (101 ref.)

The role of germs and viruses in children's theories of AIDS (or, AIDS are not Band-Aids). Sigelman CK, et al. **Health Educ Behav** 1997 Apr;24(2):191–200

Correlates of change in depressive symptomatology among gay men with AIDS. Siegel K, et al. **Health Psychol** 1997 May;16(3):230–8

Women living with HIV/AIDS: the dual challenge of being a patient and caregiver. Hackl KL, et al. **Health Soc Work** 1997 Feb;22(1):53–62

Nurses' willingness to care for AIDS patients and spirituality, social support, and death anxiety. Sherman DW. **Image J Nurs Sch** 1996 Fall;28(3):205–13

Emotional distress in men with life-threatening illness. van Servellen G, et al. **Int J Nurs Stud** 1996 Oct;33(5):551–65

The judicial response to HIV/AIDS. Kirby M. **Int J STD AIDS** 1997 Apr;8(4):265–71 (35 ref.)

Behaviour in Latin American men: implications for HIV/AIDS interventions. Parker RG. **Int J STD AIDS** 1996;7 Suppl 2:62–5 (7 ref.)

Medical use of recreational drugs by AIDS patients. Dansak DA. **J Addict Dis** 1997;16(3):25–30

Physical and social correlates of perceived psychological support among hospitalized AIDS patients. Kataoka-Yahiro MR, et al. **J Adv Nurs** 1996 Jul; 24(1):167–73

Protective care-receiving: the active role of care-recipients. Russell CK, et al. **J Adv Nurs** 1997 Mar;25(3):532–40 (14 ref.)

HIV infection and suicidality. Bellini M, et al. **J Affect Disord** 1996 Jun 5;38(2–3):153–64 (57 ref.)

Support groups for professional caregivers: a role for the contemporary psychoanalyst. Merlino JP. **J Am Acad Psychoanal** 1997 Spring;25(1):111–22

Increasing perceptions of disease vulnerability through imagery. DePalma MT, et al. **J Am Coll Health** 1996 Mar; 44(5):226–34

Spirituality in the chronos of AIDS [editorial] O'Kane P. **J Assoc Nurses AIDS Care** 1996 Jul–Aug;7(4):17–8

AIDS-related obsessive compulsive disorder: deconditioning based on fluoxetine-induced inhibition of anxiety. Kraus RP, et al. **J Behav Ther Exp Psychiatry** 1996 Mar;27(1):51–6

Actual versus self-reported cognitive dysfunction in HIV-1 infection: memory-metamemory dissociations. Hinkin CH, et al. **J Clin Exp Neuropsychol** 1996 Jun;18(3):431–43

Zidovudine adherence in persons with AIDS. The relation of patient beliefs about medication to self-termination of therapy. Smith MY, et al. **J Gen Intern Med** 1997 Apr; 12(4):216–23

Activism and marginalization in the AIDS crisis. Hallett MA. **J Homosex** 1997;32(3–4):1–16 (40 ref.)

Jewish responses to AIDS. Schlesinger Y, et al. **J Homosex** 1997;33(1):17–34

AIDS mania. Lyketsos CG, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):277–9

Children's perceptions of peers with AIDS: assessing the impact of contagion information, perceived similarity, and illness conceptualization. Maieron MJ, et al. **J Pediatr Psychol** 1996 Jun;21(3):321–33

Intuitive theories of human immunodeficiency virus transmission: their development and implications. Sigelman CK, et al. **J Pediatr Psychol** 1996 Aug;21(4):555–72

Stability and change in psychosocial resources during caregiving and bereavement in partners of men with AIDS. Park CL, et al. **J Pers** 1997 Jun;65(2):421–47

Introduction to the special section: use of bereavement narratives to predict well-being in gay men whose partners died of AIDS—four theoretical perspectives. Folkman S. **J Pers Soc Psychol** 1997 Apr;72(4):851–4

Rumination and psychological distress among bereaved partners. Nolen-Hoeksema S, et al. **J Pers Soc Psychol** 1997 Apr;72(4):855–62

Linguistic predictors of adaptive bereavement. Pennebaker JW, et al. **J Pers Soc Psychol** 1997 Apr;72(4):863–71

Appraisal and goal processes as predictors of psychological well-being in bereaved caregivers. Stein N, et al. **J Pers Soc Psychol** 1997 Apr;72(4):872–84

A scale for predicting quality of recovery following the death of a partner. Weiss RS, et al. **J Pers Soc Psychol** 1997 Apr;72(4):885–91

College students' judgements and perceptions of persons with AIDS from different risk groups. Johnson ME, et al. **J Psychol** 1996 Sep;130(5):527–36

Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. Wagner GJ, et al. **J Psychosom Res** 1997 Apr;42(4):407–11

Changing conceptions of self and world through the spectrum of HIV disease. Implications for psychotherapy. Farber EW, et al. **J Psychother Pract Res** 1997 Winter; 6(1):36–44

Maryland women living with HIV/AIDS. Berger R. **Md Med J** 1996 Dec;45(12):1027–30

Infect one, infect all: Zulu youth response to the AIDS epidemic in South Africa. Leclerc-Madlala S. **Med Anthropol** 1997 Jun;17(4):363–80

Satisfaction with inpatient acquired immunodeficiency syndrome care. A national comparison of dedicated and scattered-bed units. Aiken LH, et al. **Med Care** 1997 Sep; 35(9):948–62

The influence of health-related quality of life and social characteristics on hospital use by patients with AIDS in the Boston Health Study. Weissman JS, et al. **Med Care** 1996 Oct;34(10):1037–56

AIDS knowledge among New Jersey adults. Miller JE. **N J Med** 1996 Sep;93(9):49–55

Pain in ambulatory AIDS patients. II: Impact of pain on psychological functioning and quality of life. Rosenfeld B, et al. **Pain** 1996 Dec;68(2–3):323–8

Medical, social, sexual, financial and ethical problems with AIDS—a case history. **Postgrad Med J** 1997 Aug; 73(862):521–2

Psychopathology and psychotherapy in the dying AIDS patient. O'Dowd MA. **Psychiatry Clin Neurosci** 1995 May; 49 Suppl 1:S117–21 (20 ref.)

The bereavement process in children of parents with AIDS. Aronson S. **Psychoanal Study Child** 1996;51:422–35

The face of AIDS: Effects of physical attractiveness and target gender on inferred mode of HIV infection. Boehm L, et al. **Psychol Rep** 1996 Apr;78(2):595–8

Reliability and validity of AIDS victim blaming scales. Mulford CL, et al. **Psychol Rep** 1996 Aug;79(1):191–201

Is anonymity important in AIDS survey research? Zagumny MJ, et al. **Psychol Rep** 1996 Feb;78(1):270

Psychosocial factors in HIV-AIDS [editorial] Emmelkamp PM. **Psychother Psychosom** 1996;65(5):225–8 (42 ref.)

Further validation of the AIDS Attitude Scale. Froman RD, et al. **Res Nurs Health** 1997 Apr;20(2):161–7

Women and AIDS: an analysis of media misrepresentations. Sacks V. **Soc Sci Med** 1996 Jan;42(1):59–73

Social support networks of confidants to people with AIDS. Jankowski S, et al. **Soc Work** 1996 Mar;41(2):206–13

HIV/AIDS and suicide: further precautions. Mancoske RJ. **Soc Work** 1996 May;41(3):325–6

Toward a more holistic understanding of ethics in social work. Abramson M. **Soc Work Health Care** 1996;23(2):1–14

Negotiating advance directives for persons with AIDS. Littrell J, et al. **Soc Work Health Care** 1996;23(2):43–65

Searching for information, understanding, and self-value: the utilization of peer support groups by gay men with HIV/AIDS. Sandstrom KL. **Soc Work Health Care** 1996; 23(4):51–74

A five-factor model of personality and addiction, psychiatric, and AIDS risk severity in pregnant and postpartum cocaine misusers. Ball SA, et al. **Subst Use Misuse** 1997 Jan; 32(1):25–41

Living with AIDS. Moran T. **Tex Med** 1997 Jun;93(6):47–8

[Analysis of preconceived attitudes of medical personnel toward HIV positive and AIDS patients] Zuber J, et al. **Psychother Psychosom Med Psychol** 1996 Feb;46(2):52–60 (Eng. Abstr.) **(Ger)**

[Survey of knowledge, attitudes, and opinions about AIDS expressed by a population of high-school students in Rimini] Bergamaschi A, et al. **Ann Ig** 1996 Nov–Dec; 8(6):611–20 **(Ita)**

RADIOGRAPHY

Radiologic features of Rhodococcus equi pneumonia in AIDS. Muntaner L, et al. **Eur J Radiol** 1997 Jan; 24(1):66–70

Day case insertion of Hickman lines in HIV positive patients in a radiological unit [letter] Bergin CJ, et al. **Int J STD AIDS** 1996 Aug–Sep;7(5):380–2

[AIDS-associated illnesses in radiologic diagnosis: overview and differential diagnosis] Rademaker J, et al. **Aktuelle Radiol** 1997 Mar;7(2):69–73 (30 ref.) **(Ger)**

[Computerized tomography of AIDS associated thoracic diseases] Bankier AA, et al. **Radiologe** 1996 Jul;36(7):543–9 (16 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Chilaiditi's syndrome. Incidental findings on Ga-67 scintigraphy. Chandramouly B, et al. **Clin Nucl Med** 1997 Aug;22(8):575–6

SURGERY

Spinal extradural leiomyoma in a pediatric patient with acquired immunodeficiency syndrome: case report. Choi S, et al. **Neurosurgery** 1997 May;40(5):1080–2

[The AIDS patient in anesthesia] Jalowy A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):87–97 (109 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Experimental gene therapy: the transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice. Sanhadji K, et al. **AIDS** 1997 Jul; 11(8):977–86

AIDS in the developed world: implications for the provision and financing of care [editorial] Shaw-Taylor Y, et al. **AIDS** 1997 Sep;11(11):1305–9

The validity of self-reported health-care utilization by AIDS patients. Weissman JS, et al. **AIDS Care** 1996 Jun;10(7):775–83

Therapeutic and diagnostic procedures in hospitalized AIDS patients with terminal illness. Manfredi R, et al. **AIDS Care** 1996 Jun;8(3):373–6

Heterogeneity of home care assistance needs of people with AIDS. Milanese G, et al. **AIDS Care** 1997 Feb;9(1):27–33

Evaluation of HIV/STD prevention, care and support: an update on WHO's approaches. Mertens TE, et al. **AIDS Educ Prev** 1997 Apr;9(2):133–45

Scientific, logistical, and ethical issues related to creation of a stem cell repository for use in experimental trials of gene therapy for AIDS. Fraser JK, et al. **AIDS Res Hum Retroviruses** 1997 Jul 20;13(11):905–7

Perspective: research highlights of the University of Alabama at Birmingham Center for AIDS Research. Paradigm shifts, translational research, and CFARs. Hunter E. **AIDS Res Hum Retroviruses** 1996 Sep 20;12(14):1301–3

Perspective: research highlights at the Dana-Farber Cancer Institute Center for AIDS Research (CFAR). Sodroski J. **AIDS Res Hum Retroviruses** 1996 Nov 1;12(16):1499–502 (27 ref.)

Highlights from the University of California San Diego Center for AIDS Research. Wong-Staal F. **AIDS Res Hum Retroviruses** 1997 Jan 20;13(2):117–20 (30 ref.)

A scientific plan for the evaluation of alternative medicine in the treatment of HIV/AIDS. Standish LJ, et al. **Altern Ther Health Med** 1997 Mar;3(2):58–67

White House releases first-ever national AIDS strategy [news] **Am Fam Physician** 1997 Feb 1;55(2):412

A new era in HIV care [editorial; comment] Soloway B. **Am Fam Physician** 1997 Jul;56(1):37, 40–2. Comment on: Am Fam Physician 1997 Jul;56(1):87–96.

Continuity of pharmaceutical services for patients with AIDS in the transition from hospital to home. Fan-Havard P, et al. **Am J Health Syst Pharm** 1997 Jun 15;54(12):1407–12

Position paper: providing services for persons with HIV/AIDS and their caregivers. Bedell G, et al. **Am J Occup Ther** 1996 Nov–Dec;50(10):853–4

AIDS therapy: hype or reality? [news] **Ann Oncol** 1996 Sep; 7(7):652

Quality of life: a central issue in AIDS and cancer [news] **Ann Oncol** 1996 Mar;7(3):217–8

Development and applications of vaccines and gene therapy in AIDS. Proceedings of an international workshop. Naples, Italy, June 15–16, 1995. **Antibiot Chemother** 1996; 48:IX–X, 1–246

Immune reconstitution for HIV disease. Bridges SH. **Antibiot Chemother** 1996;48:233–9 (21 ref.)

A replication-deficient human immunodeficiency virus-1 genome as an interference-inducing provirus. Federico M, et al. **Antibiot Chemother** 1996;48:217–25

Functional studies of bispecific antibodies directed against HIV-1 and the Fc gamma I receptor type I. Gorny MK, et al. **Antibiot Chemother** 1996;48:173–83

Immunological aspects of patients with HIV-1 disease following immunization with recombinant gp160 (VaxSyn). Guerra E, et al. **Antibiot Chemother** 1996;48:147–54

Preparation for HIV vaccine efficacy trials. Hoff R, et al. **Antibiot Chemother** 1996;48:155–60

Transfer Factor in the Era of AIDS. Proceedings of the Xth International Symposium on Transfer Factor. Bologna, Italy, 22–24 June 1995. **Biotherapy** 1996;9(1–3):ix–x, 1–185

Preliminary observations using HIV-specific transfer factor in AIDS. Pizza G, et al. **Biotherapy** 1996;9(1–3):41–7

AIDS and transfer factor: myths, certainties and realities. Viza D. **Biotherapy** 1996;9(1–3):17–26 (88 ref.)

Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro. Su L, et al. **Blood** 1997 Apr 1;89(7):2283–90

Who owns AIDS? [letter; comment] Shahmanesh M. **Br J Hosp Med** 1997 Mar 5–18;57(5):228. Comment on: Br J Hosp Med 1997 Mar 5–18;57(5):186–7.

Percutaneous balloon pericardiotomy: a case report and analysis of mechanism of action [see comments] Bertrand O, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):180–2. Comment in: Cathet Cardiovasc Diagn 1996 Jun;38(2):183.

Harnessing viral devices as pharmaceuticals: fighting HIV-1's fire with fire [comment] Nolan GP. **Cell** 1997 Sep 5;90(5):821–4 (11 ref.). Comment on: Cell 1997 Sep 5;90(5):841–7. Comment on: Cell 1997 Sep 5;90(5):849–57.

Use of telephone medicine for the care of patients with human immunodeficiency virus infection or AIDS: comparison of a private infectious disease practice with a university clinic practice. Morrison RE, et al. **Clin Infect Dis** 1997 Feb;24(2):269–70

"Dr. Peter" lives on through AIDS daycare centre [news] Kent H. **CMAJ** 1997 Sep 15;157(6):631

Home care for persons with AIDS: community attitude in a neighbourhood of Addis Ababa, Ethiopia. Berhane Y, et al. **East Afr Med J** 1995 Oct;72(10):626–30

Combined strategies for gene therapy of AIDS [editorial] Palù G. **Gene Ther** 1997 Mar;4(3):179–80

Survival and treatment of AIDS patients 1984–1993 [letter; comment] Coker R, et al. **Genitourin Med** 1997 Apr; 73(2):148. Comment on: Genitourin Med 1997 Feb;73(1):44–8.

Addressing AIDS long-term care issues through education and advocacy. Marder R, et al. **Health Soc Work** 1995 Feb;20(1):75-80

Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Morgan RA, et al. **Hum Gene Ther** 1996 Jun 20;7(10):1281-306

A two-sex model for treatment of HIV/AIDS and behaviour change in a population of varying size [published erratum appears in IMA J Math Appl Med Biol 1996 Dec;13(4):317] Hsieh YH. **IMA J Math Appl Med Biol** 1996 Sep; 13(3):151-73

Hot fusion breakthrough for AIDS research. **Immunol Today** 1996 Jul;17(7):299

Practical models for the care of HIV and AIDS patients. Brailsford SC, et al. **Int J STD AIDS** 1996 Mar-Apr; 7(2):91-7

HIV at the hospital/general practice interface: bridging the communication divide [letter; comment] Brettle RP, et al. **Int J STD AIDS** 1996 Mar-Apr;7(2):148-50. Comment on: Int J STD AIDS 1995 Mar-Apr;6(2):84-8.

Complementary AIDS therapies: the good, the bad and the ugly [editorial] Ernst E. **Int J STD AIDS** 1997 May; 8(5):281-5 (35 ref.)

Central venous catheters in patients with AIDS. Goodman HE, et al. **Int J STD AIDS** 1997 Jul;8(7):417-22

Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses. Kundu SK, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Aug 1;15(4):269-74

HIV/AIDS care at Tokyo Metropolitan Komagome Hospital. Negishi M. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 2:S35-7

Treatment of AIDS and HIV-related conditions--1997. Goldschmidt RH, et al. **J Am Board Fam Pract** 1997 Mar-Apr;10(2):144-67 (50 ref.)

Vaccines on the horizon: HIV and cancer. Brazeau GA, et al. **J Am Pharm Assoc (Wash)** 1996 Jan;NS36(1):14-5

Complementary and alternative medicine and HIV/AIDS. Part I: Issues and context. MacIntyre RC, et al. **J Assoc Nurses AIDS Care** 1997 Jan-Feb;8(1):23-31 (54 ref.)

Therapeutic hyperthermia in cancer and AIDS: an updated survey. Pontiggia P, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2-4):289-97 (39 ref.)

Quality in HIV/AIDS care. Specialty-related or experience-related? [editorial; comment] Holmes WC. **J Gen Intern Med** 1997 Mar;12(3):195-7. Comment on: J Gen Intern Med 1997 Mar;12(3):141-9.

AIDS clinical trials. Is there access for all? [editorial; comment] Lynn LA. **J Gen Intern Med** 1997 Mar; 12(3):198-9. Comment on: J Gen Intern Med 1997 Mar;12(3):150-7.

Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort [see comments] Stone VE, et al. **J Gen Intern Med** 1997 Mar; 12(3):150-7. Comment in: J Gen Intern Med 1997 Mar;12(3):198-9.

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. Davey RT Jr, et al. **J Infect Dis** 1997 Apr;175(4):781-9

In vitro T lymphopoiesis: a model system for stem cell gene therapy for AIDS. Rosenzweig M, et al. **J Med Primatol** 1996 Jun;25(3):192-200

Nutrition in pediatric HIV infection: setting the research agenda. Work group session report: priorities, recommendations, and strategies for supporting the research agenda. Hamilton F. **J Nutr** 1996 Oct;126(10 Suppl):2688S-2690S

Nutrition in pediatric HIV infection: setting the research agenda. Working group session report: setting the clinical research agenda: domestic and international perspectives. Oleske JM, et al. **J Nutr** 1996 Oct;126(10 Suppl):2681S-2683S

Nutrition in pediatric HIV infection: setting the research agenda. Working group session report: coordination of domestic and international effort in executing a research agenda in nutrition and pediatric HIV infection. Solomons N, et al. **J Nutr** 1996 Oct;126(10 Suppl):2684S-2687S

Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector. Inouye RT, et al. **J Virol** 1997 May;71(5):4071-8

Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA. Liu D, et al. **J Virol** 1997 May;71(5):4079-85

AIDS in a medical intensive care unit: immediate prognosis and long-term survival. Lazard T, et al. **JAMA** 1996 Oct 16;276(15):1240-5

Management of patients with HIV/AIDS. Who should care? Lewis CE. **JAMA** 1997 Oct 8;278(14):1133-4

Experts say AIDS pain 'dramatically undertreated' [news] Stephenson J. **JAMA** 1996 Nov 6;276(17):1369-70

'HIV specialists': the time has come. Zuger A, et al. **JAMA** 1997 Oct 8;278(14):1131-2

Risk of symptomatic central venous thrombotic complications in AIDS patients receiving home parenteral nutrition. Duerksen DR, et al. **JPEN J Parenter Enteral Nutr** 1996 Jul-Aug;20(4):302-5

HIV-1 researchers talk cautiously of a good year [news] Atterstam I. **Lancet** 1997 Sep 27;350(9082):937

Lessons from and about AIDS.... Feinberg MB. **Lancet** 1996 Nov 2;348(9036):1188

Medicine and HIV [interview by David Frankel] Volberding PA. **Lancet** 1996 Oct 12;348(9033):1007-8

Hairpin ribozyme gene therapy for AIDS. Duarte EA, et al. **Methods Mol Biol** 1997;74:459-68

Michigan AIDS Fraud Task Force. **Mich Med** 1996 Nov; 95(11):35

Stem cells to treat HIV [news] Fricker J. **Mol Med Today** 1997 May;3(5):186-7

Physician-assisted suicide and patients with HIV disease [letter; comment] McKeogh M. **N Engl J Med** 1997 Jul 3;337(1):56. Comment on: N Engl J Med 1997 Feb 6;336(6):417-21.

Home parenteral lipids in AIDS: a three-month study. Singer P, et al. **Nutrition** 1997 Feb;13(2):104-9

Development of HIV vectors for anti-HIV gene therapy. Poeschla E, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11395-9 (50 ref.)

The Hlabisa-Liverpool HIV link [news] Jones JS. **S Afr Med J** 1996 Sep;86(9):1048, 1050

Gene therapy for cancer. Blaese RM. **Sci Am** 1997 Jun; 276(6):111-5

Exploiting the HIV-chemokine nexus [news] Cohen J. **Science** 1997 Feb 28;275(5304):1261-4

Rethinking AIDS and cancer [letter] Shearer GM, et al. **Science** 1996 Oct 11;274(5285):163-4

Acquired immune deficiency syndrome. Knowledge, experiences, and attitudes of hospital-based registered nurses. Latman NS, et al. **Sex Transm Dis** 1996 May-Jun; 23(3):219-25

Living with AIDS. Moran T. **Tex Med** 1997 Jun;93(6):47-8

The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview. Busch MP, et al. **Transfusion** 1996 Oct;36(10):854-9 (65 ref.)

[Global and multidisciplinary management of the AIDS patient: from therapeutic follow-up to continued care] Bafza D, et al. **Rev Med Brux** 1996 Sep;17(4):171-4 (Eng. Abstr.) **(Fre)**

[Palliative care and AIDS: support] Roulin D. **Rev Med Suisse Romande** 1997 Mar;117(3):201-4 **(Fre)**

[How to manage HIV seropositive or AIDS patients in rural Burkina Faso?] Taverne B. **Sante** 1997 May-Jun; 7(3):177-86 (16 ref.) (Eng. Abstr.) **(Fre)**

[Hope for delaying demise] Wagner B. **Fortschr Med** 1997 Jun 10;115(16):66-9 **(Ger)**

[Therapeutic strategies against HIV: status in 1994 and future prospectives] **Internist (Berl)** 1994 Jul;35(7 Suppl):1-24 **(Ger)**

[Oncology '96] Hartmann F, et al. **Med Klin** 1997 Feb 15; 92(2):83-100 (231 ref.) **(Ger)**

[Totally implantable, permanent central venous catheter systems in AIDS patients--a method for home care or an unacceptable infection risk?] Armbruster C, et al. **Schweiz Med Wochenschr** 1996 Sep 21;126(38):1597-602 (Eng. Abstr.) **(Ger)**

[Recent topics on AIDS research-- study of AIDS viruses and the application for development of prevention and therapeutic methods of AIDS] Honda M. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):606-7 (0 ref.) **(Jpn)**

[Gene therapy--vectors and strategies] Huminiecki L. **Postepy Biochem** 1995;41(4):230-6 (50 ref.) **(Pol)**

[The role of general practitioners in the control of HIV infection and in the treatment of seropositive and AIDS patients (editorial)] Antunes F. **Acta Med Port** 1997 Jun-Jul;10(6-7):485-6 **(Por)**

[Home care for the terminally ill HIV patient] Bascuñana Morejón de Girón J, et al. **An Med Interna** 1997 Feb; 14(2):93-7 (22 ref.) (Eng. Abstr.) **(Spa)**

[Domiciliary hospitalization in current needs of patients with AIDS (letter)] Uriondo San Juan B, et al. **Aten Primaria** 1997 Mar 15;19(4):217-8 **(Spa)**

TRANSMISSION

Influence of HIV-infection risk on resident physicians. Ritota PC, et al. **Acad Med** 1996 Jun;71(6):684-6

Very late presentation of vertically transmitted HIV-1 infection. Español T, et al. **Acta Paediatr** 1996 Jun; 85(6):755-7

High risk of HIV disease progression after infection through a sexual partner with AIDS [see comments] Carré N, et al. **AIDS** 1996 Jan;10(1):77-80. Comment in: AIDS 1996 Sep;10(11):1292-3.

A partial explanation for the low number of vertically acquired AIDS cases in Amsterdam, The Netherlands [letter] van den Hoek A, et al. **AIDS** 1997 May;11(6):826-7

Male bisexual behavior and HIV risk in the United States: synthesis of research with implications for behavioral interventions. Doll LS, et al. **AIDS Educ Prev** 1996 Jun; 8(3):205-25 (95 ref.)

HIV risk correlates among non-injection cocaine dependent men in treatment. Malow RM, et al. **AIDS Educ Prev** 1996 Jun;8(3):226-35

AIDS: risk behaviors among rural Mexican women married to migrant workers in the United States. Salgado de Snyder VN, et al. **AIDS Educ Prev** 1996 Apr;8(2):134-42

HIV risks and risk reduction readiness in hard-to-reach, drug-using African American and Mexican American women: an exploratory study. Turner NH, et al. **AIDS Educ Prev** 1996 Jun;8(3):236-46

Mother-to-infant transmission of HIV type 1: role of major histocompatibility antigen differences. Mittleman BB, et al. **AIDS Res Hum Retroviruses** 1996 Oct 10;12(15):1397-400 (38 ref.)

Examination of HIV type 1 variants in mother-child pairs. Roth WW, et al. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):925-30

Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Mandelbrot L, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):661-7

Risky sexual behavior among substance-abusing adolescents: psychosocial and contextual factors. Langer LM, et al. **Am J Orthopsychiatry** 1997 Apr;67(2):315-22

Characteristics of women 50 years of age or older with heterosexually acquired AIDS. Schable B, et al. **Am J Public Health** 1996 Nov;86(11):1616-8

Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Pearce-Pratt R, et al. **Biol Reprod** 1996 Jan;54(1):173-82

French patient contracts AIDS from surgeon [news] Dorozynski A. **BMJ** 1997 Jan 25;314(7076):250

Florida dental AIDS mystery [letter; comment] Hardie J. **Br Dent J** 1996 Mar 9;180(5):170. Comment on: Br Dent J 1994 Dec 10-24;177(11-12):423-7.

Overview of severe mental illness. Johnson DL. **Clin Psychol Rev** 1997;17(3):247-57 (27 ref.)

AIDS and HIV infection acquired heterosexually. Garrigle CM, et al. **Commun Dis Rep CDR Rev** 1997 Aug 22; 7(9):R125-8

An overview of the HIV and AIDS epidemic in the United Kingdom. Hughes G. **Commun Dis Rep CDR Rev** 1997 Aug 22;7(9):R121-2

AIDS and HIV infection acquired through sexual intercourse between men. Macdonald ND. **Commun Dis Rep CDR Rev** 1997 Aug 22;7(9):R123-4

Paediatric AIDS and HIV infection. Molesworth A, et al. **Commun Dis Rep CDR Rev** 1997 Aug 22;7(9):R132-4

HIV infection transmitted through blood product treatment, blood transfusion, and tissue transplantation. Mortimer JY, et al. **Commun Dis Rep CDR Rev** 1997 Aug 22;7(9):R130-2

Lymphocyte immunoregulatory cells present in semen from human immunodeficiency virus (HIV)-infected individuals: a report from the HIV Heterosexual Transmission Study. Denny TN, et al. **Cytometry** 1996 Mar 15;26(1):47-51

Zimbabwean teenagers' knowledge of AIDS and other sexually transmitted diseases. Kasule J, et al. **East Afr Med J** 1997 Feb;74(2):76-81

Vertical human immunodeficiency virus-1 infection: involvement of the central nervous system and treatment. Exhenry C, et al. **Eur J Pediatr** 1996 Oct;155(10):839-50 (147 ref.)

The spectrum of eye disease in children with AIDS due to vertically transmitted HIV disease: clinical findings, virology and recommendations for surveillance. Hammond CJ, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Mar; 235(3):125-9

Litigation ... the injustice of AIDS [news] **Hosp Health Netw** 1996 Oct 5;70(19):18

Mathematical modelling of the spread of HIV/AIDS amongst injecting drug users. Greenhalgh D, et al. **IMA J Math Appl Med Biol** 1997 Mar;14(1):11-38 (42 ref.)

A two-sex model for treatment of HIV/AIDS and behaviour change in a population of varying size [published erratum appears in IMA J Math Appl Med Biol 1996 Dec;13(4):317] Hsieh YH. **IMA J Math Appl Med Biol** 1996 Sep; 13(3):151-73

Effects of treatment and prevalence-dependent recruitment on the dynamics of a fatal disease. Velasco-Hernández JX, et al. **IMA J Math Appl Med Biol** 1996 Sep;13(3):175-92

Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. Scarlatti G, et al. **Immunol Lett** 1996 Jun;51(1-2):23-8

Obstetric factors and mother-to-infant transmission of HIV-1. Zorrilla CD. **Infect Dis Clin North Am** 1997 Mar; 11(1):109-18 (34 ref.)

AIDS in rural Africa: a paradigm for HIV-1 prevention [editorial] Hudson CP. **Int J STD AIDS** 1996 Jul; 7(4):236-43 (64 ref.)

Sexual behavior and injection drug use during pregnancy and vertical transmission of HIV-1. Bulterys M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 May 1;15(1):76-82

Transmission of HIV-1 in infants born to seropositive mothers: PCR-amplified proviral DNA detected by flow cytometric analysis of immunoreactive beads. Dorenbaum A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 May 1;15(1):35-42

Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission. Townsley-Fuchs J, et al. **J Clin Invest** 1996 Oct 15;98(8):1794-801

Knowledge and attitudes of pregnant women regarding AIDS in a semi arid area of Rajasthan. Singh MB, et al. **J Commun Dis** 1997 Jun;29(2):139-44

Acquired immunodeficiency syndrome and suburban

adolescents: knowledge, attitudes, behaviors and risks. Imperato AM. **J Community Health** 1996 Oct;21(5):329–47

AIDS [letter] De TS. **J Indian Med Assoc** 1995 Oct; 93(10):397

A study on acquired immune deficiency syndrome: transmission and diagnosis--a review. Kar PK. **J Indian Med Assoc** 1996 Apr;94(4):143–4 (18 ref.)

Influence of other maternal variables on the relationship between maternal virus load and mother–to–infant transmission of human immunodeficiency virus type 1. Burns DN, et al. **J Infect Dis** 1997 May;175(5):1206–10

HIV–1 transmission to lymphoid cells from epidermal cell cultures derived from skin biopsies of AIDS patients [letter] Vella A, et al. **J Invest Dermatol** 1996 Jul;107(1):141–2

SIV/DeltaB670 transmission across oral, colonic, and vaginal mucosae in the macaque. Trichel AM, et al. **J Med Primatol** 1997 Feb–Apr;26(1–2):3–10

A comparison of AIDS–related sexual risk behaviors among African–American college students. Taylor SE, et al. **J Natl Med Assoc** 1997 Jun;89(6):397–403

AIDS dementia complex in the Italian National AIDS Registry: temporal trends (1987–93) and differential incidence according to mode of transmission of HIV–1 infection. Chiesi A, et al. **J Neurol Sci** 1996 Dec; 144(1–2):107–13

Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. Aleixo LF, et al. **J Pediatr** 1997 Jun;130(6):906–14

Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups. Dittmar MT, et al. **J Virol** 1997 Oct; 71(10):8008–13

Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS. Joag SV, et al. **J Virol** 1997 May;71(5):4016–23

Reclassified AIDS cases in Italy 1990–95 [letter] Arcieri R, et al. **Lancet** 1996 Dec 21–28;348(9043):1741–2

USA accused of funding placebo–controlled AIDS trials [news] Ault A. **Lancet** 1997 May 3;349(9061):1305

Makers of blood products settle US HIV suits [news] Barnett AA. **Lancet** 1997 May 17;349(9063):1459

Vertical transmission of HIV–2 [letter] Cavaco–Silva P, et al. **Lancet** 1997 Jan 18;349(9046):177–8

Japanese hospital list starts worry about HIV [news] Gutierrez E, et al. **Lancet** 1996 Oct 19;348(9034):1093

Spread of HIV–1 to children in Cambodia [letter] [see comments] Richner B, et al. **Lancet** 1997 May 17; 349(9063):1451–2. Comment in: Lancet 1997 Jul 26;350(9073):288.

Prostitution: to decriminalise or to legalise [letter; comment] Tirelli U, et al. **Lancet** 1996 Oct 5;348(9032):962. Comment on: Lancet 1996 Aug 10;348(9024):347.

Proposal to develop a detailed safety program for general/laser surgical patients infected with AIDS. Goldman L. **Lasers Surg Med** 1996;19(3):351–8

Genetic variation within human immunodeficiency viruses generates rapid changes in tropism, virulence, and transmission. Essex M, et al. **Leukemia** 1997 Apr;11 Suppl 3:93–4

Steady–state calculation of the risk of HIV infection from transfusion of screened blood from repeat donors. Satten GA. **Math Biosci** 1997 Apr 15;141(2):101–13

The African polio vaccine–acquired immune deficiency syndrome connection. Reinhardt V, et al. **Med Hypotheses** 1997 May;48(5):367–74 (131 ref.)

Dental and research transmission of acquired immune deficiency syndrome? Or, is there any evidence that human immunodeficiency virus is sufficient to cause acquired immune deficiency syndrome? Root–Bernstein RS. **Med Hypotheses** 1996 Aug;47(2):117–22

Epidemiology of HIV and AIDS in the Asia–Pacific region. Dore GJ, et al. **Med J Aust** 1996 Nov 4;165(9):494–8 (37 ref.)

V3 peptide binding pattern and HIV–1 transmission route in Rio de Janeiro. Pinto ME, et al. **Mem Inst Oswaldo Cruz** 1995 Nov–Dec;90(6):683–5

Prevention of mother–to–infant transmission of HIV–1. Melvin AJ, et al. **Mol Med Today** 1997 Jun;3(6):242–5 (27 ref.)

Remembering Ron. A glimpse into the heart of doctoring. Porter WG. **N C Med J** 1997 Mar–Apr;58(2):110–2

Working with AIDS patients [letter] Gauch RR. **N J Med** 1997 Mar;94(3):8

The 'high–risk' neuropathological autopsy in AIDS and Creutzfeldt–Jakob disease: principles and practice. Ironside JW, et al. **Neuropathol Appl Neurobiol** 1996 Oct; 22(5):388–93 (31 ref.)

Workplace AIDS/HIV: are you immune? Oswald E. **Occup Health Saf** 1996 Apr;65(4):39–40

A comparison of pain report and adequacy of analgesic therapy in ambulatory AIDS patients with and without a history of substance abuse. Breitbart W, et al. **Pain** 1997 Aug;72(1–2):235–43

Basic–CPR and AIDS: are volunteer life–savers prepared for a storm? Bierens JJ, et al. **Resuscitation** 1996 Oct; 32(3):185–91

Comparison of the reluctance of house staff of metropolitan and suburban hospitals to perform mouth–to–mouth resuscitation. Brenner B, et al. **Resuscitation** 1996 Jul; 32(1):5–12

Prevention of transmission of AIDS to health care workers. **Rinsho Kyobu Geka** 1988 Apr;8(2):211–3

Knowledge of HIV infection and the fear of mixing socially with HIV–infected and AIDS–sick patients among STD patients in Bergen, Norway. Tveit KS, et al. **Scand J Soc Med** 1995 Dec;23(4):242–50

Social vs biological: theories on the transmission of AIDS in Africa. Hunt CW. **Soc Sci Med** 1996 May;42(9):1283–96 (19 ref.)

Aids, violence and behavioral coding: information theory, risk behavior and dynamic process on core–group sociogeographic networks. Wallace R, et al. **Soc Sci Med** 1996 Aug;43(3):339–52

Transfusion–transmitted AIDS with blood negative for anti–HIV and HIV–antigen. Chuansumrit A, et al. **Vox Sang** 1996;71(1):64–5

[Consequences of carriage for caregivers and for the patient of a possible presumption of viral (HIV) contamination of a patient by a caregiver] Henrion R. **Bull Acad Natl Med** 1997 Feb;181(2):361–7 **(Fre)**

[Discussion of the Lazarov method, 10 years later] **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(7):645–51 **(Fre)**

[Professional risk of viral infections (hepatitis A, B, C and AIDS)] Gérard C, et al. **Rev Med Liege** 1996 May; 51(5):341–7 **(Fre)**

[Sexual behavior of Italian youths in connection to AIDS risk] Signorelli C, et al. **Soz Praventivmed** 1996;41(6):359–65 (Eng. Abstr.) **(Ger)**

[Blood, AIDS and politics (editorial)] Modan B. **Harefuah** 1996 Jun 2;130(11):748–9 **(Heb)**

[Maternal–fetal transmission of the acquired immunodeficiency virus. Authors' experience] Periti E, et al. **Minerva Ginecol** 1996 Jun;48(6):221–5 (Eng. Abstr.) **(Ita)**

[Surveillance study of HIV/AIDS epidemic in Asia by questionnaire] Okamoto M, et al. **Nippon Koshu Eisei Zasshi** 1996 Aug;43(8):644–50 **(Jpn)**

[Transmission of human immunodeficiency virus type 1 (HIV–1) from mother to child] Rogowska–Szadkowska D. **Pediatr Pol** 1996 Apr;71(4):339–42 **(Pol)**

[Social networks and diffusion of AIDS in Brazil] Barcellos C, et al. **Bol Oficina Sanit Panam** 1996 Jul;121(1):11–24 (Eng. Abstr.) **(Por)**

[Features in human immunodeficiency virus type 1 in the neonatal period] Moliner Calderón E, et al. **An Esp Pediatr** 1996 Aug;45(2):172–76 (Eng. Abstr.) **(Spa)**

[Probable HIV transmission by female homosexual contact] Troncoso AR, et al. **Medicina (B Aires)** 1995;55(4):334–6 (Eng. Abstr.) **(Spa)**

[A case report. Sexually transmitted HIV between two women] Gille–Johnson P, et al. **Lakartidningen** 1996 Sep 25;93(39):3382 **(Swe)**

[Gonorrhea is increasing among homosexual men. Is the risk of STD and AIDS forgotten?] Grützmeier S. **Lakartidningen** 1997 Jun 11;94(24):2261–2, 2265 **(Swe)**

[Generalization about promiscuity in the African culture (letter; comment)] Staugård F. **Lakartidningen** 1997 Apr 2;94(14):1261. Comment on: Lakartidningen 1997 Feb 12;94(7):547–8. **(Swe)**

VETERINARY

Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. Novembre FJ, et al. **J Virol** 1997 May;71(5):4086–91

VIROLOGY

Rabies encephalitis in a patient with AIDS: a clinicopathological study. Adle–Biassette H, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):415–20

Genotypic variants of HIV–1 from peripheral blood and lungs of AIDS patients [letter] Alimohammadi A, et al. **AIDS** 1997 May;11(6):831–2

Thrombocytopenia and AIDS: possible direct role of HIV [letter] Borgia G, et al. **AIDS** 1996 Nov;10(13):1606–8

Search for infectious HIV in gingival crevicular fluid and saliva of advanced AIDS patients with severe periodontitis [letter] Chebbi F, et al. **AIDS** 1997 Jun;11(7):927–8

Zidovudine–resistant variants of HIV–1 in lung [letter] Gates A, et al. **AIDS** 1997 Apr;11(5):702–3

Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. Katzenstein TL, et al. **AIDS** 1996 Feb;10(2):167–73

Syncytium–inducing phenotype and zidovudine susceptibility of HIV–1 isolated from post–mortem tissue. McGavin CH, et al. **AIDS** 1996 Jan;10(1):47–53

Lessons from the second AIDS virus, HIV–2 [editorial] Marlink R. **AIDS** 1996 Jun;10(7):689–99 (217 ref.)

Distribution of HIV–1 subtypes seen in an AIDS clinic in Sao Paulo City, Brazil. Sabino EC, et al. **AIDS** 1996 Nov; 10(13):1579–84

Cytokine network and HIV syncytium–inducing phenotype shift [letter] Torres Y, et al. **AIDS** 1996 Aug;10(9):1053–5

Expression of HIV regulatory and structural mRNA in the central nervous system [see comments] Wiley CA, et al. **AIDS** 1996 Jul;10(8):843–7. Comment in: AIDS 1997 Jan;11(1):133–5. Comment in: AIDS 1997 Feb;11(2):251–2. Comment in: AIDS 1997 Apr;11(5):698–9.

The role of HIV type 1 phenotype and genotype in long–term responders to zidovudine therapy. Angarano G, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):969–75

HIV type 1 subtype F sequences in Romanian children and adults. Apetrei C, et al. **AIDS Res Hum Retroviruses** 1997 Mar 1;13(4):363–5

Genetic and biological analysis of variants derived from the cerebrospinal fluid of HIV type 1 subtype B– and D–infected patients with and without AIDS dementia complex. Brengel–Pesce K, et al. **AIDS Res Hum Retroviruses** 1996 Nov 20;12(17):1643–5

Isolation and characterization of two divergent infectious molecular clones of HIV type 1 longitudinally obtained from a seropositive patient by a progressive amplification procedure. Chen M, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10;13(9):743–50

Genetic analysis of an HIV type 2 subtype B virus from a Spanish individual with AIDS. Heredia A, et al. **AIDS Res Hum Retroviruses** 1997 Jul 1;13(10):899–900

HIV type 1 subtypes in The Netherlands circulating among women originating from AIDS–endemic regions. Lukashov VV, et al. **AIDS Res Hum Retroviruses** 1996 Jul 1; 12(10):951–3

Detection of the herpesvirus–like DNA sequences in matched specimens of semen and blood from patients with AIDS–related Kaposi's sarcoma by polymerase chain reaction in situ hybridization. Huang YQ, et al. **Am J Pathol** 1997 Jan;150(1):147–53

Use of HIV viral load in clinical practice: back to the future [editorial; comment] Saag MS. **Ann Intern Med** 1997 Jun 15;126(12):983–5. Comment on: Ann Intern Med 1997 Jun 15;126(12):929–38. Comment on: Ann Intern Med 1997 Jun 15;126(12):939–45. Comment on: Ann Intern Med 1997 Jun 15;126(12):946–54.

HIV–1 genetic variability: implications for the development of HIV vaccines. Osmanov S, et al. **Antibiot Chemother** 1996;48:30–8 (51 ref.)

Asymptomatic perianal shedding of herpes simplex virus in patients with acquired immunodeficiency syndrome. Pannuti CS, et al. **Arch Dermatol** 1997 Feb;133(2):180–3

Contribution of cohort studies in understanding HIV pathogenesis: introduction of the GRIV cohort and preliminary results. Hendel H, et al. **Biomed Pharmacother** 1996;50(10):480–7 (72 ref.)

Isolation and virological characterization of HIV–1 in Cuba. Relationship with the clinical status of the patients. Lobaina L, et al. **Biomed Pharmacother** 1996;50(10):501–4

Neuropathogenesis of chimeric simian/human immunodeficiency virus infection in pig–tailed and rhesus macaques. Raghavan R, et al. **Brain Pathol** 1997 Jul; 7(3):851–61

Harnessing viral devices as pharmaceuticals: fighting HIV–1's fire with fire [comment] Nolan GP. **Cell** 1997 Sep 5;90(5):821–4 (11 ref.). Comment on: Cell 1997 Sep 5;90(5):841–7. Comment on: Cell 1997 Sep 5;90(5):849–57.

Mediawatch. Conduct unbecoming... Dixon B. **Curr Biol** 1996 Aug 1;6(8):909

Impact of PUVA therapy on HIV viremia: a pilot study. Pechère M, et al. **Dermatology** 1997;195(1):84–5

Predominance of HIV–1 among patients with AIDS and AIDS–related complex in Ghana. Brandful JA, et al. **East Afr Med J** 1997 Jan;74(1):17–20

Human parvovirus B19 in bone marrows from adults with acquired immunodeficiency syndrome: a comparative study using in situ hybridization and immunohistochemistry. Liu W, et al. **Hum Pathol** 1997 Jul;28(7):760–6

A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. Bush CE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):23–6

Effects of vitamin A supplementation on viral load in HIV–1–infected pregnant women [letter] Coutsoudis A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 May 1;15(1):86–7

Characterization of proviral DNA from an individual with long–term, nonprogressive infection with HIV–1 and nonrecoverable virus. Fujii S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Aug 1;15(4):247–56

An immunovirological study of central nervous system involvement during HIV–1 infection of chimpanzees. Grimaldi LM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):12–7

Comparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type 1 infection. Rodriguez RJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 May 1;15(1):49–53

HIV viral load and CD4+ lymphocyte counts in subjects coinfected with HTLV–I and HIV–1. Schechter M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Aug 1;15(4):308–11

Triple HIV–1 infection with group O and Group M of different clades in a single Cameroonian AIDS patient [letter] Takehisa J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jan 1;14(1):81–2

Non–HIV AIDS: nature and strategies for its management. Bird AG. **J Antimicrob Chemother** 1996 May;37 Suppl B:171–83 (66 ref.)

Herpesviruses and AIDS. Griffiths PD.
J Antimicrob Chemother 1996 May;37 Suppl B:87–95 (48 ref.)

Detection of human immunodeficiency virus type 1 (HIV–1) antibody by western blotting and HIV–1 DNA by PCR in patients with AIDS. Jackson JB, et al.
J Clin Microbiol 1997 May;35(5):1118–21

Diversity of the vif gene of human immunodeficiency virus type 1 in Uganda. Wieland U, et al. **J Gen Virol** 1997 Feb; 78 (Pt 2):393–400

Transendothelial migration of lymphocytes from HIV–1–infected donors: a mechanism for extravascular dissemination of HIV–1. Birdsall HH, et al. **J Immunol** 1997 Jun 15;158(12):5968–77

Improvement of Herpesvirus saimiri T cell immortalization procedure to generate multiple CD4+ T–cell clones from peripheral blood lymphocytes of AIDS patients. Saha K, et al. **J Immunol Methods** 1997 Aug 7;206(1–2):21–3

Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV–1 RNA Working Groups. Coombs RW, et al. **J Infect Dis** 1996 Oct;174(4):704–12

Serum levels of virus burden in early–stage human immunodeficiency virus type 1 disease in women. Evans JS, et al. **J Infect Dis** 1997 Apr;175(4):795–800

Prognostic value of plasma human immunodeficiency virus type 1 (HIV–1) RNA levels in patients with advanced HIV–1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. Welles SL, et al. **J Infect Dis** 1996 Oct;174(4):696–703

HIV infection of macrophages and pathogenesis of AIDS dementia complex: interaction of the host cell and viral genotype. Cunningham AL, et al. **J Leukoc Biol** 1997 Jul; 62(1):117–25

Initial characterization of viral sequences from a SHIV–inoculated pig–tailed macaque that developed AIDS. Stephens EB, et al. **J Med Primatol** 1996 Jun; 25(3):175–85

Isolation and long–term culture of primary ocular human immunodeficiency virus type 1 isolates in primary astrocytes. Canki M, et al. **J Neurovirol** 1997 Feb;3(1):10–5

Assessment of neuronal density in the putamen in human immunodeficiency virus (HIV) infection. Application of stereology and spatial analysis of quadrats. Everall I, et al. **J Neurovirol** 1995 Mar;1(1):126–9

Human immunodeficiency virus type 1 DNA and RNA load in brains of demented and nondemented patients with acquired immunodeficiency syndrome. Lazarini F, et al. **J Neurovirol** 1997 Aug;3(4):299–303

Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children. Zaknun D, et al. **J Pediatr** 1997 Jun;130(6):898–905

Simple i.v. inoculation of HIV–1 to Thy/Liv SCID–hu mice induce reproducible HIV infection with narrowing of medulla in human thymic implant. Okamoto Y, et al.
J Vet Med Sci 1997 Apr;59(4):259–63

Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. Delwart EL, et al. **J Virol** 1997 Oct;71(10):7498–508

Biological characterization of human immunodeficiency virus type 1 clones derived from different organs of an AIDS patient by long–range PCR. Dittmar MT, et al. **J Virol** 1997 Jul;71(7):5140–7

High viral load in semen of human immunodeficiency virus type 1–infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. Gupta P, et al. **J Virol** 1997 Aug; 71(8):6271–5

Investigation of the dynamics of the spread of human immunodeficiency virus to brain and other tissues by evolutionary analysis of sequences from the p17gag and env genes. Hughes ES, et al. **J Virol** 1997 Feb;71(2):1272–80

CD4, CXCR–4, and CCR–5 dependencies for infections by primary patient and laboratory–adapted isolates of human immunodeficiency virus type 1. Kozak SL, et al.
J Virol 1997 Feb;71(2):873–82

Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. Platt EJ, et al. **J Virol** 1997 Feb;71(2):883–90

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS–like disease after in vivo passage in rhesus monkeys. Reimann KA, et al. **J Virol** 1996 Oct;70(10):6922–8

In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. Wong JK, et al. **J Virol** 1997 Mar; 71(3):2059–71

Small animal models for acquired immune deficiency syndrome (AIDS) research. Mosier DE. **Lab Anim Sci** 1996 Jun;46(3):257–65 (106 ref.)

Rapidly progressive infection and Kaposi's sarcoma in patient with a novel syncytium–inducing HIV–B variant [letter] Husak R, et al. **Lancet** 1996 Oct 19;348(9034):1107–8

Viral genetic variation, AIDS, and the multistep nature of carcinogenesis: the feline leukemia virus model. Rohn JL, et al. **Leukemia** 1996 Dec;10(12):1867–9 (31 ref.)

Focal tuberculosis of the liver with local hemorrhage in a patient with acquired immunodeficiency syndrome. Brmbolić BJ, et al. **Liver** 1996 Jun;16(3):218–20

AIDS dementia is associated with massive, activated HIV–1 infection and concomitant expression of several cytokines. Nuovo GJ, et al. **Mol Med** 1996 May;2(3):358–66

Antiviral pressure exerted by HIV–1–specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus [see comments] Borrow P, et al. **Nat Med** 1997 Feb;3(2):205–11 . Comment in: Nat Med 1997 Feb;3(2):156–7.

Late escape from an immunodominant cytotoxic T–lymphocyte response associated with progression to AIDS. Goulder PJ, et al. **Nat Med** 1997 Feb;3(2):212–7

Brainstem CMV encephalitis in AIDS: clinical case and MRI features. Pierelli F, et al. **Neurology** 1997 Feb;48(2):529–30

Unique features in the structure of the complex between HIV–1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U–90152 explain resistance mutations for this nonnucleoside inhibitor. Esnouf RM, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3984–9

Sensitivity to inhibition by beta–chemokines correlates with biological phenotypes of primary HIV–1 isolates. Jansson M, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24; 93(26):15382–7

HIV protease and the pathogenesis of AIDS. Goldberg B, et al. **Res Virol** 1996 Nov–Dec;147(6):375–9

Active replication of hepatitis B virus (HBV) in HIV type 1 and in HIV type 2 infected patients. Barros MF, et al. **Rev Inst Med Trop Sao Paulo** 1996 Jul–Aug;38(4):253–8

HIV's other immune–system targets: macrophages [news] Balter M. **Science** 1996 Nov 29;274(5292):1464–5

Does HIV tat protein also regulate genes of other viruses present in HIV infection? [letter] Ferbeyre G, et al.
Trends Biochem Sci 1997 Apr;22(4):115–6

Distinct quasi–species in the blood and the brain of an HIV–2–infected individual. Sankalé JL, et al. **Virology** 1996 Dec 15;226(2):418–23

Human immunodeficiency virus type–1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells. Vesanen M, et al. **Virology** 1997 Sep 15;236(1):104–9

[Fibrosing cholestatic hepatitis by B virus reactivation in AIDS] Poulet B, et al. **Ann Pathol** 1996;16(3):188–91 (Eng. Abstr.) **(Fre)**

[Prognosis depends on viral load. AIDS: frequently too much time is wasted (news)] **Fortschr Med** 1997 Jun 10;115(16):14 **(Ger)**

[HIV infection and long–term non progressor] Suzuki Y, et al. **Nippon Rinsho** 1997 Jun;55(6):1563–71 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Virology on AIDS and AIDS dementia complex] Hoshino H. **No To Shinkei** 1997 Jan;49(1):39–49 (23 ref.) **(Jpn)**

[Sensitivity of Russian HIV–1 isolates to anti–HIV agents] Nosik NN, et al. **Vopr Virusol** 1997 May–Jun;42(3):111–5 (Eng. Abstr.) **(Rus)**

[Viral load and monitoring of antiretroviral treatment] Soriano V, et al. **Rev Clin Esp** 1996 Dec;196(12):872–7 (53 ref.) **(Spa)**

[The virus of human immunodeficiency: virological characteristics, natural history and physiopathology of the nervous system infection] Vidal–Lampurdanés C, et al.
Rev Neurol 1996 Dec;24(136):1563–8 (44 ref.) (Eng. Abstr.) **(Spa)**

ACQUISITION, HEALTH FACILITY see **HEALTH FACILITY MERGER**

ACREMONIUM

Right–sided pacemaker–related endocarditis due to Acremonium species. Heitmann L, et al. **Clin Infect Dis** 1997 Jul;25(1):158–60

Acremonium infection of the esophagus. Mascarenhas MR, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):356–8

Effects of environmental heat and intake of tall fescue seed infested with Acremonium coenophialum on the acid–base status of young bulls. Wallace LL, et al.
J Vet Diagn Invest 1996 Apr;8(2):233–7

CHEMISTRY

Structural elucidation of XR586, a peptaibol–like antibiotic from Acremonium persicinum. Sharman GJ, et al.
Biochem J 1996 Dec 15;320 (Pt 3):723–8

CLASSIFICATION

PCR assay based on a microsatellite–containing locus for detection and quantification of Epichloë endophytes in grass tissue. Groppe K, et al. **Appl Environ Microbiol** 1997 Apr;63(4):1543–50

DRUG EFFECTS

Regulation of neuronal and recombinant GABA(A) receptor ion channels by xenovulene A, a natural product isolated from Acremonium strictum. Thomas P, et al.
J Pharmacol Exp Ther 1997 Aug;282(2):513–20

ENZYMOLOGY

Purification and characterization of three extracellular (1—>3)–beta–D–glucan glucohydrolases from the filamentous fungus Acremonium persicinum. Pitson SM, et al. **Biochem J** 1995 Jun 15;308 (Pt 3):733–41

Refolding and purification of Cephalosporium acremonium deacetoxycephalosporin C synthetase/hydroxylase from granules of recombinant Escherichia coli. Ghag SK, et al.
Biotechnol Appl Biochem 1996 Oct;24 (Pt 2):109–19

Penicillin biosynthesis: intermediates of biosynthesis of delta–L–alpha–aminoadipyl–L–cysteinyl–D–valine formed by ACV synthetase from Acremonium chrysogenum. Kallow W, et al. **FEBS Lett** 1997 Sep 1;414(1):74–8

Proteolytic inactivation of an extracellular (1—>3)–beta–glucanase from the fungus Acremonium persicinum is associated with growth at neutral or alkaline medium pH. Pitson SM, et al. **FEMS Microbiol Lett** 1996 Dec 1;145(2):287–93

[Comparative characteristics of microbial proteases by the level of hydrolysis of protein substrates] Rimareva LV, et al. **Prikl Biokhim Mikrobiol** 1997 Jan–Feb;33(1):43–8 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Proteolytic inactivation of an extracellular (1—>3)–beta–glucanase from the fungus Acremonium persicinum is associated with growth at neutral or alkaline medium pH. Pitson SM, et al. **FEMS Microbiol Lett** 1996 Dec 1;145(2):287–93

ISOLATION & PURIFICATION

Chronic endophthalmitis caused by Acremonium falciforme. Cameron JA, et al. **Can J Ophthalmol** 1996 Dec;31(7):367–8

Acremonium kiliense endophthalmitis that occurred after cataract extraction in an ambulatory surgical center and was traced to an environmental reservoir. Fridkin SK, et al. **Clin Infect Dis** 1996 Feb;22(2):222–7

Endophthalmitis and lumbar diskitis due to Acremonium falciforme in a splenectomized patient. Noble RC, et al.
Clin Infect Dis 1997 Feb;24(2):277–8

Effect of dietary supplementation with vitamin E for lactating dairy cows fed tall fescue hay infected with endophyte. Jackson JA, et al. **J Dairy Sci** 1997 Mar;80(3):569–72

METABOLISM

Cyclosporin C is the main antifungal compound produced by Acremonium luzulae. Moussaïf M, et al.
Appl Environ Microbiol 1997 May;63(5):1739–43

Glucosylation of the peptide leucinostatin A, produced by an endophytic fungus of European yew, may protect the host from leucinostatin toxicity. Strobel GA, et al.
Chem Biol 1997 Jul;4(7):529–36

Assessment of the mitogenic potential of the alkaloids produced by endophyte (Acremonium coenophialum)–infected tall fescue (Festuca arundinacea) on bovine vascular smooth muscle in vitro. Strickland JR, et al. **J Anim Sci** 1996 Jul;74(7):1664–71

Halymecins, new antimicroalgal substances produced by fungi isolated from marine algae. Chen C, et al.
J Antibiot (Tokyo) 1996 Oct;49(10):998–1005

Recombinant Acremonium chrysogenum strains for the industrial production of cephalosporin. Díez B, et al.
Microbiologia 1996 Sep;12(3):359–70 (58 ref.)

ACRIDINAMINE see **AMINACRINE**

ACRIDINE ORANGE

Generation of biologically active anti–Cryptococcus neoformans IgG, IgE and IgA isotype switch variant antibodies by acridine orange mutagenesis. Spira G, et al.
Clin Exp Immunol 1996 Sep;105(3):436–42

Acridine orange as an indicator of bacterial susceptibility to gentamicin. Mason DJ, et al. **FEMS Microbiol Lett** 1997 Aug 1;153(1):199–204

The Acridine Orange test: a clinically relevant screening method for sperm quality during infertility investigation? Eggert–Kruse W, et al. **Hum Reprod** 1996 Apr;11(4):784–9

Evaluation of acridine–orange staining of centrifuged parasites in malarial infection. Damodar SU.
Indian J Med Sci 1996 Jul;50(7):228–30

Microbial quality of lamb carcasses during processing and the acridine orange direct count technique (a modified DEFT) for rapid enumeration of total viable counts. Sierra ML, et al. **Int J Food Microbiol** 1997 Apr 29;36(1):61–7

Effects of heat stress on mouse testicular cells and sperm chromatin structure. Sailer BL, et al. **J Androl** 1997 May–Jun;18(3):294–301

Characterization of acidic vesicles in multidrug–resistant and sensitive cancer cells by acridine orange staining and confocal microspectrofluorometry. Millot C, et al.
J Histochem Cytochem 1997 Sep;45(9):1255–64

Direct acridine orange fluorescence examination of blood slides compared to current techniques for malaria diagnosis. Gay F, et al. **Trans R Soc Trop Med Hyg** 1996 Sep–Oct; 90(5):516–8

CHEMISTRY

Highly selective acridine and ethidium staining of bacterial DNA and RNA. Bruno JG, et al. **Biotech Histochem** 1996

May;71(3):130–6

DIAGNOSTIC USE

Diagnosis of malaria by acridine orange fluorescent microscopy in an endemic area of venezuela. Bosch I, et al. **Mem Inst Oswaldo Cruz** 1996 Jan–Feb;91(1):83–6

PHARMACOLOGY

The Saccharomyces cerevisiae MFS superfamily SGE1 gene confers resistance to cationic dyes. Jacquot C, et al. **Yeast** 1997 Aug;13(10):891–902

ACRIDINES

Reactive oxygen species generation in human sperm: luminol and lucigenin chemiluminescence probes. McKinney KA, et al. **Arch Androl** 1996 Mar–Apr;36(2):119–25

Nonsuperoxide lucigenin–enhanced chemiluminescence from phospholipids and human saphenous veins. Barber DA, et al. **Free Radic Biol Med** 1995 Mar;18(3):565–9

Oxygenation activity of chicken blood phagocytes as measured by luminol– and lucigenin–dependent chemiluminescence. Desmidt M, et al. **Vet Immunol Immunopathol** 1996 Oct;53(3–4):303–11

CHEMICAL SYNTHESIS

Carbon–11 labelling of the antitumour agent N–[2–(dimethylamino)ethyl]acridine–4–carboxamide (DACA) and determination of plasma metabolites in man. Brady F, et al. **Appl Radiat Isot** 1997 Apr;48(4):487–92

Synthesis and cytotoxic and antitumor activity of esters in the 1,2–dihydroxy–1,2–dihydroacronycine series. Elomri A, et al. **J Med Chem** 1996 Nov 22;39(24):4762–6

Structure–activity relationships for acridine–substituted analogues of the mixed topoisomerase I/II inhibitor N–[2–(dimethylamino)ethyl]acridine–4–carboxamide. Spicer JA, et al. **J Med Chem** 1997 Jun 6;40(12):1919–29

CHEMISTRY

Correlations between topological resonance energy of methyl–substituted benz[c]acridines, benzo[a]phenothiazines and chrysenes, and their carcinogenic or antitumor activities. Kurihara T, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2757–65

Effect of phenothiazines, benzo[a] phenothiazines, benz[c]acridines and Pentaglobin on endotoxin. Molnár J, et al. **In Vivo** 1995 Sep–Oct;9(5):463–8

Structure–activity relationships for acridine–substituted analogues of the mixed topoisomerase I/II inhibitor N–[2–(dimethylamino)ethyl]acridine–4–carboxamide. Spicer JA, et al. **J Med Chem** 1997 Jun 6;40(12):1919–29

Quinoline, quinazoline and acridone alkaloids. Michael JP. **Nat Prod Rep** 1997 Feb;14(1):11–20 (61 ref.)

Detection of all single–base mismatches in solution by chemiluminescence. Nelson NC, et al. **Nucleic Acids Res** 1996 Dec 15;24(24):4998–5003

Quantification of reactive oxygen species generated by alveolar macrophages using lucigenin–enhanced chemiluminescence—methodical aspects. Brehm M, et al. **Toxicol Lett** 1996 Oct;87(2–3):131–8

DIAGNOSTIC USE

Lucigenin (bis–N–methylacridinium) as a mediator of superoxide anion production. Liochev SI, et al. **Arch Biochem Biophys** 1997 Jan 1;337(1):115–20

METABOLISM

Carbon–11 labelling of the antitumour agent N–[2–(dimethylamino)ethyl]acridine–4–carboxamide (DACA) and determination of plasma metabolites in man. Brady F, et al. **Appl Radiat Isot** 1997 Apr;48(4):487–92

A 15–base acridine–conjugated oligodeoxynucleotide forms triplex DNA with its IL–2R alpha promoter target with greatly improved avidity. Klysik J, et al. **Bioconjug Chem** 1997 May–Jun;8(3):318–26

Superoxide anion formation from lucigenin: an electron spin resonance spin–trapping study. Vásquez–Vivar J, et al. **FEBS Lett** 1997 Feb 17;403(2):127–30

Microbial metabolism of pyridine, quinoline, acridine, and their derivatives under aerobic and anaerobic conditions. Kaiser JP, et al. **Microbiol Rev** 1996 Sep;60(3):483–98 (146 ref.)

The acridine ring selectively intercalated into a DNA helix at various types of abasic sites: double strand formation and photophysical properties. Fukui K, et al. **Nucleic Acids Res** 1996 Oct 15;24(20):3962–7

Lucigenin luminescence as a measure of intracellular superoxide dismutase activity in Escherichia coli. Liochev SI, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):2891–6

PHARMACOKINETICS

An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Hicks KO, et al. **Br J Cancer** 1997;76(7):894–903

Studies on the metabolism of the novel antitumor agent [N–methyl–11C]N–[2–(dimethylamino)ethyl]acridine–4–carboxamide in rats and humans prior to phase I clinical trials. Osman S, et al. **Cancer Res** 1997 Jun 1;57(11):2172–80

PHARMACOLOGY

Activity and mode of action of acridine compounds against Leishmania donovani. Mesa–Valle CM, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):684–90

Studies of the K(ATP) channel opening activity of the new dihydropyridine compound 9–(3–cyanophenyl)–3,4,6,7,9,10–hexahydro–1,8–(2H,5H)–acridined ione in bladder detrusor in vitro. Li JH, et al. **Arzneimittelforschung** 1996 May;46(5):525–30

Luminol–and lucigenin–amplified chemiluminescence with rat liver microsomes. Kinetics and influence of ascorbic acid, glutathione, dimethylsulfoxide, N–t–butyl–a–phenyl–nitrone, copper–ions and a copper complex, catalase, superoxide dismutase, hexobarbital and aniline. Klinger W, et al. **Exp Toxicol Pathol** 1996 Jul; 48(5):447–60

Effects of acridines on bacterial plasmid replication and endotoxin. Barbe J, et al. **In Vivo** 1996 Nov–Dec; 10(6):601–6

Drug metabolizing enzyme induction by benzoquinolines, acridine, and quinacrine; tricyclic aromatic molecules containing a single heterocyclic nitrogen. Le HT, et al. **J Biochem Toxicol** 1996;11(6):297–303

In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells. den Ouden D, et al. **Leukemia** 1996 Dec; 10(12):1930–6

Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells. Zhou DC, et al. **Leukemia** 1997 Sep;11(9):1516–22

A macrocyclic bis–acridine shifts the equilibrium from duplexes towards DNA hairpins. Slama–Schwok A, et al. **Nucleic Acids Res** 1997 Jul 1;25(13):2574–81

[The antimicrobial activity of thio–, thioxo– and oxo–derivatives of acridine] Novosad NV. **Mikrobiol Z** 1996 Jul–Aug;58(4):55–8 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Study of the efficacy of the new antischistosomal drug 10–[2–(diethylamino)ethyl]–9–acridanone–(thiazolidin–2–ylidene) hydrazone against an Egyptian strain of S. mansoni in mice. Metwally A, et al. **Arzneimittelforschung** 1997 Aug; 47(8):975–9

Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Zalupski MM, et al. **Cancer Chemother Pharmacol** 1997;40(3):225–7

Clinical trials referral resource. Clinical trials with pyrazoloacridine. Murgo AJ, et al. **Oncology (Huntingt)** 1997 Jul;11(7):991–4

[Neovir, an interferon inductor, modifies expression of steroid hormone receptors in hormone–dependent tissues and restores sensitivity to tamoxifen in patients with inoperable breast cancer] Surkov KG, et al. **Vopr Onkol** 1996; 42(6):28–32 (Eng. Abstr.) **(Rus)**

[Effectiveness of the interferon inducers ridostin and camedon in prevention and treatment of experimental alpha– and flavivirus infections] Barinskii IF, et al. **Vopr Virusol** 1996 May–Jun;41(3):133–5 (Eng. Abstr.) **(Rus)**

TOXICITY

Diverse mutagenicity of methylbenz[c]acridines in the direct Ames' Salmonella mutagenicity assay. Tanaka M, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2837–41

The potential of N–[2–(dimethylamino)ethyl]acridine–4–carboxamide to circumvent three multidrug–resistance phenotypes in vitro. Davey RA, et al. **Cancer Chemother Pharmacol** 1997; 39(5):424–30

The subchronic toxicity of acridine in the rat. Moir D, et al. **J Environ Sci Health B** 1997 Jul;32(4):545–64

ACRIFLAVINE

ANALYSIS

Liquid chromatographic determination of acriflavine and proflavine residues in channel catfish muscle. Plakas SM, et al. **J AOAC Int** 1997 May–Jun;80(3):486–90

PHARMACOLOGY

Enhanced anti–tumour effects of acriflavine in combination with guanosine in mice. Kim SG, et al. **J Pharm Pharmacol** 1997 Feb;49(2):216–22

ACRO–OSTEOLYSIS SYNDROMES see **OSTEOLYSIS, ESSENTIAL**

ACROCEPHALOSYNDACTYLIA

Genetic drift. Prying open the box. Marion RW. **Am J Med Genet** 1996 May 17;63(2):329–31

A four–pulp flap technique for creating nail folds in the separation of a mid–digital mass in a patient with Apert's disease. Noguchi M, et al. **Ann Plast Surg** 1996 Oct; 37(4):444–8

Hearing loss in the Saethre–Chotzen syndrome. Ensink RJ, et al. **J Laryngol Otol** 1996 Oct;110(10):952–7

[Carpenter syndrome] Kumagai K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):244–6 (8 ref.) **(Jpn)**

[Apert syndrome] Shimizu K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):238–40 (7 ref.) **(Jpn)**

[Pfeiffer syndrome associated with clover–leaf skull: 1st case described in Venezuela] Martínez–Basalo C, et al. **Invest Clin** 1997 Jun;38(2):95–106 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

New classification for the hand anomalies in Apert's syndrome [letter; comment] Anderson PJ, et al. **J Hand Surg [Br]** 1997 Feb;22(1):140–1. Comment on: J Hand Surg [Br] 1996 Apr;21(2):266–8.

COMPLICATIONS

Audiologic and otologic characteristics of Pfeiffer syndrome. Vallino–Napoli LD. **Cleft Palate Craniofac J** 1996 Nov; 33(6):524–9

Bilateral suprarenal cryptorchidism in a patient with the Pfeiffer syndrome. Goldfischer ER, et al. **J Urol** 1997 Aug; 158(2):597–8

DIAGNOSIS

Type 3 Pfeiffer syndrome with normal thumbs. Kerr NC, et al. **Am J Med Genet** 1996 Dec 11;66(2):138–43

Saethre–Chotzen syndrome: a clinical, EEG and neuroradiological study. Elia M, et al. **Childs Nerv Syst** 1996 Nov;12(11):699–704

Prenatal molecular diagnosis for Apert syndrome. Osada H, et al. **Int J Gynaecol Obstet** 1996 Nov;55(2):171–2

Apert syndrome. Deshmukh LS, et al. **J Indian Med Assoc** 1996 Apr;94(4):162

[Mental prognosis of Apert syndrome] Renier D, et al. **Arch Pediatr** 1996 Aug;3(8):752–60 (Eng. Abstr.) **(Fre)**

GENETICS

Pfeiffer mutation in an Apert patient: how wide is the spectrum of variability due to mutations in the FGFR2 gene? [letter] Passos–Bueno MR, et al. **Am J Med Genet** 1997 Aug 8;71(2):243–5

Craniosynostosis, Philadelphia type: a new autosomal dominant syndrome with sagittal craniosynostosis and syndactyly of the fingers and toes. Robin NH, et al. **Am J Med Genet** 1996 Mar 15;62(2):184–91

A case of Carpenter syndrome diagnosed in a 20–week–old fetus with postmortem examination. Balci S, et al. **Clin Genet** 1997 Jun;51(6):412–6

Craniosynostosis: novel insights into pathogenesis and treatment. Wilkie AO, et al. **Curr Opin Neurol** 1996 Apr; 9(2):146–52 (84 ref.)

Trp290Cys mutation in exon IIIa of the fibroblast growth factor receptor 2 (FGFR2) gene is associated with Pfeiffer syndrome. Tartaglia M, et al. **Hum Genet** 1997 May; 99(5):602–6

Translocation breakpoint maps 5 kb 3' from TWIST in a patient affected with Saethre–Chotzen syndrome. Krebs I, et al. **Hum Mol Genet** 1997 Jul;6(7):1079–86

Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Bellus GA, et al. **Nat Genet** 1996 Oct; 14(2):174–6

Twist and shout [news; comment] Dixon MJ. **Nat Genet** 1997 Jan;15(1):3–4. Comment on: Nat Genet 1997 Jan;15(1):36–41. Comment on: Nat Genet 1997 Jan;15(1):42–6.

Mutations of the TWIST gene in the Saethre–Chotzen syndrome [see comments] el Ghouzzi V, et al. **Nat Genet** 1997 Jan;15(1):42–6. Comment in: Nat Genet 1997 Jan;15(1):3–4.

Mutations in TWIST, a basic helix–loop–helix transcription factor, in Saethre–Chotzen syndrome [see comments] Howard TD, et al. **Nat Genet** 1997 Jan;15(1):36–41. Comment in: Nat Genet 1997 Jan;15(1):3–4.

METABOLISM

Apert's syndrome: differential in vitro production of matrix macromolecules and its regulation by interleukins. Bodo M, et al. **Eur J Clin Invest** 1997 Jan;27(1):36–42

PATHOLOGY

Prenatal diagnosis of cloverleaf skull in the subtype 2 Pfeiffer syndrome [letter] Martinelli P, et al. **Clin Dysmorphol** 1997 Jan;6(1):89–90

A clinical study of the craniofacial features in Apert syndrome. Cohen MM Jr, et al. **Int J Oral Maxillofac Surg** 1996 Feb;25(1):45–53

Finger duplication in Apert's syndrome. Anderson PJ, et al. **J Hand Surg [Br]** 1996 Oct;21(5):649–51

The Apert syndrome hand: pathologic anatomy and clinical manifestations. Holten IW, et al. **Plast Reconstr Surg** 1997 May;99(6):1681–7

Imaging of the Apert syndrome hand using three–dimensional CT and MRI. Holten IW, et al. **Plast Reconstr Surg** 1997 May;99(6):1675–80

PHYSIOPATHOLOGY

Dental development in Apert syndrome. Kaloust S, et al. **Cleft Palate Craniofac J** 1997 Mar;34(2):117–21

ACROCEPHALOSYNDACTYLIA

PSYCHOLOGY

[Parent stress in complex craniofacial abnormalities] Sarimski K. **Prax Kinderpsychol Kinderpsychiatr** 1997 Jan;46(1):2–14 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

The hands in Saethre–Chotzen syndrome. Anderson PJ, et al. **J Craniofac Genet Dev Biol** 1996 Oct–Dec;16(4):228–33

Congenital cervical spinal fusion: a study in Apert syndrome. Thompson DN, et al. **Pediatr Neurosurg** 1996 Jul;25(1):20–7

Knee radiographs in Pfeiffer and Crouzon syndromes [letter] Anderson PJ, et al. **Plast Reconstr Surg** 1997 Aug; 100(2):550

SURGERY

Consensus: craniofacial synostoses. Apert and Crouzon syndromes. Bruce DA. **Childs Nerv Syst** 1996 Nov; 12(11):734–6 (0 ref.)

Faciocraniosynostosis: from infancy to adulthood. Marchac D, et al. **Childs Nerv Syst** 1996 Nov;12(11):669–77

Management of secondary turricephaly in craniofacial surgery. Sonstein WJ, et al. **Childs Nerv Syst** 1996 Nov; 12(11):705–12

Two-stage reconstruction of apert acrosyndactyly. Van Heest AE, et al. **J Hand Surg [Am]** 1997 Mar;22(2):315–22

Cloverleaf skull--when should one operate? Goh KY, et al. **Singapore Med J** 1997 May;38(5):217–20

ULTRASONOGRAPHY

Ultrasound detection of Apert syndrome: a case report and literature review. Kaufmann K, et al. **Am J Perinatol** 1997 Aug;14(7):427–30 (15 ref.)

A case of Carpenter syndrome diagnosed in a 20–week–old fetus with postmortem examination. Balci S, et al. **Clin Genet** 1997 Jun;51(6):412–6

Prenatal diagnosis of type 2 Pfeiffer syndrome. Bernstein PS, et al. **Ultrasound Obstet Gynecol** 1996 Dec;8(6):425–8

ACROCEPHALY see **CRANIOSYNOSTOSES**

ACRODERMATITIS

COMPLICATIONS

Infantile acrodermatitis of Gianotti–Crosti and Lyme borreliosis [letter] Baldari U, et al. **Acta Derm Venereol** 1996 May;76(3):242–3

Acrodermatitis chronica atrophicans in an Italian child [letter] Menni S, et al. **Acta Derm Venereol** 1996 May; 76(3):243

Hailey–Hailey disease with acrokeratosis verruciformis Hopf [letter] Yakis G, et al. **Acta Derm Venereol** 1996 Mar; 76(2):157 (4 ref.)

Bony anomalies in a patient with reticulate acropigmentation of Kitamura. el–Hoshy K, et al. **J Dermatol** 1996 Oct; 23(10):713–5

DIAGNOSIS

Acrokeratoelastoidosis. Dyall–Smith D. **Australas J Dermatol** 1996 Nov;37(4):213–4 (6 ref.)

Current aspects of Lyme disease and other Borrelia burgdorferi infections. Berger BW. **Dermatol Clin** 1997 Apr;15(2):247–55 (58 ref.)

DRUG THERAPY

Long–term prognosis in patients treated for erythema chronicum migrans and acrodermatitis chronica atrophicans [see comments] Hulshof MM, et al. **Arch Dermatol** 1997 Jan;133(1):33–7. Comment in: Arch Dermatol 1997 Jan;133(1):93–4.

Successful treatment for acrodermatitis continua of Hallopeau using topical calcipotriol. Emtestam L, et al. **Br J Dermatol** 1996 Oct;135(4):644–6

Acrodermatitis continua of Hallopeau: response to combined treatment with acitretin and calcipotriol ointment. Kuijpers AL, et al. **Dermatology** 1996;192(4):357–9

Success and failure in the treatment of acrodermatitis chronica atrophicans. Aberer E, et al. **Infection** 1996 Jan–Feb;24(1):85–7

EPIDEMIOLOGY

Peripheral neuropathy in acrodermatitis chronica atrophicans – a late Borrelia manifestation. Kindstrand E, et al. **Acta Neurol Scand** 1997 Jun;95(6):338–45

ETIOLOGY

Gianotti–Crosti syndrome in an adult patient following a recently acquired Epstein–Barr virus infection [letter] Mempel M, et al. **Acta Derm Venereol** 1996 Nov; 76(6):502–3

Acrodermatitis enteropathica–like eruption during treatment of maple syrup urine disease: report of one case. Tain YL, et al. **Acta Paediatr Sin** 1996 Sep–Oct;37(5):357–60

Acquired acrodermatitis enteropathica during chemotherapy for acute lymphocytic leukaemia in a child with Down syndrome [letter] Sawai T, et al. **Br J Dermatol** 1996 Oct; 135(4):659–60

Acquired acromelanosis due to phenytoin [letter] Kanwar AJ, et al. **Dermatology** 1997;194(4):373–4

Acrodermatitis enteropathica secondary to Crohn's disease. Krasovec M, et al. **Dermatology** 1996;193(4):361–3 (14 ref.)

Pseudo–Kaposi's sarcoma associated with acquired arteriovenous fistula. Kim TH, et al. **J Dermatol** 1997 Jan; 24(1):28–33

Gianotti–Crosti syndrome associated with Epstein–Barr virus infection. Hofmann B, et al. **Pediatr Dermatol** 1997 Jul–Aug;14(4):273–7

[Cutaneous necrosis of the extremities during carbon monoxide poisoning] del Giudice P, et al. **Ann Dermatol Venereol** 1995;122(11–12):780–2 (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Long–term prognosis in patients treated for erythema chronicum migrans and acrodermatitis chronica atrophicans [see comments] Hulshof MM, et al. **Arch Dermatol** 1997 Jan;133(1):33–7. Comment in: Arch Dermatol 1997 Jan;133(1):93–4.

Acrodermatitis chronica atrophicans in an 11–year–old girl. Muellegger RR, et al. **Br J Dermatol** 1996 Oct; 135(4):609–12

PATHOLOGY

Acrodermatitis enteropathica. Khanna N, et al. **Indian Pediatr** 1996 Nov;33(11):967–8

Acrodermatitis enteropathica [letter] Kumar S, et al. **J Dermatol** 1997 Feb;24(2):135–6

PHYSIOPATHOLOGY

[Heavy legs, venular microangiopathy and stasis acrodermatitis] Piérard GE. **Rev Med Liege** 1996 Aug; 51(8):510–3 (22 ref.) **(Fre)**

SURGERY

Acroangiodermatitis (pseudo–Kaposi's sarcoma) associated with Klippel–Trénaunay syndrome. Lyle WG, et al. **Ann Plast Surg** 1996 Dec;37(6):654–6

VETERINARY

Serum concentrations of zinc and copper in bull terriers with lethal acrodermatitis and tail–chasing behavior. Uchida Y, et al. **Am J Vet Res** 1997 Aug;58(8):808–10

What is your diagnosis? Lethal acrodermatitis of English bull terriers. Patel A. **J Small Anim Pract** 1996 Dec;37(12):567, 600

ACRODYSPLASIA V see **LANGER–GIEDION SYNDROME**

ACROLEIN

Acrolein. **IARC Monogr Eval Carcinog Risks Hum** 1995; 63:337–72 (187 ref.)

ANALOGS & DERIVATIVES

In vitro activity of Cinnamomum zeylanicum against azole resistant and sensitive Candida species and a pilot study of cinnamon for oral candidiasis. Quale JM, et al. **Am J Chin Med** 1996;24(2):103–9

Cross–reactions in patch testing and photopatch testing with ketoprofen, thiaprophenic acid, and cinnamic aldehyde. Pigatto P, et al. **Am J Contact Dermat** 1996 Dec;7(4):220–3

Liquid chromatography--electrospray ionization mass spectrometric detection of an ethenodeoxyguanosine adduct and its hemiaminal precursors in DNA reacted with alpha–acetoxy–N–nitrosopiperidine and cis–4–Oxo–2–pentenal. Liu Z, et al. **Chem Res Toxicol** 1996 Jun;9(4):774–80

Mechanism of reaction of beta–(aryloxy)acroleins with nucleosides. Reddy GR, et al. **Chem Res Toxicol** 1996 Jan–Feb;9(1):12–5

Threshold responses in cinnamic–aldehyde–sensitive subjects: results and methodological aspects. Johansen JD, et al. **Contact Dermatitis** 1996 Mar;34(3):165–71

Studies on the basis for the toxicity of acrolein mercapturates. Ramu K, et al. **Toxicol Appl Pharmacol** 1996 Oct; 140(2):487–98

ANALYSIS

High–performance liquid chromatographic determination of acrolein as a marker for cyclophosphamide bioactivation in human liver microsomes. Bohnenstengel F, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):163–8

CHEMISTRY

In vitro reactivity of the antineoplastic drug carmustin and acrolein with model peptides. Carbone V, et al. **J Pept Res** 1997 Jun;49(6):586–95

METABOLISM

[14]C acrolein accumulation and metabolism in leaf lettuce. Nordone AJ, et al. **Bull Environ Contam Toxicol** 1997 May; 58(5):787–92

Simultaneous determination of acrolein, malonaldehyde and 4–hydroxy–2–nonenal produced from lipids oxidized with Fenton's reagent. Miyake T, et al. **Food Chem Toxicol** 1996 Oct;34(10):1009–11

Metabolism and distribution of [2,3–14C]acrolein in Sprague–Dawley rats. Parent RA, et al. **J Appl Toxicol** 1996 Sep–Oct;16(5):449–57

Human neutrophils employ the myeloperoxidase–hydrogen peroxide–chloride system to convert hydroxy–amino acids into glycolaldehyde, 2–hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha–hydroxy and alpha,beta–unsaturated aldehydes by phagocytes at sites of inflammation. Anderson MM, et al. **J Clin Invest** 1997 Feb 1;99(3):424–32

PHARMACOLOGY

Mechanism of reaction of beta–(aryloxy)acroleins with nucleosides. Reddy GR, et al. **Chem Res Toxicol** 1996 Jan–Feb;9(1):12–5

TOXICITY

Sensory irritation to mixtures of formaldehyde, acrolein, and acetaldehyde in rats. Cassee FR, et al. **Arch Toxicol** 1996; 70(6):329–37

Toxicity of formaldehyde and acrolein mixtures: in vitro studies using nasal epithelial cells. Cassee FR, et al. **Exp Toxicol Pathol** 1996 Nov;48(6):481–3

Mutagenic activity of acrolein in S. typhimurium and E. coli. Parent RA, et al. **J Appl Toxicol** 1996 Mar–Apr;16(2):103–8

Acrolein–induced cell death in human alveolar macrophages. Li L, et al. **Toxicol Appl Pharmacol** 1997 Aug;145(2):331–9

Studies on the basis for the toxicity of acrolein mercapturates. Ramu K, et al. **Toxicol Appl Pharmacol** 1996 Oct; 140(2):487–98

Relationships between cell density, glutathione and proliferation of A549 human lung adenocarcinoma cells treated with acrolein. Horton ND, et al. **Toxicology** 1997 Sep 26;122(1–2):111–22

ACROMEGALY

[Pituitary diseases] Yamasaki T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):7–10 (13 ref.) **(Jpn)**

BLOOD

Interassay differences in growth hormone measurement in acromegaly. Barth JH, et al. **Ann Clin Biochem** 1997 Mar; 34 (Pt 2):156–9

LDL subfractions in acromegaly: relation to growth hormone and insulin–like growth factor–I. Tan KC, et al. **Atherosclerosis** 1997 Feb 28;129(1):59–65

Plasma GH, TSH, and PRL responses to recombinant human insulin–like growth factor–I (IGF–I) in normal and acromegalic subjects. Hanew K, et al. **Endocr J** 1996 Oct; 43 Suppl:S81–3

A case of active acromegalic woman with a marked increase in serum insulin–like growth factor–1 levels after delivery. Okada Y, et al. **Endocr J** 1997 Feb;44(1):117–20

Serum Insulin–like growth factor–II (IGF–II) levels in patients with acromegaly and growth hormone deficiency: correlation with IGF–I and IGF binding protein–3. Shimatsu A, et al. **Endocr J** 1996 Oct;43 Suppl:S71–3

Acromegalic pregnancy associated with a Beckwith–Wiedemann fetus. Luton D, et al. **Fetal Diagn Ther** 1996 Mar–Apr;11(2):154–8

Circulating non–22–kilodalton growth hormone isoforms in acromegalic men before and after transsphenoidal surgery. Boguszewski CL, et al. **J Clin Endocrinol Metab** 1997 May; 82(5):1516–21

Acromegaly. Melmed S. **Metabolism** 1996 Aug;45(8 Suppl 1):51–2 (5 ref.)

Comparative study of insulin–like growth factor–I (IGF–I) and IGF–binding protein–3 (IGFBP–3) level and IGF–I/IGFBP–3 ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly. Páramo C, et al. **Metabolism** 1997 May;46(5):494–8

Effects of sumatriptan on growth hormone releasing hormone–stimulated growth hormone secretion in acromegaly. Cuttica CM, et al. **Recenti Prog Med** 1997 Jun;88(6):264–8

COMPLICATIONS

Heart valve operation in acromegaly. Ohtsuka G, et al. **Ann Thorac Surg** 1997 Aug;64(2):390–3

Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Colao A, et al. **Clin Endocrinol (Oxf)** 1997 Jul;47(1):23–8

Ocular naevus and melanoma in acromegaly. Corcuff JB, et al. **Clin Endocrinol (Oxf)** 1997 Jul;47(1):119–21

Acromegaly, colonic polyps and carcinoma. Jenkins PJ, et al. **Clin Endocrinol (Oxf)** 1997 Jul;47(1):17–22

Acromegaly and thyroid carcinoma [letter] Ozgen AG, et al. **Clin Endocrinol (Oxf)** 1996 Aug;45(2):244–5

Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Rosenow F, et al. **Clin Endocrinol (Oxf)** 1996 Nov;45(5):563–9

Acromegaly or chronic renal failure: a diagnostic dilemma. Wong NA, et al. **Clin Endocrinol (Oxf)** 1997 Feb; 46(2):221–6

Acute promyelocytic leukemia in the course of acromegaly: a case report. Beyan C, et al. **Endocr J** 1996 Oct;43(5):565–8

Acromegaly associated with Chiari-I malformation and polycystic ovary syndrome. Hara M, et al. **Intern Med** 1996 Oct;35(10):803–7

A patient with acromegaly who showed remarkable improvement of hyperglycemia after treatment with octreotide [see comments] Hirose T, et al. **Intern Med** 1997 May;36(5):345–50. Comment in: Intern Med 1997 May;36(5):319–20.

Pituitary apoplexy after subtotal thyroidectomy in an acromegalic patient with a large goiter. Kato K, et al. **Intern Med** 1996 Jun;35(6):472–7

Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. Kumar S, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3465–8

Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? López-Velasco R, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1047–53

The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients [letter; comment] Terzolo M, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2406–7. Comment on: J Clin Endocrinol Metab 1995 Nov;80(11):3223–6.

Acromegalic cardiomyopathy: evaluation of the left ventricular diastolic function in the subclinical stage. Ozbey N, et al. **J Endocrinol Invest** 1997 Jun;20(6):305–11

A rare case of gastric cancer in an acromegalic patient. Asai K, et al. **J Gastroenterol** 1997 Aug;32(4):528–32

Acromegaly and cutis verticis gyrata. O'Reilly FM, et al. **J R Soc Med** 1997 Feb;90(2):79

Factors predicting pituitary adenoma invasiveness in acromegalic patients. Rieger A, et al. **Neurosurg Rev** 1997; 20(3):182–7

Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Kayath MJ, et al. **Osteoporos Int** 1997;7(3):226–30

Acromegaly presenting with diabetic ketoacidosis. Katz JR, et al. **Postgrad Med J** 1996 Nov;72(853):682–3

Bilateral slipped capital femoral epiphysis occuring in an adult with acromegalic gigantism. Feydy A, et al. **Skeletal Radiol** 1997 Mar;26(3):188–90

[A case of acromegaly associated with variegated spinal disorders] Suga T, et al. **No Shinkei Geka** 1996 Oct; 24(10):927–32 (Eng. Abstr.) **(Jpn)**

[The prevalence of hypertension in acromegaly] Barros L, et al. **Acta Med Port** 1997 Jan;10(1):15–8 (Eng. Abstr.) **(Por)**

[Reduction of upper airway obstruction in a patient with acromegaly treated with octreotide (letter)] Rojas I, et al. **Med Clin (Barc)** 1996 Feb 3;106(4):158 **(Spa)**

DIAGNOSIS

Case report: acromegaly. D'Urzo AD. **Can Fam Physician** 1997 Jun;43:1121–2

A comparison of different methods for diagnosing acromegaly. Stoffel-Wagner B, et al. **Clin Endocrinol (Oxf)** 1997 May;46(5):531–7

The diagnosis and management of acromegaly: a Canadian consensus report. Ezzat S, et al. **Clin Invest Med** 1996 Aug; 19(4):259–70 (60 ref.)

A case report of an elderly patient with acromegaly. Wada M, et al. **Endocr J** 1996 Dec;43(6):715–8

Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults. Thissen JP, et al. **Growth Regul** 1996 Dec;6(4):222–9

Acromegaly. Colao A, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2777–81

MRI of pituitary adenomas in acromegaly. Marro B, et al. **Neuroradiology** 1997 Jun;39(6):394–9

[Current concepts in the diagnosis and treatment of acromegaly] Diez JJ. **Rev Clin Esp** 1996 Sep;196(9):622–35 (279 ref.) **(Spa)**

DRUG THERAPY

An audit of long-term octreotide therapy for acromegaly. Cheung NW, et al. **Aust N Z J Med** 1997 Feb;27(1):12–8

Cabergoline treatment of acromegaly: a preliminary dose finding study. Jackson SN, et al. **Clin Endocrinol (Oxf)** 1997 Jun;46(6):745–9

The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. al-Maskari M, et al. **Clin Endocrinol (Oxf)** 1996 Oct;45(4):415–21

Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Gillis JC, et al. **Drugs** 1997 Apr;53(4):681–99 (71 ref.)

Heterogeneous responses to the long-term treatment of active acromegaly with octreotide. Chang CL, et al. **Endocr J** 1996 Aug;43(4):447–56

Octreotide and bromocriptine suppress thyroid hormone levels and thyroid nodule in an acromegalic patient with nontoxic autonomous goiter. Sakane N, et al. **Endocr J** 1997 Apr;44(2):305–10

Short-term effects of octreotide on glucose tolerance in patients with acromegaly. Sato K, et al. **Endocr J** 1995 Dec;42(6):739–45

Clinical results of long-term slow-release lanreotide treatment of acromegaly. Giusti M, et al. **Eur J Clin Invest** 1997 Apr;27(4):277–84

Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits? [comment] Chanson P. **Eur J Endocrinol** 1997 Apr;136(4):359–61. Comment on: Eur J Endocrinol 1997 Apr;136(4):369–76.

Growth hormone binding protein and growth hormone availability in acromegalic patients treated with long-acting octreotide (Sandostatin-LAR). Fisker S, et al. **Eur J Endocrinol** 1997 Jan;136(1):61–6

Relief of sleep apnoea after treatment of acromegaly: report of three cases and review of the literature. Buyse B, et al. **Eur Respir J** 1997 Jun;10(6):1401–4

Incomplete analgesic effect of lanreotide in acromegaly [letter] Maffei P, et al. **Headache** 1997 May;37(5):299–300

A patient with acromegaly who showed remarkable improvement of hyperglycemia after treatment with octreotide [see comments] Hirose T, et al. **Intern Med** 1997 May;36(5):345–50. Comment in: Intern Med 1997 May;36(5):319–20.

Divergent effects of octreotide on glucose tolerance in patients with acromegaly [editorial; comment] Hizuka N. **Intern Med** 1997 May;36(5):319–20. Comment on: Intern Med 1997 May;36(5):345–50.

Octreotide and lanreotide treatment in active acromegaly [letter; comment] Cannavò S, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2376–7. Comment on: J Clin Endocrinol Metab 1996 Dec;81(12):4502–3.

Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide [see comments] Caron P, et al. **J Clin Endocrinol Metab** 1997 Jan; 82(1):18–22. Comment in: J Clin Endocrinol Metab 1997 Jan;82(1):15–7.

Effect of different dopaminergic agents in the treatment of acromegaly. Colao A, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):518–23

Prediction of efficacy of octreotide therapy in patients with acromegaly. Colao A, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2356–62

Sandostatin LAR in acromegalic patients: long-term treatment [see comments] Fløgstad AK, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):23–8. Comment in: J Clin Endocrinol Metab 1997 Jan;82(1):15–7.

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group [see comments] Giusti M, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2089–97. Comment in: J Clin Endocrinol Metab 1996 Dec;81(12):4502–3.

Depot somatostatin analogs--a new first line therapy for acromegaly [editorial; comment] Robbins RJ. **J Clin Endocrinol Metab** 1997 Jan;82(1):15–7. Comment on: J Clin Endocrinol Metab 1997 Jan;82(1):18–22. Comment on: J Clin Endocrinol Metab 1997 Jan;82(1):23–8.

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicentre study [letter; comment] [see comments] Soule S, et al. **J Clin Endocrinol Metab** 1996 Dec; 81(12):4502–3. Comment on: J Clin Endocrinol Metab 1996 Jun;81(6):2089–97. Comment in: J Clin Endocrinol Metab 1997 Jul;82(7):2376–7.

Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients. Invitti C, et al. **J Endocrinol Invest** 1996 Sep;19(8):548–55

Twenty-four hour melatonin pattern in acromegaly: effect of acute octreotide administration. Sinisi AA, et al. **J Endocrinol Invest** 1997 Mar;20(3):128–33

Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Grass P, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):27–30

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Lancranjan I, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):67–71

Metabolic aspects of acromegaly and its treatment. Quabbe HJ, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):61–2 (25 ref.)

Treatment options for acromegaly. Sheppard MC, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):63–4 (10 ref.)

Presurgical Octreotide: treatment in acromegaly. Stevenaert A, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):72–4

The role of somatostatin agonistic analogs in the treatment of acromegaly. Tolis G. **Metabolism** 1996 Aug;45(8 Suppl 1):109–10 (16 ref.)

The pharmacological aspects of the treatment of acromegaly. Giustina A, et al. **Pharmacol Res** 1996 Nov-Dec; 34(5-6):247–68 (115 ref.)

[Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index] Görges R, et al. **Nuklearmedizin** 1997 Jun;36(4):117–24 (Eng. Abstr.) **(Ger)**

[Lanreotide + +: a new therapeutic option in acromegaly] Díez JJ. **Med Clin (Barc)** 1996 Sep 7;107(7):257–69 (200 ref.) **(Spa)**

ETIOLOGY

Molecular pathophysiology of acromegaly. Melmed S. **Acta Paediatr Suppl** 1996 Oct;417:45–8 (28 ref.)

Overgrowth. Hormonal Causes. Sotos JF. **Clin Pediatr (Phila)** 1996 Nov;35(11):579–90 (64 ref.)

Growth hormone-releasing hormone (GRH)-producing pancreatic tumor with no evidence of multiple endocrine neoplasia type 1. Kawa S, et al. **Dig Dis Sci** 1997 Jul; 42(7):1480–5

Development of acromegaly during treatment of hyperprolactinemia with bromocriptine: an unusual acidophil stem cell adenoma. Page MD, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4484–7

A growth hormone-releasing hormone-producing pancreatic islet cell tumor metastasized to the pituitary is associated with pituitary somatotroph hyperplasia and acromegaly. Sanno N, et al. **J Clin Endocrinol Metab** 1997 Aug; 82(8):2731–7

Unwanted effects of growth hormone excess in the adult. Melmed S. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:369–74 (31 ref.)

Ectopic acromegaly. Platts JK, et al. **Postgrad Med J** 1997 Jun;73(860):349–51

GENETICS

Molecular biology of growth-hormone-secreting human pituitary tumours: biochemical consequences and potential clinical significance. Adams EF, et al. **Acta Neurochir Suppl (Wien)** 1996;65:7–10 (18 ref.)

Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior. Thapar K, et al. **Am J Pathol** 1997 Sep; 151(3):769–84

Two cases of acromegaly in a family. Kakiya S, et al. **Endocr J** 1997 Apr;44(2):227–31 (14 ref.)

Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production. Ohtsuka H, et al. **Endocr J** 1995 Dec;42(6):781–7

Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Yang I, et al. **Eur J Endocrinol** 1996 Jun;134(6):720–6

An autosomal dominant syndrome of acromegaloid facial appearance and generalised hypertrichosis terminalis. Irvine AD, et al. **J Med Genet** 1996 Nov;33(11):972–4

HISTORY

Acromegaly, Mr Punch and caricature. Bryson D. **J Audiov Media Med** 1996 Sep;19(3):119–22

METABOLISM

Growth hormone-releasing hormone receptor mRNA in acromegalic pituitary tumors. Lopes MB, et al. **Am J Pathol** 1997 Jun;150(6):1885–91

Comparison of different body composition models in acromegaly. Brummer RJ, et al. **Growth Regul** 1996 Dec; 6(4):191–200

Divergent effects of octreotide on glucose tolerance in patients with acromegaly [editorial; comment] Hizuka N. **Intern Med** 1997 May;36(5):319–20. Comment on: Intern Med 1997 May;36(5):345–50.

Zollinger-Ellison syndrome, acromegaly, and colorectal neoplasia. Tobi M, et al. **J Clin Gastroenterol** 1997 Jan; 24(1):21–4

Gonadotrophin and free alpha-subunit secretion in patients with acromegaly and clinically non-functioning pituitary tumors: anterior pituitary function and the effect of thyrotrophin-releasing hormone. Damjanović SS, et al. **J Endocrinol Invest** 1996 Nov;19(10):663–9

Metabolic aspects of acromegaly and its treatment. Quabbe HJ, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):61–2 (25 ref.)

Relationships between pathological diagnosis and clinical parameters in acromegaly. Trouillas J, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):53–6

[Relationship between fasting glycemia, serum peptide C, insulin, growth hormone and plasma glucagon in acromegaly] Piniewska-Hułas D, et al. **Pol Arch Med Wewn** 1996 Jun;95(6):524–33 (Eng. Abstr.) **(Pol)**

PATHOLOGY

Acromegaly with normal basal growth hormone levels. Mohr G, et al. **Can J Neurol Sci** 1997 Aug;24(3):250–3

Relationships between pathological diagnosis and clinical parameters in acromegaly. Trouillas J, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):53–6

[Intestinal cell proliferation, acromegaly and colon tumors] Fehmann HC, et al. **Z Gastroenterol** 1997 Apr;35(4):305–6 **(Ger)**

PHYSIOPATHOLOGY

Self-organized segmentation of time series: separating growth hormone secretion in acromegaly from normal controls. Prank K, et al. **Biophys J** 1996 Jun;70(6):2540–7

Growth hormone- and growth-hormone-releasing hormone-producing tumors. Shimon I, et al. **Cancer Treat Res** 1997;89:1–24 (78 ref.)

Pituitary insufficiency and regression of acromegaly caused by pituitary apoplexy following cerebral angiography. Louwerens M, et al. **Eur J Endocrinol** 1996 Jun; 134(6):737–40

Respiratory muscle function and control of breathing in patients with acromegaly. Iandelli I, et al. **Eur Respir J** 1997 May;10(5):977–82

Growth hormone response to the hypothalamic somatostatinergic activity in acromegalic patients. Yang I, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2492–6

Thyroid volume and function in patients with acromegaly living in iodine deficient areas. Junik R, et al.

ACROMEGALY

J Endocrinol Invest 1997 Mar;20(3):134–7

Cardiovascular aspects in acromegaly: effects of treatment. Lombardi G, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):57–60

Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) level and IGF-I/IGFBP-3 ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly. Páramo C, et al. **Metabolism** 1997 May;46(5):494–8

[Early diagnosis of impaired glomerular and renal tubule function in patients with acromegaly] Sindelka G, et al. **Cas Lek Cesk** 1996 Oct 23;135(20):657–9 (Eng. Abstr.) **(Cze)**

[Heart disease in acromegaly. Study of 27 patients] Marín F, et al. **Med Clin (Barc)** 1996 Sep 21;107(9):326–30 (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

[Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index] Görges R, et al. **Nuklearmedizin** 1997 Jun;36(4):117–24 (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

The influence of air cavities on the optic chiasm dose during pituitary radiotherapy for acromegaly. Jones B, et al. **Br J Radiol** 1996 Aug;69(824):723–5

Long-term effects of radiotherapy for acromegaly. Wass JA. **Metabolism** 1996 Aug;45(8 Suppl 1):107–8 (8 ref.)

SURGERY

Polycythemia vera in acromegaly [letter; comment] Teramoto S, et al. **Ann Intern Med** 1997 Jan 1;126(1):87 . Comment on: Ann Intern Med 1996 Mar 1;124(5):495–6.

Elevated fibrinogen levels decrease following treatment of acromegaly. Landin-Wilhelmsen K, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):69–74

Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Sheaves R, et al. **Clin Endocrinol (Oxf)** 1996 Oct;45(4):407–13

Retrospective analysis of long-term surgical results in acromegaly: preoperative and postoperative factors predicting outcome. Yamada S, et al. **Clin Endocrinol (Oxf)** 1996 Sep;45(3):291–8

The results of transsphenoidal surgery for 44 consecutive acromegalic patients. Yamada S, et al. **Endocr J** 1997 Jun; 44(3):395–402

Circulating non-22-kilodalton growth hormone isoforms in acromegalic men before and after transsphenoidal surgery. Boguszewski CL, et al. **J Clin Endocrinol Metab** 1997 May; 82(5):1516–21

Surgical outcome after repeated transsphenoidal surgery in acromegaly. Long H, et al. **J Neurosurg** 1996 Aug; 85(2):239–47

Acromegaly—the place of the neurosurgeon. Fahlbusch R, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):65–6

Treatment options for acromegaly. Sheppard MC, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):63–4 (10 ref.)

Intrasellar pituitary gangliocyto-adenoma presenting with acromegaly: case report. Morikawa M, et al. **Neurosurgery** 1997 Mar;40(3):611–4; discussion 614–5 (34 ref.)

Transnasal stereotactic surgery of pituitary adenomas concomitant with acromegaly. Metyolkina L, et al. **Stereotact Funct Neurosurg** 1995;65(1–4):184–6

THERAPY

The diagnosis and management of acromegaly: a Canadian consensus report. Ezzat S, et al. **Clin Invest Med** 1996 Aug; 19(4):259–70 (60 ref.)

Acromegaly. Newman CB. **Curr Ther Endocrinol Metab** 1997;6:47–51 (13 ref.)

Acromegaly. Colao A, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2777–81

Cardiovascular aspects in acromegaly: effects of treatment. Lombardi G, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):57–60

Acromegaly. Melmed S. **Metabolism** 1996 Aug;45(8 Suppl 1):51–2 (5 ref.)

Recent management of pituitary adenomas. Teramoto A. **Nippon Ika Daigaku Zasshi** 1996 Aug;63(4):255–8 (8 ref.)

[Attrition of goiter and elimination of autoantibody to the thyroid caused by treatment of acromegaly: a case study] Sakamoto M, et al. **Nippon Naika Gakkai Zasshi** 1997 May 10;86(5):835–7 **(Jpn)**

[Current concepts in the diagnosis and treatment of acromegaly] Diez JJ. **Rev Clin Esp** 1996 Sep;196(9):622–35 (279 ref.) **(Spa)**

ULTRASONOGRAPHY

The thyroid gland in acromegaly: an ultrasonographic study. Cheung NW, et al. **Clin Endocrinol (Oxf)** 1997 May; 46(5):545–9

Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? López-Velasco R, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1047–53

ACROMIOCLAVICULAR JOINT

Ganglion of the acromioclavicular joint. Segmüller HE, et al. **J Shoulder Elbow Surg** 1997 Jul-Aug;6(4):410–2

INJURIES

Bone-ligament transfer of coracoacromial ligament for acromioclavicular dislocation. A new fixation method used in 6 cases. Kutschera HP, et al. **Acta Orthop Scand** 1997 Jun;68(3):246–8

Aseptic foreign body reaction to Dacron graft material used for coracoclavicular ligament reconstruction after type III acromioclavicular dislocation. Colosimo AJ, et al. **Am J Sports Med** 1996 Jul-Aug;24(4):561–3

The management of common dislocations in the upper limb. Bell S, et al. **Aust Fam Physician** 1996 Sep;25(9):1413–5, 1418–23, 1425, passim

The results of coraco-clavicular slings for acromio-clavicular dislocation. Clayer M, et al. **Aust N Z J Surg** 1997 Jun;67(6):343–6

Treatment of grade III acromioclavicular separations. Operative versus nonoperative management. Press J, et al. **Bull Hosp Jt Dis** 1997;56(2):77–83

Floating clavicle--simultaneous dislocation of both ends of the clavicle. Eni-Olotu DO, et al. **Injury** 1997 May; 28(4):319–20 (4 ref.)

A taping technique for the treatment of acromioclavicular joint sprains: a case study. Shamus JL, et al. **J Orthop Sports Phys Ther** 1997 Jun;25(6):390–4

Infections after surgical repair of acromioclavicular separations with nonabsorbable tape or suture. Neault MA, et al. **J Shoulder Elbow Surg** 1996 Nov-Dec;5(6):477–8

Acromioclavicular joint injury in competitive golfers. Mallon WJ, et al. **J South Orthop Assoc** 1995 Winter;4(4):277–82

Scapulothoracic dissociation caused by blunt trauma. Damschen DD, et al. **J Trauma** 1997 Mar;42(3):537–40

Surgical treatment of complete acromioclavicular separations. Chen SK, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Mar; 13(3):175–81

[Treatment of acromioclavicular dislocation with resorbable fixation material] Juřica Z. **Rozhl Chir** 1996 Oct; 75(10):513–4 (Eng. Abstr.) **(Cze)**

[Osteolysis of the lateral clavicle after Tossy II injury in ice hockey players] Stöhr H, et al. **Sportverletz Sportschaden** 1996 Sep;10(3):70–3 (Eng. Abstr.) **(Ger)**

[Treatment of fresh Tossy III acromioclavicular joint dislocation by ligament suture and temporary fixation with the clavicular hooked plate] Henkel T, et al. **Swiss Surg** 1997;3(4):160–6 (Eng. Abstr.) **(Ger)**

[Therapy and outcome of lateral clavicular fractures] Hessmann M, et al. **Unfallchirurg** 1997 Jan;100(1):17–23 (Eng. Abstr.) **(Ger)**

[Results of reconstruction of acromioclavicular joint rupture with PDS implants] Hessmann M, et al. **Unfallchirurg** 1997 Mar;100(3):193–7 (Eng. Abstr.) **(Ger)**

[Comparison and outcome of grade II and III acromioclavicular joint injuries] Reichkendler M, et al. **Unfallchirurg** 1996 Oct;99(10):778–83 (Eng. Abstr.) **(Ger)**

[Methods for evaluating surgical treatment results of complete acromioclavicular dislocation] Kącik W, et al. **Chir Narzadow Ruchu Ortop Pol** 1997;62(2):97–103 (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

[Impingement syndrome] Mach J. **Dtsch Med Wochenschr** 1997 Sep 5;122(36):1096 **(Ger)**

RADIOGRAPHY

Post-traumatic osteolysis of the distal clavicle. Reber P, et al. **Arch Orthop Trauma Surg** 1996;115(2):120–2 (17 ref.)

Clavicular fractures and ipsilateral acromioclavicular arthrosis. Edelson JG. **J Shoulder Elbow Surg** 1996 May-Jun;5(3):181–5

Does osteolysis of the distal clavicle occur following spinal cord injury? Roach NA, et al. **Skeletal Radiol** 1997 Jan; 26(1):16–9

SURGERY

Aseptic foreign body reaction to Dacron graft material used for coracoclavicular ligament reconstruction after type III acromioclavicular dislocation. Colosimo AJ, et al. **Am J Sports Med** 1996 Jul-Aug;24(4):561–3

The SLAP lesion: a cause of failure after distal clavicle resection. Berg EE, et al. **Arthroscopy** 1997 Feb;13(1):85–9

"The results of operative resection of the lateral end of the clavicle" [letter; comment] Green A. **J Bone Joint Surg Am** 1997 Apr;79(4):633–4; discussion 634. Comment on: J Bone Joint Surg Am 1996 Apr;78(4):584–7.

"The results of operative resection of the lateral end of the clavicle" [letter] Günal I. **J Bone Joint Surg Am** 1997 Apr; 79(4):634; discussion 634

Surgical treatment of complete acromioclavicular separations. Chen SK, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Mar; 13(3):175–81

The results of open acromioplasty in impingement syndrome--a retrospective study. Chui CH, et al. **Singapore Med J** 1997 Jan;38(1):22–4

[Treatment of acromioclavicular dislocation with resorbable fixation material] Juřica Z. **Rozhl Chir** 1996 Oct; 75(10):513–4 (Eng. Abstr.) **(Cze)**

[Arthroscopic therapy of tendinitis calcarea--acromioplasty or removal of calcium?] Jerosch J, et al. **Unfallchirurg** 1996 Dec;99(12):946–52 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Standardized ultrasound examination for evaluation of instability of the acromioclavicular joint. Kock HJ, et al. **Arch Orthop Trauma Surg** 1996;115(3–4):136–40

ACROMION

Pigmented villonodular synovitis of the subacromial bursa. Konrath GA, et al. **J Shoulder Elbow Surg** 1997 Jul-Aug; 6(4):400–4

The os acromiale: another cause of impingement [published erratum appears in Med Sci Sports Exerc 1997 Apr;29(4):569] Swain RA, et al. **Med Sci Sports Exerc** 1996 Dec;28(12):1459–62

ANATOMY & HISTOLOGY

The acromion: morphologic condition and age-related changes. A study of 420 scapulas. Nicholson GP, et al. **J Shoulder Elbow Surg** 1996 Jan-Feb;5(1):1–11

Changes in acromial morphology with age. Wang JC, et al. **J Shoulder Elbow Surg** 1997 Jan-Feb;6(1):55–9

Interobserver reliability of acromial morphology classification: an anatomic study. Zuckerman JD, et al. **J Shoulder Elbow Surg** 1997 May-Jun;6(3):286–7

[The acromio-humeral interval. A study of the factors influencing its height] Nové-Josserand L, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(5):379–85 (Eng. Abstr.) **(Fre)**

INJURIES

Traumatic posterior dislocation of the shoulder with fracture of the acromion in a child. Nakae H, et al. **Arch Orthop Trauma Surg** 1996;115(3–4):238–9

Concomitant fracture of the coracoid and acromion after direct shoulder trauma. Lim KE, et al. **J Orthop Trauma** 1996;10(6):437–9 (14 ref.)

[An autopsy case of pulmonary thromboembolism: a delayed complication of a victim by traffic accident] Yamazaki M, et al. **Nippon Hoigaku Zasshi** 1997 Feb;51(1):48–55 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Histological analysis of the coracoacromial arch: correlation between age-related changes and rotator cuff tears. Panni AS, et al. **Arthroscopy** 1996 Oct;12(5):531–40

Lateral down-sloping of the acromion: a useful MR sign? Yao L, et al. **Clin Radiol** 1996 Dec;51(12):869–72

Anatomy of the normal acromion investigated using MRI. Schippinger G, et al. **Langenbecks Arch Chir** 1997; 382(3):141–4

Os acromiale: evaluation of markers for identification on sagittal and coronal oblique MR images. Uri DS, et al. **Skeletal Radiol** 1997 Jan;26(1):31–4

SURGERY

Functional assessment for shoulder impingement syndrome after anterior acromioplasty. Hsieh KH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Jun;59(6):354–8

Anterior acromioplasty. A comparison of two techniques. Ingvarsson T, et al. **Int Orthop** 1996;20(5):290–2

Release and reattachment of the coracoacromial ligament: a cadaveric study. Shaffer B, et al. **J Shoulder Elbow Surg** 1997 May-Jun;6(3):297–305

Arthroscopic acromioplasty. Current status. Altchek DW, et al. **Orthop Clin North Am** 1997 Apr;28(2):157–68 (40 ref.)

ACRONINE

ANALOGS & DERIVATIVES

Synthesis and cytotoxic activity of acronycine derivatives modified at the pyran ring. Elomri A, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2165–8

Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series. Elomri A, et al. **J Med Chem** 1996 Nov 22;39(24):4762–6

CHEMICAL SYNTHESIS

Synthesis and cytotoxic activity of acronycine derivatives modified at the pyran ring. Elomri A, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2165–8

ACRONYCINE see **ACRONINE**

ACROSIN

ANALYSIS

Determination of activable proacrosin/acrosin in bovine sperm using an irreversible isocoumarin serine protease inhibitor. Palencia DD, et al. **Biol Reprod** 1996 Sep;

55(3):536–42

ANTAGONISTS & INHIBITORS

Identification by affinity chromatography of boar sperm membrane-associated proteins bound to immobilized porcine zona pellucida. Mapping of the phosphorylethanolamine-binding region of spermadhesin AWN. Ensslin M, et al. **Biol Chem Hoppe Seyler** 1995 Dec; 376(12):733–8

CHEMISTRY

Boar sperm proacrosin infrared investigation: secondary structure analysis after autoactivation and suramin binding. Fini C, et al. **Biochem Mol Med** 1996 Jun;58(1):37–45

The structures of the bovine and porcine proacrosin genes and their conservation among mammals. Adham IM, et al. **Biol Chem Hoppe Seyler** 1996 Apr;377(4):261–5

Site-directed mutagenesis of rabbit proacrosin. Identification of residues involved in zona pellucida binding. Richardson RT, et al. **J Biol Chem** 1996 Sep 27;271(39):24069–74

Characterization of acrosin-like activity of lake sturgeon (Acipenser fulvescens) spermatozoa. Ciereszko A, et al. **Mol Reprod Dev** 1996 Sep;45(1):72–7

DEFICIENCY

Spermatozoa lacking acrosin protein show delayed fertilization. Adham IM, et al. **Mol Reprod Dev** 1997 Mar; 46(3):370–6

GENETICS

The structures of the bovine and porcine proacrosin genes and their conservation among mammals. Adham IM, et al. **Biol Chem Hoppe Seyler** 1996 Apr;377(4):261–5

IMMUNOLOGY

Major goat sperm 105 kDa maturation antigen: purification, characterization, and effect of its antiserum on acrosin activity. Sarkar M, et al. **Am J Reprod Immunol** 1997 May; 37(5):399–407

Evidence of proacrosin molecule abnormality as a possible cause of low acrosin activity and unexplained failure of fertilization in vitro. Shimizu Y, et al. **J Androl** 1997 May–Jun;18(3):281–8

Combined use of proacrosin immunocytochemistry and autosomal DNA in situ hybridisation for evaluation of human ejaculated germ cells. Mendoza C, et al. **Zygote** 1996 Nov;4(4):279–83

METABOLISM

Major goat sperm 105 kDa maturation antigen: purification, characterization, and effect of its antiserum on acrosin activity. Sarkar M, et al. **Am J Reprod Immunol** 1997 May; 37(5):399–407

Relationship of acrosin activity to sperm function tests. Nakagawa H, et al. **Andrologia** 1997 Mar–Apr;29(2):103–8

Acrosin activity in pelleted frozen sperm does not correlate with in vitro fertilization of oocytes. Yie SM, et al. **Andrologia** 1996 Nov–Dec;28(6):349–52

Proacrosin and acrosin determination during capacitation and acrosome reaction in rabbit spermatozoa. Sillerico T, et al. **Biocell** 1996 Aug;20(2):133–42

Proacrosin–acrosomal matrix binding interactions in ejaculated bovine spermatozoa. NagDas SK, et al. **Biol Reprod** 1996 Jan;54(1):111–21

Identification of hydrolase binding activities of the acrosomal matrix of hamster spermatozoa. NagDas SK, et al. **Biol Reprod** 1996 Dec;55(6):1405–14

Acrosomal morphology as a novel criterion for male fertility diagnosis: relation with acrosin activity, morphology (strict criteria), and fertilization in vitro. Menkveld R, et al. **Fertil Steril** 1996 Mar;65(3):637–44

The effect of smoking and varicocele on human sperm acrosin activity and acrosome reaction. El Mulla KF, et al. **Hum Reprod** 1995 Dec;10(12):3190–4

Effects of substrate and separation method on acrosin amidase measurements. Breden TG, et al. **J Androl** 1996 Jul–Aug; 17(4):443–8

Evidence of proacrosin molecule abnormality as a possible cause of low acrosin activity and unexplained failure of fertilization in vitro. Shimizu Y, et al. **J Androl** 1997 May–Jun;18(3):281–8

Boar proacrosin expressed in spermatids of transgenic mice does not reach the acrosome and disrupts spermatogenesis. O'Brien DA, et al. **Mol Reprod Dev** 1996 Feb;43(2):236–47

Substrate specificity of ascidian sperm trypsin-like proteases, spermosin and acrosin. Sawada H, et al. **Mol Reprod Dev** 1996 Oct;45(2):240–3

[Proacrosin and acrosin--retrospect of a multifunctional complex] Jenneckens I, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):400–3 (68 ref.) (Eng. Abstr.) **(Ger)**

ACROSOMAL PROTEINASE see **ACROSIN**

ACROSOME

Sperm acrosome defects in a patient with Aarskog-Scott syndrome. Meschede D, et al. **Am J Med Genet** 1996 Dec 18;66(3):340–2

Successful pregnancy after fertilization using intracytoplasmic sperm injection of sperm lacking acrosomes. Catt JW, et al. **Aust N Z J Obstet Gynaecol** 1996 Feb;36(1):61–2

Detection of human sperm acrosome reaction: comparison between methods using double staining, Pisum sativum agglutinin, concanavalin A and transmission electron microscopy. Köhn FM, et al. **Hum Reprod** 1997 Apr; 12(4):714–21

Assessment of the acrosome reaction in Bufo arenarum spermatozoa by immunostaining: comparison with other methods. Martínez ML, et al. **Zygote** 1996 Aug;4(3):181–90

CHEMISTRY

An antigenically related polypeptide family is a major structural constituent of a stable acrosomal matrix assembly in bovine spermatozoa. Olson GE, et al. **Biol Reprod** 1997 Aug;57(2):325–34

Genomic organization of the mouse AZ1 gene that encodes the protein localized to preacrosomes of spermatids. Aoto H, et al. **Genomics** 1997 Feb 15;40(1):138–41

Molecular characterizations of an intraacrosomal antigen defined by HS-33 monoclonal antibody. Yoshiki T, et al. **J Androl** 1996 Nov–Dec;17(6):666–73

AM67, a secretory component of the guinea pig sperm acrosomal matrix, is related to mouse sperm protein sp56 and the complement component 4-binding proteins. Foster JA, et al. **J Biol Chem** 1997 May 9;272(19):12714–22

DRUG EFFECTS

Induction of acrosome reaction in dog sperm by calcium ionophore. Szász F, et al. **Acta Vet Hung** 1997;45(2):177–87

Effects of products of activated immune cells and recombinant cytokines on spontaneous and ionophore-induced acrosome reaction. Dimitrov DG, et al. **Am J Reprod Immunol** 1996 Sep;36(3):150–6

Unesterified cholesterol content of human sperm regulates the response of the acrosome to the agonist, progesterone. Zarintash RJ, et al. **Biol Reprod** 1996 Jul;55(1):19–24

Progesterone, acrosome reaction and the use of a CD46 antibody [letter; comment] Fénichel P, et al. **Hum Reprod** 1996 Sep;11(9):2067–8. Comment on: Hum Reprod 1996 Jan;11(1):121–6.

Acrosome reaction stimulated by the GTP non-hydrolizable analogue GTP gamma S is blocked by phospholipase A2 inhibitors in human spermatozoa. Domínguez L, et al. **Int J Androl** 1996 Aug;19(4):248–52

Voltage-dependent calcium channels and Gi regulatory protein mediate the human sperm acrosomal exocytosis induced by N-acetylglucosaminyl/mannosyl neoglycoproteins. Brandelli A, et al. **J Androl** 1996 Sep–Oct;17(5):522–9

Chloride efflux during the progesterone-initiated human sperm acrosome reaction is inhibited by lavendustin A, a tyrosine kinase inhibitor. Meizel S, et al. **J Androl** 1996 Jul–Aug;17(4):327–30

Hyaluronic acid enhances the zona pellucida-induced acrosome reaction of macaque sperm. Vandevoort CA, et al. **J Androl** 1997 Jan–Feb;18(1):1–5

Sperm immobilization antibodies in infertile male sera decrease the acrosome reaction: a possible mechanism for immunologic infertility. Taşdemir I, et al. **J Assist Reprod Genet** 1996 May;13(5):413–6

Recombinant human zona pellucida glycoprotein 3 induces calcium influx and acrosome reaction in human spermatozoa. Brewis IA, et al. **Mol Hum Reprod** 1996 Aug; 2(8):583–9

Protein kinase C activation during progesterone-stimulated acrosomal exocytosis in human spermatozoa. O'Toole CM, et al. **Mol Hum Reprod** 1996 Dec;2(12):921–7

Effect of cholesterol and other sterols on human sperm acrosomal responsiveness. Cross NL. **Mol Reprod Dev** 1996 Oct;45(2):212–7

Importance of sodium ion to the progesterone-initiated acrosome reaction in human sperm. Garcia MA, et al. **Mol Reprod Dev** 1996 Dec;45(4):513–20

Studies related to progesterone-induced hamster sperm acrosome reaction. Llanos MN, et al. **Mol Reprod Dev** 1996 Nov;45(3):313–9

In vitro fertilisation of Chinese hamster oocytes by spermatozoa that have undergone ionophore A23187-induced acrosome reaction, and their subsequent development into blastocysts. Tateno H, et al. **Zygote** 1996 May;4(2):93–9

ENZYMOLOGY

Identification of hydrolase binding activities of the acrosomal matrix of hamster spermatozoa. NagDas SK, et al. **Biol Reprod** 1996 Dec;55(6):1405–14

Acrosome membrane associated protein kinase activity in hamster spermatozoa. Devi KU, et al. **FEBS Lett** 1996 Nov 4;396(2–3):123–6

Analysis of the effect of nitric oxide synthase inhibition on mouse sperm employing a modified staining method for assessment of the acrosome reaction. Viggiano JM, et al. **J Androl** 1996 Nov–Dec;17(6):692–8

IMMUNOLOGY

Effects of products of activated immune cells and recombinant cytokines on spontaneous and ionophore-induced acrosome reaction. Dimitrov DG, et al. **Am J Reprod Immunol** 1996 Sep;36(3):150–6

Monoclonal antibodies as direct probes for human sperm acrosome reaction. Dorjee S, et al. **Am J Reprod Immunol** 1997 Apr;37(4):283–90

Sperm acrosome antigen-1, a molecule intimately involved in the regulation of the acrosome reaction: analysis of expression on spermatozoa from infertile couples. Brucker C, et al. **Andrologia** 1997 Mar–Apr;29(2):91–6

High fertilization prediction by flow cytometric analysis of the CD46 antigen on the inner acrosomal membrane of spermatozoa. Carver-Ward JA, et al. **Hum Reprod** 1996 Sep;11(9):1923–8

Effect of sperm-agglutinating antibodies on sperm capacitation and acrosome reaction. Bathla H, et al. **Int J Fertil Menopausal Stud** 1996 Nov–Dec;41(6):528–33

Molecular characterizations of an intraacrosomal antigen defined by HS-33 monoclonal antibody. Yoshiki T, et al. **J Androl** 1996 Nov–Dec;17(6):666–73

Inhibition of bovine fertilization in vitro by antibodies to SP-10. Coonrod SA, et al. **J Reprod Fertil** 1996 Jul; 107(2):287–97

Autoantigen 1 of the guinea pig sperm acrosome is the homologue of mouse Tpx-1 and human TPX1 and is a member of the cysteine-rich secretory protein (CRISP) family. Foster JA, et al. **Mol Reprod Dev** 1996 Jun; 44(2):221–9

METABOLISM

Secretions of ovine uterus and oviduct induce in vitro capacitation of ram spermatozoa. Chavarría ME, et al. **Arch Androl** 1996 Jan–Feb;36(1):17–23

Protein tyrosine phosphorylation and signal transduction during capacitation-acrosome reaction and zona pellucida binding in human sperm. Naz RK. **Arch Androl** 1996 Jul–Aug;37(1):47–55 (48 ref.)

Progesterone and the zona pellucida activate different transducing pathways in the sequence of events leading to diacylglycerol generation during mouse sperm acrosomal exocytosis. Murase T, et al. **Biochem J** 1996 Dec 15;320 (Pt 3):1017–23

Modulation of sperm acrosomal exocytosis by guanyl nucleotides and G-protein-modifier agents. Brandelli A. **Biochem Mol Biol Int** 1997 May;41(6):1217–25

Proacrosin-acrosomal matrix binding interactions in ejaculated bovine spermatozoa. NagDas SK, et al. **Biol Reprod** 1996 Jan;54(1):111–21

Brefeldin A and mannose 6-phosphate regulation of acrosomic related vesicular trafficking. West AP, et al. **Eur J Cell Biol** 1996 Aug;70(4):315–21

Glucose is not essential for the occurrence of sperm binding and zona pellucida-induced acrosome reaction in the mouse. Urner F, et al. **Int J Androl** 1996 Apr;19(2):91–6

Sulfated polysaccharides from the egg jelly layer are species-specific inducers of acrosomal reaction in sperms of sea urchins. Alves AP, et al. **J Biol Chem** 1997 Mar 14;272(11):6965–71

Expression of a P-selectin ligand in zona pellucida of porcine oocytes and P-selectin on acrosomal membrane of porcine sperm cells. Potential implications for their involvement in sperm-egg interactions. Geng JG, et al. **J Cell Biol** 1997 May 5;137(3):743–54

An unexpected localization of basonuclin in the centrosome, mitochondria, and acrosome of developing spermatids. Yang Z, et al. **J Cell Biol** 1997 May 5;137(3):657–69

Boar proacrosin expressed in spermatids of transgenic mice does not reach the acrosome and disrupts spermatogenesis. O'Brien DA, et al. **Mol Reprod Dev** 1996 Feb;43(2):236–47

Sperm protein (sp50) binds to acrosome and plasma membranes in a Ca(2+)-dependent manner: possible role in acrosome reaction. Othón Hernández E, et al. **Mol Reprod Dev** 1996 Mar;43(3):366–75

[Proacrosin and acrosin--retrospect of a multifunctional complex] Jenneckens I, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):400–3 (68 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

[Seminal lactate dehydrogenase isoenzyme C4 and abnormal acrosomes] Laudat A, et al. **Ann Biol Clin (Paris)** 1997 Jul–Aug;55(4):341–2 **(Fre)**

PHYSIOLOGY

Activation of the acrosome reaction after treatment with human follicular fluid. A morphofunctional evaluation useful for in vitro fertilization. Ruvolo G, et al. **Acta Eur Fertil** 1995 Jul–Aug;26(4):125–30

Acrosomal status of human spermatozoa after follicular fluid or calcium ionophore challenge in relation to semen parameters and fertilizing capacity in vitro. Avrech O, et al. **Andrologia** 1997 Mar–Apr;29(2):97–101

Paramagnetic beads coated with Pisum sativum agglutinin bind to human spermatozoa undergoing the acrosome reaction. Köhn FM, et al. **Andrologia** 1996 Jul–Aug; 28(4):231–9

Assessment of hyperactivation, acrosome reaction and motility characteristics of spermatozoa from semen of men of proven fertility and unexplained infertility. Peedicayil J, et al. **Andrologia** 1997 Jul–Aug;29(4):209–18

Preincubation in peritoneal fluid decreases the follicular fluid-induced acrosomal reactivity of human spermatozoa. Revelli A, et al. **Andrologia** 1997 Jan–Feb;29(1):43–8

ACROSOME

Changes in sperm-bound amidase activity suggest subtle damage to ram sperm acrosomes by freezing/thawing, not detected by light microscopy. de las Heras MA, et al. **Anim Reprod Sci** 1996 Dec 2;45(1-2):81-9

Simultaneous detection of the acrosomal status and viability of incubated ram spermatozoa using fluorescent markers. Sukardi S, et al. **Anim Reprod Sci** 1997 Mar;46(1-2):89-96

Assessment of the acrosomal status of membrane-intact ram spermatozoa after freezing and thawing, by simultaneous lectin/Hoechst 33258 staining. Valcárcel A, et al. **Anim Reprod Sci** 1997 Jan;45(4):299-309

Induction of acrosome reaction in human sperm by exposing to an electrical field. Ahmadi A, et al. **Arch Androl** 1997 Jan-Feb;38(1):57-65

Correlation between intact sperm acrosome assessed using the Spermac stain and sperm fertilizing capacity. Chan PJ, et al. **Arch Androl** 1996 Jan-Feb;36(1):25-7

Prostasome fraction of human seminal plasma prevents sperm from becoming acrosomally responsive to the agonist progesterone. Cross NL, et al. **Arch Androl** 1997 Jul-Aug; 39(1):39-44

Clinical application of a new stain to detect acrosome-reacted sperm for predicting polyspermic fertilization in IVF-ET. Fujino Y, et al. **Arch Androl** 1997 Jul-Aug;39(1):25-31

Use of a triple-stain technique to detect viability and acrosome reaction in deer spermatozoa. Garde JJ, et al. **Arch Androl** 1997 Jul-Aug;39(1):1-9

A novel method for evaluating the acrosomal status of mammalian spermatozoa. Margalit I, et al. **Arch Androl** 1997 Sep-Oct;39(2):87-99

In vitro effect of Escherichia coli on human sperm acrosome reaction. el-Mulla KF, et al. **Arch Androl** 1996 Sep-Oct; 37(2):73-8

Protein involvement in the fusion between the equatorial segment of acrosome-reacted human spermatozoa and liposomes. Arts EG, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):191-8

The mammalian acrosome reaction: gateway to sperm fusion with the oocyte? Allen CA, et al. **Bioessays** 1997 Mar; 19(3):241-7 (46 ref.)

Human seminal plasma prevents sperm from becoming acrosomally responsive to the agonist, progesterone: cholesterol is the major inhibitor. Cross NL. **Biol Reprod** 1996 Jan;54(1):138-45

In vitro capacitating effect of gamma-aminobutyric acid in ram spermatozoa. de las Heras MA, et al. **Biol Reprod** 1997 Apr;56(4):964-8

Acrosome-intact boar spermatozoa initiate binding to the homologous zona pellucida in vitro. Fazeli A, et al. **Biol Reprod** 1997 Feb;56(2):430-8

Sperm capacitation and the acrosome reaction are compromised in teratospermic domestic cats. Long JA, et al. **Biol Reprod** 1996 Mar;54(3):638-46

Amino acid neurotransmitter receptor/chloride channels of mammalian sperm and the acrosome reaction. Meizel S. **Biol Reprod** 1997 Mar;56(3):569-74 (86 ref.)

Interaction of acrosome-reacted macaque sperm with the macaque zona pellucida. VandeVoort CA, et al. **Biol Reprod** 1997 May;56(5):1307-16

Progesterone triggers a wave of increased free calcium during the human sperm acrosome reaction. Meizel S, et al. **Dev Biol** 1997 Feb 1;182(1):67-75

Aminopeptidase-like protease released from oocytes affects oocyte surfaces and suppresses the acrosome reaction in establishment of polyspermy block in oocytes of the mussel Mytilus edulis. Togo T, et al. **Dev Biol** 1997 Feb 15; 182(2):219-27

Regulation of membrane stability and the acrosome reaction in mammalian sperm. Nolan JP, et al. **FASEB J** 1997 Jul; 11(8):670-82 (103 ref.)

Bicarbonate/CO2 induces rapid activation of phospholipase A2 and renders boar spermatozoa capable of undergoing acrosomal exocytosis in response to progesterone. Roldan ER, et al. **FEBS Lett** 1996 Nov 4;396(2-3):227-32

Interference of antisperm antibodies with the induction of the acrosome reaction by zona pellucida (ZP) and its relationship with the inhibition of ZP binding. Francavilla F, et al. **Fertil Steril** 1997 Jun;67(6):1128-33

Inhibition of G protein in human sperm and its influence on acrosome reaction and zona pellucida binding. Franken DR, et al. **Fertil Steril** 1996 Dec;66(6):1009-11

Induction of acrosome reaction in human spermatozoa accelerates the time of pronucleus formation of hamster oocytes after intracytoplasmic sperm injection. Lee DR, et al. **Fertil Steril** 1997 Feb;67(2):315-20

High fertilization and pregnancy rates after intracytoplasmic sperm injection in patients with disordered zona pellucida-induced acrosome reaction. Liu DY, et al. **Fertil Steril** 1997 May;67(5):955-8

A comparison of three methods for detecting the acrosome reaction in human spermatozoa. Amin AH, et al. **Hum Reprod** 1996 Apr;11(4):741-5

Classification of male factor infertility relevant to in-vitro fertilization insemination strategies using mannose ligands, acrosome status and anti-cytoskeletal antibodies. Benoff S, et al. **Hum Reprod** 1996 Sep;11(9):1905-18

The effect of smoking and varicocele on human sperm acrosin activity and acrosome reaction. El Mulla KF, et al. **Hum Reprod** 1995 Dec;10(12):3190-4

The human sperm acrosome reaction: physiology and regulatory mechanisms. An update. Brucker C, et al. **Hum Reprod Update** 1995 Jan;1(1):51-62 (103 ref.)

The acrosome reaction response assay: a new way to identify patients in whom pentoxifylline would improve the human follicular fluid-induced acrosome reaction. Briggiler CI, et al. **Int J Androl** 1997 Apr;20(2):96-103

Acrosome reaction and fertility. Hartmann M. **Int J Androl** 1995 Dec;18 Suppl 2:53-5 (10 ref.)

Hydrogen hexachloroplatinate induces the acrosome reaction in human spermatozoa. Köhn FM, et al. **Int J Androl** 1995 Dec;18(6):321-5

Stimulation of movement and acrosome reaction of human spermatozoa by PC12 liposomes encapsulating ATP. Skiba-Lahiani M, et al. **Int J Androl** 1995 Dec;18(6):287-94

Use of peanut agglutinin to assess the acrosomal status and the zona pellucida-induced acrosome reaction in stallion spermatozoa. Cheng FP, et al. **J Androl** 1996 Nov-Dec; 17(6):674-82

Chloride efflux during the progesterone-initiated human sperm acrosome reaction is inhibited by lavendustin A, a tyrosine kinase inhibitor. Meizel S, et al. **J Androl** 1996 Jul-Aug;17(4):327-30

Maturation of monkey spermatozoa in the epididymis with respect to their ability to undergo the acrosome reaction. Yeung CH, et al. **J Androl** 1996 Jul-Aug;17(4):427-32

Comparative flow cytometric analysis of the human sperm acrosome reaction using CD46 antibody and lectins. Carver-Ward JA, et al. **J Assist Reprod Genet** 1997 Feb; 14(2):111-9

Coculture of human spermatozoa with reproductive tract cell monolayers can enhance sperm functions better than coculture with Vero cell monolayers. Lai YM, et al. **J Assist Reprod Genet** 1996 May;13(5):417-22

Structure of the main saccharide chain in the acrosome reaction-inducing substance of the starfish, Asterias amurensis. Koyota S, et al. **J Biol Chem** 1997 Apr 18; 272(16):10372-6

Binding of recombinant pig zona pellucida protein 1 (ZP1) to acrosome-reacted spermatozoa. Tsubamoto H, et al. **J Reprod Fertil Suppl** 1996;50:63-7

The biochemistry of the acrosome reaction. Breitbart H, et al. **Mol Hum Reprod** 1997 Mar;3(3):195-202 (105 ref.)

Involvement of protein kinases in platelet activating factor-induced acrosome reaction of human spermatozoa. Sengoku K, et al. **Mol Hum Reprod** 1996 Jun;2(6):401-4

Single cell analysis of tyrosine kinase dependent and independent Ca2+ fluxes in progesterone induced acrosome reaction. Tesarik J, et al. **Mol Hum Reprod** 1996 Apr;2(4):225-32

Alternative pathways of acrosome reaction induction [letter] Tesarik J. **Mol Hum Reprod** 1996 Oct;2(10):813

Role for Ca2+ channels in the signal transduction pathway leading to acrosomal exocytosis in human spermatozoa. O'Toole CM, et al. **Mol Reprod Dev** 1996 Oct;45(2):204-11

Capacitation and the acrosome reaction in marsupial spermatozoa. Mate KE, et al. **Reprod Fertil Dev** 1996; 8(4):595-603 (46 ref.)

Methods for induction of capacitation and the acrosome reaction of stallion spermatozoa. Graham JK. **Vet Clin North Am Equine Pract** 1996 Apr;12(1):111-7 (42 ref.)

Structure and function of asterosaps, sperm-activating peptides from the jelly coat of starfish eggs. Nishigaki T, et al. **Zygote** 1996 Aug;4(3):237-45

[Cooling of boar spermatozoa prior to freezing and post thaw quality and evaluation of membrane state using chlortetracycline (CTC) staining] Kotzias-Bandeira E, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug; 104(8):302-6 (Eng. Abstr.) **(Ger)**

SECRETION

Protein kinase C activation during progesterone-stimulated acrosomal exocytosis in human spermatozoa. O'Toole CM, et al. **Mol Hum Reprod** 1996 Dec;2(12):921-7

ULTRASTRUCTURE

Lectin histochemistry during in vitro capacitation and acrosome reaction in boar spermatozoa: new lectins for evaluating acrosomal status of boar spermatozoa. Vazquez JM, et al. **Acta Histochem** 1996 Jan;98(1):93-100

Identification of hydrolase binding activities of the acrosomal matrix of hamster spermatozoa. NagDas SK, et al. **Biol Reprod** 1996 Dec;55(6):1405-14

Fluorometric assessments of acrosomal integrity and viability in cryopreserved bovine spermatozoa. Thomas CA, et al. **Biol Reprod** 1997 Apr;56(4):991-8

Acrosomal morphology as a novel criterion for male fertility diagnosis: relation with acrosin activity, morphology (strict criteria), and fertilization in vitro. Menkveld R, et al. **Fertil Steril** 1996 Mar;65(3):637-44

An ultrastructural and lectin-histochemical study on the seminiferous epithelium of the common tree shrew (Tupaia glis). Kurohmaru M, et al. **J Anat** 1996 Aug;189 (Pt 1):87-95

Giant, accordioned sperm acrosomes of the greater bulldog bat, Noctilio leporinus. Phillips DM, et al. **Mol Reprod Dev** 1997 Sep;48(1):90-4

ACROSPIROMA, ECCRINE

Malignant metastatic eccrine poroma. Proposal for a new therapeutic protocol. Barzi AS, et al. **Dermatol Surg** 1997 Apr;23(4):267-72 (30 ref.)

Clear cell hidradenoma of the second digit: a review of the literature with case presentation. Feldman AH, et al. **J Foot Ankle Surg** 1997 Jan-Feb;36(1):21-3 (7 ref.)

DIAGNOSIS

Stump the experts. Eccrine acrospiroma, clear cell type. Dumont KM, et al. **Dermatol Surg** 1996 Dec;22(12):998, 1069

Vulvar eccrine porocarcinoma. Katsanis WA, et al. **Gynecol Oncol** 1996 Sep;62(3):396-9 (21 ref.)

PATHOLOGY

Clear cell hidradenoma associated with the folliculo-sebaceous-apocrine unit. Histologic study of five cases. Gianotti R, et al. **Am J Dermatopathol** 1997 Aug; 19(4):351-7

Eccrine or apocrine poroma? Six poromas with divergent adnexal differentiation. Harvell JD, et al. **Am J Dermatopathol** 1996 Feb;18(1):1-9 (30 ref.)

Acrospiroma: a case report and review. Laws RA, et al. **Cutis** 1996 Nov;58(5):349-51 (6 ref.)

Pigmented sweat gland tumor mimicking melanoma. Roaf V, et al. **Cutis** 1997 Jan;59(1):43-6

Eccrine porocarcinoma. Girishkumar H, et al. **Dermatol Surg** 1997 Jul;23(7):583-4

Benign and malignant eccrine poroma--a flow cytometric comparison. Hagler J, et al. **Isr J Med Sci** 1996 Dec; 32(12):1151-3

Metastasizing eccrine porocarcinoma: report of a case and review of the literature. Huet P, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 2):860-4 (55 ref.)

Differentiation of eccrine poroma cells to cytokeratin 1- and 10-expressing cells, the intermediate layer cells of eccrine sweat duct, in the tumor cell nests. Ban M, et al. **J Cutan Pathol** 1997 Apr;24(4):246-8

Mucinous differentiation in adnexal sweat gland tumors. Fitzgibbon JF, et al. **J Cutan Pathol** 1996 Jun;23(3):259-63

Malignant eccrine poroma with multiple visceral metastases: report of a case with autopsy findings. Maeda T, et al. **J Cutan Pathol** 1996 Dec;23(6):566-70

Histogenesis of clear cell hidradenoma: immunohistochemical study of keratin expression. Ohnishi T, et al. **J Cutan Pathol** 1997 Jan;24(1):30-6

A case of eccrine poroma with multiple transepidermal elimination. Arai K, et al. **J Dermatol** 1997 Aug; 24(8):539-42

A case of rapidly-growing eccrine poroma during pregnancy [letter] Ban M, et al. **J Dermatol** 1997 Aug;24(8):554-5

Porocarcinoma of the eyelid. Boynton JR, et al. **Ophthalmology** 1997 Oct;104(10):1626-8

Test and teach. Number Eighty. Diagnosis: Malignant eccrine poroma of scalp. Ng WK. **Pathology** 1996 Jan; 28(1):39, 89

[A case of porocarcinoma arising on the penile shaft] Muraki J, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 May; 88(5):576-9 (Eng. Abstr.) **(Jpn)**

SURGERY

Malignant eccrine poroma of the hand: a case report. DaSilva MF, et al. **J Hand Surg [Am]** 1997 May;22(3):511-4

ACRYLAMIDES

Recent advances in capillary electrophoresis of DNA fragments and PCR products in poly(n-substituted acrylamides). Righetti PG, et al. **Anal Biochem** 1997 Jan 15;244(2):195-207 (82 ref.)

Molecular imprinting: synthesis of polymer particles with antibody-like binding characteristics for glucose oxidase. Burow M, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):419-22

Alternative to large acrylamide gels for DNA analysis. Epstein JL, et al. **Biotechniques** 1997 Feb;22(2):226-8, 230

Mapping of Chlamydia trachomatis proteins by immobiline-polyacrylamide two-dimensional electrophoresis: spot identification by N-terminal sequencing and immunoblotting. Bini L, et al. **Electrophoresis** 1996 Jan;17(1):185-90

Conditions for single strand conformation polymorphism (SSCP)analysis with broad applicability: a study on the effects of acrylamide, buffer and glycerol concentrations in SSCP analysis of exons of the p53 gene). Teschauer W, et al. **Eur J Clin Chem Clin Biochem** 1996 Feb;34(2):125-31

Temperature- and pH-sensitive terpolymers for modulated delivery of streptokinase. Vakkalanka SK, et al. **J Biomater Sci Polym Ed** 1996;8(2):119-29

Preparation and analysis of DNA sequencing gels. Theophilus BD. **Methods Mol Biol** 1996;65:1-9

Effects of crosslinking and temperature on the dose response of a BANG polymer gel dosimeter. Maryanski MJ, et al. **Phys Med Biol** 1997 Feb;42(2):303-11

Immobilization of enzymes on methacrylamide-based copolymers. Liao WH, et al. **Prep Biochem Biotechnol** 1997 Feb;27(1):39-46

Abnormal differentiation of thymocytes induced by free cyclosporine is avoided when cyclosporine bound to N-(2-hydroxypropyl)methacrylamide copolymer carrier is used. Šťastný M, et al. **Transplantation** 1997 Jun 27; 63(12):1818-27

ADVERSE EFFECTS

Two case reports of neurological disease in coal mine preparation plant workers. Mulloy KB. **Am J Ind Med** 1996 Jul;30(1):56–61

BLOOD

Hemoglobin adducts of acrylamide and acrylonitrile in laboratory workers, smokers and nonsmokers. Bergmark E. **Chem Res Toxicol** 1997 Jan;10(1):78–84

CHEMICAL SYNTHESIS

Novel acrylamido monomers with higher hydrophilicity and improved hydrolytic stability: I. Synthetic route and product characterization. Simò-Alfonso E, et al. **Electrophoresis** 1996 Apr;17(4):723–31

5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates. Barf TA, et al. **J Med Chem** 1996 Nov 22;39(24):4717–26

Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl] propenamide and related compounds. Kuo EA, et al. **J Med Chem** 1996 Nov 8; 39(23):4608–21

CHEMISTRY

Temperature-responsive liquid chromatography. 2. Effects of hydrophobic groups in N-isopropylacrylamide copolymer-modified silica. Kanazawa H, et al. **Anal Chem** 1997 Mar 1;69(5):823–30

Intercomparison of DNA sizing ladders in electrophoretic separation matrices and their potential for accurate typing of the D1S80 locus. Kline MC, et al. **Appl Theor Electrophor** 1996;6(1):33–41

Preparation of conjugates between oligonucleotides and N-vinylpyrrolidone/N-acryloxysuccinimide copolymers and applications in nucleic acid assays to improve sensitivity. Erout MN, et al. **Bioconjug Chem** 1996 Sep-Oct; 7(5):568–75

Partially-hydrophobized polymer particles derived from N,N-dimethylaminopropylacrylamide for endotoxin removal from acidic protein solution. Sakata M, et al. **Chem Pharm Bull (Tokyo)** 1996 Feb;44(2):328–32

Comparison of behavior of N-substituted acrylamides and celluloses on double-stranded DNA separations by capillary electrophoresis at 25 degrees and 60 degrees C. Gelfi C, et al. **Electrophoresis** 1996 Aug;17(8):1342–7

Novel acrylamido monomers with higher hydrophilicity and improved hydrolytic stability: II. Properties of N-acryloylaminopropanol. Simò-Alfonso E, et al. **Electrophoresis** 1996 Apr;17(4):732–7

'Tunable' positive and negative surface charges on a capillary wall: exploiting the Immobiline chemistry. Capelli L, et al. **J Biochem Biophys Methods** 1996 May 14;32(2):109–24

Temperature-sensitivity of liposomal lipid bilayers mixed with poly(N-isopropylacrylamide-co-acrylic acid). Kim JC, et al. **J Biochem (Tokyo)** 1997 Jan;121(1):15–9

Neural cell pattern formation on glass and oxidized silicon surfaces modified with poly(N-isopropylacrylamide). Bohanon T, et al. **J Biomater Sci Polym Ed** 1996;8(1):19–39

Study of protein binding to a silica support with a polymeric cation-exchange coating. Ratnayake CK, et al. **J Chromatogr A** 1996 Aug 30;743(1):15–23

Release of 5-fluorouracil from poly(acrylamide-co-monopropyl itaconate) hydrogels. Blanco MD, et al. **J Chromatogr B Biomed Appl** 1996 May 17;680(1-2):243–53

Analysis of peptides and proteins by temperature-responsive chromatographic system using N-isopropylacrylamide polymer-modified columns. Kanazawa H, et al. **J Pharm Biomed Anal** 1997 Jun;15(9-10):1545–50

A possible tertiary structure change induced by acrylamide in the DNA-binding domain of the Tn10-encoded Tet repressor. A fluorescence study. Bousquet JA, et al. **J Protein Chem** 1996 Feb;15(2):205–18

METABOLISM

In vitro studies on a new method for islet microencapsulation using a thermoreversible gelation polymer, N-isopropylacrylamide-based copolymer. Shimizu S, et al. **Artif Organs** 1996 Nov;20(11):1232–7

In vitro swelling studies and preliminary biocompatibility evaluation of acrylamide-based hydrogels. Karadağ E, et al. **Biomaterials** 1996 Jan;17(1):67–70

Adsorption of plasma proteins to DMAA hydrogels obtained by ionizing radiation and its relationship with blood compatibility. de Queiroz AA, et al. **J Biomater Sci Polym Ed** 1997;8(5):335–47

PHARMACOKINETICS

The metabolism and pharmacokinetics of acrylamide: implications for mechanisms of toxicity and human risk estimation. Calleman CJ. **Drug Metab Rev** 1996 Nov; 28(4):527–90 (111 ref.)

PHARMACOLOGY

Palytoxin modulates cytosolic pH in human osteoblast-like Saos-2 cells via an interaction with Na(+)-K(+)-ATPase. Monroe JJ, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1277–83

Biocompatibility of sulphonated polyurethane surfaces. Keogh JR, et al. **Biomaterials** 1996 Oct;17(20):1987–94

Tyrphostin AG 494 blocks Cdk2 activation. Osherov N, et al. **FEBS Lett** 1997 Jun 30;410(2-3):187–90

Palytoxin effects through interaction with the Na,K-ATPase in Xenopus oocyte. Wang X, et al. **FEBS Lett** 1997 Jun 16;409(3):391–5

5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates. Barf TA, et al. **J Med Chem** 1996 Nov 22;39(24):4717–26

The effect of palytoxin on neuromuscular junctions in the anococcygeus muscle of the rat. Amir I, et al. **J Neurocytol** 1997 Jun;26(6):367–76

Measurement of intracellular Na+ concentration by a Na+-sensitive fluorescent dye, sodium-binding benzofuran isophthalate, in porcine adrenal chromaffin cells--usage of palytoxin as a Na+ ionophore. Ito S, et al. **J Neurosci Methods** 1997 Jul 18;75(1):21–7

Possible mechanism of palytoxin-induced Ca++ mobilization in porcine coronary artery. Ishii K, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1077–84

Endothelium inhibits the palytoxin-induced depolarization and Ca2+ mobilization in porcine coronary artery through endothelium-derived hyperpolarizing factor and nitric oxide released by palytoxin. Ishii K, et al. **Life Sci** 1997; 60(7):PL91–7

Acrylamide and carbon disulfide treatments increase the rate of rat brain tubulin polymerization. Gupta RP, et al. **Mol Chem Neuropathol** 1997 Apr;30(3):223–37

Palytoxin-induced increase in endothelial Ca2+ concentration in the rabbit aortic valve. Amano K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jun; 355(6):751–8

Characteristics of palytoxin-induced cation currents and Ca2+ mobilization in smooth muscle cells of rabbit portal vein. Ishii K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jan; 355(1):103–10

Inhibition of sodium-dependent uptake processes in purified rat brain synaptosomes by Lophozozymus pictor toxin and palytoxin. Lau CO, et al. **Neurochem Int** 1996 Apr; 28(4):385–90

Decreased GAP-43 accumulation in neurite tips of cultured hippocampal neurons by acrylamide. Clarke CH, et al. **Neurotoxicology** 1996 Summer;17(2):397–406

TOXICITY

Early growth of regenerating neurites in acrylamide neuropathic mice: application of a film model. Torigoe K, et al. **Brain Res** 1997 Jan 23;746(1-2):269–74

The metabolism and pharmacokinetics of acrylamide: implications for mechanisms of toxicity and human risk estimation. Calleman CJ. **Drug Metab Rev** 1996 Nov; 28(4):527–90 (111 ref.)

Reproductive toxicology. Acrylamide. **Environ Health Perspect** 1997 Feb;105 Suppl 1:259–60

Reproductive toxicology. Methacrylamide. **Environ Health Perspect** 1997 Feb;105 Suppl 1:261–2

Reproductive toxicology. Methylenebisacrylamide. **Environ Health Perspect** 1997 Feb;105 Suppl 1:263–4

Reproductive toxicology. N-(hydroxymethyl)acrylamide. **Environ Health Perspect** 1997 Feb;105 Suppl 1:265–6

Simple neurobehavioral functional observational battery and objective gait analysis validation by the use of acrylamide and methanol with a built-in recovery period. Youssef AF, et al. **Environ Res** 1997;73(1-2):52–62

Quantification and in vitro toxicity studies of extractable chemicals from synthetic ion exchangers. Boschetti E, et al. **J Biochem Biophys Methods** 1996 Apr;32(1):15–25

Application of thermosensitive polymers as a new embolic material for intravascular neurosurgery. Matsumaru Y, et al. **J Biomater Sci Polym Ed** 1996;7(9):795–804

Direct effect of the neurotoxicant acrylamide on kinesin-based microtubule motility. Sickles DW, et al. **J Neurosci Res** 1996 Oct 1;46(1):7–17

Alterations in the neutral proteinase activities of central and peripheral nervous systems of acrylamide-, carbon disulfide-, or 2,5-hexanedione-treated rats. Gupta RP, et al. **Mol Chem Neuropathol** 1996 Sep;29(1):53–66

Extruded micronuclei induced by colchicine or acrylamide contain mostly lagging chromosomes identified in paintbrush smears by minor and major mouse DNA probes. Schriever-Schwemmer G, et al. **Mutagenesis** 1997 Jul; 12(4):201–7

Somatic and germ cell mutagenesis in lambda lacZ transgenic mice treated with acrylamide or ethylnitrosourea. Krebs O, et al. **Mutat Res** 1997 Feb 14;388(2-3):239–48

Palytoxin-induced single-channel currents from the sodium pump synthesized by in vitro expression. Hirsh JK, et al. **Toxicon** 1997 Feb;35(2):169–76

Intestinal injuries caused by experimental palytoxicosis in mice. Ito E, et al. **Toxicon** 1996 Jun;34(6):643–52

Effects of repeated injections of palytoxin on lymphoid tissues in mice. Ito E, et al. **Toxicon** 1997 May;35(5):679–88

ACRYLATES

Reduction in the area of the anterior capsule opening after polymethylmethacrylate, silicone, and soft acrylic intraocular lens implantation. Hayashi K, et al. **Am J Ophthalmol** 1997 Apr;123(4):441–7

Dynamic mechanical thermal analysis of denture soft lining materials. Waters M, et al. **Biomaterials** 1996 Aug; 17(16):1627–30

Acrylic bone-cement. Influence of mixer design and unmixed powder. Kurdy NM, et al. **J Arthroplasty** 1996 Oct; 11(7):813–9

Temperature- and pH-sensitive terpolymers for modulated-delivery of streptokinase. Vakkalanka SK, et al. **J Biomater Sci Polym Ed** 1996;8(2):119–29

Reduced plaque accumulation on hydrocarbon thin film deposited on restorative acrylic polymers. Bellanda M, et al. **J Biomed Mater Res** 1997 Aug;36(2):216–22

Visual function in pseudophakic eyes with poly(methyl methacrylate), silicone, and acrylic intraocular lenses. Kohnen S, et al. **J Cataract Refract Surg** 1996;22 Suppl 2:1303–7

Bisecting a foldable acrylic intraocular lens for explantation. Koo EY, et al. **J Cataract Refract Surg** 1996;22 Suppl 2:1381–2

Alterations to the AcrySof intraocular lens during folding. Milazzo S, et al. **J Cataract Refract Surg** 1996;22 Suppl 2:1351–4

Intraocular folding of an acrylic lens for explantation through a small incision cataract wound. Neuhann TH. **J Cataract Refract Surg** 1996;22 Suppl 2:1383–6

Optimal folding axis for acrylic intraocular lenses. Oh KT, et al. **J Cataract Refract Surg** 1996 Jul-Aug;22(6):667–70

Evaluation of the first 50 ACR360 acrylic intraocular lens implantations. Sanchez E, et al. **J Cataract Refract Surg** 1996;22 Suppl 2:1373–8

Implantation of multiple foldable acrylic posterior chamber lenses in the capsular bag for high hyperopia. Shugar JK, et al. **J Cataract Refract Surg** 1996;22 Suppl 2:1368–72

Implantation of AcrySof acrylic intraocular lenses. Shugar JK. **J Cataract Refract Surg** 1996;22 Suppl 2:1355–9

[A new embolic material: super absorbent polymer (SAP) microsphere and its embolic effects] Jiaqi Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jan;56(1):19–24 (Eng. Abstr.) **(Jpn)**

[Clinical assessment of calvarial reconstruction with autogenic bone graft or implants of acrylate and polypropylene-polyester knitted fabric] Zieliński A, et al. **Neurol Neurochir Pol** 1996 Nov-Dec;30(6):981–94; discussion 995 (Eng. Abstr.) **(Pol)**

ADMINISTRATION & DOSAGE

[Value of percutaneous injection of acrylic cement using a pressure regulator] Gangi A, et al. **J Radiol** 1997 May; 78(5):393–4 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Occupational allergic contact dermatitis caused by photobonded sculptured nails and a review of (meth) acrylates in nail cosmetics. Kanerva L, et al. **Am J Contact Dermat** 1996 Jun;7(2):109–15 (45 ref.)

Ethyl cyanoacrylate does not cross-react with methacrylates and acrylates [letter] Kanerva L. **Am J Contact Dermat** 1997 Mar;8(1):54–5

Ethyl cyanoacrylate does not cross-react with methacrylates and acrylates [letter] Morris DL. **Am J Contact Dermat** 1997 Mar;8(1):55–6

Plastics/acrylics: material safety data sheets need to be improved. Kanerva L, et al. **Clin Dermatol** 1997 Jul-Aug; 15(4):533–46 (67 ref.)

Occupational allergic contact dermatitis due to acrylates in Lodz. Kiec-Swierczynska MK. **Contact Dermatitis** 1996 Jun;34(6):419–22

Allergic contact dermatitis from acrylates in insulin pump infusion sets. van den Hove J, et al. **Contact Dermatitis** 1996 Aug;35(2):108

Capsular bag distension with an acrylic intraocular lens. Omar O, et al. **J Cataract Refract Surg** 1996;22 Suppl 2:1365–7

CHEMICAL SYNTHESIS

Structure-activity relationships study of two series of leukotriene B4 antagonists: novel indolyl and naphthyl compounds substituted with a 2-[methyl(2-phenethyl)amino]-2-oxoethyl side chain. Chan WK, et al. **J Med Chem** 1996 Sep 13;39(19):3756–68

CHEMISTRY

Biodegradable bone cement compositions based on acrylate and epoxide terminated poly(propylene fumarate) oligomers and calcium salt compositions. Domb AJ, et al. **Biomaterials** 1996 Feb;17(4):411–7

Changes in compressive strength on ageing in glass polyalkenoate (glass-ionomer) cements prepared from acrylic/maleic acid copolymers. Nicholson JW, et al. **Biomaterials** 1997 Jan;18(1):59–62

Use of neutral surfactants for the capillary electrophoretic separation of hydrophobically modified poly(acrylic acids). Collet J, et al. **Electrophoresis** 1996 Jul;17(7):1202–9

Gel and free solution electrophoresis of variably charged polymers. Hoagland DA, et al. **Electrophoresis** 1996 Jun; 17(6):1151–60

In vitro drug adsorption to charcoal, silicas, acrylate

copolymer and silicone oil with charcoal and with acrylate copolymer. Cassidy SL, et al. **Hum Exp Toxicol** 1997 Jan; 16(1):25–7

Temperature-sensitivity of liposomal lipid bilayers mixed with poly(N-isopropylacrylamide-co-acrylic acid). Kim JC, et al. **J Biochem (Tokyo)** 1997 Jan;121(1):15–9

Surface studies of albumin immobilized onto PE and PVC films. de Queiroz AA, et al. **J Biomater Sci Polym Ed** 1997; 8(9):667–81

Effect of mixing method on selected properties of acrylic bone cement. Lewis G, et al. **J Biomed Mater Res** 1997 Fall;38(3):221–8

Properties of acrylic bone cement: state of the art review. Lewis G. **J Biomed Mater Res** 1997 Summer;38(2):155–82 (126 ref.)

Application of tertiary amines with reduced toxicity to the curing process of acrylic bone cements. Vazquez B, et al. **J Biomed Mater Res** 1997 Jan;34(1):129–36

Calorimetric characterization of the formation of acrylic type bone cements. Yang JM, et al. **J Biomed Mater Res** 1996 Summer;33(2):83–8

Study of protein binding to a silica support with a polymeric cation-exchange coating. Ratnayake CK, et al. **J Chromatogr A** 1996 Aug 30;743(1):15–23

(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity. Daines RA, et al. **J Med Chem** 1996 Sep 13;39(19):3837–41

Structural analogues of ZAPA as GABAA agonists. Allan RD, et al. **Neurochem Int** 1997 Jun;30(6):583–91

Determination of the 13C magnetic shielding tensor in partially oriented polymer systems. Gabriëlse W, et al. **Solid State Nucl Magn Reson** 1996 Jun;6(3):231–40

DIAGNOSTIC USE

Gas chromatographic and mass spectrometric purity analysis of acrylates and methacrylates used as patch test substances. Henriks-Eckerman ML, et al. **Am J Contact Dermat** 1997 Mar;8(1):20–3

IMMUNOLOGY

[Typical symptoms of methyl acylate sensitivity in wearers of acylate dentures] Olveti E, et al. **Fogorv Sz** 1997 Jan; 90(1):19–26 (30 ref.) (Eng. Abstr.) **(Hun)**

ISOLATION & PURIFICATION

Use of neutral surfactants for the capillary electrophoretic separation of hydrophobically modified poly(acrylic acids). Collet J, et al. **Electrophoresis** 1996 Jul;17(7):1202–9

Two new aromatic constitutents from the rootwood of Aeschynomene mimosifolia. Fullas F, et al. **J Nat Prod** 1996 Feb;59(2):190–2

METABOLISM

Purification and preliminary characterization of (E)-3-(2,4-dioxo-6-methyl-5-pyrimidinyl)acrylic acid synthase, an enzyme involved in biosynthesis of the antitumor agent sparsomycin. Parry RJ, et al. **J Bacteriol** 1997 Feb;179(4):1385–92

Crystal structure of calcium bound domain VI of calpain at 1.9 A resolution and its role in enzyme assembly, regulation, and inhibitor binding [see comments] Lin GD, et al. **Nat Struct Biol** 1997 Jul;4(7):539–47. Comment in: Nat Struct Biol 1997 Jul;4(7):514–6.

Production of methyl 3-oxoartemisinate from methyl artemisinate by suspension cell culture of Mentha piperita [letter] Kim SU, et al. **Planta Med** 1996 Aug;62(4):359–60

Structure-activity relationships in the hydrolysis of acrylate and methacrylate esters by carboxylesterase in vitro. McCarthy TJ, et al. **Toxicology** 1997 Jan 15;116(1–3):153–8

PHARMACOLOGY

Alpha-mercaptoacrylic acid derivatives as novel selective calpain inhibitors. Wang KK, et al. **Adv Exp Med Biol** 1996; 389:95–101 (20 ref.)

Effect of cross-linking agents on the dynamic mechanical properties of hydrogel blends of poly(acrylic acid)-poly(vinyl alcohol-vinyl acetate). Cauich-Rodriguez JV, et al. **Biomaterials** 1996 Dec;17(23):2259–64

Effect of PVA-AA on dentine bonding of HEMA. Gung YW, et al. **Biomaterials** 1997 Feb;18(4):367–71

Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Martin DE, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):661–4

pH-dependent actions of THIP and ZAPA on an ionotropic Drosophila melanogaster GABA receptor. Matsuda K, et al. **Brain Res** 1996 Nov 11;739(1–2):335–8

Protein stabilisation using additives based on multiple electrostatic interactions. Gibson TD. **Dev Biol Stand** 1996; 87:207–17

Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Price DA, et al. **Hypertension** 1997 Aug;30(2 Pt 1):240–6

Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus. Martin DE, et al. **J Clin Pharmacol** 1997 Feb;37(2):155–9

Novel beta-methoxyacrylates of the 9-methoxystrobilurin and oudesmansin classes produced by the basidiomycete Favolaschia pustulosa. Wood KA, et al. **J Nat Prod** 1996 Jul;59(7):646–9

STANDARDS

Effect of folding on the optical quality of soft acrylic intraocular lenses. Oshika T, et al. **J Cataract Refract Surg** 1996;22 Suppl 2:1360–4

THERAPEUTIC USE

Viscous carbomer eye drops in patients with dry eyes. Efficacy and safety. A randomized, open, cross-over, multicentre study. Marner K, et al. **Acta Ophthalmol Scand** 1996 Jun;74(3):249–52

Eczema, scratching and acrylic nails [letter] O'Brien TJ. **Australas J Dermatol** 1997 Feb;38(1):50

TOXICITY

Absence of systemic in vivo genotoxicity after dermal exposure to ethyl acrylate and tripropylene glycol diacrylate in Tg.AC (v-Ha-ras) mice. Tice RR, et al. **Environ Mol Mutagen** 1997;29(3):240–9

ACRYLIC RESINS

see related

DENTAL MATERIALS

Collagen-coated acrylic microspheres for embolotherapy: in vivo and in vitro characteristics. Derdeyn CP, et al. **AJNR Am J Neuroradiol** 1997 Apr;18(4):647–53

Analysis of single-strand conformation polymorphism by capillary electrophoresis with laser-induced fluorescence detection using short-chain polyacrylamide as sieving medium. Ren J, et al. **Anal Biochem** 1997 Feb 1; 245(1):79–84

Hemodialysis urea rebound and membrane biocompatibility: accuracy of Kt/V estimations. Navarro JF, et al. **Artif Organs** 1997 Feb;21(2):91–5

Plasma-induced grafted polymerization of acrylic acid and subsequent grafting of collagen onto polymer film as biomaterials. Lee SD, et al. **Biomaterials** 1996 Aug; 17(16):1599–608

In vivo biostability of a polymeric hollow fibre membrane for cell encapsulation. Shoichet MS, et al. **Biomaterials** 1996 Feb;17(3):285–90

Modified crush-and-soak method for recovering oligodeoxynucleotides from polyacrylamide gel. Chen Z, et al. **Biotechniques** 1996 Nov;21(5):820–2

Alternative to large acrylamide gels for DNA analysis. Epstein JL, et al. **Biotechniques** 1997 Feb;22(2):226–8, 230

Removal of coomassie blue precipitates from polyacrylamide gels. Lewis SA. **Biotechniques** 1996 Nov;21(5):820

Flow-cytometric study of granulocyte activation during hemodialysis with different membranes. Mordacchini M, et al. **Blood Purif** 1995 Nov-Dec;13(6):322–6

Migraine: the effect of acrylic appliance design on clinical response [see comments] Lamey PJ, et al. **Br Dent J** 1996 Feb 24;180(4):137–40. Comment in: Br Dent J 1996 Jun 22;180(12):447.

Reversal of diabetes in non-obese diabetic mice by xenografts of porcine islets entrapped in hollow fibres composed of polyacrylonitrile-sodium methallylsulphonate copolymer. Rivereau AS, et al. **Diabetes Metab** 1997 Jun;23(3):205–12

Comparison of in-gel and on-membrane digestion methods at low to sub-pmol level for subsequent peptide and fragment-ion mass analysis using matrix-assisted laser-desorption/ionization mass spectrometry. Courchesne PL, et al. **Electrophoresis** 1997 Mar-Apr;18(3–4):369–81

Enhanced in situ gel digestion of electrophoretically separated proteins with automated peptide elution onto mini reversed-phase columns. Eckerskorn C, et al. **Electrophoresis** 1996 May;17(5):899–906

The use of elevated column temperature to extend DNA sequencing read lengths in capillary electrophoresis with replaceable polymer matrices. Klepárnik K, et al. **Electrophoresis** 1996 Dec;17(12):1860–6

Rapid mass spectrometric identification of proteins from two-dimensional polyacrylamide gels after in gel proteolytic digestion. Li G, et al. **Electrophoresis** 1997 Mar-Apr;18(3–4):391–402

S-pyridylethylation of intact polyacrylamide gels and in situ digestion of electrophoretically separated proteins: a rapid mass spectrometric method for identifying cysteine-containing peptides. Moritz RL, et al. **Electrophoresis** 1996 May;17(5):907–17

Sensitivity and mass accuracy for proteins analyzed directly from polyacrylamide gels: implications for proteome mapping. Ogorzalek Loo RR, et al. **Electrophoresis** 1997 Mar-Apr;18(3–4):382–90

Mechanisms of retardation of rigid spherical particles with 3 to 1,085 nm radius in capillary electrophoresis, using buffered polyacrylamide (molecular weight 5 x 10(6)) solutions. Radko SP, et al. **Electrophoresis** 1996 Jun; 17(6):1094–102

Direct isolation of proteins from sodium dodecyl sulfate-polyacrylamide gel electrophoresis and analysis by electrospray-ionization mass spectrometry. Schuhmacher M, et al. **Electrophoresis** 1996 May;17(5):848–54

Time-resolved EPR studies on the reaction rates of peroxyl radicals of poly(acrylic acid) and of calf thymus DNA with glutathione. Re-examination of a rate constant for DNA. Hildenbrand K, et al. **Int J Radiat Biol** 1997 Apr; 71(4):377–85

Acrylic cement creeps but does not allow much subsidence of femoral stems. Verdonschot N, et al. **J Bone Joint Surg Br** 1997 Jul;79(4):665–9

Rigid porous polyacrylamide-based monolithic columns containing butyl methacrylate as a separation medium for the rapid hydrophobic interaction chromatography of proteins. Xie S, et al. **J Chromatogr A** 1997 Jul 18; 775(1–2):65–72

Microencapsulated Eudragit RS30D-coated controlled-release pellets: the influence of dissolution variables and topographical evaluation. Govender T, et al. **J Microencapsul** 1997 Jan-Feb;14(1):1–13

The clinical success and periodontal evaluation of patients rehabilitated with light-cured obturators. Benington IC, et al. **J Oral Rehabil** 1996 Feb;23(2):135–8

Antifungal effect of zeolite-incorporated tissue conditioner against Candida albicans growth and/or acid production. Nikawa H, et al. **J Oral Rehabil** 1997 May;24(5):350–7

The effect of notch shape and self-cured acrylic resin repair on the fatigue resistance of an acrylic resin denture base. Vallittu PK, et al. **J Oral Rehabil** 1996 Feb;23(2):108–13

Acrylic resin pivot ball for the survey of mounted casts. Brenyo MR, et al. **J Prosthet Dent** 1997 Aug;78(2):228–9

Comparison of the clinical abrasion resistance of six commercially available denture teeth. Jooste C, et al. **J Prosthet Dent** 1997 Jan;77(1):23–7

The all-acrylic resin mandibular removable partial denture: design considerations. McCartney JW, et al. **J Prosthet Dent** 1997 Jun;77(6):638

Safe resin records using plastic copings. Stamoulis KS, et al. **J Prosthet Dent** 1997 Aug;78(2):223–4

Retention of Candida albicans on acrylic resin and silicone of different surface topography. Verran J, et al. **J Prosthet Dent** 1997 May;77(5):535–9

High yield elution of proteins from sodium dodecyl sulfate-polyacrylamide gels at the low-picomole level. Application to N-terminal sequencing of a scarce protein and to in-solution biological activity analysis of on-gel renatured proteins. Castellanos-Serra LR, et al. **J Protein Chem** 1997 Jul;16(5):415–9

Histopathologic appearance of arterial occlusions with hydrogel and polyvinyl alcohol embolic material in domestic swine. Link DP, et al. **J Vasc Interv Radiol** 1996 Nov-Dec;7(6):897–905

Antipolymer antibodies, silicone breast implants, and fibromyalgia [letter; comment] Angell M. **Lancet** 1997 Apr 19;349(9059):1171–2; discussion 1172–3. Comment on: Lancet 1997 Feb 15;349(9050):449–54.

Antipolymer antibodies, silicone breast implants, and fibromyalgia [letter; comment] Korn JH. **Lancet** 1997 Apr 19;349(9059):1171. Comment on: Lancet 1997 Feb 15;349(9050):449–54.

NMR microscopy of polyacrylamide hydrogel. Ding GL, et al. **Magn Reson Imaging** 1996;14(7–8):947–8

Improved dose distribution with a universal acrylic breast compensator. Johnson JM, et al. **Med Dosim** 1996 Fall; 21(3):127–32

Decentration and tilt of polymethyl methacrylate, silicone, and acrylic soft intraocular lenses. Hayashi K, et al. **Ophthalmology** 1997 May;104(5):793–8

Comparative study of silicone versus acrylic foldable lens implantation in primary glaucoma triple procedure. Lemon LC, et al. **Ophthalmology** 1997 Oct;104(10):1708–13

Intraoral expansion screw replacement using a light-cured acrylic technique. Goho C. **Pediatr Dent** 1997 May-Jun; 19(4):291

Large-pore polydimethylacrylamide resin for solid-phase peptide synthesis: applications in Fmoc chemistry. Sparrow JT, et al. **Pept Res** 1996 Nov-Dec;9(6):297–304

Acrylic bone cement injection for the treatment of bone metastases [editorial; comment] Laredo JD, et al. **Rev Rhum Engl Ed** 1997 Mar;64(3):145–6. Comment on: Rev Rhum Engl Ed 1997 Mar;64(3):177–83.

Insulin secretion of free and AN69 encapsulated islets. Rolland E, et al. **Transplant Proc** 1997 Jun;29(4):2140–1

Methods and reagents. Pouring sequencing gels the old-fashioned way. Hengen PN. **Trends Biochem Sci** 1996 Jul;21(7):273–4

Long-term success rate of resin-bonded metal crowns on the canine teeth of working dogs. van Foreest AW, et al. **Vet Q** 1997 Mar;19(1):23–8

[Percutaneous vertebral surgery. Technics and indications] Chiras J, et al. **J Neuroradiol** 1997 Jun;24(1):45–59 (Eng. Abstr.) **(Fre)**

[Immunohistochemical labeling of inner ear tissues embedded in polyethylene glycol 4000—comparative study with araldite and unicryl embedded sections] Slepecky NB, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Mar;99(3):361–9 (Eng. Abstr.) **(Jpn)**

[Glycoconjugates on the basis of polyacrylamide—tools for studying lectins, antibodies, and glycosyltransferases in glycobiology, cytochemistry, and histochemistry] Bovin NV. **Bioorg Khim** 1996 Sep;22(9):643–63 (81 ref.) (Eng. Abstr.) **(Rus)**

[Long-term results of endoprosthesis using hydrophilic polyacrylamide gel "Interfall"] Zemskov VS, et al. **Klin Khir** 1996;(5):21–3 **(Rus)**

[Soft-tissue contour plastic repair using the hydrophilic polyacrylamide gel PAAG Interfall] Zemskov VS, et al. **Klin Khir** 1996;(11–12):28–30 **(Rus)**

ADMINISTRATION & DOSAGE

Macroporous poly(sucrose acrylate) hydrogel for controlled release of macromolecules. Patil NS, et al. **Biomaterials** 1996 Dec;17(24):2343–50

Development of a microencapsulated form of cefuroxime axetil using pH-sensitive acrylic polymers. Lorenzo-Lamosa ML, et al. **J Microencapsul** 1997 Sep–Oct;14(5):607–16

ADVERSE EFFECTS

Product analysis of acrylic resins compared to information given in material safety data sheets. Henriks-Eckerman ML, et al. **Contact Dermatitis** 1997 Mar;36(3):164–5

Contact dermatitis due to an acrylic dental prosthesis. Kobayashi T, et al. **Contact Dermatitis** 1996 Dec; 35(6):370–1

Allergy caused by acrylics: past, present and prevention. Kanerva L, et al. **Curr Probl Dermatol** 1996;25:86–96 (30 ref.)

Cell aggregation and apoptosis induced by hemodialysis membranes. Carracedo J, et al. **J Am Soc Nephrol** 1995 Dec;6(6):1586–91

Transient increase in DNA strand breaks in car refinishing spray painters. Fuchs J, et al. **Scand J Work Environ Health** 1996 Dec;22(6):438–43

[The use of pulsed complexly modulated electromagnetic fields in treating the inflammatory mucosal manifestations of the denture bed] Zholudev SE, et al. **Stomatologiia (Mosk)** 1996;Spec No:56–7 **(Rus)**

ANALYSIS

Amplification of differentially displayed PCR products isolated from untreated denaturing polyacrylamide gels. Konecny P, et al. **Biotechniques** 1997 Feb;22(2):240–2, 244

CHEMICAL SYNTHESIS

Synthesis, characterization and biocompatibility of PEGA resins. Auzanneau FI, et al. **J Pept Sci** 1995 Jan–Feb; 1(1):31–44

Development of a statistical model for the formation of poly [acryloyl hydroxyethyl starch] microspheres. Huang LK, et al. **Pharm Res** 1997 Apr;14(4):469–74

Evaluation of a statistical model for the formation of poly [acryloyl hydroxyethyl starch] microspheres. Huang LK, et al. **Pharm Res** 1997 Apr;14(4):475–82

CHEMISTRY

Retention of propanal and diacetyl in experimental resins. Peutzfeldt A. **Acta Odontol Scand** 1997 Apr;55(2):94–100

Evaluation of a resin-reinforced glass ionomer cement for use as an orthodontic bonding agent. Komori A, et al. **Angle Orthod** 1997;67(3):189–95

Internalization of non-permeant materials into cultured mammalian cells by vortex-stirring in the presence of a high molecular weight polyacrylic acid: direct evidence of internalization and its dependence on the cell lines. Shimizu N, et al. **Biol Pharm Bull** 1997 Jul;20(7):727–31

Enhanced cytotoxicity of alkyl viologens and N,N'-diamino analogs toward cultured murine leukemia L1210 cells under vortex-stirring with a high molecular weight polyacrylic acid. Shimizu N, et al. **Biol Pharm Bull** 1997 Feb; 20(2):168–70

Kinetics of anhydride formation in xerogels of poly(acrylic acid). Blanco-Fuente H, et al. **Biomaterials** 1996 Sep; 17(17):1667–75

Silicone rubber-hydrogel composites as polymeric biomaterials. IX. Composites containing powdery polyacrylamide hydrogel. Hron P, et al. **Biomaterials** 1997 Aug;18(15):1069–73

THFMA in dental monomer systems. Labella R, et al. **Biomaterials** 1996 Feb;17(4):431–6

Bioactive heparin surfaces from derivatization of polyacrylamide-grafted LLDPE. Wirsén A, et al. **Biomaterials** 1996 Oct;17(19):1881–9

Effect of mobile phase composition on selectivity in preparative hydrophobic interaction chromatographic purification of glucagon. Angelova M, et al. **Biomed Chromatogr** 1996 Sep–Oct;10(5):251–5

Temperature dependence of retention in reversed-phase liquid chromatography on a porous acrylic support. Kamiyama F, et al. **Biomed Chromatogr** 1996 May–Jun; 10(3):105–10

Environmental degradation of polyacrylamides. 1. Effects of artificial environmental conditions: temperature, light, and pH. Smith EA, et al. **Ecotoxicol Environ Saf** 1996 Nov; 35(2):121–35

Environmental degradation of polyacrylamides. II. Effects of environmental (outdoor) exposure. Smith EA, et al. **Ecotoxicol Environ Saf** 1997 Jun;37(1):76–91

The effects of polymer properties on DNA separations by capillary electrophoresis in uncross-linked polymer solutions. Barron AE, et al. **Electrophoresis** 1996 Apr; 17(4):744–57

Eliciting macroporosity in polyacrylamide and agarose gels with polyethylene glycol. Charlionet R, et al. **Electrophoresis** 1996 Jan;17(1):58–66

The role of pH and membrane porosity in preparative electrophoresis. Corthals GL, et al. **Electrophoresis** 1996 Apr;17(4):771–5

Novel acrylamido monomers with higher hydrophilicity and improved hydrolytic stability: III. DNA separations by capillary electrophoresis in poly (N-acryloylaminopropanol). Gelfi C, et al. **Electrophoresis** 1996 Apr;17(4):738–43

Gel and free solution electrophoresis of variably charged polymers. Hoagland DA, et al. **Electrophoresis** 1996 Jun; 17(6):1151–60

Analysis of toxic drugs by capillary electrophoresis using polyacrylamide-coated columns. Jinno K, et al. **Electrophoresis** 1997 Feb;18(2):284–6

Novel acrylamido monomers with higher hydrophilicity and improved hydrolytic stability: II. Properties of N-acryloylaminopropanol. Simò-Alfonso E, et al. **Electrophoresis** 1996 Apr;17(4):732–7

DNA mobility anomalies are determined primarily by polyacrylamide gel concentration, not gel pore size. Stellwagen NC. **Electrophoresis** 1997 Jan;18(1):34–44

Polyacrylamide solutions for DNA sequencing by capillary electrophoresis: mesh sizes, separation and dispersion. Wu C, et al. **Electrophoresis** 1996 Jun;17(6):1103–9

Subsidence of THA stems due to acrylic cement creep is extremely sensitive to interface friction. Verdonschot N, et al. **J Biomech** 1996 Dec;29(12):1569–75

Partial thermodynamic parameters for prediction stability and washing behavior of DNA duplexes immobilized on gel matrix. Kunitsyn A, et al. **J Biomol Struct Dyn** 1996 Oct; 14(2):239–44

Lateral interaction between electrostatically adsorbed and covalently immobilized proteins on the surface of cation-exchange sorbents. Ratnayake CK, et al. **J Chromatogr A** 1996 Aug 30;743(1):25–32

Oligonucleotide analysis by capillary polymer sieving electrophoresis using acryloylaminoethoxyethanol-coated capillaries. Talmadge KW, et al. **J Chromatogr A** 1996 Sep 13;744(1–2):347–54

Synthesis and application of boronic acid-immobilized porous polymer particles: a novel packing for high-performance liquid affinity chromatography. Koyama T, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26; 679(1–2):31–40

The effect of untreated UHMWPE beads on some properties of acrylic resin denture base material. Carlos NB, et al. **J Dent** 1997 Jan;25(1):59–64

Effect of acidic primers on bonding between stainless steel and auto-polymerizing methacrylic resins. Matsumura H, et al. **J Dent** 1997 May–Jul;25(3–4):285–90

Cu(2+)-mediated complex formation between polyacrylic acid (PAA) and bovine serum albumin. Mustafaev MI, et al. **J Immunol Methods** 1996 Oct 16;197(1–2):31–7

Development of a microencapsulated form of cefuroxime axetil using pH-sensitive acrylic polymers. Lorenzo-Lamosa ML, et al. **J Microencapsul** 1997 Sep–Oct;14(5):607–16

The effects of cross-linking agents on the water sorption and solubility characteristics of denture base resin. Arima T, et al. **J Oral Rehabil** 1996 Jul;23(7):476–80

Colour changes in acrylic teeth—comparison of an objective and subjective method. Liberman R, et al. **J Oral Rehabil** 1996 Jul;23(7):464–9

Peak temperatures of some prosthetic acrylates on polymerization. Vallittu PK. **J Oral Rehabil** 1996 Nov; 23(11):776–81

Physicochemical properties of calcium polycarbophil, a water-absorbing polymer. Yamada T, et al. **J Pharm Pharmacol** 1996 Jul;48(7):665–8

Investigation of film curing stages by dielectric analysis and physical characterization. Guma NC, et al. **J Pharm Sci** 1997 Mar;86(3):329–34

Unrestricted linear dimensional changes of two hard chairside reline resins and one heat-curing acrylic resin. Cucci AL, et al. **J Prosthet Dent** 1996 Oct;76(4):414–7

Effects of chemical disinfectants on the surface characteristics and color of denture resins. Ma T, et al. **J Prosthet Dent** 1997 Feb;77(2):197–204

Color stability: denture base resins processed with the microwave method. May KB, et al. **J Prosthet Dent** 1996 Dec;76(6):581–9

The effects of surface machining on heat cured acrylic resin and two soft denture base materials: a scanning electron microscope and confocal microscope evaluation. Radford DR, et al. **J Prosthet Dent** 1997 Aug;78(2):200–8

Improved fit of maxillary complete dentures processed on high expansion stone casts. Sykora O, et al. **J Prosthet Dent** 1997 Feb;77(2):205–8

The swelling phenomenon of acrylic resin polymer teeth at the interface with denture base polymers. Vallittu PK, et al. **J Prosthet Dent** 1997 Aug;78(2):194–9

Effect of dowel lubrication on resistance to dislodgment of dowels cemented with a 4-META resinous cement. Walmann JO, et al. **J Prosthet Dent** 1996 Jul;76(1):15–8

Novel techniques for identification and characterization of proteins loaded on gels in femtomole amounts. Gevaert K, et al. **J Protein Chem** 1997 Jul;16(5):335–42

An assessment of nonspecific adsorption to Eudragit S-100 during affinity precipitation. Kumar A, et al. **Mol Biotechnol** 1996 Aug;6(1):1–6

Hot melt extrusion of acrylic films. Aitken-Nichol C, et al. **Pharm Res** 1996 May;13(5):804–8

The effects of ageing on the rheological, dielectric and mucoadhesive properties of poly(acrylic acid) gel systems. Tamburic S, et al. **Pharm Res** 1996 Feb;13(2):279–83

Three-dimensional imaging of single molecules solvated in pores of poly(acrylamide) gels. Dickson RM, et al. **Science** 1996 Nov 8;274(5289):966–9

Dissipation of heat during polymerization of acrylics used for external skeletal fixator connecting bars. Martinez SA, et al. **Vet Surg** 1997 Jul–Aug;26(4):290–4

[The polymerization process of Ethacryl acrylic plastic studied by infrared spectroscopy] Nasibullin GG, et al. **Stomatologiia (Mosk)** 1995;74(6):49–51 (Eng. Abstr.) **(Rus)**

CONTRAINDICATIONS

[Cement-free management of femoral neck fractures in elderly patients with poor cardiopulmonary prognosis] Knipprath J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:981–2 (Eng. Abstr.) **(Ger)**

METABOLISM

Low-density lipoprotein hemoperfusion using a modified polyacrylate adsorber: in vitro, ex vivo, and first clinical results. Bosch T. **Artif Organs** 1996 Apr;20(4):344–5

Mechanism of the interaction of hydrophobically-modified poly-(N-isopropylacrylamides) with liposomes. Polozova A, et al. **Biochim Biophys Acta** 1997 Jun 12;1326(2):213–24

A new method for permeabilization of the plasma membrane of cultured mammalian cells. V. A standard procedure recommended for permeabilization by vortex-stirring with high molecular weight polyacrylic acid. Shimizu N, et al. **Biol Pharm Bull** 1996 Oct;19(10):1279–84

Decalcification of calcium polycarbophil in rats. Yamada T, et al. **Biol Pharm Bull** 1997 Mar;20(3):275–7

Mechanisms and kinetics of the synthesis and release of platelet-activating factor (PAF) by polyacrylonitrile membranes. Guastoni C, et al. **Clin Nephrol** 1996 Aug; 46(2):132–8

Pathophysiological and histomorphological evaluation of polyacryloylmorpholine vs polyethylene glycol modified superoxide dismutase in a rat model of ischaemia/reperfusion injury. Rocca M, et al. **Int J Artif Organs** 1996 Dec;19(12):730–4

Beta 2-microglobulin removal by synthetic dialysis membranes. Mechanisms and kinetics of the molecule. Ronco C, et al. **Int J Artif Organs** 1997 Mar;20(3):136–43

Microencapsulation of chloroquine diphosphate by Eudragit RS100. Ndesendo VM, et al. **J Microencapsul** 1996 Jan–Feb;13(1):1–8

PHARMACOKINETICS

Tyramine-containing poly(4-nitrophenylacrylate) as iodinatable ligand carrier in biodistribution analysis. Kojima S, et al. **Pharm Res** 1997 Jul;14(7):879–86

PHARMACOLOGY

A new method for permeabilization of the plasma membrane of cultured mammalian cells. VI. Enhanced cytotoxicity of bleomycin toward leukemia P388 cells inoculated into the tail vein of mice together with high molecular weight polyacrylic acid—similarity of blood stream to vortex-stirring. Ikeda Y, et al. **Biol Pharm Bull** 1997 Jan; 20(1):25–7

A new method for permeabilization of the plasma membrane of cultured mammalian cells. VII. Permeabilization of growing and resting cells by vortex-stirring with high molecular weight polyacrylic acid. Noda Y, et al. **Biol Pharm Bull** 1996 Dec;19(12):1565–9

A new method for permeabilization of the plasma membrane of cultured mammalian cells. III. Internalization of fluorescent dextrans into cultured mammalian cells by vortex-stirring in the presence of high molecular weight polyacrylic acid. Shimizu N, et al. **Biol Pharm Bull** 1996 Aug;19(8):1023–5

A new method for permeabilization of the plasma membrane of cultured mammalian cells. II. Mechanism for potentiation of bleomycin cytotoxicity by vortex-stirring with high molecular weight polyacrylic acid. Shimizu N, et al. **Biol Pharm Bull** 1996 Jun;19(6):805–8

Delicate and crucial pH dependence in permeabilization of cultured mammalian cells by vortex-stirring with a high molecular weight polyacrylic acid. Shimizu N, et al. **Biol Pharm Bull** 1996 Nov;19(11):1533–5

Effect of polycarbophil on the absorption of nutrients. Yamada T, et al. **Biol Pharm Bull** 1996 May;19(5):771–3

Monomeric inhibitors of influenza neuraminidase enhance the hemagglutination inhibition activities of polyacrylamides presenting multiple C-sialoside groups. Choi SK, et al. **Chem Biol** 1996 Feb;3(2):97–104

Conjugates of insulin with copolymers of N-(2-hydroxypropyl) methacrylamide: effects on smooth muscle cell proliferation. Chytry V, et al. **J Biomed Mater Res** 1996 Jun;31(2):265–72

The effect of chairside relining materials on rat palatal mucosa. Barclay SC, et al. **J Dent** 1997 May–Jul; 25(3–4):251–5

Effects of polyacrylic polymers on the degradation of insulin and peptide drugs by chymotrypsin and trypsin. Bai JP, et al. **J Pharm Pharmacol** 1996 Jan;48(1):17–21

Study of interaction effects of polyacrylic acid polymers (carbopol 940) on antimicrobial activity of methyl parahydroxybenzoate against some gram-negative, gram-positive bacteria and yeast. Scalzo M, et al.

ACRYLIC RESINS

J Pharm Pharmacol 1996 Nov;48(11):1201–5

Development and in vitro evaluation of systems to protect peptide drugs from aminopeptidase N. Bernkop-Schnürch A, et al. **Pharm Res** 1997 Feb;14(2):181–5

Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Luessen HL, et al. **Pharm Res** 1996 Nov;13(11):1668–72

POISONING

[Quantification and studies of in vitro toxicity of chemicals extracted from synthetic ion exchange media] Boschetti E, et al. **Ann Pharm Fr** 1996;54(6):251–9 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Permanent ureteral occlusion with use of liquid polyacrylonitrile. Dong PR, et al. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):655–7

Efficacy and safety of 0.3% carbomer gel compared to placebo in patients with moderate-to-severe dry eye syndrome. Sullivan LJ, et al. **Ophthalmology** 1997 Sep; 104(9):1402–8

TOXICITY

Analysis of the leaching and toxicity of new amine activators for the curing of acrylic bone cements and composites. Liso PA, et al. **Biomaterials** 1997 Jan;18(1):15–20

Modification of the agar overlay assay: assessment of the influence of acrylics used in orthodontics on proliferation and differentiation of primary and transformed fibroblasts. Schuster G, et al. **J Orofac Orthop** 1996 Dec;57(6):344–53 **(Eng, Ger)**

ACRYLONITRILE

Using a simple diffusion model to predict residual monomer migration--considerations and limitations. Lickly TD, et al. **Food Addit Contam** 1997 Jan;14(1):65–74

ADMINISTRATION & DOSAGE

Refinement and verification of the physiologically based dosimetry description for acrylonitrile in rats. Kedderis GL, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):422–35

ADVERSE EFFECTS

[Acrylonitrile and chemotaxis: in vitro experiments] Monaco F, et al. **G Ital Med Lav** 1995 Jan–Nov;17(1–6):99–103 (Eng. Abstr.) **(Ita)**

ANALOGS & DERIVATIVES

Flow-cytometric study of granulocyte activation during hemodialysis with different membranes. Mordacchini M, et al. **Blood Purif** 1995 Nov–Dec;13(6):322–6

Reversal of diabetes in non-obese diabetic mice by xenografts of porcine islets entrapped in hollow fibres composed of polyacrylonitrile-sodium methallylsulphonate copolymer. Rivereau AS, et al. **Diabetes Metab** 1997 Jun;23(3):205–12

Beta 2-microglobulin removal by synthetic dialysis membranes. Mechanisms and kinetics of the molecule. Ronco C, et al. **Int J Artif Organs** 1997 Mar;20(3):136–43

Cell aggregation and apoptosis induced by hemodialysis membranes. Carracedo J, et al. **J Am Soc Nephrol** 1995 Dec;6(6):1586–91

Insulin secretion of free and AN69 encapsulated islets. Rolland E, et al. **Transplant Proc** 1997 Jun;29(4):2140–1

ANALYSIS

A study on the random distribution of a red acrylic target fibre. Brüschweiler W, et al. **Sci Justice** 1997 Apr–Jun; 37(2):85–9

Synthesis and characterization of peptide adducts for use in monitoring human exposure to acrylonitrile and ethylene oxide. Lawrence RM, et al. **Teratog Carcinog Mutagen** 1996;16(3):139–48

BLOOD

Hemoglobin adducts of acrylamide and acrylonitrile in laboratory workers, smokers and nonsmokers. Bergmark E. **Chem Res Toxicol** 1997 Jan;10(1):78–84

METABOLISM

Monitoring of exposure to acrylonitrile by determination of N-(2-cyanoethyl)valine at the N-terminal position of haemoglobin. Tavares R, et al. **Carcinogenesis** 1996 Dec; 17(12):2655–60

PHARMACOKINETICS

Comparative disposition of acrylonitrile and methacrylonitrile: quantitative whole-body autoradiographic studies in rats. Ahmed AE, et al. **Fundam Appl Toxicol** 1996 Sep;33(1):49–59

Dose dependence of covalent binding of acrylonitrile to tissue protein and globin in rats. Benz FW, et al. **Fundam Appl Toxicol** 1997 Apr;36(2):149–56

In-vitro testicular bioactivation of acrylonitrile. Abdel-Aziz AH, et al. **Pharmacol Res** 1997 Feb;35(2):129–34

Refinement and verification of the physiologically based dosimetry description for acrylonitrile in rats. Kedderis GL, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):422–35

PHARMACOLOGY

Acrylonitrile potentiates oxidative stress in rat alveolar macrophages. Bhooma T, et al. **Bull Environ Contam Toxicol** 1997 Jan;58(1):71–8

THERAPEUTIC USE

Tubal sterilization by means of selective catheterization: comparison of a hydrogel and a collagen glue. Maubon AJ, et al. **J Vasc Interv Radiol** 1996 Sep–Oct;7(5):733–6

TOXICITY

Role of glutathione modulation in acrylonitrile-induced gastric DNA damage in rats. Ahmed AE, et al. **Arch Toxicol** 1996;70(10):620–7

Effects of the carcinogen, acrylonitrile, on forestomach cell proliferation and apoptosis in the rat: comparison with methacrylonitrile. Ghanayem BI, et al. **Carcinogenesis** 1997 Apr;18(4):675–80

Biological markers of acute acrylonitrile intoxication in rats as a function of dose and time. Benz FW, et al. **Fundam Appl Toxicol** 1997 Apr;36(2):141–8

Refinement and verification of the physiologically based dosimetry description for acrylonitrile in rats. Kedderis GL, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):422–35

ACTH see **CORTICOTROPIN**

ACTH 1-24 see **COSYNTROPIN**

ACTH RECEPTORS see **RECEPTORS, CORTICOTROPIN**

ACTH-RELEASING FACTOR see **CORTICOTROPIN-RELEASING HORMONE**

ACTH SYNDROME, ECTOPIC

BLOOD

Ouabainlike compound in hypertension associated with ectopic corticotropin syndrome. Goto A, et al. **Hypertension** 1996 Sep;28(3):421–5

High plasma proopiomelanocortin in aggressive adrenocorticotropin-secreting tumors. Raffin-Sanson ML, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4272–7

COMPLICATIONS

Correction of metabolic alkalosis by potassium chloride in ectopic adrenocorticotropic hormone syndrome. Islam M, et al. **Am J Kidney Dis** 1996 Oct;28(4):610–3

Cushing's syndrome induced by occult ectopic acth secretion. Singh CP, et al. **J Assoc Physicians India** 1995 May; 43(5):364–5

Ectopic Cushing's syndrome in a young female with atypical [corrected] bronchial carcinoid tumour [published erratum appears in Singapore Med J 1997 Feb;38(2):53] Loh KC, et al. **Singapore Med J** 1997 Jan;38(1):29–31

DIAGNOSIS

[Ectopic ACTH syndrome] Sugihara H, et al. **Nippon Ika Daigaku Zasshi** 1997 Feb;64(1):65–8 **(Jpn)**

[A case report. Bronchial ACTH producing carcinoid] Bergmark V, et al. **Lakartidningen** 1997 Mar 12; 94(11):964–6 **(Swe)**

[Ectopic ACTH syndrome. An underdiagnosed condition] Oberg K. **Lakartidningen** 1997 Mar 12;94(11):941–4 (10 ref.) **(Swe)**

DRUG THERAPY

Somatostatin analogs in ectopic corticotropin production. von Werder K, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):129–31 (16 ref.)

ETIOLOGY

Cushing's syndrome secondary to ectopic ACTH secretion from a primary ovarian carcinoma. Ball SG, et al. **Clin Endocrinol (Oxf)** 1996 Dec;45(6):775–8

Spontaneous remission of ectopic Cushing's syndrome due to pheochromocytoma: a case report. Loh KC, et al. **Eur J Endocrinol** 1996 Oct;135(4):440–3

Diagnosis of ectopic ACTH production from a bronchial carcinoid by imaging with octreotide scintigraphy. Kristoffersson A, et al. **Eur J Surg** 1996 Jun;162(6):515–8

Small cell carcinoma of the vagina causing Cushing's syndrome by ectopic production and secretion of ACTH: a case report. Colleran KM, et al. **Gynecol Oncol** 1997 Jun; 65(3):526–9

Bronchopulmonary carcinoid tumors associated with Cushing's syndrome: a more aggressive variant of typical carcinoid. Shrager JB, et al. **J Thorac Cardiovasc Surg** 1997 Sep;114(3):367–75

GENETICS

Expression of glucocorticoid receptor gene isoforms in corticotropin-secreting tumors. Dahia PL, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1088–93

METABOLISM

Ectopic expression of the pituitary V3 vasopressin receptor reveals new aspects of the ectopic ACTH syndrome. Bertherat J. **Eur J Endocrinol** 1996 Aug;135(2):173–4

Expression of glucocorticoid receptor gene isoforms in corticotropin-secreting tumors. Dahia PL, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1088–93

Somatostatin analogs in ectopic corticotropin production. von Werder K, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):129–31 (16 ref.)

RADIONUCLIDE IMAGING

Characterizing an ectopic secreting carcinoid with indium-111-DTPA-D-Phe-pentetreotide. Briganti V, et al. **J Nucl Med** 1997 May;38(5):711–4

URINE

Ouabainlike compound in hypertension associated with ectopic corticotropin syndrome. Goto A, et al. **Hypertension** 1996 Sep;28(3):421–5

1-24-ACTH see **COSYNTROPIN**

ACTIHAEMYL

PHARMACOLOGY

Solcoseryl stimulates behavioural activity of rats. Braszko JJ, et al. **Acta Physiol Hung** 1996;84(1):63–72

Solcoseryl improves learning and memory in rats. Winnicka MM, et al. **Acta Physiol Hung** 1996;84(1):55–62

Influence of "Solcoseryl" during culture on the sex-dependent repair of bovine demi-embryos. Tominaga K, et al. **Mol Reprod Dev** 1996 Mar;43(3):331–5

THERAPEUTIC USE

[Solcoseryl Dental Adhesive Paste in the treatment of the oral mucosal wounds following the implantation of endosseous implants] Porteder H, et al. **Stomatologiia (Mosk)** 1997;76(3):26–8 **(Rus)**

ACTIN-BINDING PROTEINS see **MICROFILAMENT PROTEINS**

ACTING OUT

Acting on command hallucinations: a cognitive approach. Beck-Sander A, et al. **Br J Clin Psychol** 1997 Feb;36 (Pt 1):139–48

Acting out in group therapy: avoiding authority struggles. Silverstein JL. **Int J Group Psychother** 1997 Jan;47(1):31–45

The status of psychic reality in adolescence. An adult female patient's quasi-adolescent material and the analyst's counter transference response. Eiguer A. **Int J Psychoanal** 1996 Dec;77 (Pt 6):1169–80

Theresa O'Hanley, persona non grata. Maltsberger JT. **Suicide Life Threat Behav** 1996 Summer;26(2):187–8; discussion 188–94

[Remembering and acting out] Anstadt T, et al. **Z Psychosom Med Psychoanal** 1996;42(1):34–55 (Eng. Abstr.) **(Ger)**

ACTINIC RAYS see **ULTRAVIOLET RAYS**

ACTINIC RETICULOID SYNDROME see **PHOTOSENSITIVITY DISORDERS**

ACTINIDES see **METALS, ACTINOID**

ACTININ

ANALYSIS

Changes in the distribution of actin-associated proteins in psoriatic keratinocytes. Immunohistochemical study using confocal laser scanning microscopy. Magaudda L, et al. **Arch Dermatol Res** 1997 Jun;289(7):378–83

Application of combined mass spectrometry and partial amino acid sequence to the identification of gel-separated proteins. Patterson SD, et al. **Electrophoresis** 1996 May; 17(5):877–91

Molecular mimicry between HIV-1 gp41 and an astrocyte isoform of alpha-actinin. Spehar T, et al. **J Neurovirol** 1995 Dec;1(5–6):381–90

Localization of cytoskeletal proteins in Cryptosporidium parvum using double immunogold labeling. Yu JR, et al. **Korean J Parasitol** 1996 Dec;34(4):215–24

BIOSYNTHESIS

Podocyte alpha-actinin induction precedes foot process effacement in experimental nephrotic syndrome. Smoyer WE, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):F150–7

CHEMISTRY

Further analysis of the role of spectrin repeat motifs in alpha-actinin dimer formation. Flood G, et al. **Eur Biophys J** 1997;25(5–6):431–5

Flexibility and fine structure of smooth-muscle alpha-actinin. Winkler J, et al. **Eur J Biochem** 1997 Aug 15;248(1):193–9

DEFICIENCY

Deficiency of a skeletal muscle isoform of alpha-actinin (alpha-actinin-3) in merosin-positive congenital muscular dystrophy. North KN, et al. **Neuromuscul Disord** 1996 Aug; 6(4):229-35

IMMUNOLOGY

The molecular basis for cross-reaction of an anti-dystrophin antibody with alpha-actinin. James M, et al. **Biochim Biophys Acta** 1997 Apr 12;1360(2):169-76

METABOLISM

Analysis of the three-dimensional distributions of alpha-actinin, ankyrin, and filamin in developing hearts of normal and cardiac mutant axolotls (Ambystoma mexicanum). Lemanski SF, et al. **Anat Embryol (Berl)** 1997 Feb;195(2):155-63

The N-terminal Z repeat 5 of connectin/titin binds to the C-terminal region of alpha-actinin. Ohtsuka H, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):1-3

Interactions between smooth muscle alpha-actinin and lipid bilayers. Han X, et al. **Biochemistry** 1997 Aug 26; 36(34):10364-71

Co-distribution of tropomyosin and alpha-actinin with actin in Psammobatis extenta electrocytes brings out their similarity with muscle fiber cytoplasm. Vidal A, et al. **Comp Biochem Physiol A Physiol** 1997 Feb;116(2):113-8

Transient appearance of Strongylocentrotus purpuratus Otx in micromere nuclei: cytoplasmic retention of SpOtx possibly mediated through an alpha-actinin interaction. Chuang CK, et al. **Dev Genet** 1996;19(3):231-7

Further analysis of the role of spectrin repeat motifs in alpha-actinin dimer formation. Flood G, et al. **Eur Biophys J** 1997;25(5-6):431-5

Light microscopic analysis of ligand-induced actin filament suprastructures. Korneeva NL, et al. **Eur J Cell Biol** 1996 Dec;71(4):351-5

Binding of the N-terminal 63 kDa portion of connectin/titin to alpha-actinin as revealed by the yeast two-hybrid system. Ohtsuka H, et al. **FEBS Lett** 1997 Jan 13; 401(1):65-7

Biochemical characterization of cardiotin, a sarcoplasmic reticulum associated protein. Schaart G, et al. **FEBS Lett** 1997 Feb 17;403(2):168-72

Binding of the cytoplasmic domain of intercellular adhesion molecule-2 (ICAM-2) to alpha-actinin. Heiska L, et al. **J Biol Chem** 1996 Oct 18;271(42):26214-9

Physical and functional interaction of rabphilin-3A with alpha-actinin. Kato M, et al. **J Biol Chem** 1996 Dec 13; 271(50):31775-8

Interaction of PKN with alpha-actinin. Mukai H, et al. **J Biol Chem** 1997 Feb 21;272(8):4740-6

Identification of a novel marker for primordial smooth muscle and its differential expression pattern in contractile vs noncontractile cells. Hungerford JE, et al. **J Cell Biol** 1997 May 19;137(4):925-37

Characterization of the interactions of alpha-catenin with alpha-actinin and beta-catenin/plakoglobin. Nieset JE, et al. **J Cell Sci** 1997 Apr;110 (Pt 8):1013-22

The role of the cortical cytoskeleton: F-actin crosslinking proteins protect against osmotic stress, ensure cell size, cell shape and motility, and contribute to phagocytosis and development. Rivero F, et al. **J Cell Sci** 1996 Nov;109 (Pt 11):2679-91

Tissue-specific expression and alpha-actinin binding properties of the Z-disc titin: implications for the nature of vertebrate Z-discs. Sorimachi H, et al. **J Mol Biol** 1997 Aug 1;270(5):688-95

Upregulation of F-actin and alpha-actinin in reactive astrocytes. Abd-El-Basset EM, et al. **J Neurosci Res** 1997 Sep 1;49(5):608-16

Correspondence re: Duncan LM, Bouffard D, Howard C, Mihm MC Jr, Byers HR: In situ distribution of integrin alpha 2 beta 1 and alpha-actinin in melanocytic proliferation. Mod Pathol 9:938, 1996 [letter] Cramer SF. **Mod Pathol** 1996 Dec;9(12):1178-9

In situ distribution of integrin alpha 2 beta 1 and alpha-actinin in melanocytic proliferations. Duncan LM, et al. **Mod Pathol** 1996 Sep;9(9):938-43

ULTRASTRUCTURE

Flexibility and fine structure of smooth-muscle alpha-actinin. Winkler J, et al. **Eur J Biochem** 1997 Aug 15;248(1):193-9

ACTINOBACILLUS

CLASSIFICATION

Characterisation of Australian isolates of Actinobacillus capsulatus, Actinobacillus equuli, Pasteurella caballi and Bisgaard Taxa 9 and 11. Blackall PJ, et al. **Aust Vet J** 1997 Jan;75(1):52-5

Actinobacillus minor sp. nov., Actinobacillus porcinus sp. nov., and Actinobacillus indolicus sp. nov., three new V factor-dependent species from the respiratory tract of pigs. Møller K, et al. **Int J Syst Bacteriol** 1996 Oct;46(4):951-6

Biochemical and antigenic relationships between porcine and equine isolates of Actinobacillus suis. Bada R, et al. **Vet Microbiol** 1996 Aug;51(3-4):393-6

ENZYMOLOGY

The gnd gene encoding a novel 6-phosphogluconate dehydrogenase and its adjacent region of Actinobacillus actinomycetemcomitans chromosomal DNA. Yoshida Y, et al. **Biochem Biophys Res Commun** 1997 Jan 3; 230(1):220-5

GENETICS

The gnd gene encoding a novel 6-phosphogluconate dehydrogenase and its adjacent region of Actinobacillus actinomycetemcomitans chromosomal DNA. Yoshida Y, et al. **Biochem Biophys Res Commun** 1997 Jan 3; 230(1):220-5

[Whipple's disease: molecular biology--clinical aspects--therapy] Blum HE. **Schweiz Rundsch Med Prax** 1997 Jul 16;86(29-30):1143-6 (13 ref.) (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Actinobacillus suis strains isolated from healthy and diseased swine are clonal and carry apxICABDvar. suis and apxIICAvar. suis toxin genes. Van Ostaaijen J, et al. **J Clin Microbiol** 1997 May;35(5):1131-7

Actinobacillus suis-like organisms associated with septicemia in neonatal calves. DeBey BM, et al. **J Vet Diagn Invest** 1996 Apr;8(2):248-50

An outbreak of Actinobacillus suis septicemia in grow/finish pigs. Yaeger MJ. **J Vet Diagn Invest** 1996 Jul;8(3):381-3

Actinobacillus lignieresi infection in camels on the Sokoto plains, Nigeria. Daneji AI, et al. **Trop Anim Health Prod** 1996 Nov;28(4):315-6

METABOLISM

Environmental and physiological factors affecting the succinate product ratio during carbohydrate fermentation by Actinobacillus sp. 130Z. Van der Werf MJ, et al. **Arch Microbiol** 1997 Jun;167(6):332-42

Serological and biochemical properties of the major outer membrane protein within strains of the genus Actinobacillus. Hartmann L, et al. **Zentralbl Bakteriol** 1996 Jul;284(2-3):255-62

PHYSIOLOGY

Synergistic effects of Actinobacillus suis cells in combination with 5-fluorouracil on mice bearing murine L1210 leukemia cells. Watanabe T, et al. **Cancer Immunol Immunother** 1997 Jun;44(4):216-20

ACTINOBACILLUS ACTINOMYCETEMCOMITANS

Oral ciprofloxacin therapy for prosthetic valve endocarditis due to Actinobacillus actinomycetemcomitans. Babinchak TJ. **Clin Infect Dis** 1995 Dec;21(6):1517-8

Coexistence of pseudogout and arthritis due to Actinobacillus actinomycetemcomitans. Cuende E, et al. **Clin Infect Dis** 1996 Sep;23(3):657-8

Role of CD14 molecules in internalization of Actinobacillus actinomycetemcomitans by macrophages and subsequent induction of apoptosis. Muro M, et al. **Infect Immun** 1997 Apr;65(4):1147-51

HACEK group endocarditis at the Riyadh Armed Forces Hospital. el Khizzi N, et al. **J Infect** 1997 Jan;34(1):69-74

CHEMISTRY

Characterization of Actinobacillus actinomycetemcomitans hemolysin. Kimizuka R, et al. **Microbiol Immunol** 1996; 40(10):717-23

CLASSIFICATION

Rapid identification of Actinobacillus actinomycetemcomitans, Haemophilus aphrophilus, and Haemophilus paraphrophilus by restriction enzyme analysis of PCR-amplified 16S rRNA genes. Riggio MP, et al. **J Clin Microbiol** 1997 Jun;35(6):1630-2

DRUG EFFECTS

Mobile rRNA methylase genes coding for erythromycin resistance in Actinobacillus actinomycetemcomitans. Roe DE, et al. **J Antimicrob Chemother** 1996 Mar;37(3):457-64

Sensitivity of periodontal pathogens to the bactericidal activity of synthetic protegrins, antibiotic peptides derived from porcine leukocytes. Miyasaki KT, et al. **J Dent Res** 1997 Aug;76(8):1453-9

Susceptibilities of Actinobacillus actinomycetemcomitans biofilms to oral antiseptics. Thrower Y, et al. **J Med Microbiol** 1997 May;46(5):425-9

Clinical and microbiological effects of subgingival antimicrobial irrigation with citric acid as evaluated by an enzyme immunoassay and culture analysis. Renvert S, et al. **J Periodontol** 1997 Apr;68(4):346-52

GENETICS

PCR primers for the amplification of the 16S rRNA gene of oral bacteria and for the specific identification of Actinobacillus actinomycetemcomitans. Albandar JM, et al. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 1)):144-7

Novel FNR homologues identified in four representative oral facultative anaerobes: Capnocytophaga ochracea, Capnocytophaga sputigena, Haemophilus aphrophilus, and Actinobacillus actinomycetemcomitans. Hattori T, et al. **FEMS Microbiol Lett** 1996 Apr 1;137(2-3):213-20

Isolation and characterization of hemolytic genes from Actinobacillus actinomycetemcomitans. Kato T, et al. **FEMS Microbiol Lett** 1996 Oct 1;143(2-3):217-21

Cloning and characterization of the Actinobacillus actinomycetemcomitans gene encoding a heat-shock protein 90 homologue. Winston JL, et al. **Gene** 1996 Nov 14;179(2):199-204

Antigenic diversity in the periodontopathogen, Actinobacillus actinomycetemcomitans. Ebersole JL, et al. **Immunol Invest** 1996 May;25(3):203-14

Mobile rRNA methylase genes coding for erythromycin resistance in Actinobacillus actinomycetemcomitans. Roe DE, et al. **J Antimicrob Chemother** 1996 Mar;37(3):457-64

Highly toxic clone of Actinobacillus actinomycetemcomitans in geographically widespread cases of juvenile periodontitis in adolescents of African origin. Haubek D, et al. **J Clin Microbiol** 1996 Jun;34(6):1576-8

Multiplex PCR using conserved and species-specific 16S rRNA gene primers for simultaneous detection of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Tran SD, et al. **J Clin Microbiol** 1996 Nov;34(11):2674-8

Molecular analysis of a new insertion sequence from Actinobacillus (Haemophilus) actinomycetemcomitans FDC Y4. Hayashida H, et al. **Microbiology** 1996 Sep;142 (Pt 9):2449-52

Structural and segregational stability of various replicons in Actinobacillus actinomycetemcomitans. Galli DM, et al. **Plasmid** 1996 Jul;36(1):42-8

GROWTH & DEVELOPMENT

The bactericidal effects of dental ultrasound on Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. An in vitro investigation. O'Leary R, et al. **J Clin Periodontol** 1997 Jun;24(6):432-9

IMMUNOLOGY

Specific antibody reactivity against a 110-kilodalton Actinobacillus actinomycetemcomitans protein in subjects with periodontitis. Fleming TF, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):678-81

Studies of proliferative responses by long-term-cryopreserved peripheral blood mononuclear cells to bacterial components associated with periodontitis. Miller GA, et al. **Clin Diagn Lab Immunol** 1996 Nov; 3(6):710-6

Structures of the antigenic O-polysaccharides of lipopolysaccharides produced by Actinobacillus actinomycetemcomitans serotypes a, c, d and e. Perry MB, et al. **Eur J Biochem** 1996 Dec 15;242(3):682-8

Antigenic diversity in the periodontopathogen, Actinobacillus actinomycetemcomitans. Ebersole JL, et al. **Immunol Invest** 1996 May;25(3):203-14

Immunoglobulin allotypes and immunoglobulin G subclass responses to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in early-onset periodontitis. Choi JI, et al. **Infect Immun** 1996 Oct;64(10):4226-30

Heterogeneity of antibodies reactive with the dominant antigen of Actinobacillus actinomycetemcomitans. Nakashima K, et al. **Infect Immun** 1997 Sep;65(9):3794-8

Extracellular 37-kDa antigenic protein from Actinobacillus actinomycetemcomitans induces TNF-alpha, IL-1 beta, and IL-6 in murine macrophages. Tani Y, et al. **J Dent Res** 1997 Sep;76(9):1538-47

Role of alpha beta T cells and gamma delta T cells in protective immunity to Actinobacillus actinomycetemcomitans in mutant mice by targeted gene disruption. Takahashi I, et al. **J Periodontal Res** 1996 Nov; 31(8):589-95

Immunomodulatory and superantigen activities of bacteria associated with adult periodontitis. Getka TP, et al. **J Periodontol** 1996 Sep;67(9):909-17

ISOLATION & PURIFICATION

PCR primers for the amplification of the 16S rRNA gene of oral bacteria and for the specific identification of Actinobacillus actinomycetemcomitans. Albandar JM, et al. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 1)):144-7

Potential diagnostic value of sampling oral mucosal surfaces for Actinobacillus actinomycetemcomitans in young adults. Eger T, et al. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 1)):112-7

Localized juvenile periodontitis and Actinobacillus actinomycetemcomitans in a Brazilian population. Tinoco EM, et al. **Eur J Oral Sci** 1997 Feb;105(1):9-14

Multiplex PCR using conserved and species-specific 16S rRNA gene primers for simultaneous detection of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Tran SD, et al. **J Clin Microbiol** 1996 Nov;34(11):2674-8

Colonization by Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis and Prevotella intermedia in adult periodontitis patients as detected by the antibody-based Evalusite Test. Boyer BP, et al. **J Clin Periodontol** 1996 May;23(5):477-84

The detection of Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis and Prevotella intermedia using an ELISA in an adolescent population with early

periodontitis. Clerehugh V, et al. **J Clin Periodontol** 1997 Jan;24(1):57–64

Prevalence of suspected periodontal pathogens identified using ELISA in adolescents of differing ethnic origins. Ellwood R, et al. **J Clin Periodontol** 1997 Mar;24(3):141–5

Detection of Eikenella corrodens and Actinobacillus actinomycetemcomitans by use of the polymerase chain reaction (PCR) in vitro and in subgingival plaque. Furcht C, et al. **J Clin Periodontol** 1996 Oct;23(10):891–7

Occurrence of Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis and Prevotella intermedia in juvenile periodontitis. López NJ, et al. **J Clin Periodontol** 1996 Feb;23(2):101–5

Occurrence of Actinobacillus actinomycetemcomitans in patients wearing orthodontic appliances. A cross-sectional study. Paolantonio M, et al. **J Clin Periodontol** 1996 Feb; 23(2):112–8

A longitudinal study of Actinobacillus actinomycetemcomitans in army recruits [published erratum appears in J Periodontal Res 1997 May;32(4):408] Müller HP, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 1):69–78

Natural distribution of oral Actinobacillus actinomycetemcomitans in young men with minimal periodontal disease. Müller HP, et al. **J Periodontal Res** 1996 Aug;31(6):373–80

Comparison of polymerase chain reaction and culture methods for detection of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in subgingival plaque samples. Riggio MP, et al. **J Periodontal Res** 1996 Oct;31(7):496–501

Frequency of detection of Actinobacillus actinomycetemcomitans in young patients during fixed orthodontic therapy. Piccolomini R, et al. **New Microbiol** 1996 Oct;19(4):345–9

[Evaluation of non radioactive DNA probe (Affirm DP) for detecting periodontopathic bacteria] Yano K, et al. **Kokubyo Gakkai Zasshi** 1996 Sep;63(3):482–8 (Eng. Abstr.) **(Jpn)**

METABOLISM

Interaction of the salivary low-molecular-weight mucin (MG2) with Actinobacillus actinomycetemcomitans. Groenink J, et al. **Antonie Van Leeuwenhoek** 1996 Jul; 70(1):79–87

Lipopolysaccharides from Porphyromonas gingivalis, Prevotella intermedia and Actinobacillus actinomycetemcomitans promote osteoclastic differentiation in vitro. Ito HO, et al. **Arch Oral Biol** 1996 May;41(5):439–44

Interaction between Actinobacillus actinomycetemcomitans lipopolysaccharides and human hemoglobin. Grenier D, et al. **FEMS Microbiol Lett** 1997 Jun 1;151(1):77–81

The regulatory effect of fermentable sugar levels on the production of leukotoxin by Actinobacillus actinomycetemcomitans. Mizoguchi K, et al. **FEMS Microbiol Lett** 1997 Jan 1;146(1):161–6

Interactions between periodontopathogenic bacteria and cytokines. Fletcher J, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):200–5

The relationships between leukotoxin production, growth rate and the bicarbonate concentration in a toxin-production-variable strain of Actinobacillus actinomycetemcomitans. Ohta H, et al. **Microbiology** 1996 Apr;142 (Pt 4):963–70

PATHOGENICITY

Isolation and characterization of hemolytic genes from Actinobacillus actinomycetemcomitans. Kato T, et al. **FEMS Microbiol Lett** 1996 Oct 1;143(2–3):217–21

Highly toxic clone of Actinobacillus actinomycetemcomitans in geographically widespread cases of juvenile periodontitis in adolescents of African origin. Haubek D, et al. **J Clin Microbiol** 1996 Jun;34(6):1576–8

Chymotrypsin-like enzyme secretion is stimulated in cultured epithelial cells during proliferation and in response to Actinobacillus actinomycetemcomitans. Firth JD, et al. **J Periodontal Res** 1996 Jul;31(5):345–54

Strong cytotoxicity to human gingival fibroblasts by Porphyromonas gingivalis ATCC 33277. Johansson A, et al. **J Periodontal Res** 1996 Oct;31(7):477–82

Gingival fibroblast cytokine profiles in Actinobacillus actinomycetemcomitans-associated periodontitis. Dongari-Bagtzoglou AI, et al. **J Periodontol** 1996 Sep; 67(9):871–8

The role of Actinobacillus actinomycetemcomitans in the pathogenesis of periodontal disease. Meyer DH, et al. **Trends Microbiol** 1997 Jun;5(6):224–8 (51 ref.)

PHYSIOLOGY

Can one acquire periodontal bacteria and periodontitis from a family member? Asikainen S, et al. **J Am Dent Assoc** 1997 Sep;128(9):1263–71 (37 ref.)

The survival rate of Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, and Bacteroides forsythus following 4 randomized treatment modalities. Shiloah J, et al. **J Periodontol** 1997 Aug;68(8):720–8

RADIATION EFFECTS

Bactericidal effect of erbium YAG laser on periodontopathic bacteria. Ando Y, et al. **Lasers Surg Med** 1996; 19(2):190–200

VIROLOGY

Presence of bacteriophage Aa phi 23 correlates with the population genetic structure of Actinobacillus actinomycetemcomitans. Haubek D, et al. **Eur J Oral Sci** 1997 Feb;105(1):2–8

ACTINOBACILLUS INFECTIONS

Coexistence of pseudogout and arthritis due to Actinobacillus actinomycetemcomitans. Cuende E, et al. **Clin Infect Dis** 1996 Sep;23(3):657–8

HACEK group endocarditis at the Riyadh Armed Forces Hospital. el Khizzi N, et al. **J Infect** 1997 Jan;34(1):69–74

DIAGNOSIS

Serological characterization of Actinobacillus pleuropneumoniae biotype 1 strains antigenically related to both serotypes 2 and 7. Nielsen R, et al. **Acta Vet Scand** 1996;37(3):327–36

DRUG THERAPY

Oral ciprofloxacin therapy for prosthetic valve endocarditis due to Actinobacillus actinomycetemcomitans. Babinchak TJ. **Clin Infect Dis** 1995 Dec;21(6):1517–8

ETIOLOGY

Frequency of detection of Actinobacillus actinomycetemcomitans in young patients during fixed orthodontic therapy. Piccolomini R, et al. **New Microbiol** 1996 Oct;19(4):345–9

IMMUNOLOGY

Evaluation of protective efficacy of an Actinobacillus pleuropneumoniae serotype 1 lipopolysaccharide-protein conjugate in mice. Rioux S, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):63–74

Role of CD14 molecules in internalization of Actinobacillus actinomycetemcomitans by macrophages and subsequent induction of apoptosis. Muro M, et al. **Infect Immun** 1997 Apr;65(4):1147–51

MICROBIOLOGY

A riboflavin auxotroph of Actinobacillus pleuropneumoniae is attenuated in swine. Fuller TE, et al. **Infect Immun** 1996 Nov;64(11):4659–64

Actinobacillus suis strains isolated from healthy and diseased swine are clonal and carry apxICABDvar. suis and apxIICAvar. suis toxin genes. Van Ostaaijen J, et al. **J Clin Microbiol** 1997 May;35(5):1131–7

The role of Actinobacillus actinomycetemcomitans in the pathogenesis of periodontal disease. Meyer DH, et al. **Trends Microbiol** 1997 Jun;5(6):224–8 (51 ref.)

PATHOLOGY

Immunohistological evaluation on respiratory lesions of pigs intranasally inoculated with Actinobacillus pleuropneumoniae serotype 1. Ajito T, et al. **J Vet Med Sci** 1996 Apr;58(4):297–303

Characterization of polymorphic mononuclear cell in porcine Actinobacillus pleuropneumonia. Chen SD. **Proc Natl Sci Counc Repub China B** 1997 Jan;21(1):1–7

PREVENTION & CONTROL

Evaluation of protective efficacy of an Actinobacillus pleuropneumoniae serotype 1 lipopolysaccharide-protein conjugate in mice. Rioux S, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):63–74

Antibody- and cell-mediated immune responses of Actinobacillus pleuropneumoniae-infected and bacterin-vaccinated pigs. Furesz SE, et al. **Infect Immun** 1997 Feb;65(2):358–65

TRANSMISSION

Actinobacillus suis infection after a pig bite [letter] [see comments] Escande F, et al. **Lancet** 1996 Sep 28; 348(9031):888. Comment in: Lancet 1996 Nov 2;348(9036):1246.

VETERINARY

Airborne transmission of Actinobacillus pleuropneumoniae and porcine reproductive and respiratory syndrome virus in nursery pigs. Torremorell M, et al. **Am J Vet Res** 1997 Aug;58(8):828–32

Serodiagnosis of swine pleuropneumonia due to Actinobacillus pleuropneumoniae serotypes 7 and 4 using long-chain lipopolysaccharides. Gottschalk M, et al. **Can J Vet Res** 1997 Jan;61(1):62–5

Detection of antibodies against Actinobacillus pleuropneumoniae serotype 5 using an inhibition enzyme immunoassay. Stenbaek EI, et al. **Can J Vet Res** 1997 Jan; 61(1):1–7

Antibody- and cell-mediated immune responses of Actinobacillus pleuropneumoniae-infected and bacterin-vaccinated pigs. Furesz SE, et al. **Infect Immun** 1997 Feb;65(2):358–65

Actinobacillus suis-like organisms associated with septicemia in neonatal calves. DeBey BM, et al. **J Vet Diagn Invest** 1996 Apr;8(2):248–50

Serotyping Actinobacillus pleuropneumoniae by the use of monoclonal antibodies. Lacouture S, et al. **J Vet Diagn Invest** 1997 Jul;9(3):337–41

An outbreak of Actinobacillus suis septicemia in grow/finish pigs. Yaeger MJ. **J Vet Diagn Invest** 1996 Jul;8(3):381–3

Protective efficacy of an affinity-purified hemolysin vaccine against experimental swine pleuropneumonia. Haga Y, et al. **J Vet Med Sci** 1997 Feb;59(2):115–20

A field trial of oil adjuvanten trivalent Actinobacillus pleuropneumoniae vaccine. Oishi E, et al. **J Vet Med Sci** 1997 May;59(5):421–3

Virulence factors of the swine pathogen Actinobacillus pleuropneumoniae. Tascón RI, et al. **Microbiologia** 1996 Jun;12(2):171–84 (101 ref.)

Characterization of polymorphic mononuclear cell in porcine Actinobacillus pleuropneumonia. Chen SD. **Proc Natl Sci Counc Repub China B** 1997 Jan;21(1):1–7

Actinobacillus lignieresi infection in camels on the Sokoto plains, Nigeria. Daneji AI, et al. **Trop Anim Health Prod** 1996 Nov;28(4):315–6

Biochemical and antigenic relationships between porcine and equine isolates of Actinobacillus suis. Bada R, et al. **Vet Microbiol** 1996 Aug;51(3–4):393–6

Evaluation of a PCR for detection of Actinobacillus pleuropneumoniae in mixed bacterial cultures from tonsils. Gram T, et al. **Vet Microbiol** 1996 Jul;51(1–2):95–104

Cross-protection between Actinobacillus pleuropneumoniae biotypes-serotypes in pigs. Haesebrouk F, et al. **Vet Microbiol** 1996 Oct;52(3–4):277–84

Serological characterization of Actinobacillus pleuropneumoniae biotype 2 strains isolated from pigs in two Danish herds. Nielsen R, et al. **Vet Microbiol** 1997 Jan;54(1):35–46

Dual infections of PRRSV/influenza or PRRSV/Actinobacillus pleuropneumoniae in the respiratory tract. Pol JM, et al. **Vet Microbiol** 1997 Apr; 55(1–4):259–64

Implication of altered levels of plasma alpha(1)-acid glycoprotein and its derived sialic acid on plasma protein binding of trimethoprim in pigs in physiological and pathological states. Son DS, et al. **Vet Q** 1996 Mar; 18(1):10–3

Otitis in a weaned pig: a new pathological role for Actinobacillus (Haemophilus) pleuropneumoniae. Duff JP, et al. **Vet Rec** 1996 Dec 7;139(23):561–3

Antibodies against 12 serotypes of Actinobacillus pleuropneumoniae in finnish slaughter sows. Levonen K, et al. **Zentralbl Veterinarmed [B]** 1996 Oct;43(8):489–95

ACTINOBACILLUS PLEUROPNEUMONIAE

Airborne transmission of Actinobacillus pleuropneumoniae and porcine reproductive and respiratory syndrome virus in nursery pigs. Torremorell M, et al. **Am J Vet Res** 1997 Aug;58(8):828–32

Serodiagnosis of swine pleuropneumonia due to Actinobacillus pleuropneumoniae serotypes 7 and 4 using long-chain lipopolysaccharides. Gottschalk M, et al. **Can J Vet Res** 1997 Jan;61(1):62–5

Channel-forming activity and channel size of the RTX toxins ApxI, ApxII, and ApxIII of Actinobacillus pleuropneumoniae. Maier E, et al. **Infect Immun** 1996 Nov; 64(11):4415–23

Immunohistopathological characterization of pig pneumonia caused by a combined Aujeszky's disease virus and Actinobacillus pleuropneumoniae infection. Narita M, et al. **J Comp Pathol** 1997 Jul;117(1):25–33

Immunohistological evaluation on respiratory lesions of pigs intranasally inoculated with Actinobacillus pleuropneumoniae serotype 1. Ajito T, et al. **J Vet Med Sci** 1996 Apr;58(4):297–303

A field trial of oil adjuvanten trivalent Actinobacillus pleuropneumoniae vaccine. Oishi E, et al. **J Vet Med Sci** 1997 May;59(5):421–3

Characterization of polymorphic mononuclear cell in porcine Actinobacillus pleuropneumonia. Chen SD. **Proc Natl Sci Counc Repub China B** 1997 Jan;21(1):1–7

CHEMISTRY

Identification of two core types in lipopolysaccharides of Actinobacillus pleuropneumoniae representing serotypes 1 to 12. Jacques M, et al. **Can J Microbiol** 1996 Aug; 42(8):855–8

Evaluation of protective efficacy of an Actinobacillus pleuropneumoniae serotype 1 lipopolysaccharide-protein conjugate in mice. Rioux S, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):63–74

Characterization of a large transferrin-binding protein from Actinobacillus pleuropneumoniae serotype 7. Wilke M, et al. **Zentralbl Veterinarmed [B]** 1997 Apr;44(2):73–86

CLASSIFICATION

Serological characterization of Actinobacillus pleuropneumoniae biotype 1 strains antigenically related to both serotypes 2 and 7. Nielsen R, et al. **Acta Vet Scand** 1996;37(3):327–36

Identification of two core types in lipopolysaccharides of

Actinobacillus pleuropneumoniae representing serotypes 1 to 12. Jacques M, et al. **Can J Microbiol** 1996 Aug; 42(8):855–8

Serotyping of Actinobacillus pleuropneumoniae serotype 5 strains using a monoclonal-based polystyrene agglutination test. Dubreuil JD, et al. **Can J Vet Res** 1996 Jan;60(1):69–71

Characterization of monoclonal antibodies that recognize common epitopes located on O antigen of lipopolysaccharide of serotypes 1, 9 and 11 of Actinobacillus pleuropneumoniae. Rodríguez Barbosa JI, et al. **FEMS Immunol Med Microbiol** 1996 Dec 31; 16(3–4):173–81

Serotyping Actinobacillus pleuropneumoniae by the use of monoclonal antibodies. Lacouture S, et al. **J Vet Diagn Invest** 1997 Jul;9(3):337–41

Conservation and antigenic cross-reactivity of the transferrin-binding proteins of Haemophilus influenzae, Actinobacillus pleuropneumoniae and Neisseria meningitidis. Holland J, et al. **Microbiology** 1996 Dec;142 (Pt 12):3505–13

Serological characterization of Actinobacillus pleuropneumoniae biotype 2 strains isolated from pigs in two Danish herds. Nielsen R, et al. **Vet Microbiol** 1997 Jan;54(1):35–46

Detection of an Actinobacillus pleuropneumoniae serotype 2 lipopolysaccharide (LPS) variant. Stenbaek EI, et al. **Vet Microbiol** 1996 Oct;52(3–4):285–92

DRUG EFFECTS

Comparative in vitro activity of doxycycline and oxytetracycline against porcine respiratory pathogens. Bousquet E, et al. **Vet Rec** 1997 Jul 12;141(2):37–40

ENZYMOLOGY

Expression and phylogenetic relationships of a novel lacZ homologue from Actinobacillus pleuropneumoniae. Anderson TJ, et al. **FEMS Microbiol Lett** 1997 Jul 1; 152(1):117–23

GENETICS

Identification of a locus involved in the utilization of iron by Actinobacillus pleuropneumoniae. Chin N, et al. **FEMS Microbiol Lett** 1996 Sep 15;143(1):1–6

Cloning and characterization of the groE locus from Actinobacillus pleuropneumoniae. Vézina G, et al. **FEMS Microbiol Lett** 1997 Feb 1;147(1):11–6

Cloning and molecular characterization of Cu,Zn superoxide dismutase from Actinobacillus pleuropneumoniae. Langford PR, et al. **Infect Immun** 1996 Dec;64(12):5035–41

Identification and characterization of a DNA region involved in the export of capsular polysaccharide by Actinobacillus pleuropneumoniae serotype 5a. Ward CK, et al. **Infect Immun** 1997 Jun;65(6):2491–6

Genetic diversity of the genes encoding the outer membrane lipoprotein (omlA) of Actinobacillus pleuropneumoniae. Osaki M, et al. **J Vet Med Sci** 1997 Mar;59(3):213–5

[Typing of the apx toxin gene of Actinobacillus pleuropneumoniae using PCR] Frey J, et al. **Schweiz Arch Tierheilkd** 1996;138(3):121–4 (Eng. Abstr.) **(Ger)**

GROWTH & DEVELOPMENT

Growth of Actinobacillus pleuropneumoniae is promoted by exogenous hydroxamate and catechol siderophores. Diarra MS, et al. **Appl Environ Microbiol** 1996 Mar;62(3):853–9

IMMUNOLOGY

Detection of antibodies against Actinobacillus pleuropneumoniae serotype 5 using an inhibition enzyme immunoassay. Stenbaek EI, et al. **Can J Vet Res** 1997 Jan; 61(1):1–7

Activity of antibodies against Salmonella dublin, Toxoplasma gondii, or Actinobacillus pleuropneumoniae in sera after treatment with electron beam irradiation or binary ethylenimine. Kyvsgaard NC, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):628–34

Evaluation of protective efficacy of an Actinobacillus pleuropneumoniae serotype 1 lipopolysaccharide-protein conjugate in mice. Rioux S, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):63–74

Temperature-sensitive mutants of Actinobacillus pleuropneumoniae induce protection in mice. Byrd W, et al. **Infect Immun** 1997 Jun;65(6):2206–10

Antibody- and cell-mediated immune responses of Actinobacillus pleuropneumoniae-infected and bacterin-vaccinated pigs. Furesz SE, et al. **Infect Immun** 1997 Feb;65(2):358–65

Protective efficacy of an affinity-purified hemolysin vaccine against experimental swine pleuropneumonia. Haga Y, et al. **J Vet Med Sci** 1997 Feb;59(2):115–20

Antibody response to Actinobacillus pleuropneumoniae antigens after vaccination of pigs bred for high and low immune response. Magnusson U, et al. **Vaccine** 1997 Jun; 15(9):997–1000

Cross-protection between Actinobacillus pleuropneumoniae biotypes-serotypes in pigs. Haesebrouk F, et al. **Vet Microbiol** 1996 Oct;52(3–4):277–84

Antibodies against 12 serotypes of Actinobacillus pleuropneumoniae in finnish slaughter sows. Levonen K, et al. **Zentralbl Veterinarmed [B]** 1996 Oct;43(8):489–95

ISOLATION & PURIFICATION

Evaluation of a PCR for detection of Actinobacillus pleuropneumoniae in mixed bacterial cultures from tonsils. Gram T, et al. **Vet Microbiol** 1996 Jul;51(1–2):95–104

Otitis in a weaned pig: a new pathological role for Actinobacillus (Haemophilus) pleuropneumoniae. Duff JP, et al. **Vet Rec** 1996 Dec 7;139(23):561–3

METABOLISM

Identification of a locus involved in the utilization of iron by Actinobacillus pleuropneumoniae. Chin N, et al. **FEMS Microbiol Lett** 1996 Sep 15;143(1):1–6

Examination of surface polysaccharides of Actinobacillus pleuropneumoniae serotype 1 grown under iron-restricted conditions. Paradis SE, et al. **FEMS Microbiol Lett** 1996 Apr 1;137(2–3):201–6

HlyX, the FNR homologue of Actinobacillus pleuropneumoniae, is a [4Fe-4S]-containing oxygen-responsive transcription regulator that anaerobically activates FNR-dependent class I promoters via an enhanced AR1 contact. Green J, et al. **Mol Microbiol** 1997 May;24(3):593–605

Comment on the MicroReview by B. Craig Lee (Quelling the red menace: haem capture by bacteria) [letter; comment] Jacques M. **Mol Microbiol** 1996 Apr;20(1):238 . Comment on: Mol Microbiol 1995 Nov;18(3):383–90.

PATHOGENICITY

A riboflavin auxotroph of Actinobacillus pleuropneumoniae is attenuated in swine. Fuller TE, et al. **Infect Immun** 1996 Nov;64(11):4659–64

Virulence factors of the swine pathogen Actinobacillus pleuropneumoniae. Tascón RI, et al. **Microbiologia** 1996 Jun;12(2):171–84 (101 ref.)

ACTINOBACTERIA GROUP

CLASSIFICATION

The species composition of oligotrophic bacterial communities of Lake Balaton--a numerical analysis. Tóth E. **Acta Microbiol Immunol Hung** 1996;43(4):333–8

ACTINOIDS see **METALS, ACTINOID**

ACTINOMYCES

CHEMISTRY

Purification and further characterization of a haemolysin of Actinomyces pyogenes. Ding H, et al. **Zentralbl Veterinarmed [B]** 1996 May;43(3):179–88

CLASSIFICATION

Actinomyces europaeus sp. nov., isolated from human clinical specimens. Funke G, et al. **Int J Syst Bacteriol** 1997 Jul; 47(3):687–92

Characterization of some Actinomyces-like isolates from human clinical specimens: reclassification of Actinomyces suis (Soltys and Spratling) as Actinobaculum suis comb. nov. and description of Actinobaculum schaalii sp. nov. Lawson PA, et al. **Int J Syst Bacteriol** 1997 Jul; 47(3):899–903

Actinomyces graevenitzii sp. nov., isolated from human clinical specimens. Ramos CP, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):885–8

A new genus of the order Actinomycetales, Spirilliplanes gen. nov., with description of Spirilliplanes yamanashiensis sp. nov [published erratum appears in Int J Syst Bacteriol 1997 Jul;47(3):920] Tamura T, et al. **Int J Syst Bacteriol** 1997 Jan;47(1):97–102

DRUG EFFECTS

Effect of chlorhexidine varnish on Actinomyces naeslundii genospecies in plaque from dental fissures. Schaeken MJ, et al. **Caries Res** 1996;30(1):40–4

ENZYMOLOGY

Biochemical studies on LevJ, a fructanase from Actinomyces naeslundii T14V. Norman JM, et al. **Arch Oral Biol** 1996 Jun;41(6):565–70

A general approach for cloning and characterizing dNDP-glucose dehydratase genes from actinomycetes. Decker H, et al. **FEMS Microbiol Lett** 1996 Aug 1; 141(2–3):195–201

Protein degradation by Prevotella intermedia and Actinomyces meyeri supports the growth of non-protein-cleaving oral bacteria in serum. Jansen HJ, et al. **J Clin Periodontol** 1997 May;24(5):346–53

GENETICS

A general approach for cloning and characterizing dNDP-glucose dehydratase genes from actinomycetes. Decker H, et al. **FEMS Microbiol Lett** 1996 Aug 1; 141(2–3):195–201

Transfection of Actinomyces spp. by genomic DNA of bacteriophages from human dental plaque. Yeung MK, et al. **Plasmid** 1997;37(2):141–53

IMMUNOLOGY

Recognition of immunoglobulin A1 by oral actinomyces and streptococcal lectins. Ruhl S, et al. **Infect Immun** 1996 Dec; 64(12):5421–4

ISOLATION & PURIFICATION

Intrauterine bacterial findings and hormonal profiles in post-partum cows with normal puerperium. Bekana M, et al. **Acta Vet Scand** 1996;37(3):251–63

Detection of Actinomyces species using nonradioactive riboprobes coupled with polymerase chain reaction. Kiyama M, et al. **Biochem Mol Med** 1996 Aug;58(2):151–5

Actinomycotic splenic abscesses presenting with arthritis. Quintero-Del-Rio AI, et al. **Clin Exp Rheumatol** 1997 Jul-Aug;15(4):445–8 (13 ref.)

The incidence and role of actinomyces in recurrent acute tonsillitis. Gaffney R, et al. **Clin Otolaryngol** 1993 Aug; 18(4):268–71

Actinomycosis, nocardiosis, and actinomycetoma. Warren NG. **Dermatol Clin** 1996 Jan;14(1):85–95 (30 ref.)

Characterization of monoclonal antibodies for rapid identification of Actinomyces naeslundii in clinical samples. Thurnheer T, et al. **FEMS Microbiol Lett** 1997 May 15; 150(2):255–62

Actinomyces infection in porous polyethylene orbital implant. Karcioglu ZA. **Graefes Arch Clin Exp Ophthalmol** 1997 Jul;235(7):448–51

Actinomyces europaeus sp. nov., isolated from human clinical specimens. Funke G, et al. **Int J Syst Bacteriol** 1997 Jul; 47(3):687–92

Actinomyces graevenitzii sp. nov., isolated from human clinical specimens. Ramos CP, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):885–8

Spinal abscess. Louvel JP, et al. **J Belge Radiol** 1996 Dec; 79(6):271

Rapid identification of clinically significant species and taxa of aerobic actinomycetes, including Actinomadura, Gordona, Nocardia, Rhodococcus, Streptomyces, and Tsukamurella isolates, by DNA amplification and restriction endonuclease analysis. Steingrube VA, et al. **J Clin Microbiol** 1997 Apr;35(4):817–22

Colitis and lower abdominal mass by Actinomyces israelii in a patient with an IUD. Nugteren SK, et al. **Neth J Med** 1996 Aug;49(2):73–6

A rare case of disseminated actinomycosis caused by Actinomyces meyeri. van Mook WN, et al. **Neth J Med** 1997 Jul;51(1):39–45

[Primary laryngeal actinomycosis] Melgarejo Moreno PJ, et al. **Acta Otorrinolaringol Esp** 1997 Apr;48(3):237–8 (Eng. Abstr.) **(Spa)**

[Mandibular actinomycosis caused by Actinomyces odontolyticus (letter)] Gené A, et al. **Enferm Infecc Microbiol Clin** 1997 Jan;15(1):51–2 **(Spa)**

METABOLISM

UCE6, a new antitumor antibiotic with topoisomerase I-mediated DNA cleavage activity produced by actinomycetes: producing organism, fermentation, isolation and biological activity. Fujii N, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):490–5

Influence of ionic strength and substratum hydrophobicity on the co-adhesion of oral microbial pairs. Bos R, et al. **Microbiology** 1996 Sep;142 (Pt 9):2355–61

Identification of a 95 kDa putative adhesin from Actinomyces serovar WVA963 strain PK1259 that is distinct from type 2 fimbrial subunits. Klier CM, et al. **Microbiology** 1997 Mar; 143 (Pt 3):835–46

Identification and partial characterization of an Actinomyces pyogenes hemolysin. Funk PG, et al. **Vet Microbiol** 1996 May;50(1–2):129–42

Further characterization of alpha 2-macroglobulin binding properties of Actinomyces pyogenes. Ding H, et al. **Zentralbl Veterinarmed [B]** 1997 May;44(3):129–32

PHYSIOLOGY

Influence of temperature on the co-adhesion of oral microbial pairs in saliva. Bos R, et al. **Eur J Oral Sci** 1996 Aug;104(4 (Pt 1)):372–7

ULTRASTRUCTURE

Cell surface structures of Actinomyces israelii. Figdor D, et al. **Aust Dent J** 1997 Apr;42(2):125–8

VIROLOGY

Transfection of Actinomyces spp. by genomic DNA of bacteriophages from human dental plaque. Yeung MK, et al. **Plasmid** 1997;37(2):141–53

ACTINOMYCES INFECTIONS see **ACTINOMYCOSIS**

ACTINOMYCES VISCOSUS

Esophageal actinomycosis: a case report. Ng FH, et al. **Endoscopy** 1997 Feb;29(2):133

DRUG EFFECTS

[Antimicrobial properties of Flos Lonicerae against oral pathogens] Sun Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Apr;21(4):242–3

ACTINOMYCES VISCOSUS

inside backcover (Eng. Abstr.) **(Chi)**

GENETICS

Synthesis and function of Actinomyces naeslundii T14V type 1 fimbriae require the expression of additional fimbria-associated genes. Yeung MK, et al. **Infect Immun** 1997 Jul;65(7):2629-39

PHYSIOLOGY

Saliva mediated adherence, aggregation and prevalence in dental plaque of Streptococcus mutans, Streptococcus sanguis and Actinomyces spp, in young and elderly humans. Carlén A, et al. **Arch Oral Biol** 1996 Dec; 41(12):1133-40

Inhibition of a Porphyromonas gingivalis colonizing factor between Actinomyces viscosus ATCC 19246 by monoclonal antibodies against recombinant 40-kDa outer-membrane protein. Saito S, et al. **Gen Pharmacol** 1997 May;28(5):675-80

[Adherent mechanism of the mutans of Actinomyces viscosus T14V] Guan W, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Nov; 30(6):329-31, 383 (Eng. Abstr.) **(Chi)**

ACTINOMYCETACEAE

Arcanobacterium haemolyticum invasive infections, including meningitis in cancer patients [letter] Minárik T, et al. **J Infect** 1997 Jan;34(1):91

CHEMISTRY

The Arcanobacterium (Actinomyces) pyogenes hemolysin, pyolysin, is a novel member of the thiol-activated cytolysin family. Billington SJ, et al. **J Bacteriol** 1997 Oct; 179(19):6100-6

Fatty acid characterization of rapidly growing pathogenic aerobic actinomycetes as a means of identification. McNabb A, et al. **J Clin Microbiol** 1997 Jun;35(6):1361-8

CLASSIFICATION

Bogoriella caseilytica gen. nov., sp. nov., a new alkaliphilic actinomycete from a soda lake in Africa. Groth I, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):788-94

Phylogenetic analysis of the genus Actinomyces based on 16S rRNA gene sequences: description of Arcanobacterium phocae sp. nov., Arcanobacterium bernardiae comb. nov., and Arcanobacterium pyogenes comb. nov. Ramos CP, et al. **Int J Syst Bacteriol** 1997 Jan;47(1):46-53

Fatty acid characterization of rapidly growing pathogenic aerobic actinomycetes as a means of identification. McNabb A, et al. **J Clin Microbiol** 1997 Jun;35(6):1361-8

GENETICS

Phylogenetic analysis of the genus Actinomyces based on 16S rRNA gene sequences: description of Arcanobacterium phocae sp. nov., Arcanobacterium bernardiae comb. nov., and Arcanobacterium pyogenes comb. nov. Ramos CP, et al. **Int J Syst Bacteriol** 1997 Jan;47(1):46-53

ISOLATION & PURIFICATION

Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ramzan NN, et al. **Ann Intern Med** 1997 Apr 1;126(7):520-7

Cardiac Whipple disease: identification of Whipple bacillus by electron microscopy of a patient before death. Silvestry FE, et al. **Ann Intern Med** 1997 Feb 1;126(3):214-6

Prosthetic joint infection caused by Tropheryma whippelii (Whipple's bacillus). Frésard A, et al. **Clin Infect Dis** 1996 Mar;22(3):575-6

Diagnostic application of a polymerase chain reaction assay for the Whipple's disease bacterium to intestinal biopsies. von Herbay A, et al. **Gastroenterology** 1996 Jun; 110(6):1735-43

A study of the microflora of some recycled fibre pulps, boards and kitchen rolls. Suihko ML, et al. **J Appl Microbiol** 1997 Aug;83(2):199-207

[The isolation of Arcanobacterium haemolyticum from the pharyngeal exudate of children] Coman G, et al. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jul-Dec; 41(3-4):141-4 (Eng. Abstr.) **(Rum)**

METABOLISM

Production of free amino acids by some earthworm-borne microorganisms. Joy EK, et al. **Hindustan Antibiot Bull** 1995 Feb-Nov;37(1-4):16-24

PATHOGENICITY

The Arcanobacterium (Actinomyces) pyogenes hemolysin, pyolysin, is a novel member of the thiol-activated cytolysin family. Billington SJ, et al. **J Bacteriol** 1997 Oct; 179(19):6100-6

ACTINOMYCETALES

Cutaneous infection caused by Tsukamurella paurometabolum. Granel F, et al. **Clin Infect Dis** 1996 Oct; 23(4):839-40

Outbreak of dermatophilosis in a horse herd in israel. Yeruham I, et al. **Zentralbl Veterinarmed A** 1996 Sep; 43(7):393-8

[Tsukamurella infections. Review of the literature apropos of a case] Rey D, et al. **Pathol Biol (Paris)** 1997 Jan; 45(1):60-5 (27 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Screening of cell cycle inhibitors from microbial metabolites by a bioassay using a mouse cdc2 mutant cell line, tsFT210. Osada H, et al. **Bioorg Med Chem** 1997 Jan;5(1):193-203

Pyralomicins, novel antibiotics from Microtetraspora spiralis. IV. Absolute configuration. Kawamura N, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):147-9

CLASSIFICATION

Phylogeny and classification of bacteria in the genera Clavibacter and Rathayibacter on the basis of 16s rRNA gene sequence analyses. Lee IM, et al. **Appl Environ Microbiol** 1997 Jul;63(7):2631-6

Genetic analysis of Clavibacter toxicus, the agent of annual ryegrass toxicity. Johnston MS, et al. **Epidemiol Infect** 1996 Oct;117(2):393-400

Gordona hirsuta sp. nov. Klatte S, et al. **Int J Syst Bacteriol** 1996 Oct;46(4):876-80

Reassessment of the phylogenetic position of the bacterium associated with Whipple's disease and determination of the 16S-23S ribosomal intergenic spacer sequence. Maiwald M, et al. **Int J Syst Bacteriol** 1996 Oct;46(4):1078-82

Janibacter limosus gen. nov., sp. nov., a new actinomycete with meso-diaminopimelic acid in the cell wall. Martin K, et al. **Int J Syst Bacteriol** 1997 Apr;47(2):529-34

The genus Nocardiopsis represents a phylogenetically coherent taxon and a distinct actinomycete lineage: proposal of Nocardiopsaceae fam. nov. Rainey FA, et al. **Int J Syst Bacteriol** 1996 Oct;46(4):1088-92

Cryobacterium psychrophilum gen. nov., sp. nov., nom. rev., comb. nov., an obligately psychrophilic actinomycete to accommodate "Curtobacterium psychrophilum" Inoue and Komagata 1976. Suzuki K, et al. **Int J Syst Bacteriol** 1997 Apr;47(2):474-8

A proposal to transfer Microbispora bispora (Lechevalier 1965) to a new genus, Thermobispora gen. nov., as Thermobispora bispora comb. nov. Wang Y, et al. **Int J Syst Bacteriol** 1996 Oct;46(4):933-8

Tsukamurella tyrosinosolvens sp. nov. Yassin AF, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):607-14

Inter- and intraspecific genetic analysis of the genus Saccharomonospora with 16S to 23S ribosomal DNA (rDNA) and 23S to 5S rDNA internally transcribed spacer sequences. Yoon JH, et al. **Int J Syst Bacteriol** 1997 Jul; 47(3):661-9

An investigation of the intra-generic structure of Rothia by pyrolysis mass spectrometry. Sutcliffe IC, et al. **Zentralbl Bakteriol** 1997 Jan;285(2):204-11

Polyphasic taxonomic study of clinically significant actinomadurae including the description of Actinomadura latina sp.nov. Trujillo ME, et al. **Zentralbl Bakteriol** 1997 Jan;285(2):212-33

DRUG EFFECTS

Antimicrobial susceptibility patterns of some recently established coryneform bacteria. Funke G, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2874-8

ENZYMOLOGY

Transglycosylation by wild type and mutants of a beta-1,4-glycosidase from Cellulomonas fimi (Cex) for synthesis of oligosaccharides. Nikolova PV, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:19-25

Cloning, sequencing, and expression of a Thermomonospora fusca protease gene in Streptomyces lividans. Lao G, et al. **Appl Environ Microbiol** 1996 Nov;62(11):4256-9

Catalytic mechanism of the novel non-haem iron containing peroxidase produced by the thermophilic actinomycete Thermomonospora fusca BD25. Rob A, et al. **Biochem Soc Trans** 1997 Feb;25(1):64S

The detection and quantification of novel non-haem extracellular glycosylated peroxidases produced by the thermophilic actinomycete Thermomonospora fusca BD25 by means of PAGE-zymogram. Rob A, et al. **Biochem Soc Trans** 1997 Feb;25(1):37S

Redox reaction of the novel non-haem glycosylated peroxidases from thermophilic actinomycete Thermomonospora fusca BD25. Rob A, et al. **Biochem Soc Trans** 1996 Aug;24(3):455S

Production of extracellular lignocellulose degrading enzymes by Thermomonospora fusca BD25. Tuncer M, et al. **Biochem Soc Trans** 1996 Aug;24(3):378S

Optimisation of production of extracellular non-haem peroxidases by Thermomonospora fusca BD25 in aerobic bio-reactor conditions. Tuncer M, et al. **Biochem Soc Trans** 1997 Feb;25(1):65S

Structure of the N-terminal cellulose-binding domain of Cellulomonas fimi CenC determined by nuclear magnetic resonance spectroscopy. Johnson PE, et al. **Biochemistry** 1996 Nov 12;35(45):14381-94

Interaction of soluble cellooligosaccharides with the N-terminal cellulose-binding domain of Cellulomonas fimi CenC 2. NMR and ultraviolet absorption spectroscopy. Johnson PE, et al. **Biochemistry** 1996 Nov 5; 35(44):13895-906

Interaction of polysaccharides with the N-terminal cellulose-binding domain of Cellulomonas fimi CenC. 1. Binding specificity and calorimetric analysis. Tomme P, et al. **Biochemistry** 1996 Nov 5;35(44):13885-94

A unique enzyme from Saccharothrix sp. catalyzing D-amino acid transfer. Watanabe Y, et al. **Biochim Biophys Acta** 1997 Jan 4;1337(1):40-6

Tetrazolium-dye-linked alcohol dehydrogenase of the methylotrophic actinomycete Amycolatopsis methanolica is a three-component complex. Bystrykh LV, et al. **Eur J Biochem** 1997 Jul 1;247(1):280-7

Acarbose 7-phosphotransferase from Actinoplanes sp.: purification, properties, and possible physiological function. Drepper A, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):664-8

Conformational modeling of substrate binding to endocellulase E2 from Thermomonospora fusca. Taylor JS, et al. **Protein Eng** 1995 Nov;8(11):1145-52

GENETICS

Analysis of actinomycete communities by specific amplification of genes encoding 16S rRNA and gel-electrophoretic separation in denaturing gradients. Heuer H, et al. **Appl Environ Microbiol** 1997 Aug; 63(8):3233-41

Cloning, sequencing, and expression of a Thermomonospora fusca protease gene in Streptomyces lividans. Lao G, et al. **Appl Environ Microbiol** 1996 Nov;62(11):4256-9

Phylogeny and classification of bacteria in the genera Clavibacter and Rathayibacter on the basis of 16s rRNA gene sequence analyses. Lee IM, et al. **Appl Environ Microbiol** 1997 Jul;63(7):2631-6

Nested PCR for ultrasensitive detection of the potato ring rot bacterium, Clavibacter michiganensis subsp. sepedonicus. Lee IM, et al. **Appl Environ Microbiol** 1997 Jul;63(7):2625-30

Genetic diversity among Frankia strains nodulating members of the family Casuarinaceae in Australia revealed by PCR and restriction fragment length polymorphism analysis with crushed root nodules. Rouvier C, et al. **Appl Environ Microbiol** 1996 Mar;62(3):979-85

Genetic analysis of Clavibacter toxicus, the agent of annual ryegrass toxicity. Johnston MS, et al. **Epidemiol Infect** 1996 Oct;117(2):393-400

Cloning and expression of a beta-1,4-endoglucanase gene from Cellulomonas sp. CelB7 in Escherichia coli; purification and characterization of the recombinant enzyme. Fülöp L, et al. **FEMS Microbiol Lett** 1996 Dec 15;145(3):355-60

Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid. von Herbay A, et al. **Gastroenterology** 1997 Aug; 113(2):434-41

Whipple's disease: comparison of histology with diagnosis based on polymerase chain reaction in four consecutive cases. Müller C, et al. **Gut** 1997 Mar;40(3):425-7

Tsukamurella tyrosinosolvens sp. nov. Yassin AF, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):607-14

Inter- and intraspecific genetic analysis of the genus Saccharomonospora with 16S to 23S ribosomal DNA (rDNA) and 23S to 5S rDNA internally transcribed spacer sequences. Yoon JH, et al. **Int J Syst Bacteriol** 1997 Jul; 47(3):661-9

The actinomycete Thermobispora bispora contains two distinct types of transcriptionally active 16S rRNA genes. Wang Y, et al. **J Bacteriol** 1997 May;179(10):3270-6

Molecular biological evidence for the occurrence of uncultured members of the actinomycete line of descent in different environments and geographical locations. Rheims H, et al. **Microbiology** 1996 Oct;142 (Pt 10):2863-70

GROWTH & DEVELOPMENT

The Whipple bacillus lives (ex vivo)! [editorial; comment] Relman DA. **J Infect Dis** 1997 Sep;176(3):752-4. Comment on: J Infect Dis 1997 Sep;176(3):672-7.

ISOLATION & PURIFICATION

Polymerase chain reaction-based detection of Tropheryma whippelii in central nervous system Whipple's disease. Lynch T, et al. **Ann Neurol** 1997 Jul;42(1):120-4

Analysis of actinomycete communities by specific amplification of genes encoding 16S rRNA and gel-electrophoretic separation in denaturing gradients. Heuer H, et al. **Appl Environ Microbiol** 1997 Aug; 63(8):3233-41

Nested PCR for ultrasensitive detection of the potato ring rot bacterium, Clavibacter michiganensis subsp. sepedonicus. Lee IM, et al. **Appl Environ Microbiol** 1997 Jul;63(7):2625-30

Isolation of Dermatophilus sp from skin lesions in farmed saltwater crocodiles (Crocodylus porosus). Buenviaje GN, et al. **Aust Vet J** 1997 May;75(5):365-7

Oerskovia xanthineolytica bacteremia in an immunocompromised host: case report and review. Maguire JD, et al. **Clin Infect Dis** 1996 Mar;22(3):554-6 (11 ref.)

Identification of yeasts and coryneform bacteria from the surface microflora of brick cheeses. Valdés-Stauber N, et al. **Int J Food Microbiol** 1997 Feb;34(2):115-29

Coinfection with Tropheryma whippelii and a Whipple's disease-associated bacterial organism detected in a patient

with central nervous system Whipple's disease [letter] Neumann K, et al. **J Clin Microbiol** 1997 Jun;35(6):1645
Deactivation of macrophages with interleukin-4 is the key to the isolation of Tropheryma whippelii [see comments] Schoedon G, et al. **J Infect Dis** 1997 Sep;176(3):672-7. Comment in: J Infect Dis 1997 Sep;176(3):752-4.
Bacterial contamination of hydrophilic contact lens solutions marketed in spain. Durbán JJ, et al. **Optom Vis Sci** 1996 Aug;73(8):529-32

METABOLISM

Transformation of 2,4,6-trinitrotoluene (TNT) by actinomycetes isolated from TNT-contaminated and uncontaminated environments. Pasti-Grigsby MB, et al. **Appl Environ Microbiol** 1996 Mar;62(3):1120-3
Elongation factor Tu1 of the antibiotic GE2270A producer Planobispora rosea has an unexpected resistance profile against EF-Tu targeted antibiotics. Möhrle VG, et al. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):320-6
Transformations of steroid sulphates by human axillary bacteria. A mechanism for human odour formation? Gower DB, et al. **Biochem Soc Trans** 1997 Feb;25(1):16S
Bacterial degradation of natural rubber: a privilege of actinomycetes? Jendrossek D, et al. **FEMS Microbiol Lett** 1997 May 15;150(2):179-88
Janibacter limosus gen. nov., sp. nov., a new actinomycete with meso-diaminopimelic acid in the cell wall. Martin K, et al. **Int J Syst Bacteriol** 1997 Apr;47(2):529-34
Friedmanniella antarctica gen. nov., sp. nov., an LL-diaminopimelic acid-containing actinomycete from Antarctic sandstone. Schumann P, et al. **Int J Syst Bacteriol** 1997 Apr;47(2):278-83
Microbial conversion of EM574 and EM523, gastrointestinal motor stimulating agents. Funabashi Y, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):802-10
Formation of acarbose phosphate by a cell-free extract from the acarbose producer Actinoplanes sp. Goeke K, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):661-3
Pyralomicins, novel antibiotics from Microtetraspora spiralis. II. Structure determination. Kawamura N, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):651-6
Pyralomicins, novel antibiotics from Microtetraspora spiralis. III. Biosynthesis of pyralomicin 1a. Kawamura N, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):657-60
Pyralomicins, novel antibiotics from Microtetraspora spiralis. I. Taxonomy and production. Kawamura N, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):706-9
Effect of ferrous ion on mildiomycin production by Streptoverticillium rimofaciens. Kishimoto K, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):770-4
Effect of phosphate ion on mildiomycin production by Streptoverticillium rimofaciens. Kishimoto K, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):775-80
HP17, a new pigment-like antibiotic produced by a new strain of Spirillospora. Hacéne H, et al. **J Appl Bacteriol** 1996 May;80(5):565-9
Sch 54445: a new polycyclic xanthone with highly potent antifungal activity produced by Actinoplanes sp. Chu M, et al. **J Nat Prod** 1997 May;60(5):525-8
Screening of microbial extracts for tyrosine kinase inhibitors. Alvi KA, et al. **Jpn J Antibiot** 1997 Mar;50(3):264-6
Production of brominated tiacumicin derivatives. Hochlowski JE, et al. **Jpn J Antibiot** 1997 Mar;50(3):201-5

PHYSIOLOGY

Implementation of conditions of the inoculum stage for Streptosporangium cultures. Platas G, et al. **Microbiologia** 1997 Jun;13(2):193-200
An elongation factor Tu (EF-Tu) resistant to the EF-Tu inhibitor GE2270 in the producing organism Planobispora rosea. Soslo M, et al. **Mol Microbiol** 1996 Oct;22(1):43-51

RADIATION EFFECTS

Effect of gamma radiation on the survival of fungal and actinomycetal florae contaminating medicinal plants. Aziz NH, et al. **Appl Radiat Isot** 1997 Jan;48(1):71-6

ULTRASTRUCTURE

Electron microscopic characteristics of actinomycetic agents having aetiological association with human leprosy and epizootic ulcerative syndrome of fish. Chakrabarty A, et al. **Indian J Exp Biol** 1996 Aug;34(8):810-2

ACTINOMYCETALES INFECTIONS

Empyema with malakoplakic-like lesions by Rhodococcus equi as a presentation of HIV infection. Calore EE, et al. **Pathologica** 1995 Oct;87(5):525-27
Rhodococcus equi pneumonia. Johnson DH, et al. **Semin Respir Infect** 1997 Mar;12(1):57-60 (23 ref.)
Rhodococcus equi: an emerging opportunistic pathogen. Mosser DM, et al. **Trends Microbiol** 1996 Jan;4(1):29-33 (50 ref.)
[Review of 105 cases of isolation of Rhodococcus equi in humans] Votava M, et al. **Cas Lek Cesk** 1997 Jan 22; 136(2):51-3 (29 ref.) (Eng. Abstr.) **(Cze)**
[Rhodococcus equi--a newly recognized opportunistic pathogen in man] Votava M, et al. **Epidemiol Mikrobiol Imunol** 1997 May;46(2):58-66 (58 ref.) (Eng. Abstr.) **(Cze)**

COMPLICATIONS

Poststenotic cavitating pneumonia due to Rhodococcus equi in HIV infection. Sutor GC, et al. **AIDS** 1996 Mar; 10(3):339-40
Acute mediastinitis due to Rhodococcus equi in a patient with human immunodeficiency virus infection. Casado JL, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):241-4
Arcanobacterium haemolyticum invasive infections, including meningitis in cancer patients [letter] Minárik T, et al. **J Infect** 1997 Jan;34(1):91
Rhodococcus equi infection in HIV-positive subjects: a retrospective analysis of 24 cases. Arlotti M, et al. **Scand J Infect Dis** 1996;28(5):463-7
[Pharyngitis produced by Arcanobacterium haemolyticum] Dorobáť O, et al. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jul-Dec;41(3-4):135-40 (Eng. Abstr.) **(Rum)**

DIAGNOSIS

Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection [letter] Macías J, et al. **AIDS** 1997 Feb;11(2):253-4
Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ramzan NN, et al. **Ann Intern Med** 1997 Apr 1;126(7):520-7
Acute mediastinitis due to Rhodococcus equi in a patient with human immunodeficiency virus infection. Casado JL, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):241-4
Chronic pneumonia caused by Rhodococcus equi in a patient without impaired immunity. Linares MJ, et al. **Eur Respir J** 1997 Jan;10(1):248-50
Mycetoma of the calf. Locken JA, et al. **Skeletal Radiol** 1997 May;26(5):319-22
Spontaneous resolution of rhodococcal pulmonary infection in a liver transplant recipient. Schilz RJ, et al. **South Med J** 1997 Aug;90(8):851-4 (33 ref.)
[Actinomycetes granuloma of the upper eyelid] Tritten JJ, et al. **Klin Monatsbl Augenheilkd** 1997 May;210(5):339-40 (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Rhodococcus equi infections: antibiotic therapy and relapses [letter; comment] Giacometti A, et al. **AIDS** 1997 Jan; 11(1):120-1. Comment on: AIDS 1996 Apr;10(4):359-62.
Optimal treatment regimen for CAPD peritonitis caused by Rhodococcus species [letter; comment] Tang S, et al. **Nephrol Dial Transplant** 1997 May;12(5):1080-1. Comment on: Nephrol Dial Transplant 1996 Nov;11(11):2340-1.
Rhodococcus equi pneumonia in a patient with occult HIV infection: successful therapy. Volpino P, et al. **Panminerva Med** 1997 Mar;39(1):61-3

EPIDEMIOLOGY

Rhodococcus equi and Arcanobacterium haemolyticum: two "coryneform" bacteria increasingly recognized as agents of human infection. Linder R. **Emerg Infect Dis** 1997 Apr-Jun; 3(2):145-53 (43 ref.)

ETIOLOGY

Tsukamurella inchonensis bacteremia in a patient who ingested Hydrochloric acid. Chong Y, et al. **Clin Infect Dis** 1997 Jun;24(6):1267-8
Oerskovia xanthineolytica infection of a prosthetic joint: case report and review. Harrington RD, et al. **J Clin Microbiol** 1996 Jul;34(7):1821-4 (18 ref.)
Rhodococcus equi in CAPD-associated peritonitis treated with azithromycin [see comments] Hoque S, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2340-1. Comment in: Nephrol Dial Transplant 1997 May;12(5):1080-1.
Optimal treatment regimen for CAPD peritonitis caused by Rhodococcus species [letter; comment] Tang S, et al. **Nephrol Dial Transplant** 1997 May;12(5):1080-1. Comment on: Nephrol Dial Transplant 1996 Nov;11(11):2340-1.
[Generalized rhodococcosis of fatal outcome in a patient with AIDS (letter)] Steineur MP, et al. **Presse Med** 1996 Sep 7;25(25):1166 **(Fre)**

IMMUNOLOGY

Serologic responses to Rhodococcus equi in individuals with and without human immunodeficiency virus infection. Vullo V, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jul; 15(7):588-94
Virulent and avirulent Rhodococcus equi infection in T-cell deficient athymic nude mice: pathologic, bacteriologic and immunologic responses. Madarame H, et al. **FEMS Immunol Med Microbiol** 1997 Apr;17(4):251-62
Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Miettinen M, et al. **Infect Immun** 1996 Dec; 64(12):5403-5
Assessment of the immunogenic potential of Rhodococcus equi virulence associated protein (VapA) in mice. Prescott JF, et al. **Vet Microbiol** 1997 Jun 16;56(3-4):213-25

MICROBIOLOGY

Long survival of a patient with AIDS in spite of previous Rhodococcus equi infection [letter; comment] Schneider E, et al. **Acta Clin Belg** 1997;52(1):50. Comment on: Acta Clin Belg 1996;51(2):101-5.
Intraspinal mycetoma: report of two cases. Arbab MA, et al. **Am J Trop Med Hyg** 1997 Jan;56(1):27-9
Neonatal meningitis caused by Bifidobacterium breve. Nakazawa T, et al. **Brain Dev** 1996 Mar-Apr;18(2):160-2
Prosthetic joint infection caused by Tropheryma whippelii (Whipple's bacillus). Frésard A, et al. **Clin Infect Dis** 1996 Mar;22(3):575-6
Oerskovia xanthineolytica bacteremia in an immunocompromised host: case report and review. Maguire JD, et al. **Clin Infect Dis** 1996 Mar;22(3):554-6 (11 ref.)
Tsukamurella tyrosinosolvens sp. nov. Yassin AF, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):607-14
Gordona terrae central nervous system infection in an immunocompetent patient. Drancourt M, et al. **J Clin Microbiol** 1997 Feb;35(2):379-82
Coinfection with Tropheryma whippelii and a Whipple's disease-associated bacterial organism detected in a patient with central nervous system Whipple's disease [letter] Neumann K, et al. **J Clin Microbiol** 1997 Jun;35(6):1645
Bacteremia due to Gordona sputi in an immunocompromised patient [published erratum appears in J Clin Microbiol 1996 Dec;34(12):3258] Riegel P, et al. **J Clin Microbiol** 1996 Aug;34(8):2045-7
Rhodococcus equi causing bacteraemia and pneumonia in a pulmonary transplant patient [letter] Le Lay G, et al. **J Infect** 1996 Nov;33(3):239-40
[Tsukamurella infections. Review of the literature apropos of a case] Rey D, et al. **Pathol Biol (Paris)** 1997 Jan; 45(1):60-5 (27 ref.) (Eng. Abstr.) **(Fre)**
[Characterization of Rhodococcus equi isolates from horse and man] Fuhrmann C, et al. **Berl Munch Tierarztl Wochenschr** 1997 Feb;110(2):54-9 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Pulmonary malacoplakia associated with Rhodococcus equi infection in an AIDS patient. Report of a case with diagnosis by fine needle aspiration. Sughayer M, et al. **Acta Cytol** 1997 Mar-Apr;41(2):507-12
Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid. von Herbay A, et al. **Gastroenterology** 1997 Aug; 113(2):434-41

PREVENTION & CONTROL

Role of CD4+, CD8+ and double negative T-cells in the protection of SCID/beige mice against respiratory challenge with Rhodococcus equi. Ross TL, et al. **Can J Vet Res** 1996 Jul;60(3):186-92
Protective effect against Rhodococcus equi infection in mice of IgG purified from horses vaccinated with virulence associated protein (VapA)-enriched antigens. Fernandez AS, et al. **Vet Microbiol** 1997 Jun 16;56(3-4):187-92

RADIOGRAPHY

Radiological findings in nine AIDS patients with Rhodococcus equi pneumonia. Wicky S, et al. **Eur Radiol** 1996;6(6):826-30
Dense Rhodococcus cerebral abscesses in an HIV-positive patient. Perrymore WD, et al. **Neuroradiology** 1997 Aug; 39(8):581-2

THERAPY

Native and prosthetic valve endocarditis caused by Rothia dentocariosa: diagnostic and therapeutic considerations. Binder D, et al. **Infection** 1997 Jan-Feb;25(1):22-6
Spontaneous resolution of rhodococcal pulmonary infection in a liver transplant recipient. Schilz RJ, et al. **South Med J** 1997 Aug;90(8):851-4 (33 ref.)

VETERINARY

Use of Rhodococcus equi virulence-associated protein for immunization of foals against R equi pneumonia. Prescott JF, et al. **Am J Vet Res** 1997 Apr;58(4):356-9
Isolation of Dermatophilus sp from skin lesions in farmed saltwater crocodiles (Crocodylus porosus). Buenviaje GN, et al. **Aust Vet J** 1997 May;75(5):365-7
Failure of hyperimmune plasma to prevent pneumonia caused by Rhodococcus equi in foals. Hurley JR, et al. **Aust Vet J** 1995 Nov;72(11):418-20
Extra-pulmonary Rhodococcus equi in a thoroughbred foal. Nay TS. **Can Vet J** 1996 Oct;37(10):623-4
Rhodococcal pneumonia: humoral versus cell-mediated immunity [editorial; comment] Hines SA, et al. **Equine Vet J** 1996 Sep;28(5):339-40. Comment on: Equine Vet J 1996 Sep;28(5):344-9.
Use of a virulence-associated protein based enzyme-linked immunosorbent assay for Rhodococcus equi serology in horses [see comments] Prescott JF, et al. **Equine Vet J** 1996 Sep;28(5):344-9. Comment in: Equine Vet J 1996 Sep;28(5):339-40.
Emergence of rifampin-resistant Rhodococcus equi in an infected foal. Takai S, et al. **J Clin Microbiol** 1997 Jul; 35(7):1904-8
Proceedings of a workshop on the control of Amblyomma variegatum and associated diseases. Accra, Ghana, 4 November 1994. **Trop Anim Health Prod** 1996 May;28(2 Suppl):1S-89S
The pathogenesis of dermatophilosis. Ambrose NC. **Trop Anim Health Prod** 1996 May;28(2 Suppl):29S-37S (24

ref.)
Chemotherapy of dermatophilosis--a preliminary study. Aning KG, et al. **Trop Anim Health Prod** 1996 May;28(2 Suppl):38S–43S; discussion 74S–86S
The association between Amblyomma variegatum and dermatophilosis: epidemiology and immunology. Koney EB, et al. **Trop Anim Health Prod** 1996 May;28(2 Suppl):18S–25S; discussion 74S–86S
Dermatophilosis in Ghana: effect on the livestock industry. Koney EB. **Trop Anim Health Prod** 1996 May;28(2 Suppl):3S–8S; discussion 74S–86S
Control of Amblyomma variegatum and dermatophilosis on local and exotic breeds of cattle in Ghana. Morrow AN, et al. **Trop Anim Health Prod** 1996 May;28(2 Suppl):44S–49S; discussion 74S–86S
Research on dermatophilosis in Africa. Oppong EN. **Trop Anim Health Prod** 1996 May;28(2 Suppl):9S–17S; discussion 74S–86S
Dermatophilosis and abscessation of lymph nodes in a group of tick-infested horses in Uganda. Shannon D. **Trop Anim Health Prod** 1997 May;29(2):102–4
Comparison of tracheal aspiration with other tests for diagnosis of Rhodococcus equi pneumonia in foals. Anzai T, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):335–45
Immunoprophylaxis of Rhodococcus equi pneumonia in foals. Becú T, et al. **Vet Microbiol** 1997 Jun 16; 56(3–4):193–204
Protective effect against Rhodococcus equi infection in mice of IgG purified from horses vaccinated with virulence associated protein (VapA)–enriched antigens. Fernandez AS, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):187–92
Clinical manifestations, diagnosis, treatment, and prevention of Rhodococcus equi infections in foals. Giguère S, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):313–34 (97 ref.)
Immunity to Rhodococcus equi. Hines SA, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):177–85 (49 ref.)
Pathogenesis and virulence of Rhodococcus equi. Hondalus MK. **Vet Microbiol** 1997 Jun 16;56(3–4):257–68 (77 ref.)
Equine herpesvirus type 2 (EHV–2) as a predisposing factor for Rhodococcus equi pneumonia in foals: prevention of the bifactorial disease with EHV–2 immunostimulating complexes. Nordengrahn A, et al. **Vet Microbiol** 1996 Jul; 51(1–2):55–68
Epidemiology of Rhodococcus equi infections: a review. Takai S. **Vet Microbiol** 1997 Jun 16;56(3–4):167–76 (49 ref.)
Serum antibody responses of foals to virulence–associated 15– to 17–kilodalton antigens of Rhodococcus equi. Takai S, et al. **Vet Microbiol** 1996 Sep;52(1–2):63–71
Prevention of Rhodococcus equi pneumonia of foals using two different inactivated vaccines. Varga J, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):205–12
Pathogenicity and virulence of Rhodococcus equi in foals following intratracheal challenge. Wada R, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):301–12
Outbreak of dermatophilosis in a horse herd in israel. Yeruham I, et al. **Zentralbl Veterinarmed A** 1996 Sep; 43(7):393–8
[Characterization of Rhodococcus equi isolates from horse and man] Fuhrmann C, et al. **Berl Munch Tierarztl Wochenschr** 1997 Feb;110(2):54–9 (Eng. Abstr.) **(Ger)**

ACTINOMYCETE INFECTIONS see **ACTINOMYCETALES INFECTIONS**

ACTINOMYCIN see **DACTINOMYCIN**

ACTINOMYCIN D see **DACTINOMYCIN**

ACTINOMYCOSIS

Actinomycosis, nocardiosis, and actinomycetoma. Warren NG. **Dermatol Clin** 1996 Jan;14(1):85–95 (30 ref.)
Actinomycosis of the foot. Vogen KW. **J Am Podiatr Med Assoc** 1996 May;86(5):238–40
Polymicrobial brain abscess involving Haemophilus paraphrophilus and Actinomyces odontolyticus. Simpson AJ, et al. **Postgrad Med J** 1996 May;72(847):297–306
[Abdominal actinomycosis. Two cases from a department of surgery] Aaseby J, et al. **Ugeskr Laeger** 1997 Jul 14; 159(29):4534–5 (Eng. Abstr.) **(Dan)**
[Abdominopelvic actinomycosis. Apropos of 2 clinical cases] Kron C, et al. **Chirurgie** 1996;121(5):346–8; discussion 349 (Eng. Abstr.) **(Fre)**
[A rare case of primary abdominal actinomycosis] Lazzaretti MG, et al. **Minerva Chir** 1996 Sep;51(9):707–11 (Eng. Abstr.) **(Ita)**
[Primary actinomycosis of the abdominal wall (letter)] Soler Dorda G, et al. **Rev Esp Enferm Dig** 1997 Mar;89(3):228–9 **(Spa)**

COMPLICATIONS

Actinomyces chorioamnionitis and preterm labor in a twin pregnancy: a case report. Abadi MA, et al. **Am J Obstet Gynecol** 1996 Nov;175(5):1391–2
Actinomycosis associated with pilonidal sinus of the penis. Saharay M, et al. **Br J Urol** 1996 Sep;78(3):464–5
Bacteriological studies of dental caries in Ile–Ife, Nigeria. Adetunji OF, et al. **Cent Afr J Med** 1996 Aug;42(8):249–52
Intramedullary abscess of the spinal cord in a patient with a right–to–left shunt: case report. David C, et al. **Clin Infect Dis** 1997 Jan;24(1):89–90
Cutaneous and muscular abscesses secondary to Actinomyces meyeri pneumonia. Liaudet L, et al. **Clin Infect Dis** 1996 Jan;22(1):185–6 (9 ref.)
Actinomycosis and plasma cell granuloma, coincidence or coexistence: patient report and review of the literature. Dweik RA, et al. **Clin Pediatr (Phila)** 1997 Apr; 36(4):229–33 (44 ref.)
Rectal stricture caused by actinomycosis of the pelvis. Bertram P, et al. **Eur J Surg** 1996 Oct;162(10):837–9 (8 ref.)
Cervical epidural abscess due to actinomycosis: demonstration by MRI. Maeder PP, et al. **Eur Neurol** 1996; 36(1):56–7
Pancoast's syndrome secondary to thoracic actinomycosis. Tolentino A, et al. **J Ky Med Assoc** 1996 Nov;94(11):500–2
Pulmonary actinomycosis: a cause of adult respiratory distress syndrome. Crausman RS, et al. **Med Health R I** 1997 Jun;80(6):200–2
Inflammatory pseudotumor of the liver associated with extrahepatic infection. White JE, et al. **South Med J** 1997 Jan;90(1):23–9 (48 ref.)
Actinomycotic intracavity lung colonisation [letter; comment] Severo LC. **Thorax** 1996 Nov;51(11):1168. Comment on: Thorax 1996 Feb;51(2):221–2.
[Actinomyces meyeri disseminated actinomycosis disclosing pulmonary carcinoma] Chaumentin G, et al. **Rev Med Interne** 1997 Jul;18(7):563–5 (15 ref.) (Eng. Abstr.) **(Fre)**
[Actinomycosis and non–Hodgkin's malignant lymphoma: fortuitous association?] Guerci AP, et al. **Rev Med Interne** 1996;17(7):571–5 (15 ref.) (Eng. Abstr.) **(Fre)**
[Simultaneous occurrence of cervicofacial an pleuropulmonary actinomycosis] Koritsánszky L, et al. **Fogorv Sz** 1997 Aug;90(8):227–34 (Eng. Abstr.) **(Hun)**
[Skin tumor as presentation form of lung actinomycosis] Gil P, et al. **Arch Bronconeumol** 1997 Apr;33(4):198–200 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Primary actinomycosis of the urinary bladder. Case report and review of the literature. Duca S, et al. **Acta Chir Belg** 1996 Nov–Dec;96(6):295–7 (8 ref.)
Intracardiac actinomyocosis. Bashour TT, et al. **Am Heart J** 1997 Apr;133(4):467–8
Hepatic actinomycosis infiltrating the diaphragm and right lung. Kasano Y, et al. **Am J Gastroenterol** 1996 Nov; 91(11):2418–20
Intramedullary abscess of the spinal cord in a patient with a right–to–left shunt: case report. David C, et al. **Clin Infect Dis** 1997 Jan;24(1):89–90
Actinomycosis of the trachea with acute tracheal obstruction. Hagan ME, et al. **Clin Infect Dis** 1996 Jun;22(6):1126–7
A case of colonic actinomycosis difficult to distinguish from advanced colonic carcinoma. Higaki S, et al. **Endoscopy** 1995 Nov;27(9):712
Esophageal actinomycosis: a case report. Ng FH, et al. **Endoscopy** 1997 Feb;29(2):133
Actinomycosis of the middle ear and mastoid [letter] Hoshino T, et al. **Eur Arch Otorhinolaryngol** 1996;253(6):378–80
Actinomycosis of the large bowel: unusual presentations and their surgical treatment. Dayan K, et al. **Eur J Surg** 1996 Aug;162(8):657–60
Actinomycotic cholecystitis. Arora B, et al. **Indian J Gastroenterol** 1997 Apr;16(2):68
Tonsillar actinomycosis presenting as expectorated debris [letter] Blackburn LM, et al. **J Infect** 1997 May;34(3):283–4
Actinomycosis of the thyroid gland masquerading as a neoplasm. Yiotakis J, et al. **J Laryngol Otol** 1997 Feb; 111(2):172–4 (11 ref.)
Actinomycosis of the tongue associated with human immunodeficiency virus infection: case report. Vazquez AM, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):879–81 (18 ref.)
Retroperitoneal actinomycosis masquerading as inflammatory pseudotumor. Radhi J, et al. **J Pediatr Surg** 1997 Apr; 32(4):618–20
Pseudotumoral vesical actinomycosis. Guermazi A, et al. **J Urol** 1996 Dec;156(6):2002–3
Actinomycosis, a sheep in wolves' clothes. Neijens V, et al. **Lung Cancer** 1996 Aug;15(1):131–5
Pulmonary actinomycosis: a cause of adult respiratory distress syndrome. Crausman RS, et al. **Med Health R I** 1997 Jun;80(6):200–2
A rare case of disseminated actinomycosis caused by Actinomyces meyeri. van Mook WN, et al. **Neth J Med** 1997 Jul;51(1):39–45
Primary hepatic actinomycosis. Rabusin M, et al. **Pediatr Infect Dis J** 1996 Apr;15(4):382–4
The right middle–lobe syndrome--a case report and review of the literature [letter] [see comments] Bida MN, et al. **S Afr Med J** 1997 Feb;87(2):178–9. Comment in: S Afr Med J 1997 Jun;87(6):766.
[A case of genital actinomycosis--the diagnostic difficulties] Tsankova M, et al. **Akush Ginekol (Sofiia)** 1996;35(4):38–40 **(Bul)**
[Pulmonary and musculo–cutaneous thigh actinomycosis] Falchero L, et al. **Rev Mal Respir** 1997 Apr;14(2):141–3 (Eng. Abstr.) **(Fre)**
[Abdominal actinomycosis with IUD] Kamprath S, et al. **Zentralbl Gynakol** 1997;119(1):21–4 (Eng. Abstr.) **(Ger)**
[Endobronchial actinomycosis] Hashimoto A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Sep; 34(9):989–92 (Eng. Abstr.) **(Jpn)**
[Pulmonary actinomycosis--diagnosis and therapy based on past reports of actinomycosis] Tanaka S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34(12):1380–4 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Cutaneous lesions and pulmonary infiltrates, Cutaneous actinomycisis] Domínguez JR, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):269–70 **(Spa)**

DRUG THERAPY

The use of an experimental metritis model to study antibiotic distribution in genital tract secretions in the ewe. Cester CC, et al. **Vet Res** 1996;27(4–5):479–89

EPIDEMIOLOGY

The incidence and role of actinomyces in recurrent acute tonsillitis. Gaffney R, et al. **Clin Otolaryngol** 1993 Aug; 18(4):268–71

ETIOLOGY

Bilateral tubo–ovarian actinomycosis in the presence of an intrauterine device: a case report. Chang BC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Mar; 57(3):228–31
Actinomyces infection in porous polyethylene orbital implant. Karcioglu ZA. **Graefes Arch Clin Exp Ophthalmol** 1997 Jul;235(7):448–51
Nocardia brasiliensis: in vitro and in vivo growth response to steroid sex hormones. Hernandez–Hernandez F, et al. **Mycopathologia** 1995 Nov;132(2):79–85
Colitis and lower abdominal mass by Actinomyces israelii in a patient with an IUD. Nugteren SK, et al. **Neth J Med** 1996 Aug;49(2):73–6
[Pelvic actinomycosis abscess and intrauterine device] Ko–Kivok–Yun P, et al. **Contracept Fertil Sex** 1997 Mar; 25(3):239–41 (Eng. Abstr.) **(Fre)**
[Primary bronchial actinomycosis and foreign body] Mingrone H, et al. **Medicina (B Aires)** 1995;55(4):337–40 (5 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Empyema necessitatis due to Actinomyces odontolyticus [letter; comment] Pérez–Castrillón JL, et al. **Chest** 1997 Apr;111(4):1144. Comment on: Chest 1996 Apr;109(4):1109–11.
Actinomycotic splenic abscesses presenting with arthritis. Quintero–Del–Rio AI, et al. **Clin Exp Rheumatol** 1997 Jul–Aug;15(4):445–8 (13 ref.)
Severe infection due to Actinomyces bernardiae: case report. Ieven M, et al. **Clin Infect Dis** 1996 Jan;22(1):157–8
Actinomyces europaeus sp. nov., isolated from human clinical specimens. Funke G, et al. **Int J Syst Bacteriol** 1997 Jul; 47(3):687–92
Characterization of some Actinomyces–like isolates from human clinical specimens: reclassification of Actinomyces suis (Soltys and Spratling) as Actinobaculum suis comb. nov. and description of Actinobaculum schaalii sp. nov. Lawson PA, et al. **Int J Syst Bacteriol** 1997 Jul; 47(3):899–903
Actinomyces graevenitzii sp. nov., isolated from human clinical specimens. Ramos CP, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):885–8
Spinal abscess. Louvel JP, et al. **J Belge Radiol** 1996 Dec; 79(6):271
[Abdominal actinomycosis. Apropos of a case] Kabwa L, et al. **J Chir (Paris)** 1996 Nov;133(7):348–52 (11 ref.) (Eng. Abstr.) **(Fre)**
[Primary laryngeal actinomycosis] Melgarejo Moreno PJ, et al. **Acta Otorrinolaringol Esp** 1997 Apr;48(3):237–8 (Eng. Abstr.) **(Spa)**
[Pulmonary pseudotumor with mediastinal extension caused by actinomyces (letter)] Fernández Villar A, et al. **Arch Bronconeumol** 1996 Aug–Sep;32(7):374–5 **(Spa)**
[Mandibular actinomycosis caused by Actinomyces odontolyticus (letter)] Gené A, et al. **Enferm Infecc Microbiol Clin** 1997 Jan;15(1):51–2 **(Spa)**

PATHOLOGY

Cerebral manifestation of an actinomycosis infection. A case report. Winking M, et al. **J Neurosurg Sci** 1996 Jun; 40(2):145–8
[Very odd verrucae!] Ferlicot S, et al. **Ann Pathol** 1997 Jul; 17(3):209–10 (Eng. Abstr.) **(Fre)**
[Broad actinomyces abscess in pelvic cavity and abdominal wall--a case report] Terada Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Oct;48(10):904–6 **(Jpn)**
[Pulmonary actinomycosis diagnosed with transthoracic thin needle biopsy] Janiszewska–Drobińska B, et al. **Pneumonol Alergol Pol** 1996;64(5–6):323–6 (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

[Mandibular actinomycosis] Erdozáin I, et al. **Acta Otorrinolaringol Esp** 1997 Mar;48(2):165–7 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Abdominal actinomycosis associated with intrauterine device: CT features. Laurent T, et al. **Eur Radiol** 1996;6(5):670–3
Abdominal actinomycosis: barium enema and computed tomography findings. Uchiyama N, et al.
J Gastroenterol 1997 Feb;32(1):89–94
[Actinomycotic tubo-ovarian abscess. Contribution of pelvic angioscanner] Bazot M, et al. **J Radiol** 1997 Jul;78(7):513–6 (Eng. Abstr.) **(Fre)**
[Bilateral perihilar alveolar opacities with major changes in health status] Appere-de Vecchi C, et al.
Rev Pneumol Clin 1997;53(2):98–100 **(Fre)**
[Thoracic actinomycosis] Besznyák G, et al. **Orv Hetil** 1996 Sep 15;137(37):2041–3 (29 ref.) (Eng. Abstr.) **(Hun)**
[Constitutional syndrome, fever, and pulmonary infiltrates in the left upper lobe] Rubio AM, et al.
Enferm Infecc Microbiol Clin 1997 Apr;15(4):221–2 **(Spa)**

SURGERY

Actinomycosis of the large bowel: unusual presentations and their surgical treatment. Dayan K, et al. **Eur J Surg** 1996 Aug;162(8):657–60
Pulmonary actinomycosis: surgical considerations. Rizzi A, et al. **Monaldi Arch Chest Dis** 1996 Oct;51(5):369–72

ULTRASONOGRAPHY

US case of the day. Actinomycotic pelvic abscess secondary to an IUD with involvement of the bladder, sigmoid colon, left ureter, liver, and upper abdominal wall. Hochsztein JG, et al. **Radiographics** 1996 May;16(3):713–6

VETERINARY

Regulation of uterine immune function during the estrous cycle and in response to infectious bacteria in sheep. Ramadan AA, et al. **J Anim Sci** 1997 Jun;75(6):1621–32
Identification and partial characterization of an Actinomyces pyogenes hemolysin. Funk PG, et al. **Vet Microbiol** 1996 May;50(1–2):129–42

ACTINOMYCOSIS, CERVICOFACIAL

COMPLICATIONS

Unusual presentation of cervicothoracic actinomycosis complicated by pericardial effusion: a case report. Beier KH, et al. **J Emerg Med** 1997 May–Jun;15(3):303–7
[Simultaneous occurrence of cervicofacial an pleuropulmonary actinomycosis] Koritsánszky L, et al. **Fogorv Sz** 1997 Aug;90(8):227–34 (Eng. Abstr.) **(Hun)**

DIAGNOSIS

Cervicofacial actinomycosis: a diagnostic challenge. Nagler R, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jun;83(6):652–6
Cervicofacial actinomycosis with paravertebral spread: a case report. Abisheganaden J, et al. **Singapore Med J** 1996 Apr; 37(2):229–32

ETIOLOGY

[Mucormycosis-actinomycosis and caseous dental sinusitis associated with sinusal foreign body] Braun JJ, et al.
Ann Otolaryngol Chir Cervicofac 1996;113(5):289–93 (22 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

[Cervicofacial actinomycosis] Albertos JM, et al.
An Otorrinolaringol Ibero Am 1997;24(3):255–68 (Eng. Abstr.) **(Spa)**

PATHOLOGY

Actinomycosis presenting as a nasopharyngeal tumour: a case report. Scott A, et al. **J Laryngol Otol** 1997 Feb; 111(2):163–5

ACTINOSPECTACIN see **SPECTINOMYCIN**

ACTINOTHERAPY see **ULTRAVIOLET THERAPY**

ACTINS

Actin polymerization and depolymerization during apoptosis in HL-60 cells. Levee MG, et al. **Am J Physiol** 1996 Dec; 271(6 Pt 1):C1981–92
ACTIN: general principles from studies in yeast. Ayscough KR, et al. **Ann Rev Cell Dev Biol** 1996;12:129–60 (115 ref.)
Actin-based vesicle dynamics and exocytosis during wound wall formation in characean internodal cells. Foissner I, et al. **Cell Motil Cytoskeleton** 1996;35(1):35–48
The structure, function, and assembly of actin filament bundles. Furukawa R, et al. **Int Rev Cytol** 1997;175:29–90 (272 ref.)
Proposed modification of the Huxley–Simmons model for myosin head motion along an actin filament. Mitsui T, et al. **J Theor Biol** 1996 Sep 21;182(2):147–59
Disruption of actin filaments increases the activity of sodium-conducting channels in human myeloid leukemia cells. Negulyaev YA, et al. **Mol Biol Cell** 1996 Dec; 7(12):1857–64

ANALYSIS

Fatal congenital myopathy with actin filament deposits. Bornemann A, et al. **Acta Neuropathol (Berl)** 1996 Jul; 92(1):104–8
Expression of RANTES mRNA and protein in airways of patients with mild asthma. Berkman N, et al.
Am J Respir Crit Care Med 1996 Dec;154(6 Pt 1):1804–11
Onset of elastogenesis and downregulation of smooth muscle actin as distinguishing phenomena in artery differentiation in the chick embryo. Bergwerff M, et al.
Anat Embryol (Berl) 1996 Dec;194(6):545–57
Ultrastructural localization of actin in the cell body of rat spinal ganglion neurons. Pannese E, et al.
Anat Embryol (Berl) 1996 Dec;194(6):527–31
2'3'-CNPase and actin distribution in oligodendrocytes, relative to their mRNAs. McEwan NR.
Biochem Mol Biol Int 1996 Nov;40(5):975–9
Actin cytoskeleton demonstration in Trichomonas vaginalis and in other trichomonads. Brugerolle G, et al.
Biol Cell 1996;88(1–2):29–36
Nuclear and cytoplasmic actin in dinoflagellates. Soyer-Gobillard MO, et al. **Biol Cell** 1996;87(1–2):17–35
Differential distribution of the tight-junction-associated protein ZO-1 isoforms alpha+ and alpha- in guinea pig Sertoli cells: a possible association with F-actin and G-actin. Pelletier RM, et al. **Biol Reprod** 1997 Aug; 57(2):367–76
Presence of alpha smooth muscle actin in lens epithelial cells of aphakic rabbit eyes. Kurosaka D, et al.
Br J Ophthalmol 1996 Oct;80(10):906–10
Ontogenesis of rat cochlea. A quantitative study of the organ of Corti. Mu MY, et al. **Brain Res Dev Brain Res** 1997 Mar 17;99(1):29–37
Structural and functional roles of cytoskeletal proteins during repair of native guinea pig intestinal epithelium. Albers TM, et al. **Cell Biol Int** 1996 Dec;20(12):821–30
The organization and animal-vegetal asymmetry of cytokeratin filaments in stage VI Xenopus oocytes is dependent upon F-actin and microtubules. Gard DL, et al. **Dev Biol** 1997 Apr 1;184(1):95–114
Expression of smooth muscle alpha-actin in mesenchymal cells during formation of avian endocardial cushion tissue: a role for transforming growth factor beta3. Nakajima Y, et al. **Dev Dyn** 1997 Jul;209(3):296–309
Specific immunohistochemical detection of cardiac/fetal alpha-actin in human cardiomyocytes and regenerating skeletal muscle cells. Franke WW, et al. **Differentiation** 1996 Jul;60(4):245–50
Application of combined mass spectrometry and partial amino acid sequence to the identification of gel-separated proteins. Patterson SD, et al. **Electrophoresis** 1996 May; 17(5):877–91
Colocalization of stomatin (band 7.2b) and actin microfilaments in UAC epithelial cells. Snyers L, et al.
Eur J Cell Biol 1997 Jul;73(3):281–5
alphaV Integrins on HT-29 colon carcinoma cells: adhesion to fibronectin is mediated solely by small amounts of alphaVbeta6, and alphaVbeta5 is codistributed with actin fibers. Kemperman H, et al. **Exp Cell Res** 1997 Jul 10; 234(1):156–64
Hepatic stellate cells and intralobular innervation in human liver cirrhosis. Ueno T, et al. **Hum Pathol** 1997 Aug; 28(8):953–9
A phospholipase D and protein kinase C inhibitor blocks the spreading of murine mammary adenocarcinoma cells altering f-actin and beta1-integrin point contact distribution. Aguirre Ghiso JA, et al. **Int J Cancer** 1997 May 29;71(5):881–90
Distribution of alpha-vascular smooth muscle actin in the smooth muscle cells of the gastrointestinal tract of the chicken. Yamamoto Y, et al. **J Anat** 1996 Dec;189 (Pt 3):623–30
Immunolocalization of CD44 and the ERM family in bone cells of mouse tibiae. Nakamura H, et al.
J Bone Miner Res 1996 Nov;11(11):1715–22
Dexamethasone alters rapidly actin polymerization dynamics in human endometrial cells: evidence for nongenomic actions involving cAMP turnover. Koukouritaki SB, et al.
J Cell Biochem 1996 Aug;62(2):251–61
G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials. Hemstreet GP 3rd, et al.
J Cell Biochem Suppl 1996;25:197–204 (46 ref.)
F-actin bundles in Drosophila bristles are assembled from modules composed of short filaments. Tilney LC, et al.
J Cell Biol 1996 Dec;135(5):1291–308
Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. Terada T, et al. **J Hepatol** 1996 Jun;24(6):706–12
Immunohistological localization and expression of alpha-actin in the baboon (Papio anubis) corpus luteum. Khan-Dawood FS, et al. **J Histochem Cytochem** 1997 Jan; 45(1):71–7
Immunofluorescence detection of F-actin on low melting point wax sections from plant tissues. Vitha S, et al.
J Histochem Cytochem 1997 Jan;45(1):89–95
Variations in the relative mRNA levels of actins and myosin heavy chains do not produce corresponding differences in their proteins in the adult human heart. Coumans JV, et al. **J Mol Cell Cardiol** 1997 Mar;29(3):895–905
The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus. Wolffe EJ, et al. **J Virol** 1997 May;71(5):3904–15
Actin mRNA is not lowered in chronic myeloid leukemic granulocytes. Kant AM, et al. **Leuk Res** 1996 Sep; 20(9):739–41
Myofibroblastic tumor of soft tissue displaying desmin-positive and actin-negative immunophenotypes. Yang P, et al. **Pathol Int** 1996 Sep;46(9):696–703
alpha-smooth muscle actin and collagen deposition in dysfunctional renal transplants. Ko YJ, et al.
Transplantation 1997 Jan 15;63(1):156–8
[Smooth muscular cells with high alpha-actin level cloned by FGF-2 transfection] Allera C, et al.
C R Acad Sci III 1996 Aug;319(8):671–80 (Eng. Abstr.) **(Fre)**

ANTAGONISTS & INHIBITORS

High rates of actin filament turnover in budding yeast and roles for actin in establishment and maintenance of cell polarity revealed using the actin inhibitor latrunculin-A. Ayscough KR, et al. **J Cell Biol** 1997 Apr 21; 137(2):399–416

BIOSYNTHESIS

Pregnancy-induced elevation in aortic vascular smooth muscle actin in the Sprague-Dawley rat. Davidge ST, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):212–3
Regulation of thrombin-induced stress fibre formation in Swiss 3T3 cells by the 70-kDa S6 kinase. Crouch MF.
Biochem Biophys Res Commun 1997 Apr 7;233(1):193–9
Smooth muscle alpha-actin expression in rat hepatic stellate cell is regulated by nitric oxide and cGMP production. Kawada N, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):238–42
Activation effects of a prion protein fragment [PrP-(106–126)] on human leucocytes. Diomede L, et al.
Biochem J 1996 Dec 1;320 (Pt 2):563–70
Microinjection of ADP-ribosylated actin inhibits actin synthesis in hepatocyte-hepatoma hybrid cells. Reuner KH, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):843–9
Ecdysteroid mediated muscle actin synthesis during the larval development of rice moth, Corcyra cephalonica. Shanavas A, et al. **Biochem Mol Biol Int** 1996 Nov;40(5):955–63
A role for Rev in the association of HIV-1 gag mRNA with cytoskeletal beta-actin and viral protein expression. Kimura T, et al. **Biochimie** 1996;78(11–12):1075–80 (48 ref.)
Induction of alpha-smooth muscle actin expression and myofibroblast transformation in cultured corneal keratocytes. Jester JV, et al. **Cornea** 1996 Sep;15(5):505–16
TGF-beta 2 increases alpha-smooth muscle actin expression in bovine retinal pigment epithelial cells. Kurosaka D, et al. **Curr Eye Res** 1996 Nov;15(11):1144–7
Regulation of actin synthesis in rat hepatocytes by cytoskeletal rearrangements. Reuner KH, et al.
Eur J Cell Biol 1996 Feb;69(2):189–96
AL-1-induced growth cone collapse of rat cortical neurons is correlated with REK7 expression and rearrangement of the actin cytoskeleton. Meima L, et al. **Eur J Neurosci** 1997 Jan;9(1):177–88
Role of thyroid hormone in the morphological differentiation and maturation of astrocytes: temporal correlation with synthesis and organization of actin. Paul S, et al.
Eur J Neurosci 1996 Nov;8(11):2361–70
Focal adhesion and stress fiber formation is regulated by tyrosine phosphatase activity. Retta SF, et al.
Exp Cell Res 1996 Dec 15;229(2):307–17
Relationship between alpha-smooth muscle actin expression and fibrotic changes in human kidney. Boukhalfa G, et al.
Exp Nephrol 1996 Jul–Aug;4(4):241–7
Hypoosmolarity and glutamine increased the beta-actin gene transcription in isolated rat hepatocytes. Husson A, et al.
FEBS Lett 1996 Oct 7;394(3):353–5
A transforming growth factor beta (TGFbeta) control element drives TGFbeta-induced stimulation of smooth muscle alpha-actin gene expression in concert with two CArG elements. Hautmann MB, et al. **J Biol Chem** 1997 Apr 18;272(16):10948–56
Autoregulation of actin synthesis responds to monomeric actin levels. Lyubimova A, et al. **J Cell Biochem** 1997 Jun 15;65(4):469–78
Dynamics of capping protein and actin assembly in vitro: uncapping barbed ends by polyphosphoinositides. Schafer DA, et al. **J Cell Biol** 1996 Oct;135(1):169–79
The human Arp2/3 complex is composed of evolutionarily conserved subunits and is localized to cellular regions of dynamic actin filament assembly. Welch MD, et al.
J Cell Biol 1997 Jul 28;138(2):375–84
Regulation of actin polymerization in cell-free systems by GTPgammaS and Cdc42. Zigmond SH, et al.
J Cell Biol 1997 Jul 28;138(2):363–74
Cloning and analysis of an actin-encoding cDNA from the dimorphic pathogenic fungus Histoplasma capsulatum. el-Rady J, et al. **J Med Vet Mycol** 1997 May–Jun; 35(3):159–66
Axonal regrowth upregulates beta-actin and Jun D mRNA expression. Lund LM, et al. **J Neurobiol** 1996 Dec; 31(4):476–86
Regulation of actin and its mRNA by thyroid hormones in cultures of fetal human brain during second trimester of

gestation. Pal U, et al. **J Neurochem** 1997 Sep;69(3):1170–6
Effect of major surgery on neutrophil chemotaxis and actin polymerization in neonates and children. Merry C, et al. **J Pediatr Surg** 1997 Jun;32(6):813–7
Hypertensive glomerular damage as revealed by the expression of alpha-smooth muscle actin and non-muscle myosin. Kimura K, et al. **Kidney Int Suppl** 1996 Jun; 55:S169–72
Cytokinesis in fission yeast Schizosaccharomyces pombe. Balasubramanian MK, et al. **Methods Enzymol** 1997; 283:494–506
Recruitment of the tinman homolog Nkx-2.5 by serum response factor activates cardiac alpha-actin gene transcription. Chen CY, et al. **Mol Cell Biol** 1996 Nov; 16(11):6372–84
The Arabidopsis ACT11 actin gene is strongly expressed in tissues of the emerging inflorescence, pollen, and developing ovules. Huang S, et al. **Plant Mol Biol** 1997 Jan;33(1):125–39
Human prostatic smooth muscle cells in culture: estradiol enhances expression of smooth muscle cell-specific markers. Zhang J, et al. **Prostate** 1997 Feb 1;30(2):117–29
Thyroid hormone-regulated actin polymerization in brain. Leonard JL, et al. **Thyroid** 1997 Feb;7(1):147–51 (31 ref.)
Hepatic stellate cells reversibly express alpha-smooth muscle actin during acute hepatic ischemia. Rubbia-Brandt L, et al. **Transplant Proc** 1997 Aug;29(5):2390–5

BLOOD

Acute ethanol administration modulates leukocyte actin polymerization in endotoxic rats. Zhang P, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):779–83
Irreversibly sickled cell beta-actin: defective filament formation. Shartava A, et al. **Am J Hematol** 1997 Jun; 55(2):97–103
Thrombin activation of human platelets dissociates a complex containing gelsolin and actin from phosphatidylinositide-specific phospholipase Cgamma1. Baldassare JJ, et al. **Biochem J** 1997 May 15;324 (Pt 1):283–7
Impaired actin polymerization and depolymerization in neutrophils from patients with thermal injury. Vindenes HA, et al. **Burns** 1997 Mar;23(2):131–6
Detection of circulating alpha-actinin in non-insulin-dependent diabetics with autonomic dysfunction. Prados J, et al. **Cardiology** 1996 Jul-Aug; 87(4):283–6
Actin polymerization in neutrophils from patients affected by myelodysplastic syndromes—a flow cytometric study. Carulli G, et al. **Leuk Res** 1997 Jun;21(6):513–8
Actin content and polymerization in tumour, liver and serum of the hepatoma Morris 5123 tumour bearing rats. Malicka-Blaszkiewicz M, et al. **Mater Med Pol** 1995 Jul-Sep;27(3):115–8

CHEMISTRY

X-ray diffraction from a helix of any length that displays cumulative azimuthal disorder. Mu XQ, et al. **Acta Crystallogr A** 1997 Jan 1;53 (Pt 1):55–62
Distribution of myosin and actin in moving human neutrophils detected by double-fluorescence staining. Takubo T, et al. **Anal Quant Cytol Histol** 1997 Jun; 19(3):233–8
The sugar kinase/heat shock protein 70/actin superfamily: implications of conserved structure for mechanism. Hurley JH. **Annu Rev Biophys Biomol Struct** 1996;25:137–62 (75 ref.)
Effects of nucleotides on the denaturation of F actin: a differential scanning calorimetry and FTIR spectroscopy study. Bombardier H, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):798–803
Restoration of defective mechanochemical properties of cleaved actins by native tropomyosin: involvement of the 40–50 loop in subdomain 2 of actin in interaction with myosin and tropomyosin. Higashi-Fujime S, et al. **Biochem Biophys Res Commun** 1997 Aug 8;237(1):121–5
ABM-1 and ABM-2 homology sequences: consensus docking sites for actin-based motility defined by oligoproline regions in Listeria ActA surface protein and human VASP. Purich DL, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):686–91
Accelerative sliding of myosin-coated glass-beads under suspended condition from actin paracrystal. Suda H, et al. **Biochem Biophys Res Commun** 1997 Aug 18;237(2):427–31
Phalloidin binding and rheological differences among actin isoforms. Allen PG, et al. **Biochemistry** 1996 Nov 12; 35(45):14062–9
A myosin head can interact with two chemically modified G-actin monomers at ATP-modulated multiple sites. Arata T. **Biochemistry** 1996 Dec 17;35(50):16061–8
Kinetics and thermodynamics of phalloidin binding to actin filaments from three divergent species. De La Cruz EM, et al. **Biochemistry** 1996 Nov 12;35(45):14054–61
Mobility of the N-terminal segment of rabbit skeletal muscle F-actin detected by 1H and 19F nuclear magnetic resonance spectroscopy. Heintz D, et al. **Biochemistry** 1996 Oct 1;35(39):12686–93
Polymerization and in vitro motility properties of yeast actin: a comparison with rabbit skeletal alpha-actin. Kim E, et al. **Biochemistry** 1996 Dec 24;35(51):16566–72
A conformational change in F-actin when myosin binds: fluorescence resonance energy transfer detects an increase in the radial coordinate of Cys-374. Moens PD, et al. **Biochemistry** 1997 Jun 17;36(24):7353–60
Functional transitions in myosin: role of highly conserved Gly and Glu residues in the active site. Onishi H, et al. **Biochemistry** 1997 Apr 1;36(13):3767–72
Molecular contacts between nebulin and actin: cross-linking of nebulin modules to the N-terminus of actin. Shih CL, et al. **Biochemistry** 1997 Feb 18;36(7):1814–25
Actin assembly by cadmium ions. DalleDonne I, et al. **Biochim Biophys Acta** 1997 Jun 5;1357(1):5–17
Force production by chemically crosslinked myosin-actin crossbridges in rabbit skinned fibers in response to MgATP depletion. Emoto Y, et al. **Biophys Chem** 1996 Oct 30; 61(2–3):85–92
ATP-dependent fluctuations of single actin filaments in vitro. Hatori K, et al. **Biophys Chem** 1996 Feb 8;58(3):267–72
Small segmental rearrangements in the myosin head can explain force generation in muscle. Díaz Baños FG, et al. **Biophys J** 1996 Aug;71(2):576–89
The bundling of actin with polyethylene glycol 8000 in the presence and absence of gelsolin. Goverman J, et al. **Biophys J** 1996 Sep;71(3):1485–92
Three-dimensional image reconstruction of reconstituted smooth muscle thin filaments: effects of caldesmon. Hodgkinson JL, et al. **Biophys J** 1997 Jun;72(6):2398–404
Interhead distances in myosin attached to F-actin estimated by fluorescence energy transfer spectroscopy. Ishiwata S, et al. **Biophys J** 1997 Aug;73(2):895–904
Mechanism and size cutoff for steric exclusion from actin-rich cytoplasmic domains. Janson LW, et al. **Biophys J** 1996 Sep;71(3):1228–34
Tracer diffusion through F-actin: effect of filament length and cross-linking. Jones JD, et al. **Biophys J** 1996 Nov; 71(5):2742–50
Conformational changes in actin induced by its interaction with gelsolin. Khaitlina S, et al. **Biophys J** 1997 Aug; 73(2):929–37
Intermolecular coupling between loop 38–52 and the C-terminus in actin filaments. Kim E, et al. **Biophys J** 1996 Oct;71(4):1914–9
Actin-titin interaction in cardiac myofibrils: probing a physiological role. Linke WA, et al. **Biophys J** 1997 Aug; 73(2):905–19
Phosphatidylserine liposomes can be tethered by caldesmon to actin filaments. Makuch R, et al. **Biophys J** 1997 Sep; 73(3):1607–16
Cell motility driven by actin polymerization. Mogilner A, et al. **Biophys J** 1996 Dec;71(6):3030–45
Hisactophilin-mediated binding of actin to lipid lamellae: a neutron reflectivity study of protein membrane coupling. Naumann C, et al. **Biophys J** 1996 Aug;71(2):811–23
Control of actin moving trajectory by patterned poly(methylmethacrylate) tracks. Suzuki H, et al. **Biophys J** 1997 May;72(5):1997–2001
Stability and dynamics of G-actin: back-door water diffusion and behavior of a subdomain 3/4 loop. Wriggers W, et al. **Biophys J** 1997 Aug;73(2):624–39
Chaperonin-mediated folding in the eukaryotic cytosol proceeds through rounds of release of native and nonnative forms. Farr GW, et al. **Cell** 1997 Jun 13;89(6):927–37
Capping of the barbed ends of actin filaments by a high-affinity profilin-actin complex. DiNubile MJ, et al. **Cell Motil Cytoskeleton** 1997;37(3):211–25
The antiproliferative activity of the tetrapeptide Acetyl-N-SerAspLysPro, an inhibitor of haematopoietic stem cell proliferation, is not mediated by a thymosin beta 4-like effect on actin assembly. Cheviron N, et al. **Cell Prolif** 1996 Aug;29(8):437–46
The chemical mechanism of myosin-I: implications for actin-based motility and the evolution of the myosin family of motor proteins. Pollard TD, et al. **Cell Struct Funct** 1996 Oct;21(5):351–6 (30 ref.)
Viscoelasticity of actin-gelsolin networks in the presence of filamin. Goldmann WH, et al. **Eur J Biochem** 1997 Jun 1;246(2):373–9
Electrostatic effects of smooth muscle calponin on actin assembly. Tang JX, et al. **Eur J Biochem** 1997 Jul 1; 247(1):432–40
What is the diameter of the actin filament? Grazi E. **FEBS Lett** 1997 Apr 1;405(3):249–52
Probing phosphatidylinositolphosphates and adenosinenucleotides on talin nucleated actin polymerization. Isenberg G, et al. **FEBS Lett** 1996 Nov 18;397(2–3):316–20
Calcium storage and release properties of F-actin: evidence for the involvement of F-actin in cellular calcium signaling. Lange K, et al. **FEBS Lett** 1996 Oct 21;395(2–3):137–42
Primary intracerebral leiomyoma: a case with eosinophilic inclusions of actin filaments. Lin SL, et al. **Histopathology** 1996 Apr;28(4):365–9
ADP-ribosylated actin as part of the actin monomer pool in rat brain. Tsuyama S, et al. **Int J Biochem Cell Biol** 1997 Feb;29(2):293–301
FT-Raman studies on the transformation of G-actin to F-actin, the binding of cisplatin and transplatin to F-actin and the effects of the conformation of F-actin. Zeng HH, et al. **Int J Biol Macromol** 1997 Apr;20(2):107–13
Regulated crosslinked actin filaments and the decoupling between their ATPase activity and sliding motility. Honda H, et al. **J Biochem (Tokyo)** 1997 Jan;121(1):47–9
Maleimidobenzoyl actin: its biochemical properties and in vitro motility. Hozumi T, et al. **J Biochem (Tokyo)** 1996 Jan;119(1):151–6
Binding of myosin subfragment 1 to actin. Katoh T, et al. **J Biochem (Tokyo)** 1996 Jul;120(1):189–92
Mapping myosin-binding sites on actin probed by peptides that inhibit actomyosin interaction. Katoh T, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):580–6
Cooperative association of actin protomers and crosslinked actin oligomers in filaments at low ionic strength. Miyata H, et al. **J Biochem (Tokyo)** 1997 Mar;121(3):527–33
Trimeric G proteins control exocytosis in chromaffin cells. Go regulates the peripheral actin network and catecholamine secretion by a mechanism involving the small GTP-binding protein Rho. Gasman S, et al. **J Biol Chem** 1997 Aug 15;272(33):20564–71
The effects of severely decreased hydrophobicity in a subdomain 3/4 loop on the dynamics and stability of yeast G-actin. Kuang B, et al. **J Biol Chem** 1997 Feb 14; 272(7):4412–8
Misakinolide A is a marine macrolide that caps but does not sever filamentous actin. Terry DR, et al. **J Biol Chem** 1997 Mar 21;272(12):7841–5
Chemical and physical properties of the extracellular matrix are required for the actin ring formation in osteoclasts. Nakamura I, et al. **J Bone Miner Res** 1996 Dec; 11(12):1873–9
Localization of p21-activated kinase 1 (PAK1) to pinocytic vesicles and cortical actin structures in stimulated cells. Dharmawardhane S, et al. **J Cell Biol** 1997 Sep 22; 138(6):1265–78
Actin filament cables in Drosophila nurse cells are composed of modules that slide passively past one another during dumping. Guild GM, et al. **J Cell Biol** 1997 Aug 25; 138(4):783–97
Structure, subunit topology, and actin-binding activity of the Arp2/3 complex from Acanthamoeba. Mullins RD, et al. **J Cell Biol** 1997 Jan 27;136(2):331–43
Actin filament bundles are required for microtubule reorientation during growth cone turning to avoid an inhibitory guidance cue. Challacombe JF, et al. **J Cell Sci** 1996 Aug;109 (Pt 8):2031–40
The structure of an open state of beta-actin at 2.65 A resolution. Chik JK, et al. **J Mol Biol** 1996 Nov 8; 263(4):607–23
Modulation of yeast F-actin structure by a mutation in the nucleotide-binding cleft. Orlova A, et al. **J Mol Biol** 1997 Aug 15;271(2):235–43
Conformational changes due to calcium-induced calmodulin dissociation in brush border myosin I-decorated F-actin revealed by cryoelectron microscopy and image analysis. Whittaker M, et al. **J Mol Biol** 1997 Jun 20;269(4):548–57
Direct measurement of the torsional rigidity of single actin filaments. Yasuda R, et al. **J Mol Biol** 1996 Oct 25; 263(2):227–36
Structural comparisons of muscle and nonmuscle actins give insights into the evolution of their functional differences. Mounier N, et al. **J Mol Evol** 1997 Jan;44(1):89–97
Fluorescence quenching of the tryptophan emission from the F- and G-forms of actin. Hild G, et al. **J Photochem Photobiol B** 1996 Sep;35(3):175–9
The Drosophila bifocal gene encodes a novel protein which colocalizes with actin and is necessary for photoreceptor morphogenesis. Bahri SM, et al. **Mol Cell Biol** 1997 Sep; 17(9):5521–9
Only one F-actin model [letter] Egelman EH, et al. **Nat Struct Biol** 1997 Sep;4(9):683–4
The structure of an actin-crosslinking domain from human fimbrin [letter] Goldsmith SC, et al. **Nat Struct Biol** 1997 Sep;4(9):708–12
Plugging into actin's architectonic socket [news] Schutt CE, et al. **Nat Struct Biol** 1997 Mar;4(3):169–72
Actin depolymerization is developmentally regulated in rat type II cells exposed to terbutaline. Bhandari V, et al. **Pediatr Res** 1997 Feb;41(2):166–71
Detection of single-molecule interactions using correlated thermal diffusion. Mehta AD, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):7927–31
The structure of the acto-myosin subfragment 1 complex: results of searches using data from electron microscopy and x-ray crystallography. Mendelson R, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8533–8
Axial rotation of sliding actin filaments revealed by single-fluorophore imaging. Sase I, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5646–50
Torsional rigidity of single actin filaments and actin-actin bond breaking force under torsion measured directly by in vitro micromanipulation. Tsuda Y, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):12937–42
Protein-tyrosine phosphorylation and p72syk activation in human platelets stimulated with collagen is dependent upon glycoprotein Ia/IIa and actin polymerization. Asazuma N, et al. **Thromb Haemost** 1996 Apr;75(4):648–54

DRUG EFFECTS

A disrupter of actin microfilaments impairs sulfonylurea-inhibitory gating of cardiac KATP channels. Brady PA, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2710–6
1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Higashimoto Y, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2653–9
Quantitative studies on liver fibrosis and alpha-smooth

muscle actin expression in heroin abusers. de Araújo MS, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jun;43(4):589–96
Cellular changes of rat embryonic fibroblasts by an actin-polymerization inhibitor, bistheonellide A, from a marine sponge. Watabe S, et al. **Cell Struct Funct** 1996 Jun;21(3):199–212
Actin polymerisation in neutrophils of rheumatoid arthritis patients in relation to treatment with non-steroidal anti-inflammatory drugs. De Clerck LS, et al. **Clin Chim Acta** 1997 May 6;261(1):19–25
The effects of copper on actin and fibronectin organization in Mytilus galloprovincialis haemocytes. Fagotti A, et al. **Dev Comp Immunol** 1996 Nov–Dec;20(6):383–91
Oxidized low-density lipoprotein increases endothelial intracellular calcium and alters cytoskeletal f-actin distribution. Zhao B, et al. **Eur J Clin Invest** 1997 Jan; 27(1):48–54
Paraquat induces actin assembly in depolymerizing conditions. Milzani A, et al. **FASEB J** 1997 Mar; 11(4):261–70
Dephosphorylation of a 34kd triton-insoluble F-actin pool protein is associated with phorbol ester-induced actin polymerization in human polymorphonuclear leukocytes. Watts RG. **Hematopathol Mol Hematol** 1996;10(1–2):69–84
N-methyl-D-aspartate evokes rapid net depolymerization of filamentous actin in cultured rat cerebellar granule cells. Shorte SL. **J Neurophysiol** 1997 Aug;78(2):1135–43
[Structural changes in the cytoskeletal actin in cultured muscle cells when the cultures are stimulated by polystyrene latex] Samosudova NV, et al. **Tsitologiia** 1996; 38(8):829–33 (Eng. Abstr.) **(Rus)**

GENETICS

Polyadenylated RNA, actin mRNA, and myosin heavy chain mRNA in young and old human skeletal muscle. Welle S, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):E224–9
Quantitation of mouse and rat beta-actin mRNA by competitive polymerase chain reaction using capillary electrophoresis. Murata T, et al. **Anal Biochem** 1997 Jan 1;244(1):172–4
cAMP levels and up-regulation of actin mRNA in Entamoeba histolytica. Manning-Cela R, et al. **Arch Med Res** 1997;28 Spec No:134–5
Upregulation of actin gene expression in cells expressing exogenous beta-amyloid precursor protein. Ramakrishna N, et al. **Biochem Biophys Res Commun** 1997 Feb 24; 231(3):615–8
Mutational analysis of the role of the N terminus of actin in actomyosin interactions. Comparison with other mutant actins and implications for the cross-bridge cycle. Miller CJ, et al. **Biochemistry** 1996 Dec 24;35(51):16557–65
Salt-dependent performance variation of DNA polymerases in co-amplification PCR. Favre N, et al. **Biotechniques** 1996 Jul;21(1):28–30
Control genes for reverse-transcription-polymerase chain reaction: a comparison of beta actin and glyceraldehyde phosphate dehydrogenase [letter; comment] Soutar RL, et al. **Br J Haematol** 1997 Apr;97(1):247–8. Comment on: Br J Haematol 1994 May;87(1):218.
Molecular determination of the malignant potential of smooth muscle neoplasms. Trzyna W, et al. **Cancer** 1997 Jul 15; 80(2):211–7
Actin in the parasite Toxoplasma gondii is encoded by a single copy gene, ACT1 and exists primarily in a globular form. Dobrowolski JM, et al. **Cell Motil Cytoskeleton** 1997; 37(3):253–62
The glutamate dehydrogenase, E74 and putative actin gene loci in the Drosophila montium subgroup. Chromosomal homologies among the montium species and D. melanogaster. Drosopoulou E, et al. **Chromosoma** 1997 Jun; 106(1):20–8
Cloning and sequencing of a full-length sea bream (Sparus aurata) beta-actin cDNA. Santos CR, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Jun; 117(2):185–9
The actin gene of the glaucocystophyte Cyanophora paradoxa: analysis of the coding region and introns, and an actin phylogeny of eukaryotes. Bhattacharya D, et al. **Curr Genet** 1997 May;31(5):439–46
FISH localization of human cytoplasmic actin genes ACTB to 7p22 and ACTG1 to 17q25 and characterization of related pseudogenes. Ueyama H, et al. **Cytogenet Cell Genet** 1996;74(3):221–4
Skeletal and cardiac alpha-actin isoforms exhibit unanticipated temporal and tissue-specific gene expression patterns in developing avian limbs and embryos. Lin-Jones J, et al. **Dev Biol** 1997 Sep 15;189(2):322–34
Activation of the cardiac alpha-actin promoter depends upon serum response factor, Tinman homologue, Nkx-2.5, and intact serum response elements. Chen CY, et al. **Dev Genet** 1996;19(2):119–30
A competitive mechanism of CArG element regulation by YY1 and SRF: implications for assessment of Phox1/MHox transcription factor interactions at CArG elements. Martin KA, et al. **DNA Cell Biol** 1997 May;16(5):653–61
A role for the divergent actin gene, ACT2, in nuclear pore structure and function. Yan C, et al. **EMBO J** 1997 Jun; 16(12):3572–86
Substitution of just five nucleotides at and around the transcription start site of rat beta-actin promoter is sufficient to render the resulting transcript a subject for translational control. Biberman Y, et al. **FEBS Lett** 1997 Apr 1;405(3):333–6
Molecular cloning of actin genes in Trichomonas vaginalis and phylogeny inferred from actin sequences. Bricheux G, et al. **FEMS Microbiol Lett** 1997 Aug 1;153(1):205–13
Molecular cloning of, and phylogenetic analysis of, an actin in Naegleria fowleri. Gorospe S, et al. **FEMS Microbiol Lett** 1996 Aug 1;141(2–3):233–7
Actin genes with unusual organization in the parasitic angiosperm Striga asiatica L. (Kuntze). Florea CS, et al. **Gene** 1997 Feb 20;186(1):127–33
Nucleotide sequence of two actin genes of Lumbricus terrestris. Lewke N, et al. **Gene** 1996 Oct 31; 178(1–2):199–200
Two alternative promoters drive the expression of the cytoplasmic actin A4 gene of Bombyx mori. Mangé A, et al. **Gene** 1996 Dec 12;183(1–2):191–9
Structure and regulation of the porcine skeletal alpha-actin-encoding gene. Reecy JM, et al. **Gene** 1996 Nov 21;180(1–2):23–8
A Leuconostoc lactis protein with homology to ribosomal protein S1 shares common epitopes and common DNA binding properties with a mammalian DNA binding nuclear factor. Yamit-Hezi A, et al. **Gene** 1997 Jan 31;185(1):99–103
Structure and evolution of the actin gene family in Arabidopsis thaliana. McDowell JM, et al. **Genetics** 1996 Feb;142(2):587–602
Reciprocal gene expression of rat fibroglycan and beta-actin during the course of regeneration after D-galactosamine liver injury. Shinji T, et al. **Hepatogastroenterology** 1997 Jan–Feb;44(13):239–44
A cytoplasmic actin gene from the silkworm Bombyx mori is expressed in tissues of endodermal origin and previtellogenic germ cells of transgenic Drosophila. Horard B, et al. **Insect Mol Biol** 1993;2(3):175–83
ACTBP2 gene frequency distribution and sequencing of the allelic ladder and variants in the Japanese and Chinese populations. Liu C, et al. **Int J Legal Med** 1997; 110(4):208–12
Sequence polymorphism at the tetranucleotide repeat of the human beta-actin related pseudogene H-beta-Ac-psi-2 (ACTBP2) locus. Rolf B, et al. **Int J Legal Med** 1997; 110(2):69–72
Repression of transcriptional enhancer factor-1 and activator protein-1-dependent enhancer activity by vascular actin single-stranded DNA binding factor 2. Kelm RJ Jr, et al. **J Biol Chem** 1996 Sep 27;271(39):24278–85
Beryllium fluoride and phalloidin restore polymerizability of a mutant yeast actin (V266G,L267G) with severely decreased hydrophobicity in a subdomain 3/4 loop. Kuang B, et al. **J Biol Chem** 1997 Jan 10;272(2):1237–47
The myogenic regulatory factor MRF4 represses the cardiac alpha-actin promoter through a negative-acting N-terminal protein domain. Moss JB, et al. **J Biol Chem** 1996 Dec 6;271(49):31688–94
Altered secondary myogenesis in transgenic animals expressing the neural cell adhesion molecule under the control of a skeletal muscle alpha-actin promoter. Fazeli S, et al. **J Cell Biol** 1996 Oct;135(1):241–51
Chlamydomonas inner-arm dynein mutant, ida5, has a mutation in an actin-encoding gene. Kato-Minoura T, et al. **J Cell Biol** 1997 May 5;137(3):649–56
beta-Actin messenger RNA localization and protein synthesis augment cell motility. Kislauskis EH, et al. **J Cell Biol** 1997 Mar 24;136(6):1263–70
Isolation and characterization of fission yeast mutants defective in the assembly and placement of the contractile actin ring. Chang F, et al. **J Cell Sci** 1996 Jan;109 (Pt 1):131–42
Down-regulation of actin genes precedes microfilament network disruption and actin cleavage during p53-mediated apoptosis. Guénal I, et al. **J Cell Sci** 1997 Feb;110 (Pt 4):489–95
Triiodothyronine induces over-expression of alpha-smooth muscle actin, restricts myofibrillar expansion and is permissive for the action of basic fibroblast growth factor and insulin-like growth factor I in adult rat cardiomyocytes. Gosteli-Peter MA, et al. **J Clin Invest** 1996 Oct 15;98(8):1737–44
Up-regulation of action mRNA and reorganization of the cytoskeleton in Entamoeba histolytica trophozoites. Manning-Cela R, et al. **J Eukaryot Microbiol** 1997 Jan–Feb;44(1):18–24
Amplification of human beta-actin gene by the reverse transcriptase-polymerase chain reaction: implications for assessment of RNA from formalin-fixed, paraffin-embedded material. Dakhama A, et al. **J Histochem Cytochem** 1996 Oct;44(10):1205–7
Muscle actin gene from Aedes aegypti (Diptera:Culicidae). Ibrahim MS, et al. **J Med Entomol** 1996 Nov;33(6):955–62
A strong inhibitory element down-regulates SRE-stimulated transcription of the A3 cytoplasmic actin gene of Bombyx mori. Mangé A, et al. **J Mol Biol** 1997 Jan 24;265(3):266–74
Transfection with c-Ha rasEJ modulates alpha-actin and alpha 1B-adrenoceptor gene expression in vascular smooth muscle cells. Lundberg MS, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1695–702
Evolution of chordate actin genes: evidence from genomic organization and amino acid sequences. Kusakabe T, et al. **J Mol Evol** 1997 Mar;44(3):289–98
Actin gene structure in two Artemia species, A. franciscana and A. parthenogenetica. Ortega MA, et al. **J Mol Evol** 1996 Sep;43(3):224–35
Evidence for gene conversion between tandemly duplicated cytoplasmic actin genes of Helicoverpa armigera (Lepidoptera:Noctuidae). Rourke IJ, et al. **J Mol Evol** 1997 Feb;44(2):169–77
Isolation and characterization of five actin cDNAs from the cestode Diphyllobothrium dendriticum: a phylogenetic study of the multigene family. Wahlberg MH, et al. **J Mol Evol** 1997 Feb;44(2):159–68
Diurnal variations of interleukin-1 beta mRNA and beta-actin mRNA in rat brain. Taishi P, et al. **J Neuroimmunol** 1997 May;75(1–2):69–74
Phylogenetic analysis of Perkinsus based on actin gene sequences. Reece KS, et al. **J Parasitol** 1997 Jun; 83(3):417–23
Evidence for genetic control of changes in f-actin polymerization caused by pathogenic microorganisms: in vitro assessment using gingival fibroblasts from human twins. Hassell TM, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):90–8
Dissociation of beta-adrenoceptor numbers from mRNA levels during acute ischemia in rat myocardium. Nakamura K, et al. **Jpn J Pharmacol** 1997 Jan;73(1):23–8
Ribonucleases may limit recovery of ribonucleic acids from archival human temporal bones. Lee KH, et al. **Laryngoscope** 1997 Sep;107(9):1228–34
Debate round-table. Appropriate controls for RT-PCR [comment] Kidd V, et al. **Leukemia** 1997 Jun;11(6):871–81 . Comment on: Leukemia 1996 Sep;10(9):1527–8. Comment on: Leukemia 1996 Nov;10(11):1841–2.
Distal cis-acting elements restrict expression of the CyIIIb actin gene in the aboral ectoderm of the sea urchin embryo. Xu N, et al. **Mech Dev** 1996 Dec;60(2):151–62
Cloning of two actin genes from Schistosoma mansoni. Oliveira GC, et al. **Mol Biochem Parasitol** 1995 Dec; 75(1):119–22
Three main patterns in the expression of six actin genes in the pierocercoid and adult Diphyllobothrium dendriticum tapeworm (Cestoda). Wahlberg MH. **Mol Biochem Parasitol** 1997 Jun;86(2):199–209
Rapid evolution in a conserved gene family. Evolution of the actin gene family in the sea urchin genus Heliocidaris and related genera. Kissinger JC, et al. **Mol Biol Evol** 1997 Jun;14(6):654–65
Phylogeny and substitution rates of angiosperm actin genes. Moniz de Sá M, et al. **Mol Biol Evol** 1996 Nov; 13(9):1198–212
Actin gene expression in developing sea urchin embryos. Crain WR Jr, et al. **Mol Cell Biol** 1981 Aug;1(8):711–20
Volatility of internal eliminated segments in germ line genes of hypotrichous ciliates. DuBois ML, et al. **Mol Cell Biol** 1997 Jan;17(1):326–37
Characterization of a beta-actin mRNA zipcode-binding protein. Ross AF, et al. **Mol Cell Biol** 1997 Apr; 17(4):2158–65
Organization and expression of multiple actin genes in the sea urchin. Scheller RH, et al. **Mol Cell Biol** 1981 Jul; 1(7):609–28
Competition between negative acting YY1 versus positive acting serum response factor and tinman homologue Nkx-2.5 regulates cardiac alpha-actin promoter activity. Chen CY, et al. **Mol Endocrinol** 1997 Jun;11(6):812–22
Extensive maternal representation of DNA-binding proteins that interact with regulatory target sites of the Strongylocentrotus purpuratus CyIIIa gene. Calzone FJ, et al. **Mol Mar Biol Biotechnol** 1997 Jun;6(2):79–83
Intron-length polymorphism at the actin gene locus mac-1: a genetic marker for population studies in the marine mussels Mytilus galloprovincialis Lmk. and M. edulis L. Ohresser M, et al. **Mol Mar Biol Biotechnol** 1997 Jun; 6(2):123–30
Organization of the Saccharomyces cerevisiae actin gene UAS: functional significance of reiterated REB1 binding sites and AT-rich elements. McLean M, et al. **Mol Microbiol** 1995 Nov;18(4):605–14
Comparison of the activity of carp and rat beta-actin gene regulatory sequences in tilapia and rainbow trout embryos. Alam MS, et al. **Mol Reprod Dev** 1996 Oct;45(2):117–22
In postmeiotic male germ cells poly (A) shortening accompanies translation of mRNA encoding gamma enteric actin but not cytoplasmic beta and gamma actin mRNAs. Gu W, et al. **Mol Reprod Dev** 1996 Jun;44(2):141–5
Regulation of beta- and gamma-actin mRNA by thyroid hormone in the developing rat brain. Sarkar S, et al. **Neuroreport** 1997 Mar 24;8(5):1267–71
Muscle isoactin expression during in vitro differentiation of murine embryonic stem cells. Ng WA, et al. **Pediatr Res** 1997 Feb;41(2):285–92
The Arabidopsis thaliana ACT4/ACT12 actin gene subclass is strongly expressed throughout pollen development. Huang S, et al. **Plant J** 1996 Aug;10(2):189–202
Rescue of cardiac alpha-actin-deficient mice by enteric smooth muscle gamma-actin. Kumar A, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4406–11
Expression of ubiquitin, actin, and actin-like genes in African swine fever virus infected cells. Ferreira C. **Virus Res** 1996 Sep;44(1):11–21
Identification of ACT4, a novel essential actin-related gene in the yeast Saccharomyces cerevisiae. Huang ME, et al. **Yeast** 1996 Jul;12(9):839–48
Structural and phylogenetic analysis of the actin gene from the yeast Phaffia rhodozyma. Wery J, et al. **Yeast** 1996 Jun 15;12(7):641–51

ACTINS

IMMUNOLOGY

Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Czaja AJ, et al. **Hepatology** 1996 Nov;24(5):1068–73

Actin filaments facilitate two steps of endocytosis. Durrbach A, et al. **J Cell Sci** 1996 Feb;109 (Pt 2):457–65

Anti-actin autoantibodies in patients with chronic hepatitis C [letter] Chazouilleres O, et al. **J Hepatol** 1996 Apr; 24(4):513

Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1. Orth T, et al. **J Hepatol** 1997 Jan;26(1):37–47

Deposition of anti-actin antibodies in the kidney of a patient with systemic lupus erythematosus under immunosuppressive treatment. Boulila A, et al. **Nephrol Dial Transplant** 1996 Dec;11(12):2478–81

METABOLISM

Fatal congenital myopathy with actin filament deposits. Bornemann A, et al. **Acta Neuropathol (Berl)** 1996 Jul; 92(1):104–8

Force decline during muscle relaxation promotes calcium release to the cytosol. Baker AJ, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C85–91

Relationship between polyamines, actin distribution, and gastric healing in rats. Banan A, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):G893–903

Endothelial barrier dysfunction and p42 oxidation induced by TNF-alpha are mediated by nitric oxide. Ferro TJ, et al. **Am J Physiol** 1997 May;272(5 Pt 1):L979–88

Effects of F-actin stabilization or disassembly on epithelial Cl- secretion and Na-K-2Cl cotransport. Matthews JB, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):C254–62

Rat liver ferritin selectively inhibits expression of alpha-smooth muscle actin in cultured rat lipocytes. Ramm GA, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G370–5

Actin removal from cardiac myocytes shows that near Z line titin attaches to actin while under tension. Trombitás K, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C662–70

F-actin disruption attenuates agonist-induced [Ca2+], myosin phosphorylation, and force in smooth muscle. Tseng S, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):C1960–7

CGP-48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction. Wolska BM, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H24–32

Actin and tropomyosin isoforms in morphogenesis. Gunning P, et al. **Anat Embryol (Berl)** 1997 Apr;195(4):311–5 (44 ref.)

Prolonged oxidative stress on actin. Milzani A, et al. **Arch Biochem Biophys** 1997 Mar 15;339(2):267–74

Myosin I interactions with actin filaments and trans-Golgi-derived vesicles in MDCK cell monolayers. Montes de Oca G, et al. **Arch Med Res** 1997 Autumn; 28(3):321–8

The tail domain of Entamoeba histolytica myosin IB bind F-actin. Vargas MA, et al. **Arch Med Res** 1997;28 Spec No:137–8

Vitamin E protection of cell morphology under oxidative stress is related to cytoskeletal proteins in rat hepatocytes. Kuo JH, et al. **Arch Toxicol** 1997;71(4):231–7

L-selectin regulates actin polymerisation via activation of the small G-protein Rac2. Brenner B, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):802–7

Bradykinin induces actin reorganization and enhances cell motility in HaCaT keratinocytes. Coutant KD, et al. **Biochem Biophys Res Commun** 1997 Aug 18;237(2):257–61

Localization of a calcium sensitive binding site for gelsolin on actin subdomain I: implication for severing process. Feinberg J, et al. **Biochem Biophys Res Commun** 1997 Apr 7;233(1):61–5

Restoration of defective mechanochemical properties of cleaved actins by native tropomyosin: involvement of the 40–50 loop in subdomain 2 of actin in interaction with myosin and tropomyosin. Higashi-Fujime S, et al. **Biochem Biophys Res Commun** 1997 Aug 8;237(1):121–5

Nitric oxide inhibits capping in HL-60 cells. Lee JH, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):827–31

Scanning force microscopy of the interaction events between a single molecule of heavy meromyosin and actin. Nakajima H, et al. **Biochem Biophys Res Commun** 1997 May 8; 234(1):178–82

Phospholipase C-gamma 1 binds to actin-cytoskeleton via its C-terminal SH2 domain in vitro. Pei Z, et al. **Biochem Biophys Res Commun** 1996 Nov 21;228(3):802–6

Actin cytoskeleton as a target for 2-chloro adenosine: evidence for induction of apoptosis in C2C12 myoblastic cells. Rufini S, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):361–6

Modulation of actin filament sliding by mutations of the SH2 cysteine in Dictyostelium myosin II. Suzuki Y, et al. **Biochem Biophys Res Commun** 1997 May 29;234(3):701–6

Actin is cleaved during constitutive apoptosis. Brown SB, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):233–7

Correlation between calponin and myosin subfragment 1 binding to F-actin and ATPase inhibition. Szymanski PT, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):519–23

Enhancement by F-actin of MgATP-dependent dopamine uptake into isolated chromaffin granules. Morita K, et al. **Biochem Mol Biol Int** 1996 Sep;40(1):61–6

Interaction of myosin subfragment 1 with F-actin studied by differential scanning calorimetry. Nikolaeva OP, et al. **Biochem Mol Biol Int** 1996 Nov;40(4):653–61

Phosphatidylserine directs differential phosphorylation of actin and glyceraldehyde-3-phosphate dehydrogenase by protein kinase C: possible implications for regulation of actin polymerization. Reiss N, et al. **Biochem Mol Biol Int** 1996 Dec;40(6):1191–200

Altered actin polymerization dynamics in various malignant cell types: evidence for differential sensitivity to cytochalasin B. Stournaras C, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1339–46

A myosin head can interact with two chemically modified G-actin monomers at ATP-modulated multiple sites. Arata T. **Biochemistry** 1996 Dec 17;35(50):16061–8

Activation of regulated actin by SH1-modified myosin subfragment 1. Bobkov AA, et al. **Biochemistry** 1997 Jun 24;36(25):7733–8

Modulation of actin conformation and inhibition of actin filament velocity by calponin. Borovikov YuS, et al. **Biochemistry** 1996 Oct 29;35(43):13849–57

Cysteine scanning mutagenesis at 40 of 76 positions in villin headpiece maps the F-actin binding site and structural features of the domain. Doering DS, et al. **Biochemistry** 1996 Oct 1;35(39):12677–85

Kinetics of myosin subfragment-1-induced condensation of G-actin into oligomers, precursors in the assembly of F-actin-S1. Role of the tightly bound metal ion and ATP hydrolysis. Fievez S, et al. **Biochemistry** 1997 Sep 30; 36(39):11837–42

Mechanism of myosin subfragment-1-induced assembly of CaG-actin and MgG-actin into F-actin-S1-decorated filaments. Fievez S, et al. **Biochemistry** 1997 Sep 30; 36(39):11843–50

The inhibitory complex of smooth muscle caldesmon with actin and tropomyosin involves three interacting segments of the C-terminal domain 4. Fraser ID, et al. **Biochemistry** 1997 May 6;36(18):5483–92

Phenotypically selected mutations in myosin's actin binding domain demonstrate intermolecular contacts important for motor function. Giese KC, et al. **Biochemistry** 1997 Jul 15;36(28):8465–73

Arrangement of the COOH-terminal and NH2-terminal domains of caldesmon bound to actin. Graceffa P. **Biochemistry** 1997 Apr 1;36(13):3792–801

Myosin regulatory light chain and nucleotide modulation of actin binding site electric charge. Highsmith S. **Biochemistry** 1997 Feb 25;36(8):2010–6

Profilin interacts with the Gly-Pro-Pro-Pro-Pro-Pro sequences of vasodilator-stimulated phosphoprotein (VASP): implications for actin-based Listeria motility. Kang F, et al. **Biochemistry** 1997 Jul 8;36(27):8384–92

Kinetics of gelsolin interaction with phalloidin-stabilized F-actin. Rate constants for binding and severing. Kinosian HJ, et al. **Biochemistry** 1996 Dec 24;35(51):16550–6

Assembly mechanism of Dictyostelium myosin II: regulation by K+, Mg2+, and actin filaments. Mahajan RK, et al. **Biochemistry** 1996 Dec 3;35(48):15504–14

Continuous monitoring of Pi release following nucleotide hydrolysis in actin or tubulin assembly using 2-amino-6-mercapto-7-methylpurine ribonucleoside and purine-nucleoside phosphorylase as an enzyme-linked assay. Melki R, et al. **Biochemistry** 1996 Sep 17; 35(37):12038–45

Mutational analysis of the role of the N terminus of actin in actomyosin interactions. Comparison with other mutant actins and implications for the cross-bridge cycle. Miller CJ, et al. **Biochemistry** 1996 Dec 24;35(51):16557–65

A conformational change in F-actin when myosin binds: fluorescence resonance energy transfer detects an increase in the radial coordinate of Cys-374. Moens PD, et al. **Biochemistry** 1997 Jun 17;36(24):7353–60

Tropomyosin-binding site(s) on the Dictyostelium actin surface as identified by site-directed mutagenesis. Saeki K, et al. **Biochemistry** 1996 Nov 19;35(46):14465–72

Thymosin beta 4 binds actin in an extended conformation and contacts both the barbed and pointed ends. Safer D, et al. **Biochemistry** 1997 May 13;36(19):5806–16

Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes. Alvarez-Martinez MT, et al. **Biochim Biophys Acta** 1997 May 23;1330(2):331–40

Inhibitors of actin polymerization and calmodulin binding enhance protein kinase C-induced translocation of MARCKS in C6 glioma cells. Douglas DN, et al. **Biochim Biophys Acta** 1997 Apr 24;1356(2):121–30

Influence of actin binding on the conformation of the central segment of the heavy chain of skeletal myosin subfragment 1. Pliszka B. **Biochim Biophys Acta** 1997 Apr 25; 1339(1):126–32

The possible role of myosin A1 light chain in the weakening of actin-myosin interaction. Stępkowski D, et al. **Biochim Biophys Acta** 1997 Jun 20;1340(1):105–14

The rate of annealing of actin tropomyosin filaments depends strongly on the length of the filaments. Teubner A, et al. **Biochim Biophys Acta** 1996 Oct 17;1297(2):214–8

Actin-dependent pigment granule transport in retinal pigment epithelial cells. Burnside B, et al. **Biol Bull** 1997 Feb;192(1):181–2 (7 ref.)

Myosin drives retrograde F-actin flow in neuronal growth cones. Lin CH, et al. **Biol Bull** 1997 Feb;192(1):183–5 (29 ref.)

Macromolecular crowding: effects on actin polymerisation. Lindner RA, et al. **Biophys Chem** 1997 May 21;66(1):57–66

Mutual sensitization of ATP and GTP in driving F-actin on the surface-fixed H-meromyosin. Oda T, et al. **Biophys Chem** 1996 Oct 30;61(2–3):63–72

In vitro actin filament sliding velocities produced by mixtures of different types of myosin. Cuda G, et al. **Biophys J** 1997 Apr;72(4):1767–79

A 133Cs nuclear magnetic resonance study of endothelial Na(+)-K(+)-ATPase activity: can actin regulate its activity? Gruwel ML, et al. **Biophys J** 1997 Jun; 72(6):2775–82

Inhibition of cross-bridge binding to actin by caldesmon fragments in skinned skeletal muscle fibers. Heubach JF, et al. **Biophys J** 1997 Mar;72(3):1287–94

Osmotic pressure probe of actin-myosin hydration changes during ATP hydrolysis. Highsmith S, et al. **Biophys J** 1996 Jun;70(6):2830–7

Mechanism and size cutoff for steric exclusion from actin-rich cytoplasmic domains. Janson LW, et al. **Biophys J** 1996 Sep;71(3):1228–34

Intermolecular coupling between loop 38–52 and the C-terminus in actin filaments. Kim E, et al. **Biophys J** 1996 Oct;71(4):1914–9

Hisactophilin-mediated binding of actin to lipid lamellae: a neutron reflectivity study of protein membrane coupling. Naumann C, et al. **Biophys J** 1996 Aug;71(2):811–23

Calcium alone does not fully activate the thin filament for S1 binding to rigor myofibrils. Swartz DR, et al. **Biophys J** 1996 Oct;71(4):1891–904

Modulation of the junctional integrity by low or high concentrations of cytochalasin B and dihydrocytochalasin B is associated with distinct changes in F-actin and ZO-1. Nybom P, et al. **Biosci Rep** 1996 Aug;16(4):313–26

Recombinant human eotaxin induces oxygen radical production, Ca(2+)-mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein. Tenscher K, et al. **Blood** 1996 Oct 15;88(8):3195–9

Effects of calcitonin and parathyroid hormone on the distribution of F-actin in the clear zone of osteoclasts in vivo. Kuroda H, et al. **Bone** 1996 Aug;19(2):115–20

Effects of triiodothyronine on morphology, growth behavior, and the actin cytoskeleton in mouse osteoblastic cells (MC3T3-E1). Luegmayr E, et al. **Bone** 1996 Jun; 18(6):591–9

Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a). Dudani AK, et al. **Br J Haematol** 1996 Oct; 95(1):168–78

Analysis of glial fibrillary acidic protein, neurofilament protein, actin and heat shock proteins in human fetal brain during the second trimester. Aquino DA, et al. **Brain Res Dev Brain Res** 1996 Jan 22;91(1):1–10

Role of actin in the organisation of brain postsynaptic densities. Adam G, et al. **Brain Res Mol Brain Res** 1996 Dec 31;43(1-2):246–50

The tyrosine kinase inhibitor methyl 2,5-dihydroxycinnimate disrupts changes in the actin cytoskeleton required for neurite formation. Leventhal PS, et al. **Brain Res Mol Brain Res** 1996 Dec 31;43(1-2):338–40

Activation of actin-cleavable interleukin 1beta-converting enzyme (ICE) family protease CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells. Chen Z, et al. **Cancer Res** 1996 Nov 15; 56(22):5224–9

The crystal structure of plasma gelsolin: implications for actin severing, capping, and nucleation. Burtnick LD, et al. **Cell** 1997 Aug 22;90(4):661–70

Rac and Cdc42 induce actin polymerization and G1 cell cycle progression independently of p65PAK and the JNK/SAPK MAP kinase cascade. Lamarche N, et al. **Cell** 1996 Nov 1;87(3):519–29

Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Rodriguez-Viciana P, et al. **Cell** 1997 May 2;89(3):457–67

Coordinated regulation of fibronectin fibril assembly and actin stress fiber formation. Sechler JL, et al. **Cell Adhes Commun** 1997 Mar;4(6):413–24

Nitric oxide induces ADP-ribosylation of actin in murine macrophages: association with the inhibition of pseudopodia formation, phagocytic activity, and adherence on a laminin substratum. Jun CD, et al. **Cell Immunol** 1996 Nov 25;174(1):25–34

Analysis by confocal laser scanning microscopy imaging of undilated bile canaliculi F-actin staining in the hepatocytes of human extrahepatic cholestatic liver. Benköel L, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jun;43(4):477–83

Glyceraldehyde-3-phosphate dehydrogenase activity and F-actin associations in synaptosomes and postsynaptic densities of porcine cerebral cortex. Rogalski-Wilk AA, et al. **Cell Mol Neurobiol** 1997 Feb;17(1):51–70

Stimulation of cortical actin polymerization in the sea urchin egg cortex by NH4Cl, procaine and urethane: elevation of cytoplasmic pH is not the common mechanism of action. Begg DA, et al. **Cell Motil Cytoskeleton** 1996;35(3):210–24

How profilin/barbed-end synergy controls actin polymerization: a kinetic model of the ATP hydrolysis circuit. Dufort PA, et al. **Cell Motil Cytoskeleton** 1996; 35(4):309–30

Relative changes in F-actin during the first cell cycle:

evidence for two distinct pools of F-actin in the sea urchin egg. Heil-Chapdelaine RA, et al. **Cell Motil Cytoskeleton** 1996;34(1):26-35

Role of the ninaC proteins in photoreceptor cell structure: ultrastructure of ninaC deletion mutants and binding to actin filaments. Hicks JL, et al. **Cell Motil Cytoskeleton** 1996;35(4):367-79

Site-directed mutagenesis of the phosphorylation site of cofilin: its role in cofilin-actin interaction and cytoplasmic localization. Nagaoka R, et al. **Cell Motil Cytoskeleton** 1996;35(3):200-9

Bacteroides fragilis toxin rearranges the actin cytoskeleton of HT29/C1 cells without direct proteolysis of actin or decrease in F-actin content. Saidi RF, et al. **Cell Motil Cytoskeleton** 1997;37(2):159-65

Novel form of actin-based motility transports bacteria on the surfaces of infected cells. Sanger JM, et al. **Cell Motil Cytoskeleton** 1996;34(4):279-87

Beta cap73: a novel beta actin-specific binding protein. Shuster CB, et al. **Cell Motil Cytoskeleton** 1996; 35(3):175-87

Distribution of actin, myosin, and spectrin during enucleation in erythroid cells of hamster embryo. Takano-Ohmuro H, et al. **Cell Motil Cytoskeleton** 1996;34(2):95-107

Actin filament translocations in sea urchin eggs. Terasaki M. **Cell Motil Cytoskeleton** 1996;34(1):48-56

The relationship of HsEg5 and the actin cytoskeleton to centrosome separation. Whitehead CM, et al. **Cell Motil Cytoskeleton** 1996;35(4):298-308

Dynamics of filamentous actin organization in the sea urchin egg cortex during early cleavage divisions: implications for the mechanism of cytokinesis. Wong GK, et al. **Cell Motil Cytoskeleton** 1997;36(1):30-42

F-actin network formation in tethers and in pseudopods stimulated by chemoattractant. Zhelev DV, et al. **Cell Motil Cytoskeleton** 1996;35(4):331-44

Endogenous autoinhibitors regulate changes in actin tyrosine phosphorylation during Dictyostelium spore germination. Gauthier ML, et al. **Cell Signal** 1997 Jan;9(1):79-83

Formation of actin filament networks in cultured rat hepatocytes treated with DMSO and glucagon. Kojima T, et al. **Cell Struct Funct** 1997 Apr;22(2):269-78

Low molecular-weight G-actin binding proteins involved in the regulation of actin assembly during myofibrillogenesis. Obinata T, et al. **Cell Struct Funct** 1997 Feb;22(1):181-9

Stimulus-dependent disorganization of actin filaments induced by overexpression of cofilin in C2 myoblasts. Ono S, et al. **Cell Struct Funct** 1996 Dec;21(6):491-9

Dynamics of actin in cardiac myofibrils and fibroblast stress fibers. Shimada Y, et al. **Cell Struct Funct** 1997 Feb; 22(1):59-64

A role of cofilin/destrin in reorganization of actin cytoskeleton in response to stresses and cell stimuli. Yahara I, et al. **Cell Struct Funct** 1996 Oct;21(5):421-4 (34 ref.)

Spatial distribution of fluorescently labeled actin in living Dictyostelium amoebae. Yumura S. **Cell Struct Funct** 1996 Jun;21(3):189-97

Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro [see comments] DeRuiter MC, et al. **Circ Res** 1997 Apr;80(4):444-51. Comment in: Circ Res 1997 Apr;80(4):601-3. Comment in: Circ Res 1997 Apr;80(4):604-6.

Actin polymerisation in neutrophils of rheumatoid arthritis patients in relation to treatment with non-steroidal anti-inflammatory drugs. De Clerck LS, et al. **Clin Chim Acta** 1997 May 6;261(1):19-25

A family of novel actin-inhibiting marine toxins. Saito S, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):743-6

Characterization of SV40-transfected cell strains from rabbit keratocytes. Barry-Lane PA, et al. **Cornea** 1997 Jan; 16(1):72-8

Effects of basic FGF and TGF beta 1 on F-actin and ZO-1 organization during cat endothelial wound healing. Petroll WM, et al. **Cornea** 1996 Sep;15(5):525-32

Characteristics of actin fibers and ultrastructure of the contact regions involved in the separation of blastomeres of two-cell mouse embryos, frozen-thawed without the zona pellucida. Martí M, et al. **Cryobiology** 1997 Mar; 34(2):94-106

A Cdc42 target protein with homology to the non-kinase domain of FER has a potential role in regulating the actin cytoskeleton. Aspenström P. **Curr Biol** 1997 Jul 1; 7(7):479-87

Stimulation of actin stress fibre formation mediated by activation of phospholipase D. Cross MJ, et al. **Curr Biol** 1996 May 1;6(5):588-97

The swinging lever-arm hypothesis of muscle contraction. Holmes KC. **Curr Biol** 1997 Feb 1;7(2):R112-8 (27 ref.)

Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Sells MA, et al. **Curr Biol** 1997 Mar 1;7(3):202-10

Microfilament dynamics during cell movement and chemotaxis monitored using a GFP-actin fusion protein. Westphal M, et al. **Curr Biol** 1997 Mar 1;7(3):176-83

Regulation of actin filament length in erythrocytes and striated muscle. Fowler VM. **Curr Opin Cell Biol** 1996 Feb; 8(1):86-96 (73 ref.)

Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Tapon N, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):86-92 (44 ref.)

Reorganization of the cortical actin cytoskeleton during maturation division in the Tubifex egg: possible involvement of protein kinase C. Shimizu T. **Dev Biol** 1997 Aug 1;188(1):110-21

Tissue and developmental specific expression of murine smooth muscle gamma-actin fusion genes in transgenic mice. Qian J, et al. **Dev Dyn** 1996 Oct;207(2):135-44

ADP-ribosylation of actins in fibroblasts and myofibroblasts by botulinum C2 toxin: influence on microfilament morphology and migratory behavior. Rønnov-Jessen L, et al. **Electrophoresis** 1996 Nov;17(11):1776-80

A novel type of protein kinase phosphorylates actin in the actin-fragmin complex. Eichinger L, et al. **EMBO J** 1996 Oct 15;15(20):5547-56

Identification of two regions in the N-terminal domain of ActA involved in the actin comet tail formation by Listeria monocytogenes. Lasa I, et al. **EMBO J** 1997 Apr 1; 16(7):1531-40

The Schizosaccharomyces pombe actin-related protein, Arp3, is a component of the cortical actin cytoskeleton and interacts with profilin. McCollum D, et al. **EMBO J** 1996 Dec 2;15(23):6438-46

N-WASP, a novel actin-depolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2-dependent manner downstream of tyrosine kinases. Miki H, et al. **EMBO J** 1996 Oct 1;15(19):5326-35

Inhibition of apoptosis by the actin-regulatory protein gelsolin. Ohtsu M, et al. **EMBO J** 1997 Aug 1;16(15):4650-6

alpha2-Adrenoceptor stimulation promotes actin polymerization and focal adhesion in 3T3F442A and BFC-1beta preadipocytes. Bétuing S, et al. **Endocrinology** 1996 Dec;137(12):5220-9

In vivo phosphorylation of actin in Physarum polycephalum. Study of the substrate specificity of the actin-fragmin kinase. De Corte V, et al. **Eur J Biochem** 1996 Nov 1; 241(3):901-8

Association of human immunodeficiency virus Nef protein with actin is myristoylation dependent and influences its subcellular localization. Fackler OT, et al. **Eur J Biochem** 1997 Aug 1;247(3):843-51

Characterization of two F-actin-binding and oligomerization sites in the cell-contact protein vinculin. Hüttelmaier S, et al. **Eur J Biochem** 1997 Aug 1;247(3):1136-42

alpha-crystallin stabilizes actin filaments and prevents cytochalasin-induced depolymerization in a phosphorylation-dependent manner. Wang K, et al. **Eur J Biochem** 1996 Nov 15;242(1):56-66

Rearrangements of F-actin arrays in growing cells of intact maize root apex tissues: a major developmental switch occurs in the postmitotic transition region. Baluška F, et al. **Eur J Cell Biol** 1997 Feb;72(2):113-21

Dynamic changes in the state of actin polymerization in human alveolar cells exposed to the oxidant agent paraquat. Cappelletti G, et al. **Eur J Cell Biol** 1996 Nov;71(3):293-302

Disruption of the actin cytoskeleton in living nonmuscle cells by microinjection of antibodies to domain-3 of caldesmon. Lamb NJ, et al. **Eur J Cell Biol** 1996 Jan;69(1):36-44

Activation of Na+/H(+)-exchanger by transforming Ha-ras requires stimulated cellular calcium influx and is associated with rearrangement of the actin cytoskeleton. Ritter M, et al. **Eur J Cell Biol** 1997 Mar;72(3):222-8

Expression of an actin in protochordates and lower craniates defined by anti-alpha SM-1. Simoncelli F, et al. **Eur J Cell Biol** 1996 Mar;69(3):297-300

Rab4 associates with the actin terminal web in developing rat pancreatic acinar cells. Valentijn JA, et al. **Eur J Cell Biol** 1997 Jan;72(1):1-8

Differential role of actin in lung endothelial and epithelial barrier properties in perfused rabbit lungs. Ermert L, et al. **Eur Respir J** 1996 Jan;9(1):93-9

Characterization of a mutant profilin with reduced actin-binding capacity: effects in vitro and in vivo. Hájková L, et al. **Exp Cell Res** 1997 Jul 10;234(1):66-77

Involvement of phosphatidylinositide 3'-kinase and Rac in platelet-derived growth factor-induced actin reorganization and chemotaxis. Hooshmand-Rad R, et al. **Exp Cell Res** 1997 Aug 1;234(2):434-41

Changes in actin filament organization during pseudopod formation. Lee E, et al. **Exp Cell Res** 1997 Aug 25; 235(1):295-9

Nitric oxide and cGMP regulate endothelial permeability and F-actin distribution in hydrogen peroxide-treated endothelial cells. Liu SM, et al. **Exp Cell Res** 1997 Aug 25;235(1):238-44

Does actin polymerization status modulate Ca2+ storage in human neutrophils? Release and coalescence of Ca2+ stores by cytochalasins. Al-Mohanna FA, et al. **Exp Cell Res** 1997 Aug 1;234(2):379-87

The actin binding domain of the epidermal growth factor receptor is required for EGF-stimulated tissue invasion. van der Heyden MA, et al. **Exp Cell Res** 1997 Aug 1; 234(2):521-6

Bistratene A causes phosphorylation of talin and redistribution of actin microfilaments in fibroblasts: possible role for PKC-delta. Watters D, et al. **Exp Cell Res** 1996 Dec 15;229(2):327-35

ZO-1 reorganization and myofibroblast transformation of corneal endothelial cells after freeze injury in the cat. Petroll WM, et al. **Exp Eye Res** 1997 Feb;64(2):257-67

Effects of synaptic vesicles on actin polymerization. Chieregatti E, et al. **FEBS Lett** 1996 Dec 2;398(2-3):211-6

C-terminal truncation of thymosin beta10 by an intracellular protease and its influence on the interaction with G-actin studied by ultrafiltration. Huff T, et al. **FEBS Lett** 1997 Sep 1;414(1):39-44

Calcium storage and release properties of F-actin: evidence for the involvement of F-actin in cellular calcium signaling. Lange K, et al. **FEBS Lett** 1996 Oct 21;395(2-3):137-42

Different actin affinities of human cardiac essential myosin light chain isoforms. Morano I, et al. **FEBS Lett** 1997 May 12;408(1):71-4

Co-localization of glucokinase with actin filaments. Murata T, et al. **FEBS Lett** 1997 Apr 7;406(1-2):109-13

Rho effectors and reorganization of actin cytoskeleton. Narumiya S, et al. **FEBS Lett** 1997 Jun 23;410(1):68-72 (41 ref.)

Estramustine phosphate but not estramustine inhibits the interaction of microtubule associated protein 2 (MAP2) with actin filaments. Pedrotti B, et al. **FEBS Lett** 1997 Feb 17;403(2):123-6

The vaccinia virus F17R protein interacts with actin. Reckmann I, et al. **FEBS Lett** 1997 Jun 9;409(2):141-6

Evidence for an actin binding helix in gelsolin segment 2; have homologous sequences in segments 1 and 2 of gelsolin evolved to divergent actin binding functions? Van Troys M, et al. **FEBS Lett** 1996 Nov 18;397(2-3):191-6

Profilin is required for the normal timing of actin polymerization in response to thermal stress. Yeh J, et al. **FEBS Lett** 1996 Dec 2;398(2-3):303-7

Purification of a 47-kDa calmodulin-binding polypeptide as an actin-binding protein from Neurospora crassa [published erratum appears in FEMS Microbiol Lett 1997 May 1;150(1):173] Capelli N, et al. **FEMS Microbiol Lett** 1997 Feb 15;147(2):215-20

Nedd5, a mammalian septin, is a novel cytoskeletal component interacting with actin-based structures. Kinoshita M, et al. **Genes Dev** 1997 Jun 15;11(12):1535-47

A sialic acid-binding lectin from ovine placenta: purification, specificity and interaction with actin. Iglesias MM, et al. **Glycoconj J** 1996 Dec;13(6):967-76

The postnatal development of F-actin in tension fibroblasts of the spiral ligament of the gerbil cochlea. Kuhn B, et al. **Hear Res** 1997 Jun;108(1-2):180-90

Localization of actin in basal cells of stria vascularis. Nakazawa K, et al. **Hear Res** 1996 Jul;96(1-2):13-9

Disruption of actin organization by cytochalasin D does not impair biliary secretion of organic anions in the rat. St-Pierre MV, et al. **Hepatology** 1997 Apr;25(4):970-5

Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. Sempoux C, et al. **Hepatology** 1997 Jul;26(1):128-34

Muscle-specific actin expression in chondroblastomas. Povýsil C, et al. **Hum Pathol** 1997 Mar;28(3):316-20

Identification of a naturally occurring ligand for thymic positive selection. Hogquist KA, et al. **Immunity** 1997 Apr; 6(4):389-99

Effect of cytolethal distending toxin on F-actin assembly and cell division in Chinese hamster ovary cells. Aragon V, et al. **Infect Immun** 1997 Sep;65(9):3774-80

Integrin receptor involvement in actin cable formation in an in vitro model of events associated with wound contraction. Stephens P, et al. **Int J Biochem Cell Biol** 1997 Jan;29(1):121-8

FT-Raman studies on the transformation of G-actin to F-actin, the binding of cisplatin and transplatin to F-actin and the effects of the conformation of F-actin. Zeng HH, et al. **Int J Biol Macromol** 1997 Apr;20(2):107-13

Quantitative changes in cytoskeletal and nuclear actins during cellular transformation. Rao JY, et al. **Int J Cancer** 1997 Feb 7;70(4):423-9

Regulated crosslinked actin filaments and the decoupling between their ATPase activity and sliding motility. Honda H, et al. **J Biochem (Tokyo)** 1997 Jan;121(1):47-9

Maleimidobenzoyl actin: its biochemical properties and in vitro motility. Hozumi T, et al. **J Biochem (Tokyo)** 1996 Jan;119(1):151-6

Mapping myosin-binding sites on actin probed by peptides that inhibit actomyosin interaction. Katoh T, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):580-6

Effects of subtilisin cleavage of monomeric actin on its nucleotide binding. Ooi A, et al. **J Biochem (Tokyo)** 1996 Dec;120(6):1104-10

Sliding and ATPase. Oosawa F. **J Biochem (Tokyo)** 1995 Nov;118(5):863-70 (37 ref.)

Novel actin depolymerizing macrolide aplyronine A. Saito S, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):552-5

Identification of actin-binding proteins from sea urchin eggs by F-actin affinity column chromatography. Terasaki AG, et al. **J Biochem (Tokyo)** 1997 Jul;122(1):226-36

Muscle-type tropomyosin of sea urchin egg increases the actin-binding of nonmuscle-type tropomyosin. Tobita T, et al. **J Biochem (Tokyo)** 1996 Nov;120(5):922-8

Superoxide-mediated actin response in post-hypoxic endothelial cells. Crawford LE, et al. **J Biol Chem** 1996 Oct 25;271(43):26863-7

Dissection of pathways implicated in integrin-mediated actin cytoskeleton assembly. Involvement of protein kinase C, Rho GTPase, and tyrosine phosphorylation. Defilippi P, et al. **J Biol Chem** 1997 Aug 29;272(35):21726-34

The effects of smooth muscle calponin on the strong and weak myosin binding sites of F-actin. EL-Mezgueldi M, et al. **J Biol Chem** 1996 Nov 8;271(45):28161-7

Identification of an actin cytoskeletal complex that includes

IQGAP and the Cdc42 GTPase. Erickson JW, et al. **J Biol Chem** 1997 Sep 26;272(39):24443–7

Fluorescence probing of yeast actin subdomain 3/4 hydrophobic loop 262–274. Actin–actin and actin–myosin interactions in actin filaments. Feng L, et al. **J Biol Chem** 1997 Jul 4;272(27):16829–37

The sequence of the alternatively spliced sixth exon of alpha–tropomyosin is critical for cooperative actin binding but not for interaction with troponin. Hammell RL, et al. **J Biol Chem** 1997 Sep 5;272(36):22409–16

D3 phosphoinositides and outside–in integrin signaling by glycoprotein IIb–IIIa mediate platelet actin assembly and filopodial extension induced by phorbol 12–myristate 13–acetate. Hartwig JH, et al. **J Biol Chem** 1996 Dec 20; 271(51):32986–93

Substitution mutations in the myosin essential light chain lead to reduced actin–activated ATPase activity despite stoichiometric binding to the heavy chain. Ho G, et al. **J Biol Chem** 1997 Feb 14;272(7):4522–7

Down–regulation of the filamentous actin cross–linking activity of cortactin by Src–mediated tyrosine phosphorylation. Huang C, et al. **J Biol Chem** 1997 May 23;272(21):13911–5

Binding of myosin light chain kinase to cellular actin–myosin filaments. Lin Pj, et al. **J Biol Chem** 1997 Mar 14; 272(11):7412–20

Differential regulation of actin depolymerizing factor and cofilin in response to alterations in the actin monomer pool. Minamide LS, et al. **J Biol Chem** 1997 Mar 28; 272(13):8303–9

Identification of cytoplasmic actin as an abundant glutaminyl substrate for tissue transglutaminase in HL–60 and U937 cells undergoing apoptosis. Nemes Z Jr, et al. **J Biol Chem** 1997 Aug 15;272(33):20577–83

Identification of an actin binding region and a protein kinase C phosphorylation site on human fascin. Ono S, et al. **J Biol Chem** 1997 Jan 24;272(4):2527–33

A dual involvement of the amino–terminal domain of ezrin in F– and G–actin binding. Roy C, et al. **J Biol Chem** 1997 Aug 8;272(32):20088–95

Massive actin polymerization induced by phosphatidylinositol–4–phosphate 5–kinase in vivo. Shibasaki Y, et al. **J Biol Chem** 1997 Mar 21; 272(12):7578–81

Efficient mammalian protein synthesis requires an intact F–actin system. Stapulionis R, et al. **J Biol Chem** 1997 Oct 3;272(40):24980–6

Gelatinase A activation is regulated by the organization of the polymerized actin cytoskeleton. Tomasek JJ, et al. **J Biol Chem** 1997 Mar 14;272(11):7482–7

Activation of Na+–H+ exchange is necessary for RhoA–induced stress fiber formation. Vexler ZS, et al. **J Biol Chem** 1996 Sep 13;271(37):22281–4

Functional and structural relationship between the calmodulin–binding, actin–binding, and actomyosin–ATPase inhibitory domains on the C terminus of smooth muscle caldesmon. Wang Z, et al. **J Biol Chem** 1997 Jul 4;272(27):16896–903

Mammalian CAP interacts with CAP, CAP2, and actin. Hubberstey A, et al. **J Cell Biochem** 1996 Jun 1; 61(3):459–66

Dexamethasone induces rapid actin assembly in human endometrial cells without affecting its synthesis. Koukouritaki SB, et al. **J Cell Biochem** 1997 Jun 15; 65(4):492–500

Interaction of the NG2 proteoglycan with the actin cytoskeleton. Lin XH, et al. **J Cell Biochem** 1996 Dec 15; 63(4):463–77

Fluid shear stress induces actin polymerization in human neutrophils. Okuyama M, et al. **J Cell Biochem** 1996 Dec 15;63(4):432–41

Quantitative analysis of cadherin–catenin–actin reorganization during development of cell–cell adhesion. Adams CL, et al. **J Cell Biol** 1996 Dec;135(6 Pt 2):1899–911

Microtubule–associated protein 2c reorganizes both microtubules and microfilaments into distinct cytological structures in an actin–binding protein–280–deficient melanoma cell line. Cunningham CC, et al. **J Cell Biol** 1997 Feb 24;136(4):845–57

Two peptides derived from the nerve growth factor precursor are biologically active. Dicou E, et al. **J Cell Biol** 1997 Jan 27;136(2):389–98

The yeast gene, MDM20, is necessary for mitochondrial inheritance and organization of the actin cytoskeleton. Hermann GJ, et al. **J Cell Biol** 1997 Apr 7;137(1):141–53

Centractin (ARP1) associates with spectrin revealing a potential mechanism to link dynactin to intracellular organelles. Holleran EA, et al. **J Cell Biol** 1996 Dec;135(6 Pt 2):1815–29

Involvement of ZO–1 in cadherin–based cell adhesion through its direct binding to alpha catenin and actin filaments. Itoh M, et al. **J Cell Biol** 1997 Jul 14; 138(1):181–92

In vitro reconstitution of cortical actin assembly sites in budding yeast. Lechler T, et al. **J Cell Biol** 1997 Jul 14; 138(1):95–103

Bee1, a yeast protein with homology to Wiscott–Aldrich syndrome protein, is critical for the assembly of cortical actin cytoskeleton. Li R. **J Cell Biol** 1997 Feb 10; 136(3):649–58

F–actin sequesters elongation factor 1alpha from interaction with aminoacyl–tRNA in a pH–dependent reaction. Liu G, et al. **J Cell Biol** 1996 Nov;135(4):953–63

Role of actin polymerization and adhesion to extracellular matrix in Rac– and Rho–induced cytoskeletal reorganization. Machesky LM, et al. **J Cell Biol** 1997 Aug 25;138(4):913–26

Rho– and rac–dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for ezrin/radixin/moesin proteins. Mackay DJ, et al. **J Cell Biol** 1997 Aug 25;138(4):927–38

Structure, subunit topology, and actin–binding activity of the Arp2/3 complex from Acanthamoeba. Mullins RD, et al. **J Cell Biol** 1997 Jan 27;136(2):331–43

Bundling of actin filaments by elongation factor 1 alpha inhibits polymerization at filament ends. Murray JW, et al. **J Cell Biol** 1996 Dec;135(5):1309–21

Rab8 promotes polarized membrane transport through reorganization of actin and microtubules in fibroblasts. Peränen J, et al. **J Cell Biol** 1996 Oct;135(1):153–67

Molecular characterization of abLIM, a novel actin–binding and double zinc finger protein. Roof DJ, et al. **J Cell Biol** 1997 Aug 11;138(3):575–88

Xenopus actin depolymerizing factor/cofilin (XAC) is responsible for the turnover of actin filaments in Listeria monocytogenes tails [see comments] Rosenblatt J, et al. **J Cell Biol** 1997 Mar 24;136(6):1323–32. Comment in: J Cell Biol 1997 Mar 24;136(6):1165–8.

A new model for the interaction of dystrophin with F–actin. Rybakova IN, et al. **J Cell Biol** 1996 Nov;135(3):661–72

A correlative analysis of actin filament assembly, structure, and dynamics. Steinmetz MO, et al. **J Cell Biol** 1997 Aug 11;138(3):559–74

Accelerating on a treadmill: ADF/cofilin promotes rapid actin filament turnover in the dynamic cytoskeleton [comment] Theriot JA. **J Cell Biol** 1997 Mar 24; 136(6):1165–8 (28 ref.). Comment on: J Cell Biol 1997 Mar 24;136(6):1307–22. Comment on: J Cell Biol 1997 Mar 24;136(6):1323–32.

Interaction of AU–rich sequence binding proteins with actin: possible involvement of the actin cytoskeleton in lymphokine mRNA turnover. Henics T, et al. **J Cell Physiol** 1997 Oct;173(1):19–27

Rho, Rac and Cdc42 regulate actin organization and cell adhesion in macrophages. Allen WE, et al. **J Cell Sci** 1997 Mar;110 (Pt 6):707–20

Identification and characterization of espin, an actin–binding protein localized to the F–actin–rich junctional plaques of Sertoli cell ectoplasmic specializations. Bartles JR, et al. **J Cell Sci** 1996 Jun;109 (Pt 6):1229–39

TGF beta 1 promotes actin cytoskeleton reorganization and migratory phenotype in epithelial tracheal cells in primary culture. Boland S, et al. **J Cell Sci** 1996 Sep;109 (Pt 9):2207–19

Cytokinesis arrest and redistribution of actin–cytoskeleton regulatory components in cells expressing the Rho GTPase CDC42Hs. Dutartre H, et al. **J Cell Sci** 1996 Feb;109 (Pt 2):367–77

Calcium ions and tyrosine phosphorylation interact coordinately with actin to regulate cytoprotective responses to stretching. Glogauer M, et al. **J Cell Sci** 1997 Jan;110 (Pt 1):11–21

Regulation of actin filament dynamics by p38 map kinase–mediated phosphorylation of heat shock protein 27. Guay J, et al. **J Cell Sci** 1997 Feb;110 (Pt 3):357–68

Fluid–phase uptake by macropinocytosis in Dictyostelium. Hacker U, et al. **J Cell Sci** 1997 Jan;110 (Pt 2):105–12

Talin contains three actin–binding sites each of which is adjacent to a vinculin–binding site. Hemmings L, et al. **J Cell Sci** 1996 Nov;109 (Pt 11):2715–26

Cortical actin movements during the first cell cycle of the Caenorhabditis elegans embryo. Hird S. **J Cell Sci** 1996 Feb;109 (Pt 2):525–33

Sorting of actin isoforms in chicken auditory hair cells. Höfer D, et al. **J Cell Sci** 1997 Mar;110 (Pt 6):765–70

Transfected muscle and non–muscle actins are differentially sorted by cultured smooth muscle and non–muscle cells. Mounier N, et al. **J Cell Sci** 1997 Apr;110 (Pt 7):839–46

Engagement of L–selectin impairs the actin polymerizing capacity of beta 2–integrins on neutrophils. Ng–Sikorski J, et al. **J Cell Sci** 1996 Sep;109 (Pt 9):2361–9

Three–dimensional organization of rat hepatocyte cytoskeleton: relation to the asialoglycoprotein endocytosis pathway. Novikoff PM, et al. **J Cell Sci** 1996 Jan;109 (Pt 1):21–32

The role of the cortical cytoskeleton: F–actin crosslinking proteins protect against osmotic stress, ensure cell size, cell shape and motility, and contribute to phagocytosis and development. Rivero F, et al. **J Cell Sci** 1996 Nov;109 (Pt 11):2679–91

Plant and animal profilins are functionally equivalent and stabilize microfilaments in living animal cells. Rothkegel M, et al. **J Cell Sci** 1996 Jan;109 (Pt 1):83–90

Structure/function studies on the pH–dependent actin–binding protein hisactophilin in Dictyostelium mutants. Stoeckelhuber M, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1825–35

The gelsolin–related flightless I protein is required for actin distribution during cellularisation in Drosophila. Straub KL, et al. **J Cell Sci** 1996 Jan;109 (Pt 1):263–70

An Aplysia cell adhesion molecule associated with site–directed actin filament assembly in neuronal growth cones. Thompson C, et al. **J Cell Sci** 1996 Dec;109 (Pt 12):2843–54

Association of the gamma12 subunit of G proteins with actin filaments. Ueda H, et al. **J Cell Sci** 1997 Jul;110 (Pt 13):1503–11

Polarity sorting of actin filaments in cytochalasin–treated fibroblasts. Verkhovsky AB, et al. **J Cell Sci** 1997 Aug;110 (Pt 15):1693–704

Involvement of the adherens junction–actin filament system in acantholytic dyskeratosis of Hailey–Hailey disease. A histological, ultrastructural, and histochemical study of lesional and non–lesional skin. Metze D, et al. **J Cutan Pathol** 1996 Jun;23(3):211–22

Morphometric and immunocytochemical analysis of coronary arterioles in human transplanted hearts. Armstrong AT, et al. **J Heart Lung Transplant** 1996 Aug; 15(8):818–26

Optimization of immunofluorescence methods by quantitative image analysis. Mosedale DE, et al. **J Histochem Cytochem** 1996 Sep;44(9):1043–50

IL–2 signaling controls actin organization through Rho–like protein family, phosphatidylinositol 3–kinase, and protein kinase C–zeta. Gómez J, et al. **J Immunol** 1997 Feb 15; 158(4):1516–22

Effects of 5–oxo–6,8,11,14–eicosatetraenoic acid on expression of CD11b, actin polymerization, and adherence in human neutrophils. Powell WS, et al. **J Immunol** 1997 Sep 15;159(6):2952–9

Regulation of lung fibroblast alpha–smooth muscle actin expression, contractile phenotype, and apoptosis by IL–1beta. Zhang HY, et al. **J Immunol** 1997 Feb 1; 158(3):1392–9

Cytoskeletal F–actin polymerization from cytosolic G–actin occurs in the phagocytosing immunocytes of arthropods (Limulus polyphemus and Gromphadorhina portentosa): does [cAMP]i play any role? Gupta AP, et al. **J Invertebr Pathol** 1996 Sep;68(2):118–30

Evidence of the involvement of phosphatidylinositol 3–kinase in the migration, actin stress fiber formation, and alpha v beta 3–integrin–mediated adherence of human melanoma cells. Metzner B, et al. **J Invest Dermatol** 1996 Oct; 107(4):597–602

Differential expression of the 45 kDa protein (actin) during the dimorphic transition of Sporothrix schenckii. Han–Yaku H, et al. **J Med Vet Mycol** 1996 Jun–Jul; 34(3):175–80

Control of actin dynamics in cell motility. Carlier MF, et al. **J Mol Biol** 1997 Jun 20;269(4):459–67 (46 ref.)

The structure of an open state of beta–actin at 2.65 A resolution. Chik JK, et al. **J Mol Biol** 1996 Nov 8; 263(4):607–23

Modulation of yeast F–actin structure by a mutation in the nucleotide–binding cleft. Orlova A, et al. **J Mol Biol** 1997 Aug 15;271(2):235–43

Cooperative rigor binding of myosin to actin is a function of F–actin structure. Orlova A, et al. **J Mol Biol** 1997 Feb 7;265(5):469–74

Mapping of a second actin–tropomyosin and a second troponin C binding site within the C terminus of troponin I, and their importance in the Ca2+–dependent regulation of muscle contraction. Tripet B, et al. **J Mol Biol** 1997 Sep 5;271(5):728–50

A novel stopped–flow method for measuring the affinity of actin for myosin head fragments using microgram quantities of protein. Kurzawa SE, et al. **J Muscle Res Cell Motil** 1996 Dec;17(6):669–76

Ca2+ bound to the high affinity divalent cation–binding site of actin enhances actophorin–induced depolymerization of muscle F–actin but inhibits actophorin–induced depolymerization of Acanthamoeba F–actin. Mossakowska M, et al. **J Muscle Res Cell Motil** 1996 Aug;17(4):383–9

Modulation of actin filament behavior by GAP–43 (neuromodulin) is dependent on the phosphorylation status of serine 41, the protein kinase C site. He Q, et al. **J Neurosci** 1997 May 15;17(10):3515–24

Upregulation of F–actin and alpha–actinin in reactive astrocytes. Abd–El–Basset EM, et al. **J Neurosci Res** 1997 Sep 1;49(5):608–16

Myelin proteolipid protein expressed in COS–1 cells is targeted to actin–associated surfaces. Kalwy SA, et al. **J Neurosci Res** 1997 May 1;48(3):201–11

Changes in dynamin and actin mRNA expression in the dorsal column–medial lemniscal system following dorsal column lesion. Riley LA, et al. **J Neurosci Res** 1996 Apr 1;44(1):47–51

A phage display technique for a fast, sensitive, and systematic investigation of protein–protein interactions. Rossenu S, et al. **J Protein Chem** 1997 Jul;16(5):499–503

Electron microscopic study of tropomyosin binding to actin filaments reveals tethered molecules representing weak binding. Mabuchi K. **J Struct Biol** 1996 Mar–Apr; 116(2):278–89

Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. Ott DE, et al. **J Virol** 1996 Nov; 70(11):7734–43

Identification of the early actin–rearrangement–inducing factor gene, arif–1, from Autographa californica multicapsid nuclear polyhedrosis virus. Roncarati R, et al. **J Virol** 1997 Oct;71(10):7933–41

Suppression of polarity, locomotion and F–actin levels of Walker carcinosarcoma cells by the inhibitor CI–959. von Tscharner Biino N, et al. **Life Sci** 1997;61(2):137–45

Actin content and polymerization in tumour, liver and serum of the hepatoma Morris 5123 tumour bearing rats.

Malicka-Błaszkiewicz M, et al. **Mater Med Pol** 1995 Jul-Sep;27(3):115-8

Abundance of alpha 1(I) and alpha 1(III) procollagen and p21 mRNAs in fibroblasts cultured from fetal and postnatal dermis. Furth JJ, et al. **Mech Ageing Dev** 1997 Aug; 97(2):131-42

Expression of S9 and actin CyIIa mRNAs reveals dorso-ventral polarity and mesodermal sublineages in the vegetal plate of the sea urchin embryo. Miller RN, et al. **Mech Dev** 1996 Nov;60(1):3-12

Adherence of non-typeable Haemophilus influenzae promotes reorganization of the actin cytoskeleton in human or chinchilla epithelial cells in vitro. Holmes KA, et al. **Microb Pathog** 1997 Sep;23(3):157-66

Cloning and characterization of actin depolymerizing factor from Toxoplasma gondii. Allen ML, et al. **Mol Biochem Parasitol** 1997 Sep;88(1-2):43-52

Aip3p/Bud6p, a yeast actin-interacting protein that is involved in morphogenesis and the selection of bipolar budding sites. Amberg DC, et al. **Mol Biol Cell** 1997 Apr; 8(4):729-53

Evidence for physical and functional interactions among two Saccharomyces cerevisiae SH3 domain proteins, an adenylyl cyclase-associated protein and the actin cytoskeleton. Lila T, et al. **Mol Biol Cell** 1997 Feb; 8(2):367-85

NG2 proteoglycan and the actin-binding protein fascin define separate populations of actin-containing filopodia and lamellipodia during cell spreading and migration. Lin XH, et al. **Mol Biol Cell** 1996 Dec;7(12):1977-93

Interaction of a Dictyostelium member of the plastin/fimbrin family with actin filaments and actin-myosin complexes. Prassler J, et al. **Mol Biol Cell** 1997 Jan;8(1):83-95

Modification of Cys-837 identifies an actin-binding site in the beta-propeller protein scruin. Sun S, et al. **Mol Biol Cell** 1997 Mar;8(3):421-30

Role of gelsolin in actin depolymerization of adherent human neutrophils. Wang JS, et al. **Mol Biol Cell** 1997 Jan; 8(1):121-8

Expression of constitutively active alpha-PAK reveals effects of the kinase on actin and focal complexes. Manser E, et al. **Mol Cell Biol** 1997 Mar;17(3):1129-43

The PRK2 kinase is a potential effector target of both Rho and Rac GTPases and regulates actin cytoskeletal organization. Vincent S, et al. **Mol Cell Biol** 1997 Apr; 17(4):2247-56

Colchicine activates actin polymerization by microtubule depolymerization. Jung HI, et al. **Mol Cells** 1997 Jun 30; 7(3):431-7

Adhesiveness of the free surface of a human endometrial monolayer for trophoblast as related to actin cytoskeleton. Thie M, et al. **Mol Hum Reprod** 1997 Apr;3(4):275-83

Disruption of IcsP, the major Shigella protease that cleaves IcsA, accelerates actin-based motility. Shere KD, et al. **Mol Microbiol** 1997 Aug;25(3):451-62

Identification and cellular localization of the actin-binding protein ABP-120 from Entamoeba histolytica. Vargas M, et al. **Mol Microbiol** 1996 Dec;22(5):849-57

The cortical actin cytoskeleton of unactivated zebrafish eggs: spatial organization and distribution of filamentous actin, nonfilamentous actin, and myosin-II. Becker KA, et al. **Mol Reprod Dev** 1996 Apr;43(4):536-47

Actin and major sperm protein in spermatids and spermatozoa of the parasitic nematode Heligmosomoides polygyrus. Mansir A, et al. **Mol Reprod Dev** 1996 Nov; 45(3):332-41

Cofilin promotes rapid actin filament turnover in vivo. Lappalainen P, et al. **Nature** 1997 Jul 3;388(6637):78-82

Actin-dependent localization of an RNA encoding a cell-fate determinant in yeast. Takizawa PA, et al. **Nature** 1997 Sep 4;389(6646):90-3

Actin polymerization is induced by Arp2/3 protein complex at the surface of Listeria monocytogenes. Welch MD, et al. **Nature** 1997 Jan 16;385(6613):265-9

Competitive binding of alpha-actinin and calmodulin to the NMDA receptor. Wyszynski M, et al. **Nature** 1997 Jan 30;385(6615):439-42

ADP-ribosylation of actin by Clostridium perfringens iota toxin and turkey erythrocyte ADP-ribosyltransferase A: effects on profilin-regulated nucleotide exchange and ATPase activity. Sehr P, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Dec; 354(6):693-7

Effects of Clostridium botulinum C2 toxin-induced depolymerisation of actin on degranulation of suspended and attached mast cells. Wex CB, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Mar; 355(3):319-27

Promotion of microfilament polymerization by depolymerized glia filament preparation through interaction of vimentin with actin. Ito J, et al. **Neurochem Int** 1996 Oct;29(4):383-9

Actin cleavage by CPP-32/apopain during the development of apoptosis. Mashima T, et al. **Oncogene** 1997 Mar 6; 14(9):1007-12

Extracellular components implicated in the stationary organization of the actin cytoskeleton in mesophyll cells of Vallisneria. Ryu JH, et al. **Plant Cell Physiol** 1997 Apr; 38(4):420-32

F-actin and G-actin binding are uncoupled by mutation of conserved tyrosine residues in maize actin depolymerizing factor (ZmADF). Jiang CJ, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9973-8

The I/LWEQ module: a conserved sequence that signifies F-actin binding in functionally diverse proteins from yeast to mammals. McCann RO, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5679-84

Effects of methionine on the cytoplasmic distribution of actin and tubulin during neural tube closure in rat embryos. Moephuli SR, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21;94(2):543-8

In situ molecular association of dystrophin with actin revealed by sensitized emission immuno-resonance energy transfer. Root DD. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5685-90

TOR2 is required for organization of the actin cytoskeleton in yeast. Schmidt A, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13780-5

Resistance of actin to cleavage during apoptosis. Song Q, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):157-62

Overexpression, purification, and characterization of recombinant Dictyostelium discoideum calcium-regulated 34,000-dalton F-actin bundling protein from Escherichia coli. Lim RW, et al. **Protein Expr Purif** 1997 Mar; 9(2):182-90

Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Amano M, et al. **Science** 1997 Feb 28; 275(5304):1308-11

Bni1p, a yeast formin linking cdc42p and the actin cytoskeleton during polarized morphogenesis. Evangelista M, et al. **Science** 1997 Apr 4;276(5309):118-22

The many faces of WAS protein [news] Featherstone C. **Science** 1997 Jan 3;275(5296):27-8

RAC regulation of actin polymerization and proliferation by a pathway distinct from Jun kinase [published erratum appears in Science 1997 Apr 11;276(5310):185] Joneson T, et al. **Science** 1996 Nov 22;274(5291):1374-6

A multiple site, side binding model for the interaction of dystrophin with F-actin. Ervasti JM, et al. **Soc Gen Physiol Ser** 1997;52:31-44 (60 ref.)

Capping actin filament growth: tropomodulin in muscle and nonmuscle cells. Fowler VM. **Soc Gen Physiol Ser** 1997; 52:79-89 (46 ref.)

Involvement of the actin network in insulin signalling. Tsakiridis T, et al. **Soc Gen Physiol Ser** 1997;52:257-71

The roles of calmodulin, actin, and vimentin in steroid synthesis by adrenal cells. Hall PF. **Steroids** 1997 Jan; 62(1):185-9 (34 ref.)

Conservation within the myosin motor domain: implications for structure and function. Cope MJT, et al. **Structure** 1996 Aug 15;4(8):969-87

Agonist-induced actin polymerization is required for the irreversibility of platelet aggregation. Torti M, et al. **Thromb Haemost** 1996 Sep;76(3):444-9

Actin localization in ram spermatozoa: effect of freezing/thawing, capacitation and calcium ionophore-induced acrosomal exocytosis. de las Heras MA, et al. **Tissue Cell** 1997 Feb;29(1):47-53

Ultrastructural evidence of abnormally short and maldistributed actin stress fibers in osteopetrotic (toothless) rat osteoblasts in situ after detergent perfusion. Watanabe H, et al. **Tissue Cell** 1997 Feb;29(1):89-98

Okadaic acid induces changes in the organization of F-actin in intestinal cells. Fiorentini C, et al. **Toxicon** 1996 Aug; 34(8):937-45

ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Tsukita S, et al. **Trends Biochem Sci** 1997 Feb;22(2):53-8 (37 ref.)

Viral manipulations of the actin cytoskeleton. Cudmore S, et al. **Trends Microbiol** 1997 Apr;5(4):142-8 (71 ref.)

How the Listeria monocytogenes ActA protein converts actin polymerization into a motile force. Smith GA, et al. **Trends Microbiol** 1997 Jul;5(7):272-6 (42 ref.)

Overexpression of actin in AcMNPV-infected cells interferes with polyhedrin synthesis and polyhedra formation. Volkman L, et al. **Virology** 1996 Nov 15;225(2):369-76

[Expression of FGF2, FGF receptor-1 and alpha-smooth muscle actin in experimental mesangial proliferative nephritis] Jyo Y. **Nippon Jinzo Gakkai Shi** 1996 Dec; 38(12):545-54 (Eng. Abstr.) **(Jpn)**

[The coiled bodies and satellite microbodies of the oocyte nuclei in hibernating Rana temporaria frogs contain actin] Tsvetkov AG, et al. **Tsitologiia** 1997;39(1):10-4 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Actin enhances the activation of human neutrophil NADPH oxidase in a cell-free system. Morimatsu T, et al. **Biochem Biophys Res Commun** 1997 Jan 3;230(1):206-10

Microinjection of ADP-ribosylated actin inhibits actin synthesis in hepatocyte-hepatoma hybrid cells. Reuner KH, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):843-9

Calponin inhibits actin-activated MgATPase of myosin subfragment 1 (S1) without displacing S1 from its binding site on actin. Kołakowski J, et al. **Eur J Biochem** 1997 Feb 1;243(3):624-9

An inhibitory effect of actin on casein kinase II activity in vitro. Karino A, et al. **FEBS Lett** 1996 Dec 2; 398(2-3):317-21

External calcium-dependent, F-actin-independent and pertussis toxin-insensitive novel neutrophil locomotion induced by a mAb. Suzuki H, et al. **Int Immunol** 1997 May; 9(5):763-9

Actin-binding membrane proteins identified by F-actin blot overlays. Luna EJ, et al. **Soc Gen Physiol Ser** 1997;52:3-18

PHYSIOLOGY

Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease. Sheils CA, et al. **Am J Pathol** 1996 Mar;148(3):919-27

Cytoskeletal rearrangement mediates human microvascular endothelial tight junction modulation by cytokines. Blum MS, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H286-94

Role of actin in regulation of epithelial sodium channels by CFTR. Ismailov II, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1077-86

Role of Rho and myosin phosphorylation in actin stress fiber assembly in mesangial cells. Kreisberg JI, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F283-8

Putting the actin cytoskeleton into perspective: pathophysiology of ischemic alterations. Molitoris BA. **Am J Physiol** 1997 Apr;272(4 Pt 2):F430-3 (28 ref.)

Changes of actin cytoskeleton during swelling and regulatory volume decrease in cultured astrocytes. Morán J, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):C1901-7

Contribution of actin cytoskeletal alterations to ATP depletion and calcium-induced proximal tubule cell injury. Nurko S, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):F39-52

Nuclear ion channel activity is regulated by actin filaments. Prat AG, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1532-43

Calcium dependence of integrity of the actin cytoskeleton of proximal tubule cell microvilli. Sogabe K, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F292-303

Factors inducing codistribution of marginal actin fibers and fibronectin in rat aortic endothelial cells. Sugimoto K, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2188-94

F-actin disorganization in apoptotic cell death of cultured rat renal proximal tubular cells. Van de Water B, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):F593-603

Radial equilibrium lengths of actomyosin cross-bridges in muscle. Brenner B, et al. **Biophys J** 1996 Nov;71(5):2751-8

Small segmental rearrangements in the myosin head can explain force generation in muscle. Diaz Baños FG, et al. **Biophys J** 1996 Aug;71(2):576-89

A closer look at a molecular motor by atomic force microscopy. Engel A. **Biophys J** 1997 Mar;72(3):988

Smooth muscle and skeletal muscle myosins produce similar unitary forces and displacements in the laser trap [see comments] Guilford WH, et al. **Biophys J** 1997 Mar; 72(3):1006-21. Comment in: Biophys J 1997 Mar;72(3):984-6.

Cell motility driven by actin polymerization. Mogilner A, et al. **Biophys J** 1996 Dec;71(6):3030-45

Actin and the coordination of protrusion, attachment and retraction in cell crawling. Small JV, et al. **Biosci Rep** 1996 Oct;16(5):351-68 (50 ref.)

The effect of dexamethasone on functional properties of HL60 cells during all-trans retinoic acid induced differentiation. Are there implications for the retinoic acid syndrome? Sham RL, et al. **Blood Cells Mol Dis** 1996; 22(2):139-49

Regulation of cadherin-mediated adhesion by the small GTP-binding protein Rho in small cell lung carcinoma cells. Tokman MG, et al. **Cancer Res** 1997 May 1; 57(9):1785-93

Monoclonal antibodies recognizing the N- and C-terminal regions of talin disrupt actin stress fibers when microinjected into human fibroblasts. Bolton SJ, et al. **Cell Motil Cytoskeleton** 1997;36(4):363-76

Suppression of bleb formation, locomotion, and polarity of Walker carcinosarcoma cells by hypertonic media correlates with cell volume reduction but not with changes in the F-actin content. Fedier A, et al. **Cell Motil Cytoskeleton** 1997;37(4):326-37

Shigella actin-based motility in the absence of vinculin. Goldberg MB. **Cell Motil Cytoskeleton** 1997;37(1):44-53

Pre-mitotic nuclear migration in subsidiary mother cells of Tradescantia occurs in G1 of the cell cycle and requires F-actin. Kennard JL, et al. **Cell Motil Cytoskeleton** 1997; 36(1):55-67

Mitochondrial inheritance: cell cycle and actin cable dependence of polarized mitochondrial movements in Saccharomyces cerevisiae. Simon VR, et al. **Cell Motil Cytoskeleton** 1997;37(3):199-210

Actin dynamics and organization during growth cone morphogenesis in Helisoma neurons. Welnhofer EA, et al. **Cell Motil Cytoskeleton** 1997;37(1):54-71

A green fluorescent protein-actin fusion protein dominantly inhibits cytokinesis, cell spreading, and locomotion in Dictyostelium. Aizawa H, et al. **Cell Struct Funct** 1997 Jun; 22(3):335-45

Microtubule disruption induces the formation of actin stress fibers and focal adhesions in cultured cells: possible involvement of the rho signal cascade. Enomoto T. **Cell Struct Funct** 1996 Oct;21(5):317-26

Impact of alpha-skeletal actin but not alpha-cardiac actin on myoblast morphology. Gunning P, et al. **Cell Struct Funct** 1997 Feb;22(1):173-9

Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Huot J, et al. **Circ Res** 1997 Mar;80(3):383-92

Fibroblast growth factor-2 potentiates vascular smooth muscle cell migration to platelet-derived growth factor: upregulation of alpha2beta1 integrin and disassembly of

actin filaments. Pickering JG, et al. **Circ Res** 1997 May; 80(5):627–37

Biochemical evidence for the presence of an unconventional actin protein in a prokaryotic organism. Labbé JP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jul; 114(3):287–93

Actin cytoskeleton: are FH proteins local organizers? Frazier JA, et al. **Curr Biol** 1997 Jul 1;7(7):R414–7 (22 ref.)

The complex containing actin-related proteins Arp2 and Arp3 is required for the motility and integrity of yeast actin patches. Winter D, et al. **Curr Biol** 1997 Jul 1;7(7):519–29

The actin-related proteins. Frankel S, et al. **Curr Opin Cell Biol** 1996 Feb;8(1):30–7 (56 ref.)

Actin and cell pathogenesis. Higley S, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):62–9 (63 ref.)

Actin dynamics in vivo. Welch MD, et al. **Curr Opin Cell Biol** 1997 Feb;9(1):54–61 (55 ref.)

Signal transduction and actin filament organization. Zigmond SH. **Curr Opin Cell Biol** 1996 Feb;8(1):66–73 (90 ref.)

The role of actin filaments in patterning the Caenorhabditis elegans cuticle. Costa M, et al. **Dev Biol** 1997 Apr 15; 184(2):373–84

Ooplasmic redistribution in Tubifex eggs with selectively impaired cortical actin cytoskeleton. Shimizu T. **Dev Biol** 1996 Nov 25;180(1):54–62

An actin-mediated two-step mechanism is required for ventral enclosure of the C. elegans hypodermis. Williams-Masson EM, et al. **Development** 1997 Aug; 124(15):2889–901

Growth hormone-induced reorganization of the actin cytoskeleton is not required for STAT5 (signal transducer and activator of transcription-5)-mediated transcription. Goh EL, et al. **Endocrinology** 1997 Aug;138(8):3207–15

Involvement of gamma and beta actin isoforms in mouse neuroblastoma differentiation. Ulloa L, et al. **Eur J Neurosci** 1996 Jul;8(7):1441–51

Cylindrical substratum induces different patterns of actin microfilament bundles in nontransformed and in ras-transformed epitheliocytes. Levina EM, et al. **Exp Cell Res** 1996 Nov 25;229(1):159–65

Role of the actin cytoskeleton in the regulation of the cystic fibrosis transmembrane conductance regulator. Cantiello HF. **Exp Physiol** 1996 May;81(3):505–14 (17 ref.)

Ca-dependent regulation of Na+-selective channels via actin cytoskeleton modification in leukemia cells. Maximov AV, et al. **FEBS Lett** 1997 Jul 21;412(1):94–6

Bi-directional movement of actin filaments along long bipolar tracks of oriented rabbit skeletal muscle myosin molecules. Yamada A, et al. **FEBS Lett** 1997 Jun 16;409(3):380–4

The early postnatal development of F-actin patterns in the organ of Corti of the gerbil (Meriones unguiculatus) and the horseshoe bat (Rhinolophus rouxi). Kuhn B, et al. **Hear Res** 1996 Sep 15;99(1–2):47–70

Adherence of human phagocytes results in characteristic reorganization and redistribution of distinct F-actin pools. Watts RG. **Hematopathol Mol Hematol** 1996;10(4):223–32

Muscle contraction: the step-size distance and the impulse-time per ATP. Worthington CR, et al. **Int J Biol Macromol** 1996 Feb;18(1–2):123–31

The actin cytoskeleton is required for receptor-mediated endocytosis in mammalian cells. Lamaze C, et al. **J Biol Chem** 1997 Aug 15;272(33):20332–5

Both microtubules and actin filaments are required for efficient postendocytotic traffic of the polymeric immunoglobulin receptor in polarized Madin–Darby canine kidney cells. Maples CJ, et al. **J Biol Chem** 1997 Mar 7; 272(10):6741–51

A re-examination of calcium activation in the Huxley cross-bridge model. Zahalak GI, et al. **J Biomech Eng** 1997 Feb;119(1):20–9

Healing of incisional wounds in the embryonic chick wing bud: characterization of the actin purse-string and demonstration of a requirement for Rho activation. Brock J, et al. **J Cell Biol** 1996 Nov;135(4):1097–107

Actin depolymerizing factor (ADF/cofilin) enhances the rate of filament turnover: implication in actin-based motility [see comments] Carlier MF, et al. **J Cell Biol** 1997 Mar 24;136(6):1307–22. Comment in: J Cell Biol 1997 Mar 24;136(6):1165–8.

Identification of novel graded polarity actin filament bundles in locomoting heart fibroblasts: implications for the generation of motile force. Cramer LP, et al. **J Cell Biol** 1997 Mar 24;136(6):1287–305

Translocation of Src kinase to the cell periphery is mediated by the actin cytoskeleton under the control of the Rho family of small G proteins. Fincham VJ, et al. **J Cell Biol** 1996 Dec;135(6 Pt 1):1551–64

Actin filament cables in Drosophila nurse cells are composed of modules that slide passively past one another during dumping. Guild GM, et al. **J Cell Biol** 1997 Aug 25; 138(4):783–97

Actin and myosin function in directed vacuole movement during cell division in Saccharomyces cerevisiae. Hill KL, et al. **J Cell Biol** 1996 Dec;135(6 Pt 1):1535–49

Cofilin changes the twist of F-actin: implications for actin filament dynamics and cellular function. McGough A, et al. **J Cell Biol** 1997 Aug 25;138(4):771–81

Role of actin polymerization and adhesion to extracellular matrix in Rac- and Rho-induced cytoskeletal reorganization. Machesky LM, et al. **J Cell Biol** 1997 Aug 25;138(4):913–26

Drosophila kelch is an oligomeric ring canal actin organizer. Robinson DN, et al. **J Cell Biol** 1997 Aug 25;138(4):799–810

The isolated comet tail pseudopodium of Listeria monocytogenes: a tail of two actin filament populations, long and axial and short and random. Sechi AS, et al. **J Cell Biol** 1997 Apr 7;137(1):155–67

A role for the actin cytoskeleton of Saccharomyces cerevisiae in bipolar bud-site selection. Yang S, et al. **J Cell Biol** 1997 Jan 13;136(1):111–23

Destabilization of plasma membrane structure by prevention of actin polymerization. Microtubule-dependent tubulation of the plasma membrane. van Deurs B, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1655–65

The actin network in the ciliary stalk of photoreceptors functions in the generation of new outer segment discs. Hale IL, et al. **J Comp Neurol** 1996 Dec 2;376(1):128–42

Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. Matsumura T, et al. **J Immunol** 1997 Apr 1;158(7):3408–16

Complex regulation of human neutrophil activation by actin filaments: dihydrocytochalasin B and botulinum C2 toxin uncover the existence of multiple cation entry pathways. Wenzel-Seifert K, et al. **J Leukoc Biol** 1997 Jun; 61(6):703–11

Formation of binucleated cardiac myocytes in rat heart: I. Role of actin-myosin contractile ring. Li F, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1541–51

The effect of actin filament compliance on the interpretation of the elastic properties of skeletal muscle fibres. Blangé T, et al. **J Muscle Res Cell Motil** 1997 Apr;18(2):125–31

Actin filament mechanics in the laser trap. Dupuis DE, et al. **J Muscle Res Cell Motil** 1997 Feb;18(1):17–30

A simple method for automatic tracking of actin filaments in the motility assay. Marston SB, et al. **J Muscle Res Cell Motil** 1996 Aug;17(4):497–506

Simulation of the rapid regeneration of the actin-myosin working stroke with a tight coupling model of muscle contraction. Piazzesi G, et al. **J Muscle Res Cell Motil** 1996 Feb;17(1):45–53

Fish muscle cytoskeleton integrity is not dependent on intact thin filaments. Taylor RG, et al. **J Muscle Res Cell Motil** 1997 Jun;18(3):285–94

Modification of the bi-directional sliding movement of actin filaments along native thick filaments isolated from a clam. West JM, et al. **J Muscle Res Cell Motil** 1996 Dec; 17(6):637–46

Inhibition by drebrin of the actin-bundling activity of brain fascin, a protein localized in filopodia of growth cones. Sasaki Y, et al. **J Neurochem** 1996 Mar;66(3):980–8

Actin plays a role in both changes in cell shape and gene-expression associated with Schwann cell myelination. Fernandez-Valle C, et al. **J Neurosci** 1997 Jan 1; 17(1):241–50

Spectrin-actin interaction is required for neurite extension in NB 2a/dl neuroblastoma cells. Sihag RK, et al. **J Neurosci Res** 1996 Jun 1;44(5):430–7

Actin microfilament disrupters enhance K(ATP) channel opening in patches from guinea-pig cardiomyocytes. Terzic A, et al. **J Physiol (Lond)** 1996 Apr 15;492 (Pt 2):395–404

Mesangial cell actin disassembly in high glucose mediated by protein kinase C and the polyol pathway. Zhou X, et al. **Kidney Int** 1997 Jun;51(6):1797–808

Overexpression of RnRacGAP in Drosophila melanogaster deregulates cytoskeletal organisation in cellularising embryos and induces discrete imaginal phenotypes. Guichard A, et al. **Mech Dev** 1997 Jan;61(1–2):49–62

The molecular mechanisms of actin-based intracellular motility by Listeria monocytogenes. Chakraborty T. **Microbiologia** 1996 Jun;12(2):237–44 (34 ref.)

Dual role of the actin cytoskeleton in regulating cell adhesion mediated by the integrin lymphocyte function-associated molecule-1. Lub M, et al. **Mol Biol Cell** 1997 Feb; 8(2):341–51

The yeast actin-related protein Arp2p is required for the internalization step of endocytosis. Moreau V, et al. **Mol Biol Cell** 1997 Jul;8(7):1361–75

Activation of the osmo-sensitive chloride conductance involves P21rho and is accompanied by a transient reorganization of the F-actin cytoskeleton. Tilly BC, et al. **Mol Biol Cell** 1996 Sep;7(9):1419–27

Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Westwick JK, et al. **Mol Cell Biol** 1997 Mar;17(3):1324–35

The unrelated surface proteins ActA of Listeria monocytogenes and IcsA of Shigella flexneri are sufficient to confer actin-based motility on Listeria innocua and Escherichia coli respectively. Kocks C, et al. **Mol Microbiol** 1995 Nov;18(3):413–23

Muscle force is generated by myosin heads stereospecifically attached to actin. Bershitsky SY, et al. **Nature** 1997 Jul 10;388(6638):186–90

In growth cones of rat cerebral neurons and human neuroblastoma cells, activation of protein kinase C causes a shift from filopodial to lamellipodial actin dynamics. Rösner H, et al. **Neurosci Lett** 1996 Nov 29;219(3):175–8

Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton. Nolte C, et al. **Neuroscience** 1996 Aug;73(4):1091–107

Actin cytoskeleton polymerization in Dbl-transformed NIH3T3 fibroblasts is dependent on cell adhesion to specific extracellular matrix proteins. Defilippi P, et al. **Oncogene** 1997 Apr 24;14(16):1933–43

Role of actin microfilament in osmotic stretch-induced increase of voltage-operated calcium channel current in guinea-pig gastric myocytes. Xu WX, et al. **Pflugers Arch** 1997 Aug;434(4):502–4

Persisting in vitro actin motility at nanomolar adenosine triphosphate levels: comparison of skeletal and cardiac myosins. Kellermayer MS Jr, et al. **Physiol Chem Phys Med NMR** 1995;27(3):167–78

Axial rotation of sliding actin filaments revealed by single-fluorophore imaging. Sase I, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5646–50

Regulation of vasomotion of arterioles and capillaries in the cat spinal cord: role of alpha actin and endothelin-1. Toribatake Y, et al. **Spinal Cord** 1997 Jan;35(1):26–32

Tails from the hall of infection: actin-based motility of pathogens. Sanders MC, et al. **Trends Microbiol** 1996 Jun; 4(6):211–3 (18 ref.)

Pasteurella multocida enters polarized epithelial cells by interacting with host F-actin. Rabier MJ, et al. **Vet Microbiol** 1997 Mar;54(3–4):343–55

[Polarity of epithelial cells. Role of the actin microfilament system] Louvard D. **Nephrologie** 1996;17(7):351–7 (17 ref.) (Eng. Abstr.) **(Fre)**

[Molecular mechanism of force (motion) generation by actomyosin] Strzelecka-Gołaszewska H. **Postepy Biochem** 1996;42(2):185–94 (83 ref.) **(Pol)**

[The role of the actin cytoskeleton in cell transition through the middle of the G1 phase of the mitotic cycle] Barkan RS, et al. **Tsitologiia** 1996;38(7):733–41 (Eng. Abstr.) **(Rus)**

TOXICITY

Cytotoxic effects by microinjection of ADP-ribosylated skeletal muscle G-actin in PtK2 cells in the absence of Clostridium perfringens iota toxin. Kiefer G, et al. **Med Microbiol Immunol (Berl)** 1996 Feb;184(4):175–80

ULTRASTRUCTURE

Energy filtered electron tomography of ice-embedded actin and vesicles. Grimm R, et al. **Biophys J** 1997 Jan; 72(1):482–9

Three-dimensional image reconstruction of reconstituted smooth muscle thin filaments: effects of caldesmon. Hodgkinson JL, et al. **Biophys J** 1997 Jun;72(6):2398–404

Phosphatidylserine liposomes can be tethered by caldesmon to actin filaments. Makuch R, et al. **Biophys J** 1997 Sep; 73(3):1607–16

Light microscopic analysis of ligand-induced actin filament suprastructures. Korneeva NL, et al. **Eur J Cell Biol** 1996 Dec;71(4):351–5

Prosome cytodistribution relative to desmin and actin filaments in dividing C2.7 myoblasts and during myotube formation in vitro. De Conto F, et al. **Exp Cell Res** 1997 May 25;233(1):99–117

Improved visualization of F-actin in the green alga Acetabularia by microwave-accelerated fixation and simultaneous FITC-Phalloidin staining. Sawitzky H, et al. **Histochem J** 1996 May;28(5):353–60

A correlative analysis of actin filament assembly, structure, and dynamics. Steinmetz MO, et al. **J Cell Biol** 1997 Aug 11;138(3):559–74

Vaccinia virus: a model system for actin-membrane interactions. Cudmore S, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1739–47

Function of spindle microtubules in directing cortical movement and actin filament organization in dividing cultured cells. Fishkind DJ, et al. **J Cell Sci** 1996 Aug;109 (Pt 8):2041–51

Cooperative rigor binding of myosin to actin is a function of F-actin structure. Orlova A, et al. **J Mol Biol** 1997 Feb 7;265(5):469–74

Visualization of prosomes (MCP-proteasomes), intermediate filament and actin networks by "instantaneous fixation" preserving the cytoskeleton. Arcangeletti C, et al. **J Struct Biol** 1997 Jun;119(1):35–58

Actin: from cell biology to atomic detail. Steinmetz MO, et al. **J Struct Biol** 1997 Aug;119(3):295–320

Investigation of the mechanism of retraction of the cell margin and rearward flow of nodules during mitotic cell rounding. Cramer LP, et al. **Mol Biol Cell** 1997 Jan; 8(1):109–19

Phosphatidylinositol 4,5-bisphosphate phosphatase regulates the rearrangement of actin filaments. Sakisaka T, et al. **Mol Cell Biol** 1997 Jul;17(7):3841–9

[Structural changes in the cytoskeletal actin in cultured muscle cells when the cultures are stimulated by polystyrene latex] Samosudova NV, et al. **Tsitologiia** 1996; 38(8):829–33 (Eng. Abstr.) **(Rus)**

ACTION POTENTIALS

Association of preceding angina with in-hospital life-threatening ventricular tachyarrhythmias and late potentials in patients with a first acute myocardial infarction. Tamura K, et al. **Am Heart J** 1997 Mar; 133(3):297–301

Memory and complex dynamics in cardiac Purkinje fibers. Gilmour RF Jr, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1826–32

Electrode for recording direction of activation, conduction velocity, and monophasic action potential of myocardium.

Horner SM, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1917–27

Role of passive electrical properties during action potential restitution in intact heart. Laurita KR, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1205–14

Action potential generation in the small intestine of W mutant mice that lack interstitial cells of Cajal. Malysz J, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):G387–99

Computer model of electrophysiological instability in very small heterogeneous ventricular syncytia. Nordin C. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1838–56

Transient outward current contributes to Wenckebach-like rhythms in isolated rabbit ventricular cells. Yehia AR, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H1–11

Ito1 dictates behavior of ICl(Ca) during early repolarization of canine ventricle. Zygmunt AC, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1096–106

Optical monitoring of glutaminergic excitatory postsynaptic potentials from the early developing embryonic chick brain stem. Momose-Sato Y, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:454–7

Modeling stochastic spike train responses of neurons: an extended Wiener series analysis of pigeon auditory nerve fibers. Joeken S, et al. **Biol Cybern** 1997 Feb;76(2):153–62

Spontaneous action potentials due to channel fluctuations. Chow CC, et al. **Biophys J** 1996 Dec;71(6):3013–21

Calcium dynamics associated with a single action potential in a CNS presynaptic terminal. Helmchen F, et al. **Biophys J** 1997 Mar;72(3):1458–71

A gap isolation method to investigate electrical and mechanical properties of fully contracting skeletal muscle fibers. Kim AM, et al. **Biophys J** 1996 Aug;71(2):924–31

Generation of action potentials in a mathematical model of corticotrophs. LeBeau AP, et al. **Biophys J** 1997 Sep; 73(3):1263–75

Modeling the attenuation and failure of action potentials in the dendrites of hippocampal neurons. Migliore M. **Biophys J** 1996 Nov;71(5):2394–403

Dynamics of the neural discharge in snail neurons. Chillemi S, et al. **Biosystems** 1997;40(1–2):21–8

Spike train patterning and forecastability. Longtin A, et al. **Biosystems** 1997;40(1–2):111–8

Fatigue-induced changes in group IV muscle afferent activity: differences between high- and low-frequency electrically induced fatigues. Darques JL, et al. **Brain Res** 1997 Mar 7;750(1–2):147–54

Recognition of temporally structured activity in spontaneously discharging neurons in the somatosensory cortex in waking cats. Martinson J, et al. **Brain Res** 1997 Mar 7;750(1–2):129–40

Single versus repetitive spiking to the current stimulus of A-beta mechanosensitive neurons in the crotaline snake trigeminal ganglion. Terashima S, et al. **Cell Mol Neurobiol** 1997 Apr;17(2):195–206

Regional alteration of the transient outward current in human left ventricular septum during compensated hypertrophy. Bailly P, et al. **Circulation** 1997 Aug 19;96(4):1266–74

F-response multiplicity in lower motor neuron disorders. Pradhan S. **Electromyogr Clin Neurophysiol** 1996 Oct-Nov; 36(7):441–8

Correlation of EMG, CMAP and SNAP amplitude decrease in mononeuropathies with axonal loss. Wu PB, et al. **Electromyogr Clin Neurophysiol** 1996 Oct-Nov;36(7):405–9

Morphology of action potentials recorded from human nerves using microneurography. Inglis JT, et al. **Exp Brain Res** 1996 Jul;110(2):308–14

Detection, classification, and superposition resolution of action potentials in multiunit single-channel recordings by an on-line real-time neural network. Chandra R, et al. **IEEE Trans Biomed Eng** 1997 May;44(5):403–12

Ionic basis of spike after-depolarization and burst generation in adult rat hippocampal CA1 pyramidal cells. Azouz R, et al. **J Physiol (Lond)** 1996 Apr 1;492 (Pt 1):211–23

Cellular mechanisms for neuronal thermosensitivity in the rat hypothalamus. Griffin JD, et al. **J Physiol (Lond)** 1996 Apr 1;492 (Pt 1):231–42

Correlation between electrical activity and the size of rabbit sino-atrial node cells. Honjo H, et al. **J Physiol (Lond)** 1996 Nov 1;496 (Pt 3):795–808

Spike after-depolarization and burst generation in adult rat hippocampal CA1 pyramidal cells. Jensen MS, et al. **J Physiol (Lond)** 1996 Apr 1;492 (Pt 1):199–210

Motor unit number estimation by spatial-temporal summation of single motor unit potentials. Fang J, et al. **Muscle Nerve** 1997 Apr;20(4):461–8

Propagation velocity of muscle action potentials in the growing normal child. Malmström JE, et al. **Muscle Nerve** 1997 Apr;20(4):403–10

On the relationship between synaptic input and spike output jitter in individual neurons. Maršálek P, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21;94(2):735–40

[Anesthesia mechanisms: nerve excitation and temperature] Suzuki A, et al. **Masui** 1996 Jun;45(6):670–5 (31 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Effect of an intravenous angiotensin-converting enzyme inhibitor on the electrophysiologic features of normal and hypertrophied feline ventricles. Rials SJ, et al. **Am Heart J** 1996 Nov;132(5):989–94

Blocking ATP-sensitive K+ channel during metabolic inhibition impairs muscle contractility. Gramolini A, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):C1936–46

Effects of relaxin on rat atrial myocytes. II. Increased calcium influx derived from action potential prolongation. Piedras-Rentería ES, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1798–803

Effects of histamine H1 receptor antagonists on action potentials in guinea-pig isolated papillary muscles. Ki I, et al. **Arch Int Pharmacodyn Ther** 1996 Jan-Feb; 331(1):59–73

Arrhythmogenic effect of beta-adrenoceptor-blocking drugs in Purkinje fibres of guinea-pig hearts. Lemmens-Gruber R, et al. **Arch Int Pharmacodyn Ther** 1996 Jan-Feb; 331(1):46–58

Voltage- and frequency-dependent modulation of L-type Ca2+ channel by MPC-1304, a novel calcium antagonist in guinea-pig hearts. Sunami A, et al. **Arch Int Pharmacodyn Ther** 1995 Sep-Oct;330(2):151–64

Modulation of serotonin-induced currents by metals in mouse neuroblastoma cells. Uki M, et al. **Arch Toxicol** 1996; 70(10):652–60

Extracellular action potentials of skeletal muscle fibre affected by 4-aminopyridine: a model study. Slavcheva G, et al. **Biol Cybern** 1996 Mar;74(3):235–41

Depression of A and C fibre-evoked segmental reflexes by morphine and clonidine in the in vitro spinal cord of the neonatal rat. Faber ES, et al. **Br J Pharmacol** 1997 Apr; 120(7):1390–6

Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury. Fehlings MG, et al. **Brain Res** 1996 Oct 14; 736(1–2):135–45

ATP shortens atrial action potential duration in the dog: role of adenosine, the vagus nerve, and G protein. Pelleg A, et al. **Can J Physiol Pharmacol** 1996 Jan;74(1):15–22

Assessment of frequency dependency of the class III effects of almokalant: a study using programmed stimulation and recording of monophasic action potentials and ventricular paced QT intervals. Darpö B, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):539–47

Hypotonic-induced stretch counteracts the efficacy of the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Groh WJ, et al. **Cardiovasc Res** 1996 Feb; 31(2):237–45

The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers. Németh M, et al. **Cardiovasc Res** 1996 Feb;31(2):246–8

Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium. Verduyn SC, et al. **Cardiovasc Res** 1997 Jun; 34(3):453–63

Inositol-1,4,5-trisphosphate induces responses in receptor neurons in rat vomeronasal sensory slices. Inamura K, et al. **Chem Senses** 1997 Feb;22(1):93–103

Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Rials SJ, et al. **Circulation** 1997 Aug 19;96(4):1330–6

Withdrawal of acetylcholine elicits Ca2+-induced delayed afterdepolarizations in cat atrial myocytes. Wang YG, et al. **Circulation** 1997 Aug 19;96(4):1275–81

Effects of veratridine on the action potentials and contractility of right and left ventricles from normo- and hypertensive rats. Nand V, et al. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):570–6

On the antiarrhythmic actions of magnesium in single guinea-pig ventricular myocytes. Song Y, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):830–8

Remacemide HCl and its metabolite, FPL 12495AA, limit action potential firing frequency and block NMDA responses of mouse spinal cord neurons in cell culture. Wamil AW, et al. **Epilepsy Res** 1996 Feb;23(1):1–14

Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Miller AS, et al. **Eur J Pharmacol** 1996 May 23;304(1–3):29–35

Inhibitory effects of berberine on ATP-sensitive K+ channels in cardiac myocytes. Wang YX, et al. **Eur J Pharmacol** 1996 Dec 5;316(2–3):307–15

Ethanol depression of cerebellar Purkinje neuron firing involves nicotinic acetylcholine receptors. Freund RK, et al. **Exp Neurol** 1997 Feb;143(2):319–22

Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated guinea pig papillary muscle. Pankucsi C, et al. **Gen Pharmacol** 1997 Aug; 29(2):275–80

Antiarrhythmic and electrophysiological effects of the novel KATP channel opener, rilmakalim, in rabbit cardiac cells. Ricciotti Neto F, et al. **Gen Pharmacol** 1997 Aug; 29(2):201–5

Electrophysiological and morphological evaluation of the acute ototoxicity of sodium nitroprusside. Kong WJ, et al. **Hear Res** 1996 Sep 15;99(1–2):22–30

Diisopropylphosphorofluoridate-induced depression of compound action potential of frog sciatic nerve in vitro is mediated through the inhibition of cholinesterase activity. Deshpande SB, et al. **J Appl Toxicol** 1996 Nov-Dec; 16(6):497–500

Class III antiarrhythmic effects of LY-190147 on defibrillation threshold. Beatch GN, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):218–25

Analysis of the ionic basis for cocaine's biphasic effect on action potential duration in guinea-pig ventricular myocytes. Clarkson CW, et al. **J Mol Cell Cardiol** 1996 Apr;28(4):667–78

Rapid onset of lysophosphatidylcholine-induced modification of whole cell cardiac sodium current kinetics. Shander GS, et al. **J Mol Cell Cardiol** 1996 Apr; 28(4):743–53

Requirement for tyrosine phosphatase during serotonergic neuromodulation by protein kinase C. Catarsi S, et al. **J Neurosci** 1997 Aug 1;17(15):5792–7

Muscarinic modulation of spike backpropagation in the apical dendrites of hippocampal CA1 pyramidal neurons. Tsubokawa H, et al. **J Neurosci** 1997 Aug 1;17(15):5782–91

Anoxic injury in the rat spinal cord: pharmacological evidence for multiple steps in Ca(2+)-dependent injury of the dorsal columns. Imaizumi T, et al. **J Neurotrauma** 1997 May;14(5):299–311

The stereo-isomers of the anticonvulsant ARL 12495AA limit sustained repetitive firing and modify action potential properties of rat hippocampal neurons in vitro. Norris SK, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1191–8

Trans-2-en-valproic acid limits action potential firing frequency in mouse central neurons in cell culture. Wamil AW, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1349–56

Excitatory actions of GABA in developing rat hypothalamic neurones. Chen G, et al. **J Physiol (Lond)** 1996 Jul 15;494 (Pt 2):451–64

Endogenous and exogenous dopamine depress EPSCs in rat nucleus accumbens in vitro via D1 receptors activation. Harvey J, et al. **J Physiol (Lond)** 1996 Apr 1;492 (Pt 1):143–54

The hyperpolarization-activated current (Ih) and its contribution to pacemaker activity in rat CA1 hippocampal stratum oriens-alveus interneurones. Maccaferri G, et al. **J Physiol (Lond)** 1996 Nov 15;497 (Pt 1):119–30

Different types of Na+ and A-type K+ currents in dorsal root ganglion neurones innervating the rat urinary bladder. Yoshimura N, et al. **J Physiol (Lond)** 1996 Jul 1;494 (Pt 1):1–16

Effects of grayanotoxin-I on threshold intensity and compound action potential of frog sciatic nerve. Aşcioğlu M, et al. **J Physiol Pharmacol** 1996 Jun;47(2):341–9

Ethanol potentiates the depressant effects of cocaine in human fetal myocardium in vitro. Richards IS. **J Toxicol Clin Toxicol** 1997;35(4):365–9

Effect of terfenadine and KW-4679, a novel antiallergic compound, on action potential of guinea pig ventricular myocytes. Kato Y, et al. **Jpn J Pharmacol** 1996 Feb; 70(2):199–202

Effect of cortisporin otic suspension on cochlear function and efferent activity in the guinea pig. Perry BP, et al. **Laryngoscope** 1996 Dec;106(12 Pt 1):1557–61

Effects of 17 beta-estradiol on early afterdepolarizations and L-type Ca2+ currents induced by endothelin-1 in guinea pig papillary muscles and ventricular myocytes. Liu B, et al. **Methods Find Exp Clin Pharmacol** 1997 Jan-Feb; 19(1):19–25

Electrophysiological effects of the anticonvulsant remacemide hydrochloride and its metabolite ARL 12495AA on rat CA1 hippocampal neurons in vitro. Norris SK, et al. **Neuropharmacology** 1997 Jul;36(7):951–9

Acetylcholine and carbachol prevent muscle depolarization in denervated rat diaphragm. Urazaev AK, et al. **Neuroreport** 1997 Jan 20;8(2):403–6

High intracellular calcium levels during and after electrical discharges in molluscan peptidergic neurons. Kits KS, et al. **Neuroscience** 1997 Jul;79(1): 75–84

Independent depressive mechanisms of GABA and (+/-)-8-hydroxy-dipropylaminotetralin hydrobromide on young rat spinal axons. Sakuma J, et al. **Neuroscience** 1996 Dec;75(3):927–38

Determinants of the natural course of ventricular late potentials after thrombolytic therapy for acute myocardial infarction. Jung J, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1909–13

Muscarinic effects on action potential duration and its rate dependence in canine Purkinje fibers. Malfatto G, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):2023–6

Evolution of late potentials during the first 8 hours of myocardial infarction treated with thrombolysis. Peters W, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1918–22

An analysis of dimethylsulfoxide-induced action potential block: a comparative study of DMSO and other aliphatic water soluble solutes. Larsen J, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):296–314

Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Sugiyama A, et al. **Toxicol Appl Pharmacol** 1997 Mar;143(1):89–95

PHYSIOLOGY

Neurophysiological aspects of voluntary movements. Godaux E. **Acta Neurol Belg** 1996 Sep;96(3):193–202 (21 ref.)

Reversible depression of action potentials and force production in frog single muscle fibres by calmodulin-inhibitors. Bruton JD, et al. **Acta Physiol Scand** 1996 Apr;156(4):441–6

Electrical restitution in rat ventricular muscle. Nanasi PP, et al. **Acta Physiol Scand** 1996 Oct;158(2):143–53

Contribution of ATP to oxidative stress-induced changes in action potential of isolated cardiac myocytes. Bhatnagar A. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1598–608

ACTION POTENTIALS

Ca(2+)-activated K+ channels regulate action potential repolarization in urinary bladder smooth muscle. Heppner TJ, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C110–7

Roles of outward potassium currents in the action potentials of guinea pig ureteral myocytes. Sui JL, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C962–72

Propagation on a central fiber surrounded by inactive fibers in a multifibered bundle model. Roberge FA, et al. **Ann Biomed Eng** 1996 Nov–Dec;24(6):647–61

Effect of a perfusing bath on the rate of rise of an action potential propagating through a slab of cardiac tissue. Roth BJ. **Ann Biomed Eng** 1996 Nov–Dec;24(6):639–46

Interactions between adjacent fibers in a cardiac muscle bundle. Wang S, et al. **Ann Biomed Eng** 1996 Nov–Dec; 24(6):662–74

Simulation of the electrically stimulated auditory nerve. Rattay F. **Artif Organs** 1997 Mar;21(3):213–5

Postsynaptic action potentials do not alter short–term potentiation in the dentate gyrus. Foster B, et al. **Brain Res** 1997 May 30;758(1–2):59–68

Burst–firing activity of presumed 5–HT neurones of the rat dorsal raphe nucleus: electrophysiological analysis by antidromic stimulation. Hajós M, et al. **Brain Res** 1996 Nov 18;740(1–2):162–8

Changes in movement–related brain activity during transient deafferentation: a neuromagnetic study. Kristeva–Feige R, et al. **Brain Res** 1996 Apr 1;714(1–2):201–8

Multiple action potential waveforms of single units in man as signs of variability in conductivity of their myelinated fibres. Wu G, et al. **Brain Res** 1996 Dec 2;742(1–2):225–38

A measure of peripheral nerve stimulation efficacy applicable to H–reflex studies. Boorman GI, et al. **Can J Neurol Sci** 1996 Nov;23(4):264–70

Differential effects of chronic membrane depolarization on the K+ channel activities in cultured rat ventricular cells. Guo W, et al. **Cardiovasc Res** 1997 Jan;33(1):139–46

Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia. Lukas A, et al. **Cardiovasc Res** 1996 Sep;32(3):593–603

Termination of reentry by lidocaine in the tricuspid ring in vitro. Role of cycle–length oscillation, fast use–dependent kinetics, and fixed block. Fei H, et al. **Circ Res** 1997 Feb; 80(2):242–52

Resolution of late potentials with improvement in left ventricular systolic function in patients with first acute myocardial infarction. Masui A, et al. **Clin Cardiol** 1997 May;20(5):466–70

Electrical restitution in ventricular myocardium. Nańaśi PP, et al. **Clin Physiol** 1996 Sep;16(5):561

Electrical restitution in diseased human ventricular myocardium. Nánási PP, et al. **Clin Physiol** 1996 Jul; 16(4):339–51

The wavelength dependence of optically recorded action potentials in the atrial muscles of the bullfrog (Rana catesbeiana). Fujishiro N, et al. **Comp Biochem Physiol A Physiol** 1996 Jun;114(2):153–7

Clinical value of F–wave recordings in traumatic cervical spinal cord injury. Curt A, et al. **Electroencephalogr Clin Neurophysiol** 1997 Jun; 105(3):189–93

Conduction block and segmental velocities in carpal tunnel syndrome. Di Guglielmo G, et al. **Electroencephalogr Clin Neurophysiol** 1997 Aug; 105(4):321–7

The Utah intracortical Electrode Array: a recording structure for potential brain–computer interfaces. Maynard EM, et al. **Electroencephalogr Clin Neurophysiol** 1997 Mar; 102(3):228–39

A system–based study of the variation in the amplitude of the compound sensory nerve action potential recorded using surface electrodes. Pitt MC. **Electroencephalogr Clin Neurophysiol** 1996 Dec; 101(6):520–7

Motor control and kinetics during low level concentric and eccentric contractions in man. Søgaard K, et al. **Electroencephalogr Clin Neurophysiol** 1996 Oct; 101(5):453–60

Functional properties of motor units in motor neuron diseases and neuropathies. Vogt T, et al. **Electroencephalogr Clin Neurophysiol** 1997 Aug; 105(4):328–32

Electromyographic validation of basic exercises for physical conditioning programmes. III. Influence of the grip in the capacity of the rowing exercises in determining action potential levels for the deltoid and the pectoralis major muscle. Ferreira MI, et al. **Electromyogr Clin Neurophysiol** 1996 Mar;36(2):86–90

Selection of electrophysiological techniques to investigate axonal damage of peripheral motor nerve fibres. Hülser PJ, et al. **Electromyogr Clin Neurophysiol** 1997 Jan–Feb; 37(1):55–64

Cholinergic modulation of the action potential in rat hippocampal neurons. Figenschou A, et al. **Eur J Neurosci** 1996 Jan;8(1):211–9

Development of action potential–dependent and independent spontaneous GABAA receptor–mediated currents in granule cells of postnatal rat cerebellum. Wall MJ, et al. **Eur J Neurosci** 1997 Mar;9(3):533–48

Selective cortical and segmental control of primary afferent depolarization of single muscle afferents in the cat spinal cord. Eguibar JR, et al. **Exp Brain Res** 1997 Mar; 113(3):411–30

Waveform complexity of unit activity recorded with concentric needle electrodes from human peripheral nerves. Wu G, et al. **Exp Brain Res** 1997 Apr;114(2):377–83

Auditory evoked potentials in aged gerbils: responses elicited by noises separated by a silent gap. Boettcher FA, et al. **Hear Res** 1996 Dec 1;102(1–2):167–78

Changes in CM and CAP with sedation and temperature in the guinea pig: facts and interpretation. Charlet de Sauvage R, et al. **Hear Res** 1996 Dec 1;102(1–2):15–27

Tuning curves of the difference tone auditory nerve neurophonic. Henry KR. **Hear Res** 1996 Sep 15; 99(1–2):160–7

Electrochemical potentials and potassium concentration profiles recorded from perilymph, endolymph and associated inner ear tissues in adrenalectomized rats. Ma YL, et al. **Hear Res** 1996 Jul;96(1–2):151–6

Regeneration after tall hair cell damage following severe acoustic trauma in adult pigeons: correlation between cochlear morphology, compound action potential responses and single fiber properties in single animals. Müller M, et al. **Hear Res** 1996 Dec 1;102(1–2):133–54

Changes in cochlear function after double–membrane rupture in the guinea pig. Saitoh M, et al. **Hear Res** 1997 Feb; 104(1–2):147–54

Model of spatio–temporal propagation of action potentials in the Schaffer collateral pathway of the CA1 area of the rat hippocampus. Bernard C, et al. **Hippocampus** 1997; 7(1):58–72

The Z–transform of the compound action potential. A method for deriving nerve–fiber density distribution. Pollak VA, et al. **IEEE Eng Med Biol Mag** 1997 May–Jun; 16(3):80–4, 86

Determination of nerve conduction velocity distribution from sampled compound action potential signals. Gu D, et al. **IEEE Trans Biomed Eng** 1996 Aug;43(8):829–38

The shape of human atrial action potential accounts for different frequency–related changes in vitro. Dawodu AA, et al. **Int J Cardiol** 1996 Jun;54(3):237–49

Detecting low dimensional dynamics in biological experiments. Pei X, et al. **Int J Neural Syst** 1996 Sep; 7(4):429–35

Diaphragm interference pattern EMG and compound muscle action potentials: effects of chest wall configuration. Beck J, et al. **J Appl Physiol** 1997 Feb;82(2):520–30

Membrane properties of mouse anteroventral cochlear nucleus neurons in vitro. Agar E, et al. **J Basic Clin Physiol Pharmacol** 1996;7(3):179–98

Membrane properties of complex spike firing neurons of the mouse dorsal cochlear nucleus in vitro. Ağar E, et al. **J Basic Clin Physiol Pharmacol** 1996;7(2):151–65

Congenital Guillain–Barré syndrome. Jackson AH, et al. **J Child Neurol** 1996 Sep;11(5):407–10

Response properties of chemosensory peg sensilla on the pectines of scorpions. Gaffin DD, et al. **J Comp Physiol** [A] 1997 Sep;181(3):291–300

Bifurcation, bursting, and spike frequency adaptation. Guckenheimer J, et al. **J Comput Neurosci** 1997 Jul; 4(3):257–77

When inhibition not excitation synchronizes neural firing. Van Vreeswijk C, et al. **J Comput Neurosci** 1994 Dec; 1(4):313–21

Effects of activation sequence on monophasic action potential configuration in the dog. Tachibana H, et al. **J Electrocardiol** 1997 Jan;30(1):65–70

Inhibition of L–type calcium current in rat ventricular cells by the tyrosine kinase inhibitor, genistein and its inactive analog, daidzein. Yokoshiki H, et al. **J Mol Cell Cardiol** 1996 Apr;28(4):807–14

Osmotic 'detubulation' in frog muscle arises from a reversible vacuolation process. Gallagher FA, et al. **J Muscle Res Cell Motil** 1997 Jun;18(3):305–21

New electrical properties of neurons induced by a homeoprotein. Aisemberg GO, et al. **J Neurobiol** 1997 Jul; 33(1):11–7

Action potential–generating cells in human glioblastomas. Labrakakis C, et al. **J Neuropathol Exp Neurol** 1997 Mar; 56(3):243–54

GABAA mediated afterdepolarization in pyramidal neurons from rat neocortex. Cerne R, et al. **J Neurophysiol** 1997 Feb;77(2):1039–45

Axonal action–potential initiation and Na+ channel densities in the soma and axon initial segment of subicular pyramidal neurons. Colbert CM, et al. **J Neurosci** 1996 Nov 1; 16(21):6676–86

Action potential–dependent regulation of gene expression: temporal specificity in ca2+, cAMP–responsive element binding proteins, and mitogen–activated protein kinase signaling. Fields RD, et al. **J Neurosci** 1997 Oct 1; 17(19):7252–66

An ATP–dependent inwardly rectifying potassium channel, KAB–2 (Kir4. 1), in cochlear stria vascularis of inner ear: its specific subcellular localization and correlation with the formation of endocochlear potential. Hibino H, et al. **J Neurosci** 1997 Jun 15;17(12):4711–21

Differential expression of K4–AP currents and Kv3.1 potassium channel transcripts in cortical neurons that develop distinct firing phenotypes. Massengill JL, et al. **J Neurosci** 1997 May 1;17(9):3136–47

Postnatal development of membrane properties and delta oscillations in thalamocortical neurons of the cat dorsal lateral geniculate nucleus. Pirchio M, et al. **J Neurosci** 1997 Jul 15;17(14):5428–44

Resurgent sodium current and action potential formation in dissociated cerebellar Purkinje neurons. Raman IM, et al. **J Neurosci** 1997 Jun 15;17(12):4517–26

Alterations in frequency coding and activity dependence of excitability in cultured neurons of Drosophila memory mutants. Zhao ML, et al. **J Neurosci** 1997 Mar 15; 17(6):2187–99

Spike train analysis. Awiszus F. **J Neurosci Methods** 1997 Jun 27;74(2):155–66 (32 ref.)

Unit identification, sampling bias and technical issues in microneurographic recordings from muscle spindle afferents. Burke D. **J Neurosci Methods** 1997 Jun 27; 74(2):137–44 (39 ref.)

The methodology and scope of human microneurography. Gandevia SC, et al. **J Neurosci Methods** 1997 Jun 27; 74(2):123–36 (87 ref.)

Assessing changes in presynaptic inhibition of Ia afferents during movement in humans. Pierrot–Deseilligny E. **J Neurosci Methods** 1997 Jun 27;74(2):189–99 (46 ref.)

Techniques and mechanisms of action of transcranial stimulation of the human motor cortex. Rothwell JC. **J Neurosci Methods** 1997 Jun 27;74(2):113–22 (45 ref.)

Long–term culture of fully differentiated adult insect neurons. Smith PJ, et al. **J Neurosci Methods** 1996 Oct 21;69(1):113–22

DAPAS, a computerised workplace for Digital Acquisition and Processing of Analog Signals, with up to two gigabytes data per registration. Widman G, et al. **J Neurosci Methods** 1996 Jul;67(1):71–81

Information theoretic analysis of action potential trains. II. Analysis of correlation among n neurons to deduce connection structure. Yamada S, et al. **J Neurosci Methods** 1996 May;66(1):35–45

Free cyclic AMP increases in PC12 cells on depolarization. Agnihotri N, et al. **J Neurosci Res** 1997 Mar 1;47(5):555–60

Potentiation and depression of the M wave in human biceps brachii. Cupido CM, et al. **J Physiol (Lond)** 1996 Mar 1; 491 (Pt 2):541–50

Control of action potential propagation by intracellular Ca2+ in cultured rat dorsal root ganglion cells. Lüscher C, et al. **J Physiol (Lond)** 1996 Jan 15;490 (Pt 2):319–24

The pattern of stimulation influences the amount of oscillatory work done by frog muscle. Stevens ED. **J Physiol (Lond)** 1996 Jul 1;494 (Pt 1):279–85

Analysis of current fluctuations during after–hyperpolarization current in dentate granule neurones of the rat hippocampus. Valiante TA, et al. **J Physiol (Lond)** 1997 Feb 15;499 (Pt 1):121–34

Modulation of ganglion cell activity in the pineal gland of the rainbow trout: effects of cholinergic, catecholaminergic, and GABAergic receptor agonists. Brandstätter R, et al. **J Pineal Res** 1996 Sep;21(2):59–72

Chaos in weakly–coupled pacemaker cells. Endresen LP. **J Theor Biol** 1997 Jan 7;184(1):41–50

Resolving superimposed motor unit action potentials. Etawil H, et al. **Med Biol Eng Comput** 1996 Jan;34(1):33–40

Surface action potentials related to torque output in paraplegics' electrically stimulated quadriceps muscle. Rabischong E. **Med Eng Phys** 1996 Oct;18(7):538–47

Direct muscle stimulation in acute quadriplegic myopathy. Rich MM, et al. **Muscle Nerve** 1997 Jun;20(6):665–73

Stimulus–induced repetitive discharge of long latency [letter] Roth G. **Muscle Nerve** 1997 May;20(5):628–9

Action–potential propagation gated by an axonal I(A)–like K+ conductance in hippocampus. Debanne D, et al. **Nature** 1997 Sep 18;389(6648):286–9

Temporal precision of spike trains in extrastriate cortex of the behaving macaque monkey. Bair W, et al. **Neural Comput** 1996 Aug 15;8(6):1185–202

Effects of sleep deprivation on serotonergic neuronal activity in the dorsal raphe nucleus of the freely moving cat. Gardner JP, et al. **Neuropsychopharmacology** 1997 Aug; 17(2):72–81

An unusual effect of application of the amino acid L–arginine on cat visual cortical cells. Rivadulla C, et al. **Neuroreport** 1997 Mar 3;8(4):863–6

Prolonged injury discharge in unmyelinated nerve fibres following transection of the sural nerve in rats. Blenk KH, et al. **Neurosci Lett** 1996 Sep 13;215(3):185–8

Evident difference in the excitability of the motoneuron pool between normal subjects and patients with spasticity assessed by a new method using H–reflex and M–response. Funase K, et al. **Neurosci Lett** 1996 Jan 19;203(2):127–30

Cell–cell coupling occurs in dorsal medullary neurons after minimizing anatomical–coupling artifacts. Dean JB, et al. **Neuroscience** 1997 Sep;80(1):21–40

Cell–cell coupling between CO2–excited neurons in the dorsal medulla oblongata. Huang RQ, et al. **Neuroscience** 1997 Sep;80(1):41–57

High intracellular calcium levels during and after electrical discharges in molluscan peptidergic neurons. Kits KS, et al. **Neuroscience** 1997 Jul;79(1):275–84

Shortened–duration GABA(A) receptor–mediated synaptic potentials underlie enhanced CA1 excitability in a chronic model of temporal lobe epilepsy. Mangan PS, et al. **Neuroscience** 1997 Oct;80(4):1101–11

Subdivisions of the guinea–pig accessory olfactory bulb revealed by the combined method with immunohistochemistry, electrophysiological, and optical recordings. Sugai T, et al. **Neuroscience** 1997 Aug; 79(3):871–85

Two types of cholinergic neurons in the rat tegmental pedunculopontine nucleus: electrophysiological and morphological characterization. Takakusaki K, et al. **Neuroscience** 1997 Aug;79(4):1089–109

Nerve action potential recording method and equipment. Tiel RL, et al. **Neurosurgery** 1996 Jul;39(1):103–8; discussion 108–9

Mapping reentry around atriotomy scars using double potentials. Chinitz LA, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1978–83

ST reelevation at reperfusion is associated with the occurrence of late potentials in patients with acute anterior infarction. Ochiai M, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1914–7

Lack of evidence of areas of slow conduction early after radiofrequency current application at porcine atrial myocardium. Paul T, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):2009–13

Regional differences in the regulation of intracellular sodium and in action potential configuration in rabbit left ventricle. Cook SJ, et al. **Pflugers Arch** 1997 Feb;433(4):515–22

Circulating excitations and re–entry in the pregnant uterus. Lammers WJ. **Pflugers Arch** 1997 Jan;433(3):287–93

The effects of changes to action potential duration on the calcium content of the sarcoplasmic reticulum in isolated guinea–pig ventricular myocytes. Terracciano CM, et al. **Pflugers Arch** 1997 Feb;433(4):542–4

Action potential initiation and backpropagation in neurons of the mammalian CNS. Stuart G, et al. **Trends Neurosci** 1997 Mar;20(3):125–31 (101 ref.)

No evidence of polarization sensitivity in freshwater sunfish from multi–unit optic nerve recordings. Novales Flamarique I, et al. **Vision Res** 1997 Apr;37(8):967–73

ACTIVATED CHARCOAL see **CHARCOAL**

ACTIVATED COAGULATION TIME, WHOLE BLOOD see **WHOLE BLOOD COAGULATION TIME**

ACTIVATED PARTIAL THROMBOPLASTIN TIME see **PARTIAL THROMBOPLASTIN TIME**

ACTIVATION ANALYSIS

Analysis of dynamic radioligand displacement or "activation" studies. Friston KJ, et al. **J Cereb Blood Flow Metab** 1997 Jan;17(1):80–93

ACTIVATOR APPLIANCES

Initial effects of treatment of Class II malocclusion with the Herren activator, activator–headgear combination, and Jasper Jumper. Weiland FJ, et al. **Am J Orthod Dentofacial Orthop** 1997 Jul;112(1):19–27

Comparison of Hyrax and bonded expansion appliances. Asanza S, et al. **Angle Orthod** 1997;67(1):15–22

Case report: modified use of the Jasper Jumper appliance in a skeletal Class II mixed dentition case requiring palatal expansion. Mills CM, et al. **Angle Orthod** 1997;67(4):277–82

Early maxillary orthopedics in a child with an oblique facial cleft. Stellzig A, et al. **Cleft Palate Craniofac J** 1997 Mar; 34(2):147–50

The hyaline zone and associated root surface changes in experimental orthodontics in rats: a light and scanning electron microscope study. Hellsing E, et al. **Eur J Orthod** 1996 Feb;18(1):11–8

Long–term effects of Class II correction in Herbst and Bass therapy. Omblus J, et al. **Eur J Orthod** 1997 Apr; 19(2):185–93

Mandibular growth during initial treatment with the Bass orthopaedic appliance in relation to age and growth periods. Omblus J, et al. **Eur J Orthod** 1997 Feb;19(1):47–56

New clinical applications for the Jasper Jumper. Pham T, et al. **J Orofac Orthop** 1996 Dec;57(6):366–71 **(Eng, Ger)**

Dental appliances in the treatment of snoring. A comparison between an activator, a soft–palate lifter, and a mouth–shield. Marklund M, et al. **Swed Dent J** 1996; 20(5):183–8

ACTIVE LEARNING see **PROBLEM–BASED LEARNING**

ACTIVE SITE see **BINDING SITES**

ACTIVE TRANSPORT see **BIOLOGICAL TRANSPORT, ACTIVE**

ACTIVITIES OF DAILY LIVING

see related
SICKNESS IMPACT PROFILE

Relation between the instrumental activities of daily living and physical fitness tests in elderly women. Uchida H, et al. **Acta Med Okayama** 1996 Dec;50(6):325–33

Procedural memory stimulation in Alzheimer's disease: impact of a training programme. Zanetti O, et al. **Acta Neurol Scand** 1997 Mar;95(3):152–7

Unexpected dental behavior in five Alzheimer patients. Differences between cognitive and functional capacity, graphic performance, and dental behavior. Nordenram G, et al. **Acta Odontol Scand** 1995 Dec;53(6):381–8

Social function after cervical hip fracture. A comparison of hook–pins and total hip replacement in 47 patients. Jónsson B, et al. **Acta Orthop Scand** 1996 Oct;67(5):431–4

Methodological challenges in measurements of functional ability in gerontological research. A review. Avlund K. **Aging (Milano)** 1997 Jun;9(3):164–74 (123 ref.)

Different kinds of services and informal support in the daily life activities in a community–based elderly population. Gosman–Hedström G, et al. **Aging (Milano)** 1995 Oct; 7(5):371–8

Formal education as an effect modifier of the relationship between Mini–Mental State Examination score and IADLs disability in the older population. Quesada JJ, et al. **Aging (Milano)** 1997 Jun;9(3):175–9

Difficulties in mobility among elderly people and their association with socioeconomic factors, dwelling environment and use of services. Sakari–Rantala R, et al. **Aging (Milano)** 1995 Dec;7(6):433–40 (58 ref.)

Self–help and life quality in persons with HIV disease. Grimes DE, et al. **AIDS Care** 1996 Dec;8(6):691–9

Relation of daily activity levels in patients with chronic heart failure to long–term prognosis. Walsh JT, et al. **Am J Cardiol** 1997 May 15;79(10):1364–9

Distribution and association of chronic disease and mobility difficulty across four body mass index categories of African–American women. Clark DO, et al. **Am J Epidemiol** 1997 May 15;145(10):865–75

Incidence of functional decline and improvement in a community–dwelling, very elderly population. Hébert R, et al. **Am J Epidemiol** 1997 May 15;145(10):935–44

Proxy reporting in five areas of functional status. Comparison with self–reports and observations of performance. Magaziner J, et al. **Am J Epidemiol** 1997 Sep 1; 146(5):418–28

Independence and adaptive behavior in adults with Williams syndrome. Davies M, et al. **Am J Med Genet** 1997 May 16;70(2):188–95

The impact of restraints on nursing home resident outcomes. Moseley CB. **Am J Med Qual** 1997 Summer;12(2):94–102

Behavioral capabilities and mortality risk in adults with and without Down syndrome. Strauss D, et al. **Am J Ment Retard** 1996 Nov;101(3):269–81

Influence of instrumental activities of daily living assessment method on judgments of independence. Brown C, et al. **Am J Occup Ther** 1996 Mar;50(3):202–6

A meta–analysis of the effectiveness of occupational therapy for older persons. Carlson M, et al. **Am J Occup Ther** 1996 Feb;50(2):89–98

Life domains and adaptive strategies of a group of low–income, well older adults. Clark F, et al. **Am J Occup Ther** 1996 Feb;50(2):99–108 (35 ref.)

Educational participation of children with spinal cord injury. Dudgeon BJ, et al. **Am J Occup Ther** 1997 Jul–Aug; 51(7):553–61

The sensory profile: the performance of a national sample of children without disabilities. Dunn W, et al. **Am J Occup Ther** 1997 Jan;51(1):25–34

Life–style performance: from profile to conceptual model. Fidler GS. **Am J Occup Ther** 1996 Feb;50(2):139–47

Effects of object characteristics on female grasp patterns. Fuller Y, et al. **Am J Occup Ther** 1997 Jul–Aug;51(7):481–7; discussion 489

A consecutive series of adults with brain injury treated with a washing and dressing retraining program. Giles GM, et al. **Am J Occup Ther** 1997 Apr;51(4):256–66

The assessment of motor and process skills applied cross–culturally to the Japanese. Goto S, et al. **Am J Occup Ther** 1996 Nov–Dec;50(10):798–806

Evaluation of daily living tasks: the home care advantage. Rogers JC, et al. **Am J Occup Ther** 1997 Jun;51(6):410–22

Equivalence reliability of the functional independence measure for children (WeeFIM) administration methods. Sperle PA, et al. **Am J Occup Ther** 1997 Jan;51(1):35–41

Delivering occupational therapy's fullest promise: clinical interpretation of "life domains and adaptive strategies of a group of low–income, well older adults". Wood W. **Am J Occup Ther** 1996 Feb;50(2):109–12

Physiotherapy and occupational therapy: a geriatric experience in the acute care hospital. Landi F, et al. **Am J Phys Med Rehabil** 1997 Jan–Feb;76(1):38–42

Direct assessment of functional status in older patients with schizophrenia. Klapow JC, et al. **Am J Psychiatry** 1997 Jul;154(7):1022–4

US trends in disability and institutionalization among older Blacks and Whites [see comments] Clark DO. **Am J Public Health** 1997 Mar;87(3):438–40. Comment in: Am J Public Health 1997 Mar;87(3):333–4.

Disability in activities of daily living: patterns of change and a hierarchy of disability. Dunlop DD, et al. **Am J Public Health** 1997 Mar;87(3):378–83

The health status of elderly persons in the last year of life: a comparison of deaths by suicide, injury, and natural causes. Grabbe L, et al. **Am J Public Health** 1997 Mar; 87(3):434–7

The disabilities of aging--looking to the physical environment [editorial; comment] Satariano WA. **Am J Public Health** 1997 Mar;87(3):331–2. Comment on: Am J Public Health 1997 Mar;87(3):384–92. Comment on: Am J Public Health 1997 Mar;87(3):393–7.

The great efficacy of personal and equipment assistance in reducing disability [see comments] Verbrugge LM, et al. **Am J Public Health** 1997 Mar;87(3):384–92. Comment in: Am J Public Health 1997 Mar;87(3):331–2.

The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Wolinsky FD, et al. **Am J Public Health** 1997 Mar;87(3):398–403

Measuring quality of life in different cultures: translation of the Functional Living Index for Cancer (FLIC) into Chinese and Malay in Singapore. Goh CR, et al. **Ann Acad Med Singapore** 1996 May;25(3):323–34

Rehabilitation challenges in craniospinal injury: two case reports. Nam AM, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):873–7 (19 ref.)

The effect of medical conditions on the functional limitations of Mexican–American elderly. Markides KS, et al. **Ann Epidemiol** 1996 Sep;6(5):386–91

Development of a functional scoring system for rheumatoid arthritis patients with cervical myelopathy. Casey AT, et al. **Ann Rheum Dis** 1996 Dec;55(12):901–6

Human behaviour, water usage and schistosomiasis transmission in a small settlement near Yola, Nigeria. Akogun OB, et al. **Ann Trop Med Parasitol** 1996 Jun; 90(3):303–11

Relationship between difficulty in performing daily activities and clinical measures of visual function in patients with retinitis pigmentosa. Szlyk JP, et al. **Arch Ophthalmol** 1997 Jan;115(1):53–9

Developmental skills of children with spastic diplegia: functional and qualitative changes after selective dorsal rhizotomy. Buckon CE, et al. **Arch Phys Med Rehabil** 1997 Sep;78(9):946–51

Prestroke physical function predicts stroke outcomes in the elderly. Colantonio A, et al. **Arch Phys Med Rehabil** 1996 Jun;77(6):562–6

Continuous–scale physical functional performance in healthy older adults: a validation study. Cress ME, et al. **Arch Phys Med Rehabil** 1996 Dec;77(12):1243–50

Male and female performance on the assessment of motor and process skills. Duran LJ, et al. **Arch Phys Med Rehabil** 1996 Oct;77(10):1019–24

Spinal cord injury rehabilitation. 3. Functional outcomes. Formal CS, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S59–64 (58 ref.)

Structure of a combination of Functional Independence Measure and Instrumental Activity Measure items in community–living persons: a study of individuals with cerebral palsy and spina bifida. Grimby G, et al. **Arch Phys Med Rehabil** 1996 Nov;77(11):1109–14

Functional outcomes attained by T9–12 paraplegic patients with the walkabout and the isocentric reciprocal gait orthoses. Harvey LA, et al. **Arch Phys Med Rehabil** 1997 Jul;78(7):706–11

The relationship of postural sway to sensorimotor function, functional performance, and disability in the elderly. Hughes MA, et al. **Arch Phys Med Rehabil** 1996 Jun; 77(6):567–72

The Arm Motor Ability Test: reliability, validity, and sensitivity to change of an instrument for assessing disabilities in activities of daily living. Kopp B, et al. **Arch Phys Med Rehabil** 1997 Jun;78(6):615–20

Predicting prosthetic rehabilitation outcome in lower limb amputee patients with the functional independence measure. Leung EC, et al. **Arch Phys Med Rehabil** 1996 Jun;77(6):605–8

Home alone: the role of cognition in return to independent living. MacNeill SE, et al. **Arch Phys Med Rehabil** 1997 Jul;78(7):755–8

Home use of a functional electrical stimulation system for standing and mobility in adolescents with spinal cord injury. Moynahan M, et al. **Arch Phys Med Rehabil** 1996 Oct;77(10):1005–13

Therapeutic footwear: enhanced function in people with diabetes and transmetatarsal amputation. Mueller MJ, et al. **Arch Phys Med Rehabil** 1997 Sep;78(9):952–6

The reliability of the functional independence measure: a quantitative review. Ottenbacher KJ, et al. **Arch Phys Med Rehabil** 1996 Dec;77(12):1226–32

Comprehensive assessment of activities of daily living in stroke. The Copenhagen Stroke Study. Pedersen PM, et al. **Arch Phys Med Rehabil** 1997 Feb;78(2):161–5

Reliability and validity of the FIM for persons aged 80 years and above from a multilevel continuing care retirement community. Pollak N, et al. **Arch Phys Med Rehabil** 1996 Oct;77(10):1056–61

Outcomes of enhanced physical and occupational therapy service in a nursing home setting. Przybylski BR, et al. **Arch Phys Med Rehabil** 1996 Jun;77(6):554–61

Early predictors of functional independence 2 years after spinal cord injury. Saboe LA, et al. **Arch Phys Med Rehabil** 1997 Jun;78(6):644–50

Impairment–specific dimensions within the Functional Independence Measure. Stineman MG, et al. **Arch Phys Med Rehabil** 1997 Jun;78(6):636–43

Discharge motor FIM–function related groups. Stineman MG, et al. **Arch Phys Med Rehabil** 1997 Sep;78(9):980–5

Measuring unilateral spatial neglect during stepping. Suzuki E, et al. **Arch Phys Med Rehabil** 1997 Feb;78(2):173–8

Predicting patient scores between the functional independence measure and the minimum data set: development and performance of a FIM–MDS "crosswalk". Williams BC, et al. **Arch Phys Med Rehabil** 1997 Jan; 78(1):48–54

Cerebral palsy and ageing. A personal account. Lo Surdo P. **Aust Fam Physician** 1997 Apr;26(4):404–7

Can occupational therapy intervention play a part in

maintaining independence and quality of life in older people? A randomised controlled trial. Liddle J, et al. **Aust N Z J Public Health** 1996 Dec;20(6):574–8

Primary obsessional slowness: long–term findings. Takeuchi T, et al. **Behav Res Ther** 1997 May;35(5):445–9

High dependency units: role and need [editorial] Bodenham AR, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):192–3 (8 ref.)

The outcome of ankylosing spondylitis: a study of 100 patients. Gran JT, et al. **Br J Rheumatol** 1997 Jul; 36(7):766–71

The relationship of neuropsychological status and productive outcomes following traumatic brain injury. Girard D, et al. **Brain Inj** 1996 Sep;10(9):663–76

Predicting functional independence from neuropsychological tests following traumatic brain injury [see comments] Smith–Knapp K, et al. **Brain Inj** 1996 Sep;10(9):651–61. Comment in: Brain Inj 1996 sep;10(9):627–30.

Barriers and facilitators to seniors' independence. Perceptions of seniors, caregivers, and health care providers. Brown JB, et al. **Can Fam Physician** 1997 Mar;43:469–75

Asthma and limitation of activities in Fort Saskatchewan, Alberta [see comments] Hessel PA, et al. **Can J Public Health** 1996 Nov–Dec;87(6):397–400. Comment in: Can J Public Health 1997 Mar–Apr;88(2):138–40.

Impact of cerebral visual impairment on the everyday life of cerebral palsied children. Schenk–Rootlieb AJ, et al. **Child Care Health Dev** 1993 Nov–Dec;19(6):411–23

Effect of radiofrequency catheter ablation on health–related quality of life and activities of daily living in patients with recurrent arrhythmias [see comments] Bubien RS, et al. **Circulation** 1996 Oct 1;94(7):1585–91. Comment in: Circulation 1996 Oct 1;94(7):1491–3.

Exercise to improve physiologic and functional performance in old age. Chandler JM, et al. **Clin Geriatr Med** 1996 Nov; 12(4):761–84 (62 ref.)

Visual deficits and mobility. Evaluation and management. Maino JH. **Clin Geriatr Med** 1996 Nov;12(4):803–23 (50 ref.)

Autogenous iliac crest bone graft. Complications and functional assessment. Goulet JA, et al. **Clin Orthop** 1997 Jun;(339):76–81

The scalability of the Rivermead Motor Assessment in nonacute stroke patients. Adams SA, et al. **Clin Rehabil** 1997 Feb;11(1):52–9

Comparison of postal version of the Frenchay Activities Index with interviewer–administered version for use in people with stroke. Carter J, et al. **Clin Rehabil** 1997 May; 11(2):131–8

Daily functioning of the lower extremity amputee: an overview of the literature. Pernot HF, et al. **Clin Rehabil** 1997 May;11(2):93–106 (71 ref.)

Are there gender differences in functional outcome after stroke? Wyller TB, et al. **Clin Rehabil** 1997 May;11(2):171–9

Subjective well–being one year after stroke. Wyller TB, et al. **Clin Rehabil** 1997 May;11(2):139–45

Sumatriptan and lost productivity time: a time series analysis of diary data. Miller DW, et al. **Clin Ther** 1996 Nov–Dec; 18(6):1263–75

Oral impacts affecting daily performance in a low dental disease Thai population. Adulyanon S, et al. **Community Dent Oral Epidemiol** 1996 Dec;24(6):385–9

Rural–urban differences in psychiatric status and functioning among clients with severe mental illness. Dottl SL, et al. **Community Ment Health J** 1997 Aug;33(4):311–21

Self–efficacy and consumer satisfaction with housing. Seilheimer TA, et al. **Community Ment Health J** 1996 Dec; 32(6):549–59

Survival and functional outcome of children following severe traumatic brain injury [editorial; comment] Matthews DJ. **Crit Care Med** 1997 Aug;25(8):1272. Comment on: Crit Care Med 1997 Aug;25(8):1396–401.

Survival and functional outcome of children requiring endotracheal intubation during therapy for severe traumatic brain injury [see comments] Thakker JC, et al. **Crit Care Med** 1997 Aug;25(8):1396–401. Comment in: Crit Care Med 1997 Aug;25(8):1272.

They are improved, but are they better? [editorial] Brown K. **Dev Med Child Neurol** 1997 Apr;39(4):213

Disability and cognitive impairment in the elderly. Barberger–Gateau P, et al. **Disabil Rehabil** 1997 May; 19(5):175–93 (173 ref.)

Do it yourself: home–made aids for disabled elderly people. Brown AR, et al. **Disabil Rehabil** 1997 Jan;19(1):35–7

Determinants of handicap 1 and 3 years after a stroke. Harwood RH, et al. **Disabil Rehabil** 1997 May;19(5):205–11

Planning a health education programme for the elderly visually impaired person––a focus group study. Ivanoff SD, et al. **Disabil Rehabil** 1996 Oct;18(10):515–22

Does family support buffer the impact of specific chronic diseases on mobility in community–dwelling elderly? Kriegsman DM, et al. **Disabil Rehabil** 1997 Feb;19(2):71–83

Relationship between occupation and life satisfaction in people with multiple sclerosis. Lundmark P, et al. **Disabil Rehabil** 1996 Sep;18(9):449–53

What happens to patients awaiting arthritis surgery? Roy CW, et al. **Disabil Rehabil** 1996 Feb;18(2):101–5

Activities of daily living studied longitudinally between 70 and 76 years of age. Sonn U, et al. **Disabil Rehabil** 1996 Feb;18(2):91–100

The influence of age on length of stay, functional independence and discharge destination of rehabilitation inpatients in Italy. Tesio L, et al. **Disabil Rehabil** 1996 Oct; 18(10):502–8

An estimation of the functional disability burden in elderly Chinese age 70 years and over. Woo J, et al. **Disabil Rehabil** 1996 Dec;18(12):609–12

The Frenchay Activities Index in stroke patients: agreement between scores by patients and by relatives [see comments] Wyller TB, et al. **Disabil Rehabil** 1996 Sep;18(9):454–9. Comment in: Disabil Rehabil 1997 Mar;19(3):120–2.

Factors associated with work outcome after anterior temporal lobectomy for intractable epilepsy. Reeves AL, et al. **Epilepsia** 1997 Jun;38(6):689–95

Measuring functional status of chronic coronary patients. Reliability, validity and responsiveness to clinical change of the reduced version of the Duke Activity Status Index (DASI). Alonso J, et al. **Eur Heart J** 1997 Mar;18(3):414–9

Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study [see comments] Elliott PM, et al. **Eur Heart J** 1996 Jul; 17(7):1056–64. Comment in: Eur Heart J 1996 Jul;17(7):982–4.

Validation of a physical activity questionnaire in the elderly. Bonnefoy M, et al. **Eur J Appl Physiol** 1996;74(6):528–33

Health and physical performance of elderly Europeans. SENECA Investigators. Schroll M, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S105–11

Predicting stroke inpatient rehabilitation outcome: the prominent role of neuropsychological disorders. Paolucci S, et al. **Eur Neurol** 1996;36(6):385–90

Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on long–term oxygen therapy. Okubadejo AA, et al. **Eur Respir J** 1997 Jul;10(7):1572–5

Oxygen saturation during daily activities in chronic obstructive pulmonary disease. Soguel Schenkel N, et al. **Eur Respir J** 1996 Dec;9(12):2584–9

Social and psychological resources in the oldest old. Martin P, et al. **Exp Aging Res** 1996 Apr–Jun;22(2):121–39

In–shoe plantar pressures during activities of daily living: implications for therapeutic footwear design. Rozema A, et al. **Foot Ankle Int** 1996 Jun;17(6):352–9

The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease [see comments] Walker EA, et al. **Gen Hosp Psychiatry** 1996 Jul;18(4):220–9. Comment in: Gen Hosp Psychiatry 1996 Jul;18(4):215–9.

Everyday problem solving in elderly women: contributions of residence, perceived control, and age. Collins K, et al. **Gerontologist** 1997 Jun;37(3):293–302

The use of technical aids by elderly persons in The Netherlands: an application of the Andersen and Newman model. de Klerk MM, et al. **Gerontologist** 1997 Jun; 37(3):365–73

Comparison of health and functional ability between noninstitutionalized and least dependent institutionalized elderly in Finland. Noro A, et al. **Gerontologist** 1997 Jun; 37(3):374–83

Risk of institutionalization among community long–term care clients with dementia. Scott WK, et al. **Gerontologist** 1997 Feb;37(1):46–51

Awareness of deficit in Alzheimer's disease: relation to caregiver burden. Seltzer B, et al. **Gerontologist** 1997 Feb; 37(1):20–4

Everyday cognitive competence in elderly persons: conceptual issues and empirical findings. Willis SL. **Gerontologist** 1996 Oct;36(5):595–601

Impact of sumatriptan on workplace productivity, nonwork activities, and health–related quality of life among hospital employees with migraine. Mushet GR, et al. **Headache** 1996 Mar;36(3):137–43

Chronic conditions, physical limitations and dependency among seniors living in the community. Wilkins K, et al. **Health Rep** 1996 Winter;8(3):7–15(Eng); 7–15(Fre) **(Eng, Fre)**

Population–based, genetically informative sample for studies of physical frailty and aging: black elderly twin study. Miles TP. **Hum Biol** 1997 Feb;69(1):107–20

Input–output nonlinearities and time delays increase tracking errors in hand grasp neuroprostheses. Adamczyk MM, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):271–9 (18 ref.)

Enhanced rehabilitation of gait after stroke: a case report of a therapeutic approach using multichannel functional electrical stimulation. Bogataj U, et al. **IEEE Trans Rehabil Eng** 1997 Jun;5(2):221–32

Development of an upper extremity FES system for individuals with C4 tetraplegia. Smith BT, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):264–70 (26 ref.)

Detection of static and dynamic activities using uniaxial accelerometers. Veltink PH, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):375–85 (17 ref.)

Worry among Canadian seniors. Skarborn M, et al. **Int J Aging Hum Dev** 1996;43(2):169–78

Nursing diagnoses and construct validity of pain, self–care deficit and impaired mobility. Chang BL. **Int J Nurs Stud** 1995 Dec;32(6):556–67

Physical performance measures for the elderly rehabilitated at home. Bohannon RW. **Int J Rehabil Res** 1997 Mar; 20(1):107–9

Levels of engagement in hospital and community–based homes for people with learning disabilities: can individual characteristics account for differences? Dagnan D. **Int J Rehabil Res** 1996 Dec;19(4):313–9

Measuring functional competence in older persons with Alzheimer's disease. Doble SE, et al. **Int Psychogeriatr** 1997 Mar;9(1):25–38

Dysautonomy in daily activities impair the prognosis of acutely ill adults admitted to hospital [letter] Bensousan TA, et al. **Intensive Care Med** 1997 May;23(5):593

Function and visual impairment in a population–based study of older adults. The SEE project. Salisbury Eye Evaluation. West SK, et al. **Invest Ophthalmol Vis Sci** 1997 Jan;38(1):72–82

Promoting autonomy and independence for older people within nursing practice: a literature review. Davies S, et al. **J Adv Nurs** 1997 Aug;26(2):408–17 (89 ref.)

Patterns of recovery among Norwegian heart surgery patients. Kirkevold M, et al. **J Adv Nurs** 1996 Nov; 24(5):943–51

Functional status of the oldest–old in a home setting. Krach P, et al. **J Adv Nurs** 1996 Sep;24(3):456–64

Body mass index and physical function in obese older women [letter] Apovian CM, et al. **J Am Geriatr Soc** 1996 Dec; 44(12):1487–8

Test–retest reliability of self–reported disability measures in older adults. Crawford SL, et al. **J Am Geriatr Soc** 1997 Mar;45(3):338–41

Postural balance and self–reported functional ability in 75–year–old men and women: a cross–national comparative study. Era P, et al. **J Am Geriatr Soc** 1997 Jan;45(1):21–9

Short–term functional outcomes of long–term care residents with pneumonia treated with and without hospital transfer [see comments] Fried TR, et al. **J Am Geriatr Soc** 1997 Mar;45(3):302–6. Comment in: J Am Geriatr Soc 1997 Mar;45(3):380–1.

Depression without sadness: functional outcomes of nondysphoric depression in later life. Gallo JJ, et al. **J Am Geriatr Soc** 1997 May;45(5):570–8

A predictive model for ADL dependence in community–living older adults based on a reduced set of cognitive status items. Gill TM, et al. **J Am Geriatr Soc** 1997 Apr;45(4):441–5

The relationship between alcohol consumption, cognitive performance, and daily functioning in an urban sample of older black Americans. Hendrie HC, et al. **J Am Geriatr Soc** 1996 Oct;44(10):1158–65

The relationship between physical performance measures and independence in instrumental activities of daily living. The FICSIT Group. Frailty and Injury: Cooperative Studies of Intervention Trials. Judge JO, et al. **J Am Geriatr Soc** 1996 Nov;44(11):1332–41

Everyday matters in the lives of nursing home residents: wish for and perception of choice and control. Kane RA, et al. **J Am Geriatr Soc** 1997 Sep;45(9):1086–93

Is managed care good or bad for geriatric medicine? Lachs MS, et al. **J Am Geriatr Soc** 1997 Sep;45(9):1123–7

Self–report of difficulty in performing functional activities identifies a broad range of disability in old age. Langlois JA, et al. **J Am Geriatr Soc** 1996 Dec;44(12):1421–8

Cognitive and functional status of the Japanese oldest old [letter; comment] Matsubayashi K, et al. **J Am Geriatr Soc** 1997 Mar;45(3):385–6. Comment on: J Am Geriatr Soc 1996 Jun;44(6):671–4.

Inner–city older blacks have high levels of functional disability. Miller DK, et al. **J Am Geriatr Soc** 1996 Oct; 44(10):1166–73

Association of the Resident Assessment Instrument (RAI) with changes in function, cognition, and psychosocial status [see comments] Phillips CD, et al. **J Am Geriatr Soc** 1997 Aug;45(8):986–93. Comment in: J Am Geriatr Soc 1997 Aug;45(8):975–6. Comment in: J Am Geriatr Soc 1997 Aug;45(8):1025–6. Comment in: J Am Geriatr Soc 1997 Aug;45(8):1027–8.

Ethnogeriatrics and functional status [letter; comment] Reyes–Ortiz CA. **J Am Geriatr Soc** 1996 Oct;44(10):1277 . Comment on: J Am Geriatr Soc 1996 Mar;44(3):279–84.

The Barthel activities of daily living index: self–reporting versus actual performance in the old–old (> or = 75 years). Sinoff G, et al. **J Am Geriatr Soc** 1997 Jul; 45(7):832–6

Coronary disease severity and functional impairment: how strong is the relation? Sullivan M, et al. **J Am Geriatr Soc** 1996 Dec;44(12):1461–5

Assessment of mobility and ADL dependence following hip fracture surgery [letter] van Breukelen AM, et al. **J Am Geriatr Soc** 1997 Jan;45(1):119–20

Characterization of older adults who attribute functional decrements to "old age". Williamson JD, et al. **J Am Geriatr Soc** 1996 Dec;44(12):1429–34

A longitudinal examination of functional recovery among older people with subcapital hip fractures. Young Y, et al. **J Am Geriatr Soc** 1997 Mar;45(3):288–94

Task analysis training of case managers to assist seriously mentally ill patients find roommates and housing. Long SL, et al. **J Behav Ther Exp Psychiatry** 1996 Sep; 27(3):269–80

Degree of burn, location of burn, and length of hospital stay as predictors of psychosocial status and physical functioning. Baker RA, et al. **J Burn Care Rehabil** 1996 Jul–Aug;17(4):327–33

Competence and physical impairment of pediatric survivors of burns of more than 80% total body surface area. Moore P, et al. **J Burn Care Rehabil** 1996 Nov–Dec;17(6 Pt 1):547–51

Functional outcomes for the patient with burn injuries. Staley M, et al. **J Burn Care Rehabil** 1996 Jul-Aug;17(4):362-8 (38 ref.)

Procedural burn pain intensity under conditions of varying physical control by the patient. Sutherland S. **J Burn Care Rehabil** 1996 Sep-Oct;17(5):457-63

Physical activity monitoring in patients with peripheral arterial occlusive disease. Sieminski DJ, et al. **J Cardiopulm Rehabil** 1997 Jan-Feb;17(1):43-7

The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an Italian study on healthy free-living over-ninety-year-olds. Ravaglia G, et al. **J Clin Endocrinol Metab** 1996 Mar; 81(3):1173-8

Assessing the responsiveness of a functional status measure: the Sickness Impact Profile versus the SIP68. de Bruin AF, et al. **J Clin Epidemiol** 1997 May;50(5):529-40 (38 ref.)

Status versus ability in function [letter; comment] Fawcett J, et al. **J Clin Epidemiol** 1997 Apr;50(4):499. Comment on: J Clin Epidemiol 1996 Feb;49(2):193-201.

The role of change in physical performance in determining risk for dependence in activities of daily living among nondisabled community-living elderly persons. Gill TM, et al. **J Clin Epidemiol** 1997 Jul;50(7):765-72

Measuring functional status: cross-sectional and longitudinal associations between performance and self-report (Zutphen Elderly Study 1990-1993). Hoeymans N, et al. **J Clin Epidemiol** 1996 Oct;49(10):1103-10

Functional health status as a predictor of mortality in men and women over 65. Scott WK, et al. **J Clin Epidemiol** 1997 Mar;50(3):291-6

Time-activity-patterns of some selected small groups as a basis for exposure estimation: a methodological study. Dörre WH. **J Expo Anal Environ Epidemiol** 1997 Oct-Dec; 7(4):471-91

Quantifying videotaped activity patterns: video translation software and training methodologies. Zartarian VG, et al. **J Expo Anal Environ Epidemiol** 1997 Oct-Dec;7(4):535-42

Measuring prognosis and case mix in hospitalized elders. The importance of functional status [see comments] Covinsky KE, et al. **J Gen Intern Med** 1997 Apr;12(4):203-8. Comment in: J Gen Intern Med 1997 Apr;12(4):254-5.

Health status assessment. Completing the clinical database [editorial; comment] Wu AW, et al. **J Gen Intern Med** 1997 Apr;12(4):254-5. Comment on: J Gen Intern Med 1997 Apr;12(4):203-8.

Impairments in physical performance and cognitive status as predisposing factors for functional dependence among nondisabled older persons. Gill TM, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov;51(6):M283-8

Gender differences in the comparison of self-reported disability and performance measures. Merrill SS, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):M19-26

Leg extension power and walking speed in very old people living independently. Rantanen T, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):M225-31

Predicting mortality from community surveys of older adults: the importance of self-rated functional ability. Bernard SL, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May; 52(3):S155-63

The politics of dependency estimates: Social Security Board statistics, 1935-1939. Gratton B. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52(3):S117-24

Social support, depression, and activities of daily living in older heart surgery patients. Oxman TE, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Jan;52(1):P1-14

A comparative analysis of ADL questions in surveys of older people. Rodgers W, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52 Spec No:21-36

The structure of health status among Hispanic, African American, and white older adults. Stump TE, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52 Spec No:49-60

A dynamic model for explaining changes in use of IADL/ADL care in the community. Morris SA, et al. **J Health Soc Behav** 1996 Mar;37(1):91-103

Status of lung transplant recipients surviving beyond five years. Chaparro C, et al. **J Heart Lung Transplant** 1997 May;16(5):511-6

Work and nonvocational domains of functioning in persons with severe mental illness: a longitudinal analysis. Mueser KT, et al. **J Nerv Ment Dis** 1997 Jul;185(7):419-26

Verbally administered Barthel Index as functional assessment in brain tumour patients. Brazil L, et al. **J Neurooncol** 1997 Sep;34(2):187-92

Subcortical hyperintensities on MRI and activities of daily living in geriatric depression. Cahn DA, et al. **J Neuropsychiatry Clin Neurosci** 1996 Fall;8(4):404-11

Learned helplessness in the multiple sclerosis population. McGuinness S. **J Neurosci Nurs** 1996 Jun;28(3):163-70

Nutritional status of centenarians assessed by activity and anthropometric, hematological and biochemical characteristics. Chan YC, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Feb;43(1):73-81

Chewing activity and activities of daily living in the elderly. Miura H, et al. **J Oral Rehabil** 1997 Jun;24(6):457-60

Dependency after hip fracture in geriatric patients: a study of predictive factors. Koval KJ, et al. **J Orthop Trauma** 1996;10(8):531-5

Pubic rami fracture: a benign pelvic injury? Koval KJ, et al. **J Orthop Trauma** 1997 Jan;11(1):7-9

Mobility in older patients with hip fractures: examining prefracture status, complications, and outcomes at discharge from the acute-care hospital. Myers AH, et al. **J Orthop Trauma** 1996;10(2):99-107

Prevalence of maternal depression and its relationship to ADL skills in children with developmental delay. Harvey JM, et al. **J Paediatr Child Health** 1997 Feb;33(1):42-6

Moderating effects of family structure on the relationship between physical and mental health in urban children with chronic illness. Silver EJ, et al. **J Pediatr Psychol** 1996 Feb;21(1):43-56

Combined therapies in OCD. Spencer VE. **J Psychosoc Nurs Ment Health Serv** 1996 Jul;34(7):37-40

A comparison of measures of disability and health status in people with physical disabilities undergoing vocational rehabilitation. Kelly S, et al. **J Public Health Med** 1996 Jun;18(2):169-74

An evolution of exercise physiology: effects of exercise on functional independence with aging and physical disabilities [editorial] Glaser RM. **J Rehabil Res Dev** 1997 Jul; 34(3):vi-viii

Factors associated with life satisfaction among a sample of persons with neurotrauma. Warren L, et al. **J Rehabil Res Dev** 1996 Oct;33(4):404-8

Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. Gladman D, et al. **J Rheumatol** 1996 Nov;23(11):1953-5 (14 ref.)

Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. Husted J, et al. **J Rheumatol** 1996 Nov;23(11):1932-7

Continuous automated telecare assessment of the elderly. Doughty K, et al. **J Telemed Telecare** 1997;3 Suppl 1:23-5

Long-term prevalence of impairments and disabilities after multiple trauma. Anke AG, et al. **J Trauma** 1997 Jan; 42(1):54-61

Effect of body mass index on activity limitation and mortality among older women: the National Health Interview Survey, 1986-1990. Brill PA, et al. **J Womens Health** 1997 Aug;6(4):435-40

Frequency, significance, and mechanism of myocardial ischemia during daily activities detected by Holter dynamic electrocardiogram. Nishioka N, et al. **Jpn Circ J** 1996 Oct; 60(10):719-30

Facility and area variation affecting the use of physical restraints in nursing homes. Phillips CD, et al. **Med Care** 1996 Nov;34(11):1149-62

Physical and cognitive functioning among chronically ill African-American and white elderly in home care following hospital discharge. Proctor EK, et al. **Med Care** 1997 Aug;35(8):782-91

Classifying rehabilitation inpatients by expected functional gain. Stineman MG, et al. **Med Care** 1997 Sep;35(9):963-73

Measuring casemix, severity, and complexity in geriatric patients undergoing rehabilitation. Stineman MG. **Med Care** 1997 Jun;35(6 Suppl):JS90-105; discussion JS106-12 (39 ref.)

The epidemiology of physical activity and physical function in older people. DiPietro L. **Med Sci Sports Exerc** 1996 May;28(5):596-600

Determinants of physical activity in obese children assessed by accelerometer and self-report. Epstein LH, et al. **Med Sci Sports Exerc** 1996 Sep;28(9):1157-64

Physical and sedentary activity in school children grades 5-8: the Bogalusa Heart Study. Myers L, et al. **Med Sci Sports Exerc** 1996 Jul;28(7):852-9

Limb girdle muscular dystrophy: a prospective follow-up study of functional impairment. Stübgen JP, et al. **Muscle Nerve** 1997 Apr;20(4):453-60

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study [see comments] Sano M, et al. **N Engl J Med** 1997 Apr 24;336(17):1216-22. Comment in: N Engl J Med 1997 Apr 24;336(17):1245-7. Comment in: N Engl J Med 1997 Aug 21;337(8):572; discussion 573. Comment in: N Engl J Med 1997 Aug 21;337(8):572-3.

'Oops!': performance correlates of everyday attentional failures in traumatic brain injured and normal subjects. Robertson IH, et al. **Neuropsychologia** 1997 Jun; 35(6):747-58

Implementing supported housing: current trends and future directions. Carling PJ, et al. **New Dir Ment Health Serv** 1997 Summer;(74):79-94

Ethical issues relative to autonomy and personal control in independent and cognitively impaired elders. Rice VH, et al. **Nurs Outlook** 1997 Jan-Feb;45(1):27-34 (34 ref.)

Improving dressing behavior in cognitively impaired nursing home residents. Beck C, et al. **Nurs Res** 1997 May-Jun; 46(3):126-32

Exercise for recent heart disease/surgery [letter] Adams JL, et al. **Nurse Pract** 1997 Mar;22(3):15, 232, 235 passim

6-year impact of hearing impairment on psychosocial and physiologic functioning [letter] Wallhagen MI, et al. **Nurse Pract** 1996 Sep;21(9):11-4

Quality of life after radiation therapy for base of tongue cancer. Moore GJ. **Oncology (Huntingt)** 1996 Nov; 10(11):1643-8; discussion 1649-50, 1655 (20 ref.)

Activity relationships of total hip arthroplasty in patients with osteonecrosis and osteoarthritis. Letson GD, et al. **Orthopedics** 1996 Aug;19(8):665-8

Carpectomy and fusion in adult-acquired hand spasticity. Pinzur MS. **Orthopedics** 1996 Aug;19(8):675-7

Vibration, acceleration, gravitation, and movement: activity controlled rate adaptive pacing during treadmill exercise testing and daily life activities. Candinas R, et al. **Pacing Clin Electrophysiol** 1997 Jul;20(7):1777-86

Comparison of continuously recorded sensor and sinus rates during daily life activities and standardized exercise testing: efficacy of automatically optimized rate adaptive dual sensor pacing to simulate sinus rhythm. Lau CP, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1672-7

New integrated sensor pacemaker: comparison of rate responses between an integrated minute ventilation and activity sensor and single sensor modes during exercise and daily activities and nonphysiological interference. Leung SK, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1664-71

Pain and activity disturbance after paediatric day case adenoidectomy. Kokki H, et al. **Paediatr Anaesth** 1997; 7(3):227-31

Self-sufficiency at ages 27 to 33 years: factors present between birth and 18 years that predict educational attainment among children born to inner-city families. Hardy JB, et al. **Pediatrics** 1997 Jan;99(1):80-7

The Patient-Specific Functional Scale: measurement properties in patients with knee dysfunction. Chatman AB, et al. **Phys Ther** 1997 Aug;77(8):820-9

Functional limitations in patients with diabetes and transmetatarsal amputations. Mueller MJ, et al. **Phys Ther** 1997 Sep;77(9):937-43

The sensitivity and specificity of pain response to activity and position in categorizing patients with low back pain. Roach KE, et al. **Phys Ther** 1997 Jul;77(7):730-8

Reliability of impairment and physical performance measures for persons with Parkinson's disease. Schenkman M, et al. **Phys Ther** 1997 Jan;77(1):19-27

Health status measures: strategies and analytic methods for assessing change scores. Stratford PW, et al. **Phys Ther** 1996 Oct;76(10):1109-23 (33 ref.)

A little bit of toxin does you good? [clinical conference] Scrutton J, et al. **Physiother Res Int** 1996;1(3):141-7

Dynamics of the upper limb during performance of the tasks of everyday living--a review of the current knowledge base. Buckley MA, et al. **Proc Inst Mech Eng [H]** 1996; 210(4):241-7 (44 ref.)

Functional outcome of lower-limb amputees: a prospective descriptive study in a general hospital. Greive AC, et al. **Prosthet Orthot Int** 1996 Aug;20(2):79-87

Depression among aging persons with schizophrenia who live in the community. Cohen CI, et al. **Psychiatr Serv** 1996 Jun;47(6):601-7

Use of mental health services by formerly homeless adults residing in group and independent housing. Dickey B, et al. **Psychiatr Serv** 1996 Feb;47(2):152-8

Early-onset substance abuse and community violence by outpatients with chronic mental illness. Fulwiler C, et al. **Psychiatr Serv** 1997 Sep;48(9):1181-5

Effects of familiarity of task and choice on the functional performance of younger and older adults. Dickerson AE, et al. **Psychol Aging** 1997 Jun;12(2):247-54

Development of a measure of physical function for patients with bone and soft tissue sarcoma. Davis AM, et al. **Qual Life Res** 1996 Oct;5(5):508-16

Physical activity and functional independence in aging. Fiatarone MA. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S70

Life after cardiac arrest; a retrospective study. Sunnerhagen KS, et al. **Resuscitation** 1996 Apr;31(2):135-40

Self-rating Barthel index compatible with the original Barthel index and the Functional Independence Measure motor score. Hachisuka K, et al. **Sangyo Ika Daigaku Zasshi** 1997 Jun 1;19(2):107-21

Functional ability of elderly persons with diabetes or impaired glucose tolerance. Hiltunen L, et al. **Scand J Prim Health Care** 1996 Dec;14(4):229-37

Disability and quality of life in individuals with muscular dystrophy. Ahlström G, et al. **Scand J Rehabil Med** 1996 Sep;28(3):147-57

Maximal isometric knee extension strength and stair-mounting ability in 75- and 80-year-old men and women. Rantanen T, et al. **Scand J Rehabil Med** 1996 May; 28(2):89-93

Item bias in self-reported functional ability among 75-year-old men and women in three Nordic localities. Avlund K, et al. **Scand J Soc Med** 1996 Sep;24(3):206-17

Functional capacity and health of elderly people--the Evergreen project. Background, design and methods of the project. Heikkinen E. **Scand J Soc Med Suppl** 1997;53:1-18

Morbidity and disability in 75- and 80-year-old men and women. A five-year follow-up. Laukkanen P, et al. **Scand J Soc Med Suppl** 1997;53:79-106

The assessment of disability with the Groningen Activity Restriction Scale. Conceptual framework and psychometric properties. Kempen GI, et al. **Soc Sci Med** 1996 Dec;43(11):1601-10

Gender differences in correlates of disablement among the elderly in Egypt. Lamb VL. **Soc Sci Med** 1997 Jul; 45(1):127-36

Negotiating spaces in home environments: older women living with arthritis. Moss P. **Soc Sci Med** 1997 Jul; 45(1):23-33

Gender differences in medical treatment: the case of physician-prescribed activity restrictions. Safran DG, et al. **Soc Sci Med** 1997 Sep;45(5):711-22

Assisted reach and transfers in individuals with tetraplegia: towards a solution. Allison GT, et al. **Spinal Cord** 1997 Apr;35(4):217-22

A rational approach to long-term care: comparing the independent living model with agency-based care for persons with high spinal cord injuries. Mattson-Prince J. **Spinal Cord** 1997 May;35(5):326-31

Objectification of functional improvement after nonoperative care. Flores L, et al. **Spine** 1997 Jul 15;22(14):1622-33 (128 ref.)

Comparison of stroke features and disability in daily life in patients with ischemic stroke aged 55 to 70 and 71 to 85 years. Pohjasvaara T, et al. **Stroke** 1997 Apr;28(4):729-35

Effect of CPAP therapy on daytime function in patients with mild sleep apnoea/hypopnoea syndrome. Engleman HM, et al. **Thorax** 1997 Feb;52(2):114-9

Effectiveness of daily living abilities (DLA) as a tool for evaluating vocational competencies: study of non-disabled workers aged 45 and over. Kikuchi E, et al. **Tokai J Exp Clin Med** 1995 May;20(1):17-29

A study of nurses' perceptions of client mobility. Ouellet LL, et al. **West J Nurs Res** 1996 Oct;18(5):565-79

The social production of housework disability. McDonough PA. **Women Health** 1996;24(4):1-25

Women and injuries--factors influencing recovery. Ponzer S, et al. **Women Health** 1997;25(3):47-62

[Centenarians in the county of Funen. Morbidity and functional capacity] Olsen H, et al. **Ugeskr Laeger** 1996 Dec 16;158(51):7397-401 (Eng. Abstr.) **(Dan)**

[It's never too late. Possibilities for improvement of functional abilities in the elderly (editorial)] Schroll M. **Ugeskr Laeger** 1996 Dec 16;158(51):7371 **(Dan)**

[The relative importance of independent living for the social functioning of the elderly] Broese van Groenou M, et al. **Tijdschr Gerontol Geriatr** 1996 Aug;27(4):150-8 (Eng. Abstr.) **(Dut)**

[Aids in general daily activities can hardly replace professional home care. Results of a study among single 75-year-olds or older] de Klerk MM, et al. **Tijdschr Gerontol Geriatr** 1997 Feb;28(1):27-33 (Eng. Abstr.) **(Dut)**

[Information on the disabled and dependent people in France] Mormiche P. **Cah Sociol Demogr Med** 1996 Oct-Dec; 36(4):317-55 (Eng. Abstr.) **(Fre)**

[Health in the third age. Preventing handicaps related to aging] Svanborg A, et al. **J Med Liban** 1995;43(2):102-6 (13 ref.) **(Fre)**

[Measuring the burden for carers of dependent elderly with the Zarit inventory] Bocquet H, et al. **Rev Epidemiol Sante Publique** 1996 Jan;44(1):57-65 (Eng. Abstr.) **(Fre)**

[Interrater reliability of instruments for the evaluation of needs of bedridden persons: a review of the international literature] Kliebsch U, et al. **Soz Praventivmed** 1996; 41(5):303-14 (32 ref.) (Eng. Abstr.) **(Ger)**

[Prescription for aids and using aids after geriatric rehabilitation--do we prescribe the proper aids? (published erratum appears in Z Gerontol Geriatr 1996 Sep-Oct;29(5):382)] Krause D, et al. **Z Gerontol Geriatr** 1996 Jul-Aug;29(4):267-72 (Eng. Abstr.) **(Ger)**

[Risk for falls in the elderly. Role of activities of daily living and of the subjective assessment of health status. A case-control study] Gialloreti LE, et al. **Recenti Prog Med** 1996 Sep;87(9):405-11 (Eng. Abstr.) **(Ita)**

[Evaluation of environmental stimulation and its relation to physical deterioration in the elderly after 3 years--a health-social longitudinal study] Anme T. **Nippon Koshu Eisei Zasshi** 1997 Mar;44(3):159-66 (Eng. Abstr.) **(Jpn)**

[Factors affecting ADL improvement and QOL in stroke patients a community-based study] Yamashita K, et al. **Nippon Koshu Eisei Zasshi** 1996 Jun;43(6):427-33 (Eng. Abstr.) **(Jpn)**

[Evaluation of central paralysis] Imamura Y, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:322-6 (11 ref.) **(Jpn)**

[Relation of asymptomatic myocardial ischemia to impaired communication, cerebrovascular disease, and lack of ability to perform activities of daily living in elderly patients] Nakahara K, et al. **Nippon Ronen Igakkai Zasshi** 1997 Apr; 34(4):285-91 (Eng. Abstr.) **(Jpn)**

[Relationships between heart rate variabilities and psychosomatic activities of centenarians in Tokyo] Shimizu K, et al. **Nippon Ronen Igakkai Zasshi** 1996 Aug; 33(8):613-5 **(Jpn)**

[The relationship between daily activity rhythms and depression in college freshman] Yajima H. **Shinrigaku Kenkyu** 1996 Dec;67(5):403-9 (Eng. Abstr.) **(Jpn)**

[Assessment of one's own functional status. COOP-WONCA questionnaire charts in clinical practice and research] Bentsen BG, et al. **Tidsskr Nor Laegeforen** 1997 May 10; 117(12):1790-3 (Eng. Abstr.) **(Nor)**

[Instrument to measure quality of life based on daily performance in pediatric patients with leukemia] Arias-Gómez J, et al. **Gac Med Mex** 1996 Jan-Feb; 132(1):19-28 (Eng. Abstr.) **(Spa)**

[The prevalence of and factors associated with falls in older persons living in the community] Méndez Rubio JI, et al. **Med Clin (Barc)** 1997 Feb 1;108(4):128-32 (Eng. Abstr.) **(Spa)**

[Interaction between neuropsychological deficit in execution/ performance and ability to carry out daily activities in Alzheimer type dementia] Perea MV, et al. **Rev Neurol** 1997 Apr;25(140):513-8 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Unilateral pallidotomy for Parkinson's disease promptly improves a wide range of voluntary activities--especially gait and trunk movements. Meyer CH. **Acta Neurochir Suppl (Wien)** 1997;68:37-41

Activities of daily living: changes in functional ability in three samples of elderly and very elderly people. Bowling A, et al. **Age Ageing** 1997 Mar;26(2):107-14

Changes over time in the ADL status of elderly US veterans. Hisnanick JJ. **Age Ageing** 1994 Nov;23(6):505-11

Evaluation of a clinical score for prognostic stratification of elderly stroke patients. Kalra L, et al. **Age Ageing** 1994 Nov;23(6):492-8

Factors affecting contrasting results between self-reported and performance-based levels of physical limitation. Kempen GI, et al. **Age Ageing** 1996 Nov;25(6):458-64

Predicting disability in stroke--a critical review of the literature. Kwakkel G, et al. **Age Ageing** 1996 Nov; 25(6):479-89 (149 ref.)

The performance of simple instruments in detecting geriatric conditions and selecting community-dwelling older people for geriatric assessment. Maly RC, et al. **Age Ageing** 1997 May;26(3):223-31

Reported activities of daily living: agreement between elderly subjects with and without dementia and their caregivers. Ostbye T, et al. **Age Ageing** 1997 Mar;26(2):99-106

A mental-functional risk score for prediction of hip fracture. Ranstam J, et al. **Age Ageing** 1996 Nov;25(6):439-42

Functional status after cardiac surgery in elderly people [letter; comment] Rozzini R, et al. **Age Ageing** 1996 Sep; 25(5):413. Comment on: Age Ageing 1996 Jan;25(1):8-11.

Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease. Clark CM, et al. **Alzheimer Dis Assoc Disord** 1996 Spring; 10(1):31-9

Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Gauthier S, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:6-7

Static and dynamic assessment practices after head injury. Rees RJ, et al. **Brain Inj** 1996 Apr;10(4):247-57

Correlation of functional independence measure (FIM) and SPECT Iofetamine (I-123) as a predictor of functional return in stroke. Rupright J, et al. **Brain Inj** 1997 Jan; 11(1):49-57

Recovery of automatic and cognitive functions in traumatic brain injury using the functional independence measure. Tofil S, et al. **Brain Inj** 1996 Dec;10(12):901-10

H. G. Dickson's problems with the ICIDH definition of impairment [comment] [see comments] Halbertsma J. **Disabil Rehabil** 1996 Oct;18(10):533-5. Comment on: Disabil Rehabil 1996 Jan;18(1):52-4. Comment in: Disabil Rehabil 1997 Mar;19(3):122-3.

Normal versus pathological aging: knowledge of family practice residents. Beall SC, et al. **Gerontologist** 1996 Feb; 36(1):113-7

Functional limitation pathways and transitions in community-dwelling older persons. Rudberg MA, et al. **Gerontologist** 1996 Aug;36(4):430-40

Can data from the decennial census measure trends in mobility limitation among the aged? Shrestha LB, et al. **Gerontologist** 1996 Feb;36(1):106-9

Measuring psychosocial aspects of well-being in older community residents: performance of four short scales. Steiner A, et al. **Gerontologist** 1996 Feb;36(1):54-62

Cross-sectional psychometric assessment of the Functional Status Questionnaire: use with geriatric versus nongeriatric ambulatory medical patients. Yarnold PR, et al. **Int J Psychiatry Med** 1995;25(4):305-17

Using the rehab scale in a Greek context. Zissi A, et al. **Int J Rehabil Res** 1997 Jun;20(2):183-8

A dynamic long-term care system for the demented elderly. Annerstedt L, et al. **Int Psychogeriatr** 1996 Winter; 8(4):561-74

The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) Rating Scale. Auer SR, et al. **Int Psychogeriatr** 1996 Summer;8(2):247-66

The Hierarchic Dementia Scale: usage. Bickel H. **Int Psychogeriatr** 1996 Summer;8(2):213-24

Dementia treatment: a German perspective on psychosocial aspects and therapeutic approaches [published erratum appears in Int Psychogeriatr 1996 Spring;8(1):2] Möller HJ. **Int Psychogeriatr** 1995 Fall;7(3):459-70

Care dependence and activities of daily living in relation to ageing: results of a longitudinal study. Maaskant MA, et al. **J Intellect Disabil Res** 1996 Dec;40 (Pt 6):535-43

Prediction of length of hospital stay following stroke. Brock K, et al. **J Qual Clin Pract** 1997 Mar;17(1):37-46

Dilemmas faced by families during their young adults' transitions to adulthood: a brief report. Thorin E, et al. **Ment Retard** 1996 Apr;34(2):117-28

Assessment of functional fitness among independent older adults: a preliminary report. Netz Y, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):1059-74

Evidence for limited validity of the revised global assessment of functioning scale. Roy-Byrne P, et al. **Psychiatr Serv** 1996 Aug;47(8):864-6

The multi-dimensionality of the FIM motor items precludes an interval scaling using Rasch analysis. Dickson HG, et al. **Scand J Rehabil Med** 1996 Sep;28(3):159-62

[Mortality and functional limitations in chronic patients: results of a follow-up study of elderly patients after myocardial infarct] Engel S, et al. **Gesundheitswesen** 1997 Apr;59 Suppl 1:26-33 (Eng. Abstr.) **(Ger)**

[Munster Heidelberg Abilities Scale--a measuring instrument for global comparison of illness sequelae] Wolff JE, et al. **Klin Padiatr** 1996 Sep-Oct;208(5):294-8 (Eng. Abstr.) **(Ger)**

[Quality control after pelvic injuries with a scoring system] Bürk W, et al. **Unfallchirurg** 1996 Feb;99(2):112-18 (Eng. Abstr.) **(Ger)**

[Functional, neuropsychological and social outcome of polytrauma patients with severe craniocerebral trauma] Lehmann U, et al. **Unfallchirurg** 1997 Jul;100(7):552-60 (Eng. Abstr.) **(Ger)**

[Daily activities--differences and similarities in the concept between gerontology and nursing care] Brandenburg H, et al. **Z Gerontol Geriatr** 1996 Nov-Dec;29(6):387-96 (Eng. Abstr.) **(Ger)**

[Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire] Lautenschläger J, et al. **Z Rheumatol** 1997 May-Jun;56(3):144-55 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the Short-Form 36 and the Parkinson's Disease Questionnaire [letter; comment] Hobson P, et al. **Age Ageing** 1996 Jul;25(4):334-5. Comment on: Age Ageing 1995 Nov;24(6):505-9.

Age-associated differences in sensori-motor function and balance in community dwelling women. Lord SR, et al. **Age Ageing** 1994 Nov;23(6):452-60

Fear of falling and restriction of mobility in elderly fallers. Vellas BJ, et al. **Age Ageing** 1997 May;26(3):189-93

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Galasko D, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 2:S33-9

Hypnotic involuntariness and the automaticity of everyday life. Kirsch I, et al. **Am J Clin Hypn** 1997 Jul;40(1):329-48 (60 ref.)

Assessment of behavioral symptoms in community-dwelling dementia patients. Weiner MF, et al. **Am J Geriatr Psychiatry** 1997 Winter;5(1):26-30

Family responses to children with early developmental delays. II: Accommodation intensity and activity in early and middle childhood. Gallimore R, et al. **Am J Ment Retard** 1996 Nov;101(3):215-32

Essential characteristics of self-determined behavior of individuals with mental retardation. Wehmeyer ML, et al. **Am J Ment Retard** 1996 May;100(6):632-42

Understanding the transition to community living after discharge from an acute care hospital: an exploratory study. Gage M, et al. **Am J Occup Ther** 1997 Feb;51(2):96-103

Understanding the potential of occupation: a qualitative exploration of seniors' perspectives on activity. Rudman DL, et al. **Am J Occup Ther** 1997 Sep;51(8):640-50

The consumer recovery vision: will it alleviate family burden? Lefley HP. **Am J Orthopsychiatry** 1997 Apr; 67(2):210-9

Social rhythm in anxiety disorder patients. Shear MK, et al. **Anxiety** 1994;1(2):90-5

Post-stroke depression: outcome following rehabilitation. Loong CK, et al. **Aust N Z J Psychiatry** 1995 Dec; 29(4):609-14

Panic disorder or social phobia: which is worse? Norton GR, et al. **Behav Res Ther** 1996 Mar;34(3):273-6

Physical and psychosocial outcomes in cancer patients: a comparison of different age groups. Greimel ER, et al. **Br J Cancer** 1997;76(2):251-5

Therapy methodology. Riding the bus: teaching an adult with a brain injury to use a transit system to travel independently to and from work. Newbigging ED, et al. **Brain Inj** 1996 Jul;10(7):543-50

Research into the lifeworld of physically disabled children. Mulderij KJ. **Child Care Health Dev** 1996 Sep;22(5):311-22

Life stories and sickness experience: a performance perspective. Monks J. **Cult Med Psychiatry** 1995 Dec; 19(4):453-78

Nativity, declining health, and preferences in living arrangements among elderly Mexican Americans: implications for long-term care. Angel JL, et al. **Gerontologist** 1996 Aug;36(4):464-73

Older adults as a community resource: results from the National Survey of Self-Care and Aging. Kincade JE, et al. **Gerontologist** 1996 Aug;36(4):474-82

Long-stay patients with mental health problems and learning difficulties: selection and preparation for community living. Donnelly M, et al. **Int J Rehabil Res** 1996 Jun;19(2):175-9

Supporting functional behavior in Alzheimer's disease. Borell L. **Int Psychogeriatr** 1996;8 Suppl 1:123-5

Mini-Mental State Exam status of community-dwelling cognitively intact centenarians. Holtsberg PA, et al.

Int Psychogeriatr 1995 Fall;7(3):417–27
Supporting everyday activities in dementia. Josephsson S. **Int Psychogeriatr** 1996;8 Suppl 1:141–4
Squalor syndrome and psychogeriatric admissions. Shaw T, et al. **Int Psychogeriatr** 1996 Winter;8(4):669–74
Validation of the NOSGER (Nurses' Observation Scale for Geriatric Patients): reliability and validity of a caregiver rating instrument. Wahle M, et al. **Int Psychogeriatr** 1996 Winter;8(4):525–47
Relationship between dyspnea in daily life and psycho-physiologic state in patients with chronic obstructive pulmonary disease during long-term domiciliary oxygen therapy. Mishima M, et al. **Intern Med** 1996 Jun;35(6):453–8
Paths and impacts in the progressive independence model: a homelessness and substance abuse intervention in Chicago. Sosin MR, et al. **J Addict Dis** 1995;14(4):1–20
Well-being and functioning in patients with bipolar disorder assessed using the MOS 20-ITEM short form (SF-20). Cooke RG, et al. **J Affect Disord** 1996 Jul 8;39(2):93–7
Trajectories and profiles of adaptive behavior in males with fragile X syndrome: multicenter studies. Dykens E, et al. **J Autism Dev Disord** 1996 Jun;26(3):287–301
Pain expectancies, pain, and functional self-efficacy expectancies as determinants of disability in patients with chronic low back disorders. Lacker JM, et al. **J Consult Clin Psychol** 1996 Feb;64(1):212–20
The geriatric obstacle course: a training session designed to help prehospital personnel recognize geriatric stereotypes and misconceptions [see comments] Fleisher FI, et al. **J Emerg Med** 1996 Jul-Aug;14(4):439–44. Comment in: J Emerg Med 1996 Jul-Aug;14(4):499–500.
The effect of drug therapy on the perceived symptom and ADL experiences of narcoleptics. Schumacher A, et al. **J Neurosci Nurs** 1997 Feb;29(1):15–23
The relation of sleep difficulties to fatigue, mood and disability in chronic fatigue syndrome. Morriss RK, et al. **J Psychosom Res** 1997 Jun;42(6):597–605
The beat goes on: lessons learned from the rhythms of the self-advocacy movement. Cone AA. **Ment Retard** 1997 Apr;35(2):144–6
Attitudes of community-living staff members toward persons with mental retardation, mental illness, and dual diagnosis. Henry D, et al. **Ment Retard** 1996 Dec;34(6):367–79
Discrepancies in parent and teacher ratings of adaptive behavior of children with multiple disabilities. Voelker S, et al. **Ment Retard** 1997 Feb;35(1):10–7
A cross-cultural study on impaired self-awareness in Japanese patients with brain dysfunction. Prigatano GP, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr;10(2):135–43
Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients. Menditto AA, et al. **Psychiatr Serv** 1996 Jan;47(1):46–51
Training hospitalized patients with schizophrenia in community reintegration skills. Smith TE, et al. **Psychiatr Serv** 1996 Oct;47(10):1099–103
Social and living skills of new long-stay hospital patients and new long-term community patients. Sood S, et al. **Psychiatr Serv** 1996 Jun;47(6):619–22
Social relations and depressive symptomatology in a sample of community-dwelling French older adults. Antonucci TC, et al. **Psychol Aging** 1997 Mar;12(1):189–95
Relationship of physical disease and functional impairment to depression in older people. Zeiss AM, et al. **Psychol Aging** 1996 Dec;11(4):572–81
Picture activity schedules and engagement of adults with mental retardation in a group home. Anderson MD, et al. **Res Dev Disabil** 1997 Jul-Aug;18(4):231–50
The factor structure of the Reiss Screen for Maladaptive Behaviors in institutional and community populations. Sturmey P, et al. **Res Dev Disabil** 1996 Jul-Aug; 17(4):285–91
Social-Adaptive Functioning Evaluation (SAFE): a rating scale for geriatric psychiatric patients. Harvey PD, et al. **Schizophr Bull** 1997;23(1):131–45
[Quality of life and daily coping of chronic schizophrenic patients. Results of a qualitative pilot study] Kühn A, et al. **Psychother Psychosom Med Psychol** 1997 Feb; 47(2):64–71 (Eng. Abstr.) **(Ger)**
[Subjective disability caused by physical and psychological complaints in long-term follow-up after transient ischemic attacks or "minor stroke"] Schnider P, et al. **Rehabilitation (Stuttg)** 1996 Aug;35(3):143–9 (Eng. Abstr.) **(Ger)**
[German version of the Nottingham Health Profile (NHP): translation and psychometric validation] Kohlmann T, et al. **Soz Praventivmed** 1997;42(3):175–85 (Eng. Abstr.) **(Ger)**
[Development of an illness-specific instrument for assessment of quality of life in patients with arterial occlusive disease (Peripheral Arterial Occlusive Disease 86 Questionnaire)] Bullinger M, et al. **Vasa** 1996;25(1):32–40 (Eng. Abstr.) **(Ger)**
[Rehabilitation hospitalism] Barolin GS. **Wien Med Wochenschr** 1996;146(17):472–7 (Eng. Abstr.) **(Ger)**
[Retirement activities: wish or reality?] Niederfranke A. **Z Gerontol Geriatr** 1996 Sep-Oct;29(5):362–6 (Eng. Abstr.) **(Ger)**
[Human-accessible environment design. Crossroads between persons and environment] Olbrich E. **Z Gerontol Geriatr** 1996 Jul-Aug;29(4):257–66 (Eng. Abstr.) **(Ger)**
[Aging and technology] Rudinger G. **Z Gerontol Geriatr** 1996 Jul-Aug;29(4):246–56 (49 ref.) (Eng. Abstr.) **(Ger)**
[Change in daily activities in the transition to retirement in single persons and couples] Schäuble G. **Z Gerontol Geriatr** 1996 Sep-Oct;29(5):356–61 (Eng. Abstr.) **(Ger)**

ACTIVITY CYCLES

Manifestation of circadian rhythm under constant light depends on lighting conditions during lactation. Cambras T, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1039–46
Memory and complex dynamics in cardiac Purkinje fibers. Gilmour RF Jr, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1826–32
Stochastic model of admixed basal and pulsatile hormone secretion as modulated by a deterministic oscillator. Keenan DM, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1182–92
Rhythm chronotypes in a diurnal rodent, Octodon degus. Labyak SE, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1058–66
Gender differences in energy expended during activities and in daily energy expenditure of elderly people. Morio B, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):E321–7
Circadian and ultradian control of cardiac output in spontaneous hypertension in rats. Oosting J, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H66–75
Ultradian rhythms of autonomic, cardiovascular, and neuroendocrine systems are related in humans. Shannahoff-Khalsa DS, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):R873–87
Low-frequency ultradian insulin rhythms are coupled to cardiovascular, autonomic, and neuroendocrine rhythms. Shannahoff-Khalsa DS, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R962–8
Spontaneous skin temperature oscillations in normal human subjects. Shusterman V, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1173–81
Internal dissociation of the circadian markers of the cortisol rhythm in night workers. Weibel L, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):E608–13
Coupled oscillators account for the slow rhythms in sympathetic nerve discharge and phrenic nerve activity. Zhong S, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1314–24
Hierarchically coupled ultradian oscillators generating robust circadian rhythms. Barrio RA, et al. **Bull Math Biol** 1997 May;59(3):517–32
Oscillatory insulin secretion: a variable phenotypic marker. Matthews DR. **Diabet Med** 1996 Sep;13(9 Suppl 6):S53–8 (15 ref.)
Current concepts on ultradian rhythms of luteinizing hormone secretion in the human. Bergendahl M, et al. **Hum Reprod Update** 1996 Nov-Dec;2(6):507–18 (106 ref.)
Ultradian rhythms in performance on tests of specialized cognitive function. Gordon HW, et al. **Int J Neurosci** 1995 Dec;83(3–4):199–211
Long-term fitness training improves the circadian rest-activity rhythm in healthy elderly males. Van Someren EJ, et al. **J Biol Rhythms** 1997 Apr;12(2):146–56
Melatonin accelerates reentrainment of circadian locomotor activity rhythms to new light-dark cycles in the rat. Marumoto N, et al. **Jpn J Physiol** 1996 Aug;46(4):347–51
Endotoxin induces biphasic alterations in small intestinal myoelectric activity in fasted newborn piglets. Li JX, et al. **Pediatr Res** 1996 Dec;40(6):822–6
Corticosterone and the stress response in young western screech-owls: effects of captivity, gender, and activity period. Dufty AM Jr, et al. **Physiol Zool** 1997 Mar-Apr; 70(2):143–9
Daily torpor and energy expenditure in Sminthopsis macroura: interactions between food and water availability and temperature. Song X, et al. **Physiol Zool** 1997 May-Jun;70(3):331–7
Automation of data acquisition and of experiment control: application to the study of sleep-wake cycles and behavioral paradigms] Vivaldi EA. **Arch Biol Med Exp (Santiago)** 1986;19(3–4):347–57 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Biphasic alteration in the trigeminal nociceptive neuronal responses after intracerebroventricular injection of prostaglandin E2 in rats [published erratum appears in Brain Res 1997 May 23;757(2):299] Oka T, et al. **Brain Res** 1997 Feb 28;749(2):354–7
Influence of histamine receptor agonists and antagonists on ultradian rhythm of EEG in the posterior hypothalamus of the rat. Prast H, et al. **Neurosci Lett** 1996 Sep 20; 216(1):21–4
Differential effects of prenatal cocaine and retinoic acid on activity level throughout day and night. Church MW, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):595–605
Prenatal administration of buprenorphine in the rat: effects on the rest-activity cycle at 22 and 30 days of age. Hutchings DE, et al. **Pharmacol Biochem Behav** 1996 Dec; 55(4):607–13

GENETICS

Genetics in rhythm. Iwasaki K, et al. **Trends Genet** 1997 Mar; 13(3):111–5 (50 ref.)

PHYSIOLOGY

Hypothalamic homeothermy across the ultradian sleep cycle. Parmeggiani PL. **Arch Ital Biol** 1995 Dec;134(1):101–7 (25 ref.)
Circadian and ultradian rhythms of drinking behavior of albino rats maintained in constant darkness. Araujo JF, et al. **Braz J Med Biol Res** 1996 Oct;29(10):1369–72
Crab clocks sent for recalibration. Aldrich JC. **Chronobiol Int** 1997 Jul;14(4):435–7
A temperature-compensated ultradian clock of Tetrahymena: oscillations in respiratory activity and cell division. Kippert F. **Chronobiol Int** 1996 May;13(1):1–13
Crab clocks rewound [comment] Naylor E. **Chronobiol Int** 1997 Jul;14(4):427–30. Comment on: Chronobiol Int 1997 Jul;14(4):337–46.
Dueling hypotheses: circatidal versus circalunidian battle basics—second engagement. Palmer JD. **Chronobiol Int** 1997 Jul;14(4):431–3
Dueling hypotheses: circatidal versus circalunidian battle basics [see comments] Palmer JD. **Chronobiol Int** 1997 Jul; 14(4):337–46. Comment in: Chronobiol Int 1997 Jul;14(4):427–30.
On the relationship between EEG and P300: individual differences, aging, and ultradian rhythms. Polich J. **Int J Psychophysiol** 1997 Jun;26(1–3):299–317
Seasonal differences in diurnal blood pressure of hypertensive patients living in a stable environmental temperature. Fujiwara T, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1747–52
Melatonin secretion in rams maintained in constant darkness depends on the timing of a single 1-hour light pulse given the previous night. Ravault JP, et al. **J Pineal Res** 1996 Nov;21(4):218–24
Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Hartmann A, et al. **Neurobiol Aging** 1997 May-Jun;18(3):285–9
Nocturnal waking and morning dip of peak expiratory flow in clinically stable asthma patients during treatment. Occurrence and patient characteristics. Van Keimpema AR, et al. **Respiration** 1997;64(1):29–34
[Is there a bulbar pacemaker responsible for the ultradian rhythm of paradoxical sleep?] Jouvet M, et al. **Arch Ital Biol** 1995 Dec;134(1):39–56 (Eng. Abstr.) **(Fre)**
[Actimetry: simplified analysis of wake-sleep rhythms in the newborn. Preliminary results] Vanhulle C, et al. **Neurophysiol Clin** 1996;26(6):403–13 (Eng. Abstr.) **(Fre)**
[Importance of ultradian rhythms in endocrinology] Goubillon ML, et al. **Pathol Biol (Paris)** 1996 Sep; 44(7):585–91 (58 ref.) (Eng. Abstr.) **(Fre)**
[Ultradian rhythms in the nasal cycle as measured by a new method] Fukuhara H. **Shinrigaku Kenkyu** 1996 Feb; 66(6):437–42 (Eng. Abstr.) **(Jpn)**

ACTOMYOSIN

CHEMISTRY

Rescue of in vitro actin motility halted at high ionic strength by reduction of ATP to submicromolar levels. Kellermayer MS, et al. **Biochim Biophys Acta** 1996 Nov 12; 1277(1–2):107–14
Radial equilibrium lengths of actomyosin cross-bridges in muscle. Brenner B, et al. **Biophys J** 1996 Nov;71(5):2751–8
Direct inhibition of the actomyosin motility by local anesthetics in vitro. Tsuda Y, et al. **Biophys J** 1996 Nov; 71(5):2733–41
Mapping myosin-binding sites on actin probed by peptides that inhibit actomyosin interaction. Katoh T, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):580–6
Actomyosin interaction in striated muscle. Cooke R. **Physiol Rev** 1997 Jul;77(3):671–97 (157 ref.)

METABOLISM

Mutational analysis of the role of the N terminus of actin in actomyosin interactions. Comparison with other mutant actins and implications for the cross-bridge cycle. Miller CJ, et al. **Biochemistry** 1996 Dec 24;35(51):16557–65
Differential regulation of cardiac actomyosin S-1 MgATPase by protein kinase C isozyme-specific phosphorylation of specific sites in cardiac troponin I and its phosphorylation site mutants. Noland TA Jr, et al. **Biochemistry** 1996 Nov 26;35(47):14923–31
Kinetics of nucleoside triphosphate cleavage and phosphate release steps by associated rabbit skeletal actomyosin, measured using a novel fluorescent probe for phosphate. White HD, et al. **Biochemistry** 1997 Sep 30;36(39):11828–36
Force transmission in skeletal muscle: from actomyosin to external tendons. Patel TJ, et al. **Exerc Sport Sci Rev** 1997; 25:321–63 (121 ref.)
Mapping myosin-binding sites on actin probed by peptides that inhibit actomyosin interaction. Katoh T, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):580–6
Expression and regulation of mutant forms of cardiac TnI in a reconstituted actomyosin system: role of kinase

ACTOMYOSIN

dependent phosphorylation. Malhotra A, et al. **Mol Cell Biochem** 1997 May;170(1-2):99-107

[Combined effect of Pb2+ and divalent mental complexes on superprecipation and ATPase activity of myometrial actomyosin] Dabyntseva RD, et al. **Ukr Biokhim Zh** 1995 Nov-Dec;67(6):46-52 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Actomyosin interaction modulates resting length of unstimulated cardiac ventricular cells. Sollott SJ, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H896-905

PHYSIOLOGY

Inhibitory effect of Ca2+ on renin secretion elicited by chemiosmotic stimuli through actomyosin mediation. Park CS, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C248-54

A nonisometric kinetic model for smooth muscle. Yu SN, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C1025-39

The rôle of the proline-rich region in A1-type myosin essential light chains: implications for information transmission in the actomyosin complex. Timson DJ, et al. **FEBS Lett** 1997 Jan 2;400(1):31-6

Microtubules suppress actomyosin-based cortical flow in Xenopus oocytes. Canman JC, et al. **J Cell Sci** 1997 Aug; 110 (Pt 16):1907-17

Actomyosin interaction in striated muscle. Cooke R. **Physiol Rev** 1997 Jul;77(3):671-97 (157 ref.)

[Molecular mechanism of force (motion) generation by actomyosin] Strzelecka-Golaszewska H. **Postepy Biochem** 1996;42(2):185-94 (83 ref.) **(Pol)**

RADIATION EFFECTS

[Effects of 2375 MHz pulse-modulated microwave radiation on ATPase activity of the rat muscle actomyosin] Pashovskina MS, et al. **Radiats Biol Radioecol** 1996 Sep-Oct;36(5):700-5 (Eng. Abstr.) **(Rus)**

ACTOMYOSIN ADENOSINETRIPHOSPHATASE see **MYOSIN ATPASE**

ACTOMYOSIN SUBFRAGMENTS see **MYOSIN SUBFRAGMENTS**

ACTUARIAL ANALYSIS

Re: Caplan et al. IJROBP 29:1183-1186; 1994, and Bentzen et al. IJROBP 32:1531-1534; 1995 [letter; comment] Chappell R. **Int J Radiat Oncol Biol Phys** 1996 Nov 1; 36(4):988-9. Comment on: Int J Radiat Oncol Biol Phys 1994 Jul 30;29(5):1183-6. Comment on: Int J Radiat Oncol Biol Phys 1995 Jul 30;32(5):1531-4.

Income protection for the aged in the 21st century: a framework to help inform the debate. Wheeler PM, et al. **Soc Secur Bull** 1996 Summer;59(2):3-19

METHODS

Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. Lee WR, et al. **J Clin Oncol** 1997 Jan;15(1):230-8

[The characteristics of actuarial calculations for voluntary medical insurance] Poliakov IV, et al. **Probl Sotsialnoi Gig Istor Med** 1996 Jul-Aug;(4):23-4, 41 (Eng. Abstr.) **(Rus)**

[Actuarial calculations in medical insurance and the problems in their data processing support] Poliakov IV, et al. **Probl Sotsialnoi Gig Istor Med** 1994 Nov-Dec;(6):28-31 (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Actuarial status of the Social Security and Medicare Trust Funds. **Soc Secur Bull** 1996 Summer;59(2):57-63

ACUPOINTS see **ACUPUNCTURE POINTS**

ACUPRESSURE

Acupressure treatment for prevention of postoperative nausea and vomiting [see comments] Fan CF, et al. **Anesth Analg** 1997 Apr;84(4):821-5. Comment in: Anesth Analg 1997 Apr;84(4):712-4.

Acupressure versus intravenous metoclopramide to prevent nausea and vomiting during spinal anesthesia for cesarean section. Stein DJ, et al. **Anesth Analg** 1997 Feb;84(2):342-5

Are nonpharmacologic techniques useful alternatives to antiemetic drugs for the prevention of nausea and vomiting? [editorial; comment] White PF. **Anesth Analg** 1997 Apr; 84(4):712-4. Comment on: Anesth Analg 1997 Apr;84(4):821-5.

Pressure on acupoints decreases postoperative pain. Felhendler D, et al. **Clin J Pain** 1996 Dec;12(4):326-9

Acupuncture/acupressure for weight reduction? A systematic review. Ernst E. **Wien Klin Wochenschr** 1997 Jan 31;109(2):60-2

[Epileptic seizures in children: acupressure instead of diazepam! (interview by Elisabeth Moosmann M.A.)] Pothmann R. **Fortschr Med** 1997 Feb 28;115(6):45, 46 **(Ger)**

ECONOMICS

Cost-benefit of combined use of acupuncture, Shiatsu and lifestyle adjustment for treatment of patients with severe angina pectoris. Ballegaard S, et al. **Acupunct Electrother Res** 1996 Jul-Dec;21(3-4):187-97

INSTRUMENTATION

Simultaneous multiple-modality therapy for tension headaches and neck pain. Stone RG, et al. **Biomed Instrum Technol** 1997 May-Jun;31(3):259-62

STANDARDS

Acupressure for hyperemesis gravidarum [letter; comment] Hoo JJ. **Am J Obstet Gynecol** 1997 Jun;176(6):1395-7. Comment on: Am J Obstet Gynecol 1996 Feb;174(2):708-15.

Acupressure as an adjunct to a pulmonary rehabilitation program. Maa SH, et al. **J Cardiopulm Rehabil** 1997 Jul-Aug;17(4):268-76

ACUPUNCTURE

12th Annual International Symposium on Acupuncture and Electro-Therapeutics. New York City, New York, October 17-20, 1996. Abstracts. **Acupunct Electrother Res** 1997; 22(1):59-82

The role of manual acupuncture and morphine administration on the modulation of capsaicin-induced edema in rat paw. A blind controlled study. Ceccherelli F, et al. **Acupunct Electrother Res** 1996 Jan-Mar;21(1):7-14

Acupuncture treatment for balance disorders following whiplash injury. Fattori B, et al. **Acupunct Electrother Res** 1996 Jul-Dec;21(3-4):207-17

Antagonistic action of orphanin FQ on acupuncture analgesia in rat brain. Zhu CB, et al. **Acupunct Electrother Res** 1996 Jul-Dec;21(3-4):199-205

Bruce Pomeranz, PHD. Acupuncture and the raison d'être for alternative medicine [interview by Bonnie Horrigan] Pomeranz B. **Altern Ther Health Med** 1996 Nov;2(6):85-91

Experimental evidence of a plant meridian system: IV. The effects of acupuncture on growth and metabolism of Phaseolus vulgaris L. beans. Hou TZ, et al. **Am J Chin Med** 1997;25(2):135-42

Effect of acupuncture at tai-tsih (K-3) on the pulse spectrum. Wang WK, et al. **Am J Chin Med** 1996;24(3-4):305-13

Effect of acupuncture on sperm parameters of males suffering from subfertility related to low sperm quality. Siterman S, et al. **Arch Androl** 1997 Sep-Oct;39(2):155-61

Acupuncture: safety first [editorial] [see comments] Ernst E, et al. **BMJ** 1997 May 10;314(7091):1362. Comment in: BMJ 1997 Aug 16;315(7105):429-30. Comment in: BMJ 1997 Aug 16;315(7105):430.

Examination of the afferent fiber responsible for the suppression of jaw-opening reflex in heat, cold, and manual acupuncture stimulation in rats. Okada K, et al. **Brain Res** 1996 Nov 18;740(1-2):201-7

Effect of acupuncture on cardiopulmonary function. Lin JG, et al. **Chin Med J (Engl)** 1996 Jun;109(6):482-5

The physiological responses induced by superficial acupuncture: a comparative study of acupuncture stimulation during exhalation phase and continuous stimulation. Tanaka TH, et al. **Int J Neurosci** 1997 Jun; 90(1-2):45-58

The influence of acupuncture on salivary flow rates in healthy subjects. Dawidson I, et al. **J Oral Rehabil** 1997 Mar;24(3):204-8

Complementary medicine in the medical curriculum [letter] Boxx P. **J R Soc Med** 1997 May;90(5):299-300

Complementary medicine in the medical curriculum [letter; comment] Colquhoun D, et al. **J R Soc Med** 1997 Mar; 90(3):178. Comment on: J R Soc Med 1997 Jan;90(1):19-22.

Reflex modulation of catecholamine secretion and adrenal sympathetic nerve activity by acupuncture-like stimulation in anesthetized rat. Sato A, et al. **Jpn J Physiol** 1996 Oct; 46(5):411-21

Inhibitory effects of acupuncture manipulation and focal electrical stimulation of the nucleus submedius on a viscerosomatic reflex in anesthetized rats. Sumiya E, et al. **Jpn J Physiol** 1997 Feb;47(1):121-30

Vibration-induced finger flexion reflex and inhibitory effect of acupuncture on this reflex in cervical spinal cord injury patients. Takakura N, et al. **Neurosci Res** 1996 Dec; 26(4):391-4

Spinal nerves and acupuncture. Yamamura Y, et al. **Rev Assoc Med Bras** 1996 Apr-Jun;42(2):115-8 (118 ref.)

[Decreasing heart rate and shortening of the arterial pulse propagation time by acupuncture in the spectral analyses] Shinohara M. **Masui** 1997 Feb;46(2):213-21 (Eng. Abstr.) **(Jpn)**

[Possibilities of the use of Korean acupuncture Su Jok in the clinical practice] Medvedev SN, et al. **Klin Med (Mosk)** 1996;74(3):64 **(Rus)**

-Somatosensory evoked potentials by acupunctural stimulus and cortical functional projection] Abad-Alegría F, et al. **Rev Neurol** 1996 Jan;24(125):81-3 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Drop foot as a complication of acupuncture injury and intragluteal injection. Sobel E, et al. **J Am Podiatr Med Assoc** 1997 Feb;87(2):52-9

Bacterial meningitis and lumbar epidural hematoma due to lumbar acupunctures: a case report. Chen CY, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 May; 13(5):328-31

ECONOMICS

Cost-benefit of combined use of acupuncture, Shiatsu and lifestyle adjustment for treatment of patients with severe angina pectoris. Ballegaard S, et al. **Acupunct Electrother Res** 1996 Jul-Dec;21(3-4):187-97

HISTORY

[The history of acupuncture, Kemperaria (Hari = needle; Chiryo: treatment) Kemper, Doctor in Medicine, 1651-1717 (Longo. County of Lippe, Westphalia)] Baron JB. **J Belge Med Phys Rehabil** 1980;3(3):187-90 **(Fre)**

INSTRUMENTATION

Acupuncture needles and the Seebeck effect: do temperature gradients produce electrostimulation? Cohen M, et al. **Acupunct Electrother Res** 1997;22(1):9-15

METHODS

Scientific aspects of acupuncture. Mann F. **J Belge Med Phys Rehabil** 1980;3(3):202-8

Acupuncture. A review. Hsu DT. **Reg Anesth** 1996 Jul-Aug; 21(4):361-70 (61 ref.)

[Acupuncture] Bierlaire J. **J Belge Med Phys Rehabil** 1980; 3(3):183-6 **(Fre)**

[Neurophysiological basis of acupuncture] Yamamura Y, et al. **Rev Assoc Med Bras** 1995 Jul-Aug;41(4):305-10 (60 ref.) **(Por)**

STANDARDS

Safety in acupuncture. Rigorous accreditation schedule for acupuncture already exists [letter; comment] Baldwin of Bewdley E. **BMJ** 1997 Aug 16;315(7105):429-30. Comment on: BMJ 1997 May 10;314(7091):1362.

Safety in acupuncture. Core curriculum is important [letter; comment] Hicks J, et al. **BMJ** 1997 Aug 16;315(7105):430 . Comment on: BMJ 1997 May 10;314(7091):1362.

Safety in acupuncture. Guidelines on practice of acupuncture exist [letter; comment] Uddin J. **BMJ** 1997 Aug 16; 315(7105):430. Comment on: BMJ 1997 May 10;314(7091):1362.

VETERINARY

Do alternative (acupuncture, herbalism, homeopathy etc) have a role in your practice? Thompson F, et al. **Aust Vet J** 1996 Dec;74(6):426-7

More thoughts on alternative and complementary veterinary medicine [letter; comment] Ortenburger AI. **J Am Vet Med Assoc** 1997 Jan 15;210(2):169; discussion 169-70. Comment on: J Am Vet Med Assoc 1996 Nov 15;209(10):1687. Comment on: J Am Vet Med Assoc 1996 Nov 15;209(10):1687-8.

Acupuncture on animals raises questions [news] Suzik HA. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1711, 1715

ACUPUNCTURE ANALGESIA

A clinical study on physiological response in electroacupuncture analgesia and meperidine analgesia for colonoscopy. Wang HH, et al. **Am J Chin Med** 1997; 25(1):13-20

Rats with decreased brain cholecystokinin levels show increased responsiveness to peripheral electrical stimulation-induced analgesia. Zhang LX, et al. **Brain Res** 1997 Jan 16;745(1-2):158-64

Examples of the clinical use of acupuncture. Bischko J. **J Belge Med Phys Rehabil** 1980;3(3):209-14

A possible involvement of monoaminergic and opioidergic systems in the analgesia induced by electro-acupuncture in rabbits. Takagi J, et al. **Jpn J Pharmacol** 1996 Jan; 70(1):73-80

Cholecystokinin antisense RNA increases the analgesic effect induced by electroacupuncture or low dose morphine: conversion of low responder rats into high responders. Tang NM, et al. **Pain** 1997 May;71(1):71-80

Role of polymodal receptors in the acupuncture-mediated endogenous pain inhibitory systems. Kawakita K, et al. **Prog Brain Res** 1996;113:507-23 (93 ref.)

[Central mechanism of an extensive analgesic effect due to strong electroacupuncture of acupoint on spinal dorsal horn neurons] He XL, et al. **Sheng Li Hsueh Pao** 1995 Dec; 47(6):605-9 (Eng. Abstr.) **(Chi)**

ADVERSE EFFECTS

Life-threatening adverse reactions after acupuncture? A systematic review. Ernst E, et al. **Pain** 1997 Jun;71(2):123-6 (68 ref.)

METHODS

Comparisons of pain relief mechanisms between needling to the muscle, static magnetic field, external qigong and needling to the acupuncture point. Takeshige C, et al. **Acupunct Electrother Res** 1996 Apr-Jun;21(2):119-31

Painful piezogenic pedal papules: response to local electro-acupuncture. Woodrow SL, et al.

Br J Dermatol 1997 Apr;136(4):628–30

ACUPUNCTURE ANESTHESIA

Acupuncture in thoracic surgery [letter; comment] Lear E. **Pharos** 1996 Winter;59(1):38. Comment on: Pharos 1995 Fall;58(4):21–5.

[Study on combined acupuncturral and general anesthesia in pneumonectomy] Kuang X, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Feb; 16(2):84–6 (Eng. Abstr.) **(Chi)**

ACUPUNCTURE POINTS

Impression on observing psychic surgery and healing in Brazil which appear to incorporate (+) qi gong energy & the use of acupuncture points. Omura Y. **Acupunct Electrother Res** 1997;22(1):17–33

Effect of the intensity of transcutaneous acupoint electrical stimulation on the postoperative analgesic requirement. Wang B, et al. **Anesth Analg** 1997 Aug;85(2):406–13

Methodological investigations for a multisite trial of auricular acupuncture for cocaine addiction: a study of active and control auricular zones. Margolin A, et al. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):471–81

Enhancement of splenic interferon–gamma, interleukin–2, and NK cytotoxicity by S36 acupoint acupuncture in F344 rats. Yu Y, et al. **Jpn J Physiol** 1997 Apr;47(2):173–8

Increase of locomotor activity by acupuncture on Bai–Hui point in rats. Chang YH, et al. **Neurosci Lett** 1996 Jun 21;211(2):121–4

Attenuation of the catecholamine responses by electroacupuncture on Jen–Chung point during postoperative recovery period in humans. Tseng CC, et al. **Neurosci Lett** 1997 Jun 13;228(3):187–90

[Temperature oscillation spectrum at biologically active points and changes in them during activation of acupuncture meridians] Osipov VV, et al. **Biofizika** 1996 May–Jun;41(3):749–54 (Eng. Abstr.) **(Rus)**

[Puncture physiotherapy in the rehabilitation of patients with complicated forms of spinal osteochondrosis] Levitskii EF, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jul–Aug; (4):13–5 (Eng. Abstr.) **(Rus)**

[The circadian variability of the frequency characteristics of the electromagnetic field of biologically active points as a marker in the administration of physiotherapy] Oranskii IE, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jul–Aug;(4):6–9 **(Rus)**

–Somatosensory evoked potentials by acupunctural stimulus and cortical functional projection] Abad–Alegría F, et al. **Rev Neurol** 1996 Jan;24(125):81–3 (Eng. Abstr.) **(Spa)**

ACUPUNCTURE THERAPY

A controlled trial of acupuncture in psoriasis: no convincing effect. Jerner B, et al. **Acta Derm Venereol** 1997 Mar; 77(2):154–6

Impression on observing psychic surgery and healing in Brazil which appear to incorporate (+) qi gong energy & the use of acupuncture points. Omura Y. **Acupunct Electrother Res** 1997;22(1):17–33

Influence of acupuncture and pharmacotherapy on sensitivity of sensory systems to alcohol irritants in patients with alcoholism. Timofeev MF. **Am J Chin Med** 1996; 24(2):177–84

Acupuncture in the prevention of postoperative nausea and vomiting. al–Sadi M, et al. **Anaesthesia** 1997 Jul; 52(7):658–61

Acupuncture in the 1990s. A review for the primary care physician. Peterson JR. **Arch Fam Med** 1996 Apr; 5(4):237–40; discussion 241 (28 ref.)

Acute effects of acupuncture on physiological and psychological responses to cycle ergometry. Karvelas BR, et al. **Arch Phys Med Rehabil** 1996 Dec;77(12):1256–9

Reducing naltrexone–resistant hyperphagia using laser acupuncture to increase endogenous opiates. Read A, et al. **Brain Inj** 1996 Dec;10(12):911–9

Acupuncture and addiction treatment. Moner SE. **J Addict Dis** 1996;15(3):79–100 (49 ref.)

Acupuncture and AIDS. Moffet H. **J Assoc Nurses AIDS Care** 1996 May–Jun;7(3):54–6

Examples of the clinical use of acupuncture. Bischko J. **J Belge Med Phys Rehabil** 1980;3(3):209–14

Revival of Shalya Chikitsa or acupuncture [letter] Shah RL. **J Indian Med Assoc** 1996 Nov;94(11):428

Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. Appiah R, et al. **J Intern Med** 1997 Feb;241(2):119–24

Is auricular acupuncture beneficial in the inpatient treatment of substance–abusing patients? A pilot study. Gurevich MI, et al. **J Subst Abuse Treat** 1996 Mar–Apr;13(2):165–71

Methodological investigations for a multisite trial of auricular acupuncture for cocaine addiction: a study of active and control auricular zones. Margolin A, et al. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):471–81

Adductor spasmodic dysphonia: case reports with acoustic analysis following botulinum toxin injection and acupuncture. Crevier–Buchman L, et al. **J Voice** 1997 Jun; 11(2):232–7

Acupuncture treatment of patients with radiation–induced xerostomia [letter; comment] Andersen SW, et al. **Oral Oncol** 1997 Mar;33(2):146–7. Comment on: Eur J Cancer B Oral Oncol 1996 May;32B(3):182–90.

Smoking cessation rates 4 years after treatment by nicotine gum and acupuncture. Clavel–Chapelon F, et al. **Prev Med** 1997 Jan–Feb;26(1):25–8

Acupuncture for tinnitus: time to stop? Andersson G, et al. **Scand Audiol** 1996;25(4):273–5 (13 ref.)

Acupuncture and hypnotic suggestions in the treatment of non–organic male sexual dysfunction. Aydin S, et al. **Scand J Urol Nephrol** 1997 Jun;31(3):271–4

Acupuncture/acupressure for weight reduction? A systematic review. Ernst E. **Wien Klin Wochenschr** 1997 Jan 31;109(2):60–2

Acupuncture as an adjuvant therapy in stroke rehabilitation? Ernst E, et al. **Wien Med Wochenschr** 1996; 146(21–22):556–8 (25 ref.)

[The effect of acupuncture in dysmenorrhea] Tsenov D. **Akush Ginekol (Sofiia)** 1996;35(3):24–5 (Eng. Abstr.) **(Bul)**

[Clinical observation on treatment of 40 cases of apoplexy hemiplegia complicated shoulder–hand syndrome with electro–acupuncture] Guo ZX, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Nov; 15(11):646–8 (Eng. Abstr.) **(Chi)**

[Effect of acupuncture on immunomodulation in patients with malignant tumors] Wu B, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Mar; 16(3):139–41 (Eng. Abstr.) **(Chi)**

[Postoperative analgesia by auriculotherapy during laparoscopic cholecystectomy] Lequang T, et al. **Cah Anesthesiol** 1996;44(4):289–92 (Eng. Abstr.) **(Fre)**

[Transcranial Doppler ultrasound––robotics–controlled transducers for quantifying the effect of acupuncture] Litscher G, et al. **Biomed Tech (Berl)** 1997 May; 42(5):116–22 (Eng. Abstr.) **(Ger)**

[Acupuncture in treatment of inflammatory rheumatic diseases] Lautenschläger J. **Z Rheumatol** 1997 Jan–Feb; 56(1):8–20 (Eng. Abstr.) **(Ger)**

[The effect of scalp acupuncture on the blood biochemical indices of healthy volunteers] Belitskaia RA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jul–Aug;(4):27–9 (Eng. Abstr.) **(Rus)**

[Ear acupuncture has a hypotonic effect on the gastrointestinal tract] Borozan S, et al. **Vojnosanit Pregl** 1996 Jan–Feb;53(1):31–3 (Eng. Abstr.) **(Scr)**

[Acupuncture as an alternative to estrogen. New therapeutic methods for climacteric problems are tested] Hammar M, et al. **Lakartidningen** 1997 Jun 11;94(24):2300–2, 2304 **(Swe)**

ADVERSE EFFECTS

False aneurysm of the popliteal artery complicating acupuncture. Lord RV, et al. **Aust N Z J Surg** 1996 Sep; 66(9):645–7

Case reports of two patients with pneumothorax following acupuncture. Vilke GM, et al. **J Emerg Med** 1997 Mar–Apr; 15(2):155–7

[Pneumothorax as a complication of acupuncture (letter)] Candela Blanes A, et al. **An Med Interna** 1995 Aug; 12(8):412–3 **(Spa)**

HISTORY

[Acupuncture and neurology] García–Albea Ristol E. **Rev Neurol** 1997 Jun;25(142):894–8 **(Spa)**

INSTRUMENTATION

Pneumothorax following acupuncture. Olusanya O, et al. **J Am Board Fam Pract** 1997 Jul–Aug;10(4):296–7

METHODS

The combination of scalp and body acupuncture. Zeitler J. **J Belge Med Phys Rehabil** 1980;3(3):215–9

The holistic approach in acupuncture treatment: implications for clinical trials. Choi PY, et al. **J Psychosom Res** 1996 Oct;41(4):349–56

Acupuncture treatment for insomnia and acupuncture analgesia. Lin Y. **Psychiatry Clin Neurosci** 1995 May; 49(2):119–20 (17 ref.)

[The role of acupuncture in physical medicine] Vermeersch R. **J Belge Med Phys Rehabil** 1980;3(3):180–2 **(Dut)**

[The results of combined acupuncture and laser therapy of outpatients with duodenal ulcer] Burtsev VI, et al. **Klin Med (Mosk)** 1997;75(2):34–6 (Eng. Abstr.) **(Rus)**

[Laser puncture combined with drug therapy in the treatment of primary corneal stromal dystrophy] Maichuk IuF, et al. **Vestn Oftalmol** 1996 Apr–Jun;112(2):25–6 (Eng. Abstr.) **(Rus)**

STANDARDS

A review of problems in clinical acupuncture research. Ernst E, et al. **Am J Chin Med** 1997;25(1):3–11 (31 ref.)

ACUTE DISEASE

Arginine vasopressin and renin in acutely ill children: implication for fluid therapy. Gerigk M, et al. **Acta Paediatr** 1996 May;85(5):550–3

Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single–agent chemotherapy. Rosenthal NS, et al. **Am J Clin Pathol** 1996 Nov; 106(5):676–9

Health status of well vs ill adolescents. Starfield B, et al. **Arch Pediatr Adolesc Med** 1996 Dec;150(12):1249–56

Role of medical factors in 1000 fatal aviation accidents: case note study. Cullen SA, et al. **BMJ** 1997 May 31; 314(7094):1592

Audit of general practitioner referrals to a surgical assessment unit: new methods to improve the efficacy of the acute surgical service [see comments] Dookeran KA, et al. **Br J Surg** 1996 Nov;83(11):1544–7. Comment in: Br J Surg 1997 May;84(5):727–8.

Prostate–specific antigen concentrations in serum in acute illnesses. Honda SA, et al. **Clin Chem** 1996 Nov; 42(11):1785–8

Anorexia during acute and chronic disease: relevance of neurotransmitter–peptide–cytokine interactions [letter; comment] Plata–Salamán CR. **Nutrition** 1997 Feb; 13(2):159–60. Comment on: Nutrition 1997 Jan;13(1):56–7.

Impact of disease on markers of macronutrient status. Shenkin A. **Proc Nutr Soc** 1997 Mar;56(1B):433–41 (29 ref.)

The modern management of acute pancreatitis. Delivered at the University of Cape Town, 7 February 1996. Carter DC. **S Afr J Surg** 1996 Aug;34(3):126–8, 130, 132–3 passim

[Resignation on medical grounds: family physicians insufficiently aware of the background] Wind H. **Ned Tijdschr Geneeskd** 1997 Apr 12;141(15):737–40 (Eng. Abstr.) **(Dut)**

[How I explore... an afebrile difficult infant] Bourguignon JP. **Rev Med Liege** 1996 Nov;51(11):726–8 **(Fre)**

[Telephone calls in pediatrics] Grimaldi M, et al. **Rev Med Suisse Romande** 1996 Oct;116(10):763–5 **(Fre)**

CLASSIFICATION

Prospective evaluation of clinical criteria to select older persons with acute medical illness for care in a hypothetical home hospital. Leff B, et al. **J Am Geriatr Soc** 1997 Sep; 45(9):1066–73

ECONOMICS

Marginal costs in general acute care hospitals: a comparison among California, New York and Canada. Hansen KK, et al. **Health Econ** 1996 May–Jun;5(3):195–216

Acute care costs of the oldest old. Perls TT. **Hosp Pract (Off Ed)** 1997 Jul 15;32(7):123–4, 129–32, 137 (12 ref.)

Cash benefits for short–term sickness, 1970–94. Kerns WL. **Soc Secur Bull** 1997;60(1):49–53

EPIDEMIOLOGY

The role of the physician in geriatric medicine in the ageing society. 1. In acute medicine: the integrated model. Thomas A. **Age Ageing** 1994;23 Suppl 3:S22–4

Longitudinal study of early childhood injuries and acute illnesses in the offspring of adolescent mothers who were aggressive, withdrawn, or aggressive–withdrawn in childhood. Serbin LA, et al. **J Abnorm Psychol** 1996 Nov; 105(4):500–7

NURSING

Dangling practices of 51 nurses: a pilot project. Lane LD, et al. **Am J Crit Care** 1997 May;6(3):177–82

The acute care nurse practitioner and management of common health problems: a proposal. Piano MR, et al. **Am J Crit Care** 1996 Jul;5(4):289–92

The acute care nurse practitioner: evolution of the clinical nurse specialist? [editorial] Ackerman MH. **Heart Lung** 1997 Mar–Apr;26(2):85–6

A deviant comes of age. Ford LC. **Heart Lung** 1997 Mar–Apr;26(2):87–91 (20 ref.)

Counseling parents of children with acute illness: a task for nurses in an emergency clinic. Sørlie V, et al. **J Pediatr Nurs** 1996 Oct;11(5):337–41

PSYCHOLOGY

Uncertainty in acute illness. Mishel MH. **Annu Rev Nurs Res** 1997;15:57–80 (76 ref.)

Patients' accounts of calling the doctor out of hours: qualitative study in one general practice [see comments] Hopton J, et al. **BMJ** 1996 Oct 19;313(7063):991–4. Comment in: BMJ 1996 Oct 19;313(7063):954–5.

Parents' difficulties and information needs in coping with acute illness in preschool children: a qualitative study [see comments] Kai J. **BMJ** 1996 Oct 19;313(7063):987–90. Comment in: BMJ 1996 Oct 19;313(7063):954–5. Comment in: BMJ 1997 Feb 1;314(7077):373. Comment in: BMJ 1997 Feb 1;314(7077):373–4.

What worries parents when their preschool children are acutely ill, and why: a qualitative study [see comments] Kai J. **BMJ** 1996 Oct 19;313(7063):983–6. Comment in: BMJ 1996 Oct 19;313(7063):954–5. Comment in: BMJ 1997 Feb 1;314(7077):373. Comment in: BMJ 1997 Feb 1;314(7077):373–4.

Helping parents to cope when their preschool children are acutely ill. Patients and GPs need to understand each other's perceptions of a consultation [letter; comment] Townsend J, et al. **BMJ** 1997 Feb 1;314(7077):373–4. Comment on: BMJ 1996 Oct 19;313(7063):983–6. Comment on: BMJ 1996 Oct 19;313(7063):987–90.

Psychological adjustment to IDDM: 10–year follow–up of an onset cohort of child and adolescent patients. Jacobson AM, et al. **Diabetes Care** 1997 May;20(5):811–8

ACUTE DISEASE

[Psychiatric disorders and somatic diseases (letter; comment)] Klijn FA. **Ned Tijdschr Geneeskd** 1997 Mar 29; 141(13):649–50. Comment on: Ned Tijdschr Geneeskd 1997 Feb 1;141(5):228–9. Comment on: Ned Tijdschr Geneeskd 1997 Feb 1;141(5):247–9. **(Dut)**

[Psychiatric disorders and somatic diseases: relevant legislation (see comments)] Roscam Abbing HD. **Ned Tijdschr Geneeskd** 1997 Feb 1;141(5):228–9 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1997 Mar 29;141(13):649–50. **(Dut)**

REHABILITATION

The role of the physician in geriatric medicine in the ageing society. 3. In acute medicine: the traditional model. Hastie IR. **Age Ageing** 1994;23 Suppl 3:S27

The role of the physician in geriatric medicine in the ageing society. 2. In acute medicine: the age–defined model. Vallon AG. **Age Ageing** 1994;23 Suppl 3:S25–6

Understanding the transition to community living after discharge from an acute care hospital: an exploratory study. Gage M, et al. **Am J Occup Ther** 1997 Feb;51(2):96–103

THERAPY

Temporary observation in emergency medicine. Reina G. **Eur J Emerg Med** 1996 Sep;3(3):175–8

Emergency department walk–in patients study. Yu X, et al. **Eur J Emerg Med** 1996 Sep;3(3):163–74

Focus groups as a path to clinical knowledge about the acutely and severely ill child. Malterud K, et al. **Scand J Prim Health Care** 1997 Mar;15(1):26–9

[Effectiveness and efficiency of hospital care provided to elderly patients with acute disease (letter; comment)] Baztán JJ, et al. **Med Clin (Barc)** 1996 Oct 5;107(11):437 . Comment on: Med Clin (Barc) 1996 Mar 9;106(9):336–43. **(Spa)**

ACUTE LARYNGOTRACHEOBRONCHITIS VIRUS see **PARAINFLUENZA VIRUS 2, HUMAN**

ACUTE LUNG INJURY see **RESPIRATORY DISTRESS SYNDROME, ADULT**

ACUTE NECROTIZING PANCREATITIS see **PANCREATITIS, ACUTE NECROTIZING**

ACUTE PAIN SERVICE see **PAIN CLINICS**

ACUTE–PHASE PROTEINS

Interleukin 1 receptor antagonist (IL–1Ra) is an acute–phase protein [see comments] Gabay C, et al. **J Clin Invest** 1997 Jun 15;99(12):2930–40. Comment in: J Clin Invest 1997 Jun 15;99(12):2813.

ANALYSIS

Human decidua–associated protein (hDP) 200 identified as a monoclonal rheumatoid factor is not an acute phase reactant. Halperin R, et al. **Am J Reprod Immunol** 1997 Feb;37(2):195–8

Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome. Martin TR, et al. **Am J Respir Crit Care Med** 1997 Mar; 155(3):937–44

Selenium: an acute–phase reactant? Sattar N, et al. **Ann Clin Biochem** 1997 Jul;34 (Pt 4):437–9

Acute phase reactants in Alzheimer's disease. Lawlor BA, et al. **Biol Psychiatry** 1996 Jun 15;39(12):1051–2

Systemic acute–phase reactants, C–reactive protein and haptoglobin, in adult periodontitis. Ebersole JL, et al. **Clin Exp Immunol** 1997 Feb;107(2):347–52

Daily variation in circulating cytokines and acute–phase proteins correlates with clinical and laboratory indices in community–acquired pneumonia. Kosmas EN, et al. **Eur J Clin Invest** 1997 Apr;27(4):308–15

Human serum amyloid A (SAA) protein: a prominent acute–phase reactant for clinical practice. Malle E, et al. **Eur J Clin Invest** 1996 Jun;26(6):427–35 (76 ref.)

Pancreatitis associated protein as an early marker of acute pancreatitis. Kemppainen E, et al. **Gut** 1996 Nov; 39(5):675–8

Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Niederau C, et al. **Hepatogastroenterology** 1997 Jan–Feb;44(13):90–107

The role of acute–phase reactant proteins, carcinoembryonic antigen and CA 19–9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study. Yüceyar S, et al. **Int Surg** 1996 Apr–Jun;81(2):136–9

Acute phase proteins in salmonids: evolutionary analyses and acute phase response. Jensen LE, et al. **J Immunol** 1997 Jan 1;158(1):384–92

The effect of tenidap on cytokines, acute–phase proteins, and virus load in human immunodeficiency virus (HIV)–infected patients: correlation between plasma HIV–1 RNA and proinflammatory cytokine levels. Dezube BJ, et al. **J Infect Dis** 1997 Sep;176(3):807–10

Hepatocyte growth factor and acute phase proteins in patients with chronic liver diseases. Shiota G, et al. **J Med** 1995;26(5–6):295–308

Neopterin, beta 2–microglobulin, and acute phase proteins in HIV–1–seropositive and –seronegative Zambian patients with tuberculosis. Hosp M, et al. **Lung** 1997;175(4):265–75

Soluble intercellular adhesion molecule–1 in colorectal cancer and its relationship to acute phase proteins. Reinhardt KM, et al. **Neoplasma** 1996;43(2):65–7

Effects of environmental tobacco smoke on serum levels of acute phase proteins in schoolchildren. Shima M, et al. **Prev Med** 1996 Sep–Oct;25(5):617–24

Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Maes M, et al. **Psychiatry Res** 1997 Jan 15;66(1):1–11

Relations between absolute number of CD4 + CD29+ memory cells and levels of interleukin–6, rheumatoid factors, and acute phase proteins in rheumatoid synovial fluid. Lacki JK, et al. **Rev Rhum Engl Ed** 1997 Mar; 64(3):160–5

Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Körschenhausen DA, et al. **Schizophr Res** 1996 May;19(2–3):103–9

Pancreatitis–associated protein: a putative marker for pancreas graft rejection. van der Pijl JW, et al. **Transplantation** 1997 Apr 15;63(7):995–1003

[Interleukin–6 and acute phase reactants in the diagnosis of ovarian carcinoma] Svoboda B, et al. **Ceska Gynekol** 1996 Aug;61(4):234–9 (Eng. Abstr.) **(Cze)**

[Blood levels of protein markers of inflammation and nutrition in the meningo–encephalitis phase of human African trypanosomiasis] Monnet D, et al. **Bull Soc Pathol Exot** 1997;90(2):105–6 (Eng. Abstr.) **(Fre)**

[Acute–phase proteins in appendicitis in childhood: new findings] Meucci D, et al. **Pediatr Med Chir** 1996 Nov–Dec; 18(6):601–6 (Eng. Abstr.) **(Ita)**

[Changes of urinary ulinastatin and serum CRP after elective surgery for gastric cancer] Ueki M, et al. **Masui** 1996 Aug; 45(8):933–6 (Eng. Abstr.) **(Jpn)**

[Responses of cytokines, acute phase proteins, and polymorphonuclear cell elastase to surgical stress in the patients with esophageal cancer] Kikuchi K, et al. **Rinsho Byori** 1996 Jun;44(6):579–84 (Eng. Abstr.) **(Jpn)**

[Day to day changes in SAA (serum amyloid A) values of healthy subjects and the effect of dexamethasone administration] Yamada T, et al. **Rinsho Byori** 1997 Jul; 45(7):696–8 (Eng. Abstr.) **(Jpn)**

[The value of measuring acute phase protein level in pathologic cases with particular attention to nervous system diseases] Kawiak W, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1995;50:161–5 (26 ref.) (Eng. Abstr.) **(Pol)**

[Acute phase factors in blood of patients with subarachnoid hemorrhage in its earliest phase] Kawiak W, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1995;50:167–71 (Eng. Abstr.) **(Pol)**

[Behavior of some acute phase proteins in blood of patients with acute vascular brain damage in the earliest period of the disease] Bartosik–Psujek H. **Neurol Neurochir Pol** 1997 Jan–Feb;31(1):9–17 (Eng. Abstr.) **(Pol)**

[Usefulness of immunologic and protein determinations for assessment of exposure to mercury] Moszczyński P, et al. **Przegl Lek** 1996;53(3):143–6 (Eng. Abstr.) **(Pol)**

[The dynamic levels of acute–phase proteins and of the lipopolysaccharide–bonding activity of the peripheral blood neutrophils in patients with acute intestinal infections] Malov VA, et al. **Ter Arkh** 1996;68(11):23–7 (Eng. Abstr.) **(Rus)**

[Tumor–associated and acute–phase proteins in the diagnosis of cancerous exudative pleurisy] Uklistaia TA, et al. **Ter Arkh** 1996;68(10):22–8 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Effect of low dose cyclophosphamide on the synthesis of acute phase protein and its significance for cancer chemotherapy. Iwagaki H, et al. **Acta Med Okayama** 1996 Oct;50(5):271–2

The importance of acute phase proteins in acute coronary syndromes [letter; comment] Erdogan O, et al. **Am J Cardiol** 1997 May 15;79(10):1439–40. Comment on: Am J Cardiol 1996 Jul 15;78(2):142–7.

Modulation of human hepatocyte acute phase protein production in vitro by n–3 and n–6 polyunsaturated fatty acids. Wigmore SJ, et al. **Ann Surg** 1997 Jan;225(1):103–11

Coordinate expression of group II phospholipase A2 and the acute–phase proteins haptoglobin (HP) and alpha1–anti–chymotrypsin (ACH) by HepG2 cells. Vadas P, et al. **Clin Exp Immunol** 1997 Apr;108(1):175–80

Interleukin–10 and interleukin–6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Lacki JK, et al. **Clin Rheumatol** 1997 May;16(3):275–8

Increased serum interleukin–6 level and reduction of hepatic acute–phase response after major hepatectomy. Kimura F, et al. **Eur Surg Res** 1996;28(2):96–103

Expression of liver functions following sub–lethal and non–lethal doses of allyl alcohol and acetaminophen in the rat. Tygstrup N, et al. **J Hepatol** 1997 Jul;27(1):156–62

Regulation of tissue inhibitor of metalloproteinase–1 in fibroblasts and acute phase proteins in hepatocytes in vitro by mouse oncostatin M, cardiotrophin–1, and IL–6. Richards CD, et al. **J Immunol** 1997 Sep 1;159(5):2431–7

Generation of soluble recombinant human acute phase serum amyloid A2 (A–SAA2) protein and its use in development of an A–SAA specific ELISA. McCormack CC, et al. **J Immunol Methods** 1996 Oct 30;198(1):101–10

Characterization and biologic activities of recombinant rat soluble interleukin–6 receptor. Thibault V, et al. **J Interferon Cytokine Res** 1996 Nov;16(11):973–81

Acute–phase protein synthesis in rats is influenced by alterations in plasma and muscle free amino acid pools related to lower plasma volume following trauma. Sevaljević LM, et al. **J Nutr** 1996 Dec;126(12):3136–42 (39 ref.)

Effects of cytokine antagonists on the hepatic acute–phase response. Mazuski JE, et al. **J Surg Res** 1997 Mar; 68(2):161–9

Reprioritization of liver protein synthesis resulting from recombinant human growth hormone supplementation in parenterally fed trauma patients: the effect of growth hormone on the acute–phase response. Petersen SR, et al. **J Trauma** 1997 Jun;42(6):987–95; discussion 995–6

Biogenesis of hepatic acute–phase response to trauma. Fouad FM, et al. **Med Hypotheses** 1996 Aug;47(2):157–77 (75 ref.)

Uterocalin: a mouse acute phase protein expressed in the uterus around birth. Liu Q, et al. **Mol Reprod Dev** 1997 Apr;46(4):507–14

Purification and molecular cloning of an inducible gram–negative bacteria–binding protein from the silkworm, Bombyx mori. Lee WJ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7888–93

Psychoactive cannabinoids increase mortality and alter acute phase cytokine responses in mice sublethally infected with Legionella pneumophila. Smith MS, et al. **Proc Soc Exp Biol Med** 1997 Jan;214(1):69–75

Characterisation of the acute phase response of heifers to a prolonged low dose infusion of lipopolysaccharide. Werling D, et al. **Res Vet Sci** 1996 Nov;61(3):252–7

CHEMISTRY

Structural and functional analysis of the spontaneous re–formation of the thiol ester bond in human alpha 2–macroglobulin, rat alpha 1–inhibitor–3 and chemically modified derivatives. Grøn H, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):539–45

The mannose–binding protein A region of glutamic acid185–alanine221 can functionally replace the surfactant protein A region of glutamic acid195–phenylalanine228 without loss of interaction with lipids and alveolar type II cells. Honma T, et al. **Biochemistry** 1997 Jun 10; 36(23):7176–84

Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability–increasing protein. Implications in biological activity. Abrahamson SL, et al. **J Biol Chem** 1997 Jan 24;272(4):2149–55

A 32–kDa proteolytic fragment of transcription factor Stat3 is capable of specific DNA binding. Dreier B, et al. **J Biol Chem** 1997 Aug 29;272(35):22118–24

The amino acid residues immediately carboxyl–terminal to the tyrosine phosphorylation site contribute to interleukin 6–specific activation of signal transducer and activator of transcription 3. Inoue M, et al. **J Biol Chem** 1997 Apr 4; 272(14):9550–5

Characterization of functional domains of the eukaryotic co–chaperone Hip. Irmer H, et al. **J Biol Chem** 1997 Jan 24;272(4):2230–5

Complex formation between a formyl peptide and 24p3 protein with a blocked N–terminus of pyroglutamate. Chu ST, et al. **J Pept Res** 1997 Jun;49(6):582–5

DRUG EFFECTS

Action of trypsin:chymotrypsin (Chymoral forte DS) preparation on acute–phase proteins following burn injury in humans. Latha B, et al. **Burns** 1997 Mar;23 Suppl 1:S3–7

Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock. Staudinger T, et al. **Intensive Care Med** 1996 Sep;22(9):888–93

GENETICS

Distinct expression of heat shock and acute phase genes during regional hepatic ischemia–reperfusion. Gingalewski C, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R634–40

Characterization of a silencer regulatory element in the rat PAP I gene which confers tissue–specific expression and is promoter–dependent. Ortiz EM, et al. **Arch Biochem Biophys** 1997 Apr 1;340(1):111–6

Regulation of mouse pancreatitis–associated protein–I gene expression during caerulein–induced acute pancreatitis. Fu K, et al. **Digestion** 1996;57(5):333–40

Induction of hepatocyte growth factor activator messenger RNA in the liver following tissue injury and acute inflammation. Okajima A, et al. **Hepatology** 1997 Jan; 25(1):97–102

The pancreatitis–associated protein I promoter allows targeting to the pancreas of a foreign gene, whose expression is up–regulated during pancreatic inflammation. Dusetti NJ, et al. **J Biol Chem** 1997 Feb 28;272(9):5800–4

Use of the acute phase serum amyloid A2 (SAA2) gene promoter in the analysis of pro– and anti–inflammatory mediators: differential kinetics of SAA2 promoter induction by IL–1 beta and TNF–alpha compared to IL–6. Uhlar CM, et al. **J Immunol Methods** 1997 Apr 25;203(2):123–30

Mannose–binding protein and susceptibility to chronic hepatitis B infection. Ezekowitz A. **Lancet** 1996 Nov 23; 348(9039):1396–7

Mutation of gene of mannose–binding protein associated with

THE PAPER AND INK USED IN THE ORIGINAL PUBLICATION MAY AFFECT THE QUALITY OF THE MICROFORM EDITION.

chronic hepatitis B viral infection [see comments] Thomas HC, et al. **Lancet** 1996 Nov 23;348(9039):1417-9. Comment in: Lancet 1996 Nov 23;348(9039):1396-7.
STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. Pfeffer LM, et al. **Science** 1997 May 30;276(5317):1418-20
Effects of perturbations of the hypothalamic-pituitary-adrenal axis on the acute phase response: altered C/EBP and acute phase response gene expression in lipopolysaccharide-treated rats. Eastman HB, et al. **Shock** 1996 Oct;6(4):286-92

IMMUNOLOGY

IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Tilg H, et al. **Immunol Today** 1997 Sep; 18(9):428-32 (53 ref.)
Involvement of Stat3 in interleukin-6-induced IgM production in a human B-cell line. Faris M, et al. **Immunology** 1997 Mar;90(3):350-7
Rho stimulates tyrosine phosphorylation of focal adhesion kinase, p130 and paxillin. Flinn HM, et al. **J Cell Sci** 1996 May;109 (Pt 5):1133-41

ISOLATION & PURIFICATION

Purification of lipopolysaccharide-binding protein from bovine serum. Bochsler PN, et al. **Vet Immunol Immunopathol** 1996 Jun 1;51(3-4):303-14

METABOLISM

Age-dependent variation in the serum concentration of mannan-binding protein. Aittoniemi J, et al. **Acta Paediatr** 1996 Aug;85(8):906-9
Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. Hogarth MB, et al. **Age Ageing** 1997 Mar;26(2):153-8
HIP/PAP is an adhesive protein expressed in hepatocarcinoma, normal Paneth, and pancreatic cells. Christa L, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):G993-1002
Role of Rho and myosin phosphorylation in actin stress fiber assembly in mesangial cells. Kreisberg JI, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F283-8
Fever, C-reactive protein, and other acute-phase reactants during treatment of infective endocarditis. Olaison L, et al. **Arch Intern Med** 1997 Apr 28;157(8):885-92
Mechanism of PAP I gene induction during hepatocarcinogenesis: clinical implications. Dusetti NJ, et al. **Br J Cancer** 1996 Dec;74(11):1767-75
Prostate-specific antigen concentrations in serum in acute illnesses. Honda SA, et al. **Clin Chem** 1996 Nov; 42(11):1785-8
Chaperones get Hip. Protein folding. Ziegelhoffer T, et al. **Curr Biol** 1996 Mar 1;6(3):272-5 (20 ref.)
Pancreatitis-associated protein in patients with celiac disease: serum levels and immunocytochemical localization in small intestine. Carroccio A, et al. **Digestion** 1997;58(2):98-103
A novel type of binding specificity to phospholipids for rat mannose-binding proteins isolated from serum and liver. Kuroki Y, et al. **FEBS Lett** 1997 Sep 8;414(2):387-92
Localization of rat pancreatitis-associated protein during bile salt-induced pancreatitis. Morisset J, et al. **Gastroenterology** 1997 Feb;112(2):543-50
Acute phase serum proteins in diabetic retinopathy. Rema M, et al. **Indian J Ophthalmol** 1996 Jun;44(2):83-5
Influence of lipopolysaccharide-induced immune challenge and diet complexity on growth performance and acute-phase protein production in segregated early-weaned pigs. Dritz SS, et al. **J Anim Sci** 1996 Jul; 74(7):1620-8
Effects of cortisol on in vitro interferon-gamma production, acute-phase proteins, growth, and feed intake in a calf castration model. Fisher AD, et al. **J Anim Sci** 1997 Apr; 75(4):1041-7
Effects of suppressing cortisol following castration of bull calves on adrenocorticotropic hormone, in vitro interferon-gamma production, leukocytes, acute-phase proteins, growth, and feed intake. Fisher AD, et al. **J Anim Sci** 1997 Jul;75(7):1899-908
Characterization of two alternately spliced forms of phospholipase D1. Activation of the purified enzymes by phosphatidylinositol 4,5-bisphosphate, ADP-ribosylation factor, and Rho family monomeric GTP-binding proteins and protein kinase C-alpha. Hammond SM, et al. **J Biol Chem** 1997 Feb 7;272(6):3860-8
Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. Sah VP, et al. **J Biol Chem** 1996 Dec 6; 271(49):31185-90
Acute phase response in heifers with experimentally induced mastitis. Hirvonen J, et al. **J Dairy Res** 1996 Aug; 63(3):351-60
Participation of JAK, STAT and unknown proteins in human placental lactogen-induced signaling: a unique signaling pathway different from prolactin and growth hormone. Takeda T, et al. **J Endocrinol** 1997 Apr;153(1):R1-3
Interaction of human mannose-binding protein with Mycobacterium avium. Polotsky VY, et al. **J Infect Dis** 1997 May;175(5):1159-68
Rheumatoid arthritis exhibits reduced acute phase and enhanced constitutive serum amyloid A protein in synovial fluid relative to serum. A comparison with C-reactive protein. Kumon Y, et al. **J Rheumatol** 1997 Jan;24(1):14-9
Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Sasse J, et al. **Mol Cell Biol** 1997 Aug;17(8):4677-86
Functional differences between Stat3alpha and Stat3beta. Schaefer TS, et al. **Mol Cell Biol** 1997 Sep;17(9):5307-16
Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Sluzewska A, et al. **Neuropsychobiology** 1997;35(3):123-7
Presence of pancreatitis-associated protein in pancreatic acinar cells of rats treated with chlorophenylalanine methyl ester. Chen P, et al. **Pancreas** 1996 Aug;13(2):147-53
Lower total serum protein, albumin, and beta- and gamma-globulin in major and treatment-resistant depression: effects of antidepressant treatments. Van Hunsel F, et al. **Psychiatry Res** 1996 Dec 20;65(3):159-69
Acute phase proteins in male Chinese schizophrenic patients in Singapore. Wong CT, et al. **Schizophr Res** 1996 Nov 15;22(2):165-71
Do changes in clinical improvement in rheumatoid arthritis patients treated with immunosuppressive drugs reflect the changes in acute phase proteins? Lacki JK, et al. **Ups J Med Sci** 1995;100(3):233-42
The acute phase response of acid soluble glycoprotein, alpha(1)-acid glycoprotein, ceruloplasmin, haptoglobin and C-reactive protein, in the pig. Eckersall PD, et al. **Vet Immunol Immunopathol** 1996 Jun 1;51(3-4):377-85
[Phospholipase A2--acute phase protein after liver surgery?] Gerhard F, et al. **Z Gastroenterol** 1997 Apr;35(4):247-53 (Eng. Abstr.) **(Ger)**
[Non-enzyme cation proteins of peripheral blood leukocytes-factor of nonspecific reaction of body to injury] Priima OB. **Klin Med (Mosk)** 1997;75(2):4-6 (36 ref.) **(Rus)**

PHARMACOKINETICS

Differential plasma clearance of murine acute-phase serum amyloid A proteins SAA1 and SAA2. Kluve-Beckerman B, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):663-9

PHARMACOLOGY

Influence of acute-phase proteins on erythrocyte aggregation. Weng X, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2346-52
Structural and functional analysis of the spontaneous re-formation of the thiol ester bond in human alpha 2-macroglobulin, rat alpha 1-inhibitor-3 and chemically modified derivatives. Grøn H, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):539-45
Lipopolysaccharide binding protein participation in cellular activation by LPS. Su GL, et al. **Crit Rev Immunol** 1995; 15(3-4):201-14 (97 ref.)

PHYSIOLOGY

Acute phase proteins and transformed cells. Mackiewicz A. **Int Rev Cytol** 1997;170:225-300 (500 ref.)
Healing of incisional wounds in the embryonic chick wing bud: characterization of the actin purse-string and demonstration of a requirement for Rho activation. Brock J, et al. **J Cell Biol** 1996 Nov;135(4):1097-107
Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. van Leeuwen MA, et al. **J Rheumatol** 1997 Jan; 24(1):20-7
Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Badolato R, et al. **Semin Arthritis Rheum** 1996 Oct;26(2):526-38 (143 ref.)
[Acute-phase proteins in children from industrially polluted regions: influence of treatment] Sojka L, et al. **Pediatr Pol** 1996 Feb;71(2):111-6 (Eng. Abstr.) **(Pol)**
[Kallikrein-kinin indices and biological composition of exhaled condensate in acute bronchitis patients with varying disease course] Goncharova VA, et al. **Klin Med (Mosk)** 1996;74(7):46-8 (Eng. Abstr.) **(Rus)**
[Functional activity of the liver and lipopolysaccharide-positive neutrophils of peripheral blood in patients with acute dysentery] Malov VA, et al. **Klin Med (Mosk)** 1996;74(7):52-4 (Eng. Abstr.) **(Rus)**
[Acute phase proteins] Cavor-Zečević L. **Vojnosanit Pregl** 1997 May-Jun;54(3):237-48 (51 ref.) **(Scr)**

RADIATION EFFECTS

Changes acute phase proteins by radiation treatment [letter] Damatopoulou A, et al. **Acta Oncol** 1996;35(6):766

SECRETION

Primary bovine hepatocytes in the study of cytokine induced acute-phase protein secretion in vitro. Alsemgeest SP, et al. **Vet Immunol Immunopathol** 1996 Sep;53(1-2):179-84

ACUTE-PHASE REACTANTS see **ACUTE-PHASE PROTEINS**

ACUTE-PHASE REACTION

Time-course study of the Golgi-lysosome region of rat hepatocytes during early acute phase response to inflammation. Thorne-Tjomsland G, et al. **Anat Rec** 1996 Jan;244(1):15-27
Prostaglandin E2 enters the brain following stimulation of the acute phase immune response. Abul HT, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:287-95
Altered acute phase responses to inflammation in IL-1 and TNF receptor knockout mice. Leon LR, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:244-54
Plasminogen activator inhibitor-1, the acute phase response and vitamin C. Woodhouse PR, et al. **Atherosclerosis** 1997 Aug;133(1):71-6
Initiation of acute phase response and synthesis of cytokines. Koj A. **Biochim Biophys Acta** 1996 Nov 15;1317(2):84-94 (21 ref.)
Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Liuzzo G, et al. **Circulation** 1996 Nov 15;94(10):2373-80
Some aspects of the acute phase response after a marathon race, and the effects of glutamine supplementation. Castell LM, et al. **Eur J Appl Physiol** 1997;75(1):47-53
Structural and functional homology between the 29 kD rat liver nucleoprotein and the high mobility group 1 protein. Petrović M, et al. **Mol Biol Rep** 1996;23(2):79-85

BLOOD

Serum cytokines of acute phase response in the amebic liver abscess. Medina de la Garza CE, et al. **Arch Med Res** 1997; 28 Spec No:250-2
Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Young E, et al. **Arterioscler Thromb Vasc Biol** 1997 Aug;17(8):1568-74
Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. de Maat MP, et al. **Atherosclerosis** 1996 Apr 5;121(2):185-91
Plasma leptin, energy intake and hunger following total hip replacement surgery. Stratton RJ, et al. **Clin Sci (Colch)** 1997 Aug;93(2):113-7
Plasma interleukin-1alpha, interleukin-1beta and interleukin-1 receptor antagonist levels in pre-eclampsia. Kimya Y, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 May;73(1):17-21
Increased serum interleukin-6 level and reduction of hepatic acute-phase response after major hepatectomy. Kimura F, et al. **Eur Surg Res** 1996;28(2):96-103
Serial measurement of serum C-reactive protein facilitates evaluation in alcoholic hepatitis. Gupta S, et al. **Hepatogastroenterology** 1995 Sep-Oct;42(5):516-21
Soluble intercellular adhesion molecule-1 in colorectal cancer and its relationship to acute phase proteins. Reinhardt KM, et al. **Neoplasma** 1996;43(2):65-7
Acute phase response and plasma carotenoid concentrations in older women: findings from the nun study. Boosalis MG, et al. **Nutrition** 1996 Jul-Aug;12(7-8):475-8
The acute phase response to cardiopulmonary bypass in children. Mitchell IM, et al. **Perfusion** 1996 Mar; 11(2):103-12
Acute phase reaction and the hemostatic balance. Cucuianu M, et al. **Rom J Intern Med** 1996 Jan-Jun;34(1-2):13-8 (28 ref.)
A rapid method of monitoring the acute phase response in a rat model. Moodie IM, et al. **S Afr Med J** 1997 Jan;87(1 Suppl):100-2
Time-scale of interleukin-6, myeloid related proteins (MRP), C reactive protein (CRP), and endotoxin plasma levels during the postoperative acute phase reaction. Berger D, et al. **Shock** 1997 Jun;7(6):422-6
Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Gardemann A, et al. **Thromb Haemost** 1997 Jun; 77(6):1120-6
Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Myrup B, et al. **Thromb Res** 1996 Feb 15;81(4):485-90
The acute phase response of acid soluble glycoprotein, alpha(1)-acid glycoprotein, ceruloplasmin, haptoglobin and C-reactive protein, in the pig. Eckersall PD, et al. **Vet Immunol Immunopathol** 1996 Jun 1;51(3-4):377-85
Serum haptoglobin as an indicator of the acute phase response in bovine respiratory disease. Godson DL, et al. **Vet Immunol Immunopathol** 1996 Jun 1;51(3-4):277-92
[Effect of endovascular surgery of infrarenal aortic aneurysms on circulating endothelial adhesion molecules, cytokines and proteinase inhibitors] Schumacher H, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:15-9 (Eng. Abstr.) **(Ger)**
[Non-enzyme cation proteins of peripheral blood leukocytes-factor of nonspecific reaction of body to injury] Priima OB. **Klin Med (Mosk)** 1997;75(2):4-6 (36 ref.) **(Rus)**
[Changes in the antioxidative activity of blood serum in inflammation] Volchegorskiĭ IA, et al. **Vopr Med Khim** 1997 Jul-Aug;43(4):233-8 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

IL-1 type I receptor mediates acute phase response to turpentine, but not lipopolysaccharide, in mice. Leon LR, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1668-75
Toxic damage to the respiratory epithelium induces acute phase changes in vitamin A metabolism without depleting retinol stores of South African children. Willumsen JF,

et al. **J Nutr** 1997 Jul;127(7):1339–43

The effect of factor Xa/phospholipid infusion on the acute phase response in baboons. Kruithof EK, et al. **Thromb Haemost** 1997 Feb;77(2):308–11

COMPLICATIONS

Arterial thrombosis enhanced by an acute phase response. Jones R, et al. **Ann Plast Surg** 1996 Jan;36(1):14–7

Association between preoperative acute phase response and postoperative complications. Haupt W, et al. **Eur J Surg** 1997 Jan;163(1):39–44

DIAGNOSIS

Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. Hogarth MB, et al. **Age Ageing** 1997 Mar;26(2):153–8

Value of neutrophil CD16 expression for detection of left shift and acute-phase response. Hübl W, et al. **Am J Clin Pathol** 1997 Feb;107(2):187–96

An acute phase reaction in diabetic patients with foot ulcers. Upchurch GR Jr, et al. **Cardiovasc Surg** 1997 Feb;5(1):32–6

Evaluation of possible tissue damage in patients undergoing extracorporeal shock wave lithotripsy employing C-reactive protein. Wolff JM, et al. **Scand J Urol Nephrol** 1997 Feb;31(1):31–4

[Systemic release of mediators at the accident site and in the early phase after trauma] Gebhard F, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:489–94 (Eng. Abstr.) **(Ger)**

[Phospholipase A2—acute phase protein after liver surgery?] Gerhard F, et al. **Z Gastroenterol** 1997 Apr;35(4):247–53 (Eng. Abstr.) **(Ger)**

[Changes of urinary ulinastatin and serum CRP after elective surgery for gastric cancer] Ueki M, et al. **Masui** 1996 Aug; 45(8):933–6 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Elliott MJ, et al. **Br J Rheumatol** 1997 May;36(5):589–93

Parenteral zinc supplementation in adult humans during the acute phase response increases the febrile response. Braunschweig CL, et al. **J Nutr** 1997 Jan;127(1):70–4

Acute phase response in rheumatoid arthritis patients treated with immunosuppressive drugs. Lącki JK, et al. **Mater Med Pol** 1995 Apr-Jun;27(2):47–51

ETIOLOGY

Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. Munro R, et al. **Ann Rheum Dis** 1997 May;56(5):326–9

Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Young E, et al. **Arterioscler Thromb Vasc Biol** 1997 Aug;17(8):1568–74

The acute phase response and laboratory testing. Jupe D. **Aust Fam Physician** 1996 Mar;25(3):324–9 (4 ref.)

Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Messmann H, et al. **Gut** 1997 Jan;40(1):80–5

Modulation of C4b-binding protein isoforms during the acute phase response caused by orthopedic surgery. Criado-García O, et al. **Haemostasis** 1997 Jan-Feb; 27(1):25–34

Thermoregulation and the pathogenesis of fever. Dinarello CA. **Infect Dis Clin North Am** 1996 Jun;10(2):433–49 (50 ref.)

Febrile reactions to platelet transfusion: the effect of increased interleukin 6 levels in concentrates prepared by the platelet-rich plasma method. Muylle L, et al. **Transfusion** 1996 Oct;36(10):886–90

GENETICS

Expression and regulation of constitutive and acute phase serum amyloid A mRNAs in hepatic and non-hepatic cell lines. Steel DM, et al. **Scand J Immunol** 1996 Nov; 44(5):493–500

IMMUNOLOGY

Immunological response in laparoscopic surgery. Smit MJ, et al. **Acta Gastroenterol Belg** 1996 Oct-Dec;59(4):245–7 (14 ref.)

Significance of the inflammatory response in brain ischemia. Hallenbeck JM. **Acta Neurochir Suppl (Wien)** 1996;66:27–31 (28 ref.)

Inflammation of the brain after ischemia. Kogure K, et al. **Acta Neurochir Suppl (Wien)** 1996;66:40–3 (14 ref.)

Leukocytes, macrophages and secondary brain damage following cerebral ischemia. Tomita M, et al. **Acta Neurochir Suppl (Wien)** 1996;66:32–9 (58 ref.)

Acute phase reactants in Alzheimer's disease. Lawlor BA, et al. **Biol Psychiatry** 1996 Jun 15;39(12):1051–2

Inhibition of the acute-phase response in vivo by anti-gp130 monoclonal antibodies. Harrison P, et al. **Br J Haematol** 1996 Dec;95(3):443–51

Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Wigmore SJ, et al. **Clin Sci (Colch)** 1997 Feb; 92(2):215–21

Increased plasma concentrations of serum amyloid A: an indicator of the acute-phase response after cardiopulmonary bypass. Berendes E, et al. **Crit Care Med** 1997 Sep;25(9):1527–33

Serotonin-immune interactions in major depression: lower serum tryptophan as a marker of an immune-inflammatory response. Maes M, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(3):154–61

C-reactive protein: structural biology, gene expression, and host defense function. Szalai AJ, et al. **Immunol Res** 1997; 16(2):127–36 (34 ref.)

Evidence for a protective role of tumor necrosis factor in the acute phase of Trypanosoma cruzi infection in mice. Lima EC, et al. **Infect Immun** 1997 Feb;65(2):457–65

The acute immune response to exercise: what does it mean? Gabriel H, et al. **Int J Sports Med** 1997 Mar;18 Suppl 1:S28–45 (79 ref.)

Alterations in iron metabolism and the erythron in major depression: further evidence for a chronic inflammatory process. Maes M, et al. **J Affect Disord** 1996 Sep 9; 40(1-2):23–33

Expression of a biologically active recombinant mouse IL-1 receptor antagonist and its use in vivo to modulate aspects of the acute phase response. Grehan S, et al. **J Immunol** 1997 Jul 1;159(1):369–78

Increased acute-phase response and renal amyloidosis in aged CD2-fas-transgenic mice. Hsu HC, et al. **J Immunol** 1997 Jun 15;158(12):5988–96

Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. Lacki JK, et al. **J Med** 1997;28(1-2):99–107

[Naloxone impairs cell-mediated immune function after hemorrhagic shock] Wichmann MW, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:585–8 (Eng. Abstr.) **(Ger)**

[Changes in the cytokine concentration (Il-6, Il-8, Il-1ra) and their cellular expression of membrane molecules (CD25, CD30, HLA-DR) after surgical trauma] Decker D, et al. **Zentralbl Chir** 1997;122(3):157–63; discussion 163–4 (Eng. Abstr.) **(Ger)**

METABOLISM

Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting. Berendes E, et al. **Anesth Analg** 1997 May;84(5):950–7

Differential plasma clearance of murine acute-phase serum amyloid A proteins SAA1 and SAA2. Kluve-Beckerman B, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):663–9

LPS and cytokines regulate extra hepatic mRNA levels of apolipoproteins during the acute phase response in Syrian hamsters. Hardardóttir I, et al. **Biochim Biophys Acta** 1997 Feb 18;1344(3):210–20

Properties of nuclear matrix proteins that bind the 5' flanking region of the haptoglobin gene are changed during the acute-phase response. Poznanović G, et al. **Cell Biol Int** 1996 Nov;20(11):751–62

Incomplete or absent acute phase response in some postoperative patients. Bourguignat A, et al. **Clin Chim Acta** 1997 Aug 8;264(1):27–35

Hamster antithrombin III: purification, characterization and acute phase response. Mak P, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Sep; 115(1):135–41

Acute phase reaction of the exocrine pancreas. Dagorn JC. **Digestion** 1997;58 Suppl 1:50–2 (4 ref.)

Parathyroid hormone-related protein is induced in the adult liver during endotoxemia and stimulates the hepatic acute phase response. Funk JL, et al. **Endocrinology** 1997 Jul; 138(7):2665–73

Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Messmann H, et al. **Gut** 1997 Jan;40(1):80–5

Effect of acute phase response on phenytoin metabolism in neurotrauma patients. McKindley DS, et al. **J Clin Pharmacol** 1997 Feb;37(2):129–39

Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice. Peters M, et al. **J Immunol** 1997 Aug 1; 159(3):1474–81

HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. Cabana VG, et al. **J Lipid Res** 1996 Dec; 37(12):2662–74

Toxic damage to the respiratory epithelium induces acute phase changes in vitamin A metabolism without depleting retinol stores of South African children. Willumsen JF, et al. **J Nutr** 1997 Jul;127(7):1339–43

Cytokines and the hepatic acute phase response. Moshage H. **J Pathol** 1997 Mar;181(3):257–66 (114 ref.)

Effects of cytokine antagonists on the hepatic acute-phase response. Mazuski JE, et al. **J Surg Res** 1997 Mar; 68(2):161–9

The complement-activating protease P100 is expressed by hepatocytes and is induced by IL-6 in vitro and during the acute phase reaction in vivo. Knittel T, et al. **Lab Invest** 1997 Sep;77(3):221–30

A role for B1 and B2 kinin receptors in the modulation of T-kininogen during the acute phase response of inflammation. Raymond P, et al. **Peptides** 1996; 17(7):1163–70

Glomerular handling of immune complex in the acute phase of active in situ immune complex glomerulonephritis employing cationized ferritin in rats. Ultrastructural localization of immune complex, complements and inflammatory cells. Fujigaki Y, et al. **Virchows Arch** 1997 Jul;431(1):53–61

PATHOLOGY

beta-Amyloid converts an acute phase injury response to chronic injury responses. Cotman CW, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):723–31 (96 ref.)

PHYSIOPATHOLOGY

Interleukins 6 and 8 as mediators of acute phase response in acute myocardial infarction. Pannitteri G, et al. **Am J Cardiol** 1997 Sep 1;80(5):622–5

The acute phase response and the hematopoietic system: the role of cytokines. Trey JE, et al. **Crit Rev Oncol Hematol** 1995 Nov;21(1-3):1–18 (175 ref.)

The role of cytokines in cardiac surgery. Tønnesen E, et al. **Int J Cardiol** 1996 Apr 26;53 Suppl:S1–10 (77 ref.)

Aging and the acute phase response to exercise: implications for the role of systemic factors on skeletal muscle protein turnover. Fielding RA, et al. **Int J Sports Med** 1997 Mar; 18 Suppl 1:S22–7 (59 ref.)

Relationship between pulmonary oxygen consumption, lung inflammation, and calculated venous admixture in patients with acute lung injury [letter; comment] Revelly JP, et al. **Intensive Care Med** 1997 Apr;23(4):481–2. Comment on: Intensive Care Med 1996 Apr;22(4):277–85.

Zidovudine potentiates local and systemic inflammatory responses in the rat. Raymond P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 15;14(5):399–407

Bacterial products and the control of ingestive behavior: clinical implications. Langhans W. **Nutrition** 1996 May; 12(5):303–15 (110 ref.)

Reduction of hepatic acute phase response after partial hepatectomy in elderly patients. Kimura F, et al. **Res Exp Med (Berl)** 1996;196(5):281–90

Hemostatic balance during the acute inflammatory reaction. (II). With special reference to plasma protein C. Plesca L, et al. **Rom J Physiol** 1995 Jan-Dec;32(1-4):35–8

Hemostatic balance during the acute inflammatory reaction; with special reference to antithrombin III. Pleşca LA, et al. **Rom J Physiol** 1995 Jan-Dec;32(1-4):71–6

PREVENTION & CONTROL

Aprotinin diminishes inflammatory processes. Soeparwata R, et al. **Int J Cardiol** 1996 Apr 26;53 Suppl:S55–63

[Improved outcome by preoperative administration of methylprednisolone before large abdominal surgery interventions—a prospective double-blind study] Fu ZX, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997; 114:663–6 (Eng. Abstr.) **(Ger)**

SURGERY

Modulation of C4b-binding protein isoforms during the acute phase response caused by orthopedic surgery. Criado-García O, et al. **Haemostasis** 1997 Jan-Feb; 27(1):25–34

THERAPY

[Mechanisms of action of intravenous immunoglobulins] Poehlau D, et al. **Fortschr Med** 1996 Nov 10;114(31):420–4 (Eng. Abstr.) **(Ger)**

VETERINARY

Effects of pentoxifylline and polymyxin B on the acute-phase-response to Escherichia coli endotoxin in dwarf goats. van Miert AS, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):61–8

Dietary copper level affects copper metabolism during lipopolysaccharide-induced immunological stress in chicks. Koh TS, et al. **Poult Sci** 1996 Jul;75(7):867–72

The acute phase response of acid soluble glycoprotein, alpha(1)-acid glycoprotein, ceruloplasmin, haptoglobin and C-reactive protein, in the pig. Eckersall PD, et al. **Vet Immunol Immunopathol** 1996 Jun 1;51(3-4):377–85

Serum haptoglobin as an indicator of the acute phase response in bovine respiratory disease. Godson DL, et al. **Vet Immunol Immunopathol** 1996 Jun 1;51(3-4):277–92

The effect of the acute-phase response on in vitro drug metabolism and plasma protein binding in the horse. Mills PC, et al. **Vet Res Commun** 1997 Jul;21(5):361–8

ACUTE-PHASE STATE see **ACUTE-PHASE REACTION**

ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATION see **APACHE**

ACUTE RESPIRATORY DISEASE VIRUSES see **ADENOVIRUSES, HUMAN**

ACUTE RETINAL NECROSIS see **RETINAL NECROSIS SYNDROME, ACUTE**

ACUTE YELLOW ATROPHY see **LIVER DISEASES**

ACYCLOGUANOSINE see **ACYCLOVIR**

ACYCLOVIR

ADMINISTRATION & DOSAGE

Dose-dependent effects of oral acyclovir in the incubation period of varicella. Suga S, et al. **Acta Paediatr** 1996 Dec; 85(12):1418-21

Comparison of specific immunities to varicella-zoster virus following post-exposure prophylaxis of varicella by oral acyclovir observed in a family. Asano Y, et al. **Acta Paediatr Jpn** 1996 Dec;38(6):692-4

Treatment of Ramsay Hunt syndrome with acyclovir-prednisone: significance of early diagnosis and treatment. Murakami S, et al. **Ann Neurol** 1997 Mar; 41(3):353-7

A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. The Epithelial Keratitis Trial. The Herpetic Eye Disease Study Group. **Arch Ophthalmol** 1997 Jun;115(6):703-12

Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Bodsworth NJ, et al. **Genitourin Med** 1997 Apr;73(2):110-6

Is long-term continuous therapy for recurrent herpes simplex safe? [letter] Wolf R, et al. **J Am Acad Dermatol** 1997 Sep; 37(3 Pt 1):508-10

More on continuous-infusion acyclovir for severe varicella [letter; comment] Krolewiecki AJ, et al. **N Engl J Med** 1997 Jul 17;337(3):203-4. Comment on: N Engl J Med 1997 Mar 6;336(10):732-3.

Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Randolph AG, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):603-10

[Acyclovir freely obtainable (letter; comment)] Lekkerkerker JF, et al. **Ned Tijdschr Geneeskd** 1996 Sep 7;140(36):1832 . Comment on: Ned Tijdschr Geneeskd 1996 Jul 6;140(27):1412-3. **(Dut)**

[Herpes neonatorum--prevention and therapy. Which newborn infants are at risk? When cesarean section, when acyclovir?] Gabler-Sandberger E. **Fortschr Med** 1996 Oct 30;114(30):393-4 **(Ger)**

[Improvement in ichthyosis congenita after varicella infection] Anton-Lanprecht I. **Hautarzt** 1996 Nov; 47(11):869-70 **(Ger)**

ADVERSE EFFECTS

Acyclovir-induced colitis. Wardle TD, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):415-7

Allergic contact dermatitis to Zovirax cream. Bourezane Y, et al. **Allergy** 1996 Oct;51(10):755-6 (10 ref.)

Reversible brain MRI changes in acyclovir neurotoxicity. Blohm ME, et al. **Bone Marrow Transplant** 1997 May; 19(10):1049-51

Neuropsychiatric toxicity in a patient undergoing hemodialysis and receiving treatment with oral acyclovir. Collins A, et al. **Clin Infect Dis** 1996 Jan;22(1):187-8

Fixed drug eruption due to acyclovir. Montoro J, et al. **Contact Dermatitis** 1997 Apr;36(4):225

Unusual course of herpes simplex virus encephalitis after acyclovir therapy. Preiser W, et al. **Infection** 1996 Sep-Oct; 24(5):384-9

Neurotoxicity associated with acyclovir in end stage renal failure. Kitching AR, et al. **N Z Med J** 1997 May 9; 110(1043):167-9 (19 ref.)

[Coma induced by intravenous acyclovir in a hemodialyzed patient (letter)] Abad S, et al. **Presse Med** 1997 Jun 28; 26(22):1050 **(Fre)**

[A patient with thyroid carcinoma who developed consciousness disturbance during acyclovir administration for herpes zoster] Matsumoto R, et al. **Rinsho Shinkeigaku** 1996 Apr;36(4):590-3 (Eng. Abstr.) **(Jpn)**

[Ciprofloxacin nephropathy, acyclovir nephropathy] Ohno I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):556-9 (18 ref.) **(Jpn)**

[Management of acyclovir-induced renal insufficiency (letter; comment)] Rodríguez González A, et al. **An Med Interna** 1996 Sep;13(9):459-60. Comment on: An Med Interna 1995 Oct;12(10):501-2. **(Spa)**

ANALOGS & DERIVATIVES

Valacyclovir. Acosta EP, et al. **Ann Pharmacother** 1997 Feb; 31(2):185-91 (36 ref.)

Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Korba BE, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1282-4

The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Lin E, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):413-18

Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Wang LH, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):80-5

Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. Thust R, et al. **Antiviral Res** 1996 Jun;31(1-2):105-13

Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro. Hostetler KY, et al. **Biochem Pharmacol** 1997 Jun 15; 53(12):1815-22

In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Rashidi MR, et al. **Drug Metab Dispos** 1997 Jul; 25(7):805-13

Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Perry CM, et al. **Drugs** 1996 Nov; 52(5):754-72 (70 ref.)

Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Bodsworth NJ, et al. **Genitourin Med** 1997 Apr;73(2):110-6

Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group [see comments] Patel R, et al. **Genitourin Med** 1997 Apr; 73(2):105-9. Comment in: Genitourin Med 1997 Apr;73(2):83-4.

Beyond efficacy: new issues for HSV antiviral therapy [editorial; comment] Wald A. **Genitourin Med** 1997 Apr; 73(2):83-4. Comment on: Genitourin Med 1997 Apr;73(2):105-9.

Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro [see comments] Colledge D, et al. **Hepatology** 1997 Jul; 26(1):216-25. Comment in: Hepatology 1997 Jul;26(1):234-7.

Combination therapy for chronic hepatitis B [editorial; comment] Fontana RJ, et al. **Hepatology** 1997 Jul; 26(1):234-7. Comment on: Hepatology 1997 Jul;26(1):216-25.

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Shaw T, et al. **Hepatology** 1996 Nov;24(5):996-1002

Treatment of herpes simplex & varicella zoster infection [editorial] Barrg C, et al. **Ir Med J** 1996 Jul-Aug; 89(4):132-4 (8 ref.)

Pharmacology of new antiherpes agents: famciclovir and valacyclovir. Stein GE. **J Am Pharm Assoc (Wash)** 1997 Mar-Apr;NS37(2):157-63 (39 ref.)

A transferred NOE study of a tricyclic analog of acyclovir bound to thymidine kinase. Czaplicki J, et al. **J Biomol NMR** 1996 Oct;8(3):261-72

Penciclovir cream for herpes simplex labialis. Lawless C, et al. **J Fam Pract** 1997 Aug;45(2):105-6

Pharmacokinetics of acyclovir in the cat. Owens JG, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):488-90

Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. Spruance SL, et al. **JAMA** 1997 May 7; 277(17):1374-9

Topical penciclovir for herpes labialis. **Med Lett Drugs Ther** 1997 Jun 20;39(1003):57-8

Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Grant DM, et al. **Pharmacotherapy** 1997 Mar-Apr;17(2):333-41

Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis. Taskintuna I, et al. **Retina** 1997;17(1):57-64

[Future prospects of valacyclovir in treating and preventing herpesviridae infections in immunosuppressed patients] Raffi F. **Presse Med** 1997 Jan;26 Suppl 1:19-21 (13 ref.) **(Fre)**

[The course for a successor for acyclovir] Ramos JM, et al. **Rev Clin Esp** 1996 Nov;196(11):761-5 (66 ref.) **(Spa)**

ANALYSIS

Comparison of high performance capillary electrophoresis and liquid chromatography for the determination of acyclovir and guanine in pharmaceuticals and urine. Zhang SS, et al. **Biomed Chromatogr** 1996 Sep-Oct;10(5):256-7

BLOOD

A simple high performance liquid chromatography (HPLC) assay for aciclovir and ganciclovir in serum [letter] McMullin CM, et al. **J Antimicrob Chemother** 1996 Oct; 38(4):739-40

Determination of acyclovir in human plasma by high-performance liquid chromatography. Boulieu R, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):233-6

Simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma using fluorescence detection. Peh KK, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):241-4

Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanine in serum and urine using solid-phase extraction and high-performance liquid chromatography. Svensson JO, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1-2):363-6

Scintillation proximity radioimmunoassay for the measurement of acyclovir. Tadepalli SM, et al. **J Pharm Biomed Anal** 1996 Nov;15(2):157-63

CHEMISTRY

The preparation, characterisation and solubility characteristics of a hydrogen-bonded complex between acyclovir and cytosine. Newby CS, et al. **J Pharm Biomed Anal** 1996 Oct;15(1):39-47

ECONOMICS

Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Grant DM, et al. **Pharmacotherapy** 1997 Mar-Apr;17(2):333-41

METABOLISM

Relationship of skin target site free drug concentration (C*) to the in vivo efficacy: an extensive evaluation of the predictive value of the C* concept using acyclovir as a model drug. Mehta SC, et al. **J Pharm Sci** 1997 Jul; 86(7):797-801

In vivo evaluation of acyclovir prodrug penetration and metabolism through rat skin using a diffusion/bioconversion model. Bando H, et al. **Pharm Res** 1997 Jan;14(1):56-62

PHARMACOKINETICS

Cutaneously applied acyclovir acts systemically in the treatment of herpetic infection in the hairless mouse. Bolger GT, et al. **Antiviral Res** 1997 Aug;35(3):157-65

Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. Hughes PM, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):209-24

Pharmacokinetics of acyclovir in the cat. Owens JG, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):488-90

Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. Stathoulopoulou F, et al. **Nephron** 1996;74(2):337-41

PHARMACOLOGY

Evaluation of prodrugs ability to induce effective ablation of cells transduced with viral thymidine kinase gene. Kuriyama S, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2623-8

Inhibition of theophylline metabolism by aciclovir. Maeda Y, et al. **Biol Pharm Bull** 1996 Dec;19(12):1591-5

Anti-asthma effect of an antiviral drug, acyclovir: a clinical case and experimental study. Okada H, et al. **Clin Exp Allergy** 1997 Apr;27(4):431-7

The effect of acyclovir on the proliferative capacity of mononuclear cells from patients with chronic lymphocytic leukemia. Bessler H, et al. **Isr J Med Sci** 1996 Dec; 32(12):1228-31

Antiviral activity of 5,6,7-trimethoxyflavone and its potentiation of the antiherpes activity of acyclovir. Hayashi K, et al. **J Antimicrob Chemother** 1997 Jun;39(6):821-4

Efficacy of Cafon gel on cutaneous infection with herpes simplex virus (HSV)-2 and acyclovir-resistant HSV in mice. Yoshida Y, et al. **J Dermatol Sci** 1996 Dec; 13(3):237-41

Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. Sasadeusz JJ, et al. **J Virol** 1997 May;71(5):3872-8

The emergence of acyclovir resistance in mucocutaneous herpes simplex viral infections: implications for clinical practice [news] Grodesky MJ. **Nurse Pract** 1997 Jun; 22(6):155-6

Acyclovir. Abadi J. **Pediatr Rev** 1997 Feb;18(2):70-1

Testing of some pharmacological characteristics of the autochthonous product Acyclovir. Muțiu A, et al. **Rom J Virol** 1995 Jan-Jun;46(1-2):9-19

Effects of ganciclovir and acyclovir on vascular cell proliferation of cytomegalovirus-positive and negative donors. Mohacsi PJ, et al. **Transplant Proc** 1996 Dec; 28(6):3234-5

POISONING

Progressive somnolence leading to coma in a 68-year-old man. Bradley J, et al. **Chest** 1997 Aug;112(2):538-40

Nephrotoxicity of acyclovir and ganciclovir in rats: evaluation of glomerular hemodynamics. Dos Santos M de F, et al. **J Am Soc Nephrol** 1997 Mar;8(3):361-7

THERAPEUTIC USE

Herpetic stromal disease: response to acyclovir/steroid therapy. O'Brien WJ, et al. **Acta Ophthalmol Scand** 1996 Jun;74(3):265-70

Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Mocroft A, et al. **AIDS** 1996 Sep;10(10):1101-5

Varicella pneumonia in adults--clinical spectrum. Oh HM, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):816-9

Acyclovir plus steroids for herpes zoster [letter; comment] Atkins CD. **Ann Intern Med** 1997 May 15;126(10):831; discussion 832. Comment on: Ann Intern Med 1996 Sep 1;125(5):376-83.

Acyclovir plus steroids for herpes zoster [letter; comment] Carson MP. **Ann Intern Med** 1997 May 15;126(10):831-2 . Comment on: Ann Intern Med 1996 Sep 1;125(5):376-83.

Acyclovir plus steroids for herpes zoster [letter; comment]

Herbert DA. **Ann Intern Med** 1997 May 15;126(10):831; discussion 832. Comment on: Ann Intern Med 1996 Sep 1;125(5):376–83.

Acyclovir suppresses subclinical shedding of herpes simplex virus [letter; comment] Straus SE, et al. **Ann Intern Med** 1996 Nov 1;125(9):776–7. Comment on: Ann Intern Med 1996 Jan 1;124(1 Pt 1):8–15.

Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Dickinson BI, et al. **Ann Pharmacother** 1996 Dec;30(12):1452–64 (35 ref.)

The past as prelude to the future: history, status, and future of antiviral drugs [see comments] Whitley RJ. **Ann Pharmacother** 1996 Sep;30(9):967–71 (9 ref.). Comment in: Ann Pharmacother 1996 Sep;30(9):964–6.

Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice: an evaluation of the predictive value of the C* concept. Patel PJ, et al. **Antiviral Res** 1996 Mar;29(2–3):279–86

Treatment of acyclovir-resistant perianal herpetic ulceration with intramuscular interferon alfa. Borrego L, et al. **Arch Dermatol** 1996 Oct;132(10):1157–8

The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Jackson JL, et al. **Arch Intern Med** 1997 Apr 28; 157(8):909–12

Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Wang FZ, et al. **Blood** 1996 Nov 1; 88(9):3615–20

Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. Amir J, et al. **BMJ** 1997 Jun 21;314(7097):1800–3

Advising patients with genital herpes [editorial] Patel R, et al. **BMJ** 1997 Jan 11;314(7074):85–6

Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Prentice HG, et al. **Bone Marrow Transplant** 1997 Jan;19(2):129–33

Supraglottitis due to herpes simplex virus type 1 in an adult. Bengualid V, et al. **Clin Infect Dis** 1996 Feb;22(2):382–3

Myelitis due to varicella-zoster virus in two patients with AIDS: successful treatment with acyclovir. Lionnet F, et al. **Clin Infect Dis** 1996 Jan;22(1):138–40

Acyclovir therapy for immunocompetent children with chickenpox. Acyclovir-chickenpox Italian Study Group. Manfredi R, et al. **Clin Infect Dis** 1997 Jun;24(6):1261–2

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Wood MJ, et al. **Clin Infect Dis** 1996 Feb;22(2):341–7

Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Colin J, et al. **Cornea** 1997 Jul; 16(4):393–9

"Stat." single dose of acyclovir for prevention of herpes simplex. Shelley WB, et al. **Cutis** 1996 Jun;57(6):453

Acyclovir therapy for angioedema and chronic urticaria. Shelley WB, et al. **Cutis** 1997 Apr;59(4):185–8

Current clinical issues in the management of herpes simplex virus infections in patients with HIV. Conant M. **Dermatology** 1997;194(2):93–7

Severity of varicella infection in Saudis with diabetes mellitus: a possible role of acyclovir in treatment. Kubeyinje EP. **East Afr Med J** 1995 Nov;72(11):739–41

Combination of chemotherapy and antiviral therapy for Epstein-Barr virus-associated non-Hodgkin's lymphoma of high grade malignancy in cases of HIV infection. Brockmeyer NH, et al. **Eur J Med Res** 1997 Mar 24; 2(3):133–5

A retrospective study on the effectiveness of oral acyclovir to prevent herpes simplex recurrence in corneal grafts. van Rooij J, et al. **Eur J Ophthalmol** 1995 Oct-Dec;5(4):214–8

Effects of acyclovir on sensory axonal neuropathy, segmental motor paresis and postherpetic neuralgia in herpes zoster patients. Mondelli M, et al. **Eur Neurol** 1996;36(5):288–92

Sharing prescribing of continuous aciclovir treatment: effects of a new policy and general practitioner responses [letter] Vonau B, et al. **Genitourin Med** 1997 Jun;73(3):225–6

Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates. Yao YF, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234 Suppl 1:S126–32

Acyclovir therapy in chickenpox. Aggarwal V, et al. **Indian Pediatr** 1996 Apr;33(4):313–7 (19 ref.)

Acyclovir in chickenpox [letter] Singh H. **Indian Pediatr** 1996 Dec;33(12):1061

Management of herpes simplex virus type 1 pneumonia following liver transplantation. Liebau P, et al. **Infection** 1996 Mar-Apr;24(2):130–5

Unusual course of herpes simplex virus encephalitis after acyclovir therapy. Preiser W, et al. **Infection** 1996 Sep-Oct; 24(5):384–9

Cost-benefit of oral acyclovir in the treatment of herpes zoster. Kubeyinje EP. **Int J Dermatol** 1997 Jun;36(6):457–9

Oral acyclovir therapy for varicella in pregnancy. Mutalik S, et al. **Int J Dermatol** 1997 Jan;36(1):49–51

Survey of the management of genital herpes in general practice. Woolley PD, et al. **Int J STD AIDS** 1996 May-Jun;7(3):206–11

Treatment of herpes simplex & varicella zoster infection [editorial] Barrg C, et al. **Ir Med J** 1996 Jul-Aug; 89(4):132–4 (8 ref.)

Viral infection and tic exacerbation [letter] Budman CL, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Feb;36(2):162

Zoster myelitis and its response to Acyclovir. Sharma R, et al. **J Assoc Physicians India** 1996 Mar;44(3):220–1

Potential benefit of acyclovir for chickenpox acquired from household contacts. The Italian Acyclovir-Chickenpox Study Group. Manfredi R, et al. **J Chemother** 1997 Jun; 9(3):199–202

Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. Wald A, et al. **J Clin Invest** 1997 Mar 1;99(5):1092–7

Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. Bergmann OJ, et al. **J Clin Oncol** 1997 Jun;15(6):2269–74

A case of herpes zoster associated with colitis. Okimura H, et al. **J Dermatol** 1996 Sep;23(9):631–4 (6 ref.)

Acyclovir or prednisone for treating herpes zoster. Becker LA, et al. **J Fam Pract** 1996 Dec;43(6):539–40

Acyclovir in pregnancy for primary prevention of neonatal herpes. Stiffman MN, et al. **J Fam Pract** 1997 Jan; 44(1):29–30

Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. The Multinational Sorivudine Study Group. Bodsworth NJ, et al. **J Infect Dis** 1997 Jul;176(1):103–11

Effect of acyclovir and prednisolone on the serological response in herpes zoster. Bates CJ, et al. **J Med Virol** 1996 Nov;50(3):244–8

Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation. Lao WC, et al. **J Med Virol** 1997 Mar; 51(3):152–8

Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. Tencza MG, et al. **J Med Virol** 1997 Jan;51(1):6–16

Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. Lycke J, et al. **J Neurol** 1996 Mar;243(3):214–24

Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir. Kim SH, et al. **J Neurooncol** 1997 Jul;33(3):189–94

Recurrence of chickenpox in an acyclovir-treated patient [letter] Ijichi N, et al. **J Paediatr Child Health** 1997 Jun; 33(3):272

Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy. Kesson AM, et al. **J Paediatr Child Health** 1996 Jun;32(3):211–7 (73 ref.)

Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective? Goral S, et al. **Kidney Int Suppl** 1996 Dec;57:S62–5 (22 ref.)

A continuous infusion of acyclovir for severe hemorrhagic varicella [letter] [see comments] Kakinuma H, et al. **N Engl J Med** 1997 Mar 6;336(10):732–3. Comment in: N Engl J Med 1997 Jul 17;337(3):203–4.

Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3. Gómez E, et al. **Nephron** 1996;74(2):367–72

Zoster myelitis: improvement with antiviral therapy in two cases. de Silva SM, et al. **Neurology** 1996 Oct;47(4):929–31

Treatment of herpetic keratitis with acyclovir: benefits and problems. Ohashi Y. **Ophthalmologica** 1997;211 Suppl 1:29–32 (26 ref.)

Long-term oral acyclovir therapy. Effect on recurrent infectious herpes simplex keratitis in patients with and without grafts [see comments] Simon AL, et al. **Ophthalmology** 1996 Sep;103(9):1399–404; discussion 1404–5. Comment in: Ophthalmology 1997 Mar;104(3):343.

Long-term oral acyclovir therapy [letter; comment] Wessels HA. **Ophthalmology** 1997 Mar;104(3):343. Comment on: Ophthalmology 1996 Sep;103(9):1399–404; discussion 1404–5.

Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Kimberlin D, et al. **Pediatr Infect Dis J** 1996 Mar;15(3):247–54

Chickenpox complications among immunocompetent hospitalized children in Italy. Acyclovir-Chickenpox Italian Study Group. Manfredi R, et al. **Pediatr Med Chir** 1997 Mar-Apr;19(2):99–104

Successful treatment of progressive outer retinal necrosis syndrome. Spaide RF, et al. **Retina** 1996;16(6):479–87

Over-the-counter acyclovir. An idea whose time has come [editorial] Fife KH. **Sex Transm Dis** 1996 May-Jun; 23(3):174–6

Acyclovir should not be approved for marketing without prescription [editorial] Handsfield HH. **Sex Transm Dis** 1996 May-Jun;23(3):171–3

Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Pouteil-Noble C, et al. **Transplant Proc** 1996 Oct;28(5):2811

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Badley AD, et al. **Transplantation** 1997 Jul 15;64(1):66–73

Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Darenkov IA, et al. **Transplantation** 1997 Sep 27;64(6):848–52

Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation. Shen GK, et al. **Transplantation** 1997 Sep 27;64(6):931–3

Protection and therapy of experimental herpesvirus infections in mice with immunomodulating Propionibacterium avidum KP-40 and/or acyclovir. Kobus M, et al. **Zentralbl Bakteriol** 1997 Feb;285(3):445–9

[Bell's palsy treated with acyclovir (see comments)] Jørgensen KE. **Ugeskr Laeger** 1996 Dec 9;158(50):7249–50 . Comment in: Ugeskr Laeger 1997 Mar 31;159(14):2105. **(Dan)**

[Bell's palsy treated with acyclovir (letter; comment)] Jørgensen KE. **Ugeskr Laeger** 1997 Jun 9;159(24):3799. Comment on: Ugeskr Laeger 1997 Mar 31;159(14):2105. **(Dan)**

[Bell's palsy treated with acyclovir (comment) (see comments)] Peitersen E. **Ugeskr Laeger** 1997 Mar 31; 159(14):2105. Comment on: Ugeskr Laeger 1996 Dec 9;158(50):7249–50. Comment in: Ugeskr Laeger 1997 Jun 9;159(24):3799. **(Dan)**

[Acyclovir freely obtainable (letter; comment)] Schippers HM. **Ned Tijdschr Geneeskd** 1996 Sep 7;140(36):1831–2. Comment on: Ned Tijdschr Geneeskd 1996 Jul 6;140(27):1412–3. **(Dut)**

[Herpesvirus and varicella-zoster virus after bone marrow transplantation] Milpied N. **Presse Med** 1997 Jan;26 Suppl 1:4–6 (18 ref.) **(Fre)**

TOXICITY

Toxic effect of concomitant administration of cyclosporin A and acyclovir on renal function and morphology in rats. Hannemann J, et al. **Arch Toxicol** 1997;71(9):556–62

In vitro lymphotoxicity and selective T cell immunotoxicity of high doses of acyclovir and its derivatives in mice. Poluektova L, et al. **Int J Immunopharmacol** 1996 Jun-Jul; 18(6-7):429–38

[Neurotoxicity of acyclovir (letter)] Calvo Romero JM, et al. **Rev Clin Esp** 1997 Apr;197(4):297 **(Spa)**

URINE

Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanine in serum and urine using solid-phase extraction and high-performance liquid chromatography. Svensson JO, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):363–6

ACYL CARRIER PROTEIN

CHEMISTRY

Hydrodynamic properties of Vibrio harveyi acyl carrier protein and its fatty-acylated derivatives. de la Roche MA, et al. **Arch Biochem Biophys** 1997 Aug 1;344(1):159–64

Solution structure of the actinorhodin polyketide synthase acyl carrier protein from Streptomyces coelicolor A3(2). Crump MP, et al. **Biochemistry** 1997 May 20;36(20):6000–8

Quantitation of chemical exchange rates using pulsed-field-gradient diffusion measurements. Andrec M, et al. **J Biomol NMR** 1997 Feb;9(2):136–50

Peptide synthesis on Sepharose beads. Tegge W, et al. **J Pept Res** 1997 Apr;49(4):355–62

Structural homology of spinach acyl carrier protein and Escherichia coli acyl carrier protein based on NMR data. Oswood MC, et al. **Proteins** 1997 Jan;27(1):131–43

GENETICS

Identification of a cotton fiber-specific acyl carrier protein cDNA by differential display. Song P, et al. **Biochim Biophys Acta** 1997 Apr 10;1351(3):305–12

Relationships between fatty acid and polyketide synthases from Streptomyces coelicolor A3(2): characterization of the fatty acid synthase acyl carrier protein. Revill WP, et al. **J Bacteriol** 1996 Oct;178(19):5660–7

ISOLATION & PURIFICATION

A special acyl carrier protein for transferring long hydroxylated fatty acids to lipid A in Rhizobium. Brozek KA, et al. **J Biol Chem** 1996 Dec 13;271(50):32126–36

METABOLISM

Decarboxylation of malonyl-(acyl carrier protein) by 3-oxoacyl-(acyl carrier protein) synthases in plant fatty acid biosynthesis. Winter E, et al. **Biochem J** 1997 Jan 15; 321 (Pt 2):313–8

Utilization of enzymatically phosphopantetheinylated acyl carrier proteins and acetyl-acyl carrier proteins by the actinorhodin polyketide synthase. Carreras CW, et al. **Biochemistry** 1997 Sep 30;36(39):11757–61

Ability of Streptomyces spp. acyl carrier proteins and coenzyme A analogs to serve as substrates in vitro for E. coli holo-ACP synthase. Gehring AM, et al. **Chem Biol** 1997 Jan;4(1):17–24

Mitochondrial acyl carrier protein is involved in lipoic acid synthesis in Saccharomyces cerevisiae. Brody S, et al. **FEBS Lett** 1997 May 19;408(2):217–20

Post-translational modification of heterologously expressed

Streptomyces type II polyketide synthase acyl carrier proteins. Cox RJ, et al. **FEBS Lett** 1997 Apr 1; 405(3):267–72

Analysis of the in vivo activation of hemolysin (HlyA) from Escherichia coli. Ludwig A, et al. **J Bacteriol** 1996 Sep; 178(18):5422–30

Acyl–acyl carrier protein is a donor of fatty acids in the NodA–dependent step in biosynthesis of lipochitin oligosaccharides by rhizobia. Ritsema T, et al. **J Bacteriol** 1997 Jun;179(12):4053–5

Domains of Escherichia coli acyl carrier protein important for membrane–derived–oligosaccharide biosynthesis. Tang L, et al. **J Bacteriol** 1997 Jun;179(11):3697–705

A new metabolic link. The acyl carrier protein of lipid synthesis donates lipoic acid to the pyruvate dehydrogenase complex in Escherichia coli and mitochondria. Jordan SW, et al. **J Biol Chem** 1997 Jul 18;272(29):17903–6

Characterization of a structurally and functionally diverged acyl–acyl carrier protein desaturase from milkweed seed. Cahoon EB, et al. **Plant Mol Biol** 1997 Apr;33(6):1105–10

Why do mitochondria synthesize fatty acids? Evidence for involvement in lipoic acid production. Wada H, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1591–6

PHYSIOLOGY

Specific nicking at the 3' ends of the terminal inverted repeat sequences in transposon Tn3 by transposase and an E. coli protein ACP. Maekawa T, et al. **Genes Cells** 1996 Nov; 1(11):1017–30

ACYL COA see **ACYL COENZYME A**

ACYL–COA–CHOLESTEROL ACYLTRANSFERASE see **CHOLESTEROL ACYLTRANSFERASE**

ACYL COA DEHYDROGENASES see **FATTY ACID DESATURASES**

ACYL COA DESATURASES see **FATTY ACID DESATURASES**

ACYL COA HYDROLASE see **PALMITOYL–COA HYDROLASE**

ACYL COA LYSOLECITHIN ACYLTRANSFERASE see **LYSOLECITHIN ACYLTRANSFERASE**

ACYL COA SYNTHETASES see **COENZYME A SYNTHETASES**

ACYL COENZYME A

ANALYSIS

Long–term l–carnitine treatment prolongs the survival in rats with adriamycin–induced heart failure. Kawasaki N, et al. **J Card Fail** 1996 Dec;2(4):293–9

ANTAGONISTS & INHIBITORS

Drug therapy of severe hypercholesterolemia in patients with coronary artery disease. Parhofer KG, et al. **Artif Organs** 1996 Apr;20(4):286–91 (40 ref.)

Multiple–dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG–CoA reductase, in healthy subjects. Cilla DD Jr, et al. **Clin Pharmacol Ther** 1996 Dec;60(6):687–95

BIOSYNTHESIS

Incorporation of [U–14C]palmitate into rat brain: effect of an inhibitor of beta–oxidation. Chang MC, et al. **J Lipid Res** 1997 Feb;38(2):295–300

CHEMICAL SYNTHESIS

Synthesis of nonhydrolyzable acyl–coenzyme A analogs. Abend A, et al. **Methods Enzymol** 1997;279:224–39 (22 ref.)

Large–scale synthesis of coenzyme A esters. Padmakumar R, et al. **Methods Enzymol** 1997;279:220–4 (10 ref.)

CHEMISTRY

Titration calorimetric analysis of AcylCoA recognition by myristoylCoA:protein N–myristoyltransferase. Bhatnagar RS, et al. **Biochemistry** 1997 Jun 3;36(22):6700–8

Thermodynamics of ligand binding to acyl–coenzyme A binding protein studied by titration calorimetry. Faergeman NJ, et al. **Biochemistry** 1996 Nov 12;35(45):14118–26

Isoforms of rat liver fatty acid binding protein differ in structure and affinity for fatty acids and fatty acyl CoAs. Frolov A, et al. **Biochemistry** 1997 May 27;36(21):6545–55

Time–resolved fluorescence of intestinal and liver fatty acid binding proteins: role of fatty acyl CoA and fatty acid. Frolov A, et al. **Biochemistry** 1997 Jan 21;36(3):505–17

A carbon–skeleton walk: a novel double rearrangement of glutaryl–CoA catalyzed by the human methylmalonyl–CoA mutase. Padmakumar R, et al. **Biofactors** 1995–96;5(2):83–6

Stereochemistry of peroxisomal and mitochondrial beta–oxidation of alpha–methylacyl–CoAs. Schmitz W, et al. **Eur J Biochem** 1997 Mar 1;244(2):434–40

Synthesis of nonhydrolyzable acyl–coenzyme A analogs. Abend A, et al. **Methods Enzymol** 1997;279:224–39 (22 ref.)

DRUG EFFECTS

Effect of sulphide on short chain acyl–CoA metabolism in rat colonocytes. Moore JW, et al. **Gut** 1997 Jul;41(1):77–81

GENETICS

3–hydroxy–3–methylglutaryl coenzyme A reductase of Sulfolobus solfataricus: DNA sequence, phylogeny, expression in Escherichia coli of the hmgA gene, and purification and kinetic characterization of the gene product. Bochar DA, et al. **J Bacteriol** 1997 Jun; 179(11):3632–8

METABOLISM

Synthesis of [9–14C]nonanoic acid via 2–thienyl(14CH3)(cyano)cuprate and its oxidation by newborn piglet muscle strips. Tetrick MA, et al. **Anal Biochem** 1997 May 15;248(1):1–6

Peroxisome proliferators and signal transduction. Bronfman M, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:403–12

Evidence for acetyl coenzyme A and cinnamoyl coenzyme A in the anaerobic toluene mineralization pathway in Azoarcus tolulyticus Tol–4. Chee–Sanford JC, et al. **Appl Environ Microbiol** 1996 Mar;62(3):964–73

Substrate specificity modification of the stromal glycerol–3–phosphate acyltransferase. Ferri SR, et al. **Arch Biochem Biophys** 1997 Jan 15;337(2):202–8

Sterol carrier protein X (SCPx) is a peroxisomal branched–chain beta–ketothiolase specifically reacting with 3–oxo–pristanoyl–CoA: a new, unique role for SCPx in branched–chain fatty acid metabolism in peroxisomes. Wanders RJ, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):565–9

Fatty acyl–CoA esters and the permeability of rat liver microsomal vesicles [letter] Bánhegyi G, et al. **Biochem J** 1996 Nov 15;320 (Pt 1):343–4

The effect of respiratory chain impairment of beta–oxidation in rat heart mitochondria. Eaton S, et al. **Biochem J** 1996 Oct 15;319 (Pt 2):633–40

Fatty acyl–CoA–acyl–CoA–binding protein complexes activate the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum. Fulceri R, et al. **Biochem J** 1997 Jul 15;325 (Pt 2):423–8

Triacsin C blocks de novo synthesis of glycerolipids and cholesterol esters but not recycling of fatty acid into phospholipid: evidence for functionally separate pools of acyl–CoA. Igal RA, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):529–34

Evidence that both the acyl–CoA– and malonyl–CoA binding sites of mitochondrial overt carnitine palmitoyltransferase (CPT I) are exposed on the cytosolic face of the outer membrane. Fraser F, et al. **Biochem Soc Trans** 1996 May;24(2):184S

Titration calorimetric analysis of AcylCoA recognition by myristoylCoA:protein N–myristoyltransferase. Bhatnagar RS, et al. **Biochemistry** 1997 Jun 3;36(22):6700–8

Inactivation of 3–hydroxy–3–methylglutaryl–CoA synthase and other Acyl–CoA–utilizing enzymes by 3–Oxobutylsulfoxyl–CoA. Charlier HA Jr, et al. **Biochemistry** 1997 Feb 11;36(6):1551–8

Acyl–CoA binding proteins inhibit the nonenzymic S–acylation of cysteinyl–containing peptide sequences by long–chain acyl–CoAs. Leventis R, et al. **Biochemistry** 1997 May 6;36(18):5546–53

Isothermal titration microcalorimetric studies for the binding of octenoyl–CoA to medium chain acyl–CoA dehydrogenase. Srivastava DK, et al. **Biochemistry** 1997 May 27;36(21):6359–66

Oleate 6–hydroxylase activity in the membrane fraction from an oleaginous fungus, Mortierella ramanniana var. angulispora. Certik M, et al. **Biochim Biophys Acta** 1996 Nov 11;1304(1):56–64

Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. Cuthbert JA, et al. **Cancer Res** 1997 Aug 15; 57(16):3498–505

Regulation of mevalonate synthesis in rat mammary glands by dietary n–3 and n–6 polyunsaturated fatty acids. El–Sohemy A, et al. **Cancer Res** 1997 Sep 1;57(17):3685–7

Stereochemistry of peroxisomal and mitochondrial beta–oxidation of alpha–methylacyl–CoAs. Schmitz W, et al. **Eur J Biochem** 1997 Mar 1;244(2):434–40

Is an ATPase involved in uncoating of plasma membrane adaptor complex AP–2? Sosa MA, et al. **FEBS Lett** 1997 Apr 28;407(2):173–6

In vivo evidence that acyl coenzyme A regulates DNA binding by the Escherichia coli FadR global transcription factor. Cronan JE Jr. **J Bacteriol** 1997 Mar;179(5):1819–23

Evidence for a unique long chain acyl–CoA ester binding site on the ATP–regulated potassium channel in mouse pancreatic beta cells. Bränström R, et al. **J Biol Chem** 1997 Jul 11;272(28):17390–4

Disruption of the gene encoding the acyl–CoA–binding protein (ACB1) perturbs acyl–CoA metabolism in Saccharomyces cerevisiae. Schjerling CK, et al. **J Biol Chem** 1996 Sep 13;271(37):22514–21

Changes in cerebral acyl–CoA concentrations following ischemia–reperfusion in awake gerbils. Rabin O, et al. **J Neurochem** 1997 May;68(5):2111–8

Demonstration and purification of a myristoyl–CoA binding protein from bovine cardiac muscle. Raju RV, et al. **Life Sci** 1997;60(23):2145–53

Influence of diet on the kinetic behavior of hepatic carnitine palmitoyltransferase I toward different acyl CoA esters. Power GW, et al. **Lipids** 1997 Jan;32(1):31–7

Acylation of endogenous acyl acceptors by mouse sciatic nerve microsomes. Juguelin H, et al. **Neurochem Int** 1996 Mar;28(3):271–6

Relation between free fatty acid and acyl–CoA concentrations in rat brain following decapitation. Deutsch J, et al. **Neurochem Res** 1997 Jul;22(7):759–65

Steroids, fatty acyl–CoA, and sterols are substrates of 80–kDa multifunctional protein. Adamski J, et al. **Steroids** 1997 Jan; 62(1):159–63

PHARMACOLOGY

Inhibition of UDP–glucuronosyltransferase activity by fatty acyl–CoA. Kinetic studies and structure–activity relationship. Yamashita A, et al. **Biochem Pharmacol** 1997 Feb 21;53(4):561–70

Inactivation of 3–hydroxy–3–methylglutaryl–CoA synthase and other Acyl–CoA–utilizing enzymes by 3–Oxobutylsulfoxyl–CoA. Charlier HA Jr, et al. **Biochemistry** 1997 Feb 11;36(6):1551–8

Inhibitory effect of acyl–CoA and acyl–carnitine compounds on the ischemia–inducing activity of Bordetella heat–labile toxin in guinea pig skin. Nagai M, et al. **Biol Pharm Bull** 1997 Feb;20(2):193–5

Inhibition of the mitochondrial KATP channel by long–chain acyl–CoA esters and activation by guanine nucleotides. Paucek P, et al. **J Biol Chem** 1996 Dec 13;271(50):32084–8

Effect of long–chain acyl–CoAs and acylcarnitines on gel–fluid and lamellar–hexagonal phospholipid phase transitions. Veiga MP, et al. **Mol Membr Biol** 1996 Jul–Sep; 13(3):165–72

PHYSIOLOGY

Role of long–chain fatty acyl–CoA esters in the regulation of metabolism and in cell signalling. Faergeman NJ, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):1–12 (185 ref.)

THERAPEUTIC USE

Likely gains in life expectancy of patients with coronary artery disease treated with HMG–CoA reductase inhibitors, as predicted by a decision analysis model. Kellett J. **Eur J Surg** 1997 Jul;163(7):539–46

ACYL COENZYME A SYNTHETASES see **COENZYME A SYNTHETASES**

ACYLATION

Myristoylation. Boutin JA. **Cell Signal** 1997 Jan;9(1):15–35 (326 ref.)

Oxidative acylation using thioacids. Liu R, et al. **Nature** 1997 Sep 4;389(6646):52–4

ACYLNEURAMINATE CYTIDYLYLTRANSFERASE

METABOLISM

Reaction engineering aspects of activated sugar production. CMP–Neu5Ac as an example. Kragl U, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:577–83

ACYLTRANSFERASES

ANALYSIS

Different distribution of dihydrolipoamide succinyltransferase, dihydrolipoamide acetyltransferase and ATP synthase beta–subunit in monkey brain. Takase C, et al. **In Vivo** 1996 Sep–Oct;10(5):495–501

Identification of extracellular phospholipase B, lysophospholipase, and acyltransferase produced by Cryptococcus neoformans. Chen SC, et al. **Infect Immun** 1997 Feb;65(2):405–11

Measurement of dihydroxyacetone–phosphate acyltransferase (DHAPAT) in chorionic villous samples, blood cells and cultured cells. Wanders RJ, et al. **J Inherit Metab Dis** 1995; 18 Suppl 1:90–100

In vivo modulation of N–myristoyltransferase activity by orthovanadate. King MJ, et al. **Mol Cell Biochem** 1995 Dec 6–20;153(1–2):151–5

ANTAGONISTS & INHIBITORS

Inhibitors of arachidonate metabolism and effects on PAF production. Winkler JD, et al. **Adv Exp Med Biol** 1996; 416:11–5

Substrate and inhibitor specificity of glutamine cyclotransferase (QC). Gololobov MY, et al. **Biol Chem Hoppe Seyler** 1996 Jun;377(6):395–8

Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA: protein N–myristoyltransferase: a new approach to antifungal therapy. Sikorski JA, et al. **Biopolymers** 1997;43(1):43–71 (58 ref.)

Palmitoyl carnitine, a lysophospholipase–transacylase inhibitor, prevents Candida adherence in vitro. Prakobphol A, et al. **FEMS Microbiol Lett** 1997 Jun 1;151(1):89–94

AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Boritzki TJ, et al. **Invest New Drugs**

1996;14(3):295–303
Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Mendelsohn LG, et al. **Invest New Drugs** 1996; 14(3):287–94
Viridiofungins, novel inhibitors of sphingolipid synthesis. Mandala SM, et al. **J Antibiot (Tokyo)** 1997 Apr; 50(4):339–43
Amidepsine E, an inhibitor of diacylglycerol acyltransferase produced by Humicola sp. FO–5969. Tomoda H, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):929–31
Design and synthesis of novel imidazole–substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N–myristoyltransferase and identification of related tripeptide inhibitors with mechanism–based antifungal activity. Devadas B, et al. **J Med Chem** 1997 Aug 1;40(16):2609–25
Conformationally constrained [p–(omega–aminoalkyl)phenacetyl]–L–seryl–L–lysyl dipeptide amides as potent peptidomimetic inhibitors of Candida albicans and human myristoyl–CoA:protein N–myristoyl transferase. Nagarajan SR, et al. **J Med Chem** 1997 May 9;40(10):1422–38
Protein structure–based design, synthesis, and biological evaluation of 5–thia–2,6–diamino–4(3H)–oxopyrimidines: potent inhibitors of glycinamide ribonucleotide transformylase with potent cell growth inhibition. Varney MD, et al. **J Med Chem** 1997 Aug 1;40(16):2502–24
Novel nonclassical inhibitors of glycinamide ribonucleotide formyltransferase: 10–formyl and 10–hydroxymethyl derivatives of 5,8,10–trideazapteroic acid. Liu L, et al. **J Mol Recognit** 1996 Mar–Apr;9(2):169–74
Inhibitors of coenzyme A–independent transacylase induce apoptosis in human HL–60 cells. Winkler JD, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):956–66
A protein tyrosine kinase associated with the ATP–dependent inactivation of adipose diacylglycerol acyltransferase. Lau TE, et al. **Lipids** 1996 Mar;31(3):277–83
N–myristoylation of Arf proteins in Candida albicans: an in vivo assay for evaluating antifungal inhibitors of myristoyl–CoA: protein N–myristoyltransferase. Lodge JK, et al. **Microbiology** 1997 Feb;143 (Pt 2):357–66

BIOSYNTHESIS

Ontogeny and location of HMG–CoA reductase, ACAT, and MGAT in human small intestine. Loirdighi N, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):G62–7
cDNA and genomic DNA clonings of chalcone synthase from Pueraria lobata. Nakajima O, et al. **Biol Pharm Bull** 1996 Jan;19(1):71–6
N–Myristoyltransferase overexpression in human colorectal adenocarcinomas. Raju RV, et al. **Exp Cell Res** 1997 Aug 25;235(1):145–54
Functional expression of the PHA synthase gene phaC1 from Pseudomonas aeruginosa in Escherichia coli results in poly(3–hydroxyalkanoate) synthesis. Langenbach S, et al. **FEMS Microbiol Lett** 1997 May 15;150(2):303–9
kan–1 (bile acid CoA:amino acid N–acyltransferase) messenger RNA as a novel predictive indicator for prognosis of hepatocellular carcinoma patients after partial hepatectomy. Furutani M, et al. **Hepatology** 1996 Dec; 24(6):1441–5
UV–B, UV–A, and blue light signal transduction pathways interact synergistically to regulate chalcone synthase gene expression in Arabidopsis. Fuglevand G, et al. **Plant Cell** 1996 Dec;8(12):2347–57
An ozone–responsive region of the grapevine resveratrol synthase promoter differs from the basal pathogen–responsive sequence. Schubert R, et al. **Plant Mol Biol** 1997 Jun;34(3):417–26
Overexpression of human N–myristoyltransferase utilizing a T7 polymerase gene expression system. Raju RV, et al. **Protein Expr Purif** 1996 Jun;7(4):431–7

CHEMISTRY

A human cDNA sequence with homology to non–mammalian lysophosphatidic acid acyltransferases. Stamps AC, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):455–61
Structural similarities between 6–methylsalicylic acid synthase from Penicillium patulum and vertebrate type I fatty acid synthase: evidence from thiol modification studies. Child CJ, et al. **Biochemistry** 1996 Sep 24; 35(38):12267–74
Solution structure of the actinorhodin polyketide synthase acyl carrier protein from Streptomyces coelicolor A3(2). Crump MP, et al. **Biochemistry** 1997 May 20;36(20):6000–8
Structure of crystalline Escherichia coli methionyl–tRNA(f)Met formyltransferase: comparison with glycinamide ribonucleotide formyltransferase. Schmitt E, et al. **EMBO J** 1996 Sep 2;15(17):4749–58
The disulfide bond in the Aeromonas hydrophila lipase/acyltransferase stabilizes the structure but is not required for secretion or activity. Brumlik MJ, et al. **J Bacteriol** 1997 May;179(10):3116–21
Determination of the sequence of the aralkyl acyl–CoA:amino acid N–acyltransferase from bovine liver mitochondria. Vessey DA, et al. **J Biochem Toxicol** 1996; 11(5):211–5
Scanning alanine mutagenesis and de–peptidization of a Candida albicans myristoyl–CoA:protein N–myristoyltransferase octapeptide substrate reveals three elements critical for molecular recognition. McWherter CA, et al. **J Biol Chem** 1997 May 2;272(18):11874–80
Expression in Escherichia coli and refolding of the malonyl–/acetyltransferase domain of the multifunctional animal fatty acid synthase. Rangan VS, et al. **J Biol Chem** 1996 Dec 6;271(49):31749–55
Glycinamide ribonucleotide transformylase undergoes pH–dependent dimerization. Mullen CA, et al. **J Mol Biol** 1996 Oct 11;262(5):746–55
Three–dimensional structure of the lipoyl domain from the dihydrolipoyl succinyltransferase component of the 2–oxoglutarate dehydrogenase multienzyme complex of Escherichia coli. Ricaud PM, et al. **J Mol Biol** 1996 Nov 22;264(1):179–90
Purification and characterization of human heart fatty acid ethyl ester synthase/carboxylesterase [published erratum appears in J Mol Cell Cardiol 1997 Jan;29(1):425–7] Bora PS, et al. **J Mol Cell Cardiol** 1996 Sep;28(9):2027–32
Lipoylation of acyltransferase components of 2–oxo acid dehydrogenase complexes. Quinn J. **Methods Enzymol** 1997;279:193–202 (25 ref.)
Combinatorial manipulation of three key active site residues in glycinamide ribonucleotide transformylase. Warren MS, et al. **Protein Eng** 1997 Jan;10(1):63–8
Crystallization and preliminary crystallographic analysis of tetrahydrodipicolinate–N–succinyltransferase. Binder DA, et al. **Proteins** 1996 Sep;26(1):115–7
Crystallization and preliminary X–ray analysis of Escherichia coli methionyl–tRNA(fMet) formyltransferase. Schmitt E, et al. **Proteins** 1996 May;25(1):139–41

DEFICIENCY

Barth syndrome may be due to an acyltransferase deficiency [letter] Neuwald AF. **Curr Biol** 1997 Aug 1;7(8):R465–6
Isolated dihydroxyacetonephosphate–acyl–transferase deficiency in rhizomelic chondrodysplasia punctata: clinical presentation, metabolic and histological findings. Hebestreit H, et al. **Eur J Pediatr** 1996 Dec;155(12):1035–9
Abnormal myelination in peroxisomal isolated dihydroxyacetonephosphate acyltransferase deficiency. Sztriha LS, et al. **Pediatr Neurol** 1997 Apr;16(3):232–6

GENETICS

Saccharomyces cerevisiae expresses two genes encoding isozymes of 5–aminoimidazole–4–carboxamide ribonucleotide transformylase. Tibbetts AS, et al. **Arch Biochem Biophys** 1997 Apr 15;340(2):195–200
Nucleotide sequence and functional analysis of the luxE gene encoding acyl–protein synthetase of the lux operon from Photobacterium leiognathi. Lin JW, et al. **Biochem Biophys Res Commun** 1996 Nov 21;228(3):764–73
A human cDNA sequence with homology to non–mammalian lysophosphatidic acid acyltransferases. Stamps AC, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):455–61
Molecular cloning and nucleotide sequencing of bioF (7–keto–8–amino pelargonic acid synthetase), bioC and bioD (dethiobiotin synthetase) genes of Erwinia herbicola. Wu CH, et al. **Biochem Mol Biol Int** 1997 Feb;41(2):311–5
RNA–mediated RNA degradation and chalcone synthase A silencing in petunia. Metzlaff M, et al. **Cell** 1997 Mar 21; 88(6):845–54
Increase of the expression of midecamycin 4"–hydroxyl propionyltransferase gene (mpt) by a promoter–like fragment from the midecamycin producing strain. Gu H, et al. **Chin J Biotechnol** 1996;12(3):147–52
Resveratrol: a molecule whose time has come? And gone? Soleas GJ, et al. **Clin Biochem** 1997 Mar;30(2):91–113 (183 ref.)
Barth syndrome may be due to an acyltransferase deficiency [letter] Neuwald AF. **Curr Biol** 1997 Aug 1;7(8):R465–6
Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine–induced signaling responses in cells. West J, et al. **DNA Cell Biol** 1997 Jun;16(6):691–701
Isolation of human purH gene expressed in the rodent transformant cells by subtractive enrichment of 3'–untranslated region of human transcript. Yamauchi M, et al. **DNA Res** 1995 Dec 31;2(6):269–75
An Escherichia coli gene divergently transcribed from a promoter overlapping the metA promoter. Gery S, et al. **FEMS Microbiol Lett** 1997 Sep 15;154(2):219–22
Sphingolipid synthesis: identification and characterization of mammalian cDNAs encoding the Lcb2 subunit of serine palmitoyltransferase. Nagiec MM, et al. **Gene** 1996 Oct 24; 177(1–2):237–41
Isolation and characterization of the Neisseria meningitidis lpxD–fabZ–lpxA gene cluster involved in lipid A biosynthesis. Steeghs L, et al. **Gene** 1997 May 6; 190(2):263–70
Arg538 to Cys mutation in a CpG dinucleotide of the human biotinidase gene is the second most common cause of profound biotinidase deficiency in symptomatic children. Pomponio RJ, et al. **Hum Genet** 1997 Apr;99(4):506–12
Cloning, sequencing, and oxygen regulation of the Rhodobacter capsulatus alpha–ketoglutarate dehydrogenase operon. Dastoor FP, et al. **J Bacteriol** 1997 Jul;179(14):4559–66
Open reading frame 3, which is adjacent to the mycocerosic acid synthase gene, is expressed as an acyl coenzyme A synthase in Mycobacterium bovis BCG. Fitzmaurice AM, et al. **J Bacteriol** 1997 Apr;179(8):2608–15
Cloning and analysis of the poly(3–hydroxybutyrate–co–3–hydroxyhexanoate) biosynthesis genes of Aeromonas caviae. Fukui T, et al. **J Bacteriol** 1997 Aug;179(15):4821–30
The rkpGHI and –J genes are involved in capsular polysaccharide production by Rhizobium meliloti. Kiss E, et al. **J Bacteriol** 1997 Apr;179(7):2132–40
Molecular characterization of the oafA locus responsible for acetylation of Salmonella typhimurium O–antigen: oafA is a member of a family of integral membrane trans–acylases. Slauch JM, et al. **J Bacteriol** 1996 Oct; 178(20):5904–9
Mutation of the htrB gene in a virulent Salmonella typhimurium strain by intergeneric transduction: strain construction and phenotypic characterization. Sunshine MG, et al. **J Bacteriol** 1997 Sep;179(17):5521–33
Amino acid and adenine cross–pathway regulation act through the same 5'–TGACTC–3' motif in the yeast HIS7 promoter. Springer C, et al. **J Biol Chem** 1996 Nov 22; 271(47):29637–43
Molecular cloning and characterization of two isoforms of Saccharomyces cerevisiae acyl–CoA:sterol acyltransferase. Yu C, et al. **J Biol Chem** 1996 Sep 27;271(39):24157–63
Sequence and expression of Drosophila myristoyl–CoA: protein N–myristoyl transferase: evidence for proteolytic processing and membrane localisation. Ntwasa M, et al. **J Cell Sci** 1997 Jan;110 (Pt 2):149–56
E2 transacylase–deficient (type II) maple syrup urine disease. Aberrant splicing of E2 mRNA caused by internal intronic deletions and association with thiamine–responsive phenotype. Chuang JL, et al. **J Clin Invest** 1997 Aug 1; 100(3):736–44
Cloning, expression, and chromosomal localization of mouse liver bile acid CoA:amino acid N–acyltransferase. Falany CN, et al. **J Lipid Res** 1997 Jun;38(6):1139–48
Cloning of the polyketide synthase gene atX from Aspergillus terreus and its identification as the 6–methylsalicylic acid synthase gene by heterologous expression. Fujii I, et al. **Mol Gen Genet** 1996 Nov 27;253(1–2):1–10
Molecular evolution and functional relevance of the chalcone synthase genes of pea. Ito M, et al. **Mol Gen Genet** 1997 Jun;255(1):28–37
Membrane glycerophospholipid biosynthesis in Neisseria meningitidis and Neisseria gonorrhoeae: identification, characterization, and mutagenesis of a lysophosphatidic acid acyltransferase. Swartley JS, et al. **Mol Microbiol** 1995 Nov;18(3):401–12
Induction of chalcone synthase expression by rhizobia and nod factors in root hairs and roots. Krause A, et al. **Mol Plant Microbe Interact** 1997 Apr;10(3):388–93
PHA synthase activity controls the molecular weight and polydispersity of polyhydroxybutyrate in vivo [see comments] Sim SJ, et al. **Nat Biotechnol** 1997 Jan; 15(1):63–7. Comment in: Nat Biotechnol 1997 Jan;15(1):17–8.
Intronic polyadenylation in the human glycinamide ribonucleotide formyltransferase gene. Kan JL, et al. **Nucleic Acids Res** 1997 Aug 1;25(15):3118–23
Distinct UV–B and UV–A/blue light signal transduction pathways induce chalcone synthase gene expression in Arabidopsis cells. Christie JM, et al. **Plant Cell** 1996 Sep; 8(9):1555–67
Modification of seed oil content and acyl composition in the brassicaceae by expression of a yeast sn–2 acyltransferase gene. Zou J, et al. **Plant Cell** 1997 Jun;9(6):909–23
Identification of new chalcone synthase genes for flower pigmentation in the Japanese and common morning glories. Fukada–Tanaka S, et al. **Plant Cell Physiol** 1997 Jun; 38(6):754–8
PcMYB1, a novel plant protein containing a DNA–binding domain with one MYB repeat, interacts in vivo with a light–regulatory promoter unit. Feldbrügge M, et al. **Plant J** 1997 May;11(5):1079–93
Functional dissection of a bean chalcone synthase gene promoter in transgenic tobacco plants reveals sequence motifs essential for floral expression. Faktor O, et al. **Plant Mol Biol** 1996 Dec;32(5):849–59
Chalcone synthase cosuppression phenotypes in petunia flowers: comparison of sense vs. antisense constructs and single–copy vs. complex T–DNA sequences. Jorgensen RA, et al. **Plant Mol Biol** 1996 Aug;31(5):957–73
Chalcone synthase in rice (Oryza sativa L.): detection of the CHS protein in seedlings and molecular mapping of the chs locus. Reddy AR, et al. **Plant Mol Biol** 1996 Nov; 32(4):735–43
Isolation of cDNAs encoding two purine biosynthetic enzymes of soybean and expression of the corresponding transcripts in roots and root nodules. Schnorr KM, et al. **Plant Mol Biol** 1996 Nov;32(4):751–7
An ozone–responsive region of the grapevine resveratrol synthase promoter differs from the basal pathogen–responsive sequence. Schubert R, et al. **Plant Mol Biol** 1997 Jun;34(3):417–26
Duplication and functional divergence in the chalcone synthase gene family of Asteraceae: evolution with substrate change and catalytic simplification. Helariutta Y, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9033–8
Assembly of an active enzyme by the linkage of two protein modules. Nixon AE, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1069–73
The common nodABC genes of Rhizobium meliloti are host–range determinants. Roche P, et al.

Proc Natl Acad Sci U S A 1996 Dec 24;93(26):15305–10
Cloning of the gene for monogalactosyldiacylglycerol synthase and its evolutionary origin. Shimojima M, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):333–7
Combinatorial manipulation of three key active site residues in glycinamide ribonucleotide transformylase. Warren MS, et al. **Protein Eng** 1997 Jan;10(1):63–8
Serine palmitoyltransferase (scs1/lcb2) mutants have elevated copy number of the L-A dsRNA virus. Garnepudi VR, et al. **Yeast** 1997 Mar 30;13(4):299–304

IMMUNOLOGY

Tubulointerstitial nephritis with renal tubular acidosis and asymptomatic primary biliary cirrhosis accompanied by antibody to a 52-kDa mitochondrial protein alone. Kodama T, et al. **Clin Nephrol** 1996 Jun;45(6):401–5

ISOLATION & PURIFICATION

The human glycinamide ribonucleotide transformylase domain: purification, characterization, and kinetic mechanism. Caperelli CA, et al. **Arch Biochem Biophys** 1997 May 1;341(1):98–103
Purification and characterization of rat liver microsomal fatty acid ethyl and 2-chloroethyl ester synthase and their relationship with carboxylesterase (pI 6.1). Kaphalia BS, et al. **Chem Res Toxicol** 1997 Feb;10(2):211–8
Purification, characterization and partial amino acid sequencing of hydroxycinnamoyl-CoA:tyramine N-(hydroxycinnamoyl)transferase from tobacco cell-suspension cultures. Negrel J, et al. **Eur J Biochem** 1997 Aug 1;247(3):1127–35
Purification and biochemical characterization of a protein-palmitoyl acyltransferase from human erythrocytes. Das AK, et al. **J Biol Chem** 1997 Apr 25; 272(17):11021–5
Purification and characterization of human heart fatty acid ethyl ester synthase/carboxylesterase. Bora PS, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):425
Immunopurification and characterization of a 40-kD 1-aminocyclopropane-1-carboxylic acid N-malonyltransferase from mung bean seedling hypocotyls. Chick WS, et al. **Plant Physiol** 1997 Jan; 113(1):119–26
Expression and analysis of a bacterial poly(hydroxyalkanoate) synthase in insect cells using a baculovirus system. Williams MD, et al. **Protein Expr Purif** 1996 Mar;7(2):203–11

METABOLISM

The human glycinamide ribonucleotide transformylase domain: purification, characterization, and kinetic mechanism. Caperelli CA, et al. **Arch Biochem Biophys** 1997 May 1;341(1):98–103
Regulation of hepatic lecithin:retinol acyltransferase activity by retinoic acid receptor-selective retinoids. Shimada T, et al. **Arch Biochem Biophys** 1997 Aug 1;344(1):220–7
Synthesis of sn-1,2-diacylglycerols by monoacylglycerol acyltransferase from Manduca sexta fat body. Arrese EL, et al. **Arch Insect Biochem Physiol** 1996;31(3):325–35
Cofactor role for 10-formyldihydrofolic acid. Baggott JE, et al. **Biochem J** 1995 Jun 15;308 (Pt 3):1031–6
Overt and latent activities of diacylglycerol acytransferase in rat liver microsomes: possible roles in very-low-density lipoprotein triacylglycerol secretion. Owen MR, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):17–21
Evidence for overt and latent forms of DGAT in rat liver microsomes. Implications for the pathways of triacylglycerol incorporation into VLDL. Owen M, et al. **Biochem Soc Trans** 1997 Feb;25(1):21S
Transacylase and phospholipases in the synthesis of bis(monoacylglycero)phosphate. Amidon B, et al. **Biochemistry** 1996 Nov 5;35(44):13995–4002
Three-dimensional structure of tetrahydrodipicolinate N-succinyltransferase. Beaman TW, et al. **Biochemistry** 1997 Jan 21;36(3):489–94
Titration calorimetric analysis of AcylCoA recognition by myristoylCoA:protein N-myristoyltransferase. Bhatnagar RS, et al. **Biochemistry** 1997 Jun 3;36(22):6700–8
Utilization of enzymatically phosphopantetheinylated acyl carrier proteins and acetyl-acyl carrier proteins by the actinorhodin polyketide synthase. Carreras CW, et al. **Biochemistry** 1997 Sep 30;36(39):11757–61
Formyl phosphate: a proposed intermediate in the reaction catalyzed by Escherichia coli PurT GAR transformylase. Marolewski AE, et al. **Biochemistry** 1997 Jun 3; 36(22):6709–16
Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase. Sanghani SP, et al. **Biochemistry** 1997 Aug 26;36(34):10506–16
Regulation of platelet-activating factor (PAF) biosynthesis via coenzyme A-independent transacylase in the macrophage cell line IC-21 stimulated with lipopolysaccharide. Svetlov SI, et al. **Biochim Biophys Acta** 1997 Jun 2;1346(2):120–30
A unique enzyme from Saccharothrix sp. catalyzing D-amino acid transfer. Watanabe Y, et al. **Biochim Biophys Acta** 1997 Jan 4;1337(1):40–6
Evidence that 85 kDa phospholipase A2 is not linked to CoA-independent transacylase-mediated production of platelet-activating factor in human monocytes. Winkler JD, et al. **Biochim Biophys Acta** 1997 Jun 2;1346(2):173–84
Substrate and inhibitor specificity of glutamine cyclotransferase (QC). Gololobov MY, et al. **Biol Chem Hoppe Seyler** 1996 Jun;377(6):395–8
Myristoylation. Boutin JA. **Cell Signal** 1997 Jan;9(1):15–35 (326 ref.)
Biotinidase and its roles in biotin metabolism. Hymes J, et al. **Clin Chim Acta** 1996 Nov 15;255(1):1–11 (64 ref.)
X-linked dominant chondrodysplasia punctata with decreased dihydroxyacetone phosphate acyltransferase activity. Sato M, et al. **Dermatology** 1996;192(1):23–7
Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Sugiura T, et al. **Eur J Biochem** 1996 Aug 15;240(1):53–62
Evaluation of biochemical indices as a hair cycle marker in C3H mice. Hamada K, et al. **Exp Anim** 1996 Jul;45(3):251–6
Microsomal diacylglycerol acyltransferase in rat parotid and submandibular glands: acylation of 1,2-dioleoyl-sn-glycerol dispersed with phospholipids. Yashiro K, et al. **Int J Biochem Cell Biol** 1996 Aug; 28(8):895–903
Polymerase C1 levels and poly(R-3-hydroxyalkanoate) synthesis in wild-type and recombinant Pseudomonas strains. Kraak MN, et al. **J Bacteriol** 1997 Aug; 179(16):4985–91
Control of poly-beta-hydroxybutyrate synthase mediated by acetyl phosphate in cyanobacteria. Miyake M, et al. **J Bacteriol** 1997 Aug;179(16):5009–13
Acyltransferases and transacylases involved in fatty acid remodeling of phospholipids and metabolism of bioactive lipids in mammalian cells. Yamashita A, et al. **J Biochem (Tokyo)** 1997 Jul;122(1):1–16 (149 ref.)
Aminoacyl-tRNA recognition by the leucyl/phenylalanyl-tRNA-protein transferase. Abramochkin G, et al. **J Biol Chem** 1996 Sep 13; 271(37):22901–7
Lipopolysaccharide biosynthesis in Rhizobium leguminosarum. Novel enzymes that process precursors containing 3-deoxy-D-manno-octulosonic acid. Brozek KA, et al. **J Biol Chem** 1996 Dec 13;271(50):32112–8
Human lysophosphatidic acid acyltransferase. cDNA cloning, expression, and localization to chromosome 9q34.3. Eberhardt C, et al. **J Biol Chem** 1997 Aug 8; 272(32):20299–305
Lysine 207 as the site of cross-linking between the 3'-end of Escherichia coli initiator tRNA and methionyl-tRNA formyltransferase. Gite S, et al. **J Biol Chem** 1997 Feb 21; 272(8):5305–12
A new metabolic link. The acyl carrier protein of lipid synthesis donates lipoic acid to the pyruvate dehydrogenase complex in Escherichia coli and mitochondria. Jordan SW, et al. **J Biol Chem** 1997 Jul 18;272(29):17903–6
Purification of a protein palmitoyltransferase that acts on H-Ras protein and on a C-terminal N-Ras peptide. Liu L, et al. **J Biol Chem** 1996 Sep 20;271(38):23269–76
Scanning alanine mutagenesis and de-peptidization of a Candida albicans myristoyl-CoA:protein N-myristoyltransferase octapeptide substrate reveals three elements critical for molecular recognition. McWherter CA, et al. **J Biol Chem** 1997 May 2;272(18):11874–80
Shortened hydroxyacyl chains on lipid A of Escherichia coli cells expressing a foreign UDP-N-acetylglucosamine O-acyltransferase. Odegaard TJ, et al. **J Biol Chem** 1997 Aug 8;272(32):19688–96
p260/270 expressed in embryonic abdominal leg cells of Bombyx mori can transfer palmitate to peptides. Ueno K, et al. **J Biol Chem** 1997 May 23;272(21):13519–26
cis-4-Methylsphingosine decreases sphingolipid biosynthesis by specifically interfering with serine palmitoyltransferase activity in primary cultured neurons. van Echten-Deckert G, et al. **J Biol Chem** 1997 Jun 20;272(25):15825–33
Molecular cloning and characterization of two isoforms of Saccharomyces cerevisiae acyl-CoA:sterol acyltransferase. Yu C, et al. **J Biol Chem** 1996 Sep 27;271(39):24157–63
N-(4-hydroxyphenyl)-retinamide increases lecithin:retinol acyltransferase activity in rat liver. Matsuura T, et al. **J Nutr** 1996 Oct;126(10):2474–80
Lecithin:retinol acyltransferase and retinyl ester hydrolase activities are differentially regulated by retinoids and have distinct distributions between hepatocyte and nonparenchymal cell fractions of rat liver. Matsuura T, et al. **J Nutr** 1997 Feb;127(2):218–24
Lack of lecithin: retinol acyltransferase activity in chick lungs. Takase S, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Aug;42(4):267–75
Developmental profile of mitochondrial glycine N-acyltransferase in human liver. Mawal Y, et al. **J Pediatr** 1997 Jun;130(6):1003–7
Lipoate addition to acyltransferases of alpha-keto acid dehydrogenase complexes and H-protein of glycine cleavage system. Fujiwara K, et al. **Methods Enzymol** 1997; 279:184–93 (23 ref.)
Coenzyme A dependent myristoylation and demyristoylation in the regulation of bovine spleen N-myristoyltransferase. Raju RV, et al. **Mol Cell Biochem** 1996 May 24; 158(2):107–13
Expression of human N-myristoyltransferase in Escherichia coli. Comparison with N-myristoyltransferases expressed in different tissues. Raju RV, et al. **Mol Cell Biochem** 1996 Feb 9;155(1):69–76
The NodA proteins of Rhizobium meliloti and Rhizobium tropici specify the N-acylation of Nod factors by different fatty acids. Debellé F, et al. **Mol Microbiol** 1996 Oct; 22(2):303–14
Independent interaction of the acyltransferase HlyC with two maturation domains of the Escherichia coli toxin HlyA. Stanley P, et al. **Mol Microbiol** 1996 May;20(4):813–22
Mutagenic analysis of 2,3-diaminophenazine and 2-amino-3-hydroxyphenazine in Salmonella strains expressing different levels of O-acetyltransferase with and without plant and mammalian activation. Wagner ED, et al. **Mutat Res** 1996 Nov 11;372(1):65–74
PHA synthase activity controls the molecular weight and polydispersity of polyhydroxybutyrate in vivo [see comments] Sim SJ, et al. **Nat Biotechnol** 1997 Jan; 15(1):63–7. Comment in: Nat Biotechnol 1997 Jan;15(1):17–8.
Regulation of acyltransferase activity in immature maize embryos by abscisic acid and the osmotic environment. Pacheco-Moisés F, et al. **Plant Physiol** 1997 Jul; 114(3):1095–101
COOH-terminal processing of nascent polypeptides by the glycosylphosphatidylinositol transamidase in the presence of hydrazine is governed by the same parameters as glycosylphosphatidylinositol addition. Ramalingam S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7528–33
Biosynthesis of triacylglycerols. Lehner R, et al. **Prog Lipid Res** 1996;35(2):169–201 (208 ref.)
Characterization of the malonyl-/acetyltransacylase domain of the multifunctional animal fatty acid synthase by expression in Escherichia coli and refolding in vitro. Rangan VS, et al. **Protein Eng** 1997 May;10(5):561–6
The delta 5-3 beta-hydroxy steroid acyl transferase activities in tissues of the male rat and sheep. Smith AJ, et al. **Steroids** 1997 May;62(5):422–6
[Preparation of the myristoylated and nonmyristoylated form of recombinant recoverin in E. coli cells and comparison of their functional activity] Zargarov AA, et al. **Bioorg Khim** 1996 Jul;22(7):483–8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

The distribution of fatty acid ethyl esters among lipoproteins and albumin in human serum. Bird DA, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):602–5
Ethyl palmitate and ethyl oleate are the predominant fatty acid ethyl esters in the blood after ethanol ingestion and their synthesis is differentially influenced by the extracellular concentrations of their corresponding fatty acids. Dan L, et al. **Alcohol Clin Exp Res** 1997 Apr; 21(2):286–92
Acyl-acyl carrier protein is a donor of fatty acids in the NodA-dependent step in biosynthesis of lipochitin oligosaccharides by rhizobia. Ritsema T, et al. **J Bacteriol** 1997 Jun;179(12):4053–5
Biochemical studies of Saccharomyces cerevisiae myristoyl-coenzyme A:protein N-myristoyltransferase mutants. Zhang L, et al. **J Biol Chem** 1996 Dec 20; 271(51):33131–40

SECRETION

The disulfide bond in the Aeromonas hydrophila lipase/acyltransferase stabilizes the structure but is not required for secretion or activity. Brumlik MJ, et al. **J Bacteriol** 1997 May;179(10):3116–21

ULTRASTRUCTURE

Glycinamide ribonucleotide transformylase undergoes pH-dependent dimerization. Mullen CA, et al. **J Mol Biol** 1996 Oct 11;262(5):746–55

ADAMANTANE

ANALOGS & DERIVATIVES

1-Acetyl-3-hydroxyadamantane and 1-carboxy-3-hydroxyadamantane. Rath NP, et al. **Acta Crystallogr C** 1997 Jul 15;53 (Pt 7):944–6
Effects of U-37883A, a vascular selective KATP+ channel antagonist, in the pulmonary and hindlimb circulation. DeWitt BJ, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):L924–31
Interactive effects of stimulation of D1 and D2 dopamine receptors on Fos expression in the lateral habenula. Wirtshafter D, et al. **Brain Res** 1997 Mar 7;750(1-2):245–50
Dopamine D1 receptor desensitization profile in MPTP-lesioned primates. Blanchet PJ, et al. **Eur J Pharmacol** 1996 Aug 1;309(1):13–20
An antagonist of ATP-regulated potassium channels, the guanidine derivative U-37883A, stimulates the synthesis of phosphatidylserine in rat liver endoplasmic reticulum membranes. Makowski P, et al. **FEBS Lett** 1997 Jun 9; 409(2):292–6
Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma. Boder N, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):115–22
Synthesis and bioactivity studies of 1-adamantanamine derivatives of peptides. Horvat S, et al. **J Pept Sci** 1995 Sep-Oct;1(5):303–10
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. Gully D, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):802–12

ADAMANTANE

Voltage-dependent interaction of open-channel blocking molecules with gating of NMDA receptors in rat cortical neurons. Antonov SM, et al. **J Physiol (Lond)** 1996 Jun 1;493 (Pt 2):425-45

Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. Barrie SE, et al. **J Steroid Biochem Mol Biol** 1997 Mar;60(5-6):347-51

Cardiovascular effects of the K-ATP channel blocker U-37883A and structurally related morpholinoguanidines. Humphrey SJ, et al. **Methods Find Exp Clin Pharmacol** 1996 May;18(4):247-60

Tumor cell cytolysis mediated by valorphin, an opioid-like fragment of hemoglobin beta-chain. Blishchenko EYu, et al. **Peptides** 1997;18(1):79-85

Behavioral effects of HT-90B, a putative novel anxiolytic agent with potent antidepressive activity. Inagawa K, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jan; 20(1):129-45

[Comparative study of the mechanism of inhibition of Sindbis virus reproduction by adamantane derivatives: remantadine and amide of 1-adamantane carboxylic acid] Andronova VL. **Antibiot Khimioter** 1996;41(7-8):26-30 (Eng. Abstr.) **(Rus)**

[Effect of the amide of 1-adamantanecarboxylic acid (AACA) and its combination with ribavirin on the course of experimental infection, caused by the sindbis virus in tissue culture and in mouse brain. Possible isolation of the virus mutant resistant to ribavirin and to a combination of the inhibitors] Andronova VL. **Antibiot Khimioter** 1997; 42(7):3-7 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Different modes of inhibition by adamantane amine derivatives and natural polyamines of the functionally reconstituted influenza virus M2 proton channel protein. Lin TI, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):767-74

ADAMANTINOMA see **AMELOBLASTOMA**

ADAMS-STOKES SYNDROME

[Adams-Stokes syndrome] Iijima M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):497-500 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

Conduction defect following pentavalent antimony therapy in visceral leishmaniasis [letter] Ahasan HA, et al. **Trop Doct** 1997 Jan;27(1):59-61

DIAGNOSIS

Geriatrics photo quiz. Stokes-Adams attack. Shua-Haim J, et al. **Geriatrics** 1997 Jun;52(6):75

Defibrillation conundrum. Nikolic G. **Heart Lung** 1996 Nov-Dec;25(6):495-6

DRUG THERAPY

[Digitoxin overdose with reversible thrombocytopenia] Dahmen KG, et al. **Med Klin** 1996 Dec 15;91(12):791-5 (35 ref.) **(Ger)**

ADAPTATION, BIOLOGICAL

Osmoadaptation by rhizosphere bacteria. Miller KJ, et al. **Annu Rev Microbiol** 1996;50:101-36 (167 ref.)

Alkaline stress response in Enterococcus faecalis: adaptation, cross-protection, and changes in protein synthesis. Flahaut S, et al. **Appl Environ Microbiol** 1997 Feb;63(2):812-4

Acid adaptation sensitizes Salmonella typhimurium to hypochlorous acid. Leyer GJ, et al. **Appl Environ Microbiol** 1997 Feb;63(2):461-7

Intestinal adaptation following massive small bowel resection in the mouse. Helmrath MA, et al. **J Am Coll Surg** 1996 Nov;183(5):441-9

Cellular and molecular physiology of Escherichia coli in the adaptation to aerobic environments. Iuchi S, et al. **J Biochem (Tokyo)** 1996 Dec;120(6):1055-63 (50 ref.)

Adaptive regulation of hepatic bile salt transport: role of bile salt hydrophobicity and microtubule-dependent vesicular pathway. Arrese M, et al. **J Hepatol** 1997 Mar; 26(3):694-702

Adaptive differentiations of the skin of the head in a subterranean rodent, Spalax ehrenbergi. Klauer G, et al. **J Morphol** 1997 Jul;233(1):53-66

Low-temperature damage and subsequent recovery of fab1 mutant Arabidopsis exposed to 2 degrees C. Wu J, et al. **Plant Physiol** 1997 Feb;113(2):347-56

[Bacterial adaptation to change in environmental pH] Kobayashi H. **Nippon Saikingaku Zasshi** 1996 Aug; 51(3):745-53 (36 ref.) **(Jpn)**

[Ecological aggression and adaptation mechanisms] Liubchenko PN. **Med Tr Prom Ekol** 1996;(11):1-5 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Enteral supplementation with ornithine alpha ketoglutarate improves the early adaptive response to resection. Czernichow B, et al. **Gut** 1997 Jan;40(1):67-72

[Development of the adaptive response in human cells exposed to cadmium chloride] Meliksetova IA, et al. **Dokl Akad Nauk** 1997 Jun;354(4):573-4 **(Rus)**

GENETICS

Conservation genetics. Frankham R. **Annu Rev Genet** 1995; 29:305-27 (170 ref.)

Genome-wide hypermutation in a subpopulation of stationary-phase cells underlies recombination-dependent adaptive mutation. Torkelson J, et al. **EMBO J** 1997 Jun 2;16(11):3303-11

Independent modulation of Arabidopsis thaliana polyubiquitin mRNAs in different organs and in response to environmental changes. Sun CW, et al. **Plant J** 1997 May;11(5):1017-27

PHYSIOLOGY

Quantitative evidence that both Hsc70 and Hsp70 contribute to thermal adaptation in hybrids of the livebearing fishes Poeciliopsis [published erratum appears in Cell Stress Chaperones 1996 Sep;1(3):207] diIorio PJ, et al. **Cell Stress Chaperones** 1996 Jun;1(2):139-47

Earliest phases in the evolution of sickness and healing. Fabrega H Jr. **Med Anthropol Q** 1997 Mar;11(1):26-55 (62 ref.)

ADAPTATION, MARGINAL (DENTISTRY) see **MARGINAL ADAPTATION (DENTISTRY)**

ADAPTATION, OCULAR

The mechanisms of vertebrate light adaptation: speeded recovery versus slowed activation. Detwiler PB, et al. **Curr Opin Neurobiol** 1996 Aug;6(4):440-4 (41 ref.)

Spectral plasticity of H1 horizontal cells in carp retina: independent modulation by dopamine and light-adaptation. Djamgoz MB, et al. **Eur J Neurosci** 1996 Aug;8(8):1571-9

Glucose metabolism in cat outer retina. Effects of light and hyperoxia. Wang L, et al. **Invest Ophthalmol Vis Sci** 1997 Jan;38(1):48-55

Role of remote adaptation in perceived subjective color. Rotgold G, et al. **J Opt Soc Am A** 1997 Jun;14(6):1223-30

Interpreting the prism adaptation study [letter; comment] Tennant JS. **Ophthalmology** 1996 Dec;103(12):1985. Comment on: Ophthalmology 1996 Jun;103(6):922-8.

The perceived direction of textured gratings and their motion aftereffects. Alais D, et al. **Perception** 1995;24(12):1383-96

Adaptation to spatial offsets. Hess RF, et al. **Perception** 1995; 24(12):1407-26

Spatial filter combination in human pattern vision: channel interactions revealed by adaptation. Meese TS, et al. **Perception** 1996;25(3):255-77

The aftereffect to relative motion does not show interocular transfer. Symons LA, et al. **Perception** 1996;25(6):651-60

Comparison of dark- and light-adapted carp retinas with NADPH diaphorase staining. Ye B, et al. **Sci China C Life Sci** 1996 Jun;39(3):251-7

High refresh rate and oculomotor adaptation facilitate reading from video displays. Montegut MJ, et al. **Spat Vis** 1997;10(4):305-22

Direction repulsion in motion transparency. Hiris E, et al. **Vis Neurosci** 1996 Jan-Feb;13(1):187-97

Enduring stereoscopic motion aftereffects induced by prolonged adaptation. Bowd C, et al. **Vision Res** 1996 Nov; 36(22):3655-60

DRUG EFFECTS

Influence of picrotoxin and strychnine on the spectral sensitivity of the turtle ERG b- and d-waves: II. Light adaptation. Vitanova L, et al. **Acta Physiol Scand** 1997 Mar; 159(3):227-35

Serotonin agonists mimic the phase shifting effects of light on the melatonin rhythm in rats. Kennaway DJ, et al. **Brain Res** 1996 Oct 21;737(1-2):301-7

PHYSIOLOGY

Electroretinography of central retinal vein occlusion under scotopic and photopic conditions: what to measure? Williamson TH, et al. **Acta Ophthalmol Scand** 1997 Feb; 75(1):48-53

Dopaminergic behaviour in chicken retina and the effect of form deprivation. Megaw PL, et al. **Aust N Z J Ophthalmol** 1997 May;25 Suppl 1:S76-8

A fundamental step-transition in retinal function at low light intensities. Morgan IG, et al. **Aust N Z J Ophthalmol** 1997 May;25 Suppl 1:S70-2 (15 ref.)

Both high- and low voltage-activated calcium currents contribute to the light-evoked responses of luminosity horizontal cells in the Xenopus retina. Akopian A, et al. **Brain Res** 1997 Jul 11;762(1-2):121-30

Pyroglutamyl peptidase I levels and their left-right distribution in the rat retina and hypothalamus are influenced by light-dark conditions. Sánchez B, et al. **Brain Res** 1996 Aug 26;731(1-2):254-7

Anti-arrestin immunoreactivity in the human retina: difference between light- and dark-adaptation. Loeffler KU, et al. **Curr Eye Res** 1995 Dec;14(12):1165-8

Factors that influence the increase in the electroretinogram 30-Hz flicker amplitude during light adaptation. Raether K, et al. **Ger J Ophthalmol** 1996 Sep;5(5):285-8

Adaptation to monocular torsion after macular translocation. Seaber JH, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Feb;235(2):76-81

Using two preferred retinal loci for different lighting conditions in patients with central scotomas. Lei H, et al. **Invest Ophthalmol Vis Sci** 1997 Aug;38(9):1812-8

Persistent activation of transducin by bleached rhodopsin in salamander rods. Matthews HR, et al. **J Gen Physiol** 1996 Dec;108(6):557-63

Dynamics of adaptation at high luminances: adaptation is faster after luminance decrements than after luminance increments. Poot L, et al. **J Opt Soc Am A** 1997 Sep; 14(9):2499-508

Rapid sensitivity changes on flickering backgrounds: tests of models of light adaptation. Wu S, et al. **J Opt Soc Am A** 1997 Sep;14(9):2367-78

Phase-shifted direction adaptation of the vestibulo-ocular reflex in cat. Powell KD, et al. **J Vestib Res** 1996 Jul-Aug; 6(4):277-93

Adaptation of colour vision to sunlight [letter] Jordan G, et al. **Nature** 1997 Mar 13;386(6621):135-6

Changes in NADPH diaphorase reactivity and neuronal nitric oxide synthase in the rat retina following constant illumination. Goldstein J, et al. **Neurosci Lett** 1997 Aug 1;231(1):45-8

Tonic vergence and vergence adaptation. Rosenfield M. **Optom Vis Sci** 1997 May;74(5):303-28 (188 ref.)

Hard contact lenses alter accommodative gain but do not prevent refractive adaptation in chicks. Schmid KL, et al. **Optom Vis Sci** 1997 Jan;74(1):20-7

Influence of constant light and darkness on arginyl aminopeptidase activity. Sánchez B, et al. **Rev Esp Fisiol** 1997 Jun;53(2):249-50

Stochastic retinal mechanisms of light adaptation and gain control. Rudd ME, et al. **Spat Vis** 1996;10(2):125-48

Monocular mechanisms determine plaid motion coherence. Alais D, et al. **Vis Neurosci** 1996 Jul-Aug;13(4):615-26

The influence of center-surround antagonism on light adaptation in cones in the retina of the turtle. Burkhardt DA. **Vis Neurosci** 1995 Sep-Oct;12(5):877-85

Contrast adaptation and excitatory amino acid receptors in cat striate cortex. McLean J, et al. **Vis Neurosci** 1996 Nov-Dec;13(6):1069-87

Effects of adaptation level and hypoglycemia on function of the cat retina during hypoxemia. McRipley MA, et al. **Vis Neurosci** 1997 Mar-Apr;14(2):339-50

Adaptation of visually evoked responses of relay cells in the dorsal lateral geniculate nucleus of the cat following prolonged exposure to drifting gratings. Shou T, et al. **Vis Neurosci** 1996 Jul-Aug;13(4):605-13

Modulation of endogenous dopamine release in the fish retina by light and prolonged darkness. Weiler R, et al. **Vis Neurosci** 1997 Mar-Apr;14(2):351-6

Volume transmission of dopamine may modulate light-adaptive plasticity of horizontal cell dendrites in the recovery phase following dopamine depletion in goldfish retina. Yazulla S, et al. **Vis Neurosci** 1995 Sep-Oct; 12(5):827-36

NADPH diaphorase activity in mammalian retinas is modulated by the state of visual adaptation. Zemel E, et al. **Vis Neurosci** 1996 Sep-Oct;13(5):863-71

Adaptation to peripheral flicker. Anstis S. **Vision Res** 1996 Nov;36(21):3479-85

Adaptation-dependent changes of bipolar cell terminals in fish retina: effects on overall morphology and spinule formation in Ma and Mb cells. Behrens UD, et al. **Vision Res** 1996 Dec;36(24):3901-11

Specificity of saccadic adaptation in three-dimensional space. Chaturvedi V, et al. **Vision Res** 1997 May;37(10):1367-82

A model of temporal adaptation in fly motion vision. Clifford CW, et al. **Vision Res** 1996 Aug;36(16):2595-608

Perceptual stability and the selective adaptation of perceived and unperceived motion directions. Hock HS, et al. **Vision Res** 1996 Oct;36(20):3311-23

Probed-sinewave paradigm: a test of models of light-adaptation dynamics. Hood DC, et al. **Vision Res** 1997 May;37(9):1177-91

Cyclopean and disconjugate adaptive recovery from post-saccadic drift in strabismic children before and after surgery. Inchingolo P, et al. **Vision Res** 1996 Sep; 36(18):2897-913

The size of the horizontal cell receptive fields adapts to the stimulus in the light adapted goldfish retina. Kamermans M, et al. **Vision Res** 1996 Dec;36(24):4105-19

Disconjugate adaptation of the vertical oculomotor system. Kapoula Z, et al. **Vision Res** 1996 Sep;36(17):2735-45

Horizontal cell spinule dynamics in fish are affected by rearing in monochromatic light. Kröger RH, et al. **Vision Res** 1996 Dec;36(24):3879-89

Context-specific adaptation of vertical vergence to correlates of eye position. Schor CM, et al. **Vision Res** 1997 Jul; 37(14):1929-37

Color contrast under controlled chromatic adaptation reveals opponent rectification. Smith VC, et al. **Vision Res** 1996 Oct;36(19):3087-105

Adaptation to the prismatic effects of refractive lenses. Tuan KM, et al. **Vision Res** 1997 Jul;37(13):1851-7

Gain control and hyperpolarization level in cat horizontal cells as a function of light and dark adaptation. van de Grind WA, et al. **Vision Res** 1996 Dec;36(24):3969-85

Modulation of horizontal cell receptive fields in the light adapted goldfish retina. Verweij J, et al. **Vision Res** 1996 Dec;36(24):3913-23

Color appearance changes resulting from iso-luminant

chromatic adaptation. Wuerger SM. **Vision Res** 1996 Oct; 36(19):3107–18

[Spontaneous and visually–induced oculomotor reactions in microgravity (Results of Austrian–Russian Experiment "Optovert" performed within the frame of program "Austromir", part II)] Kornilova LN, et al. **Aviakosm Ekolog Med** 1996;30(1):10–6 (Eng. Abstr.) **(Rus)**

ADAPTATION, PHYSIOLOGICAL

Short–term adaptation of excitation and inhibition shapes binaural processing. Finlayson PG, et al. **Acta Otolaryngol (Stockh)** 1997 Mar;117(2):187–91

The capillarity of the subendocardium of left ventricle in rats reared at a low temperature for many generations. Gao M, et al. **Acta Physiol Scand** 1997 May;160(1):67–70

Adaptation of caprinised rinderpest virus to grow in Vero cells in vitro. Parida MM, et al. **Acta Virol** 1996 Feb; 40(1):45–8

The step–by–step development of epithelial cancer: from phenotype to genotype. Farber E. **Adv Cancer Res** 1996; 70:21–48 (162 ref.)

The changes of skin and mesenteric microvascular permeability in adaptation to hypoxia in rats. Dubina MV, et al. **Adv Exp Med Biol** 1996;388:363–6

Adaptation and nutritional needs [letter; comment] Bronner F. **Am J Clin Nutr** 1997 May;65(5):1570. Comment on: Am J Clin Nutr 1996 Apr;63(4):579–83. Comment on: Am J Clin Nutr 1996 Nov;64(5):826–8.

Transition from compensatory hypertrophy to dilated failing left ventricle in Dahl–Iwai salt–sensitive rats. Kihara Y, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):78S–82S

Locomotor adaptations reflected in the wrist joints of early tertiary primates (adapiformes). Hamrick MW. **Am J Phys Anthropol** 1996 Aug;100(4):585–604

Fueguian cranial morphology: the adaptation to a cold, harsh environment. Hernández M, et al. **Am J Phys Anthropol** 1997 May;103(1):103–17

Hindlimb suspension and hind foot reversal in Varecia variegata and other arboreal mammals. Meldrum DJ, et al. **Am J Phys Anthropol** 1997 May;103(1):85–102 (35 ref.)

Central V1 AVP receptors are involved in cardiovascular adaptation to hypovolemia in WKY but not in SHR. Budzikowski AS, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1057–64

Adaptations of intestinal nutrient transport to chronic caloric restriction in mice. Casirola DM, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):G192–200

Influence of age on the sympathetic neural adjustments to alterations in systemic oxygen levels in humans. Davy KP, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R690–5

Analysis of cloned cDNAs differentially expressed in adapting remnant small intestine after partial resection. Dodson BD, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G347–56

Adaptation to low–K+ media increases H(+)–K(+)–ATPase but not H(+)–ATPase–mediated pHi recovery in OMCD1 cells. Guntupalli J, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C558–71

Metabolic adaptation to protein restriction in insulin–dependent diabetes mellitus. Hoffer LJ, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E59–67

Oxidative damage and antioxidants in Rana sylvatica, the freeze–tolerant wood frog. Joanisse DR, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R545–53

Adaptations of glutathione antioxidant system to endurance training are tissue and muscle fiber specific. Leeuwenburgh C, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R363–9

Atrial natriuretic peptide and sodium homeostasis in compensated heart failure. Lohmeier TE, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1353–63

Short–day–like body weight changes do not prevent fat pad compensation after lipectomy in Siberian hamsters. Mauer MM, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R68–77

Hemorrhage induces acute cardioadaptation to ischemia–reperfusion by an alpha1–adrenoceptor–mediated, protein synthesis–independent mechanism. Meldrum DR, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R718–25

Dynamics of myocardial adaptation to low–flow ischemia and hypoxemia. Merati G, et al. **Am J Physiol** 1996 Dec; 271(6 Pt 2):H2300–5

Differential activation of NF–kappa B in human aortic endothelial cells conditioned to specific flow environments. Mohan S, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C572–8

Progressive effect of endurance training on metabolic adaptations in working skeletal muscle. Phillips SM, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):E265–72

Enterocytic gene expression in intestinal adaptation: evidence for a specific cellular response. Rubin DC, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):G143–52

Mechanisms compensating Na and water retention induced by long–term reduction of renal perfusion pressure. Seeliger E, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R646–54

Adaptation to fat markedly increases pancreatic secretory response to intraduodenal fat in rats. Spannagel AW, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):G128–35

Lack of antioxidant adaptation to short–term aerobic training in human muscle. Tiidus PM, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R832–6

Early collateral and microvascular adaptations to intestinal artery occlusion in rat. Unthank JL, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H914–23

Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease. Maltais F, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):555–61

The effect of continuing regular endurance exercise on the physiologic adaptations to pregnancy and pregnancy outcome. Clapp JF 3rd. **Am J Sports Med** 1996;24(6 Suppl):S28–9

Neuromuscular adaptations in isokinetic, isotonic, and agility training programs. Wojtys EM, et al. **Am J Sports Med** 1996 Mar–Apr;24(2):187–92

Endothelial cell adaptation to chronic thrombosis. Rose DA, et al. **Am J Surg** 1997 Aug;174(2):210–3

Skin morphology and cytology in marine eels adapted to different lifestyles. Fishelson L. **Anat Rec** 1996 Sep; 246(1):15–29

Evidence of structural and material adaptation to specific strain features in cortical bone. Skedros JG, et al. **Anat Rec** 1996 Sep;246(1):47–63

Characteristics of compensatory hypertrophied muscle in the rat: I. Electron microscopic and immunohistochemical studies. Tamaki T, et al. **Anat Rec** 1996 Nov;246(3):325–34

Characteristics of compensatory hypertrophied muscle in the rat: II. Comparison of histochemical and functional properties. Tamaki T, et al. **Anat Rec** 1996 Nov; 246(3):335–42

Lip adaptation to simulated dental arch expansion. Part 2: One week of simulated expansion. Moawad MI, et al. **Angle Orthod** 1996;66(4):255–60

Lip adaptation to simulated dental arch expansion. Part 1: Reliability and precision of two lip pressure measurement mechanisms. Shellhart WC, et al. **Angle Orthod** 1996; 66(4):249–54

A prospective study of lip adaptation during six months of simulated mandibular dental arch expansion. Shellhart WC, et al. **Angle Orthod** 1997;67(1):47–54

Adaptive defense of the organism. Architecture of the structural trace and cross protective effects of adaptation. Meerson FZ, et al. **Ann N Y Acad Sci** 1996 Sep 30; 793:371–85 (40 ref.)

Adaptation to sublethal environmental stresses protects Listeria monocytogenes against lethal preservation factors. Lou Y, et al. **Appl Environ Microbiol** 1997 Apr;63(4):1252–5

The energetic cost of photoreception in retinal rods of mammals. Demontis GC, et al. **Arch Ital Biol** 1997 Mar; 135(2):95–109

Mechanical work adaptations of above–knee amputee ambulation. Seroussi RE, et al. **Arch Phys Med Rehabil** 1996 Nov;77(11):1209–14

Quantitative ultrasonography of muscle: detection of adaptations to training in elderly women. Sipilä S, et al. **Arch Phys Med Rehabil** 1996 Nov;77(11):1173–8

Absence of rapid adaptation of the exocrine pancreas of conscious dogs to diets enriched in fat or carbohydrates. Mañas M, et al. **Arch Physiol Biochem** 1996 Dec; 104(7):819–25

Exocrine pancreatic secretion in suckling goats. Adaptative effects of maternal milk and a milk substitute. Naranjo JA, et al. **Arch Physiol Biochem** 1997 Apr;105(2):190–6

Long–term effects on lipid metabolism in miniature swine (Sus scrofa) of diets enriched in saturated, monounsaturated and polyunsaturated (N–6 and N–3) fatty acids. Seiquer I, et al. **Arch Physiol Biochem** 1996;104(1):20–9

Effects of the amount and type of dietary fat on exocrine pancreatic secretion in dogs after different periods of adaptation. Yago MD, et al. **Arch Physiol Biochem** 1997 Feb;105(1):78–85

Pointing arm movements in short– and long–term spaceflights. Berger M, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):781–7

Effects of exercise mode on hematologic adaptations to endurance training in adult females. Branch JD 3rd, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):788–94

An engineering approach to miogravity syndrome. Sieving DL. **Aviat Space Environ Med** 1997 Apr;68(4):346–8 (25 ref.)

Pointing at memorized targets during prolonged microgravity. Watt DG. **Aviat Space Environ Med** 1997 Feb;68(2):99–103

Mechanisms of adaptive supersensitivity: correlation of guinea pig atrial supersensitivity with modifications in adenylyl cyclase activity. Roberts MI, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):347–56

Trypsin and trypsinogen from an Antarctic fish: molecular basis of cold adaptation. Genicot S, et al. **Biochim Biophys Acta** 1996 Nov 14;1298(1):45–57

On Hebbian–like adaptation in heart muscle: a proposal for 'cardiac memory'. Chakravarthy SV, et al. **Biol Cybern** 1997 Mar;76(3):207–15

Potential of microsensor–based feedback bioactuators for biophysical cancer treatment. Wolf B, et al. **Biosens Bioelectron** 1997;12(4):301–9 (58 ref.)

Transmission of acquired adjustments to salinity in Sorghum bicolor. Seligmann H. **Biosystems** 1997;40(3):257–61

Adaptive changes in trabecular architecture in relation to functional strain patterns and disuse. Biewener AA, et al. **Bone** 1996 Jul;19(1):1–8

Different loads can produce similar bone density distributions. Fischer KJ, et al. **Bone** 1996 Aug;19(2):127–35

Dynamic relationships of trabecular bone density, architecture, and strength in a computational model of osteopenia. Siffert RS, et al. **Bone** 1996 Feb;18(2):197–206

Adaptation to differential loading: comparison of growth–related changes in cross–sectional properties of the human femur and humerus. Sumner DR, et al. **Bone** 1996 Aug;19(2):121–6

Tissue adaptation as a dynamical process far from equilibrium. Weinans H, et al. **Bone** 1996 Aug;19(2):143–9 (75 ref.)

Maternal manipulation of brown adipose tissue and liver development in the ovine fetus during late gestation. Clarke L, et al. **Br J Nutr** 1997 Jun;77(6):871–83

Metabolic adaptation to fat–supplemented diet by the thoroughbred horse. Orme CE, et al. **Br J Nutr** 1997 Sep; 78(3):443–58

Effect of prewarming in the cold season on thermoregulatory responses during exercise. Torii M, et al. **Br J Sports Med** 1996 Jun;30(2):102–11

Muscle activity adapts to anti–gravity posture during pedalling in persons with post–stroke hemiplegia. Brown DA, et al. **Brain** 1997 May;120 (Pt 5):825–37

Changes in apical organization of choroidal cells in rats adapted to spaceflight or head–down tilt. Gabrion J, et al. **Brain Res** 1996 Sep 23;734(1–2):301–15

Hypoxia triggers neuroprotective alterations in hippocampal gene expression via a heme–containing sensor. Gage AT, et al. **Brain Res** 1996 May 6;719(1–2):172–8

Graded expression of immunomolecules on activated microglia in the hippocampus following ischemia in a rat model of ischemic tolerance. Kato H, et al. **Brain Res** 1995 Oct 2;694(1–2):85–93

Orienting a spatial attention––its reflexive, compensatory, and voluntary mechanisms. Hikosaka O, et al. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):1–9 (32 ref.)

Fish antioxidant defenses––a comparative approach. Wilhelm Filho D. **Braz J Med Biol Res** 1996 Dec;29(12):1735–42

The heart of the icefish: bioconstruction and adaptation. Zummo G, et al. **Braz J Med Biol Res** 1995 Nov–Dec; 28(11–12):1265–76 (40 ref.)

Cardiac hypertrophy, arrhythmogenicity and the new myocardial phenotype. II. The cellular adaptational process. Swynghedauw B, et al. **Cardiovasc Res** 1997 Jul; 35(1):6–12 (43 ref.)

Moratorium on mayhem lest there be a requiem. Weber KT. **Cardiovasc Res** 1997 Jul;35(1):4–5 (43 ref.)

Structural plasticity of optic synapses in the rat suprachiasmatic nucleus: adaptation to long–term influence of light and darkness. Güldner FH, et al. **Cell Tissue Res** 1997 Jan;287(1):43–60

Adaptation of lung antioxidants to cigarette smoking in humans. Hilbert J, et al. **Chest** 1996 Oct;110(4):916–20

Myocyte adaptation to chronic hypoxia and development of tolerance to subsequent acute severe hypoxia. Silverman HS, et al. **Circ Res** 1997 May;80(5):699–707

Skeletal muscle and cardiovascular adaptations to exercise conditioning in older coronary patients. Ades PA, et al. **Circulation** 1996 Aug 1;94(3):323–30

Metabolic adaptation during a sequence of no–flow and low–flow ischemia. A possible trigger for hibernation. Ferrari R, et al. **Circulation** 1996 Nov 15;94(10):2587–96

Significant difference of focal compensatory enlargement process between human coronary arteries and coronary saphenous vein bypass grafts [letter; comment] Friedrich GJ, et al. **Circulation** 1996 Dec 1;94(11):2987–8. Comment on: Circulation 1996 Feb 15;93(4):683–90.

Cardiac atrophy after bed–rest deconditioning: a nonneural mechanism for orthostatic intolerance. Levine BD, et al. **Circulation** 1997 Jul 15;96(2):517–25

Absence of focal compensatory enlargement or constriction in bypass grafts [letter; comment] Mendelsohn FO, et al. **Circulation** 1996 Dec 1;94(11):3005–6. Comment on: Circulation 1996 Feb 15;93(4):683–90.

Contribution of inadequate arterial remodeling to the development of focal coronary artery stenoses. An intravascular ultrasound study. Mintz GS, et al. **Circulation** 1997 Apr 1;95(7):1791–8

Spectral analysis of blood pressure and heart rate, catecholamine and neuropeptide Y plasma levels in a new model of neurogenic orthostatic hypotension in dog. Verwaerde P, et al. **Clin Auton Res** 1996 Apr;6(2):75–82

Compensatory and adaptive changes in microcirculation and left ventricular function of patients with chronic iron–deficiency anaemia. Georgieva Z, et al. **Clin Hemorheol Microcirc** 1997 Jan–Feb;17(1):21–30

Nutrients and intestinal adaptation. Thomson AB, et al. **Clin Invest Med** 1996 Oct;19(5):331–45 (140 ref.)

Isolation and characterization of two cDNAs from Atlantic cod encoding two distinct psychrophilic elastases. Gudmundsdóttir E, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Apr; 113(4):795–801

Metabolic adaptations supporting anoxia tolerance in reptiles: recent advances. Storey KB. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):23–35 (92 ref.)

Danger – pathogen on the premises! Immunological tolerance. Janeway CA Jr, et al. **Curr Biol** 1996 May 1; 6(5):519–22 (20 ref.)

Retinal physiology: adapting to the changing scene. Shapley R. **Curr Biol** 1997 Jul 1;7(7):R421–3 (14 ref.)

Compensation for spectacle lenses involves changes in proteoglycan synthesis in both the sclera and choroid [published erratum appears in Curr Eye Res 1997 Jun;16(6):624–5] Nickla DL, et al. **Curr Eye Res** 1997 Apr;

16(4):320–6
Starvation for a specific amino acid induces high frequencies of rho– mutants in Saccharomyces cerevisiae. Heidenreich E, et al. **Curr Genet** 1997 May;31(5):408–13
Cellular and molecular biology of vascular remodeling. Cowan DB, et al. **Curr Opin Lipidol** 1996 Apr;7(2):94–100 (54 ref.)
Barrier recompensation mechanisms. Grunewald AM, et al. **Curr Probl Dermatol** 1996;25:206–13
Physiologic response of chronically inflamed and accommodated human skin. Rietschel RL. **Curr Probl Dermatol** 1995;23:104–7
Sperm competition: evolution and mechanisms. Birkhead TR. **Curr Top Dev Biol** 1996;33:103–58 (163 ref.)
Adaptation of cellular metabolism to anisosmotic conditions in a glial cell line, as assessed by 13C–NMR spectroscopy. Flögel U, et al. **Dev Neurosci** 1996;18(5–6):449–59
Cerebral energy metabolism, glucose transport and blood flow: changes with maturation and adaptation to hypoglycaemia. Nehlig A. **Diabetes Metab** 1997 Feb; 23(1):18–29 (133 ref.)
Adaptation of esophageal mucosa to acid– and pepsin–induced damage: role of nitric oxide and epidermal growth factor. Lanas AI, et al. **Dig Dis Sci** 1997 May; 42(5):1003–12
Adaptation of intestinal nutrient transport in health and disease. Part I. Thomson AB, et al. **Dig Dis Sci** 1997 Mar; 42(3):453–69 (254 ref.)
Adaptation of intestinal nutrient transport in health and disease. Part II. Thomson AB, et al. **Dig Dis Sci** 1997 Mar; 42(3):470–88 (271 ref.)
Motor control research in rehabilitation medicine. Latash ML, et al. **Disabil Rehabil** 1996 Jun;18(6):293–9 (40 ref.)
Cerebellar afferents to neuroendocrine cells: implications for adaptive responses to simulated weightlessness. Katafuchi T, et al. **Endocr J** 1995 Dec;42(6):729–37 (42 ref.)
The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Glinoer D. **Endocr Rev** 1997 Jun;18(3):404–33 (276 ref.)
Correlative morphometry and morphology of normal equine intestinal mucosa and comparison after adaptation to extensive large colon resection. Bertone AL, et al. **Equine Vet J Suppl** 1989 Jun;(7):46–51
Adaptations to daily exercise in hot and humid ambient conditions in trained thoroughbred horses. Geor RJ, et al. **Equine Vet J Suppl** 1996 Jul;(22):63–8
Cardiorespiratory adaptations in neonatal foals. Rose RJ. **Equine Vet J Suppl** 1988 Sep;(5):11–3 (24 ref.)
Adaptation of maximal aerobic and anaerobic tests for disabled swimmers. Pelayo P, et al. **Eur J Appl Physiol** 1995;71(6):512–17
Cardiorespiratory and metabolic adaptations to hyperoxic training. Ploutz–Snyder LL, et al. **Eur J Appl Physiol** 1996; 73(1–2):38–48
Are region–specific changes in fibre types attributable to nonuniform muscle hypertrophy by overloading? Sakuma K, et al. **Eur J Appl Physiol** 1995;71(6):499–504
Pre–adaptation, adaptation and de–adaptation to high altitude in humans: cardio–ventilatory and haematological changes. Savourey G, et al. **Eur J Appl Physiol** 1996;73(6):529–35
Enzymes from cold–adapted microorganisms. The class C beta–lactamase from the antarctic psychrophile Psychrobacter immobilis A5. Feller G, et al. **Eur J Biochem** 1997 Feb 15;244(1):186–91
Energy intake adaptation of food intake to extreme energy densities of food by obese and non–obese women. Westerterp–Plantenga MS, et al. **Eur J Clin Nutr** 1996 Jun; 50(6):401–7
Remarks on specific adaptive scale structure of the hair cuticle in some European bats. Meyer W, et al. **Eur J Morphol** 1995 Nov;33(5):509–13
Clinical and immunological condition of newborns of mothers treated for recurrent spontaneous abortions with paternal lymphocytes immunization. Malinowski A, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 May;73(1):55–61
Neurotensin increases intestinal adaptation and reduces enteroglucagon–like immunoreactivity after large bowel resection in rats. Mata A, et al. **Eur J Surg** 1997 May; 163(5):387–93
No differences in mucosal adaptive growth one week after intestinal resection in rats given enteral glutamine supplementation or deprived of glutamine. Wirén ME, et al. **Eur J Surg** 1996 Jun;162(6):489–98
Interaction of linear and angular vestibulo–ocular reflexes of human subjects in response to transient motion. Anastasopoulos D, et al. **Exp Brain Res** 1996 Aug; 110(3):465–72
Adaptation of the precentral cortical command to elbow muscle fatigue. Belhaj–Saïf A, et al. **Exp Brain Res** 1996 Oct;111(3):405–16
Effects of early cerebellar removal on the classically conditioned bradycardia of adult rabbits. Ghelarducci B, et al. **Exp Brain Res** 1996 Oct;111(3):417–23
Adaptation to gradual as compared with sudden visuo–motor distortions. Kagerer FA, et al. **Exp Brain Res** 1997 Jul; 115(3):557–61
On the short–term adaptation of eye saccades and its transfer to head movements. Kröller J, et al. **Exp Brain Res** 1996 Oct;111(3):477–82
Neuromuscular activation patterns during treadmill walking after space flight. Layne CS, et al. **Exp Brain Res** 1997 Jan;113(1):104–16
Anticipatory locomotor adjustments for accommodating versus avoiding level changes in humans. McFadyen BJ, et al. **Exp Brain Res** 1997 May;114(3):500–6
Inter– and intra–limb coordination in arm tremor. Morrison S, et al. **Exp Brain Res** 1996 Aug;110(3):455–64
Adaptive modifications of human postsaccadic pursuit eye movements induced by a step–ramp–ramp paradigm. Ogawa T, et al. **Exp Brain Res** 1997 Aug;116(1):83–96
Adaptational and learning processes during human split–belt locomotion: interaction between central mechanisms and afferent input. Prokop T, et al. **Exp Brain Res** 1995; 106(3):449–56
Effect of neck posture on patterns of activation of feline neck muscles during horizontal rotation. Thomson DB, et al. **Exp Brain Res** 1996 Aug;110(3):392–400
Adaptation to the nephrotoxicity of heme proteins. Nath KA. **Exp Nephrol** 1996 May–Jun;4(3):139–43 (27 ref.)
The effect of intraluminal flow rate on glomerulotubular balance in the proximal tubule of the rat kidney. Romano G, et al. **Exp Physiol** 1996 Jan;81(1):95–105
Selected morphological features of overweighed children's foot as overload adaptation indices. Jaworski JM, et al. **Folia Morphol (Warsz)** 1996;55(4):290–2
Short–chain fatty acid–supplemented total parenteral nutrition enhances functional adaptation to intestinal resection in rats. Tappenden KA, et al. **Gastroenterology** 1997 Mar;112(3):792–802
On the specificity of adaptive mutations. Hall BG. **Genetics** 1997 Jan;145(1):39–44
Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Colombato LA, et al. **Gut** 1996 Oct;39(4):600–4
The effect of repeated daily noise exposure on sound–conditioned and unconditioned guinea pigs. Dagli S, et al. **Hear Res** 1997 Feb;104(1–2):39–46
Excitatory and inhibitory response adaptation in the superior olive complex affects binaural acoustic processing. Finlayson PG, et al. **Hear Res** 1997 Jan;103(1–2):1–18
Adaptation of myocardial blood flow to increased metabolic demand is not dependent on endothelial vasodilators in the rat heart. Tiefenbacher CP, et al. **Heart** 1997 Feb; 77(2):147–53
Adaptive reduction of heart sounds from lung sounds using fourth–order statistics. Hadjileontiadis LJ, et al. **IEEE Trans Biomed Eng** 1997 Jul;44(7):642–8
An optimized index of human cardiovascular adaptation to simulated weightlessness. Wang M, et al. **IEEE Trans Biomed Eng** 1996 May;43(5):502–11
Experimental evaluation of an adaptive feedforward controller for use in functional neuromuscular stimulation systems. Abbas JJ, et al. **IEEE Trans Rehabil Eng** 1997 Mar;5(1):12–22
Role of lipids in ethanol tolerance of Candida lambica. el Dein MM. **Indian J Exp Biol** 1997 Jan;35(1):89–91
Inducible protective processes in animal systems: adaptive response to a low dose of methyl methanesulfonate in mouse bone marrow cells. Mahmood R, et al. **Indian J Exp Biol** 1996 Jun;34(6):502–7
A low–dimensional, time–resolved and adapting model neuron. Cartling B. **Int J Neural Syst** 1996 Jul;7(3):237–46 (54 ref.)
Reafference and attractors in the olfactory system during odor recognition. Kay LM, et al. **Int J Neural Syst** 1996 Sep;7(4):489–95
An adaptive Boolean automation to model circadian cycles. Perazzo RP, et al. **Int J Neural Syst** 1996 Mar;7(1):83–99 (10 ref.)
Structural and functional adaptations of the cardiovascular system by training. Huonker M, et al. **Int J Sports Med** 1996 Nov;17 Suppl 3:S164–72 (74 ref.)
Determinants of morphologic cardiac adaptation in elite athletes: the role of athletic training and constitutional factors. Pelliccia A. **Int J Sports Med** 1996 Nov;17 Suppl 3:S157–63 (85 ref.)
Sports–specific adaptation of left ventricular muscle mass in athlete's heart. I. An echocardiographic study with combined isometric and dynamic exercise trained athletes (male and female rowers). Urhausen A, et al. **Int J Sports Med** 1996 Nov;17 Suppl 3:S145–51
Sports–specific adaptation of left ventricular muscle mass in athlete's heart. II: An echocardiographic study with 400–m runners and soccer players. Urhausen A, et al. **Int J Sports Med** 1996 Nov;17 Suppl 3:S152–6
Left ventricular hypertrophy in hypertensive patients is associated with abnormal rate adaptation of QT interval. Singh JP, et al. **J Am Coll Cardiol** 1997 Mar 15;29(4):778–84
Adaptational changes in renal vacuolar H(+)–ATPase in the rat remnant kidney. Bastani B, et al. **J Am Soc Nephrol** 1997 Jun;8(6):868–79
Effects of age on the role of atrial natriuretic factor in renal adaptation to physiologic variations of dietary salt intake. Leosco D, et al. **J Am Soc Nephrol** 1996 Jul;7(7):1045–51
Adaptation in the vertebral column: a comparative study of patterns of metameric variation in mice and men. O'Higgins P, et al. **J Anat** 1997 Jan;190 (Pt 1):105–13
Changes in muscle fibre type, muscle mass and IGF–I gene expression in rabbit skeletal muscle subjected to stretch. Yang H, et al. **J Anat** 1997 May;190 (Pt 4):613–22
Sherpa brain glucose metabolism and defense adaptations against chronic hypoxia. Hochachka PW, et al. **J Appl Physiol** 1996 Sep;81(3):1355–61
Skeletal muscle biochemical adaptations to exercise training in miniature swine. McAllister RM, et al. **J Appl Physiol** 1997 Jun;82(6):1862–8
Muscle adaptations to hindlimb suspension in mature and old Fischer 344 rats. Stump CS, et al. **J Appl Physiol** 1997 Jun;82(6):1875–81
Suppression of mutants aberrant in light intensity responses of complementary chromatic adaptation. Casey ES, et al. **J Bacteriol** 1997 Jul;179(14):4599–606
Induction of the heat shock protein ClpB affects cold acclimation in the cyanobacterium Synechococcus sp. strain PCC 7942. Porankiewicz J, et al. **J Bacteriol** 1997 Aug;179(16):5111–7
Differential carotenoid composition of the B875 and B800–850 photosynthetic antenna complexes in Rhodobacter sphaeroides 2.4.1: involvement of spheroidene and spheroidenone in adaptation to changes in light intensity and oxygen availability. Yeliseev AA, et al. **J Bacteriol** 1996 Oct;178(20):5877–83
H+ secretion induced by hypertonic stress in the cellular slime mold Dictyostelium discoideum. Oyama M, et al. **J Biochem (Tokyo)** 1997 Jul;122(1):64–70
Testing the daily stress stimulus theory of bone adaptation with natural and experimentally controlled strain histories. Adams DJ, et al. **J Biomech** 1997 Jul;30(7):671–8
Neural adaptations with chronic physical activity. Enoka RM. **J Biomech** 1997 May;30(5):447–55 (117 ref.)
Biomechanical studies of the remodeling of knee joint tendons and ligaments. Hayashi K. **J Biomech** 1996 Jun; 29(6):707–16 (55 ref.)
Adaptation of bone to physiological stimuli. Judex S, et al. **J Biomech** 1997 May;30(5):421–9
Temporal stability of node–based internal bone adaptation simulations. Levenston ME. **J Biomech** 1997 Apr; 30(4):403–7
A uniform strain criterion for trabecular bone adaptation: do continuum–level strain gradients drive adaptation? Turner CH, et al. **J Biomech** 1997 Jun;30(6):555–63
Evidence for both abnormal set point of PTH stimulation by calcium and adaptation to serum calcium in hemodialysis patients with hyperparathyroidism. Rodriguez M, et al. **J Bone Miner Res** 1997 Mar;12(3):347–55
Osmolarity is an independent trigger of Acanthamoeba castellanii differentiation. Cordingley JS, et al. **J Cell Biochem** 1996 May;61(2):167–71
Resistance to neuroglycopenia: an adaptive response during intensive insulin treatment of diabetes. Jones TW, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1713–8
Growth markers in the human gastric mucosa during adaptation to continued aspirin administration. Stachura J, et al. **J Clin Gastroenterol** 1996 Jun;22(4):282–7
Adaptation: a new concept in radiation biology and oncology and its clinical relevance. Lin HS. **J Formos Med Assoc** 1996 Nov;95(11):817–21 (37 ref.)
The response to calorie restriction in mammals shows features also common to hibernation: a cross–adaptation hypothesis. Walford RL, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):B179–83 (58 ref.)
Dietary adaptations of Plio–Pleistocene Bovidae: implications for hominid habitat use. Spencer LM. **J Hum Evol** 1997 Feb–Mar;32(2–3):201–28
Renal adaptation to stress: a possible role of endothelin release and prostaglandin modulation in the human subject. Castellani S, et al. **J Lab Clin Med** 1997 Apr;129(4):462–9
Complete adaptation to chronic potassium loading after adrenalectomy: possible humoral mechanisms. Dekel B, et al. **J Lab Clin Med** 1997 Apr;129(4):453–61
Adaptation to changes in dietary phosphorus intake in health and in renal failure. Loghman–Adham M. **J Lab Clin Med** 1997 Feb;129(2):176–88 (153 ref.)
Normal and inhibited cholesterol synthesis in the cultured rat embryo. Llirbat B, et al. **J Lipid Res** 1997 Jan; 38(1):22–34
Reduction of I(Ca,L) and I(to1) density in hypertrophied right ventricular cells by simulated high altitude in adult rats. Chouabe C, et al. **J Mol Cell Cardiol** 1997 Jan; 29(1):193–206
Importance of the early alterations of energy metabolism in the induction and the disappearance of ischemic preconditioning in the isolated rat heart. Garnier A, et al. **J Mol Cell Cardiol** 1996 Aug;28(8):1671–82
Facilitative interactions between noradrenergic and purinergic signaling during preconditioning of the rat heart. Winter CB, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):163–73
Angiotensin II receptors in the gill of sea water– and freshwater–adapted eel. Marsigliante S, et al. **J Mol Endocrinol** 1997 Feb;18(1):67–76
A tendon–locking mechanism in two climbing rodents, Muscardinus avellanarius and Micromys minutus (Mammalia, Rodentia). Haffner M. **J Morphol** 1996 Aug; 229(2):219–27
Adaptation of primate vestibuloocular reflex to altered peripheral vestibular inputs. II Spatiotemporal properties of the adapted slow–phase eye velocity. Angelaki DE, et al. **J Neurophysiol** 1996 Nov;76(5):2954–71
Adaptation of primate vestibuloocular reflex to altered peripheral vestibular inputs. I. Frequency–specific recovery of horizontal VOR after inactivation of the lateral semicircular canals. Angelaki DE, et al. **J Neurophysiol** 1996 Nov;76(5):2941–53
Plasticity in an electrosensory system. I. General features of a dynamic sensory filter. Bastian J. **J Neurophysiol** 1996 Oct;76(4):2483–96

Differential distribution of potassium channels in acutely demyelinated, primary-auditory neurons in vitro. Davis RL. **J Neurophysiol** 1996 Jul;76(1):438-47

Motor adaptation to Coriolis force perturbations of reaching movements: endpoint but not trajectory adaptation transfers to the nonexposed arm. Dizio P, et al. **J Neurophysiol** 1995 Oct;74(4):1787-92

Transfer of gain changes from targeting to other types of saccade in the monkey: constraints on possible sites of saccadic gain adaptation. Fuchs AF, et al. **J Neurophysiol** 1996 Oct;76(4):2522-35

Mechanical states encoded by stretch-sensitive neurons in feline joint capsule. Khalsa PS, et al. **J Neurophysiol** 1996 Jul;76(1):175-87

Effect of temperature on the normal and adapted vestibulo-ocular reflex in the goldfish. McElligott JG, et al. **J Neurophysiol** 1995 Oct;74(4):1463-72

Response sensitivity and voltage gain of the rod- and cone-horizontal cell synapses in dark- and light-adapted tiger salamander retina. Yang XL, et al. **J Neurophysiol** 1996 Dec;76(6):3863-74

Neural coding mechanisms in tactile pattern recognition: the relative contributions of slowly and rapidly adapting mechanoreceptors to perceived roughness. Blake DT, et al. **J Neurosci** 1997 Oct 1;17(19):7480-9

The role of internal models in motion planning and control: evidence from grip force adjustments during movements of hand-held loads. Flanagan JR, et al. **J Neurosci** 1997 Feb 15;17(4):1519-28

Removal of spike frequency adaptation via neuromodulation intrinsic to the Tritonia escape swim central pattern generator. Katz PS, et al. **J Neurosci** 1997 Oct 15; 17(20):7703-13

Prism adaptation of reaching movements: specificity for the velocity of reaching. Kitazawa S, et al. **J Neurosci** 1997 Feb 15;17(4):1481-92

Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. Staley JK, et al. **J Neurosci** 1996 Oct 1;16(19):6100-6

Differential reinforcing effects of cocaine and GBR-12909: biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system. Tella SR, et al. **J Neurosci** 1996 Dec 1;16(23):7416-27

Functional recovery from sciatic nerve crush lesion in the rat correlates with individual differences in responses to chronic intermittent stress. van Meeteren NL, et al. **J Neurosci Res** 1997 Jun 15;48(6):524-32

Brightness fading during Ganzfeld adaptation. Knau H, et al. **J Opt Soc Am A** 1997 Jun;14(6):1213-22

Fourier models and the loci of adaptation. Makous WL. **J Opt Soc Am A** 1997 Sep;14(9):2323-45

Equivalent background speed in recovery from motion adaptation. Simpson WA, et al. **J Opt Soc Am A** 1997 Jan; 14(1):13-22

Contrast adaptation and the spatial structure of natural images. Webster MA, et al. **J Opt Soc Am A** 1997 Sep; 14(9):2355-66

Growth hormone and glutamine do not stimulate intestinal adaptation following massive small bowel resection in the rat. Vanderhoof JA, et al. **J Pediatr Gastroenterol Nutr** 1997 Sep;25(3):327-31

Effect of hydroxylamine on photon-like events during dark adaptation in toad rod photoreceptors. Leibrock CS, et al. **J Physiol (Lond)** 1997 May 15;501 (Pt 1):97-109

Dynamics of functional connectivity in visual cortical networks: an overview. Frégnac Y. **J Physiol Paris** 1996; 90(3-4):113-39 (185 ref.)

Effect of training and nutrition on the development of skeletal muscle. Henriksson J. **J Sports Sci** 1995 Summer;13 Spec No:S25-30 (55 ref.)

Epidermal growth factor selectively enhances functional enterocyte adaptation after massive small bowel resection. Dunn JC, et al. **J Surg Res** 1997 Jan;67(1):90-3

A defective EGF-receptor in waved-2 mice attenuates intestinal adaptation. Helmrath MA, et al. **J Surg Res** 1997 Apr;69(1):76-80

Effect of extent of resection on intestinal muscle adaptation. Nguyen BL, et al. **J Surg Res** 1996 Feb 15;61(1):147-51

Cardioadaptation induced by cyclic ischemic preconditioning is mediated by translational regulation of de novo protein synthesis. Rowland RT, et al. **J Surg Res** 1997 Aug; 71(2):155-60

The design of adaptive systems: optimal parameters for variation and selection in learning and development. Frank SA. **J Theor Biol** 1997 Jan 7;184(1):31-9

Splanchnic erythrocyte content decreases during hemodialysis: a new compensatory mechanism for hypovolemia. Yu AW, et al. **Kidney Int** 1997 Jun; 51(6):1986-90

Intrauterine programming of hypertension by glucocorticoids. Langley-Evans SC. **Life Sci** 1997; 60(15):1213-21 (96 ref.)

Social deprivation stress induces adaptative changes of opioid mechanisms in the rat tail artery. Parra L, et al. **Life Sci** 1997;60(25):2315-22

Adaptations of myonuclei to hypertrophy in patagialis muscle fibers from aged quail. Lee J, et al. **Mech Ageing Dev** 1996 Jul 17;88(3):185-97

Human diversity, environmental adaptation and neural crest. Irmak MK, et al. **Med Hypotheses** 1997 May;48(5):407-10 (34 ref.)

Modeling signal transduction in normal and cancer cells using complex adaptive systems. Schwab ED, et al. **Med Hypotheses** 1997 Feb;48(2):111-23 (55 ref.)

Regional blood flow in microgravity: adaptation and deconditioning. Arbeille P, et al. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S70-9

Effects of altered loading states on muscle plasticity: what have we learned from rodents? Baldwin KM. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S101-6

Musculoskeletal adaptations to weightlessness and development of effective countermeasures. Baldwin KM, et al. **Med Sci Sports Exerc** 1996 Oct;28(10):1247-53

Changes in gas exchange kinetics with training in patients with spinal cord injury. Barstow TJ, et al. **Med Sci Sports Exerc** 1996 Oct;28(10):1221-8

Regulation of the systemic circulation at microgravity and during readaptation to 1G. Blomqvist GC. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S9-13 (24 ref.)

Exercise as a countermeasure for physiological adaptation to prolonged spaceflight. Convertino VA. **Med Sci Sports Exerc** 1996 Aug;28(8):999-1014 (99 ref.)

Critical discussion of integrated physiology of microG. Edgerton R. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S107-8; discussion S108-10

Cardiovascular adaptation to spaceflight. Hargens AR, et al. **Med Sci Sports Exerc** 1996 Aug;28(8):977-82 (57 ref.)

Critical discussion of research issues in mechanisms of cardiovascular adaptation to actual and simulated microG. Levine BD. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S90-2; discussion S92-3

Adaptive strategies of respiratory muscles in response to endurance exercise. Powers SK, et al. **Med Sci Sports Exerc** 1996 Sep;28(9):1115-22 (54 ref.)

Physiological adaptations and countermeasures associated with long-duration spaceflights. Tipton CM, et al. **Med Sci Sports Exerc** 1996 Aug;28(8):974-6

Adaptation of the hypothalamopituitary adrenal axis to chronic exercise stress in humans. Wittert GA, et al. **Med Sci Sports Exerc** 1996 Aug;28(8):1015-9

Acid tolerance in Listeria monocytogenes: the adaptive acid tolerance response (ATR) and growth-phase-dependent acid resistance. Davis MJ, et al. **Microbiology** 1996 Oct;142 (Pt 10):2975-82

Comparative physiology of salt tolerance in Candida tropicalis and Saccharomyces cerevisiae. García MJ, et al. **Microbiology** 1997 Apr;143 (Pt 4):1125-31

Adaptation of proteases and carbohydrates of saprophytic, phytopathogenic and entomopathogenic fungi to the requirements of their ecological niches. St Leger RJ, et al. **Microbiology** 1997 Jun;143 (Pt 6):1983-92

The role of mechanical stresses in microvascular remodeling. Skalak TC, et al. **Microcirculation** 1996 Jun;3(2):143-65 (198 ref.)

Analysis of DNA damage recovery processes in the adaptive response to ionizing radiation in human lymphocytes. Wojcik A, et al. **Mutagenesis** 1996 May;11(3):291-7

Radiation effects induced by low doses in complex tissue and their relation to cellular adaptive responses. Feinendegen LE, et al. **Mutat Res** 1996 Nov 4; 358(2):199-205

The role of poly(ADP-ribosyl)ation in the adaptive response. Kleczkowska HE, et al. **Mutat Res** 1996 Nov 4; 358(2):215-21 (40 ref.)

Correlation between the adaptive response and individual sensitivity to monoepoxybutene in in vitro experiments on human lymphocytes. Sasiadek M, et al. **Mutat Res** 1997 May 23;390(3):239-43

Symbiosis. Making light work of adaptation [news; comment] Buddemeier RW. **Nature** 1997 Jul 17;388(6639):229-30. Comment on: Nature 1997 Jul 17;388(6639):265-9.

Role of posterior parietal cortex in the recalibration of visually guided reaching. Clower DM, et al. **Nature** 1996 Oct 17;383(6601):618-21

Olfactory adaptation. The nose leads the eye [news; comment] Gold GH, et al. **Nature** 1997 Feb 20; 385(6618):677, 679. Comment on: Nature 1997 Feb 20;385(6618):725-9.

Mechanism of odorant adaptation in the olfactory receptor cell [see comments] Kurahashi T, et al. **Nature** 1997 Feb 20;385(6618):725-9. Comment in: Nature 1997 Feb 20;385(6618):677, 679.

Episodic adaptive evolution of primate lysozymes. Messier W, et al. **Nature** 1997 Jan 9;385(6612):151-4

Adaptation of retinal processing to image contrast and spatial scale. Smirnakis SM, et al. **Nature** 1997 Mar 6; 386(6620):69-73

Role of mutator alleles in adaptive evolution [see comments] Taddei F, et al. **Nature** 1997 Jun 12;387(6634):700-2. Comment in: Nature 1997 Jun 12;387(6634):659, 661-2.

Spontaneous daily torpor in malagasy mouse lemurs. Ortmann S, et al. **Naturwissenschaften** 1997 Jan;84(1):28-32

Is the Mg(2+)-ATP-dependent proton pumping activity of the synaptic vesicles a factor involved in the cerebral hypoxia? Benzi G, et al. **Neurochem Res** 1996 Jan;21(1):7-18

Alteration in IGF-I binding in the cerebral cortex and cerebellum of neonatal rats during protein-calorie malnutrition. Maheshwari HG, et al. **Neurochem Res** 1997 Mar;22(3):313-9

Cellular adaptive responses to low oxygen tension: apoptosis and resistance. Yun JK, et al. **Neurochem Res** 1997 Apr; 22(4):517-21 (44 ref.)

Adaptation to prolonged or repeated stress--comparison between rat strains showing intrinsic differences in reactivity to acute stress. Dhabhar FS, et al. **Neuroendocrinology** 1997 May;65(5):360-8

Impaired adaptation of the hypothalamic-pituitary-adrenal axis to chronic ethanol stress in aged rats. Spencer RL, et al. **Neuroendocrinology** 1997 May;65(5):353-9

Analysis of cerebellar dysmetria associated with lithium intoxication. Manto M, et al. **Neurol Res** 1996 Oct; 18(5):416-24

Target predictability influences the distribution of coordinated eye-head gaze saccades in patients with homonymous hemianopia. Schoepf D, et al. **Neurol Res** 1996 Oct;18(5):425-39

Vestibular compensation in a patient with a cerebellar infarction. Furman JM, et al. **Neurology** 1997 Apr; 48(4):916-20

Background adaptation and synapse plasticity in the pars intermedia of Xenopus laevis. Berghs CA, et al. **Neuroscience** 1996 Feb;70(3):833-41

Middle term intestinal adaptation after massive distal small bowel resection in oral feeding dogs. García-Caballero M, et al. **Nutr Hosp** 1996 Sep-Oct;11(5):265-73

The sensitivity of the chick eye to refractive defocus. Schmid KL, et al. **Ophthalmic Physiol Opt** 1997 Jan;17(1):61-7

Noxious and innocuous cold discrimination in humans: evidence for separate afferent channels. Chen CC, et al. **Pain** 1996 Nov;68(1):33-43

Neurophysiological assessment of brain function and maturation: I. A measure of brain adaptation in high risk infants. Scher MS. **Pediatr Neurol** 1997 Apr;16(3):191-8 (100 ref.)

Regulation of the renal response to atrial natriuretic peptide by sodium intake in preweaned rats. Chevalier RL, et al. **Pediatr Res** 1996 Aug;40(2):294-9

Regulatory adaptation of isoprenoid biosynthesis and the LDL receptor pathway in fibroblasts from patients with mevalonate kinase deficiency. Hoffmann GF, et al. **Pediatr Res** 1997 Apr;41(4 Pt 1):541-6

Hepatic heme oxygenase is inducible in neonatal rats during the early postnatal period. Tom DJ, et al. **Pediatr Res** 1996 Aug;40(2):288-93

Adaptation to optokinetic rotation-induced motion sickness without experiencing nausea. Hu S, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 2):1235-40

The regulation of GLUT5 and GLUT2 activity in the adaptation of intestinal brush-border fructose transport in diabetes. Corpe CP, et al. **Pflugers Arch** 1996 Jun; 432(2):192-201

Influence of gender and endogenous sex steroids on catecholaminergic structures involved in physiological adaptation to hypoxia. Pequignot JM, et al. **Pflugers Arch** 1997 Mar;433(5):580-6

Influence of the dopamine D2 receptor (DRD2) genotype on neuroadaptive effects of alcohol and the clinical outcome of alcoholism. Finckh U, et al. **Pharmacogenetics** 1997 Aug;7(4):271-81

Adaptive metabolic responses in females of the fighting breed submitted to different sequences of stress stimuli. Sánchez JM, et al. **Physiol Behav** 1996 Oct;60(4):1047-52

Is diet shifting facilitated by modulation of intestinal nutrient uptake? Test of an adaptational hypothesis in yellow-rumped warblers. Afik D, et al. **Physiol Zool** 1997 Mar-Apr;70(2):213-21

Thermal sensitivity of Drosophila melanogaster: evolutionary responses of adults and eggs to laboratory natural selection at different temperatures. Gilchrist GW, et al. **Physiol Zool** 1997 Jul-Aug;70(4):403-14

Accumulation of 19-kDa plasma membrane polypeptide during induction of freezing tolerance in wheat suspension-cultured cells by abscisic acid. Koike M, et al. **Plant Cell Physiol** 1997 Jun;38(6):707-16

Enhancement of oxidative stress tolerance in transgenic tobacco plants overproducing Fe-superoxide dismutase in chloroplasts. Van Camp W, et al. **Plant Physiol** 1996 Dec; 112(4):1703-14

Working underground: respiratory adaptations in the blind mole rat. Widmer HR, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):2062-7

Modulations of autonomic functions by somatic nociceptive inputs. Budgell B, et al. **Prog Brain Res** 1996;113:525-39 (57 ref.)

The polymodal receptor: bio-warning and defense system. Kumazawa T. **Prog Brain Res** 1996;113:3-18 (129 ref.)

Cold adaptation parameters derived from cDNA sequencing and molecular modelling of elastase from Antarctic fish Notothenia neglecta. Aittaleb M, et al. **Protein Eng** 1997 May;10(5):475-7

High-resolution crystal structure of M-protease: phylogeny aided analysis of the high-alkaline adaptation mechanism. Shirai T, et al. **Protein Eng** 1997 Jun;10(6):627-34

An adaptationist view of apoptosis. LeGrand EK. **Q Rev Biol** 1997 Jun;72(2):135-47 (73 ref.)

Effects of iron supplementation on iron uptake by differentiating cytotrophoblasts. Starreveld JS, et al. **Reprod Fertil Dev** 1996;8(3):417-22

Adaptation to training and performance in elite athletes. Keul J, et al. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S29-36 (45 ref.)

Airway inflammation despite loss of bronchial hyper-responsiveness after multiple ozone exposures. Sun J, et al. **Respir Med** 1997 Jan;91(1):47-55

Adaptation by hyperpolarization [comment] Barlow H. **Science** 1997 May 9;276(5314):913-4. Comment on: Science

1997 May 9;276(5314):949–52.
School age outcome in low birth weight preterm infants. Leonard CH, et al. **Semin Perinatol** 1997 Jun;21(3):240–53 (52 ref.)
Cardio–respiratory physiological adaptation of pregnancy. O'Day MP. **Semin Perinatol** 1997 Aug;21(4):268–75 (68 ref.)
Endothelium–medicated control of the coronary circulation. Exercise training–induced vascular adaptations. Laughlin MH, et al. **Sports Med** 1996 Oct;22(4):228–50 (162 ref.)
Biochemical adaptations in the mesolimbic dopamine system in response to heroin self–administration. Self DW, et al. **Synapse** 1995 Dec;21(4):312–8
Intestinal adaptation in short bowel syndrome. Gambarara M, et al. **Transplant Proc** 1997 May;29(3):1862–3
Dark adaptation in vertebrate photoreceptors. Fain GL, et al. **Trends Neurosci** 1996 Nov;19(11):502–7 (84 ref.)
Adaptation to arid environment: Haemonchus longistipes in dromedaries of Saharo–Sahelian areas of Mauritania. Jacquiet P, et al. **Vet Parasitol** 1996 Nov 15;66(3–4):193–204
Adaptation of egg–grown and transfectant influenza viruses for growth in mammalian cells: selection of hemagglutinin mutants with elevated pH of membrane fusion. Lin YP, et al. **Virology** 1997 Jul 7;233(2):402–10
Light–induced modulation of coupling between AII amacrine cells in the rabbit retina. Bloomfield SA, et al. **Vis Neurosci** 1997 May–Jun;14(3):565–76
Dynamic shifts of the contrast–response function. Victor JD, et al. **Vis Neurosci** 1997 May–Jun;14(3):577–87
A neural model of foveal light adaptation and afterimage formation. Wilson HR. **Vis Neurosci** 1997 May–Jun; 14(3):403–23 (82 ref.)
Changes in perceived speed following adaptation to first–order and second–order motion. Ledgeway T, et al. **Vision Res** 1997 Jan;37(2):215–24
[Complex biomedical studies of the body under conditions of extreme marine factors] Sachanska T. **Probl Khig** 1996; 21:67–73 (Eng. Abstr.) **(Bul)**
[The general and specific mechanisms of adaptation of the body to extreme exposures] Sachanska T, et al. **Probl Khig** 1996;21:51–66 (Eng. Abstr.) **(Bul)**
[Preliminary analysis of the modifications of spinal curves, in extreme amplitudes, observed in rhythmic and athletic gymnastics] Vanneuville G, et al. **Bull Assoc Anat (Nancy)** 1996 Mar;80(248):33–5 (Eng. Abstr.) **(Fre)**
[Comparative study of static curves of the human spine in vivo during exercise and stretching in men and women] Vanneuville G, et al. **Bull Assoc Anat (Nancy)** 1996 Mar; 80(248):37–9 (Eng. Abstr.) **(Fre)**
[Adaptation of insulin therapy in the evening and/or at bedtime. Experience of night hospitalization] Bennis D, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:233–47 (21 ref.) **(Fre)**
[Production of Plasmodium falciparum gametocytes: adaptation of a diabolical dissemination process of endemic malaria?] Robert–Gangneux F. **Sante** 1997 Mar–Apr; 7(2):146 **(Fre)**
[Adaptations of the heart and vessels in arterial hypertension] Borghetti A, et al. **Cardiologia** 1997 Feb;42(2):139–48 (129 ref.) **(Ita)**
[Biventricular–pulmonary interaction as the prime mechanism in the adaptation of the human heart to orthostatic posture] Guazzi M, et al. **Cardiologia** 1997 Jan; 42(1):69–76 (Eng. Abstr.) **(Ita)**
[An intrapatient comparison of adaptation to aerobic and anaerobic exertion during 3 types of physiological cardiac stimulation in chronotropic failure of the sinus node: DDD, VVIR and DDDR] Occhetta E, et al. **Cardiologia** 1997 Jan;42(1):51–7 (Eng. Abstr.) **(Ita)**
[Center for the Prevention, Diagnosis, Care and Rehabilitation of Pathology due to Work Disadaptation (news)] Gilioli R. **Med Lav** 1996 May–Jun;87(3):270–2 **(Ita)**
[Adaptive responses and signal transduction in bacteria] Aiba H, et al. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):549–57 (34 ref.) **(Jpn)**
[Relationship between adaptation mechanisms and the level of functioning of the cardiovascular system in children with abnormalities of the large intestine and anorectal region] Agzamkhodzhaev TS, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):27–31 (Eng. Abstr.) **(Rus)**
[The intermitochondrial contacts of cardiomyocytes during cardiac adaptation under pathological conditions] Paukov VS, et al. **Arkh Patol** 1996 Nov–Dec;58(6):43–50 (Eng. Abstr.) **(Rus)**
[Adaptation to weightlessness and stress] Grigor'ev AI, et al. **Aviakosm Ekolog Med** 1996;30(3):4–8 (53 ref.) (Eng. Abstr.) **(Rus)**
[Awareness of the subjective vertical in weightlessness (results of Austrian–Russian experiment Optovert performed within the framework of the program Austromir, part III)] Kornilova LN, et al. **Aviakosm Ekolog Med** 1996;30(2):11–5 (Eng. Abstr.) **(Rus)**
[Adaptive potentials of mammals under conditions of weightlessness] Serova LV. **Aviakosm Ekolog Med** 1996; 30(2):5–11 (69 ref.) (Eng. Abstr.) **(Rus)**
[Magnetic fields, adaptation reaction and self–organization of live systems] Garkavi LKh, et al. **Biofizika** 1996 Jul–Aug;41(4):898–905 (Eng. Abstr.) **(Rus)**
[Adaptive changes in the body upon exposure to electromagnetic radiation] Zubkova SM. **Biofizika** 1996 Jul–Aug;41(4):906–12 (Eng. Abstr.) **(Rus)**
[Changes in the rhythmo–inotropic reactions of the myocardium during chronic ischemia: pathology or adaptation?] Afanas'ev SA, et al. **Biull Eksp Biol Med** 1994 May;117(5):457–9 **(Rus)**
[The effect of adaptation of hypoxia on cytochrome levels in rat brain and liver] Dudchenko AM, et al. **Biull Eksp Biol Med** 1995 Dec;120(12):576–9 **(Rus)**
[Comparative study of lipid peroxidation indicators in the heart, liver and brain of rats with varying resistance to hypoxia] Khachatur'ian ML, et al. **Biull Eksp Biol Med** 1996 Feb;121(2):138–43 **(Rus)**
[The role of cnetral and peripheral mu and delta opiate receptors in the realization of the anti–arrhythmic effect of adaptation] Lishmonov IuB, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):378–81 **(Rus)**
[Effect of periodic adaptation to hypoxia on oxidative phosphorylation in brain mitochondria from rats with varying tolerance to oxygen insufficiency] Lukianova LD, et al. **Biull Eksp Biol Med** 1995 Dec;120(12):572–5 **(Rus)**
[Differences in stress reaction and development of adaptation to stress in August and Wistar rats] Pshennikova MG, et al. **Biull Eksp Biol Med** 1996 Aug;122(8):156–9 **(Rus)**
[Adaptation to physical exertion increases activity of prostaglandins E and I2 and reduces the stress–reaction] Pshennikova MG, et al. **Biull Eksp Biol Med** 1996 Dec; 122(12):622–4 **(Rus)**
[Drifting cascade–like slowly developing adaptation mechanism during action of extreme factors on the body] Shakhov VP. **Biull Eksp Biol Med** 1996 May;121(5):571–4 **(Rus)**
[Adapting to physical load increases resistance of the heart to the damaging effect of adrenaline and calcium] Prodius PA, et al. **Dokl Akad Nauk** 1997 Feb;352(5):711–4 **(Rus)**
[Adaptation of the cardiovascular system in adolescents] Agadzhanian NA, et al. **Fiziol Cheloveka** 1997 Jan–Feb; 23(1):93–7 **(Rus)**
[Adaptation reactions of the heart to local muscular work in preschool children] Alferova–Popova TV, et al. **Fiziol Cheloveka** 1996 Sep–Oct;22(5):118–22 **(Rus)**
[Medico–physiological aspects of individually differentiated teaching of senior pupils] Antropova MV, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):98–102 **(Rus)**
[Features of hormonal status in aborigines of Northeast Russia as a function of the level of hypoxic resistance] Batosh TP, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):5–9 **(Rus)**
[Normalizing effect of normobaric hypoxic hypoxia] Chizhov AIa, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):108–12 **(Rus)**
[Character of the changes in bioelectrical activity of the brain in persons performing operator work under conditions of high–altitude hypoxia] Dzhunusova GS, et al. **Fiziol Cheloveka** 1997 Jul–Aug;23(4):52–7 **(Rus)**
[Stress: cardiologic aspects] Fedorov BM. **Fiziol Cheloveka** 1997 Mar–Apr;23(2):89–99 **(Rus)**
[Status of the cardiorespiratory system in representatives of various climato–geographic regions during adaptation to to the hot climate of Central Asia] Fedorova OI, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):25–8 **(Rus)**
[Analysis of EEG resonance reactions in evaluation of the effectiveness of sensory stimulation] Fedotchev AI. **Fiziol Cheloveka** 1997 Jul–Aug;23(4):117–23 (67 ref.) **(Rus)**
[Physiologic effects of weightlessness on man under spaceflight conditions] Gazenko OG, et al. **Fiziol Cheloveka** 1997 Mar–Apr;23(2):138–46 (29 ref.) **(Rus)**
[Effect of hypoxic training on the health of school children residing in ecologically unfavorable regions] Glazachev OS, et al. **Fiziol Cheloveka** 1996 Jan–Feb;22(1):88–92 **(Rus)**
[Medico–biological aspects of a Mars expedition] Grigor'ev AI, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):88–92 (30 ref.) **(Rus)**
[Role of the processes of disinhibition of pacemakers in reflex activity of neural centers] Gurin VN, et al. **Fiziol Cheloveka** 1997 Mar–Apr;23(2):147–9 **(Rus)**
[The limits of human physiological adaptation to the consequences of modern disasters] Ivanov KP. **Fiziol Cheloveka** 1997 May–Jun;23(3):109–21 (65 ref.) **(Rus)**
[Functional state of the temperature analyzer of operators in the gas condensation industry under conditions of hot climate] Khudaĭberdiev MD, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):20–4 **(Rus)**
[Use of parameters of energy metabolism for determining body adaptation in highly qualified female athletes] Milashius KM. **Fiziol Cheloveka** 1996 Nov–Dec;22(6):5–9 **(Rus)**
[Intellectual ability and the success of flight training] Ponomarenko VA, et al. **Fiziol Cheloveka** 1996 Jul–Aug; 22(4):86–90 **(Rus)**
[Features of the adaptation of migrants (Indians) to conditions of the European North] Ruvinova LG, et al. **Fiziol Cheloveka** 1997 Jul–Aug;23(4):90–4 **(Rus)**
[Bioclimatic evaluation of mountainous territories] Shanazarov AS, et al. **Fiziol Cheloveka** 1997 Jan–Feb; 23(1):15–9 **(Rus)**
[Physiologic features of the cardiovascular and respiratory systems in patients undergoing heart surgery under artificial circulation] Shevchenko IuL. **Fiziol Cheloveka** 1997 Mar–Apr;23(2):100–6 **(Rus)**
[Correlational adaptometry as a method for evaluating cardiovascular and respiratory interaction] Svetlichnaia GN, et al. **Fiziol Cheloveka** 1997 May–Jun;23(3):58–62 **(Rus)**
[Adaptation of cardiac activity and status of gas exchange in athletes to physical load] Vaniushin IuS, et al. **Fiziol Cheloveka** 1997 Jul–Aug;23(4):69–73 **(Rus)**
[Adaptation of the circulatory system to medium– and high–altitude hypoxia in heterozygous and homozygous adolescent twins] Zaslavskaia RM, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):29–32 **(Rus)**
[Dynamics of parameters of the functional activity of the thyroid gland and adrenal cortex during human adaptation to new ecologic conditions] Zhekalov AN, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):10–4 **(Rus)**
[The role of endogenous opioid peptides in the mechanisms of the antiarrhythmic effect of adaptation] Lishmanov IuB, et al. **Fiziol Zh Im I M Sechenova** 1996 May–Jun; 82(5–6):48–52 (Eng. Abstr.) **(Rus)**
[The effect of adaptation to a physical load on the endothelium–mediated reactions of isolated vessels and NO production in rats] Manukhina EB, et al. **Fiziol Zh Im I M Sechenova** 1996 Jul;82(7):54–60 (Eng. Abstr.) **(Rus)**
[The limitation of acute hypotension and hyperactivation of the vascular endothelium in rats with an experimental myocardial infarct by using preliminary adaptation to physical load] Manukhina EB, et al. **Fiziol Zh Im I M Sechenova** 1996 Dec;82(12):57–64 (Eng. Abstr.) **(Rus)**
[The biochemical changes in the blood of variously adapted persons under exposure to different physical loads who develop tolerance] Milašius K. **Fiziol Zh Im I M Sechenova** 1996 Oct–Nov; 82(10–11):98–107 (Eng. Abstr.) **(Rus)**
[Geography of effective size of rural populations of Northern Eurasia. Geographic correlation between effective size and level of heterozygosity of populations] Evsiukov AN, et al. **Genetika** 1996 Nov;32(11):1583–91 (Eng. Abstr.) **(Rus)**
[Specificity and time of the appearance of His+ reversions induced by histidine starvation in Salmonella typhimurium] Gizatullin FSh, et al. **Genetika** 1996 Oct;32(10):1333–40 (Eng. Abstr.) **(Rus)**
[Phenotypic and genotypic structure of a natural Drosophila population with respect to the reaction of individuals to an increase in population density and its seasonal change] Grechanyĭ GV, et al. **Genetika** 1996 Oct;32(10):1341–8 (Eng. Abstr.) **(Rus)**
[Role of juvenile hormone metabolism in the adaptation of Drosophila populations to stressful environmental conditions] Gruntenko NE, et al. **Genetika** 1996 Sep; 32(9):1191–8 (Eng. Abstr.) **(Rus)**
[Radio–adaptive response in repair–defective cells from patients with homocystinuria] Zasukhina GD, et al. **Genetika** 1996 Nov;32(11):1592–5 (Eng. Abstr.) **(Rus)**
[Phenotypic plasticity of wing size and shape in Drosophila melanogaster and D. simulans] Zhivotovskiĭ LA, et al. **Genetika** 1996 Apr;32(4):517–22 (Eng. Abstr.) **(Rus)**
[Comparative study of adaptation of school children from regions with radiation pollution and from Moscow to conditions of rest at Artek, a health center] Rybakov VP, et al. **Gig Sanit** 1996 Nov–Dec;(6):35–6 **(Rus)**
[Adaptation of regulatory physiological systems in surgical treatment of patients with bronchial asthma] Savchenko ZI, et al. **Klin Med (Mosk)** 1996;74(7):38–9 (Eng. Abstr.) **(Rus)**
[The characteristics of cardiac rhythm regulation in patients with duodenal peptic ulcer] Dudina EA, et al. **Lik Sprava** 1995 Mar–Apr;(3–4):143–4 (Eng. Abstr.) **(Rus)**
[The sites of detecting, isolating and the adaptation of Toxoplasma gondii strains in cell cultures] Alimov AG, et al. **Med Parazitol (Mosk)** 1997 Apr–Jun;(2):28–9 **(Rus)**
[Adaptational autoregulation of humans during work activities (literature review)] Akhlakov MK, et al. **Med Tr Prom Ekol** 1997;(5):21–4 (21 ref.) **(Rus)**
[Substantiation of physiologic and hygienic regulations of work environment, expedition and shift work in the Far North (Yamburg settlement)] Matiukhin VV, et al. **Med Tr Prom Ekol** 1996;(6):38–40 **(Rus)**
[Physiologic and hygienic problems in improving human life conditions in the North] Potapov AI, et al. **Med Tr Prom Ekol** 1996;(6):1–4 (Eng. Abstr.) **(Rus)**
[Physiological aspects of optimization of expedition and work shift schedules in Arctic Regions] Sidorov PI, et al. **Med Tr Prom Ekol** 1996;(6):4–7 (Eng. Abstr.) **(Rus)**
[Importance of dietary calcium in adaptation to combined stress in regions of the Far North] Sukhanov BP, et al. **Med Tr Prom Ekol** 1997;(2):13–5 (Eng. Abstr.) **(Rus)**
[Problem of adaptation and characteristics of the etiology of diseases in the Far North] Tarasova LA, et al. **Med Tr Prom Ekol** 1996;(5):11–4 (Eng. Abstr.) **(Rus)**
[Physiological bases for work and rest schedules during shift work in Arctic tundra] Viktorov VS, et al. **Med Tr Prom Ekol** 1996;(6):30–3 (Eng. Abstr.) **(Rus)**
[Participation of exometabolites in adaptation of Escherichia coli to stressors] Nikolaev IuA. **Mikrobiologiia** 1997

Jan-Feb;66(1):38-41 (Eng. Abstr.) **(Rus)**

[Multiple protective effect of an exometabolite (exometabolites) released by Escherichia coli during treatment with tetracycline] Nikolaev IuA. **Mikrobiologiia** 1996 Nov-Dec;65(6):749-52 (Eng. Abstr.) **(Rus)**

[Release of protein into the extracellular space as a nonspecific response to stress in Escherichia coli] Roshchina EK, et al. **Mikrobiologiia** 1997 Mar-Apr; 66(2):179-84 (Eng. Abstr.) **(Rus)**

[Role of putrescine and potassium transport in the adaptation of Escherichia coli to ammonium starvation] Tkachenko AG, et al. **Mikrobiologiia** 1996 Nov-Dec;65(6):740-4 (Eng. Abstr.) **(Rus)**

[Exchange of putrescine and potassium between cells and media as a factor in the adaptation of Escherichia coli to hyperosmotic shock] Tkachenko AG, et al. **Mikrobiologiia** 1997 May-Jun;66(3):329-34 (Eng. Abstr.) **(Rus)**

[Morphological changes in the adrenal gland during adaptation to multiple individually measured physical loads] Kol'tiukova NV. **Morfologiia** 1997;111(2):79-83 (Eng. Abstr.) **(Rus)**

[Various mechanisms of protective action of interval hypoxic training during preparation for abdominal delivery] Adiiatulin AI, et al. **Patol Fiziol Eksp Ter** 1997 Jul-Sep; (3):26-9 (Eng. Abstr.) **(Rus)**

[Disorders developing under combined exposure to ionizing radiation and stress] Fedorov VI. **Patol Fiziol Eksp Ter** 1997 Jan-Mar;(1):31-3 (Eng. Abstr.) **(Rus)**

[Effect of adaptation to medium altitude (1600 m) on the stability of parameters of lipid metabolism of the myocardium during stress] Kostiuchenko LS. **Patol Fiziol Eksp Ter** 1996 Apr-Jun;(2):18-20 (Eng. Abstr.) **(Rus)**

[Do endogenous opioid peptides participate in the realization of the cardioprotective effect of adaptation?] Lishmanov IuB, et al. **Patol Fiziol Eksp Ter** 1997 Jul-Sep;(3):3-5 (Eng. Abstr.) **(Rus)**

[The role of free radical processes in the uterus--placenta--fetus system during adaptation to interval hypoxia] Piliavskaia AN, et al. **Patol Fiziol Eksp Ter** 1997 Jul-Sep;(3):24-6 (Eng. Abstr.) **(Rus)**

[A change in the composition of cardiac membrane phospholipids in the process of nonspecific myocardial adaptation] Sapronov NS, et al. **Patol Fiziol Eksp Ter** 1997 Jul-Sep;(3):8-10 (Eng. Abstr.) **(Rus)**

[Experience in treating patients with cardiovascular diseases by means of adaptation to periodic barochamber hypoxia] Aleshin IA, et al. **Ter Arkh** 1997;69(1):54-8 (Eng. Abstr.) **(Rus)**

[The characteristics of the adaptation to the hypoxic conditions at a low-altitude health resort in IHD patients after an aortocoronary bypass] Amiiants VIu. **Ter Arkh** 1996;68(9):52-4 (Eng. Abstr.) **(Rus)**

[The electrophoretic mobility of the erythrocytes in rats during body adaptation to low-temperature exposure] Matiushichev VB, et al. **Tsitologiia** 1996;38(11):1171-3 (Eng. Abstr.) **(Rus)**

[The nonspecific mechanisms of CNS adaptation to intermittent stimuli, EEG spectral structure and the optimal parameters of rhythmic sensory actions] Fedotchev AI, et al. **Usp Fiziol Nauk** 1996 Oct-Dec;27(4):44-62 (173 ref.) (Eng. Abstr.) **(Rus)**

[Changes in the physiological functions, the mechanisms of their recovery and the temperature limits for life under hypothermia] Ivanov KP. **Usp Fiziol Nauk** 1996 Jul-Sep; 27(3):84-105 (66 ref.) (Eng. Abstr.) **(Rus)**

[The role of the opioid system in body adaptation and protection of the heart in stress] Lishmanov IuB, et al. **Usp Fiziol Nauk** 1997 Jan-Mar;28(1):75-96 (120 ref.) (Eng. Abstr.) **(Rus)**

[Possibilities of normobaric hypoxic training in rehabilitation of patients with chronic bronchitis] Aleksandrov OV, et al. **Vestn Ross Akad Med Nauk** 1997;(5):27-30 (Eng. Abstr.) **(Rus)**

[Analysis of the effectiveness of interval hypoxic training in rehabilitation of apparently healthy persons: an individual approach] Glazachev OS, et al. **Vestn Ross Akad Med Nauk** 1997;(5):50-5 **(Rus)**

[Biomedical aspects of health preservation strategy: role of catecholaminergic neuronal populations] Iarygin VN, et al. **Vestn Ross Akad Med Nauk** 1997;(4):60-2 (Eng. Abstr.) **(Rus)**

[Medical use of stepwise adaptation to hypoxia] Kolchinskaia AZ. **Vestn Ross Akad Med Nauk** 1997;(5):12-9 (Eng. Abstr.) **(Rus)**

[Adaptation to hypoxia as a factor enhancing work capacity] Kozlov SA. **Vestn Ross Akad Med Nauk** 1997;(5):46-50 (Eng. Abstr.) **(Rus)**

[Morphology of myocardial adaptive responses to extreme environmental factors] Nepomniashchkh LM. **Vestn Ross Akad Med Nauk** 1997;(3):49-54 (42 ref.) (Eng. Abstr.) **(Rus)**

[Method of adaptometry in the evaluation of gastric secretory function in children under conditions of the North] Pokidysheva LI, et al. **Vestn Ross Akad Med Nauk** 1996; (5):42-5 (Eng. Abstr.) **(Rus)**

[Use of hypoxic training in sports medicine] Radzievskii PA. **Vestn Ross Akad Med Nauk** 1997;(5):41-6 (Eng. Abstr.) **(Rus)**

[The enhancement of the adaptive resistance of wounded patients to the action of the factors in air transport evacuation] Grechko AT, et al. **Voen Med Zh** 1996 Nov; 317(11):11-3 **(Rus)**

[Adaptation and military professional training] Korshever NG. **Voen Med Zh** 1997 Apr;318(4):51-3 **(Rus)**

[Bromide-iodide baths and magnetic-laser radiation in the correction of disorders of hemodynamics and of the adaptation processes in metallurgical workers] Konevskikh LA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jul-Aug;(4):20-2 (Eng. Abstr.) **(Rus)**

[Swimming as a means of enhancing the adaptive potentials of the disabled after amputation of the lower extremities] Kurdybailo SF, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Jan-Feb;(1):25-8 (Eng. Abstr.) **(Rus)**

[An integrated evaluation of the adaptation system and existing risk factors as a method for the objective assessment of the efficacy of sanatorium-health resort treatment] Treshutin VA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Mar-Apr; (2):30-4 **(Rus)**

[The participation of antioxidant systems in adaptive body reactions to the action of physical factors] Zubkova SM. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Mar-Apr;(2):3-7 (Eng. Abstr.) **(Rus)**

[Key mechanisms of damage and adaptation in the body under the multi-factoral effect of ecotoxicants] Gil'miiarova FN, et al. **Vopr Med Khim** 1996 Oct-Dec; 42(4):344-7 (Eng. Abstr.) **(Rus)**

[The ratio 3H/14C as an indicator of body adaptation to various dietary factors] Antonova ZhV, et al. **Vopr Pitan** 1996;(2):7-10 (Eng. Abstr.) **(Rus)**

[Bacterial virulence as a function of adaptation] Domaradskiĭ IV. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jul-Aug; (4):16-20 (38 ref.) **(Rus)**

[The problems of the adaptation of pathogenic bacteria to the environment] Domaradskiĭ IV. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jul-Aug;(4):31-5 (52 ref.) **(Rus)**

[Intersensory correlations in diabetic neuropathy during adaptation to intervalic normobaric hypoxia] Starkova NT, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997; 97(3):40-4 (Eng. Abstr.) **(Rus)**

[The adaptive regulation of the nonlinear dynamics of brain electrical activity] Mogilevskiĭ Ala, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Jan-Feb; 47(1):147-58 (Eng. Abstr.) **(Rus)**

[The role of bone morphogenetic proteins in compensatory renal growth] Bašić N. **Lijec Vjesn** 1997 Feb;119(2):53-5 (Eng. Abstr.) **(Scr)**

[Use of biological feedback in persons with complete new dental prostheses during the initial period of functional adaptation] Miljković Z, et al. **Vojnosanit Pregl** 1996 May-Jun;53(3):209-13 (Eng. Abstr.) **(Scr)**

[The effect of functional asymmetry of the brain on the processes of adaptation to dentures] Dmytrenko AM, et al. **Fiziol Zh** 1996;42(5-6):101-4 (Eng. Abstr.) **(Ukr)**

[Disorders of myocardial contractile function and the mechanisms of their compensation in ischemic heart disease in man] Moĭbenko OO, et al. **Fiziol Zh** 1995 Sep-Dec; 41(5-6):70-9 (Eng. Abstr.) **(Ukr)**

[The adaptive characteristics of the small intestine under chronic experimental conditions] Voloshenovych MI, et al. **Fiziol Zh** 1996;42(1-2):113-9 (Eng. Abstr.) **(Ukr)**

DRUG EFFECTS

Effect of theophylline on adaptation of the heart to myocardial ischemia during percutaneous transluminal coronary angioplasty in patients with stable angina pectoris. Hashimura K, et al. **Am J Cardiol** 1997 Feb 15;79(4):475-7

LPS-induced delayed myocardial adaptation enhances acute preconditioning to optimize postischemic cardiac function. Rowland RT, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2708-15

Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. Demopoulos L, et al. **Circulation** 1997 Apr 1;95(7):1764-7

Adaptive changes in the proenkephalin and D2 dopamine receptor mRNA expression after chronic cocaine in the nucleus accumbens and striatum of the rat. Przewlocka B, et al. **Eur Neuropsychopharmacol** 1995 Dec;5(4):465-9

The opioid receptor antagonist, naloxone, enhances ocular motor compensation in guinea pig following peripheral vestibular deafferentation. Dutia MB, et al. **Exp Neurol** 1996 Sep;141(1):141-4

Adaptation to ozone in rats and its association with ascorbic acid in the lung. Wiester MJ, et al. **Fundam Appl Toxicol** 1996 May;31(1):56-64

Adaptive control of arterial blood pressure with a learning controller based on multilayer neural networks. Chen CT, et al. **IEEE Trans Biomed Eng** 1997 Jul;44(7):601-9

Norepinephrine-induced sustained myocardial adaptation to ischemia is dependent on alpha 1-adrenoceptors and protein synthesis. Meng X, et al. **J Mol Cell Cardiol** 1996 Sep;28(9):2017-25

Adaptive changes in the rat dopaminergic transmission following repeated lithium administration. Dziedzicka-Wasylewska M, et al. **J Neural Transm Gen Sect** 1996;103(7):765-76

Responses of gustatory cells in the nucleus of the solitary tract of the hamster after NaCl or amiloride adaptation. Smith DV, et al. **J Neurophysiol** 1996 Jul;76(1):47-58

Early diazepam treatment following unilateral labyrinthectomy does not impair vestibular compensation of spontaneous nystagmus in guinea pig. Martin J, et al. **J Vestib Res** 1996 Mar-Apr;6(2):135-9

Both bovine and rabbit lymphocytes conditioned with hydrogen peroxide show an adaptive response to radiation damage. Flores MJ, et al. **Mutat Res** 1996 Nov 11; 372(1):9-15

Evidence that short ACTH fragments enhance vestibular compensation via direct action on the ipsilateral vestibular nucleus. Gilchrist DP, et al. **Neuroreport** 1996 Jun 17; 7(9):1489-92

The effect of Losartan, an angiotensin II antagonist, on cardiac function, mass and morphology in rats after repeated hyperbaric exposures. Stuhr LE, et al. **Scand J Clin Lab Invest** 1997 May;57(3):253-61

[The effect of ximedon on adaptation to prolonged immobilization stress] Zor'kina AV, et al. **Eksp Klin Farmakol** 1997 Jan-Feb;60(1):65-7 (Eng. Abstr.) **(Rus)**

[The adaptation-protective effect of corticosteroids on the rat gastric mucosa and its mechanism] Filaretov AA, et al. **Fiziol Zh Im I M Sechenova** 1996 Mar;82(3):141-50 (Eng. Abstr.) **(Rus)**

[Antistressor action of neutrophilokine] Kolesnikov OL, et al. **Patol Fiziol Eksp Ter** 1996 Apr-Jun;(2):20-2 (Eng. Abstr.) **(Rus)**

[Role of glutathione containing amino acids in the correction of body's dysadaptation states] Pavlov VA. **Probl Tuberk** 1997;(3):51-3 (10 ref.) (Eng. Abstr.) **(Rus)**

[The effect of dietary calcium on the level of body adaptation under conditions of cesium-137 and lead loading] Korolev AA, et al. **Vopr Pitan** 1996;(3):34-7 (Eng. Abstr.) **(Rus)**

GENETICS

Adaptive mutation: a general phenomenon or special case? Benson S. **Bioessays** 1997 Jan;19(1):9-11 (32 ref.)

Removal of O6-methylguanine from plant DNA in vivo is accelerated under conditions of clastogenic adaptation. Baranczewski P, et al. **Environ Mol Mutagen** 1997; 29(4):400-5

Osmoregulation and protein expression in a pbs2delta mutant of Saccharomyces cerevisiae during adaptation to hypersaline stress. Akhtar N, et al. **FEBS Lett** 1997 Feb 17;403(2):173-80

Long-term experimental evolution in Escherichia coli. VI. Environmental constraints on adaptation and divergence. Travisano M. **Genetics** 1997 Jun;146(2):471-9

A novel RNA species from the turtle mitochondrial genome: induction and regulation of transcription and processing under anoxic and freezing stresses. Cai Q, et al. **Genome** 1997 Aug;40(4):534-43

Mechanisms for solvent tolerance in bacteria. Ramos JL, et al. **J Biol Chem** 1997 Feb 14;272(7):3887-90

Heritability of adaptive variation: an old problem revisited [editorial] Klissouras V. **J Sports Med Phys Fitness** 1997 Mar;37(1):1-6 (30 ref.)

Mutation rates as adaptations. Maley C. **J Theor Biol** 1997 Jun 7;186(3):339-48

The limit to human longevity: an approach through a stress theory of ageing. Parsons PA. **Mech Ageing Dev** 1996 Jun 25;87(3):211-8 (46 ref.)

Adaptive mutations: an additional view [letter] Savic DJ. **Mol Microbiol** 1996 Jul;21(2):429-30

Interaction of low-dose irradiation with subsequent mutagenic treatment: role of mitotic delay. Salone B, et al. **Mutat Res** 1996 Nov 4;358(2):155-60

Adaptive mutations: a challenge to neo-Darwinism? Savic DJ. **Sci Prog** 1997;80 (Pt 2):125-45 (53 ref.)

QTL for insect resistance and drought tolerance in tropical maize: prospects for marker assisted selection. Hoisington D, et al. **Symp Soc Exp Biol** 1996;50:39-44

Mechanisms of salt tolerance conferred by overexpression of the HAL1 gene in Saccharomyces cerevisiae. Rios G, et al. **Yeast** 1997 May;13(6):515-28

[Hereditary biochemical diversity in the processes of evolution and individual development] Altukhov IuP, et al. **Genetika** 1996 Nov;32(11):1450-73 (199 ref.) (Eng. Abstr.) **(Rus)**

[Effect of exogamy on morbidity among children during the first three years of life] Dubrova IuE, et al. **Genetika** 1997 Jan;33(1):116-22 (Eng. Abstr.) **(Rus)**

[Resistance to hunger as an element of the adaptive strategy of malaria mosquito larva] Gordeev MI. **Genetika** 1997 Jun; 33(6):844-51 (Eng. Abstr.) **(Rus)**

[Detection of the adaptive significance of human blood group polymorphism by analyzing a series of loci. Level of heterozygosity and variety of phenotypes in two generations] Kurbatova OL. **Genetika** 1996 Jul; 32(7):996-1006 (Eng. Abstr.) **(Rus)**

[Cytogenetic and cytobiophysical study of temperature adaptation and heterosis mechanisms in Drosophila melanogaster Meig] Strashniuk VIu, et al. **Genetika** 1997 Jun;33(6):793-9 (Eng. Abstr.) **(Rus)**

[Gene-enzyme alcohol dehydrogenase system and adaptability in Drosophila melanogaster] Tots'kiĭ VM, et al. **Ukr Biokhim Zh** 1996 May-Jun;68(3):62-9 (Eng. Abstr.) **(Ukr)**

ADAPTATION, PHYSIOLOGICAL

IMMUNOLOGY

Selection and adaptation of cells expressing major histocompatibility complex class I–specific receptors of the natural killer complex. Bendelac A. **J Exp Med** 1997 Aug 4;186(3):349–51

Immunologic adaptations during pregnancy. Priddy KD. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug;26(4):388–94 (18 ref.)

Trophic effects of interleukin–11 in rats with experimental short bowel syndrome. Liu Q, et al. **J Pediatr Surg** 1996 Aug;31(8):1047–50; discussion 1050–1

The use of tolerance for transplantation across xenogeneic barriers. Greenstein JL, et al. **Nat Biotechnol** 1997 Mar; 15(3):235–8 (57 ref.)

T-cell homeostasis in HIV infection is neither failing nor blind: modified cell counts reflect an adaptive response of the host. Grossman Z, et al. **Nat Med** 1997 May;3(5):486–90

Events in the adaptation of natural killer cell receptors to MHC class I polymorphisms. Parham P. **Res Immunol** 1997 Mar–Apr;148(3):190–4 (19 ref.)

Effects of resuscitation fluids on nonadaptive immune responses. Sillett HK, et al. **Transfusion** 1997 Sep; 37(9):953–9

[Immunological reactions during adaptation to measured heat factor] Solov'ev AS. **Biull Eksp Biol Med** 1994 May; 117(5):502–4 **(Rus)**

[Role of T-lymphocytes in impaired adaptive reaction of the hemopoietic system in emotional stress developed after preliminary gamma-irradiation] Moroz BB, et al. **Patol Fiziol Eksp Ter** 1996 Jul–Sep;(3):10–3 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Changes in the genetic expression of membrane proteins as a determinant of myocardial dysfunction. Swynghedauw B. **Acta Cardiol** 1996;51(4):301–14

Morphologic changes in the vestibular nerves and nuclei after labyrinthectomy in the cat: a case for the neurotrophin hypothesis in vestibular compensation. Gacek RR, et al. **Acta Otolaryngol (Stockh)** 1997 Mar;117(2):244–9

Neonatal insulin secretion: implications for the programming of metabolic homeostasis. Aynsley-Green A, et al. **Acta Paediatr Jpn** 1997 Apr;39 Suppl 1:S21–5 (31 ref.)

Role of increased insulin demand in the adaptation of the endocrine pancreas to pregnancy. Nieuwenhuizen AG, et al. **Acta Physiol Scand** 1997 Apr;159(4):303–12

Serine proteinases from cold-adapted organisms. Kristjánsson MM, et al. **Adv Exp Med Biol** 1997;415:27–46 (93 ref.)

Regulation of neuronal nitric oxide synthase gene expression by hypoxia. Role of nitric oxide in respiratory adaptation to low pO2. Prabhakar NR, et al. **Adv Exp Med Biol** 1996; 410:345–8

Gender dimorphism in cardiac adaptation to hypertension is unveiled by prior treatment and efficacy. Zabalgoitia M, et al. **Am J Cardiol** 1996 Oct 1;78(7):838–40

Gender-specific cardiovascular adaptation due to circadian blood pressure variations in essential hypertension. Schmieder RE, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 1):1160–6

Correlates of maladaptive behavior in children and adults with Prader-Willi syndrome. Dykens EM, et al. **Am J Med Genet** 1995 Dec 18;60(6):546–9

Protein kinase C mediates Ca2(+)-induced cardioadaptation to ischemia-reperfusion injury. Meldrum DR, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R718–26

The role of blink adaptation in the pathophysiology of benign essential blepharospasm. Hasan SA, et al. **Arch Ophthalmol** 1997 May;115(5):631–6

Heart rate as a measure of adaptation to stress in cattle. Cook CJ, et al. **Aust Vet J** 1996 Dec;74(6):471–2

Ambulatory blood pressure monitoring in clinically healthy subjects adapted to living in Antarctica. Cugini P, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):795–801

ACTH and growth hormone in myocardial LDH adaptation to hypoxia in rats. Kaaja R, et al. **Basic Res Cardiol** 1996 Jul–Aug;91(4):269–74

Activity-dependent regulation of neural networks: the role of inhibitory synaptic plasticity in adaptive gain control in the siphon withdrawal reflex of Aplysia. Fischer TM, et al. **Biol Bull** 1997 Feb;192(1):164–6

Behavioural adaptation of laying hens to dilution of diets under mash and pellet form. Vilariño M, et al. **Br Poult Sci** 1996 Dec;37(5):895–907

Morphine dependence in human neuroblastoma SH-SY5Y cells is associated with adaptive changes in both the quantity and functional interaction of PGE1 receptors and stimulatory G proteins. Ammer H, et al. **Brain Res** 1996 Jan 29;707(2):235–44

Temporal relationship between the expression of fos, jun and krox-24 in the guinea pig vestibular nuclei during the development of vestibular compensation for unilateral vestibular deafferentation. Darlington CL, et al. **Brain Res** 1996 Sep 30;735(1):173–6

Monkey superior colliculus activity during short-term saccadic adaptation. Frens MA, et al. **Brain Res Bull** 1997; 43(5):473–83

Oxidative stress: animal adaptations in nature. Storey KB. **Braz J Med Biol Res** 1996 Dec;29(12):1715–33 (85 ref.)

Morphological adaptations of neuromuscular junctions depend on fiber type. Sieck GC, et al. **Can J Appl Physiol** 1997 Jun;22(3):197–230 (156 ref.)

Loss of cardiovascular adaptations after physical inactivity. Ehsani AA, et al. **Cardiol Clin** 1997 Aug;15(3):431–8 (54 ref.)

Considerations for racial differences in the athlete's heart and related cardiovascular disease. Lewis JF. **Cardiol Clin** 1997 Aug;15(3):485–91 (64 ref.)

Pemenone and androstenone do not cross-adapt reciprocally. Stevens DA, et al. **Chem Senses** 1996 Dec;21(6):711–7

Mouth movements diminish taste adaptation, but rate of mouth movement does not affect adaptation. Theunissen MJ, et al. **Chem Senses** 1996 Oct;21(5):545–51

Psychophysics of motion adaptation parallels insect electrophysiology. Clifford CW, et al. **Curr Biol** 1996 Oct 1;6(10):1340–2

Gait analysis by measuring ground reaction forces in children: changes to an adaptive gait pattern between the ages of one and five years. Preis S, et al. **Dev Med Child Neurol** 1997 Apr;39(4):228–33

Involvement of capsaicin-sensitive sensory nerves in gastric adaptive relaxation in isolated guinea-pig stomachs. Uno H, et al. **Digestion** 1997;58(3):232–9

The two isoenzymes for yeast NAD+-dependent glycerol 3-phosphate dehydrogenase encoded by GPD1 and GPD2 have distinct roles in osmoadaptation and redox regulation. Ansell R, et al. **EMBO J** 1997 May 1;16(9):2179–87

Some aspects of perinatal maturation and adaptation. Mellor DJ. **Equine Vet J Suppl** 1993 Apr;(14):17–22 (110 ref.)

High intensity knee extensor training, in patients with chronic heart failure. Major skeletal muscle improvement. Magnusson G, et al. **Eur Heart J** 1996 Jul;17(7):1048–55

Distinguishing between the warm-up phenomenon and training during repeated exercise testing [letter; comment] Maybaum S, et al. **Eur Heart J** 1997 Feb;18(2):352–3. Comment on: Eur Heart J 1996 Jul;17(7):1022–7.

Neuromuscular adaptations in rats trained by muscle stretch-shortening. Almeida-Silveira MI, et al. **Eur J Appl Physiol** 1996;72(3):261–6

Sweat distribution before and after repeated heat exposure. Cotter JD, et al. **Eur J Appl Physiol** 1997;76(2):181–6

Metabolic and performance adaptations to interval training in endurance-trained cyclists. Westgarth-Taylor C, et al. **Eur J Appl Physiol** 1997;75(4):298–304

Reaction of term newborns with prolonged postnatal dyspnoea to early oxygen, mask CPAP and volume expansion: a prospective randomized clinical trial [letter; comment] Roberton NR. **Eur J Pediatr** 1997 May; 156(5):419–20. Comment on: Eur J Pediatr 1996 Sep;155(9):805–10.

Functional adaptations in patients with ACL-deficient knees. Hurwitz DE, et al. **Exerc Sport Sci Rev** 1997;25:1–20 (43 ref.)

Steroids modulate the excitability of crayfish (Procambarus digueti) photoreceptors: long- and short-term actions. Hernández-Falcón J, et al. **Gen Comp Endocrinol** 1997 Feb; 105(2):255–69

Changes in plasma atrial and ventricular natriuretic peptide concentrations after transfer of eels from freshwater to seawater or vice versa. Kaiya H, et al. **Gen Comp Endocrinol** 1996 Dec;104(3):337–45

Atrial and ventricular natriuretic peptide concentrations in plasma of freshwater- and seawater-adapted eels. Kaiya H, et al. **Gen Comp Endocrinol** 1996 May;102(2):183–90

Diurnal changes in plasma arginine vasotocin and isotocin in rainbow trout adapted to fresh water and brackish Baltic water. Kulczykowska E, et al. **Gen Comp Endocrinol** 1996 Nov;104(2):197–202

Adaptation of rainbow trout to seawater: changes in calcitonin gene-related peptide levels are associated with an increase in hormone-receptor interaction in gill membranes. Najib L, et al. **Gen Comp Endocrinol** 1996 May; 102(2):274–80

Adaptive plasticity of Xenopus glial cells in vitro and after CNS fiber tract lesions in vivo. Lang DM, et al. **Glia** 1996 Oct;18(2):92–106

Hemodynamic adaptation to orthostatic stress after orthotopic heart transplantation. Doering LV, et al. **Heart Lung** 1996 Sep-Oct;25(5):339–51

Metabolic control during preimplantation mammalian development. Leese HJ. **Hum Reprod Update** 1995 Jan; 1(1):63–72 (106 ref.)

Endogenous opioid peptides stimulate post-exercise insulin response to glucose in rats. Bouix O, et al. **Int J Sports Med** 1996 Feb;17(2):80–4

Modeling of adaptations to physical training by using a recursive least squares algorithm. Busso T, et al. **J Appl Physiol** 1997 May;82(5):1685–93

Greater initial adaptations to submaximal muscle lengthening than maximal shortening. Hortobágyi T, et al. **J Appl Physiol** 1996 Oct;81(4):1677–82

Physiological adaptations to a weight-loss dietary regimen and exercise programs in women. Kraemer WJ, et al. **J Appl Physiol** 1997 Jul;83(1):270–9

Adaptation to hypercapnia vs. intracellular pH in cat carotid body: responses in vitro. Lahiri S, et al. **J Appl Physiol** 1996 Apr;80(4):1090–9

Maximal exercise performance after adaptation to microgravity. Levine BD, et al. **J Appl Physiol** 1996 Aug; 81(2):686–94

Ovine fetal adaptations to chronically reduced urine flow: preservation of amniotic fluid volume. Mann SE, et al. **J Appl Physiol** 1996 Dec;81(6):2588–94

"Adaptation to hypercapnia vs. intracellular pH in cat carotid body: responses in vitro" [editorial] Nattie E. **J Appl Physiol** 1996 Apr;80(4):1088–9

Adaptive responses of hypertrophying skeletal muscle to endurance training. Stone J, et al. **J Appl Physiol** 1996 Aug; 81(2):665–72

Metabolic and phenotypic adaptations of diaphragm muscle fibers with inactivation. Zhan WZ, et al. **J Appl Physiol** 1997 Apr;82(4):1145–53

Effect of acute cold exposure on norepinephrine turnover rates in rat white adipose tissue. Garofalo MA, et al. **J Auton Nerv Syst** 1996 Sep 12;60(3):206–8

Conflicting bright light exposure during night shifts impedes circadian adaptation. Mitchell PJ, et al. **J Biol Rhythms** 1997 Feb;12(1):5–15

Changes in selected aspects of immune function in the leopard frog, Rana pipiens, associated with exposure to cold. Maniero GD, et al. **J Comp Physiol [B]** 1997 May; 167(4):256–63

Effect of yeast culture (Saccharomyces cerevisiae) on adaptation of cows to diets postpartum. Robinson PH. **J Dairy Sci** 1997 Jun;80(6):1119–25

Hypometabolic homeostasis in overwintering aquatic amphibians. Boutilier RG, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):387–400 (122 ref.)

Contrasting strategies for anoxic brain survival--glycolysis up or down. Lutz PL, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):411–9 (59 ref.)

Light adaptation in Pecten hyperpolarizing photoreceptors. Insensitivity to calcium manipulations. Gomez MP, et al. **J Gen Physiol** 1997 Mar;109(3):371–84

Membrane phospholipids in temperature adaptation of Candida utilis: alterations in fatty acid chain length and unsaturation. Suutari M, et al. **J Lipid Res** 1997 Apr; 38(4):790–4

Motor skill learning in Parkinson's disease. Agostino R, et al. **J Neurol Sci** 1996 Aug;139(2):218–26

Effects of adaptation on neural coding by primary sensory interneurons in the cricket cercal system. Clague H, et al. **J Neurophysiol** 1997 Jan;77(1):207–20

Short-term adaptation of electrically induced saccades in monkey superior colliculus. Melis BJ, et al. **J Neurophysiol** 1996 Sep;76(3):1744–58

Characteristics of saccadic gain adaptation in rhesus macaques. Straube A, et al. **J Neurophysiol** 1997 Feb; 77(2):874–95

Logarithmic time course of sensory adaptation in electrosensory afferent nerve fibers in a weakly electric fish. Xu Z, et al. **J Neurophysiol** 1996 Sep;76(3):2020–32

Developmental adaptation of rat nociceptive withdrawal reflexes after neonatal tendon transfer. Holmberg H, et al. **J Neurosci** 1997 Mar 15;17(6):2071–8

Retinoic acid stimulates early cellular proliferation in the adapting remnant rat small intestine after partial resection. Wang JL, et al. **J Nutr** 1997 Jul;127(7):1297–303

A novel role for HERG K+ channels: spike-frequency adaptation. Chiesa N, et al. **J Physiol (Lond)** 1997 Jun 1; 501 (Pt 2):313–8

Developmental adaptation of withdrawal reflexes to early alteration of peripheral innervation in the rat. Holmberg H, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):399–409

Role of cytoplasmic calcium concentration in the bleaching adaptation of salamander cone photoreceptors. Matthews HR, et al. **J Physiol (Lond)** 1996 Jan 15;490 (Pt 2):293–303

"Torso rotation" experiments; 1: Adaptation to motion sickness does not correlate with changes in VOR gain. Bouyer LJ, et al. **J Vestib Res** 1996 Sep-Oct;6(5):367–75

"Torso rotation" experiments; 2: Gaze stability during voluntary head movements improves with adaptation to motion sickness. Bouyer LJ, et al. **J Vestib Res** 1996 Sep-Oct;6(5):377–85

New treatment for patients with short-bowel syndrome: growth hormone, glutamine and a modified diet. Sax HC. **JPEN J Parenter Enteral Nutr** 1996 Sep-Oct;20(5):375–6

Short-chain fatty acids increase proglucagon and ornithine decarboxylase messenger RNAs after intestinal resection in rats. Tappenden KA, et al. **JPEN J Parenter Enteral Nutr** 1996 Sep-Oct;20(5):357–62

Luminal short-chain fatty acids and postresection intestinal adaptation. Thompson JS, et al. **JPEN J Parenter Enteral Nutr** 1996 Sep-Oct;20(5):338–43

Changes of the plasma endothelin in adaptation to increased salt intake in rats. Oh HS, et al. **Korean J Intern Med** 1997 Jan;12(1):62–6

Intensive exercise training during bed rest attenuates deconditioning. Greenleaf JE. **Med Sci Sports Exerc** 1997 Feb;29(2):207–15

Skeletal muscle adaptations to training under normobaric hypoxic versus normoxic conditions. Melissa L, et al. **Med Sci Sports Exerc** 1997 Feb;29(2):238–43

Role of radioadaptation on radiation-induced thymic lymphoma in mice. Bhattacharjee D. **Mutat Res** 1996 Nov 4;358(2):231–5

Radioadaptation for gene mutation and the possible molecular mechanisms of the adaptive response. Rigaud O, et al. **Mutat Res** 1996 Nov 4;358(2):127–34 (46 ref.)

Radioadaptive response: an implication for the biological consequences of low dose-rate exposure to radiations. Sasaki MS. **Mutat Res** 1996 Nov 4;358(2):207–13

Aspects of the adaptive response to very low doses of radiation and other agents. Wolff S. **Mutat Res** 1996 Nov 4;358(2):135–42

Phosphate analogs block adaptation in hair cells by inhibiting

adaptation–motor force production. Yamoah EN, et al. **Neuron** 1996 Sep;17(3):523–33

Biochemical adaptations in the mesolimbic dopamine system in response to repeated stress. Ortiz J, et al. **Neuropsychopharmacology** 1996 Jun;14(6):443–52

Role of neurotrophic factors in adaptational processes of the nervous system. Akoev GN, et al. **Neurosci Behav Physiol** 1997 May–Jun;27(3):207–11

Basic molecular–cellular mechanisms of adaptive responses of the brain. Samoilov MO. **Neurosci Behav Physiol** 1997 May–Jun;27(3):200–6 (32 ref.)

Localization of NADPH–diaphorase activity in the salt gland of the saltwater–acclimated Pekin duck. Hübschle T, et al. **Neurosci Lett** 1995 Nov 24;200(3):163–6

Changes in eye blink responses following hypoglossal–facial anastomosis in the cat: evidence of adult mammal motoneuron unadaptability to new motor tasks. Gruart A, et al. **Neuroscience** 1996 Jul;73(1):233–47

PR interval adaptation in the denervated transplanted heart. Koller–Strametz J, et al. **Pacing Clin Electrophysiol** 1997 May;20(5 Pt 1):1247–51

Grooming secretions and seasonal adaptations in the blind mole rat (Spalax ehrenbergi). Shanas U, et al. **Physiol Behav** 1996 Aug;60(2):653–6

Group selection for adaptation to multiple–hen cages: behavioral responses. Craig JV, et al. **Poult Sci** 1996 Oct; 75(10):1145–55

Group selection for adaptation to multiple–hen cages: hematology and adrenal function. Hester PY, et al. **Poult Sci** 1996 Nov;75(11):1295–307

Group selection for adaptation to multiple–hen cages: production traits during heat and cold exposures. Hester PY, et al. **Poult Sci** 1996 Nov;75(11):1308–14

Group selection for adaptation to multiple–hen cages: humoral immune response. Hester PY, et al. **Poult Sci** 1996 Nov;75(11):1315–20

The central adaptation syndrome: psychosocial stress as a trigger for adaptive modifications of brain structure and brain function. Huether G. **Prog Neurobiol** 1996 Apr; 48(6):569–612 (455 ref.)

Long–term adaptation to electrically induced cycle training in severe spinal cord injured individuals. Mohr T, et al. **Spinal Cord** 1997 Jan;35(1):1–16

Adaptive changes in the somatotopic properties of individual thalamic neurons immediately following microlesions in connected regions of the nucleus cuneatus. Alloway KD, et al. **Synapse** 1996 Jan;22(1):1–14

An adaptive Reichardt detector model of motion adaptation in insects and mammals. Clifford CW, et al. **Vis Neurosci** 1997 Jul–Aug;14(4):741–9

Effects of different energy levels, concentrate/forage ratios and lipid supplementation to the diet on the adaptation of the energy metabolism at calving in dairy cows. Holtenius P, et al. **Zentralbl Veterinarmed A** 1996 Sep;43(7):427–35

[Evolution promotes a minimal effect of fetal labor stress during birth] Wenderlein JM. **Z Geburtshilfe Neonatol** 1997 May–Jun;201(3):82–5 (Eng. Abstr.) **(Ger)**

[Homeostasis and adaptability in the elderly] Schütz RM. **Z Gerontol Geriatr** 1997 May–Jun;30(3):180–4 **(Ger)**

[The effect of the 120–day antiorthostatic hypokinesia on the functional state of female thyroid] Goncharova AG. **Aviakosm Ekolog Med** 1996;30(6):60–2 (Eng. Abstr.) **(Rus)**

[Making of the clinicophysiological diagnosis within the system of medical flight certification] Karlov VN. **Aviakosm Ekolog Med** 1996;30(6):52–7 (Eng. Abstr.) **(Rus)**

[Adaptational disorders of the cardiovascular regulation during brief exposure to hypobaric hypoxia] Karlov VN, et al. **Aviakosm Ekolog Med** 1996;30(5):19–22 (Eng. Abstr.) **(Rus)**

[Spontaneous and visually–induced oculomotor reactions in microgravity (Results of Austrian–Russian Experiment "Optovert" performed within the frame of program "Austromir", part II)] Kornilova LN, et al. **Aviakosm Ekolog Med** 1996;30(1):10–6 (Eng. Abstr.) **(Rus)**

[Tolerance of +Gz loads by space physician Poliakov VV during the active phases of his 438–days space mission] Kotovskaia AR, et al. **Aviakosm Ekolog Med** 1997; 31(1):29–34 (Eng. Abstr.) **(Rus)**

[Tolerance of +Gx–loads by females before and after a 120–day hypokinesia] Lukianiuk VI, et al. **Aviakosm Ekolog Med** 1997;31(1):68–74 (Eng. Abstr.) **(Rus)**

[The problem of adaptation to space flight] Malkin VB, et al. **Aviakosm Ekolog Med** 1996;30(6):64–6 (14 ref.) (Eng. Abstr.) **(Rus)**

[Cytological features of human lymphocytes after long space flights] Novoderzhkina IK, et al. **Aviakosm Ekolog Med** 1996;30(5):66–9 **(Rus)**

[Developing and testing of decompression regimes for caisson operations while constructing Moscow metro] Rodchenkov SV, et al. **Aviakosm Ekolog Med** 1996;30(5):23–8 (Eng. Abstr.) **(Rus)**

[Prediction of G–load (Gz) tolerance based on various functional tests] Suvorov PM, et al. **Aviakosm Ekolog Med** 1996;30(5):4–9 (Eng. Abstr.) **(Rus)**

[Opiatergic mechanisms of antiarrhythmic effect of adaptation] Lishmanov IuB, et al. **Biull Eksp Biol Med** 1996 Sep;122(9):276–8 **(Rus)**

[Morphological changes in dogs liver during altitude adaptation] Orlova EV, et al. **Biull Eksp Biol Med** 1997 Jun;123(6):714–7 **(Rus)**

[Opposite effects of adaptation to physical exertion on the myocardium and skeletal muscle. Ca–transporting system of the sarcoplasmic reticulum and the enzymes of the antioxidant defense] Sazontova TG, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):623–8 **(Rus)**

[Development of increased resistance of Ca–pump of the myocardial sarcoplasmic reticulum during adaptation to stress] Sazontova TG, et al. **Biull Eksp Biol Med** 1997 Mar; 123(3):272–6 **(Rus)**

[Relationship between the adaptation capacity of the organism and the type of response of the opioid system to the stress physical load] Surkina ID, et al. **Biull Eksp Biol Med** 1996 Aug;122(8):135–8 **(Rus)**

[Post–clinical period of disease: metabolic aspects] Endakova EA, et al. **Vestn Ross Akad Med Nauk** 1997;(8):15–9 (21 ref.) (Eng. Abstr.) **(Rus)**

[Adaptation to exercises after exposure to restriction stress] Inchina VI, et al. **Vestn Ross Akad Med Nauk** 1996; (9):18–20 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Light adaptation and reliability in blowfly photoreceptors. de Ruyter van Steveninck RR, et al. **Int J Neural Syst** 1996 Sep;7(4):437–44

Characterization of the adaptive response to ionizing radiation induced by low doses of X–rays to Vibrio cholerae cells. Basak J. **Mutat Res** 1996 Nov 11; 372(1):115–8

Relationship between radiation induced adaptive response in human fibroblasts and changes in chromatin conformation. Belyaev IYa, et al. **Mutat Res** 1996 Nov 4;358(2):223–30

Altered G1 checkpoint control determines adaptive survival responses to ionizing radiation. Boothman DA, et al. **Mutat Res** 1996 Nov 4;358(2):143–53

Radioadaptive response: efficient repair of radiation–induced DNA damage in adapted cells. Ikushima T, et al. **Mutat Res** 1996 Nov 4;358(2):193–8

Hypersensitivity to very–low single radiation doses: its relationship to the adaptive response and induced radioresistance. Joiner MC, et al. **Mutat Res** 1996 Nov 4; 358(2):171–83 (71 ref.)

Radioadaptation for gene mutation and the possible molecular mechanisms of the adaptive response. Rigaud O, et al. **Mutat Res** 1996 Nov 4;358(2):127–34 (46 ref.)

Interaction of low–dose irradiation with subsequent mutagenic treatment: role of mitotic delay. Salone B, et al. **Mutat Res** 1996 Nov 4;358(2):155–60

Radioadaptive response: an implication for the biological consequences of low dose–rate exposure to radiations. Sasaki MS. **Mutat Res** 1996 Nov 4;358(2):207–13

A low, adaptive dose of gamma–rays reduced the number and altered the spectrum of S1– mutants in human–hamster hybrid AL cells. Ueno AM, et al. **Mutat Res** 1996 Nov 4;358(2):161–9

Aspects of the adaptive response to very low doses of radiation and other agents. Wolff S. **Mutat Res** 1996 Nov 4;358(2):135–42

Two types of X–ray–induced radioresistance in mice: presence of 4 dose ranges with distinct biological effects. Yonezawa M, et al. **Mutat Res** 1996 Nov 4;358(2):237–43

UVA II exposure of human skin results in decreased immunization capacity, increased induction of tolerance and a unique pattern of epidermal antigen–presenting cell alteration. LeVee GJ, et al. **Photochem Photobiol** 1997 Apr; 65(4):622–9

[The possible role of the elements of protein secondary structure in adaptation to the action of ionizing radiation] Kharchenko LI, et al. **Izv Akad Nauk Ser Biol** 1997 Jan–Feb;(1):5–10 (Eng. Abstr.) **(Rus)**

[Effect of UV–irradiation of blood on the course of adaptation to conditions of hypodynamia] Zorkina AV, et al. **Patol Fiziol Eksp Ter** 1996 Apr–Jun;(2):22–4 (Eng. Abstr.) **(Rus)**

[An analysis of the cellular distribution of chromosome aberrations induced in human lymphocytes after a single irradiation and under conditions of preliminary adaptive exposure] Riabchenko NI, et al. **Radiats Biol Radioecol** 1996 Nov–Dec;36(6):825–33 (Eng. Abstr.) **(Rus)**

[The adaptation of natural plant populations to chronic irradiation due to the accident at the Chernobyl Atomic Electric Power Station] Dmitrieva SA. **Tsitol Genet** 1996 Jul–Aug;30(4):3–8 (Eng. Abstr.) **(Rus)**

[The effect of dietary calcium on the level of body adaptation under conditions of cesium–137 and lead loading] Korolev AA, et al. **Vopr Pitan** 1996;(3):34–7 (Eng. Abstr.) **(Rus)**

ADAPTATION, PSYCHOLOGICAL

see related

SOCIAL ADJUSTMENT

Fatigue, workload and adaptive driver systems. Hancock PA, et al. **Accid Anal Prev** 1997 Jul;29(4):495–506

Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis. Jønsson A, et al. **Acta Neurol Scand** 1996 Apr;93(4):229–35

Psychological adjustment of infertile women entering IVF treatment: differentiating aspects and influencing factors. Bringhenti F, et al. **Acta Obstet Gynecol Scand** 1997 May; 76(5):431–7

Young adults with alpha 1–antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high–risk condition. Sveger T, et al. **Acta Paediatr** 1997 Jan;86(1):37–40

Psychological reactions at the onset of insulin–dependent diabetes mellitus in children and later adjustment and metabolic control. Thernlund G, et al. **Acta Paediatr** 1996 Aug;85(8):947–53

Psychosocial problems of children and adolescents with a chronic disease: coping strategies. Milousheva J, et al. **Acta Paediatr Jpn** 1996 Feb;38(1):41–5

Vulnerable but invincible: high–risk children from birth to adulthood. Werner EE. **Acta Paediatr Suppl** 1997 Jul; 422:103–5

Coping styles and suicide risk. Horesh N, et al. **Acta Psychiatr Scand** 1996 Jun;93(6):489–93

A new questionnaire assessing coping strategies in relatives of patients with schizophrenia: development and factor analysis. Magliano L, et al. **Acta Psychiatr Scand** 1996 Oct; 94(4):224–8

Coping strategies among the long–term mentally ill: categorization and clinical determinants. Middelboe T, et al. **Acta Psychiatr Scand** 1997 Sep;96(3):188–94

Changing patterns of distress during the adjustment of recent immigrants: a 1–year follow–up study. Ritsner M, et al. **Acta Psychiatr Scand** 1997 Jun;95(6):494–9

Coping strategies and continued drug use among methadone maintenance patients. Belding MA, et al. **Addict Behav** 1996 May–Jun;21(3):389–401

A bi–directional theory of addiction: examining coping and the factors related to substance relapse. Castellani B, et al. **Addict Behav** 1997 Jan–Feb;22(1):139–44

Disruption of family rituals as a mediator of the relationship between parental drinking and adult adjustment in offspring. Hawkins CA. **Addict Behav** 1997 Mar–Apr; 22(2):219–31

Illness severity and self–efficacy as course predictors of DSM–IV alcohol dependence in a multisite clinical sample. Langenbucher J, et al. **Addict Behav** 1996 Sep–Oct; 21(5):543–53

Early onset cannabis use and psychosocial adjustment in young adults. Fergusson DM, et al. **Addiction** 1997 Mar; 92(3):279–96

The role of coping in relapse crisis outcome: a prospective study of treated alcoholics. Moser AE, et al. **Addiction** 1996 Aug;91(8):1101–13 (32 ref.)

Male and female adolescents' perceived interpersonal communication skills according to history of sexual coercion. Anderson V, et al. **Adolescence** 1997 Summer; 32(126):419–27

Sex–of–sibling effects: a review. Part II. Personality and mental and physical health. Wagner ME, et al. **Adv Child Dev Behav** 1996;26:137–79

Psychosocial problem assessment and end–stage renal disease patient outcomes. Vourlekis BS, et al. **Adv Ren Replace Ther** 1997 Apr;4(2):136–44 (18 ref.)

Dealing with a life–threatening diagnosis: the experience of people with the human immunodeficiency virus. Chidwick A, et al. **AIDS Care** 1996 Jun;8(3):271–84

Living with HIV and AIDS. Vancouver Conference Review. du Plessis P. **AIDS Care** 1997 Feb;9(1):103–6

Sub–populations of alcohol–dependent patients: differences in psychological functioning between high– and low–frequency alcohol consumers. Hiltunen AJ, et al. **Alcohol Alcohol** 1996 Jul;31(4):429–38

Self–regulation in children. Moore NG. **Altern Ther Health Med** 1996 Nov;2(6):30–1

"When I am lonely the mountains call me": the impact of sacred geography on Navajo psychological well being. Griffin–Pierce T. **Am Indian Alsk Native Ment Health Res** 1997;7(3):1–10

Coping with AIDS. A longitudinal study. Brook JS, et al. **Am J Addict** 1997 Winter;6(1):11–20

A grounded theory of protecting recovery during transition to motherhood. Brudenell I. **Am J Drug Alcohol Abuse** 1997 Aug;23(3):453–66

Relationship of hardiness to alcohol and drug use in adolescents. Maddi SR, et al. **Am J Drug Alcohol Abuse** 1996 May;22(2):247–57

Effects of social support and personal coping resources on mortality in older age: the Longitudinal Aging Study Amsterdam. Penninx BW, et al. **Am J Epidemiol** 1997 Sep 15;146(6):510–9

Psychosocial predictors of mental health in a population of elderly women. Test of an explanatory model. Bienenfeld D, et al. **Am J Geriatr Psychiatry** 1997 Winter;5(1):43–53

Independence and adaptive behavior in adults with Williams syndrome. Davies M, et al. **Am J Med Genet** 1997 May 16;70(2):188–95

Longitudinal study of cognitive abilities and adaptive behavior levels in fragile X males: a prospective multicenter analysis. Fisch GS, et al. **Am J Med Genet** 1996 Aug 9; 64(2):356–61

Lack of association between mutation size and cognitive/behavior deficits in fragile X males: a brief report. Fisch GS, et al. **Am J Med Genet** 1996 Aug 9; 64(2):362–4

The impact of restraints on nursing home resident outcomes. Moseley CB. **Am J Med Qual** 1997 Summer;12(2):94–102

Family responses to children with early developmental delays. II: Accommodation intensity and activity in early

and middle childhood. Gallimore R, et al. **Am J Ment Retard** 1996 Nov;101(3):215–32
Back to basics: helping families cope with type I diabetes. Maffeo R. **Am J Nurs** 1997 Jun;97(6):36–9
Understanding the transition to community living after discharge from an acute care hospital: an exploratory study. Gage M, et al. **Am J Occup Ther** 1997 Feb;51(2):96–103
Anticipating retirement: the formation of narratives concerning an occupational transition. Jonsson H, et al. **Am J Occup Ther** 1997 Jan;51(1):49–56
Continuity and change: past experience as adaptive repertoire in occupational adaptation. Spencer JC, et al. **Am J Occup Ther** 1996 Jul–Aug;50(7):526–34
Legitimizing occupational therapy's knowledge. Wood W. **Am J Occup Ther** 1996 Sep;50(8):626–34 (90 ref.)
Distress and coping among women with HIV infection: preliminary findings from a multiethnic sample. Kaplan MS, et al. **Am J Orthopsychiatry** 1997 Jan;67(1):80–91
Exploring the social construction of bereavement: perceptions of adjustment and recovery in bereaved men. Rubin SS, et al. **Am J Orthopsychiatry** 1997 Apr; 67(2):279–89
On an engaging patient with paranoid schizophrenia [letter; comment] Abrahamson D. **Am J Psychiatry** 1997 Aug; 154(8):1178. Comment on: Am J Psychiatry 1996 Aug;153(8):1084–7.
Refugees' time perspective and mental health. Beiser M, et al. **Am J Psychiatry** 1997 Jul;154(7):996–1002
Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. Pallanti S, et al. **Am J Psychiatry** 1997 Jun; 154(6):792–8
Toward a multimodal communication theory of psychotherapy: the vicarious coprocessing of experience. Adler HM. **Am J Psychother** 1997 Winter;51(1):54–66
Adaptive responses among Dutch elderly: the impact of eight chronic medical conditions on health-related quality of life. Kempen GI, et al. **Am J Public Health** 1997 Jan;87(1):38–44
Dating and remarriage over the first two years of widowhood. Schneider DS, et al. **Ann Clin Psychiatry** 1996 Jun;8(2):51–7
Effects of prenatal stress on behavior in adolescent rhesus monkeys. Clarke AS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:490–1
Conflict resolution and distress alleviation in monkeys and apes. de Wall FB, et al. **Ann N Y Acad Sci** 1997 Jan 15; 807:317–28 (57 ref.)
Psychological well-being of Cambodian women in resettlement. Catolico O. **ANS Adv Nurs Sci** 1997 Jun; 19(4):75–84 (52 ref.)
Responding to threats to integrity of self. Morse JM. **ANS Adv Nurs Sci** 1997 Jun;19(4):21–36
Toward a middle-range theory of resilience. Polk LV. **ANS Adv Nurs Sci** 1997 Mar;19(3):1–13 (42 ref.)
Danger expectancies and insight in spider phobia. Jones MK, et al. **Anxiety** 1996;2(4):179–85
Coping with chaos and change. Strickland D. **AORN J** 1996 Nov;64(5):804–7
The Open Window Phase: helpseeking and reality behaviors by battered women. Curnow SA. **Appl Nurs Res** 1997 Aug; 10(3):128–35
Behavioral correlates of health and illness in youths with chronic illness. Frey M. **Appl Nurs Res** 1996 Nov; 9(4):167–76
A comparison of structured versus guided preheart catheterization information on mood states and coping resources. Houston S, et al. **Appl Nurs Res** 1996 Nov; 9(4):189–94
The experience of fatigue and strategies of self-care among persons with multiple sclerosis. Stuifbergen AK, et al. **Appl Nurs Res** 1997 Feb;10(1):2–10
Angry? Let's talk about it! Thomas SP. **Appl Nurs Res** 1997 May;10(2):80–5
Relationships among illness uncertainty, stress, coping, and emotional well-being at entry into a clinical drug trial. Wineman NM, et al. **Appl Nurs Res** 1996 May;9(2):53–60
Pain, quality of life, and coping in sickle cell disease. Fuggle P, et al. **Arch Dis Child** 1996 Sep;75(3):199–203
Values, stress, and coping among practicing family physicians. Post DM. **Arch Fam Med** 1997 May–Jun; 6(3):252–5
Children in the process of becoming [editorial; comment] Wilson JM, et al. **Arch Pediatr Adolesc Med** 1996 Dec; 150(12):1234–5. Comment on: Arch Pediatr Adolesc Med 1996 Dec;150(12):1238–45.
Sexual adjustment and quality of relationship in spinal paraplegia: a controlled study. Kreuter M, et al. **Arch Phys Med Rehabil** 1996 Jun;77(6):541–8
Caffeine and chronic back pain [letter; comment] Sheetz DA. **Arch Phys Med Rehabil** 1997 Jul;78(7):786. Comment on: Arch Phys Med Rehabil 1997 Jan;78(1):61–3.
Spinal cord injury rehabilitation. 4. Individual experience, personal adaptation, and social perspectives. Stiens SA, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3 Suppl):S65–72 (97 ref.)
The strengths of families coping with serious mental illness. Doornbos MM. **Arch Psychiatr Nurs** 1996 Aug; 10(4):214–20
Resilience: analysis of the concept. Dyer JG, et al. **Arch Psychiatr Nurs** 1996 Oct;10(5):276–82 (25 ref.)
Healing from incest: resurrecting the buried self. Godbey JK, et al. **Arch Psychiatr Nurs** 1996 Oct;10(5):304–10 (35 ref.)
Sense of belonging and indicators of social and psychological functioning. Hagerty BM, et al. **Arch Psychiatr Nurs** 1996 Aug;10(4):235–44
Jealousy, general creativity, and coping with social frustration during the menstrual cycle. Krug R, et al. **Arch Sex Behav** 1996 Apr;25(2):181–99
Primary juvenile fibromyalgia: psychological adjustment, family functioning, coping, and functional disability. Reid GJ, et al. **Arthritis Rheum** 1997 Apr;40(4):752–60
The importance of rules in coping with behavior [editorial] Teuscher GW. **ASDC J Dent Child** 1996 May–Jun;63(3):168
The use of an open-ended questionnaire to identify positive aspects of acquired hearing loss. Kerr PC, et al. **Audiology** 1997 Jan–Feb;36(1):19–28
I was a teenage mutant diabetic. Cresp M. **Aust Fam Physician** 1996 Feb;25(2):203, 206–7
Post-stroke depression: outcome following rehabilitation. Loong CK, et al. **Aust N Z J Psychiatry** 1995 Dec; 29(4):609–14
The concept of resilience. Wolff S. **Aust N Z J Psychiatry** 1995 Dec;29(4):565–74 (61 ref.)
Female United States Air Force (USAF) pilots: themes, challenges, and possible solutions. McGlohn SE, et al. **Aviat Space Environ Med** 1997 Feb;68(2):132–6
Psychiatric syndromes associated with problems in aeronautical adaptation among military student pilots. Picano JJ, et al. **Aviat Space Environ Med** 1996 Dec; 67(12):1119–23
Perceptual and coping processes across the menstrual cycle: an investigation in a premenstrual syndrome clinic and a community sample. Fontana AM, et al. **Behav Med** 1997 Winter;22(4):152–9
Embarrassment about the first panic attack predicts agoraphobia in panic disorder patients. Amering M, et al. **Behav Res Ther** 1997 Jun;35(6):517–21
What do patients do with their obsessive thoughts? Freeston MH, et al. **Behav Res Ther** 1997 Apr;35(4):335–48
Panic disorder or social phobia: which is worse? Norton GR, et al. **Behav Res Ther** 1996 Mar;34(3):273–6
Helping parents to cope when their preschool children are acutely ill. Educational interventions may defuse parents' concern [letter; comment] Impicciatore P, et al. **BMJ** 1997 Feb 1;314(7077):373. Comment on: BMJ 1996 Oct 19;313(7063):983–6. Comment on: BMJ 1996 Oct 19;313(7063):987–90.
Parents' difficulties and information needs in coping with acute illness in preschool children: a qualitative study [see comments] Kai J. **BMJ** 1996 Oct 19;313(7063):987–90. Comment in: BMJ 1996 Oct 19;313(7063):954–5. Comment in: BMJ 1997 Feb 1;314(7077):373. Comment in: BMJ 1997 Feb 1;314(7077):373–4.
Helping parents to cope when their preschool children are acutely ill. Patients and GPs need to understand each other's perceptions of a consultation [letter; comment] Townsend J, et al. **BMJ** 1997 Feb 1;314(7077):373–4. Comment on: BMJ 1996 Oct 19;313(7063):983–6. Comment on: BMJ 1996 Oct 19;313(7063):987–90.
Cognitive and adaptive behavior 1 and 3 years following bone marrow transplantation. Kramer JH, et al. **Bone Marrow Transplant** 1997 Mar;19(6):607–13
Maternal handling during pregnancy reduces DMBA-induced mammary tumorigenesis among female offspring. Hilakivi-Clarke L. **Br J Cancer** 1997;76(2):150–5
Ways of coping with psychological distress after trauma. Charlton PF, et al. **Br J Clin Psychol** 1996 Nov;35 (Pt 4):517–30
Meaning in life: clinical relevance and predictive power. Debats DL. **Br J Clin Psychol** 1996 Nov;35 (Pt 4):503–16
Coping with hallucinations: exploring stress and coping framework. Farhall J, et al. **Br J Clin Psychol** 1997 May; 36 (Pt 2):259–61
Cognitive therapy of dissociative symptoms associated with trauma. Kennerley H. **Br J Clin Psychol** 1996 Sep;35 (Pt 3):325–40
Psychological adjustment and family functioning in a group of British children with sickle cell disease: preliminary empirical findings and a meta-analysis. Midence K, et al. **Br J Clin Psychol** 1996 Sep;35 (Pt 3):439–50
Primary teachers' knowledge and acquisition of stress relieving strategies. Cockburn AD. **Br J Educ Psychol** 1996 Sep;66 (Pt 3):399–410
Overachievement and coping strategies in adolescent males. Parsons A, et al. **Br J Educ Psychol** 1996 Mar;66 (Pt 1):109–14
Stresses, coping mechanisms and job satisfaction in general practitioner registrars. Chambers R, et al. **Br J Gen Pract** 1996 Jun;46(407):343–8
The role of coping strategies in protecting individuals against long-term tranquillizer use. Bish A, et al. **Br J Med Psychol** 1996 Jun;69 (Pt 2):101–15
Natural cognitive coping strategies in schizophrenia. McNally SE, et al. **Br J Med Psychol** 1997 Jun;70 (Pt 2):159–67
Coping style and situational appraisals as predictors of coping strategies following stressful events in sport as a function of gender and skill level. Anshel MH, et al. **Br J Psychol** 1997 May;88 (Pt 2):263–76
Illusions of well-being and the repressive coping style. Myers LB, et al. **Br J Soc Psychol** 1996 Dec;35 (Pt 4):443–57
The ascending neuromodulatory systems in learning by reinforcement: comparing computational conjectures with experimental findings. Pennartz CM. **Brain Res Brain Res Rev** 1995 Nov;21(3):219–45 (235 ref.)
Breast cancer survivors: psychosocial concerns and quality of life. Ganz PA, et al. **Breast Cancer Res Treat** 1996; 38(2):183–99
What harm—pain behavior? Psychological and physical factors in the development of chronicity. Main CJ, et al. **Bull Hosp Jt Dis** 1996;55(4):210–2
The evolution of adjustment issues in HIV/AIDS. Kobayashi JS. **Bull Menninger Clin** 1997 Spring;61(2):146–88
Practitioner, heal thyself: coping with stress in clinical practice. Menninger WW. **Bull Menninger Clin** 1996 Spring;60(2):197–205
The challenge for women with a drug-abusing family member: the Jamaican perspective. Boyce-Reid K. **Bull Narc** 1995;47(1–2):23–30 (11 ref.)
A study of self-monitoring processes and coping behaviour in burns victims. Fong J. **Burns** 1997 Mar;23 Suppl 1:S8–11
About changing faces: promoting a good quality of life for people with visible disfigurements. Partridge J. **Burns** 1997 Mar;23(2):186–7
Applying what burn survivors have to say to future therapeutic interventions. Robert R, et al. **Burns** 1997 Feb; 23(1):50–4
Symptom distress and life situation in adolescents with cancer. Enskär K, et al. **Cancer Nurs** 1997 Feb;20(1):23–33
Causal attributions, coping strategies, and adjustment to breast cancer. Lavery JF, et al. **Cancer Nurs** 1996 Feb; 19(1):20–8
Exploring the psychosocial meaning of recurrent cancer: a descriptive study. Mahon SM, et al. **Cancer Nurs** 1997 Jun; 20(3):178–86
Experiences of cancer in children and adolescents. Novakovic B, et al. **Cancer Nurs** 1996 Feb;19(1):54–9
Anxiety, needs, and coping in family members of the bone marrow transplant patient. Wochna V. **Cancer Nurs** 1997 Aug;20(4):244–50 (18 ref.)
A quality of life instrument for adolescents with chronic headache. Langeveld JH, et al. **Cephalalgia** 1996 May; 16(3):183–96; discussion 137
Assessment of coping strategies of child abusing mothers. Cantos AL, et al. **Child Abuse Negl** 1997 Jul;21(7):631–6
School age children's coping with sexual abuse: abuse stresses and symptoms associated with four coping strategies [see comments] Chaffin M, et al. **Child Abuse Negl** 1997 Feb; 21(2):227–40. Comment in: Child Abuse Negl 1997 Feb;21(2):207–9.
A process model for understanding adaptation to sexual abuse: the role of shame in defining stigmatization. Feiring C, et al. **Child Abuse Negl** 1996 Aug;20(8):767–82 (144 ref.)
Resilient child sexual abuse survivors: cognitive coping and illusion. Himelein MJ, et al. **Child Abuse Negl** 1996 Aug; 20(8):747–58
Social support and coping strategies as mediators of the effects of child abuse and neglect [editorial; comment] Jones DP. **Child Abuse Negl** 1997 Feb;21(2):207–9. Comment on: Child Abuse Negl 1997 Feb;21(2):211–26. Comment on: Child Abuse Negl 1997 Feb;21(2):227–40.
Secondary traumatization in parents following the disclosure of extrafamilial child sexual abuse: initial effects. Manion IG, et al. **Child Abuse Negl** 1996 Nov;20(11):1095–109
Social support and coping strategies as mediators of adult adjustment following childhood maltreatment [see comments] Runtz MG, et al. **Child Abuse Negl** 1997 Feb; 21(2):211–26. Comment in: Child Abuse Negl 1997 Feb;21(2):207–9.
Perceptions of abuse: effects on adult psychological and social adjustment. Varia R, et al. **Child Abuse Negl** 1996 Jun;20(6):511–26
Contemporaneous and longitudinal prediction of children's social functioning from regulation and emotionality. Eisenberg N, et al. **Child Dev** 1997 Aug;68(4):642–64
Coping socialization in middle childhood: tests of maternal and paternal influences. Kliewer W, et al. **Child Dev** 1996 Oct;67(5):2339–57
Children's narrative representations of mothers: their development and associations with child and mother adaptation. Oppenheim D, et al. **Child Dev** 1997 Feb; 68(1):127–38
Models of traumatic experiences and children's psychological adjustment: the roles of perceived parenting and the children's own resources and activity. Punamäki RL, et al. **Child Dev** 1997 Aug;68(4):718–28
Appraisals of negative events by preadolescent children of divorce. Sheets V, et al. **Child Dev** 1996 Oct;67(5):2166–82
Openness in adoption and the level of child participation. Wrobel GM, et al. **Child Dev** 1996 Oct;67(5):2358–74
Japanese and United States preschool children's responses to conflict and distress. Zahn-Waxler C, et al. **Child Dev** 1996 Oct;67(5):2462–77
Defense reactions and coping strategies in normal adolescents. Erickson S, et al. **Child Psychiatry Hum Dev** 1997 Fall;28(1):45–56
Rethinking the effects of homelessness on children: resiliency and competency. Douglass A. **Child Welfare** 1996 Nov–Dec;75(6):741–51 (16 ref.)
Evolutionary adaptationism: another biological approach to criminal and antisocial behaviour. Daly M. **Ciba Found Symp** 1996;194:183–91; discussion 192–5 (30 ref.)
Stress, coping, lifestyle and hypertension: a paradigm for research, prevention and non-pharmacological

management of hypertension. Beilin LJ.
Clin Exp Hypertens 1997 Jul–Aug;19(5–6):739–52 (24 ref.)
Pain in young adults—III: Relationships of three pain–coping measures to pain and activity interference. Lester N, et al. **Clin J Pain** 1996 Dec;12(4):291–300
CSQ: five factors or fiction? Riley JL 3rd, et al.
Clin J Pain 1997 Jun;13(2):156–62
The Coping Strategies Questionnaire: a large sample, item level factor analysis. Robinson ME, et al. **Clin J Pain** 1997 Mar;13(1):43–9
Bias effects in three common self–report pain assessment measures. Robinson ME, et al. **Clin J Pain** 1997 Mar; 13(1):74–81
Relationship of sexual and physical abuse to pain description, coping, psychological distress, and health–care utilization in a chronic pain sample. Toomey TC, et al.
Clin J Pain 1995 Dec;11(4):307–15
Gender differences in psychosocial adjustment to chronic pain and expenditures for health care services used. Weir R, et al. **Clin J Pain** 1996 Dec;12(4):277–90
Psychological factors affecting health after toxicological disasters. Havenaar JM, et al. **Clin Psychol Rev** 1997; 17(4):359–74 (90 ref.)
Integration of coping and social support perspectives: implications for the study of adaptation to chronic diseases. Schreurs KM, et al. **Clin Psychol Rev** 1997;17(1):89–112 (126 ref.)
Mothers of children evaluated for transplantation: stress, coping resources, and perceptions of family functioning. Rodrigue JR, et al. **Clin Transplant** 1996 Oct;10(5):447–50
My daughter is dying. Wong TY. **CMAJ** 1997 Jul 15; 157(2):172–4
Use of Dental Coping Beliefs Scale to measure cognitive changes following oral hygiene interventions. Wolfe GR, et al. **Community Dent Oral Epidemiol** 1996 Feb;24(1):37–41
A general model for the adaptive function of self–knowledge in animals and humans. Parker ST. **Conscious Cogn** 1997 Mar;6(1):75–86
Suicide: how to survive as a survivor? Grad OT. **Crisis** 1996; 17(3):136–42 (38 ref.)
Stress, social support, and college adjustment among Latino students. Jarama Alvan SL, et al.
Cult Divers Ment Health 1996;2(3):193–203
Coping with psoriasis: a guide for counseling patients. Ginsburg IH. **Cutis** 1996 May;57(5):323–5
Gender–specific pathways between maternal depressive symptoms, family discord, and adolescent adjustment. Davies PT, et al. **Dev Psychol** 1997 Jul;33(4):657–68
"You can try or you can just give up": the impact of perceived control and coping style on childhood homesickness. Thurber CA, et al. **Dev Psychol** 1997 May;33(3):508–17
A person–oriented approach in research on developmental psychopathology. Bergman LR, et al. **Dev Psychopathol** 1997 Spring;9(2):291–319 (120 ref.)
The relationship between attachment cognitions and psychological adjustment in late adolescent women. Burge D, et al. **Dev Psychopathol** 1997 Winter;9(1):151–67
The Problem Areas in Diabetes Scale. An evaluation of its clinical utility. Welch GW, et al. **Diabetes Care** 1997 May; 20(5):760–6
Emotional adjustment and metabolic control in newly diagnosed diabetic persons. Pibernik–Okanović M, et al. **Diabetes Res Clin Pract** 1996 Oct;34(2):99–105
Dynamic and static physical training in patients with rheumatoid arthritis: application of a self–appraisal and coping model. Andersson SI, et al. **Disabil Rehabil** 1996 Sep;18(9):469–75
Interactions between recovery in aphasia, emotional and psychosocial factors in subjects with aphasia, their significant others and speech pathologists. Hemsley G, et al. **Disabil Rehabil** 1996 Nov;18(11):567–84
Coping with chronic neurological impairment: a contrastive analysis of Parkinson's disease and stroke. Herrmann M, et al. **Disabil Rehabil** 1997 Jan;19(1):6–12
Psychological distress, social support and coping behaviour among polio survivors: a 5–year perspective on 63 polio patients. Schanke AK. **Disabil Rehabil** 1997 Mar; 19(3):108–16
Racism and the physical and mental health status of African Americans: a thirteen year national panel study. Jackson JS, et al. **Ethn Dis** 1996 Winter–Spring;6(1–2):132–47
The perceived racism scale: a multidimensional assessment of the experience of white racism among African Americans. McNeilly MD, et al. **Ethn Dis** 1996 Winter–Spring;6(1–2):154–66
The children of the Lundby study as adults: a salutogenic perspective. Cederblad M. **Eur Child Adolesc Psychiatry** 1996;5 Suppl 1:38–43
Vulnerable but invincible: high risk children from birth to adulthood. Werner EE. **Eur Child Adolesc Psychiatry** 1996; 5 Suppl 1:47–51
Disclosing the cancer diagnosis: the patients' experiences. Loge JH, et al. **Eur J Cancer** 1997 May;33(6):878–82
A comparative study of post–operative psychosocial function in women with primary operable breast cancer randomized to breast conservation therapy or mastectomy. Poulsen B, et al. **Eur J Surg Oncol** 1997 Aug;23(4):327–34
Sense of coherence and outcome of low–back surgery: 5–year follow–up of 80 patients. Santavirta N, et al.
Eur Spine J 1996;5(4):229–35
Shifting attention from objective risk factors to patients' self–assessed health resources: a clinical model for general practice. Hollnagel H, et al. **Fam Pract** 1995 Dec; 12(4):423–9 (50 ref.)
Coping with stress in families of servicemen: searching for "win–win" solutions to a conflict between the family and the military organization. Desivilya HS, et al.
Fam Process 1996 Jun;35(2):211–25
Toward a definition of family resilience: integrating life–span and family perspectives. Hawley DR, et al.
Fam Process 1996 Sep;35(3):283–98 (66 ref.)
Coping strategies of immigrant parents: directions for family therapy. Strier DR. **Fam Process** 1996 Sep;35(3):363–76 (46 ref.)
The concept of family resilience: crisis and challenge. Walsh F. **Fam Process** 1996 Sep;35(3):261–81 (112 ref.)
Psychosocial adjustment and the quality of the mother–child relationship at four months postpartum after conception by in vitro fertilization. McMahon CA, et al.
Fertil Steril 1997 Sep;68(3):492–500
Psychological opportunities and hazards in predictive genetic testing for cancer risk. Codori AM.
Gastroenterol Clin North Am 1997 Mar;26(1):19–39 (118 ref.)
The influence of ethnicity and culture on the caregiver stress and coping process: a sociocultural review and analysis. Aranda MP, et al. **Gerontologist** 1997 Jun;37(3):342–54 (92 ref.)
Between stressors and outcomes: can we simplify caregiving process variables? Braithwaite V. **Gerontologist** 1996 Feb; 36(1):42–53
Theoretical perspectives concerning positive aspects of caring for elderly persons with dementia: stress/adaptation and existentialism. Farran CJ. **Gerontologist** 1997 Apr; 37(2):250–6 (51 ref.)
Differential predictors of strain and gain among husbands caring for wives with dementia. Kramer BJ.
Gerontologist 1997 Apr;37(2):239–49
Gain in the caregiving experience: where are we? What next? Kramer BJ. **Gerontologist** 1997 Apr;37(2):218–32 (86 ref.)
Religious attendance and psychological well–being in Mexican Americans: a panel analysis of three–generations data. Levin JS, et al. **Gerontologist** 1996 Aug;36(4):454–63
Religiosity and perceived rewards of black and white caregivers. Picot SJ, et al. **Gerontologist** 1997 Feb; 37(1):89–101
Understanding the well–being of care receivers. Pruchno RA, et al. **Gerontologist** 1997 Feb;37(1):102–9
A cross–cultural validation of coping strategies and their associations with caregiving distress. Shaw WS, et al.
Gerontologist 1997 Aug;37(4):490–504
Relationship between psychological status and compliance in a sample of patients treated for cancer of the head and neck. McDonough EM, et al. **Head Neck** 1996 May–Jun; 18(3):269–76
The stress response in headache sufferers: physiological and psychological reactivity. Holm JE, et al. **Headache** 1997 Apr;37(4):221–7
Coping self–efficacy buffers psychological and physiological disturbances in HIV–infected men following a natural disaster. Benight CC, et al. **Health Psychol** 1997 May; 16(3):248–55
Coping styles associated with psychological adjustment to advanced breast cancer. Classen C, et al.
Health Psychol 1996 Nov;15(6):434–7
Predictors of psychological adjustment to genetic testing for Huntington's disease. Codori AM, et al. **Health Psychol** 1997 Jan;16(1):36–50
Motivational implications of pain: chronicity, psychological distress, and work goal construal in a national sample of adults. Karoly P, et al. **Health Psychol** 1996 Sep; 15(5):383–90
Assessment of self–efficacy and coping with cancer: development and validation of the cancer behavior inventory. Merluzzi TV, et al. **Health Psychol** 1997 Mar; 16(2):163–70
Psychosocial outcomes of breast–conserving surgery versus mastectomy: a meta–analytic review. Moyer A.
Health Psychol 1997 May;16(3):284–98
Doing the right thing at the right time? The interaction of stages and processes of change in successful smoking cessation. Perz CA, et al. **Health Psychol** 1996 Nov; 15(6):462–8
Temptations to smoke after quitting: a comparison of lapsers and maintainers. Shiffman S, et al. **Health Psychol** 1996 Nov;15(6):455–61
Three–year follow–up after presymptomatic testing for Huntington's disease in tested individuals and partners. Tibben A, et al. **Health Psychol** 1997 Jan;16(1):20–35
Adult adjustment to chronic illness: a review of the literature. Sidell NL. **Health Soc Work** 1997 Feb;22(1):5–11 (45 ref.)
The experiences of families with a relative in the intensive care unit. Jamerson PA, et al. **Heart Lung** 1996 Nov–Dec; 25(6):467–74 (36 ref.)
Qualitative analysis of patients' work during mechanical ventilation and weaning. Logan J, et al. **Heart Lung** 1997 Mar–Apr;26(2):140–7
Turning points of recovery from cardiac surgery during the intensive care unit transition. Shih FJ, et al.
Heart Lung 1997 Mar–Apr;26(2):99–108
Psychological approaches to the management of pain in patients with advanced cancer. Loscalzo M.
Hematol Oncol Clin North Am 1996 Feb;10(1):139–55 (59 ref.)
Influence of lifestyle, coping, and job stress on blood pressure in men and women. Lindquist TL, et al. **Hypertension** 1997 Jan;29(1 Pt 1):1–7
An exploration of factors influencing adjustment among relocating rural elders. Armer JM. **Image J Nurs Sch** 1996 Spring;28(1):35–9
Balancing engagement and detachment in caregiving. Carmack BJ. **Image J Nurs Sch** 1997;29(2):139–44
Preliminary testing of a proposition from the Roy Adaptation Model. Hamner JB. **Image J Nurs Sch** 1996 Fall; 28(3):215–20
Managing health problems among homeless women with children in a transitional shelter. Hatton DC.
Image J Nurs Sch 1997 Spring;29(1):33–7
Advice from affected persons about living with human papillomavirus infection. Taylor CA, et al.
Image J Nurs Sch 1997 Spring;29(1):27–32
Internal resourcefulness, task demands, coping, and dysphoric affect among caregivers of the frail elderly. Fingerman KL, et al. **Int J Aging Hum Dev** 1996;42(3):229–48
Equity/inequity and patterns of guardianship of older persons. Keith PM. **Int J Aging Hum Dev** 1996;43(2):155–68
Participation in leisure activities by older adults after a stressful life event: the loss of a spouse. Patterson I.
Int J Aging Hum Dev 1996;42(2):123–42
Reasons for living and coping abilities among older adults. Range LM, et al. **Int J Aging Hum Dev** 1996;43(1):1–5
Pacemaker therapy: how do patients cope with the icon of modern antibradycard treatment? [editorial] Schüppel R, et al. **Int J Artif Organs** 1997 Jan;20(1):7–11 (46 ref.)
Eating disorders and panic: four cases of pathological coping. Chesler BE. **Int J Eat Disord** 1997 Sep;22(2):219–22
Appraisal and coping strategies in stressful situations: a comparison of individuals who binge eat and controls. Hansel SL, et al. **Int J Eat Disord** 1997 Jan;21(1):89–93
Effects of coping style and negative body image on eating disturbance. Koff E, et al. **Int J Eat Disord** 1997 Jul; 22(1):51–6
Avoidance coping, binge eating, and depression: an examination of the escape theory of binge eating. Paxton SJ, et al. **Int J Eat Disord** 1997 Jul;22(1):83–7
Skills training treatment for adaptive affect regulation in a woman with binge–eating disorder. Telch CF.
Int J Eat Disord 1997 Jul;22(1):77–81
Coping, sexual abuse, and compensatory behavior. Tobin DL, et al. **Int J Eat Disord** 1996 Sep;20(2):143–8
Behavioral and adaptive status in an experimental model of Alzheimer's disease in rats. Popović M, et al.
Int J Neurosci 1996 Sep;86(3–4):281–99
The work of auxiliary nurses in Mexico: stressors, satisfiers and coping strategies. Douglas MK, et al.
Int J Nurs Stud 1996 Oct;33(5):495–505
Stress, coping, and social support as psychosocial factors in readmissions for ischaemic heart disease. Stewart MJ, et al. **Int J Nurs Stud** 1997 Apr;34(2):151–63
Coping with chronic low back pain: an idiographic exploration through focus groups. Strong J, et al.
Int J Psychiatry Med 1995;25(4):371–87
A pilot study to assess the relationships among coping, self–efficacy and functional improvement in men with paraplegia. Lou MF, et al. **Int J Rehabil Res** 1997 Mar; 20(1):99–105
Acquired hearing loss: social and psychological issues and adjustment processes. Rutman D, et al.
Int J Rehabil Res 1995 Dec;18(4):313–23
Stress, coping and burnout in mental health nurses: findings from three research studies. Fagin L, et al.
Int J Soc Psychiatry 1996 Summer;42(2):102–11
Coping effectiveness training for men living with HIV: preliminary findings. Chesney M, et al.
Int J STD AIDS 1996;7 Suppl 2:75–82 (62 ref.)
Mnemonics usage and cognitive decline in age–associated memory impairment. Small GW, et al. **Int Psychogeriatr** 1997 Mar;9(1):47–56
Social and psychological adjustment of Soviet–born and Israeli–born adolescents: the effect of the family. Slonim–Nevo V, et al. **Isr J Psychiatry Relat Sci** 1997; 34(2):128–38
Is adolescent adjustment following parental divorce a function of predivorce adjustment? Forehand R, et al.
J Abnorm Child Psychol 1997 Apr;25(2):157–64
Locus of control as a stress moderator and mediator in children of divorce. Kim LS, et al.
J Abnorm Child Psychol 1997 Apr;25(2):145–55
Self–regulation as a moderator of the relation between coping and symptomatology in children of divorce. Lengua LJ, et al. **J Abnorm Child Psychol** 1996 Dec;24(6):681–701
The role of family processes and coping strategies in the relationship between parental chronic illness and childhood internalizing problems. Steele RG, et al.
J Abnorm Child Psychol 1997 Apr;25(2):83–94
Individual differences in emotion regulation and behavior problems in preschool children. Cole PM, et al.
J Abnorm Psychol 1996 Nov;105(4):518–29
The response styles theory of depression: tests and an extension of the theory. Just N, et al.
J Abnorm Psychol 1997 May;106(2):221–9
Coping strategies, drinking motives, and stressful life events among middle adolescents: associations with emotional and behavioral problems and with academic functioning. Windle M, et al. **J Abnorm Psychol** 1996 Nov;105(4):551–60
Treatment structure, client coping methods, and response to

brief individual counseling: preliminary findings in a substance dependent sample. Gottheil E, et al. **J Addict Dis** 1997;16(3):51–65

Psychosocial resources, adolescent risk behaviour and young adult adjustment: is risk taking more dangerous for some than others? Maggs JL, et al. **J Adolesc** 1997 Feb; 20(1):103–19

Adolescent knowledge, values, and coping strategies: implications for health in sub–Saharan Africa. Balmer DH, et al. **J Adolesc Health** 1997 Jul;21(1):33–8

Searching for resilience among African–American youth exposed to community violence: theoretical issues. Howard DE. **J Adolesc Health** 1996 Apr;18(4):254–62 (66 ref.)

Substance use, coping, and safer sex practices among adolescents with hemophilia and human immunodeficiency virus. The Hemophilia Behavioral Intervention Evaluative Project Committee. King G, et al. **J Adolesc Health** 1996 Jun;18(6):435–41

Research project to aid caregivers of people with Alzheimer's disease [news] **J Adv Nurs** 1996 Jul;24(1):3

Strategies used by chronically ill older women and their caregiving daughters in managing posthospital care. Bull MJ, et al. **J Adv Nurs** 1997 Mar;25(3):541–7

Assessment of pain coping styles: development of an inventory. Crow CS, et al. **J Adv Nurs** 1996 Nov; 24(5):890–8

Effect of preparatory information prior to elective total hip replacement on psychological coping outcomes. Gammon J, et al. **J Adv Nurs** 1996 Aug;24(2):303–8

Hope from the perspective of homeless families. Herth K. **J Adv Nurs** 1996 Oct;24(4):743–53

The trait and process of resilience. Jacelon CS. **J Adv Nurs** 1997 Jan;25(1):123–9 (25 ref.)

Hospital nursing: 'it's a battle!' A follow–up study of English graduate nurses. Kelly B. **J Adv Nurs** 1996 Nov; 24(5):1063–9

Functional status of the oldest–old in a home setting. Krach P, et al. **J Adv Nurs** 1996 Sep;24(3):456–64

A comparison study of children with sickle cell disease and their non–diseased siblings on hopelessness, depression, and perceived competence. Lee EJ, et al. **J Adv Nurs** 1997 Jan;25(1):79–86

Health within illness: experiences of chronically ill/disabled people. Lindsey E. **J Adv Nurs** 1996 Sep;24(3):465–72

The nature of social support as experienced by women treated for breast cancer. Lugton J. **J Adv Nurs** 1997 Jun; 25(6):1184–91

From nurse to teacher: recognizing a status passage. MacNeil M. **J Adv Nurs** 1997 Mar;25(3):634–42

Perceived stressors and coping strategies among individuals with rheumatoid arthritis. Mahat G. **J Adv Nurs** 1997 Jun; 25(6):1144–50

Patients' perceptions of pre–operative preparation for day surgery. Mitchell M. **J Adv Nurs** 1997 Aug;26(2):356–63

To meet with a stroke: patients' experiences and aspects seen through a screen of crises. Nilsson I, et al. **J Adv Nurs** 1997 May;25(5):953–63

'Becoming a mother'--developing a new theory of early motherhood. Rogan F, et al. **J Adv Nurs** 1997 May; 25(5):877–85

Getting sick and getting well: a qualitative study of aetiologic explanations of people with cancer. Tishelman C. **J Adv Nurs** 1997 Jan;25(1):60–7

The Roy Adaptation Model: a consideration of its properties as a conceptual framework for an intervention study. Tolson D, et al. **J Adv Nurs** 1996 Nov;24(5):981–7

Women's experiences of non–invasive breast cancer: literature review and study report. Webb C, et al. **J Adv Nurs** 1997 Mar;25(3):514–25 (62 ref.)

Risk and protective factors affecting the adjustment of siblings of children with chronic disabilities. Fisman S, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Nov; 35(11):1532–41

Israeli preschool children under Scuds: a 30–month follow–up. Laor N, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Mar;36(3):349–56

Symptomatology and adaptive functioning for children exposed to normative stressors, dog attack, and parental violence. Rossman BR, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Aug; 36(8):1089–97

Adjustment of children facing the death of a parent due to cancer. Siegel K, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Apr;35(4):442–50

Coping resources and self–perceived well–being of college students who report a parental drinking problem. Hall AE. **J Am Coll Health** 1997 Jan;45(4):159–64

Ethnicity, gender identity, stress, and coping among female African–American medical students. Shervington DO, et al. **J Am Med Womens Assoc** 1996 Aug–Oct;51(4):153–4

Maternal expectations and attributions about coping in anxious children. Kortlander E, et al. **J Anxiety Disord** 1997 May–Jun;11(3):297–315

Helping others: a response to HIV disease. Gaskins S, et al. **J Assoc Nurses AIDS Care** 1997 May–Jun;8(3):35–9

HIV, self–transcendence, and quality of life. Mellors MP, et al. **J Assoc Nurses AIDS Care** 1997 Mar–Apr;8(2):59–69

Trajectories and profiles of adaptive behavior in males with fragile X syndrome: multicenter studies. Dykens E, et al. **J Autism Dev Disord** 1996 Jun;26(3):287–301

Anger management style, degree of expressed anger, and gender influence cardiovascular recovery from interpersonal harassment. Faber SD, et al. **J Behav Med** 1996 Feb;19(1):31–53

Relation of cognitive coping and catastrophizing to acute pain and analgesic use following breast cancer surgery. Jacobsen PB, et al. **J Behav Med** 1996 Feb;19(1):17–29

Supportive and negative responses in the partner relationship: their association with psychological adjustment among individuals with cancer. Manne SL, et al. **J Behav Med** 1997 Apr;20(2):101–25

Coping with the physical and psychosocial sequelae of bone marrow transplantation among long–term survivors. Somerfield MR, et al. **J Behav Med** 1996 Apr;19(2):163–84

Perception of traumatic onset, compensation status, and physical findings: impact on pain severity, emotional distress, and disability in chronic pain patients. Turk DC, et al. **J Behav Med** 1996 Oct;19(5):435–53

Paget's disease of bone and quality of life. Gold DT, et al. **J Bone Miner Res** 1996 Dec;11(12):1897–904

Positive self–regard as a coping mechanism for pediatric burn survivors. LeDoux JM, et al. **J Burn Care Rehabil** 1996 Sep–Oct;17(5):472–6; discussion 471–2

Postburn psychologic adaptation of family members of patients with burns. Watkins PN, et al. **J Burn Care Rehabil** 1996 Jan–Feb;17(1):78–92

Children's methods of coping with stress: a twin study of genetic and environmental influences. Mellins CA, et al. **J Child Psychol Psychiatry** 1996 Sep;37(6):721–30

Kindergarten–aged children's reactions to an emotionally charged naturalistic event: relations between cognitions, self–reported emotions, and emotional behaviour. Olthof T, et al. **J Child Psychol Psychiatry** 1997 May;38(4):449–56

Risk factors in the adjustment of siblings of children with cancer. Sloper P, et al. **J Child Psychol Psychiatry** 1996 Jul;37(5):597–607

Life stressors, neighborhood disadvantage, and resources: a focus on inner–city children's adjustment. Dubow EF, et al. **J Clin Child Psychol** 1997 Jun;26(2):130–44

Therapeutic connection and client progress in drug abuse treatment. Bell DC, et al. **J Clin Psychol** 1997 Apr; 53(3):215–24

Cross–cultural validation of Antonovsky's Sense Of Coherence Scale. Bowman BJ. **J Clin Psychol** 1996 Sep; 52(5):547–9

Cultural pathways toward Antonovsky's sense of coherence. Bowman BJ. **J Clin Psychol** 1997 Feb;53(2):139–42

Psychological functioning of adolescent transsexuals: personality and psychopathology. Cohen L, et al. **J Clin Psychol** 1997 Feb;53(2):187–96

Relationships between coping style and PAI profiles in a community sample. Deisinger JA, et al. **J Clin Psychol** 1996 May;52(3):303–10

Fantasies, coping behavior, and psychopathology. Greenwald DF, et al. **J Clin Psychol** 1997 Feb;53(2):91–7

Coping and problem solving of self–mutilators. Haines J, et al. **J Clin Psychol** 1997 Feb;53(2):177–86

Effects of stressful stimuli: a comparison between two time periods. Koslowsky M, et al. **J Clin Psychol** 1996 May; 52(3):279–83

Profile characteristics of the MPI–DLV clusters of pain patients. Lousberg R, et al. **J Clin Psychol** 1996 Mar; 52(2):161–7

Improvement in psychosocial adjustment for psychiatric patients after a 16–week life skills education program. Reddon JR, et al. **J Clin Psychol** 1996 Mar;52(2):169–72

MMPI–2 patterns in African–American females. Reed MK, et al. **J Clin Psychol** 1996 Jul;52(4):437–41

Comparing two self–report measures of coping--the Sense of Coherence Scale and the Defense Style Questionnaire. Sammallahti PR, et al. **J Clin Psychol** 1996 Sep; 52(5):517–24

Psychological adjustment of adults with sickle cell anemia: stability over 20 months, correlates, and predictors. Thompson RJ Jr, et al. **J Clin Psychol** 1996 May; 52(3):253–61

Differential effects of coping in mental disorders: a prospective study in psychiatric outpatients. Vollrath M, et al. **J Clin Psychol** 1996 Mar;52(2):125–35

Behavior therapy and the transdermal nicotine patch: effects on cessation outcome, affect, and coping. Cinciripini PM, et al. **J Consult Clin Psychol** 1996 Apr;64(2):314–23

The relation between methods of coping during adulthood with a history of childhood sexual abuse and current psychological adjustment. Coffey P, et al. **J Consult Clin Psychol** 1996 Oct;64(5):1090–3

Acute and chronic distress and posttraumatic stress disorder as a function of responsibility for serious motor vehicle accidents. Delahanty DL, et al. **J Consult Clin Psychol** 1997 Aug;65(4):560–7

Behavioral couples therapy for male substance–abusing patients: effects on relationship adjustment and drug–using behavior. Fals–Stewart W, et al. **J Consult Clin Psychol** 1996 Oct;64(5):959–72

Appraisal, coping, and social support as mediators of well–being in black and white family caregivers of patients with Alzheimer's disease. Haley WE, et al. **J Consult Clin Psychol** 1996 Feb;64(1):121–9

Anticipatory nausea and vomiting in pediatric cancer patients: an analysis of conditioning and coping variables. Tyc VL, et al. **J Dev Behav Pediatr** 1997 Feb;18(1):27–33

Coping, drinking motives, goal attainment expectancies and family models in relation to alcohol use among college students. Karwacki SB, et al. **J Drug Educ** 1996; 26(3):243–55

College students' smoking behavior, perceived stress, and coping styles. Naquin MR, et al. **J Drug Educ** 1996; 26(4):367–76

Stalking on campus: the prevalence and strategies for coping with stalking. Fremouw WJ, et al. **J Forensic Sci** 1997 Jul; 42(4):666–9

Balance and source of social support in relation to well–being. Jung J. **J Gen Psychol** 1997 Jan;124(1):77–90

Effects of parent drug use and personality on toddler adjustment. Brook JS, et al. **J Genet Psychol** 1996 Mar; 157(1):19–35

Coping with crises: an examination of the impact of traumatic events on religious beliefs. Overcash WS, et al. **J Genet Psychol** 1996 Dec;157(4):455–64

Positive and negative social exchanges: weighing their effects in later life [editorial; comment] Rook KS. **J Gerontol B Psychol Sci Soc Sci** 1997 Jul;52(4):S167–9. Comment on: J Gerontol B Psychol Sci Soc Sci 1997 Jul;52(4):S190–9.

The psychological consequences of multiple roles: the nonnormative case. Hong J, et al. **J Health Soc Behav** 1995 Dec;36(4):386–98

Rural gay men in northern New England: life experiences and coping styles. Cody PJ, et al. **J Homosex** 1997; 33(1):51–67

Internalized homophobia in a sample of HIV+ gay men, and its relationship to psychological distress, coping, and illness progression. Wagner G, et al. **J Homosex** 1996; 32(2):91–106

Dementia in older people with intellectual disability: symptoms of physical and mental illness, and levels of adaptive behaviour. Moss S, et al. **J Intellect Disabil Res** 1997 Feb;41 (Pt 1):60–9

Coping with cancer. Graham BL Jr, et al. **J Miss State Med Assoc** 1997 Aug;38(8):295–8

The impact of culture on physician stress and coping. Post DM, et al. **J Natl Med Assoc** 1997 Sep;89(9):585–90

Brain metabolism of progesterone, coping behaviour and emotional reactivity in male rats from two psychogenetically selected lines. Steimer T, et al. **J Neuroendocrinol** 1997 Mar;9(3):169–75

Hope facilitating strategies for the family of the head injury patient. Johnson LH, et al. **J Neurosci Nurs** 1996 Aug; 28(4):259–66 (35 ref.)

Quality of life in children with well–controlled epilepsy. Wildrick D, et al. **J Neurosci Nurs** 1996 Jun;28(3):192–8

Spiral processes of becoming: women's experiences within the context of doctoral education. Gray DP, et al. **J Nurs Educ** 1997 Feb;36(2):60–6

Strategies to assist students to be successful the next time around on the NCLEX–RN. Vance A, et al. **J Nurs Educ** 1997 Apr;36(4):190–2

Informational coping styles: a validity study. Ross CJ, et al. **J Nurs Meas** 1995 Winter;3(2):145–58

Depot medroxyprogesterone. Management of side–effects commonly associated with its contraceptive use. Archer B, et al. **J Nurse Midwifery** 1997 Mar–Apr;42(2):104–11

Survival strategies for nurse–midwifery students. Carveth JA, et al. **J Nurse Midwifery** 1996 Jan–Feb;41(1):50–4

Student to nurse–midwife role transition process. Smoothing the way. Hunter LP, et al. **J Nurse Midwifery** 1996 Jul–Aug;41(4):328–33

Find yourself in the neutral zone? [editorial] Haller KB. **J Obstet Gynecol Neonatal Nurs** 1996 Jun;25(5):373

Parents' experience surrounding the death of a newborn whose birth is at the margin of viability. Kavanaugh K. **J Obstet Gynecol Neonatal Nurs** 1997 Jan–Feb;26(1):43–51

Psychosocial adjustment during pregnancy: the experience of mature gravidas. Stark MA. **J Obstet Gynecol Neonatal Nurs** 1997 Mar–Apr; 26(2):206–11

Facilitating perinatal grieving between the mother and the father. Wallerstedt C, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jun;25(5):389–94 (35 ref.)

Regional back pain: you've got it, you're my patient [comment] Van Dyke MW. **J Occup Environ Med** 1996 Oct;38(10):979–80. Comment on: J Occup Environ Med 1996 Oct;38(10):973–8.

Children's coping with venipuncture. Hodgins MJ, et al. **J Pain Symptom Manage** 1997 May;13(5):274–85

Coping with labor pain. Niven CA, et al. **J Pain Symptom Manage** 1996 Feb;11(2):116–25

An exploratory study of pain, coping, and depressed mood following burn injury. Ulmer JF. **J Pain Symptom Manage** 1997 Mar;13(3):148–57

A systems approach to adolescent transitions: an opportunity for nurses [editorial] Betz CL. **J Pediatr Nurs** 1996 Oct; 11(5):271–2

A child with chronic illness and the process of family adaptation. Clawson JA. **J Pediatr Nurs** 1996 Feb; 11(1):52–61 (37 ref.)

Family response to childhood chronic illness: description of management styles. Knafl K, et al. **J Pediatr Nurs** 1996 Oct;11(5):315–26

Foster parents' early adaptation to the placement of a child with developmental disabilities in their home. Rodriguez JA, et al. **J Pediatr Nurs** 1996 Apr;11(2):111–8

Fostering children's resilience. Stewart M, et al. **J Pediatr Nurs** 1997 Feb;12(1):21–31 (107 ref.)

Emotional support in pediatric trauma: remembering children

like Caleb [editorial] Zink KA. **J Pediatr Nurs** 1996 Dec; 11(6):345–6
Development of two instruments examining stress and adjustment in children with cancer. Hockenberry-Eaton M, et al. **J Pediatr Oncol Nurs** 1997 Jul;14(3):178–85
Uncertainty and coping in fathers of children with cancer. Sterken DJ. **J Pediatr Oncol Nurs** 1996 Apr;13(2):81–8; discussion 89–90
The Behavioral Approach–Avoidance and Distress Scale: an investigation of reliability and validity during painful medical procedures. Bachanas PJ, et al. **J Pediatr Psychol** 1996 Oct;21(5):671–81
Psychological aspects of childhood obesity: a controlled study in a clinical and nonclinical sample. Braet C, et al. **J Pediatr Psychol** 1997 Feb;22(1):59–71
Factors predicting distress among caregivers to children with chronic medical conditions. Canning RD, et al. **J Pediatr Psychol** 1996 Oct;21(5):735–49
Behavioral adjustment of children with surgically palliated complex congenital heart disease. Casey FA, et al. **J Pediatr Psychol** 1996 Jun;21(3):335–52
Transactional patterns of child, mother, and father adjustment in insulin-dependent diabetes mellitus: a prospective study. Chaney JM, et al. **J Pediatr Psychol** 1997 Apr;22(2):229–44
Parents of children with cancer: a longitudinal study of emotional distress, coping style, and marital adjustment two and twenty months after diagnosis. Dahlquist LM, et al. **J Pediatr Psychol** 1996 Aug;21(4):541–54
Relating parent and family functioning to the psychological adjustment of children with chronic health conditions: what have we learned? What do we need to know? Drotar D. **J Pediatr Psychol** 1997 Apr;22(2):149–65 (88 ref.)
Maternal, paternal, and marital functioning in families of preadolescents with spina bifida. Holmbeck GN, et al. **J Pediatr Psychol** 1997 Apr;22(2):167–81
A social support intervention for parents of children with juvenile rheumatoid arthritis: results of a randomized trial. Ireys HT, et al. **J Pediatr Psychol** 1996 Oct;21(5):633–41
Hope, coping, and adjustment among children with sickle cell disease: tests of mediator and moderator models. Lewis HA, et al. **J Pediatr Psychol** 1996 Feb;21(1):25–41
Mental health of mothers of children with juvenile rheumatoid arthritis: appraisal as a mediator. Lustig JL, et al. **J Pediatr Psychol** 1996 Oct;21(5):719–33
Psychosocial and family functioning in children with insulin-dependent diabetes at diagnosis and one year later. Northam E, et al. **J Pediatr Psychol** 1996 Oct;21(5):699–717
Development of the role-play inventory of situations and coping strategies for parents of children with cystic fibrosis. Quittner AL, et al. **J Pediatr Psychol** 1996 Apr;21(2):209–35
Adjustment in childhood brain tumor survival: child, mother, and teacher report. Radcliffe J, et al. **J Pediatr Psychol** 1996 Aug;21(4):529–39
Mothers' resolution of their child's diagnosis and self-reported measures of parenting stress, marital relations, and social support. Sheeran T, et al. **J Pediatr Psychol** 1997 Apr;22(2):197–212
Moderating effects of family structure on the relationship between physical and mental health in urban children with chronic illness. Silver EJ, et al. **J Pediatr Psychol** 1996 Feb;21(1):43–56
Commentary: pitfalls in the use of brief screening measures of coping. Spirito A. **J Pediatr Psychol** 1996 Aug; 21(4):573–5
Ethnographic detection and description of family strategies for child care: applications to the study of cerebral palsy. Weiss KL, et al. **J Pediatr Psychol** 1997 Apr;22(2):263–78
Somatic function, mental health, and psychosocial adjustment of adolescents with anorectal anomalies. Diseth TH, et al. **J Pediatr Surg** 1996 May;31(5):638–43
Construing benefits from adversity: adaptational significance and dispositional underpinnings. Affleck G, et al. **J Pers** 1996 Dec;64(4):899–922 (85 ref.)
The development of coping resources in adulthood. Aldwin CM, et al. **J Pers** 1996 Dec;64(4):837–71
A dispositional and situational assessment of children's coping: testing alternative models of coping. Ayers TS, et al. **J Pers** 1996 Dec;64(4):923–58
The mismeasure of coping by checklist. Coyne JC, et al. **J Pers** 1996 Dec;64(4):959–91 (70 ref.)
The interactional context of problem–, emotion–, and relationship–focused coping: the role of the big five personality factors. O'Brien TB, et al. **J Pers** 1996 Dec; 64(4):775–813 (100 ref.)
Personality and coping: three generations of research. Suls J, et al. **J Pers** 1996 Dec;64(4):711–35 (92 ref.)
Coping and personality: third time's the charm? Suls J, et al. **J Pers** 1996 Dec;64(4):993–1005 (43 ref.)
Positive illusions and coping with adversity. Taylor SE, et al. **J Pers** 1996 Dec;64(4):873–98 (80 ref.)
Patient adherence in chronic illness: personality and coping in context. Wiebe JS, et al. **J Pers** 1996 Dec;64(4):815–35 (95 ref.)
Repressive coping: distraction using pleasant thoughts and memories. Boden JM, et al. **J Pers Soc Psychol** 1997 Jul; 73(1):45–62
The moderating roles of self-esteem and self-construal in reaction to a threat to the self: evidence from the People's Republic of China and the United States. Brockner J, et al. **J Pers Soc Psychol** 1996 Sep;71(3):603–15
Introduction to the special section: use of bereavement narratives to predict well-being in gay men whose partners died of AIDS—four theoretical perspectives. Folkman S. **J Pers Soc Psychol** 1997 Apr;72(4):851–4
The self as a mediator between personality and adjustment. Graziano WG, et al. **J Pers Soc Psychol** 1997 Aug; 73(2):392–404
Social context, coping strategies, and depressive symptoms: an expanded model with cardiac patients. Holahan CJ, et al. **J Pers Soc Psychol** 1997 Apr;72(4):918–28
Discriminant validity of well-being measures. Lucas RE, et al. **J Pers Soc Psychol** 1996 Sep;71(3):616–28
Mixed messages: implications of social conflict and social support within close relationships for adjustment to a stressful life event. Major B, et al. **J Pers Soc Psychol** 1997 Jun;72(6):1349–63
Rumination and psychological distress among bereaved partners. Nolen-Hoeksema S, et al. **J Pers Soc Psychol** 1997 Apr;72(4):855–62
Received and perceived social support in times of stress: a test of the social support deterioration deterrence model. Norris FH, et al. **J Pers Soc Psychol** 1996 Sep;71(3):498–511
Linguistic predictors of adaptive bereavement. Pennebaker JW, et al. **J Pers Soc Psychol** 1997 Apr;72(4):863–71
Facilitating and debilitating trait anxiety, situational anxiety, and coping with an anticipated stressor: a process analysis. Raffety BD, et al. **J Pers Soc Psychol** 1997 Apr; 72(4):892–906
Organization of self-knowledge: implications for recovery from sad mood. Showers CJ, et al. **J Pers Soc Psychol** 1996 Mar;70(3):578–90
Appraisal and goal processes as predictors of psychological well-being in bereaved caregivers. Stein N, et al. **J Pers Soc Psychol** 1997 Apr;72(4):872–84
Predicting women's well-being in midlife: the importance of personality development and social role involvements. Vandewater EA, et al. **J Pers Soc Psychol** 1997 May; 72(5):1147–60
Stability in extraversion and aspects of social support at midlife. Von Dras DD, et al. **J Pers Soc Psychol** 1997 Jan; 72(1):233–41
A scale for predicting quality of recovery following the death of a partner. Weiss RS, et al. **J Pers Soc Psychol** 1997 Apr;72(4):885–91
Self-injurious behavior and mood regulation in borderline patients. Kemperman I, et al. **J Personal Disord** 1997 Summer;11(2):146–57
Hardiness, coping, and burnout in the nursing workplace. Simoni PS, et al. **J Prof Nurs** 1997 May-Jun;13(3):178–85
The influence of a big brothers program on the adjustment of boys in single-parent families. Abbott DA, et al. **J Psychol** 1997 Mar;131(2):143–56
Laboratory pain and styles of coping with anger. Gelkopf M. **J Psychol** 1997 Jan;131(1):121–3
A multidimensional approach to the study of the structure of coping with stress. Livneh H, et al. **J Psychol** 1996 Sep; 130(5):501–12
The relationship between job involvement and well-being. Riipinen M. **J Psychol** 1997 Jan;131(1):81–9
Coping with job loss: an attributional model. Thomson NF. **J Psychol** 1997 Jan;131(1):73–80 (26 ref.)
Stress intervention. A model of stress inoculation training. Admi H. **J Psychosoc Nurs Ment Health Serv** 1997 Aug; 35(8):37–41
My quest for inner peace. Buchanan D. **J Psychosoc Nurs Ment Health Serv** 1996 Sep;34(9):32
Consumers as faculty: experts on their own lives. Chapman V. **J Psychosoc Nurs Ment Health Serv** 1996 Aug; 34(8):47–9
Helping spouses with chronic sorrow related to multiple sclerosis. Hainsworth MA. **J Psychosoc Nurs Ment Health Serv** 1996 Jun;34(6):36–40
Stressors and coping strategies of homeless men. Murray RB. **J Psychosoc Nurs Ment Health Serv** 1996 Aug;34(8):16–22
Visual coping scenarios to facilitate discussion of coping responses with impoverished women at risk for AIDS. Nyamathi A, et al. **J Psychosoc Nurs Ment Health Serv** 1997 Aug;35(8):17–23
Inpatients with bipolar disorder: their quest to understand. Pollack LE. **J Psychosoc Nurs Ment Health Serv** 1996 Jun; 34(6):19–24
Walking a mile in their shoes... Symbolic interactionism for families living with severe mental illness. Saunders J. **J Psychosoc Nurs Ment Health Serv** 1997 Jun;35(6):8–13 (24 ref.)
Mall walking. An effective mental health intervention for older adults. Travis SS, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Aug;34(8):36–8
Well-being and the menopausal transition. Dennerstein L, et al. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):95–101
Coping with illness-related problems and quality of life in adult individuals with muscular dystrophy. Ahlström G, et al. **J Psychosom Res** 1996 Oct;41(4):365–76
Survival and psychosocial adjustment to stoma surgery and nonstoma bowel resection: a 4-year follow-up. Bekkers MJ, et al. **J Psychosom Res** 1997 Mar;42(3):235–44
Tinnitus coping style and its relationship to tinnitus severity and emotional distress. Budd RJ, et al. **J Psychosom Res** 1996 Oct;41(4):327–35
Are coping strategies related to disease outcome in early breast cancer? Buddeberg C, et al. **J Psychosom Res** 1996 Mar;40(3):255–64
Women and HIV infection: investigation of its psychosocial consequences. Catalan J, et al. **J Psychosom Res** 1996 Jul; 41(1):39–47
Coping strategies and psychiatric morbidity in women attending breast assessment clinics. Chen CC, et al. **J Psychosom Res** 1996 Mar;40(3):265–70
Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. Fortune DG, et al. **J Psychosom Res** 1997 May;42(5):467–75
Self-efficacy as a component of active coping: effects on cardiovascular reactivity. Gerin W, et al. **J Psychosom Res** 1996 May;40(5):485–93
Symptom distress, coping style and biological variables as predictors of survival after bone marrow transplantation. Molassiotis A, et al. **J Psychosom Res** 1997 Mar; 42(3):275–85
Active confrontational coping predicts decreased clinical progression over a one-year period in HIV-infected homosexual men. Mulder CL, et al. **J Psychosom Res** 1995 Nov;39(8):957–65
The factor structure of coping strategies in hemophilia. Santavirta N, et al. **J Psychosom Res** 1996 Jun;40(6):617–24
Psychosexual adjustment following sterilization: a prospective study on Chinese women. Tang CS, et al. **J Psychosom Res** 1997 Feb;42(2):187–96
Coping with multiple sclerosis in medical practice. Hillman JG. **J R Coll Physicians Lond** 1996 Nov-Dec;30(6):582
Resilience in children with disabilities—transition to adulthood [editorial] White PH. **J Rheumatol** 1996 Jun; 23(6):960–2
Use of a projective technique to assess young children's appraisal and coping responses to a venipuncture. Caty S, et al. **J Soc Pediatr Nurs** 1997 Apr-Jun;2(2):83–92
Teaching teens to cope: coping skills training for adolescents with insulin-dependent diabetes mellitus. Davidson M, et al. **J Soc Pediatr Nurs** 1997 Apr-Jun;2(2):65–72
Mothering children who survive brain injuries: playing the hand you're dealt. Guerriere D, et al. **J Soc Pediatr Nurs** 1997 Jul-Sep;2(3):105–15
Children, coping, and the stress of illness: a synthesis of the research. Ryan-Wenger NA. **J Soc Pediatr Nurs** 1996 Oct-Dec;1(3):126–38 (43 ref.)
Parents' resources and home management of the care of chronically ill infants. Sterling YM, et al. **J Soc Pediatr Nurs** 1996 Oct-Dec;1(3):103–9; quiz 111–2
Mastery of stress in mothers of preterm infants. Younger JB, et al. **J Soc Pediatr Nurs** 1997 Jan-Mar;2(1):29–35
Acculturation mode, identity variation, and psychosocial adjustment. Damji T, et al. **J Soc Psychol** 1996 Aug; 136(4):493–500
The capacity to be alone as a stress buffer. Larson R, et al. **J Soc Psychol** 1996 Feb;136(1):5–16
Anger coping styles and perceived social support. Palfai TP, et al. **J Soc Psychol** 1997 Aug;137(4):405–11
The temptation–coping questionnaire: development and validation. Myers MG, et al. **J Subst Abuse** 1995; 7(4):463–79
The coping styles of alcoholics with axis II disorders. Smyth NJ, et al. **J Subst Abuse** 1995;7(4):425–35
The effects of stressor type on projected coping. Bjorck JP, et al. **J Trauma Stress** 1997 Jul;10(3):481–97
Anger regulation deficits in combat-related posttraumatic stress disorder. Chemtob CM, et al. **J Trauma Stress** 1997 Jan;10(1):17–36 (28 ref.)
Extent of victimization, traumatic stress symptoms, and adjustment of terrorist assault survivors: a long-term follow-up. Desivilya HS, et al. **J Trauma Stress** 1996 Oct; 9(4):881–9
Hope, coping, and social support in combat-related posttraumatic stress disorder. Irving LM, et al. **J Trauma Stress** 1997 Jul;10(3):465–79
Resiliency and adult adaptation in women with and without self-reported histories of childhood sexual abuse. Lam JN, et al. **J Trauma Stress** 1997 Apr;10(2):175–96
Children's selective coping after a bus disaster: confronting behavior and perceived support. Milgram N, et al. **J Trauma Stress** 1996 Oct;9(4):687–702
Thematic resolution, PTSD, and complex PTSD: the relationship between meaning and trauma-related diagnoses. Newman E, et al. **J Trauma Stress** 1997 Apr; 10(2):197–213
The Posttraumatic Growth Inventory: measuring the positive legacy of trauma. Tedeschi RG, et al. **J Trauma Stress** 1996 Jul;9(3):455–71
At the bedside: when a doctor's wife is ill. Belinson JL. **J Womens Health** 1997 Feb;6(1):41–4
Quality-of-life ratings in patients with chronic illnesses [letter] Adang EM, et al. **JAMA** 1997 Apr 2;277(13):1038
Genetic testing of families with hereditary diseases [letter; comment] Wexler A. **JAMA** 1996 Oct 9;276(14):1139–40; discussion 1140. Comment on: JAMA 1996 Jun 26;275(24):1885–92.
Hassles, appraisals, coping and distress: a closer look at the stress process. Lu L. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Aug; 13(8):503–10
Parental coping with childhood hospitalization: a theoretical framework to guide research and clinical interventions. Melnyk BM. **Matern Child Nurs J** 1995 Oct-Dec; 23(4):123–31 (51 ref.)
Effects of movies on children's emotional health. Bierman J, et al. **Md Med J** 1996 Mar;45(3):218–21
Should medical ecology be political? [comment] McElroy

A. **Med Anthropol Q** 1996 Dec;10(4):519–22. Comment on: Med Anthropol Q 1996 Dec;10(4):455–75. Comment on: Med Anthropol Q 1996 Dec;10(4):476–95. Comment on: Med Anthropol Q 1996 Dec;10(4):496–515.

More than dialogue: contributions to the recapturing of anthropology [comment] Morsy SA. **Med Anthropol Q** 1996 Dec;10(4):516–9. Comment on: Med Anthropol Q 1996 Dec;10(4):455–75. Comment on: Med Anthropol Q 1996 Dec;10(4):476–95. Comment on: Med Anthropol Q 1996 Dec;10(4):496–515.

Farewell to adaptationism: unnatural selection and the politics of biology [see comments] Singer M. **Med Anthropol Q** 1996 Dec;10(4):496–515 (74 ref.). Comment in: Med Anthropol Q 1996 Dec;10(4):451–4. Comment in: Med Anthropol Q 1996 Dec;10(4):516–9. Comment in: Med Anthropol Q 1996 Dec;10(4):519–22.

American medical students in Israel: stress and coping. Schreier AR, et al. **Med Educ** 1996 Nov;30(6):445–52

Dissociation as complex adaptation. Sel R. **Med Hypotheses** 1997 Mar;48(3):205–8 (31 ref.)

Psychological functioning of adolescent and young adult survivors of pediatric malignancy. Elkin TD, et al. **Med Pediatr Oncol** 1997 Dec;29(6):582–8

Coping with terrorism: the OPM-SANG experience. Applewhite L, et al. **Mil Med** 1997 Apr;162(4):240–3

Military family adaptation to United Nations Operations in Somalia. Zeff KN, et al. **Mil Med** 1997 Jun;162(6):384–7

My encounter with cancer. One woman's battle with cancer and today's health system. Vaughn-D'Annibale T. **N C Med J** 1997 Jan–Feb;58(1):52–5

Postresuscitation changes in brain free radical-mediated processes and nitric oxide synthase activity in rats: effects of individual behavior in "emotional resonance" test. Stepanichev MYu, et al. **Neurochem Res** 1997 Jun; 22(6):743–52

Acute adaptive changes in food intake pattern following olfactory ablation in rats. Meguid MM, et al. **Neuroreport** 1997 Apr 14;8(6):1439–44

Increasing metamemory in older adults. Dellefield KS, et al. **Nurs Res** 1996 Sep–Oct;45(5):284–90

Dissociation, somatization, substance abuse, and coping in women with chronic pelvic pain. Badura AS, et al. **Obstet Gynecol** 1997 Sep;90(3):405–10

Women's experiences of lymphedema. Carter BJ. **Oncol Nurs Forum** 1997 Jun;24(5):875–82

Spiritual well-being, religiosity, hope, depression, and other mood states in elderly people coping with cancer. Fehring RJ, et al. **Oncol Nurs Forum** 1997 May;24(4):663–71

Exploring the everyday world of the patient in isolation. Gaskill D, et al. **Oncol Nurs Forum** 1997 May;24(4):695–700

Adjustment responses of children and their mothers to cancer: self-care and anxiety. Moore JB, et al. **Oncol Nurs Forum** 1997 Apr;24(3):519–25

Coping with a breast biopsy: how healthcare professionals can help women and their husbands. Northouse LL, et al. **Oncol Nurs Forum** 1997 Apr;24(3):473–80

Coping strategies of family caregivers of home hospice patients with cancer. Steele RG, et al. **Oncol Nurs Forum** 1996 Jul;23(6):955–60

Commentary: psychosocial concerns. Vorpahl C. **Oncol Nurs Forum** 1996 Sep;23(8):1177–8

Concerns, affect, and cognitive disruption following completion of radiation treatment for localized breast or prostate cancer. Walker BL, et al. **Oncol Nurs Forum** 1996 Sep;23(8):1181–7

Psychological distress can be predicted early in cancer patients [news] **Oncology (Huntingt)** 1995 Jul;9(7):597–8 passim

The crisis of cancer: psychological impact on family caregivers. Blanchard CG, et al. **Oncology (Huntingt)** 1997 Feb;11(2):189–94; discussion 196, 201–2

Chaplaincy: a continuum of caring. Handzo RG. **Oncology (Huntingt)** 1996 Sep;10(9 Suppl):45–7

Supportive care of the patient with pancreatic cancer: the role of the oncology social worker. Kennedy VN. **Oncology (Huntingt)** 1996 Sep;10(9 Suppl):35–7 (9 ref.)

The psychosocial impact of the diagnosis and treatment of laryngeal cancer. McQuellon RP, et al. **Otolaryngol Clin North Am** 1997 Apr;30(2):231–41 (44 ref.)

Fear and avoidance in dysfunctional chronic back pain patients. Asmundson GJ, et al. **Pain** 1997 Feb;69(3):231–6

A comparison of pain report and adequacy of analgesic therapy in ambulatory AIDS patients with and without a history of substance abuse. Breitbart W, et al. **Pain** 1997 Aug;72(1–2):235–43

Psychological dysfunction in patients with reflex sympathetic dystrophy. Ciccone DS, et al. **Pain** 1997 Jul;71(3):323–33

Determinants of pain expression in hospitalized burn patients. Difede J, et al. **Pain** 1997 Aug;72(1–2):245–51

Predictive utility of the CSQ in low back pain: individual vs. composite measures. Dozois DJ, et al. **Pain** 1996 Aug; 66(2–3):171–80

The cortisol response to psychological stress in temporomandibular dysfunction. Jones DA, et al. **Pain** 1997 Aug;72(1–2):171–82

Pain coping strategies and coping efficacy in rheumatoid arthritis: a daily process analysis. Keefe FJ, et al. **Pain** 1997 Jan;69(1–2):35–42

Readiness to adopt a self-management approach to chronic pain: the Pain Stages of Change Questionnaire (PSOCQ). Kerns RD, et al. **Pain** 1997 Aug;72(1–2):227–34

Coping strategies predict disability in patients with primary fibromyalgia. Martin MY, et al. **Pain** 1996 Nov;68(1):45–53

Pain in ambulatory AIDS patients. II: Impact of pain on psychological functioning and quality of life. Rosenfeld B, et al. **Pain** 1996 Dec;68(2–3):323–8

Good patients cope with their pain: postoperative analgesia and nurses' perceptions of their patients' pain. Salmon P, et al. **Pain** 1996 Nov;68(1):63–8

Coping with chronic pain: flexible goal adjustment as an interactive buffer against pain-related distress. Schmitz U, et al. **Pain** 1996 Sep;67(1):41–51

Effects of type of symptom onset on psychological distress and disability in fibromyalgia syndrome patients. Turk DC, et al. **Pain** 1996 Dec;68(2–3):423–30

Development of the Waldron/Varni pediatric pain coping inventory. Varni JW, et al. **Pain** 1996 Sep;67(1):141–50

Communicating the diagnosis of motor neurone disease. Johnston M, et al. **Palliat Med** 1996 Jan;10(1):23–34

Family coping and bereavement outcome. Kissane DW, et al. **Palliat Med** 1997 May;11(3):191–201

Evaluation of the psychological status of ventilatory-supported patients with ALS/MND. McDonald ER, et al. **Palliat Med** 1996 Jan;10(1):35–41

Psychosocial stress and adaptive functioning in children and adolescents suffering from hypohidrotic ectodermal dysplasia. Hummel P, et al. **Pediatr Dermatol** 1997 May–Jun;14(3):180–5

Outcome of congenital adrenal hyperplasia. Kuhnle U, et al. **Pediatr Surg Int** 1997 Sep;12(7):511–5

French adaptation of the Ways of Coping Checklist. Bruchon-Schweitzer M, et al. **Percept Mot Skills** 1996 Aug;83(1):104–6

Dispositional optimism and coping with academic examinations. Lai JC, et al. **Percept Mot Skills** 1996 Aug; 83(1):23–7

Effects of subliminal symbiotic stimuli on anxiety reduction. Malik R, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):771–84

Benefits of physical activity. Silvestri L. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):890

Patient and family adjustment to heart transplantation. Hwang HF. **Prog Cardiovasc Nurs** 1996 Spring;11(2):16–8, 39 (18 ref.)

Psychiatric sequelae in seriously ill children and their families. Stuber ML. **Psychiatr Clin North Am** 1996 Sep; 19(3):481–93 (71 ref.)

Successful coping, adaptation and resilience in the elderly: an interpretation of epidemiologic data. Foster JR. **Psychiatr Q** 1997 Fall;68(3):189–219 (96 ref.)

Is adaptive coping possible for adult survivors of childhood sexual abuse? Binder RL, et al. **Psychiatr Serv** 1996 Feb; 47(2):186–8

Homelessness, negative affect, and coping among veterans with gambling problems who misused substances. Castellani B, et al. **Psychiatr Serv** 1996 Mar;47(3):298–9

Crossing new bridges: the process of adaptation and psychological distress of Russian immigrants in Israel. Baider L, et al. **Psychiatry** 1996 Summer;59(2):175–83

The role of neurocognitive deficits in understanding adaptive functioning in severe psychiatric illness: commentary on Hawkins and Cooper [comment] Nuechterlein KH, et al. **Psychiatry** 1996 Winter;59(4):389–92. Comment on: Psychiatry 1996 Winter;59(4):382–8.

Validity and reliability of the Japanese version of the Stress and Coping Inventory. Fukunishi I, et al. **Psychiatry Clin Neurosci** 1995 Aug;49(4):195–9

Liaison psychiatry and HIV infection (I): Avoidance coping responses associated with depressive symptoms accompanying somatic complaints. Fukunishi I, et al. **Psychiatry Clin Neurosci** 1997 Feb;51(1):1–4

The effect of coping on the caregiver of elderly patients with dementia [published erratum appears in Psychiatry Clin Neurosci 1995 Dec;49(5–6):308] Matsuda O. **Psychiatry Clin Neurosci** 1995 Aug;49(4):209–11

Pain and self-injury in borderline patients: sensory decision theory, coping strategies, and locus of control. Russ MJ, et al. **Psychiatry Res** 1996 Jun 26;63(1):57–65

The role of the other in mourning. Hagman G. **Psychoanal Q** 1996 Apr;65(2):327–52

Observations on the long-term effects of child analysis. Implications for technique. Ritvo S. **Psychoanal Study Child** 1996;51:365–85

Patterns of coping preferences for male and female caregivers of frail older adults. DeVries HM, et al. **Psychol Aging** 1997 Jun;12(2):263–7

Effects of memory training on the subjective memory functioning and mental health of older adults: a meta-analysis. Floyd M, et al. **Psychol Aging** 1997 Mar; 12(1):150–61

Caregivers' appraisals of efficacy in coping with dementia. Gignac MA, et al. **Psychol Aging** 1996 Jun;11(2):214–25

Distinctive late-life challenges: implications for coping and well-being. Kling KC, et al. **Psychol Aging** 1997 Jun; 12(2):288–95

What do older good and poor sleepers do during periods of nocturnal wakefulness? The Sleep Behaviors Scale: 60+. Libman E, et al. **Psychol Aging** 1997 Mar;12(1):170–82

Coping strategies of people living in multigenerational households: effects on well-being. Pruchno RA, et al. **Psychol Aging** 1997 Mar;12(1):115–24

Adaptation to community relocation: the interactive influence of psychological resources and contextual factors. Smider NA, et al. **Psychol Aging** 1996 Jun;11(2):362–72

A stitch in time: self-regulation and proactive coping. Aspinwall LG, et al. **Psychol Bull** 1997 May;121(3):417–36 (175 ref.)

Maladaptive coping and affective disorders among cancer patients. Parle M, et al. **Psychol Med** 1996 Jul;26(4):735–44

Setting the scene for eating disorders, II. Childhood helplessness and mastery. Troop NA, et al. **Psychol Med** 1997 May;27(3):531–8

Religion and psychological well-being in later life. Francis LJ, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):1050

Companion animals and the psychological health of Alzheimer patients' caregivers. Fritz CL, et al. **Psychol Rep** 1996 Apr;78(2):467–81

Subclinical depressive symptoms in HIV are related to avoidance coping responses: a comparison with end-stage renal failure and breast cancer. Fukunishi I, et al. **Psychol Rep** 1996 Apr;78(2):483–8

Poststroke anxiety and its relationship to coping and stage of recovery. Gillespie DC. **Psychol Rep** 1997 Jun;80(3 Pt 2):1059–64

An interim report on the development of the Psychological Trauma and Resources Scales. Holmes GR, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):819–31

Adaptors and innovators: a description of staff nurses. Pettigrew AC, et al. **Psychol Rep** 1997 Aug;81(1):16–8

Stress factors in the aftermath of Hurricanes Erin and Opal: data from small business owners. Piotrowski C, et al. **Psychol Rep** 1997 Jun;80(3 Pt 2):1387–91

Weinberger adjustment typology and the five factor model of personality. Ramanaiah NV, et al. **Psychol Rep** 1996 Apr;78(2):432–4

The subjectivity of loneliness and coping with it. Rokach A. **Psychol Rep** 1996 Oct;79(2):475–81

Stress, coping, and social support in hypothetically psychosis-prone subjects. Schuldberg D, et al. **Psychol Rep** 1996 Jun;78(3 Pt 2):1267–83

Psychometric properties of the Self-perceived Stress in Retirement Scale. Sharpley CF. **Psychol Rep** 1997 Aug; 81(1):319–22

Adjustment of children and interaction of parent and child among single mothers in a disadvantaged South African community. Skuy M, et al. **Psychol Rep** 1997 Jun;80(3 Pt 2):1171–80

Sense of coherence, negative affectivity, and general health in farm supervisors. Strümpfer DJ. **Psychol Rep** 1997 Jun; 80(3 Pt 1):963–6

Optimism, Type A behavior, and psychological well-being in Japanese women. Sumi K, et al. **Psychol Rep** 1997 Feb; 80(1):43–8

Contextual effects on adolescent disorders relevant to coping. Tiffany DW, et al. **Psychol Rep** 1996 Apr;78(2):593–4

Categorizing coping responses for envy: a multidimensional analysis of workplace perceptions. Vecchio RP. **Psychol Rep** 1997 Aug;81(1):137–8

Response set of social desirability in relation to the Mental, Physical and Spiritual Well-Being Scale. Vella-Brodrick DA, et al. **Psychol Rep** 1997 Aug;81(1):127–30

Being a "joiner" and psychological well-being. Wann DL, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1186

Is the wish to participate in a cancer rehabilitation program an indicator of the need? Comparisons of participants and non-participants in a randomized study. Berglund G, et al. **Psychooncology** 1997 Mar;6(1):35–46

Predictors of parental emotional adjustment to childhood cancer. Grootenhuis MA, et al. **Psychooncology** 1997 Jun; 6(2):115–28

Psychopathological verbal expression of self-perceived stress in three groups of psychotic patients. Jimeno Bulnes N, et al. **Psychopathology** 1997;30(1):39–48

Coping styles in abstainers from alcohol. Watten RG. **Psychopathology** 1996 Nov–Dec;29(6):340–6

Coping and psychosocial adaptation: longitudinal effects over time and stages in breast cancer. Heim E, et al. **Psychosom Med** 1997 Jul–Aug;59(4):408–18

Determinants of perceived health in patients with left ventricular dysfunction: a structural modeling analysis. Rosen RC, et al. **Psychosom Med** 1997 Mar–Apr; 59(2):193–200

Perceptions of parental caring predict health status in midlife: a 35-year follow-up of the Harvard Mastery of Stress Study [see comments] Russek LG, et al. **Psychosom Med** 1997 Mar–Apr;59(2):144–9. Comment in: Psychosom Med 1997 Mar–Apr;59(2):150–1.

Influence of ethnicity and gender on cardiovascular responses to active coping and inhibitory-passive coping challenges. Saab PG, et al. **Psychosom Med** 1997 Jul–Aug;59(4):434–46

Health outcomes and cognitive aspects of recalled negative life events. Suedfeld P, et al. **Psychosom Med** 1997 Mar–Apr;59(2):172–7

Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. van't Spijker A, et al. **Psychosom Med** 1997 May–Jun;59(3):280–93

The role of psychological variables in a group of melanoma patients. An Israeli sample. Baider L, et al. **Psychosomatics** 1997 Jan–Feb;38(1):45–53

Psychological distress among adult patients being evaluated for bone marrow transplantation. Baker F, et al. **Psychosomatics** 1997 Jan–Feb;38(1):10–9

Avoidance coping behaviors and low social support are related to depressive symptoms in HIV-positive patients in Japan. Fukunishi I, et al. **Psychosomatics** 1997 Mar–Apr; 38(2):113–8

Coping style and social support in women suffering from cluster headache or migraine. Blomkvist V, et al. **Psychother Psychosom** 1997;66(3):150–4

Somatization, dissociation, and tension-reducing behaviors in psychiatric outpatients. Farley M, et al. **Psychother Psychosom** 1997;66(3):133–40

Psychological well-being: meaning, measurement, and implications for psychotherapy research. Ryff CD, et al. **Psychother Psychosom** 1996;65(1):14–23 (56 ref.)

The retirement transition and the later life family unit. Smith SD. **Public Health Nurs** 1997 Aug;14(4):207–16

The use and efficacy of coping strategies and coping styles in a Swedish sample. Cronqvist A, et al. **Qual Life Res** 1997 Jan;6(1):87–96

Quality of life in predialytic uremic patients. Klang B, et al. **Qual Life Res** 1996 Feb;5(1):109–16

Expectant fathers: influence of perinatal education on stress, coping, and spousal relations. Diemer GA. **Res Nurs Health** 1997 Aug;20(4):281–93

Helping mothers cope with a critically ill child: a pilot test of the COPE intervention. Melnyk BM, et al. **Res Nurs Health** 1997 Feb;20(1):3–14

Effect of support groups with coaching on adaptation to early stage breast cancer. Samarel N, et al. **Res Nurs Health** 1997 Feb;20(1):15–26

Effects of formal supports on stress outcomes in family caregivers of Alzheimer's patients. Winslow BW. **Res Nurs Health** 1997 Feb;20(1):27–37

Macrosocial transition and health hazards. Schröder H, et al. **Rev Environ Health** 1996 Jan–Jun;11(1–2):1–5 (9 ref.)

Dealing with devastation [editorial] Freeman JW. **S D J Med** 1996 Oct;49(10):359–60

Ménière's disease: trauma, distress and adaptation studied through focus interview analyses. Erlandsson SI, et al. **Scand Audiol Suppl** 1996;43:45–56

Occupational hearing loss: coping and family life. Hallberg LR. **Scand Audiol Suppl** 1996;43:25–33 (30 ref.)

Crisis-related observations in competition: a case study in basketball. Bar-Eli M, et al. **Scand J Med Sci Sports** 1996 Oct;6(5):313–21

Relationships between social support, social coping and life events in the relapse of schizophrenic patients. Hultman CM, et al. **Scand J Psychol** 1997 Mar;38(1):3–13

Unemployment, coping and psychological distress. Smári J, et al. **Scand J Psychol** 1997 Jun;38(2):151–6

Aging and work—coping with strengths and weaknesses [editorial] Ilmarinen J. **Scand J Work Environ Health** 1997; 23 Suppl 1:3–5

Social support and patterns of adjustment to breast cancer. Hoskins CN, et al. **Sch Inq Nurs Pract** 1996 Summer; 10(2):99–123; discussion 125–33

Bandura's theory of self-efficacy: applications to oncology. Lev EL. **Sch Inq Nurs Pract** 1997 Spring;11(1):21–37; discussion 39–43 (62 ref.)

Chronic sorrow in persons with Parkinson's and their spouses. Lindgren CL. **Sch Inq Nurs Pract** 1996 Winter; 10(4):351–66; discussion 367–70

Correlates of the caregiving process in multiple sclerosis. O'Brien RA, et al. **Sch Inq Nurs Pract** 1995 Winter; 9(4):323–38; discussion 339–42

Coping with negative symptoms of schizophrenia: patient and family perspectives. Mueser KT, et al. **Schizophr Bull** 1997;23(2):329–39

Benign familial neonatal convulsions; psychosocial adjustment to the threat of recurrent seizures. Psenka TM, et al. **Seizure** 1996 Sep;5(3):243–5

The role of relationship-based developmentally supportive newborn intensive care in strengthening outcome of preterm infants. Als H, et al. **Semin Perinatol** 1997 Jun; 21(3):178–89 (84 ref.)

School age outcome in low birth weight preterm infants. Leonard CH, et al. **Semin Perinatol** 1997 Jun;21(3):240–53 (52 ref.)

Normal aging and environmental effects on communication. Lubinski R, et al. **Semin Speech Lang** 1997 May; 18(2):107–25; quiz 125–6 (90 ref.)

Family adaptation to a child's feeding and swallowing disorder: a social work perspective. Parrish M. **Semin Speech Lang** 1997 Feb;18(1):71–7; quiz 77–8

Gender response to neurofibromatosis 1. Ablon J. **Soc Sci Med** 1996 Jan;42(1):99–109

Quality of life: a dynamic construct. Allison PJ, et al. **Soc Sci Med** 1997 Jul;45(2):221–30 (60 ref.)

Prediction of psychological adjustment to multiple sclerosis. Barnwell AM, et al. **Soc Sci Med** 1997 Aug;45(3):411–8

Women physicians in Quebec. De Koninck M, et al. **Soc Sci Med** 1997 Jun;44(12):1825–32

Beliefs on coping with illness: a consumer's perspective. de Ridder D, et al. **Soc Sci Med** 1997 Mar;44(5):553–9

Social networks, social support and coping with serious illness: the family connection. Ell K. **Soc Sci Med** 1996 Jan;42(2):173–83 (173 ref.)

Chronic stress and psychological well-being: evidence from Thailand on household crowding. Fuller TD, et al. **Soc Sci Med** 1996 Jan;42(2):265–80

Social networks, social support, personal empowerment, and the adaptation of psychiatric consumers/survivors: path analytic models. Hall GB, et al. **Soc Sci Med** 1996 Dec; 43(12):1743–54

Sex differences in coping and depression among young adults. Hänninen V, et al. **Soc Sci Med** 1996 Nov;43(10):1453–60

Coping with loss of ability: "good grief" or episodic stress responses? Hewson D. **Soc Sci Med** 1997 Apr;44(8):1129–39

Negotiating spaces in home environments: older women living with arthritis. Moss P. **Soc Sci Med** 1997 Jul; 45(1):23–33

Adaptive demands along the HIV disease continuum. Pakenham KI, et al. **Soc Sci Med** 1996 Jan;42(2):245–56

Direct and buffer effects of social support and personal coping resources in individuals with arthritis. Penninx BW, et al. **Soc Sci Med** 1997 Feb;44(3):393–402

Chronic work stress, sickness absence, and hypertension in middle managers: general or specific sociological explanations? Peter R, et al. **Soc Sci Med** 1997 Oct; 45(7):1111–20

Couples' adjustment to one partner's disability: the relationship between sense of coherence and adjustment. Rena F, et al. **Soc Sci Med** 1996 Jul;43(2):163–71

Coping with chronic pain: assessing narrative approaches. Kelley P, et al. **Soc Work** 1997 May;42(3):266–77

Personal styles and ways of coping in individuals who use wheelchairs. Wheeler G, et al. **Spinal Cord** 1996 Jun; 34(6):351–7

The effect of litigation status on adjustment to whiplash injury. Swartzman LC, et al. **Spine** 1996 Jan 1;21(1):53–8

Psychological impact of injuries in athletes. Smith AM. **Sports Med** 1996 Dec;22(6):391–405 (78 ref.)

Coping with a partner who drinks too much: does anything work? Barber JG, et al. **Subst Use Misuse** 1997 Mar; 32(4):485–94

Parental bereavement after suicide and accident: a comparative study. Séguin M, et al. **Suicide Life Threat Behav** 1995 Winter;25(4):489–92

The psychological challenges facing melanoma patients. Kneier AW. **Surg Clin North Am** 1996 Dec;76(6):1413–21 (23 ref.)

Living with AIDS. Moran T. **Tex Med** 1997 Jun;93(6):47–8

Coping styles among Japanese women with breast cancer. Hosaka T, et al. **Tokai J Exp Clin Med** 1995 Jul; 20(2):137–41

Dating violence: the association between methods of coping and women's psychological adjustment. Coffey P, et al. **Violence Vict** 1996 Fall;11(3):227–38

Adjusting to criminal victimization: the correlates of postcrime distress. Davis RC, et al. **Violence Vict** 1996 Spring;11(1):21–38

Conducting research on child maltreatment: effects on researchers. Kinard EM. **Violence Vict** 1996 Spring; 11(1):65–9

Risk and resilience among children exposed to family violence. Kolbo JR. **Violence Vict** 1996 Summer; 11(2):113–28

A triangulation approach to testing a family instrument. Friedemann ML, et al. **West J Nurs Res** 1997 Jun; 19(3):364–78

Coping with HIV disease among seropositive women: psychosocial correlates. Nannis ED, et al. **Women Health** 1997;25(1):1–22

Attitudes toward genetic carrier screening for cystic fibrosis among pregnant women: the role of health beliefs and avoidant coping style. Fang CY, et al. **Womens Health** 1997 Spring;3(1):31–51

[Regulative music therapy and training as a means for enhancing adaptive potentials and for overcoming fatigue and stress] Tsenova B. **Probl Khig** 1996;21:44–51 (Eng. Abstr.) **(Bul)**

[Coping behaviors of the elderly with positive physical examination results in Kaohsiung City] Guo SE, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Jun; 13(6):378–87 (Eng. Abstr.) **(Chi)**

[Post-traumatic stress disorder or maladjustment to stress? (letter)] Nuutila A. **Duodecim** 1995;111(16):1582–5 **(Fin)**

[Strategies for coping in schizophrenia] Lalonde P, et al. **Encephale** 1996 Jul–Aug;22(4):240–6 (Eng. Abstr.) **(Fre)**

[Depression and individual reactions] Spadone C, et al. **Encephale** 1996 Dec;22 Spec No 7:73–4 **(Fre)**

[Management of patients afflicted with chronic maladies. Difficulties and obstacles from the standpoint of the patients, from the standpoint of the doctors, from the standpoint of the institution] Assal JP, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:175–83 (10 ref.) **(Fre)**

[Parenthood and child development after reproduction medicine treatment. Psychosomatic follow-up of 46 parents after assisted reproduction] Bindt C, et al. **Fortschr Med** 1996 Sep 30;114(27):337–40 (Eng. Abstr.) **(Ger)**

[Psychiatric and sexual sequelae of hysterectomy—a comparison of different surgical methods] Strauss B, et al. **Geburtshilfe Frauenheilkd** 1996 Sep;56(9):473–81 (Eng. Abstr.) **(Ger)**

[Psychology of patient management: evaluation and quality assurance of psychosocial management in pediatric oncology] Kusch M, et al. **Gesundheitswesen** 1997 Feb; 59(2):87–94 (Eng. Abstr.) **(Ger)**

[Unfulfilled desire for children in the man: coping and pain. Results of a psychosomatic-andrologic cooperative study] Schilling S, et al. **Hautarzt** 1996 Sep;47(9):686–92 (Eng. Abstr.) **(Ger)**

[Research in psychosocial aspects of ENT tumor surgery (excluding laryngectomy): 4–part analysis of the literature. 3: Results of research] Kollbrunner J, et al. **HNO** 1997 Jul;45(7):523–32 (0 ref.) (Eng. Abstr.) **(Ger)**

[Coping with illness by young diabetic patients: a comparison from the viewpoint of patients, their parents and personal physicians] Wittich A, et al. **Klin Padiatr** 1996 Jan–Feb; 208(1):19–25 (Eng. Abstr.) **(Ger)**

[Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation] Gärtner U, et al. **Med Klin** 1996 Aug 15; 91(8):501–8 (Eng. Abstr.) **(Ger)**

[A training program for coping with maladaptive emotions of schizophrenic patients. Initial results and experiences] Hodel B, et al. **Nervenarzt** 1996 Jul;67(7):564–71 (Eng. Abstr.) **(Ger)**

[Psychosocial aspects of mucoviscidosis/cystic fibrosis in adulthood] Ullrich G. **Pneumologie** 1996 Dec;50 Suppl 3:817–21 **(Ger)**

[Family-oriented management of children and adolescents with cancer] Häberle H, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Jul–Aug; 46(6):405–19 (50 ref.) (Eng. Abstr.) **(Ger)**

[Psychological aspects of severe burn injuries in childhood and adolescence] Landolt M. **Prax Kinderpsychol Kinderpsychiatr** 1996 Feb;45(2):47–56 (125 ref.) (Eng. Abstr.) **(Ger)**

[Working through the Nazi past by the German psychoanalytic community. Attempt at an assessment from close distance] Wangh M. **Psyche (Stuttg)** 1996 Feb; 50(2):97–122 (Eng. Abstr.) **(Ger)**

[Family group in schizophrenic diseases. Overview, personal concept and report of experiences] Pott W. **Psychiatr Prax** 1996 Sep;23(5):219–25 (36 ref.) (Eng. Abstr.) **(Ger)**

[Do psychological factors modify survival of cancer patients? II: Results of an empirical study with bronchial carcinoma patients] Faller H, et al. **Psychother Psychosom Med Psychol** 1997 Jun;47(6):206–18 (Eng. Abstr.) **(Ger)**

[Do psychological factors modify survival of cancer patients? I: Review of the literature] Faller H. **Psychother Psychosom Med Psychol** 1997 May;47(5):163–9 (65 ref.) (Eng. Abstr.) **(Ger)**

[Function and structure of families with chronically ill children] Hauser E, et al. **Psychother Psychosom Med Psychol** 1996 Nov; 46(11):379–84 (Eng. Abstr.) **(Ger)**

[Coping with stress and self-awareness in idiopathic sudden deafness] Kröger F, et al. **Psychother Psychosom Med Psychol** 1996 Aug; 46(8):298–303 (Eng. Abstr.) **(Ger)**

[Confounding effects in social science studies and their control. The examples of personality, social support, psychiatric disease] Manz R. **Psychother Psychosom Med Psychol** 1997 Jun; 47(6):198–205 (Eng. Abstr.) **(Ger)**

[Sense of coherence and psychosomatic treatment outcome. An empirical study of salutogenesis] Sack M, et al. **Psychother Psychosom Med Psychol** 1997 May;47(5):149–55 (Eng. Abstr.) **(Ger)**

[Personal values and goal orientations of chronically ill adolescents and young adults] Schmitt GM. **Psychother Psychosom Med Psychol** 1997 Jun;47(6):189–97 (80 ref.) (Eng. Abstr.) **(Ger)**

[Quality of life and coping with illness in patients with acute myeloid leukemia] Schumacher A, et al. **Psychother Psychosom Med Psychol** 1996 Nov; 46(11):385–90 (Eng. Abstr.) **(Ger)**

[Age dependence of coping strategies in children and adolescents with diabetes mellitus] Zangerle M, et al. **Psychother Psychosom Med Psychol** 1997 Jul;47(7):240–8 (Eng. Abstr.) **(Ger)**

[The Bern Coping Forms BEFO—an instrument for self- and observer rating of coping with illness] Heim E, et al. **Rehabilitation (Stuttg)** 1996 Nov;35(4):XXXI–XLI (60 ref.) (Eng. Abstr.) **(Ger)**

[Adjusting to illness and secondary prevention in unemployed patients from the medical psychology viewpoint] Dauer S, et al. **Wien Med Wochenschr** 1997;147(11):283–6 (Eng. Abstr.) **(Ger)**

[Basic principles of psychological adjustment in the chronically ill child] Colditz K. **Z Arztl Fortbild Qualitatssich** 1997 Jun;91(3):203–12 (Eng. Abstr.) **(Ger)**

[Cardiovascular effects of active coping behavior in mental and social stress situations during various incentive conditions] Gramer M, et al. **Z Exp Psychol** 1996; 43(2):256–78 (Eng. Abstr.) **(Ger)**

[A bio-psychosocial treatment concept improves coping with illness by geriatric patients] Schmeling-Kludas C. **Z Gerontol Geriatr** 1997 May–Jun;30(3):242–7 (Eng. Abstr.) **(Ger)**

[Questionnaire to assess perception of chronic disease in couples. Perceptual pattern in coronary patients and their partners] Biskup J, et al. **Z Psychosom Med Psychoanal** 1996;42(1):56–70 (Eng. Abstr.) **(Ger)**

[Psychosocial acceptance of surgical interventions of the breast in oncological gynecology] Jackisch C, et al. **Zentralbl Gynakol** 1997;119(5):218–24 (Eng. Abstr.) **(Ger)**

[Delays produced by prolonged viewing in the recognition of Kanji characters: analysis of the "Gestaltzerfall" phenomenon] Ninose Y, et al. **Shinrigaku Kenkyu** 1996 Aug;67(3):227–31 (Eng. Abstr.) **(Jpn)**

[Self-acceptance as adaptively resigning the self to low self-evaluation] Ueda T. **Shinrigaku Kenkyu** 1996 Oct;

67(4):327–32 (Eng. Abstr.) **(Jpn)**
[Methods of coping with the disease and treatment in children with neoplastic blood diseases] Szweda E, et al. **Pediatr Pol** 1996 Aug;71(8):655–8 (Eng. Abstr.) **(Pol)**
[Psychological adaptation of patients after cardiosurgery on the mitral valve] Rynkun D, et al. **Przegl Lek** 1995; 52(11):547–51 (Eng. Abstr.) **(Pol)**
[Effects of mental adaptation on vegetative, hormonal and sensory reactions in preoperative period] Sergeenko NI, et al. **Anesteziol Reanimatol** 1997 Mar–Apr;(2):37–40 (Eng. Abstr.) **(Rus)**
[Formalized R. Rosenzweig frustration test in occupational selection of personnel] Noss IN, et al. **Fiziol Cheloveka** 1997 Mar–Apr;23(2):150–3 **(Rus)**
[The psychosomatic aspects of patient adaptation to hemodialysis treatment] Petrova NN, et al. **Ter Arkh** 1997; 69(4):66–9 **(Rus)**
[The current aspects of the social and biological adaptation of epilepsy patients in Russia] Gromov SA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(2):14–7 (Eng. Abstr.) **(Rus)**
[Adaptation problems of soldiers to the military environment] Dedić G, et al. **Vojnosanit Pregl** 1996 Jan–Feb;53(1):19–24 (Eng. Abstr.) **(Scr)**
[Psychosocial adaptation in children and adolescents with craniofacial malformations] Sauceda-García JM, et al. **Gac Med Mex** 1997 May–Jun;133(3):203–9 (Eng. Abstr.) **(Spa)**
[Complex memory function for mental trauma. Memory and forgetting ae necessary for the emotional adaptation process] Christianson SA, et al. **Lakartidningen** 1997 Apr 30;94(18):1721–4 (20 ref.) **(Swe)**

CLASSIFICATION

Repressive coping style and the architecture of emotion-related memories: is their relationship that simple? Orbach I, et al. **Br J Soc Psychol** 1996 Dec;35 (Pt 4):459–71
Relationship between hardiness and risk of burnout in a sample of 92 nurses working in oncology and AIDS wards. Costantini A, et al. **Psychother Psychosom** 1997;66(2):78–82

DRUG EFFECTS

Inositol has behavioral effects with adaptation after chronic administration. Cohen H, et al. **J Neural Transm** 1997; 104(2–3):299–305
[The clinical aspects and psychopharmacotherapy of adaptive neurotic disorders] Munchaeva ER, et al. **Ter Arkh** 1997; 69(4):65–6 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Life situation, self reported health and coping ability of 35-year old twins and controls—a follow-up of a longitudinal Swedish twin study at adolescence. Lange AL, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(4):405–16
Is repression adaptive? Relationships to socioemotional adjustment, academic performance, and self-image. Bybee J, et al. **Am J Orthopsychiatry** 1997 Jan;67(1):59–69
Adaptation to cognitive deficit? An exploration of apparent dissociations between everyday memory and test performance late after stroke. Sunderland A, et al. **Br J Clin Psychol** 1996 Sep;35 (Pt 3):463–76
Causal attribution by patients, their spouses and the physicians in relation to patient outcome after a first myocardial infarction: subjective and objective outcome. Billing E, et al. **Cardiology** 1997 Jul–Aug;88(4):367–72
The stability of pain coping strategies in young children adolescents, and adults with sickle cell disease over an 18-month period. Gil KM, et al. **Clin J Pain** 1997 Jun; 13(2):110–5
Relationship of learned resourcefulness to measures of pain description, psychopathology and health behavior in a sample of chronic pain patients. Toomey TC, et al. **Clin J Pain** 1995 Dec;11(4):259–66
Self-esteem and the relation between risk behavior and perceptions of vulnerability to unplanned pregnancy in college women. Smith GE, et al. **Health Psychol** 1997 Mar; 16(2):137–46
Cerebral correlates of anticipated fear: a PET study of specific phobia. Wik G, et al. **Int J Neurosci** 1996 Nov; 87(3–4):267–76
Pre- and post-stimulus processes in affective task and event-related desynchronization (ERD): do they discriminate anxiety coping styles? Aftanas LI, et al. **Int J Psychophysiol** 1996 Dec;24(3):197–212
Primary dysthymia: a study of several psychosocial, endocrine and immune correlates. Ravindran AV, et al. **J Affect Disord** 1996 Sep 9;40(1–2):73–84
Psychological coping with acute pain: an examination of the role of endogenous opioid mechanisms. Bruehl S, et al. **J Behav Med** 1996 Apr;19(2):129–42
Physiological stress reactivity and recovery: conceptual siblings separated at birth? Linden W, et al. **J Psychosom Res** 1997 Feb;42(2):117–35 (59 ref.)
REM sleep in depressed patients: different attempts to achieve adaptation. Rotenberg VS, et al. **J Psychosom Res** 1997 Jun;42(6):565–75
Delayed response tasks in basal ganglia lesions in man: further evidence for a striato-frontal cooperation in behavioural adaptation. Partiot A, et al. **Neuropsychologia** 1996 Jul; 34(7):709–21
Superconsolidated conditioned reflex—a highly adaptive system of behavior. Serdyuchenko VM. **Neurosci Behav Physiol** 1996 Jul–Aug;26(4):344–8
Neuroendocrine mechanisms of the formation of adaptive behavior. Shalyapina VG, et al. **Neurosci Behav Physiol** 1997 May–Jun;27(3):275–9 (25 ref.)
Regional activation of human cerebral cortex upon an adaptation in mirror drawing. Imamura K, et al. **Neurosci Lett** 1996 May 17;209(3):185–8
Anger management style, hostility and spouse responses: gender differences in predictors of adjustment among chronic pain patients. Burns JW, et al. **Pain** 1996 Mar; 64(3):445–53
Active and passive coping strategies in chronic pain patients. Snow-Turek AL, et al. **Pain** 1996 Mar;64(3):455–62
Cortisol responses in adults who stutter: coping preferences and apprehension about communication. Blood GW, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):883–9
Columnar organization in the midbrain periaqueductal gray and the integration of emotional expression. Bandler R, et al. **Prog Brain Res** 1996;107:285–300 (84 ref.)
The neurobiology of the central nucleus of the amygdala in relation to neuroendocrine and autonomic outflow. Bohus B, et al. **Prog Brain Res** 1996;107:447–60 (91 ref.)
Trait anxiety, coping with stress, and norharman. Verheij R, et al. **Psychol Rep** 1997 Feb;80(1):51–9
Effects of the Transcendental Meditation program on adaptive mechanisms: changes in hormone levels and responses to stress after 4 months of practice. MacLean CR, et al. **Psychoneuroendocrinology** 1997 May; 22(4):277–95
Emotional reactivity, defensiveness, and ambulatory cardiovascular response at work. Melamed S. **Psychosom Med** 1996 Sep–Oct;58(5):500–7
[The general and specific mechanisms of adaptation of the body to extreme exposures] Sachanska T, et al. **Probl Khig** 1996;21:51–66 (Eng. Abstr.) **(Bul)**
[Psychological features of new male and female cases of pulmonary tuberculosis and their social adaptation] Lomachenkov VD, et al. **Probl Tuberk** 1997;(3):9–11 (Eng. Abstr.) **(Rus)**
[The adaptive capacities of patients with panic disorders (a psychophysiological study)] Siniachkin MS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(4):20–4 (Eng. Abstr.) **(Rus)**

ADCC see **ANTIBODY-DEPENDENT CELL CYTOTOXICITY**

ADDICTIVE BEHAVIOR see **BEHAVIOR, ADDICTIVE**

ADDISON'S ANEMIA see **ANEMIA, PERNICIOUS**

ADDISON'S DISEASE

Type 2 polyglandular autoimmune disease (Schmidt's syndrome). Betterle C, et al. **J Pediatr Endocrinol Metab** 1996 Mar;9 Suppl 1:113–23 (51 ref.)

BLOOD

High plasma levels of endothelin-1 in untreated Addison's disease [see comments] Letizia C, et al. **Eur J Endocrinol** 1996 Dec;135(6):696–9. Comment in: Eur J Endocrinol 1996 Dec;135(6):645–8.
Hyper-adrenocorticotropinemia in a patient with Addison's disease after treatment with corticosteroids. Sugiyama K, et al. **Intern Med** 1996 Jul;35(7):555–9

CHEMICALLY INDUCED

Mineralocorticoid insufficiency due to suramin therapy. Kobayashi K, et al. **Cancer** 1996 Dec 1;78(11):2411–20

COMPLICATIONS

Oral squamous cell carcinoma in a young person with candidosis endocrinopathy syndrome: a case report. Firth NA, et al. **Int J Oral Maxillofac Surg** 1997 Feb;26(1):42–4
Reversible cardiomyopathy in a child with Addison's disease. Derish M, et al. **Intensive Care Med** 1996 May;22(5):460–3 (15 ref.)
A case of Addison's disease associated with the Lambert–Eaton myasthenic syndrome. Ozata M, et al. **J Endocrinol Invest** 1997 Jun;20(6):338–41
Association of primary antiphospholipid syndrome with primary adrenal insufficiency. González G, et al. **J Rheumatol** 1996 Jul;23(7):1286–7
Adrenal failure in systemic lupus erythematosus. Koren S, et al. **J Rheumatol** 1997 Jul;24(7):1410–2
Addison's disease and selective IgA deficiency in two coeliac patients. Heneghan MA, et al. **Scand J Gastroenterol** 1997 May;32(5):509–11
[Corticotropic adenoma in slow adrenal insufficiency] Fabreguettes C, et al. **Ann Endocrinol (Paris)** 1996; 57(2):111–5 (Eng. Abstr.) **(Fre)**
[Diagnosis of active tuberculosis by prostatic biopsy in a patient with Addison disease (letter)] Serrano Alférez I, et al. **An Med Interna** 1997 May;14(5):266 **(Spa)**
[Severe hypercalcemia secondary to an addisonian crisis and hyperthyroidism (letter)] Camblor Alvarez M, et al. **Rev Clin Esp** 1997 Jun;197(6):465–6 (10 ref.) **(Spa)**

DIAGNOSIS

Emergency! Addisonian crisis. O'Donnell M. **Am J Nurs** 1997 Mar;97(3):41
Addison disease in patients treated with glucocorticoid therapy. Cronin CC, et al. **Arch Intern Med** 1997 Feb 24; 157(4):456–8
Presentations of pituitary insufficiency and Addison's disease in insulin dependent diabetes may be similar [letter; comment] Hardy K, et al. **BMJ** 1996 Oct 5;313(7061):885 . Comment on: BMJ 1996 Jun 22;312(7046):1601–2.
Primary adrenal lymphoma presenting as Addisonian crisis. Pitfalls in the diagnosis of bilateral adrenal swelling [letter] Sone H, et al. **Horm Metab Res** 1996 Feb;28(2):116
Adrenal crisis in active duty service members. McDermott MT, et al. **Mil Med** 1996 Oct;161(10):624–6

DRUG THERAPY

Hyper-adrenocorticotropinemia in a patient with Addison's disease after treatment with corticosteroids. Sugiyama K, et al. **Intern Med** 1996 Jul;35(7):555–9
[Laboratory monitoring of therapy in Addison's disease] Kreze A, et al. **Vnitr Lek** 1996 Sep;42(9):627–31 (Eng. Abstr.) **(Slo)**

EPIDEMIOLOGY

The prevalence of Addison's disease in Coventry, UK. Willis AC, et al. **Postgrad Med J** 1997 May;73(859):286–8

ETIOLOGY

Melanoderma revealing primary antiphospholipid syndrome. Guibal F, et al. **Dermatology** 1996;192(1):75–7
Endothelin: culprit or bystander in Addison's disease? [comment] Ruschitzka FT, et al. **Eur J Endocrinol** 1996 Dec;135(6):645–8. Comment on: Eur J Endocrinol 1996 Dec;135(6):696–9.
II. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison's disease. Betterle C, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):939–42
I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease. Betterle C, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):932–8
Bilateral adrenal hemorrhage and acute addisonian crisis—a complication of antiphospholipid syndrome. Garris GW, et al. **J Tenn Med Assoc** 1996 Apr;89(4):120
Primary adrenal lymphoma associated with adrenal insufficiency: a distinct clinical entity. Pimentel M, et al. **Leuk Lymphoma** 1997 Jan;24(3-4):363–7 (23 ref.)
Adrenomyeloneuropathy: a rare cause of Addison's disease? Hochstenbag MM, et al. **Neth J Med** 1996 Aug;49(2):77–81
Hypoadrenocorticism in beagles exposed to aerosols of plutonium-238 dioxide by inhalation. Weller RE, et al. **Radiat Res** 1996 Dec;146(6):688–93
[Bilateral non-Hodgkin's lymphoma of the adrenal glands with adrenal insufficiency] Takahashi T, et al. **Rinsho Ketsueki** 1996 Sep;37(9):867–9 (Eng. Abstr.) **(Jpn)**
[Addison's disease as the first manifestation of bilateral suprarenal tumor (letter; comment)] Chocarro Martínez A, et al. **An Med Interna** 1996 Sep;13(9):464–5. Comment on: An Med Interna 1995 Dec;12(12):619–20. **(Spa)**
[Adrenal mass and adrenal insufficiency] Martínez Albaladejo M, et al. **An Med Interna** 1996 Dec;13(12):595–7 (Eng. Abstr.) **(Spa)**

HISTORY

The conquest of Addison's disease. Hiatt JR, et al. **Am J Surg** 1997 Sep;174(3):280–3

IMMUNOLOGY

Adrenal autoantibodies and organ-specific autoimmunity in patients with Addison's disease. Söderbergh A, et al. **Clin Endocrinol (Oxf)** 1996 Oct;45(4):453–60
21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison's disease. Belgian Diabetes Registry. Falorni A, et al. **Clin Exp Immunol** 1997 Feb;107(2):341–6
Autoantigens in Addison's disease and associated syndromes [editorial; [comment] Weetman AP. **Clin Exp Immunol** 1997 Feb;107(2):227–9. Comment on: Clin Exp Immunol 1997 Feb;107(2):335–40.
The autoimmune basis of adrenocortical destruction in Addison's disease. Winqvist O, et al. **Mol Med Today** 1996 Jul;2(7):282–9 (41 ref.)

PATHOLOGY

Addison's disease presenting with cerebral edema. Geenen C, et al. **Can J Neurol Sci** 1996 May;23(2):141–4

RADIOGRAPHY

Computed tomography morphology of the adrenal glands of patients with Addison's disease. Ammini AC, et al. **Australas Radiol** 1996 Feb;40(1):38–42

VETERINARY

Duplex Doppler measurements of renal blood flow in a dog with Addison's disease. Koch J, et al. **J Small Anim Pract** 1997 Mar;38(3):124–6

ADENINE

Exchange transfusion with red blood cells preserved in adenine clears a child of severe falciparum malaria. Boctor FN, et al. **Ann Clin Lab Sci** 1997 May–Jun;27(3):193–5

Methoxyamine–induced mutagenesis of nucleic acids. A proton NMR study of oligonucleotides containing N4–methoxycytosine paired with adenine or guanine. Gdaniec Z, et al. **Eur J Biochem** 1996 Dec 1;242(2):271–9

Reading–frame restoration by transcriptional slippage at long stretches of adenine residues in mammalian cells. Linton MF, et al. **J Biol Chem** 1997 May 30;272(22):14127–32

The detailed structure of tandem G.A mismatched base–pair motifs in RNA duplexes is context dependent. Heus HA, et al. **J Mol Biol** 1997 Aug 8;271(1):147–58

Evidence for AT–transversion bias in wasp (Hymenoptera: Symphyta) mitochondrial genes and its implications for the origin of parasitism. Dowton M, et al. **J Mol Evol** 1997 Apr;44(4):398–405

Evaluation of canine red blood cells stored in a saline, adenine, and glucose solution for 35 days. Wardrop KJ, et al. **J Vet Intern Med** 1997 Jan–Feb;11(1):5–8

Structural features of the DNA hairpin d(ATCCTA–GTTA–TAGGAT): formation of a G–A base pair in the loop. van Dongen MJ, et al. **Nucleic Acids Res** 1997 Apr 15;25(8):1537–47

A curved RNA helix incorporating an internal loop with G.A and A.A non–Watson–Crick base pairing. Baeyens KJ, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12; 93(23):12851–5

A cytokine mRNA–destabilizing element that is structurally and functionally distinct from A+U–rich elements. Brown CY, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13721–5

Recurrent G–to–A substitution in a single codon of SREBP cleavage–activating protein causes sterol resistance in three mutant Chinese hamster ovary cell lines. Nohturfft A, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13709–14

The 1691 G–>A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Leroy–Matheron C, et al. **Thromb Haemost** 1996 Jan;75(1):4–10

Identification of a new thyroglobulin variant: a guanine–to–adenine transition resulting in the substitution of arginine 2510 by glutamine. Mendive FM, et al. **Thyroid** 1997 Aug;7(4):587–91

Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G–>A hypermutation. Günther S, et al. **Virology** 1997 Aug 18;235(1):104–8

ANALOGS & DERIVATIVES

Early treatment with 9–(2–phosphonylmethoxyethyl)adenine reduces virus burdens for a prolonged period in SIV–infected rhesus macaques. Joag SV, et al. **AIDS Res Hum Retroviruses** 1997 Feb 10;13(3):241–6

Effects of (R)–9–(2–phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. Tsai CC, et al. **AIDS Res Hum Retroviruses** 1997 May 20; 13(8):707–12

Inhibition of peroxisomal degradation by 3–methyladenine (3MA) in primary cultures of rat hepatocytes. Kondo K, et al. **Anat Rec** 1997 Apr;247(4):449–54

Stability and analysis of 2–chloro–2'–deoxyadenosine, 2–chloro–2'–arabino–fluoro–2'–deoxyadenosine and 2–chloroadenine in human blood plasma. Lindemalm S, et al. **Anticancer Drugs** 1997 Jun;8(5):445–53

Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9–[2–(phosphonomethoxy)ethyl]adenine in vitro. Cherrington JM, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2212–6

Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)–9–(2–phosphonylmethoxyethyl) adenine, the bis(pivaloyloxymethyl) ester prodrug of 9–(2–phosphonylmethoxyethyl)adenine. Naesens L, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):22–8

Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)–9–(3–hydroxy–2–phosphonylmethoxypropyl)adenine in Plasmodium berghei–infected mice. Smeijsters LJ, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1584–8

9–[2–(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Van Rompay KK, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2586–91

In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9–[2–(phosphonomethoxy)ethyl]adenine (PMEA). Foli A, et al. **Antiviral Res** 1996 Oct;32(2):91–8

Application of a gastric cancer cell line (MKN–28) for anti–adenovirus screening using the MTT method. Kodama E, et al. **Antiviral Res** 1996 Jul;31(3):159–64

Red blood cells mediated delivery of 9–(2–phosphonylmethoxyethyl)adenine to primary macrophages: efficiency metabolism and activity against human immunodeficiency virus or herpes simplex virus. Perno CF, et al. **Antiviral Res** 1997 Feb;33(3):153–64

The base analog 6–N–hydroxylaminopurine (HAP) mutagenesis is dependent on the integrity of the uvsE, uvsF and uvsB genes in Aspergillus nidulans. Babudri N, et al. **Antonie Van Leeuwenhoek** 1997 Mar;71(3):249–55

Eimeria tenella: genetic recombination of markers for precocious development and arprinocid resistance. Shirley MW, et al. **Appl Parasitol** 1996 Dec;37(4):293–9

Action of adenine derivatives on experimental atrial flutter in the canine heart. Alvarado JL, et al. **Arch Med Res** 1997 Autumn;28(3):329–35

Styrene oxide DNA adducts: in vitro reaction and sensitive detection of modified oligonucleotides using capillary zone electrophoresis interfaced to electrospray mass spectrometry. Schrader W, et al. **Arch Toxicol** 1997; 71(9):588–95

Furfural, a precursor of the cytokinin hormone kinetin, and base propenals are formed by hydroxyl radical damage of DNA. Barciszewski J, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):317–9

Mutagenic DNA base modifications are correlated with lesions in nonneoplastic hepatic tissue of the English sole carcinogenesis model. Malins DC, et al. **Cancer Res** 1996 Dec 15;56(24):5563–5

Urinary excretion of 3–methyladenine after consumption of fish containing high levels of dimethylamine. Fay LB, et al. **Carcinogenesis** 1997 May;18(5):1039–44

Effects of 1–methyladenine on nuclear Ca2+ transients and meiosis resumption in starfish oocytes are mimicked by the nuclear injection of inositol 1,4,5–trisphosphate and cADP–ribose. Santella L, et al. **Cell Calcium** 1997 Jul; 22(1):11–20

Bindings of metallothionein to supranucleosomal fibers in mouse pancreatic nuclei after induction by 4–aminopyrazolo [3,4–D] pyrimidine. Tohno Y, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 Dec;42(8):1121–7

Cigarette smoking and urinary 3–alkyladenine excretion in man. Prevost V, et al. **Chem Res Toxicol** 1996 Mar; 9(2):439–44

Adenine phosphoribosyltransferase deficiency identified by urinary sediment analysis: cellular and molecular confirmation. Terai C, et al. **Clin Genet** 1995 Nov; 48(5):246–50

Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Shaw JP, et al. **Drug Metab Dispos** 1997 Mar;25(3):362–6

A mechanism for the in vivo formation of N6–furfuryladenine, kinetin, as a secondary oxidative damage product of DNA. Barciszewski J, et al. **FEBS Lett** 1997 Sep 8;414(2):457–60

Evidence for the presence of kinetin in DNA and cell extracts. Barciszewski J, et al. **FEBS Lett** 1996 Sep 16; 393(2–3):197–200

Different efficiencies of the Tag and AlkA DNA glycosylases from Escherichia coli in the removal of 3–methyladenine from single–stranded DNA. Bjelland S, et al. **FEBS Lett** 1996 Nov 11;397(1):127–9

Mice with adenine phosphoribosyltransferase deficiency develop fatal 2,8–dihydroxyadenine lithiasis. Redhead NJ, et al. **Hum Gene Ther** 1996 Aug 20;7(13):1491–502

Antitumor activity of novel purine acyclic nucleotide analogs PMEA and PMEDAP. Otová B, et al. **In Vivo** 1997 Mar–Apr;11(2):163–7

Internal 6–methyladenine residues increase the in vitro translation efficiency of dihydrofolate reductase messenger RNA. Heilman KL, et al. **Int J Biochem Cell Biol** 1996 Jul;28(7):823–9

Inhibition of tumor necrosis factor signal transduction in endothelial cells by dimethylaminopurine. Marino MW, et al. **J Biol Chem** 1996 Nov 8;271(45):28624–9

cGMP–stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. Rivet–Bastide M, et al. **J Clin Invest** 1997 Jun 1;99(11):2710–8

Anti–human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9–[2–(bis–pivaloyloxymethyl)–phosphonylmethoxyethyl]adenine) in HIV–infected patients. Barditch–Crovo P, et al. **J Infect Dis** 1997 Aug; 176(2):406–13

Effect of hypocholesterolemic doses of 17 alpha–ethinyl estradiol on cholesterol balance in liver and extrahepatic tissues. Bertolotti M, et al. **J Lipid Res** 1996 Aug; 37(8):1812–22

Synthesis, in vitro antiviral evaluation, and stability studies of bis(S–acyl–2–thioethyl) ester derivatives of 9–[2–(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. Benzaria S, et al. **J Med Chem** 1996 Dec 6;39(25):4958–65

9–Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors. Bourguignon JJ, et al. **J Med Chem** 1997 Jun 6;40(12):1768–70

Acyclic nucleotide analogs derived from 8–azapurines: synthesis and antiviral activity. Holý A, et al. **J Med Chem** 1996 Sep 27;39(20):4073–88

Carbocyclic oxetanocins lacking the C–3' methylene. Wu J, et al. **J Med Chem** 1997 Apr 25;40(9):1401–6

Dietary eritadenine modifies plasma phosphatidylcholine molecular species profile in rats fed different types of fat. Sugiyama K, et al. **J Nutr** 1997 Apr;127(4):593–9

Solid phase extraction and HPLC determination of 9–benzyladenine and isomeric 9–(nitrobenzyl)adenines and their metabolic N1–oxides present in microsomal incubates. Liu DY, et al. **J Pharm Biomed Anal** 1997 Jul; 15(11):1741–50

Synchronization of cell division in eight–cell bovine embryos produced in vitro: effects of 6–dimethylaminopurine. Samaké S, et al. **J Reprod Fertil** 1997 May;110(1):21–7

2,8–Dihydroxyadenine stone formation in a renal transplant recipient due to adenine phosphoribosyltransferase deficiency. de Jong DJ, et al. **J Urol** 1996 Nov; 156(5):1754–5

Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. Nowak MA, et al. **J Virol** 1997 Oct;71(10):7518–25

Correlation of suppressed linoleic acid metabolism with the hypocholesterolemic action of eritadenine in rats. Sugiyama K, et al. **Lipids** 1997 Aug;32(8):859–66

Dietary eritadenine–induced alteration of molecular species composition of phospholipids in rats. Sugiyama K, et al. **Lipids** 1996 Apr;31(4):399–404

Effect of UVM induction on mutation fixation at non–pairing and mispairing DNA lesions. Rahman MS, et al. **Mol Microbiol** 1996 Nov;22(4):747–55

Evidence for distinction of the differentiation–inducing activities and cytostatic properties of 9–(2–phosphonylmethoxyethyl)adenine and a variety of differentiation–inducing agents in human erythroleukemia K562 cells. Hatse S, et al. **Mol Pharmacol** 1996 Nov; 50(5):1231–42

Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication. Pisarev VM, et al. **Mol Pharmacol** 1997 Jul;52(1):63–8

DNA replication initiation by 6–DMAP treatment in maturing oocytes and dividing embryos from marine invertebrates. Néant I, et al. **Mol Reprod Dev** 1996 Aug; 44(4):443–51

Base analog N6–hydroxylaminopurine mutagenesis in Escherichia coli: genetic control and molecular specificity. Pavlov YI, et al. **Mutat Res** 1996 Oct 25;357(1–2):1–15

Synthesis and antiviral activities of 9–cyclopentylpurine derivatives. Kojima E, et al. **Nucleic Acids Symp Ser** 1995; (34):107–8

Synthesis of carbocyclic oxetanocin analogs bearing fluorine and their antiviral activities. Sato, et al. **Nucleic Acids Symp Ser** 1995;(34):159–60

A fas antigen receptor mutation allows development of toxic shock syndrome toxin–1–induced lethal shock in V beta 8.2 T–cell receptor transgenic mice. Cullen CM, et al. **Pathobiology** 1995;63(6):293–304

Characterization of metal–ion–nucleotide based particulate matter in solutions of 9–[2–(phosphonomethoxy)ethyl]adenine (PMEA). Yuan LC, et al. **PDA J Pharm Sci Technol** 1997 Jan–Feb; 51(1):30–5

Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)–ester prodrug of 9–(2–phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco–2). Annaert P, et al. **Pharm Res** 1997 Apr;14(4):492–6

Safety of 9–(2–phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection: a pilot study. Arends S, et al. **Pharm World Sci** 1996 Jan; 18(1):30–4

Radiation damage to DNA base pairs. I. Electron paramagnetic resonance and electron nuclear double resonance study of single crystals of the complex 1–methylthymine.9–methyladenine X–irradiated at 10K. Sagstuen E, et al. **Radiat Res** 1996 Oct;146(4):425–35

Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection. Grimaldi S, et al. **Res Virol** 1997 Mar–Apr;148(2):177–80

Inhibition of acute graft–versus–host disease in (LEW.1W x LEW.1A)F1 rats using 9–(2–phosphonomethoxyethyl)–2,6–diaminopurine. Otová B, et al. **Transplant Proc** 1997 May;29(3):1736–7

Effect of endogenous adenosine augmentation on ischemia and reperfusion injury to the liver. Zhang S, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1336–7

Cortical changes in starfish (Asterina pectinifera) oocytes during 1–methyladenine–induced maturation and fertilisation/activation. Longo FJ, et al. **Zygote** 1995 Aug; 3(3):225–39

[Effects of sand and hormone treatment on seed germination of Bupleurum chinese DC. and B. falcatum L.] Deng Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Apr; 21(4):208–10, 255 (Eng. Abstr.) **(Chi)**

[A case of lithiasis caused by 2,8 dihydroxyadenine. Evolutive characteristics. Therapeutic problems] Thomas J, et al. **J Urol (Paris)** 1996;102(4):161–7 (Eng. Abstr.) **(Fre)**

[Genetic control of metabolism of a mutagenic analog of 6–N–hydroxylaminopurine bases in Saccharomyces cerevisiae yeasts] Koz'min SG, et al. **Genetika** 1997 May; 33(5):591–8 (Eng. Abstr.) **(Rus)**

ANALYSIS

Genome size and AT content in Anguilliformes. Ronchetti E, et al. **Eur J Histochem** 1995;39(4):259–64

Solid phase extraction and HPLC determination of 9–benzyladenine and isomeric 9–(nitrobenzyl)adenines and their metabolic N1–oxides present in microsomal incubates. Liu DY, et al. **J Pharm Biomed Anal** 1997 Jul; 15(11):1741–50

ADENINE

BIOSYNTHESIS

The red/white colony color assay in the yeast Saccharomyces cerevisiae: epistatic growth advantage of white ade8-18, ade2 cells over red ade2 cells. Ugolini S, et al. **Curr Genet** 1996 Dec;30(6):485-92

apd1+, a gene required for red pigment formation in ade6 mutants of Schizosaccharomyces pombe, encodes an enzyme required for glutathione biosynthesis: a role for glutathione and a glutathione-conjugate pump. Chaudhuri B, et al. **Genetics** 1997 Jan;145(1):75-83

BLOOD

Lack of expansion of cytosine adenine guanine trinucleotide repeat in the dentatorubral and pallidoluysian atrophy gene in Swedish schizophrenic patients. Jönsson E, et al. **Biol Psychiatry** 1996 Aug 1;40(3):228-9

CHEMISTRY

Molecular imprinting approach for the recognition of adenine in aqueous medium and hydrolysis of adenosine 5'-triphosphate. Mathew J, et al. **Bioconjug Chem** 1995 Sep-Oct;6(5):524-8

Novel Hoogsteen-like bases for configurational recognition of the T-A base pair by DNA triplex formation. Rothman JH, et al. **Biopolymers** 1996 Dec;39(6):795-812

Reaction of adenine with 6-hydroxyestrogen 6-sulfates: model compounds to demonstrate carcinogenesis by estrogen. Itoh S, et al. **Chem Pharm Bull (Tokyo)** 1996 Sep; 44(9):1754-7

Synthesis and structure determination of the adducts formed by electrochemical oxidation of 1,2,3,4-Tetrahydro-7,12-dimethylbenz[a]anthracene in the presence of deoxyribonucleosides or adenine. Mulder PP, et al. **Chem Res Toxicol** 1996 Dec;9(8):1264-77

Hydrolysis of extracellular adenine nucleotides by equine epidydimal spermatozoa. Minelli A, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Aug; 117(4):531-4

Hb Valletta [beta 87(F3)Thr-->Pro] due to an A-->C substitution at codon 87 in a Calabrian family with alpha-thalassemia. Qualtieri A, et al. **Hemoglobin** 1997 Jan; 21(1):97-103

NMR investigation of echinomycin binding to d(ACGTTAACGT)2: Hoogsteen versus Watson-Crick A.T base pairing between echinomycin binding sites. Park JY, et al. **J Biochem (Tokyo)** 1995 Nov;118(5):989-95

Through-bond correlation of adenine H2 and H8 protons in unlabeled DNA fragments by HMBC spectroscopy. van Dongen MJ, et al. **J Biomol NMR** 1996 Sep;8(2):207-12

Hydrogen-bonded trimers of DNA bases and their interaction with metal cations: ab initio quantum-chemical and empirical potential study. Sponer J, et al. **J Biomol Struct Dyn** 1997 Apr;14(5):613-28

Branch-site selection in a group II intron mediated by active recognition of the adenine amino group and steric exclusion of non-adenine functionalities. Liu Q, et al. **J Mol Biol** 1997 Mar 21;267(1):163-71

Chiral symmetry breaking during the self-assembly of monolayers from achiral purine molecules. Sowerby SJ, et al. **J Mol Evol** 1996 Nov;43(5):419-24

Combined hereditary disorders of haemophilia B Leyden (-6 G-->A) and type 1 von Willebrand disease. Pernod G, et al. **Thromb Haemost** 1996 Aug;76(2):151-5

METABOLISM

Identification of adenine binding domain peptides of the NADP+ active site within porcine heart NADP(+)-dependent isocitrate dehydrogenase. Sankaran B, et al. **Biochemistry** 1996 Oct 22;35(42):13501-10

Substrate nucleotide-determined non-templated addition of adenine by Taq DNA polymerase: implications for PCR-based genotyping and cloning. Magnuson VL, et al. **Biotechniques** 1996 Oct;21(4):700-9

Nonselective URA3 colony-color assay in yeast ade1 or ade2 mutants. Weng YS, et al. **Biotechniques** 1997 Aug; 23(2):237-41

Identification and quantitation of DNA adducts from calf thymus DNA exposed to 3,4-epoxy-1-butene. Tretyakova N, et al. **Carcinogenesis** 1997 Jan;18(1):137-47

Inhalation exposure of rats and mice to 1,3-butadiene induces N6-adenine adducts of epoxybutene detected by 32P-postlabeling and HPLC. Koivisto P, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:655-7

A method to search for similar protein local structures at ligand binding sites and its application to adenine recognition. Kobayashi N, et al. **Eur Biophys J** 1997; 26(2):135-44

Accumulation of Ade+ reversions in isoauxotrophic stains of Saccharomyces cerevisiae allelic in RAD6 during adenine starvation. Storchová Z, et al. **Folia Microbiol (Praha)** 1997;42(1):47-51

Amino acid and adenine cross-pathway regulation act through the same 5'-TGACTC-3' motif in the yeast HIS7 promoter. Springer C, et al. **J Biol Chem** 1996 Nov 22; 271(47):29637-43

Adenine auxotrophic heterozygosity in Candida krusei. Cao B, et al. **J Med Vet Mycol** 1997 Jan-Feb;35(1):33-6

Diversity of adenine conversion in staphylococci. Krasuski A, et al. **Microbios** 1996;86(349):225-32

Nebularine (9-2'-deoxy-beta-D-ribofuranosylpurine) has the template characteristics of adenine in vivo and in vitro. Rahman MS, et al. **Mutat Res** 1997 Jul 3;377(2):263-8

Mechanism of bracken fern carcinogenesis: evidence for H-ras activation via initial adenine alkylation by ptaquiloside. Prakash AS, et al. **Nat Toxins** 1996;4(5):221-7

Effect of partial outlet obstruction on 14C-adenine incorporation in the rabbit urinary bladder. Hypolite JA, et al. **Neurourol Urodyn** 1997;16(3):201-8

PHARMACOLOGY

Action of adenine derivatives on experimental atrial flutter in the canine heart. Alvarado JL, et al. **Arch Med Res** 1997 Autumn;28(3):329-35

Adenine-induced arrest of mammalian cells in early S-phase is related to the prevention of DNA synthesis inhibition caused by gamma-irradiation. Mlejnek P, et al. **Int J Radiat Biol** 1997 May;71(5):505-13

Concanavalin A, ribose, and adenine resuscitate preserved rat hearts. Tan ZT, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):26-32

Synthesis and antiviral activities of 9-cyclopentylpurine derivatives. Kojima E, et al. **Nucleic Acids Symp Ser** 1995; (34):107-8

Protective effect of adenine on DNA synthesis in irradiated Ehrlich ascites tumor cells. Mlejnek P, et al. **Radiat Res** 1997 Apr;147(4):477-83

A clinical trial of red-cell concentrate prepared from blood collected in half-strength citrate anticoagulant. Murphy WG, et al. **Transfus Med** 1991 Mar;1(1):25-9

PHYSIOLOGY

Evidence that complex formation by Bas1p and Bas2p (Pho2p) unmasks the activation function of Bas1p in an adenine-repressible step of ADE gene transcription. Zhang F, et al. **Mol Cell Biol** 1997 Jun;17(6):3272-83

THERAPEUTIC USE

[Prediction of the effects of energy-stabilizing drugs in diabetes mellitus] Chobitko VG, et al. **Klin Lab Diagn** 1993 May-Jun;(3):15-7 (Eng. Abstr.) **(Rus)**

URINE

Cigarette smoking and urinary 3-alkyladenine excretion in man. Prevost V, et al. **Chem Res Toxicol** 1996 Mar; 9(2):439-44

ADENINE ARABINOSIDE see **VIDARABINE**

ADENINE ARABINOSIDE MONOPHOSPHATE see **VIDARABINE PHOSPHATE**

ADENINE DEOXYRIBONUCLEOSIDES see **DEOXYADENOSINES**

ADENINE NUCLEOTIDE TRANSLOCASE

ANALYSIS

Functional analysis of autoantibodies against ADP/ATP carrier from dilated cardiomyopathy. Liao YH. **Int J Cardiol** 1996 May;54(2):165-9 (43 ref.)

ANTAGONISTS & INHIBITORS

3'-Azido-3'-deoxythmidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator. Barile M, et al. **Biochem Pharmacol** 1997 Apr 4;53(7):913-20

[Inhibitors of the ADP/ATP antiporter induce two Ca2+-dependent uncoupling systems in rat liver mitochondria] Mikhaĭlova LM, et al. **Biokhimiia** 1996 Jul; 61(7):1270-8 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Tissue-specific transcription pattern of the adenine nucleotide translocase isoforms in humans. Doerner A, et al. **FEBS Lett** 1997 Sep 8;414(2):258-62

Thyroid hormone activates transcription from the promoter regions of some human nuclear-encoded genes of the oxidative phosphorylation system. Li R, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1-2):69-75

CHEMISTRY

Probing the role of positive residues in the ADP/ATP carrier from yeast. The effect of six arginine mutations on transport and the four ATP versus ADP exchange modes. Heidkämper D, et al. **Biochemistry** 1996 Dec 17; 35(50):16144-52

Conformational changes of the yeast mitochondrial adenosine diphosphate/adenosine triphosphate carrier studied through its intrinsic fluorescence. 1. Tryptophanyl residues of the carrier can be mutated without impairing protein activity. Le Saux A, et al. **Biochemistry** 1996 Dec 17; 35(50):16116-24

Probing the role of positive residues in the ADP/ATP carrier from yeast. The effect of six arginine mutations of oxidative phosphorylation and AAC expression. Müller V, et al. **Biochemistry** 1996 Dec 17;35(50):16132-43

Conformational changes of the yeast mitochondrial adenosine diphosphate/adenosine triphosphate carrier studied through its intrinsic fluorescence. 2. Assignment of tryptophanyl residues of the carrier to the responses to specific ligands. Roux P, et al. **Biochemistry** 1996 Dec 17; 35(50):16125-31

Direct thyroid hormone signalling via ADP-ribosylation controls mitochondrial nucleotide transport and membrane leakiness by changing the conformation of the adenine nucleotide transporter. Mowbray J, et al. **FEBS Lett** 1996 Sep 23;394(1):61-5

GENETICS

Differential regulation of the mitochondrial ADP/ATP translocase gene in wood frogs under freezing stress. Cai Q, et al. **Biochim Biophys Acta** 1997 Jul 17;1353(1):69-78

Genes located in and near the human pseudoautosomal region are located in the X-Y pairing region in dog and sheep. Toder R, et al. **Chromosome Res** 1997 Aug;5(5):301-6

Genetic mapping of the adenine nucleotide translocase-2 gene (Ant2) to the mouse proximal X chromosome. Ellison JW, et al. **Genomics** 1996 Sep 1;36(2):369-71

A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Graham BH, et al. **Nat Genet** 1997 Jul; 16(3):226-34

IMMUNOLOGY

Autoantibodies against ADP/ATP carrier from patients with dilated cardiomyopathy increase activity of voltage-dependent Ca channels in isolated cardiac myocytes. Liao YH, et al. **Blood Press Suppl** 1996;3:41-4

Study of autoantibodies against the adenine nucleotide translocator in idiopathic dilated cardiomyopathy. Zhang WG, et al. **Blood Press Suppl** 1996;3:45-8

ISOLATION & PURIFICATION

Characterization of a novel eukaryotic ATP/ADP translocator located in the plastid envelope of Arabidopsis thaliana L. Neuhaus HE, et al. **Plant J** 1997 Jan;11(1):73-82

Purification and characterization of the reconstitutively active adenine nucleotide carrier from maize mitochondria. Genchi G, et al. **Plant Physiol** 1996 Oct;112(2):845-51

METABOLISM

ATP/ADP antiporter- and aspartate/glutamate antiporter-mediated fatty acid-induced uncoupling of liver mitochondria in incubation media differing in ion composition. Samartsev VN, et al. **Biochem Mol Biol Int** 1997 Jun;42(1):29-34

Complexes between hexokinase, mitochondrial porin and adenylate translocator in brain: regulation of hexokinase, oxidative phosphorylation and permeability transition pore. Beutner G, et al. **Biochem Soc Trans** 1997 Feb;25(1):151-7

Peroxidative modification of a membrane protein. Conformation-dependent chemical modification of adenine nucleotide translocase in Cu2+/tert-butyl hydroperoxide treated mitochondria. Girón-Calle J, et al. **Biochemistry** 1996 Dec 3;35(48):15440-6

Probing the role of positive residues in the ADP/ATP carrier from yeast. The effect of six arginine mutations on transport and the four ATP versus ADP exchange modes. Heidkämper D, et al. **Biochemistry** 1996 Dec 17; 35(50):16144-52

Conformational changes of the yeast mitochondrial adenosine diphosphate/adenosine triphosphate carrier studied through its intrinsic fluorescence. 1. Tryptophanyl residues of the carrier can be mutated without impairing protein activity. Le Saux A, et al. **Biochemistry** 1996 Dec 17; 35(50):16116-24

Probing the role of positive residues in the ADP/ATP carrier from yeast. The effect of six arginine mutations of oxidative phosphorylation and AAC expression. Müller V, et al. **Biochemistry** 1996 Dec 17;35(50):16132-43

Conformational changes of the yeast mitochondrial adenosine diphosphate/adenosine triphosphate carrier studied through its intrinsic fluorescence. 2. Assignment of tryptophanyl residues of the carrier to the responses to specific ligands. Roux P, et al. **Biochemistry** 1996 Dec 17; 35(50):16125-31

Isolation and properties of an ATP transporter from a strain of Aspergillus niger. Chowdhury B, et al. **Eur J Biochem** 1997 Jul 15;247(2):673-80

Expression of the ADP/ATP carrier and expansion of the mitochondrial (ATP + ADP) pool contribute to postnatal maturation of the rat heart. Schönfeld P, et al. **Eur J Biochem** 1996 Nov 1;241(3):895-900

Photomodification of mitochondrial proteins by azido fatty acids and its effect on mitochondrial energetics. Further evidence for the role of the ADP/ATP carrier in fatty-acid-mediated uncoupling. Schönfeld P, et al. **Eur J Biochem** 1996 Sep 1;240(2):387-93

Complexes between kinases, mitochondrial porin and adenylate translocator in rat brain resemble the permeability transition pore. Beutner G, et al. **FEBS Lett** 1996 Nov 4;396(2-3):189-95

Fatty acids induced uncoupling of Saccharomyces cerevisiae mitochondria requires an intact ADP/ATP carrier. Polcic P, et al. **FEBS Lett** 1997 Jul 21;412(1):207-10

The pH-dependent reciprocal changes in contributions of ADP/ATP antiporter and aspartate/glutamate antiporter

to the fatty acid-induced uncoupling. Samartsev VN, et al. **FEBS Lett** 1997 Jul 21;412(1):179–82

Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. Halestrap AP, et al. **J Biol Chem** 1997 Feb 7;272(6):3346–54

Significance of the adenine nucleotide translocator in the pathogenesis of viral heart disease. Schultheiss HP, et al. **Mol Cell Biochem** 1996 Oct–Nov;163–164:319–27

Mobilization of Mg2+ from rat heart and liver mitochondria following the interaction of thyroid hormone with the adenine nucleotide translocase. Romani A, et al. **Thyroid** 1996 Oct;6(5):513–9

ADENINE NUCLEOTIDES

Small bowel preservation: evaluation of different solutions. Gundlach M, et al. **Transplant Proc** 1996 Oct;28(5):2622–3

ANALYSIS

The effect of Iloprost (ZK 36374) on creatine phosphate, adenine nucleotides and superoxide dismutase activity in ischaemic canine myocardium. Ogonowska-Kobusiewicz M, et al. **Arch Vet Pol** 1995;35(1–2):73–8

Employment of bioluminescence for the quantification of adenosine phosphates in the human cornea. Salla S, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234(8):521–6

BIOSYNTHESIS

Ap3A and Ap4A are primers for oligoadenylate synthesis catalyzed by interferon-inducible 2–5A synthetase. Turpaev K, et al. **FEBS Lett** 1997 May 19;408(2):177–81

BLOOD

Determination of adenosine phosphates in whole blood by capillary zone electrophoresis. Kamarýt J, et al. **Eur J Clin Chem Clin Biochem** 1996 Dec;34(12):969–73

Alterations in erythrocyte plasma membrane ATPase activity and adenine nucleotide content in a spontaneously diabetic subline of the Chinese hamster. Bettin D, et al. **Horm Metab Res** 1996 Jan;28(1):1–6

[Adenine nucleotide metabolism in acute myocardial infarct and the initiation of free-radical oxidation] Zhdanov GG, et al. **Anesteziol Reanimatol** 1996 May–Jun;(3):25–7 (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Synthesis and characterization of composite nucleic acids containing 2', 5'-oligoriboadenylate linked to antisense DNA. Xiao W, et al. **Antisense Nucleic Acid Drug Dev** 1996 Winter;6(4):247–58

Efficient functionalization of 2',5'-oligoadenylates with sulfur. Lesiak K, et al. **Bioconjug Chem** 1997 Mar–Apr; 8(2):199–203

Synthesis of nonhydrolyzable analogues of thiazole-4-carboxamide and benzamide adenine dinucleotide containing fluorine atom at the C2' of adenine nucleoside: induction of K562 differentiation and inosine monophosphate dehydrogenase inhibitory activity. Lesiak K, et al. **J Med Chem** 1997 Aug 1;40(16):2533–8

The practical synthesis of a methylenebisphosphonate analogue of benzamide adenine dinucleotide: inhibition of human inosine monophosphate dehydrogenase (type I and II). Pankiewicz KW, et al. **J Med Chem** 1997 Apr 11; 40(8):1287–91

Synthesis and properties of 2',5'-oligoadenylates containing alpha-adenosine. Ito T, et al. **Nucleic Acids Symp Ser** 1995; (34):179–80

CHEMISTRY

Synthesis of dehydroluciferin by firefly luciferase: effect of dehydroluciferin, coenzyme A and nucleoside triphosphates on the luminescent reaction. Fontes R, et al. **Biochem Biophys Res Commun** 1997 Aug 18;237(2):445–50

Efficient functionalization of 2',5'-oligoadenylates with sulfur. Lesiak K, et al. **Bioconjug Chem** 1997 Mar–Apr; 8(2):199–203

Orientation of intermediate nucleotide states of indane dione spin-labeled myosin heads in muscle fibers. Roopnarine O, et al. **Biophys J** 1996 Jun;70(6):2795–806

Nucleotide and calcium-induced conformational changes in histone H1. Tarkka T, et al. **FEBS Lett** 1997 Apr 7; 406(1–2):56–60

Synthesis and properties of second-generation 2–5A-antisense chimeras with enhanced resistance to exonucleases. Li G, et al. **J Med Chem** 1997 Aug 29; 40(18):2959–66

Protein recognition of adenylate: an example of a fuzzy recognition template. Moodie SL, et al. **J Mol Biol** 1996 Nov 1;263(3):486–500

GENETICS

Correlation of selective modifications to a 2',5'-oligoadenylate-3',5'-deoxyribonucleotide antisense chimera with affinity for the target nucleic acid and with ability to activate RNase L. Xiao W, et al. **J Med Chem** 1997 Apr 11;40(8):1195–200

METABOLISM

Hepatic energy charge and adenine nucleotide status in rats anesthetized with halothane, isoflurane or enflurane. Mets B, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):252–5

Exercise and recovery in frog muscle: metabolism of PCr, adenine nucleotides, and related compounds. Krause U, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):R811–20

Hypertrophy of colonic smooth muscle: structural remodeling, chemical composition, and force output. Siegman MJ, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):G1560–70

Studies of rat lung viability and adenine nucleotide metabolism after death. D'Armini AM, et al. **Ann Thorac Surg** 1996 Nov;62(5):1448–53

Non-transferrin-bound iron and tumor cells. Anghileri LJ, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2529–33

Recruiting the 2-5A system for antisense therapeutics. Torrence PF, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):203–6 (7 ref.)

Evidences for adenine nucleotide binding in the subunits of Neurospora mitochondrial processing peptidase. Botweva R, et al. **Arch Biochem Biophys** 1996 Aug 15;332(2):329–34

Inhibition of P-glycoprotein ATPase activity by procedures involving trapping of nucleotide in catalytic sites. Sankaran B, et al. **Arch Biochem Biophys** 1997 May 1;341(1):160–9

Suppression of the degradation of adenine nucleotides during ischemia may not be a sufficient mechanism for infarct size limitation by preconditioning. Miura T, et al. **Basic Res Cardiol** 1996 Nov–Dec;91(6):425–32

Tight links between adenine and guanine nucleotide pools in mouse pancreatic islets: a study with mycophenolic acid. Detimary P, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):467–71

Essential lysine residues in the N-terminal and the C-terminal domain of human adenylate kinase interact with adenine nucleotides as found by site-directed random mutagenesis. Ayabe T, et al. **Biochemistry** 1997 Apr 1;36(13):4027–33

Regulation of the mitochondrial Ca2+ uniporter by external adenine nucleotides: the uniporter behaves like a gated channel which is regulated by nucleotides and divalent cations. Litsky ML, et al. **Biochemistry** 1997 Jun 10; 36(23):7071–80

Domain-specific stabilization of photoreceptor membrane guanylyl cyclase by adenine nucleotides and guanylyl cyclase activating proteins (GCAPs). Tucker CL, et al. **Biochemistry** 1997 Sep 30;36(39):11995–2000

FSBA modifies both alpha- and beta-subunits of F1 specifically and can be bound together with AXP at the same alpha-subunit. Hartog AF, et al. **Biochim Biophys Acta** 1997 Jan 16;1318(1–2):107–22

Role of adenine nucleotides in the activation of microsomal cholesterol ester hydrolase by fructose or adenosine in rat hepatocytes. Hernandez ML, et al. **Biochimie** 1996; 78(1):26–32

Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides. Cunha RA, et al. **Br J Pharmacol** 1996 Sep;119(2):253–60

Inorganic phosphate enhances phosphonucleotide concentrations in cultured fetal rat cortical neurons. Glinn M, et al. **Brain Res** 1997 May 16;757(1):85–92

Competition of adenine nucleotides for a 1,3-[3H]-dipropyl-8-cyclopentylxanthine binding site in rat vas deferens. Smith AD, et al. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):492–7

Pathways of adenine nucleotide metabolism: degradation and resynthesis of IMP in ageing chicken heart. Wegelin I, et al. **Comp Biochem Physiol A Physiol** 1996 Jun;114(2):99–104

Differential degradation of extracellular adenine nucleotides by folliculated oocytes of Xenopus laevis. Ziganshin AU, et al. **Comp Biochem Physiol A Physiol** 1996 Aug; 114(4):335–40

Nucleotide binding to the heat-shock protein DnaK as studied by ESR spectroscopy. Neuhofen S, et al. **Eur J Biochem** 1996 Aug 15;240(1):78–82

Identification of an adenine-nucleotide-binding site on interferon alpha2. Olcott MC, et al. **Eur J Biochem** 1997 Aug 1;247(3):762–9

Expression of the ADP/ATP carrier and expansion of the mitochondrial (ATP + ADP) pool contribute to postnatal maturation of the rat heart. Schönfeld P, et al. **Eur J Biochem** 1996 Nov 1;241(3):895–900

Direct thyroid hormone signalling via ADP-ribosylation controls mitochondrial nucleotide transport and membrane leakiness by changing the conformation of the adenine nucleotide transporter. Mowbray J, et al. **FEBS Lett** 1996 Sep 23;394(1):61–5

Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). Taguchi Y, et al. **FEBS Lett** 1997 Jan 13;401(1):11–4

Reconsideration of the sequence of rigor mortis through postmortem changes in adenosine nucleotides and lactic acid in different rat muscles. Kobayashi M, et al. **Forensic Sci Int** 1996 Oct 25;82(3):243–53

Adenine nucleotide metabolism in primary rat neuronal cultures. Brosh S, et al. **Int J Biochem Cell Biol** 1996 Mar; 28(3):319–28

When does the lung die? Kfc, cell viability, and adenine nucleotide changes in the circulation-arrested rat lung. Jones DR, et al. **J Appl Physiol** 1997 Jul;83(1):247–52

Extracellular metabolism of nucleotides in the nervous system. Zimmermann H, et al. **J Auton Pharmacol** 1996 Dec;16(6):397–400 (40 ref.)

A novel type of pyridine nucleotide-disulfide oxidoreductase is essential for NAD+- and NADPH-dependent degradation of epoxyalkanes by Xanthobacter strain Py2. Swaving J, et al. **J Bacteriol** 1996 Nov;178(22):6644–6

Dynamic compartmentation of vacuolar amino acids in Penicillium cyclopium. Cytosolic adenylates act as a control signal for efflux into the cytosol. Roos W, et al. **J Biol Chem** 1997 Jun 20;272(25):15849–55

A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. Castelli JC, et al. **J Exp Med** 1997 Sep 15;186(6):967–72

Cerebral energy metabolism during severe ischemia of varying duration and following reperfusion. Phillis JW, et al. **J Neurochem** 1996 Oct;67(4):1525–31

Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. Dunwiddie TV, et al. **J Neurosci** 1997 Oct 15; 17(20):7673–82

The relationship between the adenine nucleotide metabolism and the conversion of the xanthine oxidase enzyme system in ischemia-reperfusion of the rat small intestine. Hirata Y, et al. **J Pediatr Surg** 1996 Sep;31(9):1199–204

Conformational changes in the GroEL oligomer during the functional cycle. Llorca O, et al. **J Struct Biol** 1997 Feb; 118(1):31–42

Changes in adenine nucleotides during hemorrhagic shock and reperfusion. Van Way CW, et al. **J Surg Res** 1996 Dec;66(2):159–66

Adenine nucleotide metabolism of canine pancreas graft preserved by the two-layer (euro-collins' solution/perfluorochemical) method after reperfusion. Kim Y, et al. **Kobe J Med Sci** 1996 Feb;42(1):31–41

Regulation of and intervention into the oxidative pentose phosphate pathway and adenine nucleotide metabolism in the heart. Zimmer HG. **Mol Cell Biochem** 1996 Jul–Aug; 160–161:101–9 (49 ref.)

Effect of hypoxia and glucose deprivation on ATP level, adenylate energy charge and [Ca2+]o-dependent and independent release of [3H]dopamine in rat striatal slices. Milusheva EA, et al. **Neurochem Int** 1996 May–Jun; 28(5–6):501–7

Effects of an inhibitor of adenosine deaminase, deoxycoformycin, and of nucleoside transport, propentofylline, on post-ischemic recovery of adenine nucleotides in rat brain. Phillis JW, et al. **Neurochem Res** 1996 Mar;21(3):347–53

The effect of bacterial toxins on levels of intracellular adenosine nucleotides and human ciliary beat frequency. Kanthakumar K, et al. **Pulm Pharmacol** 1996 Aug; 9(4):223–30

Hepatic adenine nucleotides and microsomal cholesterol 7 alpha-hydroxylase activity in the obstructed and freely draining lobes of the liver after selective bile duct obstruction. Chijiiwa K, et al. **Res Exp Med (Berl)** 1997; 197(1):13–22

Hepatic adenine nucleotides and microsomal cholesterol 7 alpha-hydroxylase activity in the obstructed and freely draining lobes of the liver after selective bile duct obstruction. Chijiiwa K, et al. **Res Exp Med (Berl)** 1997; 196(6):345–53

Antimony-induced alterations in thiol homeostasis and adenine nucleotide status in cultured cardiac myocytes. Tirmenstein MA, et al. **Toxicology** 1997 May 16; 119(3):203–11

Retrograde oxygen persufflation in combination with UW solution enhances adenine nucleotide contents in ischemically damaged rat kidney during cold storage. Yin M, et al. **Transpl Int** 1996;9(4):396–402

Adenine nucleotide metabolism of the small bowel during preservation by the cavitary two-layer method. Sakai T, et al. **Transplant Proc** 1996 Oct;28(5):2615–9

Impact of arterialization on hepatic oxygen supply, tissue energy phosphates, and outcome after liver transplantation in the rat. Reck T, et al. **Transplantation** 1996 Sep 15; 62(5):582–7

Release, metabolism and interconversion of adenine and uridine nucleotides: implications for G protein-coupled P2 receptor agonist selectivity. Harden TK, et al. **Trends Pharmacol Sci** 1997 Feb;18(2):43–6 (15 ref.)

[The effect of catalase inhibitor 3-amino-1,2,4-triazole on coupled oxidative phosphorylation and the state of adenyl system in liver mitochondria of albino rats] Manoĭlov SE, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):638–40 **(Rus)**

PHARMACOLOGY

Role of purinergic receptors in chloride secretion in Caco-2 cells. Inoue CN, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):C1862–70

Ca2+ flux in human placental trophoblasts. Karl PI, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):C1776–80

Characterization of extracellular nucleotide-induced Mac-1 (alphaM beta2 integrin) surface expression on peripheral blood leukocytes. Akbar GK, et al. **Biochem Biophys Res Commun** 1997 Apr 7;233(1):71–5

Lack of nucleotide-promoted second messenger signaling responses in 1321N1 cells expressing the proposed P2Y receptor, p2y7. Herold CL, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):717–21

Diadenosine polyphosphate-stimulated gluconeogenesis in isolated rat proximal tubules. Edgecombe M, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):451–6

ADENINE NUCLEOTIDES

Effect of adenine nucleotides on myo-inositol-1,4,5-trisphosphate-induced calcium release. Missiaen L, et al. **Biochem J** 1997 Aug 1;325 (Pt 3):661-6

C1q is a nucleotide binding protein and is responsible for the ability of clusterin preparations to promote immune complex formation. Roeth PJ, et al. **Biochim Biophys Acta** 1996 Oct 17;1297(2):159-66

Effects of extracellular nucleotides on single cells and populations of human osteoblasts: contribution of cell heterogeneity to relative potencies. Dixon CJ, et al. **Br J Pharmacol** 1997 Mar;120(5):777-80

Extracellular nucleotides act through P2U purinoceptors to elevate [Ca2+]i and enhance basic fibroblast growth factor-induced proliferation in sheep chondrocytes. Kaplan AD, et al. **Endocrinology** 1996 Nov;137(11):4757-66

Inhibitory effects of nucleoside 5'-alkylphosphates on sexual agglutination in Saccharomyces cerevisiae. Machida K, et al. **FEMS Microbiol Lett** 1997 Feb 1;147(1):17-22

Activation of RNase L by 2',5'-oligoadenylates. Kinetic characterization. Carroll SS, et al. **J Biol Chem** 1997 Aug 1;272(31):19193-8

Activation of RNase L by 2',5'-oligoadenylates. Biophysical characterization. Cole JL, et al. **J Biol Chem** 1997 Aug 1;272(31):19187-92

Use of firefly luciferase for ATP measurement: other nucleotides enhance turnover. Ford SR, et al. **J Biolumin Chemilumin** 1996 May-Jun;11(3):149-67

Effects of adenine nucleotide analogues on myocardial dysfunction during reperfusion after ischemia in dogs. Nakai T, et al. **J Cardiovasc Pharmacol** 1996 Aug; 28(2):264-70

Voltage-dependent anion channel of Arabidopsis hypocotyls: nucleotide regulation and pharmacological properties. Thomine S, et al. **J Membr Biol** 1997 Sep 1;159(1):71-82

Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells. Cirino NM, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1937-42

PHYSIOLOGY

Adenine nucleotides via activation of ATP-sensitive K+ channels modulate hypoxic response in rat pulmonary artery. Shigemori K, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L803-9

Possible role of diadenosine polyphosphates as modulators of cardiac sensory-motor neurotransmission in guinea-pigs. Rubino A, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):515-23

Adenine nucleotides and intracellular Ca2+ regulate a voltage-dependent and glucose-sensitive potassium channel in neurosecretory cells. Onetti CG, et al. **Pflugers Arch** 1996 May;432(1):144-54

[Regulation of expression of the surface structure of the lymphocyte membrane by purine compounds in health and in disease] Poriadin GV, et al. **Patol Fiziol Eksp Ter** 1997 Jan-Mar;(1):42-5 (82 ref.) **(Rus)**

RADIATION EFFECTS

A novel property of adenine nucleotides: sensitivity to helium-neon laser in mitochondrial reactions. Gagliardi S, et al. **Biochem Mol Biol Int** 1997 Mar;41(3):449-60

TOXICITY

Hypotensive effects of stroma-free haemoglobin solutions attributable to adenine nucleotides. MacDonald SL, et al. **Transfus Med** 1991 Mar;1(1):17-23

ADENINE PHOSPHORIBOSYLTRANSFERASE

[Adenine phosphoribosyltransferase (APRT)] Kamatani N. **Nippon Rinsho** 1996 Dec;54(12):3213-9 (30 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Crystallization of the purine salvage enzyme adenine phosphoribosyltransferase. Phillips CL, et al. **Proteins** 1996 Aug;25(4):510-3

DEFICIENCY

Adenine phosphoribosyltransferase deficiency identified by urinary sediment analysis: cellular and molecular confirmation. Terai C, et al. **Clin Genet** 1995 Nov; 48(5):246-50

Mice with adenine phosphoribosyltransferase deficiency develop fatal 2,8-dihydroxyadenine lithiasis. Redhead NJ, et al. **Hum Gene Ther** 1996 Aug 20;7(13):1491-502

HPRT-APRT-deficient mice are not a model for lesch-nyhan syndrome. Engle SJ, et al. **Hum Mol Genet** 1996 Oct;5(10):1607-10

2,8-Dihydroxyadenine stone formation in a renal transplant recipient due to adenine phosphoribosyltransferase deficiency. de Jong DJ, et al. **J Urol** 1996 Nov; 156(5):1754-5

[Adenine phosphoribosyltransferase(APRT) deficiency] Kamatani N. **Nippon Rinsho** 1996 Dec;54(12):3321-7 (19 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Sequence analysis of spontaneously-arising mutations at the aprt locus in wild-type and thymidine kinase-deficient Friend cells: evidence for strand slippage-misalignment mechanism in formation of deletions. Hyland PL, et al. **Biochem Soc Trans** 1997 Feb;25(1):127S

High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination. Gupta PK, et al. **Cancer Res** 1997 Mar 15;57(6):1188-93

Loss of heterozygosity analysis in a human fibrosarcoma cell line. Gupta PK, et al. **Cytogenet Cell Genet** 1997; 76(3-4):214-8

Complex chromosomal mechanisms lead to APRT loss of heterozygosity in heteroploid cells. Shao C, et al. **Cytogenet Cell Genet** 1996;75(4):216-21

APRT: a versatile in vivo resident reporter of local mutation and loss of heterozygosity. Stambrook PJ, et al. **Environ Mol Mutagen** 1996;28(4):471-82

Evolutionary rate variation within Mus APRT. Fieldhouse D, et al. **Genome** 1996 Oct;39(5):909-13

Substitution rate variation in closely related rodent species. Fieldhouse D, et al. **Heredity** 1997 Jan;78 (Pt 1):21-31

Intervention of somatic mutational events in vivo by a germline defect at the adenine phosphoribosyltransferase locus. Hakoda M, et al. **Hum Genet** 1997 Feb;99(2):164-70

The origin of the most common mutation of adenine phosphoribosyltransferase among Japanese goes back to a prehistoric era. Kamatani N, et al. **Hum Genet** 1996 Nov; 98(5):596-600

Identification and application of polymorphisms flanking the human adenine phosphoribosyltransferase gene. Boyadjiev SA, et al. **Hum Mutat** 1996;8(3):214-5

Creation of homozygous mutants of Leishmania donovani with single targeting constructs. Hwang HY, et al. **J Biol Chem** 1996 Nov 29;271(48):30840-6

Loss of heterozygosity and base substitution at the APRT locus in mismatch-repair-proficient and -deficient colorectal carcinoma cell lines. Phear G, et al. **Mol Cell Biol** 1996 Nov;16(11):6516-23

Similarity of in vivo somatic mutations at an autosomal adenine phosphoribosyltransferase locus between T- and B-cells in human peripheral blood. Hakoda M, et al. **Mutat Res** 1996 Oct 25;357(1-2):107-13

Benzo[a]pyrenediol-epoxide induces loss of heterozygosity in Chinese hamster ovary cells heterozygous at the aprt locus. Mazur-Melnyk M, et al. **Mutat Res** 1996 Oct 28; 358(1):89-96

Isolation of an APRT heterozygote from TK6 human lymphoblasts: predominance of multi-locus loss of heterozygosity among spontaneous APRT-mutants. Pongsaensook P, et al. **Mutat Res** 1997 Jun 9;377(1):27-36

Targeted base substitutions and small deletions induced by neocarzinostatin at the APRT locus in plateau-phase CHO cells. Wang P, et al. **Mutat Res** 1997 Jan 3;373(1):17-29

Specificity and kinetics of interstrand and intrastrand bifunctional alkylation by nitrogen mustards at a G-G-C sequence. Bauer GB, et al. **Nucleic Acids Res** 1997 Mar 15;25(6):1211-8

METABOLISM

An investigation of the role of adenine phosphoribosyltransferase for excision repair following UV irradiation in Friend cells. Nelson AA, et al. **Biochem Soc Trans** 1997 Feb;25(1):149S

Prenatal diagnosis by enzyme analysis in 15 pregnancies at risk for the Lesch-Nyhan syndrome. Graham GW, et al. **Prenat Diagn** 1996 Jul;16(7):647-51

A role for certain mouse Aprt sequences in resistance to toxic adenine analogs. Khattar NH, et al. **Somat Cell Mol Genet** 1997 Jan;23(1):51-61

ADENINE POLYNUCLEOTIDES see **POLY A**

ADENITIS see **LYMPHADENITIS**

ADENO-ASSOCIATED VIRUSES see **DEPENDOVIRUS**

ADENOCARCINOMA

Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Rose GS, et al. **Am J Obstet Gynecol** 1996 Sep; 175(3 Pt 1):593-9

Metastatic adenocarcinoma involving a mesothelial/monocytic incidental cardiac excrescence (cardiac MICE). Argani P, et al. **Am J Surg Pathol** 1997 Aug;21(8):970-4

Tubular carcinoma of the breast: an institutional review. McBoyle MF, et al. **Am Surg** 1997 Jul;63(7):639-44; discussion 644-5

Primary adenocarcinoma of the angle of Treitz. Case report and review of the literature. Fronticelli CM, et al. **Arch Surg** 1996 Oct;131(10):1109-11 (8 ref.)

Concurrent colonic adenocarcinoma and two ileal carcinoids in a 72-year-old male. Tse V, et al. **Aust N Z J Surg** 1997 Oct;67(10):739-41 (10 ref.)

Detection of endothelial cells by MEC 13.3 monoclonal antibody in mice mammary tumors. Vanzulli S, et al. **Biocell** 1997 Apr;21(1):39-46

Prostatic orbital metastases and the role of the ophthalmologist. Hingorani M, et al. **Br J Urol** 1996 Oct; 78(4):654-7

Pancreatic adenocarcinoma in the pregnant patient: case report and review of the literature. Blackbourne LH, et al. **Cancer** 1997 May 1;79(9):1776-9 (21 ref.)

Pancreatic adenocarcinoma. Howard TJ. **Curr Probl Cancer** 1996 Sep-Oct;20(5):281-328 (193 ref.)

Primary carcinoma of the fallopian tube: report on two cases. Nappi R, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec;70(1):93-6

Precursors of prostatic adenocarcinoma: recent findings and new concepts. **Eur Urol** 1996;30(2):131-279

Risk-specific follow-up for endometrial carcinoma patients. Shumsky AG, et al. **Gynecol Oncol** 1997 Jun;65(3):379-82

Ovarian malignancy in remnant ovarian tissue. Hamid R, et al. **Int J Gynaecol Obstet** 1997 Sep;58(3):319-20

Primary adenocarcinoma of the bladder presenting during pregnancy. An unusual case report. Katzman N, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(5):267-9 (18 ref.)

Adenocarcinoma cells are targeted by the new GnRH-PE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites. Nechushtan A, et al. **J Biol Chem** 1997 Apr 25;272(17):11597-603

Carcinoma of the exocrine pancreas: our experience. Comunale S, et al. **J Chemother** 1997 Apr;9(2):149-50

Helicobacter pylori infection and the risk of gastric cancer among the Korean population. Kim HY, et al. **J Gastroenterol Hepatol** 1997 Feb;12(2):100-3

Eccrine carcinoma of the hand: a case report. Katzman BM, et al. **J Hand Surg [Am]** 1997 Jul;22(4):737-9 (12 ref.)

Analysis of 23 cases of primary carcinoma of the fallopian tube over 50 years. Huber-Buchholz MM, et al. **J Obstet Gynaecol Res** 1996 Jun;22(3):193-9

Prostate cancer--in search of certain knowledge [editorial] Rukstalis DB. **J Urol** 1996 Oct;156(4):1386-7

Development of donor-derived prostate cancer in a recipient following orthotopic heart transplantation [see comments] Loh E, et al. **JAMA** 1997 Jan 8;277(2):133-7. Comment in: JAMA 1997 Jan 8;277(2):154-5. Comment in: JAMA 1997 May 7;277(17):1354; discussion 1355. Comment in: JAMA 1997 May 7;277(17):1355.

Colorectal adenocarcinoma as a second malignant neoplasm following Wilms' tumor and rhabdomyosarcoma. Densmore TL, et al. **Med Pediatr Oncol** 1996 Dec; 27(6):556-60

An overview of adenocarcinoma of the small intestine. Neugut AI, et al. **Oncology (Huntingt)** 1997 Apr; 11(4):529-36; discussion 545, 549-50 (62 ref.)

Early gastric carcinoma. Bhat MG, et al. **Trop Gastroenterol** 1996 Jul-Sep;17(3):174-5

Primary small intestinal adenocarcinoma. Bheerappa N, et al. **Trop Gastroenterol** 1997 Jan-Mar;18(1):24-5

Neoplasms in long-term Hartmann's pouches. Thaemert BC, et al. **Wis Med J** 1996 Feb;95(2):105-7

[Advances in the study on adenoma maligum of the uterine cervix] He S, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Dec;30(12):753-5 (21 ref.) **(Chi)**

[Adenocarcinoma of the uterine cervix--retrospective clinico-pathologic study] Freitag P, et al. **Ceska Gynekol** 1996 Jun;61(3):162-4 (Eng. Abstr.) **(Cze)**

[Occurrence of adenocarcinoma of the cervix in data from the 3rd Institute of Pathology of Charles University Medical School and FNKV 1990-1995] Rychterová V, et al. **Ceska Gynekol** 1996 Aug;61(4):262-3 **(Cze)**

[Prostatic cancer (editorial)] Iversen P. **Ugeskr Laeger** 1997 Apr 21;159(17):2519 **(Dan)**

[Hürthle cell thyroid carcinoma] Bourcigaux N, et al. **Ann Endocrinol (Paris)** 1997;58(3):257-62 (37 ref.) **(Fre)**

[Oncocytic tumors of the thyroid. Diagnostic and therapeutic problems. Report of 17 cases and review of the literature] Gaschignard N, et al. **J Chir (Paris)** 1996 Jul;133(5):201-7 (51 ref.) (Eng. Abstr.) **(Fre)**

[Metastatic implants after laparoscopic cholecystectomy in unsuspected gallbladder cancer. A case report and review of the literature] Younan A, et al. **J Med Liban** 1996; 44(3):161-4 (Eng. Abstr.) **(Fre)**

[Prognostic factors of renal adenocarcinoma: study of a series of 233 patients] Koutani A, et al. **Prog Urol** 1996 Dec; 6(6):884-90 (Eng. Abstr.) **(Fre)**

[Gallbladder adenocarcinoma in villous adenomatosis (papillomatosis) of the gallbladder and common bile duct] Kunisch M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 May;166(5):454-6 **(Ger)**

[Plasma-cell granuloma of the sigmoid colon concomitant with adenocarcinoma of the cecum. Viewpoint for debate, literature review on pseudotumors, idiopathic colitis and cancer] De Monti M, et al. **Ann Ital Chir** 1997 Mar-Apr; 68(2):245-51 (55 ref.) (Eng. Abstr.) **(Ita)**

[Abdominal wall metastasis of pancreatic adenocarcinoma following laparoscopy] Iuppa A, et al. **Ann Ital Chir** 1996 Mar-Apr;67(2):265-9; discussion 269-70 (Eng. Abstr.) **(Ita)**

[Duodenal adenocarcinoma] Interlandi A, et al. **Minerva Chir** 1996 Oct;51(10):825-8 (Eng. Abstr.) **(Ita)**

[Primary microinvasive adenocarcinoma of the cervix. A clinical case] Martino A, et al. **Minerva Ginecol** 1997 Apr; 49(4):161-3 (Eng. Abstr.) **(Ita)**

[Regression of 4th-stage cancer of the rectum] Petrov VP, et al. **Khirurgiia (Mosk)** 1996;(2):119 **(Rus)**

[Synchronous neoplasms: multiple myeloma and gastric adenocarcinoma (letter)] Mediavilla García JD, et al. **An Med Interna** 1996 Sep;13(9):463-4 **(Spa)**

[Synchronous multiple renal carcinoma. Review of the literature and report of a new case] Borrego Hernando

J, et al. **Arch Esp Urol** 1996 Sep;49(7):760–3 (20 ref.) (Eng. Abstr.) **(Spa)**
[Renal tumors smaller that 3 cm] Vega Vega A, et al. **Arch Esp Urol** 1997 Jan–Feb;50(1):27–31 (Eng. Abstr.) **(Spa)**
[Adenocarcinoma of the Bahuin valve and the terminal ileum (letter)] Sebastián JJ, et al. **Gastroenterol Hepatol** 1997 Jun–Jul;20(6):335–6 **(Spa)**
[Association of esophageal carcinoma and previous upper airways and digestive neoplasm (letter)] de Castro Carpeño J, et al. **Med Clin (Barc)** 1997 Feb 22;108(7):277 **(Spa)**
[Unsuspected tumor of the colon] Guzmán Valdivia Gómez G, et al. **Rev Gastroenterol Mex** 1996 Oct–Dec;61(4):362–5 (Eng. Abstr.) **(Spa)**

BLOOD

Haematological variables in prostatic carcinoma patients. Geenen RW, et al. **Acta Urol Belg** 1996 Sep;64(3):21–6
Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Endo K, et al. **Anticancer Res** 1997 May–Jun;17(3C):2253–8
Sensitivity and specificity of in situ bacterial chain reaction (BCR) in detecting sparse human tumor cells in peripheral blood. Rotman B, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):80–5
Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Theyer G, et al. **Br J Cancer** 1997;75(10):1515–8
Serum PICP as a bone formation marker in 89Sr and external beam radiotherapy of prostatic bony metastases. Papatheofanis FJ. **Br J Radiol** 1997 Jun;70(834):594–8
Comparative studies of CAM 123–6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma. Kohno N, et al. **Cancer Detect Prev** 1997; 21(2):124–8
Sialic acid levels in serum and tissue from colorectal cancer patients. Feijoo C, et al. **Cancer Lett** 1997 Jan 30; 112(2):155–60
The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Grem J. **Curr Opin Oncol** 1997 Jul;9(4):380–7 (38 ref.)
Fibrin and fibrinogen degradation products in plasma of patients with colorectal adenocarcinoma. Okholm M, et al. **Dis Colon Rectum** 1996 Oct;39(10):1102–6
Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Suwa H, et al. **Gut** 1997 May; 40(5):647–53
Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Bolger BS, et al. **Gynecol Oncol** 1997 May; 65(2):309–13
Gastrin levels in patients with colorectal cancer. Fontanesi BV, et al. **Hepatogastroenterology** 1997 Jul–Aug; 44(16):1082–4
Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Ikeguchi M, et al. **Hepatogastroenterology** 1997 May–Jun;44(15):866–71
Sex hormone levels in the serum of patients with pancreatic adenocarcinoma. Fyssas I, et al. **Horm Metab Res** 1997 Mar;29(3):115–8
Preoperative CEA and TAG-72 serum levels as prognostic indicators in resectable gastric carcinoma. González A, et al. **Int J Biol Markers** 1996 Jul–Sep;11(3):165–71
Hepatoid gastric carcinoma. A case report. Lorenzi M, et al. **Int J Biol Markers** 1996 Oct–Dec;11(4):216–9
Intracellular carotenoid levels measured by Raman microspectroscopy: comparison of lymphocytes from lung cancer patients and healthy individuals. Bakker Schut TC, et al. **Int J Cancer** 1997 Feb 20;74(1):20–5
Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy. Lankford SP, et al. **Int J Radiat Oncol Biol Phys** 1997 May 1;38(2):327–33
Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Sartor CI, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15;38(5):941–7
Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19–9 and CA 72–4 in gastric cancer. Fernández-Fernández L, et al. **Int Surg** 1996 Oct–Dec;81(4):400–2
The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19–9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study. Yüceyar S, et al. **Int Surg** 1996 Apr–Jun;81(2):136–9
Raised prostate-specific antigen in adenocarcinoma of the colon. Yamamoto M, et al. **Int Urol Nephrol** 1997; 29(2):221–5
Association between serum gastrin levels, gastric acid secretion and age in early gastric cancer. Miyaji M, et al. **Tumour Biol** 1997;18(5):311–20
A transient increase in serum procollagen 1 carboxyterminal peptide following effective treatment in prostate cancer patients with bone metastases. Nakashima J, et al. **Urol Int** 1997;58(4):236–8
[Half-life of blood PSA after radical prostatectomy. Correlations with pathological stage and clinical course of the disease] Di Federico G, et al. **Arch Ital Urol Androl** 1997 Feb;69 Suppl 1:97–100 (Eng. Abstr.) **(Ita)**
[Concentration of epidermal growth factor (EGF) in serum of women with endometrial cancer] Tomaszewski J, et al. **Ginekol Pol** 1996 May;67(5):248–53 (Eng. Abstr.) **(Pol)**
[Correlation between specific prostatic antigen and findings with total body bone scintigraphy] López M, et al. **Arch Esp Urol** 1996 Nov;49(9):953–5 (Eng. Abstr.) **(Spa)**
[Correlation between prostate specific antigen and histopathologic findings in ileum–obturator node dissection] Scorticati C Jr, et al. **Arch Esp Urol** 1997 Jan–Feb;50(1):41–4 (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Time and dose dependency of radiation-induced changes in tumor microvascular characteristics using contrast-enhanced magnetic resonance imaging: impact on the delivery of chemotherapeutic agents. Schmidt HC, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S347–8
Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Fukumura D, et al. **Am J Pathol** 1997 Sep;151(3):679–88
Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Fukumura D, et al. **Am J Pathol** 1997 Feb; 150(2):713–25
Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Engel CJ, et al. **Am J Surg Pathol** 1996 Oct;20(10):1260–5
Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Janvier R, et al. **Anticancer Res** 1997 May–Jun; 17(3A):1551–7
The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion. Parkins CS, et al. **Br J Cancer** 1997;75(3):319–23
High endothelial cell proliferation index and high microvessel density in vascular hotspots suggest an active angiogenic process in human colorectal adenocarcinomas. Angiogenesis Group [letter; comment] Vermeulen PB, et al. **Br J Cancer** 1996 Nov;74(9):1506–7. Comment on: Br J Cancer 1995 May;71(5):1081–6.
Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Vermeulen PB, et al. **Breast Cancer Res Treat** 1997 Jan;42(2):165–72
Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Kimura H, et al. **Cancer Res** 1996 Dec 1; 56(23):5522–8
Microvessel density in unknown primary tumors. Hillen HF, et al. **Int J Cancer** 1997 Feb 20;74(1):81–5
Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas [published erratum appears in Int J Cancer 1997 Aug 7;72(4):706–7] Max R, et al. **Int J Cancer** 1997 May 2;71(3):320–4
Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Mayr NA, et al. **Int J Radiat Oncol Biol Phys** 1996 Oct 1;36(3):623–33
Preoperative assessment of blood vessel involvement in patients with pancreatic cancer [see comments] Melzer E, et al. **Isr J Med Sci** 1996 Nov;32(11):1086–8. Comment in: Isr J Med Sci 1996 Nov;32(11):1124–6.
Perfusion to colorectal cancer liver metastases is not uniform and depends on tumor location and feeding vessel. Casillas S, et al. **J Surg Res** 1997 Feb 1;67(2):179–85
Quantification of tumor vascularity and flow with amplitude color Doppler sonography in an experimental model: preliminary results [published erratum appears in J Ultrasound Med 1997 Mar;16(3):218] Meyerowitz CB, et al. **J Ultrasound Med** 1996 Dec;15(12):827–33
Perfusion of single tumor microvessels: application to vascular permeability measurement. Lichtenbeld HC, et al. **Microcirculation** 1996 Dec;3(4):349–57
Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Netti PA, et al. **Microvasc Res** 1996 Jul;52(1):27–46
Angiogenic vascular growth in the rat peritoneal disseminated tumor model. Yanagi K, et al. **Microvasc Res** 1996 Jan;51(1):15–28
Stroma-free human hemoglobin A decreases R3230Ac rat mammary adenocarcinoma blood flow and oxygen partial pressure. Hahn JS, et al. **Radiat Res** 1997 Feb;147(2):185–94
Tumour blood flow influences combined radiation and doxorubicin treatments. Durand RE, et al. **Radiother Oncol** 1997 Feb;42(2):171–9

CHEMICALLY INDUCED

Case-control study of oestrogen replacement therapy and risk of cervical cancer. Parazzini F, et al. **BMJ** 1997 Jul 12;315(7100):85–8
Effects of dehydroepiandrosterone and other sex steroid hormones on mammary carcinogenesis by direct injection of 7,12-dimethylbenz(a) anthracene (DMBA) in hyperprolactinemic female rats. Kohama T, et al. **Breast Cancer Res Treat** 1997 Apr;43(2):105–15
Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats. Sakamoto S, et al. **Cancer Detect Prev** 1997;21(4):340–5
Enhancement of experimental colon cancer by genistein. Rao CV, et al. **Cancer Res** 1997 Sep 1;57(17):3717–22
Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Aldaz CM, et al. **Carcinogenesis** 1996 Sep;17(9):2069–72
Induction of mammary cancer and lymphoma by multiple, low oral doses of 7,12-dimethylbenz[a]anthracene in SENCAR mice. Qing WG, et al. **Carcinogenesis** 1997 Mar; 18(3):553–9
Intensity of multigenerational carcinogenesis from diethylstilbestrol in mice. Walker BE, et al. **Carcinogenesis** 1997 Apr;18(4):791–3
Adenocarcinoma of the mouth in a patient with psoriasis under short-term cyclosporine therapy [letter] Yamamoto T, et al. **Dermatology** 1996;193(1):72–3 (9 ref.)
Effect of age on the induction of endometrial lesions by a single intra-uterine administration of N-ethyl-N'-nitro-N-nitrosoguanidine in F344 rats. Kitamura T, et al. **In Vivo** 1995 Sep–Oct;9(5):489–94
Phenobarbital promotes multistage pulmonary carcinogenesis in MNU-inoculated L-W rats. Pollard M, et al. **In Vivo** 1997 Jan–Feb;11(1):55–60
Differential carcinogenicity of benzo[a]pyrene in male and female CD-1 mouse lung. Sharma R, et al. **J Toxicol Environ Health** 1997 Sep;52(1):45–62
Dose-dependent induction of mammary carcinomas in female Sprague-Dawley rats with 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridine. Imaida K, et al. **Jpn J Cancer Res** 1996 Nov;87(11):1116–20
Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol. Couse JF, et al. **Mol Carcinog** 1997 Aug;19(4):236–42
Digestive tract neoplasms among employees with past exposure to brominated dioxins [letter; comment] Zober A, et al. **Occup Environ Med** 1997 Jan;54(1):66. Comment on: Occup Environ Med 1996 Dec;53(12):844–6.
Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rats: dose-response studies. Shirai T, et al. **Princess Takamatsu Symp** 1995;23:232–9
High incidence and histogenesis of seminal vesicle adenocarcinoma and lower incidence of prostate carcinomas in the Lobund-Wistar prostate cancer rat model using N-nitrosomethylurea and testosterone. Tamano S, et al. **Vet Pathol** 1996 Sep;33(5):557–67
[Three cases of ovarian cancer after ovulation induction for infertility] Abboud J, et al. **Contracept Fertil Sex** 1997 Jan; 25(1):64–5 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Adenocarcinoma in females detected in serous effusions. Cytomorphologic aspects and immunocytochemical reactivity to cytokeratins 7 and 20. Longatto Filho A, et al. **Acta Cytol** 1997 Jul–Aug;41(4):961–71
Multiparameter absorption measurements in automated microscopy. Simultaneous quantitative determination of DNA and nuclear antigen. Oud PS, et al. **Acta Cytol** 1997 Jan–Feb;41(1):188–96
Anticytokeratin antibody 34 beta E12 staining in prostate carcinoma. Googe PB, et al. **Am J Clin Pathol** 1997 Feb; 107(2):219–23
p53 overexpression in advanced-stage endometrial adenocarcinoma [see comments] Kohler MF, et al. **Am J Obstet Gynecol** 1996 Nov;175(5):1246–52. Comment in: Am J Obstet Gynecol 1997 Jul;177(1):243.
Tumor suppressor activity of neural cell adhesion molecule in colon carcinoma. Roesler J, et al. **Am J Surg** 1997 Sep; 174(3):251–7
Role of computed quantitation of immunohistochemical staining of Ki-67 antigen in diagnosing ampullary lesions. Minimo C, et al. **Anal Quant Cytol Histol** 1996 Oct; 18(5):400–4
Tamoxifen mediated human endometrial carcinogenesis may not involve estrogenic pathways: a preliminary note. Kuwashima Y, et al. **Anticancer Res** 1996 Sep–Oct; 16(5A):2993–6
Proliferating patterns of salivary gland adenocarcinomas with the use of PCNA labeling. Zhao M, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2693–8
Expression of tissue-type plasminogen activator, plasminogen activator inhibitor and von Willebrand factor in the supernatant of endothelial cell cultures in response to the seeding of adenocarcinoma cell line HRT-18. Morganti M, et al. **Biomed Pharmacother** 1996;50(8):373–5
Changes in biomarker expression in the development of prostatic adenocarcinoma. Myers RB, et al. **Biotech Histochem** 1997 Mar;72(2):86–95 (73 ref.)
A case report and review: the gross, histological and immunohistochemical characteristics of a carcinoma of ectopic thyroid in a dog. Constantino-Casas P, et al. **Br Vet J** 1996 Nov;152(6):669–72 (10 ref.)
Adenocarcinoma of the cervix. Expression and clinical significance of estrogen and progesterone receptors. Fujiwara H, et al. **Cancer** 1997 Feb 1;79(3):505–12
The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Ishida H, et al. **Cancer** 1997 Sep 15; 80(6):1034–45
Distinct patterns of expression of keratinocyte growth factor and its receptor in endometrial carcinoma. Siegfried S, et

al. **Cancer** 1997 Mar 15;79(6):1166–71

Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Vollmers HP, et al. **Cancer** 1997 Feb 1;79(3):433–40

Immunohistochemical evaluation of cathepsin D expression in colorectal cancer. Mayer A, et al. **Cancer Invest** 1997; 15(2):106–10

Evaluation of glycogen level in human lung carcinoma tissues by an infrared spectroscopic method. Yano K, et al. **Cancer Lett** 1996 Dec 20;110(1–2):29–34

Characterization of two different cytoplasmic protein tyrosine kinases from human breast cancer. Chedin M, et al. **Carcinogenesis** 1997 Aug;18(8):1463–72

Microtiter plate immunoenzymometric assay for estrogen receptor. Delage V, et al. **Clin Chem** 1996 Dec; 42(12):1955–60

Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Hardwick RH, et al. **Eur J Surg Oncol** 1997 Feb;23(1):30–5

Investigation of oesophageal adenocarcinoma for viral genomic sequences. Morgan RJ, et al. **Eur J Surg Oncol** 1997 Feb;23(1):24–9

The flow cytometric analysis of total p53 protein content and proliferation indices in colorectal cancer, in relation to clinical outcome. Rew DA, et al. **Eur J Surg Oncol** 1996 Oct;22(5):508–15

CDX1 protein expression in normal, metaplastic, and neoplastic human alimentary tract epithelium [see comments] Silberg DG, et al. **Gastroenterology** 1997 Aug; 113(2):478–86. Comment in: Gastroenterology 1997 Aug;113(2):680–2.

Immunohistochemical localization of integrins and basement membrane components in colorectal epithelial tumors correlates with their histologic architecture. Ban S, et al. **Gen Diagn Pathol** 1997 Feb;142(3–4):165–73

Transforming growth factor-beta negatively modulates proliferation and c-fos expression of the human endometrial adenocarcinoma cell line HEC-1-A. Bergman CA, et al. **Gynecol Oncol** 1997 Apr;65(1):63–8

Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma. Rice LW, et al. **Gynecol Oncol** 1997 Apr; 65(1):149–57

Relationship between hormone receptor levels and cell-kinetics in human colorectal cancer. Korenaga D, et al. **Hepatogastroenterology** 1997 Jan-Feb;44(13):78–83

Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Kaufmann O, et al. **Histopathology** 1996 Sep;29(3):233–40

Immunohistochemical study of c-erbB-2 expression in carcinoma ex-pleomorphic adenoma. Rosa JC, et al. **Histopathology** 1996 Mar;28(3):247–52

Pleural mesotheliomas have an integrin profile distinct from visceral carcinomas. Koukoulis GK, et al. **Hum Pathol** 1997 Jan;28(1):84–90

Metastatic adenocarcinoma to the brain: an immunohistochemical approach. Perry A, et al. **Hum Pathol** 1997 Aug;28(8):938–43

Catabolic factors in cancer cachexia. Tisdale MJ, et al. **In Vivo** 1996 Mar-Apr;10(2):131–6

Complement-regulatory proteins in ovarian malignancies. Bjørge L, et al. **Int J Cancer** 1997 Jan 6;70(1):14–25

Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Endo K, et al. **Int J Cancer** 1996 Nov 4;68(3):372–7

Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Niikura H, et al. **Int J Gynecol Pathol** 1997 Jan;16(1):60–8

Minimal deviation adenocarcinoma of the uterine cervix has abnormal expression of sex steroid receptors, CA125, and gastric mucin. Toki T, et al. **Int J Gynecol Pathol** 1997 Apr;16(2):111–6

Characterization of integrin expression in a well differentiated endometrial adenocarcinoma cell line (Ishikawa). Castelbaum AJ, et al. **J Clin Endocrinol Metab** 1997 Jan; 82(1):136–42

Low density lipoprotein receptors and polyamine levels in human colorectal adenocarcinoma. Notarnicola M, et al. **J Gastroenterol** 1995 Dec;30(6):705–9

p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. Grignon DJ, et al. **J Natl Cancer Inst** 1997 Jan 15;89(2):158–65

Re: loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer [letter; comment] Manne U, et al. **J Natl Cancer Inst** 1997 Apr 16;89(8):585–6. Comment on: J Natl Cancer Inst 1996 Aug 7;88(15):1015–6. Comment on: J Natl Cancer Inst 1996 Aug 7;88(15):1054–9.

Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1,25-dihydroxyvitamin D3 on endometrial carcinoma cell lines. Yabushita H, et al. **J Obstet Gynaecol Res** 1996 Dec;22(6):529–39

Increased estrogen receptor and epidermal growth factor receptor gene product co-expression in surgically resected gastric adenocarcinomas. Koullias GJ, et al. **J Surg Oncol** 1996 Nov;63(3):166–71

Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study. Takanami I, et al. **J Surg Oncol** 1997 Apr;64(4):262–7

Effect of radiotherapy and chemotherapy on composition of tumor membrane phospholipids. Street JC, et al. **Lipids** 1997 Jan;32(1):45–9

KM195 as an immunohistochemical marker of adenocarcinoma of the lung. Kawai T, et al. **Lung Cancer** 1996 Aug;15(1):41–50

Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Bejarano PA, et al. **Mod Pathol** 1996 Apr;9(4):445–52

Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Berezowski K, et al. **Mod Pathol** 1996 Apr;9(4):426–9

Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation. Kallakury BV, et al. **Mod Pathol** 1996 Jan;9(1):41–7

CD44v6 expression in primary bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma. Ohori NP, et al. **Mod Pathol** 1996 May;9(5):507–12

Immunohistochemical detection of bcl-2 protein in adenocarcinoma and non-neoplastic cellular compartments of the lung. Rao SK, et al. **Mod Pathol** 1996 May;9(5):555–9

Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Sosolik RC, et al. **Mod Pathol** 1997 Jul;10(7):716–9

Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. Monden N, et al. **Oncology** 1997 Sep-Oct;54(5):391–9

Transforming growth factor-beta isoforms expressions in pulmonary adenocarcinomas as prognostic markers: an immunohistological study of one hundred and twenty patients. Takanami I, et al. **Oncology** 1997 Mar-Apr; 54(2):122–8

Small pancreatic tubular adenocarcinomas: clinicopathological analysis with immunohistochemical and histochemical evaluation. Matsukuma S, et al. **Pathol Int** 1996 Aug;46(8):581–8

Models of DNA structure achieve almost perfect discrimination between normal prostate, benign prostatic hyperplasia (BPH), and adenocarcinoma and have a high potential for predicting BPH and prostate cancer. Malins DC, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):259–64

Lipid analysis and surfactant-associated protein expression in lung adenocarcinoma cells from pleural effusion. Takahashi H, et al. **Respiration** 1996;63(6):390–6

The significance of nm23 protein expression in human gastric carcinomas. Ura H, et al. **Surg Today** 1996;26(12):957–65

Chromogranin-A expression in neoplastic neuroendocrine cells and prognosis in colorectal cancer. Secco GB, et al. **Tumori** 1996 Jul-Aug;82(4):390–3

Immunohistochemical detection of truncated APC protein in sporadic human colorectal adenomas and adenocarcinomas. Akehi S, et al. **Virchows Arch** 1996 Sep; 429(1):21–6

Expression of cyclin E in colorectal adenomas and adenocarcinomas: correlation with expression of Ki-67 antigen and p53 protein. Yasui W, et al. **Virchows Arch** 1996 Sep;429(1):13–9

[Malignancy of colorectal cancer analyzed by expression of cyclin D1] Maeda K, et al. **Gan To Kagaku Ryoho** 1997 Jul;24 Suppl 2:259–62 (Eng. Abstr.) **(Jpn)**

[Analysis of nuclear matrix protein in human lung cancer cells] Yamazaki H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Mar;45(3):401–2 **(Jpn)**

[Immunohistochemical study of cytokeratin and vimentin expression in mixed type of adenocarcinoma and squamous cell carcinoma] Yuasa T. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Oct; 48(10):867–74 (Eng. Abstr.) **(Jpn)**

[Analysis of steroid hormone receptors in endometrial cancer] Kędzia W. **Ginekol Pol** 1996 May;67(5):254–8 (Eng. Abstr.) **(Pol)**

[Prostaglandins E in the primary tumor, metastases, and ascitic fluid of patients with ovarian cancer] Kushlinskiĭ NE, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):83–6 **(Rus)**

[Apparent heterogeneous distribution of progesterone receptors in certain cases of endometrial carcinoma] Bernal A, et al. **Ginecol Obstet Mex** 1997 Mar;65:96–100 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Well-differentiated fetal adenocarcinoma of lung. Fujino S, et al. **Lung Cancer** 1995 Dec;13(3):311–6

Can endoscopic biopsy specimens be used for reliable Laurén classification of gastric cancer? Hansson LE, et al. **Scand J Gastroenterol** 1996 Jul;31(7):711–5

Adenocarcinoma of the gastric antrum: does D2 total gastrectomy with splenectomy improve prognosis compared to D1 subtotal gastrectomy? A long-term survival analysis with emphasis on Lauren classification. Roukos D, et al. **Surg Oncol** 1995;4(6):323–32

COMPLICATIONS

Pericardial tamponade as the first manifestation of adenocarcinoma. de la Gándara I, et al. **Acta Oncol** 1997; 36(4):429–31

Severe tetanus in a patient with ulcerating inflammatory breast carcinoma. A case report and review of management. Toh HC, et al. **Acta Oncol** 1997;36(1):94–6 (22 ref.)

Subtotal colectomy in a patient with collagenous colitis associated with colonic carcinoma and systemic lupus erythematosus. Alikhan M, et al. **Am J Gastroenterol** 1997 Jul;92(7):1213–5

Streptococcus sanguis bacteremia associated with cecal carcinoma: case report and review of the literature. Marinella MA. **Am J Gastroenterol** 1997 Sep;92(9):1541–2 (12 ref.)

Endoscopic biliary stenting for the palliation of pancreatic cancer: results, survival predictive factors, and comparison of 10-French with 11.5-French gauge stents. Pereira-Lima JC, et al. **Am J Gastroenterol** 1996 Oct;91(10):2179–84

Inverted papilloma associated with squamous cell carcinoma and adenocarcinoma: case report and review of the literature. Kerschner JE, et al. **Am J Otolaryngol** 1996 Jul-Aug;17(4):257–9

Chagasic megacolon associated with colon cancer. Oliveira EC, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):596–8

Paraneoplastic cerebellar degeneration. Case report and literature review. Bolla L, et al. **Arch Intern Med** 1997 Jun 9;157(11):1258–62 (33 ref.)

Microfilarial pleural effusion associated with adenocarcinoma [letter] Sivakumaran P, et al. **Aust N Z J Med** 1997 Jun; 27(3):341

The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA). Speden D, et al. **Aust N Z J Med** 1997 Jun;27(3):307–10

Imaging appearances of ileouterine fistula complicating recurrent adenocarcinoma of the rectum. Hession P, et al. **Br J Radiol** 1997 Apr;70:415–7

Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Wigmore SJ, et al. **Br J Surg** 1997 Feb;84(2):196–7

Adenocarcinoma of the small bowel presenting as ureteric colic. Allkins JA, et al. **Br J Urol** 1997 Jul;80(1):153

Residents' corner. Answer to case of the month #40. Hypertension caused by left renal reninoma. Noël B, et al. **Can Assoc Radiol J** 1996 Oct;47(5):378–80

Colonic carcinoma in two adult cystic fibrosis patients. Chaun H, et al. **Can J Gastroenterol** 1996 Nov-Dec; 10(7):440–2

Abdominal pain, heart murmur, and lung infiltrates in a 40-year-old man. Schultz M, et al. **Chest** 1997 Feb; 111(2):498–500

Eczema craquelé as a pointer of internal malignancy--a case report. Guillet MH, et al. **Clin Exp Dermatol** 1996 Nov; 21(6):431–3 (24 ref.)

Association of Gemella morbillorum endocarditis with adenomatous polyps and carcinoma of the colon: case report and review. Lopez-Dupla M, et al. **Clin Infect Dis** 1996 Feb;22(2):379–80

Successful outcome of treating hemolytic uremic syndrome associated with cancer chemotherapy with immunoadsorption. D'Souza RJ, et al. **Clin Nephrol** 1997 Jan;47(1):58–9

Minimal change nephrotic syndrome with cecum adenocarcinoma. Gandini E, et al. **Clin Nephrol** 1996 Apr; 45(4):268–70 (27 ref.)

Papuloerythroderma of Ofuji: a report of 2 cases including the first European case associated with visceral carcinoma. Schepers C, et al. **Dermatology** 1996;193(2):131–5 (22 ref.)

Colorectal adenocarcinoma in Crohn's disease: a retrospective histologic study. Rubio CA, et al. **Dis Colon Rectum** 1997 Sep;40(9):1072–8

Initial results of a new procedure for treatment of malignant obstruction of the left colon. Tejero E, et al. **Dis Colon Rectum** 1997 Apr;40(4):432–6

Acute appendicitis and colonic carcinoma in the young: report of two cases. Adebamowo AC, et al. **East Afr Med J** 1996 Aug;73(8):563–4

Adult colorectal invagination associated with colonic cancer and established by fiberscopy of the sigmoid colon. Kimura H, et al. **Endoscopy** 1996 Sep;28(7):636

Association of risk factors for cervical cancer and human papilloma viruses in invasive cervical cancer. Uršič-Vrščaj M, et al. **Eur J Gynaecol Oncol** 1996;17(5):368–71

Prior radiation and chemotherapy increase the risk of life-threatening complications after insertion of metallic stents for esophagogastric malignancy [see comments] Kinsman KJ, et al. **Gastrointest Endosc** 1996 Mar; 43(3):196–203. Comment in: Gastrointest Endosc 1996 Mar;43(3):258–60.

Unusual ERCP appearance of obstructive jaundice caused by pancreatic cancer [letter] Lee JG. **Gastrointest Endosc** 1996 Dec;44(6):757–8

Endoscopic injection of gelatin solution for severe hemorrhagic gastric cancer. Tajika M, et al. **Gastrointest Endosc** 1996 Mar;43(3):247–50 (10 ref.)

Malignant acanthosis nigricans and tripe palms in a patient with endometrial adenocarcinoma--a case report and review of literature. Gorisek B, et al. **Gynecol Oncol** 1997 Jun;65(3):539–42 (17 ref.)

Adenocarcinoma of the ileum with an enterotubal fistula presenting as an adnexal mass. Hamid AM, et al. **Gynecol Oncol** 1997 Feb;64(2):270–3

Spontaneous arterial thrombosis with an advanced ovarian malignancy. Minjarez DA, et al. **Gynecol Oncol** 1997 Jan; 64(1):176–9 (18 ref.)

Syndrome of inappropriate antidiuresis in ovarian serous carcinoma with neuroendocrine differentiation. Taskin M, et al. **Gynecol Oncol** 1996 Sep;62(3):400–4

Adenocarcinoma of prostate and schistosomiasis: a rare association. Ma TK, et al. **Histopathology** 1995 Aug; 27(2):187–9

Transhepatic venous angioplasty and stenting: a treatment option in bleeding from gastric varices secondary to pancreatic carcinoma. Ferguson JM, et al. **HPB Surg** 1997; 10(3):173–5

Chronic pancreatitis and neoplasia: correlation or coincidence. Zografos GN, et al. **HPB Surg** 1997; 10(4):235–9

Pancreatic carcinoma complicating tropical pancreatitis in north India. Das K, et al. **Indian J Gastroenterol** 1996 Jul; 15(3):103

Hematuria: a presentation of carcinoma of the stomach. Nijhawan S, et al. **Indian J Gastroenterol** 1996 Jul;15(3):102

Synchronous adenocarcinoma and lymphoma of the colon. Wagle SD, et al. **Indian J Gastroenterol** 1997 Jan;16(1):28–9

Digital ischemia and occult malignancy. Paw P, et al. **Int J Colorectal Dis** 1996;11(4):196–7 (12 ref.)

Dermatomyositis accompanied by prostatic cancer and elevated serum CA 19.9. Ansai S, et al. **Int J Dermatol** 1996 Aug;35(8):570–1

Amyopathic dermatomyositis associated with malignancy. Finger DR, et al. **Int J Dermatol** 1996 Sep;35(9):663–4 (10 ref.)

Unsuspected rectal adenocarcinoma causing a urinoma. Sayeed R, et al. **Int J Urol** 1997 Jan;4(1):99–100

Primary adenocarcinoma in the urethrorectal fistula. Takaki R, et al. **Int J Urol** 1997 Jan;4(1):97–8

Transurethral hyperthermia for relieving obstructive voiding symptoms in patients with hormone refractory prostate cancer. Nativ O, et al. **Isr J Med Sci** 1997 Mar;33(3):182–5

Malignancy and pedal gangrene [letter] Pacheco NM, et al. **J Am Podiatr Med Assoc** 1996 Nov;86(11):564–6

Progressive systemic sclerosis with breast cancer. Lehl SS, et al. **J Assoc Physicians India** 1996 May;44(5):350

Prurigo nodularis associated with advanced gastric cancer: report of a case. Funaki M, et al. **J Dermatol** 1996 Oct; 23(10):703–7

Hereditary onset of multiple seborrheic keratoses: a variant of Leser Trélat sign? Yamamoto T, et al. **J Dermatol** 1996 Mar;23(3):191–5

Parathyroid hormone/parathyroid hormone-related protein receptor expression in nude mice with a transplantable canine apocrine adenocarcinoma (CAC-8) and humoral hypercalcaemia of malignancy. Gröne A, et al. **J Endocrinol** 1997 Apr;153(1):123–9

A rare case of gastric cancer in an acromegalic patient. Asai K, et al. **J Gastroenterol** 1997 Aug;32(4):528–32

Colonic cancer in a patient with primary sclerosing cholangitis and long-standing ulcerative colitis. Seo M, et al. **J Gastroenterol** 1997 Feb;32(1):83–8

Pancreatic cancer and hypercalcemia associated with von Recklinghausen's disease. Yamamoto M, et al. **J Gastroenterol** 1996 Oct;31(5):728–31 (28 ref.)

Case report: multiple cancers: hepatocellular carcinoma and adenocarcinomas of the common bile duct and the gall-bladder in a woman with primary biliary cirrhosis. Imada J, et al. **J Gastroenterol Hepatol** 1996 Jun; 11(6):546–50

Ileocaecal tuberculosis associated with adenocarcinoma of the Caecum and Colon. -letter- Jain BK. **J Indian Med Assoc** 1996 Jan;94(1):36

Ileocaecal tuberculosis associated with adenocarcinoma of the caecum and colon. Maheshwari V, et al. **J Indian Med Assoc** 1995 Oct;93(10):392–3

Jejunal adenocarcinoma presenting as iron deficiency in a young man. Trowers EA, et al. **J Natl Med Assoc** 1997 Mar;89(3):205–7

Significant morbidity associated with bone metastases in a patient with breast cancer. Oneschuk D, et al. **J Palliat Care** 1996 Winter;12(4):51–4

Obstructive jaundice resulting from adenocarcinoma of the ampulla of Vater in an 11-year-old boy. Andiran F, et al. **J Pediatr Surg** 1997 Apr;32(4):636–7

Remitting seronegative symmetrical synovitis with pitting edema associated with gastric carcinoma. Tada Y, et al. **J Rheumatol** 1997 May;24(5):974–5

Giant cell temporal arteritis in the young [letter] Webb J. **J Rheumatol** 1996 Jan;23(1):197

Adenocarcinoma of the rete testis: report of a case with surgical history of adenomatous hyperplasia of the rete testis. Gruber H, et al. **J Urol** 1997 Oct;158(4):1525–6 (6 ref.)

Enteric type adenocarcinoma of the upper tract urothelium associated with ectopic ureter and renal dysplasia: an oncological rationale for complete extirpation of this aberrant developmental anomaly. Rao DS, et al. **J Urol** 1996 Oct;156(4):1272–4

Gastroesophageal tumor embolization to the popliteal arteries. Nicholas GG, et al. **J Vasc Surg** 1997 Aug; 26(2):333–6

Subacute pulmonary hypertension due to pulmonary tumor microembolism as a clinical manifestation of occult gallbladder adenocarcinoma. Ando H, et al. **Jpn Circ J** 1997 Jan;61(1):82–6

Fibrillary glomerulonephritis in a patient with adenocarcinoma of stomach. Amir-Ansari B, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):210–1

Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Tisdale MJ. **Nutrition** 1996 Jan; 12(1 Suppl):S31–3

Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Bruera E, et al. **Pain** 1997 Jan; 69(1–2):199–201

Breast carcinoma with myeloid metaplasia--a case report. Setsu Y, et al. **Pathol Res Pract** 1997;193(3):219–22; discussion 223–4

Malakoplakia and colorectal adenocarcinoma. Bates AW, et al. **Postgrad Med J** 1997 Mar;73(857):171–3 (10 ref.)

Follow-up of mycoplasma pneumonia [letter; comment] Hopewell J. **Postgrad Med J** 1996 Oct;72(852):637. Comment on: Postgrad Med J 1996 Apr;72(846):241–2.

Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin. Beshara S, et al. **Prostate** 1997 May 15;31(3):153–60

Periampullary carcinoma in a patient with sarcoidosis [letter] Kadayifci A, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1997 Mar;14(1):87–8

Barrett's cancer: indications, extent, and results of surgical resection. Siewert JR, et al. **Semin Surg Oncol** 1997 Jul–Aug;13(4):245–52 (54 ref.)

Endometrial hyperplasia and the risk of endometrial carcinoma. Ho SP, et al. **Singapore Med J** 1997 Jan; 38(1):11–5

Gastric adenocarcinoma and low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Hardman WJ 3rd, et al. **South Med J** 1997 Apr;90(4):426–30

Primary adenocarcinoma of the stomach associated with peripheral neurofibromatosis: report of a case. Basu S, et al. **Surg Today** 1997;27(1):57–9

Relapse of colon cancer followed by polymyositis: report of a case and review of the literature. Nyui S, et al. **Surg Today** 1997;27(6):559–62 (11 ref.)

Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Kelsen DP, et al. **Surgery** 1997 Jul; 122(1):53–9

High coincidence of Mirizzi syndrome and gallbladder carcinoma. Redaelli CA, et al. **Surgery** 1997 Jan; 121(1):58–63

Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature. Sarver RG, et al. **Urology** 1997 May;49(5):781–5 (27 ref.)

[Gas gangrene of ischemic myocardial tissue caused by Clostridium septicum] den Bakker MA, et al. **Ned Tijdschr Geneeskd** 1996 Dec 21;140(51):2547–50 (Eng. Abstr.) **(Dut)**

[Ménétrier disease associated with a gastric adenocarcinoma. Apropos of 2 cases] Jouini M, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Nov-Dec; 31(6):341–5 (Eng. Abstr.) **(Fre)**

[Minimal deviation adenocarcinoma of the uterine cervix in a woman with Peutz-Jeghers syndrome. Report of a case] Chatti S, et al. **Ann Pathol** 1997 Jul;17(3):193–5 (Eng. Abstr.) **(Fre)**

[A case of degenerated diffuse biliary papillomatosis associated with cystic dilatation of the intrahepatic biliary ducts. Value of radiotherapy and review of the literature] Pillet G, et al. **Bull Cancer** 1996 Nov;83(11):957–63 (83 ref.) (Eng. Abstr.) **(Fre)**

[Malaria attack: a very late relapse due to Plasmodium vivax] Maslin J, et al. **Bull Soc Pathol Exot** 1997;90(1):25–6 (Eng. Abstr.) **(Fre)**

[Pulmonary artery hypertension caused by carcinomatous lymphangitis] Durieu J, et al. **Rev Mal Respir** 1997 Jan; 14(1):55–8 (Eng. Abstr.) **(Fre)**

[Synchronous bronchial cancers disclosed by Pierre Marie Bamberger syndrome and Schwartz-Bartter syndrome (letter)] Bour-Guichenez G, et al. **Rev Pneumol Clin** 1996; 52(4):263–4 **(Fre)**

[Spontaneous retroperitoneal hematoma in adrenal metastasis] Tappe U, et al. **Dtsch Med Wochenschr** 1997 Apr 11; 122(15):471–4 (Eng. Abstr.) **(Ger)**

[Coincidence of Pneumocystis carinii pneumonia and lung carcinoma in AIDS] Klinker H, et al. **Pneumologie** 1996 Jul;50(7):496–501 (Eng. Abstr.) **(Ger)**

[Nonbacterial thrombotic endocarditis: a contribution to the clinical differential diagnosis in culture-negative endocarditis] Christen R, et al. **Schweiz Med Wochenschr** 1996 Nov 30;126(48):2087–9 (Eng. Abstr.) **(Ger)**

[Intestinal foreign body with sigmoid perforation in an area of carcinomatous stenosis: incidental finding or etiology?] Stiefel D, et al. **Swiss Surg** 1997;3(3):100–3 (Eng. Abstr.) **(Ger)**

[A case of lung adenocarcinoma associated with remarkably high levels of CA 19-9 and lymphangitis carcinomatosa] Akiyama Y, et al. **Gan To Kagaku Ryoho** 1997 Jan; 24(1):93–6 (Eng. Abstr.) **(Jpn)**

[A case of one stage operation for primary lung cancer and abdominal aortic aneurysm] Tanaka K, et al. **Kyobu Geka** 1996 Jul;49(7):599–601 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a patient with erythroderma] Hattori S, et al. **Masui** 1996 Sep;45(9):1127–30 (Eng. Abstr.) **(Jpn)**

[A dual occurrence of endometrial and gastric adenocarcinomas in systemic lupus erythematosus] Yamane K, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun; 19(3):232–7 (Eng. Abstr.) **(Jpn)**

[Dynamic stent useful for trachocarinal stenosis due to lung cancer] Hayashi K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep;44(9):1787–91 (Eng. Abstr.) **(Jpn)**

[A case of primary adenocarcinoma of the fallopian tube complicated with paraneoplastic cerebellar degeneration] Matsushita H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Nov; 48(11):1093–6 **(Jpn)**

[A case of clonic cancer with Leser-Trélat sign] Iwakawa K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Dec; 93(12):911–4 (Eng. Abstr.) **(Jpn)**

[A case of double choledochus with early gallbladder cancer] Ohta H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan; 94(1):62–7 (23 ref.) **(Jpn)**

[A case of ulcerative colitis with minute gastric cancer and intraductal papillary adenoma of the pancreas] Yamamoto T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug; 94(8):532–7 (12 ref.) **(Jpn)**

[A case of IGF-II producing rectal cancer with recurrent hypoglycemia] Yasuda T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Mar;94(3):210–4 **(Jpn)**

[Sigmoid-vesical fistula as a consequence of sigmoid tumor] Kazuka B, et al. **Pol Merkuriusz Lek** 1996 Sep;1(3):195–7 (Eng. Abstr.) **(Pol)**

[Radical surgical treatment of gastric cancer complicated by perforation and hemorrhage in the aged] Chernov KM, et al. **Khirurgiia (Mosk)** 1997;(4):69 **(Rus)**

[Closing of duodenal stump and crater of giant cancerous profusely bleeding ulcer] Kholiavko VK, et al. **Klin Khir** 1996;(6):50–1 **(Rus)**

[Microangiopathic anemia and leukoerythroblastic reaction associated with a pulmonary adenocarcinoma (letter)] Calvo Villas JM, et al. **An Med Interna** 1996 Jul;13(7):356–7 (Eng. Abstr.) **(Spa)**

[Association of lung adenocarcinoma and human immunodeficiency virus infection] De Miguel Díez J, et al. **An Med Interna** 1997 May;14(5):250–2 (Eng. Abstr.) **(Spa)**

[A case of protein S deficiency associated with ovarian cancer (letter)] Marcos Sánchez F, et al. **An Med Interna** 1997 Mar;14(3):156–7 **(Spa)**

[Trousseau's syndrome in lung adenocarcinoma. The rare appearance of venous gangrene] Bellido Casado J, et al. **Arch Bronconeumol** 1997 Jun;33(6):312–4 (Eng. Abstr.) **(Spa)**

[Bordetella bronchiseptica in a patient with prostatic adenocarcinoma (letter) (see comments)] Peraire J, et al. **Enferm Infecc Microbiol Clin** 1996 Aug-Sep;14(7):458–9. Comment in: Enferm Infecc Microbiol Clin 1997 Jan;15(1):48–9. **(Spa)**

[Erythema nodosum and adenocarcinoma of the colon (letter)] Lillo A, et al. **Med Clin (Barc)** 1997 Mar 1; 108(8):318 **(Spa)**

[Gastric adenocarcinoma in 2 cases of Bloom syndrome (letter)] Robles Campos R, et al. **Med Clin (Barc)** 1996 Feb 3;106(4):156–7 **(Spa)**

[Gastric tumor and jaundice with biliary tract dilatation] Acea Nebril B, et al. **Rev Clin Esp** 1996 Jul;196(7):473–4 **(Spa)**

[Recurrent or episodic fever of unknown origin as the sole symptom of colon neoplasm (letter)] Sánchez Rodríguez A, et al. **Rev Clin Esp** 1997 Mar;197(3):213–4 **(Spa)**

[Adenocarcinoma of the sigmoid in incarcerated inguinoscrotal hernia (letter)] Alonso Poza A, et al. **Rev Esp Enferm Dig** 1996 Dec;88(12):883–4 **(Spa)**

[Chylothorax as presenting form of a gastric adenocarcinoma] Martín-Jóven A, et al. **Rev Esp Enferm Dig** 1996 Dec; 88(12):880–1 (Eng. Abstr.) **(Spa)**

[Small intestine adenocarcinoma with Crohn's disease] Rodríguez Ramos C, et al. **Rev Esp Enferm Dig** 1997 Apr; 89(4):321–4 (Eng. Abstr.) **(Spa)**

[Gas gangrene secondary to carcinoma of the colon] Ruiz de Adana JC, et al. **Rev Esp Enferm Dig** 1997 Jun; 89(6):479–80 (Eng. Abstr.) **(Spa)**

[Clinical images in gastroenterology. Barrett esophagus of distinctive type and adenocarcinoma] Barinagarrementeria Aldatz R, et al. **Rev Gastroenterol Mex** 1997 Jan-Mar; 62(1):58 **(Spa)**

DIAGNOSIS

Comparison of helical CT and MR imaging in detecting and staging small pancreatic adenocarcinoma. Irie H, et al. **Abdom Imaging** 1997 Jul–Aug;22(4):429–33

Carcinoma of the gallbladder: color Doppler ultrasound and CT findings. Wilbur AC, et al. **Abdom Imaging** 1997 Mar–Apr;22(2):187–9

Cervical carcinoma: role of imaging. Yu KK, et al. **Abdom Imaging** 1997 Mar–Apr;22(2):208–15 (50 ref.)

Skeletal muscle mass in an asymptomatic male. Weinberg E, et al. **Acad Radiol** 1997 Jun;4(6):458–60

Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1. Bailey ME, et al. **Acta Cytol** 1996 Nov-Dec; 40(6):1212–6

Comparison of the CytoRich system with conventional cervical cytology. Preliminary data on 2,032 cases from a clinical trial site. Bishop JW. **Acta Cytol** 1997 Jan-Feb; 41(1):15–23

Brush cytology and biopsy in the diagnosis of colorectal cancer. A comparison. Halpern M, et al. **Acta Cytol** 1997 May-Jun;41(3):628–32

Differential diagnosis of Hürthle cell neoplasms on fine needle aspirates. Can we do any better with morphometry?

Pambuccian SE, et al. **Acta Cytol** 1997 Jan–Feb; 41(1):197–208

Cervical cancer screening in Japan. A case–control study. Sato S, et al. **Acta Cytol** 1997 Jul–Aug;41(4):1103–6

Comparison of the sensitivity of sputum and brush cytology in the diagnosis of lung carcinomas. Sing A, et al. **Acta Cytol** 1997 Mar–Apr;41(2):399–408 (67 ref.)

Benign pairs. A useful discriminating feature in fine needle aspirates of the breast. Yu GH, et al. **Acta Cytol** 1997 May–Jun;41(3):721–6

MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. Silverman JM, et al. **AJR Am J Roentgenol** 1997 Feb;168(2):379–85

Pancreatic adenocarcinoma: assessment of vascular invasion with high–field MR imaging and a phased–array coil. Sironi S, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):997–1001

Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Brown RW, et al. **Am J Clin Pathol** 1997 Jan;107(1):12–9

Microglandular carcinoma of the pancreas [letter; comment] Klimstra DS, et al. **Am J Clin Pathol** 1997 Jun;107(6):711–3 . Comment on: Am J Clin Pathol 1996 Jun;105(6):727–32.

Papanicolaou smear sensitivity for adenocarcinoma in situ of the cervix. A study of 34 cases [see comments] Lee KR, et al. **Am J Clin Pathol** 1997 Jan;107(1):30–5. Comment in: Am J Clin Pathol 1997 Jul;108(1):114.

Papanicolaou smear sensitivity for adenocarcinoma in situ [letter; comment] York GL. **Am J Clin Pathol** 1997 Jul; 108(1):114. Comment on: Am J Clin Pathol 1997 Jan;107(1):30–5.

Meningeal carcinomatosis as the presenting manifestation of gastric adenocarcinoma. Deeb LS, et al. **Am J Gastroenterol** 1997 Feb;92(2):329–31 (22 ref.)

False elevation of CA 19–9 levels in a patient with a history of pancreatic cancer. Goetz M, et al. **Am J Gastroenterol** 1997 Aug;92(8):1390–1

Metastatic breast cancer masquerading as sarcoidosis. Urschel JD, et al. **Am J Med Sci** 1997 Aug;314(2):124–5

Significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma. McNeal JE, et al. **Am J Surg Pathol** 1996 Nov;20(11):1351–60

Multimodality staging optimizes resectability in patients with pancreatic and ampullary cancer. Awad SS, et al. **Am Surg** 1997 Jul;63(7):634–8

MIB1 in colorectal carcinomas: its evaluation by three different methods reveals lack of prognostic significance. Ofner D, et al. **Anal Cell Pathol** 1996 Nov;12(2):61–70

Prognostic value of DNA image cytometry in colorectal carcinoma. Sampedro A, et al. **Anal Quant Cytol Histol** 1996 Jun;18(3):214–20

Laparoscopy in the management of gastric adenocarcinoma. Burke EC, et al. **Ann Surg** 1997 Mar;225(3):262–7 (9 ref.)

Liposome–encapsulated superparamagnetic iron oxide particles as markers in an MRI–guided search for tumor–specific drug carriers. Päuser S, et al. **Anticancer Drug Des** 1997 Mar;12(2):125–35

PSA excess in the differential diagnosis of prostate carcinoma. Diaz F, et al. **Arch Esp Urol** 1997 May; 50(4):415–8

Modified clearing technique to identify lymph node metastases in post–irradiated surgical specimens from rectal adenocarcinoma. Sanchez W, et al. **Arch Med Res** 1996 Spring;27(1):31–6

Radial scar and tubular carcinoma of the breast. Tükel S, et al. **Australas Radiol** 1997 May;41(2):190–2

Relationship between TA01 and TA02 polypeptides associated with lung adenocarcinoma and histocytological features. Hirano T, et al. **Br J Cancer** 1997;75(7):978–85

Mutant plasma p53 protein levels: prognostication in colorectal carcinoma. Wong SK, et al. **Br J Surg** 1997 May; 84(5):664–5

Demonstration of silver–stained nucleolar organizer region associated proteins (AgNORs) after wet autoclave pretreatment in breast carcinoma: correlation to tumor stage and long–term survival. Ofner D, et al. **Breast Cancer Res Treat** 1996;39(2):165–76

MRI in patients with axillary metastases of occult breast carcinoma. Tilanus–Linthorst MM, et al. **Breast Cancer Res Treat** 1997 Jun;44(2):179–82

Immunohistochemically detected p53 and HER–2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas. Auranen A, et al. **Cancer** 1997 Jun 1;79(11):2147–53

p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Eltabbakh GH, et al. **Cancer** 1997 Sep 1;80(5):892–8

Selective decrease of serum immunoglobulin G1 as a marker of malignant transformation in colorectal tissue. Schauenstein E, et al. **Cancer** 1997 Apr 15;79(8):1482–6

Detection of p53 nuclear protein accumulation in brushings and biopsies of Barrett's esophagus. Tsai TT, et al. **Cancer Detect Prev** 1997;21(4):326–31

A small depressed early cancer of the second portion of duodenum: report of a case and review of Japanese literature. Tanigawa K, et al. **Chin Med J (Engl)** 1996 Oct; 109(10):810–3

Clinical usefulness of percentage of free serum prostate specific antigen. Vogl M, et al. **Clin Chim Acta** 1997 Feb 3;258(1):79–90

Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate–specific antigen. Positron emission tomography and biopsy correlation. Haseman MK, et al. **Clin Nucl Med** 1996 Sep;21(9):704–13

Early detection and management of esophageal cancer. Margulies C, et al. **Compr Ther** 1996 Sep;22(9):565–78 (98 ref.)

Minimum prostate–specific antigen (PSA) level diagnostic of prostate cancer. Yesner R, et al. **Conn Med** 1996 Jul; 60(7):399–404

The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Grem J. **Curr Opin Oncol** 1997 Jul;9(4):380–7 (38 ref.)

Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Delahaye M, et al. **Diagn Cytopathol** 1997 Aug;17(2):115–20

Utility of fine–needle aspiration biopsy in solid renal masses. Kelley CM, et al. **Diagn Cytopathol** 1996 Feb;14(1):14–9

Contribution of transmission electron microscopy to fine–needle aspiration biopsy diagnosis: comparison of cytology and combined cytology and transmission electron microscopy with final histological diagnosis. Quinonez GE, et al. **Diagn Cytopathol** 1996 Nov;15(4):282–7

Dysplasia in Barrett's esophagus: diagnosis, surveillance and treatment [see comments] Clark GW, et al. **Dig Dis** 1996 Jul–Aug;14(4):213–27 (94 ref.). Comment in: Dig Dis 1996 Jul–Aug;14(4):211–2.

Standards and perspectives in the diagnosis and treatment of pancreatic adenocarcinoma. Sulkowski U. **Digestion** 1996;57 Suppl 1:34–5 (9 ref.)

p53, c–erbB–2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma. MacKinnon M, et al. **Eur J Cardiothorac Surg** 1997 May; 11(5):838–42

Diagnostic use of endoscopic mucosal resection. Ghosh S, et al. **Eur J Gastroenterol Hepatol** 1997 May;9(5):539–41

Successful outcome of a 9 week pregnancy managed by bilateral salpingo–oophorectomy for ovarian cancer: case report. Colavita M, et al. **Eur J Gynaecol Oncol** 1996; 17(6):522–3 (7 ref.)

Aggressive endometrial cancer in a young patient. Flam F, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jul;74(1):45–7

Amyloidosis of the seminal vesicles simulating tumor invasion of prostatic carcinoma on endorectal MR images. Jager GJ, et al. **Eur Radiol** 1997;7(4):552–4

Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer. Abbas F, et al. **Eur Urol** 1996;30(3):322–6

Biomarkers for malignancy in the columnar–lined esophagus. Rustgi AK. **Gastroenterol Clin North Am** 1997 Sep; 26(3):599–606 (57 ref.)

Solitary cystic tumor of the pancreas: EUS–pathologic correlation. Koito K, et al. **Gastrointest Endosc** 1997 Mar; 45(3):268–76

Neoplasia distal to the splenic flexure in patients with proximal colon cancer [see comments] Lemmel GT, et al. **Gastrointest Endosc** 1996 Aug;44(2):109–11. Comment in: Gastroenterology 1996 Aug;44(2):203–4.

Bulimia nervosa complicated by Barrett's esophagus and esophageal cancer. Navab F, et al. **Gastrointest Endosc** 1996 Oct;44(4):492–4 (15 ref.)

Superficial esophageal carcinoma detected on extensive esophageal varices before endoscopic injection sclerotherapy. Takasaki M, et al. **Gastrointest Endosc** 1997 Jan;45(1):96–8

Atypical (carcinoma–like) and simple glandular inclusions in retroperitoneal lymph nodes. Horn LC, et al. **Gen Diagn Pathol** 1996 May;141(5–6):319–25

Adenocarcinoma of the retinal pigment epithelium: a diagnostic and therapeutic challenge. Finger PT, et al. **Graefes Arch Clin Exp Opthalmol** 1996 Aug;234 Suppl 1:S22–7 (23 ref.)

Detection of adenocarcinoma in Barrett's oesophagus by means of laser induced fluorescence. von Holstein CS, et al. **Gut** 1996 Nov;39(5):711–6

Endometrial adenocarcinoma in early pregnancy. Kovács AG, et al. **Gynecol Obstet Invest** 1996;41(1):70–2

A difficult early diagnosis of pancreatic body neoplasia. Boldrini E, et al. **Hepatogastroenterology** 1996 May–Jun; 43(9):730–3

Expression of tumor–associated carbohydrate antigens correlates with hepatic metastasis of pancreatic cancer: clinical and experimental studies. Takamori H, et al. **Hepatogastroenterology** 1996 May–Jun;43(9):748–55

Endocervical tubal metaplasia and adenocarcinoma in situ: role of immunohistochemistry for carcinoembryonic antigen and vimentin in differential diagnosis. Marques T, et al. **Histopathology** 1996 Jun;28(6):549–50

P–glycoprotein as a prognostic indicator in pre– and postchemotherapy ovarian adenocarcinoma. Khalifa MA, et al. **Int J Gynecol Pathol** 1997 Jan;16(1):69–75

Atypical polypoid adenomyofibroma (APA) versus well–differentiated endometrial carcinoma with prominent stromal matrix: an immunohistochemical study. Soslow RA, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):209–16

Detection of circulating tumor cells in patients with prostate cancer using prostate specific membrane–derived primers in the polymerase chain reaction. Noguchi M, et al. **Int J Urol** 1997 Jul;4(4):374–9

A rare case of ectopic antidiuretic hormone–producing pancreatic adenocarcinoma: new diagnostic approach. Nagashima Y, et al. **Intern Med** 1996 Apr;35(4):280–4

A very small juxtaglomerular cell tumor preoperatively identified by magnetic resonance imaging. Tanabe A, et al. **Intern Med** 1996 Apr;35(4):295–300

Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection. Runge VM, et al. **Invest Radiol** 1996 Aug;31(8):472–8

Colon carcinoma discovered in an adolescent during inguinal hernia repair. LeClair LL, et al. **J Am Osteopath Assoc** 1997 Feb;97(2):100–1 (11 ref.)

Barrett's esophagus and adenocarcinoma. The need for a consensus conference [editorial] Richter JE, et al. **J Clin Gastroenterol** 1996 Sep;23(2):88–90

Hypertrophic osteoarthropathy. Burstein HJ, et al. **J Clin Oncol** 1997 Jul;15(7):2759–60

beta hCG as a prognostic marker in prostatic adenocarcinoma [letter; comment] Furness P. **J Clin Pathol** 1996 Aug; 49(8):693–4. Comment on: J Clin Pathol 1996 Apr;49(4):329–32.

MRI of the breast in the differential diagnosis of mastitis versus inflammatory carcinoma and follow–up. Rieber A, et al. **J Comput Assist Tomogr** 1997 Jan–Feb;21(1):128–32

Skeletal muscle metastasis from lung carcinoma: MR findings. Suto Y, et al. **J Comput Assist Tomogr** 1997 Mar–Apr; 21(2):304–5

Esophageal metastasis from prostate cancer: diagnostic use of reverse transcriptase–polymerase chain reaction for prostate–specific antigen. Nakamura T, et al. **J Gastroenterol** 1997 Apr;32(2):236–40

A rare uterine tumor presenting as deep venous thrombosis. Theuer HH, et al. **J Ky Med Assoc** 1997 Mar;95(3):102–4

MR lesion detection in a breast cancer population. Obdeijn IM, et al. **J Magn Reson Imaging** 1996 Nov–Dec; 6(6):849–54

Ampullary carcinoma: demonstration by current MR techniques. Semelka RC, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):153–6

Diagnosis and treatment of pancreatic and ampullary cancer. Murr MM, et al. **J Med Liban** 1995;43(4):200–7 (55 ref.)

von Hippel–Lindau disease gene alterations associated with endolymphatic sac tumor [letter] Vortmeyer AO, et al. **J Natl Cancer Inst** 1997 Jul 2;89(13):970–2

Paraneoplastic opsoclonus associated with cancer of the gall bladder [letter] Corcia P, et al. **J Neurol Neurosurg Psychiatry** 1997 Mar;62(3):293

Increased phantom limb pain as an initial symptom of spinal–neoplasia [published erratum appears in J Pain Symptom Manage 1997 Sep;14(3):135] Chang VT, et al. **J Pain Symptom Manage** 1997 Jun;13(6):362–4 (18 ref.)

Cervical and vaginal cytologic smears suggestive of adenocarcinoma. Pretorius R, et al. **J Reprod Med** 1996 Jul;41(7):478–82

Preoperative laparoscopy in management of patients with carcinoma of the esophagus and of the esophagogastric junction. Bonavina L, et al. **J Surg Oncol** 1997 Jul; 65(3):171–4

Correlation of DNA ploidy and histologic diagnosis from prostate core–needle biopsies: is DNA ploidy more sensitive than histology for the diagnosis of carcinoma in small specimens? Lo J, et al. **J Surg Oncol** 1996 Sep; 63(1):41–5

Synchronous multiple colorectal adenocarcinomas. Takeuchi H, et al. **J Surg Oncol** 1997 Apr;64(4):304–7

Coexistent tuberculosis and carcinoma of the colon. Sheikh MY, et al. **JPMA J Pak Med Assoc** 1995 Nov;45(11):305–6 (10 ref.)

Preoperative evaluation of the curative resectability of gastric cancer by abdominal computed tomography and ultrasonography: a prospective comparison study. Kim JJ, et al. **Korean J Intern Med** 1997 Jan;12(1):1–6

Diagnosis of gastric carcinoma in Japan and western countries [letter] Stolte M. **Lancet** 1997 Aug 9; 350(9075):448

Adenocarcinoma of the lung presenting as a diffuse interstitial process in a 25–year–old man. Mapel DW, et al. **Lung Cancer** 1996 Sep;15(2):239–44

In vivo imaging of extraction fraction of low molecular weight MR contrast agents and perfusion rate in rodent tumors. Kovar DA, et al. **Magn Reson Med** 1997 Aug; 38(2):259–68

Prostate cancer masquerading as a zygomatic posttraumatic mass. Harlan JW, et al. **Mayo Clin Proc** 1997 Mar; 72(3):248–50

Duodenal obstruction: diagnosis by gastroduodenal manometry. Loftus EV Jr, et al. **Mayo Clin Proc** 1997 Feb; 72(2):130–2

DNA–analysis is mandatory in case of an uncommon malignancy. van den Berg H, et al. **Med Pediatr Oncol** 1997 Jul;29(1):65–6

Interobserver variability in the diagnosis of high–grade prostatic intraepithelial neoplasia and adenocarcinoma. Allam CK, et al. **Mod Pathol** 1996 Jul;9(7):742–51

Expression of bcl–2 by breast cancer: a possible diagnostic application. Alsabeh R, et al. **Mod Pathol** 1996 Apr; 9(4):439–44

Pigment in prostatic epithelium and adenocarcinoma: a potential source of diagnostic confusion with seminal vesicular epithelium. Amin MB, et al. **Mod Pathol** 1996 Jul;9(7):791–5

Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer. Griebling TL, et al. **Mod Pathol** 1997 Aug;10(8):804–9

Cytokeratin immunostaining in differentiating primary

ovarian carcinoma from metastatic colonic adenocarcinoma. Loy TS, et al. **Mod Pathol** 1996 Nov; 9(11):1040–4

Pitfalls in diagnostic cervicovaginal cytology. Sidawy MK, et al. **Monogr Pathol** 1997;(39):1–15 (45 ref.)

DNA testing to refute a diagnosis of cancer [letter] Gelmann EP, et al. **N Engl J Med** 1997 Oct 23;337(17):1245–7

Eccrine adenocarcinoma of the lacrimal sac region. Karim MM, et al. **Ophthalmologica** 1997;211(1):44–8

Thyroid cancers. I. Papillary, follicular, and Hürthle cell. Goldman ND, et al. **Otolaryngol Clin North Am** 1996 Aug; 29(4):593–609 (41 ref.)

FNB diagnosis of breast carcinoma associated with HIV infection: a case report and review of HIV associated malignancy. Mayer AP, et al. **Pathology** 1996 Jan; 28(1):90–5 (40 ref.)

Carcinoma of the sigmoid colon presenting as a scrotal swelling. Bryan NP, et al. **Postgrad Med J** 1997 Jan; 73(855):47–8 (10 ref.)

Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment. Losa M, et al. **Prostate** 1997 Sep 1; 32(4):241–5

Renal pelvic and ureteral carcinoma with huge hydronephrosis: US, CT, and MR findings. Kanematsu M, et al. **Radiat Med** 1996 Nov–Dec;14(6):321–3

Esophageal cancer. Clinical and pathologic features. Gore RM. **Radiol Clin North Am** 1997 Mar;35(2):243–63 (131 ref.)

Papillary endolymphatic sac tumors: CT, MR imaging, and angiographic findings in 20 patients. Mukherji SK, et al. **Radiology** 1997 Mar;202(3):801–8

Distinction between pleural mesothelioma and pulmonary adenocarcinoma using MOC31 in an asbestos sprayer. Ryan PJ, et al. **Respir Med** 1997 Jan;91(1):57–60

Natural history of gallbladder carcinoma: clinical and pathologic factors. Hidalgo Grau LA, et al. **Rev Esp Enferm Dig** 1997 Mar;89(3):186–95 **(Eng, Spa)**

Concurrence of benign edematous polysynovitis in the elderly (RS3PE syndrome) and endometrial adenocarcinoma. Olivo D, et al. **Scand J Rheumatol** 1997; 26(1):67–8

Esophageal carcinoma: current controversies. DeMeester TR. **Semin Surg Oncol** 1997 Jul–Aug;13(4):217–33 (93 ref.)

Perforated cecal adenocarcinoma presenting as a thigh abscess. Mann GN, et al. **South Med J** 1997 Sep; 90(9):949–51 (7 ref.)

Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma. Audisio RA, et al. **Surg Oncol** 1996 Apr;5(2):49–63 (171 ref.)

Pseudomyxoma peritonei concomitant with early gastric cancer: report of a case. Ikejiri K, et al. **Surg Today** 1996; 26(11):923–5

Ampullary carcinoma in familial adenomatous polyposis: report of a case. Tomita H, et al. **Surg Today** 1996; 26(7):522–6 (16 ref.)

The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Katz AE, et al. **Urol Clin North Am** 1996 Nov;23(4):541–9 (40 ref.)

Ureteroscopic diagnosis of intraluminal metastatic rectal carcinoma. Fazeli-Matin S, et al. **Urology** 1997 Jun; 49(6):955–6

Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancer. Ingenito AC, et al. **Urology** 1997 Jul;50(1):73–8

Prostate imaging may not be necessary in nonpalpable carcinoma of the prostate. Werner-Wasik M, et al. **Urology** 1997 Sep;50(3):385–9

[The application of high molecular weight cytokeratin in differential diagnosis of prostate adenocarcinoma] Kong X, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Aug; 25(4):199–201 (Eng. Abstr.) **(Chi)**

[Clinical detection of adenocarcinoma of the uterine cervix] Ondruš J. **Ceska Gynekol** 1996 Aug;61(4):258–9 **(Cze)**

[Immunohistochemical detection of estradiol and progesterone receptors in paraffin sections after treatment with microwaves. Comparison with biochemical assay of receptors in a series of 123 breast cancers with determination of the threshold of optimal positivity] Vilain MO, et al. **Ann Pathol** 1997 Apr;17(2):82–8 **(Fre)**

[Comparison between spiral x-ray computed tomography and endosonography in the diagnosis and staging of adenocarcinoma of the pancreas. Clinical preliminary study] Dufour B, et al. **Gastroenterol Clin Biol** 1997; 21(2):124–30 (Eng. Abstr.) **(Fre)**

[Adenocarcinoma of the meibomian gland with invasion of the orbit] Cernea P, et al. **Oftalmologia** 1997;41(1):44–6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)] de la Taille A, et al. **Prog Urol** 1997 Apr;7(2):240–5 (Eng. Abstr.) **(Fre)**

[Detection of an asymptomatic sigmoid carcinoma after extramural foreign body perforation (letter)] Wunsch M, et al. **Chirurg** 1996 Jul;67(7):766 **(Ger)**

[Is an endoscopic-bioptic monitoring program for Barrett esophagus sensible? (comment)] Riemann JF. **Dtsch Med Wochenschr** 1997 Apr 4;122(14):425–6 (16 ref.) . Comment on: Dtsch Med Wochenschr 1997 Apr 4;122(14):427–31. **(Ger)**

[Improved diagnosis of pancreatic carcinoma by preoperative Ki-ras detection in pancreatic juice] Hünerbein M, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:97–9 (Eng. Abstr.) **(Ger)**

[The value of MR-mammography at 1.5 tesla in the differential diagnosis of non-puerperal mastitis and inflammatory breast carcinoma] Tomczak R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Aug;165(2):148–51 (Eng. Abstr.) **(Ger)**

[Bladder tumors] Egli U. **Ther Umsch** 1996 Sep;53(9):697–701 (Eng. Abstr.) **(Ger)**

[Simultaneous occurrence of small intestine mesenchymoma and rectal carcinoma] Tasi R, et al. **Orv Hetil** 1997 Mar 30;138(13):805–6 (Eng. Abstr.) **(Hun)**

[Aspiration cytology in the diagnosis of gastrointestinal tumors] Vámosi-Nagy I, et al. **Orv Hetil** 1996 Nov 3; 137(44):2455–7 (Eng. Abstr.) **(Hun)**

[Carcinoma of the extrahepatic bile ducts] Cappelletti F, et al. **G Chir** 1996 Nov–Dec;17(11–12):589–92 (Eng. Abstr.) **(Ita)**

[Early diagnosis of endometrial carcinoma and its precursors in asymptomatic postmenopausal women. Proposal of a diagnostic protocol] Mele GA, et al. **Minerva Ginecol** 1997 Apr;49(4):133–7 (Eng. Abstr.) **(Ita)**

[The role of hysteroscopy in the early diagnosis of small, focal endometrial neoplasms] Vigada G, et al. **Minerva Ginecol** 1996 Nov;48(11):493–5 (Eng. Abstr.) **(Ita)**

[Villoglandular adenocarcinoma of the cervix uteri. A case report and analysis of the literature] Wiesenfeld U, et al. **Minerva Ginecol** 1997 May;49(5):221–4 (5 ref.) (Eng. Abstr.) **(Ita)**

[Role of computerized tomography following transrectal air insufflation and hypotonization and transrectal ultrasonography in the staging of rectal tumors] Osti MF, et al. **Radiol Med (Torino)** 1996 Nov;92(5):581–7 (Eng. Abstr.) **(Ita)**

[The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group] Hirao Y, et al. **Hinyokika Kiyo** 1996 Oct; 42(10):795–804 (Eng. Abstr.) **(Jpn)**

[Adenocarcinoma of the bladder producing carcinoembryonic antigen and carbohydrate antigen 19-9: report of a case] Iwaki H, et al. **Hinyokika Kiyo** 1997 May; 43(5):355–8 (Eng. Abstr.) **(Jpn)**

[A case of prostate cancer diagnosed one and half year after retropubic prostatectomy for benign prostatic hypertrophy] Kato Y, et al. **Hinyokika Kiyo** 1996 Nov;42(11):907–9 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Early urachal carcinoma diagnosed by magnetic resonance imaging: a case report] Suzuki K, et al. **Hinyokika Kiyo** 1997 Jan;43(1):57–9 (Eng. Abstr.) **(Jpn)**

[Prostatic cancer with cystic formation: a case report] Takayama H, et al. **Hinyokika Kiyo** 1996 Dec;42(12):977–80 (7 ref.) (Eng. Abstr.) **(Jpn)**

[A case of lung adenocarcinoma: detection and resection of the metastatic lesion was managed effectively by serum CEA level] Hiyoshi H, et al. **Kyobu Geka** 1996 Sep; 49(10):873–5 (Eng. Abstr.) **(Jpn)**

[Immunohistochemical study of androgen receptor in adenocarcinoma of the human prostatic cancer] Yoshikawa H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jul; 87(7):956–63 (Eng. Abstr.) **(Jpn)**

[Rapid progression of adenocarcinoma of the lung in a patient with high levels of granulocyte colony-stimulating factor] Tomizawa Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Nov; 34(11):1249–54 (Eng. Abstr.) **(Jpn)**

[Early gastric cancer] Tada M, et al. **Nippon Rinsho** 1996 May;54(5):1371–4 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis of Epstein-Barr virus-associated gastric carcinoma and its background gastric mucosa] Yanai H, et al. **Nippon Rinsho** 1997 Feb;55(2):374–80 (31 ref.) (Eng. Abstr.) **(Jpn)**

[The expression of c-myc protein in uterine cervical cancer: a possible prognostic indicator] Wu HJ. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jul;48(7):515–21 (Eng. Abstr.) **(Jpn)**

[A case of early rectal cancer with the sign of Leser-Trélat] Hattori M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Nov;93(11):841–4 **(Jpn)**

[A 64-year-old woman with severe headache and progressive disturbance of consciousness (clinical conference)] Ito T, et al. **No To Shinkei** 1997 Jun; 49(6):571–81 (Eng. Abstr.) **(Jpn)**

[Paraneoplastic cerebellar degeneration. A case report] Storstein A, et al. **Tidsskr Nor Laegeforen** 1997 Aug 30; 117(20):2947–8 (Eng. Abstr.) **(Nor)**

[Stomach cancer. A 10-year material with emphasis on early cancer] Wasmuth HH, et al. **Tidsskr Nor Laegeforen** 1997 Mar 10;117(7):931–4 (Eng. Abstr.) **(Nor)**

[Early adenocarcinoma of the duodenum--report of a case] Jukemura J, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Nov–Dec;51(6):258–60 (Eng. Abstr.) **(Por)**

[Diagnostic and treatment problems in primary malignant tumors of the small intestine] Angelescu N, et al. **Chirurgia (Bucur)** 1996 Nov–Dec;45(6):285–8 (Eng. Abstr.) **(Rum)**

[Choledochal cyst in adults and cancer of the biliary tract] Târcoveanu E, et al. **Chirurgia (Bucur)** 1997 Mar–Apr; 92(2):121–8 (8 ref.) (Eng. Abstr.) **(Rum)**

[Clinical significance of tumor markers CYFRA 21-1 and neuron-specific enolase in lung cancer] Kushlinskii NE, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):98–100 **(Rus)**

[A case of synchronous cancer of the stomach and colon] Sheptulin AA, et al. **Klin Med (Mosk)** 1996;74(9):64–6 **(Rus)**

[Magnetic resonance tomography for the detection and staging of kidney cancer] Otvetchikov IN, et al. **Urol Nefrol (Mosk)** 1996 Jul–Aug;(4):9–14 (Eng. Abstr.) **(Rus)**

[Incidental prostatic adenocarcinoma in the ere of the PSA] Picurelli Oltra L, et al. **Actas Urol Esp** 1997 Apr; 21(4):354–6 (Eng. Abstr.) **(Spa)**

[Incidental versus clinical renal adenocarcinoma: comparative study (1970–1994)] Vega Vega A, et al. **Actas Urol Esp** 1996 Jul–Aug;20(7):605–13 (29 ref.) (Eng. Abstr.) **(Spa)**

[Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA] Rodríguez Rodríguez R, et al. **Arch Esp Urol** 1997 May;50(4):333–8 (Eng. Abstr.) **(Spa)**

[Clinical utility of available diagnostic tests in prostatic carcinoma.Results of 500 biopsies. II. Rectal palpation, PSA, and transrectal echography] Rodríguez Rodríguez R, et al. **Arch Esp Urol** 1997 May;50(4):339–45 (Eng. Abstr.) **(Spa)**

[Neuroendocrine carcinoma of the ampullar region with oat-cell histological features and adenocarcinoma] Fresno MF, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):60–4 (24 ref.) (Eng. Abstr.) **(Spa)**

[Duodenal bulb adenocarcinoma presenting as a refractory bulbar ulcer (letter)] Guilarte López-Mañas J, et al. **Rev Esp Enferm Dig** 1997 Jun;89(6):490–1 **(Spa)**

[Angiosarcoma of the spleen (letter)] Marín Pérez-Tabernero A, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):70–1 **(Spa)**

[Gallbladder cancer: immunohistochemical expression of the protein related to estrogen receptor (p29) and of the protein induced by estrogen (pS2)] Roa I, et al. **Rev Med Chil** 1995 Nov;123(11):1333–40 (Eng. Abstr.) **(Spa)**

[Brain miliary metastases secondary to a renal adenocarcinoma (letter; comment)] Arjona A, et al. **Rev Neurol** 1996 Oct;24(134):1305–6. Comment on: Rev Neurol 1996 Mar;24(127):352–3. **(Spa)**

DRUG THERAPY

Effect of low dose cyclophosphamide on the synthesis of acute phase protein and its significance for cancer chemotherapy. Iwagaki H, et al. **Acta Med Okayama** 1996 Oct;50(5):271–2

Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma. Colleoni M, et al. **Am J Clin Oncol** 1997 Jun;20(3):303–7

Phase II study of ZD1694 in patients with advanced gastric cancer. Meropol NJ, et al. **Am J Clin Oncol** 1996 Dec; 19(6):628–30

Megestrol acetate in the treatment of hormone refractory prostate cancer. Osborn JL, et al. **Am J Clin Oncol** 1997 Jun;20(3):308–10

A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate. Pienta KJ, et al. **Am J Clin Oncol** 1996 Oct;19(5):500–3

Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Sparano JA, et al. **Am J Clin Oncol** 1996 Dec;19(6):546–51

Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin. Sporn JR, et al. **Am J Clin Oncol** 1997 Feb;20(1):81–3

Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703). Thomas CR Jr, et al. **Am J Clin Oncol** 1997 Apr;20(2):161–5

A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program Trial. Vaughn DJ, et al. **Am J Clin Oncol** 1997 Jun;20(3):242–6

Secondary acute myelogenous leukemia following treatment with oral etoposide [letter] Katato K, et al. **Am J Hematol** 1996 Sep;53(1):54–5

5-Fluorouracil continuous infusion in metastatic colorectal cancer. Tan EH, et al. **Ann Acad Med Singapore** 1996 Sep; 25(5):748–51

A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Braybrooke JP, et al. **Ann Oncol** 1997 Mar;8(3):294–6

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group [published erratum appears in Ann Oncol 1997 Apr;8(4):407] Cunningham D, et al. **Ann Oncol** 1996 Nov;7(9):961–5

5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. Kok TC, et al. **Ann Oncol** 1996 Jul;7(5):533–4

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer [see comments]

Rothenberg ML, et al. **Ann Oncol** 1996 Apr;7(4):347–53. Comment in: Ann Oncol 1996 Apr;7(4):333–4. Comment in: Ann Oncol 1996 Apr;7(4):335–7.

Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Nakajima T, et al. **Ann Surg Oncol** 1997 Apr–May;4(3):203–8

Photodynamic therapy for esophageal malignancy: a prospective twelve-year study. McCaughan JS Jr, et al. **Ann Thorac Surg** 1996 Oct;62(4):1005–9; discussion 1009–10

c-erbB-2/p185-directed therapy in human lung adenocarcinoma. Snider JM, et al. **Ann Thorac Surg** 1996 Nov;62(5):1454–9

Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Pei XH, et al. **Anticancer Drugs** 1997 Mar;8(3):231–7

Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. Punt CJ, et al. **Anticancer Drugs** 1997 Jun;8(5):454–8

Advanced colorectal carcinoma: redefining the role of oral ftorafur. Ron IG, et al. **Anticancer Drugs** 1996 Aug; 7(6):649–54

Taxane sensitivity of ovarian carcinoma in vitro. Engblom P, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2475–9

Multidisciplinary treatment with anthracyclines in inflammatory breast cancer. Iino Y, et al. **Anticancer Res** 1996 Sep–Oct;16(5B):3111–5

Paclitaxel and N-methylformamide: in vitro interactions in human colon cancer cell line. Valenti AM, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2491–7

Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents. Villa R, et al. **Anticancer Res** 1997 Mar–Apr;17(2A):961–8

Conjugated linoleic acid suppresses the growth of human breast adenocarcinoma cells in SCID mice. Visonneau S, et al. **Anticancer Res** 1997 Mar–Apr;17(2A):969–73

Prevention of hepatic metastases by liver lectin blocking with D-galactose in colon cancer patients. A prospectively randomized clinical trial. Warczynski P, et al. **Anticancer Res** 1997 Mar–Apr;17(2B):1223–6

Observations with an S-adenosylmethionine decarboxylase inhibitor in rats with prostatic adenocarcinoma. Seiler N, et al. **Arzneimittelforschung** 1996 Mar;46(3):311–5

Oestrogen increases S-phase fraction and oestrogen and progesterone receptors in human cervical cancer in vivo. Bhattacharya D, et al. **Br J Cancer** 1997;75(4):554–8

Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Burger AM, et al. **Br J Cancer** 1996 Nov;74(9):1369–74

Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells. Courage C, et al. **Br J Cancer** 1996 Oct;74(8):1199–205

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. Goey SH, et al. **Br J Cancer** 1996 Dec; 74(12):2018–23

Modulation of sensitivity to cis-diamminedichloroplatinum (II) by thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines. Kasahara K, et al. **Br J Cancer** 1996 Nov;74(10):1553–8

Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Prott FJ, et al. **Br J Cancer** 1997;75(4):597–601 (29 ref.)

A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. Rigg A, et al. **Br J Cancer** 1997;75(1):101–5

In vivo anti-tumour effect of 3'-sulphonoquinovosyl 1'-monoacylglyceride isolated from sea urchin (Strongylocentrotus intermedius) intestine. Sahara H, et al. **Br J Cancer** 1997;75(3):324–32

Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours. Sargent JM, et al. **Br J Cancer** 1996 Dec;74(11):1730–3

Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Schneider HJ, et al. **Br J Cancer** 1997; 75(3):427–31

Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Theyer G, et al. **Br J Cancer** 1997;75(10):1515–8

The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Béhar A, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):653–8

Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Beerblock K, et al. **Cancer** 1997 Mar 15;79(6):1100–5

Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Chung YS, et al. **Cancer** 1997 Jul 1; 80(1):1–7

Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Crookes P, et al. **Cancer** 1997 May 1;79(9):1767–75

Vinblastine, ifosfamide, and gallium nitrate--an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892). Dreicer R, et al. **Cancer** 1997 Jan 1;79(1):110–4

Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma. Figg WD, et al. **Cancer** 1997 May 15;79(10):1964–8

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Gebbia V, et al. **Cancer** 1996 Sep 15;78(6):1300–7

Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma. Hejna M, et al. **Cancer** 1996 Oct 15;78(8):1646–50

Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Ishii H, et al. **Cancer** 1997 Apr 15;79(8):1516–20

Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Kim YB, et al. **Cancer** 1997 Jan 15;79(2):320–7 (38 ref.)

Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. Poplin EA, et al. **Cancer** 1996 Nov 1;78(9):1851–6

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Schellhammer PF, et al. **Cancer** 1996 Nov 15;78(10):2164–9

A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Spiridonidis CH, et al. **Cancer** 1996 Nov 15;78(10):2070–7

Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Tournigand C, et al. **Cancer** 1997 Mar 15;79(6):1094–9

Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells. Poulain L, et al. **Cancer Chemother Pharmacol** 1997;40(5):385–90

Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas. Van Laar JA, et al. **Cancer Chemother Pharmacol** 1996;39(1-2):79–89

A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. Dreicer R, et al. **Cancer Invest** 1997;15(4):311–7

Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus [see comments] Forastiere AA, et al. **Cancer J Sci Am** 1997 May–Jun;3(3):144–52. Comment in: Cancer J Sci Am 1997 May–Jun;3(3):137–9.

The Annonaceous acetogenin bullatacin is cytotoxic against multidrug-resistant human mammary adenocarcinoma cells. Oberlies NH, et al. **Cancer Lett** 1997 May 1; 115(1):73–9

Sulindac sulfide inhibits the proliferation of colon cancer cells: diminished expression of the proliferation markers PCNA and Ki-67. Qiao L, et al. **Cancer Lett** 1997 May 19;115(2):229–34

Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination. Adam L, et al. **Cancer Res** 1997 Mar 15;57(6):1023–9

A permanently charged tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents. Biegon A, et al. **Cancer Res** 1996 Oct 1; 56(19):4328–31

In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Fink D, et al. **Cancer Res** 1997 May 15;57(10):1841–5

DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Matsui SI, et al. **Cancer Res** 1996 Oct 15; 56(20):4715–23

GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Miquel K, et al. **Cancer Res** 1997 May 15;57(10):1846–50

The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Seed MP, et al. **Cancer Res** 1997 May 1;57(9):1625–9

Adjuvant hyperthermic intraperitoneal chemotherapy for adenocarcinoma of the pancreas. Ettinghausen SE, et al. **Cancer Treat Res** 1996;81:227–37 (69 ref.)

Toxicity of chemotherapy for esophageal carcinoma. Ilson D. **Chest Surg Clin N Am** 1997 Aug;7(3):551–63; discussion 564 (49 ref.)

Exploration for drug therapy in endometrial carcinoma. Zhang X, et al. **Chin Med J (Engl)** 1996 May;109(5):356–60

Interstitial pneumonitis as a late complication of high dose therapy with cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast. Mahendra P, et al. **Clin Oncol (R Coll Radiol)** 1996; 8(3):198–200

Combined therapy with Ukrain and chemotherapy in ovarian cancer (case report). Lohninger A, et al. **Drugs Exp Clin Res** 1996;22(3-5):259–62

A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. Chao D, et al. **Eur J Cancer** 1997 Jul;33(8):1230–3

Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. Comella P, et al. **Eur J Cancer** 1996 Sep;32A(10):1719–26

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. de Gramont A, et al. **Eur J Cancer** 1997 Feb;33(2):214–9

Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma [letter] Gebbia N, et al. **Eur J Cancer** 1996 Sep;32A(10):1822–3

Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma [letter] Raymond E, et al. **Eur J Cancer** 1997 Apr;33(4):696–7

The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis. van der Wall E, et al. **Eur J Cancer** 1996 Aug;32A(9):1490–7

Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study. Wagener DJ, et al. **Eur J Cancer** 1996 Jul;32A(8):1310–3

Cis-platinum chemotherapy after surgical treatment for bilateral adenocarcinoid of the ovary. Case report. Azzena A, et al. **Eur J Gynaecol Oncol** 1997;18(2):130–2

Weekly cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer: a well-tolerated alternative. Giardina G, et al. **Eur J Gynaecol Oncol** 1997;18(3):173–6

Sclerosis of lytic metastatic bone lesions during treatment with pamidronate in a patient with adenocarcinoma of unknown primary site. Tanaka M, et al. **Eur Spine J** 1996; 5(3):198–200

The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer. Chao D, et al. **Eur Urol** 1997;31(1):7–10

Prognostic significance of prostate-specific antigen levels two months after hormonal manipulation of metastatic prostate cancer. Kawakami S, et al. **Eur Urol** 1997; 32(1):58–63

Effects of neoadjuvant androgen deprivation therapy on prostatic cancer. Polito M, et al. **Eur Urol** 1996;30 Suppl 1:26–31; discussion 38–9

A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Thorpe SC, et al. **Eur Urol** 1996;29(1):47–54

Progress in treating esophageal adenocarcinoma. Shanahan F, et al. **Gastroenterology** 1997 Apr;112(4):1417–8

Adenocarcinoma arising from a mature cystic teratoma of the ovary: a case report of successful treatment with cisplatin-based chemotherapy. Nasu K, et al. **Gynecol Obstet Invest** 1996;41(2):143–6

Decrease in tumor volume and histologic response to intraarterial neoadjuvant chemotherapy in patients with cervical and endometrial adenocarcinoma. Fujiwaki R, et al. **Gynecol Oncol** 1997 May;65(2):258–64

Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma. Pierga JY, et al. **Gynecol Oncol** 1997 Aug;66(2):246–9

A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Rose PG, et al. **Gynecol Oncol** 1996 Oct;63(1):101–4

A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Sutton GP, et al. **Gynecol Oncol** 1996 Oct;63(1):25–7

Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma. Zanetta G, et al. **Gynecol Oncol** 1997 Mar; 64(3):431–5

The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas. Horimi T, et al. **Hepatogastroenterology** 1996 Sep–Oct;43(11):1225–9

Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Yonemura Y, et al. **Hepatogastroenterology** 1996 Sep–Oct; 43(11):1260–72

Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: a report of two cases. Mai KT, et al. **Hum Pathol** 1996 Dec;27(12):1377–81

Low-dose heparin treatment does not inhibit SW480 human colon cancer growth and metastasis in vivo. Antachopoulos CT, et al. **In Vivo** 1996 Sep–Oct;10(5):527–31

The effect of toremifene on the expression of genes in a rat mammary adenocarcinoma. Kellen JA, et al. **In Vivo** 1996 Sep–Oct;10(5):511–3

The effect of high dose vitamin A on the morphology and proliferative activity of xenograft lung and head and neck cancer. Mourad WA, et al. **In Vivo** 1996 May–Jun; 10(3):329–33

Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Endo K, et al. **Int J Cancer** 1996 Nov 4;68(3):372–7

Effect of angiogenesis inhibitor TNP-470 on the progression

of human gastric cancer xenotransplanted into nude mice. **Kanai T, et al. Int J Cancer** 1997 May 29;71(5):838–41

Hypofractionated radiotherapy with concurrent 5–fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. **Skarlatos J, et al. Int J Colorectal Dis** 1996;11(5):206–10

P–glycoprotein as a prognostic indicator in pre– and postchemotherapy ovarian adenocarcinoma. **Khalifa MA, et al. Int J Gynecol Pathol** 1997 Jan;16(1):69–75

"Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: impact of treatment intensity on local control and survival. **Chan AK, et al. Int J Radiat Oncol Biol Phys** 1997 Feb 1;37(3):629–37

A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92–07): preliminary toxicity report. **Gaspar LE, et al. Int J Radiat Oncol Biol Phys** 1997 Feb 1;37(3):593–9

Antitumor diarylsulfonylureas: novel agents with unfulfilled promise. **Houghton PJ, et al. Invest New Drugs** 1996; 14(3):271–80 (34 ref.)

Efficacy of HMAF (MGI–114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. **Kelner MJ, et al. Invest New Drugs** 1996; 14(2):161–7

An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group. **Leaf AN, et al. Invest New Drugs** 1997;15(2):165–72

Phase II trial of low–dose N–(phosphonacetyl)–disodium L–aspartic acid and high–dose 24–hour infusional 5–fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study. **Martino RL, et al. Invest New Drugs** 1996;14(4):419–21

A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma. **Miller KD, et al. Invest New Drugs** 1996;14(2):207–12

Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. **Scher RM, et al. Invest New Drugs** 1996;13(4):347–54

NF00659A1, A2, A3, B1 and B2, novel antitumor antibiotics produced by Aspergillus sp. NF 00659. I. Taxonomy, fermentation, isolation and biological activities. **Suzuki K, et al. J Antibiot (Tokyo)** 1997 Apr;50(4):314–7

Immunocytochemical detection of P–glycoprotein in the management of malignant effusions. **Athanassiadou P, et al. J Cancer Res Clin Oncol** 1997;123(8):456–60

Suramin/epidoxorubicin association in hormone–refractory prostate cancer: preliminary results of a pilot phase II study. **Miglietta L, et al. J Cancer Res Clin Oncol** 1997; 123(7):407–10

Phase II trial of 96–hour paclitaxel plus oral estramustine phosphate in metastatic hormone–refractory prostate cancer. **Hudes GR, et al. J Clin Oncol** 1997 Sep; 15(9):3156–63

Phase II trial of 9–aminocamptothecin administered as a 72–hour continuous infusion in metastatic colorectal carcinoma. **Pazdur R, et al. J Clin Oncol** 1997 Aug; 15(8):2905–9

Phase III trial of androgen suppression using goserelin in unfavorable–prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. **Pilepich MV, et al. J Clin Oncol** 1997 Mar;15(3):1013–21

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. **Pitot HC, et al. J Clin Oncol** 1997 Aug;15(8):2910–9

Mutational activation of the K–ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. **Rodenhuis S, et al. J Clin Oncol** 1997 Jan;15(1):285–91

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. **Spitz FR, et al. J Clin Oncol** 1997 Mar;15(3):928–37 (44 ref.)

Adjuvant postoperative fluorouracil–modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. **Tepper JE, et al. J Clin Oncol** 1997 May;15(5):2030–9

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. **Webb A, et al. J Clin Oncol** 1997 Jan;15(1):261–7

Phase II trial of paclitaxel and granulocyte colony–stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. **Whitehead RP, et al. J Clin Oncol** 1997 Jun;15(6):2414–9

Dual modulation of 5–fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. **de Gramont A, et al. J Infus Chemother** 1996 Spring;6(2):97–101

The French experience with infusional 5–FU in gastric and pancreatic cancer. **Ducreux M, et al. J Infus Chemother** 1996 Fall;6(4):203–5

The dead end of 5–fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer. **Köhne CH, et al. J Infus Chemother** 1996 Fall;6(4):206–10 (31 ref.)

Intermittent continuous infusion of 5–fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity. **Poorter RL, et al. J Infus Chemother** 1996 Spring;6(2):87–91

Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL–12) or other cytokines compared with exogenous IL–12. **Cavallo F, et al. J Natl Cancer Inst** 1997 Jul 16;89(14):1049–58

PET 2–fluoro–2–deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. **Haberkorn U, et al. J Nucl Med** 1997 Aug;38(8):1215–21

Influence of chemotherapy on FDG uptake by human cancer xenografts in nude mice. **Yoshioka T, et al. J Nucl Med** 1997 May;38(5):714–7

Exacerbation of rheumatoid arthritis after termination of chemotherapy for breast carcinoma. **Rosenstein ED, et al. J Rheumatol** 1996 Nov;23(11):1988–90

Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer. **Içli F, et al. J Surg Oncol** 1997 Apr; 64(4):318–23

Effect of preoperative 5–fluorouracil on apoptosis of advanced gastric cancer. **Inada T, et al. J Surg Oncol** 1997 Jun;65(2):106–10

Side effects and photosensitization of human tissues after aminolevulinic acid. **Webber J, et al. J Surg Res** 1997 Feb 15;68(1):31–7

Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not? **Drew PA, et al. J Urol** 1997 Jun;157(6):2201–5

Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer. **Kyriakakis Z, et al. J Urol** 1997 Aug;158(2):408–11

Lentinan enhances sensitivity of mouse colon 26 tumor to cis–diamminedichloroplatinum (II) and decreases glutathione transferase expression. **Murata T, et al. Jpn J Cancer Res** 1996 Nov;87(11):1171–8

In vivo anti–tumor efficacy of polyethylene glycol–modified tumor necrosis factor–alpha against tumor necrosis factor–resistant tumors. **Tsutsumi Y, et al. Jpn J Cancer Res** 1996 Oct;87(10):1078–85

A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics. **Boku N, et al. Jpn J Clin Oncol** 1996 Oct;26(5):379–83

Mitomycin–C induced hemolytic uremic syndrome: a case report and literature review. **Wu DC, et al. Jpn J Clin Oncol** 1997 Apr;27(2):115–8 (27 ref.)

Subacute encephalopathic toxicity of cisplatin. **Verschraegen C, et al. Lung Cancer** 1995 Dec;13(3):305–9 (13 ref.)

In vivo and ex vivo study of metabolic and cellular effects of 5–fluorouracil chemotherapy in a mouse mammary carcinoma. **Street JC, et al. Magn Reson Imaging** 1997; 15(5):587–96

Phytoestrogens and prostate cancer: possible preventive role. **Stephens FO. Med J Aust** 1997 Aug 4;167(3):138–40

Gemcitabine for treatment of pancreatic cancer. **Med Lett Drugs Ther** 1996 Nov 8;38(987):102

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. **Einzig AI, et al. Med Oncol** 1996 Jun; 13(2):87–93

How to optimize the effect of 5–fluorouracil modulated therapy in advanced colorectal cancer. **Ragnhammar P, et al. Med Oncol** 1995 Sep;12(3):187–201 (137 ref.)

Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF–beta 1 in a rat orthotopic prostate adenocarcinoma. **Lievano G, et al. Methods Find Exp Clin Pharmacol** 1997 May; 19(4):261–7

Intrapericardial administration of cisplatin in treatment of metastatic pericardial involvement in adenocarcinoma of the lung. **Tomkowski WZ, et al. Monaldi Arch Chest Dis** 1997 Jun;52(3):221–4

Prostate cancer—the therapeutic challenge of locally advanced disease [editorial; comment] **Blasko JC, et al. N Engl J Med** 1997 Jul 31;337(5):340–1. Comment on: N Engl J Med 1997 Jul 31;337(5):295–300.

Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [see comments] **Bolla M, et al. N Engl J Med** 1997 Jul 31; 337(5):295–300. Comment in: N Engl J Med 1997 Jul 31;337(5):340–1.

Gemcitabine: a ray of hope for pancreatic cancer? **Gupta P. Natl Med J India** 1997 Mar–Apr;10(2):72–3

Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. **Feliu J, et al. Oncology** 1997;54 Suppl 1:30–7

Inhibitory effect of the somatostatin analogue SMS 201–995 and cytokines on the proliferation of human colon adenocarcinoma cell lines. **di Paolo A, et al. Pharmacol Res** 1995 Sep;32(3):135–9

Effect of turosteride, a 5 alpha–reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. **Zaccheo T, et al. Prostate** 1997 Feb 1;30(2):85–91

Factors influencing outcome following radio–chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG) [see comments] **Denham JW, et al. Radiother Oncol** 1996 Jul;40(1):31–43. Comment in: Radiother Oncol 1997 Jan;42(1):91–2.

Chemotherapy for patients with adenocarcinoma of the pancreas. **Riess H, et al. Recent Results Cancer Res** 1996; 142:415–24 (39 ref.)

Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. **Ajani JA, et al. Semin Oncol** 1996 Oct;23(5 Suppl 12):55–8

An ongoing European organization for research and treatment of cancer crossover trial comparing single–agent paclitaxel and doxorubicin as first– and second–line treatment of advanced breast cancer. **Piccart–Gebhart MJ, et al. Semin Oncol** 1996 Oct;23(5 Suppl 11):11–5

Paradoxical clinical deterioration despite near–complete pathological response to neoadjuvant chemotherapy for locally advanced gastro–oesophageal adenocarcinoma. **Windsor AC, et al. Surg Oncol** 1995;4(5):277–9

Small intestinal cancer with extensive lymph node metastases showing complete remission by methotrexate/5–fluorouracil sequential therapy: report of a case. **Onodera H, et al. Surg Today** 1997;27(1):60–3

Dehydroepiandrosterone–sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo. **Melvin WS, et al. Surgery** 1997 Apr;121(4):392–7

Indomethacin enhances the cytotoxicity of VCR and ADR in human pulmonary adenocarcinoma cells. **Kobayashi S, et al. Tohoku J Exp Med** 1997 Mar;181(3):361–70

5–Fluorouracil prodrug, ftorafur, modulated by uracil (UFT): preclinical and clinical prospective. **Cao S, et al. Tumori** 1997 Jan–Feb;83(1 Suppl):S90–3

Health–related quality of life among patients with metastatic prostate cancer. **Albertsen PC, et al. Urology** 1997 Feb; 49(2):207–16; discussion 216–7

Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. **Bazinet M, et al. Urology** 1997 May; 49(5):721–5

Finasteride and flutamide as potency–sparing androgen–ablative therapy for advanced adenocarcinoma of the prostate. **Brufsky A, et al. Urology** 1997 Jun; 49(6):913–20

Neoadjuvant hormonal therapy: the Canadian experience. **Labrie F, et al. Urology** 1997 Mar;49(3A Suppl):56–64

Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. **Reuter VE. Urology** 1997 Mar;49(3A Suppl):16–22 (31 ref.)

Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. **Zietman AL, et al. Urology** 1997 Mar;49(3A Suppl):74–83 (43 ref.)

[Regional and systemic neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri] **Baĭchev G, et al. Akush Ginekol (Sofiia)** 1996;35(4):17–8 (Eng. Abstr.) **(Bul)**

[The influence on prognosis of intraoperative chemotherapy for adenocarcinoma of gastric cardia] **Li Q, et al. Chung Hua Chung Liu Tsa Chih** 1996 Mar;18(2):137–9 (Eng. Abstr.) **(Chi)**

[ACNU and methyl–CCNU in combination chemotherapy for advanced gastric cancer: a randomized comparative study. Shanghai ACNU Collaborative Study Group] **Xiao S, et al. Chung Hua Chung Liu Tsa Chih** 1996 Jan;18(1):30–3 (Eng. Abstr.) **(Chi)**

[Preoperative intraluminal 5–FU osmosis chemotherapy as an adjuvant to radical resection for rectal cancer] **Lu J, et al. Chung Hua Wai Ko Tsa Chih** 1996 Jan;34(1):54–6 (Eng. Abstr.) **(Chi)**

[Hormonal therapy in the treatment of endometrial adenocarcinoma] **Rob L. Ceska Gynekol** 1996 Aug; 61(4):249–50 **(Cze)**

[Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer] **Patel H, et al. J Urol (Paris)** 1996;102(3):123–5 (12 ref.) (Eng. Abstr.) **(Fre)**

[Adjuvant treatment of colonic cancers] **Freyer G, et al. Presse Med** 1996 Sep 21;25(27):1241–6 (27 ref.) (Eng. Abstr.) **(Fre)**

[Effectiveness and tolerance of three month sustained release leuprorelin in the treatment of metastatic prostatic cancer (comparative, randomized, multicentric study] **Zerbib M, et al. Prog Urol** 1997 Apr;7(2):246–53 (Eng. Abstr.) **(Fre)**

[Results of adjuvant chemotherapy of operated high risk cervix carcinoma] **Dimpfl T, et al. Geburtshilfe Frauenheilkd** 1996 Oct;56(10):517–9 (Eng. Abstr.) **(Ger)**

[Downstaging of esophageal carcinoma after preoperative radio– and chemotherapy] **Staar S. Strahlenther Onkol** 1996 Dec;172(12):693–5 **(Ger)**

[The value of adjuvant and neoadjuvant chemotherapy in treatment of stomach carcinoma] **Ausch C, et al. Wien Klin Wochenschr** 1996;108(16):496–504 (50 ref.) (Eng. Abstr.) **(Ger)**

[Neoadjuvant combined hormonal therapy and radiotherapy with external beam irradiation in prostatic carcinoma] **Cellini N, et al. Radiol Med (Torino)** 1997 Apr;93(4):446–50 (Eng. Abstr.) **(Ita)**

[A case of Borrmann type 4 gastric cancer successfully treated with MTX and 5–FU therapy through the hepatic artery] **Gonda T, et al. Gan To Kagaku Ryoho** 1996 Sep; 23(11):1561–3 (Eng. Abstr.) **(Jpn)**

[Moderately differentiated adenocarcinoma of the rectum: a case report of remarkable response to preoperative administration of FT suppository] **Izumi M, et al.**

Gan To Kagaku Ryoho 1997 Aug;24(10):1321–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical analysis of adjuvant chemotherapy using 5–fluorouracil, leucovorin and cis–diamminedichloroplatinum for patients with advanced and recurrent gastric cancer] Katsumata K, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):309–14 (Eng. Abstr.) **(Jpn)**

[Arterial infusion chemotherapy for advanced gastric cancer by sequential MTX/5–FU] Kitamura M, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1464–6 (Eng. Abstr.) **(Jpn)**

[A two–year asymptomatic case with postoperative lung metastasis of sigmoid colon cancer responding to sequential methotrexate and 5–fluorouracil] Kitao Y, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):613–7 (Eng. Abstr.) **(Jpn)**

[A case of inoperable advanced gastric cancer remarkably responding to combined chemotherapy with UFT–E, MMC and PSK] Kogure A, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):875–8 (Eng. Abstr.) **(Jpn)**

[Neoadjuvant chemotherapy in high–grade advanced gastric cancer with protracted infusional 5–fluorouracil and consecutive low–dose cisplatin] Kondo K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1299–303 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for peritoneal dissemination in gastric cancer under ureteral catheterization] Kubo Y, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1951–7 (Eng. Abstr.) **(Jpn)**

[Successful UFT–E granule and 5–FUCDDP combination therapy for an unresectable advanced gastric cancer complicated with liver metastasis] Kushibiki K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1313–5 (Eng. Abstr.) **(Jpn)**

[Secondary hepatic resections in a case of sigmoid colon cancer with multiple liver metastasis (H3) after successful continuous hepatic artery infusion chemotherapy oriented by in vitro chemosensitivity test] Miura M, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):1031–4 (Eng. Abstr.) **(Jpn)**

[A randomized comparative study of surgical adjuvant chemotherapy using 5–fluorouracil and dl–leucovorin with CDDP 5–FU and dl–leucovorin for colorectal cancer] Okabo S, et al. **Gan To Kagaku Ryoho** 1997 May; 24(7):849–54 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer with multiple liver metastasis successfully treated with combination chemotherapy using UFT, CDDP and etoposide] Ono T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1709–12 (Eng. Abstr.) **(Jpn)**

[Combination chemotherapy of continuous infusion 5–fluorouracil and daily low–dose cisplatin in advanced gastrointestinal and lung adenocarcinoma] Sasaki K, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):959–64 (Eng. Abstr.) **(Jpn)**

[Sequential methotrexate and 5–fluorouracil] Sasaki T. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1907–10 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Two cases of advanced gastric cancer effectively treated with chemotherapy of 5–fluorouracil, cisplatin and cytarabine] Satoh T, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):879–82 (Eng. Abstr.) **(Jpn)**

[A case of advanced colon cancer with marked response to combination chemotherapy with 5–FU, low dose CDDP, and leucovorin] Takayanagi N, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):357–60 (Eng. Abstr.) **(Jpn)**

[Combination therapy with 5'–DFUR, MMC and CDDP in patient with far advanced gastric cancer: report of a case] Tomita H, et al. **Gan To Kagaku Ryoho** 1997 Aug; 24(10):1311–4 (Eng. Abstr.) **(Jpn)**

[Pyrimidine nucleoside phosphorylase activity, 5–fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'–doxifluridine] Tomoda H, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):971–4 (Eng. Abstr.) **(Jpn)**

[A pilot study of low dose etoposide therapy for recurrenced prostate cancer in complicated over 75 years old stage D2 cases] Wada T, et al. **Gan To Kagaku Ryoho** 1996 Nov; 23(13):1851–4 **(Jpn)**

[Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment] Yamada Y, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1335–40 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature] Yamazaki N. **Gan To Kagaku Ryoho** 1997 Jan;24(1):30–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment of clinically localized prostatic cancer––endocrine therapy] Hirano A. **Hinyokika Kiyo** 1996 Oct;42(10):829–32 (Eng. Abstr.) **(Jpn)**

[Total androgen blockade for prostate cancer] Kagebayashi Y, et al. **Hinyokika Kiyo** 1997 Mar;43(3):197–201 (Eng. Abstr.) **(Jpn)**

[Luteinizing hormone–releasing hormone for prostate cancer in a hemodialysis patient: a case report] Mizusawa H, et al. **Hinyokika Kiyo** 1997 Jun;43(6):421–3 (Eng. Abstr.) **(Jpn)**

[Ethanol injection therapy to the lung cancer] Masaki Y, et al. **Kyobu Geka** 1997 May;50(5):384–8 (Eng. Abstr.) **(Jpn)**

[Immunohistochemical study of androgen receptor in adenocarcinoma of the human prostatic cancer] Yoshikawa H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jul; 87(7):956–63 (Eng. Abstr.) **(Jpn)**

[A long surviving case of carcinoma of the common hepatic duct treated by chemotherapy with CDDP in the percutaneous external biliary tube and endoprosthesis] Yamashina T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Dec;93(12):927–31 **(Jpn)**

[Effects of biochemical modulation chemotherapy with CDDP and 5–FU on metastatic brain tumor from lung cancer] Nakagawa H, et al. **No Shinkei Geka** 1997 Mar; 25(3):215–23 (39 ref.) (Eng. Abstr.) **(Jpn)**

[The chemotherapy of metastases of unknown origin] Shparyk IaV, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):45–52 (51 ref.) **(Ukr)**

ECONOMICS

Advanced colorectal carcinoma: redefining the role of oral ftorafur. Ron IG, et al. **Anticancer Drugs** 1996 Aug; 7(6):649–54

ENZYMOLOGY

Expression of ALDH3 and NMO1 in human corneal epithelial and breast adenocarcinoma cells. Marks–Hull H, et al. **Adv Exp Med Biol** 1997;414:59–68

Telomerase activity in human urothelial tumors [see comments] Kyo S, et al. **Am J Clin Pathol** 1997 May; 107(5):555–60. Comment in: Am J Clin Pathol 1997 May;107(5):505.

N–acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Oyama T, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):577–81

Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Oyama T, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):583–7

Bidirectional regulation of telomerase activity in a subline derived from human lung adenocarcinoma. Katakura Y, et al. **Biochem Biophys Res Commun** 1997 Aug 18; 237(2):313–7

Analysis of expression and promoter function of the human inducible nitric oxide synthase gene in DLD–1 cells and monkey hepatocytes. Laubach VE, et al. **Biochim Biophys Acta** 1997 Apr 10;1351(3):287–95

Identification and purification of Ca2+/calmodulin–dependent protein kinase V from human gastric carcinoma. Ohta H, et al. **Biochim Biophys Acta** 1996 Dec 16;1317(3):175–82

Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer. Escot C, et al. **Breast Cancer Res Treat** 1996;38(2):217–26

Immunohistochemical expression of pi–class glutathione S–transferase is down–regulated in adenocarcinoma of the prostate. Moskaluk CA, et al. **Cancer** 1997 Apr 15; 79(8):1595–9

Multienzyme–mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics. Rekha GK, et al. **Cancer Chemother Pharmacol** 1997; 40(3):215–24

Adenosine deaminase activity in patients with the intestinal type of gastric carcinoma. Namiot Z, et al. **Cancer Lett** 1996 Dec 3;109(1–2):199–202

Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma. Tanigawa N, et al. **Cancer Lett** 1996 Nov 29;108(2):281–90

Human apurinic endonuclease 1 expression in a colorectal adenoma–carcinoma sequence. Kakolyris S, et al. **Cancer Res** 1997 May 1;57(9):1794–7

Expression of cyclooxygenase–2 in human gastric carcinoma. Ristimäki A, et al. **Cancer Res** 1997 Apr 1;57(7):1276–80

Blockade of the stimulatory effect of estrogens, OH–tamoxifen, OH–toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM–800 in human endometrial adenocarcinoma Ishikawa cells. Simard J, et al. **Cancer Res** 1997 Aug 15;57(16):3494–7

Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Takahashi M, et al. **Cancer Res** 1997 Apr 1;57(7):1233–7

Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Thomsen LL, et al. **Cancer Res** 1997 Aug 1; 57(15):3300–4

Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c–Src. Staley CA, et al. **Cell Growth Differ** 1997 Mar; 8(3):269–74

Alterations of glycosidases in human colonic adenocarcinoma. Gil–Martín E, et al. **Clin Biochem** 1997 Feb;30(1):17–25

Chronic increased serum lipase in a patient with suspected pancreatic adenocarcinoma [letter] Muñoz–Perez M, et al. **Clin Chem** 1997 Jan;43(1):191–3

Enhanced urokinase–type plasminogen activator activity by extracellular matrix protein obtained from highly metastatic human lung adenocarcinoma cell line. Hagiya Y, et al. **Clin Chim Acta** 1996 Sep 30;253(1–2):37–50

A variant alkaline phosphatase–producing gastric carcinoma with super bone scan. Tokushima K, et al. **Dig Dis Sci** 1997 Jan;42(1):66–73

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas–adenocarcinomas. Tomita T, et al. **Dis Colon Rectum** 1996 Nov;39(11):1255–64

Differentiation of BCS–TC2 human colon adenocarcinoma cells by sodium butyrate: increase in 5'–nucleotidase activity. Navarro JM, et al. **Eur J Clin Invest** 1997 Jul; 27(7):620–8

Expression of the activated p185erbB2 tyrosine kinase in human epithelial cells leads to MAP kinase activation but does not confer oncogenicity. Nowak F, et al. **Exp Cell Res** 1997 Mar 15;231(2):251–9

Effects of cytotoxic drugs on translocation of nucleolar RNA helicase RH–II/Gu. Perlaky L, et al. **Exp Cell Res** 1997 Sep 15;235(2):413–20

N–Myristoyltransferase overexpression in human colorectal adenocarcinomas. Raju RV, et al. **Exp Cell Res** 1997 Aug 25;235(1):145–54

Expression of CuZn– and Mn–superoxide dismutase in human colorectal neoplasms. Van Driel BE, et al. **Free Radic Biol Med** 1997;23(3):435–44

Altered mRNA expression of specific molecular species of fucosyl– and sialyl–transferases in human colorectal cancer tissues. Ito H, et al. **Int J Cancer** 1997 May 16;71(4):556–64

Autoreactive epitopes within the human alpha–enolase and their recognition by sera from patients with endometriosis. Walter M, et al. **J Autoimmun** 1995 Dec;8(6):931–45

Quantitative measurement of heme oxygenase–1 in the human renal adenocarcinoma. Goodman AI, et al. **J Cell Biochem** 1996 Dec 1;63(3):342–8

Serial lectin affinity chromatography with concavalin A and wheat germ agglutinin demonstrates altered asparagine–linked sugar–chain structures of prostatic acid phosphatase in human prostate carcinoma. Yoshida KI, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1; 695(2):439–43

Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colon. Sato Y, et al. **J Gastroenterol** 1996 Feb;31(1):12–7

Phosphatidyl serine is involved in the reduced rate of transcription of the inducible nitric oxide synthase gene in macrophages from tumor–bearing mice. DiNapoli MR, et al. **J Immunol** 1997 Feb 15;158(4):1810–7

Overexpression of tissue inhibitors of metalloproteinase–1 and –2 in the stroma of gastric cancer. Hong SI, et al. **J Korean Med Sci** 1996 Dec;11(6):474–9

Development of oxygen insensitivity of the quantitative histochemical assay of G6PDH activity during colorectal carcinogenesis. Van Driel BE, et al. **J Pathol** 1997 Aug; 182(4):398–403

Immunohistochemical localization of insulin–degrading enzyme along the rat intestine, in the human colon adenocarcinoma cell line (Caco–2), and in human ileum. Chang LL, et al. **J Pharm Sci** 1997 Jan;86(1):116–9

Steroid sulphotransferase and 17beta–hydroxysteroid dehydrogenase activities in Ishikawa human endometrial adenocarcinoma cells. Chetrite G, et al. **J Steroid Biochem Mol Biol** 1997 Apr;61(1–2):27–34

Characterization of type I 5 alpha–reductase activity in DU145 human prostatic adenocarcinoma cells. Kaefer M, et al. **J Steroid Biochem Mol Biol** 1996 May;58(2):195–205

Influence of cathepsin D expression in lung adenocarcinoma on prognosis: possible importance of its expression in tumor cells and stromal cells, and its intracellular polarization in tumor cells. Higashiyama M, et al. **J Surg Oncol** 1997 May; 65(1):10–9

Evaluation of cathepsin D immunostaining in colorectal adenocarcinoma. Theodoropoulos GE, et al. **J Surg Oncol** 1997 Aug;65(4):242–8

Telomerase activity in primary prostate cancer. Lin Y, et al. **J Urol** 1997 Mar;157(3):1161–5

Lentinan enhances sensitivity of mouse colon 26 tumor to cis–diamminedichloroplatinum (II) and decreases glutathione transferase expression. Murata T, et al. **Jpn J Cancer Res** 1996 Nov;87(11):1171–8

Expression of interstitial collagenase (matrix metalloproteinase–1) in gastric cancers. Sakurai Y, et al. **Jpn J Cancer Res** 1997 Apr;88(4):401–6

Dose–dependent induction of both pepsinogen–altered pyloric glands and adenocarcinomas in the glandular stomach of C3H mice treated with N–methyl–N–nitrosourea. Yamamoto M, et al. **Jpn J Cancer Res** 1997 Mar;88(3):238–44

gamma–Glutamyl transpeptidase in normal and neoplastic prostate glands. Frierson HF Jr, et al. **Mod Pathol** 1997 Jan;10(1):1–6

Shortened telomere length and increased telomerase activity in hamster pancreatic duct adenocarcinomas and cell lines. Kobitsu K, et al. **Mol Carcinog** 1997 Mar;18(3):153–9

H–RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer. Wang XC, et al. **Mol Med** 1996 Mar;2(2):189–203

Location of 72–kd metalloproteinase (type IV collagenase) in untreated prostatic adenocarcinoma. Montironi R, et al. **Pathol Res Pract** 1995 Nov;191(11):1140–6

Expression of antioxidant enzymes in human prostatic adenocarcinoma. Baker AM, et al. **Prostate** 1997 Sep 1; 32(4):229–33

Coenzyme Q10 and colorectal neoplasms in aged patients.

Palazzoni G, et al. **Rays** 1997 Jan-Mar;22(1 Suppl):73-6

Increased levels of nm23 H1/nucleoside diphosphate kinase A mRNA associated with adenocarcinoma of the prostate. Jensen SL, et al. **World J Urol** 1996;14 Suppl 1:S21-5

[PyNPase activity in primary and metastatic colorectal cancer] Kameyama M, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):563-7 (Eng. Abstr.) **(Jpn)**

[A case of ectopic amylase-producing lung cancer] Nakao M, et al. **Kyobu Geka** 1996 Dec;49(13):1069-73 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Barrett's esophagus: does the incidence of adenocarcinoma matter? [editorial; comment] Cameron AJ. **Am J Gastroenterol** 1997 Feb;92(2):193-4. Comment on: Am J Gastroenterol 1997 Feb;92(2):212-5.

The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years [see comments] Drewitz DJ, et al. **Am J Gastroenterol** 1997 Feb;92(2):212-5. Comment in: Am J Gastroenterol 1997 Feb;92(2):193-4.

Sinonasal cancer and occupation. Results from the reanalysis of twelve case-control studies. Leclerc A, et al. **Am J Ind Med** 1997 Feb;31(2):153-65

Gastric adenocarcinoma in patients 40 years of age or younger. Theuer CP, et al. **Am J Surg** 1996 Nov; 172(5):473-6; discussion 476-7

Recent trends in the epidemiology of esophageal cancer. Comparison of epidermoid- and adenocarcinomas. Moyana TN, et al. **Ann Clin Lab Sci** 1996 Nov-Dec;26(6):480-6

Ethnic variations in lung cancer. Groeger AM, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2849-57

Increased incidence of second malignancies associated with small bowel adenocarcinoma. Ripley D, et al. **Can J Gastroenterol** 1997 Jan-Feb;11(1):65-8 (16 ref.)

Kidney cancer in Canada: the rapidly increasing incidence of adenocarcinoma in adults and seniors. Liu S, et al. **Can J Public Health** 1997 Mar-Apr;88(2):99-104

Incidence of colorectal adenocarcinoma by anatomic subsite. An epidemiologic study of time trends and racial differences in the Detroit, Michigan area. Demers RY, et al. **Cancer** 1997 Feb 1;79(3):441-7

Nutritional factors and prostate cancer: a case-control study of French Canadians in Montreal, Canada. Ghadirian P, et al. **Cancer Causes Control** 1996 Jul;7(4):428-36

Occupational exposure to magnetic fields in relation to male breast cancer and testicular cancer: a Swedish case-control study. Stenlund C, et al. **Cancer Causes Control** 1997 Mar; 8(2):184-91

Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Potter JD, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Oct;5(10):779-84

Increasing incidence of adenocarcinomas and carcinoid tumors of the small intestine in adults. Severson RK, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Feb;5(2):81-4

Relationship of food groups and water intake to colon cancer risk. Shannon J, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jul;5(7):495-502

Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. Zhang ZF, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Oct;5(10):761-8

Colorectal adenocarcinoma in a defined Jordanian population from 1990 to 1995. Al-Jaberi TM, et al. **Dis Colon Rectum** 1997 Sep;40(9):1089-94

Time trends in oesophageal cancer incidence in Côte d'Or (France), 1976-93. Liabeuf A, et al. **Eur J Cancer Prev** 1997 Feb;6(1):24-30

The age-related incidences of oesophageal carcinoma in intellectually disabled individuals in institutes in The Netherlands. Böhmer CJ, et al. **Eur J Gastroenterol Hepatol** 1997 Jun;9(6):589-92

Epidemiology of columnar-lined esophagus and adenocarcinoma. Cameron AJ. **Gastroenterol Clin North Am** 1997 Sep;26(3):487-94 (60 ref.)

Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites. Hansen S, et al. **Int J Cancer** 1997 May 2;71(3):340-4

Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand, 1978-1992. Armstrong RW, et al. **Int J Epidemiol** 1996 Oct;25(5):941-7

The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Charloux A, et al. **Int J Epidemiol** 1997 Feb;26(1):14-23 (100 ref.)

A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990. Chow JS, et al. **Int J Epidemiol** 1996 Aug;25(4):722-8

The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. Zheng T, et al. **Int J Epidemiol** 1996 Apr;25(2):252-8

Case report: a case of primary ileal carcinoma in a young woman and a review of the Japanese literature. Horiuchi A, et al. **J Gastroenterol Hepatol** 1997 Apr;12(4):349-51 (6 ref.)

Pancreatic adenocarcinoma: epidemiology and genetics. Flanders TY, et al. **J Med Genet** 1996 Nov;33(11):889-98 (121 ref.)

Changing incidence of invasive adenocarcinoma of the uterine cervix in East Anglia. Stockton D, et al. **J Med Screen** 1997;4(1):40-3

Malignant cytological washings from radical prostatectomy specimens: a possible mechanism for local recurrence of prostate cancer following surgical treatment of organ confined disease. Ward JF, et al. **J Urol** 1996 Oct; 156(4):1381-4; discussion 1384-5

The trends in histological types of lung cancer during 1980-1988, Guangzhou, China. Cha Q, et al. **Lung Cancer** 1997 Jul;17(2-3):219-30

International differences in epidemiology of lung adenocarcinoma. Charloux A, et al. **Lung Cancer** 1997 Mar; 16(2-3):133-43

Impact of filter cigarette smoking on lung cancer histology. Stellman SD, et al. **Prev Med** 1997 Jul-Aug;26(4):451-6

Medical factors in the morbidity and mortality associated with emergency colorectal cancer surgery. Tobaruela E, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):13-22 **(Eng, Spa)**

Epidemiology and molecular biology of Barrett's adenocarcinoma. Altorki NK, et al. **Semin Surg Oncol** 1997 Jul-Aug;13(4):270-80 (189 ref.)

Clinicopathological trends in colorectal carcinoma in a Black South African population. Degiannis E, et al. **Trop Gastroenterol** 1995 Oct-Dec;16(4):55-61

Is the incidence of primary adenocarcinoma of the lung increasing? Caldwell CJ, et al. **Virchows Arch** 1996 Dec; 429(6):359-63

[Symptoms, tumor stage and primary treatment in patients with colorectal carcinoma] Mezger J, et al. **Dtsch Med Wochenschr** 1997 May 30;122(22):703-8 (Eng. Abstr.) **(Ger)**

[Ovarian cancer in Israel, 1960-1989] Mor-Yosef S, et al. **Harefuah** 1997 Feb 2;132(3):153-5, 240 (Eng. Abstr.) **(Heb)**

[Clinical analysis of 683 prostatic cancer patients in the Tokai Urological Cancer Registry] Obata JK, et al. **Hinyokika Kiyo** 1996 Jul;42(7):503-7 (Eng. Abstr.) **(Jpn)**

[Risk of second primary cancer in two-year survivors of small cell lung cancer] Yoshida T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul;34(7):741-6 (Eng. Abstr.) **(Jpn)**

[Incidence of synchronous or metachronous multiple primary cancers and aggregation of cancers in families of patients with endometrial cancer] Ichikawa Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Sep;48(9):835-40 (Eng. Abstr.) **(Jpn)**

[Renal adenocarcinoma in young patients] Fernández Gómez JM, et al. **Actas Urol Esp** 1997 Jan;21(1):22-7 (Eng. Abstr.) **(Spa)**

[Lung cancer in the Island of Menorca (1990-1993)] Segui Díaz M, et al. **Gac Sanit** 1996 Jul-Aug;10(55):169-73 (Eng. Abstr.) **(Spa)**

[Epidemiology of cervical invasive cancer in the Gerona health area in 1980-1989. Cancer registry of Gerona] Garrido Victoria S, et al. **Rev Esp Salud Publica** 1997 Jan-Feb;71(1):19-26 (Eng. Abstr.) **(Spa)**

[Helicobacter pylori infection and gastric cancer in Mexico. A challenge for prevention and population control] López Carrillo L, et al. **Rev Gastroenterol Mex** 1997 Jan-Mar; 62(1):22-8 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Lung carcinoma in African Americans and whites. A population-based study in metropolitan Detroit, Michigan. Schwartz AG, et al. **Cancer** 1997 Jan 1;79(1):45-52

A case-control study of diet and colorectal cancer in a multiethnic population in Hawaii (United States): lipids and foods of animal origin. Le Marchand L, et al. **Cancer Causes Control** 1997 Jul;8(4):637-48

Impact of ethnicity on the incidence of high-risk endometrial carcinoma. Plaxe SC, et al. **Gynecol Oncol** 1997 Apr; 65(1):8-12

Clinicopathological significance of intestinal and diffuse types of gastric carcinoma in Taiwan Chinese. Wu CW, et al. **J Gastroenterol Hepatol** 1996 Nov;11(11):1083-8

A pathological analysis of clinical adenocarcinoma of the prostate in black patients [letter] Bereczky ZB. **S Afr Med J** 1997 Mar;87(3):344

ETIOLOGY

The lack of association between adenocarcinoma of the esophagus and gastric surgery: a retrospective study. Birgisson S, et al. **Am J Gastroenterol** 1997 Feb; 92(2):216-21

APC gene alterations in Barrett's metaplasia are implicated at an early stage in the carcinogenesis of esophageal adenocarcinoma. Fein M. **Am J Gastroenterol** 1997 Feb; 92(2):359-60

Gastric Crohn's disease complicated by adenocarcinoma of the stomach: case report and review of the literature. Patel M, et al. **Am J Gastroenterol** 1997 Aug;92(8):1368-71 (19 ref.)

Sinonasal cancer and occupational exposure to textile dust. Luce D, et al. **Am J Ind Med** 1997 Sep;32(3):205-10

Gastric cancer in the bypassed segment after operation for morbid obesity. Lord RV, et al. **Aust N Z J Surg** 1997 Aug;67(8):580-2

Adenocarcinoma of the residual bladder following caecocystoplasty for cyclophosphamide-induced cystitis. Khawaja MA, et al. **Br J Urol** 1996 Sep;78(3):465-6

Breast cancer in previously burned skin: a postburn skin adnexal malignancy? Vögelin E, et al. **Burns** 1997 Jun; 23(4):366-8

The role of dietary factors in the intestinal and diffuse histologic subtypes of gastric adenocarcinoma: a case-control study in the U.S. Harrison LE, et al. **Cancer** 1997 Sep 15;80(6):1021-8

Risk of squamous cell carcinoma and adenocarcinoma of the lung in relation to lifetime filter cigarette smoking. Stellman SD, et al. **Cancer** 1997 Aug 1;80(3):382-8

A case-control study of diet and colorectal cancer in a multiethnic population in Hawaii (United States): lipids and foods of animal origin. Le Marchand L, et al. **Cancer Causes Control** 1997 Jul;8(4):637-48

Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Tangrea J, et al. **Cancer Causes Control** 1997 Jul;8(4):615-25

Association of family history of cervical, ovarian, and uterine cancer with histological categories of lung cancer: the Iowa Women's Health Study. Anderson KE, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jun;6(6):401-5

Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Kim R, et al. **Cancer Epidemiol Biomarkers Prev** 1997 May;6(5):369-77 (124 ref.)

Non-promoting effects of iron from beef in the rat colon carcinogenesis model. Lai C, et al. **Cancer Lett** 1997 Jan 15;112(1):87-91

Stage of susceptibility to carcinogenicity of prenatal dietary fat exposure tested by blastocyst transfer. Walker BE, et al. **Cancer Lett** 1997 Jan 30;112(2):177-80

Fasting during promotion, but not during initiation, enhances the growth of methylnitrosourea-induced mammary tumours. Tessitore L, et al. **Carcinogenesis** 1997 Aug; 18(8):1679-81

The carcinogenicity of environmental tobacco smoke. Witschi H, et al. **Carcinogenesis** 1997 Mar;18(3):575-86

Effect of caloric restriction on pre-malignant and malignant stages of mammary carcinogenesis. Zhu Z, et al. **Carcinogenesis** 1997 May;18(5):1007-12

Case report: gastric carcinoma as a complication of dyskeratosis congenita in an adolescent boy. Chatura KR, et al. **Dig Dis Sci** 1996 Dec;41(12):2340-2

Development of invasive adenocarcinoma in a long-standing Kock continent ileostomy: report of a case. Cox CL, et al. **Dis Colon Rectum** 1997 Apr;40(4):500-3

Endometrioid carcinoma arising in a scar of caesarean section. Case report. Markopoulos C, et al. **Eur J Gynaecol Oncol** 1996;17(6):520-1 (13 ref.)

Development of adenocarcinoma in Barrett's oesophagus after successful antireflux surgery. Håkansson HO, et al. **Eur J Surg** 1997 Jun;163(6):469-71

Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Bostwick DG. **Eur Urol** 1996; 30(2):145-52 (38 ref.)

Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Zwick A, et al. **Gastroenterology** 1997 Aug;113(2):659-63

Helicobacter pylori infection and adenocarcinoma arising in Barrett's esophagus. Quddus MR, et al. **Hum Pathol** 1997 Sep;28(9):1007-9

Risk of adenocarcinoma of the stomach and esophagus with meat cooking method and doneness preference. Ward MH, et al. **Int J Cancer** 1997 Mar 28;71(1):14-9

Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma. Wu AH, et al. **Int J Cancer** 1997 Mar 4;70(5):512-7

Cancer in the anal canal (transitional zone) after restorative proctocolectomy with stapled ileal pouch-anal anastomosis. Sequens R. **Int J Colorectal Dis** 1997; 12(4):254-5

Not so benign endometrial hyperplasia: endometrial cancer after endometrial ablation. Gimpelson RJ. **J Am Assoc Gynecol Laparosc** 1997 Aug;4(4):507-11

Rapid progression of gastroesophageal junction adenocarcinoma after liver transplantation. Yao F, et al. **J Clin Gastroenterol** 1997 Jan;24(1):54-5

Duodeno-jejunal adenocarcinoma and coeliac disease [letter] Mason CH, et al. **J Clin Pathol** 1997 Jul;50(7):619

Reduction of gap junction protein connexin 32 in rat atrophic gastric mucosa as an early event in carcinogenesis. Nagahara A, et al. **J Gastroenterol** 1996 Aug;31(4):491-7

Second colon cancer following Hodgkin's disease. A case report. Kreiker J, et al. **J Med Liban** 1996;44(2):107-8

Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia [see comments] Gammon MD, et al. **J Natl Cancer Inst** 1997 Sep 3;89(17):1277-84. Comment in: J Natl Cancer Inst 1997 Sep 3;89(17):1247-9.

Cigarette smoking and esophageal and gastric cardia adenocarcinoma [editorial; comment] Zhang ZF, et al. **J Natl Cancer Inst** 1997 Sep 3;89(17):1247-9. Comment on: J Natl Cancer Inst 1997 Sep 3;89(17):1277-84.

Wood dust and nasal cancer risk. A review of the evidence from North America. Blot WJ, et al. **J Occup Environ Med** 1997 Feb;39(2):148-56 (51 ref.)

Occult small bowel adenocarcinoma in a Crohn's stricture. Balaji V, et al. **J R Soc Med** 1997 Jan;90(1):45

Early development of adenocarcinoma in a young woman following augmentation cystoplasty for undiversion. Carr LK, et al. **J Urol** 1997 Jun;157(6):2255-6 (3 ref.)

ADENOCARCINOMA

Calcium-channel blockers and cancer [letter; comment] Zhang ZF, et al. **Lancet** 1996 Oct 26;348(9035):1166-7. Comment on: Lancet 1996 Aug 24;348(9026):493-7.

Adenocarcinomas of the esophagus and gastric cardia: the role of diet. Zhang ZF, et al. **Nutr Cancer** 1997; 27(3):298-309

Adenocarcinoma arising within a colonic diverticulum [letter] Kajiwara H, et al. **Pathol Int** 1996 Jul;46(7):538-9

Molecular pathogenesis of adenoma and differentiated adenocarcinoma of the stomach. Tamura G. **Pathol Int** 1996 Nov;46(11):834-41 (69 ref.)

Colorectal cancer in idiopathic inflammatory bowel disease. Harpaz N, et al. **Semin Diagn Pathol** 1996 Nov;13(4):339-57 (188 ref.)

Esophageal carcinoma: current controversies. DeMeester TR. **Semin Surg Oncol** 1997 Jul-Aug;13(4):217-33 (93 ref.)

Influence of high-fat diets on the occurrence of spontaneous uterine endometrial adenocarcinomas in rats. Nagaoka T, et al. **Teratog Carcinog Mutagen** 1995;15(4):167-77

Donor origin of a posttransplant liver allograft malignancy identified by fluorescence in situ hybridization for the Y chromosome and DNA genotyping. Donovan JA, et al. **Transplantation** 1997 Jan 15;63(1):80-4

[Variety of pancreatic lesions observed in von Hippel-Lindau disease. Apropos of 8 cases] Hammel P, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):1011-7 (Eng. Abstr.) **(Fre)**

[Tuberculous pleurisy followed by bronchial cancer in a patient with HIV infection] N'Gbesso RD, et al. **Rev Pneumol Clin** 1996;52(6):398-403 (35 ref.) (Eng. Abstr.) **(Fre)**

[A case of adenocarcinoma of the reconstructed bladder following ileocystoplasty] Ishida T, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 Mar;88(3):439-42 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Adenocarcinoma arising from gallbladder fosa with duodenal involvement 14 years after cholecystectomy: a case report] Shimizu K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Nov;93(11):857-61 **(Jpn)**

[Effect of the light regime and electromagnetic fields on mammary carcinogenesis in female rats] Anisimov VN, et al. **Biofizika** 1996 Jul-Aug;41(4):807-14 (Eng. Abstr.) **(Rus)**

[Cancer of gastric stump after surgery of peptic ulcer] Dudenko GI, et al. **Klin Khir** 1996;(6):33-5 **(Rus)**

[Cancer of the gastric stump (letter)] Larrubia Marfil JR, et al. **An Med Interna** 1996 Feb;13(2):102 **(Spa)**

[Gastric adenocarcinoma in hamartomatous polyp in Peutz-Jeghers syndrome] Bujanda L, et al. **Gastroenterol Hepatol** 1996 Nov;19(9):452-5 (Eng. Abstr.) **(Spa)**

[Duodenal adenocarcinoma in celiac disease with late diagnosis and treatment] Nogales-Muñoz AL, et al. **Gastroenterol Hepatol** 1997 Apr;20(4):184-6 (Eng. Abstr.) **(Spa)**

GENETICS

Cytologic changes in two cervical carcinoma cell lines after transfection of the wild-type p53 gene. Iwasaka T, et al. **Acta Obstet Gynecol Scand** 1996 Oct;75(9):797-803

Pleomorphic (giant and spindle cell) carcinoma is genetically distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2 and p53 analysis. Przygodzki RM, et al. **Am J Clin Pathol** 1996 Oct;106(4):487-92

Polymerase chain reaction-based approaches for detection of allelic loss in the p53 tumor suppressor gene in colon neoplasms. Yamaguchi K, et al. **Am J Gastroenterol** 1997 Feb;92(2):307-12

Cyclin-dependent kinase inhibitor p21 in endometrial carcinoma [letter; comment] Backe J, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):243. Comment on: Am J Obstet Gynecol 1996 Nov;175(5):1246-52.

Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Clifford SL, et al. **Am J Obstet Gynecol** 1997 Jun;176(6):S229-32

The differential expression of the HER-2/neu oncogene among high-risk human papillomavirus-infected glandular lesions of the uterine cervix. Roland PY, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):133-8

The structural basis of molecular genetic deletions. An integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma. Brat DJ, et al. **Am J Pathol** 1997 Feb;150(2):383-91

Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Ishikawa T, et al. **Am J Pathol** 1997 Sep; 151(3):761-8

Expression of the Ets-1 proto-oncogene in human gastric carcinoma: correlation with tumor invasion. Nakayama T, et al. **Am J Pathol** 1996 Dec;149(6):1931-9

Tumor progression and cellular differentiation of pulmonary adenocarcinomas in SV40 large T antigen transgenic mice. Wikenheiser KA, et al. **Am J Respir Cell Mol Biol** 1997 Jun;16(6):713-23

Detection of p53 gene mutations in cytopathology and biopsy specimens from patients with lung cancer. Murakami I, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):1117-23

Does any correlation exist between the Gleason classification system and the computer-assisted microscope analysis of Feulgen-stained nuclei features in human prostate adenocarcinoma? Petein M, et al. **Anal Cell Pathol** 1996 Dec;12(3):159-71

DNA quantification as a prognostic factor in prostatic adenocarcinoma. Azúa J, et al. **Anal Quant Cytol Histol** 1996 Aug;18(4):330-6

Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53. Iannettoni MD, et al. **Ann Thorac Surg** 1996 Nov;62(5):1460-5; discussion 1465-6

Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells. Côté S, et al. **Anticancer Drugs** 1997 Jan;8(1):56-61

Cytogenetical observations in a cultured polymorphous low-grade adenocarcinoma originating from the minor salivary glands. Dahlenfors R, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):105-6

Mutation of ras oncogene in gastric adenocarcinoma: association with histological phenotype. Kim TY, et al. **Anticancer Res** 1997 Mar-Apr;17(2B):1335-9

Expression of bcl-2 and apoptotic DNA fragmentation in human endometrial adenocarcinoma cells. Kuwashima Y, et al. **Anticancer Res** 1996 Sep-Oct;16(5B):3221-4

Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Oyama T, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):583-7

Focal microsatellite mutations in relatives with prostatic adenocarcinoma. Wille AH, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3883-6

Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. Chappell SA, et al. **Br J Cancer** 1997;75(9):1324-9

Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes. Hatta Y, et al. **Br J Cancer** 1997; 75(9):1256-62

Infrequent microsatellite instability in oesophageal cancers. Muzeau F, et al. **Br J Cancer** 1997;75(9):1336-9 (40 ref.)

p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma. Runnebaum IB, et al. **Br J Cancer** 1996 Oct;74(8):1157-60

Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours. Schuyer M, et al. **Br J Cancer** 1996 Oct;74(7):1069-73

Involvement of chromosome 6 in endometrial cancer. Tibiletti MG, et al. **Br J Cancer** 1997;75(12):1831-5

p53 mutations in primary colorectal adenocarcinomas and liver metastases. Yao J, et al. **Br J Surg** 1996 Sep; 83(9):1245-6

Immunohistochemically detected p53 and HER-2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas. Auranen A, et al. **Cancer** 1997 Jun 1;79(11):2147-53

Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Gomyo Y, et al. **Cancer** 1997 Jun 1; 79(11):2067-72

Assessment of microsatellite alterations in young patients with gastric adenocarcinoma. Hayden JD, et al. **Cancer** 1997 Feb 15;79(4):684-7

Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Correlation with p53 expression. Li X, et al. **Cancer** 1997 Jun 15;79(12):2314-9

Morphologic, histologic, and molecular similarities between adenocarcinomas arising in the gastric stump and the intact stomach. Safatle-Ribeiro AV, et al. **Cancer** 1996 Dec 1; 78(11):2288-99

The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Younes N, et al. **Cancer** 1997 May 1;79(9):1804-8

Increased expression of the cyclin D1 gene in Barrett's esophagus. Arber N, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jun;5(6):457-9

High frequency of p53 gene mutation in adenocarcinomas of the gallbladder. Fujii K, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jun;5(6):461-6

DNA ploidy pattern and tumor suppressor gene p53 expression in gallbladder carcinoma. Roa I, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jul;6(7):547-50

Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma. Godfrey TE, et al. **Cancer Genet Cytogenet** 1997 Oct 1; 98(1):36-42

Cytogenetic analysis of Barrett's mucosa and adenocarcinoma of the distal esophagus and cardia. Menke-Pluymers MB, et al. **Cancer Genet Cytogenet** 1996 Sep;90(2):109-17

Cytogenetic abnormalities and microsatellite instability in endometrial adenocarcinoma. Sirchia SM, et al. **Cancer Genet Cytogenet** 1997 Apr;94(2):113-9

Band 1p36 abnormalities and t(1;17) in ovarian carcinoma. Thompson FH, et al. **Cancer Genet Cytogenet** 1997 Jul 15; 96(2):106-10

Multiple synchronous primaries of the gastrointestinal tract: a molecular case report. Herring JA, et al. **Cancer Lett** 1996 Dec 20;110(1-2):1-9

Infrequent hMSH2 mutations in sporadic gastric adenocarcinoma with microsatellite instability. Wu MS, et al. **Cancer Lett** 1997 Jan 30;112(2):161-6

Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma. El-Zein RA, et al. **Cancer Lett** 1997 Jan 15;112(1):71-8

Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population. Chung YJ, et al. **Cancer Res** 1996 Oct 15;56(20):4662-5

Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cunningham JM, et al. **Cancer Res** 1996 Oct 1;56(19):4475-82

Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Goggins M, et al. **Cancer Res** 1996 Dec 1;56(23):5360-4

Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Grau AM, et al. **Cancer Res** 1997 Sep 15;57(18):3929-34

Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Hammoud ZT, et al. **Cancer Res** 1996 Oct 1;56(19):4499-502

Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Kane MF, et al. **Cancer Res** 1997 Mar 1;57(5):808-11

Construction of a representative cDNA library from prostatic intraepithelial neoplasia. Krizman DB, et al. **Cancer Res** 1996 Dec 1;56(23):5380-3

Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Latil A, et al. **Cancer Res** 1997 Mar 15; 57(6):1058-62

High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Man S, et al. **Cancer Res** 1996 Dec 1;56(23):5484-9

p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Moskaluk CA, et al. **Cancer Res** 1997 Jun 1;57(11):2140-3

Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Mutter GL, et al. **Cancer Res** 1996 Oct 1; 56(19):4483-6

Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Petersen I, et al. **Cancer Res** 1997 Jun 15;57(12):2331-5

Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Reyes G, et al. **Cancer Res** 1996 Dec 15;56(24):5713-9

Microsatellite instability is associated with the histological features of the tumor in nonfamilial colorectal cancer. Risio M, et al. **Cancer Res** 1996 Dec 1;56(23):5470-4

Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Ritland SR, et al. **Cancer Res** 1997 Aug 15;57(16):3520-5

Tumor-suppressive pathways in pancreatic carcinoma. Rozenblum E, et al. **Cancer Res** 1997 May 1;57(9):1731-4

Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. Shridhar R, et al. **Cancer Res** 1996 Oct 1;56(19):4347-50

Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Souza RF, et al. **Cancer Res** 1997 Jun 15;57(12):2350-3

Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Stanford JL, et al. **Cancer Res** 1997 Mar 15;57(6):1194-8

p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Wong DJ, et al. **Cancer Res** 1997 Jul 1;57(13):2619-22

Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Katoh T, et al. **Carcinogenesis** 1996 Sep;17(9):1855-9

p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Kure EH, et al. **Carcinogenesis** 1996 Oct;17(10):2201-5

Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) polymorphisms and lung cancer risk among Northwestern Mediterraneans. To-Figueras J, et al. **Carcinogenesis** 1997 Aug;18(8):1529-33

Transgenic mice bearing the polyomavirus large T antigen directed by 2.1 kb of the keratin 19 promoter develop bronchiolar papillary tumors with progression to lung adenocarcinomas. Lebel M, et al. **Cell Growth Differ** 1995 Dec;6(12):1591-600

Detection of chromosomal aneuploidy by interphase fluorescence in situ hybridization in bronchoscopically gained cells from lung cancer patients. Schenk T, et al. **Chest** 1997 Jun;111(6):1691-6

Simultaneous detection of genetic and immunological markers in non-small cell lung cancer: prediction of metastatic potential of tumor. Zborovskaya I, et al. **Clin Exp Metastasis** 1996 Nov;14(6):490-500

The molecular biology of endometrial adenocarcinoma. Baker VV. **Clin Obstet Gynecol** 1996 Sep;39(3):707-15 (55 ref.)

Molecular advances in prostate cancer. Dong JT, et al. **Curr Opin Oncol** 1997 Jan;9(1):101-7 (99 ref.)

Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma. Visscher DW, et al. **Diagn Mol Pathol** 1997 Feb;6(1):64-9

Ki-ras point mutation in different types of colorectal

carcinomas in early stages. Kojima M, et al. **Dis Colon Rectum** 1997 Feb;40(2):161–7

Characteristics of metachronous colorectal carcinoma occurring despite colonoscopic surveillance. Leggett BA, et al. **Dis Colon Rectum** 1997 May;40(5):603–8

Detection of somatic mutations in the mitochondrial DNA control region of colorectal and gastric tumors by heteroduplex and single-strand conformation analysis. Alonso A, et al. **Electrophoresis** 1997 May;18(5):682–5

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Palmberg C, et al. **Eur Urol** 1997;31(2):216–9

A genetic sequence change in the 3'-noncoding region of the androgen receptor gene in prostate carcinoma. Paz A, et al. **Eur Urol** 1997;31(2):209–15

Potential markers of aggressiveness in prostatic intraepithelial neoplasia detected by fluorescence in situ hybridization. Qian J, et al. **Eur Urol** 1996;30(2):177–84 (49 ref.)

The molecular basis for carcinogenesis in metaplastic columnar-lined esophagus. Souza RF, et al. **Gastroenterol Clin North Am** 1997 Sep;26(3):583–97 (105 ref.)

The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Kapitanović S, et al. **Gastroenterology** 1997 Apr; 112(4):1103–13

Genetic alterations in sporadic and Crohn's-associated adenocarcinomas of the small intestine. Rashid A, et al. **Gastroenterology** 1997 Jul;113(1):127–35

A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasms [see comments] Souza RF, et al. **Gastroenterology** 1997 Jan; 112(1):40–5. Comment in: Gastroenterology 1997 Jan;112(1):297–302.

Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Fukushige S, et al. **Genes Chromosomes Cancer** 1997 Jul; 19(3):161–9

Detailed deletion mapping on chromosome arm 12q in human pancreatic adenocarcinoma: identification of a I–cM region of common allelic loss. Kimura M, et al. **Genes Chromosomes Cancer** 1996 Oct;17(2):88–93

Commonly deleted regions on the long arm of chromosome 21 in differentiated adenocarcinoma of the stomach. Sakata K, et al. **Genes Chromosomes Cancer** 1997 Apr;18(4):318–21

Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Tricoli JV, et al. **Genes Chromosomes Cancer** 1996 Feb;15(2):108–14

DNA fingerprint detection of somatic mutations in benign prostatic hyperplasia and prostatic adenocarcinoma. Werely CJ, et al. **Genes Chromosomes Cancer** 1996 Sep; 17(1):31–6

Germline APC mutation (Gln1317) in a cancer-prone family that does not result in familial adenomatous polyposis. White S, et al. **Genes Chromosomes Cancer** 1996 Feb; 15(2):122–8

Comparative genomic hybridization and molecular cytogenetic characterization of two prostate cancer xenografts. Williams BJ, et al. **Genes Chromosomes Cancer** 1997 Apr;18(4):299–304

Global DNA hypomethylation occurs in the early stages of intestinal type gastric carcinoma. Cravo M, et al. **Gut** 1996 Sep;39(3):434–8

Identification of differentially expressed mRNAs in normal and neoplastic (adenocarcinoma) human endometrium. Crescenzi E, et al. **Gynecol Oncol** 1996 Nov;63(2):228–33

p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines. Janicek MF, et al. **Gynecol Oncol** 1997 Jul;66(1):94–102

Molecular characterization of adenocarcinoma of the cervix. Parker MF, et al. **Gynecol Oncol** 1997 Feb;64(2):242–51

Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix. Uchiyama M, et al. **Gynecol Oncol** 1997 Apr; 65(1):23–9

Isolated expression of the Muir–Torre phenotype in a member of a family with hereditary non-polyposis colorectal cancer. Weitzer M, et al. **Histopathology** 1995 Dec;27(6):573–5

KRAS oncogene mutations suggest a common histogenetic origin for pleomorphic giant cell tumor of the pancreas, osteoclastoma of the pancreas, and pancreatic duct adenocarcinoma. Gocke CD, et al. **Hum Pathol** 1997 Jan; 28(1):80–3

Amplification of stromelysin-3 transcripts from carcinomas of the colon. Johnson LD, et al. **Hum Pathol** 1996 Sep; 27(9):964–8

Effect of K-ras mutation on morphogenesis of colorectal adenomas and early cancers: relationship to distribution of proliferating cells. Kobayashi M, et al. **Hum Pathol** 1996 Oct;27(10):1042–9

Mutations associated with carcinomas arising from pleomorphic adenomas of the salivary glands. Yamamoto Y, et al. **Hum Pathol** 1996 Aug;27(8):782–6

Representativeness of microorgans from human colorectal tumors [letter] Finkelstein SD, et al. **In Vitro Cell Dev Biol Anim** 1996 Apr;32(4):189–91

Cytogenetic findings in metastases from colorectal cancer. Bardi G, et al. **Int J Cancer** 1997 Aug 7;72(4):604–7

Frequent detection of aberrant RNA transcripts of the CDKN2 gene in human gastric adenocarcinoma. Chen YJ, et al. **Int J Cancer** 1997 May 2;71(3):350–4

Chromosome 3p24–26 and 3p22–12 loss in human prostatic adenocarcinoma. Dahiya R, et al. **Int J Cancer** 1997 Mar 28;71(1):20–5

Microsatellite instability in cervical and endometrial carcinomas. Helland A, et al. **Int J Cancer** 1997 Mar 4; 70(5):499–501

Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method. Keohavong P, et al. **Int J Cancer** 1997 Apr 22;74(2):162–70

Chromosome 16 in primary prostate cancer: a microsatellite analysis. Osman I, et al. **Int J Cancer** 1997 May 16; 71(4):580–4

Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy. Thompson JA, et al. **Int J Cancer** 1997 Jul 3;72(1):197–202

Genetic diversity at the p53 locus between primary human colorectal adenocarcinomas and their lymph-node metastases. Zhang JS, et al. **Int J Cancer** 1997 Mar 17; 70(6):674–8

Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Dergham ST, et al. **Int J Pancreatol** 1997 Apr;21(2):127–43

The use of crude tissue section lysates for PCR assessment of gene copy number with human tumour biopsy samples. Schmitt JF, et al. **J Biochem Biophys Methods** 1996 Dec 30;33(3):217–30

A kappaB-related binding site is an integral part of the mts1 gene composite enhancer element located in the first intron of the gene. Tulchinsky E, et al. **J Biol Chem** 1997 Feb 21;272(8):4828–35

WAF1 expression and p53 mutations in human colorectal cancers. Wang A, et al. **J Cancer Res Clin Oncol** 1997; 123(2):118–23

Contrasting effects of K8 and K18 on stabilizing K19 expression, cell motility and tumorigenicity in the BSp73 adenocarcinoma. Pankov R, et al. **J Cell Sci** 1997 Apr;110 (Pt 8):965–74

Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. Rodenhuis S, et al. **J Clin Oncol** 1997 Jan;15(1):285–91

Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. González MV, et al. **J Clin Pathol** 1997 Mar;50(3):212–7

Molecular genetic analysis of TGF-beta1 in ovarian neoplasia. Cardillo MR, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):49–56

Quantitative analysis of numerical chromosome aberrations in various morphological types of colorectal carcinomas. Nanashima A, et al. **J Gastroenterol** 1996 Dec; 31(6):793–800

Detection of colorectal cancer K-ras mutations using a simplified oligonucleotide ligation assay. Rothschild CB, et al. **J Immunol Methods** 1997 Aug 7;206(1–2):11–9

Amplification of c-erbB-2 proto-oncogene in cancer foci, adjacent normal, metastatic and normal tissues of human primary gastric adenocarcinomas. Kim JS, et al. **J Korean Med Sci** 1997 Aug;12(4):311–5

Pancreatic adenocarcinoma: epidemiology and genetics. Flanders TY, et al. **J Med Genet** 1996 Nov;33(11):889–98 (121 ref.)

Fertility and incidence of KRAS2 mutations in borderline ovarian adenocarcinomas [letter] Chenevix-Trench G, et al. **J Natl Cancer Inst** 1997 Jun 18;89(12):890–1

von Hippel-Lindau disease gene alterations associated with endolymphatic sac tumor [letter] Vortmeyer AO, et al. **J Natl Cancer Inst** 1997 Jul 2;89(13):970–2

Microsatellite instability in intestinal- and diffuse-type gastric carcinoma. Buonsanti G, et al. **J Pathol** 1997 Jun; 182(2):167–73

The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. Cooper CA, et al. **J Pathol** 1997 Apr; 181(4):401–4

Allelotype of adenoma and differentiated adenocarcinoma of the stomach. Tamura G, et al. **J Pathol** 1996 Dec; 180(4):371–7

Flow cytometry in cervical adenocarcinoma. Correlating DNA content analysis with the clinical picture. Kaspar HG, et al. **J Reprod Med** 1997 Mar;42(3):170–2

Immunosuppressive cytokines (IL-10, TGF-beta) genes expression in human gastric carcinoma tissues. Morisaki T, et al. **J Surg Oncol** 1996 Dec;63(4):234–9

Activation of Raf-1 in human pancreatic adenocarcinoma. Berger DH, et al. **J Surg Res** 1997 Apr;69(1):199–204

Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers. Mitsudomi T, et al. **J Thorac Cardiovasc Surg** 1997 Sep;114(3):354–60

Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization [see comments] Geburek BM, et al. **J Urol** 1997 Jan; 157(1):223–7. Comment in: J Urol 1997 Jan;157(1):228–9.

Growth characteristics in the initial stage of micrometastasis formation by bacterial LacZ gene-tagged rat prostatic adenocarcinoma cells. Kobayashi K, et al. **Jpn J Cancer Res** 1996 Dec;87(12):1227–34

PRLTS gene alterations in human prostate cancer. Komiya A, et al. **Jpn J Cancer Res** 1997 Apr;88(4):389–93

Infrequent overexpression of p53 protein in Epstein-Barr virus-associated gastric carcinomas. Ojima H, et al. **Jpn J Cancer Res** 1997 Mar;88(3):262–6

Microsatellite instability in lung cancer patients 40 years of age or younger. Sekine I, et al. **Jpn J Cancer Res** 1997 Jun;88(6):559–63

Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart. Esteller M, et al. **Lab Invest** 1997 Jan;76(1):109–16

Genetic evidence for the multicentric origin of synchronous multiple gastric carcinoma. Kang GH, et al. **Lab Invest** 1997 Mar;76(3):407–17

DNA-analysis is mandatory in case of an uncommon malignancy. van den Berg H, et al. **Med Pediatr Oncol** 1997 Jul;29(1):65–6

Expression of bcl-2 by breast cancer: a possible diagnostic application. Alsabeh R, et al. **Mod Pathol** 1996 Apr; 9(4):439–44

bcl-2 is down-regulated in atypical endometrial hyperplasia and adenocarcinoma. Henderson GS, et al. **Mod Pathol** 1996 Apr;9(4):430–8

Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation. Kallakury BV, et al. **Mod Pathol** 1996 Jan;9(1):41–7

Immunohistochemical analysis of p53 mutations in bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma. Wang X, et al. **Mod Pathol** 1995 Dec; 8(9):919–23

Genetic alterations and oxidative metabolism in sporadic colorectal tumors from a Spanish community. Oliva MR, et al. **Mol Carcinog** 1997 Apr;18(4):232–43

Expression of estrogen receptor variants in normal and neoplastic human uterus. Hu C, et al. **Mol Cell Endocrinol** 1996 Apr 19;118(1–2):173–9

Detection of K-ras point mutation by enriched PCR-colorimetric plate assay. Santiago FS, et al. **Mol Cell Probes** 1997 Feb;11(1):33–8

H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer. Wang XC, et al. **Mol Med** 1996 Mar;2(2):189–203

Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mass MJ, et al. **Mutat Res** 1997 Jun;386(3):263–77

BRCA1 mutations and survival in women with ovarian cancer [letter; comment] Cannistra SA. **N Engl J Med** 1997 Apr 24;336(17):1254; discussion 1256–7. Comment on: N Engl J Med 1996 Nov 7;335(19):1413–6.

Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1 [see comments] Rubin SC, et al. **N Engl J Med** 1996 Nov 7; 335(19):1413–6. Comment in: N Engl J Med 1996 Nov 7;336(19):1455–6. Comment in: N Engl J Med 1997 Apr 24;336(17):1254; discussion 1256–7. Comment in: N Engl J Med 1997 Apr 24;336(17):1254–5; discussion 1256–7. Comment in: N Engl J Med 1997 Apr 24;336(17):1255; discussion 1256–7. Comment in: N Engl J Med 1997 Apr 24;336(17):1255–6; discussion 1256–7. Comment in: N Engl J Med 1997 Apr 24;336(17):1256; discussion 1256–7.

Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis [see comments] Hemminki A, et al. **Nat Genet** 1997 Jan;15(1):87–90. Comment in: Nat Genet 1997 Jan;15(1):5–6.

A high throughput screening for rarely transcribed differentially expressed genes. von Stein OD, et al. **Nucleic Acids Res** 1997 Jul 1;25(13):2598–602

Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus. Kerr J, et al. **Oncogene** 1996 Oct 17;13(8):1815–8

Apparent protection from instability of repeat sequences in cancer-related genes in replication error positive gastrointestinal cancers. Simms LA, et al. **Oncogene** 1997 May 29;14(21):2613–8

HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Dugan MC, et al. **Pancreas** 1997 Apr;14(3):229–36

Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Rall CJ, et al. **Pancreas** 1996 Jan; 12(1):10–7

The correlation between p53 tumor suppressor gene and proliferating cell nuclear antigen expressions in colorectal adenocarcinoma [letter] Ozdamar SO, et al. **Pathol Int** 1995 Dec;45(12):973–4

Numerical chromosomal changes in high-grade prostatic intraepithelial neoplasia (PIN) and concomitant invasive carcinoma. Erbersdobler A, et al. **Pathol Res Pract** 1996 May;192(5):418–27

Expression of homeobox gene-GBX2 in human prostatic cancer cells. Gao AC, et al. **Prostate** 1996 Dec;29(6):395–8

Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Kawana Y, et al. **Prostate** 1997 Aug 1;32(3):205–13

Comparison of ras activation in prostate carcinoma in Japanese and American men. Konishi N, et al. **Prostate** 1997 Jan 1;30(1):53–7

Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy. Ljung G, et al. **Prostate** 1997 Jul 1;32(2):99–105

Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical

and molecular detection of p53 mutations. Mottaz AE, et al. **Prostate** 1997 Jun 1;31(4):209–15

The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation. Pollack A, et al. **Prostate** 1997 Apr 1; 31(1):21–8

Rb and p53 gene deletions in lung adenocarcinomas from irradiated and control mice. Zhang Y, et al. **Radiat Res** 1997 Jul;148(1):81–9

Expression and significance of tumoral suppressor p53 gene in lung adenocarcinomas. Cornianu M, et al. **Rom J Morphol Embryol** 1996 Jan–Jun;42(1–2):73–82

Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Rampino N, et al. **Science** 1997 Feb 14;275(5302):967–9

Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells. Dai JL, et al. **Steroids** 1996 Sep;61(9):531–9

Numerical aberrations of chromosomes 11 and 17 in colorectal adenocarcinomas. Tagawa Y, et al. **Surg Today** 1996;26(11):869–74

Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Torres MJ, et al. **Tissue Antigens** 1996 May;47(5):372–81

A transgenic mouse prostate cancer model [see comments] Gingrich JR, et al. **Toxicol Pathol** 1996 Jul–Aug; 24(4):502–4. Comment in: Toxicol Pathol 1996 Jul–Aug;24(4):506.

Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms. Yaman O, et al. **Urol Int** 1997;58(4):199–202

Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment. Wikström P, et al. **Urol Res** 1997; 25(2):103–11

A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate. Ahlgren G, et al. **Urology** 1997 Sep;50(3):379–84

[Relation between loss of heterozygosity at APC and MCC genetic loci and biological behaviour of gastric carcinoma] Liu B, et al. **Chung Hua Chung Liu Tsa Chih** 1996 Jan; 18(1):3–5 (Eng. Abstr.) **(Chi)**

[A study on expression of tumor suppressor gene p53 in endometrial carcinoma] Xue F, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Nov;30(11):647–50 (Eng. Abstr.) **(Chi)**

[Correlation of multiple gene changes with malignant phenotype of human gastric carcinoma] Gao C, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Sep;76(9):671–5 (Eng. Abstr.) **(Chi)**

[Studies on MDM2 oncogene expression and its effect on pancreatic carcinoma cells] Guo H, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Aug;25(4):232–5 (Eng. Abstr.) **(Chi)**

[Detection of the expression of P21, P53, P185 proteins and the mutation of ras, p53 genes in colorectal adenoma and carcinoma] Liang Z, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Dec;24(6):352–5 (Eng. Abstr.) **(Chi)**

[nm23 gene product/NDPK expression and its clinical significance in human colorectal carcinoma] Wang C, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Dec; 24(6):356–8 (Eng. Abstr.) **(Chi)**

[Detection of c-Ki-ras oncogene codon 12 point mutations in lung carcinoma, gastric carcinoma and hepatic carcinoma] Cui Q, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Apr; 18(2):95–8 (Eng. Abstr.) **(Chi)**

[Relationship between the express product of src gene (pp60c-src) and the initiation of gastric carcinoma] Wang X, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1996 Mar; 27(1):71–4 (Eng. Abstr.) **(Chi)**

[A study of the expression of MDR1 gene in solid tumors. Initial results of a multicenter evaluation] Chevillard S, et al. **Bull Cancer** 1996 Aug;83(8):626–33 (Eng. Abstr.) **(Fre)**

[Mutations of the androgen receptor gene a possible role in prostate cancer] Mowszowicz I, et al. **Bull Cancer** 1997 Feb;84(2):183–8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Localization of a tumor suppressor gene distal to D22S270 in colorectal cancers] Duriez C, et al. **Gastroenterol Clin Biol** 1997;21(5):358–64 (Eng. Abstr.) **(Fre)**

[Search for genetic risk in surgical indications in oncology] Dauplat J, et al. **Presse Med** 1996 Nov 9;25(34):1633–5 (Eng. Abstr.) **(Fre)**

[Ribozyme targeting reduces erb-B2 expression of SKOV3 carcinoma cells and inhibits tumor growth in vivo] Juhl H, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997; 114:41–5 (Eng. Abstr.) **(Ger)**

[Significance of the MTS II gene for the growth behavior of adenocarcinoma of the pancreas] Lynen P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:91–5 (Eng. Abstr.) **(Ger)**

[Expression and prognostic significance of HLA-class I and II antigens, ICAM-1 and costimulatory molecule B7 in esophageal carcinoma] Stoecklein NH, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:785–8 (Eng. Abstr.) **(Ger)**

[Findings of genetic changes in small intestinal carcinomas] Hirai A, et al. **Gan To Kagaku Ryoho** 1997 Jul;24 Suppl 2:332–6 (Eng. Abstr.) **(Jpn)**

[Flow cytometry analysis of the DNA content of the prostate cancer—study on the tumor heterogeneity in prostate cancer] Michinaga S, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jun;87(6):937–41 (Eng. Abstr.) **(Jpn)**

[Clinical significance of genetic instability in gastrointestinal cancers] Mori M, et al. **Nippon Rinsho** 1996 Apr; 54(4):1025–30 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Multistep stomach carcinogenesis] Yokozaki H, et al. **Nippon Rinsho** 1996 Apr;54(4):1066–71 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Microsatellite instability in gastric cancer with varied structure] Wang Y, et al. **Rinsho Byori** 1997 Jul;45(7):651–5 (Eng. Abstr.) **(Jpn)**

[Gene K-ras mutation in cells of endometrial adenocarcinoma in women] Semczuk A, et al. **Ginekol Pol** 1996 May;67(5):259–63 (Eng. Abstr.) **(Pol)**

[Flow-cytometric study of aneuploidy and proliferative activity of colonic cancer cells] Bychkova NV, et al. **Vopr Onkol** 1996;42(5):40–4 (Eng. Abstr.) **(Rus)**

[Study of DNA content and its association with staging, tumor size, architecture, cell type, and nuclear grade in renal adenocarcinoma] Ruiz Cerdá JL, et al. **Actas Urol Esp** 1997 Jan;21(1):6–14 (Eng. Abstr.) **(Spa)**

[Introduction to molecular biology of endometrial cancer (editorial)] Esteller M, et al. **Med Clin (Barc)** 1996 Jun 29; 107(5):175–7 **(Spa)**

IMMUNOLOGY

Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Krajewska M, et al. **Am J Pathol** 1996 Nov;149(5):1449–57

Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. McAneny D, et al. **Ann Surg Oncol** 1996 Sep;3(5):495–500

Expression of tumor-related antigens Lewis(a) Lewis(b), X, Y, Span-1 and CEA in relation to differentiation and prognosis in rectal adenocarcinomas. Sun XF, et al. **APMIS** 1996 Nov;104(11):784–8

The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Coca S, et al. **Cancer** 1997 Jun 15;79(12):2320–8

Functional expression of CD11a on CD8+ cells is suppressed in regional lymph nodes with cancer involvement in patients with gastrointestinal carcinoma. Shinkal H, et al. **Cancer** 1996 Oct 15;78(8):1677–85

Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF. Aruga E, et al. **Cancer Gene Ther** 1997 May-Jun; 4(3):157–66

Antigen-presenting function of human peritoneum mesothelial cells isolated from a pancreatic carcinoma patient after mutant Ras peptide vaccination. Gjersten MK, et al. **Cancer Immunol Immunother** 1996 Dec;43(5):262–8

Lymphocyte subpopulations of regional lymph nodes in human colon and gastric adenocarcinomas. Lores-Vazquez B, et al. **Cancer Immunol Immunother** 1996 Jul;42(6):339–42

Increased expression of alpha6-integrin receptors and of mRNA encoding the putative 37 kDa laminin receptor precursor in pancreatic carcinoma. Halatsch ME, et al. **Cancer Lett** 1997 Sep 16;118(1):7–11

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer. Seki N, et al. **Cell Immunol** 1997 Feb 1;175(2):101–10

Simultaneous detection of genetic and immunological markers in non-small cell lung cancer: prediction of metastatic potential of tumor. Zborovskaya I, et al. **Clin Exp Metastasis** 1996 Nov;14(6):490–500

Detection of interleukin-8 mRNA and protein in human colorectal carcinoma cells. Brew R, et al. **Eur J Cancer** 1996 Nov;32A(12):2142–7

Within-subject variation of carcinoembryonic antigen in colorectal cancer — application of reference of change values and individual reference ranges to patient follow-up. Mora J, et al. **Eur J Clin Chem Clin Biochem** 1997 Jun; 35(6):453–7

The HER2/neu-derived peptide p654–662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Peiper M, et al. **Eur J Immunol** 1997 May;27(5):1115–23

In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody. Brusa P, et al. **Farmaco** 1997 Feb; 52(2):71–81

The differentiation antigen Ly-6E.1 is expressed in mouse metastatic tumor cell lines. Cohn MA, et al. **FEBS Lett** 1997 Feb 17;403(2):181–5

Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Hammel P, et al. **Gut** 1997 Mar; 40(3):356–61

Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon. Bon GG, et al. **Gynecol Obstet Invest** 1996;42(1):58–62

Relationship of blood transfusion, post-operative infections and immunoreactivity in patients undergoing surgery for gastrointestinal cancer. Quintiliani L, et al. **Haematologica** 1997 May-Jun;82(3):318–23

CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma. Attanoos RL, et al. **Histopathology** 1997 Mar;30(3):260–3

Peptide mimicry of adenocarcinoma-associated carbohydrate antigens. Kieber-Emmons T, et al. **Hybridoma** 1997 Feb; 16(1):3–10

The role of MHC class I expression in rat NK cell-mediated lysis of syngeneic tumor cells and virus-infected cells. Giezeman-Smits KM, et al. **Immunobiology** 1996 Aug; 195(3):286–99

Homologous complement activation on drug-induced apoptotic cells from a human lung adenocarcinoma cell line. Hara T, et al. **Immunobiology** 1996–97;196(5):491–503

In vivo studies of macrophages and intercellular adhesion molecule-1 following lipopolysaccharide treatment in tumour-bearing rats. Nilsson TM, et al. **Immunol Cell Biol** 1996 Oct;74(5):408–12

Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Chaux P, et al. **Int J Cancer** 1997 Aug 7;72(4):619–24

T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines. Farace F, et al. **Int J Cancer** 1997 Jun 11;71(6):972–7

HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Hoshino T, et al. **Int J Cancer** 1997 Mar 17; 70(6):631–8

Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Jarvis GA, et al. **Int J Cancer** 1997 Jun 11; 71(6):1049–55

Apoptosis in rat prostatic adenocarcinoma is associated with rapid infiltration of cytotoxic T-cells and activated macrophages. Landström M, et al. **Int J Cancer** 1997 May 2;71(3):451–5

Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma. Morecki S, et al. **Int J Cancer** 1997 Mar 28;71(1):59–63

Human pancreatic cancer cells (MPanc-96) recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion. Peiper M, et al. **Int J Cancer** 1997 Jun 11;71(6):993–9

Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity [published erratum appears in Int J Gynecol Pathol 1996 Oct;15(4):369] Yamauchi N, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):202–8

Expression of carbohydrate antigen sialyl Le(a): a new functional prognostic factor in gastric cancer. Nakamori S, et al. **J Clin Oncol** 1997 Feb;15(2):816–25

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. Tempero M, et al. **J Clin Oncol** 1997 Apr; 15(4):1518–28

Sequential development of structural and functional alterations in T cells from tumor-bearing mice. Correa MR, et al. **J Immunol** 1997 Jun 1;158(11):5292–6

Immunoisolation of tumor cells: generation of antitumor immunity through indirect presentation of antigen. Geller RL, et al. **J Immunother** 1997 Mar;20(2):131–7

Independent prognostic value of the 67-kd laminin receptor in human prostate cancer. Waltregny D, et al. **J Natl Cancer Inst** 1997 Aug 20;89(16):1224–7

Cryosurgical ablation of the normal ventral prostate plus adjuvant does not protect Copenhagen rats from Dunning prostatic adenocarcinoma challenge. Friedman EJ, et al. **J Urol** 1997 Oct;158(4):1585–8

Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer. Gohara R, et al. **Jpn J Cancer Res** 1997 Feb; 88(2):198–204

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Gong J, et al. **Nat Med** 1997 May;3(5):558–61

Total synthesis of the potential anticancer vaccine KH-1 adenocarcinoma antigen [published erratum appears in Nature 1997 Jul 10;388(6638):210] Deshpande PP, et al. **Nature** 1997 May 8;387(6629):164–6

Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Shiraki K, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6420–5

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen [see comments] Xue BH, et al. **Prostate** 1997 Feb 1;30(2):73–8. Comment in: Prostate 1997 Jun 15;32(1):73–4.

Expression of MHC class I and class II antigens in pancreatic adenocarcinomas [published erratum appears in Tissue Antigens 1997 Apr;49(4):429] Scupoli MT, et al. **Tissue Antigens** 1996 Oct;48(4 Pt 1):301–11

Characterization of a new breast cancer-associated antigen and its relationship to MUC1 and TAG-72 antigens. Harada Y, et al. **Tohoku J Exp Med** 1996 Nov; 180(3):273–88

[Detection of T-antigen in colorectal adenocarcinoma and polyps] Xu S, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):693–5 (Eng. Abstr.) **(Chi)**

[Establishing a new human pancreatic carcinoma cell line as an in vitro and in vivo model for adaptive immunotherapy and identification of tumor-specific antigens in pancreatic carcinoma] Bernstorff W, et al.

Langenbecks Arch Chir Suppl Kongressbd 1997;114:47–50 (Eng. Abstr.) **(Ger)**
[Lymphocytes from regional lymph nodes of advanced pancreatic carcinoma display reduced immune reactivity in comparison with blood cells] Staib L, et al.
Langenbecks Arch Chir Suppl Kongressbd 1997;114:75–8 (Eng. Abstr.) **(Ger)**
[Lewis antigens in human colon carcinoma] Duś D, et al.
Postepy Hig Med Dosw 1996;50(5):549–53 (Eng. Abstr.) **(Pol)**

METABOLISM

1H-magnetic resonance spectroscopic observation of cultured malignant cells pharmacologically induced to different phenotypes. Nakai T, et al. **Acad Radiol** 1996 Sep; 3(9):742–50

Cytopathology of granulocyte colony-stimulating factor-producing lung adenocarcinoma [letter] Kimura M, et al. **Acta Cytol** 1997 May–Jun;41(3):952–3

Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. Hayashi H, et al.
Am J Pathol 1997 Aug;151(2):461–70

MUC1 expressed in PanC1 cells decreases adhesion to type 1 collagen but increases contraction in collagen lattices. Hudson MJ, et al. **Am J Pathol** 1996 Mar;148(3):951–60

Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Jiang SX, et al.
Am J Pathol 1996 Mar;148(3):837–46

Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Ueda T, et al.
Am J Pathol 1996 Nov;149(5):1435–40

Ca(2+)-dependent nitric oxide release in endothelial but not R3230Ac rat mammary adenocarcinoma cells. Lindberg RA, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C332–7

Increased L-arginine transport in a nitric oxide-producing metastatic colon cancer cell line. Cendan JC, et al.
Ann Surg Oncol 1996 Sep;3(5):501–8

Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53. Iannettoni MD, et al.
Ann Thorac Surg 1996 Nov;62(5):1460–5; discussion 1465–6

Liposome-encapsulated superparamagnetic iron oxide particles as markers in an MRI-guided search for tumor-specific drug carriers. Päuser S, et al.
Anticancer Drug Des 1997 Mar;12(2):125–35

Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells. Côté S, et al. **Anticancer Drugs** 1997 Jan;8(1):56–61

Retinoblastoma (pRb) protein immunoexpression in colorectal cancer. Chetty R, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2593–7

Metallopanstimulin is overexpressed in a patient with colonic carcinoma. Ganger DR, et al. **Anticancer Res** 1997 May–Jun;17(3C):1993–9

Heterogeneity of expression of the calcium-binding protein calretinin in human colonic cancer cell lines. Gotzos V, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3491–8

Expression of bcl-2 and apoptotic DNA fragmentation in human endometrial adenocarcinoma cells. Kuwashima Y, et al. **Anticancer Res** 1996 Sep–Oct;16(5B):3221–4

Gene expression of granulocyte colony stimulating factor (G-CSF) in non-small cell lung cancer. Nakamura M, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):573–6

Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. Valassiadou KE, et al. **Anticancer Res** 1997 Jul–Aug; 17(4A):2571–6

Expression of CD44, ICAM-1 and N-CAM in colorectal cancer. Correlation with the tumor stage and the phenotypical characteristics of tumor-infiltrating lymphocytes. Wimmenauer S, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2395–400

Immunohistological distribution of heparan sulfate proteoglycan and chondroitin 6-sulfate in carcinomas with eccrine differentiation. Kazama T, et al.
Arch Dermatol Res 1996 Oct;288(11):718–21

An immunohistochemical study of the simultaneous expression of bcl-2 and p53 oncoproteins in epithelial tumors of the colon and rectum. Mosnier JF, et al.
Arch Pathol Lab Med 1996 Jul;120(7):654–9

2,3,7,8-Tetrachlorodibenzo-p-dioxin increases mRNA levels for interleukin-1beta, urokinase plasminogen activator, and tumor necrosis factor-alpha in human uterine endometrial adenocarcinoma RL95-2 cells. Charles GD, et al.
Biochem Biophys Res Commun 1997 Sep 18;238(2):338–42

Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers. Seo Y, et al. **Biochem Biophys Res Commun** 1997 Feb 24; 231(3):705–11

Colon adenoma and cancer cells aberrantly express the leukocyte-associated sialoglycoprotein CD43. Sikut R, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):612–6

Leptin induces tyrosine phosphorylation of cellular proteins including STAT-1 in human renal adenocarcinoma cells, ACHN. Takahashi Y, et al.
Biochem Biophys Res Commun 1996 Nov 21;228(3):859–64

Reduced connexin 43 expression in high grade, human prostatic adenocarcinoma cells. Tsai H, et al.
Biochem Biophys Res Commun 1996 Oct 3;227(1):64–9

The expression of the molecular chaperone calnexin is decreased in cancer cells grown as colonies compared to monolayer. Yeates LC, et al.
Biochem Biophys Res Commun 1997 Sep 8;238(1):66–70

Early steps in the biosynthesis of MUC2 epithelial mucin in colon cancer cells. McGuckin MA, et al.
Biochem Cell Biol 1996;74(1):87–93

Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. McBain JA, et al. **Biochem Pharmacol** 1997 May 9;53(9):1357–68

Overproduction of urokinase-type plasminogen activator is regulated by phospholipase D- and protein kinase C-dependent pathways in murine mammary adenocarcinoma cells. Aguirre Ghiso JA, et al.
Biochim Biophys Acta 1997 Apr 24;1356(2):171–84

Mechanisms and kinetics of alpha-linolenic acid uptake in Caco-2 clone TC7. Tranchant T, et al.
Biochim Biophys Acta 1997 Apr 1;1345(2):151–61

Accumulation of NCC-CO-411 monoclonal antibody in human colorectal adenocarcinoma through binding of the released carcinoembryonic antigen in nude mice. Wang DS, et al. **Biol Pharm Bull** 1996 Jul;19(7):915–21

bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Apakama I, et al. **Br J Cancer** 1996 Oct; 74(8):1258–62

Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients. Dellian M, et al. **Br J Cancer** 1996 Oct;74(8):1206–15

Characterization of a clonal human colon adenocarcinoma line intrinsically resistant to doxorubicin. Dolfini E, et al. **Br J Cancer** 1997;76(1):67–76

Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer. Hirono Y, et al. **Br J Cancer** 1996 Dec;74(12):2003–7

Metabolism and pharmacokinetics of the anti-tumour agent 2,3,5-trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504). Hussey HJ, et al. **Br J Cancer** 1996 Nov; 74(9):1349–53

Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. Marchini S, et al. **Br J Cancer** 1997;76(2):146–9

The expression and localisation of beta-nerve growth factor (beta-NGF) in benign and malignant human prostate tissue: relationship to neuroendocrine differentiation. Paul AB, et al. **Br J Cancer** 1996 Dec;74(12):1990–6

TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Powe DG, et al. **Br J Cancer** 1997; 75(11):1678–83

Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Vaage J, et al.
Br J Cancer 1997;75(4):482–6

Plasminogen activators in oesophageal carcinoma. Hewin DF, et al. **Br J Surg** 1996 Aug;83(8):1152–5

The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Byrne RL, et al. **Br J Urol** 1997 Feb; 79(2):190–5

A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma. Leung HY, et al. **Br J Urol** 1997 Feb;79(2):212–6

Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. McWilliam LJ, et al. **Br J Urol** 1997 Aug; 80(2):287–90

Effects of secretory products of breast cancer cells on osteoblast-like cells. Lacroix M, et al.
Breast Cancer Res Treat 1996;38(2):209–16

Relaxin and breast cancer. Bani D. **Bull Cancer** 1997 Feb; 84(2):179–82

Oxygen tension in mouse mammary carcinomas and osteosarcomas after irradiation with reactor fission neutrons. Weissfloch L, et al. **Bull Cancer Radiother** 1996; 83 Suppl:32s–6s

The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma. Dergham ST, et al. **Cancer** 1997 Aug 1;80(3):372–81

Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Kallakury BV, et al. **Cancer** 1996 Oct 1;78(7):1461–9

Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. Korst AE, et al. **Cancer Chemother Pharmacol** 1996;39(1-2):162–6

Formation, intracellular distribution and efflux of glutathione-bimane conjugates in drug-sensitive and -resistant MCF-7 cells. Millis KK, et al.
Cancer Chemother Pharmacol 1997;40(2):101–11

Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Mosure KW, et al. **Cancer Chemother Pharmacol** 1997; 40(3):251–8

Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft. Stribbling SM, et al. **Cancer Chemother Pharmacol** 1997; 40(4):277–84

Differential reduction in the expression of keratin polypeptides in human gastric carcinomas. Gupta A, et al. **Cancer Detect Prev** 1997;21(2):129–34

Sialic acid levels in serum and tissue from colorectal cancer patients. Feijoo C, et al. **Cancer Lett** 1997 Jan 30; 112(2):155–60

Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues. Heyerdahl H, et al. **Cancer Lett** 1997 Jan 30; 112(2):225–31

The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Miller DW, et al. **Cancer Lett** 1996 Oct 22;107(2):301–6

Expression and identification of aberrant c-kit transcripts in human cancer cells. Takaoka A, et al. **Cancer Lett** 1997 May 19;115(2):257–61

Colon cancer mucin: a new ligand for the beta-galactoside-binding protein galectin-3. Bresalier RS, et al. **Cancer Res** 1996 Oct 1;56(19):4354–7

Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Duncan JR, et al. **Cancer Res** 1997 Feb 15;57(4):659–71

Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Esposito V, et al.
Cancer Res 1997 Aug 15;57(16):3381–5

Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Jiang S, et al.
Cancer Res 1997 Apr 15;57(8):1475–80

Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Joseph IB, et al. **Cancer Res** 1997 Mar 15;57(6):1054–7

Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Kawakami M, et al. **Cancer Res** 1997 Jun 15;57(12):2321–4

Down-regulation of carcinoembryonic antigen family member 2 expression is an early event in colorectal tumorigenesis. Thompson J, et al. **Cancer Res** 1997 May 1;57(9):1776–84

Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Stayrook KR, et al.
Carcinogenesis 1997 Aug;18(8):1655–8

Expression of receptors for gut peptides in pancreata of BOP-treated and control hamsters. Tang C, et al.
Carcinogenesis 1996 Oct;17(10):2171–5

Transforming growth factor beta 1-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bcl-2. Lafon C, et al.
Cell Growth Differ 1996 Aug;7(8):1095–104

Quantitative mapping of platinum and essential trace metal in cisplatin resistant and sensitive human ovarian adenocarcinoma cells. Ortega R, et al.
Cell Mol Biol (Noisy-le-grand) 1996 Feb;42(1):77–88

Comparison of mathematical formulas used for estimation of DNA synthesis time of bromodeoxyuridine-labelled cell populations with different proliferative characteristics. Johansson MC, et al. **Cell Prolif** 1996 Oct;29(10):525–38

Neurotrophin-Trk receptor interactions in neoplasia: a possible role in interstitial and perineural invasion in ductal pancreatic cancer. Miknyoczki SJ, et al.
Crit Rev Oncog 1996;7(1-2):89–100 (109 ref.)

Expression of insulin-like growth factor-I receptor and transferrin receptor by breast cancer cells in pleural effusion smears. Athanassiadou P, et al. **Cytopathology** 1996 Dec;7(6):400–5

Alteration of dopamine D2 receptors in human malignant stomach tissue. Basu S, et al. **Dig Dis Sci** 1997 Jun; 42(6):1260–4

Polyamine levels and ODC activity in intestinal-type and diffuse-type gastric carcinoma. Russo F, et al.
Dig Dis Sci 1997 Mar;42(3):576–9

Up-regulation of insulin/insulin-like growth factor-I hybrid receptors during differentiation of HT29-D4 human colonic carcinoma cells. Garrouste FL, et al.
Endocrinology 1997 May;138(5):2021–32

Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Srikant CB, et al. **Endocrinology** 1996 Aug;137(8):3461–8

Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Swinnen JV, et al. **Endocrinology** 1996 Oct; 137(10):4468–74

pS2 protein expression in gastric carcinoma. An immunohistochemical and immunoradiometric study. Machado JC, et al. **Eur J Cancer** 1996 Aug;32A(9):1585–90

Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Murant SJ, et al.
Eur J Cancer 1997 Feb;33(2):263–71

Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Sun XF, et al. **Eur J Cancer** 1996 Oct; 32A(11):1963–7

The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers. Takanami I, et al.
Eur J Cancer 1996 Aug;32A(9):1504–9

Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5. van den Brûle FA, et al. **Eur J Cancer** 1996 Aug; 32A(9):1598–602

Prognostic significance of epidermal growth factor receptor (EGFR) and c-erbB-2 protein overexpression in adenocarcinoma of the uterine cervix. Altavilla G, et al.
Eur J Gynaecol Oncol 1996;17(4):267–70

Differences in AgNOR quantity between colorectal cancer

and corresponding metastases: are they useful for prognostic purposes? Giuffrè G, et al. **Eur J Histochem** 1997;41(2):111–8

Ras p21 protein immunoreactivity and its relationship to p53 expression and prognosis in gallbladder and extrahepatic biliary carcinoma. Lee CS. **Eur J Surg Oncol** 1997 Jun; 23(3):233–7

p53 overexpression and proliferative activity do not correlate with lymph node metastasis in early gastric cancer. Kanai T, et al. **Eur Surg Res** 1997;29(1):35–41

Biomarker expression in prostatic intraepithelial neoplasia. Myers RB, et al. **Eur Urol** 1996;30(2):153–66 (126 ref.)

Relationship between DNA ploidy and functional estrogen receptors in operable prostate cancer. Nativ O, et al. **Eur Urol** 1997;32(1):96–9

Vacuolating toxin from Helicobacter pylori activates cellular signaling and pepsinogen secretion in human gastric adenocarcinoma cells. Chan EC, et al. **FEBS Lett** 1996 Dec 9;399(1–2):127–30

GATA–6 DNA binding protein expressed in human gastric adenocarcinoma MKN45 cells. Yoshida T, et al. **FEBS Lett** 1997 Sep 8;414(2):333–7

Oxidative damage and transforming growth factor beta 1 expression in pretumoral and tumoral lesions of human intestine. Chiarpotto E, et al. **Free Radic Biol Med** 1997; 22(5):889–94

Antiestrogenic compounds inhibit estrogen–induced expressions of basic fibroblast growth factor and its mRNA in well–differentiated endometrial cancer cells. Fujimoto J, et al. **Gen Pharmacol** 1997 Feb;28(2):215–9

alpha–Fetoprotein–producing (hepatoid) carcinoma of the fallopian tube. Aoyama T, et al. **Gynecol Oncol** 1996 Nov; 63(2):261–6

p53 interference and growth inhibition in p53–mutant and overexpressing endometrial cancer cell lines. Janicek MF, et al. **Gynecol Oncol** 1997 Jul;66(1):94–102

Epithelial and stromal estrogen and progesterone receptor expression in endometrial cancer: true color computer–assisted image analysis versus subjective scoring. Kohlberger PD, et al. **Gynecol Oncol** 1997 Mar; 64(3):404–10

Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. Niemann TH, et al. **Gynecol Oncol** 1997 May;65(2):232–6

Pregnancy associated with colon carcinoma overexpressing p53. Rojansky N, et al. **Gynecol Oncol** 1997 Mar; 64(3):516–20

DNA ploidy and S + G2M fraction (proliferative index) as prognostic determinants in human periampullary cancer. Jorba R, et al. **Hepatogastroenterology** 1995 Sep–Oct; 42(5):740–7

p53 and CD44 as clinical markers of tumour progression in colorectal carcinogenesis. Mulder JW, et al. **Histochem J** 1997 Jun;29(6):439–52 (163 ref.)

Histochemical alterations of mucin in normal colon, inflammatory bowel disease and colonic adenocarcinoma. Owen DA, et al. **Histochem J** 1995 Nov;27(11):882–9

Immunohistochemical expression of metallothionein in normal human colorectal mucosa, in adenomas and in adenocarcinomas and their associated metastases. Giuffrè G, et al. **Histopathology** 1996 Oct;29(4):347–54

Vimentin–positive adenocarcinomas of the stomach: co–expression of vimentin and cytokeratin. Utsunomiya T, et al. **Histopathology** 1996 Dec;29(6):507–16

Extracellular matrix expression in metastasizing and nonmetastasizing adenocarcinomas of the lung. Clarke MR, et al. **Hum Pathol** 1997 Jan;28(1):54–9

Differential expression of N–cadherin in pleural mesotheliomas and E–cadherin in lung adenocarcinomas in formalin–fixed, paraffin–embedded tissues [see comments] Han AC, et al. **Hum Pathol** 1997 Jun; 28(6):641–5. Comment in: Hum Pathol 1997 Jun;28(6):639–40.

E–cadherin in mesothelioma [letter; comment] Jeffers M. **Hum Pathol** 1996 Nov;27(11):1245–6. Comment on: Hum Pathol 1995 Dec;26(12):1363–9.

Association of p53 protein expression in stage I lung adenocarcinoma with reference to cytological subtypes. Konishi T, et al. **Hum Pathol** 1997 May;28(5):544–8

Expression of nm23–H1 in prostatic intraepithelial neoplasia and adenocarcinoma. Myers RB, et al. **Hum Pathol** 1996 Oct;27(10):1021–4

Immunohistochemical localization of p21(WAF1/CIP1) in normal, hyperplastic, and neoplastic uterine tissues. Palazzo JP, et al. **Hum Pathol** 1997 Jan;28(1):60–6

Mucin antigen expression in gastric carcinomas of young and old adults. Sakamoto H, et al. **Hum Pathol** 1997 Sep; 28(9):1056–65

Establishment and characterization of a novel human myoepithelial cell line and matrix–producing xenograft from a parotid basal cell adenocarcinoma. Sternlicht MD, et al. **In Vitro Cell Dev Biol Anim** 1996 Oct;32(9):550–63

Estradiol influences p53 expression in a human endometrial adenocarcinoma heterotransplanted into nude mice. Horvath G, et al. **In Vivo** 1996 Jan–Feb;10(1):29–32

Characterisation of a human endometrial adenocarcinoma established in vivo and in vitro. Karlsson L, et al. **In Vivo** 1996 Jul–Aug;10(4):421–8

Enhancement of bFGF export associated with malignant progression of human salivary gland cell clones. Azuma M, et al. **Int J Cancer** 1997 May 29;71(5):891–6

Inhibition of tumorigenicity in lung adenocarcinoma cells by c–erbB–2 antisense expression. Casalini P, et al. **Int J Cancer** 1997 Aug 7;72(4):631–6

Down–regulation of protein and mRNA expression for transforming growth factor–beta (TGF–beta1) type I and type II receptors in human prostate cancer. Guo Y, et al. **Int J Cancer** 1997 May 16;71(4):573–9

Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Maeda K, et al. **Int J Cancer** 1997 Jun 20;74(3):310–5

Elevated serum levels of p105(erbB–2) in patients with advanced–stage prostatic adenocarcinoma. Myers RB, et al. **Int J Cancer** 1996 Oct 21;69(5):398–402

Heparan sulfate proteoglycan expression in human lung–cancer cells. Nackaerts K, et al. **Int J Cancer** 1997 Jun 20;74(3):335–45

Differential localization of transforming growth factor–beta isoforms in human gastric mucosa and overexpression in gastric carcinoma. Naef M, et al. **Int J Cancer** 1997 Apr 10;71(2):131–7

Overexpression of matrix metalloproteinase–2 and tissue inhibitor of matrix metalloproteinase–2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastasis. Théret N, et al. **Int J Cancer** 1997 Aug 22;74(4):426–32

Hepatoid adenocarcinoma of the endometrium associated with alpha–fetoprotein production. Hoshida Y, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):266–9

Heat response of HT29 cells depends strongly on perfusion—a 31P NMR spectroscopy, HPLC and cell survival analysis. Hentschel M, et al. **Int J Hyperthermia** 1997 Jan–Feb;13(1):69–82

A rare case of ectopic antidiuretic hormone–producing pancreatic adenocarcinoma: new diagnostic approach. Nagashima Y, et al. **Intern Med** 1996 Apr;35(4):280–4

Gastrin levels in colorectal cancer. Niv Y, et al. **Isr J Med Sci** 1997 Mar;33(3):186–9

Post–translational fate of a mucin–like leukocyte sialoglycoprotein (CD43) aberrantly expressed in a colon carcinoma cell line. Baeckström D. **J Biol Chem** 1997 Apr 25;272(17):11503–9

Strikingly different localization of galectin–3 and galectin–4 in human colon adenocarcinoma T84 cells. Galectin–4 is localized at sites of cell adhesion. Huflejt ME, et al. **J Biol Chem** 1997 May 30;272(22):14294–303

Overexpression of cyclin B1 in human colorectal cancers. Wang A, et al. **J Cancer Res Clin Oncol** 1997;123(2):124–7

Dissection of the signaling mechanism for capsule detachment of lipid droplets in rat adrenocortical cells. Fong TH, et al. **J Cell Biochem** 1997 Apr;65(1):67–74

Role of alpha v beta 5 and alpha v beta 6 integrin glycosylation in the adhesion of a colonic adenocarcinoma cell line (HT29–D4). Lehmann M, et al. **J Cell Biochem** 1996 May;61(2):266–77

Epidermal growth factor and sex steroids dynamically regulate a marker of endometrial receptivity in Ishikawa cells. Somkuti SG, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2192–7

Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. Weinberg DS, et al. **J Clin Invest** 1997 Aug 1;100(3):597–603

Expression and localization of inhibin/activin and activin receptors in GH3 cells, a rat pituitary adenocarcinoma cell line. Ying C, et al. **J Endocrinol Invest** 1996 Jan;19(1):6–11

Transforming growth factor–alpha (TGF alpha)–producing gastric carcinoma with acanthosis nigricans: an endocrine effect of TGF alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. Koyama S, et al. **J Gastroenterol** 1997 Feb; 32(1):71–7

Histochemical and immunohistochemical study of human gastric carcinoma differentiation with special reference to supplementary role for endosonography in evaluating depth of invasion. Nakamura T, et al. **J Gastroenterol** 1997 Apr; 32(2):176–83

Liposomes as drug delivery vehicles for boron agents. Hawthorne MF, et al. **J Neurooncol** 1997 May;33(1–2):53–8

PET 2–fluoro–2–deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. Haberkorn U, et al. **J Nucl Med** 1997 Aug;38(8):1215–21

Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L–methionine and L–leucine. Torizuka T, et al. **J Nucl Med** 1997 Mar;38(3):382–6

Ferrous iron uptake but not transfer is down–regulated in Caco–2 cells grown in high iron serum–free medium. Gangloff MB, et al. **J Nutr** 1996 Dec;126(12):3118–27

Expression of parathyroid hormone–related peptide (PTHrP) in gastric tumours. Alipov GK, et al. **J Pathol** 1997 Jun; 182(2):174–9

Expression of cripto in human gall bladder lesions. Fujii K, et al. **J Pathol** 1996 Oct;180(2):166–8

Expression of bcl–2 and p53 in de novo and ex–adenoma colon carcinoma: a comparative immunohistochemical study. Mueller J, et al. **J Pathol** 1996 Nov;180(3):259–65

Ki67 labelling index in gastric carcinomas. An immunohistochemical study using double staining for the evaluation of the proliferative activity of diffuse–type carcinomas. Ramires M, et al. **J Pathol** 1997 May; 182(1):62–7

Expression of Met protein in thyroid tumours. Ruco LP, et al. **J Pathol** 1996 Nov;180(3):266–70

Extracellular matrix remodelling in a murine mammary adenocarcinoma transfected with the interferon–alpha 1 gene. Scarpa S, et al. **J Pathol** 1997 Jan;181(1):116–23

Expression of the laminin gamma 2 chain in pancreatic adenocarcinoma. Soini Y, et al. **J Pathol** 1996 Nov; 180(3):290–4

Expression of cyclin–dependent kinase inhibitor p21WAF1/CIP1 in non–neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. Yasui W, et al. **J Pathol** 1996 Oct; 180(2):122–8

Primary adenocarcinoma of the ureter producing carbohydrate antigen 19–9. Iwaki H, et al. **J Urol** 1996 Oct;156(4):1437

p53, bcl–2 and retinoblastoma proteins as long–term prognostic markers in localized carcinoma of the prostate. Theodorescu D, et al. **J Urol** 1997 Jul;158(1):131–7

Reduced expression of cyclin–dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Yasui W, et al. **Jpn J Cancer Res** 1997 Jul;88(7):625–9

Estrogens and glucocorticoids induce the expression of c–erbB2/NEU receptor in Ishikawa human endometrial cells. Markogiannakis E, et al. **Life Sci** 1997;61(11):1083–95

Expression of nm23 protein in pulmonary adenocarcinomas: inverse 1orrelation to tumor progression. Kawakubo Y, et al. **Lung Cancer** 1997 May;17(1):103–13

Is thrombomodulin useful as a tumor marker of a lung cancer? Tamura A, et al. **Lung Cancer** 1996 Sep;15(2):189–95

Interleukin–2 receptors in pulmonary adenocarcinoma tissue. Yano T, et al. **Lung Cancer** 1996 Dec;16(1):13–9

Alpha–fetoprotein–producing adenocarcinoma of the lung. Yoshino I, et al. **Lung Cancer** 1996 Aug;15(1):125–30 (16 ref.)

Effect of 6–aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies. Koutcher JA, et al. **Magn Reson Med** 1996 Dec; 36(6):887–92

Spectroscopic imaging of the water resonance with short repetition time to study tumor response to hyperoxia. Oikawa H, et al. **Magn Reson Med** 1997 Jul;38(1):27–32

Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd–DTPA–enhanced MRI. Su MY, et al. **Magn Reson Med** 1996 Dec;36(6):868–77

MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Ambros RA, et al. **Mod Pathol** 1996 Dec;9(12):1165–9

Expression of surfactant protein B precursor and surfactant protein B mRNA in adenocarcinoma of the lung. Khoor A, et al. **Mod Pathol** 1997 Jan;10(1):62–7

The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Maeda T, et al. **Mod Pathol** 1996 Sep;9(9):901–9

bcl–2 and p53 in endometrial adenocarcinoma. Taskin M, et al. **Mod Pathol** 1997 Jul;10(7):728–34

Midkine in the progression of rat N–nitroso–N–methylurea–induced mammary tumors. Chen Y, et al. **Mol Carcinog** 1996 Nov;17(3):112–6

Expression of bcl–2, bax, and bcl–XL proteins in azoxymethane–induced rat colonic adenocarcinomas. Hirose Y, et al. **Mol Carcinog** 1997 May;19(1):25–30

Metastasis induced by overexpression of p185neu–T after orthotopic injection into a prostatic epithelial cell line (NbE). Marengo SR, et al. **Mol Carcinog** 1997 Jul; 19(3):165–75

Aspirin–triggered lipoxins (15–epi–LX) are generated by the human lung adenocarcinoma cell line (A549)–neutrophil interactions and are potent inhibitors of cell proliferation. Clària J, et al. **Mol Med** 1996 Sep;2(5):583–96

Interstitial pH and pO2 gradients in solid tumors in vivo: high–resolution measurements reveal a lack of correlation. Helmlinger G, et al. **Nat Med** 1997 Feb;3(2):177–82

Increased proteasome–dependent degradation of the cyclin–dependent kinase inhibitor p27 in aggressive colorectal carcinomas [see comments] Loda M, et al. **Nat Med** 1997 Feb;3(2):231–4. Comment in: Nat Med 1997 Feb;3(2):152–4.

Effect of methionine on glycolysis in tumor cells: in vivo and in vitro NMR studies. Collet V, et al. **NMR Biomed** 1996 Apr;9(2):47–52

Hexafluorobenzene: a sensitive 19F NMR indicator of tumor oxygenation. Mason RP, et al. **NMR Biomed** 1996 May; 9(3):125–34

Positron emission tomography (PET) with 11C–5–hydroxytryptophan (5–HTP) in patients with metastatic hormone–refractory prostatic adenocarcinoma. Kälkner KM, et al. **Nucl Med Biol** 1997 May;24(4):319–25

Feasibility of labeled alpha–acetamido–aminoisobutyric acid as new tracer compound for kinetic labeling of neutral amino acid transport: preparation of alpha–(N–[1–11C]acetyl)– and alpha–(N–[1–14C]acetyl)–aminoisobutyric acid. Prenant C, et al. **Nucl Med Biol** 1996 Apr;23(3):359–63

Biodistribution in tumour–bearing mice of two 90Y–labelled biotins using three–step tumour targeting. Chinol M, et al. **Nucl Med Commun** 1997 Feb;18(2):176–82

Selenite supplementation decreases expression of MAZ in HT29 human colon adenocarcinoma cells. Nelson KK, et al. **Nutr Cancer** 1996;26(1):73–81

K–ras modulates the cell cycle via both positive and negative regulatory pathways. Fan J, et al. **Oncogene** 1997 May 29; 14(21):2595–607

Effects of estradiol on the expression and production of IGFBP-2 by R3230AC mammary tumor cells. Korc-Grodzicki B, et al. **Oncol Res** 1996;8(12):473-83

Relationship between p53 overexpression and gastric cancer progression. Kim JH, et al. **Oncology** 1997 Mar-Apr; 54(2):166-70

Islet hormone secretion in pancreatic cancer patients with diabetes. Permert J, et al. **Pancreas** 1997 Jul;15(1):60-8

Overexpression of intercellular adhesion molecule-1 (ICAM-1) in pancreatic adenocarcinoma in comparison with normal pancreas. Shimoyama S, et al. **Pancreas** 1997 Mar;14(2):181-6

Nuclear p53 accumulation by small-sized adenocarcinomas of the lung. Kawasaki M, et al. **Pathol Int** 1996 Jul; 46(7):486-90

Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Kodate M, et al. **Pathol Int** 1997 Jul;47(7):461-9

Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression. Yasui W, et al. **Pathol Int** 1997 Jul;47(7):470-7

Correlation of alpha 2 beta 1 integrin expression with histological type and hormonal receptor status in breast carcinomas. Lanzafame S, et al. **Pathol Res Pract** 1996 Oct; 192(10):1031-8

Overexpression of the 67 kD laminin receptor correlates with the progression of gastric carcinoma. Lee WA, et al. **Pathol Res Pract** 1996 Dec;192(12):1195-201

Interleukin (IL)-6 as a pancreas carcinoma-derived vascular permeability regulator in vitro. Omi M, et al. **Pathol Res Pract** 1996 Nov;192(11):1107-12

Expression of PDGF, IGF-II, bFGF and TGF-beta 1 in pulmonary adenocarcinoma. Takanami I, et al. **Pathol Res Pract** 1996 Nov;192(11):1113-20

A proposal of additional immunohistochemical markers for hepatoid carcinomas of the foregut [letter; comment] Caruso RA, et al. **Pathology** 1996 Aug;28(3):288. Comment on: Pathology 1995 Jul;27(3):277-9.

Expression of transforming growth factor-beta 1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment. Lindström P, et al. **Prostate** 1996 Oct;29(4):209-18

Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy. Lipponen P, et al. **Prostate** 1997 Jun 15;32(1):9-15

Assessment of human colon cancer protein kinetics in vivo. Gore DC, et al. **Surgery** 1997 Sep;122(3):593-9

Hydroxylated polychlorinated biphenyl metabolites are anti-estrogenic in a stably transfected human breast adenocarcinoma (MCF7) cell line. Kramer VJ, et al. **Toxicol Appl Pharmacol** 1997 Jun;144(2):363-76

Nuclear protein as a prognostic factor of growth activity in prostatic adenocarcinoma. Dohle GR, et al. **Urol Res** 1996;24(5):251-5

Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment. Wikström P, et al. **Urol Res** 1997; 25(2):103-11

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Darson MF, et al. **Urology** 1997 Jun;49(6):857-62

Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study. Castellà EM, et al. **Virchows Arch** 1996 Nov;429(4-5):191-5

Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours. Kamio N. **Virchows Arch** 1996 May;428(2):75-83

Immunohistochemical analysis of intercellular adhesion molecule-1 expression in human gastric adenoma and adenocarcinoma. Nasu R, et al. **Virchows Arch** 1997 Apr; 430(4):279-83

P53 overexpression in gastric adenocarcinoma with Helicobacter pylori infection. Chang KH, et al. **Yonsei Med J** 1997 Apr;38(2):117-24

[The overexpression of c-met oncogene correlation with gastric mucosal lesion] Wang J, et al. **Chung Hua I Hsueh Tsa Chih** 1996 May;76(5):359-62 **(Eng. Abstr.)** **(Chi)**

[Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines] Bachmann-Moisson N, et al. **Bull Cancer** 1996 Oct;83(10):808-15 (37 ref.) (Eng. Abstr.) **(Fre)**

[A case of alpha-fetoprotein-producing pancreatic carcinoma--review of 41 cases reported in Japan] Shimizu E, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Dec; 93(12):921-6 (20 ref.) **(Jpn)**

[The body's antioxidative systems in bronchopulmonary disease] Khyshiktuev BS. **Vestn Ross Akad Med Nauk** 1996; (9):23-7 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Vibrio cholerae 01 isolated in the gallbladder of a patient presenting with cholecystitis. Asnis DS, et al. **Am J Gastroenterol** 1996 Oct;91(10):2241-2

Serum antibodies against Helicobacter pylori proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma. Rudi J, et al. **Dig Dis Sci** 1997 Aug; 42(8):1652-9

Relation between histologic subtypes and location of gastric cancer and Helicobacter pylori. Martín-de-Argila C, et al. **Scand J Gastroenterol** 1997 Apr;32(4):303-7

[Is gastric cancer an infectious disease?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1996 Aug;88(8):555-62 (91 ref.) **(Spa)**

MORTALITY

Endoscopic biliary stenting for the palliation of pancreatic cancer: results, survival predictive factors, and comparison of 10-French with 11.5-French gauge stents. Pereira-Lima JC, et al. **Am J Gastroenterol** 1996 Oct;91(10):2179-84

Factors influencing long-term survival in 100 cases of small intestine primary adenocarcinoma. Veyrières M, et al. **Am J Surg** 1997 Mar;173(3):237-9

Tumor size as a simple prognostic indicator for gastric carcinoma. Adachi Y, et al. **Ann Surg Oncol** 1997 Mar; 4(2):137-40

An audit of the women who died during 1994 from cancer of the cervix in Victoria, Australia. Mitchell H, et al. **Aust N Z J Obstet Gynaecol** 1996 Feb;36(1):73-6

Cervical cancer in New South Wales women: five-year survival, 1972 to 1991. Taylor R, et al. **Aust N Z J Public Health** 1996 Aug;20(4):413-20

Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. McWilliam LJ, et al. **Br J Urol** 1997 Aug; 80(2):287-90

Prognostic indicators for survival after curative resection for patients with carcinoma of the stomach. Wu CW, et al. **Dig Dis Sci** 1997 Jun;42(6):1265-9

Prognostic differences between early squamous-cell and adenocarcinoma of the esophagus. Hölscher AH, et al. **Dis Esophagus** 1997 Jul;10(3):179-84 (52 ref.)

Survival in small intestinal adenocarcinoma. Zar N, et al. **Eur J Cancer** 1996 Nov;32A(12):2114-9

Rectal cancer: the influence of type of operation on local recurrence and survival. Bjerkeset T, et al. **Eur J Surg** 1996 Aug;162(8):643-8

Impact of minimal lymph node metastasis on long-term prognosis after radical prostatectomy. Schmid HP, et al. **Eur Urol** 1997;31(1):11-6

Primary adenocarcinoma of the duodenum: treatment and survival in 89 patients. Santoro E, et al. **Hepatogastroenterology** 1997 Jul-Aug;44(16):1157-63

Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II. Kodama S, et al. **Int J Gynaecol Obstet** 1997 Feb;56(2):147-53

Pre-, intra- and postoperative staging of gastric carcinoma and clinical outcome. Schweizer W, et al. **Int Surg** 1995 Jul-Sep;80(3):204-7

Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? Lenzi R, et al. **J Clin Oncol** 1997 May;15(5):2056-66

Poorer prognosis in older patients with endometrial adenocarcinoma. Hernandez E, et al. **J Natl Med Assoc** 1996 Feb;88(2):107-11

Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987-1991. Wade TP, et al. **J Surg Oncol** 1997 Mar;64(3):242-5

Gastric cancer in the province of Zaragoza (Spain): a survival study. Jimeno-Aranda A, et al. **Neoplasma** 1996; 43(3):199-203

Colorectal cancer in patients aged 30 years or younger. Rodriguez-Bigas MA, et al. **Surg Oncol** 1996 Aug; 5(4):189-94

Population-based analysis of treatment of pancreatic cancer and Whipple resection: Department of Defense hospitals, 1989-1994. Wade TP, et al. **Surgery** 1996 Oct;120(4):680-5; discussion 686-7

[The factors determining survivorship in patients with colorectal carcinoma complicated by obstructive ileus of the large intestine] Stoianov Kh, et al. **Khirurgiia (Sofiia)** 1996;49(2):17-20 (Eng. Abstr.) **(Bul)**

[Prognosis factors in stomach carcinoma] Sendler A, et al. **Dtsch Med Wochenschr** 1997 Jun 13;122(24):794-800 (40 ref.) **(Ger)**

PATHOLOGY

Glandular lesions of the cervix. Validity of cytologic criteria used to differentiate reactive changes, glandular intraepithelial lesions and adenocarcinoma [published erratum appears in Acta Cytol 1997 Mar-Apr;41(2):619-20] DiTomasso JP, et al. **Acta Cytol** 1996 Nov-Dec; 40(6):1127-35

Fine needle aspiration cytology of tubular carcinoma of the breast. Gupta RK, et al. **Acta Cytol** 1997 Jul-Aug; 41(4):1139-43

Criteria for differential diagnosis of complex hyperplasia or beyond in endometrial cytology. Ishii Y, et al. **Acta Cytol** 1997 Jul-Aug;41(4):1095-102

Cytopathology of granulocyte colony-stimulating factor-producing lung adenocarcinoma [letter] Kimura M, et al. **Acta Cytol** 1997 May-Jun;41(3):952-3

Cytologic features of colonic adenocarcinoma. Differences between primary and metastatic neoplasms. Koizumi JH, et al. **Acta Cytol** 1997 Mar-Apr;41(2):419-26

Adenocarcinoma in females detected in serous effusions. Cytomorphologic aspects and immunocytochemical reactivity to cytokeratins 7 and 20. Longatto Filho A, et al. **Acta Cytol** 1997 Jul-Aug;41(4):961-71

Clinical usefulness of endometrial aspiration cytology and CA-125 in the detection of fallopian tube carcinoma. Takeshima N, et al. **Acta Cytol** 1997 Sep-Oct;41(5):1445-50

"Atypical parakeratosis" cells in cervical carcinoma cytology [letter] Vela Velasquez CT. **Acta Cytol** 1997 Mar-Apr; 41(2):614-6

Cathepsin B in the growth of colorectal cancer: increased activity of cathepsin B in human colorectal cancer. Satoh Y, et al. **Acta Med Okayama** 1996 Dec;50(6):305-11

Adenocarcinoma of the fallopian tube. Natural history of an isolated splenic metastasis. Dubecq-Princeteau F, et al. **Acta Oncol** 1997;36(2):221-3

The preoperative staging of pancreatic adenocarcinoma. Rivera JA, et al. **Adv Surg** 1996;30:97-122 (90 ref.)

TNM staging of pancreatic carcinoma using helical CT. Zeman RK, et al. **AJR Am J Roentgenol** 1997 Aug; 169(2):459-64

A case of inflammatory breast cancer [letter; comment] Ostergaard CA, et al. **Am Fam Physician** 1996 Oct; 54(5):1470, 1473. Comment on: Am Fam Physician 1995 Sep 1;52(3):929-34.

Cancerization of small ectatic ducts of the breast by ductal carcinoma in situ cells with apocrine snouts: a lesion associated with tubular carcinoma. Goldstein NS, et al. **Am J Clin Pathol** 1997 May;107(5):561-6

Histology of the mucosa in sigmoid colon specimens with diverticular disease: observations for the interpretation of sigmoid colonoscopic biopsy specimens. Goldstein NS, et al. **Am J Clin Pathol** 1997 Apr;107(4):438-44

Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. Renshaw AA, et al. **Am J Clin Pathol** 1997 Jun;107(6):704-8

Female pseudohermaphroditism due to congenital adrenal hyperplasia complicated by adenocarcinoma of the prostate and clear cell carcinoma of the endometrium. Winters JL, et al. **Am J Clin Pathol** 1996 Nov;106(5):660-4

Metastatic endometrial adenocarcinoma to the skin of a toe. Giardina VN, et al. **Am J Dermatopathol** 1996 Feb; 18(1):94-8 (40 ref.)

Malignant mesothelioma metastatic to the skin, presenting as inflammatory carcinoma. Prieto VG, et al. **Am J Dermatopathol** 1997 Jun;19(3):261-5

Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Cameron AJ, et al. **Am J Gastroenterol** 1997 Apr;92(4):586-91

Three histologically different tiny gastric cancers developing adjacent to each other, resected endoscopically in a single mucosal piece. Matsuhashi N, et al. **Am J Gastroenterol** 1996 Oct;91(10):2200-2

Low epithelial cell proliferation and absence of oncoprotein expression in juvenile polyposis of the stomach, with or without tumors. Mitomi H, et al. **Am J Gastroenterol** 1997 Aug;92(8):1374-7

Primary signet ring cell carcinoma of colorectum: an age- and sex-matched controlled study. Tung SY, et al. **Am J Gastroenterol** 1996 Oct;91(10):2195-9

Recurrence of unclassifiable uterine cancer after modified laparoscopic hysterectomy with morcellation. Schneider A. **Am J Obstet Gynecol** 1997 Aug;177(2):478-9

Rapidly progressive cervical cancer: the Connecticut experience. Schwartz PE, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 2):1105-9

Identification of anterior uveal tumor border by transscleral transillumination and an ophthalmic endoscope. Terasaki H, et al. **Am J Ophthalmol** 1997 Jan;123(1):138-40

Expression of the Ets-1 proto-oncogene in human gastric carcinoma: correlation with tumor invasion. Nakayama T, et al. **Am J Pathol** 1996 Dec;149(6):1931-9

Experimental evidence for the origin of ductal-type adenocarcinoma from the islets of Langerhans. Pour PM, et al. **Am J Pathol** 1997 Jun;150(6):2167-80

Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Qian J, et al. **Am J Pathol** 1996 Oct;149(4):1193-9

Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma. Transfer of platelet-derived growth factor-AB/BB to stromal cells. Sundberg C, et al. **Am J Pathol** 1997 Aug;151(2):479-92

Analysis of cell damage and proliferation in Helicobacter pylori-infected human gastric mucosa from patients with gastric adenocarcinoma. Yabuki N, et al. **Am J Pathol** 1997 Sep;151(3):821-9

Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Chu YW, et al. **Am J Respir Cell Mol Biol** 1997 Sep;17(3):353-60

Immunocytochemical detection of isolated epithelial tumor cells in bone marrow of patients with pancreatic carcinoma. Thorban S, et al. **Am J Surg** 1996 Sep;172(3):297-8

Hepatoid adenocarcinoma of the lung: report of a case of an unusual alpha-fetoprotein-producing lung tumor. Arnould L, et al. **Am J Surg Pathol** 1997 Sep;21(9):1113-8

Adenocarcinoma of the prostate with atrophic features. Cina SJ, et al. **Am J Surg Pathol** 1997 Mar;21(3):289-95

Increasing incidence of minimal residual cancer in radical prostatectomy specimens. DiGiuseppe JA, et al. **Am J Surg Pathol** 1997 Feb;21(2):174-8

Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process. Egan AJ, et al. **Am J Surg Pathol** 1997 Aug;21(8):931-5

Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Engel CJ, et al. **Am J Surg Pathol** 1996 Oct;20(10):1260-5

Synchronous mucosa-associated lymphoid tissue lymphoma and adenocarcinoma of the stomach. Goteri G, et al. **Am J Surg Pathol** 1997 May;21(5):505–9

A comparative study of pure tubular and tubulolobular carcinoma of the breast. Green I, et al. **Am J Surg Pathol** 1997 Jun;21(6):653–7

The significance of intraluminal crystalloids in benign prostatic glands on needle biopsy. Henneberry JM, et al. **Am J Surg Pathol** 1997 Jun;21(6):725–8

Intrabiliary growth of metastatic colonic adenocarcinoma: a pattern of intrahepatic spread easily confused with primary neoplasia of the biliary tract. Riopel MA, et al. **Am J Surg Pathol** 1997 Sep;21(9):1030–6

Distinguishing Cowper's glands from neoplastic and pseudoneoplastic lesions of prostate: immunohistochemical and ultrastructural studies. Saboorian MH, et al. **Am J Surg Pathol** 1997 Sep;21(9):1069–74

Distribution pattern of basal cells detected by cytokeratin 34 beta E12 in primary prostatic duct adenocarcinoma. Samaratunga H, et al. **Am J Surg Pathol** 1997 Apr; 21(4):435–40

Foamy gland carcinoma of the prostate [letter; comment] Schindler S, et al. **Am J Surg Pathol** 1997 May;21(5):616–8 . Comment on: Am J Surg Pathol 1996 Apr;20(4):419–26.

Implications of fine-needle aspiration in patients with resectable pancreatic cancer. Johnson DE, et al. **Am Surg** 1997 Aug;63(8):675–9; discussion 679–80

Does any correlation exist between the Gleason classification system and the computer-assisted microscope analysis of Feulgen-stained nuclei features in human prostate adenocarcinoma? Petein M, et al. **Anal Cell Pathol** 1996 Dec;12(3):159–71

Evaluation of the reproducibility of Auer's classification of DNA histogram in breast carcinoma. Verderio P, et al. **Anal Cell Pathol** 1996 Jul;11(2):97–106

Cytologic differentiation grade and malignancy DNA index in prostatic adenocarcinoma. Azúa J, et al. **Anal Quant Cytol Histol** 1997 Apr;19(2):102–6

Early gastric cancer and gastric dysplasia. Pascal RR, et al. **Ann Ital Chir** 1996 May–Jun;67(3):391–7; discussion 397–8 (51 ref.)

Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Dirix LY, et al. **Ann Oncol** 1996 Oct; 7(8):843–8

Tumor size as a simple prognostic indicator for gastric carcinoma. Adachi Y, et al. **Ann Surg Oncol** 1997 Mar; 4(2):137–40

State of differentiation affects the response of endometrial adenocarcinoma cells to retinoic acid. Carter CA, et al. **Anticancer Res** 1997 May–Jun;17(3C):1973–83

Clinicopathologic characteristics of gastric cancer patients with cancer infiltration at surgical margin at gastrectomy. Fujimoto S, et al. **Anticancer Res** 1997 Jan–Feb; 17(1B):689–94

Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Janvier R, et al. **Anticancer Res** 1997 May–Jun; 17(3A):1551–7

Benign and malignant stellate breast lesions: structural differences in 5 microns sections and thick tissue slices. Kulka J, et al. **Anticancer Res** 1996 Nov–Dec; 16(6C):3965–70

Intratumoral heterogeneity in prostate cancer demonstrated by volume-weighted mean nuclear volume. Fujikawa K, et al. **APMIS** 1997 Apr;105(4):322–8

Cutaneous metastases from gastric adenocarcinoma. Report of two cases and review of the literature. Boscaino A, et al. **Arch Anat Cytol Pathol** 1996;44(1):60–4 (8 ref.)

Immunohistological distribution of heparan sulfate proteoglycan and chondroitin 6-sulfate in carcinomas with eccrine differentiation. Kazama T, et al. **Arch Dermatol Res** 1996 Oct;288(11):718–21

Adenocarcinoma of the iris pigment epithelium. Spraul CW, et al. **Arch Ophthalmol** 1996 Dec;114(12):1512–7 (35 ref.)

Progressive increase of apoptosis in prostatic intraepithelial neoplasia and carcinoma: comparison between in situ end-labeling of fragmented DNA and detection by routine hematoxylin-eosin staining. Drachenberg CB, et al. **Arch Pathol Lab Med** 1997 Jan;121(1):54–8

Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Katada N, et al. **Arch Surg** 1997 Jul;132(7):728–33

Follicular and Hürthle cell thyroid neoplasms. Is frozen-section evaluation worthwhile? Paphavasit A, et al. **Arch Surg** 1997 Jun;132(6):674–8; discussion 678–80

Node-positive duodenal carcinoma is curable. Pickleman J, et al. **Arch Surg** 1997 Mar;132(3):241–4

Disorders of male genitalia. Clearihan L. **Aust Fam Physician** 1996 Apr;25(4):584–5

Re: Adenocarcinoma in situ of the uterine cervix progressing to invasive adenocarcinoma [letter; comment] Chang T, et al. **Aust N Z J Obstet Gynaecol** 1997 Feb;37(1):132–3 . Comment on: Aust N Z J Obstet Gynaecol 1996 May;36(2):218–20.

Adenocarcinoma in situ of the uterine cervix progressing to invasive adenocarcinoma [see comments] Hocking GR, et al. **Aust N Z J Obstet Gynaecol** 1996 May;36(2):218–20. Comment in: Aust N Z J Obstet Gynaecol 1997 Feb;37(1):132–3.

Adverse impact of pneumoperitoneum on intraperitoneal implantation and growth of tumour cell suspension in an experimental model. Mathew G, et al. **Aust N Z J Surg** 1997 May;67(5):289–92

Flavone acetic acid stimulates nitric oxide and peroxynitrite production in subcutaneous mouse tumors. Harris SR, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):509–14

Laminin mediates basement membrane induced differentiation of HEC 1B endometrial adenocarcinoma cells. Behrens P, et al. **Biochem Cell Biol** 1996;74(6):875–86

Basement membrane induced differentiation of HEC-1B(L) endometrial adenocarcinoma cells affects both morphology and gene expression. Hopfer H, et al. **Biochem Cell Biol** 1996;74(2):165–77

Variants of integrin beta 4 subunit in human endometrial adenocarcinoma cells: mediators of ECM-induced differentiation? Strunck E, et al. **Biochem Cell Biol** 1996; 74(6):867–73

Immunohistochemical analysis of p185 in normal and transformed human tissues. Pagani R, et al. **Biochem Soc Trans** 1996 May;24(2):306S

Induction of apoptosis by ubenimex (Bestatin) in human non-small-cell lung cancer cell lines. Ezawa K, et al. **Biomed Pharmacother** 1996;50(6-7):283–9

Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Guarini A, et al. **Blood** 1997 Jan 1;89(1):212–8

Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells. Courage C, et al. **Br J Cancer** 1996 Oct;74(8):1199–205

p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma. Runnebaum IB, et al. **Br J Cancer** 1996 Oct;74(8):1157–60

Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Schneider HJ, et al. **Br J Cancer** 1997; 75(3):427–31

Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s). Suarez Pestana E, et al. **Br J Cancer** 1997;75(2):213–20

Polymorphous low-grade adenocarcinoma of parotid gland. Merchant WJ, et al. **Br J Oral Maxillofac Surg** 1996 Aug; 34(4):328–30 (11 ref.)

Polymorphous low-grade adenocarcinoma of the palate in a 16-year-old male patient [letter] Minić AJ. **Br J Oral Maxillofac Surg** 1996 Dec;34(6):540–1

Oesophagogastrectomy for iatrogenic perforation of oesophageal and cardia carcinoma. Adam DJ, et al. **Br J Surg** 1996 Oct;83(10):1429–32

Prospective comparison of laparoscopy, ultrasonography and computed tomography in the staging of gastric cancer. Stell DA, et al. **Br J Surg** 1996 Sep;83(9):1260–2

Primary adenocarcinoma of the rete testis. Okada H, et al. **Br J Urol** 1997 Feb;79(2):300–2

Adenosquamous carcinoma of the prostate. Orhan D, et al. **Br J Urol** 1996 Oct;78(4):646–7

A case report and review: the gross, histological and immunohistochemical characteristics of a carcinoma of ectopic thyroid in a dog. Constantino-Casas P, et al. **Br Vet J** 1996 Nov;152(6):669–72 (10 ref.)

Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Vermeulen PB, et al. **Breast Cancer Res Treat** 1997 Jan;42(2):165–72

Signet-ring sinus histiocytosis: a reactive disorder that mimics metastatic adenocarcinoma. Guerrero-Medrano J, et al. **Cancer** 1997 Jul 15;80(2):277–85

The role of dietary factors in the intestinal and diffuse histologic subtypes of gastric adenocarcinoma: a case-control study in the U.S. Harrison LE, et al. **Cancer** 1997 Sep 15;80(6):1021–8

Multiple early gastric carcinomas. Clinicopathologic features and histogenesis. Isozaki H, et al. **Cancer** 1996 Nov 15; 78(10):2078–86

The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Kallakury BV, et al. **Cancer** 1997 Aug 15;80(4):753–63

Lymphatic flow and neural plexus invasion associated with carcinoma of the body and tail of the pancreas. Kayahara M, et al. **Cancer** 1996 Dec 15;78(12):2485–91

Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract. Lee CS. **Cancer** 1996 Nov 1; 78(9):1881–7

Basal cell adenocarcinoma of the salivary glands. Report of seven cases and review of the literature. Muller S, et al. **Cancer** 1996 Dec 15;78(12):2471–7 (26 ref.)

Synchronous and metachronous primary gastric lymphoma and adenocarcinoma: a clinicopathological study of 12 patients. Nakamura S, et al. **Cancer** 1997 Mar 15; 79(6):1077–85

Aggressive variants of chromophobe renal cell carcinoma. Renshaw AA, et al. **Cancer** 1996 Oct 15;78(8):1756–61 (24 ref.)

Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Ross JS, et al. **Cancer** 1997 Jun 1;79(11):2162–70

Morphologic, histologic, and molecular similarities between adenocarcinomas arising in the gastric stump and the intact stomach. Safatle-Ribeiro AV, et al. **Cancer** 1996 Dec 1; 78(11):2288–99

Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes. Samlal RA, et al. **Cancer** 1997 Oct 1;80(7):1234–40

Assessment of microsatellite alterations in young patients with gastric adenocarcinoma [letter] Seruca R, et al. **Cancer** 1997 Oct 1;80(7):1358–60

Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Silberman MA, et al. **Cancer** 1997 Feb 15;79(4):772–9

Lymph node spread from carcinoma of the gallbladder. Tsukada K, et al. **Cancer** 1997 Aug 15;80(4):661–7

Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Yang G, et al. **Cancer** 1996 Sep 15;78(6):1267–71

Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas. Van Laar JA, et al. **Cancer Chemother Pharmacol** 1996;39(1-2):79–89

Use of strip biopsy for early duodenal cancer—a case report. Obata S, et al. **Cancer Detect Prev** 1995;19(6):535–8

Decrease in Le(x) expression in esophageal adenocarcinomas arising in Barrett's epithelium. Engel U, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Apr;6(4):245–8

1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Schwartz GG, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Sep; 6(9):727–32

Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia. Younes M, et al. **Cancer Epidemiol Biomarkers Prev** 1997 May; 6(5):303–5

Retention and processing of the monoclonal anti-prostate E4 antibody after binding to prostatic adenocarcinoma DU 145 cells. Essand M, et al. **Cancer Immunol Immunother** 1996 Sep;43(1):39–43

Differential effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro. Ogasawara M, et al. **Cancer Lett** 1997 Jun 3;116(1):111–6

Staurosporine inhibits the proliferation, alters the cell cycle distribution and induces apoptosis in HT-29 human colon adenocarcinoma cells. Qiao L, et al. **Cancer Lett** 1996 Oct 1;107(1):83–9

Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma. El-Zein RA, et al. **Cancer Lett** 1997 Jan 15;112(1):71–8

Active transport of glutathione S-conjugate in human colon adenocarcinoma cells. Zhang K, et al. **Cancer Lett** 1996 Nov 12;108(1):143–51

Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Bright RK, et al. **Cancer Res** 1997 Mar 1; 57(5):995–1002

Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Foster BA, et al. **Cancer Res** 1997 Aug 15;57(16):3325–30

Inhibition of apoptosis in colon tumors induced in the rat by 2-amino-3-methylimidazo[4,5-f]quinoline. Hayashi R, et al. **Cancer Res** 1996 Oct 1;56(19):4307–10

Suppression of experimental lung colonization of mouse colon adenocarcinoma 26 in vivo by an anti-idiotype monoclonal antibody recognizing a platelet surface molecule. Kato Y, et al. **Cancer Res** 1997 Jul 15; 57(14):3040–5

Isolation of murine and human homologues of the fission-yeast dis3+ gene encoding a mitotic-control protein and its overexpression in cancer cells with progressive phenotype. Lim J, et al. **Cancer Res** 1997 Mar 1;57(5):921–5

GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Miquel K, et al. **Cancer Res** 1997 May 15;57(10):1846–50

Prostate cancer progression, metastasis, and gene expression in transgenic mice. Perez-Stable C, et al. **Cancer Res** 1997 Mar 1;57(5):900–6

Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Sartor CI, et al. **Cancer Res** 1997 Mar 1;57(5):978–87

Novel estrogenic action of the pesticide residue beta-hexachlorocyclohexane in human breast cancer cells. Steinmetz R, et al. **Cancer Res** 1996 Dec 1;56(23):5403–9

Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Swinnen JV, et al. **Cancer Res** 1997 Mar 15;57(6):1086–90

Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Tanigawa N, et al. **Cancer Res** 1997 Mar 15;57(6):1043–6

Predictive value of proliferation, differentiation and apoptosis as intermediate markers for colon tumorigenesis. Chang WC, et al. **Carcinogenesis** 1997 Apr;18(4):721–30

The calcium-binding protein calretinin-22k, an alternative splicing product of the calretinin gene is expressed in several colon adeno carcinoma cell lines. Gander JC, et al. **Cell Calcium** 1996 Jul;20(1):63–72

Growth inhibitory effect of interferon-beta is associated with

the induction of cyclin-dependent kinase inhibitor p27Kip1 in a human gastric carcinoma cell line. Kuniyasu H, et al. **Cell Growth Differ** 1997 Jan;8(1):47–52

Cyclin-dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice. Magdaleno SM, et al. **Cell Growth Differ** 1997 Feb;8(2):145–55

Calcifying liver metastases in a case of primary lung cancer. Balikó Z, et al. **Chest** 1997 Apr;111(4):1121–2

Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer. Liang Z, et al. **Chin Med J (Engl)** 1996 May;109(5):353–5

The route of seminal vesicle involvement in adenocarcinoma of prostate: lymphaticovascular or local extension? Chuang YC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Feb; 59(2):95–8

Effects of ionizing radiation on the adhesive interaction of human tumor and endothelial cells in vitro. Kiani MF, et al. **Clin Exp Metastasis** 1997 Jan;15(1):12–8

Transforming growth factor beta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Kostenuik PJ, et al. **Clin Exp Metastasis** 1997 Jan;15(1):41–52

Inhibitory effects of fluorinated pyrimidines, 5'-DFUR, UFT and T-506, in a model of hepatic metastasis of mouse colon 26 adenocarcinoma-assessment of inhibitory activity and adverse reactions at the maximum tolerated dose. Tazawa K, et al. **Clin Exp Metastasis** 1997 May;15(3):266–71

Transformation of residual mature ovarian teratoma to adenocarcinoma 10 years after initial treatment. Ahmed FY, et al. **Clin Oncol (R Coll Radiol)** 1996;8(2):125–6

Review of the screening history of Alberta women with invasive cervical cancer. Stuart GC, et al. **CMAJ** 1997 Sep 1;157(5):513–9

Granular cell basal cell carcinoma. Reichel M. **Cutis** 1997 Feb;59(2):88–90 (6 ref.)

Comparison of automated and manual analysis of interphase in situ hybridization signals in tissue sections and nuclear suspensions. Krijtenburg PJ, et al. **Cytometry** 1996 Sep 1; 25(1):99–103

Correlation of endoscopic cytology and histology in oesophageal cancer: results in Porto Alegre, RS—Brazil. Frantz MA, et al. **Cytopathology** 1996 Feb;7(1):38–53

Glandular lesions of the cervix-cytological and histological correlation. Jackson SR, et al. **Cytopathology** 1996 Feb; 7(1):10–6

Salivary duct carcinoma: a cytological and histopathological study. Simpson RH, et al. **Cytopathology** 1996 Apr; 7(2):141–4

Salivary epithelial-myoepithelial carcinoma: report of a case misinterpreted as pleomorphic adenoma on fine needle aspiration (FNA). Stewart CJ, et al. **Cytopathology** 1997 Jun;8(3):203–9

Apocrine adenocarcinoma presenting as a large ulcerated axillary mass. Zehr KJ, et al. **Dermatol Surg** 1997 Jul; 23(7):585–7

Fine-needle biopsy technique for diagnosis of inflammatory carcinoma of the breast. Akhtar M. **Diagn Cytopathol** 1996 Jul;15(1):76–7

Fine-needle aspiration of inflammatory carcinoma of the breast. Dodd LG, et al. **Diagn Cytopathol** 1996 Dec; 15(5):363–6

Cytodiagnosis of Hashimoto's thyroiditis associated with a metastatic adenocarcinoma. [letter] Gupta RK, et al. **Diagn Cytopathol** 1996 Feb;14(1):90–1

Utility of fine-needle aspiration biopsy in solid renal masses. Kelley CM, et al. **Diagn Cytopathol** 1996 Feb;14(1):14–9

Malignant pleural effusions due to adeno-endocrine-cell carcinoma of the appendix: a case report. Kobayashi TK, et al. **Diagn Cytopathol** 1997 Jun;16(6):522–5

Ciliated cell adenocarcinoma of the endometrium diagnosed by endometrial brush cytology and confirmed by hysterectomy: a case report detailing a highly efficient cytology collection and processing technique. Maksem JA. **Diagn Cytopathol** 1997 Jan;16(1):78–82

Microinvasive adenocarcinoma of the cervix: a cytohistopathologic study of 40 cases. Mulvany N, et al. **Diagn Cytopathol** 1997 May;16(5):430–6

Diagnostic significance of signet ring cells in fine-needle aspirates of the breast. Sethi S, et al. **Diagn Cytopathol** 1997 Feb;16(2):117–21

Cytologic features of neoplastic lesions in endocervical glands. Siziopikou KP, et al. **Diagn Cytopathol** 1997 Jul; 17(1):1–7

Distal intramural spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis. Andreola S, et al. **Dis Colon Rectum** 1997 Jan;40(1):25–9

Possible effect of pneumoperitoneum on the spreading of colon cancer tumor cells. Chen WS, et al. **Dis Colon Rectum** 1997 Jul;40(7):791–7

Synchronous anorectal malignant melanoma and rectal adenocarcinoma: report of a case. Delikaris P, et al. **Dis Colon Rectum** 1997 Jan;40(1):105–8

Carcinoma of the rectum. Possible cellular predictors of metastatic potential and response to radiation therapy. Desai GR, et al. **Dis Colon Rectum** 1996 Oct;39(10):1090–6

Preoperative staging of irradiated rectal cancers using digital rectal examination, computed tomography, endorectal ultrasound, and magnetic resonance imaging does not accurately predict T0,N0 pathology. Kahn H, et al. **Dis Colon Rectum** 1997 Feb;40(2):140–4

Flat cancers do develop in the polyp-free large intestine. Kuramoto S, et al. **Dis Colon Rectum** 1997 May; 40(5):534–39; discussion 539–42

Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki67. Kyzer S, et al. **Dis Colon Rectum** 1997 Mar;40(3):322–5

Esophageal achalasia and adenocarcinoma in Barrett's esophagus: a report of two cases and a review of the literature. Ellis FH Jr, et al. **Dis Esophagus** 1997 Jan; 10(1):55–60 (25 ref.)

Prognostic differences between early squamous-cell and adenocarcinoma of the esophagus. Hölscher AH, et al. **Dis Esophagus** 1997 Jul;10(3):179–84 (52 ref.)

Prevalence, management and outcome of early adenocarcinoma (pT1) of the esophago-gastric junction. Comparison between early cancer in Barrett's esophagus (type I) and early cancer of the cardia (type II). Ruol A, et al. **Dis Esophagus** 1997 Jul;10(3):190–5

Helicobacter pylori colonization of Barrett's esophagus and its progression to cancer. Wright TA, et al. **Dis Esophagus** 1997 Jul;10(3):196–200

Simultaneous adenocarcinoma and malignant lymphoma of the stomach. Matsushita M, et al. **Endoscopy** 1997 Feb; 29(2):134

Gastric carcinoma with discrete intragastric and duodenal metastases: endoscopic and histological findings. Young TH, et al. **Endoscopy** 1996 May;28(4):404

Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Price JT, et al. **Eur J Cancer** 1996 Oct;32A(11):1977–82

Carcino-embryonic antigen in monitoring the growth of human colon adenocarcinoma tumour cells SK-CO-1 and HT-29 in vitro and in nude mice. Sölétormos G, et al. **Eur J Cancer** 1997 Jan;33(1):108–14

Non-neoplastic changes in gastric antrum: are they different in distally located intestinal and diffuse-type gastric adenocarcinoma? Knawy BA, et al. **Eur J Cancer Prev** 1997 Apr;6(2):167–70

Differentiation of BCS-TC2 human colon adenocarcinoma cells by sodium butyrate: increase in 5'-nucleotidase activity. Navarro JM, et al. **Eur J Clin Invest** 1997 Jul; 27(7):620–8

Untreated endometrial adenocarcinoma: a case report. Armentano G, et al. **Eur J Gynaecol Oncol** 1997;18(2):144–5

Prognostic significance of serum tumour markers in carcinoma of the cervix. Ngan HY, et al. **Eur J Gynaecol Oncol** 1996;17(6):512–7

Postoperative management of patients with stage Ib endometrial carcinoma. Sainz de la Cuesta R, et al. **Eur J Gynaecol Oncol** 1996;17(5):338–41

The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Hatzoglou A, et al. **Eur J Pharmacol** 1996 Jan 25;296(2):199–207

Diagnostic limits in precursor lesions of prostatic cancer. Algaba F, et al. **Eur Urol** 1996;30(2):212–21 (27 ref.)

Knowledge-based image analysis in the precursors of prostatic adenocarcinoma. Bartels PH, et al. **Eur Urol** 1996; 30(2):234–42 (17 ref.)

Staging prostate cancer—1997: current methods and limitations. Bostwick DG. **Eur Urol** 1997;32 Suppl 3:2–14 (86 ref.)

Indications for preoperative seminal vesicle biopsies in staging of clinically localized prostatic cancer. Guillonneau B, et al. **Eur Urol** 1997;32(2):160–5

Prostate cancer: indicators of aggressiveness. Sakr WA, et al. **Eur Urol** 1997;32 Suppl 3:15–23 (91 ref.)

Polarized expression of HD1: relationship with the cytoskeleton in cultured human colonic carcinoma cells. Fontao L, et al. **Exp Cell Res** 1997 Mar 15;231(2):319–27

PKC-dependent long-term effect of PMA on protein cell surface expression in Caco-2 cells. Sapin C, et al. **Exp Cell Res** 1997 Mar 15;231(2):308–18

Differential effects of EGF and amphiregulin on adhesion molecule expression and migration of colon carcinoma cells. Solic N, et al. **Exp Cell Res** 1997 Aug 1;234(2):465–76

Retinoids differentially regulate the proliferation of colon cancer cell lines. Stewart LV, et al. **Exp Cell Res** 1997 Jun 15;233(2):321–9

All-trans-retinoic acid blocks cell cycle progression of human ovarian adenocarcinoma cells at late G1. Wu S, et al. **Exp Cell Res** 1997 May 1;232(2):277–86

Insulin-like growth factor-II participates in the biphasic effect of a gonadotropin-releasing hormone agonist on ovarian cancer cell growth. Ho MN, et al. **Fertil Steril** 1997 May;67(5):870–6

Morphology of Barrett's esophagus and Barrett's-associated dysplasia and adenocarcinoma. Antonioli DA, et al. **Gastroenterol Clin North Am** 1997 Sep;26(3):495–506 (52 ref.)

Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology [see comments] Falk GW, et al. **Gastroenterology** 1997 Jun;112(6):1787–97. Comment in: Gastroenterology 1997 Jun;112(6):2138–42.

The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Kapitanović S, et al. **Gastroenterology** 1997 Apr; 112(4):1103–13

Radial scanning and linear array endosonography for staging pancreatic cancer: a prospective randomized comparison. Gress F, et al. **Gastrointest Endosc** 1997 Feb;45(2):138–42

Biopsies of the ampullary region in sphincter of Oddi dysfunction [letter; comment] Martin DF. **Gastrointest Endosc** 1996 Aug;44(2):208. Comment on: Gastrointest Endosc 1995 Oct;42(4):296–300.

Sarcomatoid chromophobe cell renal carcinoma: immunohistochemical and lectin study in one case. Gómez-Román JJ, et al. **Gen Diagn Pathol** 1997 Jul; 143(1):63–9

Atypical (carcinoma-like) and simple glandular inclusions in retroperitoneal lymph nodes. Horn LC, et al. **Gen Diagn Pathol** 1996 May;141(5–6):319–25

Stereologic estimates of volume-weighted mean nuclear volume in colorectal adenocarcinoma: correlation with histologic grading, Dukes' staging, cell proliferation activity and p53 protein expression. Martín R, et al. **Gen Diagn Pathol** 1997 Jul;143(1):29–38

Nucleolar organizer regions in exocrine pancreas in chronic pancreatitis and ductal adenocarcinoma. Diagnostic value and cytophysiologic correlate. Pollok A. **Gen Diagn Pathol** 1997 Feb;142(3–4):199–209

The mixed type in Laurén's classification of gastric carcinoma. Histologic description and biologic behavior. Stelzner S, et al. **Gen Diagn Pathol** 1997 Jul;143(1):39–48

Elevation of an alpha(1,3)fucosyltransferase activity correlated with apoptosis in the human colon adenocarcinoma cell line, HT-29. Akamatsu S, et al. **Glycoconj J** 1996 Dec;13(6):1021–9

Brain metastases from a primary carcinoma of the fallopian tube. Cormio G, et al. **Gynecol Obstet Invest** 1996; 41(4):286–8

Urethral caruncle: an unusual presentation of ovarian tumour. Hammadeh MY, et al. **Gynecol Obstet Invest** 1996; 42(4):279–80

Transforming growth factor-beta negatively modulates proliferation and c-fos expression of the human endometrial adenocarcinoma cell line HEC-1-A. Bergman CA, et al. **Gynecol Oncol** 1997 Apr;65(1):63–8

Extramammary Paget's disease of the vulva: metastases to the bone marrow in the absence of an underlying adenocarcinoma—case report and literature review. Cappuccini F, et al. **Gynecol Oncol** 1997 Jul;66(1):146–50 (14 ref.)

Abdominal dissemination of malignant cells with hysteroscopy. Egarter C, et al. **Gynecol Oncol** 1996 Oct; 63(1):143–4

Primary peritoneal adenocarcinoma metastatic to the brain. Eltabbakh GH, et al. **Gynecol Oncol** 1997 Jul;66(1):160–3

Early adenocarcinoma of the uterine cervix. Kaku T, et al. **Gynecol Oncol** 1997 May;65(2):281–5

Adenocarcinoma of the uterine cervix with predominantly villogladular papillary growth pattern. Kaku T, et al. **Gynecol Oncol** 1997 Jan;64(1):147–52

An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Look KY, et al. **Gynecol Oncol** 1996 Dec; 63(3):304–11

Adenocarcinoma of the breast metastatic to benign ovarian fibroma. Perry LJ, et al. **Gynecol Oncol** 1996 Sep; 62(3):408–10

Pretreatment transperitoneal laparoscopic staging pelvic and paraaortic lymphadenectomy in large (> or = 5 cm) stage IB2 cervical carcinoma: report of a pilot study. Recio FO, et al. **Gynecol Oncol** 1996 Dec;63(3):333–6

A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Rose PG, et al. **Gynecol Oncol** 1996 Oct;63(1):101–4

Villoglandular adenocarcinoma of the cervix: a report of three cases and review of the literature. Stanley-Christian H, et al. **Gynecol Oncol** 1997 Aug;66(2):327–30 (12 ref.)

A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Sutton GP, et al. **Gynecol Oncol** 1996 Oct;63(1):25–7

Prognostic value of peritoneal cytology in patients with carcinoma of the uterine cervix. Takeshima N, et al. **Gynecol Oncol** 1997 Jan;64(1):136–40

Distribution of epithelial-specific antigen in uterine cervix with endocervical glandular dysplasia. Umezaki K, et al. **Gynecol Oncol** 1997 Sep;66(3):393–8

Prognostic value of the TNM-classification for small bowel cancer. Contant CM, et al. **Hepatogastroenterology** 1997 Mar-Apr;44(14):430–4

Relationship between hematogenic metastasis of gastric cancer and the maximum extent of venous invasion by cancer cells in the gastric wall. Ikeguchi M, et al. **Hepatogastroenterology** 1995 Sep-Oct;42(5):660–5

Clinical and pathologic features of early gastric cancer in elderly patients. Ishigami S, et al. **Hepatogastroenterology** 1997 Jul-Aug;44(16):1164–8

Clinicopathological analysis of gastric cancer in young adults. Kitamura K, et al. **Hepatogastroenterology** 1996 Sep-Oct; 43(11):1273–80

The regrowth of rectal adenocarcinoma after pre-operative radiotherapy with a report of two cases. Kotera H, et al. **Hepatogastroenterology** 1997 Mar-Apr;44(14):394–7

Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Malecka-Panas E, et al. **Hepatogastroenterology** 1997 Mar-Apr;44(14):435–40

DNA ploidy, proliferative index and EGF-R status in 130

cases of resected gastric cancer--a multivariate analysis. Santoro E, et al. **Hepatogastroenterology** 1997 May-Jun; 44(15):826-37

Portal tumor thrombi due to gastric cancer. Sugawara Y, et al. **Hepatogastroenterology** 1996 Jul-Aug;43(10):1000-5 (25 ref.)

Hepatoid adenocarcinoma of the stomach: a case report. Sugawara Y, et al. **Hepatogastroenterology** 1996 Jul-Aug; 43(10):995-9

Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Yonemura Y, et al. **Hepatogastroenterology** 1996 Sep-Oct; 43(11):1260-72

Origin of an oral adenocarcinoma as suggested by cytogenetical observations. Havel G, et al. **Hereditas** 1996; 125(2-3):297-8

Comparative FISH analysis of numerical chromosome 7 abnormalities in 5-micron and 15-micron paraffin-embedded tissue sections from prostatic carcinoma. Aubele M, et al. **Histochem Cell Biol** 1997 Feb; 107(2):121-6

Localization of binding sites of Ulex europaeus I, Helix pomatia and Griffonia simplicifolia I-B4 lectins and analysis of their backbone structures by several glycosidases and poly-N-acetyllactosamine-specific lectins in human breast carcinomas. Ito N, et al. **Histochem Cell Biol** 1996 Sep; 106(3):331-9

The alveolar type II cell is a pluripotential stem cell in the genesis of human adenocarcinomas and squamous cell carcinomas. Ten Have-Opbroek AA, et al. **Histol Histopathol** 1997 Apr;12(2):319-36

Syringocystadenocarcinoma papilliferum. Bondi R, et al. **Histopathology** 1996 May;28(5):475-7

Dual carcinoid/epithelial neoplasia of the appendix. Carr NJ, et al. **Histopathology** 1995 Dec;27(6):557-62

Ovarian adenosarcoma. Fukunaga M, et al. **Histopathology** 1997 Mar;30(3):283-7

Gastrointestinal hepatoid adenocarcinoma: venous permeation and mimicry of hepatocellular carcinoma, a report of four cases. Ishikura H, et al. **Histopathology** 1997 Jul;31(1):47-54 (28 ref.)

Differentiation towards gastric foveolar, mucopeptic and intestinal goblet cells in gallbladder adenocarcinomas. Kushima R, et al. **Histopathology** 1996 Nov;29(5):443-8

Immunohistochemical study of c-erbB-2 expression in carcinoma ex-pleomorphic adenoma. Rosa JC, et al. **Histopathology** 1996 Mar;28(3):247-52

Early adenocarcinoma of the oesophagus and oesophageal cyst. Santacroce CM, et al. **Histopathology** 1997 Jul; 31(1):87-90

Metastatic carcinoma of the prostate presenting as parotid tumour. Simpson RH, et al. **Histopathology** 1997 Jan; 30(1):70-4 (14 ref.)

Isolated expression of the Muir-Torre phenotype in a member of a family with hereditary non-polyposis colorectal cancer. Weitzer M, et al. **Histopathology** 1995 Dec;27(6):573-5

Villous adenocarcinoma of the duodenum invading the ampulla of Vater case report and review of literature. Catania G, et al. **HPB Surg** 1996;10(2):105-9 (23 ref.)

Laparoscopic cholecystectomy: incidental carcinoma of the gallbladder with abdominal wall and axillary node metastasis. Johnson RC, et al. **HPB Surg** 1997;10(3):169-71

Collision tumour of the ampulla of Vater: carcinoid and adenocarcinoma. Williams IM, et al. **HPB Surg** 1997; 10(4):241-4

Synergistic antitumor effects of human interferon-beta and interferon-gamma on human gastric adenocarcinoma cells. Nagao S, et al. **Hum Cell** 1997 Mar;10(1):95-104

Effect of K-ras mutation on morphogenesis of colorectal adenomas and early cancers: relationship to distribution of proliferating cells. Kobayashi M, et al. **Hum Pathol** 1996 Oct;27(10):1042-9

Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: a report of two cases. Mai KT, et al. **Hum Pathol** 1996 Dec;27(12):1377-81

p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Moskaluk CA, et al. **Hum Pathol** 1996 Nov;27(11):1211-20

The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Qian J, et al. **Hum Pathol** 1997 Feb; 28(2):143-8

Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Soini Y, et al. **Hum Pathol** 1997 Feb;28(2):220-6

Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. van den Brule FA, et al. **Hum Pathol** 1996 Nov;27(11):1185-91

Three-dimensional endothelial-tumor epithelial cell interactions in human cervical cancers. Chopra V, et al. **In Vitro Cell Dev Biol Anim** 1997 Jun;33(6):432-42

Comparative pathology of benign prostatic hyperplasia and prostate cancer. Maini A, et al. **In Vivo** 1997 Jul-Aug; 11(4):293-9 (57 ref.)

Primary carcinoma of the fallopian tube. A clinicopathologic study. Pai RR, et al. **Indian J Cancer** 1996 Jun;33(2):92-6

Collision tumor with three components at esophagogastric junction. Pai SA, et al. **Indian J Gastroenterol** 1997 Jul; 16(3):116

Synchronous adenocarcinoma and lymphoma of the colon. Wagle SD, et al. **Indian J Gastroenterol** 1997 Jan;16(1):28-9

A phospholipase D and protein kinase C inhibitor blocks the spreading of murine mammary adenocarcinoma cells altering f-actin and beta1-integrin point contact distribution. Aguirre Ghiso JA, et al. **Int J Cancer** 1997 May 29;71(5):881-90

Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Fajac A, et al. **Int J Cancer** 1996 Sep 27;68(1):67-74

Invasion of human colorectal carcinoma cells is promoted by endogenous basic fibroblast growth factor. Galzie Z, et al. **Int J Cancer** 1997 May 2;71(3):390-5

Change in morphological and functional cytodifferentiation induced by seminal vesicle mesenchyme in cell suspensions of rat Dunning prostatic adenocarcinoma cells. Hayashi N, et al. **Int J Cancer** 1996 Dec 11;68(6):788-94

Apoptosis in rat prostatic adenocarcinoma is associated with rapid infiltration of cytotoxic T-cells and activated macrophages. Landström M, et al. **Int J Cancer** 1997 May 2;71(3):451-5

Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Murata T, et al. **Int J Cancer** 1997 Jan 17;70(2):230-40

Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Saunders DE, et al. **Int J Cancer** 1997 Jan 17;70(2):214-20

Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Tu H, et al. **Int J Cancer** 1996 Oct 21;69(5):357-63

Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil. Ueda M, et al. **Int J Cancer** 1997 May 16;71(4):668-74

Tumor recurrence associated with use of a percutaneous bladder catheter after surgery for large bowel carcinoma. Strigård K. **Int J Colorectal Dis** 1996;11(3):122

Solitary sebaceoma in Muir-Torre syndrome [letter; comment] Donati P. **Int J Dermatol** 1996 Aug;35(8):601-2 . Comment on: J Am Acad Dermatol 1990 Oct;23(4 Pt 1):638-40.

Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II. Kodama S, et al. **Int J Gynaecol Obstet** 1997 Feb;56(2):147-53

Transvaginal uterine morcellation with unsuspected adenocarcinoma of the endometrium. Pelosi MA 3rd, et al. **Int J Gynaecol Obstet** 1997 May;57(2):207-8

Ovarian neuroendocrine carcinomas of non-small-cell type associated with surface epithelial adenocarcinomas. A study of five cases and review of the literature. Eichhorn JH, et al. **Int J Gynecol Pathol** 1996 Oct;15(4):303-14 (33 ref.)

Hepatoid adenocarcinoma of the endometrium associated with alpha-fetoprotein production. Hoshida Y, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):266-9

Atypical polypoid adenomyofibroma (APA) versus well-differentiated endometrial carcinoma with prominent stromal matrix: an immunohistochemical study. Soslow RA, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):209-16

Taking another look at endometrial adenocarcinoma [editorial] Zaino RJ. **Int J Gynecol Pathol** 1996 Jul; 15(3):187-90

Arrhenius analysis of the thermal response of human colonic adenocarcinoma cells in vitro using the multi-target, single-hit and the linear-quadratic model. Jordan A, et al. **Int J Hyperthermia** 1997 Jan-Feb;13(1):83-8

Comparison of antiproliferative effects of 1-histamine-2 receptor antagonists, cimetidine, ranitidine, and famotidine, in gastric cancer cells. Hahm KB, et al. **Int J Immunopharmacol** 1996 Jun-Jul;18(6-7):393-9

Four cases of polymorphous low-grade adenocarcinoma. Crean SJ, et al. **Int J Oral Maxillofac Surg** 1996 Feb; 25(1):40-4

Heterotopic salivary gland adenocarcinoma in the cervical region. Hata T, et al. **Int J Oral Maxillofac Surg** 1997 Aug; 26(4):290-2

Adnexal adenocarcinoma of the upper lip. Stavrianos SD, et al. **Int J Oral Maxillofac Surg** 1996 Jun;25(3):196-8

Cell kinetic measurements in prostate cancer. Haustermans KM, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 15; 37(5):1067-70

Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. Komaki R, et al. **Int J Radiat Oncol Biol Phys** 1996 Oct 1;36(3):601-5

Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy. Lankford SP, et al. **Int J Radiat Oncol Biol Phys** 1997 May 1;38(2):327-33

Tumor size evaluated by pelvic examination compared with 3-D quantitative analysis in the prediction of outcome for cervical cancer. Mayr NA, et al. **Int J Radiat Oncol Biol Phys** 1997 Sep 1;39(2):395-404

"Collision phenomenon" of prostate and bladder cancers in lymph node metastases. Gohji K, et al. **Int J Urol** 1997 Mar;4(2):222-4

Urethral recurrence of an urachal carcinoma: a case report. Yasui T, et al. **Int J Urol** 1997 Jan;4(1):106-8

Vitamin A and apoptosis in colonic tumor cells. Maziere S, et al. **Int J Vitam Nutr Res** 1997;67(4):237-41

Pre-, intra- and postoperative staging of gastric carcinoma and clinical outcome. Schweizer W, et al. **Int Surg** 1995 Jul-Sep;80(3):204-7

The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19-9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study. Yüceyar S, et al. **Int Surg** 1996 Apr-Jun;81(2):136-9

Comparative clinical features of stage A1 and stage A2 prostate cancers. Is the concept of stage A changing from the current status? Kunimi K, et al. **Int Urol Nephrol** 1995; 27(5):575-85

Evidence for the polyp-cancer sequence in gallbladder cancer. Harbison J, et al. **Ir Med J** 1997 Apr-May;90(3):98

Clinico-pathological correlation and prognostic significance of nuclear p53 protein in colorectal cancer. Colorectal Cancer Study Group of the University and Health Care District of Modena. Fante R, et al. **Ital J Gastroenterol** 1996 May;28(4):205-10

Solitary Peutz-Jeghers type polyp of the duodenum containing a focus of adenocarcinoma. Ichiyoshi Y, et al. **Ital J Gastroenterol** 1996 Feb-Mar;28(2):95-7

Adenocarcinoma of the uterine cervix. Jerant AF. **J Am Board Fam Pract** 1997 Jan-Feb;10(1):36-42

Rapidly progressive prostate cancer in the primary care setting. Woolf SH, et al. **J Am Board Fam Pract** 1996 Sep-Oct;9(5):375-9

Hürthle cell carcinoma of the thyroid. Gray MW, et al. **J Am Osteopath Assoc** 1996 Apr;96(4):250-2

Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines. Lokshin A, et al. **J Cell Biochem Suppl** 1996;24:186-97

Barrett's adenocarcinoma in a patient with acquired immune deficiency syndrome. Chalasani N, et al. **J Clin Gastroenterol** 1997 Apr;24(3):184-6

A review of gastrointestinal epithelial renewal and its relevance to the development of adenocarcinomas of the gastrointestinal tract. Eastwood GL. **J Clin Gastroenterol** 1995;21 Suppl 1:S1-11 (116 ref.)

Possibility of defense against colorectal tumor by foamy cells. Hirota S, et al. **J Clin Gastroenterol** 1997 Mar;24(2):82-6

Malignant transformation in a duodenal villous adenoma of the afferent limb of Billroth II anastomosis. Kapur A, et al. **J Clin Gastroenterol** 1997 Jun;24(4):290-1

Five primary synchronous neoplasms of the gastrointestinal tract. Mitchell ME, et al. **J Clin Gastroenterol** 1996 Dec; 23(4):284-8

Synchronous primary neuroendocrine carcinoma and adenocarcinoma in Barrett's esophagus. Saw EC, et al. **J Clin Gastroenterol** 1997 Mar;24(2):116-9

Prognostic factors in adenocarcinoma of the gastric cardia: pathologic stage analysis and multivariate regression analysis. Kajiyama Y, et al. **J Clin Oncol** 1997 May; 15(5):2015-21

Malignancy-associated microangiopathic hemolytic anemia. Schiller D. **J Clin Oncol** 1997 Jun;15(6):2474-5

Adenocarcinoma of the anal glands. Behan WM, et al. **J Clin Pathol** 1996 Dec;49(12):1009-11

Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. Colecchia M, et al. **J Clin Pathol** 1997 May;50(5):384-8

Ki-67 expression in early prostate cancer and associated pathological lesions. Feneley MR, et al. **J Clin Pathol** 1996 Sep;49(9):741-8

Quintuple cancers: report of a case with triple cancers in the head and neck. Martin-Granizo R, et al. **J Craniomaxillofac Surg** 1997 Jun;25(3):153-7 (34 ref.)

Multiple malignant cylindromas of skin in association with basal cell adenocarcinoma with adenoid cystic features of minor salivary gland. Antonescu CR, et al. **J Cutan Pathol** 1997 Aug;24(7):449-53

A unique case of squamous cell carcinoma showing adenocarcinomatous features with focal apocrine differentiation. Yamamoto O, et al. **J Dermatol** 1997 Apr; 24(4):249-54

Multiple early esophageal cancers arising from Barrett's esophagus, and a review of cases of early adenocarcinoma in Barrett's esophagus in Japan. Itatsu T, et al. **J Gastroenterol** 1997 Jun;32(3):389-95 (40 ref.)

Double cancers of the gallbladder and bile duct associated with anomalous choledochopancreatic duct junction. Nakao A, et al. **J Gastroenterol** 1997 Feb;32(1):110-3 (12 ref.)

Endoscopic treatment of submucosal invasive colorectal carcinoma with special reference to risk factors for lymph node metastasis. Tanaka S, et al. **J Gastroenterol** 1995 Dec; 30(6):710-7

Adenosquamous carcinoma of the stomach associated with separate early gastric cancer (type IIc). Toyota N, et al. **J Gastroenterol** 1996 Feb;31(1):105-8 (18 ref.)

Intestinal-type tumour in resected gastric remnant cancer. Lo SS, et al. **J Gastroenterol Hepatol** 1997 Jun;12(6):434-6

Clinicopathological significance of intestinal and diffuse types of gastric carcinoma in Taiwan Chinese. Wu CW, et al. **J Gastroenterol Hepatol** 1996 Nov;11(11):1083-8

Primary adenocarcinoma of the jejunum masquerading as abdominal tuberculosis. Pethe VV, et al. **J Indian Med Assoc** 1996 Oct;94(10):389-90

Primary adenocarcinoma, signet-ring, and transitional cell carcinoma of the bladder with penile metastasis. Allen RA, et al. **J Natl Med Assoc** 1997 Apr;89(4):253-6

Flow cytometry in colon cancer: does flow cytometric cell cycle analysis help predict for short-term recurrence in patients with colorectal carcinoma? Hixon C, et al. **J Natl Med Assoc** 1995 Nov;87(11):803-6

The occurrence of endometrial adenocarcinoma in a patient

with basal cell nevus syndrome. Khalifa MA, et al. **J Natl Med Assoc** 1997 Aug;89(8):549–52

Dietary fat and protein intake differ in modulation of prostate tumor growth, prolactin secretion and metabolism, and prostate gland prolactin binding capacity in rats. Clinton SK, et al. **J Nutr** 1997 Feb;127(2):225–37

Adenocarcinoma originating in the sublingual gland: report of a case. Sakashita H, et al. **J Oral Maxillofac Surg** 1997 Jul;55(7):764–7

Interleukin 6 gene–transfected mouse mammary adenocarcinoma: tumour cell growth and metastatic potential. Di Carlo E, et al. **J Pathol** 1997 May;182(1):76–85

Three–dimensional reconstruction of perineural invasion in carcinoma of the extrahepatic bile ducts. Maxwell P, et al. **J Pathol** 1996 Oct;180(2):142–5

Subtle changes in benign tissue adjacent to prostate neoplasia detected with a Bayesian belief network. Montironi R, et al. **J Pathol** 1997 Aug;182(4):442–9

Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor? Rogatsch H, et al. **J Pathol** 1997 Jun;182(2):205–10

Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. Ruijter ET, et al. **J Pathol** 1996 Nov;180(3):295–9

Synchronous endometrioid tumors of the ovary and endometrium. A clinicopathologic study of 22 cases. Falkenberry SS, et al. **J Reprod Med** 1996 Oct;41(10):713–8

Staging endometrioid adenocarcinoma. Clinical and financial comparison of laparoscopic and traditional approaches. Hidlebaugh DA, et al. **J Reprod Med** 1997 Aug;42(8):482–8

p53lyn and p56lyn: a new signaling pathway in human endometrium and endometrial adenocarcinomas. Couchman GM, et al. **J Soc Gynecol Investig** 1997 Mar–Apr;4(2):103–9

Sex steroids regulate the expression of plasminogen activator inhibitor–1 (PAI–1) and its mRNA in uterine endometrial cancer cell line Ishikawa. Fujimoto J, et al. **J Steroid Biochem Mol Biol** 1996 Sep;59(1):1–8

Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone–induced expression of the alpha1 integrin [published erratum appears in J Steroid Biochem Mol Biol 1997 Jan;60(1–2):161] Lessey BA, et al. **J Steroid Biochem Mol Biol** 1996 Sep;59(1):31–9

Inhibition of placental estrone sulfatase activity and MCF–7 breast cancer cell proliferation by estrone–3–amino derivatives. Selcer KW, et al. **J Steroid Biochem Mol Biol** 1996 Sep;59(1):83–91

Perianal mucinous adenocarcinoma. Anthony T, et al. **J Surg Oncol** 1997 Mar;64(3):218–21

Effect of preoperative 5–fluorouracil on apoptosis of advanced gastric cancer. Inada T, et al. **J Surg Oncol** 1997 Jun;65(2):106–10

Morphologic pattern of tenascin as a diagnostic biomarker in colon cancer. Iskaros BF, et al. **J Surg Oncol** 1997 Feb; 64(2):98–101

Clinicopathologic study of advanced gastric cancer without serosal invasion in young and old patients. Wang JY, et al. **J Surg Oncol** 1996 Sep;63(1):36–40

Reliability of frozen section diagnosis of gallbladder tumor for detecting carcinoma and depth of its invasion. Yamaguchi K, et al. **J Surg Oncol** 1997 Jun;65(2):132–6

Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. Carter HB, et al. **J Urol** 1997 Jun;157(6):2206–9 (10 ref.)

Outcome based staging for clinically localized adenocarcinoma of the prostate. D'Amico AV, et al. **J Urol** 1997 Oct;158(4):1422–6

Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not? Drew PA, et al. **J Urol** 1997 Jun;157(6):2201–5

Staging pelvic lymphadenectomy for localized carcinoma of the prostate: a comparison of 3 surgical techniques. Herrell SD, et al. **J Urol** 1997 Apr;157(4):1337–9

The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy [see comments] Krijnen JL, et al. **J Urol** 1997 Jul;158(1):171–4. Comment in: J Urol 1997 Jul;158(1):178.

Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi–institutional trial [see comments] Smith JA Jr, et al. **J Urol** 1997 Mar;157(3):902–6. Comment in: J Urol 1997 Mar;157(3):919–20.

One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. Wang X, et al. **J Urol** 1997 Oct;158(4):1431–5

Malignant cytological washings from radical prostatectomy specimens: a possible mechanism for local recurrence of prostate cancer following surgical treatment of organ confined disease. Ward JF, et al. **J Urol** 1996 Oct; 156(4):1381–4; discussion 1384–5

Evidence that expression of a mutated p53 gene attenuates apoptotic cell death in human gastric intestinal–type carcinomas in vivo. Ishida M, et al. **Jpn J Cancer Res** 1997 May;88(5):468–75

Reduced expression of cyclin–dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Yasui W, et al. **Jpn J Cancer Res** 1997 Jul;88(7):625–9

Clinicopathological studies on coexisting gastric malignant lymphoma and gastric adenocarcinoma: report of four cases and review of the Japanese literature. Ishihama T, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):101–6 (24 ref.)

Immunohistochemical detection of basic fibroblast growth factor as a prognostic indicator in pulmonary adenocarcinoma. Takanami I, et al. **Jpn J Clin Oncol** 1996 Oct;26(5):293–7

Adenocarcinoma of the anterior urethra in the male. Tawfik O, et al. **Kans Med** 1996 Summer–Fall;97(2):26–8

Genetic evidence for the multicentric origin of synchronous multiple gastric carcinoma. Kang GH, et al. **Lab Invest** 1997 Mar;76(3):407–17

Do the worst histological elements in needle biopsy specimens of prostate cancer predict prognosis? [letter] Kubota Y, et al. **Lancet** 1996 Sep 21;348(9030):822–3

Evidence against flat dysplasia as a regional field defect in small bowel adenocarcinoma associated with celiac sprue. Bruno CJ, et al. **Mayo Clin Proc** 1997 Apr;72(4):320–2

Correlation of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinoma is independent of tumor histiotype and microvessel density. Vermeulen PB, et al. **Microvasc Res** 1997 Jul;54(1):88–92

Recommendations for reporting resected prostatic carcinomas. Association of Directors of Anatomic and Surgical Pathology. **Mod Pathol** 1996 Apr;9(4):453–6

Pigment in prostatic epithelium and adenocarcinoma: a potential source of diagnostic confusion with seminal vesicular epithelium. Amin MB, et al. **Mod Pathol** 1996 Jul;9(7):791–5

Surfactant proteins and thyroid transcription factor–1 in pulmonary and breast carcinomas. Bejarano PA, et al. **Mod Pathol** 1996 Apr;9(4):445–52

Correspondence re: Association of directors of anatomic and surgical pathology: recommendations for the reporting of resected large intestinal carcinomas. Mod Pathol 9:73, 1996 [letter; comment] Lev R. **Mod Pathol** 1996 Dec; 9(12):1177–8. Comment on: Mod Pathol 1996 Jan;9(1):73–6.

Lack of correlation between flow cytometric and immunohistologic proliferation measurements of tumors. Linden MD, et al. **Mod Pathol** 1996 Jun;9(6):682–9

Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Randolph TL, et al. **Mod Pathol** 1997 Jun;10(6):612–29 (133 ref.)

Immunohistochemical detection of bcl–2 protein in adenocarcinoma and non–neoplastic cellular compartments of the lung. Rao SK, et al. **Mod Pathol** 1996 May;9(5):555–9

Comparative analysis of the nuclear proliferative index (Ki–67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma. Tamboli P, et al. **Mod Pathol** 1996 Oct;9(10):1015–9

Differentiation of atypical adenomatous hyperplasia and adenocarcinoma of the lung by use of DNA ploidy and morphometric analysis. Yokozaki M, et al. **Mod Pathol** 1996 Dec;9(12):1156–64

Midkine in the progression of rat N–nitroso–N–methylurea–induced mammary tumors. Chen Y, et al. **Mol Carcinog** 1996 Nov;17(3):112–6

Pancreatic adenocarcinoma presenting as a monomelic motor neuronopathy [see comments] Carter GT, et al. **Muscle Nerve** 1997 Jan;20(1):103–5. Comment in: Muscle Nerve 1997 Sep;20(9):1204–5.

Images in clinical medicine. A metastasis caught in the act. Brat DJ, et al. **N Engl J Med** 1996 Dec 5;335(23):1733

Percutaneous biopsy of operable liver lesions: is it necessary or advisable? Jourdan JL, et al. **N Z Med J** 1996 Dec 13; 109(1035):469–70

Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix. Denehy TR, et al. **Obstet Gynecol** 1997 Jul;90(1):1–6

Microinvasive adenocarcinoma of the cervix: a clinicopathologic study of 77 women. Ostör A, et al. **Obstet Gynecol** 1997 Jan;89(1):88–93

Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis. Kaufmann AM, et al. **Oncogene** 1996 Dec 5;13(11):2349–58

Commentary: malignant fibrous histiocytoma versus adenocarcinoma of the breast. Weiskittel S. **Oncol Nurs Forum** 1996 Sep;23(8):1178

Cytokine regulation of the matrix metalloproteinases and their inhibitors in human papillomavirus–18 transformed human prostatic tumor cell lines. Wang M, et al. **Oncol Res** 1996;8(7–8):303–15

Transferrin and insulin enhance human colon tumor cell growth by differentiation class specific mechanisms. Yeoman LC, et al. **Oncol Res** 1996;8(7–8):273–9

Glandular tumors of the lacrimal sac. Their histopathologic patterns and possible origins. Pe'er J, et al. **Ophthalmology** 1996 Oct;103(10):1601–5

Acquired neoplasms of the nonpigmented ciliary epithelium (adenoma and adenocarcinoma). Shields JA, et al. **Ophthalmology** 1996 Dec;103(12):2007–16

Tumors arising in the palpebral lobe of the lacrimal gland. Vangveeravong S, et al. **Ophthalmology** 1996 Oct; 103(10):1606–12 (38 ref.)

Polymorphous low–grade adenocarcinoma: glial fibrillary acidic protein staining in the differential diagnosis with cellular mixed tumors. Gnepp DR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jun;83(6):691–5

Low–grade adenocarcinoma of nasal passages. Cawte T, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):116–9

Computed tomography of pancreatic adenocarcinoma: comparison of tumor size measured by dynamic computed tomography and histopathologic examination. Furukawa H, et al. **Pancreas** 1996 Oct;13(3):231–5

Oncocytic hepatocellular carcinoma with numerous globular hyaline bodies. Fukunaga N, et al. **Pathol Int** 1996 Apr; 46(4):286–91

Adenocarcinoma arising within a colonic diverticulum [letter] Kajiwara H, et al. **Pathol Int** 1996 Jul;46(7):538–9

Nuclear p53 accumulation by small–sized adenocarcinomas of the lung. Kawasaki M, et al. **Pathol Int** 1996 Jul; 46(7):486–90

Small pancreatic tubular adenocarcinomas: clinicopathological analysis with immunohistochemical and histochemical evaluation. Matsukuma S, et al. **Pathol Int** 1996 Aug;46(8):581–8

Lung cancer associated with usual interstitial pneumonia. Matsushita H, et al. **Pathol Int** 1995 Dec;45(12):925–32

Salivary duct carcinoma: a clinicopathologic study of three cases with a review of the literature. Minamiguchi S, et al. **Pathol Int** 1996 Aug;46(8):614–22 (22 ref.)

p53 and Ki–67 immunoreactivity and nuclear morphometry of 'carcinoma–in–adenoma' and adenoma of the gall–bladder [corrected and republished article originally printed in Pathol Int 1996 Jun; 46(6):426–35] Takei K, et al. **Pathol Int** 1996 Nov;46(11):908–17

p53 and Ki–67 immunoreactivity and nuclear morphometry of 'carcinoma–in–adenoma' and adenoma of the gall–bladder [corrected and republished in Pathol Int 1996 Nov;46(11):908–17] Takei K, et al. **Pathol Int** 1996 Jun; 46(6):426–35

Small–cell neuroendocrine carcinoma of the uterine cervix associated with micro–invasive squamous cell carcinoma and adenocarcinoma in situ. Toki T, et al. **Pathol Int** 1996 Jul;46(7):520–5

Primary adenocarcinoma of the renal pelvis with special reference to histochemical observations. Tsuzuki T, et al. **Pathol Int** 1996 Oct;46(10):791–6

Numerical chromosomal changes in high–grade prostatic intraepithelial neoplasia (PIN) and concomitant invasive carcinoma. Erbersdobler A, et al. **Pathol Res Pract** 1996 May;192(5):418–27

Neuroendocrine differentiation in pancreatic duct carcinoma special emphasis on duct–endocrine cell carcinoma of the pancreas. Kamisawa T, et al. **Pathol Res Pract** 1996 Sep; 192(9):901–8

Correlation of alpha 2 beta 1 integrin expression with histological type and hormonal receptor status in breast carcinomas. Lanzafame S, et al. **Pathol Res Pract** 1996 Oct; 192(10):1031–8

Adenocarcinoma of the cardia in a young man: detection of somatic p53 mutation by immunohistochemistry and automated direct sequencing. Poremba C, et al. **Pathol Res Pract** 1995 Oct;191(10):1004–9

Oncocytic adenocarcinoma of minor salivary gland. An unusual glossal presentation of a minor salivary gland tumor. Ruby SG, et al. **Pathol Res Pract** 1996 Aug; 192(8):856–64; discussion 865–8

Rectal adenocarcinoma with rhabdoid phenotype. Mačák J, et al. **Pathologica** 1995 Dec;87(6):696–9

A high apoptotic index occurs in subtypes of endometrial adenocarcinoma associated with a poor prognosis. Heatley MK. **Pathology** 1997 Aug;29(3):272–5

Test and teach. Number Eighty–one. Diagnosis: Pulmonary endodermal tumor. Kesavan S, et al. **Pathology** 1996 May; 28(2):146–7, 193

FNB diagnosis of breast carcinoma associated with HIV infection: a case report and review of HIV associated malignancy. Mayer AP, et al. **Pathology** 1996 Jan; 28(1):90–5 (40 ref.)

Adenocarcinoma of minor salivary gland origin with skeletal metastasis in a child. McDermott M, et al. **Pediatr Pathol Lab Med** 1996 Jan–Feb;16(1):89–98

Synchronous carcinoma and primary MALT–lymphoma of the stomach. A report of two cases. Heitzman J, et al. **Pol J Pathol** 1997;48(1):57–62

Proliferation of cancer cells and stromal cells in colorectal adenocarcinomas as assessed with anti–PCNA/cyclin monoclonal antibody. Markiewski M, et al. **Pol J Pathol** 1996;47(3):101–4

Advanced colonic carcinoma in children. Khan AM, et al. **Postgrad Med J** 1997 Mar;73(857):169–70

Cancer–stromal interaction through growth factor/cytokine networks implicated in growth of stomach cancer. Tahara E. **Princess Takamatsu Symp** 1994;24:187–94 (19 ref.)

Expression of homeobox gene–GBX2 in human prostatic cancer cells. Gao AC, et al. **Prostate** 1996 Dec;29(6):395–8

Assessment of proliferation indicators in residual prostatic adenocarcinoma cells after radical external beam radiotherapy. Ljung G, et al. **Prostate** 1996 Nov; 29(5):303–10

Classification of air density areas in CT–pathologic correlation of pulmonary adenocarcinoma. Koizumi N, et al. **Radiat Med** 1995 Nov–Dec;13(6):279–84

Esophageal cancer. Clinical and pathologic features. Gore RM. **Radiol Clin North Am** 1997 Mar;35(2):243–63 (131 ref.)

A cancer survivor, not a statistic [letter] Eade JL. **Radiol Technol** 1996 Nov–Dec;68(2):153–4

Adenoma malignum: MR imaging and pathologic study. Doi T, et al. **Radiology** 1997 Jul;204(1):39–42

Rectal cancer: evaluation of staging with endosonography.

Lindmark GE, et al. **Radiology** 1997 Aug;204(2):533–8

Natural history of superficial depressed colorectal cancer: retrospective radiographic and histologic analysis. Matsui T, et al. **Radiology** 1996 Oct;201(1):226–32

Spontaneous metastasis, proliferation characteristics and radiation sensitivity of fractionated irradiation recurrent and unirradiated human xenografts. Huang P, et al. **Radiother Oncol** 1996 Oct;41(1):73–81

Diagnostic concordance in biopsies of deceptive prostatic carcinoma. Arista-Nasr J, et al. **Rev Invest Clin** 1996 Jul–Aug;48(4):289–96

Low grade adenocarcinoma simulating benign glandular lesions in needle prostatic biopsy. Arista-Nasr J, et al. **Rev Invest Clin** 1997 Jan–Feb;49(1):37–40

A pathological analysis of clinical adenocarcinoma of the prostate in black patients [letter] Bereczky ZB. **S Afr Med J** 1997 Mar;87(3):344

Can endoscopic biopsy specimens be used for reliable Laurén classification of gastric cancer? Hansson LE, et al. **Scand J Gastroenterol** 1996 Jul;31(7):711–5

Relation between histologic subtypes and location of gastric cancer and Helicobacter pylori. Martín-de-Argila C, et al. **Scand J Gastroenterol** 1997 Apr;32(4):303–7

Progression from adenocarcinoma to small cell carcinoma of the prostate with normalization of prostate-specific antigen (PSA) levels. Valle J, et al. **Scand J Urol Nephrol** 1996 Dec;30(6):509–12

Unusual malignant epithelial tumors of the gallbladder. Albores-Saavedra J, et al. **Semin Diagn Pathol** 1996 Nov; 13(4):326–38 (41 ref.)

The role of imaging in staging renal adenocarcinoma. Zagoria RJ, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):91–9 (27 ref.)

High grade dysplasia/esophageal adenocarcinoma in short segment Barrett's esophagus. Iqbal M, et al. **South Med J** 1997 Aug;90(8):828–30

Immediately preoperative laparoscopic staging for gastric cancer. D'Ugo DM, et al. **Surg Endosc** 1996 Oct; 10(10):996–9

The influence of laparotomy and laparoscopy on tumor growth in a rat model. Jacobi CA, et al. **Surg Endosc** 1997 Jun;11(6):618–21

Inflammatory breast carcinoma. Chambler AF, et al. **Surg Oncol** 1995;4(5):245–54 (102 ref.)

Orthotopic engraftment of human lung tumours in SCID mice for the study of metastasis. Cuenca RE, et al. **Surg Oncol** 1996 Apr;5(2):85–91

The incidence of chromogranin A defined endocrine cells decreases with tumour progression in gastric adenocarcinoma. Ikeda Y, et al. **Surg Oncol** 1995; 4(5):255–60

Peritoneal cytology in the determination of free tumour cells within the abdomen in colon cancer. Uras C, et al. **Surg Oncol** 1996 Oct–Dec;5(5–6):259–63

The adenoma–carcinoma sequence in colorectal neoplasia. O'Brien MJ, et al. **Surg Oncol Clin N Am** 1996 Jul; 5(3):513–30 (96 ref.)

Cronkhite–Canada syndrome associated with carcinoma of the sigmoid colon: report of a case. Nakatsubo N, et al. **Surg Today** 1997;27(4):345–8 (28 ref.)

Synchronous lymphoma and adenocarcinoma occurring as a collision tumor in the stomach: report of a case. Nishino N, et al. **Surg Today** 1996;26(7):508–12

Soybean agglutinin binding as a useful prognostic indicator in stomach cancer. Terashima S, et al. **Surg Today** 1997; 27(4):293–7

Clinical significance of extrabowel skipped cancer infiltration in rectal cancer. Ueno H, et al. **Surg Today** 1997; 27(7):617–22

Colorectal cancer in a patient younger than 20 years of age: report of a case and a review of the Japanese literature. Yamamoto T, et al. **Surg Today** 1996;26(10):810–3 (18 ref.)

Pneumoperitoneum with carbon dioxide stimulates growth of malignant colonic cells. Jacobi CA, et al. **Surgery** 1997 Jan;121(1):72–8

Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon. Abril E, et al. **Tissue Antigens** 1996 May;47(5):391–8

A transgenic mouse prostate cancer model [see comments] Gingrich JR, et al. **Toxicol Pathol** 1996 Jul–Aug; 24(4):502–4. Comment in: Toxicol Pathol 1996 Jul–Aug;24(4):506.

Relationships between cell density, glutathione and proliferation of A549 human lung adenocarcinoma cells treated with acrolein. Horton ND, et al. **Toxicology** 1997 Sep 26;122(1–2):111–22

Influence of mast cells on two murine mammary adenocarcinomas. de Cidre LL, et al. **Tumour Biol** 1996; 17(6):345–53

Pathological and genetic correlates of apoptosis in the progression of colorectal neoplasia. Hawkins N, et al. **Tumour Biol** 1997;18(3):146–56

Adenocarcinoma simulating mesothelioma. Corrin B, et al. **Ultrastruct Pathol** 1996 Jul–Aug;20(4):327–9

Case for the panel. Mitochondrial inclusions in prostate adenocarcinoma. Ghadially FN. **Ultrastruct Pathol** 1997 Sep–Oct;21(5):475–7

Selective sampling of yellow prostate chips: a specific method for detecting prostatic adenocarcinoma. Geddy PM, et al. **Urol Int** 1996;56(1):33–5

Argyrophilic nucleolar organizer regions in atypical adenomatous hyperplasias, prostatic intraepithelial neoplasias and prostatic neoplasms. Mukherjee J, et al. **Urol Int** 1997;58(2):75–9

A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate. Ahlgren G, et al. **Urology** 1997 Sep;50(3):379–84

Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Bazinet M, et al. **Urology** 1997 May; 49(5):721–5

Stage D1 (T1–3, N1–3, M0) prostate cancer: a case–controlled comparison of conservative treatment versus radical prostatectomy. Cadeddu JA, et al. **Urology** 1997 Aug;50(2):251–5

Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Carter HB, et al. **Urology** 1997 Mar;49(3):379–84

Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up. Corica FA, et al. **Urology** 1997 Sep;50(3):427–31 (29 ref.)

Effect of antifreeze proteins on frozen primary prostatic adenocarcinoma cells. Koushafar H, et al. **Urology** 1997 Mar;49(3):421–5

Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer. Linzer DG, et al. **Urology** 1996 Nov; 48(5):757–61

Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Reuter VE. **Urology** 1997 Mar;49(3A Suppl):16–22 (31 ref.)

Rudolf-Virchow-Preis 1996. Priesträgerrede. Detection of surfactant protein gene expression by reverse transcriptase–polymerase chain reaction (RT-PCR) identifies metastases and occult tumor spread of pulmonary adenocarcinomas. Papadopoulos T. **Verh Dtsch Ges Pathol** 1996;80:LVII–LXI

Helicobacter mustelae–associated gastric adenocarcinoma in ferrets (Mustela putorius furo). Fox JG, et al. **Vet Pathol** 1997 May;34(3):225–9

Adenocarcinoma of the hepatopancreatic ampulla in a domestic cat. Haines VL, et al. **Vet Pathol** 1996 Jul; 33(4):439–41

Cell proliferation in salivary gland adenocarcinomas with myoepithelial participation. A study of 78 cases. Fonseca I, et al. **Virchows Arch** 1997 Mar;430(3):227–32

Establishment and characterization of two cell lines derived from human diffuse gastric carcinomas xenografted in nude mice. Gärtner F, et al. **Virchows Arch** 1996 May;428(2):91–8

Proliferation and apoptosis in proliferative lesions of the colon and rectum. Kikuchi Y, et al. **Virchows Arch** 1997 Aug;431(2):111–7

Oncocytic adenocarcinoma of the ovary. Miranda D, et al. **Virchows Arch** 1996 Oct;429(2–3):181–3

Co-existing endometrial adenocarcinoma and tubal ectopic pregnancy: a case report. Stead JA, et al. **W V Med J** 1997 May–Jun;93(3):133–5

Accuracy of current educational literature on the staging of gastric carcinoma. Fung AS. **World J Surg** 1997 Mar–Apr;21(3):237–9

Adenocarcinoma of the rete testis. Glazier DB, et al. **World J Urol** 1996;14(6):397–400 (25 ref.)

Can prostate-specific antigen reverse transcriptase-polymerase chain reaction be used as a prospective test to diagnose prostate cancer? Goldman HB, et al. **World J Urol** 1997;15(4):257–61

[Symplastic leiomyoma combined with focal adenocarcinoma of the endometrium] Veselinova T, et al. **Akush Ginekol (Sofiia)** 1996;35(3):47–9 (6 ref.) (Eng. Abstr.) **(Bul)**

[A dynamic study of the cytotoxic effects of hyperthermia combined with cis-diaminedichlorolplatinum (DDP) on human gastric cancer cell lines MKN28 and MKN45 in vitro] Chen W, et al. **Chung Hua Chung Liu Tsa Chih** 1996 Mar;18(2):116–8 (Eng. Abstr.) **(Chi)**

[The variation in motility, adhesion of mouse lung adenocarcinoma variants with low and high metastatic potential under the action of laminin (LN): a comparative study] Zhang H, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Aug;76(8):591–3 (Eng. Abstr.) **(Chi)**

[Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance] Zhou Y, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Sep; 76(9):680–3 (Eng. Abstr.) **(Chi)**

[Missed diagnosis in prostate incidental carcinoma] Ye M, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Dec; 24(6):359–62 (Eng. Abstr.) **(Chi)**

[Barrett esophagus and Barrett carcinoma] Kruyt PH, et al. **Ned Tijdschr Geneeskd** 1997 May 3;141(18):869–73 (35 ref.) (Eng. Abstr.) **(Dut)**

[Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors] Feyaerts A, et al. **Acta Urol Belg** 1997 Mar;65(1):11–8 (Eng. Abstr.) **(Fre)**

[Primary colonic type appendicular adenocarcinoma in a 17 years old patient. Plea for routine pathologic examination in the young (letter)] Finkeltin F, et al. **Ann Chir** 1996; 50(6):474 **(Fre)**

[Value of scintigraphic explorations by radiomarkers others than iodine radioisotope in differentiated thyroid cancer] Sassolas G, et al. **Ann Endocrinol (Paris)** 1997;58(1):55–63 (Eng. Abstr.) **(Fre)**

[Association of a low-grade MALT lymphoma and a slightly differentiated adenocarcinoma of the stomach] Brochériou I, et al. **Ann Pathol** 1997 Apr;17(2):109–12 (12 ref.) (Eng. Abstr.) **(Fre)**

[Polymorphic sweat gland adenocarcinoma of low grade of malignancy] Gorguet B, et al. **Ann Pathol** 1996 Dec; 16(6):442–4 (Eng. Abstr.) **(Fre)**

[Vulvar dermatoses and intra-epithelial neoplasia. Classification, criticism and suggestions] Leibowitch M, et al. **Ann Pathol** 1996 Nov;16(5):334–42 (18 ref.) **(Fre)**

[Adenocarcinoma in situ of the cervix uteri. Cytologic and histologic aspects] Saurel J. **Ann Pathol** 1996 Nov; 16(5):374–80 **(Fre)**

[Diagnostic problems in prostatic pathology: microglandular lesions and intraductal epithelial proliferations] Berger N, et al. **Arch Anat Cytol Pathol** 1996;44(4):141–59 (78 ref.) (Eng. Abstr.) **(Fre)**

[Adenocarcinoma of the gallbladder associated with endocrine pancreatic tumor and disclosed by biliary tumor migration (letter)] Fouchard I, et al. **Gastroenterol Clin Biol** 1996;20(8–9):708–9 **(Fre)**

[New site of adenocarcinoma after incomplete resection of endobrachyesophagus (letter)] Tenière P, et al. **Gastroenterol Clin Biol** 1997;21(6–7):527–8 **(Fre)**

[Meibomian adenocarcinoma in its blepharo-conjunctival form. Apropos of a case] Cherif N, et al. **J Fr Ophtalmol** 1997;20(4):293–6 (Eng. Abstr.) **(Fre)**

[Umbilical metastasis of an endometrial adenocarcinoma: "Sister (Mary) Joseph's nodule". Review of the literature] Poncelet C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):799–803 (13 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic value of a positive single ultrasound-guided prostatic biopsy regarding tumor volume and intracapsular nature of prostatic adenocarcinoma] Barthelemy Y, et al. **Prog Urol** 1996 Dec;6(6):920–5 (Eng. Abstr.) **(Fre)**

[Discontinuous lymph node metastases ("skipping") in malignant lung tumors] Junker K, et al. **Chirurg** 1997 Jun; 68(6):596–9; discussion 600 (Eng. Abstr.) **(Ger)**

[Endosonographic diagnosis in preoperative radiotherapy of locally advanced rectal carcinoma] Kuntz C, et al. **Chirurg** 1997 Jan;68(1):57–62 (Eng. Abstr.) **(Ger)**

[Peritoneal instillation of taurolidine and heparin for preventing intraperitoneal tumor growth and trocar metastases in laparoscopic operations in the rat model] Jacobi CA, et al. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S31–6 (Eng. Abstr.) **(Ger)**

[Prognostic and therapeutic significance of single disseminated tumor cells in lymph nodes in esophageal carcinoma] Izbicki JR, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:781–4 (Eng. Abstr.) **(Ger)**

[Incidence and prognostic significance of epithelioid cell reactions and microcarcinoses in regional lymph nodes in stomach carcinoma] Kestlmeier R, et al. **Pathologe** 1997 Mar;18(2):124–30 (Eng. Abstr.) **(Ger)**

[Intestinal cell proliferation, acromegaly and colon tumors] Fehmann HC, et al. **Z Gastroenterol** 1997 Apr;35(4):305–6 **(Ger)**

[Systematic lymphadenectomy in stomach carcinoma—staging and therapy] Jähne J, et al. **Zentralbl Chir** 1996;121(2):126–30 (Eng. Abstr.) **(Ger)**

[Neuroendocrine differentiated carcinoma of the uterine cervix] Horn LC, et al. **Zentralbl Gynakol** 1996; 118(12):679–83 (Eng. Abstr.) **(Ger)**

[Reproducibility of malignancy grading in prostatic cancers using the Gleason-Böckling system] Kiss F, et al. **Orv Hetil** 1997 May 11;138(19):1195–9 (Eng. Abstr.) **(Hun)**

[Preoperative staging of prostatic carcinoma: evaluation of the role of transrectal echography] Lorusso A, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):83–5 (Eng. Abstr.) **(Ita)**

[Echo-guided biopsy of the transitional zone in the diagnosis of prostatic carcinoma] Pagliarulo A, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):221–4 (Eng. Abstr.) **(Ita)**

[Carcinoma of the prostate: correlation between local staging and systemic progression] Rosi P, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):91–5 (Eng. Abstr.) **(Ita)**

[Adenocarcinoma of the anal glands. Description of a clinical case and review of the literature] Larghero GC, et al. **Minerva Chir** 1996 Jul–Aug;51(7–8):573–6 (Eng. Abstr.) **(Ita)**

[Combined conventional magnetic resonance, magnetic resonance angiography, and magnetic resonance cholangiopancreatography in the diagnosis and staging of pancreatic carcinoma] Catalano C, et al. **Radiol Med (Torino)** 1997 May;93(5):556–60 (Eng. Abstr.) **(Ita)**

[Gastric adenocarcinoma: magnetic resonance versus surgical staging] Costanzi A, et al. **Radiol Med (Torino)** 1996 Dec; 92(6):726–30 (Eng. Abstr.) **(Ita)**

[Study of prostatic carcinoma with ultrasonography and magnetic resonance with "dedicated" surface coil] Preziosi P, et al. **Radiol Med (Torino)** 1996 Dec;92(6):752–7 (Eng. Abstr.) **(Ita)**

[Role of peritoneal lavage smears and gastric wall brushing smears in gastric cancer surgery] Shirakawa T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1472–5 (Eng. Abstr.) **(Jpn)**

[Metastatic tumor of spermatic cord and tunica vaginalis testis

from gastric cancer: a case report] Kageyama Y, et al. **Hinyokika Kiyo** 1997 Jun;43(6):429–31 (Eng. Abstr.) **(Jpn)**

[Comparative histological analysis of needle biopsy specimens, prostatectomized specimens and metastatic lymph nodes in prostatic adenocarcinoma--on the basis of the WHO histological classification] Kondo I, et al. **Hinyokika Kiyo** 1997 Feb;43(2):97–101 (Eng. Abstr.) **(Jpn)**

[Clinical analysis of 169 patients with prostate cancer] Okaneya T, et al. **Hinyokika Kiyo** 1996 Aug;42(8):563–7 (Eng. Abstr.) **(Jpn)**

[Proliferation and differentiation of human salivary gland adenocarcinoma cell line HSG] Ota M, et al. **Hum Cell** 1996 Mar;9(1):79–88 (Eng. Abstr.) **(Jpn)**

[A carcinoma arising from benign pleomorphic adenoma of the trachea] Mori S, et al. **Kyobu Geka** 1997 Jul;50(7):602–5 (Eng. Abstr.) **(Jpn)**

[Flow cytometry analysis of the DNA content of the prostate cancer--study on the tumor heterogeneity in prostate cancer] Michinaga S, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jun;87(6):937–41 (Eng. Abstr.) **(Jpn)**

[Clinicopathological study on patients with chromophobe cell renal carcinoma] Onishi T, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Oct;87(10):1167–74 (Eng. Abstr.) **(Jpn)**

[Biological effect of carbon beams on cultured human cells] Ka WJ, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Aug;56(9):669–73 (Eng. Abstr.) **(Jpn)**

[Analysis of small peripheral lung cancer diagnosed by open lung or thoracoscopic biopsy] Nomori H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):146–8 (Eng. Abstr.) **(Jpn)**

[Lung cancer with a sarcoid-like reaction in the primary tumor] Aoki K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Apr; 35(4):466–70 (Eng. Abstr.) **(Jpn)**

[Case of Barrett esophageal neoplasm] Morita H, et al. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):133–5 **(Jpn)**

[Lung cancer: Progress in diagnosis and treatment. I. Diagnosis and physiopathology: 5. Pathology--pathological classification and the origin of adenocarcinoma] Okamura A, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):27–32 (5 ref.) **(Jpn)**

[Clinicopathology of Epstein-Barr virus-related gastric carcinoma] Itoh T, et al. **Nippon Rinsho** 1997 Feb; 55(2):363–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of Bcl-2 and Bax in human gastric cancer tissue] Komatsu K, et al. **Nippon Rinsho** 1996 Jul;54(7):1929–34 (20 ref.) (Eng. Abstr.) **(Jpn)**

[A case of duodenal cancer arising in a tubulo-villous adenoma] Hirai R, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Feb;94(2):117–22 **(Jpn)**

[A case of von Recklinghausen's disease complicated by adenocarcinoma of the papilla of Vater] Nagayama K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Feb;94(2):123–8 (16 ref.) **(Jpn)**

[Clinicopathologic evaluation on colorectal laterally spreading tumor (LST)] Okamoto T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb;93(2):83–9 (Eng. Abstr.) **(Jpn)**

[A case of synchronous triple early cancer occurring in the stomach, colon and gallbladder] Yazawa K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jun;94(6):440–4 (12 ref.) **(Jpn)**

[Chromophobe renal cell carcinoma] Kuroda N, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):456–8 (16 ref.) **(Jpn)**

[The point of view of otolaryngologist and head and neck surgeon on thyroid diseases] Betkowski A, et al. **Otolaryngol Pol** 1995;49(6):574–82 (Eng. Abstr.) **(Pol)**

[The morphocytometric characteristics of the level of differentiation in cancer of the large intestine] Bagdasarian AA, et al. **Lik Sprava** 1996 Mar-Apr;(3-4):158–61 (Eng. Abstr.) **(Rus)**

[The clinico-morphological characteristics, diagnosis and treatment of early stomach cancer] Simonov NN, et al. **Vestn Khir Im I I Grek** 1997;156(1):28–31 (Eng. Abstr.) **(Rus)**

[Relationship of prostatic carcinoma of the peripheral zone with glandular atrophy and prostatic intraepithelial neoplasia] Algaba Arrea F, et al. **Actas Urol Esp** 1997 Jan; 21(1):40–3 (Eng. Abstr.) **(Spa)**

[Nuclear area versus nuclear grade in the prognosis of renal carcinoma. Long-term results] Gutiérrez Bañnos JL, et al. **Actas Urol Esp** 1996 Oct;20(9):794–9 (Eng. Abstr.) **(Spa)**

[Study of DNA content and its association with staging, tumor size, architecture, cell type, and nuclear grade in renal adenocarcinoma] Ruiz Cerdá JL, et al. **Actas Urol Esp** 1997 Jan;21(1):6–14 (Eng. Abstr.) **(Spa)**

[Cytohistological agreement of fine-needle transthoracic lung puncture-aspiration (FNTLPA) in malignant lesions] Hernández Borge J, et al. **Arch Bronconeumol** 1997 May; 33(5):225–9 (Eng. Abstr.) **(Spa)**

[Transformation of glandular cystitis into bladder transitional carcinoma with adenocarcinoma areas] García Rojo D, et al. **Arch Esp Urol** 1997 Mar;50(2):187–9 (Eng. Abstr.) **(Spa)**

[Multifocal renal carcinoma] Montserrat Orri V, et al. **Arch Esp Urol** 1996 Nov;49(9):967–9 (Eng. Abstr.) **(Spa)**

[Correlation between prostate specific antigen and histopathologic findings in ileum-obturator node dissection] Scorticati C Jr, et al. **Arch Esp Urol** 1997 Jan-Feb;50(1):41–4 (Eng. Abstr.) **(Spa)**

[Early gastric cancer in the remnant stomach. Case report] Castro D, et al. **G E N** 1995 Oct-Dec;49(4):314–6 (Eng. Abstr.) **(Spa)**

[Carcinoma of fallopian tubes. Presentation of 2 cases] Reyna-Hinojosa R, et al. **Ginecol Obstet Mex** 1996 Oct; 64:463–6 (Eng. Abstr.) **(Spa)**

[Left hemiparesis with atypical course in a 79-year-old man (clinico-pathologic conference)] Obach V, et al. **Med Clin (Barc)** 1997 Apr 12;108(14):549–55 **(Spa)**

[Palinopsia: first manifestation of a brain metastasis] Martin Estefanía C, et al. **Neurologia** 1996 Nov;11(9):357–8 **(Spa)**

[Determination of nutritional parameters affected in patients with gastric adenocarcinoma who are candidates for surgery according to tumor stage] Saló Solá E, et al. **Nutr Hosp** 1996 May-Jun;11(3):185–94 (Eng. Abstr.) **(Spa)**

[Interstitial lesion of poor course in an HIV-positive patient (clinical conference)] **Rev Clin Esp** 1996 Jun;196(6):395–402 **(Spa)**

[Gastric collision tumor with osseous metaplasia] Camuñas Mohinelo FA, et al. **Rev Esp Enferm Dig** 1997 Apr; 89(4):317–9 (Eng. Abstr.) **(Spa)**

[Analysis of 1017 large intestine adenocarcinomas resected in 978 patients] Duarte I, et al. **Rev Med Chil** 1996 Jun; 124(6):681–7 (Eng. Abstr.) **(Spa)**

[Miliary metastases to the brain (letter) (see comments)] Beltrán I, et al. **Rev Neurol** 1996 Mar;24(127):352–3. Comment in: Rev Neurol 1996 Oct;24(134):1305–6. **(Spa)**

[The morphological aspects of a study of the efficacy of chemotherapy in ovarian cancer] Iakymova TP, et al. **Lik Sprava** 1996 Jul-Sep;(7-9):103–6 (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

Thyroid autoantibodies and thyroid function in patients with pancreatic adenocarcinoma. Fyssas I, et al. **Acta Oncol** 1997;36(1):65–8

Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Takanami I, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2811–4

Unilateral facial pain and lung cancer. Shakespeare TP, et al. **Australas Radiol** 1996 Feb;40(1):45–6 (14 ref.)

Increased susceptibility to metastasis during pro-oestrus/oestrus in rats: possible role of oestradiol and natural killer cells. Ben-Eliyahu S, et al. **Br J Cancer** 1996 Dec;74(12):1900–7

Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Vollmers HP, et al. **Cancer** 1997 Feb 1;79(3):433–40

Characteristics of patients with vulvar cancer: an analysis of 94 patients. Edwards CL, et al. **Eur J Gynaecol Oncol** 1996;17(5):351–3

Correlation of body fat distribution with grade of endometrial cancer. Douchi T, et al. **Gynecol Oncol** 1997 Apr; 65(1):138–42

Improved prognosis of solid-type poorly differentiated colorectal adenocarcinoma: a clinicopathological and immunohistochemical study. Sugao Y, et al. **Histopathology** 1997 Aug;31(2):123–33

Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Fujita J, et al. **Int J Cancer** 1996 Nov 27;68(5):637–43

Change in morphological and functional cytodifferentiation induced by seminal vesicle mesenchyme in cell suspensions of rat Dunning prostatic adenocarcinoma cells. Hayashi N, et al. **Int J Cancer** 1996 Dec 11;68(6):788–94

pS2 transfection of murine adenocarcinoma cell line 410.4 enhances dispersed growth pattern in a 3-D collagen gel. Williams R, et al. **J Cell Sci** 1996 Jan;109 (Pt 1):63–71

Fertility and incidence of KRAS2 mutations in borderline ovarian adenocarcinomas [letter] Chenevix-Trench G, et al. **J Natl Cancer Inst** 1997 Jun 18;89(12):890–1

Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange. Donahue KM, et al. **Magn Reson Med** 1996 Dec;36(6):858–67

Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays. Markiewicz L, et al. **Methods Find Exp Clin Pharmacol** 1997 May;19(4):215–22

Effects of in vivo culture of murine mammary adenocarcinoma cells on tumor and metastatic growth. Aguirre Ghiso J, et al. **Tumour Biol** 1997;18(1):41–52

Metastatic behavior of prostatic tumor as influenced by the hematopoietic and hematogenous factors. Bhatti RA, et al. **Tumour Biol** 1997;18(1):1–5

[Juxtaglomerular cell tumor] Kihara I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):516–9 (16 ref.) **(Jpn)**

[Juxtaglomerular cell tumor] Tanabe A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):33–5 (9 ref.) **(Jpn)**

PREVENTION & CONTROL

Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Pienta KJ, et al. **Am J Clin Oncol** 1997 Feb;20(1):36–9

Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Ireland AP, et al. **Ann Surg** 1996 Sep;224(3):358–70; discussion 370–1

Correspondence re: J. Shannon et al., Relationship of food groups and water intake to colon cancer risk. Cancer Epidemiol., Biomarkers & Prev., 5: 495–502 [letter] Stookey JD, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Aug; 6(8):657–8

Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Clark JI, et al. **Cancer Immunol Immunother** 1997 Jul;44(5):265–72

Soy and rye diets inhibit the development of Dunning R3327 prostatic adenocarcinoma in rats. Zhang JX, et al. **Cancer Lett** 1997 Mar 19;114(1-2):313–4

Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Reddy BS, et al. **Cancer Res** 1997 Feb 1; 57(3):420–5

Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Samaha HS, et al. **Cancer Res** 1997 Apr 1;57(7):1301–5

Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Schmelz EM, et al. **Cancer Res** 1996 Nov 1;56(21):4936–41

Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Anisimov VN, et al. **Carcinogenesis** 1997 Aug;18(8):1549–53

Participants' perceptions of a phase I colon cancer chemoprevention trial. Hudmon KS, et al. **Control Clin Trials** 1996 Dec;17(6):494–508

Adenocarcinoma of the esophagus: preventable but at what cost? [editorial; comment] DeVault KR. **Dig Dis** 1996 Jul-Aug;14(4):211–2. Comment on: Dig Dis 1996 Jul-Aug;14(4):213–27.

Surveillance of Barrett's esophagus: a need for guidelines? Ackroyd R, et al. **Dis Esophagus** 1997 Jul;10(3):185–9

Role of surveillance endoscopy, biopsy and biomarkers in early detection of Barrett's adenocarcinoma. Ellis FH Jr, et al. **Dis Esophagus** 1997 Jul;10(3):165–71 (85 ref.)

Double blind randomized trial on occult blood bead (OBB) and gastroscopy-pathology screening for gastro-oesophageal cancer. Qin DX, et al. **Eur J Cancer Prev** 1997 Apr;6(2):158–61

NSAIDs, Barrett's oesophagus and adenocarcinoma prevention [letter] Vainio H, et al. **Eur J Cancer Prev** 1997 Apr;6(2):200

Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. Cole DJ, et al. **Hum Gene Ther** 1996 Jul 10;7(11):1381–94

Reasons for cervical cancer despite extensive screening. Stenkvist B, et al. **J Med Screen** 1996;3(4):204–7

Inhibition of mammary carcinogenesis in rats by parenteral high-dose vitamin E [letter] Ömer B, et al. **J Natl Cancer Inst** 1997 Jul 2;89(13):972–3

Chemoprevention of colon cancer by organoselenium compounds and impact of high- or low-fat diets. Reddy BS, et al. **J Natl Cancer Inst** 1997 Apr 2;89(7):506–12

Cryosurgical ablation of the normal ventral prostate plus adjuvant does not protect Copenhagen rats from Dunning prostatic adenocarcinoma challenge. Friedman EJ, et al. **J Urol** 1997 Oct;158(4):1585–8

Prostate cancer's complexities of causation, detection, and treatment challenge researchers [news] Gunby P. **JAMA** 1997 May 28;277(20):1580, 1582

Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Sekine K, et al. **Jpn J Cancer Res** 1997 Jun;88(6):523–6

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Hodge JW, et al. **Vaccine** 1997 Apr-May;15(6-7):759–68

[Polyps and polyposis--limits of endoscopic therapy. Are we currently overtreating by removing colorectal polyps?] Rösch W. **Fortschr Med** 1997 May 30;115(15):20, 23–5 (Eng. Abstr.) **(Ger)**

[Barrett syndrome and risk of carcinoma. To screen or not to screen--that is the question] Eckardt VF. **Z Gastroenterol** 1997 Jul;35(7):597–9 **(Ger)**

[Does regular administration of aspirin reduce the risk of gastrointestinal carcinomas?] Folwaczny C, et al. **Z Gastroenterol** 1996 Dec;34(12):823–5 **(Ger)**

[Inhibitory effect of the radiosensitizer AK-2123 on experimental liver metastasis and active transport of calcium ions] Konovalova NP, et al. **Vopr Onkol** 1997; 43(3):309–12 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Detection of pancreatic adenocarcinoma: relative value of arterial and late phases of spiral CT. Choi BI, et al. **Abdom Imaging** 1997 Mar-Apr;22(2):199–203

Esophageal carcinoma [editorial; comment] Thompson WM.

Abdom Imaging 1997 Mar–Apr;22(2):138–42. Comment on: Abdom Imaging 1997 Mar–Apr;22(2):132–7.
Computed tomography scanning of hepatic tumors with polyiodinated triglycerides. Weichert JP, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S229–31
Cystic renal masses: a reevaluation of the usefulness of the Bosniak classification system. Wilson TE, et al. **Acad Radiol** 1996 Jul;3(7):564–70
Thin–section oblique CT with 25 degrees cranially tilted images. Evaluation of pulmonary tumors adjacent to the interlobar fissures. Uchisako H, et al. **Acta Radiol** 1997 Mar; 38(2):246–9
Arterial versus portal venous helical CT for revealing pancreatic adenocarcinoma: conspicuity of tumor and critical vascular anatomy. Graf O, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):119–23
Carcinoma of the esophagus and esophagogastric junction: sensitivity of radiographic diagnosis. Levine MS, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1423–6
Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic–phase, thin–section helical CT. Lu DS, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1439–43
The use of helical CT and CT angiography to predict vascular involvement from pancreatic cancer: correlation with findings at surgery. Raptopoulos V, et al. **AJR Am J Roentgenol** 1997 Apr;168(4):971–7
Preoperative assessment of advanced gastric carcinoma using computed tomography. Adachi Y, et al. **Am J Gastroenterol** 1997 May;92(5):872–5
The changing presentation of lung adenocarcinoma [letter; comment] Jeanfaivre T, et al. **Chest** 1997 Aug;112(2):573–4 . Comment on: Chest 1996 Dec;110(6):1474–9.
Spiral CT and the pre–operative assessment of pancreatic adenocarcinoma. Coley SC, et al. **Clin Radiol** 1997 Jan; 52(1):24–30
CT of pancreatic neoplasms. Part I: Adenocarcinoma. Stephens DH. **Curr Probl Diagn Radiol** 1997 Mar–Apr; 26(2):59–80 (45 ref.)
Adenocarcinoma of the gastro–esophageal junction: CT for monitoring during neoadjuvant chemotherapy. Helmberger H 3rd, et al. **Eur J Radiol** 1996 Sep;23(2):107–10
Mammographic patterns of inflammatory breast carcinoma: a retrospective study of 92 cases. Tardivon AA, et al. **Eur J Radiol** 1997 Feb;24(2):124–30
Late contrast–enhanced CT for small pancreatic carcinoma: delayed enhanced area on CT with histopathological correlation. Furukawa H, et al. **Hepatogastroenterology** 1996 Sep–Oct;43(11):1230–7
Enhancement of prostate tumor volume definition with intravesical contrast: a three–dimensional dosimetric evaluation. Sharma R, et al. **Int J Radiat Oncol Biol Phys** 1997 Jun 1;38(3):575–82
Fluoroscopic–guided in vivo gastric mapping for assessment of gastric carcinoma. Makuch RS, et al. **Invest Radiol** 1997 Aug;32(8):496–9
Periprosthetic metastatic carcinoma. Pitfalls in the management of two cases initially diagnosed as osteolysis. Schmidt AH, et al. **J Arthroplasty** 1996 Aug;11(5):613–9
Adenocarcinoma of the lung––pleomorphic radiographic appearances [letter] Sundaram P, et al. **J Assoc Physicians India** 1996 Apr;44(4):291
Ossification of a rectal tumor: CT evaluation. Beauchamp NJ, et al. **J Comput Assist Tomogr** 1997 Jul–Aug; 21(4):671–3 (8 ref.)
Lung cancer in patients with idiopathic pulmonary fibrosis: CT findings. Lee HJ, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):979–82
Delayed intravenous contrast medium washout from the small bowel in patients with pancreatic carcinoma and splanchnic venous invasion. Sheiman RG, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):924–9
Utility of low–dose helical CT as a second step after plain chest radiography for mass screening for lung cancer. Mori K, et al. **J Thorac Imaging** 1997 Jul;12(3):173–80
Images in clinical medicine. Sister Joseph's node in carcinoma of the cecum. Moll S. **N Engl J Med** 1996 Nov 21; 335(21):1568
Computed tomography of pancreatic adenocarcinoma: comparison of tumor size measured by dynamic computed tomography and histopathologic examination. Furukawa H, et al. **Pancreas** 1996 Oct;13(3):231–5
Classification of air density areas in CT–pathologic correlation of pulmonary adenocarcinoma. Koizumi N, et al. **Radiat Med** 1995 Nov–Dec;13(6):279–84
Recurrent pancreatic adenocarcinoma: spiral CT evaluation following the Whipple procedure. Bluemke DA, et al. **Radiographics** 1997 Mar–Apr;17(2):303–13
Clinical usefulness of CT in the treatment of stage I endometrial carcinoma. La Fianza A, et al. **Radiol Med (Torino)** 1997 May;93(5):567–71
Natural history of superficial depressed colorectal cancer: retrospective radiographic and histologic analysis. Matsui T, et al. **Radiology** 1996 Oct;201(1):226–32
[Value of the esophagogram in preoperative assessment of esophageal carcinoma] Hackländer T, et al. **Aktuelle Radiol** 1997 Jan;7(1):35–40 (Eng. Abstr.) **(Ger)**
[Adenocarcinoma of the lobus v. azygos, characteristics of lymphogenous and hematogenous metastasis] Metzmann U, et al. **Aktuelle Radiol** 1996 Jan;6(1):32–4 (Eng. Abstr.) **(Ger)**
[The locoregional recurrence of rectal carcinoma. A computed tomographic analysis and a target volume concept for adjuvant radiotherapy] Bagatzounis A, et al. **Strahlenther Onkol** 1997 Feb;173(2):68–75 (Eng. Abstr.) **(Ger)**
[Role of endorectal ultrasonography and CT in preoperative staging of rectal cancer. Personal experience] Garretti L, et al. **Minerva Chir** 1997 Jun;52(6):717–25 (Eng. Abstr.) **(Ita)**
[Combined conventional magnetic resonance, magnetic resonance angiography, and magnetic resonance cholangiopancreatography in the diagnosis and staging of pancreatic carcinoma] Catalano C, et al. **Radiol Med (Torino)** 1997 May;93(5):556–60 (Eng. Abstr.) **(Ita)**
[Enhancement pattern of hepatic metastases from colorectal cancer on CT arteriography] Inaba Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Jul;57(8):483–6 (Eng. Abstr.) **(Jpn)**
[CT–image analysis of resected peripheral adenocarcinomas of the lung less than 1 cm in diameter] Isobe T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Oct; 34(10):1084–92 (Eng. Abstr.) **(Jpn)**
[Correlation between computed axial tomography and ileum obturating lymphadenectomy in localized adenocarcinoma of the prostate] Suárez P, et al. **Arch Esp Urol** 1997 Mar; 50(2):131–3 (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

99mTc tetrofosmin uptake in lung cancer. A case report. Ishibashi M, et al. **Acta Radiol** 1996 Sep;37(5):763–6
Incidental 67Ga uptake into an appendiceal mucocele in a patient with sigmoid colon cancer. Ohta H, et al. **Ann Nucl Med** 1996 May;10(2):257–9
When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Haukaas S, et al. **Br J Urol** 1997 May;79(5):770–6
18F–fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Nakata B, et al. **Cancer** 1997 Feb 15;79(4):695–9
Positron emission tomography with F–18–fluorodeoxyglucose to evaluate the results of hepatic chemoembolization [see comments] Vitola JV, et al. **Cancer** 1996 Nov 15;78(10):2216–22. Comment in: Cancer 1996 Nov 15;78(10):2039–42.
F–18 FDG uptake by recurrent Hürthle cell carcinoma of the thyroid using high–energy planar scintigraphy. Blount CL, et al. **Clin Nucl Med** 1996 Nov;21(11):831–3
Soft–tissue involvement by adenocarcinoma imaged during bone scintigraphy. Bordy Z, et al. **Clin Nucl Med** 1997 Jul;22(7):508
Ga–67 visualizing metastases of malignant melanoma to gastric cancer. Fukumoto M, et al. **Clin Nucl Med** 1997 Jun;22(6):415–6
Adenocarcinoma mimicking primary gastric lymphoma demonstrated by Ga–67 citrate imaging. Hirano T, et al. **Clin Nucl Med** 1997 Mar;22(3):187–8
Tc–99m sestamibi SPECT imaging of a brain metastasis in a man with lung tumor and increased sexual activity. Mira ML, et al. **Clin Nucl Med** 1996 Sep;21(9):745–6
Small lung cancer demonstrated with Tc–99m tetrofosmin imaging. Ohtake E, et al. **Clin Nucl Med** 1996 Jul;21(7):576
An unusual adrenal metastasis secondary to Hürthle cell carcinoma of the thyroid. Orsolon P, et al. **Clin Nucl Med** 1996 Apr;21(4):312–5
Tc–99m tetrofosmin accumulation in lung cancer and its metastases. Schillaci O, et al. **Clin Nucl Med** 1997 Jan; 22(1):46–7
Infected sebaceous cyst. A cause for false–positive total–body I–123 metastatic survey for thyroid cancer. Turoglu HT, et al. **Clin Nucl Med** 1996 Nov;21(11):887
The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model. Davies Q, et al. **Eur J Nucl Med** 1997 Feb; 24(2):206–9
Comparison of uptake of 99mTc–MIBI, 99mTc–tetrofosmin and 99mTc–Q12 into human breast cancer cell lines. de Jong M, et al. **Eur J Nucl Med** 1996 Oct;23(10):1361–6
Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium–99m labelled monoclonal antibody 170H.82: report of a phase II study. McQuarrie SA, et al. **Eur J Nucl Med** 1997 Apr;24(4):381–9
Value of radioimmunoscintigraphy with technetium–99m labelled anti–CEA monoclonal antibody (BW431/26) in the detection of colorectal cancer. Poshyachinda M, et al. **Eur J Nucl Med** 1996 Jun;23(6):624–30
Fluorine–18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Zimny M, et al. **Eur J Nucl Med** 1997 Jun;24(6):678–82
Use of 111In–DTPA–octreotide scintigraphy in the diagnosis of neuroendocrine and non–neuroendocrine tumors of the lung. Preliminary results. Oliaro A, et al. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):313–5
Resected sigmoid carcinoma with 13–year metastasis–free interval. Sternal recurrence detected by immunoscintigraphy. Vasireddi SS, et al. **J Clin Gastroenterol** 1996 Sep;23(2):128–30
Detection of lung tumor by single–photon emission computed tomographic sestamibi imaging. McDonald J, et al. **J Nucl Cardiol** 1996 Mar–Apr;3(2):185
Clinical significance of hepatic visualization on iodine–131 whole–body scan in patients with thyroid carcinoma. Chung JK, et al. **J Nucl Med** 1997 Aug;38(8):1191–5
Staging recurrent metastatic colorectal carcinoma with PET. Delbeke D, et al. **J Nucl Med** 1997 Aug;38(8):1196–201
Pharmacokinetics and experimental PET imaging of a bromine–76–labeled monoclonal anti–CEA antibody. Lövqvist A, et al. **J Nucl Med** 1997 Mar;38(3):395–401
First impressions. A 21–yr–old woman with adenocarcinoma of the pelvis. What is the radiopharmaceutical? What are the findings? Yeung H, et al. **J Nucl Med** 1996 Dec; 37(12):7A, 1994
Influence of chemotherapy on FDG uptake by human cancer xenografts in nude mice. Yoshioka T, et al. **J Nucl Med** 1997 May;38(5):714–7
Correlation between bone metabolic markers and bone scan in prostatic cancer. Maeda H, et al. **J Urol** 1997 Feb; 157(2):539–43
Radioimmunodetection with 111In–labeled monoclonal antibody Nd2 in patients with pancreatic cancer. Chung YS, et al. **Jpn J Cancer Res** 1997 Apr;88(4):427–34
123I–vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Virgolini I, et al. **Nucl Med Biol** 1996 Aug;23(6):685–92
Positron emission tomography study of human prostatic adenocarcinoma using carbon–11 putrescine. Wang GJ, et al. **Nucl Med Biol** 1994 Jan;21(1):77–82
Radioimaging of human breast carcinoma xenografts in mice by [123I]–labeled Z–17 alpha–iodovinyl–11 beta–chloromethyl–estradiol. Zeicher M, et al. **Nucl Med Biol** 1996 Jan;23(1):69–73
Visualization of lung cancer with 99Tcm–tetrofosmin imaging: a comparison with 201T1. Takekawa H, et al. **Nucl Med Commun** 1997 Apr;18(4):341–5
Effectiveness of Tc–99m MIBI scintigraphy in diagnosing lung cancer. Tanaka S, et al. **Surg Today** 1997;27(7):623–6
Use of monoclonal antibodies in colorectal cancer: a review. Schulte WJ. **World J Surg** 1996 Feb;20(2):238–40 (6 ref.)
[Gallium scintigraphy disclosing tumor of the small intestine! (letter)] Lambert M, et al. **Rev Med Interne** 1997 Jul; 18(7):587–8 **(Fre)**
[Second phase 99mTc–HMDP accumulation using three phase bone scintigraphy in a case of primary breast cancer] Nishiyama Y, et al. **Kaku Igaku** 1996 Jul;33(7):767–70 (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Great particles [32P]chromic phosphate for treatment of solid tumors. Zubillaga MB, et al. **Acta Physiol Pharmacol Ther Latinoam** 1996;46(2):103–10
High dose rate vaginal brachytherapy in early stage endometrial carcinoma: preliminary analysis. Hong JJ, et al. **Am J Clin Oncol** 1997 Jun;20(3):254–8
Concomitant intraarterial cisplatin, intravenous 5–flourouracil, and split–course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC–703). Thomas CR Jr, et al. **Am J Clin Oncol** 1997 Apr;20(2):161–5
Stage I corpus cancer: is teletherapy necessary? Orr JW Jr, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):777–88; discussion 788–9
Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer. Farrell TJ, et al. **Ann Surg** 1997 Jul;226(1):66–9
Randomized study on preoperative radiotherapy in rectal carcinoma. Stockholm Colorectal Cancer Study Group [see comments] **Ann Surg Oncol** 1996 Sep;3(5):423–30. Comment in: Ann Surg Oncol 1996 Sep;3(5):419–20.
Postoperative radiotherapy for locally advanced colon cancer [see comments] Amos EH, et al. **Ann Surg Oncol** 1996 Sep;3(5):431–6. Comment in: Ann Surg Oncol 1996 Sep;3(5):421–2.
Postoperative radiotherapy for locally advanced colon cancer [editorial; comment] Janjan NA. **Ann Surg Oncol** 1996 Sep;3(5):421–2. Comment on: Ann Surg Oncol 1996 Sep;3(5):431–6.
Patterns of recurrence following pelvic exenteration and external radiotherapy for locally advanced primary rectal adenocarcinoma. Luna–Perez P, et al. **Ann Surg Oncol** 1996 Nov;3(6):526–33
Preoperative radiotherapy for rectal cancer: benefits and controversies [editorial; comment] Ota DM. **Ann Surg Oncol** 1996 Sep;3(5):419–20. Comment on: Ann Surg Oncol 1996 Sep;3(5):423–30.
Radioimmunotherapy for advanced breast cancer using I–131–ChL6 antibody. Denardo SJ, et al. **Anticancer Res** 1997 May–Jun;17(3B):1745–51
Neuromuscular fatigue in prostate cancer patients undergoing radiation therapy. Monga U, et al. **Arch Phys Med Rehabil** 1997 Sep;78(9):961–6
Four–week arc radiotherapy for B2–C prostate cancer: the need for prospective evaluation of short fractionation schemes. Graham PH, et al. **Australas Radiol** 1997 Aug; 41(3):266–9
Postoperative radiotherapy for Dukes' B and C rectal cancer: Peter MacCallum Cancer Institute experience [see comments] Guiney MJ, et al. **Australas Radiol** 1996 Aug; 40(3):326–30. Comment in: Australas Radiol 1997 May;41(2):223.
Adjuvant VHF therapy in locally recurrent and primary unresectable rectal cancer. Trotter JM, et al. **Australas Radiol** 1996 Aug;40(3):298–305

Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Prott FJ, et al. **Br J Cancer** 1997;75(4):597–601 (29 ref.)

High dose rate brachytherapy before external beam irradiation in inoperable oesophageal cancer. Taal BG, et al. **Br J Cancer** 1996 Nov;74(9):1452–7

Short communication: CT–MRI image fusion for 3D conformal prostate radiotherapy: use in patients with altered pelvic anatomy. Lau HY, et al. **Br J Radiol** 1996 Dec;69(828):1165–70

Comparison of hyperfractionated conformal photon with conformal mixed neutron/photon irradiation in locally advanced prostate cancer. Forman JD, et al. **Bull Cancer Radiother** 1996;83 Suppl:101s–5s

Protracted 5–fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Ishii H, et al. **Cancer** 1997 Apr 15;79(8):1516–20

Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. Poplin EA, et al. **Cancer** 1996 Nov 1;78(9):1851–6

Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus [see comments] Forastiere AA, et al. **Cancer J Sci Am** 1997 May–Jun;3(3):144–52. Comment in: Cancer J Sci Am 1997 May–Jun;3(3):137–9.

Dosimetric considerations in the treatment of inoperable endometrial carcinoma by a high dose rate afterloading packing technique. Bond MG, et al. **Clin Oncol (R Coll Radiol)** 1997;9(1):41–7

The absence of an adverse effect of prolongation of radiation treatment of primary rectal adenocarcinoma. Brierley JD, et al. **Clin Oncol (R Coll Radiol)** 1996;8(2):97–101

CT appearance of the Syed–Neblett device for interstitial brachytherapy of gynecologic malignancies. Yeung N, et al. **Comput Med Imaging Graph** 1996 Sep–Oct;20(5):403–6

Carcinoma of the esophagus treated with radical chemoradiation 19 years after irradiation for recurrent breast cancer. MacLeod C, et al. **Dis Esophagus** 1997 Apr; 10(2):145–8

Palliative endoscopic therapy of rectal carcinoma [letter; comment] Glynne–Jones R, et al. **Eur J Cancer** 1996 Oct; 32A(11):2031. Comment on: Eur J Cancer 1996 Jan;32A(1):25–9.

The toxicity of radiotherapy following high–dose chemotherapy with peripheral blood stem cell support in high–risk breast cancer: a preliminary analysis. van der Wall E, et al. **Eur J Cancer** 1996 Aug;32A(9):1490–7

Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5–fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study. Wagener DJ, et al. **Eur J Cancer** 1996 Jul;32A(8):1310–3

Progress in the management of T3–4 adenocarcinoma of the prostate. Zietman AL, et al. **Eur J Cancer** 1997 Apr; 33(4):555–9 (33 ref.)

Postoperative management of patients with stage Ib endometrial carcinoma. Sainz de la Cuesta R, et al. **Eur J Gynaecol Oncol** 1996;17(5):338–41

IORT in primary rectal cancer (T3–4Nx): multi–institutional experience with conventional treatment sequence. Spanish Group of IORT. Azinovic I, et al. **Front Radiat Ther Oncol** 1997;31:193–5

IORT in pancreatic adenocarcinoma. Gilly FN, et al. **Front Radiat Ther Oncol** 1997;31:181–3

Whole abdominal external beam radiation in the treatment of primary carcinoma of the fallopian tube. Kojs Z, et al. **Gynecol Oncol** 1997 Jun;65(3):473–7

Perineal template interstitial brachytherapy salvage for recurrent endometrial adenocarcinoma metastatic to the vagina. Nag S, et al. **Gynecol Oncol** 1997 Jul;66(1):16–9

Isolated vaginal recurrences in endometrial carcinoma: treatment results using high–dose–rate intracavitary brachytherapy and external beam radiotherapy. Pai HH, et al. **Gynecol Oncol** 1997 Aug;66(2):300–7 (27 ref.)

Combined treatment with lasertherapy (Nd:YAG) and endocavitary radiation in the palliation of rectal cancer. Conio M, et al. **Hepatogastroenterology** 1996 Nov–Dec; 43(12):1518–22

Radioimmunotherapy of experimental pancreatic cancer with 131I–labeled monoclonal antibody PAM4. Gold DV, et al. **Int J Cancer** 1997 May 16;71(4):660–7

Preoperative radiotherapy for resectable cancer of the middle–distal rectum: its effect on the primary lesion as determined by endorectal ultrasound using flexible echo colonoscope. Bozzetti F, et al. **Int J Colorectal Dis** 1996; 11(6):283–6

Hypofractionated radiotherapy with concurrent 5–fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. Skarlatos J, et al. **Int J Colorectal Dis** 1996;11(5):206–10

Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. Anscher MS, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 15;37(5):1059–65

Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors. Barillot I, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15; 38(5):969–78

Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. Berger C, et al. **Int J Radiat Oncol Biol Phys** 1997 Feb 1;37(3):619–27

Biochemical disease–free survival following 125I prostate implantation. Beyer DC, et al. **Int J Radiat Oncol Biol Phys** 1997 Feb 1;37(3):559–63

"Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: impact of treatment intensity on local control and survival. Chan AK, et al. **Int J Radiat Oncol Biol Phys** 1997 Feb 1;37(3):629–37

Excellent long–term survival and absence of vaginal recurrences in 332 patients with low–risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Eltabbakh GH, et al. **Int J Radiat Oncol Biol Phys** 1997 May 1;38(2):373–80

Postoperative radiotherapy for malignant tumors of the parotid gland. Garden AS, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 1;37(1):79–85

American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Clinical Research Committee, American Brachytherapy Society, Philadelphia, PA. Gaspar LE, et al. **Int J Radiat Oncol Biol Phys** 1997 Apr 1;38(1):127–32

A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92–07): preliminary toxicity report. Gaspar LE, et al. **Int J Radiat Oncol Biol Phys** 1997 Feb 1;37(3):593–9

Stereotactic radiosurgery of the rat dunning R3327–AT1 prostate tumor. Henke K, et al. **Int J Radiat Oncol Biol Phys** 1996 Sep 1;36(2):385–91

Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. Katcher J, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 1;37(4):871–6

Treatment planning for adenocarcinoma of the rectum and sigmoid: a patterns of care study. PCS Committee. Kline RW, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15; 37(2):305–11 (3 ref.)

Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90–20). Lawton CA, et al. **Int J Radiat Oncol Biol Phys** 1996 Oct 1;36(3):673–80

Radiation–induced apoptosis in different pH environments in vitro. Lee HS, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15;38(5):1079–87

Preoperative radiotherapy in rectal cancer: are all protocols comparable? [letter] Nguyen TD, et al. **Int J Radiat Oncol Biol Phys** 1996 Nov 1;36(4):987–8

Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Perez CA, et al. **Int J Radiat Oncol Biol Phys** 1996 Oct 1;36(3):573–84

Magnetic resonance imaging in the treatment planning of radiation therapy in carcinoma of the cervix treated with the four–field pelvic technique. Thomas L, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 1;37(4):827–32

Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: preliminary results of a phase I/II study. Yonemoto LT, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 1;37(1):21–9

Transanal excision and postoperative radiation therapy in selected patients with cancer of the low rectum. Romano G, et al. **Int Surg** 1996 Jan–Mar;81(1):40–4

Phase III trial of androgen suppression using goserelin in unfavorable–prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. Pilepich MV, et al. **J Clin Oncol** 1997 Mar;15(3):1013–21

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. Spitz FR, et al. **J Clin Oncol** 1997 Mar;15(3):928–37 (44 ref.)

Adjuvant postoperative fluorouracil–modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. Tepper JE, et al. **J Clin Oncol** 1997 May;15(5):2030–9

The use of transrectal ultrasound placement of radioactive seeds for the definitive treatment of prostate cancer. Zachow SE, et al. **J Miss State Med Assoc** 1996 Oct; 37(10):771–5

Variables influencing tumor dosimetry in radioimmunotherapy of CEA–expressing cancers with anti–CEA and antimucin monoclonal antibodies. Behr TM, et al. **J Nucl Med** 1997 Mar;38(3):409–18

Risk of incontinence with transurethral resection of the prostate after radiation therapy for prostate cancer. Patel H, et al. **J Surg Oncol** 1997 Feb;64(2):127–9

Laparoscopic pelvic lymph node dissection following definitive radiotherapy for carcinoma of the prostate. Lund GO, et al. **J Urol** 1997 Feb;157(2):548–51

Radiotherapy for high grade clinically localized adenocarcinoma of the prostate [see comments] Roach M 3rd, et al. **J Urol** 1996 Nov;156(5):1719–23. Comment in: J Urol 1996 Nov;156(5):1724.

Long–term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. Zelefsky MJ, et al. **J Urol** 1997 Jul;158(1):23–9; discussion 29–30

Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Medical Research Council Rectal Cancer Working Party [see comments] **Lancet** 1996 Dec 14;348(9042):1605–10. Comment in: Lancet 1996 Dec 14;348(9042):1600. Comment in: Lancet 1997 Mar 22;349(9055):877; discussion 877–8.

Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Medical Research Council Rectal Cancer Working Party [see comments] **Lancet** 1996 Dec 14;348(9042):1610–4. Comment in: Lancet 1996 Dec 14;348(9042):1600. Comment in: Lancet 1997 Mar 22;349(9055):877; discussion 877–8.

A three–dimensional approach for re–irradiation of recurrent colorectal adenocarcinoma. Watson B, et al. **Med Dosim** 1996 Summer;21(2):79–82

Prostate cancer––the therapeutic challenge of locally advanced disease [editorial; comment] Blasko JC, et al. **N Engl J Med** 1997 Jul 31;337(5):340–1. Comment on: N Engl J Med 1997 Jul 31;337(5):295–300.

Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [see comments] Bolla M, et al. **N Engl J Med** 1997 Jul 31; 337(5):295–300. Comment in: N Engl J Med 1997 Jul 31;337(5):340–1.

Use of colloids of chromic [32P] phosphate in treatment of solid tumors. Zubillaga MB, et al. **Nucl Med Biol** 1996 Oct; 23(7):907–10

Apoptosis and response to radiation: implications for radiation therapy. Meyn RE. **Oncology (Huntingt)** 1997 Mar;11(3):349–56; discussion 356, 361, 365 (45 ref.)

Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate–specific antigen, prostatic acid phosphatase, and cytokeratin 8. Ljung G, et al. **Prostate** 1997 May 1;31(2):91–7

Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy. Ljung G, et al. **Prostate** 1997 Jul 1;32(2):99–105

Assessment of proliferation indicators in residual prostatic adenocarcinoma cells after radical external beam radiotherapy. Ljung G, et al. **Prostate** 1996 Nov; 29(5):303–10

Select transition zone prostate cancers may be radiocurable despite markedly elevated prostate–specific antigen levels. D'Amico AV, et al. **Radiother Oncol** 1996 Jan;38(1):73–6

Factors influencing outcome following radio–chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG) [see comments] Denham JW, et al. **Radiother Oncol** 1996 Jul;40(1):31–43. Comment in: Radiother Oncol 1997 Jan;42(1):91–2.

Acute lumbosacral plexopathy during and after preoperative radiotherapy of rectal adenocarcinoma. Frykholm GJ, et al. **Radiother Oncol** 1996 Feb;38(2):121–30

Combined curative radiation therapy alone in (T1) T2–3 rectal adenocarcinoma: a pilot study of 29 patients. Gerard JP, et al. **Radiother Oncol** 1996 Feb;38(2):131–7

Short–term preoperative radiotherapy results in down–staging of rectal cancer: a study of 1316 patients. Graf W, et al. **Radiother Oncol** 1997 May;43(2):133–7

Carcinoma of the cervical stump: retrospective analysis of 77 cases. Hannoun–Lévi JM, et al. **Radiother Oncol** 1997 May;43(2):147–53

Spontaneous metastasis, proliferation characteristics and radiation sensitivity of fractionated irradiation recurrent and unirradiated human xenografts. Huang P, et al. **Radiother Oncol** 1996 Oct;41(1):73–81

Long source–skin distance rectal irradiation technique: a review of results. Mahajan A, et al. **Radiother Oncol** 1996 Jul;40(1):63–7

Preoperative radiotherapy in stage I/II endometrial adenocarcinoma. Maingon P, et al. **Radiother Oncol** 1996 Jun;39(3):201–8

SN–38, a metabolite of the camptothecin derivative CPT–11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids. Omura M, et al. **Radiother Oncol** 1997 May;43(2):197–201

Transient perfusion and radiosensitizing effect after nicotinamide, carbogen, and perflubron emulsion administration. Thomas CD, et al. **Radiother Oncol** 1996 Jun;39(3):235–41

Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1–2 adenocarcinoma of the prostate. Zietman AL, et al. **Radiother Oncol** 1996 Aug;40(2):159–62

Brachytherapy for cancer of the female urethra. Micaily B, et al. **Semin Surg Oncol** 1997 May–Jun;13(3):208–14 (29 ref.)

Marked hyperlipasemia after radiotherapy in a patient with prostate cancer [letter] Thanigaraj S, et al. **South Med J** 1996 Nov;89(11):1127–8

High–dose rate intracavitary irradiation for carcinoma of the uterine cervix. The adverse effect of treatment prolongation. Chatani M, et al. **Strahlenther Onkol** 1997 Jul;173(7):379–84

Primary carcinoma of the gallbladder: role of external beam radiation therapy in patients with locally advanced tumor. Uno T, et al. **Strahlenther Onkol** 1996 Sep;172(9):496–500

Adjuvant radiation therapy for adenocarcinoma of the rectum. Fleshman JW, et al. **Surg Clin North Am** 1997 Feb; 77(1):15–25 (31 ref.)

Morbidity and mortality following preoperative radiation therapy and total pelvic exenteration for primary rectal adenocarcinoma. Luna–Perez P, et al. **Surg Oncol** 1995;

4(6):295–301

High dose rate transurethral brachytherapy as a boost dose for localized adenocarcinoma of the prostate. Serin M, et al. **Urol Int** 1997;58(1):30–3

Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Zietman AL, et al. **Urology** 1997 Mar;49(3A Suppl):74–83 (43 ref.)

[Locally advanced carcinoma of the cervix (distal II, Barrel-shaped and III) treated by irradiation alone: impact of individual treatment planning on results, sequelae and complications] Barillot I, et al. **Bull Cancer Radiother** 1996; 83(4):364–9 **(Fre)**

[Three-dimensional radiation therapy. Report of the "2nd International Symposium 3-D Radiation Treatment Planning and Conformal Therapy". 11-13 April 1996, Saint-Louis, Missouri, USA] Touboul E, et al. **Bull Cancer Radiother** 1996;83(3):187–95 **(Fre)**

[Effect radiotherapy on postoperative staging and residual tumor cell density in rectal cancers] Berger C, et al. **Cancer Radiother** 1997;1(3):240–8 (31 ref.) (Eng. Abstr.) **(Fre)**

[Results of the treatment with fast neutrons (d.T 13 MeV) in recurrent rectal carcinoma] Prott FJ, et al. **Strahlenther Onkol** 1997 Jun;173(6):316–22 (Eng. Abstr.) **(Ger)**

[The results of primary radiotherapy in vaginal carcinoma] Schäfer U, et al. **Strahlenther Onkol** 1997 May; 173(5):272–80 (Eng. Abstr.) **(Ger)**

[Downstaging of esophageal carcinoma after preoperative radio- and chemotherapy] Staar S. **Strahlenther Onkol** 1996 Dec;172(12):693–5 **(Ger)**

[Laparoscopic lymphadenectomy in prostate carcinoma. Experiences with 120 patients] Effert P, et al. **Urologe A** 1996 Sep;35(5):413–7 (Eng. Abstr.) **(Ger)**

[Neoadjuvant combined hormonal therapy and radiotherapy with external beam irradiation in prostatic carcinoma] Cellini N, et al. **Radiol Med (Torino)** 1997 Apr;93(4):446–50 (Eng. Abstr.) **(Ita)**

[Trial of radiation and cisplatin, carboplatin combination chemotherapy for advanced cancer (W-platinum chemoradiotherapy] Kato M, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):723–7 (Eng. Abstr.) **(Jpn)**

[High-dose endobronchial brachytherapy in malignant tumors of the lung] Escobar Sacristán J, et al. **Arch Bronconeumol** 1997 Jun;33(6):278–83 (Eng. Abstr.) **(Spa)**

SECONDARY

Skeletal muscle mass in an asymptomatic male. Weinberg E, et al. **Acad Radiol** 1997 Jun;4(6):458–60

Cytologic features of colonic adenocarcinoma. Differences between primary and metastatic neoplasms. Koizumi JH, et al. **Acta Cytol** 1997 Mar-Apr;41(2):419–26

MR imaging of a metastasis in a meningioma. Van Zandijcke M, et al. **Acta Neurol Belg** 1996 Dec;96(4):329–31

Adenocarcinoma of the fallopian tube. Natural history of an isolated splenic metastasis. Dubecq-Princeteau F, et al. **Acta Oncol** 1997;36(2):221–3

Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung—a study from a cohort of 259 consecutive patients treated with chemotherapy. Stenbygaard LE, et al. **Acta Oncol** 1997;36(3):301–6 (27 ref.)

Metastasis to the thyroid gland with laryngeal involvement [letter] Chong VF, et al. **AJR Am J Roentgenol** 1996 Oct; 167(4):1071–2

Metastatic adenocarcinoma within an adrenal adenoma: detection with chemical shift imaging. Shifrin RY, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):891–2

Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma. Colleoni M, et al. **Am J Clin Oncol** 1997 Jun;20(3):303–7

Acute renal failure in a patient receiving treatment with suramin. Smith A, et al. **Am J Clin Oncol** 1997 Aug; 20(4):433–4

A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program Trial. Vaughn DJ, et al. **Am J Clin Oncol** 1997 Jun;20(3):242–6

Isolated facial nerve palsy from metastasis to the temporal bone: report of two cases and a review of the literature. Weiss MD, et al. **Am J Clin Oncol** 1997 Feb;20(1):19–23 (18 ref.)

Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Brown RW, et al. **Am J Clin Pathol** 1997 Jan;107(1):12–9

Metastatic breast carcinoma presenting as obstructive jaundice. Papo M, et al. **Am J Gastroenterol** 1996 Oct; 91(10):2240–1

Duodenal obstruction secondary to a metastasis from an adenocarcinoma of the cecum: a case report. Sebastián JJ, et al. **Am J Gastroenterol** 1997 Jun;92(6):1051–2

Superior mediastinal dissection in the treatment of Hürthle cell carcinoma of the thyroid. Maillard AA, et al. **Am J Otolaryngol** 1997 Jan-Feb;18(1):47–50

Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Delcore R, et al. **Am J Surg** 1996 Nov;172(5):463–8; discussion 468–9

Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Shaha AR, et al. **Am J Surg** 1996 Dec;172(6):692–4

Prostate cancer metastatic to a hamartoma [letter; comment] Kuo T. **Am J Surg Pathol** 1996 Mar;20(3):384. Comment on: Am J Surg Pathol 1995 Apr;19(4):472–5.

Acute appendicitis secondary to metastatic bronchogenic adenocarcinoma. Gopez EV, et al. **Am Surg** 1997 Sep; 63(9):778–80

Recurrent gallbladder carcinoma at laparoscopy port sites diagnosed by positron emission tomography: implications for primary and radical second operations. Lomis KD, et al. **Am Surg** 1997 Apr;63(4):341–5

Recurrent adenocarcinoma of the fallopian tube presenting as leptomeningeal carcinomatosis. Vadmal MS, et al. **Ann Clin Lab Sci** 1996 Mar-Apr;26(2):119–21

Laparoscopy in the management of gastric adenocarcinoma. Burke EC, et al. **Ann Surg** 1997 Mar;225(3):262–7 (9 ref.)

Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Harrison LE, et al. **Ann Surg** 1996 Sep;224(3):342–7; discussion 347–9

Colorectal carcinoma and brain metastasis: distribution, treatment, and survival. Hammoud MA, et al. **Ann Surg Oncol** 1996 Sep;3(5):453–63

Pulmonary metastases in metastatic prostate cancer: host tissue–tumor cell interactions and response to hormone therapy. Behrakis P, et al. **Anticancer Res** 1997 May-Jun; 17(3A):1517–8

Paraneoplastic cerebellar degeneration. Case report and literature review. Bolla L, et al. **Arch Intern Med** 1997 Jun 9;157(11):1258–62 (33 ref.)

Malignant secondary deposit in the iliac crest masquerading as meralgia paresthetica. Tharion G, et al. **Arch Phys Med Rehabil** 1997 Sep;78(9):1010–1

A case of atypical chest pain. Mann-Segal D. **Aust Fam Physician** 1997 Mar;26(3):297–8

Bone changes in tuberous sclerosis mimicking metastases. Pui MH, et al. **Australas Radiol** 1996 Feb;40(1):77–9

Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells. Nanni P, et al. **Br J Cancer** 1996 Nov;74(10):1564–9

Tumour presenting as a retrosternal abscess following median sternotomy. Martin IR, et al. **Br J Clin Pract** 1997 Apr-May;51(3):185

Peculiar inflammatory cutaneous metastasis from stomach adenocarcinoma [letter] Sahin S, et al. **Br J Dermatol** 1997 Apr;136(4):650–2

Carcinoma of the colon with mandible and liver metastases [letter; comment] Bentley RP, et al. **Br J Oral Maxillofac Surg** 1997 Jun;35(3):221–2. Comment on: Br J Oral Maxillofac Surg 1996 Feb;34(1):133–4.

Relationship between histological type and endosonographic detection of regional lymph node metastases in gastric cancer. Hamada S, et al. **Br J Radiol** 1997 Jul; 70(835):697–702

Serum PICP as a bone formation marker in 89Sr and external beam radiotherapy of prostatic bony metastases. Papatheofanis FJ. **Br J Radiol** 1997 Jun;70(834):594–8

Peritoneal seeding of pancreatic head carcinoma following percutaneous transhepatic drainage and stenting [letter] Crinnion JN, et al. **Br J Surg** 1997 Aug;84(8):1171

Pancreatic and ampullary carcinomas with intrascrotal metastases. Dookeran KA, et al. **Br J Surg** 1997 Feb; 84(2):198–9

Spontaneous resolution of histologically proven liver metastases from colorectal cancer. Francis A, et al. **Br J Surg** 1997 Jun;84(6):818

Wound metastases following laparoscopic and open surgery for abdominal cancer in a rat model. Mathew G, et al. **Br J Surg** 1996 Aug;83(8):1087–90

Adenocarcinoma arising on the site of a Gelpi retractor after coloanal anastomosis for rectal cancer [letter] Thomson WH. **Br J Surg** 1997 Aug;84(8):1176

Adenocarcinoma arising on the site of a Gelpi retractor after coloanal anastomosis for rectal cancer. Zinzindohoue F, et al. **Br J Surg** 1997 Mar;84(3):362

Penile metastasis of sigmoid carcinoma: comparative analysis of different imaging modalities. Andresen R, et al. **Br J Urol** 1997 Mar;79(3):477–8

Penile metastases from carcinoma of the prostate. Pandian SS, et al. **Br J Urol** 1997 May;79(5):807

The appendix as a metastatic target for male urogenital tumours. Stein A, et al. **Br J Urol** 1996 Oct;78(4):647–8

Orbital tumours as a first indication of urological malignancies. Weijerman PC, et al. **Br J Urol** 1997 Feb; 79(2):288–9

Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization [see comments] Vitola JV, et al. **Cancer** 1996 Nov 15;78(10):2216–22. Comment in: Cancer 1996 Nov 15;78(10):2039–42.

Lipid-laden macrophage infiltration of human adenocarcinoma in vivo associated with taxol and GCSF treatment. Abramson N, et al. **Cancer Invest** 1997; 15(1):18–22

Enhancement of metastasis of prostate adenocarcinoma cells by immune-suppressive cyclosporine A. Pollard M. **Cancer Lett** 1997 Jan 1;111(1-2):221–4

P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). Iwamura T, et al. **Cancer Res** 1997 Mar 15;57(6):1206–12

Role of transesophageal echocardiography in the management of metastatic tumors invading the left atrium. Lee TM, et al. **Cardiology** 1997 Mar-Apr;88(2):214–7

Colonic carcinoma metastasis to ovary having serous cystadenocarcinoma -- an unusual case of double ovarian malignancy. Visweswara RN, et al. **Cent Afr J Med** 1995 Nov;41(11):357–9

Calcifying liver metastases in a case of primary lung cancer. Balikó Z, et al. **Chest** 1997 Apr;111(4):1121–2

Isolated dural metastasis from colon cancer. Higuchi M, et al. **Clin Neurol Neurosurg** 1997 May;99(2):135–7

Soft-tissue involvement by adenocarcinoma imaged during bone scintigraphy. Bordy Z, et al. **Clin Nucl Med** 1997 Jul;22(7):508

Ga-67 citrate and Tc-99m MDP uptake in peritoneal metastases from a poorly differentiated adenocarcinoma of gynecologic origin. Bykov S, et al. **Clin Nucl Med** 1997 May;22(5):342–3

Tc-99m sestamibi SPECT imaging of a brain metastasis in a man with lung tumor and increased sexual activity. Mira ML, et al. **Clin Nucl Med** 1996 Sep;21(9):745–6

Low-back pain and a vertebral lesion. Mitjavila M, et al. **Clin Nucl Med** 1996 Apr;21(4):321

An unusual adrenal metastasis secondary to Hürthle cell carcinoma of the thyroid. Orsolon P, et al. **Clin Nucl Med** 1996 Apr;21(4):312–5

Infected sebaceous cyst. A cause for false-positive total-body I-123 metastatic survey for thyroid cancer. Turoglu HT, et al. **Clin Nucl Med** 1996 Nov;21(11):887

An unusual perfusion pattern of hepatic metastases. VanHoose JD, et al. **Clin Nucl Med** 1997 Jun;22(6):420–1

Pulmonary metastases, an occult prostatic adenocarcinoma and delayed administration of antiandrogens. Harris SJ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(2):118–9

Right thigh mass in a 59-year-old man [clinical conference] Oates KM, et al. **Clin Orthop** 1997 Sep;(342):248–53, 270–2

Non-squamous malignancy in lymph nodes: the occult primary. Jones AS, et al. **Clin Otolaryngol** 1993 Aug; 18(4):311–6

Skin metastases from prostate cancer associated with malignant melanoma. Offidani A, et al. **Cutis** 1997 May; 59(5):278–80

Cytology of metastatic adenocarcinoma of the prostate in pleural effusions. Renshaw AA, et al. **Diagn Cytopathol** 1996 Aug;15(2):103–7

A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. Chao D, et al. **Eur J Cancer** 1997 Jul;33(8):1230–3

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. de Gramont A, et al. **Eur J Cancer** 1997 Feb;33(2):214–9

Umbilical port metastasis from gallbladder carcinoma after laparoscopic cholecystectomy. Karayiannakis AJ, et al. **Eur J Surg Oncol** 1997 Apr;23(2):186–7

Sclerosis of lytic metastatic bone lesions during treatment with pamidronate in a patient with adenocarcinoma of unknown primary site. Tanaka M, et al. **Eur Spine J** 1996; 5(3):198–200

Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma. Hosoya Y, et al. **Eur Urol** 1997;31(2):220–3

Metastatic lung cancer to ankle synovium: a case report. Koss SD, et al. **Foot Ankle Int** 1996 Jan;17(1):51–3

Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration of the left adrenal gland. Chang KJ, et al. **Gastrointest Endosc** 1996 Nov;44(5):568–72

Brain metastases from a primary carcinoma of the fallopian tube. Cormio G, et al. **Gynecol Obstet Invest** 1996; 41(4):286–8

Successful management of a solitary peritoneal metastasis of unknown origin. Report of a case. Wang PH, et al. **Gynecol Obstet Invest** 1997;43(3):212–4

Metastatic breast carcinoma to the abdomen and pelvis. Abu-Rustum NR, et al. **Gynecol Oncol** 1997 Jul;66(1):41–4

Primary peritoneal adenocarcinoma metastatic to the brain. Eltabbakh GH, et al. **Gynecol Oncol** 1997 Jul;66(1):160–3

Ovarian carcinoma initially presenting as metastatic axillary lymphadenopathy. Hockstein S, et al. **Gynecol Oncol** 1997 Jun;65(3):543–7

Endometrial adenocarcinoma metastatic to the scalp: case report and literature review. Kushner DM, et al. **Gynecol Oncol** 1997 Jun;65(3):530–3 (9 ref.)

Urethral carcinoma metastatic to bone: a case report and literature review. Mirzayan R, et al. **Gynecol Oncol** 1996 Oct;63(1):127–32 (29 ref.)

Perineal template interstitial brachytherapy salvage for recurrent endometrial adenocarcinoma metastatic to the vagina. Nag S, et al. **Gynecol Oncol** 1997 Jul;66(1):16–9

Adenocarcinoma of the breast metastatic to benign ovarian fibroma. Perry LJ, et al. **Gynecol Oncol** 1996 Sep; 62(3):408–10

Identification of high-risk groups among node-positive patients with stage IB and IIA cervical carcinoma. Samlal RA, et al. **Gynecol Oncol** 1997 Mar;64(3):463–7 (31 ref.)

Liver metastasis rare in colorectal cancer patients with fatty liver. Hayashi S, et al. **Hepatogastroenterology** 1997

Jul–Aug;44(16):1069–75
Partial hepatectomy for metastatic seeding complicating pancreatoduodenectomy. Sano T, et al. **Hepatogastroenterology** 1997 Jan–Feb;44(13):263–7
Factors influencing incidence and extension of metachronous liver metastases of colorectal adenocarcinoma. A multivariate analysis. Secco GB, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):1057–62
Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival? Takada T, et al. **Hepatogastroenterology** 1997 Mar–Apr;44(14):567–73
Expression of tumor-associated carbohydrate antigens correlates with hepatic metastasis of pancreatic cancer: clinical and experimental studies. Takamori H, et al. **Hepatogastroenterology** 1996 May–Jun;43(9):748–55
Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Kaufmann O, et al. **Histopathology** 1996 Sep;29(3):233–40
Is immunostaining with HAM56 antibody useful in identifying ovarian origin of metastatic adenocarcinomas? Cheung AN, et al. **Hum Pathol** 1997 Jan;28(1):91–4 (35 ref.)
Metastatic adenocarcinoma to the brain: an immunohistochemical approach. Perry A, et al. **Hum Pathol** 1997 Aug;28(8):938–43
Carcinoma gallbladder presenting with skeletal metastases. Misra S, et al. **Indian J Gastroenterol** 1997 Apr;16(2):74
Hematuria: a presentation of carcinoma of the stomach. Nijhawan S, et al. **Indian J Gastroenterol** 1996 Jul;15(3):102
Sister Mary Joseph's nodule--diagnosis of umbilical metastases by fine needle aspiration. Mallya MV, et al. **Indian J Pathol Microbiol** 1995 Jan;38(1):95–8
Cutaneous metastases in pancreatic adenocarcinoma. Puri AS, et al. **Indian J Pathol Microbiol** 1995 Jan;38(1):99–101
Cytogenetic findings in metastases from colorectal cancer. Bardi G, et al. **Int J Cancer** 1997 Aug 7;72(4):604–7
Microvessel density in unknown primary tumors. Hillen HF, et al. **Int J Cancer** 1997 Feb 20;74(1):81–5
Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Pantel K, et al. **Int J Cancer** 1997 May 16;71(4):521–5
Genetic diversity at the p53 locus between primary human colorectal adenocarcinomas and their lymph-node metastases. Zhang JS, et al. **Int J Cancer** 1997 Mar 17; 70(6):674–8
Ovarian metastasis from cervical carcinoma. Wu HS, et al. **Int J Gynaecol Obstet** 1997 May;57(2):173–8
Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Sartor CI, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15;38(5):941–7
Metastasis of prostate adenocarcinoma to testis. Baykal K, et al. **Int J Urol** 1997 Jan;4(1):104–5
Urethral recurrence of an urachal carcinoma: a case report. Yasui T, et al. **Int J Urol** 1997 Jan;4(1):106–8
Oculomotor nerve palsy caused by lung cancer metastasis. Ishikawa H, et al. **Intern Med** 1997 Apr;36(4):301–3
Efficacy of HMAF (MGI–114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Kelner MJ, et al. **Invest New Drugs** 1996; 14(2):161–7
Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection. Runge VM, et al. **Invest Radiol** 1996 Aug;31(8):472–8
Metastasis in an electrodesiccation and curettage scar [published erratum appears in J Am Acad Dermatol 1997 May;36(5 Pt 1):704] Dunn PT, et al. **J Am Acad Dermatol** 1997 Jan;36(1):117–8
Generalized cutaneous metastases from breast adenocarcinoma. Gade JN, et al. **J Am Acad Dermatol** 1997 Jul;37(1):129–30
Adenocarcinoma of the lung with metastasis to the skull presenting as cystic lesions. Gray LC, et al. **J Am Acad Dermatol** 1997 Apr;36(4):644–6
Choroidal metastases resulting from carcinoma of the lung. Abundo RE, et al. **J Am Optom Assoc** 1997 Feb; 68(2):95–108
Anterior hip pain in the adult: an algorithmic approach to diagnosis. Mansour ES, et al. **J Am Osteopath Assoc** 1997 Jan;97(1):32–8 (29 ref.)
Periprosthetic metastatic carcinoma. Pitfalls in the management of two cases initially diagnosed as osteolysis. Schmidt AH, et al. **J Arthroplasty** 1996 Aug;11(5):613–9
Treatment of metastatic adenocarcinoma of the pelvis and the extremities. Aaron AD. **J Bone Joint Surg Am** 1997 Jun;79(6):917–32 (130 ref.)
Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour. Van de Vrie W, et al. **J Cancer Res Clin Oncol** 1997;123(1):21–4
Resected sigmoid carcinoma with 13-year metastasis-free interval. Sternal recurrence detected by immunoscintigraphy. Vasireddi SS, et al. **J Clin Gastroenterol** 1996 Sep;23(2):128–30
Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. Pazdur R, et al. **J Clin Oncol** 1997 Aug; 15(8):2905–9
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. Pitot HC, et al. **J Clin Oncol** 1997 Aug;15(8):2910–9
Skeletal muscle metastasis from lung carcinoma: MR findings. Suto Y, et al. **J Comput Assist Tomogr** 1997 Mar–Apr; 21(2):304–5
An unusual case of adrenal failure due to isolated metastases of breast cancer. Davì MV, et al. **J Endocrinol Invest** 1996 Jul–Aug;19(7):488–9
Adenocarcinoma of the lung with metatarsal metastasis. Kemnitz MJ, et al. **J Foot Ankle Surg** 1996 May–Jun; 35(3):210–2
Double cancer of the stomach, one AFP-producing tumor. Hyodo T, et al. **J Gastroenterol** 1996 Dec;31(6):851–4
Esophageal metastasis from prostate cancer: diagnostic use of reverse transcriptase-polymerase chain reaction for prostate-specific antigen. Nakamura T, et al. **J Gastroenterol** 1997 Apr;32(2):236–40
Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. MacLean GD, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jan; 19(1):59–68
Secondary penile carcinoma originated from pancreas. Ahn TY, et al. **J Korean Med Sci** 1997 Feb;12(1):67–9
Metastatic involvement of the Meckel's cave and trigeminal nerve. A case report. Mastronardi L, et al. **J Neurooncol** 1997 Mar;32(1):87–90
Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. Chung JK, et al. **J Nucl Med** 1997 Aug;38(8):1191–5
Staging recurrent metastatic colorectal carcinoma with PET. Delbeke D, et al. **J Nucl Med** 1997 Aug;38(8):1196–201
Significant morbidity associated with bone metastases in a patient with breast cancer. Oneschuk D, et al. **J Palliat Care** 1996 Winter;12(4):51–4
Metastasis from carcinoma of breast masquerading as chilblains. Tan BB, et al. **J R Soc Med** 1997 Mar;90(3):162
A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. Hirahatake K, et al. **J Surg Oncol** 1997 Jun;65(2):82–7
Development of a reliable colorectal cancer liver metastasis model. Brand MI, et al. **J Surg Res** 1996 Jul 1;63(2):425–32
Perfusion to colorectal cancer liver metastases is not uniform and depends on tumor location and feeding vessel. Casillas S, et al. **J Surg Res** 1997 Feb 1;67(2):179–85
Metastatic adenocarcinoma of the prostate to the orbit as a presenting symptom. Gonzalez CM, et al. **J Urol** 1997 Feb;157(2):625 (4 ref.)
The use of metallic stents to bypass ureteral strictures secondary to metastatic prostate cancer: experience with 8 patients. López-Martínez RA, et al. **J Urol** 1997 Jul; 158(1):50–3
Correlation between bone metabolic markers and bone scan in prostatic cancer. Maeda H, et al. **J Urol** 1997 Feb; 157(2):539–43
Adenocarcinoma of the ampulla of Vater and head of the pancreas metastatic to the ureter: report of 2 cases. Stenner J, et al. **J Urol** 1996 Nov;156(5):1765
Carcinoma of prostate presenting as visceral (pulmonary) metastases. Qureshi AM. **JPMA J Pak Med Assoc** 1995 Aug;45(8):218–9
A case of liver metastasis from colon cancer masquerading as focal sparing in a fatty liver. Kato M, et al. **Jpn J Clin Oncol** 1997 Jun;27(3):189–92
Meningeal carcinomatosis in patient with esophagus adenocarcinoma. Girola SS, et al. **Minerva Med** 1997 Mar; 88(3):105–7
Metastatic tumor of the spermatic cord from a primary silent colorectal adenocarcinoma. Melone F, et al. **Minerva Urol Nefrol** 1997 Mar;49(1):57–61
Metastasis induced by overexpression of p185neu-T after orthotopic injection into a prostatic epithelial cell line (NbE). Marengo SR, et al. **Mol Carcinog** 1997 Jul; 19(3):165–75
Intrapericardial administration of cisplatin in treatment of metastatic pericardial involvement in adenocarcinoma of the lung. Tomkowski WZ, et al. **Monaldi Arch Chest Dis** 1997 Jun;52(3):221–4
Images in clinical medicine. Sister Joseph's node in carcinoma of the cecum. Moll S. **N Engl J Med** 1996 Nov 21; 335(21):1568
Incidence and kinetics of distant metastases in patients with operable breast cancer. Kryj M, et al. **Neoplasma** 1997; 44(1):3–11
Solitary metastasis of lung cancer to the cerebellopontine angle--case report. Minami M, et al. **Neurol Med Chir (Tokyo)** 1996 Mar;36(3):172–4
MRI in carcinomatous encephalitis. Shirai H, et al. **Neuroradiology** 1997 Jun;39(6):437–40
Dorsal approach to presacral biopsy: technical case report. Rapport RL 2nd, et al. **Neurosurgery** 1997 May; 40(5):1087–8
Two cases of recurrent pulmonary metastasis resected after operation for gastric cancer. Urabe M, et al. **Nippon Geka Hokan** 1996 Jan 1;65(1):22–9
Ovarian and uterine disease in women with colorectal cancer. Abu-Rustum N, et al. **Obstet Gynecol** 1997 Jan;89(1):85–7
Intraperitoneal spread of cervical carcinoma after laparoscopic lymphadenectomy. Cohn DE, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):864
Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis. Kaufmann AM, et al. **Oncogene** 1996 Dec 5;13(11):2349–58
Non-primary cervical adenocarcinomas. Mulvany NJ, et al. **Pathology** 1996 Nov;28(4):293–7
Metastatic adenocarcinoma in a thyroid colloid nodule: a rare presentation of colon cancer. Osin P, et al. **Pathology** 1996 Aug;28(3):236–7
Malignancy metastatic to the products of conception: a case report with literature review. Ackerman J, et al. **Pediatr Pathol Lab Med** 1997 Jul–Aug;17(4):577–86 (71 ref.)
Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment. Losa M, et al. **Prostate** 1997 Sep 1; 32(4):241–5
Endobronchial metastasis from rectal adenocarcinoma. Lee YC, et al. **Respir Med** 1997 Apr;91(4):245–8
A case of secondary pulmonary hypertension due to microscopic pulmonary tumor cell embolism from gallbladder carcinoma. de Luis DA, et al. **Respiration** 1997; 64(3):244–6
Leptomeningeal metastasis with urological presentation. Chua JJ, et al. **Singapore Med J** 1997 Jun;38(6):266–7
Adenocarcinoma of the lung metastatic to the psoas muscle. Nash S, et al. **Skeletal Radiol** 1996 Aug;25(6):585–7
Prostate cancer metastatic only to the penis. Celebi MM, et al. **South Med J** 1997 Sep;90(9):959–61
Isolated splenic metastases from colon cancer. Indudhara R, et al. **South Med J** 1997 Jun;90(6):633–6 (24 ref.)
Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer [letter] Krongrad A, et al. **South Med J** 1997 Apr;90(4):460–1
Port-site metastases of adenocarcinoma of the fallopian tube after laparoscopically assisted vaginal hysterectomy and salpingo-oophorectomy. Bacha EA, et al. **Surg Endosc** 1996 Nov;10(11):1102–3
The incidence of port-site metastases might be reduced. Reymond MA, et al. **Surg Endosc** 1997 Sep;11(9):902–6
Utility of mapping lymph nodes cleared from rectal adenocarcinoma specimens. Sanchez-Maldonado W, et al. **Surg Oncol** 1996 Jun;5(3):123–6
Disease-free survival for 6 years and 4 months after dissection of recurrent abdominal paraaortic nodes (no. 16) in gastric cancer: report of a case. Nashimoto A, et al. **Surg Today** 1997;27(2):169–73
Portsite and intraabdominal metastases of unsuspected gallbladder carcinoma after laparoscopic cholecystectomy: report of a case. Shibata N, et al. **Surg Today** 1996; 26(12):1014–6
Resection of liver metastasis from alpha-fetoprotein-producing early gastric cancer: report of a case. Tsurumachi T, et al. **Surg Today** 1997;27(6):563–6 (11 ref.)
Intracranial metastatic adenocarcinoma of the prostate presenting as visual disturbance. Preston DM, et al. **Tech Urol** 1997 Spring;3(1):51–3
Temporomandibular joint metastasis from rectal carcinoma: CT findings before and after radiotherapy. A case report. Balestreri L, et al. **Tumori** 1997 May–Jun;83(3):718–20 (6 ref.)
Brain metastases from cervical carcinoma. Cormio G, et al. **Tumori** 1996 Jul–Aug;82(4):394–6
Characterization of a liver metastatic variant of murine colon 26 carcinoma cells. Ohnishi Y, et al. **Tumour Biol** 1997; 18(2):113–22
Ureteroscopic diagnosis of intraluminal metastatic rectal carcinoma. Fazeli-Matin S, et al. **Urology** 1997 Jun; 49(6):955–6
Intracranial metastases as the first manifestation of prostate cancer. Sutton MA, et al. **Urology** 1996 Nov;48(5):789–93 (28 ref.)
[Thoraco-cranial operation for treatment of lung cancer with brain metastasis] Chen J, et al. **Chung Hua Chung Liu Tsa Chih** 1996 Jan;18(1):67–9 (Eng. Abstr.) **(Chi)**
[Ovarian metastasis in uterine cervical cancer: analysis of 17 cases] Ma S, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 May;31(5):305–7 (Eng. Abstr.) **(Chi)**
[Recurrence of early gastric cancer] Shan J, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Oct;76(10):750–2 (Eng. Abstr.) **(Chi)**
[Limited liver resection for liver metastases in colorectal carcinoma] Visokai V, et al. **Rozhl Chir** 1996 Mar; 75(3):139–42 (Eng. Abstr.) **(Cze)**
[Penile metastasis of recto-sigmoid adenocarcinoma. Apropos of a case] Lange G, et al. **Ann Chir** 1997; 51(3):294–6 (Eng. Abstr.) **(Fre)**
[Metastasis of an adenocarcinoma of the colon to the 1st metacarpal bone] Méndez López JM, et al. **Ann Chir Main Memb Super** 1997;16(2):134–7 (8 ref.) (Eng. Abstr.) **(Fre)**
[Metastatic sites of colonic adenocarcinoma in the ORL system: 2 cases (letter)] Petit T, et al. **Ann Med Interne (Paris)** 1996;147(5):377–8 **(Fre)**
[An umbilical nodule to be considered religiously] Gigon M, et al. **Ann Pathol** 1997 Mar;17(1):59–60 **(Fre)**
[Orbital metastasis of prostatic cancer. Clinical and therapeutic aspects. Apropos of a case (clinical case)] Aubert J, et al. **Chirurgie** 1997 Jan;121(9–10):672–5 (Eng. Abstr.) **(Fre)**
[Colonic cancer disclosed by solitary cerebral metastasis (letter)] Alamowitch B, et al. **Gastroenterol Clin Biol** 1996; 20(8–9):703–4 **(Fre)**

[Ischemic colitis disclosing neoplastic microangiopathy (letter)] Baty V, et al. **Gastroenterol Clin Biol** 1996; 20(11):1028–9 **(Fre)**

[Metastasis to the 3rd ventricle of colonic adenocarcinoma (letter)] Brandicourt P, et al. **Presse Med** 1997 Feb 1; 26(2):75 **(Fre)**

[Gastric perforation caused by metastasis of breast cancer in a man (letter; comment)] Fra J, et al. **Presse Med** 1996 Sep 14;25(26):1215. Comment on: Presse Med 1994 Dec 3;23(38):1758–9. **(Fre)**

[Orbital metastasis of a prostatic cancer. A therapeutic emergency] Aubert J, et al. **Prog Urol** 1997 Feb;7(1):81–4 (Eng. Abstr.) **(Fre)**

[Kidney cancer and pancreatic metastases. Report of 3 cases] Masson J, et al. **Prog Urol** 1996 Jun;6(3):443–6 (17 ref.) (Eng. Abstr.) **(Fre)**

[Muscular metastases disclosing adenocarcinoma] Perrin AE, et al. **Rev Med Interne** 1997;18(4):328–31 (Eng. Abstr.) **(Fre)**

[Metastasis of adenocarcinoma of the ovary to the subglottis. A laryngologic rarity] Oeken J, et al. **HNO** 1996 Jan; 44(1):27–31 (Eng. Abstr.) **(Ger)**

[Carcinoma-in-carcinoma metastasis. In situ DNA quantification and immunohistochemical diagnosis] Sperb RA, et al. **Pathologe** 1996 Sep;17(5):385–90 (39 ref.) (Eng. Abstr.) **(Ger)**

[Krukenberg tumor: a clinical case report] Fölsing C, et al. **Rontgenpraxis** 1997 Feb;50(2):31–3 **(Ger)**

[Coincidence of bone infarct and aggressive bone metastasis] Hüfner T, et al. **Unfallchirurg** 1997 Jan;100(1):69–72 (Eng. Abstr.) **(Ger)**

[Isolated ovarian metastasis of primary gallbladder carcinoma with estrogen and androgen production] Hamm W, et al. **Zentralbl Gynakol** 1996;118(12):676–8 (Eng. Abstr.) **(Ger)**

[Metastasis in metastasis] Gajdos C, et al. **Orv Hetil** 1997 Jul 27;138(30):1911–2 (Eng. Abstr.) **(Hun)**

[A case of male breast metastasis from adenocarcinoma of the colon] Bruscagnin A. **Radiol Med (Torino)** 1997 Apr; 93(4):463–4 **(Ita)**

[A case of Borrmann type 4 gastric cancer successfully treated with MTX and 5-FU therapy through the hepatic artery] Gonda T, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1561–3 (Eng. Abstr.) **(Jpn)**

[PyNPase activity in primary and metastatic colorectal cancer] Kameyama M, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):563–7 (Eng. Abstr.) **(Jpn)**

[A two-year asymptomatic case with postoperative lung metastasis of sigmoid colon cancer responding to sequential methotrexate and 5-fluorouracil] Kitao Y, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):613–7 (Eng. Abstr.) **(Jpn)**

[A case of solitary metastatic splenic tumor of ovarian carcinoma] Kobayashi A, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1341–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Liver resection in a case of multiple liver metastases of gastric cancer following hepatic arterial infusion chemotherapy] Kobayashi T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1321–4 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for peritoneal dissemination in gastric cancer under ureteral catheterization] Kubo Y, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1951–7 (Eng. Abstr.) **(Jpn)**

[Successful UFT-E granule and 5-FUCDDP combination therapy for an unresectable advanced gastric cancer complicated with liver metastasis] Kushibiki K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1313–5 (Eng. Abstr.) **(Jpn)**

[Secondary hepatic resections in a case of sigmoid colon cancer with multiple liver metastasis (H3) after successful continuous hepatic artery infusion chemotherapy oriented by in vitro chemosensitivity test] Miura M, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):1031–4 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer with multiple liver metastasis successfully treated with combination chemotherapy using UFT, CDDP and etoposide] Ono T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1709–12 (Eng. Abstr.) **(Jpn)**

[Relation between the stromal volume and liver metastasis in gastric cancer] Teshima S, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):737–9 **(Jpn)**

[Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment] Yamada Y, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1335–40 (Eng. Abstr.) **(Jpn)**

[Metastatic tumor to the penis from lung and pancreas cancer: report of two cases] Danno S, et al. **Hinyokika Kiyo** 1997 Jan;43(1):61–3 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Metastatic tumor of spermatic cord and tunica vaginalis testis from gastric cancer: a case report] Kageyama Y, et al. **Hinyokika Kiyo** 1997 Jun;43(6):429–31 (Eng. Abstr.) **(Jpn)**

[A case of lung adenocarcinoma: detection and resection of the metastatic lesion was managed effectively by serum CEA level] Hiyoshi H, et al. **Kyobu Geka** 1996 Sep; 49(10):873–5 (Eng. Abstr.) **(Jpn)**

[Pulmonary metastasis from breast cancer: a case report with 19-year disease-free interval] Kamiyoshihara M, et al. **Kyobu Geka** 1997 Mar;50(3):194–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A case of solitary splenic metastasis from colon cancer] Sawai T, et al. **Nippon Geka Gakkai Zasshi** 1996 Dec; 97(12):1109–11 (Eng. Abstr.) **(Jpn)**

[Tumor disseminate in site following laparoscopic cholecystectomy] Shibata N, et al. **Nippon Geka Gakkai Zasshi** 1997 Apr;98(4):462–5 (25 ref.) **(Jpn)**

[Enhancement pattern of hepatic metastases from colorectal cancer on CT arteriography] Inaba Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Jul;57(8):483–6 (Eng. Abstr.) **(Jpn)**

[A case of fallopian tube carcinoma with diffuse metastatic leptomeningeal carcinomatosis] Kanamori T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Apr; 48(4):299–302 **(Jpn)**

[A case of cecum cancer metastasizing to the spleen after right hemicolectomy] Fuku A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):33–7 (8 ref.) **(Jpn)**

[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer] Nakagawa H, et al. **No Shinkei Geka** 1997 Mar; 25(3):215–23 (39 ref.) (Eng. Abstr.) **(Jpn)**

[A 36-year-old woman with acute onset left hemiplegia and anosognosia (clinical conference)] Goto K, et al. **No To Shinkei** 1997 Mar;49(3):291–300 (Eng. Abstr.) **(Jpn)**

[Stereotactic radiosurgery for the treatment of brain metastases] Hiyama H, et al. **No To Shinkei** 1996 Feb; 48(2):113–9 **(Jpn)**

[Bladder tumor, metastasis from breast carcinoma. A case report with literature review] Lund JA, et al. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1082–3 (13 ref.) (Eng. Abstr.) **(Nor)**

[Breast adenocarcinoma metastatic to the pituitary gland: report of a case] Zambelli HJ, et al. **Arq Neuropsiquiatr** 1996 Mar;54(1):124–6 (Eng. Abstr.) **(Por)**

[Complete remission of endobronchial, parenchymal and hilar lymphatic lung metastases of prostatic carcinoma after anti-androgenic hormotherapy] Morrone N, et al. **Rev Assoc Med Bras** 1996 Jan-Mar;42(1):57–60 (Eng. Abstr.) **(Por)**

[Endobronchial metastases from primary breast cancer] Pereira JR, et al. **Rev Assoc Med Bras** 1996 Apr-Jun; 42(2):119–22 (Eng. Abstr.) **(Por)**

[Subcutaneous metastasis as the first manifestation of kidney cancer dissemination] Martínez Sarmiento M, et al. **Actas Urol Esp** 1997 Apr;21(4):402–5 (21 ref.) (Eng. Abstr.) **(Spa)**

[Fulminant hepatic insufficiency secondary to a metastatic pulmonary adenocarcinoma (letter)] Haro M, et al. **Arch Bronconeumol** 1996 Dec;32(10):552–3 **(Spa)**

[Correlation between specific prostatic antigen and findings with total body bone scintigraphy] López M, et al. **Arch Esp Urol** 1996 Nov;49(9):953–5 (Eng. Abstr.) **(Spa)**

[Gas gangrene due to Clostridium septicum in a patient with an occult colonic neoplasm. A case report and review of the literature] Sáez Castillo AI, et al. **Gastroenterol Hepatol** 1997 Feb;20(2):55–8 (13 ref.) (Eng. Abstr.) **(Spa)**

[Palinopsia: first manifestation of a brain metastasis] Martin Estefanía C, et al. **Neurologia** 1996 Nov;11(9):357–8 **(Spa)**

[Vaginal metastasis of adenocarcinoma of the left colon (letter)] Sánchez López JD, et al. **Rev Esp Enferm Dig** 1997 Apr;89(4):335–6 **(Spa)**

SECRETION

Rhomboid secretion granules in a juxtaglomerular cell tumour of the kidney. Hasegawa A, et al. **Br J Urol** 1997 Feb;79(2):296–7

A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Zhang K, et al. **Cell Immunol** 1997 Mar 15;176(2):158–65

Assessment of PCB estrogenicity in a human breast cancer cell line. Gierthy JF, et al. **Chemosphere** 1997 Mar-Apr; 34(5-7):1495–505

Mucins secreted by cell lines derived from colorectal mucinous carcinoma and adenocarcinoma. Cho M, et al. **Eur J Cancer** 1997 May;33(6):931–41

Differential transforming growth factor-beta secretion in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Santin AD, et al. **Gynecol Oncol** 1997 Mar; 64(3):477–80

Dissociated secretion of islet amyloid polypeptide and insulin in serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines. Wang F, et al. **Int J Pancreatol** 1997 Apr;21(2):157–64

Comments on different states of secretory autonomy of juxtaglomerular cell tumors of the kidney [editorial] Kihara I. **Intern Med** 1996 Apr;35(4):239–40 (13 ref.)

SURGERY

Functional results after total gastrectomy with enteric pouch reconstruction. A review of 34 cases. Michielsen D, et al. **Acta Chir Belg** 1996 Jul-Aug;96(4):155–7

One case of Stewart-Treves syndrome successfully treated at two years by chemotherapy and radiation therapy in a 73-year-old woman. Malhaire JP, et al. **Acta Oncol** 1997; 36(4):442–3

Intermediate-risk endometrial cancer. A management approach. Corn BW. **Am J Clin Oncol** 1996 Dec; 19(6):631–5 (17 ref.)

Minimum number of lymph nodes to be recovered from colorectal resection specimens [letter; comment] Bush ST. **Am J Clin Pathol** 1997 Apr;107(4):494; discussion 494–5. Comment on: Am J Clin Pathol 1996 Aug;106(2):209–16.

Minimum number of lymph nodes to be recovered from colorectal resection specimens [letter; comment] Frankel K. **Am J Clin Pathol** 1997 Apr;107(4):494; discussion 494–5 . Comment on: Am J Clin Pathol 1996 Aug;106(2):209–16.

Subtotal colectomy in a patient with collagenous colitis associated with colonic carcinoma and systemic lupus erythematosus. Alikhan M, et al. **Am J Gastroenterol** 1997 Jul;92(7):1213–5

Esophageal reflux after total or proximal gastrectomy in patients with adenocarcinoma of the gastric cardia. Hsu CP, et al. **Am J Gastroenterol** 1997 Aug;92(8):1347–50

Three histologically different tiny gastric cancers developing adjacent to each other, resected endoscopically in a single mucosal piece. Matsuhashi N, et al. **Am J Gastroenterol** 1996 Oct;91(10):2200–2

Superior mediastinal dissection in the treatment of Hürthle cell carcinoma of the thyroid. Maillard AA, et al. **Am J Otolaryngol** 1997 Jan-Feb;18(1):47–50

Radical esophageal resection for adenocarcinoma arising in Barrett's esophagus. Collard JM, et al. **Am J Surg** 1997 Sep;174(3):307–11

Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Delcore R, et al. **Am J Surg** 1996 Nov;172(5):463–8; discussion 468–9

Colorectal carcinoma and the relationship of peritoneal cytology. Horattas MC, et al. **Am J Surg** 1997 Sep; 174(3):334–7; discussion 337–8

Sphincter-saving resection, or not, for cancer of the midrectum. Huguier M, et al. **Am J Surg** 1997 Jul; 174(1):11–5

Inadvertent perforation of the rectum during abdominoperineal resection [see comments] Porter GA, et al. **Am J Surg** 1996 Oct;172(4):324–7. Comment in: Am J Surg 1997 May;173(5):458.

Transhiatal versus transthoracic esophagectomy for adenocarcinoma of the distal esophagus and cardia. Stark SP, et al. **Am J Surg** 1996 Nov;172(5):478–81; discussion 481–2

A study of forty-nine consecutive Whipple resections for periampullary adenocarcinoma. Sung JP, et al. **Am J Surg** 1997 Jul;174(1):6–10

Multimodality staging optimizes resectability in patients with pancreatic and ampullary cancer. Awad SS, et al. **Am Surg** 1997 Jul;63(7):634–8

Reconstruction of pelvic exenterative wounds with transpelvic rectus abdominis flaps: a case series. Jain AK, et al. **Ann Plast Surg** 1997 Feb;38(2):115–22; discussion 122–3

Parotid cribriform salivary carcinoma of the excretory ducts. Winkler PA. **Ann Plast Surg** 1996 Aug;37(2):214–6

The management of tumors of the ampulla of Vater by local resection. Branum GD, et al. **Ann Surg** 1996 Nov; 224(5):621–7

Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer. Farrell TJ, et al. **Ann Surg** 1997 Jul;226(1):66–9

Proximal gastric cancers resected via a transabdominal-only approach. Results and comparisons to distal adenocarcinoma of the stomach. Harrison LE, et al. **Ann Surg** 1997 Jun;225(6):678–83; discussion 683–5

Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Harrison LE, et al. **Ann Surg** 1996 Sep;224(3):342–7; discussion 347–9

Adenocarcinoma of the ampulla of Vater. A 28-year experience. Talamini MA, et al. **Ann Surg** 1997 May; 225(5):590–9; discussion 599–600

Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Yeo CJ, et al. **Ann Surg** 1997 May;225(5):621–33; discussion 633–6

Routine compared with nonscheduled follow-up of patients with "curative" surgery for colorectal cancer. Bergamaschi R, et al. **Ann Surg Oncol** 1996 Sep;3(5):464–9

Patterns of recurrence following pelvic exenteration and external radiotherapy for locally advanced primary rectal adenocarcinoma. Luna-Perez P, et al. **Ann Surg Oncol** 1996 Nov;3(6):526–33

Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Nakajima T, et al. **Ann Surg Oncol** 1997 Apr-May;4(3):203–8

Extended resection for locally advanced colorectal carcinoma. Rowe VL, et al. **Ann Surg Oncol** 1997 Mar; 4(2):131–6

Esophagectomy for cancer in the patient aged 70 years and older [see comments] Jougon JB, et al. **Ann Thorac Surg** 1997 May;63(5):1423–7. Comment in: Ann Thorac Surg 1997 May;63(5):1225–6.

Improved results in the management of surgical candidates with lung cancer. Knott-Craig CJ, et al. **Ann Thorac Surg** 1997 May;63(5):1405–9; discussion 1409–10

One hundred video-assisted thoracic surgical simultaneously

stapled lobectomies without rib spreading. Lewis RJ, et al. **Ann Thorac Surg** 1997 May;63(5):1415–21; discussion 1421–2

Esophageal resection for cancer of the esophagus: long–term function and quality of life. McLarty AJ, et al. **Ann Thorac Surg** 1997 Jun;63(6):1568–72

Single–stage management of abdominal aortic aneurysm and colon carcinoma. Gouny P, et al. **Ann Vasc Surg** 1996 May; 10(3):299–305

Influence of acute cholecystitis on surgical strategy and outcome of inapparent carcinoma of the gallbladder: a report on two cases. Mingoli A, et al. **Anticancer Res** 1997 Mar–Apr;17(2B):1235–7

Modified clearing technique to identify lymph node metastases in post–irradiated surgical specimens from rectal adenocarcinoma. Sanchez W, et al. **Arch Med Res** 1996 Spring;27(1):31–6

Node–positive duodenal carcinoma is curable. Pickleman J, et al. **Arch Surg** 1997 Mar;132(3):241–4

Cryosurgery of breast cancer. Staren ED, et al. **Arch Surg** 1997 Jan;132(1):28–33; discussion 34

Simple technique for pancreatogastrostomy and the histological findings of pancreatogastric anastomosis. Yamamoto J, et al. **Arch Surg** 1997 Jul;132(7):785–8 (08 ref.)

Colonic J–pouch as a neorectum: functional assessment. Chew SB, et al. **Aust N Z J Surg** 1997 Sep;67(9):607–10

Lymphoscintigraphy pre– and post–surgical lymphatic leak repair. Andrews JT, et al. **Australas Radiol** 1996 Feb; 40(1):19–21

Is loop excision adequate primary management of adenocarcinoma in situ of the cervix? Houghton SJ, et al. **Br J Obstet Gynaecol** 1997 Mar;104(3):325–9

Outcome of treatment for distal bile duct cancer. Fong Y, et al. **Br J Surg** 1996 Dec;83(12):1712–5

Radical lymphadenectomy in the management of early gastric cancer. Hayes N, et al. **Br J Surg** 1996 Oct;83(10):1421–3

Influence of hospital– and surgeon–related factors on outcome after treatment of rectal cancer with or without preoperative radiotherapy. Holm T, et al. **Br J Surg** 1997 May;84(5):657–63

Selective approach to the treatment of oesophageal cancer. Junginger T, et al. **Br J Surg** 1996 Oct;83(10):1473–7

Surgical treatment for carcinoma of the oesophagus in Chinese language publications. Li H, et al. **Br J Surg** 1997 Jun;84(6):855–7

Prospective randomized study of laparoscopic versus open colonic resection for adenocarcinoma [letter] McCall JL, et al. **Br J Surg** 1997 Aug;84(8):1174; discussion 1174–5

Wound metastases following laparoscopic and open surgery for abdominal cancer in a rat model. Mathew G, et al. **Br J Surg** 1996 Aug;83(8):1087–90

Prospective randomized study of laparoscopic versus open colonic resection for adenocarcinoma [letter] Papagrigoriadis S. **Br J Surg** 1997 Aug;84(8):1173–4; discussion 1174–5

Pathological evidence in support of total mesorectal excision in the management of rectal cancer. Reynolds JV, et al. **Br J Surg** 1996 Aug;83(8):1112–5

First clinical experience with fundus rotation gastroplasty as a substitute for the oesophagus. Schilling M, et al. **Br J Surg** 1997 Jan;84(1):126–8

Prospective randomized study of laparoscopic versus open colonic resection for adenocarcinoma. Stage JG, et al. **Br J Surg** 1997 Mar;84(3):391–6

Changing patterns and surgical results in adenocarcinoma of the oesophagus. Thomas P, et al. **Br J Surg** 1997 Jan; 84(1):119–25

Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. Schmeller N, et al. **Br J Urol** 1997 Feb; 79(2):226–34

Swedish randomized trial of radical prostatectomy versus watchful waiting. Norlén BJ. **Can J Oncol** 1994 Nov;4 Suppl 1:38–40; discussion 41–2

Duodenal seromyectomy in the management of adherent colonic carcinoma in elderly patients. Sharma P, et al. **Can J Surg** 1997 Aug;40(4):289–93

Modified type IV–V radical hysterectomy with systematic pelvic and aortic lymphadenectomy in the treatment of patients with stage III cervical carcinoma. Feasibility, technique, and clinical results. Benedetti–Panici P, et al. **Cancer** 1996 Dec 1;78(11):2359–65

Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Crookes P, et al. **Cancer** 1997 May 1;79(9):1767–75

Breast–conserving therapy for stage I–II synchronous bilateral breast carcinoma. Gollamudi SV, et al. **Cancer** 1997 Apr 1;79(7):1362–9

Cryosurgical ablation of the prostate: treatment alternative for localized prostate cancer. Cohen JK, et al. **Cancer Treat Res** 1996;88:167–86

Beyond the nerve–sparing radical prostatectomy. Smith RC, et al. **Cancer Treat Res** 1996;88:129–45 (145 ref.)

The suitable treatment for adenocarcinoma in situ of uterine cervix: a report of four cases. Liu YC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Oct;58(4):294–8

Resection for cure of adenocarcinoma of the head of the pancreas: the greater Hartford experience. Ross HM, et al. **Conn Med** 1997 Jan;61(1):3–7

Prognostic indicators for survival after curative resection for patients with carcinoma of the stomach. Wu CW, et al. **Dig Dis Sci** 1997 Jun;42(6):1265–9

Distal intramural spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis. Andreola S, et al. **Dis Colon Rectum** 1997 Jan;40(1):25–9

Prospective evaluation of local excision for small rectal cancers. Bleday R, et al. **Dis Colon Rectum** 1997 Apr; 40(4):388–92

Early results of laparoscopic surgery for colorectal cancer. Retrospective analysis of 372 patients treated by Clinical Outcomes of Surgical Therapy (COST) Study Group. Fleshman JW, et al. **Dis Colon Rectum** 1996 Oct;39(10 Suppl):S53–8

Total anorectal reconstruction with a double dynamic graciloplasty after abdominoperineal reconstruction for low rectal cancer. Geerdes BP, et al. **Dis Colon Rectum** 1997 Jun;40(6):698–705

Preliminary results of preoperative 5–fluorouracil, low–dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Grann A, et al. **Dis Colon Rectum** 1997 May;40(5):515–22

Role of peptide YY and enteroglucagon after low anterior resection. Comparison between straight and colonic J–pouch anastomosis. Hallböök O, et al. **Dis Colon Rectum** 1996 Oct;39(10):1153–8

Causes of rectal incontinence after sphincter–preserving operations for rectal cancer. Otto IC, et al. **Dis Colon Rectum** 1996 Dec;39(12):1423–7

Variations in treatment of rectal cancer: the influence of hospital type and caseload. Simons AJ, et al. **Dis Colon Rectum** 1997 Jun;40(6):641–6

Extent of resection and lymphadenectomy in early Barrett's cancer. Korst RJ, et al. **Dis Esophagus** 1997 Jul;10(3):172–8 (42 ref.)

Endoscopic mucosectomy using an esophageal variceal ligation device for minute gastric cancer. Lee DK, et al. **Endoscopy** 1996 May;28(4):386–9

Endosonographic follow–up after local excision of a pT1 rectal carcinoma. Maunoury V. **Endoscopy** 1996 Jun; 28(5):468

Endoscopic snare mucosectomy in the esophagus without any additional equipment: a simple technique for resection of flat early cancer. Soehendra N, et al. **Endoscopy** 1997 Jun;29(5):380–3

Surgical therapy of esophageal carcinoma: the influence of surgical approach and esophageal resection on cardiopulmonary function. Jacobi CA, et al. **Eur J Cardiothorac Surg** 1997 Jan;11(1):32–7

Extensive resection with selective cerebral perfusion for a lung cancer invading the aortic arch. Okubo K, et al. **Eur J Cardiothorac Surg** 1996;10(5):389–91

Resectional surgery in carcinoma of the oesophagus and cardia: what influences long–term survival? Sharpe DA, et al. **Eur J Cardiothorac Surg** 1996;10(5):359–63; discussion 363–4

Complications of pelvic and para–aortic lymphadenectomy in patients with endometrial cancer. Arduino S, et al. **Eur J Gynaecol Oncol** 1997;18(3):208–10

Cis–platinum chemotherapy after surgical treatment for bilateral adenocarcinoid of the ovary. Case report. Azzena A, et al. **Eur J Gynaecol Oncol** 1997;18(2):130–2

Successful outcome of a 9 week pregnancy managed by bilateral salpingo–oophorectomy for ovarian cancer: case report. Colavita M, et al. **Eur J Gynaecol Oncol** 1996; 17(6):522–3 (7 ref.)

Rectal cancer: the influence of type of operation on local recurrence and survival. Bjerkeset T, et al. **Eur J Surg** 1996 Aug;162(8):643–8

Leakage of intrathoracic oesophagovisceral anastomoses in adenocarcinoma of the gastric cardia: changes in serial APACHE II scores and their prognostic significance. Fahn HJ, et al. **Eur J Surg** 1997 May;163(5):345–50

Management of the pelvic space with or without omentoplasty after abdominoperineal resection for carcinoma of the rectum: a prospective multicenter study. The French Association for Surgical Research. Hay JM, et al. **Eur J Surg** 1997 Mar;163(3):199–206

Adenocarcinoma of bladder. Dandekar NP, et al. **Eur J Surg Oncol** 1997 Apr;23(2):157–60

Extended lymph node dissection for gastric cancer: results of a prospective, multi–centre analysis of morbidity and mortality in 118 consecutive cases. Degiuli M, et al. **Eur J Surg Oncol** 1997 Aug;23(4):310–4

Recurrent melanoma of the leg and polypoid lesions of the gallbladder—a management dilemma. Gould SW, et al. **Eur J Surg Oncol** 1997 Aug;23(4):368–9

Long–term follow–up after open perineal cryotherapy in patients with locally confined prostate cancer. Mack D, et al. **Eur Urol** 1997;32(2):129–32

Surgical treatment of dysplasia and adenocarcinoma. DeMeester TR. **Gastroenterol Clin North Am** 1997 Sep; 26(3):669–84 (47 ref.)

Progress in treating esophageal adenocarcinoma. Shanahan F, et al. **Gastroenterology** 1997 Apr;112(4):1417–8

Endoscopic mucosal resection of gastric tumors located in the lesser curvature of the upper third of the stomach. Matsushita M, et al. **Gastrointest Endosc** 1997 Jun; 45(6):512–5

Band ligation–assisted endoscopic resection of a flat rectal adenoma containing infiltrating adenocarcinoma. Van Os EC, et al. **Gastrointest Endosc** 1997 Mar;45(3):322–4

Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases. Dorandeu A, et al. **Gut** 1997 Mar;40(3):350–5

Metastatic breast carcinoma to the abdomen and pelvis. Abu–Rustum NR, et al. **Gynecol Oncol** 1997 Jul;66(1):41–4

An atypical recurrence of endometrial carcinoma following estrogen replacement therapy. Carr JA, et al. **Gynecol Oncol** 1996 Mar;60(3):498–9

Pretreatment transperitoneal laparoscopic staging pelvic and paraaortic lymphadenectomy in large (> or = 5 cm) stage IB2 cervical carcinoma: report of a pilot study. Recio FO, et al. **Gynecol Oncol** 1996 Dec;63(3):333–6

Who is best benefited by radical prostatectomy? Nadler RB, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):581–93 (39 ref.)

Combined treatment with lasertherapy (Nd:YAG) and endocavitary radiation in the palliation of rectal cancer. Conio M, et al. **Hepatogastroenterology** 1996 Nov–Dec; 43(12):1518–22

Surgical outcome in early gastric cancer with lymph node metastasis. Hanazaki K, et al. **Hepatogastroenterology** 1997 May–Jun;44(15):907–11

Cancer of the exocrine pancreas. A plea for resection. Huguier M, et al. **Hepatogastroenterology** 1996 May–Jun; 43(9):721–9

Circular stapling techniques for low anterior resection of rectal carcinoma. Miller K, et al. **Hepatogastroenterology** 1996 Jul–Aug;43(10):823–31

Coincidence of pancreatic and biliary leakages after pancreaticoduodenal resections. Parviainen MC, et al. **Hepatogastroenterology** 1996 Sep–Oct;43(11):1246–9

Surgery for carcinoma of the gallbladder. Rückert JC, et al. **Hepatogastroenterology** 1996 May–Jun;43(9):527–33

DNA ploidy, proliferative index and EGF–R status in 130 cases of resected gastric cancer—a multivariate analysis. Santoro E, et al. **Hepatogastroenterology** 1997 May–Jun; 44(15):826–37

Primary adenocarcinoma of the duodenum: treatment and survival in 89 patients. Santoro E, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):1157–63

Intra–operative diagnosis of N2 lymph node metastasis of gastric cancer. Seto Y, et al. **Hepatogastroenterology** 1997 May–Jun;44(15):838–41

A case of gallbladder cancer with para–aortic lymph node metastasis who has survived more than seven years after the primary extended radical operation. Shinkai H, et al. **Hepatogastroenterology** 1996 Sep–Oct;43(11):1370–6

Improved results for resection of periampullary adenocarcinoma. Obertop H, et al. **HPB Surg** 1996; 10(2):125–8

A preliminary comparison of a consecutive series of open versus laparoscopic abdomino–perineal resection for rectal adenocarcinoma. Seow–Choen F, et al. **Int J Colorectal Dis** 1997;12(2):88–90

Tumor recurrence associated with use of a percutaneous bladder catheter after surgery for large bowel carcinoma. Strigård K. **Int J Colorectal Dis** 1996;11(3):122

Rectal cancer recurrence after prior resection and radiotherapy: palliation following additional surgery. Verrees JF, et al. **Int J Colorectal Dis** 1996;11(5):211–6

Complete resolution of psoriasis vulgaris after excision of thyroid cancer. Kano Y, et al. **Int J Dermatol** 1997 Apr; 36(4):280–2

Conservative surgery for ovarian cancer and effect on fertility. Gonzalez–Lira G, et al. **Int J Gynaecol Obstet** 1997 Feb;56(2):155–62

Transvaginal uterine morcellation with unsuspected adenocarcinoma of the endometrium. Pelosi MA 3rd, et al. **Int J Gynaecol Obstet** 1997 May;57(2):207–8

Excellent long–term survival and absence of vaginal recurrences in 332 patients with low–risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Eltabbakh GH, et al. **Int J Radiat Oncol Biol Phys** 1997 May 1;38(2):373–80

Comparison of miniature multileaf collimation (MMLC) with circular collimation for stereotactic treatment. Shiu AS, et al. **Int J Radiat Oncol Biol Phys** 1997 Feb 1;37(3):679–88

Hurthle cell tumor. Chen HY, et al. **Int Surg** 1996 Apr–Jun; 81(2):168–70

Surgical treatment of pancreatic adenocarcinoma: Taiwan experience. Jan YY, et al. **Int Surg** 1996 Jan–Mar;81(1):52–6

Transanal excision and postoperative radiation therapy in selected patients with cancer of the low rectum. Romano G, et al. **Int Surg** 1996 Jan–Mar;81(1):40–4

Pelvic recurrence following resection of rectal cancer: a multivariate predictive model. Romano G, et al. **Int Surg** 1997 Jan–Mar;82(1):67–71

Morbidity after D2 and D3 gastrectomy for node–positive gastric carcinoma. Adachi Y, et al. **J Am Coll Surg** 1997 Mar;184(3):240–4

Surgical management of carcinoma of the stomach in elderly patients [editorial; comment] Karl RC. **J Am Coll Surg** 1997 Jan;184(1):77–9. Comment on: J Am Coll Surg 1997 Jan;184(1):9–15.

Surgical treatment of Borrmann type IV gastric carcinoma: relevance of lymphadenectomy in improving survival [see comments] Kodera Y, et al. **J Am Coll Surg** 1996 Nov; 183(5):480–5. Comment in: J Am Coll Surg 1997 Aug;185(2):200–1.

Factors predicting hospitalization after operative treatment for gastric carcinoma in patients older than 70 years [see comments] Schwarz RE, et al. **J Am Coll Surg** 1997 Jan;

184(1):9–15. Comment in: J Am Coll Surg 1997 Jan;184(1):77–9.
Carcinoma of stomach complicating pregnancy. Lo SS, et al. **J Clin Gastroenterol** 1996 Dec;23(4):299–300
Superficial elevated-type early gallbladder carcinoma treated by laparoscopic cholecystectomy. Fujita N, et al. **J Gastroenterol** 1997 Aug;32(4):566–9
Endoscopic treatment of submucosal invasive colorectal carcinoma with special reference to risk factors for lymph node metastasis. Tanaka S, et al. **J Gastroenterol** 1995 Dec; 30(6):710–7
Intestinal-type tumour in resected gastric remnant cancer. Lo SS, et al. **J Gastroenterol Hepatol** 1997 Jun;12(6):434–6
Trocar site seeding of inapparent gallbladder carcinoma during laparoscopic cholecystectomy. Cotlar AM, et al. **J Laparoendosc Surg** 1996 Feb;6(1):35–45 (53 ref.)
Colorectal cancer surgery in a district general hospital. Wakefield SE, et al. **J R Coll Surg Edinb** 1996 Dec; 41(6):374–8
Intrathoracic anastomosis after oesophageal resection for cancer. Agrawal S, et al. **J Surg Oncol** 1996 Sep;63(1):52–6
Survival benefit of extended D2 resection for proximal gastric cancer. Volpe CM, et al. **J Surg Oncol** 1997 Mar; 64(3):231–6
Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987–1991. Wade TP, et al. **J Surg Oncol** 1997 Mar;64(3):242–5
Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. Ellis FH Jr, et al. **J Thorac Cardiovasc Surg** 1997 May;113(5):836–46; discussion 846–8
Color flow sonography in evaluating the resectability of periampullary and pancreatic tumors. Ralls PW, et al. **J Ultrasound Med** 1997 Feb;16(2):131–40
Tumors in bladder remnant after augmentation enterocystoplasty. Barrington JW, et al. **J Urol** 1997 Feb; 157(2):482–5; discussion 485–6
Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center. Chen ME, et al. **J Urol** 1997 Jun; 157(6):2120–3 (13 ref.)
Staging pelvic lymphadenectomy for localized carcinoma of the prostate: a comparison of 3 surgical techniques. Herrell SD, et al. **J Urol** 1997 Apr;157(4):1337–9
Laparoscopic pelvic lymph node dissection following definitive radiotherapy for carcinoma of the prostate. Lund GO, et al. **J Urol** 1997 Feb;157(2):548–51
Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate [see comments] Oefelein MG, et al. **J Urol** 1997 Oct;158(4):1460–5. Comment in: J Urol 1997 Oct;158(4):1476.
Enteric type adenocarcinoma of the upper tract urothelium associated with ectopic ureter and renal dysplasia: an oncological rationale for complete extirpation of this aberrant developmental anomaly. Rao DS, et al. **J Urol** 1996 Oct;156(4):1272–4
Hematolymphoid malignancies diagnosed at the time of radical prostatectomy. Terris MK, et al. **J Urol** 1997 Oct; 158(4):1457–9
One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. Wang X, et al. **J Urol** 1997 Oct;158(4):1431–5
Preoperative evaluation of the curative resectability of gastric cancer by abdominal computed tomography and ultrasonography: a prospective comparison study. Kim JJ, et al. **Korean J Intern Med** 1997 Jan;12(1):1–6
Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Medical Research Council Rectal Cancer Working Party [see comments] **Lancet** 1996 Dec 14;348(9042):1610–4. Comment in: Lancet 1996 Dec 14;348(9042):1600. Comment in: Lancet 1997 Mar 22;349(9055):877; discussion 877–8.
Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Medical Research Council Rectal Cancer Working Party [see comments] **Lancet** 1996 Dec 14;348(9042):1605–10. Comment in: Lancet 1996 Dec 14;348(9042):1600. Comment in: Lancet 1997 Mar 22;349(9055):877; discussion 877–8.
Long-term survival of surgical cases of lung cancer. Wada H, et al. **Lung Cancer** 1995 Dec;13(3):269–74
Growth hormone modulates amino acid oxidation in the surgical patient: leucine kinetics during the fasted and fed state using moderate nitrogenous and caloric diet and recombinant human growth hormone. Carli F, et al. **Metabolism** 1997 Jan;46(1):23–8
Hemifacial dismasking flap for anterior skull base tumor—technical note. Kyutoku S, et al. **Neurol Med Chir (Tokyo)** 1996 Sep;36(9):666–9; discussion 669–70
Anterior transcranial (craniofacial) resection of tumors of the paranasal sinuses: surgical technique and results [letter; comment] Kaye AH. **Neurosurgery** 1997 Jan;40(1):219; discussion 219–20. Comment on: Neurosurgery 1996 Mar;38(3):471–9; discussion 479–80.
Two cases of recurrent pulmonary metastasis resected after operation for gastric cancer. Urabe M, et al. **Nippon Geka Hokan** 1996 Jan 1;65(1):22–9
Carcinoma of the duodenum: management and survival in 14 cases. Cangemi V, et al. **Panminerva Med** 1997 Mar; 39(1):24–9
Colon carcinoma in the adolescent. Sebbag G, et al. **Pediatr Surg Int** 1997 Jul;12(5–6):446–8
Pancreatic adenocarcinoma: why and when should it be resected? Ravichandran D, et al. **Postgrad Med J** 1997 Aug; 73(862):469–75 (58 ref.)
Expression of transforming growth factor-beta 1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment. Lindström P, et al. **Prostate** 1996 Oct;29(4):209–18
Endoscopic polypectomy in the treatment of colonic adenomas containing adenocarcinoma. Naranjo Rodríguez A, et al. **Rev Esp Enferm Dig** 1997 Jun;89(6):435–44 **(Eng, Spa)**
Quality of life measurement after rectal excision for cancer. Comparison between straight and colonic J-pouch anastomosis. Hallböök O, et al. **Scand J Gastroenterol** 1997 May;32(5):490–3
Inflammatory breast cancer: the evolution of multimodality treatment strategies. Gradishar WJ. **Semin Surg Oncol** 1996 Sep–Oct;12(5):352–63 (103 ref.)
Esophageal cancer surgery: the value of controlled clinical trials. Law SY, et al. **Semin Surg Oncol** 1997 Jul–Aug; 13(4):281–7 (75 ref.)
Barrett's cancer: indications, extent, and results of surgical resection. Siewert JR, et al. **Semin Surg Oncol** 1997 Jul–Aug;13(4):245–52 (54 ref.)
Management of adenocarcinoma arising in Barrett's esophagus. DeMeester TR. **Semin Thorac Cardiovasc Surg** 1997 Jul;9(3):290–301 (38 ref.)
Gastric stump carcinoma: a surgical challenge. Looi KP, et al. **Singapore Med J** 1996 Apr;37(2):184–5 (15 ref.)
Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer [letter] Krongrad A, et al. **South Med J** 1997 Apr;90(4):460–1
Radical thoracoscopic esophagectomy for cancer. Dexter SP, et al. **Surg Endosc** 1996 Feb;10(2):147–51
Laparoscopic surgery in the rat. Beneficial effect on body weight and tumor take [letter] Watson DI, et al. **Surg Endosc** 1997 Feb;11(2):165–6
A new technique to facilitate laparoscopic resection of low rectal tumors. Lezoche E, et al. **Surg Laparosc Endosc** 1997 Feb;7(1):9–12
Laparoscopically assisted sigmoid colectomy in human immunodeficiency virus (HIV) patients: a good indication for laparoscopic surgery. Oliveira L, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):414–6
Abdominoperineal resection: laparoscopic versus conventional. Ramos JR, et al. **Surg Laparosc Endosc** 1997 Apr;7(2):148–52
Laparoscopic local excision of the cecum for cecal creeping tumor. Watanabe M, et al. **Surg Laparosc Endosc** 1997 Apr; 7(2):144–7
Adenocarcinoma of the gastric antrum: does D2 total gastrectomy with splenectomy improve prognosis compared to D1 subtotal gastrectomy? A long-term survival analysis with emphasis on Lauren classification. Roukos D, et al. **Surg Oncol** 1995;4(6):323–32
Utility of mapping lymph nodes cleared from rectal adenocarcinoma specimens. Sanchez-Maldonado W, et al. **Surg Oncol** 1996 Jun;5(3):123–6
Disease-free survival for 6 years and 4 months after dissection of recurrent abdominal paraaortic nodes (no. 16) in gastric cancer: report of a case. Nashimoto A, et al. **Surg Today** 1997;27(2):169–73
Combined thoracoscopic lung resection and laser ablation for lung cancer with pulmonary emphysema: report of a case. Sugi K, et al. **Surg Today** 1997;27(1):68–70
Chest wall implantation of lung cancer at the drainage tube site: report of a case. Sugi K, et al. **Surg Today** 1997; 27(7):666–8
An improved technique for low anterior resection using a PDS endoloop. Terashima S, et al. **Surg Today** 1996; 26(10):857–9
Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Kelsen DP, et al. **Surgery** 1997 Jul; 122(1):53–9
Hürthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. McDonald MP, et al. **Surgery** 1996 Dec;120(6):1000–4; discussion 1004–5
Pelvic exenteration for locally advanced rectal carcinoma: factors predicting improved survival. Meterissian SH, et al. **Surgery** 1997 May;121(5):479–87 (31 ref.)
Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Mosca F, et al. **Surgery** 1997 Sep;122(3):553–66
Population-based analysis of treatment of pancreatic cancer and Whipple resection: Department of Defense hospitals, 1989–1994. Wade TP, et al. **Surgery** 1996 Oct;120(4):680–5; discussion 686–7
Is video-assisted thoracoscopic surgery suitable for resection of primary lung cancer? Iwasaki A, et al. **Thorac Cardiovasc Surg** 1997 Feb;45(1):13–5
Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: a prospective study [see comments] Houbiers JG, et al. **Transfusion** 1997 Feb;37(2):126–34. Comment in: Transfusion 1997 Feb;37(2):121–5.
Primary vaginal urinary calculus following abdominoperineal resection of rectum. Dhall JC, et al. **Urol Int** 1997; 58(3):197–8
Stage D1 (T1–3, N1–3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Cadeddu JA, et al. **Urology** 1997 Aug;50(2):251–5
Collagen mass in prostatic bed after radical retropubic prostatectomy. Davis JW, et al. **Urology** 1997 Jul;50(1):121
Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Dillioglugil O, et al. **Urology** 1997 Jul;50(1):93–9
Neoadjuvant hormonal therapy: the Canadian experience. Labrie F, et al. **Urology** 1997 Mar;49(3A Suppl):56–64
Comparison of bladder neck preservation to bladder neck resection in maintaining postrostatectomy urinary continence. Lowe BA. **Urology** 1996 Dec;48(6):889–93
[Thoraco-cranial operation for treatment of lung cancer with brain metastasis] Chen J, et al. **Chung Hua Chung Liu Tsa Chih** 1996 Jan;18(1):67–9 (Eng. Abstr.) **(Chi)**
[The most important prognostic factors for 736 patients with adenocarcinoma of the gastric cardia: a multivariate analysis using COX proportion hazard model] Li J, et al. **Chung Hua Chung Liu Tsa Chih** 1996 Mar;18(2):134–6 (Eng. Abstr.) **(Chi)**
[A clinical study on the incidence of retroperitoneal lymph node metastasis and its risk factors in ovarian cancer] Wu X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Sep; 31(9):543–7 (Eng. Abstr.) **(Chi)**
[Conservative surgery and radiation therapy in the treatment of operable breast cancer] Sun M, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Oct;33(10):606–8 (Eng. Abstr.) **(Chi)**
[Anastomotic leakage after low anterior resection for rectal cancer (see comments)] Bülow S, et al. **Ugeskr Laeger** 1997 Jan 13;159(3):297–301 (Eng. Abstr.). Comment in: Ugeskr Laeger 1997 May 19;159(21):3194. **(Dan)**
[Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors] Feyaerts A, et al. **Acta Urol Belg** 1997 Mar;65(1):11–8 (Eng. Abstr.) **(Fre)**
[Negative second-look laparatomy in ovarian cancers. Survival analysis and prognostic factors from 64 cases treated at the Gustave Roussy Institute] Pautier P, et al. **Bull Cancer** 1997 Feb;84(2):147–54 (37 ref.) (Eng. Abstr.) **(Fre)**
[Palliative treatment of rectal cancer by the trans-anal approach using a urologic prostatectomy device] Arnaud JP, et al. **Chirurgie** 1996;121(6):437–40; discussion 440–1 (Eng. Abstr.) **(Fre)**
[Has amputation of the rectum by pure perineal approach or Lisfranc operation still a role in the treatment of rectal cancer?] Gautier-Benoit C, et al. **Chirurgie** 1996; 121(3):193–6; discussion 196–7 (Eng. Abstr.) **(Fre)**
[Management of cervical cancers in Yaounde. 111 cases] Yomi J, et al. **Med Trop (Mars)** 1996;56(2):159–62 (Eng. Abstr.) **(Fre)**
[Cancer of the upper 3rd of the extra-hepatic bile ducts: surgical indication] Parc Y, et al. **Presse Med** 1996 Sep 14;25(26):1186–90 (Eng. Abstr.) **(Fre)**
[Tumor dissemination after thoracoscopic resection of malignant pulmonary coin lesions] Buhr J, et al. **Chirurg** 1996 Jan;67(1):81–5 (Eng. Abstr.) **(Ger)**
[Liberation of neopterin after lung resecting interventions with and without bronchial carcinoma] Gebhard F, et al. **Chirurg** 1996 Jul;67(7):725–9 (Eng. Abstr.) **(Ger)**
[Cronkhite-Canada syndrome. Epidemiology, symptoms, morphology and therapy based on a case report and literature review] Zügel N, et al. **Chirurg** 1997 Jul; 68(7):710–4 (44 ref.) (Eng. Abstr.) **(Ger)**
[Cervical anastomotic stenosis after gastric tube reconstruction in esophageal carcinoma. Evaluation of a patient sample 1989–1995] Bruns CJ, et al. **Langenbecks Arch Chir** 1997;382(3):145–8 (Eng. Abstr.) **(Ger)**
[Current indications for pylorus saving duodenopancreatic head resection in malignancy] Reith HB, et al. **Langenbecks Arch Chir** 1996;381(4):207–11 (Eng. Abstr.) **(Ger)**
[Subtotal esophagectomy with stomach transposition as standard operation for adenocarcinoma of the esophagogastric junction] Fass J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:166–8 (Eng. Abstr.) **(Ger)**
[Extent of radical surgery in cardia carcinoma—esophagectomy or gastrectomy?] Hölscher AH, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:169–72 (Eng. Abstr.) **(Ger)**
[Gastrectomy with radical lymphadenectomy—standard therapy of adenocarcinoma of the stomach] Thybusch A, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:173–5 (Eng. Abstr.) **(Ger)**
[The vaginal stump recurrence rate in endometrial carcinoma in relation to the target volume of postoperative HDR-afterloading brachytherapy] Kloetzer KH, et al. **Strahlenther Onkol** 1997 Jan;173(1):13–7 (Eng. Abstr.) **(Ger)**
[Laparoscopic lymphadenectomy in prostate carcinoma. Experiences with 120 patients] Effert P, et al. **Urologe A** 1996 Sep;35(5):413–7 (Eng. Abstr.) **(Ger)**
[Transthoracic-transabdominal resection of esophageal carcinoma] Schröder H, et al. **Zentralbl Chir** 1997;

122(3):165–9; discussion 170 (Eng. Abstr.) **(Ger)**

[Pelvic exenteration: effects of surgical method on quality of life] Hawighorst-Knapstein S, et al. **Zentralbl Gynakol** 1997;119(4):160–5 (Eng. Abstr.) **(Ger)**

[Synchronous surgical removal of esophageal and pulmonary cancer by endoscopic mucosectomy and video-assisted lobectomy through minimal thoracotomy] Szántó I, et al. **Orv Hetil** 1997 Jun 15;138(24):1567–9 (Eng. Abstr.) **(Hun)**

[Early gastric cancer: our experience] Gangi S, et al. **Ann Ital Chir** 1996 May–Jun;67(3):387–90 (Eng. Abstr.) **(Ita)**

[Half-life of blood PSA after radical prostatectomy. Correlations with pathological stage and clinical course of the disease] Di Federico G, et al. **Arch Ital Urol Androl** 1997 Feb;69 Suppl 1:97–100 (Eng. Abstr.) **(Ita)**

[100 orthotopic neobladders in men after cystectomy: a 5-year experience] Mandressi A, et al. **Arch Ital Urol Androl** 1996 Dec;68(5):323–31 (Eng. Abstr.) **(Ita)**

[Echographic follow-up after radical prostatectomy] Rosi P, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):43–8 (7 ref.) (Eng. Abstr.) **(Ita)**

[Surgical strategy in gastric cancer in aged patients] Caporale A, et al. **G Chir** 1997 Jan–Feb;18(1–2):36–40 (Eng. Abstr.) **(Ita)**

[Treatment of the residual pancreatic stump after pancreatoduodenectomy: pancreatogastrostomy] Catania G, et al. **G Chir** 1996 Aug–Sep;17(8–9):425–30 (54 ref.) (Eng. Abstr.) **(Ita)**

[Carcinoma of the splenic flexure. Nosological and therapeutic contribution] Tocchi A, et al. **G Chir** 1996 Jun–Jul;17(6–7):345–8 (Eng. Abstr.) **(Ita)**

[Minimally invasive surgery and neoplasms of the inferior third of the rectum: personal technique] Trignano M, et al. **G Chir** 1997 Apr;18(4):241–4 (Eng. Abstr.) **(Ita)**

[Carcinoma of the gastric stump. Our experience in 28 treated cases] Barillari P, et al. **Minerva Chir** 1997 Jun;52(6):713–6 (Eng. Abstr.) **(Ita)**

[Prognostic clinical and anatomopathological factors in surgery of carcinoma of the right colon] Erba M, et al. **Minerva Chir** 1997 Jun;52(6):727–33 (Eng. Abstr.) **(Ita)**

[Gallbladder carcinoma. Our experience] Gentilli S, et al. **Minerva Chir** 1996 Apr;51(4):183–6 (Eng. Abstr.) **(Ita)**

[Cancer of the gallbladder] Nardi M, et al. **Minerva Chir** 1997 May;52(5):583–7 (Eng. Abstr.) **(Ita)**

[Intra-abdominal desmoid tumor in a patient surgically treated for rectal carcinoma. Report of a case] Capra S, et al. **Radiol Med (Torino)** 1996 Jul–Aug;92(1–2):141–2 **(Ita)**

[Recent advance in laparoscopic-assisted colectomy for colon cancer] Konishi F, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):538–43 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Limited operation and simple lobectomy for primary lung cancer in poor risk patients] Ohta S, et al. **Kyobu Geka** 1996 Jul;49(7):519–23; discussion 523–5 (Eng. Abstr.) **(Jpn)**

[A case of one stage operation for primary lung cancer and abdominal aortic aneurysm] Tanaka K, et al. **Kyobu Geka** 1996 Jul;49(7):599–601 (Eng. Abstr.) **(Jpn)**

[Experience with surgery for synchronous double cancer of rectum and lung detected after long-term follow-up for pneumoconiosis] Tsuji K, et al. **Kyobu Geka** 1996 Dec; 49(13):1130–3 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a patient with erythroderma] Hattori S, et al. **Masui** 1996 Sep;45(9):1127–30 (Eng. Abstr.) **(Jpn)**

[Tumor disseminate in site following laparoscopic cholecystectomy] Shibata N, et al. **Nippon Geka Gakkai Zasshi** 1997 Apr;98(4):462–5 (25 ref.) **(Jpn)**

[Video-assisted thoracoscopic surgery for a 89-year-old patient with primary lung cancer—report of a case] Kamiyoshihara M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):628–31 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Synchronous multiple early gastric cancer; study of surgically resected stomach] Iwafuchi M, et al. **Nippon Rinsho** 1996 May;54(5):1217–23 (Eng. Abstr.) **(Jpn)**

[Endoscopic treatment of early gastric cancer with heat probe method] Otsuka S. **Nippon Rinsho** 1996 May; 54(5):1351–3 (11 ref.) (Eng. Abstr.) **(Jpn)**

[A case of synchronous triple cancers with curative resection] Matsuoka M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Oct;93(10):732–7 (11 ref.) **(Jpn)**

[Stereotactic radiosurgery for the treatment of brain metastases] Hiyama H, et al. **No To Shinkei** 1996 Feb; 48(2):113–9 **(Jpn)**

[The point of view of otolaryngologist and head and neck surgeon on thyroid diseases] Betkowski A, et al. **Otolaryngol Pol** 1995;49(6):574–82 (Eng. Abstr.) **(Pol)**

[Cancer of the head of the pancreas with a unique evolution] Angelescu N, et al. **Chirurgia (Bucur)** 1996 May–Jun; 45(3):129–32 (15 ref.) (Eng. Abstr.) **(Rum)**

[Radical surgical treatment of gastric cancer complicated by perforation and hemorrhage in the aged] Chernov KM, et al. **Khirurgiia (Mosk)** 1997;(4):69 **(Rus)**

[Results of pneumonectomy with resection of the tracheal bifurcation] Giller DB, et al. **Khirurgiia (Mosk)** 1997; (3):15–20 (Eng. Abstr.) **(Rus)**

[Endoscopic treatment of early gastric cancer using laser destruction and electrosurgical methods] Romanov VA, et al. **Khirurgiia (Mosk)** 1997;(4):15–9 (Eng. Abstr.) **(Rus)**

[Use of peritoneo-anal resection with levator sphincteroplasty in the treatment of cancer of the lower ampullary part of the rectum] Bondar' GV, et al. **Klin Khir** 1996;(6):22–4 **(Rus)**

[Peritoneo-anal resection with remucosation of the anal canal in the treatment of cancer of the middle ampullary section of the rectum] Bondar' GV, et al. **Klin Khir** 1996;(4):8–10 **(Rus)**

[Role of endoscopic laser surgery in the surgical treatment of bronchial tumors] Grubnik VV, et al. **Klin Khir** 1996; (10):3–5 **(Rus)**

[The surgical treatment of patients with tumors of the pancreas and pancreatoduodenal area] Shalimov AA, et al. **Klin Khir** 1996;(9):3–6 **(Rus)**

[A malignant tumor of the ileum strangulated in a postoperative abdominal hernia] Stavitskiĭ VV. **Klin Khir** 1995;(2):45–6 **(Rus)**

[The correction of the thyroid status in the surgical treatment of malignant tumors of the stomach and large intestine] Beletskaia OM. **Lik Sprava** 1996 Jul–Sep;(7–9):121–5 (Eng. Abstr.) **(Rus)**

[Urethral invagination by Solovov's technic in a patient with obliteration of the posterior urethra and a small bladder as a consequence of prostatic cancer] Baranov SD, et al. **Urol Nefrol (Mosk)** 1996 Nov–Dec;(6):45–8 (Eng. Abstr.) **(Rus)**

[The surgical results in malignant bladder tumors using the Scalpel-1 carbon-dioxide laser] Dmitriev BV, et al. **Urol Nefrol (Mosk)** 1997 Jan–Feb;(1):25–8 (Eng. Abstr.) **(Rus)**

[Rational support of combined operations in locally disseminated stomach cancer] Simonov NN, et al. **Vestn Khir Im I I Grek** 1997;156(3):22–5 (Eng. Abstr.) **(Rus)**

[One-step transpleural or transmediastinal esophagogastroplasty in resection of the esophagus for cancer] Simonov NN, et al. **Vestn Khir Im I I Grek** 1996; 155(6):14–6 (Eng. Abstr.) **(Rus)**

[Successful surgical treatment of cancer with multiple location] Roman LD, et al. **Vopr Onkol** 1997;43(2):230 (Eng. Abstr.) **(Rus)**

[Ultrasonographic (intra- and extraluminal) pattern of cervico-urethral anastomosis after radical prostatectomy] Castiñeiras J, et al. **Actas Urol Esp** 1996 May;20(5):443–7 (Eng. Abstr.) **(Spa)**

[Conservative surgery in renal adenocarcinoma] Diez Cordero JM, et al. **Actas Urol Esp** 1996 Jul–Aug; 20(7):597–600 (Eng. Abstr.) **(Spa)**

[Complications of radical nephrectomy in the treatment of kidney adenocarcinoma] Herranz Amo F, et al. **Actas Urol Esp** 1997 Jan;21(1):15–21 (Eng. Abstr.) **(Spa)**

[Effect of complete androgen block before radical prostatectomy for cancer of the prostate] Gómez Veiga F, et al. **Arch Esp Urol** 1997 May;50(4):355–63 (Eng. Abstr.) **(Spa)**

[Histologic regression of localized prostatic tumor with neoadjuvant hormonal therapy] López López C, et al. **Arch Esp Urol** 1996 Oct;49(8):819–23 (Eng. Abstr.) **(Spa)**

[Pancreatoduodenectomy in the treatment of carcinoma of Vater's ampulla] Morales-Linares JC, et al. **Rev Invest Clin** 1996 May–Jun;48(3):185–9 (25 ref.) (Eng. Abstr.) **(Spa)**

[Prolonged case of adenocarcinoma of the large intestine with spreading to the neighboring organs] Baramiia NM, et al. **Klin Khir** 1996;(8):44 **(Ukr)**

[A case of rectal cancer and extra-abdominal desmoid] Ievtushenko AV, et al. **Klin Khir** 1995;(2):51 **(Ukr)**

THERAPY

Maximal androgen blockade versus total androgen suppression. Dumez H, et al. **Acta Urol Belg** 1997 Mar; 65(1):49–54

Integration of surgery in multimodality therapy for esophageal cancer. Ebie N, et al. **Am J Clin Oncol** 1997 Feb;20(1):11–5

Adenocarcinoma of the prostate: innovations in management. Petrovich Z, et al. **Am J Clin Oncol** 1997 Apr;20(2):111–9 (62 ref.)

Herpes simplex thymidine kinase gene transfer is required for complete regression of murine colon adenocarcinoma. Nielsen CS, et al. **Am Surg** 1997 Jul;63(7):617–20

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Glimelius B, et al. **Ann Oncol** 1997 Feb; 8(2):163–8

Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. Jones DR, et al. **Ann Thorac Surg** 1997 Jul;64(1):185–91; discussion 191–2

Association of docetaxel/paclitaxel with irradiation in ovarian carcinoma cell lines in bidimensional (sulforhodamine B assay) and tridimensional (spheroids) cultures. Griffon-Etienne G, et al. **Anticancer Drugs** 1996 Aug;7(6):660–70

In vitro evaluation of temozolomide combined with X-irradiation. Wedge SR, et al. **Anticancer Drugs** 1997 Jan; 8(1):92–7

Interferon gamma is highly effective against orthotopically-implanted human pleural adenocarcinoma in nude mice. An Z, et al. **Anticancer Res** 1996 Sep–Oct; 16(5A):2545–51

Invasive cervical cancer in pregnancy [see comments] Allen DG, et al. **Aust N Z J Obstet Gynaecol** 1995 Nov; 35(4):408–12. Comment in: Aust N Z J Obstet Gynaecol 1996 May;36(2):228. Comment in: Aust N Z J Obstet Gynaecol 1996 Nov;36(4):496–7.

Enhancement of the antitumor effect of gamma-ray irradiation in combination with camptothecin against human colorectal adenocarcinoma. Wang DS, et al. **Biol Pharm Bull** 1996 Mar;19(3):354–9

A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer. Pizza G, et al. **Biotherapy** 1996;9(1–3):123–32

Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity. Saxton ML, et al. **Blood** 1997 Apr 1;89(7):2529–36

Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells. Nanni P, et al. **Br J Cancer** 1996 Nov;74(10):1564–9

Nicotinamide reduces tumour interstitial fluid pressure in a dose- and time-dependent manner. Peters CE, et al. **Br J Radiol** 1997 Feb;70:160–7

National Cancer Data Base report on esophageal carcinoma. Daly JM, et al. **Cancer** 1996 Oct 15;78(8):1820–8

Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Ueno NT, et al. **Cancer Chemother Pharmacol** 1997;40(4):321–9

Development of a bispecific F(ab')2 conjugate against the complement receptor CR3 of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage-mediated tumor cytotoxicity. Somasundaram C, et al. **Cancer Immunol Immunother** 1996 Jul;42(6):343–50

Peritoneal carcinomatosis from adenocarcinoma of the colon. Schellinx ME, et al. **Cancer Treat Res** 1996;81:247–60

Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules. Frey AB, et al. **Cell Immunol** 1997 May 25;178(1):79–90

Case report: palliative treatment of a rectal tumour with a self-expanding metallic stent. Maclennan AC, et al. **Clin Radiol** 1997 Aug;52(8):633–5

Early detection and management of esophageal cancer. Margulies C, et al. **Compr Ther** 1996 Sep;22(9):565–78 (98 ref.)

Adenocarcinoma of the cervix--are there arguments for a different treatment policy? Quinn MA. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):21–4 (35 ref.)

Standards and perspectives in the diagnosis and treatment of pancreatic adenocarcinoma. Sulkowski U. **Digestion** 1996;57 Suppl 1:34–5 (9 ref.)

A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Hyams DM, et al. **Dis Colon Rectum** 1997 Feb;40(2):131–9

Initial results of a new procedure for treatment of malignant obstruction of the left colon. Tejero E, et al. **Dis Colon Rectum** 1997 Apr;40(4):432–6

Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer. Giovannini M, et al. **Endoscopy** 1997 Jan;29(1):4–9

Photodynamic therapy for the treatment of tumor ingrowth in expandable esophageal stents. Scheider DM, et al. **Endoscopy** 1997 May;29(4):271–4

Adenocarcinoma of the cervix: a regional retrospective study. Hebblethwaite N, et al. **Eur J Gynaecol Oncol** 1997; 18(1):47–52

Endometrial carcinoma in women 45 years of age or younger. Leo L, et al. **Eur J Gynaecol Oncol** 1996;17(5):403–5

Androgen-deprived prostate adenocarcinoma: evaluation of treatment-related changes versus no distinctive treatment effect with a Bayesian belief network. A methodological approach. Montironi R, et al. **Eur Urol** 1996;30(3):307–15

Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation. Schmidt JD, et al. **Eur Urol** 1996;29(4):425–33

Photodynamic efficiency of macrophage activity using a photosensitizer, lumin, with near-IR laser light for photoimmunotherapy of a cancer. Mito K. **Front Med Biol Eng** 1996;7(2):81–92

Multimodality therapy for adenocarcinoma of the esophagus. Kelsen D. **Gastroenterol Clin North Am** 1997 Sep; 26(3):635–45 (22 ref.)

Prior radiation and chemotherapy increase the risk of life-threatening complications after insertion of metallic stents for esophagogastric malignancy [see comments] Kinsman KJ, et al. **Gastrointest Endosc** 1996 Mar; 43(3):196–203. Comment in: Gastrointest Endosc 1996 Mar;43(3):258–60.

Tandem expandable stent technique for a fractured nitinol stent [letter] Trowers EA, et al. **Gastrointest Endosc** 1997 Feb;45(2):217–8

Self-expanding metal stent for obstructing adenocarcinoma of the sigmoid. Vandervoort J, et al.

Gastrointest Endosc 1996 Dec;44(6):739–41

Partial regression, yet incomplete eradication of mammary tumors in transgenic mice by retrovirally mediated HSVtk transfer 'in vivo'. Sacco MG, et al. **Gene Ther** 1996 Dec; 3(12):1151–6

Combination of laser treatment and intraluminal radiotherapy for malignant dysphagia. Shmueli E, et al. **Gut** 1996 Jun; 38(6):803–5

Laser and brachytherapy in the palliation of adenocarcinoma of the oesophagus and cardia. Spencer GM, et al. **Gut** 1996 Nov;39(5):726–31

Successful management of a solitary peritoneal metastasis of unknown origin. Report of a case. Wang PH, et al. **Gynecol Obstet Invest** 1997;43(3):212–4

Evaluating early-stage prostate cancer. What pretreatment criteria best guide therapeutic decision making? Corless CL. **Hematol Oncol Clin North Am** 1996 Jun;10(3):565–79 (113 ref.)

How is androgen-dependent metastatic prostate cancer best treated? Robson M, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):727–47 (149 ref.)

Adjuvant therapy following pancreatic resection for pancreatic duct carcinoma: a prospective randomized study. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 May-Jun;43(9):671–80

Phase Ia trial of a polynucleotide anti-tumor immunization to human carcinoembryonic antigen in patients with metastatic colorectal cancer. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama. **Hum Gene Ther** 1996 Apr 10; 7(6):755–72

Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors. Gaken JA, et al. **Hum Gene Ther** 1997 Mar 1;8(4):477–88

Limitations of retrovirus-mediated HSV-tk gene transfer to pulmonary adenocarcinoma cells in vitro and in vivo. Zhang L, et al. **Hum Gene Ther** 1997 Mar 20;8(5):563–74

Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression. Casalini P, et al. **Int J Cancer** 1997 Aug 7;72(4):631–6

Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Jordan A, et al. **Int J Hyperthermia** 1996 Nov-Dec;12(6):705–22

Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. Lawton CA, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15;38(5):931–9

Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Zietman AL, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15; 38(5):1067–70

Combined modality therapy for stage II and stage III pancreatic carcinoma. Kamthan AG, et al. **J Clin Oncol** 1997 Aug;15(8):2920–7

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. Tempero M, et al. **J Clin Oncol** 1997 Apr; 15(4):1518–28

Postoperative combined radiohyperthermia in Astler-Coller stages B2 and C distal rectal cancer. Caporale A, et al. **J Exp Clin Cancer Res** 1997 Jun;16(2):195–9

A decision analysis for treatment of clinically localized prostate cancer. Kattan MW, et al. **J Gen Intern Med** 1997 May;12(5):299–305

Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. Rodolfo M, et al. **J Immunol** 1996 Dec 15;157(12):5536–42

Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine. Abrams SI, et al. **J Immunother** 1997 Jan;20(1):48–59

Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. MacLean GD, et al. **J Immunother** 1997 Jan;20(1):70–8

Targeting immunotherapy using the avidin-biotin system for a human colon adenocarcinoma in vitro. Nakaki M, et al. **J Int Med Res** 1997 Jan-Feb;25(1):14–23

A needle type therapeutic system incorporating laser light and lumin for immunotherapy of cancer growing in deep organs. Mito K. **J Med Eng Technol** 1996 May-Jun; 20(3):121–6

Perianal mucinous adenocarcinoma. Anthony T, et al. **J Surg Oncol** 1997 Mar;64(3):218–21

Locally advanced rectal cancer with a pelvic kidney complicating adjuvant radiation therapy. Bokhari MB, et al. **J Surg Oncol** 1996 Sep;63(1):57–60 (14 ref.)

Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. Link CJ Jr, et al. **J Surg Oncol** 1997 Apr;64(4):289–94

Appendiceal carcinoma: patterns of failure following surgery and implications for adjuvant therapy. Proulx GM, et al. **J Surg Oncol** 1997 Sep;66(1):51–3

Effect of radiotherapy and chemotherapy on composition of tumor membrane phospholipids. Street JC, et al. **Lipids** 1997 Jan;32(1):45–9

Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer. Kimura H, et al. **Lung Cancer** 1996 Jun;14(2-3):301–14

Multimodal therapy for esophageal adenocarcinoma [letter; comment] Badwe RA, et al. **N Engl J Med** 1997 Jan 30; 336(5):374–5; discussion 375–6. Comment on: N Engl J Med 1996 Aug 15;335(7):462–7.

Multimodal therapy for esophageal adenocarcinoma [letter] Funk EM, et al. **N Engl J Med** 1997 Jan 30;336(5):375; discussion 375–6

Multimodal therapy for esophageal adenocarcinoma [letter] Gaffney P. **N Engl J Med** 1997 Jan 30;336(5):375; discussion 375–6

Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumours with 131I-labelled monoclonal antibodies. Behr TM, et al. **Nucl Med Commun** 1996 Sep; 17(9):767–80

Will current clinical trials answer the most important questions about prostate adenocarcinoma? Thompson IM, et al. **Oncology (Huntingt)** 1997 Aug;11(8):1109–17; discussion 1117–8, 1121 (27 ref.)

Management of asymptomatic rising PSA after prostatectomy or radiation therapy. Waxman S, et al. **Oncology (Huntingt)** 1997 Apr;11(4):457–60, 465; discussion 465–6, 469 (48 ref.)

Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Block A, et al. **Pancreas** 1997 Jul;15(1):25–34

A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Nakashima E, et al. **Pharm Res** 1996 Dec;13(12):1896–901

What should be the routine follow-up after definitive therapy of localized lung cancer? Pieters RS, et al. **Semin Oncol** 1996 Aug;23(4):xv–xxvii, comment xxvii–xxviii

Management of stage T1b (A2) and stage T1c adenocarcinoma of the prostate. Konety BR, et al. **Semin Urol Oncol** 1996 Aug;14(3):183–94 (110 ref.)

Effect of radiation therapy alone or in combination with surgery and/or chemotherapy on tumor and symptom control of recurrent rectal cancer. Knol HP, et al. **Strahlenther Onkol** 1997 Jan;173(1):43–9

Treatment of cervical lymph node metastasis from an unknown primary tumor, with a review of the literature. van der Planken HJ, et al. **Strahlenther Onkol** 1997 Mar; 173(3):163–9

Carcinoma of the oesophagus: the time for a multidiciplinary approach? Clark GW, et al. **Surg Oncol** 1996 Aug; 5(4):149–64 (118 ref.)

Aggressive versus conventional strategies in the treatment of rectal adenocarcinoma. Havenga K, et al. **Surg Oncol** 1996 Aug;5(4):183–8

Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. Bagshawe KD, et al. **Transplant Proc** 1996 Dec;28(6):3156–8

Aggressive bone metastases in urachal carcinoma. Mohanti HK, et al. **Urol Int** 1996;57(2):132–4

[Adenocarcinoma of the cervix in data from the Masaryk Oncology Institute in Brno--therapy and results] Ptáčková B, et al. **Ceska Gynekol** 1996 Aug;61(4):252–3 **(Cze)**

[Induction treatment of locally advanced operable cancers of the esophagus. Prognostic significance of the histologic response] Thomas P, et al. **Ann Chir** 1997;51(3):222–31 (Eng. Abstr.) **(Fre)**

[Cancer of the uterine cervix in young women. A retrospective study of 337 cases] Acharki A, et al. **Bull Cancer** 1997 Apr;84(4):373–8 (44 ref.) (Eng. Abstr.) **(Fre)**

[Adjuvant radiotherapy after radical prostatectomy. Apropos of a series of 73 patients in Lyons (France)] Fric D, et al. **Cancer Radiother** 1997;1(1):52–9 (35 ref.) (Eng. Abstr.) **(Fre)**

[Role of radiotherapy in the management of adenocarcinoma of the breast accessible to conservative surgery] Romestaing P, et al. **Cancer Radiother** 1997;1(1):14–28 (134 ref.) (Eng. Abstr.) **(Fre)**

[Adenocarcinoma of the ethmoid sinus in woodworkers. Retrospective study of 25 cases] Moreau JJ, et al. **Neurochirurgie** 1997;43(2):111–7 (Eng. Abstr.) **(Fre)**

[Ovarian adenocarcinomas: current strategies] Varette C. **Presse Med** 1997 Mar 15;26(8):384–8 (29 ref.) **(Fre)**

[Are MAGE-1 and MAGE-3 suitable as vaccination antigens in esophageal carcinomas?] Stremmel C, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:789–92 (Eng. Abstr.) **(Ger)**

[Prostate carcinoma associated spontaneous factor VIII:C inhibitor hemophilia. Successful therapy of severe hemorrhagic complication with porcine factor VIII in a 75-year-old patient] Orth T, et al. **Med Klin** 1997 Apr 15;92(4):241–5 (Eng. Abstr.) **(Ger)**

[Occlusion of an esophagobronchial fistula by implantation of a Montgomery esophageal and a dynamic tracheal stent after failure of conventional endoprosthesis] Alexiou C, et al. **Z Gastroenterol** 1997 Apr;35(4):277–83 (Eng. Abstr.) **(Ger)**

[Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas] Ishikawa O, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1635–41 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Liver resection in a case of multiple liver metastases of gastric cancer following hepatic arterial infusion chemotherapy] Kobayashi T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1321–4 (Eng. Abstr.) **(Jpn)**

[A case of colon cancer with local recurrence successfully treated by systemic and local intra-arterial chemotherapy using a combination of 5-fluorouracil, interferon-alpha 2A, leucovorin and carboplatin] Takasaki S, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):109–13 (Eng. Abstr.) **(Jpn)**

[A patient with unresectable cancer of pancreas head, effectively treated by a local injection of the mixture of OK-432, fibrinogen and thrombin] Takekuni K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1621–3 (Eng. Abstr.) **(Jpn)**

[Choice of optimum method and analysis of results of the treatment of patients with cancer of the oropharynx] Shuvalov SM. **Klin Khir** 1996;(8):26–7 **(Rus)**

[A case of a cure of synchronous multiple primary neoplasm of the laryngopharynx and stomach] Klochikhin AL, et al. **Vestn Otorinolaringol** 1997;(1):56 **(Rus)**

ULTRASONOGRAPHY

Preoperative endosonographic staging of cancer of the cardia. François E, et al. **Abdom Imaging** 1996 Nov-Dec; 21(6):483–7

Endosonography for preoperative staging of rectal tumours. Nielsen MB, et al. **Acta Radiol** 1996 Sep;37(5):799–803

Pre-operative TN staging of gastric cancer using a 15 MHz ultrasound miniprobe. Akahoshi K, et al. **Br J Radiol** 1997 Jul;70(835):703–7

Relationship between histological type and endosonographic detection of regional lymph node metastases in gastric cancer. Hamada S, et al. **Br J Radiol** 1997 Jul; 70(835):697–702

Preoperative detection of distal intramural spread of lower rectal carcinoma using transrectal ultrasonography. Yanagi H, et al. **Dis Colon Rectum** 1996 Nov;39(11):1210–4

Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer. Giovannini M, et al. **Endoscopy** 1997 Jan;29(1):4–9

Endosonographic follow-up after local excision of a pT1 rectal carcinoma. Maunoury V. **Endoscopy** 1996 Jun; 28(5):468

Endoscopic ultrasound staging criteria for esophageal cancer. Brugge WR, et al. **Gastrointest Endosc** 1997 Feb; 45(2):147–52

The use of EUS to diagnose malignant portal venous system invasion by pancreatic cancer [see comments] Brugge WR, et al. **Gastrointest Endosc** 1996 Jun;43(6):561–7. Comment in: Gastrointest Endosc 1996 Jun;43(6):626–8.

Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration of the left adrenal gland. Chang KJ, et al. **Gastrointest Endosc** 1996 Nov;44(5):568–72

Radial scanning and linear array endosonography for staging pancreatic cancer: a prospective randomized comparison. Gress F, et al. **Gastrointest Endosc** 1997 Feb;45(2):138–42

Endoscopic ultrasonography for colorectal cancer using submucosal saline solution injection. Watanabe H, et al. **Gastrointest Endosc** 1997 Jun;45(6):508–11

Preoperative assessment of blood vessel involvement in patients with pancreatic cancer [see comments] Melzer E, et al. **Isr J Med Sci** 1996 Nov;32(11):1086–8. Comment in: Isr J Med Sci 1996 Nov;32(11):1124–6.

Abnormal echo adjacent to the pulmonary artery in a 70-year-old man. Tei C. **J Cardiol** 1997 Jan;29(1):43–4

Histochemical and immunohistochemical study of human gastric carcinoma differentiation with special reference to supplementary role for endosonography in evaluating depth of invasion. Nakamura T, et al. **J Gastroenterol** 1997 Apr; 32(2):176–83

The presence of endometrial fluid in asymptomatic postmenopausal women is associated with clinically relevant cervical stenosis [letter; comment] Goldstein SR. **J Ultrasound Med** 1997 Mar;16(3):208. Comment on: J Ultrasound Med 1996 Jul;15(7):513–5.

Quantification of tumor vascularity and flow with amplitude color Doppler sonography in an experimental model: preliminary results [published erratum appears in J Ultrasound Med 1997 Mar;16(3):218] Meyerowitz CB, et al. **J Ultrasound Med** 1996 Dec;15(12):827–33

Color flow sonography in evaluating the resectability of periampullary and pancreatic tumors. Ralls PW, et al. **J Ultrasound Med** 1997 Feb;16(2):131–40

Contrast enhanced color Doppler ultrasonography in diagnosis of pancreatic tumor: two case reports. Ueno N, et al. **J Ultrasound Med** 1996 Jul;15(7):527–30

Clinical significance of endometrial fluid collections in asymptomatic postmenopausal women [see comments] Zalel Y, et al. **J Ultrasound Med** 1996 Jul;15(7):513–5. Comment in: J Ultrasound Med 1997 Mar;16(3):208.

Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial [see comments] Smith JA Jr, et al. **J Urol** 1997 Mar;157(3):902–6. Comment in: J Urol 1997 Mar;157(3):919–20.

US case of the day. Gastric polyp in conjunction with poorly differentiated gastric adenocarcinoma. Kirpekar M, et al. **Radiographics** 1997 Jul-Aug;17(4):1003–5

Rectal cancer: evaluation of staging with endosonography.

Lindmark GE, et al. **Radiology** 1997 Aug;204(2):533–8

Endosonography and endosonography-guided biopsy of upper-GI-tract tumors using a curved-array echoendoscope. Hünerbein M, et al. **Surg Endosc** 1996 Dec; 10(12):1205–9

Diagnosis of occult colon cancer: possible new use of transvaginal color imaging [letter] Crade M. **Ultrasound Obstet Gynecol** 1997 May;9(5):352–3

[Ultrasound-guided fine-needle aspiration biopsy of focal liver lesions] Járay B, et al. **Orv Hetil** 1997 Jul 6; 138(27):1731–6 (Eng. Abstr.) **(Hun)**

[Preoperative staging of prostatic carcinoma: evaluation of the role of transrectal echography] Lorusso A, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):83–5 (Eng. Abstr.) **(Ita)**

[Role of expectant therapy in prostatic carcinoma of low grade and staging] Lorusso A, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):155–7 (Eng. Abstr.) **(Ita)**

[Echography and follow-up of prostate carcinoma: "follow up echography in the course of drug therapy"] Martino P, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):37–42 (10 ref.) (Eng. Abstr.) **(Ita)**

[Echographic follow-up after radical prostatectomy] Rosi P, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):43–8 (7 ref.) (Eng. Abstr.) **(Ita)**

[Role of endorectal ultrasonography and CT in preoperative staging of rectal cancer. Personal experience] Garretti L, et al. **Minerva Chir** 1997 Jun;52(6):717–25 (Eng. Abstr.) **(Ita)**

[Study of prostatic carcinoma with ultrasonography and magnetic resonance with "dedicated" surface coil] Preziosi P, et al. **Radiol Med (Torino)** 1996 Dec;92(6):752–7 (Eng. Abstr.) **(Ita)**

[Relationship between peripheral hypoechoic nodules of the prostatic gland and prostate cancer] Herranz Amo F, et al. **Actas Urol Esp** 1996 Sep;20(8):725–32 (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

Activity satellite association and polymorphism of Ag stained nucleolus organizer regions (Ag+ NORs) in lymphocytes from women with cervical uterine cancer. Cortés-Gutiérrez EI, et al. **Arch Med Res** 1997 Spring; 28(1):19–23

Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumour-free pancreas. Tang C, et al. **Br J Cancer** 1997;75(10):1467–73

Nuclear morphometry as a predictor of disease outcome in gastric cancer. Setälä L, et al. **J Pathol** 1997 Jan; 181(1):46–50

Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol. Couse JF, et al. **Mol Carcinog** 1997 Aug;19(4):236–42

123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Virgolini I, et al. **Nucl Med Biol** 1996 Aug;23(6):685–92

Apocrine carcinoma of the lip: a case report including immunohistochemical and ultrastructural study, discussion of differential diagnosis, and review of the literature. Hayes MM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Aug;82(2):193–9 (65 ref.)

Carcinoma arising in ectopic hamartomatous thymoma. An ultrastructural study. Michal M, et al. **Pathol Res Pract** 1996 Jun;192(6):610–8; discussion 619–21

Silver-stained nucleolar organizer regions in adenocarcinoma of the cervix--a light and electron microscopic study. Yokoyama Y, et al. **Pathol Res Pract** 1997;193(4):275–81

Fine structural studies of induced tumors arising within the prostatic complex of Lobund-Wistar rats. Heidger PM Jr, et al. **Prostate** 1997 Aug 1;32(3):173–8

Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas. Hammar SP, et al. **Ultrastruct Pathol** 1996 Jul-Aug;20(4):293–325

[A cytofluorometric study of the stability of secondary DNA structure in the epithelial cells in endometrial hyperplasia and cancer] Ganina KP, et al. **Tsitol Genet** 1996 Nov-Dec; 30(6):23–7 (Eng. Abstr.) **(Rus)**

URINE

Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Miyanaga N, et al. **Eur Urol** 1997;31(2):163–8

VETERINARY

Tumours of the glandular stomach. Takahashi M, et al. **IARC Sci Publ** 1996;(126):127–35 (29 ref.)

Tumours of the gallbladder. Turusov VS, et al. **IARC Sci Publ** 1996;(126):109–25 (21 ref.)

Apocrine gland adenocarcinoma and pheochromocytoma in a cat. Chun R, et al. **J Am Anim Hosp Assoc** 1997 Jan-Feb; 33(1):33–6

Primary adenocarcinoma of the gland of the nictitating membrane in a cat. Komaromy AM, et al. **J Am Anim Hosp Assoc** 1997 Jul-Aug;33(4):333–6

Ceruminous gland tumors in dogs and cats: a review of 124 cases. Moisan PG, et al. **J Am Anim Hosp Assoc** 1996 Sep-Oct;32(5):448–52 (9 ref.)

Canine gastric neoplasia: utility of ultrasonography in diagnosis. Rivers BJ, et al. **J Am Anim Hosp Assoc** 1997 Mar-Apr;33(2):144–55

Esophageal/gastric adenocarcinoma in a dog. Takiguchi M, et al. **J Am Anim Hosp Assoc** 1997 Jan-Feb;33(1):42–4

Hypertrophic osteopathy associated with an intrathoracic neoplasm in a rabbit. DeSanto J. **J Am Vet Med Assoc** 1997 May 1;210(9):1322–3

Equine adenocarcinomas of the large intestine with osseous metaplasia. Kirchhof N, et al. **J Comp Pathol** 1996 May; 114(4):451–6

Intestinal adenocarcinoma with neuroendocrine cells in a clouded leopard (Neofelis nebulosa). Wada Y, et al. **J Comp Pathol** 1996 Oct;115(3):305–10

Colonic adenocarcinoma in a rhesus macaque (Macaca mulatta). Johnson EH, et al. **J Med Primatol** 1996 Dec; 25(6):435–8

Amebiasis in a dog with gastric ulcers and adenocarcinoma. Steele KE, et al. **J Vet Diagn Invest** 1997 Jan;9(1):91–3

Long-term survival after total gastrectomy for gastric adenocarcinoma in a dog. Sellon RK, et al. **J Vet Intern Med** 1996 Sep-Oct;10(5):333–5

Prognosis for canine malignant mammary tumors based on TNM and histologic classification. Yamagami T, et al. **J Vet Med Sci** 1996 Nov;58(11):1079–83

Changes in glucose transport activities in mammary adenocarcinoma of dogs. Arai T, et al. **Res Vet Sci** 1997 Jan-Feb;62(1):85–6

Retrovirus-associated neoplasms of the respiratory system of sheep and goats. Ovine pulmonary carcinoma and enzootic nasal tumor. DeMartini JC, et al. **Vet Clin North Am Food Anim Pract** 1997 Mar;13(1):55–70 (73 ref.)

Helicobacter mustelae-associated gastric adenocarcinoma in ferrets (Mustela putorius furo). Fox JG, et al. **Vet Pathol** 1997 May;34(3):225–9

Adenocarcinoma of the hepatopancreatic ampulla in a domestic cat. Haines VL, et al. **Vet Pathol** 1996 Jul; 33(4):439–41

Apocrine gland tumor of the eyelid in a dog. Hirai T, et al. **Vet Pathol** 1997 May;34(3):232–4

Exocrine pancreatic insufficiency in a yellow-naped Amazon (Amazona ochrocephala) with pancreatic adenocarcinoma. Ritchey JW, et al. **Vet Pathol** 1997 Jan;34(1):55–7

Ultrasonographic features of intestinal adenocarcinoma in five cats. Rivers BJ, et al. **Vet Radiol Ultrasound** 1997 Jul-Aug;38(4):300–6

Renal adenocarcinoma in a reticulated python (Python reticulatus). Gravendyck M, et al. **Vet Rec** 1997 Apr 5; 140(14):374–5

Sclerosing adenocarcinoma of the extrahepatic bile duct in a cat. Pastor J, et al. **Vet Rec** 1997 Apr 5;140(14):367–8

[Metastasis of a mammary carcinoma in the central nervous system of a cat] Atasever A, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Nov;103(11):472–4 (Eng. Abstr.) **(Ger)**

[Intraocular metastasis of bronchial carcinoma in a cat] Heider HJ, et al. **Tierarztl Prax** 1997 May;25(3):271–4 (Eng. Abstr.) **(Ger)**

VIROLOGY

Discrepancy between clinical and pathological lymph node evaluation in Epstein-Barr virus-associated gastric cancers. Ojima H, et al. **Anticancer Res** 1996 Sep-Oct;16(5B):3081–4

Adenocarcinoma of the cervix and adenocarcinoma of the endometrium: distinction with PCR-mediated detection of HPV DNA. Hording U, et al. **APMIS** 1997 Apr; 105(4):313–6

Human papillomavirus type 18 DNA sequences in adenocarcinoma and adenosquamous carcinoma of the uterine cervix. Teshima H, et al. **Arch Gynecol Obstet** 1997; 259(4):169–77

Type of human papillomavirus is related to clinical features of cervical carcinoma. Nakagawa S, et al. **Cancer** 1996 Nov 1;78(9):1935–41

Human papillomavirus detection in adenocarcinoma and adenosquamous carcinoma of the uterine cervix in Taiwan. Tseng HH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jan;57(1):47–53

Investigation of oesophageal adenocarcinoma for viral genomic sequences. Morgan RJ, et al. **Eur J Surg Oncol** 1997 Feb;23(1):24–9

Human papillomavirus 16 and 18 infection is absent in urinary bladder carcinomas. Lu QL, et al. **Eur Urol** 1997; 31(4):428–32

Human papillomavirus in tissue of bladder and bladder carcinoma specimens. A preliminary study. Ludwig M, et al. **Eur Urol** 1996;30(1):96–102

Molecular characterization of adenocarcinoma of the cervix. Parker MF, et al. **Gynecol Oncol** 1997 Feb;64(2):242–51

Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Huang S, et al. **Int J Cancer** 1997 Feb 7;70(4):408–11

Human papillomavirus type 16 DNA in esophageal carcinomas from Alaska Natives. Miller BA, et al. **Int J Cancer** 1997 Apr 10;71(2):218–22

Epstein-Barr virus in gastric carcinoma in Suzhou, China and Osaka, Japan: association with clinico-pathologic factors and HLA-subtype. Qiu K, et al. **Int J Cancer** 1997 Apr 10;71(2):155–8

High prevalence of human papillomavirus types 16 and 18 in middle-ear carcinomas. Tsai ST, et al. **Int J Cancer** 1997 Apr 10;71(2):208–12

Glandular lesions of the uterine cervix: prognostic implications of human papillomavirus status. Anciaux D, et al. **Int J Gynecol Pathol** 1997 Apr;16(2):103–10

Infrequent overexpression of p53 protein in Epstein-Barr virus-associated gastric carcinomas. Ojima H, et al. **Jpn J Cancer Res** 1997 Mar;88(3):262–6

Absence of human papillomavirus genomic sequences detected by the polymerase chain reaction in oesophageal and gastric carcinomas in Japan. Saegusa M, et al. **Mol Pathol** 1997 Apr;50(2):101–4

Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma [see comments] Soini Y, et al. **Thorax** 1996 Sep;51(9):887–93. Comment in: Thorax 1996 Sep;51(9):878–9.

[Virological studies on Epstein-Barr virus-positive gastric carcinoma] Imai S. **Nippon Rinsho** 1997 Feb;55(2):368–73 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Clinicopathology of Epstein-Barr virus-related gastric carcinoma] Itoh T, et al. **Nippon Rinsho** 1997 Feb; 55(2):363–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

ADENOCARCINOMA, BASAL CELL see **ADENOCARCINOMA**

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR

CHEMISTRY

CD44v6 expression in primary bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma. Ohori NP, et al. **Mod Pathol** 1996 May;9(5):507–12

COMPLICATIONS

Refractory hypoxemia due to intrapulmonary shunting associated with bronchioloalveolar carcinoma. Chetty KG, et al. **Chest** 1997 Apr;111(4):1120–1

Bronchioloalveolar carcinoma in a child with congenital cystic adenomatoid malformation. Kaslovsky RA, et al. **Chest** 1997 Aug;112(2):548–51

[Bronchioalveolar adenocarcinoma associated with a chylous ascites. An unusual case] Martínez Bruna MS, et al. **An Med Interna** 1995 Aug;12(8):401–3 (Eng. Abstr.) **(Spa)**

[Bronchioloalveolar carcinoma associated with active tuberculosis: a case report (letter)] Rodríguez Perdomo E, et al. **Arch Bronconeumol** 1996 Feb;32(2):112 **(Spa)**

DIAGNOSIS

Persistent pulmonary infiltrate and bronchorrhea in a young woman. Casey KR, et al. **Chest** 1997 May;111(5):1442–5

Case records of the University of Maryland and Baltimore VA Medical Centers. A 73-year-old woman with hemoptysis and shortness of breath [clinical conference] Shanholtz C. **Md Med J** 1997 Mar;46(3):131–7

[Diffuse bronchiolo-alveolar cell carcinoma that produced both amylase and CA19-9] Nonogaki T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Apr; 35(4):426–31 (Eng. Abstr.) **(Jpn)**

[CA-19-9 antigen analysis of bronchoalveolar lavage fluid contributing to therapeutic decision of pulmonary alveolar epithelial tumor] Abe K, et al. **Nippon Naika Gakkai Zasshi** 1996 Jun 10;85(6):925–6 **(Jpn)**

[The diagnosis of bronchiolo-alveolar lung cancer] Pozmogov AI, et al. **Lik Sprava** 1996 Jul-Sep;(7-9):125–8 **(Rus)**

[A case of bronchiolo-alveolar carcinoma] Nersesian ON, et al. **Probl Tuberk** 1997;(3):59–60 **(Rus)**

[Bronchioalveolar carcinoma. Problems of differential diagnosis. Report of a case (letter)] Cremades Romero MJ, et al. **An Med Interna** 1996 Sep;13(9):465–6 **(Spa)**

[Dyspnea and cough in a 58-year-old male (clinical conference)] Blavia R, et al. **Med Clin (Barc)** 1997 Jun 21; 109(4):147–55 **(Spa)**

[Slow-resolving pneumonia in an 86-year-old man] Méndez Piñeiro MX, et al. **Rev Clin Esp** 1996 Oct;196(10):721–2 **(Spa)**

GENETICS

DNA ploidy and protein content in bronchioloalveolar carcinoma multi-variable flow cytometry. Huang MS, et al. **Cytometry** 1996 Dec 15;26(4):253–9

An RGD containing peptide from HIV-1 Tat-(65-80) modulates protooncogene expression in human bronchoalveolar carcinoma cell line, A549. el-Solh A, et al. **Immunol Invest** 1997 Apr;26(3):351–70

Immunohistochemical analysis of p53 mutations in bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma. Wang X, et al. **Mod Pathol** 1995 Dec; 8(9):919–23

METABOLISM

DNA ploidy and protein content in bronchioloalveolar carcinoma multi-variable flow cytometry. Huang MS, et al. **Cytometry** 1996 Dec 15;26(4):253–9

An RGD containing peptide from HIV-1 Tat-(65-80) modulates protooncogene expression in human

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR

bronchoalveolar carcinoma cell line, A549. el-Solh A, et al. **Immunol Invest** 1997 Apr;26(3):351–70

PATHOLOGY

Beta 4 integrin subunit expression is downregulated in low metastatic carcinoma variants. Cimino L, et al. **Cancer Detect Prev** 1997;21(2):158–66

Differentiating cytological features of bronchioloalveolar carcinoma from adenocarcinoma of the lung in fine-needle aspirations: a statistical analysis of 27 cases. Auger M, et al. **Diagn Cytopathol** 1997 Mar;16(3):253–7

Distinction between bronchioloalveolar carcinoma and hyperplastic pulmonary proliferations: a cytologic and morphometric analysis. Zaman SS, et al. **Diagn Cytopathol** 1997 May;16(5):396–401

Potential utility of p53 immunopositivity in differentiation of adenocarcinomas from reactive epithelial atypias of the lung. Cagle PT, et al. **Hum Pathol** 1996 Nov; 27(11):1198–203

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40–1996. A 58-year-old man with progressive hypotension and respiratory failure after treatment for apparent pulmonary tuberculosis [clinical conference] **N Engl J Med** 1996 Dec 26; 335(26):1974–82

PHYSIOPATHOLOGY

Activation of paracrine growth factors by heparan sulphate induced by glucocorticoid in A549 lung carcinoma cells. Yevdokimova N, et al. **Br J Cancer** 1997;76(3):281–9

RADIOGRAPHY

High-resolution CT findings of mucinous bronchioloalveolar carcinoma: a case of pseudopulmonary alveolar proteinosis. Tan RT, et al. **AJR Am J Roentgenol** 1997 Jan; 168(1):99–100

Bronchioloalveolar carcinoma: computed tomography findings. Trigaux JP, et al. **Eur Respir J** 1996 Jan;9(1):9–11

Bronchioloalveolar carcinoma with widespread ground-glass shadow on CT in two cases. Kobayashi T, et al. **J Comput Assist Tomogr** 1997 Jan-Feb;21(1):133–5

Utility of low-dose helical CT as a second step after plain chest radiography for mass screening for lung cancer. Mori K, et al. **J Thorac Imaging** 1997 Jul;12(3):173–80

Cloudy nodule on HRCT: a new clinico-radiologic entity of pulmonary adenocarcinoma. Koizumi N, et al. **Radiat Med** 1995 Nov-Dec;13(6):273–8

[High-resolution computerized tomography in diffuse forms of bronchiolo-alveolar carcinoma] Dellafiore L, et al. **Radiol Med (Torino)** 1996 Dec;92(6):709–12 (Eng. Abstr.) **(Ita)**

[Multiple cystic pulmonary lesions caused by bronchoalveolar carcinoma. Report of a case] Gaeta M, et al. **Radiol Med (Torino)** 1996 Jul-Aug;92(1-2):138 **(Ita)**

RADIONUCLIDE IMAGING

Intense and prolonged Tl-201 accumulation in a slow growing bronchioloalveolar carcinoma. Kinuya S, et al. **Ann Nucl Med** 1996 May;10(2):261–4

SURGERY

Resection rates and postoperative mortality in 7,899 patients with lung cancer. Damhuis RA, et al. **Eur Respir J** 1996 Jan;9(1):7–10

ADENOCARCINOMA, CLEAR CELL

[Incidentaloma of the adrenal gland. A clinical case] Letizia C, et al. **Minerva Endocrinol** 1997 Jun;22(2):45–50 (Eng. Abstr.) **(Ita)**

BLOOD SUPPLY

Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Delahunt B, et al. **Br J Urol** 1997 Sep;80(3):401–4

CHEMISTRY

EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Fischer-Colbrie J, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):613–9

Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. Yanagibashi T, et al. **Br J Cancer** 1997; 76(7):829–35

In situ detection of parathyroid hormone-related protein in ovarian clear cell carcinoma. Kitazawa R, et al. **Hum Pathol** 1997 Mar;28(3):379–82

Clear cell carcinoma of the gallbladder. A histological and immunohistochemical study. Bittinger A, et al. **Pathol Res Pract** 1995 Dec;191(12):1259–65; discussion 1266

Reduplicated basal lamina in clear-cell carcinoma of the ovary: an immunohistochemical and electron microscopic study. Kwon TJ, et al. **Ultrastruct Pathol** 1996 Nov-Dec; 20(6):529–36

COMPLICATIONS

Digital necrosis with Ogilvie's syndrome. Wright GD, et al. **Ann Rheum Dis** 1997 Apr;56(4):224–5

Spontaneous renal hemorrhage associated with renal tumors. Mydlo JH, et al. **Clin Imaging** 1997 Jul-Aug;21(4):287–9

[Multiple clear cell kidney cysts and in situ renal clear cell carcinoma in a case of Hippel-Lindau disease] Bralet MP, et al. **Ann Pathol** 1996;16(3):207–9 (Eng. Abstr.) **(Fre)**

[Massive hemorrhage from a gastric neuroma associated with a kidney neoplasm] Lukasiewicz S, et al. **Wiad Lek** 1996; 49(7-12):124–6 (Eng. Abstr.) **(Pol)**

[Embolism of the small branches of the pulmonary artery in x-ray endovascular occlusion of the renal vessels in cancer] Iurin AG. **Arkh Patol** 1996 Nov-Dec;58(6):62–4 (9 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Fine-needle aspiration of metastatic clear cell carcinoma of the kidney: employment of microdissection and the polymerase chain reaction as a potential diagnostic tool. Beaty MW, et al. **Cancer** 1997 Jun 25;81(3):180–6

A pregnant woman with clear cell adenocarcinoma of the ovary arising from endometriosis and with benign and borderline adenofibroma of the clear cell and endometrioid types. Sugiyama T, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72(1):47–50

Lipid in renal clear cell carcinoma: detection on opposed-phase gradient-echo MR images [see comments] Outwater EK, et al. **Radiology** 1997 Oct;205(1):103–7. Comment in: Radiology 1997 Oct;205(1):39–40.

[Study on expression of proliferating cell nuclear antigen (PCNA) in ovarian cancer] Terauchi F, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Nov; 48(11):1058–62 (Eng. Abstr.) **(Jpn)**

[Analysis of clinical symptoms of renal clear cell carcinoma] Brzozowski C, et al. **Pol Merkuriusz Lek** 1996 Nov; 1(5):332–3 (Eng. Abstr.) **(Pol)**

[Renal adenocarcinoma in a girl 13 years old] Varo Solís C, et al. **Actas Urol Esp** 1997 Apr;21(4):398–401 (12 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Clear clinical remission of a diffuse metastasized ovarian clear cell carcinoma with third line chemotherapy. Debois JM. **Acta Obstet Gynecol Scand** 1997 Aug;76(7):709–12

Childhood renal tumours with intravascular extension. Mushtaq I, et al. **Br J Urol** 1996 Nov;78(5):772–6

Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Recio FO, et al. **Cancer** 1996 Nov 15; 78(10):2157–63

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Goff BA, et al. **Gynecol Oncol** 1996 Mar;60(3):412–7

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. Fennelly D, et al. **J Clin Oncol** 1997 Jan;15(1):187–92

[Efficacy of chemotherapy for clear cell adenocarcinoma of the ovary] Okubo T, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1279–83 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks. Hanselaar A, et al. **Cancer** 1997 Jun 1;79(11):2229–36

GENETICS

Deletion mapping on chromosome 10q25-q26 in human endometrial cancer. Nagase S, et al. **Br J Cancer** 1996 Dec; 74(12):1979–83

Inherited renal cell carcinoma. Maher ER. **Br J Urol** 1996 Oct;78(4):542–5 (45 ref.)

Comparison of DNA gains and losses in primary renal clear cell carcinomas and metastatic sites: importance of 1q and 3p copy number changes in metastatic events. Gronwald J, et al. **Cancer Res** 1997 Feb 1;57(3):481–7

Familial non-VHL non-papillary clear-cell renal cancer [letter] Teh BT, et al. **Lancet** 1997 Mar 22;349(9055):848–9

Losses at 3p common deletion sites in subtypes of kidney tumours: histopathological correlations. Hadaczek P, et al. **Virchows Arch** 1996 Sep;429(1):37–42

METABOLISM

Excessive formation of basement membrane substance in clear-cell carcinoma of the ovary: diagnostic value of the "raspberry body" in ascites cytology. Ito H, et al. **Diagn Cytopathol** 1997 Jun;16(6):500–4

bcl-2 expression in endometrial hyperplasia and carcinoma. Niemann TH, et al. **Gynecol Oncol** 1996 Dec;63(3):318–22

p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix [see comments] Waggoner SE, et al. **Gynecol Oncol** 1996 Mar;60(3):339–44 . Comment in: Gynecol Oncol 1996 Mar;60(3):337–8.

MORTALITY

Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Matthews RP, et al. **Gynecol Oncol** 1997 May;65(2):206–12

PATHOLOGY

Aspiration cytology of glycogen-rich squamous cell carcinoma: significance of a tigroid smear background [letter] Dusenbery D. **Acta Cytol** 1997 May-Jun; 41(3):941–2

Cytology of glycogen-rich (clear cell) carcinoma of the breast. A report of two cases. Kern SB, et al. **Acta Cytol** 1997 Mar-Apr;41(2):556–60

Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analyses. Ghazizadeh M, et al. **Am J Clin Pathol** 1997 Apr; 107(4):451–8

Female pseudohermaphroditism due to congenital adrenal hyperplasia complicated by adenocarcinoma of the prostate and clear cell carcinoma of the endometrium. Winters JL, et al. **Am J Clin Pathol** 1996 Nov;106(5):660–4

Esophageal metastasis from clear cell carcinoma of the kidney. Trentino P, et al. **Am J Gastroenterol** 1997 Aug; 92(8):1381–2

Clear cell carcinoma of the minor salivary glands. Report of a case. Triantafillidou E, et al. **Aust Dent J** 1997 Feb; 42(1):8–10

Cytologic features of clear cell carcinoma of the urethra and urinary bladder. Doria MI Jr, et al. **Diagn Cytopathol** 1996 Mar;14(2):150–4

Clear cell follicular adenoma of the thyroid: a case report. Sauer T, et al. **Diagn Cytopathol** 1996 Aug;15(2):124–6

Renal clear cell carcinoma appearing as a left neck mass. Boggess MA, et al. **Ear Nose Throat J** 1996 Sep; 75(9):620–22 (13 ref.)

Cytological distinction between clear cell carcinoma and yolk sac tumor of the ovary. Kuwashima Y, et al. **Eur J Gynaecol Oncol** 1996;17(5):345–50

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Goff BA, et al. **Gynecol Oncol** 1996 Mar;60(3):412–7

Clear cell malignant myoepithelioma of the salivary glands. Michal M, et al. **Histopathology** 1996 Apr;28(4):309–15

Evaluation with MIB1 antibody of proliferative activity in ovarian clear cell adenocarcinoma. Morimura Y, et al. **Int J Gynecol Pathol** 1996 Oct;15(4):315–9

Uterine cervical clear-cell adenocarcinoma with a choriocarcinomatous component: a case report. Morimura Y, et al. **J Obstet Gynaecol Res** 1996 Oct;22(5):437–41

Hyalinizing clear cell carcinoma: report of a case. Urban SD, et al. **J Oral Pathol Med** 1996 Nov;25(10):562–4

Clear cell adenocarcinoma of the urethra: a clinicopathologic analysis of 19 cases. Oliva E, et al. **Mod Pathol** 1996 May; 9(5):513–20

Clinicopathologic study on clear cell hepatocellular carcinoma. Yang SH, et al. **Pathol Int** 1996 Jul;46(7):503–9

Clear cell carcinoma of the gallbladder. A histological and immunohistochemical study. Bittinger A, et al. **Pathol Res Pract** 1995 Dec;191(12):1259–65; discussion 1266

Quantitative evaluation of apoptosis and proliferation in renal cell carcinoma. Correlation to tumor subtype, cytological grade according to thoenes-classification and the occurrence of metastasis. Hindermann W, et al. **Pathol Res Pract** 1997;193(1):1–7

Clear cell tumors of the breast. Dina R, et al. **Semin Diagn Pathol** 1997 Aug;14(3):175–82 (44 ref.)

Clear cell tumors of the alimentary tract and abdominal cavity. Ritter JH, et al. **Semin Diagn Pathol** 1997 Aug; 14(3):213–9 (42 ref.)

Clear cell tumors of the skin. Suster S. **Semin Diagn Pathol** 1996 Feb;13(1):40–59 (74 ref.)

Clear cell neoplasms of the endocrine system and thymus. Wick MR, et al. **Semin Diagn Pathol** 1997 Aug; 14(3):183–202 (84 ref.)

[Renal clear cell carcinoma in children] Brochériou I, et al. **Arch Anat Cytol Pathol** 1996;44(1):34–6 (Eng. Abstr.) **(Fre)**

[Carcinoid tumors of the lung] Kharchenko VP, et al. **Arkh Patol** 1996 Jul-Aug;58(4):48–56 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Vaginal clear cell adenocarcinoma in an infant. Yavuz H, et al. **Pediatr Hematol Oncol** 1996 Nov-Dec;13(6):577–80

RADIOGRAPHY

Renal cell carcinoma of clear type: correlation of CT features with tumor size, architectural patterns, and pathologic staging. Soyer P, et al. **Eur Radiol** 1997;7(2):224–9

[Can primary kidney clear cell adenocarcinoma be differentiated from kidney metastasis with computed tomography?] Le Normand S, et al. **Prog Urol** 1997 Jun; 7(3):403–7 (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Prognostic factors in endometrial carcinoma: risk groups and adjuvant radiotherapy. García-Doménech RV, et al. **Eur J Gynaecol Oncol** 1997;18(3):164–70

SECONDARY

Esophageal metastasis from clear cell carcinoma of the kidney. Trentino P, et al. **Am J Gastroenterol** 1997 Aug; 92(8):1381–2

Clear cell adenocarcinoma affecting the bladder, kidney and ureter—an unusual distribution. Ceccherini AF, et al. **Br J Urol** 1997 Apr;79(4):652–3

Fine-needle aspiration of metastatic clear cell carcinoma of the kidney: employment of microdissection and the polymerase chain reaction as a potential diagnostic tool. Beaty MW, et al. **Cancer** 1997 Jun 25;81(3):180–6

[Intraluminal metastasis of the common bile duct from renal carcinoma] Hakami F, et al. **Prog Urol** 1996 Jun;6(3):436–8 (9 ref.) (Eng. Abstr.) **(Fre)**

[Skull base metastasis from renal cell carcinoma presenting as abducens nerve paresis: report of two cases] Sagoh M, et al. **No Shinkei Geka** 1996 Sep;24(9):829–33 (Eng. Abstr.) **(Jpn)**

[Metastases of small intestine from lung cancer] Yamashita N, et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):186–9 (Eng. Abstr.) **(Jpn)**

[Metastasis of clear cell carcinoma of the kidney to the thyroid gland] Jamski J, et al. **Przegl Lek** 1997;54(2):135–6 (Eng. Abstr.) **(Pol)**

SURGERY

Second-look operation in clear cell carcinoma of the ovary. Nishida T, et al. **Int J Gynaecol Obstet** 1997 Sep; 58(3):331–2

THERAPY

Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Onda T, et al. **Br J Cancer** 1997;75(12):1836–41

Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Abeler VM, et al. **Cancer** 1996 Oct 15; 78(8):1740–7

ULTRASTRUCTURE

The prognostic value of semiquantitative nuclear grading in endometrial carcinomas. Hachisuga T, et al. **Gynecol Oncol** 1997 Apr;65(1):115–20

Reduplicated basal lamina in clear-cell carcinoma of the ovary: an immunohistochemical and electron microscopic study. Kwon TJ, et al. **Ultrastruct Pathol** 1996 Nov–Dec; 20(6):529–36

Clear-cell carcinoma: an ultrastructural study of 57 tumors from various sites. Kwon TJ, et al. **Ultrastruct Pathol** 1996 Nov–Dec;20(6):519–27

ADENOCARCINOMA, FOLLICULAR

Ectopic thyroid malignancy in the right ventricle of the heart. Hirnle T, et al. **Eur J Cardiothorac Surg** 1997 Jul; 12(1):147–9

Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. Dottorini ME, et al. **J Nucl Med** 1997 May;38(5):669–75

[Differentiated thyroid cancer in Arabs in northern Israel] Zidan J, et al. **Harefuah** 1997 Jan 1;132(1):6–9, 72 (Eng. Abstr.) **(Heb)**

[Thyroid carcinoma. Retrospective analysis of case records of the III. Surgery Department at the Umberto I Clinics in Rome in the years 1990–93] Picchi P, et al. **Minerva Endocrinol** 1996 Dec;21(4):115–21 (Eng. Abstr.) **(Ita)**

BLOOD

Measuring serum thyroglobulin in patients with follicular thyroid nodule: its diagnostic implications. Okamoto T, et al. **Endocr J** 1997 Feb;44(1):187–93

The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Roelants V, et al. **Eur J Nucl Med** 1997 Jul;24(7):722–7

BLOOD SUPPLY

Angiogenesis in follicular tumors of the thyroid. Segal K, et al. **J Surg Oncol** 1996 Oct;63(2):95–8

CHEMICALLY INDUCED

Follicular cell carcinoma of the thyroid in a child after bone marrow transplantation for acute lymphoblastic leukemia. Rovelli A, et al. **Acta Haematol** 1997;97(4):225–7

CHEMISTRY

E-cadherin gene alterations are rare events in thyroid tumors. Soares P, et al. **Int J Cancer** 1997 Jan 6;70(1):32–8

Proton magnetic resonance and human thyroid neoplasia III. Ex vivo chemical-shift microimaging. Rutter A, et al. **J Magn Reson B** 1996 Mar;110(3):240–8

Mixed medullary-follicular carcinoma of the thyroid. A morphological, immunohistochemical and in situ hybridization analysis of 11 cases. Papotti M, et al. **Virchows Arch** 1997 May;430(5):397–405

COMPLICATIONS

Thyroid storm due to functioning metastatic thyroid carcinoma in a burn patient. Naito Y, et al. **Anesthesiology** 1997 Aug;87(2):433–5

Metastatic thyroid cancer with hyperthyroidism. Kobayashi T, et al. **Eur J Surg** 1997 Jan;163(1):67–8

Right ventricular outflow tract obstruction by cardiac metastasis as the first manifestation of follicular thyroid carcinoma. Kasprzak JD, et al. **J Am Soc Echocardiogr** 1996 Sep–Oct;9(5):733–5

[Tracheal stenosis as the presenting form of follicular thyroid carcinoma] Carrión Valero F, et al. **An Med Interna** 1996 Jun;13(6):282–4 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Clinical presentations and treatment for 74 occult thyroid carcinoma. Comparison with nonoccult thyroid carcinoma in Taiwan. Lin JD, et al. **Am J Clin Oncol** 1996 Oct; 19(5):504–8

Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Umbricht CB, et al. **Cancer Res** 1997 Jun 1;57(11):2144–7

Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. Franceschi M, et al. **J Nucl Med** 1996 Mar;37(3):446–51

Thyroid carcinoma as first manifestation of familial adenomatous polyposis. Stigt JA, et al. **Neth J Med** 1996 Sep;49(3):116–8 (17 ref.)

Thyroid cancers. I. Papillary, follicular, and Hürthle cell. Goldman ND, et al. **Otolaryngol Clin North Am** 1996 Aug; 29(4):593–609 (41 ref.)

Insular component as a risk factor of thyroid carcinoma. Sasaki A, et al. **Pathol Int** 1996 Dec;46(12):939–46

Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Miettinen M, et al. **Virchows Arch** 1996 Nov;429(4–5):213–9

[Clinical aspects and preoperative diagnosis in differentiated thyroid gland carcinoma] Mann K, et al. **Zentralbl Chir** 1997;122(4):246–51 (41 ref.) (Eng. Abstr.) **(Ger)**

[Hyperthyroidism and carcinoma of the thyroid gland] Ardito G, et al. **Ann Ital Chir** 1997 Jan–Feb;68(1):23–7; discussion 27–8 (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma. Olveira G, et al. **Clin Endocrinol (Oxf)** 1997 Jun;46(6):707–11

EPIDEMIOLOGY

Parental cancer and risk of papillary and follicular thyroid carcinoma. Galanti MR, et al. **Br J Cancer** 1997;75(3):451–6

Follicular cell-derived thyroid carcinomas. Grebe SK, et al. **Cancer Treat Res** 1997;89:91–140 (264 ref.)

Risk factors of thyroid cancer among women in Tokai, Japan. Takezaki T, et al. **J Epidemiol** 1996 Sep;6(3):140–7

ETIOLOGY

Reproductive history and cigarette smoking as risk factors for thyroid cancer in women: a population-based case-control study. Galanti MR, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jun;5(6):425–31

[Development of a thyroid carcinoma after irradiation of the head/neck region] Grobholz R, et al. **Dtsch Med Wochenschr** 1997 Mar 21;122(12):362–5 (Eng. Abstr.) **(Ger)**

GENETICS

Parental cancer and risk of papillary and follicular thyroid carcinoma. Galanti MR, et al. **Br J Cancer** 1997;75(3):451–6

Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Tung WS, et al. **Genes Chromosomes Cancer** 1997 May;19(1):43–51

METABOLISM

Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein. Lazzereschi D, et al. **Cancer Res** 1997 May 15;57(10):2071–6

Effect of co-culture with thyroid follicular cells on expression of calcitonin gene in parafollicular TT cells. Zabel M, et al. **Folia Histochem Cytobiol** 1996;34 Suppl 1:65–6

p53 in a thyroid follicular carcinoma with foci of poorly differentiated and anaplastic carcinoma. Matias-Guiu X, et al. **Pathol Res Pract** 1996 Dec;192(12):1242–9; discussion 1250–1

MORTALITY

Follicular carcinoma of the thyroid [letter; comment] Anand A, et al. **Head Neck** 1996 Nov–Dec;18(6):582. Comment on: Head Neck 1996 Mar–Apr;18(2):118–24; discussion 124–6.

Survival of differentiated thyroid carcinoma studied in 500 patients. Lerch H, et al. **J Clin Oncol** 1997 May; 15(5):2067–75

[Identification and validation of prognostic factors in differentiated thyroid carcinoma] Gómez Arnaiz N, et al. **Med Clin (Barc)** 1997 Jan 18;108(2):45–9 (Eng. Abstr.) **(Spa)**

PATHOLOGY

Follicular neoplasms of the thyroid. Decision tree approach using morphologic and morphometric parameters. Deshpande V, et al. **Acta Cytol** 1997 Mar–Apr;41(2):369–76

Microinvasive follicular thyroid carcinoma detected by fine needle aspiration skeletal metastases. A case report. Dhimes P, et al. **Acta Cytol** 1997 Mar–Apr;41(2):565–8

Thyroid follicular neoplasms diagnosed by high-resolution ultrasonography with fine needle aspiration cytology. Lin JD, et al. **Acta Cytol** 1997 May–Jun;41(3):687–91

Preservation of recurrent laryngeal nerve invaded by differentiated thyroid cancer. Nishida T, et al. **Ann Surg** 1997 Jul;226(1):85–91

Poorly differentiated carcinoma of the thyroid: an aggressive type of tumour arising from thyroid follicular epithelium. Sakamoto A. **Curr Top Pathol** 1997;91:45–50 (22 ref.)

Minimally invasive follicular thyroid carcinoma: a clinico-pathological study. Schmid KW, et al. **Curr Top Pathol** 1997;91:37–43

Follicular carcinoma arising in ectopic thyroid tissue: case report with fine-needle aspiration findings. Subramony C, et al. **Diagn Cytopathol** 1997 Jan;16(1):39–41

Effect of co-culture with thyroid follicular cells on expression of calcitonin gene in parafollicular TT cells. Zabel M, et al. **Folia Histochem Cytobiol** 1996;34 Suppl 1:65–6

Follicular carcinoma in lingual thyroid presenting as a latero-cervical mass. Case report and review of the literature. Bigotti G, et al. **J Oral Pathol Med** 1997 Mar; 26(3):142–6 (37 ref.)

Follicular carcinoma of the thyroid appearing as a solitary renal mass [letter] Lam KY, et al. **Nephron** 1996;73(2):323–4

Late bone metastasis from an encapsulated follicular carcinoma of the thyroid without capsular and vascular invasion. Mizukami Y, et al. **Pathol Int** 1996 Jun; 46(6):457–61

Oncofetal expression of blood group-related antigen on morules in thyroid carcinoma. Okamoto Y, et al. **Pathol Int** 1996 Nov;46(11):867–73

Special features of childhood and juvenile thyroid carcinomas. Balázs G, et al. **Surg Today** 1996;26(7):536–40

Mixed medullary-follicular carcinoma of the thyroid. A morphological, immunohistochemical and in situ hybridization analysis of 11 cases. Papotti M, et al. **Virchows Arch** 1997 May;430(5):397–405

[Role of nuclear medicine in the diagnosis and treatment of macroscopic metastases] Chatal LF. **Ann Endocrinol (Paris)** 1997;58(3):248–50 (6 ref.) (Eng. Abstr.) **(Fre)**

[Anatomo-pathology and histological prognosis of follicular thyroid carcinoma] de Micco C. **Ann Endocrinol (Paris)** 1997;58(3):172–82 (96 ref.) (Eng. Abstr.) **(Fre)**

[Mediastinal metastasis of differentiated thyroid cancers. Treatment by total mediastinal curettage in 9 cases] Sarrazin R, et al. **Ann Endocrinol (Paris)** 1997;58(3):242–7 (Eng. Abstr.) **(Fre)**

[Is hemithyroidectomy as standard intervention of suspicious puncture cytology justified?] Friedrich J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:189–91 (Eng. Abstr.) **(Ger)**

[T3 hyperthyroidism with metastatic follicular thyroid carcinoma in substitution therapy] Lang M, et al. **Nuklearmedizin** 1996 Oct;35(5):186–9 (Eng. Abstr.) **(Ger)**

[Autonomy and malignancy of thyroid glad tumors. A critical analysis of the literature on the existence of hyperfunctioning follicular and papillary thyroid gland carcinomas] Schröder S, et al. **Pathologe** 1996 Sep; 17(5):349–57 (74 ref.) (Eng. Abstr.) **(Ger)**

[The "cold" nodule of the thyroid gland: 20 years experience with 2,071 patients and diagnostic limits of fine needle biopsy] Raber W, et al. **Wien Klin Wochenschr** 1997 Feb 28;109(4):116–22 (Eng. Abstr.) **(Ger)**

[Significance of lymph node metastases of differentiated thyroid gland carcinomas and C-cell carcinomas for prognosis—a meta-analysis] Witte J, et al. **Zentralbl Chir** 1997;122(4):259–65 (Eng. Abstr.) **(Ger)**

[Pathohistologic procedures in encapsulated follicular tumors of the thyroid gland] Separović V, et al. **Lijec Vjesn** 1996 May–Jun;118(5–6):138–41 (Eng. Abstr.) **(Scr)**

[Follicular carcinoma originating in the lingual thyroid: a case report] Polo Tomás I, et al. **Acta Otorrinolaringol Esp** 1996 Sep–Oct;47(5):407–10 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Follicular carcinoma of the thyroid appearing as a solitary renal mass [letter] Lam KY, et al. **Nephron** 1996;73(2):323–4

RADIONUCLIDE IMAGING

Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer. Carril JM, et al. **J Nucl Med** 1997 May;38(5):686–92

Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. Muratet JP, et al. **J Nucl Med** 1997 Sep;38(9):1362–8

RADIOTHERAPY

False-positive I-131 whole-body imaging after I-131 therapy for a follicular carcinoma. Andreas J, et al. **Clin Nucl Med** 1997 Feb;22(2):123–4

ADENOCARCINOMA, FOLLICULAR

I-131 accumulation in folliculitis of the scalp. Kinuya S, et al. **Clin Nucl Med** 1996 Oct;21(10):807-8

Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors. Challeton C, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 1;37(1):163-9

Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Mazzaferri EL. **Thyroid** 1997 Apr; 7(2):265-71

SECONDARY

Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Shaha AR, et al. **Am J Surg** 1996 Dec;172(6):692-4

Skin metastases from follicular thyroid carcinoma: a case report. Kuo MC, et al. **Chang Keng I Hsueh** 1996 Mar; 19(1):77-82

Right ventricular outflow tract obstruction by cardiac metastasis as the first manifestation of follicular thyroid carcinoma. Kasprzak JD, et al. **J Am Soc Echocardiogr** 1996 Sep-Oct;9(5):733-5

A giant metastasis from follicular thyroid carcinoma. Caracò C, et al. **J Chemother** 1997 Apr;9(2):159-60

False-positive iodine-131 whole-body scans due to cholecystitis and sebaceous cyst. Brucker-Davis F, et al. **J Nucl Med** 1996 Oct;37(10):1690-3

Factors that predict metastasis of papillary and follicular thyroid cancers in Taiwan. Lin JD, et al. **Otolaryngol Head Neck Surg** 1997 Apr;116(4):475-82

[Selective organ metastasis in follicular thyroid gland carcinoma] Hoelting T, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:761-4 (Eng. Abstr.) **(Ger)**

[Primary cerebral T-cell lymphoma] Vajtai I, et al. **Orv Hetil** 1996 Mar 24;137(12):637-41 (32 ref.) (Eng. Abstr.) **(Hun)**

SURGERY

Well-differentiated thyroid carcinoma. Segal K, et al. **Am J Otolaryngol** 1996 Nov-Dec;17(6):401-6

Surgical complications after total thyroidectomy and resections for differentiated thyroid carcinoma. Sand J, et al. **Ann Chir Gynaecol** 1996;85(4):305-8

Preservation of recurrent laryngeal nerve invaded by differentiated thyroid cancer. Nishida T, et al. **Ann Surg** 1997 Jul;226(1):85-91

Low-risk differentiated thyroid cancer: the need for selective treatment. Shaha AR, et al. **Ann Surg Oncol** 1997 Jun; 4(4):328-33

Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma. Scheumann GF, et al. **Eur J Surg** 1996 Sep;162(9):677-84

Surgical treatment of papillary and follicular thyroid carcinoma. Lin JD, et al. **Int Surg** 1996 Jan-Mar;81(1):61-6

Postsurgical management of differentiated thyroid carcinoma. Mazzaferri EL, et al. **Otolaryngol Clin North Am** 1996 Aug;29(4):637-62 (115 ref.)

Selective treatment of differentiated thyroid carcinoma. Gemsenjäger E, et al. **World J Surg** 1997 Jun;21(5):546-51; discussion 551-2

Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. Simon D, et al. **World J Surg** 1996 Sep;20(7):860-6; discussion 866

[The results after an organ-preserving operation and total thyroidectomy in differentiated thyroid carcinoma] Mziuad A, et al. **Khirurgiia (Sofiia)** 1996;49(6):33-7 (Eng. Abstr.) **(Bul)**

[Loco-regional persistence and recurrences of operated differentiated thyroid cancers. 22 cases on 589 treated patients from 1964 to 1990, follow-up from 5 to 31 years] Proye C, et al. **Ann Endocrinol (Paris)** 1997;58(3):233-9; discussion 240-1 (Eng. Abstr.) **(Fre)**

[Treatment of differentiated thyroid cancer. Management of invasive cancer] Squifflet JP. **Ann Endocrinol (Paris)** 1997; 58(3):225-8 (12 ref.) **(Fre)**

[Management of differentiated thyroid cancer of nodular type] Visset J, et al. **Ann Endocrinol (Paris)** 1997; 58(3):216-24 (56 ref.) (Eng. Abstr.) **(Fre)**

[How good is the prognosis in differentiated thyroid gland carcinoma] Ommer A, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:192-5 (Eng. Abstr.) **(Ger)**

[Is total thyroidectomy and lymph node excision as therapy of differentiated thyroid gland carcinomas in childhood justified?] Witte J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:196-8 (Eng. Abstr.) **(Ger)**

[Surgical therapy of differentiated thyroid gland carcinoma] Walgenbach S, et al. **Zentralbl Chir** 1997;122(4):252-8 (43 ref.) (Eng. Abstr.) **(Ger)**

[Nodular goiter and thyroid cancer] Valdina EA. **Vestn Khir Im I I Grek** 1997;156(2):23-6 (Eng. Abstr.) **(Rus)**

THERAPY

[Invasive differentiated thyroid cancers: discussion of therapeutics, multidisciplinary approach] Andry G. **Ann Endocrinol (Paris)** 1997;58(3):229-32 (19 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of differentiated thyroid cancers of nodular type] Tourniaire J, et al. **Ann Endocrinol (Paris)** 1997;58(3):211-5 (40 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of differentiated thyroid cancers in children. Study and follow-up of a series of 130 cases at the Gustave-Roussy Institute] Travagli JP, et al. **Ann Endocrinol (Paris)** 1997;58(3):254-6 **(Fre)**

ULTRASONOGRAPHY

Thyroid follicular neoplasms diagnosed by high-resolution ultrasonography with fine needle aspiration cytology. Lin JD, et al. **Acta Cytol** 1997 May-Jun;41(3):687-91

ULTRASTRUCTURE

Usefulness of nucleolar organiser region staining (AgNORs) in the evaluation of follicular tumours of the thyroid. Dzięcioł J, et al. **Folia Histochem Cytobiol** 1996;34 Suppl 1:35-6

Insular (poorly differentiated) carcinoma of the thyroid: an ultrastructural and immunocytochemical study of two cases. Begin LR, et al. **J Submicrosc Cytol Pathol** 1996 Jan;28(1):121-31

ADENOCARCINOMA, GRANULAR CELL see **ADENOCARCINOMA**

ADENOCARCINOMA, MUCINOUS

Bladder adenocarcinoma during pregnancy: a case report. FitzGerald MP, et al. **J Reprod Med** 1996 Jan;41(1):59-63

Primary mucinous carcinoma of the skin. Report of case. Boscaino A, et al. **Pathologica** 1995 Dec;87(6):689-91

Mucinous adenocarcinoma of the male urethra. Nishimura K, et al. **Urol Int** 1996;57(4):246-8

CHEMISTRY

EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Fischer-Colbrie J, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):613-9

Histochemical analysis of estrogen and progesterone receptors and gastric-type mucin in mucinous ovarian tumors with reference to their pathogenesis. Shiohara S, et al. **Cancer** 1997 Sep 1;80(5):908-16

Intraductal papillary-mucinous neoplasm of the pancreas: a report of five cases with immunohistochemical findings. Kench JG, et al. **Pathology** 1997 Feb;29(1):7-11

COMPLICATIONS

Gastric adenocarcinoma with microangiopathic hemolytic anemia and disseminated intravascular coagulation: a case report. Jiang CF, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Mar;59(3):204-9

Adenocarcinoma arising from a strictureplasty site in Crohn's disease. Report of a case. Marchetti F, et al. **Dis Colon Rectum** 1996 Nov;39(11):1315-21

Carcinoma of the gall-bladder producing mucous obstruction of the common bile duct: a cautionary note. Hughes OD, et al. **J R Coll Surg Edinb** 1997 Aug;42(4):280-2

Non occlusive ileocaecocolic intussusception caused by caecum cancer--case report. De Monti M, et al. **Swiss Surg** 1996;2(5):201-2

[Crohn's disease and intestinal carcinoma: presentation of 2 cases and review of the literature] Picardi P, et al. **Pathologica** 1995 Oct;87(5):513-7 (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Intraductal papillary-mucinous tumours of the pancreas. Clinical and radiological aspects. De Ronde T, et al. **Acta Gastroenterol Belg** 1996 Jul-Sep;59(3):208-10

Mucinous adenocarcinoma of urinary bladder type arising from the prostatic urethra. Distinction from mucinous adenocarcinoma of the prostate. Tran KP, et al. **Am J Surg Pathol** 1996 Nov;20(11):1346-50

Pancreatic mucinous ductal ectasia and intraductal papillary neoplasms. A single malignant clinicopathologic entity. Rivera JA, et al. **Ann Surg** 1997 Jun;225(6):637-44; discussion 644-6

Sister Joseph's nodule. Leow CK, et al. **Can J Surg** 1997 Jun;40(3):167

The value of pancreatoscopy in patients with mucinous ductal ectasia. Seo DW, et al. **Endoscopy** 1997 May; 29(4):315-8

Invasive mucinous carcinoma of the breast missed by contrast-enhancing MR imaging of the breast. Fischer U, et al. **Eur Radiol** 1996;6(6):929-31

Pancreatoscopy and diagnosis of mucinous neoplasms of the pancreas. Schoonbroodt D, et al. **Gastrointest Endosc** 1996 Oct;44(4):479-82

Microglandular adenocarcinoma of the endometrium: a form of mucinous adenocarcinoma that may be confused with microglandular hyperplasia of the cervix. Zaloudek C, et al. **Int J Gynecol Pathol** 1997 Jan;16(1):52-9

A case of intraductal papillary tumor of pancreas associated with mucinous ductal ectasia. Baek IS, et al. **Korean J Intern Med** 1997 Jan;12(1):100-4 (11 ref.)

Primary mucinous carcinoma of the skin. Abe S, et al. **Plast Reconstr Surg** 1997 Apr;99(4):1160-4

Clinics in diagnostic imaging (22). Calcified peritoneal carcinomatosis. Wong LL, et al. **Singapore Med J** 1997 Feb;38(2):88-91

The unusual presentation of mucinous carcinoma in the colon making preoperative diagnosis difficult: report of a case. Baba M, et al. **Surg Today** 1996;26(2):123-5

[Pincoffs-Bard's syndrome in a 15-year old girl] Pakulski C, et al. **Pneumonol Alergol Pol** 1996;64(11-12):809-14 (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Clinicopathological trends in colorectal carcinoma in a Black South African population. Degiannis E, et al. **Trop Gastroenterol** 1995 Oct-Dec;16(4):55-61

Mucinous adenocarcinoma of the renal pelvis in natives of India. Terris MK, et al. **Urol Int** 1997;58(2):121-3 (21 ref.)

[Ovarian cancer in Israel, 1960-1989] Mor-Yosef S, et al. **Harefuah** 1997 Feb 2;132(3):153-5, 240 (Eng. Abstr.) **(Heb)**

ETIOLOGY

Histochemical analysis of estrogen and progesterone receptors and gastric-type mucin in mucinous ovarian tumors with reference to their pathogenesis. Shiohara S, et al. **Cancer** 1997 Sep 1;80(5):908-16

GENETICS

Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Tapper J, et al. **Br J Cancer** 1997;75(12):1782-7

Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Kondo H, et al. **Cancer** 1997 Mar 1;79(5):900-5

Microsatellite instability is associated with the histological features of the tumor in nonfamilial colorectal cancer. Risio M, et al. **Cancer Res** 1996 Dec 1;56(23):5470-4

Using genetic information to make surgical decisions: report of a case of a 13-year-old boy with colon cancer. Madlensky L, et al. **Dis Colon Rectum** 1997 Feb;40(2):240-3

Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin. Werness BA, et al. **Hum Pathol** 1997 May;28(5):626-30

Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinico-pathological variables. Messerini L, et al. **J Pathol** 1997 Aug;182(4):380-4

Interphase cytogenetic analysis of mucinous ovarian neoplasms. Diebold J, et al. **Lab Invest** 1997 May; 76(5):661-70

[Findings of genetic changes in small intestinal carcinomas] Hirai A, et al. **Gan To Kagaku Ryoho** 1997 Jul;24 Suppl 2:332-6 (Eng. Abstr.) **(Jpn)**

METABOLISM

Overexpression of folate binding protein in ovarian cancers. Toffoli G, et al. **Int J Cancer** 1997 Apr 22;74(2):193-8

Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. Hanski C, et al. **J Pathol** 1997 Aug;182(4):385-91

Mucin-producing adenocarcinoma of the lung, with special reference to goblet cell type adenocarcinoma: immunohistochemical observation and Ki-ras gene mutation. Maeshima A, et al. **Pathol Int** 1997 Jul; 47(7):454-60

PATHOLOGY

Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analyses. Ghazizadeh M, et al. **Am J Clin Pathol** 1997 Apr; 107(4):451-8

Primary signet ring cell carcinoma of colorectum: an age- and sex-matched controlled study. Tung SY, et al. **Am J Gastroenterol** 1996 Oct;91(10):2195-9

Solid papillary carcinoma of the breast [letter; comment] Quinn CM, et al. **Am J Surg Pathol** 1997 Feb;21(2):256-8 . Comment on: Am J Surg Pathol 1995 Nov;19(11):1237-44.

Section thickness and mitotic counts in ovarian mucinous carcinoma. Methodological study with scanning confocal microscopy. Kujari HP, et al. **Anal Cell Pathol** 1996 May; 10(3):253-62

Colorectal cancer after pelvic irradiation: case reports. Tsunoda A, et al. **Anticancer Res** 1997 Jan-Feb; 17(1B):729-32

Periorbital solitary nodule and multiple small papules in a 63-year-old women. Primary mucinous carcinoma (nodule) and syringom (papules). Friednash M, et al. **Arch Dermatol** 1997 Sep;133(9):1161, 1164 (18 ref.)

Mucoid breast carcinomas: histology and prognosis. Fentiman IS, et al. **Br J Cancer** 1997;75(7):1061-5

Histopathology of breast cancer in relation to age. Fisher CJ, et al. **Br J Cancer** 1997;75(4):593-6

Immunocytochemical detection of p53 protein as an adjunct in cytologic diagnosis from pancreatic duct brushings in mucin-producing tumors of the pancreas. Iwao T, et al. **Cancer** 1997 Jun 25;81(3):163-71

Sweat gland carcinoma diagnosed by fine needle aspiration (FNA). Gottschalk-Sabag S, et al. **Cytopathology** 1996 Feb; 7(1):66-9

Peritoneal mucinous carcinomatosis. A possible explanation for an unusual laparoscopic appearance. Han SH, et al.

Dig Dis Sci 1997 Jun;42(6):1270–3
Invasive carcinoma in juvenile polyposis—report of a case in an African patient. Vaizey CJ, et al.
Eur J Surg Oncol 1997 Jun;23(3):272–4 (27 ref.)
Duct-ectatic type of mucin producing tumor of the pancreas—new concept of pancreatic neoplasia. Kimura W, et al. **Hepatogastroenterology** 1996 May–Jun; 43(9):692–709
Neuroendocrine differentiation in eccrine carcinoma [letter; comment] Banerjee SS, et al. **Histopathology** 1996 Oct; 29(4):389–90. Comment on: Histopathology 1995 Jul;27(1):82–6.
Mammary mucinous lesions: congeners, prevalence and important pathological associations. Chinyama CN, et al. **Histopathology** 1996 Dec;29(6):533–9
Mucinous cholangiocarcinoma: an unusual complication of hepatolithiasis and recurrent pyogenic cholangitis. Chow LT, et al. **Histopathology** 1997 May;30(5):491–4
Mucinous carcinoma of the skin. Karimipour DJ, et al.
J Am Acad Dermatol 1997 Feb;36(2 Pt 2):323–6
Adenocarcinoma combined with malignant peripheral nerve sheath tumor of the gallbladder. Chang BC, et al.
J Formos Med Assoc 1997 Jul;96(7):545–8
Mucinous adenocarcinoma of the sublingual gland. Krogdahl AS, et al. **J Oral Pathol Med** 1997 Apr;26(4):198–200
Mucinous adenocarcinoma arising from a suprapubic cystostomy site without bladder involvement. King DH, et al. **J Spinal Cord Med** 1997 Apr;20(2):244–6
Mucinous adenocarcinoma of the stomach–clinicopathological studies. Koufuji K, et al.
Kurume Med J 1996;43(4):289–94
Abdominal wall implantation of an endocervical-like mucinous borderline tumor. Measham C, et al.
Mod Pathol 1996 Apr;9(4):381–5
Mucinous adenocarcinoma arising in a giant urachal cyst associated with pseudomyxoma peritonei and stromal osseous metaplasia. Sasano H, et al. **Pathol Int** 1997 Jul; 47(7):502–5
Rectal adenocarcinoma with rhabdoid phenotype. Mačák J, et al. **Pathologica** 1995 Dec;87(6):696–9
Appendix carcinoma invading the urinary bladder. Dahms SE, et al. **Urol Int** 1997;58(2):124–7 (24 ref.)
Mucinous adenocarcinoma in the abomasum of a cow. Ritchey JW, et al. **Vet Pathol** 1996 Jul;33(4):454–6
Endocrine cells in intraductal papillary-mucinous neoplasms of the pancreas. A histochemical and immunohistochemical study. Terada T, et al. **Virchows Arch** 1997 Jul;431(1):31–6
[Studies on the phenotype deviation of the single-cell subclones of human stomach carcinoma MGC-803 cell line] Han YL, et al. **Shih Yen Sheng Wu Hsueh Pao** 1996 Mar;29(1):13–23 (Eng. Abstr.) **(Chi)**
[Intraductal papillary mucinous tumors of the pancreas. Clinical and morphological aspects in 30 patients] Barbe L, et al. **Gastroenterol Clin Biol** 1997;21(4):278–86 (Eng. Abstr.) **(Fre)**
[Intraductal papillary mucinous tumors of the pancreas. An emerging entity? (editorial)] Bernard JP, et al.
Gastroenterol Clin Biol 1997;21(4):275–7 **(Fre)**
[Clinico-pathological features and biological characterization of mucoid colorectal carcinoma] Lanza G Jr, et al.
Pathologica 1995 Dec;87(6):631–9 (32 ref.) (Eng. Abstr.) **(Ita)**
[A case of adenosquamous carcinoma of the esophagus, having signet ring cell carcinoma and mucinous adenocarcinoma in the component of well differentiated adenocarcinoma] Tomimatsu H, et al.
Nippon Shokakibyo Gakkai Zasshi 1996 Sep;93(9):644–9 (18 ref.) **(Jpn)**
[The morphological aspects of a study of the efficacy of chemotherapy in ovarian cancer] Iakymova TP, et al.
Lik Sprava 1996 Jul–Sep;(7–9):103–6 (Eng. Abstr.) **(Ukr)**

RADIOGRAPHY

Musculoskeletal case of the day. Metastatic carcinomatous arthritis from mucinous adenocarcinoma of the colon. Hatem SF, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):286, 291–2
High-resolution CT findings of mucinous bronchioloalveolar carcinoma: a case of pseudopulmonary alveolar proteinosis. Tan RT, et al. **AJR Am J Roentgenol** 1997 Jan; 168(1):99–100
Calcified gastric cancer—CT findings before and after chemotherapy. Case report and discussion of the pathogenesis of this type of calcification. Balestreri L, et al. **Clin Imaging** 1997 Mar–Apr;21(2):122–5
Breast imaging case of the day. Pure mucinous carcinoma with calcifying matrix. Wilson DA, et al. **Radiographics** 1997 May–Jun;17(3):800–4

RADIONUCLIDE IMAGING

Adenocarcinoma of a foregut cyst: detection with positron emission tomography. Smith SM, et al.
AJR Am J Roentgenol 1996 Nov;167(5):1153–4

SECONDARY

Musculoskeletal case of the day. Metastatic carcinomatous arthritis from mucinous adenocarcinoma of the colon. Hatem SF, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):286, 291–2
Solitary adenocarcinoma metastasis mimicking sarcomatous degeneration in Paget's disease. Conrad GR, et al.
Clin Nucl Med 1997 May;22(5):300–2
Peritoneal mucinous carcinomatosis. A possible explanation for an unusual laparoscopic appearance. Han SH, et al.
Dig Dis Sci 1997 Jun;42(6):1270–3
Metastatic mucinous adenocarcinoma of the heart. Arzouman DA, et al. **J Card Surg** 1997 Jan–Feb;12(1):49–50
Clinics in diagnostic imaging (22). Calcified peritoneal carcinomatosis. Wong LL, et al. **Singapore Med J** 1997 Feb;38(2):88–91
[Cardiac metastases from a colonic tumor] Teixeira H, et al. **Acta Med Port** 1997 Apr;10(4):331–4 (11 ref.) (Eng. Abstr.) **(Por)**

SECRETION

[Mucous-secreting breast cancer] Frank GA, et al.
Arkh Patol 1997 Jul–Aug;59(4):46–9 (Eng. Abstr.) **(Rus)**

SURGERY

Adenocarcinoma of the urachus: 3 case reports and a review of the literature. Mattelaer P, et al. **Acta Urol Belg** 1997 Mar;65(1):63–7 (18 ref.)
Rectal carcinoma in pregnancy. Gard GB, et al.
Aust N Z J Obstet Gynaecol 1996 May;36(2):161–4
Adenocarcinoma complicating an anorectal sinus in a patient with Crohn's disease. Lumley JW, et al.
Aust N Z J Surg 1997 Jan;67(1):66–7
Using genetic information to make surgical decisions: report of a case of a 13-year-old boy with colon cancer. Madlensky L, et al. **Dis Colon Rectum** 1997 Feb;40(2):240–3
Recurrent mucinous adenocarcinoma of the ovary presenting as an inguino-labial hernia. Ben-Hur H, et al.
Eur J Gynaecol Oncol 1996;17(4):299–302
Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions [see comments] White RE, et al. **J Am Coll Surg** 1996 Dec; 183(6):575–82. Comment in: J Am Coll Surg 1997 Jun;184(6):671–3.
Metastatic mucinous adenocarcinoma of the heart. Arzouman DA, et al. **J Card Surg** 1997 Jan–Feb;12(1):49–50
Is partial cystectomy the treatment of choice for mucinous adenocarcinoma of the urachus? Santucci RA, et al.
Urology 1997 Apr;49(4):536–40 (26 ref.)
[Pancreatectomy for intraductal papillary mucinous tumor of the pancreas] Partensky C, et al.
Gastroenterol Clin Biol 1996;20(11):938–45 (Eng. Abstr.) **(Fre)**
[Noninvasive mucinous cystic pancreas carcinoma with a 16-year course] Aletras H, et al. **Chirurg** 1996 Aug; 67(8):858–61 (Eng. Abstr.) **(Ger)**
[Mucinous adenocarcinomas of the large intestine in Crohn disease] Birkenmeier G, et al. **Chirurg** 1997 Jan;68(1):51–6 (Eng. Abstr.) **(Ger)**

THERAPY

Mucinous adenocarcinoma of the prostate: a report of a case of long-term survival [letter; comment] Teichman JM.
Urology 1996 Oct;48(4):660. Comment on: Urology 1996 Feb;47(2):256–8.
[Naloxone in ethanol overdose after alcoholization of hepatic metastasis] Iannarone C, et al. **Minerva Chir** 1996 Jul–Aug; 51(7–8):621–3 (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Endosonographic detection of a mucinous adenocarcinoma in an anal fistula. Cerwenka H, et al. **Endoscopy** 1997 May; 29(4):335

VETERINARY

Mucinous adenocarcinoma in the abomasum of a cow. Ritchey JW, et al. **Vet Pathol** 1996 Jul;33(4):454–6

ADENOCARCINOMA, OXYPHILIC see **ADENOCARCINOMA**

ADENOCARCINOMA, PAPILLARY

Primary carcinoma of the fallopian tube: report on two cases. Nappi R, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec;70(1):93–6

CHEMISTRY

Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. Yanagibashi T, et al. **Br J Cancer** 1997; 76(7):829–35

COMPLICATIONS

Papillary thyroid carcinoma associated with ulcerative colitis. Evgenikos N, et al. **Postgrad Med J** 1996 Oct;72(852):621–2
Adenocarcinoma in the anal canal associated with a fistula: report of a case. Taniguchi S, et al. **Surg Today** 1996; 26(9):707–10
[Two cases of papillary adenocarcinoma of the thyroid gland associated with chylothorax] Ishii T, et al.
Nippon Ronen Igakkai Zasshi 1997 May;34(5):421–7 (Eng. Abstr.) **(Jpn)**
[A case of double choledochus with early gallbladder cancer] Ohta H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan; 94(1):62–7 (23 ref.) **(Jpn)**
[A patient with thyroid carcinoma who developed consciousness disturbance during acyclovir administration for herpes zoster] Matsumoto R, et al.
Rinsho Shinkeigaku 1996 Apr;36(4):590–3 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Choledochal cyst with adenocarcinoma in the cystically dilated intrahepatic bile duct. Tajiri K, et al.
Abdom Imaging 1997 Mar–Apr;22(2):190–3
Increasing serum levels of alpha-fetoprotein in a patient with relapsing gallbladder carcinoma. Cocquyt V, et al.
Am J Clin Oncol 1996 Oct;19(5):465–8
Role of nuclear magnetic resonance spectroscopy (MRS) in cancer diagnosis and treatment: 31P, 23Na, and 1H MRS studies of three models of pancreatic cancer. Kaplan O, et al. **Cancer Res** 1997 Apr 15;57(8):1452–9
Early carcinoma of the gallbladder diagnosed by percutaneous cholecystoscopy. MacGillivray DC, et al.
Gastrointest Endosc 1997 Feb;45(2):207–10 (25 ref.)
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20–1997. A 74-year-old man with progressive cough, dyspnea, and pleural thickening [clinical conference] Scully RE, et al.
N Engl J Med 1997 Jun 26;336(26):1895–903
Aggressive digital papillary adenoma. Viroslav S, et al.
Orthopedics 1996 Oct;19(10):899–900

DRUG THERAPY

[A case of advanced gastric cancer showing complete disappearance of cancer cells in multiple liver metastases due to low-dose PMUE therapy] Ueda N, et al.
Gan To Kagaku Ryoho 1996 Nov;23(13):1833–6 (Eng. Abstr.) **(Jpn)**

METABOLISM

p53 overexpression and proliferative activity do not correlate with lymph node metastasis in early gastric cancer. Kanai T, et al. **Eur Surg Res** 1997;29(1):35–41

PATHOLOGY

Three histologically different tiny gastric cancers developing adjacent to each other, resected endoscopically in a single mucosal piece. Matsuhashi N, et al. **Am J Gastroenterol** 1996 Oct;91(10):2200–2
Papillary adenocarcinoma of the ciliary body simulating retinoblastoma. Günalp I, et al. **Am J Ophthalmol** 1997 Feb;123(2):268–9
Adenocarcinoma in situ of the uterine cervix progressing to invasive adenocarcinoma [see comments] Hocking GR, et al. **Aust N Z J Obstet Gynaecol** 1996 May;36(2):218–20. Comment in: Aust N Z J Obstet Gynaecol 1997 Feb;37(1):132–3.
Urachal carcinoma: a report of two cases. Lin CN, et al.
Chung Hua I Hsueh Tsa Chih (Taipei) 1995 Dec;56(6):436–9
Exfoliative cytology of papillary serous adenocarcinomas of the uterine cervix [letter] Nguyen GK, et al.
Diagn Cytopathol 1997 Jun;16(6):548–50
Enteric type villoglandular papillary adenocarcinoma of the uterine cervix associated with in situ squamous cell carcinoma. Case report and review of the literature. Skopelitou A, et al. **Eur J Gynaecol Oncol** 1996; 17(4):309–14 (42 ref.)
Intraductal papillary tumors and mucinous cystic tumors of the pancreas: clinicopathologic study of 38 cases. Fukushima N, et al. **Hum Pathol** 1997 Sep;28(9):1010–7
Papillary hurthle cell tumours of thyroid. Diagnostic features in eight cases with review of literature. Goyal A, et al.
Indian J Cancer 1996 Sep;33(3):130–5
Double cancers of the gallbladder and bile duct associated with anomalous choledochopancreatic duct junction. Nakao A, et al. **J Gastroenterol** 1997 Feb;32(1):110–3 (12 ref.)
Intestinal-type sinonasal adenocarcinoma: a sporadic case. Böör A, et al. **J Laryngol Otol** 1996 Aug;110(8):805–10
Adenocarcinoma of the esophagus in an 8-year-old boy [letter] Gangopadhyay AN, et al. **J Pediatr Surg** 1997 Aug; 32(8):1259–60 (8 ref.)
Papillary adenocarcinoma of the sigmoid colon associated with psammoma bodies and hyaline globules: report of a case. Nakayama H, et al. **Jpn J Clin Oncol** 1997 Jun; 27(3):193–6
Peripheral lung carcinomas associated with central fibrosis and mixed small cell and other histologic components. Usuda H, et al. **Pathol Int** 1995 Dec;45(12):940–6
Well-differentiated papillary villoglandular adenocarcinoma of the uterine cervix. Datta CK. **W V Med J** 1997 Jul–Aug; 93(4):186–8 (10 ref.)
[Low-grade papillary adenocarcinoma of the endolymphatic sac. Report of three cases with immunohistochemical study] Rouquette I, et al. **Ann Pathol** 1996 Sep;16(4):271–5 (Eng. Abstr.) **(Fre)**
[Is hemithyroidectomy as standard intervention of suspicious puncture cytology justified?] Friedrich J, et al.
Langenbecks Arch Chir Suppl Kongressbd 1996;113:189–91 (Eng. Abstr.) **(Ger)**
[Morphological changes in human colon carcinoma after chemotherapy with 5-fluorouracil—a study in the nude mouse model] Lohwasser S, et al. **Z Gastroenterol** 1997

ADENOCARCINOMA, PAPILLARY

May;35(5):319–26 (Eng. Abstr.) **(Ger)**

[Bellini duct carcinoma of kidney with invasive growth pattern: a case report] Jinza S, et al. **Hinyokika Kiyo** 1997 Apr;43(4):291–4 (Eng. Abstr.) **(Jpn)**

[Two cases of breast cancer, simultaneously associated with uterine cancer] Saito C, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jul;48(7):544–7 **(Jpn)**

RADIOGRAPHY

Cystic papillary adenocarcinoma of the submandibular gland in a child. Czarnecki EJ, et al. **AJNR Am J Neuroradiol** 1996 Jun–Jul;17(6):1038–40

Case report: malignant transformation of biliary cystadenoma with mesenchymal stroma: documentation by CT. Matsuoka Y, et al. **Clin Radiol** 1997 Apr;52(4):318–21

[Natural history of cloudy zone of pulmonary adenocarcinoma on HRCT] Koizumi N, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Sep; 56(11):715–9 (Eng. Abstr.) **(Jpn)**

SECONDARY

Low grade papillary adenocarcinoma of minor salivary gland origin. Diagnosis by fine needle aspiration cytology. Pisharodi LR. **Acta Cytol** 1997 Sep–Oct;41(5):1407–11

Increasing serum levels of alpha–fetoprotein in a patient with relapsing gallbladder carcinoma. Cocquyt V, et al. **Am J Clin Oncol** 1996 Oct;19(5):465–8

[A case of advanced gastric cancer showing complete disappearance of cancer cells in multiple liver metastases due to low–dose PMUE therapy] Ueda N, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1833–6 (Eng. Abstr.) **(Jpn)**

[A case of liver metastasis from so–called hepatoid adenocarcinoma of stomach with lipiodol accumulation] Ueda H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb; 93(2):120–5 (14 ref.) **(Jpn)**

SURGERY

Three histologically different tiny gastric cancers developing adjacent to each other, resected endoscopically in a single mucosal piece. Matsuhashi N, et al. **Am J Gastroenterol** 1996 Oct;91(10):2200–2

Polymorphous low–grade adenocarcinoma (PLGA) of the tongue [letter; comment] al–Otieschan AT, et al. **J Laryngol Otol** 1997 Feb;111(2):198. Comment on: J Laryngol Otol 1996 Jul;110(7):700–3.

Aggressive surgical treatment of digital papillary adenocarcinoma. Singla AK, et al. **Plast Reconstr Surg** 1997 Jun;99(7):2058–60

Resection of the inferior head of the pancreas: report of a case. Nakagohri T, et al. **Surg Today** 1996;26(8):640–4

[Papillary thyroid gland carcinoma in childhood] Hacker HW, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:205–7 (Eng. Abstr.) **(Ger)**

[How good is the prognosis in differentiated thyroid gland carcinoma] Ommer A, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:192–5 (Eng. Abstr.) **(Ger)**

[Is total thyroidectomy and lymph node excision as therapy of differentiated thyroid gland carcinomas in childhood justified?] Witte J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:196–8 (Eng. Abstr.) **(Ger)**

[Cancer of the gallbladder] Nardi M, et al. **Minerva Chir** 1997 May;52(5):583–7 (Eng. Abstr.) **(Ita)**

[Surgical treatment to the lung cancer in a patient receiving hemodialysis] Yamamoto N, et al. **Kyobu Geka** 1996 Aug; 49(9):787–90 (Eng. Abstr.) **(Jpn)**

THERAPY

Role of nuclear magnetic resonance spectroscopy (MRS) in cancer diagnosis and treatment: 31P, 23Na, and 1H MRS studies of three models of pancreatic cancer. Kaplan O, et al. **Cancer Res** 1997 Apr 15;57(8):1452–9

VETERINARY

Papillary ductal adenocarcinoma in the mammary glands of two horses. Reppas GP, et al. **Vet Rec** 1996 May 25; 138(21):518–9

ADENOCARCINOMA, RENAL CELL see **CARCINOMA, RENAL CELL**

ADENOCARCINOMA, SCIRRHOUS

DIAGNOSIS

[A case of synchronous cancer of the stomach and colon] Sheptulin AA, et al. **Klin Med (Mosk)** 1996;74(9):64–6 **(Rus)**

DRUG THERAPY

Tranilast (N–(3,4–dimethoxycinnamoyl) anthranilic acid) down–regulates the growth of scirrhous gastric cancer. Yashiro M, et al. **Anticancer Res** 1997 Mar–Apr; 17(2A):895–900

Pilot study for preoperative administration of l–OHP to patients with advanced scirrhous type gastric cancer. Eriguchi M, et al. **Biomed Pharmacother** 1997;51(5):217–20

Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin. Suga S, et al. **Intern Med** 1996 Dec;35(12):930–6

PATHOLOGY

Differential responses of scirrhous and well–differentiated gastric cancer cells to orthotopic fibroblasts. Yashiro M, et al. **Br J Cancer** 1996 Oct;74(7):1096–103

Localization of binding sites of Ulex europaeus I, Helix pomatia and Griffonia simplicifolia I–B4 lectins and analysis of their backbone structures by several glycosidases and poly–N–acetyllactosamine–specific lectins in human breast carcinomas. Ito N, et al. **Histochem Cell Biol** 1996 Sep; 106(3):331–9

CD44H plays an important role in peritoneal dissemination of scirrhous gastric cancer cells. Nishimura S, et al. **Jpn J Cancer Res** 1996 Dec;87(12):1235–44

RADIOTHERAPY

Pleurocutaneous fistula as a complication of radiation treatment in locally advanced breast cancer. Samuel LM, et al. **J R Coll Surg Edinb** 1997 Apr;42(2):138–9

SECONDARY

Role of alpha 2 beta 1– and alpha 3 beta 1–integrin in the peritoneal implantation of scirrhous gastric carcinoma. Nishimura S, et al. **Br J Cancer** 1996 Nov;74(9):1406–12

Transforming growth factor–beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Inoue T, et al. **Jpn J Cancer Res** 1997 Feb;88(2):152–9

[Enophthalmos caused by orbital metastasis of breast carcinoma] Lagrèze WD, et al. **Klin Monatsbl Augenheilkd** 1997 Jul;211(1):68–9 (Eng. Abstr.) **(Ger)**

SURGERY

Extended surgery—left upper abdominal exenteration plus Appleby's method—for type 4 gastric carcinoma. Furukawa H, et al. **Ann Surg Oncol** 1997 Apr–May; 4(3):209–14

Pilot study for preoperative administration of l–OHP to patients with advanced scirrhous type gastric cancer. Eriguchi M, et al. **Biomed Pharmacother** 1997;51(5):217–20

Surgically curable and incurable scirrhous carcinomas of the stomach. Kinugasa S, et al. **J Surg Oncol** 1997 Jul; 65(3):194–200

[A rare combination of stomach cancer and a foreign body of the abdominal cavity] Munasypov FR, et al. **Klin Khir** 1995;(1):48 **(Rus)**

ULTRASONOGRAPHY

[Potentialities of ultrasound examination in differential diagnosis of benign nodules and breast cancer] Vetshev PS, et al. **Khirurgiia (Mosk)** 1997;(6):15–20 (Eng. Abstr.) **(Rus)**

ADENOCARCINOMA, SEBACEOUS

DIAGNOSIS

Ocular sebaceous carcinoma. Two unusual cases, and their histochemical and immunohistochemical findings. Sugiki H, et al. **Dermatology** 1996;192(4):364–7

PATHOLOGY

Diffuse intraepithelial sebaceous carcinoma of the conjunctiva [letter] Loeffler KU, et al. **Br J Ophthalmol** 1997 Feb;81(2):168

Sebaceous carcinoma of the vulva: a case report and review of the literature. Carlson JW, et al. **Gynecol Oncol** 1996 Mar;60(3):489–91 (8 ref.)

Sebaceous carcinoma of buccal mucosa. Report of a case. Liu CJ, et al. **Int J Oral Maxillofac Surg** 1997 Aug; 26(4):293–4

Oral sebaceous carcinoma: report of a case. Li TJ, et al. **J Oral Maxillofac Surg** 1997 Jul;55(7):751–4

SECONDARY

Metastatic lesion of the cervical spine secondary to an extraocular sebaceous carcinoma. Antuña SA, et al. **Acta Orthop Belg** 1996 Dec;62(4):229–32

An eyelid swelling with a parotid mass. Seenu V, et al. **Postgrad Med J** 1997 Feb;73(856):123–5

SURGERY

Sebaceous carcinoma of the eyelids: a review of six cases. Chee SP, et al. **Ann Acad Med Singapore** 1996 Mar; 25(2):273–8 (18 ref.)

Management of eyelid sebaceous carcinomas. Dogru M, et al. **Ophthalmologica** 1997;211(1):40–3

ADENOCARCINOMA, TUBULAR see **ADENOCARCINOMA**

ADENOFIBROMA

DIAGNOSIS

Longstanding ovarian serous cystadenofibroma sonographically mimicking a urachal cyst. Abulafia O, et al. **Acta Obstet Gynecol Scand** 1996 Aug;75(7):685–7

Pancreaticoduodenal tuberculosis simulating metastatic ovarian carcinoma. Zalev AH, et al. **Can J Gastroenterol** 1997 Jan–Feb;11(1):41–3

A pregnant woman with clear cell adenocarcinoma of the ovary arising from endometriosis and with benign and borderline adenofibroma of the clear cell and endometrioid types. Sugiyama T, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72(1):47–50

Bilateral serous cystadenofibromas clinically simulating hyperreactio luteinalis following controlled ovarian hyperstimulation and in vitro fertilization. Ditkoff EC, et al. **J Assist Reprod Genet** 1997 Apr;14(4):230–3

GENETICS

Monosomy 22 in a case of biliary adenofibroma [letter] Parada LA, et al. **Cancer Genet Cytogenet** 1997 Feb; 93(2):183–4

MORTALITY

The importance of histologic type on breast cancer survival. Northridge ME, et al. **J Clin Epidemiol** 1997 Mar; 50(3):283–90

PATHOLOGY

Papillary müllerian cystadenofibroma of the vagina. Kerner H, et al. **Histopathology** 1997 Jan;30(1):84–6

Ovarian fibromas and cystadenofibromas: MRI features of the fibrous component. Outwater EK, et al. **J Magn Reson Imaging** 1997 May–Jun;7(3):465–71

Papillary adenofibroma of the uterine cervix. A case report. Fratini D, et al. **Pathologica** 1996 Apr;88(2):135–6

ULTRASONOGRAPHY

Sonographic characteristics of adenofibroma of the endometrium following tamoxifen therapy for breast cancer: two case reports. Huang KT, et al. **Ultrasound Obstet Gynecol** 1996 May;7(5):363–6

ADENOHYPOPHYSIS see **PITUITARY GLAND, ANTERIOR**

ADENOIDECTOMY

Acoustic rhinometry in the pre–operative assessment of adenoidectomy candidates. Fisher EW, et al. **Acta Otolaryngol (Stockh)** 1995 Nov;115(6):815–22

Effect of tonsillectomy and adenoidectomy on obese children with sleep–associated breathing disorders. Kudoh F, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:216–8

Effect of surgery on obstructive sleep apnea. Nishimura T, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:231–3

Does adenotonsillectomy affect the course of bronchial asthma and nasal allergy? Saito H, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:212–5

Effects of adenoidectomy on sinusitis. Takahashi H, et al. **Acta Otorhinolaryngol Belg** 1997;51(2):85–7

Severe postadenoidectomy bleeding revealing congenital alpha 2 antiplasmin deficiency in a child. Paqueron X, et al. **Anesth Analg** 1997 May;84(5):1147–9

Clinical audit on tonsils and adenoid surgery. Is day surgery a reasonable option? Chee NW, et al. **Ann Acad Med Singapore** 1996 Mar;25(2):245–50

Predictive factors for respiratory complications after tonsillectomy and adenoidectomy in children. Biavati MJ, et al. **Arch Otolaryngol Head Neck Surg** 1997 May; 123(5):517–21

Efficacy of adenoidectomy in relieving symptoms of chronic sinusitis in children. Vandenberg SJ, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jul;123(7):675–8

IV perioperative ketoprofen in small children during adenoidectomy. Nikanne E, et al. **Br J Anaesth** 1997 Jan; 78(1):24–7

Day–case adenoidectomy—is it safe? Ahmed K, et al. **Clin Otolaryngol** 1993 Oct;18(5):406–9

Assessment of sequelae at home following adenotonsillectomy. A basis for day–case management? Benson–Mitchell R, et al. **Clin Otolaryngol** 1993 Aug; 18(4):282–4

Suitability of children for ENT day case procedures. Drake–Lee A, et al. **Clin Otolaryngol** 1997 Jun;22(3):215–8

Endoscopic adenoidectomy with the microdebrider. Yanagisawa E, et al. **Ear Nose Throat J** 1997 Feb;76(2):72, 74

Ondansetron decreases postoperative vomiting in pediatric patients undergoing tonsillectomy and adenoidectomy. Lawhorn CD, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jul;36(2):99–108

Dexamethasone in adenotonsillectomy. Tom LW, et al. **Int J Pediatr Otorhinolaryngol** 1996 Oct;37(2):115–20

Day–case adenoidectomy: how popular and safe in a rural environment? Siddiqui N, et al. **J Laryngol Otol** 1997 May; 111(5):444–6

How I do it: transnasal endoscopic approach to assist in difficult adenoidectomies. Janzen VD. **J Otolaryngol** 1997

Jun;26(3):213–4
Management of enuresis [letter; comment] Wengraf C. **Lancet** 1997 Jul 19;350(9072):221–2. Comment on: Lancet 1997 May 31;349(9065):1604.
Atlantoaxial subluxation after tonsillectomy and adenoidectomy. Onerci M, et al. **Otolaryngol Head Neck Surg** 1997 Feb;116(2):271–3
Pain and activity disturbance after paediatric day case adenoidectomy. Kokki H, et al. **Paediatr Anaesth** 1997; 7(3):227–31
Comparison of diclofenac and tenoxicam for postoperative analgesia with and without fentanyl in children undergoing adenotonsillectomy or tonsillectomy. Mendham JE, et al. **Paediatr Anaesth** 1996;6(6):467–73
Tonsillectomy and adenoidectomy. Changing indications. Deutsch ES. **Pediatr Clin North Am** 1996 Dec; 43(6):1319–38 (102 ref.)
[Use of the laryngeal mask in adenoidectomy in childhood––a comparison with endotracheal intubation] Schnurer U, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Mar;32(3):155–63 (Eng. Abstr.) **(Ger)**
[Effect of adenotomy on mental performance of children with adenoid vegetations] Paditz E, et al. **Wien Med Wochenschr** 1996;146(13–14):327–8 (Eng. Abstr.) **(Ger)**
[Emergency amygdalectomy and adenoidectomy in children with upper respiratory obstruction] Rodrigo Chiner OJ, et al. **Acta Otorrinolaringol Esp** 1996 Sep–Oct;47(5):411–3 (Eng. Abstr.) **(Spa)**
[On adenoidectomy] Lacosta JL, et al. **An Otorrinolaringol Ibero Am** 1996;23(5):491–502 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Identification and assessment of velopharyngeal inadequacy. Conley SF, et al. **Am J Otolaryngol** 1997 Jan–Feb; 18(1):38–46 (85 ref.)
Management of children with von Willebrand disease undergoing adenotonsillectomy. Derkay CS, et al. **Am J Otolaryngol** 1996 May–Jun;17(3):172–7
Outpatient adenotonsillectomy. Is it safe in children younger than 3 years? Mitchell RB, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jul;123(7):681–3
Velopharyngeal incompetence after adenotonsillectomy in non-cleft patients. Fernandes DB, et al. **Br J Oral Maxillofac Surg** 1996 Oct;34(5):364–7
Subhypnotic propofol does not treat postoperative vomiting in children after adenotonsillectomy. Zestos MM, et al. **Can J Anaesth** 1997 Apr;44(4):401–4
Management of secondary hemorrhage following pediatric adenotonsillectomy. Irani DB, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jun 20;40(2–3):115–24
The utility of preoperative hemostatic assessment in adenotonsillectomy. Zwack GC, et al. **Int J Pediatr Otorhinolaryngol** 1997 Feb 14;39(1):67–76
Prospective, randomized, double-blind, placebo-controlled comparison of metoclopramide and ondansetron for prevention of posttonsillectomy or adenotonsillectomy emesis. Stene FN, et al. **J Clin Anesth** 1996 Nov;8(7):540–4
Management of nasopharyngeal and oropharyngeal stenosis in children. McLaughlin KE, et al. **Laryngoscope** 1997 Oct; 107(10):1322–31
Ondansetron reduces nausea and vomiting after paediatric adenotonsillectomy. Morton NS, et al. **Paediatr Anaesth** 1997;7(1):37–45
[Subcutaneous emphysema and pneumomediastinum after tonsillectomy and adenoidectomy] López González MA, et al. **Acta Otorrinolaringol Esp** 1997 Jan–Feb;48(1):65–8 (Eng. Abstr.) **(Spa)**

ECONOMICS

Value-based pathology: a cost-benefit analysis of the examination of routine and nonroutine tonsil and adenoid specimens [see comments] Netser JC, et al. **Am J Clin Pathol** 1997 Aug;108(2):158–65. Comment in: Am J Clin Pathol 1997 Aug;108(2):123–6.

HISTORY

Tonsils and adenoids: snapshots from The Laryngoscope scrapbook. Bailey BJ. **Laryngoscope** 1997 Mar;107(3):301–6
Speech made at the unveiling of the Wilhelm Meyer monument, at Copenhagen. Semon F. **Laryngoscope** 1997 Mar;107(3):307–9

INSTRUMENTATION

Power-assisted adenoidectomy. Koltai PJ, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jul;123(7):685–8

METHODS

Ablative adenoidectomy: a new technique using simultaneous liquefaction/aspiration. Wright ED, et al. **J Otolaryngol** 1997 Feb;26(1):36–43

NURSING

Pediatric tonsillectomy and adenoidectomy procedures. Derkay CS, et al. **AORN J** 1995 Dec;62(6):887–904; quiz 906–10 (36 ref.)

PSYCHOLOGY

Perioperative psychosocial interventions for autistic children undergoing ENT surgery. Seid M, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jun 20;40(2–3):107–13 (11 ref.)
Behavioural changes following routine ENT operations in two-to-ten-year-old children. Kotiniemi LH, et al. **Paediatr Anaesth** 1996;6(1):45–9

STATISTICS & NUMERICAL DATA

Glue ear surgery in Scottish children 1990–1994: still plenty of ENT and public health challenges. Bisset F. **Clin Otolaryngol** 1997 Jun;22(3):233–8

ADENOIDS

see related
ADENOIDECTOMY

ABNORMALITIES

Adenotonsillar hypertrophy and skeletal morphology of children with obstructive sleep apnea syndrome. Shintani T, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:222–4

CHEMISTRY

Surface expression of intercellular adhesion molecule 1 on epithelial cells in the human adenoid. Winther B, et al. **J Infect Dis** 1997 Aug;176(2):523–5

CYTOLOGY

Rapid proliferation of B cells from adenoids in response to Epstein–Barr virus infection. Zeidler R, et al. **Cancer Res** 1996 Dec 15;56(24):5610–4
Age-associated changes in the cellular composition of the human adenoid. Mattila PS, et al. **Scand J Immunol** 1997 Apr;45(4):423–7

IMMUNOLOGY

Secretory IgA and squamous epithelization in adenoids of children with otitis media with effusion. Fujihara K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:155–7
Profile of immunoglobulin production in adenoid and tonsil lymphocytes. Hata M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:84–6
Adenoid lymphocyte responses to outer membrane protein P6 of nontypable Haemophilus influenzae in children with and without otitis media. Kodama H, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:153–4
B- and T-lymphocyte subpopulations in the adenoids of children with otitis media. Mattila PS, et al. **APMIS** 1996 Oct;104(10):698–704
Age-associated changes in the cellular composition of the human adenoid. Mattila PS, et al. **Scand J Immunol** 1997 Apr;45(4):423–7

METABOLISM

Concentrations of azithromycin in tonsilar and/or adenoid tissue from paediatric patients. Vaudaux BP, et al. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:45–51

MICROBIOLOGY

Persistence of nontypeable Haemophilus influenzae in adenoid macrophages: a putative colonization mechanism. Forsgren J, et al. **Acta Otolaryngol (Stockh)** 1996 Sep; 116(5):766–73
Adenoid lymphocyte responses to outer membrane protein P6 of nontypable Haemophilus influenzae in children with and without otitis media. Kodama H, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:153–4
The role of adenoids in nasopharyngeal colonization with nontypeable Haemophilus influenzae. Kurono Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:147–9
Detection of Haemophilus influenzae in adenoids and nasopharyngeal secretions by polymerase chain reaction. Sakamoto N, et al. **Acta Otolaryngol Suppl (Stockh)** 1996; 523:145–6
Role of adenoids in the pathogenesis of otitis media: a bacteriologic and immunohistochemical analysis. Linder TE, et al. **Ann Otol Rhinol Laryngol** 1997 Aug; 106(8):619–23
Adenoid bacteriology and sinonasal symptoms in children. Lee D, et al. **Otolaryngol Head Neck Surg** 1997 Mar; 116(3):301–7

PATHOLOGY

Value-based pathology: a cost-benefit analysis of the examination of routine and nonroutine tonsil and adenoid specimens [see comments] Netser JC, et al. **Am J Clin Pathol** 1997 Aug;108(2):158–65. Comment in: Am J Clin Pathol 1997 Aug;108(2):123–6.
Abundance of intraepithelial gamma delta T cells in hypertrophic obstructive but not in chronically infected adenoids. Olofsson K, et al. **Clin Exp Immunol** 1996 Nov; 106(2):396–403
Assessment of adenoid size in children by fibreoptic examination. Wang DY, et al. **Clin Otolaryngol** 1997 Apr; 22(2):172–7
Detection of adenoidal hypertrophy using acoustic rhinomanometry. Mostafa BE. **Eur Arch Otorhinolaryngol Suppl** 1997;1:S27–9
Acute right heart failure due to adenotonsillar hypertrophy. Sie KC, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jul 18; 41(1):53–8
Do systemic corticosteroids effectively treat obstructive sleep apnea secondary to adenotonsillar hypertrophy? Al-Ghamdi SA, et al. **Laryngoscope** 1997 Oct; 107(10):1382–7
Adenoidal hypertrophy [letter; comment] Knox GW. **Laryngoscope** 1996 Sep;106(9 Pt 1):1187. Comment on: Laryngoscope 1995 Nov;105(11):1202–8.
Polysomnographic studies in children with adenotonsillar hypertrophy and suspected obstructive sleep apnea. Sanchez-Armengol A, et al. **Pediatr Pulmonol** 1996 Aug; 22(2):101–5
[Adeno-tonsillar hyperplasia and obstructive sleep related respiratory disorders] Scholle S, et al. **Pneumologie** 1997 Aug;51 Suppl 3:811–3 (Eng. Abstr.) **(Ger)**
[Nasal polyps and adenoid vegetations (letter)] Elverland HH. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1187 **(Nor)**
[Current aspects of the problem of tonsillar disease] Bykov VP. **Arkh Patol** 1996 May–Jun;58(3):23–30 (37 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Dual signal transduction mechanisms modulate ciliary beat frequency in upper airway epithelium. Yang B, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L745–51

PHYSIOPATHOLOGY

Histopathological comparison between tonsil and adenoid responses to allergy. Endo LH, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:17–9
Relapsing infective-phlogistic pathology of Waldeyer's ring and its relationship with secretory otitis media. Passali D, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:138–41 (10 ref.)
Sleep apnea associated with congenital diseases and moderate hypertrophy of tonsils. Suzuki K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:225–7
[The morphofunctional characteristics of the palatine and pharyngeal tonsils in children with chronic tonsillitis and adenoids] Bykova VP, et al. **Arkh Patol** 1996 Nov–Dec; 58(6):16–22 (Eng. Abstr.) **(Rus)**
[Emergency amygdalectomy and adenoidectomy in children with upper respiratory obstruction] Rodrigo Chiner OJ, et al. **Acta Otorrinolaringol Esp** 1996 Sep–Oct;47(5):411–3 (Eng. Abstr.) **(Spa)**

SURGERY

Nasal hypersensitivity and recurrent adenoids disease. Filiaci F, et al. **Allergol Immunopathol (Madr)** 1997 Jul–Aug; 25(4):199–202
Management of children with von Willebrand disease undergoing adenotonsillectomy. Derkay CS, et al. **Am J Otolaryngol** 1996 May–Jun;17(3):172–7
Tonsillectomy and adenoidectomy. Changing indications. Deutsch ES. **Pediatr Clin North Am** 1996 Dec; 43(6):1319–38 (102 ref.)

ULTRASTRUCTURE

Expression of adhesion molecules on the microvasculature of the pharyngeal tonsil (adenoid). Perry ME, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:47–51

VIROLOGY

Epstein–Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Zalani S, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9194–9
HIV-1 in oropharyngeal lymphoid tissues [letter; comment] Rinfret A, et al. **Science** 1996 Nov 15;274(5290):1067–8. Comment on: Science 1996 Apr 5;272(5258):115–7.

ADENOLYMPHOMA

[Warthin's tumor. Description of 2 cases] Rea N, et al. **Ann Ital Chir** 1996 Jul–Aug;67(4):537–47; discussion 547–8 (Eng. Abstr.) **(Ita)**
[Warthin's tumor of the parotid gland] Frazzetta M, et al. **G Chir** 1997 Mar;18(3):101–5 (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Membranous nephropathy complicating adenolymphoma of the parotid (Warthin's tumour). Kon SP, et al. **Nephron** 1996;73(4):692–4

DIAGNOSIS

Warthin's tumor of the parotid gland with extension into the parapharyngeal space. Takashima S, et al. **Eur J Radiol** 1997 May;24(3):227–9
[Simultaneous occurrence of a cystadenolymphoma (Warthin tumor) in the parotid gland and larynx] Pätz S, et al. **HNO** 1997 Feb;45(2):91–3 (Eng. Abstr.) **(Ger)**
[Synchronous double tumors of the parotid gland] Franzen A, et al. **Laryngorhinootologie** 1996 Jul;75(7):437–40 (Eng. Abstr.) **(Ger)**

ADENOLYMPHOMA

[Comments on the clinical picture of Warthin's tumors] Gierek T, et al. **Otolaryngol Pol** 1995;49(6):549–54 (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

Over-expression of glutathione S-transferases, DT-diaphorase and an apparently tumour-specific cytosolic class-3 aldehyde dehydrogenase by Warthin tumours and mucoepidermoid carcinomas of the human parotid gland. Sreerama L, et al. **Arch Oral Biol** 1996 Jun; 41(6):597–605

ETIOLOGY

Warthin's tumor and cigarette smoking. Vories AA, et al. **South Med J** 1997 Apr;90(4):416–8

[Smoking and the development of Warthin tumor of the parotid gland] Yu G, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Jul; 30(4):195–7, 255 (Eng. Abstr.) **(Chi)**

METABOLISM

Expression of cytokeratins in Warthin's tumour (adenolymphoma) of parotid glands: specific detection of individual cytokeratin types by monoclonal antibodies. Li C, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):352–8

Are differences in the expression of carbohydrate-binding sites (endogenous lectins) responsible for recurrences of benign tumours of the parotid gland? Steuer MK, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Nov–Dec; 57(6):343–7

PATHOLOGY

Atypical squamous cells in a fine needle aspirate from Warthin's tumor [letter] Kumar N, et al. **Acta Cytol** 1996 Sep–Oct;40(5):1115–7

Cystadenolymphoma of the parotid gland an immunohistochemical study of the epithelial component of twenty cases. Deftos C, et al. **Arch Anat Cytol Pathol** 1996;44(4):180–7

Sources of diagnostic error in the fine-needle aspiration diagnosis of Warthin's tumor and clues to a correct diagnosis. Ballo MS, et al. **Diagn Cytopathol** 1997 Sep; 17(3):230–4

Fine-needle sampling of salivary gland lesions. II. Cytology and histology correlation of 71 cases of Warthin's tumor (adenolymphoma). Klijanienko J, et al. **Diagn Cytopathol** 1997 Mar;16(3):221–5

Bilateral mucoepidermoid carcinomas arising in bilateral pre-existing Warthin's tumours of the parotid gland. Seifert G. **Oral Oncol** 1997 Jul;33(4):284–7

Unilateral multiple adenolymphomas originating in the parotid gland: a clinicopathological study. Uchinuma E, et al. **Scand J Plast Reconstr Surg Hand Surg** 1997 Sep; 31(3):239–43

[Warthin tumor of the palate: an unusual location] Chiapasco M, et al. **Minerva Stomatol** 1996 Dec;45(12):605–10 (25 ref.) (Eng. Abstr.) **(Ita)**

[Comments on the clinical picture of Warthin's tumors] Gierek T, et al. **Otolaryngol Pol** 1995;49(6):549–54 (Eng. Abstr.) **(Pol)**

RADIONUCLIDE IMAGING

Tl-201 uptake and retention in a Warthin's tumor. Arbab AS, et al. **Ann Nucl Med** 1996 Aug;10(3):335–8

Value of technetium-99m pertechnetate imaging in the differential of salivary gland lesions. Bongers V, et al. **Ann Otol Rhinol Laryngol** 1997 May;106(5):432–4

Interpretation of scintigraphy of papillary cystadenoma lymphomatosum (Warthin's tumor) on the basis of histopathologic findings. Sato T, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jul;82(1):101–7

SURGERY

Adenolymphomas of the parotid and neck with a coexistent pleomorphic adenoma. Case report. Hosokawa K, et al. **Scand J Plast Reconstr Surg Hand Surg** 1997 Sep; 31(3):267–9

[Warthin's tumor] Tanzillo A, et al. **Minerva Chir** 1997 Jun; 52(6):851–6 (Eng. Abstr.) **(Ita)**

THERAPY

Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre. Renehan A, et al. **Br J Surg** 1996 Dec;83(12):1750–4

VIROLOGY

Adenolymphoma and non-Hodgkin's lymphoma of the salivary glands and oral cavity in immunocompetent patients are not associated with latent Epstein-Barr virus. Wolvius EB, et al. **Oral Oncol** 1997 Mar;33(2):119–23

No Epstein Barr and cytomegalovirus DNA found in salivary gland tumours. Kärjä V, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 Mar–Apr; 59(2):97–9

ADENOMA

Diagnosis & management of pituitary tumors. Weinstein J, et al. **Compr Ther** 1997 Sep;23(9):594–604 (66 ref.)

Detection and management of parathyroid tumors. Hodin RA, et al. **Curr Opin Oncol** 1997 Jan;9(1):75–8 (23 ref.)

Preoperative imaging for parathyroid localization in primary hyperparathyroidism. Okada Y, et al. **Int J Urol** 1997 Jul; 4(4):338–42

6th European Workshop on Pituitary Adenomas. Berlin, Germany, July 24–27, 1996. Abstracts. **J Endocrinol Invest** 1996;19(5 Suppl):1–52

Idiopathic hyperplasia of the adrenal gland behaving like an aldosterone producing adenoma. Rao A, et al. **J Endocrinol Invest** 1997 Jan;20(1):29–31

Characterization of GH3 cells overexpressing basic fibroblast growth factor (FGF-2). Wada S, et al. **J Neuroendocrinol** 1997 Jun;9(6):423–30

Pituitary ectopic adenoma [letter; comment] Goel A. **J Neurosurg** 1996 Aug;85(2):362. Comment on: J Neurosurg 1995 Dec;83(6):1092–4.

Nonfunctioning adenomas of the pituitary. Liuzzi A, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):80–2 (16 ref.)

[Large hepatic adenoma in a male patient] Gutiérrez ML, et al. **Rev Esp Enferm Dig** 1997 Mar;89(3):222–4 (Eng. Abstr.) **(Spa)**

BLOOD

Serum lipids and adenomas of the left colon and rectum. Bird CL, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):607–12

Serum neuron-specific enolase in patients with pituitary adenoma. Heshmati HM, et al. **Clin Chem** 1997 Mar; 43(3):540–1

Plasma endothelin-1 levels in patients with aldosterone-producing adenoma and pheochromocytoma. Letizia C, et al. **Clin Exp Hypertens** 1996 Oct;18(7):921–31

Serum levels of dehydroepiandrosterone sulfate in patients with asymptomatic cortisol producing adrenal adenoma: comparison with adrenal Cushing's syndrome and non-functional adrenal tumor. Morio H, et al. **Endocr J** 1996 Aug;43(4):387–96

Measuring serum thyroglobulin in patients with follicular thyroid nodule: its diagnostic implications. Okamoto T, et al. **Endocr J** 1997 Feb;44(1):187–93

Unexplained increase in serum corticosteroid-binding globulin levels in a patient with chronic thyroiditis, pituitary adenoma and empty sella. Tojo K, et al. **Endocr J** 1996 Dec;43(6):665–70

Hyperprolactinaemia is associated with a higher prevalence of pituitary-adrenal dysfunction in non-functioning pituitary macroadenoma. Tjeerdsma G, et al. **Eur J Endocrinol** 1996 Sep;135(3):299–308

Plasma dehydroepiandrosterone sulfate levels in patients with hyperfunctioning and non-hyperfunctioning adrenal tumors before and after adrenal surgery. Tóth M, et al. **Eur J Endocrinol** 1997 Mar;136(3):290–5

Free luteinizing-hormone beta-subunit in normal subjects and patients with pituitary adenomas. Chanson P, et al. **J Clin Endocrinol Metab** 1997 May;82(5):1397–402

17-Hydroxyprogesterone response to ACTH in bilateral and monolateral adrenal incidentalomas. Bernini GP, et al. **J Endocrinol Invest** 1996 Dec;19(11):745–52

Intraoperative secretion of intact parathyroid hormone and amino-terminal parathyroid hormone fragments from normal parathyroid glands associated with solitary parathyroid adenoma. Bergenfelz A, et al. **World J Surg** 1997 Jan;21(1):30–4; discussion 34–5

[Thyroid-stimulating hormone hypophyseal adenoma. A case report] Gannage MH, et al. **J Med Liban** 1997;45(2):97–101 (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Differences in angiogenesis and collagenesis between exophytic and flat adenomas of the colorectal mucosa. Rubio CA. **Anticancer Res** 1997 Jan–Feb;17(1B):737–42

Angiogenesis in follicular tumors of the thyroid. Segal K, et al. **J Surg Oncol** 1996 Oct;63(2):95–8

[Vascularization of single thyroid nodule as an indicator malignant neoplasm: a study using echo-color-Doppler] Urso M, et al. **Ann Ital Med Int** 1996 Jul–Sep;11(3):175–9 (Eng. Abstr.) **(Ita)**

[Headache and decreased visual acuteness of sudden onset] Martínez Mata AM, et al. **Rev Clin Esp** 1997 Feb; 197(2):129–30 **(Spa)**

CHEMICALLY INDUCED

Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Duperron C, et al. **Carcinogenesis** 1997 May;18(5):1001–6

Both K-ras and H-ras protooncogene mutations are associated with Harderian gland tumorigenesis in B6C3F1 mice exposed to isoprene for 26 weeks. Hong HL, et al. **Carcinogenesis** 1997 Apr;18(4):783–9

Chronic toxicity and carcinogenicity studies of 2-methylnaphthalene in B6C3F1 mice. Murata Y, et al. **Fundam Appl Toxicol** 1997 Mar;36(1):90–3

Phenobarbital promotes multistage pulmonary carcinogenesis in MNU-inoculated L-W rats. Pollard M, et al. **In Vivo** 1997 Jan–Feb;11(1):55–60

Folate and alcohol intakes: related or independent roles in the adenoma-carcinoma sequence? Boutron-Ruault MC, et al. **Nutr Cancer** 1996;26(3):337–46

Leydig cell hyperplasia and adenoma formation: mechanisms and relevance to humans. Clegg ED, et al. **Reprod Toxicol** 1997 Jan–Feb;11(1):107–21 (170 ref.)

Effect of a dopamine agonist on the development of Leydig cell hyperplasia in Sprague-Dawley rats. Dirami G, et al. **Toxicol Appl Pharmacol** 1996 Nov;141(1):169–77

Mechanism of thiazopyr-induced effects on thyroid hormone homeostasis in male Sprague-Dawley rats. Hotz KJ, et al. **Toxicol Appl Pharmacol** 1997 Jan;142(1):133–42

CHEMISTRY

In situ hybridization analysis of Pit-1 mRNA and hormonal production in human pituitary adenomas. Sanno N, et al. **Acta Neuropathol (Berl)** 1996;91(3):263–8

Ki-67, p53, and Bcl-2 expression of serrated adenomas of the colon. Kang M, et al. **Am J Surg Pathol** 1997 Apr; 21(4):417–23

Role of computed quantitation of immunohistochemical staining of Ki-67 antigen in diagnosing ampullary lesions. Minimo C, et al. **Anal Quant Cytol Histol** 1996 Oct; 18(5):400–4

Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression. Reincke M, et al. **Clin Endocrinol (Oxf)** 1997 May;46(5):619–26

The different expression of proteins recognized by monoclonal anti-heat shock protein 70 (hsp70) antibody in human colonic diseases. Stulík J, et al. **Electrophoresis** 1997 Mar–Apr;18(3–4):625–8

Demonstration of activin in normal pituitary and in various human pituitary adenomas by immunohistochemistry. Demura R, et al. **Endocr J** 1996 Aug;43(4):429–32

Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology [see comments] Plöckinger U, et al. **Eur J Endocrinol** 1997 Apr;136(4):369–76. Comment in: Eur J Endocrinol 1997 Apr;136(4):359–61.

CDX1 protein expression in normal, metaplastic, and neoplastic human alimentary tract epithelium [see comments] Silberg DG, et al. **Gastroenterology** 1997 Aug; 113(2):478–86. Comment in: Gastroenterology 1997 Aug;113(2):680–2.

Immunohistochemical localization of integrins and basement membrane components in colorectal epithelial tumors correlates with their histologic architecture. Ban S, et al. **Gen Diagn Pathol** 1997 Feb;142(3–4):165–73

p53 protein expression in colorectal adenomas: an immunohistochemical study using an antigen retrieval system. Karamitopoulou E, et al. **Histopathology** 1995 Dec; 27(6):517–23

Preclinical Cushing's syndrome: report of four cases and analysis of steroid contents in adenomas. Morioka M, et al. **Horm Res** 1996;46(3):117–23

The clinicopathological characteristics of gonadotroph cell adenoma: a study of 118 cases. Ho DM, et al. **Hum Pathol** 1997 Aug;28(8):905–11

Differences in the distribution of acidic mucins between flat tubular adenomas and flat serrated adenomas of the colorectal mucosa. Rubio CA, et al. **In Vivo** 1996 May–Jun; 10(3):383–8

E-cadherin gene alterations are rare events in thyroid tumors. Soares P, et al. **Int J Cancer** 1997 Jan 6;70(1):32–8

Cellular receptors for sex steroids in human pituitary adenomas. Jaffrain-Rea ML, et al. **J Endocrinol** 1996 Nov; 151(2):175–84

TGF beta 1 immunostaining patterns and locations in adenoma which later recurred. Morosini PP, et al. **J Endocrinol Invest** 1996 Jul–Aug;19(7):422–6

Analysis of bile acids in colon residual liquid or fecal material in patients with colorectal neoplasia and control subjects. Kishida T, et al. **J Gastroenterol** 1997 Jun;32(3):306–11

Evaluation of hormonal function in a series of incidentally discovered adrenal masses. Bondanelli M, et al. **Metabolism** 1997 Jan;46(1):107–13

Folliculo-stellate cells of human pituitary adenomas: immunohistochemical study of the monocyte/macrophage phenotype expression. Giometto B, et al. **Neuroendocrinology** 1997 Jan;65(1):47–52

Tubular adenoma of the breast: an immunohistochemical study of ten cases. Maiorano E, et al. **Pathol Res Pract** 1995 Dec;191(12):1222–30

Immunodetection of c-met-oncogene's protein product in renal cell neoplasia. Nakopoulou L, et al. **Pathol Res Pract** 1997;193(4):299–304

Immunohistochemical detection of truncated APC protein in sporadic human colorectal adenomas and adenocarcinomas. Akehi S, et al. **Virchows Arch** 1996 Sep; 429(1):21–6

Reciprocal control of colon-specific sulfomucin and sialosyl-Tn antigen expression in human colorectal neoplasia. Yamachika T, et al. **Virchows Arch** 1997 Jul; 431(1):25–30

Expression of cyclin E in colorectal adenomas and adenocarcinomas: correlation with expression of Ki-67 antigen and p53 protein. Yasui W, et al. **Virchows Arch** 1996 Sep;429(1):13–9

CLASSIFICATION

Classification of pituitary adenomas [letter; comment] Mindermann T. **Acta Neurochir (Wien)** 1997;139(3):267–70 . Comment on: Acta Neurochir (Wien)

1996;138(10):1186–92.
Clinical and cytofunctional classification of pituitary adenomas: proposal of a new classification [see comments] **Sanno N, et al. Acta Neurochir (Wien)** 1996;138(10):1186–92 . Comment in: Acta Neurochir (Wien) 1997;139(3):267–70.
SIPAP--a new MR classification for pituitary adenomas. Suprasellar, infrasellar, parasellar, anterior and posterior. **Edal AL, et al. Acta Radiol** 1997 Jan;38(1):30–6
[Classification, pathology and molecular biology of pituitary adenoma] **Tapar K, et al. Arkh Patol** 1997 May–Jun; 59(3):7–17 (22 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Fibromuscular dysplasia of the renal artery and adrenal adenoma in a 36–year–old woman with hypertension. **Mattix H, et al. Am J Med Sci** 1997 Jul;314(1):51–3
Ecchymoses may have been due to extracapsular haemorrhage from parathyroid adenoma [letter] **Hellier WP, et al. BMJ** 1997 Sep 13;315(7109):683
Symptomatic Rathke's cleft cyst with hypophysitis. **Wearne MJ, et al. Br J Neurosurg** 1995;9(6):799–803
Ectopic parathyroid adenoma with severe hungry bone syndrome: a case report. **Chen CH, et al. Chang Keng I Hsueh** 1996 Jun;19(2):196–202
Association of pituitary adenoma with intracranial arteriovenous malformation. **Xu Q, et al. Chin Med J (Engl)** 1996 Sep;109(9):734–6
Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. **Rossi GP, et al. Circulation** 1997 Mar 18;95(6):1471–8
Pituitary tumours presenting in the elderly: management and outcome. **Benbow SJ, et al. Clin Endocrinol (Oxf)** 1997 Jun;46(6):657–60
Clinico–pathological study of Cushing's disease with large pituitary adenoma. **Ikeda H, et al. Clin Endocrinol (Oxf)** 1997 Jun;46(6):669–79
Fluctuating hyper–hypocortisolaemia: a variant of Cushing's syndrome. **Liebowitz G, et al. Clin Endocrinol (Oxf)** 1997 Jun;46(6):759–63
Corticotrophic macroadenoma of the pituitary associated with hypoadrenalism. **Peacock I, et al. Clin Endocrinol (Oxf)** 1997 Jun;46(6):765–8
Double adenomas with different pathological and hormonal features in the left adrenal gland of a patient with Cushing's syndrome. **Satoh F, et al. Clin Endocrinol (Oxf)** 1997 Feb; 46(2):227–34
Adrenal tumour associated with silent 21–hydroxylase deficiency in a male or with a classic form of 21–hydroxylase defect in a female? [letter] [see comments] **Tóth M, et al. Clin Endocrinol (Oxf)** 1996 Sep;45(3):369–70 . Comment in: Clin Endocrinol (Oxf) 1997 May;46(5):644.
Autonomous thyroid adenoma, papillary thyroid carcinoma, and ectopic parathyroid adenoma in a patient with primary hyperparathyroidism and a nontoxic multinodular goiter. **Kirkwood ID, et al. Clin Nucl Med** 1997 Jul;22(7):491–3
Manifestation of subclinical diabetes insipidus due to pituitary tumor during pregnancy. **Hashimoto M, et al. Endocr J** 1996 Oct;43(5):577–83
A case of Schmidt syndrome accompanied by a pituitary adenoma. **Otsuka F, et al. Endocr J** 1996 Oct;43(5):495–502
Hypertrophic subaortic stenosis and hyperparathyroidism [letter] **Macieira–Coelho E, et al. Eur Heart J** 1996 Nov; 17(11):1763–4
Nephrogenic adenoma in children. Case report and review of literature. **Schumacher K, et al. Eur J Pediatr Surg** 1997 Apr;7(2):115–7 (24 ref.)
Metastatic thyroid cancer with hyperthyroidism. **Kobayashi T, et al. Eur J Surg** 1997 Jan;163(1):67–8
Apoplexy of a pituitary macroadenoma as a severe complication of preoperative thyrotropin–releasing hormone (TRH) testing. **Szabolcs I, et al. Exp Clin Endocrinol Diabetes** 1997;105(4):234–6
Migrainelike headache in a patient with a hemorrhagic pituitary macroadenoma. **Evans RW. Headache** 1997 Jul–Aug;37(7):455–6
Clusterlike headache in a patient with a pituitary adenoma. With a review of the literature. **Milos P, et al. Headache** 1996 Mar;36(3):184–8 (29 ref.)
Preoperative localization of parathyroid adenomas using 99mTc–MIBI scintigraphy in patients with hyperparathyroidism. **Ebisuno S, et al. Int J Urol** 1997 Mar; 4(2):126–9
Acromegaly associated with Chiari–I malformation and polycystic ovary syndrome. **Hara M, et al. Intern Med** 1996 Oct;35(10):803–7
Pituitary apoplexy after subtotal thyroidectomy in an acromegalic patient with a large goiter. **Kato K, et al. Intern Med** 1996 Jun;35(6):472–7
Spontaneous remission of primary hyperparathyroidism due to hemorrhagic infarction in the parathyroid adenoma. **Natsui K, et al. Intern Med** 1996 Aug;35(8):646–9
Stercoral perforation associated with parathyroid adenoma. **Gul YA, et al. Ir Med J** 1997 Jan–Feb;90(1):20
Successful pregnancy in an infertile woman with a thyrotropin–secreting macroadenoma treated with somatostatin analog (octreotide). **Caron P, et al. J Clin Endocrinol Metab** 1996 Mar;81(3):1164–8
Criteria of cure and follow–up of central hyperthyroidism due to thyrotropin–secreting pituitary adenomas. **Losa M, et al. J Clin Endocrinol Metab** 1996 Aug;81(8):3084–90
Coexistence of psoriasis vulgaris, ulcerative colitis, and thyroid adenoma [letter] **Yamamoto T, et al. J Dermatol** 1997 Apr;24(4):275–6
Growth hormone–secreting pituitary adenoma associated with multiple bone cysts, skin pigmentation and aortitis syndrome. **Ihara C, et al. J Endocrinol Invest** 1996 Dec; 19(11):753–7
Hypertensive cardiomegaly caused by an aldosterone–secreting adenoma in a newborn. **Pozzan GB, et al. J Endocrinol Invest** 1997 Feb;20(2):86–9
Cyproheptadine treatment in Cushing's disease. **Tanakol R, et al. J Endocrinol Invest** 1996 Apr;19(4):242–7
Adenoma of the common human bile duct in Gardner's syndrome may cause relapsing acute pancreatitis. **Futami H, et al. J Gastroenterol** 1997 Aug;32(4):558–61
Case report: hepatic adenoma with bone marrow metaplasia in a patient with glycogen storage disease type Ia. **Moriura S, et al. J Gastroenterol Hepatol** 1996 Jun;11(6):556–9
Ectopic pituitary adenoma in the sphenoid causing Nelson's syndrome. **Esteban F, et al. J Laryngol Otol** 1997 Jun; 111(6):565–7
Extracapsular haemorrhage from a parathyroid adenoma presenting as a massive cervical haematoma. **Hellier WP, et al. J Laryngol Otol** 1997 Jun;111(6):585–7
Why fatheads just don't see. **Kosmorsky GS, et al. J Neuroophthalmol** 1997 Jun;17(2):124–6
Graves' disease triggered by autoinfarction of an autonomously functioning thyroid adenoma. **Gallegos E, et al. J Nucl Med** 1997 Feb;38(2):260–2
Reversible extraskeletal uptake of bone scanning in primary hyperparathyroidism. **Hwang GJ, et al. J Nucl Med** 1996 Mar;37(3):469–71
Nephrogenic adenoma of the urethra presenting as gross hematuria in a child. **Kidd CJ, et al. J Urol** 1997 Mar; 157(3):983
A case of idiopathic thyrotropin (TSH) deficiency. **Ichida T, et al. Korean J Intern Med** 1997 Jan;12(1):96–9
A blinding headache. **Embil JM, et al. Lancet** 1997 Jul 19; 350(9072):182
A case of renal amyloidosis associated with hepatic adenoma: the pathogenetic role of tumor necrosis factor–alpha. **Shibasaki T, et al. Nephron** 1997;75(3):350–3
Incidence of intracranial aneurysm associated with pituitary adenoma. **Pant B, et al. Neurosurg Rev** 1997;20(1):13–7
Humoral hypercalcemia due to an occult renal adenoma. **Mahoney CP, et al. Pediatr Nephrol** 1997 Jun;11(3):339–42
Bone insufficiency fractures as an inaugural manifestation of primary hyperparathyroidism. **Lafforgue P, et al. Rev Rhum Engl Ed** 1996 Jul–Sep;63(7–8):475–9 (26 ref.)
Spontaneous vocal cord paresis and return to normocalcemia: an unusual presentation of parathyroid adenoma with concomitant abscess. **Angelos P, et al. Surgery** 1997 Jun; 121(6):704–7
Long–standing goiter and hypothyroidism: an unusual presentation of a TSH–secreting adenoma. **Langlois MF, et al. Thyroid** 1996 Aug;6(4):329–35
Diplopia associated with hyperparathyroidism: report of a case. **Forman BH, et al. Yale J Biol Med** 1996 Sep–Dec; 68(5–6):215–7
[Intracavernous invagination of pituitary macro–adenomas] **Roux FX, et al. Ann Endocrinol (Paris)** 1996;57(5):403–10 (Eng. Abstr.) **(Fre)**
[Aldosterone precursors and hypertension with hypokalemia and adrenal module non caused by primary hyperaldosteronism] **Chamontin B, et al. Arch Mal Coeur Vaiss** 1996 Aug;89(8):1055–8 (Eng. Abstr.) **(Fre)**
[Hyperthyroidism in TSH–producing hypophyseal adenoma] **Reschke K, et al. Dtsch Med Wochenschr** 1997 Feb 7; 122(6):150–5 (Eng. Abstr.) **(Ger)**
[With safety in danger] **Callies F, et al. Med Klin** 1996 Dec 15;91(12):776–9 **(Ger)**
[Hypothyroidism caused by TSH producing hypophyseal adenoma] **Pichler R, et al. Wien Klin Wochenschr** 1997 Apr 25;109(8):281–5 (Eng. Abstr.) **(Ger)**
[A case of concurrent bilateral adrenocortical adenoma causing Cushing's syndrome] **Koga F, et al. Hinyokika Kiyo** 1997 Apr;43(4):275–8 (Eng. Abstr.) **(Jpn)**
[A case of mediastinal goiter with hyperthyroidisms] **Tsushima T, et al. Kyobu Geka** 1997 May;50(5):429–33 (Eng. Abstr.) **(Jpn)**
[A case of ulcerative colitis with minute gastric cancer and intraductal papillary adenoma of the pancreas] **Yamamoto T, et al. Nippon Shokakibyo Gakkai Zasshi** 1997 Aug; 94(8):532–7 (12 ref.) **(Jpn)**
[Hippocampal hemosiderin deposit due to large pituitary adenoma presenting temporal lobe epilepsy--a case report] **Hashizume K, et al. No To Shinkei** 1997 Apr;49(4):366–71 (Eng. Abstr.) **(Jpn)**
[Massive trabecular adenoma of the liver complicated with bleeding from esophageal varicosities] **Shmurun RI. Vopr Onkol** 1996;42(4):89–90 **(Rus)**
[Headache and decreased visual acuteness of sudden onset] **Martínez Mata AM, et al. Rev Clin Esp** 1997 Feb; 197(2):129–30 **(Spa)**
[Magnetic resonance imaging usefulness in the diagnosis of intratumor bleeding in hypophyseal adenomas] **García–Asensio S, et al. Rev Neurol** 1996 Oct; 24(134):1237–40 (Eng. Abstr.) **(Spa)**

CONGENITAL

The congenital basal cell adenoma of salivary glands. Contribution to the differential diagnosis of congenital salivary gland tumours. **Seifert G, et al. Virchows Arch** 1997 Apr;430(4):311–9

DIAGNOSIS

Polyorchidism and rete testis adenoma: ultrasound and MR findings. **Figler TJ, et al. Abdom Imaging** 1996 Sep–Oct; 21(5):470–2
Brush cytology and biopsy in the diagnosis of colorectal cancer. A comparison. **Halpern M, et al. Acta Cytol** 1997 May–Jun;41(3):628–32
Hyalinizing trabecular adenoma of the thyroid. A report of two cases with cytologic, histologic and immunohistochemical findings. **Kaleem Z, et al. Acta Cytol** 1997 May–Jun;41(3):883–8
MR imaging of residual tumor tissue after transsphenoidal surgery of hormone–inactive pituitary macroadenomas: a prospective study. **Kremer P, et al. Acta Neurochir Suppl (Wien)** 1996;65:27–30
Value of ultrasonography, CT and MR imaging in the diagnosis of primary hyperparathyroidism. **Tziakouri C, et al. Acta Radiol** 1996 Sep;37(5):720–6
Dynamic and conventional spin–echo MR of pituitary microlesions. **Bartynski WS, et al. AJNR Am J Neuroradiol** 1997 May;18(5):965–72
Hemorrhagic pituitary adenomas of adolescence. **Poussaint TY, et al. AJNR Am J Neuroradiol** 1996 Nov–Dec; 17(10):1907–12
Sialoblastoma (embryoma): MR findings of a rare pediatric salivary gland tumor. **Som PM, et al. AJNR Am J Neuroradiol** 1997 May;18(5):847–50
Intrasellar mixed gangliocytoma–adenoma [letter] **Castillo M, et al. AJR Am J Roentgenol** 1997 Oct;169(4):1199–200
Change in the composition of adrenal nodules after therapy as revealed by opposed–phase MR imaging. **Kainz G, et al. AJR Am J Roentgenol** 1997 Aug;169(2):549–50
Aggressive papillary adenoma of the cerebellopontine angle: case report of an endolymphatic sac tumor. **Folker RJ, et al. Am J Otolaryngol** 1997 Mar–Apr;18(2):135–9 (9 ref.)
Brown tumor in the cricoid cartilage: an unusual manifestation of primary hyperparathyroidism. **Blinder G, et al. Ann Otol Rhinol Laryngol** 1997 Mar;106(3):252–3
Sellar and suprasellar hemangiopericytoma mimicking pituitary adenoma. **Morrison DA, et al. Arch Ophthalmol** 1997 Sep;115(9):1201–3
Papillary parathyroid adenoma. A rare occurrence and its importance in differentiation from papillary carcinoma of the thyroid. **Ho KJ. Arch Pathol Lab Med** 1996 Sep; 120(9):883–4
Technetium–99m sestamibi scintigraphy, magnetic resonance imaging and venous blood sampling in persistent and recurrent hyperparathyroidism. **Fayet P, et al. Br J Radiol** 1997 May;70(833):459–64
Mutant plasma p53 protein levels: prognostication in colorectal carcinoma. **Wong SK, et al. Br J Surg** 1997 May; 84(5):664–5
Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. **Umbricht CB, et al. Cancer Res** 1997 Jun 1;57(11):2144–7
Hypothyroidism presenting as a pituitary adenoma: an old problem underrecognized. **Durham LG, et al. Clin Pediatr (Phila)** 1996 Dec;35(12):649–51
Cytomorphology of cystic parathyroid lesions: report of four cases evaluated preoperatively by fine–needle aspiration. **Lerud KS, et al. Diagn Cytopathol** 1996 Nov;15(4):306–11
Elevation of serum ferritin is superior to fecal occult blood testing as a screening test for colonic adenoma... and not only because patients do not have to handle their own stool [letter] **Nelson RL. Dis Colon Rectum** 1996 Dec; 39(12):1441–2
ACTH–independent macronodular adrenocortical hyperplasia (AIMAH): report of two cases and the analysis of steroidogenic activity in adrenal nodules. **Morioka M, et al. Endocr J** 1997 Feb;44(1):65–72
Diagnosis of borderline adenomas of the stomach by endoscopic mucosal resection. **Fujiwara Y, et al. Endoscopy** 1996 Jun;28(5):425–30
Small colorectal serrated adenomas: endoscopic findings. **Jaramillo E, et al. Endoscopy** 1997 Jan;29(1):1–3
Multiple adrenal masses: MRI tissue differentiation of pheochromocytoma and adenoma at 1.5 T. **Slapa RZ, et al. Eur Radiol** 1997;7(1):38–40
The significance of the immunocytochemical investigations in diagnosis and prognosis of pituitary adenomas. **Pawlikowski M. Folia Histochem Cytobiol** 1997; 35(2):109–10
Initial management and follow–up surveillance of patients with colorectal adenomas. **Zauber AG, et al. Gastroenterol Clin North Am** 1997 Mar;26(1):85–101 (51 ref.)
Little polyps: are they a big problem? **Fennerty MB, et al. Gastroenterology** 1997 Oct;113(4):1413–4
Colonoscopic miss rates of adenomas determined by back–to–back colonoscopies [see comments] **Rex DK, et al. Gastroenterology** 1997 Jan;112(1):24–8. Comment in: ACP J Club 1997 Jul–Aug;127(1):16.
Solitary cystic tumor of the pancreas: EUS–pathologic correlation. **Koito K, et al. Gastrointest Endosc** 1997 Mar; 45(3):268–76
Risk of colorectal adenomas in patients with a family history of colorectal cancer: some implications for screening programmes. **Novis B, et al. Gastrointest Endosc** 1997 Jun; 45(6):543–4

ADENOMA

Colonic chromoscopy. A new perspective on polyps and flat adenomas. Kim CY, et al. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):423–37 (67 ref.)

Comparison of three faecal occult blood tests in the detection of colorectal neoplasia. Hope RL, et al. **Gut** 1996 Nov; 39(5):722–5

Chemical and immunological testing for faecal occult blood in screening subjects at risk of familial colorectal cancer. Hunt LM, et al. **Gut** 1997 Jan;40(1):110–2

Adenoma of nonpigmented epithelium of the ciliary body presenting as anterior uveitis and glaucoma: a case report. Biswas J, et al. **Indian J Ophthalmol** 1995 Sep;43(3):137–40

Nephrogenic adenoma of the ureter—a case report. Koirala TR, et al. **Indian J Pathol Microbiol** 1997 Jan;40(1):61–2

CT diagnosis of intraductal papillary neoplasm of the pancreas in comparison with histopathologic findings. Kyokane T, et al. **Int J Pancreatol** 1996 Dec;20(3):163–7

Three cases of clinical or preclinical Cushing's syndrome due to adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia: pituitary–adrenocortical function and immunohistochemistry. Murakami O, et al. **Intern Med** 1995 Nov;34(11):1074–81

Secretory and nonsecretory pituitary adenomas are distinguishable by 1/T1 magnetic relaxation rates at very low magnetic fields in vitro. Spiller M, et al. **Invest Radiol** 1997 Jun;32(6):320–9

MRI–demonstrable regression of a pituitary mass in a case of primary hypothyroidism after a week of acute thyroid hormone therapy. Sarlis NJ, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):808–11

Detection rate of immunochemical fecal occult blood test for colorectal adenomatous polyps with severe dysplasia. Nakama H, et al. **J Gastroenterol** 1997 Aug;32(4):492–5

Early diagnosis of Nelson's syndrome. Kasperlik–Zaluska AA, et al. **J Mol Neurosci** 1996 Summer;7(2):87–90

Intrasellar vascular malformation mimicking a pituitary macroadenoma. Gould TJ, et al. **J Neuroophthalmol** 1996 Sep;16(3):199–203

Papillary adenoma of endolymphatic sac origin: a temporal bone tumor in von Hippel–Lindau disease. Case report. Ouallet JC, et al. **J Neurosurg** 1997 Sep;87(3):445–9 (11 ref.)

Adenoma in the orthotopic neobladder. Okada H, et al. **J Urol** 1997 Apr;157(4):1358

How (not) to diagnose growth hormone deficiency in adults: stimulated serum concentrations of growth hormone in healthy subjects and in patients with pituitary macroadenomas. Vierhapper H, et al. **Metabolism** 1997 Jun; 46(6):680–3

MRI of pituitary adenomas in acromegaly. Marro B, et al. **Neuroradiology** 1997 Jun;39(6):394–9

MRI of microadenomas in patients with hyperprolactinaemia. Rand T, et al. **Neuroradiology** 1996 Nov;38(8):744–6

Value of quantitative DNA analysis in endocrine tumors of the pancreas. Böttger T, et al. **Oncology** 1997 Jul–Aug; 54(4):318–23

Pituitary adenomas: current methods of diagnosis and treatment. Buatti JM, et al. **Oncology (Huntingt)** 1997 Jun; 11(6):791–6; discussion 798, 803–4 (43 ref.)

Aggressive digital papillary adenoma. Viroslav S, et al. **Orthopedics** 1996 Oct;19(10):899–900

Magnetic resonance imaging of adrenocortical adenomas in childhood: correlation with computed tomography and ultrasound. Hanson JA, et al. **Pediatr Radiol** 1996 Nov; 26(11):794–9

Detection of early stages of carcinogenesis in adenomas of murine lung by 5-aminolevulinic acid–induced protoporphyrin IX fluorescence. Campbell DL, et al. **Photochem Photobiol** 1996 Oct;64(4):676–82

MR imaging of pituitary adenomas with sphenoid sinus invasion: characteristic MR findings indicating fibrosis. Ishii K, et al. **Radiat Med** 1996 Jul–Aug;14(4):173–8

Parathyroid adenomas in the aortopulmonary window [see comments] Doppman JL, et al. **Radiology** 1996 Nov; 201(2):456–62. Comment in: Radiology 1996 Nov;201(2):317–8.

Papillary endolymphatic sac tumors: CT, MR imaging, and angiographic findings in 20 patients. Mukherji SK, et al. **Radiology** 1997 Mar;202(3):801–8

Collision tumors of the adrenal gland: demonstration and characterization at MR imaging. Schwartz LH, et al. **Radiology** 1996 Dec;201(3):757–60

Parathyroid imaging: the myth and the reality [editorial; comment] Udelsman R. **Radiology** 1996 Nov;201(2):317–8 . Comment on: Radiology 1996 Nov;201(2):456–62.

Significance of serum iron and ferritin in patients with colorectal adenomas. Kishida T, et al. **Scand J Gastroenterol** 1997 Mar;32(3):233–7

Discovering a dys-covering lid. Landau K. **Surv Ophthalmol** 1997 Jul–Aug;42(1):87–91

Bilateral aldosterone-producing adenomas in two patients diagnosed by immunohistochemical analysis of steroidogenic enzymes. Watanabe N, et al. **Tohoku J Exp Med** 1996 Jun;179(2):123–9

[A case of choledochal adenoma] Mladenov V, et al. **Khirurgiia (Sofiia)** 1996;49(5):38–9 **(Bul)**

[Thyroid-stimulating hormone hypophyseal adenoma. A case report] Gannage MH, et al. **J Med Liban** 1997;45(2):97–101 (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging in Cushing disease. Prediction of surgical results] Barrou Z, et al. **Presse Med** 1997 Jan 18–25;26(1):7–11 (Eng. Abstr.) **(Fre)**

[Hypophyseal adenomas: functional and tumor evaluation and therapeutic approaches] Tielmans D, et al. **Rev Med Interne** 1996;17(11):901–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[Radiologic diagnosis of hypophyseal adenomas] Brechtelsbauer D, et al. **Aktuelle Radiol** 1996 Nov; 6(6):301–7 (38 ref.) (Eng. Abstr.) **(Ger)**

[MRI: incidence and evaluation of size and form criteria in hypophysis–healthy probands and in patients with detectable microadenomas] Dietrich CF, et al. **Aktuelle Radiol** 1997 May;7(3):130–4 (Eng. Abstr.) **(Ger)**

[Initial symptoms and anamnestic time in 517 patients with pituitary adenoma] Stoffel-Wagner B, et al. **Dtsch Med Wochenschr** 1997 Feb 21;122(8):213–9 (Eng. Abstr.) **(Ger)**

[Papillary tumor of the endolymphatic sac] Schick B, et al. **HNO** 1996 Jun;44(6):329–32 (Eng. Abstr.) **(Ger)**

[The differentiation of adrenal gland tumors: an improvement in accuracy by a combination of fat-sensitive, T2-weighted and contrast-enhanced MR sequences] Zimmermann GG, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):153–9 (Eng. Abstr.) **(Ger)**

[Adrenal cortex adenoma in Conn syndrome] Kolokythas O, et al. **Rontgenpraxis** 1996 Jul;49(7):180–2 **(Ger)**

[Adenoma of the gallbladder] Nüssle K, et al. **Rontgenpraxis** 1996 Aug;49(8):213–4 **(Ger)**

[Large Brunner's adenoma of the duodenal bulb—a case report] Rhiner R, et al. **Swiss Surg** 1997;3(1):13–6 (Eng. Abstr.) **(Ger)**

[Hysteroscopic diagnosis and follow-up of adenomatous hyperplasia and therapeutic consequences] Schmidt T, et al. **Zentralbl Gynakol** 1997;119(1):12–5 (Eng. Abstr.) **(Ger)**

[A case of minute intraductal papillary adenoma in main pancreatic duct with acute pancreatitis as the first diagnostic clue] Nakamura Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Apr;94(4):310–4 **(Jpn)**

[Renal adenoma] Takahashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):498–500 (19 ref.) **(Jpn)**

[The diagnosis and treatment of hormonally inactive adrenal formations] Maistrenko NA, et al. **Vestn Khir Im I I Grek** 1996;155(6):39–43 (Eng. Abstr.) **(Rus)**

[Severe hyponatremia as presentation of a hypophyseal lesion (letter)] Palacios N, et al. **Rev Clin Esp** 1997 Aug;197(8):594 **(Spa)**

[Uncontrolled hypertension after Cushing's syndrome] Tinahones FJ, et al. **Rev Clin Esp** 1997 Apr;197(4):293–5 **(Spa)**

[Acute abdomen caused by jejunal perforation as a clinical presentation of MEN-1 syndrome] Uriarte C, et al. **Rev Esp Enferm Dig** 1996 Apr;88(4):289–91 (Eng. Abstr.) **(Spa)**

DIET THERAPY

Chemoprevention of metachronous adenomas of the large bowel: design and interim results of a randomized trial of calcium and fibre. ECP Colon Group. Faivre J, et al. **Eur J Cancer Prev** 1997 Apr;6(2):132–8

DRUG THERAPY

Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. Lundin P, et al. **AJNR Am J Neuroradiol** 1997 Apr;18(4):765–72

Use of somatostatin analogue in management of a thyrotrophin secreting pituitary adenoma [letter] Stiles MK, et al. **Aust N Z J Med** 1996 Feb;26(1):122–3

Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume– and hormone-response to ocreotide therapy and do not correlate with tumor histology [see comments] Plöckinger U, et al. **Eur J Endocrinol** 1997 Apr;136(4):369–76. Comment in: Eur J Endocrinol 1997 Apr;136(4):359–61.

Transformation of a human mixed GH–PRL adenoma cell population in response to long-term bromocriptine treatment. Bácsy E, et al. **Folia Histochem Cytobiol** 1997; 35(2):69–74

Histological changes of parathyroid adenoma after percutaneous injection of ethanol. Chow LT, et al. **Histopathology** 1997 Jan;30(1):87–9

Sulindac for periampullary polyps in FAP patients. Richard CS, et al. **Int J Colorectal Dis** 1997;12(1):14–8

Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. Biller BM, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2338–43

Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). Caron P, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1164–8

MRI–demonstrable regression of a pituitary mass in a case of primary hypothyroidism after a week of acute thyroid hormone therapy. Sarlis NJ, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):808–11

Methimazole-induced cholestatic liver injury, mimicking sclerosing cholangitis. Schwab GP, et al. **Langenbecks Arch Chir** 1996;381(4):225–7

Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone. Leese G, et al. **Postgrad Med J** 1997 Aug;73(862):507–8

[Management of pituitary adenoma in pregnancy] Cheng W, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Sep; 31(9):537–9 (Eng. Abstr.) **(Chi)**

[Elimination of thyroid cysts and controlling autonomous adenomas of the thyroid gland by local alcohol injection] Braun B, et al. **Med Klin** 1996 Feb 15;91 Suppl 1:1–2 **(Ger)**

[Seizures as a late complication of bromocriptine therapy in patients with prolactin-producing macroadenomas: correlation between lateral extension of the adenoma and seizure onset] Niwa J, et al. **No Shinkei Geka** 1996 Oct; 24(10):913–9 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas. Sordat I, et al. **Am J Pathol** 1997 Jan;150(1):283–95

Phospholipase C activation in rat pituitary adenoma (GH) cells. Gordeladze JO, et al. **Biosci Rep** 1996 Feb;16(1):65–74

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas–adenocarcinomas. Tomita T, et al. **Dis Colon Rectum** 1996 Nov;39(11):1255–64

Impairment of 11 beta-hydroxylase but not 21-hydroxylase in adrenal 'incidentalomas'. Reincke M, et al. **Eur J Endocrinol** 1997 Feb;136(2):196–200

Expression of CuZn- and Mn-superoxide dismutase in human colorectal neoplasms. Van Driel BE, et al. **Free Radic Biol Med** 1997;23(3):435–44

Protein kinase C tissue localization in human colonic tumors suggests a role for adenoma growth control. Kahl-Rainer P, et al. **Gastroenterology** 1996 Jun;110(6):1753–9

Elevated cyclooxygenase-2 levels in Min mouse adenomas. Williams CS, et al. **Gastroenterology** 1996 Oct; 111(4):1134–40

Analysis of a protein kinase C–alpha mutation in human pituitary tumours. Schiemann U, et al. **J Endocrinol** 1997 Apr;153(1):131–7

Morphological changes in a hyperfunctioning thyroid adenoma after percutaneous ethanol injection: histological, enzymatic and sub-microscopical alterations. Crescenzi A, et al. **J Endocrinol Invest** 1996 Jun;19(6):371–6

Development of oxygen insensitivity of the quantitative histochemical assay of G6PDH activity during colorectal carcinogenesis. Van Driel BE, et al. **J Pathol** 1997 Aug; 182(4):398–403

Optimization of a classical aromatase activity assay and application in normal, adenomatous and malignant breast parenchyma. Dikkeschei LD, et al. **J Steroid Biochem Mol Biol** 1996 Nov;59(3–4):305–13

Immunolocalization of glutathione-peroxidase (GSH-PO) in human adrenal gland—studies on adrenocortical adenomas associated with primary aldosteronism and Cushing's syndrome. Murakoshi M, et al. **Tokai J Exp Clin Med** 1995 Jul;20(2):89–97

EPIDEMIOLOGY

Recent and past physical activity and prevalence of colorectal adenomas. Enger SM, et al. **Br J Cancer** 1997; 75(5):740–5

Meat preparation and colorectal adenomas in a large sigmoidoscopy-based case–control study in California (United States). Probst-Hensch NM, et al. **Cancer Causes Control** 1997 Mar;8(2):175–83

Dietary intake of specific carotenoids and vitamins A, C, and E, and prevalence of colorectal adenomas. Enger SM, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Mar; 5(3):147–53

Nutritional and lifestyle habits and water–fiber interaction in colorectal adenoma etiology. Lubin F, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Feb;6(2):79–85

Reproductive history, use of exogenous hormones, and risk of colorectal adenomas. Peipins LA, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Sep;6(9):671–5

Dietary fiber and distal colorectal adenoma in men. Platz EA, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Sep; 6(9):661–70

Meat consumption and preparation, and genetic susceptibility in relation to colorectal adenomas. Voskuil DW, et al. **Cancer Lett** 1997 Mar 19;114(1–2):309–11

Calcium does not protect against colorectal neoplasia. Bergsma–Kadijk JA, et al. **Epidemiology** 1996 Nov; 7(6):590–7

Environmental and familial risk factors in relation to the colorectal adenoma--carcinoma sequence: results of a case–control study in Burgundy (France). Faivre J, et al. **Eur J Cancer Prev** 1997 Apr;6(2):127–31

High prevalence of adenomas and microadenomas of the duodenal papilla and periampullary region in patients with familial adenomatous polyposis. Bertoni G, et al. **Eur J Gastroenterol Hepatol** 1996 Dec;8(12):1201–6

5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons [see comment] Rex DK, et al. **Gastroenterology** 1996 Nov;111(5):1178–81. Comment on: Gastroenterology 1996 Nov;111(5):1385–7.

Prevalence of proximal colonic polyps in average-risk asymptomatic patients with negative fecal occult blood tests and flexible sigmoidoscopy [see comments] Kadakia SC, et al. **Gastrointest Endosc** 1996 Aug;44(2):112–7.

Comment in: Gastroenterology 1996 Aug;44(2):203–4.
Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas. Sciallero S, et al. **Gastrointest Endosc** 1997 Aug; 46(2):124–30
Prevalence and incidence of colorectal adenomas and cancer in asymptomatic persons. Neugut AI, et al. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):387–99 (63 ref.)
Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy [see comments] Read TE, et al. **N Engl J Med** 1997 Jan 2;336(1):8–12. Comment in: N Engl J Med 1997 Jun 12;336(24):1761–2.

ETIOLOGY

Nephrogenic adenoma arising in an urethral diverticulum. Paik SS, et al. **Br J Urol** 1997 Jul;80(1):150
Meat preparation and colorectal adenomas in a large sigmoidoscopy-based case-control study in California (United States). Probst-Hensch NM, et al. **Cancer Causes Control** 1997 Mar;8(2):175–83
Coffee and tea and the risk of recurrent colorectal adenomas. Baron JA, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jan;6(1):7–10
The carcinogenicity of environmental tobacco smoke. Witschi H, et al. **Carcinogenesis** 1997 Mar;18(3):575–86
Interactions between genetic and environmental factors in colorectal carcinogenesis [editorial] Hill MJ. **Eur J Cancer Prev** 1997 Feb;6(1):1–2
Body mass index and adenomas of the sigmoid colon in Japanese men [letter] Kono S, et al. **Eur J Epidemiol** 1996 Aug;12(4):425–6
Small flat adenoma: important in colon carcinogenesis? Shivaprasad P, et al. **Gastroenterologist** 1996 Sep;4(3):216–8 (16 ref.)
Predictors of the early development of advanced metachronous colon adenomas. Triantafyllou K, et al. **Hepatogastroenterology** 1997 Mar-Apr;44(14):533–8
Tobacco, colorectal cancer, and adenomas: a review of the evidence. Giovannucci E, et al. **J Natl Cancer Inst** 1996 Dec 4;88(23):1717–30 (118 ref.)
Nephrogenic adenoma after urethral reconstruction using bladder mucosa: report of 6 cases and review of the literature. Weingärtner K, et al. **J Urol** 1997 Sep;158(3 Pt 2):1175–7 (20 ref.)
Investigation of a cluster of pituitary adenomas in workers in the aluminum industry. Cullen MR, et al. **Occup Environ Med** 1996 Nov;53(11):782–6
Molecular pathogenesis of adenoma and differentiated adenocarcinoma of the stomach. Tamura G. **Pathol Int** 1996 Nov;46(11):834–41 (69 ref.)
[A case of rectal cancer in adenoma diagnosed 7 years after renal transplantation] Kobayashi T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Oct;93(10):738–42 **(Jpn)**

GENETICS

Isochromosome 15q of maternal origin in a Prader-Willi patient with pituitary adenoma. Bettio D, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(1-2):213–6
Molecular biology of growth-hormone-secreting human pituitary tumours: biochemical consequences and potential clinical significance. Adams EF, et al. **Acta Neurochir Suppl (Wien)** 1996;65:7–10 (18 ref.)
Molecular pathophysiology of acromegaly. Melmed S. **Acta Paediatr Suppl** 1996 Oct;417:45–8 (28 ref.)
Polymerase chain reaction-based approaches for detection of allelic loss in the p53 tumor suppressor gene in colon neoplasms. Yamaguchi K, et al. **Am J Gastroenterol** 1997 Feb;92(2):307–12
Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas. Samowitz WS, et al. **Am J Pathol** 1997 Jul;151(1):33–5
Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior. Thapar K, et al. **Am J Pathol** 1997 Sep; 151(3):769–84
Galanin gene expression in radiothyroidectomy-induced thyrotroph adenomas. Hyde JF, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E24–30
Genotypic alterations in benign and malignant salivary gland tumors: histogenetic and clinical implications. el-Naggar AK, et al. **Am J Surg Pathol** 1997 Jun;21(6):691–7
A somatic mutation of the p21(Waf1/Cip1) gene in a human adrenocortical adenoma. Iida S, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):633–6
Cytogenetic comparisons of synchronous carcinomas and polyps in patients with colorectal cancer. Bardi G, et al. **Br J Cancer** 1997;76(6):765–9
A detailed analysis of the role of K-ras gene mutation in the progression of colorectal adenoma. Ohnishi T, et al. **Br J Cancer** 1997;75(3):341–7
p53 and K-ras status in duodenal adenomas in familial adenomatous polyposis. Kashiwagi H, et al. **Br J Surg** 1997 Jun;84(6):826–9
Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Saretzki G, et al. **Cancer** 1997 Oct 1; 80(7):1241–9
Evidence of clonal divergence in colorectal carcinoma. Tollenaar RA, et al. **Cancer** 1997 Apr 1;79(7):1304–14
Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Ward RL, et al. **Cancer** 1997 Mar 15;79(6):1106–13
Molecular characterization of a complex chromosomal rearrangement in a pleomorphic salivary gland adenoma involving the 3'-UTR of HMGIC. Geurts JM, et al. **Cancer Genet Cytogenet** 1997 Jun;95(2):198–205
Trisomy 18 in a canine thyroid adenoma. Reimann N, et al. **Cancer Genet Cytogenet** 1996 Sep;90(2):154–6
Colorectal carcinogenesis: from chromosomal evolution pathways to molecular pathogenesis. Remvikos Y, et al. **Cancer Genet Cytogenet** 1997 Jan;93(1):63–73
Meat consumption and preparation, and genetic susceptibility in relation to colorectal adenomas. Voskuil DW, et al. **Cancer Lett** 1997 Mar 19;114(1-2):309–11
Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. Farrell WE, et al. **Cancer Res** 1997 Jul 1;57(13):2703–9
Differential loss of heterozygosity in the region of the Cowden locus within 10q22-23 in follicular thyroid adenomas and carcinomas. Marsh DJ, et al. **Cancer Res** 1997 Feb 1;57(3):500–3
Genetic resistance to urethan-induced pulmonary adenomas in SMXA recombinant inbred mouse strains. Pataer A, et al. **Cancer Res** 1997 Jul 15;57(14):2904–8
Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma. Takano T, et al. **Cancer Res** 1997 Sep 1;57(17):3792–7
K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Zhu D, et al. **Cancer Res** 1997 Jun 15;57(12):2485–92
Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Probst-Hensch NM, et al. **Carcinogenesis** 1996 Oct;17(10):2125–9
The c-erbB-2/neu proto-oncogene in human pituitary tumours. Ezzat S, et al. **Clin Endocrinol (Oxf)** 1997 May; 46(5):599–606
Genomic sequence analysis of a key residue (Arg183) in human G alpha q in invasive non-functional pituitary adenomas. Farrell WE, et al. **Clin Endocrinol (Oxf)** 1997 Aug;47(2):241–4
Follicle stimulating hormone-beta subunit gene is expressed in parallel with a transcription factor Ad4BP/SF-1 in human pituitary adenomas. Ikuyama S, et al. **Clin Endocrinol (Oxf)** 1996 Aug;45(2):187–93
PCR-SSCP analysis of the promoter region of the renin gene in patients with aldosterone-producing adenomas. Ballantine DM, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):584–6
Inhibin alpha and beta A subunit messenger ribonucleic acids expression in human pituitary adenomas: studies by quantitative reverse transcription-polymerase chain reaction. Suzuki T, et al. **Endocr J** 1996 Jun;43(3):353–6
Analysis of c-erbB-2 amplification in salivary gland tumours by differential polymerase chain reaction. Birek C, et al. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):47–50
Oncogenic mutations in thyroid adenoma: methodological criteria [letter] Tonacchera M, et al. **Eur J Endocrinol** 1996 Oct;135(4):444–6
Infrequent mutations of p16INK4A and p15INK4B genes in human pituitary adenomas. Yoshimoto K, et al. **Eur J Endocrinol** 1997 Jan;136(1):74–80
Molecular aspects of the pathogenesis of nodular goiters, thyroid nodules and adenomas. Derwahl M. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:32–5 (15 ref.)
Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism. Paschke R. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:129–32 (18 ref.)
The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Kapitanović S, et al. **Gastroenterology** 1997 Apr; 112(4):1103–13
Is the development of adenoma and carcinoma in proximal colon related to apolipoprotein E phenotype? [see comments] Kervinen K, et al. **Gastroenterology** 1996 Jun; 110(6):1785–90. Comment in: Gastroenterology 1996 Jun;110(6):2006–9.
Genetic alterations in sporadic and Crohn's-associated adenocarcinomas of the small intestine. Rashid A, et al. **Gastroenterology** 1997 Jul;113(1):127–35
Microsatellite instability in colorectal adenomas. Samowitz WS, et al. **Gastroenterology** 1997 May;112(5):1515–9
Flow cytometric DNA ploidy and cells phase fractions in recurrent human pituitary adenomas. A correlative study of flow cytometric analysis and the expression of proliferating cell nuclear antigen. Chae YS, et al. **Gen Diagn Pathol** 1996 Oct;142(2):89–95
Somatic genetic events linked to the Apc locus in intestinal adenomas of the Min mouse. Luongo C, et al. **Genes Chromosomes Cancer** 1996 Nov;17(3):194–8
The effect of different TP53 mutations on the chromosomal stability of a human colonic adenoma derived cell line with endogenous wild type TP53 activity, before and after DNA damage. Williams AC, et al. **Genes Chromosomes Cancer** 1997 Sep;20(1):44–52
Mom1 is a semi-dominant modifier of intestinal adenoma size and multiplicity in Min/+ mice. Gould KA, et al. **Genetics** 1996 Dec;144(4):1769–76
Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice. Gould KA, et al. **Genetics** 1996 Dec;144(4):1777–85
Risk of colorectal adenomas in patients with a family history of colorectal cancer: some implications for screening programmes. Aitken JF, et al. **Gut** 1996 Jul;39(1):105–8
Frequency of germline hereditary non-polyposis colorectal cancer gene mutations in patients with multiple or early onset colorectal adenomas. Beck NE, et al. **Gut** 1997 Aug; 41(2):235–8
Abnormal transduction mechanisms in pituitary adenomas. Barlier A, et al. **Horm Res** 1997;47(4-6):227–34 (61 ref.)
Protein kinase C alpha and tumorigenesis of the endocrine gland. Prévostel C, et al. **Horm Res** 1997;47(4-6):140–4
Effect of K-ras mutation on morphogenesis of colorectal adenomas and early cancers: relationship to distribution of proliferating cells. Kobayashi M, et al. **Hum Pathol** 1996 Oct;27(10):1042–9
Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Hiltunen MO, et al. **Int J Cancer** 1997 Mar 17;70(6):644–8
Over-expression of bcl-xL gene in human gastric adenomas and carcinomas. Kondo S, et al. **Int J Cancer** 1996 Dec 11;68(6):727–30
Clinical features and molecular analysis of a family with multiple colon tumours and reduced plasminogen activator activity. Tomlinson IP, et al. **Int J Colorectal Dis** 1997; 12(1):1–3
A possible tumor suppressor gene for parathyroid adenomas. Iwasaki H. **Int Surg** 1996 Jan-Mar;81(1):71–6
Bladder washing flow cytometry assessment of nephrogenic adenoma of the bladder. Kontothanassis D, et al. **Int Urol Nephrol** 1996;28(4):495–7
Adrenocorticotropin-independent macronodular adrenocortical hyperplasia associated with multiple colon adenomas/carcinomas which showed a point mutation in the APC gene [see comments] Yamakita N, et al. **Intern Med** 1997 Aug;36(8):536–42. Comment in: Intern Med 1997 Aug;36(8):533–4.
Retinoic acid stimulates growth hormone synthesis in human somatotropic adenoma cells: characterization of its nuclear receptors. Guibourdenche J, et al. **J Cell Biochem** 1997 Apr;65(1):25–31
Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. Bates AS, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):818–24
Aldosterone-producing adenomas do not contain glucocorticoid-remediable aldosteronism chimeric gene duplications. Carroll J, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4310–2
Tumor-specific expression of alternatively spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenomas. Chaidarun SS, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1058–65
Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. Davies E, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):611–5
TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas--a note of caution [editorial] Derwahl M. **J Clin Endocrinol Metab** 1996 Aug; 81(8):2783–5 (27 ref.)
Gs alpha mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome. Dötsch J, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):3839–42
Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. Parma J, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2695–701
Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. Reincke M, et al. **J Clin Endocrinol Metab** 1997 Sep; 82(9):3054–8
Corticotropin-releasing factor up-regulates its own receptor gene expression in corticotropic adenoma cells in vitro. Sakai Y, et al. **J Clin Endocrinol Metab** 1997 Apr; 82(4):1229–34
Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. Tanaka C, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3141–7
Molecular screening for somatic mutations in corticotropic adenomas of dogs with pituitary-dependent hyperadrenocorticism. van Wijk PA, et al. **J Endocrinol Invest** 1997 Jan;20(1):1–7
Quantitative analysis of numerical chromosome aberrations in various morphological types of colorectal carcinomas. Nanashima A, et al. **J Gastroenterol** 1996 Dec; 31(6):793–800
Detection of c-Ki-ras oncogene mutation in gastric adenomas with formalin-fixed, paraffin-embedded biopsy materials. Tsuchiya C, et al. **J Gastroenterol** 1997 Feb; 32(1):28–33
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene and loss of the insertion allele in aldosterone-producing adenoma. Tunny TJ, et al. **J Hum Hypertens** 1996 Dec;10(12):827–30

Detection of colorectal cancer K-ras mutations using a simplified oligonucleotide ligation assay. Rothschild CB, et al. **J Immunol Methods** 1997 Aug 7;206(1-2):11-9

Multiple endocrine neoplasia type 1: an interesting Canadian pedigree. Pelausa EO, et al. **J Otolaryngol** 1996 Aug; 25(4):261-6

Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal mucosa. Morris RG, et al. **J Pathol** 1996 Dec;180(4):357-63

Genetic heterogeneity in sporadic colorectal adenomas. Saraga E, et al. **J Pathol** 1997 Mar;181(3):281-6

Allelotype of adenoma and differentiated adenocarcinoma of the stomach. Tamura G, et al. **J Pathol** 1996 Dec; 180(4):371-7

Analysis of the RET proto-oncogene in sporadic parathyroid adenomas. Williams GH, et al. **J Pathol** 1996 Oct; 180(2):138-41

Simultaneous chromosome 7 and 17 gain and sex chromosome loss provide evidence that renal metanephric adenoma is related to papillary renal cell carcinoma. Brown JA, et al. **J Urol** 1997 Aug;158(2):370-4

p53 mutations in two patients with intraductal papillary adenoma of the pancreas. Kaino M, et al. **Jpn J Cancer Res** 1996 Dec;87(12):1195-8

The familial occurrence of brain tumors. Chang DS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Apr; 13(4):268-71

Expression of human Krev-1 gene in lungs of transgenic mice and subsequent reduction in multiplicity of ethyl carbamate-induced lung adenomas. Damak S, et al. **Mol Carcinog** 1996 Oct;17(2):84-91

Matrilysin gene expression in sporadic and familial colorectal adenomas. Takeuchi N, et al. **Mol Carcinog** 1997 Aug; 19(4):225-9

Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Woloschak M, et al. **Mol Carcinog** 1997 Aug;19(4):221-4

Interleukin-2 (IL-2) and IL-6 regulate c-fos protooncogene expression in human pituitary adenoma explants. Pereda MP, et al. **Mol Cell Endocrinol** 1996 Nov 29;124(1-2):33-42

Expression and alternative splicing of Pit-1 messenger ribonucleic acid in pituitary adenomas. Hamada K, et al. **Neurosurgery** 1996 Feb;38(2):362-6

Identification of the Par2 (Pulmonary adenoma resistance) locus on mouse chromosome 18, a major genetic determinant for lung carcinogen resistance in BALB/cByJ mice. Obata M, et al. **Oncogene** 1996 Oct 17;13(8):1599-604

Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells. Procellini A, et al. **Oncogene** 1997 Aug 14;15(7):781-9

APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Itoi T, et al. **Pathol Int** 1996 May;46(5):333-40

Localized gene action controlling intestinal neoplasia in mice. Gould KA, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5848-53

Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Wilson CL, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1402-7

Introduction of human adenomatous polyposis coli gene into Min mice via cationic liposomes. Arenas RB, et al. **Surgery** 1996 Oct;120(4):712-7; discussion 717-8

Low incidence of the stimulatory G protein alpha-subunit mutations in autonomously functioning thyroid adenomas in Japan. Tanaka K, et al. **Thyroid** 1996 Jun;6(3):195-9

[Homeoproteins and pituitary adenoma] Barlier A, et al. **Ann Endocrinol (Paris)** 1997;58(1):3-10 (34 ref.) (Eng. Abstr.) **(Fre)**

[TSH receptor double mutation in functional autonomic thyroid nodule] Semlitsch G, et al. **Acta Med Austriaca** 1995;22(4):75-7 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

An immunohistochemical study of leu 7 and PCNA expression in thyroid neoplasms. Fucich LF, et al. **Biotech Histochem** 1996 Nov;71(6):298-303

CD5 B cells in autoimmune and non immune-mediated thyroid dysfunctions. Afeltra A, et al. **Endocr Res** 1997 Feb-May;23(1-2):81-94

Hepatocellular carcinoma arising in an adenoma: value of QBend 10 immunostaining in diagnosis of liver cell carcinoma [see comments] Scott FR, et al. **Histopathology** 1996 May;28(5):472-4. Comment in: Histopathology 1996 Dec;29(6):593-4.

Immunohistochemical detection of human natural killer cell like immunoreactivity in human pituitary adenomas, using monoclonal antibody NK-1. Sanno N, et al. **J Neurooncol** 1997 Oct;35(1):29-38

Comparison of integrin alpha chain expression in benign and malignant salivary gland tumors. Franchi A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 May;83(5):588-95

METABOLISM

The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Ekramullah SM, et al. **Acta Neurochir (Wien)** 1996;138(12):1449-55

Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Kawamoto H, et al. **Acta Neurochir (Wien)** 1996;138(12):1442-8

Carbohydrate antigen 19-9 expression by folliculo-tubular structures of normal and neoplastic pituitary. Okubo T, et al. **Acta Neuropathol (Berl)** 1997 May;93(5):471-6

Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Jin L, et al. **Am J Pathol** 1997 Aug;151(2):509-19

Growth hormone-releasing hormone receptor mRNA in acromegalic pituitary tumors. Lopes MB, et al. **Am J Pathol** 1997 Jun;150(6):1885-91

Co-secretion of parathyroid hormone and parathyroid-hormone-related protein via a regulated pathway in human parathyroid adenoma cells. Matsushita H, et al. **Am J Pathol** 1997 Mar;150(3):861-71

Differences in angiogenesis and collagenesis between exophytic and flat adenomas of the colorectal mucosa. Rubio CA. **Anticancer Res** 1997 Jan-Feb;17(1B):737-42

Detection of apoptotic cells and expression of Ki-67 antigen, Bcl-2, p53 oncoproteins in human parathyroid adenoma. Wang W, et al. **APMIS** 1996 Nov;104(11):789-96

An immunohistochemical study of the simultaneous expression of bcl-2 and p53 oncoproteins in epithelial tumors of the colon and rectum. Mosnier JF, et al. **Arch Pathol Lab Med** 1996 Jul;120(7):654-9

Loss of hIRH mRNA expression from premalignant adenomas and malignant cell lines. Begum NA, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):864-8

Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers. Seo Y, et al. **Biochem Biophys Res Commun** 1997 Feb 24; 231(3):705-11

Colon adenoma and cancer cells aberrantly express the leukocyte-associated sialoglycoprotein CD43. Sikut R, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):612-6

Is Ki-67 a better proliferative marker in the colon than proliferating cell nuclear antigen? Holt PR, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Feb;6(2):131-5

Role of tissue antioxidant defence in thyroid cancers. Sadani GR, et al. **Cancer Lett** 1996 Dec 3;109(1-2):231-5

Expression of CD66a (human C-CAM) and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas. Nollau P, et al. **Cancer Res** 1997 Jun 15;57(12):2354-7

Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Zhang T, et al. **Cancer Res** 1997 May 1;57(9):1638-43

Depletion of hepatocyte nuclear estrogen receptor expression is associated with promotion of tamoxifen induced GST-P foci to tumours in rat liver. Carthew P, et al. **Carcinogenesis** 1997 May;18(5):1109-12

Oestrogen producing adrenocortical adenoma: clinical, biochemical and immunohistochemical studies. Goto T, et al. **Clin Endocrinol (Oxf)** 1996 Nov;45(5):643-8

Cytokine expression in human anterior pituitary adenomas. Green VL, et al. **Clin Endocrinol (Oxf)** 1996 Aug; 45(2):179-85

Pit-1 gene expression in human pituitary adenomas using the reverse transcription polymerase chain reaction method. Yamada S, et al. **Clin Endocrinol (Oxf)** 1996 Sep; 45(3):263-72

PCR-SSCP analysis of the promoter region of the renin gene in patients with aldosterone-producing adenomas. Ballantine DM, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):584-6

Gonadotroph adenomas. Snyder PJ. **Curr Ther Endocrinol Metab** 1997;6:56-8 (4 ref.)

Stress-response proteins in human pituitary adenomas. Expression of heat-shock protein 72 (HSP-72). Kontogeorgos G, et al. **Endocrine** 1997 Feb;6(1):25-9

Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Weber MM, et al. **Eur J Endocrinol** 1997 Mar;136(3):296-303

Colorectal adenoma-carcinoma sequence [letter; comment] Khosraviani K. **Gut** 1996 Aug;39(2):342. Comment on: Gut 1996 Feb;38(2):254-9.

Immunohistochemical expression of metallothionein in normal human colorectal mucosa, in adenomas and in adenocarcinomas and their associated metastases. Giuffrè G, et al. **Histopathology** 1996 Oct;29(4):347-54

Pit-1 gene expression in human pituitary adenomas. Pellegrini-Bouiller I, et al. **Horm Res** 1997;47(4-6):251-8 (43 ref.)

Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Gansler TS, et al. **Hum Pathol** 1997 Jun;28(6):686-92

Significance of AgNOR counts for distinguishing carcinoma from adenoma and hyperplasia in parathyroid gland. Kanematsu E, et al. **Hum Pathol** 1997 Apr;28(4):421-7

Significance of the expression of proliferation-associated nucleolar antigen p120 in human colorectal tumors. Ueki T, et al. **Hum Pathol** 1997 Jan;28(1):74-9

Over-expression of a novel member of the immunoglobulin superfamily in Min mouse intestinal adenomas. Chadéneau C, et al. **Int J Cancer** 1996 Dec 11;68(6):817-21

Thyrotropin-producing pituitary adenoma discovered as a pituitary incidentaloma. Yamakita N, et al. **Intern Med** 1995 Nov;34(11):1055-60

Altered expression of fibroblast growth factor receptors in human pituitary adenomas. Abbass SA, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1160-6

Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. Davies E, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):611-5

Prolactin receptor messenger ribonucleic acid in normal and neoplastic human pituitary tissues. Jin L, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):963-8

Suppression of tyrosine kinase activity inhibits [3H]thymidine uptake in cultured human pituitary tumor cells. Jones TH, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2143-7

MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas. Ajioka Y, et al. **J Clin Pathol** 1997 May; 50(5):417-21

Expression of bcl-2 oncoprotein in pituitary tumours: comparison with c-myc. Wang DG, et al. **J Clin Pathol** 1996 Oct;49(10):795-7

Gonadotrophin and free alpha-subunit secretion in patients with acromegaly and clinically non-functioning pituitary tumors: anterior pituitary function and the effect of thyrotrophin-releasing hormone. Damjanović SS, et al. **J Endocrinol Invest** 1996 Nov;19(10):663-9

Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn. Pozzan GB, et al. **J Endocrinol Invest** 1997 Feb;20(2):86-9

Immunodetection of glycoprotein hormone subunits in nonfunctioning and glycoprotein hormone-secreting pituitary adenomas. Saccomanno K, et al. **J Endocrinol Invest** 1997 Feb;20(2):59-64

Localization of immunoreactive secretory leukocyte protease inhibitor (SLPI) in intestinal mucosa. Bergenfeldt M, et al. **J Gastroenterol** 1996 Feb;31(1):18-23

Altered carbohydrate composition in colorectal adenomas and carcinomas: histochemical characterization of N-acetylgalactosamine, L-fucose, and o-acetylated sialic acid. Iwakawa K, et al. **J Gastroenterol** 1996 Feb; 31(1):24-32

Tobacco, colorectal cancer, and adenomas: a review of the evidence. Giovannucci E, et al. **J Natl Cancer Inst** 1996 Dec 4;88(23):1717-30 (118 ref.)

Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction. Murabe H, et al. **J Neuroendocrinol** 1996 Aug;8(8):605-10

Proton magnetic resonance spectroscopy and intracranial tumours: clinical perspectives. Falini A, et al. **J Neurol** 1996 Oct;243(10):706-14

Expression of cripto in human gall bladder lesions. Fujii K, et al. **J Pathol** 1996 Oct;180(2):166-8

Expression of bcl-2 and p53 in de novo and ex-adenoma colon carcinoma: a comparative immunohistochemical study. Mueller J, et al. **J Pathol** 1996 Nov;180(3):259-65

Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. Yasui W, et al. **J Pathol** 1996 Oct; 180(2):122-8

Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Yasui W, et al. **Jpn J Cancer Res** 1997 Jul;88(7):625-9

Differential expression of transthyretin in papillary tumors of the endolymphatic sac and choroid plexus. Megerian CA, et al. **Laryngoscope** 1997 Feb;107(2):216-21

Matrilysin gene expression in sporadic and familial colorectal adenomas. Takeuchi N, et al. **Mol Carcinog** 1997 Aug; 19(4):225-9

Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Woloschak M, et al. **Mol Carcinog** 1997 Aug;19(4):221-4

125I-Tyr0-hCRH labelling characteristics of corticotropin-releasing hormone receptors: differences between normal and adenomatous corticotrophs. Abs R, et al. **Neurochem Int** 1997 Mar;30(3):291-7

Immunohistochemical expression of retinoid X receptor isoforms in human pituitaries and pituitary adenomas. Sanno N, et al. **Neuroendocrinology** 1997 Apr;65(4):299-306

Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter: KRAS expression in thyroids analyzed by in situ hybridization. Chiappetta G, et al. **Oncol Res** 1996;8(2):85-93

Regular immunohistochemical localization of endothelin-1 and endothelin-B receptor in normal, hyperplastic and neoplastic human adrenocortical cells. Hiraki H, et al. **Pathol Int** 1997 Feb-Mar;47(2-3):117-25

Different expression of Bcl-2 protein in gastric adenomas and carcinomas. Uesugi H, et al. **Pathol Int** 1996 Apr; 46(4):274-80

p53 expression patterns in colorectal adenomas and early carcinomas: a special reference to depressed adenoma and non-polypoid carcinoma. Yao T, et al. **Pathol Int** 1996 Dec; 46(12):962-7

Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression. Yasui W, et al. **Pathol Int** 1997 Jul;47(7):470-7

Secretogranin II (SgII) distribution and processing studies in human normal and adenomatous anterior pituitaries using new polyclonal antibodies. Vallet VS, et al. **Regul Pept** 1997 Feb 26;68(3):155-63

Expression patterns of extracellular matrix components in native and cultured normal human thyroid tissue and in human toxic adenoma tissue. Bürgi-Saville ME, et al.

Thyroid 1997 Jun;7(3):347–56

Long–standing goiter and hypothyroidism: an unusual presentation of a TSH–secreting adenoma. Langlois MF, et al. **Thyroid** 1996 Aug;6(4):329–35

A case of thyrotropin–secreting pituitary microadenoma with normal thyrotropin alpha–subunit level. Ozata M, et al. **Thyroid** 1997 Jun;7(3):441–7

Bilateral aldosterone–producing adenomas in two patients diagnosed by immunohistochemical analysis of steroidogenic enzymes. Watanabe N, et al. **Tohoku J Exp Med** 1996 Jun;179(2):123–9

Immunohistochemical analysis of intercellular adhesion molecule–1 expression in human gastric adenoma and adenocarcinoma. Nasu R, et al. **Virchows Arch** 1997 Apr; 430(4):279–83

[Inadequate TSH secretion due to a probable pituitary microadenoma (letter)] Rubio Herrera MA, et al. **Med Clin (Barc)** 1997 Mar 1;108(8):316–7 **(Spa)**

MORTALITY

Randomised controlled trial of faecal–occult–blood screening for colorectal cancer [see comments] Hardcastle JD, et al. **Lancet** 1996 Nov 30;348(9040):1472–7. Comment in: Lancet 1997 Feb 1;349(9048):356; discussion 358. Comment in: Lancet 1997 Feb 1;349(9048):356–7; discussion 358. Comment in: Lancet 1997 Feb 1;349(9048):357; discussion 358. Comment in: Lancet 1997 Feb 1;349(9048):357–8. Comment in: ACP J Club 1997 May–Jun;126(3):63.

Randomised study of screening for colorectal cancer with faecal–occult–blood test [see comments] Kronborg O, et al. **Lancet** 1996 Nov 30;348(9040):1467–71. Comment in: Lancet 1997 Feb 1;349(9048):356; discussion 358. Comment in: Lancet 1997 Feb 1;349(9048):356–7; discussion 358. Comment in: Lancet 1997 Feb 1;349(9048):357; discussion 358. Comment in: Lancet 1997 Feb 1;349(9048):357–8. Comment in: ACP J Club 1997 May–Jun;126(3):62–3.

PATHOLOGY

Follicular neoplasms of the thyroid. Decision tree approach using morphologic and morphometric parameters. Deshpande V, et al. **Acta Cytol** 1997 Mar–Apr;41(2):369–76

Multinucleated giant cells in thyroid neoplasms. A cytologic, histologic and immunohistochemical study. Tabbara SO, et al. **Acta Cytol** 1996 Nov–Dec;40(6):1184–8

Cathepsin B in the growth of colorectal cancer: increased activity of cathepsin B in human colorectal cancer. Satoh Y, et al. **Acta Med Okayama** 1996 Dec;50(6):305–11

Proliferation parameters for pituitary adenomas. Buchfelder M, et al. **Acta Neurochir Suppl (Wien)** 1996;65:18–21 (20 ref.)

Molecular biological research in pituitary adenomas from the pathologists' view. Kovacs K. **Acta Neurochir Suppl (Wien)** 1996;65:4–6 (8 ref.)

Current pathological classification of pituitary adenomas. Saeger W. **Acta Neurochir Suppl (Wien)** 1996;65:1–3 (8 ref.)

Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Kawamoto H, et al. **Acta Neurochir (Wien)** 1996;138(4):390–5

MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Mizoue T, et al. **Acta Neurochir (Wien)** 1997;139(5):426–31; discussion 431–2

Hyalinizing trabecular adenoma of thyroid masquerading as thyroid carcinoma. Savaş MC, et al. **Acta Oncol** 1997; 36(4):436–7

Adenoma of anogenital mammary–like glands. Donati P, et al. **Am J Dermatopathol** 1996 Feb;18(1):73–6

Spiradenoma and dermal cylindroma: comparative immunohistochemical analysis and histogenetic considerations. Meybehm M, et al. **Am J Dermatopathol** 1997 Apr;19(2):154–61

Lack of spontaneous regression of tubular adenomas in two years of follow–up. Bersentes K, et al. **Am J Gastroenterol** 1997 Jul;92(7):1117–20

Coexistence of aldosteronoma and contralateral nonfunctioning adrenal adenoma in primary aldosteronism. Fallo F, et al. **Am J Hypertens** 1997 Apr;10(4 Pt 1):476–8

Hepatocellular neoplasms induced by low–number pancreatic islet transplants in streptozotocin diabetic rats. Dombrowski F, et al. **Am J Pathol** 1997 Mar; 150(3):1071–87

In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas. Sordat I, et al. **Am J Pathol** 1997 Jan;150(1):283–95

Genotypic alterations in benign and malignant salivary gland tumors: histogenetic and clinical implications. el–Naggar AK, et al. **Am J Surg Pathol** 1997 Jun;21(6):691–7

Solid serous adenoma of the pancreas. The solid variant of serous cystadenoma? Perez–Ordonez B, et al. **Am J Surg Pathol** 1996 Nov;20(11):1401–5

Nuclear area measurements of parathyroid adenoma, parathyroid hyperplasia and thyroid follicular adenoma. A comparison. Tsai TH, et al. **Anal Quant Cytol Histol** 1997 Feb;19(1):45–8

VIP– and PACAP–containing nerve fibers in human parathyroid glands and adenomas: comparison of innervation pattern with animal species. Luts L, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:661–5

Reduced expression of molecules of the cadherin/catenin complex in the transition from colorectal adenoma to carcinoma. Hao X, et al. **Anticancer Res** 1997 May–Jun; 17(3C):2241–7

Malignant myoepithelioma of the minor salivary glands arising in a pleomorphic adenoma. Tralongo V, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2671–5

Solitary facial lesion. Sebaceous adenoma in association with Muir–Torre syndrome (MTS). Pehoushek JF, et al. **Arch Dermatol** 1997 Jan;133(1):98, 101–2

Immunocytochemical localization of macrophage migration inhibitory factor in human hypophysis and pituitary adenomas. Tampanaru–Sarmesiu A, et al. **Arch Pathol Lab Med** 1997 Apr;121(4):404–10

Ultrasound–guided parathyroid aspiration to diagnose parathyroid adenomas. Campbell J, et al. **Australas Radiol** 1996 Aug;40(3):273–5

Immunohistochemical analysis of p185 in normal and transformed human tissues. Pagani R, et al. **Biochem Soc Trans** 1996 May;24(2):306S

Cell–cell contact and specific cytokines inhibit apoptosis of colonic epithelial cells: growth factors protect against c–myc–independent apoptosis. Hague A, et al. **Br J Cancer** 1997;75(7):960–8

The A1 syndrome: a clinical entity? Millares–Martin P, et al. **Br J Neurosurg** 1996 Dec;10(6):599–601

Symptomatic Rathke's cleft cyst with hypophysitis. Wearne MJ, et al. **Br J Neurosurg** 1995;9(6):799–803

Synchronous salivary gland neoplasia [letter; comment] Curtis A, et al. **Br J Oral Maxillofac Surg** 1997 Feb; 35(1):73–4. Comment on: Br J Oral Maxillofac Surg 1996 Feb;34(1):135.

Immunocytochemical detection of p53 protein as an adjunct in cytologic diagnosis from pancreatic duct brushings in mucin–producing tumors of the pancreas. Iwao T, et al. **Cancer** 1997 Jun 25;81(3):163–71

Prostatic intraepithelial neoplasia in surgical resections: relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate. Skjørten FJ, et al. **Cancer** 1997 Mar 15;79(6):1172–9

Clonality of dysplastic epithelium in colorectal adenomas from familial adenomatous polyposis patients. Bjerknes M, et al. **Cancer Res** 1997 Feb 1;57(3):355–61

Accidentally detected brain tumors: clinical analysis of a series of 110 patients. Kamiguchi H, et al. **Clin Neurol Neurosurg** 1996 May;98(2):171–5

Lymphocytic hypophysitis simulating a pituitary adenoma in a nonpregnant woman. Hartmann I, et al. **Clin Neuropathol** 1996 Jul–Aug;15(4):234–9

Erosive adenomatosis of the nipple: a benign imitator of malignant breast disease. Miller L, et al. **Cutis** 1997 Feb; 59(2):91–2 (11 ref.)

Proliferating tricholemmal cyst: a possible pitfall in cytological diagnosis. Biernat W, et al. **Diagn Cytopathol** 1996 Jul;15(1):73–5

Cytologic features of a combined tubular adenoma and fibroadenoma of the breast [letter] Liu K, et al. **Diagn Cytopathol** 1997 Feb;16(2):184–6

Cytologic and fluorescence in situ hybridization (FISH) examination of metanephric adenoma. Renshaw AA, et al. **Diagn Cytopathol** 1997 Feb;16(2):107–11

Embryonal adenoma of the kidney: a report of two cases. Zafar N, et al. **Diagn Cytopathol** 1997 Jan;16(1):42–6

Feasibility study for use of brush cytology as a complementary method for diagnosis of rectal cancer. Farouk R, et al. **Dis Colon Rectum** 1997 May;40(5):609–13

Correlation between macroscopic morphologic features and malignant potential of colorectal sessile adenomas. Ishikawa M, et al. **Dis Colon Rectum** 1996 Nov; 39(11):1275–81

Adenoma of the middle ear mucosa. Arnold B, et al. **Eur Arch Otorhinolaryngol** 1996;253(1–2):65–8

Apoptosis and p53 suppressor gene protein expression in human anterior pituitary adenomas. Green VL, et al. **Eur J Endocrinol** 1997 Apr;136(4):382–7

Nephrogenic adenoma in children. Case report and review of literature. Schumacher K, et al. **Eur J Pediatr Surg** 1997 Apr;7(2):115–7 (24 ref.)

Metastatic pulmonary and rectal calcifications secondary to primary hyperparathyroidism. De Nardi P, et al. **Eur J Surg** 1996 Sep;162(9):735–8

Renal cell tumours in mice: electron microscopy versus immunohistochemistry. Kondalenko VF, et al. **Exp Toxicol Pathol** 1997 Feb;49(1–2):129–34

The expression of p185(HER–2/neu) correlates with the stage of disease and survival in colorectal cancer. Kapitanović S, et al. **Gastroenterology** 1997 Apr; 112(4):1103–13

Fluorescence endoscopic imaging of human colonic adenomas. Wang TD, et al. **Gastroenterology** 1996 Nov; 111(5):1182–91

Nonpolypoid adenomas of the duodenum in patients with familial adenomatous polyposis (Gardner's syndrome). Iida M, et al. **Gastrointest Endosc** 1996 Sep;44(3):305–8

Diagnosis of colorectal tumorous lesions by magnifying endoscopy [see comments] Kudo S, et al. **Gastrointest Endosc** 1996 Jul;44(1):8–14. Comment in: Gastrointest Endosc 1996 Jul;44(1):95–6.

Small flat adenomas [letter; comment] Muto T. **Gastrointest Endosc** 1996 Nov;44(5):632. Comment on: Gastrointest Endosc 1995 Aug;42(2):184–7.

The problem of "flat" colonic adenoma. Kudo S, et al. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):87–98 (28 ref.)

Ciliated metaplasia in a patient of Mediterranean origin with gastric adenoma. Alujevic A, et al. **Gen Diagn Pathol** 1996 Oct;142(2):113–7

Metanephric adenoma of the kidney: histologic, immunohistochemical and DNA content analysis study. A case report. Fraggetta F, et al. **Gen Diagn Pathol** 1997 Jul; 143(1):59–62

Effect of cereal fibre source and processing on rectal epithelial cell proliferation. Macrae FA, et al. **Gut** 1997 Aug;41(2):239–44

Differences between colorectal adenomas removed endoscopically and surgically. Nusko G, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):1063–8

Metastatic potential of colorectal adenoma containing carcinoma determined by pre–operative assessment of morphology. Orita H, et al. **Hepatogastroenterology** 1997 Mar–Apr;44(14):452–7

Histochemical study of expression of lectin–reactive carbohydrate epitopes and glycoligand–binding sites in normal human appendix vermiformis, colonic mucosa, acute appendicitis and colonic adenoma. Brinck U, et al. **Histol Histopathol** 1996 Oct;11(4):919–30

Dual carcinoid/epithelial neoplasia of the appendix. Carr NJ, et al. **Histopathology** 1995 Dec;27(6):557–62

Histological changes of parathyroid adenoma after percutaneous injection of ethanol. Chow LT, et al. **Histopathology** 1997 Jan;30(1):87–9

Mammary adenohibernoma. Damiani S, et al. **Histopathology** 1996 Jun;28(6):554–5

p53 protein expression in colorectal adenomas: an immunohistochemical study using an antigen retrieval system. Karamitopoulou E, et al. **Histopathology** 1995 Dec; 27(6):517–23

Middle–ear adenoma (MEA): a report of two cases, one with predominant "plasmacytoid' features. Ribé A, et al. **Histopathology** 1997 Apr;30(4):359–64

Flow cytometry analysis of pituitary adenomas. Fornas O, et al. **Horm Res** 1996;46(6):257–62

Chromosome abnormalities in colorectal adenomas: two cytogenetic subgroups characterized by deletion of 1p and numerical aberrations. Bomme L, et al. **Hum Pathol** 1996 Nov;27(11):1192–7

Intraductal papillary tumors and mucinous cystic tumors of the pancreas: clinicopathologic study of 38 cases. Fukushima N, et al. **Hum Pathol** 1997 Sep;28(9):1010–7

Gastric epithelial dysplasia and adenoma: historical review and histological criteria for grading. Goldstein NS, et al. **Hum Pathol** 1997 Feb;28(2):127–33 (100 ref.)

Growth kinetics of colorectal adenoma–carcinoma sequence: an immunohistochemical study of proliferating cell nuclear antigen expression. Yang HB, et al. **Hum Pathol** 1996 Oct; 27(10):1071–6

Human anterior pituitary adenoma cell attachment in vitro [letter] Atkin SL, et al. **In Vitro Cell Dev Biol Anim** 1997 Mar;33(3):158–60

Histologic differences between flat tubular colorectal neoplasias in Japan and Sweden. Rubio C, et al. **In Vivo** 1997 Jan–Feb;11(1):93–4

Flat serrated adenomas of the colorectal mucosa in Japanese patients. Rubio CA, et al. **In Vivo** 1996 May–Jun; 10(3):339–43

MIB–1 proliferative index in parathyroid adenoma & hyperplasia. Karak AK, et al. **Indian J Med Res** 1997 May; 105:235–8

Nucleolar organizer regions in pituitary adenomas. Radhakrishnan VV, et al. **Indian J Pathol Microbiol** 1995 Jan;38(1):25–32

A salivary gland–type monomorphic adenoma with trabecular proliferation in the lung. Shirasaki A, et al. **Intern Med** 1995 Nov;34(11):1086–8

Superficial papillary adenomatosis of the nipple [letter; comment] Moulin G. **J Am Acad Dermatol** 1997 Jan; 36(1):133. Comment on: J Am Acad Dermatol 1995 Nov;33(5 Pt 2):871–5.

Large bowel adenomas: markers of risk and endpoints. Baron JA. **J Cell Biochem Suppl** 1996;25:142–8 (34 ref.)

Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. Bates AS, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):818–24

Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeratins. Demirkesen C, et al. **J Cutan Pathol** 1995 Dec;22(6):518–35

Morphological changes in a hyperfunctioning thyroid adenoma after percutaneous ethanol injection: histological, enzymatic and sub–microscopical alterations. Crescenzi A, et al. **J Endocrinol Invest** 1996 Jun;19(6):371–6

Significance of rectosigmoid adenomas. Kramar J, et al. **J Fam Pract** 1997 Apr;44(4):339–40

Flat adenoma of the colon: two cases. Huang PC, et al. **J Formos Med Assoc** 1997 Aug;96(8):649–52

Co–existing pleomorphic and tubular basal cell adenomas of the parotid gland. Chow LT, et al. **J Laryngol Otol** 1997 Feb;111(2):182–5

Distribution of the solitary adenoma over the parathyroid glands. Debruyne F, et al. **J Laryngol Otol** 1997 May; 111(5):459–60

Adenoma of thyroid gland containing fat (thyrolipoma). Report of a case. Laforga JB, et al. **J Laryngol Otol** 1996 Nov;110(11):1088–9

Expression of epithelial cadherin and cavernous sinus invasion in human pituitary adenomas. Kawamoto H, et al. **J Neurooncol** 1997 Sep;34(2):105–9

Dural tail in pituitary adenoma. Celli P, et al.

J Neuroradiol 1997 Jun;24(1):68–9

A comparison of proliferation indices in human anterior pituitary adenomas using formalin–fixed tissue and in vitro cell culture. Atkin SL, et al. **J Neurosurg** 1997 Jul; 87(1):85–8

Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application. Hamilton HB, et al. **J Neurosurg** 1996 Aug;85(2):329–34

Differentiating neuroblastoma of pituitary gland: neuroblastic transformation of epithelial adenoma cells. Case report. Lach B, et al. **J Neurosurg** 1996 Nov;85(5):953–60

Sialadenoma papilliferum of the hard palate: a case report and review of literature. Asahina I, et al.
J Oral Maxillofac Surg 1997 Sep;55(9):1000–3 (25 ref.)

Basaloid monomorphic adenoma presenting as an expanding buccal mass: a case report. Lucas JH, et al.
J Oral Maxillofac Surg 1997 Jun;55(6):631–4

Sialadenoma papilliferum: an immunohistochemical study of five cases. Maiorano E, et al. **J Oral Pathol Med** 1996 Jul; 25(6):336–42

Synchronous endometrioid tumors of the ovary and endometrium. A clinicopathologic study of 22 cases. Falkenberry SS, et al. **J Reprod Med** 1996 Oct;41(10):713–8

Reliability of frozen section diagnosis of gallbladder tumor for detecting carcinoma and depth of its invasion. Yamaguchi K, et al. **J Surg Oncol** 1997 Jun;65(2):132–6

Reduced expression of cyclin–dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Yasui W, et al.
Jpn J Cancer Res 1997 Jul;88(7):625–9

Characterization of novel cell lines from pleomorphic adenomas of the parotid gland established in a collagen gel system. Steiner MG, et al. **Laryngoscope** 1997 May; 107(5):654–60

Correspondence re: Lavoie M, Morency RM: Low–grade papillary adenomatous tumors of the temporal bone: report of two cases and review of the literature. Mod Pathol 8:603, 1995 [letter; comment] Pollak A. **Mod Pathol** 1996 Apr; 9(4):460–1. Comment on: Mod Pathol 1995 Aug;8(6):603–8.

Lipoadenoma of the parotid gland with probable striated duct differentiation. Yau KC, et al. **Mod Pathol** 1997 Mar; 10(3):242–6

Differentiation of atypical adenomatous hyperplasia and adenocarcinoma of the lung by use of DNA ploidy and morphometric analysis. Yokozaki M, et al. **Mod Pathol** 1996 Dec;9(12):1156–64

Importance of colonic adenomas 5 mm or less in diameter [letter; comment] Selby JV, et al. **N Engl J Med** 1997 Jun 12;336(24):1761–2. Comment on: N Engl J Med 1997 Jan 2;336(1):8–12.

Rapidly–growing ectopic pituitary adenoma within the sphenoid sinus—case report. Horiuchi T, et al.
Neurol Med Chir (Tokyo) 1997 May;37(5):399–402

Postoperative follow–up of pituitary adenomas after trans–sphenoidal resection: MRI and clinical correlation. Rodriguez O, et al. **Neuroradiology** 1996 Nov;38(8):747–54

A role for epidermal growth factor receptor, c–Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Brunton VG, et al. **Oncogene** 1997 Jan 23;14(3):283–93

Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer
TSH–independent growth to thyroid cells. Procellini A, et al. **Oncogene** 1997 Aug 14;15(7):781–9

Acquired neoplasms of the nonpigmented ciliary epithelium (adenoma and adenocarcinoma). Shields JA, et al.
Ophthalmology 1996 Dec;103(12):2007–16

Sebaceous adenoma of the submandibular gland: a case report. Ribeiro K de C, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Aug;82(2):200–3

Origin of intraepithelial apoptotic cells in human colorectal adenomas [letter] Arai T, et al. **Pathol Int** 1997 May; 47(5):333–5

Late bone metastasis from an encapsulated follicular carcinoma of the thyroid without capsular and vascular invasion. Mizukami Y, et al. **Pathol Int** 1996 Jun; 46(6):457–61

p53 and Ki–67 immunoreactivity and nuclear morphometry of 'carcinoma–in–adenoma' and adenoma of the gall–bladder [corrected and republished in Pathol Int 1996 Nov;46(11):908–17] Takei K, et al. **Pathol Int** 1996 Jun; 46(6):426–35

p53 and Ki–67 immunoreactivity and nuclear morphometry of 'carcinoma–in–adenoma' and adenoma of the gall–bladder [corrected and republished article originally printed in Pathol Int 1996 Jun; 46(6):426–35] Takei K, et al. **Pathol Int** 1996 Nov;46(11):908–17

Early hepatocellular carcinoma macroscopically resembling adenomatous hyperplasia: pathological resemblance to carcinoma–in–situ. Wakasa K, et al. **Pathol Int** 1997 Jan; 47(1):54–9

Endometrioid adenoma (polypoid endometriosis) of the omentum maius. Grouls V, et al. **Pathol Res Pract** 1995 Oct;191(10):1049–52

Pyloric gland type adenoma of the gallbladder with squamoid spindle cell metaplasia. Kushima R, et al.
Pathol Res Pract 1996 Sep;192(9):963–9; discussion 970–1

Tubular adenoma of the breast: an immunohistochemical study of ten cases. Maiorano E, et al. **Pathol Res Pract** 1995 Dec;191(12):1222–30

Spiradenoma associated with apocrine adenoma component. Michal M. **Pathol Res Pract** 1996 Nov;192(11):1135–9; discussion 1140–1

Carcinoma in basal cell adenoma of the parotid gland. Nagao T, et al. **Pathol Res Pract** 1997;193(3):171–8

Tubular adenoma of the choroid plexus: evidence for glandular differentiation of the neuroepithelium. Varga Z, et al. **Pathol Res Pract** 1996 Aug;192(8):840–4

Adenoma malignum of the cervix: a reappraisal. Mulvany NJ, et al. **Pathology** 1997 Feb;29(1):17–20

Fine–needle aspiration of solid and papillary cystic tumor of the pancreas. Buchino JJ. **Pediatr Pathol Lab Med** 1996 Mar–Apr;16(2):235–42

Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. Fazeli A, et al.
Proc Natl Acad Sci U S A 1997 Sep 16;94(19):10199–204

MR imaging of pituitary adenomas with sphenoid sinus invasion: characteristic MR findings indicating fibrosis. Ishii K, et al. **Radiat Med** 1996 Jul–Aug;14(4):173–8

Leydig cell hyperplasia and adenoma formation: mechanisms and relevance to humans. Clegg ED, et al.
Reprod Toxicol 1997 Jan–Feb;11(1):107–21 (170 ref.)

Pathology of parathyroid tumors. Grimelius L, et al.
Semin Surg Oncol 1997 Mar–Apr;13(2):142–54 (62 ref.)

The adenoma–carcinoma sequence in colorectal neoplasia. O'Brien MJ, et al. **Surg Oncol Clin N Am** 1996 Jul; 5(3):513–30 (96 ref.)

Immunohistochemical characterization of
"hyperplasia–adenoma sequence" in the pituitaries of transgenic mice expressing a human growth
hormone–releasing factor gene. Umemura S, et al.
Tokai J Exp Clin Med 1995 Jul;20(2):71–9

Pathological and genetic correlates of apoptosis in the progression of colorectal neoplasia. Hawkins N, et al.
Tumour Biol 1997;18(3):146–56

Metanephric adenoma of the kidney. Munichor M, et al.
Urol Int 1997;58(2):117–20

Pulmonary nodule caused by an alveolar adenoma of the lung. Böhm J, et al. **Virchows Arch** 1997 Feb;430(2):181–4 (9 ref.)

Proliferation and apoptosis in proliferative lesions of the colon and rectum. Kikuchi Y, et al. **Virchows Arch** 1997 Aug;431(2):111–7

Alveolar adenoma of the lung: further characterization of this uncommon tumour. Oliveira P, et al.
Virchows Arch 1996 Oct;429(2–3):101–8

The congenital basal cell adenoma of salivary glands. Contribution to the differential diagnosis of congenital salivary gland tumours. Seifert G, et al. **Virchows Arch** 1997 Apr;430(4):311–9

Endocrine cells in intraductal papillary–mucinous neoplasms of the pancreas. A histochemical and immunohistochemical study. Terada T, et al. **Virchows Arch** 1997 Jul;431(1):31–6

Parathyroid function and histology in patients with parathyroid adenoma: correlation of clinical and morphologic findings. Luts L, et al. **World J Surg** 1997 Jun;21(5):553–63

Assessment of proliferative activity of glandular cells in hyperfunctioning parathyroid gland using flow cytometric and immunohistochemical methods. Xiao–Lin P, et al.
World J Surg 1996 Mar–Apr;20(3):361–6; discussion 367

Melanosis coli—a harmless pigmentation or a precancerous condition? Nusko G, et al. **Z Gastroenterol** 1997 May; 35(5):313–8

[A clinicopathological study of 3 dimensional structure in adenoma of large intestine] Zhang Y, et al.
Chung Hua Ping Li Hsueh Tsa Chih 1995 Dec;24(6):363–5 (Eng. Abstr.) **(Chi)**

[Alveolar adenoma of the lung (case report)] Haškovcová I, et al. **Cesk Patol** 1997 May;33(2):49–52 (Eng. Abstr.) **(Cze)**

[Differentiating parathyroid adenoma from microfollicular thyroid nodule in fine–needle aspiration cytology] Ryška A, et al. **Cesk Patol** 1996 Aug;32(3):110–4 (Eng. Abstr.) **(Cze)**

[Adenoma developed on the parathyroid tissue transplanted to the forearm after parathyroidectomy in recurrent familial hyperparathyroidism (letter)] Eulry F, et al.
Ann Med Interne (Paris) 1997;148(1):103–5 **(Fre)**

[Pancreatic adenomatous hyperplasia and sudden infant death] Léger–Ravet MB, et al. **Ann Pathol** 1997 Jul; 17(3):206–8 (Eng. Abstr.) **(Fre)**

[Adenoma and neuroendocrine carcinoma: 2 adjacent intestinal neoplasias. Simple coincidence? Report of 2 cases] Salmeron M, et al. **Rev Med Suisse Romande** 1997 Feb; 117(2):143–6 **(Fre)**

[Intestinal cell proliferation, acromegaly and colon tumors] Fehmann HC, et al. **Z Gastroenterol** 1997 Apr;35(4):305–6 **(Ger)**

[Biological bases of the colorectal adenoma–carcinoma sequence (editorial)] Stella S, et al. **G Chir** 1996 Oct; 17(10):473–6 **(Ita)**

[Adenomatous tissue in colorectal carcinomas: clinical significance and probable histogenetic implications of morphological differences] Giuliani A, et al.
Minerva Chir 1997 Mar;52(3):201–8 (Eng. Abstr.) **(Ita)**

[Nephrogenic metaplasia. A particular clinical and anatomopathologic entity] Messinetti S, et al.
Minerva Urol Nefrol 1997 Mar;49(1):51–5 (Eng. Abstr.) **(Ita)**

[The point of view of otolaryngologist and head and neck surgeon on thyroid diseases] Betkowski A, et al.
Otolaryngol Pol 1995;49(6):574–82 (Eng. Abstr.) **(Pol)**

[Monomorphic adenoma of basal cells in a minor salivary gland] Zabaleta M, et al. **Acta Otorrinolaringol Esp** 1997 Mar;48(2):169–72 (Eng. Abstr.) **(Spa)**

[Hepatic adenoma and focal nodular hyperplasia: difficult differential diagnosis. Presentation of a case of focal nodular hyperplasia] Rodríguez Dapena S, et al.
Rev Esp Enferm Dig 1996 Jul;88(7):509–1 (Eng. Abstr.) **(Spa)**

[Colonic adenoma: risk factors for their malignant transformation] Rocha Ramírez JL, et al.
Rev Gastroenterol Mex 1996 Jul–Sep;61(3):178–83 (Eng. Abstr.) **(Spa)**

[Anatomopathological study of 86 gastric adenomas. Experience in 14 years] Pisano R, et al. **Rev Med Chil** 1996 Feb;124(2):204–8 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Comparison of thermoregulatory characteristics of patients with intra– and suprasellar pituitary adenomas. Behr R, et al. **Acta Neurochir Suppl (Wien)** 1996;65:44–9

Protein kinase C and growth regulation of pituitary adenomas. Couldwell WT, et al.
Acta Neurochir Suppl (Wien) 1996;65:22–6

Proliferative potential in pituitary adenomas: measurement by monoclonal antibody MIB–1. Abe T, et al.
Acta Neurochir (Wien) 1997;139(7):613–8

Enhancement of Ca2+ currents by GHRH and its relation to PKA and [Ca2+]i in human GH–secreting adenoma cells. Takei T, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):E801–7

Adrenocortical neoplasms: role of prognostic markers MIB–1, P53, and RB. Vargas MP, et al.
Am J Surg Pathol 1997 May;21(5):556–62

Effect of PACAP on ion channels involved in stimulating growth hormone secretion from the somatotrophs. Murakami Y, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:666–9

Divergence between growth hormone responses to insulin–induced hypoglycaemia and growth
hormone–releasing hormone in patients with
non–functioning pituitary macroadenomas and hyperprolactinaemia. Beentjes JA, et al.
Clin Endocrinol (Oxf) 1996 Oct;45(4):391–8

Combined beta FSH and beta LH response to TRH in patients with clinically non–functioning pituitary adenomas. Somjen D, et al. **Clin Endocrinol (Oxf)** 1997 May;46(5):555–62

Incidentally discovered adrenocortical adenomas are not fully nonfunctioning: immunohistochemical and dispersed adrenocortical cell study. Tobinaga J, et al. **Endocr J** 1996 Feb;43(1):79–86

Gi3 mediates somatostatin–induced activation of an inwardly rectifying K+ current in human growth
hormone–secreting adenoma cells. Takano K, et al.
Endocrinology 1997 Jun;138(6):2405–9

Hyperprolactinaemia is associated with a higher prevalence of pituitary–adrenal dysfunction in non–functioning pituitary macroadenoma. Tjeerdsma G, et al.
Eur J Endocrinol 1996 Sep;135(3):299–308

Enhanced functional activity in thyroid adenomas in vitro. Poertl S, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:39–40 (9 ref.)

Visual status in suprasellar pituitary tumours. Kaur A, et al.
Indian J Ophthalmol 1995 Sep;43(3):131–4

Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function. Mason RB, et al. **J Neurosurg** 1997 Sep; 87(3):343–51

Parathyroid function and histology in patients with parathyroid adenoma: correlation of clinical and morphologic findings. Luts L, et al. **World J Surg** 1997 Jun;21(5):553–63

[Visual function in hypophyseal tumors] Hejcmanová D, et al. **Cesk Slov Oftalmol** 1996 Nov;52(6):362–6 (Eng. Abstr.) **(Cze)**

[Fatal hemorrhagic necrosis of pituitary macro–adenoma after a stimulation test] Grunenberger F, et al.
Presse Med 1996 Nov 2;25(33):1592–4 (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Micronutrients and the risk of colorectal adenomas [see comments] Tseng M, et al. **Am J Epidemiol** 1996 Dec 1; 144(11):1005–14. Comment in: Am J Epidemiol 1996 Dec 1;144(11):1026–7.

Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer. Stoner GD, et al. **Cancer Lett** 1997 Mar 19;114(1–2):113–9

Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with
1,2–dimethylhydrazine: implications for dietary
sphingolipids and colon carcinogenesis. Schmelz EM, et al. **Cancer Res** 1996 Nov 1;56(21):4936–41

Chemopreventive effects of myo–inositol and dexamethasone on benzo[a]pyrene and
4–(methylnitrosoamino)–1–(3–pyridyl)–1–butanone–
induced pulmonary carcinogenesis in female A/J mice. Wattenberg LW, et al. **Cancer Res** 1996 Nov 15; 56(22):5132–5

The risk factor profile of recto-sigmoid adenomas: a prospective screening study of 665 patients in a clinical rehabilitation centre. Manus B, et al. **Eur J Cancer Prev** 1997 Feb;6(1):38–43

Surveillance of familial adenomatous polyposis patients after ileorectal anastomosis or ileoanal pouch anastomosis. Tytgat GNJ. **Gastrointest Endosc Clin N Am** 1997 Jan; 7(1):111–27 (55 ref.)

Leisure and occupational physical activity and risk of colorectal adenomatous polyps. Neugut AI, et al. **Int J Cancer** 1996 Dec 11;68(6):744–8

The Norwegian guidelines for surveillance after polypectomy: 10-year intervals. Hoff G, et al. **Scand J Gastroenterol** 1996 Sep;31(9):834–6

Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence. Weiss HA, et al. **Scand J Gastroenterol Suppl** 1996;220:137–41 (29 ref.)

RADIOGRAPHY

Small depressed neoplasms of the large bowel: radiographic visualization and clinical significance. Fujiya M, et al. **Abdom Imaging** 1997 May-Jun;22(3):325–31

Radiologic features of papillary adenoma and papillomatosis of the biliary tract. Kawakatsu M, et al. **Abdom Imaging** 1997 Jan-Feb;22(1):87–90

Retropharyngeal parathyroid adenoma: precise preoperative localization with CT and arterial infusion of contrast material. Miller DL, et al. **AJR Am J Roentgenol** 1997 Sep; 169(3):695–6

Case in point. Benign adrenal adenoma. Ansari A. **Hosp Pract (Off Ed)** 1997 Mar 15;32(3):246

Radiological case of the month. Ectopic parathyroid adenoma of the upper mediastinum. Walker RC, et al. **J Ark Med Soc** 1997 Apr;93(11):565–6

Adrenal cortical adenoma with extensive fat cell metaplasia [letter; comment] Arana E, et al. **Pathol Res Pract** 1996 Dec;192(12):1288. Comment on: Pathol Res Pract 1996 Jan;192(1):62–5; discussion 66.

Quantitative CT evaluation of adrenal gland masses: a step forward in the differentiation between adenomas and nonadenomas? Szolar DH, et al. **Radiology** 1997 Feb; 202(2):517–21

[Alveolar cell adenoma of the lung] Nüssle K, et al. **Rontgenpraxis** 1997 Feb;50(2):29–30 **(Ger)**

RADIONUCLIDE IMAGING

Preoperative detection of sporadic parathyroid adenomas using technetium-99m-sestamibi: what role in clinical practice? Carter WB, et al. **Am Surg** 1997 Apr;63(4):317–21

Sestamibi parathyroid scanning and preoperative localization studies for patients with recurrent/persistent hyperparathyroidism or significant comorbid conditions: development of an optimal localization strategy. Peeler BB, et al. **Am Surg** 1997 Jan;63(1):37–46

Tc-99m-MIBI scintigraphy for detecting parathyroid adenoma and hyperplasia. Arbab AS, et al. **Ann Nucl Med** 1997 Feb;11(1):45–9

Detection of an intrathymic parathyroid adenoma by Tc-99m tetrofosmin: a comparison with Tl-201. Giordano A, et al. **Clin Nucl Med** 1996 Dec;21(12):996–8

Tc-99m sestamibi and I-123 detection of a parathyroid adenoma in the presence of a cold thyroid nodule. Jeanguillaume C, et al. **Clin Nucl Med** 1997 Apr; 22(4):258–60

Localization of a parathyroid adenoma by the addition of pinhole imaging to Tc-99m sestamibi dual-phase scintigraphy. Report of a case and review of experience. Kipper MS, et al. **Clin Nucl Med** 1997 Feb;22(2):73–5

Kinetics of Tc-99m sestamibi and Tc-99m tetrofosmin in a case of parathyroid adenoma. Mansi L, et al. **Clin Nucl Med** 1996 Sep;21(9):700–3

Combined Tc-99m MIBI and Tc-99m RBC for anatomic localization of ectopic mediastinal parathyroid adenomas. Mastin ST, et al. **Clin Nucl Med** 1996 Dec;21(12):928–31

Pin-hole collimator, parallax, and the localization of mediastinal parathyroid adenoma. Mavai R, et al. **Clin Nucl Med** 1996 Jul;21(7):527–9

Preliminary experience with double-phase SPECT using Tc-99m sestamibi in patients with hyperparathyroidism. Neumann DR, et al. **Clin Nucl Med** 1997 Apr;22(4):217–21

Tc-99m sestamibi SPECT imaging of a retroesophageal parathyroid adenoma. Nguyen BD, et al. **Clin Nucl Med** 1996 Nov;21(11):880

'False-positive' uptake of FDG in a hepatic adenoma. Patel PM, et al. **Clin Nucl Med** 1997 Jul;22(7):490–1

SPECT and subtraction imaging of an ectopic parathyroid adenoma. Serchuk LS, et al. **Clin Nucl Med** 1997 Jul; 22(7):459–62

Parathyroid scintigraphy: comparison of technetium-99m methoxyisobutylisonitrile and technetium-99m tetrofosmin studies [see comments] Aigner RM, et al. **Eur J Nucl Med** 1996 Jun;23(6):693–6. Comment in: Eur J Nucl Med 1997 Mar;24(3):347.

Parathyroid scintigraphy: first experiences with technetium (III)-99m-Q12. Aigner RM, et al. **Eur J Nucl Med** 1997 Mar;24(3):326–9

Presurgical localization of abnormal parathyroid glands using a single injection of technetium-99m methoxyisobutylisonitrile: comparison of different techniques including factor analysis of dynamic structures. Blocklet D, et al. **Eur J Nucl Med** 1997 Jan;24(1):46–51

Differences between technetium-99m tetrofosmin and technetium-99m sestamibi in parathyroid scintigraphy [letter; comment] Giordano A, et al. **Eur J Nucl Med** 1997 Mar;24(3):347. Comment on: Eur J Nucl Med 1996 Jun;23(6):693–6.

Technetium-99m tetrofosmin imaging in thyroid diseases: comparison with Tc-99m-pertechnetate, thallium-201 and Tc-99m-methoxyisobutylisonitrile scans. Klain M, et al. **Eur J Nucl Med** 1996 Dec;23(12):1568–74

Parathyroid imaging with technetium-99m labelled cationic complexes: which tracer and which technique should be used? [editorial] Lind P. **Eur J Nucl Med** 1997 Mar; 24(3):243–5

Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels. Losa M, et al. **Eur J Nucl Med** 1997 Jul;24(7):728–31

Radioiodinated metaiodobenzylguanidine scintigraphy for pheochromocytoma. A false-positive case of adrenocortical adenoma and literature review. Sone H, et al. **Horm Res** 1996;46(3):138–42 (27 ref.)

Preoperative localization of parathyroid adenomas using 99mTc-MIBI scintigraphy in patients with hyperparathyroidism. Ebisuno S, et al. **Int J Urol** 1997 Mar; 4(2):126–9

The use of thallium-201 and technetium-99m subtraction scintigraphy for the localisation of parathyroid adenomas. Renaut AJ, et al. **Int Surg** 1996 Jul-Sep;81(3):302–3

Technetium 99m tetrofosmin parathyroid imaging. Results with double-phase study and SPECT in primary and secondary hyperparathyroidism. Gallowitsch HJ, et al. **Invest Radiol** 1997 Aug;32(8):459–65

Radiological case of the month. Ectopic parathyroid adenoma of the upper mediastinum. Walker RC, et al. **J Ark Med Soc** 1997 Apr;93(11):565–6

Comparison of parathyroid imaging with technetium-99m-pertechnetate/sestamibi subtraction, double-phase technetium-99m-sestamibi and technetium-99m-sestamibi SPECT [see comments] Chen CC, et al. **J Nucl Med** 1997 Jun;38(6):834–9. Comment in: J Nucl Med 1997 Jun;38(6):840–1.

Technetium-99m-tetrofosmin for parathyroid scintigraphy: a comparison with sestamibi [see comments] Fjeld JG, et al. **J Nucl Med** 1997 Jun;38(6):831–4. Comment in: J Nucl Med 1997 Jun;38(6):840–1.

Graves' disease triggered by autoinfarction of an autonomously functioning thyroid adenoma. Gallegos E, et al. **J Nucl Med** 1997 Feb;38(2):260–2

Technetium-99m-pertechnetate uptake by intrathyroidal parathyroid adenoma. Leslie WD, et al. **J Nucl Med** 1996 May;37(5):861–2

Radionuclide parathyroid imaging [editorial; comment] O'Doherty MJ. **J Nucl Med** 1997 Jun;38(6):840–1. Comment on: J Nucl Med 1997 Jun;38(6):831–4. Comment on: J Nucl Med 1997 Jun;38(6):834–9.

Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. Pirker W, et al. **J Nucl Med** 1996 Dec;37(12):1931–7

Utility of preoperative radionuclide scanning for primary hyperparathyroidism. Sinha CK, et al. **Laryngoscope** 1997 Jun;107(6):753–8

Somatostatin receptor scintigraphy in patients with pituitary adenoma. Rieger A, et al. **Neurosurg Rev** 1997;20(1):7–12

Preoperative scintigraphic and intraoperative scintimetric localization of parathyroid adenoma with cationic Tc-99m complexes and a hand-held gamma-probe. Gallowitsch HJ, et al. **Nuklearmedizin** 1997 Jan;36(1):13–8

[111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas. Boni G, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):90–3

111In-octreotide scintigraphy in pituitary adenomas. Tofani A, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):94–7

Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide. Tumiati MN, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):98–100

Primary hyperparathyroidism: higher success rate of first surgery after preoperative Tc-99m sestamibi-I-123 subtraction scanning. Hindié E, et al. **Radiology** 1997 Jul; 204(1):221–8

Parathyroid adenomas: accurate detection and localization with Tc-99m sestamibi SPECT. Perez-Monte JE, et al. **Radiology** 1996 Oct;201(1):85–91

Mediastinal parathyroid adenoma detected by 99mTc-methoxyisobutylisonitrile: report of a case. Ipponsugi S, et al. **Surg Today** 1997;27(1):80–3

Sestamibi versus thallium subtraction scintigraphy in parathyroid localization: a prospective comparative study in patients with predominantly mild primary hyperparathyroidism. Bergenfelz A, et al. **Surgery** 1997 Jun; 121(6):601–5

[Gonadotropi adenoma linking labeled somatostatin analogs. Lack of relationship with therapeutic effect] Ev.ard A, et al. **Ann Endocrinol (Paris)** 1996;57(3):209–14 (Eng. Abstr.) **(Fre)**

[Use of a gamma probe for intraoperative localization of parathyroid adenomas with Tc-99m-tetrofosmin and Tc-99m-sestamibi] Gallowitsch HJ, et al. **Acta Med Austriaca** 1997;24(2):73–8 (Eng. Abstr.) **(Ger)**

[Value of 99mTc-MIBI scintigraphy in diagnostic localization of hyperparathyroidism. A prospective study] Schoenemann B, et al. **Chirurg** 1996 Jan;67(1):32–6 (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Combined surgery and radiotherapy of invasive pituitary adenomas--problems of radiogenic encephalopathy. Rauhut F, et al. **Acta Neurochir Suppl (Wien)** 1996;65:37–40

Radiotherapy for pituitary adenomas: an endocrinologist's perspective. O'Halloran DJ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(2):79–84 (58 ref.)

Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors. Challeton C, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 1;37(1):163–9

Radiotherapy for pituitary adenoma: long-term outcome and sequelae. McCord MW, et al. **Int J Radiat Oncol Biol Phys** 1997 Sep 1;39(2):437–44

Symptom resolution, tumor control, and side effects following postoperative radiotherapy for pituitary macroadenomas. Rush S, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 15;37(5):1031–4

Use of fluid attenuating inversion recovery, MR angiogram, and diffusion-weighted MRI techniques for assessment of pontine infarction in a patient treated with radiation therapy for pituitary neoplasm. Graef LM, et al. **Neurology** 1997 Feb;48(2):540–2

Role of radiation therapy in clinical hormonally-active pituitary adenomas. Tsang RW, et al. **Radiother Oncol** 1996 Oct;41(1):45–53

Suprasellar meningioma subsequent to treatment for a pituitary adenoma: case report. Rao MB, et al. **Surg Neurol** 1997 May;47(5):443–6 (11 ref.)

[Pituitary radiotherapy. Current data and future prospects] Cortet-Rudelli C, et al. **Ann Endocrinol (Paris)** 1997; 58(1):21–9 (44 ref.) (Eng. Abstr.) **(Fre)**

[Radioiodine therapy of small, solitary autonomous adenomas] Steiner D, et al. **Nuklearmedizin** 1997 Apr; 36(3):76–80 (Eng. Abstr.) **(Ger)**

[Radiation dose in critical organs due to non-coplanar irradiation of the hypophysis] Schulte RW, et al. **Strahlenther Onkol** 1996 Sep;172(9):501–6 (Eng. Abstr.) **(Ger)**

[Endocavitary radiotherapy of distal rectal tumors] Tanum G, et al. **Tidsskr Nor Laegeforen** 1997 Feb 20;117(5):654–6 (Eng. Abstr.) **(Nor)**

SECRETION

Functional adrenocortical adenoma in a case with B cell chronic lymphoproliferative disorder. Adachi Y, et al. **Acta Haematol** 1997;97(4):239–41

A case of pituitary somatotroph adenoma with concomitant secretion of growth hormone, prolactin, and adrenocorticotropic hormone--an adenoma derived from primordial stem cell, studied by immunohistochemistry, in situ hybridization, and cell culture. Matsuno A, et al. **Acta Neurochir (Wien)** 1996;138(8):1002–7

Galanin gene expression in radiothyroidectomy-induced thyrotroph adenomas. Hyde JF, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E24–30

Use of somatostatin analogue in management of a thyrotrophin secreting pituitary adenoma [letter] Stiles MK, et al. **Aust N Z J Med** 1996 Feb;26(1):122–3

Giant growth-hormone secreting pituitary tumour with extracranial extension. Ip TP, et al. **Australas Radiol** 1996 Feb;40(1):88–90

Results of the lateral rhinotomy approach in transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma. Jakobsson KE, et al. **Br J Neurosurg** 1995; 9(6):763–8

Growth hormone- and growth-hormone-releasing hormone-producing tumors. Shimon I, et al. **Cancer Treat Res** 1997;89:1–24 (78 ref.)

Gonadotroph and other clinically nonfunctioning pituitary adenomas. Snyder PJ. **Cancer Treat Res** 1997;89:57–72 (39 ref.)

Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Rossi GP, et al. **Circulation** 1997 Mar 18;95(6):1471–8

Intracellular calcium ion responses to somatostatin in cells from human somatotroph adenomas. Chen ZP, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):45–53

Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH. Persani L, et al. **Clin Endocrinol (Oxf)** 1997 Aug;47(2):207–14

Occult eutopic Cushing's syndrome--failure of simultaneous bilateral petrosal sinus sampling to diagnose pituitary-dependent Cushing's syndrome. Heppner C, et al. **Eur J Endocrinol** 1997 Jul;137(1):74–8

Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels. Losa M, et al. **Eur J Nucl Med** 1997 Jul;24(7):728–31

Primary aldosteronism with bilateral multiple aldosterone-producing adrenal adenomas [see comments] Matsuda A, et al. **Intern Med** 1996 Dec;35(12):970–5. Comment in: Intern Med 1996 Dec;35(12):919–21.

Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. Biller BM, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2338–43

Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release. Freese A, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2401–4

Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. Losa M, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):3084–90

A gonadotroph adenoma with a high proportion of basic FSH isohormones by chromatofocusing [letter] Pigny P, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2407–8

Steroid secretions in patients with adrenal incidentalomas [letter; comment] Reincke M. **J Clin Endocrinol Metab** 1996 Oct;81(10):3811–2. Comment on: J Clin Endocrinol Metab 1996 Feb;81(2):740–4.

Corticotropin-releasing hormone excites adrenocorticotropin-secreting human pituitary adenoma cells by activating a nonselective cation current. Takano K, et al. **J Clin Invest** 1996 Nov 1;98(9):2033–41

An unusual case of bilateral virilizing adrenal adenoma co-secreting androgens and cortisol. Delgrange E, et al. **J Endocrinol Invest** 1996 Jun;19(6):377–81

A prolactin-secreting tumor in a patient with Klinefelter's syndrome: a case report. Pinto AC, et al. **J Endocrinol Invest** 1996 Apr;19(4):248–52

Differences in PTH (1–84) release in response to ambient calcium concentrations of parathyroid adenoma fragments and dispersed parathyroid adenoma cells in culture. Yu M, et al. **J Endocrinol Invest** 1996 Jun;19(6):342–7

Thyrotropin-secreting pituitary adenomas. Beck-Peccoz P, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):75–9 (28 ref.)

Inhibitory effects of galanin on growth hormone (GH) release in cultured GH-secreting adenoma cells: comparative study with octreotide, GH-releasing hormone, and thyrotropin-releasing hormone. Giustina A, et al. **Metabolism** 1997 Apr;46(4):425–30

Relationship between protein kinase C and adenylyl cyclase activity in the regulation of growth hormone secretion by human pituitary somatotrophinomas. Lei T, et al. **Neurosurgery** 1996 Sep;39(3):569–75; discussion 575–6

Difficulty in differentiating thyrotropin secreting pituitary microadenoma from pituitary-selective thyroid hormone resistance accompanied by pituitary incidentaloma. Akiyoshi F, et al. **Thyroid** 1996 Dec;6(6):619–25

[The role of Ca2+ in the pathogenesis of human pituitary GH-secreting adenomas] Yin J, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Feb; 18(1):23–8 (Eng. Abstr.) **(Chi)**

[Gonadotropi adenoma linking labeled somatostatin analogs. Lack of relationship with therapeutic effect] Evrard A, et al. **Ann Endocrinol (Paris)** 1996;57(3):209–14 (Eng. Abstr.) **(Fre)**

[Thyreotropic adenoma: review of the literature. Apropos of 2 cases] Prévost G, et al. **Ann Endocrinol (Paris)** 1996; 57(3):194–202 (40 ref.) (Eng. Abstr.) **(Fre)**

[Secretory reactions to somatoliberin and somatostatin of cultured cells of human pituitary adenomas producing growth hormone] Komolov IS, et al. **Biull Eksp Biol Med** 1997 Mar;123(3):323–6 **(Rus)**

SURGERY

Surgical treatment of benign tumours of the salivary glands. Van Hee R, et al. **Acta Chir Belg** 1996 Jul–Aug;96(4):161–4

Surgical results in microadenomas. Giovanelli M, et al. **Acta Neurochir Suppl (Wien)** 1996;65:11–2

The role of transcranial surgery in the management of pituitary adenoma. Patterson RH. **Acta Neurochir Suppl (Wien)** 1996;65:16–7

Surgical treatment of pituitary adenomas in elderly patients. Pospiech J, et al. **Acta Neurochir Suppl (Wien)** 1996;65:35–6

Management of huge pituitary adenomas. Takakura K, et al. **Acta Neurochir Suppl (Wien)** 1996;65:13–5

LINAC-radiosurgery (LINAC-RS) in pituitary adenomas: preliminary results. Voges J, et al. **Acta Neurochir Suppl (Wien)** 1996;65:41–3

Surgical management of giant pituitary tumours--a review of 30 cases. Goel A, et al. **Acta Neurochir (Wien)** 1996; 138(9):1042–9

Endoscopy assisted transsphenoidal surgery for pituitary adenoma. Technical note. Jho HD, et al. **Acta Neurochir (Wien)** 1996;138(12):1416–25

Arterial injuries in transsphenoidal surgery for pituitary adenoma; the role of angiography and endovascular treatment. Raymond J, et al. **AJNR Am J Neuroradiol** 1997 Apr;18(4):655–65

Long-term results of unilateral neck exploration for preoperatively localized nonfamilial parathyroid adenomas. Robertson GS, et al. **Am J Surg** 1996 Oct;172(4):311–4

A local sphincter-saving treatment of distal rectal cancer (editorial)] Viola G. **Ann Ital Chir** 1996 Sep–Oct; 67(5):603–6

Transcranial erosion of a benign dermal cylindroma. Wyld L, et al. **Ann Plast Surg** 1996 Feb;36(2):194–6

The management of tumors of the ampulla of Vater by local resection. Branum GD, et al. **Ann Surg** 1996 Nov; 224(5):621–7

A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Jaskowiak N, et al. **Ann Surg** 1996 Sep;224(3):308–20; discussion 320–1

Transsphenoidal surgery for pituitary tumours. Massoud AF, et al. **Arch Dis Child** 1997 May;76(5):398–404

Surgical treatment of parathyroid disease. Scott-Coombes DM, et al. **Br J Hosp Med** 1997 May 21–Jun 3; 57(10):488–91 (20 ref.)

Value of visual evoked potential monitoring during trans-sphenoidal pituitary surgery. Chacko AG, et al. **Br J Neurosurg** 1996 Jun;10(3):275–8

Results of the lateral rhinotomy approach in transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma. Jakobsson KE, et al. **Br J Neurosurg** 1995; 9(6):763–8

Nasal complications of the direct transnasal approach to the pituitary fossa. Tan LK, et al. **Br J Neurosurg** 1995; 9(6):739–42

TUR syndrome and endoscopic transanal resection: no evidence for a clinically important association in 38 procedures. Boyle JR, et al. **Br J Surg** 1997 Jun;84(6):831–3

Thoracoscopic parathyroidectomy of an ectopic mediastinal adenoma. Gullstrand P, et al. **Br J Surg** 1996 Dec; 83(12):1757

Thoracoscopic parathyroidectomy of an ectopic mediastinal adenoma [letter] Porte H. **Br J Surg** 1997 Aug;84(8):1175

Basal interhemispheric supra- and/or infrachiasmal approaches via superomedial orbitotomy for hypothalamic lesions: preservation of hypothalamo-pituitary functions in combination treatment with radiosurgery. Inoue HK, et al. **Childs Nerv Syst** 1997 May;13(5):250–6

Elevated fibrinogen levels decrease following treatment of acromegaly. Landin-Wilhelmsen K, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):69–74

Remission of non-insulin-dependent diabetes mellitus following resection of a parathyroid adenoma. Quin JD, et al. **Diabet Med** 1997 Jan;14(1):80–1

Transanal endoscopic microsurgery. Initial registry results. Smith LE, et al. **Dis Colon Rectum** 1996 Oct;39(10 Suppl):S79–84

Anaesthesia and surgical aspects of thyroid swelling: the Ibadan experience. Soyannwo OA, et al. **East Afr Med J** 1995 Oct;72(10):675–7

Effect of surgery on gonadal function of premenopausal women with pituitary adenomas other than prolactinomas. Arita K, et al. **Endocr J** 1996 Apr;43(2):131–8

Effects of surgery on testosterone secretion in male patients with pituitary adenomas. Tominaga A, et al. **Endocr J** 1996 Jun;43(3):307–12

The results of transsphenoidal surgery for 44 consecutive acromegalic patients. Yamada S, et al. **Endocr J** 1997 Jun; 44(3):395–402

Diagnosis of borderline adenomas of the stomach by endoscopic mucosal resection. Fujiwara Y, et al. **Endoscopy** 1996 Jun;28(5):425–30

Endoscopic resection of large colorectal adenomas: a combination of snare and laser ablation. Hintze RE, et al. **Endoscopy** 1995 Nov;27(9):665–70

Plasma dehydroepiandrosterone sulfate levels in patients with hyperfunctioning and non-hyperfunctioning adrenal tumors before and after adrenal surgery. Tóth M, et al. **Eur J Endocrinol** 1997 Mar;136(3):290–5

Transduodenal excision of tumours of the ampulla of Vater. Alstrup N, et al. **Eur J Surg** 1996 Dec;162(12):961–7 (22 ref.)

Initial experience of laparoscopic resection of adrenal tumours. Casaccia M Jr, et al. **Eur J Surg** 1997 Feb; 163(2):93–6

Recurrent melanoma of the leg and polypoid lesions of the gallbladder--a management dilemma. Gould SW, et al. **Eur J Surg Oncol** 1997 Aug;23(4):368–9

Thyroid morphology and function after surgical treatment of thyroid diseases. Mann B, et al. **Exp Clin Endocrinol Diabetes** 1996;104(3):271–7

Endoscopic mucosal resection of gastric neoplasms using a ligating device. Akiyama M, et al. **Gastrointest Endosc** 1997 Feb;45(2):182–6

Laser photoablation of ileal reservoir adenomas. Geller A, et al. **Gastrointest Endosc** 1996 Oct;44(4):473–7 (57 ref.)

Endoscopic mucosal resection of gastric tumors located in the lesser curvature of the upper third of the stomach. Matsushita M, et al. **Gastrointest Endosc** 1997 Jun; 45(6):512–5

Band ligation-assisted endoscopic resection of a flat rectal adenoma containing infiltrating adenocarcinoma. Van Os EC, et al. **Gastrointest Endosc** 1997 Mar;45(3):322–4

Endoscopic laser treatment of mucous gland adenoma arising in the trachea [editorial; comment] Dambara T. **Intern Med** 1996 Nov;35(11):841. Comment on: Intern Med 1996 Nov;35(11):890–3.

Increased serum thyrotropin in a subacute thyroiditis patients after incomplete removal of thyrotropin-producing pituitary adenoma [letter] Yamakita N, et al. **Intern Med** 1996 Sep;35(9):752

Treatment of Cushing's disease by transsphenoidal, pituitary microsurgery: prognosis factors and long-term follow-up. Bakiri F, et al. **J Endocrinol Invest** 1996 Oct;19(9):572–80

Adrenal-sparing laparoscopic surgery for aldosterone-producing adenoma. Janetschek G, et al. **J Endourol** 1997 Apr;11(2):145–8

Unusual scotomas after transsphenoidal surgery of a pituitary macroadenoma. Dollfus H, et al. **J Neuroophthalmol** 1997 Sep;17(3):204–6

Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function. Mason RB, et al. **J Neurosurg** 1997 Sep; 87(3):343–51

Surgical management of TSH-secreting pituitary adenomas. Wang CJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Oct; 12(10):590–4

Surgical therapy of pituitary adenomas. Giovanelli M, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):115–6 (7 ref.)

Stereotactic radiosurgery of pituitary adenomas. Motti ED, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):111–4 (11 ref.)

Renovascular hypertension after laparoscopic adrenalectomy in a patient with adrenal adenoma [letter] Wu TH, et al. **Nephron** 1996;74(2):464–5

Postoperative follow-up of pituitary adenomas after trans-sphenoidal resection: MRI and clinical correlation. Rodríguez O, et al. **Neuroradiology** 1996 Nov;38(8):747–54

Modified coronal computerized tomographic cuts for transsphenoidal surgery. Technical note. Naim-Ur-Rahman, et al. **Neurosurg Rev** 1996;19(2):85–8

Rhinological complications of sublabial transseptal transsphenoidal surgery for sellar and suprasellar lesions: prevention and management. Sharma K, et al. **Neurosurg Rev** 1996;19(3):163–7

Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Ciric I, et al. **Neurosurgery** 1997 Feb; 40(2):225–36; discussion 236–7 (101 ref.)

Transnasal microsurgery in children and adolescents with Cushing's disease. Knappe UJ, et al. **Neurosurgery** 1996 Sep;39(3):484–92; discussion 492–3

Results of treatment of pituitary disease in multiple endocrine neoplasia, type I. O'Brien T, et al. **Neurosurgery** 1996 Aug; 39(2):273–8; discussion 278–9

Transnasal endoscopic surgery of the pituitary gland: technical note. Rodziewicz GS, et al. **Neurosurgery** 1996 Jul;39(1):189–92; discussion 192–3

Endoscopic transseptal transsphenoidal surgery for pituitary tumors. Yaniv E, et al. **Neurosurgery** 1997 May;40(5):944–6

Preoperative scintigraphic and intraoperative scintimetric localization of parathyroid adenoma with cationic Tc-99m complexes and a hand-held gamma-probe. Gallowitsch HJ, et al. **Nuklearmedizin** 1997 Jan;36(1):13–8

Endoscopic polypectomy in the treatment of colonic adenomas containing adenocarcinoma. Naranjo Rodríguez A, et al. **Rev Esp Enferm Dig** 1997 Jun;89(6):435–44 **(Eng, Spa)**

The Norwegian guidelines for surveillance after polypectomy: 10-year intervals. Hoff G, et al. **Scand J Gastroenterol** 1996 Sep;31(9):834–6

Successful resection of multifocal hepatic adenoma during pregnancy. Hill MA, et al. **South Med J** 1997 Mar; 90(3):357–61

Transnasal stereotactic surgery of pituitary adenomas concomitant with acromegaly. Metyolkina L, et al. **Stereotact Funct Neurosurg** 1995;65(1–4):184–6

A four-point fixation method for the resection of early gastric cancer, with particular reference to the analysis of cases of incomplete resection. Tanaka M, et al. **Surg Endosc** 1997 Mar;11(3):295–8

Transsphenoidal adenomectomy in Cushing's disease via a lateral rhinotomy approach. Petruson K, et al. **Surg Neurol** 1997 Jul;48(1):37–43; discussion 44–5

Ventral pancreatic resection for adenoma and low-grade malignancies of the head of the pancreas. Ryu M, et al. **Surg Today** 1996;26(7):476–81

Surgical management of hyperparathyroidism in view of a reliable parathyroid adenoma localization test [letter; comment] Takami H. **Surgery** 1997 Jul;122(1):120. Comment on: Surgery 1996 Nov;120(5):845–51.

Thoracoscopic resection of an ectopic giant parathyroid adenoma: indication, technique, and three years follow-up. Furrer M, et al. **Thorac Cardiovasc Surg** 1996 Aug; 44(4):208–9

Acute renal failure complicating liver transplantation in twin sisters with glycogen storage disease type Ia. Reid CJ, et al. **Transplant Proc** 1996 Dec;28(6):3629–31

Side localization of parathyroid adenomas by simplified intraoperative venous sampling for parathyroid hormone. Bergenfelz A, et al. **World J Surg** 1996 Mar–Apr; 20(3):358–60

Gamma knife surgery in pituitary microadenomas. Park YG, et al. **Yonsei Med J** 1996 Jun;37(3):165–73

[Evaluation of surgical treatment for patients with multiple aldosteronoma: analysis of 11 cases] Liu D, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Nov;33(11):681–3 (Eng. Abstr.) **(Chi)**

[Adrenal cortex adenomas. A retrospective series of twenty cases] Mhiri MN, et al. **Ann Urol (Paris)** 1996;30(5):217–24 (Eng. Abstr.) **(Fre)**

[Parathyroidectomy under local anesthesia. First two cases in Lebanon and review of the literature] Abboud B, et al. **J Med Liban** 1997;45(2):107–11 (31 ref.) (Eng. Abstr.) **(Fre)**

[New strategies in the surgery of primary hyperparathyroidism] Demard F, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(3):203–14 (25 ref.) (Eng. Abstr.) **(Fre)**

[Retroperitoneal phlegmon after transanal endoscopic microsurgical excision of rectal adenoma] Klaue HJ, et al. **Chirurg** 1997 Jan;68(1):84–6 (Eng. Abstr.) **(Ger)**

[Morbidity in concomitant interventions in neck exploration for primary hyperparathyroidism. Results of a prospective study] Walgenbach S, et al. **Chirurg** 1996 Sep;67(9):933–8; discussion 938–9 (Eng. Abstr.) **(Ger)**

[Endoscopic, extraperitoneal adrenalectomy--an expansion of the approach to the adrenal gland] Heintz A, et al.

Langenbecks Arch Chir Suppl Kongressbd 1996;113:617–8 (Eng. Abstr.) **(Ger)**

[Microsurgery in prospective comparison with conventional transanal excision or anterior rectum resection in adenomas and superficial carcinomas] Winde G, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:265–8 (Eng. Abstr.) **(Ger)**

[Primary hyperthyroidism 1996] Schweizer I, et al. **Schweiz Med Wochenschr** 1997 Feb 15;127(7):243–53 (58 ref.) (Eng. Abstr.) **(Ger)**

[Large Brunner's adenoma of the duodenal bulb--a case report] Rhiner R, et al. **Swiss Surg** 1997;3(1):13–6 (Eng. Abstr.) **(Ger)**

[Method of biopsy and ultrastructural study of the parathyroid gland in patients with primary hyperparathyroidism] D'Andrea V, et al. **Ann Ital Chir** 1996 Sep–Oct;67(5):671–5; discussion 675–6 (Eng. Abstr.) **(Ita)**

[Validity, limitations and indications of intraoperative dosage of parathyroid hormone (I-PTH) in the surgical treatment of primary hyperparathyroidism] Leopaldi E, et al. **Ann Ital Chir** 1997 Jan–Feb;68(1):37–41; discussion 41–2 (Eng. Abstr.) **(Ita)**

[Sudden and unusual onset of penile plastic induration in 2 patients neurosurgically treated for pituitary macroadenoma] Foppiani L, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):61–4 (Eng. Abstr.) **(Ita)**

[Laparoscopic versus laparotomic adrenalectomy: preliminary experiences] Sorrentino M, et al. **Minerva Chir** 1997 Mar;52(3):181–4 (Eng. Abstr.) **(Ita)**

[Removal of complete type of mediastinal goiter in thirty-six-year-old female--a case report] Koyama S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Nov; 44(11):2068–71 (Eng. Abstr.) **(Jpn)**

[Synchronous multiple early gastric cancer; study of surgically resected stomach] Iwafuchi M, et al. **Nippon Rinsho** 1996 May;54(5):1217–23 (Eng. Abstr.) **(Jpn)**

[Transsphenoidal surgery for a case of empty sella syndrome associated with GH secreting pituitary adenoma] Aihara H, et al. **No Shinkei Geka** 1996 Dec;24(12):1119–23 (Eng. Abstr.) **(Jpn)**

[Endoscope assisted transsphenoidal approach for pituitary adenomas] Kitano M, et al. **No Shinkei Geka** 1997 Mar; 25(3):197–203 (14 ref.) **(Jpn)**

[The point of view of otolaryngologist and head and neck surgeon on thyroid diseases] Betkowski A, et al. **Otolaryngol Pol** 1995;49(6):574–82 (Eng. Abstr.) **(Pol)**

[Alveolar thyroid cancer with Hurthle cells in a 12-year old boy] Gardziejczyk M, et al. **Pol Merkuriusz Lek** 1996 Oct; 1(4):274–5 (Eng. Abstr.) **(Pol)**

[The laparoscopic removal of an adrenal tumor] Maĭstrenko NA, et al. **Vestn Khir Im I I Grek** 1997;156(1):106–7 (14 ref.) **(Rus)**

[The surgical treatment of polyps and early forms of cancer of the large intestine] Mel'nikov RA, et al. **Vestn Khir Im I I Grek** 1995;154(4–6):24–8 (Eng. Abstr.) **(Rus)**

[The staged use of transcranial and transphenoidal surgical approaches in treating hypophyseal adenomas] Kadashev BA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct–Dec;(4):6–10 (Eng. Abstr.) **(Rus)**

[Indication for liver transplantation in hepatic adenoma (letter)] Torrella E, et al. **Med Clin (Barc)** 1996 Feb 3; 106(4):154–5 **(Spa)**

THERAPY

Selective management of hepatic adenomas. Ault GT, et al. **Am Surg** 1996 Oct;62(10):825–9

Successful repeat transcatheter ablation of a mediastinal parathyroid adenoma 6 years after alcohol embolization. Cook GJ, et al. **Cardiovasc Intervent Radiol** 1997 Jul–Aug; 20(4):314–6

Pituitary adenomas. Andrews DW. **Curr Opin Oncol** 1997 Jan;9(1):55–60 (59 ref.)

Nonfunctioning pituitary adenoma. Vance ML. **Curr Ther Endocrinol Metab** 1997;6:33–5 (4 ref.)

New modalities in treating pituitary adenomas. Jackson I, et al. **Med Health R I** 1996 Jun;79(6):224–8 (15 ref.)

Recent management of pituitary adenomas. Teramoto A. **Nippon Ika Daigaku Zasshi** 1996 Aug;63(4):255–8 (8 ref.)

Pituitary adenomas: current methods of diagnosis and treatment. Buatti JM, et al. **Oncology (Huntingt)** 1997 Jun; 11(6):791–6; discussion 798, 803–4 (43 ref.)

ULTRASONOGRAPHY

Polyorchidism and rete testis adenoma: ultrasound and MR findings. Figler TJ, et al. **Abdom Imaging** 1996 Sep–Oct; 21(5):470–2

Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Kasperlik-Zeluska AA, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):29–37

Usefulness of echo-color Doppler in differentiating parathyroid lesions from other cervical masses. Mazzeo S, et al. **Eur Radiol** 1997;7(1):90–5

Endoscopic ultrasonography for colorectal cancer using submucosal saline solution injection. Watanabe H, et al. **Gastrointest Endosc** 1997 Jun;45(6):508–11

The value of endorectal ultrasound in the assessment of adenomas, T1- and T2-carcinomas. Sailer M, et al. **Int J Colorectal Dis** 1997;12(4):214–9

Lactating adenoma of the breast: antepartum and postpartum sonographic and color Doppler imaging appearances with histopathologic correlation. Yang WT, et al. **J Ultrasound Med** 1997 Feb;16(2):145–7

Magnetic resonance imaging of adrenocortical adenomas in childhood: correlation with computed tomography and ultrasound. Hanson JA, et al. **Pediatr Radiol** 1996 Nov; 26(11):794–9

Real time ultrasound diagnosis of non-vaterian duodenal adenoma--a brief case report. Chan SC, et al. **Singapore Med J** 1997 Feb;38(2):81–2

High-resolution ultrasonography: highly sensitive, specific technique for preoperative localization of parathyroid adenoma in the absence of multinodular thyroid disease. Gofrit ON, et al. **World J Surg** 1997 Mar–Apr;21(3):287–90; discussion 290–1

[Androgen-producing adrenocortical adenoma in childhood. Pitfalls of differential diagnosis] Gyulay K, et al. **Orv Hetil** 1997 Sep 14;138(37):2357–62 (42 ref.) (Eng. Abstr.) **(Hun)**

[Vascularization of single thyroid nodule as an indicator malignant neoplasm: a study using echo-color-Doppler] Urso M, et al. **Ann Ital Med Int** 1996 Jul–Sep;11(3):175–9 (Eng. Abstr.) **(Ita)**

[Infrequent application of intraoperative ultrasonography in urology] Trombetta C, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):31–6 (Eng. Abstr.) **(Ita)**

ULTRASTRUCTURE

Metanephric adenoma of the kidney: ultrastructural, immunohistochemical and lectin histochemical studies. Ban S, et al. **Pathol Int** 1996 Sep;46(9):661–6

VETERINARY

Immunocytochemical localization of adrenocorticotropic hormone-immunoreactive cells of the pars intermedia in thoroughbreds. Okada T, et al. **Am J Vet Res** 1997 Aug; 58(8):920–4

A pulmonary adenoma in an Australian sheep. Hooper PT, et al. **Aust Vet J** 1995 Dec;72(12):477

Tumours of the mammary gland. Fernandez PL, et al. **IARC Sci Publ** 1996;(126):45–58 (29 ref.)

Tumours of the lower respiratory tract. Mohr U, et al. **IARC Sci Publ** 1996;(126):189–222 (162 ref.)

Tumours of the pancreas. Pour PM, et al. **IARC Sci Publ** 1996;(126):149–73 (29 ref.)

Tumours of the female genital system. Ribas JL, et al. **IARC Sci Publ** 1996;(126):281–305 (118 ref.)

Tumours of the endocrine glands. Schmidt RE, et al. **IARC Sci Publ** 1996;(126):307–20 (50 ref.)

Tumours of the nasal cavity. Schuller HM. **IARC Sci Publ** 1996;(126):175–87 (28 ref.)

Tumours of the gallbladder. Turusov VS, et al. **IARC Sci Publ** 1996;(126):109–25 (21 ref.)

Ceruminous gland tumors in dogs and cats: a review of 124 cases. Moisan PG, et al. **J Am Anim Hosp Assoc** 1996 Sep–Oct;32(5):448–52 (9 ref.)

Adenomatous polyps and carcinoma in situ of the canine colon and rectum: 34 cases (1982–1994). Valerius KD, et al. **J Am Anim Hosp Assoc** 1997 Mar–Apr;33(2):156–60

Results of a combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test in healthy horses and horses suspected to have a pars intermedia pituitary adenoma. Eiler H, et al. **J Am Vet Med Assoc** 1997 Jul 1;211(1):79–81

Use of technetium Tc 99m sestamibi for detection of a parathyroid adenoma in a dog with primary hyperparathyroidism. Matwichuk CL, et al. **J Am Vet Med Assoc** 1996 Nov 15;209(10):1733–6

Production of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor by carcinomas in a dog and a cat with paraneoplastic leukocytosis [see comments] Sharkey LC, et al. **J Vet Intern Med** 1996 Nov–Dec;10(6):405–8. Comment in: J Vet Intern Med 1997 Mar–Apr;11(2):95.

Pituitary corticotroph macrotumors. Diagnosis and treatment. Ihle SL. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):287–97 (58 ref.)

Diagnosis and management of canine cortisol-secreting adrenal tumors. Kintzer PP, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):299–307 (13 ref.)

Canine tumour suppressor gene p53--mutation in a case of adenoma of circumanal glands. Mayr B, et al. **Vet Res Commun** 1997 Jul;21(5):369–73

ADENOMA, ACIDOPHIL

see related
ACROMEGALY
GIGANTISM

BLOOD

Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones. Kimura N, et al. **Endocr J** 1997 Apr;44(2):319–27

ETIOLOGY

Development of acromegaly during treatment of hyperprolactinemia with bromocriptine: an unusual acidophil stem cell adenoma. Page MD, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4484–7

METABOLISM

Diabetes mellitus in a dog with a growth hormone-producing acidophilic adenoma of the adenohypophysis. van Keulen LJ, et al. **Vet Pathol** 1996 Jul;33(4):451–3

PATHOLOGY

Diabetes mellitus in a dog with a growth hormone-producing acidophilic adenoma of the adenohypophysis. van Keulen LJ, et al. **Vet Pathol** 1996 Jul;33(4):451–3

SECRETION

The role of GRH mediated AC-cAMP system in the pathogenesis of human pituitary GH-secreting adenomas. Shi Y, et al. **Chin Med J (Engl)** 1996 Aug;109(8):603–8

VETERINARY

Lactation associated with acidophilic pituitary adenoma, pheochromocytoma, and cystic endometrial hyperplasia in two goats. Miller CC, et al. **J Am Vet Med Assoc** 1997 Feb 1;210(3):378–81

ADENOMA, ADRENAL CORTICAL

COMPLICATIONS

[Corticotropic adenoma in slow adrenal insufficiency] Fabreguettes C, et al. **Ann Endocrinol (Paris)** 1996; 57(2):111–5 (Eng. Abstr.) **(Fre)**

[Heart failure, arterial hypertension, and hypokalemic alkalosis] Rivero M, et al. **Rev Clin Esp** 1996 Aug; 196(8):565–6 **(Spa)**

DIAGNOSIS

Comparison of two algorithms and their associated charges when evaluating adrenal masses in patients with malignancies. Schwartz LH, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1575–8

Metastatic adenocarcinoma within an adrenal adenoma: detection with chemical shift imaging. Shifrin RY, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):891–2

Adrenal mass with virilisation: importance of endocrine investigation [see comments] Nasir J, et al. **BMJ** 1996 Oct 5;313(7061):872–3. Comment in: BMJ 1997 Jan 18;314(7075):229–30.

A functioning black adenoma of the adrenal gland. Ueda Y, et al. **Intern Med** 1997 Jun;36(6):398–402 (29 ref.)

Clinical characteristics of small functioning adrenocortical tumors in children. Michalkiewicz EL, et al. **Med Pediatr Oncol** 1997 Mar;28(3):175–8

Pediatric case of the day. Adrenocortical adenoma. Medina LS, et al. **Radiographics** 1996 Mar;16(2):449–51

Correction to a previously published case: recurrence of invasive adrenocortical tumor after excision of atypical adenoma. Outwater EK, et al. **Radiology** 1997 Feb; 202(2):531–2

ENZYMOLOGY

Immunolocalization of dehydroepiandrosterone sulfotransferase in normal and pathologic human adrenal gland. Sasano H, et al. **Mod Pathol** 1995 Dec;8(9):891–6

METABOLISM

Different allelic patterns at chromosome 11q13 in paired aldosterone-producing tumours and blood DNA. Gordon R, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul; 23(6–7):594–6

Expression of p53 in adrenocortical tumours: clinicopathological correlations. McNicol AM, et al. **J Pathol** 1997 Feb;181(2):146–52

Viscosity of rat adrenocortical lipids in different functional states: morphological characteristics. Szabó D, et al. **J Steroid Biochem Mol Biol** 1996 Jun;58(3):329–35

PATHOLOGY

Image cytometric DNA analysis of adrenocortical neoplasms as a prognostic parameter: a clinico-pathologic study of 13 patients. Lü X, et al. **Anal Cell Pathol** 1996 Oct; 12(1):1–11

[Bilateral adrenocortical adenomas and the pheochromocytoma syndrome] Dušková J, et al. **Cesk Patol** 1996 Aug;32(3):101–4 (Eng. Abstr.) **(Cze)**

RADIONUCLIDE IMAGING

Simultaneous scintigraphic depiction of aldosteronoma and adrenal infarction. Gianchandani RY, et al. **J Nucl Med** 1996 May;37(5):852–4

Scintigraphic assessment of therapeutic success in aldosteronomas treated by transcatheter arterial embolization using absolute ethanol. Nakajo M, et al. **J Nucl Med** 1997 Feb;38(2):237–41

ADENOMA, ADRENAL CORTICAL

SECRETION

Bilateral deoxycorticosterone-secreting adrenocortical adenoma. Nitta T, et al. **Int J Urol** 1996 Nov;3(6):494–6

Adrenocortical adenoma producing 18-hydroxycorticosterone. Un-no T, et al. **Int J Urol** 1996 Nov;3(6):491–3

SURGERY

[Adrenal gland incidentaloma is not a "time bomb"—arguments for follow-up control] Hensen J, et al. **Zentralbl Chir** 1997;122(6):487–93 (47 ref.) (Eng. Abstr.) **(Ger)**

[Conventional operation for therapy of incidentaloma] Simon D, et al. **Zentralbl Chir** 1997;122(6):473–6 (29 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Scintigraphic assessment of therapeutic success in aldosteronomas treated by transcatheter arterial embolization using absolute ethanol. Nakajo M, et al. **J Nucl Med** 1997 Feb;38(2):237–41

VETERINARY

Stranguria in a castrated male ferret [clinical conference] [see comments] Rosenthal KL, et al. **J Am Vet Med Assoc** 1996 Jul 1;209(1):62–3; discussion 63–4. Comment in: J Am Vet Med Assoc 1996 Sep 1;209(5):893–4.

ADENOMA, ALPHA-CELL see **GLUCAGONOMA**

ADENOMA, BASAL CELL see **ADENOMA**

ADENOMA, BASOPHIL

see related
CUSHING'S SYNDROME

PATHOLOGY

Coexistence of primary empty sella and silent corticotrophic adenoma. Ho KL. **Mod Pathol** 1996 May;9(5):521–5

ADENOMA, BETA-CELL see **INSULINOMA**

ADENOMA, BILE DUCT

[Biliary cystadenoma] Martínez Isla A, et al. **Rev Esp Enferm Dig** 1996 Sep;88(9):634–6 (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Radiologically identifiable intratumoral portal vein in intrahepatic cholangiomas: a diagnostic pitfall. Kaneko K, et al. **Abdom Imaging** 1996 Sep-Oct;21(5):445–7

DIAGNOSIS

Case report: biliary cystadenoma with mucin-secretion mimicking a simple hepatic cyst. Matsumoto S, et al. **Clin Radiol** 1997 Apr;52(4):316–8

Cystadenoma with mesenchymal stroma mistaken for hepatic hydatid cyst. Kapoor R, et al. **Indian J Gastroenterol** 1997 Apr;16(2):73–4

Multiloculated cystic liver lesions: radiologic-pathologic differential diagnosis. Singh Y, et al. **Radiographics** 1997 Jan-Feb;17(1):219–24

METABOLISM

p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Ajiki T, et al. **Hepatogastroenterology** 1996 May-Jun;43(9):521–6

PATHOLOGY

Spontaneous rupture of hepatobiliary cystadenoma: a case report. Chang MS, et al. **Chang Keng I Hsueh** 1995 Dec; 18(4):392–7

RADIOGRAPHY

Case report: malignant transformation of biliary cystadenoma with mesenchymal stroma: documentation by CT. Matsuoka Y, et al. **Clin Radiol** 1997 Apr;52(4):318–21

Intrahepatic biliary cystadenoma demonstrated by intraoperative cholangiography. Hanazaki K. **Hepatogastroenterology** 1996 Jul-Aug;43(10):1024–8

SURGERY

Laser therapy for multiple biliary papillomatosis via choledochoscopy. Meng WC, et al. **Aust N Z J Surg** 1997 Sep;67(9):664–6

ADENOMA, CHROMOPHOBE

BLOOD SUPPLY

Intratumoral flow void in pituitary adenomas [letter] Okamoto K, et al. **AJR Am J Roentgenol** 1996 Oct; 167(4):1070–1

DIAGNOSIS

A case of nonfunctioning pituitary adenoma resembling so-called silent corticotroph adenoma. Sakaguchi H, et al. **Endocr J** 1997 Apr;44(2):329–33

[Progressive, unilateral vision loss with changing nonspecific visual field findings. Chromophobic anterior pituitary adenoma] Auffarth GU, et al. **Ophthalmologe** 1997 Jul; 94(7):532–3 **(Ger)**

PATHOLOGY

Intrathecal metastatic pituitary prolactinoma. Rockwell BH, et al. **AJR Am J Roentgenol** 1996 Nov;167(5):1295–6

VETERINARY

Non-functional pituitary chromophobe adenoma in a calf. Shimada A, et al. **J Comp Pathol** 1996 Jul;115(1):89–93

ADENOMA, EOSINOPHILIC see **ADENOMA, ACIDOPHIL**

ADENOMA, FOLLICULAR see **ADENOMA**

ADENOMA, HEPATOCELLULAR see **ADENOMA, LIVER CELL**

ADENOMA, ISLET CELL

Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract. Pelley RJ, et al. **Curr Opin Oncol** 1997 Jan;9(1):68–74 (74 ref.)

Gastrointestinal endocrine tumors. Krejs GJ. **Scand J Gastroenterol Suppl** 1996;220:121–3 (20 ref.)

[Malignant acinar-endocrine cell tumor of the pancreas] Cosić M, et al. **Vojnosanit Pregl** 1996 Mar-Apr;53(2):145–8 **(Scr)**

COMPLICATIONS

Fatty infiltration of the liver distal to a metastatic liver tumor. Hoshiba K, et al. **Abdom Imaging** 1997 Sep-Oct;22(5):496–8

Cushings syndrome due to a pancreatic islet cell tumour [letter] Pradeep PV, et al. **J Assoc Physicians India** 1996 Nov;44(11):840

DIAGNOSIS

Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Pelosi G, et al. **Hum Pathol** 1996 Nov; 27(11):1124–34

Value of quantitative DNA analysis in endocrine tumors of the pancreas. Böttger T, et al. **Oncology** 1997 Jul-Aug; 54(4):318–23

Islet cell tumors of the pancreas: clinical, radiologic, and pathologic correlation in diagnosis and localization. Buetow PC, et al. **Radiographics** 1997 Mar-Apr; 17(2):453–72; quiz 472A–472B

DRUG THERAPY

Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Trendle MC, et al. **Cancer** 1997 Feb 15; 79(4):830–4

ENZYMOLOGY

Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. Tomita T, et al. **Mod Pathol** 1997 Jan;10(1):47–54

Prohormone convertases (PC1/3 and PC2) in rat and human pancreas and islet cell tumors: subcellular immunohistochemical analysis. Itoh Y, et al. **Pathol Int** 1996 Oct;46(10):726–37

GENETICS

DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice. Shi YP, et al. **Genes Chromosomes Cancer** 1997 Jun;19(2):104–11

Absence of RET proto-oncogene mutations in a father and son with pheochromocytoma and pancreatic islet cell tumor. Kawasaki T, et al. **Int J Urol** 1997 Mar;4(2):169–71

METABOLISM

Expression of peptide receptors in human endocrine tumours of the pancreas. Tang C, et al. **Gut** 1997 Feb;40(2):267–71

A growth hormone-releasing hormone-producing pancreatic islet cell tumor metastasized to the pituitary is associated with pituitary somatotroph hyperplasia and acromegaly. Sanno N, et al. **J Clin Endocrinol Metab** 1997 Aug; 82(8):2731–7

Somatostatin-14, somatostatin-28, and prosomatostatin[1-10] are independently and efficiently processed from prosomatostatin in the constitutive secretory pathway in islet somatostatin tumor cells (1027B2). Patel YC, et al. **Mol Cell Endocrinol** 1997 Aug 8;131(2):183–94

Lack of p53 immunoreactivity in pancreatic endocrine tumors. Lee CS. **Pathology** 1996 May;28(2):139–41

PATHOLOGY

Cytologic features of solid and cystic tumor of the pancreas. Kashima K, et al. **Acta Cytol** 1997 Mar-Apr;41(2):443–9

Fine-needle aspiration cytology of islet cell tumors. Collins BT, et al. **Diagn Cytopathol** 1996 Jul;15(1):37–45 (22 ref.)

Comparative cytologic features of pancreatic acinar cell carcinoma and islet cell tumor. Labate AM, et al. **Diagn Cytopathol** 1997 Feb;16(2):112–6

Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Lam KY, et al. **Eur J Surg Oncol** 1997 Feb;23(1):36–42 (46 ref.)

Islet cell tumour with vacuolated lipid-rich cytoplasm: a new histological variant of islet cell tumour. Ordóñez NG, et al. **Histopathology** 1997 Aug;31(2):157–60

DNA ploidy and proliferating cell nuclear antigen in islet cell tumors. Tomita T. **Pancreas** 1996 Jan;12(1):36–47

Intravascular tumor: a previously unreported finding of glucagonoma. Geehan DM, et al. **South Med J** 1997 Jul; 90(7):743–7

Somatostatin receptor localization of pancreatic endocrine tumors. Corleto VD, et al. **World J Surg** 1996 Feb; 20(2):241–4

[Adenocarcinoma of the gallbladder associated with endocrine pancreatic tumor and disclosed by biliary tumor migration (letter)] Fouchard I, et al. **Gastroenterol Clin Biol** 1996;20(8-9):708–9 **(Fre)**

PHYSIOPATHOLOGY

Islet cell tumors. Stabile BE. **Gastroenterologist** 1997 Sep; 5(3):213–32 (161 ref.)

Mechanism of gastric acid hypersecretion in patients with islet cell tumor without hypergastrinemia: studies in rats. Song Y, et al. **Gastroenterology** 1997 Oct;113(4):1129–35

RADIOGRAPHY

Functioning islet cell tumor of the pancreas. Localization with dynamic spiral CT. Chung MJ, et al. **Acta Radiol** 1997 Jan;38(1):135–8

RADIONUCLIDE IMAGING

Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors. Meko JB, et al. **Surgery** 1996 Dec;120(6):975–83; discussion 983–4

SURGERY

Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort. Madura JA, et al. **Am Surg** 1997 Jul;63(7):573–7; discussion 577–8

Early experience with laparoscopic resections of islet cell tumors. Gagner M, et al. **Surgery** 1996 Dec;120(6):1051–4

ULTRASTRUCTURE

Prohormone convertases (PC1/3 and PC2) in rat and human pancreas and islet cell tumors: subcellular immunohistochemical analysis. Itoh Y, et al. **Pathol Int** 1996 Oct;46(10):726–37

VETERINARY

Tumours of the endocrine glands. Schmidt RE, et al. **IARC Sci Publ** 1996;(126):307–20 (50 ref.)

ADENOMA, LIVER CELL

Intrahepatic splenosis mimicking hepatic adenoma. Gruen DR, et al. **AJR Am J Roentgenol** 1997 Mar;168(3):725–6

Solitary hepatocellular adenoma in infancy. Milillo F, et al. **Pediatr Med Chir** 1997 Mar-Apr;19(2):125–6

CHEMICALLY INDUCED

Disappearance of liver cell adenoma: CT and MR imaging. Kawakatsu M, et al. **Abdom Imaging** 1997 May-Jun; 22(3):274–6

Role of oral contraceptives in the growth of a multilobular adenoma associated with a hepatocellular carcinoma in a young woman. Perret AG, et al. **J Hepatol** 1996 Dec; 25(6):976–9

COMPLICATIONS

Spontaneous rupture of a liver cell adenoma. Angunawela P, et al. **Ceylon Med J** 1997 Mar;42(1):42–3

Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. Labrune P, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar; 24(3):276–9 (25 ref.)

Severe upper abdominal pain due to a large hepatocellular adenoma. Reijnierse JE, et al. **Neth J Med** 1997 Jul; 51(1):46–50

[Association of hepatic adenomatosis and hepatoportal sclerosis in a woman with incontinentia pigmenti] Oberti F, et al. **Gastroenterol Clin Biol** 1997;21(2):147–51 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Disappearance of liver cell adenoma: CT and MR imaging. Kawakatsu M, et al. **Abdom Imaging** 1997 May-Jun; 22(3):274–6

Hepatic adenomatosis in an adolescent. Gokhale R, et al.

J Pediatr Gastroenterol Nutr 1996 Nov;23(4):482–6 (24 ref.)
[Hepatic angiomyolipoma simulating hepatocytic tumor. 3 cases] Arblade S, et al. **Gastroenterol Clin Biol** 1996; 20(11):1022–6 (39 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Childhood hepatocellular adenoma in familial adenomatous polyposis: mutations in adenomatous polyposis coli gene and p53. Bala S, et al. **Gastroenterology** 1997 Mar; 112(3):919–22

METABOLISM

Large encapsulated hepatocellular adenoma in a male. Ramakrishna B, et al. **Liver** 1996 Aug;16(4):235–6

MICROBIOLOGY

Helicobacter hepaticus, a recently recognized bacterial pathogen, associated with chronic hepatitis and hepatocellular neoplasia in laboratory mice. Rice JM. **Emerg Infect Dis** 1995 Oct–Dec;1(4):129–31

PATHOLOGY

Are hepatic adenomas premalignant? Nagorney DM. **HPB Surg** 1996;10(1):59–61

SURGERY

Spontaneously occurring liver cell adenoma in an adult male. Deodhar KK, et al. **Indian J Gastroenterol** 1996 Jan; 15(1):28–9
[Laparoscopic surgery of benign tumors of the liver. Apropos of 5 cases] Laporte J, et al. **J Chir (Paris)** 1996; 133(9–10):432–6 (15 ref.) (Eng. Abstr.) **(Fre)**

ADENOMA, MICROCYSTIC see **ADENOMA**

ADENOMA, MONOMORPHIC see **ADENOMA**

ADENOMA, OXYPHILIC

Adrenocortical oncocytoma: two case reports and review of literature. Waters PR, et al. **Urology** 1997 Apr; 49(4):624–8 (14 ref.)
[Bilateral multifocal oncocytoma of the kidney] Baše J. **Rozhl Chir** 1996 Dec;75(12):573–5 (Eng. Abstr.) **(Cze)**
[Oncocytic tumors of the thyroid. Diagnostic and therapeutic problems. Report of 17 cases and review of the literature] Gaschignard N, et al. **J Chir (Paris)** 1996 Jul;133(5):201–7 (51 ref.) (Eng. Abstr.) **(Fre)**
[Renal oncocytoma] Nakamura H. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):471–3 (15 ref.) **(Jpn)**

CHEMISTRY

Immunocytochemical and immunoelectron microscopical analysis of BCL2 expression in thyroid oxyphilic tumors. Lombardi L, et al. **Ultrastruct Pathol** 1997 Jan–Feb; 21(1):33–9

COMPLICATIONS

Sporadic primary hyperparathyroidism in the setting of multiple endocrine neoplasia type 1. Teh BT, et al. **Arch Surg** 1996 Nov;131(11):1230–2
Oncocytoma of the lacrimal sac associated with chronic dacryocystitis. Chow DR, et al. **Can J Ophthalmol** 1996 Aug;31(5):249–51
Oxyphil parathyroid adenoma associated with primary hyperparathyroidism and marked post–operative hungry bone syndrome. Natsui K, et al. **Intern Med** 1996 Jul; 35(7):545–9
Panhypopituitarism due to Rathke's cleft cyst associated with pituitary oncocytoma. Yamakita N, et al. **Intern Med** 1997 Feb;36(2):107–12

DIAGNOSIS

Differential diagnosis of Hürthle cell neoplasms on fine needle aspirates. Can we do any better with morphometry? Pambuccian SE, et al. **Acta Cytol** 1997 Jan–Feb; 41(1):197–208
Transitional features of benign and malignant oncocytic tumors: report of two cases. Watson D, et al. **Am J Otolaryngol** 1996 Sep–Oct;17(5):335–9
Antimitochondrial antibody (113–1) in the differential diagnosis of granular renal cell tumors. Tickoo SK, et al. **Am J Surg Pathol** 1997 Aug;21(8):922–30
Preoperative diagnosis of renal oncocytoma by fine needle aspiration (FNA). Caputo V, et al. **Cytopathology** 1996 Oct; 7(5):366–71
[Renal oncocytoma. Report of 13 cases] Li GR, et al. **Ann Urol (Paris)** 1997;31(3):123–30 (Eng. Abstr.) **(Fre)**
[Oncocytoma of the conjunctiva] Spraul CW, et al. **Klin Monatsbl Augenheilkd** 1996 Aug–Sep;209(2–3):176–7 (Eng. Abstr.) **(Ger)**
[The case of malignant oncocytoma of the parotid gland] Namysłowski G, et al. **Otolaryngol Pol** 1996;50(3):321–4 (Eng. Abstr.) **(Pol)**

GENETICS

A singular case of near–haploid stemline karyotype in a renal oncocytoma. Gregori–Romero MA, et al. **Cancer Genet Cytogenet** 1996 Nov;92(1):28–30
Involvement of the chromosomal region 11q13 in renal oncocytoma: case report and literature review. Neuhaus C, et al. **Cancer Genet Cytogenet** 1997 Apr;94(2):95–8 (20 ref.)
Fine mapping of the human renal oncocytoma–associated translocation (5;11)(q35;q13) breakpoint. Sinke RJ, et al. **Cancer Genet Cytogenet** 1997 Jul 15;96(2):95–101
The t(1;12)(p36;q13) in a renal oncocytoma. Dal Cin P, et al. **Genes Chromosomes Cancer** 1996 Oct;17(2):136–9
Comparative genomic hybridization for genetic analysis of renal oncocytomas. Presti JC Jr, et al. **Genes Chromosomes Cancer** 1996 Dec;17(4):199–204
Loss of heterozygosity studies indicate that chromosome arm 1p harbors a tumor supressor gene for renal oncocytomas. Thrash–Bingham CA, et al. **Genes Chromosomes Cancer** 1996 May;16(1):64–7

METABOLISM

Lectin staining of renal cell tumours with special emphasis on oncocytomas. Engel U, et al. **APMIS** 1996 Dec; 104(12):933–7

PATHOLOGY

Immunocytochemical study of pituitary oncocytic adenomas. Nishioka H, et al. **Acta Neuropathol (Berl)** 1997 Jul; 94(1):42–7
Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases [published erratum appears in Am J Surg Pathol 1997 Jun;21(6):742] Amin MB, et al. **Am J Surg Pathol** 1997 Jan;21(1):1–12
Renal oncocytoma: a clinicopathologic study of 70 cases. Perez–Ordonez B, et al. **Am J Surg Pathol** 1997 Aug; 21(8):871–83
Oncocytic meningioma. Roncaroli F, et al. **Am J Surg Pathol** 1997 Apr;21(4):375–82
Oncocytic cells and parenchymal tumors of the kidney. Vecchioli Scaldazza C, et al. **Arch Esp Urol** 1996 Jun; 49(5):538–44
Fine–needle aspiration of chromophobe renal cell carcinoma. Analysis of six cases. Granter SR, et al. **Cancer** 1997 Apr 25;81(2):122–8
Oncocytomas of the submandibular gland. A series of 22 cases and a review of the literature. Thompson LD, et al. **Cancer** 1996 Dec 1;78(11):2281–7 (55 ref.)
Tall cell variant of papillary thyroid carcinoma: cytologic features and differential diagnostic considerations. Bocklage T, et al. **Diagn Cytopathol** 1997 Jul;17(1):25–9
Coexisting non–functioning pheochromocytoma and renal oncocytoma: a case report and review of the literature. Daskalopoulos G, et al. **Eur J Radiol** 1996 Sep;23(2):138–42 (22 ref.)
Ostensible oncocytoma of accessory lacrimal glands. Pecorella I, et al. **Histopathology** 1997 Mar;30(3):264–70
Hyaline globules in renal cell carcinomas and oncocytomas. Gatalica Z, et al. **Hum Pathol** 1997 Apr;28(4):400–3
Papillary hurthle cell tumours of thyroid. Diagnostic features in eight cases with review of literature. Goyal A, et al. **Indian J Cancer** 1996 Sep;33(3):130–5
Oncocytoma of the nasal cavity: report of a case and review of the literature. Comin CE, et al. **J Laryngol Otol** 1997 Jul;111(7):671–3 (13 ref.)
An incidental finding––bilateral multifocal renal oncocytoma. Bender BU, et al. **Nephrol Dial Transplant** 1997 May; 12(5):1034–6 (27 ref.)
Glandular tumors of the lacrimal sac. Their histopathologic patterns and possible origins. Pe'er J, et al. **Ophthalmology** 1996 Oct;103(10):1601–5
Quantitative evaluation of apoptosis and proliferation in renal cell carcinoma. Correlation to tumor subtype, cytological grade according to thoenes–classification and the occurrence of metastasis. Hindermann W, et al. **Pathol Res Pract** 1997;193(1):1–7
Oncocytic adenocarcinoma of minor salivary gland. An unusual glossal presentation of a minor salivary gland tumor. Ruby SG, et al. **Pathol Res Pract** 1996 Aug; 192(8):856–64; discussion 865–8
Rare association of unilateral renal oncocytoma and angiomyolipoma. Talic RF, et al. **Scand J Urol Nephrol** 1997 Feb;31(1):91–3
[Oncocytoma of the caruncle. Anatomo–clinical study apropos of a case] Girard B, et al. **J Fr Ophtalmol** 1996; 19(10):619–22 (23 ref.) (Eng. Abstr.) **(Fre)**
[Oncocytes and oncocytic cell neoplasms (editorial)] Tallini G. **Pathologica** 1996 Apr;88(2):85–90 **(Ita)**
[A case of malignant oncocytoma of the parotid gland] Nakagawa M, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jan;99(1):1–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Diagnostic difficulties and value of partial surgery in multiple tumors of the kidney. Apropos of 4 cases] De la Taille A, et al. **J Urol (Paris)** 1996;102(4):139–43 (Eng. Abstr.) **(Fre)**

SURGERY

Oncocytomas of the upper jaw. Corbridge RJ, et al. **Head Neck** 1996 Jul–Aug;18(4):374–80 (46 ref.)
Renal oncocytoma treated by surgical enucleation: a case report. Mitsui K, et al. **Hinyokika Kiyo** 1996 May; 42(5):369–72
Hurthle cell tumor. Chen HY, et al. **Int Surg** 1996 Apr–Jun; 81(2):168–70
[Renal oncocytoma: nephrectomy or tumorectomy? Description of five cases and review of the literature] Gabellon S, et al. **Ann Urol (Paris)** 1997;31(3):131–6 (32 ref.) (Eng. Abstr.) **(Fre)**
[Renal oncocytoma. Report of 13 cases] Li GR, et al. **Ann Urol (Paris)** 1997;31(3):123–30 (Eng. Abstr.) **(Fre)**
[Parapharyngeal oncocytoma of the parotid gland] Carluccio F, et al. **Acta Otorhinolaryngol Ital** 1996 Feb;16(1):57–61 (Eng. Abstr.) **(Ita)**

ULTRASTRUCTURE

Immunocytochemical and immunoelectron microscopical analysis of BCL2 expression in thyroid oxyphilic tumors. Lombardi L, et al. **Ultrastruct Pathol** 1997 Jan–Feb; 21(1):33–9

VETERINARY

Imprint and brush cytology in the diagnosis of canine intranasal tumours. Clercx C, et al. **J Small Anim Pract** 1996 Sep;37(9):423–7

ADENOMA, PAPILLARY see **ADENOMA**

ADENOMA, PLEOMORPHIC

Pleomorphic adenoma of the parotid. Wolf IS, et al. **Am Fam Physician** 1997 Jul;56(1):185–92 (25 ref.)
Malignant chondroid syringoma of scalp with cervical lymph node metastases. Seenu V, et al. **J Assoc Physicians India** 1996 Aug;44(8):565–6
Pleomorphic adenoma of the trachea. Bizal JC, et al. **Otolaryngol Head Neck Surg** 1997 Jan;116(1):139–40

CHEMISTRY

Malignant chondroid syringoma: immunohistopathology. Metzler G, et al. **Am J Dermatopathol** 1996 Feb;18(1):83–9
DNA flow cytometry and glial fibrillary acidic protein reactivity in pleomorphic adenomas of the salivary glands. Desinan L, et al. **Anal Quant Cytol Histol** 1996 Oct; 18(5):355–60
Pleomorphic adenoma with extensive adipose content. Jin YT, et al. **Histopathology** 1996 Jan;28(1):87–9
Immunohistochemical study of c–erbB–2 expression in carcinoma ex–pleomorphic adenoma. Rosa JC, et al. **Histopathology** 1996 Mar;28(3):247–52
Immunohistochemical localization of fibroblast growth factor–1 (FGF–1), FGF–2 and fibroblast growth factor receptor–1 (FGFR–1) in pleomorphic adenoma of the salivary glands. Myoken Y, et al. **J Oral Pathol Med** 1997 Jan;26(1):17–22
Immunohistochemical pattern of Bcl–2– and PTHrP–positive cells in primary, in recurrent and in carcinoma in pleomorphic adenomas. Sunardhi–Widyaputra S, et al. **Pathol Res Pract** 1995 Dec;191(12):1186–91

COMPLICATIONS

Sectorial choroidal ischemia associated with ipsilateral lacrimal gland tumor. Khairallah M, et al. **Am J Ophthalmol** 1997 Aug;124(2):263–5
Hyperthyroidism caused by an ectopic TSH–secreting pituitary tumor. Cooper DS, et al. **Thyroid** 1996 Aug; 6(4):337–43 (50 ref.)

CONGENITAL

Salivary gland anlage tumor. A case with widespread necrosis and large cyst formation. Michal M, et al. **Pathology** 1996 May;28(2):128–30

DIAGNOSIS

The usefulness of MR in establishing the diagnosis of parotid pleomorphic adenoma. Ikeda K, et al. **AJNR Am J Neuroradiol** 1996 Mar;17(3):555–9
Pleomorphic adenoma of the tongue base. Magliulo G, et al. **Ann Otol Rhinol Laryngol** 1996 Oct;105(10):835–7
Recurrent pleomorphic adenoma of the parotid gland involving the osseous external auditory canal. With a note on the foramen of Huschke. Rabinov CR, et al. **Ann Otol Rhinol Laryngol** 1997 Jul;106(7 Pt 1):589–93
Pleomorphic adenoma of the breast: report of a case. Mochinaga N, et al. **Surg Today** 1997;27(3):278–81
[Synchronous double tumors of the parotid gland] Franzen A, et al. **Laryngorhinootologie** 1996 Jul;75(7):437–40 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Evidence of bimodal distribution of age in patients affected by pleomorphic adenoma of the parotid gland [letter] Farina A, et al. **Oral Oncol** 1997 Jul;33(4):288–9

GENETICS

Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Correlation with p53 expression. Li X, et al. **Cancer** 1997 Jun 15;79(12):2314–9

ADENOMA, PLEOMORPHIC

Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Geurts JM, et al. **Cancer Res** 1997 Jan 1;57(1):13–7

Mapping of the 8q12 translocation breakpoint to a 40-kb region in a pleomorphic adenoma with an ins(8;3)(q12;p21.3p14.1). Röijer E, et al. **Cytogenet Cell Genet** 1997;76(1–2):23–6

Identification of a yeast artificial chromosome spanning the 8q12 translocation breakpoint in pleomorphic adenomas with t(3;8)(p21;q12). Röijer E, et al. **Genes Chromosomes Cancer** 1996 Nov;17(3):166–71

Mutations associated with carcinomas arising from pleomorphic adenomas of the salivary glands. Yamamoto Y, et al. **Hum Pathol** 1996 Aug;27(8):782–6

Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations [published erratum appears in Nat Genet 1997 Apr;15(4):411] Kas K, et al. **Nat Genet** 1997 Feb;15(2):170–4

[Relationship between c-erbB-2 oncoprotein expression and prognosis in salivary gland malignant pleomorphic adenoma] Yan Y, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Nov; 30(6):326–8, 383 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Chondroid syringoma: an immunohistochemical study using antibodies to Ca 15-3, KA-93, Ca 19-9, CD44 and BM-1. Tsuji T. **J Cutan Pathol** 1996 Dec;23(6):530–6

Salivary gland anlage tumor of the nasopharynx: a clinicopathologic and immunohistochemical study of three cases. Boccon-Gibod LA, et al. **Pediatr Pathol Lab Med** 1996 Nov-Dec;16(6):973–83 (23 ref.)

METABOLISM

Immunomorphological characteristics of pleomorphic adenoma of salivary glands. Angelov A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1996 Jun-Sep; 39(3–4):67–75

Synthesis of elastin by pleomorphic adenomas. Grosso LE. **J Oral Pathol Med** 1996 Jan;25(1):5–9

Are differences in the expression of carbohydrate-binding sites (endogenous lectins) responsible for recurrences of benign tumours of the parotid gland? Steuer MK, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Nov–Dec; 57(6):343–7

Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumor. Cooper DS, et al. **Thyroid** 1996 Aug; 6(4):337–43 (50 ref.)

[Relationship between cellular DNA and expression of epidermal growth factor receptor in pleomorphic adenoma of lacrimal gland] Zheng L, et al. **Chung Hua Yen Ko Tsa Chih** 1996 Mar;32(2):133–5 (Eng. Abstr.) **(Chi)**

[Lectin-histochemical analysis of pleomorphic adenoma of the lacrimal gland] Uehara F, et al. **Nippon Ganka Gakkai Zasshi** 1997 Apr;101(4):355–8 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Fine needle aspiration cytology of cellular pleomorphic adenoma. Elsheikh TM, et al. **Acta Cytol** 1996 Nov-Dec; 40(6):1165–75

Fine needle aspiration of pleomorphic adenoma and adenoid cystic carcinoma of salivary gland origin. Kapadia SB, et al. **Acta Cytol** 1997 Mar-Apr;41(2):487–92

Fine needle aspiration cytology of predominant plasmacytoid myoepithelial cells in pleomorphic adenoma of the palate [letter] Kuwabara H, et al. **Acta Cytol** 1997 Sep-Oct; 41(5):1637–40

Differential diagnosis of adenoid cystic carcinoma from pleomorphic adenoma of the salivary gland on fine needle aspiration cytology. Lee SS, et al. **Acta Cytol** 1996 Nov-Dec;40(6):1246–52

Fine needle aspiration cytology of pleomorphic adenoma. An analysis of 212 cases. Viguer JM, et al. **Acta Cytol** 1997 May-Jun;41(3):786–94

Malignant chondroid syringoma: immunohistopathology. Metzler G, et al. **Am J Dermatopathol** 1996 Feb;18(1):83–9

Salivary gland double tumor: synchronous ipsilateral pleomorphic adenoma and acinic cell carcinoma of the parotid gland. Misselevich I, et al. **Ann Otol Rhinol Laryngol** 1997 Mar;106(3):226–9

Accessory parotid gland tumor: a case report. Horii A, et al. **Auris Nasus Larynx** 1997;24(1):105–10

Synchronous salivary gland neoplasia [letter; comment] Curtis A, et al. **Br J Oral Maxillofac Surg** 1997 Feb; 35(1):73–4. Comment on: Br J Oral Maxillofac Surg 1996 Feb;34(1):135.

Multiple pleomorphic adenomas arising in the parotid and submandibular lymph nodes. Shinohara M, et al. **Br J Oral Maxillofac Surg** 1996 Dec;34(6):515–9

Effect of adenosine 3',5'-cyclic monophosphate (cAMP) on human non-tumorigenic and tumorigenic parotid acinar cells in culture. Krause G, et al. **Cancer Lett** 1996 Nov 12;108(1):73–9

Salivary epithelial-myoepithelial carcinoma: report of a case misinterpreted as pleomorphic adenoma on fine needle aspiration (FNA). Stewart CJ, et al. **Cytopathology** 1997 Jun;8(3):203–9

Immunohistochemical study of mixed tumor of the skin with marked ossification. Shimizu S, et al. **Dermatology** 1996; 193(3):255–7

Fine-needle aspiration biopsy of adenoid cystic carcinoma of the breast: a case report. Culubret M, et al. **Diagn Cytopathol** 1996 Dec;15(5):431–4

Case of myoepithelioma originating from the palate: collagenogenesis in myoepithelial tumor cells. Hara H, et al. **Diagn Cytopathol** 1996 Dec;15(5):415–20

Chondroid syringoma of the head and neck: clinical management and literature review. Chen AH, et al. **Ear Nose Throat J** 1996 Feb;75(2):104–8

Comparison of proliferating cell nuclear antigen index in benign and malignant salivary pleomorphic adenoma. Yang L, et al. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):56–60

Intra-vascular tumour in pleomorphic adenomas--a report of four cases. Altini M, et al. **Histopathology** 1997 Jul; 31(1):55–9

Mixed tumour of the vagina. Fukunaga M, et al. **Histopathology** 1996 May;28(5):457–61

Immunohistochemical study of c-erbB-2 expression in carcinoma ex-pleomorphic adenoma. Rosa JC, et al. **Histopathology** 1996 Mar;28(3):247–52

Pleomorphic adenoma of the palate in a child: 9-year follow-up. de Courten A, et al. **Int J Oral Maxillofac Surg** 1996 Aug;25(4):293–5 (13 ref.)

Pleomorphic adenoma of the palate in children: report of a case. López-Cedrún JL, et al. **Int J Oral Maxillofac Surg** 1996 Jun;25(3):206–7 (11 ref.)

Cutaneous mixed tumor containing ossification, hair matrix, and sebaceous ductal differentiation. Akasaka T, et al. **J Dermatol** 1997 Feb;24(2):125–31

Malignant chondroid syringoma. Sun TB, et al. **J Formos Med Assoc** 1996 Jul;95(7):575–8

Chondroid syringoma of the scrotum. Poku JW, et al. **J Int Med Res** 1996 Nov-Dec;24(6):482–6

Carcinoma ex pleomorphic adenoma of the palate--a case report. Kim KM, et al. **J Korean Med Sci** 1997 Feb; 12(1):63–6

Co-existing pleomorphic and tubular basal cell adenomas of the parotid gland. Chow LT, et al. **J Laryngol Otol** 1997 Feb;111(2):182–5

Stromal bone formation in pleomorphic adenoma of minor salivary gland origin. Takeda Y, et al. **J Nihon Univ Sch Dent** 1996 Jul;38(2):102–4 (6 ref.)

A massive pleomorphic adenoma of the submandibular salivary gland. Erol B, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1011–4 (22 ref.)

Quantitation and localization of cycling tumor cells in pleomorphic adenomas and myoepitheliomas: an immunohistochemical analysis. Norberg L, et al. **J Oral Pathol Med** 1997 Mar;26(3):124–8

Atypical features in salivary gland mixed tumors: their relationship to malignant transformation. Auclair PL, et al. **Mod Pathol** 1996 Jun;9(6):652–7

Carcinomatous change in the cranial metastasis from a metastasizing mixed tumor of the salivary gland--case report. Fujimura M, et al. **Neurol Med Chir (Tokyo)** 1997 Jul;37(7):546–50

Glandular tumors of the lacrimal sac. Their histopathologic patterns and possible origins. Pe'er J, et al. **Ophthalmology** 1996 Oct;103(10):1601–5

Tumors arising in the palpebral lobe of the lacrimal gland. Vangveeravong S, et al. **Ophthalmology** 1996 Oct; 103(10):1606–12 (38 ref.)

Salivary gland anlage tumor. A case with widespread necrosis and large cyst formation. Michal M, et al. **Pathology** 1996 May;28(2):128–30

Salivary gland anlage tumor of the nasopharynx: a clinicopathologic and immunohistochemical study of three cases. Boccon-Gibod LA, et al. **Pediatr Pathol Lab Med** 1996 Nov-Dec;16(6):973–83 (23 ref.)

Malignant chondroid syringoma presenting as multiple pulmonary nodules. Kiely JL, et al. **Thorax** 1997 Apr; 52(4):395–6

Effect of spatial arrangement of the basement membrane on cultured pleomorphic adenoma cells. Study by immunocytochemistry and electron and confocal microscopy. Jaeger MM, et al. **Virchows Arch** 1997 Jun; 430(6):467–77

Pleomorphic adenoma of the trachea--a case report. Paik HC, et al. **Yonsei Med J** 1996 Feb;37(1):81–5

[Case report: pleomorphic adenoma of the lateral nasal wall] Castello E, et al. **Acta Otorhinolaryngol Ital** 1996 Oct; 16(5):433–7 (Eng. Abstr.) **(Ita)**

[Rare association of a mixed tumor of the skin with a carcinoma of low grade malignancy. Clinical case] Riboni V, et al. **Minerva Chir** 1996 Jul-Aug;51(7–8):617–20 (Eng. Abstr.) **(Ita)**

[A carcinoma arising from benign pleomorphic adenoma of the trachea] Mori S, et al. **Kyobu Geka** 1997 Jul;50(7):602–5 (Eng. Abstr.) **(Jpn)**

[Two cases of pleomorphic adenoma of the nasal cavity] Wakami S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jan;99(1):38–45 (60 ref.) (Eng. Abstr.) **(Jpn)**

[A case of gigantic pleomorphic adenoma of the parotid gland] Namysłowski G, et al. **Otolaryngol Pol** 1996; 50(2):169–72 (Eng. Abstr.) **(Pol)**

[Phenotypic characterization of cells and structure of the extracellular matrix in pleomorphic adenoma of the salivary glands] Ivanova SA, et al. **Arkh Patol** 1997 Jul-Aug; 59(4):49–55 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Pleomorphic adenoma of the trachea--a case report. Paik HC, et al. **Yonsei Med J** 1996 Feb;37(1):81–5

SURGERY

Surgical treatment of benign tumours of the salivary glands. Van Hee R, et al. **Acta Chir Belg** 1996 Jul-Aug;96(4):161–4

An analysis of the treatment of 114 patients with recurrent pleomorphic adenomas of the parotid gland. Renehan A, et al. **Am J Surg** 1996 Dec;172(6):710–4

Huge pleomorphic adenoma of the upper retromolar area. Hirabayashi S, et al. **Ann Plast Surg** 1997 Feb;38(2):184–6

Complications associated with excision of a submandibular salivary gland tumor. McEwen DR, et al. **AORN J** 1996 Jul;64(1):109–11

Surgical management of 246 previously untreated pleomorphic adenomas of the parotid gland. Leverstein H, et al. **Br J Surg** 1997 Mar;84(3):399–403

Clinical significance of the tumour capsule in the treatment of parotid pleomorphic adenomas. McGurk M, et al. **Br J Surg** 1996 Dec;83(12):1747–9

Intrascrotal chondroid syringoma. Miyakawa A, et al. **Br J Urol** 1997 Feb;79(2):293–5

Benign pleomorphic adenoma of the larynx: report of a case and review and analysis of 20 additional cases in the literature. Dubey SP, et al. **Ear Nose Throat J** 1997 Aug; 76(8):548–50, 552, 554–7 (27 ref.)

A transpalatal approach to the parapharyngeal space. Myatt HM, et al. **J Laryngol Otol** 1997 Feb;111(2):159–62

Surgical management of pleomorphic adenomas of the parotid gland: a follow-up study of three methods. Laskawi R, et al. **J Oral Maxillofac Surg** 1996 Oct;54(10):1176–9

Adenolymphomas of the parotid and neck with a coexistent pleomorphic adenoma. Case report. Hosokawa K, et al. **Scand J Plast Reconstr Surg Hand Surg** 1997 Sep; 31(3):267–9

[Development and results of surgical treatment of pleomorphic adenoma of the parotid gland in 245 patients, 1974–1994 (see comments)] Leverstein H, et al. **Ned Tijdschr Geneeskd** 1996 Sep 7;140(36):1812–6 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1996 Dec 14;140(50):2529. **(Dut)**

[Developments in and results of surgical treatment of pleomorphic adenoma of the parotid gland in 245 patients, 1974–1994 (letter; comment)] Oomen JL. **Ned Tijdschr Geneeskd** 1996 Dec 14;140(50):2529. Comment on: Ned Tijdschr Geneeskd 1996 Sep 7;140(36):1812–6. **(Dut)**

[Reoperation and recurrence of pleomorphic adenoma of the parotid. A propos of 62 cases] Chevalier D, et al. **Ann Otolaryngol Chir Cervicofac** 1996;113(2):56–60 (Eng. Abstr.) **(Fre)**

[Oral transmuscular adenoma removal of the submandibular gland] Müller-Driver O. **HNO** 1996 Feb;44(2):89–93 (Eng. Abstr.) **(Ger)**

[A case of gigantic pleomorphic adenoma of the parotid gland] Namysłowski G, et al. **Otolaryngol Pol** 1996; 50(2):169–72 (Eng. Abstr.) **(Pol)**

THERAPY

Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre. Renehan A, et al. **Br J Surg** 1996 Dec;83(12):1750–4

VETERINARY

Imprint and brush cytology in the diagnosis of canine intranasal tumours. Clercx C, et al. **J Small Anim Pract** 1996 Sep;37(9):423–7

ADENOMA, PROLACTIN-SECRETING, PITUITARY see **PROLACTINOMA**

ADENOMA, PROSTATIC see **PROSTATIC HYPERPLASIA**

ADENOMA, SWEAT GLAND

DIAGNOSIS

Eccrine spiradenoma mimicking adenoid cystic carcinoma on fine needle aspiration. A case report. Kolda TF, et al. **Acta Cytol** 1997 May-Jun;41(3):852–8

Dermal cylindroma and eccrine spiradenoma. Lee MW, et al. **Australas J Dermatol** 1996 Feb;37(1):48–9

Sweat gland carcinoma [editorial] Geisse JK, et al. **Dermatol Surg** 1997 Apr;23(4):235

GENETICS

Identification of aneuploidy in recurrent clear cell hidradenoma by DNA image cytometry (ICM-DNA). Kiehl P, et al. **J Cutan Pathol** 1997 May;24(5):314–21

METABOLISM

p53 expression in intraductal epithelial hyperplasia, atypical intraductal hyperplasia, and intraductal carcinoma of the breast [letter; comment] Fischler DF, et al. **Histopathology** 1996 Jan;28(1):93–4. Comment on: Histopathology 1995 May;26(5):439–43.

PATHOLOGY

Syringocystadenoma papilliferum, basal cell carcinoma and trichilemmoma arising from nevus sebaceus of Jadassohn [letter] Yoon DH, et al. **Acta Derm Venereol** 1997 May; 77(3):242–3

An unusual, recurring breast tumor with features of eccrine spiradenoma: a case report. Panico L, et al. **Am J Clin Pathol** 1996 Nov;106(5):665–9

Phenotypic heterogeneity of nodular hidradenoma. Immunohistochemical analysis with emphasis on cytokeratin expression. Biernat W, et al. **Am J Dermatopathol** 1996 Dec;18(6):592–6

Cutaneous adnexal carcinoma arising within a solitary cylindroma–spiradenoma. Biernat W, et al. **Am J Dermatopathol** 1996 Feb;18(1):77–82

Syringofibrocarcinoma versus squamous cell carcinoma involving syringofibroadenoma: is there a malignant counterpart of Mascaro's syringofibroadenoma? González-Serva A, et al. **Am J Dermatopathol** 1997 Feb; 19(1):58–65

Spiradenoma and dermal cylindroma: comparative immunohistochemical analysis and histogenetic considerations. Meybehm M, et al. **Am J Dermatopathol** 1997 Apr;19(2):154–61

Oncocytic nodular hidradenoma. Roth MJ, et al. **Am J Dermatopathol** 1996 Jun;18(3):314–6

Nodular hidradenoma of the eyelid [letter] Tsuda Y, et al. **Arch Ophthalmol** 1996 Oct;114(10):1287–8

Mossy leg with eccrine syringofibroadenomatous hyperplasia resembling multiple eccrine syringofibroadenoma. Rongioletti F, et al. **Clin Exp Dermatol** 1996 Nov; 21(6):454–6

Sweat gland carcinoma. Case report and review of the literature. Ashley I, et al. **Dermatol Surg** 1997 Feb; 23(2):129–33

Solitary eccrine syringofibroadenoma (or eccrine syringofibroadenomatous hyperplasia?) and diabetic polyneuropathy. Gambini C, et al. **Dermatology** 1996; 193(1):68–9 (13 ref.)

Fine-needle aspiration of nodular hidradenoma: a case report. Gottschalk-Sabag S, et al. **Diagn Cytopathol** 1996 Dec; 15(5):395–7

Clear cell hidradenoma simulating breast carcinoma: a diagnostic pitfall in fine-needle aspiration of breast. Kumar N, et al. **Diagn Cytopathol** 1996 Jul;15(1):70–2

Syringocystadenocarcinoma papilliferum. Bondi R, et al. **Histopathology** 1996 May;28(5):475–7

p53 expression in intraductal epithelial hyperplasia, atypical intraductal hyperplasia, and intraductal carcinoma of the breast [letter; comment] Fischler DF, et al. **Histopathology** 1996 Jan;28(1):93–4. Comment on: Histopathology 1995 May;26(5):439–43.

An unusual case of syringocystadenoma papilliferum of the eyelid. Rao VA, et al. **Indian J Ophthalmol** 1996 Sep; 44(3):168–9

Eccrine syringofibroadenoma: multiple lesions representing a new cutaneous marker of the Schöpf syndrome, and solitary nonhereditary tumors. Starink TM. **J Am Acad Dermatol** 1997 Apr;36(4):569–76 (38 ref.)

Eccrine syringofibroadenoma surrounding a squamous cell carcinoma: a case report. Lele SM, et al. **J Cutan Pathol** 1997 Mar;24(3):193–6

Malignant eccrine spiradenoma with smooth muscle cell differentiation: histological and immunohistochemical study. Itoh T, et al. **Pathol Int** 1996 Nov;46(11):887–93 (23 ref.)

Spiradenoma associated with apocrine adenoma component. Michal M. **Pathol Res Pract** 1996 Nov;192(11):1135–9; discussion 1140–1

[Eccrine syringofibroadenoma. Report of a case] Grimaud H, et al. **Ann Pathol** 1997 Mar;17(1):52–4 (Eng. Abstr.) **(Fre)**

[Syringomatous breast carcinoma and correlated lesions] Urso C. **Pathologica** 1996 Jun;88(3):196–9 (20 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Congenital syringocystadenoma papilliferum of the ear and neck treated with the CO2 laser. Jordan JA, et al. **Int J Pediatr Otorhinolaryngol** 1996 Dec 5;38(1):81–7

Eccrine spiradenoma of the hand clinically mimicking a lipoma. Al-Qattan MM. **J Hand Surg [Br]** 1996 Aug; 21(4):551–2

ADENOMA, TRABECULAR see **ADENOMA**

ADENOMA, VILLOUS

Villous adenoma of the gallbladder: a case report. Nagahama M, et al. **Hepatogastroenterology** 1997 May–Jun; 44(15):681–4

CHEMISTRY

Tumor suppressor activity of neural cell adhesion molecule in colon carcinoma. Roesler J, et al. **Am J Surg** 1997 Sep; 174(3):251–7

COMPLICATIONS

Pancreatitis in childhood associated with villous adenoma of the ampulla of Vater [letter; comment] Abbasakoor F, et al. **Br J Surg** 1997 Apr;84(4):581. Comment on: Br J Surg 1996 Sep;83(9):1211.

Pancreatitis in childhood associated with villous adenoma of the ampulla of Vater [see comments] Arif Mateen Khan M, et al. **Br J Surg** 1996 Sep;83(9):1211. Comment in: Br J Surg 1997 Apr;84(4):581.

Acromegaly, colonic polyps and carcinoma. Jenkins PJ, et al. **Clin Endocrinol (Oxf)** 1997 Jul;47(1):17–22

Perforated villous adenoma of the cecum: report of a case. Rothstein RD, et al. **Dis Colon Rectum** 1997 Feb; 40(2):244–6

An unusual case of villous adenoma of the ampulla Vateri in a renal allograft recipient. Pascual J, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):833–4

Dermatomyositis in association with tubulovillous adenoma: resolution after resection of adenoma. Badr AS, et al. **South Med J** 1997 Mar;90(3):321–4

DIAGNOSIS

Villous adenoma of the colon. Teoh SK, et al. **AJR Am J Roentgenol** 1996 Nov;167(5):1146

Villous adenoma of the common bile duct. Blot E, et al. **J Clin Gastroenterol** 1996 Jan;22(1):77–9

[Villous adenoma of the duodenum. Apropos of a case] Lepront D, et al. **J Chir (Paris)** 1996 Jul;133(5):236–8 (Eng. Abstr.) **(Fre)**

GENETICS

Polymerase chain reaction-based approaches for detection of allelic loss in the p53 tumor suppressor gene in colon neoplasms. Yamaguchi K, et al. **Am J Gastroenterol** 1997 Feb;92(2):307–12

A very large villous adenoma with an adjacent cancer of the rectum: an informative case for testing the proposed molecular basis of colorectal tumorigenesis. Kanaoka S, et al. **Jpn J Clin Oncol** 1996 Oct;26(5):384–90

METABOLISM

Altered mucin core peptide immunoreactivity in the colon polyp–carcinoma sequence. Ho SB, et al. **Oncol Res** 1996; 8(2):53–61

PATHOLOGY

Accuracy of staging rectal tumors with contrast-enhanced transrectal MR imaging. Vogl TJ, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1427–34

Cytologic features of villous adenoma of the ampullary region. Veronezi-Gurwell A, et al. **Diagn Cytopathol** 1996 Mar;14(2):145–9

High-grade dysplasia in an adenoma of the upper esophagus developing on heterotopic gastric mucosa. Mion F, et al. **Endoscopy** 1996 Sep;28(7):633–5

Villous adenoma of the distal appendix. Taylor JV, et al. **Eur J Surg Oncol** 1997 Apr;23(2):185–6

Diagnosis of colorectal tumorous lesions by magnifying endoscopy [see comments] Kudo S, et al. **Gastrointest Endosc** 1996 Jul;44(1):8–14. Comment in: Gastrointest Endosc 1996 Jul;44(1):95–6.

Malignant transformation in a duodenal villous adenoma of the afferent limb of Billroth II anastomosis. Kapur A, et al. **J Clin Gastroenterol** 1997 Jun;24(4):290–1

[Adenoma and neuroendocrine carcinoma: 2 adjacent intestinal neoplasias. Simple coincidence? Report of 2 cases] Salmeron M, et al. **Rev Med Suisse Romande** 1997 Feb; 117(2):143–6 **(Fre)**

[A case of duodenal cancer arising in a tubulo-villous adenoma] Hirai R, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Feb;94(2):117–22 **(Jpn)**

RADIOGRAPHY

Quiz case of the month. Villous tumor of the duodenum. Rueda O, et al. **Eur Radiol** 1997;7(6):951–2

SURGERY

Pancreatoduodenectomy for giant benign villous adenoma of the ampulla of Vater. Abolhoda AM, et al. **Am Surg** 1997 May;63(5):392–4

Villous tumors of the ampulla Vater. Gibbs ER, et al. **Am Surg** 1997 Jun;63(6):467–71

Rectal carcinoma in pregnancy. Gard GB, et al. **Aust N Z J Obstet Gynaecol** 1996 May;36(2):161–4

Local resection or pancreaticoduodenectomy for villous adenoma of the ampulla of Vater diagnosed before operation. Cahen DL, et al. **Br J Surg** 1997 Jul;84(7):948–51

Functional results after transanal endoscopic microsurgery. Kreis ME, et al. **Dis Colon Rectum** 1996 Oct;39(10):1116–21

Extracorporeal polypectomy. Aydin A, et al. **Endoscopy** 1997 Jan;29(1):57–8

Segmental resection of the duodenum including the papilla of Vater for focal cancer in adenoma. Ryu M, et al. **Hepatogastroenterology** 1996 Jul–Aug;43(10):835–8

Laparoscopic bowel mobilization combined with intraoperative colonoscopic polypectomy in patients with an inaccessible polyp of the colon. Smedh K, et al. **Surg Endosc** 1997 Jun;11(6):643–4

Surgical excision of large rectal villous adenomas. Whitlow CB, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):723–34 (56 ref.)

[Mason paracoccygeal trans-sphincteric approach to the rectum: good outcome only in highly selective indications?] Meissner K, et al. **Chirurg** 1996 Feb;67(2):145–9 (Eng. Abstr.) **(Ger)**

ADENOMATOID TUMOR

[Epididymal adenomatoid tumor. Review of the national literature and report of a case] Romero Pérez P, et al. **Actas Urol Esp** 1996 Oct;20(9):839–43 (26 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Thrombomodulin immunoreactivity in adenomatoid tumour of the uterus. Shintaku M, et al. **Histopathology** 1996 Apr; 28(4):375–7

COMPLICATIONS

Sarcoidosis involving a paratesticular adenomatoid tumor. Berkowitz JM, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Sep;13(2):183–5

DIAGNOSIS

[Adenomatoid tumor of the uterus--2 case reports] Dietterle S, et al. **Zentralbl Gynakol** 1997;119(2):82–5 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Thrombomodulin immunoreactivity in adenomatoid tumour of the uterus. Shintaku M, et al. **Histopathology** 1996 Apr; 28(4):375–7

PATHOLOGY

Adenomatoid tumors of the pleura. Kaplan MA, et al. **Am J Surg Pathol** 1996 Oct;20(10):1219–23

Adenomatoid tumor of intratesticular localization. Samad AA, et al. **Eur Urol** 1996;30(1):127–8

Composite multicystic mesothelioma and adenomatoid tumour of the uterus: different morphological manifestations of the same process? Chan JK, et al. **Histopathology** 1996 Oct;29(4):375–7

Adenomatoid tumor of the adrenal gland: a report of four new cases and a review of the literature. Raaf HN, et al. **Mod Pathol** 1996 Nov;9(11):1046–51 (21 ref.)

[Adenomatoid tumors of the uterus. Study of 5 cases with immunohistochemical and ultrastructural confirmation of the mesothelial origin] Mainguené C, et al. **Arch Anat Cytol Pathol** 1996;44(4):174–9 (Eng. Abstr.) **(Fre)**

[Three cases of adenomatoid tumor of the uterus] Yo H, et al. **Nippon Ika Daigaku Zasshi** 1996 Aug;63(4):294–8 (Eng. Abstr.) **(Jpn)**

ADENOMATOSIS, FAMILIAL ENDOCRINE see **MULTIPLE ENDOCRINE NEOPLASIA**

ADENOMATOSIS, PULMONARY

CHEMISTRY

Expression of p53 and CEA in atypical adenomatous hyperplasia of the lung [letter; comment] Pueblitz S, et al. **Am J Surg Pathol** 1997 Jul;21(7):867–8. Comment on: Am J Surg Pathol 1996 May;20(5):553–62.

ADENOMATOSIS, PULMONARY, BOVINE see **PNEUMONIA, ATYPICAL INTERSTITIAL, OF CATTLE**

ADENOMATOSIS, PULMONARY, OVINE see **PULMONARY ADENOMATOSIS, OVINE**

ADENOMATOUS POLYPOSIS COLI

see related
GENES, APC

Hereditary colon cancer. Gilchrist DM. **Can J Gastroenterol** 1997 Jul–Aug;11(5):421–3

Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Giardiello FM, et al. **Cancer Res** 1997 Jan 15;57(2):199–201

Growth inhibition by phospholipase C inhibitor peptides of colorectal carcinoma cells derived from familial adenomatous polyposis. Homma MK, et al. **Cell Growth Differ** 1996 Mar;7(3):281–8

Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Vasen HF, et al. **Gut** 1997 Jun;40(6):716–9

A mouse model of human familial adenomatous polyposis. Yang K, et al. **J Exp Zool** 1997 Feb 15;277(3):245–54

Multiple ependymomas in a patient with Turcot's syndrome. Torres CF, et al. **Med Pediatr Oncol** 1997 Jan;28(1):59–61

Hereditary intestinal polyposis syndromes. Dean PA. **Rev Gastroenterol Mex** 1996 Apr–Jun;61(2):100–11 (108 ref.)

[Familial colonic polyposis associated with malignant tumors of the central nervous system: Turcot's syndrome (letter)] Alonso V, et al. **Rev Clin Esp** 1996 Nov;196(11):798–9 **(Spa)**

ADENOMATOUS POLYPOSIS COLI

COMPLICATIONS

Congenital hypertrophy of the retinal pigment epithelium (CHRPE) and familial adenomatous polyposis (FAP). Rossato M, et al. **Acta Ophthalmol Scand** 1996 Aug; 74(4):338–42

MR appearances of desmoid tumors in familial adenomatous polyposis. Healy JC, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):465–72

Surgery, desmoid tumors, and familial adenomatous polyposis: case report and literature review. Lynch HT, et al. **Am J Gastroenterol** 1996 Dec;91(12):2598–601 (16 ref.)

Regression of an aggressive abdominal desmoid tumor in a patient with familial adenomatous polyposis by hyperthermoradiotherapy. Oohata Y, et al. **Am J Gastroenterol** 1997 Jan;92(1):156–8

Extracolonic features of familial adenomatous polyposis in patients with sporadic colorectal cancer. Dunlop MG, et al. **Br J Cancer** 1996 Dec;74(11):1789–95

Desmoids in familial adenomatous polyposis [see comments] Clark SK, et al. **Br J Surg** 1996 Nov;83(11):1494–504 (176 ref.). Comment in: Br J Surg 1997 May;84(5):728.

Risk of extracolonic cancer in familial adenomatous polyposis. Nugent KP, et al. **Br J Surg** 1996 Aug; 83(8):1121–2

Colorectal cancer in familial adenomatous polyposis. Jang YS, et al. **Dis Colon Rectum** 1997 Mar;40(3):312–6

Adrenal masses in patients with familial adenomatous polyposis. Marchesa P, et al. **Dis Colon Rectum** 1997 Sep; 40(9):1023–8

Chemotherapy for desmoid tumors in association with familial adenomatous polyposis. Schnitzler M, et al. **Dis Colon Rectum** 1997 Jul;40(7):798–801

Childhood hepatocellular tumors in FAP [letter] Cetta F, et al. **Gastroenterology** 1997 Sep;113(3):1051–2

Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Zwick A, et al. **Gastroenterology** 1997 Aug;113(2):659–63

Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle Polyposis Group. Bülow C, et al. **Int J Colorectal Dis** 1997; 12(4):240–2

Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Heiskanen I, et al. **Int J Colorectal Dis** 1996;11(4):157–62

Prednisolone therapy for intra-abdominal desmoid tumors in a patient with familial adenomatous polyposis. Nakada I, et al. **J Gastroenterol** 1997 Apr;32(2):255–9

Pigmented ocular fundus lesions and APC mutations in familial adenomatous polyposis. Traboulsi EI, et al. **Ophthalmic Genet** 1996 Dec;17(4):167–74

Signet ring cell carcinoma in hyperplastic polyp [letter; comment] Carneiro F, et al. **Scand J Gastroenterol** 1996 Jan;31(1):95–6. Comment on: Scand J Gastroenterol 1995 Jun;30(6):604–8.

DIAGNOSIS

Endoscopic screening and surgery for familial adenomatous polyposis: dangerous delays. Mills SJ, et al. **Br J Surg** 1997 Jan;84(1):74–7

Role of upper gastrointestinal surveillance in patients with familial adenomatous polyposis. Sawada T, et al. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):99–111

The use of DNA markers in the pre-clinical diagnosis of familial adenomatous polyposis [see comments] Amikam D, et al. **Isr J Med Sci** 1997 Jan;33(1):8–13. Comment in: Isr J Med Sci 1997 Jan;33(1):63–5.

Colonic ganglioneuroma presenting as filiform polyposis. Dellinger GW, et al. **J Clin Gastroenterol** 1996 Jan; 22(1):66–70

Parents' responses to predictive genetic testing in their children [letter; comment] Clarke A. **J Med Genet** 1997 Feb;34(2):174–5. Comment on: J Med Genet 1994 Oct;31(10):743. Comment on: J Med Genet 1994 Oct;31(10):785–97. Comment on: J Med Genet 1996 Apr;33(4):313–8.

Familial adenomatous polyposis in a 5 year old child: a clinical, pathological, and molecular genetic study. Distante S, et al. **J Med Genet** 1996 Feb;33(2):157–60

Thyroid carcinoma as first manifestation of familial adenomatous polyposis. Stigt JA, et al. **Neth J Med** 1996 Sep;49(3):116–8 (17 ref.)

The presymptomatic molecular diagnosis of familial adenomatous polyposis in Singapore. Khine K, et al. **Singapore Med J** 1995 Oct;36(5):521–4

[The diagnosis and therapy of familial adenomatous polyposis coli] Schürmann G, et al. **Dtsch Med Wochenschr** 1997 Jul 25;122(30):935–9 (19 ref.) **(Ger)**

DRUG THERAPY

Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Seow-Choen F, et al. **Br J Surg** 1996 Dec;83(12):1763–6

Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Hirota C, et al. **Cancer** 1996 Oct 15;78(8):1660–5

Adverse effects of sulindac used for prevention of colorectal cancer [letter] Ishikawa H, et al. **J Natl Cancer Inst** 1997 Sep 17;89(18):1381

ENZYMOLOGY

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Oshima M, et al. **Cell** 1996 Nov 29;87(5):803–9

Group II phospholipase A2 is not a major modifier of colonic adenomatous polyps in humans [letter] Minami T, et al. **J Gastroenterol** 1997 Jun;32(3):431–2

EPIDEMIOLOGY

High prevalence of adenomas and microadenomas of the duodenal papilla and periampullary region in patients with familial adenomatous polyposis. Bertoni G, et al. **Eur J Gastroenterol Hepatol** 1996 Dec;8(12):1201–6

The incidence rate of familial adenomatous polyposis. Results from the Danish Polyposis Register. Bülow S, et al. **Int J Colorectal Dis** 1996;11(2):88–91

Molecular screening of families affected by familial adenomatous polyposis (FAP). Gazzoli I, et al. **J Med Screen** 1996;3(4):195–9

ETIOLOGY

Solitary juvenile polyps in children and colon cancer. Kapetanakis AM, et al. **Hepatogastroenterology** 1996 Nov-Dec;43(12):1530–1

GENETICS

APC mutation and the crypt cycle in murine and human intestine. Bjerknes M, et al. **Am J Pathol** 1997 Mar; 150(3):833–9

Variants at the secretory phospholipase A2 (PLA2G2A) locus: analysis of associations with familial adenomatous polyposis and sporadic colorectal tumours. Tomlinson IP, et al. **Ann Hum Genet** 1996 Sep;60 (Pt 5):369–76

Phenotypic expression of disease in families that have mutations in the 5' region of the adenomatous polyposis coli gene. Giardiello FM, et al. **Ann Intern Med** 1997 Apr 1;126(7):514–9

von Hippel-Lindau disease and familial polyposis coli in the same family. Kilmartin DJ, et al. **Arch Ophthalmol** 1996 Oct;114(10):1294

Retinal pigment epithelium abnormalities in mice with adenomatous polyposis coli gene disruption. Marcus DM, et al. **Arch Ophthalmol** 1997 May;115(5):645–50

Genetic testing for cancer in children. Short-term psychological effect. Codori AM, et al. **Arch Pediatr Adolesc Med** 1996 Nov;150(11):1131–8

The adenomatous polyposis coli (APC) tumor suppressor. Polakis P. **Biochim Biophys Acta** 1997 Jun 7; 1332(3):F127–47 (149 ref.)

Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the src or polyoma middle T oncogenes: cooperation between src and HGF/Met in invasion. Empereur S, et al. **Br J Cancer** 1997;75(2):241–50

Inherited predisposition to colorectal neoplasia. Stephenson BM, et al. **Br J Hosp Med** 1994 Jan 19–Feb 1;51(1–2):15–20, 22–3 (38 ref.)

p53 and K-ras status in duodenal adenomas in familial adenomatous polyposis. Kashiwagi H, et al. **Br J Surg** 1997 Jun;84(6):826–9

The APC gene product and colorectal carcinogenesis. Bonneton C, et al. **C R Acad Sci III** 1996 Oct;319(10):861–9 (68 ref.)

Congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis. Novel criteria of assessment and correlations with constitutional adenomatous polyposis coli gene mutations. Valanzano R, et al. **Cancer** 1996 Dec 1;78(11):2400–10

Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies? Le Marchand L, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jun; 5(6):449–55

Allele loss in colorectal cancer at the Cowden disease/juvenile polyposis locus on 10q. Frayling IM, et al. **Cancer Genet Cytogenet** 1997 Aug;97(1):64–9

An update of HNPCC (Lynch syndrome). Lynch HT, et al. **Cancer Genet Cytogenet** 1997 Jan;93(1):84–99 (106 ref.)

Absence of germline mutations in exons 5–9 of the p53 gene in patients with Li-Fraumeni-like (SBLA) and familial adenomatous polyposis heritable cancer syndromes. Moore SK, et al. **Cancer Genet Cytogenet** 1996 Sep;90(2):125–9

Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Dove WF, et al. **Cancer Res** 1997 Mar 1;57(5):812–4

Lessons from hereditary colorectal cancer. Kinzler KW, et al. **Cell** 1996 Oct 18;87(2):159–70 (97 ref.)

APC intragenic haplotypes in familial adenomatous polyposis. Almeida R, et al. **Clin Genet** 1996 Dec; 50(6):483–5

Exceptions to the rule: individuals with FAP specific CHRPE and mutations in exon 6 of the APC gene [letter] Pack K, et al. **Clin Genet** 1996 Aug;50(2):110–1

Genotype-phenotype correlations at the adenomatous polyposis coli (APC) gene. Fodde R, et al. **Crit Rev Oncog** 1995;6(3–6):291–303 (87 ref.)

Mechanisms of carcinogenesis and the mutant mouse. Williams BO, et al. **Curr Opin Genet Dev** 1996 Feb; 6(1):65–70 (71 ref.)

Use of wide-bore capillaries in constant denaturant capillary electrophoresis. Li XC, et al. **Electrophoresis** 1996 Dec; 17(12):1884–9

Association of extracolonic manifestations of familial adenomatous polyposis with acetylation phenotype in a large FAP kindred. Scott RJ, et al. **Eur J Hum Genet** 1997 Jan-Feb;5(1):43–9

Childhood hepatocellular adenoma in familial adenomatous polyposis: mutations in adenomatous polyposis coli gene and p53. Bala S, et al. **Gastroenterology** 1997 Mar; 112(3):919–22

The clinical correlates of a 3' truncating mutation (codons 1982–1983) in the adenomatous polyposis coli gene. Gardner RJ, et al. **Gastroenterology** 1997 Jul;113(1):326–31

Hereditary mixed polyposis syndrome: a zebra or a horse dressed in pinstripes [editorial; comment] Giardiello FM, et al. **Gastroenterology** 1997 Feb;112(2):643–5 (26 ref.). Comment on: Gastroenterology 1997 Feb;112(2):327–34.

Clinical and molecular features of the hereditary mixed polyposis syndrome [see comments] Whitelaw SC, et al. **Gastroenterology** 1997 Feb;112(2):327–34. Comment in: Gastroenterology 1997 Feb;112(2):643–5.

Silent APC (adenomatous polyposis coli) gene polymorphism in the Portuguese population. Marshall B, et al. **Gene Geogr** 1995 Dec;9(3):207–10

Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Giardiello FM, et al. **Gut** 1996 Dec; 39(96):867–9

APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis. Giardiello FM, et al. **Gut** 1997 Apr; 40(4):521–5

Multiple products in the protein truncation test due to alternative splicing in the adenomatous polyposis coli (APC) gene. Bala S, et al. **Hum Genet** 1996 Nov; 98(5):528–33

Identification of a modifier gene locus on chromosome 1p35–36 in familial adenomatous polyposis. Dobbie Z, et al. **Hum Genet** 1997 May;99(5):653–7

Loss of the PLA2G2A gene in a sporadic colorectal tumor of a patient with a PLA2G2A germline mutation and absence of PLA2G2A germline alterations in patients with FAP. Nimmrich I, et al. **Hum Genet** 1997 Sep; 100(3–4):345–9

Germline mutations in the 3' part of APC exon 15 do not result in truncated proteins and are associated with attenuated adenomatous polyposis coli. van der Luijt RB, et al. **Hum Genet** 1996 Dec;98(6):727–34

Characterization of 19 novel and six recurring APC mutations in Italian adenomatous polyposis patients, using two different mutation detection techniques. Gismondi V, et al. **Hum Mutat** 1997;9(4):370–3

Three novel APC gene mutations in Portuguese FAP kindreds. Marshall B, et al. **Hum Mutat** 1996;8(4):395–6

Three novel germline mutations in the adenomatous polyposis coli gene. Scarano MI, et al. **Hum Mutat** 1997; 9(2):191–3

Molecular analysis of the APC gene in 105 Dutch kindreds with familial adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and southern analysis. van der Luijt RB, et al. **Hum Mutat** 1997;9(1):7–16

APC gene mutations and allelic losses in sporadic ampullary tumours: evidence of genetic difference from tumours associated with familial adenomatous polyposis. Achille A, et al. **Int J Cancer** 1996 Nov 4;68(3):305–12

The use of DNA markers in the pre-clinical diagnosis of familial adenomatous polyposis [see comments] Amikam D, et al. **Isr J Med Sci** 1997 Jan;33(1):8–13. Comment in: Isr J Med Sci 1997 Jan;33(1):63–5.

Expanded size span and multiple alleles exhibited by Ethiopian Jews analyzed with APC gene-linked DNA markers [letter] [see comments] Amikam D, et al. **Isr J Med Sci** 1997 Jan;33(1):78–9. Comment in: Isr J Med Sci 1997 Jan;33(1):63–5.

Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34. Trzepacz C, et al. **J Biol Chem** 1997 Aug 29; 272(35):21681–4

Brain tumor-polyposis syndrome: two genetic diseases? Paraf F, et al. **J Clin Oncol** 1997 Jul;15(7):2744–58 (128 ref.)

Thyroid neoplasia and familial adenomatous polyposis/Gardner's syndrome. Hizawa K, et al. **J Gastroenterol** 1997 Apr;32(2):196–9

RP1, a new member of the adenomatous polyposis coli-binding EB1-like gene family, is differentially expressed in activated T cells. Renner C, et al. **J Immunol** 1997 Aug 1;159(3):1276–83

Quantitation of in vivo gene delivery by restriction enzyme PCR generated polymorphism. Fichera A, et al. **J Surg Res** 1997 Apr;69(1):188–92

Genetic testing in hereditary colorectal cancer [clinical conference] Giardiello FM. **JAMA** 1997 Oct 15; 278(15):1278–81

Familial adenomatous polyposis presenting with childhood desmoids [letter] Clark SK, et al. **Lancet** 1997 Feb 15; 349(9050):471–2

Lipid metabolism and APC: implications for colorectal cancer prevention. Watson AJ, et al. **Lancet** 1997 Feb 15; 349(9050):444–5

The use and interpretation of commercial APC gene testing for familial adenomatous polyposis [see comments] Giardiello FM, et al. **N Engl J Med** 1997 Mar 20; 336(12):823–7. Comment in: N Engl J Med 1997 Mar 20;336(12):869–70. Comment in: N Engl J Med 1997 Jul 24;337(4):282.

Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Laken SJ, et al. **Nat Genet** 1997 Sep;17(1):79–83

Homeosis and intestinal tumours in Cdx2 mutant mice. Chawengsaksophak K, et al. **Nature** 1997 Mar 6; 386(6620):84–7

Variations in the expression of the adenomatous polyposis coli (APC) tumor suppressor gene in human cancer cell lines of different tissue origin. Dihlmann S, et al. **Oncol Res** 1997;9(3):119–27

Mutational state of von Hippel–Lindau and adenomatous polyposis coli genes in renal tumors. Suzuki H, et al. **Oncology** 1997 May–Jun;54(3):252–7

APC mutations in colorectal tumors with mismatch repair deficiency. Huang J, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9049–54

Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Wilson CL, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1402–7

Clinical findings in a family with familial adenomatous polyposis and a missense mutation of the adenomatous polyposis coli gene. Marchese CA, et al. **Scand J Gastroenterol** 1996 Sep;31(9):917–20

Familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC): a review of clinical, genetic and therapeutic aspects. Soravia C, et al. **Schweiz Med Wochenschr** 1997 Apr 19;127(16):682–90 (118 ref.)

New kind of cancer mutation found [news] Gura T. **Science** 1997 Aug 29;277(5330):1201–2

Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Shibata H, et al. **Science** 1997 Oct 3;278(5335):120–3

The genetics of colorectal cancer. Howe JR, et al. **Surg Clin North Am** 1997 Feb;77(1):175–95 (119 ref.)

[Familial adenomatous polyposis and thyroid cancer] Paraf F, et al. **Gastroenterol Clin Biol** 1997;21(1):74–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[Familial adenomatous polyposis (FAP): integration of clinical and genetic parameters in the screening of subjects at risk. A one-family example] Chautems R, et al. **Swiss Surg** 1996;2(5):196–200 (Eng. Abstr.) **(Fre)**

[Mutational screening using restriction fragment length analysis (RFLA) exemplified by the gene for familial adenomatous polyposis (APC gene)] Hahn M, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:65–8 (Eng. Abstr.) **(Ger)**

[Familial adenomatous polyposis: establishing a registry and genetic and molecular analysis] Shomrat R, et al. **Harefuah** 1997 Jan 15;132(2):81–6, 151, 152 (Eng. Abstr.) **(Heb)**

[APC, beta-catenin, DLG] Akiyama T. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1432–5 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Chemoprevention of familial cancer] Ishikawa H. **Gan To Kagaku Ryoho** 1997 Jun;24(8):951–7 (38 ref.) (Eng. Abstr.) **(Jpn)**

[The APC gene] Akiyama T. **Nippon Rinsho** 1996 Apr; 54(4):955–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic and environmental factors in colorectal cancer. Mutations in the familial adenomatous polyposis gene] Steffensen IL, et al. **Tidsskr Nor Laegeforen** 1997 May 30; 117(14):2046–51 (25 ref.) (Eng. Abstr.) **(Nor)**

METABOLISM

Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Zhang T, et al. **Cancer Res** 1997 Jan 1;57(1):169–75

Expression of the APC tumor suppressor protein in oligodendroglia. Bhat RV, et al. **Glia** 1996 Jun;17(2):169–74

NH2-terminal deletion of beta-catenin results in stable colocalization of mutant beta-catenin with adenomatous polyposis coli protein and altered MDCK cell adhesion. Barth AI, et al. **J Cell Biol** 1997 Feb 10;136(3):693–706

The use of 32P-postlabelling in studies of the nature and origin of DNA adducts formed by bile from patients with familial adenomatous polyposis and from normal patients. Scates DK, et al. **Mutat Res** 1997 Aug 1;378(1–2):113–25

MORTALITY

Changing causes of mortality in patients with familial adenomatous polyposis. Belchetz LA, et al. **Dis Colon Rectum** 1996 Apr;39(4):384–7

PATHOLOGY

Genetic alterations and epithelial dysplasia in juvenile polyposis syndrome and sporadic juvenile polyps. Wu TT, et al. **Am J Pathol** 1997 Mar;150(3):939–47

Clonality of dysplastic epithelium in colorectal adenomas from familial adenomatous polyposis patients. Bjerknes M, et al. **Cancer Res** 1997 Feb 1;57(3):355–61

Inward growth of colonic adenomatous polyps. Moss SF, et al. **Gastroenterology** 1996 Dec;111(6):1425–32

Cell proliferation of the duodenal mucosa in patients affected by familial adenomatous polyposis. Santucci R, et al. **Gastroenterology** 1997 Oct;113(4):1159–62

Clinical and molecular features of the hereditary mixed polyposis syndrome [see comments] Whitelaw SC, et al. **Gastroenterology** 1997 Feb;112(2):327–34. Comment in: Gastroenterology 1997 Feb;112(2):643–5.

Papillary thyroid carcinoma in three siblings with familial adenomatous polyposis. Civitelli S, et al. **Int J Colorectal Dis** 1996;11(1):34–7

Florid oral manifestations in an atypical familial adenomatous polyposis family with late presentation of colorectal polyps. Thakker NS, et al. **J Oral Pathol Med** 1996 Sep; 25(8):459–62

Gastroduodenal polyps in familial adenomatous polyposis [letter] Petrelli NJ, et al. **Surg Endosc** 1996 Nov; 10(11):1118–9

Ampullary carcinoma in familial adenomatous polyposis: report of a case. Tomita H, et al. **Surg Today** 1996; 26(7):522–6 (16 ref.)

[Effect of phospholipase C inhibitor peptides on cancer cell growth] Homma M, et al. **Gan To Kagaku Ryoho** 1997 Jan; 24(2):156–63 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

The presymptomatic molecular diagnosis of familial adenomatous polyposis in Singapore. Khine K, et al. **Singapore Med J** 1995 Oct;36(5):521–4

PREVENTION & CONTROL

Food and phytochemicals, magic bullets and measurement error: a commentary [comment] Potter JD. **Am J Epidemiol** 1996 Dec 1;144(11):1026–7. Comment on: Am J Epidemiol 1995 Dec 1;144(11):1005–14. Comment on: Am J Epidemiol 1996 Dec 1;144(11):1015–25.

Relation of vegetable, fruit, and grain consumption to colorectal adenomatous polyps [see comments] Witte JS, et al. **Am J Epidemiol** 1996 Dec 1;144(11):1015–25. Comment in: Am J Epidemiol 1996 Dec 1;144(11):1026–7.

NSAID-induced polyp regression in familial adenomatous polyposis patients. Giardiello FM. **Gastroenterol Clin North Am** 1996 Jun;25(2):349–62 (63 ref.)

Screening modalities in familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. Spigelman AD. **Gastrointest Endosc Clin N Am** 1997 Jan;7(1):81–6 (27 ref.)

Sulindac slows growth of colon polyps, may prevent colon cancer [news] **Oncology (Huntingt)** 1996 Feb;10(2):218

Genetic testing and counseling in familial adenomatous polyposis. Petersen GM. **Oncology (Huntingt)** 1996 Jan; 10(1):89–94; discussion 97–8 (25 ref.)

Prophylaxis against colorectal cancer. Bülow S, et al. **Scand J Gastroenterol Suppl** 1996;216:160–8 (63 ref.)

[Chemoprevention of familial cancer] Ishikawa H. **Gan To Kagaku Ryoho** 1997 Jun;24(8):951–7 (38 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Total colectomy with rectal mucosectomy and ileoanal anastomosis with en-J reservoir in multiple familial polyposis] Rojas Ortega S, et al. **Rev Gastroenterol Mex** 1996 Apr–Jun;61(2):112 **(Spa)**

SURGERY

Sulindac-associated ulcerative pouchitis in familial adenomatous polyposis. Bertoni G, et al. **Am J Gastroenterol** 1996 Nov;91(11):2431–2

Biomechanical stabilization of the nipple valve in continent ileostomy. Ecker KW, et al. **Br J Surg** 1996 Nov; 83(11):1582–5

Pouch-related fistula following restorative proctocolectomy. Paye F, et al. **Br J Surg** 1996 Nov;83(11):1574–7

Results after restorative proctocolectomy and ileal pouch-anal anastomosis in patients with familial adenomatous polyposis and coexisting colorectal cancer. Ziv Y, et al. **Br J Surg** 1996 Nov;83(11):1578–80

Quality of life after prophylactic colectomy and ileorectal anastomosis in patients with familial adenomatous polyposis. Church JM, et al. **Dis Colon Rectum** 1996 Dec; 39(12):1404–8

Colorectal cancer in familial adenomatous polyposis. Jang YS, et al. **Dis Colon Rectum** 1997 Mar;40(3):312–6

Laparoscopic total abdominal colectomy with ileorectal anastomosis for familial adenomatous polyposis. Milsom JW, et al. **Dis Colon Rectum** 1997 Jun;40(6):675–8

Results of a thirty-year study of familial adenomatous polyposis coli. Nikitin AM, et al. **Dis Colon Rectum** 1997 Jun;40(6):679–84

Electrophysiologic assessments in pudendal and sacral motor nerves after ileal J-pouch-anal anastomosis for patients with ulcerative colitis and adenomatosis coli. Tomita R, et al. **Dis Colon Rectum** 1996 Apr;39(4):410–5

Ileal pouch-anal anastomosis with mesorectal excision for rectal cancer complicating familial adenomatous polyposis. Panis Y, et al. **Eur J Surg** 1996 Oct;162(10):817–21

Laser photoablation of ileal reservoir adenomas. Geller A, et al. **Gastrointest Endosc** 1996 Oct;44(4):473–7 (57 ref.)

Surveillance of familial adenomatous polyposis patients after ileorectal anastomosis or ileoanal pouch anastomosis. Tytgat GNJ. **Gastrointest Endosc Clin N Am** 1997 Jan; 7(1):111–27 (55 ref.)

Fate of the rectal stump after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Heiskanen I, et al. **Int J Colorectal Dis** 1997;12(1):9–13

Causes of failure and life expectancy of the ileoanal pouch. Körsgen S, et al. **Int J Colorectal Dis** 1997;12(1):4–8

Sulindac for periampullary polyps in FAP patients. Richard CS, et al. **Int J Colorectal Dis** 1997;12(1):14–8

Joint symptoms after restorative proctocolectomy in ulcerative colitis and familial polyposis coli. Andreyev HJ, et al. **J Clin Gastroenterol** 1996 Jul;23(1):35–9

Restorative proctocolectomy in children and adolescents. Romanos J, et al. **J Pediatr Surg** 1996 Dec;31(12):1655–8

Efficacy of the straight endorectal pull-through in the management of familial adenomatous polyposis—a 16-year experience. Shilyansky J, et al. **J Pediatr Surg** 1997 Aug; 32(8):1139–43

Polypectomy of adenomas in the prevention of colorectal cancer: 10 years' follow-up of the Telemark Polyp Study I. A prospective, controlled population study. Hoff G, et al. **Scand J Gastroenterol** 1996 Oct;31(10):1006–10

Operations for familial adenomatous polyposis. Sagar PM, et al. **Surg Oncol Clin N Am** 1996 Jul;5(3):675–88 (69 ref.)

Abdominopreanal proctocolectomy and ileal U-pouch in ulcerative colitis or familial adenomatous polyposis. Oh NG. **Surg Today** 1996;26(11):861–8

Restorative proctocolectomy or rectum-preserving surgery in patients with familial adenomatous polyposis: results of a prospective study. Tonelli F, et al. **World J Surg** 1997 Jul–Aug;21(6):653–8; discussion 659

[Genetic test as a guide for surgical management in familial adenomatous polyposis] Kronborg O. **Ugeskr Laeger** 1996 Dec 9;158(50):7248 **(Dan)**

[Timing of surgery for familial polyposis coli] Sahm S, et al. **Dtsch Med Wochenschr** 1996 Sep 20;121(38):1176 **(Ger)**

[Secure anastomoses of the large intestine (especially with transanal drainage] Klein P, et al. **Zentralbl Chir** 1997; 122(7):528–32; discussion 533–4 (Eng. Abstr.) **(Ger)**

[Familial adenomatous polyposis. Problems encountered with rectum preservation in surgical treatment and life expectancy] Colombo PL, et al. **Ann Ital Chir** 1995 Sep–Oct;66(5):671–83 (67 ref.) (Eng. Abstr.) **(Ita)**

[Surgical implications of familial polyposis coli] Fratino G, et al. **Minerva Chir** 1996 Nov;51(11):919–24 (Eng. Abstr.) **(Ita)**

[Proctocolectomy with ileoanal anastomosis: morbidity and functional results in patients with and without colorectal cancer] Luna-Pérez P, et al. **Rev Gastroenterol Mex** 1996 Jul–Sep;61(3):184–92 (45 ref.) (Eng. Abstr.) **(Spa)**

[Total colectomy with rectal mucosectomy and ileoanal anastomosis with en-J reservoir in multiple familial polyposis] Rojas Ortega S, et al. **Rev Gastroenterol Mex** 1996 Apr–Jun;61(2):112 **(Spa)**

ADENOMATOUS POLYPS

COMPLICATIONS

Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Colao A, et al. **Clin Endocrinol (Oxf)** 1997 Jul;47(1):23–8

Acromegaly, colonic polyps and carcinoma. Jenkins PJ, et al. **Clin Endocrinol (Oxf)** 1997 Jul;47(1):17–22

Association of Gemella morbillorum endocarditis with adenomatous polyps and carcinoma of the colon: case report and review. Lopez-Dupla M, et al. **Clin Infect Dis** 1996 Feb;22(2):379–80

Perforated villous adenoma of the cecum: report of a case. Rothstein RD, et al. **Dis Colon Rectum** 1997 Feb; 40(2):244–6

DIAGNOSIS

Small colorectal serrated adenomas: endoscopic findings. Jaramillo E, et al. **Endoscopy** 1997 Jan;29(1):1–3

Detection of dysplasia at colonoscopy using laser-induced fluorescence: a blinded study. Cothren RM, et al. **Gastrointest Endosc** 1996 Aug;44(2):168–76

Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy [see comments] Read TE, et al. **N Engl J Med** 1997 Jan 2;336(1):8–12. Comment in: N Engl J Med 1997 Jun 12;336(24):1761–2.

DIET THERAPY

A truncated poisson regression model with applications to occurrence of adenomatous polyps. Xie T, et al. **Stat Med** 1997 Aug 30;16(16):1845–57

DRUG THERAPY

Effects of sulindac on sporadic colorectal adenomatous polyps [see comments] Matsuhashi N, et al. **Gut** 1997 Mar; 40(3):344–9. Comment in: Gut 1997 Mar;40(3):430.

Discouraging colonic polyps [comment] Williams CB. **Gut** 1997 Mar;40(3):430. Comment on: Gut 1997 Mar;40(3):344–9.

ENZYMOLOGY

Group II phospholipase A2 is not a major modifier of colonic adenomatous polyps in humans [letter] Minami T, et al. **J Gastroenterol** 1997 Jun;32(3):431–2

EPIDEMIOLOGY

Plasma carotenoids and the prevalence of adenomatous polyps of the distal colon and rectum. Shikany JM, et al. **Am J Epidemiol** 1997 Mar 15;145(6):552–7

Incidence of adenomas after curative resection for colorectal

cancer. Neugut AI, et al. **Am J Gastroenterol** 1996 Oct; 91(10):2096–8

The prevalence of colonic neoplasia in patients with Barrett's esophagus: prospective assessment in patients 50–80 years old. Poorman JC, et al. **Am J Gastroenterol** 1997 Apr; 92(4):592–6

Alcohol and smoking in relation to the prevalence of adenomatous colorectal polyps detected at sigmoidoscopy. Longnecker MP, et al. **Epidemiology** 1996 May;7(3):275–80

Association of diet and colorectal adenomatous polyps: dietary fiber, calcium, and total fat. Martínez ME, et al. **Epidemiology** 1996 May;7(3):264–8

Follow-up of patients with hyperplastic polyps of the large bowel. Croizet O, et al. **Gastrointest Endosc** 1997 Aug; 46(2):119–23

Incidence of adenomatous colorectal polyps in cardiac transplant recipients. Rodriguez-Larrain JM, et al. **Transplantation** 1997 Aug 15;64(3):528–30

GENETICS

Hierarchical modeling of gene-environment interactions: estimating NAT2 genotype-specific dietary effects on adenomatous polyps. Aragaki CC, et al. **Cancer Epidemiol Biomarkers Prev** 1997 May;6(5):307–14

Attitudes to predictive DNA testing in familial adenomatous polyposis. Whitelaw S, et al. **J Med Genet** 1996 Jul; 33(7):540–3

METABOLISM

Altered mucin core peptide immunoreactivity in the colon polyp–carcinoma sequence. Ho SB, et al. **Oncol Res** 1996; 8(2):53–61

Stromelysin-3 expression in early (pT1) carcinomas and pseudoinvasive lesions of the colorectum. Mueller J, et al. **Virchows Arch** 1997 Mar;430(3):213–9

PATHOLOGY

Colonic xanthelasma due to glyceride accumulation associated with an adenoma. Boruchowicz A, et al. **Am J Gastroenterol** 1997 Jan;92(1):159–61

Low epithelial cell proliferation and absence of oncoprotein expression in juvenile polyposis of the stomach, with or without tumors. Mitomi H, et al. **Am J Gastroenterol** 1997 Aug;92(8):1374–7

Clinico-pathological features of colorectal adenomatous polyps with negative results on immunochemical fecal occult blood test. Abdul Fattah AS, et al. **Eur J Med Res** 1997 Aug 28;2(8):361–4

Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Malecka-Panas E, et al. **Hepatogastroenterology** 1997 Mar-Apr;44(14):435–40

Evidence for the polyp-cancer sequence in gallbladder cancer. Harbison J, et al. **Ir Med J** 1997 Apr–May;90(3):98

Tubular adenoma of the gall bladder. Logani KB, et al. **J Indian Med Assoc** 1995 Oct;93(10):402

Automated location of dysplastic fields in colorectal histology using image texture analysis. Hamilton PW, et al. **J Pathol** 1997 May;182(1):68–75

Colon adenomatous polyps--do they grow inward? Shiff SJ, et al. **Lancet** 1997 Jun 28;349(9069):1853–4

Importance of colonic adenomas 5 mm or less in diameter [letter; comment] Selby JV, et al. **N Engl J Med** 1997 Jun 12;336(24):1761–2. Comment on: N Engl J Med 1997 Jan 2;336(1):8–12.

Mixed epithelial polyps in association with hereditary non-polyposis colorectal cancer providing an alternative pathway of cancer histogenesis. Jass JR, et al. **Pathology** 1997 Feb;29(1):28–33

Stromelysin-3 expression in early (pT1) carcinomas and pseudoinvasive lesions of the colorectum. Mueller J, et al. **Virchows Arch** 1997 Mar;430(3):213–9

[Bone metaplasia in adenomatous intestinal polyp. Report of a case and review of the literature] Cavazza A, et al. **Pathologica** 1996 Dec;88(6):511–3 (17 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Vitamin C status and colonic neoplasia. Lysy J, et al. **Dis Colon Rectum** 1996 Nov;39(11):1235–7

PREVENTION & CONTROL

The polyp prevention trial II: dietary intervention program and participant baseline dietary characteristics [published erratum appears in Cancer Epidemiol Biomarkers Prev 1996 Jul;5(7):584] Lanza E, et al. **Cancer Epidemiol Biomarkers Prev** 1996 May;5(5):385–92

The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics. Schatzkin A, et al. **Cancer Epidemiol Biomarkers Prev** 1996 May;5(5):375–83

Correlation of polypoid lesions in the distal colorectum and proximal colon in asymptomatic screening subjects [see comments] Nusko G, et al. **Eur J Gastroenterol Hepatol** 1996 Apr;8(4):351–4. Comment in: Eur J Gastroenterol Hepatol 1996 Apr;8(4):335–6.

Chemoprevention of colorectal tumors: role of lactulose and of other agents. Ponz de Leon M, et al. **Scand J Gastroenterol Suppl** 1997;222:72–5

Screening programs in the population at large and in high-risk groups. Lush DT. **Surg Oncol Clin N Am** 1996 Jul;5(3):545–52 (35 ref.)

SURGERY

The effect of wheat bran fiber and calcium supplementation on rectal mucosal proliferation rates in patients with resected adenomatous colorectal polyps. Alberts DS, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Mar;6(3):161–9

[Polyps and polyposis--limits of endoscopic therapy. Are we currently overtreating by removing colorectal polyps?] Rösch W. **Fortschr Med** 1997 May 30;115(15):20, 23–5 (Eng. Abstr.) **(Ger)**

ADENOMYOMA

COMPLICATIONS

A benign polypoid adenomyoma: an unusual cause of persistent fetal transverse lie. Lau WC, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jul;74(1):23–5

[Obstructive jaundice from an adenomyoma of the ampulla of Vater (letter)] Ligorred L, et al. **Rev Esp Enferm Dig** 1997 May;89(5):411–2 **(Spa)**

DIAGNOSIS

Adenomyoepithelioma of the breast diagnosed by fine needle aspiration (FNA) biopsy; a case report. Pogačnik A, et al. **Cytopathology** 1997 Feb;8(1):45–52

Atypical polypoid adenomyofibroma (APA) versus well-differentiated endometrial carcinoma with prominent stromal matrix: an immunohistochemical study. Soslow RA, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):209–16

Magnetic resonance imaging for diagnosing adenomyomata [published erratum appears in J Am Assoc Gynecol Laparosc 1996 May;3(3):486] Phillips DR, et al. **J Am Assoc Gynecol Laparosc** 1996 Feb;3(2):245–50

[Adenomyomatosis of the gallbladder] **Rontgenpraxis** 1996 Jan;49(1):14–5 **(Ger)**

PATHOLOGY

Adenomyomatosis of the gallbladder. Yang WG, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jul;58(1):12–7

Fine needle aspiration (FNA) cytology of adenoid cystic carcinoma and adenomyoepithelioma of breast: two lesions rich in myoepithelial cells. McCluggage WG, et al. **Cytopathology** 1997 Feb;8(1):31–9

Atypical polypoid adenomyofibroma (APA) versus well-differentiated endometrial carcinoma with prominent stromal matrix: an immunohistochemical study. Soslow RA, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):209–16

SURGERY

Laparoscopic bipolar coagulation for the conservative treatment of adenomyomata. Phillips DR, et al. **J Am Assoc Gynecol Laparosc** 1996 Nov;4(1):19–24

ULTRASONOGRAPHY

Adenomyoma of the common bile duct imaged with endoscopic ultrasonography: case report. Asch MR, et al. **Can Assoc Radiol J** 1997 Apr;48(2):101–4 (15 ref.)

Bizarre sonographic appearance of an adenomyoma and its presentation. Batzer FR, et al. **J Ultrasound Med** 1996 Aug; 15(8):599–602

ADENOMYOSIS see **ENDOMETRIOSIS**

ADENOSARCOMA

BLOOD

Serum insulin-like growth factors (IGFs) and IGF binding protein (IGFBP)-3 in patients with gastric cancer: IGFBP-3 protease activity induced by surgery. Lee DY, et al. **J Korean Med Sci** 1997 Feb;12(1):32–9

CHEMICALLY INDUCED

Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Clement PB, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):222–9 (59 ref.)

PATHOLOGY

Müllerian adenosarcoma of the uterus. Ventura L, et al. **J Exp Clin Cancer Res** 1997 Jun;16(2):221–6

SECONDARY

Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent? Saltzman DA, et al. **J Pediatr Surg** 1997 Feb;32(2):301–6

THERAPY

Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent? Saltzman DA, et al. **J Pediatr Surg** 1997 Feb;32(2):301–6

ULTRASTRUCTURE

Adenosarcoma of the uterus with extensive smooth muscle differentiation: ultrastructural study and review of the literature. Fehmian C, et al. **Ultrastruct Pathol** 1997 Jan–Feb;21(1):73–9 (15 ref.)

ADENOSINE

Intentional asystole during endoluminal thoracic aortic surgery without cardiopulmonary bypass. Baker AB, et al. **Br J Anaesth** 1997 Apr;78(4):444–8

Comparison of intravenous adenosine to intracoronary papaverine for calculation of pressure-derived fractional flow reserve. van der Voort PH, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):120–5

RNA aptamers to the adenosine moiety of S-adenosyl methionine: structural inferences from variations on a theme and the reproducibility of SELEX. Burke DH, et al. **Nucleic Acids Res** 1997 May 15;25(10):2020–4

Ethanol-induced alterations in beta-endorphin levels in specific rat brain regions: modulation by adenosine agonist and antagonist. Anwer J, et al. **Pharmacology** 1995 Dec; 51(6):364–9

ADMINISTRATION & DOSAGE

Antinociceptive effect of perioperative adenosine infusion in abdominal hysterectomy. Segerdahl M, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):473–9

Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery. Mentzer RM Jr, et al. **Am J Cardiol** 1997 Jun 19;79(12A):38–43

Influence of beta-adrenergic and vagal activity on the effect of exogenous adenosine on supraventricular tachycardia termination. Tai CT, et al. **Am J Cardiol** 1997 Jun 15; 79(12):1628–31

Potentiation to vasodilators by nitric oxide synthase blockade in superior mesenteric but not hepatic artery. Macedo MP, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):G507–14

Adenosine reduces postbypass transfusion requirements in humans after heart surgery. Mentzer RM Jr, et al. **Ann Surg** 1996 Oct;224(4):523–9; discussion 529–30

Hemolysis within infusion systems may accelerate adenosine degradation [letter] Demmy TL, et al. **Ann Thorac Surg** 1996 Oct;62(4):1242

Functional and metabolic effects of adenosine in cardioplegia: role of temperature and concentration. Katayama O, et al. **Ann Thorac Surg** 1997 Feb;63(2):449–54; discussion 454–5

Transient ventricular asystole using adenosine during minimally invasive and open sternotomy coronary artery bypass grafting. Robinson MC, et al. **Ann Thorac Surg** 1997 Jun;63(6 Suppl):S30–4

Impaired endothelium-dependent vasodilation of coronary resistance vessels in severely stunned porcine myocardium. McFalls EO, et al. **Basic Res Cardiol** 1995 Nov–Dec; 90(6):498–506

Preconditioning of human myocardium with adenosine during coronary angioplasty. Leesar MA, et al. **Circulation** 1997 Jun 3;95(11):2500–7

Does pharmacologic coronary flow reserve reflect vasodilator responsiveness to increased myocardial demand in humans? Rossen JD, et al. **Coron Artery Dis** 1996 Jun; 7(6):479–84

Effects of adenosine infusion on renal function, plasma ANP and ADH concentrations and central hemodynamics in anesthetized pigs. Elias AN, et al. **Gen Pharmacol** 1997 Mar;28(3):429–33

Adenosine-sensitive bundle branch reentry. Rubenstein DS, et al. **J Cardiovasc Electrophysiol** 1997 Jan;8(1):80–8

Intravenous co-infusion of adenosine and norepinephrine preconditions the heart without adverse hemodynamic effects [see comments] Cohen MV, et al. **J Thorac Cardiovasc Surg** 1997 Aug;114(2):236–42. Comment in: J Thorac Cardiovasc Surg 1997 Aug;114(2):234–5.

Intravenous co-infusion of adenosine and norepinephrine [editorial; comment] Kloner RA, et al. **J Thorac Cardiovasc Surg** 1997 Aug;114(2):234–5. Comment on: J Thorac Cardiovasc Surg 1997 Aug;114(2):236–42.

Adenosine mediates the antiarrhythmic effect of ischemic preconditioning in isolated rat hearts. Miyatake Y, et al. **Jpn Circ J** 1996 Jun;60(6):341–8

Is it safe to inject adenosine through a central line? Drew BJ, et al. **Prog Cardiovasc Nurs** 1997 Winter;12(1):47–8

[Exogenous adenosine in cardioplegia] Haverich A, et al. **Z Kardiol** 1996;85 Suppl 6:201–4 (35 ref.) (Eng. Abstr.) **(Ger)**

[Exogenous adenosine as an anti-arrhythmia agent] Tebbenjohanns J, et al. **Z Kardiol** 1996;85 Suppl 6:191–9 (47 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Adenosine-induced atrial arrhythmia: a prospective analysis. Strickberger SA, et al. **Ann Intern Med** 1997 Sep 15; 127(6):417–22

More about adenosine and arrhythmias [letter; comment] Tomcsányi J, et al. **Cardiovasc Res** 1997 Jun;34(3):603–5. Comment on: Cardiovasc Res 1996 Nov;32(5):797–813.

Adenosine induced polymorphic ventricular tachycardia in adults without structural heart disease. Smith JR, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 1):743–5

Does adenosine infusion improve oxygenation in term infants with respiratory failure? [letter; comment] LeBlanc MH. **Pediatrics** 1996 Dec;98(6 Pt 1):1224–5. Comment on: Pediatrics 1996 Mar;97(3):295–300.

AGONISTS

Cardiac output in Xenopus laevis tadpoles during development and in response to an adenosine agonist. Tang YY, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R997–1004

Stimulation of human sperm during capacitation in vitro by an adenosine agonist with specificity for A2 receptors. Fénichel P, et al. **Biol Reprod** 1996 Jun;54(6):1405–11

Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Tian B, et al. **Exp Eye Res** 1997 Jun;64(6):979–89

ANALOGS & DERIVATIVES

Adenosine receptor-mediated relaxation of rabbit airway smooth muscle: a role for nitric oxide. Ali S, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):L581–7

Effects of adenosine analogues on tension and cytosolic Ca2+ in porcine coronary artery. Olanrewaju HA, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H134–41

Effect of adenosine on adrenergic neurotransmission and modulation by endothelium in canine pulmonary artery. Tamaoki J, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1100–5

Cardiac output in Xenopus laevis tadpoles during development and in response to an adenosine agonist. Tang YY, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R997–1004

The effect of N6-cyclohexyladenosine and 5'-(N-cyclopropyl)- carboxamidoadenosine on pyrogen fever in rabbits. Gagalo IT, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:353–9

Thermoregulatory effects of 5'-N-ethylcarboxamidoadenosine in rabbits. Matuszek MT, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:360–8

The cytotoxicity of adenosine 5'-[N,N-di-(gamma-o-carboranyl)propyl] phosphorodiamidate in human Tmolt3 leukemic cells. Hall IH, et al. **Anticancer Res** 1997 Jan–Feb;17(1A):151–6

Synthesis and antitrypanosomal activities of a series of 7-deaza-5'-norariste romycin derivatives with variations in the cyclopentyl ring substituents. Seley KL, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1658–61

The mechanism of inactivation of human placental S-adenosylhomocysteine hydrolase by (E)-4',5'-didehydro-5'-methoxyadenosine and adenosine 5'-carboxaldehyde oxime. Huang H, et al. **Arch Biochem Biophys** 1997 Jul 1;343(1):109–17

Vasorelaxation of noradrenaline-constricted guinea-pig and rabbit aorta by the adenosine analogue NECA: roles of intra-and extracellular calcium. Ford WR, et al. **Arch Int Pharmacodyn Ther** 1996 May–Jun;331(3):285–300

Intramyocardial infusion of tool drugs for the study of molecular mechanisms in ischemic preconditioning. Vogt AM, et al. **Basic Res Cardiol** 1996 Sep–Oct;91(5):389–400

Peptidyl conjugates of adenosine 5'-carboxylic acid synthesized and evaluated as ligands for P2 purinoceptors. Järlebark L, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):363–9

Effect of adenosine analogues on the expression of matrix metalloproteinases and their inhibitors from human dermal fibroblasts. Svendsrud DH, et al. **Biochem Pharmacol** 1997 May 15;53(10):1511–20

FSBA modifies both alpha- and beta-subunits of F1 specifically and can be bound together with AXP at the same alpha-subunit. Hartog AF, et al. **Biochim Biophys Acta** 1997 Jan 16;1318(1–2):107–22

Chemical modifications of striatal A2A adenosine receptors: a possible role for tyrosine at the ligand binding sites. Martini C, et al. **Biochim Biophys Acta** 1997 May 22; 1326(1):67–74

Role of cysteine residues of rat A2a adenosine receptors in agonist binding. Mazzoni MR, et al. **Biochim Biophys Acta** 1997 Feb 21;1324(1):159–70

Desensitization and internalization of adenosine A1 receptors in rat brain by in vivo treatment with R-PIA: involvement of coated vesicles. Ruiz A, et al. **Biochim Biophys Acta** 1997 Jan 10;1310(1):168–74

Modification of membrane-bound F1 by p-fluorosulfonylbenzoyl-5'-adenosine: sites of binding and effect on activity. van der Zwet-de Graaff I, et al. **Biochim Biophys Acta** 1997 Jan 16;1318(1–2):123–32

Carbamazepine inhibits the potentiation by adenosine analogues of agonist induced inositolphosphate formation in hippocampal astrocyte cultures. Biber K, et al. **Biol Psychiatry** 1996 Oct 1;40(7):563–7

Stimulation of human sperm during capacitation in vitro by an adenosine agonist with specificity for A2 receptors. Fénichel P, et al. **Biol Reprod** 1996 Jun;54(6):1405–11

Conformational search for the N6-substituted adenosine analogues and related adenosine A1 receptor antagonists. Dooley MJ, et al. **Bioorg Med Chem** 1996 Jun;4(6):917–21

Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurones. Nörenberg W, et al. **Br J Pharmacol** 1997 Sep;122(1):71–80

Activation of multiple sites by adenosine analogues in the rat isolated aorta. Prentice DJ, et al. **Br J Pharmacol** 1996 Jul;118(6):1509–17

Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding. Varani K, et al. **Br J Pharmacol** 1996 Apr;117(8):1693–701

Augmented release of serotonin by adenosine A2a receptor activation and desensitization by CGS 21680 in the rat nucleus tractus solitarius. Barraco RA, et al. **Brain Res** 1996 Sep 16;733(2):155–61

Neurotoxicity in organotypic hippocampal slices mediated by adenosine analogues and nitric oxide. Barth A, et al. **Brain Res** 1997 Jul 11;762(1–2):79–88

2-Phenylaminoadenosine stimulates dopamine synthesis in rat forebrain in vitro and in vivo via adenosine A2 receptors. Choksi NY, et al. **Brain Res** 1997 Jun 27;761(1):151–5

Mouse cerebellar adenosinergic modulation of ethanol-induced motor incoordination: possible involvement of cAMP. Dar MS. **Brain Res** 1997 Feb 28; 749(2):263–74

[125I]4-aminobenzyl-5'-N-methylcarboxamidoadenosine (125I)AB-MECA) labels multiple adenosine receptor subtypes in rat brain. Shearman LP, et al. **Brain Res** 1997 Jan 16;745(1–2):10–20

Stimulation of the A2A adenosine receptor increases expression of the tyrosine hydroxylase gene. Chae HD, et al. **Brain Res Mol Brain Res** 1997 Feb;44(1):31–8

Suppression by phenobarbital of ethionine-induced hepatocellular carcinoma formation and hepatic S-adenosylethionine levels. Allen PT, et al. **Carcinogenesis** 1997 May;18(5):1103–7

Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Tracey WR, et al. **Cardiovasc Res** 1997 Feb;33(2):410–5

Inhibition of human tumour cell proliferation by analogues of adenosine. Colquhoun A, et al. **Cell Biochem Funct** 1997 Jun;15(2):135–9

New neplanocin analogues. VIII. Synthesis and biological activity of 6'-C-ethyl, -ethenyl, and -ethynyl derivatives of neplanocin A. Shuto S, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1163–8

New neplanocin analogues. IX. A practical preparation of (6'R)-6'-C-methylneplanocin A (RMNPA), a potent antiviral agent, and the determination of its 6'-configuration. Diastereoselective deamination by adenosine deaminase. Shuto S, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan;45(1):138–42

Characterization of N1- and N6-adenosine adducts and N1-inosine adducts formed by the reaction of butadiene monoxide with adenosine: evidence for the N1-adenosine adducts as major initial products. Selzer RR, et al. **Chem Res Toxicol** 1996 Jul–Aug;9(5):875–81

Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Auchampach JA, et al. **Circ Res** 1997 Jun;80(6):800–9

Effects of A1 adenosine receptor agonism using N6-cyclohexyl-2'-O-methyladenosine in patients with left ventricular dysfunction. Bertolet BD, et al. **Circulation** 1996 Sep 15;94(6):1212–5

Pharmacological stress thallium scintigraphy with 2-cyclohexylmethylidenehydrazinoadenosine (WRC-0470). A novel, short-acting adenosine A2A receptor agonist. Glover DK, et al. **Circulation** 1996 Oct 1;94(7):1726–32

Inhibition of complete development of Cryptosporidium parvum in Caco-2 cells [letter] Egraz-Bernard M, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):897–900

N6-2-(4-aminophenyl)ethyl-adenosine enhances the anticonvulsive activity of antiepileptic drugs. Borowicz KK, et al. **Eur J Pharmacol** 1997 May 30;327(2–3):125–33

Synergistic interactions between human transfected adenosine A1 receptors and endogenous cholecystokinin receptors in CHO cells. Dickenson JM, et al. **Eur J Pharmacol** 1996 Apr 29;302(1–3):141–51

Motor depressant effects mediated by dopamine D2 and adenosine A2A receptors in the nucleus accumbens and the caudate-putamen. Hauber W, et al. **Eur J Pharmacol** 1997 Apr 4;323(2–3):127–31

Expression of inducible nitric oxide synthase in mice: pharmacological evaluation of adenosine receptor agonists. Moochhala SM, et al. **Eur J Pharmacol** 1996 Dec 5; 316(2–3):287–96

Effects of adenosine A2A receptor agonist, CGS 21680, on blood pressure, cardiac index and arterial conductance in anaesthetized rats. Nekooeian AA, et al. **Eur J Pharmacol** 1996 Jun 27;307(2):163–9

Adenosine analogues relax guinea-pig taenia caeci via an adenosine A2B receptor and a xanthine-resistant site. Prentice DJ, et al. **Eur J Pharmacol** 1997 Mar 26; 323(1):103–6

Analysis of the bronchoconstrictor responses to adenosine receptor agonists in sensitized guinea-pig lungs and trachea. Thorne JR, et al. **Eur J Pharmacol** 1996 Dec 5; 316(2–3):263–71

Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Van Schaick EA, et al. **Eur J Pharmacol** 1996 Jul 25;308(3):311–4

Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist. Von Lubitz DK, et al. **Eur J Pharmacol** 1996 Apr 29;302(1–3):43–8

Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Von Lubitz DK, et al. **Eur J Pharmacol** 1996 Dec 5;316(2–3):171–9

Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. Von Lubitz DK, et al. **Eur J Pharmacol** 1995 Dec 20;287(3):295–302

Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Tian B, et al. **Exp Eye Res** 1997 Jun;64(6):979–89

Cardioprotective actions of adenosine and adenosine analogs. Cook MA, et al. **EXS** 1996;76:325–44 (110 ref.)

Smooth muscle relaxant activity of A1- and A2-selective adenosine receptor agonists in guinea pig trachea: involvement of potassium channels. Hadjkaddour K, et al. **Fundam Clin Pharmacol** 1996;10(3):269–77

The effect of N6-cyclohexyladenosine and 5'-N-ethylcarboxamidoadenosine on body temperature in normothermic rabbits. Matuszek M, et al. **Gen Pharmacol** 1996 Apr;27(3):467–9

Unusual discrimination against carrier protein antibodies during partial purification of hapten-protein polyclonal antibodies to plant stress hormones. Manju RV, et al. **Indian J Exp Biol** 1995 Jan;33(1):1–5

Adenophostin A can stimulate Ca2+ influx without depleting the inositol 1,4,5-trisphosphate-sensitive Ca2+ stores in the Xenopus oocyte. DeLisle S, et al. **J Biol Chem** 1997 Apr 11;272(15):9956–61

Isozyme-dependent sensitivity of adenylyl cyclases to P-site-mediated inhibition by adenine nucleosides and nucleoside 3'-polyphosphates. Johnson RA, et al. **J Biol Chem** 1997 Apr 4;272(14):8962–6

Mechanism and pressor relevance of the short-term cardiovascular and renin excitatory actions of the selective A2A-adenosine receptor agonists. Alberti C, et al. **J Cardiovasc Pharmacol** 1997 Sep;30(3):320–4

Determination of sinefungin in rat plasma by high-performance liquid chromatography. Tharasse-Bloch C, et al. **J Chromatogr B Biomed Appl** 1995 Dec 15; 674(2):247–52

Effects of adenosine-receptor agonists on renin release in anaesthetized rats. Protasoni G, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1753–7

New neplanocin analogues. 7. Synthesis and antiviral activity of 2-halo derivatives of neplanocin A. Obara T, et al. **J Med Chem** 1996 Sep 13;39(19):3847–52

(+)-7-Deaza-5'-norariste romycin as an anti-trypanosomal agent. Seley KL, et al. **J Med Chem** 1997 Feb 14; 40(4):622–4

Synthesis and anti-trypanosomal activity of various 8-aza-7-deaza-5'norariste romycin derivatives. Seley KL, et al. **J Med Chem** 1997 Feb 14;40(4):625–9

2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors. Vittori S, et al. **J Med Chem** 1996 Oct 11; 39(21):4211–7

Inactivation of S-adenosyl-L-homocysteine hydrolase by amide and ester derivatives of adenosine-5'-carboxylic acid. Wnuk SF, et al. **J Med Chem** 1996 Oct 11; 39(21):4162–6

Differential binding of S-adenosylmethionine S-adenosylhomocysteine and Sinefungin to the adenine-specific DNA methyltransferase M.TaqI. Schluckebier G, et al. **J Mol Biol** 1997 Jan 10;265(1):56–67

Concentration-response relationships for adenosine agonists during preconditioning of rabbit cardiomyocytes. Rice PJ, et al. **J Mol Cell Cardiol** 1996 Jun;28(6):1355–65

Activation of phosphodiesterase IV during desensitization of the A2A adenosine receptor-mediated cyclic AMP response in rat pheochromocytoma (PC12) cells. Chang YH, et al. **J Neurochem** 1997 Sep;69(3):1300–9

Inosine mediates the protective effect of adenosine in rat astrocyte cultures subjected to combined glucose-oxygen deprivation. Haun SE, et al. **J Neurochem** 1996 Nov; 67(5):2051–9

Chronic exposure to adenosine receptor agonists and antagonists reciprocally regulates the A1 adenosine receptor-adenylyl cyclase system in cerebellar granule cells. Hettinger-Smith BD, et al. **J Neurochem** 1996 Nov; 67(5):1921–30

Adenosine A1 receptors in cultured cerebellar granule cells: role of endogenous adenosine. Sanz JM, et al. **J Neurochem** 1996 Oct;67(4):1469–77

A tandem solid phase extraction, reversed-phase HPLC method for determining SDZ WAG 994 in dog, monkey and rat blood. Cramer JA, et al. **J Pharm Biomed Anal** 1997 Mar;15(6):749–58

Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. Jordan JE, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):301–9

Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo. Mathot RA, et al. **J Pharmacol Exp Ther** 1996 Dec; 279(3):1439–46

In vivo role of the adenosine A3 receptor: N6-2-(4-aminophenyl)ethyladenosine induces bronchospasm in BDE rats by a neurally mediated mechanism involving cells resembling mast cells. Meade CJ, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1148–56

Dispersion characteristics of [3H]-labeled adenosine

agonist/antagonist following their intrastriatal microinfusion. Meng ZH, et al. **Methods Find Exp Clin Pharmacol** 1996 Jul-Aug; 18(6):373-86

Effects of adenophostin-A and inositol-1,4,5-trisphosphate on Cl- currents in Xenopus laevis oocytes. Hartzell HC, et al. **Mol Pharmacol** 1997 Apr;51(4):683-92

Persistent activation by and receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1 MF-2 cells and in guinea pig heart. Zhang J, et al. **Mol Pharmacol** 1997 Sep;52(3):491-8

The selective adenosine A2A receptor antagonist SCH 58261 discriminates between two different binding sites for [3H]-CGS 21680 in the rat brain. Lindström K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Oct; 354(4):539-41

Adenosine A2A agonists: a potential new type of atypical antipsychotic. Rimondini R, et al. **Neuropsychopharmacology** 1997 Aug;17(2):82-91

Intrathecal and systemic R-phenylisopropyl-adenosine reduces scratching behaviour in a rat mononeuropathy model. Sjölund KF, et al. **Neuroreport** 1996 Jul 29; 7(11):1856-60

The effects of 5'-N-ethylcarboxamidoadenosine on evoked release of [3H]serotonin in the rat nucleus tractus solitarius. Helfman CC, et al. **Neurosci Lett** 1996 Jul 26;213(1):61-5

Modification of cardiovascular response of adenosine A1 receptor agonist by cyclic AMP in the spinal cord of the rats. Koh HC, et al. **Neurosci Lett** 1996 Nov 29; 219(3):195-8

The structure of 3'-O-anthraniloyladenosine, an analogue of the 3'-end of aminoacyl-tRNA. Nawrot B, et al. **Nucleic Acids Res** 1997 Mar 1;25(5):948-54

IP3 receptor-ligand. 2: Synthesis and molecular mechanics calculation of adenophostin A. Hotoda H, et al. **Nucleic Acids Symp Ser** 1995;(34):163-4

Chronic ethanol intoxication enhances [3H]CCPA binding and does not reduce A1 adenosine receptor function in rat cerebellum. Concas A, et al. **Pharmacol Biochem Behav** 1996 Feb;53(2):249-55

Hemodynamic changes do not mediate the cardioprotection induced by the A1, adenosine receptor agonist CCPA in the rabbit. Casati C, et al. **Pharmacol Res** 1997 Jan; 35(1):51-5

Prolonged exposure to 5'-N-ethylcarboxamidoadenosine (NECA) does not affect the adenosine A2A-mediated vasodilation in porcine coronary arteries. Conti A, et al. **Pharmacol Res** 1997 Feb;35(2):123-8

Cardioprotective effects of adenosine A1 and A2A receptor agonists in the isolated rat heart. Lozza G, et al. **Pharmacol Res** 1997 Jan;35(1):57-64

Influence of adenosinergic drugs on ethanol withdrawal syndrome in rats. Malec D, et al. **Pol J Pharmacol** 1996 Nov-Dec;48(6):583-8

[The effect of adenosine receptor agonists on the normal cerebral blood flow and in subsequent ischemia] Kulinskii VI, et al. **Eksp Klin Farmakol** 1996 May-Jun;59(3):37-9 (Eng. Abstr.) **(Rus)**

[4-branched nucleosides. I. Molecular structure of conformationally limited nucleoside analogs--4'-oxymethyl-2',3'-anhydroiboadnosine and 2',3'-anhydrolyxocytidine. Synthesis and antiviral activity] Gurskaia GV, et al. **Mol Biol (Mosk)** 1996 Jul-Aug; 30(4):911-20 **(Rus)**

ANALYSIS

The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Blay J, et al. **Cancer Res** 1997 Jul 1;57(13):2602-5

Interstitial adenosine and function in rat heart in vivo: effects of adrenaline and 8-cyclopentyl-1,3-dimethylxanthine. Headrick JP. **Clin Exp Pharmacol Physiol** 1996 May; 23(5):386-94

Measurement of adenosine by capillary zone electrophoresis with on-column isotachophoretic preconcentration. Wang CC, et al. **J Chromatogr B Biomed Appl** 1996 Feb 9; 676(1):19-28

ANTAGONISTS & INHIBITORS

Inhibition of glucose transport in human red blood cells by adenosine antagonists. Gabel SA, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1415-9

Adenosine transport inhibition ameliorates postischemic hypoperfusion in pigs. Gidday JM, et al. **Brain Res** 1996 Sep 23;734(1-2):261-8

Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis. Forrest EH, et al. **Gut** 1997 Jan; 40(1):139-44

Markers of adenosine removal in normotensive and hypertensive rat nervous tissue. Castillo-Meléndez M, et al. **Hypertension** 1996 Dec;28(6):1026-33

Inhibitory and excitatory effects of adenosine antagonists on spontaneous locomotor activity in mice. Florio C, et al. **Life Sci** 1997;60(17):1477-86

Dispersion characteristics of [3H]-labeled adenosine agonist/antagonist following their intrastriatal microinfusion. Meng ZH, et al. **Methods Find Exp Clin Pharmacol** 1996 Jul-Aug; 18(6):373-86

Asthma. Blocking adenosine with antisense [news; comment] Richardson PJ. **Nature** 1997 Feb 20;385(6618):684-5. Comment on: Nature 1997 Feb 20;385(6618):721-5.

Increase of adenosine release by adenosine antagonists in hearts with coronary occlusion and reperfusion. Bernauer W. **Pharmacology** 1996 Nov;53(5):311-9

BIOSYNTHESIS

Contribution of cytosolic and membrane-bound 5'-nucleotidases to cardiac adenosine production. Darvish A, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H2162-7

Inorganic phosphate as regulator of adenosine formation in isolated guinea pig hearts. Gorman MW, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H913-20

Phosphorylation potential, adenosine formation, and critical PO2 in stimulated rat cardiomyocytes. Stumpe T, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H756-66

Inhibition of nitric oxide synthesis increases adenosine production via an extracellular pathway through activation of protein kinase C. Minamino T, et al. **Circulation** 1997 Sep 2;96(5):1586-92

Effects of ethanol and acetate on adenosine production in rat hippocampal slices. Fredholm BB, et al. **Pharmacol Toxicol** 1996 Sep;79(3):120-3

BLOOD

Plasma adenosine responses during repeated episodes of umbilical cord occlusion. Kubonoya K, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):395-401

Temporal variations of adenosine metabolism in human blood. Chagoya de Sánchez V, et al. **Chronobiol Int** 1996 Aug;13(3):163-77

Plasma adenosine levels increase in patients with chronic heart failure. Funaya H, et al. **Circulation** 1997 Mar 18; 95(6):1363-5

Adenosine in painful legs and moving toes syndrome. Guieu R, et al. **Clin Neuropharmacol** 1994 Oct;17(5):460-9

Rapid radioassay for metabolites of adenosine and deoxyadenosine in erythrocytes. Szabados E, et al. **J Chromatogr B Biomed Appl** 1995 Dec 1;674(1):132-7

Effect of i.v. dipyridamole on cerebral blood flow, blood pressure, plasma adenosine and cAMP levels in rabbits. Hegedüs K, et al. **J Neurol Sci** 1997 May 29;148(2):153-61

Caffeine alters plasma adenosine levels [letter] Conlay LA, et al. **Nature** 1997 Sep 11;389(6647):136

Effect of diltiazem on plasma concentrations of oxypurines and uric acid. Yeung PK, et al. **Ther Drug Monit** 1997 Jun;19(3):286-91

CHEMISTRY

Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of cAMP-dependent protein kinase complexed with the peptide inhibitor PKI(5-24) and adenosine. Narayana N, et al. **Biochemistry** 1997 Apr 15; 36(15):4438-48

Adenosine conformations of nucleotides bound to methionyl tRNA synthetase by transferred nuclear Overhauser effect spectroscopy. Murali N, et al. **Biophys J** 1997 May; 72(5):2275-84

Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney. van der Giet M, et al. **Br J Pharmacol** 1997 Apr;120(8):1453-60

Reaction of mucochloric and mucobromic acids with adenosine and cytidine: formation of chloro- and bromopropenal derivatives. Kronberg L, et al. **Chem Res Toxicol** 1996 Dec;9(8):1257-63

Identification of adducts formed in reaction of adenosine with 3-chloro-4-methyl-5-hydroxy-2(5H)-furanone, a bacterial mutagen present in chloride disinfected drinking water. Munter T, et al. **Chem Res Toxicol** 1996 Jun; 9(4):703-8

Structural analysis of 11C, 15N labeled adenosine by solid-state NMR. Fujiwara T, et al. **Nucleic Acids Symp Ser** 1995;(34):193-4

Supercoiling-dependent flexibility of adenosine-tract-containing DNA detected by a topological method. Tsen H, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):2817-22

Functional group substitutions of the branchpoint adenosine in a nuclear pre-mRNA and a group II intron. Gaur RK, et al. **RNA** 1997 Aug;3(8):861-9

DIAGNOSTIC USE

Correlation of adenosine thallium 201 perfusion patterns with markers for inducible ischemia. Fenster MS, et al. **Am Heart J** 1997 Apr;133(4):406-12

The effect of aminophylline on pharmacological stress with intravenous adenosine. Nahser PJ Jr, et al. **Am J Card Imaging** 1996 Jul;10(3):149-53

Usefulness of hemodynamic changes during adenosine infusion in predicting the diagnostic accuracy of adenosine technetium-99m sestamibi single-photon emission computed tomography (SPECT). Amanullah AM, et al. **Am J Cardiol** 1997 May 15;79(10):1319-22

Identification of severe or extensive coronary artery disease in women by adenosine technetium-99m sestamibi SPECT. Amanullah AM, et al. **Am J Cardiol** 1997 Jul 15;80(2):132-7

Adenosine stress echocardiography. Chaudhry FA. **Am J Cardiol** 1997 Jun 19;79(12A):25-9 (43 ref.)

Comparison of adenosine to dipyridamole in degree of coronary hyperemic response in heart transplant recipients. Chou TM, et al. **Am J Cardiol** 1996 Oct 15;78(8):908-13

Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia. Hachamovitch R, et al. **Am J Cardiol** 1997 Aug 15;80(4):426-33

Myocardial perfusion imaging during adenosine-induced coronary hyperemia. Iskandrian AE, et al. **Am J Cardiol** 1997 Jun 19;79(12A):20-4 (37 ref.)

Role of adenosine in the cardiac catheterization laboratory. Ogilby JD. **Am J Cardiol** 1997 Jun 19;79(12A):15-9 (19 ref.)

Differences of regional coronary flow reserve assessed by adenosine thallium-201 scintigraphy early and six months after successful percutaneous transluminal coronary angioplasty or stent implantation. Versaci F, et al. **Am J Cardiol** 1996 Nov 15;78(10):1097-102

Comparison of adenosine, dobutamine, and exercise radionuclide ventriculography in the detection of coronary artery disease. Nagaoka H, et al. **Cardiology** 1997 Mar-Apr; 88(2):180-8

Coronary vein flow velocity changes during transluminal balloon angioplasty: a study using the Doppler guide wire. Manginas A, et al. **Cathet Cardiovasc Diagn** 1997 Jan; 40(1):85-91 (23 ref.)

Preoperative cardiac risk assessment with adenosine stress dual-isotope myocardial single-photon emission computed tomography. Maunoury C, et al. **Clin Cardiol** 1996 Jun; 19(6):488-90

Slow bolus injection of ribose in the identification of thallium-201 redistribution following combined adenosine/dynamic exercise stress. Gunning MG, et al. **Eur Heart J** 1996 Sep;17(9):1438-43

Assessment of coronary reserve by transoesophageal Doppler echocardiography. Direct comparison between different modalities of dipyridamole and adenosine administration. Kozàkovà M, et al. **Eur Heart J** 1997 Mar;18(3):514-23

Adenosine echocardiography in the diagnosis of coronary artery disease. Marwick TH. **Eur Heart J** 1997 Jun;18 Suppl D:D31-6 (26 ref.)

Intracoronary demonstration of adenosine-induced coronary collateral steal. Seiler C, et al. **Heart** 1997 Jan;77(1):78-81

Adenosine-induced chest pain: is it due to myocardial ischaemia? Clinical, electrocardiographic, haemodynamic and metabolic study. Mehta AB, et al. **Indian Heart J** 1997 May-Jun;49(3):267-70

Effect of inhaled heparin on adenosine-induced bronchial hyperreactivity. Ceyhan BB, et al. **Int J Clin Pharmacol Ther** 1997 May;35(5):208-13

High dose adenosine stress echocardiography for noninvasive detection of coronary artery disease. Djordjevic-Dikic AD, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1689-95

Adenosine thallium-201 tomography in evaluation of graft patency late after coronary artery bypass graft surgery. Khoury AF, et al. **J Am Coll Cardiol** 1997 May; 29(6):1290-5

Detection of myocardial perfusion abnormalities during dobutamine and adenosine stress echocardiography with transient myocardial contrast imaging after minute quantities of intravenous perfluorocarbon-exposed sonicated dextrose albumin. Porter TR, et al. **J Am Soc Echocardiogr** 1996 Nov-Dec;9(6):779-86

Technetium 99m-labeled tetrofosmin myocardial tomography in patients with coronary artery disease: comparison between adenosine and dynamic exercise stress testing. Cuocolo A, et al. **J Nucl Cardiol** 1996 May-Jun; 3(3):194-203

Are the differences between adenosine and dipyridamole clinically relevant? [editorial; comment] Iskandrian AS. **J Nucl Cardiol** 1996 May-Jun;3(3):281-3. Comment on: J Nucl Cardiol 1996 May-Jun;3(3):204-11.

Comparison between dipyridamole and adenosine as pharmacologic coronary vasodilators in detection of coronary artery disease with thallium 201 imaging [see comments] Taillefer R, et al. **J Nucl Cardiol** 1996 May-Jun; 3(3):204-11. Comment in: J Nucl Cardiol 1996 May-Jun;3(3):281-3.

Emergency department evaluation of an infant with chaotic atrial tachycardia. Cetta F, et al. **Pediatr Emerg Care** 1997 Apr;13(2):120-2

The comparative safety and diagnostic accuracy of adenosine myocardial perfusion imaging in women versus men. Mohiuddin SM, et al. **Pharmacotherapy** 1996 Jul-Aug; 16(4):646-51

ECONOMICS

Cost-minimization analysis of intravenous adenosine and dipyridamole in thallous chloride TI 201 SPECT myocardial perfusion imaging. Hilleman DE, et al. **Ann Pharmacother** 1997 Sep;31(9):974-9

Outcomes and costs of positron emission tomography: comparison of intravenous adenosine and intravenous dipyridamole. Holmberg MJ, et al. **Clin Ther** 1997 May-Jun;19(3):570-81; discussion 538-9

METABOLISM

Purine derivatives in the study of allergic inflammation in respiratory diseases. Crimi N, et al. **Allergy** 1997;52(34 Suppl):48-54 (70 ref.)

Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Shryock JC, et al. **Am J Cardiol** 1997 Jun 19;79(12A):2-10

(123 ref.)
Dissociation between adenosine release, MVO2, and energy status in working guinea pig hearts. Decking UK, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H371–81
Preconditioning cultured human pediatric myocytes requires adenosine and protein kinase C. Ikonomidis JS, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1220–30
Adenosine kinetics in canine coronary circulation. Kroll K, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):H1469–83
Intracellular lactate controls adenosine output from dog gracilis muscle during moderate systemic hypoxia. Mo FM, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H318–24
Disparate effects of preconditioning and MLA on 5'-NT and adenosine levels during coronary occlusion. Przyklenk K, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H945–51
Cardioprotection with ischemic preconditioning and MLA: role of adenosine-regulating enzymes? Przyklenk K, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1004–14
Bovine adrenal endothelial cells express nucleoside transporters nonregulated by protein kinases A and C. Sen RP, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C504–10
Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Yao Y, et al. **Biochem Biophys Res Commun** 1997 Mar 17; 232(2):317–22
Modelling of purine nucleoside metabolism during mouse embryonic development: relative routes of adenosine, deoxyadenosine, and deoxyguanosine metabolism. Jenuth JP, et al. **Biochem Cell Biol** 1996;74(2):219–25
Adenosine-AMP exchange activity is an integral part of the mammalian adenosine kinase. Gupta RS. **Biochem Mol Biol Int** 1996 Jun;39(3):493–502
Characterization of a novel adenosine binding protein sensitive to cyclic AMP in rat brain cytosolic and particulate fractions. Lorenzen A, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1375–85
The target of PKC induced suppression of adenosine inhibition of glutamate release from synaptosomes is downstream of the A1 receptor and G-protein coupling. Budd DC, et al. **Biochem Soc Trans** 1996 Aug;24(3):429S
Enzymatic conversion of adenosine to inosine and to N1-methylinosine in transfer RNAs: a review. Grosjean H, et al. **Biochimie** 1996;78(6):488–501 (98 ref.)
Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine. Gleiter CH, et al. **Br J Clin Pharmacol** 1996 Dec;42(6):729–35
Inhibition of muscarinic K+ current in guinea-pig atrial myocytes by PD 81,723, an allosteric enhancer of adenosine binding to A1 receptors. Brandts B, et al. **Br J Pharmacol** 1997 Jul;121(6):1217–23
KW-3902, a selective high affinity antagonist for adenosine A1 receptors. Nonaka H, et al. **Br J Pharmacol** 1996 Apr; 117(8):1645–52
Up-regulation of adenosine transporter-binding sites in striatum and hypothalamus of opiate tolerant mice. Kaplan GB, et al. **Brain Res** 1997 Jul 25;763(2):215–20
Hypothermic cardioplegic arrest is associated with increased myocardial adenosine. Shortt KG, et al. **Cardiology** 1996 Nov-Dec;87(6):516–23
Endogenous adenosine increases O2 utilisation efficiency in isoprenaline-stimulated canine myocardium. Mallet RT, et al. **Cardiovasc Res** 1996 Jan;31(1):102–16
Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Decking UK, et al. **Circ Res** 1997 Aug;81(2):154–64
Direct measurement of the release of ATP and its major metabolites from the nerve fibres of the guinea-pig taenia coli. McConalogue K, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):807–12
Nucleoside transporter-mediated uptake and release of [3H]L-adenosine in DDT1 MF-2 smooth muscle cells. Foga IO, et al. **Eur J Pharmacol** 1996 Dec 30; 318(2–3):455–60
Adenosine kinase inhibitors augment release of adenosine from spinal cord slices. Golembiowska K, et al. **Eur J Pharmacol** 1996 Jun 27;307(2):157–62
Indomethacin and piroxicam inhibit Na+-adenosine transport in rat renal brush-border membranes. González-Castillo C, et al. **Eur J Pharmacol** 1997 Jun 25; 329(2–3):245–52
Adenosine transport inhibitors enhance high K(+)-evoked taurine release from rat hippocampus. Hada J, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):101–7
[3H]adenosine transport in DDT1 MF-2 smooth muscle cells: inhibition by metabolites of propentofylline. Parkinson FE, et al. **Eur J Pharmacol** 1996 Jul 11;308(1):97–102
Potentiation of excitatory amino acid-evoked adenosine release from rat cortex by inhibitors of adenosine kinase and adenosine deaminase and by acadesine. White TD. **Eur J Pharmacol** 1996 May 6;303(1–2):27–38
Suppression of cAMP formation by adenosine in myenteric ganglia from guinea-pig small intestine. Xia Y, et al. **Eur J Pharmacol** 1997 Feb 5;320(1):95–101
Plasmodium falciparum: transport of enantiomers of nucleosides into Sendai-treated trophozoites. Gero AM, et al. **Exp Parasitol** 1997 Jul;86(3):228–31
Crithidia luciliae: regulation of purine nucleoside transport by extracellular purine concentrations. Hall ST, et al. **Exp Parasitol** 1996 Aug;83(3):314–21
Studies investigating the possible involvement of adenosine in the antisecretory action of morphine. Hancock DL, et al. **Gen Pharmacol** 1997 May;28(5):709–13
Adenosine transporters. Thorn JA, et al. **Gen Pharmacol** 1996 Jun;27(4):613–20 (75 ref.)
Myocardial infarction related atrial fibrillation: role of endogenous adenosine. Bertolet BD, et al. **Heart** 1997 Jul; 78(1):88–90
Protective effect of preconditioning on the injury associated to hepatic ischemia-reperfusion in the rat: role of nitric oxide and adenosine. Peralta C, et al. **Hepatology** 1997 Apr; 25(4):934–7
Markers of adenosine removal in normotensive and hypertensive rat nervous tissue. Castillo-Meléndez M, et al. **Hypertension** 1996 Dec;28(6):1026–33
Metabolism of adenosine and deoxyadenosine by human erythrocytes and CCRF-CEM leukemia cells. Szabados E, et al. **Int J Biochem Cell Biol** 1996 Dec;28(12):1405–15
Stimulated transport of adenosine, guanosine and hypoxanthine in Crithidia luciliae: metabolic machinery in which the parasite has a distinct advantage over the host. Gero AM, et al. **Int J Parasitol** 1997 Feb;27(2):241–9
Radioligand binding and autoradiographic visualization of adenosine transport sites in human inferior vagal ganglia and their axonal transport along rat vagal afferent neurons. Castillo-Meléndez M, et al. **J Auton Nerv Syst** 1996 Feb 5;57(1–2):36–42
Adenosine metabolism during phorbol myristate acetate-mediated induction of HL-60 cell differentiation: changes in expression pattern of adenosine kinase, adenosine deaminase, and 5'-nucleotidase. Spychala J, et al. **J Immunol** 1997 May 15;158(10):4947–52
2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors. Vittori S, et al. **J Med Chem** 1996 Oct 11; 39(21):4211–7
Intermittent ischemia: energy metabolism, cellular volume regulation, adenosine and insights into preconditioning. Askenasy N, et al. **J Mol Cell Cardiol** 1997 Jun; 29(6):1715–30
A comparison of AMP degradation in the perfused rat heart during 2-deoxy-D-glucose perfusion and anoxia. Part I: The release of adenosine and inosine. Chen W, et al. **J Mol Cell Cardiol** 1996 Oct;28(10):2163–74
Determinants of the S-adenosylhomocysteine (SAH) technique for the local assessment of cardiac free cytosolic adenosine. Loncar R, et al. **J Mol Cell Cardiol** 1997 May; 29(5):1289–305
Kainate-evoked release of adenosine from the hippocampus of the anaesthetised rat: possible involvement of free radicals. Carswell HV, et al. **J Neurochem** 1997 Jan; 68(1):240–7
Preferential release of ATP and its extracellular catabolism as a source of adenosine upon high- but not low-frequency stimulation of rat hippocampal slices. Cunha RA, et al. **J Neurochem** 1996 Nov;67(5):2180–7
Adenosine A1 receptors in cultured cerebellar granule cells: role of endogenous adenosine. Sanz JM, et al. **J Neurochem** 1996 Oct;67(4):1469–77
M3 muscarinic receptor-mediated enhancement of NMDA-evoked adenosine release in rat cortical slices in vitro. Semba K, et al. **J Neurochem** 1997 Sep;69(3):1066–72
Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. Dunwiddie TV, et al. **J Neurosci** 1997 Oct 15; 17(20):7673–82
A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. Harvey J, et al. **J Neurosci** 1997 Jul 15;17(14):5271–80
Stimulation of alpha 1-adrenoceptors and protein kinase C-mediated activation of ecto-5'-nucleotidase in rat hearts in vivo. Sato T, et al. **J Physiol (Lond)** 1997 Aug 15;503 (Pt 1):119–27
S-adenosylhomocysteine-hydrolase from bovine kidney: enzymatic and binding properties. Kloor D, et al. **Kidney Blood Press Res** 1996;19(2):100–8
ATP catabolism and adenosine generation during ischemia in the aging heart. Ramani K, et al. **Mech Ageing Dev** 1996 Aug 15;89(2):113–24
Diversity of adenosine degradation in staphylococci. Krasuski A, et al. **Microbios** 1996;88(354):27–34
Enhanced acquisition of purine nucleosides and nucleobases by purine-starved Crithidia luciliae. Alleman MM, et al. **Mol Biochem Parasitol** 1996 Feb-Mar;76(1–2):279–87
Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Jiang Q, et al. **Mol Pharmacol** 1996 Sep;50(3):512–21
Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes. Yao SY, et al. **Mol Pharmacol** 1996 Dec;50(6):1529–35
Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs [see comments] Griffiths M, et al. **Nat Med** 1997 Jan; 3(1):89–93. Comment in: Nat Med 1997 Jan;3(1):25–6.
DNA antisense therapy for asthma in an animal model [see comments] Nyce JW, et al. **Nature** 1997 Feb 20; 385(6618):721–5. Comment in: Nature 1997 Feb 20;385(6618):684–5.
The contribution of different types of calcium channels to electrically-evoked adenosine release from rat hippocampal slices. Latini S, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):250–5
Mechanism of adenosine accumulation in the hippocampal slice during energy deprivation. Doolette DJ. **Neurochem Int** 1997 Feb;30(2):211–23
Effects of an inhibitor of adenosine deaminase, deoxycoformycin, and of nucleoside transport, propentofylline, on post-ischemic recovery of adenine nucleotides in rat brain. Phillis JW, et al. **Neurochem Res** 1996 Mar;21(3):347–53
Forskolin evokes extracellular adenosine accumulation in rat cortical cultures. Rosenberg PA, et al. **Neurosci Lett** 1996 Jun 14;211(1):49–52
Extracellular adenosine levels in neostriatum and hippocampus during rest and activity periods of rats. Huston JP, et al. **Neuroscience** 1996 Jul;73(1):99–107
Polynucleotide:adenosine glycosidase activity of ribosome-inactivating proteins: effect on DNA, RNA and poly(A). Barbieri L, et al. **Nucleic Acids Res** 1997 Feb 1; 25(3):518–22
Sodium-dependent adenosine transport is diminished in brush border membrane vesicles from hypothyroid rat kidney. Martínez F, et al. **Pflugers Arch** 1997 Jan;433(3):269–75
Effect of ethanol on human placental transport and metabolism of adenosine. Acevedo CG, et al. **Placenta** 1997 Jul-Aug;18(5–6):387–92
3H-adenosine uptake selectively labels rod horizontal cells in goldfish retina. Studholme KM, et al. **Vis Neurosci** 1997 Mar-Apr;14(2):207–12

PHARMACOKINETICS

Localisation of the adenosine uptake site in the human brain: a comparison with the distribution of adenosine A1 receptors. Glass M, et al. **Brain Res** 1996 Feb 26; 710(1–2):79–91
Alteration to one of three adenosine transporters is associated with resistance to cymelarsan in Trypanosoma evansi. Ross CA, et al. **Parasitol Res** 1996;82(2):183–8
Pharmacokinetics of rinse solutions at 4 degrees celsius. Schilling M, et al. **Transpl Int** 1996;9 Suppl 1:S477–8
[Adenosine pharmacokinetics in rats] Prokopenko VM, et al. **Eksp Klin Farmakol** 1997 Mar-Apr;60(2):56–7 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Effects on skeletal muscle oxygenation and capillary blood flow by adenosine-, sodium nitroprusside- and acetylcholine-induced hypotension. Gustafsson U, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):832–7
Peroperative adenosine infusion reduces isoflurane concentrations during general anesthesia for shoulder surgery. Segerdahl M, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):792–7
On the cardioprotective effect of adenosine. Szabó JZ, et al. **Acta Physiol Hung** 1996;84(3):337–8
Effects of adenosine on ex vivo filtragometry platelet aggregation in relation to plasma levels. Jonzon B, et al. **Acta Physiol Scand** 1997 Mar;159(3):245–8
Global cerebral blood flow during infusion of adenosine in humans: assessment by magnetic resonance imaging and positron emission tomography. Stånge K, et al. **Acta Physiol Scand** 1997 Jun;160(2):117–22
Modifications of carotid body CO2 chemosensitivity in vitro. Kumar P, et al. **Adv Exp Med Biol** 1996;410:203–10
Adenosine increases the cAMP content of the rat carotid body in vitro. Monteiro EC, et al. **Adv Exp Med Biol** 1996; 410:299–303
Purine derivatives in the study of allergic inflammation in respiratory diseases. Crimi N, et al. **Allergy** 1997;52(34 Suppl):48–54 (70 ref.)
Effects of verapamil, propranolol, and procainamide on adenosine-induced negative dromotropism in human beings. Lai WT, et al. **Am Heart J** 1996 Oct;132(4):768–75
Pharmacologic stress-induced regional myocardial blood flow heterogeneity and left ventricular wall thickening abnormality: comparison of intravenous adenosine with dipyridamole in a model of critical coronary stenosis. Ofili EO, et al. **Am Heart J** 1997 Jan;133(1):78–86
Effects of adenosine on wavelength of premature atrial complexes in patients without structural heart disease. Kabell G, et al. **Am J Cardiol** 1996 Dec 15;78(12):1443–6
Adenosine receptor-mediated relaxation of rabbit airway smooth muscle: a role for nitric oxide. Ali S, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):L581–7
Effects of intravenous adenosine on renal function in healthy human subjects. Balakrishnan VS, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F374–81
Cellular mechanisms underlying adenosine actions on cholinergic transmission in enteric neurons. Barajas-López C, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C264–75
Beta-blockade reduces effects of adenosine and carbachol by transregulation of inhibitory receptors and Gi proteins. Borst MM, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1672–9
Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Bouma MG, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):C522–9
Apical adenosine activates an amiloride-sensitive conductance in human intestinal cell line HT29cl.19A.

Bouritius H, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C931–6

Adenosine stimulation of DNA synthesis in human endothelial cells. Ethier MF, et al. **Am J Physiol** 1997 Mar; 272(3 Pt 2):H1470–9

Antecedent ischemia reverses effects of adenosine on glycolysis and mechanical function of working hearts. Finegan BA, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H2116–25

Adenosine causes cAMP–dependent activation of chick embryo red cell carbonic anhydrase and 2,3–DPG synthesis. Glombitza S, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R973–81

Adenosine stimulates nitric oxide synthesis in rat cardiac myocytes. Ikeda U, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H59–65

Interaction between adenosine and flow–induced dilation in coronary microvascular network. Liao JC, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1571–81

Integration of vascular, contractile and metabolic responses to hypoxia: effects of maturation and adenosine. Matherne GP, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):R895–905

Adenosine inhibits leukocyte–induced vasoconstriction. Minamino T, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2622–8

Effector mechanism of adenosine in acute ischemic preconditioning of skeletal muscle against infarction. Pang CY, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R887–95

Effects of dipyridamole and adenosine infusions on ovine pulmonary and systemic circulations. Skimming JW, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H921–6

Nonspecific inhibition of adenosine–activated K+ current by glibenclamide in guinea pig atrial myocytes. Song Y, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2430–7

Electrophysiological and functional effects of adenosine on ventricular myocytes of various mammalian species. Song Y, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1233–43

Effect of adenosine on adrenergic neurotransmission and modulation by endothelium in canine pulmonary artery. Tamaoki J, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1100–5

Adenosine exerts a glycogen–sparing action in contracting rat skeletal muscle. Vergauwen L, et al. **Am J Physiol** 1997 May;272(5 Pt 1):E762–8

Intrathecal adenosine analog administration reduces substance P in cerebrospinal fluid along with behavioral effects that suggest antinociception in rats. Sjölund KF, et al. **Anesth Analg** 1997 Sep;85(3):627–32

Comparative effects of hypotension due to isoflurane, nitroglycerin, and adenosine on subendocardial microcirculation: observation of the in situ beating swine heart under critical stenosis. Fujita Y, et al. **Anesthesiology** 1997 Aug;87(2):343–53

Adenosine and K(+)–induced Ca2+ loading [letter; comment] Cheng TO. **Ann Thorac Surg** 1997 Aug; 64(2):588–9. Comment on: Ann Thorac Surg 1997 Jan;63(1):153–61.

Protective effects of adenosine on myocyte contractility during cardioplegic arrest. Cox MH, et al. **Ann Thorac Surg** 1997 Apr;63(4):981–7

Adenosine prevents hyperkalemia–induced calcium loading in cardiac cells: relevance for cardioplegia [see comments] Jovanović A, et al. **Ann Thorac Surg** 1997 Jan;63(1):153–61 . Comment in: Ann Thorac Surg 1997 Aug;64(2):588–9.

A model of anoxic preconditioning in the isolated rat cardiac myocyte. Importance of adenosine and insulin. Cave AC, et al. **Basic Res Cardiol** 1996 May–Jun;91(3):210–8

Adenosine–mediated inhibition of glutathione synthesis in rat isolated hepatocytes. Atmaca M, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1423–8

Role of adenine nucleotides in the activation of microsomal cholesterol ester hydrolase by fructose or adenosine in rat hepatocytes. Hernandez ML, et al. **Biochimie** 1996; 78(1):26–32

Atrioventricular conduction during adenosine–induced hypotension in dogs anaesthetized with sevoflurane. Ishii R, et al. **Br J Anaesth** 1996 Sep;77(3):393–8

Predominant role of A1 adenosine receptors in mediating adenosine induced vasodilatation of rat diaphragmatic arterioles: involvement of nitric oxide and the ATP–dependent K+ channels. Danialou G, et al. **Br J Pharmacol** 1997 Aug;121(7):1355–63

Purinoceptor modulation of noradrenaline release in rat tail artery: tonic modulation mediated by inhibitory P2Y– and facilitatory A2A–purinoceptors. Gonçalves J, et al. **Br J Pharmacol** 1996 Jan;117(1):156–60

Synergistic inhibition of thrombin–induced platelet aggregation by the novel nitric oxide–donor GEA 3175 and adenosine. Grenegård M, et al. **Br J Pharmacol** 1996 Aug;118(8):2140–4

Characterization of adenosine receptors involved in adenosine–induced bronchoconstriction in allergic rabbits. el–Hashim A, et al. **Br J Pharmacol** 1996 Nov;119(6):1262–8

The effects of purine compounds on the isolated aorta of the frog Rana temporaria. Knight GE, et al. **Br J Pharmacol** 1996 Mar;117(5):873–8

Adenosine A2 receptor–induced inhibition of leukotriene B4 synthesis in whole blood ex vivo. Krump E, et al. **Br J Pharmacol** 1996 Apr;117(8):1639–44

Characterization of P1–purinoceptors on rat isolated duodenum longitudinal muscle and muscularis mucosae. Nicholls J, et al. **Br J Pharmacol** 1996 Jan;117(1):170–4

Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurones. Nörenberg W, et al. **Br J Pharmacol** 1997 Sep;122(1):71–80

Adenosine inhibitory effect on enhanced growth of aortic smooth muscle cells from streptozotocin–induced diabetic rats. Parés–Herbuté N, et al. **Br J Pharmacol** 1996 Jun; 118(3):783–9

Activation of multiple sites by adenosine analogues in the rat isolated aorta. Prentice DJ, et al. **Br J Pharmacol** 1996 Jul;118(6):1509–17

Mediation by nitric oxide of the indirect effects of adenosine on calcium current in rabbit heart pacemaker cells. Shimoni Y, et al. **Br J Pharmacol** 1996 Dec;119(7):1463–9

Hypercapnia–induced increases in cerebral blood flow: roles of adenosine, nitric oxide and cortical arousal. Estevez AY, et al. **Brain Res** 1997 May 30;758(1–2):1–8

Adenosine by activating A1 receptors prevents GABAA–mediated actions during hypoxia in the rat hippocampus. Lucchi R, et al. **Brain Res** 1996 Sep 2; 732(1–2):261–6

Adenosine A1–receptor agonist attenuates the light–induced phase shifts and fos expression in vivo and optic nerve stimulation–evoked field potentials in the suprachiasmatic nucleus in vitro. Watanabe A, et al. **Brain Res** 1996 Nov 18;740(1–2):329–36

ATP and adenosine act as a mitogen for osteoblast–like cells (MC3T3–E1). Shimegi S. **Calcif Tissue Int** 1996 Feb; 58(2):109–13

A method to evaluate the response of the coronary circulation of perfused rat heart to adenosine. Harrison GJ, et al. **Can J Physiol Pharmacol** 1996 Feb;74(2):145–9

ATP shortens atrial action potential duration in the dog: role of adenosine, the vagus nerve, and G protein. Pelleg A, et al. **Can J Physiol Pharmacol** 1996 Jan;74(1):15–22

Comparison of hemodynamic and sympathoneural responses to adenosine and lower body negative pressure in man. Rongen GA, et al. **Can J Physiol Pharmacol** 1997 Feb; 75(2):128–34

Cultured dog aortic endothelial cells release vasodilatory products in response to acetylcholine and adenosine. Woodley N, et al. **Can J Physiol Pharmacol** 1996 Aug; 74(8):949–56

Differential antagonism of cardiac actions of adenosine by theophylline. Bertolet BD, et al. **Cardiovasc Res** 1996 Nov; 32(5):839–45

Carbohydrate– and CD18–dependent neutrophil adhesion to cardiac myocytes: effects of adenosine. Bullough DA, et al. **Cardiovasc Res** 1996 Aug;32(2):328–34

Adenosine stimulates nitric oxide synthesis in vascular smooth muscle cells. Ikeda U, et al. **Cardiovasc Res** 1997 Jul;35(1):168–74

Adenosine–induced renal vasoconstriction in man. Marraccini P, et al. **Cardiovasc Res** 1996 Nov;32(5):949–53

Role of nitric oxide, cyclic GMP and superoxide in inhibition by adenosine of calcium current in rabbit atrioventricular nodal cells. Martynyuk AE, et al. **Cardiovasc Res** 1997 May; 34(2):360–7

Pre–conditioning with adenosine leads to concentration–dependent infarct size reduction in the isolated rabbit heart. Woolfson RG, et al. **Cardiovasc Res** 1996 Jan;31(1):148–51

Inhibition of human tumour cell proliferation by analogues of adenosine. Colquhoun A, et al. **Cell Biochem Funct** 1997 Jun;15(2):135–9

Adenosine activates mesangial cell proliferation. MacLaughlin M, et al. **Cell Signal** 1997 Jan;9(1):59–63

New neplanocin analogues. VIII. Synthesis and biological activity of 6'–C–ethyl, –ethenyl, and –ethynyl derivatives of neplanocin A. Shuto S, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1163–8

Phase 1 human trial of adenosine–potassium cardioplegia. Fremes SE, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II370–5

Pharmacological modulation of the human collateral vascular resistance in acute and chronic coronary occlusion assessed by intracoronary blood flow velocity analysis in an angioplasty model. Piek JJ, et al. **Circulation** 1997 Jul 1; 96(1):106–15

Reflexes mediated by cardiac sympathetic afferents during myocardial ischaemia: role of adenosine. Thames MD, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):709–14 (33 ref.)

Adenosine increases interleukin 6 release and decreases tumour necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages. Ritchie PK, et al. **Cytokine** 1997 Mar;9(3):187–98

Electrophysiology of retina and optic nerve: effects of changes in serum glucose and of exogenous adenosine in vitro. Niemeyer G, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;46:141–6 (22 ref.)

Coronary vasodilation without myocardial erection. Simultaneous haemodynamic, echocardiographic and arteriographic findings during adenosine and dipyridamole infusion. Beleslin BD, et al. **Eur Heart J** 1997 Jul; 18(7):1166–74

Mechanisms of adenosine–induced epicardial coronary artery dilatation. Lupi A, et al. **Eur Heart J** 1997 Apr;18(4):614–7

Preserved vasodilator response to adenosine in insulin–dependent diabetes mellitus. Rongen GA, et al. **Eur J Clin Invest** 1996 Mar;26(3):192–8

The affinity of adenosine for the high– and low–affinity states of the human adenosine A1 receptor. Cohen FR, et al. **Eur J Pharmacol** 1996 Aug 1;309(1):111–4

Pharmacological characterization of P2 purinoceptor types in rat locus coeruleus neurons. Fröhlich R, et al. **Eur J Pharmacol** 1996 Nov 21;315(3):255–61

A biphasic response to adenosine in the coronary vasculature of the K(+)–arrested perfused rat heart. Harden FA, et al. **Eur J Pharmacol** 1996 Jun 20;307(1):49–53

Adenosine activates the K+ channel and enhances cytosolic Ca2+ release via a P2Y purinoceptor in hippocampal neurons. Ikeuchi Y, et al. **Eur J Pharmacol** 1996 May 23; 304(1–3):191–9

Cytosolic Ca2+ domain–dependent protective action of adenosine in cardiomyocytes. Jovanovic A, et al. **Eur J Pharmacol** 1996 Feb 29;298(1):63–9

Cardioprotection with a novel adenosine regulating agent mediated by intravascular adenosine. Kurz MA, et al. **Eur J Pharmacol** 1997 Mar 19;322(2–3):211–20

The effects of P2 purinoceptor agonists on the isolated portal vein of the guinea pig. Orre M, et al. **Eur J Pharmacol** 1996 Dec 5;316(2–3):229–36

Analysis of the bronchoconstrictor responses to adenosine receptor agonists in sensitized guinea–pig lungs and trachea. Thorne JR, et al. **Eur J Pharmacol** 1996 Dec 5; 316(2–3):263–71

Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Von Lubitz DK, et al. **Eur J Pharmacol** 1996 Dec 5;316(2–3):171–9

Asymmetrical response of the intraluminal and extraluminal surfaces of the porcine retinal artery to exogenous adenosine. Alder VA, et al. **Exp Eye Res** 1996 Nov; 63(5):557–64

Cardioprotective actions of adenosine and adenosine analogs. Cook MA, et al. **EXS** 1996;76:325–44 (110 ref.)

Effect of adenosine on phorbol myristate acetate induced–reactive oxygen metabolite production in cultured mesangial cells. Nosaka K, et al. **Free Radic Biol Med** 1996; 20(1):151–5

Interplay between milrinone and adenosine in the inhibition of human platelet response. Anfossi G, et al. **Gen Pharmacol** 1996 Oct;27(7):1149–54

Purines and neutrophil leukocytes. Fredholm BB. **Gen Pharmacol** 1997 Mar;28(3):345–50 (100 ref.)

Different roles of endothelium–derived substances on inhibiting platelet aggregation in whole blood. Kurata M, et al. **Gen Pharmacol** 1997 May;28(5):671–3

Effect of African–American race and hypertensive left ventricular hypertrophy on coronary vascular reactivity and endothelial function. Houghton JL, et al. **Hypertension** 1997 Mar;29(3):706–14

Adenosine inhibits superoxide production in rat peritoneal macrophages via elevation of cAMP level. Si QS, et al. **Immunopharmacology** 1997 Apr;36(1):1–7

Effects of adenosine on the functions of circulating polymorphonuclear leukocytes during hyperdynamic endotoxemia. Thiel M, et al. **Infect Immun** 1997 Jun; 65(6):2136–44

Effects of adenosine on guinea pig pulmonary eosinophils. Walker BA. **Inflammation** 1996 Feb;20(1):11–21

Adenosine modulates endothelin–induced bronchoconstriction in guinea pig airway. Kanazawa H, et al. **Int Arch Allergy Immunol** 1997 Jan;112(1):83–7

Neurite outgrowth of striatal neurons in vitro: involvement of purines in the growth–promoting effect of myenteric plexus explants. Höpker VH, et al. **Int J Dev Neurosci** 1996 Jul;14(4):439–51

The influence of adenosine on red blood cell flow cessation in skeletal muscle. Bosman J, et al. **Int J Microcirc Clin Exp** 1996 Mar–Apr;16(2):74–81

KATP channels mediate adenosine–induced hyperemia in retina. Gidday JM, et al. **Invest Ophthalmol Vis Sci** 1996 Dec;37(13):2624–33

Suppressive action of endogenous adenosine on ovine fetal nonshivering thermogenesis. Ball KT, et al. **J Appl Physiol** 1996 Dec;81(6):2393–8

Exogenous infusion of adenosine depresses whole body O2 use in fetal/neonatal sheep. Karimi A, et al. **J Appl Physiol** 1996 Aug;81(2):541–7

Effects of neonatal immunization and repeated allergen exposure on airway responsiveness in the rabbit. Minshall E, et al. **J Appl Physiol** 1996 Jun;80(6):2108–19

Effects of adenosine on pressure–flow relationships in an in vitro model of compartment syndrome. Shrier I, et al. **J Appl Physiol** 1997 Mar;82(3):755–9

Identification of a bacterial inhibitor of protein kinases. Mechanism and role in host cell invasion. Berger SA, et al. **J Biol Chem** 1996 Sep 20;271(38):23431–7

Use of firefly luciferase for ATP measurement: other nucleotides enhance turnover. Ford SR, et al. **J Biolumin Chemilumin** 1996 May–Jun;11(3):149–67

Adenosine–sensitive atrial reentrant tachycardia originating from the atrioventricular nodal transitional area. Iesaka Y, et al. **J Cardiovasc Electrophysiol** 1997 Aug;8(8):854–64

Adenosine–sensitive ventricular tachycardia: a conceptual approach. Lerman BB, et al. **J Cardiovasc Electrophysiol** 1996 Jun;7(6):559–69 (54 ref.)

Hemodynamic response to adenosine infusion before and after coronary artery bypass surgery. Anderson RE, et al. **J Cardiovasc Pharmacol** 1997 Mar;29(3):331–6

Increased responses to adenosine in isolated left atria from

streptozotocin-diabetic rats: evidence for the involvement of hypothyroidism. Gür S, et al.
J Cardiovasc Pharmacol 1997 Feb;29(2):174–9

Impairment of coronary blood flow regulation by endothelium-derived nitric oxide in dogs with alloxan-induced diabetes. Matsunaga T, et al.
J Cardiovasc Pharmacol 1996 Jul;28(1):60–7

Coronary effects of diadenosine tetraphosphate resemble those of adenosine in anesthetized pigs: involvement of ATP-sensitive potassium channels. Nakae I, et al.
J Cardiovasc Pharmacol 1996 Jul;28(1):124–33

Measurement of adenylylcyclase activity in the AV nodal region of the canine heart: evidence for inhibition by adenosine and acetylcholine. Sugiyama A, et al.
J Cardiovasc Pharmacol 1997 Jun;29(6):734–9

Evidence for a role of G protein beta gamma subunits in the enhancement of cAMP accumulation and DNA synthesis by adenosine in human cells. Ahmed AH, et al.
J Cell Physiol 1997 Mar;170(3):263–71

Adenosine inhibits DNA synthesis stimulated with TSH, insulin, and phorbol 12-myristate 13-acetate in rat thyroid FRTL-5 cells. Vainio M, et al. **J Cell Physiol** 1997 Jun; 171(3):336–42

Purinergic agonists stimulate the secretion of endothelin-1 in rat thyroid FRTL-5 cells. Vainio M, et al.
J Cell Physiol 1996 Dec;169(3):538–43

Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. Ciaraldi TP, et al.
J Clin Endocrinol Metab 1997 May;82(5):1421–5

Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptor. Apasov SG, et al. **J Immunol** 1997 Jun 1;158(11):5095–105

Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors. Bouma MG, et al. **J Immunol** 1997 Jun 1; 158(11):5400–8

Effect of adenosine and intracellular GTP on KATP channels of mammalian skeletal muscle. Barrett-Jolley R, et al.
J Membr Biol 1996 Jul;152(2):111–6

Adenosine slows the rate of K(+)-induced membrane depolarization in ventricular cardiomyocytes: possible implication in hyperkalemic cardioplegia. Alekseev AE, et al. **J Mol Cell Cardiol** 1996 Jun;28(6):1193–202

Adenosine preconditioning of human myocardium is dependent upon the ATP-sensitive K+ channel. Cleveland JC Jr, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):175–82

Use of the MTT assay in adult ventricular cardiomyocytes to assess viability: effects of adenosine and potassium on cellular survival. Gomez LA, et al. **J Mol Cell Cardiol** 1997 Apr;29(4):1255–66

Concentration-response relationships for adenosine agonists during preconditioning of rabbit cardiomyocytes. Rice PJ, et al. **J Mol Cell Cardiol** 1996 Jun;28(6):1355–65

Inosine mediates the protective effect of adenosine in rat astrocyte cultures subjected to combined glucose-oxygen deprivation. Haun SE, et al. **J Neurochem** 1996 Nov; 67(5):2051–9

Stimulation of interleukin-6 secretion and gene transcription in primary astrocytes by adenosine. Schwaninger M, et al.
J Neurochem 1997 Sep;69(3):1145–50

Adenosine inhibits L- and N-type calcium channels in pituitary melanotrophs. Evidence for the involvement of a G protein in calcium channel gating. Mei YA, et al.
J Neuroendocrinol 1996 Feb;8(2):85–91

Endogenous adenosine mediates the presynaptic inhibition induced by aglycemia at corticostriatal synapses. Calabresi P, et al. **J Neurosci** 1997 Jun 15;17(12):4509–16

Effects of oxyhemoglobin on local and propagated vasodilatory responses induced by adenosine, adenosine diphosphate, and adenosine triphosphate in rat cerebral arterioles. Kajita Y, et al. **J Neurosurg** 1996 Nov; 85(5):908–16

Adenosine coronary vasodilation in coronary artery disease: technetium-99m tetrofosmin myocardial tomography versus echocardiography. Cuocolo A, et al.
J Nucl Med 1997 Jul;38(7):1089–94

Effects of adenosine on NANC bronchoconstriction in anaesthetized guinea-pigs. Nieri P, et al.
J Pharm Pharmacol 1996 Apr;48(4):422–8

Modulation by adenosine of GABA-activated current in rat dorsal root ganglion neurons. Hu HZ, et al.
J Physiol (Lond) 1997 May 15;501 (Pt 1):67–75

The behaviour of muscle microcirculation in chronically hypoxic rats: the role of adenosine. Mian R, et al.
J Physiol (Lond) 1996 Mar 1;491 (Pt 2):489–98

Activation of A2-purinoceptors by adenosine stimulates L-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells. Sobrevia L, et al.
J Physiol (Lond) 1997 Feb 15;499 (Pt 1):135–40

A case of adenosine-sensitive ventricular tachycardia in a very elderly male. Betsuyaku T, et al. **Jpn Circ J** 1996 Nov;60(11):901–7

Adenosine and its receptor agonists potentiate nitric oxide synthase expression induced by lipopolysaccharide in RAW 264.7 murine macrophages. Hon WM, et al. **Life Sci** 1997; 60(16):1327–35

Epidermal growth factor protects GH3 cells from adenosine induced growth arrest. Lewis MD, et al.
Mol Cell Endocrinol 1997 Mar 28;127(2):137–42

Adenosine modulation of neurotransmission in human uterine arteries. Tsai EM, et al. **Mol Hum Reprod** 1996 Feb; 2(2):105–9

Adenosine A2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leucocytes. Fredholm BB, et al.
Naunyn Schmiedebergs Arch Pharmacol 1996 Aug–Sep; 354(3):262–7

Crosstalk between thrombin and adenylyl cyclase-stimulating agonists in proliferating human erythroid progenitor cells. Porzig H, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec;353(1):21–7

Effects of adenosine and adenosine analogues on mean circulatory filling pressure and cardiac output in anesthetized rats. Tabrizchi R.
Naunyn Schmiedebergs Arch Pharmacol 1997 Jul; 356(1):69–75

Adenosine-induced release of nitric oxide from cortical astrocytes. Janigro D, et al. **Neuroreport** 1996 Jul 8; 7(10):1640–4

Intrathecal and systemic R-phenylisopropyl-adenosine reduces scratching behaviour in a rat mononeuropathy model. Sjölund KF, et al. **Neuroreport** 1996 Jul 29; 7(11):1856–60

Neuroprotective effects of adenosine in cerebral ischemia: window of opportunity. Sweeney MI.
Neurosci Biobehav Rev 1997 Mar;21(2):207–17 (132 ref.)

A role for adenosine in the regulation of long-term depression in the adult rat hippocampus in vitro. Kemp N, et al. **Neurosci Lett** 1997 Apr 11;225(3):189–92

Programmed cell death in rat microglia is controlled by extracellular adenosine. Ogata T, et al. **Neurosci Lett** 1996 Nov 1;218(2):91–4

Anoxic preconditioning in hippocampal slices: role of adenosine. Pérez-Pinzón MA, et al. **Neuroscience** 1996 Dec; 75(3):687–94

Role of adenosine in behavioral state modulation: a microdialysis study in the freely moving cat. Portas CM, et al. **Neuroscience** 1997 Jul;79(1):225–35

Acute adenosine treatment is effective in augmentation of ischemic tolerance in muscle flaps in the pig. Forrest CR, et al. **Plast Reconstr Surg** 1997 Jan;99(1):172–82

Purinergic regulation of acetylcholine release. Ribeiro JA, et al. **Prog Brain Res** 1996;109:231–41 (41 ref.)

Magnesium ion augmentation of inhibitory effects of adenosine on dopamine release in the rat striatum. Okada M, et al. **Psychiatry Clin Neurosci** 1996 Jun;50(3):147–56

Endogenous adenosine curtails
lipopolysaccharide-stimulated tumour necrosis factor synthesis. Eigler A, et al. **Scand J Immunol** 1997 Feb; 45(2):132–9

Excitatory actions of adenosine on ventricular automaticity. Hernández J, et al. **Trends Pharmacol Sci** 1996 Apr; 17(4):141–4 (39 ref.)

Adenosine in the mammalian heart: nothing to get excited about. Pelleg A, et al. **Trends Pharmacol Sci** 1997 Jul; 18(7):236–8 (23 ref.)

Impairment of adenosine-induced dilation of forearm resistance arteries in patients with arterial hypertension. Preik M, et al. **Vasa** 1997 May;26(2):70–5

[Anomalous reaction to adenosine of lymphocytes from patients with atopic bronchial asthma. Is it a link in pathogenesis or a compensatory reaction?] Poriadin GV, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):474–7 **(Rus)**

[The effect of adenosine receptor agonists on the normal cerebral blood flow and in subsequent ischemia] Kulinskiĭ VI, et al. **Eksp Klin Farmakol** 1996 May–Jun;59(3):37–9 (Eng. Abstr.) **(Rus)**

[The protective action of adenosine in the development of the "calcium paradox" in the isolated heart] Alabovskiĭ VV, et al. **Fiziol Zh** 1997;43(3–4):48–53 (Eng. Abstr.) **(Rus)**

[4-branched nucleosides. I. Molecular structure of conformationally limited nucleoside
analogs--4'-oxymethyl-2',3'-anhydroiboadnosine and 2',3'-anhydrolyxocytidine. Synthesis and antiviral activity] Gurskaia GV, et al. **Mol Biol (Mosk)** 1996 Jul–Aug; 30(4):911–20 **(Rus)**

[Effect of adenosine on glycolysis of cultured cardiac myocytes of newborn rats] Diaz A, et al.
Arch Inst Cardiol Mex 1996 May–Jun;66(3):202–9 **(Eng. Abstr.)** **(Spa)**

PHYSIOLOGY

Role of adenosine as a modulator of synaptic activity in the central nervous system. Brundege JM, et al.
Adv Pharmacol 1997;39:353–91 (200 ref.)

Autonomic neural control of cardiac function: modulation by adenosine and adenosine 5'-triphosphate. Pelleg A, et al. **Am J Cardiol** 1997 Jun 19;79(12A):11–4 (72 ref.)

Extracellular ATP and adenosine cause apoptosis of pulmonary artery endothelial cells. Dawicki DD, et al.
Am J Physiol 1997 Aug;273(2 Pt 1):L485–94

Cardiac contractile function during coronary stenosis in dogs: association of adenosine in glycolytic dependence. Fang HK, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2195–203

Participation of adenosine in the renal hemodynamic abnormalities of hypothyroidism. Franco M, et al.
Am J Physiol 1996 Feb;270(2 Pt 2):F254–62

Impact of aging on adenosine levels, A1/A2 responses, arrhythmogenesis, and energy metabolism in rat heart. Headrick JP. **Am J Physiol** 1996 Mar;270(3 Pt 2):H897–906

Basal and adenosine-mediated protein flux from isolated coronary arterioles. Huxley VH, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1099–108

Arteriolar constriction in skeletal muscle during vascular stunning: role of mast cells. Keller MW. **Am J Physiol** 1997 May;272(5 Pt 2):H2154–63

Effects of adenosine and protein kinase C stimulation on mechanical properties of rat cardiac myocytes. Lester JW, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1778–85

Role of adenosine in regulation of coronary flow in dogs with inhibited synthesis of endothelium-derived nitric oxide. Matsunaga T, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):H427–34

Endogenous adenosine inhibits evoked substance P release from perifused networks of myenteric ganglia. Moneta NA, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):G38–45

A role for adenosine in metabolic depression in the marine invertebrate Sipunculus nudus. Reipschläger A, et al.
Am J Physiol 1997 Jan;272(1 Pt 2):R350–6

A source of adenosine involved in cardiovascular responses to defense area stimulation. St Lambert JH, et al.
Am J Physiol 1997 Jan;272(1 Pt 2):R195–200

K+ATP channels and adenosine are not necessary for coronary autoregulation. Stepp DW, et al.
Am J Physiol 1997 Sep;273(3 Pt 2):H1299–308

Role of adenosine in norepinephrine-induced coronary vasodilation. Van Bibber R, et al. **Am J Physiol** 1997 Aug; 273(2 Pt 2):H557–65

KATP channels and memory of ischemic preconditioning in dogs: synergism between adenosine and KATP channels. Yao Z, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H334–42

The effect of N6-cyclohexyladenosine and 5'-(N-cyclopropyl)- carboxamidoadenosine on pyrogen fever in rabbits. Gagalo IT, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:353–9

Adenosine acts through a novel extracellular receptor to inhibit granule exocytosis by natural killer cells. Williams BA, et al. **Biochem Biophys Res Commun** 1997 Feb 13; 231(2):264–9

Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Huang S, et al. **Blood** 1997 Aug 15;90(4):1600–10

Erythropoietin production in healthy volunteers subjected to controlled hypobaric hypoxia: further evidence against a role for adenosine. Gleiter CH, et al.
Br J Clin Pharmacol 1997 Aug;44(2):203–5

Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides. Cunha RA, et al. **Br J Pharmacol** 1996 Sep;119(2):253–60

Endogenous adenosine mediates the sustained inhibition of excitatory synaptic transmission during moderate hypoxia. Arlinghaus L, et al. **Brain Res** 1996 Jun 17;724(2):265–8

Endogenous adenosine facilitates neurotransmission via A2A adenosine receptors in the rat superior colliculus in vivo. Ishikawa S, et al. **Brain Res** 1997 May 23;757(2):268–75

Role of adenosine in the heart and circulation [see comments] Mubagwa K, et al. **Cardiovasc Res** 1996 Nov;32(5):797–813 (191 ref.). Comment in: Cardiovasc Res 1997 Jun;34(3):603–5.

Pulse pressure-related changes in coronary flow in vivo are modulated by nitric oxide and adenosine. Recchia FA, et al. **Circ Res** 1996 Oct;79(4):849–56

Modulation of atrioventricular nodal function by metabolic and allosteric regulators of endogenous adenosine in guinea pig heart. Dennis DM, et al. **Circulation** 1996 Nov 15; 94(10):2551–9

Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart [see comments] Kitakaze M, et al. **Circulation** 1997 Apr 15;95(8):2108–14. Comment in: Circulation 1997 Apr 15;95(8):1989–91.

Adenosine and the nervous system: clinical implications. Guieu R, et al. **Clin Neuropharmacol** 1996 Dec;19(6):459–74 (208 ref.)

Adrenergic activation confers cardioprotection mediated by adenosine, but is not required for ischemic preconditioning. Haessler R, et al. **Coron Artery Dis** 1996 Apr;7(4):305–14

The action of ATP on the hepatic arterial and portal venous vascular networks of the rabbit liver: the role of adenosine. Browse DJ, et al. **Eur J Pharmacol** 1997 Feb 12; 320(2-3):139–44

Role of adenosine in the ethanol-induced potentiation of the effects of general anesthetics in rats. Campisi P, et al.
Eur J Pharmacol 1997 May 1;325(2-3):165–72

The contribution of adenosine to paired-pulse inhibition in the normal and disinhibited hippocampal slice. Higgins MJ, et al. **Eur J Pharmacol** 1996 Dec 19;317(2-3):215–23

Altered sensory behaviors in mice following manipulation of endogenous spinal adenosine neurotransmission. Keil GJ 2nd, et al. **Eur J Pharmacol** 1996 Sep 19;312(1):7–14

The effect of dipyridamole and theophylline on hypercapnic ventilatory responses: the role of adenosine. Griffiths TL, et al. **Eur Respir J** 1997 Jan;10(1):156–60

Roles of purine nucleotides and adenosine in enhancing NOS II gene expression in interleukin-1 beta-stimulated rat vascular smooth muscle cells. Seo HG, et al.
Free Radic Res 1997 May;26(5):409–18

Mast cell adenosine induced calcium mobilization via Gi3 and Gq proteins. Hoffman HM, et al. **Inflammation** 1997 Feb;21(1):55–68

Involvement of adenosine in retinal ischemia. Studies on the rat. Larsen AK, et al. **Invest Ophthalmol Vis Sci** 1996 Dec; 37(13):2603–11

ADENOSINE

Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Takagi H, et al. **Invest Ophthalmol Vis Sci** 1996 Oct;37(11):2165–76

Role of adenosine in pathogenesis of syndrome X: assessment with coronary hemodynamic measurements and thallium-201 myocardial single-photon emission computed tomography. Inobe Y, et al. **J Am Coll Cardiol** 1996 Oct; 28(4):890–6

Isolated defect of adenosine-mediated coronary vasodilation: functional evidence for a new microangiopathic entity. Koglin J, et al. **J Am Coll Cardiol** 1997 Jul;30(1):103–7

cAMP production in rabbit carotid body: role of adenosine. Chen J, et al. **J Appl Physiol** 1997 Jun;82(6):1771–5

Role of adenosine in tubuloglomerular feedback and acute renal failure. Osswald H, et al. **J Auton Pharmacol** 1996 Dec;16(6):377–80 (34 ref.)

Purinergic modulation of neural control of cardiac function. Pelleg A, et al. **J Auton Pharmacol** 1996 Dec;16(6):401–5 (56 ref.)

Interactions of adenosine with sympathetic neurotransmission: protective effect in myocardial ischemia. Richardt G, et al. **J Auton Pharmacol** 1996 Dec; 16(6):333–5 (18 ref.)

Role of nitric oxide, cyclic nucleotides, and the activation of ATP-sensitive K+ channels in the contribution of adenosine to hypoxia-induced pial artery dilation. Armstead WM. **J Cereb Blood Flow Metab** 1997 Jan; 17(1):100–8

Role for adenosine in channel arrest in the anoxic turtle brain. Pék M, et al. **J Exp Biol** 1997 Jul;200 (Pt 13):1913–7

Ischemic preconditioning: bioenergetic and metabolic changes and the role of endogenous adenosine. Headrick JP. **J Mol Cell Cardiol** 1996 Jun;28(6):1227–40

Adenosine modulation of calcium currents and presynaptic inhibition of GABA release in suprachiasmatic and arcuate nucleus neurons. Chen G, et al. **J Neurophysiol** 1997 Jun; 77(6):3035–47

Modulation of excitatory synaptic transmission by adenosine released from single hippocampal pyramidal neurons. Brundege JM, et al. **J Neurosci** 1996 Sep 15;16(18):5603–12

Endogenous adenosine mediates the presynaptic inhibition induced by aglycemia at corticostriatal synapses. Calabresi P, et al. **J Neurosci** 1997 Jun 15;17(12):4509–16

Dopamine-adenosine interactions in the striatum and the globus pallidus: inhibition of striatopallidal neurons through either D2 or A2A receptors enhances D1 receptor-mediated effects on c-fos expression. Le Moine C, et al. **J Neurosci** 1997 Oct 15;17(20):8038–48

Postnatal development of the pattern of respiratory and cardiovascular response to systemic hypoxia in the piglet: the roles of adenosine. Elnazir B, et al. **J Physiol (Lond)** 1996 Apr 15;492 (Pt 2):573–85

Studies on the roles of ATP, adenosine and nitric oxide in mediating muscle vasodilatation induced in the rat by acute systemic hypoxia. Skinner MR, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):553–60

The roles of adenosine in regulating the respiratory and cardiovascular systems in chronically hypoxic, adult rats. Thomas T, et al. **J Physiol (Lond)** 1997 Jun 1;501 (Pt 2):439–47

Differential effects of adenosine preconditioning on the postischemic rat myocardium. Meldrum DR, et al. **J Surg Res** 1996 Oct;65(2):159–64

Roles of nitric oxide and adenosine in the regulation of coronary conductance in the basal state and during reactive hyperemia. Otomo J, et al. **Jpn Circ J** 1997 May;61(5):441–9

Adenosine and neuronal plasticity. de Mendonça A, et al. **Life Sci** 1997;60(4–5):245–51 (52 ref.)

Acute effects of progesterone on glucose metabolism in rat adipocytes: are they modulated by endogenous adenosine? Sutter-Dub MT, et al. **Metabolism** 1997 Jun;46(6):595–604

Modulation of glial cell signaling by adenosine and pharmacological reinforcement. A neuroprotective strategy? Schubert P, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):185–90 (19 ref.)

Polarization of adenosine effects on intracellular pH in A6 renal epithelial cells. Casavola V, et al. **Mol Pharmacol** 1997 Mar;51(3):516–23

Adenosine receptors. Knockouts anxious for new therapy [news; comment] Snyder SH. **Nature** 1997 Aug 14; 388(6643):624. Comment on: Nature 1997 Aug 14;388(6643):674–8.

Kainate receptors are involved in the glutamate-induced indirect, purinergic inhibition of [3H]-noradrenaline release in rabbit brain cortex. von Kugelgen I, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec; 353(1):46–54

In vivo amino acid release from the striatum of aging rats: adenosine modulation. Corsi C, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):243–50

Endogenous adenosine attenuates long-term depression and depotentiation in the CA1 region of the rat hippocampus. de Mendonça A, et al. **Neuropharmacology** 1997 Feb; 36(2):161–7

Endogenous adenosine on membrane properties of CA1 neurons in rat hippocampal slices during normoxia and hypoxia. Zhu PJ, et al. **Neuropharmacology** 1997 Feb; 36(2):169–76

Adenosine depresses transmitter release but is not the basis for 'tetanic fade' at the neuromuscular junction of the rat. Malinowski MN, et al. **Neurosci Lett** 1997 Jul 18; 230(2):81–4

Adenosine uptake and deamination regulate tonic A2a receptor facilitation of evoked [3H]acetylcholine release from the rat motor nerve terminals. Correia-de-Sá P, et al. **Neuroscience** 1996 Jul;73(1):85–92

Adenosinic modulation of 7–14 Hz spindle rhythms in interconnected thalamic relay and nucleus reticularis neurons. Wallenstein GV. **Neuroscience** 1996 Jul;73(1):93–8

Adenosine modulates inspiratory neurons and the respiratory pattern in the brainstem of neonatal rats. Herlenius E, et al. **Pediatr Res** 1997 Jul;42(1):46–53

Adenosine physiology and pharmacology: how about A2 receptors? Daval JL, et al. **Pharmacol Ther** 1996; 71(3):325–35 (117 ref.)

Purinergic regulation of acetylcholine release. Ribeiro JA, et al. **Prog Brain Res** 1996;109:231–41 (41 ref.)

Role of adenosine in blood flow in the rat intestine. Obata T, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jun; 92(3):369–72

Role of adenosine and nitric oxide in the hyperemic response to superficial and deep gastric mucosal injury and H+ back-diffusion in cats. Gislason H, et al. **Scand J Gastroenterol** 1996 Jan;31(1):14–23

Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Porkka-Heiskanen T, et al. **Science** 1997 May 23;276(5316):1265–8

Modulation of venous endothelial activity and transcellular calcium transport by defibrotide: the adenosine hypothesis. Pasini FL, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:15–20 (43 ref.)

Evidence that adenosine contributes to maintenance of hepatosplanchnic blood flow during peritoneal sepsis in rats. Motew SJ, et al. **Shock** 1997 Jun;7(6):439–46

Cytosolic phospholipase A2 induction after global ischemia: don't forget the role of adenosine [letter; comment] Di Napoli MP, et al. **Stroke** 1996 Sep;27(9):1698–700. Comment on: Stroke 1996 Mar;27(3):527–35.

Effect of endogenous adenosine augmentation on ischemia and reperfusion injury to the liver. Zhang S, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):1336–7

Attenuation of ischemic liver injury by augmentation of endogenous adenosine. Todo S, et al. **Transplantation** 1997 Jan 27;63(2):217–23

[Interaction of adenosine with leukocytes and thrombocytes] Becker BF, et al. **Z Kardiol** 1996;85 Suppl 6:161–70 (Eng. Abstr.) **(Ger)**

[The role of adenosine in "ischemic preconditioning"] Schaper W, et al. **Z Kardiol** 1996;85 Suppl 6:185–90 (34 ref.) (Eng. Abstr.) **(Ger)**

[Regulation of coronary circulation by adenosine] Schrader J, et al. **Z Kardiol** 1996;85 Suppl 6:153–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Hibernating myocardium: no involvement of endogenous adenosine] Schulz R, et al. **Z Kardiol** 1996;85 Suppl 6:177–84 (38 ref.) (Eng. Abstr.) **(Ger)**

[Interactions of adenosine with sympathetic neurotransmission in the heart] Ungerer M, et al. **Z Kardiol** 1996;85 Suppl 6:171–5 (33 ref.) (Eng. Abstr.) **(Ger)**

SECRETION

Synergy between mu/delta-opioid receptors mediates adenosine release from spinal cord synaptosomes. Cahill CM, et al. **Eur J Pharmacol** 1996 Feb 29;298(1):45–9

Release of adenosine from human sensitized lung fragments and its effect on antigen-induced mediator release. Konnaris K, et al. **Pulm Pharmacol** 1996 Jun;9(3):141–8

THERAPEUTIC USE

Treatment of out-of-hospital supraventricular tachycardia: adenosine vs verapamil [see comments] Brady WJ Jr, et al. **Acad Emerg Med** 1996 Jun;3(6):574–85. Comment in: Acad Emerg Med 1996 Jun;3(6):564–6.

Adenosine for pain control. Sollevi A. **Acta Anaesthesiol Scand Suppl** 1997;110:135–6 (14 ref.)

Pharmacologic approaches to reperfusion injury. Willerson JT. **Adv Pharmacol** 1997;39:291–312 (120 ref.)

Adenosine for myocardial protection in acute myocardial infarction. Granger CB. **Am J Cardiol** 1997 Jun 19; 79(12A):44–8 (55 ref.)

Adenosine as an antiarrhythmic agent. Wilbur SL, et al. **Am J Cardiol** 1997 Jun 19;79(12A):30–7 (69 ref.)

Adenosine for the treatment of paroxysmal supraventricular tachycardia in full-term and preterm newborn infants. Paret G, et al. **Am J Perinatol** 1996 Aug;13(6):343–6

Adenosine in wide-complex tachycardia. Herbert ME, et al. **Ann Emerg Med** 1997 Jan;29(1):172–4 (15 ref.)

Intravascular adenosine at reperfusion reduces infarct size and neutrophil adherence. Todd J, et al. **Ann Thorac Surg** 1996 Nov;62(5):1364–72

Modulation of neuronal and glial cell function by adenosine and neuroprotection in vascular dementia. Rudolphi KA, et al. **Behav Brain Res** 1997 Feb;83(1–2):123–8 (27 ref.)

Adenosine therapy at reperfusion on myocardial infarct size [letter; comment] Forman MB, et al. **Cardiovasc Res** 1997 Feb;33(2):497–500. Comment on: Cardiovasc Res 1996 May;31(5):711–8.

Adenosine in treating cardiac arrhythmias. Zehender M, et al. **J Auton Pharmacol** 1996 Dec;16(6):329–31

Effect of adenosine on ventricular parasystole. Tomcsányi J, et al. **J Electrocardiol** 1996 Jan;29(1):61–3

Exogenous adenosine, supplied transiently during reperfusion, ameliorates depressed endogenous adenosine production in the post-ischemic rat heart. Smolenski RT, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):333–46

Adenosine for reversal of hemorrhagic shock in rabbits. Abdel-Zaher AO, et al. **Jpn J Pharmacol** 1996 Nov; 72(3):247–54

Analgesic effects of adenosine during exercise-provoked myocardial ischaemia. Sylvén C, et al. **Neuroreport** 1996 Jun 17;7(9):1521–5

Adenosine and neuropathic pain. Guieu R, et al. **Pain** 1996 Dec;68(2–3):271–4

Adenosine: an effective and safe antiarrhythmic drug in pediatrics. Paul T, et al. **Pediatr Cardiol** 1997 Mar-Apr; 18(2):118–26 (82 ref.)

Influence of adenosinergic drugs on ethanol withdrawal syndrome in rats. Malec D, et al. **Pol J Pharmacol** 1996 Nov-Dec;48(6):583–8

Effect of adenosine infusion on oxygen induced carbon dioxide retention in severe chronic obstructive pulmonary disease. Griffiths TL, et al. **Thorax** 1996 Nov;51(11):1083–6

[Adenosin: an anti-arrhythmia agent with therapeutic and diagnostic potential] **Z Kardiol** 1995 Mar;84(3 Suppl):1–8 **(Ger)**

[Adenosine-sensitive atrial tachycardia] Tomcsányi J, et al. **Orv Hetil** 1996 Jul 14;137(28):1535–7 (Eng. Abstr.) **(Hun)**

[The effect of adenosine receptor agonists on the normal cerebral blood flow and in subsequent ischemia] Kulinskiĭ VI, et al. **Eksp Klin Farmakol** 1996 May-Jun;59(3):37–9 (Eng. Abstr.) **(Rus)**

[Treatment with adenosine for supraventricular paroxysmal tachycardia during pregnancy (letter; comment)] Varela Aguilar JM, et al. **Med Clin (Barc)** 1997 Jun 21;109(4):159 . Comment on: Med Clin (Barc) 1996 Jun 1;107(1):29–36. **(Spa)**

URINE

Urinary adenosine excretion in patients receiving amphotericin B. Carlson MA, et al. **Surgery** 1997 Feb; 121(2):190–3

ADENOSINE AMINOHYDROLASE see **ADENOSINE DEAMINASE**

ADENOSINE CYCLIC MONOPHOSPHATE-DEPENDENT PROTEIN KINASES see **CYCLIC AMP-DEPENDENT PROTEIN KINASES**

ADENOSINE CYCLIC 3',5'-MONOPHOSPHATE see **CYCLIC AMP**

ADENOSINE DEAMINASE

ADMINISTRATION & DOSAGE

The entrapment of polyethylene glycol-bound adenosine deaminase (Pegademase) in human carrier erythrocytes. Bax BE, et al. **Biochem Soc Trans** 1996 Aug;24(3):442S

ANALYSIS

The low cost of the adenosine deaminase assay [letter; comment] Gakis C. **Chest** 1996 Nov;110(5):1376–7. Comment on: Chest 1995 Dec;108(6):1766.

Adenosine deaminase in pleural effusions [letter; comment] Ungerer JP, et al. **Clin Chem** 1996 Nov;42(11):1880. Comment on: Clin Chem 1996 Feb;42(2):218–21.

Determination of the kinetic parameters of adenosine deaminase by electrophoretically mediated microanalysis. Saevels J, et al. **Electrophoresis** 1996 Jul;17(7):1222–7

Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy. Valdés L, et al. **Eur Respir J** 1996 Apr;9(4):747–51

Tuberculous peritonitis: can ADA keep the laparoscope away? Harlan WR 3rd, et al. **Gastroenterology** 1997 Aug; 113(2):687–9

Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States. Hillebrand DJ, et al. **Hepatology** 1996 Dec;24(6):1408–12

New scoring system using tumor markers in diagnosing patients with moderate pericardial effusions. Koh KK, et al. **Int J Cardiol** 1997 Aug 29;61(1):5–13

Case 25-1996: tuberculous pleuritis [letter; comment] Montero E, et al. **N Engl J Med** 1997 Jan 23;336(4):297; discussion 297–8. Comment on: N Engl J Med 1996 Aug 15;335(7):499–505.

Adenosine deaminase in rodent median eminence: detection by antibody to the mouse enzyme and co-localization with adenosine deaminase-complexing protein (CD26). Nagy JI, et al. **Neuroscience** 1996 Jul;73(2):459–71

[False negatives of ADA in pleural tuberculosis (letter; comment)] Echave-Sustaeta J, et al. **An Med Interna** 1996 Nov;13(11):562. Comment on: An Med Interna 1996 Mar;13(3):149–50. **(Spa)**

[Comparative study of soluble interleukin 2 receptor and adenosine deaminase levels in tuberculous and other etiologies pleural fluids] Avilés Inglés MJ, et al. **Arch Bronconeumol** 1996 Dec;32(10):523–6 (Eng. Abstr.) **(Spa)**

[Analysis of 90 cases of pleural tuberculosis in relation to adenosine deaminase levels] Haro M, et al. **Med Clin (Barc)** 1997 Mar 29;108(12):452–4 (Eng. Abstr.) **(Spa)**

ANTAGONISTS & INHIBITORS

2-Chlorodeoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukaemia [letter] Warzocha K, et al. **Eur J Cancer** 1997 Jan;33(1):170–3

Potentiation of excitatory amino acid-evoked adenosine release from rat cortex by inhibitors of adenosine kinase and adenosine deaminase and by acadesine. White TD. **Eur J Pharmacol** 1996 May 6;303(1–2):27–38

An adenosine deaminase inhibitor prevents puromycin aminonucleoside nephrotoxicity. Nosaka K, et al. **Free Radic Biol Med** 1997;22(4):597–605

Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. Greiner D, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):950–5

Effects of an inhibitor of adenosine deaminase, deoxycoformycin, and of nucleoside transport, propentofylline, on post-ischemic recovery of adenine nucleotides in rat brain. Phillis JW, et al. **Neurochem Res** 1996 Mar;21(3):347–53

BIOSYNTHESIS

Increased plasma adenosine deaminase activity in the early phase of Legionella pneumophila infection in guinea pigs. Nikaido Y, et al. **FEMS Immunol Med Microbiol** 1996 May; 14(1):39–43

Two forms of human double-stranded RNA-specific editase 1 (hRED1) generated by the insertion of an Alu cassette. Gerber A, et al. **RNA** 1997 May;3(5):453–63

BLOOD

Adenosine deaminase isoenzymes in typhoid fever. Ungerer JP, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jun; 15(6):510–2

Serum erythrocyte and leukocyte adenosine deaminase activities in patients with vivax malaria in Turkey. Ozcan E, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):445–54

Injured erythrocytes release adenosine deaminase into the circulation. Jackson EK, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1250–60

Adenosine deaminase activity in nephrotic syndrome. Mishra OP, et al. **J Trop Pediatr** 1997 Feb;43(1):33–7

Adenosine deaminase in childhood malignancy: should there be a second look? [editorial; comment] Blatt J. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):301–3 (8 ref.) . Comment on: Pediatr Hematol Oncol 1996 Jul–Aug;13(4):339–47.

Prognostic significance of adenosine deaminase in children with malignancies [see comments] Hatzistilianou M, et al. **Pediatr Hematol Oncol** 1996 Jul–Aug;13(4):339–47. Comment in: Pediatr Hematol Oncol 1996 Jul–Aug;13(4):301–3.

Activity of adenosine deaminase in red blood cells of patients suffering from multiple sclerosis treated with adrenocorticotropic hormone. Kopff M, et al. **Pol J Pharmacol** 1995 Nov–Dec;47(6):525–30

Adenosine deaminase activity in the aetiological diagnosis of community-acquired pneumonia. Molinos L, et al. **Scand J Infect Dis** 1997;29(3):287–90

[Relationship between the activity of serum adenosine deaminase including its isozymes and lymphocyte subpopulation in patients with pulmonary tuberculosis] Ishii S, et al. **Kekkaku** 1997 Mar;72(3):153–9 (Eng. Abstr.) **(Jpn)**

[Hemolytic anemia due to abnormalities in erythrocyte nucleotide metabolism] Masuda M, et al. **Nippon Rinsho** 1996 Sep;54(9):2473–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

CEREBROSPINAL FLUID

[Adenosine deaminase in the cerebrospinal fluid of patients with acquired immunodeficiency syndrome] Machado LD, et al. **Arq Neuropsiquiatr** 1995 Dec;53(4):755–9 (Eng. Abstr.) **(Por)**

[Usefulness of adenosine deaminase determination in cerebrospinal fluid for the diagnosis of meningeal tuberculosis: 4 years experience at a public hospital] Baró M, et al. **Rev Med Chil** 1996 Mar;124(3):319–26 (Eng. Abstr.) **(Spa)**

CHEMISTRY

How important is the N-3 sugar moiety in the tight-binding interaction of coformycin with adenosine deaminase? Hosmane RS, et al. **Biochem Biophys Res Commun** 1997 Jul 9;236(1):88–93

New neplanocin analogues. IX. A practical preparation of (6'R)-6'-C-methylneplanocin A (RMNPA), a potent antiviral agent, and the determination of its 6'-configuration. Diastereoselective deamination by adenosine deaminase. Shuto S, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan;45(1):138–42

RED2, a brain-specific member of the RNA-specific adenosine deaminase family. Melcher T, et al. **J Biol Chem** 1996 Dec 13;271(50):31795–8

Primary structure of bovine adenosine deaminase. Kelly MA, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1513–9

A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase. Herbert A, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8421–6

The role of divalent cations in structure and function of murine adenosine deaminase. Cooper BF, et al. **Protein Sci** 1997 May;6(5):1031–7

CLASSIFICATION

A standardized nomenclature for adenosine deaminases that act on RNA [letter] Bass BL, et al. **RNA** 1997 Sep; 3(9):947–9

DEFICIENCY

Adenosine deaminase deficiency in adults. Ozsahin H, et al. **Blood** 1997 Apr 15;89(8):2849–55

Generation of normal lymphocyte populations following transplantation of adenosine-deaminase-deficient fetal liver cells. Migchielsen AA, et al. **Bone Marrow Transplant** 1997 Jun;19(11):1137–43

Sensorineural deafness in siblings with adenosine deaminase deficiency. Tanaka C, et al. **Brain Dev** 1996 Jul–Aug; 18(4):304–6

Keratinocyte gene therapy for adenosine deaminase deficiency: a model approach for inherited metabolic disorders. Fenjves ES, et al. **Hum Gene Ther** 1997 May 20;8(8):911–7

Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector. Mullen CA, et al. **Hum Gene Ther** 1996 Jun 10;7(9):1123–9

Two newly identified mutations (Thr233Ile and Leu152Met) in partially adenosine deaminase-deficient (ADA-) individuals that result in differing biochemical and metabolic phenotypes. Hirschhorn R, et al. **Hum Genet** 1997 Jul;100(1):22–9

SCID: the role of adenosine deaminase deficiency. Resta R, et al. **Immunol Today** 1997 Aug;18(8):371–4 (25 ref.)

Insights into thymic purine metabolism and adenosine deaminase deficiency revealed by transgenic mice overexpressing ecto-5'-nucleotidase (CD73). Resta R, et al. **J Clin Invest** 1997 Feb 15;99(4):676–83

Clinical expression, genetics and therapy of adenosine deaminase (ADA) deficiency. Hershfield MS, et al. **J Inherit Metab Dis** 1997 Jun;20(2):179–85 (53 ref.)

[Clinical study of gene therapy for adenosine deaminase deficiency] Sakiyama Y. **Arerugi** 1996 Jul;45(7):621–6 (12 ref.) **(Jpn)**

[The gene therapy for a patient with ADA deficiency; report of the first gene therapy trial in Japan] Ariga T, et al. **Nippon Rinsho** 1997 Jun;55(6):1572–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Long-term maintenance of hematopoiesis in irradiated mice by retrovirally transduced peripheral blood stem cells. Drize N, et al. **Blood** 1997 Mar 1;89(5):1811–7

Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Hoogerbrugge PM, et al. **Gene Ther** 1996 Feb;3(2):179–83

Cloning of a human RNA editing deaminase (ADARB1) of glutamate receptors that maps to chromosome 21q22.3. Mittaz L, et al. **Genomics** 1997 Apr 15;41(2):210–7

Novel tetranucleotide repeat polymorphism in the human adenosine deaminase gene: interethnic comparison of three major human groups. Scozzari R, et al. **Hum Biol** 1996 Apr;68(2):315–20

Long-term persistence of canine hematopoietic cells genetically marked by retrovirus vectors. Kiem HP, et al. **Hum Gene Ther** 1996 Jan;7(1):89–96

Two newly identified mutations (Thr233Ile and Leu152Met) in partially adenosine deaminase-deficient (ADA-) individuals that result in differing biochemical and metabolic phenotypes. Hirschhorn R, et al. **Hum Genet** 1997 Jul;100(1):22–9

Localization of a novel human RNA-editing deaminase (hRED2 or ADARB2) to chromosome 10p15. Mittaz L, et al. **Hum Genet** 1997 Sep;100(3–4):398–400

Full genetic rescue of adenosine deaminase-deficient mice through introduction of the human gene. Migchielsen AA, et al. **Hum Mol Genet** 1996 Oct;5(10):1523–32

Characterization and developmental expression of a testis-specific adenosine deaminase mRNA in the mouse. Meng JP, et al. **J Androl** 1997 Jan–Feb;18(1):88–95

Diverse genetic regulatory motifs required for murine adenosine deaminase gene expression in the placenta. Shi D, et al. **J Biol Chem** 1997 Jan 24;272(4):2334–41

Isolation and characterization of intranuclear ribonucleoprotein complexes associated with double-stranded RNA adenosine deaminase from brain cells: implications for RNA-editing and hypermutation of viral RNA in the CNS. Chen Z, et al. **J Neurovirol** 1995 Sep;1(3–4):295–306

Analysis of Xenopus dsRNA adenosine deaminase cDNAs reveals similarities to DNA methyltransferases. Hough RF, et al. **RNA** 1997 Apr;3(4):356–70

An intron 1 regulatory region from the murine adenosine deaminase gene can activate heterologous promoters for ubiquitous expression in transgenic mice. Winston JH, et al. **Somat Cell Mol Genet** 1996 Jul;22(4):261–78

Genetic structure of Plasmodium vivax isolates in India. Joshi H, et al. **Trans R Soc Trop Med Hyg** 1997 Mar-Apr; 91(2):231–5

ISOLATION & PURIFICATION

Purification of human double-stranded RNA-specific editase 1 (hRED1) involved in editing of brain glutamate receptor B pre-mRNA. O'Connell MA, et al. **J Biol Chem** 1997 Jan 3;272(1):473–8

Molecular forms of adenosine deaminase do not aid the diagnosis of tuberculosis. Venkatesh J, et al. **Trans R Soc Trop Med Hyg** 1996 Nov–Dec;90(6):652–3

METABOLISM

Enzymatic treatment to eliminate the extracellular ATP for improving the detectability of bacterial intracellular ATP. Sakakibara T, et al. **Anal Biochem** 1997 Aug 1;250(2):157–61

Pulsed ultrafiltration mass spectrometry: a new method for screening combinatorial libraries. van Breemen RB, et al. **Anal Chem** 1997 Jun 1;69(11):2159–64

Adenosine deaminase is a specific partner for the Grb2 isoform Grb3-3. Ramos-Morales F, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):735–40

Effect of various types of exercise training on 5'-nucleotidase and adenosine deaminase activities in rat heart: influence of a single bout of endurance exercise. Langfort J, et al. **Biochem Mol Med** 1996 Oct;59(1):28–32

Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase. Jeanfavre DD, et al. **Biochem Pharmacol** 1996 Dec 13;52(11):1757–65

Detection of inosine in messenger RNA by inosine-specific cleavage. Morse DP, et al. **Biochemistry** 1997 Jul 15; 36(28):8429–34

Site-directed mutagenesis of histidine 238 in mouse adenosine deaminase: substitution of histidine 238 does not impede hydroxylate formation. Sideraki V, et al. **Biochemistry** 1996 Nov 26;35(47):15019–28

Activity of the enzymes participating in purine metabolism of cancerous and noncancerous human kidney tissues. Durak I, et al. **Cancer Invest** 1997;15(3):212–6

Adenosine deaminase activity in patients with the intestinal type of gastric carcinoma. Namiot Z, et al. **Cancer Lett** 1996 Dec 3;109(1–2):199–202

CD26/dipeptidyl peptidase IV does not work as an adenosine deaminase-binding protein in rat cells. Iwaki-Egawa S, et al. **Cell Immunol** 1997 Jun 15;178(2):180–6

RNA editing: rewriting receptors. O'Connell MA. **Curr Biol** 1997 Jul 1;7(7):R437–9 (28 ref.)

Mammalian RNA-dependent deaminases and edited mRNAs. Maas S, et al. **Curr Opin Cell Biol** 1997 Jun;9(3):343–9 (49 ref.)

Determination of the kinetic parameters of adenosine deaminase by electrophoretically mediated microanalysis. Saevels J, et al. **Electrophoresis** 1996 Jul;17(7):1222–7

Serum adenosine deaminase estimation in relation to BCG vaccination. Thora S, et al. **Indian Pediatr** 1995 Oct; 32(10):1087–8

Functionally distinct double-stranded RNA-binding domains associated with alternative splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase. Liu Y, et al. **J Biol Chem** 1997 Feb 14;272(7):4419–28

Adenosine metabolism during phorbol myristate acetate-mediated induction of HL-60 cell differentiation: changes in expression pattern of adenosine kinase, adenosine deaminase, and 5'-nucleotidase. Spychala J, et al. **J Immunol** 1997 May 15;158(10):4947–52

Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. Valenzuela A, et al. **J Immunol** 1997 Apr 15;158(8):3721–9

The use of adenosine deaminase activity as a biochemical marker for the diagnosis of tuberculous meningitis. Rohani MY, et al. **Malays J Pathol** 1995 Dec;17(2):67–71

Theophylline-induced changes in mammalian adenosine deaminase activity and corticosterone status: possible relation to immune response. Bandyopadhyay BC, et al. **Methods Find Exp Clin Pharmacol** 1997 Apr;19(3):181–4

Editing of glutamate receptor B subunit ion channel RNAs by four alternatively spliced DRADA2 double-stranded RNA adenosine deaminases. Lai F, et al. **Mol Cell Biol** 1997 May;17(5):2413–24

Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: an enzymatic blood-brain barrier for dideoxynucleosides? Johnson MD, et al. **Pharm Res** 1996 Dec;13(12):1881–6

Role of brain tissue localized purine metabolizing enzymes in the central nervous system delivery of anti-HIV agents 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats. Singhal D, et al. **Pharm Res** 1997 Jun;14(6):786–92

Purification and characterization of a human RNA adenosine deaminase for glutamate receptor B pre-mRNA editing. Yang JH, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29; 94(9):4354–9

Cell surface adenosine deaminase: much more than an ectoenzyme. Franco R, et al. **Prog Neurobiol** 1997 Jul; 52(4):283–94 (104 ref.)

The role of divalent cations in structure and function of murine adenosine deaminase. Cooper BF, et al. **Protein Sci** 1997 May;6(5):1031–7

High adenosine deaminase level in pleural effusion due to

Waldenström's macroglobulinemia. Plaza V, et al. **Respiration** 1996;63(1):59–60

The value of adenosine deaminase (ADA) determination in the diagnosis of tuberculous ascites. Brant CQ, et al. **Rev Inst Med Trop Sao Paulo** 1995 Sep–Oct;37(5):449–53

5'-Nucleotidase and adenosine deaminase activities in hypertrophied rat heart. The effect of tachycardia. Czarnowski D, et al. **Rocz Akad Med Bialymst** 1996; 41(2):334–40

RNA editing and hypermutation by adenosine deamination [published erratum appears in Trends Biochem Sci 1997 Jul;22(7):278] Bass BL. **Trends Biochem Sci** 1997 May; 22(5):157–62 (54 ref.)

[The value of measuring adenosine deaminase activity in pericardial effusion fluid for diagnosing the etiology of pericardial effusion] Fijałkowska A, et al. **Pneumonol Alergol Pol** 1996;64 Suppl 2:174–9 (Eng. Abstr.) **(Pol)**

[Value of determining the activity of adenosine deaminase (ADA) in the differential diagnosis of pleural effusions] Chalhoub M, et al. **Rev Assoc Med Bras** 1996 Jul–Sep; 42(3):139–46 (Eng. Abstr.) **(Por)**

[The role of tryptophan in appearance of adenosine deaminase activity] Antonian AA, et al. **Biokhimiia** 1996 Sep;61(9):1563–9 (Eng. Abstr.) **(Rus)**

[Natural killer cells and adenosine deaminase activity in patients with pulmonary tuberculosis] Mamadbekov EN, et al. **Probl Tuberk** 1996;(5):39–41 (Eng. Abstr.) **(Rus)**

[Prospects for determining the activity of adenosine deaminase in biological fluids in tuberculosis] Titarenko OT, et al. **Probl Tuberk** 1996;(5):52–4 (42 ref.) **(Rus)**

PHARMACOLOGY

Transient ischemia in the presence of an adenosine deaminase plus a nucleoside transport inhibitor confers protection against contractile depression produced by hydrogen peroxide. Possible role of glycogen. Gan XT, et al. **J Mol Cell Cardiol** 1996 May;28(5):1165–76

Central inhibitory effect of adenosine deaminase on carotid blood flow increase at high pressure. Guerrero F, et al. **Physiol Behav** 1996 Feb;59(2):283–6

PHYSIOLOGY

Genetically engineered mice demonstrate that adenosine deaminase is essential for early postimplantation development. Blackburn MR, et al. **Development** 1997 Aug; 124(16):3089–97

Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2: diagnostic and biological role [editorial] Gakis C. **Eur Respir J** 1996 Apr;9(4):632–3

AMP degradation in the perfused rat heart during 2-deoxy-D-glucose perfusion and anoxia. Part II: The determination of the degradation pathways using an adenosine deaminase inhibitor. Chen W, et al. **J Mol Cell Cardiol** 1996 Oct;28(10):2175–82

ADENOSINE DEAMINASE-BINDING PROTEINS see **ANTIGENS, CD26**

ADENOSINE DIPHOSPHATASE see **APYRASE**

ADENOSINE DIPHOSPHATE

Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. Peng P, et al. **J Immunol Methods** 1997 May 12;204(1):13–21

ANALOGS & DERIVATIVES

Mg2+ and other polyvalent cations catalyze nucleotide fluorolysis. London RE, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):332–40

Modulation of platelet responses by 2-[3-(bromo-2-oxopropylthio)]adenosine-5'-diphosphate involves its binding to as well as covalent modification of an ADP-receptor, aggregin. Puri RN, et al. **Arch Biochem Biophys** 1997 Jul 1;343(1):140–5

5'-Diphosphoadenosine 3'-phosphate is a potent inhibitor of bovine pancreatic ribonuclease A. Russo N, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):671–4

Crystal structures of ribonuclease A complexes with 5'-diphosphoadenosine 3'-phosphate and 5'-diphosphoadenosine 2'-phosphate at 1.7 A resolution. Leonidas DD, et al. **Biochemistry** 1997 May 6; 36(18):5578–88

Effect of metal cations on the conformation of myosin subfragment-1-ADP-phosphate analog complexes: a near-UV circular dichroism study. Peyser YM, et al. **Biochemistry** 1997 Apr 29;36(17):5170–8

A two-site mechanism for ATP hydrolysis by the asymmetric Rep dimer P2S as revealed by site-specific inhibition with ADP-A1F4. Wong I, et al. **Biochemistry** 1997 Mar 18; 36(11):3115–25

Effect of complexes of ADP and phosphate analogs on the conformation of the Cys707-Cys697 region of myosin subfragment 1. Phan BC, et al. **Eur J Biochem** 1997 Feb 1;243(3):636–42

Changes of creatine kinase secondary structure induced by the release of nucleotides from caged compounds. An infrared difference-spectroscopy study. Raimbault C, et al. **Eur J Biochem** 1996 Aug 15;240(1):134–42

Probing phosphatidylinositolphosphates and adenosinenucleotides on talin nucleated actin polymerization. Isenberg G, et al. **FEBS Lett** 1996 Nov 18;397(2-3):316–20

Binding of TNP-ATP and TNP-ADP to the non-catalytic sites of Escherichia coli F1-ATPase. Weber J, et al. **FEBS Lett** 1997 Jul 21;412(1):169–72

Cytotoxic effects by microinjection of ADP-ribosylated skeletal muscle G-actin in PtK2 cells in the absence of Clostridium perfringens iota toxin. Kiefer G, et al. **Med Microbiol Immunol (Berl)** 1996 Feb;184(4):175–80

Synthesis and application of pyridoxal polyphosphoryl derivatives as active-site probes for nucleotide-binding enzymes. Fukui T, et al. **Methods Enzymol** 1997;280:41–50

Labelling, control and radiopharmacological evaluation of 99mTc-adenosine 5'-diphosphate (99mTc-ADP) as tumour seeking agent. León AS, et al. **Q J Nucl Med** 1996 Jun;40(2):170–5

Deficiency of (33P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Cattaneo M, et al. **Thromb Haemost** 1997 May; 77(5):986–90

ANALYSIS

31P-magnetic resonance spectroscopy studies of nucleated and non-nucleated erythrocytes; time domain data analysis (VARPRO) incorporating prior knowledge can give information on the binding of ADP. Stubbs M, et al. **Biochim Biophys Acta** 1996 Oct 24;1291(2):143–8

The bound adenine nucleotides of purified bovine mitochondrial ATP synthase. Beharry S, et al. **Eur J Biochem** 1996 Aug 15;240(1):165–72

31P NMR methods for the direct determination of ADP in the presence of ATP. Ben-Bashat D, et al. **J Magn Reson B** 1996 Mar;110(3):231–9

ANTAGONISTS & INHIBITORS

Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation. Cook JJ, et al. **J Pharmacol Exp Ther** 1997 May;281(2):677–89

BIOSYNTHESIS

ADP-regenerating enzyme systems in mitochondria of guinea pig myometrium and heart. Clark JF, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C399–404

BLOOD

[Concentration of adenine nucleotides in blood of predialysis patients with chronic renal failure] Bułło B, et al. **Pol Arch Med Wewn** 1995 Nov;94(5):389–94 (Eng. Abstr.) **(Pol)**

[The levels of adenine nucleotides and hypoxanthine in blood of patients on long-term hemodialysis using dialysis fluid containing acetate or bicarbonate] Bułło B, et al. **Przegl Lek** 1997;54(1):3–5 (Eng. Abstr.) **(Pol)**

CHEMICAL SYNTHESIS

Pyrophosphate and adenosine 5'-diphosphate synthesis from phospho(enol)pyruvate: catalysis by phosphate minerals and modulation by dimethyl sulfoxide. Hermes-Lima M, et al. **J Mol Evol** 1997 Jan;44(1):106–11

CHEMISTRY

Covalent modification of nitrogenase MoFe protein by ADP. Miller RW, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):737–44

X-ray structures of the MgADP, MgATPgammaS, and MgAMPPNP complexes of the Dictyostelium discoideum myosin motor domain. Gulick AM, et al. **Biochemistry** 1997 Sep 30;36(39):11619–28

Structure of ADP x AlF4(-)-stabilized nitrogenase complex and its implications for signal transduction. Schindelin H, et al. **Nature** 1997 May 22;387(6631):370–6

The crystal structure of the asymmetric GroEL-GroES-(ADP)7 chaperonin complex [see comments] Xu Z, et al. **Nature** 1997 Aug 21; 388(6644):741–50. Comment in: Nature 1997 Aug 21;388(6644):720–1, 723.

METABOLISM

Adenosine nucleotides in bile. Chari RS, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G246–52

Inotropic agent EMD-53998 weakens nucleotide and phosphate binding to cross bridges in porcine myocardium. Zhao Y, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1394–406

Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Humbert M, et al. **Arterioscler Thromb Vasc Biol** 1996 Dec;16(12):1532–43

Regulation of pancreatic beta-cell mitochondrial metabolism: influence of Ca2+, substrate and ADP. Civelek VN, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):615–21

Resolution of two ADP-ribosylation factor 1 GTPase-activating proteins from rat liver. Randazzo PA. **Biochem J** 1997 Jun 1;324 (Pt 2):413–9

Involvement of a tyrosine residue in the ADP binding site of creatine kinase. A second-derivative UV-spectroscopy study. Leydier C, et al. **Biochem Mol Biol Int** 1997 Apr; 41(4):777–84

Probing the hydrophobic interactions in the skeletal actomyosin subfragment 1 and its nucleotide complexes by zero-length cross-linking with a nickel-peptide chelate. Bertrand R, et al. **Biochemistry** 1997 Aug 12;36(32):9703–14

ADP-fluoroaluminate complexes are formed cooperatively at two catalytic sites of wild-type and mutant alpha3beta3gamma subcomplexes of the F1-ATPase from the thermophilic Bacillus PS3. Dou C, et al. **Biochemistry** 1997 Mar 25;36(12):3719–27

A pseudo-michaelis quaternary complex in the reverse reaction of a ligase: structure of Escherichia coli B glutathione synthetase complexed with ADP, glutathione, and sulfate at 2.0 A resolution. Hara T, et al. **Biochemistry** 1996 Sep 17;35(37):11967–74

Myosin regulatory light chain and nucleotide modulation of actin binding site electric charge. Highsmith S. **Biochemistry** 1997 Feb 25;36(8):2010–6

Exchange of ATP for ADP on high-force cross-bridges of skinned rabbit muscle fibers. Seow CY, et al. **Biophys J** 1997 Jun;72(6):2719–35

Major domain swiveling revealed by the crystal structures of complexes of E. coli Rep helicase bound to single-stranded DNA and ADP. Korolev S, et al. **Cell** 1997 Aug 22;90(4):635–47

Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Prodromou C, et al. **Cell** 1997 Jul 11;90(1):65–75

P2T purinoceptors: ADP receptors on platelets. Hourani SM, et al. **Ciba Found Symp** 1996;198:53–64; discussion 64–70 (50 ref.)

Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Tian R, et al. **Circulation** 1997 Aug 19;96(4):1313–9

Direct measurement of the release of ATP and its major metabolites from the nerve fibres of the guinea-pig taenia coli. McConalogue K, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):807–12

Differential degradation of extracellular adenine nucleotides by folliculated oocytes of Xenopus laevis. Ziganshin AU, et al. **Comp Biochem Physiol A Physiol** 1996 Aug; 114(4):335–40

Effect of ammonia on survival and adenylate energy charge in the shrimp Palaemonetes varians. Marazza D, et al. **Ecotoxicol Environ Saf** 1996 Jul;34(2):103–8

ADP-binding and ATP-binding sites in native and proteinase-K-digested creatine kinase, probed by reaction-induced difference infrared spectroscopy. Raimbault C, et al. **Eur J Biochem** 1997 Aug 1; 247(3):1197–208

Analysis of nucleotide binding by a vacuolar proton-translocating adenosine triphosphatase. Webster LC, et al. **Eur J Biochem** 1996 Aug 15;240(1):156–64

Enzyme kinetics and the activation energy of Mg-ATPase in cardiac sarcolemma: ADP as an alternative substrate. Vrbjar N, et al. **Gen Physiol Biophys** 1995 Aug;14(4):313–21

Purification and characterization of two reversible and ADP-dependent acetyl coenzyme A synthetases from the hyperthermophilic archaeon Pyrococcus furiosus. Mai X, et al. **J Bacteriol** 1996 Oct;178(20):5897–903

Activation of Clostridium botulinum C3 exoenzyme-catalyzed ADP-ribosylation of RhoA by K+ in a Mg2+ -dependent manner. Miyaoka T, et al. **J Biochem (Tokyo)** 1996 Jan;119(1):200–7

Does the gamma subunit move to an abortive position of ATP hydrolysis when the F1.ADP.Mg complex isomerizes to the inactive F1*.ADP.Mg complex? Allison WS, et al. **J Bioenerg Biomembr** 1996 Oct;28(5):433–8 (30 ref.)

Unisite hydrolysis of [gamma 32 P]ATP by soluble mitochondrial F1-ATPase and its release by excess ADP and ATP. Effect of trifluoperazine. García JJ, et al. **J Bioenerg Biomembr** 1997 Feb;29(1):61–70

Modulation of the P1 plasmid partition protein ParA by ATP, ADP, and P1 ParB. Davey MJ, et al. **J Biol Chem** 1997 Jun 13;272(24):15286–92

The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. Grenert JP, et al. **J Biol Chem** 1997 Sep 19;272(38):23843–50

The alpha3beta3gamma subcomplex of the F1-ATPase from the thermophilic bacillus PS3 with the betaT165S substitution does not entrap inhibitory MgADP in a catalytic site during turnover. Jault JM, et al. **J Biol Chem** 1996 Nov 15;271(46):28818–24

The signal transduction function for oxidative phosphorylation is at least second order in ADP. Jeneson JAL, et al. **J Biol Chem** 1996 Nov 8;271(45):27995–8

Structural studies of kinesin-nucleotide intermediates. Rosenfeld SS, et al. **J Biol Chem** 1996 Nov 22; 271(47):30212–21

Differential scanning calorimetric study of the complexes of modified myosin subfragment 1 with ADP and vanadate or beryllium fluoride. Golitsina NL, et al. **J Muscle Res Cell Motil** 1996 Aug;17(4):475–85

Mechanical study of rat soleus muscle using caged ATP and X-ray diffraction: high ADP affinity of slow cross-bridges. Horiuti K, et al. **J Physiol (Lond)** 1997 Jul 15;502 (Pt

2):433–47
Enhancement by melatonin of GTP exchange and ADP ribosylation reactions. Bubis M, et al. **Mol Cell Endocrinol** 1996 Oct 30;123(2):139–48
Luteinizing hormone/choriogonadotropin–dependent, cholera toxin–catalyzed adenosine 5'–diphosphate (ADP)–ribosylation of the long and short forms of Gs alpha and pertussis toxin–catalyzed ADP–ribosylation of Gi alpha*. Rajagopalan–Gupta RM, et al. **Mol Endocrinol** 1997 May;11(5):538–49
ADP–ribosylation by the extracellular fibrils of Myxococcus xanthus. Hildebrandt K, et al. **Mol Microbiol** 1997 Jan; 23(2):231–5
Establishing differential gene expression in sporulating Bacillus subtilis: phosphorylation of SpoIIAA (anti–anti–sigmaF) alters its conformation and prevents formation of a SpoIIAA/SpoIIAB/ADP complex. Magnin T, et al. **Mol Microbiol** 1996 Feb;19(4):901–7
ADP recovery after a brief ischemic exercise in normal and diseased human muscle—a 31P MRS study. Argov Z, et al. **NMR Biomed** 1996 Jun;9(4):165–72
Kinetics of ATP to ADP beta–phosphoryl conversion in contracting skeletal muscle by in vivo 31P NMR magnetization transfer. Le Rumeur E, et al. **NMR Biomed** 1997 Apr;10(2):67–72
The ADP/ATP transport system: a paradigm of metabolite transport in mitochondria. Brandolin G, et al. **Soc Gen Physiol Ser** 1996;51:173–85 (48 ref.)
[Arginine–specific ADP–ribosylation reaction in eukaryotic cells] Tsuchiya M. **Seikagaku** 1996 Sep;68(9):1538–42 (15 ref.) **(Jpn)**

PHARMACOLOGY

Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro. Wun T, et al. **Am J Hematol** 1997 Mar; 54(3):225–32
Sensitivity of volume–sensitive Cl– conductance in human epithelial cells to extracellular nucleotides. Tsumura T, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):C1872–8
Endothelial–mediated dilations of rat middle cerebral arteries by ATP and ADP. You J, et al. **Am J Physiol** 1997 Sep; 273(3 Pt 2):H1472–7
Effects of the co–polymer surfactant, Pluronic F–68, on platelet aggregation in human whole blood. Edwards CM, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1997 Sep;25(5):493–9
Effects of ADP, DTT, and Mg2+ on the ion–conductive property of chloroplast H+–ATPase(CF0–CF1) reconstituted into bilayer membrane. Ma XH, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):461–3
Regulation of pancreatic beta–cell mitochondrial metabolism: influence of Ca2+, substrate and ADP. Civelek VN, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):615–21
A possible dual physiological role of extracellular ATP in the modulation of platelet aggregation. Soslau G, et al. **Biochim Biophys Acta** 1997 Feb 4;1355(2):131–40
Effects of MgATP and MgADP on the cross–bridge kinetics of rabbit soleus slow–twitch muscle fibers. Wang G, et al. **Biophys J** 1996 Sep;71(3):1450–61
Changes in the composition of the platelet cytoskeleton in response to ADP: effects of MK–852 and ARL 66096. May JA, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):221–4
cAMP is not an important messenger for ADP–induced platelet aggregation. Savi P, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):249–52
ADP–induced P–selectin expression on platelets as a predictor of successful thrombolysis. Yusuf SW, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):266–9
ADP indirectly supports activation of non–selective cation channels by AlF complex in guinea–pig chromaffin cells. Inoue M, et al. **Brain Res** 1996 Jan 29;707(2):298–302
The essential role of the Walker A motifs of SUR1 in K–ATP channel activation by Mg–ADP and diazoxide. Gribble FM, et al. **EMBO J** 1997 Mar 17;16(6):1145–52
Striking differences between the kinetics of regulation of respiration by ADP in slow–twitch and fast–twitch muscles in vivo. Kuznetsov AV, et al. **Eur J Biochem** 1996 Nov 1;241(3):909–15
Effect of complexes of ADP and phosphate analogs on the conformation of the Cys707–Cys697 region of myosin subfragment 1. Phan BC, et al. **Eur J Biochem** 1997 Feb 1;243(3):636–42
Stimulation of postmortem platelets with adenosine–5–diphosphate and epinephrine. Thomsen H, et al. **Forensic Sci Int** 1997 Sep 19;89(1–2):47–55
Stimulation of hepatocyte glycerolipid synthesis by iron/ADP is due to ADP rather than oxidative stress. Girón–Calle J, et al. **Free Radic Biol Med** 1997;23(1):173–6
The mitochondrial hsp70 chaperone system. Effect of adenine nucleotides, peptide substrate, and mGrpE on the oligomeric state of mhsp70. Azem A, et al. **J Biol Chem** 1997 Aug 15;272(33):20901–6
Reversible translocation of phosphoinositide 3–kinase to the cytoskeleton of ADP–aggregated human platelets occurs independently of Rho A and without synthesis of phosphatidylinositol (3,4)–bisphosphate. Gachet C, et al. **J Biol Chem** 1997 Feb 21;272(8):4850–4
MgADP antagonism to Mg2+–independent ATP binding of the sulfonylurea receptor SUR1. Ueda K, et al. **J Biol Chem** 1997 Sep 12;272(37):22983–6
Sequential potentiation and inhibition of PMN reactivity by maximally stimulated platelets. Aziz KA, et al. **J Leukoc Biol** 1997 Mar;61(3):322–8
Direct activation of the ATP–sensitive potassium channel by oxygen free radicals in guinea–pig ventricular cells: its potentiation by MgADP [published erratum appears in J Mol Cell Cardiol 1997 Feb;29(2):855] Ichinari K, et al. **J Mol Cell Cardiol** 1996 Sep;28(9):1867–77
Effects of oxyhemoglobin on local and propagated vasodilatory responses induced by adenosine, adenosine diphosphate, and adenosine triphosphate in rat cerebral arterioles. Kajita Y, et al. **J Neurosurg** 1996 Nov; 85(5):908–16
ADP–induced rapid inward currents through Ca(2+)–permeable cation channels in mouse, rat and guinea–pig megakaryocytes: a patch–clamp study. Kawa K. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):339–52
Changes in platelet response to adenosine 5'–diphosphate caused by verapamil. Walkowiak B, et al. **Pol J Pharmacol** 1996 May–Jun;48(3):303–5
Thrombopoietin modulates platelet activation in vitro through protein–tyrosine phosphorylation. Kubota Y, et al. **Stem Cells** 1996 Jul;14(4):439–44
Deficiency of (33P)2MeS–ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Cattaneo M, et al. **Thromb Haemost** 1997 May; 77(5):986–90
Platelets from bleeding Simmental cattle have a long delay in both ADP–activated expression of GpIIB–IIIA receptors and fibrinogen–dependent platelet aggregation. Frojmovic MM, et al. **Thromb Haemost** 1996 Dec; 76(6):1047–52
Surface–secreted von Willebrand factor mediates aggregation of ADP–activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb–IIIa. Frojmovic MM, et al. **Thromb Haemost** 1997 Mar; 77(3):568–76
Enhanced increases in cytosolic Ca2+ in ADP–stimulated platelets from patients with delta–storage pool deficiency—a possible indicator of interactions between granule–bound ADP and the membrane ADP receptor. Lages B, et al. **Thromb Haemost** 1997 Feb;77(2):376–82
ADP–mimicking platelet aggregation caused by rugosin E, an ellagitannin isolated from Rosa rugosa Thunb. Teng CM, et al. **Thromb Haemost** 1997 Mar;77(3):555–61
The influence of isoprostanes on ADP–induced platelet aggregation and cyclic AMP–generation in human platelets. Leitinger N, et al. **Thromb Res** 1997 May 15; 86(4):337–42
Inhibition of ADP–induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion [corrected and republished article originally printed in Thromb Res 1995 Dec 15;80(6):499–508] Riddell DR, et al. **Thromb Res** 1996 Mar 1;81(5):597–606
Adenosine nucleotides induce E–selectin expression in porcine endothelial cells. von Albertini MA, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1062
[Calcium transport in microsomes isolated from rat parotid gland. Effects of ADP and an ATP–regenerating system.] Eboué D, et al. **Arch Physiol Biochem** 1996 Dec; 104(7):826–32 (Eng. Abstr.) **(Fre)**
[Inhibition of ADP–induced platelet aggregation by guanidine thiols—a novel class of guanylate cyclase activators and NO–synthase substrates] Belushkina NN, et al. **Biokhimiia** 1996 Dec;61(12):2140–6 (Eng. Abstr.) **(Rus)**
[Stimulating effect of ADP on the calcium ion transport system in yeast mitochondria] Bazhenova EN, et al. **Dokl Akad Nauk** 1997 Apr;353(4):550–2 **(Rus)**
[Features of noradrenaline stimulation of rat liver mitochondria respiration by ADP and calcium ions] Stefankiv IuS, et al. **Ukr Biokhim Zh** 1995 Nov–Dec; 67(6):22–7 (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

Endogenous ADP prevents PGE1–induced tyrosine dephosphorylation of focal adhesion kinase in thrombin–activated platelets. Vostal JG, et al. **Biochim Biophys Acta** 1996 Nov 8;1314(1–2):1–12
The role of ADP in endotoxin–induced equine platelet activation. Jarvis GE, et al. **Eur J Pharmacol** 1996 Nov 14;315(2):203–12
Role of MgADP in the development of diastolic dysfunction in the intact beating rat heart. Tian R, et al. **J Clin Invest** 1997 Feb 15;99(4):745–51
Nerve tissue–specific human glutamate dehydrogenase that is thermolabile and highly regulated by ADP. Shashidharan P, et al. **J Neurochem** 1997 May;68(5):1804–11
Muscle contraction and fatigue. The role of adenosine 5'–diphosphate and inorganic phosphate. McLester JR Jr. **Sports Med** 1997 May;23(5):287–305 (124 ref.)

SECRETION

Platelet dense–granule centralization and the persistence of ADP secretion. Fogelson AL, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):H1131–40

ADENOSINE DIPHOSPHATE GLUCOSE

ADVERSE EFFECTS

ADP–sugar as a cause of disease [letter] Stockdale T. **Nutr Health** 1996;11(1):79–80

PHYSIOLOGY

ADP–glucose drives starch synthesis in isolated maize endosperm amyloplasts: characterization of starch synthesis and transport properties across the amyloplast envelope. Möhlmann T, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):503–9

ADENOSINE DIPHOSPHATE RIBOSE

ANALOGS & DERIVATIVES

Ca(2+)–signalling in human T–lymphocytes. Potential roles for cyclic ADP–ribose and 2'–phospho–cyclic ADP–ribose. Guse AH, et al. **Adv Exp Med Biol** 1997; 419:431–6 (16 ref.)
Metabolism and actions of ADP–riboses in coronary arterial smooth muscle. Li P, et al. **Adv Exp Med Biol** 1997; 419:437–41
Involvement of bovine spleen NAD+ glycohydrolase in the metabolism of cyclic ADP–ribose–mechanism of the cyclization reaction. Muller–Steffner H, et al. **Adv Exp Med Biol** 1997;419:399–409
Intramolecular ADP–ribose transfer reactions and calcium signalling. Potential role of 2'–phospho–cyclic ADP–ribose in oxidative stress. Vu CQ, et al. **Adv Exp Med Biol** 1997; 419:381–8 (31 ref.)
Cyclic ADP–ribose signaling in sea urchin gametes: metabolism in spermatozoa. Chini EN, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C416–20
Palmitoyl–CoA potentiates the Ca2+ release elicited by cyclic ADP–ribose. Chini EN, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):C530–7
Adenine nucleotide diphosphates: emerging second messengers acting via intracellular Ca2+ release. Dousa TP, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1007–24 (136 ref.)
Cyclic ADP–ribose stimulates sarcoplasmic reticulum calcium release in porcine coronary artery smooth muscle. Kannan MS, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):H801–6
cADP–ribose releases Ca2+ from cardiac sarcoplasmic reticulum independently of ryanodine receptor. Lahouratate P, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1082–9
Natural occurrence of 2'–phospho–cyclic ADP ribose in mammalian tissues. Vu CQ, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):723–6
Ectocellular in vitro and in vivo metabolism of cADP–ribose in cerebellum. De Flora A, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):665–71
Nicotinamide inhibits cyclic ADP–ribose–mediated calcium signalling in sea urchin eggs. Sethi JK, et al. **Biochem J** 1996 Oct 15;319 (Pt 2):613–7
Roles for adenosine ribose hydroxyl groups in cyclic adenosine 5'–diphosphate ribose–mediated Ca2+ release. Ashamu GA, et al. **Biochemistry** 1997 Aug 5;36(31):9509–17
Cyclic ADP–ribose and calcium signaling in eggs. Lee HC. **Biol Signals** 1996 Mar–Apr;5(2):101–10 (58 ref.)
7–Deaza cyclic adenosine 5'–diphosphate ribose: first example of a Ca(2+)–mobilizing partial agonist related to cyclic adenosine 5'–diphosphate ribose. Bailey VC, et al. **Chem Biol** 1997 Jan;4(1):51–61
Cyclic ADP–ribose does not regulate sarcoplasmic reticulum Ca2+ release in intact cardiac myocytes. Guo X, et al. **Circ Res** 1996 Jul;79(1):147–51
A specific cyclic ADP–ribose antagonist inhibits cardiac excitation–contraction coupling. Rakovic S, et al. **Curr Biol** 1996 Aug 1;6(8):989–96
Oscillation of ADP–ribosyl cyclase activity during the cell cycle and function of cyclic ADP–ribose in a unicellular organism, Euglena gracilis. Masuda W, et al. **FEBS Lett** 1997 Mar 17;405(1):104–6
Pharmacology of Ca2+ release from red beet microsomes suggests the presence of ryanodine receptor homologs in higher plants. Muir SR, et al. **FEBS Lett** 1996 Oct 14; 395(1):39–42
Role of cyclic ADP–ribose in ATP–activated potassium currents in alveolar macrophages. Ebihara S, et al. **J Biol Chem** 1997 Jun 20;272(25):16023–9
Cyclic ADP–ribose enhances coupling between voltage–gated Ca2+ entry and intracellular Ca2+ release. Empson RM, et al. **J Biol Chem** 1997 Aug 22; 272(34):20967–70
Cyclic ADP–ribose–gated Ca2+ release in sea urchin eggs requires an elevated. Guo X, et al. **J Biol Chem** 1997 Jul 4;272(27):16984–9
Ca2+ entry induced by cyclic ADP–ribose in intact T–lymphocytes. Guse AH, et al. **J Biol Chem** 1997 Mar 28;272(13):8546–50
Regulation of cADP–ribose–induced Ca2+ release by Mg2+ and inorganic phosphate. Guse AH, et al. **J Biol Chem** 1996 Sep 27;271(39):23946–53
Stimulation of cyclic ADP–ribose synthesis by acetylcholine and its role in catecholamine release in bovine adrenal

chromaffin cells. Morita K, et al. **J Biol Chem** 1997 Aug 22;272(34):21002–9
Mechanism of cyclization of pyridine nucleotides by bovine spleen NAD+ glycohydrolase. Muller-Steffner HM, et al. **J Biol Chem** 1996 Sep 27;271(39):23967–72
Cyclic ADP-ribose binds to FK506-binding protein 12.6 to release Ca2+ from islet microsomes. Noguchi N, et al. **J Biol Chem** 1997 Feb 7;272(6):3133–6
7-Deaza-8-bromo-cyclic ADP-ribose, the first membrane-permeant, hydrolysis-resistant cyclic ADP-ribose antagonist. Sethi JK, et al. **J Biol Chem** 1997 Jun 27;272(26):16358–63
Characterization of ryanodine-sensitive Ca2+ release from microsomal vesicles of rat parotid acinar cells: regulation by cyclic ADP-ribose. Ozawa T, et al. **J Membr Biol** 1997 Apr 1;156(3):231–9
Activation of Ca2+-dependent currents in dorsal root ganglion neurons by metabotropic glutamate receptors and cyclic ADP-ribose precursors. Crawford JH, et al. **J Neurophysiol** 1997 May;77(5):2573–84
Cyclic ADP-ribose metabolism in rat kidney: high capacity for synthesis in glomeruli. Chini EN, et al. **Kidney Int** 1997 May;51(5):1500–6
Preparation of low molecular weight model conjugates for ADP-ribose linkages to protein. Cervantes-Laurean D, et al. **Methods Enzymol** 1997;280:275–87
Radioimmunoassay for measuring endogenous levels of cyclic ADP-ribose in tissues. Graeff RM, et al. **Methods Enzymol** 1997;280:230–41
Preparation of cyclic ADP-ribose, 2'-phospho-cyclic ADP-ribose, and nicotinate adenine dinucleotide phosphate: possible second messengers of calcium signaling. Jacobson MK, et al. **Methods Enzymol** 1997;280:265–75
Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38: inhibition of hydrolysis by ATP and physiological significance. Okamoto H, et al. **Methods Enzymol** 1997;280:306–18
Bioassay for determining endogenous levels of cyclic ADP-ribose. Walseth TF, et al. **Methods Enzymol** 1997; 280:287–94
Preparation of cyclic ADP-ribose antagonists and caged cyclic ADP-ribose. Walseth TF, et al. **Methods Enzymol** 1997;280:294–305
Synthetic study on carbocyclic analogues of cyclic ADP-ribose. Shirato M, et al. **Nucleic Acids Symp Ser** 1995; (34):165–6
Effect of estrogen upon cyclic ADP ribose metabolism: beta-estradiol stimulates ADP ribosyl cyclase in rat uterus. Chini EN, et al. **Proc Natl Acad Sci U S A** 1997 May 27; 94(11):5872–6
Metabolism of cyclic ADP-ribose: a new role for NAD+ glycohydrolases. Ziegler M, et al. **Rev Physiol Biochem Pharmacol** 1997;131:89–126 (198 ref.)

ANALYSIS

Cyclic ADP-ribose measurements in rat pancreatic islets. Malaisse WJ, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):546–8

ANTAGONISTS & INHIBITORS

Traumatic neuroprotection with inhibitors of nitric oxide and ADP-ribosylation. Wallis RA, et al. **Brain Res** 1996 Feb 26;710(1-2):169–77

BLOOD

Platelet endogenous adenosine 5'-diphosphate ribosylation in drug-free and lithium-treated subjects with bipolar disorder. Young LT, et al. **Biol Psychiatry** 1997 Sep 1; 42(5):413–5

CHEMISTRY

CD38 and ADP-ribosyl cyclase catalyze the synthesis of a dimeric ADP-ribose that potentiates the calcium-mobilizing activity of cyclic ADP-ribose. De Flora A, et al. **J Biol Chem** 1997 May 16;272(20):12945–51

HISTORY

ADP-ribose. A historical overview. Hilz H. **Adv Exp Med Biol** 1997;419:15–24

IMMUNOLOGY

Multiparametric staining to identify apoptotic human cells. Negri C, et al. **Exp Cell Res** 1997 Jul 10;234(1):174–7

ISOLATION & PURIFICATION

Use of biotinylated NAD to label and purify ADP-ribosylated proteins. Zhang J. **Methods Enzymol** 1997;280:255–65

METABOLISM

Biological Significance of Mono- ADP-ribosylation in Animal Tissues. Proceedings of an international workshop. Hamburg, Germany, May 19–23, 1996. **Adv Exp Med Biol** 1997;419:1–471
Mouse RT6 locus 1 and rat RT6.2 are NAD+. Arginine ADP-ribosyltransferases with auto-ADP-ribosylation activity. Bortell R, et al. **Adv Exp Med Biol** 1997; 419:169–73
Brefeldin A-induced ADP-ribosylation in the structure and function of the Golgi complex. Colanzi A, et al. **Adv Exp Med Biol** 1997;419:331–5
Modulatory role of GTP-binding proteins in the endogenous ADP-ribosylation of cytosolic proteins. Di Girolamo M, et al. **Adv Exp Med Biol** 1997;419:343–7 (18 ref.)
Endogenous mono-ADP-ribosylation in retina and peripheral nervous system. Effects of diabetes. Gorio A, et al. **Adv Exp Med Biol** 1997;419:289–95
A proposed role for protein. Protein complexes in the regulation of the reversible ADP-ribosylation of dinitrogenase reductase. Grunwald SK, et al. **Adv Exp Med Biol** 1997;419:61–9 (30 ref.)
Role of ADP-ribosylation in activated monocytes/macrophages. Hauschildt S, et al. **Adv Exp Med Biol** 1997;419:249–52
ADP-ribose in glycation and glycoxidation reactions. Jacobson EL, et al. **Adv Exp Med Biol** 1997;419:371–9 (24 ref.)
ADP-ribosylarginine hydrolases and ADP-ribosyltransferases. Partners in ADP-ribosylation cycles. Moss J, et al. **Adv Exp Med Biol** 1997;419:25–33 (39 ref.)
ADP-ribosylating and glucosylating toxins as tools to study secretion in RBL cells. Prepens U, et al. **Adv Exp Med Biol** 1997;419:349–53
Enhanced degradation of stimulatory G-protein (Gs alpha) by cholera toxin is mediated by ADP-ribosylation of Gs alpha protein but not by increased cyclic AMP levels. Shah BH. **Adv Exp Med Biol** 1997;419:93–7
Possible role of BARS-50, a substrate of brefeldin A-dependent mono-ADP-ribosylation, in intracellular transport. Silletta MG, et al. **Adv Exp Med Biol** 1997; 419:321–30
Characterization of the endogenous mono-ADP-ribosylation stimulated by brefeldin A. Weigert R, et al. **Adv Exp Med Biol** 1997;419:337–42
ADP-ribosylation and early transcription regulation by bacteriophage T4. Wilkens K, et al. **Adv Exp Med Biol** 1997;419:71–82 (34 ref.)
Bovine liver mitochondrial NAD+ glycohydrolase. Relationship to ADP-ribosylation and calcium fluxes. Ziegler M, et al. **Adv Exp Med Biol** 1997;419:443–6
The alpha 7 integrin as a target protein for cell surface mono-ADP-ribosylation in muscle cells. Zolkiewska A, et al. **Adv Exp Med Biol** 1997;419:297–303
Endogenous ADP-ribosylation of phosphoprotein B-50/GAP-43 and other neuronal substrates. Zwiers H, et al. **Adv Exp Med Biol** 1997;419:279–88
Gi protein activation of gonadotropin-releasing hormone-mediated protein dephosphorylation in human endometrial carcinoma. Imai A, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):371–6
Intracellular ADP-ribose inhibits ATP-sensitive K+ channels in rat ventricular myocytes. Kwak YG, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C464–8
Characterization of ADP-ribosylation sites on desmin and restoration of desmin intermediate filament assembly by de-ADP-ribosylation [published erratum appears in Arch Biochem Biophys 1997 Feb 1;338(1):128] Zhou H, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):214–22
Regulation of NAD+ glycohydrolase activity by NAD(+)-dependent auto-ADP-ribosylation. Han MK, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):903–8
Cell-surface ADP-ribosylation of fibroblast growth factor-2 by an arginine-specific ADP-ribosyltransferase. Jones EM, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):173–7
The contribution of endogenous mono-ADP-ribosylation to kindling-induced epileptogenesis. Suzuki K, et al. **Brain Res** 1997 Jan 16;745(1-2):109–13
ADP-ribosylation of serum proteins: elevated levels in neoplastic cases due to altered NAD/ADP-ribose metabolism. Albeniz IU, et al. **Cancer Invest** 1997; 15(3):217–23
ADP-ribosylation of serum proteins: evaluation as a potential tumor marker. Albeniz IU, et al. **Cancer Lett** 1996 Nov 29;108(2):239–45
Nitric oxide induces ADP-ribosylation of actin in murine macrophages: association with the inhibition of pseudopodia formation, phagocytic activity, and adherence on a laminin substratum. Jun CD, et al. **Cell Immunol** 1996 Nov 25;174(1):25–34
The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Snider DP. **Crit Rev Immunol** 1995; 15(3-4):317–48 (276 ref.)
ADP-ribosylation of myelin basic protein and inhibition of phospholipid vesicle aggregation. Yamamori C, et al. **Enzyme Protein** 1994-95;48(4):202–12
Overexpression of human poly(ADP-ribose) polymerase in transfected hamster cells leads to increased poly(ADP-ribosyl)ation and cellular sensitization to gamma irradiation. Van Gool L, et al. **Eur J Biochem** 1997 Feb 15;244(1):15–20
ADP-ribosylation of Rho-proteins with botulinum C3 exoenzyme inhibits invasion and shape changes of T-lymphoma cells. Verschueren H, et al. **Eur J Cell Biol** 1997 Jun;73(2):182–7
Alterations of protein mono-ADP-ribosylation and diabetic neuropathy: a novel pharmacological approach. Gorio A, et al. **Eur J Pharmacol** 1996 Sep 5;311(1):21–8
Mood stabilizers have differential effects on endogenous ADP ribosylation in C6 glioma cells. Young LT, et al. **Eur J Pharmacol** 1996 Aug 8;309(2):215–8
Direct thyroid hormone signalling via ADP-ribosylation controls mitochondrial nucleotide transport and membrane leakiness by changing the conformation of the adenine nucleotide transporter. Mowbray J, et al. **FEBS Lett** 1996 Sep 23;394(1):61–5
ADP-ribosylation of tuftsin suppresses its receptor-binding capacity and phagocytosis-stimulating activity to murine peritoneal macrophages. Terashima M, et al. **FEBS Lett** 1997 Jul 21;412(1):227–32
Two novel human members of an emerging mammalian gene family related to mono-ADP-ribosylating bacterial toxins. Koch-Nolte F, et al. **Genomics** 1997 Feb 1;39(3):370–6
Long-term alcohol intake enhances ADP-ribosylation of the multifunctional enzyme, phosphoglucomutase, in rat liver. Nomura F, et al. **Hepatology** 1996 Nov;24(5):1246–9
Neutrons affect ADP-ribosylation of proteins in human kidney T1-cells in vitro. Sharan RN, et al. **Indian J Biochem Biophys** 1996 Aug;33(4):281–4
Endogenous ADP-ribosylation of proteins in Mycobacterium smegmatis. Serres MH, et al. **J Bacteriol** 1996 Oct; 178(20):6074–7
Cell-permeable ceramides prevent the activation of phospholipase D by ADP-ribosylation factor and RhoA. Abousalham A, et al. **J Biol Chem** 1997 Jan 10; 272(2):1069–75
Residues within the polycationic region of cGMP phosphodiesterase gamma subunit crucial for the interaction with transducin alpha subunit. Identification by endogenous ADP-ribosylation and site-directed mutagenesis. Bondarenko VA, et al. **J Biol Chem** 1997 Jun 20;272(25):15856–64
Evidence for endogenous ADP-ribosylation of GTP-binding proteins in neuronal cell nucleus. Possible induction by membrane depolarization. Cohen-Armon M, et al. **J Biol Chem** 1996 Oct 18;271(42):26200–8
Characterization of two alternately spliced forms of phospholipase D1. Activation of the purified enzymes by phosphatidylinositol 4,5-bisphosphate, ADP-ribosylation factor, and Rho family monomeric GTP-binding proteins and protein kinase C-alpha. Hammond SM, et al. **J Biol Chem** 1997 Feb 7;272(6):3860–8
Glutamic acid 207 in rodent T-cell RT6 antigens is essential for arginine-specific ADP-ribosylation. Hara N, et al. **J Biol Chem** 1996 Nov 22;271(47):29552–5
Arfaptin 1, a putative cytosolic target protein of ADP-ribosylation factor, is recruited to Golgi membranes. Kanoh H, et al. **J Biol Chem** 1997 Feb 28;272(9):5421–9
ADPribosylation reaction by free ADPribose in Sulfolobus solfataricus, a thermophilic archaeon. Faraone-Mennella MR, et al. **J Cell Biochem** 1997 Jul 1;66(1):37–42
ADP-ribosylation of p53 tumor suppressor protein: mutant but not wild-type p53 is modified. Węsierska-Gądek J, et al. **J Cell Biochem** 1996 Jul;62(1):90–101
Blue light induced ADP ribosylation of 38 and 56 kDa proteins in the soluble fraction of mycelia of Neurospora crassa. Mizoguchi K, et al. **J Photochem Photobiol B** 1996 Sep;35(3):197–201
ADP-ribosylation of G alpha i and G alpha o in pituitary cells enhances their recognition by antibodies directed against their carboxyl termini. Cussac D, et al. **J Recept Signal Transduct Res** 1996 May-Jul; 16(3-4):169–90
Alterations in inotropy, nitric oxide and cyclic GMP synthesis, protein phosphorylation and ADP-ribosylation in the endotoxin-treated rat myocardium and cardiomyocytes. Sulakhe PV, et al. **Mol Cell Biochem** 1996 Oct-Nov;163-164:305–18
ADP-ribosylation of actin by Clostridium perfringens iota toxin and turkey erythrocyte ADP-ribosyltransferase A: effects on profilin-regulated nucleotide exchange and ATPase activity. Sehr P, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Dec; 354(6):693–7
Possible involvement of ADP-ribosylation of particular enzymes in cell death induced by nitric oxide-donors in human neuroblastoma cells. Kamoshima W, et al. **Neurochem Int** 1997 Mar;30(3):305–11
Long-term neuroleptic treatments counteract dopamine D2 agonist inhibition of adenylate cyclase but do not affect pertussis toxin ADP-ribosylation in the rat brain. Okada F, et al. **Neurochem Int** 1996 Feb;28(2):161–8
Time-dependent effects of in vivo pertussis toxin on morphine analgesia and G-proteins in mice. Shah S, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):465–9

PHARMACOLOGY

Metabolism and actions of ADP-riboses in coronary arterial smooth muscle. Li P, et al. **Adv Exp Med Biol** 1997; 419:437–41
Extracellularly applied ruthenium red and cADP ribose elevate cytosolic Ca2+ in isolated rat osteoclasts. Adebanjo OA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):F469–75
A competitive inhibition of the mitochondrial NADH-ubiquinone oxidoreductase (complex I) by ADP-ribose. Zharova TV, et al. **Biochim Biophys Acta** 1997 Jul 4;1320(3):256–64

RADIATION EFFECTS

Overexpression of human poly(ADP-ribose) polymerase in transfected hamster cells leads to increased

poly(ADP-ribosyl)ation and cellular sensitization to gamma irradiation. Van Gool L, et al. **Eur J Biochem** 1997 Feb 15;244(1):15-20

ADENOSINE DIPHOSPHOGLUCOSE see **ADENOSINE DIPHOSPHATE GLUCOSE**

ADENOSINE DIPHOSPHORIBOSE see **ADENOSINE DIPHOSPHATE RIBOSE**

ADENOSINE KINASE

ANTAGONISTS & INHIBITORS

The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Wang B, et al. **Anesth Analg** 1997 Sep;85(3):675-80

Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Decking UK, et al. **Circ Res** 1997 Aug;81(2):154-64

Adenosine kinase inhibitors augment release of adenosine from spinal cord slices. Golembiowska K, et al. **Eur J Pharmacol** 1996 Jun 27;307(2):157-62

Adenosine kinase inhibition protects brain against transient focal ischemia in rats. Jiang N, et al. **Eur J Pharmacol** 1997 Feb 12;320(2-3):131-7

Potentiation of excitatory amino acid-evoked adenosine release from rat cortex by inhibitors of adenosine kinase and adenosine deaminase and by acadesine. White TD. **Eur J Pharmacol** 1996 May 6;303(1-2):27-38

Pre- and peristroke treatment with the adenosine kinase inhibitor, 5'-deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats. Miller LP, et al. **Neurosci Lett** 1996 Dec 13;220(2):73-6

GENETICS

Cloning and expression of the adenosine kinase gene from rat and human tissues. McNally T, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):645-50

Cloning and characterization of cDNA for adenosine kinase from mammalian (Chinese hamster, mouse, human and rat) species. High frequency mutants of Chinese hamster ovary cells involve structural alterations in the gene. Singh B, et al. **Eur J Biochem** 1996 Oct 15;241(2):564-71

METABOLISM

Adenosine-AMP exchange activity is an integral part of the mammalian adenosine kinase. Gupta RS. **Biochem Mol Biol Int** 1996 Jun;39(3):493-502

Pentavalent ions dependency of mammalian adenosine kinase. Hao W, et al. **Biochem Mol Biol Int** 1996 Apr;38(5):889-99

Adenosine metabolism during phorbol myristate acetate-mediated induction of HL-60 cell differentiation: changes in expression pattern of adenosine kinase, adenosine deaminase, and 5'-nucleotidase. Spychala J, et al. **J Immunol** 1997 May 15;158(10):4947-52

ADENOSINE MONOPHOSPHATE

ANALOGS & DERIVATIVES

Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. Balzarini J, et al. **FEBS Lett** 1997 Jun 30;410(2-3):324-8

Mutagenesis and chemical rescue indicate residues involved in beta-aspartyl-AMP formation by Escherichia coli asparagine synthetase B. Boehlein SK, et al. **J Biol Chem** 1997 May 9;272(19):12384-92

Biotinyl-5'-adenylate synthesis catalyzed by Escherichia coli repressor of biotin biosynthesis. Xu Y, et al. **Methods Enzymol** 1997;279:405-21 (25 ref.)

Characterization of the allosteric binding pocket of human liver fructose-1,6-bisphosphatase by protein crystallography and inhibitor activity studies. Iversen LF, et al. **Protein Sci** 1997 May;6(5):971-82

ANALYSIS

Phosphorous metabolites in boar spermatozoa. Identification of AMP by multinuclear magnetic resonance. Kalic M, et al. **Biochim Biophys Acta** 1997 Jun 13;1320(2):208-16

Staurosporine and herbimycin A augment agonist-induced elevation of cAMP in Jurkat T-lymphoblasts. Buc HA, et al. **Int J Immunopharmacol** 1996 Feb;18(2):135-9

BIOSYNTHESIS

IMP reamination to AMP in rat skeletal muscle fiber types. Tullson PC, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):C1067-74

BLOOD

[Concentration of adenine nucleotides in blood of predialysis patients with chronic renal failure] Bułto B, et al. **Pol Arch Med Wewn** 1995 Nov;94(5):389-94 (Eng. Abstr.) **(Pol)**

CHEMISTRY

The interaction of Fe(III), adriamycin and daunomycin with nucleotides and DNA and their effects on cell growth of fibroblasts (NIH-3T3). Di Liegro I, et al. **Biometals** 1996 Apr;9(2):121-30

Adenosine conformations of nucleotides bound to methionyl tRNA synthetase by transferred nuclear Overhauser effect spectroscopy. Murali N, et al. **Biophys J** 1997 May; 72(5):2275-84

Structural basis for the activation of phenylalanine in the non-ribosomal biosynthesis of gramicidin S. Conti E, et al. **EMBO J** 1997 Jul 16;16(14):4174-83

Specific labeling approaches to guanine and adenine imino and amino proton assignments in the AMP-RNA aptamer complex. Jiang F, et al. **J Biomol NMR** 1997 Jan;9(1):55-62

Imino proton exchange and base-pair kinetics in the AMP-RNA aptamer complex. Nonin S, et al. **J Mol Biol** 1997 May 2;268(2):359-74

Divalent cations modify adsorption of 5'-AMP onto precipitated calcium phosphate: a model for cation modulation of adsorptive processes in primitive aqueous environments. Tessis AC, et al. **J Mol Evol** 1996 Nov; 43(5):425-30

Characterization of the allosteric binding pocket of human liver fructose-1,6-bisphosphatase by protein crystallography and inhibitor activity studies. Iversen LF, et al. **Protein Sci** 1997 May;6(5):971-82

DIAGNOSTIC USE

Differences in the effect of allergen avoidance on bronchial hyperresponsiveness as measured by methacholine, adenosine 5'-monophosphate, and exercise in asthmatic children. Benckhuijsen J, et al. **Pediatr Pulmonol** 1996 Sep; 22(3):147-53

Differential inhibitory effect of regular inhaled corticosteroid on airway responsiveness to adenosine 5' monophosphate, methacholine, and bradykinin in symptomatic children with recurrent wheeze. Doull IJ, et al. **Pediatr Pulmonol** 1997 Jun;23(6):404-11

Adenosine monophosphate and histamine induced bronchoconstriction: repeatability and protection by terbutaline. Egbagbe E, et al. **Thorax** 1997 Mar; 52(3):239-43

Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients [see comments] Tan KS, et al. **Thorax** 1997 Jul;52(7):608-11. Comment in: Thorax 1997 Jul;52(7):591-2.

METABOLISM

Adenosine nucleotides in bile. Chari RS, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G246-52

Adenosine-AMP exchange activity is an integral part of the mammalian adenosine kinase. Gupta RS. **Biochem Mol Biol Int** 1996 Jun;39(3):493-502

RNA folding topology and intermolecular contacts in the AMP-RNA aptamer complex. Jiang F, et al. **Biochemistry** 1996 Oct 8;35(40):13250-66

Isolation of novel ribozymes that ligate AMP-activated RNA substrates. Hager AJ, et al. **Chem Biol** 1997 Aug;4(8):607-17

Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Decking UK, et al. **Circ Res** 1997 Aug;81(2):154-64

Direct measurement of the release of ATP and its major metabolites from the nerve fibres of the guinea-pig taenia coli. McConalogue K, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):807-12

Glucose repression/derepression in budding yeast: SNF1 protein kinase is activated by phosphorylation under derepressing conditions, and this correlates with a high AMP:ATP ratio. Wilson WA, et al. **Curr Biol** 1996 Nov 1;6(11):1426-34

Effect of ammonia on survival and adenylate energy charge in the shrimp Palaemonetes varians. Marazza D, et al. **Ecotoxicol Environ Saf** 1996 Jul;34(2):103-8

Identification of a yeast peroxisomal member of the family of AMP-binding proteins. Blobel F, et al. **Eur J Biochem** 1996 Sep 1;240(2):468-76

Towards a mechanism of AMP-substrate inhibition in adenylate kinase from Escherichia coli. Sinev MA, et al. **FEBS Lett** 1996 Nov 18;397(2-3):273-6

In vitro assembly of FAD, AMP, and the two subunits of electron-transferring flavoprotein: an important role of AMP related with the conformational change of the apoprotein. Sato K, et al. **J Biochem (Tokyo)** 1997 Mar; 121(3):477-86

Thermodynamic characterization of 5'-AMP binding to bovine liver glycogen phosphorylase a. García-Fuentes L, et al. **J Biol Chem** 1996 Nov 1;271(44):27569-74

Importance of the dimer-dimer interface for allosteric signal transduction and AMP cooperativity of pig kidney fructose-1,6-bisphosphatase. Site-specific mutagenesis studies of Glu-192 and Asp-187 residues on the 190's loop. Lu G, et al. **J Biol Chem** 1997 Feb 21;272(8):5076-81

Effect of extracellular AMP on cell proliferation and metabolism of breast cancer cell lines with high and low glycolytic rates. Mazurek S, et al. **J Biol Chem** 1997 Feb 21;272(8):4941-52

AMP is a component of the low molecular weight mitogenic activity present in human pituitary tumours. Lewis MD, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1296-8

Small-molecule-substrate interactions with a self-aminoacylating ribozyme. Illangasekare M, et al. **J Mol Biol** 1997 May 9;268(3):631-9

AMP degradation in the perfused rat heart during 2-deoxy-D-glucose perfusion and anoxia. Part II: The determination of the degradation pathways using an adenosine deaminase inhibitor. Chen W, et al. **J Mol Cell Cardiol** 1996 Oct;28(10):2175-82

A comparison of AMP degradation in the perfused rat heart during 2-deoxy-D-glucose perfusion and anoxia. Part I: The release of adenosine and inosine. Chen W, et al. **J Mol Cell Cardiol** 1996 Oct;28(10):2163-74

A possible role of adenylate metabolism in human erythrocytes. 2. Adenylate metabolism is able to improve the erythrocyte volume stabilization. Ataullakhanov FI, et al. **J Theor Biol** 1996 Dec 7;183(3):307-16

Cell shape change reveals the cyclic AMP-mediated action of follicle stimulating hormone, human chorionic gonadotrophin and vasoactive intestinal peptide in primary cultured human granulosa-lutein cells. Furger C, et al. **Mol Hum Reprod** 1996 Apr;2(4):251-7

Evidence for an active T-state pig kidney fructose 1,6-bisphosphatase: interface residue Lys-42 is important for allosteric inhibition and AMP cooperativity. Lu G, et al. **Protein Sci** 1996 Nov;5(11):2333-42

PHARMACOLOGY

Mechanisms of inhibition of amido phosphoribosyltransferase from mouse L1210 leukemia cells. Schoettle SL, et al. **Biochemistry** 1997 May 27;36(21):6377-83

Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5'-monophosphate. Boyer JL, et al. **Br J Pharmacol** 1996 Aug;118(8):1959-64

Analogous activation of bovine liver glycogen phosphorylase by AMP and IMP. Cámara-Artigas A, et al. **Int J Biochem Cell Biol** 1997 May;29(5):849-56

Time course of changes in adenosine 5'-monophosphate airway responsiveness with inhaled heparin in allergic asthma. Polosa R, et al. **J Allergy Clin Immunol** 1997 Mar; 99(3):338-44

Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. Winder WW, et al. **J Appl Physiol** 1997 Jan;82(1):219-25

Role of adenosine in blood flow in the rat intestine. Obata T, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jun; 92(3):369-72

PHYSIOLOGY

Phosphatase-mediated enhancement of cardiac cAMP-activated Cl-conductance by a Cl- channel blocker, anthracene-9-carboxylate. Zhou SS, et al. **Circ Res** 1997 Aug;81(2):219-28

ADENOSINE PHOSPHATES see **ADENINE NUCLEOTIDES**

ADENOSINE PHOSPHOSULFATE

PHARMACOKINETICS

Disposition of intravenously administered adenosine 5'-phosphosulfate (APS) in rats. Iwata K, et al. **Biol Pharm Bull** 1996 Mar;19(3):438-43

ADENOSINE PYROPHOSPHATE see **ADENOSINE DIPHOSPHATE**

ADENOSINE PYROPHOSPHATEGLUCOSE see **ADENOSINE DIPHOSPHATE GLUCOSE**

ADENOSINE RECEPTORS see **RECEPTORS, PURINERGIC P1**

ADENOSINE TRIPHOSPHATE

[Other antiarrhythmic agents] Sato T. **Nippon Rinsho** 1996 Aug;54(8):2138-43 (8 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Impaired endothelium-dependent vasodilation of coronary resistance vessels in severely stunned porcine myocardium. McFalls EO, et al. **Basic Res Cardiol** 1995 Nov-Dec; 90(6):498-506

Liposomal ATP protects the liver from injury during shock. Konno H, et al. **Eur Surg Res** 1996;28(2):140-5

[Adenosine triphosphate: an additive myocardial agent in cardioplegia] Mochizuki Y, et al. **Rinsho Kyobu Geka** 1989 Apr;9(2):176-9 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

[The risk of severe bradycardia from the use of adenosine triphosphate in pheochromocytoma surgery under total intravenous anesthesia with propofol (letter)] Munar F, et al. **Rev Esp Anestesiol Reanim** 1997 Jun-Jul;44(6):254-5 **(Spa)**

[Transient atrioventricular conduction 1:1 in a patient with common atrial flutter following the administration of adenosine triphosphate] Falces Salvador C, et al. **Rev Esp Cardiol** 1996 Oct;49(10):767-9 (Eng. Abstr.) **(Spa)**

ADENOSINE TRIPHOSPHATE

ANALOGS & DERIVATIVES

Electrophysiological-anatomic correlates of ATP-triggered vagal reflex in the dog. IV. Role of LV vagal afferents. Katchanov G, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1898-903

Inhibition of ecto-ATPase by the P2 purinoceptor agonists, ATPgammaS, alpha,beta-methylene-ATP, and AMP-PNP, in endothelial cells. Chen BC, et al. **Biochem Biophys Res Commun** 1997 Apr 17;233(2):442-6

Single molecule imaging of fluorophores and enzymatic reactions achieved by objective-type total internal reflection fluorescence microscopy. Tokunaga M, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):47-53

Binding of ATP and ATP analogues to the uncoating ATPase Hsc70 (70 kDa heat-shock cognate protein). Buxbaum E, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):923-9

Role of P2-purinergic receptors in rat Leydig cell steroidogenesis. Foresta C, et al. **Biochem J** 1996 Dec 1; 320 (Pt 2):499-504

Exploiting nucleotide thiophosphates to probe mechanistic aspects of Escherichia coli DNA gyrase. Cullis PM, et al. **Biochemistry** 1997 May 20;36(20):6059-68

X-ray structures of the MgADP, MgATPgammaS, and MgAMPPNP complexes of the Dictyostelium discoideum myosin motor domain. Gulick AM, et al. **Biochemistry** 1997 Sep 30;36(39):11619-28

Solution structure of the quaternary MutT-M2+-AMPCPP-M2+ complex and mechanism of its pyrophosphohydrolase action. Lin J, et al. **Biochemistry** 1997 Feb 11;36(6):1199-211

Mechanism for coupling free energy in ATPase to the myosin active site. Park S, et al. **Biochemistry** 1997 Mar 18; 36(11):3368-72

Time-dependent inhibition of recA protein-catalyzed ATP hydrolysis by ATPgammaS: evidence for a rate-determining isomerization of the recA-ssDNA complex. Paulus BF, et al. **Biochemistry** 1997 Jun 24; 36(25):7832-8

Monitoring the myosin ATPase reaction using a sensitive fluorescent probe: pyrene-labeled ATP. Hiratsuka T. **Biophys J** 1997 Feb;72(2 Pt 1):843-9

Changes in the composition of the platelet cytoskeleton in response to ADP: effects of MK-852 and ARL 66096. May JA, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):221-4

Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood. Sanderson HM, et al. **Blood Coagul Fibrinolysis** 1996 Mar; 7(2):245-8

Rise in cytosolic Ca2+ concentration induced by P2-purinoceptor activation in isolated myocytes from the rat gastrointestinal tract. Blottière HM, et al. **Br J Pharmacol** 1996 Mar;117(5):775-80

Enhancement of the response to purinergic agonists in P2Y1 transfected 1321N1 cells by antagonists suramin and PPADS. Brown CA, et al. **Br J Pharmacol** 1997 Mar; 120(6):1049-52

Responses of the longitudinal muscle and the muscularis mucosae of the rat duodenum to adenine and uracil nucleotides. Johnson CR, et al. **Br J Pharmacol** 1996 Mar; 117(5):823-30

The binding characteristics of a human bladder recombinant P2X purinoceptor, labelled with [3H]-alpha beta meATP, [35S]-ATP gamma S or [33P]-ATP. Michel AD, et al. **Br J Pharmacol** 1996 Mar;117(6):1254-60

High affinity P2x-purinoceptor binding sites for [35S]-adenosine 5'-O-[3-thiotriphosphate] in rat vas deferens membranes. Michel AD, et al. **Br J Pharmacol** 1996 Jan;117(1):63-70

Characterization of [35S]-ATP alpha S and [3H]-alpha, beta-MeATP binding sites in rat brain cortical synaptosomes: regulation of ligand binding by divalent cations. Schäfer R, et al. **Br J Pharmacol** 1997 Jul; 121(5):913-22

Enhancement of sympathetic purinergic neurotransmission in the guinea-pig isolated vas deferens by the novel ecto-ATPase inhibitor ARL 67156. Westfall TD, et al. **Br J Pharmacol** 1996 Mar;117(5):867-72

The possible role of ATP and PACAP as mediators of apaminsensitive NANC inhibitory junction potentials in circular muscle of guinea-pig colon. Zagorodnyuk V, et al. **Br J Pharmacol** 1996 Nov;119(5):779-86

Characterization of alpha, beta-methylene ATP binding sites in mouse crude synaptic membranes. Hori S, et al. **Brain Res Bull** 1997;43(1):59-63

Decay rates of anti-HIV dideoxynucleotides in tissue culture systems: a simple correction for the effect of cell replication. Ahluwalia GS, et al. **Drug Metab Dispos** 1997 Jul;25(7):893-6

Affinity labeling of Escherichia coli histidyl-tRNA synthetase with reactive ATP analogues. Identification of labeled amino acid residues by matrix assisted laser desorption-ionization mass spectrometry. Gillet S, et al. **Eur J Biochem** 1996 Oct 1;241(1):133-41

Changes of creatine kinase secondary structure induced by the release of nucleotides from caged compounds. An infrared difference-spectroscopy study. Raimbault C, et al. **Eur J Biochem** 1996 Aug 15;240(1):134-42

ATP and beta,gamma-methylene ATP produce relaxation of guinea-pig isolated trachealis muscle via actions at P1 purinoceptors. Piper AS, et al. **Eur J Pharmacol** 1996 Jun 27;307(2):183-9

The ecto-ATPase inhibitor ARL 67156 enhances parasympathetic neurotransmission in the guinea-pig urinary bladder. Westfall TD, et al. **Eur J Pharmacol** 1997 Jun 25;329(2-3):169-73

Probing phosphatidylinositolphosphates and adenosinenucleotides on talin nucleated actin polymerization. Isenberg G, et al. **FEBS Lett** 1996 Nov 18;397(2-3):316-20

Binding of TNP-ATP and TNP-ADP to the non-catalytic sites of Escherichia coli F1-ATPase. Weber J, et al. **FEBS Lett** 1997 Jul 21;412(1):169-72

Characterization and autoradiographic localization of [3H] alpha,beta-methylene ATP binding sites in cat urinary bladder. Zhao M, et al. **Gen Pharmacol** 1996 Apr; 27(3):509-12

Inhibitory action of extracellular adenosine 5'-triphosphate on parietal cells isolated from rabbit gastric mucosa. Gil-Rodrigo CE, et al. **Gen Physiol Biophys** 1996 Jun; 15(3):251-64

An infrared fluorescent dATP for labeling DNA. Steffens DL, et al. **Genome Res** 1995 Nov;5(4):393-9

Activation of P2x-purinoceptors in the nucleus tractus solitarius elicits differential inhibition of lumbar and renal sympathetic nerve activity. Scislo TJ, et al. **J Auton Nerv Syst** 1997 Jan 12;62(1-2):103-10

The heterogeneous interaction of substoichiometric TNP-ATP and F1-ATPase from Escherichia coli. Muneyuki E, et al. **J Biochem (Tokyo)** 1996 Nov; 120(5):940-5

Modification of domains of alpha and beta subunits of F1-ATPase from the thermophylic bacterium PS3, in their isolated and associated forms, by 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate (BzATP). Bar-Zvi D, et al. **J Bioenerg Biomembr** 1996 Dec;28(6):471-81

Electron tomography of insect flight muscle in rigor and AMPPNP at 23 degrees C. Schmitz H, et al. **J Mol Biol** 1996 Nov 29;264(2):279-301

Three-dimensional structure of nucleotide-bearing crossbridges in situ: oblique section reconstruction of insect flight muscle in AMPPNP at 23 degrees C. Winkler H, et al. **J Mol Biol** 1996 Nov 29;264(2):302-22

Antagonistic effect of Na+ and Mg2+ on P2z purinoceptor-associated pores in dibutyryl cyclic AMP-differentiated NG108-15 cells. Song SL, et al. **J Neurochem** 1996 Oct;67(4):1694-701

Identification and characterization of P2Y2 nucleotide receptors in human retinal pigment epithelial cells. Sullivan DM, et al. **J Neurosci Res** 1997 Jul 1;49(1):43-52

P2T purinoceptor antagonists. A QSAR study of some 2-substituted ATP analogues. Tomkinson NP, et al. **J Pharm Pharmacol** 1996 Feb;48(2):206-9

Mechanical study of rat soleus muscle using caged ATP and X-ray diffraction: high ADP affinity of slow cross-bridges. Horiuti K, et al. **J Physiol (Lond)** 1997 Jul 15;502 (Pt 2):433-47

P2X purinoceptors in cultured myenteric neurons of guinea-pig small intestine. Zhou X, et al. **J Physiol (Lond)** 1996 Nov 1;496 (Pt 3):719-29

Endotoxin-induced apoptosis in ovarian follicles is partially blocked by 2-methylthioATP or 2-chloroATP. Perez GI, et al. **Mol Reprod Dev** 1996 Jul;44(3):360-9

Autoradiography of [3H]alpha,beta-methylene-ATP binding sites in medulla oblongata and spinal cord of the rat. Tuyau M, et al. **Neurochem Int** 1997 Feb;30(2):159-69

Kinetic variability and modulation of dSlo, a cloned calcium-dependent potassium channel. Bowlby MR, et al. **Neuropharmacology** 1996;35(7):867-75

Functional evidence for multiple purinoceptor subtypes in the rat medial vestibular nucleus. Chessell IP, et al. **Neuroscience** 1997 Apr;77(3):783-91

Kinetics of force generation by single kinesin molecules activated by laser photolysis of caged ATP. Higuchi H, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4395-400

Distribution of [3H] alpha, beta-methylene ATP binding sites in pulmonary blood vessels of different species. Zhao M, et al. **Pulm Pharmacol** 1996 Jun;9(3):167-74

ANALYSIS

Characterization of fluorescent nucleoside triphosphates by capillary electrophoresis with laser-induced fluorescence detection: action of alkaline phosphatase and DNA polymerase. Evangelista RA, et al. **Anal Biochem** 1996 Mar 1;235(1):89-97

Cationic liposomes enhanced firefly bioluminescent assay of adenosine 5'-triphosphate disodium salt. Kamidate T, et al. **Anal Biochem** 1997 Jan 1;244(1):62-6

Batch analysis of the ATP content of bovine sperm, oocytes, and early embryos using a scintillation counter to measure the chemiluminescence produced by the luciferin-luciferase reaction. Rieger D. **Anal Biochem** 1997 Mar 1;246(1):67-70

Enzymatic treatment to eliminate the extracellular ATP for improving the detectability of bacterial intracellular ATP. Sakakibara T, et al. **Anal Biochem** 1997 Aug 1;250(2):157-61

VDAC channels mediate and gate the flow of ATP: implications for the regulation of mitochondrial function. Rostovtseva T, et al. **Biophys J** 1997 May;72(5):1954-62

Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay. Kurbacher CM, et al. **Breast Cancer Res Treat** 1996; 41(2):161-70

Rapid detection of susceptibility to fluconazole in Candida species by a bioluminescence assay of intracellular ATP. Kretschmar M, et al. **Diagn Microbiol Infect Dis** 1996 Jul; 25(3):117-21

The bound adenine nucleotides of purified bovine mitochondrial ATP synthase. Beharry S, et al. **Eur J Biochem** 1996 Aug 15;240(1):165-72

Use of firefly luciferase for ATP measurement: other nucleotides enhance turnover. Ford SR, et al. **J Biolumin Chemilumin** 1996 May-Jun;11(3):149-67

Long-term l-carnitine treatment prolongs the survival in rats with adriamycin-induced heart failure. Kawasaki N, et al. **J Card Fail** 1996 Dec;2(4):293-9

31P NMR methods for the direct determination of ADP in the presence of ATP. Ben-Bashat D, et al. **J Magn Reson B** 1996 Mar;110(3):231-9

Multi-echo 31P spectroscopic imaging of ATP: a scan time reduction strategy. Chao H, et al. **J Magn Reson Imaging** 1997 Mar-Apr;7(2):425-33

Effect of temperature in focal ischemia of rat brain studied by 31P and 1H spectroscopic imaging. Kozlowski P, et al. **Magn Reson Med** 1997 Mar;37(3):346-54

Analysis of the bound nucleotide in the acto-heavy meromyosin in vitro motility assay. Kellermayer MS. **Physiol Chem Phys Med NMR** 1996;28(3):143-51

The intracellular ATP content of fresh and cultured human islets isolated from different donors. Brandhorst D, et al. **Transplant Proc** 1997 Jun;29(4):1979

ATP content of isolated islets: indication for species-dependent vulnerability for cell-mediated graft rejection? Brandhorst D, et al. **Transplant Proc** 1997 Jun; 29(4):2058

The effects of ischemia and reperfusion on mucosal respiratory function, adenosine triphosphate, electrolyte, and water content in the ascending colon of ponies. McAnulty JF, et al. **Vet Surg** 1997 May-Jun;26(3):172-81

ANTAGONISTS & INHIBITORS

Nordihydroguaiaretic acid depletes ATP and inhibits a swelling-activated, ATP-sensitive taurine channel. Ballatori N, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1429-36

Tyrphostin inhibition of ATP-stimulated DNA synthesis, cell proliferation and fos-protein expression in vascular smooth muscle cells. Erlinge D, et al. **Br J Pharmacol** 1996 Jun; 118(4):1028-34

Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. Denny WA, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):424-7

Cromakalim blocks the purinergic response evoked in rat vas deferens by single-pulse electrical stimulation. Grana E, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):57-64

BIOSYNTHESIS

Recovery of adenosine triphosphate tissue levels of grafts preserved by the two-layer method after reperfusion. Kim Y, et al. **Artif Organs** 1996 Oct;20(10):1120-4

Stimulation of ATP synthesis via oxidative phosphorylation in wheat mitochondria irradiated with helium-neon laser. Pastore D, et al. **Biochem Mol Biol Int** 1996 May; 39(1):149-57

The ATP-induced K(+)-transport pathway of yeast mitochondria may function as an uncoupling pathway. Manon S, et al. **Biochim Biophys Acta** 1997 Feb 15; 1318(3):317-21

Increased oxidative and delayed glycogenolytic ATP synthesis in exercising skeletal muscle of obese (insulin-resistant) Zucker rats. Sanderson AL, et al. **Clin Sci (Colch)** 1996 Dec;91(6):691-702

Are insulin resistance and atherosclerosis the consequences of oxidative stress? [letter; comment] Wittmann I, et al. **Diabetologia** 1996 Aug;39(8):1002-3. Comment on: Diabetologia 1995 Dec;38(12):1484-5.

The effect of repeated muscle biopsy sampling on ATP and glycogen resynthesis following exercise in man. Constantin-Teodosiu D, et al. **Eur J Appl Physiol** 1996; 73(1-2):186-90

Turnover number of Escherichia coli F0F1 ATP synthase for ATP synthesis in membrane vesicles. Etzold C, et al. **Eur J Biochem** 1997 Jan 15;243(1-2):336-43

Toxoplasma gondii: metabolism of intracellular tachyzoites is affected by host cell ATP production. Sorensen SW, et al. **Exp Parasitol** 1997 Jan;85(1):101-4

Frontiers in ATP synthase research: understanding the relationship between subunit movements and ATP synthesis. Pedersen PL. **J Bioenerg Biomembr** 1996 Oct; 28(5):389-95 (46 ref.)

Coupling H+ transport and ATP synthesis in F1F0-ATP synthases: glimpses of interacting parts in a dynamic molecular machine. Fillingame RH. **J Exp Biol** 1997 Jan; 200 (Pt 2):217-24 (68 ref.)

Generation of inorganic pyrophosphate from extracellular adenosine triphosphate by human serum and plasma. Park W, et al. **J Rheumatol** 1996 Jul;23(7):1233-6

Glycolytic ATP production estimated from 31P magnetic resonance spectroscopy measurements during ischemic exercise in vivo. Wackerhage H, et al. **MAGMA** 1996 Sep-Dec;4(3-4):151-5

Does excessive adenosine 5'-triphosphate formation in cells lead to malignancy? A hypothesis on cancer. Ray S, et al. **Med Hypotheses** 1997 Jun;48(6):473-6

Anaerobic ATP production and accumulated O2 deficit in

cyclists. Green S, et al. **Med Sci Sports Exerc** 1996 Mar; 28(3):315–21

Adenosine triphosphate production rates, metabolic economy calculations, pH, phosphomonoesters, phosphodiesters, and force output during short–duration maximal isometric plantar flexion exercises and repeated maximal isometric plantar flexion exercises. Newcomer BR, et al. **Muscle Nerve** 1997 Mar;20(3):336–46

Regulation of oxidative and glycogenolytic ATP synthesis in exercising rat skeletal muscle studied by 31P magnetic resonance spectroscopy. Kemp GJ, et al. **NMR Biomed** 1996 Sep;9(6):261–70

Changes in the ability of ATP synthesis in the mitochondrial membrane in the rat liver injured by carbon tetrachloride. Seya K, et al. **Tohoku J Exp Med** 1996 Apr;178(4):425–30

BLOOD

Modulation of K–Cl cotransport in volume–clamped low–K sheep erythrocytes by pH, magnesium, and ATP. Ortiz–Carranza O, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1049–58

Kinetic analysis of enzymatic hydrolysis of ATP in human and rat blood serum. Yegutkin GG. **Biochemistry (Mosc)** 1997 Jun;62(6):619–22

The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets. Horie S, et al. **Biol Pharm Bull** 1997 Jun;20(6):625–31

Diabetes mellitus and subjects' ageing: a study on the ATP content and ATP–related enzyme activities in human erythrocytes. Rabini RA, et al. **Eur J Clin Invest** 1997 Apr; 27(4):327–32

Evidence that most high–affinity ATP binding sites on aortic endothelial cells and membranes do not correspond to P2 receptors. Motte S, et al. **Eur J Pharmacol** 1996 Jun 27; 307(2):201–9

G––>T transition at cDNA nt 110 (K37Q) in the PKLR (pyruvate kinase) gene is the molecular basis of a case of hereditary increase of red blood cell ATP. Beutler E, et al. **Hum Mutat** 1997;9(3):282–5

Adenosine triphosphate levels in human plasma. Ryan LM, et al. **J Rheumatol** 1996 Feb;23(2):214–9

Changes in Na,K–adenosine triphosphatase (ATPase) concentration and Na,K–ATPase–dependent adenosine triphosphate turnover in human erythrocytes in diabetes. Garner MH. **Metabolism** 1996 Aug;45(8):927–34

Effect of P2–purinoceptor antagonists on hemolysate–induced and adenosine 5'–triphosphate–induced contractions of dog basilar artery in vitro. Sima B, et al. **Neurosurgery** 1996 Oct;39(4):815–21; discussion 821–2

Cell membrane fluctuations are regulated by medium macroviscosity: evidence for a metabolic driving force. Tuvia S, et al. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):5045–9

Critical evaluation of the quantification of ATP release reaction in whole blood. Knöfler R, et al. **Thromb Res** 1996 Nov 1;84(3):157–65

Hyperammonemia inhibits platelet aggregation in rats. Shinya H, et al. **Thromb Res** 1996 Jan 15;81(2):195–201

[Studies on Rehmanniae radix. III. The relation between changes of constituents and improvable effects on hemorheology with the processing of roots of Rehmannia glutinosa] Kubo M, et al. **Yakugaku Zasshi** 1996 Feb; 116(2):158–68 (Eng. Abstr.) **(Jpn)**

[Concentration of adenine nucleotides in blood of predialysis patients with chronic renal failure] Bułło B, et al. **Pol Arch Med Wewn** 1995 Nov;94(5):389–94 (Eng. Abstr.) **(Pol)**

[The levels of adenine nucleotides and hypoxanthine in blood of patients on long–term hemodialysis using dialysis fluid containing acetate or bicarbonate] Bułło B, et al. **Przegl Lek** 1997;54(1):3–5 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Conformational transition of DnaA protein by ATP: structural analysis of DnaA protein, the initiator of Escherichia coli chromosome replication. Kubota T, et al. **Biochem Biophys Res Commun** 1997 Mar 6;232(1):130–5

Crystal structures of three misacylating mutants of Escherichia coli glutaminyl–tRNA synthetase complexed with tRNA(Gln) and ATP. Arnez JG, et al. **Biochemistry** 1996 Nov 26;35(47):14725–33

The effects of temperature, pH, and magnesium on the diffusion coefficient of ATP in solutions of physiological ionic strength. Hubley MJ, et al. **Biochim Biophys Acta** 1996 Oct 24;1291(2):115–21

Rescue of in vitro actin motility halted at high ionic strength by reduction of ATP to submicromolar levels. Kellermayer MS, et al. **Biochim Biophys Acta** 1996 Nov 12; 1277(1–2):107–14

Molecular imprinting approach for the recognition of adenine in aqueous medium and hydrolysis of adenosine 5'–triphosphate. Mathew J, et al. **Bioconjug Chem** 1995 Sep–Oct;6(5):524–8

Force production by chemically crosslinked myosin–actin crossbridges in rabbit skinned fibers in response to MgATP depletion. Emoto Y, et al. **Biophys Chem** 1996 Oct 30; 61(2–3):85–92

ATP–dependent fluctuations of single actin filaments in vitro. Hatori K, et al. **Biophys Chem** 1996 Feb 8;58(3):267–72

Adenosine conformations of nucleotides bound to methionyl tRNA synthetase by transferred nuclear Overhauser effect spectroscopy. Murali N, et al. **Biophys J** 1997 May; 72(5):2275–84

The assisted self–association of ATP4– by a poly(amino acid) [poly(Lys)] and its significance for cell organelles that contain high concentrations of nucleotides. Sigel H, et al. **Eur J Biochem** 1996 Sep 15;240(3):508–17

High–resolution crystal structures of human cyclin–dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. Schulze–Gahmen U, et al. **J Med Chem** 1996 Nov 8; 39(23):4540–6

Distinct actions of cis and trans ATP within the double ring of the chaperonin GroEL [see comments] Rye HS, et al. **Nature** 1997 Aug 21;388(6644):792–8. Comment in: Nature 1997 Aug 21;388(6644):720–1, 723.

Change in chemical shift and splitting of 31P gamma–ATP signal in human skeletal muscle during exercise and recovery. Widmaier S, et al. **NMR Biomed** 1996 Feb; 9(1):1–7

DEFICIENCY

No influence of echinocytic shape transformation of erythrocytes on phagocytosis by autologous monocytes in vitro. Reinhart WH, et al. **Acta Haematol** 1997;97(3):132–6

Disassociation of oxidant–induced ATP depletion and DNA damage from early cytotoxicity in LLC–PK1 cells. Andreoli SP, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):F729–35

Loss of plasma membrane structural support in ATP–depleted renal epithelia. Doctor RB, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C439–49

Cellular ATP depletion induces disruption of the spectrin cytoskeletal network. Molitoris BA, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):F790–8

Contribution of actin cytoskeletal alterations to ATP depletion and calcium–induced proximal tubule cell injury. Nurko S, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):F39–52

Two mechanisms by which ATP depletion potentiates induction of the mitochondrial permeability transition. Simbula G, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C479–88

ATP depletion alters myosin I beta cellular location in LLC–PK1 cells. Wagner MC, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1680–90

Cytosolic–free calcium increases to greater than 100 micromolar in ATP–depleted proximal tubules. Weinberg JM, et al. **J Clin Invest** 1997 Aug 1;100(3):713–22

DIAGNOSTIC USE

Can adenosine 5'–triphosphate be used to select treatment in severe vasovagal syndrome? Flammang D, et al. **Circulation** 1997 Aug 19;96(4):1201–8

Comparison of adenosine triphosphate and dipyridamole in diagnosis by thallium–201 myocardial scintigraphy. Watanabe K, et al. **J Nucl Med** 1997 Apr;38(4):577–81

ISOLATION & PURIFICATION

[Comparative evaluation of methods of intracellular ATP extraction from different types of microorganisms for bioluminescent determinationof microbial cells] Romanova NA, et al. **Prikl Biokhim Mikrobiol** 1997 May–Jun; 33(3):344–9 (Eng. Abstr.) **(Rus)**

METABOLISM

Blockade of ATP–sensitive K+ channel abolishes the anti–ischemic effects of isoflurane in dog hearts. Nakayama M, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):531–5

Changes in ATP level and iron–induced ultra–weak photon emission in bull spermatozoa, caused by membrane peroxidation during thermal stress. Gumińska M, et al. **Acta Biochim Pol** 1997;44(1):131–8

The NTP phosphate donor in kinase reactions: is ATP a monopolist? Shugar D. **Acta Biochim Pol** 1996;43(1):9–23 (68 ref.)

Is post–hypoxic–ischemic cell damage associated with excessive ATP consumption rather than a failure of ATP production? Harkness RA. **Acta Paediatr** 1997 Jan;86(1):1–5 (70 ref.)

Critical oxygen extraction in piglet hindlimb is impaired after inhibition of ATP–sensitive potassium channels. Vallet B, et al. **Adv Exp Med Biol** 1996;388:311–7

Proton–decoupled myocardial 31P NMR spectroscopy reveals decreased PCr/Pi in patients with severe hypertrophic cardiomyopathy. Sieverding L, et al. **Am J Cardiol** 1997 Aug 4;80(3A):34A–40A

Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer. Sevin BU, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):759–66; discussion 766–8

Contribution of ATP to oxidative stress–induced changes in action potential of isolated cardiac myocytes. Bhatnagar A. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1598–608

ATP–dependent copper transporter, in the Golgi apparatus of rat hepatocytes, transports Cu(II) not Cu(I). Bingham MJ, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):G741–6

Heat stress ameliorates ATP depletion–induced sublethal injury in mouse proximal tubule cells. Borkan SC, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):F347–55

Expression of Drosophila melanogaster P–glycoproteins is associated with ATP channel activity. Bosch I, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1527–38

Adenosine nucleotides in bile. Chari RS, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G246–52

Energy turnover of vascular endothelial cells. Culic O, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C205–13

Effects of extracellular ATP on ion transport and [Ca2+]i in Mongolian gerbil middle ear epithelium. Furukawa M, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C827–36

CFTR–independent ATP release from epithelial cells triggered by mechanical stimuli. Grygorczyk R, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C1058–66

Effects of extracellular ATP on hepatic fatty acid metabolism. Guzmán M, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):G701–7

Acidosis has no effect on the ATP cost of contraction in cat fast– and slow–twitch skeletal muscles. Harkema SJ, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C485–90

In vivo brain phosphocreatine and ATP regulation in mice fed a creatine analog. Holtzman D, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1567–77

Extracellular ATP modulates [Ca2+]i in retinoic acid–treated embryonic chondrocytes. Hung CT, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1611–7

Alveolar type II cell cNOS activity and ATP levels are increased by lung surfactant or DPPC vesicles. Miles PR, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):L339–46

Developmental changes in ATP utilization during graded hypoxia and reoxygenation in the heart in vivo. Portman MA, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H216–23

Cellular ATP release by the cystic fibrosis transmembrane conductance regulator. Prat AG, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):C538–45

Changes in ATP, phosphocreatine, and 16 metabolites in muscle stimulated for up to 96 hours. Salmons S, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1167–71

ATP–dependent transport of beta–estradiol 17–(beta–D–glucuronide) in rat canalicular membrane vesicles. Vore M, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):G791–8

Primary structure and evolution of the ATP–binding domains of the P–type ATPases in Tetrahymena thermophila. Wang S, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C715–28

Inotropic agent EMD–53998 weakens nucleotide and phosphate binding to cross bridges in porcine myocardium. Zhao Y, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1394–406

L–canavanine improves organ function and tissue adenosine triphosphate levels in rodent endotoxemia. Liaudet L, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1643–8

Enzymatic treatment to eliminate the extracellular ATP for improving the detectability of bacterial intracellular ATP. Sakakibara T, et al. **Anal Biochem** 1997 Aug 1;250(2):157–61

Isoflurane and halothane increase adenosine triphosphate preservation, but do not provide additive recovery of function after ischemia, in preconditioned rat hearts. Boutros A, et al. **Anesthesiology** 1997 Jan;86(1):109–17

Mechanism of myocardial protection by isoflurane. Role of adenosine triphosphate–regulated potassium (KATP) channels. Kersten JR, et al. **Anesthesiology** 1996 Oct; 85(4):794–807; discussion 27A

Alteration in cardiac sarcolemmal ATP receptors by oxyradicals. Musat S, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:1–12

Inhibition of the cystic fibrosis transmembrane conductance regulator by ATP–sensitive K+ channel regulators. Sheppard DN, et al. **Ann N Y Acad Sci** 1993 Dec 20; 707:275–84 (41 ref.)

Topology of ATP–binding domain of adrenoleukodystrophy gene product in peroxisomes. Contreras M, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):369–79

Selenophosphate synthetase: enzyme labeling studies with [gamma–32P]ATP, [beta–32P]ATP, [8–14C]ATP, and [75Se]selenide. Liu SY, et al. **Arch Biochem Biophys** 1997 May 15;341(2):353–9

In vitro interaction of nonsteroidal anti–inflammatory drugs on oxidative phosphorylation of rat kidney mitochondria: respiration and ATP synthesis. Mingatto FE, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):303–8

The nature and regulation of the ATP–induced anion permeability in Saccharomyces cerevisiae mitochondria. Prieto S, et al. **Arch Biochem Biophys** 1996 Oct 1; 334(1):43–9

Enhancement of coproporphyrinogen III transport into isolated transformed leukocyte mitochondria by ATP. Rebeiz N, et al. **Arch Biochem Biophys** 1996 Sep 15; 333(2):475–81

Metabolism of extracellular ATP by rat parotid cells. Dowd FJ, et al. **Arch Oral Biol** 1996 Aug–Sep;41(8–9):855–62

Protective effect of nifedipine on myocardial stunning in isolated rabbit hearts: role of high energy phosphates stores. Moreyra AE, et al. **Arch Physiol Biochem** 1996; 104(3):265–71

Involvement of phosphatidylcholine hydrolysis by phospholipase D in extracellular ATP–induced arachidonic acid release in aortic smooth muscle cells. Shinoda J, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):295–9

Possible involvement of ATP–dependent K–channel related mechanisms in the antihypertensive and cough suppressant effects of the novel ACE inhibitor (2S, 3aS, 7aS)–1–(N2–nicotinoyl–L–lysyl–gamma–D–glutamyl)

octahydro-1H- indole-2-carboxylic acid. Nagata S, et al. **Arzneimittelforschung** 1997 Jun;47(6):726-30

Electrophysiological properties of human coronary endothelial cells. Zünkler BJ, et al. **Basic Res Cardiol** 1995 Nov-Dec;90(6):435-42

Effect of ATP binding cassette/multidrug resistance proteins on ATP efflux of Saccharomyces cerevisiae. Boyum R, et al. **Biochem Biophys Res Commun** 1997 Jan 3;230(1):22-6

Sac1p of Saccharomyces cerevisiae is not involved in ATP release to the extracellular fluid. Boyum R, et al. **Biochem Biophys Res Commun** 1997 Jul 9;236(1):50-3

Nucleotide binding to autotaxin: crosslinking of bound substrate followed by lysC digestion identifies two labeled peptides. Clair T, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):449-54

Regulation of carnitine binding to plasma membranes by an ATP-dependent mechanism. Gustafson B, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):249-53

Role of (ADP-ribose)n catabolism in DNA repair. Maruta H, et al. **Biochem Biophys Res Commun** 1997 Jul 18; 236(2):265-9

Decreased ATP-induced synthesis and Ca(2+)-stimulated degradation of polyphosphoinositides in pancreatic islets from neonatally streptozotocin-diabetic rats. Morin L, et al. **Biochem Biophys Res Commun** 1996 Nov 12; 228(2):573-8

CFTR expression in C127 cells is associated with enhanced cell shrinkage and ATP extrusion in Cl(-)-free medium. Rotoli BM, et al. **Biochem Biophys Res Commun** 1996 Oct 23;227(3):755-61

ATP binding, but not its hydrolysis, is required for assembly and proteolytic activity of the HslVU protease in Escherichia coli. Yoo SJ, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):581-5

Poly-L-lysine activates both peptide and ATP hydrolysis by the ATP-dependent HslVU protease in Escherichia coli. Yoo SJ, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):531-5

Evidence for rapid consumption of millimolar concentrations of cytoplasmic ATP during rigor-contracture of metabolically compromised single cardiomyocytes. Allue I, et al. **Biochem J** 1996 Oct 15;319 (Pt 2):463-9

Caenorhabditis elegans LIN-2A and mammalian neuronal CASK are prototypical members of a subfamily of MAGUKs (membrane-associated guanylate kinases) characterized by a common kinase-like domain and a guanylate kinase domain predicted to bind ATP [letter] Baines AJ. **Biochem J** 1996 Dec 1;320 (Pt 2):694-6

Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature region. Bakos E, et al. **Biochem J** 1997 May 1;323 (Pt 3):777-83

Interaction between ATP, oleandomycin and the OleB ATP-binding cassette transporter of Streptomyces antibioticus involved in oleandomycin secretion. Buche A, et al. **Biochem J** 1997 Jan 1;321 (Pt 1):139-44

Binding of ATP and ATP analogues to the uncoating ATPase Hsc70 (70 kDa heat-shock cognate protein). Buxbaum E, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):923-9

Oligomycin inhibits store-operated channels by a mechanism independent of its effects on mitochondrial ATP. Cho JH, et al. **Biochem J** 1997 Jun 15;324 (Pt 3):971-80

Novel 30 kDa protein possessing ATP-binding and chaperone activities. Itoh H, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):567-72

Chromatin condensation during apoptosis requires ATP. Kass GE, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):749-52

Kinetics of extracellular ATP hydrolysis by microvascular endothelial cells from rat heart. Meghji P, et al. **Biochem J** 1995 Jun 15;308 (Pt 3):725-31

Role of ATP and Pi in the mechanism of insulin secretion in the mouse insulinoma betaTC3 cell line. Papas KK, et al. **Biochem J** 1997 Sep 15;326 (Pt 3):807-14

ATP depletion inhibits glucocorticoid-induced thymocyte apoptosis. Stefanelli C, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):909-17

Rat liver mitochondria can synthesize nicotinamide adenine dinucleotide from nicotinamide mononucleotide and ATP via a putative matrix nicotinamide mononucleotide adenylyltransferase. Barile M, et al. **Biochem Mol Biol Int** 1996 Feb;38(2):297-306

Enhancement by F-actin of MgATP-dependent dopamine uptake into isolated chromaffin granules. Morita K, et al. **Biochem Mol Biol Int** 1996 Sep;40(1):61-6

Interaction of ATP with erythroblast glucose-6-phosphate dehydrogenase. Ninfali P, et al. **Biochem Mol Biol Int** 1996 May;39(2):377-85

Serotonin decreases cytoskeletal and cytosolic glycolytic enzymes and the levels of ATP and glucose 1,6-bisphosphate in skin, which is prevented by the calmodulin antagonists thioridazine and clotrimazole. Ashkenazy-Shahar M, et al. **Biochem Mol Med** 1997 Apr; 60(2):187-93

Possible auto-phosphorylation of pyruvate carboxylase. Branson JP, et al. **Biochem Soc Trans** 1997 Feb;25(1):87S

Structural determinants that make hexokinase susceptible to ubiquitin- and ATP-dependent proteolysis. Crinelli R, et al. **Biochem Soc Trans** 1997 Feb;25(1):69S

A myosin head can interact with two chemically modified G-actin monomers at ATP-modulated multiple sites. Arata T. **Biochemistry** 1996 Dec 17;35(50):16061-8

Probing the hydrophobic interactions in the skeletal actomyosin subfragment 1 and its nucleotide complexes by zero-length cross-linking with a nickel-peptide chelate. Bertrand R, et al. **Biochemistry** 1997 Aug 12;36(32):9703-14

Kinetics of myosin subfragment-1-induced condensation of G-actin into oligomers, precursors in the assembly of F-actin-S1. Role of the tightly bound metal ion and ATP hydrolysis. Fievez S, et al. **Biochemistry** 1997 Sep 30; 36(39):11837-42

Phosphorylation of the sodium-potassium adenosinetriphosphatase with adenosine triphosphate and sodium ion that requires subconformations in addition to principal E1 and E2 conformations of the enzyme. Ghosh MC, et al. **Biochemistry** 1996 Sep 24;35(38):12587-90

Myosin regulatory light chain and nucleotide modulation of actin binding site electric charge. Highsmith S. **Biochemistry** 1997 Feb 25;36(8):2010-6

The core domain of the tissue transglutaminase Gh hydrolyzes GTP and ATP. Iismaa SE, et al. **Biochemistry** 1997 Sep 30;36(39):11655-64

Cystic fibrosis transmembrane conductance regulator: the first nucleotide binding fold targets the membrane with retention of its ATP binding function. Ko YH, et al. **Biochemistry** 1997 Apr 22;36(16):5053-64

Kinetic mechanism for p38 MAP kinase. LoGrasso PV, et al. **Biochemistry** 1997 Aug 26;36(34):10422-7

Continuous monitoring of Pi release following nucleotide hydrolysis in actin or tubulin assembly using 2-amino-6-mercapto-7-methylpurine ribonucleoside and purine-nucleoside phosphorylase as an enzyme-linked assay. Melki R, et al. **Biochemistry** 1996 Sep 17; 35(37):12038-45

Mechanism for coupling free energy in ATPase to the myosin active site. Park S, et al. **Biochemistry** 1997 Mar 18; 36(11):3368-72

Opening of the myosin nucleotide triphosphate binding domain during the ATPase cycle. Pate E, et al. **Biochemistry** 1997 Oct 7;36(40):12155-66

ATP-dependent transport of lipophilic cytotoxic drugs by membrane vesicles prepared from MRP-overexpressing HL60/ADR cells. Paul S, et al. **Biochemistry** 1996 Nov 5;35(44):14003-11

Time-dependent inhibition of recA protein-catalyzed ATP hydrolysis by ATPgammaS: evidence for a rate-determining isomerization of the recA-ssDNA complex. Paulus BF, et al. **Biochemistry** 1997 Jun 24; 36(25):7832-8

Consequences of mutations to the phosphorylation site of the alpha-subunit of Na, K-ATPase for ATP binding and E1-E2 conformational equilibrium. Pedersen PA, et al. **Biochemistry** 1996 Dec 17;35(50):16085-93

Rhodobacter sphaeroides phosphoribulokinase: binary and ternary complexes with nucleotide substrate analogs and effectors. Runquist JA, et al. **Biochemistry** 1996 Nov 26; 35(47):15049-56

The rate-determining step on the recA protein-catalyzed ssDNA-dependent ATP hydrolysis reaction pathway. Stole E, et al. **Biochemistry** 1997 Mar 25;36(12):3483-90

Characterization of microtubule-phosphofructokinase complex: specific effects of MgATP and vinblastine. Vértessy BG, et al. **Biochemistry** 1997 Feb 25;36(8):2051-62

Kinetics of the RNA-DNA helicase activity of Escherichia coli transcription termination factor rho. 2. Processivity, ATP consumption, and RNA binding. Walstrom KM, et al. **Biochemistry** 1997 Jul 1;36(26):7993-8004

A two-site mechanism for ATP hydrolysis by the asymmetric Rep dimer P2S as revealed by site-specific inhibition with ADP-A1F4. Wong I, et al. **Biochemistry** 1997 Mar 18; 36(11):3115-25

ATP-binding site of human brain hexokinase as studied by molecular modeling and site-directed mutagenesis. Zeng C, et al. **Biochemistry** 1996 Oct 8;35(40):13157-64

Overexpression of the sodium ATPase of Saccharomyces cerevisiae: conditions for phosphorylation from ATP and Pi. Benito B, et al. **Biochim Biophys Acta** 1997 Sep 4; 1328(2):214-26

Source of ATP for hexokinase-catalyzed glucose phosphorylation in tumor cells: dependence on the rate of oxidative phosphorylation relative to that of extramitochondrial ATP generation. Shinohara Y, et al. **Biochim Biophys Acta** 1997 Apr 11;1319(2-3):319-30

Identification of critical amino acid residues of Saccharomyces cerevisiae carbamoyl-phosphate synthetase: definition of the ATP site involved in carboxy-phosphate formation. Zheng W, et al. **Biochim Biophys Acta** 1997 Aug 15;1341(1):35-48

Uptake of 1-methyl-4-phenylpyridinium ion (MPP+) and ATP content in synaptosomes. Matsunaga M, et al. **Biol Pharm Bull** 1996 Jan;19(1):29-33

Mutual sensitization of ATP and GTP in driving F-actin on the surface-fixed H-meromyosin. Oda T, et al. **Biophys Chem** 1996 Oct 30;61(2-3):63-72

Optical activity of a nucleotide-sensitive tryptophan in myosin subfragment 1 during ATP hydrolysis. Park S, et al. **Biophys Chem** 1996 Dec 10;63(1):67-80

Mechanical components of motor enzyme function. Brokaw CJ. **Biophys J** 1997 Aug;73(2):938-51

Comparison of Na+/K(+)-ATPase pump currents activated by ATP concentration or voltage jumps. Friedrich T, et al. **Biophys J** 1997 Jul;73(1):186-94

Na+,K(+)-ATPase pump currents in giant excised patches activated by an ATP concentration jump. Friedrich T, et al. **Biophys J** 1996 Nov;71(5):2486-500

Time-resolved charge translocation by the Ca-ATPase from sarcoplasmic reticulum after an ATP concentration jump. Hartung K, et al. **Biophys J** 1997 Jun;72(6):2503-14

Osmotic pressure probe of actin-myosin hydration changes during ATP hydrolysis. Highsmith S, et al. **Biophys J** 1996 Jun;70(6):2830-7

A new metal-binding site for yeast phosphoglycerate kinase as determined by the use of a metal-ATP analog. Pappu KM, et al. **Biophys J** 1997 Feb;72(2 Pt 1):928-35

VDAC channels mediate and gate the flow of ATP: implications for the regulation of mitochondrial function. Rostovtseva T, et al. **Biophys J** 1997 May;72(5):1954-62

Exchange of ATP for ADP on high-force cross-bridges of skinned rabbit muscle fibers. Seow CY, et al. **Biophys J** 1997 Jun;72(6):2719-35

Coupling of protein surface hydrophobicity change to ATP hydrolysis by myosin motor domain. Suzuki M, et al. **Biophys J** 1997 Jan;72(1):18-23

Nucleotide-dependent contractile properties of Ca(2+)-activated fast and slow skeletal muscle fibers. Wahr PA, et al. **Biophys J** 1997 Feb;72(2 Pt 1):822-34

Changes in membrane properties during energy depletion-induced cell injury studied with fluorescence microscopy. Wu Y, et al. **Biophys J** 1996 Jul;71(1):91-100

The ATP-binding site of Ca(2+)-ATPase revealed by electron image analysis. Yonekura K, et al. **Biophys J** 1997 Mar;72(3):997-1005

Nucleotide transport through the cystic fibrosis transmembrane conductance regulator. Cantiello HF. **Biosci Rep** 1997 Apr;17(2):147-71 (102 ref.)

Types and sources of fuels for platelets in a medium containing minimal added fuels and a low carryover plasma. Niu X, et al. **Br J Haematol** 1997 Jun;97(4):908-16

Beta-adrenoceptor mediated facilitation of noradrenaline and adenosine 5'-triphosphate release from sympathetic nerves supplying the rat tail artery. Brock JA, et al. **Br J Pharmacol** 1997 Mar;120(5):769-76

Effects of hydroxyethylrutosides on hypoxia-induced activation of human endothelial cells in vitro. Janssens D, et al. **Br J Pharmacol** 1996 Jun;118(3):599-604

The binding characteristics of a human bladder recombinant P2X purinoceptor, labelled with [3H]-alpha beta meATP, [35S]-ATP gamma S or [33P]-ATP. Michel AD, et al. **Br J Pharmacol** 1996 Mar;117(6):1254-60

Modulation by extracellular ATP of L-type calcium channels in guinea-pig single sinoatrial nodal cell. Qi AD, et al. **Br J Pharmacol** 1996 Dec;119(7):1454-62

Analysis of high-energy phosphometabolites in delayed experimental skin flaps using 31P nuclear magnetic resonance spectroscopy. Ha B, et al. **Br J Plast Surg** 1997 Jun;50(4):272-9

Salutary and deleterious effects of acidity on an indirect measure of metabolic rate and ATP concentrations in CNS cultures. Trafton J, et al. **Brain Res** 1996 Aug 26; 731(1-2):122-31

Relative phosphocreatine and nucleoside triphosphate concentrations in cerebral gray and white matter measured in vivo by 31P nuclear magnetic resonance. Tsuji MK, et al. **Brain Res** 1996 Jan 29;707(2):146-54

Myosin-V: a class of unconventional molecular motors. Larson RE. **Braz J Med Biol Res** 1996 Mar;29(3):309-18 (46 ref.)

Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion. Nord LD, et al. **Cancer Chemother Pharmacol** 1997;40(5):376-84

The relationship of a novel drug-resistant phenotype in C3H10T1/2 cells selected with alkylating agents to neoplastic transformation and ATP metabolism. Wroblewski-Giorgio D, et al. **Cancer Lett** 1997 Feb 26; 113(1-2):195-203

Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Eguchi Y, et al. **Cancer Res** 1997 May 15;57(10):1835-40

Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Masuda M, et al. **Cancer Res** 1997 Aug 15;57(16):3506-10

Hypothermic cardioplegic arrest is associated with increased myocardial adenosine. Shortt KG, et al. **Cardiology** 1996 Nov-Dec;87(6):516-23

Mechanisms of action of various ATP-sensitive potassium channel openers [letter; comment] Grover GJ. **Cardiovasc Res** 1996 Jan;31(1):177-9. Comment on: Cardiovasc Res 1995 Jul;30(1):1-17.

Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Baumann P, et al. **Cell** 1996 Nov 15;87(4):757-66

ACF, an ISWI-containing and ATP-utilizing chromatin assembly and remodeling factor. Ito T, et al. **Cell** 1997 Jul 11;90(1):145-55

ATP-dependent positive supercoiling of DNA by 13S condensin: a biochemical implication for chromosome condensation. Kimura K, et al. **Cell** 1997 Aug 22; 90(4):625-34

Coordinate binding of ATP and origin DNA regulates the ATPase activity of the origin recognition complex. Klemm RD, et al. **Cell** 1997 Feb 21;88(4):493-502

Gating of the skeletal calcium release channel by ATP is inhibited by protein phosphatase 1 but not by Mg2+. Sonnleitner A, et al. **Cell Calcium** 1997 Apr;21(4):283-90

Mechanisms involved in ATP-evoked Ca2+ oscillations in

isolated human granulosa-luteal cells. Squires PE, et al. **Cell Calcium** 1997 May;21(5):365-74

Interaction of BiP with substance P and nucleotides. Weissbach H, et al. **Cell Mol Biol Res** 1995;41(5):397-403

How profilin/barbed-end synergy controls actin polymerization: a kinetic model of the ATP hydrolysis circuit. Dufort PA, et al. **Cell Motil Cytoskeleton** 1996; 35(4):309-30

Cell cycle-dependent regulation of cellular ATP concentration, and depolymerization of the interphase microtubular network induced by elevated cellular ATP concentration in whole fibroblasts. Marcussen M, et al. **Cell Motil Cytoskeleton** 1996;35(2):94-9

ATP transport and ABC proteins. Guidotti G. **Chem Biol** 1996 Sep;3(9):703-6 (26 ref.)

Effects of extracellular ATP on Ca2+ mobilization in Madin Darby canine kidney (MDCK) cells. Liu PS, et al. **Chin J Physiol** 1996;39(3):189-96

Features of P2X receptor-mediated synapses in the rat brain: why doesn't ATP kill the postsynaptic cell? Edwards FA. **Ciba Found Symp** 1996;198:278-86; discussion 286-9 (15 ref.)

P2 purinoceptors and pyrimidinoceptors of catecholamine-producing cells and immunocytes. Illes P, et al. **Ciba Found Symp** 1996;198:110-25; discussion 125-9 (59 ref.)

ATP as a co-transmitter with noradrenaline in sympathetic nerves--function and fate. Kennedy C, et al. **Ciba Found Symp** 1996;198:223-35; discussion 235-8 (38 ref.)

ATP release and its prejunctional modulation. Starke K, et al. **Ciba Found Symp** 1996;198:239-49; discussion 249-59

Challenges in developing P2 purinoceptor-based therapeutics. Williams M. **Ciba Found Symp** 1996; 198:309-21 (53 ref.)

Enhancement of the ATP-sensitive K+ current by extracellular ATP in rat ventricular myocytes. Involvement of adenylyl cyclase-induced subsarcolemmal ATP depletion. Babenko A, et al. **Circ Res** 1997 Apr; 80(4):589-600

Hydroxyl radical inhibits sarcoplasmic reticulum Ca(2+)-ATPase function by direct attack on the ATP binding site. Xu KY, et al. **Circ Res** 1997 Jan;80(1):76-81

Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. Denny WA, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):424-7

Extracellular ATP increases cytosolic calcium in cultured rat renal arterial smooth muscle cells. Inscho EW, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):503-7

Direct measurement of the release of ATP and its major metabolites from the nerve fibres of the guinea-pig taenia coli. McConalogue K, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):807-12

Two novel missense mutations in the ATP-binding domain of the adrenoleukodystrophy gene: immunoblotting and immunocytological study of two patients. Imamura A, et al. **Clin Genet** 1997 May;51(5):322-5

Late ATP-dependent and Ca++-activated steps of dense core granule exocytosis. Martin TF, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:197-204

Differential degradation of extracellular adenine nucleotides by folliculated oocytes of Xenopus laevis. Ziganshin AU, et al. **Comp Biochem Physiol A Physiol** 1996 Aug; 114(4):335-40

Glucose repression/derepression in budding yeast: SNF1 protein kinase is activated by phosphorylation under derepressing conditions, and this correlates with a high AMP:ATP ratio. Wilson WA, et al. **Curr Biol** 1996 Nov 1;6(11):1426-34

The ABCs of ATP-sensitive potassium channels: more pieces of the puzzle. Bryan J, et al. **Curr Opin Cell Biol** 1997 Aug;9(4):553-9 (44 ref.)

The cystic fibrosis transmembrane conductance regulator and ATP. Devidas S, et al. **Curr Opin Cell Biol** 1997 Aug; 9(4):547-52 (53 ref.)

ATP compartmentation in human erythrocytes. Hoffman JF. **Curr Opin Hematol** 1997 Mar;4(2):112-5 (23 ref.)

Does hepatic ATP depletion impair glycine conjugation in vivo? Gregus Z, et al. **Drug Metab Dispos** 1996 Dec; 24(12):1347-54

Effect of ammonia on survival and adenylate energy charge in the shrimp Palaemonetes varians. Marazza D, et al. **Ecotoxicol Environ Saf** 1996 Jul;34(2):103-8

A microsomal ATP-binding protein involved in efficient protein transport into the mammalian endoplasmic reticulum. Dierks T, et al. **EMBO J** 1996 Dec 16; 15(24):6931-42

The essential role of the Walker A motifs of SUR1 in K-ATP channel activation by Mg-ADP and diazoxide. Gribble FM, et al. **EMBO J** 1997 Mar 17;16(6):1145-52

Negative control of DNA replication by hydrolysis of ATP bound to DnaA protein, the initiator of chromosomal DNA replication in Escherichia coli. Mizushima T, et al. **EMBO J** 1997 Jun;16(12):3724-30

The nucleotide exchange factor MGE exerts a key function in the ATP-dependent cycle of mt-Hsp70-Tim44 interaction driving mitochondrial protein import. Schneider HC, et al. **EMBO J** 1996 Nov 1;15(21):5796-803

Essential role of adenosine triphosphate in activation of 17beta-hydroxysteroid dehydrogenase in the rat Leydig cell. Khanum A, et al. **Endocrinology** 1997 Apr; 138(4):1612-20

Hypothesis: the thermosynthesis model for the origin of life and the emergence of regulation by Ca2+. Muller AW. **Essays Biochem** 1996;31:103-19 (34 ref.)

Application of the ATP-bioluminescence assay to thermosensitivity testing for head and neck cancer. Ohtsubo T, et al. **Eur Arch Otorhinolaryngol** 1996; 253(4-5):278-82

Skeletal muscle alterations in patients with chronic heart failure. Schaufelberger M, et al. **Eur Heart J** 1997 Jun; 18(6):971-80

Isolation and properties of an ATP transporter from a strain of Aspergillus niger. Chowdhury B, et al. **Eur J Biochem** 1997 Jul 15;247(2):673-80

Theoretical approaches to the evolutionary optimization of glycolysis: thermodynamic and kinetic constraints. Heinrich R, et al. **Eur J Biochem** 1997 Jan 15; 243(1-2):191-201

ADP-binding and ATP-binding sites in native and proteinase-K-digested creatine kinase, probed by reaction-induced difference infrared spectroscopy. Raimbault C, et al. **Eur J Biochem** 1997 Aug 1; 247(3):1197-208

Complex ATP-activation kinetics of plant H+-transporting ATPase may or may not require two substrate sites. Roberts G, et al. **Eur J Biochem** 1997 May 15;246(1):228-32

The heat-shock protein HslVU from Escherichia coli is a protein-activated ATPase as well as an ATP-dependent proteinase. Seol JH, et al. **Eur J Biochem** 1997 Aug 1; 247(3):1143-50

The assisted self-association of ATP4- by a poly(amino acid) [poly(Lys)] and its significance for cell organelles that contain high concentrations of nucleotides. Sigel H, et al. **Eur J Biochem** 1996 Sep 15;240(3):508-17

The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Kawamura H, et al. **Eur J Cancer** 1997 May;33(6):960-6

Interaction of flagellar inner arm dynein isolated from sea urchin sperm with microtubules in the presence of ATP. Yokota E, et al. **Eur J Cell Biol** 1997 Mar;72(3):214-21

Regulation of quantal transmitter secretion by ATP and protein kinases at developing neuromuscular synapses. Fu WM, et al. **Eur J Neurosci** 1997 Apr;9(4):676-85

Non-synaptic release of ATP by electrical stimulation in slices of rat hippocampus, cerebellum and habenula. Hamann M, et al. **Eur J Neurosci** 1996 Jul;8(7):1510-5

Calmodulin antagonists decrease glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, ATP and viability of melanoma cells. Glass-Marmor L, et al. **Eur J Pharmacol** 1996 Oct 17;313(3):265-71

Inhibition of KATP channel activity by troglitazone in CRI-G1 insulin-secreting cells. Lee K, et al. **Eur J Pharmacol** 1996 Oct 10;313(1-2):163-7

Potent inhibition by trivalent cations of ATP-gated channels. Nakazawa K, et al. **Eur J Pharmacol** 1997 May 1; 325(2-3):237-43

Ptilomycalin A, a novel Na+, K(+)- or Ca2(+)-ATPase inhibitor, competitively interacts with ATP at its binding site. Ohizumi Y, et al. **Eur J Pharmacol** 1996 Aug 22; 310(1):95-8

Different sulfonylurea and ATP sensitivity characterizes the juvenile and the adult form of KATP channel complex of rat skeletal muscle. Tricarico D, et al. **Eur J Pharmacol** 1997 Mar 5;321(3):369-78

The ecto-ATPase inhibitor ARL 67156 enhances parasympathetic neurotransmission in the guinea-pig urinary bladder. Westfall TD, et al. **Eur J Pharmacol** 1997 Jun 25;329(2-3):169-73

Kinetics of high-energy phosphates in allopurinol-pretreated ischaemic and post-ischaemic skeletal muscle: an in vivo magnetic resonance spectroscopy study. Gürke L, et al. **Eur Surg Res** 1997;29(2):101-6

Preischemic bolus application of piroximone studied on the isolated rabbit heart--a second look including biochemical data. Podesser B, et al. **Eur Surg Res** 1996;28(5):388-94

Detection of the ATP-dependent nonmitochondrial calcium store in a cell surface-derived vesicle fraction from isolated rat hepatocytes. Lange J, et al. **Exp Cell Res** 1996 Nov 1;228(2):189-96

The role of ATP-sensitive potassium channels in myocardial ischemia: pharmacology and implications for the future. Grover GJ. **EXS** 1996;76:313-24 (31 ref.)

Interaction of annexins IV and VI with ATP. An alternative mechanism by which a cellular function of these calcium- and membrane-binding proteins is regulated. Bandorowicz-Pikula J, et al. **FEBS Lett** 1997 Jun 9; 409(2):300-6

Control of energy fluxes by the sarcoplasmic reticulum Ca2+-ATPase: ATP hydrolysis, ATP synthesis and heat production. de Meis L, et al. **FEBS Lett** 1997 Apr 7; 406(1-2):201-4

Cytosolic NAD+ content strictly depends on ATP concentration in isolated liver cells. Devin A, et al. **FEBS Lett** 1997 Jun 30;410(2-3):329-32

A novel 13 kDa cytoplasmic soluble protein is required for the nucleotide (MgATP) modulation of the Na/Ca exchange in squid nerve fibers. DiPolo R, et al. **FEBS Lett** 1997 Jan 13;401(1):6-10

Single molecular assay of individual ATP turnover by a myosin-GFP fusion protein expressed in vitro. Iwane AH, et al. **FEBS Lett** 1997 Apr 28;407(2):235-8

Mitochondrial deenergization underlies neuronal calcium overload following a prolonged glutamate challenge. Khodorov B, et al. **FEBS Lett** 1996 Nov 18;397(2-3):230-4

Cloning and functional expression of a novel isoform of ROMK inwardly rectifying ATP-dependent K+ channel, ROMK6 (Kir1.1f). Kondo C, et al. **FEBS Lett** 1996 Dec 9;399(1-2):122-6

Mutational analysis of the ATP-binding site in HslU, the ATPase component of HslVU protease in Escherichia coli. Shin DH, et al. **FEBS Lett** 1996 Dec 2;398(2-3):151-4

The effect of mild trypsin digestion of F1 on energy coupling in the mitochondrial ATP synthase. Xu T, et al. **FEBS Lett** 1996 Nov 18;397(2-3):308-12

Effects of carbamylcholine and pyridostigmine on cytoskeleton-bound and cytosolic phosphofructokinase and ATP levels in different rat tissues. Glass-Marmor L, et al. **Gen Pharmacol** 1996 Oct;27(7):1241-6

Enzyme kinetics and the activation energy of Mg-ATPase in cardiac sarcolemma: ADP as an alternative substrate. Vrbjar N, et al. **Gen Physiol Biophys** 1995 Aug;14(4):313-21

Gain-of-function mutations in TnsC, an ATP-dependent transposition protein that activates the bacterial transposon Tn7. Stellwagen AE, et al. **Genetics** 1997 Mar; 145(3):573-85

Polysialic acid export in Escherichia coli K1: the role of KpsT, the ATP-binding component of an ABC transporter, in chain translocation. Bliss JM, et al. **Glycobiology** 1996 Jun;6(4):445-52

Adenosine 5'-triphosphate (ATP) concentrations in the endolymph and perilymph of the guinea-pig cochlea. Muñoz DJ, et al. **Hear Res** 1995 Oct;90(1-2):119-25

Quinacrine staining of marginal cells in the stria vascularis of the guinea-pig cochlea: a possible source of extracellular ATP? White PN, et al. **Hear Res** 1995 Oct;90(1-2):97-105

A simple luciferase assay to measure atp levels in small numbers of cells using a fluorescent plate reader [letter] Turman MA, et al. **In Vitro Cell Dev Biol Anim** 1996 Jan; 32(1):1-4

Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Fujita J, et al. **Int J Cancer** 1996 Nov 27;68(5):637-43

Heat response of HT29 cells depends strongly on perfusion--a 31P NMR spectroscopy, HPLC and cell survival analysis. Hentschel M, et al. **Int J Hyperthermia** 1997 Jan-Feb;13(1):69-82

The effect of lead on lactate formation, ATP level and membrane ATPase activities in human erythrocytes in vitro. Grabowska M, et al. **Int J Occup Med Environ Health** 1996;9(3):265-74

31P magnetic resonance spectroscopy detection of response-predictive adenosine triphosphate decrease in irradiated radiation-induced fibrosarcoma-1 tumors. Sijens PE, et al. **Invest Radiol** 1997 Jan;32(1):39-43

A purinergic hypothesis for immunomodulation. Di Virgilio F, et al. **Ital J Biochem** 1996 Dec;45(4):195-203 (42 ref.)

Phospholipase A2: a potentially important determinant of adenosine triphosphate levels during hypoxic-reoxygenation tubular injury. Zager RA, et al. **J Am Soc Nephrol** 1996 Nov;7(11):2327-39

Phospholipase A2-induced cytoprotection of proximal tubules: potential determinants and specificity for ATP depletion-mediated injury. Zager RA, et al. **J Am Soc Nephrol** 1996 Jan;7(1):64-72

Morphogenesis, ATP content and oxytetracycline production by Streptomyces rimosus in solid substrate cultivation. Yang SS, et al. **J Appl Bacteriol** 1996 May;80(5):545-50

Contribution of phosphocreatine and aerobic metabolism to energy supply during repeated sprint exercise. Bogdanis GC, et al. **J Appl Physiol** 1996 Mar;80(3):876-84

Extracellular ATP in the human kidney: mode of release and vascular effects. Rump LC, et al. **J Auton Pharmacol** 1996 Dec;16(6):371-5

Differences between the regulation of noradrenaline and ATP release. Westfall DP, et al. **J Auton Pharmacol** 1996 Dec;16(6):393-5

Changes in host cell energetics in response to bacteriophage PRD1 DNA entry. Daugelavicius R, et al. **J Bacteriol** 1997 Aug;179(16):5203-10

Effects of lysine-to-glycine mutations in the ATP-binding consensus sequences in the AddA and AddB subunits on the Bacillus subtilis AddAB enzyme activities. Haijema BJ, et al. **J Bacteriol** 1996 Sep;178(17):5130-7

Structure/function analysis of the PII signal transduction protein of Escherichia coli: genetic separation of interactions with protein receptors. Jiang P, et al. **J Bacteriol** 1997 Jul;179(13):4342-53

Expression and characterization of DrrA and DrrB proteins of Streptomyces peucetius in Escherichia coli: DrrA is an ATP binding protein. Kaur P. **J Bacteriol** 1997 Feb; 179(3):569-75

Characterization of fhlA mutations resulting in ligand-independent transcriptional activation and ATP hydrolysis. Korsa I, et al. **J Bacteriol** 1997 Jan;179(1):41-5

Nitrogenase activity and regeneration of the cellular ATP pool in Azotobacter vinelandii adapted to different oxygen concentrations. Linkerhägner K, et al. **J Bacteriol** 1997 Feb; 179(4):1362-7

Characterization of UreG, identification of a UreD-UreF-UreG complex, and evidence suggesting that a nucleotide-binding site in UreG is required for in vivo metallocenter assembly of Klebsiella aerogenes urease.

Moncrief MB, et al. **J Bacteriol** 1997 Jul;179(13):4081–6

Identification of cytoplasmic subdomains that control pH–sensing of the Na+/H+ exchanger (NHE1): pH–maintenance, ATP–sensitive, and flexible loop domains. Ikeda T, et al. **J Biochem (Tokyo)** 1997 Feb; 121(2):295–303

Unexpectedly general replaceability of ATP in ATP–requiring enzymes. Kinoshita Y, et al. **J Biochem (Tokyo)** 1997 Jul;122(1):205–11

Sliding and ATPase. Oosawa F. **J Biochem (Tokyo)** 1995 Nov;118(5):863–70 (37 ref.)

Lysyl–tRNA synthetase from Bacillus stearothermophilus. Formation and isolation of an enzyme–lysyladenylate complex and its analogue. Takita T, et al. **J Biochem (Tokyo)** 1997 Feb;121(2):244–50

Does the gamma subunit move to an abortive position of ATP hydrolysis when the F1.ADP.Mg complex isomerizes to the inactive F1*.ADP.Mg complex? Allison WS, et al. **J Bioenerg Biomembr** 1996 Oct;28(5):433–8 (30 ref.)

Unisite hydrolysis of [gamma 32 P]ATP by soluble mitochondrial F1–ATPase and its release by excess ADP and ATP. Effect of trifluoperazine. García JJ, et al. **J Bioenerg Biomembr** 1997 Feb;29(1):61–70

Skeletal muscle: a paradigm for testing principles of bioenergetics. Kushmerick MJ. **J Bioenerg Biomembr** 1995 Dec;27(6):555–69 (65 ref.)

Regulation of energy metabolism in liver. Soboll S. **J Bioenerg Biomembr** 1995 Dec;27(6):571–82 (92 ref.)

ATP–regulated K+ channel in mitochondria: pharmacology and function. Szewczyk A, et al. **J Bioenerg Biomembr** 1996 Apr;28(2):147–52 (41 ref.)

FtsH (HflB) is an ATP–dependent protease selectively acting on SecY and some other membrane proteins. Akiyama Y, et al. **J Biol Chem** 1996 Dec 6;271(49):31196–201

Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. Arteaga CL, et al. **J Biol Chem** 1997 Sep 12; 272(37):23247–54

ABC1, an ATP binding cassette transporter required for phagocytosis of apoptotic cells, generates a regulated anion flux after expression in Xenopus laevis oocytes. Becq F, et al. **J Biol Chem** 1997 Jan 31;272(5):2695–9

ATP depletion affects the phosphorylation state, ligand binding, and nuclear transport of the 4 S polycyclic aromatic hydrocarbon–binding protein in rat hepatoma cells. Bhat R, et al. **J Biol Chem** 1996 Dec 20; 271(51):32551–6

A partially functional DNA helicase II mutant defective in forming stable binary complexes with ATP and DNA. A role for helicase motif III. Brosh RM Jr, et al. **J Biol Chem** 1996 Oct 11;271(41):25360–8

The RecD subunit of the RecBCD enzyme from Escherichia coli is a single–stranded DNA–dependent ATPase. Chen HW, et al. **J Biol Chem** 1997 Apr 11;272(15):10072–9

Purification and properties of an enzyme involved in the ATP–dependent activation of the methanol:2–mercaptoethanesulfonic acid methyltransferase reaction in Methanosarcina barkeri. Daas PJ, et al. **J Biol Chem** 1996 Sep 13;271(37):22339–45

Modulation of the P1 plasmid partition protein ParA by ATP, ADP, and P1 ParB. Davey MJ, et al. **J Biol Chem** 1997 Jun 13;272(24):15286–92

Isoprenylated human brain type I inositol 1,4,5–trisphosphate 5–phosphatase controls Ca2+ oscillations induced by ATP in Chinese hamster ovary cells. De Smedt F, et al. **J Biol Chem** 1997 Jul 11;272(28):17367–75

Interactions of forskolin and ATP with the cytosolic domains of mammalian adenylyl cyclase. Dessauer CW, et al. **J Biol Chem** 1997 Aug 29;272(35):22272–7

Role of cyclic ADP–ribose in ATP–activated potassium currents in alveolar macrophages. Ebihara S, et al. **J Biol Chem** 1997 Jun 20;272(25):16023–9

Reversal of the ATP–liganded state of ATP–sensitive K+ channels by adenylate kinase activity. Elvir–Mairena JR, et al. **J Biol Chem** 1996 Dec 13;271(50):31903–8

Phosphorylation of Na,K–ATPase by protein kinase C at Ser18 occurs in intact cells but does not result in direct inhibition of ATP hydrolysis. Feschenko MS, et al. **J Biol Chem** 1997 Jul 11;272(28):17726–33

In vivo interaction of human MCM heterohexameric complexes with chromatin. Possible involvement of ATP. Fujita M, et al. **J Biol Chem** 1997 Apr 18;272(16):10928–35

Reconstitution of ATP–dependent leukotriene C4 transport by Co–expression of both half–molecules of human multidrug resistance protein in insect cells. Gao M, et al. **J Biol Chem** 1996 Nov 1;271(44):27782–7

ATP hydrolysis is critical for induction of conformational changes in GroEL that expose hydrophobic surfaces. Gorovits BM, et al. **J Biol Chem** 1997 Mar 14; 272(11):6842–5

Biochemical analyses of mutations in the HSV–1 helicase–primase that alter ATP hydrolysis, DNA unwinding, and coupling between hydrolysis and unwinding. Graves–Woodward KL, et al. **J Biol Chem** 1997 Feb 14;272(7):4623–30

The amino–terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. Grenert JP, et al. **J Biol Chem** 1997 Sep 19;272(38):23843–50

Yeast Rad7–Rad16 complex, specific for the nucleotide excision repair of the nontranscribed DNA strand, is an ATP–dependent DNA damage sensor. Guzder SN, et al. **J Biol Chem** 1997 Aug 29;272(35):21665–8

Mutation of a highly conserved arginine in motif IV of Escherichia coli DNA helicase II results in an ATP–binding defect. Hall MC, et al. **J Biol Chem** 1997 Jul 25;272(30):18614–20

Role of the glycine triad in the ATP–binding site of cAMP–dependent protein kinase. Hemmer W, et al. **J Biol Chem** 1997 Jul 4;272(27):16946–54

Evidence of the presence of a specific ATPase responsible for ATP–initiated calcification by matrix vesicles isolated from cartilage and bone. Hsu HHT, et al. **J Biol Chem** 1996 Oct 18;271(42):26383–8

A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP–sensitive K+ channel. Isomoto S, et al. **J Biol Chem** 1996 Oct 4;271(40):24321–4

ATP–facilitated chromatin assembly with a nucleoplasmin–like protein from Drosophila melanogaster. Ito T, et al. **J Biol Chem** 1996 Oct 4;271(40):25041–8

Monomeric kinesin head domains hydrolyze multiple ATP molecules before release from a microtubule. Jiang W, et al. **J Biol Chem** 1997 Feb 28;272(9):5616–21

Identification of arginyl residues located at the ATP binding site of sarcoplasmic reticulum Ca2+–ATPase. Modification with 1,2–cyclohexanedione. Kimura K, et al. **J Biol Chem** 1996 Nov 15;271(46):28933–41

Novel insights into the chemical mechanism of ATP synthase. Evidence that in the transition state the gamma–phosphate of ATP is near the conserved alanine within the P–loop of the beta–subunit. Ko YH, et al. **J Biol Chem** 1997 Jul 25;272(30):18875–81

Interaction of ATP binding sites in the ArsA ATPase, the catalytic subunit of the Ars pump. Li J, et al. **J Biol Chem** 1996 Oct 11;271(41):25247–52

RecA as a motor protein. Testing models for the role of ATP hydrolysis in DNA strand exchange. MacFarland KJ, et al. **J Biol Chem** 1997 Jul 11;272(28):17675–85

Mutagenesis of segment 487Phe–Ser–Arg–Asp–Arg–Lys492 of sarcoplasmic reticulum Ca2+–ATPase produces pumps defective in ATP binding. McIntosh DB, et al. **J Biol Chem** 1996 Oct 18;271(42):25778–89

The nucleotidylylation of herpes simplex virus 1 regulatory protein alpha22 by human casein kinase II. Mitchell C, et al. **J Biol Chem** 1997 Oct 3;272(40):25394–400

Molecular design of inhibitors of in vitro oriC DNA replication based on the potential to block the ATP binding of DnaA protein. Mizushima T, et al. **J Biol Chem** 1996 Oct 11;271(41):25178–83

GroEL locked in a closed conformation by an interdomain cross–link can bind ATP and polypeptide but cannot process further reaction steps. Murai N, et al. **J Biol Chem** 1996 Nov 8;271(45):28229–34

A yeast ATP–binding cassette–type protein mediating ATP–dependent bile acid transport. Ortiz DF, et al. **J Biol Chem** 1997 Jun 13;272(24):15358–65

A DNA helicase from Schizosaccharomyces pombe stimulated by single–stranded DNA–binding protein at low ATP concentration. Park JS, et al. **J Biol Chem** 1997 Jul 25;272(30):18910–9

Cystic fibrosis transmembrane conductance regulator–associated ATP and adenosine 3'–phosphate 5'–phosphosulfate channels in endoplasmic reticulum and plasma membranes. Pasyk EA, et al. **J Biol Chem** 1997 Mar 21;272(12):7746–51

Hepatocellular ATP–binding cassette protein expression enhances ATP release and autocrine regulation of cell volume. Roman RM, et al. **J Biol Chem** 1997 Aug 29; 272(35):21970–6

ATP flux is controlled by a voltage–gated channel from the mitochondrial outer membrane. Rostovtseva T, et al. **J Biol Chem** 1996 Nov 8;271(45):28006–8

ATP–binding properties of human Hsp90. Scheibel T, et al. **J Biol Chem** 1997 Jul 25;272(30):18608–13

Importance of the ATP–ubiquitin–proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. Solomon V, et al. **J Biol Chem** 1996 Oct 25;271(43):26690–7

Yeast Rad51 recombinase mediates polar DNA strand exchange in the absence of ATP hydrolysis. Sung P, et al. **J Biol Chem** 1996 Nov 8;271(45):27983–6

ATP–, K+–dependent heptamer exchange reaction produces hybrids between GroEL and chaperonin from Thermus thermophilus. Taguchi H, et al. **J Biol Chem** 1997 Jul 18; 272(29):18155–60

Translocation of full–length Pseudomonas exotoxin from endosomes is driven by ATP hydrolysis but requires prior exposure to acidic pH. Taupiac MP, et al. **J Biol Chem** 1996 Oct 18;271(42):26170–3

2'–O–Dansyl analogs of ATP bind with high affinity to the low affinity ATP site of Na+/K+–ATPase and reveal the interaction of two ATP sites during catalysis. Thoenges D, et al. **J Biol Chem** 1997 Jun 27;272(26):16315–21

Lysine 129 of CD38 (ADP–ribosyl cyclase/cyclic ADP–ribose hydrolase) participates in the binding of ATP to inhibit the cyclic ADP–ribose hydrolase. Tohgo A, et al. **J Biol Chem** 1997 Feb 14;272(7):3879–82

MgADP antagonism to Mg2+–independent ATP binding of the sulfonylurea receptor SUR1. Ueda K, et al. **J Biol Chem** 1997 Sep 12;272(37):22983–6

ATP–dependent degradation of CcdA by Lon protease. Effects of secondary structure and heterologous subunit interactions. Van Melderen L, et al. **J Biol Chem** 1996 Nov 1;271(44):27730–8

Interaction of endoplasmic reticulum chaperone GRP94 with peptide substrates is adenine nucleotide–independent. Wearsch PA, et al. **J Biol Chem** 1997 Feb 21;272(8):5152–6

Sodium salicylate decreases intracellular ATP, induces both heat shock factor binding and chromosomal puffing, but does not induce hsp 70 gene transcription in Drosophila. Winegarden NA, et al. **J Biol Chem** 1996 Oct 25; 271(43):26971–80

Pyridinyl imidazole inhibitors of p38 mitogen–activated protein kinase bind in the ATP site. Young PR, et al. **J Biol Chem** 1997 May 2;272(18):12116–21

Bioluminescence measurements of the antilisterial activity of nisin: comparison with ampicillin and streptomycin. Ukuku DO, et al. **J Biolumin Chemilumin** 1996 May–Jun; 11(3):169–73

Assignment methodology for larger RNA oligonucleotides: application to an ATP–binding RNA aptamer. Dieckmann T, et al. **J Biomol NMR** 1997 Apr;9(3):259–72

Modular organization of the PDZ domains in the human discs–large protein suggests a mechanism for coupling PDZ domain–binding proteins to ATP and the membrane cytoskeleton. Marfatia SM, et al. **J Cell Biol** 1996 Nov; 135(3):753–66

Cellular metabolic homeostasis during large–scale change in ATP turnover rates in muscles. Hochachka PW, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):381–6 (46 ref.)

Adjustment of K' for the creatine kinase, adenylate kinase and ATP hydrolysis equilibria to varying temperature and ionic strength. Teague WE Jr, et al. **J Exp Biol** 1996 Feb; 199 (Pt 2):509–12

Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. Leist M, et al. **J Exp Med** 1997 Apr 21;185(8):1481–6

Relationship between cellular ATP content and cellular functions of primary cultured rat hepatocytes in hypoxia. Hayashi K, et al. **J Gastroenterol Hepatol** 1997 Mar; 12(3):249–56

Adrenocorticotropic hormone and cAMP inhibit noninactivating K+ current in adrenocortical cells by an A–kinase–independent mechanism requiring ATP hydrolysis. Enyeart JJ, et al. **J Gen Physiol** 1996 Oct; 108(4):251–64

Kinetics of oxygen consumption and light–induced changes of nucleotides in solitary rod photoreceptors. Poitry S, et al. **J Gen Physiol** 1996 Aug;108(2):75–87

Phosphorylation generates different forms of rotavirus NSP5. Afrikanova I, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2059–65

Non–invasive assessment of ATP regeneration potential of the preserved donor liver. A 31P MRS study in pig liver. Changani KK, et al. **J Hepatol** 1997 Feb;26(2):336–42

Cardioselective antiischemic ATP–sensitive potassium channel (KATP) openers. 5. Identification of 4–(N–aryl)–substituted benzopyran derivatives with high selectivity. Rovnyak GC, et al. **J Med Chem** 1997 Jan 3; 40(1):24–34

Opening of cardiac sarcolemmal KATP channels by dinitrophenol separate from metabolic inhibition. Alekseev AE, et al. **J Membr Biol** 1997 May 15;157(2):203–14

Burst kinetics of co–expressed Kir6.2/SUR1 clones: comparison of recombinant with native ATP–sensitive K+ channel behavior. Alekseev AE, et al. **J Membr Biol** 1997 Sep 15;159(2):161–8

Ionic permeability on isolated mouse liver nuclei: influence of ATP and Ca2+. Assandri R, et al. **J Membr Biol** 1997 Jun 1;157(3):301–9

Modeling the current–voltage characteristics of Chara membranes: I. The effect of ATP removal and zero turgor. Beilby MJ, et al. **J Membr Biol** 1996 Jan;149(2):89–101

Role and source of ATP for activation of nonselective cation channels by AlF complex in guinea pig chromaffin cells. Inoue M, et al. **J Membr Biol** 1996 Nov;154(2):183–95

A bicarbonate– and weak acid–permeable chloride conductance controlled by cytosolic Ca2+ and ATP in rat submandibular acinar cells. Ishikawa T. **J Membr Biol** 1996 Sep;153(2):147–59

ATP–sensitive voltage– and calcium–dependent chloride channels in sarcoplasmic reticulum vesicles from rabbit skeletal muscle. Kourie JI. **J Membr Biol** 1997 May 1; 157(1):39–51

ATP hydrolysis stimulates binding and release of single stranded DNA from alternating subunits of the dimeric E. coli Rep helicase: implications for ATP–driven helicase translocation. Bjornson KP, et al. **J Mol Biol** 1996 Nov 1;263(3):411–22

Modulation of yeast F–actin structure by a mutation in the nucleotide–binding cleft. Orlova A, et al. **J Mol Biol** 1997 Aug 15;271(2):235–43

Mutations in the Res subunit of the EcoPI restriction enzyme that affect ATP–dependent reactions. Saha S, et al. **J Mol Biol** 1997 Jun 13;269(3):342–54

The second step of ATP binding to DnaK induces peptide release. Theyssen H, et al. **J Mol Biol** 1996 Nov 15; 263(5):657–70

KATP channel activation in a rabbit model of chronic myocardial hypoxia. Baker JE, et al. **J Mol Cell Cardiol** 1997 Feb;29(2):845–8

Pinacidil but not nicorandil opens ATP–sensitive K+ channels and protects against simulated ischemia in rabbit myocytes. Critz SD, et al. **J Mol Cell Cardiol** 1997 Apr; 29(4):1123–30

Effect of ATP depletion on kinetics of Na/Ca exchange–mediated Ca influx in Na–loaded heart cells.

Haworth RA, et al. **J Mol Cell Cardiol** 1997 Feb; 29(2):503–14

ATP content measured by 31P NMR correlates with post-ischaemic recovery of external work output in an isolated rat heart perfused with erythrocyte suspension. Houston RJ, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1763–6

Why are ATP depletion rates in situ in ischemic myocardium so much lower than one might predict from the activity of the mitochondrial ATPase in sonicated heart mitochondria? [editorial] Rouslin W, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1505–10 (13 ref.)

Release of proteins from isolated neonatal rat cardiomyocytes subjected to simulated ischemia or metabolic inhibition is independent of molecular mass. Van Nieuwenhoven FA, et al. **J Mol Cell Cardiol** 1996 Jul;28(7):1429–34

Sequence variations in the surface loop near the nucleotide binding site modulate the ATP turnover rates of molluscan myosins. Perreault-Micale CL, et al. **J Muscle Res Cell Motil** 1996 Oct;17(5):543–53

Effects of fructose-1,6-bisphosphate on glutamate release and ATP loss from rat brain slices during hypoxia. Bickler PE, et al. **J Neurochem** 1996 Oct;67(4):1463–8

Preferential release of ATP and its extracellular catabolism as a source of adenosine upon high- but not low-frequency stimulation of rat hippocampal slices. Cunha RA, et al. **J Neurochem** 1996 Nov;67(5):2180–7

Adenosine triphosphate degradation products after oxidative stress and metabolic dysfunction in cultured retinal cells. Rego AC, et al. **J Neurochem** 1997 Sep;69(3):1228–35

Interleukin-1 enhances the ATP-evoked release of arachidonic acid from mouse astrocytes. Stella N, et al. **J Neurosci** 1997 May 1;17(9):2939–46

Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. Traxler P, et al. **J Pharm Belg** 1997 Mar-Apr; 52(2):88–96 (26 ref.)

Studies with inhibitors of the glycolytic enzyme phosphoglycerate kinase for potential treatment of cardiovascular and respiratory disorders. Mcharg J, et al. **J Pharm Pharmacol** 1996 Feb;48(2):201–5

BIBP 3226, suramin and prazosin identify neuropeptide Y, adenosine 5'-triphosphate and noradrenaline as sympathetic cotransmitters in the rat arterial mesenteric bed. Donoso MV, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):691–8

Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). Ishizuka H, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1304–11

Mechanical study of rat soleus muscle using caged ATP and X-ray diffraction: high ADP affinity of slow cross-bridges. Horiuti K, et al. **J Physiol (Lond)** 1997 Jul 15;502 (Pt 2):433–47

The relationship between mitochondrial state, ATP hydrolysis, [Mg2+]i and [Ca2+]i studied in isolated rat cardiomyocytes. Leyssens A, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):111–28

Modulation of Ca2+ channel activity by ATP metabolism and internal Mg2+ in guinea-pig basilar artery smooth muscle cells. McHugh D, et al. **J Physiol (Lond)** 1996 Apr 15;492 (Pt 2):359–76

Increase in ATP consumption during shortening in skinned fibres from rabbit psoas muscle: effects of inorganic phosphate. Potma EJ, et al. **J Physiol (Lond)** 1996 Oct 1; 496 (Pt 1):1–12

Chemo-mechanical energy transduction in relation to myosin isoform composition in skeletal muscle fibres of the rat. Reggiani C, et al. **J Physiol (Lond)** 1997 Jul 15;502 (Pt 2):449–60

Evidence for the differential release of the cotransmitters ATP and noradrenaline from sympathetic nerves of the guinea-pig vas deferens. Todorov LD, et al. **J Physiol (Lond)** 1996 Nov 1;496 (Pt 3):731–48

Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel. Yamada M, et al. **J Physiol (Lond)** 1997 Mar 15;499 (Pt 3):715–20

Optimal ligand binding by the recombinant human glucocorticoid receptor and assembly of the receptor complex with heat shock protein 90 correlate with high intracellular ATP levels in Spodoptera frugiperda cells. Srinivasan G, et al. **J Steroid Biochem Mol Biol** 1997 Jan; 60(1-2):1–9

Cerebral protection during moderate hypothermic circulatory arrest: histopathology and magnetic resonance spectroscopy of brain energetics and intracellular pH in pigs. Filgueiras CL, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):1073–80

trans-Dominant and non-trans-dominant mutant simian virus 40 large T antigens show distinct responses to ATP. Castellino AM, et al. **J Virol** 1997 Oct;71(10):7549–59

Bluetongue virus VP6 protein binds ATP and exhibits an RNA-dependent ATPase function and a helicase activity that catalyze the unwinding of double-stranded RNA substrates. Stäuber N, et al. **J Virol** 1997 Oct;71(10):7220–6

Suppressing Na+ influx induces an increase in intracellular ATP concentration in mouse pancreatic beta-cells. Ding WG, et al. **Jpn J Physiol** 1997 Jun;47(3):299–306

Response of the neonatal rat cardiomyocyte in culture to energy depletion: effects of cytokines, nitric oxide, and heat shock proteins. Wang D, et al. **Lab Invest** 1996 Dec; 75(6):809–18

P2X-purinoceptors in the heart: actions of ATP and UTP. Froldi G, et al. **Life Sci** 1997;60(17):1419–30

Physiochemical characterization of ATP binding to human 5-lipoxygenase. Noguchi M, et al. **Lipids** 1996 Apr; 31(4):367–71

Phosphorus J-coupling constants of ATP in human brain. Jung WI, et al. **Magn Reson Med** 1997 May;37(5):802–4

The cytoskeleton in ATP-depleted erythrocytes: the effect of shape transformation [published erratum appears in Mech Ageing Dev 1996 Nov 13;91(3):229] Marikovsky Y. **Mech Ageing Dev** 1996 Feb 24;86(2):137–44

ATP catabolism and adenosine generation during ischemia in the aging heart. Ramani K, et al. **Mech Ageing Dev** 1996 Aug 15;89(2):113–24

Effect of oral creatine supplementation on muscle [PCr] and short-term maximum power output. Odland LM, et al. **Med Sci Sports Exerc** 1997 Feb;29(2):216–9

Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38: inhibition of hydrolysis by ATP and physiological significance. Okamoto H, et al. **Methods Enzymol** 1997;280:306–18

An ATP bioluminescence assay applicable to rapid fluconazole susceptibility testing of dermatophytes. Yoshida T, et al. **Microbiol Immunol** 1997;41(5):377–86

Identification of genes in Rhizobium leguminosarum bv. trifolii whose products are homologues to a family of ATP-binding proteins. Król J, et al. **Microbiology** 1997 Apr;143 (Pt 4):1389–94

Is cysteine residue important in FITC-sensitive ATP-binding site of P-type ATPases? A commentary to the state of the art. Breier A, et al. **Mol Cell Biochem** 1996 Jul-Aug; 160-161:89–93 (30 ref.)

E-1020, a water soluble imidazopyridine, has direct effects on Ca(2+)-dependent force and ATP hydrolysis of canine and bovine cardiac myofilaments. Powers FM, et al. **Mol Cell Biochem** 1996 Jul-Aug;160-161:33–9

Stimulatory effect of regucalcin on ATP-dependent calcium transport in rat liver plasma membranes. Takahashi H, et al. **Mol Cell Biochem** 1997 Mar;168(1-2):149–53

Glucose is essential for the initiation of fatty acid oxidation in ATP-depleted cultured ventricular myocytes. Tirosh R, et al. **Mol Cell Biochem** 1996 Sep 20;162(2):159–63

Genetic and biochemical analysis of Msh2p-Msh6p: role of ATP hydrolysis and Msh2p-Msh6p subunit interactions in mismatch base pair recognition. Alani E, et al. **Mol Cell Biol** 1997 May;17(5):2436–47

Sarcolemmal phosphatidylethanolamine reorganization during simulated ischaemia and reperfusion: reversibility and ATP dependency. Musters RJ, et al. **Mol Membr Biol** 1996 Jul-Sep;13(3):159–64

A recombinational defect in the C-terminal domain of Escherichia coli RecA2278-5 protein is compensated by protein binding to ATP. Alexseyev AA, et al. **Mol Microbiol** 1997 Jan;23(2):255–65

The A184V missense mutation of the dnaA5 and dnaA46 alleles confers a defect in ATP binding and thermolability in initiation of Escherichia coli DNA replication. Carr KM, et al. **Mol Microbiol** 1996 Jun;20(6):1307–18

Replacement of the lysine residue in the consensus ATP-binding sequence of the AddA subunit of AddAB drastically affects chromosomal recombination in transformation and transduction of Bacillus subtilis. Haijema BJ, et al. **Mol Microbiol** 1996 Sep;21(5):989–99

A TonB-like protein and a novel membrane protein containing an ATP-binding cassette function together in exotoxin secretion. Howard SP, et al. **Mol Microbiol** 1996 Nov;22(4):595–604

Integration of SecA protein into the Escherichia coli inner membrane is regulated by its amino-terminal ATP-binding domain. Rajapandi T, et al. **Mol Microbiol** 1996 Apr; 20(1):43–51

ATP binding proteins with different folds share a common ATP-binding structural motif. Kobayashi N, et al. **Nat Struct Biol** 1997 Jan;4(1):6–7

The ATP-dependent HslVU protease from Escherichia coli is a four-ring structure resembling the proteasome. Rohrwild M, et al. **Nat Struct Biol** 1997 Feb;4(2):133–9

Distinct ATP receptors on pain-sensing and stretch-sensing neurons. Cook SP, et al. **Nature** 1997 May 29; 387(6632):505–8

Coupling of kinesin steps to ATP hydrolysis. Hua W, et al. **Nature** 1997 Jul 24;388(6640):390–3

Kinesin hydrolyses one ATP per 8-nm step. Schnitzer MJ, et al. **Nature** 1997 Jul 24;388(6640):386–90

Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor. Tucker SJ, et al. **Nature** 1997 May 8;387(6629):179–83

Binding of [3H]-P1075, an opener of ATP-sensitive K+ channels, to rat glomerular preparations. Metzger F, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Oct; 354(4):452–9

ATP-sensitive K+ channels in the kidney. Quast U. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug-Sep; 354(3):213–25 (136 ref.)

Effect of subtype-specific Ca(2+)-antagonists and Ca(2+)-free media on the field stimulation-evoked release of ATP and [3H]acetylcholine from rat habenula slices. Sperlágh B, et al. **Neurochem Res** 1997 Aug;22(8):967–75

Effect of hyperglycemia on reperfusion-associated recovery of intracellular pH and high energy phosphates after transient cerebral ischemia in gerbils. Dempsey RJ, et al. **Neurol Res** 1996 Dec;18(6):546–52

The effects of 2-chloroadenosine and deoxycoformycin on the ATP level, Na-K ATPase activity in experimental brain ischemia of gerbil. Türközkan N, et al. **Neurol Res** 1996 Aug;18(4):345–8

Leigh-type neuropathology in Pearson syndrome associated with impaired ATP production and a novel mtDNA deletion. Santorelli FM, et al. **Neurology** 1996 Nov; 47(5):1320–3

The protective action of tetrodotoxin and (+/-)-kavain on anaerobic glycolysis, ATP content and intracellular Na+ and Ca2+ of anoxic brain vesicles. Gleitz J, et al. **Neuropharmacology** 1996;35(12):1743–52

Effect of vesamicol on the release of ATP from cortical synaptosomes. Salgado AH, et al. **Neurosci Lett** 1996 Feb 2;204(1-2):37–40

Tityustoxin-induced release of ATP from rat brain cortical synaptosomes. Salgado AH, et al. **Neurosci Lett** 1997 Jun 27;229(2):113–6

Effects of hypothermia on the neuronal activity, [Ca2+]i accumulation and ATP levels during oxygen and/or glucose deprivation in hippocampal slices of guinea pigs. Takata T, et al. **Neurosci Lett** 1997 May 9;227(1):41–4

Release of ATP from cultured rat astrocytes elicited by glutamate receptor activation. Queiroz G, et al. **Neuroscience** 1997 Jun;78(4):1203–8

Studies on the release and extracellular metabolism of endogenous ATP in rat superior cervical ganglion: support for neurotransmitter role of ATP. Vizi ES, et al. **Neuroscience** 1997 Aug;79(3):893–903

Kinetics of ATP to ADP beta-phosphoryl conversion in contracting skeletal muscle by in vivo 31P NMR magnetization transfer. Le Rumeur E, et al. **NMR Biomed** 1997 Apr;10(2):67–72

Phosphorus metabolites in different muscles of the rat leg by 31P image-selected in vivo spectroscopy. Madhu B, et al. **NMR Biomed** 1996 Dec;9(8):327–32

Relationship between gluconeogenesis and phosphoenergetics in rat liver assessed by in vivo 13C and 31P NMR spectroscopy. Morikawa S, et al. **NMR Biomed** 1997 Jan;10(1):18–24

Change in chemical shift and splitting of 31P gamma-ATP signal in human skeletal muscle during exercise and recovery. Widmaier S, et al. **NMR Biomed** 1996 Feb; 9(1):1–7

Probing the role of the ATP-operated clamp in the strand-passage reaction of DNA gyrase. Tingey AP, et al. **Nucleic Acids Res** 1996 Dec 15;24(24):4868–73

Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade. Martin DS, et al. **Oncol Res** 1997;9(1):1–5

Recovery of pancreatic tissue perfusion and ATP tissue level after reperfusion in canine pancreas grafts preserved by the two-layer method. Kim Y, et al. **Pancreas** 1997 Apr; 14(3):285–9

GP-2 is the major ATP-binding protein of pig pancreatic zymogen granule membranes [letter] Soriani M, et al. **Pancreas** 1997 Jan;14(1):102–3

Glycolysis is not responsible for the tolerance of immature renal tubules to anoxia. Gaudio KM, et al. **Pediatr Res** 1996 Sep;40(3):457–61

Membrane responses to extracellular ATP in rat isolated white adipocytes. Lee SC, et al. **Pflugers Arch** 1997 Aug; 434(4):422–8

ATP regulates cardiac Ca2+ channel activity via a mechanism independent of protein phosphorylation. Yazawa K, et al. **Pflugers Arch** 1997 Mar;433(5):557–62

Analysis of the ATP/GTP binding site of casein kinase II by site-directed mutagenesis. Jakobi R, et al. **Physiol Chem Phys Med NMR** 1995;27(4):293–301

Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Rolfe DF, et al. **Physiol Rev** 1997 Jul;77(3):731–58 (221 ref.)

Secondary ischemia caused by venous or arterial occlusion shows differential effects on myocutaneous island flap survival and muscle ATP levels. Hauge EM, et al. **Plast Reconstr Surg** 1997 Mar;99(3):825–33

Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Bogyo M, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6629–34

Significance of chaperonin 10-mediated inhibition of ATP hydrolysis by chaperonin 60. Dubaquié Y, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9011–6

Functional and idling rotatory motion within F1-ATPase. Sabbert D, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29; 94(9):4401–5

Activation and inhibition of K-ATP currents by guanine nucleotides is mediated by different channel subunits. Trapp S, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8872–7

Autocrine signaling through ATP release represents a novel mechanism for cell volume regulation. Wang Y, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):12020–5

A novel receptor mediated ATP transport system regulated by tyrosine and serine/threonine phosphokinases in Trypanosoma cruzi trypomastigotes. Sadigursky M, et al. **Recept Signal Transduct** 1997;7(1):29–43

Cystic fibrosis transmembrane conductance regulator and adenosine triphosphate [letter] Abraham EH, et al. **Science** 1997 Feb 28;275(5304):1324–6

The ADP/ATP transport system: a paradigm of metabolite transport in mitochondria. Brandolin G, et al. **Soc Gen Physiol Ser** 1996;51:173–85 (48 ref.)

Conservation within the myosin motor domain: implications for structure and function. Cope MJT, et al. **Structure** 1996 Aug 15;4(8):969–87

Acidic conditions ameliorate both adenosine triphosphate depletion and the development of hyperpermeability in cultured Caco–2BBe enterocytic monolayers subjected to metabolic inhibition. Unno N, et al. **Surgery** 1997 Jun; 121(6):668–80

Tissue–specific bioenergetic effects and increased enzymatic activities following acute sublethal peroral exposure to cyanide in the mallard duck. Ma J, et al. **Toxicol Appl Pharmacol** 1997 Feb;142(2):297–302

Why is fatty liver unsuitable for transplantation? Deterioration of mitochondrial ATP synthesis and sinusoidal structure during cold preservation of a liver with steatosis. Fukumori T, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):412–5

Transporters of nucleotide sugars, nucleotide sulfate and ATP in the Golgi apparatus. Abeijon C, et al. **Trends Biochem Sci** 1997 Jun;22(6):203–7 (30 ref.)

ATP–dependent proteases that also chaperone protein biogenesis. Suzuki CK, et al. **Trends Biochem Sci** 1997 Apr; 22(4):118–23 (48 ref.)

Isolation and characterization of vesicular stomatitis virus PolR revertants: polymerase readthrough of the leader–N gene junction is linked to an ATP–dependent function. Chuang JL, et al. **Virology** 1997 Mar 3;229(1):57–67

[Calcium transport in microsomes isolated from rat parotid gland. Effects of ADP and an ATP–regenerating system.] Éboué D, et al. **Arch Physiol Biochem** 1996 Dec; 104(7):826–32 (Eng. Abstr.) **(Fre)**

[ACE inhibitors with SH groups have no effect of ATP–dependent K channels—a dissertation] Köppel H, et al. **Acta Med Austriaca** 1996;23(3):109–12 (Eng. Abstr.) **(Ger)**

[Effects of steroids on hepatic ATP and L/P ratio in rats subjected to acute hemorrhage] Ikeya K, et al. **Masui** 1997 May;46(5):613–7 (Eng. Abstr.) **(Jpn)**

[ATP–dependent glutathione conjugate export pump] Furukawa T, et al. **Nippon Rinsho** 1997 May;55(5):1083–90 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of hydrogen peroxide on cellular level of ATP, and relationship between ATP depletion and luteolytic effects in human granulosa luteal cells] Endo T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Dec; 48(12):1157–8 **(Jpn)**

[Measurement of ATP in intact Escherichia coli cells, containing recombinant firefly luciferase] Dement'eva EI, et al. **Biokhimiia** 1996 Jul;61(7):1285–93 (Eng. Abstr.) **(Rus)**

[Conservative motifs in enzyme superfamily catalyzing formation of acyladenylates and compounds with carboxy group] Morozov VM, et al. **Biokhimiia** 1996 Aug; 61(8):1505–11 (Eng. Abstr.) **(Rus)**

[Two components of sodium–azide insensitive Mg2+,ATP–dependent Ca2+ transport in ureteral smooth muscle membrane structures] Prishchepa LA, et al. **Biokhimiia** 1996 Jul;61(7):1250–6 (Eng. Abstr.) **(Rus)**

[Effect of dielectric permeability of culture media on the kinetics of the ATP hydrolysis reaction, catalyzed by Ca2+–transporting ATPase, solubilized from smooth muscle cell membrane] Slinchenko NN, et al. **Biokhimiia** 1996 Jul;61(7):1189–97 (Eng. Abstr.) **(Rus)**

[Toxic effect of glutamate on cultured cerebellar granular cells reduces the intracellular level of ATP. The role of Ca2+ ions] Pinelis VG, et al. **Biull Eksp Biol Med** 1997 Feb;123(2):162–4 **(Rus)**

PHARMACOLOGY

Transesophageal Doppler echocardiographic assessment of systolic and diastolic coronary blood flow velocities at baseline and during adenosine triphosphate–induced coronary vasodilation in chronic aortic regurgitation. Kisanuki A, et al. **Am Heart J** 1997 Jan;133(1):71–7

Presence of a metabotropic and an ionotropic purinergic receptor on rat submandibular ductal cells. Amsallem H, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1546–55

An endogenous ATP–sensitive glutathione S–conjugate efflux mechanism in Xenopus laevis oocytes. Ballatori N, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R1156–62

Activation of ATP–sensitive potassium channels contributes to reactive hyperemia in humans. Banitt PF, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1594–8

A disrupter of actin microfilaments impairs sulfonylurea–inhibitory gating of cardiac KATP channels. Brady PA, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2710–6

Role of KATP channels on modulating diaphragmatic microvascular flow during hemorrhagic hypotension. Chang HY, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H272–8

Extracellular ATP stimulates K+ secretion across cultured human airway epithelium. Clarke LL, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):L1084–91

Effect of extracellular ATP on cytosolic Ca2+ concentration in rat pulmonary artery myocytes. Guibert C, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):L450–8

Purinergic agonists, but not cAMP, stimulate coupled granule fusion and Cl– conductance in HT29–Cl.16E. Guo XW, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C804–9

UTP and ATP induce different membrane voltage responses in rat mesangial cells. Huber–Lang M, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):F704–11

Role of purinergic receptors in chloride secretion in Caco–2 cells. Inoue CN, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):C1862–70

Cyanide suppression of inwardly rectifying K+ channels in guinea pig chromaffin cells involves dephosphorylation. Inoue M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C137–47

Physiological properties of ATP–activated cation channels in rat brain microvascular endothelial cells. Janigro D, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):H1423–34

Ca2+ handling by rat myocardium exposed to ATP solutions of different [Ca2+] and Ca2+ buffering capacity. Kabbara AA, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1347–57

Ca2+ flux in human placental trophoblasts. Karl PI, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):C1776–80

Electrophysiological–anatomic correlates of ATP–triggered vagal reflex in the dog. IV. Role of LV vagal afferents. Katchanov G, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1898–903

Electrophysiological–anatomic correlates of ATP–triggered vagal reflex in the dog. III. Role of cardiac afferents. Katchanov G, et al. **Am J Physiol** 1996 May;270(5 Pt 2):H1785–90

ATP–dependent regulation of a G protein–coupled K+ channel (GIRK1/GIRK4) expressed in oocytes. Kim D, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H195–206

Modulation of ATP–sensitive K+ channels in rabbit ventricular myocytes by adenosine A1 receptor activation. Kim E, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H325–33

ATP–sensitive potassium channels in cultured arterial segments. Kleppisch T, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2462–8

Arginine analogues inhibit responses mediated by ATP–sensitive K+ channels. Kontos HA, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1498–506

Intracellular ADP–ribose inhibits ATP–sensitive K+ channels in rat ventricular myocytes. Kwak YG, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C464–8

Direct preconditioning of cardiac ventricular myocytes via adenosine A1 receptor and KATP channel. Liang BT. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1769–77

Dependence of Ca2+ channel currents on endogenous and exogenous sources of ATP in portal vein smooth muscle. Lorenz JN, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H987–94

Arteriolar responses to extracellular ATP in striated muscle. McCullough WT, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1886–91

Molecular site for nucleotide binding on an ATP–sensitive renal K+ channel (ROMK2). McNicholas CM, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F275–85

Salutary effects of ATP–MgCl2 on altered hepatocyte signal transduction after hemorrhagic shock. Mahmoud MS, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):G1347–54

Extracellular ATP as an autocrine/paracrine regulator of prolactin release. Nuñez L, et al. **Am J Physiol** 1997 Jun; 272(6 Pt 1):E1117–23

Muscarinic receptors inhibit ATP–sensitive K+ channels in swine tracheal smooth muscle. Nuttle LC, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):L478–84

Confocal imaging analysis of ATP–induced Ca2+ response in individual endothelial cells of the artery in situ. Ohata H, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):C1980–7

MgATP acts before Ca2+ to prime amylase secretion from permeabilized rat pancreatic acini. Padfield PJ, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G655–60

ATP–activated basolateral Na+/H+ exchange in human normal and cystic fibrosis airway epithelium. Paradiso AM. **Am J Physiol** 1997 Jul;273(1 Pt 1):L148–58

Mechanism of ATP–induced leukocyte adherence to cultured pulmonary artery endothelial cells. Parker AL, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L695–703

Xanthine affects [Ca2+]i and contractile responses of ventricular cardiocytes to electrical stimulation. Rohn TT, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C909–17

Functional hyperemia in striated muscle is reduced following blockade of ATP–sensitive potassium channels. Saito Y, et al. **Am J Physiol** 1996 May;270(5 Pt 2):H1649–54

Adenine nucleotides via activation of ATP–sensitive K+ channels modulate hypoxic response in rat pulmonary artery. Shigemori K, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L803–9

ATP activates K and Cl channels via purinoceptor–mediated release of Ca2+ in human coronary artery smooth muscle. Strøbaek D, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1463–71

ATP activates a cation conductance and Ca(2+)–dependent Cl– conductance in Hensen cells of guinea pig cochlea. Sugasawa M, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):C1817–27

An ATP–sensitive potassium channel activator reduces infarct volume in focal cerebral ischemia in rats. Takaba H, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R583–6

Openings of cardiac KATP channel by oxygen free radicals produced by xanthine oxidase reaction. Tokube K, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H478–89

Sensitivity of volume–sensitive Cl– conductance in human epithelial cells to extracellular nucleotides. Tsumura T, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):C1872–8

Inhibition of the voltage–dependent calcium current by extracellular ATP in hamster ventricular cardiomyocytes. Von zur Mühlen F, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H250–6

ATP–sensitive potassium channels regulate stimulated ANF secretion in isolated rat heart. Xu T, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2339–45

ATP–induced rise in apamin–sensitive Ca(2+)–dependent K+ conductance in adult rat hepatocytes. Yamashita Y, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G307–13

KATP channels and memory of ischemic preconditioning in dogs: synergism between adenosine and KATP channels. Yao Z, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H334–42

Endothelial–mediated dilations of rat middle cerebral arteries by ATP and ADP. You J, et al. **Am J Physiol** 1997 Sep; 273(3 Pt 2):H1472–7

ATP–induced mucin release from cultured airway goblet cells involves, in part, activation of protein kinase C. Ko KH, et al. **Am J Respir Cell Mol Biol** 1997 Feb;16(2):194–8

Role of adenosine triphosphate–sensitive potassium channels in coronary vasodilation by halothane, isoflurane, and enflurane. Crystal GJ, et al. **Anesthesiology** 1997 Feb; 86(2):448–58

Halothane attenuates endothelium–dependent pulmonary vasorelaxant response to lemakalim, an adenosine triphosphate (ATP)–sensitive potassium channel agonist. Seki S, et al. **Anesthesiology** 1997 Sep;87(3):625–34

Halothane and enflurane attenuate pulmonary vasodilation mediated by adenosine triphosphate–sensitive potassium channels compared to the conscious state. Seki S, et al. **Anesthesiology** 1997 Apr;86(4):923–35

Modulation of cyclic AMP and inositol phosphate production in rat prostatic cultures by VIP/PACAP, ATP, and carbachol: role in prostatic proliferation. Guijarro LG, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:723–8

The use of P31 magnetic resonance spectroscopy to evaluate the effect of ATP–MgCl2 perfusion on the metabolism of rat skin island flaps. Koh KS, et al. **Ann Plast Surg** 1997 Mar;38(3):252–6

Identification of ATP–dependent phosphofructokinase as a regulatory step in the glycolytic pathway of the actinomycete Streptomyces coelicolor A3(2). Alves AM, et al. **Appl Environ Microbiol** 1997 Mar;63(3):956–61

Effects of extracellular ATP on cytosolic Ca2+ concentration and secretory responses in rat parotid acinar cells. Tojyo Y, et al. **Arch Oral Biol** 1997 May;42(5):393–9

Contractile agonists preferentially activate CL– over K+ currents in arterial myocytes. Bakhramov A, et al. **Biochem Biophys Res Commun** 1996 Oct 3;227(1):168–75

Extracellular ATP triggers cyclic AMP–dependent differentiation of HL–60 cells [corrected and republished in Biochem Biophys Res Commun 1997 Jul 9;236(1):626–30] Jiang L, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):626–30

Extracellular ATP triggers cyclic AMP–dependent differentiation of HL–60 cells [corrected and republished with original paging, article originally printed in Biochem Biophys Res Commun 1997 Mar 27;232(3): 626–30] Jiang L, et al. **Biochem Biophys Res Commun** 1997 Jul 9; 236(1):626–30

CD45 regulates apoptosis induced by extracellular adenosine triphosphate and cytotoxic T lymphocytes. Macino B, et al. **Biochem Biophys Res Commun** 1996 Sep 24; 226(3):769–76

Electrophysiological responses to oxytocin and ATP in monolayers of a human sweat gland cell line. Ring A, et al. **Biochem Biophys Res Commun** 1997 May 8;234(1):30–4

Nuclear and cytosolic calcium signaling induced by extracellular ATP in rat kidney inner medullary collecting duct cells. Suko Y, et al. **Biochem Biophys Res Commun** 1997 May 8;234(1):224–9

ATP– and EGF–stimulated phosphatidulinositol synthesis by two different pathways, phospholipase D and diacylglycerol kinase, in A–431 epidermoid carcinoma cells. Hosoi K, et al. **Biochem Cell Biol** 1996;74(2):197–209

Desensitization of P2U receptor in neuronal cell line. Different control by the agonists ATP and UTP, as demonstrated by single–cell Ca2+ responses. Czubayko U, et al. **Biochem J** 1996 Nov 15;320 (Pt 1):215–9

Distinct inhibitory ATP–regulated modulatory domain (ARMi) in membrane guanylate cyclases. Duda T, et al. **Biochem J** 1996 Oct 1;319 (Pt 1):279–83

Role of P2–purinergic receptors in rat Leydig cell steroidogenesis. Foresta C, et al. **Biochem J** 1996 Dec 1; 320 (Pt 2):499–504

Purinergic stimulation of rat cardiomyocytes induces tyrosine phosphorylation and membrane association of phospholipase C gamma: a major mechanism for InsP3 generation. Puceat M, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):723–8

The control of oxygen affinity in the three human embryonic haemoglobins by respiration linked metabolites. Hofmann OM, et al. **Biochem Mol Biol Int** 1997 Jul;42(3):553–66

ATP–induced calcium mobilization in glomerular mesangial cells is mediated by P2U purinoceptor. Takeda M, et al. **Biochem Mol Biol Int** 1996 Aug;39(6):1193–200

Extracellular ATP–stimulated increase of cytosolic cAMP in HL–60 cells. Choi SY, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):429–32

Conditions allowing different states of ATP– and GDP–induced permeability in mitochondria from different strains of Saccharomyces cerevisiae. Roucou X, et al. **Biochim Biophys Acta** 1997 Feb 21;1324(1):120–32

A possible dual physiological role of extracellular ATP in the modulation of platelet aggregation. Soslau G, et al. **Biochim Biophys Acta** 1997 Feb 4;1355(2):131–40

Effects of MgATP and MgADP on the cross-bridge kinetics of rabbit soleus slow-twitch muscle fibers. Wang G, et al. **Biophys J** 1996 Sep;71(3):1450-61

ATP-sensitive anion channel from rat brain synaptosomal membranes incorporated into planar lipid bilayers. Yuto J, et al. **Biophys J** 1997 Feb;72(2 Pt 1):720-7

Extracellular nucleotides stimulate proliferation in MCF-7 breast cancer cells via P2-purinoceptors. Dixon CJ, et al. **Br J Cancer** 1997;75(1):34-9

Purinergic facilitation of ATP-sensitive potassium current in rat ventricular myocytes. Babenko AP, et al. **Br J Pharmacol** 1997 Feb;120(4):631-8

Predominant role of A1 adenosine receptors in mediating adenosine induced vasodilatation of rat diaphragmatic arterioles: involvement of nitric oxide and the ATP-dependent K+ channels. Danialou G, et al. **Br J Pharmacol** 1997 Aug;121(7):1355-63

Fading and rebound of currents induced by ATP in PC12 cells. Giniatullin R, et al. **Br J Pharmacol** 1996 Nov; 119(5):1045-53

Stimulation by the nucleotides, ATP and UTP of mitogen-activated protein kinase in EAhy 926 endothelial cells. Graham A, et al. **Br J Pharmacol** 1996 Mar; 117(6):1341-7

Sulprostone-induced reduction of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Hide EJ, et al. **Br J Pharmacol** 1996 Jul; 118(6):1409-14

Stimulation by extracellular ATP and UTP of the stress-activated protein kinase cascade in rat renal mesangial cells. Huwiler A, et al. **Br J Pharmacol** 1997 Mar;120(5):807-12

Potentiation by cadmium ion of ATP-evoked dopamine release in rat phaeochromocytoma cells. Ikeda M, et al. **Br J Pharmacol** 1996 Mar;117(5):950-4

Responses of the longitudinal muscle and the muscularis mucosae of the rat duodenum to adenine and uracil nucleotides. Johnson CR, et al. **Br J Pharmacol** 1996 Mar; 117(5):823-30

Potentiation by 2,2'-pyridylisatogen tosylate of ATP-responses at a recombinant P2Y1 purinoceptor. King BF, et al. **Br J Pharmacol** 1996 Mar;117(6):1111-8

Dissociation of P2 purinoceptor-mediated increase in intracellular Ca2+ level from myosin light chain phosphorylation and contraction in rat aorta. Kitajima S, et al. **Br J Pharmacol** 1996 Jun;118(3):543-8

The effects of purine compounds on the isolated aorta of the frog Rana temporaria. Knight GE, et al. **Br J Pharmacol** 1996 Mar;117(5):873-8

Inhibition by ATP of calcium oscillations in rat cultured hippocampal neurones. Koizumi S, et al. **Br J Pharmacol** 1997 Sep;122(1):51-8

Action of suramin upon ecto-apyrase activity and synaptic depression of Torpedo electric organ. Martí E, et al. **Br J Pharmacol** 1996 Jul;118(5):1232-6

Evidence for two distinct P2-purinoceptors subserving contraction of the rat anococcygeus smooth muscle. Najbar AT, et al. **Br J Pharmacol** 1996 Jun;118(3):537-42

Characterization of the P2Y-purinoceptor involved in the ATP-induced rise in cytosolic Ca2+ concentration in rat ileal myocytes. Pacaud P, et al. **Br J Pharmacol** 1996 Aug; 118(8):2213-9

P2-purinoceptors mediating spasm of the isolated uterus of the non-pregnant guinea-pig. Piper AS, et al. **Br J Pharmacol** 1996 Apr;117(8):1721-9

Characterization of the P2 receptors in rabbit pulmonary artery. Qasabian RA, et al. **Br J Pharmacol** 1997 Feb; 120(4):553-8

Characterization of a P2X-purinoceptor in cultured neurones of the rat dorsal root ganglia. Robertson SJ, et al. **Br J Pharmacol** 1996 Jun;118(4):951-6

Effect of englitazone on KATP and calcium-activated non-selective cation channels in CRI-G1 insulin-secreting cells. Rowe IC, et al. **Br J Pharmacol** 1997 Jun;121(3):531-9

An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor. Schachter JB, et al. **Br J Pharmacol** 1997 May;121(2):338-44

KATP-channel on the somata of spiny neurones in rat caudate nucleus: regulation by drugs and nucleotides. Schwanstecher C, et al. **Br J Pharmacol** 1997 May; 121(2):193-8

Potentiation by nitric oxide of the ATP-sensitive K+ current induced by K+ channel openers in guinea-pig ventricular cells. Shinbo A, et al. **Br J Pharmacol** 1997 Apr; 120(8):1568-74

ATP and nitric oxide: inhibitory NANC neurotransmitters in the longitudinal muscle-myenteric plexus preparation of the rat ileum. Smits GJ, et al. **Br J Pharmacol** 1996 Jun;118(3):695-703

Potentiation of ATP-responses at a recombinant P2x2 receptor by neurotransmitters and related substances. Wildman SS, et al. **Br J Pharmacol** 1997 Jan;120(2):221-4

Responsiveness to ATP with an increase in intracellular free Ca2+ is not a distinctive feature of calbindin-D28 immunoreactive neurons in myenteric ganglia. Christofi FL, et al. **Brain Res** 1996 Jul 1;725(2):241-6

Substance P potentiates ATP-activated currents in rat primary sensory neurons. Hu HZ, et al. **Brain Res** 1996 Nov 11;739(1-2):163-8

Dissociation of SNAP-25 and VAMP-2 by MgATP in permeabilized adrenal chromaffin cells. Misonou H, et al. **Brain Res** 1996 Oct 21;737(1-2):351-5

Activation of ATP-sensitive potassium channels decreases neuronal injury caused by chemical hypoxia. Wind T, et al. **Brain Res** 1997 Mar 21;751(2):295-9

Characterization of alpha, beta-methylene ATP binding sites in mouse crude synaptic membranes. Hori S, et al. **Brain Res Bull** 1997;43(1):59-63

Molecular characterization and pharmacological properties of the human P2X3 purinoceptor. Garcia-Guzman M, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1-2):59-66

ATP and adenosine act as a mitogen for osteoblast-like cells (MC3T3-E1). Shimegi S. **Calcif Tissue Int** 1996 Feb; 58(2):109-13

ATP shortens atrial action potential duration in the dog: role of adenosine, the vagus nerve, and G protein. Pelleg A, et al. **Can J Physiol Pharmacol** 1996 Jan;74(1):15-22

Protein kinase C induced calcium influx and sustained enhancement of ciliary beating by extracellular ATP. Levin R, et al. **Cell Calcium** 1997 Feb;21(2):103-13

Synchronized Ca2+ oscillations induced in Madin Darby canine kidney cells by bradykinin and thrombin but not by ATP. Røttingen JA, et al. **Cell Calcium** 1997 Mar; 21(3):195-211

Extracellular ATP induces cytosolic calcium oscillations associated with an increase in intracellular pH in human Chang liver cells. Bay BH. **Cell Mol Biol (Noisy-le-grand)** 1997 Jun;43(4):521-8

ATP-dependent lysis of isolated lysosomes by basic substances and acidic ionophores. Ohkuma S, et al. **Cell Struct Funct** 1997 Apr;22(2):253-68

Rational design of allosteric ribozymes. Tang J, et al. **Chem Biol** 1997 Jun;4(6):453-9

Trophic actions of extracellular ATP on astrocytes, synergistic interactions with fibroblast growth factors and underlying signal transduction mechanisms. Neary JT. **Ciba Found Symp** 1996;198:130-9; discussion 139-41 (31 ref.)

Role of nitric oxide towards vasodilator effects of substance P and ATP in human forearm vessels. Shiramoto M, et al. **Clin Sci (Colch)** 1997 Feb;92(2):123-31

Simultaneous measurement of Ca2+ and pH by laser cytometry using fluo-3 and SNARF-1. Atsumi T, et al. **Cytometry** 1996 Jun 1;24(2):99-105

Leptin suppression of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic beta-cells. Kieffer TJ, et al. **Diabetes** 1997 Jun;46(6):1087-93

Diminished fraction of blockable ATP-sensitive K+ channels in islets transplanted into diabetic mice. Soria B, et al. **Diabetes** 1996 Dec;45(12):1755-60

ATP and a mitochondrial electrochemical gradient are required for functional activity of the steroidogenic acute regulatory (StAR) protein in isolated mitochondria. King SR, et al. **Endocr Res** 1996 Nov;22(4):505-14

Role of protein kinase C in the regulation of ATP-triggered intracellular Ca2+ oscillations in chicken granulosa cells. Morley P, et al. **Eur J Endocrinol** 1996 Jun;134(6):743-50

Regulation of quantal transmitter secretion by ATP and protein kinases at developing neuromuscular synapses. Fu WM, et al. **Eur J Neurosci** 1997 Apr;9(4):676-85

The action of ATP on the hepatic arterial and portal venous vascular networks of the rabbit liver: the role of adenosine. Browse DJ, et al. **Eur J Pharmacol** 1997 Feb 12; 320(2-3):139-44

Pharmacological characterization of P2 purinoceptor types in rat locus coeruleus neurons. Fröhlich R, et al. **Eur J Pharmacol** 1996 Nov 21;315(3):255-61

Dual effects of extracellular ATP on the muscarinic acetylcholine receptor-operated K+ current in guinea-pig atrial cells. Hara Y, et al. **Eur J Pharmacol** 1997 Apr 18; 324(2-3):295-303

Involvement of ATP-sensitive K+ channels in the inhibitory effect of calcitonin gene-related peptide on neurotransmission in rat vas deferens. Huang Y, et al. **Eur J Pharmacol** 1997 May 30;327(2-3):209-14

Modulation of the contractility of guinea pig papillary muscle by the activation of ATP-sensitive K+ channels. Kocić I. **Eur J Pharmacol** 1996 Apr 22;301(1-3):115-9

Effects of neuroamines and divalent cations on cloned and mutated ATP-gated channels. Nakazawa K, et al. **Eur J Pharmacol** 1997 Apr 23;325(1):101-8

Dopamine and 5-hydroxytryptamine selectively potentiate neuronal type ATP receptor channels. Nakazawa K, et al. **Eur J Pharmacol** 1996 Jan 18;296(1):119-22

The effects of P2 purinoceptor agonists on the isolated portal vein of the guinea pig. Orre M, et al. **Eur J Pharmacol** 1996 Dec 5;316(2-3):229-36

ATP and beta,gamma-methylene ATP produce relaxation of guinea-pig isolated trachealis muscle via actions at P1 purinoceptors. Piper AS, et al. **Eur J Pharmacol** 1996 Jun 27;307(2):183-9

Purinergic and adrenergic transmission and their presynaptic modulation in canine isolated perfused splenic arteries. Ren LM, et al. **Eur J Pharmacol** 1996 Jan 4;295(1):61-8

Peripheral adenosine 5'-triphosphate enhances nociception in the formalin test via activation of a purinergic p2X receptor. Sawynok J, et al. **Eur J Pharmacol** 1997 Jul 9; 330(2-3):115-21

Influence of age on cholinergic and inhibitory nonadrenergic noncholinergic responses in the rat ileum. Smits GJ, et al. **Eur J Pharmacol** 1996 May 6;303(1-2):79-86

Trypsin alters ATP sensitivity of KATP channels in control and hypertrophied myocytes. Sodder VH, et al. **Eur J Pharmacol** 1996 Nov 7;315(1):115-8

Histamine inhibits ATP-induced [Ca2+]i rise through the activation of protein kinase A in HL-60 cells. Song SK, et al. **Eur J Pharmacol** 1997 Mar 19;322(2-3):265-73

Effects of ATP on specific [3H](+)-isradipine binding in rat ventricular cardiomyocytes. Stokke M, et al. **Eur J Pharmacol** 1996 May 6;303(1-2):115-22

ATP-sensitive K+ channel openers block sulpiride-induced dopamine release in the rat striatum. Tanaka T, et al. **Eur J Pharmacol** 1996 Feb 15;297(1-2):35-41

P2 purinoceptor-mediated stimulation of adenylyl cyclase in PC12 cells. Yakushi Y, et al. **Eur J Pharmacol** 1996 Oct 24;314(1-2):243-8

The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. Léon C, et al. **FEBS Lett** 1997 Feb 10;403(1):26-30

Channel activators regulate ATP-sensitive potassium channel (KIR6.1) expression in chick cardiomyocytes. Lu C, et al. **FEBS Lett** 1997 Jul 21;412(1):121-5

Defective ATP-dependent mucin secretion by cystic fibrosis pancreatic epithelial cells. Montserrat C, et al. **FEBS Lett** 1996 Sep 16;393(2-3):264-8

Mutagenesis of two N-terminal Thr and five Ser residues in HslV, the proteolytic component of the ATP-dependent HslVU protease. Yoo SJ, et al. **FEBS Lett** 1997 Jul 21; 412(1):57-60

Sodium, hydrogen antiporter activation by extracellular adenosine triphosphate in biliary epithelial cells. Elsing C, et al. **Gastroenterology** 1996 Nov;111(5):1321-32

Purines and neutrophil leukocytes. Fredholm BB. **Gen Pharmacol** 1997 Mar;28(3):345-50 (100 ref.)

Direct inhibition by taurine of the ATP-sensitive k+ channel in guinea pig ventricular cardiomyocytes. Satoh H. **Gen Pharmacol** 1996 Jun;27(4):625-7

Inhibitory action of extracellular adenosine 5'-triphosphate on parietal cells isolated from rabbit gastric mucosa. Gil-Rodrigo CE, et al. **Gen Physiol Biophys** 1996 Jun; 15(3):251-64

ATP-evoked inositol phosphates formation through activation of P2U purinergic receptors in cultured astrocytes: regulation by PKC subtypes alpha, delta, and theta. Chen CC, et al. **Glia** 1996 May;17(1):63-71

Calcitonin gene-related peptide and ATP induce immediate early gene expression in cultured rat microglial cells. Priller J, et al. **Glia** 1995 Dec;15(4):447-57

Extracellular adenosine 5'-triphosphate (ATP) in the endolymphatic compartment influences cochlear function. Muñoz DJ, et al. **Hear Res** 1995 Oct;90(1-2):106-118

KATP channel opening does not contribute significantly to the vasodilatory effect of SH-group-containing ACE inhibitors. Köppel H, et al. **Heart Vessels** 1996;11(4):192-6

Effects of tolbutamide on vascular ATP-sensitive potassium channels in humans. Comparison with literature data on glibenclamide and glimepiride. Bijlstra PJ, et al. **Horm Metab Res** 1996 Sep;28(9):512-6

Ion channel effects of antidiabetic sulfonylureas. Lazdunski M. **Horm Metab Res** 1996 Sep;28(9):488-95 (95 ref.)

Acute paw oedema formation induced by ATP: re-evaluation of the mechanisms involved. Ziganshina LE, et al. **Inflamm Res** 1996 Feb;45(2):96-102

Stimulation of movement and acrosome reaction of human spermatozoa by PC12 liposomes encapsulating ATP. Skiba-Lahiani M, et al. **Int J Androl** 1995 Dec;18(6):287-94

Myofibril-bound muscle phosphofructokinase is less sensitive to inhibition by ATP than the free enzyme, but retains its sensitivity to stimulation by bisphosphorylated hexoses. Andrés V, et al. **Int J Biochem Cell Biol** 1996 Oct; 28(10):1179-84

Coronary vasoconstrictive effects of neuropeptide Y and their modulation by the ATP-sensitive potassium channel in anesthetized dogs. Tanaka E, et al. **J Am Coll Cardiol** 1997 May;29(6):1380-9

Pulmonary vasoreactivity to serotonin during hypoxia is modulated by ATP-sensitive potassium channels. Barman SA. **J Appl Physiol** 1997 Aug;83(2):569-74

Effect of ATP-induced permeabilization on loading of the Na+ probe SBFI into endothelial cells. Cutaia M, et al. **J Appl Physiol** 1996 Jul;81(1):509-15

Segmental pulmonary vascular responses to ATP in rat lungs: role of nitric oxide. Hakim TS, et al. **J Appl Physiol** 1997 Mar;82(3):852-8

Differences in the responses to purinergic nerve stimulation and applied ATP in the guinea-pig vas deferens. Reilly MJ, et al. **J Auton Nerv Syst** 1996 Feb 5;57(1-2):93-100

Electrophysiological effects of ATP on brain neurones. Illes P, et al. **J Auton Pharmacol** 1996 Dec;16(6):407-11 (51 ref.)

Neuropeptide Y-ATP interactions and release at the vascular neuroeffector junction. Westfall TC, et al. **J Auton Pharmacol** 1996 Dec;16(6):345-8

The mitochondrial hsp70 chaperone system. Effect of adenine nucleotides, peptide substrate, and mGrpE on the oligomeric state of mhsp70. Azem A, et al. **J Biol Chem** 1997 Aug 15;272(33):20901-6

ATP-dependent choline phosphate-induced mitogenesis in fibroblasts involves activation of pp70 S6 kinase and phosphatidylinositol 3'-kinase through an extracellular site. Synergistic mitogenic effects of choline phosphate and sphingosine 1-phosphate. Chung T, et al. **J Biol Chem** 1997 Jan 31;272(5):3064-72

Promoter escape by RNA polymerase II. A role for an ATP cofactor in suppression of arrest by polymerase at

promoter-proximal sites. Dvir A, et al. **J Biol Chem** 1996 Sep 20;271(38):23352-6
Heat shock-induced DNA relaxation in vitro by DNA gyrase of Escherichia coli in the presence of ATP. Kataoka K, et al. **J Biol Chem** 1996 Oct 4;271(40):24806-10
Feedback regulation of ATP-induced Ca2+ signaling in HL-60 cells is mediated by protein kinase A- and C-mediated changes in capacitative Ca2+ entry. Lee H, et al. **J Biol Chem** 1997 Aug 29;272(35):21831-8
Functional analysis of in vivo and in organello footprinting of HeLa cell mitochondrial DNA in relationship to ATP and ethidium bromide effects on transcription. Micol V, et al. **J Biol Chem** 1997 Jul 25;272(30):18896-904
Extracellular ATP induces anchorage-independent expression of cyclin A and rescues the transformed phenotype of a ras-resistant mutant cell line. Yang JJ, et al. **J Biol Chem** 1997 Jan 31;272(5):3103-8
Ca2+ oscillations and intercellular Ca2+ waves in ATP-stimulated articular chondrocytes. D'Andrea P, et al. **J Bone Miner Res** 1996 Jul;11(7):946-54
ATP-stimulated release of ATP by human endothelial cells. Bodin P, et al. **J Cardiovasc Pharmacol** 1996 Jun; 27(6):872-5
Nonadrenergic contractile response of guinea pig portal vein to electrical field stimulation mimics response to UTP but not to ATP. Ishizaki M, et al. **J Cardiovasc Pharmacol** 1997 Mar;29(3):360-6
Cardioprotective effects of NIP-121, a novel ATP-sensitive potassium channel opener, during ischemia and reperfusion in coronary perfused guinea pig myocardium. Tanaka H, et al. **J Cardiovasc Pharmacol** 1996 May;27(5):695-701
A multistep, ATP-dependent pathway for assembly of human immunodeficiency virus capsids in a cell-free system. Lingappa JR, et al. **J Cell Biol** 1997 Feb 10;136(3):567-81
Stabilization of acetylcholine receptors by exogenous ATP and its reversal by cAMP and calcium. O'Malley JP, et al. **J Cell Biol** 1997 Jul 14;138(1):159-65
Dynamics of ATP-induced calcium signaling in single mouse thymocytes. Ross PE, et al. **J Cell Biol** 1997 Sep 8; 138(5):987-98
Purinergic agonists stimulate the secretion of endothelin-1 in rat thyroid FRTL-5 cells. Vainio M, et al. **J Cell Physiol** 1996 Dec;169(3):538-43
ATP is required in platelet serotonin exocytosis for protein phosphorylation and priming of secretory vesicles docked on the plasma membrane. Morimoto T, et al. **J Cell Sci** 1996 Jan;109 (Pt 1):113-8
Role of nitric oxide, cyclic nucleotides, and the activation of ATP-sensitive K+ channels in the contribution of adenosine to hypoxia-induced pial artery dilation. Armstead WM. **J Cereb Blood Flow Metab** 1997 Jan; 17(1):100-8
Vasoconstrictors inhibit ATP-sensitive K+ channels in arterial smooth muscle through protein kinase C. Bonev AD, et al. **J Gen Physiol** 1996 Oct;108(4):315-23
Mechanism of action of K channel openers on skeletal muscle KATP channels. Interactions with nucleotides and protons. Forestier C, et al. **J Gen Physiol** 1996 Apr;107(4):489-502
Acceleration of sodium-calcium exchange activity during ATP-induced calcium release in transfected Chinese hamster ovary cells. Vázquez M, et al. **J Gen Physiol** 1997 Jan;109(1):53-60
Adenosine triphosphate-dependent copper transport in human liver. Dijkstra M, et al. **J Hepatol** 1996 Jul; 25(1):37-42
Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptor. Apasov SG, et al. **J Immunol** 1997 Jun 1;158(11):5095-105
Sequential potentiation and inhibition of PMN reactivity by maximally stimulated platelets. Aziz KA, et al. **J Leukoc Biol** 1997 Mar;61(3):322-8
Regulation of Cl- secretion by extracellular ATP in cultured mouse endometrial epithelium. Chan HC, et al. **J Membr Biol** 1997 Mar 1;156(1):45-52
Identification of ATP-sensitive potassium channel in frog ventricular myocytes. Munemori M, et al. **J Membr Biol** 1996 Nov;154(1):45-51
Cl- currents activated by extracellular nucleotides in human bronchial cells. Zegarra-Moran O, et al. **J Membr Biol** 1997 Apr 1;156(3):297-305
Adenosine preconditioning of human myocardium is dependent upon the ATP-sensitive K+ channel. Cleveland JC Jr, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):175-82
Direct activation of the ATP-sensitive potassium channel by oxygen free radicals in guinea-pig ventricular cells: its potentiation by MgADP [published erratum appears in J Mol Cell Cardiol 1997 Feb;29(2):855] Ichinari K, et al. **J Mol Cell Cardiol** 1996 Sep;28(9):1867-77
ATP-activated cationic current in rabbit sino-atrial node cells. Shoda M, et al. **J Mol Cell Cardiol** 1997 Feb; 29(2):689-95
Regulation of astrocyte nitric oxide synthase type II expression by ATP and glutamate involves loss of transcription factor binding to DNA. Lin HL, et al. **J Neurochem** 1997 Aug;69(2):612-6
A2A adenosine receptors inhibit ATP-induced Ca2+ influx in PC12 cells by involving protein kinase A. Park TJ, et al. **J Neurochem** 1997 May;68(5):2177-85
Proton potentiation of ATP-gated ion channel responses to ATP and Zn2+ in rat nodose ganglion neurons. Li C, et al. **J Neurophysiol** 1996 Nov;76(5):3048-58
ATP P2X receptors mediate fast synaptic transmission in the dorsal horn of the rat spinal cord. Bardoni R, et al. **J Neurosci** 1997 Jul 15;17(14):5297-304
Brain synaptosomes display a diadenosine tetraphosphate (Ap4A)-mediated Ca2+ influx distinct from ATP-mediated influx. Pivorun EB, et al. **J Neurosci Res** 1996 Jun 1;44(5):478-89
Identification and characterization of P2Y2 nucleotide receptors in human retinal pigment epithelial cells. Sullivan DM, et al. **J Neurosci Res** 1997 Jul 1;49(1):43-52
Effects of oxyhemoglobin on local and propagated vasodilatory responses induced by adenosine, adenosine diphosphate, and adenosine triphosphate in rat cerebral arterioles. Kajita Y, et al. **J Neurosurg** 1996 Nov; 85(5):908-16
Effects of ATP on phosphoinositide hydrolysis and prostaglandin E2 generation in rabbit astrocytes. Ishimoto H, et al. **J Pharm Pharmacol** 1997 May;49(5):520-4
Involvement of sigma-receptors in the increase in contraction of mouse vas deferens induced by exogenous ATP. Matsuno K, et al. **J Pharm Pharmacol** 1996 Jan;48(1):96-9
Modulation of ATP-sensitive and large-conductance Ca++-activated K+ channels by Zeneca ZD6169 in guinea pig bladder smooth muscle cells. Hu S, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):38-45
Adenosine triphosphate attenuates renal sympathetic nerve activity through left ventricular chemosensitive receptors. Taneyama C, et al. **J Pharmacol Exp Ther** 1997 Feb; 280(2):570-5
The sulphonylurea receptor confers diazoxide sensitivity on the inwardly rectifying K+ channel Kir6.1 expressed in human embryonic kidney cells. Ammälä C, et al. **J Physiol (Lond)** 1996 Aug 1;494 (Pt 3):709-14
Properties of cloned ATP-sensitive K+ currents expressed in Xenopus oocytes. Gribble FM, et al. **J Physiol (Lond)** 1997 Jan 1;498 (Pt 1):87-98
P2 purinoceptor-activated inward currents in follicular oocytes of Xenopus laevis. King BF, et al. **J Physiol (Lond)** 1996 Jul 1;494 (Pt 1):17-28
Protein kinase C requirement of Ca2+ channel stimulation by intracellular ATP in guinea-pig basilar artery smooth muscle cells. McHugh D, et al. **J Physiol (Lond)** 1997 Apr 15;500 (Pt 2):311-7
Purinoceptor-operated cationic channels in human B lymphocytes. Markwardt F, et al. **J Physiol (Lond)** 1997 Jan 1;498 (Pt 1):143-51
Selective enhancement of the slow component of delayed rectifier K+ current in guinea-pig atrial cells by external ATP. Matsuura H, et al. **J Physiol (Lond)** 1997 Aug 15; 503 (Pt 1):45-54
ATP-activated cation conductance in a Xenopus renal epithelial cell line. Mori M, et al. **J Physiol (Lond)** 1996 Mar 1;491 (Pt 2):281-90
Calcium release from intracellular stores evoked by extracellular ATP in a Xenopus renal epithelial cell line. Mori M, et al. **J Physiol (Lond)** 1997 Jul 15;502 (Pt 2):365-73
ATP-sensitive K+ channels are functional in expiratory neurones of normoxic cats. Pierrefiche O, et al. **J Physiol (Lond)** 1996 Jul 15;494 (Pt 2):399-409
Ca2+ responses to ATP via purinoceptors in the early embryonic chick retina. Sugioka M, et al. **J Physiol (Lond)** 1996 Jun 15;493 (Pt 3):855-63
Actin microfilament disrupters enhance K(ATP) channel opening in patches from guinea-pig cardiomyocytes. Terzic A, et al. **J Physiol (Lond)** 1996 Apr 15;492 (Pt 2):395-404
P2X purinoceptors in cultured myenteric neurons of guinea-pig small intestine. Zhou X, et al. **J Physiol (Lond)** 1996 Nov 1;496 (Pt 3):719-29
Effect of ATP and platelet-activating factor on intracellular calcium concentrations of cultured oviductal cells from cows. Tiemann U, et al. **J Reprod Fertil** 1996 Sep;108(1):1-9
Effects of purinergic agonists on mechanical and electrical activities of gastric smooth muscle of guinea-pig. Ahn SC, et al. **J Smooth Muscle Res** 1995 Dec;31(6):407-10
Interdoublet sliding in bovine spermatozoa: its relationship to flagellar motility and the action of inhibitory agents. Bird Z, et al. **J Struct Biol** 1996 May-Jun;116(3):418-28
ATP-MgCL2 reduces intestinal permeability during mesenteric ischemia. Kreienberg PB, et al. **J Surg Res** 1996 Nov;66(1):69-74
Changes in cholinergic and purinergic neurotransmission in pathologic bladder of chronic spinal rabbit. Yokota T, et al. **J Urol** 1996 Nov;156(5):1862-6
Characterization of an ATP-dependent DNA ligase encoded by Chlorella virus PBCV-1. Ho CK, et al. **J Virol** 1997 Mar;71(3):1931-7
Effects of intracoronary adenosine triphosphate on coronary flow velocity dynamics in children. Hamaoka K, et al. **Jpn Heart J** 1997 Jan;38(1):39-52
Cooperation of ATP and norepinephrine in inducing contraction in guinea pig vas deferens is not associated with change in intracellular Ca2+ level. Fujita A, et al. **Jpn J Pharmacol** 1996 Mar;70(3):273-6
Implication of ATP-sensitive K+ channels in various stress-induced analgesia (SIA) in mice. Nakao K, et al. **Jpn J Pharmacol** 1996 Jul;71(3):269-72
ATP, thapsigargin and cAMP increase Ca2+ in rat hepatocytes by activating three different Ca2+ influx pathways. Ikari A, et al. **Jpn J Physiol** 1997 Apr; 47(2):235-9
Molecular aspects of ATP-sensitive K+ channels in the cardiovascular system. Isomoto S, et al. **Jpn J Physiol** 1997; 47 Suppl 1:S5-6 (7 ref.)
Modulation of inwardly rectifying ATP-regulated K+ channel by phosphorylation process in opossum kidney cells. Kubokawa M, et al. **Jpn J Physiol** 1997 Feb; 47(1):111-9
Molecular basis of functional diversity of ATP-sensitive K+ channels. Seino S, et al. **Jpn J Physiol** 1997;47 Suppl 1:S3-4 (12 ref.)
Regulation of glucose metabolism and opening of K(ATP) channels in pancreatic beta-cells by NO. Tsuura Y, et al. **Jpn J Physiol** 1997;47 Suppl 1:S12
Intracellular mechanism of ATP-induced depolarizing response in the bullfrog sympathetic ganglion cells. Somei K, et al. **Methods Find Exp Clin Pharmacol** 1996 Sep; 18(7):443-8
ATP-sensitive potassium channels are altered in ventricular myocytes from diabetic rats. Smith JM, et al. **Mol Cell Biochem** 1996 May 10;158(1):43-51
ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Loe DW, et al. **Mol Pharmacol** 1997 Jun;51(6):1034-41
Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells [published erratum appears in Mol Pharmacol 1997 Mar;51(3):533] Yu SM, et al. **Mol Pharmacol** 1996 Oct;50(4):1000-9
New insights on P2X purinoceptors. Humphrey PP, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec; 352(6):585-96 (94 ref.)
Contribution of ATP-sensitive potassium channels to beta-adrenoceptor-mediated responses. Hüsken BC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jan; 355(1):97-102
Potentiation of stimulus-induced phosphoinositide breakdown by calmodulin antagonists in C6 glioma cells. Lin WW. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec;352(6):679-84
Functional characterisation of P2 purinoceptors in PC12 cells by measurement of radiolabelled calcium influx. Michel AD, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov;354(5):562-71
Extracellular ATP promotes cellular growth of renal inner medullary collecting duct cells mediated via P2u receptors. Ishikawa S, et al. **Nephron** 1997;76(2):208-14
Selegiline induces dopamine release through ATP-sensitive potassium channels in the rat caudate-putamen in vitro. Neusch C, et al. **Neurochem Int** 1997 Aug;31(2):307-11
Intracellular Ca2+ signals induced by ATP and thapsigargin in glioma C6 cells. Calcium pools sensitive to inositol 1,4,5-trisphosphate and thapsigargin. Sabała P, et al. **Neurochem Int** 1997 Jul;31(1):55-64
ATP induces release of newly synthesized dopamine in the rat striatum. Zhang YX, et al. **Neurochem Int** 1996 Apr; 28(4):395-400
ATP-dependent formation of free synaptic vesicles from PC12 membranes in vitro. Cleves AE, et al. **Neurochem Res** 1997 Aug;22(8):933-40
ATP-induced oscillations of cytosolic Ca2+ activity in cultured astrocytes from rat brain are modulated by medium osmolarity indicating a control of [Ca2+]i oscillations by cell volume. Reetz G, et al. **Neurochem Res** 1997 May;22(5):621-8
State-dependent modulation of mSlo, a cloned calcium-dependent potassium channel. Müller M, et al. **Neuropharmacology** 1996;35(7):877-86
Acid pH augments excitatory action of ATP on a dissociated mammalian sensory neuron. Li C, et al. **Neuroreport** 1996 Sep 2;7(13):2151-4
Extracellular ATP induces formation of AP-1 complexes in astrocytes via P2 purinoceptors. Neary JT, et al. **Neuroreport** 1996 Nov 25;7(18):2893-6
ATP induces Ca2+ release from IP3-sensitive Ca2+ stores exclusively in large DRG neurones. Svichar N, et al. **Neuroreport** 1997 May 6;8(7):1555-9
P2 purinoceptor-mediated intracellular Ca2+ transients in human sural nerve. Wächtler J, et al. **Neuroreport** 1996 May 17;7(7):1289-92
Single channel properties of ATP-gated cation channels (P2X receptors) heterologously expressed in Chinese hamster ovary cells. Evans RJ. **Neurosci Lett** 1996 Jul 19; 212(3):212-4
Repetitive applications of ATP potentiate potassium current by Ca2+/calmodulin kinase in cultured rat hippocampal neurons. Ikeuchi Y, et al. **Neurosci Lett** 1996 Jan 19; 203(2):115-8
Cu2+ potently enhances ATP-activated current in rat nodose ganglion neurons. Li C, et al. **Neurosci Lett** 1996 Nov 15;219(1):45-8
InsP3-induced Ca2+ release in dorsal root ganglion neurones. Svichar N, et al. **Neurosci Lett** 1997 May 16; 227(2):107-10
Extracellular ATP increases intracellular calcium in cultured adult Schwann cells. Ansselin AD, et al. **Neuroscience** 1997 Feb;76(3):947-55
Functional evidence for multiple purinoceptor subtypes in the rat medial vestibular nucleus. Chessell IP, et al. **Neuroscience** 1997 Apr;77(3):783-91
ATP acting on P2Y receptors triggers calcium mobilization in Schwann cells at the neuroelectrocyte junction in skate. Green AC, et al. **Neuroscience** 1997 Sep;80(2):635-51
ATP-induced membrane currents in ameboid microglia

acutely isolated from mouse brain slices. Haas S, et al. **Neuroscience** 1996 Nov;75(1):257–61

Electrophysiological investigation of adenosine trisphosphate-sensitive potassium channels in the rat substantia nigra pars reticulata. Stanford IM, et al. **Neuroscience** 1996 Sep;74(2):499–509

Differences in the mode of stimulation of cultured rat sympathetic neurons between ATP and UDP. von Kügelgen I, et al. **Neuroscience** 1997 Jun;78(4):935–41

ATP induces large channel endocytosis with concomitant increase in cell density. Bay BH, et al. **Okajimas Folia Anat Jpn** 1996 Aug;73(2–3):113–7

Effect of genistein on ATP-induced cell retraction and rounding in human Chang liver cells. Bay BH. **Okajimas Folia Anat Jpn** 1997 May;74(1):33–7

The in vitro effects of extracellular adenosine triphosphate on the ultrastructure of Trypanosoma cruzi epimastigotes. Bogitsh BJ, et al. **Parasitol Res** 1997;83(6):624–6

ATP increases [Ca2+]i and ion secretion via a basolateral P2Y-receptor in rat distal colonic mucosa. Leipziger J, et al. **Pflugers Arch** 1997 May;434(1):77–83

Enhancement of ATP-activated current by protons in dorsal root ganglion neurons. Li C, et al. **Pflugers Arch** 1997 Feb; 433(4):446–54

Effect of cAMP and ATP on the hyperpolarization-activated current in mouse dorsal root ganglion neurons. Raes A, et al. **Pflugers Arch** 1997 Sep;434(5):543–50

Simultaneous recording of ATP-sensitive K+ current and intracellular Ca2+ in anoxic rat ventricular myocytes. Effects of glibenclamide. Russ U, et al. **Pflugers Arch** 1996 May;432(1):75–80

Evidence against the association of the sulphonylurea receptor with endogenous Kir family members other than KATP in coronary vascular smooth muscle. Wellman GC, et al. **Pflugers Arch** 1996 Jun;432(2):355–7

Disruption of actin cytoskeleton attenuates sulfonylurea inhibition of cardiac ATP-sensitive K+ channels. Yokoshiki H, et al. **Pflugers Arch** 1997 Jun;434(2):203–5

Zeneca ZD6169 activates ATP-sensitive K+ channels in the urinary bladder of the guinea pig. Heppner TJ, et al. **Pharmacology** 1996 Sep;53(3):170–9

Sensitivity of a renal K+ channel (ROMK2) to the inhibitory sulfonylurea compound glibenclamide is enhanced by coexpression with the ATP-binding cassette transporter cystic fibrosis transmembrane regulator. McNicholas CM, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8083–8

P2Y1 purinergic receptors in sensory neurons: contribution to touch-induced impulse generation. Nakamura F, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10465–70

Dynamic electron microscopy of ATP-induced myosin head movement in living muscle thick filaments. Sugi H, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4378–82

Domains of P2X receptors involved in desensitization. Werner P, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24; 93(26):15485–90

ATP modification of serotonin-induced contraction of the rat pulmonary artery. Soslau G, et al. **Proc Soc Exp Biol Med** 1997 Mar;214(3):233–41

The allosteric activator ATP induces a substrate-dependent alteration of the quaternary structure of a mutant aspartate transcarbamoylase impaired in active site closure. Baker DP, et al. **Protein Sci** 1996 Nov;5(11):2276–86

ATP-induced Cl- secretion with suppressed Na+ absorption in rabbit tracheal epithelium. Iwase N, et al. **Respir Physiol** 1997 Feb;107(2):173–80

Global ischemia impairs ATP-sensitive K+ channel function in cerebral arterioles in piglets. Bari F, et al. **Stroke** 1996 Oct;27(10):1874–80; discussion 1880–1

Changes of adenosine triphosphate-dependent calcium uptake in microsomal fractions of rat liver during sepsis. Hwang TL, et al. **Surgery** 1997 Jun;121(6):662–7

Adenosine nucleotides induce E-selectin expression in porcine endothelial cells. von Albertini MA, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1062

Two opposite effects of ATP on the apparent sensitivity of the cGMP-gated channel of the carp retinal cone. Watanabe S, et al. **Vis Neurosci** 1997 Jul–Aug;14(4):609–15

Effect of Mg(2+)-ATP on acetylcholinesterase of Electrophorus electricus (L.). Nery da Matta A, et al. **Z Naturforsch [C]** 1996 Jan–Feb;51(1–2):65–9

[Protective effect of ATP-MgCl2 on gut mucosa in burn rat] Su Y, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 May;12(3):171–3 (Eng. Abstr.) **(Chi)**

[ATP-induced electric current in rat aortic smooth muscle cells] Muraki K, et al. **J Smooth Muscle Res** 1995 Dec; 31(6):387–8 **(Jpn)**

[Effect of tyrosine kinase and tyrosine phosphatase inhibitors on ATP- and thapsigargin-induced CA2+ entry in rat peritoneal macrophages] Krutetskaia ZI, et al. **Tsitologiia** 1997;39(2–3):164–76 (Eng. Abstr.) **(Rus)**

[Effect of adenosine triphosphate on the cleavage of H1 histones in nuclei of rat spleen and liver] Tiulenev VI, et al. **Ukr Biokhim Zh** 1996 Nov–Dec;68(6):23–9 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Effect of glimepiride and glibenclamide, inhibitors of ATP-dependent K(+)-channel, on ischaemia-reperfusion induced arrhythmias in rats. Bozdogan O, et al. **Acta Physiol Hung** 1996;84(3):265–6

Autonomic neural control of cardiac function: modulation by adenosine and adenosine 5'-triphosphate. Pelleg A, et al. **Am J Cardiol** 1997 Jun 19;79(12A):11–4 (72 ref.)

Role of ATP-sensitive K+ channels in cGMP-mediated pial artery vasodilation. Armstead WM. **Am J Physiol** 1996 Feb; 270(2 Pt 2):H423–6

Nordihydroguaiaretic acid depletes ATP and inhibits a swelling-activated, ATP-sensitive taurine channel. Ballatori N, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1429–36

cAMP activates an ATP-conductive pathway in cultured shark rectal gland cells. Cantiello HF, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C466–75

NO release and the opening of K+ATP channels mediate vasodilator responses to histamine in the cat. Champion HC, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H928–37

Extracellular ATP and adenosine cause apoptosis of pulmonary artery endothelial cells. Dawicki DD, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):L485–94

Regulation and translocation of ATP-dependent apical membrane proteins in rat liver. Gatmaitan ZC, et al. **Am J Physiol** 1997 May;272(5 Pt 1):G1041–9

Extracellular ATP regulates transcervical permeability by modulating two distinct paracellular pathways. Gorodeski GI, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1602–10

Swelling-activated anion conductance in skate hepatocytes: regulation by cell Cl- and ATP. Jackson PS, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C57–66

Endothelium-dependent regulation of cerebrovascular tone by extracellular and intracellular ATP. Janigro D, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H878–85

Extracellular ATP mediates Ca2+ signaling in cultured myenteric neurons via a PLC-dependent mechanism. Kimball BC, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):G587–93

Alterations in ATP-sensitive potassium channel sensitivity to ATP in failing human hearts. Koumi SI, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1656–65

Protein kinase C-mediated preconditioning of cardiac myocytes: role of adenosine receptor and KATP channel. Liang BT. **Am J Physiol** 1997 Aug;273(2 Pt 2):H847–53

Prolactin increases ATP-dependent taurocholate transport in canalicular plasma membrane from rat liver. Liu Y, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):G46–53

A KATP channel opener protects cardiomyocytes from Ca2+ waves: a laser confocal microscopy study. López JR, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):H1384–9

Dependence of Ca2+ channel currents on endogenous and exogenous sources of ATP in portal vein smooth muscle. Lorenz JN, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H987–94

KATP channels mediate late preconditioning against infarction produced by monophosphoryl lipid A. Mei DA, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2723–9

Hydrolytic and nonhydrolytic interactions in the ATP regulation of CFTR Cl- conductance. Reddy MM, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C35–42

K(ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Salzman AL, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H688–94

ATP: the red blood cell link to NO and local control of the pulmonary circulation. Sprague RS, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2717–22

Cl- current in IMCD cells activated by hypotonicity: time course, ATP dependence, and inhibitors. Volk KA, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F552–9

Mechanism of [Ca2+]i increase by extracellular ATP in isolated rabbit renal proximal tubules. Yamada H, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):C1096–104

Regulation of Ca2+ channel currents by intracellular ATP in smooth muscle cells of rat mesenteric artery. Yokoshiki H, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H814–9

Regulation of insulin secretion via ATP-sensitive K+ channel independent mechanisms: role of phospholipase C. Zawalich WS, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E671–7

Glucocorticoid receptors: ATP and cell cycle dependence, phosphorylation, and hormone resistance. Bodwell JE, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S2–6 (35 ref.)

Single-channel recordings of an ATP-sensitive K channel in rat cultured cortical neurons. Ohno-Shosaku T, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:396–8

Cytoplasmic ATP-dependent regulation of ion transporters and channels: mechanisms and messengers. Hilgemann DW. **Annu Rev Physiol** 1997;59:193–220 (166 ref.)

Studies of the K(ATP) channel opening activity of the new dihydropyridine compound 9-(3-cyanophenyl)-3,4,6,7,9,10-hexahydro-1,8-(2H,5H)-acridined ione in bladder detrusor in vitro. Li JH, et al. **Arzneimittelforschung** 1996 May;46(5):525–30

Modulation of ATP-sensitive K+ channel by insulin in rat skeletal muscle fibers. Tricarico D, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):536–9

Neuropeptide Y modulates ATP-induced increases in internal calcium via the adenylate cyclase/protein kinase A system in a human neuroblastoma cell line. Soares Lemos V, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):439–44

Ubiquitin aldehyde increases adenosine triphosphate-dependent proteolysis of hemoglobin alpha-subunits in beta-thalassemic hemolysates. Shaeffer JR, et al. **Blood** 1997 Aug 1;90(3):1300–8

The involvement of ATP-sensitive potassium channels in beta 2-adrenoceptor agonist-induced vasodilatation on rat diaphragmatic microcirculation. Chang HY. **Br J Pharmacol** 1997 Jul;121(5):1024–30

Characterization of Na+ influx mediated by ATP(4-)-activated P2 purinoceptors in PC12 cells. Choi SY, et al. **Br J Pharmacol** 1996 Jun;118(4):935–40

Diadenosine tetraphosphate-induced inhibition of ATP-sensitive K+ channels in patches excised from ventricular myocytes. Jovanovic A, et al. **Br J Pharmacol** 1996 Jan;117(2):233–5

Evidence for a P2-purinoceptor mediating vasoconstriction by UTP, ATP and related nucleotides in the isolated pulmonary vascular bed of the rat. Rubino A, et al. **Br J Pharmacol** 1996 Jul;118(6):1415–20

Involvement of ATP in the non-adrenergic non-cholinergic inhibitory neurotransmission of lamb isolated coronary small arteries. Simonsen U, et al. **Br J Pharmacol** 1997 Feb; 120(3):411–20

Pre-synaptic effect of the ATP-sensitive potassium channel opener diazoxide on rat substantia nigra pars reticulata neurons. Ye GL, et al. **Brain Res** 1997 Apr 4;753(1):1–7

Blockade of ATP-dependent K+ channels in myocardium and coronary artery smooth muscle: a possible cause of increased cardiovascular mortality in sulfonylurea-treated patients [letter] Gasser R, et al. **Cardiovasc Drugs Ther** 1997 Mar;11(1):87–9

SWI2/SNF2 and related proteins: ATP-driven motors that disrupt protein-DNA interactions? Pazin MJ, et al. **Cell** 1997 Mar 21;88(6):737–40 (20 ref.)

Simulation of action potentials from metabolically impaired cardiac myocytes. Role of ATP-sensitive K+ current. Ferrero JM Jr, et al. **Circ Res** 1996 Aug;79(2):208–21

Beta 2-adrenergic dilation of resistance coronary vessels involves KATP channels and nitric oxide in conscious dogs. Ming Z, et al. **Circulation** 1997 Mar 18;95(6):1568–76

Role of cerebral ATP-sensitive K+ channels in arterial pressure regulation during acute cerebral ischaemia in SHR and WKY rats. Nishimura M, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S70–2

Neuropharmacology: a part for purines in pattern generation. Halliday FC, et al. **Curr Biol** 1997 Jan 1;7(1):R47–9

Cardiovascular effects of sulphonylurea derivatives. Smits P, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S55–9 (24 ref.)

Haemodynamic and other effects of sulphonylurea drugs on the heart. Végh A, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S43–53 (75 ref.)

Multidrug resistance in Lactococcus lactis: evidence for ATP-dependent drug extrusion from the inner leaflet of the cytoplasmic membrane. Bolhuis H, et al. **EMBO J** 1996 Aug 15;15(16):4239–45

AAA proteases with catalytic sites on opposite membrane surfaces comprise a proteolytic system for the ATP-dependent degradation of inner membrane proteins in mitochondria. Leonhard K, et al. **EMBO J** 1996 Aug 15;15(16):4218–29

KATP channels and glucose-induced insulin release: lessons from persistent hyperinsulinemic hypoglycemia of infancy. Vischer U. **Eur J Endocrinol** 1997 May;136(5):471–2

Hydroxylamine, a nitric oxide donor, inhibits insulin release and activates K+ATP channels. Antoine MH, et al. **Eur J Pharmacol** 1996 Oct 17;313(3):229–35

K(ATP) channels do not mediate vasodilation by 3-morpholinosydnonimine in goat coronary artery. Deka DK, et al. **Eur J Pharmacol** 1997 Jul 9;330(2–3):157–64

ATP-regulated K+ channel and cytosolic Ca2+ mobilization in cultured rat spinal neurons. Ikeuchi Y, et al. **Eur J Pharmacol** 1996 Apr 29;302(1–3):163–9

Anti- and proconvulsive actions of levcromakalim, an opener of ATP-sensitive K+ channel, in the model of hippocampus-generating partial seizures in rats. Katsumori H, et al. **Eur J Pharmacol** 1996 Sep 5;311(1):37–44

The effects of pharmacological modulation of KATP on the guinea-pig isolated diaphragm. Wickenden AD, et al. **Eur J Pharmacol** 1996 Apr 29;302(1–3):79–88

Subunit stoichiometry of the pancreatic beta-cell ATP-sensitive K+ channel. Inagaki N, et al. **FEBS Lett** 1997 Jun 9;409(2):232–6

An antagonist of ATP-regulated potassium channels, the guanidine derivative U-37883A, stimulates the synthesis of phosphatidylserine in rat liver endoplasmic reticulum membranes. Makowski P, et al. **FEBS Lett** 1997 Jun 9; 409(2):292–6

Adenosine triphosphate mediates intercellular communication in liver: talk ain't exactly cheap. Lidofsky S. **Hepatology** 1997 Mar;25(3):778–9

Extracellular adenosine 5' triphosphate involvement in the death of LAK-engaged human tumor cells via P2X-receptor activation. Correale P, et al. **Immunol Lett** 1997 Feb;55(2):69–78

Muscle contraction: the step-size distance and the impulse-time per ATP. Worthington CR, et al. **Int J Biol Macromol** 1996 Feb;18(1–2):123–31

Role of ATP and related purine compounds on urethral relaxation in male rabbits. Ohnishi N, et al. **Int J Urol** 1997 Mar;4(2):191–7

KATP channels mediate adenosine-induced hyperemia in retina. Gidday JM, et al. **Invest Ophthalmol Vis Sci** 1996 Dec;37(13):2624–33

ATP as a cotransmitter in perivascular sympathetic nerves. Kennedy C. **J Auton Pharmacol** 1996 Dec;16(6):337–40 (11 ref.)

ADENOSINE TRIPHOSPHATE

Extracellular ATP regulates glomerular endothelial cell function. Pavenstädt H, et al. **J Auton Pharmacol** 1996 Dec; 16(6):389–91 (20 ref.)

Purinergic modulation of neural control of cardiac function. Pelleg A, et al. **J Auton Pharmacol** 1996 Dec;16(6):401–5 (56 ref.)

Extracellular nucleotides as signalling molecules for renal mesangial cells. Schulze-Lohoff E, et al. **J Auton Pharmacol** 1996 Dec;16(6):381–4 (16 ref.)

Molecular switch of F0F1-ATP synthase, G-protein, and other ATP-driven enzymes. Noji H, et al. **J Bioenerg Biomembr** 1996 Oct;28(5):451–7 (35 ref.)

Tight junction proteins form large complexes and associate with the cytoskeleton in an ATP depletion model for reversible junction assembly. Tsukamoto T, et al. **J Biol Chem** 1997 Jun 27;272(26):16133–9

Oxygen-induced pulmonary vasodilation is mediated by adenosine triphosphate in newborn lambs. Crowley MR. **J Cardiovasc Pharmacol** 1997 Jul;30(1):102–9

Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. Price SR, et al. **J Clin Invest** 1996 Oct 15;98(8):1703–8

Pravastatin transport across the hepatocyte canalicular membrane requires both ATP and a transmembrane pH gradient. Adachi Y, et al. **J Gastroenterol Hepatol** 1996 Jun;11(6):580–5

ATP modulates sulfobromophthalein uptake in rat liver plasma membrane vesicles. Torres AM. **J Gastroenterol Hepatol** 1996 Nov;11(11):1065–71

ATP dependence of Na+/H+ exchange. Nucleotide specificity and assessment of the role of phospholipids. Demaurex N, et al. **J Gen Physiol** 1997 Feb;109(2):117–28

Cell swelling activates ATP-dependent voltage-gated chloride channels in M-1 mouse cortical collecting duct cells. Meyer K, et al. **J Gen Physiol** 1996 Sep;108(3):177–93

Control of rectification and gating of cloned KATP channels by the Kir6.2 subunit. Shyng S, et al. **J Gen Physiol** 1997 Aug;110(2):141–53

Presence of ATP-dependent copper transport in the hepatocyte canalicular membrane of the Long-Evans cinnamon rat, an animal model of Wilson disease [letter] Adachi Y, et al. **J Hepatol** 1997 Jan;26(1):216–7

Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. Ferrari D, et al. **J Immunol** 1997 Aug 1;159(3):1451–8

Reduced dihydroxyacetone sensitivity and normal sensitivity to glyceraldehyde and oxidizing agent of ATP-sensitive K+ channels of pancreatic beta cells in NIDDM rats. Song DK, et al. **J Korean Med Sci** 1997 Aug;12(4):286–92

ATP-dependent phosphatidylcholine translocation in rat liver canalicular plasma membrane vesicles. Nies AT, et al. **J Lipid Res** 1996 May;37(5):1125–36

Kinetic analysis of the inhibitory effect of glibenclamide on KATP channels of mammalian skeletal muscle. Barrett-Jolley R, et al. **J Membr Biol** 1997 Feb 1; 155(3):257–62

Cholinergic short-term conditioning and activation of ATP-sensitive K+ current in cat atrial myocytes. Lipsius SL, et al. **J Mol Cell Cardiol** 1997 Mar;29(3):907–14

Biphasic response of action potential duration to metabolic inhibition in rabbit and human ventricular myocytes: role of transient outward current and ATP-regulated potassium current. Verkerk AO, et al. **J Mol Cell Cardiol** 1996 Dec; 28(12):2443–56

Contribution of ATP-sensitive potassium channels to hypoxic hyperpolarization in rat hippocampal CA1 neurons in vitro. Fujimura N, et al. **J Neurophysiol** 1997 Jan; 77(1):378–85

Modulation of K+ channels by intracellular ATP in human neocortical neurons. Jiang C, et al. **J Neurophysiol** 1997 Jan;77(1):93–102

Mg2+ inhibition of ATP-activated current in rat nodose ganglion neurons: evidence that Mg2+ decreases the agonist affinity of the receptor. Li C, et al. **J Neurophysiol** 1997 Jun;77(6):3391–5

Voltage-dependent gating of ATP-activated channels in PC12 cells. Nakazawa K, et al. **J Neurophysiol** 1997 Aug; 78(2):884–90

Similarity of ATP-dependent K+ channels in skeletal muscle fibres from normal and mutant mdx mice. Allard B, et al. **J Physiol (Lond)** 1997 Jan 15;498 (Pt 2):319–25

The role of ATP in the regulation of intracellular Ca2+ release in single fibres of mouse skeletal muscle. Allen DG, et al. **J Physiol (Lond)** 1997 Feb 1;498 (Pt 3):587–600

Ionic permeability of, and divalent cation effects on, two ATP-gated cation channels (P2X receptors) expressed in mammalian cells. Evans RJ, et al. **J Physiol (Lond)** 1996 Dec 1;497 (Pt 2):413–22

ATP-gated cation channels (P2X purinoceptors) in trigeminal mesencephalic nucleus neurons of the rat. Khakh BS, et al. **J Physiol (Lond)** 1997 Feb 1;498 (Pt 3):709–15

Intracellular ATP activates inwardly rectifying K+ channels in human and monkey retinal Müller (glial) cells. Kusaka S, et al. **J Physiol (Lond)** 1997 May 1;500 (Pt 3):593–604

Effect of low [ATP] on depolarization-induced Ca2+ release in skeletal muscle fibres of the toad. Owen VJ, et al. **J Physiol (Lond)** 1996 Jun 1;493 (Pt 2):309–15

Functional interaction between K(ATP) channels and the Na(+)-K(+) pump in metabolically inhibited heart cells of the guinea-pig. Priebe L, et al. **J Physiol (Lond)** 1996 Apr 15;492 (Pt 2):405–17

Two K(+)-selective conductances in single proximal tubule cells isolated from frog kidney are regulated by ATP. Robson L, et al. **J Physiol (Lond)** 1997 May 1;500 (Pt 3):605–16

Studies on the roles of ATP, adenosine and nitric oxide in mediating muscle vasodilatation induced in the rat by acute systemic hypoxia. Skinner MR, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):553–60

An ATP-gated cation channel with some P2Z-like characteristics in gastric smooth muscle cells of toad. Ugur M, et al. **J Physiol (Lond)** 1997 Jan 15;498 (Pt 2):427–42

Cross-talk between ATP-regulated K+ channels and Na+ transport via cellular metabolism in frog skin principal cells. Urbach V, et al. **J Physiol (Lond)** 1996 Feb 15;491 (Pt 1):99–109

Rapid activation of KATP channels by aldosterone in principal cells of frog skin. Urbach V, et al. **J Physiol (Lond)** 1996 Feb 15;491 (Pt 1):111–20

Pathophysiological functions of ATP-sensitive K+ channels in myocardial ischemia. Hiraoka M. **Jpn Heart J** 1997 May; 38(3):297–315 (116 ref.)

Functional interaction between Na(+)-K+ pump and KATP channels in the CNS neurons under experimental brain ischemia. Akaike N, et al. **Jpn J Physiol** 1997;47 Suppl 1:S50–1

Volume-sensitive Cl- channel in human epithelial cells: regulation by ATP and relation to P-glycoprotein. Okada Y, et al. **Jpn J Physiol** 1997;47 Suppl 1:S19–20

Effect of phytohormones on ATP-dependent accumulation of Ca2+ in plasma membrane vesicles from tubers of potato Solanum tuberosum L. Ladyzhenskaya EP, et al. **Membr Cell Biol** 1997;11(1):77–85

ATP-dependent potassium channel from rat liver mitochondria: inhibitory analysis, channel clusterization. Mironova GD, et al. **Membr Cell Biol** 1997;10(5):583–91

Activatory effect of calcium-binding protein regucalcin on ATP-dependent calcium transport in the basolateral membranes of rat kidney cortex. Kurota H, et al. **Mol Cell Biochem** 1997 Apr;169(1-2):149–56

Reinstatement of the ATP high energy paradigm. Repke KR. **Mol Cell Biochem** 1996 Jul-Aug;160-161:95–9 (44 ref.)

Loss of functional KATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy [see comments] Kane C, et al. **Nat Med** 1996 Dec; 2(12):1344–7. Comment in: Nat Med 1996 Dec;2(12):1301–2.

Enhanced lipid peroxidation by extracellular ATP in PC12 cells. Cheng Y, et al. **Neurochem Res** 1996 Jan;21(1):27–33

Association and stoichiometry of K(ATP) channel subunits. Clement JP 4th, et al. **Neuron** 1997 May;18(5):827–38

Expression of the P2X2 receptor subunit of the ATP-gated ion channel in the retina. Greenwood D, et al. **Neuroreport** 1997 Mar 24;8(5):1083–8

ATP-activated cationic and anionic conductances in cultured rat hippocampal neurons. Balachandran C, et al. **Neurosci Lett** 1996 Feb 2;204(1-2):73–6

Central noradrenergic neurons signal via ATP to elicit vasopressin responses to haemorrhage. Buller KM, et al. **Neuroscience** 1996 Aug;73(3):637–42

Identification of the major transport pathway for the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. Dunigan CD, et al. **Neuroscience** 1996 Nov;75(1):37–41

Cation requirements of basal and ATP-regulated dopamine transport in rat pheochromocytoma cells. Dunigan CD, et al. **Neuroscience** 1996 Sep;74(1):275–82

Studies on the release and extracellular metabolism of endogenous ATP in rat superior cervical ganglion: support for neurotransmitter role of ATP. Vizi ES, et al. **Neuroscience** 1997 Aug;79(3):893–903

Extracellular ATP modulates ion transport via P2Y purinoceptors in a middle-ear epithelial cell line. Yen PT, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 May-Jun; 59(3):170–5

ATP-dependent redistribution of phosphatidylethanolamine in the plasma membrane of an epithelial and a hepatocytic cell line. Pomorski T, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R243–4

Region-dependent ATP-sensitive neurotransmission not related to smooth muscle cell excitability in rat vas deferens. Matsuki N, et al. **Pharmacol Toxicol** 1996 Jun; 78(6):435–8

Effect of the class III antiarrhythmic agent E-4031 on the ATP-sensitive potassium channel in rabbit ventricular myocytes. West PD, et al. **Pharmacol Toxicol** 1996 Feb; 78(2):89–93

Effects of tolbutamide on ATP-sensitive K+ channels from human right atrial cardiac myocytes. Zünkler BJ, et al. **Pharmacol Toxicol** 1997 Feb;80(2):69–75

Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat hearts. D'Alonzo AJ, et al. **Pharmacology** 1996 Feb; 52(2):101–12

Persisting in vitro actin motility at nanomolar adenosine triphosphate levels: comparison of skeletal and cardiac myosins. Kellermayer MS Jr, et al. **Physiol Chem Phys Med NMR** 1995;27(3):167–78

Cardiopharmacological profile of HOE 234, the new activator of ATP-sensitive K+ channels in the guinea pig heart. Kocić I, et al. **Pol J Pharmacol** 1995 Sep-Oct; 47(5):457–60

Methylmercury efflux from brain capillary endothelial cells is modulated by intracellular glutathione but not ATP. Kerper LE, et al. **Toxicol Appl Pharmacol** 1996 Dec; 141(2):526–31

Myosin light chain kinase: an actin-binding protein that regulates an ATP-dependent interaction with myosin. Kohama K, et al. **Trends Pharmacol Sci** 1996 Aug; 17(8):284–7 (33 ref.)

Structure and function of the low conductance KATP channel, ROMK. Hebert SC, et al. **Wien Klin Wochenschr** 1997 Jun 27;109(12-13):471–6 (46 ref.)

[Myocardial protection from ischemic damage: effects of preconditioning and pharmacologic activation of KATP channels] Galiè N, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):77–82 (23 ref.) **(Ita)**

[Electrophysiologic features of the modulation of ATP-dependent potassium channels] Schwartz PJ, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):83–6 **(Ita)**

[Nicorandil, as ATP-sensitive K+ channel opener, potentiated morphine analgesia] Asano T, et al. **Masui** 1996 Nov;45(11):1342–6 (Eng. Abstr.) **(Jpn)**

[Treatment of intact myometrial cells with oxytocin inhibits Mg2+, ATP-dependent accumulation of Ca2+ in endoplasmic reticulum] Shlykov SG, et al. **Ukr Biokhim Zh** 1996 Sep-Oct;68(5):25–34 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

[The ATP content of the neutrophils and whole blood in the inhabitants of regions in the Altai Territory subjected to nuclear testing exposure] Frundzhian VG, et al. **Radiats Biol Radioecol** 1997 Jan-Feb;37(1):13–9 (Eng. Abstr.) **(Rus)**

SECRETION

Storage pool disease in chronic lymphocytic leukemia: abnormal aggregation and secretion without bleeding. Carr ME Jr, et al. **Am J Med Sci** 1997 Mar;313(3):176–81

Inhibition of neural ATP release by atrial natriuretic peptide in guinea-pig vas deferens. Driessen B, et al. **Eur J Pharmacol** 1996 Feb 5;296(3):261–5

Pharmacological studies to examine the source of ATP released by pelvic nerve stimulation in the feline lower urinary tract. Theobald RJ. **J Auton Pharmacol** 1996 Apr; 16(2):111–5

ATP and [3H]noradrenaline release and the presence of ecto-Ca(2+)-ATPases in the capsule-glomerulosa fraction of the rat adrenal gland. Jurányi Z, et al. **J Endocrinol** 1997 Apr;153(1):105–14

Glucose-dependent, cAMP-mediated ATP efflux from Saccharomyces cerevisiae. Boyum R, et al. **Microbiology** 1997 Jun;143 (Pt 6):1901–8

ATP release by angiotensin II from segments and cultured smooth muscle cells of guinea-pig taenia coli. Katsuragi T, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Dec; 354(6):796–9

THERAPEUTIC USE

Adenosine triphosphate treatment for meconium aspiration-induced pulmonary hypertension in pigs. Kääpä P, et al. **Acta Physiol Scand** 1997 Jul;160(3):283–9

Administration of ATP-MgCl2 after trauma-hemorrhage and resuscitation restores the depressed cardiac performance. Robinson DA, et al. **J Surg Res** 1997 Apr; 69(1):159–65

Effects of adenosine triphosphate on ventriculoatrial conduction--usefulness and problems in assessment of catheter ablation of accessory pathways. Miyata A, et al. **Jpn Circ J** 1997 Apr;61(4):323–30

Effects of adenosine triphosphate on wide QRS tachycardia. Analysis in 18 patients. Hina K, et al. **Jpn Heart J** 1996 Jul;37(4):463–70

[Comparative study between verapamil and adenosine triphosphate in the treatment of paroxysmal supraventricular tachycardia] Ferreira JF, et al. **Arq Bras Cardiol** 1996 Feb;66(2):55–7 (Eng. Abstr.) **(Por)**

[The use of adenosine triphosphate in supraventricular paroxysmal tachycardia (editorial)] Maia IG. **Arq Bras Cardiol** 1996 Feb;66(2):87 **(Por)**

ADENOSINETRIPHOSPHATASE

[Detection of TBP-interacting proteins (TIPs) and demonstration of a novel complex containing TBP and ATPases] Makino Y, et al. **Tanpakushitsu Kukusan Koso** 1996 Jun;41(8 Suppl):1170–7 (16 ref.) **(Jpn)**

ANALYSIS

A continuous spectrophotometric assay for aspartate transcarbamylase and ATPases. Rieger CE, et al. **Anal Biochem** 1997 Mar 1;246(1):86–95

Thyroid status and adenosine Triphosphatase activity in experimental Trypanosoma congolense infection in rabbits. Lomo PO, et al. **Br Vet J** 1996 Nov;152(6):659–67

Morphological and histochemical study of nonhemiplegic muscle in acute stroke patients manifesting respiratory failure. Sato Y, et al. **Eur Neurol** 1996;36(1):13–9

Existence of two different species of mitochondrially translated proteolipids in ATPase complex of yeast

mitochondria. Esparza M, et al. **FEBS Lett** 1981 Nov 2; 134(1):63–6

CADp44: a novel regulatory subunit of the 26S proteasome and the mammalian homolog of yeast Sug2p. Bauer VW, et al. **Gene** 1996 Nov 28;181(1–2):63–9

Immunocytochemical localization of the Menkes copper transport protein (ATP7A) to the trans-Golgi network. Dierick HA, et al. **Hum Mol Genet** 1997 Mar;6(3):409–16

Katanin, the microtubule-severing ATPase, is concentrated at centrosomes. McNally FJ, et al. **J Cell Sci** 1996 Mar; 109 (Pt 3):561–7

Biochemical characterization and intracellular localization of the Menkes disease protein. Yamaguchi Y, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):14030–5

[Effects of 2375 MHz pulse-modulated microwave radiation on ATPase activity of the rat muscle actomyosin] Pashovskina MS, et al. **Radiats Biol Radioecol** 1996 Sep-Oct;36(5):700–5 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Inhibition of P-glycoprotein ATPase activity by procedures involving trapping of nucleotide in catalytic sites. Sankaran B, et al. **Arch Biochem Biophys** 1997 May 1;341(1):160–9

Inhibition of ecto-ATPase by the P2 purinoceptor agonists, ATPgammaS, alpha,beta-methylene-ATP, and AMP-PNP, in endothelial cells. Chen BC, et al. **Biochem Biophys Res Commun** 1997 Apr 17;233(2):442–6

Inhibition of DNA unwinding and ATPase activities of human DNA helicase II by chemotherapeutic agents. Tuteja N, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):636–40

Correlation between calponin and myosin subfragment 1 binding to F-actin and ATPase inhibition. Szymanski PT, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):519–23

Reaction of rabbit skeletal myosin with D-glucose 6-phosphate. Avigad G, et al. **Biochem Mol Biol Int** 1996 Oct;40(2):273–84

Inhibition of preprotein translocation and reversion of the membrane inserted state of SecA by a carboxyl terminus binding mAb. den Blaauwen T, et al. **Biochemistry** 1997 Jul 29;36(30):9159–68

Inhibition of P-glycoprotein ATPase activity by beryllium fluoride. Sankaran B, et al. **Biochemistry** 1997 Jun 3; 36(22):6847–53

Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages. Chen BC, et al. **Br J Pharmacol** 1996 Dec; 119(8):1628–34

Enhancement of sympathetic purinergic neurotransmission in the guinea-pig isolated vas deferens by the novel ecto-ATPase inhibitor ARL 67156. Westfall TD, et al. **Br J Pharmacol** 1996 Mar;117(5):867–72

Functional interaction between Chlamydomonas outer arm dynein subunits: the gamma subunit suppresses the ATPase activity of the alpha beta dimer. Nakamura K, et al. **Cell Motil Cytoskeleton** 1997;37(4):338–45

Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase--further experimental evidence for a multisite model. Garrigos M, et al. **Eur J Biochem** 1997 Mar 1; 244(2):664–73

The ecto-ATPase inhibitor ARL 67156 enhances parasympathetic neurotransmission in the guinea-pig urinary bladder. Westfall TD, et al. **Eur J Pharmacol** 1997 Jun 25;329(2-3):169–73

Inhibitory action of the defensive discharge of the grasshopper, Poecilocerus pictus, on certain enzymes in the lizard, Calotes nemoricola. Sreenivasulu Y, et al. **J Enzyme Inhib** 1996 Oct;11(2):135–40

Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. Dröse S, et al. **J Exp Biol** 1997 Jan;200 (Pt 1):1–8 (69 ref.)

Digoxin-like immunoreactive substance and sodium-potassium-adenosine triphosphatase inhibition in normal pregnancy: a longitudinal study. Gilson GJ, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):743–6

Inhibitory effect of ethanol on the Na(+)-ATPase activity of rat kidney proximal tubular cell plasma membranes. Rothman A, et al. **Physiol Res** 1996;45(3):205–11

BIOSYNTHESIS

Localization of Menkes gene expression in the mouse brain; its association with neurological manifestations in Menkes model mice. Iwase T, et al. **Acta Neuropathol (Berl)** 1996; 91(5):482–8

Regulation of hepatocyte bile salt transporters during hepatic regeneration. Green RM, et al. **Am J Physiol** 1997 Sep; 273(3 Pt 1):G621–7

Overexpression of the hslVU operon suppresses SOS-mediated inhibition of cell division in Escherichia coli. Khattar MM. **FEBS Lett** 1997 Sep 8;414(2):402–4

Cloning, sequencing and expression of VAT, a CDC48/p97 ATPase homologue from the archaeon Thermoplasma acidophilum. Pamnani V, et al. **FEBS Lett** 1997 Mar 10; 404(2-3):263–8

Role of interferon regulatory factor-1 in the induction of biliary glycoprotein (cell CAM-1) by interferon-gamma. Chen CJ, et al. **J Biol Chem** 1996 Nov 8;271(45):28181–8

Biochemical characterization and intracellular localization of the Menkes disease protein. Yamaguchi Y, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):14030–5

Decreased expression of glomerular ecto-ATPase in kidney grafts with delayed graft function. van Son WJ, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):352–4

BLOOD

Multiple routes and regulation by tyrosine phosphorylation characterize the ATP-dependent transport of 2,4-dinitrophenyl S-glutathione in inside-out vesicles from human erythrocytes. Saxena M, et al. **Arch Biochem Biophys** 1997 Feb 15;338(2):173–82

Protonophoric activity of NADH coenzyme Q reductase and ATP synthase in coupled submitochondrial particles from horse platelets. Baracca A, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):469–73

Kinetic analysis of enzymatic hydrolysis of ATP in human and rat blood serum. Yegutkin GG. **Biochemistry (Mosc)** 1997 Jun;62(6):619–22

Alterations in erythrocyte plasma membrane ATPase activity and adenine nucleotide content in a spontaneously diabetic subline of the Chinese hamster. Bettin D, et al. **Horm Metab Res** 1996 Jan;28(1):1–6

[Effect of dialysis on Na+/K+-ATP-ase activity in uremic children] Vásárhelyi B, et al. **Orv Hetil** 1996 Oct 6; 137(40):2193–6 (Eng. Abstr.) **(Hun)**

CHEMISTRY

Primary structure and evolution of the ATP-binding domains of the P-type ATPases in Tetrahymena thermophila. Wang S, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C715–28

Identification of export proteins from Mycobacterium tuberculosis that interact with SecA. Owens MU, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:240–1

Structural interactions of the oligomycin sensitivity-conferring protein in the yeast ATP synthase. Mao Y, et al. **Arch Biochem Biophys** 1997 Jan 1;337(1):8–16

The primary structure of the Cl(-)-translocating ATPase, b subunit of Acetabularia acetabulum, which belongs to the F-type ATPase family. Moritani C, et al. **Arch Biochem Biophys** 1997 Mar 1;339(1):115–24

cDNA cloning of a chick homologue of human ATPase complex subunit 4, quantitative tissue distribution and tertiary structure comparison of the ATPase domain to RecA. Singh I, et al. **Arch Biochem Biophys** 1996 Sep 1; 333(1):260–6

Non-functional variants of yeast mitochondrial ATP synthase subunit 8 that assemble into the complex. Papakonstantinou T, et al. **Biochem Mol Biol Int** 1996 May; 39(2):253–60

Domain interactions of the peripheral preprotein Translocase subunit SecA. den Blaauwen T, et al. **Biochemistry** 1996 Sep 17;35(37):11194–2004

Oligomycin sensitivity conferring protein of mitochondrial ATP synthase: deletions in the N-terminal end cause defects in interactions with F1, while deletions in the C-terminal end cause defects in interactions with F0. Joshi S, et al. **Biochemistry** 1996 Sep 17;35(37):12094–103

A two-site mechanism for ATP hydrolysis by the asymmetric Rep dimer P2S as revealed by site-specific inhibition with ADP-A1F4. Wong I, et al. **Biochemistry** 1997 Mar 18; 36(11):3115–25

Characterization of the preprotein translocase of the outer mitochondrial membrane by blue native electrophoresis. Dekker PJ, et al. **Biol Chem** 1996 Jul-Aug;377(7-8):535–8

RSC, an essential, abundant chromatin-remodeling complex. Cairns BR, et al. **Cell** 1996 Dec 27;87(7):1249–60

The chloride pump: a Cl(-)-translocating P-type ATPase. Gerencser GA. **Crit Rev Biochem Mol Biol** 1996; 31(4):303–37 (186 ref.)

Homophilic intercellular adhesion mediated by C-CAM is due to a domain 1-domain 1 reciprocal binding. Wikström K, et al. **Exp Cell Res** 1996 Sep 15;227(2):360–6

The complete inventory of the yeast Saccharomyces cerevisiae P-type transport ATPases. Catty P, et al. **FEBS Lett** 1997 Jun 16;409(3):325–32 (57 ref.)

Two-dimensional crystals of the Kdp-ATPase of Escherichia coli. Iwane AH, et al. **FEBS Lett** 1996 Nov 4;396(2-3):172–6

Six-fold rotational symmetry of ClpQ, the E. coli homolog of the 20S proteasome, and its ATP-dependent activator, ClpY. Kessel M, et al. **FEBS Lett** 1996 Dec 2; 398(2-3):274–8

Mutagenesis of two N-terminal Thr and five Ser residues in HslV, the proteolytic component of the ATP-dependent HslVU protease. Yoo SJ, et al. **FEBS Lett** 1997 Jul 21; 412(1):57–60

NBP35 encodes an essential and evolutionary conserved protein in Saccharomyces cerevisiae with homology to a superfamily of bacterial ATPases. Vitale G, et al. **Gene** 1996 Oct 31;178(1-2):97–106

In vivo cross-linking of the SecA and SecY subunits of the Escherichia coli preprotein translocase. Manting EH, et al. **J Bacteriol** 1997 Sep;179(18):5699–704

Comparison of ncd and kinesin motor domains by circular dichroism spectroscopy. Shimizu T, et al. **J Biochem (Tokyo)** 1996 Dec;120(6):1176–81

A point mutation in Escherichia coli DNA helicase II renders the enzyme nonfunctional in two DNA repair pathways. Evidence for initiation of unwinding from a nick in vivo. Brosh RM Jr, et al. **J Biol Chem** 1997 Jan 3;272(1):572–9

His-8 lowers the pKa of the essential Cys-12 residue of the ArsC arsenate reductase of plasmid R773. Gladysheva T, et al. **J Biol Chem** 1996 Dec 27;271(52):33256–60

Biochemical characterization of the Wilson disease protein and functional expression in the yeast Saccharomyces cerevisiae. Hung IH, et al. **J Biol Chem** 1997 Aug 22; 272(34):21461–6

Influence of the kinesin neck domain on dimerization and ATPase kinetics. Jiang W, et al. **J Biol Chem** 1997 Mar 21;272(12):7626–32

Ligand interactions of the ArsC arsenate reductase. Liu J, et al. **J Biol Chem** 1997 Aug 22;272(34):21084–9

Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12. Loo TW, et al. **J Biol Chem** 1997 Aug 22; 272(34):20986–9

Topology of the integral membrane form of Escherichia coli SecA protein reveals multiple periplasmically exposed regions and modulation by ATP binding. Ramamurthy V, et al. **J Biol Chem** 1997 Sep 12;272(37):23239–46

Specific interactions between ATPase subunits of the 26 S protease. Richmond C, et al. **J Biol Chem** 1997 May 16; 272(20):13403–11

Site-directed mutagenesis within an ectoplasmic ATPase consensus sequence abrogates the cell aggregating properties of the rat liver canalicular bile acid transporter/ecto-ATPase/cell CAM 105 and carcinoembryonic antigen. Sippel CJ, et al. **J Biol Chem** 1996 Dec 20;271(51):33095–104

Domain structure of human nuclear DNA helicase II (RNA helicase A). Zhang S, et al. **J Biol Chem** 1997 Apr 25; 272(17):11487–94

Tryptophan fluorescence reports nucleotide-induced conformational changes in a domain of the ArsA ATPase. Zhou T, et al. **J Biol Chem** 1997 Aug 8;272(32):19731–7

Structure of the transmembrane cysteine residues in phospholamban. Arkin IT, et al. **J Membr Biol** 1997 Feb 1;155(3):199–206

The thermosome: alternating alpha and beta-subunits within the chaperonin of the archaeon Thermoplasma acidophilum. Nitsch M, et al. **J Mol Biol** 1997 Mar 21; 267(1):142–9

The ATP-dependent HslVU protease from Escherichia coli is a four-ring structure resembling the proteasome. Rohrwild M, et al. **Nat Struct Biol** 1997 Feb;4(2):133–9

Characterization of 26S proteasome alpha- and beta-type and ATPase subunits from spinach and their expression during early stages of seedling development. Ito N, et al. **Plant Mol Biol** 1997 May;34(2):307–16

Crystal structure of heat shock locus V (HslV) from Escherichia coli. Bochtler M, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6070–4

Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Bogyo M, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6629–34

Use of electrospray ionization mass spectrometry and tandem mass spectrometry to study binding of F0 inhibitors to ceroid lipofuscinosis protein, a model system for subunit c of mitochondrial ATP synthase. Buzy A, et al. **Rapid Commun Mass Spectrom** 1996;10(7):790–6

Crystal structure of the nucleotide exchange factor GrpE bound to the ATPase domain of the molecular chaperone DnaK. Harrison CJ, et al. **Science** 1997 Apr 18; 276(5311):431–5

Evidence for a family of archaeal ATPases [letter; comment] Koonin EV. **Science** 1997 Mar 7;275(5305):1489–90. Comment on: Science 1996 Aug 23;273(5278):1058–73.

Isolation, characterization, and substrate specificity of the plasma membrane ATPase of the hlophilic achaeon Haloferax volcanii. Steinert K, et al. **Z Naturforsch [C]** 1996 Jan-Feb;51(1-2):29–39

CLASSIFICATION

P-type ATPases [letter; comment] Lutsenko S, et al. **Trends Biochem Sci** 1996 Dec;21(12):467. Comment on: Trends Biochem Sci 1996 Jul;21(7):237–41.

DRUG EFFECTS

K depletion modifies the properties of Sch-28080-sensitive K-ATPase in rat collecting duct. Buffin-Meyer B, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):F124–31

Contribution of plasma membrane and endoplasmic reticulum Ca(2+)-ATPases to the synaptosomal [Ca2+]i increase during oxidative stress. Pereira C, et al. **Brain Res** 1996 Mar 25;713(1-2):269–77

P2-purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin. Bültmann R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Oct; 354(4):498–504

P2-purinoceptor antagonists: I. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanato-sulphonates. Bültmann R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Oct; 354(4):481–90

P2-purinoceptor antagonists: II. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue. Wittenburg H, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Oct; 354(4):491–7

Apical ouabain-sensitive K+-activated-ATPase activity in

colon and caecum of the chick. Calonge ML, et al. **Pflugers Arch** 1997 Jan;433(3):330–5

GENETICS

Localization of Menkes gene expression in the mouse brain; its association with neurological manifestations in Menkes model mice. Iwase T, et al. **Acta Neuropathol (Berl)** 1996; 91(5):482–8

Human peroxisome assembly factor-2 (PAF-2): a gene responsible for group C peroxisome biogenesis disorder in humans. Fukuda S, et al. **Am J Hum Genet** 1996 Dec; 59(6):1210–20

Haplotype and mutation analysis in Japanese patients with Wilson disease. Nanji MS, et al. **Am J Hum Genet** 1997 Jun;60(6):1423–9

A C2055T transition in exon 8 of the ATP7A gene is associated with exon skipping in an occipital horn syndrome family [letter] Ronce N, et al. **Am J Hum Genet** 1997 Jul;61(1):233–8

Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype–phenotype correlation, and functional analyses. Shah AB, et al. **Am J Hum Genet** 1997 Aug;61(2):317–28

Identification of point mutations in 41 unrelated patients affected with Menkes disease. Tümer Z, et al. **Am J Hum Genet** 1997 Jan;60(1):63–71

Functional expression of the cDNA encoded by the human ATP1AL1 gene. Grishin AV, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F539–51

Cloning of peroxisome assembly factor-2. Tsukamoto T, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:656–7

cDNA cloning of a chick homologue of human ATPase complex subunit 4, quantitative tissue distribution and tertiary structure comparison of the ATPase domain to RecA. Singh I, et al. **Arch Biochem Biophys** 1996 Sep 1; 333(1):260–6

The long and the short isoform of cell–CAM 105 show variant-specific modifications in adult rat organs. Baum O, et al. **Biochem Biophys Res Commun** 1996 Oct 23; 227(3):775–81

Disruption of the hslU gene, which encodes an ATPase subunit of the eukaryotic 26S proteasome homolog in Escherichia coli, suppresses the temperature-sensitive dnaA46 mutation. Katayama T, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):219–24

Mutational analysis of the nucleotide binding domain of the mismatch repair enzyme hMSH–2. Whitehouse A, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):147–53

The nuclear autoantigen La/SS-associated antigen B: one gene, three functional mRNAs. Grölz D, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):151–8

Two forms of Wilson disease protein produced by alternative splicing are localized in distinct cellular compartments. Yang XL, et al. **Biochem J** 1997 Sep 15;326 (Pt 3):897–902

Successful early copper therapy in menkes disease associated with a mutant transcript containing a small In–frame deletion. Kaler SG, et al. **Biochem Mol Med** 1996 Feb; 57(1):37–46

An3 protein encoded by a localized maternal mRNA in Xenopus laevis is an ATPase with substrate-specific RNA helicase activity. Gururajan R, et al. **Biochim Biophys Acta** 1997 Feb 7;1350(2):169–82

Cloning of a cDNA encoding a putative metal–transporting P–type ATPase from Arabidopsis thaliana. Tabata K, et al. **Biochim Biophys Acta** 1997 May 22;1326(1):1–6

Werner syndrome: entering the helicase era. Epstein CJ, et al. **Bioessays** 1996 Dec;18(12):1025–7 (23 ref.)

A regulatory switch involving a Clp ATPase. Lazazzera BA, et al. **Bioessays** 1997 Jun;19(6):455–8 (38 ref.)

Isolation of a trifluoroleucine–resistant mutant of Saccharomyces cerevisiae deficient in both high– and low–affinity L–leucine transport. Chianelli MS, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 Sep;42(6):847–57

Characterization of the properties of a human homologue of Escherichia coli RecQ from xeroderma pigmentosum group C and from HeLa cells. Tada S, et al. **Cell Struct Funct** 1996 Apr;21(2):123–32

Three genes for mitochondrial proteins suppress null–mutations in both Afg3 and Rca1 when over–expressed. Rep M, et al. **Curr Genet** 1996 Aug; 30(3):206–11

The Schizosaccharomyces pombe rad3 checkpoint gene. Bentley NJ, et al. **EMBO J** 1996 Dec 2;15(23):6641–51

Targeting presequence acquisition after mitochondrial gene transfer to the nucleus occurs by duplication of existing targeting signals. Kadowaki K, et al. **EMBO J** 1996 Dec 2;15(23):6652–61

Isolation and characterization of peroxisome–deficient Chinese hamster ovary cell mutants representing human complementation group III. Okumoto K, et al. **Exp Cell Res** 1997 May 25;233(1):11–20

Spirodela oligorhiza chloroplast DNA codes for ATPase subunits alpha and beta. Immunological evidence from a coupled transcription–translation system. De Heij JT, et al. **FEBS Lett** 1981 Nov 2;134(1):6–10

Acylphosphate formation by the Menkes copper ATPase. Solioz M, et al. **FEBS Lett** 1997 Jul 21;412(1):165–8

Helicobacter pylori genes hpcopA and hpcopP constitute a cop operon involved in copper export. Ge Z, et al. **FEMS Microbiol Lett** 1996 Dec 1;145(2):181–8

The target of sodium toxicity in Saccharomyces cerevisiae. Almagro A, et al. **Folia Microbiol (Praha)** 1996;41(1):82–3

Muddying the water: Wilson's disease challenges will not soon disappear [editorial; comment] Dufour JF, et al. **Gastroenterology** 1997 Jul;113(1):348–50. Comment on: Gastroenterology 1997 Jul;113(1):212–8.

Characterization of the secA gene of Streptomyces lividans encoding a protein translocase which complements and Escherichia coli mutant defective in the ATPase activity of SecA. Blanco J, et al. **Gene** 1996 Oct 17;176(1–2):61–5

Isolation and characterization of the Haemophilus influenzae uvrA gene. de la Morena ML, et al. **Gene** 1996 Oct 24; 177(1–2):23–8

Sequence and transcriptional analysis of clpX, a class–III heat–shock gene of Bacillus subtilis. Gerth U, et al. **Gene** 1996 Nov 28;181(1–2):77–83

A mutation in a Saccharomyces cerevisiae gene (RAD3) required for nucleotide excision repair and transcription increases the efficiency of mismatch correction. Yang Y, et al. **Genetics** 1996 Oct;144(2):459–66

Genomic organization of the mottled gene, the mouse homologue of the human Menkes disease gene. Cecchi C, et al. **Genomics** 1996 Oct 1;37(1):96–104

Efficient detection of mutations in Wilson disease by manifold sequencing. Waldenström E, et al. **Genomics** 1996 Nov 1; 37(3):303–9

Defects of the respiratory chain in the normal human liver and in cirrhosis during aging. Müller–Höcker J, et al. **Hepatology** 1997 Sep;26(3):709–19

Localization of genes encoding two human one–domain members of the AAA family: PSMC5 (the thyroid hormone receptor–interacting protein, TRIP1) and PSMC3 (the Tat–binding protein, TBP1). Hoyle J, et al. **Hum Genet** 1997 Feb;99(2):285–8

The mottled mouse as a model for human Menkes disease: identification of mutations in the Atp7a gene. Cecchi C, et al. **Hum Mol Genet** 1997 Mar;6(3):425–33

The mottled mouse as a model for human Menkes disease: identification of mutations in the Atp7a gene. Cecchi C, et al. **Hum Mol Genet** 1997 May;6(5):829

Molecular basis of the brindled mouse mutant (Mo(br)): a murine model of Menkes disease. Grimes A, et al. **Hum Mol Genet** 1997 Jul;6(7):1037–42

Developmental expression of the mouse mottled and toxic milk genes suggests distinct functions for the Menkes and Wilson disease copper transporters. Kuo YM, et al. **Hum Mol Genet** 1997 Jul;6(7):1043–9

A repeated element in the regulatory region of the MNK gene and its deletion in a patient with occipital horn syndrome. Levinson B, et al. **Hum Mol Genet** 1996 Nov; 5(11):1737–42

Mutation analysis provides additional proof that mottled is the mouse homologue of Menkes' disease. Reed V, et al. **Hum Mol Genet** 1997 Mar;6(3):417–23

The toxic milk mouse is a murine model of Wilson disease. Theophilos MB, et al. **Hum Mol Genet** 1996 Oct; 5(10):1619–24

24 bp deletion and Ala1278 to Val mutation of the ATP7B gene in a Sardinian family with Wilson disease. Orrù S, et al. **Hum Mutat** 1997;10(1):84–5

Analysis of F1F0–ATPase from Helicobacter pylori. McGowan CC, et al. **Infect Immun** 1997 Jul;65(7):2640–7

Identification and characterization of uvrA, a DNA repair gene of Deinococcus radiodurans. Agostini HJ, et al. **J Bacteriol** 1996 Dec;178(23):6759–65

Isolation and characterization of a sporulation initiation mutation in the Bacillus subtilis secA gene. Asai K, et al. **J Bacteriol** 1997 Jan;179(2):544–7

Sequencing, expression, and genetic characterization of the Helicobacter pylori ftsH gene encoding a protein homologous to members of a novel putative ATPase family. Ge Z, et al. **J Bacteriol** 1996 Nov;178(21):6151–7

The Streptomyces ATP–binding component MsiK assists in cellobiose and maltose transport. Schlösser A, et al. **J Bacteriol** 1997 Mar;179(6):2092–5

The kdp system of Clostridium acetobutylicum: cloning, sequencing, and transcriptional regulation in response to potassium concentration. Treuner–Lange A, et al. **J Bacteriol** 1997 Jul;179(14):4501–12

Suppression of mutant phenotypes of the Agrobacterium tumefaciens VirB11 ATPase by overproduction of VirB proteins. Zhou XR, et al. **J Bacteriol** 1997 Sep; 179(18):5835–42

Complementary DNA cloning and sequencing of the chicken muscle ecto–ATPase. Homology with the lymphoid cell activation antigen CD39. Kirley TL. **J Biol Chem** 1997 Jan 10;272(2):1076–81

Intracellular Na+ regulates transcription of the ntp operon encoding a vacuolar–type Na+–translocating ATPase in Enterococcus hirae. Murata T, et al. **J Biol Chem** 1996 Sep 27;271(39):23661–6

CopY is a copper–inducible repressor of the Enterococcus hirae copper ATPases. Strausak D, et al. **J Biol Chem** 1997 Apr 4;272(14):8932–6

The preprotein translocase of the inner mitochondrial membrane: evolutionary conservation of targeting and assembly of Tim17. Bömer U, et al. **J Mol Biol** 1996 Oct 4;262(4):389–95

The DNA replication protein PriA and the recombination protein RecG bind D–loops. McGlynn P, et al. **J Mol Biol** 1997 Jul 11;270(2):212–21

Dual regulation of Escherichia coli secA translation by distinct upstream elements. McNicholas P, et al. **J Mol Biol** 1997 Jan 17;265(2):128–41

Identification of elements on GeneX–secA RNA of Escherichia coli required for SecA binding and secA auto–regulation. Salavati R, et al. **J Mol Biol** 1997 Jan 17; 265(2):142–52

Mitochondrial disease associated with the T8993G mutation of the mitochondrial ATPase 6 gene: a clinical, biochemical, and molecular study in six families. Uziel G, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):16–22

Cloning and mapping of a human and mouse gene with homology to ecto–ATPase genes. Chadwick BP, et al. **Mamm Genome** 1997 Sep;8(9):668–72

A serine–to–proline mutation in the copper–transporting P–type ATPase gene of the macular mouse. Mori M, et al. **Mamm Genome** 1997 Jun;8(6):407–10

Mutants in the CtpA copper transporting P–type ATPase reduce virulence of Listeria monocytogenes. Francis MS, et al. **Microb Pathog** 1997 Feb;22(2):67–78

Analysis of a cation–transporting ATPase of Plasmodium falciparum. Dyer M, et al. **Mol Biochem Parasitol** 1996 Jun;78(1–2):1–12

Cloning of cDNAs from a mammalian expression library by a direct selection–amplification method. Chapman L, et al. **Mol Biotechnol** 1996 Apr;5(2):77–83

Cloning, nucleotide sequence and transcriptional analysis of the uvrA gene from Neisseria gonorrhoeae. Black CG, et al. **Mol Gen Genet** 1997 May 20;254(5):479–85

The Listeria monocytogenes gene ctpA encodes a putative P–type ATPase involved in copper transport. Francis MS, et al. **Mol Gen Genet** 1997 Jan 27;253(4):484–91

Streptomyces linear plasmids that contain a phage–like, centrally located, replication origin. Chang PC, et al. **Mol Microbiol** 1996 Dec;22(5):789–800

The P1 ParA protein and its ATPase activity play a direct role in the segregation of plasmid copies to daughter cells. Davis MA, et al. **Mol Microbiol** 1996 Sep;21(5):1029–36

Identification of a ClpC ATPase required for stress tolerance and in vivo survival of Listeria monocytogenes. Rouquette C, et al. **Mol Microbiol** 1996 Sep;21(5):977–87

Expression of the Pseudomonas aeruginosa uvrA gene is constitutive. Rivera E, et al. **Mutat Res** 1997 Jun 9; 377(1):149–55

Deletion of the promoter region in the Atp7a gene of the mottled dappled mouse [letter] Levinson B, et al. **Nat Genet** 1997 Jul;16(3):224–5

A non–epistatic interaction of agouti and extension in the fox, Vulpes vulpes. Våge DI, et al. **Nat Genet** 1997 Mar; 15(3):311–5

Leigh syndrome associated with the T9176C mutation in the ATPase 6 gene of mitochondrial DNA. Campos Y, et al. **Neurology** 1997 Aug;49(2):595–7

p72: a human nuclear DEAD box protein highly related to p68. Lamm GM, et al. **Nucleic Acids Res** 1996 Oct 1; 24(19):3739–47

RecQ DNA helicase is a suppressor of illegitimate recombination in Escherichia coli. Hanada K, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3860–5

IMMUNOLOGY

Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non–structural 3 protein. Sällberg M, et al. **J Gen Virol** 1996 Nov;77 (Pt 11):2721–8

ISOLATION & PURIFICATION

Condensins, chromosome condensation protein complexes containing XCAP–C, XCAP–E and a Xenopus homolog of the Drosophila Barren protein. Hirano T, et al. **Cell** 1997 May 16;89(4):511–21

Comparative characterization of SecA from the alpha–subclass purple bacterium Rhodobacter capsulatus and Escherichia coli reveals differences in membrane and precursor specificity. Helde R, et al. **J Bacteriol** 1997 Jun; 179(12):4003–12

Purification and reconstitution of Na+–translocating vacuolar ATPase from Enterococcus hirae. Murata T, et al. **J Biol Chem** 1997 Oct 3;272(40):24885–90

Isolation and characterization of SUG2. A novel ATPase family component of the yeast 26 S proteasome. Russell SJ, et al. **J Biol Chem** 1996 Dec 20;271(51):32810–7

METABOLISM

ATP–dependent copper transporter, in the Golgi apparatus of rat hepatocytes, transports Cu(II) not Cu(I). Bingham MJ, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):G741–6

K depletion modifies the properties of Sch–28080–sensitive K–ATPase in rat collecting duct. Buffin–Meyer B, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):F124–31

Calcium removal kinetics of the sarcoplasmic reticulum ATPase in skeletal muscle. Burmeister Getz EE, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1087–98

Ion pumps in epithelial cells: sorting, stabilization, and polarity. Caplan MJ. **Am J Physiol** 1997 Jun;272(6 Pt 1):G1304–13 (73 ref.)

Ecto–ATPase activity and labeling with the anti–ecto–ATPase antibody in renal brush border do not coincide [letter] Sabolić I, et al. **Am J Physiol** 1996 Nov; 271(5 Pt 2):F1100–1

Primary structure and evolution of the ATP–binding domains of the P–type ATPases in Tetrahymena thermophila. Wang S, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C715–28

Sensing antimonite and arsenite at the subattomole level with genetically engineered bioluminescent bacteria.

Ramanathan S, et al. **Anal Chem** 1997 Aug 15;69(16):3380–4
Carbonyl cyanide phenylhydrazones as probes of the anionic activator site of the human erythrocyte glutathione adduct transport ATPase. DeLuca DC, et al.
Arch Biochem Biophys 1997 Jun 1;342(1):182–6
Identification and partial characterization of ectoATPase expressed by immortalized B lymphocytes. Dombrowski KE, et al. **Arch Biochem Biophys** 1997 Apr 1;340(1):10–8
Mg-dependent ecto-ATPase activity in Leishmania tropica. Meyer-Fernandes JR, et al. **Arch Biochem Biophys** 1997 May 1;341(1):40–6
A soluble ecto-ATPase from Tetrahymena thermophila: purification and similarity to the membrane-bound ecto-ATPase of smooth muscle. Smith TM Jr, et al.
Arch Biochem Biophys 1997 Jan 15;337(2):351–9
Structure-function relationships in Escherichia coli transcription termination protein Rho revealed by radiation target analysis. Stitt BL, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):268–76
Metabolism of extracellular ATP by rat parotid cells. Dowd FJ, et al. **Arch Oral Biol** 1996 Aug-Sep;41(8–9):855–62
The nucleolar phosphoprotein P130 is a GTPase/ATPase with intrinsic property to form large complexes triggered by F- and Mg2+. Chen HK, et al.
Biochem Biophys Res Commun 1997 Jan 13;230(2):370–5
The carboxyl-terminal region is essential for Sec-A dimerization. Hirano M, et al.
Biochem Biophys Res Commun 1996 Dec 4;229(1):90–5
Vacuolar-type ATPase in a hyperthermophilic archaeum, Thermococcus sp. KI. Iida T, et al.
Biochem Biophys Res Commun 1996 Dec 13;229(2):559–64
Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal antibody against P-glycoprotein. Kokubu N, et al. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):398–401
The ATPase activity of chaperonin GroEL is highly stimulated at elevated temperatures. Mendoza JA, et al.
Biochem Biophys Res Commun 1996 Dec 4;229(1):271–4
RNA helicase activity of Escherichia coli SecA protein. Park SK, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):593–7
Cloning of a cDNA encoding a novel importin-alpha homologue, Qip1: discrimination of Qip1 and Rch1 from hSrp1 by their ability to interact with DNA helicase Q1/RecQL. Seki T, et al.
Biochem Biophys Res Commun 1997 May 8;234(1):48–53
Single molecule imaging of fluorophores and enzymatic reactions achieved by objective-type total internal reflection fluorescence microscopy. Tokunaga M, et al.
Biochem Biophys Res Commun 1997 Jun 9;235(1):47–53
Poly-L-lysine activates both peptide and ATP hydrolysis by the ATP-dependent HslVU protease in Escherichia coli. Yoo SJ, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):531–5
ATP binding, but not its hydrolysis, is required for assembly and proteolytic activity of the HslVU protease in Escherichia coli. Yoo SJ, et al.
Biochem Biophys Res Commun 1997 Sep 18;238(2):581–5
Binding of ATP and ATP analogues to the uncoating ATPase Hsc70 (70 kDa heat-shock cognate protein). Buxbaum E, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):923–9
Activation of the ATPase activity of heat-shock proteins Hsc70/Hsp70 by cysteine-string protein. Chamberlain LH, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):853–8
Evidence for regulated dimerization of cell-cell adhesion molecule (C-CAM) in epithelial cells. Hunter I, et al.
Biochem J 1996 Dec 15;320 (Pt 3):847–53
Oxidative phosphorylation and F(O)F(1) ATP synthase activity of human hepatocellular carcinoma. Capuano F, et al. **Biochem Mol Biol Int** 1996 Apr;38(5):1013–22
Role of PM-ATPase, amino acid transport and free amino acid pool in the salt stress of, Candida membranefaciens [corrected and republished article originally printed in Biochem Mol Biol Int 1996 Mar;38(3): 635–43] Khaware RK, et al. **Biochem Mol Biol Int** 1996 May;39(2):421–9
A monoclonal antibody specific for carboxy-terminal region of yeast translation elongation factor-3 inhibits ribosome-activated ATPase activity but not intrinsic ATPase activity. Masahiro U, et al.
Biochem Mol Biol Int 1996 May;39(2):227–34
Domain interactions of the peripheral preprotein Translocase subunit SecA. den Blaauwen T, et al. **Biochemistry** 1996 Sep 17;35(37):11194–2004
Three tRNA binding sites in rabbit liver ribosomes and role of the intrinsic ATPase in 80S ribosomes from higher eukaryotes. El'skaya AV, et al. **Biochemistry** 1997 Aug 26; 36(34):10492–7
Synthesis of a radioactive azido derivative of thapsigargin and photolabeling of the sarcoplasmic reticulum ATPase. Hua S, et al. **Biochemistry** 1997 Sep 30;36(39):11865–72
Oligomycin sensitivity conferring protein (OSCP) of bovine heart mitochondrial ATP synthase: high-affinity OSCP-Fo interactions require a local alpha-helix at the C-terminal end of the subunit. Joshi S, et al. **Biochemistry** 1997 Sep 9;36(36):10936–43
Oligomycin sensitivity conferring protein of mitochondrial ATP synthase: deletions in the N-terminal end cause defects in interactions with F1, while deletions in the C-terminal end cause defects in interactions with F0. Joshi S, et al. **Biochemistry** 1996 Sep 17;35(37):12094–103
A proposal for the Mg2+ binding site of P-type ion motive ATPases and the mechanism of phosphoryl group transfer. Kasho VN, et al. **Biochemistry** 1997 Jul 1;36(26):8045–52
GrpE accelerates nucleotide exchange of the molecular chaperone DnaK with an associative displacement mechanism. Packschies L, et al. **Biochemistry** 1997 Mar 25;36(12):3417–22
Opening of the myosin nucleotide triphosphate binding domain during the ATPase cycle. Pate E, et al.
Biochemistry 1997 Oct 7;36(40):12155–66
A two-site mechanism for ATP hydrolysis by the asymmetric Rep dimer P2S as revealed by site-specific inhibition with ADP-A1F4. Wong I, et al. **Biochemistry** 1997 Mar 18; 36(11):3115–25
Overexpression of the sodium ATPase of Saccharomyces cerevisiae: conditions for phosphorylation from ATP and Pi. Benito B, et al. **Biochim Biophys Acta** 1997 Sep 4; 1328(2):214–26
An3 protein encoded by a localized maternal mRNA in Xenopus laevis is an ATPase with substrate-specific RNA helicase activity. Gururajan R, et al.
Biochim Biophys Acta 1997 Feb 7;1350(2):169–82
ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines. Litman T, et al. **Biochim Biophys Acta** 1997 Aug 22;1361(2):147–58
Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Litman T, et al. **Biochim Biophys Acta** 1997 Aug 22;1361(2):159–68
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Litman T, et al.
Biochim Biophys Acta 1997 Aug 22;1361(2):169–76
The hydrophobic region of signal peptides is involved in the interaction with membrane-bound SecA. Mori H, et al.
Biochim Biophys Acta 1997 May 22;1326(1):23–36
Protease Ti (Clp), a multi-component ATP-dependent protease in Escherichia coli. Chung CH, et al.
Biol Chem 1996 Sep;377(9):549–54 (37 ref.)
A comparative study of (Ca(2+)-Mg2+)-ATPase on the lysosomal membrane and ecto-ATPase on the plasma membrane from rat liver. Adachi T, et al.
Biol Pharm Bull 1996 Oct;19(10):1291–7
A new chelation method for determining ATPase activity in skeletal muscle. Hawcroft DM, et al.
Biotech Histochem 1996 Mar;71(2):88–91
Characterization of brain ecto-apyrase: evidence for only one ecto-apyrase (CD39) gene. Wang TF, et al.
Brain Res Mol Brain Res 1997 Jul;47(1–2):295–302
Influence of textile dyeing and printing industry effluent on ATPases in liver, brain, and muscle of mudskipper, Periophthalmus dipes. Chhaya J, et al.
Bull Environ Contam Toxicol 1997 May;58(5):793–800
Fenbutatin acute toxicity on Artemia nauplii: effects of sublethal concentrations on ATPase activity. Machera K, et al. **Bull Environ Contam Toxicol** 1996 Jan;56(1):159–64
Age-related change in rat testicular ATPase activities in response to HCH treatment. Roy A, et al.
Bull Environ Contam Toxicol 1996 Jan;56(1):165–70
ACF, an ISWI-containing and ATP-utilizing chromatin assembly and remodeling factor. Ito T, et al. **Cell** 1997 Jul 11;90(1):145–55
ATP-dependent positive supercoiling of DNA by 13S condensin: a biochemical implication for chromosome condensation. Kimura K, et al. **Cell** 1997 Aug 22; 90(4):625–34
Coordinate binding of ATP and origin DNA regulates the ATPase activity of the origin recognition complex. Klemm RD, et al. **Cell** 1997 Feb 21;88(4):493–502
Major domain swiveling revealed by the crystal structures of complexes of E. coli Rep helicase bound to single-stranded DNA and ADP. Korolev S, et al. **Cell** 1997 Aug 22;90(4):635–47
Helicase-contrahelicase interaction and the mechanism of termination of DNA replication. Manna AC, et al. **Cell** 1996 Nov 29;87(5):881–91
Characterization of the properties of a human homologue of Escherichia coli RecQ from xeroderma pigmentosum group C and from HeLa cells. Tada S, et al.
Cell Struct Funct 1996 Apr;21(2):123–32
On the road to translocase. Wickner W, et al.
Cold Spring Harb Symp Quant Biol 1995;60:285–90 (59 ref.)
Kinetic characteristics of nucleoside mono-, di- and triphosphatase activities of the periplasmic 5'-nucleotidase of Escherichia coli. García L, et al.
Comp Biochem Physiol B Biochem Mol Biol 1997 May; 117(1):135–42
Implications of altered Na+-K+-adenosine triphosphatase in hypertension accompanying early stage kidney disease. Schiffl H, et al. **Contrib Nephrol** 1996;119:31–4
Failure to unwind causes cancer. Genome stability. Watt PM, et al. **Curr Biol** 1996 Mar 1;6(3):265–7 (10 ref.)
Control of cell cycle arrest by the Mec1sc/Rad3sp DNA structure checkpoint pathway. Carr AM.
Curr Opin Genet Dev 1997 Feb;7(1):93–8 (57 ref.)
Endosomal transport function in yeast requires a novel AAA-type ATPase, Vps4p. Babst M, et al. **EMBO J** 1997 Apr 15;16(8):1820–31
Distinct catalytic roles of the SecYE, SecG and SecDFyajC subunits of preprotein translocase holoenzyme. Duong F, et al. **EMBO J** 1997 May 15;16(10):2756–68
The SecDFyajC domain of preprotein translocase controls preprotein movement by regulating SecA membrane cycling. Duong F, et al. **EMBO J** 1997 Aug 15; 16(16):4871–9
The protease-protected 30 kDa domain of SecA is largely inaccessible to the membrane lipid phase. Eichler J, et al.
EMBO J 1997 May 1;16(9):2188–96
UvrAB activity at a damaged DNA site: is unpaired DNA present? Gordienko I, et al. **EMBO J** 1997 Feb 17; 16(4):880–8
The limited strand-separating activity of the UvrAB protein complex and its role in the recognition of DNA damage. Gordienko I, et al. **EMBO J** 1997 Feb 17;16(4):889–95
AAA proteases with catalytic sites on opposite membrane surfaces comprise a proteolytic system for the ATP-dependent degradation of inner membrane proteins in mitochondria. Leonhard K, et al. **EMBO J** 1996 Aug 15;15(16):4218–29
Identification and characterization of HsIV HsIU (ClpQ ClpY) proteins involved in overall proteolysis of misfolded proteins in Escherichia coli. Missiakas D, et al.
EMBO J 1996 Dec 16;15(24):6899–909
Negative control of DNA replication by hydrolysis of ATP bound to DnaA protein, the initiator of chromosomal DNA replication in Escherichia coli. Mizushima T, et al.
EMBO J 1997 Jun;16(12):3724–30
Subunit interactions in ABC transporters: a conserved sequence in hydrophobic membrane proteins of periplasmic permeases defines an important site of interaction with the ATPase subunits. Mourez M, et al. **EMBO J** 1997 Jun 2; 16(11):3066–77
Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking. Petris MJ, et al. **EMBO J** 1996 Nov 15; 15(22):6084–95
Benzoyl-CoA reductase (dearomatizing), a key enzyme of anaerobic aromatic metabolism. A study of adenosinetriphosphatase activity, ATP stoichiometry of the reaction and EPR properties of the enzyme. Boll M, et al. **Eur J Biochem** 1997 Mar 15;244(3):840–51
The heat-shock protein HslVU from Escherichia coli is a protein-activated ATPase as well as an ATP-dependent proteinase. Seol JH, et al. **Eur J Biochem** 1997 Aug 1; 247(3):1143–50
Homophilic intercellular adhesion mediated by C-CAM is due to a domain 1-domain 1 reciprocal binding. Wikström K, et al. **Exp Cell Res** 1996 Sep 15;227(2):360–6
Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. Hooijberg JH, et al.
FEBS Lett 1997 Aug 18;413(2):344–8
Expression and biochemical analyses of the recombinant potato virus X 25K movement protein. Kalinina NO, et al. **FEBS Lett** 1996 Nov 11;397(1):75–8
Involvement of soluble proteinous factors in auxin-induced modulation of P-type ATPase in rice (Oryza sativa L.) seedlings. Kim D, et al. **FEBS Lett** 1997 Jun 9;409(2):273–6
Expression of a 26S proteasome ATPase subunit, MS73, in muscles that undergo developmentally programmed cell death, and its control by ecdysteroid hormones in the insect Manduca sexta. Löw P, et al. **FEBS Lett** 1997 Jan 6; 400(3):345–9
K+ is an indispensable cofactor for GrpE stimulation of ATPase activity of DnaK x DnaJ complex from Thermus thermophilus. Motohashi K, et al. **FEBS Lett** 1997 Aug 4;412(3):633–6
Lack of vacuolar proton ATPase association with the cytoskeleton in osteoclasts of osteosclerotic (oc/oc) mice. Nakamura I, et al. **FEBS Lett** 1997 Jan 20;401(2–3):207–12
A novel fluorescent marker for assembled mitochondria ATP synthase of yeast. OSCP subunit fused to green fluorescent protein is assembled into the complex in vivo. Prescott M, et al. **FEBS Lett** 1997 Jul 7;411(1):97–101
A recombinant polypeptide model of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator functions as an active ATPase, GTPase and adenylate kinase. Randak C, et al. **FEBS Lett** 1997 Jun 30;410(2–3):180–6
Mutational analysis of the ATP-binding site in HslU, the ATPase component of HslVU protease in Escherichia coli. Shin DH, et al. **FEBS Lett** 1996 Dec 2;398(2–3):151–4
Acylphosphate formation by the Menkes copper ATPase. Solioz M, et al. **FEBS Lett** 1997 Jul 21;412(1):165–8
Is an ATPase involved in uncoating of plasma membrane adaptor complex AP-2? Sosa MA, et al. **FEBS Lett** 1997 Apr 28;407(2):173–6
Phosphoenzyme formation by purified, reconstituted copper ATPase of Enterococcus hirae. Wyler-Duda P, et al.
FEBS Lett 1996 Dec 9;399(1–2):143–6
Characterization of the ATPase activity of the N-terminal nucleotide binding domain of an ABC transporter involved in oleandomycin secretion by Streptomyces antibioticus. Aparicio G, et al. **FEMS Microbiol Lett** 1996 Aug 1; 141(2–3):157–62
Evidence for an ATP-dependent bile acid transport protein other than the canalicular liver ecto-ATPase in rats. Luther TT, et al. **Gastroenterology** 1997 Jul;113(1):249–54
Characterization of the secA gene of Streptomyces lividans encoding a protein translocase which complements and Escherichia coli mutant defective in the ATPase activity of SecA. Blanco J, et al. **Gene** 1996 Oct 17;176(1–2):61–5
U2AF65 recruits a novel human DEAD box protein required for the U2 snRNP-branchpoint interaction. Fleckner J, et al. **Genes Dev** 1997 Jul 15;11(14):1864–72
ClpX and MuB interact with overlapping regions of Mu

transposase: implications for control of the transposition pathway. Levchenko I, et al. **Genes Dev** 1997 Jun 15; 11(12):1561–72

Isolation of the ATP-binding human homolog of the arsA component of the bacterial arsenite transporter. Kurdi-Haidar B, et al. **Genomics** 1996 Sep 15;36(3):486–91

Ectonucleotidase activity in the perilymphatic compartment of the guinea pig cochlea. Vlajkovic SM, et al. **Hear Res** 1996 Sep 15;99(1–2):31–7

Internalization of ecto-ATPase activity in human neutrophils upon stimulation with phorbol ester or formyl peptide. Kobayashi T, et al. **Histochem Cell Biol** 1997 May; 107(5):353–63

Expression of cytoskeletal proteins and ATPase activity in bovine femoral artery and vein intima. Trosheva M, et al. **Histol Histopathol** 1996 Apr;11(2):335–42

Molecular basis of the brindled mouse mutant (Mo(br)): a murine model of Menkes disease. Grimes A, et al. **Hum Mol Genet** 1997 Jul;6(7):1037–42

The effect of lead on lactate formation, ATP level and membrane ATPase activities in human erythrocytes in vitro. Grabowska M, et al. **Int J Occup Med Environ Health** 1996;9(3):265–74

The VirB4 ATPase of Agrobacterium tumefaciens is a cytoplasmic membrane protein exposed at the periplasmic surface. Dang TA, et al. **J Bacteriol** 1997 Jan;179(2):453–62

Modulation of recombination and DNA repair by the RecG and PriA helicases of Escherichia coli K-12. Al-Deib AA, et al. **J Bacteriol** 1996 Dec;178(23):6782–9

An Na+-pumping V1V0-ATPase complex in the thermophilic bacterium Clostridium fervidus. Höner zu Bentrup K, et al. **J Bacteriol** 1997 Feb;179(4):1274–9

MinCD-independent inhibition of cell division by a protein that fuses MalE to the topological specificity factor MinE. Pichoff S, et al. **J Bacteriol** 1997 Jul;179(14):4616–9

Characterization of membrane and protein interaction determinants of the Agrobacterium tumefaciens VirB11 ATPase. Rashkova S, et al. **J Bacteriol** 1997 Feb; 179(3):583–91

The Streptomyces ATP-binding component MsiK assists in cellobiose and maltose transport. Schlösser A, et al. **J Bacteriol** 1997 Mar;179(6):2092–5

Regulated crosslinked actin filaments and the decoupling between their ATPase activity and sliding motility. Honda H, et al. **J Biochem (Tokyo)** 1997 Jan;121(1):47–9

Sliding and ATPase. Oosawa F. **J Biochem (Tokyo)** 1995 Nov;118(5):863–70 (37 ref.)

Reconstituted Cl- pump protein: a novel ion(Cl-)-motive ATPase. Gerencser GA, et al. **J Bioenerg Biomembr** 1996 Dec;28(6):459–69

FtsH (HflB) is an ATP-dependent protease selectively acting on SecY and some other membrane proteins. Akiyama Y, et al. **J Biol Chem** 1996 Dec 6;271(49):31196–201

Yeast DNA repair proteins Rad6 and Rad18 form a heterodimer that has ubiquitin conjugating, DNA binding, and ATP hydrolytic activities. Bailly V, et al. **J Biol Chem** 1997 Sep 12;272(37):23360–5

Spatial proximity of Cys113, Cys172, and Cys422 in the metalloactivation domain of the ArsA ATPase. Bhattacharjee H, et al. **J Biol Chem** 1996 Oct 4; 271(40):24465–70

Characterization of the nucleoside triphosphate phosphohydrolase and helicase activities of the reovirus lambda1 protein. Bisaillon M, et al. **J Biol Chem** 1997 Jul 18;272(29):18298–303

The cysteine string secretory vesicle protein activates Hsc70 ATPase. Braun JEA, et al. **J Biol Chem** 1996 Oct 18; 271(42):25989–93

A partially functional DNA helicase II mutant defective in forming stable binary complexes with ATP and DNA. A role for helicase motif III. Brosh RM Jr, et al. **J Biol Chem** 1996 Oct 11;271(41):25360–8

A complex consisting of human replication factor C p40, p37, and p36 subunits is a DNA-dependent ATPase and an intermediate in the assembly of the holoenzyme. Cai J, et al. **J Biol Chem** 1997 Jul 25;272(30):18974–81

The RecD subunit of the RecBCD enzyme from Escherichia coli is a single-stranded DNA-dependent ATPase. Chen HW, et al. **J Biol Chem** 1997 Apr 11;272(15):10072–9

A significant fraction of functional SecA is permanently embedded in the membrane. SecA cycling on and off the membrane is not essential during protein translocation. Chen X, et al. **J Biol Chem** 1996 Nov 22;271(47):29698–706

Autotaxin is an exoenzyme possessing 5'-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities. Clair T, et al. **J Biol Chem** 1997 Jan 10; 272(2):996–1001

An ATPase component of the transcription elongation complex is required for factor-dependent transcription termination by vaccinia RNA polymerase. Deng L, et al. **J Biol Chem** 1996 Nov 15;271(46):29386–92

Enzymatic characterization of FliI. An ATPase involved in flagellar assembly in Salmonella typhimurium. Fan F, et al. **J Biol Chem** 1996 Dec 13;271(50):31981–8

Mutation of a highly conserved arginine in motif IV of Escherichia coli DNA helicase II results in an ATP-binding defect. Hall MC, et al. **J Biol Chem** 1997 Jul 25;272(30):18614–20

Substitution mutations in the myosin essential light chain lead to reduced actin-activated ATPase activity despite stoichiometric binding to the heavy chain. Ho G, et al. **J Biol Chem** 1997 Feb 14;272(7):4522–7

Evidence of the presence of a specific ATPase responsible for ATP-initiated calcification by matrix vesicles isolated from cartilage and bone. Hsu HHT, et al. **J Biol Chem** 1996 Oct 18;271(42):26383–8

Proteolytic activity of the ATP-dependent protease HslVU can be uncoupled from ATP hydrolysis. Huang H, et al. **J Biol Chem** 1997 Aug 22;272(34):21364–72

Monomeric kinesin head domains hydrolyze multiple ATP molecules before release from a microtubule. Jiang W, et al. **J Biol Chem** 1997 Feb 28;272(9):5616–21

Alternate energy coupling of ArsB, the membrane subunit of the Ars anion-translocating ATPase. Kuroda M, et al. **J Biol Chem** 1997 Jan 3;272(1):326–31

C-terminal deletion of human tissue transglutaminase enhances magnesium-dependent GTP/ATPase activity. Lai TS, et al. **J Biol Chem** 1996 Dec 6;271(49):31191–5

A 16-kDa protein functions as a new regulatory protein for Hsc70 molecular chaperone and is identified as a member of the Nm23/nucleoside diphosphate kinase family [published erratum appears in J Biol Chem 1997 May 2;272(18):12248] Leung SM, et al. **J Biol Chem** 1997 Jan 31;272(5):2607–14

Immunolocalization of the ecto-ATPase and ecto-apyrase in chicken gizzard and stomach. Purification and N-terminal sequence of the stomach ecto-apyrase. Lewis-Carl S, et al. **J Biol Chem** 1997 Sep 19; 272(38):23645–52

ATPase activity of the cystic fibrosis transmembrane conductance regulator. Li C, et al. **J Biol Chem** 1996 Nov 8;271(45):28463–8

Interaction of ATP binding sites in the ArsA ATPase, the catalytic subunit of the Ars pump. Li J, et al. **J Biol Chem** 1996 Oct 11;271(41):25247–52

Characterization of the adenosine triphosphatase activity of the periplasmic histidine permease, a traffic ATPase (ABC transporter). Liu CE, et al. **J Biol Chem** 1997 Aug 29; 272(35):21883–91

Inhibition of oxidative cross-linking between engineered cysteine residues at positions 332 in predicted transmembrane segments (TM) 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates. Loo TW, et al. **J Biol Chem** 1996 Nov 1;271(44):27482–7

N-terminal domains of human copper-transporting adenosine triphosphatases (the Wilson's and Menkes disease proteins) bind copper selectively in vivo and in vitro with stoichiometry of one copper per metal-binding repeat. Lutsenko S, et al. **J Biol Chem** 1997 Jul 25;272(30):18939–44

SUG1, a component of the 26 S proteasome, is an ATPase stimulated by specific RNAs. Makino Y, et al. **J Biol Chem** 1997 Sep 12;272(37):23201–5

Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart. Mundiña-Weilenmann C, et al. **J Biol Chem** 1996 Dec 27;271(52):33561–7

Purification and reconstitution of Na+-translocating vacuolar ATPase from Enterococcus hirae. Murata T, et al. **J Biol Chem** 1997 Oct 3;272(40):24885–90

The Saccharomyces cerevisiae Prp5 protein has RNA-dependent ATPase activity with specificity for U2 small nuclear RNA. O'Day CL, et al. **J Biol Chem** 1996 Dec 27;271(52):33261–7

A steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain. Preugschat F, et al. **J Biol Chem** 1996 Oct 4;271(40):24449–57

Separable ATPase and membrane insertion domains of the SecA subunit of preprotein translocase. Price A, et al. **J Biol Chem** 1996 Dec 6;271(49):31580–4

An essential myosin light chain peptide induces supramaximal stimulation of cardiac myofibrillar ATPase activity. Rarick HM, et al. **J Biol Chem** 1996 Oct 25;271(43):27039–43

Human transcription-repair coupling factor CSB/ERCC6 is a DNA-stimulated ATPase but is not a helicase and does not disrupt the ternary transcription complex of stalled RNA polymerase II. Selby CP, et al. **J Biol Chem** 1997 Jan 17;272(3):1885–90

Identification of a region of interaction between Escherichia coli SecA and SecY proteins. Snyders S, et al. **J Biol Chem** 1997 Apr 25;272(17):11302–6

Phosphorylation site mutations in the human multidrug transporter modulate its drug-stimulated ATPase activity. Szabó K, et al. **J Biol Chem** 1997 Sep 12;272(37):23165–71

ATP-, K+-dependent heptamer exchange reaction produces hybrids between GroEL and chaperonin from Thermus thermophilus. Taguchi H, et al. **J Biol Chem** 1997 Jul 18; 272(29):18155–60

Escherichia coli preprotein translocase. Wickner W, et al. **J Biol Chem** 1996 Nov 22;271(47):29514–6 (68 ref.)

Mechanism of clathrin basket dissociation: separate functions of protein domains of the DnaJ homologue auxilin. Holstein SE, et al. **J Cell Biol** 1996 Nov;135(4):925–37

Inhibitory action of the defensive discharge of the grasshopper, Poecilocerus pictus, on certain enzymes in the lizard, Calotes nemoricola. Sreenivasulu Y, et al. **J Enzyme Inhib** 1996 Oct;11(2):135–40

An electrogenic chloride pump in a zoological membrane. Gerencser GA, et al. **J Exp Zool** 1996 Jul 1;275(4):256–61 (27 ref.)

A Cl- pump in rat brain neurons. Inagaki C, et al. **J Exp Zool** 1996 Jul 1;275(4):262–8

The beet yellows closterovirus p65 homologue of HSP70 chaperones has ATPase activity associated with its conserved N-terminal domain but does not interact with unfolded protein chains. Agranovsky AA, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):535–42

ATP hydrolysis stimulates binding and release of single stranded DNA from alternating subunits of the dimeric E. coli Rep helicase: implications for ATP-driven helicase translocation. Bjornson KP, et al. **J Mol Biol** 1996 Nov 1;263(3):411–22

Role of mitochondrial GrpE and phosphate in the ATPase cycle of matrix Hsp70. Dekker PJ, et al. **J Mol Biol** 1997 Jul 18;270(3):321–7

Partitioning of plasmid R1. The ParM protein exhibits ATPase activity and interacts with the centromere-like ParR-parC complex. Jensen RB, et al. **J Mol Biol** 1997 Jun 20;269(4):505–13

Biochemical properties of RuvBD113N: a mutation in helicase motif II of the RuvB hexamer affects DNA binding and ATPase activities. Mézard C, et al. **J Mol Biol** 1997 Sep 5;271(5):704–17

Identification of elements on GeneX-secA RNA of Escherichia coli required for SecA binding and secA auto-regulation. Salavati R, et al. **J Mol Biol** 1997 Jan 17; 265(2):142–52

Communication of ClpXP protease hypersensitivity to bacteriophage Mu repressor isoforms. Welty DJ, et al. **J Mol Biol** 1997 Sep 12;272(1):31–41

The kinetic mechanism of formation of the bacteriophage T4 DNA polymerase sliding clamp. Young MC, et al. **J Mol Biol** 1996 Dec 6;264(3):440–52

Activation of creatine kinase-B and phospholamban gene expression in transformed latissimus dorsi muscle: evaluation of mRNA by polymerase chain reaction. Alam M, et al. **J Mol Cell Cardiol** 1996 Sep;28(9):1901–10

ATPase activity and force production in skinned rat cardiac muscle under isometric and dynamic conditions. Ebus JP, et al. **J Mol Cell Cardiol** 1996 Aug;28(8):1747–57

Why are ATP depletion rates in situ in ischemic myocardium so much lower than one might predict from the activity of the mitochondrial ATPase in sonicated heart mitochondria? [editorial] Rouslin W, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1505–10 (13 ref.)

ATPase kinetics on activation of rabbit and frog permeabilized isometric muscle fibres: a real time phosphate assay. He ZH, et al. **J Physiol (Lond)** 1997 May 15;501 (Pt 1):125–48

Force generation in muscle: time-resolved measurements of ATPase activity using a phosphate-sensitive fluorophore. Moss RL. **J Physiol (Lond)** 1997 May 15;501 (Pt 1):1

Chemo-mechanical energy transduction in relation to myosin isoform composition in skeletal muscle fibres of the rat. Reggiani C, et al. **J Physiol (Lond)** 1997 Jul 15;502 (Pt 2):449–60

Myofibrillar ATPase activity in skinned human skeletal muscle fibres: fibre type and temperature dependence. Stienen GJ, et al. **J Physiol (Lond)** 1996 Jun 1;493 (Pt 2):299–307

trans-Dominant and non-trans-dominant mutant simian virus 40 large T antigens show distinct responses to ATP. Castellino AM, et al. **J Virol** 1997 Oct;71(10):7549–59

Identification of an ATPase activity associated with a 71-kilodalton polypeptide encoded in gene 1 of the human coronavirus 229E. Heusipp G, et al. **J Virol** 1997 Jul; 71(7):5631–4

ATPase, GTPase, and RNA binding activities associated with the 206-kilodalton protein of turnip yellow mosaic virus. Kadaré G, et al. **J Virol** 1996 Nov;70(11):8169–74

Characterization of an ATPase activity in reovirus cores and its genetic association with core-shell protein lambda1. Noble S, et al. **J Virol** 1997 Mar;71(3):2182–91

Bluetongue virus VP6 protein binds ATP and exhibits an RNA-dependent ATPase function and a helicase activity that catalyze the unwinding of double-stranded RNA substrates. Stäuber N, et al. **J Virol** 1997 Oct;71(10):7220–6

Reduction of ATPase activity accompanied by photodecomposition of ergosterol by near-UV irradiation in plasma membranes prepared from Saccharomyces cerevisiae. Arami S, et al. **Microbiology** 1997 Jul;143 (Pt 7):2465–71

Renal ATPases twenty-four hours after uninephrectomy: the role of IGF-1. Eiam-ong S, et al. **Miner Electrolyte Metab** 1996;22(4):234–41

A Plasmodium falciparum homologue of the ATPase subunit of a multi-protein complex involved in chromatin remodelling for transcription. Ji DD, et al. **Mol Biochem Parasitol** 1997 Sep;88(1–2):151–62

Domains of alpha-SNAP required for the stimulation of exocytosis and for N-ethylmalemide-sensitive fusion protein (NSF) binding and activation. Barnard RJ, et al. **Mol Biol Cell** 1996 May;7(5):693–701

The 26S-proteasome: regulation and substrate recognition. Dawson S, et al. **Mol Biol Rep** 1997 Mar;24(1–2):39–44

ATPase and ubiquitin-binding proteins of the yeast proteasome. Rubin DM, et al. **Mol Biol Rep** 1997 Mar; 24(1–2):17–26

Is cysteine residue important in FITC-sensitive ATP-binding site of P-type ATPases? A commentary to the state of the art. Breier A, et al. **Mol Cell Biochem** 1996 Jul-Aug; 160–161:89–93 (30 ref.)

Molecular analysis of the SNF2/SWI2 protein family member MOT1, an ATP-driven enzyme that dissociates TATA-binding protein from DNA. Auble DT, et al. **Mol Cell Biol** 1997 Aug;17(8):4842–51

Human La protein: a stabilizer of histone mRNA. McLaren RS, et al. **Mol Cell Biol** 1997 Jun;17(6):3028–36
Genetic and biochemical characterization of mutations in the ATPase and helicase regions of the Upf1 protein. Weng Y, et al. **Mol Cell Biol** 1996 Oct;16(10):5477–90
Identification of a member of a DNA–dependent ATPase family that causes interference with silencing. Zhang Z, et al. **Mol Cell Biol** 1997 Sep;17(9):5461–72
Integration of SecA protein into the Escherichia coli inner membrane is regulated by its amino–terminal ATP–binding domain. Rajapandi T, et al. **Mol Microbiol** 1996 Apr; 20(1):43–51
Proteolysis of the phage lambda CII regulatory protein by FtsH (HflB) of Escherichia coli. Shotland Y, et al. **Mol Microbiol** 1997 Jun;24(6):1303–10
SecA is an intrinsic subunit of the Escherichia coli preprotein translocase and exposes its carboxyl terminus to the periplasm. van der Does C, et al. **Mol Microbiol** 1996 Nov; 22(4):619–29
The Clp ATPases define a novel class of molecular chaperones. Wawrzynow A, et al. **Mol Microbiol** 1996 Sep; 21(5):895–9 (26 ref.)
Differential expression of ornithine decarboxylase, poly(ADP)ribose polymerase, and mitochondrial mRNAs following testosterone administration to hypophysectomized rats. Alcivar–Warren A, et al. **Mol Reprod Dev** 1996 Mar;43(3):283–9
Hrs–2 is an ATPase implicated in calcium–regulated secretion. Bean AJ, et al. **Nature** 1997 Feb 27; 385(6619):826–9
Chromatin–remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Varga–Weisz PD, et al. **Nature** 1997 Aug 7;388(6642):598–602
ADP–ribosylation of actin by Clostridium perfringens iota toxin and turkey erythrocyte ADP–ribosyltransferase A: effects on profilin–regulated nucleotide exchange and ATPase activity. Sehr P, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Dec; 354(6):693–7
Sensitivity of ATPase–ADPase activities from synaptic plasma membranes of rat forebrain to lipid peroxidation in vitro and the protective effect of vitamin E. Vietta M, et al. **Neurochem Res** 1996 Mar;21(3):299–304
The effect of thyrotropin releasing hormone on carbon dioxide laser induced lesion of the cerebral artery. Haciyakupoğlu S, et al. **Neurol Res** 1997 Feb;19(1):78–83
Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. Fergusson J, et al. **Neurosci Lett** 1996 Nov 29;219(3):167–70
Characterization of DbpA, an Escherichia coli DEAD box protein with ATP independent RNA unwinding activity. Böddeker N, et al. **Nucleic Acids Res** 1997 Feb 1; 25(3):537–45
DNA damage–dependent recruitment of nucleotide excision repair and transcription proteins to Escherichia coli inner membranes. Lin CG, et al. **Nucleic Acids Res** 1997 Aug 1;25(15):3151–8
Functional analysis of the DNA–stimulated ATPase domain of yeast SWI2/SNF2. Richmond E, et al. **Nucleic Acids Res** 1996 Oct 1;24(19):3685–92
Characteristics of ecto–ATPase of Xenopus oocytes and the inhibitory actions of suramin on ATP breakdown [letter; comment] van der Ven P, et al. **Pflugers Arch** 1996 Apr; 431(6):993–6. Comment on: Pflugers Arch 1995 Jan;429(3):412–8.
Light–stimulated degradation of an unassembled Rieske FeS protein by a thylakoid–bound protease: the possible role of the FtsH protease. Ostersetzer O, et al. **Plant Cell** 1997 Jun;9(6):957–65
High expression of plasmid–encoded tetracycline resistance gene in E. coli causes a decrease in membrane–bound ATPase activity. Valenzuela MS, et al. **Plasmid** 1996 Jul; 36(1):19–25
Both an N–terminal 65–kDa domain and a C–terminal 30–kDa domain of SecA cycle into the membrane at SecYEG during translocation. Eichler J, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5574–81
Regulation of SOS mutagenesis by proteolysis. Frank EG, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10291–6
Mechanism of protein remodeling by ClpA chaperone. Pak M, et al. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):4901–6
The motor domain and the regulatory domain of myosin solely dictate enzymatic activity and phosphorylation–dependent regulation, respectively. Sata M, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):91–6
Spare the rod, spoil the regulation: necessity for a myosin rod. Trybus KM, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):48–52
ATPase activity of Escherichia coli Rep helicase crosslinked to single–stranded DNA: implications for ATP driven helicase translocation. Wong I, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10051–6
Biochemistry, localization and functional roles of ecto–nucleotidases in the nervous system. Zimmermann H. **Prog Neurobiol** 1996 Aug;49(6):589–618 (340 ref.)
Kdp–like system in Salmonella typhimurium LT–2. Garcia–Cuellar C, et al. **Rev Latinoam Microbiol** 1995 Jul–Sep;37(3):227–36
Kinetic measurement of the step size of DNA unwinding by Escherichia coli UvrD helicase [published erratum appears in Science 1997 Apr 4;276(5309):21] Ali JA, et al. **Science** 1997 Jan 17;275(5298):377–80
Human Hsp70 molecular chaperone binds two calcium ions within the ATPase domain. Sriram M, et al. **Structure** 1997 Mar 15;5(3):403–14
Effects of chromium(VI) on some ion–dependent ATPases in gills, kidney and intestine of a coastal teleost Periophthalmus dipes. Thaker J, et al. **Toxicology** 1996 Sep 2;112(3):237–44
Why is fatty liver unsuitable for transplantation? Deterioration of mitochondrial ATP synthesis and sinusoidal structure during cold preservation of a liver with steatosis. Fukumori T, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):412–5
P–type ATPases [letter; comment] Lutsenko S, et al. **Trends Biochem Sci** 1996 Dec;21(12):467. Comment on: Trends Biochem Sci 1996 Jul;21(7):237–41.
CPx–type ATPases: a class of P–type ATPases that pump heavy metals [see comments] Solioz M, et al. **Trends Biochem Sci** 1996 Jul;21(7):237–41. Comment in: Trends Biochem Sci 1996 Dec;21(12):467.
Modulation of bovine papillomavirus DNA replication by phosphorylation of the viral E1 protein. Zanardi TA, et al. **Virology** 1997 Feb 3;228(1):1–10
Isolation, characterization, and substrate specificity of the plasma membrane ATPase of the hlophilic achaeon Haloferax volcanii. Steinert K, et al. **Z Naturforsch [C]** 1996 Jan–Feb;51(1–2):29–39
[Complementarity of microscopies in the structural analysis of DNA minicircles associated to protein MC1] Larquet E, et al. **C R Acad Sci III** 1996 Jun;319(6):461–71 (Eng. Abstr.) **(Fre)**
[The demonstration of the vessels of the microcirculatory bed of the dura mater by using ATPase] Chertok VM. **Arkh Anat Gistol Embriol** 1981 Dec;81(12):45–50 (Eng. Abstr.) **(Rus)**
[ATPase and regulatory properties of skeletal muscle myosin in Citellus undulatus susliks during various stages of winter hibernation] Lukoianova NA, et al. **Biofizika** 1997 Mar–Apr;42(2):343–8 (Eng. Abstr.) **(Rus)**
[Ecto–ATPases and receptors for ATP] Ziganshin AU, et al. **Eksp Klin Farmakol** 1997 May–Jun;60(3):78–82 (59 ref.) (Eng. Abstr.) **(Rus)**
[Bacterial cell membrane ATPase in assessing heavy metal toxicity] Gruzina TG, et al. **Mikrobiologiia** 1997 Jan–Feb; 66(1):14–8 (Eng. Abstr.) **(Rus)**
[Combined effect of Pb2+ and divalent mental complexes on superprecipation and ATPase activity of myometrial actomyosin] Dabyntseva RD, et al. **Ukr Biokhim Zh** 1995 Nov–Dec;67(6):46–52 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Optimal ratios of biliary glycoprotein isoforms required for inhibition of colonic tumor cell growth. Turbide C, et al. **Cancer Res** 1997 Jul 1;57(13):2781–8
The chloride pump: a Cl(–)–translocating P–type ATPase. Gerencser GA. **Crit Rev Biochem Mol Biol** 1996; 31(4):303–37 (186 ref.)
A flagellar–specific ATPase (FliI) is necessary for flagellar export in Helicobacter pylori. Jenks PJ, et al. **FEMS Microbiol Lett** 1997 Jul 15;152(2):205–11
Effects of tissue fractionation on exercise–induced alterations in SR function in rat gastrocnemius muscle. Chin ER, et al. **J Appl Physiol** 1996 Mar;80(3):940–8
SR Ca(2+)–ATPase/phospholamban in cardiomyocyte function. Tada M, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S77–85 (39 ref.)
A proteasome cap subunit required for spindle pole body duplication in yeast. McDonald HB, et al. **J Cell Biol** 1997 May 5;137(3):539–53
Centrosome and spindle function of the Drosophila Ncd microtubule motor visualized in live embryos using Ncd–GFP fusion proteins. Endow SA, et al. **J Cell Sci** 1996 Oct;109 (Pt 10):2429–42
The renal adenosine triphosphatases: functional integration and clinical significance. Laski ME, et al. **Miner Electrolyte Metab** 1996;22(5–6):410–22 (95 ref.)
p47 is a cofactor for p97–mediated membrane fusion [see comments] Kondo H, et al. **Nature** 1997 Jul 3; 388(6637):75–8. Comment in: Nature 1997 Jul 3;388(6637):20–1.
Membrane fusion. Bridging the gap by AAA ATPases [news; comment] Rowe T, et al. **Nature** 1997 Jul 3;388(6637):20–1 . Comment on: Nature 1997 Jul 3;388(6637):75–8.
Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C–CAM1): the adhesion and growth suppression are mediated by different domains. Luo W, et al. **Oncogene** 1997 Apr 10;14(14):1697–704

ADENOSINETRIPHOSPHATASE, ACTOMYOSIN see **MYOSIN ATPASE**

ADENOSINETRIPHOSPHATASE, CALCIUM see **CA(2+)-TRANSPORTING ATPASE**

ADENOSINETRIPHOSPHATASE, CALCIUM, MAGNESIUM see **CA(2+) MG(2+)-ATPASE**

ADENOSINETRIPHOSPHATASE, DYNEIN see **DYNEIN ATPASE**

ADENOSINETRIPHOSPHATASE F1 see **H(+)-TRANSPORTING ATP SYNTHASE**

ADENOSINETRIPHOSPHATASE, HYDROGEN, POTASSIUM see **H(+)-K(+)-EXCHANGING ATPASE**

ADENOSINETRIPHOSPHATASE, MAGNESIUM see **CA(2+) MG(2+)-ATPASE**

ADENOSINETRIPHOSPHATASE, MYOSIN see **MYOSIN ATPASE**

ADENOSINETRIPHOSPHATASE, SODIUM, POTASSIUM see **NA(+)-K(+)-EXCHANGING ATPASE**

ADENOSIS OF BREAST see **FIBROCYSTIC DISEASE OF BREAST**

S-ADENOSYLHOMOCYSTEINE

BLOOD

Influence of oral S–adenosylmethionine on plasma 5–methyltetrahydrofolate, S–adenosylhomocysteine, homocysteine and methionine in healthy humans. Loehrer FM, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):845–50

IMMUNOLOGY

S–adenosylhomocysteine as a physiological modulator of Apo–1–mediated apoptosis. Ratter F, et al. **Int Immunol** 1996 Jul;8(7):1139–47

METABOLISM

Effect of L–Dopa and the catechol–O–methyltransferase inhibitor Ro 41–0960 on sulfur amino acid metabolites in rats. Miller JW, et al. **Clin Neuropharmacol** 1997 Feb; 20(1):55–66
Levels of L–methionine S–adenosyltransferase activity in erythrocytes and concentrations of S–adenosylmethionine and S–adenosylhomocysteine in whole blood of patients with Parkinson's disease. Cheng H, et al. **Exp Neurol** 1997 Jun;145(2 Pt 1):580–5
Enzymatic C5–cytosine methylation of DNA: mechanistic implications of new crystal structures for HhaI methyltransferase–DNA–AdoHcy complexes. O'Gara M, et al. **J Mol Biol** 1996 Sep 6;261(5):634–45
Differential binding of S–adenosylmethionine S–adenosylhomocysteine and Sinefungin to the adenine–specific DNA methyltransferase M.TaqI. Schluckebier G, et al. **J Mol Biol** 1997 Jan 10;265(1):56–67
Determinants of the S–adenosylhomocysteine (SAH) technique for the local assessment of cardiac free cytosolic adenosine. Loncar R, et al. **J Mol Cell Cardiol** 1997 May; 29(5):1289–305

PHARMACOLOGY

Pancreatic exocrine secretion is blocked by inhibitors of methylation. Capdevila A, et al. **Arch Biochem Biophys** 1997 Sep 1;345(1):47–55

S-ADENOSYLMETHIONINE

ADMINISTRATION & DOSAGE

Valproate–induced developmental modifications maybe partially prevented by coadministration of folinic acid and S–adenosylmethionine. Ubeda N, et al. **Int J Dev Biol** 1996; Suppl 1:291S–292S

BIOSYNTHESIS

Enzymatic synthesis of S–adenosyl–L–methionine on the preparative scale. Park J, et al. **Bioorg Med Chem** 1996 Dec;4(12):2179–85
S–adenosylmethionine synthesis: molecular mechanisms and clinical implications. Mato JM, et al. **Pharmacol Ther** 1997; 73(3):265–80 (174 ref.)

CHEMISTRY

RNA aptamers to the adenosine moiety of S–adenosyl methionine: structural inferences from variations on a theme and the reproducibility of SELEX. Burke DH, et al. **Nucleic Acids Res** 1997 May 15;25(10):2020–4
The structure of the C–terminal domain of methionine synthase: presenting S–adenosylmethionine for reductive methylation of B12. Dixon MM, et al. **Structure** 1996 Nov 15;4(11):1263–75

METABOLISM

Transport of S–adenosylmethionine in isolated rat liver mitochondria. Horne DW, et al. **Arch Biochem Biophys** 1997 Jul 15;343(2):201–6
Biotin synthase, a new member of the family of enzymes which uses S–adenosylmethionine as a source of deoxyadenosyl radical. Guianvarc'h D, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):402–6
The PvuII DNA (cytosine–N4)–methyltransferase comprises two trypsin–defined domains, each of which binds a molecule of S–adenosyl–L–methionine. Adams GM, et al. **Biochemistry** 1997 Jul 8;36(27):8284–92
Cobalamin–dependent methionine synthase is a modular

protein with distinct regions for binding homocysteine, methyltetrahydrofolate, cobalamin, and adenosylmethionine. Goulding CW, et al. **Biochemistry** 1997 Jul 1;36(26):8082–91

Effect of L–Dopa and the catechol–O–methyltransferase inhibitor Ro 41–0960 on sulfur amino acid metabolites in rats. Miller JW, et al. **Clin Neuropharmacol** 1997 Feb; 20(1):55–66

Levels of L–methionine S–adenosyltransferase activity in erythrocytes and concentrations of S–adenosylmethionine and S–adenosylhomocysteine in whole blood of patients with Parkinson's disease. Cheng H, et al. **Exp Neurol** 1997 Jun;145(2 Pt 1):580–5

A unique transporter of S–adenosylmethionine in African trypanosomes. Goldberg B, et al. **FASEB J** 1997 Mar; 11(4):256–60

Quorum sensing in Vibrio fischeri: evidence that S–adenosylmethionine is the amino acid substrate for autoinducer synthesis. Hanzelka BL, et al. **J Bacteriol** 1996 Sep;178(17):5291–4

Activation of the anaerobic ribonucleotide reductase from Escherichia coli. The essential role of the iron–sulfur center for S–adenosylmethionine reduction. Ollagnier S, et al. **J Biol Chem** 1997 Sep 26;272(39):24216–23

Hydroxyindole–O–methyltransferase activity assay using high–performance liquid chromatography with fluorometric detection: determination of melatonin enzymatically formed from N–acetylserotonin and S–adenosyl–L–methionine. Itoh MT, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):217–21

Differential binding of S–adenosylmethionine S–adenosylhomocysteine and Sinefungin to the adenine–specific DNA methyltransferase M.TaqI. Schluckebier G, et al. **J Mol Biol** 1997 Jan 10;265(1):56–67

Met31p and Met32p, two related zinc finger proteins, are involved in transcriptional regulation of yeast sulfur amino acid metabolism. Blaiseau PL, et al. **Mol Cell Biol** 1997 Jul;17(7):3640–8

Down–regulation of S–adenosylhomocysteine hydrolase in the active methyl transfer system in the brain of genetically epileptic El mice. Ohmori O, et al. **Neurochem Res** 1996 Oct;21(10):1173–80

Crystal structure of the chemotaxis receptor methyltransferase CheR suggests a conserved structural motif for binding S–adenosylmethionine. Djordjevic S, et al. **Structure** 1997 Apr 15;5(4):545–58

PHARMACOKINETICS

Beneficial effects of S–adenosyl–L–methionine on blood–brain barrier breakdown and neuronal survival after transient cerebral ischemia in gerbils. Rao AM, et al. **Brain Res Mol Brain Res** 1997 Feb;44(1):134–8

PHARMACOLOGY

Effects of S–adenosyl–L–methionine on platelet thromboxane and vascular prostacyclin. De La Cruz JP, et al. **Biochem Pharmacol** 1997 Jun 1;53(11):1761–3

SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necrosis factor alpha on cultured rabbit synovial cells. Gutierrez S, et al. **Br J Rheumatol** 1997 Jan; 36(1):27–31

Methionine derivatives diminish sulphide damage to colonocytes—implications for ulcerative colitis. Roediger WE, et al. **Gut** 1996 Jul;39(1):77–81

S–adenosyl–L–methionine protects the liver against the cholestatic, cytotoxic, and vasoactive effects of leukotriene D4: a study with isolated and perfused rat liver. Cincu RN, et al. **Hepatology** 1997 Aug;26(2):330–5

Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol–treated rats: effect of membrane physical properties and S–adenosyl–L–methionine. Colell A, et al. **Hepatology** 1997 Sep;26(3):699–708

Effects of S–adenosyl–L–methionine on hepatic and renal oxidative stress in an experimental model of acute biliary obstruction in rats. Gonzalez–Correa JA, et al. **Hepatology** 1997 Jul;26(1):121–7

Effects of S–adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride–induced cirrhosis. Gassó M, et al. **J Hepatol** 1996 Aug;25(2):200–5

Influence of oral S–adenosylmethionine on plasma 5–methyltetrahydrofolate, S–adenosylhomocysteine, homocysteine and methionine in healthy humans. Loehrer FM, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):845–50

Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S–adenosylmethionine: a model that may explain the occurrence of depression in Parkinson's disease. Charlton CG. **Life Sci** 1997;61(5):495–502

Effect of S–adenosyl methionine on muscarinic receptors in young rats. Pavia J, et al. **Life Sci** 1997;60(11):825–32

Metabolism of methionine in liver disease. Mato JM, et al. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:35–46 (87 ref.)

PHYSIOLOGY

Disturbances of one–carbon metabolism in neuropsychiatric disorders: a review. Smythies JR, et al. **Biol Psychiatry** 1997 Jan 15;41(2):230–3 (35 ref.)

THERAPEUTIC USE

S–adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. Floreani A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug;67(2):109–13

Pharmacological treatment of cholestasis. Alvaro D. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:47–51 (42 ref.)

Double–blind, placebo–controlled cross–over study of intravenous S–adenosyl–L–methionine in patients with fibromyalgia. Volkmann H, et al. **Scand J Rheumatol** 1997; 26(3):206–11

Treatment of experimental ischemia/reperfusion injury with S–adenyosylmethionine: evidence that donor pretreatment complements other regimens. Dunne JB, et al. **Transplantation** 1997 Feb 27;63(4):500–6

[A trial of using Geptral in patients with chronic liver diseases] Gorbakov VV, et al. **Voen Med Zh** 1996 Dec; 317(12):29–31 **(Rus)**

S–ADENOSYLMETHIONINE DECARBOXYLASE

ANTAGONISTS & INHIBITORS

In vivo trypanocidal activities of new S–adenosylmethionine decarboxylase inhibitors. Bacchi CJ, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1448–53

In vitro trypanocidal activities of new S–adenosylmethionine decarboxylase inhibitors. Brun R, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1442–7

Observations with an S–adenosylmethionine decarboxylase inhibitor in rats with prostatic adenocarcinoma. Seiler N, et al. **Arzneimittelforschung** 1996 Mar;46(3):311–5

CGP 48664, a potent and specific S–adenosylmethionine decarboxylase inhibitor: effects on regulation and stability of the enzyme. Svensson F, et al. **Biochem J** 1997 Feb 15; 322 (Pt 1):297–302

4–Amidinoindan–1–one 2'–amidinohydrazone (CGP 48664A) exerts in vitro growth inhibitory effects that are not only related to S–adenosylmethionine decarboxylase (SAMdc) inhibition. Dorhout B, et al. **Biochim Biophys Acta** 1997 Apr 17;1335(1–2):144–52

Structure–activity relations of S–adenosylmethionine decarboxylase inhibitors on the growth of MCF–7 breast cancer cells. Thomas T, et al. **Breast Cancer Res Treat** 1996;39(3):293–306

Automated quantitative determination of a new polyamine biosynthesis inhibitor (CGP 48 664) and a potential metabolite in human and animal plasma by high–performance liquid chromatography. Degen PH, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):339–45

Combined action of inhibitors of S–adenosylmethionine decarboxylase with an antimalarial drug, chloroquine, on Plasmodium falciparum. Das B, et al. **J Eukaryot Microbiol** 1997 Jan–Feb;44(1):12–7

Antileishmanial effect of a potent S–adenosylmethionine decarboxylase inhibitor: CGP 40215A. Mukhopadhyay R, et al. **Pharmacol Res** 1996 Jan;33(1):67–70

BIOSYNTHESIS

A novel trans–spliced mRNA from Onchocerca volvulus encodes a functional S–adenosylmethionine decarboxylase. Da'Dara AA, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):519–30

Characterization and expression of two members of the S–adenosylmethionine decarboxylase gene family in carnation flower. Lee MM, et al. **Plant Mol Biol** 1997 Jun; 34(3):371–82

DRUG EFFECTS

CGP 48664, a potent and specific S–adenosylmethionine decarboxylase inhibitor: effects on regulation and stability of the enzyme. Svensson F, et al. **Biochem J** 1997 Feb 15; 322 (Pt 1):297–302

GENETICS

A novel trans–spliced mRNA from Onchocerca volvulus encodes a functional S–adenosylmethionine decarboxylase. Da'Dara AA, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):519–30

Down regulation of S–adenosyl–L–methionine decarboxylase activity of Trypanosoma brucei during transition from long slender to short stumpy–like forms in axenic culture. Selzer PM, et al. **Eur J Cell Biol** 1996 Feb;69(2):173–9

The upstream open reading frame of the mRNA encoding S–adenosylmethionine decarboxylase is a polyamine–responsive translational control element. Ruan H, et al. **J Biol Chem** 1996 Nov 22;271(47):29576–82

Rat S–adenosylmethionine decarboxylase gene family: intronic genes are alleles. Heljasvaara R, et al. **Mamm Genome** 1996 Oct;7(10):776–9

Characterization and expression of two members of the S–adenosylmethionine decarboxylase gene family in carnation flower. Lee MM, et al. **Plant Mol Biol** 1997 Jun; 34(3):371–82

METABOLISM

Transgenic mice overexpressing ornithine and S–adenosylmethionine decarboxylases maintain a physiological polyamine homoeostasis in their tissues. Heljasvaara R, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):457–62

S–adenosylmethionine decarboxylase activity is decreased in the rat cortex after traumatic brain injury. Henley CM, et al. **J Neurochem** 1997 Jul;69(1):259–65

Regulation of ornithine decarboxylase and S–adenosylmethionine decarboxylase in a polyamine auxotrophic cell line. Svensson F, et al. **Mol Cell Biochem** 1996 Sep 20;162(2):113–9

PHARMACOLOGY

Effects of secretagogues on insulin biosynthesis and secretion in polyamine–depleted pancreatic beta–cells. Sjöholm A. **Am J Physiol** 1996 Apr;270(4 Pt 1):C1105–10

PHYSIOLOGY

Importance of intracellular S–adenosylmethionine decarboxylase activity for the regulation of camostate–induced pancreatic polyamine metabolism and growth: in vivo effect of two novel S–adenosylmethionine decarboxylase inhibitors. Löser C, et al. **Digestion** 1997; 58(3):258–65

S–ADENOSYLMETHIONINE SYNTHETASE see **METHIONINE ADENOSYLTRANSFERASE**

ADENOVIRIDAE

Enterotoxigenic Escherichia coli, rotavirus, porcine epidemic diarrhoea virus, adenovirus and calici–like virus in porcine postweaning diarrhoea in Hungary. Nagy B, et al. **Acta Vet Hung** 1996;44(1):9–19

Adenoviral gene transfer of macrophage inflammatory protein–2 in rat lung. Foley R, et al. **Am J Pathol** 1996 Oct;149(4):1395–403

Adenovirus–vector–mediated cytokine gene transfer to lung tissue. Gauldie J, et al. **Ann N Y Acad Sci** 1996 Oct 31; 796:235–44 (26 ref.)

Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene. Rosenfeld ME, et al. **Ann Surg** 1997 May;225(5):609–18; discussion 618–20

Transduction of murine and human tumors using recombinant adenovirus vectors. Toloza EM, et al. **Ann Surg Oncol** 1997 Jan;4(1):70–9

Construction and characterization of a recombinant adenovirus vector carrying the human preproinsulin gene under the control of the metallothionein gene promoter. Yajima H, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):778–87

Adenovirus vector infection of chronic lymphocytic leukemia B cells. Cantwell MJ, et al. **Blood** 1996 Dec 15; 88(12):4676–83

In vivo adenovirus–mediated gene transfer and the expression in ischemic and reperfused rat brain. Abe K, et al. **Brain Res** 1997 Jul 25;763(2):191–201

Adenoviral gene transfer of nitric oxide synthase: high level expression in human vascular cells. Channon KM, et al. **Cardiovasc Res** 1996 Nov;32(5):962–72

The effects of sialoglycoconjugates on adenovirus–mediated gene transfer to epithelial cells in vitro and in human airway xenografts. Arcasoy SM, et al. **Chest** 1997 Jun;111(6 Suppl):142S–143S

Adenoviral vectors for hepatic gene transfer in animals. Kay MA. **Chest** 1997 Jun;111(6 Suppl):138S–142S (43 ref.)

Transient gene transfer and expression in the lung. Sime PJ, et al. **Chest** 1997 Jun;111(6 Suppl):89S–94S (33 ref.)

Enhancer stimulation unmasks latent gene transfer after adenovirus–mediated gene delivery into human vascular smooth muscle cells. Clesham GJ, et al. **Circ Res** 1996 Dec; 79(6):1188–95

Potential gene therapy for lecithin–cholesterol acyltransferase (LCAT)–deficient and hypoalphalipoproteinemic patients with adenovirus–mediated transfer of human LCAT gene [see comments] Séguret–Macé S, et al. **Circulation** 1996 Nov 1;94(9):2177–84. Comment in: Circulation 1996 Nov 1;94(9):2046–51.

Adenoviral constructs encoding phosphorylation–competent full–length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation [see comments] Smith RC, et al. **Circulation** 1997 Sep 16;96(6):1899–905. Comment in: Circulation 1997 Sep 16;96(6):1717–9.

Gene transfer into kidney tubules and vasculature by adenoviral vectors. Sukhatme VP, et al. **Exp Nephrol** 1997 Mar–Apr;5(2):137–43 (20 ref.)

Long–term transgene expression in fetal rat suprachiasmatic nucleus neurografts following ex vivo adenoviral vector–mediated gene transfer. Boer GJ, et al. **Exp Neurol** 1997 Jun;145(2 Pt 1):536–45

Polycations increase the efficiency of adenovirus–mediated gene transfer to epithelial and endothelial cells in vitro. Arcasoy SM, et al. **Gene Ther** 1997 Jan;4(1):32–8

Adenovirus–mediated gene transfer into human hepatocytes: analysis of the biochemical functionality of transduced cells. Castell JV, et al. **Gene Ther** 1997 May;4(5):455–64

Adenovirus–mediated expression of green fluorescent protein. de Martin R, et al. **Gene Ther** 1997 May;4(5):493–5

Isolated–organ perfusion for local gene delivery: efficient

adenovirus-mediated gene transfer into the liver. de Roos WK, et al. **Gene Ther** 1997 Jan;4(1):55-62
In vitro correction of iduronate-2-sulfatase deficiency by adenovirus-mediated gene transfer. Di Francesco C, et al. **Gene Ther** 1997 May;4(5):442-8
Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors. Feldman LJ, et al. **Gene Ther** 1997 Mar;4(3):189-98
Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer. Larochelle N, et al. **Gene Ther** 1997 May;4(5):465-72
Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Michou AI, et al. **Gene Ther** 1997 May;4(5):473-82
Ex vivo adenovirus-mediated gene transfer and immunomodulatory protein production in human cornea. Oral HB, et al. **Gene Ther** 1997 Jul;4(7):639-47
Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Poller W, et al. **Gene Ther** 1996 Jun;3(6):521-30
Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Scaria A, et al. **Gene Ther** 1997 Jun;4(6):611-7
Adenovirus-mediated gene transfer into monocyte-derived macrophages of patients with X-linked chronic granulomatous disease: ex vivo correction of deficient respiratory burst. Schneider SD, et al. **Gene Ther** 1997 Jun; 4(6):524-32
Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Wang Q, et al. **Gene Ther** 1997 May;4(5):393-400
Adenoviral mediated gene transfer can be accomplished in human myeloid cell lines and is inhibited by all-trans retinoic acid-induced differentiation. Tosi P, et al. **Haematologica** 1997 Jul-Aug;82(4):387-91
In vivo and in vitro gene transfer and expression in rat intestinal epithelial cells by E1-deleted adenoviral vector. Cheng DY, et al. **Hum Gene Ther** 1997 Apr 10;8(6):755-64
Increased contact time improves adenovirus-mediated CFTR gene transfer to nasal epithelium of CF mice. Jiang C, et al. **Hum Gene Ther** 1997 Apr 10;8(6):671-80
Functional consequences of adenovirus-mediated murine pancreatic gene transfer. McClane SJ, et al. **Hum Gene Ther** 1997 Apr 10;8(6):739-46
Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. Overturf K, et al. **Hum Gene Ther** 1997 Mar 20;8(5):513-21
Recombinant adenoviral vector disrupts surfactant homeostasis in mouse lung. Zsengellér ZK, et al. **Hum Gene Ther** 1997 Jul 20;8(11):1331-44
Adenovirus-mediated gene transfer of the tumor suppressor, p53, induces apoptosis in postmitotic neurons. Slack RS, et al. **J Cell Biol** 1996 Nov;135(4):1085-96
Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. Ilan Y, et al. **J Clin Invest** 1996 Dec 1;98(11):2640-7
Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. van Ginkel FW, et al. **J Immunol** 1997 Jul 15;159(2):685-93
Adenoviral-mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma. Bonnekoh B, et al. **J Invest Dermatol** 1996 Jun; 106(6):1163-8
Adenovirus-mediated gene transfer in olfactory neurons in vivo. Zhao H, et al. **J Neurobiol** 1996 Aug;30(4):521-30
Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene. Vincent AJ, et al. **J Neurosurg** 1996 Oct;85(4):648-54
Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells. Baker AH, et al. **Matrix Biol** 1996 Dec;15(6):383-95
The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. O'Malley BW Jr, et al. **Mol Endocrinol** 1997 Jun;11(6):667-73
Sensitivity and reproducibility in adenoviral infectious titer determination. Nyberg-Hoffman C, et al. **Nat Med** 1997 Jul;3(7):808-11
Delivery of bacterial artificial chromosomes into mammalian cells with psoralen-inactivated adenovirus carrier. Baker A, et al. **Nucleic Acids Res** 1997 May 15;25(10):1950-6
Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Caruso M, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11302-6
Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Elkon KB, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2; 94(18):9814-9
Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Ilan Y, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2587-92
A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Parks RJ, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13565-70
Improved adenoviral vectors: cautious optimism for gene therapy. Channon KM, et al. **QJM** 1997 Feb;90(2):105-9 (42 ref.)
A cold for cancer. Gibbs WW. **Sci Am** 1997 Aug;277(2):36-7
Immunologic barriers to hepatic adenoviral gene therapy for transplantation. DeMatteo RP, et al. **Transplantation** 1997 Jan 27;63(2):315-9
Strategies for targeted gene therapy. Harris JD, et al. **Trends Genet** 1996 Oct;12(10):400-5 (67 ref.)
The implications for childhood leukemia of infection with adenovirus. Dorak MT. **Trends Microbiol** 1996 Feb; 4(2):60-3 (52 ref.)
[Adenovirus gene therapy for liver metastases of gastrointestinal tumors. Development status and future prospectives] Block A, et al. **Dtsch Med Wochenschr** 1997 May 30;122(22):728-32 (17 ref.) **(Ger)**

CHEMISTRY

Automated microfluorometric determination of DNA in recombinant adenoviral samples. Bondoc LL Jr, et al. **Anal Biochem** 1997 May 1;247(2):443-5
Adenovirus 3 penton dodecahedron exhibits structural changes of the base on fibre binding. Schoehn G, et al. **EMBO J** 1996 Dec 16;15(24):6841-6
HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Tomko RP, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3352-6

CLASSIFICATION

Restriction site mapping of a bovine adenovirus type 10 strain. Matiz K, et al. **Acta Vet Hung** 1996;44(3):389-94
Sequence of the avian adenovirus FAV 1 (CELO) DNA encoding the hexon-associated protein pVI and hexon. Akopian TA, et al. **Arch Virol** 1996;141(9):1759-65
Early stage of human adenovirus type 12-inoculated retinal tissue of F344 newborn rat. Kato Y, et al. **Pathol Int** 1996 Aug;46(8):548-56
Isolation of adenovirus type 7 from the urine of children with acute hemorrhagic cystitis. Lee HJ, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):633-4 (13 ref.)
Close phylogenetic relationship between egg drop syndrome virus, bovine adenovirus serotype 7, and ovine adenovirus strain 287. Harrach B, et al. **Virology** 1997 Mar 3; 229(1):302-8

DRUG EFFECTS

Ammonium salt of glycyrrhizic acid as an antiviral [letter] Badam L. **Natl Med J India** 1997 Mar-Apr;10(2):98

ENZYMOLOGY

Pyridoxal 5'-phosphate inhibition of adenovirus DNA polymerase. Monaghan A, et al. **J Biol Chem** 1996 Sep 27;271(39):24242-8
Heterologous expression, purification, and characterization of adenovirus DNA polymerase and preterminal protein. Ramachandra M, et al. **Methods Enzymol** 1996;275:168-94
Processive proofreading by the adenovirus DNA polymerase. Association with the priming protein reduces exonucleolytic degradation. King AJ, et al. **Nucleic Acids Res** 1997 May 1;25(9):1745-52
Sequence analysis of equine adenovirus 2 hexon and 23K proteinase genes indicates a phylogenetic origin distinct from equine adenovirus 1. Reubel GH, et al. **Virus Res** 1997 Jul;50(1):41-56

GENETICS

Human adenovirus vectors for gene transfer into mammalian cells. Hitt MM, et al. **Adv Pharmacol** 1997;40:137-206 (445 ref.)
Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. Behbakht K, et al. **Am J Obstet Gynecol** 1996 Nov;175(5):1260-5
Intrapericardial administration of adenovirus for gene transfer. Lamping KG, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H310-7
Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Kolls JK, et al. **Am J Respir Cell Mol Biol** 1997 Feb; 16(2):112-8
Ex vivo adenoviral-mediated gene transfer to lung isografts during cold preservation [see comments] Boasquevisque CH, et al. **Ann Thorac Surg** 1997 Jun;63(6):1556-61. Comment in: Ann Thorac Surg 1997 Jun;63(6):1527-8.
In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Spitz FR, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3415-22
Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy. Tong XW, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):811-3
Conserved sequences in the fibers of epidemic keratoconjunctivitis associated human adenoviruses. Pring-Akerblom P, et al. **Arch Virol** 1997;142(1):205-11
Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Ueno H, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):898-904
Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor alpha receptor gene. Le CH, et al. **Arthritis Rheum** 1997 Sep;40(9):1662-9
Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo. Tanaka T, et al. **Biochem Biophys Res Commun** 1997 Feb 24; 231(3):775-9
Inducibility of E4BP4 suggests a novel mechanism of negative gene regulation by glucocorticoids. Wallace AD, et al. **Biochem Biophys Res Commun** 1997 Mar 17; 232(2):403-6
Proinsulin processing in the rat insulinoma cell line INS after overexpression of the endoproteases PC2 or PC3 by recombinant adenovirus. Irminger JC, et al. **Biochem J** 1996 Nov 15;320 (Pt 1):11-5
Gene transfer into cultured bovine ciliary epithelial cells using adenovirus vectors. Walker VE, et al. **Biochem Soc Trans** 1996 Aug;24(3):423S
A new concept in (adenoviral) oncogenesis: integration of foreign DNA and its consequences. Doerfler W. **Biochim Biophys Acta** 1996 Oct 9;1288(2):F79-99 (111 ref.)
Adenovirus-mediated gene transfer to rat testis in vivo. Blanchard KT, et al. **Biol Reprod** 1997 Feb;56(2):495-500
Adenovirus-mediated gene transfer by perivitelline microinjection of mouse, rat, and cow embryos. Kubisch HM, et al. **Biol Reprod** 1997 Jan;56(1):119-24
Transduction of human trophoblast cells by recombinant adenoviruses is differentiation dependent. MacCalman CD, et al. **Biol Reprod** 1996 Mar;54(3):682-91
Rapid method for preparing adenovirus DNA. Deryckere F, et al. **Biotechniques** 1997 May;22(5):868-70
Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Vrancken Peeters MJ, et al. **Biotechniques** 1996 Feb; 20(2):278-85
Adenoviral vectors in hematology: purging, stem cell gene transfer, or both [letter; comment] Wroblewski JM, et al. **Blood** 1997 Jun 15;89(12):4664-5. Comment on: Blood 1996 Jun 15;87(12):5032-9.
Adenovirus-mediated expression of a reporter gene in thalamocortical cocultures. Wilkemeyer MF, et al. **Brain Res** 1995 Dec 12;703(1-2):129-38
Rapid gene transfer into cultured hippocampal neurons and acute hippocampal slices using adenoviral vectors. Griesbeck O, et al. **Brain Res Mol Brain Res** 1997 Feb; 44(1):171-7
The ups and downs of adenovirus vectors. Ginsberg HS. **Bull N Y Acad Med** 1996 Summer;73(1):53-8 (14 ref.)
Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Alemany R, et al. **Cancer Gene Ther** 1996 Sep-Oct;3(5):296-301
Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Brand K, et al. **Cancer Gene Ther** 1997 Jan-Feb;4(1):9-16
High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cusack JC, et al. **Cancer Gene Ther** 1996 Jul-Aug; 3(4):245-9
Adenoviral-mediated suicide gene therapy for hepatic metastases of breast cancer. Kwong YL, et al. **Cancer Gene Ther** 1996 Sep-Oct;3(5):339-44
Increased immunogenicity of tumors bearing mutant p53 and P1A epitopes after transduction of B7-1 via recombinant adenovirus. Lee CT, et al. **Cancer Gene Ther** 1996 Jul-Aug; 3(4):238-44
Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Li Z, et al. **Cancer Gene Ther** 1997 Mar-Apr;4(2):113-7
Gene delivery into malignant cells in vivo by a conjugated adenovirus/DNA complex. Nguyen DM, et al. **Cancer Gene Ther** 1997 May-Jun;4(3):183-90
Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Nguyen DM, et al. **Cancer Gene Ther** 1997 May-Jun;4(3):191-8
Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Nielsen LL, et al. **Cancer Gene Ther** 1997 Mar-Apr;4(2):129-38
Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. Schrump DS, et al. **Cancer Gene Ther** 1996 Nov-Dec;3(6):357-64
Selective elimination (purging) of contaminating malignant cells from hematopoietic stem cell autografts using recombinant adenovirus. Wroblewski JM, et al. **Cancer Gene Ther** 1996 Jul-Aug;3(4):257-64
Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Gallardo D, et al. **Cancer Res** 1996 Nov 1;56(21):4891-3
Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Goldman CK, et al. **Cancer Res** 1997 Apr 15;57(8):1447-51
Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. He D, et al. **Cancer Res** 1997 May 15;57(10):1868-72
Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Hu SX, et al. **Cancer Res** 1997 Aug 15; 57(16):3339-43
In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Kanai F, et al. **Cancer Res**

1997 Feb 1;57(3):461–5
Osteocalcin promoter–based toxic gene therapy for the treatment of osteosarcoma in experimental models. Ko SC, et al. **Cancer Res** 1996 Oct 15;56(20):4614–9
Genetic immunization for the melanoma antigen MART–1/Melan–A using recombinant adenovirus–transduced murine dendritic cells. Ribas A, et al. **Cancer Res** 1997 Jul 15;57(14):2865–9
The anti–human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin–6 gene using adenovirus vector. Tanaka F, et al. **Cancer Res** 1997 Apr 1;57(7):1335–43
Measurement of changes in sarcoplasmic reticulum [Ca2+] in rat tail artery with targeted apoaequorin delivered by an adenoviral vector. Rembold CM, et al. **Cell Calcium** 1997 Jan;21(1):69–79
Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Hajjar RJ, et al. **Circulation** 1997 Jan 21; 95(2):423–9
Adenovirus–mediated gene transfer as an in vivo probe of lipoprotein metabolism [editorial; comment] Leiden JM. **Circulation** 1996 Nov 1;94(9):2046–51. Comment on: Circulation 1996 Nov 1;94(9):2177–84.
Adenovirus for neurodegenerative diseases: in vivo strategies and ex vivo gene therapy using human neural progenitors. Sabaté O, et al. **Clin Neurosci** 1995–96;3(5):317–21 (42 ref.)
Use of viral vectors to promote neuroregeneration. Verhaagen J, et al. **Clin Neurosci** 1995–96;3(5):275–83 (59 ref.)
Combination of gene targeting and gene transfer by adenoviral vectors in the analysis of neurotrophin–mediated neuronal plasticity. Griesbeck O, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:77–83 (39 ref.)
beta–cell function in normal rats made chronically hyperleptinemic by adenovirus–leptin gene therapy. Koyama K, et al. **Diabetes** 1997 Aug;48(8):1276–80
Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: long term expression, cell cycle dependency, and effects on hormone secretion. Castro MG, et al. **Endocrinology** 1997 May; 138(5):2184–94
Adenovirus–mediated blockade of lymphotoxin–beta inhibits the induction of contact sensitivity in mice. Trueb RM, et al. **Exp Dermatol** 1997 Aug;6(4):175–80
Recombinant adenovirus: a gene transfer vector for study and treatment of CNS diseases. Davidson BL, et al. **Exp Neurol** 1997 Mar;144(1):125–30 (66 ref.)
Adenovirus–mediated gene transfer to the central nervous system for Parkinson's disease. Horellou P, et al. **Exp Neurol** 1997 Mar;144(1):131–8 (68 ref.)
Adenoviral vectors given intravenously to immunocompromised mice yield stable transduction of the colonic epithelium [see comments] Brown GR, et al. **Gastroenterology** 1997 May;112(5):1586–94. Comment in: Gastroenterology 1997 May;112(5):1753–6.
Tumor–specific gene expression in carcinoembryonic antigen—producing gastric cancer cells using adenovirus vectors. Lan KH, et al. **Gastroenterology** 1996 Nov; 111(5):1241–51
Construction of adenoviral and retroviral vectors coexpressing the genes encoding the hepatitis B surface antigen and B7–1 protein. He XS, et al. **Gene** 1996 Oct 10;175(1–2):121–5
Efficient gene activation system on mammalian cell chromosomes using recombinant adenovirus producing Cre recombinase. Kanegae Y, et al. **Gene** 1996 Nov 28; 181(1–2):207–12
Recombinant adenovirus synthesizing cell surface–anchored beta hCG induces bioneutralizing antibodies in rats. Raikwar SP, et al. **Gene** 1997 Apr 29;190(1):197–202
Adenovirus E1a interferes with expression of vaccinia viral genes. Strauss D, et al. **Gene** 1997 Jan 15;184(2):279–84
Development and characterization of a binary gene expression system based on bacteriophage T7 components in adenovirus vectors. Tomanin R, et al. **Gene** 1997 Jul 9;193(2):129–40
Restoration of hexosaminidase A activity in human Tay–Sachs fibroblasts via adenoviral vector–mediated gene transfer. Akli S, et al. **Gene Ther** 1996 Sep;3(9):769–74
Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Amalfitano A, et al. **Gene Ther** 1997 Mar;4(3):258–63
A stable cell line carrying adenovirus–inducible rep and cap genes allows for infectivity titration of adeno–associated virus vectors. C'ark KR, et al. **Gene Ther** 1996 Dec; 3(12):1124–32
In vivo muscle gene transfer of full–length dystrophin with an adenoviral vector that lacks all viral genes. Clemens PR, et al. **Gene Ther** 1996 Nov;3(11):965–72
E1A RNA transcripts amplify adenovirus–mediated tumor reduction. Dion LD, et al. **Gene Ther** 1996 Nov; 3(11):1021–5
Gene therapy for hepatocellular carcinoma: long–term remission of primary and metastatic tumors in mice by interleukin–2 gene therapy in vivo. Huang H, et al. **Gene Ther** 1996 Nov;3(11):980–7
Adenovirus vector–transduced hepatocytes implanted via a preformed collagen/PTFE support persist for at least 4 weeks in vivo. Kremer EJ, et al. **Gene Ther** 1996 Oct; 3(10):932–6
Macrophage depletion increases the safety, efficacy and persistence of adenovirus–mediated gene transfer in vivo. Kuzmin AI, et al. **Gene Ther** 1997 Apr;4(4):309–16
Reversal of potassium channel deficiency in cells from failing hearts by adenoviral gene transfer: a prototype for gene therapy for disorders of cardiac excitability and contractility. Nuss HB, et al. **Gene Ther** 1996 Oct; 3(10):900–12
Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Ring CJ, et al. **Gene Ther** 1996 Dec;3(12):1094–103
HBV–derived promoters direct liver–specific expression of an adenovirally transduced LDL receptor gene. Sandig V, et al. **Gene Ther** 1996 Nov;3(11):1002–9
Heterologous expression of adenovirus E3–gp19K in an E1a–deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Schowalter DB, et al. **Gene Ther** 1997 Apr;4(4):351–60
In vivo gene transfer to the human biliary tract. Vickers SM, et al. **Gene Ther** 1996 Sep;3(9):825–8
Safety studies of the intraperitoneal injection of E1A—liposome complex in mice. Xing X, et al. **Gene Ther** 1997 Mar;4(3):238–43
Adenoviral vector–mediated interleukin–10 expression in vivo: intramuscular gene transfer inhibits cytokine responses in endotoxemia. Xing Z, et al. **Gene Ther** 1997 Feb;4(2):140–9
NAP–I is a functional homologue of TAF–I that is required for replication and transcription of the adenovirus genome in a chromatin–like structure. Kawase H, et al. **Genes Cells** 1996 Dec;1(12):1045–56
Adenovirus–mediated gene transfer into injured arteries: quantitative analysis of repeated administration. Ueno H. **Gerontology** 1996;42 Suppl 1:25–36
Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti–erbB–2 intracellular single–chain antibody for ovarian cancer gene therapy. Deshane J, et al. **Gynecol Oncol** 1997 Mar;64(3):378–85
Adenovirus–mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Hamada K, et al. **Gynecol Oncol** 1996 Nov;63(2):219–27
Growth inhibition of human cervical cancer cells with the recombinant adenovirus p53 in vitro. Hamada K, et al. **Gynecol Oncol** 1996 Mar;60(3):373–9
Transient immunosuppression with FK506 permits long–term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Ilan Y, et al. **Hepatology** 1997 Oct;26(4):949–56
Expansion of donor hepatocytes after recombinant adenovirus–induced liver regeneration in mice. Vrancken Peeters MJ, et al. **Hepatology** 1997 Apr;25(4):884–8
Immediate inflammatory responses to adenovirus–mediated gene transfer in rat salivary glands. Adesanya MR, et al. **Hum Gene Ther** 1996 Jun 10;7(9):1085–93
A phase I study of recombinant adenovirus vector–mediated delivery of an anti–erbB–2 single–chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients. Alvarez RD, et al. **Hum Gene Ther** 1997 Jan 20; 8(2):229–42
In vitro and in vivo hepatoma cell–specific expression of a gene transferred with an adenoviral vector. Arbuthnot PB, et al. **Hum Gene Ther** 1996 Aug 20;7(13):1503–14
Adenovirus–mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. Cayouette M, et al. **Hum Gene Ther** 1997 Mar 1;8(4):423–30
Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro–drug 5–fluorocytosine. Crystal RG, et al. **Hum Gene Ther** 1997 May 20;8(8):985–1001
Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Dong JY, et al. **Hum Gene Ther** 1996 Feb 10;7(3):319–31
Induction of a cAMP–stimulated chloride secretion in regenerating poorly differentiated airway epithelial cells by adenovirus–mediated CFTR gene transfer. Dupuit F, et al. **Hum Gene Ther** 1997 Aug 10;8(12):1439–50
Viral gene delivery to skeletal muscle: insights on maturation–dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Feero WG, et al. **Hum Gene Ther** 1997 Mar 1;8(4):371–80
Intramarrow cytokine gene transfer by adenoviral vectors in dogs. Foley R, et al. **Hum Gene Ther** 1997 Mar 20; 8(5):545–53
Use of the cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors. Fu S, et al. **Hum Gene Ther** 1997 Jul 20;8(11):1321–30
In vivo expression of full–length human dystrophin from adenoviral vectors deleted of all viral genes. Haecker SE, et al. **Hum Gene Ther** 1996 Oct 1;7(15):1907–14
Adenoviral vector–mediated gene expression in the nervous system of immunocompetent Wistar and T cell–deficient nude rats: preferential survival of transduced astroglial cells in nude rats. Hermens WT, et al. **Hum Gene Ther** 1997 Jun 10;8(9):1049–63
Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Jooss K, et al. **Hum Gene Ther** 1996 Aug 20;7(13):1555–66
Immune responses to adenoviral vectors during gene transfer in the brain. Kajiwara K, et al. **Hum Gene Ther** 1997 Feb 10;8(3):253–65
Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Kaplan JM, et al. **Hum Gene Ther** 1997 Jan 1;8(1):45–56
Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Kaplan JM, et al. **Hum Gene Ther** 1997 Jun 10;8(9):1095–104
Exogenous surfactant enhances the delivery of recombinant adenoviral vectors to the lung. Katkin JP, et al. **Hum Gene Ther** 1997 Jan 20;8(2):171–6
Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC–deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter. Kiwaki K, et al. **Hum Gene Ther** 1996 May 1;7(7):821–30
Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates. Kucharczuk JC, et al. **Hum Gene Ther** 1996 Dec 1;7(18):2225–33
Vasomotor dysfunction early after exposure of normal rabbit arteries to an adenoviral vector. Lafont A, et al. **Hum Gene Ther** 1997 Jun 10;8(9):1033–40
Genetic immunotherapy of established tumors with adenovirus–murine granulocyte–macrophage colony–stimulating factor. Lee CT, et al. **Hum Gene Ther** 1997 Jan 20;8(2):187–93
Enhanced distribution of adenovirus–mediated gene transfer to lung parenchyma by perfluorochemical liquid. Lisby DA, et al. **Hum Gene Ther** 1997 May 20;8(8):919–28
Efficient adenovirus–mediated ectopic gene expression of human lipoprotein lipase in human hepatic (HepG2) cells. Liu G, et al. **Hum Gene Ther** 1997 Jan 20;8(2):205–14
Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Magovern CJ, et al. **Hum Gene Ther** 1997 Jan 20; 8(2):215–27
Two–step gene transfer using an adenoviral vector carrying the CD4 gene and human immunodeficiency viral vectors. Miyake K, et al. **Hum Gene Ther** 1996 Dec 1;7(18):2281–6
Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Morral N, et al. **Hum Gene Ther** 1997 Jul 1;8(10):1275–86
Adenovirus–mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo–infected pancreatic islet allografts and isografts. Muruve DA, et al. **Hum Gene Ther** 1997 May 20;8(8):955–63
Adenovirus–mediated hepatic gene transfer in mice: comparison of intravascular and biliary administration. Peeters MJ, et al. **Hum Gene Ther** 1996 Sep 10;7(14):1693–9
Adenovirus–mediated gene transfer of viral interleukin–10 inhibits the immune response to both alloantigen and adenoviral antigen. Qin L, et al. **Hum Gene Ther** 1997 Jul 20;8(11):1365–74
Delayed–type hypersensitivity response to high doses of adenoviral vectors. Russi TJ, et al. **Hum Gene Ther** 1997 Feb 10;8(3):323–30
Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Shi Q, et al. **Hum Gene Ther** 1997 Mar 1;8(4):403–10
Intracranial administration of adenovirus expressing HSV–TK in combination with ganciclovir produces a dose–dependent, self–limiting inflammatory response. Smith JG, et al. **Hum Gene Ther** 1997 May 20;8(8):943–54
Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Song W, et al. **Hum Gene Ther** 1997 Jul 1; 8(10):1207–17
A phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma. Stewart AK, et al. **Hum Gene Ther** 1997 Jul 20;8(11):1403–14
Liver–directed gene transfer in non–human primates. Sullivan DE, et al. **Hum Gene Ther** 1997 Jul 1; 8(10):1195–206
Dendritic cells transduced with an adenoviral vector encoding a model tumor–associated antigen for tumor vaccination. Wan Y, et al. **Hum Gene Ther** 1997 Jul 20; 8(11):1355–63
Safety of adenovirus–mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates. Wilmott RW, et al. **Hum Gene Ther** 1996 Feb 10;7(3):301–18
Adenovirus–mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Yee D, et al. **Hum Gene Ther** 1996 Jun 20; 7(10):1251–7
High–efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Zeng M, et al. **Hum Gene Ther** 1997 Jun 10;8(9):1025–32
Anti–T cell receptor antibody prolongs transgene expression and reduces lung inflammation after adenovirus–mediated gene transfer. Zsengellér ZK, et al. **Hum Gene Ther** 1997 May 20;8(8):935–41
Targeted complementation of MHC class II deficiency by intrathymic delivery of recombinant adenoviruses. Rooke R, et al. **Immunity** 1997 Jul;7(1):123–34

Gene transfer into mouse embryonic stem cell-derived cardiac myocytes mediated by recombinant adenovirus. **Rust EM**, et al. **In Vitro Cell Dev Biol Anim** 1997 Apr; 33(4):270–6

Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Hall SJ, et al. **Int J Cancer** 1997 Jan 17;70(2):183–7

Expression and immunogenicity in rats of recombinant adenovirus 5 DNA plasmids and vaccinia virus containing the HTLV-I env gene. Kazanji M, et al. **Int J Cancer** 1997 Apr 10;71(2):300–7

Transfection of neonatal rat cochlear cells in vitro with an adenovirus vector. Dazert S, et al. **Int J Dev Neurosci** 1997 Jul;15(4–5):595–600

Viral-mediated gene transfer in the cochlea. Weiss MA, et al. **Int J Dev Neurosci** 1997 Jul;15(4–5):577–83

Tumor necrosis factor alpha induces the adenovirus early 3 promoter by activation of NF-kappaB. Deryckere F, et al. **J Biol Chem** 1996 Nov 22;271(47):30249–55

Dissociation of the protein primer and DNA polymerase after initiation of adenovirus DNA replication. King AJ, et al. **J Biol Chem** 1997 Sep 26;272(39):24617–23

Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. Takahashi M, et al. **J Biol Chem** 1996 Oct 25;271(43):26536–42

The Oct-1 POU homeodomain stabilizes the adenovirus preinitiation complex via a direct interaction with the priming protein and is displaced when the replication fork passes. van Leeuwen HC, et al. **J Biol Chem** 1997 Feb 7;272(6):3398–405

Detection of group C adenovirus DNA in small-cell lung cancer with the nested polymerase chain reaction. Kuwano K, et al. **J Cancer Res Clin Oncol** 1997;123(7):377–82

Assessment of androgen receptor function in genital skin fibroblasts using a recombinant adenovirus to deliver an androgen-responsive reporter gene [published erratum appears in J Clin Endocrinol Metab 1997 Aug;82(8):2670] McPhaul MJ, et al. **J Clin Endocrinol Metab** 1997 Jun; 82(6):1944–8

Potentiation of beta-adrenergic signaling by adenoviral-mediated gene transfer in adult rabbit ventricular myocytes. Drazner MH, et al. **J Clin Invest** 1997 Jan 15;99(2):288–96

Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. Kim S, et al. **J Clin Invest** 1997 Sep 1;100(5):1006–14

Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. Zabner J, et al. **J Clin Invest** 1997 Sep 1; 100(5):1144–9

E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections. Leppard KN. **J Gen Virol** 1997 Sep;78 (Pt 9):2131–8 (66 ref.)

Complete DNA sequence of canine adenovirus type 1. Morrison MD, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):873–8

A cis-acting element 7 bp upstream of the ESF-1-binding motif is involved in E1A 13S autoregulation of the adenovirus 12 TS2 promoter. Pützer BM, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):879–91

Interleukin-10 immunoadhesin production by a replication-defective adenovirus. Anglade E, et al. **J Immunol Methods** 1997 Mar 10;202(1):41–8

Neutralization of endogenous interferon-beta increases the efficiency of adenoviral vector-mediated gene transduction. Dong Z, et al. **J Interferon Cytokine Res** 1997 Jul;17(7):401–7

Delivery of human interferon-gamma via gene transfer in vitro: prolonged expression and induction of macrophage antimicrobial activity. Stoeckle MY, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):1015–9

Adenovirus-mediated gene transfer of a heat shock protein 70 (hsp 70i) protects against simulated ischemia. Mestril R, et al. **J Mol Cell Cardiol** 1996 Dec;28(12):2351–8

Adenovirus-mediated overexpression of human transforming growth factor-beta 1 in rat cardiac fibroblasts, myocytes and smooth muscle cells. Villarreal FJ, et al. **J Mol Cell Cardiol** 1996 Apr;28(4):735–42

Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. Rosenfeld ME, et al. **J Mol Med** 1996 Aug; 74(8):455–62

Adenoviral vector-directed expression of neurotrophin-3 in rat dorsal root ganglion explants results in a robust neurite outgrowth response. Dijkhuizen PA, et al. **J Neurobiol** 1997 Aug;33(2):172–84

An adenoviral vector-based system to study neuronal gene expression: analysis of the rat tyrosine hydroxylase promoter in cultured neurons. Robert JJ, et al. **J Neurochem** 1997 May;68(5):2152–60

Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers neuroprotection that exceeds the transduced population. Baumgartner BJ, et al. **J Neurosci** 1997 Sep 1; 17(17):6504–11

Adenoviral vector-mediated expression of B-50/GAP-43 induces alterations in the membrane organization of olfactory axon terminals in vivo. Holtmaat AJ, et al. **J Neurosci** 1997 Sep 1;17(17):6575–86

Phenotypic alteration of astrocytes induced by ciliary neurotrophic factor in the intact adult brain, As revealed by adenovirus-mediated gene transfer. Lisovoski F, et al. **J Neurosci** 1997 Oct 1;17(19):7228–36

Adenovirus-mediated gene transfer to the brain: methodological assessment. Peltékian E, et al. **J Neurosci Methods** 1997 Jan;71(1):77–84 (37 ref.)

Adenoviral vector-mediated gene transfer and neurotransplantation: possibilities and limitations in grafting of the fetal rat suprachiasmatic nucleus. van Esseveldt KE, et al. **J Neurosci Methods** 1997 Jan;71(1):113–23

Prevention of motoneuron death by adenovirus-mediated neurotrophic factors. Giménez y Ribotta M, et al. **J Neurosci Res** 1997 May 1;48(3):281–5

Adenovirus-mediated gene transfer into dissociated and explant cultures of rat hippocampal neurons. Wilkemeyer MF, et al. **J Neurosci Res** 1996 Jan 15;43(2):161–74

Adenovirus vector-mediated gene transduction to chondrocytes: in vitro evaluation of therapeutic efficacy of transforming growth factor-beta 1 and heat shock protein 70 gene transduction. Arai Y, et al. **J Rheumatol** 1997 Sep;24(9):1787–95

In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. Evoy D, et al. **J Surg Res** 1997 Apr; 69(1):226–31

Adenoviral thymidine kinase prodrug gene therapy inhibits sarcoma growth in vivo. Ross HM, et al. **J Surg Res** 1997 Jun;70(1):7–11

Adenoviral transfection of isolated pancreatic islets: a study of programmed cell death (apoptosis) and islet function. Weber M, et al. **J Surg Res** 1997 Apr;69(1):23–32

Intracoronary gene transfer of immunosuppressive cytokines to cardiac allografts: method and efficacy of adenovirus-mediated transduction. Brauner R, et al. **J Thorac Cardiovasc Surg** 1997 Jun;113(6):1059–66; discussion 1066–7

Transplantation of genetically marked cardiac muscle cells. Gojo S, et al. **J Thorac Cardiovasc Surg** 1997 Jan; 113(1):10–8

Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. Armentano D, et al. **J Virol** 1997 Mar;71(3):2408–16

Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. Dedieu JF, et al. **J Virol** 1997 Jun;71(6):4626–37

High level of transgene expression in cell cultures and in the mouse by replication-incompetent adenoviruses harboring modified VAI genes. Eloit M, et al. **J Virol** 1997 Jul;71(7):5375–81

Diminishing adenovirus gene expression and viral replication by promoter replacement. Fang B, et al. **J Virol** 1997 Jun; 71(6):4798–803

Construction of adenovirus vectors through Cre-lox recombination. Hardy S, et al. **J Virol** 1997 Mar; 71(3):1842–9

Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. Krasnykh VN, et al. **J Virol** 1996 Oct;70(10):6839–46

Interaction of an adenovirus 14.7-kilodalton protein inhibitor of tumor necrosis factor alpha cytolysis with a new member of the GTPase superfamily of signal transducers. Li Y, et al. **J Virol** 1997 Feb;71(2):1576–82

Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. Lieber A, et al. **J Virol** 1996 Dec;70(12):8782–91

Constitutive retinoid receptors expressed from adenovirus vectors that specifically activate chromosomal target genes required for differentiation of promyelocytic leukemia and teratocarcinoma cells. Lipkin SM, et al. **J Virol** 1996 Oct; 70(10):7182–9

The initiator element of the adenovirus major late promoter has an important role in transcription initiation in vivo. Lu H, et al. **J Virol** 1997 Jan;71(1):102–9

The product of the adenovirus intermediate gene IX is a transcriptional activator. Lutz P, et al. **J Virol** 1997 Jul; 71(7):5102–9

Structure, function, and evolution of adenovirus-associated RNA: a phylogenetic approach. Ma Y, et al. **J Virol** 1996 Aug;70(8):5083–99 (78 ref.)

Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. Mittereder N, et al. **J Virol** 1996 Nov;70(11):7498–509

A single gene encoding the fiber is responsible for variations in virulence in the fowl adenoviruses. Pallister J, et al. **J Virol** 1996 Aug;70(8):5115–22

Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro. Rittner K, et al. **J Virol** 1997 Apr; 71(4):3307–11

Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. Stevenson SC, et al. **J Virol** 1997 Jun;71(6):4782–90

A carboxy-terminal region required by the adenovirus type 9 E4 ORF1 oncoprotein for transformation mediates direct binding to cellular polypeptides. Weiss RS, et al. **J Virol** 1997 Oct;71(10):7873–80

Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. Wickham TJ, et al. **J Virol** 1996 Oct;70(10):6831–8

Adenovirus-mediated gene transfer to ciliated airway epithelia requires prolonged incubation time. Zabner J, et al. **J Virol** 1996 Oct;70(10):6994–7003

Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. Zhou H, et al. **J Virol** 1996 Oct;70(10):7030–8

Gene transfer to the patellar tendon. Gerich TG, et al. **Knee Surg Sports Traumatol Arthrosc** 1997;5(2):118–23

Relationship between the cellular distribution of the alpha(v)beta3/5 integrins and adenoviral infection in salivary glands. Delporte C, et al. **Lab Invest** 1997 Aug; 77(2):167–73

Adenoviral delivery of low-density lipoprotein receptors to hyperlipidemic rabbits: receptor expression modulates high-density lipoproteins. Brown DR, et al. **Metabolism** 1996 Dec;45(12):1447–57

Adenovirus mediated-gene transfer into cardiomyocytes. Kirshenbaum LA. **Mol Cell Biochem** 1997 Jul; 172(1-2):13–21

Novel methods for adenovirus-mediated gene transfer to blood vessels in vivo. Ooboshi H, et al. **Mol Cell Biochem** 1997 Jul;172(1-2):37–46

Control of adenovirus early gene expression: posttranscriptional control mediated by both viral and cellular gene products. Katze MG, et al. **Mol Cell Biol** 1981 Sep;1(9):807–13

Adenovirus-mediated gene transfer of dominant negative ras(asn17) in 3T3L1 adipocytes does not alter insulin-stimulated P13-kinase activity or glucose transport. Gnudi L, et al. **Mol Endocrinol** 1997 Jan;11(1):67–76

Survival, mutagenesis, and host cell reactivation in a Chinese hamster ovary cell ERCC1 knock-out mutant. Rolig RL, et al. **Mutagenesis** 1997 Jul;12(4):277–83

Adenovirus dodecahedron, a new vector for human gene transfer [see comments] Fender P, et al. **Nat Biotechnol** 1997 Jan;15(1):52–6. Comment in: Nat Biotechnol 1997 Jan;15(1):17.

Safe gene vectors made simpler [news; comment] Morsy MA, et al. **Nat Biotechnol** 1997 Jan;15(1):17. Comment on: Nat Biotechnol 1997 Jan;15(1):52–6.

Gene therapy: progress, problems, prospects [news] Blau H, et al. **Nat Med** 1997 Jun;3(6):612–3

Progress of the smart bomb cancer virus [news; comment] Lowe SW. **Nat Med** 1997 Jun;3(6):606–8. Comment on: Nat Med 1997 Jun;3(6):639–45.

Adenovirus mediated gene transfer in organotypic brain slices. Ridoux V, et al. **Neurobiol Dis** 1995 Feb;2(1):49–54

Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors. Douglas JT, et al. **Neuromuscul Disord** 1997 Jul;7(5):284–98 (98 ref.)

Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. Hauser MA, et al. **Neuromuscul Disord** 1997 Jul;7(5):277–83

Labeling neural cells using adenoviral gene transfer of membrane-targeted GFP. Moriyoshi K, et al. **Neuron** 1996 Feb;16(2):255–60

Alteration of GABAA receptor function following gene transfer of the CLC-2 chloride channel. Staley K, et al. **Neuron** 1996 Sep;17(3):543–51

Hypoxanthine-guanine phosphoribosyltransferase (HPRT) expression in the central nervous system of HPRT-deficient mice following adenoviral-mediated gene transfer. Plumb TJ, et al. **Neurosci Lett** 1996 Aug 23; 214(2-3):159–62

Efficient gene expression in mammalian clock pacemaker cell in vitro by an adenovirus vector. Yamazaki N, et al. **Neurosci Lett** 1997 Jan 17;221(2-3):193–6

Preclinical testing of recombinant adenoviral herpes simplex virus-thymidine kinase gene therapy for central nervous system malignancies. Vincent AJ, et al. **Neurosurgery** 1997 Aug;41(2):442–51; discussion 451–2

A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Craig C, et al. **Oncogene** 1997 May 15; 14(19):2283–9

Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Block A, et al. **Pancreas** 1997 Jul;15(1):25–34

Adenovirus-mediated in vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge. Ye X, et al. **Pediatr Res** 1997 Apr; 41(4 Pt 1):527–34

Persistence in muscle of an adenoviral vector that lacks all viral genes. Chen HH, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1645–50

Role of p300-family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection. Cook JL, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13985–90

Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Delporte C, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3268–73

Ultrarapid, highly efficient viral gene transfer to the heart. Donahue JK, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4664–8

Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. Huang S, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22; 94(15):8156–61

Oncogenic potential of the adenovirus E4orf6 protein. Moore M, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;

93(21):11295–301

Adenovirus–mediated gene transfer and expression of human beta–glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. Ohashi T, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18; 94(4):1287–92

Expression of adenoviral E3 transgenes in beta cells prevents autoimmune diabetes. von Herrath MG, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9808–13

Gene transfer by adenovirus in smooth muscle cells. Yu MF, et al. **Respir Physiol** 1996 Aug;105(1–2):155–62

Adenovirus–mediated gene transfer using ex vivo perfusion of the heart graft. Shiraishi M, et al. **Surg Today** 1996; 26(8):624–8

Adenovirus–mediated transfer of tissue–type plasminogen activator gene to human endothelial cells. Sugawara Y, et al. **Surgery** 1997 Jul;122(1):91–100

Viral vector–mediated gene therapy for hemophilia B. Eisensmith RC, et al. **Thromb Haemost** 1997 Jul;78(1):24–30 (81 ref.)

Adenovirus–mediated gene transfer using in–situ perfusion of the liver graft. Shiraishi M, et al. **Transpl Int** 1997; 10(3):202–6

Comparison of adenovirus gene transfer to vascular endothelial cells in cell culture, organ culture, and in vivo. Merrick AF, et al. **Transplantation** 1996 Oct 27; 62(8):1085–9

Ex vivo adenovirus–mediated gene delivery leads to long–term expression in pancreatic islet transplants. Muruve DA, et al. **Transplantation** 1997 Aug 15;64(3):542–6

Viruses and interstitial cystitis: adenovirus genomes cannot be demonstrated in urinary bladder biopsies. Hukkanen V, et al. **Urol Res** 1996;24(4):235–8

Adenovirus–mediated suicide gene therapy for experimental bladder cancer. Sutton MA, et al. **Urology** 1997 Feb; 49(2):173–80

Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Makimura M, et al. **Vaccine** 1996 Jan;14(1):28–36

Functional characterization of the major late promoter of mouse adenovirus type 1. Song B, et al. **Virology** 1997 Aug 18;235(1):109–17

Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences. Xu ZZ, et al. **Virology** 1997 Mar 31;230(1):62–71

Sequence analysis of equine adenovirus 2 hexon and 23K proteinase genes indicates a phylogenetic origin distinct from equine adenovirus 1. Reubel GH, et al. **Virus Res** 1997 Jul;50(1):41–56

[Aerosol administration of a replication defective recombinant adenovirus expressing normal human cDNA–CFTR in the respiratory tractus in patients with cystic fibrosis] Bellon G, et al. **C R Seances Soc Biol Fil** 1996;190(1):109–42 (Eng. Abstr.) **(Fre)**

[Development of adenoviral vectors in gene therapy: application to gene transfer in muscles] Ragot T, et al. **C R Seances Soc Biol Fil** 1996;190(1):13–31 (37 ref.) (Eng. Abstr.) **(Fre)**

[Gene therapy: development of adenovirus vectors] Siegfried W. **Pneumologie** 1996 Dec;50 Suppl 3:860–4 (31 ref.) **(Ger)**

[Expression of the ribozyme gene in the recombinant defective adenovirus genome] Zakharchuk AN, et al. **Mol Biol (Mosk)** 1997 Jan–Feb;31(1):81–5 **(Rus)**

GROWTH & DEVELOPMENT

Managed care for viruses [news] Crystal RG. **Nat Med** 1997 Apr;3(4):383–4

IMMUNOLOGY

Virus–induced apoptosis. Hardwick JM. **Adv Pharmacol** 1997;41:295–336 (337 ref.)

The mechanism of down–regulation of major histocompatibility complex (MHC) class I antigens in highly oncogenic adenovirus 12–transformed cells. Hall KT, et al. **Biochem Soc Trans** 1997 May;25(2):353S

Studies on the down–regulation of major histocompatibility complex class I gene expression in adenovirus–transformed cells. Philpott NJ, et al. **Biochem Soc Trans** 1997 May; 25(2):352S

Cryo–EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. Stewart PL, et al. **EMBO J** 1997 Mar 17;16(6):1189–98

Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Yang Y, et al. **Gene Ther** 1996 May;3(5):412–20

Neonatal cotton rats do not exhibit destructive immune responses to adenoviral vectors. Zepeda M, et al. **Gene Ther** 1996 Nov;3(11):973–9

Circumvention of anti–adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Mack CA, et al. **Hum Gene Ther** 1997 Jan 1; 8(1):99–109

Evasion of apoptosis by DNA viruses. Cuff S, et al. **Immunol Cell Biol** 1996 Dec;74(6):527–37 (137 ref.)

Molecular basis of immune evasion strategies by adenoviruses. Hayder H, et al. **Immunol Cell Biol** 1996 Dec; 74(6):504–12 (138 ref.)

Oral tolerization to adenoviral antigens permits long–term gene expression using recombinant adenoviral vectors. Ilan Y, et al. **J Clin Invest** 1997 Mar 1;99(5):1098–106

Virus–mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. Brossart P, et al. **J Immunol** 1997 Apr 1;158(7):3270–6

Human colorectal cancer (CRC) antigen CO17–1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. Li W, et al. **J Immunol** 1997 Jul 15; 159(2):763–9

Characterization of monoclonal antibodies raised against p300: both p300 and CBP are present in intracellular TBP complexes. Dallas PB, et al. **J Virol** 1997 Feb;71(2):1726–31

Long–lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression. DeMatteo RP, et al. **J Virol** 1997 Jul;71(7):5330–5

Adenovirus–pulsed dendritic cells stimulate human virus–specific T–cell responses in vitro. Smith CA, et al. **J Virol** 1996 Oct;70(10):6733–40

Adenovirus vector–infected cells can escape adenovirus antigen–specific cytotoxic T–lymphocyte killing in vivo. Wadsworth SC, et al. **J Virol** 1997 Jul;71(7):5189–96

Role of viral antigens in destructive cellular immune responses to adenovirus vector–transduced cells in mouse lungs. Yang Y, et al. **J Virol** 1996 Oct;70(10):7209–12

Fathers of the adenovirus vaccines [letter] Gaydos JO, et al. **Mil Med** 1997 Aug;162(8):iii–iv

Safe gene vectors made simpler [news; comment] Morsy MA, et al. **Nat Biotechnol** 1997 Jan;15(1):17. Comment on: Nat Biotechnol 1997 Jan;15(1):52–6.

Long–term protection of chimpanzees against high–dose HIV–1 challenge induced by immunization. Lubeck MD, et al. **Nat Med** 1997 Jun;3(6):651–8

Beneficial use of inactivated porcine adenovirus vaccine and antibody response of young pigs. Kadoi K. **New Microbiol** 1997 Jan;20(1):89–91

Transient immunomodulation with anti–CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus–mediated gene transfer into mouse liver. Kay MA, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4686–91

Subversion of the MHC class I antigen–presentation pathway by adenoviruses and herpes simplex viruses. Burgert HG. **Trends Microbiol** 1996 Mar;4(3):107–12 (61 ref.)

Prevalence of antibodies against respiratory viruses (parainfluenza virus type 3, respiratory syncytial virus, reovirus and adenovirus) in relation to productivity in Syrian Awassi sheep. Giangaspero M, et al. **Trop Anim Health Prod** 1997 May;29(2):83–91

Comparison of the efficacy of replication–defective adenovirus and Nyvac poxvirus as vaccine vectors in mice. Gonin P, et al. **Vaccine** 1996 Aug;14(11):1083–7

ISOLATION & PURIFICATION

Infectious canine hepatitis: detection of canine adenovirus type 1 by polymerase chain reaction. Kiss I, et al. **Acta Vet Hung** 1996;44(2):253–8

Detection of respiratory syncytial virus, parainfluenzavirus 3, adenovirus and rhinovirus sequences in respiratory tract of infants by polymerase chain reaction and hybridization. Freymuth F, et al. **Clin Diagn Virol** 1997 May;8(1):31–40

Analytical anion–exchange HPLC of recombinant type–5 adenoviral particles. Shabram PW, et al. **Hum Gene Ther** 1997 Mar 1;8(4):453–65

Ultrastructure of virus–induced soft–tissue tumours. Levenbook IS, et al. **IARC Sci Publ** 1996;(126):351–63 (27 ref.)

Polymerase chain reaction for detection of guinea pig adenovirus. Pring–Akerblom P, et al. **J Vet Diagn Invest** 1997 Jul;9(3):232–6

Isolation of viruses from clinical specimens in microtitre plates with cells inoculated in suspension. O'Neill HJ, et al. **J Virol Methods** 1996 Dec;62(2):169–78

A case of bronchiolitis obliterans organizing pneumonia associated with adenovirus. Jeon JS, et al. **Korean J Intern Med** 1997 Jan;12(1):70–4

Adenovirus isolation from spleen lymphocytes of apparently healthy pigs. Kadoi K, et al. **New Microbiol** 1997 Jul; 20(3):215–20

Detection and significance of adenoviruses in cases of sudden infant death. Bajanowski T, et al. **Virchows Arch** 1996 May; 428(2):113–8

METABOLISM

Analysis of chicken progesterone receptor function and phosphorylation using an adenovirus–mediated procedure for high–efficiency DNA transfer. Allgood VE, et al. **Biochemistry** 1997 Jan 7;36(1):224–32

Use of west–western blotting for detection of adenovirus receptors. Tarassishin LA, et al. **Biochemistry (Mosc)** 1997 Jan;62(1):38–40

A recombinant adenovirus that directs secretion of biologically active kappa–bungarotoxin from mammalian cells. Gorman S, et al. **Brain Res Mol Brain Res** 1997 Feb; 44(1):143–6

Multimerization of the adenovirus DNA–binding protein is the driving force for ATP–independent DNA unwinding during strand displacement synthesis. Dekker J, et al. **EMBO J** 1997 Mar 17;16(6):1455–63

Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor–specific peptide motifs. Wickham TJ, et al. **Gene Ther** 1995 Dec;2(10):750–6

Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Bellon G, et al. **Hum Gene Ther** 1997 Jan 1;8(1):15–25

Interleukin–2 gene transduction into freshly isolated lung adenocarcinoma cells with adenoviral vectors. Heike Y, et al. **Hum Gene Ther** 1997 Jan 1;8(1):1–14

In vivo correction with recombinant adenovirus of 4–hydroxyphenylpyruvic acid dioxygenase deficiencies in strain III mice. Kubo S, et al. **Hum Gene Ther** 1997 Jan 1;8(1):65–71

Analytical anion–exchange HPLC of recombinant type–5 adenoviral particles. Shabram PW, et al. **Hum Gene Ther** 1997 Mar 1;8(4):453–65

Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Worgall S, et al. **Hum Gene Ther** 1997 Jan 1;8(1):37–44

The adenovirus 12 E1A proteins can bind directly to proteins of the p300 transcription co–activator family, including the CREB–binding protein CBP and p300. Dorsman JC, et al. **J Gen Virol** 1997 Feb;78 (Pt 2):423–6

Structural analysis of the adenovirus type 5 E1B 55–kilodalton–E4orf6 protein complex. Rubenwolf S, et al. **J Virol** 1997 Feb;71(2):1115–23

The activity of cytosolic phospholipase A2 is required for the lysis of adenovirus–infected cells by tumor necrosis factor. Thorne TE, et al. **J Virol** 1996 Dec;70(12):8502–7

Importance of the Ser–132 phosphorylation site in cell transformation and apoptosis induced by the adenovirus type 5 E1A protein. Whalen SG, et al. **J Virol** 1996 Aug; 70(8):5373–83

An adenovirus encoding CuZnSOD protects cultured striatal neurones against glutamate toxicity. Barkats M, et al. **Neuroreport** 1996 Jan 31;7(2):497–501

Immune responses to adenovirus vectors in the nervous system. Wood MJ, et al. **Trends Neurosci** 1996 Nov; 19(11):497–501 (47 ref.)

PATHOGENICITY

Pathogenesis of infection induced by an adenovirus isolated from a goat. Lehmkuhl HD, et al. **Am J Vet Res** 1997 Jun;58(6):608–11

Ultrastructure of virus–induced soft–tissue tumours. Levenbook IS, et al. **IARC Sci Publ** 1996;(126):351–63 (27 ref.)

Early stage of human adenovirus type 12–inoculated retinal tissue of F344 newborn rat. Kato Y, et al. **Pathol Int** 1996 Aug;46(8):548–56

Acute and chronic human adenovirus pneumonia: cellular and extracellular matrix components. Rosman FC, et al. **Pediatr Pathol Lab Med** 1996 May–Jun;16(3):521–41

PHYSIOLOGY

Latent adenoviral infection in follicular bronchiectasis [letter; comment] Teramoto S. **Am J Respir Crit Care Med** 1997 Jun;155(6):2113–4. Comment on: Am J Respir Crit Care Med 1995 Jan;151(1):170–6.

Effect of adenovirus 2 on cellular gene activation in blood–derived monocytes and macrophages. Kristoffersen AK, et al. **APMIS** 1997 May;105(5):402–9

VSV–G–pseudotyped retroviral packaging through adenovirus–mediated inducible gene expression. Yoshida Y, et al. **Biochem Biophys Res Commun** 1997 Mar 17; 232(2):379–82

Quantitative and in vivo activity of adenoviral–producing cells made by cotransduction of a replication–defective adenovirus and a replication–enabling plasmid. Dion LD, et al. **Cancer Gene Ther** 1996 Jul–Aug;3(4):230–7

Adenovirus infection enhances killing of melanoma cells by a mitotoxin. Satyamoorthy K, et al. **Cancer Res** 1997 May 15;57(10):1873–6

Avoidance of immune response prolongs expression of genes delivered to the adult rat myocardium by replication–defective adenovirus. Quiñones MJ, et al. **Circulation** 1996 Sep 15;94(6):1394–401

Gene transfer to ex vivo stored corneas. Fehervari Z, et al. **Cornea** 1997 Jul;16(4):459–64

The E1A N terminus (aa 1–29) of the highly oncogenic adenovirus type 12 harbours a trans–activation function not detectable in the non–oncogenic serotype 2. Lipinski KS, et al. **J Gen Virol** 1997 Feb;78 (Pt 2):413–21

Inflammatory damage following first–generation replication–defective adenovirus controlled by anti–LFA–1. Guérette B, et al. **J Leukoc Biol** 1997 Apr; 61(4):533–8

Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. Bruder JT, et al. **J Virol** 1997 Oct;71(10):7623–8

Integrin alpha5beta1–mediated adenovirus infection is enhanced by the integrin–activating antibody TS2/16. Davison E, et al. **J Virol** 1997 Aug;71(8):6204–7

Bipartite structure and functional independence of adenovirus type 5 packaging elements. Schmid SI, et al. **J Virol** 1997 May;71(5):3375–84

ULTRASTRUCTURE

Cryo–EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. Stewart PL, et al. **EMBO J** 1997 Mar 17;16(6):1189–98

Maximum-entropy three-dimensional reconstruction with deconvolution of the contrast transfer function: a test application with adenovirus. Skoglund U, et al. **J Struct Biol** 1996 Nov-Dec;117(3):173-88

Electron microscopic demonstration of an adenovirus in the hepatocytes of birds experimentally infected with hydropericardium syndrome. Chandra R, et al. **Vet Rec** 1997 Jan 18;140(3):70-1

ADENOVIRIDAE INFECTIONS

Co-occurring adenoviral keratitis and hemorrhagic cystitis. A case report. Basti S, et al. **Cornea** 1996 May;15(3):317-9

The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. Krajcsi P, et al. **J Virol** 1996 Aug;70(8):4904-13

[Adenovirus CNS infections] Kaji M, et al. **Nippon Rinsho** 1997 Apr;55(4):876-9 (11 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Latent adenoviral infection in follicular bronchiectasis [letter; comment] Teramoto S. **Am J Respir Crit Care Med** 1997 Jun;155(6):2113-4. Comment on: Am J Respir Crit Care Med 1995 Jan;151(1):170-6.

Parotid enlargement due to adenovirus infection in patient with human immunodeficiency virus infection. Duarte MI, et al. **Rev Soc Bras Med Trop** 1996 Sep-Oct;29(5):503-6

DIAGNOSIS

A 5-year evaluation of the adenoclone test for the rapid diagnosis of adenovirus from conjunctival swabs. Wiley LA, et al. **Cornea** 1996 Jul;15(4):363-7

Rapid detection and serotyping of adenovirus by direct immunofluorescence. Wood SR, et al. **J Med Virol** 1997 Mar;51(3):198-201

A case of bronchiolitis obliterans organizing pneumonia associated with adenovirus. Jeon JS, et al. **Korean J Intern Med** 1997 Jan;12(1):70-4

Adenovirus and respiratory syncytial virus in chronic sinusitis using polymerase chain reaction. Ramadan HH, et al. **Laryngoscope** 1997 Jul;107(7):923-5

Rapid diagnosis of adenoviral conjunctivitis on conjunctival swabs by 10-minute immunochromatography. Uchio E, et al. **Ophthalmology** 1997 Aug;104(8):1294-9

[Enteral adenovirus and infantile intussusception] Horváth M, et al. **Orv Hetil** 1996 Sep 1;137(35):1933-4 (Eng. Abstr.) **(Hun)**

DRUG THERAPY

Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Eck SL, et al. **Hum Gene Ther** 1996 Aug 1;7(12):1465-82

EPIDEMIOLOGY

Adenovirus gastroenteritis [letter] Baskin E, et al. **Indian Pediatr** 1995 Oct;32(10):1128-9

Outbreak of adenovirus 35 pneumonia among adult residents and staff of a chronic care psychiatric facility. Sanchez MP, et al. **J Infect Dis** 1997 Sep;176(3):760-3

GENETICS

Expression of human cholesterol 7alpha-hydroxylase in atherosclerosis-susceptible mice via adenovirus infection. Moore GL, et al. **Biochem J** 1997 Jun 15;324 (Pt 3):863-7

IMMUNOLOGY

Evidence for transudation of specific antibody into the middle ears of parenterally immunized chinchillas after an upper respiratory tract infection with adenovirus. Bakaletz LO, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):223-5

Humoral immune response of chicks to different clinical isolates of avian adenovirus type-1. Maiti NK, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):59-62

Evasion of apoptosis by DNA viruses. Cuff S, et al. **Immunol Cell Biol** 1996 Dec;74(6):527-37 (137 ref.)

Adenovirus infection in cystic fibrosis patients: implications for the use of adenoviral vectors for gene transfer. Rosenecker J, et al. **Infection** 1996 Jan-Feb;24(1):5-8

Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. Schulick AH, et al. **J Clin Invest** 1997 Jan 15;99(2):209-19

Lack of effect of mouse adenovirus type 1 infection on cell surface expression of major histocompatibility complex class I antigens. Kring SC, et al. **J Virol** 1996 Aug; 70(8):5495-502

Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. Smith CA, et al. **J Virol** 1996 Oct;70(10):6733-40

Previous enteric adenovirus infection does not protect against subsequent symptomatic infection: longitudinal follow-up of eight infants. Unicomb LE, et al. **Microbiol Immunol** 1996;40(2):161-8

The implications for childhood leukemia of infection with adenovirus. Dorak MT. **Trends Microbiol** 1996 Feb; 4(2):60-3 (52 ref.)

How viruses hide from T cells. McMichael A. **Trends Microbiol** 1997 Jun;5(6):211-2; discussion 212-3 (20 ref.)

METABOLISM

Recombinant adenoviral vector disrupts surfactant homeostasis in mouse lung. Zsengellér ZK, et al. **Hum Gene Ther** 1997 Jul 20;8(11):1331-44

MICROBIOLOGY

An ocular model of Adenovirus type 5 infection in the rabbit. De Hauwere B, et al. **Bull Soc Belge Ophtalmol** 1995; 259:33-42

PATHOLOGY

The oncogenic potential of eleven avian adenovirus strains. Dhillon AS, et al. **Avian Dis** 1997 Jan-Mar;41(1):247-51

Adenovirus infection of the cornea causes histopathologic changes in the lacrimal gland. Wood RL, et al. **Curr Eye Res** 1997 May;16(5):459-66

The behavior of the coiled body in cells infected with adenovirus in vitro. Rodrigues SH, et al. **Mol Biol Rep** 1996;23(3-4):183-9

Fractal analysis of lung alveoli during the acute phase vs. repair phase of an adenoviral infection in canines. Tinajero JP, et al. **Res Commun Mol Pathol Pharmacol** 1997 Mar; 95(3):275-85

Experimental infections with some pneumotropic viruses in the mouse. Note I. Virological and pathomorphological aspects of the associated infections with influenza virus, adenovirus and respiratory syncytial virus. Petica M, et al. **Rom J Virol** 1995 Jan-Jun;46(1-2):21-32

Adenoviral infection of thyroid cells: a rationale for gene therapy for metastatic thyroid carcinoma. Zeiger MA, et al. **Surgery** 1996 Dec;120(6):921-5

PHYSIOPATHOLOGY

Adenovirus infection enhances killing of melanoma cells by a mitotoxin. Satyamoorthy K, et al. **Cancer Res** 1997 May 15;57(10):1873-6

Experimental infections with some pneumotropic viruses in the mouse. Note II. Virological and pathomorphological aspects of experimental associated infections with parainfluenza virus, adenovirus and respiratory syncytial virus in the mouse. Petica M, et al. **Rom J Virol** 1995 Jul-Dec;46(3-4):145-60

Adenovirus infection of the human intestinal allograft: a case report. Levy MF, et al. **Transplant Proc** 1996 Oct; 28(5):2786-7

PREVENTION & CONTROL

Beneficial use of inactivated porcine adenovirus vaccine and antibody response of young pigs. Kadoi K. **New Microbiol** 1997 Jan;20(1):89-91

TRANSMISSION

Transfer of adenovirus infection from patient to anaesthetist during emergency tracheal intubation. Sidebotham D, et al. **Anaesth Intensive Care** 1997 Feb;25(1):83-5

VETERINARY

Pathogenesis of infection induced by an adenovirus isolated from a goat. Lehmkuhl HD, et al. **Am J Vet Res** 1997 Jun;58(6):608-11

DNA in situ hybridization for the rapid diagnosis of massive necrotizing avian adenovirus hepatitis and pancreatitis in chicks. Goodwin MA, et al. **Avian Dis** 1996 Oct-Dec; 40(4):828-31

Variations in response of four lines of ring-necked pheasants to infection with marble spleen disease virus. Kunze LS, et al. **Avian Dis** 1996 Apr-Jun;40(2):306-11

Adenovirus-induced inclusion body hepatitis in four-day-old broiler breeders. Pilkington P, et al. **Avian Dis** 1997 Apr-Jun;41(2):472-4

Ultrastructure of virus-induced soft-tissue tumours. Levenbook IS, et al. **IARC Sci Publ** 1996;(126):351-63 (27 ref.)

Lesions in lambs experimentally infected with ovine adenovirus serotype 6 and Pasteurella haemolytica. Cutlip RC, et al. **J Vet Diagn Invest** 1996 Jul;8(3):296-303

Polymerase chain reaction for detection of guinea pig adenovirus. Pring-Akerblom P, et al. **J Vet Diagn Invest** 1997 Jul;9(3):232-6

Asymptomatic adenoviral respiratory tract infection in guinea pigs. Crippa L, et al. **Lab Anim Sci** 1997 Apr; 47(2):197-9

Beneficial use of inactivated porcine adenovirus vaccine and antibody response of young pigs. Kadoi K. **New Microbiol** 1997 Jan;20(1):89-91

Immunopathogenesis and physical maps of fowl adenovirus serotype 9. Erny KM, et al. **Res Vet Sci** 1996 Sep; 61(2):174-5

Electron microscopic evidence for infection of splenic dendritic cells by adenovirus in psittacine birds. Gómez-Villamandos JC, et al. **Res Virol** 1995 Nov-Dec; 146(6):389-395

Egg Drop syndrome 76 in Bolivia. Bishop SC, et al. **Trop Anim Health Prod** 1996 Aug;28(3):199-206

Isolation and identification of adenoviruses from ostriches (Struthio camelus). Gough RE, et al. **Vet Rec** 1997 Apr 12;140(15):402-3

[Adenovirus-induced pneumonia in two guinea pigs] Breuer W, et al. **Berl Munch Tierarztl Wochenschr** 1997 Feb; 110(2):51-3 (Eng. Abstr.) **(Ger)**

VIROLOGY

Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. de Oliveira CB, et al. **Antiviral Res** 1996 Jul;31(3):165-72

Structural features unique to enteric adenoviruses. Brown M, et al. **Arch Virol Suppl** 1996;12:301-7 (46 ref.)

A 5-year evaluation of the adenoclone test for the rapid diagnosis of adenovirus from conjunctival swabs. Wiley LA, et al. **Cornea** 1996 Jul;15(4):363-7

Evasion of apoptosis by DNA viruses. Cuff S, et al. **Immunol Cell Biol** 1996 Dec;74(6):527-37 (137 ref.)

Neonatal adenoviral pneumonia--report of three autopsy cases. Kim JS, et al. **J Korean Med Sci** 1997 Apr; 12(2):146-50

Seroepidemiology of new AIDS-associated adenoviruses among the San Francisco Men's Health Study. Crawford-Miksza L, et al. **J Med Virol** 1996 Nov; 50(3):230-6

Comparison of primer sets for detection of fecal and ocular adenovirus infection using the polymerase chain reaction. Hussain MA, et al. **J Med Virol** 1996 Jul;49(3):187-94

Molecular epidemiology of adenovirus acute lower respiratory infections of children in the south cone of South America (1991-1994). Kajon AE, et al. **J Med Virol** 1996 Feb;48(2):151-6

Molecular epidemiology of adenovirus types 3 and 7 isolated from children with pneumonia in Beijing. Li QG, et al. **J Med Virol** 1996 Jul;49(3):170-7

A case of bronchiolitis obliterans organizing pneumonia associated with adenovirus. Jeon JS, et al. **Korean J Intern Med** 1997 Jan;12(1):70-4

Adenovirus conjunctivitis mimics preseptal and orbital cellulitis in young children. Ruttum MS, et al. **Pediatr Infect Dis J** 1996 Mar;15(3):266-7

ADENOVIRUS EARLY PROTEINS

METABOLISM

The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function. Nevels M, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1206-11

ADENOVIRUS EARLY REGION TRANSFORMING PROTEINS see **ADENOVIRUS EARLY PROTEINS**

ADENOVIRUS E1 PROTEINS

DEFICIENCY

Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. Dedieu JF, et al. **J Virol** 1997 Jun;71(6):4626-37

GENETICS

Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Amalfitano A, et al. **Gene Ther** 1997 Mar;4(3):258-63

Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Wang Q, et al. **Gene Ther** 1997 May;4(5):393-400

Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. Gao GP, et al. **J Virol** 1996 Dec;70(12):8934-43

Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. Hehir KM, et al. **J Virol** 1996 Dec; 70(12):8459-67

Repression of cyclin D1 expression does not contribute to initiation or maintenance of cell transformation by adenovirus type 5 E1. Kranenburg O, et al. **J Virol** 1996 Nov;70(11):7804-10

Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro. Rittner K, et al. **J Virol** 1997 Apr; 71(4):3307-11

Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. Zhou H, et al. **J Virol** 1996 Oct;70(10):7030-8

Tumour suppressive properties of the adenovirus 5 E1A oncogene. Mymryk JS. **Oncogene** 1996 Oct 17;13(8):1581-9 (153 ref.)

ADENOVIRUS E1A PROTEIN DOMAIN 3 see **ADENOVIRUS E1A PROTEINS**

ADENOVIRUS E1A PROTEINS

BIOSYNTHESIS

Adenovirus E1A upregulates interleukin-8 expression induced by endotoxin in pulmonary epithelial cells. Keicho

ADENOVIRUS E1A PROTEINS

N, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):L1046–52

Bent DNA in the human adenovirus type 2 E1A enhancer is an architectural element for transcription stimulation. Ohyama T. **J Biol Chem** 1996 Nov 1;271(44):27823–8

CHEMISTRY

In vitro analysis of the E1A–homologous sequences of RIZ. Buyse IM, et al. **J Virol** 1997 Aug;71(8):6200–3

The adenovirus E1A repression domain disrupts the interaction between the TATA binding protein and the TATA box in a manner reversible by TFIIB. Song CZ, et al. **Mol Cell Biol** 1997 Apr;17(4):2186–93

GENETICS

Antisense E1AF transfection restrains oral cancer invasion by reducing matrix metalloproteinase activities. Hida K, et al. **Am J Pathol** 1997 Jun;150(6):2125–32

Adenovirus E1A gene dysregulates ICAM-1 expression in transformed pulmonary epithelial cells. Keicho N, et al. **Am J Respir Cell Mol Biol** 1997 Jan;16(1):23–30

Activation of the p21(Waf1/Cip1) promoter by the ets oncogene family transcription factor E1AF. Funaoka K, et al. **Biochem Biophys Res Commun** 1997 Jul 9;236(1):79–82

Immortalization of primary epithelial cells by E1A 12S requires late, second exon–encoded functions in addition to complex formation with pRB and p300. Gopalakrishnan S, et al. **Cell Growth Differ** 1997 May;8(5):541–51

Adenovirus E1a interferes with expression of vaccinia viral genes. Strauss D, et al. **Gene** 1997 Jan 15;184(2):279–84

E1A RNA transcripts amplify adenovirus–mediated tumor reduction. Dion LD, et al. **Gene Ther** 1996 Nov; 3(11):1021–5

Safety studies of the intraperitoneal injection of E1A—liposome complex in mice. Xing X, et al. **Gene Ther** 1997 Mar;4(3):238–43

Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Kaneko Y, et al. **Genes Chromosomes Cancer** 1996 Feb;15(2):115–21

Cell lines expressing the adenovirus E1A 12S protein derived from rat sublingual glands [letter] Culp DJ. **In Vitro Cell Dev Biol Anim** 1996 Mar;32(3):123–6

Establishment of an E1A–immortalized retinal cell culture [letter] Seigel GM. **In Vitro Cell Dev Biol Anim** 1996 Feb; 32(2):66–8

Mechanism of E1A–induced transforming growth factor–beta (TGF–beta) resistance in mouse keratinocytes involves repression of TGF–beta type II receptor transcription. Kim DH, et al. **J Biol Chem** 1997 Jan 3; 272(1):688–94

Degradation of topoisomerase IIalpha during adenovirus E1A–induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. Nakajima T, et al. **J Biol Chem** 1996 Oct 4;271(40):24842–9

A cis–acting element 7 bp upstream of the ESF–1–binding motif is involved in E1A 13S autoregulation of the adenovirus 12 TS2 promoter. Pütter BM, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):879–91

Restoration of interferon responses of adenovirus E1A–expressing HT1080 cell lines by overexpression of p48 protein. Leonard GT, et al. **J Virol** 1997 Jul; 71(7):5095–101

Distinct domains of adenovirus E1A interact with specific cellular factors to differentially modulate human immunodeficiency virus transcription. Parker SF, et al. **J Virol** 1997 Mar;71(3):2004–12

The viral oncoprotein E1A blocks transforming growth factor beta–mediated induction of p21/WAF1/Cip1 and p15/INK4B. Datto MB, et al. **Mol Cell Biol** 1997 Apr; 17(4):2030–7

The adenovirus E1A–regulated transcription factor E4F is generated from the human homolog of nuclear factor phiAP3. Fernandes ER, et al. **Mol Cell Biol** 1997 Apr; 17(4):1890–903

Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Chang JY, et al. **Oncogene** 1996 Oct 3;13(7):1405–12

Induction of a complex between rasGAP and a novel 110 kD protein is required for immortalization of primary epithelial cells by the E1A 12S oncoprotein of adenovirus. Gopalakrishnan S, et al. **Oncogene** 1996 Dec 19; 13(12):2659–69

The growth–inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by E1a and Ras. Hansen RS, et al. **Oncogene** 1996 Sep 5;13(5):995–1007

Carcinoma cell lines become sensitive to DNA–damaging agents by the expression of the adenovirus E1A gene. Sánchez–Prieto R, et al. **Oncogene** 1996 Sep 5; 13(5):1083–92

Inhibition of p53–mediated transactivation and cell cycle arrest by E1A through its p300/CBP–interacting region. Somasundaram K, et al. **Oncogene** 1997 Mar 6; 14(9):1047–57

SV40 and adenovirus may act as cocarcinogens by downregulating glutathione S–transferase expression. Sompayrac L. **Virology** 1997 Jun 23;233(1):130–5

Spontaneous occurrence of early region 1A reiteration mutants of type 5 adenovirus in persistently infected human T–lymphocytes. Tang Q, et al. **Virology** 1997 Apr 14; 230(2):281–91

[Degradation of topoisomerase II alpha precedes nuclei degeneration during adenovirus E1A–induced apoptosis and is mediated by the activation of the ubiquitin dependent proteolysis system] Nakajima T. **Nippon Rinsho** 1996 Jul; 54(7):1828–35 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Transcription factor p91/stat1alpha is constitutively activated and localizes in the nucleus of rat embryonal fibroblasts transformed with E1A and Ha–ras oncogenes] Pospelov VA, et al. **Dokl Akad Nauk** 1996 May; 348(2):261–4 **(Rus)**

IMMUNOLOGY

Characterization of monoclonal antibodies raised against p300: both p300 and CBP are present in intracellular TBP complexes. Dallas PB, et al. **J Virol** 1997 Feb;71(2):1726–31

Peptide vaccination can lead to enhanced tumor growth through specific T–cell tolerance induction. Toes RE, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7855–60

Susceptibility to natural killer cells and down regulation of MHC class I expression in adenovirus 12 transformed cells are regulated by different E1A domains. Huvent I, et al. **Virus Res** 1996 Dec;45(2):123–34

METABOLISM

Retinoid–dependent transcription: the RAR/RXR–TBP–EIA/EIA–LA connection. Meyer M, et al. **Biochem Soc Symp** 1996;62:97–109 (50 ref.)

The transcriptional co–activator proteins p300 and CBP stimulate adenovirus E1A conserved region 1 transactivation independent of a direct interaction. Mannervik M, et al. **FEBS Lett** 1997 Sep 1;414(1):111–6

Involvement of co–activator p300 in the transcriptional regulation of the HER–2/neu gene. Chen H, et al. **J Biol Chem** 1997 Mar 7;272(10):6101–4

mUBC9, a novel adenovirus E1A–interacting protein that complements a yeast cell cycle defect. Hateboer G, et al. **J Biol Chem** 1996 Oct 18;271(42):25906–11

Roles of p300, pocket proteins, and hTBP in E1A–mediated transcriptional regulation and inhibition of p53 transactivation activity. Sang N, et al. **J Cell Biochem** 1997 Sep 1;66(3):277–85

Extreme N terminus of E1A oncoprotein specifically associates with a new set of cellular proteins. Sang N, et al. **J Cell Physiol** 1997 Feb;170(2):182–91

The adenovirus 12 E1A proteins can bind directly to proteins of the p300 transcription co–activator family, including the CREB–binding protein CBP and p300. Dorsman JC, et al. **J Gen Virol** 1997 Feb;78 (Pt 2):423–6

The transactivation domain of adenovirus E1A interacts with the C terminus of human TAF(II)135. Mazzarelli JM, et al. **J Virol** 1997 Oct;71(10):7978–83

Importance of the Ser–132 phosphorylation site in cell transformation and apoptosis induced by the adenovirus type 5 E1A protein. Whalen SG, et al. **J Virol** 1996 Aug; 70(8):5373–83

The adenovirus E1A–regulated transcription factor E4F is generated from the human homolog of nuclear factor phiAP3. Fernandes ER, et al. **Mol Cell Biol** 1997 Apr; 17(4):1890–903

A novel E1A domain mediates skeletal–muscle–specific enhancer repression independently of pRB and p300 binding. Sandmöller A, et al. **Mol Cell Biol** 1996 Oct; 16(10):5846–56

The adenovirus E1A repression domain disrupts the interaction between the TATA binding protein and the TATA box in a manner reversible by TFIIB. Song CZ, et al. **Mol Cell Biol** 1997 Apr;17(4):2186–93

Viral transactivators E1A and VP16 interact with a large complex that is associated with CTD kinase activity and contains CDK8. Gold MO, et al. **Nucleic Acids Res** 1996 Oct 1;24(19):3771–7

Basal transcription factors TBP and TFIIB and the viral coactivator E1A 13S bind with distinct affinities and kinetics to the transactivation domain of NF–kappaB p65. Paal K, et al. **Nucleic Acids Res** 1997 Mar 1;25(5):1050–5

The tumor suppression activity of E1A in HER–2/neu–overexpressing breast cancer. Chang JY, et al. **Oncogene** 1997 Feb 6;14(5):561–8

Mapping of adenovirus 5 E1A domains responsible for suppression of neu–mediated transformation via transcriptional repression of neu. Chen H, et al. **Oncogene** 1997 Apr 24;14(16):1965–71

The HMG–box transcription factor HBP1 is targeted by the pocket proteins and E1A. Lavender P, et al. **Oncogene** 1997 Jun 5;14(22):2721–8

Inhibition of p53–mediated transactivation and cell cycle arrest by E1A through its p300/CBP–interacting region. Somasundaram K, et al. **Oncogene** 1997 Mar 6; 14(9):1047–57

Role of p300–family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection. Cook JL, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13985–90

Transcriptional coactivator cAMP response element binding protein mediates induction of the human proliferating cell nuclear antigen promoter by the adenovirus E1A oncoprotein. Lee BH, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4481–6

Mutations in CR1 of E1A 12S yield dominant negative suppressors of immortalization and the lytic cycle. Malladi A, et al. **Virology** 1997 Jun 23;233(1):51–62

Interaction of mouse adenovirus type 1 early region 1A protein with cellular proteins pRb and p107. Smith K, et al. **Virology** 1996 Oct 1;224(1):184–97

The adenoviral transcription factor, E1A 13S, trans–activates the human tumor necrosis factor–alpha promoter. Rhoades KL, et al. **Virus Res** 1996 Jan;40(1):65–74

PHARMACOLOGY

Adenovirus E1A 13S gene product upregulates tumor necrosis factor gene. Metcalf JP. **Am J Physiol** 1996 Apr; 270(4 Pt 1):L535–40

E1A–induced immortalization of rat type II alveolar epithelial cells. Pasternack M, et al. **Exp Lung Res** 1996 Sep–Oct;22(5):525–39

Chemosensitization of HER–2/neu–overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Ueno NT, et al. **Oncogene** 1997 Aug 18;15(8):953–60

PHYSIOLOGY

Downregulation of major histocompatibility complex class I expression and susceptibility to natural killer cells in cells transformed with the oncogenic adenovirus 12 are regulated by different E1A domains. Huvent I, et al. **Cancer Detect Prev** 1997;21(1):12–21

A common mechanism underlying the E1A repression and the cAMP stimulation of the H ferritin transcription. Bevilacqua MA, et al. **J Biol Chem** 1997 Aug 15; 272(33):20736–41

Adenovirus E1A inhibits cardiac myocyte–specific gene expression through its amino terminus. Bishopric NH, et al. **J Biol Chem** 1997 Aug 15;272(33):20584–94

The E1A N terminus (aa 1–29) of the highly oncogenic adenovirus type 12 harbours a trans–activation function not detectable in the non–oncogenic serotype 2. Lipinski KS, et al. **J Gen Virol** 1997 Feb;78 (Pt 2):413–21

p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. Chiou SK, et al. **J Virol** 1997 May;71(5):3515–25

Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis. Querido E, et al. **J Virol** 1997 May;71(5):3526–33

Phosphorylation within the transactivation domain of adenovirus E1A protein by mitogen–activated protein kinase regulates expression of early region 4. Whalen SG, et al. **J Virol** 1997 May;71(5):3545–53

Two transcription factors, E1AF and N–myc, correlate with the invasiveness of neuroblastoma cell lines. Taguchi K, et al. **Jpn J Cancer Res** 1997 Apr;88(4):394–400

Adenovirus E1A specifically blocks SWI/SNF–dependent transcriptional activation. Miller ME, et al. **Mol Cell Biol** 1996 Oct;16(10):5737–43

Expression of E1A in terminally differentiated muscle cells reactivates the cell cycle and suppresses tissue–specific genes by separable mechanisms. Tiainen M, et al. **Mol Cell Biol** 1996 Oct;16(10):5302–12

A c–Fos– and E1A–interacting component of the tissue factor basal promoter complex mediates synergistic activation of transcription by transforming growth factor–beta1. Felts SJ, et al. **Oncogene** 1997 Apr 10; 14(14):1679–85

Human cytomagalovirus IE1 and IE2 proteins are mutagenic and mediate "hit–and–run" oncogenic transformation in cooperation with the adenovirus E1A proteins. Shen Y, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3341–5

Effects of adenovirus E1A protein on interferon–signaling. Leonard GT, et al. **Virology** 1996 Oct 1;224(1):25–33

ADENOVIRUS E1B 19K PROTEIN see **ADENOVIRUS E1B PROTEINS**

ADENOVIRUS E1B PROTEINS

ANALYSIS

Structural analysis of the adenovirus type 5 E1B 55–kilodalton–E4orf6 protein complex. Rubenwolf S, et al. **J Virol** 1997 Feb;71(2):1115–23

BIOSYNTHESIS

Bcl–2, Bcl–XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Huang DC, et al. **Oncogene** 1997 Jan 30;14(4):405–14

GENETICS

ONYX–015, an E1B gene–attenuated adenovirus, causes tumor–specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments] Heise C, et al. **Nat Med** 1997 Jun;3(6):639–45 . Comment in: Nat Med 1997 Jun;3(6):606–8.

An adenovirus mutant that replicates selectively in p53–deficient human tumor cells [see comments] Bischoff JR, et al. **Science** 1996 Oct 18;274(5286):373–6. Comment in: Science 1996 Oct 18;274(5286):342–3.

Will a twist of viral fate lead to a new cancer treatment? [news; comment] Pennisi E. **Science** 1996 Oct 18; 274(5286):342–3. Comment on: Science 1996 Oct 18;274(5286):373–6.

METABOLISM

Nuclear export of the E1B 55–kDa and E4 34–kDa

adenoviral oncoproteins mediated by a rev-like signal sequence. Dobbelstein M, et al. **EMBO J** 1997 Jul 16; 16(14):4276–84

Adenovirus E1B 19-kDa death suppressor protein interacts with Bax but not with Bad. Chen G, et al. **J Biol Chem** 1996 Sep 27;271(39):24221–5

The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. Goodrum FD, et al. **J Virol** 1997 Jan; 71(1):548–61

Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K. Han J, et al. **Mol Cell Biol** 1996 Oct;16(10):5857–64

PHARMACOLOGY

Expression of p53 in Saos-2 osteosarcoma cells induces apoptosis which can be inhibited by Bcl-2 or the adenovirus E1B-55 kDa protein. Marcellus RC, et al. **Cell Growth Differ** 1996 Dec;7(12):1643–50

PHYSIOLOGY

Adenovirus type 12 early region 1B 54K protein significantly extends the life span of normal mammalian cells in culture. Gallimore PH, et al. **J Virol** 1997 Sep;71(9):6629–40

Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. Querido E, et al. **J Virol** 1997 May;71(5):3788–98

Regulation of p53-dependent apoptosis, transcriptional repression, and cell transformation by phosphorylation of the 55-kilodalton E1B protein of human adenovirus type 5. Teodoro JG, et al. **J Virol** 1997 May;71(5):3620–7

Adenovirus E1B 19K protein is required for efficient DNA replication in U937 cells. Hu MC, et al. **Virology** 1997 Jan 20;227(2):295–304

ADENOVIRUS E2 PROTEINS

GENETICS

E2A gene products are not required for insulin gene expression. Itkin-Ansari P, et al. **Endocrinology** 1996 Aug; 137(8):3540–3

Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Morral N, et al. **Hum Gene Ther** 1997 Jul 1;8(10):1275–86

Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro. Rittner K, et al. **J Virol** 1997 Apr; 71(4):3307–11

Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. Zhou H, et al. **J Virol** 1996 Oct;70(10):7030–8

Human adenovirus type 5 variants with sequence alterations flanking the E2A gene: effects on E2 expression and DNA replication. Caravokyri C, et al. **Virus Genes** 1996; 12(1):65–75

METABOLISM

T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice. Condorelli GL, et al. **Cancer Res** 1996 Nov 15;56(22):5113–9

Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors. Hara E, et al. **EMBO J** 1997 Jan 15;16(2):332–42

ADENOVIRUS E2A DNA-BINDING PROTEINS see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E2A 72K PROTEIN see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E2A PROTEINS see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E2F PROTEINS see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E3 19K PROTEIN see **ADENOVIRUS E3 PROTEINS**

ADENOVIRUS E3 PROTEINS

BIOSYNTHESIS

Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. Bruder JT, et al. **J Virol** 1997 Oct;71(10):7623–8

GENETICS

Conserved sequences in the fibers of epidemic keratoconjunctivitis associated human adenoviruses. Pring-Akerblom P, et al. **Arch Virol** 1997;142(1):205–11

Potential salmon sperm origin of the E3 region insert of the adenovirus 5 dl309 mutant. Gingras MC, et al. **Cancer Gene Ther** 1996 May-Jun;3(3):151–4

Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Poller W, et al. **Gene Ther** 1996 Jun;3(6):521–30

Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Schowalter DB, et al. **Gene Ther** 1997 Apr;4(4):351–60

Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro. Rittner K, et al. **J Virol** 1997 Apr; 71(4):3307–11

Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Ilan Y, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2587–92

Expression of adenoviral E3 transgenes in beta cells prevents autoimmune diabetes. von Herrath MG, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9808–13

Porcine adenoviruses types 1, 2 and 3 have short and simple early E-3 regions. Reddy PS, et al. **Virus Res** 1996 Aug; 43(2):99–109

IMMUNOLOGY

Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Ilan Y, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2587–92

Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. Chengalvala MV, et al. **Vaccine** 1997 Feb;15(3):335–9

METABOLISM

Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes. Dimitrov T, et al. **J Virol** 1997 Apr;71(4):2830–7

PHARMACOLOGY

The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. Krajcsi P, et al. **J Virol** 1996 Aug;70(8):4904–13

ADENOVIRUS E4 PROTEINS

ANALYSIS

Structural analysis of the adenovirus type 5 E1B 55-kilodalton-E4orf6 protein complex. Rubenwolf S, et al. **J Virol** 1997 Feb;71(2):1115–23

DEFICIENCY

Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. Dedieu JF, et al. **J Virol** 1997 Jun;71(6):4626–37

GENETICS

E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections. Leppard KN. **J Gen Virol** 1997 Sep;78 (Pt 9):2131–8 (66 ref.)

Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. Armentano D, et al. **J Virol** 1997 Mar;71(3):2408–16

Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. Gao GP, et al. **J Virol** 1996 Dec;70(12):8934–43

Human adenovirus early region 4 open reading frame 1 genes encode growth-transforming proteins that may be distantly related to dUTP pyrophosphatase enzymes. Weiss RS, et al. **J Virol** 1997 Mar;71(3):1857–70

Phosphorylation within the transactivation domain of adenovirus E1A protein by mitogen-activated protein kinase regulates expression of early region 4. Whalen SG, et al. **J Virol** 1997 May;71(5):3545–53

METABOLISM

Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence. Dobbelstein M, et al. **EMBO J** 1997 Jul 16; 16(14):4276–84

Expression of adenovirus type 5 E4 Orf2 protein during lytic infection. Dix I, et al. **J Gen Virol** 1995 Apr;76 (Pt 4):1051–5

Oncogenic potential of the adenovirus E4orf6 protein. Moore M, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11295–301

The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function. Nevels M, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1206–11

PHYSIOLOGY

Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. Querido E, et al. **J Virol** 1997 May;71(5):3788–98

Early region 4 modulates adenovirus DNA replication by two genetically separable mechanisms. Medghalchi S, et al. **Virology** 1997 Sep 15;236(1):8–17

ADENOVIRUS E4F PROTEIN see **ADENOVIRUS E4 PROTEINS**

ADENOVIRUS E19 PROTEINS see **ADENOVIRUS EARLY PROTEINS**

ADENOVIRUS E29 PROTEINS see **ADENOVIRUS EARLY PROTEINS**

ADENOVIRUS 2, HUMAN see **ADENOVIRUSES, HUMAN**

ADENOVIRUS INFECTIONS see **ADENOVIRIDAE INFECTIONS**

ADENOVIRUS INFECTIONS, HUMAN

Viruses and idiopathic pulmonary fibrosis [editorial; comment] Egan JJ, et al. **Eur Respir J** 1997 Jul;10(7):1433–7 (47 ref.). Comment on: Eur Respir J 1997 Jul;10(7):1445–9.

BLOOD

Benign transient hyperphosphatasaemia associated with adenovirus infection. Ng PC, et al. **J Paediatr Child Health** 1995 Dec;31(6):561–2

COMPLICATIONS

Acanthamoeba keratitis: masquerading as adenoviral keratitis [letter] Goodall K, et al. **Eye** 1996;10 (Pt 5):643–4

Detection of adenovirus DNA by polymerase chain reaction in peripheral blood lymphocytes from HIV-infected patients and a control group: preliminary results [letter] Durepaire N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Feb 1;14(2):189–90

DIAGNOSIS

Diagnosis of adenovirus conjunctivitis by enzyme immunoassay. Bryden AS, et al. **Br J Biomed Sci** 1996 Sep; 53(3):182–4

Evaluation of rapid culture centrifugation method for adenovirus detection in stools. Durepaire N, et al. **Diagn Microbiol Infect Dis** 1996 Jan;24(1):25–9

Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction [see comments] Kuwano K, et al. **Eur Respir J** 1997 Jul;10(7):1445–9. Comment in: Eur Respir J 1997 Jul;10(7):1433–7.

Systemic infection resembling hemorrhagic fever with the renal syndrome caused by adenovirus type 11. Usami T, et al. **J Urol** 1997 Feb;157(2):617–8

Adenovirus viremia in human immunodeficiency virus-infected children. Ferdman RM, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):413–5

Acute red eye. Differentiating viral conjunctivitis from other, less common causes. Weber CM, et al. **Postgrad Med** 1997 May;101(5):185–6, 189–92, 195–6 (6 ref.)

[A potential rapid immunoperoxidase method of diagnosis in infections due to the respiratory syncytial virus, parainfluenza viruses and adenoviruses] Tecu C, et al. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jul-Dec; 41(3-4):145–6 (Eng. Abstr.) **(Rum)**

[Bronchopneumonia, obstructive bronchitis and bronchiectasis in children with adenovirus infections] Koncul I, et al. **Lijec Vjesn** 1997 Jan;119(1):11–5 (Eng. Abstr.) **(Scr)**

DRUG THERAPY

Treatment of adenoviral conjunctivitis with topical cidofovir [letter] Gordon YJ, et al. **Cornea** 1996 Sep;15(5):546

Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model. Romanowski EG, et al. **Invest Ophthalmol Vis Sci** 1997 Jan;38(1):253–7

[Local cyclosporin A therapy of nummuli after epidemic keratoconjunctivitis--case report] Reinhard T, et al. **Klin Monatsbl Augenheilkd** 1997 Mar;210(3):165–8 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Benign transient hyperphosphatasaemia associated with adenovirus infection. Ng PC, et al. **J Paediatr Child Health** 1995 Dec;31(6):561–2

EPIDEMIOLOGY

Surveillance and control of epidemic keratoconjunctivitis. Gottsch JD. **Trans Am Ophthalmol Soc** 1996;94:539–87

[Adenovirus 9 nosocomial infection] Gallo E, et al. **Boll Ist Sieroter Milan** 1966 May-Jun;45(5-6):250–4 **(Ita)**

IMMUNOLOGY

The role of nitric oxide in limiting gene transfer: parallels to viral host defenses [comment] Beckman JS, et al. **Am J Respir Cell Mol Biol** 1997 May;16(5):495–6. Comment on: Am J Respir Cell Mol Biol 1997 May;16(5):501–9.

Molecular basis of immune evasion strategies by adenoviruses. Hayder H, et al. **Immunol Cell Biol** 1996 Dec; 74(6):504–12 (138 ref.)

ADENOVIRUS INFECTIONS, HUMAN

PATHOLOGY

The dynamics of coiled bodies in the nucleus of adenovirus-infected cells. Rebelo L, et al. **Mol Biol Cell** 1996 Jul;7(7):1137-51

THERAPY

Intravenous ribavirin therapy in a neonate with disseminated adenovirus infection undergoing extracorporeal membrane oxygenation: pharmacokinetics and clearance by hemofiltration. Aebi C, et al. **J Pediatr** 1997 Apr; 130(4):612-5

[Laferon in the treatment of meningoencephalitis] Rudenko AA, et al. **Lik Sprava** 1995 Mar-Apr;(3-4):109-12 (Eng. Abstr.) **(Rus)**

TRANSMISSION

Aerosolization of infectious virus by excimer laser. Moreira LB, et al. **Am J Ophthalmol** 1997 Mar;123(3):297-302

VIROLOGY

Molecular basis of immune evasion strategies by adenoviruses. Hayder H, et al. **Immunol Cell Biol** 1996 Dec; 74(6):504-12 (138 ref.)

Detection and typing of subgroup F adenoviruses using the polymerase chain reaction. Tiemessen CT, et al. **J Virol Methods** 1996 May;59(1-2):73-82

PCR-based detection and typing of human adenoviruses in clinical samples. Pring-Akerblom P, et al. **Res Virol** 1997 May-Jun;148(3):225-31

Detection of enteric adenoviruses 40 and 41 in stool specimens by monoclonal antibody-based enzyme immunoassays. Vizzi E, et al. **Res Virol** 1996 Nov-Dec; 147(6):333-9

Chronic intestinal infection due to subgenus F type 40 adenovirus in a patient with AIDS. Dionisio D, et al. **Scand J Infect Dis** 1997;29(3):305-7

[Rapid detection and identification of human adenovirus directly from conjunctival scrapings by polymerase chain reaction and restriction fragment length polymorphism analysis] Saitoh W, et al. **Nippon Ganka Gakkai Zasshi** 1996 Feb;100(2):163-8 (Eng. Abstr.) **(Jpn)**

ADENOVIRUSES, AVIAN see **AVIADENOVIRUS**

ADENOVIRUSES, CANINE

GENETICS

[Sequencing of right terminal fragment of canine adenovirus type 1 vaccine strain DNA] Tang Q, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Feb; 18(1):1-4 (Eng. Abstr.) **(Chi)**

ISOLATION & PURIFICATION

Focal mesangial-sclerosing glomerulonephritis and acute-spontaneous infectious canine hepatitis: structural, immunohistochemical and subcellular studies. Hervás J, et al. **Vet Immunol Immunopathol** 1997 Jun;57(1-2):25-32

PHYSIOLOGY

Fractal analysis of lung alveoli during the acute phase vs. repair phase of an adenoviral infection in canines. Tinajero JP, et al. **Res Commun Mol Pathol Pharmacol** 1997 Mar; 95(3):275-85

ADENOVIRUSES, HUMAN

Transduction of hippocampal CA1 by adenovirus in vivo. Kammesheidt A, et al. **Brain Res** 1996 Oct 14; 736(1-2):297-304

Potential salmon sperm origin of the E3 region insert of the adenovirus 5 dl309 mutant. Gingras MC, et al. **Cancer Gene Ther** 1996 May-Jun;3(3):151-4

Persistent transgene expression in the hypothalamus following stereotaxic delivery of a recombinant adenovirus: suppression of the immune response with cyclosporin. Geddes BJ, et al. **Endocrinology** 1996 Nov;137(11):5166-9

Gradient of RGD-dependent entry of adenoviral vector in nasal and intrapulmonary epithelia: implications for gene therapy of cystic fibrosis. Goldman M, et al. **Gene Ther** 1996 Sep;3(9):811-8

Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Smith TA, et al. **Gene Ther** 1996 Jun;3(6):496-502

Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. Addison CL, et al. **J Gen Virol** 1997 Jul;78 (Pt 7):1653-61

Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells. Gnatenko D, et al. **J Investig Med** 1997 Feb; 45(2):87-98

Adenoviral-mediated gene transfer to murine small intestine is more efficient in neonates than adults. Hamilton T, et al. **J Pediatr Surg** 1997 Feb;32(2):373-7

Targeted adenovirus-mediated gene delivery to T cells via CD3. Wickham TJ, et al. **J Virol** 1997 Oct;71(10):7663-9

The behavior of the coiled body in cells infected with adenovirus in vitro. Rodrigues SH, et al. **Mol Biol Rep** 1996;23(3-4):183-9

Cap-binding protein (eukaryotic initiation factor 4E) and 4E-inactivating protein BP-1 independently regulate cap-dependent translation. Feigenblum D, et al. **Mol Cell Biol** 1996 Oct;16(10):5450-7

Adenoviral-mediated gene transfer into guinea pig cochlear cells in vivo. Raphael Y, et al. **Neurosci Lett** 1996 Mar 29;207(2):137-41

Adenovirus-mediated gene transfer of A20 renders endothelial cells resistant to activation: a means of evaluating the role of endothelial cell activation in xenograft rejection. Ferran C, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):879-80

Adenoviral-mediated gene transfer to the small intestinal isograft. Hamilton TE, et al. **Transplant Proc** 1996 Oct; 28(5):2444

[The in vitro antitumor responses of murine peritoneal macrophages induced by adenovirus-mediated IL-4 and/or M-CSF gene therapy] Yu Y, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jul;76(7):493-6 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Hydropathic characteristics of adenovirus hexons. Li QG, et al. **Arch Virol** 1997;142(7):1307-22

Structural features unique to enteric adenoviruses. Brown M, et al. **Arch Virol Suppl** 1996;12:301-7 (46 ref.)

Regulation of p53-dependent apoptosis, transcriptional repression, and cell transformation by phosphorylation of the 55-kilodalton E1B protein of human adenovirus type 5. Teodoro JG, et al. **J Virol** 1997 May;71(5):3620-7

CLASSIFICATION

Rapid subgenus identification of human adenovirus isolates by a general PCR. Kidd AH, et al. **J Clin Microbiol** 1996 Mar;34(3):622-7

Molecular epidemiology of adenovirus acute lower respiratory infections of children in the south cone of South America (1991-1994). Kajon AE, et al. **J Med Virol** 1996 Feb;48(2):151-6

Rapid detection and serotyping of adenovirus by direct immunofluorescence. Wood SR, et al. **J Med Virol** 1997 Mar;51(3):198-201

DRUG EFFECTS

Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. de Oliveira CB, et al. **Antiviral Res** 1996 Jul;31(3):165-72

Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method. Kodama E, et al. **Antiviral Res** 1996 Jul;31(3):159-64

Inhibitory activity of 3'-fluoro-2' deoxythymidine and related nucleoside analogues against adenoviruses in vitro. Mentel R, et al. **Antiviral Res** 1997 May;34(3):113-9

Inhibition of adenovirus infection with protease inhibitors. Sircar S, et al. **Antiviral Res** 1996 May;30(2-3):147-53

Antiviral activity of galangin isolated from the aerial parts of Helichrysum aureonitens. Meyer JJ, et al. **J Ethnopharmacol** 1997 Apr;56(2):165-9

Fluorescent focus reduction assay for the screening of antiadenoviral agents. Mentel R, et al. **J Virol Methods** 1996 May;59(1-2):99-104

ENZYMOLOGY

Cleavage efficiency by adenovirus protease is site-dependent. Diouri M, et al. **J Biol Chem** 1996 Dec 20;271(51):32511-4

Adenovirus type 2 endoprotease: isoforms and redox effects. Keyvani-Amineh H, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2201-7

New stimulation ligand of the adenovirus 2 protease. Diouri M, et al. **Virology** 1996 Oct 15;224(2):510-6

Mutagenesis of conserved residues of the adenovirus protease. Rancourt C, et al. **Virology** 1996 Oct 15; 224(2):561-3

GENETICS

Ability of adenovirus vectors containing different CFTR transcriptional cassettes to correct ion transport defects in CF cells. Jiang C, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):L527-37

Modulation of adenovirus-mediated gene transfer by nitric oxide [see comments] Haddad IY, et al. **Am J Respir Cell Mol Biol** 1997 May;16(5):501-9. Comment in: Am J Respir Cell Mol Biol 1997 May;16(5):495-6.

Replication-deficient adenoviral vector for gene transfer potentiates airway neurogenic inflammation. Piedimonte G, et al. **Am J Respir Cell Mol Biol** 1997 Mar;16(3):250-8

Antiviral activity of an oligo(nucleoside methylphosphonate) that targets HSV-1 immediate-early pre-mRNA 4,5 is augmented by cotreatment with replication-defective adenovirus. Kulka M, et al. **Antisense Res Dev** 1995 Winter; 5(4):243-9

Adenoviral vector infection of the human exocrine pancreas. Vickers SM, et al. **Arch Surg** 1997 Sep;132(9):1006-9

Expression of transgenes in human and rat retinal pigment epithelium in vitro using an adenoviral vector. da Cruz L, et al. **Aust N Z J Ophthalmol** 1996 May;24(2 Suppl):78-81

Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. Yoshida Y, et al. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):426-30

Characterization of a human adenovirus 5: rabies glycoprotein recombinant vaccine reisolated from orally vaccinated skunks. Lutze-Wallace C, et al. **Biologicals** 1995 Dec;23(4):271-7

Retrograde transfer of replication deficient recombinant adenovirus vector in the central nervous system for tracing studies. Kuo H, et al. **Brain Res** 1995 Dec 24;705(1-2):31-8

Clonal origin of adenovirus type 12-induced hamster tumors: nonspecific chromosomal integration sites of viral DNA. Hilger-Eversheim K, et al. **Cancer Res** 1997 Jul 15; 57(14):3001-9

Adenovirus-mediated gene transfer: strategies and applications in lipoprotein research. Gerard RD, et al. **Curr Opin Lipidol** 1996 Apr;7(2):105-11 (37 ref.)

Recombinant human adenovirus with rat MIP-2 gene insertion causes prolonged PMN recruitment to the murine brain. Bell MD, et al. **Eur J Neurosci** 1996 Sep;8(9):1803-11

Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. Bilbao G, et al. **FASEB J** 1997 Jul;11(8):624-34 (112 ref.)

Advances in adenoviral vectors: from genetic engineering to their biology. Yeh P, et al. **FASEB J** 1997 Jul; 11(8):615-23 (50 ref.)

Augmentation of ouabain sensitivity of rat liver Na/K-ATPase by in vivo adenovirus-mediated expression of the Na/K-ATPase alpha2 subunit. Askari FK, et al. **FEBS Lett** 1997 Mar 17;405(1):5-10

The MHC-encoded TAP1/LMP2 bidirectional promoter is down-regulated in highly oncogenic adenovirus type 12 transformed cells. Proffitt JA, et al. **FEBS Lett** 1997 Jan 3;400(2):141-4

Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Guo ZS, et al. **Gene Ther** 1996 Sep;3(9):802-10

Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidney perfusion system - first steps towards gene therapy of Alport syndrome. Heikkila P, et al. **Gene Ther** 1996 Jan;3(1):21-7

Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. Imler JL, et al. **Gene Ther** 1996 Jan; 3(1):49-58

Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. Imler JL, et al. **Gene Ther** 1996 Jan; 3(1):75-84

Surfactant enhances adenovirus-mediated gene expression in rabbit lungs. Jobe AH, et al. **Gene Ther** 1996 Sep;3(9):775-9

Towards the use of replicative adenoviral vectors for cancer gene therapy [editorial] Miller R, et al. **Gene Ther** 1996 Jul;3(7):557-9

Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. Mühlhauser J, et al. **Gene Ther** 1996 Feb; 3(2):145-53

Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Raben D, et al. **Gene Ther** 1996 Jul;3(7):567-80

Heart muscle-specific gene expression using replication defective recombinant adenovirus. Rothmann T, et al. **Gene Ther** 1996 Oct;3(10):919-26

Biological response of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. St George JA, et al. **Gene Ther** 1996 Feb;3(2):103-16

A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Wang Q, et al. **Gene Ther** 1995 Dec;2(10):775-83

Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas. Bao JJ, et al. **Hum Gene Ther** 1996 Feb 10;7(3):355-65

Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Bramson J, et al. **Hum Gene Ther** 1996 Feb 10;7(3):333-42

Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Bramson JL, et al. **Hum Gene Ther** 1996 Oct 20;7(16):1995-2002

In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Dong Y, et al. **Hum Gene Ther** 1996 Apr 10;7(6):713-20

Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Eck SL, et al. **Hum Gene Ther** 1996 Aug 1;7(12):1465-82

A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Fisher KJ, et al. **Hum Gene Ther** 1996 Nov 10; 7(17):2079-87

Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies. Goodman JC, et al. **Hum Gene Ther** 1996 Jun 20;7(10):1241-50

Surfactant effects on aerosolized and instilled adenoviral-mediated gene transfer. Jobe AH, et al. **Hum Gene Ther** 1996 Apr 10;7(6):697-704

In vitro assessment of variables affecting the efficiency and efficacy of adenovirus-mediated gene transfer to cystic

fibrosis airway epithelia. Johnson LG, et al. **Hum Gene Ther** 1996 Jan;7(1):51–9

Molecular therapy with recombinant p53 adenovirus in an androgen–independent, metastatic human prostate cancer model. Ko SC, et al. **Hum Gene Ther** 1996 Sep 10; 7(14):1683–91

Nondepleting anti–CD4 antibody treatment prolongs lung–directed E1–deleted adenovirus–mediated gene expression in rats. Lei D, et al. **Hum Gene Ther** 1996 Dec 1;7(18):2273–9

High–efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin–2 vectors. Leimig T, et al. **Hum Gene Ther** 1996 Jun 20;7(10):1233–9

Safety of airway gene transfer with Ad2/CFTR2: aerosol administration in the nonhuman primate. McDonald RJ, et al. **Hum Gene Ther** 1997 Mar 1;8(4):411–22

Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB–IND 6274). Treat J, et al. **Hum Gene Ther** 1996 Oct 20;7(16):2047–57

Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Kumar–Singh R, et al. **Hum Mol Genet** 1996 Jul; 5(7):913–21

An adenovirus vector encoding tyrosine hydroxylase activity may enter human CNS cells in primary dissociated cultures. Levallois C, et al. **Int J Dev Neurosci** 1996 Aug;14(5):613–9

Dynamics of gene transfer to retinal pigment epithelium. da Cruz L, et al. **Invest Ophthalmol Vis Sci** 1996 Nov; 37(12):2447–54

Detection of adenovirus DNA by polymerase chain reaction in peripheral blood lymphocytes from HIV–infected patients and a control group: preliminary results [letter] Durepaire N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Feb 1;14(2):189–90

Overexpression of cell cycle inhibitors (p16INK4 and p21Cip1) and cyclin D1 using adenovirus vectors regulates proliferation of rat mesangial cells. Terada Y, et al. **J Am Soc Nephrol** 1997 Jan;8(1):51–60

Adenovirus E1B 19–kDa death suppressor protein interacts with Bax but not with Bad. Chen G, et al. **J Biol Chem** 1996 Sep 27;271(39):24221–5

Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. Fasbender A, et al. **J Biol Chem** 1997 Mar 7;272(10):6479–89

Bent DNA in the human adenovirus type 2 E1A enhancer is an architectural element for transcription stimulation. Ohyama T. **J Biol Chem** 1996 Nov 1;271(44):27823–8

Established immunity precludes adenovirus–mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. Schulick AH, et al. **J Clin Invest** 1997 Jan 15;99(2):209–19

Isogenic adenoviruses type 5 expressing or not expressing the E1A gene: efficiency as virus vectors in the vaccination of permissive and non–permissive species. Eloit M, et al. **J Gen Virol** 1995 Jul;76 (Pt 7):1583–9

A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long–lived immune responses in mice. Flanagan B, et al. **J Gen Virol** 1997 May;78 (Pt 5):991–7

Adenovirus–mediated in vivo gene transfer in a rabbit model of allograft vasculopathy. Mehra MR, et al. **J Heart Lung Transplant** 1996 Jan;15(1 Pt 1):51–7

Comparison of primer sets for detection of fecal and ocular adenovirus infection using the polymerase chain reaction. Hussain MA, et al. **J Med Virol** 1996 Jul;49(3):187–94

Molecular epidemiology of adenovirus types 3 and 7 isolated from children with pneumonia in Beijing. Li QG, et al. **J Med Virol** 1996 Jul;49(3):170–7

Adenovirus–mediated gene transfer into infarcted myocardium: feasibility, timing, and location of expression. Leor J, et al. **J Mol Cell Cardiol** 1996 Oct;28(10):2057–67

Adenovirus–mediated increase of exogenous and inhibition of endogenous fosB gene expression in cultured pulmonary arterial smooth muscle cells. Lu CY, et al. **J Mol Cell Cardiol** 1996 Aug;28(8):1703–13

Adenovirus–mediated gene transfer in neurons: construction and characterization of a vector for heterologous expression of the axonal cell adhesion molecule axonin–1. Giger RJ, et al. **J Neurosci Methods** 1997 Jan;71(1):99–111

Transient gene transfer to neurons and glia: analysis of adenoviral vector performance in the CNS and PNS. Hermens WT, et al. **J Neurosci Methods** 1997 Jan; 71(1):85–98

Biology of adenovirus vectors with E1 and E4 deletions for liver–directed gene therapy. Gao GP, et al. **J Virol** 1996 Dec;70(12):8934–43

Molecular characterization of replication–competent variants of adenovirus vectors and genome modifications to prevent their occurrence. Hehir KM, et al. **J Virol** 1996 Dec; 70(12):8459–67

Recombinant adenoviruses with large deletions generated by Cre–mediated excision exhibit different biological properties compared with first–generation vectors in vitro and in vivo. Lieber A, et al. **J Virol** 1996 Dec; 70(12):8944–60

Mutant adenovirus type 9 E4 ORF1 genes define three protein regions required for transformation of CREF cells. Weiss RS, et al. **J Virol** 1997 Jun;71(6):4385–94

Enhancement of in vivo adenovirus–mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. Wolff G, et al. **J Virol** 1997 Jan; 71(1):624–9

Generation, validation, and large scale production of adenoviral recombinants with large size inserts such as a 6.3 kb human dystrophin cDNA. Jani A, et al. **J Virol Methods** 1997 Mar;64(2):111–24

Kinetics of adenovirus–mediated gene transfer to human lung fibroblasts. Teramoto S, et al. **Life Sci** 1997;61(9):891–7

Altered beta–adrenergic receptor signaling in heart failure, in vivo gene transfer via adeno and adeno–associated virus. Ping P, et al. **Microcirculation** 1996 Jun;3(2):225–8

The adenovirus E1A–regulated transcription factor E4F is generated from the human homolog of nuclear factor phiAP3. Fernandes ER, et al. **Mol Cell Biol** 1997 Apr; 17(4):1890–903

Transcription of adenovirus type 2 genes in a cell–free system: apparent heterogeneity of initiation at some promoters. Lee DC, et al. **Mol Cell Biol** 1981 Jul; 1(7):635–51

Sequence–mediated regulation of adenovirus gene expression by repression of mRNA accumulation. Prescott JC, et al. **Mol Cell Biol** 1997 Apr;17(4):2207–16

Striking similarities are exhibited by two small Epstein–Barr virus–encoded ribonucleic acids and the adenovirus–associated ribonucleic acids VAI and VAII. Rosa MD, et al. **Mol Cell Biol** 1981 Sep;1(9):785–96

Direct intracerebral nerve growth factor gene transfer using a recombinant adenovirus: effect on basal forebrain cholinergic neurons during aging. Castel–Barthe MN, et al. **Neurobiol Dis** 1996 Feb;3(1):76–86

Surfactant protein A–producing cells in human fetal lung are good targets for recombinant adenovirus–mediated gene transfer. Messina E, et al. **Pediatr Res** 1996 Jul; 40(1):142–7

Recombinational construction in Escherichia coli of infectious adenoviral genomes. Crouzet J, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1414–9

Characterization of a replication–incompetent adenovirus type 5 mutant deleted for the preterminal protein gene. Schaack J, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10; 93(25):14686–91

Hexon sequence of adenovirus type 7 and comparison with other serotypes of subgenus B. Pring–Akerblom P, et al. **Res Virol** 1995 Nov–Dec;146(6):383–388

Secondary and tertiary structure in the central domain of adenovirus type 2 VA RNA I. Ma Y, et al. **RNA** 1996 Sep;2(9):937–51

Use of adenoviral VAI small RNA as a carrier for cytoplasmic delivery of ribozymes. Prislei S, et al. **RNA** 1997 Jun;3(6):677–87

Human adenovirus type 5 vectors expressing rabies glycoprotein. Yarosh OK, et al. **Vaccine** 1996 Sep; 14(13):1257–64

Adenovirus–mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver. Yao SN, et al. **Viral Immunol** 1996;9(3):141–53

Fiber genes of adenoviruses with tropism for the eye and the genital tract. Arnberg N, et al. **Virology** 1997 Jan 6; 227(1):239–44

Adenovirus serotype evolution is driven by illegitimate recombination in the hypervariable regions of the hexon protein. Crawford–Miksza LK, et al. **Virology** 1996 Oct 15;224(2):357–67

Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Dion LD, et al. **Virology** 1997 May 12;231(2):201–9

Cloning and sequencing of the cellular–viral junctions from the human adenovirus type 5 transformed 293 cell line. Louis N, et al. **Virology** 1997 Jul 7;233(2):423–9

Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD. Mittal SK, et al. **Virology** 1996 Aug 15;222(2):299–309

Functional characterization of the major late promoter of mouse adenovirus type 1. Song B, et al. **Virology** 1997 Aug 18;235(1):109–17

Spontaneous occurrence of early region 1A reiteration mutants of type 5 adenovirus in persistently infected human T–lymphocytes. Tang Q, et al. **Virology** 1997 Apr 14; 230(2):281–91

Human adenovirus type 5 variants with sequence alterations flanking the E2A gene: effects on E2 expression and DNA replication. Caravokyri C, et al. **Virus Genes** 1996; 12(1):65–75

Human immunodeficiency virus type 1 Rev–dependent effects on the late gene expression of recombinant human adenovirus. Williams RD, et al. **Virus Genes** 1996; 13(2):111–20

Anti–interferon activity of adenovirus–2–encoded VAI and VAII RNAs in translation in cultured human cells. Mori K, et al. **Virus Res** 1996 Jun;42(1–2):53–63

[Gene therapy and adenovirus vectors] Zhang D, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Dec; 17(6):470–5 (14 ref.) **(Chi)**

[Adenovirus gene transfer in xenogenic nerve transplantation] Hebebrand D, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:289–93 (Eng. Abstr.) **(Ger)**

[Receptor mediated gene transfer in squamous epithelial carcinoma of the head–neck area] Wollenberg B, et al. **Laryngorhinootologie** 1997 Jul;76(7):411–4 (Eng. Abstr.) **(Ger)**

[Mutant adenoviruses. A new anticancer strategy] Benítez–Bribiesca L. **Gac Med Mex** 1997 Jan–Feb; 133(1):47–8 **(Spa)**

[Gene therapy in neurology. State of the art and future prospects] Duarte RG. **Neurologia** 1995 Dec;10 Suppl 1:56–61 (14 ref.) (Eng. Abstr.) **(Spa)**

GROWTH & DEVELOPMENT

Roberts syndrome fibroblasts showing cisplatin hypersensitivity have normal host cell reactivation of cisplatin–treated adenovirus and normal capacity of cisplatin–treated cells for adenovirus DNA synthesis. Davis K, et al. **Somat Cell Mol Genet** 1996 Sep;22(5):393–402

IMMUNOLOGY

Intertype specific epitopes on the hexons of adenovirus types 1, 2, 5 and 6. Adám E, et al. **Acta Microbiol Immunol Hung** 1996;43(1):75–82

Characterization of adenovirus hexons by their epitope composition. Adám E, et al. **Arch Virol** 1996; 141(10):1891–907

Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus–induced Ig subclass shifts. Gahéry–Ségard H, et al. **Eur J Immunol** 1997 Mar;27(3):653–9

Role of T cells in inflammation caused by adenovirus vectors in the brain. Byrnes AP, et al. **Gene Ther** 1996 Jul; 3(7):644–51

Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion. DeMatteo RP, et al. **Gene Ther** 1996 Jan;3(1):4–12

Humoral and cellular immune responses of nonhuman primates to long–term repeated lung exposure to Ad2/CFTR–2. Kaplan JM, et al. **Gene Ther** 1996 Feb; 3(2):117–27

Circumventing the immune response to adenovirus–mediated gene therapy. Kass–Eisler A, et al. **Gene Ther** 1996 Feb; 3(2):154–62

Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus–infected hepatocytes in vivo. Yang Y, et al. **Gene Ther** 1996 Feb; 3(2):137–44

Humoral response after administration of E1–deleted adenoviruses: immune privilege of the subretinal space. Bennett J, et al. **Hum Gene Ther** 1996 Sep 10;7(14):1763–9

Prevention of immune reactions triggered by first–generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Guérette B, et al. **Hum Gene Ther** 1996 Aug 1;7(12):1455–63

"Sero–switch" adenovirus–mediated in vivo gene transfer: circumvention of anti–adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Mastrangeli A, et al. **Hum Gene Ther** 1996 Jan;7(1):79–87

Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Yang Y, et al. **Hum Mol Genet** 1996 Nov;5(11):1703–12

Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Christ M, et al. **Immunol Lett** 1997 Jun 1;57(1–3):19–25

Adenovirus infection in cystic fibrosis patients: implications for the use of adenoviral vectors for gene transfer. Rosenecker J, et al. **Infection** 1996 Jan–Feb;24(1):5–8

Molecular characterization of the type–specific gamma–determinant located on the adenovirus fiber. Eiz B, et al. **J Virol** 1997 Sep;71(9):6576–81

Lack of effect of mouse adenovirus type 1 infection on cell surface expression of major histocompatibility complex class I antigens. Kring SC, et al. **J Virol** 1996 Aug; 70(8):5495–502

Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunizations with adenovirus vectors is dependent on haplotype. Sparer TE, et al. **J Virol** 1997 Mar;71(3):2277–84

Previous enteric adenovirus infection does not protect against subsequent symptomatic infection: longitudinal follow–up of eight infants. Unicomb LE, et al. **Microbiol Immunol** 1996;40(2):161–8

Recombinant fibre proteins of human adenoviruses Ad9, Ad15 and Ad19: localization of the haemagglutination properties and the type–specific determinant. Eiz B, et al. **Res Virol** 1997 Jan–Feb;148(1):5–10

Replication and immunogenicity of Ad7–, Ad4–, and Ad5–hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. Chengalvala MV, et al. **Vaccine** 1997 Feb;15(3):335–9

Susceptibility to natural killer cells and down regulation of MHC class I expression in adenovirus 12 transformed cells are regulated by different E1A domains. Huvent I, et al. **Virus Res** 1996 Dec;45(2):123–34

ISOLATION & PURIFICATION

Diagnosis of adenovirus conjunctivitis by enzyme immunoassay. Bryden AS, et al. **Br J Biomed Sci** 1996 Sep; 53(3):182–4

Evaluation of rapid culture centrifugation method for adenovirus detection in stools. Durepaire N, et al. **Diagn Microbiol Infect Dis** 1996 Jan;24(1):25–9

ADENOVIRUSES, HUMAN

Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction [see comments] Kuwano K, et al. **Eur Respir J** 1997 Jul;10(7):1445–9. Comment in: Eur Respir J 1997 Jul;10(7):1433–7.

Use of continuous human lung cell culture for adenovirus isolation. Leonardi GP, et al. **Intervirology** 1995;38(6):352–5

Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir. Gordon YJ, et al. **Invest Ophthalmol Vis Sci** 1996 Dec;37(13):2774–8

Rapid diagnosis of adenoviral conjunctivitis by PCR and restriction fragment length polymorphism analysis. Saitoh–Inagawa W, et al. **J Clin Microbiol** 1996 Sep; 34(9):2113–6

Seroepidemiology of new AIDS–associated adenoviruses among the San Francisco Men's Health Study. Crawford–Miksza L, et al. **J Med Virol** 1996 Nov; 50(3):230–6

Detection of adenovirus DNA in peripheral blood mononuclear cells by polymerase chain reaction assay. Flomenberg P, et al. **J Med Virol** 1997 Mar;51(3):182–8

Rapid detection and serotyping of adenovirus by direct immunofluorescence. Wood SR, et al. **J Med Virol** 1997 Mar;51(3):198–201

Detection and typing of subgroup F adenoviruses using the polymerase chain reaction. Tiemessen CT, et al. **J Virol Methods** 1996 May;59(1–2):73–82

Adenovirus conjunctivitis mimics preseptal and orbital cellulitis in young children. Ruttum MS, et al. **Pediatr Infect Dis J** 1996 Mar;15(3):266–7

PCR–based detection and typing of human adenoviruses in clinical samples. Pring–Akerblom P, et al. **Res Virol** 1997 May–Jun;148(3):225–31

Detection of enteric adenoviruses 40 and 41 in stool specimens by monoclonal antibody–based enzyme immunoassays. Vizzi E, et al. **Res Virol** 1996 Nov–Dec; 147(6):333–9

Chronic intestinal infection due to subgenus F type 40 adenovirus in a patient with AIDS. Dionisio D, et al. **Scand J Infect Dis** 1997;29(3):305–7

[Adenovirus and intranuclear inclusions in the appendix in children with acute intussusception] Berrebi D, et al. **Ann Pathol** 1997 Apr;17(2):89–93 (Eng. Abstr.) **(Fre)**

[Rapid detection and identification of human adenovirus directly from conjunctival scrapings by polymerase chain reaction and restriction fragment length polymorphism analysis] Saitoh W, et al. **Nippon Ganka Gakkai Zasshi** 1996 Feb;100(2):163–8 (Eng. Abstr.) **(Jpn)**

METABOLISM

Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. Hong SS, et al. **EMBO J** 1997 May 1;16(9):2294–306

Nuclear organization of adenovirus RNA biogenesis. Bridge E, et al. **Exp Cell Res** 1996 Dec 15;229(2):233–9 (36 ref.)

Anchorage of adenoviral RNAs to clusters of interchromatin granules. Besse S, et al. **Gene Expr** 1995;5(2):79–92

Bent DNA in the human adenovirus type 2 E1A enhancer is an architectural element for transcription stimulation. Ohyama T. **J Biol Chem** 1996 Nov 1;271(44):27823–8

Expression of adenovirus type 5 E4 Orf2 protein during lytic infection. Dix I, et al. **J Gen Virol** 1995 Apr;76 (Pt 4):1051–5

Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin–8 expression. Bruder JT, et al. **J Virol** 1997 Jan;71(1):398–404

Adenovirus E3–10.4K/14.5K protein complex inhibits tumor necrosis factor–induced translocation of cytosolic phospholipase A2 to membranes. Dimitrov T, et al. **J Virol** 1997 Apr;71(4):2830–7

The early region 1B 55–kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. Goodrum FD, et al. **J Virol** 1997 Jan; 71(1):548–61

A single locus on human chromosome 21 directs the expression of a receptor for adenovirus type 2 in mouse A9 cells. Mayr GA, et al. **J Virol** 1997 Jan;71(1):412–8

Comparative analysis of adenovirus fiber–cell interaction: adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment. Roelvink PW, et al. **J Virol** 1996 Nov; 70(11):7614–21

Insufficient levels of NF1II and its low affinity for the origin of adenovirus type 12 (Ad12) DNA replication contribute to the abortive infection of BHK21 hamster cells by Ad12. Schiedner G, et al. **J Virol** 1996 Nov;70(11):8003–9

Domain organization of the adenovirus preterminal protein. Webster A, et al. **J Virol** 1997 Jan;71(1):539–47

Human adenovirus early region 4 open reading frame 1 genes encode growth–transforming proteins that may be distantly related to dUTP pyrophosphatase enzymes. Weiss RS, et al. **J Virol** 1997 Mar;71(3):1857–70

A replication–deficient adenovirus enhances liposome–mediated nucleic acid transfer into a stable cell line expressing T7 RNA polymerase. Honda M, et al. **J Virol Methods** 1996 Apr 26;58(1–2):41–51

The adenovirus E1A–regulated transcription factor E4F is generated from the human homolog of nuclear factor phiAP3. Fernandes ER, et al. **Mol Cell Biol** 1997 Apr; 17(4):1890–903

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Bergelson JM, et al. **Science** 1997 Feb 28;275(5304):1320–3

Inhibition of cell adhesion to the virus by synthetic peptides of fiber knob of human adenovirus serotypes 2 and 3 and virus neutralisation by anti–peptide antibodies. Liebermann H, et al. **Virus Res** 1996 Dec;45(2):111–22

The adenoviral transcription factor, E1A 13S, trans–activates the human tumor necrosis factor–alpha promoter. Rhoades KL, et al. **Virus Res** 1996 Jan;40(1):65–74

PATHOGENICITY

The dynamics of coiled bodies in the nucleus of adenovirus–infected cells. Rebelo L, et al. **Mol Biol Cell** 1996 Jul;7(7):1137–51

PHYSIOLOGY

Aerosolization of infectious virus by excimer laser. Moreira LB, et al. **Am J Ophthalmol** 1997 Mar;123(3):297–302

Adenovirus–assisted lipofection: efficient in vitro gene transfer of luciferase and cytosine deaminase to human smooth muscle cells. Kreuzer J, et al. **Atherosclerosis** 1996 Jul;124(1):49–60

Adenoviral vectors and hematopoietic cells [letter; comment] Fu SQ, et al. **Blood** 1997 Feb 15;89(4):1460–2. Comment on: Blood 1996 Jun 15;87(12):5032–9.

Efficient adenoviral vector–directed expression of a foreign gene to neurons and sustentacular cells in the mouse olfactory neuroepithelium. Holtmaat AJ, et al. **Brain Res Mol Brain Res** 1996 Sep 5;41(1–2):148–56

Infection of A549 cells with a recombinant adenovirus vector induces ICAM–1 expression and increased CD–18–dependent adhesion of activated neutrophils. Stark JM, et al. **Hum Gene Ther** 1996 Sep 10;7(14):1669–81

Prevention of bleomycin–induced pulmonary fibrosis after adenovirus–mediated transfer of the bacterial bleomycin resistance gene. Tran PL, et al. **J Clin Invest** 1997 Feb 15;99(4):608–17

Adenovirus–receptor interaction with human lymphocytes. Mentel R, et al. **J Med Virol** 1997 Mar;51(3):252–7

Adenovirus type 12 early region 1B 54K protein significantly extends the life span of normal mammalian cells in culture. Gallimore PH, et al. **J Virol** 1997 Sep;71(9):6629–40

Domains required for assembly of adenovirus type 2 fiber trimers. Hong JS, et al. **J Virol** 1996 Oct;70(10):7071–8

Encapsidation of adeno–associated virus type 2 Rep proteins in wild–type and recombinant progeny virions: Rep–mediated growth inhibition of primary human cells. Kube DM, et al. **J Virol** 1997 Oct;71(10):7361–71

The transactivation domain of adenovirus E1A interacts with the C terminus of human TAF(II)135. Mazzarelli JM, et al. **J Virol** 1997 Oct;71(10):7978–83

A helper–dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. Parks RJ, et al. **J Virol** 1997 Apr;71(4):3293–8

Regulation of p53 levels by the E1B 55–kilodalton protein and E4orf6 in adenovirus–infected cells. Querido E, et al. **J Virol** 1997 May;71(5):3788–98

Adenovirus type 12 DNA firmly associates with mammalian chromosomes early after virus infection or after DNA transfer by the addition of DNA to the cell culture medium. Schröer J, et al. **J Virol** 1997 Oct;71(10):7923–32

Role of preterminal protein processing in adenovirus replication. Webster A, et al. **J Virol** 1997 Sep;71(9):6381–9

Adenovirus 41 replication: cell–related differences in viral gene transcription. Tiemessen CT, et al. **Mol Cell Probes** 1996 Aug;10(4):279–87

Monomeric scAlu and nascent dimeric Alu RNAs induced by adenovirus are assembled into SRP9/14–containing RNPs in HeLa cells. Chang DY, et al. **Nucleic Acids Res** 1996 Nov 1;24(21):4165–70

An adenovirus mutant that replicates selectively in p53–deficient human tumor cells [see comments] Bischoff JR, et al. **Science** 1996 Oct 18;274(5286):373–6. Comment in: Science 1996 Oct 18;274(5286):342–3.

Will a twist of viral fate lead to a new cancer treatment? [news; comment] Pennisi E. **Science** 1996 Oct 18; 274(5286):342–3. Comment on: Science 1996 Oct 18;274(5286):373–6.

Adenovirus E1B 19K protein is required for efficient DNA replication in U937 cells. Hu MC, et al. **Virology** 1997 Jan 20;227(2):295–304

Early region 4 modulates adenovirus DNA replication by two genetically separable mechanisms. Medghalchi S, et al. **Virology** 1997 Sep 15;236(1):8–17

ADENOVIRUSES, MAMMALIAN see **MASTADENOVIRUS**

ADENOVIRUSES, SIMIAN

Chronic social stress, social status, and susceptibility to upper respiratory infections in nonhuman primates [see comments] Cohen S, et al. **Psychosom Med** 1997 May–Jun; 59(3):213–21. Comment in: Psychosom Med 1997 May–Jun;59(3):222–3.

GENETICS

[Transcripts of integrated simian adenovirus SA7 oncogenes in SH2 rat fibroblasts, transformed by adenovirus SA7 DNA] Kurabekova RM, et al. **Mol Biol (Mosk)** 1996 Jul–Aug;30(4):808–17 **(Rus)**

ADENYL CYCLASE

AGONISTS

Ascorbic acid augments the adenylyl cyclase–cAMP system mediated POMC mRNA expression and beta–endorphin secretion from hypothalamic neurons in culture. Yang Z, et al. **Brain Res** 1996 Jan 15;706(2):243–8

ANALYSIS

Assay of adenylyl cyclase activity by quantitative mass spectrometry. el–Shazley H, et al. **Biochem Soc Trans** 1996 Aug;24(3):474S

Quantitation of adenylate cyclase of Bordetella pertussis by enzyme linked immunosorbent assay. Hozbor D, et al. **Biologicals** 1995 Dec;23(4):279–84

Targeted disruption of Gnas in embryonic stem cells. Schwindinger WF, et al. **Endocrinology** 1997 Oct; 138(10):4058–63

Identification and subcellular localization of the subunits of L–type calcium channels and adenylyl cyclase in cardiac myocytes. Gao T, et al. **J Biol Chem** 1997 Aug 1; 272(31):19401–7

ANTAGONISTS & INHIBITORS

TNF–alpha inhibits isoproterenol–stimulated adenylyl cyclase activity in cultured airway smooth muscle cells. Emala CW, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):L644–50

Adenylyl cyclase inhibitory pathway is differentially modified in rat white and brown fat by high–energy diets. Kenan Y, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E1043–9

Muscarinic inhibition of adenylyl cyclase regulates intracellular calcium in single airway smooth muscle cells. Madison JM, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):L208–14

Somatostatin inhibits interleukin 6 release from rat cortical type I astrocytes via the inhibition of adenylyl cyclase. Grimaldi M, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):242–8

Inhibition of adenylyl cyclases by 12(S)–hydroxyeicosatetraenoic acid. Wang XQ, et al. **Biochem Biophys Res Commun** 1996 Nov 1;228(1):81–7

Pertussis toxin reverses the inhibition of the adenylyl cyclase system by khellin in HeLa cells. Di Stefano A, et al. **Biochim Biophys Acta** 1996 Nov 8;1314(1–2):105–8

tTGase/G alpha h protein expression inhibits adenylate cyclase activity in Balb–C 3T3 fibroblasts membranes. Gentile V, et al. **Biochim Biophys Acta** 1997 Jun 5; 1357(1):115–22

Antagonism of striatal muscarinic receptors inhibiting dopamine D1 receptor–stimulated adenylyl cyclase activity by cholinoceptor antagonist used to treat Parkinson's disease. Olianas MC, et al. **Br J Pharmacol** 1996 Jun; 118(4):827–8

The P2Y purinoceptor in rat brain microvascular endothelial cells couple to inhibition of adenylate cyclase. Webb TE, et al. **Br J Pharmacol** 1996 Dec;119(7):1385–92

Continuous cocaine administration enhances mu– but not delta–opioid receptor–mediated inhibition of adenylyl cyclase activity in nucleus accumbens. Izenwasser S, et al. **Eur J Pharmacol** 1996 Feb 15;297(1–2):187–91

Isozyme–dependent sensitivity of adenylyl cyclases to P–site–mediated inhibition by adenine nucleosides and nucleoside 3'–polyphosphates. Johnson RA, et al. **J Biol Chem** 1997 Apr 4;272(14):8962–6

Somatostatin receptor–mediated signaling in smooth muscle. Activation of phospholipase C–beta3 by Gbetagamma and inhibition of adenylyl cyclase by Galphai1 and Galphao. Murthy KS, et al. **J Biol Chem** 1996 Sep 20; 271(38):23458–63

Dopamine enhances somatostatin receptor–mediated inhibition of adenylate cyclase in rat striatum and hippocampus. Rodríguez–Sánchez MN, et al. **J Neurosci Res** 1997 May 1;48(3):238–48

Structure–activity studies of hydrophobic amino acid replacements at positions 9, 11 and 16 of glucagon. Sturm NS, et al. **J Pept Res** 1997 Apr;49(4):293–9

Opioid mu, delta, and kappa receptor–induced activation of phospholipase C–beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle. Murthy KS, et al. **Mol Pharmacol** 1996 Oct;50(4):870–7

Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Robinson SW, et al. **Mol Pharmacol** 1997 Sep;52(3):508–14

Alpha2–adrenoceptors in opossum kidney cells couple to stimulation of mitogen–activated protein kinase independently of adenylyl cyclase inhibition. Kribben A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Aug; 356(2):225–32

Pharmacological characterizations of recombinant human 5–HT1D alpha and 5–HT1D beta receptor subtypes coupled to adenylate cyclase inhibition in clonal cell lines: apparent differences in drug intrinsic efficacies between human 5–HT1D subtypes. Zgombick JM, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug–Sep; 354(3):226–36

Long–term neuroleptic treatments counteract dopamine D2 agonist inhibition of adenylate cyclase but do not affect pertussis toxin ADP–ribosylation in the rat brain. Okada F, et al. **Neurochem Int** 1996 Feb;28(2):161–8

BIOSYNTHESIS

Ca(2+)-inhibitable adenylyl cyclase and pulmonary microvascular permeability. Chetham PM, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):L22-30

Expression of adenylyl cyclase mRNAs in the adult, in developing, and in the Brattleboro rat kidney. Shen T, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C323-30

Expression of adenylyl cyclase type I in cochlear inner hair cells. Drescher MJ, et al. **Brain Res Mol Brain Res** 1997 May;45(2):325-30

Molecular cloning and expression of an adenylyl cyclase from Xenopus laevis oocytes. Torrejón M, et al. **FEBS Lett** 1997 Mar 3;404(1):91-4

Construction of a full-length Ca2+-sensitive adenylyl cyclase/aequorin chimera. Nakahashi Y, et al. **J Biol Chem** 1997 Jul 18;272(29):18093-7

BLOOD

Platelet adenylyl cyclase activity in alcoholics and subtypes of alcoholics. WHO/ISBRA Study Clinical Centers. Parsian A, et al. **Alcohol Clin Exp Res** 1996 Jun; 20(4):745-51

Allosteric equilibrium model explains steady-state coupling of beta-adrenergic receptors to adenylate cyclase in turkey erythrocyte membranes. Ugur O, et al. **Biochem J** 1997 May 1;323 (Pt 3):765-76

Forskolin-stimulated platelet adenylyl cyclase activity is lower in persons with major depression. Menninger JA, et al. **Biol Psychiatry** 1997 Jul 1;42(1):30-8

Analysis of effects of adrenaline and collagen on the activity of prostaglandin E1-stimulated human platelet adenylyl cyclase. Juška A. **Blood Coagul Fibrinolysis** 1996 Mar; 7(2):199-201

CHEMISTRY

Characterization of mutant Bordetella pertussis adenylate cyclase toxins with reduced affinity for calmodulin. Implications for the mechanism of toxin entry into target cells. Heveker N, et al. **Eur J Biochem** 1997 Feb 1; 243(3):643-9

Gbeta subunit interacts with a peptide encoding region 956-982 of adenylyl cyclase 2. Cross-linking of the peptide to free Gbetagamma but not the heterotrimer. Weng G, et al. **J Biol Chem** 1996 Oct 25;271(43):26445-8

Adenylyl cyclases: structure, regulation and function in an enzyme superfamily. Hanoune J, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1-2):179-94 (113 ref.)

A polymerase I palm in adenylyl cyclase? [letter; comment] Artymiuk PJ, et al. **Nature** 1997 Jul 3;388(6637):33-4. Comment on: Nature 1997 Mar 20;386(6622):247-53.

Structure of the adenylyl cyclase catalytic core [see comments] [published erratum appears in Nature 1997 Jul 10;388(6638):204] Zhang G, et al. **Nature** 1997 Mar 20; 386(6622):247-53. Comment in: Nature 1997 Jul 3;388(6637):33-4.

A surface on the G protein beta-subunit involved in interactions with adenylyl cyclases. Chen Y, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2711-4

Characterization and crystallization of a minimal catalytic core domain from mammalian type II adenylyl cyclase. Zhang G, et al. **Protein Sci** 1997 Apr;6(4):903-8

[Structure and regulation of adenylyl cyclase] Itoh H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):371-8 (53 ref.) **(Jpn)**

DEFICIENCY

A post-receptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease. Reithmann C, et al. **Eur J Pharmacol** 1997 Jul 2; 330(1):79-86

DRUG EFFECTS

Polyunsaturated fatty acid deficiencies: effects on hepatic plasma membrane fatty acid composition and enzyme activity. Angulo O. **Arch Latinoam Nutr** 1995 Dec; 45(4):295-304

Mechanisms of adaptive supersensitivity: correlation of guinea pig atrial supersensitivity with modifications in adenylyl cyclase activity. Roberts MI, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):347-56

Impaired activation of adenylyl cyclase in lung of the Basenji-greyhound model of airway hyperresponsiveness: decreased numbers of high affinity beta-adrenoceptors. Emala CW, et al. **Br J Pharmacol** 1996 Aug;118(8):2009-16

Constitutive activity of human prostaglandin E receptor EP3 isoforms. Jin J, et al. **Br J Pharmacol** 1997 May; 121(2):317-23

PK 11195 blockade of benzodiazepine-induced inhibition of forskolin-stimulated adenylate cyclase activity in the striatum. Tenn CC, et al. **Br J Pharmacol** 1996 Sep; 119(2):223-8

Ontogeny of beta-adrenoceptor/adenylyl cyclase desensitization mechanisms: the role of neonatal innervation. Slotkin TA, et al. **Brain Res** 1996 Dec 2; 742(1-2):317-28

Modulation of adenylyl cyclase by Aplysia bag cell peptides: evidence for a common receptor. Berry RW. **Brain Res Mol Brain Res** 1996 May;38(1):176-8

Acute effects of D1- and D2-receptor agonist and antagonist drugs on somatostatin binding, inhibition of adenylyl cyclase activity and accumulation of inositol 1,4,5-trisphosphate in the rat striatum. Izquierdo-Claros RM, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1-2):99-107

Influence of fluoxetine and p-chloroamphetamine on the somatostatin receptor-adenylyl cyclase system in the rat frontoparietal cortex. Muñoz-Acedo G, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1-2):117-24

Modulation by 5-hydroxytryptamine of the somatostatin receptor-effector system and somatostatin levels in rat brain. Muñoz-Acedo G, et al. **Brain Res Mol Brain Res** 1996 Apr;37(1-2):259-66

Interaction of the delta-opioid receptor with GM1 ganglioside: conversion from inhibitory to excitatory mode. Wu G, et al. **Brain Res Mol Brain Res** 1997 Mar;44(2):341-6

Comparison of effects of vasoactive agents on adenylate cyclase activity in endothelial and smooth muscle cells from the same specimen of fetal bovine aorta. Ashikaga T, et al. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):36-42

Calmodulin-regulated adenylyl cyclases and neuromodulation. Xia Z, et al. **Curr Opin Neurobiol** 1997 Jun;7(3):391-6 (41 ref.)

Ibogaine and noribogaine potentiate the inhibition of adenylyl cyclase activity by opioid and 5-HT receptors. Rabin RA, et al. **Eur J Pharmacol** 1996 Dec 5;316(2-3):343-8

Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors. Sato Y, et al. **Eur J Pharmacol** 1996 Nov 21;315(3):363-7

Effect of estradiol and progesterone on growth of porcine myometrial smooth muscle cells and phospholipase C and adenylate cyclase signalling systems in vitro. Kisielewska J, et al. **Folia Histochem Cytobiol** 1997;35(3):143-9

Hypothyroidism alters the effect of GTP on adenylyl cyclase in forebrain and hindbrain synaptosomal membranes from 15-day-old rats. Leung FC, et al. **Int J Dev Neurosci** 1996 Oct;14(6):701-5

Lack of effect of antidepressants on mononuclear leukocyte G-protein levels or function in depressed outpatients. Young LT, et al. **J Affect Disord** 1996 Jul 29;39(3):201-7

Conformation-dependent activation of type II adenylyl cyclase by protein kinase C. Ebina T, et al. **J Cell Biochem** 1997 Mar 1;64(3):492-8

Isoform-specific regulation of adenylyl cyclase by oxidized catecholamines. Ebina T, et al. **J Mol Cell Cardiol** 1997 Apr;29(4):1247-54

Long-term effect of forskolin on the activation of adenylyl cyclase in astrocytes. el Jamali A, et al. **J Neurochem** 1996 Dec;67(6):2532-9

Non-epithelial endothelin-A receptors activate adenylate cyclase in rat trachea: biochemical mechanisms and physiological implications. El-Mowafy AM, et al. **Life Sci** 1997;61(15):1529-38

Treatment with haloperidol or clozapine causes changes in dopamine receptors but not adenylate cyclase or protein kinase C in the rat forebrain. Wan DC, et al. **Life Sci** 1996; 59(23):2001-8

The pharmacology of adenylyl cyclase modulation by GABAB receptors in rat brain slices. Knight AR, et al. **Neuropharmacology** 1996 Jun;35(6):703-12

Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the beta-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex. Neliat G, et al. **Neuropharmacology** 1996 May;35(5):589-93

Pharmacological characterization of metabotropic glutamate receptors linked to the inhibition of adenylate cyclase activity in rat striatal slices. Schaffhauser H, et al. **Neuropharmacology** 1997 Jul;36(7):933-40

MDL 12330A inhibits the non-neuronal adenylyl cyclase from the freshwater snail Planorbarius corneus, but the neuronal enzyme is activated by this compound. Ferretti ME, et al. **Neurosci Lett** 1996 Apr 5;207(3):191-4

Decreased beta-adrenoceptor-stimulated adenylyl cyclase activity in lymphocytes from Alzheimer's disease patients. Garlind A, et al. **Neurosci Lett** 1997 Apr 18;226(1):37-40

Opposite role of delta 1- and delta 2-opioid receptors activated by endogenous or exogenous opioid agonists on the endogenous cholecystokinin system: further evidence for delta-opioid receptor heterogeneity. Noble F, et al. **Neuroscience** 1996 Dec;75(3):917-26

Prostaglandin E2 both stimulates and inhibits adenyl cyclase on platelets: comparison of effects on cloned EP4 and EP3 prostaglandin receptor subtypes. Mao GF, et al. **Prostaglandins** 1996 Sep;52(3):175-85

[3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding. Seiler SM, et al. **Prostaglandins** 1997 Jan;53(1):21-35

Effects of ceruletide on perioral movements and the dopamine receptor-adenylate cyclase system in rats chronically treated with fluphenazine. Ashizawa T, et al. **Psychopharmacology (Berl)** 1996 Jun;125(3):185-94

GENETICS

Human adenylyl cyclase type 7 contains polymorphic repeats in the 3' untranslated region: investigations of association with alcoholism. Hellevuo K, et al. **Am J Med Genet** 1997 Feb 21;74(1):95-8

Regulation of type II adenylyl cyclase mRNA in rabbit skeletal muscle by chronic motor nerve pacing. Torgan CE, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):E253-60

Agonist regulation of adenylate cyclase activity in neuroblastoma x glioma hybrid NG108-15 cells transfected to co-express adenylate cyclase type II and the beta 2-adrenoceptor. Evidence that adenylate cyclase is the limiting component for receptor-mediated stimulation of adenylate cyclase activity. MacEwan DJ, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):1033-9

Comparative analysis of the cya locus in enterobacteria and related gram-negative facultative anaerobes. Trotot P, et al. **Biochimie** 1996;78(4):277-87

Isolation, expression and characterization of the gene for an ADP-ribosylation factor from the human malaria parasite, Plasmodium falciparum. Stafford WH, et al. **Eur J Biochem** 1996 Nov 15;242(1):104-13

Molecular cloning and expression of an adenylyl cyclase from Xenopus laevis oocytes. Torrejón M, et al. **FEBS Lett** 1997 Mar 3;404(1):91-4

Cloning and characterization of the gene encoding Halobacterium halobium adenylate kinase. Song S, et al. **Gene** 1996 Oct 10;175(1-2):65-70

Isolation and characterization of multiple adenylate cyclase genes from the cyanobacterium Anabaena sp. strain PCC 7120. Katayama M, et al. **J Bacteriol** 1997 Jun; 179(11):3588-93

The conserved asparagine and arginine are essential for catalysis of mammalian adenylyl cyclase. Yan SZ, et al. **J Biol Chem** 1997 May 9;272(19):12342-9

Retinoic acid abolishes the calcitonin gene-related peptide autocrine system in F9 teratocarcinoma cells. Segond N, et al. **J Cell Biochem** 1997 Mar 1;64(3):447-57

Differential expression of type I, II, and V adenylyl cyclase gene in the postnatal developing rat brain. Matsuoka I, et al. **J Neurochem** 1997 Feb;68(2):498-506

Cra-mediated regulation of Escherichia coli adenylate cyclase. Crasnier-Mednansky M, et al. **Microbiology** 1997 Mar;143 (Pt 3):785-92

Families of adenylate cyclase genes in Trypanosoma brucei. Alexandre S, et al. **Mol Biochem Parasitol** 1996 May; 77(2):173-82

Phosphorylation-dependent binding of BvgA to the upstream region of the cyaA gene of Bordetella pertussis. Karimova G, et al. **Mol Microbiol** 1996 May;20(3):489-96

Effects of repeated methamphetamine administration on dopamine D1 receptor, D2 receptor and adenylate cyclase type V mRNA levels in the rat striatum. Shishido T, et al. **Neurosci Lett** 1997 Feb 7;222(3):175-8

The Spirulina platensis adenylate cyclase gene, cyaC, encodes a novel signal transduction protein. Kasahara M, et al. **Plant Cell Physiol** 1997 Jul;38(7):828-36

IMMUNOLOGY

Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Saron MF, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1; 94(7):3314-9

ISOLATION & PURIFICATION

Purification of bovine brain adenylyl cyclase with a novel derivative of forskolin: evidence for a high specific activity form of the enzyme. Moos M Jr, et al. **Prep Biochem Biotechnol** 1996 May;26(2):155-67

METABOLISM

Interaction of gamma-L-glutamyltaurine with kainate-induced cyclic AMP formation in the rat hippocampus. Varga V, et al. **Adv Exp Med Biol** 1996; 403:473-9

Alterations of receptor-G protein-adenylyl cyclase coupling in alcoholics. Saito T, et al. **Alcohol Alcohol Suppl** 1994; 2:211-5

Nitric oxide synthase inhibition by N(omega)-nitro-L-arginine methyl ester modulates G-protein expression and adenylyl cyclase activity in rat heart. Di Fusco F, et al. **Am J Hypertens** 1997 Apr;10(4 Pt 1):471-5

Modulation of G-protein expression by the angiotensin converting enzyme inhibitor captopril in hearts from spontaneously hypertensive rats. Relationship with adenylyl cyclase. Pandey SK, et al. **Am J Hypertens** 1996 Aug;9(8):833-7

Effects of triiodothyronine administration on the adenylyl cyclase system in brown adipose tissue of rat. Adli H, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):E247-53

Temporal effects of cytokines on neonatal cardiac myocyte Ca2+ transients and adenylate cyclase activity. Bick RJ, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1937-44

Perinatal expression of adenylyl cyclase subtypes in rat brown adipose tissue. Chaudhry A, et al. **Am J Physiol** 1996 Apr; 270(4 Pt 2):R755-60

Effect of hypothyroidism on adenylyl cyclase activity and subtype gene expression in brown adipose tissue. Chaudhry A, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R762-7

Alterations of adenylyl cyclase-linked G proteins in rat liver during aging. Eakes AT, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):E126-32

Adenylate cyclase-coupled ATP receptor and surfactant secretion in type II pneumocytes from newborn rats. Gobran LI, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):L187-96

IL-1 beta alters beta-adrenergic receptor adenylyl cyclase system function in human airway epithelial cells. Kelsen

SG, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):L694–700

Adenylyl cyclase and G protein receptor kinase expression during development of heart failure. Ping P, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H707–17

Chronic carbachol pretreatment decreases adenylyl cyclase activity in airway smooth muscle. Schears G, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):L640–7

Differential changes in left and right ventricular adenylyl cyclase activities in congestive heart failure. Sethi R, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H884–93

Cytosolic Ca2+ and adenylyl cyclase responses in phenotypically distinct pulmonary endothelial cells. Stevens T, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):L51–9

Histamine H2 receptor activates adenylate cyclase and PLC via separate GTP-dependent pathways. Wang L, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):G613–20

Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin. Wookey PJ, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):F289–94

Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements. Yasui M, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):F443–50

Adenylyl cyclase isoforms and vasopressin enhancement of agonist-stimulated cAMP in vascular smooth muscle cells. Zhang J, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H971–80

A bioluminescent enzymatic assay for adenylylcyclase activity. McKnite S, et al. **Anal Biochem** 1996 Mar 1; 235(1):103–6

Analysis of 3',5'-cAMP and adenylyl cyclase activity in higher plants using polyclonal chicken egg yolk antibodies. Roef L, et al. **Anal Biochem** 1996 Jan 15;233(2):188–96

A beta-adrenoceptor agonist evokes a nitric oxide–cGMP relaxation mechanism modulated by adenylyl cyclase in rat aorta. Halothane does not inhibit this mechanism. Iranami H, et al. **Anesthesiology** 1996 Nov;85(5):1129–38

Pancreatic beta-cell receptors and G proteins coupled to adenylyl cyclase. Marie JC, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:122–31; discussion 132 (61 ref.)

Adenylate cyclase activation by VIP and PACAP in the retina and choroid: effects of antagonists. Nilsson SF, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:749–52

Nitric oxide synthase and adenylyl and guanylyl cyclase activity in porcine interposition vein grafts. Jeremy JY, et al. **Ann Thorac Surg** 1997 Feb;63(2):470–6

Phorbol ester-induced sensitisation of adenylyl cyclase type II is related to phosphorylation of threonine 1057. Böl GF, et al. **Biochem Biophys Res Commun** 1997 Aug 18; 237(2):251–6

Chimeric D2/D3 dopamine receptor coupling to adenylyl cyclase. Lachowicz JE, et al. **Biochem Biophys Res Commun** 1997 Aug 18;237(2):394–9

Follitropin signal transduction: alternative splicing of the FSH receptor gene produces a dominant negative form of receptor which inhibits hormone action. Sairam MR, et al. **Biochem Biophys Res Commun** 1996 Sep 24; 226(3):717–22

1 alpha,25-(OH)2-vitamin D3 stimulates the adenylyl cyclase pathway in muscle cells by a GTP-dependent mechanism which presumably involves phosphorylation of G alpha i. Vazquez G, et al. **Biochem Biophys Res Commun** 1997 May 8;234(1):125–8

Agonist regulation of adenylate cyclase activity in neuroblastoma x glioma hybrid NG108–15 cells transfected to co-express adenylate cyclase type II and the beta 2-adrenoceptor. Evidence that adenylate cyclase is the limiting component for receptor-mediated stimulation of adenylate cyclase activity. MacEwan DJ, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):1033–9

Evidence for the shuttle model for Gs alpha activation of adenylyl cyclase. Krumins AM, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):43–59

Examination of the effects of increasing Gs protein on beta2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Krumins AM, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):61–72

On the tyrosine kinase mechanism of the novel effect of insulin and insulinlike growth factor I. Stimulation of the adenylyl cyclase system in muscle tissues. Pertseva MN, et al. **Biochem Pharmacol** 1996 Dec 24;52(12):1867–74

The gastrin-releasing peptide receptor is differentially coupled to adenylate cyclase and phospholipase C in different tissues. Garcia LJ, et al. **Biochim Biophys Acta** 1997 May 27;1356(3):343–54

The thrombin receptor in adrenal medullary microvascular endothelial cells is negatively coupled to adenylyl cyclase through a Gi protein. Manolopoulos VG, et al. **Biochim Biophys Acta** 1997 May 27;1356(3):321–32

Glutathione alters the mode of calcium-mediated regulation of adenylyl cyclase in membranes from mouse brain. Nakamura J, et al. **Biochim Biophys Acta** 1997 May 23; 1339(2):239–46

Effect of transmembrane Ca2+ gradient on the coupling of beta-adrenergic receptors and adenylyl cyclase. Fan GF, et al. **Biosci Rep** 1996 Aug;16(4):327–41

Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Wetterwald A, et al. **Bone** 1996 Feb;18(2):125–32

Identification of 5-hydroxytryptamine receptors positively coupled to adenylyl cyclase in rat cultured astrocytes. Hirst WD, et al. **Br J Pharmacol** 1997 Feb;120(3):509–15

Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment. Noble F, et al. **Br J Pharmacol** 1996 Jan;117(1):161–9

The effects of recombinant rat mu-opioid receptor activation in CHO cells on phospholipase C, [Ca2+]i and adenylyl cyclase. Smart D, et al. **Br J Pharmacol** 1997 Mar; 120(6):1165–71

PK 11195 blockade of benzodiazepine-induced inhibition of forskolin-stimulated adenylate cyclase activity in the striatum. Tenn CC, et al. **Br J Pharmacol** 1996 Sep; 119(2):223–8

Impaired G-protein-stimulated adenylyl cyclase activity in Alzheimer's disease brain is not accompanied by reduced cyclic-AMP-dependent protein kinase A activity. Bonkale WL, et al. **Brain Res** 1996 Oct 21;737(1–2):155–61

Beta-adrenoceptor control of cardiac adenylyl cyclase during development: agonist pretreatment in the neonate uniquely causes heterologous sensitization, not desensitization. Giannuzzi CE, et al. **Brain Res** 1995 Oct 2;694(1–2):271–8

The expression of a novel Ca2+/CaM stimulated adenylyl cyclase activity in the neuroblastoma cell line Lan-1 is regulated by cell density. Kluxen FW, et al. **Brain Res** 1996 Nov 18;740(1–2):169–74

Adenylate cyclase in striatal cholinergic interneurons regulates acetylcholine release. Login IS, et al. **Brain Res** 1996 Oct 7;735(2):330–4

Differences among mouse strains in the regulation by mu, delta 1 and delta 2 opioid receptors of striatal adenylyl cyclases activated by dopamine D1 or adenosine A2a receptors. Noble F, et al. **Brain Res** 1996 Apr 15; 716(1–2):107–17

Involvement of metabotropic glutamate receptors in Gi- and Gs-dependent modulation of adenylate cyclase activity induced by a novel cognition enhancer NS-105 in rat brain. Oka M, et al. **Brain Res** 1997 Apr 18;754(1–2):121–30

Evidence for the presence of G-proteins, adenylyl cyclase and phospholipase C activities in lymphatic smooth muscle cell membranes. Kelly J, et al. **Cell Signal** 1996 Sep; 8(6):425–32

Effect of endurance physical training on rat liver adenylyl cyclase system. Nieto JL, et al. **Cell Signal** 1996 Jun; 8(4):317–22

Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase [see comments] Jansen-Olesen I, et al. **Cephalalgia** 1996 Aug;16(5):310–6. Comment in: Cephalalgia 1996 Aug;16(5):287.

Forskolin derivatives. I. Synthesis, and cardiovascular and adenylate cyclase-stimulating activities of water-soluble forskolins. Tatee T, et al. **Chem Pharm Bull (Tokyo)** 1996 Dec;44(12):2274–9

Visualizing signal transduction: receptors, G-proteins, and adenylate cyclases [published erratum appears in Clin Sci (Colch) 1997 Feb;92(2):223] Dessauer CW, et al. **Clin Sci (Colch)** 1996 Nov;91(5):527–37 (56 ref.)

Perioperative lymphocyte adenylyl cyclase function in the pediatric cardiac surgical patient. Sun LS, et al. **Crit Care Med** 1996 Oct;24(10):1654–9

Modulation of FSH receptor phosphorylation correlates with hormone-induced coupling to the adenylate cyclase system. Selvaraj N, et al. **Endocrine** 1997 Apr;6(2):179–85

Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide. Aoki Y, et al. **Endocrinology** 1997 May; 138(5):1930–4

Effects of hypothyroidism on brown adipose tissue adenylyl cyclase activity. Carvalho SD, et al. **Endocrinology** 1996 Dec;137(12):5519–29

Costimulation of adenylyl cyclase and phospholipase C by a mutant alpha 1B-adrenergic receptor transgene promotes malignant transformation of thyroid follicular cells. Ledent C, et al. **Endocrinology** 1997 Jan;138(1):369–78

Melatonin receptors in the chicken kidney are up-regulated by pinealectomy and linked to adenylate cyclase. Song Y, et al. **Eur J Endocrinol** 1996 Jul;135(1):128–33

Synergistic activation of adenylyl cyclase is dependent upon phospholipase C-mediated processes in human neuroblastoma SK-N-BE(2)C cells. Suh BC, et al. **Eur J Pharmacol** 1996 Oct 24;314(1–2):235–42

P2 purinoceptor-mediated stimulation of adenylyl cyclase in PC12 cells. Yakushi Y, et al. **Eur J Pharmacol** 1996 Oct 24;314(1–2):243–8

Activation of the adenylyl cyclase/cyclic AMP/protein kinase A pathway in endothelial cells exposed to cyclic strain. Cohen CR, et al. **Exp Cell Res** 1997 Feb 25; 231(1):184–9

Age-related postreceptor mechanisms: changes in adenylate cyclase but not phosphodiesterase in isolated mouse renal medullary collecting ducts. Davidson YS, et al. **Exp Gerontol** 1995 Nov-Dec;30(6):594–604

Isoform-dependent activation of adenylyl cyclase by proteolysis. Ebina T, et al. **FEBS Lett** 1997 Jan 20; 401(2–3):223–6

Potential CRE suppression by familial Alzheimer's mutants of APP independent of adenylyl cyclase regulation. Giambarella U, et al. **FEBS Lett** 1997 Jul 21;412(1):97–101

Functional role of carboxyl-terminal tail of prostaglandin EP3 receptor in Gi coupling. Hizaki H, et al. **FEBS Lett** 1997 Sep 8;414(2):323–6

Overexpression of G(s)alpha in NG108–15, neuroblastomaXglioma cells: effects on receptor regulation of the stimulatory adenylyl cyclase cascade. Mullaney I, et al. **FEBS Lett** 1996 Nov 18;397(2–3):325–30

Responsiveness of adenylate cyclase to pituitary gonadotropins and evidence of a hormone-induced desensitization in the lizard ovary. Borrelli L, et al. **Gen Comp Endocrinol** 1997 Jul;107(1):23–31

The human 5-hydroxytryptamine 1A receptor differentially modulates phospholipase C and adenylyl cyclase activities. Fenrick R, et al. **Gen Pharmacol** 1996 Mar;27(2):263–8

Potentiation of the relaxing action of isoproterenol by forskolin in rabbit aortic rings: the involvement of beta 2-adrenoceptors. Satake N, et al. **Gen Pharmacol** 1997 May; 28(5):753–6

Developmental differences in the expression of the cholera toxin sensitive subunit (Gs alpha) of adenylate cyclase in the rat small intestine. Sanderson IR, et al. **Gut** 1996 Jun; 38(6):853–8

The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Castellano M, et al. **Hypertension** 1997 Mar;29(3):715–22 (52 ref.)

Beta-adrenoceptor desensitization despite cardiac denervation in human failing transplanted myocardium. Reithmann C, et al. **Int J Cardiol** 1996 Sep;56(1):11–5

Adenylate cyclase of gastric mucosa in patients with chronic renal failure. Gladziwa U, et al. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):477–81

Evidence for the direct involvement of transmembrane region 6 of the lutropin/choriogonadotropin receptor in activating Gs. Abell AN, et al. **J Biol Chem** 1997 Jun 6; 272(23):14586–91

Dissociation of chemotaxis from agonist-induced receptor internalization in a lymphocyte cell line transfected with CCR2B. Evidence that directed migration does not require rapid modulation of signaling at the receptor level. Arai H, et al. **J Biol Chem** 1997 Oct 3;272(40):25037–42

Opiate-induced adenylyl cyclase superactivation is isozyme-specific. Avidor-Reiss T, et al. **J Biol Chem** 1997 Feb 21;272(8):5040–7

A truncated form of RGS3 negatively regulates G protein-coupled receptor stimulation of adenylyl cyclase and phosphoinositide phospholipase C. Chatterjee TK, et al. **J Biol Chem** 1997 Jun 13;272(24):15481–7

Interactions of forskolin and ATP with the cytosolic domains of mammalian adenylyl cyclase. Dessauer CW, et al. **J Biol Chem** 1997 Aug 29;272(35):22272–7

Identification of common and distinct residues involved in the interaction of alphai2 and alphas with adenylyl cyclase. Grishina G, et al. **J Biol Chem** 1997 Aug 15; 272(33):20619–26

Differential regulation of adenylyl cyclases by Galphas. Harry A, et al. **J Biol Chem** 1997 Jul 25;272(30):19017–21

Arfaptin 1, a putative cytosolic target protein of ADP-ribosylation factor, is recruited to Golgi membranes. Kanoh H, et al. **J Biol Chem** 1997 Feb 28;272(9):5421–9

Protein kinase C inhibits adenylyl cyclase type VI activity during desensitization of the A2a-adenosine receptor-mediated cAMP response. Lai HL, et al. **J Biol Chem** 1997 Feb 21;272(8):4970–7

Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. Moro O, et al. **J Biol Chem** 1997 Jan 10;272(2):966–70

Differential coupling of muscarinic m2 and m3 receptors to adenylyl cyclases V/VI in smooth muscle. Concurrent M2-mediated inhibition via Galphai3 and m3-mediated stimulation via Gbetagammaq. Murthy KS, et al. **J Biol Chem** 1997 Aug 22;272(34):21317–24

Differential regulation of type I and type VIII Ca2+-stimulated adenylyl cyclases by Gi-coupled receptors in vivo. Nielsen MD, et al. **J Biol Chem** 1996 Dec 27;271(52):33308–16

Interaction of Gsalpha with the cytosolic domains of mammalian adenylyl cyclase. Sunahara RK, et al. **J Biol Chem** 1997 Aug 29;272(35):22265–71

Phosphorylation and inhibition of type III adenylyl cyclase by calmodulin-dependent protein kinase II in vivo. Wei J, et al. **J Biol Chem** 1996 Sep 27;271(39):24231–5

Three discrete regions of mammalian adenylyl cyclase form a site for Gsalpha activation. Yan SZ, et al. **J Biol Chem** 1997 Jul 25;272(30):18849–54

The bioactive phospholipid, lysophosphatidylcholine, induces cellular effects via G-protein-dependent activation of adenylyl cyclase. Yuan Y, et al. **J Biol Chem** 1996 Oct 25;271(43):27090–8

Protein kinase C alters the responsiveness of adenylyl cyclases to G protein alpha and betagamma subunits. Zimmermann G, et al. **J Biol Chem** 1996 Oct 25; 271(43):27161–6

Expression of adenylyl cyclase and G-protein beta subunit in end-stage human heart failure. Holmer SR, et al. **J Card Fail** 1996 Dec;2(4):279–83

Measurement of adenylylcyclase activity in the AV nodal region of the canine heart: evidence for inhibition by adenosine and acetylcholine. Sugiyama A, et al. **J Cardiovasc Pharmacol** 1997 Jun;29(6):734–9

Parathyroid hormone uses both adenylate cyclase and protein kinase C to regulate acid production in osteoclasts. May LG, et al. **J Cell Biochem** 1997 Jun 15;65(4):565–73

Activation of adenylyl cyclase in human myometrial smooth muscle cells by neuropeptides. Casey ML, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3087–92

Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor. Ohta K, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2633–8

Elevated blood pressure and enhanced myocardial contractility in mice with severe IGF-1 deficiency. Lembo G, et al. **J Clin Invest** 1996 Dec 1;98(11):2648–55

1,25-Dihydroxyvitamin D3 increased beta-adrenergic adenylate cyclase response of fetal rat keratinizing epidermal cells (FRSK cells). Takahashi H, et al. **J Dermatol Sci** 1996 Feb;11(2):121–8

Cyclic AMP levels, adenylyl cyclase activity, and their stimulation by serotonin quantified in intact neurons. Sudlow LC, et al. **J Gen Physiol** 1997 Sep;110(3):243–55

Bioactivities and secondary structures of constrained analogues of human parathyroid hormone: cyclic lactams of the receptor binding region. Barbier JR, et al. **J Med Chem** 1997 Apr 25;40(9):1373–80

Agonist-independent tonic inhibitory influence of Gi on adenylate cyclase activity in rabbit ventricular myocardium and its removal by pertussis toxin: a role of empty receptor-mediated Gi activation. Akaishi Y, et al. **J Mol Cell Cardiol** 1997 Feb;29(2):765–75

Isoform-specific regulation of adenylyl cyclase by oxidized catecholamines. Ebina T, et al. **J Mol Cell Cardiol** 1997 Apr;29(4):1247–54

The effect of age on adenosine A1 receptor function in the rat heart. Gao E, et al. **J Mol Cell Cardiol** 1997 Feb; 29(2):593–602

Receptor-independent activation of cardiac adenylyl cyclase by GDP and membrane-associated nucleoside diphosphate kinase. A new cardiotonic mechanism? Niroomand F, et al. **J Mol Cell Cardiol** 1997 May;29(5):1479–86

Mechanism of cardiac involvement in the WBN/Kob rat. Tsuruta S, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):247–53

Ontogeny of regulatory mechanisms for beta-adrenoceptor control of rat cardiac adenylyl cyclase: targeting of G-proteins and the cyclase catalytic subunit. Zeiders JL, et al. **J Mol Cell Cardiol** 1997 Feb;29(2):603–15

Regulation of delta-opioid receptor mRNA levels by receptor-mediated and direct activation of the adenylyl cyclase-protein kinase A pathway. Buzas B, et al. **J Neurochem** 1997 Feb;68(2):610–5

Attenuation of cyclic AMP production by carbamazepine. Chen G, et al. **J Neurochem** 1996 Nov;67(5):2079–86

In vivo evidence that GABA(B) receptors are negatively coupled to adenylate cyclase in rat striatum. Hashimoto T, et al. **J Neurochem** 1997 Jul;69(1):365–70

Chronic exposure to adenosine receptor agonists and antagonists reciprocally regulates the A1 adenosine receptor-adenylyl cyclase system in cerebellar granule cells. Hettinger-Smith BD, et al. **J Neurochem** 1996 Nov; 67(5):1921–30

Long-term effect of forskolin on the activation of adenylyl cyclase in astrocytes. el Jamali A, et al. **J Neurochem** 1996 Dec;67(6):2532–9

Opposite regulation of adenylyl cyclase by protein kinase C in astrocyte and microglia cultures. Patrizio M, et al. **J Neurochem** 1997 Sep;69(3):1267–77

Involvement of presynaptic histamine H3 receptors in the modulation of somatostatin binding and its effects on adenylyl cyclase activity in the rat frontoparietal cortex. Puebla L, et al. **J Neurochem** 1996 Mar;66(3):1051–9

Pharmacological analysis of mast cell mediator and neurotransmitter receptors coupled to adenylate cyclase and phospholipase C on immunocytochemically-defined human conjunctival epithelial cells. Sharif NA, et al. **J Ocul Pharmacol Ther** 1997 Aug;13(4):321–36

Interactions between neuropeptide Y and the adenylate cyclase pathway in rat mesenteric small arteries: role of membrane potential. Prieto D, et al. **J Physiol (Lond)** 1997 Jul 15;502 (Pt 2):281–92

Measles virus modulates human T-cell somatostatin receptors and their coupling to adenylyl cyclase. Krantic S, et al. **J Virol** 1997 Oct;71(10):7470–7

Dual actions of (-)-stepholidine on the dopamine receptor-mediated adenylate cyclase activity in rat corpus striatum. Dong ZJ, et al. **Life Sci** 1997;61(4):465–72

Dimeric tubulin-stimulated adenylyl cyclase activity is augmented after long-term amitriptyline treatment. Kamada H, et al. **Life Sci** 1997;60(1):57–66

Impairment of muscarinic stimulation of adenylyl cyclase by heparin in rat olfactory bulb. Olianas MC, et al. **Life Sci** 1997;61(5):515–22

Regulation of Escherichia coli adenylate cyclase activity during hexose phosphate transport. Dumay V, et al. **Microbiology** 1996 Mar;142 (Pt 3):575–83

Evidence for physical and functional interactions among two Saccharomyces cerevisiae SH3 domain proteins, an adenylyl cyclase-associated protein and the actin cytoskeleton. Lila T, et al. **Mol Biol Cell** 1997 Feb; 8(2):367–85

Reversal of defective G-proteins and adenylyl cyclase/cAMP signal transduction in diabetic rats by vanadyl sulphate therapy. Anand-Srivastava MB, et al. **Mol Cell Biochem** 1995 Dec 6-20;153(1-2):113–9

Differences in response to activation of adenylyl cyclase by various stimulants in human myocardium. Hynie S, et al. **Mol Cell Biochem** 1996 Oct-Nov;163-164:329–33

Effect of association with adenylyl cyclase-associated protein on the interaction of yeast adenylyl cyclase with Ras protein. Shima F, et al. **Mol Cell Biol** 1997 Mar; 17(3):1057–64

Regulation of type I adenylyl cyclase by calmodulin kinase IV in vivo. Wayman GA, et al. **Mol Cell Biol** 1996 Nov; 16(11):6075–82

Adenylyl cyclases: structure, regulation and function in an enzyme superfamily. Hanoune J, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1-2):179–94 (113 ref.)

Activation of FSH-responsive adenylate cyclase by staurosporine: role for protein phosphorylation in gonadotropin receptor desensitization. Keren-Tal I, et al. **Mol Cell Endocrinol** 1996 Jan 15;116(1):39–48

Stable expression of normal and mutant human ACTH receptor: study of ACTH binding and coupling to adenylate cyclase. Naville D, et al. **Mol Cell Endocrinol** 1997 Apr 25;129(1):83–90

Phosphorylation of the lutropin/choriogonadotropin receptor facilitates uncoupling of the receptor from adenylyl cyclase and endocytosis of the bound hormone. Wang Z, et al. **Mol Endocrinol** 1997 Feb;11(2):183–92

Increased expression of Gs(alpha) enhances activation of the adenylyl cyclase signal transduction cascade. Yang X, et al. **Mol Endocrinol** 1997 Jul;11(8):1053–61

Down regulation of cAMP production by cAMP receptor protein in Escherichia coli: an assessment of the contributions of transcriptional and posttranscriptional control of adenylate cyclase. Inada T, et al. **Mol Gen Genet** 1996 Nov 27;253(1-2):198–204

Angiotensin II type 1 receptor signals through Raf-1 by a protein kinase C-dependent, Ras-independent mechanism. Arai H, et al. **Mol Pharmacol** 1996 Sep;50(3):522–8

Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor. Chidiac P, et al. **Mol Pharmacol** 1996 Sep;50(3):662–9

Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors. Watts VJ, et al. **Mol Pharmacol** 1997 Aug;52(2):181–6

GTP gamma S and forskolin-stimulated adenylyl cyclase activity in post-mortem brain from depressed suicides and controls. Lowther S, et al. **Mol Psychiatry** 1996 Dec; 1(6):470–7

Opioid receptor agonists activate pertussis toxin-sensitive G proteins and inhibit adenylyl cyclase in canine cardiac sarcolemma. Niroomand F, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):643–9

A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture. Oka M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Aug; 356(2):189–96

Crosstalk between thrombin and adenylyl cyclase-stimulating agonists in proliferating human erythroid progenitor cells. Porzig H, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec;353(1):21–7

Decrease in adenylate cyclase activity antecedes neurofibrillary tangle formation. Ohm TG, et al. **Neurobiol Aging** 1997 May-Jun;18(3):275–9

Effect of serotonin and neuropeptides on adenylate cyclase of the central nervous system and peripheral organs of the freshwater snail Planorbarius corneus. Ferretti ME, et al. **Neurochem Int** 1996 Apr;28(4):417–24

Functional coupling of Gi subtype with GABAB receptor/adenylyl cyclase system: analysis using a reconstituted system with purified GTP-binding protein from bovine cerebral cortex. Nishikawa M, et al. **Neurochem Int** 1997 Jul;31(1):21–5

Effect of guanine nucleotides on [3H]glutamate binding and on adenylate cyclase activity in rat brain membranes. Rubin MA, et al. **Neurochem Res** 1997 Feb;22(2):181–7

Immortalized schwann cells express endothelin receptors coupled to adenylyl cyclase and phospholipase C. Wilkins PL, et al. **Neurochem Res** 1997 Apr;22(4):409–18

Adenylyl cyclase activity in clonally derived human myoblast cultures: evidence for myoblast heterogeneity. Hardiman O, et al. **Neuromuscul Disord** 1996 Aug; 6(4):283–91

VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor. Vertongen P, et al. **Neuropeptides** 1996 Oct; 30(5):491–6

Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Chen G, et al. **Neuropsychopharmacology** 1996 Sep; 15(3):271–80

Differential regulation of adenylyl cyclase in fibroblasts from sporadic and familial Alzheimer's disease cases with PS1 and APP mutations. Vestling M, et al. **Neuroreport** 1997 May 27;8(8):2031–5

Reduced immunoreactivity of adenylyl cyclase in dementia of the Alzheimer type. Yamamoto M, et al. **Neuroreport** 1996 Nov 25;7(18):2965–70

Activity of adenylate cyclase and 5'-nucleotidase in the sensorimotor and limbic structures of the brain in rats after manipulatory training. Zhuravin IA, et al. **Neurosci Behav Physiol** 1996 Nov-Dec;26(6):552–7

Regulation of stimulatory adenylyl cyclase signaling during forskolin-induced differentiation of mouse neuroblastoma x rat glioma (NG108-15) cells. Ammer H, et al. **Neurosci Lett** 1997 Jul 25;230(3):143–6

Neuropeptide FF receptors of mouse olfactory bulb: binding properties and stimulation of adenylate cyclase activity. Gherardi N, et al. **Peptides** 1997;18(4):577–83

Effect of low pH treatment on opioid peptides binding to their receptors and functional coupling of G-proteins to adenylyl cyclase in the rat spinal cord. Reddy PL, et al. **Peptides** 1996;17(4):625–8

A match between binding to beta-adrenoceptors and stimulation of adenylyl cyclase parameters of (-)isoproterenol and salbutamol on rat brain. Garnier V, et al. **Pharmacol Res** 1997 Apr;35(4):303–12

Bicarbonate secretion in the guinea pig duodenum: functional characterization of peptide hormone receptors in duodenal enterocytes. Reimer R, et al. **Pharmacology** 1996 Jun; 52(6):339–46

A surface on the G protein beta-subunit involved in interactions with adenylyl cyclases. Chen Y, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2711–4

Gsalpha contains an unidentified covalent modification that increases its affinity for adenylyl cyclase. Kleuss C, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6116–20

Identification of an intramolecular interaction between small regions in type V adenylyl cyclase that influences stimulation of enzyme activity by Gsalpha. Scholich K, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9602–7

Characterization of soluble forms of nonchimeric type V adenylyl cyclases. Scholich K, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):2915–20

Diurnal variation of the adenylyl cyclase type 1 in the rat pineal gland. Tzavara ET, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):11208–12

Effects of age on beta adrenergic subtype activation of adenylyl cyclase in brown adipose tissue. Scarpace PJ, et al. **Proc Soc Exp Biol Med** 1996 Dec;213(3):262–7

Adenylate and guanylate cyclases in Tetrahymena. Umeki S, et al. **Prog Mol Subcell Biol** 1996;17:40–60 (84 ref.)

Metabotropic glutamate receptor subtype 1A activates adenylate cyclase when expressed in baby hamster kidney cells. Thomsen C. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 May; 20(4):709–26

The role of adenylate cyclase, cAMP and PGE2 in the in vitro growth regulation of murine melanoma cells by vitamin E. Ottino P, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 May; 54(5):375–83

Effect of vitamin E and indomethacin treatment on adenylate cyclase activity, PGE2 and cAMP levels in murine melanoma cells. Ottino P, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Feb; 56(2):143–9

G-proteins and beta-adrenergic stimulation of adenylate cyclase activity in the diabetic rat prostate. Carmena MJ, et al. **Prostate** 1997 Sep 15;33(1):46–54

Behavioral stimulation without alteration of beta and 5-HT receptors and adenylate cyclase activity in rat brain after chronic sertraline administration. Tadokoro C, et al. **Psychopharmacology (Berl)** 1997 Mar;130(2):124–30

Kinetic analysis and multiple component monitoring of effectors of adenylyl cyclase activity by quantitative fast-atom bombardment mass spectrometry. Newton RP, et al. **Rapid Commun Mass Spectrom** 1997;11(9):1060–6

Functional reconstitution of detergent-solubilized bovine calf testis luteinizing hormone/chorionic gonadotropin receptor into phospholipid vesicles. Grasso P. **Recept Signal Transduct** 1996;6(2):53–62

Interaction between adrenergic agonists and forskolin on adenylate cyclase activity in the rabbit proximal tubule. Beck JS, et al. **Ren Physiol Biochem** 1995 Sep-Oct; 18(5):231–6

Neither protein kinase C nor adenylate cyclase are altered in the striatum from subjects with schizophrenia. Opeskin K, et al. **Schizophr Res** 1996 Nov 15;22(2):159–64

Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Guo HF, et al. **Science** 1997 May 2;276(5313):795–8

Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Schatz AR, et al. **Toxicol Appl Pharmacol** 1997 Feb;142(2):278–87

Cellular mechanisms for developmental toxicity of chlorpyrifos: targeting the adenylyl cyclase signaling cascade. Song X, et al. **Toxicol Appl Pharmacol** 1997 Jul; 145(1):158–74

Tailoring cAMP-signalling responses through isoform multiplicity. Houslay MD, et al. **Trends Biochem Sci** 1997 Jun;22(6):217–24 (49 ref.)

[Beta adrenergic signal transduction and heart adenyl cyclase] Mercadier JJ, et al. **C R Seances Soc Biol Fil** 1996; 190(2-3):207–18 (23 ref.) (Eng. Abstr.) **(Fre)**

[Morphologic characteristics of epidermal cells in HIV infection] Barkhina TG, et al. **Arkh Patol** 1996 Sep-Oct; 58(5):64–7 (Eng. Abstr.) **(Rus)**

[Humoral and metabolic regulation of pulmonary surfactant production] Serebrovskaia IA, et al. **Fiziol Cheloveka** 1997 Jul-Aug;23(4):83–9 (88 ref.) **(Rus)**

PHYSIOLOGY

Response to: possible contribution of transmembrane Ca2+ influx to adenylate cyclase-mediated NO-cGMP relaxation in rat aorta [letter] Wu SN. **Anesthesiology** 1997 Sep; 87(3):712–3

The adenylyl cyclases as integrators of transmembrane signal transduction. Ishikawa Y, et al. **Circ Res** 1997 Mar;

ADENYL CYCLASE

80(3):297–304 (89 ref.)
Differentiation of F9 teratocarcinoma stem cells to primitive endoderm is regulated by the Gialpha2/Gsalpha axis via phospholipase C and not adenylylcyclase. Gao P, et al. **J Biol Chem** 1996 Nov 29;271(48):30692–8
Factors determining the specificity of signal transduction by guanine nucleotide-binding protein–coupled receptors. Integration of stimulatory and inhibitory input to the effector adenylyl cyclase. Marjamaki A, et al. **J Biol Chem** 1997 Jun 27;272(26):16466–73
Adenylyl cyclase G, an osmosensor controlling germination of Dictyostelium spores. van Es S, et al. **J Biol Chem** 1996 Sep 27;271(39):23623–5
Potentiation of NMDA currents by pituitary adenylate cyclase activating polypeptide in neonatal rat sympathetic preganglionic neurons. Wu SY, et al. **J Neurophysiol** 1997 Aug;78(2):1175–9
Impaired contractile response to beta adrenoceptor stimulation in diabetic rat hearts: alterations in beta adrenoceptors–G protein–adenylate cyclase system and phospholamban phosphorylation. Gando S, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):475–84
Aging and glucocorticoids: effects on cell signaling mediated through adenylyl cyclase. Slotkin TA, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):478–91
Altered beta-adrenergic receptor signaling in heart failure, in vivo gene transfer via adeno and adeno-associated virus. Ping P, et al. **Microcirculation** 1996 Jun;3(2):225–8
G proteins, adenylyl cyclase and related phosphoproteins in the developing rat heart. Bartel S, et al. **Mol Cell Biochem** 1996 Oct–Nov;163–164:31–8
Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors. Watts VJ, et al. **Mol Pharmacol** 1996 Oct;50(4):966–76
Relationship between protein kinase C and adenylyl cyclase activity in the regulation of growth hormone secretion by human pituitary somatotrophinomas. Lei T, et al. **Neurosurgery** 1996 Sep;39(3):569–75; discussion 575–6
[Structure and regulation of adenylyl cyclase] Itoh H. **Tanpakushitsu Kakusan Koso** 1997 Feb;42(3 Suppl):371–8 (53 ref.) **(Jpn)**

RADIATION EFFECTS

A pitfall in the interpretation of data on adenylate cyclase inactivation by irradiation. Swillens S, et al. **FEBS Lett** 1981 Nov 2;134(1):29–31

TOXICITY

Structure–function studies of the adenylate cyclase toxin of Bordetella pertussis and the leukotoxin of Pasteurella haemolytica by heterologous C protein activation and construction of hybrid proteins. Westrop G, et al. **J Bacteriol** 1997 Feb;179(3):871–9

ADENYL IMIDODIPHOSPHATE see **ADENYLYL IMIDODIPHOSPHATE**

ADENYLATE CYCLASE see **ADENYL CYCLASE**

ADENYLATE DEAMINASE see **AMP DEAMINASE**

ADENYLATE KINASE

ANTAGONISTS & INHIBITORS

Inhibition of rabbit muscle adenylate kinase by vitamin C. Russell PJ, et al. **Biochem Biophys Res Commun** 1997 Apr 17;233(2):386–8
Towards a mechanism of AMP-substrate inhibition in adenylate kinase from Escherichia coli. Sinev MA, et al. **FEBS Lett** 1996 Nov 18;397(2–3):273–6

BLOOD

Differentiation and resolution of erythrocyte and muscle adenylate kinase activities in serum by electrophoresis. Murthy VV, et al. **J Clin Lab Anal** 1997;11(4):235–7

CEREBROSPINAL FLUID

Low frequency of adenylate kinase release into cerebrospinal fluid during balanced, normotensive anaesthesia and a non-orthognathic surgical procedure. Enlund M, et al. **J Int Med Res** 1997 Mar–Apr;25(2):92–7
Adenylate kinase activity in the cerebrospinal fluid of children with tuberculous meningitis and its relationship to neurological outcome. Carlini SM, et al. **Scand J Infect Dis** 1997;29(3):275–80

CHEMISTRY

Adenylate kinase from Sulfolobus acidocaldarius: expression in Escherichia coli and characterization by Fourier transform infrared spectroscopy. Bönisch H, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):75–84
Characterization of metal and nucleotide liganded forms of adenylate kinase by electrospray ionization mass spectrometry. Briand G, et al. **Arch Biochem Biophys** 1997 Mar 15;339(2):291–7
Activation of adenylate kinase by denaturants is due to the increasing conformational flexibility at its active sites. Zhang HJ, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):382–6
Modelling the 2-kinase domain of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase on adenylate kinase [published erratum appears in Biochem J 1997 May 1;323(Pt 3):864] Bertrand L, et al. **Biochem J** 1997 Feb 1;321 (Pt 3):615–21
A new non-heme iron environment in Paracoccus denitrificans adenylate kinase studied by electron paramagnetic resonance and electron spin echo envelope modulation spectroscopy. Deligiannakis Y, et al. **Biochemistry** 1997 Aug 5;36(31):9446–52
A new approach to secondary structure evaluation: secondary structure prediction of porcine adenylate kinase and yeast guanylate kinase by CD spectroscopy of overlapping synthetic peptide segments. Behrends HW, et al. **Biopolymers** 1997 Feb;41(2):213–31
Domain movement in rabbit muscle adenylate kinase might involve proline isomerization. Sheng XR, et al. **FEBS Lett** 1997 Aug 25;413(3):429–32
The adenylate kinase genes of M. voltae, M. thermolithotrophicus, M. jannaschii, and M. igneus define a new family of adenylate kinases. Ferber DM, et al. **Gene** 1997 Feb 7;185(2):239–44
The structure of bovine mitochondrial adenylate kinase: comparison with isoenzymes in other compartments. Schlauderer GJ, et al. **Protein Sci** 1996 Mar;5(3):434–41
Study of global motions in proteins by weighted masses molecular dynamics: adenylate kinase as a test case. Elamrani S, et al. **Proteins** 1996 May;25(1):79–88
Structural basis for thermostability and identification of potential active site residues for adenylate kinases from the archaeal genus Methanococcus. Haney P, et al. **Proteins** 1997 May;28(1):117–30
Adenylate kinase motions during catalysis: an energetic counterweight balancing substrate binding. Müller CW, et al. **Structure** 1996 Feb 15;4(2):147–56

DEFICIENCY

[Hemolytic anemia due to abnormalities in erythrocyte nucleotide metabolism] Masuda M, et al. **Nippon Rinsho** 1996 Sep;54(9):2473–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

A new DNA marker, U15557, is linked to protease inhibitor and adenylate kinase-1 in the laboratory opossum, Monodelphis domestica. Perelygin AA, et al. **Anim Genet** 1996 Apr;27(2):113–6
Adenylate kinase from Sulfolobus acidocaldarius: expression in Escherichia coli and characterization by Fourier transform infrared spectroscopy. Bönisch H, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):75–84
Construction of the plasmid PMEX8-HAK1 and random site-directed mutagenesis of human cytosolic adenylate kinase. Ayabe T, et al. **Biochem Mol Biol Int** 1996 Feb; 38(2):373–81
Cloning and characterization of cDNA for human adenylate kinase 2A. Lee Y, et al. **Biochem Mol Biol Int** 1996 Jul; 39(4):833–42
The adenylate kinase genes of M. voltae, M. thermolithotrophicus, M. jannaschii, and M. igneus define a new family of adenylate kinases. Ferber DM, et al. **Gene** 1997 Feb 7;185(2):239–44
Cloning and characterization of the gene encoding Halobacterium halobium adenylate kinase. Song S, et al. **Gene** 1996 Oct 10;175(1–2):65–70
A comparison of the nucleotide sequences of the adk and recA genes of pathogenic and commensal Neisseria species: evidence for extensive interspecies recombination within adk. Feil E, et al. **J Mol Evol** 1996 Dec;43(6):631–40

ISOLATION & PURIFICATION

Differentiation and resolution of erythrocyte and muscle adenylate kinase activities in serum by electrophoresis. Murthy VV, et al. **J Clin Lab Anal** 1997;11(4):235–7

METABOLISM

A bioluminescent enzymatic assay for adenylylcyclase activity. McKnite S, et al. **Anal Biochem** 1996 Mar 1; 235(1):103–6
Substrate-binding and catalytic roles of Lys194 in the C-terminus in human adenylate kinase by site-directed random mutagenesis. Ayabe T, et al. **Biochem Mol Biol Int** 1997 Feb;41(2):367–75
Catalytic roles of lysines (K9, K27, K31) in the N-terminal domain in human adenylate kinase by random site-directed mutagenesis. Ayabe T, et al. **Biochem Mol Biol Int** 1996 Nov;40(5):897–906
Glycogen phosphorylase may be activated by AMP-kinase in skeletal muscle. Young ME, et al. **Biochem Soc Trans** 1996 May;24(2):268S
Essential lysine residues in the N-terminal and the C-terminal domain of human adenylate kinase interact with adenine nucleotides as found by site-directed random mutagenesis. Ayabe T, et al. **Biochemistry** 1997 Apr 1;36(13):4027–33
Three extremely thermostable proteins from Sulfolobus and a reappraisal of the 'traffic rules'. Schäfer T, et al. **Biol Chem** 1996 Jul–Aug;377(7–8):505–12
Steady-state kinetics of Thr35 and Thr39 mutants in human adenylate kinase by site-directed mutagenesis. Ayabe T, et al. **Enzyme Protein** 1996;49(5–6):305–12
A recombinant polypeptide model of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator functions as an active ATPase, GTPase and adenylate kinase. Randak C, et al. **FEBS Lett** 1997 Jun 30;410(2–3):180–6
Towards a mechanism of AMP-substrate inhibition in adenylate kinase from Escherichia coli. Sinev MA, et al. **FEBS Lett** 1996 Nov 18;397(2–3):273–6
Modified nucleotides as substrates and inhibitors of adenylate kinase from different sources. Skoblov JS, et al. **FEBS Lett** 1996 Oct 21;395(2–3):283–5
Reversal of the ATP-liganded state of ATP-sensitive K+ channels by adenylate kinase activity. Elvir-Mairena JR, et al. **J Biol Chem** 1996 Dec 13;271(50):31903–8
Adjustment of K' for the creatine kinase, adenylate kinase and ATP hydrolysis equilibria to varying temperature and ionic strength. Teague WE Jr, et al. **J Exp Biol** 1996 Feb; 199 (Pt 2):509–12
Study of global motions in proteins by weighted masses molecular dynamics: adenylate kinase as a test case. Elamrani S, et al. **Proteins** 1996 May;25(1):79–88

PHYSIOLOGY

Neuropeptide Y modulates ATP-induced increases in internal calcium via the adenylate cyclase/protein kinase A system in a human neuroblastoma cell line. Soares Lemos V, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):439–44

ADENYLATE PHOSPHATASE see **5'-NUCLEOTIDASE**

ADENYLIC ACID see **ADENOSINE MONOPHOSPHATE**

ADENYLOSUCCINASE see **ADENYLOSUCCINATE LYASE**

ADENYLOSUCCINATE LYASE

DEFICIENCY

Failure of muscle energy metabolism in a patient with adenylosuccinate lyase deficiency. An in vivo study by phosphorus NMR spectroscopy. Salerno C, et al. **Biochim Biophys Acta** 1997 May 24;1360(3):271–6
Adenylosuccinate lyase deficiency and disorders of saccharide metabolism; experience with combined screening test [letter] [published erratum appears in Clin Chim Acta 1996 Nov 15;255(1):89] Valik D, et al. **Clin Chim Acta** 1996 May 30;249(1–2):197–200
Inborn errors of the purine nucleotide cycle: adenylosuccinase deficiency. Van den Berghe G, et al. **J Inherit Metab Dis** 1997 Jun;20(2):193–202 (34 ref.)
First U.S. case of adenylosuccinate lyase deficiency with severe hypotonia. Valik D, et al. **Pediatr Neurol** 1997 Apr; 16(3):252–5

GENETICS

Adenylosuccinate lyase (ADSL) and infantile autism: absence of previously reported point mutation. Fon EA, et al. **Am J Med Genet** 1995 Dec 18;60(6):554–7
The purB gene of Escherichia coli K-12 is located in an operon. Green SM, et al. **Microbiology** 1996 Nov;142 (Pt 11):3219–30
Characterisation of the gene encoding adenylosuccinate lyase of Plasmodium falciparum. Marshall VM, et al. **Mol Biochem Parasitol** 1997 Sep;88(1–2):237–41

ULTRASTRUCTURE

Identification of His141 in the active site of Bacillus subtilis adenylosuccinate lyase by affinity labeling with 6-(4-bromo-2,3-dioxobutyl)thioadenosine 5'-monophosphate. Lee TT, et al. **J Biol Chem** 1997 Jan 3;272(1):458–65

ADENYLOSUCCINATE SYNTHETASE

CHEMISTRY

Refined crystal structure of adenylosuccinate synthetase from Escherichia coli complexed with hydantocidin 5'-phosphate, GDP, HPO4(2-), Mg2+, and hadacidin. Poland BW, et al. **Biochemistry** 1996 Dec 10;35(49):15753–9
Residues essential for catalysis and stability of the active site of Escherichia coli adenylosuccinate synthetase as revealed by directed mutation and kinetics. Kang C, et al. **J Biol Chem** 1997 May 2;272(18):11881–5
Entrapment of 6-thiophosphoryl-IMP in the active site of crystalline adenylosuccinate synthetase from Escherichia coli. Poland BW, et al. **J Biol Chem** 1997 Jun 13; 272(24):15200–5
A study of Escherichia coli adenylosuccinate synthetase association states and the interface residues of the homodimer. Wang W, et al. **J Biol Chem** 1997 Mar 14; 272(11):7078–84
Homology modeling of adenylosuccinate synthetase from Saccharomyces cerevisiae reveals a possible binding region for single-stranded ARS sequences. Sticht H, et al. **J Biomol Struct Dyn** 1997 Jun;14(6):667–75
Crystal structures of adenylosuccinate synthetase from Escherichia coli complexed with GDP, IMP hadacidin, NO3-, and Mg2+. Poland BW, et al. **J Mol Biol** 1996 Dec 20;264(5):1013–27

DRUG EFFECTS

Adenylosuccinate synthetase: site of action of hydantocidin, a microbial phytotoxin. Siehl DL, et al. **Plant Physiol** 1996 Mar;110(3):753–8

GENETICS

Subunit complementation of Escherichia coli adenylosuccinate synthetase. Kang C, et al. **J Biol Chem** 1996 Nov 22;271(47):29722–8

Structure and expression of the murine muscle adenylosuccinate synthetase gene. Lewis AL, et al. **J Biol Chem** 1996 Sep 13;271(37):22647–56

ISOLATION & PURIFICATION

Adenylosuccinate synthetase from maize. Purification, properties, and mechanism of inhibition by 5'-phosphohydantocidin. Walters EW, et al. **Plant Physiol** 1997 Jun;114(2):549–55

METABOLISM

Chemical arrows for enzymatic targets. Colman RF. **FASEB J** 1997 Mar;11(4):217–26 (27 ref.)

Residues essential for catalysis and stability of the active site of Escherichia coli adenylosuccinate synthetase as revealed by directed mutation and kinetics. Kang C, et al. **J Biol Chem** 1997 May 2;272(18):11881–5

Relationship of conserved residues in the IMP binding site to substrate recognition and catalysis in Escherichia coli adenylosuccinate synthetase. Wang W, et al. **J Biol Chem** 1997 Jul 4;272(27):16911–6

ADENYLPYROPHOSPHATE see **ADENOSINE TRIPHOSPHATE**

ADENYLYL IMIDODIPHOSPHATE

CHEMISTRY

X-ray structures of the MgADP, MgATPgammaS, and MgAMPPNP complexes of the Dictyostelium discoideum myosin motor domain. Gulick AM, et al. **Biochemistry** 1997 Sep 30;36(39):11619–28

METABOLISM

Hydrolysis of AMPPNP by the motor domain of ncd, a kinesin-related protein. Suzuki Y, et al. **FEBS Lett** 1997 Jun 2;409(1):29–32

PHARMACOLOGY

Inhibition of ecto-ATPase by the P2 purinoceptor agonists, ATPgammaS, alpha,beta-methylene-ATP, and AMP-PNP, in endothelial cells. Chen BC, et al. **Biochem Biophys Res Commun** 1997 Apr 17;233(2):442–6

Plus-end motors override minus-end motors during transport of squid axon vesicles on microtubules. Muresan V, et al. **J Cell Biol** 1996 Oct;135(2):383–97

Electron tomography of insect flight muscle in rigor and AMPPNP at 23 degrees C. Schmitz H, et al. **J Mol Biol** 1996 Nov 29;264(2):279–301

Three-dimensional structure of nucleotide-bearing crossbridges in situ: oblique section reconstruction of insect flight muscle in AMPPNP at 23 degrees C. Winkler H, et al. **J Mol Biol** 1996 Nov 29;264(2):302–22

Selected P2 purinoceptor modulators prevent glutamate-evoked cytotoxicity in cultured cerebellar granule neurons. Volonté C, et al. **J Neurosci Res** 1996 Jul 15;45(2):183–93

ADENYLYL SULFATE see **ADENOSINE PHOSPHOSULFATE**

ADHESINS, BACTERIAL

see related
BACTERIAL ADHESION

The FimH protein of type 1 fimbriae. An adaptable adhesin. Klemm P, et al. **Adv Exp Med Biol** 1996;408:193–5 (5 ref.)

Host–bacteria interactions in foreign body infections. François P, et al. **Infect Control Hosp Epidemiol** 1996 Aug; 17(8):514–20 (63 ref.)

ADMINISTRATION & DOSAGE

Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine. Pichichero ME, et al. **Scand J Infect Dis** 1996;28(2):159–63

ANALYSIS

Expression of P, S, and F1C adhesins by cytotoxic necrotizing factor 1-producing Escherichia coli from septicemic and diarrheic pigs. Dozois CM, et al. **FEMS Microbiol Lett** 1997 Jul 15;152(2):307–12

Identification of two minor subunits in the pilus of Haemophilus influenzae. McCrea KW, et al. **J Bacteriol** 1997 Jul;179(13):4227–31

[Significance of the detection of fimbriae protein type adhesins on bacteria isolated in acute pyelonephritis in children] Lebret T, et al. **Ann Urol (Paris)** 1997;31(2):92–6 (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Norepinephrine-induced expression of the K99 pilus adhesin of enterotoxigenic Escherichia coli. Lyte M, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):682–6

Peptide methionine sulfoxide reductase contributes to the maintenance of adhesins in three major pathogens. Wizemann TM, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7985–90

Construction and oral immunogenicity of a Salmonella typhimurium strain expressing a streptococcal adhesin linked to the A2/B subunits of cholera toxin. Hajishengallis G, et al. **Vaccine** 1996 Nov;14(16):1545–8

CHEMISTRY

Fimbrial adhesins: similarities and variations in structure and biogenesis. Smyth CJ, et al. **FEMS Immunol Med Microbiol** 1996 Dec 1;16(2):127–39 (65 ref.)

Primary structure analysis and adhesion studies on the major outer membrane protein of Campylobacter jejuni. Schröder W, et al. **FEMS Microbiol Lett** 1997 May 1;150(1):141–7

The type-4 pilus is the major virulence-associated adhesin of Pseudomonas aeruginosa—a review. Hahn HP. **Gene** 1997 Jun 11;192(1):99–108 (64 ref.)

Repetitive elements of the Mycoplasma hominis adhesin p50 can be differentiated by monoclonal antibodies. Henrich B, et al. **Infect Immun** 1996 Oct;64(10):4027–34

Identification of phosphatidylinositol mannoside as a mycobacterial adhesin mediating both direct and opsonic binding to nonphagocytic mammalian cells. Hoppe HC, et al. **Infect Immun** 1997 Sep;65(9):3896–905

GENETICS

Detection and differentiation of 3 K88 serogroups using polymerase chain reaction techniques. K88 serogroup detection and differentiation. Franklin MA, et al. **Adv Exp Med Biol** 1997;412:77–9

Molecular determinants of the interaction between Haemophilus influenzae and human cells. Geme JW 3rd. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S192–6 (54 ref.)

Recognition of mucin by the adhesin-flagellar system of Pseudomonas aeruginosa. Ramphal R, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S170–4 (32 ref.)

Genes specifying receptors for F18 fimbriated Escherichia coli, causing oedema disease and postweaning diarrhoea in pigs, map to chromosome 6. Vögeli P, et al. **Anim Genet** 1996 Oct;27(5):321–8

Frequency of pap and pil operons in Escherichia coli strains associated with urinary infections. Perugini MR, et al. **Braz J Med Biol Res** 1996 Mar;29(3):351–7

Isolation and characterization of transposon Tn4001-generated, cytadherence-deficient transformants of Mycoplasma pneumoniae and Mycoplasma genitalium. Reddy SP, et al. **FEMS Immunol Med Microbiol** 1996 Oct; 15(4):199–211

The adhesin related 30-kDa protein of Mycoplasma pneumoniae exhibits size and antigen variability. Layh-Schmitt G, et al. **FEMS Microbiol Lett** 1997 Jul 1; 152(1):101–8

Linker insertion analysis of the FimH adhesin of type 1 fimbriae in an Escherichia coli fimH-null background. Schembri MA, et al. **FEMS Microbiol Lett** 1996 Apr 1; 137(2–3):257–63

Molecular analysis of the gene encoding a protein component of the Eikenella corrodens adhesin complex that is close to the carbohydrate recognition domain. Azakami H, et al. **Gene** 1996 Nov 21;180(1–2):207–12

Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Berry AM, et al. **Infect Immun** 1996 Dec; 64(12):5255–62

Transcriptional regulation of the Staphylococcus aureus collagen adhesion gene, cna. Gillaspy AF, et al. **Infect Immun** 1997 Apr;65(4):1536–40

Reevaluation of the virulence phenotype of the inv yadA double mutants of Yersinia pseudotuberculosis. Han YW, et al. **Infect Immun** 1997 Jan;65(1):327–30

Proteus mirabilis mannose-resistant, Proteus-like fimbriae: MrpG is located at the fimbrial tip and is required for fimbrial assembly. Li X, et al. **Infect Immun** 1997 Apr; 65(4):1327–34

Cloning and characterization of the gene encoding the OmpU outer membrane protein of Vibrio cholerae. Sperandio V, et al. **Infect Immun** 1996 Dec;64(12):5406–9

Insertional inactivation of an intrageneric coaggregation-relevant adhesin locus from Streptococcus gordonii DL1 (Challis). Whittaker CJ, et al. **Infect Immun** 1996 Oct;64(10):4137–42

The Tla protein of Porphyromonas gingivalis W50: a homolog of the RI protease precursor (PrpRI) is an outer membrane receptor required for growth on low levels of hemin. Aduse-Opoku J, et al. **J Bacteriol** 1997 Aug; 179(15):4778–88

Nature of DNA binding and RNA polymerase interaction of the Bordetella pertussis BvgA transcriptional activator at the fha promoter. Boucher PE, et al. **J Bacteriol** 1997 Mar;179(5):1755–63

Constitutive expression of fibronectin binding in Streptococcus pyogenes as a result of anaerobic activation of rofA. Fogg GC, et al. **J Bacteriol** 1997 Oct; 179(19):6172–80

Cloning and functional analysis of the P97 swine cilium adhesin gene of Mycoplasma hyopneumoniae. Hsu T, et al. **J Bacteriol** 1997 Feb;179(4):1317–23

Characterization of the genetic locus encoding Haemophilus influenzae type b surface fibrils. St. Geme JW 3rd, et al. **J Bacteriol** 1996 Nov;178(21):6281–7

Molecular cloning and characterization of Porphyromonas gingivalis lysine-specific gingipain. A new member of an emerging family of pathogenic bacterial cysteine proteinases. Pavloff N, et al. **J Biol Chem** 1997 Jan 17; 272(3):1595–600

Rapid and specific detection of F17-related pilin and adhesin genes in diarrheic and septicemic Escherichia coli strains by multiplex PCR. Bertin Y, et al. **J Clin Microbiol** 1996 Dec;34(12):2921–8

Analysis of the protease and adhesin domains of the PrpRI of Porphyromonas gingivalis. Curtis MA. **J Periodontal Res** 1997 Jan;32(1 Pt 2):133–9

Interruption of the Streptococcus gordonii M5 sspA/sspB intergenic region by an insertion sequence related to IS1167 of Streptococcus pneumoniae. Demuth DR, et al. **Microbiology** 1997 Jun;143 (Pt 6):2047–55

Tandem genes encode cell-surface polypeptides SspA and SspB which mediate adhesion of the oral bacterium Streptococcus gordonii to human and bacterial receptors. Demuth DR, et al. **Mol Microbiol** 1996 Apr;20(2):403–13

Transcriptional regulation of the Yersinia pseudotuberculosis pH6 antigen adhesin by two envelope-associated components. Yang Y, et al. **Mol Microbiol** 1997 May; 24(3):499–510

IMMUNOLOGY

Adhesins of Staphylococcus aureus that bind Lewis(a) antigen. Relationship to sudden infant death syndrome. Blackwell CC, et al. **Adv Exp Med Biol** 1996;408:95–105 (55 ref.)

Adhesion molecules in leukocyte endothelial interaction. Etzioni A. **Adv Exp Med Biol** 1996;408:151–7 (15 ref.)

Towards anti-Pseudomonas aeruginosa adhesion therapy. Gilboa-Garber N. **Adv Exp Med Biol** 1996;408:39–50 (63 ref.)

The Gal alpha 1-4 Gal-binding adhesin of Streptococcus suis, a gram-positive meningitis-associated bacterium. Haataja S, et al. **Adv Exp Med Biol** 1996;408:25–34 (21 ref.)

Alternative inhibitors of mycoplasma adherence. Kahane I, et al. **Adv Exp Med Biol** 1996;408:107–11 (14 ref.)

Interactions of bacterial adhesins with the extracellular matrix. Ljungh A, et al. **Adv Exp Med Biol** 1996;408:129–40 (72 ref.)

Studies on the molecular mechanisms of meningococcal interactions with human cells. Towards anti-adhesion measures for the control of meningococcal disease. Virji M. **Adv Exp Med Biol** 1996;408:113–22 (40 ref.)

Anti-adhesins of Streptococcus sobrinus. Wang Q, et al. **Adv Exp Med Biol** 1996;408:249–62 (48 ref.)

Pertussis antigens that abrogate bacterial adherence and elicit immunity. Brennan MJ, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S145–9 (34 ref.)

Purification and seroreactivity of pneumococcal surface adhesin A (PsaA). Tharpe JA, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):227–9

Detection of antibodies to Mycoplasma pneumoniae adhesion P1 in serum specimens from infected and non-infected subjects by immunoblotting. Rastawicki W, et al. **Diagn Microbiol Infect Dis** 1996 Nov-Dec;26(3–4):141–3

Fimbriae and the hemagglutinating adhesin HA-Ag2 mediate adhesion of Porphyromonas gingivalis to epithelial cells. Du L, et al. **Infect Immun** 1997 Sep;65(9):3875–81

Streptococcus sanguis expresses a 150-kilodalton two-domain adhesin: characterization of several independent adhesin epitopes. Gong K, et al. **Infect Immun** 1997 Sep;65(9):3815–21

Characterization of a recombinant fragment that contains a carbohydrate recognition domain of the filamentous hemagglutinin. Liu DF, et al. **Infect Immun** 1997 Aug; 65(8):3465–8

Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection. Thankavel K, et al. **J Clin Invest** 1997 Sep 1;100(5):1123–36

Immunodominant domains present on the Bordetella pertussis vaccine component filamentous hemagglutinin. Leininger E, et al. **J Infect Dis** 1997 Jun;175(6):1423–31

Monoclonal antibodies against fimbrial subunits of colonization factor antigen I (CFA/I) inhibit binding to human enterocytes and protect against enterotoxigenic Escherichia coli expressing heterologous colonization factors. Rudin A, et al. **Microb Pathog** 1996 Jul;21(1):35–45

Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis. Renauld-Mongénie G, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7944–9

Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination [see comments] Langermann S, et al. **Science** 1997 Apr 25;276(5312):607–11 . Comment in: Science 1997 Apr 25;276(5312):533–4.

ADHESINS, BACTERIAL

New vaccines may ward off urinary tract infections [news; comment] Service RF. **Science** 1997 Apr 25;276(5312):533 . Comment on: Science 1997 Apr 25;276(5312):607–11.

ISOLATION & PURIFICATION

Purification and seroreactivity of pneumococcal surface adhesin A (PsaA). Tharpe JA, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):227–9

Receptor affinity purification of a lipid–binding adhesin from Haemophilus influenzae. Busse J, et al. **J Infect Dis** 1997 Jan;175(1):77–83

New fimbrial adhesins of Serratia marcescens isolated from urinary tract infections: description and properties. Leranoz S, et al. **J Urol** 1997 Feb;157(2):694–8

Identification of a 95 kDa putative adhesin from Actinomyces serovar WVA963 strain PK1259 that is distinct from type 2 fimbrial subunits. Klier CM, et al. **Microbiology** 1997 Mar; 143 (Pt 3):835–46

METABOLISM

Proteins F1 and F2 of Streptococcus pyogenes. Properties of fibronectin binding. Hanski E, et al. **Adv Exp Med Biol** 1996;408:141–50 (23 ref.)

Binding between Pseudomonas aeruginosa adhesins and human salivary, tracheobronchial and nasopharyngeal mucins. Reddy MS. **Biochem Mol Biol Int** 1996 Oct; 40(2):403–8

Adherence of Helicobacter pylori to the gastric mucosa. Clyne M, et al. **Can J Gastroenterol** 1997 Apr;11(3):243–8 (93 ref.)

Interactions of bacterial adhesins with extracellular matrix and plasma proteins: pathogenic implications and therapeutic possibilities. Ljungh A, et al. **FEMS Immunol Med Microbiol** 1996 Dec 1;16(2):117–26 (79 ref.)

Bordetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutinin. Berggård K, et al. **Infect Immun** 1997 Sep;65(9):3638–43

Lack of functional complementation between Bordetella pertussis filamentous hemagglutinin and Proteus mirabilis HpmA hemolysin secretion machineries. Jacob–Dubuisson F, et al. **J Bacteriol** 1997 Feb;179(3):775–83

Activation of blood coagulation factor X by arginine–specific cysteine proteinases (gingipain–Rs) from Porphyromonas gingivalis. Imamura T, et al. **J Biol Chem** 1997 Jun 20; 272(25):16062–7

Diversity of the Escherichia coli type 1 fimbrial lectin. Differential binding to mannosides and uroepithelial cells. Sokurenko EV, et al. **J Biol Chem** 1997 Jul 11; 272(28):17880–6

Receptor affinity purification of a lipid–binding adhesin from Haemophilus influenzae. Busse J, et al. **J Infect Dis** 1997 Jan;175(1):77–83

A cell–associated protein complex of Porphyromonas gingivalis W50 composed of Arg– and Lys–specific cysteine proteinases and adhesins. Bhogal PS, et al. **Microbiology** 1997 Jul;143 (Pt 7):2485–95

Mycoplasma pneumoniae cytadherence: unravelling the tie that binds. Krause DC. **Mol Microbiol** 1996 Apr; 20(2):247–53 (35 ref.)

PHARMACOLOGY

Pseudomonas aeruginosa II lectin stops human ciliary beating: therapeutic implications of fucose. Adam EC, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):2102–4

Cilia from a cystic fibrosis patient react to the ciliotoxic Pseudomonas aeruginosa II lectin in a similar manner to normal control cilia—a case report. Adam EC, et al. **J Laryngol Otol** 1997 Aug;111(8):760–2

PHYSIOLOGY

Fimbrial adhesins of Salmonella typhimurium. Role in bacterial interactions with epithelial cells. Bäumler AJ, et al. **Adv Exp Med Biol** 1997;412:149–58 (56 ref.)

Bacterial adhesins: determinants of microbial colonization and pathogenicity. St. Geme JW 3rd. **Adv Pediatr** 1997; 44:43–72 (144 ref.)

PSP expression in murine lacrimal glands and function as a bacteria binding protein in exocrine secretions. Robinson CP, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):G863–71

Cell envelope characteristics of Helicobacter pylori: their role in adherence to mucosal surfaces and virulence. Clyne M, et al. **FEMS Immunol Med Microbiol** 1996 Dec 1; 16(2):141–55

Type–4 pili and meningococcal adhesiveness. Nassif X, et al. **Gene** 1997 Jun 11;192(1):149–53 (28 ref.)

Candida albicans binding to the oral bacterium Streptococcus gordonii involves multiple adhesin–receptor interactions. Holmes AR, et al. **Infect Immun** 1996 Nov;64(11):4680–5

In vitro attachment and invasion of chicken ovarian granulosa cells by Salmonella enteritidis phage type 8. Thiagarajan D, et al. **Infect Immun** 1996 Dec; 64(12):5015–21

Association of biofilm production of coagulase–negative staphylococci with expression of a specific polysaccharide intercellular adhesin. Mack D, et al. **J Infect Dis** 1996 Oct; 174(4):881–4

Role of Staphylococcus aureus surface adhesins in orthopaedic device infections: are results model–dependent? Darouiche RO, et al. **J Med Microbiol** 1997 Jan;46(1):75–9

Multiple colonization defects in a cysteine protease mutant of Porphyromonas gingivalis. Kuramitsu H, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):140–2

Molecular evidence for pap–G specific adhesion of Escherichia coli to human renal cells. Söderhäll M, et al. **J Urol** 1997 Jan;157(1):346–50

[Allergic inflammation—participation and role of adhesion molecules] Pawliczak R, et al. **Postepy Hig Med Dosw** 1997; 51(1):39–53 (61 ref.) (Eng. Abstr.) **(Pol)**

RADIATION EFFECTS

Heat shock transcription factor, HSF, is activated by ultraviolet irradiation. Ohnishi K, et al. **Photochem Photobiol** 1996 Dec;64(6):949–52

TOXICITY

Relation of YadA to arthritogenicity of Yersinia enterocolitica: experimental studies in the rat. Gripenberg–Lerche C, et al. **Contrib Microbiol Immunol** 1995;13:188–90

ADHESINS, ESCHERICHIA COLI

ANALYSIS

Occurrence of S and F1C/S–related fimbrial determinants and their expression in Escherichia coli strains isolated from extraintestinal infections. Sokolowska–Köhler W, et al. **FEMS Immunol Med Microbiol** 1997 May;18(1):1–6

BIOSYNTHESIS

Autodisplay: one–component system for efficient surface display and release of soluble recombinant proteins from Escherichia coli. Maurer J, et al. **J Bacteriol** 1997 Feb; 179(3):794–804

Processing of the AIDA–I precursor: removal of AIDAc and evidence for the outer membrane anchoring as a beta–barrel structure. Suhr M, et al. **Mol Microbiol** 1996 Oct;22(1):31–42

CHEMISTRY

Transferred nuclear Overhauser effect spectroscopy study of a peptide from the PapG pilus subunit bound by the Escherichia coli PapD chaperone. Walse B, et al. **FEBS Lett** 1997 Jul 21;412(1):115–20

Adhesive factor/rabbit 2, a new fimbrial adhesin and a virulence factor from Escherichia coli O103, a serogroup enteropathogenic for rabbits. Fiederling F, et al. **Infect Immun** 1997 Feb;65(2):847–51

Bacterial adhesins as a drug carrier: covalent attachment of K99 fimbriae to 6–methylprednisolone. Bernkop–Schnürch A, et al. **Pharmazie** 1997 Jan;52(1):41–4

DRUG EFFECTS

Anti–Escherichia coli adhesin activity of cranberry and blueberry juices. Ofek I, et al. **Adv Exp Med Biol** 1996; 408:179–83 (16 ref.)

GENETICS

Detection of the fimbrial gene F18 (F107) from swine enteritis Escherichia coli. Schultz L, et al. **Adv Exp Med Biol** 1997;412:95–7

Presence of pap–, sfa–, and afa–related sequences in necrotoxigenic Escherichia coli isolates from cattle: evidence for new variants of the AFA family. Mainil JG, et al. **Can J Vet Res** 1997 Jul;61(3):193–9

Adhesive factor/rabbit 2, a new fimbrial adhesin and a virulence factor from Escherichia coli O103, a serogroup enteropathogenic for rabbits. Fiederling F, et al. **Infect Immun** 1997 Feb;65(2):847–51

Characteristics and prevalence within serogroup O4 of a J96–like clonal group of uropathogenic Escherichia coli O4:H5 containing the class I and class III alleles of papG. Johnson JR, et al. **Infect Immun** 1997 Jun;65(6):2153–9

Distribution of drb genes coding for Dr binding adhesins among uropathogenic and fecal Escherichia coli isolates and identification of new subtypes. Zhang L, et al. **Infect Immun** 1997 Jun;65(6):2011–8

Dr fimbriae operon of uropathogenic Escherichia coli mediate microtubule–dependent invasion to the HeLa epithelial cell line. Goluszko P, et al. **J Infect Dis** 1997 Jul;176(1):158–67

Receptor specificities of variant Gal(alpha1–4)Gal–binding PapG adhesins of uropathogenic Escherichia coli as assessed by hemagglutination phenotypes. Johnson JR, et al. **J Infect Dis** 1997 Feb;175(2):373–81

Discovery of disseminated J96–like strains of uropathogenic Escherichia coli O4:H5 containing genes for both PapG(J96) (class I) and PrsG(J96) (class III) Gal(alpha1–4)Gal–binding adhesins. Johnson JR, et al. **J Infect Dis** 1997 Apr;175(4):983–8

A PCR–based method of detection and differentiation of K88+ adhesive Escherichia coli. Franklin MA, et al. **J Vet Diagn Invest** 1996 Oct;8(4):460–3

The afimbrial adhesive sheath encoded by the afa–3 gene cluster of pathogenic Escherichia coli is composed of two adhesins. Garcia MI, et al. **Mol Microbiol** 1996 Feb; 19(4):683–93

An Escherichia coli CS31A fibrillum chimera capable of inducing memory antibodies in outbred mice following booster immunization with the entero–pathogenic coronavirus transmissible gastroenteritis virus. Der Vartanian M, et al. **Vaccine** 1997 Feb;15(2):111–20

IMMUNOLOGY

Nonfimbrial adhesins of Escherichia coli. Goldhar J. **Adv Exp Med Biol** 1996;408:63–72 (29 ref.)

Adhesion and invasion of Escherichia coli. Studies on function and regulation. Oelschlaeger TA, et al. **Adv Exp Med Biol** 1996;408:57–62 (29 ref.)

Induction of protective immunity after escherichia coli bladder infection in primates. Dependence of the globoside–specific P–fimbrial tip adhesin and its cognate receptor. Söderhäll M, et al. **J Clin Invest** 1997 Jul 15; 100(2):364–72

Epitopes of the P–fimbrial adhesin of E. coli cause different urinary tract infections [see comments] Roberts JA, et al. **J Urol** 1997 Oct;158(4):1610–3. Comment in: J Urol 1997 Oct;158(4):1330.

This month in investigative urology: epitopes of the P–fimbrial adhesin of Escherichia coli and urinary tract infection [comment] Schaeffer AJ. **J Urol** 1997 Oct; 158(4):1330. Comment on: J Urol 1997 Oct;158(4):1610–3.

METABOLISM

PapG adhesin from E. coli J96 recognizes the same saccharide epitope when present on whole bacteria and as isolated protein. Nilsson U, et al. **Bioorg Med Chem** 1996 Nov;4(11):1809–17

PHYSIOLOGY

Molecular evidence for pap–G specific adhesion of Escherichia coli to human renal cells. Söderhäll M, et al. **J Urol** 1997 Jan;157(1):346–50

Mutational analysis of receptor binding mediated by the Dr family of Escherichia coli adhesins. Carnoy C, et al. **Mol Microbiol** 1997 Jan;23(2):365–79

Role of Adhesive Factor/Rabbit 2 in experimental enteropathogenic Escherichia coli O103 diarrhea of weaned rabbit. Pillien F, et al. **Vet Microbiol** 1996 May; 50(1–2):105–15

ADHESINS, FIMBRIAL see **ADHESINS, BACTERIAL**

ADHESION, BACTERIAL see **BACTERIAL ADHESION**

ADHESIONS

The role of growth factors in peritoneal healing: transforming growth factor beta (TGF–beta). Chegini N. **Eur J Surg Suppl** 1997;(577):17–23 (41 ref.)

The clinical significance of adhesions: focus on intestinal obstruction. Ellis H. **Eur J Surg Suppl** 1997;(577):5–9 (29 ref.)

Adhesions: pathogenesis and prevention–panel discussion and summary. Holmdahl L, et al. **Eur J Surg Suppl** 1997; (577):56–62 (57 ref.)

Deposition of extracellular matrix on silicone intraocular lens implants in rabbits. Saika S, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Aug;235(8):517–22

[Postoperative intra–abdominal adhesions: prevention and treatment] Enrico S, et al. **Minerva Chir** 1996 Apr; 51(4):223–6 (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Anatomic distortion of clinically normal appearing fallopian tube: to what extent does it contribute to infertility? Zorlu CG, et al. **Gynecol Obstet Invest** 1996;41(1):44–6

Clinical problem of intraperitoneal postsurgical adhesion formation following general surgery and the use of adhesion prevention barriers. DeCherney AH, et al. **Surg Clin North Am** 1997 Jun;77(3):671–88 (80 ref.)

DIAGNOSIS

Microlaparoscopy: a comparative study of diagnostic accuracy. Faber BM, et al. **Fertil Steril** 1997 May; 67(5):952–4

[The debatable aspects of the adhesive syndrome] Shal'kov IuL. **Vestn Khir Im I I Grek** 1996;155(5):99–103 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Water–soluble contrast material [letter; comment] Freund HR. **Am J Surg** 1997 Feb;173(2):148–9. Comment on: Am J Surg 1996 Feb;171(2):227–9.

EPIDEMIOLOGY

Anterior abdominal wall adhesions after laparotomy or laparoscopy. Levrant SG, et al. **J Am Assoc Gynecol Laparosc** 1997 May;4(3):353–6

ETIOLOGY

Endogenous versus exogenous IL–10 in postoperative intraperitoneal adhesion formation in a murine model. Holschneider CH, et al. **J Surg Res** 1997 Jul 1;70(2):138–43

Effects of polyglycolic acid and polypropylene meshes on postoperative adhesion formation in mice. Baykal A, et al. **World J Surg** 1997 Jul–Aug;21(6):579–82; discussion 582–3

METABOLISM

The role of adhesion molecules in reducing cerebral ischemic cell damage. Chopp M, et al. **Adv Neurol** 1996;71:315–26; discussion 326–7

Restraint stress–induced changes in lymphocyte subsets and the expression of adhesion molecules. Tarcic N, et al. **Neuroimmunomodulation** 1995 Sep–Oct;2(5):249–57

Expression of CD44H in the cells of neural crest origin in peripheral nervous system. Ikeda K, et al. **Neuroreport** 1996 Jul 29;7(11):1713–6

PATHOLOGY

Peritoneal dialysis catheter malfunction due to compartmentalization [letter] Diaz–Buxo JA. **Perit Dial Int** 1997 Mar–Apr;17(2):209–10

PHYSIOPATHOLOGY

Biochemical events in peritoneal tissue repair. diZerega GS. **Eur J Surg Suppl** 1997;(577):10–6 (44 ref.)

The role of fibrinolysis in adhesion formation. Holmdahl L. **Eur J Surg Suppl** 1997;(577):24–31 (44 ref.)

Pathophysiology of adhesion formation and strategies for prevention. Gomel V, et al. **J Reprod Med** 1996 Jan; 41(1):35–41 (65 ref.)

[Role of local fibrinolytic activity of the uterine horns in rats in the pathogenesis of formation of postoperative adhesions] Mynbaev OA, et al. **Patol Fiziol Eksp Ter** 1997 Jan–Mar;(1):35–8 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Prevention of adhesions by Seprafilm, an absorbable adhesion barrier: an incisional hernia model in rats. Alponat A, et al. **Am Surg** 1997 Sep;63(9):818–9

The prevention of experimentally induced postoperative adhesions. Bhatia DS, et al. **Am Surg** 1997 Sep;63(9):775–7

The peritoneal response to expanded polytetrafluoroethylene and oxidized regenerated cellulose surgical adhesion barriers. Haney AF, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1996 Mar; 24(2):121–41

New surgical technique for treatment of extraarticular knee ankylosis. Wang Y, et al. **Clin Orthop** 1997 Apr;(337):172–9

Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery. Nyska M, et al. **Connect Tissue Res** 1996; 34(2):97–103

Adhesions: prevention and complications in general surgery. Holmdahl L, et al. **Eur J Surg** 1997 Mar;163(3):169–74

The role of Seprafilm bioresorbable membrane in adhesion prevention. Beck DE. **Eur J Surg Suppl** 1997;(577):49–55

Preclinical evaluation of Seprafilm bioresorbable membrane. Burns JW, et al. **Eur J Surg Suppl** 1997;(577):40–8 (21 ref.)

Adhesions: preventive strategies. Risberg B. **Eur J Surg Suppl** 1997;(577):32–9 (32 ref.)

A hyaluronate based gel for the prevention of postsurgical adhesions: evaluation in two animal species. Burns JW, et al. **Fertil Steril** 1996 Nov;66(5):814–21

Use of medroxyprogesterone acetate in the prevention of postoperative adhesions. Montanino–Oliva M, et al. **Fertil Steril** 1996 Mar;65(3):650–4

Reduction of adhesion formation with hyaluronic acid after peritoneal surgery in rabbits. Rodgers KE, et al. **Fertil Steril** 1997 Mar;67(3):553–8

Prevention of de–novo adhesion formation after laparoscopic myomectomy: a randomized trial to evaluate the effectiveness of an oxidized regenerated cellulose absorbable barrier. Mais V, et al. **Hum Reprod** 1995 Dec; 10(12):3133–5

Adhesion prevention in laparoscopic surgery. Tulandi T. **Int J Fertil Menopausal Stud** 1996 Sep–Oct;41(5):452–7 (42 ref.)

Prevention of postoperative abdominal adhesions by a sodium hyaluronate–based bioresorbable membrane: a prospective, randomized, double–blind multicenter study [see comments] Becker JM, et al. **J Am Coll Surg** 1996 Oct; 183(4):297–306. Comment in: J Am Coll Surg 1996 Oct;183(4):406–7.

Can adhesions be prevented? [editorial; comment] Hunt TK. **J Am Coll Surg** 1996 Oct;183(4):406–7. Comment on: J Am Coll Surg 1996 Oct;183(4):297–306.

Biodegradable polyurethanes: biodegradable low adherence films for the prevention of adhesions after surgery. Rehman IU. **J Biomater Appl** 1996 Oct;11(2):182–257

Use of nonporous polytetrafluoroethylene prosthesis in combination with polypropylene prosthetic abdominal wall implants in prevention of peritoneal adhesions. Bellón JM, et al. **J Biomed Mater Res** 1997 Fall;38(3):197–202

Efficacy of hyaluronic acid/nonsteroidal anti–inflammatory drug systems in preventing postsurgical tendon adhesions. Miller JA, et al. **J Biomed Mater Res** 1997 Spring; 38(1):25–33

Use of sodium hetastarch (Hespan) solution for reduction of postoperative adhesion formation in rabbits. Gist RS, et al. **J Invest Surg** 1996 Sep–Oct;9(5):369–73

Reduction of adhesion formation by intraperitoneal administration of a recombinant Hirudin analog. Rodgers KE, et al. **J Invest Surg** 1996 Sep–Oct;9(5):385–91

Reduction of adhesion formation by intraperitoneal administration of anti–inflammatory peptide 2. Rodgers KE, et al. **J Invest Surg** 1997 Jan–Apr;10(1–2):31–6

Effects of physical barriers in prevention of adhesions: an incisional hernia model in rats. Alponat A, et al. **J Surg Res** 1997 Mar;68(2):126–32

Adhesion prevention with ancrod released via a tissue–adherent hydrogel. Chowdhury SM, et al. **J Surg Res** 1996 Feb 15;61(1):58–64

Formation of abdominal adhesions is inhibited by antibodies to transforming growth factor–beta1. Lucas PA, et al. **J Surg Res** 1996 Oct;65(2):135–8

Influence of polyethylene glycol 4000 and dextran 70 on adhesion formation in rats. Nagelschmidt M, et al. **J Surg Res** 1997 Feb 1;67(2):113–8

Prevention of postoperative pericardial adhesions using tissue–protective solutions. Seeger JM, et al. **J Surg Res** 1997 Feb 15;68(1):63–6

Application of polyvinyl alcohol hydrogel membrane as anti–adhesive interposition after spinal surgery [letter; comment] Bao C. **Spine** 1997 Jun 15;22(12):1418–9. Comment on: Spine 1995 Nov 1;20(21):2272–7.

Clinical problem of intraperitoneal postsurgical adhesion formation following general surgery and the use of adhesion prevention barriers. DeCherney AH, et al. **Surg Clin North Am** 1997 Jun;77(3):671–88 (80 ref.)

Adhesion formation in laparoscopic inguinal hernia repair. Vader VL, et al. **Surg Endosc** 1997 Aug;11(8):825–9

Prevention of experimental postoperative peritoneal adhesions by N,O–carboxymethyl chitosan. Kennedy R, et al. **Surgery** 1996 Nov;120(5):866–70

[Effect of hyaluronase electrophoresis on formation of postoperative adhesions] Kulakov VI, et al. **Biull Eksp Biol Med** 1995 Dec;120(12):589–91 **(Rus)**

SURGERY

A simplified method of open laparoscopic entry and abdominal wall adhesiolysis. Pelosi MA 3rd, et al. **J Am Assoc Gynecol Laparosc** 1995 Nov;3(1):91–8

[Laparoscopic adhesiolysis] Târcoveanu E, et al. **Chirurgia (Bucur)** 1996 Sep–Oct;45(5):271–5 (Eng. Abstr.) **(Rum)**

THERAPY

[Gastrografin for mechanical partial, small bowel obstruction due to adhesions] Assalia A, et al. **Harefuah** 1997 May 1; 132(9):629–33 (Eng. Abstr.) **(Heb)**

VETERINARY

Development of a laboratory animal model of postoperative small intestinal adhesion formation in the rabbit. Singer ER, et al. **Can J Vet Res** 1996 Oct;60(4):296–304

Utilization of the serosal scarification model of postoperative intestinal adhesion formation to investigate potential adhesion–preventing substances in the rabbit. Singer ER, et al. **Can J Vet Res** 1996 Oct;60(4):305–11

Omento–omental adhesion around the uterine horn as a cause of recurrent colic in a mare. Butson RJ, et al. **Vet Rec** 1996 Dec 7;139(23):571–2

Evaluation of percutaneous gastrostomy as a technique for permanent gastropexy. Waschak MJ, et al. **Vet Surg** 1997 May–Jun;26(3):235–41

ADHESIVE CAPSULITIS see **BURSITIS**

ADHESIVENESS

see related
PLATELET ADHESIVENESS

ADHESIVES

see related
TISSUE ADHESIVES

Adhesives in otology and neurotology. Selesnick S, et al. **Am J Otolaryngol** 1997 Mar–Apr;18(2):81–9 (59 ref.)

Mussel adhesive enhances the immobilization of human chorionic gonadotrophin to a solid support. Burzio VA, et al. **Anal Biochem** 1996 Oct 15;241(2):190–4

Biologic glue increases capillary ingrowth after cardiomyoplasty in an ischemic cardiomyopathy model. Chekanov VS, et al. **ASAIO J** 1996 Sep–Oct;42(5):M480–7

Clinical performance of two dentine adhesives: 2–year results. Tyas MJ. **Aust Dent J** 1996 Oct;41(5):324–7

Adhesive pre–coated brackets, a comparative clinical study. Ash S, et al. **Br J Orthod** 1996 Nov;23(4):325–9

Use of cyanoacrylate glue to repair punctured tissue expanders [letter] Cavadas PC. **Burns** 1996 May;22(3):252

Adhesive labels cause high thyroxine results [letter] Bieglmayer C, et al. **Clin Chem** 1997 Mar;43(3):548

Surgical pearl: easy and (usually) painless removal of adhesive dressings. Haas AF, et al. **J Am Acad Dermatol** 1997 Jul;37(1):114–5

A new biological glue from gelatin and poly (L–glutamic acid). Otani Y, et al. **J Biomed Mater Res** 1996 Jun; 31(2):158–66

Fifth generation bonding systems: state of the art in adhesive dentistry. Freedman G, et al. **J Can Dent Assoc** 1997 Jun; 63(6):439–43 (24 ref.)

An investigation of bioadhesion for periodontal and oral mucosal drug delivery. Needleman IG, et al. **J Clin Periodontol** 1997 Jun;24(6):394–400

Efficacy of bioadhesive patches in the treatment of recurrent aphthous stomatitis. Mahdi AB, et al. **J Oral Pathol Med** 1996 Sep;25(8):416–9

Microbial contamination in four commercially available denture adhesives [letter; comment] Leusch MS, et al. **J Prosthet Dent** 1995 Nov;74(5):554. Comment on: J Prosthet Dent 1994 Feb;71(2):154–8.

Effects of adhesive primers on bond strength of self–curing resin to cobalt–chromium alloy. Yoshida K, et al. **J Prosthet Dent** 1997 Jun;77(6):617–20

Effects of diode laser welding with dye–enhanced glue on tensile strength of sutures commonly used in urology. Kirsch AJ, et al. **Lasers Surg Med** 1996;18(2):167–70

Scale–up of adhesive transdermal drug delivery systems. Van Buskirk GA, et al. **Pharm Res** 1997 Jul;14(7):848–52

ADMINISTRATION & DOSAGE

Pelviscopic organ–preserving treatment of ectopic pregnancy using fibrin sealant. Rudelstorfer B, et al. **J Am Assoc Gynecol Laparosc** 1995 Nov;3(1):81–5

Bioadhesion of lectin–latex conjugates to rat intestinal mucosa. Irache JM, et al. **Pharm Res** 1996 Nov; 13(11):1716–9

ADVERSE EFFECTS

Results of patch testing with a specialized collection of plastic and glue allergens. Holness DL, et al. **Am J Contact Dermat** 1997 Jun;8(2):121–4

Product analysis of acrylic resins compared to information given in material safety data sheets. Henriks–Eckerman ML, et al. **Contact Dermatitis** 1997 Mar;36(3):164–5

Milia as unusual sequelae to allergic contact dermatitis. Ibbotson SH, et al. **Contact Dermatitis** 1996 Jul;35(1):49–50

Ocular superglue injury [see comments] McLean CJ. **J Accid Emerg Med** 1997 Jan;14(1):40–1. Comment in: J Accid Emerg Med 1997 May;14(3):199.

Cyanoacrylate adhesive mistaken for ear drops [letter; comment] O'Donnell JJ, et al. **J Accid Emerg Med** 1997 May;14(3):199. Comment on: J Accid Emerg Med 1997 Jan;14(1):40–1.

Inflammatory reactions of the skin caused by adhesive EEG electrodes. Litscher G, et al. **J Neurosurg Anesthesiol** 1997 Jul;9(3):277–9

[The reactive airways dysfunction syndrome induced by glue (letter)] Alvarez MJ, et al. **Med Clin (Barc)** 1996 Apr 6; 106(13):517–8 (5 ref.) **(Spa)**

CHEMISTRY

Fluoride level in saliva after bonding orthodontic brackets with a fluoride containing adhesive. Ogaard B, et al. **Am J Orthod Dentofacial Orthop** 1997 Feb;111(2):199–202

Rapidly curable biological glue composed of gelatin and poly(L–glutamic acid). Otani Y, et al. **Biomaterials** 1996 Jul;17(14):1387–91

Resin bonding to enamel and dentin with one–component UDMA/HEMA adhesives. Finger WJ, et al. **Eur J Oral Sci** 1997 Apr;105(2):183–6

UV curable bioadhesives: copolymers of N–vinyl pyrrolidone. Kao FJ, et al. **J Biomed Mater Res** 1997 Fall; 38(3):191–6

Adaptation and radiographic evaluation of four adhesive systems. Opdam NJ, et al. **J Dent** 1997 Sep;25(5):391–7

Shear bond strengths produced by composite and compomer light cured orthodontic adhesives. Rock WP, et al. **J Dent** 1997 May–Jul;25(3–4):243–9

Effect of dentine depth on the fracture toughness of dentine–composite adhesive interfaces. Tam LE, et al. **J Dent** 1997 May–Jul;25(3–4):339–46

In vitro peel/shear bond strength of orthodontic adhesives. Willems G, et al. **J Dent** 1997 May–Jul;25(3–4):263–70

In vitro peel/shear bond strength evaluation of orthodontic bracket base design. Willems G, et al. **J Dent** 1997 May–Jul; 25(3–4):271–8

Bonding of a mica–based castable ceramic material with a tri–n–butylborane–initiated adhesive resin. Morikawa T, et al. **J Oral Rehabil** 1996 Jul;23(7):450–5

Effect of provisional cements on the bond strength of various adhesive bonding systems on dentine. Paul SJ, et al. **J Oral Rehabil** 1997 Jan;24(1):8–14

Bonding of titanium with acidic primers and a tri–n–butylborane–initiated luting agent. Taira Y, et al. **J Oral Rehabil** 1997 May;24(5):385–8

Shear bond strengths of a two–paste system resin luting agent used to bond alloys to enamel. Dixon DL, et al. **J Prosthet Dent** 1997 Aug;78(2):132–5

Influence of adhesive systems on the bonding of dental amalgam to glass ionomer cement. Nobilo MA, et al. **J Prosthet Dent** 1997 Feb;77(2):127–30

Bond strength of an adhesive resin system with various dental substrates. Triolo PT, et al. **J Prosthet Dent** 1995 Nov; 74(5):463–8

The efficacy of primer on sealant shear bond strength. Choi JW, et al. **Pediatr Dent** 1997 May–Jun;19(4):286–8

Composite rebonding to stainless steel metal using different bonding agents. al–Shalan TA, et al. **Pediatr Dent** 1997 May–Jun;19(4):273–6

Development and mechanical characterization of bioadhesive semi–solid, polymeric systems containing tetracycline for the treatment of periodontal diseases. Jones DS, et al. **Pharm Res** 1996 Nov;13(11):1734–8

Textural analysis and flow rheometry of novel, bioadhesive antimicrobial oral gels. Jones DS, et al. **Pharm Res** 1997 Apr;14(4):450–7

ADHESIVES

Chemical and biological evaluation of proteins and mucilages from roots and seeds of Glossostemon bruguieri Desf. (Moghat). Ibrahim N, et al. **Plant Foods Hum Nutr** 1997; 50(1):55–61

ISOLATION & PURIFICATION

Marine adhesive proteins and some biotechnological applications. Yamamoto H. **Biotechnol Genet Eng Rev** 1996; 13:133–65 (96 ref.)

Environmental bioadhesion: themes and applications. Burzio LO, et al. **Curr Opin Biotechnol** 1997 Jun;8(3):309–12 (32 ref.)

METABOLISM

Rapidly curable biological glue composed of gelatin and poly(L-glutamic acid). Otani Y, et al. **Biomaterials** 1996 Jul;17(14):1387–91

Bioadhesion of lectin-latex conjugates to rat intestinal mucosa. Irache JM, et al. **Pharm Res** 1996 Nov; 13(11):1716–9

PHARMACOLOGY

Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Luessen HL, et al. **Pharm Res** 1996 Nov;13(11):1668–72

THERAPEUTIC USE

Facial hair and securing the endotracheal tube: a new method [letter] Khorasani A, et al. **Anesth Analg** 1996 Oct;83(4):886

Successful embolization of persistent endoleak from a patent inferior mesenteric artery. van Schie G, et al. **J Endovasc Surg** 1997 Aug;4(3):312–5

[Experimental therapy of perforating wounds of cornea with adhelon] Gundorova RA, et al. **Vestn Oftalmol** 1997 Mar–Apr;113(2):12–6 (Eng. Abstr.) **(Rus)**

TOXICITY

Effects of subchronic inhalation of vaporized plastic cement on exploratory behavior and Purkinje cell differentiation in the rat. Pascual R, et al. **J Toxicol Environ Health** 1996 Dec 6;49(5):525–32

Topical application of fibrin adhesive in the rat brain: effects on different cellular elements of the wound. Ghulam Muhammad AK, et al. **Neurol Res** 1997 Feb;19(1):84–8

ADIE'S SYNDROME

Adie's syndrome in childhood. Söylev MF, et al. **Acta Paediatr Jpn** 1997 Jun;39(3):395–6

DIAGNOSIS

Adie syndrome as the initial sign of primary Sjögren syndrome. Bachmeyer C, et al. **Am J Ophthalmol** 1997 May; 123(5):691–2

[Adie's tonic pupil] Iranzo A, et al. **Neurologia** 1996 Aug–Sep;11(7):262 **(Spa)**

PHYSIOPATHOLOGY

[Adie's tonic pupil] Iranzo A, et al. **Neurologia** 1996 Aug–Sep;11(7):262 **(Spa)**

ADIPIC ACIDS

ANALYSIS

Migration of dioctyladipate plasticizer from food-grade PVC film into chicken meat products: effect of gamma-radiation. Goulas AE, et al. **Z Lebensm Unters Forsch** 1996 Mar; 202(3):250–5

[Gas chromatographic determination of dicyclohexyl ethers of succinic, glutaric and adipic acids in the workplace air] Guglia EB. **Gig Sanit** 1996 Jul–Aug;(4):52–3 **(Rus)**

METABOLISM

The beta-ketoadipate pathway and the biology of self-identity. Harwood CS, et al. **Annu Rev Microbiol** 1996; 50:553–90 (163 ref.)

PHARMACOLOGY

2-chloromuconate and ClcR-mediated activation of the clcABD operon: in vitro transcriptional and DNase I footprint analyses. McFall SM, et al. **J Bacteriol** 1997 Jun; 179(11):3655–63

URINE

Ethylmalonic adipic aciduria—a treatable hepatomuscular disorder in two adult brothers. Elias E, et al. **J Hepatol** 1997 Feb;26(2):433–6

ADIPIODON see **IODIPAMIDE**

ADIPOCERE see **POSTMORTEM CHANGES**

ADIPOCYTES

Fat cells. Ramsay TG. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):847–70 (184 ref.)

Phosphatidylinositol 3-kinase is a requirement for insulin-like growth factor I-induced differentiation, but not for mitogenesis, in fetal brown adipocytes. Valverde AM, et al. **Mol Endocrinol** 1997 May;11(5):595–607

CHEMISTRY

Adipocyte differentiation-related protein is secreted into milk as a constituent of milk lipid globule membrane. Heid HW, et al. **Biochem J** 1996 Dec 15;320 (Pt 3):1025–30

Adipocyte fatty acid-binding protein: interaction with phospholipid membranes and thermal stability studied by FTIR spectroscopy. Gericke A, et al. **Biochemistry** 1997 Jul 8;36(27):8311–7

Lipid structure of rat adipocyte plasma membranes following dietary lard and fish oil. Parrish CC, et al. **Biochim Biophys Acta** 1997 Jan 31;1323(2):253–62

Expressed alpha 1-adrenoceptors in adult rat brown adipocytes are primarily of alpha 1A subtype. Costain WJ, et al. **Can J Physiol Pharmacol** 1996 Mar;74(3):234–40

Peculiar distribution of fodrin in fat-storing cells. Aoki T, et al. **Exp Cell Res** 1997 Aug 1;234(2):313–20

Immunohistochemical detection of the ob gene product (leptin) in rat white and brown adipocytes. Tsuruo Y, et al. **Horm Metab Res** 1996 Dec;28(12):753–5

Influence of nutritional weaning on porcine adipocyte beta-adrenergic and adenosine A1 receptors. Mersmann HJ, et al. **J Anim Sci** 1997 Sep;75(9):2368–77

The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. Lavan BE, et al. **J Biol Chem** 1997 Apr 25;272(17):11439–43

Isolation by preparative free-flow electrophoresis and aqueous two-phase partition from rat adipocytes of an insulin-responsive small vesicle fraction with glucose transport activity. Morré DM, et al. **J Chromatogr B Biomed Appl** 1996 May 17;680(1–2):201–12

Purinergic receptor stimulation increases membrane trafficking in brown adipocytes. Pappone PA, et al. **J Gen Physiol** 1996 Nov;108(5):393–404

Immunocytochemical evidence that GLUT4 resides in a specialized translocation post-endosomal VAMP2-positive compartment in rat adipose cells in the absence of insulin. Malide D, et al. **J Histochem Cytochem** 1997 Aug; 45(8):1083–96

Changes in the size and docosahexaenoic acid content of adipocytes during chick embryo development. Farkas K, et al. **Lipids** 1996 Mar;31(3):313–21

Differences in the estrogen content of breast adipose tissue in women by menopausal status and hormone use. O'Brien SN, et al. **Obstet Gynecol** 1997 Aug;90(2):244–8

Down-regulation of glucagon receptors on the surface of broiler adipocytes. Oscar TP. **Poult Sci** 1996 Aug; 75(8):1027–34

CYTOLOGY

Role of the matrixin MMP-2 in multicellular organization of adipocytes cultured in basement membrane components. Brown LM, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C937–49

Relationship between replication and differentiation in cultured human adipocyte precursor cells. Entenmann G, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):C1011–6

Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Aubert J, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):606–11

Early adipocyte differentiation. Ailhaud G. **Biochem Soc Trans** 1996 May;24(2):400–2 (15 ref.)

Treatment of pluripotential C3H 10T1/2 fibroblasts with bone morphogenetic protein-4 induces adipocyte commitment. Butterwith SC, et al. **Biochem Soc Trans** 1996 May;24(2):163S

Adrenergic regulation of brown adipocyte differentiation. Cannon B, et al. **Biochem Soc Trans** 1996 May;24(2):407–12 (29 ref.)

Protein kinase C isoform expression during differentiation of 3T3-F442A preadipocytes. Fleming IM, et al. **Biochem Soc Trans** 1997 May;25(2):211S

Physiological approach to maturation of brown adipocytes in primary cell culture. Encke D, et al. **Biochim Biophys Acta** 1997 Jul 24;1357(3):339–47

Functional differentiation of white and brown adipocytes. Klaus S. **Bioessays** 1997 Mar;19(3):215–23 (72 ref.)

The function of adipocytes in the bone marrow stroma: an update. Gimble JM, et al. **Bone** 1996 Nov;19(5):421–8 (108 ref.)

The timing of insulin/c-Ras signal is critical for its effect upon the differentiation of C3H10T1/2-derived preadipocytes. Preston T, et al. **Cancer Lett** 1997 May 19; 115(2):165–71

Three-dimensional structure of extracellular matrix reversibly regulates morphology, proliferation and collagen metabolism of perisinusoidal stellate cells (vitamin A-storing cells). Senoo H, et al. **Cell Biol Int** 1996 Jul; 20(7):501–12

p21ras induced differentiation-related gene expression in fetal brown adipocyte primary cells and cell lines. Lorenzo M, et al. **Cell Growth Differ** 1996 Sep;7(9):1251–9

Differential expression of gas and gadd genes at distinct growth arrest points during adipocyte development. Shugart EC, et al. **Cell Growth Differ** 1995 Dec; 6(12):1541–7

Regulation of adipose cell number in man [editorial] Prins JB, et al. **Clin Sci (Colch)** 1997 Jan;92(1):3–11 (101 ref.)

Effect of lipoproteins on the differentiation of 3T3-L1 and human preadipocytes in cell culture. Stanton LA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Jan; 116(1):65–73

Adipocyte differentiation: a transcriptional regulatory cascade. Brun RP, et al. **Curr Opin Cell Biol** 1996 Dec; 8(6):826–32 (68 ref.)

Conference report: renal disease, metformin, and the adipocyte. Bloomgarden ZT. **Diabetes Care** 1996 Sep; 19(9):1038–41

Norepinephrine potentiates the mitogenic effect of growth factors in quiescent brown preadipocytes: relationship with uncoupling protein messenger ribonucleic acid expression. García B, et al. **Endocrinology** 1997 Oct;138(10):4227–33

Differentiation of rat preadipocytes is accompanied by expression of thyrotropin receptors. Haraguchi K, et al. **Endocrinology** 1996 Aug;137(8):3200–5

Site-related specificities of the control by androgenic status of adipogenesis and mitogen-activated protein kinase cascade/c-fos signaling pathways in rat preadipocytes. Lacasa D, et al. **Endocrinology** 1997 Aug;138(8):3181–6

Calcitriol down-modulates the 3,5,3' triiodothyronine (T3) receptors and affects, in a biphasic manner, the T3-dependent adipose differentiation of Ob 17 preadipocytes. Lenoir C, et al. **Endocrinology** 1996 Oct; 137(10):4268–76

Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. McAveney KM, et al. **Endocrinology** 1996 Dec;137(12):5723–6

The mechanism of inhibition of 3T3-L1 preadipocyte differentiation by prostaglandin F2alpha. Miller CW, et al. **Endocrinology** 1996 Dec;137(12):5641–50

Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Tafuri SR. **Endocrinology** 1996 Nov;137(11):4706–12

TNF alpha-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARgamma without effects on Pref-1 expression. Xing H, et al. **Endocrinology** 1997 Jul;138(7):2776–83

The effect of platelet-derived growth factor and adipogenic hormones on the expression of CCAAT/enhancer-binding proteins in 3T3-L1 cells in serum-free conditions. Bachmeier M, et al. **Eur J Biochem** 1997 Jan 15; 243(1–2):128–33

v-Ras and v-Raf block differentiation of transformable C3H10T1/2-derived preadipocytes at lower levels than required for neoplastic transformation. Raptis L, et al. **Exp Cell Res** 1997 Aug 25;235(1):188–97

Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Chen PL, et al. **Genes Dev** 1996 Nov 1; 10(21):2794–804

Transient postweaning expression of excessive fat deposition and diabetes mellitus in ob/ob mice. Dubuc PU. **Growth Dev Aging** 1996 Autumn-Winter;60(3–4):145–51

An anti-adipocyte monoclonal antibody is cytotoxic to porcine preadipocytes in vitro and depresses the development of pig adipose tissue. De clercq L, et al. **J Anim Sci** 1997 Jul;75(7):1791–7

Evaluation of alternative methods to prepare porcine adipocytes for measurement with an electronic particle number and size determination apparatus. Fakler T, et al. **J Anim Sci** 1996 Oct;74(10):2385–93

The influence of extracellular matrix substrata on preadipocyte development in serum-free cultures of stromal-vascular cells. Hausman GJ, et al. **J Anim Sci** 1996 Sep;74(9):2117–28

Insulin and hydrocortisone, but not triiodothyronine, are required for the differentiation of pig preadipocytes in primary culture. Suryawan A, et al. **J Anim Sci** 1997 Jan; 75(1):105–11

Effect of retinoic acid on differentiation of cultured pig preadipocytes. Suryawan A, et al. **J Anim Sci** 1997 Jan; 75(1):112–7

cAMP activates the expression of stearoyl-CoA desaturase gene 1 during early preadipocyte differentiation. Casimir DA, et al. **J Biol Chem** 1996 Nov 22;271(47):29847–53

CSF-1 receptor/insulin receptor chimera permits CSF-1-dependent differentiation of 3T3-L1 preadipocytes. Chaika OV, et al. **J Biol Chem** 1997 May 2; 272(18):11968–74

Regulating adipogenesis. Mandrup S, et al. **J Biol Chem** 1997 Feb 28;272(9):5367–70 (56 ref.)

Regulation and expression of retinoblastoma proteins p107 and p130 during 3T3-L1 adipocyte differentiation. Richon VM, et al. **J Biol Chem** 1997 Apr 11;272(15):10117–24

Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. Shao D, et al. **J Biol Chem** 1997 Aug 22;272(34):21473–8

Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation. Tai TAC, et al. **J Biol Chem** 1996 Nov 22;271(47):29909–14

Phenotypic expression of marrow cells when grown on various substrata. Fried A, et al. **J Cell Biochem** 1996 May; 61(2):246–254

Effect of activating and inactivating mutations of Gs- and Gi2-alpha protein subunits on growth and differentiation of 3T3-L1 preadipocytes. Gordeladze JO, et al.

J Cell Biochem 1997 Feb;64(2):242–57

Differentiation of embryonic stem cells into adipocytes in vitro. Dani C, et al. **J Cell Sci** 1997 Jun;110 (Pt 11):1279–85

In vitro influence of sublethal hypoxia on differentiation of the 3T3–L1 preadipose cell line and its physiological implications. Macfarlane CM. **Life Sci** 1997;60(21):1923–31

Adipose tissue fatty acids and size and number of fat cells from birth to 9 years of age—a cross–sectional study in 96 boys. Soriguer Escofet FJ, et al. **Metabolism** 1996 Nov; 45(11):1395–401

Induction of mRNAs for the growth hormone receptor gene during mouse 3T3–L1 preadipocyte differentiation. Zou L, et al. **Metabolism** 1997 Jan;46(1):114–8

Mitogen–activated protein kinase activation is not necessary for, but antagonizes, 3T3–L1 adipocytic differentiation. Font de Mora J, et al. **Mol Cell Biol** 1997 Oct; 17(10):6068–75

Retinoic acid blocks adipogenesis by inhibiting C/EBPbeta–mediated transcription. Schwarz EJ, et al. **Mol Cell Biol** 1997 Mar;17(3):1552–61

Cleavage of membrane–associated pref–1 generates a soluble inhibitor of adipocyte differentiation. Smas CM, et al. **Mol Cell Biol** 1997 Feb;17(2):977–88

Peroxisome proliferator–activated receptor–gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Gimble JM, et al. **Mol Pharmacol** 1996 Nov;50(5):1087–94

Adipocyte differentiation is regulated by a prostaglandin liganded to the nuclear peroxisome proliferator–activated receptor. Wolf G. **Nutr Rev** 1996 Sep;54(9):290–2 (9 ref.)

Influence of thyroxine in vivo on preadipocyte development and insulin–like growth factor–I and IGF binding protein secretion in fetal stromal vascular cell cultures. Chen NX, et al. **Obes Res** 1996 Jul;4(4):357–66

Preadipocyte recruitment in stromal vascular cultures after depletion of committed preadipocytes by immunocytotoxicity. Yu ZK, et al. **Obes Res** 1997 Jan; 5(1):9–15

Induction of proto–oncogenes during 3–deazaadenosine–stimulated differentiation of 3T3–L1 fibroblasts to adipocytes: mimicry of insulin action. Zeng G, et al. **Oncol Res** 1997;9(4):205–11

Regulators of adipocyte precursor cells. Butterwith SC. **Poult Sci** 1997 Jan;76(1):118–23 (58 ref.)

Changes in body composition and adipocyte cellularity of male broilers subjected to varying degrees of early–life feed restriction. Zubair AK, et al. **Poult Sci** 1996 Jun; 75(6):719–28

Inhibition of adipogenesis through MAP kinase–mediated phosphorylation of PPARgamma. Hu E, et al. **Science** 1996 Dec 20;274(5295):2100–3

[Adipocyte differentiation and nuclear receptor] Hirose T, et al. **Nippon Rinsho** 1997 Jun;55(6):1596–604 (30 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Comparative effects of insulin and isoproterenol on lipoprotein lipase in rat adipose cells. Chiappe de Cingalani GE, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1461–7

Compartmentalization of protein traffic in insulin–sensitive cells. Kandror KV, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E1–14 (134 ref.)

Inhibitors of preadipocyte differentiation induce COUP–TF binding to a PPAR/RXR binding sequence. Brodie AE, et al. **Biochem Biophys Res Commun** 1996 Nov 21; 228(3):655–61

Antisense oligonucleotides to differentiation–specific element binding protein (DSEB) mRNA inhibit adipocyte differentiation. Lyle RE, et al. **Biochem Biophys Res Commun** 1996 Nov 21;228(3):709–15

Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Serrero G, et al. **Biochem Biophys Res Commun** 1997 Apr 7;233(1):200–2

Insulin stimulates tyrosine phosphorylation of the proto–oncogene product of c–Cbl in 3T3–L1 adipocytes. Ribon V, et al. **Biochem J** 1997 Jun 15;324 (Pt 3):839–45

Effects of calcium on brazilin–induced glucose transport in isolated rat epididymal adipocytes. Khil LY, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):97–101

Effects of peroxovanadate and vanadate on insulin binding, degradation and sensitivity in rat adipocytes. Yu ZW, et al. **Biochim Biophys Acta** 1997 Jan 10;1310(1):103–9

Histone H4 stimulates glucose uptake through the insulin receptor. Louters LL, et al. **Biochimie** 1996;78(1):39–45

Zinc attenuation of GDP binding to brown adipocytes mitochondria in genetically obese (ob/ob) mice. Chen MD, et al. **Biol Trace Elem Res** 1997 May;57(2):139–45

Beta–adrenoceptor subtype expression and function in rat white adipocytes. Germack R, et al. **Br J Pharmacol** 1997 Jan;120(2):201–10

Inhibition by pentoxifylline of extracellular signal–regulated kinase activation by platelet–derived growth factor in hepatic stellate cells. Pinzani M, et al. **Br J Pharmacol** 1996 Nov;119(6):1117–24

Growth hormone, osteoblasts, and marrow adipocytes: a case report. Kröger H, et al. **Calcif Tissue Int** 1997 Jul;61(1):33–5

Effects of breed and adipose depot location on responsiveness and sensitivity to adrenergic stimulation in ovine adipose tissue. Gilson TL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Sep;115(1):19–26

Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3–L1 cells. Casimir DA, et al. **Differentiation** 1996 Jul; 60(4):203–10

Norepinephrine potentiates the mitogenic effect of growth factors in quiescent brown preadipocytes: relationship with uncoupling protein messenger ribonucleic acid expression. García B, et al. **Endocrinology** 1997 Oct;138(10):4227–33

The antilipolytic effects of insulin and epidermal growth factor in rat adipocytes are mediated by different mechanisms. Tebar F, et al. **Endocrinology** 1996 Oct; 137(10):4181–8

Impairment of vitamin A uptake by rat hepatocytes and fat storing cells determined by Monensin—morphological observations. Novelli A, et al. **Exp Toxicol Pathol** 1995 Nov;47(5):413–20

PHAS–I phosphorylation in response to foetal bovine serum (FBS) is regulated by an ERK1/ERK2–independent and rapamycin–sensitive pathway in 3T3–L1 adipocytes. Arnott CH, et al. **FEBS Lett** 1997 Apr 7;406(1–2):179–83

Retinoic acid modulates retinoid X receptor alpha and retinoic acid receptor alpha levels of cultured brown adipocytes. Bonet ML, et al. **FEBS Lett** 1997 Apr 7; 406(1–2):196–200

The effect of neuropeptides kyotorphin and neokyotorphin on proliferation of cultured brown preadipocytes. Bronnikov G, et al. **FEBS Lett** 1997 Apr 21;407(1):73–7

Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF–beta in liver stellate cells [see comments] Okuno M, et al. **Hepatology** 1997 Oct; 26(4):913–21. Comment in: Hepatology 1997 Oct;26(4):1067–8.

The effect of in vivo thyroxine treatment on insulin receptors, glucose transport and GLUT4 in rat adipocytes. Fickova M, et al. **Horm Metab Res** 1997 Jan;29(1):16–9

Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Müller G, et al. **Horm Metab Res** 1996 Sep;28(9):469–87 (111 ref.)

Proliferation and differentiation of progeny of ovine unilocular fat cells (adipofibroblasts). Vierck JL, et al. **In Vitro Cell Dev Biol Anim** 1996 Oct;32(9):564–72

Effects of acute administration of dehydroepiandrosterone–sulfate on adipose tissue mass and cellularity in male rats. Lea–Currie YR, et al. **Int J Obes Relat Metab Disord** 1997 Feb;21(2):147–54

Comparison of isoproterenol with BRL37344 in activation of beta 3–adrenoceptors to inhibit the uptake of [14C]deoxy–D–glucose and translocation of glucose transporter (GLUT4) to membrane fraction in rat adipocytes. Chang CJ, et al. **J Auton Nerv Syst** 1996 Nov 6;61(2):191–4

Protein–tyrosine phosphatases PTP1B and syp are modulators of insulin–stimulated translocation of GLUT4 in transfected rat adipose cells. Chen H, et al. **J Biol Chem** 1997 Mar 21;272(12):8026–31

Differential regulation by tumor necrosis factor–alpha of beta1–, beta2–, and beta3–adrenoreceptor gene expression in 3T3–F442A adipocytes. Hadri KE, et al. **J Biol Chem** 1997 Sep 26;272(39):24514–21

Control of the translational regulators PHAS–I and PHAS–II by insulin and cAMP in 3T3–L1 adipocytes. Lin TA, et al. **J Biol Chem** 1996 Nov 22;271(47):30199–204

Regulation of protein kinase B and glycogen synthase kinase–3 by insulin and beta–adrenergic agonists in rat epididymal fat cells. Activation of protein kinase B by wortmannin–sensitive and –insensitive mechanisms. Moule SK, et al. **J Biol Chem** 1997 Mar 21;272(12):7713–9

Regulation of stearoyl–CoA desaturase 1 mRNA stability by polyunsaturated fatty acids in 3T3–L1 adipocytes. Sessler AM, et al. **J Biol Chem** 1996 Nov 22; 271(47):29854–8

Steroid–induced adipogenesis in a pluripotential cell line from bone marrow. Cui Q, et al. **J Bone Joint Surg Am** 1997 Jul;79(7):1054–63

Dexamethasone stimulates leptin release from human adipocytes: unexpected inhibition by insulin. Considine RV, et al. **J Cell Biochem** 1997 May;65(2):254–8

Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. Ciaraldi TP, et al. **J Clin Endocrinol Metab** 1997 May;82(5):1421–5

Isoproterenol decreases LDL receptor expression in rat adipose cells: activation of cyclic AMP–dependent proteolysis. Kraemer FB, et al. **J Lipid Res** 1996 Feb; 37(2):237–49

Perilla oil prevents the excessive growth of visceral adipose tissue in rats by down–regulating adipocyte differentiation. Okuno M, et al. **J Nutr** 1997 Sep;127(9):1752–7

Some histamine–related compounds interacting with the benzylamine–oxidizing activity of rat white adipocytes. Raimondi L, et al. **J Pharm Pharmacol** 1997 May; 49(5):542–50

Effect of triiodothyronine on glucose transport in rat adipocytes. Goto H, et al. **Life Sci** 1997;61(2):193–204

Antihyperglycemic mechanism of M16209, an antidiabetic agent, in 3T3–L1 adipocytes. Murakami N, et al. **Life Sci** 1997;60(20):1821–31

Effect of glucocorticoid receptor antagonist RU 38486 on acute glucocorticoid–induced insulin resistance in rat adipocytes. Ishizuka T, et al. **Metabolism** 1997 Sep; 46(9):997–1002

Negative regulation of peroxisome proliferator–activated receptor–gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor–alpha. Zhang B, et al. **Mol Endocrinol** 1996 Nov;10(11):1457–66

CCAAT/enhancer–binding protein beta is not affected by tetrachlorodibenzo–p–dioxin (TCDD) inhibition of 3T3–L1 preadipocyte differentiation. Chen CL, et al. **Obes Res** 1997 Mar;5(2):146–52

Influence of androgenicity on adipocytes and precursor cells in female rats. James RG, et al. **Obes Res** 1996 Sep; 4(5):463–70

Growth hormone treatment of hypophysectomized rats increases catecholamine–induced lipolysis and the number of beta–adrenergic receptors in adipocytes: no differences in the effects of growth hormone on different fat depots. Yang S, et al. **Obes Res** 1996 Sep;4(5):471–8

Mitogenic and antiadipogenic properties of human growth hormone in differentiating human adipocyte precursor cells in primary culture. Wabitsch M, et al. **Pediatr Res** 1996 Sep;40(3):450–6

Effects of atrial natriuretic factor on glucose metabolism in isolated adipocytes. Crilley CT, et al. **Regul Pept** 1997 Jan 29;68(2):125–30

Inhibition of increases of transcription factor mRNAs during differentiation of primary rat adipocytes by in vivo 2,3,7,8–tetrachlorodibenzo–p–dioxin (TCDD) treatment. Brodie AE, et al. **Toxicol Lett** 1997 Feb 7;90(2–3):91–5

ENZYMOLOGY

Comparative effects of insulin and isoproterenol on lipoprotein lipase in rat adipose cells. Chiappe de Cingalani GE, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1461–7

T3 potentiates the adrenergic stimulation of type II 5'–deiodinase activity in cultured rat brown adipocytes. Hernández A, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E15–23

Physiological concentrations of insulin and T3 stimulate 3T3–L1 adipocyte acyl–CoA synthetase gene transcription. Kansara MS, et al. **Am J Physiol** 1996 May;270(5 Pt 1):E873–81

Insulin stimulation of human adipocytes activates the kinase of only a fraction of the insulin receptors. Klein HH, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E576–83

The alpha2L111R,N122D isoform of the Na,K–ATPase expressed in HeLa cells does not undergo an adipocyte–like increase in activity in response to insulin. Coppi MV, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):444–8

Insulin stimulates the release of the glycosyl phosphatidylinositol–anchored membrane dipeptidase from 3T3–L1 adipocytes through the action of a phospholipase C. Movahedi S, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):531–7

Contrasting adrenergic effects on lipoprotein lipase gene expression in the brown adipose tissue of intact mice and in cultured brown adipocytes from mice. Kuusela P, et al. **Biochim Biophys Acta** 1997 Apr 21;1345(3):327–37

Differential activation of mitogen–activated protein kinase by insulin and epidermal growth factor in 3T3–L1 adipocytes: a possible involvement of PI3–kinase in the activation of the MAP kinase by insulin. Suga J, et al. **Diabetes** 1997 May;46(5):735–41

Insulin regulated PKC isoform mRNA in rat adipocytes. Ishizuka T, et al. **Diabetes Res Clin Pract** 1996 Aug; 33(3):159–67

Increased mitogen–activated protein kinase expression and activity in white adipose tissue of ventromedial hypothalamus–lesioned rats. Combettes–Souverain M, et al. **Diabetologia** 1997 May;40(5):533–40

Expression of a constitutively activated form of protein kinase B (c–Akt) in 3T3–L1 preadipose cells causes spontaneous differentiation. Magun R, et al. **Endocrinology** 1996 Aug;137(8):3590–3

Inducible nitric oxide synthase in rat brown adipocytes: implications for blood flow to brown adipose tissue. Nisoli E, et al. **Endocrinology** 1997 Feb;138(2):676–82

The histaminase activity of rat white adipocytes. Raimondi L, et al. **Inflamm Res** 1997 Apr;46(4):125–31

Glycosylation and secretion of lipoprotein lipase by 3T3–L1 adipocytes: effects of brefeldin A. Masuno H, et al. **J Atheroscler Thromb** 1995;2(1):46–52

Insulin stimulates mitogen–activated protein kinase by a Ras–independent pathway in 3T3–L1 adipocytes. Carel K, et al. **J Biol Chem** 1996 Nov 29;271(48):30625–30

Effect of insulin on farnesyltransferase activity in 3T3–L1 adipocytes. Goalstone ML, et al. **J Biol Chem** 1996 Nov 1;271(44):27585–9

Activation and translocation of Rho (and ADP ribosylation factor) by insulin in rat adipocytes. Apparent involvement of phosphatidylinositol 3–kinase. Karnam P, et al. **J Biol Chem** 1997 Mar 7;272(10):6136–40

Membrane amine oxidase cloning and identification as a major protein in the adipocyte plasma membrane. Morris NJ, et al. **J Biol Chem** 1997 Apr 4;272(14):9388–92

Regulation of protein kinase B in rat adipocytes by insulin, vanadate, and peroxovanadate. Membrane translocation in response to peroxovanadate. Wijkander J, et al. **J Biol Chem** 1997 Aug 22;272(34):21520–6

Transcriptional and posttranscriptional mechanisms of glucocorticoid–mediated repression of phosphoenolpyruvate carboxykinase gene expression in adipocytes. Franckhauser–Vogel S, et al. **J Cell Biochem** 1997 Sep 1;66(3):386–93

Some histamine–related compounds interacting with the

benzylamine-oxidizing activity of rat white adipocytes. Raimondi L, et al. **J Pharm Pharmacol** 1997 May; 49(5):542–50

Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Ahmad F, et al. **Metabolism** 1997 Oct;46(10):1140–5

Differential effects of constitutively active phosphatidylinositol 3-kinase on glucose transport, glycogen synthase activity, and DNA synthesis in 3T3-L1 adipocytes. Frevert EU, et al. **Mol Cell Biol** 1997 Jan; 17(1):190–8

Adipocyte hormone-sensitive lipase: a major regulator of lipid metabolism. Langin D, et al. **Proc Nutr Soc** 1996 Mar; 55(1B):93–109 (83 ref.)

IMMUNOLOGY

An anti-adipocyte monoclonal antibody is cytotoxic to porcine preadipocytes in vitro and depresses the development of pig adipose tissue. De clercq L, et al. **J Anim Sci** 1997 Jul;75(7):1791–7

Antibodies fight fat cells in humans as well as in animals? [news] Jack DB. **Mol Med Today** 1997 Feb;3(2):49

METABOLISM

The effect of lesions of the sympathoadrenal system on training induced adaptations in adipocytes and pancreatic islets in rats. Stallknecht B, et al. **Acta Physiol Scand** 1996 Apr;156(4):465–73

Chronic salt overload increases blood pressure and improves glucose metabolism without changing insulin sensitivity. da Costa Lima NK, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 1):720–7

Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Kuroda M, et al. **Am J Pathol** 1997 Sep; 151(3):735–44

Lactate production by white adipocytes in relation to insulin sensitivity. Faintrenie G, et al. **Am J Physiol** 1996 Apr; 270(4 Pt 1):C1061–6

Growth hormone increases calcium uptake in rat fat cells by a mechanism dependent on protein kinase C. Gaur S, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1485–92

Growth hormone regulates cytosolic free calcium in rat fat cells by maintaining L-type calcium channels. Gaur S, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1478–84

Desensitization of beta-adrenergic receptors in adipocytes causes increased insulin sensitivity of glucose transport. Green A, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):E271–6

Lactate production by swine adipocytes: effects of age, nutritional status, glucose concentration, and insulin. Heckler BK, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E957–66

Insulin stimulates cell surface aminopeptidase activity toward vasopressin in adipocytes. Herbst JJ, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E600–6

Upregulation of adipocyte metabolism by agouti protein: possible paracrine actions in yellow mouse obesity. Jones BH, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):E192–6

Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Jones BH, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R236–42

Compartmentalization of protein traffic in insulin-sensitive cells. Kandror KV, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E1–14 (134 ref.)

Roles of PI 3-kinase and Ras on insulin-stimulated glucose transport in 3T3-L1 adipocytes. Katagiri H, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):E326–31

Adenylyl cyclase inhibitory pathway is differentially modified in rat white and brown fat by high-energy diets. Kenan Y, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E1043–9

Rat adipose tissue amino acid metabolism in vivo as assessed by microdialysis and arteriovenous techniques. Kowalski TJ, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E613–22

Glycogen: a carbohydrate source for GLUT-1 glycosylation during glucose deprivation of 3T3-L1 adipocytes. McMahon RJ, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):E640–5

Visceral adiposity, increased adipocyte lipolysis, and metabolic dysfunction in obese postmenopausal women. Nicklas BJ, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):E72–8

Exercise blunts declines in lipolysis and fat oxidation after dietary-induced weight loss in obese older women. Nicklas BJ, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E149–55

Poor fetal nutrition causes long-term changes in expression of insulin signaling components in adipocytes. Ozanne SE, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E46–51

Rat liver ferritin selectively inhibits expression of alpha-smooth muscle actin in cultured rat lipocytes. Ramm GA, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G370–5

Growth hormone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4. Smith TR, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E1071–9

Chronic ethanol feeding in a high-fat diet decreases insulin-stimulated glucose transport in rat adipocytes. Wilkes JJ, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E477–84

Serum complement and familial combined hyperlipidemia. Ylitalo K, et al. **Atherosclerosis** 1997 Mar 21;129(2):271–7

Inhibition of the binding of SNAP-23 to syntaxin 4 by Munc18c. Araki S, et al. **Biochem Biophys Res Commun** 1997 May 8;234(1):257–62

Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Aubert J, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):606–11

Osteocalcin (BGP), gene expression, and protein production by marrow stromal adipocytes. Benayahu D, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):442–6

Functional consequences of constitutively active alpha2A-adrenergic receptor expression in 3T3F442A preadipocytes and adipocytes. Bétuing S, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):765–73

Developmental profile of homeobox gene expression during 3T3-L1 adipogenesis. Cowherd RM, et al. **Biochem Biophys Res Commun** 1997 Aug 18;237(2):470–5

Identification of macrophage migration inhibitory factor in adipose tissue and its induction by tumor necrosis factor-alpha. Hirokawa J, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):94–8

Effect of enteral versus parenteral nutrition on leptin gene expression and release into the circulation. Levy JR, et al. **Biochem Biophys Res Commun** 1997 Aug 8; 237(1):98–102

ob gene expression and secretion of leptin following differentiation of rat preadipocytes to adipocytes in primary culture. Mitchell SE, et al. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):360–4

Detection of cytochrome P4503A (CYP3A) in human hepatic stellate cells. Parola M, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):420–4

Clostridium botulinum C3 exoenzyme stimulates GLUT4-mediated glucose transport, but not glycogen synthesis, in 3T3-L1 adipocytes--a potential role of rho? van den Berghe N, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):430–9

Down-regulation of beta3-adrenergic receptor expression in rat adipose tissue during the fasted/fed transition: evidence for a role of insulin. Hadri KE, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):359–64

Selective release of human adipocyte fatty acids according to molecular structure. Raclot T, et al. **Biochem J** 1997 Jun 15;324 (Pt 3):911–5

Regulation by fatty acids of angiotensinogen gene expression in preadipose cells. Safonova I, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):235–9

Pervanadate stimulation of wortmannin-sensitive and -resistant 2-deoxyglucose transport in adipocytes. Ida M, et al. **Biochem Pharmacol** 1996 Apr 26;51(8):1061–7

Reduced insulin sensitivity of isolated skeletal muscle but enhanced lipogenic capacity of adipocytes in both spontaneously hypertensive and Wistar Kyoto rats. Pearson SL, et al. **Biochem Soc Trans** 1996 May;24(2):234S

Trafficking, targeting and translocation of the insulin-responsive glucose transporter, GLUT4, in adipocytes. Rice JE, et al. **Biochem Soc Trans** 1996 May; 24(2):540–6 (47 ref.)

Effect of insulin on glucose transport in adipose tissue in lactation. Rogers MP, et al. **Biochem Soc Trans** 1996 May; 24(2):168S

Botulinum neurotoxin B inhibits insulin-stimulated glucose uptake into 3T3-L1 adipocytes and cleaves cellubrevin unlike type A toxin which failed to proteolyze the SNAP-23 present. Chen F, et al. **Biochemistry** 1997 May 13;36(19):5719–28

The 60 kDa insulin receptor substrate functions like an IRS protein (pp60IRS3) in adipose cells. Smith-Hall J, et al. **Biochemistry** 1997 Jul 8;36(27):8304–10

Differential inhibition of lipolysis by 2-bromopalmitic acid and 4-bromocrotonic acid in 3T3-L1 adipocytes. Fong JC, et al. **Biochim Biophys Acta** 1997 Jan 7;1344(1):65–73

Analysis of lipid metabolism in adipocytes using a fluorescent fatty acid derivative. I. Insulin stimulation of lipogenesis. Müller G, et al. **Biochim Biophys Acta** 1997 Jul 12; 1347(1):23–39

Selenium: potent stimulator of tyrosyl phosphorylation and activator of MAP kinase. Stapleton SR, et al. **Biochim Biophys Acta** 1997 Mar 1;1355(3):259–69

Altered adipocyte properties in the offspring of protein malnourished rats. Shepherd PR, et al. **Br J Nutr** 1997 Jul;78(1):121–9

p21ras induced differentiation-related gene expression in fetal brown adipocyte primary cells and cell lines. Lorenzo M, et al. **Cell Growth Differ** 1996 Sep;7(9):1251–9

G proteins in adipocytes and preadipocytes: characterization, subcellular distribution, and potential roles for Gi2 and/or Gi3 in the control of cell proliferation. Denis-Henriot D, et al. **Cell Signal** 1996 Mar;8(3):225–34

Arachidonic acid stimulates the intrinsic activity of ubiquitous glucose transporter (GLUT1) in 3T3-L1 adipocytes by a protein kinase C-independent mechanism. Fong JC, et al. **Cell Signal** 1996 Mar;8(3):179–83

Leptin--fat messenger or fat controller? Qureshi A, et al. **Clin Endocrinol (Oxf)** 1997 Aug;47(2):169–71

Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Hallakou S, et al. **Diabetes** 1997 Sep;46(9):1393–9

Reduced expression of the leptin gene (ob) by catecholamine through a G(S) protein-coupled pathway in 3T3-L1 adipocytes. Kosaki A, et al. **Diabetes** 1996 Dec; 45(12):1744–9

Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Montague CT, et al. **Diabetes** 1997 Mar; 46(3):342–7

Epidermal growth factor induces glucose storage in transgenic 3T3-L1 adipocytes overexpressing epidermal growth factor receptors. Van Epps-Fung M, et al. **Diabetes** 1996 Nov;45(11):1619–25

Acute effects of phorbol ester and insulin on insulin-induced glucose uptake and protein kinase C activation in rat adipocytes. Ishizuka T, et al. **Diabetes Res Clin Pract** 1997 Jul;37(1):49–52

GTPase activating protein activity for Rab4 is enriched in the plasma membrane of 3T3-L1 adipocytes. Possible involvement in the regulation of Rab4 subcellular localization. Bortoluzzi MN, et al. **Diabetologia** 1996 Aug; 39(8):899–906

Adipocyte lipolysis in normal weight subjects with obesity among first-degree relatives. Hellström L, et al. **Diabetologia** 1996 Aug;39(8):921–8

Ras proteins mediate induction of uncoupling protein, IGF-I, and IGF-I receptor in rat fetal brown adipocyte cell lines. Porras A, et al. **DNA Cell Biol** 1996 Nov;15(11):921–8

Effect of CL316,243, a highly specific beta(3)-adrenoceptor agonist, on lipolysis of epididymal, mesenteric and subcutaneous adipocytes in rats. Umekawa T, et al. **Endocr J** 1997 Feb;44(1):181–5

A constitutively active version of the Ser/Thr kinase Akt induces production of the ob gene product, leptin, in 3T3-L1 adipocytes. Barthel A, et al. **Endocrinology** 1997 Aug;138(8):3559–62

Insulin induces a change in Rab5 subcellular localization in adipocytes independently of phosphatidylinositol 3-kinase activation. Cormont M, et al. **Endocrinology** 1996 Aug; 137(8):3408–15

Effects of beta-adrenoceptor subtype stimulation on obese gene messenger ribonucleic acid and on leptin secretion in mouse brown adipocytes differentiated in culture. Deng C, et al. **Endocrinology** 1997 Feb;138(2):548–52

Insulin promotes and cyclic adenosine 3',5'-monophosphate impairs functional insertion of insulin receptors in the plasma membrane of rat adipocytes: evidence for opposing effects of tyrosine and serine/threonine phosphorylation. Eriksson JW, et al. **Endocrinology** 1997 Feb;138(2):607–12

Adrenalectomy after weaning restores beta3-adrenergic receptor expression in white adipocytes from C57BL/6J-ob/ob mice. Gettys TW, et al. **Endocrinology** 1997 Jul;138(7):2697–704

The beta 3-adrenergic receptor inhibits insulin-stimulated leptin secretion from isolated rat adipocytes. Gettys TW, et al. **Endocrinology** 1996 Sep;137(9):4054–7

Differentiation of rat preadipocytes is accompanied by expression of thyrotropin receptors. Haraguchi K, et al. **Endocrinology** 1996 Aug;137(8):3200–5

Antilipolytic actions of vanadate and insulin in rat adipocytes mediated by distinctly different mechanisms. Li J, et al. **Endocrinology** 1997 Jun;138(6):2274–9

Association of N-ethylmaleimide sensitive fusion (NSF) protein and soluble NSF attachment proteins-alpha and -gamma with glucose transporter-4-containing vesicles in primary rat adipocytes. Mastick CC, et al. **Endocrinology** 1997 Jun;138(6):2391–7

Phosphoinositolglycan-peptides from yeast potently induce metabolic insulin actions in isolated rat adipocytes, cardiomyocytes, and diaphragms. Müller G, et al. **Endocrinology** 1997 Aug;138(8):3459–75

The effect of modulating the glycogen-associated regulatory subunit of protein phosphatase-1 on insulin action in rat skeletal muscle cells. Ragolia L, et al. **Endocrinology** 1997 Jun;138(6):2398–404

Effects of tyrosine kinase inhibitors on tyrosine phosphorylations and the insulin-like effects in response to human growth hormone in isolated rat adipocytes. Ridderstråle M, et al. **Endocrinology** 1996 Nov; 137(11):4650–6

Potential role of protein kinase B in glucose transporter 4 translocation in adipocytes. Tanti JF, et al. **Endocrinology** 1997 May;138(5):2005–10

The antilipolytic effects of insulin and epidermal growth factor in rat adipocytes are mediated by different mechanisms. Tebar F, et al. **Endocrinology** 1996 Oct; 137(10):4181–8

Influence of prolonged fasting and thyroid hormone on the alpha 2-adrenergic response in isolated epididymal adipocytes of Wistar rats. Ben Cheikh R, et al. **Eur J Endocrinol** 1997 Feb;136(2):223–9

Regulation of obese mRNA expression by hormonal factors in primary cultures of rat adipocytes. Yoshida T, et al. **Eur J Endocrinol** 1996 Nov;135(5):619–25

Regulation of energy balance by leptin. Hamann A, et al. **Exp Clin Endocrinol Diabetes** 1996;104(4):293–300 (46 ref.)

Impairment of vitamin A uptake by rat hepatocytes and fat storing cells determined by Monensin--morphological observations. Novelli A, et al. **Exp Toxicol Pathol** 1995 Nov;47(5):413–20

Analyses of the co-localization of cellubrevin and the GLUT4 glucose transporter in rat and human insulin-responsive tissues. Aledo JC, et al. **FEBS Lett** 1996 Oct 21;395(2–3):211–6

Evidence for a novel regulatory pathway activated by (carba)prostacyclin in preadipose and adipose cells. Aubert J, et al. **FEBS Lett** 1996 Nov 11;397(1):117–21

Suppression of insulin-stimulated phosphatidylinositol 3-kinase activity by the beta3-adrenoceptor agonist CL316243 in rat adipocytes. Ohsaka Y, et al. **FEBS Lett** 1997 Feb 3;402(2–3):246–50

Etomoxir, sodium 2-[6-(4-chlorophenoxy)hexyl] oxirane-2-carboxylate, inhibits triacylglycerol depletion in hepatocytes and lipolysis in adipocytes. Spurway TD, et al. **FEBS Lett** 1997 Mar 3;404(1):111-4

Human adipocytes express alpha 2-adrenergic receptor of the alpha 2A-subtype only: pharmacological and genetic evidence. Castan I, et al. **Fundam Clin Pharmacol** 1995; 9(6):569-75

Triiodothyronine and amiodarone effects on beta 3-adrenoceptor density and lipolytic response to the beta 3-adrenergic agonist BRL 37344 in rat white adipocytes. Germack R, et al. **Fundam Clin Pharmacol** 1996; 10(3):289-97

Assignment of the human adipocyte fatty acid-binding protein gene (FABP4) to chromosome 8q21 using somatic cell hybrid and fluorescence in situ hybridization techniques. Prinsen CF, et al. **Genomics** 1997 Feb 15; 40(1):207-9

The plasminogen-activating system in hepatic stellate cells. Leyland H, et al. **Hepatology** 1996 Nov;24(5):1172-8

Regulation of leptin production in cultured mature white adipocytes. Hardie LJ, et al. **Horm Metab Res** 1996 Dec; 28(12):685-9

The lipolytic effects of thyrotropin and isoprenaline are not affected by growth hormone in infant adipocytes. Janson A, et al. **Horm Metab Res** 1997 Apr;29(4):164-7

Effect of CL316,243, a highly specific beta 3-adrenoceptor agonist, on lipolysis of human and rat adipocytes. Umekawa T, et al. **Horm Metab Res** 1996 Aug;28(8):394-6

3T3-L1 adipocytes as a cell culture model of insulin resistance [letter] Knutson VP, et al. **In Vitro Cell Dev Biol Anim** 1997 Feb;33(2):77-81

Microcalorimetric and biochemical investigations of thermogenesis and metabolic pathways in human white adipocytes. Böttcher H, et al. **Int J Obes Relat Metab Disord** 1996 Sep;20(9):874-81

Decreased white fat cell thermogenesis in obese individuals. Böttcher H, et al. **Int J Obes Relat Metab Disord** 1997 Jun;21(6):439-44

Regulation of lipolysis in fat cells of obese women during long-term hypocaloric diet. Hellström L, et al. **Int J Obes Relat Metab Disord** 1996 Aug;20(8):745-52

ASP stimulates glucose transport in cultured human adipocytes. Maslowska M, et al. **Int J Obes Relat Metab Disord** 1997 Apr;21(4):261-6

A new microcatheter enables microcalorimetric assessment of thermogenesis after stimulation in cell cultures. Böttcher H, et al. **J Biochem Biophys Methods** 1996 Jul 10; 32(3):191-4

Beta-Adrenergic receptors in rat fat cells and their relationship with lipolysis. Okuda H, et al. **J Biochem (Tokyo)** 1996 May;119(5):852-6

Uptake of long chain free fatty acids is selectively up-regulated in adipocytes of Zucker rats with genetic obesity and non-insulin-dependent diabetes mellitus. Berk PD, et al. **J Biol Chem** 1997 Mar 28;272(13):8830-5

Identification of glycerol-3-phosphate acyltransferase as an adipocyte determination and differentiation factor 1- and sterol regulatory element-binding protein-responsive gene. Ericsson J, et al. **J Biol Chem** 1997 Mar 14;272(11):7298-305

Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes. Fadden P, et al. **J Biol Chem** 1997 Apr 11;272(15):10240-7

Beta3-adrenergic receptors on white and brown adipocytes mediate beta3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice. Grujic D, et al. **J Biol Chem** 1997 Jul 11;272(28):17686-93

Functional antagonism between CCAAT/Enhancer binding protein-alpha and peroxisome proliferator-activated receptor-gamma on the leptin promoter. Hollenberg AN, et al. **J Biol Chem** 1997 Feb 21;272(8):5283-90

Insulin-induced activation of NADPH-dependent H2O2 generation in human adipocyte plasma membranes is mediated by Galphai2. Krieger-Brauer HI, et al. **J Biol Chem** 1997 Apr 11;272(15):10135-43

A synthetic peptide corresponding to the GLUT4 C-terminal cytoplasmic domain causes insulin-like glucose transport stimulation and GLUT4 recruitment in rat adipocytes. Lee W, et al. **J Biol Chem** 1997 Aug 22;272(34):21427-31

Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells. Mastick CC, et al. **J Biol Chem** 1997 Aug 15;272(33):20706-14

Overexpression of Rad inhibits glucose uptake in cultured muscle and fat cells. Moyers JS, et al. **J Biol Chem** 1996 Sep 20;271(38):23111-6

Leptin impairs metabolic actions of insulin in isolated rat adipocytes. Müller G, et al. **J Biol Chem** 1997 Apr 18; 272(16):10585-93

Cross-talk between the platelet-derived growth factor and the insulin signaling pathways in 3T3-L1 adipocytes. Ricort JM, et al. **J Biol Chem** 1997 Aug 8;272(32):19814-8

Insulin stimulates guanine nucleotide exchange on Rab4 via a wortmannin-sensitive signaling pathway in rat adipocytes. Shibata H, et al. **J Biol Chem** 1997 Jun 6; 272(23):14542-6

Overexpression of a constitutively active form of phosphatidylinositol 3-kinase is sufficient to promote Glut 4 translocation in adipocytes. Tanti JF, et al. **J Biol Chem** 1996 Oct 11;271(41):25227-32

Development of insulin resistance in 3T3-L1 adipocytes. Thomson MJ, et al. **J Biol Chem** 1997 Mar 21; 272(12):7759-64

The amino terminus of insulin-responsive aminopeptidase causes Glut4 translocation in 3T3-L1 adipocytes. Waters SB, et al. **J Biol Chem** 1997 Sep 12;272(37):23323-7

Retinyl ester hydrolysis and retinol efflux from BFC-1beta adipocytes. Wei S, et al. **J Biol Chem** 1997 May 30; 272(22):14159-65

Dexamethasone stimulates leptin release from human adipocytes: unexpected inhibition by insulin. Considine RV, et al. **J Cell Biochem** 1997 May;65(2):254-8

Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. Montrose-Rafizadeh C, et al. **J Cell Physiol** 1997 Sep; 172(3):275-83

Human immortalized brown adipocytes express functional beta3-adrenoceptor coupled to lipolysis. Zilberfarb V, et al. **J Cell Sci** 1997 Apr;110 (Pt 7):801-7

Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: a possible link to insulin resistance? Ek I, et al. **J Clin Endocrinol Metab** 1997 Apr; 82(4):1147-53

Catecholamine-induced adipocyte lipolysis in human hyperthyroidism. Hellström L, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):159-66

Beta 3-adrenergic receptor-mediated lipolysis and oxygen consumption in brown adipocytes from cynomolgus monkeys. Meyers DS, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):395-401

Growth inhibitory properties of endothelin-1 in activated human hepatic stellate cells: a cyclic adenosine monophosphate-mediated pathway. Inhibition of both extracellular signal-regulated kinase and c-Jun kinase and upregulation of endothelin B receptors. Mallat A, et al. **J Clin Invest** 1996 Dec 15;98(12):2771-8

Hepatic stellate cell activation in genetic haemochromatosis. Lobular distribution, effect of increasing hepatic iron and response to phlebotomy. Ramm GA, et al. **J Hepatol** 1997 Mar;26(3):584-92

Estradiol-17beta as an antioxidant: some distinct features when compared with common fat-soluble antioxidants [see comments] Ayres S, et al. **J Lab Clin Med** 1996 Oct; 128(4):367-75. Comment in: J Lab Clin Med 1996 Oct;128(4):344-5.

Evidence from in vitro differentiating cells that adrenoceptor agonists can increase uncoupling protein mRNA level in adipocytes of adult humans: an RT-PCR study. Champigny O, et al. **J Lipid Res** 1996 Sep;37(9):1907-14

Isoproterenol decreases LDL receptor expression in rat adipose cells: activation of cyclic AMP-dependent proteolysis. Kraemer FB, et al. **J Lipid Res** 1996 Feb; 37(2):237-49

Acute in vitro production of acylation stimulating protein in differentiated human adipocytes. Maslowska M, et al. **J Lipid Res** 1997 Jan;38(1):1-11

Expression of beta3-adrenoceptors with low lipolytic action in human subcutaneous white adipocytes. Tavernier G, et al. **J Lipid Res** 1996 Jan;37(1):87-97

Reversible binding of long-chain fatty acids to purified FAT, the adipose CD36 homolog. Baillie AGS, et al. **J Membr Biol** 1996 Sep;153(1):75-81

Transcription, adipocyte differentiation, and obesity. Auwerx J, et al. **J Mol Med** 1996 Jul;74(7):347-52 (74 ref.)

Molecular mechanism of insulin-stimulated glucose transport in 3T3-L1 adipocytes. Oka Y, et al. **Jpn J Physiol** 1997; 47 Suppl 1:S49

Adrenergic and purinergic receptors-mediated calcium responses in brown adipocytes. Omatsu-Kanbe M, et al. **Jpn J Physiol** 1997;47 Suppl 1:S47-8

Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates insulin secretion in islets and potentiates glucose-transport in adipocytes. Yada T, et al. **Jpn J Physiol** 1997;47 Suppl 1:S27

Antihyperglycemic mechanism of M16209, an antidiabetic agent, in 3T3-L1 adipocytes. Murakami N, et al. **Life Sci** 1997;60(20):1821-31

Acute effects of progesterone on glucose metabolism in rat adipocytes: are they modulated by endogenous adenosine? Sutter-Dub MT, et al. **Metabolism** 1997 Jun;46(6):595-604

Evidence for selective effects of vanadium on adipose cell metabolism involving actions on cAMP-dependent protein kinase. Brownsey RW, et al. **Mol Cell Biochem** 1995 Dec 6-20;153(1-2):131-7

Specific inhibition of the cGMP-inhibited cAMP phosphodiesterase blocks the insulin-like antilipolytic effect of growth hormone in rat adipocytes. Eriksson H, et al. **Mol Cell Biochem** 1997 Apr;169(1-2):37-42

Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Fantus IG, et al. **Mol Cell Biochem** 1995 Dec 6-20;153(1-2):103-12 (76 ref.)

Fatty acid uptake in diabetic rat adipocytes. Fraser H, et al. **Mol Cell Biochem** 1997 Feb;167(1-2):51-60

Differential regulation of GRP78 and GLUT1 expression in 3T3-L1 adipocytes. Kitzman HH Jr, et al. **Mol Cell Biochem** 1996 Sep 6;162(1):51-8

Expression of c-Fos in subcutaneous adipose tissue of the fetal pig. Lee K, et al. **Mol Cell Biochem** 1996 Feb 9; 155(1):31-5

Insulin-like actions of vanadate are mediated in an insulin-receptor-independent manner via non-receptor protein tyrosine kinases and protein phosphotyrosine phosphatases. Shechter Y, et al. **Mol Cell Biochem** 1995 Dec 6-20;153(1-2):39-47

Potential role of Rab4 in the regulation of subcellular localization of Glut4 in adipocytes. Cormont M, et al. **Mol Cell Biol** 1996 Dec;16(12):6879-86

Syntaxin 4, VAMP2, and/or VAMP3/cellubrevin are functional target membrane and vesicle SNAP receptors for insulin-stimulated GLUT4 translocation in adipocytes. Olson AL, et al. **Mol Cell Biol** 1997 May;17(5):2425-35

Presence and mRNA expression of T3 receptors in differentiating rat brown adipocytes. Hernández A, et al. **Mol Cell Endocrinol** 1996 Jul 23;121(1):37-46

The insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes is mediated by a calcium-dependent thiol protease. Smith LK, et al. **Mol Cell Endocrinol** 1996 Aug 30;122(1):81-92

Regulation of the murine adipocyte fatty acid transporter gene by insulin. Man MZ, et al. **Mol Endocrinol** 1996 Aug; 10(8):1021-8

Phosphoinositide 3-kinase is required for insulin-induced but not for growth hormone- or hyperosmolarity-induced glucose uptake in 3T3-L1 adipocytes. Sakaue H, et al. **Mol Endocrinol** 1997 Sep;11(10):1552-62

Insulin-stimulated glucose uptake involves the transition of glucose transporters to a caveolae-rich fraction within the plasma membrane: implications for type II diabetes. Gustavsson J, et al. **Mol Med** 1996 May;2(3):367-72

Characterization of 6-deoxy-6-iodo-D-glucose: a potential new tool to assess glucose transport. Henry C, et al. **Nucl Med Biol** 1997 Jan;24(1):99-104

Effect of aging on norepinephrine and phenylephrine stimulated lactate production by white adipocytes. Faintrenie G, et al. **Obes Res** 1997 Mar;5(2):100-4

Antilipolytic effect of insulin and insulin receptor messenger RNA expression in adipocytes of infants, children, and adults. Kamel A, et al. **Pediatr Res** 1997 Apr;41(4 Pt 1):563-7

Membrane responses to extracellular ATP in rat isolated white adipocytes. Lee SC, et al. **Pflugers Arch** 1997 Aug; 434(4):422-8

Studies on pyrazinoylguanidine. 3. Downregulation of lipolysis in isolated adipocytes. A-Rahim YI, et al. **Pharmacology** 1996 Oct;53(4):197-210

Insulin-stimulated translocation of GLUT4 glucose transporters requires SNARE-complex proteins. Cheatham B, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24; 93(26):15169-73

Intracellular pH in adipocytes: effects of free fatty acid diffusion across the plasma membrane, lipolytic agonists, and insulin. Civelek VN, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10139-44

Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Rondinone CM, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):4171-5

Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. Zhou YT, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6386-90

Fatty acids and expression of lipid-related genes in adipose cells. Ailhaud G, et al. **Proc Nutr Soc** 1996 Mar; 55(1B):151-4 (19 ref.)

The mitochondrial uncoupling protein: structural and genetic studies. Ricquier D, et al. **Prog Nucleic Acid Res Mol Biol** 1997;56:83-108 (81 ref.)

Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport. Sfeir Z, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):17-21

Lipogenic and lipolytic activities in isolated adipocytes from cattle with fat necrosis. Katamoto H, et al. **Res Vet Sci** 1996 Nov;61(3):214-7

Inhibition of increases of transcription factor mRNAs during differentiation of primary rat adipocytes by in vivo 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) treatment. Brodie AE, et al. **Toxicol Lett** 1997 Feb 7;90(2-3):91-5

[Hormones and adipocyte development] Ailhaud G. **Ann Endocrinol (Paris)** 1997;58(2):129-31 (20 ref.) (Eng. Abstr.) **(Fre)**

[Mechanism of catecholamine-induced lipolysis in adipocytes] Okuda H. **Seikagaku** 1997 Jun;69(6):420-4 (15 ref.) **(Jpn)**

PARASITOLOGY

Toxoplasma gondii: metabolism of intracellular tachyzoites is affected by host cell ATP production. Sorensen SW, et al. **Exp Parasitol** 1997 Jan;85(1):101-4

PATHOLOGY

Insulin-induced lipoatrophy in type I diabetes. A possible tumor necrosis factor-alpha-mediated dedifferentiation of adipocytes. Atlan-Gepner C, et al. **Diabetes Care** 1996 Nov; 19(11):1283-5

The cytotoxic effect of endotoxin on bone marrow cells in zinc deficient rats. Nakajima K, et al. **Tohoku J Exp Med** 1996 Jul;179(3):183-91

PHYSIOLOGY

Paracrine stimulation of preadipocyte-enriched cell cultures

by mature adipocytes. Considine RV, et al. **Am J Physiol** 1996 May;270(5 Pt 1):E895–9

Insulin resistance in adipocytes after downregulation of Gi subtypes. Green A, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):E254–61

Oxidant stress reduces insulin responsiveness in 3T3–L1 adipocytes. Rudich A, et al. **Am J Physiol** 1997 May;272(5 Pt 1):E935–40

Leptin and other secretory products of adipocytes modulate multiple physiological functions. Weigle DS. **Ann Endocrinol (Paris)** 1997;58(2):132–6 (34 ref.)

Adipose tissue development in the chick embryo. Speake BK, et al. **Biochem Soc Trans** 1996 May;24(2):161S

Insulin signal transduction in adipocytes from lactating sheep. Wilson LA, et al. **Biochem Soc Trans** 1996 May;24(2):162S

PPAR gamma and the control of adipogenesis. Spiegelman BM, et al. **Biochimie** 1997 Feb–Mar;79(2–3):111–2 (4 ref.)

Ras(leu61) blocks differentiation of transformable 3T3 L1 and C3H10T1/2–derived preadipocytes in a dose– and time–dependent manner. Raptis L, et al. **Cell Growth Differ** 1997 Jan;8(1):11–21

Conference report: renal disease, metformin, and the adipocyte. Bloomgarden ZT. **Diabetes Care** 1996 Sep; 19(9):1038–41

alpha2–Adrenoceptor stimulation promotes actin polymerization and focal adhesion in 3T3F442A and BFC–1beta preadipocytes. Bétuing S, et al. **Endocrinology** 1996 Dec;137(12):5220–9

Strain–specific response to beta 3–adrenergic receptor agonist treatment of diet–induced obesity in mice. Collins S, et al. **Endocrinology** 1997 Jan;138(1):405–13

Site–related specificities of the control by androgenic status of adipogenesis and mitogen–activated protein kinase cascade/c–fos signaling pathways in rat preadipocytes. Lacasa D, et al. **Endocrinology** 1997 Aug;138(8):3181–6

Fatty acid–induced insulin resistance in adipocytes. Van Epps–Fung M, et al. **Endocrinology** 1997 Oct; 138(10):4338–45

Developmental expression and functional activity of beta 1– and beta 3–adrenoceptors in murine 3T3–F442A differentiating adipocytes. El Hadri K, et al. **Eur J Pharmacol** 1996 Feb 15;297(1–2):107–19

Cell growth and differentiation of a novel mouse Ito (fat–storing) cell line transformed by a temperature–sensitive mutant of simian virus 40. Kitamura Y, et al. **Hepatology** 1997 Aug;26(2):323–9

Lipolysis in human fat cells obtained under local and general anesthesia. Large V, et al. **Int J Obes Relat Metab Disord** 1997 Jan;21(1):78–82

Characterization of Munc–18c and syntaxin–4 in 3T3–L1 adipocytes. Putative role in insulin–dependent movement of GLUT–4. Tellam JT, et al. **J Biol Chem** 1997 Mar 7; 272(10):6179–86

Disruption of the vimentin intermediate filament system during adipose conversion of 3T3–L1 cells inhibits lipid droplet accumulation. Lieber JG, et al. **J Cell Sci** 1996 Dec;109 (Pt 13):3047–58

Variation in adrenergic regulation of lipolysis between omental and subcutaneous adipocytes from obese and non–obese men. Hoffstedt J, et al. **J Lipid Res** 1997 Apr; 38(4):795–804

Biochemical assessment of cellular damage after adipocyte harvest. Lalikos JF, et al. **J Surg Res** 1997 Jun;70(1):95–100

Cell biology of insulin action on glucose transport. Cushman W, et al. **Jpn J Physiol** 1997;47 Suppl 1:S39

Ectopic expression of Hel–N1, an RNA–binding protein, increases glucose transporter (GLUT1) expression in 3T3–L1 adipocytes. Jain RG, et al. **Mol Cell Biol** 1997 Feb;17(2):954–62

Hepatic stellate cells. Friedman SL. **Prog Liver Dis** 1996; 14:101–30 (185 ref.)

[Secretory function of the adipocyte] Ailhaud G. **Journ Annu Diabetol Hotel Dieu** 1997;:125–9 (45 ref.) **(Fre)**

SECRETION

Leptin and other secretory products of adipocytes modulate multiple physiological functions. Weigle DS. **Ann Endocrinol (Paris)** 1997;58(2):132–6 (34 ref.)

Human liposarcoma cell line, SW872, secretes cholesteryl ester transfer protein in response to cholesterol. Richardson MA, et al. **J Lipid Res** 1996 May;37(5):1162–6

TRANSPLANTATION

Obese gene expression at in vivo levels by fat pads derived from s.c. implanted 3T3–F442A preadipocytes [see comments] Mandrup S, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4300–5. Comment in: Proc Natl Acad Sci U S A 1997 Apr 29;94(9):4242–5.

ULTRASTRUCTURE

Association of cytosolic Rab4 with GDI isoforms in insulin–sensitive 3T3–L1 adipocytes. Shisheva A, et al. **Biochemistry** 1997 Jun 3;36(22):6564–70

Multivesicular stellate cells in primary biliary cirrhosis. Cameron RG, et al. **Hepatology** 1997 Oct;26(4):819–22

Subcellular localization of G–proteins in primary–cultured mouse preadipocytes and adipocytes. Bégin–Heick N, et al. **J Cell Biochem** 1997 May;65(2):259–66

ADIPOGENESIS INHIBITORY FACTOR see **INTERLEUKIN–11**

ADIPOSE TISSUE

see related
ADIPOCYTES
BROWN FAT
LIPECTOMY
SKINFOLD THICKNESS

Fat injection: long–term follow–Up. Chajchir A. **Aesthetic Plast Surg** 1996 Jul–Aug;20(4):291–6

Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice. Abate N, et al. **Am J Clin Nutr** 1997 Feb;65(2):403–8

Regional body fat distribution in relation to pubertal stage: a dual–energy X–ray absorptiometry study of New Zealand girls and young women. Goulding A, et al. **Am J Clin Nutr** 1996 Oct;64(4):546–51

Body fat estimation in late pregnancy and early postpartum: comparison of two–, three–, and four–component models. Hopkinson JM, et al. **Am J Clin Nutr** 1997 Feb;65(2):432–8

Nutrient balance and android body fat distribution: why not a role for protein? [letter; comment] Rolland–Cachera MF, et al. **Am J Clin Nutr** 1996 Oct;64(4):663–4. Comment on: Am J Clin Nutr 1996 Feb;63(2):254–60.

Prediction of percentage body fat from anthropometric measurements: comparison of New Zealand European and Polynesian young women [comment] Rush EC, et al. **Am J Clin Nutr** 1997 Jul;66(1):2–7. Comment on: Am J Clin Nutr 1997 Jul;66(1):26–32.

The fatness–specific bioelectrical impedance analysis equations of Segal et al: are they generalizable and practical? Stolarczyk LM, et al. **Am J Clin Nutr** 1997 Jul; 66(1):8–17

Regional fat distribution in women and risk of cardiovascular disease [see comments] Williams MJ, et al. **Am J Clin Nutr** 1997 Mar;65(3):855–60. Comment in: Am J Clin Nutr 1997 Sep;66(3):712–3.

Effects of age on body fat distribution and cardiovascular risk factors in women. Zamboni M, et al. **Am J Clin Nutr** 1997 Jul;66(1):111–5

Re: "Sex–specific associations of magnetic resonance imaging–derived intra–abdominal and subcutaneous fat areas with conventional anthropometric indices: the Atherosclerosis in Communities Study" [letter; comment] Kahn HS. **Am J Epidemiol** 1997 Jan 1;145(1):83–4. Comment on: Am J Epidemiol 1996 Aug 15;144(4):335–45.

Total and sports activity in older men and women: relation with body fat distribution. Visser M, et al. **Am J Epidemiol** 1997 Apr 15;145(8):752–61

Genomewide search for genes influencing percent body fat in Pima Indians: suggestive linkage at chromosome 11q21–q22. Pima Diabetes Gene Group. Norman RA, et al. **Am J Hum Genet** 1997 Jan;60(1):166–73

Sutural exostoses, rib hyperostoses, craniosynostosis, mental retardation with focal fat deposition: Proteus syndrome? Christianson AL, et al. **Am J Med Genet** 1996 Dec 11; 66(2):150–3

Myxoid liposarcoma of the retropatellar fat pad. Lundy DW, et al. **Am J Orthop** 1997 Apr;26(4):287–9

Association between intra–abdominal fat and hypertension in android obese diabetics. Sepulveda–Lavados A, et al. **Ann Med Interne (Paris)** 1996;147(6):393–16

Value of fat suppression magnetic resonance imaging in the diagnosis of lipomas of the internal auditory canal. Hara A, et al. **Ann Otol Rhinol Laryngol** 1997 Apr;106(4):343–7 (27 ref.)

Re: Scarpa's adipofascial flap for repair of wide scalp defects [letter; comment] Southern S, et al. **Ann Plast Surg** 1996 Sep;37(3):343–4. Comment on: Ann Plast Surg 1996 Jan;36(1):88–92.

Resumption of menses in anorexia nervosa [see comments] Golden NH, et al. **Arch Pediatr Adolesc Med** 1997 Jan; 151(1):16–21. Comment in: Arch Pediatr Adolesc Med 1997 Jan;151(1):14–5. Comment in: Arch Pediatr Adolesc Med 1997 Jun;151(6):634–5.

Weight–independent cardiovascular fitness and coronary risk factors. Gutin B, et al. **Arch Pediatr Adolesc Med** 1997 May;151(5):462–5

Reduced bone mass and fat–free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid Use. Formica CA, et al. **Calcif Tissue Int** 1997 Aug; 61(2):129–33

Adiposity and androstenedione production in relation to delayed ovulation in the Indian bat, Scotophilus heathi. Abhilasha, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jan;116(1):97–101

Reduced serum cholecystokinin and increase in body fat during oral contraception. Hirschberg AL, et al. **Contraception** 1996 Feb;53(2):109–13

Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Abate N, et al. **Diabetes** 1996 Dec;45(12):1684–93

Fat cells. Ramsay TG. **Endocrinol Metab Clin North Am** 1996 Dec;25(4):847–70 (184 ref.)

Total body protein status assessed by different estimates of fat–free mass in adult peritoneal dialysis patients. Borovnicar DJ, et al. **Eur J Clin Nutr** 1996 Sep; 50(9):607–16

Comparisons between fat measurements by dual–energy X–ray absorptiometry, underwater weighing and magnetic resonance imaging in healthy women. Tothill P, et al. **Eur J Clin Nutr** 1996 Nov;50(11):747–52

Serum leptin in obesity is related to gender and body fat topography but does not predict successful weight loss. Niskanen LK, et al. **Eur J Endocrinol** 1997 Jul;137(1):61–7

A role for pancreatic hormones in the regulation of autumnal fat deposition of the garden warbler (Sylvia borin)? Totzke U, et al. **Gen Comp Endocrinol** 1997 Aug;107(2):166–71

Plasma leptin is directly related to body adiposity in subjects with spinal cord injury. Bauman WA, et al. **Horm Metab Res** 1996 Dec;28(12):732–6

Hyperleptinemia: relationship to adiposity and insulin resistance in the spontaneously obese rhesus monkey. Bodkin NL, et al. **Horm Metab Res** 1996 Dec;28(12):674–8

The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks. Campfield LA, et al. **Horm Metab Res** 1996 Dec;28(12):619–32 (96 ref.)

Dissociation of serum leptin concentration and body fat content during long term dietary intervention in obese individuals. Scholz GH, et al. **Horm Metab Res** 1996 Dec; 28(12):718–23

Plasma leptin levels and body fat distribution. Takahashi M, et al. **Horm Metab Res** 1996 Dec;28(12):751–2

New age–adjusted measure of body fat distribution in children and adolescents: standardization of waist–hip ratio using multivariate analysis. Asayama K, et al. **Int J Obes Relat Metab Disord** 1997 Jul;21(7):594–9

Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Bonora E, et al. **Int J Obes Relat Metab Disord** 1996 Nov;20(11):975–80

Visceral adiposity, fasting plasma insulin, and lipid and lipoprotein levels in Japanese Americans. Boyko EJ, et al. **Int J Obes Relat Metab Disord** 1996 Sep;20(9):801–8

Obesity, adiposity, and lengthening of the QT interval: improvement after weight loss. Carella MJ, et al. **Int J Obes Relat Metab Disord** 1996 Oct;20(10):938–42

Relationship of obesity and body fat distribution with ceruloplasmin serum levels. Cignarelli M, et al. **Int J Obes Relat Metab Disord** 1996 Sep;20(9):809–13

Increase in both pro–thrombotic and anti–thrombotic factors in obese premenopausal women: relationship with body fat distribution. De Pergola G, et al. **Int J Obes Relat Metab Disord** 1997 Jul;21(7):527–535

Measuring body fatness in children and young adults: comparison of bioelectric impedance analysis, total body electrical conductivity, and dual–energy X–ray absorptiometry. Ellis KJ. **Int J Obes Relat Metab Disord** 1996 Sep;20(9):866–73

Physical activity related energy expenditure and fat mass in young children. Goran MI, et al. **Int J Obes Relat Metab Disord** 1997 Mar;21(3):171–8

DEXA supports the use of BMI as a measure of fatness in young girls. Goulding A, et al. **Int J Obes Relat Metab Disord** 1996 Nov;20(11):1014–21

Leptin concentrations in relation to overall adiposity and regional body fat distribution in Mexican Americans. Haffner SM, et al. **Int J Obes Relat Metab Disord** 1996 Oct;20(10):904–8

Predicting intra–abdominal fatness from anthropometric measures: the influence of stature. Han TS, et al. **Int J Obes Relat Metab Disord** 1997 Jul;21(7):587–93

The prevalence of low back pain and associations with body fatness, fat distribution and height. Han TS, et al. **Int J Obes Relat Metab Disord** 1997 Jul;21(7):600–7

Intra–abdominal adipose tissue, physical activity and cardiovascular risk in pre– and post–menopausal women. Hunter GR, et al. **Int J Obes Relat Metab Disord** 1996 Sep;20(9):860–5

Anthropometric correlates to changes in visceral adipose tissue over 7 years in women. Lemieux S, et al. **Int J Obes Relat Metab Disord** 1996 Jul;20(7):618–24

Importance of intra–abdominal visceral fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemia. Nakamura T, et al. **Int J Obes Relat Metab Disord** 1997 Jul;21(7):580–6

Effects of body fat distribution on body size estimation accuracy among obese women. Rhodes SK, et al. **Int J Obes Relat Metab Disord** 1997 Mar;21(3):250–3

The influence of occupational and social factors on obesity and body fat distribution in middle–aged men. Rosmond R, et al. **Int J Obes Relat Metab Disord** 1996 Jul; 20(7):599–607

Serum leptin concentration is associated with total body fat mass, but not abdominal fat distribution. Shimizu H, et al. **Int J Obes Relat Metab Disord** 1997 Jul;21(7):536–41

The reallocation of body fat toward the abdomen persists to very old age, while body mass index declines after middle age in Chinese. Teh BH, et al. **Int J Obes Relat Metab Disord** 1996 Jul;20(7):683–7

Relationship between physical activity related energy expenditure and body composition: a gender difference. Westerterp KR, et al. **Int J Obes Relat Metab Disord** 1997 Mar;21(3):184–8

Dietary fat and body fat: an intervention study. Westerterp KR, et al. **Int J Obes Relat Metab Disord** 1996 Nov; 20(11):1022–6

Intra–abdominal adipose tissue cut–points related to elevated cardiovascular risk in women. Williams MJ, et al.

Int J Obes Relat Metab Disord 1996 Jul;20(7):613–7

Visceral fat accumulation and vascular complications associated with VMH lesioning of spontaneously non–insulin–dependent diabetic GK rat. Yoshida S, et al. **Int J Obes Relat Metab Disord** 1996 Oct;20(10):909–16

Body fat percentage and gender: associations with exercise energy expenditure, substrate utilization, and mechanical work efficiency. Keim NL, et al. **Int J Sport Nutr** 1996 Dec;6(4):356–69

Abdominal fat determines growth hormone–binding protein levels in healthy nonobese adults. Fisker S, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):123–8

Gain in body fat is inversely related to the nocturnal rise in serum leptin level in young females. Matkovic V, et al. **J Clin Endocrinol Metab** 1997 May;82(5):1368–72

Effects of gender, ethnicity, body composition, and fat distribution on serum leptin concentrations in children. Nagy TR, et al. **J Clin Endocrinol Metab** 1997 Jul; 82(7):2148–52

Androstane–3alpha,17beta–diol glucuronide as a steroid correlate of visceral obesity in men. Tchernof A, et al. **J Clin Endocrinol Metab** 1997 May;82(5):1528–34

Relationship between body condition scores and milk yield in a large dairy herd of high yielding Holstein cows. Domecq JJ, et al. **J Dairy Sci** 1997 Jan;80(1):101–12

Relationship between body condition scores and conception at first artificial insemination in a large dairy herd of high yielding Holstein cows. Domecq JJ, et al. **J Dairy Sci** 1997 Jan;80(1):113–20

Factors affecting body tissue mobilization in early lactation dairy cows. 1. Effect of dietary protein on mobilization of body fat and protein. Komaragiri MV, et al. **J Dairy Sci** 1997 May;80(5):929–37

Influence of menopause on blood cholesterol levels in women: the role of body composition, fat distribution and hormonal milieu. Virgilio Menopause Health Group. Pasquali R, et al. **J Intern Med** 1997 Mar;241(3):195–203

The size of the vertebral canal and the significance of epidural fat in lumbar spinal stenosis. Prasartritha T, et al. **J Med Assoc Thai** 1997 Apr;80(4):247–56

Genetic influences on the response of body fat and fat distribution to positive and negative energy balances in human identical twins. Bouchard C, et al. **J Nutr** 1997 May; 127(5 Suppl):943S–947S (18 ref.)

Effects of intermittent food restriction and refeeding on energy efficiency and body fat deposition in sedentary and exercised rats. Lim K, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Oct;42(5):449–68

The relation between body-fat distribution and lipid metabolism in postmenopausal women. Douchi T, et al. **J Obstet Gynaecol Res** 1996 Aug;22(4):353–8

Urinary stress incontinence due to intrinsic sphincteric deficiency: experience with fat and collagen periurethral injections [see comments] [published erratum appears in J Urol 1997 Jul;158(1):188] Haab F, et al. **J Urol** 1997 Apr; 157(4):1283–6. Comment in: J Urol 1997 Apr;157(4):1287.

Autologous fat implantation for vocal fold scar: a preliminary report. Sataloff RT, et al. **J Voice** 1997 Jun;11(2):238–46

Predictive accuracy of bioimpedance in estimating fat–free mass of African–American women. Ainsworth BE, et al. **Med Sci Sports Exerc** 1997 Jun;29(6):781–7

Assessment of fat–mass loss during weight reduction in obese women. Fogelholm GM, et al. **Metabolism** 1997 Aug; 46(8):968–75

Validity of percent body fat predicted from circumferences: classification of men for weight control regulations [see comments] Friedl KE, et al. **Mil Med** 1997 Mar; 162(3):194–200. Comment in: Mil Med 1997 Jun;162(6):ii.

The right weight: body fat, menarche, and fertility [editorial] Frisch RE. **Nutrition** 1996 Jun;12(6):452–3

A comparison of body fat estimates using anthropometry and bioelectrical impedance analysis with distinct prediction equations in elderly persons in the Republic of Guatemala. Mazariegos M, et al. **Nutrition** 1996 Mar;12(3):168–75

Birth weight and its relationship to size attained and relative fat distribution at 7 to 12 years of age. Malina RM, et al. **Obes Res** 1996 Jul;4(4):385–90

A low sympathoadrenal activity is associated with body weight gain and development of central adiposity in Pima Indian men. Tataranni PA, et al. **Obes Res** 1997 Jul; 5(4):341–7

Effect of high sucrose feeding on fat accumulation in the male Wistar rat. Toida S, et al. **Obes Res** 1996 Nov; 4(6):561–8

Comparisons for body mass index and body fat percent among Puerto Ricans, blacks, whites and Asians living in the New York City area. Wang J, et al. **Obes Res** 1996 Jul;4(4):377–84

Effects of visceral fat and weight loss on lipoprotein(a) concentration in subjects with obesity. Zamboni M, et al. **Obes Res** 1997 Jul;5(4):332–7

Longitudinal changes in the relationship between body mass index and percent body fat in pregnancy. Lindsay CA, et al. **Obstet Gynecol** 1997 Mar;89(3):377–82

The utility of body mass index as a measure of body fatness in children and adolescents: differences by race and gender. Daniels SR, et al. **Pediatrics** 1997 Jun;99(6):804–7

Lateral pharyngeal fat pad pressure during breathing. Winter WC, et al. **Sleep** 1996 Dec;19(10 Suppl):S178–9

The importance of fat free mass maintenance in weight loss programmes. Marks BL, et al. **Sports Med** 1996 Nov; 22(5):273–81 (45 ref.)

Perivesical fat closure during suprapubic prostatectomy: does it prevent urinary leakage? A prospective randomized study. Stein A, et al. **Tech Urol** 1996 Summer;2(2):99–101

[The dimension of animal carcass disposal in Germany and Europe–– quantification and differentiation] Böhm R. **DTW Dtsch Tierarztl Wochenschr** 1997 Jul;104(7):232–8 (Eng. Abstr.) **(Ger)**

[Oropharyngeal fat hernia in Madelung's neck as a rare cause of acute dysphagia] Baier G, et al. **Laryngorhinootologie** 1997 Jul;76(7):425–7 (Eng. Abstr.) **(Ger)**

[Glass fragment in the corpus adiposum infrapatellare] **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jun;166(6):576–8 **(Ger)**

[The evaluation of fat and muscles of the arm in the nutritional study in pre–school children in Madrid] Tejedor García V, et al. **An Esp Pediatr** 1997 Apr;46(4):335–43 (Eng. Abstr.) **(Spa)**

[Cytological changes in the vagina following therapy with conjugated estrogens in relation to body weight and adipose tissue distribution in postmenopause] Carranza–Lira S, et al. **Ginecol Obstet Mex** 1996 Sep; 64:399–401 (Eng. Abstr.) **(Spa)**

[Correlation of histopathologic findings with ultrasonography variables of the endometrium according to body weight and adipose tissue distribution in postmenopause] Carranza–Lira S, et al. **Ginecol Obstet Mex** 1996 Nov;64:517–21 (Eng. Abstr.) **(Spa)**

[Obesity and distribution of body fat. Correlation between anthropometric and tomographic data on areas at the abdominal level] Lara Fernández A, et al. **Rev Clin Esp** 1996 Jul;196(7):437–45 (41 ref.) (Eng. Abstr.) **(Spa)**

[Body fat distribution: anthropometric indicators] Yáñez M, et al. **Rev Med Chil** 1995 Dec;123(12):1520–4 (35 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Relationship between anthropometric indices of body fat distribution and basal energy metabolism in healthy Maltese women. Pullicino E, et al. **Acta Diabetol** 1996 Sep; 33(3):198–204

Measurement of the total body fat content of growing rabbits by X–ray computerised tomography and direct chemical analysis. Romvári R, et al. **Acta Vet Hung** 1996; 44(2):145–51

Pre– and post–weaning piglet performance, sow food intake and change in backfat thickness in a group–housing system for lactating sows. Hultén F, et al. **Acta Vet Scand** 1997; 38(1):119–33

Study of aspirated adipose tissue. Carpaneda CA. **Aesthetic Plast Surg** 1996 Sep–Oct;20(5):399–402

The abdominal diameter index and sudden coronary death in men. Kahn HS, et al. **Am J Cardiol** 1996 Oct 15; 78(8):961–4

Fitness, fatness, and the effect of training assessed by magnetic resonance imaging and skinfold–thickness measurements in healthy adolescent females. Eliakim A, et al. **Am J Clin Nutr** 1997 Aug;66(2):223–31

A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group. Hla MM, et al. **Am J Clin Nutr** 1996 Sep;64(3):354–60

Why bioelectrical impedance analysis should be used for estimating adiposity. Houtkooper LB, et al. **Am J Clin Nutr** 1996 Sep;64(3 Suppl):436S–448S (73 ref.)

Changes in body composition and fat distribution after short–term weight gain in patients with anorexia nervosa. Orphanidou CI, et al. **Am J Clin Nutr** 1997 Apr; 65(4):1034–41

Abnormal characteristics in young offspring of parents with non–insulin–dependent diabetes mellitus. The Bogalusa Heart Study. Berenson GS, et al. **Am J Epidemiol** 1996 Nov 15;144(10):962–7

Whole body bone, fat and lean mass in children: comparison of three ethnic groups. Nelson DA, et al. **Am J Phys Anthropol** 1997 Jun;103(2):157–62

Leptin is related to body fat content in male distance runners. Hickey MS, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):E938–40

Feeding patterns of S. crassicaudata (Marsupialia:Dasyuridae): role of gender, photoperiod, and fat stores. Hope PJ, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R78–83

Gender differences in muscle sympathetic nerve activity: effect of body fat distribution. Jones PP, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):E363–6

Age–related increase in muscle sympathetic nerve activity is associated with abdominal adiposity. Jones PP, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E976–80

Photoperiod–dependent fat pad mass and cellularity changes after partial lipectomy in Siberian hamsters. Mauer MM, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):R383–92

Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat. Paolisso G, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E471–8

Plasma leptin responses to fasting in Pima Indians. Pratley RE, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E644–9

Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Vahl N, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E1108–16

Density of fat–free body mass: relationship with race, age, and level of body fatness. Visser M, et al. **Am J Physiol** 1997 May;272(5 Pt 1):E781–7

Bichat's fat–pad: correlations with some anthropometric parameters. Gravante G, et al. **Ann Hum Biol** 1997 Mar–Apr;24(2):181–5

Relation between plasma leptin levels and measures of body fat in identical twins discordant for obesity. Rönnemaa T, et al. **Ann Intern Med** 1997 Jan 1;126(1):26–31

Serum HDL cholesterol values are associated with apoB–containing lipoprotein metabolism and triglyceride–body fat interrelation in young Japanese men. Kazumi T, et al. **Atherosclerosis** 1997 Apr;130(1–2):93–100

The effect of feeding diets with different n–6/n–3 fatty acids ratios on adipose tissue of deposition in the rat. Sherrington EJ, et al. **Biochem Soc Trans** 1996 May;24(2):160S

Measurement of soft tissue composition by dual energy X–ray absorptiometry. Jebb SA. **Br J Nutr** 1997 Feb;77(2):151–63 (57 ref.)

Subcutaneous and visceral fat distribution and daily physical activity: comparison between young and middle aged women. Abe T, et al. **Br J Sports Med** 1996 Dec; 30(4):297–300

Magnetic resonance imaging provides new insights into the characterization of adipose and lean tissue distribution. Ross R. **Can J Physiol Pharmacol** 1996 Jun;74(6):778–85

Effects of obesity and fat distribution on ventilatory function: the normative aging study [see comments] Lazarus R, et al. **Chest** 1997 Apr;111(4):891–8. Comment in: Chest 1997 Apr;111(4):844–5.

Visceral fat and race–dependent health risks in obese nondiabetic premenopausal women. Albu JB, et al. **Diabetes** 1997 Mar;46(3):456–62

Leptin: a significant indicator of total body fat but not of visceral fat and insulin insensitivity in African–American women. Dua A, et al. **Diabetes** 1996 Nov;45(11):1635–7

Depot– and sex–specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Montague CT, et al. **Diabetes** 1997 Mar; 46(3):342–7

Measurement of central adiposity. A bet each way? [letter; comment] Campbell LV, et al. **Diabetes Care** 1996 Sep; 19(9):1033–4. Comment on: Diabetes Care 1996 Mar;19(3):287–91. Comment on: Diabetes Care 1996 Mar;19(3):292–4.

The effect of metformin on the metabolic abnormalities associated with upper–body fat distribution. BIGPRO Study Group. Fontbonne A, et al. **Diabetes Care** 1996 Sep; 19(9):920–6

Seven–year changes in body fat and visceral adipose tissue in women. Association with indexes of plasma glucose–insulin homeostasis. Lemieux S, et al. **Diabetes Care** 1996 Sep;19(9):983–91

Separate associations between visceral and subcutaneous adipose tissue distribution, insulin and glucose levels in obese women. Ross R, et al. **Diabetes Care** 1996 Dec; 19(12):1404–11

Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience. Matsuzawa Y. **Diabetes Metab Rev** 1997 Mar;13(1):3–13 (76 ref.)

Renal function and insulin resistance as determinants of plasma leptin levels in patients with NIDDM. Shoji T, et al. **Diabetologia** 1997 Jun;40(6):676–9

Association between Ala54Thr substitution of the fatty acid–binding protein 2 gene with insulin resistance and intra–abdominal fat thickness in Japanese men. Yamada K, et al. **Diabetologia** 1997 Jun;40(6):706–10

Dehydroepiandrosterone sulfate and testosterone are independently associated with body fat distribution in premenopausal women. Mantzoros CS, et al. **Epidemiology** 1996 Sep;7(5):513–6

Correlation of body fat distribution with grade of endometrial cancer. Douchi T, et al. **Gynecol Oncol** 1997 Apr; 65(1):138–42

Sex differences in the relationship of body fat distribution with psychosocial variables. Hoffman JM, et al. **Int J Eat Disord** 1997 Sep;22(2):139–45

Usefulness of fat–suppression magnetic resonance imaging for oral and maxillofacial lesions. Kitagawa Y, et al. **Int J Oral Maxillofac Surg** 1996 Dec;25(6):457–62

Body fat percentage of children varies according to their diet composition. Tucker LA, et al. **J Am Diet Assoc** 1997 Sep;97(9):981–6

Anatomical compartments of the parasellar region: adipose tissue bodies represent intracranial continuations of extracranial spaces. Weninger WJ, et al. **J Anat** 1997 Aug; 191 (Pt 2):269–75

Whole body bone, fat, and lean mass in black and white men. Barondess DA, et al. **J Bone Miner Res** 1997 Jun; 12(6):967–71

Abdominal fat distribution and insulin levels only partially explain adverse cardiovascular risk profile in Asian Indians. Hodge AM, et al. **J Cardiovasc Risk** 1996 Jun;3(3):263–70

Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. Gambacciani M, et al. **J Clin Endocrinol Metab** 1997 Feb; 82(2):414–7

Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. Havel PJ, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4406–13

Relation between plasma leptin concentration and body fat,

gender, diet, age, and metabolic covariates. Ostlund RE Jr, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):3909–13

The effects of acute hyperglycemia and hyperinsulinemia on plasma leptin levels: its relationships with body fat, visceral adiposity, and age in women. Ryan AS, et al.
J Clin Endocrinol Metab 1996 Dec;81(12):4433–8

Independent genetic factors determine the amount and distribution of fat in women after the menopause. Samaras K, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):781–5

Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated GH secretion in healthy adults. Vahl N, et al.
J Clin Endocrinol Metab 1996 Jun;81(6):2209–15

Identification of an obesity quantitative trait locus on mouse chromosome 2 and evidence of linkage to body fat and insulin on the human homologous region 20q. Lembertas AV, et al. **J Clin Invest** 1997 Sep 1;100(5):1240–7

Body composition and blood pressure: which indices of fatness show the strongest correlation? Ahmed M-el B, et al. **J Hum Hypertens** 1996 Jun;10(6):365–8

Separation of water and fat MR images in a single scan at .35 T using "sandwich" echoes. Zhang W, et al.
J Magn Reson Imaging 1996 Nov–Dec;6(6):909–17

Relationship between physical inactivity and adiposity in prepubertal boys. Maffeis C, et al. **J Pediatr** 1997 Aug; 131(2):288–92

Distribution of subcutaneous fat and equations for predicting percent body fat from skinfold measurements: a comparison between Chinese females from two age cohorts. Fu FH, et al. **J Sports Med Phys Fitness** 1995 Sep;35(3):224–7

Fat mass, fat mass percentage, body mass index, and mid–upper arm circumference in a healthy population of Nigerian children. Owa JA, et al. **J Trop Pediatr** 1997 Feb; 43(1):13–9

Analysis of sinusoidal–shaped frequency–selective RF pulses. Hua J, et al. **Magn Reson Imaging** 1996;14(5):533–9

Validity of skinfold estimates of percent fat in high school female gymnasts. Housh TJ, et al.
Med Sci Sports Exerc 1996 Oct;28(10):1331–5

Fat distribution, physical activity, and cardiovascular risk factors. Hunter GR, et al. **Med Sci Sports Exerc** 1997 Mar; 29(3):362–9

Regional fat placement in physically fit males and changes with weight loss. Nindl BC, et al.
Med Sci Sports Exerc 1996 Jul;28(7):786–93

Ethnic and age trends for body composition in women residing in the U.S. Southwest: I. Regional fat. Thomas KT, et al. **Med Sci Sports Exerc** 1997 Jan;29(1):82–9

Ethnic and age trends for body composition in women residing in the U.S. Southwest: II. Total fat. Thomas KT, et al. **Med Sci Sports Exerc** 1997 Jan;29(1):90–8

Computed axial tomographic scan measurement of abdominal fat distribution and its correlation with anthropometry and insulin secretion in healthy Asian Indians. Snehalatha C, et al. **Metabolism** 1997 Oct;46(10):1220–4

Relationship between resting metabolic rate and the composition of the fat–free mass. Sparti A, et al.
Metabolism 1997 Oct;46(10):1225–30

Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. Takahashi S, et al.
Metabolism 1997 Oct;46(10):1162–5

Simplified percent body fat predictor [letter; comment] Wilson LW. **Mil Med** 1997 Jun;162(6):ii. Comment on: Mil Med 1997 Mar;162(3):194–200.

A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2. Comuzzie AG, et al. **Nat Genet** 1997 Mar;15(3):273–6

Development of a rapid and efficient magnetic resonance imaging technique for analysis of body fat distribution. Barnard ML, et al. **NMR Biomed** 1996 Jun;9(4):156–64

Sagittal diameter minus subcutaneous thickness. An easy–to–obtain parameter that improves visceral fat prediction. Armellini F, et al. **Obes Res** 1997 Jul; 5(4):315–20

Relationship of anterior and posterior subcutaneous abdominal fat to insulin sensitivity in nondiabetic men. Misra A, et al. **Obes Res** 1997 Mar;5(2):93–9

Gamma–ray scattering for fat fraction measurement. Shakeshaft J, et al. **Phys Med Biol** 1997 Jul;42(7):1403–13

Detection of animal tissue thickness using simple vertical electric sounding (VES). Gonzalez CA, et al.
Physiol Meas 1997 Feb;18(1):85–91

The nasolabial fold in facial rejuvenation [letter; comment] de la Plaza R. **Plast Reconstr Surg** 1997 Jul;100(1):278–80 . Comment on: Plast Reconstr Surg 1996 Sep;98(4):622–36.

Evaluation of fat in breast tissue removed by vertical mammaplasty. Lejour M. **Plast Reconstr Surg** 1997 Feb; 99(2):386–93

The surgical anatomy of the fat in the upper eyelid medial compartment. Ullmann Y, et al. **Plast Reconstr Surg** 1997 Mar;99(3):658–61

Sex differences in cardiovascular risk factors independent of abdominal fat distribution. Nilsson P, et al.
Scand J Prim Health Care 1996 Sep;14(3):177–83

Posterior lumbar epidural fat as a functional structure? Histologic specificities. Beaujeux R, et al. **Spine** 1997 Jun 1;22(11):1264–8; discussion 1269

Serum levels of sex hormones, thyroid hormones, growth hormone, IGF I, and cortisol and their relations to body fat distribution in healthy women dependent on their menopausal status. Kirchengast S, et al.
Z Morphol Anthropol 1996 Sep;81(2):223–34

[Predictive value of back fat thickness for body fat content in cattle] Klawuhn D, et al. **Tierarztl Prax** 1997 Apr; 25(2):133–8 (Eng. Abstr.) **(Ger)**

[Visceral fat syndrome and arteriosclerosis] Matsuzawa Y. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):369–73 (8 ref.) **(Jpn)**

[Techniques for the measurement of body composition and body fat distribution] Katsukawa F, et al.
Nippon Rinsho 1997 Mar;55 Suppl 1:282–6 (7 ref.) **(Jpn)**

[The distribution of adipose tissue and the metabolic profile in hypertensive and normotensive adults] Peña González P, et al. **Nutr Hosp** 1997 Mar–Apr;12(2):92–101 (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Modulation of vascular tone and glycerol levels measured by in situ microdialysis in rat adipose tissue. Darimont C, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):E631–5

Rat adipose tissue amino acid metabolism in vivo as assessed by microdialysis and arteriovenous techniques. Kowalski TJ, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E613–22

In situ assessment of the role of the beta 1–, beta 2– and beta 3–adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Barbe P, et al. **Br J Pharmacol** 1996 Mar;117(5):907–13

Small artery structural alterations of patients with microvascular angina (syndrome X). Bund SJ, et al.
Clin Sci (Colch) 1996 Dec;91(6):739–43

Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Summers LK, et al. **Clin Sci (Colch)** 1996 Dec;91(6):679–83

Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Magovern CJ, et al. **Hum Gene Ther** 1997 Jan 20; 8(2):215–27

Effects of hyperinsulinemia and hyperglycemia on lactate release and local blood flow in subcutaneous adipose tissue of healthy humans. Henry S, et al.
J Clin Endocrinol Metab 1996 Aug;81(8):2891–5

A possible role of a blood vessel in formation of the fat area in the quadrate lobe of porcine liver. Mochizuki S, et al. **J Vet Med Sci** 1997 May;59(5):341–5

Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lamszus K, et al. **Lab Invest** 1997 Mar; 76(3):339–53

A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Crandall DL, et al. **Microcirculation** 1997 Jun;4(2):211–32 (152 ref.)

Preadipocyte recruitment in stromal vascular cultures after depletion of committed preadipocytes by immunocytotoxicity. Yu ZK, et al. **Obes Res** 1997 Jan; 5(1):9–15

Establishment and characterization of a line of adipose–derived human microvascular endothelial cells (HADMEC–5) transformed by simian virus 40 large T antigen expression: application to endotoxin research. Flynn JT, et al. **Shock** 1997 Jul;8(1):45–54

Application of in situ microdialysis to measure metabolic and vascular responses in adipose tissue. Lafontan M, et al.
Trends Pharmacol Sci 1996 Sep;17(9):309–13 (25 ref.)

CHEMISTRY

Plasma and tissue levels of lipids, fatty acids and plasma carnitine in neonates receiving a new fat emulsion. Magnusson G, et al. **Acta Paediatr** 1997 Jun;86(6):638–44

Visceral fat in white and African American prepubertal children [see comments] Goran MI, et al.
Am J Clin Nutr 1997 Jun;65(6):1703–8. Comment in: Am J Clin Nutr 1997 Jun;65(6):1887–8.

Dietary fat in relation to body fat and intraabdominal adipose tissue: a cross–sectional analysis [see comments] Larson DE, et al. **Am J Clin Nutr** 1996 Nov;64(5):677–84. Comment in: Am J Clin Nutr 1996 Nov;64(5):787–8.

Diagnostic screening of systemic amyloidosis by abdominal fat aspiration: an analysis of 100 cases. Masouye I.
Am J Dermatopathol 1997 Feb;19(1):41–5

Influences of breed, sex, and susceptibility to malignant hyperthermia on lipid composition of skeletal muscle and adipose tissue in swine. Hartmann S, et al.
Am J Vet Res 1997 Jul;58(7):738–43

Correlates of leptin concentration in the San Antonio Heart Study [editorial; comment] Nagy TR, et al.
Ann Epidemiol 1997 Feb;7(2):79–80. Comment on: Ann Epidemiol 1997 Feb;7(2):81–6.

Fatty acid composition and CD36 expression in breast adipose tissue of premenopausal and postmenopausal women. Abbadia Z, et al. **Anticancer Res** 1997 Mar–Apr; 17(2A):1217–21

Vitamin E concentration in breast adipose tissue of breast cancer patients (Kuopio, Finland). Zhu Z, et al.
Cancer Causes Control 1996 Nov;7(6):591–5

Subcutaneous, omentum and tumor fatty acid composition, and serum insulin status in patients with benign or cancerous ovarian or endometrial tumors. Do tumors preferentially utilize polyunsaturated fatty acids? Yam D, et al. **Cancer Lett** 1997 Jan 1;111(1–2):179–85

Genotoxicity of human mammary lipid. Martin FL, et al.
Cancer Res 1996 Dec 1;56(23):5342–6

Organochlorine contaminants in blubber of four seal species: integrating biomonitoring and specimen banking. Krahn MM, et al. **Chemosphere** 1997 May;34(9–10):2109–21

Lipid extraction from blood and biological samples and concentrations of dioxin–like compounds. Ryan JJ, et al. **Chemosphere** 1997 Mar–Apr;34(5–7):999–1009

Interlaboratory comparison study for PCB congeners and chlorinated pesticides in beluga whale blubber. Schantz MM, et al. **Chemosphere** 1996 Oct;33(7):1369–90

Toxaphene, PCB, DDT, and Chlordane Analyses of Beluga whale blubber. Wade TL, et al. **Chemosphere** 1997 Mar–Apr;34(5–7):1351–7

Fatty acids in extremity tissues of Finnish beavers (Castor canadensis and Castor fiber) and muskrats (Ondatra zibethicus). Käkelä R, et al.
Comp Biochem Physiol B Biochem Mol Biol 1996 Jan; 113(1):113–24

Vitamins A1 (retinol), A2 (3,4–didehydroretinol) and E (alpha–tocopherol) in the liver and blubber of lacustrine and marine ringed seals (Phoca hispida sp.). Käkelä R, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Jan; 116(1):27–33

Self–monitoring of blood glucose in type I diabetic patients: comparison with continuous microdialysis measurements of glucose in subcutaneous adipose tissue during ordinary life conditions. Bolinder J, et al. **Diabetes Care** 1997 Jan; 20(1):64–70

Long–term and rapid regulation of ob mRNA levels in adipose tissue from normal (Sprague Dawley rats) and obese (db/db mice, fa/fa rats) rodents. Igel M, et al.
Diabetologia 1996 Jul;39(7):758–65

Immunohistochemical localization of leptin and uncoupling protein in white and brown adipose tissue. Cinti S, et al.
Endocrinology 1997 Feb;138(2):797–804

Exposure assessment for workers applying DDT to control malaria in Veracruz, Mexico. Rivero–Rodriguez L, et al.
Environ Health Perspect 1997 Jan;105(1):98–101

Methylsulfonyl metabolites of PCBs and DDE in human tissues. Weistrand C, et al. **Environ Health Perspect** 1997 Jun;105(6):644–9

Plasma factor VII and its relation to adipose tissue fatty acids and other atherogenic risk factors in healthy men. Cigolini M, et al. **Eur J Clin Invest** 1996 Mar;26(3):247–53

Identification of steroid receptors in human adipose tissue. Pedersen SB, et al. **Eur J Clin Invest** 1996 Dec; 26(12):1051–6

Predictors of adipose tissue tocopherol and toenail selenium levels in nine countries: the EURAMIC study. European Multicentre Case–Control Study on Antioxidants, Myocardial Infarction, and Cancer of the Breast. Virtanen SM, et al. **Eur J Clin Nutr** 1996 Sep;50(9):599–606

Tissue–specific alterations in insulin–like growth factor–I concentrations in response to 3,3',5–triiodo–L–thyronine supplementation in the growth hormone receptor–deficient sex–linked dwarf chicken. Vasilatos–Younken R, et al.
Gen Comp Endocrinol 1997 Jan;105(1):31–9

Changes in adipose tissue composition in malnourished patients before and after liver transplantation: a carbon–13 magnetic resonance spectroscopy and gas–liquid chromatography study. Thomas EL, et al. **Hepatology** 1997 Jan;25(1):178–83

Fatty acid composition of subcutaneous adipose tissue from male calves at different stages of growth. Huerta–Leidenz NO, et al. **J Anim Sci** 1996 Jun;74(6):1256–64

Liquid chromatographic determination of progestogens in animal fat. Andresen MT, et al. **J AOAC Int** 1996 Sep–Oct; 79(5):1037–42

Investigation of the triacylglycerol composition of iceman's mummified tissue by high–temperature gas chromatography. Mayer BX, et al.
J Chromatogr B Biomed Appl 1997 Apr 25;692(1):1–6

Fatty acid composition of adipose tissue, an indication of dietary fatty acids, and breast cancer prognosis. Petrek JA, et al. **J Clin Oncol** 1997 Apr;15(4):1377–84

Expression of natriuretic peptide receptors in human adipose and other tissues. Sarzani R, et al. **J Endocrinol Invest** 1996 Oct;19(9):581–5

Biodiscrimination of the eight alpha–tocopherol stereoisomers results in preferential accumulation of the four 2R forms in tissues and plasma of rats. Weiser H, et al. **J Nutr** 1996 Oct;126(10):2539–49

Concentration of etretinate in plasma and subcutaneous fat after long–term acitretin [letter] Maier H, et al. **Lancet** 1996 Oct 19;348(9034):1107

An in vivo 13C magnetic resonance spectroscopic study of the relationship between diet and adipose tissue composition. Thomas EL, et al. **Lipids** 1996 Feb; 31(2):145–51

Noninvasive characterization of neonatal adipose tissue by 13C magnetic resonance spectroscopy. Thomas EL, et al.
Lipids 1997 Jun;32(6):645–51

Leptin: an annotated addendum. Remesar X, et al.
Med Res Rev 1997 Sep;17(5):499–504 (167 ref.)

Adipose tissue fatty acids and size and number of fat cells from birth to 9 years of age--a cross–sectional study in 96 boys. Soriguer Escofet FJ, et al. **Metabolism** 1996 Nov; 45(11):1395–401

Elevated expression of transforming growth factor–beta in adipose tissue from obese mice. Samad F, et al.
Mol Med 1997 Jan;3(1):37–48

Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. Stenvinkel P, et al.
Nephrol Dial Transplant 1997 Jul;12(7):1321–5

Effects of dietary fatty acid pattern on melting point and composition of adipose tissues and intramuscular fat of broiler carcasses. Hrdinka C, et al. **Poult Sci** 1996 Feb; 75(2):208–15

Organochlorine pesticide residues in adipose tissue of Mexicans. Waliszewski SM, et al. **Sci Total Environ** 1996 Mar 15;181(2):125–31

Differences in prostate and adipose tissue basic fibroblast growth factor: analysis of preliminary results. Mydlo JH, et al. **Urology** 1997 Sep;50(3):472–8

[Polychlorinated biphenyls in human subepicardial fat] Strejc P, et al. **Soud Lek** 1997 Feb;42(1):2–4 (Eng. Abstr.) **(Cze)**

[Co-genotoxic potential of PCB mixtures from pediatric fatty tissue] Mersch-Sundermann V, et al. **Gesundheitswesen** 1996 Jul;58(7):400–5 (Eng. Abstr.) **(Ger)**

[Compounds from the chlordane group in adipose tissue of harbour seals from the Gulf of Gdansk] Strandberg L, et al. **Rocz Panstw Zakl Hig** 1997;48(1):79–86 (Eng. Abstr.) **(Pol)**

CYTOLOGY

Calcitriol is a positive effector of adipose differentiation in the OB 17 cell line: relationship with the adipogenic action of triiodothyronine. Dace A, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):771–6

Uncoupling protein in brown adipose tissue: molecular differentiation of the adipose tissues. Trayhurn P. **Biochem Soc Trans** 1996 May;24(2):402–6 (36 ref.)

Functional differentiation of white and brown adipocytes. Klaus S. **Bioessays** 1997 Mar;19(3):215–23 (72 ref.)

In vitro induction of osteogenic differentiation from non-osteogenic mesenchymal cells. Lecoeur L, et al. **Biomaterials** 1997 Jul;18(14):989–93

Acute effects of phorbol ester and insulin on insulin-induced glucose uptake and protein kinase C activation in rat adipocytes. Ishizuka T, et al. **Diabetes Res Clin Pract** 1997 Jul;37(1):49–52

Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Jones BH, et al. **Endocrinology** 1997 Apr; 138(4):1512–9

Control of rat preadipocyte adipose conversion by ovarian status: regional specificity and possible involvement of the mitogen-activated protein kinase-dependent and c-fos signaling pathways. Lacasa D, et al. **Endocrinology** 1997 Jul;138(7):2729–34

Calcitriol down-modulates the 3,5,3' triiodothyronine (T3) receptors and affects, in a biphasic manner, the T3-dependent adipose differentiation of Ob 17 preadipocytes. Lenoir C, et al. **Endocrinology** 1996 Oct; 137(10):4268–76

Regulation of thyrotropin receptor gene expression in 3T3-L1 adipose cells is distinct from its regulation in FRTL-5 thyroid cells. Shimura H, et al. **Endocrinology** 1997 Apr;138(4):1483–90

Preadipocyte function and aging: links between age-related changes in cell dynamics and altered fat tissue function. Kirkland JL, et al. **J Am Geriatr Soc** 1997 Aug;45(8):959–67 (60 ref.)

Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. Bulun SE, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1273–7

Culture conditions supporting adipose conversion of stromal-vascular cells from bovine intramuscular adipose tissues. Sato K, et al. **J Vet Med Sci** 1996 Nov;58(11):1073–8

Identification of novel genes involved in adipose differentiation by differential display. Hu E, et al. **Methods Mol Biol** 1997;85:195–204

Id3 prevents differentiation of preadipose cells. Moldes M, et al. **Mol Cell Biol** 1997 Apr;17(4):1796–804

Adenovirus-mediated gene transfer of dominant negative ras(asn17) in 3T3L1 adipocytes does not alter insulin-stimulated P13-kinase activity or glucose transport. Gnudi L, et al. **Mol Endocrinol** 1997 Jan;11(1):67–76

Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Zhao Y, et al. **Mol Endocrinol** 1996 Nov;10(11):1350–7

Surface coverage of vascular grafts with cultured human endothelial cells from subcutaneous fat tissue obtained with a biopsy needle. Koyama M, et al. **Thromb Haemost** 1996 Oct;76(4):610–4

[Long-term culture: evidence of the capacity of stroma to sustain hematopoiesis of a second inoculum] López Holgado N, et al. **Sangre (Barc)** 1996 Oct;41(5):345–9 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Attenuation of leptin-mediated effects by monosodium glutamate-induced arcuate nucleus damage. Dawson R, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E202–6

Leptin reduces juvenile fat stores by altering the circadian cycle of energy expenditure. Stehling O, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1770–4

Aminophylline for cellulite removal. Dickinson BI, et al. **Ann Pharmacother** 1996 Mar;30(3):292–3

Calcitriol is a positive effector of adipose differentiation in the OB 17 cell line: relationship with the adipogenic action of triiodothyronine. Dace A, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):771–6

Regulation of expression of leptin mRNA and secretion of leptin by thyroid hormone in 3T3-L1 adipocytes. Yoshida T, et al. **Biochem Biophys Res Commun** 1997 Mar 27; 232(3):822–6

Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Long SD, et al. **Biochem J** 1996 Oct 1;319 (Pt 1):179–84

Insulin and insulin-like growth factor 1 antagonize the stimulation of ob gene expression by dexamethasone in cultured rat adipose tissue. Reul BA, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):605–10

Hypertrophy of brown adipocytes in brown and white adipose tissues and reversal of diet-induced obesity in rats treated with a beta3-adrenoceptor agonist. Ghorbani M, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):121–31

Endocrine regulation of fetal adipose tissue metabolism in the pig: ontogeny of thyroxine influence. Hausman DB, et al. **Biol Neonate** 1996;70(1):41–51

In situ assessment of the role of the beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Barbe P, et al. **Br J Pharmacol** 1996 Mar;117(5):907–13

Dose-dependent effects of chronic ethanol on mouse adipose tissue lipase activity and cyclic AMP accumulation. Shih MF, et al. **Br J Pharmacol** 1997 Feb;120(4):721–7

Cadmium inhibits the in vitro conversion of thyroxine to triiodothyronine in rat brown adipose tissue. Paier B, et al. **Bull Environ Contam Toxicol** 1997 Jul;59(1):164–70

Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. Florkowski CM, et al. **Clin Endocrinol (Oxf)** 1996 Dec;45(6):769–73

Effects of breed and adipose depot location on responsiveness and sensitivity to adrenergic stimulation in ovine adipose tissue. Gilson TL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Sep;115(1):19–26

Insulin stimulates both leptin secretion and production by rat white adipose tissue. Barr VA, et al. **Endocrinology** 1997 Oct;138(10):4463–72

Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. Cross DA, et al. **FEBS Lett** 1997 Apr 7; 406(1–2):211–5

Effects of acute administration of dehydroepiandrosterone-sulfate on adipose tissue mass and cellularity in male rats. Lea-Currie YR, et al. **Int J Obes Relat Metab Disord** 1997 Feb;21(2):147–54

Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. Stephens JM, et al. **J Biol Chem** 1997 Jan 10;272(2):971–6

Temporal activation of Ca2+-calmodulin-sensitive protein kinase type II is obligate for adipogenesis. Wang Hy, et al. **J Biol Chem** 1997 Jan 17;272(3):1817–21

Long-term testosterone administration increases visceral fat in female to male transsexuals. Elbers JM, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2044–7

Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women--a clinical research center study. Lovejoy JC, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2198–203

RU486 is a potent inhibitor of aromatase induction in human breast adipose tissue stromal cells. Schmidt M, et al. **J Steroid Biochem Mol Biol** 1997 Feb;60(3–4):197–204

Piroxicam inhibits epinephrine-induced stimulation of glycerol production in isolated rat adipocytes. Pimentel-Velazquez L, et al. **Proc West Pharmacol Soc** 1996;39:31–2

Gender differences in the mechanism of dioxin toxicity in rodents and in nonhuman primates. Enan E, et al. **Reprod Toxicol** 1996 Sep-Oct;10(5):401–11

Lipolytic effects of beta1, beta2 and beta3-adrenergic agonists in isolated human fat cells from omental and retroperitoneal adipose tissues. Portillo MP, et al. **Rev Esp Fisiol** 1995 Dec;51(4):193–200

Effect of butylated hydroxytoluene on alpha-tocopherol content in liver and adipose tissue of rats. Simán CM, et al. **Toxicol Lett** 1996 Oct;87(2–3):103–8

EMBRYOLOGY

Adipose tissue development in the chick embryo. Speake BK, et al. **Biochem Soc Trans** 1996 May;24(2):161S

The preferential mobilisation of C20 and C22 polyunsaturated fatty acids from the adipose tissue of the chick embryo: potential implications regarding the provision of essential fatty acids for neural development. Speake BK, et al. **Biochim Biophys Acta** 1997 Apr 21;1345(3):317–26

Endocrine regulation of fetal adipose tissue metabolism in the pig: ontogeny of thyroxine influence. Hausman DB, et al. **Biol Neonate** 1996;70(1):41–51

Differentiation of embryonic stem cells into adipocytes in vitro. Dani C, et al. **J Cell Sci** 1997 Jun;110 (Pt 11):1279–85

Influence of thyroxine in vivo on preadipocyte development and insulin-like growth factor-I and IGF binding protein secretion in fetal stromal vascular cell cultures. Chen NX, et al. **Obes Res** 1996 Jul;4(4):357–66

ENZYMOLOGY

Regulation of lipogenic enzyme expression by glucose in liver and adipose tissue: a review of the potential cellular and molecular mechanisms. Foufelle F, et al. **Adv Enzyme Regul** 1996;36:199–226 (91 ref.)

Hexokinase II activity and messenger ribonucleic acid abundance in adipose tissue and skeletal muscle during pregnancy and lactation in rats. Yanase S, et al. **Am J Obstet Gynecol** 1997 Mar;176(3):651–5

Diurnal rhythms and effects of fasting and refeeding on rat adipose tissue lipoprotein lipase. Bergö M, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):E1092–7

Partial purification and identification of hormone-sensitive lipase from chicken adipose tissue. Anthonsen MW, et al. **Biochem Biophys Res Commun** 1997 Jul 9;236(1):94–9

Regulation of acetyl coenzyme-A carboxylase gene in a transgenic animal model. Ekhterae D, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):547–52

cGMP-inhibited phosphodiesterases (PDE3 gene family). Degerman E, et al. **Biochem Soc Trans** 1996 Nov; 24(4):1010–4 (28 ref.)

Lipoprotein lipase mRNA levels in adipose tissue in lactation. Rogers MP, et al. **Biochem Soc Trans** 1996 May;24(2):169S

Regulation of acetyl CoA carboxylase gene expression in adipose tissue from lactating sheep. Travers MT, et al. **Biochem Soc Trans** 1996 May;24(2):223S

Regulation of gene expression for lipogenic enzymes in the liver and adipose tissue of hereditary hypertriglyceridemic, insulin-resistant rats: effect of dietary sucrose and marine fish oil. Seböková E, et al. **Biochim Biophys Acta** 1996 Sep 6;1303(1):56–62

alpha-Adrenergic receptors may contribute to the hypertriglyceridemia associated with tumour growth. López-Soriano J, et al. **Cancer Lett** 1996 Dec 20; 110(1–2):213–6

Developmental changes in lipogenic enzymes in muscle compared to liver and extramuscular adipose tissues in the rabbit (Oryctolagus cuniculus). Gondret F, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Jun; 117(2):259–65

Increased mitogen-activated protein kinase expression and activity in white adipose tissue of ventromedial hypothalamus-lesioned rats. Combettes-Souverain M, et al. **Diabetologia** 1997 May;40(5):533–40

Relationship between insulin-mediated glucose disposal and regulation of plasma and adipose tissue lipoprotein lipase. Maheux P, et al. **Diabetologia** 1997 Jul;40(7):850–8

Orthovanadate stimulates cyclic guanosine monophosphate-inhibited cyclic adenosine monophosphate phosphodiesterase activity in isolated rat fat pads through activation of particulate myelin basic protein kinase by protein tyrosine kinase. Ueki H, et al. **Endocrinology** 1997 Jul;138(7):2784–9

Relationship between adipose polyamine concentrations and triacylglycerol synthetic enzymes in lean and obese Zucker rats. Jamdar SC, et al. **Enzyme Protein** 1996;49(4):222–30

Vp165 and GLUT4 share similar vesicle pools along their trafficking pathways in rat adipose cells. Malide D, et al. **FEBS Lett** 1997 Jun 16;409(3):461–8

The effects of the inhibition of fatty acid oxidation on pyruvate dehydrogenase complex activity in tissues of lean and obese mice. Bryson JM, et al. **Int J Obes Relat Metab Disord** 1996 Aug;20(8):738–44

Comparison of the enzyme activities between the thickest and the thinnest parts of the abdominal pannus. Cazes L, et al. **J Am Coll Nutr** 1997 Aug;16(4):341–5

Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. Kohn AD, et al. **J Biol Chem** 1996 Dec 6;271(49):31372–8

Alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of women. Agarwal VR, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):70–4

Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. Agarwal VR, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):3843–9

Sepsis-induced regulation of lipoprotein lipase expression in rat adipose tissue and soleus muscle. Lanza-Jacoby S, et al. **J Lipid Res** 1997 Apr;38(4):701–10

11 beta-Hydroxysteroid dehydrogenase 1 activity and gene expression in human adipose stromal cells: effect on aromatase activity. Yang K, et al. **J Steroid Biochem Mol Biol** 1997 Feb;60(3–4):247–53

Effects of triton X-100 and concanavalin A on the properties of 5'-nucleotidase in rat liver and adipose plasma membranes: a role of membrane structure in the regulation of enzyme activity. Yegutkin GG. **Membr Cell Biol** 1997; 10(6):631–8

Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Ahmad F, et al. **Metabolism** 1997 Oct;46(10):1140–5

Evidence for sex steroid inhibition of lipoprotein lipase in men: comparison of abdominal and femoral adipose tissue. Ramirez ME, et al. **Metabolism** 1997 Feb;46(2):179–85

Expression of the two isoforms of prostaglandin endoperoxide synthase (PGHS-1 and PGHS-2) during adipose cell differentiation. Børglum JD, et al. **Mol Cell Endocrinol** 1997 Jul 4;131(1):67–77

Targeted expression of Cre recombinase to adipose tissue of transgenic mice directs adipose-specific excision of

loxP-flanked gene segments. Barlow C, et al. **Nucleic Acids Res** 1997 Jun 15;25(12):2543–5

Studies on pyrazinoylguanidine. 4. Upregulation of phosphodiesterase activity in rat adipose tissue and downregulation of gluconeogenesis and adenosine 3',5'-monophosphate concentrations in perfused rat liver. A-Rahim YI, et al. **Pharmacology** 1996 Oct;53(4):211–8

GROWTH & DEVELOPMENT

Differential growth of fetal tissues during the second half of pregnancy. Bernstein IM, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):28–32

Developmental changes in the levels of molecular species of triacylglycerol that contain docosahexaenoic acid in adipose tissue of the chick embryo. Farkas K, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Sep; 115(1):1–6

Effect of rearing temperature on perirenal adipose tissue development and thermoregulation following methimazole treatment of postnatal lambs. Symonds ME, et al. **Exp Physiol** 1996 Nov;81(6):995–1006

The infrapatellar adipose body in humans of various age groups. Jędrzejczyk T, et al. **Folia Morphol (Warsz)** 1996; 55(1):51–5

Effects of day length and temperature on gonadal development, body mass, and fat depots in white-crowned sparrows, Zonotrichia leucophrys pugetensis. Wingfield JC, et al. **Gen Comp Endocrinol** 1997 Jul;107(1):44–62

Development and tracking of central patterns of subcutaneous fat in adolescence and adulthood: the Amsterdam Growth and Health Study. van Lenthe FJ, et al. **Int J Epidemiol** 1996 Dec;25(6):1162–71

Associations between 12 year changes in body fatness and lipoprotein-lipid levels in men and women of the Québec Family Study. Couillard C, et al. **Int J Obes Relat Metab Disord** 1996 Dec;20(12):1081–8

Effects of acute or chronic administration of tumor necrosis factor on rat adipose tissue development. De clercq L, et al. **J Anim Sci** 1996 Nov;74(11):2745–51

Lipoprotein metabolism and fattening in poultry. Hermier D. **J Nutr** 1997 May;127(5 Suppl):805S–808S (33 ref.)

Perilla oil prevents the excessive growth of visceral adipose tissue in rats by down-regulating adipocyte differentiation. Okuno M, et al. **J Nutr** 1997 Sep;127(9):1752–7

Development of fat tissue and body mass index from infancy to adulthood. Gasser T. **Pediatr Nephrol** 1996 Jun; 10(3):340–2

Influence of thyroid hormones and temperature on adipose tissue development and lung maturation. Symonds ME, et al. **Proc Nutr Soc** 1996 Mar;55(1B):561–9 (58 ref.)

IMMUNOLOGY

Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells [published erratum appears in Mol Cell Endocrinol 1996 Jul 1;120(2):215] Crichton MB, et al. **Mol Cell Endocrinol** 1996 Apr 19;118(1–2):215–20

INJURIES

Traumatic herniation of the buccal fat pad: a report of two cases and a review of the literature. Zipfel TE, et al. **Int J Pediatr Otorhinolaryngol** 1996 Dec 20;38(2):175–9 (15 ref.)

Vertical transmission of the hip rolls due to wearing of TLSO for scoliosis. Korovessis P, et al. **J Spinal Disord** 1996 Aug; 9(4):326–33

INNERVATION

Increased sympathetic activity in rat white adipose tissue during prolonged fasting. Migliorini RH, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R656–61

The effect of glucose and other sugars on the efferent activity of the sympathetic nerves innervating the fatty tissue. Niijima A. **Jpn J Physiol** 1997;47 Suppl 1:S40–2

METABOLISM

Microdialysis in human skeletal muscle and adipose tissue at low flow rates is possible if dextran-70 is added to prevent loss of perfusion fluid. Rosdahl H, et al. **Acta Physiol Scand** 1997 Mar;159(3):261–2

In vitro insulinomimetic [corrected] effects of GLP-1 in liver, muscle and fat [published erratum appears in Acta Physiol Scand 1996 Nov;158(3):297] Valverde I, et al. **Acta Physiol Scand** 1996 Jul;157(3):359–60 (11 ref.)

Characterization and regulation of angiotensin II receptors in rat adipose tissue. Angiotensin receptors in adipose tissue. Cassis LA, et al. **Adv Exp Med Biol** 1996;396:39–47

Measurement of retinoids and carotenoids in breast adipose tissue and a comparison of concentrations in breast cancer cases and control subjects. Zhang S, et al. **Am J Clin Nutr** 1997 Sep;66(3):626–32

Predictors of adipose tissue carotenoid and retinol levels in nine countries. The EURAMIC Study. Virtanen SM, et al. **Am J Epidemiol** 1996 Nov 15;144(10):968–79

Age-related changes in interstitial norepinephrine. A microdialysis study in spontaneously hypertensive rats. Cabassi A, et al. **Am J Hypertens** 1996 Sep;9(9):878–83

Beta 3-adrenoceptor in guinea pig brown and white adipocytes: low expression and lack of function. Atgié C, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1729–38

Modulation of vascular tone and glycerol levels measured by in situ microdialysis in rat adipose tissue. Darimont C, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):E631–5

Role of fat-derived substrates in the regulation of gluconeogenesis during fasting. Féry F, et al. **Am J Physiol** 1996 May;270(5 Pt 1):E822–30

Adipose-specific overexpression of GLUT-4 in transgenic mice alters lipoprotein lipase activity. Gnudi L, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):R785–92

Absolute concentrations of glycerol and lactate in human skeletal muscle, adipose tissue, and blood. Hagström-Toft E, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E584–92

Adipose tissue stearoyl-CoA desaturase mRNA is increased by obesity and decreased by polyunsaturated fatty acids. Jones BH, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E44–9

Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Jones BH, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R236–42

Rat adipose tissue amino acid metabolism in vivo as assessed by microdialysis and arteriovenous techniques. Kowalski TJ, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E613–22

Specific adaptations in muscle and adipose tissue in response to chronic systemic glucose oversupply in rats. Laybutt DR, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E1–9

beta 3-Adrenergic-mediated suppression of leptin gene expression in rats. Li H, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E1031–6

Regional differences in adipose tissue metabolism between sedentary and endurance-trained women. Mauriège P, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E497–506

Regulation of lipid metabolism in adipose tissue during early starvation. Samra JS, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E541–6

Influence of two dairy fats on lipid synthesis in the pig: comparative study of liver, muscle and the two backfat layers. Camara M, et al. **Ann Nutr Metab** 1996;40(5):287–95

Lipolysis: contribution from regional fat. Jensen MD. **Annu Rev Nutr** 1997;17:127–39 (42 ref.)

Gentamicin concentrations in human subcutaneous tissue. Lorentzen H, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1785–9

Ponderostat: hoarding behavior satisfies the condition for a lipostat in the rat. Cabanac M, et al. **Appetite** 1996 Dec; 27(3):251–61

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and congeners in infants. A toxicokinetic model of human lifetime body burden by TCDD with special emphasis on its uptake by nutrition. Kreuzer PE, et al. **Arch Toxicol** 1997;71(6):383–400

Sex differences in visceral fat lipolysis and metabolic complications of obesity. Lönnqvist F, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1472–80

Effect of enteral versus parenteral nutrition on leptin gene expression and release into the circulation. Levy JR, et al. **Biochem Biophys Res Commun** 1997 Aug 8; 237(1):98–102

The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats. Pearson SL, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):752–7

Effects of overexpressing wild-type and mutant PDGF receptors on translocation of GLUT4 in transfected rat adipose cells. Quon MJ, et al. **Biochem Biophys Res Commun** 1996 Sep 24;226(3):587–94

Chronic high-fat feeding and middle-aging reduce in an additive fashion Glut4 expression in skeletal muscle and adipose tissue. Sevilla L, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):89–93

Rapid inhibition of ob gene expression and circulating leptin levels in lean mice by the beta 3-adrenoceptor agonists BRL 35135A and ZD2079. Trayhurn P, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):605–10

Differential expression of PPAR gamma1 and gamma2 isoforms in human adipose tissue. Yanase T, et al. **Biochem Biophys Res Commun** 1997 Apr 17;233(2):320–4

Expression of leptin and beta 3-adrenergic receptors in rat adipose tissue in altered thyroid states. Fain JN, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):145–50

Rab 3D in rat adipose cells and its overexpression in genetic obesity (Zucker fatty rat). Guerre-Millo M, et al. **Biochem J** 1997 Jan 1;321 (Pt 1):89–93

Proteolytic cleavage of cellubrevin and vesicle-associated membrane protein (VAMP) by tetanus toxin does not impair insulin-stimulated glucose transport or GLUT4 translocation in rat adipocytes. Hajduch E, et al. **Biochem J** 1997 Jan 1;321 (Pt 1):233–8

Selective mobilization of fatty acids from white fat cells: evidence for a relationship to the polarity of triacylglycerols. Raclot T. **Biochem J** 1997 Mar 1;322 (Pt 2):483–9

Developmental and nutritional changes of ob and PPAR gamma 2 gene expression in rat white adipose tissue. Rousseau V, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):451–6

Identification of SNAP receptors in rat adipose cell membrane fractions and in SNARE complexes co-immunoprecipitated with epitope-tagged N-ethylmaleimide-sensitive fusion protein. Timmers KI, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):429–36

Changes in fatty acid composition in rat adipose tissue induced by dietary obesity. Lladó I, et al. **Biochem Mol Biol Int** 1996 Oct;40(2):295–303

Evidence for posttranscriptional regulation of GLUT4 expression in muscle and adipose tissue from streptozotocin-induced diabetic and benfluorex-treated rats. Muñoz P, et al. **Biochem Pharmacol** 1996 Dec 13; 52(11):1665–73

Beta 3-adrenoceptors and the regulation of metabolism in adipose tissues. Arch JR, et al. **Biochem Soc Trans** 1996 May;24(2):412–8 (51 ref.)

Preferential mobilisation of docosahexaenoic acid from adipose tissue triacylglycerol of the chick embryo. Cerolini S, et al. **Biochem Soc Trans** 1996 May;24(2):165S

Nutritional influences on human adipose-tissue metabolism. Frayn KN, et al. **Biochem Soc Trans** 1996 May;24(2):422–6 (28 ref.)

Ob (obese) gene expression in white adipose tissue of obese Zucker (fa/fa) rats. Rayner DV, et al. **Biochem Soc Trans** 1996 May;24(2):156S

Expression of the ob (obese) gene during lactation in mice. Rubio-Aliaga I, et al. **Biochem Soc Trans** 1996 May; 24(2):157S

Effect of plane of nutrition and growth hormone treatment on insulin receptor gene expression and kinase activity of sheep muscle and adipose tissue. Wilson LA, et al. **Biochem Soc Trans** 1996 May;24(2):222S

Assessment of beta 2- and beta 3-adrenoceptors in rat white adipose tissues by radioligand binding assay. Kubo S, et al. **Biol Pharm Bull** 1997 Feb;20(2):142–8

Involvement of the rapid increase in cAMP content in the vanadate-stimulated release of lipoprotein lipase activity from rat fat pads. Motoyashiki T, et al. **Biol Pharm Bull** 1996 Nov;19(11):1412–6

Expression of the RET receptor tyrosine kinase and GDNFR-alpha in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment. Gattei V, et al. **Blood** 1997 Apr 15; 89(8):2925–37

Protein utilization during energy undernutrition in sheep sustained by intragastric infusion: effects of protein infusion level, with or without sub-maintenance amounts of energy from volatile fatty acids, on energy and protein metabolism. Chowdhury SA, et al. **Br J Nutr** 1997 Apr;77(4):565–76

Mammary sensitivity to protein restriction and re-alimentation. Goodwill MG, et al. **Br J Nutr** 1996 Sep; 76(3):423–34

Weaning marginally affects glucose transporter (GLUT4) expression in calf muscles and adipose tissues. Hocquette JF, et al. **Br J Nutr** 1997 Aug;78(2):251–71

The effects of feeding suet-enriched chow on site-specific differences in the composition of triacylglycerol fatty acids in adipose tissue and its interactions in vitro with lymphoid cells. Mattacks CA, et al. **Br J Nutr** 1997 Apr;77(4):621–43

In situ assessment of the role of the beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Barbe P, et al. **Br J Pharmacol** 1996 Mar;117(5):907–13

Respective degree of expression of beta 1-, beta 2- and beta 3-adrenoceptors in human brown and white adipose tissues. Deng C, et al. **Br J Pharmacol** 1996 Jun;118(4):929–34

Accumulation of chlordanes in adipose tissues of mice caused by long-term exposure of low level technical chlordane. Asakawa F, et al. **Bull Environ Contam Toxicol** 1996 Dec; 57(6):909–16

Adipose tissue trans fatty acids and breast cancer in the European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer. Kohlmeier L, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Sep; 6(9):705–10

Xenobiotics released from fat during fasting produce estrogenic effects in ovariectomized mice. Bigsby RM, et al. **Cancer Res** 1997 Mar 1;57(5):865–9

Occurrence of non-ortho, mono-ortho and di-ortho substituted PCB congeners in polecats, stone martens and badgers from the state of Baden-Württemberg, Germany. Behnisch P, et al. **Chemosphere** 1997 Jun;34(11):2293–300

Pharmacokinetic model of dioxin and furan levels in adipose tissue from sawmill work involving chlorophenate fungicides. Campbell CA, et al. **Chemosphere** 1996 Dec; 33(12):2373–81

Background contamination by coplanar polychlorinated biphenyls (PCBs) in trace level high resolution gas chromatography/high resolution mass spectrometry (HRGC/HRMS) analytical procedures. Ferrario J, et al. **Chemosphere** 1997 Jun;34(11):2451–65

Polycyclic musk fragrances in human adipose tissue and human milk. Rimkus GG, et al. **Chemosphere** 1996 Nov; 33(10):2033–43

Obesity genes. Beales PL, et al. **Clin Endocrinol (Oxf)** 1996 Oct;45(4):373–8 (50 ref.)

Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution. Korbonits M, et al. **Clin Endocrinol (Oxf)** 1996 Dec;45(6):699–706

Monitoring norepinephrine levels by microdialysis in the white adipose tissue of spontaneously hypertensive rats. Cabassi A, et al. **Clin Exp Pharmacol Physiol Suppl** 1995; 1:S83–5

Effects of adrenaline infusion on the interstitial environment of subcutaneous adipose tissue as studied by microdialysis. Samra JS, et al. **Clin Sci (Colch)** 1996 Oct;91(4):425–30

Is familial combined hyperlipidaemia a genetic disorder of adipose tissue? Arner P. **Curr Opin Lipidol** 1997 Apr; 8(2):89–94 (34 ref.)

Peroxisome proliferator-activated receptor gamma and the

control of adipogenesis. Brun RP, et al. **Curr Opin Lipidol** 1997 Aug;8(4):212–8 (55 ref.)

R.D. Lawrence Lecture 1995 Mrs Sprat's diabetes: some metabolic insights. Coppack SW. **Diabet Med** 1996 Jul; 13(7):616–24 (87 ref.)

Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Alessi MC, et al. **Diabetes** 1997 May;46(5):860–7

CL–316,243, a beta3–specific adrenoceptor agonist, enhances insulin–stimulated glucose disposal in nonobese rats. de Souza CJ, et al. **Diabetes** 1997 Aug;48(8):1257–63

Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Hotamisligil GS, et al. **Diabetes** 1997 Mar;46(3):451–5

Counterregulation in peripheral tissues: effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissue. Maggs DG, et al. **Diabetes** 1997 Jan;46(1):70–6

Depot– and sex–specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Montague CT, et al. **Diabetes** 1997 Mar; 46(3):342–7

Insulin and cortisol promote leptin production in cultured human fat cells. Wabitsch M, et al. **Diabetes** 1996 Oct; 45(10):1435–8

Mobilization of visceral adipose tissue related to the improvement in insulin sensitivity in response to physical training in NIDDM. Effects of branched–chain amino acid supplements. Mourier A, et al. **Diabetes Care** 1997 Mar; 20(3):385–91

Stimulation of adipose tissue lipolysis following insulin–induced hypoglycaemia: evidence of increased beta–adrenoceptor–mediated lipolytic response in IDDM. Bolinder J, et al. **Diabetologia** 1996 Jul;39(7):845–53

Increased adipose tissue PC–1 protein content, but not tumour necrosis factor–alpha gene expression, is associated with a reduction of both whole body insulin sensitivity and insulin receptor tyrosine–kinase activity. Frittitta L, et al. **Diabetologia** 1997 Mar;40(3):282–9

The metabolic syndrome is related to beta 3–adrenoceptor sensitivity in visceral adipose tissue. Hoffstedt J, et al. **Diabetologia** 1996 Jul;39(7):838–44

Regional variation in adipose tissue insulin action and GLUT4 glucose transporter expression in severely obese premenopausal women. Marette A, et al. **Diabetologia** 1997 May;40(5):590–8

No effect of the Trp64Arg beta 3–adrenoceptor variant on in vivo lipolysis in subcutaneous adipose tissue. Snitker S, et al. **Diabetologia** 1997 Jul;40(7):838–42

Leptin receptor mRNA is expressed in ewe anterior pituitary and adipose tissues and is differentially expressed in hypothalamic regions of well–fed and feed–restricted ewes. Dyer CJ, et al. **Domest Anim Endocrinol** 1997 Mar; 14(2):119–28

Insulin stimulates both leptin secretion and production by rat white adipose tissue. Barr VA, et al. **Endocrinology** 1997 Oct;138(10):4463–72

Influence of estrogenic status on the lipolytic activity of parametrial adipose tissue in vivo: an in situ microdialysis study. Darimont C, et al. **Endocrinology** 1997 Mar; 138(3):1092–6

Decreased expression of murine PPARgamma in adipose tissue during endotoxemia. Hill MR, et al. **Endocrinology** 1997 Jul;138(7):3073–6

Antilipolytic actions of vanadate and insulin in rat adipocytes mediated by distinctly different mechanisms. Li J, et al. **Endocrinology** 1997 Jun;138(6):2274–9

Amelioration of insulin resistance in streptozotocin diabetic mice by transgenic overexpression of GLUT4 driven by an adipose–specific promoter. Tozzo E, et al. **Endocrinology** 1997 Apr;138(4):1604–11

Influence of prolonged fasting and thyroid hormone on the alpha 2–adrenergic response in isolated epididymal adipocytes of Wistar rats. Ben Cheikh R, et al. **Eur J Endocrinol** 1997 Feb;136(2):223–9

Effects of endurance exercise on adipose tissue metabolism. Nicklas BJ. **Exerc Sport Sci Rev** 1997;25:77–103 (125 ref.)

Short photoperiod reduces leptin gene expression in white and brown adipose tissue of Djungarian hamsters. Klingenspor M, et al. **FEBS Lett** 1996 Dec 16;399(3):290–4

Vp165 and GLUT4 share similar vesicle pools along their trafficking pathways in rat adipose cells. Malide D, et al. **FEBS Lett** 1997 Jun 16;409(3):461–8

Suppression of insulin–stimulated phosphatidylinositol 3–kinase activity by the beta3–adrenoceptor agonist CL316243 in rat adipocytes. Ohsaka Y, et al. **FEBS Lett** 1997 Feb 3;402(2–3):246–50

Identification of fatty acid methyl esters (FAMEs) in postmortem tissue. A new marker of alcohol abuse? Emrich J, et al. **Forensic Sci Int** 1997 Feb 7;85(1):41–9

Pleomorphic adenoma with extensive adipose content. Jin YT, et al. **Histopathology** 1996 Jan;28(1):87–9

Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. Hube F, et al. **Horm Metab Res** 1996 Dec;28(12):690–3

Intracerebroventricular injection of leptin increases thermogenesis and mobilizes fat metabolism in ob/ob mice. Hwa JJ, et al. **Horm Metab Res** 1996 Dec;28(12):659–63

Adipose fatty acids and cancers of the breast, prostate and colon: an ecological study. EURAMIC Study Group. Bakker N, et al. **Int J Cancer** 1997 Aug 7;72(4):587–91

Hematological changes in anorexia nervosa are correlated with total body fat mass depletion. Lambert M, et al. **Int J Eat Disord** 1997 May;21(4):329–34

Adipose tissue extraction of circulating insulin in anaesthetized Zucker obese rats. Ardévol A, et al. **Int J Obes Relat Metab Disord** 1996 Sep;20(9):837–41

Liver fat, serum triglycerides and visceral adipose tissue in insulin–sensitive and insulin–resistant black men with NIDDM [see comments] Banerji MA, et al. **Int J Obes Relat Metab Disord** 1995 Dec;19(12):846–50. Comment in: Int J Obes Relat Metab Disord 1995 Dec;19(12):839–40.

Plasma leptin concentrations and OB gene expression in subcutaneous adipose tissue are not regulated acutely by physiological hyperinsulinaemia in lean and obese humans. Clapham JC, et al. **Int J Obes Relat Metab Disord** 1997 Mar;21(3):179–83

Net carbon flux across subcutaneous adipose tissue after a standard meal in normal–weight and insulin–resistant obese subjects. Frayn KN, et al. **Int J Obes Relat Metab Disord** 1996 Sep;20(9):795–800

Lipolytic catecholamine resistance linked to alpha 2–adrenoceptor sensitivity—a metabolic predictor of weight loss in obese subjects. Hellström L, et al. **Int J Obes Relat Metab Disord** 1997 Apr;21(4):314–20

Effect of saturated and polyunsaturated fatty acids rich diets on hepatic and adipose tissue lipid metabolism in rats. da Silva MH, et al. **Int J Vitam Nutr Res** 1996;66(3):258–62

Effects of growth hormone administration and dietary protein intake on insulin–like growth factor I and growth hormone receptor mRNA Expression in porcine liver, skeletal muscle, and adipose tissue. Brameld JM, et al. **J Anim Sci** 1996 Aug;74(8):1832–41

Effects of prenatal androgenization and lactation on adipose tissue metabolism in finishing single–calf heifers. Reiling BA, et al. **J Anim Sci** 1997 Jun;75(6):1504–13

Teicoplanin concentrations in serum, pericardium, pericardial fluid and thoracic wall fat in patients undergoing cardio–pulmonary bypass surgery. Miglioli PA, et al. **J Antimicrob Chemother** 1997 Feb;39(2):229–33

Influence of diet and exercise on skeletal muscle and visceral adipose tissue in men. Ross R, et al. **J Appl Physiol** 1996 Dec;81(6):2445–55

Relationships between subcutaneous fat and muscle distributions and serum HDL–cholesterol. Abe T, et al. **J Atheroscler Thromb** 1994;1(1):15–22

Effect of acute cold exposure on norepinephrine turnover rates in rat white adipose tissue. Garofalo MA, et al. **J Auton Nerv Syst** 1996 Sep 12;60(3):206–8

Nutritional regulation of lipogenic enzyme gene expression in rat epididymal adipose tissue. Iritani N, et al. **J Biochem (Tokyo)** 1996 Aug;120(2):242–8

Protective action of dehydroascorbic acid on the Ah receptor–dependent and receptor–independent induction of lipid peroxidation in adipose tissue of male guinea pig caused by TCDD administration. Ashida H, et al. **J Biochem Toxicol** 1996;11(6):269–78

Cholesteryl ester transfer protein mediates selective uptake of high density lipoprotein cholesteryl esters by human adipose tissue. Benoist F, et al. **J Biol Chem** 1997 Sep 19; 272(38):23572–7

Induction of Galphaq–specific antisense RNA in vivo causes increased body mass and hyperadiposity. Galvin–Parton PA, et al. **J Biol Chem** 1997 Feb 14;272(7):4335–41

Beta3–adrenergic receptors on white and brown adipocytes mediate beta3–selective agonist–induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice. Grujic D, et al. **J Biol Chem** 1997 Jul 11;272(28):17686–93

Insulin stimulates guanine nucleotide exchange on Rab4 via a wortmannin–sensitive signaling pathway in rat adipocytes. Shibata H, et al. **J Biol Chem** 1997 Jun 6; 272(23):14542–6

In vivo increase in beta–adrenergic lipolytic response in subcutaneous adipose tissue of obese subjects submitted to a hypocaloric diet. Barbe P, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):63–9

Thyrotropin receptor transcripts in human adipose tissue. Crisp MS, et al. **J Clin Endocrinol Metab** 1997 Jun; 82(6):2003–5

Variability of glutathione levels in normal breast tissue and subcutaneous fat during the menstrual cycle: an in vivo study with microdialysis technique. Dabrosin C, et al. **J Clin Endocrinol Metab** 1997 May;82(5):1382–4

Microdialysis of adipose tissue during surgery: effect of local alpha– and beta–adrenoceptor blockade on blood flow and lipolysis. Felländer G, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2919–24

Effects of hyperinsulinemia and hyperglycemia on lactate release and local blood flow in subcutaneous adipose tissue of healthy humans. Henry S, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2891–5

Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. Mårin P, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1018–22

Leptin production during moderate–intensity aerobic exercise. Racette SB, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2275–7

Adipose tissue lipolysis and hormone–sensitive lipase expression during very–low–calorie diet in obese female identical twins. Stich V, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):739–44

Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. Lönnqvist F, et al. **J Clin Invest** 1997 May 15;99(10):2398–404

Peroxisome proliferator–activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. Vidal–Puig AJ, et al. **J Clin Invest** 1997 May 15;99(10):2416–22

Stratification and age–related differences in blubber fatty acids of the male harbour porpoise (Phocoena phocoena). Koopman HN, et al. **J Comp Physiol [B]** 1996;165(8):628–39

Regulation of lipolysis by somatotropin: functional alteration of adrenergic and adenosine signaling in bovine adipose tissue. Houseknecht KL, et al. **J Endocrinol** 1997 Mar; 152(3):465–75

Estrogen increases in vivo leptin production in rats and human subjects. Shimizu H, et al. **J Endocrinol** 1997 Aug; 154(2):285–92

Estrogen biosynthesis in adipose tissue: regulation by paracrine and autocrine mechanisms. Simpson ER, et al. **J Endocrinol** 1996 Sep;150 Suppl:S51–7

Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones. Tchernof A, et al. **J Endocrinol** 1996 Sep;150 Suppl:S155–64 (97 ref.)

Effect of lactation on insulin signal transduction in sheep adipose tissue and skeletal muscle. Wilson LA, et al. **J Endocrinol** 1996 Dec;151(3):469–80

Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. Sarraf P, et al. **J Exp Med** 1997 Jan 6;185(1):171–5

Adipose tissue–derived tumor necrosis factor–alpha activity is elevated in older rats. Morin CL, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):B190–5

Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue. Sarzani R, et al. **J Hypertens** 1995 Nov;13(11):1241–6

Differential mobilization of fatty acids from adipose tissue. Conner WE, et al. **J Lipid Res** 1996 Feb;37(2):290–8

Release of individual fatty acids from human adipose tissue in vivo after an overnight fast. Halliwell KJ, et al. **J Lipid Res** 1996 Sep;37(9):1842–8

Norepinephrine–induced lipolysis in rat fat cells from visceral and subcutaneous sites: role of hormone–sensitive lipase and lipid droplets. Morimoto C, et al. **J Lipid Res** 1997 Jan;38(1):132–8

Lipoprotein lipase degradation by adipocytes: receptor–associated protein (RAP)–sensitive and proteoglycan–mediated pathways. Obunike JC, et al. **J Lipid Res** 1996 Nov;37(11):2439–49

Effects of streptozotocin–induced diabetes on low density lipoprotein receptor expression in rat adipose tissue. Swami S, et al. **J Lipid Res** 1996 Feb;37(2):229–36

Dietary modulation of omega–3/omega–6 polyunsaturated fatty acid ratios in patients with breast cancer. Bagga D, et al. **J Natl Cancer Inst** 1997 Aug 6;89(15):1123–31

The majority of dietary linoleate in growing rats is beta–oxidized or stored in visceral fat. Cunnane SC, et al. **J Nutr** 1997 Jan;127(1):146–52

Porcine somatotrophin differentially down–regulates expression of the GLUT4 and fatty acid synthase genes in pig adipose tissue. Donkin SS, et al. **J Nutr** 1996 Oct; 126(10):2568–77

Maternal semistarvation and streptozotocin–diabetes in rats have different effects on the in vivo glucose uptake by peripheral tissues in their female adult offspring. Holemans K, et al. **J Nutr** 1997 Jul;127(7):1371–6

Nutritional strategies for promoting fat utilization and delaying the onset of fatigue during prolonged exercise. Lambert EV, et al. **J Sports Sci** 1997 Jun;15(3):315–24

Quality assurance/quality control procedures for chlorinated hydrocarbons in human breast adipose tissue. Archibeque–Engle S, et al. **J Toxicol Environ Health** 1996 Dec 27;49(6):589–98

Culture conditions supporting adipose conversion of stromal–vascular cells from bovine intramuscular adipose tissues. Sato K, et al. **J Vet Med Sci** 1996 Nov;58(11):1073–8

Morphologic and molecular changes induced by recombinant human leptin in the white and brown adipose tissues of C57BL/6 mice. Sarmiento U, et al. **Lab Invest** 1997 Sep; 77(3):243–56

Early dietary intervention with structured triacylglycerols containing docosahexaenoic acid. Effect on brain, liver, and adipose tissue lipids. Christensen MM, et al. **Lipids** 1997 Feb;32(2):185–91

Very–low–density lipoprotein subfraction composition and metabolism by adipose tissue. Fisher RM, et al. **Metabolism** 1997 Jun;46(6):605–10

Unusual increase of lipogenesis in rat white adipose tissue after multiple cycles of starvation–refeeding. Kochan Z, et al. **Metabolism** 1997 Jan;46(1):10–7

Role of body fat loss in the exercise–induced improvement of the plasma lipid profile in non–insulin–dependent diabetes mellitus. Poirier P, et al. **Metabolism** 1996 Nov; 45(11):1383–7

The isolated hind limb preparation as a drug distribution model. Casquero–Dorado AC, et al. **Methods Find Exp Clin Pharmacol** 1996 Sep;18(7):453–8

Obesity. Jéquir E, et al. **Mol Aspects Med** 1997 Aug; 18(4):247–305 (240 ref.)

Expression of c–Fos in subcutaneous adipose tissue of the fetal pig. Lee K, et al. **Mol Cell Biochem** 1996 Feb 9;

155(1):31–5

Id3 prevents differentiation of preadipose cells. Moldes M, et al. **Mol Cell Biol** 1997 Apr;17(4):1796–804

Expression of c-erbA alpha, c-erbA beta and Rev-erbA alpha mRNA during the conversion of brown adipose tissue into white adipose tissue. Reyne Y, et al. **Mol Cell Endocrinol** 1996 Jan 15;116(1):59–65

Transgenic mice overexpressing the beta 1-adrenergic receptor in adipose tissue are resistant to obesity. Soloveva V, et al. **Mol Endocrinol** 1997 Jan;11(1):27–38

Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia [see comments] Fleury C, et al. **Nat Genet** 1997 Mar;15(3):269–72. Comment in: Nat Genet 1997 Mar;15(3):223–4.

Thiobarbituric acid reactive substances are increased in the subcutaneous fat tissue of patients with end-stage renal disease. Gotoh M, et al. **Nephrol Dial Transplant** 1997 Apr; 12(4):713–7

Role of adipose tissue in whole body metabolism [editorial; comment] Elwyn DH. **Nutrition** 1996 Sep;12(9):640. Comment on: Nutrition 1996 Sep;12(9):589–94.

Carbohydrate three-carbon metabolism of adipose tissue during surgery [see comments] Felländer G, et al. **Nutrition** 1996 Sep;12(9):589–94. Comment in: Nutrition 1996 Sep;12(9):640.

Abdominal visceral fat is associated with a BclI restriction fragment length polymorphism at the glucocorticoid receptor gene locus. Buemann B, et al. **Obes Res** 1997 May; 5(3):186–92

Regulation of alternative pathway activation and C3a production by adipose cells. Choy LN, et al. **Obes Res** 1996 Nov;4(6):521–32

Running exercise improves metabolic abnormalities and fat accumulation in sucrose-induced insulin-resistant rats. Nara M, et al. **Obes Res** 1997 Jul;5(4):348–53

Differential expression of immunoreactive HLA-DR and ICAM-1 in human cultured orbital fibroblasts and orbital tissue. Klett ZG, et al. **Ophthal Plast Reconstr Surg** 1996 Sep;12(3):153–62

Agonist and antagonist properties of beta 3-adrenoceptors in human omental and mouse 3T3-L1 adipocytes. Shimizu M, et al. **Pharmacol Toxicol** 1996 Apr;78(4):254–63

Daily exercise reduces fat, protein and body mass in male but not female rats. Cortright RN, et al. **Physiol Behav** 1997 Jul;62(1):105–11

Leptin expression and action: new experimental paradigms [comment] Flier JS. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4242–5. Comment on: Proc Natl Acad Sci U S A 1997 Apr 29;94(9):4300–5. Comment on: Proc Natl Acad Sci U S A 1997 Apr 29;94(9):4637–41.

Obese gene expression at in vivo levels by fat pads derived from s.c. implanted 3T3-F442A preadipocytes [see comments] Mandrup S, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4300–5. Comment in: Proc Natl Acad Sci U S A 1997 Apr 29;94(9):4242–5.

Lipoprotein lipase controls fatty acid entry into adipose tissue, but fat mass is preserved by endogenous synthesis in mice deficient in adipose tissue lipoprotein lipase. Weinstock PH, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10261–6

Over-expression of GLUT4 selectively in adipose tissue in transgenic mice: implications for nutrient partitioning. Gnudi L, et al. **Proc Nutr Soc** 1996 Mar;55(1B):191–9 (30 ref.)

Adipose tissue metabolism during lactation: where do we go from here? McNamara JP. **Proc Nutr Soc** 1997 Mar; 56(1A):149–67 (72 ref.)

Short-term regulation of acetyl CoA carboxylase in tissues of higher animals. Allred JB, et al. **Prog Lipid Res** 1996 Dec;35(4):371–85 (186 ref.)

Lipogenic and lipolytic activities in isolated adipocytes from cattle with fat necrosis. Katamoto H, et al. **Res Vet Sci** 1996 Nov;61(3):214–7

Regulation of energy balance and adiposity: a model with new approaches. Martinez JA, et al. **Rev Esp Fisiol** 1996 Dec;52(4):255–8 (21 ref.)

Change in fat-free mass assessed by bioelectrical impedance, total body potassium and dual energy X-ray absorptiometry during prolonged weight loss. Hendel HW, et al. **Scand J Clin Lab Invest** 1996 Dec;56(8):671–9

Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Hotamisligil GS, et al. **Science** 1996 Nov 22; 274(5291):1377–9

Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. Parham FM, et al. **Toxicol Appl Pharmacol** 1997 Jun; 144(2):340–7 (27 ref.)

Regulated membrane transport of free fatty acids in adipocytes: role in obesity and non-insulin dependent diabetes mellitus. Berk PD, et al. **Trans Am Clin Climatol Assoc** 1996;108:26–40; discussion 41–3

Application of in situ microdialysis to measure metabolic and vascular responses in adipose tissue. Lafontan M, et al. **Trends Pharmacol Sci** 1996 Sep;17(9):309–13 (25 ref.)

[Leptin—a new weight-loss agent?] Holst JJ. **Nord Med** 1996 Nov;111(9):300–3 (13 ref.) (Eng. Abstr.) **(Dan)**

[Hormones and adipocyte development] Ailhaud G. **Ann Endocrinol (Paris)** 1997;58(2):129–31 (20 ref.) (Eng. Abstr.) **(Fre)**

[OB protein and its receptor: signal transduction between adipose tissue and central nervous system] Campfield LA, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:131–48 (63 ref.) **(Fre)**

[Deposition of subepicardial fat] Iwasaka T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):524–7 (25 ref.) **(Jpn)**

[Polychlorinated naphthalenes in Harbour porpoises Phocoena phocoena] Falandysz J, et al. **Rocz Panstw Zakl Hig** 1996;47(3):265–71 (Eng. Abstr.) **(Pol)**

PATHOLOGY

Dural chondroma with fat tissue. Takano M, et al. **Acta Neurochir (Wien)** 1997;139(7):690–1

Differences in body composition between female geriatric hip fracture patients and healthy controls: body fat is more important as explanatory factor for the fracture than body weight and lean body mass. Galvard H, et al. **Aging (Milano)** 1996 Aug;8(4):282–6

Limitations of the bioelectrical impedance method for the assessment of body fat in severe obesity. Deurenberg P. **Am J Clin Nutr** 1996 Sep;64(3 Suppl):449S–452S

Lipomatous hypertrophy ("massive fatty deposits") of the interatrial septum [letter; comment] Devine WA, et al. **Am J Forensic Med Pathol** 1997 Mar;18(1):107–8. Comment on: Am J Forensic Med Pathol 1996 Mar;17(1):43–8.

Clinical and morphologic features of lipomatous hypertrophy ("massive fatty deposits") of the interatrial septum [see comments] Gay JD, et al. **Am J Forensic Med Pathol** 1996 Mar;17(1):43–8. Comment in: Am J Forensic Med Pathol 1997 Mar;18(1):107–8.

Lipomatous hypertrophy of the cardiac interatrial septum. López-Beltrán A, et al. **Am J Forensic Med Pathol** 1997 Jun;18(2):206–7

The fat pad. Clinical observations [see comments] Duri ZA, et al. **Am J Knee Surg** 1996 Spring;9(2):55–66. Comment in: Am J Knee Surg 1996 Spring;9(2):43.

Intrapatellar fat pad [editorial; comment] McGinty JB. **Am J Knee Surg** 1996 Spring;9(2):43. Comment on: Am J Knee Surg 1996 Spring;9(2):55–66.

Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Banerji MA, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):E425–32

Loss of body fat in lean parabiotic partners of ob/ob mice. Harris RB. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1809–15

Reduction of dietary obesity in aP2-Ucp transgenic mice: mechanism and adipose tissue morphology. Kopecký J, et al. **Am J Physiol** 1996 May;270(5 Pt 1):E776–86

Perinatal energy stores and excessive fat deposition in genetically obese (fa/fa) rats. Meierfrankenfeld B, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):E700–8

Visceral adiposity, increased adipocyte lipolysis, and metabolic dysfunction in obese postmenopausal women. Nicklas BJ, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):E72–8

Different physiological traits underlying increased body fat of fatty (fa/fa) and heterozygous (+/fa) rats. Schwarzer K, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E100–6

Quantitative analysis of synovial fibrosis in the infrapatellar fat pad before and after anterior cruciate ligament reconstruction. Murakami S, et al. **Am J Sports Med** 1997 Jan-Feb;25(1):29–34

Obesity genes and the regulation of body fat content. Weigle DS, et al. **Bioessays** 1996 Nov;18(11):867–74 (79 ref.)

Pictures in medicine 12. Insulin-induced lipohypertrophy. Iqbal P. **Br J Hosp Med** 1996 Feb 7–20;55(3):138

Cellular proliferative activity of mammographic normal dense and fatty tissue determined by DNA S phase percentage. Stomper PC, et al. **Breast Cancer Res Treat** 1996;37(3):229–36

Lipomatous metaplasia in left ventricular scar. Baroldi G, et al. **Can J Cardiol** 1997 Jan;13(1):65–71

Insulin-induced lipoatrophy in type I diabetes. A possible tumor necrosis factor-alpha-mediated dedifferentiation of adipocytes. Atlan-Gepner C, et al. **Diabetes Care** 1996 Nov; 19(11):1283–5

Lipoatrophy with human insulin. Jaap AJ, et al. **Diabetes Care** 1996 Nov;19(11):1289–90

Are epithelial cells in fat or connective tissue a reliable indicator of tumor invasion in fine-needle aspiration of the breast? Maygarden SJ, et al. **Diagn Cytopathol** 1997 Feb; 16(2):137–42

Partial prolapse of the antero-medial corpus adiposum in the horse. Bedford PG, et al. **Equine Vet J Suppl** 1990 Sep; (10):2–4

Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase-mRNA [see comments] Proebstle TM, et al. **Eur J Cancer** 1996 Sep;32A(10):1664–7. Comment in: Eur J Cancer 1996 Sep;32A(10):1627–9.

Central neurocytoma: one associated with a fourth ventricular PNET/medulloblastoma and the second mixed with adipose tissue. Horoupian DS, et al. **Hum Pathol** 1997 Sep;28(9):1111–4

Intra-abdominal fat, lipid metabolism and insulin resistance in coronary artery disease. Kawamoto T, et al. **Hypertens Res** 1996 Jun;19 Suppl 1:S69–74

Membranous lipodystrophy associated with insulin lipoatrophy. Kim KT, et al. **Int J Dermatol** 1997 Apr; 36(4):299–301

Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats. Ghorbani M, et al. **Int J Obes Relat Metab Disord** 1997 Jun;21(6):465–75

Surgical pearl: the trephine punch for diagnosing panniculitis. Tok J, et al. **J Am Acad Dermatol** 1996 Dec;35(6):980–1

Comparison of the enzyme activities between the thickest and the thinnest parts of the abdominal pannus. Cazes L, et al. **J Am Coll Nutr** 1997 Aug;16(4):341–5

Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure [see comments] Johannsson G, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):727–34. Comment in: J Clin Endocrinol Metab 1997 Mar;82(3):725–6.

The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. Kennedy A, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1293–300

Visceral adipose tissue is associated with circulating high affinity growth hormone-binding protein. Roelen CA, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):760–4

Effect of regional fat distribution and Prader-Willi syndrome on plasma leptin levels. Weigle DS, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):566–70

Clinical image. MR demonstration of submucosal fat in a patient with Crohn's disease. Funt SA, et al. **J Comput Assist Tomogr** 1996 Nov-Dec;20(6):940–1 (5 ref.)

Determination of 1H relaxation times of water in human bone marrow by fat-suppressed turbo spin echo in comparison to MR spectroscopic methods. Träber F, et al. **J Magn Reson Imaging** 1996 May-Jun;6(3):541–8

Frequency-selective fat suppression MR imaging. Localized asymmetric failure of fat suppression mimicking orbital disease. Borges AR, et al. **J Neuroophthalmol** 1997 Mar; 17(1):12–7

Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. Gratacos J, et al. **J Rheumatol** 1997 May; 24(5):912–5

Fatty degeneration in the supraspinatus muscle after rotator cuff tear. Nakagaki K, et al. **J Shoulder Elbow Surg** 1996 May-Jun;5(3):194–200

Lymph node and perinodal tissue tumor involvement in patients with esophagectomy and three-field lymphadenectomy for carcinoma of the esophagus. Baba M, et al. **J Surg Oncol** 1997 Jan;64(1):12–6

Morphologic and molecular changes induced by recombinant human leptin in the white and brown adipose tissues of C57BL/6 mice. Sarmiento U, et al. **Lab Invest** 1997 Sep; 77(3):243–56

MR quantification of muscle fatty replacement in McArdle's disease. De Kerviler E, et al. **Magn Reson Imaging** 1996; 14(10):1137–41

Expression of the obese gene product (leptin). Bhatia E. **Natl Med J India** 1996 Jul-Aug;9(4):175–6

Lipoblastic differentiation in a primary localized fibrous mesothelioma of the peritoneum. Donna A, et al. **Pathol Res Pract** 1996 Dec;192(12):1252–6; discussion 1257–8

Pseudoherniation of the buccal fat pad: a new clinical syndrome. Matarasso A. **Plast Reconstr Surg** 1997 Sep; 100(3):723–30; discussion 731–6

MR imaging of the infrapatellar fat pad of Hoffa. Jacobson JA, et al. **Radiographics** 1997 May-Jun;17(3):675–91

Chondroid lipoma: MRI appearances with clinical and histologic correlation. Logan PM, et al. **Skeletal Radiol** 1996 Aug;25(6):592–5

Systematic inspection of insulin injection sites for local complications related to incorrect injection technique. Seyoum B, et al. **Trop Doct** 1996 Oct;26(4):159–61

[Cadaver lipid: various origins add to the difficulty of assessing postmortem time] Rothschild MA, et al. **Arch Kriminol** 1996 May-Jun;197(5-6):165–74 (Eng. Abstr.) **(Ger)**

[Lipoemulsification. A histological study on the action of ultrasound, access site and adipose tissue] Palmieri B, et al. **Minerva Chir** 1997 Jun;52(6):795–800 (Eng. Abstr.) **(Ita)**

[A case of Morgagni hernia composed of hypertrophic adipose tissue in the falciform ligament] Ichihashi T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May; 45(5):787–91 (Eng. Abstr.) **(Jpn)**

Morphological reactions in the subcutaneous fat after lymphotropic administration of isoniazid: experimental study] Gedymin LE, et al. **Probl Tuberk** 1997;(2):51–4 (Eng. Abstr.) **(Rus)**

[Relation between the abdominal sagittal diameter, fat tissue distribution and metabolic complications] Stokić E, et al. **Med Pregl** 1996;49(9-10):365–8 (Eng. Abstr.) **(Scr)**

PHYSIOLOGY

Effect of weight loss on body fat distribution in obese children. Torigoe K, et al. **Acta Paediatr Jpn** 1997 Feb; 39(1):28–33

Poststarvation hyperphagia and body fat overshooting in humans: a role for feedback signals from lean and fat tissues. Dulloo AG, et al. **Am J Clin Nutr** 1997 Mar;65(3):717–23

Why are large legs protective? [letter; comment] Kahn HS. **Am J Clin Nutr** 1997 Sep;66(3):712–3. Comment on: Am J Clin Nutr 1997 Mar;65(3):855–60.

A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Lemieux S, et al.

Am J Clin Nutr 1996 Nov;64(5):685–93
Critical fatness hypothesis [letter; comment] Frisch RE. **Am J Physiol** 1997 Jul;273(1 Pt 1):E231–2. Comment on: Am J Physiol 1996 Jan;270(1 Pt 1):E1–19.
Lactate production by swine adipocytes: effects of age, nutritional status, glucose concentration, and insulin. Heckler BK, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E957–66
Adenylyl cyclase inhibitory pathway is differentially modified in rat white and brown fat by high–energy diets. Kenan Y, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E1043–9
Short–day–like body weight changes do not prevent fat pad compensation after lipectomy in Siberian hamsters. Mauer MM, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R68–77
Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat. Paolisso G, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E471–8
Effects of epinephrine infusion on adipose tissue: interactions between blood flow and lipid metabolism. Samra JS, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):E834–9
Effects of morning rise in cortisol concentration on regulation of lipolysis in subcutaneous adipose tissue. Samra JS, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):E996–1002
A hypercaloric load induces thermogenesis but inhibits stress responses in the SNS and HPA system. Strack AM, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R840–8
Partial lipectomy, but not PVN lesions, increases food hoarding by Siberian hamsters. Wood AD, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R783–92
Menopause–associated differences in female fat patterning estimated by dual–energy X–ray absorptiometry. Kirchengast S, et al. **Ann Hum Biol** 1997 Jan–Feb; 24(1):45–54
OB protein: A peripheral signal linking adiposity and central neural networks. Campfield LA, et al. **Appetite** 1996 Jun; 26(3):302
Body size and subcutaneous fat patterning in adolescence. Matthes JW, et al. **Arch Dis Child** 1996 Dec;75(6):521–3
Immunological manipulation of adiposity. Flint DJ. **Biochem Soc Trans** 1996 May;24(2):418–22 (19 ref.)
Regulation of lipogenic enzyme expression by glucose in liver and adipose tissue: is glucose 6–phosphate the signalling metabolite? Foufelle F, et al. **Biochem Soc Trans** 1996 May; 24(2):372–8 (43 ref.)
Functional interpretation of the organization of mammalian adipose tissue: its relationship to the immune system. Pond CM. **Biochem Soc Trans** 1996 May;24(2):393–400 (25 ref.)
Lack of effect of different dietary saturated fatty acids on adipose tissue deposition in the rat. Sherrington EJ, et al. **Biochem Soc Trans** 1996 May;24(2):158S
The effect of feeding diets with different n–6/n–3 fatty acids ratios on adipose tissue of deposition in the rat. Sherrington EJ, et al. **Biochem Soc Trans** 1996 May;24(2):160S
Uncoupling protein in brown adipose tissue: molecular differentiation of the adipose tissues. Trayhurn P. **Biochem Soc Trans** 1996 May;24(2):402–6 (36 ref.)
Conductivities of pig dermis and subcutaneous fat measured with rectangular pulse electrical current. Cheng K, et al. **Bioelectromagnetics** 1996;17(6):458–66
Body fat and sympathetic nerve activity. Scherrer U, et al. **Cardiovasc Drugs Ther** 1996 Jun;10 Suppl 1:215–22 (55 ref.)
Adipogenesis and obesity: rounding out the big picture. Spiegelman BM, et al. **Cell** 1996 Nov 1;87(3):377–89 (110 ref.)
Efferent vagal innervation of the canine atria and sinus and atrioventricular nodes. The third fat pad. Chiou CW, et al. **Circulation** 1997 Jun 3;95(11):2573–84
Regulation of adipose cell number in man [editorial] Prins JB, et al. **Clin Sci (Colch)** 1997 Jan;92(1):3–11 (101 ref.)
Body composition and fat distribution by dual energy X–ray absorptiometry in overweight postmenopausal women. Effect of energy–restriction and exercise. Svendsen OL. **Dan Med Bull** 1996 Jun;43(3):249–62 (161 ref.)
Plasma leptin levels correlate to islet function independently of body fat in postmenopausal women. Larsson H, et al. **Diabetes** 1996 Nov;45(11):1580–4
Supraphysiological hyperinsulinemia increases plasma leptin concentrations after 4 h in normal subjects. Utriainen T, et al. **Diabetes** 1996 Oct;45(10):1364–6
Voluntary wheel running decreases adipose tissue mass and expression of leptin mRNA in Osborne–Mendel rats. Zachwieja JJ, et al. **Diabetes** 1997 Jul;46(7):1159–66
Intra–abdominal fat: is it a major factor in developing diabetes and coronary artery disease? Kissebah AH. **Diabetes Res Clin Pract** 1996 Feb;30 Suppl:25–30 (37 ref.)
Jejunal brake [letter; comment] Vidon N, et al. **Dig Dis Sci** 1996 Dec;41(12):2317–8. Comment on: Dig Dis Sci 1996 Feb;41(2):326–9.
Human leptin: the hormone of adipose tissue. Sinha MK. **Eur J Endocrinol** 1997 May;136(5):461–4 (33 ref.)
Analysis of an expression profile of genes in the human adipose tissue. Maeda K, et al. **Gene** 1997 May 6; 190(2):227–35
Effects of leptin administration on long–term selected fat mice. Bünger L, et al. **Genet Res** 1997 Jun;69(3):215–25
Leptin: a hormone of reproduction [editorial] Conway GS, et al. **Hum Reprod** 1997 Apr;12(4):633–5
Adiposity and regional body fat distribution in physically active young and middle–aged women. Davy KP, et al. **Int J Obes Relat Metab Disord** 1996 Aug;20(8):777–83
Anthropometric equations for estimating abdominal adipose tissue distribution in women. Kekes–Szabo T, et al. **Int J Obes Relat Metab Disord** 1996 Aug;20(8):753–8
Lateral pharyngeal fat pad pressure during breathing in anesthetized pigs. Winter WC, et al. **J Appl Physiol** 1997 Sep;83(3):688–94
The effects of porosity on endothelialization of ePTFE implanted in subcutaneous and adipose tissue. Salzmann DL, et al. **J Biomed Mater Res** 1997 Mar 15;34(4):463–76
Differential healing and neovascularization of ePTFE implants in subcutaneous versus adipose tissue. Williams SK, et al. **J Biomed Mater Res** 1997 Jun 15;35(4):473–81
Desensitization of human adipose tissue to adrenaline stimulation studied by microdialysis. Stallknecht B, et al. **J Physiol (Lond)** 1997 Apr 1;500 (Pt 1):271–82
Establishment and characterization of a human stroma–dependent myeloma cell line (MM5.1) and its stroma–independent variant (MM5.2). Van Riet I, et al. **Leukemia** 1997 Feb;11(2):284–93
Visceral adipose tissue impairs insulin secretion and insulin sensitivity but not energy expenditure in obesity. Macor C, et al. **Metabolism** 1997 Feb;46(2):123–9
Insulin–stimulated glucose disposal: does adipose play a role? Frost SC. **Nutr Rev** 1996 Oct;54(10):329–31 (37 ref.)
Relationship of anterior and posterior subcutaneous abdominal fat to insulin sensitivity in nondiabetic men. Misra A, et al. **Obes Res** 1997 Mar;5(2):93–9
Photoperiod, sex, gonadal steroids, and housing density affect body fat in hamsters. Bartness TJ. **Physiol Behav** 1996 Aug; 60(2):517–29
Combined effects of insulin treatment and adipose tissue–specific agouti expression on the development of obesity. Mynatt RL, et al. **Proc Natl Acad Sci U S A** 1997 Feb 4;94(3):919–22
Interactions between adipose tissue and the immune system. Pond CM. **Proc Nutr Soc** 1996 Mar;55(1B):111–26 (61 ref.)
JAK/STAT eats the fat. Miller RJ, et al. **Trends Neurosci** 1996 May;19(5):159–61

PHYSIOPATHOLOGY

Hyperleptinemia: an early sign of juvenile obesity. Relations to body fat depots and insulin concentrations. Caprio S, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E626–30
The validity of body mass index for the assessment of adiposity in children with disease states. Warner JT, et al. **Ann Hum Biol** 1997 May–Jun;24(3):209–15
Regulation of body adiposity and the problem of obesity. Schwartz MW, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):233–8 (73 ref.)
Patterns of muscle and fat mass repair during recovery from advanced infantile protein–energy malnutrition. Castilla–Serna L, et al. **Eur J Clin Nutr** 1996 Jun; 50(6):392–7
Superficial wound disruption after cesarean delivery: effect of the depth and closure of subcutaneous tissue. Çetin A, et al. **Int J Gynaecol Obstet** 1997 Apr;57(1):17–21
Glucose metabolism in identical twins discordant for obesity. The critical role of visceral fat. Rönnemaa T, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):383–7
Menopause, fat and lean distribution in obese women. Panotopoulos G, et al. **Maturitas** 1996 Aug;25(1):11–9

RADIOGRAPHY

Orbital fat edema in anorexia nervosa: a reversible finding. Demaerel P, et al. **AJNR Am J Neuroradiol** 1996 Oct; 17(9):1782–4
Displaced extrapleural fat as revealed by CT scanning: evidence of extrapleural hematoma. Aquino SL, et al. **AJR Am J Roentgenol** 1997 Sep;169(3):687–9
CT appearance of lipomatous hypertrophy of the interatrial septum. Meaney JF, et al. **AJR Am J Roentgenol** 1997 Apr; 168(4):1081–4
Computerized tomography assessment of women with weight changes associated with adjuvant treatment for breast cancer. Cheney CL, et al. **Am J Clin Nutr** 1997 Jul; 66(1):141–6
Increased intra–abdominal fat deposition in patients with major depressive illness as measured by computed tomography. Thakore JH, et al. **Biol Psychiatry** 1997 Jun 1;41(11):1140–2
Risk factors in obese women, with particular reference to visceral fat component. Lerário AC, et al. **Diabetes Metab** 1997 Feb;23(1):68–74
Computed tomography analysis of the anterior mediastinal fat after left upper lobectomy. Toei H, et al. **Invest Radiol** 1997 Mar;32(3):174–9
CT evaluation of normal interatrial fat thickness. Broderick LS, et al. **J Comput Assist Tomogr** 1996 Nov–Dec; 20(6):950–3
Fat density in renal cell carcinoma: demonstration with computerized tomography. Henderson RJ, et al. **J Urol** 1997 Apr;157(4):1347–8
Pericaval fat collection that mimics thrombosis of the inferior vena cava: demonstration with use of multi–directional reformation CT. Han BK, et al. **Radiology** 1997 Apr; 203(1):105–8
[The computed tomographic determination of intra–abdominal fat volume by single–layer measurement] Jacobi V, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):115–9 (Eng. Abstr.) **(Ger)**
[CT analysis of the anterior mediastinal fat: before and after lobectomy] Toei H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Jul;57(8):493–8 (Eng. Abstr.) **(Jpn)**

SECRETION

Effect of dietary vitamin E supplements on cholesteryl ester transfer activity in hamster adipose tissue. Shen GX, et al. **Atherosclerosis** 1996 Aug 2;124(2):211–9
Regulation of expression of leptin mRNA and secretion of leptin by thyroid hormone in 3T3–L1 adipocytes. Yoshida T, et al. **Biochem Biophys Res Commun** 1997 Mar 27; 232(3):822–6

SURGERY

Importance of fat conservation in lower blepharoplasty. Eder H. **Aesthetic Plast Surg** 1997 May–Jun;21(3):168–74
Benefits of the rotating cannula in the treatment of lipodystrophies. Mole B. **Aesthetic Plast Surg** 1997 May–Jun;21(3):148–52
Short–day–like body weight changes do not prevent fat pad compensation after lipectomy in Siberian hamsters. Mauer MM, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R68–77
Insulin–induced lipohypertrophy treated by liposuction. Barak A, et al. **Ann Plast Surg** 1996 Oct;37(4):415–7
Re: Reverse first dorsal metatarsal artery adipofascial flap [letter; comment] Wechselberger G, et al. **Ann Plast Surg** 1996 Oct;37(4):453–4. Comment on: Ann Plast Surg 1996 Feb;36(2):158–61.
Retrosternal fat pad for prevention of suppurative sternitis. Kejriwal NK, et al. **Ann Thorac Surg** 1997 May; 63(5):1484–5
The management of unilateral vocal cord palsy by augmentation using autologous fat. Oluwole M, et al. **Clin Otolaryngol** 1996 Aug;21(4):357–9
Direct fixation of the malar pad. Barton FE Jr, et al. **Clin Plast Surg** 1997 Apr;24(2):329–35
Autologous fat grafting for body contouring. Guerrerosantos J. **Clin Plast Surg** 1996 Oct;23(4):619–31
The suborbicularis oculi fat in aesthetic and reconstructive surgery. Hoenig JA, et al. **Int Ophthalmol Clin** 1997 Summer;37(3):179–91 (20 ref.)
Importance of soft tissue integrity on biomechanical studies of the patella after TKA. Luo ZP, et al. **J Biomech Eng** 1996 Feb;118(1):130–2
Microdialysis of adipose tissue during surgery: effect of local alpha– and beta–adrenoceptor blockade on blood flow and lipolysis. Felländer G, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2919–24
Effects of heterogeneous absorption of laser radiation in biotissue ablation: characterization of ablation of fat with a pulsed CO2 laser. Ross EV, et al. **Lasers Surg Med** 1997; 21(1):59–64
Ultrasonic liposculpturing: extrapolations from the analysis of in vivo sonicated adipose tissue. Adamo C, et al. **Plast Reconstr Surg** 1997 Jul;100(1):220–6
Use of a tourniquet in panniculus resection. Daw JL, et al. **Plast Reconstr Surg** 1997 Jun;99(7):2082–4
Flap defatting with an ultrasonic surgical aspirator. Yamanaka K, et al. **Plast Reconstr Surg** 1997 Mar; 99(3):888–91
[Hoffa disease: diagnosis and arthroscopic treatment] Wu H, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Oct;33(10):581–3 (Eng. Abstr.) **(Chi)**
[Surgical interventions in patients with a history of alimentary constitutional obesity] Markov VK, et al. **Khirurgiia (Mosk)** 1996;(3):46–9 (Eng. Abstr.) **(Rus)**

TRANSPLANTATION

Long–term survival of free fat grafts in muscle: an experimental study in rats. Guerrerosantos J, et al. **Aesthetic Plast Surg** 1996 Sep–Oct;20(5):403–8
Large liponecrotic pseudocyst formation following cheek augmentation by fat injection. Har–Shai Y, et al. **Aesthetic Plast Surg** 1996 Sep–Oct;20(5):417–9
Fat grafting of the buttocks and lower limbs. Pereira LH, et al. **Aesthetic Plast Surg** 1996 Sep–Oct;20(5):409–16
Use of buccal fat pad to repair intraoral defects: review of 30 cases. Martín–Granizo R, et al. **Br J Oral Maxillofac Surg** 1997 Apr;35(2):81–4
Comparison of various interpositional materials in the prevention of transphyseal bone bridge formation. Martiana K, et al. **Clin Orthop** 1996 Apr;(325):218–24
Facial recontouring with lipostructure. Coleman SR. **Clin Plast Surg** 1997 Apr;24(2):347–67
Bilateral fat graft myringoplasty in children. Mitchell RB, et al. **Ear Nose Throat J** 1996 Oct;75(10):652, 655–6
Repeated lipoinjections for stress urinary incontinence. Palma PC, et al. **J Endourol** 1997 Feb;11(1):67–70
Simultaneous tendon transfer and autogenous augmentation of the first web space of the hand with intrinsic paralysis. al–Qattan MM. **J Hand Surg [Br]** 1996 Aug;21(4):486–7
Fat graft myringoplasty in children—a safe and successful day–stay procedure. Mitchell RB, et al. **J Laryngol Otol** 1997 Feb;111(2):106–8
The use of fat grafts to prevent heterotopic bone formation in the temporomandibular joint [letter] Garrett WR, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):1037
Autologous fat transplantation around temporomandibular joint total joint prostheses: preliminary treatment outcomes. Wolford LM, et al. **J Oral Maxillofac Surg** 1997 Mar; 55(3):245–51; discussion 251–2
Biochemical assessment of cellular damage after adipocyte

ADIPOSE TISSUE

harvest. Lalikos JF, et al. **J Surg Res** 1997 Jun;70(1):95–100

Lipoid meningitis due to aseptic necrosis of a free fat graft placed during neurotologic surgery. Hwang PH, et al. **Laryngoscope** 1996 Dec;106(12 Pt 1):1482–6

Autologous fat injection into the vocal folds: technical considerations and long-term follow-up. Shaw GY, et al. **Laryngoscope** 1997 Feb;107(2):177–86

Experience of a new surgical procedure for the treatment of unilateral obstructive lymphedema of the lower extremity: adipo-lymphatico venous transfer. Tanaka Y, et al. **Microsurgery** 1996;17(4):209–16

"Spaghetti" fat grafting: a new technique [letter] Nordström RE, et al. **Plast Reconstr Surg** 1997 Mar;99(3):917–8

Dermal grafting for a patient with scleroderma. Case report. Ho-Asjoe M, et al. **Scand J Plast Reconstr Surg Hand Surg** 1996 Dec; 30(4):325–7

Brain stem compression secondary to adipose graft prolapse after transpetrosal approach: case report. Spallone A, et al. **Surg Neurol** 1997 Jul;48(1):80–3; discussion 84

[Lumbar disk prolapse surgery with or without free fat transplantation. A prospective triple-blind randomized study] Jensen TT, et al. **Ugeskr Laeger** 1997 Mar 31; 159(14):2091–5 (Eng. Abstr.) **(Dan)**

[Peri-ureteral injections for stress urinary incontinence] Haab F. **Prog Urol** 1997 Apr;7(2):293–6 (15 ref.) **(Fre)**

[Indications for middle ear obliteration within the scope of cochlear implant management] Issing PR, et al. **Laryngorhinootologie** 1996 Dec;75(12):727–31 (Eng. Abstr.) **(Ger)**

[Dermal fatty tissue transplant as primary and secondary orbital implant. Complications and results] Hintschich CR, et al. **Ophthalmologe** 1996 Oct;93(5):617–22 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Ultrasonographic assessment of adipose tissue volume [letter; comment] Moscrip V, et al. **Br J Sports Med** 1997 Mar; 31(1):84–5. Comment on: Br J Sports Med 1994 Mar;28(1):9–13.

Ultrasonographic intra-abdominal depth and its relation to haemostatic factors in healthy males. Targher G, et al. **Int J Obes Relat Metab Disord** 1996 Sep;20(9):882–5

Total and segmental subcutaneous adipose tissue volume measured by ultrasound. Abe T, et al. **Med Sci Sports Exerc** 1996 Jul;28(7):908–12

Finite amplitude distortion and its relationship to linear derating formulae for diagnostic ultrasound systems. Christopher T, et al. **Ultrasound Med Biol** 1996; 22(8):1103–16 (36 ref.)

Real-time assessment of the parameter of nonlinearity in tissue using "nonlinear shadowing". Fatemi M, et al. **Ultrasound Med Biol** 1996;22(9):1215–28

ULTRASTRUCTURE

Effect of increasing concentrations of nonionic detergent Triton X-100 on solubilization and structure of rat liver and adipose plasma membranes. Yegutkin GG. **Membr Cell Biol** 1997;10(5):515–20

VIROLOGY

Infection and replication of human cytomegalovirus in bone marrow stromal cells: effects on the production of IL-6, MIP-1alpha, and TGF-beta1. Taichman RS, et al. **Bone Marrow Transplant** 1997 Mar;19(5):471–80

ADIPOSE TISSUE, BROWN see **BROWN FAT**

ADIPOSIS DOLOROSA

DIAGNOSIS

[Adiposis dolorosa (Dercum's disease)] Pardal Refoyo JL. **An Otorrinolaringol Ibero Am** 1996;23(4):435–40 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Is EMLA effective in Dercum's disease? [letter] Reggiani M, et al. **Acta Derm Venereol** 1996 Mar;76(2):170–1

ADJUSTMENT DISORDERS

Anxiety and depression in adult untreated celiac subjects and in patients affected by inflammatory bowel disease: a personality "trait" or a reactive illness? Addolorato G, et al. **Hepatogastroenterology** 1996 Nov-Dec;43(12):1513–7

Consultation with the specialist. The vulnerable child. Leslie LK, et al. **Pediatr Rev** 1996 Sep;17(9):323–6 (9 ref.)

COMPLICATIONS

Psychosocial problems and adjustment of children with beta-thalassemia and their families. Tsiantis J, et al. **Eur Child Adolesc Psychiatry** 1996 Dec;5(4):193–203

A study of deliberate self-poisoning in patients with adjustment disorders. Mitrev I. **Folia Med (Plovdiv)** 1996; 38(3-4):11–6

Psychiatric morbidity among dermatology inpatients. Pulimood S, et al. **Natl Med J India** 1996 Sep-Oct; 9(5):208–10

DIAGNOSIS

Psychogenic (reactive) and hysterical psychoses: a cross-system reliability study. Pitta JC, et al. **Acta Psychiatr Scand** 1997 Feb;95(2):112–8

Traumatic grief: a case of loss-induced trauma [clinical conference] Prigerson HG, et al. **Am J Psychiatry** 1997 Jul;154(7):1003–9

Factor analysis of the Montgomery-Asberg Depression Rating Scale. Craighead WE, et al. **Depression** 1996; 4(1):31–3

Symptom profile, Axis II comorbidity and suicidal behaviour in young males with DSM-III-R depressive illnesses. Spalletta G, et al. **J Affect Disord** 1996 Jul 8;39(2):141–8

Relationship between narcissistic tendencies and psychiatric conditions in patients undergoing physical rehabilitation. Fukunishi I, et al. **Percept Mot Skills** 1996 Oct;83(2):403–8

Early memories and maladjustment. Spirrison CL, et al. **Psychol Rep** 1997 Aug;81(1):227–33

[Personality and adjustment disorders] Leppävuori A. **Duodecim** 1995;111(17):1679–82 **(Fin)**

DRUG THERAPY

Restless legs syndrome and paroxetine. Sanz-Fuentenebro FJ, et al. **Acta Psychiatr Scand** 1996 Dec;94(6):482–4

A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Bourin M, et al. **Fundam Clin Pharmacol** 1997;11(2):127–32

New antidepressant drugs and the treatment of depression in the medically ill patient. Stoudemire A. **Psychiatr Clin North Am** 1996 Sep;19(3):495–514 (85 ref.)

EPIDEMIOLOGY

Psychiatric morbidity following miscarriage: a prevalence study of Chinese women in Hong Kong. Lee DT, et al. **J Affect Disord** 1997 Mar;43(1):63–8

Children's response to parental separation during operation desert storm. Jensen PS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Apr;35(4):433–41

Adjustment in childhood brain tumor survival: child, mother, and teacher report. Radcliffe J, et al. **J Pediatr Psychol** 1996 Aug;21(4):529–39

A comparative review of psychosocial and occupational environment in native Swedes and immigrants. Rosmond R, et al. **Scand J Soc Med** 1996 Dec;24(4):237–42

The mental health impact of stillbirth, neonatal death or SIDS: prevalence and patterns of distress among mothers. Boyle FM, et al. **Soc Sci Med** 1996 Oct;43(8):1273–82

ETHNOLOGY

Intercountry adoption of Latin American children: the importance of early bilingual/bicultural services. de Verthelyi RF. **Cult Divers Ment Health** 1996;2(1):53–63 (33 ref.)

ETIOLOGY

Physical punishment/maltreatment during childhood and adjustment in young adulthood. Fergusson DM, et al. **Child Abuse Negl** 1997 Jul;21(7):617–30

Dimensions and disorders of adolescent adjustment: a quantitative genetic analysis of unselected samples and selected extremes. Deater-Deckard K, et al. **J Child Psychol Psychiatry** 1997 Jul;38(5):515–25

Psychological functioning of adolescent and young adult survivors of pediatric malignancy. Elkin TD, et al. **Med Pediatr Oncol** 1997 Dec;29(6):582–8

Psychiatric morbidity and depressive symptomatology in patients with permanent pacemakers. Aydemir O, et al. **Pacing Clin Electrophysiol** 1997 Jun;20(6):1628–32

GENETICS

Dimensions and disorders of adolescent adjustment: a quantitative genetic analysis of unselected samples and selected extremes. Deater-Deckard K, et al. **J Child Psychol Psychiatry** 1997 Jul;38(5):515–25

NURSING

The effect of psychosocial nursing intervention on the mood state of patients with implantable cardioverter defibrillators and their caregivers. Sneed NV, et al. **Prog Cardiovasc Nurs** 1997 Spring;12(2):4–14

PHYSIOPATHOLOGY

Social rhythm stability following late-life spousal bereavement: associations with depression and sleep impairment. Brown LF, et al. **Psychiatry Res** 1996 May 17;62(2):161–9

[The EEG rhythms and psychological indices of emotions in reactive depression] Strelets VB, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Jan-Feb; 47(1):11–21 (Eng. Abstr.) **(Rus)**

[The disordered organization of the cortical processes in depression] Strelets VB, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Mar-Apr; 46(2):274–81 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Abnormal illness behaviour in rehabilitation from stroke. Clark MS, et al. **Clin Rehabil** 1997 May;11(2):162–70

Intercountry adoption of Latin American children: the importance of early bilingual/bicultural services. de Verthelyi RF. **Cult Divers Ment Health** 1996;2(1):53–63 (33 ref.)

Perceived social support from family, school, and peers: relationship with emotional and behavioral problems among adolescents. Garnefski N, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Dec; 35(12):1657–64

Children's selective coping after a bus disaster: confronting behavior and perceived support. Milgram N, et al. **J Trauma Stress** 1996 Oct;9(4):687–702

[Adjusting to illness and secondary prevention in unemployed patients from the medical psychology viewpoint] Dauer S, et al. **Wien Med Wochenschr** 1997;147(11):283–6 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Recognition of adjustment disorder in college athletes: a case study. Shell D, et al. **Clin J Sport Med** 1996 Jan;6(1):60–2

Contextual strategy instruction: socially/emotionally maladjusted adolescents with language impairments. Ward-Lonergan JM, et al. **J Commun Disord** 1996 Mar-Apr;29(2):107–24

Psychological characteristics of infertile patients: discriminating etiological factors from reactive changes. Stoléru S, et al. **J Psychosom Obstet Gynaecol** 1996 Jun; 17(2):103–18

Age, birthdays, and suicide in Taiwan. Chuang HL, et al. **J Soc Psychol** 1996 Oct;136(5):659–60

Relationship between narcissistic tendencies and psychiatric conditions in patients undergoing physical rehabilitation. Fukunishi I, et al. **Percept Mot Skills** 1996 Oct;83(2):403–8

Psychiatric sequelae in seriously ill children and their families. Stuber ML. **Psychiatr Clin North Am** 1996 Sep; 19(3):481–93 (71 ref.)

Empathy and reactive depression. Gawronski I, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):1043–9

Psychological factors in the development of mood disorders with a seasonal pattern. Beratis S, et al. **Psychopathology** 1996 Nov-Dec;29(6):331–9

Human immunodeficiency virus (HIV) infection and quality of life: the potential impact of Axis I psychiatric disorders in a sample of 95 HIV seropositive men. Holmes WC, et al. **Psychosom Med** 1997 Mar-Apr;59(2):187–92

[Do psychological factors modify survival of cancer patients? II: Results of an empirical study with bronchial carcinoma patients] Faller H, et al. **Psychother Psychosom Med Psychol** 1997 Jun;47(6):206–18 (Eng. Abstr.) **(Ger)**

THERAPY

Measuring treatment outcome by the Beck Depression Inventory. Richter P, et al. **Psychopathology** 1997; 30(4):234–40

[Psychiatric disorders and their treatment in immigrants--2 case reports] Bauer M. **Psychiatr Prax** 1996 Jul;23(4):194–6 **(Ger)**

ADJUSTMENT, SOCIAL see **SOCIAL ADJUSTMENT**

ADJUVANT ARTHRITIS see **ARTHRITIS, ADJUVANT**

ADJUVANTS, IMMUNOLOGIC

The role of adjuvants and delivery systems in modulation of immune response to vaccines. Gupta RK, et al. **Adv Exp Med Biol** 1996;397:105–13 (44 ref.)

Unique immunomodulating properties of dimethyl dioctadecyl ammonium bromide (DDA) in experimental viral vaccines. Katz D, et al. **Adv Exp Med Biol** 1996; 397:115–25 (22 ref.)

RU-486 blocks differentially suppressive effect of stress on in vivo anti-KLH immunoglobulin response. Fleshner M, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1344–52

Interleukin-12 as vaccine adjuvant. Characteristics of primary, recall, and long-term responses. Bliss J, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:26–35

Protective immunity to Listeria monocytogenes elicited by immunization with heat-killed Listeria and IL-12. Potential mechanism of IL-12 adjuvanticity. Miller MA, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:207–27

Interleukin-12 as adjuvant in peptide vaccines. O'Toole M, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:379–81

Reversal of orally induced T-cell tolerance by subcutaneous administration of interleukin-12 at the site of attempted sensitization. Scheper RJ, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:403–9

Interleukin-12 as an adjuvant in the generation of protective immunity to an intracellular pathogen. Skeen MJ, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:416–9

Role of adjuvants in HIV vaccine design. Vogel FR. **Antibiot Chemother** 1996;48:84–91 (48 ref.)

BCG vaccination and interpretation of purified protein derivative test results [letter] Li VW, et al. **Arch Dermatol** 1997 Jul;133(7):916–7

Phosprenyl: a novel drug with antiviral and immunomodulatory activity. Danilov LL, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(5-6):395–400 (13 ref.)

Efficacy of aluminum hydroxide-adjuvanted Escherichia coli bacterin in turkey poults. Trampel DW, et al. **Avian Dis** 1997 Apr-Jun;41(2):263-8

Large scale comparison of adjuvant effects on immunogenicity and protection in a herpes simplex virus type 1 vaccination model. Simms JR, et al. **Biochem Soc Trans** 1997 May;25(2):272S

Immunogenicity & reactogenicity of a recombinant HPV6 fusion protein vaccine adjuvanted with monophosphoryl lipid A. Thompson S, et al. **Biochem Soc Trans** 1997 May; 25(2):274S

Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Martin JT. **Biologicals** 1997 Jun;25(2):209-13 (12 ref.)

Effect of adjuvants on the antibody response of mice to Bothrops asper (Terciopelo) snake venom. Rucavado A, et al. **Braz J Med Biol Res** 1996 Oct;29(10):1337-40

Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. Mbawuike IN, et al. **Cell Immunol** 1996 Oct 10;173(1):64-78

Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Bahar K, et al. **Clin Dermatol** 1996 Sep-Oct; 14(5):489-95

Saponins as vaccine adjuvants. Kensil CR. **Crit Rev Ther Drug Carrier Syst** 1996;13(1-2):1-55 (178 ref.)

Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response. Villacres-Eriksson M, et al. **Cytokine** 1997 Feb;9(2):73-82

Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen. Tsuji T, et al. **Eur J Immunol** 1997 Mar;27(3):782-7

Characterisation of a novel airway late phase model in the sensitized guinea pig which uses silica and Bordetella pertussis as adjuvant for sensitization. Heuer HO, et al. **Eur J Pharmacol** 1996 Dec 19;317(2-3):361-8

Study of the immunostimulating effect of glycophosphopeptical (AM3) in mice. Gallego Olivella J, et al. **FEMS Immunol Med Microbiol** 1997 May;18(1):87-9

Plant immunomodulators for termination of unwanted pregnancy and for contraception and reproductive health. Talwar GP, et al. **Immunol Cell Biol** 1997 Apr;75(2):190-2

Mucosal immunoadjuvant activity of liposomes: role of alveolar macrophages. de Haan A, et al. **Immunology** 1996 Dec;89(4):488-93

Increased adjuvant efficacy in stimulation of antibody responses after macrophage elimination in vivo. Leenaars PP, et al. **Immunology** 1997 Mar;90(3):337-43

Immune enhancing effects of dehydroepiandrosterone and dehydroepiandrosterone sulphate and the role of steroid sulphatase. Suitters AJ, et al. **Immunology** 1997 Jun; 91(2):314-21

Saponin adjuvant primes for a dominant interleukin-10 production to ovalbumin and to Trypanosoma cruzi antigen. Tadokoro CE, et al. **Immunology** 1996 Nov; 89(3):368-74

HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine. Tsuji T, et al. **Immunology** 1997 Jan;90(1):1-6

Immunoreactivity of mycobacterial 70 kDa protein in different physico-chemical forms. Verma I, et al. **Indian J Med Res** 1997 Jul;106:13-5

Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Douce G, et al. **Infect Immun** 1997 Jul;65(7):2821-8

Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Sasaki S, et al. **Infect Immun** 1997 Sep;65(9):3520-8

Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models. Van De Verg LL, et al. **Infect Immun** 1996 Dec; 64(12):5263-8

Cytokines as adjuvants for ruminant vaccines. Lofthouse SA, et al. **Int J Parasitol** 1996 Aug-Sep;26(8-9):835-42 (57 ref.)

Induction of experimental autoimmune anterior uveitis by a self-antigen: melanin complex without adjuvant. Bora NS, et al. **Invest Ophthalmol Vis Sci** 1997 Sep;38(10):2171-5

A purinergic hypothesis for immunomodulation. Di Virgilio F, et al. **Ital J Biochem** 1996 Dec;45(4):195-203 (42 ref.)

Immunomodulatory activities of whey fractions in efferent prefemoral lymph of sheep. Wong CW, et al. **J Dairy Res** 1996 May;63(2):257-67

Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. Iwasaki A, et al. **J Immunol** 1997 May 15; 158(10):4591-601

Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. Tempero RM, et al. **J Immunol** 1997 Feb 1;158(3):1377-82

Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide. Corvaïa N, et al. **J Infect Dis** 1997 Sep;176(3):560-9

Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. Katz JM, et al. **J Infect Dis** 1997 Feb;175(2):352-63

Optimal dose of enterococcal preparation (FK-23) supplemented perorally for stimulation of leukocyte reconstitution in dogs treated with cyclophosphamide. Kanasugi H, et al. **J Vet Med Sci** 1996 Jun;58(6):563-5

Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. Hancock GE, et al. **J Virol** 1996 Nov;70(11):7783-91

New developments in adjuvants. Donnelly JJ. **Mech Ageing Dev** 1997 Feb;93(1-3):171-7 (17 ref.)

Increasing the immunogenicity of a trivalent influenza virus vaccine with adjuvant-active nonionic block copolymers for potential use in the elderly. Newman MJ, et al. **Mech Ageing Dev** 1997 Feb;93(1-3):189-203

Differential immunologic modulatory effects of tetrahydrocannabinol as a function of age. Ramarathinam L, et al. **Mech Ageing Dev** 1997 Jun;96(1-3):117-26

Expression of Neisseria meningitidis class 1 porin as a fusion protein in Escherichia coli: the influence of liposomes and adjuvants on the production of a bactericidal immune response. Ward SJ, et al. **Microb Pathog** 1996 Dec; 21(6):499-512

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants [see comments] Roman M, et al. **Nat Med** 1997 Aug;3(8):849-54. Comment in: Nat Med 1997 Aug;3(8):829-31.

Fever and production of cytokines in response to repeated injections of muramyl dipeptide in guinea-pigs. Roth J, et al. **Pflugers Arch** 1997 Sep;434(5):525-33

Investigation of silicone oil and fumed silica in an adjuvant animal model. Picha GJ, et al. **Plast Reconstr Surg** 1997 Sep;100(3):643-52

Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant. Bengtsson KL, et al. **Vaccine** 1996 Jun;14(8):753-60

Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. del Guercio MF, et al. **Vaccine** 1997 Mar;15(4):441-8

Immune responses following cocktails of inactivated measles vaccine and Arachis hypogaea L. (groundnut) or Cocos nucifera L. (coconut) oils adjuvant. Eghafona NO. **Vaccine** 1996 Dec;14(17-18):1703-6

Protection of cattle against Fasciola hepatica infection by vaccination with glutathione S-transferase. Morrison CA, et al. **Vaccine** 1996 Dec;14(17-18):1603-12

Adjuvant effect of biodegradable poly(DL-lactic acid) granules capable for antigen release following intraperitoneal injection. Nakaoka R, et al. **Vaccine** 1996 Dec;14(17-18):1671-6

Antibody responses and protection in mice immunized orally against influenza virus. Takase H, et al. **Vaccine** 1996 Dec; 14(17-18):1651-6

Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Williamson ED, et al. **Vaccine** 1996 Dec;14(17-18):1613-9

Comparative efficacy of Freund's and Montanide ISA50 adjuvants for the immunisation of goats against heartwater with inactivated Cowdria ruminantium. Martinez D, et al. **Vet Parasitol** 1996 Dec 31;67(3-4):175-84

[Stimulation of synthesis of secretory immunoglobulin A in the lung by oral immunization: an approach with therapeutic relevance?] Kofler N, et al. **Wien Klin Wochenschr** 1996;108(14):432-7 (Eng. Abstr.) **(Ger)**

[The new vaccines and immunologic response (and II). The antigenic presentation. Adjuvants as inducers of inducer T-lymphocyte cell-mediated response] Villarrubia VG, et al. **Med Clin (Barc)** 1996 Jun 29;107(5):185-96 (162 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Linkup of a fast protein liquid chromatography system with a stirred thermostated cell for sterile preparation of liposomes by the proliposome-liposome method: application to encapsulation of antibiotics, synthetic peptide immunomodulators, and a photosensitizer. Turánek J, et al. **Anal Biochem** 1997 Jul 1;249(2):131-9

A streptococcal preparation (OK-432) enhances monoclonal antibody NCC-ST-421 cytotoxicity against human colon cancer. Kawano Y, et al. **Anticancer Res** 1997 Jul-Aug; 17(4A):2449-53

Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections. Mirchamsy H, et al. **Biologicals** 1996 Dec;24(4):343-50

Transfer technique for minimizing waste of sonified adjuvant emulsions. Spack EG, et al. **Biotechniques** 1996 Jan; 20(1):28-30

Lenograstim administration to HLA-identical donor-recipient pairs to accelerate marrow recovery post-transplant. Atkinson K, et al. **Bone Marrow Transplant** 1997 Jan;19(1):15-21

Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study. López-Jiménez J, et al. **Bone Marrow Transplant** 1997 Mar;19(5):429-34

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma. Ahmed FY, et al. **Br J Cancer** 1996 Oct;74(7):1109-13

Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. Kirkwood JM, et al. **Cancer Immunol Immunother** 1997 May; 44(3):137-49

A non-specific defence inducer in preventing clinical signs of infectious bovine rhinotracheitis in calves. Castrucci G, et al. **Comp Immunol Microbiol Infect Dis** 1996 Jun; 19(3):163-9

Targeting of drugs to cell surface receptors. Říhová B. **Crit Rev Biotechnol** 1997;17(2):149-69 (147 ref.)

Adjuvants and immunostimulants for enhancing vaccine potency in fish. Anderson DP. **Dev Biol Stand** 1997; 90:257-65 (41 ref.)

BCG update: intravesical therapy. Martínez-Piñeiro JA, et al. **Eur Urol** 1997;31 Suppl 1:31-41 (69 ref.)

Oral bropirimine immunotherapy of rodent prostate cancer. Sarosdy MF. **Eur Urol** 1997;31 Suppl 1:5-9

Enhancement of host resistance to microbial infections in mice fed a high fat diet by Lactobacillus casei cells. Watanabe T, et al. **Hiroshima J Med Sci** 1996 Jun; 45(2):63-8

The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide. Partidos CD, et al. **Immunology** 1996 Dec;89(4):483-7

Granulocyte-macrophage colony-stimulating factor given as an adjuvant to persons not responding to hepatitis B vaccine [letter] Carlsson T, et al. **Infection** 1997 Mar-Apr; 25(2):129

Effects of monophosphoryllipid-A on the immunization of mice with keyhole limpet hemocyanin- and muramyldipeptide-ganglioside Gfpt1 conjugates. Jennemann R, et al. **J Biochem (Tokyo)** 1996 Feb; 119(2):378-84

Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. Centanni S, et al. **J Chemother** 1997 Aug;9(4):273-8

Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy [letter] O'Connell MJ, et al. **J Clin Oncol** 1996 Oct;14(10):2887

Role of gamma delta TCR+ lymphocytes in the augmented resistance of trehalose 6,6'-dimycolate-treated mice to influenza virus infection. Hoq MM, et al. **J Gen Virol** 1997 Jul;78 (Pt 7):1597-603

Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. Agren LC, et al. **J Immunol** 1997 Apr 15;158(8):3936-46

Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. Jankovic D, et al. **J Immunol** 1997 Sep 1;159(5):2409-17

Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. Porgador A, et al. **J Immunol** 1997 Jan 15;158(2):834-41

Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines. Sarkar K, et al. **J Immunol** 1997 Jun 1; 158(11):5357-65

Thymopentin loaded microsphere preparation by w/o/w emulsion technique: in vitro/ex vivo evaluation. Conti B, et al. **J Microencapsul** 1997 May-Jun;14(3):303-10

Production of BCG alginate-PLL microcapsules by emulsification/internal gelation. Esquisabel A, et al. **J Microencapsul** 1997 Sep-Oct;14(5):627-38

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria [see comments] Edan G, et al. **J Neurol Neurosurg Psychiatry** 1997 Feb;62(2):112-8. Comment in: ACP J Club 1997 Jul-Aug;127(1):12.

Education and self-management of interferon beta-1b therapy for multiple sclerosis. Keating MM, et al. **J Neurosci Nurs** 1996 Dec;28(6):350-2, 357-8

Controlled delivery of antigens and adjuvants in vaccine development. Zhao Z, et al. **J Pharm Sci** 1996 Dec; 85(12):1261-70 (185 ref.)

A 12 versus 6-week course of bacillus Calmette-Guerin prophylaxis for the treatment of high risk superficial bladder cancer. Gruenwald IE, et al. **J Urol** 1997 Feb; 157(2):487-91

Palliative effect of intravesical bacillus Calmette-Guerin in elderly patients with advanced bladder carcinoma. Holmäng S, et al. **J Urol** 1997 Sep;158(3 Pt 1):812-3

Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy [see comments] Hurle R, et al. **J Urol** 1996 Nov;156(5):1602-5. Comment in: J Urol 1996 Nov;156(5):1609-10.

Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial. Uehling DT, et al. **J Urol** 1997 Jun;157(6):2049-52

Enhancement of respiratory immunity to Pasteurella multocida by cholera toxin in rabbits. Suckow MA, et al. **Lab Anim** 1996 Apr;30(2):120-6

Effect of a novel saponin adjuvant derived from Quillaja saponaria on the immune response to recombinant hepatitis B surface antigen. So HS, et al. **Mol Cells** 1997 Apr 30; 7(2):178-86

ADJUVANTS, IMMUNOLOGIC

Survival and quality of life in HIV-positive patients treated with a polyantigenic immunomodulator. Colón JI, et al. **P R Health Sci J** 1997 Mar;16(1):9-14

Influence of adjuvants on murine immune responses against the C-terminal 19 kDa fragment of Plasmodium vivax merozoite surface protein-1 (MSP-1). Yang C, et al. **Parasite Immunol** 1996 Nov;18(11):547-58

Preparation of liposome formulations containing immunomodulatory peptides. Panico A, et al. **Pharm Acta Helv** 1997 Feb;72(1):1-10

Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity. Baldridge JR, et al. **Vaccine** 1997 Mar;15(4):395-401

International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants. Barnett PV, et al. **Vaccine** 1996 Sep;14(13):1187-98

A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Cryz SJ, et al. **Vaccine** 1996 Oct;14(14):1381-3

A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization. de Geus B, et al. **Vaccine** 1997 Jul;15(10):1110-3

A randomized, placebo-controlled study of oral cimetidine as an immunopotentiator of parenteral immunization with a group B meningococcal vaccine. Drabick JJ, et al. **Vaccine** 1997 Jul;15(10):1144-8

The use of oral dehydroepiandrosterone sulfate as an adjuvant in tetanus and influenza vaccination of the elderly. Evans TG, et al. **Vaccine** 1996 Nov;14(16):1531-7

Oral administration of a bacterial immunomodulator enhances the immune response to cholera toxin. Fló J, et al. **Vaccine** 1996 Aug;14(12):1167-73

Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Hashigucci K, et al. **Vaccine** 1996 Feb; 14(2):113-9

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Lawrence GW, et al. **Vaccine** 1997 Feb;15(2):176-8

Oral application of romurtide, a synthetic muramyl dipeptide derivative, stimulates nonspecific resistance to microbial infections and hematopoiesis in mice. Namba K, et al. **Vaccine** 1996 Aug;14(12):1149-53

[Immune modulation in multiple sclerosis: linomide (published erratum appears in Nervenarzt 1996 Oct;67(10):885)] Weilbach EX, et al. **Nervenarzt** 1996 Aug; 67(8):701-5 (48 ref.) **(Ger)**

[JOMOL—immunostimulation and rejection of tumor cells?] Allewelt MC, et al. **Schweiz Rundsch Med Prax** 1997 May 14;86(20):856-60 (29 ref.) (Eng. Abstr.) **(Ger)**

[Drug therapy of activated arthrosis. On the effectiveness of an enzyme mixture versus diclofenac] Singer F, et al. **Wien Med Wochenschr** 1996;146(3):55-8 (Eng. Abstr.) **(Ger)**

[Immunomodulatory effect of daily low-dose cisplatin treatment] Nakagomi H, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):323-7 (Eng. Abstr.) **(Jpn)**

[The effect of herbal medicines on the immunodeficient animals by injecting cancer chemotherapeutic agent-special reference to age related recovery of the function] Li AL, et al. **Kansenshogaku Zasshi** 1996 Jul;70(7):717-26 (Eng. Abstr.) **(Jpn)**

[Adjuvant treatment in operable colonic and rectal cancer. A new possibility] Tveit KM. **Tidsskr Nor Laegeforen** 1997 Aug 30;117(20):2991-2 **(Nor)**

[Selected immune response parameters in respiratory tract infections in mice—effect of combined treatment with tienamycin and coparvax] Korczak E, et al. **Pneumonol Alergol Pol** 1996;64(5-6):303-8 (Eng. Abstr.) **(Pol)**

[Approaches to perfection of Reaferon therapy in hepatitis B] Korochkina OV. **Klin Med (Mosk)** 1996;74(4):22-3 **(Rus)**

[The effect of vitamins on the natural body resistance of patients with malignant lymphomas] Kindzel'skiĭ LP, et al. **Lik Sprava** 1995 Sep-Dec;(9-12):164-6 **(Rus)**

[Importance of toxicological studies in animals for elaboration of pathogenetic therapy of hydrazine intoxication] Baryshnikov II. **Med Tr Prom Ekol** 1997;(6):22-5 (Eng. Abstr.) **(Rus)**

[Indications for the use of tactivin in the combined treatment of phlegmons of the maxillofacial area] Drobyshev VIu, et al. **Stomatologiia (Mosk)** 1996;75(4):27-30 (Eng. Abstr.) **(Rus)**

[The antifungal and immunomodulating lymphotropic therapy of candidiasis of the oral mucosa] Shumskiĭ AV, et al. **Stomatologiia (Mosk)** 1996;75(4):17-9 (Eng. Abstr.) **(Rus)**

[Lymphotropic therapy with trental in the treatment of chronic herpetic stomatitis] Shumskiĭ AV. **Stomatologiia (Mosk)** 1997;76(1):15-7 (Eng. Abstr.) **(Rus)**

[Thymogen in the treatment of type-1 diabetes mellitus] Zhuk EA, et al. **Ter Arkh** 1996;68(10):12-4 (Eng. Abstr.) **(Rus)**

[Experience in the use of viferon suppositories in young children with juvenile respiratory papillomatosis (preliminary report)] Onufrieva EK, et al. **Vestn Otorinolaringol** 1996 Jul-Aug;(4):32-3 (Eng. Abstr.) **(Rus)**

[A new therapeutic-prophylactic product with an immunomodulating additive] Borovskaia GA, et al. **Vopr Pitan** 1996;(4):28-30 **(Rus)**

[Response of lymphocytes and cytokines in patients with superficial bladder cancer treated with 1 mg of BCG vaccine instillations] Rivera P, et al. **Actas Urol Esp** 1996 Oct;20(9):812-7 (Eng. Abstr.) **(Spa)**

[Transference factor in moderate and severe atopic dermatitis] Navarro Cruz D, et al. **Rev Alerg Mex** 1996 Sep-Oct;43(5):116-23 (Eng. Abstr.) **(Spa)**

[The effect of tactivin and the intraduodenal administration of drug mixtures on the efficacy of the therapy of duodenal peptic ulcer] Katerenchuk ip. **Lik Sprava** 1996 Mar-Apr; (3-4):60-3 (Eng. Abstr.) **(Ukr)**

[The initial experience of using the preparation Ukrain in treating cancer patients in Ukraine] Zemskov VS, et al. **Lik Sprava** 1996 Jan-Feb;(1-2):158-61 (Eng. Abstr.) **(Ukr)**

ADVERSE EFFECTS

Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature. Weinberg JM, et al. **Acta Derm Venereol** 1997 Mar;77(2):146-8

Liver toxicity in a nephrotic patient treated with levamisole [letter; comment] Bulugahapitiya DT. **Arch Dis Child** 1997 Mar;76(3):289. Comment on: Arch Dis Child 1996 Oct;75(4):355-6.

Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Schwid SR, et al. **Arch Neurol** 1997 Sep;54(9):1169-90

An analytical review of silicone immunology [see comments] Marcus DM. **Arthritis Rheum** 1996 Oct;39(10):1619-26 (75 ref.). Comment in: Arthritis Rheum 1996 Oct;39(10):1615-8.

Oral tuberculosis following autologous bone marrow transplantation for Hodgkin's disease with interleukin-2 and alpha-interferon immunotherapy. Toren A, et al. **Bone Marrow Transplant** 1996 Jul;18(1):209-10

A pityriasis rosea-like eruption secondary to bacillus Calmette-Guérin therapy for bladder cancer. Honl BA, et al. **Cutis** 1996 Jun;57(6):447-50

Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis. Feldmann R, et al. **Dermatology** 1997;195(1):52-3

Primary inoculation tuberculosis after immunotherapy for malignant melanoma with BCG vaccine. Caplan SE, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):783-5

An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. Kuniyuki S, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):303-4 (15 ref.)

Silicone gel and octamethylcyclotetrasiloxane (D4) enhances antibody production to bovine serum albumin in mice. Nicholson JJ 3rd, et al. **J Biomed Mater Res** 1996 Jul; 31(3):345-53

Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy. Olencki T, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jan; 19(1):69-80

Granulomatous mass in a nonrefluxing renal unit after bacillus Calmette-Guerin therapy for bladder cancer. Siskron FT 4th, et al. **J Urol** 1997 Sep;158(3 Pt 1):882-3

Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. Vegt PD, et al. **J Urol** 1997 Apr;157(4):1246-9

Melatonin and the immune-hematopoietic system therapeutic and adverse pharmacological correlates. Maestroni GJ, et al. **Neuroimmunomodulation** 1996 Nov-Dec;3(6):325-32 (66 ref.)

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Andersen O, et al. **Neurology** 1996 Oct;47(4):895-900

Evaluation of the safety of cantastim in normal humans. Olinescu A, et al. **Roum Arch Microbiol Immunol** 1996 Jul-Sep;55(3):183-92

Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. LaFontaine PD, et al. **Urology** 1997 Mar;49(3):363-6

[Severe necrosis during treatment with interferon beta-1b (letter)] Albani C, et al. **Minerva Med** 1997 Jun;88(6):271-2 **(Ita)**

[Granulomatous prostatitis as a complication of BCG intravesical instillation. Report of a case] Luján Galán M, et al. **Arch Esp Urol** 1996 Nov;49(9):979-81 (Eng. Abstr.) **(Spa)**

ANALYSIS

The use of reporter antigens in the popliteal lymph node assay to assess immunomodulation by chemicals. Albers R, et al. **Toxicol Appl Pharmacol** 1997 Mar;143(1):102-9

Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens [published erratum appears in Vaccine 1996 Jun;14(8):1] Gupta RK, et al. **Vaccine** 1996 Feb; 14(3):219-25

BIOSYNTHESIS

Expression of an immunomodulatory protein known as progesterone induced blocking factor (PIBF) does not correlate with first trimester spontaneous abortions in progesterone supplemented women. Check JH, et al. **Am J Reprod Immunol** 1997 Apr;37(4):330-4

Identification of cells secreting a thymostimulin-like substance and examination of some histoenzymatic pathways in aging avian primary lymphatic organs: I. thymus. Aita M, et al. **Eur J Histochem** 1995;39(4):289-300

Synthesis and immunostimulant activity of novel analogs of human casein fragment (54-59). Sahai R, et al. **Immunopharmacol Immunotoxicol** 1996 Nov;18(4):511-28

Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. Knoefel B, et al. **J Interferon Cytokine Res** 1997 Feb;17(2):95-102

A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. Szekeres-Bartho J, et al. **J Reprod Immunol** 1996 Aug;31(1-2):81-95

BLOOD

Determination of amiprilose in human plasma by high-performance liquid chromatography with fluorimetric detection. Wu ST, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):149-56

Plasma protein binding of levamisole in several species. Sahagún A, et al. **Methods Find Exp Clin Pharmacol** 1997 Apr;19(3):185-7

CHEMICAL SYNTHESIS

Fused pyrrolo[2,3-c]carbazol-6-ones: novel immunostimulants that enhance human interferon-gamma activity. Hudkins RL, et al. **J Med Chem** 1997 Sep 12; 40(19):2994-6

Synthesis and activity of 6-substituted purine linker amino acid immunostimulants. Zacharie B, et al. **J Med Chem** 1997 Aug 29;40(18):2883-94

Synthetic S-(2,3-dihydroxypropyl)-cysteinyl peptides derived from the N-terminus of the cytochrome subunit of the photoreaction centre of Rhodopseudomonas viridis enhance murine splenocyte proliferation. Metzger JW, et al. **J Pept Sci** 1995 May-Jun;1(3):184-90

CHEMISTRY

Fip-vvo, a new fungal immunomodulatory protein isolated from Volvariella volvacea. Hsu HC, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):557-65

Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity. Petrov RV, et al. **Biopolymers** 1997;43(2):139-46 (25 ref.)

Parainfluenza-3-virus infection enhances allergic sensitization in the guinea-pig. Riedel F, et al. **Clin Exp Allergy** 1996 May;26(5):603-9

Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Bauer L, et al. **Clin Exp Immunol** 1997 Mar; 107(3):536-41

Complete NMR structural elucidation of the capsular polysaccharide adjuvant from Klebsiella I-714. Adam O, et al. **Eur J Biochem** 1996 Oct 15;241(2):602-10

ISCOMs (immunostimulating complexes): the first decade. Barr IG, et al. **Immunol Cell Biol** 1996 Feb;74(1):8-25 (152 ref.)

Nucleic acid vaccination of sheep: Use in combination with a conventional adjuvanted vaccine against Taenia ovis. Rothel JS, et al. **Immunol Cell Biol** 1997 Feb;75(1):41-6

Functional consequences of the binding of MHC class II-derived peptides to MHC class II. Feili-Hariri M, et al. **Int Immunol** 1996 Dec;8(12):1857-65

Analysis of a monophosphoryl lipid A immunostimulant preparation from Salmonella minnesota R595 by high-performance liquid chromatography. Hagen SR, et al. **J Chromatogr A** 1997 Apr 11;767(1-2):53-61

Structural requirements for agonist activity of a murine interferon-gamma peptide. Szente BE, et al. **J Interferon Cytokine Res** 1996 Oct;16(10):813-7

Stabilized analogs of thymopentin. 1. 4,5-Ketomethylene pseudopeptides. DeGraw JI, et al. **J Med Chem** 1997 Jul 18;40(15):2386-97

Stabilized analogs of thymopentin. 2. 1,2- and 3,4-ketomethylene pseudopeptides. DeGraw JI, et al. **J Med Chem** 1997 Jul 18;40(15):2398-406

Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. Khanolkar AD, et al. **J Med Chem** 1996 Oct 25;39(22):4515-9

Preparation of influenza virosome vaccine with muramyldipeptide derivative B30-MDP. Ando S, et al. **J Microencapsul** 1997 Jan-Feb;14(1):79-90

Production of BCG alginate-PLL microcapsules by emulsification/internal gelation. Esquisabel A, et al. **J Microencapsul** 1997 Sep-Oct;14(5):627-38

Isomerization and formulation stability of the vaccine adjuvant QS-21. Cleland JL, et al. **J Pharm Sci** 1996 Jan; 85(1):22-8

Interferon- beta-1b (Betaseron): A model for hydrophobic therapeutic proteins. Lin LS, et al. **Pharm Biotechnol** 1996; 9:275-301 (62 ref.)

Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein-Barr virus iscoms. Dotsika E, et al. **Scand J Immunol** 1997 Mar;45(3):261-8

Selection of potent immunological adjuvants for vaccine construction. McElrath MJ. **Semin Cancer Biol** 1995 Dec; 6(6):375-85 (74 ref.)

OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant. Erdile LF, et al. **Vaccine** 1997 Jun;15(9):988–96

Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine. Frankenburg S, et al. **Vaccine** 1996 Jun;14(9):923–9

Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Newman MJ, et al. **Vaccine** 1997 Jun;15(9):1001–7

Novel adjuvants and vaccine delivery systems. Morein B, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):373–84

CLASSIFICATION

Adjuvants--a classification and review of their modes of action. Cox JC, et al. **Vaccine** 1997 Feb;15(3):248–56 (118 ref.)

GENETICS

The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Leclerc C, et al. **Cell Immunol** 1997 Aug 1;179(2):97–106

Toward genetic dissection of high and low antibody responsiveness in Biozzi mice. Puel A, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14742–6

HISTORY

The historical development of interferons as multiple sclerosis therapies. Johnson KP. **J Mol Med** 1997 Feb;75(2):89–94

ISOLATION & PURIFICATION

Immunomodulation and antitumor activity of polysaccharide-protein complex from the culture filtrates of a local edible mushroom, Tricholoma lobayense. Liu F, et al. **Gen Pharmacol** 1996 Jun;27(4):621–4

The isolation and characterization of an immunomodulatory and anti-tumor polysaccharide preparation from Flammulina velutipes. Leung MY, et al. **Immunopharmacology** 1997 Jan;35(3):255–63

Effect of a novel saponin adjuvant derived from Quillaja saponaria on the immune response to recombinant hepatitis B surface antigen. So HS, et al. **Mol Cells** 1997 Apr 30; 7(2):178–86

Macrophage modifying factor secreted by the tetrathyridia of Mesocestoides corti (Cestoda): monoclonal antibody to the modifying factor antagonizes its immunological activity. Kadian SK, et al. **Parasite Immunol** 1996 Feb; 18(2):65–70

Isolation and immunomodulatory effect of flavonol glycosides from Epimedium hunanense. Liang HR, et al. **Planta Med** 1997 Aug;63(4):316–9

METABOLISM

Metabolism of 4-[1-(2-fluoro-4-biphenylyl)ethyl]-2-methylaminothiazole (SM-8849) in rats. Yabuki M, et al. **Eur J Drug Metab Pharmacokinet** 1997 Jan-Mar; 22(1):25–33

Dimerization of the N-terminal amphipathic alpha-helix domain of the fungal immunomodulatory protein from Ganoderma tsugae (Fip-gts) defined by a yeast two-hybrid system and site-directed mutagenesis. Lin WH, et al. **J Biol Chem** 1997 Aug 8;272(32):20044–8

Synthesis of a new template with a built-in adjuvant and its use in constructing peptide vaccine candidates through polyoxime chemistry. Zeng W, et al. **J Pept Sci** 1996 Jan-Feb;2(1):66–72

Transport and metabolic pathway of thymocartin (TP4) in excised bovine nasal mucosa. Lang S, et al. **J Pharm Pharmacol** 1996 Nov;48(11):1190–6

PHARMACOKINETICS

Absorption kinetics of a 14C-labelled Escherichia coli extract after oral administration in mice. Burckhart MF, et al. **Arzneimittelforschung** 1997 Mar;47(3):325–8

Absorption, kinetics, antibody-bound and free serum determination of a 14C-labeled Escherichia coli extract after single oral administration in rats. van Dijk A, et al. **Arzneimittelforschung** 1997 Mar;47(3):329–34

Pharmacokinetics of thiamine derivatives especially of benfotiamine. Loew D. **Int J Clin Pharmacol Ther** 1996 Feb;34(2):47–50 (30 ref.)

Pharmacokinetics of osthole in rat plasma using high-performance liquid chromatography. Tsai TH, et al. **J Pharm Biomed Anal** 1996 Apr;14(6):749–53

Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients. Brocks DR, et al. **Pharm Res** 1996 May; 13(5):794–7

Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Meier W, et al. **Ther Immunol** 1995 Jun;2(3):159–71

In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Flarend RE, et al. **Vaccine** 1997 Aug-Sep;15(12-13):1314–8

PHARMACOLOGY

Inhibitory effect of vasoactive intestinal polypeptide and ketanserin on established allergic contact dermatitis in man. Bondesson L, et al. **Acta Derm Venereol** 1996 Mar; 76(2):102–6

Cyclophosphamide and interleukin-12 synergistically upregulate the acquisition of allergic contact dermatitis in the mouse. Maguire HC Jr. **Acta Derm Venereol** 1996 Jul; 76(4):277–9

Summing up, weak immunomodulating signals of Tahyna virus and immunomodulating drugs induce immunosuppression in mice. Semenova IB, et al. **Acta Virol** 1997 Apr;41(2):97–9

Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria. Kensil CR, et al. **Adv Exp Med Biol** 1996;404:165–72

VIP modulation of immune cell functions. De la Fuente M, et al. **Adv Neuroimmunol** 1996;6(1):75–91 (132 ref.)

Vasoactive intestinal peptide differentially modulates human immunoglobulin production. Kimata H. **Adv Neuroimmunol** 1996;6(1):107–15 (28 ref.)

Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors. Oberholtzer E, et al. **Adv Neuroimmunol** 1996;6(3):233–47

Immunoregulatory role of neurotransmitters. Qiu Y, et al. **Adv Neuroimmunol** 1996;6(3):223–31 (51 ref.)

Cordyceps sinensis as an immunomodulatory agent. Kuo YC, et al. **Am J Chin Med** 1996;24(2):111–25

Polysaccharide peptide (PSP) restores immunosuppression induced by cyclophosphamide in rats. Qian ZM, et al. **Am J Chin Med** 1997;25(1):27–35

Cardioprotection with ischemic preconditioning and MLA: role of adenosine-regulating enzymes? Przyklenk K, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1004–14

The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production. Szekeres-Bartho J, et al. **Am J Reprod Immunol** 1996 Apr;35(4):348–51

Effect of macrophage stimulation on collagen biosynthesis in the healing wound. Portera CA, et al. **Am Surg** 1997 Feb;63(2):125–31

Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo. Aman MJ, et al. **Ann Hematol** 1996 Nov;73(5):231–8

Bacterial immunomodulators affect programmed cell death of mouse spleen lymphocytes. Sinkora M, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:492–5

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Stüve O, et al. **Ann Neurol** 1996 Dec;40(6):853–63

Activation of human Kupffer cells by thymostimulin (TP-1) to produce cytotoxicity against human hepatocellular cancer. Balch G, et al. **Ann Surg Oncol** 1997 Mar; 4(2):149–55

Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents. Monteith DK, et al. **Anticancer Drug Des** 1997 Jul;12(5):421–32

Stimulation of the specific immune system by mistletoe extracts. Fischer S, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S33–7 (32 ref.)

Enhanced immunostimulation by novel platinum anticancer agents. Muenchen HJ, et al. **Anticancer Drugs** 1997 Apr; 8(4):323–8

Mistletoe therapy for human cancer: the role of the natural killer cells. Schink M. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S47–51 (50 ref.)

Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Stein GM, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S39–42

Improvement of intestinal toxicity of 5-fluorouracil by conagenin, a low molecular immunomodulator. Kawatsu M, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2937–41

Modulation by conagenin of inflammatory mediator productions in mice given 5-fluorouracil. Kawatsu M, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):917–22

Effects of coffee cherry on the activation of splenic lymphocytes in mice. Kobayashi T, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):913–6

Activation of multiple effector pathways of immune system by the antineoplastic immunostimulator acidic polysaccharide ginsan isolated from Panax ginseng. Lee YS, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):323–31

Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Matsumoto T, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):308–13

In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs. Viora M, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1294–7

Ginseng treatment enhances bacterial clearance and decreases lung pathology in athymic rats with chronic P. aeruginosa pneumonia. Song ZJ, et al. **APMIS** 1997 Jun;105(6):438–44

Effect of glucan immunomodulator on the immune response and larval burdens in mice with experimental toxocarosis. Soltys J, et al. **Appl Parasitol** 1996 Sep;37(3):161–7

Retinoic acids and dexamethasone alter cell-surface density of beta 2-integrins and ICAM-1 on human leukemic (HMC-1) mast cells. Babina M, et al. **Arch Dermatol Res** 1997 Jan;289(2):111–5

Influence of Uro-Vaxom on sIgA level in urine in children with recurrent urinary tract infections. Czerwionka-Szaflarska M, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(2-3):195–7

Seleno-organic compounds as immunostimulants: an approach to the structure-activity relationship. Inglot AD, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(1):67–75

Effect of a proline-rich polypeptide on IgG level in Chickens. Janusz M, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(1):23–6

Effect of bacterial extract, IRS-19, on the concentration of hydrogen peroxide and myeloperoxidase activity in nasal washings of patients with chronic bronchitis. Nowak D, et al. **Arch Immunol Ther Exp (Warsz)** 1997;45(1):67–72

Immunomodulatory activity of conformationally restricted peptides related to TGF-beta-2 90-99 sequence. Wieczorek Z, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(4):209–14

Increment of immune responses in mice perinatal stages after zinc supplementation. Lastra MD, et al. **Arch Med Res** 1997 Spring;28(1):67–72

Suppression of cytokine production of human memory T cells by roxithromycin. Hirohata S, et al. **Arerugi** 1995 Nov; 44(11):1322–30

Studies on the immunogenicity of an Escherichia coli extract after oral application in mice. Baier W, et al. **Arzneimittelforschung** 1997 Aug;47(8):980–5

Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract. Beuth J, et al. **Arzneimittelforschung** 1995 Nov;45(11):1240–2

Murine thymocyte proliferation, maturation and emigration in response to selenium. Stoffel B, et al. **Arzneimittelforschung** 1996 Aug;46(8):829–31

Effect of adjuvants on antibody responses of sheep immunised with recombinant pili from Dichelobacter nodosus. Walduck AK, et al. **Aust Vet J** 1996 Dec;74(6):451–5

Linomide increases plasma corticosterone in normal rats, but does not prevent the inhibitory action of IL-1 on beta-cells in vivo or ex vivo. Christensen UB, et al. **Autoimmunity** 1996;23(4):257–68

Influence of adjuvants on the induction of autoantibodies to the thyrotropin receptor. Seetharamaiah GS, et al. **Autoimmunity** 1996;24(4):205–15

Nanomolar concentrations of gangliosides stimulate primary humoral response. Dozmorov IM, et al. **Biochem Mol Biol Int** 1997 Jun;42(1):57–63

Immunomodulation and enhancement of antitumor activity by co-administration of 1,3-bis(2-chloroethyl)-1-nitrosourea and thymidine. Poo WJ, et al. **Biochem Pharmacol** 1997 Mar 7;53(5):705–13

Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. Zhao Q, et al. **Biochem Pharmacol** 1996 Nov 22;52(10):1537–44

Molecular mechanisms of immunomodulating effect of chorionic gonadotropin on T- and B-lymphocytes of intact spleen. Shirshev SV. **Biochemistry (Mosc)** 1997 May; 62(5):514–22

Effect of beta-glucans on the nitric oxide synthesis by peritoneal macrophage in mice. Ohno N, et al. **Biol Pharm Bull** 1996 Apr;19(4):608–12

Z-100, extracted from Mycobacterium tuberculosis strain Aoyama B, inhibits the development of collagen-induced arthritis in mice. Omata T, et al. **Biol Pharm Bull** 1997 Jun;20(6):694–7

Polysaccharides in fungi. XXXVII. Immunomodulating activities of carboxymethylated derivatives of linear (1-->3)-alpha-D-glucans extracted from the fruiting bodies of Agrocybe cylindracea and Amanita muscaria. Yoshida I, et al. **Biol Pharm Bull** 1996 Jan;19(1):114–21

Supplementation with selenium augments the functions of natural killer and lymphokine-activated killer cells. Kiremidjian-Schumacher L, et al. **Biol Trace Elem Res** 1996 Jun;52(3):227–39

Restoration of aging reduced immunity is possible with immunomodulators and is applicable to cancer treatment and prevention [editorial] Mathé G, et al. **Biomed Pharmacother** 1997;51(5):193–9 (58 ref.)

Bromocriptine has little direct effect on murine lymphocytes, the immunomodulatory effect being mediated by the suppression of prolactin secretion. Neidhart M. **Biomed Pharmacother** 1997;51(3):118–25

Ergot alkaloid glycosides with immunomodulatory activities. Křen V, et al. **Bioorg Med Chem** 1996 Jun;4(6):869–76

Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity. Petrov RV, et al. **Biopolymers** 1997;43(2):139–46 (25 ref.)

Rationale and clinical results of using leucocyte-derived immunosupportive therapies in HIV disease. Gottlieb AA, et al. **Biotherapy** 1996;9(1-3):27–31

Effect of sizofiran on regional lymph nodes in patients with head and neck cancer. Kano Y, et al. **Biotherapy** 1996; 9(4):257–62

Morphological study of cytotoxicity produced by PSK-induced polymorphonuclear leukocytes (PMNs) and Nocardia rubra cell wall skeleton. Kata H, et al. **Biotherapy** 1996;9(4):229–39

Improvement of glucose tolerance with immunomodulators on type 2 diabetic animals. Zhu XP, et al. **Biotherapy** 1996; 9(4):189–97

N-acetyl-L-cysteine exhibits antitumoral activity by increasing tumor necrosis factor alpha-dependent T-cell cytotoxicity. Delneste Y, et al. **Blood** 1997 Aug 1; 90(3):1124–32

Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's

lymphoma patients after autologous bone marrow transplantation. Lauria F, et al. **Bone Marrow Transplant** 1996 Jul;18(1):79–85

Ex vivo neutrophil function in response to three different doses of glycosylated rHuG–CSF (Lenograstim). Turzanski J, et al. **Br J Haematol** 1997 Jan;96(1):46–54

Crossover study of the haematological effects and pharmacokinetics of glycosylated and non–glycosylated G–CSF in healthy volunteers. Watts MJ, et al. **Br J Haematol** 1997 Aug;98(2):474–9

Myocardial protection after monophosphoryl lipid A: studies of delayed anti–ischaemic properties in rabbit heart. Baxter GF, et al. **Br J Pharmacol** 1996 Apr;117(8):1685–92

Immunoadhesins for immunomodulation of autoimmune and rheumatic disease [editorial] Isaacs JD. **Br J Rheumatol** 1997 Mar;36(3):305–7

Evidence for the involvement of catecholamines in the 2–DG–induced immunomodulatory effects in spleen. Chou SH, et al. **Brain Behav Immun** 1997 Jun;11(2):79–93

Effects of thymosin alpha1 on the development of amoeboid microglial cells in the corpus callosum of neonatal BALB/c and athymic mice. Htain WW, et al. **Brain Res** 1997 Apr 25;755(1):63–73

Immunosuppression by breast cancer associated p43–effect of immunomodulators. Rosen HR, et al. **Breast Cancer Res Treat** 1996;41(2):171–6

Interferon–beta and –gamma, but not tumor necrosis factor–alpha, demonstrate immunoregulatory effects on carcinoma cell lines infected with human papillomavirus. Bornstein J, et al. **Cancer** 1997 Mar 1;79(5):924–34

Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony–stimulating factors in neutropenic and nonneutropenic CD rats. Nohynek GJ, et al. **Cancer Chemother Pharmacol** 1997;39(3):259–66

Human retinoblastoma: in vitro differentiation and immunoglobulin superfamily antigen modulation by retinoic acid. Conway RM, et al. **Cancer Immunol Immunother** 1997 Jun;44(4):189–96

Hematopoietic augmentation by a beta–(1,4)–linked mannan. Egger SF, et al. **Cancer Immunol Immunother** 1996 Dec; 43(4):195–205

Levamisole regulates the proliferation of murine liver T cells through Kupffer–cell–derived cytokines. Johnkoski JA, et al. **Cancer Immunol Immunother** 1996 Dec;43(5):299–306

Tumor–associated antigen 90K activates myelomonocytic cell line THP–1. Altindag ZZ, et al. **Cancer Lett** 1996 Oct 1;107(1):143–8

Effect of dimerization of the D–glucose analogue of muramyl dipeptide on stimulation of macrophage–like cells. Murata J, et al. **Carbohydr Res** 1997 Jan 2;297(2):127–33

IL–4 and IL–13 modulate IL–10 release in endotoxin–stimulated murine peritoneal mononuclear phagocytes. Kambayashi T, et al. **Cell Immunol** 1996 Jul 10;171(1):153–8

Nonionic triblock copolymers facilitate delivery of exogenous proteins into the MHC class I and class II processing pathways. Ke Y, et al. **Cell Immunol** 1997 Mar 15;176(2):113–21

The immunomodulator AS–101 inhibits IL–10 release and augments TNF alpha and IL–1 alpha release by mouse and human mononuclear phagocytes. Strassmann G, et al. **Cell Immunol** 1997 Mar 15;176(2):180–5

Effect of isoprinosine on 3'–Azido–3'–deoxythymidine uptake and phosphorylation in human peripheral blood mononuclear cells. Riva C, et al. **Chemotherapy** 1996 May–Jun;42(3):192–8

Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells. Yoshimura T, et al. **Chemotherapy** 1996 Nov–Dec; 42(6):459–64

Expansion of restricted cellular immune responses to HIV–1 envelope by vaccination: IL–7 and IL–12 differentially augment cellular proliferative responses to HIV–1. Kim JH, et al. **Clin Exp Immunol** 1997 May;108(2):243–50

Methylprednisolone differentially regulates IL–10 and tumour necrosis factor (TNF) production during murine endotoxaemia. Marchant A, et al. **Clin Exp Immunol** 1996 Oct;106(1):91–6

Immunogenicity of HIV–1LAI gp160 and env peptides in squirrel monkey Saimiri sciureus using alumine and experimental adjuvants. Perraut R, et al. **Clin Exp Immunol** 1996 Dec;106(3):434–41

Immunomodulatory effects of linomide in animals immunized with immunopathogenic retinal antigens: dissociation between different immune functions. Shirkey BL, et al. **Clin Exp Immunol** 1997 Jun;108(3):539–44

Regulation of cytokine gene expression by adjuvants in vivo. Victoratos P, et al. **Clin Exp Immunol** 1997 Sep; 109(3):569–78

Interleukin–7 modulates intracytoplasmatic CD23 production and induces adhesion molecule expression and adhesiveness in activated CD4+CD23+ T cell subsets. Fratazzi C, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):261–70

Lymphocyte muscarinic cholinergic activity and PGE2 involvement in experimental Trypanosoma cruzi infection. Sterin–Borda L, et al. **Clin Immunol Immunopathol** 1996 Nov;81(2):122–8

Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Lin R, et al. **Clin Infect Dis** 1995 Dec;21(6):1439–49 (134 ref.)

Adjuvanticity of pGPL–Mc and LRS in the immune responses of monkeys to oral immunization with diphtheria and tetanus toxoids. Mirchamsy H, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):13–20

Selective potentiation of cytokine expression in human whole blood by murabutide, a muramyl dipeptide analogue. Darcissac EC, et al. **Cytokine** 1996 Aug;8(8):658–66

Glucan–induced disease resistance in tiger shrimp (Penaeus monodon). Song YL, et al. **Dev Biol Stand** 1997;90:413–21

A plasma protein isolated from brown shrimp (Penaeus californiensis) which enhances the activation of prophenoloxidase system by beta–1,3–glucan. Vargas–Albores F, et al. **Dev Comp Immunol** 1996 Sep–Oct; 20(5):299–306

Effects of adjuvant, dose and carrier pre–sensitisation on the immunisation efficacy of a GnRH analogue. Ferro VA, et al. **Drug Des Discov** 1996 Dec;14(3):179–95

Action of Ukrain, a cytostatic and immunomodulating drug, on effects of irradiation. Boyko VN, et al. **Drugs Exp Clin Res** 1996;22(3–5):167–71

Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570). Liepins A, et al. **Drugs Exp Clin Res** 1996;22(3–5):103–13

Is tolerance induction a possible mode of action of OM–89? Willis D, et al. **Drugs Exp Clin Res** 1995;21(6):207–10

Cytokine–containing liposomes as vaccine adjuvants. Lachman LB, et al. **Eur Cytokine Netw** 1996 Dec;7(4):693–8 (30 ref.)

Lack of effect of zinc supplementation on antipyrine clearance in alcoholic liver disease. Grønbaek K, et al. **Eur J Clin Pharmacol** 1996;49(5):397–9

Metabolism of 4–[1–(2–fluoro–4–biphenylyl)ethyl]–2–methylaminothiazole (SM–8849) in rats. Yabuki M, et al. **Eur J Drug Metab Pharmacokinet** 1997 Jan–Mar; 22(1):25–33

Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. Yeung JH, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct–Dec; 20(4):287–92

Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects. Barrios C, et al. **Eur J Immunol** 1996 Nov; 26(11):2666–70

Immunodominance of cytotoxic T lymphocyte epitopes co–injected in vivo and modulation by interleukin–12. Eberl G, et al. **Eur J Immunol** 1996 Nov;26(11):2709–16

Modulation of Apo–1/Fas (CD95)–induced programmed cell death in myeloma cells by interferon–alpha 2. Egle A, et al. **Eur J Immunol** 1996 Dec;26(12):3119–26

Interleukin–12 acts as an adjuvant for humoral immunity through interferon–gamma–dependent and –independent mechanisms. Metzger DW, et al. **Eur J Immunol** 1997 Aug; 27(8):1958–65

Regulation of interleukin–10 production by beta–adrenergic agonists. Suberville S, et al. **Eur J Immunol** 1996 Nov; 26(11):2601–5

Immune modulation with interleukin–4 and interleukin–10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Tipping PG, et al. **Eur J Immunol** 1997 Feb;27(2):530–7

Evaluation of the effect of microencapsulation and immuno–modulation on islet immunogenicity in vitro. Siebers U, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:140–2

Tamm–Horsfall protein inhibits binding of S– and P–fimbriated Escherichia coli to human renal tubular epithelial cells. Leeker A, et al. **Exp Nephrol** 1997 Jan–Feb; 5(1):38–46

5–Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler's virus. Lucchinetti CF, et al. **Exp Neurol** 1997 Sep;147(1):123–9

Endogenously produced peroxynitrite induces the oxidation of mitochondrial and nuclear proteins in immunostimulated macrophages. Szabó C, et al. **FEBS Lett** 1997 Jun 9; 409(2):147–50

Molecular analysis of the modulatory factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. Bouige P, et al. **FEMS Immunol Med Microbiol** 1996 Jan;13(1):71–9

Induction of an epitope–specific humoral immune response by lipopeptide–hapten conjugates: enhancement of the anti–melittin response by a synthetic T helper (Th)–cell epitope. Hoffmann P, et al. **FEMS Immunol Med Microbiol** 1997 Apr;17(4):225–34

Bacterial immunomodulator Olimunostim inhibits degranulation of mastocytes in vitro. Merkunová A, et al. **Folia Biol (Praha)** 1996;42(5):235–9

Immunomodulating activity of allopurinol in experimental lens–induced uveitis. Grus FH, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Feb;235(2):118–23

Immune stimulatory and anti–tumor properties of anti–CD3 and BAT monoclonal antibodies: a comparative study. Hardy B, et al. **Hum Antibodies** 1997;8(2):95–8

Augmentation of immune response by an analog of the antigenic peptide in a human T–cell clone recognizing mutated Ras–derived peptides. Yokomizo H, et al. **Hum Immunol** 1997 Jan;52(1):22–32

Binding of human leukocytes to fibronectin is augmented by an anti–CD44 mAb (TL–1) and blocked by another anti–CD44 mAb (Hermes–3) but not by anti–VLA–4/VLA–5 mAbs. Cao L, et al. **Immunobiology** 1996–97;196(5):504–12

Immunomodulatory effects of IL–7 on dengue virus–specific cytotoxic CD4+ T cell clones. Berrios V, et al. **Immunol Invest** 1996 May;25(3):231–40

Does silicone in any form have adjuvancy potential [letter] Brent J, et al. **Immunol Invest** 1997 Jun;26(4):505–8

Immunoregulatory effect of substance P in human eosinophil migratory function. El–Shazly AE, et al. **Immunol Invest** 1996 May;25(3):191–201

The effect of immunomodulation of stimulator antigen presenting cells on subsequent responder T–cell function. Chung SW, et al. **Immunol Lett** 1997 Mar;55(3):133–7

Antigen–induced unresponsiveness in contact sensitivity: association of depressed T lymphocyte proliferative responses with decreased interleukin 6 secretion. Dearman RJ, et al. **Immunol Lett** 1996 Apr;50(1–2):29–34

TPSg, an anti–human immunodeficiency virus (HIV–1) agent, isolated from the Cupressaceae Thuja occidentale L. (Arborvitae) enhances in vivo hemopoietic progenitor cells recovery in sublethally irradiated mice. Hassan HT, et al. **Immunol Lett** 1996 Apr;50(1–2):119–22

Chlorpromazine inhibits concanavalin A–induced liver injury independently of cytokine modulation. Ikeda K, et al. **Immunol Lett** 1997 Mar;55(3):127–31

Effect of the peptide of thymic origin (synthetic thymohexine–RKNVYR) on hemopoietic cell progenitors in intact and irradiated animals. Semina OV, et al. **Immunol Lett** 1996 Jul;51(3):137–40

The in vitro effect of Pidotimod on some immune functions in cancer patients. Di Renzo M, et al. **Immunopharmacol Immunotoxicol** 1997 Feb;19(1):37–51

Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals: the role of protein kinase–C. Heuser G, et al. **Immunopharmacol Immunotoxicol** 1997 Aug;19(3):291–312

Effect of DTC on humoral response of SRBC–immunized mice exposed to restraint stress. Comparison with calf thymus extract. Obmińska–Domoradzka B, et al. **Immunopharmacol Immunotoxicol** 1996 Aug;18(3):421–31

Spirulina platensis exposure enhances macrophage phagocytic function in cats. Qureshi MA, et al. **Immunopharmacol Immunotoxicol** 1996 Aug;18(3):457–63

Dietary Spirulina platensis enhances humoral and cell–mediated immune functions in chickens. Qureshi MA, et al. **Immunopharmacol Immunotoxicol** 1996 Aug; 18(3):465–76

Synthesis and immunostimulant activity of novel analogs of human casein fragment (54–59). Sahai R, et al. **Immunopharmacol Immunotoxicol** 1996 Nov;18(4):511–28

The immunosenescent phenotype in mice and humans can be defined by alterations in the natural immunity reversal by immunomodulation with oral AM3. Villarrubia VG, et al. **Immunopharmacol Immunotoxicol** 1997 Feb; 19(1):53–74

Immunomodulation by two potent analogs of met–enkephalin. Bajpai K, et al. **Immunopharmacology** 1997 Jan;35(3):213–20

Mirfentanil antagonizes morphine–induced suppression of splenic NK activity in mice. Carr DJ, et al. **Immunopharmacology** 1996 Aug;34(1):9–16

Vitamin A and retinoic acids immunomodulation on human gut lymphocytes. Elitsur Y, et al. **Immunopharmacology** 1997 Jan;35(3):247–53

Photofrin II induces cytokine secretion by mouse spleen cells and human peripheral mononuclear cells. Herman S, et al. **Immunopharmacology** 1996 Mar;31(2–3):195–204

The isolation and characterization of an immunomodulatory and anti–tumor polysaccharide preparation from Flammulina velutipes. Leung MY, et al. **Immunopharmacology** 1997 Jan;35(3):255–63

Haloperidol and spiperone potentiate murine splenic B cell proliferation. Liu Y, et al. **Immunopharmacology** 1996 Sep; 34(2–3):147–59

Restoration of immune responses in tumor–bearing mice by ONO–4007, an antitumor lipid A derivative. Matsumoto N, et al. **Immunopharmacology** 1997 Apr;36(1):69–78

Immunomodulating and articular protecting activities of a new anti–rheumatic drug, TAK–603. Ohta Y, et al. **Immunopharmacology** 1996 Aug;34(1):17–26

Immunomodulatory assays to study structure–activity relationships of thalidomide. Shannon EJ, et al. **Immunopharmacology** 1997 Jan;35(3):203–12

The immunomodulatory and antitumor activities of lectins from the mushroom Tricholoma mongolicum. Wang HX, et al. **Immunopharmacology** 1996 Mar;31(2–3):205–11

Activation of a mouse macrophage cell line by acemannan: the major carbohydrate fraction from Aloe vera gel. Zhang L, et al. **Immunopharmacology** 1996 Nov;35(2):119–28

Growth of transplanted tumours in mice treated with macrophages and their products. Stern K, et al. **In Vivo** 1995 Sep–Oct;9(5):479–88

Adjuvant effect of DEAE–dextran and tetanus toxoid on whole cell heat inactivated phenol preserved typhoid vaccine. Kaistha J, et al. **Indian J Pathol Microbiol** 1996 Oct;39(4):287–92

Immunomodulatory properties of porins of some members of the family Enterobacteriaceae. Alurkar V, et al. **Infect Immun** 1997 Jun;65(6):2382–8

Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Lindblad EB, et al. **Infect Immun** 1997 Feb;65(2):623–9

Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis. Dimitrijevic M,

et al. **Inflamm Res** 1996 Nov;45(11):550–6

Immunostimulatory effects of platinum compounds: correlation between sensitizing properties in vivo and modulation of receptor-mediated endocytosis in vitro. Schuppe HC, et al. **Int Arch Allergy Immunol** 1997 Feb; 112(2):125–32

The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production. Venkataprasad N, et al. **Int Arch Allergy Immunol** 1997 Sep;114(1):23–9

Linomide, an immunomodulator that inhibits Th1 cytokine gene expression. Arad G, et al. **Int Immunol** 1996 Oct; 8(10):1603–7

The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Wang SY, et al. **Int J Cancer** 1997 Mar 17; 70(6):699–705

Immunomodulation induced by synthetic peptides derived from tumor-rejection antigens. Perez-Diez A, et al. **Int J Dev Biol** 1996;Suppl 1:311S

Immunomodulatory activity of amphiphilic antimicrobials on mouse macrophages. Bukovský M, et al. **Int J Immunopharmacol** 1996 Jun-Jul;18(6–7):423–6

Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A. Funk JO, et al. **Int J Immunopharmacol** 1995 Dec; 17(12):1007–16

RU 41 740 (Biostim) and IL-4, or IL-13, have opposite effects on CD14, CD23, HLA-DR and HLA-DQ on monocytes. Garin L, et al. **Int J Immunopharmacol** 1996 Jan;18(1):69–74

Enhancement of in vivo production of IL-1 alpha and IL-6 in mice by Y-25510, a 1H-pyrazolo[3,4-b]pyridine-1 acetic acid derivative. Hisadome M, et al. **Int J Immunopharmacol** 1996 Jun-Jul;18(6–7):379–84

Modulation of immune responses by anabolic androgenic steroids. Hughes TK, et al. **Int J Immunopharmacol** 1995 Nov;17(11):857–63

Distinctive immunomodulating properties and interactivity with model membranes and cells of two homologous muramyl dipeptide derivatives differing by their lipophilicity. Kalyuzhin OV, et al. **Int J Immunopharmacol** 1996 Nov;18(11):651–9

Vesnarinone is a selective inhibitor of macrophage TNF(alpha) release. Kambayashi T, et al. **Int J Immunopharmacol** 1996 Jun-Jul;18(6–7):371–8

Augmentation of tumor immunity by 6-MPG, a water-soluble derivative of 6-mercaptopurine, in mice. Kashida T, et al. **Int J Immunopharmacol** 1996 May; 18(5):311–9

N-acetylglucosamine-containing muramyl peptides directly affect macrophages. Khaidukov SV, et al. **Int J Immunopharmacol** 1995 Nov;17(11):903–11

Amelioration of rat experimental arthritides by treatment with the alkaloid sinomenine. Liu L, et al. **Int J Immunopharmacol** 1996 Oct;18(10):529–43

OM-85 BV upregulates the expression of adhesion molecules on phagocytes through a CD 14-independent pathway. Marchant A, et al. **Int J Immunopharmacol** 1996 Apr; 18(4):259–62

Possible immunomodulating activities of carotenoids in in vitro cell culture experiments. Okai Y, et al. **Int J Immunopharmacol** 1996 Dec;18(12):753–8

Immunostimulating properties of the complexes of inosine derivatives. Poluektova L, et al. **Int J Immunopharmacol** 1995 Nov;17(11):941–7

Effects of the adjuvant MPL + TDM on tumor challenge in the B16 mouse melanoma model. Price JA 3rd, et al. **Int J Immunopharmacol** 1996 Feb;18(2):163–5

Positive and negative immunomodulation by opioid peptides. Roda LG, et al. **Int J Immunopharmacol** 1996 Jan; 18(1):1–16 (167 ref.)

Relationship between NO-synthase activity and TNF-alpha secretion in mouse macrophage lines stimulated by a muramyl peptide entrapped in nanocapsules. Seyler I, et al. **Int J Immunopharmacol** 1996 Jun-Jul;18(6–7):385–92

Relationship of aging and cytokines to the immunomodulation by delta-9-tetrahydrocannabinol on murine lymphoid cells. Snella E, et al. **Int J Immunopharmacol** 1995 Dec;17(12):1045–54

Upregulation of phagocytosis and candidicidal activity of macrophages exposed to the immunostimulant acemannan. Stuart RW, et al. **Int J Immunopharmacol** 1997 Feb; 19(2):75–82

Neurotropin inhibits accumulation of eosinophils induced by allergen through the suppression of sensitized T-cells. Yoshii H, et al. **Int J Immunopharmacol** 1995 Nov; 17(11):879–86

Fu-Ling, a Chinese herbal drug, modulates cytokine secretion by human peripheral blood monocytes. Yu SJ, et al. **Int J Immunopharmacol** 1996 Jan;18(1):37–44

beta-(1-->3, 1-->4) oat glucan enhances resistance to Eimeria vermiformis infection in immunosuppressed mice. Yun CH, et al. **Int J Parasitol** 1997 Mar;27(3):329–37

7th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators. Geneva, Switzerland, 19–21 May 1997. Abstracts. **Int J Tissue React** 1997;19(1–2):17–128

Lisofylline prevents leak, but not neutrophil accumulation, in lungs of rats given IL-1 intratracheally. Hybertson BM, et al. **J Appl Physiol** 1997 Jan;82(1):226–32

Argininosuccinate synthetase overexpression in vascular smooth muscle cells potentiates immunostimulant-induced NO production. Xie L, et al. **J Biol Chem** 1997 Jun 27; 272(26):16624–30

Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol. Lissoni P, et al. **J Biol Regul Homeost Agents** 1996 Jan-Mar; 10(1):27–30

Vesnarinone: a potential cytokine inhibitor. Sasayama S, et al. **J Card Fail** 1996 Sep;2(3):251–8 (52 ref.)

Immunomodulatory activity of beta-casein permeate medium fermented by lactic acid bacteria. Laffineur E, et al. **J Dairy Sci** 1996 Dec;79(12):2112–20

Immunomodulatory activities of Cedrela tubiflora leaf aqueous extracts. Benencia F, et al. **J Ethnopharmacol** 1995 Dec 15;49(3):133–9

Antimicrobial and immunological activity of ethanol extracts and fractions from Isopyrum thalictroides. Ivanovska N, et al. **J Ethnopharmacol** 1996 Nov;54(2–3):143–51

Immunomodulatory effects of NIM-76, a volatile fraction from Neem oil. SaiRam M, et al. **J Ethnopharmacol** 1997 Jan;55(2):133–9

Activity of a crude extract formulation in experimental hepatic amoebiasis and in immunomodulation studies. Sohni YR, et al. **J Ethnopharmacol** 1996 Nov;54(2–3):119–24

In vitro cytotoxicity and immunomodulating property of Rhaphidophora korthalsii. Wong KT, et al. **J Ethnopharmacol** 1996 May;52(1):53–7

Both L- and D-isomers of allotrap 2702 prolong cardiac allograft survival in mice. Gao L, et al. **J Heart Lung Transplant** 1996 Jan;15(1 Pt 1):78–87

Thymosin-alpha 1, but not interferon-alpha, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells. Moshier JA, et al. **J Hepatol** 1996 Dec;25(6):814–20

Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. Fujimoto T, et al. **J Immunol** 1997 Jun 15;158(12):5619–26

Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12. Gollob JA, et al. **J Immunol** 1996 Sep 1;157(5):1886–93

In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. Harvill ET, et al. **J Immunol** 1996 Oct 1;157(7):3165–70

Differential effect of the immunomodulator AS101 on B7-1 and B7-2 costimulatory molecules: role in the antitumoral effects of AS101. Kalechman Y, et al. **J Immunol** 1996 Jul 15;157(2):589–97

Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. Kalechman Y, et al. **J Immunol** 1997 Sep 15;159(6):2658–67

IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice. Khan IA, et al. **J Immunol** 1996 Sep 1;157(5):2103–8

Contrasting responses to multiple chemotactic stimuli in transendothelial migration: heterologous desensitization in neutrophils and augmentation of migration in eosinophils. Kitayama J, et al. **J Immunol** 1997 Mar 1;158(5):2340–9

IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. Roilides E, et al. **J Immunol** 1997 Jan 1; 158(1):322–9

Immunomodulatory effects of IL-12 on allergic lung inflammation depend on timing of doses. Sur S, et al. **J Immunol** 1996 Nov 1;157(9):4173–80

Altered T cell ligands derived from a major house dust mite allergen enhance IFN-gamma but not IL-4 production by human CD4+ T cells. Tsitoura DC, et al. **J Immunol** 1996 Sep 1;157(5):2160–5

Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. Visco V, et al. **J Immunol** 1996 Jul 15;157(2):956–62

Zinc enhances lipopolysaccharide-induced monokine secretion by alteration of fluidity state of lipopolysaccharide. Wellinghausen N, et al. **J Immunol** 1996 Oct 1;157(7):3139–45

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. Albertini MR, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):278–95

Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro. Fleming MD, et al. **J Immunother Emphasis Tumor Immunol** 1995 Oct; 18(3):147–55

MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. Traquina P, et al. **J Infect Dis** 1996 Dec;174(6):1168–75

Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. Zwingenberger K, et al. **J Inflamm** 1995–96;46(4):177–211 (215 ref.)

Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production. Fujisawa H, et al. **J Interferon Cytokine Res** 1996 Jul; 16(7):555–9

Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer. Schuler M, et al. **J Interferon Cytokine Res** 1996 Nov;16(11):903–10

Effect of recombinant bovine interleukin-1 beta in normal calves and in calves infected with bovine herpesvirus type 1. Van Kessel AG, et al. **J Interferon Cytokine Res** 1996 Nov;16(11):881–90

Current views on the pharmacological properties of the immunomodulator, lobenzarit disodium. González R, et al. **J Investig Allergol Clin Immunol** 1997 Mar-Apr;7(2):77–82 (49 ref.)

Modulation of nitric oxide production in RAW 264.7 cells by transforming growth factor-beta and interleukin-10: differential effects on free and encapsulated immunomodulator. Seyler I, et al. **J Leukoc Biol** 1997 Sep; 62(3):374–80

Fused pyrrolo[2,3-c]carbazol-6-ones: novel immunostimulants that enhance human interferon-gamma activity. Hudkins RL, et al. **J Med Chem** 1997 Sep 12; 40(19):2994–6

Stabilized analogs of thymopentin. 3. Evaluation of ketomethylene pseudopeptides for antiarthritic properties. Smith RL, et al. **J Med Chem** 1997 Jul 18;40(15):2407–11

Prolongation of murine cardiac allograft survival with vesnarinone. Hirozane T, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):67–76

Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. Bai XF, et al. **J Neuroimmunol** 1997 Jun; 76(1–2):177–84

beta-Interferon regulates the immunomodulatory activity of neonatal rodent microglia. Hall GL, et al. **J Neuroimmunol** 1997 Jan;72(1):11–9

Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. Lehmann D, et al. **J Neuroimmunol** 1997 Apr;74(1–2):102–10

Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis. Zhang GX, et al. **J Neuroimmunol** 1997 Mar;73(1–2):175–82

The immunomodulatory activity of peptides related to the DNA contacting loop of p53 protein. Bolewska-Pedyczak E, et al. **J Pept Sci** 1996 Sep-Oct;2(5):318–24

Synthetic S-(2,3-dihydroxypropyl)-cysteinyl peptides derived from the N-terminus of the cytochrome subunit of the photoreaction centre of Rhodopseudomonas viridis enhance murine splenocyte proliferation. Metzger JW, et al. **J Pept Sci** 1995 May-Jun;1(3):184–90

Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. Cleland JL, et al. **J Pharm Sci** 1996 Dec; 85(12):1350–7

Isomerization and formulation stability of the vaccine adjuvant QS-21. Cleland JL, et al. **J Pharm Sci** 1996 Jan; 85(1):22–8

Liposomal subunit vaccines: effects of lipid A and aluminum hydroxide on immunogenicity. Richards RL, et al. **J Pharm Sci** 1996 Dec;85(12):1286–9

Role of corticosterone in the enhancement of the antibody response after acute cocaine administration. Stanulis ED, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):284–91

Effect of melatonin and corticosteroid on in vitro cellular immune function in humans. Rogers N, et al. **J Pineal Res** 1997 Mar;22(2):75–80

Acceleration of granulocytic cell recovery in irradiated mice by a single subcutaneous injection of a heat-killed Lactobacillus casei preparation. Furuse M, et al. **J Radiat Res (Tokyo)** 1997 Jun;38(2):111–20

Synthetic trehalose dicorynomycolate (S-TDCM): behavioral effects and radioprotection. Landauer MR, et al. **J Radiat Res (Tokyo)** 1997 Mar;38(1):45–54

A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. Szekeres-Bartho J, et al. **J Reprod Immunol** 1996 Aug;31(1–2):81–95

Domon L, an immunopotentiating agent, acts as an NF-kappaB activator. Tanaka S, et al. **J Vet Med Sci** 1997 Jul;59(7):575–9

Antitumor effect of Streptococcus pyogenes by inducing hydrogen peroxide production. Higuchi Y. **Jpn J Cancer Res** 1996 Dec;87(12):1271–9

The cytocidal activity of OK-432-activated mononuclear cells against human glioma cells is partly mediated through the Fas ligand/Fas system. Toda K, et al. **Jpn J Cancer Res** 1996 Sep;87(9):972–6

Long-term melatonin supplementation does not recover the impairment of natural killer cell activity and lymphocyte proliferation in aging mice. Provinciali M, et al. **Life Sci** 1997;61(9):857–64

Pentoxifylline pretreatment enhances the oxidative burst activity of human peripheral blood mononuclear cells. Chang FY, et al. **Microbiol Immunol** 1996;40(10):787–90

Adjuvanticity of an ornithine-containing lipid of Flavobacterium meningosepticum as a candidate vaccine adjuvant. Kato H, et al. **Microbiol Immunol** 1997; 41(2):101–6

Neutralizing murine monoclonal anti-interleukin-10 antibodies enhance binding of antibodies against a different epitope. Sabat R, et al. **Mol Immunol** 1996 Oct; 33(14):1103–11

Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. O'Hagan DT, et al. **Mol Med Today** 1997 Feb;3(2):69–75 (47 ref.)

Chemotherapy and immunomodulation in the elderly. Fraschini F, et al. **Nephrol Dial Transplant** 1996;11 Suppl

9:31–3 (38 ref.)
The effect of interferon beta–1b on cytokine–induced adhesion molecule expression. Jiang H, et al. **Neurochem Int** 1997 Apr–May;30(4–5):449–53
Receptor biology of the melanocortins, a family of neuroimmunomodulatory peptides. Tatro JB. **Neuroimmunomodulation** 1996 Sep–Oct;3(5):259–84 (224 ref.)
Neuroimmunomodulation in immune privilege: role of neuropeptides in ocular immunosuppression. Taylor AW. **Neuroimmunomodulation** 1996 Jul–Aug;3(4):195–204 (101 ref.)
Interferon–beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein–specific, T–helper type 1 lymphocytes. Pette M, et al. **Neurology** 1997 Aug;49(2):385–92
Evaluation of dithiol chelating agents as potential adjuvants for anti–IL–2 receptor lead or bismuth alpha radioimmunotherapy. Jones SB, et al. **Nucl Med Biol** 1996 Feb;23(2):105–13
Activation of resident tissue–specific macrophages by swainsonine. Das PC, et al. **Oncol Res** 1995;7(9):425–33
KRN7000, a novel immunomodulator, and its antitumor activities. Kobayashi E, et al. **Oncol Res** 1995; 7(10–11):529–34
Enhancing effects of (2S,3S,4R)–1–O–(alpha–D–galactopyranosyl)–2–(N–hexacosanoylamino) –1,3,4–octadecanetriol (KRN7000) on antigen–presenting function of antigen–presenting cells and antimetastatic activity of KRN7000–pretreated antigen–presenting cells. Yamaguchi Y, et al. **Oncol Res** 1996;8(10–11):399–407
Antibabesial effect of the immunomodulator AS101 in mice: role of increased production of nitric oxide. Rosenblatt–Bin H, et al. **Parasite Immunol** 1996 Jun;18(6):297–306
Quantitative reverse transcription polymerase chain reaction shows that ethanol enhances interleukin–6 mRNA expression in cultured mesangial cells. Meleg–Smith S, et al. **Pathobiology** 1995;63(5):265–9
Oxytetracycline–mediated alteration of murine immunocompetence. Myers MJ, et al. **Pathobiology** 1995; 63(5):270–7
A comparative study of immunomodulation produced by in vitro exposure to delta opioid receptor agonist peptides. House RV, et al. **Peptides** 1996;17(1):75–81
Potential therapeutic indications for synthetic desmuramyl MDP analogue (LK–409). Kotnik V, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R235–6
Immunostimulating polysaccharides from Panax notoginseng. Gao H, et al. **Pharm Res** 1996 Aug;13(8):1196–200
Analgesic and immunomodulatory effects of codeine and codeine 6–glucuronide. Srinivasan V, et al. **Pharm Res** 1996 Feb;13(2):296–300
Immunopharmacological activity of aporphinoid alkaloid oxoglaucine. Ivanovska N, et al. **Pharmacol Res** 1997 Apr; 35(4):267–72
The effect of SM–8849 on experimental arthritis in mice. Nagai H, et al. **Pharmacology** 1996 Jun;52(6):377–86
Immunostimulating activity of Celosian, an antihepatotoxic polysaccharide isolated from Celosia argentea. Hase K, et al. **Planta Med** 1997 Jun;63(3):216–9
Immunomodulatory activity of disulphide bridged peptides related to lactoferrin immunosuppressive mini–domain. Wieczorek Z, et al. **Pol J Pharmacol** 1995 Sep–Oct; 47(5):451–5
Immunomodulatory activity of a potent thymopentin analog: disulphide bridged beta–mercaptopropionyl–arginyl–lysyl–aspartyl–valyl–tyrosyl–cysteine amide. Wieczorek Z, et al. **Pol J Pharmacol** 1996 Jan–Feb;48(1):31–8
Immunomodulation of murine experimental autoimmune encephalomyelitis by pertussis toxin: the protective activity, but not the disease–enhancing activity, can be attributed to the nontoxic B–oligomer. Ben–Nun A, et al. **Proc Assoc Am Physicians** 1997 Mar;109(2):120–5
Immunomodulation contributes to the anticancer activity of morinda citrifolia (noni) fruit juice. Hirazumi A, et al. **Proc West Pharmacol Soc** 1996;39:7–9
Immunomodulation and epidural anesthesia and analgesia. de Leon–Casasola OA. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):24–5 (16 ref.)
Interleukin–12: a proinflammatory cytokine with immunoregulatory functions [editorial] Trinchieri G, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):423–31 (42 ref.)
Stimulatory effects of polar glycopeptidolipids of Mycobacterium chelonae on murine haematopoietic stem cells and megakaryocyte progenitors. Vincent–Naulleau S, et al. **Res Immunol** 1997 Feb;148(2):127–36
Biochemical and cytogenetical study of the mycoplasmal antigen and of the cyclophosphamide action in mammalians, in vivo. The action of some immunomodulatory antioxidants. Dumitrescu M, et al. **Roum Arch Microbiol Immunol** 1996 Jul–Sep;55(3):225–39
Biological effects of the immunomodulator beta 1–3D polyglucose are strongly potentiated by conjugation to biodegradable microbeads. Seljelid R, et al. **Scand J Immunol** 1997 Jun;45(6):683–7
Extract of astragalus membranaceus and ligustrum lucidum does not prevent cyclophosphamide–induced myelosuppression. Khoo KS, et al. **Singapore Med J** 1995 Aug;36(4):387–90
Antiviral and immunomodulatory activities of ascorbic acid. Jariwalla RJ, et al. **Subcell Biochem** 1996;25:213–31 (92 ref.)
Immunomodulation by LFA3TIP, an LFA–3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Meier W, et al. **Ther Immunol** 1995 Jun;2(3):159–71
Single–organism model of host defense against infection: a novel immunotoxicologic approach to evaluate immunomodulatory drugs [see comments] Herzyk DJ, et al. **Toxicol Pathol** 1997 Jul–Aug;25(4):351–62. Comment in: Toxicol Pathol 1997 Jul–Aug;25(4):419–20.
Immunomodulatory and protective effects of N–acetylcysteine in mitogen–activated murine splenocytes in vitro. Omara FO, et al. **Toxicology** 1997 Jan 15; 116(1–3):219–26
The effects of cyclosporin A, dexamethasone and other immunomodulatory drugs on induced expression of IL–3, IL–4 and IL–8 mRNA in a human mast cell line. Warbrick EV, et al. **Toxicology** 1997 Jan 15;116(1–3):211–8
Moderate additive immunosuppressive effect of thalidomide combined with cyclosporin A in rat cardiac transplantation. Ostraat O, et al. **Transpl Immunol** 1996 Sep;4(3):241–6
Immunomodulatory effects of the alkaloid sinomenine in the high responder ACI–to–Lewis cardiac allograft model. Candinas D, et al. **Transplantation** 1996 Dec 27; 62(12):1855–60
Effect in supralethally irradiated rats of granulocyte colony–stimulating factor and lisofylline on hematopoietic reconstitution by syngeneic bone marrow or whole organ passenger leukocytes. Murase N, et al. **Transplantation** 1997 Jun 27;63(12):1840–3
Immunomodulatory properties of the metal chelators desferrioxamine and diethylenetriamine penta–acetic acid in vitro. Scholz M, et al. **Transplantation** 1996 Nov 15; 62(9):1371–4
Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants. Benne CA, et al. **Vaccine** 1997 Jun;15(9):1039–44
Adjuvants—a classification and review of their modes of action. Cox JC, et al. **Vaccine** 1997 Feb;15(3):248–56 (118 ref.)
Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration. Delmastro P, et al. **Vaccine** 1997 Aug;15(11):1276–85
Effect of MDP–Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus. Fukushima A, et al. **Vaccine** 1996 Apr; 14(6):485–91
The effects of adjuvants on CTL induction by V3:Ty–virus–like particles (V3–VLPs) in mice. Harris SJ, et al. **Vaccine** 1996 Jul;14(10):971–6
MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Higgins DA, et al. **Vaccine** 1996 Apr;14(6):478–84
The effect of Syntex adjuvant formulation (SAF–m) on humoral immunity to the influenza virus in the mouse. Hjorth RN, et al. **Vaccine** 1997 Apr;15(5):541–6
Effect of context and adjuvant on the immunogenicity of recombinant proteins and peptide conjugates derived from the polymorphic malarial surface antigen MSA2. Jones GL, et al. **Vaccine** 1996 Jan;14(1):77–84
Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV–1 replication in vitro. Krivorutchenko YL, et al. **Vaccine** 1997 Aug–Sep; 15(12–13):1479–86
Mechanisms of adjuvancy: I—Metal oxides as adjuvants. Naim JO, et al. **Vaccine** 1997 Aug;15(11):1183–93
Immunopharmacological activities of the nontoxic monophosphoryl lipid A of Porphyromonas gingivalis. Ogawa T, et al. **Vaccine** 1996 Jan;14(1):70–76
Evaluation of tolerability and antibody response after recombinant human granulocyte–macrophage colony–stimulating factor (rhGM–CSF) and a single dose of recombinant hepatitis B vaccine. Tarr PE, et al. **Vaccine** 1996 Sep;14(13):1199–204
Development of an adjuvant–active nonionic block copolymer for use in oil–free subunit vaccines formulations. Todd CW, et al. **Vaccine** 1997 Apr;15(5):564–70
Regulation of mucosal IgA responses in vivo: cytokines and adjuvants. Husband AJ, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):179–86
Immunostimulating effect of growth hormone: in–vivo administration of growth hormone in rainbow trout enhances resistance to Vibrio anguillarum infection. Sakai M, et al. **Vet Immunol Immunopathol** 1997 Jun; 57(1–2):147–52
Modulation of endotoxin–induced inflammation in the bovine teat using antagonists/inhibitors to leukotrienes, platelet activating factor and interleukin 1 beta. Waller KP. **Vet Immunol Immunopathol** 1997 Jul;57(3–4):239–51
Effects of purified bovine whey factors on cellular immune functions in ruminants. Wong CW, et al. **Vet Immunol Immunopathol** 1997 May;56(1–2):85–96
An apparent effect of immunopotentiation during late gestation on the postpartum reproductive performance of Nili–Ravi buffaloes (Bubalus bubalis). Qureshi ZI, et al. **Vet Res Commun** 1997 Jul;21(5):375–80
Effect of a paramunity inducer on reproductive performance of gilts. Kyriakis SC, et al. **Zentralbl Veterinarmed A** 1996 Oct;43(8):483–7
[Effect of lysostaphin on phagocyte function in burn mice] Huan J, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Jul;11(4):255–7 (Eng. Abstr.) **(Chi)**
[The effect of dynorphin A on intracellular cAMP and cGMP contents in spleen cells of burn rats and its relation to immune function] Ni X, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Jul;11(4):258–61 (Eng. Abstr.) **(Chi)**
[Study of the membrane oxidative response of phagocytes after treatment with marbofloxacin in healthy cattle] Spehner V, et al. **C R Seances Soc Biol Fil** 1996; 190(5–6):633–9 (Eng. Abstr.) **(Fre)**
[Role of the thymus and normal microbial flora on plasma fibronectin concentration in mice treated with immunomodulatory drugs] Anderlik P, et al. **Acta Pharm Hung** 1996 Jul;66(4):165–9 (Eng. Abstr.) **(Hun)**
[The effect of products of plant and microbial origin on phagocytic function and on the release of oxygen free radicals by mouse peritoneal macrophages] Dolganiuc A, et al. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan–Jun; 42(1–2):65–9 (Eng. Abstr.) **(Rum)**
[Immunomodulating, antioxidant and hepatoprotective action of the phytopreparation lochein] Konoplia EN, et al. **Antibiot Khimioter** 1997;42(7):12–5 (Eng. Abstr.) **(Rus)**
[Naphthoquinones as immunomodulators during intensive exertion] Rybnikov VN, et al. **Antibiot Khimioter** 1997; 42(3):6–10 (Eng. Abstr.) **(Rus)**
[The role of dopaminergic mechanism in the realization of immunostimulating effect of substance P and its analog] Cheído MA. **Biull Eksp Biol Med** 1997 Feb;123(2):135–7 **(Rus)**
[Reaction to antigenic information after treatment with elevated doses of angiogenin] Eliseeva LS, et al. **Biull Eksp Biol Med** 1997 Apr;123(4):427–30 **(Rus)**
[Effect of novel derivatives of muramyl dipeptide on the immune system] Kaliuzhin OV, et al. **Biull Eksp Biol Med** 1994 May;117(5):510–3 **(Rus)**
[The effect of vitamin D on the humoral and cellular immune response and functional activity of peritoneal macrophages] Pletsityĭ KD, et al. **Biull Eksp Biol Med** 1997 Jan; 123(1):63–5 **(Rus)**
[Immunocorrecting, antianemia, and adaptogenic effects of polysaccharides from Melilotus officinalis] Podkolzin AA, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):661–3 **(Rus)**
[Dynamics of changes in macrophage activity, metabolic activity of the liver, and level of cortisol in murine serum when administering bacterial immunostimulants] Sibiriak SV, et al. **Biull Eksp Biol Med** 1996 Feb;121(2):177–80 **(Rus)**
[Mechanism of immunomodulating effect of vitamin D: possible involvement of lipid peroxidation system] Pletsitnyĭ KD, et al. **Dokl Akad Nauk** 1996 Sep; 350(2):275–7 **(Rus)**
[The immunobiological properties of trimezon and levamisole on models of humoral and cell–mediated immunogenesis] Liubin GS, et al. **Eksp Klin Farmakol** 1997 Jan–Feb; 60(1):50–2 (Eng. Abstr.) **(Rus)**
[The immunomodulating action of retinol acetate and beta–carotene in benzylpenicillin–induced immunosuppression] Ushchev BS, et al. **Eksp Klin Farmakol** 1996 Mar–Apr;59(2):31–4 (Eng. Abstr.) **(Rus)**
[The effect of myelopid on the ultrastructural changes in the rat myocardium induced by an endotoxin] Kharlanova NG, et al. **Fiziol Zh** 1996;42(1–2):25–30 (Eng. Abstr.) **(Rus)**
[Enteral correction of homeostasis in acute pancreatitis] Penin VA, et al. **Khirurgiia (Mosk)** 1996;(2):8–11 (Eng. Abstr.) **(Rus)**
[Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)] Ivanov VT, et al. **Klin Med (Mosk)** 1997; 75(3):11–5 (45 ref.) **(Rus)**
[Experimental bases of the use of pharmacologic agents aimed at higher heat resistance of humans as means of individual protection] Makarov VI, et al. **Med Tr Prom Ekol** 1997; (5):35–8 (Eng. Abstr.) **(Rus)**
[The immunomodulating properties of the filtrates of Klebsiella culture broth and the nature of the immunomodulating factor] Borisova EV, et al. **Mikrobiol Z** 1996 Nov–Dec;58(6):55–62 (Eng. Abstr.) **(Rus)**
[Differential effect of glucosaminylmuramyl dipeptide on the phenotype of melanoma sublines with different metastatic potential] Valiakina TI, et al. **Mol Biol (Mosk)** 1996 Nov–Dec;30(6):1394–401 **(Rus)**
[Mechanism of the immunomodulating action of extracorporeally essentiale–modified syngeneic erythrocytes during strenuous exertion] Laskova IL, et al. **Patol Fiziol Eksp Ter** 1996 Apr–Jun;(2):27–30 (Eng. Abstr.) **(Rus)**
[Mechanism of immunologic homeostasis during administration of essentiale fo animals performing physical exercise] Laskova IL, et al. **Patol Fiziol Eksp Ter** 1996 Oct–Dec;(4):9–12 (Eng. Abstr.) **(Rus)**
[Antimicrobial and immunomodulatory activities of Lactobacillus acidophilus Ke–10] Zalashko MV, et al. **Prikl Biokhim Mikrobiol** 1997 May–Jun;33(3):305–9 (Eng. Abstr.) **(Rus)**
[The immunomodulating action of cyclosporin A in vitro and in vivo on the lymphocytes of patients with alveolitis] Kosmiadi GA, et al. **Probl Tuberk** 1996;(4):51–3 (Eng.

Abstr.) (Rus)
[The effect of thymogen on the chromosome aberration level in a culture of human peripheral blood lymphocytes] Rushkovskiĭ SR, et al. **Tsitol Genet** 1996 Sep–Oct; 30(5):81–5 (Eng. Abstr.) (Rus)
[The growth-stimulating and immunomodulating activity of culture media conditioned by transformed fibroblasts from serum-free lines] Pleskach VA, et al. **Tsitologiia** 1996; 38(6):616–29 (Eng. Abstr.) (Rus)
[Immunomodulating action of eubiotics] Lopatina TK, et al. **Vestn Ross Akad Med Nauk** 1997;(3):30–4 (Eng. Abstr.) (Rus)
[An experimental study of the effect of immunomodulators on the immune response to the anatoxin components of adsorbed DPT vaccine against a background of poisoning] Karal'nik BV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct;(5):56–9 (Eng. Abstr.) (Rus)
[The effect of immunomodulating doses of purified staphylococcal anatoxin on the spontaneous and mitogen-induced proliferation of mouse splenocytes] Semenova IB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Mar–Apr; (2):57–60 (Eng. Abstr.) (Rus)
[The effect of platelet-activating factor and its synthetic analogs on Ia-antigen expression by mouse peritoneal macrophages] Shebzukhov IuV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May–Jun; (3):114–7 (Eng. Abstr.) (Rus)
[The function of the granulocytic system during immobilization stress with immunostimulation] Sheĭko VI, et al. **Fiziol Zh** 1996;42(1–2):91–5 (Eng. Abstr.) (Ukr)
[The anti-immunodepressive action of kumiss made from cow's milk] Fedechko IM, et al. **Lik Sprava** 1995 Sep–Dec; (9–12):104–6 (Eng. Abstr.) (Ukr)

PHYSIOLOGY

Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy. Fernandez-Botran R, et al. **Adv Immunol** 1996;63:269–336 (325 ref.)
The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Bellinger DL, et al. **Adv Neuroimmunol** 1996;6(1):5–27 (171 ref.)
Immune modulators in the context of the ovulatory process: a role for interleukin-1. Adashi EY. **Am J Reprod Immunol** 1996 Mar;35(3):190–4 (49 ref.)
Modulation of the humoral immune response by placental secretory factors. Malan Borel I, et al. **Am J Reprod Immunol** 1996 Jun;35(6):529–33
One step ahead of the game: viral immunomodulatory molecules. Spriggs MK. **Annu Rev Immunol** 1996;14:101–30 (207 ref.)
Signaling pathway triggered by a short immunomodulating peptide on human monocytes. López-Zabalza MJ, et al. **Arch Biochem Biophys** 1997 Feb 15;338(2):136–42
Serotonin modulation of lymphocyte proliferation via 5-HT1A receptors in rainbow trout (Oncorhynchus mykiss). Ferriere F, et al. **Dev Comp Immunol** 1996 Jul–Aug;20(4):273–83
Interleukin-15 acts as an immunological co-adjuvant for liposomal antigen in vivo. Gursel M, et al. **Immunol Lett** 1997 Mar;55(3):161–5
Bcl-x and the regulation of survival in the immune system. Behrens TW, et al. **Immunol Res** 1997;16(2):149–60 (72 ref.)
IL-12: a key cytokine in immune regulation. Lamont AG, et al. **Immunol Today** 1996 May;17(5):214–7 (0 ref.)
Host genetic and adjuvant factors influence epitope specificity to a major recombinant grass allergen. Yang M, et al. **Int Arch Allergy Immunol** 1996 Oct;111(2):173–81
HIV type 1 Tat protein enhances activation-but not Fas (CD95)-induced peripheral blood T cell apoptosis in healthy individuals. Katsikis PD, et al. **Int Immunol** 1997 Jun;9(6):835–41
S-adenosylhomocysteine as a physiological modulator of Apo-1-mediated apoptosis. Ratter F, et al. **Int Immunol** 1996 Jul;8(7):1139–47
Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. Douni E, et al. **J Inflamm** 1995–96;47(1–2):27–38 (64 ref.)
Influence of mouse placental factors on in vitro antibody synthesis. Miranda S, et al. **J Reprod Immunol** 1996 May; 30(2–3):151–71
Teratogen-induced apoptosis may be affected by immunopotentiation. Toder V, et al. **J Reprod Immunol** 1996 May;30(2–3):173–85
Immunomodulative effects of bovine immunodeficiency-like virus (BIV)-infection and mixed infection of BIV and bovine leukemia virus on sheep. Hirai N, et al. **Jpn J Vet Res** 1996 Dec;44(3):153–63
The influence of IL12 on the development of Th1 and Th2 cells and its adjuvant effect for humoral immune responses. Germann T, et al. **Res Immunol** 1995 Sep–Oct; 146(7–8):481–6 (40 ref.)
The role of IL12 in modulating an established Th2 response in experimental leishmaniasis. Hondowicz B, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):560–5 (21 ref.)
IL12 in Candida albicans infections. Romani L, et al. **Res Immunol** 1995 Sep–Oct;146(7–8):532–8 (31 ref.)
Activity of IL12 as adjuvant in promoting Th1 and Th2 recall responses. Wolf SF, et al. **Res Immunol** 1995 Sep–Oct; 146(7–8):486–9 (26 ref.)
Vaccine adjuvants. Macy DW. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):206–11 (42 ref.)
[Mechanism of development of immunosuppression in acute renal insufficiency] Afanas'ev VA, et al. **Patol Fiziol Eksp Ter** 1997 Jul–Sep;(3):31–5 (Eng. Abstr.) (Rus)
[Regulation of expression of the surface structure of the lymphocyte membrane by purine compounds in health and in disease] Poriadin GV, et al. **Patol Fiziol Eksp Ter** 1997 Jan–Mar;(1):42–5 (82 ref.) (Rus)

THERAPEUTIC USE

Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials. Frank JA, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S173–5
Isoprenosine improves symptoms in young females with chronic vulvodynia [letter] Sand Petersen C, et al. **Acta Derm Venereol** 1996 Sep;76(5):404
Adjuvant therapy with hydrolytic enzymes in recurrent laryngeal papillomatosis. Mudrák J, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;527:128–30
Combined protective effect of an immunostimulatory bacterial preparation and rimantadine in experimental influenza A virus infection. Serkedjieva J, et al. **Acta Virol** 1997 Apr;41(2):65–70
The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. Merigan TC, et al. **AIDS** 1996 Feb; 10(2):159–65
Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP). Ballestrero A, et al. **Am J Clin Oncol** 1997 Jun;20(3):266–71
Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer. Michael M, et al. **Am J Clin Oncol** 1997 Jun;20(3):259–62
Phase II study of roquinimex in myelodysplastic syndrome. Rosenfeld CS, et al. **Am J Clin Oncol** 1997 Apr; 20(2):189–92
The effects of post-treatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs. Hasegawa N, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):928–36
The use of glucan as immunostimulant in the treatment of paracoccidioidomycosis. Meira DA, et al. **Am J Trop Med Hyg** 1996 Nov;55(5):496–503
Histamine-2 receptor antagonists as immunomodulators: new therapeutic views? Nielsen HJ. **Ann Med** 1996 Apr; 28(2):107–13 (122 ref.)
Pharmacologic myocardial preconditioning with monophosphoryl lipid A (MLA) reduces infarct size and stunning in dogs and rabbits. Elliott GT. **Ann N Y Acad Sci** 1996 Sep 30;793:386–99 (63 ref.)
Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria. Tzianabos AO, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:285–7
Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Leppert D, et al. **Ann Neurol** 1996 Dec;40(6):846–52
Clinical relevance of immunoactive mistletoe lectin-I. Beuth J. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S53–5 (19 ref.)
Viscum album L. preparation Isorel modifies the immune response in normal and in tumour-bearing mice. Jurin M, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S27–31
Lentinan potentiates immunity and prolongs the survival time of some patients. Matsuoka H, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2751–5
HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Yokoe T, et al. **Anticancer Res** 1997 Jul–Aug; 17(4A):2815–8
Is cimetidine effective for nongenital warts: a double-blind, placebo-controlled study [letter] Karabulut AA, et al. **Arch Dermatol** 1997 Apr;133(4):533–4
Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine. Ambriz Fernandez R, et al. **Arch Med Res** 1996 Spring;27(1):15–8
Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Mohr DC, et al. **Arch Neurol** 1997 May;54(5):531–3
Immunologic mechanisms of uveitis. New targets for immunomodulation. Whitcup SM, et al. **Arch Ophthalmol** 1997 Apr;115(4):520–5 (49 ref.)
Inhibition by streptococcal immunopotentiator OK432 of lymph-node metastasis in hamster cheek-pouch carcinoma with enhancement of tumour necrosis factor-alpha and interleukin-6 in serum. Nakajima J, et al. **Arch Oral Biol** 1996 May;41(5):513–6
Extracorporeal immunomodulation relevant to organ substitutions. Agishi T. **Artif Organs** 1996 Aug;20(8):917–21 (18 ref.)
Immune modulation associated with extracorporeal immunoadsorption treatments utilizing protein A/silica columns. Balint JP Jr. **Artif Organs** 1996 Aug;20(8):906–13
Current status in extracorporeal immunomodulation: immune disorders. Bosch T. **Artif Organs** 1996 Aug;20(8):902–5 (22 ref.)
Selective immunomodulation: utilization of CD29/VLA molecules. Morimoto C, et al. **Artif Organs** 1996 Aug; 20(8):828–31 (29 ref.)
Effect of adamantylamide dipeptide on reinfection resistance after primary infection eradication in experimental Schistosomiasis mansoni. Botros S, et al. **Arzneimittelforschung** 1996 Jan;46(1):74–8
Prospects and advances in hormonal immunomodulatory therapy. Jorgensen C, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):379–92 (84 ref.)
A polysaccharide-peptide complex from cultured mycelia of the mushroom Tricholoma mongolicum with immunoenhancing and antitumor activities. Wang HX, et al. **Biochem Cell Biol** 1996;74(1):95–100
Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Miller JS, et al. **Biol Blood Marrow Transplant** 1997 Apr;3(1):34–44
Dysfunctional monocytes from a patient with disseminated Mycobacterium kansasii infection are activated in vitro and in vivo by GM-CSF. Bermudez LE, et al. **Biotherapy** 1994; 8(2):135–42
Effect of Z-100, an immunomodulator extracted from human type tubercle bacilli, on the pulmonary metastases of Lewis lung carcinoma in attempt to regulate suppressor T cells and suppressor factor, IL-4. Emori Y, et al. **Biotherapy** 1996;9(4):249–56
The influence of age on transfer factor treatment of cellular immunodeficiency, chronic fatigue syndrome and/or chronic viral infections. Hana I, et al. **Biotherapy** 1996; 9(1–3):91–5
Transfer factor in chronic mucocutaneous candidiasis. Masi M, et al. **Biotherapy** 1996;9(1–3):97–103
Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Pilotti V, et al. **Biotherapy** 1996; 9(1–3):117–21
Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: a pilot study. Prasad U, et al. **Biotherapy** 1996;9(1–3):109–15
Host F1 mice pretreated with granulocyte colony-stimulating factor accept parental bone marrow grafts in hybrid resistance system. Iizuka K, et al. **Blood** 1997 Feb 15;89(4):1446–51
Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Kiani A, et al. **Blood** 1997 Aug 15;90(4):1673–83
Treatment of chronic graft-versus-host disease with clofazimine. Lee SJ, et al. **Blood** 1997 Apr 1;89(7):2298–302
Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Wooldridge JE, et al. **Blood** 1997 Apr 15;89(8):2994–8
Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated [letter; comment] Cardy P. **BMJ** 1996 Nov 16;313(7067):1263. Comment on: BMJ 1996 Aug 3,313(7052):297–8.
Use of interferon beta 1b for multiple sclerosis. Patients will put up with side effects because of their desire to beat the disease [letter; comment] Chellingsworth M. **BMJ** 1996 Nov 16;313(7067):1263. Comment on: BMJ 1996 Aug 3;313(7052):297–8.
Use of interferon beta 1b for multiple sclerosis. Manufacturer defends the drug [letter; comment] Longthorne PN. **BMJ** 1996 Nov 16;313(7067):1263. Comment on: BMJ 1996 Aug 3;313(7052):297–8.
Interferon beta in multiple sclerosis [editorial] [see comments] Richards RG. **BMJ** 1996 Nov 9;313(7066):1159. Comment in: BMJ 1996 Nov 9;313(7066):1157–8. Comment in: BMJ 1997 Feb 22;314(7080):600. Comment in: BMJ 1997 Feb 22;314(7080):600–1. Comment in: BMJ 1997 Feb 22;314(7080):601. Comment in: BMJ 1997 Feb 22;314(7080):601–2. Comment in: BMJ 1997 Feb 22;314(7080):602.
Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study. Robinson N, et al. **Bone Marrow Transplant** 1997 Mar;19(5):435–42
A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Miles DW, et al. **Br J Cancer** 1996 Oct;74(8):1292–6
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Frost JD, et al. **Cancer** 1997 Jul 15;80(2):317–33
Postoperative immunostimulation after complete resection improves survival of patients with stage I nonsmall cell lung carcinoma. Fujisawa T, et al. **Cancer** 1996 Nov 1; 78(9):1892–8
A phase I study of 5-fluorouracil, leucovorin and levamisole. Cleary JF, et al. **Cancer Chemother Pharmacol** 1997; 39(4):300–6
Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Hayakawa K, et al. **Cancer Detect Prev** 1997;21(1):71–7
Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation. Ino K, et al. **Cancer Immunol Immunother** 1996 Dec;43(4):206–12
Laser-photosensitizer assisted immunotherapy: a novel modality for cancer treatment. Chen WR, et al. **Cancer Lett** 1997 May 1;115(1):25–30

ADJUVANTS, IMMUNOLOGIC

Interleukin-2: its rationale and role in the treatment of patients with cancer. Rubin JT. **Cancer Treat Res** 1995; 80:83-105 (188 ref.)

Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (quinoline-3-carboxamide). Slavin S, et al. **Cell Transplant** 1996 Nov-Dec;5(6):627-30

Antitumor, immunomodulatory and anti-HIV effect of mangiferin, a naturally occurring glucosylxanthone. Guha S, et al. **Chemotherapy** 1996 Nov-Dec;42(6):443-51

Fungemia in patients with hematologic malignancies: therapeutic effects of concomitant administration of fluconazole and granulocyte-colony-stimulating factor. Niitsu N, et al. **Chemotherapy** 1996 May-Jun;42(3):215-19

Atopic dermatitis: immunobiology and treatment with immune modulators. Leung DY. **Clin Exp Immunol** 1997 Jan;107 Suppl 1:25-30 (36 ref.)

Interferon beta in multiple sclerosis. Arnason BG. **Clin Immunol Immunopathol** 1996 Oct;81(1):1-11 (101 ref.)

The effects of thymostimulin on immunological function in patients with head and neck cancer. Kerrebijn JD, et al. **Clin Otolaryngol** 1996 Oct;21(5):455-62

Use of Broncho-Vaxom in private practice: phase IV trial in 587 children. Berber AC, et al. **Clin Ther** 1996 Nov-Dec; 18(6):1068-79

Lisofylline decreases white cell adhesiveness and improves survival after experimental hemorrhagic shock. Waxman K, et al. **Crit Care Med** 1996 Oct;24(10):1724-8

Immunopharmacology. Terezhalmy GT, et al. **Dent Clin North Am** 1996 Jul;40(3):685-707 (45 ref.)

Diphencyprone in the management of refractory palmoplantar and periungual warts: an open study. Rampen FH, et al. **Dermatology** 1996;193(3):236-8

Newer versus older treatments for relapsing-remitting multiple sclerosis. Weinstock-Guttman B, et al. **Drug Saf** 1996 Feb;14(2):121-30 (22 ref.)

Immunostimulating agents: what next? A review of their present and potential medical applications. Werner GH, et al. **Eur J Biochem** 1996 Nov 15;242(1):1-19 (156 ref.)

Failure of beta interferon therapy in X-linked adrenoleukodystrophy [letter] Korenke GC, et al. **Eur J Pediatr** 1996 Sep;155(9):833

Immunomodulation as asthma therapy: where do we stand? Barnes PJ. **Eur Respir J Suppl** 1996 Aug;22:154s-159s (48 ref.)

A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract. Sarosdy MF. **Eur Urol** 1997;31 Suppl 1:20-6 (36 ref.)

Treatment of carcinoma in situ of the urinary bladder with bropirimine. Witjes JA. **Eur Urol** 1997;31 Suppl 1:27-30 (16 ref.)

Long-term low dose interferon alpha-2b in the treatment of chronic hepatitis B in multi-ethnic patients in Hawaii. Ching N, et al. **Hawaii Med J** 1996 Oct;55(10):201-3

Thymostimulin enhancement of T-cell infiltration into head and neck squamous cell carcinoma. Kerrebijn JD, et al. **Head Neck** 1996 Jul-Aug;18(4):335-42

Covalent chemical events in immune induction: fundamental and therapeutic aspects [see comments] Rhodes J. **Immunol Today** 1996 Sep;17(9):436-41 (44 ref.). Comment in: Immunol Today 1997 Jul;18(7):362.

Host immunologic augmentation for the control of infection. Wingard JR, et al. **Infect Dis Clin North Am** 1996 Jun; 10(2):345-64 (111 ref.)

The anti-tumoral activity of human glycoprotein HGP.92: a study with the mouse Lewis-lung-tumor cell. Fontan E, et al. **Int J Cancer** 1997 Feb 7;70(4):416-22

Immune modulation and sepsis. Karzai W, et al. **Int J Clin Pract** 1997 Jun;51(4):232-7 (62 ref.)

Combined modality radioprotection: enhancement of survival and hematopoietic recovery in gamma-irradiated mice by the joint use of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and indomethacin. Fedoročko P, et al. **Int J Immunopharmacol** 1996 May; 18(5):329-37

Adoptive immunotherapy of poorly immunogenic tumors with in vitro sensitized cells generated by intratumoral administration of biological response modifiers. Mukai S, et al. **Int J Immunopharmacol** 1995 Dec;17(12):963-71

Enhancement by muramyl peptides of the protective response of interferon-alpha/beta against encephalomyocarditis virus infection. Pouillart PR, et al. **Int J Immunopharmacol** 1996 Mar;18(3):183-92

Immunohistochemical study of tumor-infiltrating lymphocytes before and after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer. Honda S, et al. **Int J Urol** 1997 Jan;4(1):68-73

Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up. Shinka T, et al. **Int J Urol** 1997 Mar;4(2):139-43

BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes. Melekos MD, et al. **Int Urol Nephrol** 1996;28(4):499-509

Modulation of T-cell response to phospholipase A2 and phospholipase A2-derived peptides by conventional bee venom immunotherapy. Kämmerer R, et al. **J Allergy Clin Immunol** 1997 Jul;100(1):96-103

Immunomodulation: a new horizon for medical treatment of heart failure. Sasayama S, et al. **J Card Fail** 1996 Dec; 2(4 Suppl):S287-94 (37 ref.)

A pilot study of thymosin-alpha 1 therapy for chronic hepatitis D. Zavaglia C, et al. **J Clin Gastroenterol** 1996 Sep;23(2):162-3

Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. Genç K, et al. **J Clin Invest** 1997 Jun 1;99(11):2664-71

Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. Quan WD Jr, et al. **J Clin Oncol** 1997 May; 15(5):2103-10

Systemic 70% deacetylated chitin (DAC-70) as a treatment for MRL/lpr murine lupus; reduction of immunoglobulin deposition in the skin and kidneys [letter] Horiuchi Y, et al. **J Dermatol** 1997 Jan;24(1):63-5

Immunomodulatory activities of Cedrela lilloi and Trichilia elegans aqueous leaf extracts. Nores MM, et al. **J Ethnopharmacol** 1997 Jan;55(2):99-106

IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-alpha, IFN-gamma, and IL-12 production. Muchamuel T, et al. **J Immunol** 1997 Mar 15; 158(6):2898-903

Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR-mediated activation of p21(ras). Rapoport MJ, et al. **J Immunol** 1996 Nov 15;157(10):4721-5

Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo. Davis-Daneshfar A, et al. **J Immunother** 1997 May;20(3):208-13

Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group. Kirkwood JM, et al. **J Immunother** 1997 Mar;20(2):146-57

A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. Fenton RG, et al. **J Immunother Emphasis Tumor Immunol** 1996 Sep; 19(5):364-74

Inhibition of murine Lewis lung carcinoma metastases by combined chemotherapy and intranasal THF-gamma 2 immunotherapy. Rashid G, et al. **J Immunother Emphasis Tumor Immunol** 1996 Sep; 19(5):324-33

Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. Clerici M, et al. **J Infect Dis** 1997 May;175(5):1210-5

Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide. Bahr GM, et al. **J Interferon Cytokine Res** 1996 Apr;16(4):297-306

Cryoglobulinemia in hepatitis C virus chronic active hepatitis: effects of interferon-alpha therapy. Casaril M, et al. **J Interferon Cytokine Res** 1996 Aug;16(8):585-8

A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm3. Gordon M, et al. **J Med** 1995;26(5-6):193-207

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Millefiorini E, et al. **J Neurol** 1997 Mar; 244(3):153-9

Effects of an immune-enhancing diet in critically injured patients. Mendez C, et al. **J Trauma** 1997 May;42(5):933-40; discussion 940-1

Randomized trial of immune-enhancing enteral nutrition in burn patients. Saffle JR, et al. **J Trauma** 1997 May; 42(5):793-800; discussion 800-2

Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor. Kadhim SA, et al. **J Urol** 1997 Aug; 158(2):646-52

Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. Thalmann GN, et al. **J Urol** 1997 Oct;158(4):1340-4

Effect of chitosan implantation on activation of canine macrophages and polymorphonuclear cells after surgical stress. Kosaka T, et al. **J Vet Med Sci** 1996 Oct;58(10):963-7

The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. Hess G, et al. **J Viral Hepat** 1996 May;3(3):149-53

The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Blaise D, et al. **Leuk Lymphoma** 1997 May;25(5-6):469-78

New perspectives on the approach to chronic lymphocytic leukemia. Goodman MG, et al. **Leuk Lymphoma** 1996 Jun; 22(1-2):1-10 (51 ref.)

Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease. Schlegel PG, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):11-6 (47 ref.)

Modulation of experimental systemic lupus erythematosus with linomide. Zandman-Goddard G, et al. **Lupus** 1996 Aug;5(4):328-33

Glatiramer acetate for relapsing multiple sclerosis. **Med Lett Drugs Ther** 1997 Jul 4;39(1004):61-2

Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy. Fagerberg J. **Med Oncol** 1996 Sep;13(3):155-60 (52 ref.)

DNCB for local control of malignant melanoma: don't forget a winning horse! [letter] Inbar M, et al. **Melanoma Res** 1996 Dec;6(6):457-9

BCG and praziquantel for Schistosomiasis treatment. Viana L de G, et al. **Mem Inst Oswaldo Cruz** 1996 Sep-Oct; 91(5):637

Cell Therapeutics Inc. reports novel therapy for acute respiratory distress syndrome--the largest cause of mortality in patients with multiple traumatic injuries. **Mol Biotechnol** 1996 Feb;5(1):66

Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mohr DC, et al. **Mult Scler** 1996 Dec; 2(5):222-6

Clinical and immunologic effects of T-activin therapy in early stage melanoma patients. Stanojević-Bakić N, et al. **Neoplasma** 1996;43(4):245-52

Melatonin and the immune-hematopoietic system therapeutic and adverse pharmacological correlates. Maestroni GJ, et al. **Neuroimmunomodulation** 1996 Nov-Dec;3(6):325-32 (66 ref.)

Treatment of multiple sclerosis with interferon beta-1 b [letter; comment] Abdul-Ahad A, et al. **Neurology** 1997 Aug;49(2):641-2. Comment on: Neurology 1996 Oct;47(4):889-94.

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Andersen O, et al. **Neurology** 1996 Oct;47(4):895-900

Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Karussis DM, et al. **Neurology** 1996 Aug;47(2):341-6

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Stone LA, et al. **Neurology** 1997 Sep;49(3):862-9

Topical thymopentin therapy in HIV positive patients with recurrent oral candidiasis: a pilot study. Coppola S, et al. **New Microbiol** 1996 Oct;19(4):351-5

Antitumor activities of combined treatment with a novel immunomodulator, (2S,3S,4R)-1-O-(alpha-D-Galactopyranosyl)-2-(N-Hexacosanoylamino)-1,3,4 - octadecanetriol (KRN7000), and radiotherapy in tumor-bearing mice. Motoki K, et al. **Oncol Res** 1996;8(4):155-62

Levamisole therapy in corticosteroid-dependent nephrotic syndrome. Bagga A, et al. **Pediatr Nephrol** 1997 Aug; 11(4):415-7

Protracted levamisole in children with frequent-relapse nephrotic syndrome [letter] Ginevri F, et al. **Pediatr Nephrol** 1996 Aug;10(4):550

Interferon- beta-1b (Betaseron): A model for hydrophobic therapeutic proteins. Lin LS, et al. **Pharm Biotechnol** 1996; 9:275-301 (62 ref.)

Effect of KE-298 on experimental arthritis in mice. Nagai H, et al. **Pharmacology** 1996 Sep;53(3):190-6

Immunopotentiating activity of Clostridium butyricum in mice. Wang GR, et al. **Proc Natl Sci Counc Repub China B** 1996 Oct;20(4):101-9

Therapeutic applications of cytokines for immunostimulation and immunosuppression: an update. Cardi G, et al. **Prog Drug Res** 1996;47:211-50 (256 ref.)

Role of IL12 as an anti-tumour agent: current status and future directions. Brunda MJ. **Res Immunol** 1995 Sep-Oct; 146(7-8):622-28 (29 ref.)

IL12 as an adjuvant for vaccines designed to prevent infection and immunopathology by schistosomes. Wynn TA, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):582-90 (59 ref.)

Effectiveness of immunomodulating treatment (thymostimulin) in chronic obstructive pulmonary disease. Banos V, et al. **Respiration** 1997;64(3):220-3

The assessment of the therapeutic effectiveness of IRS-19 in allergic children with recurrent or chronic respiratory infections. Maciorkowska E, et al. **Rocz Akad Med Bialymst** 1995;40(3):619-24

Augmenting the immunogenicity of carbohydrate tumor antigens. Livingston PO. **Semin Cancer Biol** 1995 Dec; 6(6):357-66 (56 ref.)

Selection of potent immunological adjuvants for vaccine construction. McElrath MJ. **Semin Cancer Biol** 1995 Dec; 6(6):375-85 (74 ref.)

The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis. Kaplan MM. **Semin Liver Dis** 1997 May; 17(2):129-36 (57 ref.)

Adjuvant application of interferons. el Kassas H, et al. **Semin Oncol** 1996 Dec;23(6):737-43 (35 ref.)

Biologic therapy of melanoma with cytokines and lymphocytes. Bear HD, et al. **Semin Surg Oncol** 1996 Nov-Dec;12(6):436-45 (63 ref.)

Diagnosis and treatment of superficial bladder cancer: an update. Crawford ED. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):1-9 (70 ref.)

Intravesical chemotherapy versus immunotherapy for superficial bladder cancer. Huben RP. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):17-22 (26 ref.)

Update on the Dutch Cooperative Trial: mitomycin versus

bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Witjes WP, et al. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):10-6

The use of danazol in the therapy of immune-mediated disease of dogs. Miller E. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):167-9 (24 ref.)

Monocyte function associated with intermittent lentinan therapy after resection of gastric cancer. Takeshita K, et al. **Surg Oncol** 1996 Feb;5(1):23-8

Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow. Hale DA, et al. **Transplantation** 1997 Feb 15; 63(3):359-64

Effect of pretransplant erythropoietin therapy on renal allograft outcome. Vasquez EM, et al. **Transplantation** 1996 Oct 15;62(7):1026-8

Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response. Bui TT, et al. **Urology** 1997 May;49(5):687-90; discussion 690-1

Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment. Ick K, et al. **Urology** 1997 Apr; 49(4):541-6; discussion 546-7

Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Stricker P, et al. **Urology** 1996 Dec;48(6):957-61; discussion 961-2

Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model. Namba K, et al. **Vaccine** 1996 Oct;14(14):1322-6

Romurtide, a synthetic muramyl dipeptide derivative, promotes megakaryocytopoiesis through stimulation of cytokine production in nonhuman primates with myelosuppression. Namba K, et al. **Vaccine** 1997 Mar; 15(4):405-13

Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Neuzil KM, et al. **Vaccine** 1997 Apr;15(5):525-32

Adjuvancy and reactogenicity of N-acetylglucosaminyl-N-acetylmuramyl-dipeptide (GMDP) orally administered just prior to trivalent influenza subunit vaccine. A double-blind placebo-controlled study in nursing home residents. Palache AM, et al. **Vaccine** 1996 Oct;14(14):1327-30

Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Pye D, et al. **Vaccine** 1997 Jun; 15(9):1017-23

Augmentation of cell-mediated immunotherapy against herpes simplex virus by interleukins: comparison of in vivo effects of IL-2 and IL-7 on adoptively transferred T cells. Wiryana P, et al. **Vaccine** 1997 Apr;15(5):561-3

Enhanced immunity to Hyalomma anatolicum anatolicum ticks in cross-bred (Bos indicus x Bos taurus) calves using ascaris extract immunomodulator with the tick salivary gland extract antigens. Sran HS, et al. **Vet Immunol Immunopathol** 1996 Jun 1;51(3-4):333-43

Furunculosis control using a paraimmunization stimulant (Baypamun) in rainbow trout. Ortega C, et al. **Vet Res** 1996;27(6):561-8

Protection and therapy of experimental herpesvirus infections in mice with immunomodulating Propionibacterium avidum KP-40 and/or acyclovir. Kobus M, et al. **Zentralbl Bakteriol** 1997 Feb;285(3):445-9

[Clinical testing of the treatment effect of interferon-beta Ia and Ib in multiple sclerosis] de Haan RJ, et al. **Ned Tijdschr Geneeskd** 1996 Nov 2;140(44):2168-71 (24 ref.) **(Dut)**

[The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG] Shekarsarai H, et al. **Acta Urol Belg** 1997 Mar;65(1):1-4 (Eng. Abstr.) **(Fre)**

[Immunosuppressive and immunomodulator treatment of severe systemic lupus] Guillevin L. **Ann Med Interne (Paris)** 1996;147(7):498-505 (74 ref.) (Eng. Abstr.) **(Fre)**

[Cellular growth factors in the treatment of bronchogenic cancers] Pujol JL, et al. **Rev Mal Respir** 1996;13(4):335-8 (17 ref.) **(Fre)**

[Immuno-nutritional recovery of children with severe malnutrition] Chevalier P, et al. **Sante** 1996 Jul-Aug; 6(4):201-8 (Eng. Abstr.) **(Fre)**

[Cystitis treatment with immunoactive Escherichia coli fractions] Conrad S, et al. **Dtsch Med Wochenschr** 1997 Apr 4;122(14):460 **(Ger)**

[Effect of immunostimulating agents on the occurrence of puerperal diseases in swine] Wawron W. **DTW Dtsch Tierarztl Wochenschr** 1997 Jun;104(6):220-3 (Eng. Abstr.) **(Ger)**

[Immunoactive peptides in chronic polyarthritis] **Internist (Berl)** 1994 Mar;35(3 Suppl):1-8 **(Ger)**

[Etiopathogenetic differentiation of inflammatory cardiomyopathy. Immunosuppression and immunomodulation] Kühl U, et al. **Internist (Berl)** 1997 Jun;38(6):590-601 (105 ref.) **(Ger)**

[Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland] Huber S, et al. **Schweiz Med Wochenschr** 1996 Aug 31;126(35):1475-81 (Eng. Abstr.) **(Ger)**

[Placebo-controlled double-blind study on the efficacy of a paramunity inducer in the treatment of naturally FeLV-infected cats] Block A, et al. **Tierarztl Prax** 1997 May;25(3):261-6 (Eng. Abstr.) **(Ger)**

[Levels of monokines in peripheral monocytes in patients with superficial tumors of the bladder treated with BCG. Results after 1- and 3-year follow-up] Iantorno R, et al. **Arch Ital Urol Androl** 1997 Feb;69 Suppl 1:69-70 (Eng. Abstr.) **(Ita)**

[Role of MCP-1 chemokine in the response of monocytes of patients with superficial tumors of the bladder treated with BCG immunotherapy] Iantorno R, et al. **Arch Ital Urol Androl** 1997 Feb;69 Suppl 1:71-2 (Eng. Abstr.) **(Ita)**

[A clinico-laboratory evaluation of an immunomodulating drug of bacterial derivation] Castello D, et al. **Minerva Pediatr** 1996 Jan-Feb;48(1-2):55-62 (Eng. Abstr.) **(Ita)**

[Evaluation of the effectiveness of Uro-Vaxom in recurrent urinary tract infections in children] Czerwionka-Szaflarska M, et al. **Pediatr Pol** 1996 Jul;71(7):599-604 (Eng. Abstr.) **(Pol)**

[Curative and prophylactic immunomodulation by vaccination in mucocutaneous streptococcal infections] Topciu V, et al. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jan-Jun;41(1-2):71-3 **(Rum)**

[The characteristics of the pathogenesis and immunomodulator treatment in the postoperative period in pseudophakia patients] Boiştean V, et al. **Oftalmologia** 1996 Jul-Sep;40(3):210-3 (Eng. Abstr.) **(Rum)**

[Immobilized proteases and their activators as immunocorrective agents] Khmelevskaia IG, et al. **Antibiot Khimioter** 1997;42(3):11-4 (Eng. Abstr.) **(Rus)**

[Immunomodulating and hepatoprotective action of retinoids in toxic liver involvement induced by D-galactosamine] Konoplia EN, et al. **Antibiot Khimioter** 1996;41(7-8):22-5 (Eng. Abstr.) **(Rus)**

[Antioxidants and immunomodulating action of antibiotics and antibiotic-treated erythrocytes in staphylococcal infections] Prokopenko LG, et al. **Antibiot Khimioter** 1997; 42(3):15-9 (Eng. Abstr.) **(Rus)**

[Immunomodulating effects of alpha-interferon in Pseudomonas aeruginosa infection] Ganova LA, et al. **Biull Eksp Biol Med** 1996 Aug;122(8):124-7 **(Rus)**

[The effect of 2-methyl-4-amino-6-hydroxypyrimidine on delayed hypersensitivity] Ismagilova AF, et al. **Eksp Klin Farmakol** 1997 Jan-Feb;60(1):45-6 (Eng. Abstr.) **(Rus)**

[The evaluation of the effect of zinc sulfate on primary immune response indices under alcoholic intoxication] Proskuriakova TV, et al. **Eksp Klin Farmakol** 1996 Mar-Apr;59(2):47-9 (Eng. Abstr.) **(Rus)**

[Lidocaine as an immunomodulator in a toxic liver lesion] Uteshev BS, et al. **Eksp Klin Farmakol** 1997 Mar-Apr; 60(2):45-8 (Eng. Abstr.) **(Rus)**

[Evaluation of the effectiveness of immunomodulators in the treatment of patients with postoperative suppurative-septic complications] Bulava GV, et al. **Khirurgiia (Mosk)** 1996; (2):104-7 (Eng. Abstr.) **(Rus)**

[Use of immunomodulator polyoxydony in treatment and prevention of septic conditions in surgical patients] Khaitov RM, et al. **Khirurgiia (Mosk)** 1997;(1):49-54 (Eng. Abstr.) **(Rus)**

[Clinicoimmunological features and treatment of acute intestinal infection of Proteus etiology] Iushchuk ND, et al. **Klin Med (Mosk)** 1996;74(4):67 **(Rus)**

[Immunomodulators and some aspects of their clinical use] Khaitov RM, et al. **Klin Med (Mosk)** 1996;74(8):7-12 (16 ref.) **(Rus)**

[The clinico-immunological efficacy of the new drug preparation Erbisol in patients with chronic hepatitis] Bychkova NG, et al. **Lik Sprava** 1995 Mar-Apr;(3-4):65-7 (Eng. Abstr.) **(Rus)**

[The efficacy of immunomodulating therapy in patients with chronic cholestatic liver diseases] Petrunia AM, et al. **Lik Sprava** 1996 Mar-Apr;(3-4):125-7 (Eng. Abstr.) **(Rus)**

[The individual selection of immunomodulating and vitamin preparations for miners who are frequently ill with ARVI] Trunova OA. **Lik Sprava** 1996 Oct-Dec;(10-12):148-53 (Eng. Abstr.) **(Rus)**

[The clinico-immunological effects of T-activin in the combined treatment of patients with acute suppurative pyelonephritis] Vozianov AF, et al. **Lik Sprava** 1995 Sep-Dec;(9-12):81-3 (Eng. Abstr.) **(Rus)**

[The clinico-immunological effects of leukinferon in the treatment of patients with acute suppurative pyelonephritis] Vozianov AF, et al. **Lik Sprava** 1997 Jan-Feb;(1):88-92 (Eng. Abstr.) **(Rus)**

[The effect of bacterial polysaccharides on the course of a Mycoplasma infection] Rudenko AV, et al. **Mikrobiol Z** 1996 Jul-Aug;58(4):67-73 (Eng. Abstr.) **(Rus)**

[Study of immunobiological properties of specific immunomodulators of the adjuvant type in experimental tuberculosis] Gorelova LA, et al. **Probl Tuberk** 1996; (3):46-7 (Eng. Abstr.) **(Rus)**

[Tactivin in the combined treatment of acute inflammatory diseases of the maxillofacial area] Bazhanov NN, et al. **Stomatologiia (Mosk)** 1996;75(2):31-3 (Eng. Abstr.) **(Rus)**

[A clinical and experimental validation of the use of Stimuloss in patients with chronic generalized periodontitis] Fedosenko TD, et al. **Stomatologiia (Mosk)** 1997; 76(3):18-22 (Eng. Abstr.) **(Rus)**

[Immunocorrection in the combined treatment of patients with sialoadenitis] Pinelis IS, et al. **Stomatologiia (Mosk)** 1997;76(1):32-3 **(Rus)**

[The immunomodulating therapy of odontogenic phlegmons with complexes of antibacterial preparations and water-soluble polymers for medical use] Tsarev VN, et al. **Stomatologiia (Mosk)** 1996;Spec No:88 **(Rus)**

[The use of tactivin in the combined treatment and prevention of complications in reconstructive operations on the bones of the facial skeleton] Volozhin AI, et al. **Stomatologiia (Mosk)** 1996;75(2):46-8 (Eng. Abstr.) **(Rus)**

[Immunomodulating therapy in insulin-dependent diabetes mellitus: problems and new prospects] Galenok VA, et al. **Ter Arkh** 1995;67(12):80-4 (66 ref.) **(Rus)**

[A trial of the use of the immunocorrective preparation Imunofan for treating diphtheria] Lebedev VV, et al. **Ter Arkh** 1996;68(2):66-8 (Eng. Abstr.) **(Rus)**

[Combined immunomodulating therapy in rheumatoid arthritis] Oliunin IuA, et al. **Ter Arkh** 1996;68(5):13-6 (Eng. Abstr.) **(Rus)**

[Immune system function and the efficacy of immunocorrective treatment in patients with a chronic persistent chlamydial infection] Solov'ev AM. **Ter Arkh** 1996;68(11):48-51 **(Rus)**

[Immunological indicators in children with laryngeal papillomatosis and possible ways of immunocorrection] Garashchenko TI, et al. **Vestn Otorinolaringol** 1996 Jul-Aug;(4):15-8 (Eng. Abstr.) **(Rus)**

[Assessment of the formation of antibodies to interferon in patients with juvenile respiratory papillomatosis on interferon therapy] Kol'tsov VD, et al. **Vestn Otorinolaringol** 1996 Jul-Aug;(4):25-7 (Eng. Abstr.) **(Rus)**

[Use of immunomocorrection in the combined treatment of laryngeal papillomatosis in children] Savenko IV, et al. **Vestn Otorinolaringol** 1996 Jul-Aug;(4):12-4 (Eng. Abstr.) **(Rus)**

[Various biochemical indices of wound healing during treatment with preparation SK] Shurygin AIa, et al. **Vopr Med Khim** 1996 Jul-Sep;42(3):227-31 (Eng. Abstr.) **(Rus)**

[Therapeutic-prophylactic milk products with a new immunocorrector of natural origin] Besednova NN, et al. **Vopr Pitan** 1997;(3):31-4 (Eng. Abstr.) **(Rus)**

[Effectiveness of peroral application of a new immunocorrective agent of natural origin] Epshtein LM, et al. **Vopr Pitan** 1997;(1):10-3 (Eng. Abstr.) **(Rus)**

[Efficacy of herpetic vaccine, larifan, myelopid and their combinations during herpesvirus infection in irradiated animals] Alimbarova LM, et al. **Vopr Virusol** 1996 Nov-Dec;41(6):270-4 (Eng. Abstr.) **(Rus)**

[Immunomodulators in the prevention and therapy of viral infections] Ershov FI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May-Jun; (3):122-5 (Eng. Abstr.) **(Rus)**

[The concept of immunocorrection in multifactor immunodeficiency states, infectious and cancerous diseases] Kuznetsov VP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep-Oct; (5):104-10 (60 ref.) **(Rus)**

[An immunomodifier--staphylococcal anatoxin--prevents the development of immunosuppression caused by informational stress in mice] Ozherelkov SV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul-Aug;(4):71-4 (Eng. Abstr.) **(Rus)**

[The comparative characteristics of the effect of immunomodulators on the indices of body nonspecific protection and on the structure of the populations of the causative agents in mixed infections] Shatalova EV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan-Feb;(1):54-8 (Eng. Abstr.) **(Rus)**

[Methods for assessing the efficacy of immunocorrection] Zemskov AM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan-Feb;(1):51-3 (Eng. Abstr.) **(Rus)**

[A system of individual immunotherapy with leakadin in the combined therapy of acoustic neurinomas] Starchenko AA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct-Dec; (4):15-8 (Eng. Abstr.) **(Rus)**

[BCG immunotherapy and vulgar warts (letter)] Palou J, et al. **Actas Urol Esp** 1996 Nov-Dec;20(10):928-9 **(Spa)**

[Results of a prospective study of chemoprophylaxis with alternating mitomycin-C and BCG: complete response and recurrence and progression index] Nohales Taurines G, et al. **Arch Esp Urol** 1996 Sep;49(7):689-92 (Eng. Abstr.) **(Spa)**

[Use of transfer++factor in allergic bronchial asthma] Salazar Villa RM, et al. **Rev Alerg** 1993 Mar-Apr; 40(2):42-5 (41 ref.) (Eng. Abstr.) **(Spa)**

[Treatment of extrinsic bronchial asthma with transfer factor] Valdés Sánchez AF, et al. **Rev Alerg Mex** 1993 Sep-Oct; 40(5):124-31 (Eng. Abstr.) **(Spa)**

[The typological characteristics of the stress activation of lipid peroxidation and its correction by thymopentin] Tarasenko LM, et al. **Fiziol Zh** 1997;43(1-2):113-6 (Eng.

Abstr.) **(Ukr)**

[The immunomodulating effect of vilozen in the combined treatment of children with rheumatism associated with an allergy] Moshchych PS, et al. **Lik Sprava** 1997 Mar–Apr; (2):76–9 (Eng. Abstr.) **(Ukr)**

[Bottled Zbruch naftusia mineral water--a new immunocorrective for regions ecologically at crisis] Raksha-Sliusareva OA. **Lik Sprava** 1997 Mar–Apr; (2):116–9 (Eng. Abstr.) **(Ukr)**

TOXICITY

The mucosal adjuvant activities of ADP–ribosylating bacterial enterotoxins. Snider DP. **Crit Rev Immunol** 1995; 15(3–4):317–48 (276 ref.)

Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action. Tsuji T, et al. **Immunology** 1997 Feb;90(2):176–82

Mutants in the ADP–ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. Yamamoto S, et al. **J Exp Med** 1997 Apr 7;185(7):1203–10

Lysosomal storage of sulphated glycosaminoglycans induced by dicationic amphiphilic drug molecules: significance of the central planar ring system. Lüllmann–Rauch R, et al. **Pharmacol Toxicol** 1996 Sep;79(3):109–13

Developmental aspects of anandamide: ontogeny of response and prenatal exposure. Fride E, et al. **Psychoneuroendocrinology** 1996 Feb;21(2):157–72

Adjuvant effect of respiratory irritation on pulmonary allergic sensitization: time and site dependency. Siegel PD, et al. **Toxicol Appl Pharmacol** 1997 Jun;144(2):356–62

Assessment of altered immune status induced by immunomodulatory drugs via an apical test in mice [editorial; comment] Bertram TA. **Toxicol Pathol** 1997 Jul–Aug;25(4):419–20. Comment on: Toxicol Pathol 1997 Jul–Aug;25(4):351–62.

Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Goto N, et al. **Vaccine** 1997 Aug–Sep; 15(12–13):1364–71

Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani. Santos WR, et al. **Vaccine** 1997 Jun;15(9):1024–9

Immunomodulative effects of aflatoxins and selenium on human peripheral blood lymphocytes. Methenitou G, et al. **Vet Hum Toxicol** 1996 Aug;38(4):274–7

[Immunotoxicity assessment in the preclinical study of biologically active compounds] Uteshev BS, et al. **Eksp Klin Farmakol** 1996 May–Jun;59(3):3–8 (71 ref.) (Eng. Abstr.) **(Rus)**

URINE

Patients with recurrent renal stones have a physico–chemically altered urinary Tamm–Horsfall glycoprotein profile. Jefferson A, et al. **Ann Clin Biochem** 1996 Nov;33 (Pt 6):540–4

Urinary excretion of Tamm–Horsfall protein in normotensive, normo–albuminuric type 1 diabetic patients. Catalano C, et al. **Nephron** 1996;72(3):436–41

ADJUVANTS, PHARMACEUTIC

Pharmacokinetic, angiographic, and histologic comparison of catheter–directed chemoembolization versus systemic chemotherapy in a canine model. Zhan X, et al. **Can J Physiol Pharmacol** 1996 Oct;74(10):1117–25

Improvement of some pharmaceutical properties of drugs by cyclodextrin complexation. Part 6: Ampicillin. Ammar HO, et al. **Pharmazie** 1996 Aug;51(8):568–70

ADMINISTRATION & DOSAGE

Antipsychotic drug doses and adjunctive drugs in the outpatient treatment of schizophrenia. Galletly CA, et al. **Ann Clin Psychiatry** 1997 Jun;9(2):77–80

A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. McElroy SL, et al. **Ann Clin Psychiatry** 1997 Jun;9(2):99–103

ANALYSIS

Separation and quantitation of glycolipids as penetration modifiers in human skin using high–performance liquid chromatography–mass spectrometry with electrospray ionization. Wolf R, et al. **J Chromatogr A** 1997 Apr 4; 766(1–2):71–5

PHARMACOLOGY

The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Jorga K, et al. **Eur Neurol** 1997;38(1):59–67

Indomethacin enhances the cytotoxicity of VCR and ADR in human pulmonary adenocarcinoma cells. Kobayashi S, et al. **Tohoku J Exp Med** 1997 Mar;181(3):361–70

THERAPEUTIC USE

No identifiable effect of ginseng (Gericomplex) as an adjuvant in the treatment of geriatric patients. Thommessen B, et al. **Aging (Milano)** 1996 Dec;8(6):417–20

Safety and efficacy of repeated shockwave lithotripsy of gallstones with and without adjuvant bile acid therapy [see comments] Sauter G, et al. **Gastroenterology** 1997 May; 112(5):1603–9. Comment in: Gastroenterology 1997 May;112(5):1756–8.

Adjunctive therapy and surgical considerations in the management of bacterial ulcerative keratitis. Pineda R 2nd, et al. **Int Ophthalmol Clin** 1996 Summer;36(3):37–48 (32 ref.)

ADL see **ACTIVITIES OF DAILY LIVING**

ADMINISTRATION see **ORGANIZATION AND ADMINISTRATION**

ADMINISTRATION, CUTANEOUS

see related
SKIN ABSORPTION

Composite poly(2–hydroxyethyl methacrylate) membranes as rate–controlling barriers for transdermal applications. Sun YM, et al. **Biomaterials** 1997 Apr;18(7):527–33

Safe, simple subcutaneous fluid administration. Farrand S, et al. **Br J Hosp Med** 1996 Jun 5–18;55(11):690–2 (5 ref.)

Evaluation of skin permeability of drugs by newly prepared polymer membranes. Yamaguchi Y, et al. **Chem Pharm Bull (Tokyo)** 1997 Mar;45(3):537–41

Sensitization of mice to topically applied drugs: albuterol, chlorpheniramine, clonidine and nadolol. Kalish R, et al. **Contact Dermatitis** 1996 Aug;35(2):76–82

Formulation for transfollicular drug administration: some recent advances. Illel B. **Crit Rev Ther Drug Carrier Syst** 1997;14(3):207–19 (51 ref.)

Recent developments in topical and transdermal delivery. Hadgraft J. **Eur J Drug Metab Pharmacokinet** 1996 Apr–Jun;21(2):165–73 (35 ref.)

Transdermal drug delivery: useful paradigms. Potts RO, et al. **J Drug Target** 1995;3(4):247–51 (32 ref.)

Novel diffusion cell for in vitro transdermal permeation, compatible with automated dynamic sampling. Bosman IJ, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1015–23

Synergistic effects of chemical enhancers and therapeutic ultrasound on transdermal drug delivery. Johnson ME, et al. **J Pharm Sci** 1996 Jul;85(7):670–9

Theoretical model of iontophoresis utilized in transdermal drug delivery. Ferry LL. **Pharm Acta Helv** 1995 Dec; 70(4):279–87

Transdermal peptide delivery using electroporation. Potts RO, et al. **Pharm Biotechnol** 1997;10:213–38 (50 ref.)

Current status and future prospects of transdermal drug delivery. Guy RH. **Pharm Res** 1996 Dec;13(12):1765–9 (35 ref.)

Scale–up of adhesive transdermal drug delivery systems. Van Buskirk GA, et al. **Pharm Res** 1997 Jul;14(7):848–52

Advances in transdermal drug delivery. Hadgraft J. **Practitioner** 1996 Nov;240(1568):656–8

ADMINISTRATION, INHALATION

see related
ADMINISTRATION, INTRANASAL
AEROSOLS
ANESTHESIA, INHALATION
RESPIRATORY THERAPY

Inhalational therapy in asthma. Oppenheimer J. **Allergy Asthma Proc** 1996 Nov–Dec;17(6):351–3 (21 ref.)

Inhaled drugs for treatment of asthma: nothing is ever as simple as it seems [editorial] Ahrens RC. **Ann Allergy Asthma Immunol** 1996 Oct;77(4):260–2

Therapeutic aerosol delivery during mechanical ventilation. Coleman DM, et al. **Ann Pharmacother** 1996 Jun; 30(6):644–55 (54 ref.)

Pharmacokinetics of inhaled drugs. Lipworth BJ. **Br J Clin Pharmacol** 1996 Dec;42(6):697–705 (55 ref.)

A multicenter clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. Charpin D, et al. **Eur Arch Otorhinolaryngol** 1995;252(8):455–8

Toxic inhalation of ethylene glycol: a pharmacological improbability [letter] Hodgman MJ, et al. **J Toxicol Clin Toxicol** 1997;35(1):109–11

Comparison of the pulmonary distribution and efficacy of antibodies given to mice by intratracheal instillation or aerosol inhalation. Vogel P, et al. **Lab Anim Sci** 1996 Oct; 46(5):516–23

Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia. Kugelman A, et al. **Pediatrics** 1997 Jan;99(1):71–5

In situ and in vivo methods for pulmonary delivery. Eljamal M, et al. **Pharm Biotechnol** 1996;8:361–74 (30 ref.)

Relationship between solvent inhalation and antisocial behavior: special emphasis on two types of violence seen in solvent abusers. Morita N, et al. **Psychiatry Clin Neurosci** 1996 Feb;50(1):21–30

Large porous particles for pulmonary drug delivery. Edwards DA, et al. **Science** 1997 Jun 20;276(5320):1868–71

Drug delivery takes a deep breath [news] Service RF. **Science** 1997 Aug 29;277(5330):1199–200

[Use of inhaled bronchodilators by primary care patients] Benito Ortiz L, et al. **Aten Primaria** 1996 Nov 30; 18(9):497–501 (Eng. Abstr.) **(Spa)**

ADMINISTRATION, INTRANASAL

see related
NEBULIZERS AND VAPORIZERS

Study on specific mucosal immunity by intranasal immunization of outer membrane protein P6 of Haemophilus influenzae with cholera toxin B subunit. Hotomi M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996; 523:150–2

Nasal steroid sprays and septal perforations. Ferguson BJ. **Ear Nose Throat J** 1997 Feb;76(2):75–6

ADMINISTRATION, INTRAVAGINAL

see related
VAGINAL CREAMS, FOAMS AND JELLIES

ADMINISTRATION, INTRAVESICAL

Electromotive drug administration to the urinary bladder: an animal model and preliminary results. Gürpinar T, et al. **J Urol** 1996 Oct;156(4):1496–501

ADMINISTRATION, ORAL

"Inappropriate" physician habits in prescribing oral nifedipine capsules in hospitalized patients. Rehman F, et al. **Am J Hypertens** 1996 Oct;9(10 Pt 1):1035–9

Oral administration of antibiotics: a rational alternative to the parenteral route. MacGregor RR, et al. **Clin Infect Dis** 1997 Mar;24(3):457–67 (139 ref.)

Changes in the prescribing of liquid oral medicines (LOMs) in the northern region of England between 1987 and 1992 with special regard to sugar content and long–term use in children. Maguire A, et al. **Community Dent Health** 1997 Mar;14(1):31–5

Patient preferences for oral versus intravenous palliative chemotherapy. Liu G, et al. **J Clin Oncol** 1997 Jan; 15(1):110–5

Medicine formulations for oral use for children. Bansal SK. **J Indian Med Assoc** 1996 Jun;94(6):234–6

Oral delivery of microencapsulated proteins. DiBiase MD, et al. **Pharm Biotechnol** 1997;10:255–88 (210 ref.)

[Oral drug administration] Delgado O, et al. **Med Clin (Barc)** 1997 Mar 22;108(11):426–35 (67 ref.) **(Spa)**

ADMINISTRATION, RECTAL

see related
SUPPOSITORIES

Practical use of rectal medications in palliative care [see comments] Warren DE. **J Pain Symptom Manage** 1996 Jun; 11(6):378–87 (37 ref.). Comment in: J Pain Symptom Manage 1997 May;13(5):250. Comment in: J Pain Symptom Manage 1997 May;13(5):250–1. Comment in: J Pain Symptom Manage 1997 Jun;13(6):313–4. Comment in: J Pain Symptom Manage 1997 Jun;13(6):314–5.

Rectal administration of paracetamol: a comparison of a solution and suppositories in adult volunteers. Kollöffel WJ, et al. **Pharm World Sci** 1996 Jan;18(1):26–9

ADMINISTRATION RESEARCH, NURSING see **NURSING ADMINISTRATION RESEARCH**

ADMINISTRATION SCHEDULE, DRUG see **DRUG ADMINISTRATION SCHEDULE**

ADMINISTRATION, SUBLINGUAL

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study [see comments] Quirino T, et al. **Clin Exp Allergy** 1996 Nov; 26(11):1253–61. Comment in: Clin Exp Allergy 1996 Nov;26(11):1228–31.

ADMINISTRATION, TOPICAL

Effects of topical nasal steroids on human respiratory mucosa and human granulocytes in vitro. Steinsvåg SK, et al. **Acta Otolaryngol (Stockh)** 1996 Nov;116(6):868–75

Recent developments in topical and transdermal delivery. Hadgraft J. **Eur J Drug Metab Pharmacokinet** 1996 Apr–Jun;21(2):165–73 (35 ref.)

Effect of vehicle on topical liposomal drug delivery: petrolatum bases. Foldvari M. **J Microencapsul** 1996 Sep–Oct;13(5):589–600

ADMINISTRATIVE PERSONNEL

Roles for state–level local health liaison officials in local public health surveillance and capacity building. Turnock BJ, et al. **Am J Prev Med** 1995 Nov–Dec;11(6 Suppl):41–4

Gay and lesbian physicians in training: family practice program directors' attitudes and students' perceptions of bias. Oriel KA, et al. **Fam Med** 1996 Nov–Dec;28(10):720–5

Patient–centered care in an academic health center: an administrator's perspective. Kalkwarf KL. **J Dent Educ** 1996 Dec;60(12):951–4

Herbert Pardes, MD [interview] Pardes H. **J Investig Med** 1997 Apr;45(4):132–8

Profile of administrators of schools of nursing, Part II: Mentoring relationships and influence activities. Short JD.

J Prof Nurs 1997 Jan–Feb;13(1):13–8
Profile of administrators of schools of nursing, Part I: Resources for goal achievement. Short JD. **J Prof Nurs** 1997 Jan–Feb;13(1):7–12
The management myth. Horner JS.
J R Coll Physicians Lond 1997 Mar–Apr;31(2):149–52; discussion 152–4
The role of the transplant coordinator. Falvey S.
J R Soc Med 1996;89 Suppl 29:18
Conducting a comprehensive school health program. Resnicow K, et al. **J Sch Health** 1996 Feb;66(2):59–63 (19 ref.)
The empire strikes back. Brower V. **Nat Biotechnol** 1997 Jan;15(1):23–6
Commissioner Kessler's agbio legacy. Hoyle R.
Nat Biotechnol 1997 Jan;15(1):2
White House names AIDS policy director [news] **Nature** 1997 Feb 20;385(6618):671
Chair of GMO panel resigns over maize [news] Butler D. **Nature** 1997 Feb 20;385(6618):667
Cancer scientist takes on top job at Wellcome Trust [news] Dickson D. **Nature** 1997 Sep 25;389(6649):318
Abortion foe blamed for research head upset in Australia [news] Pockley P. **Nature** 1997 Feb 27;385(6619):758
Culture clash tarnishes the image of star laboratory [news] [see comments] Schiermeier Q. **Nature** 1997 Feb 27; 385(6619):761. Comment in: Nature 1997 Jun 12;387(6634):648–9.
Life imitating art? [letter; comment] Strom CM. **Nature** 1997 Apr 3;386(6624):432–3. Comment on: Nature 1997 Jan 16;385(6613):190.
Top FDA official named as 'de facto' chief [news] Wadman M. **Nature** 1997 Feb 6;385(6616):476
Breach of embryo ban leads to resignation [news] Wadman M. **Nature** 1997 Feb 13;385(6617):570
Sandra Thurman named as new 'AIDS Czar' [news] Wadman M. **Nature** 1997 Apr 10;386(6625):533
Advances encourage Nobel winner to head AIDS vaccine effort [news] Wadman M. **Nature** 1996 Dec 19–26; 384(6610):604
The perceptions of line and senior managers in relation to occupational health issues. Falconer L, et al.
Occup Med (Oxf) 1996 Apr;46(2):151–6
Administrative skills for dealing with issues facing contemporary pediatric dentistry programs. Henry RJ. **Pediatr Dent** 1997 May;19(3):210–3
Perception of risk by home health care administrators and field workers. Kendra MA. **Public Health Nurs** 1996 Dec; 13(6):386–93
Effects of long workhours on life–style, stress and quality of life among intermediate Japanese managers. Maruyama S, et al. **Scand J Work Environ Health** 1996 Oct;22(5):353–9
Professional characteristics of the transplant coordinator. López–Navidad A, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):1607–13

ECONOMICS

Leadership ... medical group pay goes up, up and away [news] **Hosp Health Netw** 1996 Nov 5;70(21):14
Executive advancement ... health care's millionaire club [news] **Hosp Health Netw** 1996 Dec 5;70(23):11

EDUCATION

Survey of management training in United States and Canadian pathology residency programs. Goldberg–Kahn B, et al. **Am J Clin Pathol** 1997 Jul;108(1):96–100
Mentor–based management training [editorial; comment] Horowitz RE. **Am J Clin Pathol** 1997 Jul;108(1):4–5. Comment on: Am J Clin Pathol 1997 Jul;108(1):90–5.
A leadership–management training curriculum for pathology residents [see comments] Sims KL, et al.
Am J Clin Pathol 1997 Jul;108(1):90–5. Comment in: Am J Clin Pathol 1997 Jul;108(1):4–5.
Accountability for health care: a white paper on leadership and management for the U.S. health care system. Schneller ES. **Health Care Manage Rev** 1997 Winter;22(1):38–48; discussion 49–57 (27 ref.)
Education. Info tech alliance aims high [news]
Hosp Health Netw 1997 Apr 5;71(7):34
Management training, the sooner the better [letter; comment] Chitwood J. **Mil Med** 1997 Jan;162(1):vii. Comment on: Mil Med 1996 Apr;161(4):217–20.
TRICARE: implications for military executive management education—a review of current data [see comments] Texidor MS, et al. **Mil Med** 1996 Apr;161(4):217–20 (11 ref.). Comment in: Mil Med 1997 Jan;162(1):vii.
Transplant procurement management training: concentration of responsibilities. Manyalich M. **Transplant Proc** 1997 Feb–Mar;29(1–2):1633–4

LEGISLATION & JURISPRUDENCE

Abbott sues Chiron over 'secrets' in heads of recruits [news] Lehrman S. **Nature** 1997 Feb 27;385(6619):760

ORGANIZATION & ADMINISTRATION

Who is minding the store? Sachs FL. **Conn Med** 1997 May; 61(5):296–7
The theory–practice gap in nursing: a new dimension. Hewison A, et al. **J Adv Nurs** 1996 Oct;24(4):754–61 (75 ref.)
Staff functions and administrative responsibilities of the professional optometrist in a hospital and medical center environment. Williams PA. **Optom Vis Sci** 1996 May; 73(5):338–40

PSYCHOLOGY

Leadership qualities of occupational therapy department program directors and the organizational health of their departments. Dudek–Shriber L. **Am J Occup Ther** 1997 May;51(5):369–77
Headache and stress in a group of nurses and government administrators in Japan. Nadaoka T, et al. **Headache** 1997 Jun;37(6):386–91
Personality patterns of health care and industry CEOs: similarities and differences. Van Eynde DF, et al.
Health Care Manage Rev 1996 Spring;21(2):87–95
Psychological stress in middle–aged and aged executives. Morioka C, et al. **Psychiatry Clin Neurosci** 1996 Jun; 50(3):91–3
Chronic work stress, sickness absence, and hypertension in middle managers: general or specific sociological explanations? Peter R, et al. **Soc Sci Med** 1997 Oct; 45(7):1111–20

STANDARDS

Standards of practice criteria for clinical nutrition managers. Witte SS, et al. **J Am Diet Assoc** 1997 Jun;97(6):673–8

STATISTICS & NUMERICAL DATA

A North American survey of educational background and job responsibilities of cardiopulmonary rehabilitation program directors. Sharratt MT, et al.
J Cardiopulm Rehabil 1997 Jan–Feb;17(1):9–15

ADMINISTRATORS see **ADMINISTRATIVE PERSONNEL**

ADMISSION TESTS, ROUTINE see **DIAGNOSTIC TESTS, ROUTINE**

ADMITTING DEPARTMENT, HOSPITAL

ORGANIZATION & ADMINISTRATION

Patient registration. No one leaves home without it. Appleby C. **Hosp Health Netw** 1997 Feb 5;71(3):72

STANDARDS

Accuracy of routinely collected clinical data on acute medical admissions to one hospital. Hobbs FD, et al.
Br J Gen Pract 1997 Jul;47(420):439–40

ADNEXA UTERI

Postmenopausal adnexal cysts: how clinical management has evolved. Goldstein SR. **Am J Obstet Gynecol** 1996 Dec; 175(6):1498–501 (17 ref.)
Intermittent partial adnexal torsion after electrosurgical tubal ligation. Sasso RA. **J Am Assoc Gynecol Laparosc** 1996 May;3(3):427–30

ANATOMY & HISTOLOGY

Normal adnexa uteri specimens: anatomic basis of MR imaging features. Outwater EK, et al. **Radiology** 1996 Dec; 201(3):751–5

BLOOD SUPPLY

Gray scale sonography, subjective evaluation of the color Doppler image and measurement of blood flow velocity for distinguishing benign and malignant tumors of suspected adnexal origin. Valentin L.
Eur J Obstet Gynecol Reprod Biol 1997 Mar;72(1):63–72

CHEMISTRY

Estrogen and progesterone receptors in the uterosacral ligament. Mokrzycki ML, et al. **Obstet Gynecol** 1997 Sep; 90(3):402–4

EMBRYOLOGY

Distribution of lactate dehydrogenase isoenzymes in coelomic fluid and fetal adnexae. Gulbis B, et al. **Placenta** 1996 Jul–Aug;17(5–6):367–70

ENZYMOLOGY

Distribution of lactate dehydrogenase isoenzymes in coelomic fluid and fetal adnexae. Gulbis B, et al. **Placenta** 1996 Jul–Aug;17(5–6):367–70

SURGERY

Hysterectomy with adnexectomy. Can operative laparoscopy offer advantages? Chapron C, et al. **J Reprod Med** 1997 Apr;42(4):201–6
[Total abdominal castration for septic utero–adnexal lesions. Coelo–hystero–salpingo–oophorectomy. 1897 (classical article)] Ionescu T. **Chirurgia (Bucur)** 1997 Jan–Feb; 92(1):15–21 **(Rum)**

ULTRASONOGRAPHY

Transvaginal ultrasonography in gynecologic office practice: assessment in 663 premenopausal women. Reuss ML, et al. **Am J Obstet Gynecol** 1996 Nov;175(5):1189–94
Gray scale sonography, subjective evaluation of the color Doppler image and measurement of blood flow velocity for distinguishing benign and malignant tumors of suspected adnexal origin. Valentin L.
Eur J Obstet Gynecol Reprod Biol 1997 Mar;72(1):63–72
Preoperative evaluation of cystic teratoma: what does color Doppler add? Kurjak A, et al. **J Clin Ultrasound** 1997 Jul–Aug;25(6):309–16
Conservative management of postmenopausal pelvic echo–free findings—preliminary results. Pardo J, et al.
Maturitas 1996 Apr;23(3):279–83
Diagnostic formula for the differentiation of adnexal tumors by transvaginal sonography. Prömpeler HJ, et al.
Obstet Gynecol 1997 Mar;89(3):428–33
Doppler findings in chronic ectopic pregnancy: case report. Abramov Y, et al. **Ultrasound Obstet Gynecol** 1997 May; 9(5):344–6

ADNEXAL DISEASES

Adnexal torsion in pregnancy. Mancuso A, et al.
Acta Obstet Gynecol Scand 1997 Jan;76(1):83–4

CHEMICALLY INDUCED

Adenomyosis in the broad ligament and tamoxifen: report of a case. Chung YP, et al. **J Obstet Gynaecol Res** 1997 Feb;23(1):69–73

CLASSIFICATION

Do we really have a reproducible classification system for pelvic organ prolapse? [letter; comment] Bernardes J, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):248. Comment on: Am J Obstet Gynecol 1996 Dec;175(6):1467–70; discussion 1470–1.

COMPLICATIONS

Laparoscopic oophoropexy for recurrent adnexal torsion. Righi RV, et al. **Hum Reprod** 1995 Dec;10(12):3136–8

DIAGNOSIS

Adnexal torsion in adolescents: prompt diagnosis and treatment may save the adnexa. Ben–Arie A, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Dec;63(2):169–73
Microlaparoscopy: a comparative study of diagnostic accuracy. Faber BM, et al. **Fertil Steril** 1997 May; 67(5):952–4
Adenomyosis in the broad ligament and tamoxifen: report of a case. Chung YP, et al. **J Obstet Gynaecol Res** 1997 Feb;23(1):69–73
Tuboovarian abscess in the adolescent. Huang A, et al.
J Pediatr Adolesc Gynecol 1997 May;10(2):73–7
[Operative laparoscopy and the adnexal cystic mass: where to set the limit?] Canis M, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(3):293–303 (Eng. Abstr.) **(Fre)**

ECONOMICS

Safe and cost–effective laparoscopic removal of adnexal masses. Quinlan DJ, et al.
J Am Assoc Gynecol Laparosc 1997 Feb;4(2):215–8

EPIDEMIOLOGY

The frequency and significance of adnexal lesions incidentally revealed by CT. Slanetz PJ, et al.
AJR Am J Roentgenol 1997 Mar;168(3):647–50

ETIOLOGY

Sequential bilateral adnexal torsion after a single cycle of gonadotropin ovulation induction with intrauterine insemination. Child TJ, et al. **Fertil Steril** 1997 Mar; 67(3):573–5

HISTORY

[Total abdominal castration for septic utero–adnexal lesions. Coelo–hystero–salpingo–oophorectomy. 1897 (classical article)] Ionescu T. **Chirurgia (Bucur)** 1997 Jan–Feb; 92(1):15–21 **(Rum)**

MICROBIOLOGY

Chlamydia trachomatis antibody titres by enzyme–linked immunosorbent assay are useful in predicting severity of adnexal adhesion. Tanikawa M, et al. **Hum Reprod** 1996 Nov;11(11):2418–21

PATHOLOGY

The prognostic significance of minimal intracystic vegetations during operative laparoscopy for adnexal masses in women of reproductive age. Caruana P, et al.
J Am Assoc Gynecol Laparosc 1996 Feb;3(2):241–4

PREVENTION & CONTROL

Fixation of Interceed does not improve its efficacy against adhesion formation in rats. Ramsewak S, et al.

ADNEXAL DISEASES

Clin Exp Obstet Gynecol 1996;23(3):147–9

RADIOGRAPHY

The frequency and significance of adnexal lesions incidentally revealed by CT. Slanetz PJ, et al.
AJR Am J Roentgenol 1997 Mar;168(3):647–50

SURGERY

Laparoscopic management of suspicious adnexal masses. Childers JM, et al. **Am J Obstet Gynecol** 1996 Dec; 175(6):1451–7; discussion 1457–9

The management of a persistent adnexal mass in pregnancy [letter; comment] Lavie O, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):750. Comment on: Am J Obstet Gynecol 1995 Oct;173(4):1236–40.

Use of adhesion prevention barriers in ovarian surgery, tubalplasty, ectopic pregnancy, endometriosis, adhesiolysis, and myomectomy. diZerega GS.
Curr Opin Obstet Gynecol 1996 Jun;8(3):230–7 (32 ref.)

Adnexal torsion in adolescents: prompt diagnosis and treatment may save the adnexa. Ben-Arie A, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Dec;63(2):169–73

Salpingo-oophorectomy for adnexal masses. Place and results for operative laparoscopy. Chapron C, et al.
Eur J Obstet Gynecol Reprod Biol 1997 May;73(1):43–8

Laparoscopic management of adnexal abscesses: consequences for fertility. Raiga J, et al. **Fertil Steril** 1996 Nov;66(5):712–7

Laparoscopic oophoropexy for recurrent adnexal torsion. Righi RV, et al. **Hum Reprod** 1995 Dec;10(12):3136–8

The prognostic significance of minimal intracystic vegetations during operative laparoscopy for adnexal masses in women of reproductive age. Caruana P, et al.
J Am Assoc Gynecol Laparosc 1996 Feb;3(2):241–4

Laparoscopic excision of pelvic masses during pregnancy. Neiswender LL, et al. **J Am Assoc Gynecol Laparosc** 1997 Feb;4(2):269–72

Endoscopic removal of pathologic specimens is always a challenge [letter; comment] Nimaroff ML.
J Am Assoc Gynecol Laparosc 1995 May;2(3):370–1. Comment on: J Am Assoc Gynecol Laparosc 1994 Aug;1(4 Pt 1):401–4.

Safe and cost-effective laparoscopic removal of adnexal masses. Quinlan DJ, et al.
J Am Assoc Gynecol Laparosc 1997 Feb;4(2):215–8

Management of adnexal masses by operative laparoscopy. van Herendael B, et al. **J Am Assoc Gynecol Laparosc** 1995 May;2(3):273–7

The laparoscopic approach to uterine adnexal torsion in childhood. Cohen Z, et al. **J Pediatr Surg** 1996 Nov; 31(11):1557–9

Laparoscopy for adnexal torsion in pregnant women. Morice P, et al. **J Reprod Med** 1997 Jul;42(7):435–9

Laparoscopic management of adnexal masses suspicious at ultrasound. Canis M, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):679–83

[Adnexal torsion in children: plea for early laparoscopic diagnosis and treatment] Meynol F, et al. **Arch Pediatr** 1997 May;4(5):416–9 (Eng. Abstr.) **(Fre)**

[Operative laparoscopy and the adnexal cystic mass: where to set the limit?] Canis M, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(3):293–303 (Eng. Abstr.) **(Fre)**

[Treatment of adnexal tumors with laparoscopy] Treviño Alanís R, et al. **Ginecol Obstet Mex** 1997 Apr;65:131–6 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Transvaginal sonographic diagnosis of ovarian endometrioma. Dogan MM, et al.
Int J Gynaecol Obstet 1996 Feb;52(2):145–9

Recognition of tubo-ovarian abscess in adolescents with pelvic inflammatory disease. Slap GB, et al.
J Adolesc Health 1996 Jun;18(6):397–403

Laparoscopic management of adnexal masses suspicious at ultrasound. Canis M, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):679–83

Transvaginal color Doppler sonography in adnexal masses: which parameter performs best? Alcázar JL, et al.
Ultrasound Obstet Gynecol 1996 Aug;8(2):114–9

[Adnexal torsion in children: plea for early laparoscopic diagnosis and treatment] Meynol F, et al. **Arch Pediatr** 1997 May;4(5):416–9 (Eng. Abstr.) **(Fre)**

ADNEXITIS

On "Pelvic inflammatory disease in patients seropositive for HIV" [letter; comment] Oosterhuis JW. **Eur J Surg** 1996 Aug;162(8):669. Comment on: Eur J Surg 1996 Jan;162(1):67–9.

Pelvic inflammatory disease. Mann SN, et al.
Int J STD AIDS 1996 Aug-Sep;7(5):315–21 (58 ref.)

[Pelvic inflammatory disease--associated factors and therapy--still a current topic] Ožana M, et al.
Ceska Gynekol 1997 Apr;62(2):78–81 **(Cze)**

[A rare case of primary abdominal actinomycosis] Lazzaretti MG, et al. **Minerva Chir** 1996 Sep;51(9):707–11 (Eng. Abstr.) **(Ita)**

BLOOD

Pelvic inflammatory disease. Correlation of severity with CA-125 levels. Moley KH, et al. **J Reprod Med** 1996 May; 41(5):341–6

COMPLICATIONS

Pelvic inflammatory disease and risk of ovarian cancer. Parazzini F, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):667–9

Rectal stricture caused by actinomycosis of the pelvis. Bertram P, et al. **Eur J Surg** 1996 Oct;162(10):837–9 (8 ref.)

Pelvic inflammatory disease in HIV-positive women. Sweet RL, et al. **Lancet** 1997 May 3;349(9061):1265–6

Pelvic inflammatory disease and human immunodeficiency virus infection. Barbosa C, et al. **Obstet Gynecol** 1997 Jan; 89(1):65–70

Acute pelvic inflammatory disease: associations of clinical and laboratory findings with laparoscopic findings. Eschenbach DA, et al. **Obstet Gynecol** 1997 Feb; 89(2):184–92

DIAGNOSIS

Pelvic inflammatory disease in patients with bilateral tubal ligation. Abbuhl SB, et al. **Am J Emerg Med** 1997 May; 15(3):271–4

Oral contraception and the recognition of endometritis. Ness RB, et al. **Am J Obstet Gynecol** 1997 Mar;176(3):580–5

Tubal torsion appearing as acute pelvic inflammatory disease. Maynard SR, et al. **J Am Assoc Gynecol Laparosc** 1996 May;3(3):431–3

The adolescent with pelvic inflammatory disease: assessment and management. Ivey JB. **Nurse Pract** 1997 Feb;22(2):78, 81–4, 87–8, passim; quiz 92–3 (17 ref.)

[Benign increase of tumor marker Ca 12-5 in pelvic peritonitis with ascites] Löseke A, et al.
Geburtshilfe Frauenheilkd 1996 Jul;56(7):365–7 (Eng. Abstr.) **(Ger)**

[Abdominal actinomycosis with IUD] Kamprath S, et al.
Zentralbl Gynakol 1997;119(1):21–4 (Eng. Abstr.) **(Ger)**

[Role of the immune parameter neopterin in adnexitis] Marth C, et al. **Zentralbl Gynakol** 1996;118(3):164–8 (Eng. Abstr.) **(Ger)**

[Evaluation of the assay technique for detection of anti-chlamydial IgA and IgG antibodies in PID patients] Yasuda J, et al. **Kansenshogaku Zasshi** 1997 Mar;71(3):241–7 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Incidence of Chlamydia trachomatis in women with PID: effectiveness of therapy. De Punzio C, et al.
Acta Eur .Fertil 1995 Jul-Aug;26(4):149–51

Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Arredondo JL, et al. **Clin Infect Dis** 1997 Feb; 24(2):170–8

A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. Hemsell DL, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S222–30

Recent advances in antibiotic regimens for the treatment of obstetric-gynecologic infections. Zambrano D.
Clin Ther 1996 Mar-Apr;18(2):214–27; discussion 213 (72 ref.)

ACOG educational bulletin. Antibiotics and gynecologic infections. American College of Obstetricians and Gynecologists. Number 237, June 1997 (Replaces No. 153, March 1991). **Int J Gynaecol Obstet** 1997 Sep;58(3):333–40

The adolescent with pelvic inflammatory disease: assessment and management. Ivey JB. **Nurse Pract** 1997 Feb;22(2):78, 81–4, 87–8, passim; quiz 92–3 (17 ref.)

[Lymph dilution as a method of treatment in endotoxicosis] Iarema IV, et al. **Anesteziol Reanimatol** 1997 May-Jun; (3):57–9 (Eng. Abstr.) **(Rus)**

[Comparative evaluation of the effectiveness of ofloxacin in comprehensive treatment of acute inflammatory diseases of the uterus and uterine appendages] Savel'eva GM, et al. **Antibiot Khimioter** 1996;41(9):81–3 (Eng. Abstr.) **(Rus)**

[Antibiotic therapy in the treatment of inflammatory diseases in the minor pelvis] Vasiljević M, et al.
Srp Arh Celok Lek 1996 Jul-Aug;124(7-8):193–6 (Eng. Abstr.) **(Scc)**

EPIDEMIOLOGY

Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Hillis SD, et al.
Am J Obstet Gynecol 1997 Jan;176(1 Pt 1):103–7

Vaginal douching and adverse health effects: a meta-analysis. Zhang J, et al. **Am J Public Health** 1997 Jul;87(7):1207–11

Antibody to chlamydial hsp60 predicts an increased risk for chlamydial pelvic inflammatory disease. Peeling RW, et al. **J Infect Dis** 1997 May;175(5):1153–8

A profile of inpatient STD-related pelvic inflammatory disease in the Top End of the Northern Territory of Australia [see comments] Mein J, et al. **Med J Aust** 1997 May 5;166(9):464–7. Comment in: Med J Aust 1997 May 5;166(9):456–7.

Risk factors for pelvic inflammatory disease. A case control study. Jossens MO, et al. **Sex Transm Dis** 1996 May-Jun; 23(3):239–47

[Genital tuberculosis--increased incidence or coincidence] Lueken RP, et al. **Zentralbl Gynakol** 1997;119(1):39–41 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Intrauterine device and pelvic inflammatory disease. Khomassuridze AG, et al. **Adv Contracept** 1997 Mar; 13(1):71–8

The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease. Spinillo A, et al. **Contraception** 1996 Sep;54(3):163–8

Papillary endothelial hyperplasia of adnexal vasculature [letter; comment] Johnson JS, et al. **Histopathology** 1996 Nov;29(5):492. Comment on: Histopathology 1996 Feb;28(2):157–61.

Chlamydia trachomatis in pelvic inflammatory disease. Shrikhande SN, et al. **Indian J Pathol Microbiol** 1995 Apr; 38(2):181–4

On the need to screen for Chlamydia and gonorrhea infections prior to colposcopy in adolescents. Harel Z, et al. **J Adolesc Health** 1997 Aug;21(2):87–90

Late manifestation of pelvic abscess following oocyte retrieval, for in vitro fertilization, in patients with severe endometriosis and ovarian endometriomata. Younis JS, et al. **J Assist Reprod Genet** 1997 Jul;14(6):343–6

Intrauterine devices and pelvic inflammatory disease: evolving perspectives on the data. Burkman RT.
Obstet Gynecol Surv 1996 Dec;51(12 Suppl):S35–41 (46 ref.)

[Multiple liver abscesses in long-term intrauterine device] Klare P, et al. **Zentralbl Gynakol** 1996;118(9):530–2 (Eng. Abstr.) **(Ger)**

[Infectious complications of diagnostic hysteroscopy] Bracco PL, et al. **Minerva Ginecol** 1996 Jul-Aug;48(7-8):293–8 (Eng. Abstr.) **(Ita)**

GENETICS

Evidence of genetic susceptibility to Chlamydia trachomatis-induced pelvic inflammatory disease in the pig-tailed macaque. Lichtenwalner AB, et al.
Infect Immun 1997 Jun;65(6):2250–3

IMMUNOLOGY

Prevalence and correlates of antibody to chlamydial heat shock protein in women attending sexually transmitted disease clinics and women with confirmed pelvic inflammatory disease. Eckert LO, et al. **J Infect Dis** 1997 Jun;175(6):1453–8

[The immune status of patients with acute inflammatory diseases of adnexa uteri associated with different combinations of microorganisms] Antonova LV, et al.
Zh Mikrobiol Epidemiol Immunobiol 1996 Jan-Feb; (1):49–53 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Chlamydial pelvic inflammatory disease. Paavonen J, et al. **Hum Reprod Update** 1996 Nov-Dec;2(6):519–29 (104 ref.)

Pelvic inflammatory disease isolates of Neisseria gonorrhoeae are distinguished by C1q-dependent virulence for newborn rats and by the sac-4 region. Nowicki S, et al.
Infect Immun 1997 Jun;65(6):2094–9

Association of Ureaplasma urealyticum biovars with clinical outcome for neonates, obstetric patients, and gynecological patients with pelvic inflammatory disease. Abele-Horn M, et al. **J Clin Microbiol** 1997 May;35(5):1199–202

Screening for chlamydia to prevent pelvic inflammatory disease [letter] Perez JA Jr, et al. **N Engl J Med** 1996 Nov 14;335(20):1532; discussion 1532–3

Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. Kamwendo F, et al. **Sex Transm Dis** 1996 Sep-Oct; 23(5):384–91

Mycoplasma genitalium in the cervices of Japanese women. Uno M, et al. **Sex Transm Dis** 1997 May;24(5):284–6

PATHOLOGY

[Broad actinomyces abscess in pelvic cavity and abdominal wall--a case report] Terada Y, et al.
Nippon Sanka Fujinka Gakkai Zasshi 1996 Oct;48(10):904–6 **(Jpn)**

PREVENTION & CONTROL

Preventing and managing pelvic inflammatory disease: key questions, practices, and evidence. Washington E, et al. **J Fam Pract** 1996 Sep;43(3):283–93 (29 ref.)

Screening for chlamydia to prevent pelvic inflammatory disease [letter] Abter EI, et al. **N Engl J Med** 1996 Nov 14;335(20):1531; discussion 1532–3

Screening for chlamydia to prevent pelvic inflammatory disease [letter] Pittrof R. **N Engl J Med** 1996 Nov 14; 335(20):1532; discussion 1532–3

Screening for chlamydia to prevent pelvic inflammatory disease [letter] Sellors J, et al. **N Engl J Med** 1996 Nov 14;335(20):1531–2; discussion 1532–3

Management of pelvic inflammatory disease by primary care

physicians. A comparison with Centers for Disease Control and Prevention guidelines. Hessol NA, et al. **Sex Transm Dis** 1996 Mar–Apr;23(2):157–63

Partner notification to prevent pelvic inflammatory disease in women. Cost–effectiveness of two strategies. Howell MR, et al. **Sex Transm Dis** 1997 May;24(5):287–92

REHABILITATION

[The effect of a low–frequency magnetic field on the clinico–immunological indices of patients with chronic inflammatory diseases of the organs of the female genital system] Markina LP, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Sep–Oct;(5):22–5 (Eng. Abstr.) **(Rus)**

[The treatment results in inflammatory diseases of the adnexa uteri with different methods of using sinusoidal modulated currents] Reshetov PP, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Nov–Dec; (6):27–8 (Eng. Abstr.) **(Rus)**

[An intensive regimen of supersonic–frequency–current therapy in chronic inflammation of the adnexa uteri] Strugatskiĭ VM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Mar–Apr; (2):29–33 (Eng. Abstr.) **(Rus)**

SURGERY

Laparoscopic approach to pelvic congestion syndrome. Grabham JA, et al. **Br J Surg** 1997 Sep;84(9):1264

Percutaneous abscess drainage in gynecologic cancer patients. Ramondetta LM, et al. **Gynecol Oncol** 1996 Sep; 62(3):366–9

Saline injection into the perirectal space to assist transgluteal drainage of deep pelvic abscesses. Shah H, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):119–21

THERAPY

Do women with pelvic inflammatory disease receive adequate treatment? Reid S, et al. **Int J STD AIDS** 1997 Jul;8(7):466–7

An audit of the management of pelvic inflammatory disease. Wales NM, et al. **Int J STD AIDS** 1997 Jun;8(6):409–11

Preventing and managing pelvic inflammatory disease: key questions, practices, and evidence. Washington E, et al. **J Fam Pract** 1996 Sep;43(3):283–93 (29 ref.)

ULTRASONOGRAPHY

Power Doppler ultrasound: a potentially useful alternative in diagnosing pelvic pathologic conditions. Papadimitriou A, et al. **Clin Exp Obstet Gynecol** 1996;23(4):229–32

Hemodynamic assessment in pelvic inflammatory disease by transvaginal color Doppler ultrasonography. Alataş C, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec;70(1):75–8

Benign pelvic masses: sonographic spectrum. Fried AM, et al. **Radiographics** 1996 Mar;16(2):321–34

US case of the day. Actinomycotic pelvic abscess secondary to an IUD with involvement of the bladder, sigmoid colon, left ureter, liver, and upper abdominal wall. Hochsztein JG, et al. **Radiographics** 1996 May;16(3):713–6

Transvaginal sonography in suspected pelvic inflammatory disease. Taipale P, et al. **Ultrasound Obstet Gynecol** 1995 Dec;6(6):430–4

[Vaginal ultrasound in perityphlitic abscess] Hönigl W, et al. **Ultraschall Med** 1997 Feb;18(1):39–41 (Eng. Abstr.) **(Ger)**

VIROLOGY

Recovery of cytomegalovirus and herpes simplex virus from upper and lower genital tract specimens obtained from women with pelvic inflammatory disease. Clarke LM, et al. **J Infect Dis** 1997 Jul;176(1):286–8

ADOLESCENCE

Justice system clients of a Toronto youth addiction treatment program. Ogborne AC. **Am J Drug Alcohol Abuse** 1997 May;23(2):335–41

Toward a strategy for healthy adolescent development. Hamburg DA. **Am J Psychiatry** 1997 Jun;154(6 Suppl):6–12 (34 ref.)

Annotation: preventive screening for health risks among adolescents [comment] Barnett HL. **Am J Public Health** 1996 Dec;86(12):1701. Comment on: Am J Public Health 1996 Dec;86(12):1767–72.

Youth and violence on local television news in California. Dorfman L, et al. **Am J Public Health** 1997 Aug; 87(8):1311–6

The impact of parental consent on the HIV testing of minors [see comments] Meehan TM, et al. **Am J Public Health** 1997 Aug;87(8):1338–41. Comment in: Am J Public Health 1997 Aug;87(8):1277–8.

Adolescent polycystic ovary syndrome. Dramusic V, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:194–208 (22 ref.)

The adolescent: vulnerable to develop an eating disorder and at high risk for long–term sequelae. Golden NH. **Ann N Y Acad Sci** 1997 May 28;817:94–7 (14 ref.)

Adolescents with anorexia nervosa: the impact of the disorder on bones and brains. Katzman DK, et al. **Ann N Y Acad Sci** 1997 May 28;817:127–37 (76 ref.)

Adolescent substance use and abuse. Blum RW. **Arch Pediatr Adolesc Med** 1997 Aug;151(8):805–8 (21 ref.)

Parent and adolescent perceived need for parental consent involving research with minors. Sikand A, et al. **Arch Pediatr Adolesc Med** 1997 Jun;151(6):603–7

Health status of well vs ill adolescents. Starfield B, et al. **Arch Pediatr Adolesc Med** 1996 Dec;150(12):1249–56

Your next pediatric dental patient may be a parent. Waldman HB. **ASDC J Dent Child** 1996 May–Jun;63(3):222–7, 228

Current developments in new vaccines for adolescents. Rappuoli R. **Biologicals** 1997 Jun;25(2):159–63 (36 ref.)

Cutting tobacco taxes, endangering youth [letter; comment] Birkett N. **Can Med Assoc J** 1997 May 15;156(10):1377–8 . Comment on: Can Med Assoc J 1997 Jan 15;156(2):187–91.

Lifestyle changes during adolescence and risk of breast cancer: an ecologic study of the effect of World War II in Norway. Tretli S, et al. **Cancer Causes Control** 1996 Sep; 7(5):507–12

Shelters for runaway and homeless youths: capacity and occupancy. Greene JM, et al. **Child Welfare** 1997 Jul–Aug; 76(4):549–61

Concrete strategies for sensitizing youth–serving agencies to the needs of gay, lesbian, and other sexual minority youths. Phillips S, et al. **Child Welfare** 1997 May–Jun;76(3):393–409

Understanding obesity in youth. A statement for healthcare professionals from the Committee on Atherosclerosis and Hypertension in the Young of the Council on Cardiovascular Disease in the Young and the Nutrition Committee, American Heart Association. Writing Group. Gidding SS, et al. **Circulation** 1996 Dec 15;94(12):3383–7

"A violence prevention program targeting adolescents" [editorial] Sikand VK. **Conn Med** 1996 Jan;60(1):41

Family caregiving: the positive impact on adolescent relationships. Beach DL. **Gerontologist** 1997 Apr; 37(2):233–8

General and reproductive health of adolescent girls in rural south India. Joseph GA, et al. **Indian Pediatr** 1997 Mar; 34(3):242–5

Eating disorders in adolescence in a Swiss epidemiological study. Steinhausen HC, et al. **Int J Eat Disord** 1997 Sep; 22(2):147–51

Contraception for the adolescent patient. Kaunitz AM. **Int J Fertil Womens Med** 1997 Jan–Feb;42(1):30–8 (34 ref.)

Adolescent health [editorial] Foxcroft DR. **J Adolesc** 1997 Feb;20(1):3–7

Adolescent health in Russia: a view from Moscow and St. Petersburg. Blum RW, et al. **J Adolesc Health** 1996 Oct; 19(4):308–14

"Great transitions, preparing adolescents for a new century". A commentary on the health component of the concluding report of the Carnegie Council on Adolescent Development. Cohen MI. **J Adolesc Health** 1996 Jul; 19(1):2–5

Determinants of health of North–American adolescents: evolving definitions, recent findings, and proposed research agenda. Raphael D. **J Adolesc Health** 1996 Jul;19(1):6–16 (97 ref.)

Comment on physical activity [letter; comment] Tsakok AD. **J Clin Epidemiol** 1997 May;50(5):631. Comment on: J Clin Epidemiol 1996 Feb;49(2):125–34.

Adolescent parents and medical decision–making. De Ville K. **J Med Philos** 1997 Jun;22(3):253–70 (52 ref.)

Adolescent mothering: child–grandmother attachment. Patterson DL. **J Pediatr Nurs** 1997 Aug;12(4):228–37

Ethnic differences in adolescents' perceived health status: preliminary findings. Rew L. **J Pediatr Nurs** 1997 Aug; 12(4):223–7

The evolution of gait in childhood and adolescent cerebral palsy. Johnson DC, et al. **J Pediatr Orthop** 1997 May–Jun; 17(3):392–6

Psychosocial disorders in young people: on the agenda but not on the mend. Eckersley R. **Med J Aust** 1997 Apr 21; 166(8):423–4 (23 ref.)

Meeting the challenge of adolescent mental health [editorial] Patton GC. **Med J Aust** 1997 Apr 21;166(8):399–400 (18 ref.)

The adolescent with pelvic inflammatory disease: assessment and management. Ivey JB. **Nurse Pract** 1997 Feb;22(2):78, 81–4, 87–8, passim; quiz 92–3 (17 ref.)

Adolescent assault victim needs: a review of issues and a model protocol. American Academy of Pediatrics Task Force on Adolescent Assault Victim Needs. **Pediatrics** 1996 Nov;98(5):991–1001

The teenage driver. American Academy of Pediatrics Committee on Injury and Poison Prevention and Committee on Adolescence. **Pediatrics** 1996 Nov; 98(5):987–90

Graduated licensure: a win–win proposition for teen drivers and parents. Rosenberg ML, et al. **Pediatrics** 1996 Nov; 98(5):959–60

Assessing three adolescent groups in New Mexico using the Problem–oriented Screening Instrument. French LA, et al. **Psychol Rep** 1996 Aug;79(1):242

HIV/AIDS--information and knowledge: a comparative study of Kenyan and Swedish teenagers. Eriksson T, et al. **Scand J Soc Med** 1997 Jun;25(2):111–8

The natural history of low back pain in adolescents. Burton AK, et al. **Spine** 1996 Oct 15;21(20):2323–8

Tobacco industry efforts hindering enforcement of the ban on tobacco sales to minors: actions speak louder than words. DiFranza JR, et al. **Tob Control** 1996 Summer; 5(2):127–31

[Pelvic ultrasonography in the adolescent] Ardaens Y. **Contracept Fertil Sex** 1996 Nov;24(11):811–5 (6 ref.) **(Fre)**

[Health status of adolescents: what relations with family image? Adolescents Work Group] Villani S, et al. **Epidemiol Psichiatr Soc** 1997 Jan–Apr;6(1):59–68 (Eng. Abstr.) **(Ita)**

[Family and problems of young mothers] Leshkevich IA, et al. **Probl Sotsialnoi Gig Istor Med** 1996 Mar–Apr;(2):8–11 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Retrospective longitudinal growth study of boys and girls active in sport. Malina RM, et al. **Acta Paediatr** 1996 May; 85(5):570–6

Sexual maturation in East German boys. Willers B, et al. **Acta Paediatr** 1996 Jul;85(7):785–8

Age–related changes in the pediatric brain: quantitative MR evidence of maturational changes during adolescence. Steen RG, et al. **AJNR Am J Neuroradiol** 1997 May; 18(5):819–28

Intensive dance practice. Repercussions on growth and puberty. Pigeon P, et al. **Am J Sports Med** 1997 Mar–Apr; 25(2):243–7

An overview of adolescent eating behavior barriers to implementing dietary guidelines. Adams LB. **Ann N Y Acad Sci** 1997 May 28;817:36–48 (27 ref.)

Menses in underweight Guyanese adolescents. Bontempo SA, et al. **Ann N Y Acad Sci** 1997 May 28;817:351–2

Chronic undernutrition during adolescence. Eisenstein E. **Ann N Y Acad Sci** 1997 May 28;817:138–61 (36 ref.)

Physical activity and teenage health. A program to improve cardiovascular fitness, health behavior, and coronary disease risk factors in multiethnic teenagers. Fardy PS, et al. **Ann N Y Acad Sci** 1997 May 28;817:356–8

Methodological issues regarding eating behavior of high–risk adolescents. Frank GC. **Ann N Y Acad Sci** 1997 May 28; 817:66–82 (52 ref.)

The effect of metabolic programming on atherosclerosis and obesity risk factors in UK adolescents living in poor socioeconomic areas. Harland PS, et al. **Ann N Y Acad Sci** 1997 May 28;817:361–4

Community–based nutrition interventions: reaching adolescents from low–income communities. Hinkle AJ. **Ann N Y Acad Sci** 1997 May 28;817:83–93 (13 ref.)

Risk–taking behavior in adolescents: the paradigm. Irwin CE Jr, et al. **Ann N Y Acad Sci** 1997 May 28;817:1–35 (139 ref.)

Secular trends in cholesterol for suburban high school students in Long Island, New York, 1987–1995. Kohn MR, et al. **Ann N Y Acad Sci** 1997 May 28;817:396–7

Unhealthy eating and other risk–taking behavior: are they related? Lytle LA, et al. **Ann N Y Acad Sci** 1997 May 28;817:49–65 (31 ref.)

Relationship between physical activity and body composition in adolescents. Moreno LA, et al. **Ann N Y Acad Sci** 1997 May 28;817:372–4

Overview: nutrition for pregnant and childbearing adolescents. Rees JM. **Ann N Y Acad Sci** 1997 May 28; 817:241–5 (2 ref.)

Nutrition for pregnant and childbearing adolescents: demographics, developmental needs, behavior, and outcome. Rees JM. **Ann N Y Acad Sci** 1997 May 28; 817:246–50 (17 ref.)

Preliminary results of a multidisciplinary follow–up program for obese adolescents. Vitolo MR, et al. **Ann N Y Acad Sci** 1997 May 28;817:389–92

Body size and subcutaneous fat patterning in adolescence. Matthes JW, et al. **Arch Dis Child** 1996 Dec;75(6):521–3

The effects of basic training on aerobic fitness and muscular strength and endurance of British Army recruits. Legg SJ, et al. **Ergonomics** 1996 Dec;39(12):1403–18

The effects of maturation on self–induced dynamic body sway frequencies of girls performing acrobatics or classical dance. Golomer E, et al. **Eur J Appl Physiol** 1997; 76(2):140–4

Rate of maturation during the teenage years: nutrient intake and physical activity between ages 12 and 22. Kemper HC, et al. **Int J Sport Nutr** 1997 Sep;7(3):229–40

Height and social class in male adolescents from different ethnic backgrounds in Israel. Lusky A, et al. **Isr J Med Sci** 1997 Feb;33(2):117–22

Developmental issues influencing guidelines for adolescent health research: a review. Petersen AC, et al. **J Adolesc Health** 1995 Nov;17(5):298–305 (72 ref.)

Anxious children in adulthood: a prospective study of adjustment. Last CG, et al. **J Am Acad Child Adolesc Psychiatry** 1997 May; 36(5):645–52

Follow up of young people with high casual blood pressure. Cosenzi A, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S71–5

Correspondence between theoretical models and dual energy x–ray absorptiometry measurements of femoral cross–sectional growth during adolescence. van der Meulen MC, et al. **J Orthop Res** 1997 May;15(3):473–6

Metabolic determinants of the age–related improvement in one–mile run/walk performance in youth. Cureton KJ, et al. **Med Sci Sports Exerc** 1997 Feb;29(2):259–67

Neuropsychologic functions of early treated patients with phenylketonuria, on and off diet: results of a cross–national and cross–sectional study. Burgard P, et al. **Pediatr Res** 1997 Mar;41(3):368–74

ADOLESCENCE

Bone mineral density in geographically diverse adolescent populations. Sheth RD, et al. **Pediatrics** 1996 Nov; 98(5):948–51

Care of adolescent girls. Johnston E, et al. **Prim Care** 1997 Mar;24(1):53–65

PSYCHOLOGY see ADOLESCENT PSYCHOLOGY

ADOLESCENT BEHAVIOR

Alcohol use among injured patients aged 12 to 18 years. Mannenbach MS, et al. **Acad Emerg Med** 1997 Jan;4(1):40–4

Reckless driving in adolescence: 'state' and 'trait' factors. Arnett JJ, et al. **Accid Anal Prev** 1997 Jan;29(1):57–63

The effect of parental dental health behavior on that of their adolescent offspring. Astrøm AN, et al. **Acta Odontol Scand** 1996 Aug;54(4):235–41

The relationship of social context of drinking, perceived social norms, and parental influence to various drinking patterns of adolescents. Beck KH, et al. **Addict Behav** 1996 Sep–Oct;21(5):633–44

The utility of novelty seeking, harm avoidance, and expectancy in the prediction of drinking. Galen LW, et al. **Addict Behav** 1997 Jan–Feb;22(1):93–106

Associations between drug use and deviant behavior in teenagers. Hays RD, et al. **Addict Behav** 1996 May–Jun; 21(3):291–302

Alcohol misuse and juvenile offending in adolescence. Fergusson DM, et al. **Addiction** 1996 Apr;91(4):483–94

Associations between drug use and behavioral repertoire in urban youths [published erratum appears in Addiction 1996 Nov;91(11):1731–3] Johanson CE, et al. **Addiction** 1996 Apr;91(4):523–34

Searching for the Magic Johnson effect: AIDS, adolescents, and celebrity disclosure. Brown BR Jr, et al. **Adolescence** 1996 Summer;31(122):253–64

Time perceptions and time allocation preferences among adolescent boys and girls. Bruno JE. **Adolescence** 1996 Spring;31(121):109–26

Understanding gender differences in adolescent sexuality. De Gaston JF, et al. **Adolescence** 1996 Spring;31(121):217–31

Knowledge and attitudes toward sexuality in adolescents and their association with the family and other factors. Huerta–Franco R, et al. **Adolescence** 1996 Spring; 31(121):179–91

The influence of peer affiliation and student activities on adolescent drug involvement. Jenkins JE. **Adolescence** 1996 Summer;31(122):297–306

Adolescents' perceptions of the role of part–time work. McKechnie J, et al. **Adolescence** 1996 Spring; 31(121):193–204

Adolescents in therapeutic communities. Mann–Feder VR. **Adolescence** 1996 Spring;31(121):17–28

Adolescents becoming adults: attributes for adulthood. Scheer SD, et al. **Adolescence** 1996 Spring;31(121):127–31

Family processes as predictors of adolescents' preferences for ascribed sources of moral authority: a proposed model. White FA. **Adolescence** 1996 Spring;31(121):133–44 (22 ref.)

Adolescence. Vancouver Conference Review. Elford J. **AIDS Care** 1997 Feb;9(1):62–6

Effects of a skill–based intervention to encourage condom use among high risk heterosexually active adolescents. Gillmore MR, et al. **AIDS Educ Prev** 1997 Feb;9(1 Suppl):22–43

An impact evaluation of project SNAPP: an AIDS and pregnancy prevention middle school program. Kirby D, et al. **AIDS Educ Prev** 1997 Feb;9(1 Suppl):44–61

Experimental evaluation of a modular approach to mobilizing antitobacco influences of peers and parents. Biglan A, et al. **Am J Community Psychol** 1996 Jun;24(3):311–39

Patterns of adolescent involvement in problem behaviors: relationship to self–efficacy, social competence, and life events. Chung H, et al. **Am J Community Psychol** 1996 Dec;24(6):771–84

Family, peer, and neighborhood influences on academic achievement among African–American adolescents: one–year prospective effects. Gonzales NA, et al. **Am J Community Psychol** 1996 Jun;24(3):365–87

Federal figures show teen drug use up sharply in 1995 [news] **Am J Health Syst Pharm** 1996 Oct 1;53(19):2255

The familial aggregation of depressive symptoms, antisocial behavior, and alcohol abuse. Stallings MC, et al. **Am J Med Genet** 1997 Apr 18;74(2):183–91

Youth at risk: definitions and implications for service delivery. Resnick G, et al. **Am J Orthopsychiatry** 1996 Apr; 66(2):172–88

A prosocial media strategy: "youth against violence: choose to de–fuse". Zimmerman JD. **Am J Orthopsychiatry** 1996 Jul;66(3):354–62

Impact of a one–day antismoking program on male secondary–school adolescents in southwestern Saudi Arabia. Abolfotouh MA, et al. **Am J Prev Med** 1997 May–Jun;13(3):151–2

Determinants of physical activity among female adolescents. Bungum TJ, et al. **Am J Prev Med** 1997 Mar–Apr; 13(2):115–22

The patterns and predictors of smokeless tobacco onset among urban public school teenagers. Hu FB, et al. **Am J Prev Med** 1996 Jan–Feb;12(1):22–8

Differences in the reported prevalence of adolescents who have never smoked [letter] Abernathy T. **Am J Public Health** 1997 Feb;87(2):298–9

Our view of adolescent sexuality––a focus on risk behavior without the developmental context [editorial; comment] [see comments] Ehrhardt AA. **Am J Public Health** 1996 Nov;86(11):1523–5. Comment on: Am J Public Health 1996 Nov;86(11):1570–6. Comment in: Am J Public Health 1997 Aug;87(8):1380–1.

Profiles of violent youth: substance use and other concurrent problems. Ellickson P, et al. **Am J Public Health** 1997 Jun; 87(6):985–91

Health care seeking behaviors related to sexually transmitted diseases among adolescents. Fortenberry JD. **Am J Public Health** 1997 Mar;87(3):417–20

Condom availability in New York City public high schools: relationships to condom use and sexual behavior. Guttmacher S, et al. **Am J Public Health** 1997 Sep; 87(9):1427–33

Weapon carrying among black adolescents: a social network perspective. Myers GP, et al. **Am J Public Health** 1997 Jun;87(6):1038–40

Patterns of health–compromising behaviors among Minnesota adolescents: sociodemographic variations. Neamark–Sztainer D, et al. **Am J Public Health** 1996 Nov; 86(11):1599–606

Associations between physical activity and other health behaviors in a representative sample of US adolescents. Pate RR, et al. **Am J Public Health** 1996 Nov; 86(11):1577–81

The sexual practices of adolescent virgins: genital sexual activities of high school students who have never had vaginal intercourse [see comments] Schuster MA, et al. **Am J Public Health** 1996 Nov;86(11):1570–6. Comment in: Am J Public Health 1996 Nov;86(11):1523–5. Comment in: Am J Public Health 1997 Aug;87(8):1380–1.

Adolescent smokers' provision of tobacco to other adolescents. Wolfson M, et al. **Am J Public Health** 1997 Apr;87(4):649–54

Intervention and prevention of steroid use in adolescents. Elliot D, et al. **Am J Sports Med** 1996;24(6 Suppl):S46–7

Firearm violence among youth [letter; comment] Davies DE. **Ann Emerg Med** 1997 Mar;29(3):424–5; discussion 426. Comment on: Ann Emerg Med 1996 Aug;28(2):204–12.

Firearm violence among youth [letter; comment] Fackler ML. **Ann Emerg Med** 1997 Mar;29(3):425–6. Comment on: Ann Emerg Med 1996 Aug;28(2):204–12.

Adolescent sexuality. Goldfarb AF. **Ann N Y Acad Sci** 1997 Jun 17;816:395–403 (08 ref.)

Female adolescent sexuality. The risks and management. Haka–Ikse K. **Ann N Y Acad Sci** 1997 Jun 17;816:466–70 (12 ref.)

Adolescent sexuality: an educational and counseling challenge. Ruusuvaara L. **Ann N Y Acad Sci** 1997 Jun 17; 816:411–3

Sexual health contraceptive needs of adolescents with chronic conditions. Blum RW. **Arch Pediatr Adolesc Med** 1997 Mar;151(3):290–7

Young adolescents' comfort with discussion about sexual problems with their physician [published erratum appears in Arch Pediatr Adolesc Med 1997 Feb;151(2):128] Boekeloo BO, et al. **Arch Pediatr Adolesc Med** 1996 Nov; 150(11):1146–52

Use of medication by adolescents for the management of menstrual discomfort. Campbell MA, et al. **Arch Pediatr Adolesc Med** 1997 Sep;151(9):905–13

The association of weapon carrying and fighting on school property and other health risk and problem behaviors among high school students. DuRant RH, et al. **Arch Pediatr Adolesc Med** 1997 Apr;151(4):360–6

Relationship between cigarette smoking and health risk and problem behaviors among US adolescents. Escobedo LG, et al. **Arch Pediatr Adolesc Med** 1997 Jan;151(1):66–71

Adolescent vegetarians. A behavioral profile of a school–based population in Minnesota. Neumark–Sztainer D, et al. **Arch Pediatr Adolesc Med** 1997 Aug;151(8):833–8

Do cigarette warning labels reduce smoking? Paradoxical effects among adolescents. Robinson TN, et al. **Arch Pediatr Adolesc Med** 1997 Mar;151(3):267–72

Cognitive and behavioral predictors of sexually transmitted disease risk behavior among sexually active adolescents. Sieving R, et al. **Arch Pediatr Adolesc Med** 1997 Mar; 151(3):243–51

Evolution of risk behaviors over 2 years among a cohort of urban African American adolescents. Stanton B, et al. **Arch Pediatr Adolesc Med** 1997 Apr;151(4):398–406

Psychological correlates of male child and adolescent sexual experiences with adults: a review of the nonclinical literature. Bauserman R, et al. **Arch Sex Behav** 1997 Apr; 26(2):105–41 (108 ref.)

Sexual activities and attitudes of adolescent Koreans. Youn G. **Arch Sex Behav** 1996 Dec;25(6):629–43

Just say no! sounds right, but... Waldman HB. **ASDC J Dent Child** 1996 May–Jun;63(3):216–21

Depression in adolescence. Walter G. **Aust Fam Physician** 1996 Oct;25(10):1575–82 (15 ref.)

Legal rights and responsibilities of adolescents and staff in Victorian Child and Adolescent Mental Health Services. Birleson P. **Aust N Z J Psychiatry** 1996 Dec;30(6):805–12

Referred adolescents as young adults: the relationship between psychosocial functioning and personality disorder. Rey JM, et al. **Aust N Z J Psychiatry** 1997 Apr; 31(2):219–26

Sex, alcohol and drugs? Young people's experience of Schoolies Week. Smith AM, et al. **Aust N Z J Public Health** 1997 Apr;21(2):175–80

Health risk and behaviour of out–of–school 16–year–olds in New South Wales. Tresidder J, et al. **Aust N Z J Public Health** 1997 Apr;21(2):168–74

Young people, alcohol, and designer drinks: quantitative and qualitative study [see comments] Hughes K, et al. **BMJ** 1997 Feb 8;314(7078):414–8. Comment in: BMJ 1997 May 31;314(7094):1622–3.

Which adolescents attend the GP? [letter] Kramer T, et al. **Br J Gen Pract** 1997 May;47(418):327

Understanding countertransference reactions in working with adolescent perpetrators of sexual abuse. Mintzer MB. **Bull Menninger Clin** 1996 Spring;60(2):219–28

Similarity of risk and protective behaviors among African–American pre– and early adolescent members of naturally occurring friendship groups. Fang X, et al. **Bull N Y Acad Med** 1996 Winter;73(2):285–300

Adolescent alcohol use: social determinants and the case for early family–centered prevention. Family–focused prevention of adolescent drinking. Schor EL. **Bull N Y Acad Med** 1996 Winter;73(2):335–56 (86 ref.)

School attendance, health–risk behaviors, and self–esteem in adolescents applying for working papers. Suss AL, et al. **Bull N Y Acad Med** 1996 Winter;73(2):255–66

Age and sex differences in physical inactivity among Ontario teenagers. Allison KR, et al. **Can J Public Health** 1997 May–Jun;88(3):177–80

Chewing of xylitol gum––a well adopted practice among finnish adolescents. Honkala E, et al. **Caries Res** 1996; 30(1):34–9

Reproductive biology knowledge, and behaviour of teenagers in East, Central and Southern Africa: the Zimbabwe case study. Mbizvo MT, et al. **Cent Afr J Med** 1995 Nov; 41(11):346–54

Cigarette smoking habits among schoolchildren. Meijer B, et al. **Chest** 1996 Oct;110(4):921–6

Self–reported health and behavioral problems among adolescent victims of rape in France: results of a cross–sectional survey. Choquet M, et al. **Child Abuse Negl** 1997 Sep;21(9):823–32

Diet, smoking and exercise: interrelationships between adolescent health behaviours. Coulson NS, et al. **Child Care Health Dev** 1997 May;23(3):207–16

Parenting styles, adolescents' attributions, and educational outcomes in nine heterogeneous high schools. Glasgow KL, et al. **Child Dev** 1997 Jun;68(3):507–29

Adolescents' age preferences for dating partners: support for an evolutionary model of life–history strategies. Kenrick DT, et al. **Child Dev** 1996 Aug;67(4):1499–511

Disruptiveness, friends' characteristics, and delinquency in early adolescence: a test of two competing models of development. Vitaro F, et al. **Child Dev** 1997 Aug; 68(4):676–89

An Afrocentric program for African American males in the juvenile justice system. Harvey AR, et al. **Child Welfare** 1997 Jan–Feb;76(1):197–211

Orgasm without organisms: science or propaganda? Genuis SJ, et al. **Clin Pediatr (Phila)** 1996 Jan;35(1):10–7 (105 ref.)

You won't know unless you ask: the biopsychosocial interview for adolescents. Perkins K, et al. **Clin Pediatr (Phila)** 1997 Feb;36(2):79–86; discussion 87–8

The gay adolescent: stressors, adaptations, and psychosocial interventions. Radkowsky M, et al. **Clin Psychol Rev** 1997; 17(2):191–216 (99 ref.)

Eating behaviour, weight status and depressive feelings in female adolescents. Vidović V, et al. **Coll Antropol** 1997 Jun;21(1):277–83

Health promotion of adolescents. Ye G. **Coll Antropol** 1997 Jun;21(1):93–100

Stages of change for sugar and fat reduction in an adolescent sample. Watt RG. **Community Dent Health** 1997 Jun; 14(2):102–7

Analysis of adolescents' beliefs about the outcome of using dental floss and drinking non–sugared mineral water. Astrøm AN, et al. **Community Dent Oral Epidemiol** 1996 Jun;24(3):211–6

Understanding decision–making processes for sugar consumption in adolescence. Freeman R, et al. **Community Dent Oral Epidemiol** 1997 Jun;25(3):228–32

Diagnostic comorbidity in hospitalized adolescents with conduct disorder. Fehon DC, et al. **Compr Psychiatry** 1997 May–Jun;38(3):141–5

New contraceptive options for adolescents. Neal W, et al. **Compr Ther** 1997 Jul;23(7):439–45 (23 ref.)

The relation of childhood personality types to adolescent behavior and development: a longitudinal study of Icelandic children. Hart D, et al. **Dev Psychol** 1997 Mar; 33(2):195–205

Abstaining and carousing: substance use among adolescents in the Western Isles of Scotland. Anderson K, et al. **Drug Alcohol Depend** 1996 Jul;41(3):189–96

Inhalants to heroin: a prospective analysis from adolescence to adulthood. Johnson EO, et al. **Drug Alcohol Depend** 1995 Dec;40(2):159–64

Intrusive thoughts in a non–clinical adolescent population. Allsopp M, et al. **Eur Child Adolesc Psychiatry** 1996 Apr; 5(1):25–32

Physical activity, adolescence, and health: an epidemiological perspective. Aaron DJ, et al. **Exerc Sport Sci Rev** 1997; 25:391–405 (62 ref.)

Let's party tonight: drinking patterns and breath alcohol values at high school parties. Schwartz RH, et al.

Fam Med 1997 May;29(5):326–31

Does condom availability make a difference? An evaluation of Philadelphia's health resource centers. Furstenberg FF Jr, et al. **Fam Plann Perspect** 1997 May–Jun;29(3):123–7

Maternal correlates of adolescent sexual and contraceptive behavior. Jaccard J, et al. **Fam Plann Perspect** 1996 Jul–Aug;28(4):159–65, 185

The impact of the Postponing Sexual Involvement curriculum among youths in California. Kirby D, et al. **Fam Plann Perspect** 1997 May–Jun;29(3):100–8

Adolescents' perceptions of health concerns: an exploratory study among rural midwestern youth. Weiler RM. **Health Educ Behav** 1997 Jun;24(3):287–99

The natural history of cigarette smoking from adolescence to adulthood: demographic predictors of continuity and change. Chassin L, et al. **Health Psychol** 1996 Nov; 15(6):478–84

Cluster versus individual randomization in adolescent tobacco and alcohol studies: illustrations for design decisions. Slymen DJ, et al. **Int J Epidemiol** 1997 Aug; 26(4):765–71

Improving adolescent sexual behavior: a tool for better fertility outcome and safe motherhood. Creatsas G. **Int J Gynaecol Obstet** 1997 Jul;58(1):85–92

Profile of patients attending a Dublin adolescent antenatal booking clinic. Fitzpatrick CC, et al. **Ir Med J** 1997 Apr–May;90(3):96–7

The role of adolescent peer affiliations in the continuity between childhood behavioral adjustment and juvenile offending. Fergusson DM, et al. **J Abnorm Child Psychol** 1996 Apr;24(2):205–21

Efficacy of a dating violence prevention program on attitudes justifying aggression. Avery-Leaf S, et al. **J Adolesc Health** 1997 Jul;21(1):11–7

Characteristics of students who bring weapons to school. Bailey SL, et al. **J Adolesc Health** 1997 Apr;20(4):261–70

Sexual behavior among adolescents reporting chronic conditions: a French national survey. Choquet M, et al. **J Adolesc Health** 1997 Jan;20(1):62–7

Are adolescents accurate in self-report of frequencies of sexually transmitted diseases and pregnancies? Clark LR, et al. **J Adolesc Health** 1997 Aug;21(2):91–6

Sociobehavioral influences on smoking initiation of Hispanic adolescents. Cowdery JE, et al. **J Adolesc Health** 1997 Jan; 20(1):46–50

Tobacco use among male high school athletes. Davis TC, et al. **J Adolesc Health** 1997 Aug;21(2):97–101

Dietary intakes of adolescent females consuming vegetarian, semi-vegetarian, and omnivorous diets. Donovan UM, et al. **J Adolesc Health** 1996 Apr;18(4):292–300

Comparison of two violence prevention curricula for middle school adolescents. DuRant RH, et al. **J Adolesc Health** 1996 Aug;19(2):111–7

Adolescent sexual strategies. Eyre SL, et al. **J Adolesc Health** 1997 Apr;20(4):286–93

Risky behavior and risk in adolescents with IDDM. Frey MA, et al. **J Adolesc Health** 1997 Jan;20(1):38–45

Female adolescents and onset of sexual intercourse: a theory-based review of research from 1984 to 1994. Goodson P, et al. **J Adolesc Health** 1997 Sep;21(3):147–56 (75 ref.)

Double suicide attempt among adolescents. Granboulan V, et al. **J Adolesc Health** 1997 Aug;21(2):128–30

Relationship of alcohol use and risky sexual behavior: a review and analysis of findings. Halpern-Felsher BL, et al. **J Adolesc Health** 1996 Nov;19(5):331–6 (42 ref.)

Evaluation of comprehensive violence prevention education: effects on student behavior. Hausman A, et al. **J Adolesc Health** 1996 Aug;19(2):104–10

HIV risk behaviors among adolescents at a sexually transmitted disease clinic in New York City. Heffernan R, et al. **J Adolesc Health** 1996 Jun;18(6):429–34

Predicting the stages of smoking acquisition according to the theory of planned behavior. Hill AJ, et al. **J Adolesc Health** 1997 Aug;21(2):107–15

Human immunodeficiency virus risk behavior among white and Asian/Pacific Islander high school students in the United States: does culture make a difference? Hou SI, et al. **J Adolesc Health** 1997 Jan;20(1):68–74

Amateur tattooing practices and beliefs among high school adolescents. Houghton SJ, et al. **J Adolesc Health** 1996 Dec;19(6):420–5

The rate and pattern of alcohol consumption among Chinese adolescents. Li X, et al. **J Adolesc Health** 1996 Nov; 19(5):353–61

What can we learn from Madison Avenue? [editorial] Litt IF. **J Adolesc Health** 1996 Oct;19(4):245

"Safe sun": preventing adult disease in adolescence [editorial; comment] Litt IF. **J Adolesc Health** 1996 Dec;19(6):377. Comment on: J Adolesc Health 1996 Dec;19(6):409–15.

An investigation of adolescent health from China. Liu GR. **J Adolesc Health** 1997 Apr;20(4):306–8

Adolescent heterosexual experience: a new typology. Miller KS, et al. **J Adolesc Health** 1997 Mar;20(3):179–86

Predictors of sun exposure in adolescents in a southeastern U.S. population [see comments] Reynolds KD, et al. **J Adolesc Health** 1996 Dec;19(6):409–15. Comment in: J Adolesc Health 1996 Dec;19(6):377.

Adolescent dimenhydrinate abuse: resurgence of an old problem. Rowe C, et al. **J Adolesc Health** 1997 Jul; 21(1):47–9

Puberty questions asked by early adolescents: what do they want to know? Ryan SA, et al. **J Adolesc Health** 1996 Aug;19(2):145–52

Concurrent risk factors for adolescent violence. Saner H, et al. **J Adolesc Health** 1996 Aug;19(2):94–103

Counseling sexually active teenagers treated with potential human teratogens. Shilalukey K, et al. **J Adolesc Health** 1997 Sep;21(3):143–6

The association of sexual risk behaviors and problem drug behaviors in high school students. Shrier LA, et al. **J Adolesc Health** 1997 May;20(5):377–83

Why pregnant adolescents say they did not use contraceptives prior to conception. Stevens-Simon C, et al. **J Adolesc Health** 1996 Jul;19(1):48–53; discussion 54–5

Sexual behavior of adolescents with chronic disease and disability. Suris JC, et al. **J Adolesc Health** 1996 Aug; 19(2):124–31

Problems in conceptualizing adolescent risk behaviors: international comparisons. Tursz A. **J Adolesc Health** 1997 Aug;21(2):116–27

Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. Biederman J, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Sep; 35(9):1193–204

African-American and Puerto Rican drug use: a longitudinal study. Brook JS, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Sep;36(9):1260–8

Thyroid hormone concentrations in depressed and nondepressed adolescents: group differences and behavioral relations [see comments] Dorn LD, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Mar; 35(3):299–306. Comment in: J Am Acad Child Adolesc Psychiatry 1997 Feb;36(2):159.

Gender differences in adolescent psychiatric outpatient substance use: associated behaviors and feelings. Martin CA, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Apr; 36(4):486–94

Inattentive and hyperactive behaviors and driving offenses in adolescence. Nada-Raja S, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Apr;36(4):515–22

Association of prenatal alcohol exposure with behavioral and learning problems in early adolescence. Olson HC, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Sep; 36(9):1187–94

Hyperactivity and conduct problems as risk factors for adolescent development. Taylor E, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Sep; 35(9):1213–26

Difficult decisions [editorial; comment] Lazebnik R. **J Am Board Fam Pract** 1997 Mar–Apr;10(2):170–2. Comment on: J Am Board Fam Pract 1997 Mar–Apr;10(2):96–103.

Discordance between patient self-reported visual analog scale pain scores and observed pain-related behavior in older children after surgery. Vetter TR, et al. **J Clin Anesth** 1996 Aug;8(5):371–5

Impact of exposure to community violence on violent behavior and emotional distress among urban adolescents. Farrell AD, et al. **J Clin Child Psychol** 1997 Mar;26(1):2–14

Self-concept and behavior in adolescent girls with Turner syndrome: potential estrogen effects. Ross JL, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):926–31

Self-concept and dental health behaviours in adolescents. Macgregor ID, et al. **J Clin Periodontol** 1997 May; 24(5):335–9

Acquired immunodeficiency syndrome and suburban adolescents: knowledge, attitudes, behaviors and risks. Imperato AM. **J Community Health** 1996 Oct;21(5):329–47

The relation between adolescent alcohol use and peer alcohol use: a longitudinal random coefficients model. Curran PJ, et al. **J Consult Clin Psychol** 1997 Feb;65(1):130–40

Predictors of risk for different stages of adolescent smoking in a biracial sample. Robinson LA, et al. **J Consult Clin Psychol** 1997 Aug;65(4):653–62

DSM-IV and disorders of childhood and adolescence: can structural criteria be functional? Scotti JR, et al. **J Consult Clin Psychol** 1996 Dec;64(6):1177–91

The Drug Involvement Scale for Adolescents (DISA). Eggert LL, et al. **J Drug Educ** 1996;26(2):101–30

A test of magnitude: does the strength of predictors explain differences in drug use among adolescents? Graham N. **J Drug Educ** 1997;27(1):83–104

Responsible decision making regarding alcohol: a re-emerging prevention/education strategy for the 1990s. Milgram GG. **J Drug Educ** 1996;26(4):357–65 (11 ref.)

Psychosocial correlates of substance use: comparing high school students with incarcerated offenders in Hong Kong. Wong CS, et al. **J Drug Educ** 1997;27(2):147–72

The development of gender schemata about heterosexual and homosexual others during adolescence. Mallet P, et al. **J Gen Psychol** 1997 Jan;124(1):91–104

The initiation of adolescent sexual and contraceptive behavior during changing times. Cooksey EC, et al. **J Health Soc Behav** 1996 Mar;37(1):59–74

Family cohesion as a buffer against the effects of problem-drinking fathers on psychological distress, deviant behavior, and heavy drinking in adolescents. Farrell MP, et al. **J Health Soc Behav** 1995 Dec;36(4):377–85

Teen sex, AIDS, and contraception: Part three [editorial] Dawson G. **J Natl Med Assoc** 1996 Dec;88(12):768–72

Teen sex, AIDS, and contraception: part two [editorial] Dawson G. **J Natl Med Assoc** 1996 Feb;88(2):77–80

Computer administration of a school-based adolescent health survey [see comments] Hibbert ME, et al. **J Paediatr Child Health** 1996 Oct;32(5):372–7. Comment in: J Paediatr Child Health 1996 Oct;32(5):371.

Gender differences in adolescent weight and shape-related beliefs and behaviour. Nowak M, et al. **J Paediatr Child Health** 1996 Apr;32(2):148–52

Sexuality and contraception in adolescents from Barcelona, Spain. Parera N, et al. **J Pediatr Adolesc Gynecol** 1997 Aug; 10(3):153–7

Management quandary. Quint EH. **J Pediatr Adolesc Gynecol** 1997 May;10(2):101–2

Female adolescent sexuality. Sugar M. **J Pediatr Adolesc Gynecol** 1996 Nov;9(4):175–83 (73 ref.)

Children's attitudes toward violence on television. Hough KJ, et al. **J Psychol** 1997 Jul;131(4):411–5

Why do adolescent girls watch their weight? An interview study examining sociocultural pressures to be thin. Wertheim EH, et al. **J Psychosom Res** 1997 Apr; 42(4):345–55

Teenagers' use of emergency contraception in a general practice. Seamark CJ, et al. **J R Soc Med** 1997 Aug; 90(8):443–4

Factors in adolescent drinking/driving: binge drinking, cigarette smoking, and gender. Copeland LA, et al. **J Sch Health** 1996 Sep;66(7):254–60

Safer Choices: a multicomponent school-based HIV/STD and pregnancy prevention program for adolescents. Coyle K, et al. **J Sch Health** 1996 Mar;66(3):89–94

Considering a decision-making approach to youth violence prevention programs. Haynie DL, et al. **J Sch Health** 1997 May;67(5):165–70

Youth risk behavior surveillance—United States, 1995. Kann L, et al. **J Sch Health** 1996 Dec;66(10):365–77

Sexual assault in dating relationships. Rhynard J, et al. **J Sch Health** 1997 Mar;67(3):89–93

Coping with controversy: the professional epidemic of the nineties. Spalt SW. **J Sch Health** 1996 Nov;66(9):339–40

Sexual risk-taking by Muscovite youth attending school. Westhoff WW, et al. **J Sch Health** 1996 Mar;66(3):102–5

Community reactions to reproductive health care at three school-based clinics in Louisiana. Zeanah PD, et al. **J Sch Health** 1996 Sep;66(7):237–41

Representations of eating among adolescent Italian girls. Riva G. **J Soc Psychol** 1997 Apr;137(2):205–17

An alcohol involvement typology for adolescents: convergent validity and longitudinal stability. Windle M. **J Stud Alcohol** 1996 Nov;57(6):627–37

Guns in young hands: a survey of urban teenagers' attitudes and behaviors related to handgun violence. Bergstein JM, et al. **J Trauma** 1996 Nov;41(5):794–8

Risk-taking behaviors among adolescent trauma patients. Spain DA, et al. **J Trauma** 1997 Sep;43(3):423–6

Effects of a multidimensional anabolic steroid prevention intervention. The Adolescents Training and Learning to Avoid Steroids (ATLAS) Program. Goldberg L, et al. **JAMA** 1996 Nov 20;276(19):1555–62

The National Longitudinal Study on Adolescent Health. Preliminary results: great expectations [editorial; comment] Klein JD. **JAMA** 1997 Sep 10;278(10):864–5. Comment on: JAMA 1997 Sep 10;278(10):823–32.

Protecting adolescents from harm. Findings from the National Longitudinal Study on Adolescent Health [see comments] Resnick MD, et al. **JAMA** 1997 Sep 10; 278(10):823–32. Comment in: JAMA 1997 Sep 10;278(10):864–5.

Twins behaving badly [letter] Harding JJ. **Lancet** 1997 Sep 20;350(9081):885

Genetic basis of bad behaviour in adolescents [letter] McGuffin P, et al. **Lancet** 1997 Aug 9;350(9075):411–2

Adolescents: daughters or alien sociopaths? Males M. **Lancet** 1997 Mar;349 Suppl 1:sI13–6

Preventing violence, preventing war. Ashford MW. **Med Confl Surviv** 1997 Jan–Mar;13(1):57–62 (7 ref.)

Caring for the terminally ill adolescent. Carr-Gregg MR, et al. **Med J Aust** 1997 Mar 3;166(5):255–8 (24 ref.)

Tobacco use among Missouri high school students, 1995. Miller N, et al. **Mo Med** 1997 Jul;94(7):332–7

"Sobering facts" [editorial] Thomas JR. **Mo Med** 1997 Feb; 94(2):57–8

The effect of enforcing tobacco-sales laws on adolescents' access to tobacco and smoking behavior. Rigotti NA, et al. **N Engl J Med** 1997 Oct 9;337(15):1044–51

Micro- and macrosocial conditions of adolescents' aggressiveness and antiforeigner attitudes. Klein-Allermann E, et al. **New Dir Child Dev** 1995 Winter; (70):71–83

Alternate models of positive health practices in adolescents. Yarcheski A, et al. **Nurs Res** 1997 Mar–Apr;46(2):85–92

The relationship between the frequency of exercise and the age of onset of sexual intercourse in adolescent females [letter] Brown JT, et al. **Nurse Pract** 1997 Feb;22(2):16–8, 171

Noncompliance in adolescent oral contraceptive users. Shell R. **Nurse Pract** 1995 Aug;20(8):7, 10

Television viewing and adolescent sexuality [letter] Turner HA. **Nurse Pract** 1996 Nov;21(11):15, 18, 23 (11 ref.)

Psychosocial concerns and health-compromising behaviors among overweight and nonoverweight adolescents. Neumark-Sztainer D, et al. **Obes Res** 1997 May;5(3):237–49

Inhalant abuse in children and adolescents. Henretig F. **Pediatr Ann** 1996 Jan;25(1):47–52

ADOLESCENT BEHAVIOR

Importance of dental problems according to 12- to 16-year-old children. Assink MH, et al. **Pediatr Dent** 1996 Sep-Oct;18(5):391-4

Pressures: impact on health of adolescents. Neal W, et al. **Pediatr Rev** 1996 Aug;17(8):263-4

Alcohol abuse. Takahashi A, et al. **Pediatr Rev** 1996 Feb; 17(2):39-45

American Academy of Pediatrics. Impact of music lyrics and music videos on children and youth (RE9144). Committee on Communications. **Pediatrics** 1996 Dec;98(6 Pt 1):1219-21 (38 ref.)

Maternal and perinatal risk factors for later delinquency. Conseur A, et al. **Pediatrics** 1997 Jun;99(6):785-90

Factors associated with HIV testing among sexually active adolescents: a Massachusetts survey. Samet JH, et al. **Pediatrics** 1997 Sep;100(3 Pt 1):371-7

The associations of suicide attempts in adolescents. Woods ER, et al. **Pediatrics** 1997 Jun;99(6):791-6

Psychosocial correlates of physical activity among fifth and eighth graders. Craig S, et al. **Prev Med** 1996 Sep-Oct; 25(5):506-13

Long-term responses of higher and lower risk youths to smoking prevention interventions. Flynn BS, et al. **Prev Med** 1997 May-Jun;26(3):389-94

Are adolescents receptive to current sales promotion practices of the tobacco industry? Gilpin EA, et al. **Prev Med** 1997 Jan-Feb;26(1):14-21

Summer sun exposure: knowledge, attitudes, and behaviors of Midwest adolescents. Robinson JK, et al. **Prev Med** 1997 May-Jun;26(3):364-72

Aspects of national health promotion programmes for youth. Levin D, et al. **Promot Educ** 1997 Jun;4(2):16-8

Adolescent suicidal behaviours: a population-based study of risk. Patton GC, et al. **Psychol Med** 1997 May;27(3):715-24

The changing mental health of children and adolescents: evidence for a deterioration? Prosser J, et al. **Psychol Med** 1996 Jul;26(4):715-25

Adolescent females' attitudes, subjective norms, perceived behavioral control, and intentions to use latex condoms. Rannie K, et al. **Public Health Nurs** 1997 Feb;14(1):51-7

Reproduction and resistance to the culture of femininity and masculinity in secondary school physical education. Chepyator-Thomson JR, et al. **Res Q Exerc Sport** 1997 Mar;68(1):89-99

Risk-taking behaviour of Cape Peninsula high-school students. Part IX. Evidence for a syndrome of adolescent risk behaviour. Flisher AJ, et al. **S Afr Med J** 1996 Sep; 86(9):1090-3

Risk-taking behaviour of Cape Peninsula high-school students. Part X. Multivariate relationships among behaviours. Flisher AJ, et al. **S Afr Med J** 1996 Sep; 86(9):1094-8

Factors influencing eating attitudes in secondary-school girls in South Africa--a preliminary study. Szabo CP, et al. **S Afr Med J** 1997 Apr;87(4 Suppl):531-4

Abnormal eating attitudes in secondary-school girls in South Africa--a preliminary study. Szabo CP, et al. **S Afr Med J** 1997 Apr;87(4 Suppl):524-6, 528-30

Smoking and associated factors among young Swedish females. Herlitz C, et al. **Scand J Prim Health Care** 1996 Dec;14(4):209-15

Lessons for life--past and present modes of sexuality education in Tanzanian society. Fuglesang M. **Soc Sci Med** 1997 Apr;44(8):1245-54

Socio-regional context as a determinant of adolescents' health behaviour in Finland. Karvonen S, et al. **Soc Sci Med** 1996 Nov;43(10):1467-74

Urban small area variation in adolescents' health behaviour. Karvonen S, et al. **Soc Sci Med** 1997 Oct;45(7):1089-98

Girls, pecking order and smoking. Michell L, et al. **Soc Sci Med** 1997 Jun;44(12):1861-9

Factors associated with early sexual activity among urban adolescents. Smith CA. **Soc Work** 1997 Jul;42(4):334-46

Drug use and its relationship to other behavior disorders and maladjustment signs among adolescents. Calafat A, et al. **Subst Use Misuse** 1997 Jan;32(1):1-24

Measuring change in adolescent drug misuse with the Personal Experience Inventory (PEI). Stinchfield R, et al. **Subst Use Misuse** 1997 Jan;32(1):63-76

Characteristics of suicidality among adolescents. Wetzler S, et al. **Suicide Life Threat Behav** 1996 Spring;26(1):37-45

Tobacco preventive measures by dental care staff. An attempt to reduce the use of tobacco among adolescents. Skjöldebrand J, et al. **Swed Dent J** 1997;21(1-2):49-54

Adolescent contraception. Nelson AL. **West J Med** 1996 Dec;165(6):374-6

[Sexual activity, contraception and abortions among teenagers in Bulgaria] Sirakov M, et al. **Akush Ginekol (Sofiia)** 1996;35(4):12-4 (Eng. Abstr.) **(Bul)**

[Aggression in children and adolescents] Malá E. **Ceska Slov Psychiatr** 1996 May;92 Suppl 1:58-67 (Eng. Abstr.) **(Cze)**

[How poorly fare our children?] Verhulst FC. **Ned Tijdschr Geneeskd** 1996 Nov 30;140(48):2384-7 **(Dut)**

[Therapeutic non-compliance: hard truth to say or hard truth to hear? (editorial)] Alvin P. **Arch Pediatr** 1997 May; 4(5):395-7 (5 ref.) **(Fre)**

[Prevention of violence among adolescents and children] Boulard P, et al. **Bull Acad Natl Med** 1996 Jun-Jul; 180(6):1503-13 **(Fre)**

[Violence and aggression in adolescents and young adults. Review of the recent literature] Sand EA, et al. **Rev Epidemiol Sante Publique** 1996 Aug;44(4):301-45 (134 ref.) (Eng. Abstr.) **(Fre)**

[Violence in adolescence: symptoms, causes and comprehensive measures of prevention (editorial)] Tursz A, et al. **Rev Epidemiol Sante Publique** 1996 Aug; 44(4):297-300 **(Fre)**

[Eating behavior disorders. Epidemiologic study of 434 adolescents] Lanzi G, et al. **Minerva Pediatr** 1997 Jun; 49(6):249-60 (Eng. Abstr.) **(Ita)**

[Adolescent sexual behavior and sexually transmitted diseases (STD). A preliminary study] Franchini F, et al. **Pediatr Med Chir** 1996 May-Jun;18(3):279-81 (Eng. Abstr.) **(Ita)**

[Adolescents and the conflict between generations. The role of the pediatrician] Franchini F, et al. **Pediatr Med Chir** 1997 Mar-Apr;19(2):105-7 (Eng. Abstr.) **(Ita)**

[Sexual behavior of the adolescent and sexually transmitted diseases (STD). Observations on a symptomatic population] Franchini F, et al. **Pediatr Med Chir** 1996 Sep-Oct; 18(5):525-7 (Eng. Abstr.) **(Ita)**

[Perceived access to alcohol among lower secondary school students. A longitudinal study] Klepp KI, et al. **Tidsskr Nor Laegeforen** 1996 Oct 30;116(26):3132-5 (Eng. Abstr.) **(Nor)**

[Do problems with adolescents increase?] Pedersen W. **Tidsskr Nor Laegeforen** 1997 Jan 10;117(1):81-2 **(Nor)**

[Social drinking and adolescent parties] Miguez HA, et al. **Acta Psiquiatr Psicol Am Lat** 1995 Dec;41(4):282-7 (Eng. Abstr.) **(Spa)**

[Risks and psychological problems in adolescents] Juan Del Rey Calero D. **An R Acad Nac Med (Madr)** 1996; 113(1):19-47; discussion 47-52 **(Spa)**

[Alcohol consumption and adolescence: a descriptive epidemiological study] Alonso Hernández J, et al. **Aten Primaria** 1997 Mar 15;19(4):183-7 (Eng. Abstr.) **(Spa)**

[Evaluation of the record of preventive activities of adolescents in a health district (letter)] González S, et al. **Aten Primaria** 1997 Mar 31;19(5):271-2 **(Spa)**

[Pattern of alcohol consumption in young people and associated problems] Casas Anguita J, et al. **Med Clin (Barc)** 1996 Oct 26;107(14):544-8 **(Spa)**

[The reliability of a self-administered questionnaire for investigation of the level of exercise, smoking habit and alcohol intake in school children] Comín Bertrán E, et al. **Med Clin (Barc)** 1997 Mar 1;108(8):293-8 (Eng. Abstr.) **(Spa)**

[Risk factors for the consumption of illegal drugs. Study in 1904 18-year-old boys in the city of Buenos Aires] Alvarez A. **Medicina (B Aires)** 1996;56(1):23-8 (Eng. Abstr.) **(Spa)**

[Alcohol consumption and family: a descriptive study in adolescents] Mena M, et al. **Rev Med Chil** 1996 Jun; 124(6):749-55 (Eng. Abstr.) **(Spa)**

[Sexual subcultures and degree of risk for acquiring HIV in adolescents in a marginal neighborhood] Caballero-Hoyos R, et al. **Salud Publica Mex** 1996 Jul-Aug;38(4):276-9 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Teachers' views on bullying: definitions, attitudes and ability to cope. Boulton MJ. **Br J Educ Psychol** 1997 Jun;67 (Pt 2):223-33

DRUG EFFECTS

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. McDougle CJ, et al. **J Am Acad Child Adolesc Psychiatry** 1997 May; 36(5):685-93

Early prevention of alcohol and other drug use among adolescents. James WH, et al. **J Drug Educ** 1996; 26(2):131-42

Prenatal drug exposure: behavioral functioning in late childhood and adolescence. Hans SL. **NIDA Res Monogr** 1996;164:261-76 (30 ref.)

ETHNOLOGY

Predictors of African American adolescents' condom use and HIV risk behavior. Reitman D, et al. **AIDS Educ Prev** 1996 Dec;8(6):499-515

A self-efficacy scale for HIV risk behaviors: development and evaluation. Smith KW, et al. **AIDS Educ Prev** 1996 Apr;8(2):97-105

HIV risk behaviors: a comparison of U.S. Hispanic and Dominican Republic youth. Westhoff WW, et al. **AIDS Educ Prev** 1996 Apr;8(2):106-14

Differences in patterns of tobacco use in Vietnamese, African-American, Hispanic, and Caucasian adolescents in Worcester, Massachusetts. Wiecha JM. **Am J Prev Med** 1996 Jan-Feb;12(1):29-37

Understanding suicide among indigenous adolescents: a review using the PRECEDE model [see comments] Clarke VA, et al. **Inj Prev** 1997 Jun;3(2):126-34 (126 ref.). Comment in: Inj Prev 1997 Jun;3(2):74-5.

Adolescent knowledge, values, and coping strategies: implications for health in sub-Saharan Africa. Balmer DH, et al. **J Adolesc Health** 1997 Jul;21(1):33-8

Immigrant status and risk behaviors [letter; comment] Michaud PA, et al. **J Adolesc Health** 1996 Dec;19(6):378-80 . Comment on: J Adolesc Health 1995 Aug;17(2):99-105.

Patterns of health risk behaviors for chronic disease: a comparison between adolescent and adult American Indians living on or near reservations in Montana. Nelson DE, et al. **J Adolesc Health** 1997 Jul;21(1):25-32

Gender and social differences in adolescent sexuality and reproduction in Nicaragua. Zelaya E, et al. **J Adolesc Health** 1997 Jul;21(1):39-46

An evaluation of initiatives to improve family planning use by African-American adolescents. Kissinger P, et al. **J Natl Med Assoc** 1997 Feb;89(2):110-4

Prediction of suicide intent in aboriginal and non-aboriginal adolescent inpatients: a research note. Enns MW, et al. **Suicide Life Threat Behav** 1997 Summer;27(2):218-24

Ethnocultural differences in prevalence of adolescent suicidal behaviors. Roberts RE, et al. **Suicide Life Threat Behav** 1997 Summer;27(2):208-17

PHYSIOLOGY

Adolescent sexual health [letter; comment] Dezso J. **Health Educ Q** 1996 Nov;23(4):413-4. Comment on: Health Educ Q 1996 Feb;23(1):34-47.

PSYCHOLOGY

Tailoring STD/HIV prevention messages for young adolescents. Boekeloo BO, et al. **Acad Med** 1996 Oct;71(10 Suppl):S97-9

Psychometric evaluation of the Situational Confidence Questionnaire in adolescents: fitting a graded item response model. Kirisci L, et al. **Addict Behav** 1996 May-Jun; 21(3):303-17

Detection of behavioural and emotional problems in deaf children and adolescents: comparison of two rating scales. Vostanis P, et al. **Child Care Health Dev** 1997 May; 23(3):233-46

African American female adolescent identity development: a three-dimensional perspective. Stevens JW. **Child Welfare** 1997 Jan-Feb;76(1):145-72

Psychosocial conventionality, health orientation, and contraceptive use in adolescence. Costa FM, et al. **J Adolesc Health** 1996 Jun;18(6):404-16

Types of adolescent sexual relationships and associated perceptions about condom use. Ellen JM, et al. **J Adolesc Health** 1996 Jun;18(6):471-21

Substance use, coping, and safer sex practices among adolescents with hemophilia and human immunodeficiency virus. The Hemophilia Behavioral Intervention Evaluative Project Committee. King G, et al. **J Adolesc Health** 1996 Jun;18(6):435-41

Adolescents with physical disabilities: some psychosocial aspects of health. Stevens SE, et al. **J Adolesc Health** 1996 Aug;19(2):157-64

Chronic illness and emotional distress in adolescence. Surís JC, et al. **J Adolesc Health** 1996 Aug;19(2):153-6

First coitus for adolescents: understanding why and when [see comments] Alexander E, et al. **J Am Board Fam Pract** 1997 Mar-Apr;10(2):96-103. Comment in: J Am Board Fam Pract 1997 Mar-Apr;10(2):170-2.

The Adolescent Behavior Checklist: development and initial psychometric properties of a self-report measure for adolescents with ADHD. Adams CD, et al. **J Clin Child Psychol** 1997 Mar;26(1):77-86

Identification and assessment of ongoing stressors in adolescents with a chronic illness: an application of the behavior-analytic model. DiGirolamo AM, et al. **J Clin Child Psychol** 1997 Mar;26(1):53-66

Family support decreases influence of deviant peers on Hispanic adolescents' substance use. Frauenglass S, et al. **J Clin Child Psychol** 1997 Mar;26(1):15-23

Parenting styles, adolescent substance use, and academic achievement. Cohen DA, et al. **J Drug Educ** 1997; 27(2):199-211

Adolescent counterarguing of TV beer advertisements: evidence for effectiveness of alcohol education and critical viewing discussions. Slater MD, et al. **J Drug Educ** 1996; 26(2):143-58

The theory of planned behavior applied to cigarette smoking in African-American, Puerto Rican, and non-Hispanic white teenage females. Hanson MJ. **Nurs Res** 1997 May-Jun;46(3):155-62

Intentions to use violence among young adolescents. DuRant RH, et al. **Pediatrics** 1996 Dec;98(6 Pt 1):1104-8

Encouraging teens to use Norplant is bad advice [letter] Griffin GC. **Pediatrics** 1996 Dec;98(6 Pt 1):1222

Teenage sexual attitudes in China. Kaufman G, et al. **Soc Biol** 1996 Fall-Winter;43(3-4):141-54

Social influence on southern adolescents' smoking transition: a retrospective study. Wang MQ, et al. **South Med J** 1997 Feb;90(2):218-22

Why and in what context adolescents obtain alcohol from adults: a pilot study. Jones-Webb R, et al. **Subst Use Misuse** 1997 Jan;32(2):219-28

Ted, suicide in an adolescent storm. Klein AA, et al. **Suicide Life Threat Behav** 1997 Summer;27(2):225-30

[The mental health status of urban adolescents with nondelinquent and delinquent behaviors] Derbenev DP. **Zh Nevrol Psikhiatr Im S S Korsakova** 1997;97(8):48-52 (Eng. Abstr.) **(Rus)**

ADOLESCENT HEALTH SERVICES

Transitioning adolescents from pediatric to adult dialysis units. Watson AR, et al. **Adv Perit Dial** 1996;12:176–8

Immunization of adolescents [see comments] Averhoff FM, et al. **Am Fam Physician** 1997 Jan;55(1):159–67 (30 ref.). Comment in: Am Fam Physician 1997 Jan;55(1):31, 35–6.

Assuring up-to-date immunization of children aged 11 to 12 years [editorial; comment] Zimmerman RK. **Am Fam Physician** 1997 Jan;55(1):31, 35–6. Comment on: Am Fam Physician 1997 Jan;55(1):159–67.

Filling in the gaps through research [editorial; comment] Joffe A. **Arch Pediatr Adolesc Med** 1997 Feb;151(2):121–2. Comment on: Arch Pediatr Adolesc Med 1997 Feb;151(2):123–8.

What do young people want from their GP? [letter] McPherson A, et al. **Br J Gen Pract** 1996 Oct;46(411):627

Preventing suicide in young people: what is known and what is needed. Williams K. **Child Care Health Dev** 1997 Mar;23(2):173–85 (51 ref.)

Unique needs of the teen in the health care setting. Ginsburg KR, et al. **Curr Opin Pediatr** 1996 Aug;8(4):333–7 (29 ref.)

Confidentiality issues in the adolescent population. Proimos J. **Curr Opin Pediatr** 1997 Aug;9(4):325–8 (30 ref.)

A comprehensive Afrocentric rites of passage program for black male adolescents. Harvey AR, et al. **Health Soc Work** 1997 Feb;22(1):30–7

Young people's health needs in Botswana: a challenge for nursing. Seboni N. **Int Nurs Rev** 1997 Jul–Aug;44(4):110–4

Adolescent health [editorial] Foxcroft DR. **J Adolesc** 1997 Feb;20(1):3–7

Bibliography of recent journal articles (January to June 1993). Brookman RR. **J Adolesc Health** 1995 Dec;17(6):389–99

Programs and services to prevent pregnancy, childbearing, and poor birth outcomes among adolescents in rural areas of the southeastern United States. Loda FA, et al. **J Adolesc Health** 1997 Sep;21(3):157–66

Implications of the Patient Self-Determination Act: guidelines for involving adolescents in medical decision making. Mccabe MA, et al. **J Adolesc Health** 1996 Nov;19(5):319–24 (33 ref.)

Delivery of STD/HIV preventive services to adolescents by primary care physicians. Millstein SG, et al. **J Adolesc Health** 1996 Oct;19(4):249–57

Glycemic control and transfer of health care among adolescents with insulin dependent diabetes mellitus. Orr DP, et al. **J Adolesc Health** 1996 Jan;18(1):44–7

Interviewing techniques with adolescents in primary care. Purcell JS, et al. **J Adolesc Health** 1997 Apr;20(4):300–5

Clinical preventive services for adolescents: position paper of the Society for Adolescent Medicine. Rosen DS, et al. **J Adolesc Health** 1997 Sep;21(3):203–14

They practice what we teach: more on adolescent health care in pediatric practice [letter; comment] Stevens-Simon C. **J Adolesc Health** 1997 Jul;21(1):2. Comment on: J Adolesc Health 1996 Dec;19(6):394–400.

The development, reliability, and validity of a risk factor screening survey for urban minority junior high school students. Vaughan RD, et al. **J Adolesc Health** 1996 Sep;19(3):171–8

Do adolescents want to hear preventive counseling messages in outpatient settings? Steiner BD, et al. **J Fam Pract** 1996 Oct;43(4):375–81

Opinions in pediatric and adolescent gynecology. Juszczak L, et al. **J Pediatr Adolesc Gynecol** 1997 Feb;10(1):45–8

Nurses' role in the prevention of teen pregnancy. Ferguson SL. **J Pediatr Nurs** 1997 Jun;12(3):186–7

The limits of childhood: adolescent health care in pediatric practice. Key JD. **J S C Med Assoc** 1997 Aug;93(8):305–7

Rural school-based clinics: are adolescents willing to use them and what services do they want? Rickert VI, et al. **J Sch Health** 1997 Apr;67(4):144–8

Health care of adolescents [editorial] Ebrahim GJ. **J Trop Pediatr** 1996 Dec;42(6):316–7

Evaluation of an intergenerational program for pregnant and parenting adolescents. Roye CF, et al. **Matern Child Nurs J** 1996 Jan–Mar;24(1):32–40

Anticipating adolescent turmoil. Preparing kids and parents for 'growing up' [editorial] Blum R. **Postgrad Med** 1997 Feb;101(2):13–4, 16, 19

Indigent adolescents' concerns about health care reform. Weinman ML, et al. **Psychol Rep** 1996 Feb;78(1):306

Adolescent health care providers. Establishing a dialogue and assessing sexually transmitted disease prevention practices. Gunn RA, et al. **Sex Transm Dis** 1997 Feb;24(2):90–3

Differing values don't change facts of reproductive health. Simpson DM. **Tex Med** 1996 May;92(5):8

[The Adolescent Sexuality Hot-line—a 4-year study] Graugaard CL, et al. **Ugeskr Laeger** 1996 Sep 30;158(40):5627–31 (Eng. Abstr.) **(Dan)**

[Family planning centers in France: health resource centers for adolescents and young adults] Deschamps JP, et al. **Promot Educ** 1996 Sep;3(3):22–4, 47 (Eng. Abstr.) **(Fre)**

[Confidential health care for adolescents: legal and ethical aspects] Wilf-Miron R, et al. **Harefuah** 1997 Mar 16;132(6):439–43 **(Heb)**

[Dental care for the pediatric population in the city of Moscow with inflammatory diseases] Roginskiĭ VV, et al. **Stomatologiia (Mosk)** 1996;Spec No:40 **(Rus)**

[Medical social security card for children and adolescents. Desired homogeneity and moving forward (editorial)] Moya M. **An Esp Pediatr** 1997 May;46(5):423 **(Spa)**

ECONOMICS

Children's access to mental health care: does insurance matter? Glied S, et al. **Health Aff (Millwood)** 1997 Jan–Feb;16(1):167–74

HISTORY

[The 60th anniversary of Yevpatoriya as a model children's health resort] Drinevskiĭ NP. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Sep–Oct;(5):49–51 **(Rus)**

LEGISLATION & JURISPRUDENCE

[Quality assurance in child and adolescent public health care] Meireis H. **Gesundheitswesen** 1997 Mar;59(3):159–63 (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Cardiovascular disease risk factors and dental caries in adolescents: effect of a preventive program in Northern Sweden (the Norsjö project). Larsson B, et al. **Acta Paediatr** 1997 Jan;86(1):63–71

A community research model: a challenge to public health. Brown-Peterside P, et al. **Am J Public Health** 1997 Sep;87(9):1563–4

School-based health clinics: remaining viable in a changing health care delivery system. Brindis CD, et al. **Annu Rev Public Health** 1997;18:567–87 (26 ref.)

Adolescent health services--through their eyes. Oppong-Odiseng AC, et al. **Arch Dis Child** 1997 Aug;77(2):115–9

The provision of services for rural youth with serious emotional and behavioral problems: Virginia's Comprehensive Services Act. Sheldon-Keller AE, et al. **Community Ment Health J** 1996 Oct;32(5):481–95

High touch meets high tech. Distance mental health screening for rural youth using Teleform. Puskar KR, et al. **Comput Nurs** 1996 Nov-Dec;14(6):323–9; quiz 330–2 (31 ref.)

Who's treating adolescent suicide attempters? Spirito A. **Crisis** 1996;17(3):105–7

Improving treatment compliance among adolescent suicide attempters. Spirito A. **Crisis** 1996;17(4):152–4 (18 ref.)

Teenage pregnancy prevention programs. Pierre N, et al. **Curr Opin Pediatr** 1997 Aug;9(4):310–6 (23 ref.)

Understanding the impact of effective teenage pregnancy prevention programs. Frost JJ, et al. **Fam Plann Perspect** 1995 Sep–Oct;27(5):188–95 (13 ref.)

Pregnancy prevention among urban adolescents younger than 15: results of the 'In Your Face' program. Tiezzi L, et al. **Fam Plann Perspect** 1997 Jul–Aug;29(4):173–6, 197

Paediatricians' views on renal services for children and adolescents in Scotland. Willis FR, et al. **Health Bull (Edinb)** 1997 Jan;55(1):49–51

Adolescent health in Russia: a view from Moscow and St. Petersburg. Blum RW, et al. **J Adolesc Health** 1996 Oct;19(4):308–14

Adolescent inpatient units: a position statement of the Society for Adolescent Medicine. Fisher M, et al. **J Adolesc Health** 1996 Apr;18(4):307–8

Do school-based health centers improve adolescents' access to health care, health status, and risk-taking behavior? Kisker EE, et al. **J Adolesc Health** 1996 May;18(5):335–43

School health centers and primary care for adolescents: a review of the literature. Santelli J, et al. **J Adolesc Health** 1996 May;18(5):357–66 (56 ref.)

"I believe in angels...". Shalala DE. **J Adolesc Health** 1996 Sep;19(3):195–8

The role of the community health nurse in the provision of care to youth gangs. Lee CY. **J Community Health Nurs** 1997;14(2):111–7

Impact of two social-cognitive interventions to prevent adolescent substance use: test of an amenability to treatment model. Snow DL, et al. **J Drug Educ** 1997;27(1):1–17

Enhancing outcomes in an indicated drug prevention program for high-risk youth. Thompson EA, et al. **J Drug Educ** 1997;27(1):19–41

Evaluating performance and change in mental health systems serving children and youth: an interorganizational network approach. Morrissey JP, et al. **J Ment Health Adm** 1997 Winter;24(1):4–22

Chronic illness in adolescents: transfer or transition to adult services? Sawyer SM, et al. **J Paediatr Child Health** 1997 Apr;33(2):88–90 (22 ref.)

A systems approach to adolescent transitions: an opportunity for nurses [editorial] Betz CL. **J Pediatr Nurs** 1996 Oct;11(5):271–2

A collaborative model for community-based health care screening of homeless adolescents. Busen NH, et al. **J Prof Nurs** 1997 Sep–Oct;13(5):316–24

Planning and commissioning of health services for children and young people. Webb E, et al. **J Public Health Med** 1996 Jun;18(2):217–20

Community reactions to reproductive health care at three school-based clinics in Louisiana. Zeanah PD, et al. **J Sch Health** 1996 Sep;66(7):237–41

Adolescents and alcohol: preventive opportunities for health care providers. Colby SM, et al. **Med Health R I** 1997 Jul;80(7):223–6 (21 ref.)

Meta-analysis of adolescent drug prevention programs: results of the 1993 meta-analysis. Tobler NS. **NIDA Res Monogr** 1997;170:5–68

Gay, lesbian, and bisexual adolescents: providing esteem-enhancing care to a battered population. Nelson JA. **Nurse Pract** 1997 Feb;22(2):94, 99, 103 passim (45 ref.)

Transition of care provided for adolescents with special health care needs. American Academy of Pediatrics Committee on Children with Disabilities and Committee on Adolescence. **Pediatrics** 1996 Dec;98(6 Pt 1):1203–6

Reducing cancer risk among Native American adolescents. Schinke SP, et al. **Prev Med** 1996 Mar-Apr;25(2):146–55

Managed care and public health: building a partnership. Beery WL, et al. **Public Health Nurs** 1996 Oct;13(5):305–10

Girl Talk: development of an intervention for prevention of HIV/AIDS and other sexually transmitted diseases in adolescent females. Guthrie BJ, et al. **Public Health Nurs** 1996 Oct;13(5):318–30

The Trading Cards Program--using high school role models for drug abuse prevention. Harris JL. **Public Health Rep** 1996 Nov-Dec;111(6):547–8

Prenatal power--education for life. Pan E, et al. **Public Health Rep** 1996 Nov-Dec;111(6):541–5

[Centro Universitario de Atencion del Adolescente (C.U.A.A.). Catedra e Pediatria y Neonatologia. Universidad Nacional de Cordoba (editorial)] Zamar R, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53 Suppl:5–6 **(Spa)**

STANDARDS

Primary prevention mental health programs for children and adolescents: a meta-analytic review [see comments] Durlak JA, et al. **Am J Community Psychol** 1997 Apr;25(2):115–52. Comment in: Am J Community Psychol 1997 Apr;25(2):169–76. Comment in: Am J Community Psychol 1997 Apr;25(2):177–88. Comment in: Am J Community Psychol 1997 Apr;25(2):189–95. Comment in: Am J Community Psychol 1997 Apr;25(2):207–14. Comment in: Am J Community Psychol 1997 Apr;25(2):215–9. Comment in: Am J Community Psychol 1997 Apr;25(2):221–6. Comment in: Am J Community Psychol 1997 Apr;25(2):227–32. Comment in: Am J Community Psychol 1997 Apr;25(2):233–43.

Primary prevention mental health programs: the future is exciting [comment] Durlak JA, et al. **Am J Community Psychol** 1997 Apr;25(2):233–43. Comment on: Am J Community Psychol 1997 Apr;25(2):115–52.

Meta-analysis of interventions to prevent mental health problems among youth: a public health commentary [comment] Kolbe LJ. **Am J Community Psychol** 1997 Apr;25(2):227–32. Comment on: Am J Community Psychol 1997 Apr;25(2):115–52.

An ounce of prevention research: what is it worth? [comment] Koretz DS, et al. **Am J Community Psychol** 1997 Apr;25(2):189–95. Comment on: Am J Community Psychol 1997 Apr;25(2):115–52.

One small step for science, one giant leap for prevention [comment] Manson SM. **Am J Community Psychol** 1997 Apr;25(2):215–9. Comment on: Am J Community Psychol 1997 Apr;25(2):115–52.

A policy perspective on prevention [comment] Mrazek PJ, et al. **Am J Community Psychol** 1997 Apr;25(2):221–6. Comment on: Am J Community Psychol 1997 Apr;25(2):115–52.

In praise of a cumulative prevention science [comment] Price RH. **Am J Community Psychol** 1997 Apr;25(2):169–76. Comment on: Am J Community Psychol 1997 Apr;25(2):115–52.

A meta-analytic review of primary prevention programs for children and adolescents: contributions and caveats [comment] Weissberg RP, et al. **Am J Community Psychol** 1997 Apr;25(2):207–14. Comment on: Am J Community Psychol 1997 Apr;25(2):115–52.

Don't ask, they won't tell: the quality of adolescent health screening in five practice settings [see comments] Blum RW, et al. **Am J Public Health** 1996 Dec;86(12):1767–72. Comment in: Am J Public Health 1996 Dec;86(12):1701.

GAPS (AMA Guidelines for Adolescent Preventive Services) [letter] Copperman S. **Arch Pediatr Adolesc Med** 1997 Sep;151(9):957–8

The American Medical Association Guidelines for Adolescent Preventive Services [letter] Elster A. **Arch Pediatr Adolesc Med** 1997 Sep;151(9):958–9

GAPS (AMA Guidelines for Adolescent Preventive Services). Where are the gaps? [see comments] Knishkowy B, et al. **Arch Pediatr Adolesc Med** 1997 Feb;151(2):123–8. Comment in: Arch Pediatr Adolesc Med 1997 Feb;151(2):121–2.

A systematic overview of adolescent suicide prevention programs. Ploeg J, et al. **Can J Public Health** 1996 Sep–Oct;87(5):319–24 (33 ref.)

Preventing teenage suicide in New York. Ross A. **Crisis** 1997;18(1):12–6

Needs assessment of community-based services for children and youth with emotional or behavioral disorders and their families: Part 1. A conceptual model. Epstein MH, et al. **J Ment Health Adm** 1996 Fall;23(4):418–31

Needs assessment of community-based services for children and youth with emotional or behavioral disorders and their families: Part 2. Implementation in a local system of care. Quinn K, et al. **J Ment Health Adm** 1996 Fall;23(4):432–46

Systematic literature review: outcome measures for child and

ADOLESCENT HEALTH SERVICES

adolescent mental health services. Hunter J, et al. **J Public Health Med** 1996 Jun;18(2):197–206 (90 ref.)

Guidelines for adolescent preventive services: a role for the school nurse. Allensworth DD, et al. **J Sch Health** 1996 Oct;66(8):281–5

STATISTICS & NUMERICAL DATA

Meta-analysis of adolescent drug prevention programs: results of the 1993 meta-analysis. Tobler NS. **NIDA Res Monogr** 1997;170:5–68

SUPPLY & DISTRIBUTION

GPs need to be more proactive in providing health care to teenagers [letter; comment] Cowap N. **BMJ** 1996 Oct 12; 313(7062):941. Comment on: BMJ 1996 Jun 22;312(7046):1567–9.

Update on adolescent health care in pediatric practice [see comments] Fisher M, et al. **J Adolesc Health** 1996 Dec; 19(6):394–400. Comment in: J Adolesc Health 1997 Jul;21(1):2.

TRENDS

Innovative perspectives in youth health care. McNair R, et al. **Aust Fam Physician** 1996 Mar;25(3):347–51

Promoting health and preventing disease: an international perspective on youth health promotion. Nutbeam D. **J Adolesc Health** 1997 May;20(5):396–402

Searching for solutions: the importance of including teenagers in the research process. Ginsburg KR. **J Dev Behav Pediatr** 1996 Aug;17(4):255–7

Managing the teenager with epilepsy: paediatric to adult care. Appleton RE, et al. **Seizure** 1997 Feb;6(1):27–30

[Plea for conversion of youth medical service to "school medical service"] Hurrelmann K, et al. **Gesundheitswesen** 1996 Oct;58(10):525–32 (Eng. Abstr.) **(Ger)**

UTILIZATION

Prevalence of psychiatric disorders in young people in the care system [see comments] McCann JB, et al. **BMJ** 1996 Dec 14;313(7071):1529–30. Comment in: BMJ 1996 Dec 14;313(7071):1497–8.

Adolescents' attitudes to general practice in north London. Kari J, et al. **Br J Gen Pract** 1997 Feb;47(415):109–10

Gender-specific factors in the utilization of medical services during adolescence. Settertobulte W, et al. **J Adolesc** 1997 Feb;20(1):121–32

Use of health services by urban youth: a school-based survey to assess differences by grade level, gender, and risk behavior. Aten MJ, et al. **J Adolesc Health** 1996 Oct; 19(4):258–66

Reproductive and sexual health at the school-based/school-linked health center: an analysis of services provided by 180 clinics. Peak GL, et al. **J Adolesc Health** 1996 Oct;19(4):276–81

A profile of human immunodeficiency virus-infected adolescents receiving health care services at selected sites in the United States. Rogers AS, et al. **J Adolesc Health** 1996 Dec;19(6):401–8

Influence of school enrollment on adolescent emergency department visits. Waldrop RD, et al. **J Adolesc Health** 1996 Dec;19(6):416–9

Factors associated with child mental health service use in the community. Verhulst FC, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jul;36(7):901–9

Access to ambulatory care for adolescents: the role of a usual source of care. Bartman BA, et al. **J Health Care Poor Underserved** 1997 May;8(2):214–26

Influence of physician confidentiality assurances on adolescents' willingness to disclose information and seek future health care. A randomized controlled trial. Ford CA, et al. **JAMA** 1997 Sep 24;278(12):1029–34

ADOLESCENT, HOSPITALIZED

PSYCHOLOGY

Diagnosis and assessment of depression and suicidality using the NIMH Diagnostic Interview Schedule for Children (DISC-2.3). King CA, et al. **J Abnorm Child Psychol** 1997 Jun;25(3):173–81

Depression and thyroid [letter; comment] Bhatara VS, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Feb;36(2):159. Comment on: J Am Acad Child Adolesc Psychiatry 1996 Mar;35(3):299–306.

Utility of the Inventory of Suicide Orientation-30 (ISO-30) for adolescent psychiatric inpatients: linking clinical decision making with outcome evaluation. Piersma HL, et al. **J Clin Psychol** 1997 Jan;53(1):65–72

The Hopelessness Scale for Children: psychometric properties with hospitalized adolescents. Thurber S, et al. **J Clin Psychol** 1996 Sep;52(5):543–5

Thresholds and tolerance of physical pain in suicidal and nonsuicidal adolescents. Orbach I, et al. **J Consult Clin Psychol** 1997 Aug;65(4):646–52

Communicating with children: could you use some help? McElveen KA. **MCN Am J Matern Child Nurs** 1997 Mar-Apr;22(2):108–11

A pilot HIV prevention program for adolescents in a psychiatric hospital. Brown LK, et al. **Psychiatr Serv** 1997 Apr;48(4):531–3

STATISTICS & NUMERICAL DATA

Evaluation of a hospital-based youth violence intervention. De Vos E, et al. **Am J Prev Med** 1996 Sep-Oct;12(5 Suppl):101–8

Diagnosis in adolescent inpatients: diagnostic confidence and comparison of diagnoses using ICD-9 and DSM-III. McCabe RJ, et al. **Eur Child Adolesc Psychiatry** 1996 Sep; 5(3):147–54

ADOLESCENT, INSTITUTIONALIZED

Health risk behavioral survey from 39 juvenile correctional facilities in the United States. Morris RE, et al. **J Adolesc Health** 1995 Dec;17(6):334–44

Gender-based differences in the treatment of young offenders by the police and the children's court in New South Wales, Australia. Gliksman M. **Med Sci Law** 1997 Apr;37(2):165–9

Characteristics of young offenders detained under section 53(2) at a young offenders' institution. Puri BK, et al. **Med Sci Law** 1996 Jan;36(1):69–76

Clostridium perfringens outbreak at a juvenile detention facility linked to a Thanksgiving holiday meal. Parikh AI, et al. **West J Med** 1997 Jun;166(6):417–9

[The physical capacity of Bulgarian boys from homes for children and youth] Balichev Iu. **Probl Khig** 1996;21:141–8 (Eng. Abstr.) **(Bul)**

PSYCHOLOGY

Decisions about substance abuse among adolescents in juvenile detention. Anderson NL. **Image J Nurs Sch** 1996 Spring;28(1):65–70

ADOLESCENT MEDICINE

Delivery of confidentiality assurances to adolescents by primary care physicians. Ford CA, et al. **Arch Pediatr Adolesc Med** 1997 May;151(5):505–9

Residents' self-assessed skills in providing sexuality-related care to teenagers. Wilson MD, et al. **Arch Pediatr Adolesc Med** 1997 Apr;151(4):418–22

You won't know unless you ask: the biopsychosocial interview for adolescents. Perkins K, et al. **Clin Pediatr (Phila)** 1997 Feb;36(2):79–86; discussion 87–8

Adolescent medicine [editorial] Forman SF, et al. **Curr Opin Pediatr** 1996 Aug;8(4):299–300

Confidentiality issues in the adolescent population. Proimos J. **Curr Opin Pediatr** 1997 Aug;9(4):325–8 (30 ref.)

Emergency contraception: a national survey of adolescent health experts. Gold MA, et al. **Fam Plann Perspect** 1997 Jan-Feb;29(1):15–9, 24

Care of adolescents [see comments] Mehta R. **Indian Pediatr** 1996 Sep;33(9):790. Comment in: Indian Pediatr 1996 Dec;33(12):1062.

Care of adolescents [letter; comment] Pemde HK, et al. **Indian Pediatr** 1996 Dec;33(12):1062. Comment on: Indian Pediatr 1996 Sep;33(9):790.

Society for Adolescent Medicine annual meeting. San Francisco, California, March 5–9, 1997. Abstracts. **J Adolesc Health** 1997 Feb;20(2):125–73

Society for Adolescent Medicine new members. April 5, 1996–January 3, 1997. **J Adolesc Health** 1997 Feb; 20(2):174–6

Bibliography of journal articles (July to December 1994). Brookman RR. **J Adolesc Health** 1997 Apr;20(4):320–31

Bibliography of recent journal articles (January to June 1993). Brookman RR. **J Adolesc Health** 1995 Dec;17(6):389–99

Bibliography of journal articles (January to June 1995). Brookman RR. **J Adolesc Health** 1997 Jul;21(1):54–64

Presidential address. Elster A. **J Adolesc Health** 1997 Sep; 21(3):197–202

Adolescent inpatient units: a position statement of the Society for Adolescent Medicine. Fisher M, et al. **J Adolesc Health** 1996 Apr;18(4):307–8

Research in school settings. Fisher M, et al. **J Adolesc Health** 1996 May;18(5):309–11

Choice of research setting in understanding adolescent health problems. Gans JE, et al. **J Adolesc Health** 1995 Nov; 17(5):306–13

Society for Adolescent Medicine 1997 meeting. Rosenfeld WD. **J Adolesc Health** 1996 May;18(5):373–8

Australian adolescent medicine physician appreciates journal of adolescent health issue on eating disorders [letter] Selzer R. **J Adolesc Health** 1996 Apr;18(4):246

"I believe in angels...". Shalala DE. **J Adolesc Health** 1996 Sep;19(3):195–8

Opinions in pediatric and adolescent gynecology. Hillard P, et al. **J Pediatr Adolesc Gynecol** 1996 Nov;9(4):209–11

Adolescent medicine. Muram D. **J Pediatr Adolesc Gynecol** 1996 Nov;9(4):203–5 (21 ref.)

Care of adolescent girls. Johnston E, et al. **Prim Care** 1997 Mar;24(1):53–65

[The care of the adolescent—ethical issues] Ishay R. **Harefuah** 1997 Jan 1;132(1):59–62 **(Heb)**

HISTORY

SAM memory: a link between past and future. Slap GB. **J Adolesc Health** 1996 Sep;19(3):191–4

ORGANIZATION & ADMINISTRATION

Success on the road to adulthood. Issues and hurdles for adolescents with disabilities. White PH. **Rheum Dis Clin North Am** 1997 Aug;23(3):697–707 (44 ref.)

STANDARDS

Research guidelines [editorial; comment] **J Adolesc Health** 1995 Nov;17(5):259. Comment on: J Adolesc Health 1992 Dec;13(8):640. Comment on: J Adolesc Health 1995 Nov;17(5):264–9.

Guidelines for adolescent health research. Society for Adolescent Medicine [see comments] **J Adolesc Health** 1995 Nov;17(5):264–9 (00 ref.). Comment in: J Adolesc Health 1995 Nov;17(5):259.

Guidelines for adolescent health research: legal perspectives. English A. **J Adolesc Health** 1995 Nov;17(5):277–86 (86 ref.)

Guidelines for adolescent health research: issues of race and class. Jenkins RR, et al. **J Adolesc Health** 1995 Nov; 17(5):314–22 (43 ref.)

Adolescents as research subjects without permission of their parents or guardians: ethical considerations. Levine RJ. **J Adolesc Health** 1995 Nov;17(5):287–97 (23 ref.)

Research consent by adolescent minors and institutional review boards. Mammel KA, et al. **J Adolesc Health** 1995 Nov;17(5):323–30

Developmental issues influencing guidelines for adolescent health research: a review. Petersen AC, et al. **J Adolesc Health** 1995 Nov;17(5):298–305 (72 ref.)

Guidelines for adolescent health research: a position paper of the society for adolescent medicine. Santelli JS, et al. **J Adolesc Health** 1995 Nov;17(5):270–6

[Selected certification problems for students and candidates in technical vocational schools] Mucha E, et al. **Med Pr** 1997;48(3):273–7 (Eng. Abstr.) **(Pol)**

STATISTICS & NUMERICAL DATA

The program archive on sexuality, health & adolescence: promising "prevention programs in a box". Card JJ, et al. **Fam Plann Perspect** 1996 Sep-Oct;28(5):210–20

TRENDS

The future of pediatric and adolescent endocrinology. Chrousos GP. **Ann N Y Acad Sci** 1997 Jun 17;816:4–8

Translating research into action: the critical role of adolescent health surveys [editorial; comment] Resnick MD. **J Paediatr Child Health** 1996 Oct;32(5):371. Comment on: J Paediatr Child Health 1996 Oct;32(5):372–7.

Pediatrics and adolescent medicine. Santoli JM, et al. **JAMA** 1997 Jun 18;277(23):1889–90

[Pediatric and adolescent medicine: some current aspects (editorial)] Calame A. **Rev Med Suisse Romande** 1996 Oct; 116(10):761–2 **(Fre)**

ADOLESCENT NUTRITION

Food habits and energy and nutrient intake in Swedish adolescents approaching the year 2000 [published erratum appears in Acta Paediatr Suppl 1996 Nov;85(11):1392] Samuelson G, et al. **Acta Paediatr Suppl** 1996 Sep;415:1–19

Does poor zinc nutriture retard skeletal growth and mineralization in adolescents? [editorial; comment] King JC. **Am J Clin Nutr** 1996 Sep;64(3):375–6. Comment on: Am J Clin Nutr 1996 Sep;64(3):274–82.

Effects of orthodontic treatment on nutrient intake. Riordan DJ. **Am J Orthod Dentofacial Orthop** 1997 May; 111(5):554–61

Adolescent Nutritional Disorders: Prevention and Treatment. Proceedings of a conference. New York, New York, December 3–5, 1995. **Ann N Y Acad Sci** 1997 May 28; 817:1–402

Chronic undernutrition during adolescence. Eisenstein E. **Ann N Y Acad Sci** 1997 May 28;817:138–61 (36 ref.)

Nutritional support for the pregnant adolescent. Lederman SA. **Ann N Y Acad Sci** 1997 May 28;817:304–12 (24 ref.)

Nutrition for pregnant and childbearing adolescents: demographics, developmental needs, behavior, and outcome. Rees JM. **Ann N Y Acad Sci** 1997 May 28; 817:246–50 (17 ref.)

Overview: nutrition for pregnant and childbearing adolescents. Rees JM. **Ann N Y Acad Sci** 1997 May 28; 817:241–5 (2 ref.)

Promoting healthy eating and ensuring adequate weight gain in pregnant adolescents: issues and strategies. Story M. **Ann N Y Acad Sci** 1997 May 28;817:321–33 (56 ref.)

Estimated dietary calcium intake and food sources for adolescent females: 1980–92. Albertson AM, et al. **J Adolesc Health** 1997 Jan;20(1):20–6

Does puberty alter dietary habits in adolescents living in a western society? Clavien H, et al. **J Adolesc Health** 1996 Jul;19(1):68–75

Substance use: toward an understanding of its relation to nutrition-related attitudes and behavior among Israeli high school youth. Isralowitz RE, et al. **J Adolesc Health** 1996 Sep;19(3):184–9

Marginal vitamin and mineral intakes of young adults: the Bogalusa Heart Study. Zive MM, et al. **J Adolesc Health** 1996 Jul;19(1):39–47

Ability of the Higgins Nutrition Intervention Program to improve adolescent pregnancy outcome. Dubois S, et al.

J Am Diet Assoc 1997 Aug;97(8):871–8

Parental smoking and the nutrient intake and food choice of British teenagers aged 16–17 years. Crawley HF, et al. **J Epidemiol Community Health** 1996 Jun;50(3):306–12

Fat is a health issue [editorial] Haller KB. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun;26(3):255

Gender differences in food–related concerns, beliefs and behaviours of north Queensland adolescents. Nowak M, et al. **J Paediatr Child Health** 1996 Oct;32(5):424–7

Guidelines for school health programs to promote lifelong healthy eating. **J Sch Health** 1997 Jan;67(1):9–26 (229 ref.)

Comparison of attitudes and behaviors related to nutrition, body size, dieting, and hunger in Russian, black–American, and white–American adolescents. Stevens J, et al. **Obes Res** 1997 May;5(3):227–36

Correlates of inadequate fruit and vegetable consumption among adolescents. Neumark–Sztainer D, et al. **Prev Med** 1996 Sep–Oct;25(5):497–505

Geophagy: a vestige of palaeonutrition? [editorial; comment] Ziegler JL. **Trop Med Int Health** 1997 Jul;2(7):609–11. Comment on: Trop Med Int Health 1997 Jul;2(7):617–23. Comment on: Trop Med Int Health 1997 Jul;2(7):624–30.

[Evaluation of nutrition of school children in the population of Sierra de Cádiz (Ubrique)] Failde I, et al. **Med Clin (Barc)** 1997 Feb 22;108(7):254–8 (Eng. Abstr.) **(Spa)**

EDUCATION

Nutrition knowledge among adolescent high school female athletes. Chapman P, et al. **Adolescence** 1997 Summer; 32(126):437–46

ADOLESCENT PREGNANCY see **PREGNANCY IN ADOLESCENCE**

ADOLESCENT PSYCHIATRY

Adolescent/adult differences in suicidal behavior and outcome. Safer DJ. **Ann Clin Psychiatry** 1997 Mar;9(1):61–6 (68 ref.)

Separate adolescent psychiatry? [letter; comment] Haliburn J. **Aust N Z J Psychiatry** 1997 Apr;31(2):305–6. Comment on: Aust N Z J Psychiatry 1996 Oct;30(5):563–6.

Comment on An epidemiological case for a separate adolescent psychiatry [letter; comment] Werry JS. **Aust N Z J Psychiatry** 1997 Jun;31(3):431–4. Comment on: Aust N Z J Psychiatry 1996 Oct;30(5):563–6.

Child psychiatric consultation service to community agencies: a collaborative approach involving three community agencies. Froese A, et al. **Can J Psychiatry** 1997 Aug;42(6):656–8

The attitudes of female and male residential care–workers to the perpetrators of sexual and physical assault. Harnett PH. **Child Abuse Negl** 1997 Sep;21(9):861–8

The status of child and adolescent psychiatry in EU– and EFTA–countries [news] Piha J. **Eur Child Adolesc Psychiatry** 1997 Jun;6(2):116–8

Ambivalent attachment in female adolescents: association with affective instability and eating disorders. Salzman JP. **Int J Eat Disord** 1997 Apr;21(3):251–9

Adolescents' exposure to community and school violence: prevalence and behavioral correlates. O'Keefe M. **J Adolesc Health** 1997 May;20(5):368–76

Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. Leonard HL, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jun;36(6):725–36 (109 ref.)

Dimensions and disorders of adolescent adjustment: a quantitative genetic analysis of unselected samples and selected extremes. Deater–Deckard K, et al. **J Child Psychol Psychiatry** 1997 Jul;38(5):515–25

Immediate antecedents to adolescents' offenses. Howell AJ, et al. **J Clin Psychol** 1997 Jun;53(4):355–60

[Introduction of the Work Group Primary Medical Care in the hospital for psychiatry and psychotherapy of children and adolescents] Lehmkuhl G, et al. **Soz Praventivmed** 1996;41(5):322–3 **(Ger)**

[Pediatric psychiatrists discuss on a computer network of Gotland] Fällman H. **Lakartidningen** 1997 Mar 12; 94(11):924–5 **(Swe)**

[An inquiry on quality of life among young patients with schizophrenia. Crisis intervention in the family] Levin B, et al. **Lakartidningen** 1996 Nov 20;93(47):4259–62 **(Swe)**

[Swedish research in child and adolescent psychiatry. Expanding field in spite of small resources] Zetterström R. **Lakartidningen** 1997 Aug 27;94(35):2955–8 (28 ref.) **(Swe)**

EDUCATION

Teaching child and adolescent psychiatry to family medicine trainees: a pilot experience. Fisman S, et al. **Can J Psychiatry** 1996 Dec;41(10):623–8

The British approach to child and adolescent psychiatry: a course for Russian postgraduates. Nicol R. **Eur Child Adolesc Psychiatry** 1996 Dec;5(4):212–5

Hospitalizing the suicidal adolescent: decision–making criteria of psychiatric residents. Dicker R, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jun;36(6):769–76

Gay and lesbian issues in child and adolescent psychiatry training as reported by training directors. Townsend MH, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jun; 36(6):764–8

DSM–PC: experiences in primary care practice and resident education. Marino RV. **J Dev Behav Pediatr** 1997 Jun; 18(3):174–5

METHODS

The process of engaging young people with severe developmental disturbance in psychoanalytic psychotherapy: patterns of practice. Baruch G. **Bull Menninger Clin** 1997 Summer;61(3):335–53

Contributions of risk–factor research to developmental psychopathology. Kazdin AE, et al. **Clin Psychol Rev** 1997; 17(4):375–406 (84 ref.)

Management of the suicidal child or adolescent in the emergency department. Press BR, et al. **Curr Opin Pediatr** 1997 Jun;9(3):237–41 (24 ref.)

Diagnosis and assessment of depression and suicidality using the NIMH Diagnostic Interview Schedule for Children (DISC–2.3). King CA, et al. **J Abnorm Child Psychol** 1997 Jun;25(3):173–81

More on nonaffective seasonality [letter] Weintrob A. **J Am Acad Child Adolesc Psychiatry** 1997 Aug;36(8):1019

The Hopelessness Scale for Children: psychometric properties with hospitalized adolescents. Thurber S, et al. **J Clin Psychol** 1996 Sep;52(5):543–5

ORGANIZATION & ADMINISTRATION

[Psychiatric care of neglected and abused children and their parents] Bonard O. **Rev Med Suisse Romande** 1997 May; 117(5):425–8 **(Fre)**

STANDARDS

Is psychotherapy helpful for adolescent suicide attempters? Spirito A. **Crisis** 1997;18(1):3–4 (4 ref.)

Diagnosis in adolescent inpatients: diagnostic confidence and comparison of diagnoses using ICD–9 and DSM–III. McCabe RJ, et al. **Eur Child Adolesc Psychiatry** 1996 Sep; 5(3):147–54

AACAP Official Action. Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with ADHD. Dulcan MK, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Sep;36(9):1311–7

Utility of the Inventory of Suicide Orientation–30 (ISO–30) for adolescent psychiatric inpatients: linking clinical decision making with outcome evaluation. Piersma HL, et al. **J Clin Psychol** 1997 Jan;53(1):65–72

[Pediatric psychiatry during disasters—future planning] Shimizu M, et al. **Seishin Shinkeigaku Zasshi** 1996; 98(10):765–70; discussion 777–81 **(Jpn)**

[Quality assurance of psychiatric work with autistic children and adolescents. Diagnostic value of medical examination] Sørensen E. **Tidsskr Nor Laegeforen** 1997 Aug 30; 117(20):2934–8 (Eng. Abstr.) **(Nor)**

TRENDS

Continuing the debate on a separate adolescent psychiatry. Birleson P, et al. **Aust N Z J Psychiatry** 1997 Aug; 31(4):447–51

An epidemiological case for a separate adolescent psychiatry? [see comments] Patton G. **Aust N Z J Psychiatry** 1996 Oct; 30(5):563–6. Comment in: Aust N Z J Psychiatry 1997 Apr;31(2):305–6. Comment in: Aust N Z J Psychiatry 1997 Jun;31(3):431–4.

Whither child psychiatry? [letter] Wakefield T, et al. **Aust N Z J Psychiatry** 1996 Jun;30(3):426

From genetic research to new thoughts about evaluating psychotherapy: child psychiatry approaches the year 2000 [editorial; comment] Minde K. **Can J Psychiatry** 1997 Aug; 42(6):561–2. Comment on: Can J Psychiatry 1997 Aug;42(6):569–76. Comment on: Can J Psychiatry 1997 Aug;42(6):577–83.

Implications of genetic research for child psychiatry [see comments] Rutter M. **Can J Psychiatry** 1997 Aug; 42(6):569–76 (115 ref.). Comment in: Can J Psychiatry 1997 Aug;42(6):561–2.

Forensic child and adolescent psychiatry. Cook SC. **New Dir Ment Health Serv** 1996 Spring;(69):15–24

Adolescent psychiatry—inpatient diagnostic trends [letter] Szabo CP. **S Afr Med J** 1996 Jun;86(6 Suppl):746

[Multidisciplinary quality assurance circles—a quality assurance model for child and adolescent psychiatry clinics] Bilke O, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Apr;46(4):257–67 (Eng. Abstr.) **(Ger)**

[Developmental trends in child and adolescent psychiatry] Remschmidt H. **Prax Kinderpsychol Kinderpsychiatr** 1997 Jul–Aug;46(6):445–58 (Eng. Abstr.) **(Ger)**

[Possibilities of psychoanalytic treatment in child and adolescent psychiatry in France] Renard L. **Prax Kinderpsychol Kinderpsychiatr** 1997 Apr;46(4):278–87 (Eng. Abstr.) **(Ger)**

ADOLESCENT PSYCHOLOGY

A survey of adolescents' knowledge regarding toxicity of over–the–counter medications [see comments] Huott MA, et al. **Acad Emerg Med** 1997 Mar;4(3):214–8. Comment in: Acad Emerg Med 1997 Mar;4(3):163–4.

Self–assessment of sexual maturity by mid–adolescents based on a global question. Berg–Kelly K, et al. **Acta Paediatr** 1997 Jan;86(1):10–7

Physical fighting and associated health behaviours among Swedish adolescents. Grufman M, et al. **Acta Paediatr** 1997 Jan;86(1):77–81

A literature–based approach to teaching values to adolescents: does it work? Adler ES, et al. **Adolescence** 1997 Summer;32(126):275–86

Adolescents' perceptions of family functioning in the United Arab Emirates. Alnajjar AA. **Adolescence** 1996 Summer; 31(122):433–42

Hospital–based behavior modification program for adolescents: evaluation and predictors of outcome. al Ansari A, et al. **Adolescence** 1996 Summer;31(122):469–76

Cognitive–affective sources of sport enjoyment in adolescent sport participants. Boyd MP, et al. **Adolescence** 1996 Summer;31(122):383–95

Parental bonding and mental health in adolescence. Canetti L, et al. **Adolescence** 1997 Summer;32(126):381–94

Adolescent self–esteem and locus of control: a longitudinal study of gender and age differences. Chubb NH, et al. **Adolescence** 1997 Spring;32(125):113–29

Adolescent decision making: a broadly based theory and its application to the prevention of early pregnancy. Gordon CP. **Adolescence** 1996 Fall;31(123):561–84

Urban–rural differences in adolescent self–esteem, leisure boredom, and sensation–seeking as predictors of leisure–time usage and satisfaction. Gordon WR, et al. **Adolescence** 1996 Winter;31(124):883–901

4–H Night at the Movies: a program for adolescents and their families. Jurich AP, et al. **Adolescence** 1996 Winter; 31(124):863–74

Adolescents' attitudes toward the death penalty. Lester D, et al. **Adolescence** 1997 Summer;32(126):447–9

Effects of family structure on the adolescent separation–individuation process. McCurdy SJ, et al. **Adolescence** 1996 Summer;31(122):307–19

Psychotropic medication in adolescence: psychodynamic and clinical considerations. Masi G, et al. **Adolescence** 1996 Winter;31(124):925–33

The acquisition of life skills through adventure–based activities and programs: a review of the literature. Moote GT Jr, et al. **Adolescence** 1997 Spring;32(125):143–67 (102 ref.)

Adolescents' perceptions and experiences of death and grieving. Morin SM, et al. **Adolescence** 1996 Fall; 31(123):585–95

Attachment to parents and peers in late adolescence and their relationship with self–image. O'Koon J. **Adolescence** 1997 Summer;32(126):471–82

Patterns of parenting during adolescence: perceptions of adolescents and parents. Paulson SE, et al. **Adolescence** 1996 Summer;31(122):369–81

An empirical investigation of the construct of personality authority in late adolescent women and their level of college adjustment. Protinsky H, et al. **Adolescence** 1996 Summer;31(122):291–5

Language arts achievement level, attitude survey format, and adolescents' attitudes towards reading. Smith LR, et al. **Adolescence** 1997 Summer;32(126):271–4

Adolescent gender differences in time alone and time devoted to conversation. Smith TE. **Adolescence** 1997 Summer; 32(126):483–96

Measurement of ethical behavior in leisure among high– and low–risk adolescents. Widmer MA, et al. **Adolescence** 1996 Summer;31(122):397–408

Determinants of suicide ideation: a comparison of Chinese and American college students. Zhang J, et al. **Adolescence** 1996 Summer;31(122):451–67

Assessment of major life events for Hong Kong adolescents: the Chinese Adolescent Life Event Scale. Cheng C. **Am J Community Psychol** 1997 Feb;25(1):17–33

Ethnocultural differences in prevalence of adolescent depression. Roberts RE, et al. **Am J Community Psychol** 1997 Feb;25(1):95–110

Is repression adaptive? Relationships to socioemotional adjustment, academic performance, and self–image. Bybee J, et al. **Am J Orthopsychiatry** 1997 Jan;67(1):59–69

Psychiatric symptoms in adolescence as predictors of obesity in early adulthood: a longitudinal study. Pine DS, et al. **Am J Public Health** 1997 Aug;87(8):1303–10

Aggressive youth: healing biology with relationship. Vance JE. **Ann N Y Acad Sci** 1997 Jan 15;807:587–9

Parent–adolescent communication in nondistressed families. Riesch SK. **Annu Rev Nurs Res** 1997;15:123–52 (130 ref.)

Suicidal adolescent perceptions after an art future image intervention. Walsh SM, et al. **Appl Nurs Res** 1997 Feb; 10(1):19–26

Influences of gender and social class on adolescents' perceptions of health. Goodman E, et al. **Arch Pediatr Adolesc Med** 1997 Sep;151(9): 99–904

In their own hands: adolescents' refusals of medical treatment. Traugott I, et al. **Arch Pediatr Adolesc Med** 1997 Sep;151(9):922–7 (31 ref.)

Referred adolescents as young adults: the relationship between psychosocial functioning and personality disorder. Rey JM, et al. **Aust N Z J Psychiatry** 1997 Apr; 31(2):219–26

The relationship between dimensional self–concept and juvenile gang involvement: implications for prevention, intervention, and court referred diversion programs. Herrmann DS, et al. **Behav Sci Law** 1997 Spring; 15(2):181–94

Significant others' contribution to early adolescents'

perceptions of their competence. Trent LM, et al. **Br J Educ Psychol** 1996 Mar;66 (Pt 1):95–107

Belonging nowhere and everywhere: multiracial identity development. Deters KA. **Bull Menninger Clin** 1997 Summer;61(3):368–84

Mental health concerns of Canadian adolescents [editorial; comment] Bradley SJ. **Can J Psychiatry** 1996 Feb;41(1):3–4 . Comment on: Can J Psychiatry 1996 Feb;41(1):5–10.

Mental health concerns of Canadian adolescents: a consumer's perspective [see comments] Kutcher S, et al. **Can J Psychiatry** 1996 Feb;41(1):5–10. Comment in: Can J Psychiatry 1996 Feb;41(1):3–4.

Reproductive biology knowledge, and behaviour of teenagers in East, Central and Southern Africa: the Zimbabwe case study. Mbizvo MT, et al. **Cent Afr J Med** 1995 Nov; 41(11):346–54

The academic achievement of adolescents from immigrant families: the roles of family background, attitudes, and behavior. Fuligni AJ. **Child Dev** 1997 Apr;68(2):351–63

Parenting styles, adolescents' attributions, and educational outcomes in nine heterogeneous high schools. Glasgow KL, et al. **Child Dev** 1997 Jun;68(3):507–29

Marital conflict and adolescent distress: the role of adolescent awareness. Harold GT, et al. **Child Dev** 1997 Apr; 68(2):333–50

The emergence of solitude as a constructive domain of experience in early adolescence. Larson RW. **Child Dev** 1997 Feb;68(1):80–93

Disruptiveness, friends' characteristics, and delinquency in early adolescence: a test of two competing models of development. Vitaro F, et al. **Child Dev** 1997 Aug; 68(4):676–89

Defense reactions and coping strategies in normal adolescents. Erickson S, et al. **Child Psychiatry Hum Dev** 1997 Fall;28(1):45–56

A comparison of adolescent and adult defense styles. Nasserbakht A, et al. **Child Psychiatry Hum Dev** 1996 Fall; 27(1):3–14

Talking to teens about family problems. An opportunity for prevention. Cavanaugh RM Jr, et al. **Clin Pediatr (Phila)** 1996 Feb;35(2):67–71

The gay adolescent: stressors, adaptations, and psychosocial interventions. Radkowsky M, et al. **Clin Psychol Rev** 1997; 17(2):191–216 (99 ref.)

Violence prevention program targeting Connecticut adolescents: description and preliminary results. Lane-Reticker A, et al. **Conn Med** 1996 Jan;60(1):15–9

Mom and dad are at it again: adolescent perceptions of marital conflict and adolescent psychological distress. Harold GT, et al. **Dev Psychol** 1997 Mar;33(2):333–50

Adolescent life experiences of physicians in primary care compared with other specialties. Schubot DB. **Fam Med** 1996 Sep;28(8):575–9

Urban adolescent females' views on the implant and contraceptive decision-making: a double paradox. Kuiper H, et al. **Fam Plann Perspect** 1997 Jul–Aug;29(4):167–72

Adolescent-parent attachments and family problem-solving styles. Cobb CL. **Fam Process** 1996 Mar;35(1):57–82

Teen perspectives on HIV and the relevance of Hawaii's health providers. Bidwell RJ, et al. **Hawaii Med J** 1996 Oct;55(10):205–11

Headache intensity and quality of life in adolescents. How are changes in headache intensity in adolescents related to changes in experienced quality of life? Langeveld JH, et al. **Headache** 1997 Jan;37(1):37–42

Role of the self-image and smoker stereotype in smoking onset during early adolescence: a longitudinal study. Aloise-Young PA, et al. **Health Psychol** 1996 Nov; 15(6):494–7

The natural history of cigarette smoking from adolescence to adulthood: demographic predictors of continuity and change. Chassin L, et al. **Health Psychol** 1996 Nov; 15(6):478–84

A longitudinal study of the reciprocal nature of risk behaviors and cognitions in adolescents: what you do shapes what you think, and vice versa. Gerrard M, et al. **Health Psychol** 1996 Sep;15(5):344–54

Cross-cultural differences in adolescents' perceptions of their grandparents. Hurme H. **Int J Aging Hum Dev** 1997; 44(3):221–53

The meaning of grandparents as viewed by adolescent grandchildren: an empirical study in Belgium. Van Ranst N, et al. **Int J Aging Hum Dev** 1995;41(4):311–24

Disordered eating and its psychosocial correlates among Chinese adolescent females in Hong Kong. Lee AM, et al. **Int J Eat Disord** 1996 Sep;20(2):177–83

Role of television in adolescent women's body dissatisfaction and drive for thinness. Tiggemann M, et al. **Int J Eat Disord** 1996 Sep;20(2):199–203

Reported health concerns of Israeli high school students—differences by age and sex. Palti H, et al. **Isr J Med Sci** 1997 Feb;33(2):123–8

Factors associated with continuity and changes in disruptive behavior patterns between childhood and adolescence. Fergusson DM, et al. **J Abnorm Child Psychol** 1996 Oct; 24(5):533–53

Predictive and concurrent validity of the Suicidal Ideation Questionnaire among American Indian adolescents. Keane EM, et al. **J Abnorm Child Psychol** 1996 Dec;24(6):735–47

An examination of adolescent risk-taking using a story completion task. Moore SM, et al. **J Adolesc** 1997 Aug; 20(4):369–79

The development of forgiveness in the context of adolescent friendship conflict in Korea. Park YO, et al. **J Adolesc** 1997 Aug;20(4):393–402

Late adolescent risk-taking: effects of perceived benefits and perceived risks on behavioral intentions and behavioral change. Parsons JT, et al. **J Adolesc** 1997 Aug;20(4):381–92

Imaginary companions in adolescence: sign of a deficient or positive development. Seiffge-Krenke I. **J Adolesc** 1997 Apr;20(2):137–54

Stimulating adolescents' decision-making. Taal M, et al. **J Adolesc** 1997 Apr;20(2):223–6

Personality and risk-taking: a brief report on adolescent male drivers. Vavrik J. **J Adolesc** 1997 Aug;20(4):461–5

Life satisfaction among low-income rural youth from Appalachia. Wilson SM, et al. **J Adolesc** 1997 Aug; 20(4):443–59

To the psychological effects of youth unemployment: international perspectives [editorial] Winefield AH. **J Adolesc** 1997 Jun;20(3):237–41

Adolescents as witnesses to violence. Bain JE, et al. **J Adolesc Health** 1996 Aug;19(2):83–5

Adolescent knowledge, values, and coping strategies: implications for health in sub-Saharan Africa. Balmer DH, et al. **J Adolesc Health** 1997 Jul;21(1):33–8

Daughter and mother report of individual symptoms on the Children's Depression Inventory. Bennett DS, et al. **J Adolesc Health** 1997 Jan;20(1):51–7

Embedded anti-alcohol messages on commercial television: what teenagers perceive. Borzekowski DL. **J Adolesc Health** 1996 Nov;19(5):345–52

Self-concept, family functioning and problem type: a replication and extension of a study of clinic and non-clinic adolescents. Bowles TV, et al. **J Adolesc Health** 1996 Jul; 19(1):62–7

Bibliography of recent journal articles (January to June 1993). Brookman RR. **J Adolesc Health** 1995 Dec;17(6):389–99

An exploration of the demographic and social correlates of criminal behavior among adolescent males. Cox RP. **J Adolesc Health** 1996 Jul;19(1):17–24

Searching for resilience among African-American youth exposed to community violence: theoretical issues. Howard DE. **J Adolesc Health** 1996 Apr;18(4):254–62 (66 ref.)

Premenarcheal expectations and postmenarcheal experiences of positive and negative menstrual related changes. Koff E, et al. **J Adolesc Health** 1996 Apr;18(4):286–91

Through the looking glass: self-esteem in adolescents [editorial] Litt IF. **J Adolesc Health** 1996 Jul;19(1):1

Homelessness and adolescents [editorial] Litt IF. **J Adolesc Health** 1997 May;20(5):335

Developmental issues influencing guidelines for adolescent health research: a review. Petersen AC, et al. **J Adolesc Health** 1995 Nov;17(5):298–305 (72 ref.)

The Quality of Life Profile—Adolescent Version: background, description, and initial validation. Raphael D, et al. **J Adolesc Health** 1996 Nov;19(5):366–75

The effects of peer ridicule on depression and self-image among adolescent females with Turner syndrome. Rickert VI, et al. **J Adolesc Health** 1996 Jul;19(1):34–8

Predicting contraceptive vigilance in adolescent females: a projective method for assessing ego development. Speier PL, et al. **J Adolesc Health** 1997 Jan;20(1):14–9

Why pregnant adolescents say they did not use contraceptives prior to conception. Stevens-Simon C, et al. **J Adolesc Health** 1996 Jul;19(1):48–53; discussion 54–5

Young diabetics' compliance in the framework of the MIMIC model. Kyngäs H, et al. **J Adv Nurs** 1996 Nov; 24(5):997–1005

Prediction of adolescent affective disorder: effects of prior parental affective disorders and child psychopathology. Beardslee WR, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Mar;35(3):279–88

Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. Biederman J, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Mar;35(3):343–51

Thyroid hormone concentrations in depressed and nondepressed adolescents: group differences and behavioral relations [see comments] Dorn LD, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Mar; 35(3):299–306. Comment in: J Am Acad Child Adolesc Psychiatry 1997 Feb;36(2):159.

Predictive validity of the suicide probability scale among adolescents in group home treatment. Larzelere RE, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Feb; 35(2):166–72; discussion 172–4

Case study: electroconvulsive therapy in adolescents [see comments] Moise FN, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Mar;35(3):312–8 . Comment in: J Am Acad Child Adolesc Psychiatry 1997 Apr;36(4):445–6.

Effects of war trauma on Cambodian refugee adolescents' functional health and mental health status. Mollica RF, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Aug; 36(8):1098–106

State and trait anxiety in adolescent suicide attempters. Ohring R, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Feb;35(2):154–7

Negative affect and cognitive biases in suicidal and nonsuicidal hospitalized adolescents. Pinto A, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Feb;35(2):158–65

Psychological defense styles in late adolescence and young adulthood: a follow-up study. Tuulio-Henriksson A, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Aug; 36(8):1148–53

Identity, sexuality and the self in late adolescence. Feldman B, et al. **J Anal Psychol** 1996 Oct;41(4):491–507

Assessment and phenomenology of nonclinical panic attacks in adolescent girls. Hayward C, et al. **J Anxiety Disord** 1997 Jan–Feb;11(1):17–32

An investigation of negative affectivity in Australian adolescents. Boyd CP, et al. **J Clin Child Psychol** 1997 Jun;26(2):190–7

Impact of exposure to community violence on violent behavior and emotional distress among urban adolescents. Farrell AD, et al. **J Clin Child Psychol** 1997 Mar;26(1):2–14

Acquired immunodeficiency syndrome and suburban adolescents: knowledge, attitudes, behaviors and risks. Imperato AM. **J Community Health** 1996 Oct;21(5):329–47

Preventing teen pregnancy through persuasive communications: realities, myths, and the hard-fact truths. Witte K. **J Community Health** 1997 Apr;22(2):137–54

Attachment organization and history of suicidal behavior in clinical adolescents. Adam KS, et al. **J Consult Clin Psychol** 1996 Apr;64(2):264–72

Attachment theory as a framework for understanding sequelae of severe adolescent psychopathology: an 11-year follow-up study. Allen JP, et al. **J Consult Clin Psychol** 1996 Apr;64(2):254–63

Gender differences in depressive symptoms in adolescence: comparison of national samples of clinically referred and nonreferred youths. Compas BE, et al. **J Consult Clin Psychol** 1997 Aug;65(4):617–26

Adolescent attachment and psychopathology. Rosenstein DS, et al. **J Consult Clin Psychol** 1996 Apr;64(2):244–53 (45 ref.)

DSM-IV and disorders of childhood and adolescence: can structural criteria be functional? Scotti JR, et al. **J Consult Clin Psychol** 1996 Dec;64(6):1177–91

Responsible decision making regarding alcohol: a re-emerging prevention/education strategy for the 1990s. Milgram GG. **J Drug Educ** 1996;26(4):357–65 (11 ref.)

Family communication patterns, rebelliousness, and adolescent reactions to anti-drug PSAs. Skinner ER, et al. **J Drug Educ** 1995;25(4):343–55

Do adolescents want to hear preventive counseling messages in outpatient settings? Steiner BD, et al. **J Fam Pract** 1996 Oct;43(4):375–81

Cross-cultural comparison of need importance and need satisfaction during adolescence: Turkey and the United States. Hortaçsu N. **J Genet Psychol** 1997 Sep; 158(3):287–96

Family environment and adolescent psychological well-being, school adjustment, and problem behavior: a pioneer study in a Chinese context. Shek DT. **J Genet Psychol** 1997 Mar;158(1):113–28

A longitudinal study of adolescents' attitudes about assistance in the development of moral values. Zern DS. **J Genet Psychol** 1997 Mar;158(1):79–95

Parental support and adolescent physical health status: a latent growth-curve analysis. Wickrama KA, et al. **J Health Soc Behav** 1997 Jun;38(2):149–63

Quality of life in children with well-controlled epilepsy. Wildrick D, et al. **J Neurosci Nurs** 1996 Jun;28(3):192–8

Gender differences in adolescent weight and shape-related beliefs and behaviour. Nowak M, et al. **J Paediatr Child Health** 1996 Apr;32(2):148–52

Utility of the Pediatric Symptom Checklist as a psychosocial screen to meet the federal Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) standards: a pilot study. Murphy JM, et al. **J Pediatr** 1996 Dec;129(6):864–9

Female adolescent sexuality. Sugar M. **J Pediatr Adolesc Gynecol** 1996 Nov;9(4):175–83 (73 ref.)

A systems approach to adolescent transitions: an opportunity for nurses [editorial] Betz CL. **J Pediatr Nurs** 1996 Oct; 11(5):271–2

Emotional support in pediatric trauma: remembering children like Caleb [editorial] Zink KA. **J Pediatr Nurs** 1996 Dec; 11(6):345–6

Observations from a survivor of childhood cancer. Dorfman E. **J Pediatr Oncol Nurs** 1996 Oct;13(4):235–6

An analysis of the concept of hope in the adolescent with cancer. Hendricks-Ferguson VL. **J Pediatr Oncol Nurs** 1997 Apr;14(2):73–80; discussion 81–2 (47 ref.)

Revising theories on adolescent development through observations by nurses [editorial] Hinds PS. **J Pediatr Oncol Nurs** 1997 Jan;14(1):1–2

Future directions for the MMPI-A: research and clinical issues. Archer RP. **J Pers Assess** 1997 Feb;68(1):95–109 (38 ref.)

Parental representations, self-view, and interpersonal functioning of older adolescents. Drodge EN. **J Pers Assess** 1997 Feb;68(1):152–64

Rorschach interpretation with high-ability adolescent females: psychopathology or creative thinking? Franklin KW, et al. **J Pers Assess** 1997 Feb;68(1):184–96

Clinical accuracy ratings of MMPI approaches for adolescents: adding ten years and the MMPI-A. Janus MD, et al. **J Pers Assess** 1996 Oct;67(2):364–83

Feigning psychopathology among adolescent offenders: validation of the SIRS, MMPI-A, and SIMS. Rogers R, et al. **J Pers Assess** 1996 Oct;67(2):244–57

Adolescents' well-being and perceived control across 14 sociocultural contexts. Grob A, et al. **J Pers Soc Psychol** 1996 Oct;71(4):785–95

Assessing family differentiation: four areas of competence in mother–adolescent relationships. Theriault J. **J Psychol** 1997 Sep;131(5):565–8

Body image perception in female Mexican–American adolescents. Guinn B, et al. **J Sch Health** 1997 Mar; 67(3):112–5

Coping with a new society: the unique psychosocial problems of immigrant youth. James DC. **J Sch Health** 1997 Mar; 67(3):98–102

The needs of children and the role of school nurses. Nelson KE. **J Sch Health** 1997 May;67(5):187–8

Teaching teens to cope: coping skills training for adolescents with insulin–dependent diabetes mellitus. Davidson M, et al. **J Soc Pediatr Nurs** 1997 Apr–Jun;2(2):65–72

Adolescents' opposite–sex ideal in four countries. Gibbons JL, et al. **J Soc Psychol** 1996 Aug;136(4):531–7

Multifactorial self–concept and delinquency in Australian adolescents. Levy KS. **J Soc Psychol** 1997 Jun; 137(3):277–83

Guns in young hands: a survey of urban teenagers' attitudes and behaviors related to handgun violence. Bergstein JM, et al. **J Trauma** 1996 Nov;41(5):794–8

Trauma–related symptomatology among American Indian adolescents. Jones MC, et al. **J Trauma Stress** 1997 Apr; 10(2):163–73

The association between illusions of invulnerability and exposure to trauma. Roe–Berning S, et al. **J Trauma Stress** 1997 Apr;10(2):319–27

Adolescents: daughters or alien sociopaths? Males M. **Lancet** 1997 Mar;349 Suppl 1:sI13–6

Caring for pregnant teens and their mothers, too. Roye CF, et al. **MCN Am J Matern Child Nurs** 1997 May–Jun; 22(3):153–7

Preventing violence, preventing war. Ashford MW. **Med Confl Surviv** 1997 Jan–Mar;13(1):57–62 (7 ref.)

Caring for the terminally ill adolescent. Carr–Gregg MR, et al. **Med J Aust** 1997 Mar 3;166(5):255–8 (24 ref.)

Alternate models of positive health practices in adolescents. Yarcheski A, et al. **Nurs Res** 1997 Mar–Apr;46(2):85–92

Perception of post traumatic stress disorder symptoms by children of Puerto Rican Vietnam veterans. del Valle LE, et al. **P R Health Sci J** 1996 Jun;15(2):101–6

Sexual abuse and adolescents. Adams JA. **Pediatr Ann** 1997 May;26(5):299–304

Exploring psychosocial task resolution and self–concept among African–American adolescents. Brookins CC. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):803–10

Correlations of body composition and body–image assessments of adolescents. Byrne NM, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 2):1330

Effect of framing on adolescents' decision making. Chien YC, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 1):811–9

Impulsive–reflective cognitive style, metacognition, and emotion in adolescence. Palladino P, et al. **Percept Mot Skills** 1997 Feb;84(1):47–57

Fear of fatness and adolescent girls: implications for obesity prevention. Flynn MA. **Proc Nutr Soc** 1997 Mar; 56(1B):305–17 (73 ref.)

Primary attachment in female adolescents: association with depression, self–esteem, and maternal identification. Salzman JP. **Psychiatry** 1996 Spring;59(1):20–33

Adolescents with developmental psychopathology in adulthood. Tsutsumi S. **Psychiatry Clin Neurosci** 1996 Jun; 50(3):101–7

Play in the treatment of adolescents. Markman H. **Psychoanal Q** 1997 Apr;66(2):190–218

The changing mental health of children and adolescents: evidence for a deterioration? Prosser J, et al. **Psychol Med** 1996 Jul;26(4):715–25

Adolescent reinforcement survey schedule: summary of research and future directions. Holmes GR, et al. **Psychol Rep** 1996 Feb;78(1):76–8

Characteristics and motives of adolescent volunteers in wildlife education. Kidd AH, et al. **Psychol Rep** 1997 Jun; 80(3 Pt 1):747–53

Black south African adolescents' attitudes about studying. Watson MB, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):861–2

Adolescent females' attitudes, subjective norms, perceived behavioral control, and intentions to use latex condoms. Rannie K, et al. **Public Health Nurs** 1997 Feb;14(1):51–7

Quality of life in early adolescence: a sixteen–dimensional health–related measure (16D). Apajasalo M, et al. **Qual Life Res** 1996 Apr;5(2):205–11

The utility of locus of control for predicting adolescent substance use. Bearinger LH, et al. **Res Nurs Health** 1997 Jun;20(3):229–45

Smoking and associated factors among young Swedish females. Herlitz C, et al. **Scand J Prim Health Care** 1996 Dec;14(4):209–15

Defensive styles and psychological symptoms among Chinese adolescents in Hong Kong. Chan DW. **Soc Psychiatry Psychiatr Epidemiol** 1997 Jul;32(5):269–76

HIV prevention among Zambian adolescents: developing a value utilization/norm change model. Feldman DA, et al. **Soc Sci Med** 1997 Feb;44(4):455–68

Girls, pecking order and smoking. Michell L, et al. **Soc Sci Med** 1997 Jun;44(12):1861–9

The adolescent: the individual in cultural perspective. Berman AL. **Suicide Life Threat Behav** 1997 Spring; 27(1):5–14

Correlates of suicidal behavior in a juvenile detention population. Rohde P, et al. **Suicide Life Threat Behav** 1997 Summer;27(2):164–75

Adolescent decision–making: giving weight to age–specific values. Ladd RE, et al. **Theor Med** 1995 Dec;16(4):333–45

[A method for studying the dynamic mental work capacity of pupils from upper grades] Shpangenberg S, et al. **Probl Khig** 1996;21:148–51 (Eng. Abstr.) **(Bul)**

[Borderline disorders, schizotypal and narcissistic personality disorders in adolescents: a useful distinction] Meijer M. **Ned Tijdschr Geneeskd** 1996 Dec 14;140(50):2485–7 **(Dut)**

[Knowledge of adolescents about the fetal alcohol syndrome] Weiss S. **Harefuah** 1997 Apr 15;132(8):585–6, 607 (Eng. Abstr.) **(Heb)**

[infantile and adolescent psychic disorders: a cognitive dysfunction or change manifestation?] Gamna G. **Minerva Pediatr** 1996 Dec;48(12):529–33 **(Ita)**

[Neuropsychic development in children born with spina bifida] Piazza F, et al. **Pediatr Med Chir** 1996 Nov–Dec; 18(6):597–600 (Eng. Abstr.) **(Ita)**

[Relationship between body type, subjective symptoms and health awareness in junior high school students] Monden S. **Nippon Koshu Eisei Zasshi** 1997 Feb;44(2):131–8 (Eng. Abstr.) **(Jpn)**

[Children of Alcoholics Screening Test (CAST) and influence of parent's drinking on their children] Yamazaki S. **Nippon Koshu Eisei Zasshi** 1996 Dec;43(12):1045–54 (Eng. Abstr.) **(Jpn)**

[Development of scales of relationships between grandchildren in adolescence and grandparents] Tabata O, et al. **Shinrigaku Kenkyu** 1996 Dec;67(5):375–81 (Eng. Abstr.) **(Jpn)**

[Suicidal behavior among young people—is it possible to prevent?] Mehlum L. **Tidsskr Nor Laegeforen** 1997 May 10;117(12):1733–4 **(Nor)**

[The color preferences of adolescents with character traits] Bazyma BA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(1):24–8 (Eng. Abstr.) **(Rus)**

[Characteristics of knowledge and attitude to drugs and drug addiction in a population of addicted and non–addicted adolescents] Dukanović B. **Med Arh** 1996;50(1–2):41–3 (Eng. Abstr.) **(Scr)**

[Family factors in adolescent suicide attempts] Gonzalez–Seijo JC, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jan–Feb;24(1):12–8 (Eng. Abstr.) **(Spa)**

[Risks and psychological problems in adolescents] Juan Del Rey Calero D. **An R Acad Nac Med (Madr)** 1996; 113(1):19–47; discussion 47–52 **(Spa)**

[Does role playing trigger violence? The impact of "party games" should be scientifically scrutinized (see comments)] Lindqvist P. **Lakartidningen** 1996 Sep 25;93(39):3353–5. Comment in: Lakartidningen 1996 Oct 30;93(44):3883–4. **(Swe)**

EDUCATION

The role of family support programs in building developmental assets among young adolescents: a national survey of services and staff training needs. Scales PC. **Child Welfare** 1997 Sep–Oct;76(5):611–35

ADOMET see **S–ADENOSYLMETHIONINE**

ADOPTION

Foster and adoptive mothers' assessment of permanent family placements. Holloway JS. **Arch Dis Child** 1997 Mar; 76(3):231–5

Outcome in placements for adoption or long–term fostering. Holloway JS. **Arch Dis Child** 1997 Mar;76(3):227–30

Thought disorder in schizophrenic and control adoptees and their relatives. Kinney DK, et al. **Arch Gen Psychiatry** 1997 May;54(5):475–9

Romanian adoption. The Manitoba experience. Benoit TC, et al. **Arch Pediatr Adolesc Med** 1996 Dec;150(12):1278–82

Sexual abuse of illegally adopted children [letter] de Silva DG, et al. **Ceylon Med J** 1997 Mar;42(1):44

Predisposition to criminality: Swedish adoption studies in retrospect. Bohman M. **Ciba Found Symp** 1996;194:99–109; discussion 109–14 (21 ref.) (Eng. Abstr.)

Assessing the role of genetics in crime using adoption cohorts. Brennan PA, et al. **Ciba Found Symp** 1996; 194:115–23; discussion 123–28 (25 ref.)

An adoption study of DSM–IIIR alcohol and drug dependence severity. Yates WR, et al. **Drug Alcohol Depend** 1996 May;41(1):9–15

Non–puerperal lactation in nutritional rehabilitation: case report. Eregie CO. **East Afr Med J** 1997 Jan;74(1):59–60

Disseminated histoplasmosis in an adopted infant from El Salvador. Troillet N, et al. **Eur J Pediatr** 1996 Jun; 155(6):474–6

Parents' sense of "entitlement" in adoptive and nonadoptive families. Cohen NJ, et al. **Fam Process** 1996 Dec; 35(4):441–56

Social workers' attitudes toward participants' rights in adoption and new reproductive technologies. Holbrook SM. **Health Soc Work** 1996 Nov;21(4):257–66

Health of children adopted from the former Soviet Union and Eastern Europe. Comparison with preadoptive medical records. Albers LH, et al. **JAMA** 1997 Sep 17;278(11):922–4

...as Israel offers to test adopted children [news] Watzman H. **Nature** 1997 Sep 25;389(6649):322

British agencies for adoption and fostering in Scotland—Scottish Medical Advisers' survey. Irving MA, et al. **Public Health** 1997 Jul;111(4):225–9

[Being raised by lesbian parents or in a single–parent family is no risk factor for problem behavior, however being raised as an adopted child is] Verhulst FC, et al. **Ned Tijdschr Geneeskd** 1997 Mar 1;141(9):414–8 (29 ref.) (Eng. Abstr.) **(Dut)**

[Intestinal parasitosis in internationally adopted children] Bossi L, et al. **Ann Ig** 1997 May–Jun;9(3):237–40 **(Ita)**

[Adopted children and big stomachs (letter; comment)] Olsen H. **Tidsskr Nor Laegeforen** 1997 Feb 10;117(4):559–60. Comment on: Tidsskr Nor Laegeforen 1997 Jan 10;117(1):83. **(Nor)**

[Adopted African children have large stomachs (see comments)] Spurkland A, et al. **Tidsskr Nor Laegeforen** 1997 Jan 10;117(1):83. Comment in: Tidsskr Nor Laegeforen 1997 Feb 10;117(4):559–60. **(Nor)**

ETHNOLOGY

Effects of age and race on the odds of adoption versus remaining in long–term out–of–home care. Barth RP. **Child Welfare** 1997 Mar–Apr;76(2):285–308

Intercountry adoption of Latin American children: the importance of early bilingual/bicultural services. de Verthelyi RF. **Cult Divers Ment Health** 1996;2(1):53–63 (33 ref.)

Negative outcomes of interethnic adoption of Mexican American children. Bausch RS, et al. **Soc Work** 1997 Mar; 42(2):136–43

LEGISLATION & JURISPRUDENCE

Reflections on adoption ethics. Post SG. **Camb Q Healthc Ethics** 1996 Summer;5(3):430–7; discussion 437–9

The Uniform Adoption Act. Hollinger JH. **Future Child** 1995 Winter;5(3):205–11

Legal issues in nonrelated infant adoption: nursing implications. Lobar SL, et al. **J Soc Pediatr Nurs** 1997 Jul–Sep;2(3):116–24; quiz 125–6 (29 ref.)

Towards the practice of surrogacy in Israel. Corinaldi M. **Med Law** 1995;14(5–6):425–7

Sexual orientation of parents and Dutch family law. van Nijnatten CH. **Med Law** 1995;14(5–6):359–68 (35 ref.)

PSYCHOLOGY

Emotional health of Indonesian adoptees living in Australian families. Goldney RD, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):534–9

Openness in adoption and the level of child participation. Wrobel GM, et al. **Child Dev** 1996 Oct;67(5):2358–74

Preimplantation diagnosis and other reproductive options: attitudes of male and female carriers of recessive disorders. Snowdon C, et al. **Hum Reprod** 1997 Feb;12(2):341–50

An adopted analysand's transference of a 'hole–object'. Quinodoz D. **Int J Psychoanal** 1996 Apr;77 (Pt 2):323–36

Parent–reported problems in 211 adopted children: some risk and protective factors. Howe D. **J Child Psychol Psychiatry** 1997 May;38(4):401–11

Transracial family placements. Rushton A, et al. **J Child Psychol Psychiatry** 1997 Feb;38(2):147–59 (105 ref.)

Self–reported and parent reported problems in adolescent international adoptees. Versluis–den Bieman HJ, et al. **J Child Psychol Psychiatry** 1995 Nov;36(8):1411–28

Unique issues of the adopted child: helping parents talk openly and honestly with their child and the community. Smit EM. **J Psychosoc Nurs Ment Health Serv** 1996 Jul; 34(7):29–36 (22 ref.)

Estimating genetic and environmental effects of alcohol use and dependence from a national survey: a "quasi–adoption" study. Light JM, et al. **J Stud Alcohol** 1996 Sep; 57(5):507–20 (45 ref.)

Supporting the adoptive family: a developmental approach. Peterson EA. **MCN Am J Matern Child Nurs** 1997 May–Jun;22(3):147–52 (8 ref.)

Measuring linguistic development in a child adopted from Romania. Hess CW, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):944–6

Trauma and the developmental process. Excerpts from an analysis of an adopted child. Cohen S. **Psychoanal Study Child** 1996;51:287–302

"Put yourself in the skin of the child," she said. Goldstein J, et al. **Psychoanal Study Child** 1996;51:46–55

Lie as narrative truth in abused adopted adolescents. Wilkinson S, et al. **Psychoanal Study Child** 1996;51:580–96

Is there psychopathology in the coparents of schizophrenic adoptees' half–siblings? Ingraham LJ, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1296–8

A birth father and adoption in the perinatal setting. Menard BJ. **Soc Work Health Care** 1997;24(3–4):153–63 (18 ref.)

ADOPTIVE CELL TRANSFER see **ADOPTIVE TRANSFER**

ADOPTIVE CELLULAR IMMUNOTHERAPY see **IMMUNOTHERAPY, ADOPTIVE**

ADOPTIVE TRANSFER

Rat stem cells developing in irradiated SCID mice fail to become tolerized and cause lethal graft–versus–host

disease. Surh CD, et al. **Am J Pathol** 1997 Aug;151(2):591–9
Lymphocyte immunotherapy (LI) increases serum levels of progesterone induced blocking factor (PIBF). Check JH, et al. **Am J Reprod Immunol** 1997 Jan;37(1):17–20
Enhancement of the expression of progesterone receptor on progesterone–treated lymphocytes after immunotherapy in unexplained recurrent spontaneous abortion. Chiu L, et al. **Am J Reprod Immunol** 1996 Jun;35(6):552–7
Adoptively transferred late allergic airway responses are associated with Th2–type cytokines in the rat. Watanabe A, et al. **Am J Respir Cell Mol Biol** 1997 Jan;16(1):69–74
Immunotherapy of the SL2–5 murine lymphoma with natural killer cells and tamoxifen or toremifene. Baral E, et al. **Anticancer Res** 1997 Jan–Feb;17(1A):77–83
Anti–estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes. Nagy E, et al. **Anticancer Res** 1997 Mar–Apr;17(2A):1083–8
Retention of adoptively transferred interleukin–2–activated natural killer cells in tumor tissue. Ribeiro U Jr, et al. **Anticancer Res** 1997 Mar–Apr;17(2A):1115–23
Role of CD4+CD8– thymocytes in the prevention of autoimmune diabetes. Seddon B, et al. **Biochem Soc Trans** 1997 May;25(2):620–4 (16 ref.)
A model for human B–chronic lymphocytic leukemia in human/mouse radiation chimera: evidence for tumor–mediated suppression of antibody production in low–stage disease. Shimoni A, et al. **Blood** 1997 Mar 15; 89(6):2210–8
Allogeneic bone marrow transplantation from a donor with severe active rheumatoid arthritis not resulting in adoptive transfer of disease to recipient. Snowden JA, et al. **Bone Marrow Transplant** 1997 Jul;20(1):71–3
A tumor–specific Th2 clone initiating tumor rejection via primed CD8+ cytotoxic T–lymphocyte activation in mice. Shen Y, et al. **Cancer Res** 1996 Nov 1;56(21):5005–11
Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Freedman RS, et al. **Cancer Treat Res** 1996;82:115–46 (114 ref.)
Inductive events in oral tolerance in the TCR transgenic adoptive transfer model. Chen Y, et al. **Cell Immunol** 1997 May 25;178(1):62–8
Th1 CD4+ cells adoptively transfer experimental hypersensitivity pneumonitis. Schuyler M, et al. **Cell Immunol** 1997 May 1;177(2):169–75
An unusual case of refractory Campylobacter jejuni infection in a patient with X–linked agammaglobulinemia: successful combined therapy with maternal plasma and ciprofloxacin. Autenrieth IB, et al. **Clin Infect Dis** 1996 Sep;23(3):526–31
Association between alphabetaTCR+CD4–CD8– T–cell deficiency and IDDM in NOD/Lt mice. Baxter AG, et al. **Diabetes** 1997 Apr;46(4):572–82
Immunological aspects of nutritional diabetes prevention in NOD mice: a pilot study for the cow's milk–based IDDM prevention trial. Karges W, et al. **Diabetes** 1997 Apr; 46(4):557–64
Inhibition of diabetes by an insulin–reactive CD4 T–cell clone in the nonobese diabetic mouse. Zekzer D, et al. **Diabetes** 1997 Jul;46(7):1124–32
CD4+CD8– thymocytes that express L–selectin protect rats from diabetes upon adoptive transfer. Seddon B, et al. **Eur J Immunol** 1996 Nov;26(11):2702–8
Selective down–regulation of Th2 immune responses following treatment with antigen–coupled splenocytes. Soldera S, et al. **Eur J Immunol** 1997 Apr;27(4):848–54
Analysis of pathogenesis of autoimmune insulitis in NOD mice: adoptive transfer experiments of insulitis in ILI and NOD nude mice. Nakamura M, et al. **Exp Anim** 1996 Jul; 45(3):233–8
Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Lau GK, et al. **Hepatology** 1997 Jun;25(6):1497–501
Use of adoptive transfer of T–cell–antigen–receptor–transgenic T cell for the study of T–cell activation in vivo. Pape KA, et al. **Immunol Rev** 1997 Apr;156:67–78 (59 ref.)
Adoptive transfer of allergen–specific CD4+ T cells induces airway inflammation and hyperresponsiveness in brown–Norway rats. Haczku A, et al. **Immunology** 1997 Jun;91(2):176–85
Nonatopic asthma: in vivo airway hyperreactivity adoptively transferred to naive mice by THY–1(+) and B220(+) antigen–specific cells that lack surface expression of CD3. Geba GP, et al. **J Clin Invest** 1997 Aug 1;100(3):629–38
Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL–10–transduced islet–specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes. Moritani M, et al. **J Clin Invest** 1996 Oct 15; 98(8):1851–9
Improved survival of severe combined immunodeficiency (scid) mice with cryptosporidiosis by adoptively transferring CD4+ and CD4– CD8– B220– BALB/c splenocytes (Spls). Kuhls TL, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):71S
Trafficking of adoptively transferred B lymphocytes in B–lymphocyte–deficient mice. Roth R, et al. **J Exp Biol** 1997 Jul;200 (Pt 14):2057–62
The thymus contains a high frequency of cells that prevent autoimmune diabetes on transfer into prediabetic recipients. Saoudi A, et al. **J Exp Med** 1996 Dec 1;184(6):2393–8
Suppression of human hepatoma in mice through adoptive transfer of immunity to the hepatitis B surface antigen. Ilan Y, et al. **J Hepatol** 1997 Jul;27(1):170–5
Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. Aranda R, et al. **J Immunol** 1997 Apr 1; 158(7):3464–73
Adoptive transfer of gut intraepithelial lymphocytes protects against murine infection with Toxoplasma gondii. Buzoni–Gatel D, et al. **J Immunol** 1997 Jun 15; 158(12):5883–9
Mechanisms of tolerance induction: splenocytes from total lymphoid irradiated mice inhibit the IL–2 pathway in TCR–activated CD4 cells. Field EH, et al. **J Immunol** 1996 Nov 1;157(9):3796–803
Gamma delta TCR+ hybridomas derived from mice preimmunized via the portal vein adoptively transfer increased skin allograft survival in vivo. Gorczynski RM, et al. **J Immunol** 1996 Jul 15;157(2):574–81
Inhibition of graft–versus–host disease. Use of a T cell–controlled suicide gene. Helene M, et al. **J Immunol** 1997 Jun 1;158(11):5079–82
Calpain is the target antigen of a Th1 clone that transfers protective immunity against Schistosoma mansoni. Jankovic D, et al. **J Immunol** 1996 Jul 15;157(2):806–14
Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I–dependent. Serreze DV, et al. **J Immunol** 1997 Apr 15;158(8):3978–86
High–dose regimen of interleukin–2 and interferon–alpha in combination with lymphokine–activated killer cells in patients with metastatic renal cell cancer. Kruit WH, et al. **J Immunother** 1997 Jul;20(4):312–20
Identification of a T–cell receptor from a therapeutic murine T–cell clone. Shilyansky J, et al. **J Immunother** 1997 Jul; 20(4):247–55
Adoptive transfer of bryostatin–activated tumor–sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro. Fleming MD, et al. **J Immunother Emphasis Tumor Immunol** 1995 Oct; 18(3):147–55
The impact of psychological stress on the efficacy of anti–viral adoptive immunotherapy in an immunocompromised host. Bonneau RH, et al. **J Neuroimmunol** 1997 Sep;78(1–2):19–33
IL–10 fails to abrogate experimental autoimmune encephalomyelitis. Cannella B, et al. **J Neurosci Res** 1996 Sep 15;45(6):735–46
Adoptive transfer of granulomatous inflammation to Brugia antigens in jirds. Klei TR, et al. **J Parasitol** 1997 Aug; 83(4):626–9
Effects of T cell adoptive transfer into nude mice on alveolar bone resorption induced by endotoxin. Ukai T, et al. **J Periodontal Res** 1996 Aug;31(6):414–22
Induction of degenerative brain lesions after adoptive transfer of brain lymphocytes from Borna disease virus–infected rats: presence of CD8+ T cells and perforin mRNA. Sobbe M, et al. **J Virol** 1997 Mar;71(3):2400–7
Transplantation of systemic sclerosis (SSc) skin grafts into severe combined immunodeficient mice: increased presence of SSc leukocytes in SSc skin grafts and autoantibody production following autologous leukocyte transfer. Kräling BM, et al. **Pathobiology** 1996;64(2):99–114
Primary central nervous system lymphoma following transfer of human peripheral blood lymphocytes into SCID mice. Lavi E, et al. **Pathobiology** 1995;63(4):188–91
Protective immunity to HIV–1 in SCID/beige mice reconstituted with peripheral blood lymphocytes of exposed but uninfected individuals. Zhang C, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14720–5
Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies [see comments] Lockwood CM, et al. **QJM** 1996 Dec;89(12):903–12. Comment in: QJM 1997 Jun;90(6):431.
Innate versus acquired immunity in listeriosis. Brombacher F, et al. **Res Immunol** 1996 Oct–Dec;147(8–9):505–11 (53 ref.)
Adoptive transfer of CD4 T–cell dependent allograft tolerance. Coulombe M, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1166–7
Immunization with WBC induces monocyte suppression activity in vitro. Gafter U, et al. **Transplant Proc** 1997 Sep; 29(6):2649–50
Immunization with WBC suppresses T cells and NK activity in vitro. Gafter U, et al. **Transplant Proc** 1997 Sep; 29(6):2703–5
Gamma delta TCR+, type–2 cytokine produced by hybridoma cells produced in mice given portal vein pretransplant immunization and allogeneic grafts can increase graft survival on adoptive transfer. Gorczynski R, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):865–6
Mechanisms of indirect allorecognition in graft rejection: class II MHC allopeptide–specific T cell clones transfer delayed–type hypersensitivity responses in vivo. Chen W, et al. **Transplantation** 1996 Sep 27;62(6):705–10
Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft–versus–host disease. Krenger W, et al. **Transplantation** 1996 Nov 15; 62(9):1278–85
Prevention of graft–versus–host disease by intrathymic injection of recipient–type splenocytes into donor. Vaidya S, et al. **Transplantation** 1996 Nov 15;62(9):1366–8
[Dynamics of cytotoxicity of blood mononuclear cells in patients with bladder cancer during endolymphatic immunotherapy with lymphokine– activated killer cells and recombinant interleukin–2] Malakhova NV, et al. **Biull Eksp Biol Med** 1996 Feb;121(2):188–91 **(Rus)**

METHODS

Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials. Coulam CB, et al. **Am J Reprod Immunol** 1996 Apr;35(4):352–9 (67 ref.)
Unrepresentative behavior of T cell receptor–transgenic CD4+ T cells upon adoptive transfer: lack of need for priming and an extended booster dose–response. Schuhbauer D, et al. **Immunobiology** 1996 Jul;195(2):152–9
Adoptive transfer of susceptibility to antigen–induced arthritis into severe combined immunodeficient (SCID) mice: role of CD4+ and CD8+ T cells. Petrow PK, et al. **Immunol Invest** 1996 Jul;25(4):341–53
Delineation of the human hematolymphoid system: potential applications of defined cell populations in cellular therapy. Chen BP, et al. **Immunol Rev** 1997 Jun;157:41–51 (65 ref.)
Immunological induction of flavour aversion in mice. II. Passive/adoptive transfer and pharmacological inhibition. Cara DC, et al. **Scand J Immunol** 1997 Jan;45(1):16–20
Donor–specific tolerance by perioperative intrathymic injection of bone marrow cells in the rat cardiac allograft model: use of FK506 can shorten the necessary duration of pretransplant intrathymic conditioning. Ito A, et al. **Transplantation** 1997 Sep 15;64(5):752–7

VETERINARY

Reversal of feline leukemia virus infection by adoptive transfer of activated T lymphocytes, interferon alpha, and zidovudine. Zeidner NS, et al. **Semin Vet Med Surg (Small Anim)** 1995 Nov;10(4):256–66

ADP see **ADENOSINE DIPHOSPHATE**

ADP,ATP CARRIER see **ADENINE NUCLEOTIDE TRANSLOCASE**

ADP,ATP TRANSLOCATOR PROTEIN see **ADENINE NUCLEOTIDE TRANSLOCASE**

ADP GLUCOSE see **ADENOSINE DIPHOSPHATE GLUCOSE**

ADP GLUCOSE STARCH GLUCOSYLTRANSFERASE see **STARCH (BACTERIAL GLYCOGEN) SYNTHASE**

ADP RECEPTORS see **RECEPTORS, PURINERGIC P2**

ADP RIBOSE see **ADENOSINE DIPHOSPHATE RIBOSE**

ADP–RIBOSYLTRANSFERASE (POLYMERIZING) see **NAD+ ADP–RIBOSYLTRANSFERASE**

ADPASE see **APYRASE**

ADPG see **ADENOSINE DIPHOSPHATE GLUCOSE**

ADRENAL CORTEX

Aberrant adrenal cortical tissue adjacent to immature testis. Basar M, et al. **Arch Ital Urol Androl** 1997 Jun;69(3):141–2
Papers presented at the 7th Conference on the Adrenal Cortex. Crieff, Scotland, June 27–30, 1996. **Endocr Res** 1996 Nov;22(4):vii–xxv, 333–879
From the Centers for Disease Control and Prevention. Infection with Mycobacterium abscessus associated with intramuscular injection of adrenal cortex extract––Colorado and Wyoming, 1995–1996. **JAMA** 1996 Oct 9;276(14):1130
Adrenocortical heterotopia in the placenta. Qureshi F, et al. **Pediatr Pathol Lab Med** 1995 Jan–Feb;15(1):51–6

BLOOD SUPPLY

Postnatal development of the blood vasculature in the rat adrenal gland: a scanning electron microscope study of microcorrosion casts. Tokunaga H. **Arch Histol Cytol** 1996 Oct;59(4):305–15
Vascularization of the adrenal cortex: its possible involvement in the regulation of steroid hormone release. Bassett JR, et al. **Microsc Res Tech** 1997 Mar 15; 36(6):546–57 (109 ref.)
The fine structure of fenestrated adrenocortical capillaries revealed by in–lens field–emission scanning electron microscopy and scanning transmission electron microscopy. Apkarian RP. **Scanning** 1997 Aug;19(5):361–7
[The morphological bases of transcapillary metabolism in the adrenal cortical layer] Vankov V, et al. **Arkh Anat Gistol Embriol** 1981 Dec;81(12):81–8 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Immunohistochemical analysis of AT1 receptor versus P450c17 and 3 beta HSD expression in ovine adrenals. Bird IM, et al. **Endocr Res** 1996 Nov;22(4):349–53
Induction of interferon–gamma inducing factor in the adrenal cortex. Conti B, et al. **J Biol Chem** 1997 Jan 24; 272(4):2035–7
Growth hormone receptor messenger ribonucleic acid in normal and pathologic human adrenocortical tissues––an

analysis by quantitative polymerase chain reaction technique. Lin CJ, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2671–6

Mass spectrometric identification and quantification of hemorphins extracted from human adrenal and pheochromocytoma tissue. Cerpa-Poljak A, et al. **J Neurochem** 1997 Apr;68(4):1712–9

Adrenaline cells of the rat adrenal cortex and medulla contain renin and prorenin. Berka JL, et al. **Mol Cell Endocrinol** 1996 May 31;119(2):175–84

CYTOLOGY

Regulation of growth by ACTH in the Y-1 line of mouse adrenocortical cells. Armelin HA, et al. **Endocr Res** 1996 Nov;22(4):373–83

Cellular communication in the neuro-adrenocortical axis: role of vasoactive intestinal polypeptide (VIP). Bornstein SR, et al. **Endocr Res** 1996 Nov;22(4):819–29

Phenotypic changes and proliferation of adrenocortical cells during adrenal regeneration in rats. Engeland WC, et al. **Endocr Res** 1996 Nov;22(4):395–400

Phenotype of proliferating cells stimulated during compensatory adrenal growth. Holzwarth MA, et al. **Endocr Res** 1996 Nov;22(4):401–6

ACTH-induced selective death of rat adrenocortical cells in primary culture. Kahri AI, et al. **Endocr Res** 1996 Nov; 22(4):409–10

Effects of long term stimulation of ACTH and angiotensin II–secretions on the rat adrenal cortex. Mitani F, et al. **Endocr Res** 1996 Nov;22(4):421–31

Chromaffin cell depolarization results in modulation of corticosteroidogenesis in co–culture. Shepherd SP, et al. **Endocr Res** 1996 Nov;22(4):839–43

Evaluation of apoptotic parameters in normal and neoplastic human adrenal. Wolkersdörfer GW, et al. **Endocr Res** 1996 Nov;22(4):411–9

Sympathetic effects on the steroidogenesis and proliferation of adrenocortical cells in vitro. Wu CH, et al. **Endocr Res** 1996 Nov;22(4):855–9

Relevance of major histocompatibility complex class II expression as a hallmark for the cellular differentiation in the human adrenal cortex. Marx C, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3136–40

Morphological and functional studies of the paracrine interaction between cortex and medulla in the adrenal gland. Bornstein SR, et al. **Microsc Res Tech** 1997 Mar 15;36(6):520–33 (123 ref.)

Characterization of adrenocortical cell lines produced by genetically targeted tumorigenesis in transgenic mice. Compagnone NA, et al. **Steroids** 1997 Feb;62(2):238–43

DRUG EFFECTS

Behavioral and plasma cortisol responses to sodium lactate infusion in posttraumatic stress disorder. Jensen CF, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:444–8

Influence of exogenous and endogenous acth on adrenal cortex activity in calves during the early postnatal period. Friedrich M. **Br Vet J** 1995 May;152(3):315–20

Effects of centrally administered prostaglandin EP receptor agonists on febrile and adrenocortical responses in the prepubertal pig. Parrott RF, et al. **Brain Res Bull** 1996; 41(2):97–103

The non–neurogenic catecholamine response of the fetal adrenal to hypoxia is dependent on activation of voltage sensitive Ca2+ channels. Adams MB, et al. **Brain Res Dev Brain Res** 1996 Jul 20;94(2):182–9

Thromboxane A2 acts at a site perfused by the carotid vasculature to mediate cardiovascular and adrenocortical responses. Cudd TA, et al. **Can J Physiol Pharmacol** 1997 Apr;75(4):271–8

Inhibition of cellular growth and steroid 11 beta-hydroxylation in ras-transformed adrenocortical cells by the fungal toxins beticolins. Ding G, et al. **Cell Biol Int** 1996 Aug;20(8):523–30

Mifepristone modulation of ACTH and CRH regulation of bovine adrenocorticosteroidogenesis in vitro. Carroll JA, et al. **Domest Anim Endocrinol** 1996 Jul;13(4):339–49

ACTH-induced selective death of rat adrenocortical cells in primary culture. Kahri AI, et al. **Endocr Res** 1996 Nov; 22(4):409–10

Actions of adrenomedullin on the rat adrenal cortex. Kapas S, et al. **Endocr Res** 1996 Nov;22(4):861–5

The role of ascorbic acid and xylitol in etomidate-induced adrenocortical suppression in humans. Schraag S, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):346–51

The stimulatory effect of endothelin-1 on regenerating adrenal cortex is reversed by nifedipine. Zieleniewski W. **Eur J Endocrinol** 1997 Jan;136(1):121–2

Effects of pneumadin (PNM) on the adrenal glands. 6. Further studies on the inhibitory effect of PNM on dexamethasone-induced atrophy of the rat adrenal cortex. Markowska A, et al. **Histol Histopathol** 1997 Jul; 12(3):677–82

Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome. Buyalos RP, et al. **Hum Reprod** 1997 Jun;12(6):1138–41

Interaction of histamine with adrenocorticotropic hormone: a local modulatory role for adrenocortical androgen synthesis? Orsó E, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S57–8

Histamine-induced cortisol secretion from bovine adrenocortical cells co-cultured with bovine adrenomedullary cells. Yoshida T, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S61–2

Adrenocortical responses to an adrenocorticotropic hormone in bulls and steers. Verkerk GA, et al. **J Anim Sci** 1997 Sep;75(9):2520–5

Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK–677, on 24–hour GH profiles, insulin–like growth factor I, and adrenocortical function in normal young men [see comments] Copinschi G, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2776–82. Comment in: J Clin Endocrinol Metab 1996 Aug;81(8):2773–5.

Insulin–like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells. l'Allemand D, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):3892–7

Glucocorticoids enhance corticotropin receptor mRNA levels in ovine adrenocortical cells. Picard–Hagen N, et al. **J Mol Endocrinol** 1997 Aug;19(1):29–36

Calmidazolium and other imidazole compounds affect steroidogenesis in Y1 cells: lack of involvement of the peripheral–type benzodiazepine receptor. Zisterer DM, et al. **J Steroid Biochem Mol Biol** 1997 Feb;60(3–4):189–95

Influence of acute and chronic morphine or stadol on the secretion of adrenocorticotrophin and its hypothalamic releasing hormone in the rat. el Daly ES. **Life Sci** 1996; 59(22):1881–90

Biochemical alterations in guinea pig adrenal cortex following administration of PD 132301-2, an inhibitor of acyl–CoA:cholesterol acyltransferase. Wolfgang GH, et al. **Life Sci** 1995 Feb 17;56(13):1089–93

Differential neuroendocrine and behavioral responses to cocaine in Lewis and Fischer rats. Simar MR, et al. **Neuroendocrinology** 1996 Jan;63(1):93–100

Dose–dependent suppression of adrenocortical activity with metyrapone: effects on emotion and memory. Roozendaal B, et al. **Psychoneuroendocrinology** 1996 Nov;21(8):681–93

Dexamethasone suppression of the effects of cocaine on adrenocortical secretion in Lewis and Fischer rats. Simar MR, et al. **Psychoneuroendocrinology** 1997 Apr; 22(3):141–53

Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells. Kristiansen SB, et al. **Steroids** 1997 Feb;62(2):258–65

Regulation of primary response and specific genes in adrenal cells by peptide hormones and growth factors. Penhoat A, et al. **Steroids** 1996 Apr;61(4):176–83

Difference between normal and WHHL rabbits in susceptibility to the adrenal toxicity of an acyl–CoA:cholesterol acyltransferase inhibitor, FR145237. Matsuo M, et al. **Toxicol Appl Pharmacol** 1996 Oct; 140(2):387–92

[Effects of prolactin on DNA biosynthesis, cholesterol content, and steroidogenesis in the adrenal cortex of guinea pigs treated with dexamethasone] Sautin IuIu, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):18–21 **(Rus)**

[The effect of the combined use of mineral water and rutin on the function of the adrenal cortex and pancreatic islet apparatus (an experimental study)] Polushina ND, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Jan–Feb;(1):14–6 (Eng. Abstr.) **(Rus)**

[The effect of ovariectomy and estradiol on DNA, RNA and protein metabolism in the adrenal cortex of rats] Kovzun OI. **Fiziol Zh** 1996;42(1–2):53–8 (Eng. Abstr.) **(Ukr)**

EMBRYOLOGY

Decline in adrenocorticotropin receptor messenger ribonucleic acid expression in the baboon fetal adrenocortical zone in the second half of pregnancy. Aberdeen GW, et al. **Endocrinology** 1997 Apr; 138(4):1634–41

Identical origin of adrenal cortex and gonad revealed by expression profiles of Ad4BP/SF-1. Hatano O, et al. **Genes Cells** 1996 Jul;1(7):663–71

The ontogenesis of the steroidogenic tissues. Morohashi K. **Genes Cells** 1997 Feb;2(2):95–106 (106 ref.)

Insulin–like growth factors augment steroid production and expression of steroidogenic enzymes in human fetal adrenal cortical cells: implications for adrenal androgen regulation. Mesiano S, et al. **J Clin Endocrinol Metab** 1997 May; 82(5):1390–6

Role of growth factors in the developmental regulation of the human fetal adrenal cortex. Mesiano S, et al. **Steroids** 1997 Jan;62(1):62–72 (97 ref.)

ENZYMOLOGY

Sex steroids modulate NADPH–diaphorase expression in the postnatal adrenal neurons of the rat. Cracco C, et al. **Brain Res Bull** 1997;43(5):495–9

Adrenocortical–specific transgene expression directed by steroid hydroxylase gene promoters. Morley SD, et al. **Endocr Res** 1996 Nov;22(4):631–9

Phosphoserine/threonine phosphatases and their role in the control of adrenocortical steroidogenesis. Sayed SB, et al. **Endocr Res** 1996 Nov;22(4):541–3

Mechanisms of ACTH(cAMP)–dependent transcription of adrenal steroid hydroxylases. Waterman MR, et al. **Endocr Res** 1996 Nov;22(4):615–20 (13 ref.)

Effects of gestation on enzymes controlling aldosterone synthesis in the rat adrenal. Brochu M, et al. **Endocrinology** 1997 Jun;138(6):2354–8

Differential gene expression of cytochrome P450 11beta-hydroxylase in rat adrenal cortex after in vivo activation. Engeland WC, et al. **Endocrinology** 1997 Jun; 138(6):2338–46

Differential effects of adrenocorticotropin in vivo on cytochromes P4502D16 and P450c17 in the guinea pig adrenal cortex. Jiang Q, et al. **Endocrinology** 1996 Nov; 137(11):4811–6

Isolation and molecular cloning of wortmannin–sensitive bovine type III phosphatidylinositol 4–kinases. Balla T, et al. **J Biol Chem** 1997 Jul 18;272(29):18358–66

Localization of integral membrane peptidylglycine alpha–amidating monooxygenase in neuroendocrine cells. Milgram SL, et al. **J Cell Sci** 1997 Mar;110 (Pt 6):695–706

Regulation of 3 beta–hydroxysteroid dehydrogenase expression in human adrenocortical H295R cells. Bird IM, et al. **J Endocrinol** 1996 Sep;150 Suppl:S165–73

Role of calmodulin–dependent protein kinase II in the acute stimulation of aldosterone production. Pezzi V, et al. **J Steroid Biochem Mol Biol** 1996 Jul;58(4):417–24

The regulation of 3 beta–hydroxysteroid dehydrogenase expression. Mason JI, et al. **Steroids** 1997 Jan;62(1):164–8 (41 ref.)

GROWTH & DEVELOPMENT

Activity of the adrenal fetal zone in preterm infants continues to term. Midgley PC, et al. **Endocr Res** 1996 Nov; 22(4):729–33

Retinoic acid and alcohol/retinol dehydrogenase in the mouse adrenal gland: a potential endocrine source of retinoic acid during development. Haselbeck RJ, et al. **Endocrinology** 1997 Jul;138(7):3035–41

Effects of pneumadin (PNM) on the adrenal glands. 5. Potent stimulating action of PNM on adrenocortical growth of dexamethasone–administered rats. Markowska A, et al. **Histol Histopathol** 1996 Jul;11(3):583–5

IMMUNOLOGY

Adrenal autoantibodies and organ–specific autoimmunity in patients with Addison's disease. Söderbergh A, et al. **Clin Endocrinol (Oxf)** 1996 Oct;45(4):453–60

I. Adrenal cortex and steroid 21–hydroxylase autoantibodies in adult patients with organ–specific autoimmune diseases: markers of low progression to clinical Addison's disease. Betterle C, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):932–8

II. Adrenal cortex and steroid 21–hydroxylase autoantibodies in children with organ–specific autoimmune diseases: markers of high progression to clinical Addison's disease. Betterle C, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):939–42

Relevance of major histocompatibility complex class II expression as a hallmark for the cellular differentiation in the human adrenal cortex. Marx C, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3136–40

The autoimmune basis of adrenocortical destruction in Addison's disease. Winqvist O, et al. **Mol Med Today** 1996 Jul;2(7):282–9 (41 ref.)

INNERVATION

Immunocytochemical correlates of an extrapituitary adrenocortical regulation in man. Heym C. **Histol Histopathol** 1997 Apr;12(2):567–81 (179 ref.)

Innervation of the adrenal cortex, its physiological relevance, with primary focus on the noradrenergic transmission. Tóth IE, et al. **Microsc Res Tech** 1997 Mar 15;36(6):534–45 (93 ref.)

Ultrastructural localization of nerve terminals containing nitric oxide synthase in rat adrenal gland. Tanaka K, et al. **Neurosci Lett** 1996 Feb 9;204(3):153–6

METABOLISM

Structure–activity relationship of the agonist–antagonist transition on the type 1 angiotensin II receptor; the search for inverse agonists. Pérodin J, et al. **Adv Exp Med Biol** 1996;396:131–43

Presence of renin within intramitochondrial dense bodies of the rat adrenal cortex. Peters J, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E439–50

Properties of AT1a and AT1b angiotensin receptors expressed in adrenocortical Y–1 cells. Tian Y, et al. **Am J Physiol** 1996 May;270(5 Pt 1):E831–9

Geranylgeranyl as well as farnesyl moiety is transferred to Ras p21 overproduced in adrenocortical cells transformed by c–Ha–rasEJ oncogene. Osman H, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):789–92

Selective expression of HSP70–1 gene in the adrenal cortex but not in the medulla of thermally stressed rats. Shimizu K, et al. **Biochem Biophys Res Commun** 1997 Apr 17; 233(2):550–4

The role of cytochrome P450 17 alpha–hydroxylase and 3 beta–hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the delta 5 and delta 4 pathways of steroidogenesis in mammals. Conley AJ, et al. **Biol Reprod** 1997 Apr;56(4):789–99 (147 ref.)

Adrenal proteins bound by a reactive intermediate of

mitotane. Cai W, et al. **Cancer Chemother Pharmacol** 1997; 39(6):537–40

Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress. Meaney MJ, et al. **Dev Neurosci** 1996; 18(1–2):49–72 (138 ref.)

Regulation of adrenal steroidogenesis during chronic stress. Aguilera G, et al. **Endocr Res** 1996 Nov;22(4):433–43

Ascorbate and alpha–tocopherol depletion inhibit aldosterone stimulation by sodium deficiency in the guinea pig. Bähr V, et al. **Endocr Res** 1996 Nov;22(4):595–600

Production of ouabain by rat adrenocortical cells. Beck M, et al. **Endocr Res** 1996 Nov;22(4):845–9

Multiple signal transduction systems regulate angiotensin II type 1 (AT1) receptor mRNA expression in bovine adrenocortical cells. Dell GC, et al. **Endocr Res** 1996 Nov; 22(4):363–8

Characterization of the human ACTH receptor gene and in vitro expression. Naville D, et al. **Endocr Res** 1996 Nov; 22(4):337–48

Acute stress effects on the adrenal cortex in the rat. A biochemical and immunohistochemical study. Pignatelli D, et al. **Endocr Res** 1996 Nov;22(4):445–51

Sympathetic effects on the steroidogenesis and proliferation of adrenocortical cells in vitro. Wu CH, et al. **Endocr Res** 1996 Nov;22(4):855–9

Localization of dopamine D1A receptor protein and messenger ribonucleic acid in rat adrenal cortex. Aherne AM, et al. **Endocrinology** 1997 Mar;138(3):1282–8

Expression of laminin and its possible role in adrenal cortex homeostasis. Pellerin S, et al. **Endocrinology** 1997 Mar; 138(3):1321–7

Insulin–like growth factor receptors in normal and tumorous adult human adrenocortical glands. Weber MM, et al. **Eur J Endocrinol** 1997 Mar;136(3):296–303

Identical origin of adrenal cortex and gonad revealed by expression profiles of Ad4BP/SF–1. Hatano O, et al. **Genes Cells** 1996 Jul;1(7):663–71

Sympathoadrenal activity during exercise in partial diabetic and diabetic rats. Houwing H, et al. **Horm Metab Res** 1997 Jan;29(1):25–9

Opposite feedback control of renin and aldosterone biosynthesis in the adrenal cortex by angiotensin II AT1–subtype receptors. Gigante B, et al. **Hypertension** 1997 Sep;30(3 Pt 2):563–8

Prohormone convertase PC5 is a candidate processing enzyme for prorenin in the human adrenal cortex. Mercure C, et al. **Hypertension** 1996 Nov;28(5):840–6

Interaction of histamine with adrenocorticotropic hormone: a local modulatory role for adrenocortical androgen synthesis? Orsó E, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S57–8

Adrenocortical responses to an adrenocorticotropic hormone in bulls and steers. Verkerk GA, et al. **J Anim Sci** 1997 Sep;75(9):2520–5

Differential control of 17 alpha–hydroxylase and 3 beta–hydroxysteroid dehydrogenase expression in human adrenocortical H295R cells. Bird IM, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2171–8

The zona reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulfate in the adult human adrenal cortex resulting from its low expression of 3 beta–hydroxysteroid dehydrogenase. Endoh A, et al. **J Clin Endocrinol Metab** 1996 Oct; 81(10):3558–65

Insulin–like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells. l'Allemand D, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):3892–7

17 Alpha–hydroxylase deficiency. Biglieri EG. **J Endocrinol Invest** 1995 Jul–Aug;18(7):540–4 (13 ref.)

Initial processing of human proenkephalin in bovine chromaffin cells. Liu F, et al. **J Neurochem** 1996 Oct; 67(4):1457–62

17alpha–Hydroxylase gene expression in the bovine ovary: mechanisms regulating expression differ from those in adrenal cells. Demeter Arlotto M, et al. **J Steroid Biochem Mol Biol** 1996 Sep;59(1):21–9

Effects of joining peptide (1–18) and histamine on dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulphate (DHEAS) production of human adrenocortical cells in vitro. Orsó E, et al. **J Steroid Biochem Mol Biol** 1996 May;58(2):207–10

Viscosity of rat adrenocortical lipids in different functional states: morphological characteristics. Szabó D, et al. **J Steroid Biochem Mol Biol** 1996 Jun;58(3):329–35

The H295R human adrenocortical cell line contains functional atrial natriuretic peptide receptors that inhibit aldosterone biosynthesis. Bodart V, et al. **Mol Cell Endocrinol** 1996 Apr 19;118(1–2):137–44

Differential regulation of 11 beta–hydroxylase and aldosterone synthase in human adrenocortical H295R cells. Denner K, et al. **Mol Cell Endocrinol** 1996 Jul 23; 121(1):87–91

Bovine adrenocortical cells in culture synthesize an ouabain–like compound. Perrin A, et al. **Mol Cell Endocrinol** 1997 Jan 3;126(1):7–15

Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. Li B, et al. **Neurochem Int** 1997 Sep;31(3):393–403

Attenuated stress response of hippocampal acetylcholine release and adrenocortical secretion in aged rats. Mizuno T, et al. **Neurosci Lett** 1997 Jan 24;222(1):49–52

Regular immunohistochemical localization of endothelin–1 and endothelin–B receptor in normal, hyperplastic and neoplastic human adrenocortical cells. Hiraki H, et al. **Pathol Int** 1997 Feb–Mar;47(2–3):117–25

Marked increases in neuronal nitric oxide synthase (nNOS) mRNA and NADPH–diaphorase histostaining in adrenal cortex after immobilization stress in rats. Tsuchiya T, et al. **Psychoneuroendocrinology** 1996 Apr;21(3):287–93

The roles of calmodulin, actin, and vimentin in steroid synthesis by adrenal cells. Hall PF. **Steroids** 1997 Jan; 62(1):185–9 (34 ref.)

[Imaging of calcium signaling in brain glial cells and adrenocortical cells] Kawato S, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1227–32 (7 ref.) **(Jpn)**

[Autostimulation of prolactin receptors in the guinea pig adrenal cortex] Sautin IuIu, et al. **Biull Eksp Biol Med** 1997 May;123(5):548–9 **(Rus)**

PARASITOLOGY

Adrenal cortex alterations in mice infected with Plasmodium berghei. Pulido–Méndez M, et al. **J Submicrosc Cytol Pathol** 1997 Jan;29(1):99–104

PATHOLOGY

Correlation of mast cells with spindle cell hyperplasia in the adrenal cortex of IQI/Jic mice. Kim JS, et al. **Exp Anim** 1997 Apr;46(2):103–9

Adrenocorticotropic hormone–independent adrenocortical hyperplasia and ACTH–independent bilateral adrenocortical macronodular hyperplasia [editorial; comment] Aiba M. **Intern Med** 1997 Aug;36(8):533–4. Comment on: Intern Med 1997 Aug;36(8):536–42.

Adrenocorticotropin–independent macronodular adrenocortical hyperplasia associated with multiple colon adenomas/carcinomas which showed a point mutation in the APC gene [see comments] Yamakita N, et al. **Intern Med** 1997 Aug;36(8):536–42. Comment in: Intern Med 1997 Aug;36(8):533–4.

Correlation between impairment of glucocorticoid feedback and the size of the pituitary gland in dogs with pituitary–dependent hyperadrenocorticism. Kooistra HS, et al. **J Endocrinol** 1997 Mar;152(3):387–94

Relationship between adrenal cortex pathology in Cushing's syndrome and its response to the dexamethasone suppression test. Akçay G, et al. **J Int Med Res** 1996 May–Jun;24(3):278–83

Proliferative activity of adrenal glands with adrenocortical cytomegaly measured by MIB–1 labeling index. Fasano M, et al. **Pediatr Pathol Lab Med** 1996 Sep–Oct;16(5):765–76

[Primary pigmented nodular adrenocortical dysplasia. A rare cause of Cushing's syndrome] Anding K, et al. **Dtsch Med Wochenschr** 1996 Oct 25;121(43):1321–4 (Eng. Abstr.) **(Ger)**

[Effect of external electrostatic field on structure and function of adrenal cortex of rats] Artsruni GG, et al. **Aviakosm Ekolog Med** 1996;30(1):58–60 **(Rus)**

PHYSIOLOGY

Adrenal vasoactive intestinal peptide participates in neonatal corticosteroid production in the rat. Bodnar M, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1163–72

Pituitary adenylate cyclase–activating polypeptide regulates both adrenocortical and chromaffin cell activity in the frog adrenal gland. Yon L, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:697–701

Adrenocortical response to open–field test in rats with anterodorsal thalami nuclei lesion. Suárez M, et al. **Arch Physiol Biochem** 1996;104(1):81–6

Threat–induced behavioural inhibition in Japanese quail genetically selected for contrasting adrenocortical response to mechanical restraint. Jones RB, et al. **Br Poult Sci** 1996 May;37(2):465–70

Novel environment induced inhibition of corticosterone secretion: physiological evidence for a suprachiasmatic nucleus mediated neuronal hypothalamo–adrenal cortex pathway. Buijs RM, et al. **Brain Res** 1997 May 30; 758(1–2):229–36

Ventromedial hypothalamus suppresses splenic lymphocyte activity through sympathetic innervation. Okamoto S, et al. **Brain Res** 1996 Nov 11;739(1–2):308–13

Reciprocal influences among adrenocortical activation, psychosocial processes, and the behavioral adjustment of clinic–referred children. Granger DA, et al. **Child Dev** 1996 Dec;67(6):3250–62

Size at birth and adrenocortical function in childhood. Clark PM, et al. **Clin Endocrinol (Oxf)** 1996 Dec;45(6):721–6

Corpus luteum activity, fertility, and adrenal cortex response in lactating Carora cows during rainy and dry seasons in the tropics of Venezuela [published erratum appears in Domest Anim Endocrinol 1996 Nov;13(6):539] Leyva–Ocariz H, et al. **Domest Anim Endocrinol** 1996 Jul; 13(4):297–306

An investigation of hypo–adrenocorticism in Angora goats. Swart P, et al. **Endocr Res** 1996 Nov;22(4):563–5

Role of the cytoskeleton in adrenocortical cells. Feuilloley M, et al. **Endocr Rev** 1996 Jun;17(3):269–88 (304 ref.)

Developmental and functional biology of the primate fetal adrenal cortex. Mesiano S, et al. **Endocr Rev** 1997 Jun; 18(3):378–403 (252 ref.)

Adrenalitis and the adrenocortical response of resistant and susceptible mice to acute murine cytomegalovirus infection. Price P, et al. **Eur J Clin Invest** 1996 Sep;26(9):811–9

Sympathoadrenal system and immune system in the regulation of adrenocortical function. Ehrhart–Bornstein M, et al. **Eur J Endocrinol** 1996 Jul;135(1):19–26 (133 ref.)

Sympathoadrenal system and immune system in the regulation of adrenocortical function [letter] Jolobe OM. **Eur J Endocrinol** 1996 Dec;135(6):738

TGF–beta rescues target–deprived preganglionic sympathetic neurons in the spinal cord. Blottner D, et al. **Eur J Neurosci** 1996 Jan;8(1):202–10

The use of salivary cortisol measurements for the non–invasive assessment of adrenal cortical function in guinea pigs. Fenske M. **Exp Clin Endocrinol Diabetes** 1997; 105(3):163–8

The role of neuromedin B in the regulation of rat pituitary–adrenocortical function. Malendowicz LK, et al. **Histol Histopathol** 1996 Oct;11(4):895–7

The role of endothelins in the paracrine control of the secretion and growth of the adrenal cortex. Nussdorfer GG, et al. **Int Rev Cytol** 1997;171:267–308 (196 ref.)

Effects of a 7–day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK–677, on 24–hour GH profiles, insulin–like growth factor I, and adrenocortical function in normal young men [see comments] Copinschi G, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2776–82. Comment in: J Clin Endocrinol Metab 1996 Aug;81(8):2773–5.

Adrenocorticotropic hormone and cAMP inhibit noninactivating K+ current in adrenocortical cells by an A–kinase–independent mechanism requiring ATP hydrolysis. Enyeart JJ, et al. **J Gen Physiol** 1996 Oct; 108(4):251–64

Assessment of hypothalamic–pituitary–adrenocortical axis function in dexamethasone treated very low birth weight infants by a single dose metyrapone test and gas chromatographic mass spectrometric determination of urinary steroids. Wudy SA, et al. **J Pediatr Endocrinol Metab** 1995 Oct–Dec;8(4):281–6

Effect of indomethacin on the pituitary–adrenocortical response to adrenergic stimulation. Bugajski J, et al. **Life Sci** 1996;59(14):1157–64

Effect of 5–bromo–2'–deoxyuridine on the proliferative activity of thymus and regenerating adrenal cortex. Malendowicz LK, et al. **Life Sci** 1997;61(6):641–3

Peptide growth factors and the adrenal cortex. Ho MM, et al. **Microsc Res Tech** 1997 Mar 15;36(6):558–68 (183 ref.)

Characterization of the promoter of SF–1, an orphan nuclear receptor required for adrenal and gonadal development. Woodson KG, et al. **Mol Endocrinol** 1997 Feb;11(2):117–26

Combined dexamethasone/CRH test in rats: hypothalamo–pituitary–adrenocortical system alterations in aging. Hatzinger M, et al. **Neuroendocrinology** 1996 Nov; 64(5):349–56

Effects of bacterial endotoxin on the glucocorticoid feedback regulation of adrenocortical response to stress. Weidenfeld J, et al. **Neuroimmunomodulation** 1996 Nov–Dec;3(6):352–7

Adrenocortical activation by herpes virus: involvement of IL–1 beta and central noradrenergic system. Ben Hur T, et al. **Neuroreport** 1996 Mar 22;7(4):927–31

Involvement of amygdalar alpha adrenoceptors in hypothalamo–pituitary–adrenocortical responses. Feldman S, et al. **Neuroreport** 1996 Nov 25;7(18):3055–7

Serum cortisol, dehydroepiandrosterone sulfate, and steroid–binding globulins in preterm neonates: effect of gestational age and dexamethasone therapy. Kari MA, et al. **Pediatr Res** 1996 Aug;40(2):319–24

Paracrine control of adrenal cortical function by medullary chromaffin cells. Nussdorfer GG. **Pharmacol Rev** 1996 Dec; 48(4):495–530 (544 ref.)

Genetic study of behavioral and pituitary–adrenocortical reactivity in response to an environmental challenge in pigs. Désautés C, et al. **Physiol Behav** 1997 Aug;62(2):337–45

Behavioral and adrenocortical responses to open–field test in rats selected for reduced aggressiveness toward humans. Plyusnina I, et al. **Physiol Behav** 1997 Mar;61(3):381–5

Ease of capture in Japanese quail of two lines divergently selected for adrenocortical response to immobilization. Satterlee DG, et al. **Poult Sci** 1997 Mar;76(3):469–71

Adrenocortical function in the domestic cat during treatment with levonorgestrel. Baldwin CJ, et al. **Res Vet Sci** 1996 May;60(3):205–8

Adrenal involvement in polycystic ovary syndrome. Gonzalez F. **Semin Reprod Endocrinol** 1997 May; 15(2):137–57 (129 ref.)

Role of growth factors in the developmental regulation of the human fetal adrenal cortex. Mesiano S, et al. **Steroids** 1997 Jan;62(1):62–72 (97 ref.)

Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis. Herman JP, et al. **Trends Neurosci** 1997 Feb;20(2):78–84 (81 ref.)

[Genetic and ontogenetic variability in the noradrenergic regulation of adrenocortical function] Dygalo NN, et al. **Fiziol Zh Im I M Sechenova** 1996 Apr;82(4):15–20 (Eng. Abstr.) **(Rus)**

[Current problems of regulation of adrenocortical function] Mikosha AS. **Vestn Ross Akad Med Nauk** 1997;(8):6–10 (47 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Incidentally discovered adrenocortical adenomas are not fully nonfunctioning: immunohistochemical and dispersed adrenocortical cell study. Tobinaga J, et al. **Endocr J** 1996 Feb;43(1):79–86

Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome. Buyalos RP, et al. **Hum Reprod** 1997 Jun;12(6):1138–41

Hyperkalaemia in acute leukaemia: a sign of adrenocortical insufficiency. Demiroğlu H, et al. **J Intern Med** 1997 Aug; 242(2):111–5

Effect of prenatal alcohol and cigarette exposure on two- and six-month-old infants' adrenocortical reactivity to stress. Ramsay DS, et al. **J Pediatr Psychol** 1996 Dec; 21(6):833–40

Adrenal involvement in polycystic ovary syndrome. Gonzalez F. **Semin Reprod Endocrinol** 1997 May; 15(2):137–57 (129 ref.)

[A rare cause of adrenal cortex insufficiency] Kreysel C, et al. **Internist (Berl)** 1996 May;37(5):511–4 **(Ger)**

[The prognostic value of activation of the hypophyseal and adrenal cortical systems in severe heart failure] Gallina S, et al. **Cardiologia** 1997 Jan;42(1):77–82 (Eng. Abstr.) **(Ita)**

RADIATION EFFECTS

Endocrine functions in young men exposed for one night to a 50–Hz magnetic field. A circadian study of pituitary, thyroid and adrenocortical hormones. Selmaoui B, et al. **Life Sci** 1997;61(5):473–86

[The interaction of the thyroid-adrenal system with testicular function in mice subjected to gamma irradiation] Mamina VP. **Radiats Biol Radioecol** 1997 Jan–Feb;37(1):20–4 (Eng. Abstr.) **(Rus)**

SECRETION

Urinary kallikrein excretion in pregnant adrenalectomized rats. Croxatto HR, et al. **Arch Biol Med Exp (Santiago)** 1986;19(3–4):305–9

Brain–corticosteroid hormone dialogue: slow and persistent. de Kloet ER, et al. **Cell Mol Neurobiol** 1996 Jun; 16(3):345–56 (52 ref.)

Actions of adrenomedullin on the rat adrenal cortex. Kapas S, et al. **Endocr Res** 1996 Nov;22(4):861–5

Interleukin-3 and interleukin-6 stimulate cortisol secretion from adult human adrenocortical cells. Weber MM, et al. **Endocrinology** 1997 May;138(5):2207–10

Recent progress in understanding aldosterone secretion. Foster RH, et al. **Gen Pharmacol** 1997 May;28(5):647–51 (67 ref.)

Catecholamines stimulate steroid secretion of dispersed fowl adrenocortical cells, acting through the beta-receptor subtype. Mazzocchi G, et al. **Horm Metab Res** 1997 Apr; 29(4):190–2

Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Laredo J, et al. **Hypertension** 1997 Jan;29(1 Pt 2):401–7

Histamine-induced cortisol secretion from bovine adrenocortical cells co-cultured with bovine adrenomedullary cells. Yoshida T, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S61–2

[Effect of external electrostatic field on structure and function of adrenal cortex of rats] Artsruni GG, et al. **Aviakosm Ekolog Med** 1996;30(1):58–60 **(Rus)**

TRANSPLANTATION

Bilateral adrenalectomy with autotransplantation of adrenocortical tissue or unilateral adrenalectomy: treatment options for pheochromocytomas in multiple endocrine neoplasia type 2A. Okamoto T, et al. **Endocr J** 1996 Apr; 43(2):169–75

Adrenocortical tissue formed by transplantation of normal clones of bovine adrenocortical cells in scid mice replaces the essential functions of the animals' adrenal glands [see comments] Thomas M, et al. **Nat Med** 1997 Sep;3(9):978–83 . Comment in: Nat Med 1997 Sep;3(9):935. Comment in: Nat Med 1997 Sep;3(9):951–2.

ULTRASTRUCTURE

Role of the cytoskeleton in adrenocortical cells. Feuilloley M, et al. **Endocr Rev** 1996 Jun;17(3):269–88 (304 ref.)

Adrenal cortex alterations in mice infected with Plasmodium berghei. Pulido-Méndez M, et al. **J Submicrosc Cytol Pathol** 1997 Jan;29(1):99–104

Analytical color fluorescence electron microscopy of adrenal cortex. Nakano T, et al. **Microsc Res Tech** 1997 Mar 15; 36(6):454–62

ADRENAL CORTEX DISEASES

Papers presented at the 7th Conference on the Adrenal Cortex. Crieff, Scotland, June 27–30, 1996. **Endocr Res** 1996 Nov;22(4):vii–xxv, 333–879

CHEMICALLY INDUCED

Mineralocorticoid insufficiency due to suramin therapy. Kobayashi K, et al. **Cancer** 1996 Dec 1;78(11):2411–20

COMPLICATIONS

Hypertension with identifiable cause. Secondary hypertension. Liu L. **Chin Med J (Engl)** 1996 Dec; 109(12):909–18 (36 ref.)

[Primary pigmented nodular adrenocortical dysplasia. A rare cause of Cushing's syndrome] Anding K, et al. **Dtsch Med Wochenschr** 1996 Oct 25;121(43):1321–4 (Eng. Abstr.) **(Ger)**

[A rare cause of adrenal cortex insufficiency] Kreysel C, et al. **Internist (Berl)** 1996 May;37(5):511–4 **(Ger)**

DIAGNOSIS

Evaluation of adrenal function in long standing pulmonary tuberculosis: a study of 100 cases. Siddiqi S, et al. **JPMA J Pak Med Assoc** 1997 May;47(5):132–4

Secondary adrenocortical insufficiency: avoiding potentially fatal pitfalls in diagnosis and treatment [editorial] Hockings GI, et al. **Med J Aust** 1997 Apr 21;166(8):400–1 (16 ref.)

DRUG THERAPY

Pharmacology of the endocrine pancreas, adrenal cortex, and female reproductive organ. Huber MA, et al. **Dent Clin North Am** 1996 Jul;40(3):753–77 (118 ref.)

ETIOLOGY

Bilateral massive adrenal haemorrhage complicating anaphylactic shock: a case report [see comments] Lefevre N, et al. **Intensive Care Med** 1996 May;22(5):447–9. Comment in: Intensive Care Med 1997 Feb;23(2):235–6.

Secondary adrenocortical insufficiency: avoiding potentially fatal pitfalls in diagnosis and treatment [editorial] Hockings GI, et al. **Med J Aust** 1997 Apr 21;166(8):400–1 (16 ref.)

Nephrotic syndrome, hypertension, and adrenal failure in atypical Cockayne syndrome. Reiss U, et al. **Pediatr Nephrol** 1996 Oct;10(5):602–5

GENETICS

Linkage of congenital isolated adrenocorticotropic hormone deficiency to the corticotropin releasing hormone locus using simple sequence repeat polymorphisms. Kyllo JH, et al. **Am J Med Genet** 1996 Mar 29;62(3):262–7

Difference between normal and WHHL rabbits in susceptibility to the adrenal toxicity of an acyl–CoA:cholesterol acyltransferase inhibitor, FR145237. Matsuo M, et al. **Toxicol Appl Pharmacol** 1996 Oct; 140(2):387–92

METABOLISM

Growth hormone receptor messenger ribonucleic acid in normal and pathologic human adrenocortical tissues--an analysis by quantitative polymerase chain reaction technique. Lin CJ, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2671–6

PATHOLOGY

Primary pigmented nodular adrenocortical disease: reevaluation of a patient with carney complex 27 years after unilateral adrenalectomy. Sarlis NJ, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1274–8

SURGERY

Relapse of Cushing's syndrome following the treatment of primary pigmented nodular adrenocortical disease by unilateral adrenalectomy [letter] Walsh JP, et al. **Aust N Z J Med** 1996 Jun;26(3):426–7

THERAPY

Adrenocortical insufficiency in the child. Urban MD, et al. **Curr Ther Endocrinol Metab** 1997;6:147–52 (3 ref.)

VETERINARY

Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. Couëtil L, et al. **J Vet Intern Med** 1996 Jan–Feb;10(1):1–6

Management of canine pituitary-dependent hyperadrenocorticism with l-deprenyl (Anipryl). Bruyette DS, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):273–86 (34 ref.)

Diagnosis of canine hyperadrenocorticism. Guptill L, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):215–35 (74 ref.)

Primary and secondary canine hypoadrenocorticism. Kintzer PP, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):349–57 (21 ref.)

Complications and concurrent disease associated with canine hyperadrenocorticism. Nichols R. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):309–20 (50 ref.)

Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane. Peterson ME, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):255–72 (37 ref.)

ADRENAL CORTEX FUNCTION TESTS

Abnormal thyroid and adrenocortical function test results in intensive care patients. Koh LK, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):808–15

The short Synacthen and insulin stress tests in the assessment of the hypothalamic–pituitary–adrenal axis [see comments] Hurel SJ, et al. **Clin Endocrinol (Oxf)** 1996 Feb;44(2):141–6 . Comment in: Clin Endocrinol (Oxf) 1996 Feb;44(2):147–9. Comment in: Clin Endocrinol (Oxf) 1996 Aug;45(2):245. Comment in: Clin Endocrinol (Oxf) 1997 Jun;46(6):775–6.

Failure of the short ACTH test to unequivocally diagnose long-standing symptomatic secondary hypoadrenalism [see comments] Soule SG, et al. **Clin Endocrinol (Oxf)** 1996 Feb;44(2):137–40. Comment in: Clin Endocrinol (Oxf) 1996 Feb;44(2):147–9. Comment in: Clin Endocrinol (Oxf) 1996 Jul;44(1):122–3.

[Assay of salivary cortisol. An interesting method for exploring the adrenal cortex] Barrou Z, et al. **Presse Med** 1997 Mar 8;26(7):329–31 (Eng. Abstr.) **(Fre)**

METHODS

The short Synacthen test: with 1 microgram or 250 micrograms ACTH? [letter; comment] Gerritsen RT, et al. **Ann Clin Biochem** 1997 Jan;34 (Pt 1):115–6. Comment on: Ann Clin Biochem 1996 Mar;33 (Pt 2):112–8. Comment on: Ann Clin Biochem 1996 Mar;33 (Pt 2):175–6.

[Angiotensin II analogue infusion test] Katsuragi M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:321–4 (10 ref.) **(Jpn)**

[Saline infusion test] Niimura S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:337–40 (5 ref.) **(Jpn)**

[Furosemide: upright test] Niimura S, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:325–8 (2 ref.) **(Jpn)**

[CRH-test] Tanaka K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:341–4 (15 ref.) **(Jpn)**

[ACTH test] Tanaka K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:345–8 (8 ref.) **(Jpn)**

[Metyrapone test] Tanaka K, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:349–52 (20 ref.) **(Jpn)**

[Dexamethasone suppression test] Tanaka K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:353–6 (10 ref.) **(Jpn)**

[Captopril test] Tomimoto S, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:329–32 (9 ref.) **(Jpn)**

[Clinical studies with angiotensin II and angiotensin III] Yamamoto K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:333–6 (11 ref.) **(Jpn)**

ADRENAL CORTEX HORMONES

see related
ADRENAL GLAND HYPERFUNCTION
ADRENAL GLAND HYPOFUNCTION
RECEPTORS, GLUCOCORTICOID

Corticosteroids in tuberculosis. Cisneros JR, et al. **Ann Pharmacother** 1996 Nov;30(11):1298–303 (25 ref.)

Corticosteroid use and abuse by medical practitioners for arthritis and related disorders in Pakistan. Farooqi AZ, et al. **Br J Rheumatol** 1997 Jan;36(1):91–4

Nerve blocks with local anesthetics and corticosteroids in chronic pain: a clinical follow-up study. Johansson A, et al. **J Pain Symptom Manage** 1996 Mar;11(3):181–7

The role of corticosteroids in respiratory diseases of children. de Benedictis FM, et al. **Pediatr Pulmonol** 1996 Jul; 22(1):44–57 (234 ref.)

Treatment of distal ulcerative colitis with nonsystemic corticosteroid enemas. Danielsson A. **Scand J Gastroenterol** 1996 Oct;31(10):945–53 (58 ref.)

ADMINISTRATION & DOSAGE

Crohn disease: CT findings after treatment. Gossios KJ, et al. **Abdom Imaging** 1997 Mar–Apr;22(2):160–3

Growth hormone and corticosteroid treatment of children after kidney transplantation [comment] Mehls O. **Acta Paediatr Suppl** 1996 Oct;417:80. Comment on: Acta Paediatr Suppl 1996 Oct;417 :69–71. Comment on: Acta Paediatr Suppl 1996 Oct;417 :72–5. Comment on: Acta Paediatr Suppl 1996 Oct;417 :76–9.

A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Pedersen S, et al. **Allergy** 1997; 52(39 Suppl):1–34 (173 ref.)

The management of rheumatoid nodules [letter; comment] Swezey RL. **Am J Orthop** 1997 Feb;26(2):73. Comment on: Am J Orthop 1996 Oct;25(10):706–8.

Effect of inhaled corticosteroids on the risk of cataract formation in patients with steroid-dependent asthma. Barenholtz H. **Ann Pharmacother** 1996 Nov;30(11):1324–7

Use of an objective measure of articular stiffness to record changes in finger joints after intra-articular injection of corticosteroid. Helliwell PS. **Ann Rheum Dis** 1997 Jan; 56(1):71–3

Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus [see comments] Pryor BD, et al. **Arthritis Rheum** 1996 Sep;39(9):1475–82. Comment in: Arthritis Rheum 1997 Jun;40(6):1186.

Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis. Sakiniene E, et al. **Arthritis Rheum** 1996 Sep;39(9):1596–605

Ratio of inhaled corticosteroid to bronchodilator as indicator of quality of asthma prescribing. Prescribing data need to be available by age [letter; comment] Baumer JH. **BMJ**

1997 Mar 1;314(7081):681; discussion 682. Comment on: BMJ 1996 Nov 2;313(7065):1124–6.
Ratio of inhaled corticosteroid to bronchodilator as indicator of quality of asthma prescribing. More adequate information systems are needed [letter; comment] Currie CJ, et al. **BMJ** 1997 Mar 1;314(7081):681; discussion 682 . Comment on: BMJ 1996 Nov 2;313(7065):1124–6.
Ratio of inhaled corticosteroid to bronchodilator as indicator of quality of asthma prescribing. Outcome measures need to reflect morbidity and quality of care [letter; comment] Griffiths C, et al. **BMJ** 1997 Mar 1;314(7081):681–2. Comment on: BMJ 1996 Nov 2;313(7065):1124–6.
Danish data confirm low prevalence of HRT among women prescribed oral corticosteroids [letter; comment] Olesen C, et al. **BMJ** 1996 Nov 16;313(7067):1264. Comment on: BMJ 1996 Aug 10;313(7053):344–6.
Ratio of inhaled corticosteroid to bronchodilator as indicator of quality of asthma prescribing. Authors discuss a result that was not shown [letter; comment] Roberts SJ. **BMJ** 1997 Mar 1;314(7081):680–1; discussion 682. Comment on: BMJ 1996 Nov 2;313(7065):1124–6.
Is the ratio of inhaled corticosteroid to bronchodilator a good indicator of the quality of asthma prescribing? Cross sectional study linking prescribing data to data on admissions [see comments] Shelley M, et al. **BMJ** 1996 Nov 2;313(7065):1124–6. Comment in: BMJ 1997 Mar 1;314(7081):680–1; discussion 682. Comment in: BMJ 1997 Mar 1;314(7081):681; discussion 682. Comment in: BMJ 1997 Mar 1;314(7081):681–2.
Septic arthritis by Aspergillus fumigatus: a complication of corticosteroid infiltration [letter] García-Porrúa C, et al. **Br J Rheumatol** 1997 May;36(5):610–1
Benefits of low-dose corticosteroids in rheumatoid arthritis. Cohen MD, et al. **Bull Rheum Dis** 1997 Jun;46(4):4–7 (18 ref.)
Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: downregulation by inhaled corticosteroids. Möller GM, et al. **Clin Exp Allergy** 1996 May;26(5):517–24
The rationale for use of topical corticosteroids in allergic rhinitis. Mygind N, et al. **Clin Exp Allergy** 1996 May;26 Suppl 3:2–10 (42 ref.)
Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. Friday GA. **Clin Pediatr (Phila)** 1997 Sep;36(9):551
Squamometry in rating the efficacy of topical corticosteroids in atopic dermatitis. Letawe C, et al. **Eur J Clin Pharmacol** 1996;51(3–4):253–7
In vivo noninvasive study of the mechanical properties of the human skin after single application of topical corticosteroids. Dobrev H. **Folia Med (Plovdiv)** 1996; 38(2):11–7
Nonsurgical treatment of monarticular nontraumatic synovitis of the second metatarsophalangeal joint. Mizel MS, et al. **Foot Ankle Int** 1997 Jul;18(7):424–6
A stepped-care approach to asthma management. Stoloff SW. **Hosp Pract (Off Ed)** 1996 Nov 15;31(11):33–4, 39
Evans' syndrome associated with Graves' disease. Yashiro M, et al. **Intern Med** 1996 Dec;35(12):987–90 (13 ref.)
Steroid inhalers and glaucoma [news] **J Am Dent Assoc** 1997 May;128(5):554, 558
Short-term effects of the clindamycin-steroid regimen in the treatment of ocular toxoplasmosis. Djurkovic-Djakovic O, et al. **J Chemother** 1995 Nov;7 Suppl 4:199–201
Two cases of specific adverse reactions to systemic corticosteroids. López-Serrano MC, et al. **J Investig Allergol Clin Immunol** 1996 Sep–Oct;6(5):324–7
Primary care paradigm for management of sarcoidosis, Part 1. Young RC Jr, et al. **J Natl Med Assoc** 1997 Mar; 89(3):181–90 (53 ref.)
Corticosteroid injection in rheumatoid arthritis does not increase rate of total joint arthroplasty. Roberts WN, et al. **J Rheumatol** 1996 Jun;23(6):1001–4
Chronic perioperative steroids and colonic anastomotic healing in rats. Del Rio JV, et al. **J Surg Res** 1996 Dec; 66(2):138–42
Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis [letter; comment] De Keyser J, et al. **Lancet** 1997 Jun 7;349(9066):1696; discussion 1697. Comment on: Lancet 1997 Mar 29;349(9056):902–6.
Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden 1978 to 1991. Gerdtham UG, et al. **Med Care** 1996 Dec;34(12):1188–98
Shoulder injections for subacromial bursitis [letter] Bert J. **Minn Med** 1996 Sep;79(9):6
Corticosteroid injections for sciatica [letter] Manning DC, et al. **N Engl J Med** 1997 Oct 23;337(17):1242; discussion 1242–3
Corticosteroid injections for sciatica [letter] Orlando MP, et al. **N Engl J Med** 1997 Oct 23;337(17):1242; discussion 1242–3
A GP guide to the new asthma guidelines. Holmes B. **Practitioner** 1997 Apr;241(1573):218–9
Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. Rubsamen PE, et al. **Retina** 1997;17(1):44–50
Local corticosteroid injection in sport: review of literature and guidelines for treatment. Fredberg U. **Scand J Med Sci Sports** 1997 Jun;7(3):131–9 (128 ref.)
Insufficient control of asthma: increase the dose of inhaled steroids or add long-acting beta 2-agonists? Aubert JD, et al. **Schweiz Med Wochenschr** 1997 Feb 1;127(5):176–81 (28 ref.)
Diagnosis and treatment of heel pain in chronic inflammatory arthritis using ultrasound. Cunnane G, et al. **Semin Arthritis Rheum** 1996 Jun;25(6):383–9
Injection techniques and use in the treatment of sports injuries. Scott WA. **Sports Med** 1996 Dec;22(6):406–16 (64 ref.)
Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis. Conway SP, et al. **Thorax** 1997 Apr;52 Suppl 2:S64–8 (65 ref.)
[Treatment of hay fever] Mygind N, et al. **Ugeskr Laeger** 1997 Sep 1;159(36):5358–61 **(Dan)**
[Cytokine research opens new therapeutic possibilities. Symposium: "Atopic dermatitis: New pathogenetic and therapeutic views", Vienna, 18 May 1993] **Fortschr Med Suppl** 1993;149:1–8 **(Ger)**
[Use of corticosteroids and immunoglobulins in acute and chronic immune thrombocytopenia in childhood. A clinically oriented treatment concept] Höcker-Schulz S, et al. **Klin Padiatr** 1997 Jan-Feb;209(1):30–5 (Eng. Abstr.) **(Ger)**
[Injection treatment of non-radicular lumbalgia] Wittenberg RH, et al. **Orthopade** 1997 Jun;26(6):544–52 (62 ref.) (Eng. Abstr.) **(Ger)**
[Rational intra-articular corticosteroid injection] Weber M. **Schweiz Med Wochenschr** 1997 May 31;127(22):945–53 (64 ref.) (Eng. Abstr.) **(Ger)**
[Prenatal lung maturation with corticosteroids--an overview] Hildebrand K, et al. **Z Geburtshilfe Neonatol** 1996 Nov-Dec;200(6):207–12 (54 ref.) (Eng. Abstr.) **(Ger)**
[Topical treatment of atrophic-erosive oral lichen planus with clobetasol in bioadhesive gel as well as chlorhexidine and miconazole in oral gel] Carbone M, et al. **Minerva Stomatol** 1997 Jul-Aug;46(7-8):423–8 (Eng. Abstr.) **(Ita)**
[Mixed connective tissue disease: progress in diagnosis and treatment. III. Treatment. 2. Timing for the start of the therapy with adrenocorticosteroids and immunosuppressive agents and methods of their administration] Tanaka H. **Nippon Naika Gakkai Zasshi** 1996 Aug 10;85(8):1233–6 (5 ref.) **(Jpn)**
[Update on beta-adrenergic agonists and corticosteroid aerosols (editorial)] Spector S. **Rev Alerg Mex** 1993 Nov-Dec;40(6):i–iv **(Spa)**
[Systemic steroids are not suitable in toxic pneumonia (letter)] Nettelblad H, et al. **Lakartidningen** 1997 Mar 5;94(10):811–2 **(Swe)**

ADVERSE EFFECTS

A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Bernstein CN, et al. **Aliment Pharmacol Ther** 1996 Oct;10(5):777–86
A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Pedersen S, et al. **Allergy** 1997; 52(39 Suppl):1–34 (173 ref.)
Fatal strongyloidiasis in a patient with ulcerative colitis after corticosteroid therapy. Leung VK, et al. **Am J Gastroenterol** 1997 Aug;92(8):1383–4
Corticosteroid-induced osteoporosis. Adachi JD. **Am J Med Sci** 1997 Jan;313(1):41–9 (78 ref.)
Adverse reactions to nonindicated medications [letter; comment] Sternberg TL, et al. **Anesthesiology** 1997 May; 86(5):1212–3. Comment on: Anesthesiology 1996 Nov;85(5):1194–6.
Fusarium keratitis following the use of topical antibiotic-corticosteroid therapy in traumatised eyes. Wong TY, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):862–5 (19 ref.)
Prevention of corticosteroid-induced osteoporosis [letter; comment] Birdsall TC. **Ann Intern Med** 1997 Jul 1;127(1):90 . Comment on: Ann Intern Med 1996 Dec 15;125(12):961–8.
Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects [see comments] Lacomis D, et al. **Ann Neurol** 1996 Oct; 40(4):645–54. Comment in: Ann Neurol 1997 Jul;42(1):131–2.
Risks of infection or reactivation of tuberculosis associated with chronic corticosteroid therapy. Cline JC, et al. **Ann Pharmacother** 1997 Jun;31(6):775–6 (10 ref.)
Corticosteroids and ulcers: is there an association? Pecora PG, et al. **Ann Pharmacother** 1996 Jul-Aug;30(7-8):870–2
Corticosteroids and risk of complicated varicella [letter; comment] Nishioka SA. **Arch Pediatr Adolesc Med** 1996 Dec;150(12):1314. Comment on: Arch Pediatr Adolesc Med 1996 Apr;150(4):409–14.
Does growth hormone treatment prevent corticosteroid-induced osteoporosis? Tanaka H, et al. **Bone** 1996 Jun;18(6):493–4 (28 ref.)
Complications of corticosteroids [letter; comment] Milton J. **Br J Hosp Med** 1996 Feb 7–20;55(3):147. Comment on: Br J Hosp Med 1995 May 17–Jun 6;53(10):495–9.
Bone disease in asthma. Walsh LJ, et al. **Br J Hosp Med** 1997 Apr 16–May 6;57(8):390–3
Gastroprotection in neurosurgery: the practice in Great Britain. Carroll TA, et al. **Br J Neurosurg** 1997 Feb; 11(1):39–42
Osteoporosis: a survey of consultant ophthalmologists. Hodgkins B, et al. **Br J Ophthalmol** 1997 Apr;81(4):260
Cytomegalovirus retinitis associated with long term oral corticosteroid use [letter] Kulshrestha MK, et al. **Br J Ophthalmol** 1996 Sep;80(9):849–50
Dangers of low-dose corticosteroid therapy in rheumatoid arthritis. Ramos-Remus C, et al. **Bull Rheum Dis** 1997 Jun; 46(4):1–4 (19 ref.)
A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Healey JH, et al. **Calcif Tissue Int** 1996 Feb;58(2):73–80
Adverse effects of corticosteroid therapy for COPD. A critical review. McEvoy CE, et al. **Chest** 1997 Mar; 111(3):732–43 (95 ref.)
Contact allergens--what's new? Corticosteroids. Isaksson M, et al. **Clin Dermatol** 1997 Jul-Aug;15(4):527–31 (59 ref.)
Steroid therapy and H2-receptor antagonists: pharmacoeconomic implications. Marcus P, et al. **Clin Pharmacol Ther** 1997 May;61(5):503–8 (18 ref.)
Contact allergy to corticosteroids. Diagnosis and management. Morren MA, et al. **Clin Rev Allergy Immunol** 1996 Summer;14(2):199–208 (32 ref.)
Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone. Henderson NK, et al. **Curr Opin Rheumatol** 1996 Jul;8(4):365–9 (43 ref.)
Corticosteroid therapy, nonendocrine disease, and corticosteroid withdrawal. Magiakou MA, et al. **Curr Ther Endocrinol Metab** 1997;6:138–42 (8 ref.)
Corticosteroid-induced bone loss. Prevention and management. Picado C, et al. **Drug Saf** 1996 Nov; 15(5):347–59 (125 ref.)
A risk-benefit assessment of methotrexate in corticosteroid-dependent asthma. Shulimzon TR, et al. **Drug Saf** 1996 Oct;15(4):283–90 (51 ref.)
Corticosteroid-induced osteoporosis. **Drug Ther Bull** 1996 Nov;34(11):84–6 (30 ref.)
Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Pedersen-Bjergaard U, et al. **Eur J Clin Pharmacol** 1997; 52(3):183–9
Long-, intermediate- and short-term growth studies in asthmatic children treated with inhaled glucocorticosteroids. Wolthers OD. **Eur Respir J** 1996 Apr; 9(4):821–7 (78 ref.)
A case of iatrogenic growth retardation induced by a corticosteroid containing anti-allergic drug [letter] Singh SK. **Horm Metab Res** 1996 Mar;28(3):156–7
Clinical immunotoxicity of antirheumatic drugs. Bálint G, et al. **Inflamm Res** 1996 Dec;45 Suppl 2:S91–5 (70 ref.)
Decreased nasal goblet cells in patients reporting topical corticosteroid use. Lin RY, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):265–6
Steroid inhalers and glaucoma [news] **J Am Dent Assoc** 1997 May;128(5):554, 558
Abnormalities in the bone marrow of the iliac crest in patients who have osteonecrosis secondary to corticosteroid therapy or alcohol abuse. Hernigou P, et al. **J Bone Joint Surg Am** 1997 Jul;79(7):1047–53
Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. Chappard D, et al. **J Bone Miner Res** 1996 May;11(5):676–85
Drugs and ulcers: clues about mucosal protection from epidemiologic studies. Griffin MR, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S113–9
Cutaneous lymphangiectases associated with severe photoaging and topical corticosteroid application. Pena JM, et al. **J Cutan Pathol** 1996 Apr;23(2):175–81
Flexor pollicis longus tendon rupture after corticosteroid injection [letter; comment] Bickel KD. **J Hand Surg [Am]** 1996 Jan;21(1):152–3. Comment on: J Hand Surg [Am] 1995 Mar;20(2):276–7.
Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. Wolfhagen FH, et al. **J Hepatol** 1997 Feb;26(2):325–30
Two cases of specific adverse reactions to systemic corticosteroids. López-Serrano MC, et al. **J Investig Allergol Clin Immunol** 1996 Sep–Oct;6(5):324–7
Abuse of therapy with corticosteroids in the asthmatic patient and the deficient control of suprarenal function. Indication of therapy with ACTH. Oehling A, et al. **J Investig Allergol Clin Immunol** 1996 Nov–Dec; 6(6):349–55
Potential adverse endocrine effects of inhaled corticosteroids. Batch JA. **J Paediatr Child Health** 1996 Aug;32(4):278–80 (32 ref.)
Risk/benefit ratio of inhaled steroids [letter; comment] Skoner DP, et al. **J Pediatr** 1996 Dec;129(6):942–3. Comment on: J Pediatr 1995 Dec;127(6):1000–2.
Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup [see comments] Adachi JD, et al. **J Rheumatol** 1996 Jun;23(6):995–1000. Comment in: J Rheumatol 1997 Feb;24(2):407.
Prevention of corticosteroid induced osteoporosis [letter; comment] Mier RJ. **J Rheumatol** 1997 Feb;24(2):407. Comment on: J Rheumatol 1996 Jun;23(6):995–1000.
Corticosteroid injection in rheumatoid arthritis does not increase rate of total joint arthroplasty. Roberts WN, et al. **J Rheumatol** 1996 Jun;23(6):1001–4
Calcium and vitamin D therapy in corticosteroid bone loss: what is the evidence [editorial] Sambrook PN. **J Rheumatol** 1996 Jun;23(6):963–4
Giant calcification in soft tissue after shoulder corticosteroid injection. Toussirot E, et al. **J Rheumatol** 1996 Jan;

23(1):181-2
Corticosteroid induced osteoporosis. Sambrook PN. **J Rheumatol Suppl** 1996 Aug;45:19-22 (27 ref.)
Rheumatologists issue guidelines for preventing and treating corticosteroid-induced osteoporosis [news] Skolnick AA. **JAMA** 1997 Jan 8;277(2):98, 100
Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation? Rascu A, et al. **Lupus** 1996 Aug;5(4):323-7
Respiratory muscle pharmacology. Decramer M. **Monaldi Arch Chest Dis** 1996 Dec;51(6):499-503 (47 ref.)
Cataracts and inhaled corticosteroids [editorial; comment] Chylack LT Jr. **N Engl J Med** 1997 Jul 3;337(1):46-8. Comment on: N Engl J Med 1997 Jul 3;337(1):8-14.
Use of inhaled corticosteroids and the risk of cataracts [see comments] Cumming RG, et al. **N Engl J Med** 1997 Jul 3;337(1):8-14. Comment in: N Engl J Med 1997 Jul 3;337(1):46-8.
Osteonecrosis of the femoral head in patients with inflammatory arthritis or asthma receiving corticosteroid therapy. Colwell CW Jr, et al. **Orthopedics** 1996 Nov; 19(11):941-6
Prevention of corticosteroid-induced osteoporosis [see comments] Ascott-Evans BH. **S Afr Med J** 1996 Aug;86(8 Suppl):1025-6. Comment in: S Afr Med J 1997 Mar;87(3 Suppl):388.
Prevention of corticosteroid-induced osteoporosis [letter; comment] Cassim B. **S Afr Med J** 1997 Mar;87(3 Suppl):388 . Comment on: S Afr Med J 1996 Aug;86(8 Suppl):1025-6.
Prevention of corticosteroid-induced osteoporosis [letter; comment] Schnitzler C. **S Afr Med J** 1997 Mar;87(3 Suppl):388. Comment on: S Afr Med J 1996 Aug;86(8 Suppl):1025-6.
Intermittent cyclic therapy with etidronate prevents corticosteroid-induced bone loss: two years of follow-up. Sebaldt RJ, et al. **Scand J Rheumatol Suppl** 1996;103:91-3
Antiallergic and antitussive medications: extent of use and relationship to asthma exacerbations. Van Ganse E, et al. **Therapie** 1996 Jul-Aug;51(4):373-7
Multiple pigmented cutaneous papules associated with a novel canine papillomavirus in an immunosuppressed dog. Le Net JL, et al. **Vet Pathol** 1997 Jan;34(1):8-14
[Contact allergy to local steroids. Contact allergy to corticosteroids among consecutively tested patients with eczema] Vestergaard L, et al. **Ugeskr Laeger** 1997 Sep 15; 159(38):5662-6 (Eng. Abstr.) **(Dan)**
[Dysphonia and inhalation of corticoids: a prospective study] Hone SW, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996; 117(4):331-3 (Eng. Abstr.) **(Fre)**
[Therapeutic alternatives to systemic corticotherapy in severe and chronic dermatologic disorders in the elderly patient] de la Brassinne M. **Rev Med Liege** 1997 Apr;52(4):296-8 (0 ref.) **(Fre)**
[Ophthalmological follow-up of patients receiving corticotherapy] Haus C, et al. **Rev Med Liege** 1997 Mar; 52(3):155-8 **(Fre)**
[Steroid-induced scabies norvegica] Karrer S, et al. **Hautarzt** 1997 May;48(5):343-6 (Eng. Abstr.) **(Ger)**
[Neurologic side-effects of pharmacologic corticoid therapy] Rösener M, et al. **Nervenarzt** 1996 Dec;67(12):983-6 (36 ref.) (Eng. Abstr.) **(Ger)**
[Central serous chorioretinopathy in systemic therapy with corticosteroids] Spraul CW, et al. **Ophthalmologe** 1997 Jun; 94(6):392-6 (Eng. Abstr.) **(Ger)**
[Central serous chorioretinopathy induced by corticosteroids] Song E, et al. **Nippon Ganka Gakkai Zasshi** 1997 Mar; 101(3):257-64 (43 ref.) (Eng. Abstr.) **(Jpn)**
[Pneumocystis pneumonia in patients with steroid-dependent asthma] Dziedziczko A, et al. **Pneumonol Alergol Pol** 1997; 65(5-6):399-405 (24 ref.) **(Pol)**
[Acute muscular weakness during childhood in cases of severe asthma due to the use of corticoids and neuromuscular blockers] Campistol Plana J, et al. **An Esp Pediatr** 1996 Aug;45(2):196-8 (5 ref.) **(Spa)**
[Epidural abscess: a complication of the use of corticoids in the treatment for back pain] de Andrés J, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):164-5 **(Spa)**
[Steroids and NSAID: combination increases risk for stomach ulcer] Aly A. **Lakartidningen** 1997 Feb 12;94(7):545-6 **(Swe)**

ANALYSIS

Immunosensors: The next generation [news; comment] Turner AP. **Nat Biotechnol** 1997 May;15(5):421. Comment on: Nat Biotechnol 1997 May;15(5):466-71.
Detection of corticosteroids in the presence of organic acids in a liquid chromatography eluent using the negative-ion mode of thermospray mass spectrometry. Kim Y, et al. **Rapid Commun Mass Spectrom** 1997;11(8):863-8

ANTAGONISTS & INHIBITORS

Methotrexate for lung transplant recipients with steroid-resistant acute rejection. Cahill BC, et al. **J Heart Lung Transplant** 1996 Nov;15(11):1130-7

BIOSYNTHESIS

Adrenal vasoactive intestinal peptide participates in neonatal corticosteroid production in the rat. Bodnar M, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1163-72
Corticosteroids in essential hypertension: multiple candidate loci and phenotypic variation. Connell JM, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):369-74 (46 ref.)
Mifepristone modulation of ACTH and CRH regulation of bovine adrenocorticosteroidogenesis in vitro. Carroll JA, et al. **Domest Anim Endocrinol** 1996 Jul;13(4):339-49
Regulation of adrenal steroidogenesis during chronic stress. Aguilera G, et al. **Endocr Res** 1996 Nov;22(4):433-43
Corticosteroid synthesis in the central nervous system. Gomez-Sanchez CE, et al. **Endocr Res** 1996 Nov; 22(4):463-70
Phosphoserine/threonine phosphatases and their role in the control of adrenocortical steroidogenesis. Sayed SB, et al. **Endocr Res** 1996 Nov;22(4):541-3
Chromaffin cell depolarization results in modulation of corticosteroidogenesis in co-culture. Shepherd SP, et al. **Endocr Res** 1996 Nov;22(4):839-43
Functional maturation of the primate fetal adrenal in vivo. II. Ontogeny of corticosteroid synthesis is dependent upon specific zonal expression of 3 beta-hydroxysteroid dehydrogenase/isomerase. Coulter CL, et al. **Endocrinology** 1996 Nov;137(11):4953-9
Different dysregulations in adrenal steroid biosynthesis as a prevalent cause of hyperandrogenism in women from southern Italy. Valentino R, et al. **Fertil Steril** 1997 Aug; 68(2):236-41
The thyroid hormone, 3,5,3'-triiodothyronine, is a negative modulator of domestic fowl (Gallus gallus domesticus) adrenal steroidogenic function. Carsia RV, et al. **Gen Comp Endocrinol** 1997 Aug;107(2):251-61
Burn-associated bone disease in sheep: roles of immobilization and endogenous corticosteroids. Klein GL, et al. **J Burn Care Rehabil** 1996 Nov-Dec;17(6 Pt 1):518-21
Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. Glasow A, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):3103-11
Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved [editorial] Rosenfield RL. **J Clin Endocrinol Metab** 1996 Mar;81(3):878-80 (29 ref.)
Role of the Golgi complex in adrenocortical steroidogenesis. Cheng B, et al. **Microsc Res Tech** 1997 Mar 15;36(6):503-9 (47 ref.)
Roles of microfilaments and intermediate filaments in adrenal steroidogenesis. Hall PF, et al. **Microsc Res Tech** 1997 Mar 15;36(6):463-79 (108 ref.)
Light and electron microscopic immunohistochemistry of the localization of adrenal steroidogenic enzymes. Ishimura K, et al. **Microsc Res Tech** 1997 Mar 15;36(6):445-53 (76 ref.)
Peroxisomes in adrenal steroidogenesis. Magalhães MM, et al. **Microsc Res Tech** 1997 Mar 15;36(6):493-502 (98 ref.)
Lipoproteins, lipid droplets, lysosomes, and adrenocortical steroid hormone synthesis: morphological studies. Tóth IE, et al. **Microsc Res Tech** 1997 Mar 15;36(6):480-92 (107 ref.)
beta-Lipotropin-stimulated adrenal steroid production. O'Connell Y, et al. **Steroids** 1996 May;61(5):332-6
[Cushing's syndrome due to small cell lung cancer with ectopic production of adrenocorticotropic and parathyroid hormone] Sato S, et al. **Nippon Ronen Igakkai Zasshi** 1997 Mar;34(3):215-20 (Eng. Abstr.) **(Jpn)**
[Effects of prolactin on DNA biosynthesis, cholesterol content, and steroidogenesis in the adrenal cortex of guinea pigs treated with dexamethasone] Sautin IuIu, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):18-21 **(Rus)**

BLOOD

Relationship of blood corticosterone, immunoglobulin and haematological values in young crocodiles (Crocodylus porosus) to water temperature, clutch of origin and body weight. Turton JA, et al. **Aust Vet J** 1997 Feb;75(2):114-9
Serum prolactin, growth hormone, total corticoids, thyroid hormones and thyrotropine during serial therapeutic sleep deprivation. Kuhs H, et al. **Biol Psychiatry** 1996 May 15; 39(10):857-64
Hypothalamic-pituitary-adrenocortical axis responses to physostigmine: effects of Alzheimer's disease and gender. Peskind ER, et al. **Biol Psychiatry** 1996 Jul 1;40(1):61-8
Porcine fetal and maternal adrenocorticotropic hormone and corticosteroid concentrations during gestation and their relation to fetal size. Klemcke HG, et al. **Biol Reprod** 1997 Jul;57(1):99-106
Testicular and adrenocortical function in men with prostatic cancer and in healthy age-matched controls. Carlström K, et al. **Br J Urol** 1997 Mar;79(3):427-31
Effects of incremental cortisol and adrenalectomy on plasma corticosteroid binding capacity in fetal sheep. Jeffray TM, et al. **Can J Physiol Pharmacol** 1995 Nov;73(11):1568-73
Effect of acid or aluminum on growth and adrenal function in young chickens. Capdevielle MC, et al. **Gen Comp Endocrinol** 1996 Jul;103(1):54-9
Quantification of corticosteroids in human plasma by liquid chromatography-thermospray mass spectrometry using stable isotope dilution. Shibasaki H, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):7-14
Can adrenarche influence the degree of osteopenia in thalassemic children? Filosa A, et al. **J Pediatr Endocrinol Metab** 1996 May-Jun;9(3):401-6
Corticosteroid and immune responses to cardiac surgery. Tinnikov AA, et al. **Steroids** 1996 Jul;61(7):411-5
[Effect of lithium oxybutyrate on the circadian rhythm of brain level of serotonin and plasma level of corticosteroids in mice treated with reserpine] Zamoshchina TA, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):101-5 **(Rus)**

CHEMISTRY

Electrospray mass spectrometric characterization of a corticosteroid dimer. Rendell NB, et al. **Rapid Commun Mass Spectrom** 1997;11(2):219-23

DEFICIENCY

Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. Wilder RL. **J Rheumatol Suppl** 1996 Mar;44:10-2

IMMUNOLOGY

Artificial antibodies to corticosteroids prepared by molecular imprinting. Ramström O, et al. **Chem Biol** 1996 Jun; 3(6):471-7
Granulocyte-macrophage colony-stimulating factor overrides the immunosuppressive function of corticosteroids on rat pulmonary dendritic cells. Lim TK, et al. **Stem Cells** 1996 May;14(3):292-9 (62 ref.)
[The immunological activity of corticosteroids] Scudeletti M, et al. **Recenti Prog Med** 1996 Oct;87(10):508-15 (45 ref.) (Eng. Abstr.) **(Ita)**

ISOLATION & PURIFICATION

Optimization of selectivity and resolution in micellar electrokinetic capillary chromatography with a mixed micellar system of sodium dodecyl sulfate and sodium cholate. Wiedmer SK, et al. **Electrophoresis** 1996 Dec; 17(12):1931-7

METABOLISM

Activation of the type 2 adrenal steroid receptor can rescue granule cells from death during development. Gould E, et al. **Brain Res Dev Brain Res** 1997 Jul 18;101(1-2):265-8
Collagen type I of rat cortical and trabecular bone differs in the extent of posttranslational modifications. Suarez KN, et al. **Calcif Tissue Int** 1996 Jan;58(1):65-9
Hydroxysteroid dehydrogenases as hormonal regulators. James V. **Clin Endocrinol (Oxf)** 1996 Nov;45(5):613-4
Sodium status, corticosteroid metabolism and blood pressure in normal human subjects and in a patient with abnormal salt appetite. Ingram MC, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):375-8
Activity of the adrenal fetal zone in preterm infants continues to term. Midgley PC, et al. **Endocr Res** 1996 Nov; 22(4):729-33
Does corticosteroid metabolism in target organs affect the cardiovascular system? Hierholzer K, et al. **J Auton Nerv Syst** 1996 Mar 7;57(3):188-92
Negative feedback neuroendocrine control of inflammatory response in the rat is dependent on the sympathetic postganglionic neuron. Green PG, et al. **J Neurosci** 1997 May 1;17(9):3234-8
Differential regulation of adrenocorticoid receptors in the hippocampus and spinal cord of adrenalectomized rats. Marlier LN, et al. **J Neurosci Res** 1996 Mar 1;43(5):526-34
Vascularization of the adrenal cortex: its possible involvement in the regulation of steroid hormone release. Bassett JR, et al. **Microsc Res Tech** 1997 Mar 15; 36(6):546-57 (109 ref.)
[Postnatal development of the kidney concentrating ability, the renin-angiotensin system and the adrenal cortex hormones in the calf] Abouzite M, et al. **Reprod Nutr Dev** 1997 May-Jun;37(3):285-92 (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

On sample sizes for bioequivalence studies with inhaled corticosteroids [letter] Wijnand HP, et al. **Eur J Clin Pharmacol** 1997;52(4):325-7, 329-30

PHARMACOLOGY

Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. Folli F, et al. **Acta Diabetol** 1996 Sep;33(3):185-92 (82 ref.)
Effects of corticosteroid therapy in non-allergic rhinosinusitis. Mygind N. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):164-6 (25 ref.)
The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Meltzer EO. **Allergy** 1997;52(36 Suppl):33-40 (65 ref.)
Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Nauck M, et al. **Am J Respir Cell Mol Biol** 1997 Apr;16(4):398-406
Effect of craniectomy/durotomy alone and in combination with hyperventilation, diuretics, and corticosteroids on intracranial pressure in clinically normal dogs. Bagley RS, et al. **Am J Vet Res** 1996 Jan;57(1):116-9
Insulin-like growth factor 1 and corticosteroid modulation of chondrocyte metabolic and mitogenic activities in interleukin 1-conditioned equine cartilage. Frisbie DD, et al. **Am J Vet Res** 1997 May;58(5):524-30
The effects of different corticosteroids on the healing colon anastomosis and cecum in a rat model. Eubanks TR, et al. **Am Surg** 1997 Mar;63(3):266-9

ADRENAL CORTEX HORMONES

Malignant and corticosteroid-dependent idiopathic anaphylaxis: successful responses to ketotifen. Patterson R, et al. **Ann Allergy Asthma Immunol** 1997 Aug;79(2):138–44

Corticosteroid resistance and disease. DeRijk R, et al. **Ann Med** 1997 Feb;29(1):79–82 (27 ref.)

Interference of corticosteroids with prostaglandin E2 synthesis at the level of cyclooxygenase-2 mRNA expression in kidney cells. Schaefers HJ, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1415–21

Skeletal response to corticosteroid deficiency and excess in growing male rats. Li M, et al. **Bone** 1996 Aug;19(2):81–8

Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. Martin JC, et al. **Br J Rheumatol** 1997 Jan;36(1):43–9

▲ new mechanism of methylprednisolone and other corticosteroids action demonstrated in vitro: inhibition of a proteinase (calpain) prevents myelin and cytoskeletal protein degradation. Banik NL, et al. **Brain Res** 1997 Feb 14;748(1–2):205–10

The acute effects of corticosteroids on cognition: integration of animal and human model studies. Lupien SJ, et al. **Brain Res Brain Res Rev** 1997 Jun;24(1):1–27 (209 ref.)

Corticosteroid actions on the expression of kainate receptor subunit mRNAs in rat hippocampus. Joëls M, et al. **Brain Res Mol Brain Res** 1996 Apr;37(1–2):15–20

Topical tretinoin enhances corticosteroid-induced inhibition of tumorigenesis in hairless mice previously exposed to solar simulating radiation. Kligman LH, et al. **Cancer Lett** 1996 Oct 22;107(2):217–22

Potentiation of angiotensin II action by corticosteroids in vascular tissue. Ullian ME, et al. **Cardiovasc Res** 1996 Aug; 32(2):266–73

Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: downregulation by inhaled corticosteroids. Möller GM, et al. **Clin Exp Allergy** 1996 May;26(5):517–24

Stimulation of colonic mucin synthesis by corticosteroids and nicotine. Finnie IA, et al. **Clin Sci (Colch)** 1996 Sep; 91(3):359–64

Corticosteroids alter hematopoiesis in vitro by enhancing human monocyte secretion of granulocyte colony-stimulating factor. Rinehart J, et al. **Exp Hematol** 1997 May;25(5):405–12

Glucocorticoid- and mineralocorticoid receptors in microglial cells: the two receptors mediate differential effects of corticosteroids. Tanaka J, et al. **Glia** 1997 May; 20(1):23–37

Tissue-specific regulation of sialyltransferase activities in the rat by corticosteroids in vivo. Coughlan CM, et al. **Glycobiology** 1996 Jan;6(1):15–22

Corticosteroid induction of renal and intestinal K(+)-dependent p-nitrophenylphosphatase in young and adult rats. Zemanová Z, et al. **Histochem J** 1996 Sep; 28(9):625–34

Effect of cortisol and ACTH on corticosteroid-suppressed peripheral blood natural killer cells from healthy volunteers and patients with Crohn's disease. van Ierssel GJ, et al. **Immunopharmacology** 1996 Sep;34(2–3):97–104

Contrasting effects of IL-4, IL-10 and corticosteroids on RANTES production by human monocytes. Marfaing-Koka A, et al. **Int Immunol** 1996 Oct; 8(10):1587–94

Induction of interleukin 6 by ionizing radiation in a human epithelial cell line: control by corticosteroids. Beetz A, et al. **Int J Radiat Biol** 1997 Jul;72(1):33–43

Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses. Braun CM, et al. **J Allergy Clin Immunol** 1997 Sep;100(3):400–7

Stem cell factor in nasal polyposis and allergic rhinitis: increased expression by structural cells is suppressed by in vivo topical corticosteroids. Kim YK, et al. **J Allergy Clin Immunol** 1997 Sep;100(3):389–99

New insights into the pathogenesis of severe corticosteroid-dependent asthma. Vrugt B, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 2):S22–6; discussion S33–40 (29 ref.)

Effect of interval from fetal corticosteriod treatment to delivery on postnatal lung function of preterm lambs. Ikegami M, et al. **J Appl Physiol** 1996 Feb;80(2):591–7

Postnatal lung responses and surfactant function after fetal or maternal corticosteroid treatment. Rebello CM, et al. **J Appl Physiol** 1996 May;80(5):1674–80

Postnatal lung function and protein permeability after fetal or maternal corticosteroids in preterm lambs. Rebello CM, et al. **J Appl Physiol** 1997 Jul;83(1):213–8

Effects of adrenal steroids on the concentration of Na(+)-K+ pumps in rat skeletal muscle. Dørup I, et al. **J Endocrinol** 1997 Jan;152(1):49–57

Human airway smooth muscle cells express and release RANTES in response to T helper 1 cytokines: regulation by T helper 2 cytokines and corticosteroids. John M, et al. **J Immunol** 1997 Feb 15;158(4):1841–7

Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect. Pitzalis C, et al. **J Immunol** 1997 May 15;158(10):5007–16

Methotrexate in the treatment of corticodependent asthmatic children. Solé D, et al. **J Investig Allergol Clin Immunol** 1996 Mar–Apr;6(2):126–30

Long-term corticosteroid treatment but not chronic stress affects 11beta-hydroxysteroid dehydrogenase type I activity in rat brain and peripheral tissues. Jellinck PH, et al. **J Steroid Biochem Mol Biol** 1997 Mar;60(5–6):319–23

Effects of corticosteroids on parameters related to Na+ transport by amphibian renal distal cells (A6) in culture. Lyoussi B, et al. **J Steroid Biochem Mol Biol** 1996 Nov; 59(3–4):323–31

Effects of antiglaucoma drugs and corticosteroids on the cellular glucose uptake in cultured porcine corneal endothelial cells. Wu KY, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Aug; 13(8):480–6

Corticosteroid effects on sodium and calcium currents in acutely dissociated rat CA1 hippocampal neurons. Werkman TR, et al. **Neuroscience** 1997 Jun;78(3):663–72

Epidural lipomatosis not induced by corticosteroid therapy. Three cases including one in a patient with primary Cushing's disease (review of the literature). Benamou PH, et al. **Rev Rhum Engl Ed** 1996 Mar;63(3):207–12 (18 ref.)

Differential effect of adrenocorticosteroids on 11 beta-hydroxysteroid dehydrogenase bioactivity at the anterior pituitary and hypothalamus in rats. Idrus RB, et al. **Steroids** 1996 Aug;61(8):448–52

Selective inhibition of sheep kidney 11 beta-hydroxysteroid dehydrogenase isoform 2 activity by 5 alpha-reduced (but not 5 beta) derivatives of adrenocorticosteroids. Latif SA, et al. **Steroids** 1997 Feb;62(2):230–7

Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Lipworth BJ, et al. **Thorax** 1997 May;52(5):476–82 (49 ref.)

Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action. Trapp T, et al. **Trends Pharmacol Sci** 1996 Apr;17(4):145–9 (49 ref.)

[Influence of corticosteroid on phosphatidylinositol turnover in aminonucleoside-induced nephrotic rat kidney] Watanabe K, et al. **Nippon Jinzo Gakkai Shi** 1996 Sep; 38(9):393–8 (Eng. Abstr.) **(Jpn)**

[The effect of corticosteroids on the premedullary argirophilic cell of the thymus] Iurina NA, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):461–4 **(Rus)**

PHYSIOLOGY

Hormonal modulation of inner ear fluids. Ferrary E, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):244–7

Allergen-irritant interaction and the role of corticosteroids. Davies RJ, et al. **Allergy** 1997;52(38 Suppl):59–65 (30 ref.)

The brain is an important target of adrenal steroid actions. A comparison of synthetic and natural steroids. McEwen BS. **Ann N Y Acad Sci** 1997 Aug 14;823:201–13 (84 ref.)

The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. McEwen BS, et al. **Brain Res Brain Res Rev** 1997 Feb;23(1–2):79–133 (485 ref.)

Calbindin-D28k is regulated by adrenal steroids in hypothalamic tissue during prenatal development. Lephart ED, et al. **Brain Res Dev Brain Res** 1997 May 20; 100(1):117–20

Corticosteroids in essential hypertension: multiple candidate loci and phenotypic variation. Connell JM, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):369–74 (46 ref.)

Altered calcium homeostasis in the rat cochlear duct and endogenous corticosteroid insufficiency. Ma YL, et al. **Eur Arch Otorhinolaryngol** 1997;254(4):165–8

Feelings of exhaustion, emotional distress, and pituitary and adrenocortical hormones in borderline hypertension. Räikkönen K, et al. **J Hypertens** 1996 Jun;14(6):713–8

Neuroendocrine regulation of cytokine production during experimental influenza viral infection: effects of restraint stress-induced elevation in endogenous corticosterone. Dobbs CM, et al. **J Immunol** 1996 Sep 1;157(5):1870–7

Morphological and functional studies of the paracrine interaction between cortex and medulla in the adrenal gland. Bornstein SR, et al. **Microsc Res Tech** 1997 Mar 15;36(6):520–33 (123 ref.)

Corticosteroid regulation of renal Na,K-ATPase. Verrey F, et al. **Miner Electrolyte Metab** 1996;22(5–6):279–92 (99 ref.)

Involvement of corticosteroid-like neurosteroids in pentobarbital-induced sleep. Burade VS, et al. **Neuroreport** 1996 Dec 20;8(1):139–41

Stress-induced analgesia. The role of hormones produced by the hypophyseal-adrenocortical system. Filaretov AA, et al. **Neurosci Behav Physiol** 1996 Nov–Dec;26(6):572–8

Angiotensinogen and natriuretic peptide mRNAs in rat brain: localization and differential regulation by adrenal steroids in hypothalamus. Ryan MC, et al. **Peptides** 1997; 18(4):495–504

Paracrine control of adrenal cortical function by medullary chromaffin cells. Nussdorfer GG. **Pharmacol Rev** 1996 Dec; 48(4):495–530 (544 ref.)

The neurobiology of memory for emotional events: adrenergic activation and the amygdala. Cahill L, et al. **Proc West Pharmacol Soc** 1996;39:81–4 (24 ref.)

Increase of 5-HT7 (serotonin-7) and 5-HT1A (serotonin-1A) receptor mRNA expression in rat hippocampus after adrenalectomy. Le Corre S, et al. **Psychopharmacology (Berl)** 1997 Apr;130(4):368–74

Adrenal androgens, insulin resistance, and cardiovascular disease. Casson PR, et al. **Semin Reprod Endocrinol** 1996 Feb;14(1):29–34 (54 ref.)

SECRETION

Adrenal androgen-secreting carcinoma in a fertile woman. Falsetti L, et al. **Acta Eur Fertil** 1995 May–Jun;26(3):117–21

Cellular mechanism of substance P in the regulation of corticosteroid secretion by newt adrenal gland. Gobbetti A, et al. **Biochem Biophys Res Commun** 1997 Apr 17; 233(2):395–400

Effect of endothelin-1 on corticosteroid secretion by the frog adrenal gland is mediated by an endothelinA receptor. Cartier F, et al. **Endocrinology** 1997 Oct;138(10):4358–63

Intra-adrenal 11 beta-hydroxysteroid dehydrogenase plays a role in the regulation of corticosteroid secretion: an in vitro study in the rat. Musajo F, et al. **Life Sci** 1996; 59(17):1401–6

Altered activity of the sympathetic nervous system and changes in the balance of hypophyseal, pituitary and adrenal hormones in patients with cluster headache. Strittmatter M, et al. **Neuroreport** 1996 May 17;7(7):1229–34

[Hyperadrenocorticism in ferrets] Lumeij JT. **Tijdschr Diergeneeskd** 1997 Mar 1;122(5):146–7 **(Dut)**

[The adaptation-protective effect of corticosteroids on the rat gastric mucosa and its mechanism] Filaretov AA, et al. **Fiziol Zh Im I M Sechenova** 1996 Mar;82(3):141–50 (Eng. Abstr.) **(Rus)**

[The participation of the neostriatum in realizing the action of corticoliberin on the hormonal function of the adrenal glands] Turkina EV, et al. **Fiziol Zh Im I M Sechenova** 1996 May–Jun;82(5–6):109–13 (Eng. Abstr.) **(Rus)**

[The effect of low doses of nakom on the hormonal secretion of the hypothalamo-hypophyseal-adrenal system in patients with infantile cerebral palsy] Brin IL, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(4):51–4 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Effects of corticosteroid therapy in non-allergic rhinosinusitis. Mygind N. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):164–6 (25 ref.)

The effect of methylprednisolone on acoustic trauma. Takahashi K, et al. **Acta Otolaryngol (Stockh)** 1996 Mar; 116(2):209–12

Corticosteroid treatment of chronic lung disease in ventilator-dependent neonates [letter; comment] Milerad J. **Acta Paediatr** 1996 Jun;85(6):757. Comment on: Acta Paediatr 1996 Jun;85(6):713–8.

Steroids in central nervous system injury. Nguyen T, et al. **Adv Surg** 1996;30:53–69 (61 ref.)

Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Fokkens WJ, et al. **Allergy** 1997; 52(36 Suppl):29–32 (23 ref.)

Idiopathic anaphylaxis: long-term follow-up, cost, and outlook. Krasnick J, et al. **Allergy** 1996 Oct;51(10):724–31

Sodium cromoglycate as a replacement for inhaled corticosteroids in mild-to-moderate childhood asthma. Petersen W, et al. **Allergy** 1996 Dec;51(12):870–5

Cytokines and allergic rhinitis. Fireman P. **Allergy Asthma Proc** 1996 Jul–Aug;17(4):175–8 (11 ref.)

Immunologic effects of intranasal corticosteroids [editorial] Levenson T, et al. **Allergy Asthma Proc** 1996 May–Jun; 17(3):157–9

Outpatient management of Stevens-Johnson syndrome: a report of four cases and management strategy. Noskin GA, et al. **Allergy Asthma Proc** 1997 Jan–Feb;18(1):29–32

Use of antenatal corticosteroids for fetal maturation in preterm infants. Anyaegbunam WI, et al. **Am Fam Physician** 1997 Sep 15;56(4):1093–6 (13 ref.)

A prospective, double-blind, randomized, controlled clinical trial of ampicillin-sulbactam for preterm premature rupture of membranes in women receiving antenatal corticosteroid therapy. Lovett SM, et al. **Am J Obstet Gynecol** 1997 May; 176(5):1030–8

Prognosis and treatment of sudden sensorineural hearing loss. Fetterman BL, et al. **Am J Otol** 1996 Jul;17(4):529–36

Decreased Cu,Zn-SOD activity in asthmatic airway epithelium: correction by inhaled corticosteroid in vivo. De Raeve HR, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):L148–54

Are corticosteroids really more effective than anticholinergic-drugs in the treatment of obstructive airways disease? [letter] Marabini A, et al. **Am J Respir Crit Care Med** 1996 Nov;154(5):1579

"Treatment of osteitis pubis in athletes: results of corticosteroid injections" [letter] King JB. **Am J Sports Med** 1996 Mar–Apr;24(2):248

Epidural steroids for sciatica [letter; comment] McQuay HJ, et al. **Anaesth Intensive Care** 1996 Apr;24(2):284–5. Comment on: Anaesth Intensive Care 1995 Oct;23(5):564–9.

The Cochrane collaboration [letter; comment] Murrell G, et al. **Anaesth Intensive Care** 1996 Apr;24(2):286–7. Comment on: Anaesth Intensive Care 1995 Oct;23(5):564–9.

Sweet's syndrome in a skin clinic in Singapore: an epidemiology study. Goh CL, et al. **Ann Acad Med Singapore** 1996 Mar;25(2):222–7

Corticosteroids and asthma in children [letter] Singer AJ. **Ann Emerg Med** 1997 Sep;30(3):355–6

Acyclovir plus steroids for herpes zoster [letter; comment] Atkins CD. **Ann Intern Med** 1997 May 15;126(10):831; discussion 832. Comment on: Ann Intern Med 1996 Sep 1;125(5):376–83.

Acyclovir plus steroids for herpes zoster [letter; comment] Carson MP. **Ann Intern Med** 1997 May 15;126(10):831–2

. Comment on: Ann Intern Med 1996 Sep 1;125(5):376–83.
Acyclovir plus steroids for herpes zoster [letter; comment] Herbert DA. **Ann Intern Med** 1997 May 15;126(10):831; discussion 832. Comment on: Ann Intern Med 1996 Sep 1;125(5):376–83.
Temporal artery biopsy and corticosteroid treatment: changing conclusions without changing evidence [letter] Rutz-Irastorza G. **Ann Intern Med** 1997 Aug 1;127(3):248
Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects [see comments] Lacomis D, et al. **Ann Neurol** 1996 Oct; 40(4):645–54. Comment in: Ann Neurol 1997 Jul;42(1):131–2.
Effect of inhaled corticosteroids on the risk of cataract formation in patients with steroid-dependent asthma. Barenholtz H. **Ann Pharmacother** 1996 Nov;30(11):1324–7
The START study: inhaled steroid treatment as regular therapy in early asthma. **Aust Fam Physician** 1996 Nov; 25(11):1675
Corticosteroid injection for hayfever [letter; comment] Healey D. **Aust Fam Physician** 1996 Feb;25(2):253. Comment on: Aust Fam Physician 1995 Oct;24(10):1899, 1902.
Severe allergy to sorbolene cream. MacKenzie-Wood AR, et al. **Australas J Dermatol** 1997 Feb;38(1):33–4
Corticosteroids in acute traumatic brain injury: systematic review of randomised controlled trials. Alderson P, et al. **BMJ** 1997 Jun 28;314(7098):1855–9
Patterns of hearing recovery in idiopathic sudden sensorineural hearing loss. Harada T. **Br J Audiol** 1996 Dec;30(6):363–7
Trends and variations in use of antenatal corticosteroids to prevent neonatal respiratory distress syndrome: recommendations for national and international comparative audit [letter; comment] Chow P, et al. **Br J Obstet Gynaecol** 1996 Nov;103(11):1177. Comment on: Br J Obstet Gynaecol 1996 Jun;103(6):534–40.
Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Aricò M, et al. **Cancer** 1995 Apr 1;75(7):1684–93
Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Sekiguchi M, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):495–510 (288 ref.)
Prehospitalization inhaled corticosteroid use in patients with COPD or asthma. Jackevicius C, et al. **Chest** 1997 Feb; 111(2):296–302
The in vitro and in vivo effect of corticosteroids on basophil releasability in patients with mild and severe bronchial asthma. Kivity S, et al. **Clin Exp Allergy** 1997 Aug; 27(8):909–14
Effects of prednisolone on bone turnover in patients with corticosteroid resistant asthma. Lane SJ, et al. **Clin Exp Allergy** 1996 Oct;26(10):1197–201
The rationale for use of topical corticosteroids in allergic rhinitis. Mygind N, et al. **Clin Exp Allergy** 1996 May;26 Suppl 3:2–10 (42 ref.)
The use of serum eosinophil cationic protein (ECP) in the management of steroid therapy in chronic asthma. Wever AM, et al. **Clin Exp Allergy** 1997 May;27(5):519–29
Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung. Milburn HJ, et al. **Clin Exp Immunol** 1997 Apr;108(1):105–13
Local corticosteroid injections in the treatment of rotator cuff tendinitis (except for frozen shoulder and calcific tendinitis). Groupe Rhumatologique Français de l'Epaule (G.R.E.P.). Goupille P, et al. **Clin Exp Rheumatol** 1996 Sep–Oct;14(5):561–6 (41 ref.)
Immunosuppressive treatment of the glomerulonephritis of systemic lupus. Faedda R, et al. **Clin Nephrol** 1995 Dec; 44(6):367–75
Dose-response of inhaled drugs in asthma. An update. Clark DJ, et al. **Clin Pharmacokinet** 1997 Jan;32(1):58–74 (78 ref.)
Eczema/dermatitis: management & tips. Edwards L. **Compr Ther** 1997 Feb;23(2):148–54 (10 ref.)
Corticosteroids in the treatment of rheumatologic diseases. Morand E. **Curr Opin Rheumatol** 1997 May;9(3):200–5 (46 ref.)
Corticosteroids in the treatment of rheumatologic diseases. Weisman MH. **Curr Opin Rheumatol** 1996 May;8(3):188–94 (15 ref.)
Medical management of sinusitis in pediatric patients. Hopp R, et al. **Curr Probl Pediatr** 1997 May–Jun;27(5):178–86 (43 ref.)
Corticosteroid therapy, nonendocrine disease, and corticosteroid withdrawal. Magiakou MA, et al. **Curr Ther Endocrinol Metab** 1997;6:138–42 (8 ref.)
"Tinea incognits and over-the-counter patent topical steroids" [letter; comment] Toler T. **Cutis** 1997 Apr; 59(4):216E. Comment on: Cutis 1996 Oct;58(4):295–6.
Asthma treatment during pregnancy. What can be safely taken? Schatz M. **Drug Saf** 1997 May;16(5):342–50 (28 ref.)
Newer versus older treatments for relapsing-remitting multiple sclerosis. Weinstock-Guttman B, et al. **Drug Saf** 1996 Feb;14(2):121–30 (22 ref.)
A risk-benefit assessment of corticosteroids in the management of croup. Yates RW, et al. **Drug Saf** 1997 Jan; 16(1):48–55 (41 ref.)
Intra-articular corticosteroids. Guide to selection and indications for use. Caldwell JR. **Drugs** 1996 Oct; 52(4):507–14 (29 ref.)
Asthma: an important disease to Otolaryngologists—part III: anti-inflammatory therapy. Gordon BR. **Ear Nose Throat J** 1996 Apr;75(4):216–24 (49 ref.)
Relapsing chronic low-dose corticosteroid-responsive multifocal motor neuropathy with conduction block. de Carvalho M, et al. **Electromyogr Clin Neurophysiol** 1997 Mar;37(2):95–7
Actual use of inhaled corticosteroids and risk of hospitalisation: a case-control study. van Ganse E, et al. **Eur J Clin Pharmacol** 1997;51(6):449–54
Vaccine tolerance in steroid substituted patients with congenital adrenal hyperplasia. Weiss M, et al. **Eur J Med Res** 1997 Jul 28;2(7):290–2
Thyrotropin releasing hormone and corticosteroids prior to preterm labour: a survey of current practice in nine European countries. European Union Antenatal TRH Network Steering Committee. Alfirevic Z, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Sep;68(1–2):43–5
Prolonged corticosteroid-induced remission in primary central nervous system lymphoma: report of a case and review of the literature. Herrlinger U, et al. **Eur Neurol** 1996;36(4):241–3 (11 ref.)
Airway endothelin levels in asthma: influence of endobronchial allergen challenge and maintenance corticosteroid therapy. Redington AE, et al. **Eur Respir J** 1997 May;10(5):1026–32
Outcome of cervical radiculopathy treated with periradicular/epidural corticosteroid injections: a prospective study with independent clinical review. Bush K, et al. **Eur Spine J** 1996;5(5):319–25
Nongranulomatous chronic idiopathic enterocolitis: clinicopathologic profile and response to corticosteroids. Ruan EA, et al. **Gastroenterology** 1996 Sep;111(3):629–37
Management of asthma in the geriatric population. Masood D, et al. **Gerontology** 1996;42(4):183–9
Comparison of responses to SF-36 Health Survey questions with one-week and four-week recall periods. Keller SD, et al. **Health Serv Res** 1997 Aug;32(3):367–84
Steroid therapy and leprosy. Ramu G. **Indian J Lepr** 1996 Apr–Jun;68(2):182–3
Morphology of spleen in steroid resistant idiopathic thrombocytopenic purpuras. Vaiphei K, et al. **Indian J Pathol Microbiol** 1995 Jul;38(3):311–5
Guillian–Barre syndrome: issues in etiology and management. Garg RK. **Indian Pediatr** 1997 Jan;34(1):74–7
Adrenoleukodystrophy. Raja U, et al. **Indian Pediatr** 1995 Sep;32(9):1016–19 (10 ref.)
Juvenile dermatomyositis in north India. Singh S, et al. **Indian Pediatr** 1997 Mar;34(3):193–8
Mechanisms of corticosteroid resistance in asthmatic patients. Lane SJ, et al. **Int Arch Allergy Immunol** 1997 May–Jul; 113(1–3):193–5 (33 ref.)
Granuloma faciale: successful treatment of nine cases with a combination of cryotherapy and intralesional corticosteroid injection. Dowlati B, et al. **Int J Dermatol** 1997 Jul;36(7):548–51
Extubation failure due to post-extubation stridor is better correlated with neurologic impairment than with upper airway lesions in critically ill pediatric patients. Harel Y, et al. **Int J Pediatr Otorhinolaryngol** 1997 Mar 6; 39(2):147–58
A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis [see comments] Ayabe T, et al. **Intern Med** 1997 May; 36(5):322–6. Comment in: Intern Med 1997 May;36(5):317–8.
A novel therapy for corticosteroid-dependent or corticosteroid-resistant patients with ulcerative colitis [editorial; comment] Hibi T, et al. **Intern Med** 1997 May; 36(5):317–8. Comment on: Intern Med 1997 May;36(5):322–6.
Interferon or corticosteroid: treatment of patients with chronic hepatitis C positive for serum markers of autoimmune diseases [editorial] Toda G. **Intern Med** 1997 Apr;36(4):233–5
Rifampin-induced deterioration in steroid-dependent asthma. Lin FL. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1125
Decreased nasal goblet cells in patients reporting topical corticosteroid use. Lin RY, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):265–6
Autism and related conditions [letter; comment] Volkmar FR, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Apr; 35(4):401–3. Comment on: J Am Acad Child Adolesc Psychiatry 1995 Aug;34(8):1107–11.
A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. Lieberman KV, et al. **J Am Soc Nephrol** 1996 Jan;7(1):56–63
Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. Nachman PH, et al. **J Am Soc Nephrol** 1996 Jan;7(1):33–9
Mechanisms of action of anti-inflammatory medications used for the treatment of osteoarthritis [see comments] Johnston SA, et al. **J Am Vet Med Assoc** 1997 May 15; 210(10):1486–92 (102 ref.). Comment in: J Am Vet Med Assoc 1997 May 15;210(10):1417–8.
Corticosteroids in pneumococcal meningitis [letter; comment] Denning DW. **J Antimicrob Chemother** 1997 Apr; 39(4):557–8. Comment on: J Antimicrob Chemother 1996 Jun;37(6):1051–61.
The use of corticosteroids in the management of bacterial meningitis in adults [see comments] Townsend GC, et al. **J Antimicrob Chemother** 1996 Jun;37(6):1051–61 (31 ref.). Comment in: J Antimicrob Chemother 1997 Apr;39(4):557–8.
Cytoreduction and prognosis in childhood acute lymphoblastic leukemia [letter; comment] Aricò M, et al. **J Clin Oncol** 1997 Mar;15(3):1285. Comment on: J Clin Oncol 1996 Feb;14(2):389–98. Comment on: J Clin Oncol 1996 Aug;14(8):2403–6.
Acute form of pyoderma gangrenosum induced by traumatic injury. Kitagawa N, et al. **J Dermatol** 1996 Feb;23(2):116–9
Corticosteroid injections for tennis elbow. Weir S. **J Fam Pract** 1996 Sep;43(3):232, 234
Therapeutic responses to corticosteroids in Graves' ophthalmopathy. Chang TC, et al. **J Formos Med Assoc** 1996 Nov;95(11):833–8
Abuse of therapy with corticosteroids in the asthmatic patient and the deficient control of suprarenal function. Indication of therapy with ACTH. Oehling A, et al. **J Investig Allergol Clin Immunol** 1996 Nov–Dec; 6(6):349–55
Methotrexate in the treatment of corticodependent asthmatic children. Solé D, et al. **J Investig Allergol Clin Immunol** 1996 Mar–Apr;6(2):126–30
Steroid-resistant lymphocytic enterocolitis and bronchitis responsive to 6-mercaptopurine in an adolescent. Deslandres C, et al. **J Pediatr Gastroenterol Nutr** 1997 Sep; 25(3):341–6
Increasing use of antenatal corticosteroid therapy between 1990 and 1993 in Vermont Oxford Network. Horbar JD. **J Perinatol** 1997 Jul–Aug;17(4):309–13
Improved outcomes for very low birth weight infants associated with the use of combined maternal corticosteroids and tocolytics. Piper JM, et al. **J Reprod Med** 1996 Sep;41(9):692–8
Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis [letter; comment] Beck RW. **Lancet** 1997 Jun 7;349(9066):1696; discussion 1697. Comment on: Lancet 1997 Mar 29;349(9056):902–6.
The effectiveness of corticosteroids in the treatment of long-term nerve function impairment [letter] Croft R, et al. **Lepr Rev** 1996 Dec;67(4):342–3
Interaction between corticosteroids and beta-agonists in asthma. Wilding PJ, et al. **Monaldi Arch Chest Dis** 1996 Feb;51(1):39–41 (24 ref.)
Sarcoidosis [published erratum appears in N Engl J Med 1997 Jul 10;337(2):139] Newman LS, et al. **N Engl J Med** 1997 Apr 24;336(17):1224–34 (159 ref.)
Focal segmental glomerular sclerosis. To treat or not to treat? 1. It is worthwhile to give the adult patient with nephrotic syndrome the benefit of an adequate therapeutic trial? Ponticelli C. **Nephrol Dial Transplant** 1995 Dec; 10(12):2351–4 (26 ref.)
Levamisole therapy in corticosteroid-dependent nephrotic syndrome. Bagga A, et al. **Pediatr Nephrol** 1997 Aug; 11(4):415–7
Plasma exchange in steroid and anti-thymocyte globulin resistant allograft rejection in children. Nijsten EW, et al. **Pediatr Nephrol** 1996 Oct;10(5):613–5
rhDNase in acute asthma [letter] Puterman AS, et al. **Pediatr Pulmonol** 1997 Apr;23(4):316–7
Consequences of hypogammaglobulinemia and steroid therapy in severe bronchopulmonary dysplasia. Wheeler W, et al. **Pediatr Pulmonol** 1996 Aug;22(2):96–100
Steroids with face lift [letter] Dostal GH. **Plast Reconstr Surg** 1997 Aug;100(2):551–2
Allergic rhinitis. Options for pharmacotherapy and immunotherapy. Ferguson BJ. **Postgrad Med** 1997 May; 101(5):117–20, 123–6, 131 (15 ref.)
Atopic dermatitis. Current concepts support old therapies and spur new ones. Landow K. **Postgrad Med** 1997 Mar; 101(3):101–4, 107–8, 111–2 passim (32 ref.)
New thinking on the treatment of rhinitis. Mirakian R, et al. **Practitioner** 1997 May;241(1574):286–90
Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Lipworth BJ. **Pulm Pharmacol** 1996 Feb;9(1):19–27 (48 ref.)
How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy. Cortet B, et al. **Rev Rhum Engl Ed** 1997 Mar; 64(3):153–9
Advances in treatment: immunoglobulin A nephropathy. Hogg RJ, et al. **Semin Nephrol** 1996 Nov;16(6):511–6 (31 ref.)
The pathomorphologic changes that accompany the resolution of cervical radiculopathy. A prospective study with repeat magnetic resonance imaging. Bush K, et al. **Spine** 1997 Jan 15;22(2):183–6; discussion 187
The role of corticosteroids in bronchiolitis and croup [editorial; comment] Milner AD. **Thorax** 1997 Jul; 52(7):595–7. Comment on: Thorax 1997 Jul;52(7):634–7.
Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Baschieri L, et al. **Thyroid** 1997 Aug;7(4):579–85
Anosmia following head trauma: preliminary study of steroid treatment. Ikeda K, et al. **Tohoku J Exp Med** 1995 Dec; 177(4):343–51
Successful management of hemolysis in ABO-nonidentical orthotopic liver transplantation by steroid therapy: a case report. Auwerda JJ, et al. **Transpl Int** 1996;9(5):509–12
Allograft rejection and corticosteroids in acute pancreatitis following renal and cardiac transplantation. Hagopian EJ,

ADRENAL CORTEX HORMONES

et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):583

Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis. Johnston SA, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul; 27(4):841–62 (135 ref.)

Prematurity--steroids for all. Main EK. **West J Med** 1996 Dec;165(6):372–3

[Pregnancy in primary antiphospholipid syndrome. Proposal for a common management protocol] el Kouri D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):828–31 (Eng. Abstr.) **(Fre)**

[Perioperative administration of adrenal cortex hormones] Briegel J. **Anaesthesist** 1997 Jan;46(1):57–8 **(Ger)**

[Corticosteroid therapy in the prevention of recurrent post-surgical nasal polyposis] Cassano P, et al. **Acta Otorhinolaryngol Ital** 1996 Aug;16(4):334–8 (Eng. Abstr.) **(Ita)**

[Cortisone-resistant bronchial asthma] Matucci A, et al. **Ann Ital Med Int** 1996 Jul–Sep;11(3):187–95 (47 ref.) (Eng. Abstr.) **(Ita)**

[Lipid pneumonia. Favorable outcome after treatment with intravenous immunoglobulins, steroids, cephalosporins] Amato GM, et al. **Minerva Pediatr** 1997 Apr;49(4):163–9 (Eng. Abstr.) **(Ita)**

[Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)] Baba M, et al. **Rinsho Shinkeigaku** 1996 Dec;36(12):1336–7 (Eng. Abstr.) **(Jpn)**

[The influence of corticoids, in Chronic Chagas disease, administered in virtue of associated disorders] Rassi A, et al. **Rev Soc Bras Med Trop** 1997 Mar–Apr;30(2):93–9 (Eng. Abstr.) **(Por)**

[Experience in treating uveitis of sarcoid etiology] Chernysheva MV, et al. **Probl Tuberk** 1996;(5):34–5 **(Rus)**

[Principles of drug therapy of inflammatory eye diseases] Nesterov AP. **Vestn Oftalmol** 1997 Jan–Feb;113(1):3–5 (Eng. Abstr.) **(Rus)**

[The clinico-immunological validation of a differentiated approach to the use of corticosteroids in treating S-dependent uveoretinitis] Slepova OS, et al. **Vestn Oftalmol** 1996 Apr–Jun;112(2):45–7 (Eng. Abstr.) **(Rus)**

[Acute muscular weakness during childhood in cases of severe asthma due to the use of corticoids and neuromuscular blockers] Campistol Plana J, et al. **An Esp Pediatr** 1996 Aug;45(2):196–8 (5 ref.) **(Spa)**

[Infantile laryngeal hemangioma: conservative treatment with corticoids] Delgado Moreno F, et al. **An Esp Pediatr** 1996 Aug;45(2):221–4 **(Spa)**

[Immunoglobulins and corticoids in Guillain–Barre syndrome: a report of a new case. Letter] Riol Diego M, et al. **An Esp Pediatr** 1996 Nov;45(5):547–9 **(Spa)**

[Treatment of neurological complications: cerebral edema and epileptic seizures] Vivancos Mora J. **Neurologia** 1995 Dec;10 Suppl 2:23–9 (67 ref.) (Eng. Abstr.) **(Spa)**

URINE

Urinary excretion of adrenocortical steroid metabolites by pre-term human infants: trends from birth until 3 months post term. Taylor N, et al. **Endocr Res** 1996 Nov; 22(4):741–9

A confirmatory HPLC-MS/MS method for ten synthetic corticosteroids in bovine urines. Savu SR, et al. **J Mass Spectrom** 1996 Dec;31(12):1351–63

ADRENAL CORTEX NEOPLASMS

Extensive personal experience: adrenocortical tumors. Latronico AC, et al. **J Clin Endocrinol Metab** 1997 May; 82(5):1317–24 (50 ref.)

[Adrenocortical carcinoma. Current approaches in diagnosis and treatment] Sapienza P, et al. **Ann Ital Chir** 1995 Sep–Oct;66(5):651–63 (123 ref.) (Eng. Abstr.) **(Ita)**

[Incidentaloma of the adrenal gland. A clinical case] Letizia C, et al. **Minerva Endocrinol** 1997 Jun;22(2):45–50 (Eng. Abstr.) **(Ita)**

[Adrenal cortex neoplasms in children: diagnostic and therapeutic difficulties] Caldarella A, et al. **Pathologica** 1996 Jun;88(3):175–80 (Eng. Abstr.) **(Ita)**

BLOOD

Erythropoietin-producing adrenocortical carcinoma. Oka T, et al. **Urol Int** 1996;56(4):246–9

CHEMISTRY

Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Edgren M, et al. **Anticancer Res** 1997 Mar–Apr;17(2B):1303–9

Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression. Reincke M, et al. **Clin Endocrinol (Oxf)** 1997 May;46(5):619–26

Autocrine-paracrine role of endothelin-1 in the regulation of aldosterone synthase expression and intracellular Ca2+ in human adrenocortical carcinoma NCI-H295 cells. Rossi GP, et al. **Endocrinology** 1997 Oct;138(10):4421–6

Relationship of cytoskeletal filaments to annular gap junction expression in human adrenal cortical tumor cells in culture. Murray SA, et al. **Exp Cell Res** 1997 Aug 1;234(2):398–404

Cerebellin and cerebellin mRNA in the human brain, adrenal glands and the tumour tissues of adrenal tumour, ganglioneuroblastoma and neuroblastoma. Satoh F, et al. **J Endocrinol** 1997 Jul;154(1):27–34

[Gamma interferon-like immunoreactivity in adrenal gland and cortical tumor] Li Q, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Dec;24(6):372–4 (Eng. Abstr.) **(Chi)**

COMPLICATIONS

Double adenomas with different pathological and hormonal features in the left adrenal gland of a patient with Cushing's syndrome. Satoh F, et al. **Clin Endocrinol (Oxf)** 1997 Feb; 46(2):227–34

Adrenal tumour associated with silent 21-hydroxylase deficiency in a male or with a classic form of 21-hydroxylase defect in a female? [letter] [see comments] Tóth M, et al. **Clin Endocrinol (Oxf)** 1996 Sep;45(3):369–70 . Comment in: Clin Endocrinol (Oxf) 1997 May;46(5):644.

A case of Cushing's syndrome due to adrenocortical carcinoma with recurrence 19 months after laparoscopic adrenalectomy. Ushiyama T, et al. **J Urol** 1997 Jun; 157(6):2239

Primary adrenal lymphoma associated with adrenal insufficiency: a distinct clinical entity. Pimentel M, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):363–7 (23 ref.)

Surgical treatment of left-atrial myxoma in Carney's complex. Akbaş H, et al. **Thorac Cardiovasc Surg** 1997 Jun; 45(3):148–50

[Corticotropic adenoma in slow adrenal insufficiency] Fabreguettes C, et al. **Ann Endocrinol (Paris)** 1996; 57(2):111–5 (Eng. Abstr.) **(Fre)**

[A case of concurrent bilateral adrenocortical adenoma causing Cushing's syndrome] Koga F, et al. **Hinyokika Kiyo** 1997 Apr;43(4):275–8 (Eng. Abstr.) **(Jpn)**

[Heart failure, arterial hypertension, and hypokalemic alkalosis] Rivero M, et al. **Rev Clin Esp** 1996 Aug; 196(8):565–6 **(Spa)**

DIAGNOSIS

Adrenal androgen-secreting carcinoma in a fertile woman. Falsetti L, et al. **Acta Eur Fertil** 1995 May–Jun;26(3):117–21

Comparison of two algorithms and their associated charges when evaluating adrenal masses in patients with malignancies. Schwartz LH, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1575–8

Metastatic adenocarcinoma within an adrenal adenoma: detection with chemical shift imaging. Shifrin RY, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):891–2

Adrenal mass with virilisation: importance of endocrine investigation [see comments] Nasir J, et al. **BMJ** 1996 Oct 5;313(7061):872–3. Comment in: BMJ 1997 Jan 18;314(7075):229–30.

ACTH-independent macronodular adrenocortical hyperplasia (AIMAH): report of two cases and the analysis of steroidogenic activity in adrenal nodules. Morioka M, et al. **Endocr J** 1997 Feb;44(1):65–72

Nonfunctional adrenal cortical carcinoma. Report of a case and review of the literature. Fokaefs ED, et al. **Int Urol Nephrol** 1996;28(2):145–52 (35 ref.)

Three cases of clinical or preclinical Cushing's syndrome due to adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia: pituitary-adrenocortical function and immunohistochemistry. Murakami O, et al. **Intern Med** 1995 Nov;34(11):1074–81

A functioning black adenoma of the adrenal gland. Ueda Y, et al. **Intern Med** 1997 Jun;36(6):398–402 (29 ref.)

Childhood adrenocortical tumors. Sandrini R, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2027–31

Magnetic resonance imaging differentiation of adrenal masses at 1.5 T: T2-weighted images, chemical shift imaging, and Gd-DTPA dynamic studies. Slapa RZ, et al. **MAGMA** 1996 Sep–Dec;4(3–4):163–79

Clinical characteristics of small functioning adrenocortical tumors in children. Michalkiewicz EL, et al. **Med Pediatr Oncol** 1997 Mar;28(3):175–8

Magnetic resonance imaging of adrenocortical adenomas in childhood: correlation with computed tomography and ultrasound. Hanson JA, et al. **Pediatr Radiol** 1996 Nov; 26(11):794–9

Pediatric case of the day. Adrenocortical adenoma. Medina LS, et al. **Radiographics** 1996 Mar;16(2):449–51

Correction to a previously published case: recurrence of invasive adrenocortical tumor after excision of atypical adenoma. Outwater EK, et al. **Radiology** 1997 Feb; 202(2):531–2

[Malignant adrenocortical carcinoma with atypical aspect. Value of tomodensitometry and magnetic resonance imaging. Apropos of a case] Drevet D, et al. **Ann Radiol (Paris)** 1996;39(3):126–30 (Eng. Abstr.) **(Fre)**

[Adrenal cortex adenoma in Conn syndrome] Kolokythas O, et al. **Rontgenpraxis** 1996 Jul;49(7):180–2 **(Ger)**

[The diagnosis and treatment of hormonally inactive adrenal formations] Maĭstrenko NA, et al. **Vestn Khir Im I I Grek** 1996;155(6):39–43 (Eng. Abstr.) **(Rus)**

[Uncontrolled hypertension after Cushing's syndrome] Tinahones FJ, et al. **Rev Clin Esp** 1997 Apr;197(4):293–5 **(Spa)**

DRUG THERAPY

Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Two years later [letter] Kasperlik-Załuska AA, et al. **Cancer** 1996 Oct 1; 78(7):1520–1

Effects of taxol on the human NCI-H295 adrenocortical carcinoma cell line. Fallo F, et al. **Endocr Res** 1996 Nov; 22(4):709–15

ENZYMOLOGY

Immunolocalization of dehydroepiandrosterone sulfotransferase in normal and pathologic human adrenal gland. Sasano H, et al. **Mod Pathol** 1995 Dec;8(9):891–6

Immunolocalization of glutathione-peroxidase (GSH-PO) in human adrenal gland--studies on adrenocortical adenomas associated with primary aldosteronism and Cushing's syndrome. Murakoshi M, et al. **Tokai J Exp Clin Med** 1995 Jul;20(2):89–97

EPIDEMIOLOGY

Malignant endocrine tumours in childhood and adolescence--results of a retrospective analysis. Parlowsky T, et al. **Klin Padiatr** 1996 Jul–Aug;208(4):205–9

ETIOLOGY

Adrenal incidentalomas: a manifestation of the metabolic syndrome? Reincke M, et al. **Endocr Res** 1996 Nov; 22(4):757–61

GENETICS

A somatic mutation of the p21(Waf1/Cip1) gene in a human adrenocortical adenoma. Iida S, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):633–6

Molecular markers for malignancy in adrenocortical tumors. Gicquel C, et al. **Horm Res** 1997;47(4–6):269–72

Adrenocorticotropin-independent macronodular adrenocortical hyperplasia associated with multiple colon adenomas/carcinomas which showed a point mutation in the APC gene [see comments] Yamakita N, et al. **Intern Med** 1997 Aug;36(8):536–42. Comment in: Intern Med 1997 Aug;36(8):533–4.

Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. Gicquel C, et al. **J Clin Endocrinol Metab** 1997 Aug; 82(8):2559–65

Ribonucleic acid expression of the CLA-1 gene, a human homolog to mouse high density lipoprotein receptor SR-BI, in human adrenal tumors and cultured adrenal cells. Liu J, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2522–7

Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. Reincke M, et al. **J Clin Endocrinol Metab** 1997 Sep; 82(9):3054–8

Expression patterns of the c-myc gene in adrenocortical tumors and pheochromocytomas. Liu J, et al. **J Endocrinol** 1997 Feb;152(2):175–81

Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. Perez-Stable C, et al. **Lab Invest** 1996 Feb;74(2):363–73

Gonadectomy permits adrenocortical tumorigenesis in mice transgenic for the mouse inhibin alpha-subunit promoter/simian virus 40 T-antigen fusion gene: evidence for negative autoregulation of the inhibin alpha-subunit gene. Kananen K, et al. **Mol Endocrinol** 1996 Dec; 10(12):1667–77

Characterization of adrenocortical cell lines produced by genetically targeted tumorigenesis in transgenic mice. Compagnone NA, et al. **Steroids** 1997 Feb;62(2):238–43

Gip-2 codon 179 oncogene mutations: absent in adrenal cortical tumors. Demeure MJ, et al. **World J Surg** 1996 Sep;20(7):928–31; discussion 931–2

IMMUNOLOGY

MHC class II expression--a new tool to assess dignity in adrenocortical tumours. Marx C, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4488–91

METABOLISM

Oestrogen producing adrenocortical adenoma: clinical, biochemical and immunohistochemical studies. Goto T, et al. **Clin Endocrinol (Oxf)** 1996 Nov;45(5):643–8

Different allelic patterns at chromosome 11q13 in paired aldosterone-producing tumours and blood DNA. Gordon R, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul; 23(6–7):594–6

Forskolin treatment directs steroid production towards the androgen pathway in the NCI-H295R adrenocortical tumour cell line. Cobb VJ, et al. **Endocr Res** 1996 Nov; 22(4):545–50

Calcium channels do not play a role in the steroid response to ACTH IN Y1 adrenocortical cells. Coyne MD, et al. **Endocr Res** 1996 Nov;22(4):551–6

Comparative effect of pituitary adenylate cyclase-activating polypeptide on aldosterone secretion in normal bovine and human tumorous adrenal cells. Bodart V, et al. **Endocrinology** 1997 Feb;138(2):566–73

Adrenocorticotropic hormone regulates the activities of the orphan nuclear receptor Nur77 through modulation of

phosphorylation. Li Y, et al. **Endocrinology** 1997 Oct; 138(10):4138–46

Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Weber MM, et al. **Eur J Endocrinol** 1997 Mar;136(3):296–303

Regulation of cytoskeleton organization and paxillin dephosphorylation by cAMP. Studies on murine Y1 adrenal cells. Han JD, et al. **J Biol Chem** 1996 Nov 15; 271(46):29211–5

Dissection of the signaling mechanism for capsule detachment of lipid droplets in rat adrenocortical cells. Fong TH, et al. **J Cell Biochem** 1997 Apr;65(1):67–74

Angiotensin II receptors in cortical and medullary adrenal tumors. Opocher G, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):865–9

Expression of p53 in adrenocortical tumours: clinicopathological correlations. McNicol AM, et al. **J Pathol** 1997 Feb;181(2):146–52

Viscosity of rat adrenocortical lipids in different functional states: morphological characteristics. Szabó D, et al. **J Steroid Biochem Mol Biol** 1996 Jun;58(3):329–35

Regular immunohistochemical localization of endothelin-1 and endothelin-B receptor in normal, hyperplastic and neoplastic human adrenocortical cells. Hiraki H, et al. **Pathol Int** 1997 Feb–Mar;47(2–3):117–25

PATHOLOGY

Adrenal cortical carcinoma with a liver metastasis in a child. Report of a case with fine needle aspiration findings and image analysis of nuclear DNA. Moroz K, et al. **Acta Cytol** 1997 Mar–Apr;41(2):569–76

Cytomorphology of adrenocortical carcinoma and comparison with renal cell carcinoma. Sharma S, et al. **Acta Cytol** 1997 Mar–Apr;41(2):385–92

Image cytometric DNA analysis of adrenocortical neoplasms as a prognostic parameter: a clinico-pathologic study of 13 patients. Lü X, et al. **Anal Cell Pathol** 1996 Oct; 12(1):1–11

Inferior vena cava involvement by a left side adrenocortical carcinoma: operative and prognostic considerations. Mingoli A, et al. **Anticancer Res** 1996 Sep–Oct; 16(5B):3197–200 (20 ref.)

Evaluation of apoptotic parameters in normal and neoplastic human adrenal. Wolkersdörfer GW, et al. **Endocr Res** 1996 Nov;22(4):411–9

Aldosterone-producing adrenocortical carcinoma metastases found seven years after adrenalectomy. Sakai N, et al. **Int J Urol** 1997 Jan;4(1):79–82

Childhood adrenocortical tumors: case series and reevaluation of prognosis—a 24-year experience. Mayer SK, et al. **J Pediatr Surg** 1997 Jun;32(6):911–5 (25 ref.)

Corticomedullary tumors of the adrenal glands. Report of two cases. Association of corticomedullary tumor with spindle cell sarcoma. Michal M, et al. **Pathol Res Pract** 1996 Nov;192(11):1082–9

[Bilateral adrenocortical adenomas and the pheochromocytoma syndrome] Dušková J, et al. **Cesk Patol** 1996 Aug;32(3):101–4 (Eng. Abstr.) **(Cze)**

PHYSIOPATHOLOGY

Adrenocortical neoplasms: role of prognostic markers MIB-1, P53, and RB. Vargas MP, et al. **Am J Surg Pathol** 1997 May;21(5):556–62

Neoplasms of the adrenal cortex. Clinical and basic aspects. Latronico AC, et al. **Cancer Treat Res** 1997;89:217–37 (112 ref.)

Incidentally discovered adrenocortical adenomas are not fully nonfunctioning: immunohistochemical and dispersed adrenocortical cell study. Tobinaga J, et al. **Endocr J** 1996 Feb;43(1):79–86

RADIOGRAPHY

Adrenal cortical adenoma with extensive fat cell metaplasia [letter; comment] Arana E, et al. **Pathol Res Pract** 1996 Dec;192(12):1288. Comment on: Pathol Res Pract 1996 Jan;192(1):62–5; discussion 66.

RADIONUCLIDE IMAGING

Nonfunctioning adrenocortical tumor showing concentration of Tc-99m MDP in a child. Yen TC, et al. **Clin Nucl Med** 1996 Jul;21(7):579–80

Radioiodinated metaiodobenzylguanidine scintigraphy for pheochromocytoma. A false-positive case of adrenocortical adenoma and literature review. Sone H, et al. **Horm Res** 1996;46(3):138–42 (27 ref.)

Simultaneous scintigraphic depiction of aldosteronoma and adrenal infarction. Gianchandani RY, et al. **J Nucl Med** 1996 May;37(5):852–4

Scintigraphic assessment of therapeutic success in aldosteronomas treated by transcatheter arterial embolization using absolute ethanol. Nakajo M, et al. **J Nucl Med** 1997 Feb;38(2):237–41

[The functional gammagraphic study of adrenal tumors found by chance (letter; comment)] Domínguez Gadea L, et al. **Med Clin (Barc)** 1996 Apr 6;106(13):518. Comment on: Med Clin (Barc) 1995 Mar 4;104(8):318. **(Spa)**

SECRETION

Functional adrenocortical adenoma in a case with B cell chronic lymphoproliferative disorder. Adachi Y, et al. **Acta Haematol** 1997;97(4):239–41

Bilateral deoxycorticosterone-secreting adrenocortical adenoma. Nitta T, et al. **Int J Urol** 1996 Nov;3(6):494–6

Aldosterone-producing adrenocortical carcinoma metastases found seven years after adrenalectomy. Sakai N, et al. **Int J Urol** 1997 Jan;4(1):79–82

Adrenocortical adenoma producing 18-hydroxycorticosterone. Un-no T, et al. **Int J Urol** 1996 Nov;3(6):491–3

Steroid secretions in patients with adrenal incidentalomas [letter; comment] Reincke M. **J Clin Endocrinol Metab** 1996 Oct;81(10):3811–2. Comment on: J Clin Endocrinol Metab 1996 Feb;81(2):740–4.

An unusual case of bilateral virilizing adrenal adenoma co-secreting androgens and cortisol. Delgrange E, et al. **J Endocrinol Invest** 1996 Jun;19(6):377–81

[An adrenal carcinoma producing androgens, estrogens and cortisol] De Pablos Velasco PL, et al. **An Med Interna** 1997 Apr;14(4):190–2 (12 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Adrenal cortical carcinoma associated with venous tumour thrombus extension. Figueroa AJ, et al. **Br J Urol** 1997 Sep;80(3):397–400

Retroperitoneal laparoscopic adrenalectomy for functioning adrenal tumors: comparison with conventional transperitoneal laparoscopic adrenalectomy. Takeda M, et al. **J Urol** 1997 Jan;157(1):19–23

[Adrenocortical carcinoma: report of 20 cases] Jiang W, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Oct;33(10):621–2 (Eng. Abstr.) **(Chi)**

[Evaluation of surgical treatment for patients with multiple aldosteronoma: analysis of 11 cases] Liu D, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Nov;33(11):681–3 (Eng. Abstr.) **(Chi)**

[Adrenal cortex adenomas. A retrospective series of twenty cases] Mhiri MN, et al. **Ann Urol (Paris)** 1996;30(5):217–24 (Eng. Abstr.) **(Fre)**

THERAPY

Adrenocortical carcinoma. Gicquel C, et al. **Ann Oncol** 1997 May;8(5):423–7 (57 ref.)

Transcatheter arterial renal and adrenal embolization with iohexol-ethanol solutions. Animal experimental study and clinical application. Miyazono N, et al. **Invest Radiol** 1996 Dec;31(12):755–60

Scintigraphic assessment of therapeutic success in aldosteronomas treated by transcatheter arterial embolization using absolute ethanol. Nakajo M, et al. **J Nucl Med** 1997 Feb;38(2):237–41

[Treatment of malignant adrenal cortex carcinoma] Andrès E, et al. **Presse Med** 1997 May 31;26(18):880–4 (47 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Magnetic resonance imaging of adrenocortical adenomas in childhood: correlation with computed tomography and ultrasound. Hanson JA, et al. **Pediatr Radiol** 1996 Nov; 26(11):794–9

[Androgen-producing adrenocortical adenoma in childhood. Pitfalls of differential diagnosis] Gyulay K, et al. **Orv Hetil** 1997 Sep 14;138(37):2357–62 (42 ref.) (Eng. Abstr.) **(Hun)**

VETERINARY

Stranguria in a castrated male ferret [clinical conference] [see comments] Rosenthal KL, et al. **J Am Vet Med Assoc** 1996 Jul 1;209(1):62–3; discussion 63–4. Comment in: J Am Vet Med Assoc 1996 Sep 1;209(5):893–4.

Ultrasonographic diagnosis of an adrenocortical carcinoma in a dog. Liste F, et al. **Vet Rec** 1997 Mar 29;140(13):339–41

Adrenal cortical carcinoma in a free-ranging mouflon (Ovis musimon). Marco-Sánchez I, et al. **Vet Rec** 1996 Sep 7; 139(10):236–7

[Hyperadrenocorticism in ferrets] Lumeij JT. **Tijdschr Diergeneeskd** 1997 Mar 1;122(5):146–7 **(Dut)**

ADRENAL CORTICAL REST TUMOR see **ADRENAL REST TUMOR**

ADRENAL FASCICULATA see **ZONA FASCICULATA**

ADRENAL GLAND DISEASES

Diseases of the adrenal gland. Gumowski J, et al. **Nurs Clin North Am** 1996 Dec;31(4):747–68 (32 ref.)

[Diagnosis and treatment of cystic tumors of the adrenal gland. Report of 2 cases] Wagner L, et al. **Prog Urol** 1996 Dec;6(6):940–3 (15 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess. Colombo P, et al. **Clin Endocrinol (Oxf)** 1997 Jun;46(6):661–8

Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo. Boscaro M, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2801–4

CHEMICALLY INDUCED

Bilateral massive adrenal haemorrhage complicating anaphylactic shock: a case report [letter; comment] Waldhausen E. **Intensive Care Med** 1997 Feb;23(2):235–6 . Comment on: Intensive Care Med 1996 May;22(5):447–9.

Pituitary-adrenal suppression and recovery in preterm very low birth weight infants after dexamethasone treatment for bronchopulmonary dysplasia. Ng PC, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2429–32

Methylprednisolone exposure, rather than dose, predicts adrenal suppression and growth inhibition in children with liver and renal transplants. Sarna S, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):75–7

Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB(486)interleukin-2). Cohen R, et al. **J Immunother** 1994 Oct;16(3):229–33

Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature. Sarver RG, et al. **Urology** 1997 May;49(5):781–5 (27 ref.)

COMPLICATIONS

Using CT to evaluate the acute abdomen: spectrum of urinary pathology. Johnson GL, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):273–6

Adrenalitis and the adrenocortical response of resistant and susceptible mice to acute murine cytomegalovirus infection. Price P, et al. **Eur J Clin Invest** 1996 Sep;26(9):811–9

Transient hypertension due to adrenal hemorrhage in a patient with von Recklinghausen's disease. Akuzawa N, et al. **Intern Med** 1997 Apr;36(4):289–92

[Bilateral adrenal cysts and hepatorenal polycystic disease] Bastide C, et al. **Presse Med** 1997 May 3–10;26(15):711–2 (Eng. Abstr.) **(Fre)**

[Endocrine hypertension] Tanaka Y. **Ryoikibetsu Shokogun Shirizu** 1996;(12):133–8 (8 ref.) **(Jpn)**

CONGENITAL

Glycerol kinase deficiency and adrenal hypoplasia congenita. Clarke RA, et al. **J Inherit Metab Dis** 1997 Aug;20(4):609

Bilateral cystic adrenal masses in the neonate associated with the incomplete form of Beckwith-Wiedemann syndrome. Akata D, et al. **Pediatr Radiol** 1997 Jan;27(1):1–2

DIAGNOSIS

Abnormal thyroid and adrenocortical function test results in intensive care patients. Koh LK, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):808–15

Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Terzolo M, et al. **Arch Surg** 1997 Aug;132(8):914–9

Incidentalomas. A disease of modern technology. Chidiac RM, et al. **Endocrinol Metab Clin North Am** 1997 Mar; 26(1):233–53 (155 ref.)

Outcome of incidental adrenal masses not operated on: 44 cases over 7 years [letter; comment] Courtade A, et al. **Eur J Surg** 1997 Apr;163(4):315. Comment on: Eur J Surg 1996 Apr;162(4):275–8.

Elevated serum progesterone levels during pituitary suppression may signify adrenal hyperandrogenism. Eldar-Geva T, et al. **Fertil Steril** 1997 May;67(5):959–61

Acute adrenal haemorrhage: diagnosis, treatment and follow-up. Ferreira JG, et al. **Int Urol Nephrol** 1996; 28(6):735–41

The potential for serious consequences from misinterpretation of normal responses to the rapid adrenocorticotropin test [letter] [see comments] Jolobe OM. **J Clin Endocrinol Metab** 1996 Jun;81(6):2405–6. Comment in: J Clin Endocrinol Metab 1997 Jan;82(1):322.

Adrenal paragonimiasis simulating adrenal tumor—a case report. Hahn ST, et al. **J Korean Med Sci** 1996 Jun; 11(3):275–7

Epithelial cyst of the adrenal gland: an unusual cause of recurrent flank pain. Reiher F, et al. **J Urol** 1997 Jun; 157(6):2238

The adrenal gland: radiologic-pathologic correlation. Krebs TL, et al. **Magn Reson Imaging Clin N Am** 1997 Feb; 5(1):127–46 (54 ref.)

Correspondence re: Prevot S, Penna CH, Imbert JC, Wendum D, De Saint Maur PP. Solitary fibrous tumor of the adrenal gland. Mod Pathol 1996;9:1170–74 [letter; comment] López JI. **Mod Pathol** 1997 May;10(5):520. Comment on: Mod Pathol 1996 Dec;9(12):1170–4.

Large adrenal cysts in teenage girls: diagnosis and management. Broadley P, et al. **Pediatr Radiol** 1997 Jun; 27(6):550–2

Imaging of adrenal masses. Korobkin M, et al. **Urol Clin North Am** 1997 Aug;24(3):603–22 (88 ref.)

Giant adrenal cyst: preoperative diagnosis and management. Ulusoy E, et al. **Urol Int** 1997;58(3):186–8 (14 ref.)

Urinary metabolic profile in rat of 1-(2-methoxyphenyl)-2-methyl-2-(3-pyridyl)-1-propanone: a potential radioligand for functional diagnosis of adrenal pathology. Damani LA, et al. **Xenobiotica** 1996 Feb;26(2):211–19

[Hematic pseudocysts of the adrenal gland. Apropos of a case] La Fay T, et al. **J Chir (Paris)** 1996;133(8):396–400

(26 ref.) (Eng. Abstr.) **(Fre)**

[Adrenal cysts. Description of a clinical case] Bononi M, et al. **Minerva Chir** 1997 Jan-Feb;52(1-2):117-21 (Eng. Abstr.) **(Ita)**

[Diagnosis, surgical treatment and prognosis in endocrine hypertension of adrenal origin] Shkrob OS, et al. **Khirurgiia (Mosk)** 1996;(3):17-23 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

An assessment of optimal hydrocortisone replacement therapy [see comments] Howlett TA. **Clin Endocrinol (Oxf)** 1997 Mar;46(3):263-8. Comment in: Clin Endocrinol (Oxf) 1997 Mar;46(3):269-70.

The assessment of glucocorticoid replacement therapy [comment] Monson JP. **Clin Endocrinol (Oxf)** 1997 Mar; 46(3):269-70. Comment on: Clin Endocrinol (Oxf) 1997 Mar;46(3):255-61. Comment on: Clin Endocrinol (Oxf) 1997 Mar;46(3):263-8.

Glucocorticoid replacement therapy: are patients over treated and does it matter? [see comments] Peacey SR, et al. **Clin Endocrinol (Oxf)** 1997 Mar;46(3):255-61. Comment in: Clin Endocrinol (Oxf) 1997 Mar;46(3):269-70.

ETIOLOGY

Bilateral adrenal hemorrhage and acute addisonian crisis--a complication of antiphospholipid syndrome. Garris GW, et al. **J Tenn Med Assoc** 1996 Apr;89(4):120

Adrenobronchial fistula complicating a neonatal adrenal abscess: treatment by percutaneous aspiration and antibiotics. Pointe HD, et al. **Pediatr Radiol** 1997 Feb; 27(2):184-5

Adrenal insufficiency from bilateral adrenal hemorrhage after total knee replacement surgery. Cozzolino D, et al. **Urology** 1997 Jul;50(1):125-7

[Unilateral spontaneous adrenal hematoma during the postpartum period. Apropos of a case] Badaoui R, et al. **Cah Anesthesiol** 1996;44(4):369-71 (17 ref.) (Eng. Abstr.) **(Fre)**

[Renal and adrenal involvement in von Hippel-Lindau disease: clinical features and therapeutic strategies] Chassagne S, et al. **Prog Urol** 1996 Dec;6(6):878-83 (Eng. Abstr.) **(Fre)**

[Acute adrenal gland insufficiency and disseminated tuberculosis (letter)] Medraño Martínez JC, et al. **Rev Clin Esp** 1997 Mar;197(3):212 **(Spa)**

GENETICS

Adrenocorticotropin receptor and adrenal disorders. Allolio B, et al. **Horm Res** 1997;47(4-6):273-8 (42 ref.)

New frameshift mutation in the DAX-1 gene in a patient with X-linked adrenal hypoplasia and hypogonadotropic hypogonadism. Meloni A, et al. **Hum Mutat** 1996; 8(2):183-4

MICROBIOLOGY

Bilateral isolated adrenal coccidioidomycosis. Papadopoulos KI, et al. **J Intern Med** 1996 Mar;239(3):275-8

PATHOLOGY

Adrenal histoplasmosis: diagnosis by fine-needle aspiration biopsy. Deodhare S, et al. **Diagn Cytopathol** 1997 Jul; 17(1):42-4

Vascular adrenal cysts: a clinicopathologic and immunohistochemical study of six cases and a review of the literature. Torres C, et al. **Mod Pathol** 1997 Jun; 10(6):530-6 (52 ref.)

[Usefulness of the modified Dixon technique associated with gadolinium administration in the characterization of adrenal masses] Boraschi P, et al. **Radiol Med (Torino)** 1997 Mar; 93(3):218-24 (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Depression and endocrine disorders: focus on the thyroid and adrenal system. Musselman DL, et al. **Br J Psychiatry Suppl** 1996 Jun;(30):123-8 (73 ref.)

Clinical significance of cortisone and cortisone/cortisol ratio in evaluating children with adrenal diseases. Nomura S, et al. **Clin Chim Acta** 1996 Dec 9;256(1):1-11

RADIOGRAPHY

Using CT to evaluate the acute abdomen: spectrum of urinary pathology. Johnson GL, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):273-6

A patient with haemoptysis, rapidly changing pulmonary infiltrates and left flank pain. Lai YP, et al. **Eur Respir J** 1996 Oct;9(10):2184-7

Cystic adrenal lesions: CT features. Rozenblit A, et al. **Radiology** 1996 Nov;201(2):541-8

[Kidneys and adrenal glands] Roy C, et al. **J Radiol** 1997 Mar;78(3 Suppl):36-7 **(Fre)**

[Adrenal gland hemorrhage in neonates--radiologic aspects] Smoljanić Z, et al. **Srp Arh Celok Lek** 1997 Sep-Oct; 125(9-10):295-8 (Eng. Abstr.) **(Scc)**

RADIONUCLIDE IMAGING

Metabolic and pharmacokinetic considerations in the design of 2-phenyl substituted metyrapone derivatives: 2-methoxyphenylmetyrapone as a radioligand for functional diagnosis of adrenal pathology. Damani LA, et al. **Nucl Med Biol** 1995 Nov;22(8):1067-74

SURGERY

Anterior, posterior, or laparoscopic approach for the management of adrenal diseases? Linos DA, et al. **Am J Surg** 1997 Feb;173(2):120-5

Decision to resect an adrenal mass depends on size of mass and age of patient [letter; comment] Sharma AK, et al. **BMJ** 1997 Jan 18;314(7075):229-30. Comment on: BMJ 1996 Oct 5;313(7061):872-3.

Laparoscopic trans-peritoneal adrenalectomy: a preliminary report of 14 adrenalectomies. Walmsley D, et al. **Clin Endocrinol (Oxf)** 1996 Aug;45(2):141-5

Laparoscopic adrenalectomy: history, indications, and current techniques for a minimally invasive approach to adrenal pathology. Hansen P, et al. **Endoscopy** 1997 May; 29(4):309-14 (20 ref.)

Laparoscopic unroofing of adrenal cysts. Guazzoni G, et al. **Eur Urol** 1997;31(4):499-502

Videoendoscopic adrenalectomy: multicentric study from the Belgian Group for Endoscopic Surgery (BGES). De Cannière L, et al. **Int Surg** 1996 Jan-Mar;81(1):6-8

Laparoscopic adrenalectomy via the retroperitoneal approach: first five cases. Ono Y, et al. **J Endourol** 1996 Aug;10(4):361-5

A comparison of open vs laparoscopic adrenalectomy. MacGillivray DC, et al. **Surg Endosc** 1996 Oct; 10(10):987-90

Operative experience of U.S. general surgery residents with diseases of the adrenal glands, endocrine pancreas, and other less common endocrine organs. Harness JK, et al. **World J Surg** 1996 Sep;20(7):885-90; discussion 890-1

[Adrenal gland resection with laparoscopy or lumboscopy. The Paris experience] Chapuis Y, et al. **Chirurgie** 1997; 122(2):106-10 (Eng. Abstr.) **(Fre)**

[Hemorrhagic pseudocyst of the adrenal gland: a case report] Bonati L, et al. **G Chir** 1997 May;18(5):286-9 (Eng. Abstr.) **(Ita)**

[Diagnosis, surgical treatment and prognosis in endocrine hypertension of adrenal origin] Shkrob OS, et al. **Khirurgiia (Mosk)** 1996;(3):17-23 (Eng. Abstr.) **(Rus)**

THERAPY

Giant adrenal cyst: management and review of the literature. Tagge DU, et al. **Am Surg** 1997 Aug;63(8):744-6 (17 ref.)

Nonclassic adrenal hyperplasia. Azziz R. **Curr Ther Endocrinol Metab** 1997;6:175-8 (6 ref.)

Outcome of incidental adrenal masses not operated on: 44 cases over 7 years [letter; comment] Courtade A, et al. **Eur J Surg** 1997 Apr;163(4):315. Comment on: Eur J Surg 1996 Apr;162(4):275-8.

Neonatal adrenal abscesses. Steffens J, et al. **Eur Urol** 1997; 31(3):347-9

Large adrenal cysts in teenage girls: diagnosis and management. Broadley P, et al. **Pediatr Radiol** 1997 Jun; 27(6):550-2

ULTRASONOGRAPHY

Early detection of neonatal adrenal hemorrhage by ultrasonography. Chein CL, et al. **Acta Paediatr Sin** 1996 Mar-Apr;37(2):128-32

Prenatal sonographic diagnosis of fetal adrenal gland hemorrhage. Vollersen E, et al. **Fetal Diagn Ther** 1996 Jul-Aug;11(4):286-91

The role of ultrasound tomography in diagnosing adrenal pathology. Nedeva A, et al. **Folia Med (Plovdiv)** 1996; 38(2):31-7

Fetal adrenal hemorrhage in a diamniotic, dichorionic twin: case report and review of controversies in diagnosis and management. Rahman S, et al. **J Ultrasound Med** 1997 Apr; 16(4):297-300

Scrotal hematoma due to neonatal adrenal hemorrhage: the value of ultrasonography in avoiding unnecessary surgery. Miele V, et al. **Pediatr Radiol** 1997 Aug;27(8):672-4

VETERINARY

Adrenal disorders in cats. Duesberg C, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):321-47 (92 ref.)

Adrenal gland disease in ferrets. Rosenthal KL. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):401-18 (24 ref.)

Imaging of adrenal gland disorders. Tidwell AS, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):237-54 (47 ref.)

Adrenal ultrasonography correlated with histopathology in ferrets. Neuwirth L, et al. **Vet Radiol Ultrasound** 1997 Jan-Feb;38(1):69-74

ADRENAL GLAND HYPERFUNCTION

see related

HYPERANDROGENISM

[Pre- and postsurgical treatment condition of cardiovascular and endocrine systems in patients with endogenic hypercorticism] Shustov SV, et al. **Klin Med (Mosk)** 1996; 74(7):33-6 **(Rus)**

BLOOD

Lack of an ovarian function influence on the increased adrenal androgen secretion present in women with functional ovarian hyperandrogenism. Escobar-Morreale HF, et al. **Fertil Steril** 1997 Apr;67(4):654-62

CONGENITAL see ADRENAL HYPERPLASIA, CONGENITAL

ENZYMOLOGY

Apparent cortisone reductase deficiency: a unique form of hypercortisolism. Phillipov G, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):3855-60

ETIOLOGY

Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved [editorial] Rosenfield RL. **J Clin Endocrinol Metab** 1996 Mar;81(3):878-80 (29 ref.)

PHYSIOPATHOLOGY

The relationship of endogenous cortisol to psychiatric disorder: a review. Kiraly SJ, et al. **Can J Psychiatry** 1997 May;42(4):415-20 (85 ref.)

RADIONUCLIDE IMAGING

[The use of dynamic renal scintigraphy for studying kidney functional disorders in patients with different forms of hypercorticism] Komissarenko IV, et al. **Lik Sprava** 1996 Jul-Sep;(7-9):70-4 (Eng. Abstr.) **(Rus)**

SURGERY

Persistent and recurrent hypercortisolism after transsphenoidal surgery for Cushing's disease. Knappe UJ, et al. **Acta Neurochir Suppl (Wien)** 1996;65:31-4

Role and operative risk of bilateral adrenalectomy in hypercortisolism. Chapuis Y, et al. **World J Surg** 1996 Sep; 20(7):775-9; discussion 779-80

VETERINARY

Use of low- and high-dose dexamethasone tests for distinguishing pituitary-dependent from adrenal tumor hyperadrenocorticism in dogs. Feldman EC, et al. **J Am Vet Med Assoc** 1996 Aug 15;209(4):772-5

Use of the urine cortisol: creatinine ratio to monitor treatment response in dogs with pituitary-dependent hyperadrenocorticism. Guptill L, et al. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1158-61

Medical management of a full-thickness tear of the retroperitoneal portion of the rectum in a horse with hyperadrenocorticism. Mazan MR. **J Am Vet Med Assoc** 1997 Mar 1;210(5):665-7

Systemic arterial blood pressure and urine protein/creatinine ratio in dogs with hyperadrenocorticism. Ortega TM, et al. **J Am Vet Med Assoc** 1996 Nov 15;209(10):1724-9

Evaluation of plasma androgen and estrogen concentrations in ferrets with hyperadrenocorticism. Rosenthal KL, et al. **J Am Vet Med Assoc** 1996 Sep 15;209(6):1097-102

Evaluation of the urinary cortisol: creatinine ratio in the diagnosis of hyperadrenocorticism in dogs. Jensen AL, et al. **J Small Anim Pract** 1997 Mar;38(3):99-102

Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. Couëtil L, et al. **J Vet Intern Med** 1996 Jan-Feb;10(1):1-6

Management of canine pituitary-dependent hyperadrenocorticism with l-deprenyl (Anipryl). Bruyette DS, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):273-86 (34 ref.)

Diagnosis of canine hyperadrenocorticism. Guptill L, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):215-35 (74 ref.)

Complications and concurrent disease associated with canine hyperadrenocorticism. Nichols R. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):309-20 (50 ref.)

Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane. Peterson ME, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):255-72 (37 ref.)

Urinary corticoid/creatinine ratios in the differentiation between pituitary-dependent hyperadrenocorticism and hyperadrenocorticism due to adrenocortical tumour in the dog. Galac S, et al. **Vet Q** 1997 Mar;19(1):17-20

Transsphenoidal hypophysectomy in beagle dogs: evaluation of a microsurgical technique. Meij BP, et al. **Vet Surg** 1997 Jul-Aug;26(4):295-309

[Hyperadrenocorticism in ferrets] Lumeij JT. **Tijdschr Diergeneeskd** 1997 Mar 1;122(5):146-7 **(Dut)**

ADRENAL GLAND HYPOFUNCTION

Adrenal insufficiency [see comments] Oelkers W. **N Engl J Med** 1996 Oct 17;335(16):1206-12 (43 ref.). Comment in: N Engl J Med 1997 Apr 10;336(15):1105; discussion 1106-7. Comment in: N Engl J Med 1997 Apr 10;336(15):1105-6; discussion 1106-7. Comment in: N Engl J Med 1997 Apr 10;336(15):1106; discussion 1106-7.

[Adrenal insufficiency in childhood] Casado de Frías E. **An R Acad Nac Med (Madr)** 1996;113(2):263-74; discussion, 275-7 **(Spa)**

[Allgrove syndrome (achalasia-alacrima-adrenal gland

insufficiency): report of a case] Chávez M, et al. **Rev Gastroenterol Peru** 1996 May-Aug;16(2):153-7 (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Potential adverse endocrine effects of inhaled corticosteroids. Batch JA. **J Paediatr Child Health** 1996 Aug;32(4):278-80 (32 ref.)

COMPLICATIONS

Autoimmune hemolytic anemia, primary adrenal insufficiency, and the antiphospholipid syndrome. Hsu B, et al. **Am J Med Sci** 1997 Jul;314(1):41-3

Hyperkalemia and trimethoprim-sulfamethoxazole [letter; comment] [published erratum appears in Ann Intern Med 1996 Dec 15;125(12):1015] Ougorets I, et al. **Ann Intern Med** 1996 Nov 1;125(9):779; discussion 779-80 . Comment on: Ann Intern Med 1996 Feb 1;124(3):316-20.

Adrenal insufficiency, recurrent bacteremia, and disseminated abscesses caused by Nocardia asteroides in a patient with acquired immunodeficiency syndrome. Arabi Y, et al. **Diagn Microbiol Infect Dis** 1996 Jan;24(1):47-51

Confusion after visiting the radiology department. Devendra D, et al. **Lancet** 1997 Sep 13;350(9080):780

Adrenal insufficiency in the antiphospholipid-antibody syndrome [letter; comment] Asherson RA. **Semin Arthritis Rheum** 1996 Aug;26(1):502-3. Comment on: Semin Arthritis Rheum 1995 Oct;25(2):109-16.

[Treatment of adrenal diseases using transplantation of cultured adrenal tissue from newborn piglets] Egorov IuI, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):389-91 **(Rus)**

[Calcification of the ear cartilages in a patient with kidney insufficiency: report of a new case (letter)] Miramón López J, et al. **An Med Interna** 1997 Feb;14(2):105-6 **(Spa)**

CONGENITAL

DAX-1 gene mutations and deletions in Japanese patients with adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Kinoshita E, et al. **Horm Res** 1997; 48(1):29-34

Active hypothalamic-pituitary-gonadal axis in an infant with X-linked adrenal hypoplasia congenita. Takahashi T, et al. **J Pediatr** 1997 Mar;130(3):485-8

DIAGNOSIS

Short synacthen test versus insulin stress test for the assessment of the hypothalamo-pituitary axis: controversy revisited again [letter; comment] Hockings GI, et al. **Clin Endocrinol (Oxf)** 1997 Jun;46(6):775-6. Comment on: Clin Endocrinol (Oxf) 1996 Feb;44(2):141-6. Comment on: Clin Endocrinol (Oxf) 1996 Feb;44(2):147-9.

A case of adrenal insufficiency due to acquired hypothalamic CRH deficiency. Nishihara E, et al. **Endocr J** 1997 Feb; 44(1):121-6

A case of initially undiagnosed hypoadrenalism presenting inappropriate secretion of anti-diuretic hormone. Sakurai A, et al. **Endocr J** 1995 Dec;42(6):811-5

Prenatal diagnosis of congenital adrenal hypoplasia. Peter M, et al. **Horm Res** 1996 Jul;46(1):41-5

Eosinophilia as a marker of adrenal insufficiency in the surgical intensive care unit. Angelis M, et al. **J Am Coll Surg** 1996 Dec;183(6):589-96

Adrenal insufficiency in India [letter] Sridhar GR. **J Assoc Physicians India** 1996 Apr;44(4):287-8

Low dose ACTH test--a word of caution [letter; comment] [see comments] Cohen O, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):3129-30. Comment on: J Clin Endocrinol Metab 1995 Apr;80(4):1301-5. Comment in: J Clin Endocrinol Metab 1997 Jan;82(1):322.

The potential for serious consequences from misinterpretation of normal responses to the rapid adrenocorticotropin test [letter; comment] Koshiyama H. **J Clin Endocrinol Metab** 1996 Nov;81(11):4176. Comment on: J Clin Endocrinol Metab 1996 Jan;81(1):285-90.

Secondary adrenocortical insufficiency: avoiding potentially fatal pitfalls in diagnosis and treatment [editorial] Hockings GI, et al. **Med J Aust** 1997 Apr 21;166(8):400-1 (16 ref.)

Adrenal insufficiency [letter; comment] Bromberg JS. **N Engl J Med** 1997 Apr 10;336(15):1105; discussion 1106-7 . Comment on: N Engl J Med 1996 Oct 17;335(16):1206-12.

[Isolated ACTH deficiency associated with partially empty sella turcica (letter)] Armengou A, et al. **Med Clin (Barc)** 1997 Apr 12;108(14):557-8 **(Spa)**

DRUG THERAPY

[Perioperative administration of adrenal cortex hormones] Briegel J. **Anaesthesist** 1997 Jan;46(1):57-8 **(Ger)**

[Therapy refractory arterial hypotension after heart operation] Frenzel K, et al. **Klin Padiatr** 1997 Jan-Feb; 209(1):36-8 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency. Flad TM, et al. **Clin Endocrinol (Oxf)** 1996 Nov;45(5):529-34

ETIOLOGY

Acute adrenal insufficiency after coronary artery bypass grafting [letter; comment] Fink D, et al. **Ann Thorac Surg** 1997 Aug;64(2):589-90. Comment on: Ann Thorac Surg 1996 Nov;62(5):1516-7.

Acute adrenal insufficiency after coronary artery bypass grafting [see comments] Sutherland FW, et al. **Ann Thorac Surg** 1996 Nov;62(5):1516-7 (8 ref.). Comment in: Ann Thorac Surg 1997 Aug;64(2):589-90.

Primary adrenal insufficiency following traumatic brain injury: a case report and review of the literature. Webster JB, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3):314-8 (22 ref.)

Corticotrophic macroadenoma of the pituitary associated with hypoadrenalism. Peacock I, et al. **Clin Endocrinol (Oxf)** 1997 Jun;46(6):765-8

A comparison of the adrenocortical response during septic shock and after complete recovery. Briegel J, et al. **Intensive Care Med** 1996 Sep;22(9):894-9

Adrenal insufficiency in India [letter] Sridhar GR. **J Assoc Physicians India** 1996 Jun;44(6):431

Autoimmune hepatitis and adrenal insufficiency in an infant with human herpesvirus-6 infection [letter] Schmitt K, et al. **Lancet** 1996 Oct 5;348(9032):966

Adrenal insufficiency as a manifestation of disseminated non-Hodgkin's lymphoma. Levy NT, et al. **Mayo Clin Proc** 1997 Sep;72(9):818-22

Secondary adrenocortical insufficiency: avoiding potentially fatal pitfalls in diagnosis and treatment [editorial] Hockings GI, et al. **Med J Aust** 1997 Apr 21;166(8):400-1 (16 ref.)

Adrenal insufficiency [letter; comment] Pepper GM. **N Engl J Med** 1997 Apr 10;336(15):1106; discussion 1106-7 . Comment on: N Engl J Med 1996 Oct 17;335(16):1206-12.

Adrenal insufficiency from bilateral adrenal hemorrhage after total knee replacement surgery. Cozzolino D, et al. **Urology** 1997 Jul;50(1):125-7

[A rare cause of adrenal cortex insufficiency] Kreysel C, et al. **Internist (Berl)** 1996 May;37(5):511-4 **(Ger)**

[Compression of the appendix cerebri in the sella turcica in critical states as a possible cause of acute adrenocortical insufficiency] Medvedev IuA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Apr-Jun; (2):17-21 (Eng. Abstr.) **(Rus)**

[Adrenal mass and adrenal insufficiency] Martínez Albaladejo M, et al. **An Med Interna** 1996 Dec;13(12):595-7 (Eng. Abstr.) **(Spa)**

GENETICS

Three A's and a wedding [editorial; comment] Bodurtha J. **Clin Pediatr (Phila)** 1996 Feb;35(2):101-2. Comment on: Clin Pediatr (Phila) 1996 Feb;35(2):99-100.

Adrenal insufficiency after achalasia in the triple-A syndrome [see comments] Phillip M, et al. **Clin Pediatr (Phila)** 1996 Feb;35(2):99-100. Comment in: Clin Pediatr (Phila) 1996 Feb;35(2):101-2.

The expanding world of primary adrenal insufficiencies [comment] Aubourg P. **Eur J Endocrinol** 1997 Jul; 137(1):10-2. Comment on: Eur J Endocrinol 1997 Jul;137(1):34-9. Comment on: Eur J Endocrinol 1997 Jul;137(1):40-7.

Endocrine disorders in septo-optic dysplasia (De Morsier syndrome)--evaluation and follow up of 18 patients. Willnow S, et al. **Eur J Pediatr** 1996 Mar;155(3):179-84

DAX-1 gene mutations and deletions in Japanese patients with adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Kinoshita E, et al. **Horm Res** 1997; 48(1):29-34

X-linked adrenal hypoplasia in a large Greenlandic family. Detection of a missense mutation (N440I) in the DAX-1 gene; implication for genetic counselling and carrier diagnosis. Schwartz M, et al. **Hum Genet** 1997 Jan; 99(1):83-7

Linkage of the gene for the triple A syndrome to chromosome 12q13 near the type II keratin gene cluster. Weber A, et al. **Hum Mol Genet** 1996 Dec;5(12):2061-6

Truncation at the C-terminus of the DAX-1 protein impairs its biological actions in patients with X-linked adrenal hypoplasia congenita. Nakae J, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3680-5

Identification of a large-scale mitochondrial deoxyribonucleic acid deletion in endocrinopathies and deafness: report of two unrelated cases with diabetes mellitus and adrenal insufficiency, respectively. Nicolino M, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3063-7

Active hypothalamic-pituitary-gonadal axis in an infant with X-linked adrenal hypoplasia congenita. Takahashi T, et al. **J Pediatr** 1997 Mar;130(3):485-8

DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita. Ito M, et al. **Mol Cell Biol** 1997 Mar; 17(3):1476-83

METABOLISM

A comparison of the adrenocortical response during septic shock and after complete recovery. Briegel J, et al. **Intensive Care Med** 1996 Sep;22(9):894-9

PATHOLOGY

Isolated adrenocorticotropic hormone deficiency: an autopsy case of adrenal crisis. A case report. Kubo S, et al. **Am J Forensic Med Pathol** 1997 Jun;18(2):202-5

PHYSIOPATHOLOGY

Osmoregulation of plasma vasopressin in three cases with adrenal insufficiency of diverse etiologies. Iwasaki Y, et al. **Horm Res** 1997;47(1):38-44

Occurrence of adrenocortical insufficiency in adrenomyeloneuropathy. Brennemann W, et al. **Neurology** 1996 Aug;47(2):605

A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Glowniak JV, et al. **Surgery** 1997 Feb;121(2):123-9

[The activity of the enkephalinergic systems of the brain and hypophysis in experimental hypocorticism] Kalyns'ka LM, et al. **Fiziol Zh** 1995 Sep-Dec;41(5-6):61-6 (Eng. Abstr.) **(Ukr)**

PREVENTION & CONTROL

The role of ascorbic acid and xylitol in etomidate-induced adrenocortical suppression in humans. Schraag S, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):346-51

THERAPY

Adrenal insufficiency. Malchoff CD, et al. **Curr Ther Endocrinol Metab** 1997;6:142-7 (5 ref.)

Treatment of adrenocortical insufficiency. August GP. **Pediatr Rev** 1997 Feb;18(2):59-62 (6 ref.)

VETERINARY

Hypoadrenocorticism in young related Nova Scotia duck tolling retrievers. Burton S, et al. **Can Vet J** 1997 Apr; 38(4):231-4

Glucocorticoid deficient hypoadrenocorticism in dogs: 18 cases (1986-1995). Lifton SJ, et al. **J Am Vet Med Assoc** 1996 Dec 15;209(12):2076-81

Diagnosis and treatment of naturally occurring hypoadrenocorticism in 42 dogs. Melián C, et al. **J Small Anim Pract** 1996 Jun;37(6):268-75

Treatment and long-term follow-up of 205 dogs with hypoadrenocorticism. Kintzer PP, et al. **J Vet Intern Med** 1997 Mar-Apr;11(2):43-9

Primary and secondary canine hypoadrenocorticism. Kintzer PP, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):349-57 (21 ref.)

ADRENAL GLAND NEOPLASMS

Adrenal carcinoma. Wrenn K. **Am J Med** 1996 Nov; 101(5):565

An unusual case of spontaneous rupture of a clinically "silent" phaeochromocytoma. Sapienza P, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):717-20 (24 ref.)

Bilateral recurrent phaeochromocytoma associated with a growth hormone-secreting pituitary tumour. Teh BT, et al. **Br J Surg** 1996 Aug;83(8):1132

Clinical, radiological and histological features of adrenal myelolipoma: review and experience with a further eight cases. El-Mekresh MM, et al. **Br J Urol** 1996 Sep; 78(3):345-50 (46 ref.)

Diagnosis and management of pheochromocytoma. Kenady DE, et al. **Curr Opin Oncol** 1997 Jan;9(1):61-7 (21 ref.)

Phaeochromocytoma in Northern Ireland: a 21 year review. Beatty OL, et al. **Eur J Surg** 1996 Sep;162(9):695-702 (41 ref.)

Idiopathic hyperplasia of the adrenal gland behaving like an aldosterone producing adenoma. Rao A, et al. **J Endocrinol Invest** 1997 Jan;20(1):29-31

Pheochromocytoma: study of 50 cases. Lucon AM, et al. **J Urol** 1997 Apr;157(4):1208-12

Perirenal myelolipoma. Wagner JR, et al. **Urology** 1997 Jan; 49(1):128-30

Adrenocortical oncocytoma: two case reports and review of literature. Waters PR, et al. **Urology** 1997 Apr; 49(4):624-8 (14 ref.)

[Adrenal myelolipoma: a case (letter)] Daali M, et al. **Presse Med** 1997 Mar 1;26(6):272 **(Fre)**

[Incidentaloma of the adrenal gland. A clinical case] Letizia C, et al. **Minerva Endocrinol** 1997 Jun;22(2):45-50 (Eng. Abstr.) **(Ita)**

[Pheochromocytoma] Satoh A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):11-4 (16 ref.) **(Jpn)**

[Cystic lymphangioma of the adrenal gland in adults. Review of the literature and report of a new case] Alapont Pérez FM, et al. **Actas Urol Esp** 1996 Sep;20(8):739-42 (12 ref.) (Eng. Abstr.) **(Spa)**

[Cesarean section in pregnancy with undiagnosed pheochromocytoma (letter)] Tortosa JA, et al. **Rev Esp Anestesiol Reanim** 1996 May;43(5):191-2 **(Spa)**

BLOOD

Phenoxybenzamine placental transfer during the third trimester. Santeiro ML, et al. **Ann Pharmacother** 1996 Nov; 30(11):1249-51

Plasma endothelin-1 levels in patients with aldosterone-producing adenoma and pheochromocytoma. Letizia C, et al. **Clin Exp Hypertens** 1996 Oct;18(7):921-31

Serum levels of dehydroepiandrosterone sulfate in patients with asymptomatic cortisol producing adrenal adenoma: comparison with adrenal Cushing's syndrome and

non-functional adrenal tumor. Morio H, et al. **Endocr J** 1996 Aug;43(4):387-96

Plasma dehydroepiandrosterone sulfate levels in patients with hyperfunctioning and non-hyperfunctioning adrenal tumors before and after adrenal surgery. Tóth M, et al. **Eur J Endocrinol** 1997 Mar;136(3):290-5

17-Hydroxyprogesterone response to ACTH in bilateral and monolateral adrenal incidentalomas. Bernini GP, et al. **J Endocrinol Invest** 1996 Dec;19(11):745-52

Plasma erythropoietin concentration in patients with pheochromocytoma [letter] Januszewicz A, et al. **J Hum Hypertens** 1996 Jul;10(7):497-8

BLOOD SUPPLY

Tumor angiogenesis in pheochromocytomas and paragangliomas. Liu Q, et al. **Surgery** 1996 Dec; 120(6):938-42; discussion 942-3

CHEMISTRY

Immunoreactive adrenomedullin in human adrenal glands and adrenal tumors. Satoh F, et al. **Cancer Detect Prev** 1997;21(1):51-4

Immunohistochemical identification and comparison of glial cell lineage in foetal, neonatal, adult and neoplastic human adrenal medulla. Magro G, et al. **Histochem J** 1997 Apr; 29(4):293-9

Preclinical Cushing's syndrome: report of four cases and analysis of steroid contents in adenomas. Morioka M, et al. **Horm Res** 1996;46(3):117-23

Evaluation of hormonal function in a series of incidentally discovered adrenal masses. Bondanelli M, et al. **Metabolism** 1997 Jan;46(1):107-13

Human pheochromocytoma: different patterns of catecholamines and chromogranins in the intact tumour, urine and serum in clinically unsuspected cases. Aardal S, et al. **Scand J Clin Lab Invest** 1996 Oct;56(6):511-23

[Gamma interferon-like immunoreactivity in adrenal gland and cortical tumor] Li Q, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Dec;24(6):372-4 (Eng. Abstr.) **(Chi)**

[The biological diagnosis of pheochromocytoma] Mornex R, et al. **Bull Mem Acad R Med Belg** 1996;151(3-4):269-77; discussion 277-80 (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Spontaneous retroperitoneal hemorrhage due to adrenal metastasis for non-small cell lung cancer treated by radiation therapy. Berney CR, et al. **Acta Oncol** 1997; 36(1):91-3 (25 ref.)

Retroperitoneal hemorrhage due to a ruptured adrenal myelolipoma. A case report. Catalano O. **Acta Radiol** 1996 Sep;37(5):688-90 (30 ref.)

Symptomatic leiomyoma of the adrenal gland in a woman with AIDS. Parola P, et al. **AIDS** 1996 Mar;10(3):340-1

Fibromuscular dysplasia of the renal artery and adrenal adenoma in a 36-year-old woman with hypertension. Mattix H, et al. **Am J Med Sci** 1997 Jul;314(1):51-3

Subclinical Cushing's syndrome due to adrenal myelolipoma. Boronat M, et al. **Arch Pathol Lab Med** 1997 Jul; 121(7):735-7

Primary adrenal leiomyosarcoma in acquired immunodeficiency syndrome [letter; comment] Dugan MC. **Arch Pathol Lab Med** 1996 Sep;120(9):797-8. Comment on: Arch Pathol Lab Med 1995 Dec;119(12):1164-7.

Adrenal carcinoma and hypertension presenting with catatonic stupor. Steinberg P. **Aust N Z J Psychiatry** 1996 Feb;30(1):146-9

Pheochromocytoma and primary aldosteronism. Young WF Jr. **Cancer Treat Res** 1997;89:239-61 (74 ref.)

Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Rossi GP, et al. **Circulation** 1997 Mar 18;95(6):1471-8

Molecular diagnosis of von Hippel-Lindau disease in a kindred with a predominance of familial pheochromocytoma. Garcia A, et al. **Clin Endocrinol (Oxf)** 1997 Mar;46(3):359-63

Adrenal tumour associated with silent 21-hydroxylase deficiency in a male [letter; comment] Nagasaka S, et al. **Clin Endocrinol (Oxf)** 1997 May;46(5):644. Comment on: Clin Endocrinol (Oxf) 1996 Jan;44(1):111-6. Comment on: Clin Endocrinol (Oxf) 1996 Sep;45(3):369-70.

Postoperative acute pulmonary edema: a rare presentation of pheochromocytoma. Fahmy N, et al. **Clin Nephrol** 1997 Aug;48(2):122-4

Diabetic ketoacidosis associated with the pheochromocytoma of youth. Isotani H, et al. **Diabetes Res Clin Pract** 1996 Sep;34(1):57-60

Adrenal masses in patients with familial adenomatous polyposis. Marchesa P, et al. **Dis Colon Rectum** 1997 Sep; 40(9):1023-8

Normotensive bilateral pheochromocytoma with Lindau disease: case report. Otsuka F, et al. **Endocr J** 1996 Dec; 43(6):719-23

Spontaneous remission of ectopic Cushing's syndrome due to pheochromocytoma: a case report. Loh KC, et al. **Eur J Endocrinol** 1996 Oct;135(4):440-3

Myocardial infarction as a complication of pheochromocytoma in a pregnant woman. Hamada S, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec 27; 70(2):197-200

Severe hypokalaemia due to hyperreninaemia and secondary hyperaldosteronism in a boy with pheochromocytoma [letter] Göpel W, et al. **Eur J Pediatr** 1996 Feb;155(2):147-8

Fulminant acute Budd-Chiari syndrome stemming from an adrenal tumor. Moreira V, et al. **J Clin Gastroenterol** 1997 Mar;24(2):110-2 (14 ref.)

Pheochromocytoma and bowel ischemia. Salehi A, et al. **J Emerg Med** 1997 Jan-Feb;15(1):35-8

Treatment with intravenously administered immunoglobulins of the neuroblastoma-associated opsoclonus-myoclonus [letter; comment] Borgna-Pignatti C, et al. **J Pediatr** 1996 Jul;129(1):179-80. Comment on: J Pediatr 1995 Aug;127(2):328-9.

Systemic lupus erythematosus and pheochromocytoma [letter] Mader R, et al. **J Rheumatol** 1996 Aug;23(8):1480-1

A pheochromocytoma in a cadaver kidney donor: to transplant or not to transplant? Abdalla AH, et al. **Nephrol Dial Transplant** 1996 Oct;11(10):2080-2

Five ways to be fooled by phaeochromocytoma--renal and urological complications. Crowe AV, et al. **Nephrol Dial Transplant** 1997 Feb;12(2):337-40

Clinical quiz. Left perirenal phaeochromocytoma and left upper pole renal artery stenosis. Combined excision of tumor and left total nephroadrenalectomy, after full alpha- and beta-adrenergic blockade was achieved. Eason JD, et al. **Pediatr Nephrol** 1996 Dec;10(6):804-7

Atrial septal defect and phaeochromocytoma: a diagnostic conundrum. McFarlane HJ. **Scott Med J** 1996 Jun; 41(3):90-1

Left ventricular myxoma, adrenal tumour and cutaneous vasculitis--a case report [letter; comment] Rajasoorya C. **Singapore Med J** 1996 Apr;37(2):233-4. Comment on: Singapore Med J 1995 Jun;36(3):328-30.

Adrenal failure due to metastasis both to the hypothalamic-pituitary area and the adrenals. Trincado P, et al. **Tumori** 1996 Jul-Aug;82(4):401-4

Adrenal myelolipoma with abdominal pain. Kobayashi T, et al. **Urol Int** 1997;58(4):254-6 (9 ref.)

[Aldosterone precursors and hypertension with hypokalemia and adrenal module non caused by primary hyperaldosteronism] Chamontin B, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89(8):1055-8 (Eng. Abstr.) **(Fre)**

[Cardiomyopathy induced by catecholamines in neuroblastoma] Joseph T, et al. **Arch Pediatr** 1997 Jan; 4(1):32-5 (Eng. Abstr.) **(Fre)**

[Spontaneous retroperitoneal hematoma in adrenal metastasis] Tappe U, et al. **Dtsch Med Wochenschr** 1997 Apr 11; 122(15):471-4 (Eng. Abstr.) **(Ger)**

[Splenic infarct, lactate acidosis, and pulmonary edema as manifestations of a pheochromocytoma] Bischof T, et al. **Schweiz Med Wochenschr** 1997 Feb 15;127(7):261-5 (Eng. Abstr.) **(Ger)**

[Case of pheochromocytoma with crisis of diabetic ketoacidosis] Hashida H, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1928-30 **(Jpn)**

[Case of renovascular hypertension with pheochromocytoma] Kawana K, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):110-2 **(Jpn)**

[Bilateral non-Hodgkin's lymphoma of the adrenal glands with adrenal insufficiency] Takahashi T, et al. **Rinsho Ketsueki** 1996 Sep;37(9):867-9 (Eng. Abstr.) **(Jpn)**

[Addison's disease as the first manifestation of bilateral suprarenal tumor (letter; comment)] Chocarro Martínez A, et al. **An Med Interna** 1996 Sep;13(9):464-5. Comment on: An Med Interna 1995 Dec;12(12):619-20. **(Spa)**

[Malignant bilateral pheochromocytoma and von Recklinghausen disease] Martín Huéscar A, et al. **Arch Esp Urol** 1996 Jul-Aug;49(6):627-9 (Eng. Abstr.) **(Spa)**

[37-year-old woman with Cushing's syndrome and progressive dyspnea of 1-year evolution (clinical conference)] Agustí AG, et al. **Med Clin (Barc)** 1997 Jan 25;108(3):109-16 **(Spa)**

CONGENITAL

Bronchopulmonary foregut malformation mimicking neuroblastoma. Fenton LZ, et al. **Pediatr Radiol** 1996 Oct; 26(10):729-30

DIAGNOSIS

Change in the composition of adrenal nodules after therapy as revealed by opposed-phase MR imaging. Kainz G, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):549-50

Comparison of two algorithms and their associated charges when evaluating adrenal masses in patients with malignancies. Schwartz LH, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1575-8

Fluoxetine's effect on biochemical screening for pheochromocytoma [letter] Sheps SG, et al. **Am J Hypertens** 1996 Jan;9(1):97-8

Evaluation of the incidental adrenal mass [letter] Lee JE, et al. **Am J Med** 1997 Sep;103(3):249-50

Incidentalomas of the adrenal gland: diagnostic and therapeutic implications. Bastounis EA, et al. **Am Surg** 1997 Apr;63(4):356-60

Pheochromocytoma, chronic renal insufficiency, and hemodialysis: a combination leading to a diagnostic and therapeutic dilemma. Box JC, et al. **Am Surg** 1997 Apr; 63(4):314-6

Phaeochromocytoma--a rare cause of hypertension in an 11-year-old girl. Rajalingam V, et al. **Ann Acad Med Singapore** 1996 Jul;25(4):587-9

Serotonin reuptake inhibitor unmasks a pheochromocytoma [letter] Seelen MA, et al. **Ann Intern Med** 1997 Feb 15; 126(4):333

Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Terzolo M, et al. **Arch Surg** 1997 Aug;132(8):914-9

Adrenal carcinoma presenting as Conn's syndrome [letter] Taylor W, et al. **Aust N Z J Med** 1997 Apr;27(2):201-2

Adrenal myelolipoma: case report with a review of the literature. Bayram F, et al. **Australas Radiol** 1996 Feb; 40(1):68-71 (34 ref.)

Multicentric giant cell tumour and phaeochromocytoma. Tan BS, et al. **Australas Radiol** 1996 Aug;40(3):360-3

Involvement of the inferior vena cava by adrenal phaeochromocytoma--MRI findings. Lau TN, et al. **Br J Radiol** 1997 Mar;70:303-5

Case report: rupture and growth of adrenal myelolipoma in two patients [see comments] Wong KW, et al. **Br J Radiol** 1996 Sep;69(825):873-5. Comment in: Br J Radiol 1997 Mar;70:319.

Rupture and growth of adrenal myelolipoma in two patients [letter; comment] Zammit-Maempel I. **Br J Radiol** 1997 Mar;70:319. Comment on: Br J Radiol 1996 Sep;69(825):873-5.

Prenatally diagnosed neuroblastoma. Acharya S, et al. **Cancer** 1997 Jul 15;80(2):304-10 (46 ref.)

Incidentally discovered adrenal masses. Kloos RT, et al. **Cancer Treat Res** 1997;89:263-92 (108 ref.)

Evaluating adrenal incidentalomas. Danese RD. **Cleve Clin J Med** 1997 Jun;64(6):287-91 (22 ref.)

REPCAT: desktop expert system for interpreting and validating laboratory data for pheochromocytoma diagnosis with the database application Omnis 7. Smythe GA, et al. **Clin Chem** 1997 Jan;43(1):134-40

Digital superimposition of CT and positive SPECT tumor images. Phantom study and clinical applications. Montravers F, et al. **Clin Nucl Med** 1997 Mar;22(3):151-7

MR differentiation of phaeochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times. Varghese JC, et al. **Clin Radiol** 1997 Aug;52(8):603-6

Diagnosis and management of adrenal tumors [see comments] Sloan DA, et al. **Curr Opin Oncol** 1996 Jan;8(1):30-6 (33 ref.). Comment in: Curr Opin Oncol 1996 Jan;8(1):29.

Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma [see comments] Stridsberg M, et al. **Eur J Endocrinol** 1997 Jan; 136(1):67-73. Comment in: Eur J Endocrinol 1997 Jan;136(1):28-9.

Incidentally discovered adrenal masses: evaluation with gadolinium enhancement and fat-suppressed MR imaging at 0.5 T. Boraschi P, et al. **Eur J Radiol** 1997 May; 24(3):245-52

Undiagnosed phaeochromocytomas in the perioperative period. Voros DC, et al. **Eur J Surg** 1996 Dec;162(12):985-7

Adrenal cavernous hemangioma: MRI, CT, and US appearance. Marotti M, et al. **Eur Radiol** 1997;7(5):691-4

Multiple adrenal masses: MRI tissue differentiation of pheochromocytoma and adenoma at 1.5 T. Slapa RZ, et al. **Eur Radiol** 1997;7(1):38-40

A case of exophytic hepatic hemangioma mimicking adrenal tumor. Maekawa S, et al. **Hinyokika Kiyo** 1997 Feb; 43(2):123-6

Primary adrenal lymphoma presenting as Addisonian crisis. Pitfalls in the diagnosis of bilateral adrenal swelling [letter] Sone H, et al. **Horm Metab Res** 1996 Feb;28(2):116

Incidental adrenal mass hampers the diagnosis of an extra-adrenal phaeochromocytoma. Jeck T, et al. **Horm Res** 1996;46(6):282-3

Pheochromocytoma in a long-term hemodialysis patient, discovered as an adrenal incidentaloma. Asaka S, et al. **Intern Med** 1997 Jun;36(6):403-7 (18 ref.)

Giant phaeochromocytoma: case report. Basso L, et al. **Ir J Med Sci** 1996 Jan-Mar;165(1):57-9

Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected tumors [letter; comment] Terzolo M, et al. **J Clin Endocrinol Metab** 1996 Dec; 81(12):4503-4. Comment on: J Clin Endocrinol Metab 1996 May;81(5):1726-9.

Frequency of pheochromocytoma in adrenal incidentalomas and utility of the glucagon test for the diagnosis. Bernini GP, et al. **J Endocrinol Invest** 1997 Feb;20(2):65-71

Pheochromocytoma in a pregnant woman. Liu FH, et al. **J Formos Med Assoc** 1996 Apr;95(4):333-6

Adrenal paragonimiasis simulating adrenal tumor--a case report. Hahn ST, et al. **J Korean Med Sci** 1996 Jun; 11(3):275-7

Adrenal carcinosarcoma--a case report. Lee MS, et al. **J Korean Med Sci** 1997 Aug;12(4):374-7

Management of the incidentally discovered adrenal mass or "incidentaloma". Li BD, et al. **J La State Med Soc** 1997 Aug;149(8):291-9 (33 ref.)

Pheochromocytoma with elevated metanephrines as the only biochemical finding. Shawar L, et al. **J La State Med Soc** 1996 Dec;148(12):535-8

Pheochromocytoma during pregnancy: case report. Chittacharoen A, et al. **J Obstet Gynaecol Res** 1997 Apr;

23(2):209–12
MR imaging of renal and adrenal masses in children. Bilal MM, et al. **Magn Reson Imaging Clin N Am** 1997 Feb; 5(1):179–97 (74 ref.)
Incidentally discovered adrenal masses. Francis IR, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):147–64 (82 ref.)
The adrenal gland: radiologic-pathologic correlation. Krebs TL, et al. **Magn Reson Imaging Clin N Am** 1997 Feb; 5(1):127–46 (54 ref.)
Phaeochromocytoma with adult respiratory distress syndrome mimicking septicaemic shock. Mok CC, et al. **Med J Aust** 1997 Jun 16;166(12):634–5
Correspondence re: Prevot S, Penna CH, Imbert JC, Wendum D, De Saint Maur PP. Solitary fibrous tumor of the adrenal gland. Mod Pathol 1996;9:1170–74 [letter; comment] López JI. **Mod Pathol** 1997 May;10(5):520. Comment on: Mod Pathol 1996 Dec;9(12):1170–4.
Errors and pitfalls in diagnostic cytology of abdominal organs. Silverman JF. **Monogr Pathol** 1997;(39):147–70 (107 ref.)
Urinary catecholamines and the diagnosis of phaeochromocytoma in Auckland. McNeil AR, et al. **N Z Med J** 1997 Sep 12;110(1051):331–3
Index of suspicion. Case 3. Diagnosis: Cushing syndrome. Babl FE, et al. **Pediatr Rev** 1996 Aug;17(8):291, 293–4
Phaeochromocytoma: a ten-year survey. Loh KC, et al. **QJM** 1997 Jan;90(1):51–60
Cavernous hemangioma of the adrenal gland: MRI appearance. Hayasaka K, et al. **Radiat Med** 1996 Jul–Aug; 14(4):193–5
Pheochromocytoma. Francis IR, et al. **Radiol Clin North Am** 1996 Nov;34(6):1101–12 (48 ref.)
Adrenal and extra-adrenal retroperitoneal ganglioneuroma: imaging findings in 13 adults. Radin R, et al. **Radiology** 1997 Mar;202(3):703–7
Collision tumors of the adrenal gland: demonstration and characterization at MR imaging. Schwartz LH, et al. **Radiology** 1996 Dec;201(3):757–60
Masculinizing and feminizing syndromes caused by functioning tumors. Masiakos PT, et al. **Semin Pediatr Surg** 1997 Aug;6(3):147–55 (64 ref.)
Functioning adrenal neoplasms. Sawin RS. **Semin Pediatr Surg** 1997 Aug;6(3):156–63 (52 ref.)
Ruptured phaeochromocytoma—a rare differential diagnosis of acute abdomen. Ong KL, et al. **Singapore Med J** 1996 Feb;37(1):113–4
Giant adrenal myelolipoma. O'Daniel-Pierce ME, et al. **South Med J** 1996 Nov;89(11):1116–8
Bilateral aldosterone-producing adenomas in two patients diagnosed by immunohistochemical analysis of steroidogenic enzymes. Watanabe N, et al. **Tohoku J Exp Med** 1996 Jun;179(2):123–9
Malignant pheochromocytoma in multiple endocrine neoplasia type 2B syndrome. Case report and review of the literature. Scopsi L, et al. **Tumori** 1996 Sep–Oct; 82(5):480–4 (36 ref.)
Retroperitoneal bronchogenic cyst masquerading clinically and radiologically as a phaeochromocytoma. Doggett RS, et al. **Virchows Arch** 1997 Jul;431(1):73–6
[Results of 25-year pheochromocytoma treatment in the Groningen Academic Hospital] de Graaf JS, et al. **Ned Tijdschr Geneeskd** 1997 Jan 18;141(3):148–51 (Eng. Abstr.) **(Dut)**
[Adrenal pheochromocytoma. Report of six cases] Bahloul A, et al. **Ann Urol (Paris)** 1996;30(5):225–30 (Eng. Abstr.) **(Fre)**
[Primary bilateral adrenal lymphoma as viewed by MRI. Apropos of a case] Dhôte R, et al. **J Radiol** 1997 Apr; 78(4):299–302 (20 ref.) (Eng. Abstr.) **(Fre)**
[Ganglioneuroma of the adrenal glands (letter)] Gignoux BM, et al. **Presse Med** 1996 Sep 7;25(25):1169–70 **(Fre)**
[The differentiation of adrenal gland tumors: an improvement in accuracy by a combination of fat-sensitive, T2-weighted and contrast-enhanced MR sequences] Zimmermann GG, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):153–9 (Eng. Abstr.) **(Ger)**
[Clinical and endocrine diagnosis of pheochromocytoma] Lehnert H, et al. **Zentralbl Chir** 1997;122(6):447–53 (14 ref.) (Eng. Abstr.) **(Ger)**
[Imaging methods in diagnosis of pheochromocytoma] Neumann K, et al. **Zentralbl Chir** 1997;122(6):438–42 (15 ref.) (Eng. Abstr.) **(Ger)**
[Incidentalomas of the adrenal gland] Licata A, et al. **Ann Ital Chir** 1997 Jan–Feb;68(1):55–60 (Eng. Abstr.) **(Ita)**
[Adrenal myelolipomas: their magnetic resonance assessment] Boraschi P, et al. **Clin Ter** 1996 Nov;147(11):549–57 (Eng. Abstr.) **(Ita)**
[Renal and adrenal masses in childhood: role of imaging methods] Gualdi GF, et al. **Clin Ter** 1996 Jun;147(6):327–32 (Eng. Abstr.) **(Ita)**
[Bilateral adrenal pheochromocytoma. A clinical case and review of the literature] Piazza D, et al. **Minerva Chir** 1997 May;52(5):667–72 (17 ref.) (Eng. Abstr.) **(Ita)**
[A case of lung adenocarcinoma: detection and resection of the metastatic lesion was managed effectively by serum CEA level] Hiyoshi H, et al. **Kyobu Geka** 1996 Sep; 49(10):873–5 (Eng. Abstr.) **(Jpn)**
[Clinical review of 105 cases of adrenal tumor, with special reference to incidental tumor] Koga H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jun;87(6):915–22 (Eng. Abstr.) **(Jpn)**
[Etiology and treatment of adrenal diseases of the current interest] Nawata H. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):429–33 (5 ref.) **(Jpn)**
[Pheochromocytoma with hemorrhagic necrosis and rupture with symptoms of acute abdomen and shock] Chlebus M, et al. **Pol Arch Med Wewn** 1996 Jul;96(1):58–61 (Eng. Abstr.) **(Pol)**
[Malignant pheochromocytoma—progress in diagnosis and therapy] Sworczak K, et al. **Pol Arch Med Wewn** 1996 Jul;96(1):68–74 (43 ref.) **(Pol)**
[The characteristics of the course and diagnostic difficulties in pheochromocytoma in young people] Solun MN, et al. **Ter Arkh** 1996;68(4):80–2 (8 ref.) **(Rus)**
[Primary adrenal lymphoma: review and report of a case] López Hernández E, et al. **An Med Interna** 1997 Feb; 14(2):76–8 (26 ref.) (Eng. Abstr.) **(Spa)**
[Silent pheochromocytoma. A frequent entity? (letter)] Goday A, et al. **Med Clin (Barc)** 1997 Apr 26;108(16):636–7 **(Spa)**

DRUG THERAPY

Two cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine and dacarbazine in a combined chemotherapy. Noshiro T, et al. **Endocr J** 1996 Jun;43(3):279–84

ENZYMOLOGY

Regulation of tyrosine hydroxylase gene expression by the m1 muscarinic acetylcholine receptor in rat pheochromocytoma cells. Chen Y, et al. **Brain Res Mol Brain Res** 1996 Aug;40(1):42–54
Impairment of 11 beta-hydroxylase but not 21-hydroxylase in adrenal 'incidentalomas'. Reincke M, et al. **Eur J Endocrinol** 1997 Feb;136(2):196–200
Tyrosine hydroxylase gene expression in varying forms of human pheochromocytoma [published erratum appears in Life Sci 1997;60(12):961–2] Tümer N, et al. **Life Sci** 1996; 59(19):1659–65

EPIDEMIOLOGY

Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Terzolo M, et al. **Arch Surg** 1997 Aug;132(8):914–9
Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Angeli A, et al. **Horm Res** 1997;47(4–6):279–83

ETIOLOGY

Malignant lymphoma of the adrenal gland: its possible correlation with the Epstein-Barr virus. Ohsawa M, et al. **Mod Pathol** 1996 May;9(5):534–43

GENETICS

Familial pheochromocytoma due to mutant von Hippel-Lindau disease gene [letter] Mulvihill JJ, et al. **Arch Intern Med** 1997 Jun 23;157(12):1390–1
Mutation analysis of glial cell line-derived neurotrophic factor (GDNF), a ligand for the RET/GDNF receptor alpha complex, in sporadic phaeochromocytomas. Dahia PL, et al. **Cancer Res** 1997 Jan 15;57(2):310–3
PCR-SSCP analysis of the promoter region of the renin gene in patients with aldosterone-producing adenomas. Ballantine DM, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul;23(6–7):584–6
PCR-SSCP analysis of the p53 gene in tumours of the adrenal gland. Ballantine DM, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul;23(6–7):582–3
A significant decrease of the transcriptional activity of p53 mutants deriving from human functional adrenal tumors. Lin SR, et al. **DNA Cell Biol** 1996 Oct;15(10):793–803
Absence of mutations at codon 768 of the RET proto-oncogene in sporadic and hereditary pheochromocytomas. Yoshimoto K, et al. **Endocr J** 1996 Feb;43(1):109–14
Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas. Herfarth KK, et al. **Genes Chromosomes Cancer** 1997 Sep;20(1):24–9
Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas. Rodien P, et al. **Horm Res** 1997;47(4–6):263–8
Absence of RET proto-oncogene mutations in a father and son with pheochromocytoma and pancreatic islet cell tumor. Kawasaki T, et al. **Int J Urol** 1997 Mar;4(2):169–71
Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. Davies E, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):611–5
Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. Hofstra RM, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2881–4
Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. Liu J, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1766–71
p53 mutations in adrenal tumors: Caucasian patients do not show the exon 4 "hot spot" found in Taiwan. Reincke M, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3636–8
Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease. Ritter MM, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1035–7
Expression of the apoptosis-suppressing gene BCL-2 in pheochromocytoma is associated with the expression of C-MYC. Wang DG, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1949–52
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene and loss of the insertion allele in aldosterone-producing adenoma. Tunny TJ, et al. **J Hum Hypertens** 1996 Dec;10(12):827–30
Steroidogenic factor 1 (SF-1) and SP1 are required for regulation of bovine CYP11A gene expression in bovine luteal cells and adrenal Y1 cells. Liu Z, et al. **Mol Endocrinol** 1997 Feb;11(2):127–37
Immortalization of neuro-endocrine cells from adrenal tumors arising in SV40 T-transgenic mice. Cairns LA, et al. **Oncogene** 1997 Jun 26;14(25):3093–8
[Bilateral laparoscopic transperitoneal adrenalectomy in pheochromocytoma] Manger T, et al. **Langenbecks Arch Chir** 1997;382(1):37–42 (Eng. Abstr.) **(Ger)**
[Molecular biology of incidentally diagnosed adrenal gland space-occupying lesion] Reincke M, et al. **Zentralbl Chir** 1997;122(6):430–7 (42 ref.) (Eng. Abstr.) **(Ger)**
[A case of ectopic familial pheochromocytoma] Nakada J, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Aug; 87(8):1060–3 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Sipple syndrome] Vetshev PS, et al. **Khirurgiia (Mosk)** 1996; (5):59–60 **(Rus)**

METABOLISM

PCR-SSCP analysis of the promoter region of the renin gene in patients with aldosterone-producing adenomas. Ballantine DM, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul;23(6–7):584–6
Immunoreactive brain natriuretic peptide in human adrenal glands and adrenal tumors. Totsune K, et al. **Eur J Endocrinol** 1996 Sep;135(3):352–6
Expression and prognostic value of c-erbB-2 oncogene product in human phaeochromocytomas. Castilla-Guerra L, et al. **Histopathology** 1997 Aug;31(2):144–9
Adrenal incidentaloma: an overview of hormonal data from the National Italian Study Group. Mantero F, et al. **Horm Res** 1997;47(4–6):284–9
Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. Davies E, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):611–5
Angiotensin II receptors in cortical and medullary adrenal tumors. Opocher G, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):865–9
Leu-M1 immunoreactivity and phaeochromocytoma. Masmiquel L, et al. **J Clin Pathol** 1997 Feb;50(2):168–70
Expression of interleukin-1 in human pheochromocytoma. Bornstein SR, et al. **J Endocrinol Invest** 1996 Nov; 19(10):693–8
Bilateral aldosterone-producing adenomas in two patients diagnosed by immunohistochemical analysis of steroidogenic enzymes. Watanabe N, et al. **Tohoku J Exp Med** 1996 Jun;179(2):123–9

MORTALITY

Smoking and adrenal cancer mortality among United States veterans. Chow WH, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Feb;5(2):79–80

PARASITOLOGY

Neuropeptide Y inhibits depolarization-stimulated catecholamine synthesis in rat pheochromocytoma cells. McCullough LA, et al. **Eur J Pharmacol** 1995 Dec 20; 287(3):271–7

PATHOLOGY

Adrenal pheochromocytoma mimicking small cell carcinoma on fine needle aspiration biopsy. A case report. Deodhare S, et al. **Acta Cytol** 1996 Sep–Oct;40(5):1003–6
Isolated intracranial metastasis of neuroblastoma 2 years after completion of therapy. Lydaki E, et al. **Acta Paediatr Jpn** 1997 Feb;39(1):79–82
Isolated cardiac metastasis of adrenal carcinoma: transesophageal echocardiographic features. Bilge A, et al. **Am Heart J** 1996 Nov;132(5):1066–8
Coexistence of aldosteronoma and contralateral nonfunctioning adrenal adenoma in primary aldosteronism. Fallo F, et al. **Am J Hypertens** 1997 Apr;10(4 Pt 1):476–8
Malignant pheochromocytoma, still a therapeutic challenge. Tato A, et al. **Am J Hypertens** 1997 Apr;10(4 Pt 1):479–81
Composite pheochromocytoma/ganglioneuroma of the adrenal gland associated with multiple endocrine neoplasia 2A: case report with immunohistochemical analysis. Brady S, et al. **Am J Surg Pathol** 1997 Jan;21(1):102–8
Intravascular large cell lymphoma coexisting within hemangiomas of the skin. Rubin MA, et al. **Am J Surg Pathol** 1997 Jul;21(7):860–4
Bilateral adrenal tumours: a case report of an unusual manifestation of mesenteric leiomyosarcoma. Gohji K, et al. **Br J Urol** 1997 Mar;79(3):479–80
Inhibition of cellular growth and steroid 11

beta-hydroxylation in ras-transformed adrenocortical cells by the fungal toxins beticolins. Ding G, et al. **Cell Biol Int** 1996 Aug;20(8):523-30

Improved detection of disseminated pheochromocytoma using post therapy I-131 MIBG scanning. Campbell L, et al. **Clin Nucl Med** 1996 Dec;21(12):960-3

Bone metastases in pheochromocytoma. Optimal timing of I-123 MIBG scintigraphy. Lau AK, et al. **Clin Nucl Med** 1996 Apr;21(4):316-8

Needle biopsy of the adrenal gland: retrospective review of 54 cases. Dusenbery D, et al. **Diagn Cytopathol** 1996 Mar; 14(2):126-34

Coexisting non-functioning pheochromocytoma and renal oncocytoma: a case report and review of the literature. Daskalopoulos G, et al. **Eur J Radiol** 1996 Sep;23(2):138-42 (22 ref.)

Angiotropic lymphoma with endocrine involvement. Shanks JH, et al. **Histopathology** 1997 Aug;31(2):161-6

Stage IVS neuroblastoma: a clinical, histological, and biological analysis of 45 cases. Hachitanda Y, et al. **Hum Pathol** 1996 Nov;27(11):1135-8

Multifocal hemangioendothelioma of the fetus and placenta. Marton T, et al. **Hum Pathol** 1997 Jul;28(7):866-9

Myelolipoma of adrenal gland in association with occult malignancy--a case report. Bal MS, et al. **Indian J Pathol Microbiol** 1996 Jul;39(3):229-30

Giant intra-adrenal myelolipoma associated with recurrent urinary tract infection. Houshiar AM, et al. **Int Urol Nephrol** 1997;29(2):130-6 (15 ref.)

Primary adrenal ganglioneuroblastoma in an adult. Hiroshige K, et al. **Intern Med** 1995 Dec;34(12):1168-73

Bilateral adrenal lymphoma with neoplastic angioendotheliosis. Kubo M, et al. **Intern Med** 1997 Jan; 36(1):47-52

The clinical evaluation of silent adrenal masses. Ambrosi B, et al. **J Endocrinol Invest** 1997 Feb;20(2):90-107 (111 ref.)

Frequency of pheochromocytoma in adrenal incidentalomas and utility of the glucagon test for the diagnosis. Bernini GP, et al. **J Endocrinol Invest** 1997 Feb;20(2):65-71

Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome). Morrison PJ, et al. **J Med Genet** 1996 Sep;33(9):779-82 (31 ref.)

Peroperative (123)I-MIBG scan using a sterile probe for staging and resection of neuroblastoma in children. Aslam A, et al. **J Pediatr Surg** 1996 May;31(5):719-20

Antiproliferative effect of suramin on primary cultures of human pheochromocytomas and rat PC12 pheochromocytoma cells. Zielke A, et al. **J Surg Oncol** 1997 Sep;66(1):11-8

Bilateral symptomatic adrenal myelolipoma. Bishoff JT, et al. **J Urol** 1997 Oct;158(4):1517-8 (5 ref.)

Solitary fibrous tumor of the adrenal gland [see comments] Prévot S, et al. **Mod Pathol** 1996 Dec;9(12):1170-4. Comment in: Mod Pathol 1997 May;10(5):520.

Adenomatoid tumor of the adrenal gland: a report of four new cases and a review of the literature. Raaf HN, et al. **Mod Pathol** 1996 Nov;9(11):1046-51 (21 ref.)

Vascular adrenal cysts: a clinicopathologic and immunohistochemical study of six cases and a review of the literature. Torres C, et al. **Mod Pathol** 1997 Jun; 10(6):530-6 (52 ref.)

Immortalization of neuro-endocrine cells from adrenal tumors arising in SV40 T-transgenic mice. Cairns LA, et al. **Oncogene** 1997 Jun 26;14(25):3093-8

Corticomedullary tumors of the adrenal glands. Report of two cases. Association of corticomedullary tumor with spindle cell sarcoma. Michal M, et al. **Pathol Res Pract** 1996 Nov;192(11):1082-9

Giant adrenal lipoma: a report of two cases and review of literature. Lam KY, et al. **Scand J Urol Nephrol** 1997 Feb; 31(1):89-90 (5 ref.)

Immunohistochemical and morphological characterization of spontaneously occurring pheochromocytomas in the aging mouse. Tischler AS, et al. **Vet Pathol** 1996 Sep;33(5):512-20

Pheochromocytomas: tendency to degenerate and cause paroxysmal hypertension. Ito Y, et al. **World J Surg** 1996 Sep;20(7):923-6; discussion 927

[Pheochromocytoma-ganglioneuroma of the adrenal gland] Dudorkinová D. **Cesk Patol** 1996 Aug;32(3):105-9 (Eng. Abstr.) **(Cze)**

[Myocardial pump failure in dilated cardiomyopathy and pheochromocytoma] Weickert U, et al. **Pathologe** 1997 Mar;18(2):167-71 (Eng. Abstr.) **(Ger)**

[Retroperitoneal bifocal ganglioneuroma--a case report] Hallscheidt P, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Apr;166(4):351-4 **(Ger)**

[Adrenal angioma] Borghesi MR. **Pathologica** 1996 Feb; 88(1):40-2 (9 ref.) (Eng. Abstr.) **(Ita)**

[Usefulness of the modified Dixon technique associated with gadolinium administration in the characterization of adrenal masses] Boraschi P, et al. **Radiol Med (Torino)** 1997 Mar; 93(3):218-24 (Eng. Abstr.) **(Ita)**

[Case of malignant pheochromocytoma with successful control of systemic metastasis with CVD chemotherapy] Minami T, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2078-80 (10 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Mechanisms of orthostatic hypotension and tachycardia in patients with pheochromocytoma. Streeten DH, et al. **Am J Hypertens** 1996 Aug;9(8):760-9

Heart rate variability in a case of pheochromocytoma. Stein PK, et al. **Clin Auton Res** 1996 Feb;6(1):41-4

Myelolipoma of adrenal gland in association with occult malignancy--a case report. Bal MS, et al. **Indian J Pathol Microbiol** 1996 Jul;39(3):229-30

Pheochromocytoma and paraganglioma in children: a report of 24 cases of the French Society of Pediatric Oncology. Perel Y, et al. **Pediatr Hematol Oncol** 1997 Sep-Oct; 14(5):413-22

[Pheochromocytoma as a cause of collapse and hypertension during a stay in the tropics] Maassen van den Brink KI, et al. **Ned Tijdschr Geneeskd** 1997 Jan 18;141(3):152-4 (Eng. Abstr.) **(Dut)**

[Clinical management of hypertension in patients with pheochromocytoma] Nose K, et al. **Hinyokika Kiyo** 1996 Nov;42(11):835-9 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Adrenal radiology: distinguishing benign from malignant adrenal masses. Dunnick NR, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):861-7 (69 ref.)

Primary adrenal ganglioneuroma: CT findings in four patients. Johnson GL, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):169-71

How accurate is computed tomography in predicting the real size of adrenal tumors? A retrospective study. Linos DA, et al. **Arch Surg** 1997 Jul;132(7):740-3

Case in point. Benign adrenal adenoma. Ansari A. **Hosp Pract (Off Ed)** 1997 Mar 15;32(3):246

Adrenal masses: characterization with delayed contrast-enhanced CT. Boland GW, et al. **Radiology** 1997 Mar;202(3):693-6

Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Mukherjee JJ, et al. **Radiology** 1997 Jan;202(1):227-31

Quantitative CT evaluation of adrenal gland masses: a step forward in the differentiation between adenomas and nonadenomas? Szolar DH, et al. **Radiology** 1997 Feb; 202(2):517-21

[Computerized tomography findings score in the differentiation of adrenal tumors in patients with extra-adrenal malignomas] Gufler H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Aug;165(2):118-22 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography [see comments] Erasmus JJ, et al. **AJR Am J Roentgenol** 1997 May;168(5):1357-60. Comment in: AJR Am J Roentgenol 1997 May;168(5):1361-2.

Positron emission tomography, bronchogenic carcinoma, and the adrenals [comment] Lamki LM. **AJR Am J Roentgenol** 1997 May;168(5):1361-2. Comment on: AJR Am J Roentgenol 1997 May;168(5):1357-60.

Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mIBG scintimaging in neural crest tumors. Limouris GS, et al. **Anticancer Res** 1997 May-Jun;17(3B):1589-92

Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Kopf D, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):39-44

Obstructive hydronephrosis with I-131 MIBG accumulation mimicking huge pheochromocytoma: a diagnostic pitfall found with Tc-99m MDP imaging. Kao PF, et al. **Clin Nucl Med** 1996 Dec;21(12):994-5

Could somatostatin scintigraphy be superior to MIBG scan in the staging of stage IVs neuroblastoma (Pepper's syndrome)? Manil L, et al. **Clin Nucl Med** 1996 Jul; 21(7):530-3

Pheochromocytoma diagnosed with I-123 MIBG scintigraphy in a patient with concomitant bilateral polycystic kidneys. Mansi L, et al. **Clin Nucl Med** 1997 Apr;22(4):268-70

Location of adrenal medullary pheochromocytoma by I-123 metaiodobenzylguanidine SPECT. Nielsen JT, et al. **Clin Nucl Med** 1996 Sep;21(9):695-9

An unusual adrenal metastasis secondary to Hürthle cell carcinoma of the thyroid. Orsolon P, et al. **Clin Nucl Med** 1996 Apr;21(4):312-5

Doughnut appearance on I-131 MIBG scintigraphy. Ozcan Z, et al. **Clin Nucl Med** 1996 Aug;21(8):654-5

Localization of a pheochromocytoma using I-123 MIBG adrenal scintigraphy. Shirkare S, et al. **J Postgrad Med** 1994 Apr-Jun;40(2):85-7

The role of radiolabeled somatostatin analogs in adrenal imaging. Maurea S, et al. **Nucl Med Biol** 1996 Aug; 23(6):677-80

Diagnostic dilemma of small incidentally discovered adrenal masses: role for 131I-6beta-iodomethyl-norcholesterol scintigraphy. Kloos RT, et al. **World J Surg** 1997 Jan; 21(1):36-40

[Nuclear medicine diagnosis of pheochromocytoma] Farahati J, et al. **Zentralbl Chir** 1997;122(6):443-6 (21 ref.) (Eng. Abstr.) **(Ger)**

[Positron emission tomography (PET) with fludeoxyglucose F 18 in the study of adrenal masses: comparison of benign and malignant lesions] Maurea S, et al. **Radiol Med (Torino)** 1996 Dec;92(6):782-7 (Eng. Abstr.) **(Ita)**

[A case of bilateral adrenal neuroblastomas detected by bone scintigraphy] Suga K, et al. **Kaku Igaku** 1996 Dec; 33(12):1337-42 (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Palliation of symptomatic adrenal gland metastases by radiotherapy. Short S, et al. **Clin Oncol (R Coll Radiol)** 1996;8(6):387-9

Pretreatment with [131I] metaiodobenzylguanidine and surgical resection of advanced neuroblastoma. van Hasselt EJ, et al. **Eur J Pediatr Surg** 1996 Jun;6(3):155-8

The current status of radioiodinated metaiodobenzylguanidine therapy of neuro-endocrine tumors. Shapiro B, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):55-7

[Therapeutic possibilities in metastatic pheochromocytoma] Vierhapper H, et al. **Zentralbl Chir** 1997;122(6):494-7 (28 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography [see comments] Erasmus JJ, et al. **AJR Am J Roentgenol** 1997 May;168(5):1357-60. Comment in: AJR Am J Roentgenol 1997 May;168(5):1361-2.

Positron emission tomography, bronchogenic carcinoma, and the adrenals [comment] Lamki LM. **AJR Am J Roentgenol** 1997 May;168(5):1361-2. Comment on: AJR Am J Roentgenol 1997 May;168(5):1357-60.

Comparison of two algorithms and their associated charges when evaluating adrenal masses in patients with malignancies. Schwartz LH, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1575-8

Does resection of adrenal metastases from non-small cell lung cancer improve survival? Luketich JD, et al. **Ann Thorac Surg** 1996 Dec;62(6):1614-6

Renal carcinoma with a solitary synchronous contralateral adrenal metastasis: a case report. Sapienza P, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):743-7 (13 ref.)

Micrometastatic adrenal invasion by renal carcinoma in patients undergoing nephrectomy. Li GR, et al. **Br J Urol** 1996 Dec;78(6):826-8

Long-term survival after bilateral adrenalectomy for metastatic lung cancer: a case report. Urschel JD, et al. **Chest** 1997 Sep;112(3):848-50

An unusual adrenal metastasis secondary to Hürthle cell carcinoma of the thyroid. Orsolon P, et al. **Clin Nucl Med** 1996 Apr;21(4):312-5

Palliation of symptomatic adrenal gland metastases by radiotherapy. Short S, et al. **Clin Oncol (R Coll Radiol)** 1996;8(6):387-9

Nodular hematopoiesis of the liver diagnosed by fine-needle aspiration cytology. Lemos LB, et al. **Diagn Cytopathol** 1997 Jan;16(1):51-4 (40 ref.)

Late presentation of solitary contralateral adrenal metastasis of renal cell carcinoma. Mesurolle B, et al. **Eur Radiol** 1997; 7(4):557-8

Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration of the left adrenal gland. Chang KJ, et al. **Gastrointest Endosc** 1996 Nov;44(5):568-72

Adrenal metastasis from hepatocellular carcinoma--report of a case. Kitagawa Y, et al. **Hepatogastroenterology** 1996 Sep-Oct;43(11):1383-6

An unusual case of adrenal failure due to isolated metastases of breast cancer. Davi MV, et al. **J Endocrinol Invest** 1996 Jul-Aug;19(7):488-9

Case report: right-sided periadrenal metastasis supplied by the hepatic artery. Clue to the genesis of pedunculated hepatocellular carcinoma. Iwamoto S, et al. **J Gastroenterol Hepatol** 1997 May;12(5):392-7

Persistent expression of hepatitis C virus genome in primary tumor and adrenal metastasis of a hepatocellular carcinoma developed in a non-cirrhotic liver [letter] Herr W, et al. **J Hepatol** 1996 Jul;25(1):122

Collision tumors of the adrenal gland: demonstration and characterization at MR imaging. Schwartz LH, et al. **Radiology** 1996 Dec;201(3):757-60

Contralateral adrenal metastasis in renal cell cancer. Dieckmann KP, et al. **Scand J Urol Nephrol** 1996 Apr; 30(2):139-43 (34 ref.)

Successful combined resection of carcinoma of the esophagus and adrenal metastasis: report of a case. Yoshizumi Y, et al. **Surg Today** 1997;27(4):330-3

Synchronous and metachronous contralateral adrenal metastases from primary renal cell carcinoma. Stein A, et al. **Urol Int** 1997;58(1):58-60

Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Sandock DS, et al. **Urology** 1997 Jan;49(1):28-31

[Computerized tomography findings score in the differentiation of adrenal tumors in patients with extra-adrenal malignomas] Gufler H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Aug;165(2):118-22 (Eng. Abstr.) **(Ger)**

[Adrenalectomy in metastasis of primary pulmonary carcinoma: an emerging issue] Motta G, et al. **Ann Ital Chir** 1996 Sep-Oct;67(5):661-7; discussion 667-8 (Eng. Abstr.) **(Ita)**

[A case of renal cell carcinoma with solitary metastasis to the contralateral adrenal gland] Arai G, et al. **Hinyokika Kiyo** 1997 Jan;43(1):29-31 (Eng. Abstr.) **(Jpn)**

[A case report of renal cell carcinoma with bilateral adrenal

metastases] Miyamoto S, et al. **Hinyokika Kiyo** 1997 Feb; 43(2):127–30 (17 ref.) (Eng. Abstr.) **(Jpn)**

[A case of lung adenocarcinoma: detection and resection of the metastatic lesion was managed effectively by serum CEA level] Hiyoshi H, et al. **Kyobu Geka** 1996 Sep; 49(10):873–5 (Eng. Abstr.) **(Jpn)**

SECRETION

Interleukin-6 secreting phaeochromocytoma associated with clinical markers of inflammation. Takagi M, et al. **Clin Endocrinol (Oxf)** 1997 Apr;46(4):507–9

Primary aldosteronism with bilateral multiple aldosterone-producing adrenal adenomas [see comments] Matsuda A, et al. **Intern Med** 1996 Dec;35(12):970–5. Comment in: Intern Med 1996 Dec;35(12):919–21.

[The dual effect of ketamine on dopamine release from rat pheochromocytoma (PC-12) cells] Okamoto T, et al. **Masui** 1996 Sep;45(9):1083–7 (Eng. Abstr.) **(Jpn)**

[Testosterone-producing adrenal carcinoma: report of 2 cases] Hidalgo MS, et al. **Rev Med Chil** 1996 Sep; 124(9):1111–5 (Eng. Abstr.) **(Spa)**

SURGERY

High dose intravenous labetalol for the resection of metastatic pheochromocytoma [published erratum appears in Acta Anaesthesiol Sin 1997 Mar;35(1):59] Chung PC, et al. **Acta Anaesthesiol Sin** 1996 Dec;34(4):235–8

Laparoscopic adrenalectomy in asymptomatic pheochromocytoma. Takami H, et al. **Am Surg** 1997 Sep; 63(9):820–2

Skin blood flow and plasma catecholamines during removal of pheochromocytoma. Sakuragi T, et al. **Anesthesiology** 1996 Dec;85(6):1485–8

Laparoscopic adrenalectomy. A new standard of care. Jacobs JK, et al. **Ann Surg** 1997 May;225(5):495–501; discussion 501–2

Does resection of adrenal metastases from non-small cell lung cancer improve survival? Luketich JD, et al. **Ann Thorac Surg** 1996 Dec;62(6):1614–6

Surgical treatment of pheochromocytomas. Gavaghan M. **AORN J** 1997 Jun;65(6):1041–51 passim; quiz 1072–80 (64 ref.)

Metyrosine and pheochromocytoma. Steinsapir J, et al. **Arch Intern Med** 1997 Apr 28;157(8):901–6

Tolerance of laparoscopy for resection of phaeochromocytoma [letter; comment] Jerwood C, et al. **Br J Anaesth** 1997 Jun;78(6):775–6. Comment on: Br J Anaesth 1996 Dec;77(6):795–7.

Tolerance of laparoscopy for resection of phaeochromocytoma [see comments] Mann C, et al. **Br J Anaesth** 1996 Dec;77(6):795–7. Comment in: Br J Anaesth 1997 Jun;78(6):775–6.

Comparison of three techniques for adrenalectomy. Bonjer HJ, et al. **Br J Surg** 1997 May;84(5):679–82

Anaesthesia for phaeochromocytoma in pregnancy. Hamilton A, et al. **Can J Anaesth** 1997 Jun;44(6):654–7

Bilateral adrenalectomy with autotransplantation of adrenocortical tissue or unilateral adrenalectomy: treatment options for pheochromocytomas in multiple endocrine neoplasia type 2A. Okamoto T, et al. **Endocr J** 1996 Apr; 43(2):169–75

Plasma dehydroepiandrosterone sulfate levels in patients with hyperfunctioning and non-hyperfunctioning adrenal tumors before and after adrenal surgery. Tóth M, et al. **Eur J Endocrinol** 1997 Mar;136(3):290–5

Initial experience of laparoscopic resection of adrenal tumours. Casaccia M Jr, et al. **Eur J Surg** 1997 Feb; 163(2):93–6

Transthoracal approach for the removal of adrenal tumors. Early experience with 10 cases. Halachmi S, et al. **Eur Urol** 1996;30(4):480–3

Videoendoscopic adrenalectomy: multicentric study from the Belgian Group for Endoscopic Surgery (BGES). De Cannière L, et al. **Int Surg** 1996 Jan–Mar;81(1):6–8

Adrenal-sparing laparoscopic surgery for aldosterone-producing adenoma. Janetschek G, et al. **J Endourol** 1997 Apr;11(2):145–8

Laparoscopic adrenalectomy for nonfunctioning adrenal tumors. Mugiya S, et al. **J Endourol** 1996 Dec;10(6):539–41; discussion 541–3

Renal impairment after surgical resection of neuroblastoma. Tanabe M, et al. **J Pediatr Surg** 1996 Sep;31(9):1252–5

Laparoscopic adrenalectomy for solitary metachronous contralateral adrenal metastasis from renal cell carcinoma. Elashry OM, et al. **J Urol** 1997 Apr;157(4):1217–22 (37 ref.)

The natural history and treatment of adrenal myelolipoma. Han M, et al. **J Urol** 1997 Apr;157(4):1213–6

Renovascular hypertension after laparoscopic adrenalectomy in a patient with adrenal adenoma [letter] Wu TH, et al. **Nephron** 1996;74(2):464–5

Giant adrenal myelolipoma. O'Daniel-Pierce ME, et al. **South Med J** 1996 Nov;89(11):1116–8

Laparoscopic adrenalectomy: comparison with the conventional approach. Ishikawa T, et al. **Surg Laparosc Endosc** 1997 Aug;7(4):275–80

The importance of lifelong follow-up for patients with pheochromocytoma: report of a case. Koçak S, et al. **Surg Today** 1996;26(10):839–41

Is laparoscopic adrenalectomy indicated for pheochromocytomas? Gagner M, et al. **Surgery** 1996 Dec; 120(6):1076–9; discussion 1079–80

Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Lee JE, et al. **Surgery** 1996 Dec; 120(6):1064–70; discussion 1070–1

Questionability of the benefits of routine laparotomy as the surgical approach for pheochromocytomas and abdominal paragangliomas. Pattou FN, et al. **Surgery** 1996 Dec; 120(6):1006–11; discussion 1012

Laparoscopic adrenalectomy. Fahlenkamp D, et al. **Tech Urol** 1996 Spring;2(1):48–53

Technique of transperitoneal laparoscopic adrenalectomy. Vargas HI, et al. **Tech Urol** 1996 Fall;2(3):154–8

Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Sandock DS, et al. **Urology** 1997 Jan;49(1):28–31

Laparoscopic adrenalectomy: a new standard of care. Vargas HI, et al. **Urology** 1997 May;49(5):673–8

Laparoscopic approach to pheochromocytoma: hemodynamic changes and catecholamine secretion. Fernández-Cruz L, et al. **World J Surg** 1996 Sep; 20(7):762–8; discussion 768

Adrenaloma: a call for more aggressive management. Linos DA, et al. **World J Surg** 1996 Sep;20(7):788–92; discussion 792–3

Adrenal surgery in the elderly: too risky? Lo CY, et al. **World J Surg** 1996 Mar-Apr;20(3):368–73; discussion 374

[Endoscopic retroperitoneal adrenalectomy: a surgical improvement] Bonjer HJ, et al. **Ned Tijdschr Geneeskd** 1997 Mar 1;141(9):426–9 (Eng. Abstr.) **(Dut)**

[Results of 25-year pheochromocytoma treatment in the Groningen Academic Hospital] de Graaf JS, et al. **Ned Tijdschr Geneeskd** 1997 Jan 18;141(3):148–51 (Eng. Abstr.) **(Dut)**

[Anesthesia-resuscitation in surgery for pheochromocytoma] Tavernier B, et al. **Ann Chir** 1997;51(4):352–60 (84 ref.) (Eng. Abstr.) **(Fre)**

[Is celioscopic approach of pheochromocytoma acceptable? Reflections apropos of a prospective study of 6 personal cases] Hamoir E, et al. **Ann Endocrinol (Paris)** 1997; 58(1):65–74 (Eng. Abstr.) **(Fre)**

[Laparoscopic surgery of adrenal glands: indications and limits] Henry JF, et al. **Ann Endocrinol (Paris)** 1996; 57(6):520–5 (Eng. Abstr.) **(Fre)**

[Use of urapidil during surgery for pheochromocytoma] Steib A, et al. **Ann Fr Anesth Reanim** 1996;15(2):142–8 (Eng. Abstr.) **(Fre)**

[Hemodynamic management in the surgery of pheochromocytoma (letter)] Tavernier B, et al. **Ann Fr Anesth Reanim** 1996;15(5):699 **(Fre)**

[Urapidil during surgery of pheochromocytoma: should begin in the preoperative period (letter)] Valat P, et al. **Ann Fr Anesth Reanim** 1996;15(5):698–9 **(Fre)**

[Adrenal pheochromocytoma. Report of six cases] Bahloul A, et al. **Ann Urol (Paris)** 1996;30(5):225–30 (Eng. Abstr.) **(Fre)**

[Total intravenous anesthesia with propofol and sufentanil for resection of pheochromocytoma] Kreienmeyer J. **Anaesthesiol Reanim** 1997;22(3):80–2 (Eng. Abstr.) **(Ger)**

[Results of endoscopic, retroperitoneal adrenalectomy with special reference to the intraoperative course (see comments)] Heintz A, et al. **Chirurg** 1997 Feb;68(2):154–8 (Eng. Abstr.). Comment in: Chirurg 1997 Jun;68(6):650. **(Ger)**

[Laparoscopic adrenal gland surgery] Nies C, et al. **Chirurg** 1997 Feb;68(2):99–106 (47 ref.) (Eng. Abstr.) **(Ger)**

[Bilateral laparoscopic transperitoneal adrenalectomy in pheochromocytoma] Manger T, et al. **Langenbecks Arch Chir** 1997;382(1):37–42 (Eng. Abstr.) **(Ger)**

[Endoscopic, extraperitoneal adrenalectomy--an expansion of the approach to the adrenal gland] Heintz A, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:617–8 (Eng. Abstr.) **(Ger)**

[Premedication in pheochromocytoma] Förster G, et al. **Zentralbl Chir** 1997;122(6):454–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Surgical concept in sporadic and familial pheochromocytoma] Goretzki PE, et al. **Zentralbl Chir** 1997;122(6):467–72 (Eng. Abstr.) **(Ger)**

[Endoscopic therapy of incidentaloma] Heintz A, et al. **Zentralbl Chir** 1997;122(6):477–80 (15 ref.) (Eng. Abstr.) **(Ger)**

[Adrenal gland incidentaloma is not a "time bomb"--arguments for follow-up control] Hensen J, et al. **Zentralbl Chir** 1997;122(6):487–93 (47 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of adrenal gland tumors (editorial)] Junginger T, et al. **Zentralbl Chir** 1997;122(6):429 **(Ger)**

[Conventional operation for therapy of incidentaloma] Simon D, et al. **Zentralbl Chir** 1997;122(6):473–6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Anesthetic management in pheochromocytoma] Strecker U, et al. **Zentralbl Chir** 1997;122(6):460–6 (44 ref.) (Eng. Abstr.) **(Ger)**

[Surgery of primary unilateral adrenal gland tumors--results of 154 patients] Walz MK, et al. **Zentralbl Chir** 1997; 122(6):481–6 (Eng. Abstr.) **(Ger)**

[Transthoracic approach for removing adrenal masses] Halachmi S, et al. **Harefuah** 1996 Dec 1;131(11):468–71, 536 (Eng. Abstr.) **(Heb)**

[Adrenalectomy in metastasis of primary pulmonary carcinoma: an emerging issue] Motta G, et al. **Ann Ital Chir** 1996 Sep-Oct;67(5):661–7; discussion 667–8 (Eng. Abstr.) **(Ita)**

[Current indications for video-laparoscopic surgery of adrenal gland neoplasms] Angrisani L, et al. **G Chir** 1996 Aug-Sep;17(8-9):453–7 (28 ref.) (Eng. Abstr.) **(Ita)**

[Laparoscopic versus laparotomic adrenalectomy: preliminary experiences] Sorrentino M, et al. **Minerva Chir** 1997 Mar;52(3):181–4 (Eng. Abstr.) **(Ita)**

[Anesthesia for a patient with pheochromocytoma associated with chronic renal failure] Sagara M, et al. **Masui** 1996 Oct;45(10):1256–9 (Eng. Abstr.) **(Jpn)**

[Anesthetic management for a patient with pheochromocytoma using magnesium sulfate and epidural block] Sakamoto T, et al. **Masui** 1996 Nov;45(11):1400–5 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a child with pheochromocytoma using sevoflurane, diltiazem and continuous epidural blockade] Takahashi K, et al. **Masui** 1996 Oct;45(10):1252–5 (Eng. Abstr.) **(Jpn)**

[Pheochromocytoma in a 81 year old woman treated with surgery--case report] Szmidt L, et al. **Pol Arch Med Wewn** 1997 Feb;97(2):157–60 (Eng. Abstr.) **(Pol)**

[Adrenal tumors in children] Zamfir T, et al. **Chirurgia (Bucur)** 1996 Nov-Dec;45(6):313–6 (Eng. Abstr.) **(Rum)**

[The laparoscopic removal of an adrenal tumor] Maĭstrenko NA, et al. **Vestn Khir Im I I Grek** 1997;156(1):106–7 (14 ref.) **(Rus)**

[The risk of severe bradycardia from the use of adenosine triphosphate in pheochromocytoma surgery under total intravenous anesthesia with propofol (letter)] Munar F, et al. **Rev Esp Anestesiol Reanim** 1997 Jun-Jul;44(6):254–5 **(Spa)**

THERAPY

Pulmonary interstitial disease mimicking idiopathic pneumonia syndrome as the initial site of relapse of neuroblastoma following autologous bone-marrow transplantation: a case report. Watts RG, et al. **Am J Hematol** 1996 Oct;53(2):137–40

Pheochromocytoma. Bravo EL. **Curr Ther Endocrinol Metab** 1997;6:195–7 (5 ref.)

Adrenal incidentaloma. Copeland PM. **Curr Ther Endocrinol Metab** 1997;6:189–94 (11 ref.)

Adrenal carcinoma. Freeman DA. **Curr Ther Endocrinol Metab** 1997;6:173–5 (8 ref.)

Management of the incidentally discovered adrenal mass or "incidentaloma". Li BD, et al. **J La State Med Soc** 1997 Aug;149(8):291–9 (33 ref.)

Phaeochromocytoma: a ten-year survey. Loh KC, et al. **QJM** 1997 Jan;90(1):51–60

ULTRASONOGRAPHY

Is sonographic flow imaging useful in the differential diagnosis of adrenal masses? Ghiatas AA, et al. **Br J Radiol** 1996 Nov;69(827):1005–8

Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Kasperlik-Zeluska AA, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):29–37

Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration of the left adrenal gland. Chang KJ, et al. **Gastrointest Endosc** 1996 Nov;44(5):568–72

Adrenal incidentalomas--analysis of 23 cases discovered by ultrasound. Goncalvesová E, et al. **Neoplasma** 1997; 44(2):137–41

Clinical and perinatal sonographic features of congenital adrenal cystic neuroblastoma: a case report with review of the literature. Chen CP, et al. **Ultrasound Obstet Gynecol** 1997 Jul;10(1):68–73 (31 ref.)

ULTRASTRUCTURE

[The ultrastructure of the chromaffin cells of the adrenal medullary substance in different forms of pheochromocytoma] Gordienko VM. **Tsitol Genet** 1996 Nov-Dec;30(6):8–12 (Eng. Abstr.) **(Rus)**

URINE

Vanilmandelic acid and homovanillic acid levels in patients with neural crest tumor: 24-hour urine collection versus random sample. Gregianin LJ, et al. **Pediatr Hematol Oncol** 1997 May-Jun;14(3):259–65

VETERINARY

Tumours of the endocrine glands. Schmidt RE, et al. **IARC Sci Publ** 1996;(126):307–20 (50 ref.)

Apocrine gland adenocarcinoma and pheochromocytoma in a cat. Chun R, et al. **J Am Anim Hosp Assoc** 1997 Jan-Feb; 33(1):33–6

Lactation associated with acidophilic pituitary adenoma, pheochromocytoma, and cystic endometrial hyperplasia in two goats. Miller CC, et al. **J Am Vet Med Assoc** 1997 Feb 1;210(3):378–81

Bilateral giant myelolipoma in the adrenal of a cotton-top tamarin (Saguinus oedipus). Yanai T, et al. **J Med Primatol** 1996 Aug;25(4):309–12

Diagnosis and management of canine cortisol-secreting adrenal tumors. Kintzer PP, et al.

ADRENAL GLAND NEOPLASMS

Vet Clin North Am Small Anim Pract 1997 Mar; 27(2):299–307 (13 ref.)

Pheochromocytoma in dogs and cats. Maher ER Jr, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):359–80 (46 ref.)

Adrenal incidentalomas. Diagnostic workup of the incidentally discovered adrenal mass. Myers NC 3rd. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):381–99 (71 ref.)

Immunohistochemical and morphological characterization of spontaneously occurring pheochromocytomas in the aging mouse. Tischler AS, et al. **Vet Pathol** 1996 Sep;33(5):512–20

Urinary corticoid/creatinine ratios in the differentiation between pituitary-dependent hyperadrenocorticism and hyperadrenocorticism due to adrenocortical tumour in the dog. Galac S, et al. **Vet Q** 1997 Mar;19(1):17–20

Hereditary caprine phaeochromocytoma. de Gritz BG. **Zentralbl Veterinarmed A** 1997 Jul;44(5):313–6

VIROLOGY

Malignant lymphoma of the adrenal gland: its possible correlation with the Epstein-Barr virus. Ohsawa M, et al. **Mod Pathol** 1996 May;9(5):534–43

ADRENAL GLANDS

see related

ADRENALECTOMY

The conquest of Addison's disease. Hiatt JR, et al. **Am J Surg** 1997 Sep;174(3):280–3

The adrenal response to sepsis [editorial] Remick DG. **Shock** 1997 Aug;8(2):146

ABNORMALITIES

X-linked adrenal hypoplasia and hypogonadotropic hypogonadism: multiple roles for the putative transcription factor DAX-1. Kopp P. **Eur J Endocrinol** 1997 Feb; 136(2):153–4

A horseshoe adrenal gland in an infant with asplenia. Shafaie FF, et al. **Pediatr Radiol** 1997 Jul;27(7):591–3

ANATOMY & HISTOLOGY

NADPH-diaphorase-positive ganglion cells of the rat adrenal gland: age- and sex-related changes in their number, size, and distribution. Cracco CM, et al. **J Comp Neurol** 1996 Feb 26;366(1):181–96

[Experimental morphological studies of stress-inducing effects of weightlessness in rats flown aboard Spacelab-2] Kaplanskiĭ AS, et al. **Aviakosm Ekolog Med** 1996; 30(2):16–20 (Eng. Abstr.) **(Rus)**

[The histostructure of the adrenal gland in the Campbell hamster after extirpation of a specific midventral gland] Sokolov VE, et al. **Izv Akad Nauk Ser Biol** 1997 May–Jun; (3):287–96 (Eng. Abstr.) **(Rus)**

[Morphological changes in the adrenal gland during adaptation to multiple individually measured physical loads] Kol'tiukova NV. **Morfologiia** 1997;111(2):79–83 (Eng. Abstr.) **(Rus)**

BLOOD SUPPLY

Correlation between adrenal central vein parasitism and heart fibrosis in chronic chagasic myocarditis. Teixeira V de P, et al. **Am J Trop Med Hyg** 1997 Feb;56(2):177–80

Regulation of adrenal vascular tone: role of endothelin-1 and nitric oxide. Hinson JP, et al. **Endocr Res** 1996 Nov; 22(4):875–9

Simultaneous scintigraphic depiction of aldosteronoma and adrenal infarction. Gianchandani RY, et al. **J Nucl Med** 1996 May;37(5):852–4

The adrenal-renal vascular connection contributes to increase in renal vascular resistance during an experimental hypotension in the rat. Zięcina R, et al. **J Physiol Pharmacol** 1997 Jun;48(2):179–84

Inflammatory response against Trypanosoma cruzi parasitised cells from adrenal vein and myocardium in chronic Chagas' disease. Rodrigues ML, et al. **Rev Soc Bras Med Trop** 1996 Sep–Oct;29(5):507–8

Confluence of the right adrenal vein with the accessory right hepatic veins. A potential hazard in laparoscopic right adrenalectomy. MacGillivray DC, et al. **Surg Endosc** 1996 Nov;10(11):1095–6

Primary aldosteronism: adrenal venous sampling. Young WF Jr, et al. **Surgery** 1996 Dec;120(6):913–9; discussion 919–20

Adrenal artery velocity waveforms in the appropriate and small-for-gestational-age fetus. Mari G, et al. **Ultrasound Obstet Gynecol** 1996 Aug;8(2):82–6

CHEMISTRY

Effect of reserpine treatment and hypophysectomy on the nitric oxide synthase immunoreactivity and NADPH-diaphorase staining in the rat adrenal gland. Afework M, et al. **Anat Rec** 1996 Dec;246(4):545–8

Distribution and characterization of rat immunoreactive proadrenomedullin N-terminal 20 peptide (PAMP) and the augmented cardiac PAMP in spontaneously hypertensive rat. Inatsu H, et al. **Biochem Mol Biol Int** 1996 Feb; 38(2):365–72

Purification and characterization of chromogranin-A from the adrenal gland of human and bovine. Kumar U. **Biochem Mol Biol Int** 1996 Sep;40(1):83–91

Immunoreactive adrenomedullin in human adrenal glands and adrenal tumors. Satoh F, et al. **Cancer Detect Prev** 1997;21(1):51–4

Distribution and functional significance of the endothelin receptor subtypes in the rat adrenal gland. Belloni AS, et al. **Cell Tissue Res** 1997 May;288(2):345–52

Localization of ACTH receptor mRNA by in situ hybridization in mouse adrenal gland. Xia Y, et al. **Cell Tissue Res** 1996 Oct;286(1):63–8

Angiotensin II receptors in the human adrenal gland. Breault L, et al. **Endocr Res** 1996 Nov;22(4):355–61

cDNA for the beta 1 subunit of guanyl nucleotide-binding regulatory proteins from mouse adrenal glands. Qiu R, et al. **Gene** 1996 Oct 10;175(1–2):275–7

Immunocytochemical localization of NCAM and catecholamine-synthesizing enzymes in rabbit intra- and extra-adrenal chromaffin tissue. Moftaquir A, et al. **Histochem J** 1996 Oct;28(10):661–9

Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. Kasperk CH, et al. **J Bone Miner Res** 1997 Mar;12(3):464–71

Further studies on the anatomical distribution of CART by in situ hybridization. Couceyro PR, et al. **J Chem Neuroanat** 1997 May;12(4):229–41

Ribonucleic acid expression of the CLA-1 gene, a human homolog to mouse high density lipoprotein receptor SR-BI, in human adrenal tumors and cultured adrenal cells. Liu J, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2522–7

Cortisol in human tissues at different stages of life. Costa A, et al. **J Endocrinol Invest** 1996 Jul–Aug;19(7):463–71

Immunolocalization and biochemical determination of cytochrome P450C17 in adrenals of hamsters treated with ACTH. Brière N, et al. **J Histochem Cytochem** 1997 Oct; 45(10):1409–16

Comparison of gap junction expression in the adrenal gland. Murray SA, et al. **Microsc Res Tech** 1997 Mar 15; 36(6):510–9

CYTOLOGY

Functional role of platelet-activating factor receptor in secretory response in adrenal chromaffin cells. Dohi T, et al. **Adv Exp Med Biol** 1996;416:101–5 (28 ref.)

Control of cell proliferation in the rat adrenal gland in vivo by the renin-angiotensin system. McEwan PE, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E192–8

D-aspartic acid localization during postnatal development of rat adrenal gland. Sakai K, et al. **Biochem Biophys Res Commun** 1997 Jun 18;235(2):433–6

Development of galanin- and enkephalin-like immunoreactivities in the sympathoadrenal lineage of the avian embryo. In vivo and in vitro studies. Barreto-Estrada JL, et al. **Dev Neurosci** 1997;19(4):328–36

AT1 receptors and cell proliferation in rat adrenals: effects of angiotensin infusion, low sodium diet and losartan. McEwan PE, et al. **Endocr Res** 1996 Nov;22(4):369–71

Comparative stereological studies on zonation and cellular composition of adrenal glands of normal and anencephalic human fetuses. II. Cellular composition of the gland. Bocian-Sobkowska J, et al. **Histol Histopathol** 1997 Apr; 12(2):391–9

Differential regulation of apoptosis in the normal human adrenal gland. Wolkersdörfer GW, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4129–36

Effects of neurotrophic factors and cell substrates on the differentiation of a sympathoadrenal progenitor cell line. Gaspar EM, et al. **J Neurocytol** 1997 Jun;26(6):407–22

Nuclear receptor steroidogenic factor 1 directs embryonic stem cells toward the steroidogenic lineage. Crawford PA, et al. **Mol Cell Biol** 1997 Jul;17(7):3997–4006

Dehydroepiandrosterone sulfate inhibition of catecholamine secretion from bovine adrenal chromaffin cells. Liu PS, et al. **Neurosci Lett** 1996 Feb 9;204(3):181–4

Adrenal chromaffin cells on microcarriers exhibit enhanced long-term functional effects when implanted into the mammalian brain. Cherksey BD, et al. **Neuroscience** 1996 Nov;75(2):657–64

DRUG EFFECTS

Splanchnicotomy increases adrenal sensitivity to ACTH in nonstressed rats. Jasper MS, et al. **Am J Physiol** 1997 Aug; 273(2 Pt 1):E363–8

Modulation of autotransplanted adrenal gland by endothelin-1: a morphological and biochemical study. Vendeira P, et al. **Anat Rec** 1996 Sep;246(1):98–106

Neurotoxicity of d-amphetamine in the C57BL/6J and CD-1 mouse. Interactions with stress and the adrenal system. Miller DB, et al. **Ann N Y Acad Sci** 1996 Oct 31;801:148–67

Adrenal function and high dose inhaled corticosteroids for asthma. Yiallouros PK, et al. **Arch Dis Child** 1997 May; 76(5):405–10

Clinical adrenal insufficiency in patients receiving megestrol therapy. Subramanian S, et al. **Arch Intern Med** 1997 May 12;157(9):1008–11

Effects of psychotropic drugs on aldo-keto reductase activity in rat ovary and adrenal gland. Inazu N, et al. **Biochem Pharmacol** 1996 Nov 22;52(10):1585–91

Effects of N- and L-type calcium channel antagonists and (+/-)-Bay K8644 on nerve-induced catecholamine secretion from bovine perfused adrenal glands. O'Farrell M, et al. **Br J Pharmacol** 1997 Jun;121(3):381–8

Effects of omega-conotoxin MVIIC on veratridine-induced cytotoxicity and cytosolic Ca(2+) oscillations. Maroto R, et al. **Brain Res** 1996 Apr 1;714(1–2):209–14

Adrenergic differentiation potential in PC12 cells: influence of sodium butyrate and dexamethasone. Ebert SN, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1–2):24–30

Inhibition of corticosterone secretion by thyroxine in male rats. Chen YH, et al. **Chin J Physiol** 1997;40(1):25–30

Inhibition of cortisol production by aldosterone secretion-inhibitory factor and brain natriuretic peptides. Fang VS, et al. **Chin J Physiol** 1995;38(4):247–54

Angiotensin II and the adrenal. Giacchetti G, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S119–24 (49 ref.)

Plant phenolic amines: potential effects on sympathoadrenal medullary, hypothalamic-pituitary-adrenal, and hypothalamic-pituitary-gonadal function in ruminants. Vera-Avila HR, et al. **Domest Anim Endocrinol** 1996 Jul; 13(4):285–96 (74 ref.)

Effects of ecstasy on aldosterone secretion in the rat in vivo and in vitro. Burns N, et al. **Endocr Res** 1996 Nov; 22(4):601–6

Vasoactive intestinal peptide is a local regulator of adrenocortical function. Hinson JP, et al. **Endocr Res** 1996 Nov;22(4):831–8

Role of the tissue renin-angiotensin system in the response of the rat adrenal to exogenous angiotensin II. Vinson GP, et al. **Endocr Res** 1996 Nov;22(4):589–93

Sympatho-adrenal activity and the clinical sedative effect of detomidine in horses. Raekallio M, et al. **Equine Vet J Suppl** 1992 Feb;(11):66–8

Characterization of the receptor mediating the effect of calcitonin gene-related peptide in the frog adrenal gland. Esneu M, et al. **Eur J Pharmacol** 1996 Jul 18;308(2):187–93

Apamin-sensitive SK(Ca) channels modulate adrenal catecholamine release in anesthetized dogs. Nagayama T, et al. **Eur J Pharmacol** 1997 May 30;327(2–3):135–41

Premature plasma progesterone and androgen elevation are not prevented by adrenal suppression in in vitro fertilization. Fanchin R, et al. **Fertil Steril** 1997 Jan; 67(1):115–9

Effect of acid or aluminum on growth and adrenal function in young chickens. Capdevielle MC, et al. **Gen Comp Endocrinol** 1996 Jul;103(1):54–9

The thyroid hormone, 3,5,3'-triiodothyronine, is a negative modulator of domestic fowl (Gallus gallus domesticus) adrenal steroidogenic function. Carsia RV, et al. **Gen Comp Endocrinol** 1997 Aug;107(2):251–61

Effects of secretin on the hypothalamo-pituitary-adrenal axis in the rat. Malendowicz K, et al. **Horm Metab Res** 1996 Nov;28(11):613–4

Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland. Rigotti A, et al. **J Biol Chem** 1996 Dec 27;271(52):33545–9

Effects of adrenomedullin on the human adrenal glands: an in vitro study. Andreis PG, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1167–70

Ouabain is a potent inhibitor of aldosterone secretion and angiotensin action in the human adrenal. Antonipillai I, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2335–7

Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. Glasow A, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):3103–11

The influence of prolonged dexamethasone treatment of pregnant rats on the perinatal development of the adrenal gland of their offspring. Hristić M, et al. **J Exp Zool** 1997 Sep 1;279(1):54–61

Inhibition of bradykinin-induced synovial plasma extravasation produced by intrathecal nicotine is mediated by the hypothalamopituitary adrenal axis. Miao FJ, et al. **J Neurophysiol** 1996 Nov;76(5):2813–21

Treatment and long-term follow-up of 205 dogs with hypoadrenocorticism. Kintzer PP, et al. **J Vet Intern Med** 1997 Mar–Apr;11(2):43–9

Influence of 17- alpha-estradiol on catecholamine secretion from the perfused rat adrenal gland. Park YH, et al. **Korean J Intern Med** 1996 Jan;11(1):25–39

High-dose inhaled steroids in asthmatic children [letter; comment] Lipworth BJ, et al. **Lancet** 1996 Sep 21; 348(9030):820; discussion 821. Comment on: Lancet 1996 Jul 6;348(9019):27–9.

Inhibition of the rat adrenal ornithine decarboxylase activity by immobilization stress and/or dexamethasone. Soliman KF, et al. **Life Sci** 1997;60(26):2383–7

Neurochemical activity of noradrenergic neurons and pituitary-adrenal response after naloxone-induced withdrawal: the role of calcium channels. Vargas ML, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Apr; 355(4):501–6

Effects of prenatal morphine on hypothalamic metabolism of neurotransmitters and gonadal and adrenal activities, during the early postnatal period in the rat. Lesage J, et al. **Neurochem Res** 1996 Jun;21(6):723–32

Decreased hypothalamo-pituitary-adrenal axis response to neuroendocrine challenge under repeated endotoxemia. Hadid R, et al. **Neuroimmunomodulation** 1996 Jan–Feb; 3(1):62–8

Role of the cytokines in the hypothalamic-pituitary-adrenal and gonadal axes. Spangelo BL, et al. **Neuroimmunomodulation** 1995 Sep–Oct;2(5):299–312 (159 ref.)

Effects of neuromedin-K on the rat hypothalamo-pituitary-adrenal axis. Malendowicz LK, et al. **Neuropeptides** 1995 Dec;29(6):337-41

Regulation of the priming of exocytosis and the dissociation of SNAP-25 and VAMP-2 in adrenal chromaffin cells. Misonou H, et al. **Neurosci Lett** 1997 Sep 5;232(3):182-4

Adrenomedullin stimulates steroid secretion by the isolated perfused rat adrenal gland in situ: comparison with calcitonin gene-related peptide effects. Mazzocchi G, et al. **Peptides** 1996;17(5):853-7

In vivo response of the normal and regenerating adrenal glands to thyroid manipulation in rats. Udoye MO, et al. **Res Commun Mol Pathol Pharmacol** 1997 Feb;95(2):221-4

The reversal of experimental hemorrhagic shock induced by nicotine and dimethylphenylpiperazinium is adrenal-dependent. Bazzani C, et al. **Resuscitation** 1996 Apr;31(2):145-50

Endothelin-1-induced incorporation of cholesterol into rat adrenals. Romero DG, et al. **Steroids** 1996 May; 61(5):317-22

Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Clark DJ, et al. **Thorax** 1996 Sep;51(9):941-3

Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Clark DJ, et al. **Thorax** 1997 Jan;52(1):55-8

[Isolation and study of the effect of zosterin, a pectin in sea grass from the White Sea, on the endocrine and immune systems] Korneichev ON, et al. **Dokl Akad Nauk** 1997 Jan; 352(1):121-3 **(Rus)**

[The participation of the neostriatum in realizing the action of corticoliberin on the hormonal function of the adrenal glands] Turkina EV, et al. **Fiziol Zh Im I M Sechenova** 1996 May-Jun;82(5-6):109-13 (Eng. Abstr.) **(Rus)**

[The reaction of the sympathoadrenal system to an acute peroral salt load in young persons with arterial hypertension] Berezniakov IG. **Lik Sprava** 1995 Sep-Dec; (9-12):114-7 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Ontogeny of epinephrine, norepinephrine, dopamine-beta-hydroxylase, and chromogranin A in the adrenal gland of pigs. Laroche SM, et al. **Am J Vet Res** 1996 Jul;57(7):1074-9

Effects of prenatal stress on the fetal calf. Lay DC Jr, et al. **Domest Anim Endocrinol** 1997 Mar;14(2):73-80

Functional maturation of the primate fetal adrenal in vivo: I. Role of insulin-like growth factors (IGFs), IGF-I receptor, and IGF binding proteins in growth regulation. Coulter CL, et al. **Endocrinology** 1996 Oct;137(10):4487-98

Inhibition of fetal adrenal adrenocorticotropin receptor messenger ribonucleic acid expression by betamethasone administration to the baboon fetus in late gestation. Levitt MG, et al. **Endocrinology** 1997 Jul;138(7):2705-12

Comparative stereological studies on zonation and cellular composition of adrenal glands of normal and anencephalic human fetuses. II. Cellular composition of the gland. Bocian-Sobkowska J, et al. **Histol Histopathol** 1997 Apr; 12(2):391-9

Comparative stereological study on zonation and cellular composition of adrenal glands of normal and anencephalic human fetuses. I. Zonation of the gland. Bocian-Sobkowska J, et al. **Histol Histopathol** 1997 Apr;12(2):311-7

17 alpha-Hydroxylase and chromogranin A in 6th week human fetal adrenals. Ehrhart-Bornstein M, et al. **Horm Metab Res** 1997 Jan;29(1):30-2

The role of the pituitary-thyroid axis in the developmental regulation of enkephalin-containing peptides in the superior cervical ganglia and adrenal of the fetal sheep. Simonetta G, et al. **J Auton Nerv Syst** 1996 Jun 10;59(1-2):34-40

A role for epidermal growth factor in the morphological and functional maturation of the adrenal gland in the fetal rhesus monkey in vivo. Coulter CL, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1254-60

The development of the ovine fetal adrenal gland and its regulation. Naaman Répérant E, et al. **Reprod Nutr Dev** 1997;37(1):81-95 (106 ref.)

Expression of cytochromes P450aldo and P45011 beta in rat adrenal gland during late gestational and neonatal stages. Mitani F, et al. **Steroids** 1997 Jan;62(1):57-61

ENZYMOLOGY

Functional molecular mass of rat hepatic lipase in liver, adrenal gland and ovary is different. Schoonderwoerd K, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):463-7

Effects of psychotropic drugs on aldo-keto reductase activity in rat ovary and adrenal gland. Inazu N, et al. **Biochem Pharmacol** 1996 Nov 22;52(10):1585-91

Dietary calcium supplementation and dopamine-beta-hydroxylase in spontaneously hypertensive rats. Nuglozeh E, et al. **Biochem Pharmacol** 1997 Jun 15; 53(12):1867-71

Immunological identification of cholesterol ester hydrolase in the steroidogenic tissues, adrenal glands and testis. Lee TG, et al. **Biochim Biophys Acta** 1997 Jun 2;1346(2):103-8

Adrenal 11 beta-hydroxysteroid dehydrogenase. Shimojo M, et al. **Endocr Res** 1996 Nov;22(4):771-80

Functional maturation of the primate fetal adrenal in vivo. II. Ontogeny of corticosteroid synthesis is dependent upon specific zonal expression of 3 beta-hydroxysteroid dehydrogenase/isomerase. Coulter CL, et al. **Endocrinology** 1996 Nov;137(11):4953-9

Participation of a stress-activated protein kinase cascade in the activation of tyrosine hydroxylase in chromaffin cells. Thomas G, et al. **Eur J Biochem** 1997 Aug 1;247(3):1180-9

Steroid sulfotransferases. Luu-The V, et al. **J Endocrinol** 1996 Sep;150 Suppl:S87-97

11 beta-Hydroxysteroid dehydrogenase in the rat adrenal. Shimojo M, et al. **J Mol Endocrinol** 1996 Oct;17(2):121-30

Immunocytochemical localization of GTP cyclohydrolase I in the brain, adrenal gland, and liver of mice. Nagatsu I, et al. **J Neural Transm Gen Sect** 1995;102(3):175-188

Intra-adrenal 11 beta-hydroxysteroid dehydrogenase plays a role in the regulation of corticosteroid secretion: an in vitro study in the rat. Musajo F, et al. **Life Sci** 1996; 59(17):1401-6

Tyrosine hydroxylase gene expression in varying forms of human pheochromocytoma [published erratum appears in Life Sci 1997;60(12):961-2] Tümer N, et al. **Life Sci** 1996; 59(19):1659-65

Immunolocalization of dehydroepiandrosterone sulfotransferase in normal and pathologic human adrenal gland. Sasano H, et al. **Mod Pathol** 1995 Dec;8(9):891-6

Influence of the thyroid hormone status on tyrosine hydroxylase in central and peripheral catecholaminergic structures. Claustre J, et al. **Neurochem Int** 1996 Mar; 28(3):277-81

Kyotorphin synthetase activity in rat adrenal glands and spinal cord. Kawabata A, et al. **Peptides** 1996;17(3):407-11

Dissociation between adrenal tyrosinehydroxylase and phenylethanolamine N-methyltransferase activities following repeated experience of defeats in individually housed male DBA/2J mice. Haemisch A, et al. **Physiol Behav** 1996 Jun;59(6):1117-22

A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. Kang MJ, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):2880-4

Immunolocalization of glutathione-peroxidase (GSH-PO) in human adrenal gland--studies on adrenocortical adenomas associated with primary aldosteronism and Cushing's syndrome. Murakoshi M, et al. **Tokai J Exp Clin Med** 1995 Jul;20(2):89-97

GROWTH & DEVELOPMENT

The role of early environmental events in regulating neuroendocrine development. Moms, pups, stress, and glucocorticoid receptors. Francis D, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:136-52 (81 ref.)

Adrenarche. Papadimas J. **Ann N Y Acad Sci** 1997 Jun 17; 816:57-9 (14 ref.)

Effects of food deprivation in early pregnancy on the development of ovaries and adrenals in female progeny of the water vole (Arvicola terrestris). Yakovleva TV, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jan;116(1):103-9

Adrenarche is associated with decreased 3 beta-hydroxysteroid dehydrogenase expression in the adrenal reticularis. Gell JS, et al. **Endocr Res** 1996 Nov; 22(4):723-8

Regulation of growth of the adrenal gland in DOC-salt hypertension. Role of angiotensin II receptor subtypes. Elijovich F, et al. **Hypertension** 1997 Jan;29(1 Pt 2):408-13

The roles of steroidogenic factor-1 in reproductive function. Parker KL, et al. **Steroids** 1996 Apr;61(4):161-5

IMMUNOLOGY

Absence of circulating adrenal autoantibodies in adult-onset X-linked adrenoleukodystrophy. Laureti S, et al. **Horm Metab Res** 1996 Jul;28(7):319-22

[Thyroid, ovarian and adrenal antibodies in female patients with autoimmune thyroiditis] Sterzl I, et al. **Cas Lek Cesk** 1997 Apr 16;136(8):249-52 (Eng. Abstr.) **(Cze)**

INNERVATION

Neuroendocrine effects on adrenal hormone secretion in carp (Cyprinus carpio). Gfell B, et al. **Gen Comp Endocrinol** 1997 Jun;106(3):310-9

Corticotropin-releasing hormone-like axons in the adrenal glands of fetal and postnatal sheep. Pomerantz JE, et al. **J Auton Nerv Syst** 1996 Jun 10;59(1-2):87-90

Effects of continuous and intermittent cold (SART) stress on sympathoadrenal system activity in rats. Fukuhara K, et al. **J Neuroendocrinol** 1996 Jan;8(1):65-72

Relationship of emotional behaviors induced by electrical stimulation of the hypothalamus to changes in EKG, heart, stomach, adrenal glands, and thymus. Kojima K, et al. **Psychosom Med** 1996 Jul-Aug;58(4):383-91

METABOLISM

The effect of lesions of the sympathoadrenal system on training induced adaptations in adipocytes and pancreatic islets in rats. Stallknecht B, et al. **Acta Physiol Scand** 1996 Apr;156(4):465-73

Water deprivation and rat adrenal mRNAs for tyrosine hydroxylase and the norepinephrine transporter. Brooks VL, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1897-903

Canine adrenal catecholamine response to VIP is blocked by PACAP-(6-27) in vivo. Gaspo R, et al. **Am J Physiol** 1997 May;272(5 Pt 2):R1606-12

Bovine adrenal endothelial cells express nucleoside transporters nonregulated by protein kinases A and C. Sen RP, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C504-10

Expression and cellular localization of tissue kallikrein-kinin system in human adrenal gland. Wang DZ, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F709-16

Effects of PACAP and VIP on adrenal progesterone release. Baranowska B, et al. **Ann N Y Acad Sci** 1996 Dec 26; 805:628-33

Perturbations of hypothalamic-pituitary-gonadal (HPG) axis and adrenal androgen (AA) functions in rheumatoid arthritis. Masi AT, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):295-332 (142 ref.)

Fibroblast growth factor receptor 1 in the adrenal gland and PC12 cells: developmental expression and regulation by extrinsic molecules. Meisinger C, et al. **Brain Res Mol Brain Res** 1996 Feb;36(1):70-8

Expression of neurotrophins and their receptors in the developing and adult rat adrenal gland. Suter-Crazzolara C, et al. **Brain Res Mol Brain Res** 1996 Dec 31; 43(1-2):351-5

Characteristics of cytosolic Ca2+ elevation induced by muscarinic receptor activation in single adrenal chromaffin cells of the guinea pig. Ohta T, et al. **Cell Calcium** 1996 Sep;20(3):303-14

Mn2+ can substitute for Ca2+ in causing catecholamine secretion but not for increasing tyrosine hydroxylase phosphorylation in bovine adrenal chromaffin cells. Powis DA, et al. **Cell Calcium** 1996 May;19(5):419-29

Androgens and the menopause; a study of 40-60-year-old women. Bancroft J, et al. **Clin Endocrinol (Oxf)** 1996 Nov; 45(5):577-87

Age-related changes in cerebral and peripheral monoamine contents in stroke-prone spontaneously hypertensive rats. Uchida T, et al. **Clin Exp Pharmacol Physiol Suppl** 1995; 1:S80-2

Effects of partial sympathectomy of brown fat or of adrenomedullectomy on catecholamine metabolism in cold-reared rats. Bertin R, et al. **Comp Biochem Physiol A Physiol** 1996 Jul;114(3):251-6

Peripheral chemosensitivity and central integration: neuroplasticity of catecholaminergic cells under hypoxia. Soulier V, et al. **Comp Biochem Physiol A Physiol** 1997 Sep;118(1):1-7

Characterization of the adrenal cytochrome P450C17 in the hamster, a small animal model for the study of adrenal dehydroepiandrosterone biosynthesis. Cloutier M, et al. **DNA Cell Biol** 1997 Mar;16(3):357-68

A nitric oxide synthesis inhibitor prevents the ACTH-stimulated production of aldosterone in rat adrenal gland. Nakayama T, et al. **Endocr J** 1996 Apr;43(2):157-62

Adrenocorticotropin regulates the level of the steroidogenic acute regulatory (StAR) protein mRNA in hamster adrenals. Fleury A, et al. **Endocr Res** 1996 Nov; 22(4):515-20

Production and metabolism of serotonin (5-HT) by the human adrenal gland. Lefebvre H, et al. **Endocr Res** 1996 Nov;22(4):851-3

Adrenal androgen production in response to adrenocorticotropin infusions in men. Parker CR Jr, et al. **Endocr Res** 1996 Nov;22(4):717-22

Localization, identification, and action of galanin in the frog adrenal gland. Gasman S, et al. **Endocrinology** 1996 Dec; 137(12):5311-8

Comparative study between normal rat chromaffin and PC12 rat pheochromocytoma cells: production and effects of corticotropin-releasing hormone. Venihaki M, et al. **Endocrinology** 1997 Feb;138(2):698-704

Trained versus untrained men: different immediate post-exercise responses of pituitary adrenal axis. A preliminary study. Duclos M, et al. **Eur J Appl Physiol** 1997;75(4):343-50

Immunoreactive brain natriuretic peptide in human adrenal glands and adrenal tumors. Totsune K, et al. **Eur J Endocrinol** 1996 Sep;135(3):352-6

Inhibition of [Ca2+]i transients in rat adrenal chromaffin cells by neuropeptide Y: role for a cGMP-dependent protein kinase-activated K+ conductance. Lemos VS, et al. **Eur J Neurosci** 1997 Jun;9(6):1144-52

Effect of ovarian stimulation on adrenal androgenesis? [letter; comment] Cumming DC, et al. **Fertil Steril** 1996 Dec; 66(6):1042-3. Comment on: Fertil Steril 1996 May;65(5):950-3.

Ten kilobases of 5'-flanking region confers proper regulation of the mouse alcohol dehydrogenase-1 (Adh-1) gene in kidney and adrenal of transgenic mice. Xie D, et al. **Gene** 1996 Nov 28;181(1-2):173-8

Differential distribution of endothelin peptides and receptors in human adrenal gland. Davenport AP, et al. **Histochem J** 1996 Nov;28(11):779-89

17 alpha-Hydroxylase and chromogranin A in 6th week human fetal adrenals. Ehrhart-Bornstein M, et al. **Horm Metab Res** 1997 Jan;29(1):30-2

Effects of physiological and supraphysiological doses of insulin on adrenal androgen levels. Polderman KH, et al. **Horm Metab Res** 1996 Mar;28(3):152-5

Synaptic vesicle proteins in cells of the sympathoadrenal lineage. Hou XE, et al. **J Auton Nerv Syst** 1996 Dec 14; 61(3):301-12

The role of the pituitary-thyroid axis in the developmental regulation of enkephalin-containing peptides in the superior

cervical ganglia and adrenal of the fetal sheep. Simonetta G, et al. **J Auton Nerv Syst** 1996 Jun 10;59(1–2):34–40
Nitric oxide reduces basal efflux of catecholamines from perfused dog adrenal glands. Ward LE, et al. **J Auton Nerv Syst** 1996 Dec 14;61(3):235–42
Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. Ng DS, et al. **J Biol Chem** 1997 Jun 20;272(25):15777–81
Inducible cAMP early repressor can modulate tyrosine hydroxylase gene expression after stimulation of cAMP synthesis. Tinti C, et al. **J Biol Chem** 1996 Oct 11; 271(41):25375–81
IQGAP1, a Rac- and Cdc42-binding protein, directly binds and cross-links microfilaments. Bashour AM, et al. **J Cell Biol** 1997 Jun 30;137(7):1555–66
The angiotensin AT2 receptor is present in the human fetal adrenal gland throughout the second trimester of gestation. Breault L, et al. **J Clin Endocrinol Metab** 1996 Nov; 81(11):3914–22
Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. Glasow A, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):3103–11
Novel presence of luteinizing hormone/chorionic gonadotropin receptors in human adrenal glands. Pabon JE, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2397–400
Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. Päth G, et al. **J Clin Endocrinol Metab** 1997 Jul; 82(7):2343–9
Tissue-specific changes in angiotensin II receptors in streptozotocin-diabetic rats. Brown L, et al. **J Endocrinol** 1997 Aug;154(2):355–62
Tyrosine kinases are required for catecholamine secretion and mitogen-activated protein kinase activation in bovine adrenal chromaffin cells. Cox ME, et al. **J Neurochem** 1996 Mar;66(3):1103–12
Induction of tyrosine hydroxylase protein and a transgene containing tyrosine hydroxylase 5' flanking sequences by stress in mouse adrenal gland. Osterhout CA, et al. **J Neurochem** 1997 Mar;68(3):1071–7
Differential regulation of histamine- and bradykinin-stimulated phospholipase C in adrenal chromaffin cells: evidence for involvement of different protein kinase C isoforms. Sena CM, et al. **J Neurochem** 1996 Mar;66(3):1086–94
Protein kinase C-mediated down-regulation of voltage-dependent sodium channels in adrenal chromaffin cells. Yanagita T, et al. **J Neurochem** 1996 Mar; 66(3):1249–53
Gas chromatographic-electron capture determination of 2,4'-dichlorodiphenylacetic acid from in-vitro adrenal transformations of mitotane and its analogs. Sinsheimer JE, et al. **J Pharm Biomed Anal** 1996 May;14(7):861–6
Neural stimulation of Egr-1 messenger RNA expression in rat adrenal gland: possible relation to phenylethanolamine N-methyltransferase gene regulation. Morita K, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):379–85
Evidence for spare nicotinic acetylcholine receptors and a beta 4 subunit in bovine adrenal chromaffin cells: studies using bromoacetylcholine, epibatidine, cytisine and mAb35. Wenger BW, et al. **J Pharmacol Exp Ther** 1997 May; 281(2):905–13
Ca2+ clearance mechanisms in isolated rat adrenal chromaffin cells. Park YB, et al. **J Physiol (Lond)** 1996 Apr 15;492 (Pt 2):329–46
Inositol 1,4,5-trisphosphate- and caffeine-sensitive Ca(2+)-storing organelle in bovine adrenal chromaffin cells. Teraoka H, et al. **Jpn J Pharmacol** 1996 Dec; 72(4):307–15
Pituitary transplantation--a study on the response of hypophysis-adrenal axis to physiological stress. Wang CJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Feb; 13(2):92–6
Type II (glucocorticoid) receptors mediate fast-feedback inhibition of the hypothalamic-pituitary-adrenal axis in man. Cooney JM, et al. **Life Sci** 1996;59(23):1981–8
Tonic suppression of adrenal AP-1 activity by glucocorticoids. Smith M, et al. **Mol Cell Endocrinol** 1996 Sep 18;122(2):151–8
Effect of cholinergic blockade on glucocorticoid regulation of NPY and catecholamines in the rat adrenal gland. Laborie C, et al. **Neuroendocrinology** 1997 Aug; 66(2):98–105
Feeding and the diurnal variation of the hypothalamic-pituitary-adrenal axis and its responses to CRH and ACTH in rats. Leal AM, et al. **Neuroendocrinology** 1996 Jul;64(1):14–9
Expression of trkA and p75 nerve growth factor receptors in the adrenal gland. Michael GJ, et al. **Neuroreport** 1996 Jul 8;7(10):1617–22
Serotonin increases Na(+)-dependent Ca2+ efflux from bovine adrenal chromaffin cells in culture. Minakuchi K, et al. **Neurosci Lett** 1997 Feb 14;223(1):17–20
Immunocytochemical localization of adrenomedullin-like immunoreactivity in the human hypothalamus and the adrenal gland. Satoh F, et al. **Neurosci Lett** 1996 Jan 26; 203(3):207–10
Long-term impairment in the neurochemical activity of the sympathoadrenal system after neonatal hypoxia in the rat. Soulier V, et al. **Pediatr Res** 1997 Jul;42(1):30–8
Two types of omega-agatoxin IVA-sensitive Ca2+ channels are coupled to adrenaline and noradrenaline release in bovine adrenal chromaffin cells. Baltazar G, et al. **Pflugers Arch** 1997 Sep;434(5):592–8
Stimulation of microsomal spironolactone metabolism by reduced glutathione. Colby HD, et al. **Pharmacology** 1996 Jan;52(1):30–4
Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: evidence suggesting multiple cholesterol esterification enzymes in mammals. Meiner VL, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):14041–6
Fawn-hooded rats show enhanced active behaviour in the forced swimming test, with no evidence for pituitary-adrenal axis hyperactivity. Lahmame A, et al. **Psychopharmacology (Berl)** 1996 May;125(1):74–8
Effect of splanchnic nerve section and compensatory adrenal hypertrophy on rat adrenal neuropeptide content. Hinson JP, et al. **Regul Pept** 1996 Feb 22;61(2):105–9
Neuroendocrine effects of cytokines in the rat. Rivier C. **Rev Neurosci** 1993 Jul-Sep;4(3):223–37 (157 ref.)
Control of cholesterol access to cytochrome P450scc in rat adrenal cells mediated by regulation of the steroidogenic acute regulatory protein. Kim YC, et al. **Steroids** 1997 Jan; 62(1):10–20
The testis and the adrenal are (transcriptionally) the same. Mellon SH, et al. **Steroids** 1997 Jan;62(1):46–52
Expression of cytochromes P450aldo and P45011 beta in rat adrenal gland during late gestational and neonatal stages. Mitani F, et al. **Steroids** 1997 Jan;62(1):57–61
[Adrenal glands catecholamines of August and Wistar rats in acute emotional stress] Pertsov SS, et al. **Biull Eksp Biol Med** 1997 Jun;123(6):645–8 **(Rus)**

PARASITOLOGY

Immunocytochemical study of tissue parasitism of dog adrenal glands in experimental Chagas' disease. Caliari MV, et al. **Parasite** 1994 Dec;1(4):397–400

PATHOLOGY

Change in the composition of adrenal nodules after therapy as revealed by opposed-phase MR imaging. Kainz G, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):549–50
Truncation artifact in dynamic MR imaging for small adrenal mass [letter] Kanematsu M, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):1070
Adrenal gland volume in major depression: relationship to basal and stimulated pituitary-adrenal cortical axis function. Rubin RT, et al. **Biol Psychiatry** 1996 Jul 15; 40(2):89–97
Primary aldosteronism due to unilateral adrenal hyperplasia: a case report. Chen LG, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Feb; 59(2):114–20
Unilateral adrenal enlargement due to Histoplasma capsulatum. Swartz MA, et al. **Clin Infect Dis** 1996 Oct; 23(4):813–5
Changes in the size of adrenal glands in acute pulmonary tuberculosis with therapy. Gülmez I, et al. **Endocr J** 1996 Oct;43(5):573–6
ACTH-independent macronodular adrenocortical hyperplasia (AIMAH): report of two cases and the analysis of steroidogenic activity in adrenal nodules. Morioka M, et al. **Endocr J** 1997 Feb;44(1):65–72
Outcome of incidental adrenal masses not operated on: 44 cases over 7 years [letter; comment] Courtade A, et al. **Eur J Surg** 1997 Apr;163(4):315. Comment on: Eur J Surg 1996 Apr;162(4):275–8.
State-of-the-art CT and MRI of the adrenal gland. Peppercorn PD, et al. **Eur Radiol** 1997;7(6):822–36 (117 ref.)
Adrenal glands in anencephaly. Bocian-Sobkowska J, et al. **Folia Morphol (Warsz)** 1996;55(4):214–6
Concerning the paper by Lacomte et al., entitled: 'Stressful events as a trigger of sudden death: a study of 43 medico-legal autopsies case' (Forensic Sci. Int., 79 (1996) 1–10) [letter; comment] Aragona F. **Forensic Sci Int** 1997 Feb 28;85(2):159–60. Comment on: Forensic Sci Int 1996 May 17;79(1):1–10.
Primary adrenal lymphoma presenting as Addisonian crisis. Pitfalls in the diagnosis of bilateral adrenal swelling [letter] Sone H, et al. **Horm Metab Res** 1996 Feb;28(2):116
Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. Lacroix A, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2414–22
A simple technique for identifying the adrenal glands at necropsy. Shimizu M, et al. **J Clin Pathol** 1997 Mar; 50(3):263–4
Idiopathic hyperplasia of the adrenal gland behaving like an aldosterone producing adenoma. Rao A, et al. **J Endocrinol Invest** 1997 Jan;20(1):29–31
Incidentally discovered adrenal masses. Francis IR, et al. **Magn Reson Imaging Clin N Am** 1997 Feb;5(1):147–64 (82 ref.)
The adrenal gland: radiologic-pathologic correlation. Krebs TL, et al. **Magn Reson Imaging Clin N Am** 1997 Feb; 5(1):127–46 (54 ref.)
Cushing's syndrome due to autonomous macronodular adrenal hyperplasia: long-term follow-up after unilateral adrenalectomy. Boronat M, et al. **Postgrad Med J** 1996 Oct;72(852):614–6
Adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia presenting as pre-Cushing's syndrome. Izumi T, et al. **Urol Int** 1997;58(4):262–5
ACTH-independent bilateral macronodular adrenocortical hyperplasia caused Cushing's syndrome. Miyajima A, et al. **Urol Int** 1997;58(4):259–61 (5 ref.)
Senile amyloidoses of the pituitary and adrenal glands. Morphological and statistical investigations. Röcken C, et al. **Virchows Arch** 1996 Nov;429(4–5):293–9
[The effect of interleukin-1beta on the state of thymus, adrenals and spleen during immersion emotional stress in August, Wistar and Wag rats] Pertsov SS, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):32–5 **(Rus)**
[Neonatal suprarenal abscess: a diagnosis to be taken into account] Sanz Villa N, et al. **Cir Pediatr** 1997 Jan;10(1):42–3 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Plasma angiotensins and human forearm circulation: effects of sympatho-adrenal activation. Kahan T, et al. **Acta Physiol Scand** 1997 Feb;159(2):107–11
Central trigeminal effects of somatostatin and etorphine on adrenal and autonomic function in the cat. Bereiter DA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):R636–44
Dexamethasone rapidly increases hypothalamic neuropeptide Y secretion in adrenalectomized ob/ob mice. Chen HL, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E151–8
Regulation of ANG II-receptor subtype and its gene expression in adrenal gland. Du Y, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H440–6
Role of the adrenal glands in the maturation of lung liquid secretory mechanisms in fetal sheep. Wallace MJ, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):R33–40
Role of ET(A) and ET(B) receptors in endothelin-1-induced adrenal catecholamine secretion in vivo. Yamaguchi N. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1290–7
Effect of reserpine treatment and hypophysectomy on the nitric oxide synthase immunoreactivity and NADPH-diaphorase staining in the rat adrenal gland. Afework M, et al. **Anat Rec** 1996 Dec;246(4):545–8
Pituitary adenylate cyclase-activating polypeptide regulates both adrenocortical and chromaffin cell activity in the frog adrenal gland. Yon L, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:697–701
Skeletal response to corticosteroid deficiency and excess in growing male rats. Li M, et al. **Bone** 1996 Aug;19(2):81–8
Contribution of adrenal hormones to nicotine-induced inhibition of synovial plasma extravasation in the rat. Miao FJ, et al. **Br J Pharmacol** 1997 Jan;120(2):298–304
Effect of adrenalectomy on cocaine facilitation of lateral hypothalamic self-stimulation. Abrahamsen GC, et al. **Brain Res** 1997 Apr 25;755(1):156–61
Adrenalectomy enhances pro-inflammatory cytokines gene expression, in the spleen, pituitary and brain of mice in response to lipopolysaccharide. Goujon E, et al. **Brain Res Mol Brain Res** 1996 Feb;36(1):53–62
Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche. Weber A, et al. **Clin Endocrinol (Oxf)** 1997 Apr;46(4):431–7
Differential regulation of angiotensin peptides in plasma and kidney: effects of adrenalectomy and estrogen treatment. Campbell DJ. **Clin Exp Hypertens** 1997 Jul-Aug; 19(5–6):687–98
Effects of cytokines on pituitary beta-endorphin and adrenal corticosterone release in vitro. van der Meer MJ, et al. **Cytokine** 1996 Mar;8(3):238–47
Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: leptin inhibits cortisol release directly. Bornstein SR, et al. **Diabetes** 1997 Jul;46(7):1235–8
Effects of adrenalectomy on serotonin-, somatostatin-, and gastrin-immunoreactive cells in rat gastrointestinal tract. Glória H, et al. **Dig Dis Sci** 1997 Jun;42(6):1216–20
Pro-opiomelanocortin and adrenal function. Bicknell AB, et al. **Endocr Res** 1996 Nov;22(4):385–93
Phenotypic changes and proliferation of adrenocortical cells during adrenal regeneration in rats. Engeland WC, et al. **Endocr Res** 1996 Nov;22(4):395–400
Direct effects of interleukin-6 on human adrenal cells. Päth G, et al. **Endocr Res** 1996 Nov;22(4):867–73
Localization, identification, and action of galanin in the frog adrenal gland. Gasman S, et al. **Endocrinology** 1996 Dec; 137(12):5311–8
Adrenalectomy after weaning restores beta3-adrenergic receptor expression in white adipocytes from C57BL/6J-ob/ob mice. Gettys TW, et al. **Endocrinology** 1997 Jul;138(7):2697–704
Adrenal control of erectile function and nitric oxide synthase in the rat penis. Penson DF, et al. **Endocrinology** 1997 Sep; 138(9):3925–32
A speculative review of parturition in the mare. Thorburn GD. **Equine Vet J Suppl** 1993 Apr;(14):41–9 (72 ref.)
The adrenal gland and ACTH [letter] Bornstein SR, et al. **Eur J Endocrinol** 1996 Dec;135(6):739
Sympathoadrenal system and immune system in the regulation of adrenocortical function. Ehrhart-Bornstein M, et al. **Eur J Endocrinol** 1996 Jul;135(1):19–26 (133 ref.)
Chronic loss of glucocorticoids following adrenalectomy down-regulates the expression of glucocorticoid receptor mRNA in the rat forebrain. Hu Z, et al.

Eur J Neurosci 1997 Aug;9(8):1778–83

Adrenal independence of fluid and electrolyte reabsorption in the ductuli efferentes testis of the rat. Man SY, et al. **Exp Physiol** 1997 Mar;82(2):283–90

Thymocyte and splenocyte subpopulations in normal and leukemia-bearing mice after adrenalectomy. Kawiak J, et al. **Folia Histochem Cytobiol** 1996;34(2):75–8

The thyroid hormone, 3,5,3'-triiodothyronine, is a negative modulator of domestic fowl (Gallus gallus domesticus) adrenal steroidogenic function. Carsia RV, et al. **Gen Comp Endocrinol** 1997 Aug;107(2):251–61

Perinatal development of rat cerebellum from adrenalectomized mothers. Cuchillo I, et al. **Int J Dev Biol** 1996;Suppl 1:263S–264S

The effect of acute bilateral adrenalectomy on serotonin-induced inhibition of gastric acid secretion and acute gastric mucosal injury in rats. Gidener S, et al. **Int J Exp Pathol** 1996 Aug;77(4):163–6

Decreased sympatho-adrenal activity in diabetic patients with autonomic dysfunction following mental stress. Forst T, et al. **J Auton Nerv Syst** 1996 Oct 7;61(1):31–6

Short-term estradiol treatment enhances pituitary-adrenal axis and sympathetic responses to psychosocial stress in healthy young men [see comments] Kirschbaum C, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3639–43. Comment in: J Clin Endocrinol Metab 1997 Mar;82(3):982.

Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. Liu J, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1766–71

Transcription of the human genes for cytochrome P450scc and P450c17 is regulated differently in human adrenal NCI-H295 cells than in mouse adrenal Y1 cells. Rodriguez H, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):365–71

Tonic support of luteinizing hormone secretion by adrenal progesterone in the ovariectomized monkey replaced with midfollicular phase levels of estradiol. Xiao E, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2233–8

Distinct populations of cells in the adult dentate gyrus undergo mitosis or apoptosis in response to adrenalectomy. Cameron HA, et al. **J Comp Neurol** 1996 May 20; 369(1):56–63

ATP and [3H]noradrenaline release and the presence of ecto-Ca(2+)-ATPases in the capsule-glomerulosa fraction of the rat adrenal gland. Jurányi Z, et al. **J Endocrinol** 1997 Apr;153(1):105–14

Expression patterns of the c-myc gene in adrenocortical tumors and pheochromocytomas. Liu J, et al. **J Endocrinol** 1997 Feb;152(2):175–81

Bilateral adrenal enucleation-induced changes in adenohypophyseal pro-opiomelanocortin (POMC)-related peptides synthesis and secretion: a comparative study with adrenalectomized rats. Perone MJ, et al. **J Endocrinol Invest** 1997 Apr;20(4):172–82

Activational effects of gonadal steroids on hypothalamo-pituitary-adrenal regulation in the rat disclosed by response to dexamethasone suppression. Almeida OF, et al. **J Neuroendocrinol** 1997 Feb;9(2):129–34

Long-term adrenalectomy can decrease or increase hippocampal dentate gyrus volumes. Conrad CD, et al. **J Neuroendocrinol** 1997 May;9(5):355–61

Endogenous neurotensin regulates hypothalamic-pituitary-adrenal axis activity and peptidergic neurons in the rat hypothalamic paraventricular nucleus. Nicot A, et al. **J Neuroendocrinol** 1997 Apr; 9(4):263–9

The modulatory role of estrogens on corticotropin-releasing factor gene expression in the hypothalamic paraventricular nucleus of ovariectomized rats: role of the adrenal gland. Paulmyer-Lacroix O, et al. **J Neuroendocrinol** 1996 Jul; 8(7):515–9

Plasma neuropeptide Y and catecholamines in pediatric patients undergoing cardiac operations. Sun LS, et al. **J Thorac Cardiovasc Surg** 1997 Feb;113(2):278–84

Effect of adrenalectomy on distal nephron lithium reabsorption induced by potassium depletion. Thomsen K, et al. **Kidney Blood Press Res** 1997;20(1):31–7

Hypothalamic metabolism of neurotransmitters (serotonin, norepinephrine, dopamine) and NPY, and gonadal and adrenal activities, during the early postnatal period in the rat. Lesage J, et al. **Neurochem Res** 1996 Jan;21(1):87–96

Hypothalamic-pituitary-adrenal activation by the bacterial superantigen staphylococcal enterotoxin B: role of macrophages and T cells. Shurin G, et al. **Neuroendocrinology** 1997 Jan;65(1):18–28

Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. Wilkinson CW, et al. **Neuroendocrinology** 1997 Jan;65(1):79–90

Effects of psychological stress on joint inflammation and adrenal function during induction of arthritis in the Lewis rat. Miller SC, et al. **Neuroimmunomodulation** 1995 Nov-Dec;2(6):329–38

PACAP in the adrenal gland—relationship with choline acetyltransferase, enkephalin and chromaffin cells and effects of immunological sympathectomy. Holgert H, et al. **Neuroreport** 1996 Dec 20;8(1):297–301

Phenotypic development of neonatal rat chromaffin cells in response to adrenal growth factors and glucocorticoids: focus on pituitary adenylate cyclase activating polypeptide. Wolf N, et al. **Neurosci Lett** 1995 Nov 24;200(3):207–10

Responses of adrenal function to stimulation of lumbar and thoracic interspinous tissues in the rat. Budgell B, et al. **Neurosci Res** 1997 May;28(1):33–40

Elevated basal trough levels of corticosterone suppress hippocampal 5-hydroxytryptamine(1A) receptor expression in adrenally intact rats: implication for the pathogenesis of depression. Meijer OC, et al. **Neuroscience** 1997 Sep;80(2):419–26

A low sympathoadrenal activity is associated with body weight gain and development of central adiposity in Pima Indian men. Tataranni PA, et al. **Obes Res** 1997 Jul; 5(4):341–7

Precocious enhancement of intestinal fructose uptake by diet in adrenalectomized rat pups. Monteiro IM, et al. **Pediatr Res** 1997 Mar;41(3):353–8

Calcium channel subtypes in porcine adrenal chromaffin cells. Kitamura N, et al. **Pflugers Arch** 1997 Jun; 434(2):179–87

Adrenocortical responses to repeated parachute jumping and subsequent h-CRH challenge in inexperienced healthy subjects. Deinzer R, et al. **Physiol Behav** 1997 Apr; 61(4):507–11

Group selection for adaptation to multiple-hen cages: hematology and adrenal function. Hester PY, et al. **Poult Sci** 1996 Nov;75(11):1295–307

Distinct roles of C2A and C2B domains of synaptotagmin in the regulation of exocytosis in adrenal chromaffin cells. Ohara-Imaizumi M, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):287–91

Saliva cortisol and testosterone in the guinea pig: measures for the endocrine function of adrenals and testes? Fenske M. **Steroids** 1996 Nov;61(11):647–50

Mineralocorticoids, salt and high blood pressure. Gómez-Sánchez EP, et al. **Steroids** 1996 Apr;61(4):184–8 (51 ref.)

Adrenal physiology. Kemppainen RJ, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):173–86 (26 ref.)

Postpartum adrenal, pituitary and ovarian functions in dairy cows. Torres E, et al. **Zentralbl Veterinarmed A** 1997 May; 44(3):133–42

[Changes in hemodynamics and the sympathetic-adrenal system during combined transcutaneous electric nerve stimulation in minor surgical interventions] Ostreikov IF, et al. **Anesteziol Reanimatol** 1995 Nov-Dec;(6):20–3 **(Rus)**

[Effect of opiate receptor ligands on the morpho-functional state of the sympathico-adrenal system and electrical stability of the heart in acute exposure to cold] Lishmanov IuB, et al. **Biull Eksp Biol Med** 1997 Feb;123(2):154–7 **(Rus)**

[Dynamics of parameters of the functional activity of the thyroid gland and adrenal cortex during human adaptation to new ecologic conditions] Zhekalov AN, et al. **Fiziol Cheloveka** 1997 Jan-Feb;23(1):10–4 **(Rus)**

[The effect of lessons with a computer on the function of the sympathoadrenal and hypothalamo-hypophyseal-adrenal systems in 6-year-old children] Gubareva LI, et al. **Fiziol Zh Im I M Sechenova** 1996 Apr;82(4):81–5 (Eng. Abstr.) **(Rus)**

[The conditioned-reflex reaction of the sympathoadrenal system to an aversive taste stimulus] Kassil' VG, et al. **Fiziol Zh Im I M Sechenova** 1996 Mar;82(3):57–65 (Eng. Abstr.) **(Rus)**

[Effect of adrenalectomy on alkaline phosphatase isoenzymes in intact and pregnant mice] Tsirel'nikov NI, et al. **Patol Fiziol Eksp Ter** 1996 Jul-Sep;(3):26–8 (Eng. Abstr.) **(Rus)**

[Emotional stress and sleep: a study of adrenalectomized rats] Koval'zon VM, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 May-Jun; 47(3):584–91 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Adrenalectomy protects ethanol-withdrawn rats from harmine-induced tremor. Lamblin F, et al. **Alcohol Alcohol** 1996 Mar;31(2):175–81

Pituitary and adrenals are required for hyperglycemic reflex initiated by stimulation of CBR with cyanide. Alvarez-Buylla R, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R392–9

Diagnosis of adrenal insufficiency [letter] Barron J. **Ann Clin Biochem** 1996 Jul;33 (Pt 4):357

Clinical adrenal insufficiency in patients receiving megestrol therapy. Subramanian S, et al. **Arch Intern Med** 1997 May 12;157(9):1008–11

Effect of decreased plasma low-density lipoprotein levels on adrenal and testicular function in man. Arem R, et al. **Clin Biochem** 1997 Jul;30(5):419–24

Cyclosporine A-induced hypertension in SHR and WKY: role of the sympatho-adrenal system. Grobecker HF, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S94–5

Hypothalamic-pituitary-adrenal axis in WBN/Kob rats with non-insulin dependent diabetes mellitus. Tojo C, et al. **Endocr J** 1996 Apr;43(2):233–9

Inhibition of corticosteroid-binding globulin caused by a severe stressor is apparently mediated by the adrenal but not by glucocorticoid receptors. Martí O, et al. **Endocrine** 1997 Apr;6(2):159–64

Thyroid and adrenal function in HIV-infected outpatients. Schürmeyer TH, et al. **Eur J Med Res** 1997 May 28; 2(5):220–6

Adrenal functions in patients with sepsis. Aygen B, et al. **Exp Clin Endocrinol Diabetes** 1997;105(3):182–6

Hypothalamic-pituitary-adrenal function following cranial irradiation. Oberfield SE, et al. **Horm Res** 1997;47(1):9–16

Assessment of adrenal function in women heterozygous for adrenoleukodystrophy. el-Deiry SS, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):856–60

Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. Lacroix A, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2414–22

Adrenal and gonadal function in hypothyroid adult male rats. Tohei A, et al. **J Endocrinol** 1997 Jan;152(1):147–54

An unusual case of adrenal failure due to isolated metastases of breast cancer. Davi MV, et al. **J Endocrinol Invest** 1996 Jul-Aug;19(7):488–9

Abuse of therapy with corticosteroids in the asthmatic patient and the deficient control of suprarenal function. Indication of therapy with ACTH. Oehling A, et al. **J Investig Allergol Clin Immunol** 1996 Nov-Dec; 6(6):349–55

Interrelations between sympathoadrenal system and hypothalamo-pituitary-adrenocortical/thyroid systems in rats exposed to cold stress. Fukuhara K, et al. **J Neuroendocrinol** 1996 Jul;8(7):533–41

Dynamic variations in plasma corticosteroid-binding globulin and basal HPA activity following acute stress in adult rats. Tannenbaum B, et al. **J Neuroendocrinol** 1997 Mar; 9(3):163–8

Evaluation of adrenal function in long standing pulmonary tuberculosis: a study of 100 cases. Siddiqi S, et al. **JPMA J Pak Med Assoc** 1997 May;47(5):132–4

Impaired adaptation of the hypothalamic-pituitary-adrenal axis to chronic ethanol stress in aged rats. Spencer RL, et al. **Neuroendocrinology** 1997 May;65(5):353–9

Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder. Schreiber W, et al. **Neuropsychopharmacology** 1996 Jul;15(1):7–15

Adrenal involvement in polycystic ovary syndrome. Gonzalez F. **Semin Reprod Endocrinol** 1997 May; 15(2):137–57 (129 ref.)

No increased prevalence of adrenocortical insufficiency in human immunodeficiency virus-associated tuberculosis. Hawken MP, et al. **Tuber Lung Dis** 1996 Oct;77(5):444–8

[The reactions of the sympathoadrenal system during the correction of acquired mitral defects under perfusion-free hypothermia] Tsvetovskaia GA, et al. **Anesteziol Reanimatol** 1996 May-Jun;(3):35–8 (Eng. Abstr.) **(Rus)**

[The effectiveness of correcting adrenal and thyroid functions in viral hepatitis] Mavrodii VM, et al. **Klin Med (Mosk)** 1996;74(2):28–30 **(Rus)**

[Sympathoadrenal activity during the treatment of patients with cancer of the stomach and large intestine] Ial'chenko NA. **Lik Sprava** 1997 Mar-Apr;(2):40–3 (Eng. Abstr.) **(Rus)**

[Effects of hypoxia on the activity of the sympathetic-adrenal system] Nagnibeda NN. **Vestn Ross Akad Med Nauk** 1997; (5):19–23 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Computed tomography morphology of the adrenal glands of patients with Addison's disease. Ammini AC, et al. **Australas Radiol** 1996 Feb;40(1):38–42

A horseshoe adrenal gland in an infant with asplenia. Shafaie FF, et al. **Pediatr Radiol** 1997 Jul;27(7):591–3

RADIONUCLIDE IMAGING

Adrenal glands imaging with indium-111-DTPA-D-Phe1-octreotide following ACTH therapy. Lorberboym M, et al. **J Nucl Med** 1997 Sep; 38(9):1489–91

SECRETION

Functional role of platelet-activating factor receptor in secretory response in adrenal chromaffin cells. Dohi T, et al. **Adv Exp Med Biol** 1996;416:101–5 (28 ref.)

Effects of dihydropyridines on aldosterone secretion in adrenal capsule preparations from pregnant rats. Brochu M, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E18–24

Cellular mechanism of substance P in the regulation of corticosteroid secretion by newt adrenal gland. Gobbetti A, et al. **Biochem Biophys Res Commun** 1997 Apr 17; 233(2):395–400

Interaction between G protein-operated receptors eliciting secretion in rat adrenals. A possible role of protein kinase C. Alvarez C, et al. **Biochem Pharmacol** 1997 Feb 7; 53(3):317–25

Release of amino acids and related compounds from the adrenal equivalent and caudal vein of the eel in vitro. Milakofsky L, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Nov;112(3):275–83

Vasoactive intestinal peptide is a local regulator of adrenocortical function. Hinson JP, et al. **Endocr Res** 1996 Nov;22(4):831–8

Effect of endothelin-1 on corticosteroid secretion by the frog adrenal gland is mediated by an endothelinA receptor. Cartier F, et al. **Endocrinology** 1997 Oct;138(10):4358–63

Glucocorticoids potentiate effect of ACTH on cortisol

secretion in isolated perfused guinea pig adrenal glands. Mokuda O, et al. **Exp Clin Endocrinol Diabetes** 1997; 105(2):119–21

Diurnal activity and pulsatility of the hypothalamus–pituitary–adrenal system in male depressed patients and healthy controls. Deuschle M, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):234–8

The steroidogenic effects of beta-endorphin and joining peptide: a potential role in the modulation of adrenal androgen production. Clarke D, et al. **J Endocrinol** 1996 Nov;151(2):301–7

Slow wave sleep drives inhibition of pituitary–adrenal secretion in humans. Bierwolf C, et al. **J Neuroendocrinol** 1997 Jun;9(6):479–84

Stimulation of secretion from bovine adrenal chromaffin cells by microsecond bursts of therapeutic levels of ultrasound. Robinson IM, et al. **J Physiol (Lond)** 1996 Apr 1;492 (Pt 1):257–63

The adrenal glands as suppliers of plasma L–Dopa and sources of urinary dopamine. Hansell P, et al. **Kidney Blood Press Res** 1996;19(2):109–14

Mechanisms determining the time course of secretion in neuroendocrine cells. Chow RH, et al. **Neuron** 1996 Feb; 16(2):369–76

Adrenarche and fetal growth. Francois I, et al. **Pediatr Res** 1997 Mar;41(3):440–2

Aldosterone release from adrenal cells is inhibited by reduced oxygen levels in vitro during maturation in rabbits. Papanek PE, et al. **Reprod Fertil Dev** 1996;8(8):1131–6

[Secretion of endothelin-1 by cultured human normal adrenal cells] Pu Y, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Feb; 18(1):5–10 (Eng. Abstr.) **(Chi)**

[Angiotensin II and the adrenal gland] Ying YR, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):70–2 (10 ref.) **(Chi)**

SURGERY

[Laparoscopic surgery of adrenal glands: indications and limits] Henry JF, et al. **Ann Endocrinol (Paris)** 1996; 57(6):520–5 (Eng. Abstr.) **(Fre)**

[Adrenal gland resection with laparoscopy or lumboscopy. The Paris experience] Chapuis Y, et al. **Chirurgie** 1997; 122(2):106–10 (Eng. Abstr.) **(Fre)**

TRANSPLANTATION

Modulation of autotransplanted adrenal gland by endothelin-1: a morphological and biochemical study. Vendeira P, et al. **Anat Rec** 1996 Sep;246(1):98–106

Adrenal chromaffin cells on microcarriers exhibit enhanced long-term functional effects when implanted into the mammalian brain. Cherksey BD, et al. **Neuroscience** 1996 Nov;75(2):657–64

[Simultaneous allotransplantation of the adrenal gland and the kidney] Dubernard JM, et al. **Chirurgie** 1996; 121(3):181–5; discussion 185–6 (Eng. Abstr.) **(Fre)**

[Treatment of adrenal diseases using transplantation of cultured adrenal tissue from newborn piglets] Egorov IuI, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):389–91 **(Rus)**

ULTRASONOGRAPHY

The role of ultrasound tomography in diagnosing adrenal pathology. Nedeva A, et al. **Folia Med (Plovdiv)** 1996; 38(2):31–7

Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration of the left adrenal gland. Chang KJ, et al. **Gastrointest Endosc** 1996 Nov;44(5):568–72

Adrenal incidentalomas--analysis of 23 cases discovered by ultrasound. Goncalvesová E, et al. **Neoplasma** 1997; 44(2):137–41

Ultrasonographic adrenal gland measurements in dogs without evidence of adrenal disease. Douglass JP, et al. **Vet Radiol Ultrasound** 1997 Mar–Apr;38(2):124–30

Adrenal ultrasonography correlated with histopathology in ferrets. Neuwirth L, et al. **Vet Radiol Ultrasound** 1997 Jan–Feb;38(1):69–74

ULTRASTRUCTURE

A new type of cell death, the protruded type, observed in the adrenal gland of normal rats. Chen-Pan C, et al. **J Vet Med Sci** 1996 Apr;58(4):373–6

Estimation of mean exocytic vesicle capacitance in mouse adrenal chromaffin cells. Moser T, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6735–40

ADRENAL GLOMERULOSA see **ZONA GLOMERULOSA**

ADRENAL HYPERPLASIA, CONGENITAL

see related
PUBERTY, PRECOCIOUS
VIRILISM

Congenital adrenal hyperplasia in Turkey: a review of 273 patients. Kandemir N, et al. **Acta Paediatr** 1997 Jan; 86(1):22–5

21-hydroxylase deficiency. Newfield RS, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:219–29 (25 ref.)

[Congenital adrenal hyperplasia--is there a need for a national screening program] Davidovitch N, et al. **Harefuah** 1997 Jun 1;132(11):771–5 (32 ref.) **(Heb)**

[Results of genitoplasty for virilized genitalia of 41 females with congenital adrenal hyperplasia] Kitahara S, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Dec;87(12):1289–96 (Eng. Abstr.) **(Jpn)**

[Carney syndrome] Asakura Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):501–4 (8 ref.) **(Jpn)**

[Congenital adrenal hyperplasia. Presentation of a case and review of the literature] Kleiman-Podlipsky J, et al. **Ginecol Obstet Mex** 1996 Oct;64:455–8 (19 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Late-onset congenital adrenal hyperplasia. Panitsa-Faflia C, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:230–4 (06 ref.)

Value of direct measurement of active renin concentrations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Krüger C, et al. **Eur J Pediatr** 1996 Oct; 155(10):858–61

Plasma 3 alpha-androstanediol glucuronide in normal children and in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Lopes LA, et al. **Horm Res** 1997;48(1):35–40

COMPLICATIONS

Thrombocytosis in congenital adrenal hyperplasia at diagnosis [letter; comment] Yohannan MD, et al. **Clin Pediatr (Phila)** 1997 Mar;36(3):186. Comment on: Clin Pediatr (Phila) 1996 May;35(5):267–9.

Case report. An unusual case of precocious puberty. Boulware SD. **Curr Opin Pediatr** 1997 Aug;9(4):443–6

Case of the day. Bilateral intratesticular masses (adrenal rests) in a patient with congenital adrenal hyperplasia. Townsend R, et al. **J Ultrasound Med** 1997 Apr;16(4):301

Testis sparing surgery for steroid unresponsive testicular tumors of the adrenogenital syndrome. Walker BR, et al. **J Urol** 1997 Apr;157(4):1460–3

Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin-releasing hormone analog. Soliman AT, et al. **Metabolism** 1997 May;46(5):513–7

[Pituitary enlargement in congenital adrenal hyperplasia] Bureau B, et al. **Ann Endocrinol (Paris)** 1996;57(5):443–4 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Molecular approaches for the diagnosis of 21-hydroxylase deficiency and congenital adrenal hyperplasia. Wedell A. **Clin Lab Med** 1996 Mar;16(1):125–37 (45 ref.)

Case report. An unusual case of precocious puberty. Boulware SD. **Curr Opin Pediatr** 1997 Aug;9(4):443–6

15 beta-hydroxylated steroids may be diagnostically misleading in confirming congenital adrenal hyperplasia suspected by a newborn screening programme. Lange-Kubini K, et al. **Eur J Pediatr** 1996 Nov; 155(11):928–31

Detection of CAH heterozygotes [letter; comment] Azziz R. **Fertil Steril** 1997 Jul;68(1):183; discusssion 183–4. Comment on: Fertil Steril 1996 Oct;66(4):557–63.

Detection of CAH heterozygotes [letter; comment] Chryssikopoulos A. **Fertil Steril** 1997 Jul;68(1):182; discussion 183–4. Comment on: Fertil Steril 1996 Oct;66(4):557–63.

Magnetic resonance imaging in the congenital adrenal hyperplasia population: increased frequency of white-matter abnormalities and temporal lobe atrophy. Nass R, et al. **J Child Neurol** 1997 Apr;12(3):181–6

P450scc deficiency (congenital lipoid adrenal hyperplasia): first reported case in Thailand and literature review. Jaruratanasirikul S. **J Med Assoc Thai** 1996 Aug; 79(8):531–5 (18 ref.)

Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. Allen DB, et al. **J Pediatr** 1997 Jan;130(1):128–33

Near-fatal misdiagnosis of congenital adrenal hyperplasia [letter] Frank GR, et al. **J Pediatr** 1997 Jul;131(1 Pt 1):165–6

Mothers' reactions to prenatal diagnostic procedures and dexamethasone treatment of congenital adrenal hyperplasia. Trautman PD, et al. **J Psychosom Obstet Gynaecol** 1996 Sep;17(3):175–81

Cognitive and neuroradiological findings in congenital adrenal hyperplasia. Sinforiani E, et al. **Psychoneuroendocrinology** 1994;19(1):55–64

15 beta-hydroxysteroids (part II). Steroids of the human perinatal period: the synthesis of 3 alpha,15 beta, 17 alpha-trihydroxy-5 beta-pregnan-20-one. Joannou GE, et al. **Steroids** 1996 Feb;61(2):82–8

[Diagnosis of the adrenogenital syndrome caused by 11beta-hydroxylase deficiency using gas chromatographic-mass spectrometric analysis of the urinary steroid profile] Wudy SA, et al. **Dtsch Med Wochenschr** 1997 Jan 3;122(1–2):3–10; discussion 11 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Are infants insensitive to androgen? [letter; comment] Arisaka O, et al. **Acta Paediatr** 1996 Jun;85(6):760–1. Comment on: Acta Paediatr 1995 Aug;84(8):894–8.

Elevation of serum luteinizing hormone levels during hydrocortisone treatment in infant girls with 21-hydroxylase deficiency. Belgorosky A, et al. **Acta Paediatr** 1996 Oct;85(10):1172–5

A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. Laue L, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3535–9

Treatment-induced hypoandrogenism in childhood and puberty in females with virilizing (21-hydroxylase deficiency) congenital adrenal hyperplasia. New MI. **J Endocrinol** 1996 Sep;150 Suppl:S31–2

Mothers' reactions to prenatal diagnostic procedures and dexamethasone treatment of congenital adrenal hyperplasia. Trautman PD, et al. **J Psychosom Obstet Gynaecol** 1996 Sep;17(3):175–81

Congenital adrenal hyperplasia and adult sexual behavior [letter; comment] Johnson CJ. **JAMA** 1997 Aug 20; 278(7):549. Comment on: JAMA 1997 Apr 2;277(13):1077–9.

New approaches to the treatment of congenital adrenal hyperplasia [clinical conference] Merke DP, et al. **JAMA** 1997 Apr 2;277(13):1073–6

How safe is long-term prenatal glucocorticoid treatment? [see comments] Seckl JR, et al. **JAMA** 1997 Apr 2; 277(13):1077–9. Comment in: JAMA 1997 Aug 20;278(7):549.

Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency. Hauffa BP, et al. **Klin Padiatr** 1997 Mar–Apr; 209(2):71–7

ENZYMOLOGY

Nonclassical adrenal hyperplasia due to 21-hydroxylase-deficiency: does genotyping predict the clinical manifestation? I'Allemand D, et al. **Endocr Res** 1996 Nov;22(4):735–9

Late onset adrenal hyperplasia due to 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency in north Indian hirsute women. Sundararaman PG, et al. **Indian J Med Res** 1997 Jan;105:27–31

Phenotypic heterogeneity associated with the splicing mutation in congenital adrenal hyperplasia due to 21-hydroxylase deficiency [see comments] Witchel SF, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4081–8. Comment in: J Clin Endocrinol Metab 1997 Apr;82(4):1304.

Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency with skeletal abnormalities. Ajlouni KM, et al. **J Endocrinol Invest** 1996 May;19(5):316–9

11 Beta-hydroxylase deficiency. Mantero F, et al. **J Endocrinol Invest** 1995 Jul–Aug;18(7):545–9 (21 ref.)

Steroid 21-hydroxylase expression and activity in human lymphocytes. Zhou Z, et al. **Mol Cell Endocrinol** 1997 Mar 14;127(1):11–8

[Adrenal incidentalomas disclosing enzyme block in a 66-year-old man (letter)] Turpin G, et al. **Presse Med** 1997 Jan 18–25;26(1):16 **(Fre)**

EPIDEMIOLOGY

The prevalence of non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency among hirsute women in a Turkish population. Keleştimur F, et al. **Clin Endocrinol (Oxf)** 1996 Oct;45(4):381–4

ETIOLOGY

CYP11B1 mutations causing congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Geley S, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2896–901

CYP11 beta 1 (11-beta-hydroxylase) deficiency in congenital adrenal hyperplasia. Burren CP, et al. **J Paediatr Child Health** 1996 Oct;32(5):433–8

Testicular enlargement in patients with 11-hydroxylase deficiency. Karnak I, et al. **J Pediatr Surg** 1997 May; 32(5):756–8

[Etiology and treatment of adrenal diseases of the current interest] Nawata H. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):429–33 (5 ref.) **(Jpn)**

GENETICS

Unsuspected mutation in a family with congenital adrenal hyperplasia [letter] Oriola J, et al. **Am J Med Genet** 1997 Aug 8;71(2):249–50

Molecular analysis of CYP21 and C4 genes in Brazilian families with the classical form of steroid 21-hydroxylase deficiency. de-Araujo M, et al. **Braz J Med Biol Res** 1996 Jan;29(1):1–13 (37 ref.)

Rapid screening method for detecting mutations in the 21-hydroxylase gene. Oriola J, et al. **Clin Chem** 1997 Apr; 43(4):557–61

Female pseudohermaphroditism due to classical 21-hydroxylase deficiency in a girl with Turner syndrome. Maciel-Guerra AT, et al. **Clin Genet** 1997 May;51(5):351–3

Endocrine and metabolism [editorial; comment] Root AW. **Curr Opin Pediatr** 1997 Aug;9(4):407–12 (19 ref.). Comment on: Curr Opin Pediatr 1997 Aug;9(4):413–80. Comment on: Curr Opin Pediatr 1997 Aug;9(4):419–23. Comment on:

Curr Opin Pediatr 1997 Aug;9(4):424–30.

Abnormalities of aldosterone synthesis and action in children [see comments] White PC. **Curr Opin Pediatr** 1997 Aug; 9(4):424–30 (47 ref.). Comment in: Curr Opin Pediatr 1997 Aug;9(4):407–12.

Homozygous Q258X mutation in the steroidogenic acute regulatory gene in a Japanese patient with congenital lipoid adrenal hyperplasia. Katsumata N, et al. **Endocr J** 1997 Jun;44(3):441–6

Molecular analysis of CYP21 gene mutations carried on HLA–B14 positive haplotypes. Dondi E, et al. **Eur J Immunogenet** 1994 Oct;21(5):341–50

Detection of CAH heterozygotes [letter; comment] Chryssikopoulos A. **Fertil Steril** 1997 Jul;68(1):182; discussion 183–4. Comment on: Fertil Steril 1996 Oct;66(4):557–63.

Point mutations in Italian patients with classic, non–classic, and cryptic forms of steroid 21–hydroxylase deficiency. Carrera P, et al. **Hum Genet** 1996 Dec;98(6):662–5

A cluster of missense mutations at Arg356 of human steroid 21–hydroxylase may impair redox partner interaction. Lajic S, et al. **Hum Genet** 1997 Jun;99(6):704–9

Mutation–haplotype analysis of steroid 21–hydroxylase (CYP21) deficiency in Finland. Implications for the population history of defective alleles. Levo A, et al. **Hum Genet** 1997 Apr;99(4):488–97

Identification of non–amplifying CYP21 genes when using PCR–based diagnosis of 21–hydroxylase deficiency in congenital adrenal hyperplasia (CAH) affected pedigrees. Day DJ, et al. **Hum Mol Genet** 1996 Dec;5(12):2039–48

Analysis of the steroidogenic acute regulatory protein (StAR) gene in Japanese patients with congenital lipoid adrenal hyperplasia. Nakae J, et al. **Hum Mol Genet** 1997 Apr; 6(4):571–6

E380D: a novel point mutation of CYP21 in an HLA–homozygous patient with salt–losing congenital adrenal hyperplasia due to 21–hydroxylase deficiency. Kirby–Keyser L, et al. **Hum Mutat** 1997;9(2):181–2

Novel nonsense mutation (W302X) in the steroid 21–hydroxylase gene of a Finnish patient with the salt–wasting form of congenital adrenal hyperplasia. Levo A, et al. **Hum Mutat** 1997;9(4):363–5

Inherited forms of mineralocorticoid hypertension. White PC. **Hypertension** 1996 Dec;28(6):927–36 (84 ref.)

Spontaneous feminization in a 46,XX female patient with congenital lipoid adrenal hyperplasia due to a homozygous frameshift mutation in the steroidogenic acute regulatory protein. Bose HS, et al. **J Clin Endocrinol Metab** 1997 May; 82(5):1511–5

CYP11B1 mutations causing congenital adrenal hyperplasia due to 11 beta–hydroxylase deficiency. Geley S, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2896–901

Phenotypic heterogeneity associated with the splicing mutation in congenital adrenal hyperplasia due to 21–hydroxylase deficiency [letter; comment] Miller WL. **J Clin Endocrinol Metab** 1997 Apr;82(4):1304. Comment on: J Clin Endocrinol Metab 1996 Nov;81(11):4081–8.

A novel splicing junction mutation in the gene for the steroidogenic acute regulatory protein causes congenital lipoid adrenal hyperplasia. Okuyama E, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2337–42

Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21–hydroxylase deficiency. Witchel SF, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2097–101

Phenotypic heterogeneity associated with the splicing mutation in congenital adrenal hyperplasia due to 21–hydroxylase deficiency [see comments] Witchel SF, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4081–8. Comment in: J Clin Endocrinol Metab 1997 Apr;82(4):1304.

Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. Fujieda K, et al. **J Clin Invest** 1997 Mar 15;99(6):1265–71

Characterisation of CAH alleles with non–radioactive DNA single strand conformation polymorphism analysis of the CYP21 gene. Bobba A, et al. **J Med Genet** 1997 Mar; 34(3):223–8

Non–expression of a common mutation in the 21–hydroxylase gene: implications for prenatal diagnosis and carrier testing. Rumsby G, et al. **J Med Genet** 1996 Sep;33(9):798–9

The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. International Congenital Lipoid Adrenal Hyperplasia Consortium. Bose HS, et al. **N Engl J Med** 1996 Dec 19;335(25):1870–8

New developments in congenital lipoid adrenal hyperplasia and steroidogenic acute regulatory protein [published erratum appears in Pediatr Clin North Am 1997 Jun;44(3):viii] Saenger P. **Pediatr Clin North Am** 1997 Apr; 44(2):397–421 (95 ref.)

HISTORY

17 alpha–Hydroxylase deficiency: 1963–1966. Biglieri EG. **J Clin Endocrinol Metab** 1997 Jan;82(1):48–50

IMMUNOLOGY

Vaccine tolerance in steroid substituted patients with congenital adrenal hyperplasia. Weiss M, et al. **Eur J Med Res** 1997 Jul 28;2(7):290–2

METABOLISM

Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Guo CY, et al. **Clin Endocrinol (Oxf)** 1996 Nov;45(5):535–41

Testicular histopathology in congenital lipoid adrenal hyperplasia: a light and electron microscopic study. Aya M, et al. **Horm Res** 1997;47(3):121–5

Inherited forms of mineralocorticoid hypertension. White PC. **Hypertension** 1996 Dec;28(6):927–36 (84 ref.)

Steroid 17alpha–hydroxylase deficiency: first Australian case report. Cameron FJ, et al. **J Paediatr Child Health** 1997 Jun;33(3):259–61

The 21–hydroxylase–deficient adrenal hyperplasias: more than ACTH oversecretion. Azziz R, et al. **J Soc Gynecol Investig** 1996 Nov–Dec;3(6):297–302 (39 ref.)

The role of the steroidogenic acute regulatory protein in steroidogenesis. Stocco DM, et al. **Steroids** 1997 Jan; 62(1):29–36 (87 ref.)

PATHOLOGY

Female pseudohermaphroditism due to congenital adrenal hyperplasia complicated by adenocarcinoma of the prostate and clear cell carcinoma of the endometrium. Winters JL, et al. **Am J Clin Pathol** 1996 Nov;106(5):660–4

Testicular histopathology in congenital lipoid adrenal hyperplasia: a light and electron microscopic study. Aya M, et al. **Horm Res** 1997;47(3):121–5

PHYSIOPATHOLOGY

Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21–hydroxylase deficiency. Jääskeläinen J, et al. **Clin Endocrinol (Oxf)** 1996 Dec; 45(6):707–13

Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Premawardhana LD, et al. **Clin Endocrinol (Oxf)** 1997 Mar; 46(3):327–32

Gender change from female to male in classical congenital adrenal hyperplasia. Meyer–Bahlburg HF, et al. **Horm Behav** 1996 Dec;30(4):319–32

Growth pattern during the first 36 months of life in congenital adrenal hyperplasia (21–hydroxylase deficiency). Gasparini N, et al. **Horm Res** 1997;47(1):17–22

Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. Fujieda K, et al. **J Clin Invest** 1997 Mar 15;99(6):1265–71

11 Beta–hydroxylase deficiency. Mantero F, et al. **J Endocrinol Invest** 1995 Jul–Aug;18(7):545–9 (21 ref.)

Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin–releasing hormone analog. Soliman AT, et al. **Metabolism** 1997 May;46(5):513–7

Growth of patients with 21–hydroxylase deficiency: an analysis of the factors influencing adult height. Jääskeläinen J, et al. **Pediatr Res** 1997 Jan;41(1):30–3

Bone mineral density in prepubertal and in adolescent and young adult patients with the salt–wasting form of congenital adrenal hyperplasia. Gussinyé M, et al. **Pediatrics** 1997 Oct;100(4):671–4

[Electroencephalographic changes in patients with congenital adrenal hyperplasia due to 21–hydroxylase deficiency] Oliveira MD, et al. **Arq Neuropsiquiatr** 1996 Jun; 54(2):202–6 (Eng. Abstr.) **(Por)**

[Adult height, pattern of growth and pubertal development in patients with congenital adrenal hyperplasia, salt losing form] Gussinyé M, et al. **Med Clin (Barc)** 1997 Jan 25; 108(3):87–90 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Current status of neonatal screening for congenital adrenal hyperplasia [see comments] Pang S, et al. **Curr Opin Pediatr** 1997 Aug;9(4):419–23 (19 ref.). Comment in: Curr Opin Pediatr 1997 Aug;9(4):407–12.

PSYCHOLOGY

The quality of life in adult female patients with congenital adrenal hyperplasia: a comprehensive study of the impact of genital malformations and chronic disease on female patients life [letter; comment] van der Kamp HJ, et al. **Eur J Pediatr** 1996 Jul;155(7):620–1. Comment on: Eur J Pediatr 1995 Sep;154(9):708–16.

Psychosexual development of women with congenital adrenal hyperplasia. Zucker KJ, et al. **Horm Behav** 1996 Dec;30(4):300–18

Outcome of congenital adrenal hyperplasia. Kuhnle U, et al. **Pediatr Surg Int** 1997 Sep;12(7):511–5

SURGERY

Gender reversal in 46XX congenital virilizing adrenal hyperplasia. Sripathi V, et al. **Br J Urol** 1997 May; 79(5):785–9

11 beta–hydroxylase deficiency: management of a difficult case by laparoscopic bilateral adrenalectomy. Nasir J, et al. **Clin Endocrinol (Oxf)** 1996 Aug;45(2):225–8

Anterior sagittal transanorectal approach to the urogenital sinus in adrenogenital syndrome: preliminary report. Dòmini R, et al. **J Pediatr Surg** 1997 May;32(5):714–6

The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. Elder JS. **J Urol** 1997 Oct; 158(4):1636–7

Labial skin–flap vaginoplasty using tissue expanders. Belloli G, et al. **Pediatr Surg Int** 1997 Feb;12(2–3):168–71

Reduction of scrotalized skin improves the cosmetic appearance of feminising genitoplasty. Roberts JP, et al. **Pediatr Surg Int** 1997 Feb;12(2–3):228–9

THERAPY

Congenital adrenal hyperplasia. New MI, et al. **Curr Ther Endocrinol Metab** 1997;6:179–87 (16 ref.)

ULTRASONOGRAPHY

Congenital adrenal hyperplasia. **J Perinatol** 1996 Jan–Feb; 16(1):81

Sonography of congenital adrenal hyperplasia due to partial deficiency of 3beta–hydroxysteroid dehydrogenase: a case report. Bentsen D, et al. **Pediatr Radiol** 1997 Jul;27(7):594–5

ADRENAL MEDULLA

Angiotensin II receptors in cortical and medullary adrenal tumors. Opocher G, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):865–9

Corticomedullary tumors of the adrenal glands. Report of two cases. Association of corticomedullary tumor with spindle cell sarcoma. Michal M, et al. **Pathol Res Pract** 1996 Nov;192(11):1082–9

BLOOD SUPPLY

Ecto–enzymatic hydrolysis of diadenosine polyphosphates by cultured adrenomedullary vascular endothelial cells. Mateo J, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C918–27

Postnatal development of the blood vasculature in the rat adrenal gland: a scanning electron microscope study of microcorrosion casts. Tokunaga H. **Arch Histol Cytol** 1996 Oct;59(4):305–15

The thrombin receptor in adrenal medullary microvascular endothelial cells is negatively coupled to adenylyl cyclase through a Gi protein. Manolopoulos VG, et al. **Biochim Biophys Acta** 1997 May 27;1356(3):321–32

CHEMISTRY

Co–existence of P2Y–and PPADS–insensitive P2U–purinoceptors in endothelial cells from adrenal medulla. Mateo J, et al. **Br J Pharmacol** 1996 Nov; 119(6):1223–32

NSF and SNAP are present on adrenal chromaffin granules. Burgoyne RD, et al. **FEBS Lett** 1997 Sep 8;414(2):349–52

Purification and characterization of PAMP–12 (PAMP[9–20]) in porcine adrenal medulla as a major endogenous biologically active peptide. Kuwasako K, et al. **FEBS Lett** 1997 Sep 1;414(1):105–10

Localization, expression, and characterization of guanylin in the rat adrenal medulla. Reinecke M, et al. **Histochem Cell Biol** 1996 Oct;106(4):367–74

Immunohistochemical identification and comparison of glial cell lineage in foetal, neonatal, adult and neoplastic human adrenal medulla. Magro G, et al. **Histochem J** 1997 Apr; 29(4):293–9

Antibacterial activity of glycosylated and phosphorylated chromogranin A–derived peptide 173–194 from bovine adrenal medullary chromaffin granules. Strub JM, et al. **J Biol Chem** 1996 Nov 8;271(45):28533–40

Existence of two heme B centers in cytochrome b561 from bovine adrenal chromaffin vesicles as revealed by a new purification procedure and EPR spectroscopy. Tsubaki M, et al. **J Biol Chem** 1997 Sep 12;272(37):23206–10

Cerebellin and cerebellin mRNA in the human brain, adrenal glands and the tumour tissues of adrenal tumour, ganglioneuroblastoma and neuroblastoma. Satoh F, et al. **J Endocrinol** 1997 Jul;154(1):27–34

Mass spectrometric identification and quantification of hemorphins extracted from human adrenal and pheochromocytoma tissue. Cerpa–Poljak A, et al. **J Neurochem** 1997 Apr;68(4):1712–9

Adrenaline cells of the rat adrenal cortex and medulla contain renin and prorenin. Berka JL, et al. **Mol Cell Endocrinol** 1996 May 31;119(2):175–84

Immunohistochemical localization of serotonin, galanin, cholecystokinin, and methionine–enkephalin in adrenal medullary cells of the chicken. Ohmori Y, et al. **Tissue Cell** 1997 Apr;29(2):199–205

CYTOLOGY

Morphochemical investigations on postnatal development of the adrenal medulla in guinea pigs. Kaczmarczyk D, et al. **Folia Histochem Cytobiol** 1996;34 Suppl 1:71–2

Comparative studies of chromaffin cell proliferation in the adrenal medulla of rats and mice. Tischler AS, et al. **Fundam Appl Toxicol** 1997 Feb;35(2):216–20

Immunomicroscopy of neurofilaments in chromaffin cells of the adult bovine adrenal gland. Yang HY, et al. **J Comp Neurol** 1996 Jul 29;371(3):461–8

Ca2+–dependent K+ channels in bovine adrenal chromaffin cells are modulated by lipoxygenase metabolites of arachidonic acid. Twitchell WA, et al. **J Membr Biol** 1997 Jul 1;158(1):69–75

Xenogeneic adrenal medulla graft rejection rather than

survival leads to increased rat striatal tyrosine hydroxylase immunoreactivity. Bresjanac M, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):490–8

Morphological and functional studies of the paracrine interaction between cortex and medulla in the adrenal gland. Bornstein SR, et al. **Microsc Res Tech** 1997 Mar 15;36(6):520–33 (123 ref.)

Nicotinic and muscarinic components in acetylcholine stimulation of porcine adrenal medullary cells. Nassar-Gentina V, et al. **Mol Cell Biochem** 1997 Apr; 169(1–2):107–13

Relief of intractable cancer pain by human chromaffin cell transplants: experience at two medical centers. Pappas GD, et al. **Neurol Res** 1997 Feb;19(1):71–7

DRUG EFFECTS

Extracellular acidification related to the stimulation of catecholamines release by strontium in the bovine adrenal medulla. Viglione PN, et al. **Arch Physiol Biochem** 1996 Dec;104(7):833–7

Captopril does not blunt the sympathoadrenal response to cigarette smoking in normotensive humans. Ottesen MM, et al. **Blood Press** 1997 Jan;6(1):29–34

The non-neurogenic catecholamine response of the fetal adrenal to hypoxia is dependent on activation of voltage sensitive Ca2+ channels. Adams MB, et al. **Brain Res Dev Brain Res** 1996 Jul 20;94(2):182–9

Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Puchacz E, et al. **Brain Res Mol Brain Res** 1996 Feb;36(1):193–6

Altered gonadal hormone level and constant light-induced stress interfere with the response of the adrenal medulla to oxytocin. Popović A, et al. **Braz J Med Biol Res** 1996 Feb;29(2):273–80

Histamine-stimulated phospholipase C signalling in the adrenal chromaffin cell: effects on inositol phospholipid metabolism and tyrosine hydroxylase phosphorylation. Bunn SJ, et al. **Clin Exp Pharmacol Physiol** 1997 Aug; 24(8):624–31

Pharmacological characterization and autoradiographic localization of dopamine receptors in the rat adrenal medulla. Barili P, et al. **Eur J Pharmacol** 1996 Aug 29; 310(2–3):129–35

Glucoprivation by insulin leads to trans-synaptic increase in rat adrenal tyrosine hydroxylase mRNA levels. Vietor I, et al. **Eur J Pharmacol** 1996 Oct 10;313(1–2):119–27

Inhibition by protamine of catecholamine secretion and ion influxes in bovine adrenal medullary cells in culture. Minami K, et al. **J Pharmacol Exp Ther** 1996 Nov; 279(2):838–43

Potentiation by indomethacin of receptor-mediated catecholamine secretion in rat adrenal medulla. Warashina A. **Jpn J Pharmacol** 1997 Mar;73(3):197–205

Proadrenomedullin N-terminal 20 peptide (PAMP) reduces inward currents and Ca2+ rises induced by nicotine in bovine adrenal medullary cells. Nagatomo T, et al. **Life Sci** 1996;59(20):1723–30

Mononuclear-cell peptide mediation of chromaffin-cell epinephrine secretion. Roberts JC, et al. **Neuroimmunomodulation** 1996 Mar–Jun;3(2–3):119–30

Neuropeptide K and neurokinin A stimulate CRH and ACTH release by rat adrenal medulla in vitro. Mazzocchi G, et al. **Peptides** 1997;18(4):487–90

Interrelationships between calcitonin gene-related peptide and sympathoadrenomedullary system: effects of administration of epinephrine and norepinephrine in healthy man. Trasforini G, et al. **Regul Pept** 1996 May 7;63(1):57–61

Low digestible carbohydrates (polyols and lactose): significance of adrenal medullary proliferative lesions in the rat. Lynch BS, et al. **Regul Toxicol Pharmacol** 1996 Jun;23(3):256–97 (279 ref.)

Vitamin D3, lactose, and xylitol stimulate chromaffin cell proliferation in the rat adrenal medulla. Tischler AS, et al. **Toxicol Appl Pharmacol** 1996 Sep;140(1):115–23

Biphasic effects of chromium compounds on catecholamine secretion from bovine adrenal medullary cells. Liu PS, et al. **Toxicology** 1997 Feb 14;117(1):45–53

EMBRYOLOGY

Immunochemical localization of chromaffin cells during the embryogenic migration. Souto M, et al. **Biocell** 1996 Dec; 20(3):179–84

The adrenal secretion of catecholamines during systemic metabolic acidosis in fetal sheep. Cohn HE, et al. **Biol Neonate** 1997;72(2):125–32

Effects of immunological sympathectomy on postnatal peptide expression in the rat adrenal medulla. Holgert H, et al. **Brain Res Dev Brain Res** 1996 Nov 22;97(1):88–95

Stereology of human fetal adrenal medulla. Bocian-Sobkowska J, et al. **Histol Histopathol** 1996 Apr; 11(2):389–93

ENZYMOLOGY

Pituitary adenylate cyclase-activating polypeptide induces gene expression of the catecholamine synthesizing enzymes, tyrosine hydroxylase, and dopamine beta-hydroxylase in cultured porcine adrenal medullary chromaffin cells. Isobe K, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:464–9

Mechanism-based inactivation of dopamine beta-monooxygenase in adrenal chromaffin cells. May SW, et al. **Biochem Biophys Res Commun** 1996 Nov 12; 228(2):278–84

Induction of tyrosine hydroxylase by forskolin: modulation with age. Tümer N, et al. **Eur J Pharmacol** 1997 Apr 11; 324(1):57–62

A natural variant of bovine dopamine beta-monooxygenase with phenylalanine as residue 208: purification and characterization of the variant homo- and heterotetramers of (F208)4 and (F208)2(L208)2. Narita M, et al. **FEBS Lett** 1996 Nov 4;396(2–3):208–12

Expression of catecholamine-synthesizing enzymes, peptidylglycine alpha-amidating monooxygenase, and neuropeptide Y mRNA in the rat adrenal medulla after acute systemic nicotine. Jahng JW, et al. **J Mol Neurosci** 1997 Feb;8(1):45–52

Reduced acetylcholinesterase (AChE) activity in adrenal medulla and loss of sympathetic preganglionic neurons in TrkA-deficient, but not TrkB-deficient, mice. Schober A, et al. **J Neurosci** 1997 Feb 1;17(3):891–903

GROWTH & DEVELOPMENT

Effects of immunological sympathectomy on postnatal peptide expression in the rat adrenal medulla. Holgert H, et al. **Brain Res Dev Brain Res** 1996 Nov 22;97(1):88–95

Morphochemical investigations on postnatal development of the adrenal medulla in guinea pigs. Kaczmarczyk D, et al. **Folia Histochem Cytobiol** 1996;34 Suppl 1:71–2

Developmental loss of hypoxic chemosensitivity in rat adrenomedullary chromaffin cells. Thompson RJ, et al. **J Physiol (Lond)** 1997 Jan 15;498 (Pt 2):503–10

IMMUNOLOGY

Reproducibility and persistence of neural and adrenal autoantibodies in diabetic autonomic neuropathy. Cachia MJ, et al. **Diabet Med** 1997 Jun;14(6):461–5

INNERVATION

Pituitary adenylate cyclase activating polypeptide-immunoreactive sensory neurons innervate rat adrenal medulla. Dun NJ, et al. **Brain Res** 1996 Apr 15; 716(1–2):11–21

Heterogeneous distribution of neurocalcin-immunoreactive nerve terminals in the mouse adrenal medulla. Iino S, et al. **Cell Tissue Res** 1997 Sep;289(3):439–44

Selective neural regulation of epinephrine and norepinephrine cells in the adrenal medulla — cardiovascular implications. Vollmer RR. **Clin Exp Hypertens** 1996 Aug;18(6):731–51 (75 ref.)

Phenotype of intraadrenal ganglion neurons during postnatal development in rat. Holgert H, et al. **J Comp Neurol** 1996 Aug 5;371(4):603–20

Ultrastructural localization of nerve terminals containing nitric oxide synthase in rat adrenal gland. Tanaka K, et al. **Neurosci Lett** 1996 Feb 9;204(3):153–6

Distinct preganglionic neurons innervate noradrenaline and adrenaline cells in the cat adrenal medulla. Edwards SL, et al. **Neuroscience** 1996 Feb;70(3):825–32

Capsaicin-sensitive nerves and endurance exercise in the rat. Trudeau F, et al. **Physiol Behav** 1996 Feb;59(2):355–9

METABOLISM

Leptin receptors in the adrenal medulla of the rat. Cao GY, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):E448–52

Functional evidence for L-type Ca2+ channels controlling ANG II-induced adrenal catecholamine release in vivo. Martineau D, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1713–9

Thrombin modulates vectorial secretion of extracellular matrix proteins in cultured endothelial cells. Papadimitriou E, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1112–22

Atrial natriuretic factor modifies the biosynthesis and turnover of norepinephrine in the rat adrenal medulla. Fernández BE, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):343–6

Selective expression of HSP70-1 gene in the adrenal cortex but not in the medulla of thermally stressed rats. Shimizu K, et al. **Biochem Biophys Res Commun** 1997 Apr 17; 233(2):550–4

Internalisation of short-chain isoprenyl diphosphates by chromaffin cells from bovine adrenal medulla. Van Dessel G, et al. **Biochem Biophys Res Commun** 1997 Sep 8; 238(1):7–11

Characterization of Rab3A, Rab3B and Rab3C: different biochemical properties and intracellular localization in bovine chromaffin cells. Lin CG, et al. **Biochem J** 1997 May 15;324 (Pt 1):85–90

Effects of K+ channel inhibitors on potassium transport in bovine adrenal chromaffin granules. Lobanov NA, et al. **Biochem Mol Biol Int** 1997 Apr;41(4):679–86

Importance of two adjacent C-terminal sequences of SNAP-25 in exocytosis from intact and permeabilized chromaffin cells revealed by inhibition with botulinum neurotoxins A and E. Lawrence GW, et al. **Biochemistry** 1997 Mar 18;36(11):3061–7

The photoactivatable inhibitor 7-azido-8-iodoketanserin labels the N terminus of the vesicular monoamine transporter from bovine chromaffin granules. Sagné C, et al. **Biochemistry** 1997 Mar 18;36(11):3345–52

Adrenal catecholamines after chronic erythropoietic stimulus. Di Giulio C, et al. **Boll Soc Ital Biol Sper** 1996 Jan-Feb;72(1–2):65–8

Differential expression of FGF-2 isoforms in the rat adrenal medulla during postnatal development in vivo. Meisinger C, et al. **Brain Res** 1997 May 23;757(2):291–4

The diadenosine polyphosphate receptors: P2D purinoceptors. Miras-Portugal MT, et al. **Ciba Found Symp** 1996;198:35–47; discussion 48–52

Dopamine and sympathoadrenal activity in man. Mannelli M, et al. **Clin Exp Hypertens** 1997 Jan-Feb;19(1–2):163–79

The cDNA sequence encoding bovine SP-22, a new defence system against reactive oxygen species in mitochondria. Hiroi T, et al. **DNA Seq** 1996;6(4):239–42

Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla. Grazzini E, et al. **Endocrinology** 1996 Sep;137(9):3906–14

Histamine-induced cortisol secretion from bovine adrenocortical cells co-cultured with bovine adrenomedullary cells. Yoshida T, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S61–2

Effects of stress and hypophysectomy on the uptake of [3H]2-deoxy-D-glucose in the mouse adrenal medulla: an autoradiographic study. Hirano T. **J Auton Nerv Syst** 1996 Aug 27;60(1–2):17–22

Thyroxine replacement after hypophysectomy alters the pattern of enkephalin localisation in the adrenal medulla of the fetal sheep. Simonetta G, et al. **J Auton Nerv Syst** 1996 Jun 10;59(1–2):60–5

A cysteine-rich domain defined by a novel exon in a slo variant in rat adrenal chromaffin cells and PC12 cells. Saito M, et al. **J Biol Chem** 1997 May 2;272(18):11710–7

Phosphorylation and O-glycosylation sites of bovine chromogranin A from adrenal medullary chromaffin granules and their relationship with biological activities. Strub JM, et al. **J Biol Chem** 1997 May 2;272(18):11928–36

Up-regulation of functional voltage-dependent sodium channels by insulin in cultured bovine adrenal chromaffin cells. Yamamoto R, et al. **J Neurochem** 1996 Oct; 67(4):1401–8

AP-1 mediates trans-synaptic induction of tyrosine hydroxylase gene expression in adrenal medulla but not in superior cervical ganglia. Trocmé C, et al. **J Neurosci Res** 1997 Jun 15;48(6):489–98

Nuclear accumulation of fibroblast growth factor receptors is regulated by multiple signals in adrenal medullary cells. Stachowiak MK, et al. **Mol Biol Cell** 1996 Aug; 7(8):1299–317

Deprivation of Na+, Ca2+ and Mg2+ from the extracellular solution increases cytosolic Ca2+ and stimulates catecholamine secretion from cultured bovine adrenal chromaffin cells. Luxoro M, et al. **Mol Cell Biochem** 1997 May;170(1–2):65–73

Pituitary adenylate-cyclase activating polypeptide (PACAP) evokes long-lasting secretion and de novo biosynthesis of bovine adrenal medullary neuropeptides. Babinski K, et al. **Neuropeptides** 1996 Dec;30(6):572–82

Pituitary adenylate cyclase-activating polypeptide induces gene expression of the catecholamine synthesizing enzymes, tyrosine hydroxylase and dopamine beta hydroxylase, through 3',5'-cyclic adenosine monophosphate- and protein kinase C-dependent mechanisms in cultured porcine adrenal medullary chromaffin cells. Isobe K, et al. **Neuropeptides** 1996 Apr;30(2):167–75

Evidence for cholecystokininA receptors in bovine adrenal chromaffin cells. Aarnisalo AM, et al. **Neuroreport** 1996 Sep 2;7(13):2167–70

Chromaffin granule membrane glycoprotein IV is identical with Ac45, a membrane-integral subunit of the granule's H(+)-ATPase. Getlawi F, et al. **Neurosci Lett** 1996 Nov 15;219(1):13–6

Differences in the composition of chromaffin granules in adrenaline and noradrenaline containing cells of bovine adrenal medulla. Weiss C, et al. **Neurosci Lett** 1996 Jun 14;211(1):29–32

Expression of pituitary adenylate cyclase activating peptide (PACAP) and PACAP type I receptors in the rat adrenal medulla. Moller K, et al. **Regul Pept** 1996 Jul 5; 63(2–3):129–39

[Reaction of the adrenal medulla to the effect of various extreme factors] Khlusov IA, et al. **Biull Eksp Biol Med** 1997 Mar;123(3):293–5 **(Rus)**

PHYSIOLOGY

The involvement of serotonin in the catecholamine release from the adrenal medulla. Sugimoto Y, et al. **Adv Exp Med Biol** 1996;398:561–3

Adrenal vasoactive intestinal peptide participates in neonatal corticosteroid production in the rat. Bodnar M, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1163–72

Cyanide suppression of inwardly rectifying K+ channels in guinea pig chromaffin cells involves dephosphorylation. Inoue M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C137–47

AT1 receptor blockade and the sympathoadrenal response to insulin-induced hypoglycemia in humans. Worck RH, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):E415–21

The multifunctionality of FGF-2 in the adrenal medulla. Grothe C, et al. **Anat Embryol (Berl)** 1997 Feb; 195(2):103–11 (106 ref.)

Simultaneous capacitance and amperometric measurements of exocytosis: a comparison. Oberhauser AF, et al. **Biophys J** 1996 Aug;71(2):1131–9

The cytosolic inactivation domains of BKi channels in rat chromaffin cells do not behave like simple, open-channel

blockers. Solaro CR, et al. **Biophys J** 1997 Aug; 73(2):819–30
Kinetic studies of Ca2+ binding and Ca2+ clearance in the cytosol of adrenal chromaffin cells. Xu T, et al. **Biophys J** 1997 Jul;73(1):532–45
Influence of adrenodemedullation on beta 2– and beta 3–adrenoceptors mediating relaxation of oesophageal smooth muscle of spontaneously hypertensive rats. de Boer RE, et al. **Br J Pharmacol** 1996 Dec;119(7):1355–60
Up–regulation of functional voltage–dependent sodium channels by cyclic AMP–dependent protein kinase in adrenal medulla [published erratum appears in Brain Res 1996 Aug 12;729(2):297] Yuhi T, et al. **Brain Res** 1996 Feb 12;709(1):37–43
Differential responses in adrenal and renal nerves to CNS osmotic stimulation. Bealer SL, et al. **Brain Res Bull** 1996; 39(4):205–9
Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin–induced hypoglycemia in women. Havel PJ, et al. **Diabetes** 1997 May;46(5):801–7
Specific role for the PH domain of dynamin–1 in the regulation of rapid endocytosis in adrenal chromaffin cells. Artalejo CR, et al. **EMBO J** 1997 Apr 1;16(7):1565–74
TGF–beta rescues target–deprived preganglionic sympathetic neurons in the spinal cord. Blottner D, et al. **Eur J Neurosci** 1996 Jan;8(1):202–10
Trimeric G proteins control regulated exocytosis in bovine chromaffin cells: sequential involvement of Go associated with secretory granules and Gi3 bound to the plasma membrane. Vitale N, et al. **Eur J Neurosci** 1996 Jun; 8(6):1275–85
High levels of circulating adrenomedullin in severe illness: correlation with C–reactive protein and evidence against the adrenal medulla as site of origin. Ehlenz K, et al. **Exp Clin Endocrinol Diabetes** 1997;105(3):156–62
Involvement of the adrenal medulla in ejaculatory reactions in the dog. Kihara K, et al. **Int J Androl** 1997 Apr; 20(2):104–11
Design, synthesis, tandem mass spectrometric sequencing and biological activity of NGF mimetics. Estenne–Bouhtou G, et al. **Int J Pept Protein Res** 1996 Oct;48(4):337–46
Regulated exocytosis in chromaffin cells. A potential role for a secretory granule–associated ARF6 protein. Galas MC, et al. **J Biol Chem** 1997 Jan 31;272(5):2788–93
A peptide that mimics the C–terminal sequence of SNAP–25 inhibits secretory vesicle docking in chromaffin cells. Gutierrez LM, et al. **J Biol Chem** 1997 Jan 31;272(5):2634–9
Roles for protein kinase C and mitogen–activated protein kinase in nicotine–induced secretion from bovine adrenal chromaffin cells. Cox ME, et al. **J Neurochem** 1997 Sep; 69(3):1119–30
Catecholamine secretion from bovine adrenal chromaffin cells: the role of the Na+/Ca2+ exchanger and the intracellular Ca2+ pool. Pan CY, et al. **J Neurochem** 1997 Sep;69(3):1085–92
The mechanism of calcium channel facilitation in bovine chromaffin cells. Albillos A, et al. **J Physiol (Lond)** 1996 Aug 1;494 (Pt 3):687–95
Evidence for the differential release of the cotransmitters ATP and noradrenaline from sympathetic nerves of the guinea–pig vas deferens. Todorov LD, et al. **J Physiol (Lond)** 1996 Nov 1;496 (Pt 3):731–48
Reflex modulation of catecholamine secretion and adrenal sympathetic nerve activity by acupuncture–like stimulation in anesthetized rat. Sato A, et al. **Jpn J Physiol** 1996 Oct; 46(5):411–21
Effects of adrenodemedullation and adrenalectomy on the 5–HT2 receptor agonists DOI–and mCPP–induced hypophagia in rats. Yamada J, et al. **Neurosci Lett** 1996 May 10;209(2):113–6
Arginine–vasopressin stimulates CRH and ACTH release by rat adrenal medulla, acting via the V1 receptor subtype and a protein kinase C–dependent pathway. Mazzocchi G, et al. **Peptides** 1997;18(2):191–5
Paracrine control of adrenal cortical function by medullary chromaffin cells. Nussdorfer GG. **Pharmacol Rev** 1996 Dec; 48(4):495–530 (544 ref.)
Growth factors in chromaffin cells. Unsicker K, et al. **Prog Neurobiol** 1996 Mar–Apr;48(4–5):307–24 (128 ref.)
[Effect of removal of the adrenal medulla on the hormonal response induced by acute hepatic vagotomy] Tadjore M, et al. **Arch Physiol Biochem** 1996;104(1):2–7 (Eng. Abstr.) **(Fre)**
[The role of relationship between the epiphysis and the sympathetico–adrenal system in the depressogenic effect of reserpine] Arushanian EB, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):651–3 **(Rus)**

PHYSIOPATHOLOGY

Hypoglycaemia causes functional changes within the chromaffin cells of the adrenal medulla [letter] Wilke RA. **Diabet Med** 1996 Aug;13(8):774
[Evaluation of adrenal medullary function with scintigraphy] Nakai T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:372–5 (12 ref.) **(Jpn)**
[Glucagon test] Noshiro T, et al. **Nippon Rinsho** 1997 Apr; 55 Suppl 2:357–9 (11 ref.) **(Jpn)**
[Clonidine suppression test] Sasaki M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:367–71 (10 ref.) **(Jpn)**
[Metoclopramide test] Shimizu K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:360–2 (12 ref.) **(Jpn)**
[Regitine test] Takasaki I, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:363–6 (12 ref.) **(Jpn)**

RADIOGRAPHY

[Evaluation of adrenal medullary function with CT scanning] Nakai T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:376–9 (12 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

Location of adrenal medullary pheochromocytoma by I–123 metaiodobenzylguanidine SPECT. Nielsen JT, et al. **Clin Nucl Med** 1996 Sep;21(9):695–9
[Evaluation of adrenal medullary function with scintigraphy] Nakai T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:372–5 (12 ref.) **(Jpn)**

SECRETION

The adrenal secretion of catecholamines during systemic metabolic acidosis in fetal sheep. Cohn HE, et al. **Biol Neonate** 1997;72(2):125–32
Selective neural regulation of epinephrine and norepinephrine cells in the adrenal medulla — cardiovascular implications. Vollmer RR. **Clin Exp Hypertens** 1996 Aug;18(6):731–51 (75 ref.)
Adrenomedullary secretion of epinephrine is increased in mild essential hypertension. Jacobs MC, et al. **Hypertension** 1997 Jun;29(6):1303–8
Effects of external osmotic pressure on vesicular secretion from bovine adrenal medullary cells. Borges R, et al. **J Biol Chem** 1997 Mar 28;272(13):8325–31
A difference in the cellular mechanisms of secretion of adrenaline and noradrenaline revealed with lanthanum in bovine chromaffin cells. Powis DA, et al. **Neurosci Lett** 1996 Jan 19;203(2):131–4
Reflex adrenal medullary secretion during coronary occlusion mediated by cardiac receptors with afferent vagal fibres in the rat. Godin–Ribuot D, et al. **Pflugers Arch** 1997 Jun;434(2):159–65
Biphasic effects of chromium compounds on catecholamine secretion from bovine adrenal medullary cells. Liu PS, et al. **Toxicology** 1997 Feb 14;117(1):45–53

TRANSPLANTATION

The effects of different monoaminergic antidepressants on the analgesia induced by spinal cord adrenal medullary transplants in the formalin test in rats. Ortega–Alvaro A, et al. **Anesth Analg** 1997 Apr;84(4):816–20
Parkinson's disease, trophic factors, and adrenal medullary chromaffin cell grafting: basic and clinical studies. Date I. **Brain Res Bull** 1996;40(1):1–19 (223 ref.)
Alterations in rat spinal cord cGMP by peripheral nerve injury and adrenal medullary transplantation. Siegan JB, et al. **Neurosci Lett** 1996 Aug 30;215(1):49–52
Loss of GABA–immunoreactivity in the spinal dorsal horn of rats with peripheral nerve injury and promotion of recovery by adrenal medullary grafts. Ibuki T, et al. **Neuroscience** 1997 Feb;76(3):845–58
Autologous adrenal medullary transplant in Parkinson's disease: critical review of our results in 13 patients. Porena M, et al. **Neurourol Urodyn** 1996;15(3):195–201
Attenuation of formalin pain responses in the rat by adrenal medullary transplants in the spinal subarachnoid space. Siegan JB, et al. **Pain** 1997 Apr;70(2–3):279–85
Clinical experience with cotransplantation of peripheral nerve and adrenal medulla in patients with Parkinson's disease. López–Lozano JJ, et al. **Transpl Int** 1996;9 Suppl 1:S485–91
[Adrenal transplantation and Parkinson's disease] Luquin MR, et al. **Rev Med Univ Navarra** 1994 Oct–Dec; 38(4):174–80 (38 ref.) (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

Immunoelectron microscopic localization of vimentin in sustentacular cells of the carotid body and the adrenal medulla of guinea pigs. Kameda Y. **J Histochem Cytochem** 1996 Dec;44(12):1439–49
[The ultrastructure of the chromaffin cells of the adrenal medullary substance in different forms of pheochromocytoma] Gordienko VM. **Tsitol Genet** 1996 Nov–Dec;30(6):8–12 (Eng. Abstr.) **(Rus)**

VIROLOGY

Replication of herpes simplex virus type 1 and 2 in the medulla of the adrenal gland after vaginal infection of mice. Podlech J, et al. **Arch Virol** 1996;141(10):1999–2008

ADRENAL REST TUMOR

ENZYMOLOGY

Adrenal rest tumor of the broad ligament: case report with immunohistochemical study of steroidogenic enzymes. Sasano H, et al. **Pathol Int** 1997 Jul;47(7):493–6

ETIOLOGY

Testicular enlargement in patients with 11–hydroxylase deficiency. Karnak I, et al. **J Pediatr Surg** 1997 May; 32(5):756–8

ADRENAL RETICULARIS see **ZONA RETICULARIS**

ADRENALECTOMY

Adrenalectomy protects ethanol–withdrawn rats from harmine–induced tremor. Lamblin F, et al. **Alcohol Alcohol** 1996 Mar;31(2):175–81
Adrenal hormone regulation of fibronectin synthesis by type II pulmonary epithelial cells. Dunsmore SE, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):L86–92
Change from beta– to alpha–adrenergic glycogenolysis induced by corticosteroids in female rat liver. Moriyama M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R153–60
Adrenalectomy decreases NaCl intake of rats fed low–calcium diets. Tordoff MG. **Am J Physiol** 1996 Jan; 270(1 Pt 2):R11–21
Relapse of Cushing's syndrome following the treatment of primary pigmented nodular adrenocortical disease by unilateral adrenalectomy [letter] Walsh JP, et al. **Aust N Z J Med** 1996 Jun;26(3):426–7
Decision to resect an adrenal mass depends on size of mass and age of patient [letter; comment] Sharma AK, et al. **BMJ** 1997 Jan 18;314(7075):229–30. Comment on: BMJ 1996 Oct 5;313(7061):872–3.
The alteration of glucocorticoid receptor–immunoreactivity in the rat forebrain following short–term and long–term adrenalectomy. Visser DT, et al. **Brain Res** 1996 Aug 12; 729(2):216–22
Sexually dimorphic effects of maternal adrenalectomy on hypothalamic corticotrophin–releasing factor, glucocorticoid receptor and anterior pituitary POMC mRNA levels in rat neonates. Halasz I, et al. **Brain Res Dev Brain Res** 1997 Jun 18;100(2):198–204
Calbindin–D28k is regulated by adrenal steroids in hypothalamic tissue during prenatal development. Lephart ED, et al. **Brain Res Dev Brain Res** 1997 May 20; 100(1):117–20
Impact of adrenalectomy on 5–HT6 and 5–HT7 receptor gene expression in the rat hippocampus. Yau JL, et al. **Brain Res Mol Brain Res** 1997 Apr;45(1):182–6
Regulation of corticotropin–releasing hormone secretion by ACTH at different times after adrenalectomy. Castro M, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1573–8
Effects of incremental cortisol and adrenalectomy on plasma corticosteroid binding capacity in fetal sheep. Jeffray TM, et al. **Can J Physiol Pharmacol** 1995 Nov;73(11):1568–73
Immunosuppressive phenotype of corticotropin–releasing factor transgenic mice is reversed by adrenalectomy. Boehme SA, et al. **Cell Immunol** 1997 Mar 15;176(2):103–12
Long–term survival after bilateral adrenalectomy for metastatic lung cancer: a case report. Urschel JD, et al. **Chest** 1997 Sep;112(3):848–50
11 beta–hydroxylase deficiency: management of a difficult case by laparoscopic bilateral adrenalectomy. Nasir J, et al. **Clin Endocrinol (Oxf)** 1996 Aug;45(2):225–8
Elevated des–AngI–angiotensinogen levels by nephrectomy and adrenalectomy. Hilgenfeldt U, et al. **Clin Exp Hypertens** 1996 Jul;18(5):675–89
Effects of adrenalectomy on serotonin–, somatostatin–, and gastrin–immunoreactive cells in rat gastrointestinal tract. Glória H, et al. **Dig Dis Sci** 1997 Jun;42(6):1216–20
Bilateral adrenalectomy with autotransplantation of adrenocortical tissue or unilateral adrenalectomy: treatment options for pheochromocytomas in multiple endocrine neoplasia type 2A. Okamoto T, et al. **Endocr J** 1996 Apr; 43(2):169–75
The pressor response induced by repeated injections of neostigmine into the central nervous system is desensitized in adrenalectomized, but not in intact rats. Uemura K, et al. **Endocr J** 1997 Apr;44(2):219–25
Chronic cold in adrenalectomized, corticosterone (B)–treated rats: facilitated corticotropin responses to acute restraint emerge as B increases. Akana SF, et al. **Endocrinology** 1997 Aug;138(8):3249–58
Adrenocorticotropin secretion by fetal sheep anterior and intermediate lobe pituitary cells in vitro: effects of gestation and adrenalectomy. Fora MA, et al. **Endocrinology** 1996 Aug;137(8):3394–400
Initial experience of laparoscopic resection of adrenal tumours. Casaccia M Jr, et al. **Eur J Surg** 1997 Feb; 163(2):93–6
Perinatal development of rat cerebellum from adrenalectomized mothers. Cuchillo I, et al. **Int J Dev Biol** 1996;Suppl 1:263S–264S
Aldosterone–producing adrenocortical carcinoma metastases found seven years after adrenalectomy. Sakai N, et al. **Int J Urol** 1997 Jan;4(1):79–82
Plasma catecholamine and met–enkephalin–Arg6–Phe7 responses to hypoxaemia after adrenalectomy in the fetal sheep. Simonetta G, et al. **J Auton Nerv Syst** 1996 Sep 12;60(3):108–14
Expression and glucocorticoid regulation of natriuretic peptide clearance receptor (NPR–C) mRNA in rat brain and choroid plexus. Herman JP, et al. **J Chem Neuroanat** 1996 Oct;11(4):257–65
Primary pigmented nodular adrenocortical disease: reevaluation of a patient with carney complex 27 years after unilateral adrenalectomy. Sarlis NJ, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1274–8
Effect of adrenalectomy and corticosterone substitution on glucose and glycogen metabolism in rat brain. Plaschke K, et al. **J Neural Transm** 1996;103(1–2):89–100

ADRENALECTOMY

Structural alterations of the hippocampal formation of adrenalectomized rats: an unbiased stereological study. Sousa N, et al. **J Neurocytol** 1997 Jun;26(6):423–38

Hypophysiotropic CRF neurons display a sustained immediate–early gene response to chronic stress but not to adrenalectomy. Brown ER, et al. **J Neuroendocrinol** 1997 Apr;9(4):307–16

The in vivo time course for elimination of adrenalectomy–induced apoptotic profiles from the granule cell layer of the rat hippocampus. Hu Z, et al. **J Neurosci** 1997 Jun 1;17(11):3981–9

Regulation of a putative neurotransmitter effect of corticotropin–releasing factor: effects of adrenalectomy. Pavcovich LA, et al. **J Neurosci** 1997 Jan 1;17(1):401–8

Differential regulation of adrenocorticoid receptors in the hippocampus and spinal cord of adrenalectomized rats. Marlier LN, et al. **J Neurosci Res** 1996 Mar 1;43(5):526–34

The phosphodiesterase type 4 (PDE4) inhibitor CP–80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor–alpha (TNFalpha) production in mice: effect of adrenalectomy. Cheng JB, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):621–6

Effects of food deprivation and adrenalectomy on CYP3A induction by RU486 in female rats. Cheesman MJ, et al. **J Steroid Biochem Mol Biol** 1996 Jul;58(4):447–54

The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. Elder JS. **J Urol** 1997 Oct; 158(4):1636–7

A case of Cushing's syndrome due to adrenocortical carcinoma with recurrence 19 months after laparoscopic adrenalectomy. Ushiyama T, et al. **J Urol** 1997 Jun; 157(6):2239

Effect of maternal adrenalectomy and corticosterone therapy on the early development of B–cells in the fetal pancreatic islet in the rat. Komatsu S, et al. **J Vet Med Sci** 1996 Oct; 58(10):995–9

Renovascular hypertension after laparoscopic adrenalectomy in a patient with adrenal adenoma [letter] Wu TH, et al. **Nephron** 1996;74(2):464–5

Hippocampal long– and short–term potentiation is modulated by adrenalectomy and corticosterone. Smriga M, et al. **Neuroendocrinology** 1996 Jul;64(1):35–41

Expression of MHC class II CD4+ and ED1 molecules in association with selective hippocampal neuronal degeneration after long–term adrenalectomy. Islam A, et al. **Neuroreport** 1997 Mar 3;8(4):987–90

p53–deficient mice are protected against adrenalectomy–induced apoptosis. Sakhi S, et al. **Neuroreport** 1996 Dec 20;8(1):233–5

Effects of adrenalectomy and corticosterone replacement on diurnal [3H]citalopram binding in rat midbrain. Kulikov A, et al. **Neurosci Lett** 1997 Jan 31;222(2):127–31

Effects of adrenodemedullation and adrenalectomy on the 5–HT2 receptor agonists DOI–and mCPP–induced hypophagia in rats. Yamada J, et al. **Neurosci Lett** 1996 May 10;209(2):113–6

Hepatic gluconeogenesis and the activity of PDH in individual tissues of GTG–obese mice following adrenalectomy. Blair SC, et al. **Obes Res** 1996 Jul; 4(4):367–75

Plasma insulin in response to enterostatin and effect of adrenalectomy in rats. Mei J, et al. **Obes Res** 1996 Nov; 4(6):513–9

Prevention of ACTH– and adrenalectomy–induced muricidal behavior: by benzodiazepinic ligands. Miachon S, et al. **Peptides** 1997;18(2):185–9

Adrenalectomy increases sensitivity to central insulin. Chavez M, et al. **Physiol Behav** 1997 Sep;62(3):631–4

Adrenalectomy lowers the body weight set–point in rats. Gosselin C, et al. **Physiol Behav** 1997 Sep;62(3):519–23

Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission. Piazza PV, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15445–50

Effect of adrenalectomy on the initiation and expression of cocaine–induced sensitization. Prasad BM, et al. **Psychopharmacology (Berl)** 1996 Jun;125(3):265–73

Adrenalectomy attenuates nicotine–induced dopamine release and locomotor activity in rats. Shoaib M, et al. **Psychopharmacology (Berl)** 1996 Dec;128(4):343–50

Is routine ipsilateral adrenalectomy during radical nephrectomy harmful for the patient? Hellström PA, et al. **Scand J Urol Nephrol** 1997 Feb;31(1):19–25

Does hormonal function of the tumor influence the outcome of laparoscopic adrenalectomy? Fernández–Cruz L, et al. **Surg Endosc** 1996 Nov;10(11):1088–91

Is laparoscopic adrenalectomy indicated for pheochromocytomas? Gagner M, et al. **Surgery** 1996 Dec; 120(6):1076–9; discussion 1079–80

Effects of adrenalectomy on Ca2+ currents and Ca2+ channel subunit mRNA expression in hippocampal CA1 neurons of young rats. Karst H, et al. **Synapse** 1997 Jun; 26(2):155–64

Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Sandock DS, et al. **Urology** 1997 Jan;49(1):28–31

Recurrence of endogenous cortisol secretion after bilateral total adrenalectomy—2 cases. Wright–Pascoe R. **West Indian Med J** 1996 Dec;45(4):116–8

Role and operative risk of bilateral adrenalectomy in hypercortisolism. Chapuis Y, et al. **World J Surg** 1996 Sep; 20(7):775–9; discussion 779–80

Laparoscopic approach to pheochromocytoma: hemodynamic changes and catecholamine secretion. Fernández–Cruz L, et al. **World J Surg** 1996 Sep; 20(7):762–8; discussion 768

Adrenalectomy for treatment of Cushing syndrome: results in 122 patients and long–term follow–up studies. Imai T, et al. **World J Surg** 1996 Sep;20(7):781–6; discussion 786–7

Adrenal surgery in the elderly: too risky? Lo CY, et al. **World J Surg** 1996 Mar–Apr;20(3):368–73; discussion 374

Laparoscopic adrenalectomy. Rutherford JC, et al. **World J Surg** 1996 Sep;20(7):758–60; discussion 761

Posterior retroperitoneoscopy as a new minimally invasive approach for adrenalectomy: results of 30 adrenalectomies in 27 patients. Walz MK, et al. **World J Surg** 1996 Sep; 20(7):769–74

[The necessity for perioperative cortisol substitution. Spontaneous and stimulated ACTH and cortisol secretion during unilateral adrenalectomy for renal cell carcinoma] Bischoff P, et al. **Anaesthesist** 1997 Apr;46(4):303–8 (Eng. Abstr.) **(Ger)**

[Results of endoscopic, retroperitoneal adrenalectomy with special reference to the intraoperative course (see comments)] Heintz A, et al. **Chirurg** 1997 Feb;68(2):154–8 (Eng. Abstr.). Comment in: Chirurg 1997 Jun;68(6):650. **(Ger)**

[Bilateral laparoscopic transperitoneal adrenalectomy in pheochromocytoma] Manger T, et al. **Langenbecks Arch Chir** 1997;382(1):37–42 (Eng. Abstr.) **(Ger)**

[Endoscopic therapy of incidentaloma] Heintz A, et al. **Zentralbl Chir** 1997;122(6):477–80 (15 ref.) (Eng. Abstr.) **(Ger)**

[Conventional operation for therapy of incidentaloma] Simon D, et al. **Zentralbl Chir** 1997;122(6):473–6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Adrenalectomy in metastasis of primary pulmonary carcinoma: an emerging issue] Motta G, et al. **Ann Ital Chir** 1996 Sep–Oct;67(5):661–7; discussion 667–8 (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Adrenalectomy reduces the ability of newborn rats to gasp and survive anoxia. Yuan SZ, et al. **Acta Physiol Scand** 1997 Apr;159(4):285–92

Control of venous hemorrhage during laparoscopic adrenalectomy: a case report. Carlson MA, et al. **J Laparoendosc Surg** 1996 Oct;6(5):349–51

Exacerbation of adjuvant arthritis by adrenalectomy is associated with reduced leukocyte lipocortin 1. Yang YH, et al. **J Rheumatol** 1997 Sep;24(9):1758–64

NT–4/5 protects against adrenalectomy–induced apoptosis of rat hippocampal granule cells. Qiao X, et al. **Neuroreport** 1996 Jan 31;7(2):682–6

INSTRUMENTATION

Laparoscopic adrenalectomy in a patient with Cushing syndrome. Metzger N, et al. **Md Med J** 1996 May; 45(5):407–10

[Laparoscopic adrenal gland surgery] Nies C, et al. **Chirurg** 1997 Feb;68(2):99–106 (47 ref.) (Eng. Abstr.) **(Ger)**

[Endoscopic, extraperitoneal adrenalectomy—an expansion of the approach to the adrenal gland] Heintz A, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:617–8 (Eng. Abstr.) **(Ger)**

METHODS

Use of laparoscopic techniques improves outcome from adrenalectomy. Horgan S, et al. **Am J Surg** 1997 May; 173(5):371–4

Anterior, posterior, or laparoscopic approach for the management of adrenal diseases? Linos DA, et al. **Am J Surg** 1997 Feb;173(2):120–5

Laparoscopic adrenalectomy in asymptomatic pheochromocytoma. Takami H, et al. **Am Surg** 1997 Sep; 63(9):820–2

Bilateral adrenalectomy for Cushing's syndrome. Anterior versus posterior surgical approach. Buell JF, et al. **Ann Surg** 1997 Jan;225(1):63–8

Laparoscopic unilateral and bilateral adrenalectomy for Cushing's syndrome. Transperitoneal and retroperitoneal approaches. Fernández–Cruz L, et al. **Ann Surg** 1996 Dec; 224(6):727–34; discussion 734–6

Laparoscopic adrenalectomy. A new standard of care. Jacobs JK, et al. **Ann Surg** 1997 May;225(5):495–501; discussion 501–2

Comparison of three techniques for adrenalectomy. Bonjer HJ, et al. **Br J Surg** 1997 May;84(5):679–82

Bilateral laparoscopic adrenalectomy for Cushing's disease. Chapuis Y, et al. **Br J Surg** 1997 Jul;84(7):1009

Effects of surgical and pharmacological adrenalectomy on the initiation and maintenance of intravenous cocaine self–administration in rats. Goeders NE, et al. **Brain Res** 1996 May 25;722(1–2):145–52

Laparoscopic trans–peritoneal adrenalectomy: a preliminary report of 14 adrenalectomies. Walmsley D, et al. **Clin Endocrinol (Oxf)** 1996 Aug;45(2):141–5

Laparoscopic adrenalectomy: history, indications, and current techniques for a minimally invasive approach to adrenal pathology. Hansen P, et al. **Endoscopy** 1997 May; 29(4):309–14 (20 ref.)

Direct carbon dioxide insufflation of the retroperitoneum under laparoscopic control for renal and adrenal surgery. de Cannière L, et al. **Eur J Surg** 1997 May;163(5):339–44

Transthoracal approach for the removal of adrenal tumors. Early experience with 10 cases. Halachmi S, et al. **Eur Urol** 1996;30(4):480–3

Technique and results of laparoscopic adrenalectomy. Janetschek G, et al. **Eur Urol** 1996;30(4):475–9

Videoendoscopic adrenalectomy: multicentric study from the Belgian Group for Endoscopic Surgery (BGES). De Cannière L, et al. **Int Surg** 1996 Jan–Mar;81(1):6–8

Adrenal–sparing laparoscopic surgery for aldosterone–producing adenoma. Janetschek G, et al. **J Endourol** 1997 Apr;11(2):145–8

Laparoscopic adrenalectomy for nonfunctioning adrenal tumors. Mugiya S, et al. **J Endourol** 1996 Dec;10(6):539–41; discussion 541–3

Laparoscopic adrenalectomy via the retroperitoneal approach: first five cases. Ono Y, et al. **J Endourol** 1996 Aug;10(4):361–5

Laparoscopic adrenalectomy for solitary metachronous contralateral adrenal metastasis from renal cell carcinoma. Elashry OM, et al. **J Urol** 1997 Apr;157(4):1217–22 (37 ref.)

Bilateral laparoscopic adrenalectomy for adrenocorticotropic dependent Cushing's syndrome. Ferrer FA, et al. **J Urol** 1997 Jan;157(1):16–8

Retroperitoneal laparoscopic adrenalectomy for functioning adrenal tumors: comparison with conventional transperitoneal laparoscopic adrenalectomy. Takeda M, et al. **J Urol** 1997 Jan;157(1):19–23

Laparoscopic bilateral adrenalectomy following failed hypophysectomy. Bax TW, et al. **Surg Endosc** 1996 Dec; 10(12):1150–3

Confluence of the right adrenal vein with the accessory right hepatic veins. A potential hazard in laparoscopic right adrenalectomy. MacGillivray DC, et al. **Surg Endosc** 1996 Nov;10(11):1095–6

A comparison of open vs laparoscopic adrenalectomy. MacGillivray DC, et al. **Surg Endosc** 1996 Oct; 10(10):987–90

Laparoscopic right and left adrenalectomies. Surgical procedures. Marescaux J, et al. **Surg Endosc** 1996 Sep; 10(9):912–5

Thoracoscopic transdiaphragmatic left adrenalectomy. An experimental study. Pompeo E, et al. **Surg Endosc** 1997 Apr;11(4):390–2

Endoscopic retroperitoneal right adrenalectomy with the patient in the lateral decubitus position. Demeure MJ, et al. **Surg Laparosc Endosc** 1997 Aug;7(4):307–9

Laparoscopic adrenalectomy: comparison with the conventional approach. Ishikawa T, et al. **Surg Laparosc Endosc** 1997 Aug;7(4):275–80

Cortical–sparing adrenalectomy for patients with bilateral pheochromocytoma. Lee JE, et al. **Surgery** 1996 Dec; 120(6):1064–70; discussion 1070–1

Adrenalectomy in the era of laparoscopy. Staren ED, et al. **Surgery** 1996 Oct;120(4):706–9; discussion 710–1

Laparoscopic adrenalectomy. Fahlenkamp D, et al. **Tech Urol** 1996 Spring;2(1):48–53

Technical improvements in laparoscopic adrenalectomy. Tazaki H, et al. **Tech Urol** 1995 Winter;1(4):222–6

Technique of transperitoneal laparoscopic adrenalectomy. Vargas HI, et al. **Tech Urol** 1996 Fall;2(3):154–8

Technique of laparoscopic adrenalectomy. Winfield HN, et al. **Urol Clin North Am** 1997 May;24(2):459–65

A posterior lumbar approach for retroperitoneoscopic adrenalectomy: assessment of surgical efficacy. Baba S, et al. **Urology** 1997 Jul;50(1):19–24

Laparoscopic adrenalectomy: a new standard of care. Vargas HI, et al. **Urology** 1997 May;49(5):673–8

[Endoscopic retroperitoneal adrenalectomy: a surgical improvement] Bonjer HJ, et al. **Ned Tijdschr Geneeskd** 1997 Mar 1;141(9):426–9 (Eng. Abstr.) **(Dut)**

[Endoscopic, retroperitoneal adrenalectomy (letter; comment)] Walz MK, et al. **Chirurg** 1997 Jun;68(6):650. Comment on: Chirurg 1997 Feb;68(2):154–8. **(Ger)**

[Transthoracic approach for removing adrenal masses] Halachmi S, et al. **Harefuah** 1996 Dec 1;131(11):468–71, 536 (Eng. Abstr.) **(Heb)**

[Current indications for video–laparoscopic surgery of adrenal gland neoplasms] Angrisani L, et al. **G Chir** 1996 Aug–Sep;17(8–9):453–7 (28 ref.) (Eng. Abstr.) **(Ita)**

[Laparoscopic versus laparotomic adrenalectomy: preliminary experiences] Sorrentino M, et al. **Minerva Chir** 1997 Mar;52(3):181–4 (Eng. Abstr.) **(Ita)**

[Laparoscopic adrenalectomy for Cushing's syndrome: a study of comparisons between laparoscopic and open adrenalectomy, and laparoscopic adrenalectomy for differing adrenal tumors] Ushiyama T, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jul;87(7):986–91 (Eng. Abstr.) **(Jpn)**

[Laparoscopic adrenalectomy] Ippolitov LI, et al. **Khirurgiia (Mosk)** 1997;(3):70–4 (55 ref.) **(Rus)**

[The laparoscopic removal of an adrenal tumor] Maĭstrenko NA, et al. **Vestn Khir Im I I Grek** 1997;156(1):106–7 (14 ref.) **(Rus)**

ADRENALINE see **EPINEPHRINE**

ADRENERGIC AGENTS

see related
SYMPATHOLYTICS
SYMPATHOMIMETICS

[The histopathology of ephedrone drug abuse] Pigolkin IuI, et al. **Sud Med Ekspert** 1996 Oct-Dec;39(4):26-8 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

The arrhythmogenic dose of epinephrine in halothane and isoflurane anesthetized dogs: an assessment of repeatability. Pettifer G, et al. **Can J Vet Res** 1997 Jul;61(3):221-6

Measurement of catecholamines in mouse bone marrow by means of HPLC with electrochemical detection. Marino F, et al. **Haematologica** 1997 Jul-Aug;82(4):392-4

CHEMISTRY

Predictive quantitative structure-activity relationships (QSAR) analysis of beta 3-adrenergic ligands. Blin N, et al. **Drug Des Discov** 1995 Apr;12(4):297-311

DIAGNOSTIC USE

Mechanism-based strategies for mapping heart sympathetic nerve function. Raffel DM, et al. **Nucl Med Biol** 1995 Nov; 22(8):1019-26 (45 ref.)

HISTORY

Eating or drinking elicited by direct adrenergic or cholinergic stimulation of hypothalamus. 1960 [classical article] [see comments] Grossman SP. **Obes Res** 1997 May; 5(3):291-3. Comment in: Obes Res 1997 May;5(3):271-4.

METABOLISM

The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Hamelin BA, et al. **Clin Pharmacol Ther** 1996 Nov;60(5):512-21

PHARMACOLOGY

Cytochemical effects of in vitro dopamine treatment on the Na-KATPase activity in strial marginal cells. Kanoh N, et al. **Acta Otolaryngol (Stockh)** 1996 Nov;116(6):824-7

Vestibular habituation--the effect of cholinergic, adrenergic and histaminergic agents on the process. Mierzwiński J, et al. **Acta Otorhinolaryngol Belg** 1997;51(1):39-42

From laboratory to clinic: noradrenergic enhancement of physical therapy for stroke or trauma patients. Feeney DM. **Adv Neurol** 1997;73:383-94 (49 ref.)

Chronic exercise decreases adrenergic agonist-induced vasoconstriction in spontaneously hypertensive rats. Chen HI, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H977-83

Renal organic anion secretion: evidence for dopaminergic and adrenergic regulation. Halpin PA, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1372-9

T3 potentiates the adrenergic stimulation of type II 5'-deiodinase activity in cultured rat brown adipocytes. Hernández A, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E15-23

Blockers of adrenergic neurons and receptors, tumor progression and effects of rotational stress in mice. Perissin L, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3409-13

Neurotoxic effects of DSP-4 on the noradrenergic system of the goldfish brain. Villani L, et al. **Brain Behav Evol** 1996;47(5):219-24

Role of the locus coeruleus in the sleep rebound following two different sleep deprivation methods in the rat. González MM, et al. **Brain Res** 1996 Nov 18; 740(1-2):215-26

5-Hydroxytryptamine and beta-adrenoceptors in rat isolated atria. Davy M, et al. **Cell Mol Life Sci** 1997 Mar;53(3):263-6

A dose related response of 6-OHDA on chicken spectral sensitivity and oscillatory potentials of recording electroretinograms. Li X, et al. **Chin Med J (Engl)** 1996 Oct;109(10):762-70

Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. Schmetterer L, et al. **Clin Pharmacol Ther** 1997 May;61(5):583-95

Activities of antioxidant enzymes and monoamine oxidase-A in the rat interscapular brown adipose tissue: effects of insulin and 6-hydroxydopamine. Davidović V, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jun;117(2):181-6

Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline. Korn A, et al. **Eur J Clin Pharmacol** 1996;49(4):273-8

Perinatal exposure to morphine: reactive changes in the brain after 6-hydroxydopamine. Gorio A, et al. **Eur J Pharmacol** 1996 May 6;303(1-2):21-6

Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia. Neisewander JL, et al. **Eur J Pharmacol** 1996 Jun 3;305(1-3):13-21

Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation. Harro J, et al. **Eur Neuropsychopharmacol** 1995 Dec;5(4):447-55

Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Wiederholt M, et al. **Ger J Ophthalmol** 1996 May; 5(3):146-53

Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide. Dingemanse J, et al. **Int J Clin Pharmacol Ther** 1996 Apr; 34(4):172-7

Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide. Dingemanse J, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):856-61

Characterization of the sympathetic nerve responses to amphetamine: role of central alpha 2-adrenergic receptors. Liu W, et al. **J Cardiovasc Pharmacol** 1996 Nov; 28(5):712-22

Influence of mechanical activity, adrenergic stimulation, and calcium on the expression of myosin heavy chains in cultivated neonatal cardiomyocytes. Luther HP, et al. **J Cell Biochem** 1997 Mar 1;64(3):458-65

Adrenergic agents inhibit rapid increases in cerebellar Purkinje cell glutamic acid decarboxylase (GAD67) mRNA levels after climbing fiber lesions or reserpine treatment. Drengler SM, et al. **J Neurosci** 1996 Mar 1; 16(5):1844-51

alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. Hubbard JW, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):337-46

Noradrenaline modulates transmitter release by enhancing the Ca2+ sensitivity of exocytosis in the chick ciliary presynaptic terminal. Yawo H. **J Physiol (Lond)** 1996 Jun 1;493 (Pt 2):385-91

Effect of indomethacin on the pituitary-adrenocortical response to adrenergic stimulation. Bugajski J, et al. **Life Sci** 1996;59(14):1157-64

Sustained increase in rat myocardial alpha 1A-adrenoceptors induced by 6-hydroxydopamine treatment involves a decelerated receptor turnover. Sallés J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Mar; 353(4):408-16

Chronic administration of methamphetamine does not affect the suprachiasmatic nucleus-operated circadian pacemaker in rats. Moriya T, et al. **Neurosci Lett** 1996 Apr 19; 208(2):129-32

Effects of tyramine and calcium on the kinetics of secretion in intact and electroporated chromaffin cells superfused at high speed. Michelena P, et al. **Pflugers Arch** 1995 Dec; 431(2):283-96

Synthesis and beta-adrenergic activities of R-fluoronaphthyloxypropanolamine. Adejare A, et al. **Pharm Res** 1997 Apr;14(4):533-6

Inhibition of sympathetic noradrenergic transmission by guanabenz and guanethidine in rat isolated mesenteric artery: involvement of neuronal potassium channels. Fabiani ME, et al. **Pharmacol Res** 1996 Mar;33(3):171-80

The unusual adrenergic-like excitatory action of acetylcholine on the ventricular cardiac muscle of the horned shark, Heterodontus portusjacksoni. Thompson AP, et al. **Physiol Zool** 1997 Mar-Apr;70(2):135-42

Differential effects of noradrenergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Mizuki Y, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov; 20(8):1353-67

Cortical and hippocampal EEG power spectra in animal models of schizophrenia produced with methamphetamine, cocaine, and phencyclidine. Yamamoto J. **Psychopharmacology (Berl)** 1997 Jun;131(4):379-87

Interaction between adrenergic agonists and forskolin on adenylate cyclase activity in the rabbit proximal tubule. Beck JS, et al. **Ren Physiol Biochem** 1995 Sep-Oct; 18(5):231-6

[Effects of (-) SPD and (-) THP on the firing of noradrenergic neurons in locus coeruleus] Wu JH, et al. **Sheng Li Hsueh Pao** 1995 Dec;47(6):601-4 (Eng. Abstr.) **(Chi)**

[Effects of topical application of adrenergic agents on refraction and accommodation] Otsuka N, et al. **Nippon Ganka Gakkai Zasshi** 1997 May;101(5):400-6 (Eng. Abstr.) **(Jpn)**

[Involvement of adrenergic mechanisms in developing the nervous syndrome of high pressure and nitrogen narcosis] Sledkov AI, et al. **Aviakosm Ekolog Med** 1996;30(5):28-33 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

The effect of ephedrine on the onset time of rocuronium. Muñoz HR, et al. **Anesth Analg** 1997 Aug;85(2):437-40

Effects of catecholamines and diazepam in chloroquine poisoning in barbiturate anaesthetised rats. Buckley NA, et al. **Hum Exp Toxicol** 1996 Nov;15(11):909-14

Mueller's muscle: to relax or to incise. Haddad HM. **Metab Pediatr Syst Ophthalmol** 1995;18(1-4):15-8

Enhancing recovery from ischemic stroke. Geldmacher DS. **Neurosurg Clin N Am** 1997 Apr;8(2):245-51 (59 ref.)

Peripheral analgesic effect of intra-articular clonidine. Gentili M, et al. **Pain** 1996 Mar;64(3):593-6

Adrenergic mechanisms in the control of gastrointestinal motility: from basic science to clinical applications. De Ponti F, et al. **Pharmacol Ther** 1996;69(1):59-78 (378 ref.)

The influence of chronic treatment with clonidine, yohimbine and idazoxan on morphine withdrawal. El-Kadi AO, et al. **Psychopharmacology (Berl)** 1997 Jul;132(1):67-73

TOXICITY

Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Duty S, et al. **Exp Neurol** 1997 Apr;144(2):423-32

Unlike MPP+, apoptosis induced by 6-OHDA in PC12 cells is independent of mitochondrial inhibition. Wu Y, et al. **Neurosci Lett** 1996 Dec 27;221(1):69-71

Potentiation of pyridostigmine bromide toxicity in mice by selected adrenergic agents and caffeine. Chaney LA, et al. **Vet Hum Toxicol** 1997 Aug;39(4):214-9

ADRENERGIC AGONISTS

ADMINISTRATION & DOSAGE

The effects of solution concentration and epinephrine on lateral distribution of hyperbaric tetracaine spinal anesthesia. Iselin-Chaves IA, et al. **Anesth Analg** 1996 Oct; 83(4):755-9

In vivo resistance of lipolysis to epinephrine. A new feature of childhood onset obesity. Bougnères P, et al. **J Clin Invest** 1997 Jun 1;99(11):2568-73

Enhanced ocular hypotensive response to epinephrine in rabbits with prior dexamethasone treatment. Rom ME, et al. **J Ocul Pharmacol Ther** 1997 Aug;13(4):313-20

ADVERSE EFFECTS

Bilateral massive adrenal haemorrhage complicating anaphylactic shock: a case report [letter; comment] Waldhausen E. **Intensive Care Med** 1997 Feb;23(2):235-6 . Comment on: Intensive Care Med 1996 May;22(5):447-9.

DIAGNOSTIC USE

Growth hormone response to clonidine and the cortisol response to dexamethasone in depressive patients. Valdivieso S, et al. **Psychiatry Res** 1996 Feb 28;60(1):23-32

PHARMACOLOGY

Effects of commonly used adrenergic agonists on left ventricular function and systemic vascular resistance in young piglets. Cassidy SC, et al. **Am Heart J** 1997 Feb; 133(2):174-83

Epinephrine does not impair utilization of exogenous amino acids in humans. Schiefermeier M, et al. **Am J Clin Nutr** 1997 Jun;65(6):1765-73

Effect of epinephrine on cAMP accumulation in cultured rat inner medullary collecting duct cells. Yasuda G, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):F192-7

Epinephrine increases spinal cord concentrations of [3H]-clonidine hydrochloride in rabbits after epidural infusion. Fu ES, et al. **Anesth Analg** 1997 Aug;85(2):324-7

Epinephrine infusion does not enhance net muscle glycogenolysis during prolonged aerobic exercise. Wendling PS, et al. **Can J Appl Physiol** 1996 Aug; 21(4):271-84

The effects of midazolam and ephedrine on post-exercise autonomic chronotropic control of the heart in normal subjects. Lindqvist A, et al. **Clin Auton Res** 1996 Dec; 6(6):343-9

Effects of UK-14,304, noradrenaline, and propranolol on insulin release from transplanted mouse islets. Shi CL, et al. **Eur J Endocrinol** 1996 Dec;135(6):724-8

Nitrotyrosine attenuates the hemodynamic effects of adrenoceptor agonists in vivo: relevance to the pathophysiology of peroxynitrite. Kooy NW, et al. **Eur J Pharmacol** 1996 Aug 29;310(2-3):155-61

Antispastic effects of L-dopa. Eriksson J, et al. **Exp Brain Res** 1996 Sep;111(2):296-304

Responsiveness of smooth muscle in the lower urinary tract of rabbits to various agonists. Sudoh K, et al. **Gen Pharmacol** 1997 Apr;28(4):629-31

Epinephrine or norepinephrine fail to influence pituitary-adrenal secretion in man. Oberbeck R, et al. **Horm Metab Res** 1996 Mar;28(3):142-6

Comparison of the direct and indirect effects of epinephrine on hepatic glucose production. Chu CA, et al. **J Clin Invest** 1997 Mar 1;99(5):1044-56

The effects of adrenaline on the work- and power-generating capacity of rat papillary muscle in vitro. Layland J, et al. **J Exp Biol** 1997 Feb;200 (Pt 3):503-9

Variation in adrenergic regulation of lipolysis between omental and subcutaneous adipocytes from obese and non-obese men. Hoffstedt J, et al. **J Lipid Res** 1997 Apr; 38(4):795-804

Cholesterol-fed rabbits: study of the response of the vas deferens to adrenergic and non-adrenergic stimulus and to a kappa-opioid agonist. Alfaro MJ, et al. **J Pharm Pharmacol** 1996 Apr;48(4):433-6

Role of prostaglandins in the stimulation of the hypothalamic-pituitary-adrenal axis by adrenergic and neurohormone systems. Bugajski J. **J Physiol Pharmacol** 1996 Dec;47(4):559-75 (78 ref.)

Differential regulation of the mitogen-activated protein and stress-activated protein kinase cascades by adrenergic agonists in quiescent and regenerating adult rat hepatocytes. Spector MS, et al. **Mol Cell Biol** 1997 Jul; 17(7):3556-65

ADRENERGIC AGONISTS

The enhancement and the inhibition of noradrenaline-induced cyclic AMP accumulation in rat brain by stimulation of metabotropic glutamate receptors. Pilc A, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1996 May; 20(4):673-90

[Features of endocrine function changes in hypertensive NISAG line rats after exposure to adrenaline] Iakobson GS, et al. **Biull Eksp Biol Med** 1996 May;121(5):495-8 **(Rus)**

THERAPEUTIC USE

The effects of nasolacrimal canal blockage on topical medications for glaucoma. Aritürk N, et al.
Acta Ophthalmol Scand 1996 Aug;74(4):411-3

Treatment of hypotension after hyperbaric tetracaine spinal anesthesia. A randomized, double-blind, cross-over comparison of phenylephrine and epinephrine. Brooker RF, et al. **Anesthesiology** 1997 Apr;86(4):797-805

Out-patient management of asthma & COPD. Cosentino AM. **Compr Ther** 1997 Jan;23(1):67-72

Sympathetic inhibition with clonidine improves autonomic balance in congestive heart failure. You-hua Z, et al.
Int J Cardiol 1997 Apr 18;59(2):139-44

Adrenaline, cardiac arrest, and evidence based medicine [see comments] Rainer TH, et al. **J Accid Emerg Med** 1996 Jul;13(4):234-7 (45 ref.). Comment in: J Accid Emerg Med 1996 Nov;13(6):433.

ADRENERGIC ALPHA-AGONISTS

Spinal anesthesia with meperidine. Effects of added alpha-adrenergic agonists: epinephrine versus clonidine. Acalovschi I, et al. **Anesth Analg** 1997 Jun;84(6):1333-9

Postoperative epidural infusion: a randomized, double-blind, dose-finding trial of clonidine in combination with bupivacaine and fentanyl. Paech MJ, et al.
Anesth Analg 1997 Jun;84(6):1323-8

H3-histamine receptors and clonidine analgesia in rats. Chiechio S, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S43-4

Effects of clonidine pretreatment on the local anaesthetic activity of bupivacaine in mice. Attolini L, et al.
J Pharm Pharmacol 1995 Dec;47(12A):994-6

Clonidine-induced emesis: a multitransmitter pathway concept. Japundžić-Zigon N, et al. **Pharmacol Res** 1997 Apr;35(4):287-97

Spinal clonidine fails to provide surgical anesthesia for transurethral resection of prostate. A dose-finding pilot study. Malinovsky JM, et al. **Reg Anesth** 1996 Sep-Oct; 21(5):419-23

Comparison of clonidine and epinephrine in lidocaine for cervical plexus block. Molnar RR, et al. **Reg Anesth** 1997 Mar-Apr;22(2):137-42

ADMINISTRATION & DOSAGE

Low-dose intravenous clonidine in children: plasma concentrations and haemodynamic response. Bergendahl HT, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):381-4

Caudal clonidine and bupivacaine for combined epidural and general anaesthesia in children. Motsch J, et al.
Acta Anaesthesiol Scand 1997 Aug;41(7):877-83

The efficacy of clonidine for reducing perioperative haemodynamic changes and volatile anaesthetic requirements in children. Nishina K, et al.
Acta Anaesthesiol Scand 1996 Jul;40(6):746-51

Comparison of epidural butorphanol plus clonidine with butorphanol alone for postoperative pain relief. Tan PH, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):91-6

Outpatient non-opioid detoxification for opioid withdrawal. Who is likely to benefit? McCann MJ, et al.
Am J Addict 1997 Summer;6(3):218-23

Pressure-heart rate responses to alpha-adrenergic stimulation and hormonal regulation in normotensive patients with obstructive sleep apnea. Maillard D, et al.
Am J Hypertens 1997 Jan;10(1):24-31

Analgesic doses of intrathecal but not intravenous clonidine increase acetylcholine in cerebrospinal fluid in humans. De Kock M, et al. **Anesth Analg** 1997 Apr;84(4):800-3

Changes in cerebral hemodynamics after a single dose of clonidine in severely head-injured patients. ter Minassian A, et al. **Anesth Analg** 1997 Jan;84(1):127-32

Reduction of the minimum alveolar concentration of isoflurane by dexmedetomidine. Aantaa R, et al.
Anesthesiology 1997 May;86(5):1055-60

Intrathecal alpha 2-adrenergic agonists stimulate acetylcholine and norepinephrine release from the spinal cord dorsal horn in sheep. An in vivo microdialysis study. Klimscha W, et al. **Anesthesiology** 1997 Jul;87(1):110-6

Small, oral dose of clonidine reduces the incidence of intraoperative myocardial ischemia in patients having vascular surgery. Stühmeier KD, et al. **Anesthesiology** 1996 Oct;85(4):706-12

A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Schuman JS, et al. **Arch Ophthalmol** 1997 Jul;115(7):847-52

Clonidine prophylaxis for narcotic and sedative withdrawal syndrome following laryngotracheal reconstruction. Deutsch ES, et al. **Arch Otolaryngol Head Neck Surg** 1996 Nov;122(11):1234-8

Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. Mazoit JX, et al.
Br J Clin Pharmacol 1996 Aug;42(2):242-5

Oral clonidine reduces postoperative PCA morphine requirements. Park J, et al. **Can J Anaesth** 1996 Sep; 43(9):900-6

Intracoronary administration of the alpha 1-receptor agonist, methoxamine, does not reproduce the infarct-limiting effect of ischemic preconditioning in dogs. Sebbag L, et al.
Cardiovasc Res 1996 Nov;32(5):830-8

Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Jacob G, et al. **Circulation** 1997 Jul 15;96(2):575-80

Attenuated blood pressure responsiveness during post-exercise hypotension. VanNess JM, et al.
Clin Exp Hypertens 1996 Oct;18(7):891-900

In vivo cAMP level in rabbit iris-ciliary body after topical epinephrine treatment. Liu JH, et al. **Curr Eye Res** 1996 Oct;15(10):1025-32

The addition of clonidine to prilocaine for intravenous regional anaesthesia. Kleinschmidt S, et al.
Eur J Anaesthesiol 1997 Jan;14(1):40-6

Potentiation of sufentanil by clonidine in PCEA with or without basal infusion. Vercauteren MP, et al.
Eur J Anaesthesiol 1996 Nov;13(6):571-6

The effects of long-term topical glaucoma medication on conjunctival impression cytology. Turaçli E, et al.
Int Ophthalmol 1997;21(1):27-33

Intravenous co-infusion of adenosine and norepinephrine preconditions the heart without adverse hemodynamic effects [see comments] Cohen MV, et al.
J Thorac Cardiovasc Surg 1997 Aug;114(2):236-42. Comment in: J Thorac Cardiovasc Surg 1997 Aug;114(2):234-5.

Intravenous co-infusion of adenosine and norepinephrine [editorial; comment] Kloner RA, et al.
J Thorac Cardiovasc Surg 1997 Aug;114(2):234-5. Comment on: J Thorac Cardiovasc Surg 1997 Aug;114(2):236-42.

Comparative study of epidurally administered clonidine and buprenorphine on anesthetic requirement and electroencephalographic activity. Nishimi Y.
Keio J Med 1996 Dec;45(4):324-31

Apraclonidine 0.5% versus 1% for controlling intraocular pressure elevation after argon laser trabeculoplasty. Threlkeld AB, et al. **Ophthalmic Surg Lasers** 1996 Aug; 27(8):657-60

Brimonidine tartrate: a one-month dose response study [published erratum appears in Ophthalmology 1997 Mar;104(3):346] Derick RJ, et al. **Ophthalmology** 1997 Jan; 104(1):131-6

Apraclonidine and anterior segment laser surgery. Comparison of 0.5% versus 1.0% apraclonidine for prevention of postoperative intraocular pressure rise. Rosenberg LF, et al. **Ophthalmology** 1995 Sep; 102(9):1312-8

High-dose versus standard-dose epinephrine treatment of cardiac arrest after failure of standard therapy. Sherman BW, et al. **Pharmacotherapy** 1997 Mar-Apr;17(2):242-7

Clonidine as premedication for rhinoplasty [letter] Britto JA, et al. **Plast Reconstr Surg** 1997 Aug;100(2):548-9

Postherpetic neuralgia: response to topical clonidine. Abadir AR, et al. **Proc West Pharmacol Soc** 1996;39:47-8

Lidocaine-clonidine retrobulbar block for cataract surgery in the elderly. Mjahed K, et al. **Reg Anesth** 1996 Nov-Dec; 21(6):569-75

Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Schuman JS.
Surv Ophthalmol 1996 Nov;41 Suppl 1:S27-37

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Serle JB. **Surv Ophthalmol** 1996 Nov;41 Suppl 1:S39-47

Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Walters TR. **Surv Ophthalmol** 1996 Nov;41 Suppl 1:S19-26 (26 ref.)

Medetomidine as a premedicant for ketamine, propofol or fentanyl anaesthesia in dogs. Hellebrekers LJ, et al.
Vet Rec 1997 May 24;140(21):545-8

[Support and guidelines, nicotine substitutes and clonidine have positive effects on smoking cessation. Five Cochrane meta-analyses on agents used in smoking cessation] Lous J. **Ugeskr Laeger** 1997 Sep 22;159(39):5783-6 **(Dan)**

[Clonidine for intrathecal pain therapy] Zenz M.
Dtsch Med Wochenschr 1996 Oct 25;121(43):1345 **(Ger)**

[Effectiveness of clonidine in postoperative nausea and vomiting--epidural versus oral administration] Kobayashi N, et al. **Masui** 1997 Apr;46(4):538-42 (Eng. Abstr.) **(Jpn)**

[Preoperative evaluation of patients with heart dysfunction and preanesthetic medication] Nishikawa T. **Masui** 1996 Dec;45 Suppl:S108-13 (21 ref.) **(Jpn)**

[Tizanidine for preanesthetic medication] Takenaka M, et al. **Masui** 1996 Aug;45(8):971-5 (Eng. Abstr.) **(Jpn)**

[General anesthesia with use of nubain and clopheline in myocardial revascularization surgery] Grishin VV, et al. **Anesteziol Reanimatol** 1996 Jul-Aug;(4):25-30 **(Rus)**

[Prevention of prolonged drug-induced erection by intracavernous injection of etilefrine] Fiter Gómez L, et al. **Actas Urol Esp** 1997 Feb;21(2):128-32 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Ephedrine-induced coronary artery vasospasm in a patient with prior cocaine use. Lustik SJ, et al. **Anesth Analg** 1997 Apr;84(4):931-3

Atipamezole-precipitated clonidine withdrawal induces c-Fos expression in rat central nervous system. Stornetta RL, et al. **Brain Res** 1997 Aug 1;764(1-2):81-92

Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses. Sarlis NJ, et al.
Clin Auton Res 1996 Apr;6(2):115-7

Cardiovascular and metabolic responses to clonidine and midazolam premedication. Taittonen M, et al.
Eur J Anaesthesiol 1997 Mar;14(2):190-6

Effect of epidural buprenorphine and clonidine on vesical functions in women. Batra YK, et al.
Int J Clin Pharmacol Ther 1996 Jul;34(7):309-11

Acute colonic pseudoobstruction (Ogilvie's syndrome) in two patients receiving high dose clonidine for delirium tremens. Stieger DS, et al. **Intensive Care Med** 1997 Jul;23(7):780-2

Severe alpha-2 agonist withdrawal syndrome in diabetes mellitus [letter] Takeuchi Y, et al. **Intern Med** 1996 Apr; 35(4):345

Case study: adverse response to clonidine. Cantwell DP, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Apr; 36(4):539-44

Clonidine side effect [letter] McCracken JT, et al.
J Am Acad Child Adolesc Psychiatry 1997 Feb;36(2):160-1

Uterine contraction in the development of Möbius syndrome. Graf WD, et al. **J Child Neurol** 1997 Apr;12(3):225-7

Use of anticholinergics to treat bradycardia caused by alpha1-adrenergic agonist overdose is not safe [letter; comment] Sprung J, et al. **J Clin Anesth** 1996 Aug; 8(5):426-7. Comment on: J Clin Anesth 1995 Sep;7(6):512-4.

Effects of verapamil on electroconvulsive shock- and clonidine-induced amnesia. Bojanova E, et al.
Methods Find Exp Clin Pharmacol 1997 Mar;19(2):93-7

Cardiopulmonary compromise after use of topical and submucosal alpha-agonists: possible added complication by the use of beta-blocker therapy. Kalyanaraman M, et al.
Otolaryngol Head Neck Surg 1997 Jul;117(1):56-61 (32 ref.)

[Mobitz I after accidental ingestion of eyedrops (letter)] Martínez-Albaladejo M, et al. **An Med Interna** 1996 Jul; 13(7):359-60 **(Spa)**

ANALYSIS

Presence of norepinephrine and other biogenic amines in stonefish venom. Garnier P, et al.
J Chromatogr B Biomed Appl 1996 Oct 25;685(2):364-9

BLOOD

Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Nance PW, et al. **Arch Neurol** 1997 Jun;54(6):731-6

Analytical method development for the simultaneous quantitation of dexmedetomidine and three potential metabolites in plasma. Hui YH, et al. **J Chromatogr A** 1997 Feb 21;762(1-2):281-91

Determination of dexmedetomidine in rat plasma by a sensitive [3H]clonidine radioreceptor assay. Bol CJ, et al.
J Pharm Sci 1997 Jul;86(7):822-6

No effect of the calcium antagonist, isradipine, on plasma catecholamines in irreversible chronic obstructive pulmonary disease (COPD). A randomized, double-blind, placebo-controlled study. Graudal NA, et al.
Pulm Pharmacol 1995 Apr-Jun;8(2-3):131-5

CHEMICAL SYNTHESIS

Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. Meyer MD, et al. **J Med Chem** 1996 Sep 27; 39(20):4116-9

Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potential binding interactions with alpha 2-adrenoceptors involving a "methyl pocket". Zhang X, et al. **J Med Chem** 1997 Sep 12;40(19):3014-24

CHEMISTRY

Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation. Thompson CD, et al.
Exp Eye Res 1997 May;64(5):767-73

(S)-spiro[(1,3-diazacyclopent-1-ene)-5,2'-(7'-methyl-1',2',3',4'- tetrahydronaphthalene)]: resolution, stereospecific synthesis, and preliminary pharmacological characterization as a partial alpha-adrenergic agonist. Cordi AA, et al. **J Med Chem** 1997 Aug 29;40(18):2931-5

DIAGNOSTIC USE

Growth hormone response to clonidine and L-dopa in normal volunteers. Bebchuk JM, et al. **Anxiety** 1994-95; 1(6):278-81

Pharmacological challenge test of the Tridimensional Personality Questionnaire in patients with social phobia and normal volunteers. Tancer ME, et al. **Anxiety** 1994-95; 1(5):224-6

Growth hormone response to clonidine in the nervous pointer dog model of anxiety. Uhde TW, et al. **Anxiety** 1994; 1(2):45–9

Atrial natriuretic hormone responses to clonidine in patients with panic disorder and in healthy control subjects [letter; comment] Kellner M, et al. **Eur J Endocrinol** 1997 Jul; 137(1):84–5. Comment on: Eur J Endocrinol 1995 Feb;132(2):147–51.

PET examination of the monkey heart with high specific radioactivity [11C]norepinephrine and [11C]metaraminol. Farde L, et al. **Nucl Med Biol** 1995 Nov;22(8):1053–6

An HPLC–method for determination of ligand metabolism during PET studies with [11C]metaraminol and [11C]norepinephrine. Swahn CG, et al. **Nucl Med Biol** 1995 Nov;22(8):1045–8

The stability of plasma growth hormone and MHPG responses to repeated clonidine challenge in normal males. Trestman RL, et al. **Psychoneuroendocrinology** 1994; 19(1):13–20

[Sensitivity of the clonidine and guanfacine tests (alpha–2–adrenergic agonists) as pharmacologic stimulants of growth hormone. Effects on plasma cortisol] Durá Travé T, et al. **An Esp Pediatr** 1996 Dec;45(6):575–8 (Eng. Abstr.) **(Spa)**

METABOLISM

Up–regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B–adrenoceptor by ligands that act as inverse agonists. Lee TW, et al. **Biochem J** 1997 Aug 1;325 (Pt 3):733–9

Microsomal catalyzed N–hydroxylation of guanabenz and reduction of the N–hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz. Clement B, et al. **Chem Res Toxicol** 1996 Jun;9(4):682–8

Polyclonal anti–idiotypic antibodies to idazoxan and their interaction with human brain imidazoline binding sites. Bennai F, et al. **Eur J Pharmacol** 1996 Jun 13; 306(1–3):211–8

[3H]dexmedetomidine, an alpha 2–adrenoceptor agonist, detects a novel imidazole binding site in adult rat spinal cord. Savola MK, et al. **Eur J Pharmacol** 1996 Jun 13; 306(1–3):315–23

Effect of the alpha–1 adrenoceptor blocker on tissue norepinephrine contents in human benign prostatic hyperplasia. Ishigooka M, et al. **Int Urol Nephrol** 1997; 29(2):195–200

Regulation of uveal sympathetic neurotransmission by peroxides. Opere C, et al. **Invest Ophthalmol Vis Sci** 1997 Apr;38(5):842–7

Involvement of nitric oxide in endothelin ETB receptor–mediated inhibitory actions on antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs. Matsuo G, et al. **J Cardiovasc Pharmacol** 1997 Sep;30(3):325–31

Release of noradrenaline from isolated rat tail artery induced by bafilomycin A1. Palatý V. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Mar; 353(4):431–7

Binding of new cirazoline derivative to imidazoline receptors from human brain. Dontenwill M, et al. **Neurochem Int** 1997 Jan;30(1):9–16

The novel alpha 2–adrenoceptor agonist [3H]mivazerol binds to non–adrenergic binding sites in human striatum membranes that are distinct from imidazoline receptors. Flamez A, et al. **Neurochem Int** 1997 Jul;31(1):125–9

Possible involvement of alpha 1–adrenoceptors in the modulation of [3H]noradrenaline release in rat brain cortical and hippocampal synaptosomes. Pastor C, et al. **Neurosci Lett** 1996 Oct 4;216(3):187–90

Adrenosensitivity of injured afferent neurons does not require the presence of postganglionic sympathetic terminals. Rubin G, et al. **Pain** 1997 Aug;72(1–2):183–91

PHARMACOKINETICS

Transfer of clonidine and dexmedetomidine across the isolated perfused human placenta. Ala–Kokko TI, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):313–9

Epinephrine increases spinal cord concentrations of [3H]–clonidine hydrochloride in rabbits after epidural infusion. Fu ES, et al. **Anesth Analg** 1997 Aug;85(2):324–7

Paracetamol (acetominophen) sulphoconjugation in man: no correlation with tyramine sulphoconjugation. Hannah P, et al. **Drug Metabol Drug Interact** 1996;13(2):119–28

Transport of clonidine across cultured brain microvessel endothelial cells. Huwyler J, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):81–5

Single dose pharmacokinetics of medetomidine in sheep. Muge DK, et al. **J Vet Pharmacol Ther** 1996 Apr; 19(2):109–12

Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. Eisenhofer G, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug–Sep; 354(3):287–94

An HPLC–method for determination of ligand metabolism during PET studies with [11C]metaraminol and [11C]norepinephrine. Swahn CG, et al. **Nucl Med Biol** 1995 Nov;22(8):1045–8

PHARMACOLOGY

Hemodynamic and coronary vascular effects of dexmedetomidine in the anesthetized goat. Lawrence CJ, et al. **Acta Anaesthesiol Scand** 1997 Aug;41(7):830–6

Alleviation of the peripheral hemodynamic effects of dexmedetomidine by the calcium channel blocker isradipine. Roekaerts PM, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):364–70

Mivazerol, a new alpha 2–adrenergic agonist, blunts cardiovascular effects following surgical stress in pentobarbital–anesthetized rats. Zhang X, et al. **Acta Anaesthesiol Scand** 1997 Jun;41(6):694–700

Effect of fetal ethanol exposure on the in vitro release of growth hormone, somatostatin and growth hormone–releasing factor induced by clonidine and growth hormone feedback in male and female rats. Conway S, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):826–39

Dexmedetomidine, diazepam, and propranolol in the treatment of ethanol withdrawal symptoms in the rat. Riihioja P, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):804–8

Age–related changes in interstitial norepinephrine. A microdialysis study in spontaneously hypertensive rats. Cabassi A, et al. **Am J Hypertens** 1996 Sep;9(9):878–83

Pial arteriolar constriction to alpha 2–adrenergic agonist dexmedetomidine in the rat. Asano Y, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2547–56

Effects of alpha–adrenergic stimuli on mesenteric collecting lymphatics in the rate. Benoit JN. **Am J Physiol** 1997 Jul; 273(1 Pt 2):R331–6

Role of Ca(2+)–independent PKC in alpha 1–adrenoceptor–mediated inotropic responses of neonatal rat hearts. Deng XF, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1113–8

Signals mediating stimulation of cardiomyocyte glucose transport by the alpha–adrenergic agonist phenylephrine. Fischer Y, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):C1211–20

Chronic exercise enhances cardiac alpha 1–adrenergic inotropic responsiveness in rats with mild hypertension. Korzick DH, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2599–608

Intracerebral adrenoceptor agonists influence rat duodenal mucosal bicarbonate secretion. Larson GM, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):G831–40

Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal cats. Miller PE, et al. **Am J Vet Res** 1996 Jan; 57(1):83–6

Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal dogs. Miller PE, et al. **Am J Vet Res** 1996 Jan; 57(1):79–82

Comparison of antinociceptive, cardiovascular, and respiratory effects, head ptosis, and position of pelvic limbs in mares after caudal epidural administration of xylazine and detomidine hydrochloride solution. Skarda RT, et al. **Am J Vet Res** 1996 Sep;57(9):1338–45

Effects of a single pre–operative dexmedetomidine dose on isoflurane requirements and peri–operative haemodynamic stability. Lawrence CJ, et al. **Anaesthesia** 1997 Aug; 52(8):736–44

Postoperative alpha 2–adrenergic stimulation attenuates protein catabolism: effects of clonidine on growth hormone secretion [letter; comment] De Kock M. **Anesth Analg** 1996 Nov;83(5):1134; discussion 1135. Comment on: Anesth Analg 1996 Feb;82(2):258–63.

Clonidine increases the sweating threshold, but does not reduce the gain of sweating. Delaunay L, et al. **Anesth Analg** 1996 Oct;83(4):844–8

Differential effects of two intraventricularly injected alpha 2 agonists, ST–91 and dexmedetomidine, on electroencephalogram, feeding, and electromyogram. Dowlatshahi P, et al. **Anesth Analg** 1997 Jan;84(1):133–8

Intravenous clonidine decreases minimum end–tidal isoflurane for induction of electroencephalographic burst suppression. Entholzner EK, et al. **Anesth Analg** 1997 Jul; 85(1):193–8

Postoperative alpha 2–adrenergic stimulation attenuates protein catabolism: effects of clonidine on growth hormone secretion [letter; comment] Klis R, et al. **Anesth Analg** 1996 Nov;83(5):1135. Comment on: Anesth Analg 1996 Feb;82(2):258–63.

The effect of dexmedetomidine on nutrient organ blood flow. Lawrence CJ, et al. **Anesth Analg** 1996 Dec;83(6):1160–5

Intraventricular dexmedetomidine decreases cerebral blood flow during normoxia and hypoxia in dogs. McPherson RW, et al. **Anesth Analg** 1997 Jan;84(1):139–47

Norepinephrine activation of basal cerebral metabolic rate for oxygen (CMRO2) during hypothermia in rats. Nemoto EM, et al. **Anesth Analg** 1996 Dec;83(6):1262–7

Perioperative sympatholysis. Beneficial effects of the alpha 2–adrenoceptor agonist mivazerol on hemodynamic stability and myocardial ischemia. McSPI––Europe Research Group. **Anesthesiology** 1997 Feb;86(2):346–63

Dexmedetomidine as an anesthetic adjunct in coronary artery bypass grafting. Jalonen J, et al. **Anesthesiology** 1997 Feb; 86(2):331–45

Antinociceptive interaction of intrathecal alpha2–adrenergic agonists, tizanidine and clonidine, with lidocaine in rats. Kawamata T, et al. **Anesthesiology** 1997 Aug;87(2):436–48

Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Kuhmonen J, et al. **Anesthesiology** 1997 Aug;87(2):371–7

The effect of clonidine on cerebral blood flow velocity, carbon dioxide cerebral vasoreactivity, and response to increased arterial pressure in human volunteers. Lee HW, et al. **Anesthesiology** 1997 Sep;87(3):553–8

Sympatholytic and minimum anesthetic concentration–sparing responses are preserved in rats rendered tolerant to the hypnotic and analgesic action of dexmedetomidine, a selective alpha(2)–adrenergic agonist. Rabin BC, et al. **Anesthesiology** 1996 Sep;85(3):565–73

Effects of dexmedetomidine on hypoxia–evoked glutamate release and glutamate receptor activity in hippocampal slices. Talke P, et al. **Anesthesiology** 1996 Sep;85(3):551–7

Actions of phenylephrine, isoproterenol, and epinephrine with halothane on endocardial conduction and activation in canine left ventricular papillary muscles. Vodanovic S, et al. **Anesthesiology** 1997 Jul;87(1):117–26

Alpha–2 adrenoceptor agonists decrease cyclic guanosine 3',5'–monophosphate in the mouse brain [see comments] Vulliemoz Y, et al. **Anesthesiology** 1996 Sep;85(3):544–50 . Comment in: Anesthesiology 1996 Sep;85(3):457–9.

Clonidine, but not morphine, delays the development of thermal hyperesthesia induced by sciatic nerve constriction injury in the rat. Yamamoto T, et al. **Anesthesiology** 1996 Oct;85(4):835–45

Functional study of the excitatory alpha–adrenoceptor in guinea pig ileum, in relation to the hypothesis of an atypical receptor. Bricola A, et al. **Ann N Y Acad Sci** 1997 May 30;812:189–92

Do cardiovascular mechanisms participate in thermoregulatory activity of alpha 2–adrenoceptor agonists and antagonists in rabbits? Szreder Z. **Ann N Y Acad Sci** 1997 Mar 15;813:512–25

Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Nance PW, et al. **Arch Neurol** 1997 Jun;54(6):731–6

Structure–activity relationship studies of CNS agents, Part 32: Effect of structural modifications in 1–arylpiperazine derivatives on alpha(1) –adrenoreceptor affinity. Mokrosz MJ, et al. **Arch Pharm (Weinheim)** 1997 Jun;330(6):177–80

Effect of endothelium on the aortic contraction induced by norepinephrine and KCl in isolated rat aorta. Wong KK. **Artery** 1996;22(1):55–60

Effect of mivazerol on myocardial lactate production, blood flow and electrocardiographic signs of ischaemia induced by coronary artery ligation in the anaesthetised dog. Riemersma RA, et al. **Arzneimittelforschung** 1997 Jan; 47(1):10–3

Adrenergic stimulation of lipoprotein lipase gene expression in rat brown adipocytes differentiated in culture: mediation via beta3– and alpha1–adrenergic receptors. Kuusela P, et al. **Biochem J** 1997 Feb 1;321 (Pt 3):759–67

Adrenergic regulation of brown adipocyte differentiation. Cannon B, et al. **Biochem Soc Trans** 1996 May;24(2):407–12 (29 ref.)

Role of the amino terminus of the third intracellular loop in agonist–promoted downregulation of the alpha2A–adrenergic receptor. Jewell–Motz EA, et al. **Biochemistry** 1997 Jul 22;36(29):8858–63

Cell–density–dependent expression of the alpha(2)–adrenergic response by epidermal growth factor (EGF) in primary cultures of adult rat hepatocytes. Ogihara M. **Biol Pharm Bull** 1996 Apr;19(4):518–24

Effect of clonidine on gastric emptying of liquids. Asai T, et al. **Br J Anaesth** 1997 Jan;78(1):28–33

Differential effects of clonidine and dexmedetomidine on gastric emptying and gastrointestinal transit in the rat. Asai T, et al. **Br J Anaesth** 1997 Mar;78(3):301–7

Extradural clonidine combined with sufentanil and 0.0625% bupivacaine for analgesia in labour. Chassard D, et al. **Br J Anaesth** 1996 Oct;77(4):458–62

Effects of clonidine on the pituitary hormonal response to pelvic surgery. Lyons FM, et al. **Br J Anaesth** 1997 Feb; 78(2):134–7

Effect of clonidine and dexmedetomidine premedication on perioperative oxygen consumption and haemodynamic state. Taittonen MT, et al. **Br J Anaesth** 1997 Apr; 78(4):400–6

Bisoprolol attenuates noradrenaline– and phenylephrine–evoked venoconstriction in man in vivo. Abdelmawla AH, et al. **Br J Clin Pharmacol** 1997 Jul; 44(1):61–8

Effects of L–NG–nitro–arginine on noradrenaline induced contraction in the rat anococcygeus muscle. Hoyo Y, et al. **Br J Pharmacol** 1997 Mar;120(6):1035–8

Clonidine–induced increase in osmolar clearance and free water clearance via activation of two distinct alpha 2–adrenoceptor sites. Intengan HD, et al. **Br J Pharmacol** 1996 Oct;119(4):663–70

A comparative study on the rat aorta and mesenteric arterial bed of the possible role of nitric oxide in the desensitization of the vasoconstrictor response to an alpha 1–adrenoceptor agonist. Kamata K, et al. **Br J Pharmacol** 1997 Apr; 120(7):1221–8

Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Kenny BA, et al. **Br J Pharmacol** 1996 Jun;118(4):871–8

Pharmacological characterization of an alpha 1A–adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat. Lachnit WG,

et al. **Br J Pharmacol** 1997 Mar;120(5):819–26

Evidence for functional alpha 2D-adrenoceptors in the rat intestine. Liu L, et al. **Br J Pharmacol** 1996 Mar; 117(5):787–92

Antiarrhythmic action of rilmenidine on adrenaline-induced arrhythmia via central imidazoline receptors in halothane-anaesthetized dogs. Mammoto T, et al. **Br J Pharmacol** 1996 Apr;117(8):1744–8

Altered thermoregulatory responses to clonidine in streptozotocin-diabetic rats. O'Donnell JM, et al. **Br J Pharmacol** 1996 Mar;117(5):938–42

The effect of ischaemia on endothelium-dependent vasodilatation and adrenoceptor-mediated vasoconstriction in rat isolated hearts. Pannangpetch P, et al. **Br J Pharmacol** 1996 Mar;117(6):1047–52

The inhibitory effects of alpha(2)-adrenoceptor agonists on gastrointestinal transit during croton oil-induced intestinal inflammation. Pol O, et al. **Br J Pharmacol** 1996 Dec; 119(8):1649–55

alpha-Adrenoceptor and opioid receptor modulation of clonidine-induced antinociception. Sierralta F, et al. **Br J Pharmacol** 1996 Oct;119(3):551–4

A comparative study of the reversal by different alpha 2-adrenoceptor antagonists of the central sympatho-inhibitory effect of clonidine. Vayssettes-Courchay C, et al. **Br J Pharmacol** 1996 Feb; 117(3):587–593

Medetomidine sedation in dogs and cats: a review of its pharmacology, antagonism and dose [see comments] Cullen LK. **Br Vet J** 1996 Sep;152(5):519–35 (88 ref.). Comment in: Br Vet J 1996 Sep;152(5):493–5.

Alpha 2 adrenoceptor agonists in the horse--a review. England GC, et al. **Br Vet J** 1996 Nov;152(6):641–57 (105 ref.)

Medetomidine, alpha 2 adrenoceptors and small animal practice [editorial; comment] Hall LW. **Br Vet J** 1996 Sep; 152(5):493–5. Comment on: Br Vet J 1996 Sep;152(5):519–35.

Noradrenaline modifies the spontaneous spiking activity of red nucleus neurons in the rat by activation of alpha 2- and beta-adrenoceptors. Ciranna L, et al. **Brain Res** 1996 Dec 16;743(1–2):284–93

Clonidine at induction reduces shivering after general anaesthesia. Buggy D, et al. **Can J Anaesth** 1997 Mar; 44(3):263–7

Alpha-2 adrenergic agonists. Kamibayashi T, et al. **Can J Anaesth** 1997 May;44(5 Pt 2):R13–22 (50 ref.) **(Eng, Fre)**

Clonidine decreases vasoconstriction and shivering thresholds, without affecting the sweating threshold. Nicolaou G, et al. **Can J Anaesth** 1997 Jun;44(6):636–42

Oral clonidine premedication decreases energy expenditure in human volunteers. Takahashi H, et al. **Can J Anaesth** 1997 Mar;44(3):268–72

An evaluation of the influence of medetomidine hydrochloride and atipamezole hydrochloride on the arrhythmogenic dose of epinephrine in dogs during halothane anesthesia. Pettifer GR, et al. **Can J Vet Res** 1996 Jan;60(1):1–6

Cardiovascular effects of oxymetazoline and UK14,304 in conscious and pithed rats. Bayorh MA, et al. **Clin Exp Hypertens** 1997 May;19(4):445–60

Gene regulation of brain natriuretic peptide in cardiocyte hypertrophy by alpha1-adrenergic stimulation. Nakagawa O, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S183–5

Alteration in the release of endothelium-derived relaxing factors by alpha-adrenoceptor stimulation in the aorta of stroke-prone spontaneously hypertensive rats. Shimamura K, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S144–5

Effect of methoxamine on noradrenaline release in the caudal artery of hypertensive rats. Shinozuka K, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S88–90

Elevated spontaneous activity of phenylephrine-excited neurons in the caudal ventrolateral medulla of spontaneously hypertensive rats. Wong TM, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S46–7

Do pseudoephedrine or phenylpropanolamine improve maximum oxygen uptake and time to exhaustion? Swain RA, et al. **Clin J Sport Med** 1997 Jul;7(3):168–73

Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Chu TC, et al. **Curr Eye Res** 1996 Sep;15(9):943–50

Cardiovascular, metabolic, and hormonal responses to noradrenaline in diabetic patients with autonomic neuropathy. Dejgaard A, et al. **Diabet Med** 1996 Nov; 13(11):983–9

Functional responses of the left and right heart of diabetic rats to alpha- and beta-adrenergic receptor stimulation. Irlbeck M, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S79–86

Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Wagstaff AJ, et al. **Drugs** 1997 Mar;53(3):435–52 (112 ref.)

Effects of noradrenaline on GnRH-secreting immortalized hypothalamic (GT1-7) neurons. Uemura T, et al. **Endocr J** 1997 Feb;44(1):73–8

Reduced response of the hypothalamo-pituitary-adrenal axis to alpha1-agonist stimulation during lactation. Windle RJ, et al. **Endocrinology** 1997 Sep;138(9):3741–8

Clonidine inhibits gastric motility in the rat. Asai T, et al. **Eur J Anaesthesiol** 1997 May;14(3):316–9

Loss of endothelium-mediated vascular relaxation as a response to various clamping pressures. Gersak B, et al. **Eur J Cardiothorac Surg** 1996;10(8):684–9

Effect of clonidine and yohimbine on sleep in healthy men: a double-blind, randomized, controlled trial. Gentili A, et al. **Eur J Clin Pharmacol** 1996;50(6):463–5

Noradrenalin enhances the activity of cochlear nucleus neurons in the rat. Ebert U. **Eur J Neurosci** 1996 Jun; 8(6):1306–14

Interaction between alpha- and beta-adrenergic receptor agonists modulating the slow Ca(2+)-activated K+ current IAHP in hippocampal neurons. Pedarzani P, et al. **Eur J Neurosci** 1996 Oct;8(10):2098–110

Preclinical safety profile of brimonidine. Angelov OV, et al. **Eur J Ophthalmol** 1996 Jan–Mar;6(1):21–5

Neuropeptide Y potentiates noradrenaline-induced contraction through the neuropeptide Y Y1 receptor. Bergdahl A, et al. **Eur J Pharmacol** 1996 Nov 28; 316(1):59–64

Functional evidence for an alpha 1B-adrenoceptor mediating contraction of the mouse spleen. Eltze M. **Eur J Pharmacol** 1996 Sep 12;311(2–3):187–98

Effects of clonidine on a C-fibre reflex in the rat. Gozariu M, et al. **Eur J Pharmacol** 1996 Oct 10;313(1–2):51–62

Involvement of alpha1B-adrenoceptors in the positive inotropic effect of endogenous noradrenaline in rabbit myocardium. Hattori Y, et al. **Eur J Pharmacol** 1997 Jun 25;329(2–3):165–8

Effects of imidazoline antagonists of alpha 2-adrenoceptors on endogenous adrenaline-induced inhibition of insulin release. Hiyoshi Y, et al. **Eur J Pharmacol** 1995 Dec 27; 294(1):117–23

Contribution of peripheral alpha 1A-adrenoceptors to pain induced by formalin or by alpha-methyl-5-hydroxytryptamine plus noradrenaline. Hong Y, et al. **Eur J Pharmacol** 1996 Apr 22;301(1–3):41–8

Norepinephrine attenuates serotonin inhibition of pial venous tone. Ishine T, et al. **Eur J Pharmacol** 1996 Oct 10; 313(1–2):97–102

A tyrosine kinase regulates alpha-adrenoceptor-stimulated contraction and phospholipase D activation in the rat aorta. Jinsi A, et al. **Eur J Pharmacol** 1996 Apr 29;302(1–3):183–90

Mivazerol, a selective alpha 2-adrenoceptor agonist, attenuates tachycardia by intrathecal injection of N-methyl-D-aspartate in the rat. Kim SY, et al. **Eur J Pharmacol** 1996 Dec 5;316(2–3):249–52

SDZ NVI 085, an alpha 1A-adrenoceptor agonist with 5-HT2A receptor antagonist properties. Lachnit WG, et al. **Eur J Pharmacol** 1996 Feb 15;297(1–2):83–6

Pineal melatonin in rats: suppression by the selective alpha2-adrenoceptor agonist medetomidine. Mustanoja SM, et al. **Eur J Pharmacol** 1997 May 20;326(2–3):229–36

Role of serotonergic neurotransmission in the hypnotic response to dexmedetomidine, an alpha 2-adrenoceptor agonist. Rabin BC, et al. **Eur J Pharmacol** 1996 Jun 13; 306(1–3):51–9

Inhibitory effect of phorbol 12,13-dibutyrate on norepinephrine-induced contraction in rabbit iris dilator muscle. Satoh M, et al. **Eur J Pharmacol** 1996 Jul 18; 308(2):145–52

NS-49, an alpha 1A-adrenoceptor agonist, selectively increases intraurethral pressure in dogs. Taniguchi N, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):117–22

Functional characterisation of alpha 1-adrenoceptor subtypes mediating noradrenaline-induced inositol phosphate formation in rat thalamus slices. Trejo F, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):175–84

Effects of adrenergic stimulation on sciatic nerve blood flow in diabetic and control rats. Vo PA, et al. **Eur J Pharmacol** 1997 Jun 25;329(2–3):147–52

Alpha 1D-adrenoceptors play little role in the positive inotropic action of phenylephrine. Wang SN, et al. **Eur J Pharmacol** 1997 Feb 19;321(1):39–43

Methoxamine-induced inhibition of the positive inotropic effect of endothelin via alpha1-adrenoceptors in the rabbit heart. Yang HT, et al. **Eur J Pharmacol** 1996 Jan 18; 296(1):47–54

Regulation of hamster alpha 1B-adrenoceptors expressed in Chinese hamster ovary cells. Zhu SJ, et al. **Eur J Pharmacol** 1996 Mar 28;299(1–3):205–12

The effects of medetomidine on maternal and fetal cardiovascular and pulmonary function, intrauterine pressure and uterine blood flow in pregnant goats. Sakamoto H, et al. **Exp Anim** 1997 Jan;46(1):67–73

Hyperbaric-induced enhancement of noradrenaline-evoked contraction in rat thoracic aorta. Guerrero F, et al. **Exp Physiol** 1997 Jul;82(4):687–95

Effect of adrenaline and alpha-agonists on net rate of liquid absorption from the pleural space of rabbits. Zocchi L, et al. **Exp Physiol** 1997 May;82(3):507–20

Amino acids of the alpha1B-adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes. Cavalli A, et al. **FEBS Lett** 1996 Dec 9;399(1–2):9–13

alpha-Methylnoradrenaline-induced contractions in rat aorta are mediated via alpha 1D-adrenoceptors. Castillo EF, et al. **Fundam Clin Pharmacol** 1997;11(4):339–45

Rilmenidine activates postjunctional alpha 1- and alpha 2-adrenoceptors in the canine saphenous vein. Marsault R, et al. **Fundam Clin Pharmacol** 1996;10(4):379–86

Peripheral alpha 2-adrenoceptor-mediated sympathoinhibitory effects of mivazerol. Richer C, et al. **Fundam Clin Pharmacol** 1996;10(6):529–37

Circadian melatonin rhythms in cultured zebrafish pineals are not affected by catecholamine receptor agonists. Cahill GM. **Gen Comp Endocrinol** 1997 Feb;105(2):270–5

Kininogenase secretion from dispersed cells of mouse submandibular gland. Akiu M, et al. **Gen Pharmacol** 1996 Mar;27(2):187–91

Interaction between neurotransmitters and exogenous norepinephrine in isolated rat anococcygeus muscle. Mudumbi RV, et al. **Gen Pharmacol** 1996 Mar;27(2):193–7

Clonidine-induced rhythmic activity in rabbit anococcygeus muscle. Radjaee-Behbahani N, et al. **Gen Pharmacol** 1996 Apr;27(3):525–8

Brain alpha 1-adrenoceptor in the cardiovascular responses to BHT-920 and phenylephrine. Ricci D, et al. **Gen Pharmacol** 1996 Mar;27(2):299–304

Effect of alteration in the extracellular potassium and calcium on field-stimulated relaxation of the rabbit corpus cavernosum. Saito M, et al. **Gen Pharmacol** 1996 Mar; 27(2):375–8

Endothelial modulation of contractile responses in arteries from hypertensive rats. Dohi Y, et al. **Hypertension** 1996 Nov;28(5):732–7

Role of nitric oxide in modulating the long-term renal and hypertensive actions of norepinephrine. Granger J, et al. **Hypertension** 1997 Jan;29(1 Pt 2):205–9

Afferent and efferent arteriolar vasoconstriction to angiotensin II and norepinephrine involves release of Ca2+ from intracellular stores. Inscho EW, et al. **Hypertension** 1997 Jan;29(1 Pt 2):222–7

Subconstrictor doses of neuropeptide Y potentiate alpha 1-adrenergic venoconstriction in vivo. Linder L, et al. **Hypertension** 1996 Sep;28(3):483–7

Clonidine and ST-91 may activate imidazoline binding sites in the heart to release atrial natriuretic peptide. Mukaddam-Daher S, et al. **Hypertension** 1997 Jul;30(1 Pt 1):83–7

Dose-response functions of apomorphine, SKF 38393, LY 171555, haloperidol and clonidine on the self-stimulation evoked from lateral hypothalamus and ventral tegmentum. Singh J, et al. **Indian J Physiol Pharmacol** 1996 Jan; 40(1):15–22

Endothelin-1-induced modulation of contractile responses elicited by an alpha 1-adrenergic agonist on human corpus cavernosum smooth muscle. Kim DC, et al. **Int J Impot Res** 1996 Mar;8(1):17–24

Effect of hepatic nerve stimulation and norepinephrine on the laser Doppler flux signal from the surface of the perfused rat liver. Wheatley AM, et al. **Int J Microcirc Clin Exp** 1997 Jan–Feb;17(1):48–54

Lipolytic catecholamine resistance linked to alpha 2-adrenoceptor sensitivity--a metabolic predictor of weight loss in obese subjects. Hellström L, et al. **Int J Obes Relat Metab Disord** 1997 Apr;21(4):314–20

Interactive effects of K+, acid, norepinephrine, and ischemia on the heart: implications for exercise. O'Neill M, et al. **J Appl Physiol** 1997 Apr;82(4):1046–52

Norepinephrine-induced contraction of isolated rabbit bronchial artery: role of alpha 1- and alpha 2-adrenoceptor activation. Zschauer AO, et al. **J Appl Physiol** 1997 Jun; 82(6):1918–25

Profiles of the response to noradrenaline in the whole and bisected rat vas deferens. Boselli C, et al. **J Auton Pharmacol** 1997 Apr;17(2):97–107

Cardiac vagal effects of rilmenidine in the dog: comparison with clonidine. Boucher M, et al. **J Auton Pharmacol** 1997 Apr;17(2):87–90

Pharmacological characterization of alpha 1-adrenoceptor subtype mediating regulation of arterial pressure and urethral perfusion pressure in the anaesthetized rat. Guilmard C, et al. **J Auton Pharmacol** 1996 Aug; 16(4):197–203

Propranolol stereoselectively inhibits alpha-adrenoceptor-mediated vasoconstriction in mesenteric arterial beds of rats. Stauber RE, et al. **J Auton Pharmacol** 1996 Jun;16(3):125–9

Characterization of alpha-adrenoceptor subtype(s) mediating vasoconstriction in the perfused rabbit ovarian vascular bed. Yousif M, et al. **J Auton Pharmacol** 1996 Aug; 16(4):221–7

Tyrosine phosphorylation and Syk activation are involved in thrombin-induced aggregation of epinephrine-potentiated platelets. Wang X, et al. **J Biochem (Tokyo)** 1997 Feb;121(2):325–30

Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta3-adrenergic agonists, and leptin. Gong DW, et al. **J Biol Chem** 1997 Sep 26; 272(39):24129–32

Coronary vascular effects of dexmedetomidine during reactive hyperemia in the anesthetized dog. Roekaerts PM, et al. **J Cardiothorac Vasc Anesth** 1996 Aug;10(5):619–26

Responses to norepinephrine of normal and "ischemic" canine Purkinje fibers are consistent with activation of different alpha 1-receptor subtypes. Anyukhovsky EP, et al. **J Cardiovasc Electrophysiol** 1997 Jun;8(6):658–66

Influence of the low thyroid state in diabetes mellitus on cardiac function and inotropic responsiveness to alpha 1-adrenoceptor stimulation: comparison with the role of hypothyroidism alone. Beenen OH, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):553–7

Effects of clonidine and flesinoxan on blood pressure variability in conscious spontaneously hypertensive rats.

Chaouche-Teyara K, et al. **J Cardiovasc Pharmacol** 1997 Aug;30(2):241-4

Beta-adrenoceptor stimulation-mediated preconditioning-like cardioprotection in perfused rat hearts. Nasa Y, et al. **J Cardiovasc Pharmacol** 1997 Apr; 29(4):436-43

Endothelium-dependent relaxation by alpha 2-adrenoceptor agonists in spontaneously hypertensive rat aorta. Sunano S, et al. **J Cardiovasc Pharmacol** 1996 May;27(5):733-9

alpha 1-Adrenoceptor stimulation partially inhibits ATP-sensitive K+ current in guinea pig ventricular cells: attenuation of the action potential shortening induced by hypoxia and K+ channel openers. Takizawa T, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):799-808

Effects of intravenous and oral clonidine on hemodynamic and plasma-catecholamine response due to endotracheal intubation. Zalunardo MP, et al. **J Clin Anesth** 1997 Mar; 9(2):143-7

Making sense out of antisense for the study of drug receptors [editorial; comment] Michel MC, et al. **J Clin Invest** 1996 Sep 1;98(5):1074-5. Comment on: J Clin Invest 1996 Sep 1;98(5):1076-87.

Antisense technology reveals the alpha2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat [see comments] Mizobe T, et al. **J Clin Invest** 1996 Sep 1;98(5):1076-80. Comment in: J Clin Invest 1996 Sep 1;98(5):1074-5.

Effects of haemoglobin O2 saturation on volume regulation in adrenergically stimulated red blood cells from the trout, Oncorhynchus mykiss. Nielsen OB. **J Comp Physiol [B]** 1997 Apr;167(3):159-68

Effect of alpha-adrenoreceptor stimulation on the diaphragmatic oxygen delivery-consumption relationship. Ward ME, et al. **J Crit Care** 1996 Mar;11(1):19-26

Impairment of growth hormone responsiveness to growth hormone releasing hormone and pyridostigmine in patients affected by Prader-Labhardt-Willi syndrome. Beccaria L, et al. **J Endocrinol Invest** 1996 Nov;19(10):687-92

Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. Greenfield DS, et al. **J Glaucoma** 1997 Aug;6(4):250-8 (52 ref.)

Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potential binding interactions with alpha 2-adrenoceptors involving a "methyl pocket". Zhang X, et al. **J Med Chem** 1997 Sep 12;40(19):3014-24

Alpha-adrenergic stimulation enhances inducible nitric oxide synthase expression in rat cardiac myocytes. Ikeda U, et al. **J Mol Cell Cardiol** 1996 Jul;28(7):1539-45

Betaine generation in cardiac myocytes after adrenergic activation of phosphatidylcholine hydrolysis. Meister A, et al. **J Mol Cell Cardiol** 1996 May;28(5):1109-18

Norepinephrine pretreatment attenuates Ca2+ overloading in rat trabeculae during subsequent metabolic inhibition: improved contractile recovery via an alpha 1-adrenergic, PKC-dependent signaling mechanism. Musters RJ, et al. **J Mol Cell Cardiol** 1997 May;29(5):1341-54

Effect of sleep deprivation on the growth hormone response to the alpha-3 adrenergic receptor agonist, clonidine, in normal subjects. Lal S, et al. **J Neural Transm** 1997; 104(2-3):291-8

Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D4 receptor. Lanau F, et al. **J Neurochem** 1997 Feb;68(2):804-12

Responses of Bergmann glia and granule neurons in situ to N-methyl-D-aspartate, norepinephrine, and high potassium. Shao Y, et al. **J Neurochem** 1997 Jun; 68(6):2405-11

Changes in noradrenergic sensitivity to tumor necrosis factor-alpha in brains of rats administered clonidine. Ignatowski TA, et al. **J Neuroimmunol** 1996 Oct; 70(1):55-63

Alpha 1 adrenoceptor activation potentiates taurine response mediated by protein kinase C in substantia nigra neurons. Nabekura J, et al. **J Neurophysiol** 1996 Oct;76(4):2455-60

The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. Stone LS, et al. **J Neurosci** 1997 Sep 15;17(18):7157-65

Norepinephrine facilitates the development of the murine sweat response but is not essential. Tsahai Tafari A, et al. **J Neurosci** 1997 Jun 1;17(11):4275-81

Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. Wen R, et al. **J Neurosci** 1996 Oct 1; 16(19):5986-92

Dexmedetomidine does not attenuate increases in excitatory amino acids after transient global ischemia in the rabbit. Kim HK, et al. **J Neurosurg Anesthesiol** 1996 Jul;8(3):230-6

Efficacy of oxymetazoline eye drops in non-infectious conjunctivitis, the most common cause of acute red eyes. Xuan B, et al. **J Ocul Pharmacol Ther** 1997 Aug;13(4):363-7

Inhibition of high K+ and norepinephrine-induced free intracellular calcium by tetrandrine in dissociated rabbit retina cells. Xuan B, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):151-8

Dexamethasone reduced clonidine-induced hypoactivity in mice. Capasso A, et al. **J Pharm Pharmacol** 1996 Jun; 48(6):615-8

Circadian variation of alpha 1-adrenoceptor-mediated pressor response to phenylephrine in man. Tham TC, et al. **J Pharm Pharmacol** 1996 May;48(5):526-8

Spinal infusion of N-methyl-D-aspartate antagonist MK801 induces hypersensitivity to the spinal alpha-2 agonist ST91 in the rat. Dunbar SA, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1219-25

The peripheral action of clonidine analog ST-91: involvement of atrial natriuretic factor. Gutkowska J, et al. **J Pharmacol Exp Ther** 1997 May;281(2):670-6

Alpha-2a/d adrenoceptor subtype stimulation by guanfacine increases osmolar clearance. Intengan HD, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):48-53

Synergistic behavioral interaction between ethanol and clonidine in rats: role of alpha-2 adrenoceptors. Mao L, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):443-9

Receptor reserve and turnover of alpha-2 adrenoceptors that mediate the clonidine-induced inhibition of rat locus coeruleus neurons in vivo. Pineda J, et al. **J Pharmacol Exp Ther** 1997 May;281(2):690-8

Dexmedetomidine inhibits osmotic water permeability in the rat cortical collecting duct. Rouch AJ, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):62-9

Activation of alpha-2 adrenergic receptors inhibits norepinephrine release by a pertussis toxin-insensitive pathway independent of changes in cytosolic calcium in cultured rat sympathetic neurons. Schwartz DD. **J Pharmacol Exp Ther** 1997 Jul;282(1):248-55

The role of prostaglandins and the hypothalamic and hippocampal histamine in the clonidine-induced pituitary-adrenocortical response. Bugajski J, et al. **J Physiol Pharmacol** 1996 Sep;47(3):487-95

Intracellular calcium release mediated by noradrenaline and acetylcholine in mammalian pineal cells. Marín A, et al. **J Pineal Res** 1996 Aug;21(1):15-28

Cardiovascular and respiratory effects of detomidine in isoflurane-anaesthetised horses. Still J, et al. **J S Afr Vet Assoc** 1996 Dec;67(4):199-203

Dose-sparing effects of romifidine premedication for thiopentone and halothane anaesthesia in the dog. England GC, et al. **J Small Anim Pract** 1997 Apr;38(4):141-6

The pattern of testosterone replacement influences the recovery of the stimulatory effect of clonidine on growth hormone (GH) secretion in orchidectomized rats. Tena-Sempere M, et al. **J Steroid Biochem Mol Biol** 1996 Aug;58(5-6):533-8

Nitric oxide inhibition simulates the enhancement of alpha 1 agonist-induced vasoconstriction in diabetes. Dresner LS, et al. **J Surg Res** 1997 Jul 1;70(2):119-23

Urodynamic analysis of age-related changes of alpha 1-adrenoceptor responsiveness in female beagle dogs. Takahashi S, et al. **J Urol** 1996 Oct;156(4):1485-8

The actions of medetomidine may not be mediated exclusively by alpha 2-adrenoceptors in the equine saphenous vein. Bryant CE, et al. **J Vet Pharmacol Ther** 1996 Apr;19(2):124-9

Effect of pharmacological agonists on contractile responses in aortic rings derived from endotoxaemic rats. Donaldson LL, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):389-96

An assessment of the peripheral antinociceptive potential of remoxipride, clonidine and fentanyl in sheep using the forelimb tourniquet. Main DC, et al. **J Vet Pharmacol Ther** 1997 Jun;20(3):220-8

Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Kimber JR, et al. **Lancet** 1997 Jun 28;349(9069):1877-81

Drugs acting on calcium channels modulate the diuretic and micturition effects of dexmedetomidine in rats. Horváth G, et al. **Life Sci** 1996;59(15):1247-57

Denervation of pigment cells lead to a receptor that is ultrasensitive to melatonin and noradrenaline. Moartensson LG, et al. **Life Sci** 1997;60(18):1575-82

Involvement of supraspinal GABA receptors in majonoside-R2 suppression of clonidine-induced antinociception in mice. Nguyen TT, et al. **Life Sci** 1997; 61(4):427-36

Effects of alpha 2-adrenergic agonism, imidazolines, and G-protein on insulin secretion in beta cells. Hirose H, et al. **Metabolism** 1997 Oct;46(10):1146-9

Decavanadate possesses alpha-adrenergic agonist activity and a structural motif common with trans-beta form of noradrenaline. Venkataraman BV, et al. **Mol Cell Biochem** 1997 Apr;169(1-2):27-36

Genetic alteration of alpha 2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist. Sallinen J, et al. **Mol Pharmacol** 1997 Jan;51(1):36-46

Comparison of the effects of high ambient temperature and clonidine on autonomic functions in man. Arya DK, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Mar; 355(3):376-83

Alpha 2C-adrenoceptors mediate contractile responses to noradrenaline in the human saphenous vein. Gavin KT, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Mar; 355(3):406-11

Presynaptic imidazoline receptors and alpha 2-adrenoceptors in the human heart: discrimination by clonidine and moxonidine. Likungu J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):689-92

The stimulatory effect of clonidine on locus coeruleus neurons of rats with inactivated alpha 2-adrenoceptors: involvement of imidazoline receptors located in the nucleus paragigantocellularis. Ruiz-Ortega JA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):288-94

Is alpha1D-adrenoceptor protein detectable in rat tissues? Yang M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Apr;355(4):438-46

Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients. Díez J, et al. **Nephron** 1996; 74(3):548-54

Enhancement of intermediate-term memory by an alpha-1 agonist or a partial agonist at the glycine site of the NMDA receptor. Pussinen R, et al. **Neurobiol Learn Mem** 1997 Jan;67(1):69-74

Acute and chronic effects of potassium and noradrenaline on Na+, K+-ATPase activity in cultured mouse neurons and astrocytes. Hajek I, et al. **Neurochem Int** 1996 Mar; 28(3):335-42

Clonidine administration increases neuropeptide Y immunoreactivity and neuropeptide Y mRNA in the rat cerebral cortex neurons. Smiałowska M, et al. **Neuropeptides** 1997 Jun;31(3):203-7

Noradrenaline-induced inositol phosphate formation in rat striatum is mediated by alpha 1A-adrenoceptors. Arias-Montaño JA, et al. **Neuropharmacology** 1996; 35(11):1605-13

Alpha 2-adrenergic agonists reduce glutamate release and glutamate receptor-mediated calcium changes in hippocampal slices during hypoxia. Bickler PE, et al. **Neuropharmacology** 1996 Jun;35(6):679-87

The effect of decreased catecholamine transmission on ERP indices of selective attention. Shelley AM, et al. **Neuropsychopharmacology** 1997 Mar;16(3):202-10

Effects of central alpha-adrenergic agonists on hormone-induced 3% NaCl and water intake. de Paula PM, et al. **Neurosci Lett** 1996 Aug 23;214(2-3):155-8

Regional study of spinal alpha 2-adrenoceptor densities after intraspinal noradrenergic-rich implants on adult rats bearing complete spinal cord transection or selective chemical noradrenergic denervation. Roudet C, et al. **Neurosci Lett** 1996 Apr 19;208(2):89-92

Adrenergic responses in silent and putative inhibitory pacemaker-like neurons of the rat rostral ventrolateral medulla in vitro. Hayar A, et al. **Neuroscience** 1997 Mar; 77(1):199-217

Effect of adrenergic receptor activation on post-herpetic neuralgia pain and sensory disturbances. Choi B, et al. **Pain** 1997 Jan;69(1-2):55-63

Abnormal spontaneous activity and responses to norepinephrine in dissociated dorsal root ganglion cells after chronic nerve constriction. Petersen M, et al. **Pain** 1996 Oct;67(2-3):391-7

An in vitro study of ectopic discharge generation and adrenergic sensitivity in the intact, nerve-injured rat dorsal root ganglion. Zhang JM, et al. **Pain** 1997 Aug;72(1-2):51-7

Effects of alpha-adrenergic agonists on Toxoplasma gondii replication in human umbilical vein endothelial cells. Benedetto N, et al. **Pathol Biol (Paris)** 1997 Jan;45(1):9-18

Maturation of rat renal tubular response to alpha-adrenergic agonists and neuropeptide Y: a study on the regulation of Na+,K+-ATPase. Ohtomo Y, et al. **Pediatr Res** 1996 Mar;39(3):534-8

The alpha-1 adrenergic agonist, cirazoline, impairs spatial working memory performance in aged monkeys. Arnsten AF, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):55-9

Long-term antidepressant treatment restores clonidine's effect on growth hormone secretion in a genetic animal model of depression. Aulakh CS, et al. **Pharmacol Biochem Behav** 1996 Oct;55(2):265-8

Alpha 2-adrenoceptor agonists and stress-induced analgesia in rats: influence of stressors and methods of analysis. De Kock M, et al. **Pharmacol Biochem Behav** 1997 Sep; 58(1):109-17

Effects of St-587 and prazosin on water maze and passive avoidance performance of scopolamine-treated rats. Puumala T, et al. **Pharmacol Biochem Behav** 1996 Sep; 55(1):107-15

Effects of a D2 receptor agonist RO 41-9067 alone and with clonidine on sleep parameters in the rat. Python A, et al. **Pharmacol Biochem Behav** 1996 Feb;53(2):291-6

Dissociation of hypnotic-anesthetic actions of alpha 2 agonists from cyclic AMP in the rat. Rabin BC, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):23-9

Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Rämä P, et al. **Pharmacol Biochem Behav** 1996 Nov;55(3):415-22

Chronic treatment with dexmedetomidine desensitizes alpha 2-adrenergic signal transduction. Reid K, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):63-71

Dexmedetomidine reduces response tendency, but not accuracy of rats in attention and short-term memory tasks. Ruotsalainen S, et al. **Pharmacol Biochem Behav** 1997 Jan; 56(1):31-40

Effects of the alpha 1a-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats. Wellman PJ, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):281-4

Central alpha-adrenergic agonists and need-induced 3% NaCl and water intake. Yada MM, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):137-43

ADRENERGIC ALPHA-AGONISTS

Catecholaminergic responses in vas deferens isolated from rats submitted to acute swimming stress. Chies AB, et al. **Pharmacol Res** 1995 Sep;32(3):123–7

Inhibition of sympathetic noradrenergic transmission by guanabenz and guanethidine in rat isolated mesenteric artery: involvement of neuronal potassium channels. Fabiani ME, et al. **Pharmacol Res** 1996 Mar;33(3):171–80

Neuroendocrine effects of dexmedetomidine: evidence of cross-tolerance between a mu-opioid agonist and an alpha 2-adrenoceptor agonist in growth hormone secretion of the male rat. Idänpään-Heikkilä JJ, et al. **Pharmacol Toxicol** 1996 Mar;78(3):136–42

Alpha(1)- and beta-adrenoceptor-mediated increase in 86Rb(+)-uptake in isolated cardiomyocytes from adult rat heart: evidence for interaction between the two receptor systems. Viko H, et al. **Pharmacol Toxicol** 1996 Dec; 79(6):287–92

Oxymetazoline: potential mechanisms of inhibitory effects on aqueous humor dynamics. Chu TC, et al. **Pharmacology** 1996 Oct;53(4):259–70

Inhibition of the natriuretic action of the imidazoline receptor agonist moxonidine by indometacin in the rat. Darkwa FK, et al. **Pharmacology** 1995 Dec;51(6):347–55

Effect of insulin and clonidine on the evoked release of norepinephrine and serotonin from the nucleus tractus solitarius of the diabetic rat. Dunbar JC, et al. **Pharmacology** 1995 Dec;51(6):370–80

Age-related changes in alpha-adrenoceptor-mediated blood pressure in the rat: relationship between the potency for phenylephrine and the maximum number of binding sites. Koike K, et al. **Pharmacology** 1996 Jan;52(1):16–24

Evaluation of agonist efficacy and receptor reserve for alpha 2D-adrenergic receptor regulated G protein activation in PC12 cell membranes. Tian WN, et al. **Pharmacology** 1996 Apr;52(4):252–62

Clonidine shortens circadian period in both constant light and constant darkness. Rosenwasser AM. **Physiol Behav** 1996 Aug;60(2):373–9

The actions of alpha-methylnorepinephrine on the rat aorta. Castillo EF, et al. **Proc West Pharmacol Soc** 1996;39:33–5

Noradrenergic receptor sensitivity in obsessive-compulsive disorders: I. Growth hormone response to clonidine stimulation. Brambilla F, et al. **Psychiatry Res** 1997 Mar 24;69(2-3):155–62

Noradrenergic receptor sensitivity in obsessive compulsive disorder: II. Cortisol response to acute clonidine administration. Brambilla F, et al. **Psychiatry Res** 1997 Mar 24;69(2-3):163–8

Effect of clonidine on the human acoustic startle reflex. Kumari V, et al. **Psychopharmacology (Berl)** 1996 Feb; 123(4):353–60

Inhibition of subjective and physiological sexual arousal in women by clonidine. Meston CM, et al. **Psychosom Med** 1997 Jul-Aug;59(4):399–407

Effect of modulators of tyrosine kinase activity on agonist-induced contraction in the rat pulmonary vascular smooth muscle. Savineau JP, et al. **Pulm Pharmacol** 1996 Jun;9(3):189–95

Decreased vascular sensitivity after acute exercise and chronic exercise training in rat thoracic aorta. Izawa T, et al. **Res Commun Mol Pathol Pharmacol** 1996 Sep; 93(3):331–42

The influence of total porto-systemic shunting on the noradrenaline response and on the contractile effects of various vasoactive agents in small rat portal veins and hepatic arteries. Hammarström LE, et al. **Res Exp Med (Berl)** 1997;196(6):373–9

Preclinical evaluation of brimonidine. Burke J, et al. **Surv Ophthalmol** 1996 Nov;41 Suppl 1:S9–18 (62 ref.)

Histological and ultrastructural study of the effects of cholinergic and adrenergic agonists on salivary secretion from the lingual epithelium and the lingual gland of the Tokyo Daruma pond frog. Iwasaki S, et al. **Tissue Cell** 1997 Jun;29(3):323–38

Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists [see comments] Coleman RA, et al. **Trends Pharmacol Sci** 1996 Sep;17(9):324–30 (52 ref.). Comment in: Trends Pharmacol Sci 1997 May;18(5):149–51.

Gene targeting--homing in on alpha 2-adrenoceptor-subtype function. MacDonald E, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):211–9 (48 ref.)

Cardiopulmonary effects of combinations of medetomidine hydrochloride and atropine sulphate in dogs. Alibhai HI, et al. **Vet Rec** 1996 Jan 6;138(1):11–3

Effects of alpha 2-agonists on intrauterine pressure and sedation in horses: comparison between detomidine, romifidine and xylazine. Schatzmann U, et al. **Zentralbl Veterinarmed A** 1994 Sep;41(7):523–9

[Effects of rilmenidine on rats made insulin resistant and hypertensive by a high fructose diet] Berthault MF, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89(8):1103–6 (Eng. Abstr.) **(Fre)**

[The in vitro effect of alpha-2 agonists on thrombocyte function and density of thrombocyte alpha-2 receptors] Heesen M, et al. **Anaesthesist** 1996 Mar;45(3):255–8 (Eng. Abstr.) **(Ger)**

[Hemodynamic effects of continuous intrathecal infusions of clonidine from a telemetric pump] D'Aleo P, et al. **Cardiologia** 1997 Jun;42(6):639–41 **(Ita)**

[Effect of aging on alpha-1 receptor-mediated, phenylephrine-induced contraction and pressor response: relationship with the amount of receptors] Koike K, et al. **J Smooth Muscle Res** 1995 Dec;31(6):396–7 **(Jpn)**

[Chronotropic effects of alpha-agonist on the rat isolated right atria] Nakano K. **Nippon Ika Daigaku Zasshi** 1996 Dec;63(6):473–80 (Eng. Abstr.) **(Jpn)**

[The possible mechanism of the noradrenaline enhancement of the arterial baroreceptor reflex] Eremeev VS, et al. **Fiziol Zh Im I M Sechenova** 1996 Dec;82(12):48–56 (Eng. Abstr.) **(Rus)**

[The interaction of clofelin and ketamine in the body of patients] Byshovets SN. **Lik Sprava** 1996 Jul-Sep; (7-9):157–60 (Eng. Abstr.) **(Rus)**

[The effect of carbacholine and noradrenaline on intertissue connections during the reparative process] Grabovoĭ AN. **Lik Sprava** 1996 Oct-Dec;(10-12):104–7 (Eng. Abstr.) **(Rus)**

[Laryngeal mucociliary clearance: influence of beta-2 agonists, beta antagonists, and alpha-agonists. An experimental study in rabbits] Armengot M, et al. **Acta Otorrinolaringol Esp** 1996 Nov-Dec;47(6):425–8 (Eng. Abstr.) **(Spa)**

POISONING

Yohimbine as an antidote for clonidine overdose. Roberge RJ, et al. **Am J Emerg Med** 1996 Nov;14(7):678–80

[Variants of the use of hemosorption in patients with acute clofelin poisoning] Sentsov VG, et al. **Anesteziol Reanimatol** 1997 Jan-Feb;(1):79–83 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Glucagon and phenylephrine combination vs glucagon alone in experimental verapamil overdose [see comments] Stone CK, et al. **Acad Emerg Med** 1996 Feb;3(2):120–5. Comment in: Acad Emerg Med 1996 Feb;3(2):99–100.

The place of alpha-2-agonists in anaesthesiology of today [editorial] Kanto J. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 1):4–5

Additives in neuraxial anesthesia: opioids, alpha-2 adrenergic agonists, and neostigmine as a possible future drug for perioperative pain management. Klimscha W, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:176–8

Midodrine marketed for orthostatic hypotension [news] **Am J Health Syst Pharm** 1996 Nov 1;53(21):2552, 2556

Surgical vs medical management of chronic open-angle glaucoma. Stewart WC, et al. **Am J Ophthalmol** 1996 Dec; 122(6):767–74

Preserved sympathetic response to hypotension despite perioperative alpha2 agonist administration. Dodd-o JM, et al. **Anesth Analg** 1997 Jun;84(6):1208–10

Is there a place for intrathecal clonidine for clinical analgesia? [letter; comment] Goudas LC, et al. **Anesth Analg** 1996 Oct;83(4):891. Comment on: Anesth Analg 1996 Mar;82(3):627–35.

Postoperative analgesia after peripheral nerve block for podiatric surgery: clinical efficacy and chemical stability of lidocaine alone versus lidocaine plus clonidine. Reinhart DJ, et al. **Anesth Analg** 1996 Oct;83(4):760–5

A minimum dose of clonidine added to mepivacaine prolongs the duration of anesthesia and analgesia after axillary brachial plexus block. Singelyn FJ, et al. **Anesth Analg** 1996 Nov;83(5):1046–50

Effect of dexmedetomidine on lumbar cerebrospinal fluid pressure in humans. Talke P, et al. **Anesth Analg** 1997 Aug; 85(2):358–64

alpha(2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Eisenach JC, et al. **Anesthesiology** 1996 Sep;85(3):655–74 (169 ref.)

Three methods of opioid detoxification in a primary care setting. A randomized trial. O'Connor PG, et al. **Ann Intern Med** 1997 Oct 1;127(7):526–30

Guanfacine use in children with attention deficit hyperactivity disorder. Cohn LM, et al. **Ann Pharmacother** 1997 Jul-Aug;31(7-8):918–9

Metyrosine and pheochromocytoma. Steinsapir J, et al. **Arch Intern Med** 1997 Apr 28;157(8):901–6

Beneficial effects of dexmedetomidine on ischaemic myocardium of anaesthetized dogs. Roekaerts PM, et al. **Br J Anaesth** 1996 Sep;77(3):427–9

The role of clonidine and alpha 2-agonists for postoperative analgesia [editorial; comment] Sandler AN. **Can J Anaesth** 1996 Dec;43(12):1191–4. Comment on: Can J Anaesth 1996 Dec;43(12):1195–202.

Dynamic left ventricular outflow tract obstruction in critically ill patients: role of transesophageal echocardiography in therapeutic decision making. Madu EC, et al. **Cardiology** 1997 May-Jun;88(3):292–5

Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Weber K, et al. **Cardiovasc Drugs Ther** 1996 May;10(2):113–7

Midodrine treatment for patients with hemodialysis hypotension. Flynn JJ 3rd, et al. **Clin Nephrol** 1996 Apr; 45(4):261–7

A comparison of the effects of an alpha-agonist, an anti-muscarinic agent and placebo on intranasal histamine challenge in allergic rhinitis. Birchall MA, et al. **Clin Otolaryngol** 1996 Jun;21(3):212–7

A comparison of the sensitivity of manometric rhinometry, acoustic rhinometry, rhinomanometry and nasal peak flow to detect the decongestant effect of xylometazoline. Porter MJ, et al. **Clin Otolaryngol** 1996 Jun;21(3):218–21

Effects of clonidine on prolonged postoperative sympathetic response. Dorman T, et al. **Crit Care Med** 1997 Jul; 25(7):1147–52

Gustatory sweating associated with diabetes: a general anaesthetic gives clues to potential treatments [letter] Davies MJ, et al. **Diabet Med** 1996 Jun;13(6):595–7

Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Kahn A, et al. **Drug Alcohol Depend** 1997 Jan 10;44(1):57–61

Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Wilde MI, et al. **Drugs** 1996 Dec;52(6):883–98 (73 ref.)

A dose-response study of phenylephrine in critically ill, septic surgical patients. Flancbaum L, et al. **Eur J Clin Pharmacol** 1997;51(6):461–5

Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine. Biffi M, et al. **Heart** 1997 Mar; 77(3):268–72

A comparative evaluation of pilocarpine 1% and clonidine 0.125% versus timolol 0.5%. Sihota R, et al. **Indian J Ophthalmol** 1996 Jun;44(2):87–9

Comparative study of oral clonidine and diazepam as premedicants in children. Ramesh VJ, et al. **Int J Clin Pharmacol Ther** 1997 May;35(5):218–21

New medical therapies for glaucoma. Drake MV. **Int Ophthalmol Clin** 1996 Spring;36(2):53–60 (29 ref.)

Predictors of clonidine response in Tourette syndrome: implications and inferences. Lichter DG, et al. **J Child Neurol** 1996 Mar;11(2):93–7

Postoperative analgesia using a low-dose, oral-transdermal clonidine combination: lack of clinical efficacy. Owen MD, et al. **J Clin Anesth** 1997 Feb;9(1):8–14

Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. Fuller MA, et al. **J Clin Psychiatry** 1996 Nov;57(11):514–8

Effects of apraclonidine on short-term outcome of glaucoma surgery. Azuara-Blanco A, et al. **J Glaucoma** 1996 Apr; 5(2):117–9

Efficacy of midodrine for neurogenic orthostatic hypotension [letter; comment] Berlin I. **JAMA** 1997 Aug 6;278(5):388 . Comment on: JAMA 1997 Apr 2;277(13):1046–51.

Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group [see comments] [published erratum appears in JAMA 1997 Aug 6;278(5):388] Low PA, et al. **JAMA** 1997 Apr 2;277(13):1046–51. Comment in: JAMA 1997 Aug 6;278(5):388.

Clonidine for treatment of attention-deficit/hyperactivity disorder. **Med Lett Drugs Ther** 1996 Dec 6;38(989):109–10

Midodrine for orthostatic hypotension. **Med Lett Drugs Ther** 1997 Jun 20;39(1003):59–60

Brimonidine--an alpha 2-agonist for glaucoma. **Med Lett Drugs Ther** 1997 Jun 6;39(1002):54–5

Cardiovascular parameters of heroin-withdrawn addicts treated with guanfacine. Rubio G, et al. **Methods Find Exp Clin Pharmacol** 1997 Apr;19(3):189–92

Effect of brimonidine 0.5% on intraocular pressure spikes following 360% argon laser trabeculoplasty. The Brimonidine-ALT Study Group. **Ophthalmic Surg Lasers** 1995 Sep-Oct;26(5):404–9

Hypotensive and vasorelaxing activities of a lectin from the edible mushroom Tricholoma mongolicum. Wang HX, et al. **Pharmacol Toxicol** 1996 Dec;79(6):318–23

Clonidine: a practical guide for usage in children. Oesterheld J, et al. **S D J Med** 1996 Jul;49(7):234–7

Innovations in pharmacologic therapies. Miaskowski C. **Semin Oncol Nurs** 1997 Feb;13(1):30–5 (44 ref.)

The role of brimonidine in the treatment of open-angle glaucoma. Wilensky JT. **Surv Ophthalmol** 1996 Nov;41 Suppl 1:S3–7 (24 ref.)

Urinary incontinence in cats [letter; comment] [see comments] Eyett-Burton C. **Vet Rec** 1997 Jan 25;140(4):104 . Comment on: Vet Rec 1990 Oct 6;127(14):347–50. Comment in: Vet Rec 1997 Feb 8;140(6):160.

Efficacy of an epidural combination of morphine and detomidine in alleviating experimentally induced hindlimb lameness in horses. Sysel AM, et al. **Vet Surg** 1996 Nov-Dec;25(6):511–8

New agents for the treatment of glaucoma. Hill R. **West J Med** 1997 Feb;166(2):140

[Ambulatory treatment and prevention of priapism using alpha-agonists. Apropos of 172 cases] Virag R, et al. **Chirurgie** 1997 Jan;121(9-10):648–52 (Eng. Abstr.) **(Fre)**

[Treatment of refractory ascites with clonidine and spironolactone (letter)] Lenaerts A, et al. **Gastroenterol Clin Biol** 1997;21(6-7):524–5 **(Fre)**

[Alpha 2-adrenoreceptor agonists--horse or donkey? (editorial)] Scholz J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):401–3 **(Ger)**

[Effect and side effects of apraclonidine] Stewart WC. **Klin Monatsbl Augenheilkd** 1996 Jul;209(1):A7–13 (53 ref.) (Eng. Abstr.) **(Ger)**

[Analgetic effect of guanfacine in postoperative period] Strashnov VI, et al. **Anesteziol Reanimatol** 1996 Jul-Aug; (4):43–4 **(Rus)**

[Gutron studied as an agent for preventing radiation lesions] Boĭko VN, et al. **Radiats Biol Radioecol** 1997 Mar-Apr; 37(2):154–60 (Eng. Abstr.) **(Rus)**

TOXICITY

Increased cardiac workload by adrenoceptor agonists for the estimation of potential antiischemic activity in a conscious rabbit model. Kovanecz I, et al.
J Pharmacol Toxicol Methods 1997 Apr;37(3):149–59

[The effect of guanfacine on the background and nociceptive stimulation-induced activity of spinal cord neurons in rats] Ivanov VE. **Eksp Klin Farmakol** 1997 May–Jun;60(3):12–5 (Eng. Abstr.) **(Rus)**

ADRENERGIC ALPHA-ANTAGONISTS

ADMINISTRATION & DOSAGE

Dose dependent effects of yohimbine on methadone maintained patients. Hameedi FA, et al.
Am J Drug Alcohol Abuse 1997 May;23(2):327–33

Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial. Schmitz G, et al. **Blood Press** 1996 Nov;5(6):354–9

Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Buzelin JM, et al. **Br J Urol** 1997 Jun; 79(6):898–904; discussion 904–6

Relations between symptomatology and brain function in dementias: double-blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline. Saletu B, et al. **Dement Geriatr Cogn Disord** 1997;8 Suppl 1:12–21

Prevention of cardiac hypertrophy by a sub-antihypertensive dose of the alpha 1-adrenergic antagonist bunazosin in Dahl salt-sensitive rats. Izumi Y, et al. **Hypertens Res** 1996 Sep;19(3):147–50

Influence of prostate size on terazosin efficacy. Becopoulos T, et al. **Int J Urol** 1997 Jul;4(4):358–61

Antihypertensive efficacy and orthostatic tolerance of bunazosin vs nitrendipine: a multicentre double-blind randomized controlled study. Langenfeld MR, et al.
J Hum Hypertens 1996 Dec;10(12):831–6

Dose-response study of dapiprazole HCl in the reversal of mydriasis induced by 2.5% phenylephrine. Hogan TS, et al. **J Ocul Pharmacol Ther** 1997 Aug;13(4):297–302

Idazoxan and the effect of intracerebroventricular oxytocin or vasopressin on sodium intake of sodium-depleted rats. Sato MA, et al. **Regul Pept** 1997 Apr 30;69(3):137–42

Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University YM617 Study Group. Okada H, et al. **Scand J Urol Nephrol** 1996 Oct; 30(5):379–85

Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Kunelius P, et al. **Urology** 1997 Mar;49(3):441–4

[Premedication in pheochromocytoma] Förster G, et al.
Zentralbl Chir 1997;122(6):454–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Anesthetic management in pheochromocytoma] Strecker U, et al. **Zentralbl Chir** 1997;122(6):460–6 (44 ref.) (Eng. Abstr.) **(Ger)**

[The treatment with the antidepressant Lerivon of tension headaches and autonomic crises] Filatova EG, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1996;96(3):58–62 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Surgery, drugs, and the male orgasm [editorial] Dunsmuir WD, et al. **BMJ** 1997 Feb 1;314(7077):319–20

Lichenoid drug eruption following the Blaschko lines. Muñoz MA, et al. **Dermatology** 1996;193(1):66–7 (10 ref.)

Terazosin, finasteride, or both in benign prostatic hyperplasia [letter; comment] Thien T, et al. **N Engl J Med** 1997 Jan 23;336(4):294. Comment on: N Engl J Med 1996 Aug 22;335(8):533–9.

Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. McKiernan JM, et al.
South Med J 1997 May;90(5):509–13 (20 ref.)

Glans hyperemia after penile revascularization: a late complication following alpha-1-receptor blockade for benign prostatic hyperplasia. Haupt G, et al. **Urol Int** 1997; 58(1):61–3

ANALYSIS

Highly sensitive method for the determination of tamsulosin hydrochloride in human plasma dialysate, plasma and urine by high-performance liquid chromatography-electrospray tandem mass spectrometry. Matsushima H, et al.
J Chromatogr B Biomed Sci Appl 1997 Aug 1;695(2):317–27

Differential pulse polarographic determination of prazosin hydrochloride in tablets. Altiokka G, et al. **Pharmazie** 1997 May;52(5):401–2

BLOOD

Cerebrospinal fluid and plasma disposition of yohimbine and 11-hydroxy-yohimbine in young and older healthy subjects, and Alzheimer's disease patients. Le Corre PA, et al. **Eur J Clin Pharmacol** 1997;52(2):135–8

High-performance liquid chromatographic determination of the conjugate metabolites of moxisylyte in human plasma and urine. Marquer C, et al.
J Chromatogr B Biomed Appl 1997 Apr 11;691(2):389–96

Determination of dicentrine in rat plasma by high-performance liquid chromatography and its application to pharmacokinetics. Tsai TH, et al.
J Chromatogr B Biomed Appl 1996 Jun 7;681(2):277–81

Determination of alpha 1-adrenoceptor antagonists in plasma by radioreceptor assay. Yamada S, et al.
J Pharm Biomed Anal 1996 Jan;14(3):289–94

CEREBROSPINAL FLUID

Cerebrospinal fluid and plasma disposition of yohimbine and 11-hydroxy-yohimbine in young and older healthy subjects, and Alzheimer's disease patients. Le Corre PA, et al. **Eur J Clin Pharmacol** 1997;52(2):135–8

CHEMICAL SYNTHESIS

Structure-activity relationships of some 1,4-benzodioxane aryl-piperazine derivatives as alpha-blocking agents. Corsano S, et al. **Arch Pharm (Weinheim)** 1996 Oct; 329(10):468–70

Search for new antiarrhythmic and hypotensive compounds. Synthesis, antiarrhythmic, antihypertensive, and alpha-adrenoceptor blocking activity of novel 1-[(2-hydroxy-3-amino)]-propylpyrrolidin-2-one derivatives. Filipek B, et al. **Arch Pharm (Weinheim)** 1997 Jul;330(7):225–31

Pharmacological evaluation of prazosin- and doxazosin-related compounds with modified piperazine ring. Giardinà D, et al. **Arzneimittelforschung** 1996 Nov; 46(11):1054–9

Structure-activity relationships in 1,4-benzodioxan-related compounds. 5. Effects of modification of the side chain on alpha-adrenoreceptor blocking activity. Quaglia W, et al. **Farmaco** 1996 Jan;51(1):27–32

Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole. Andersen K, et al. **J Med Chem** 1996 Sep 13;39(19):3723–38

N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists. Elworthy TR, et al. **J Med Chem** 1997 Aug 15;40(17):2674–87

Synthesis and biological profile of the enantiomers of [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-cis-octahydroquinoxalin- 1-yl]furan-2-ylmethanone (cyclazosin), a potent competitive alpha 1B- adrenoceptor antagonist. Giardinà D, et al. **J Med Chem** 1996 Nov 8; 39(23):4602–7

CHEMISTRY

Phenylalanine in the second membrane-spanning domain of alpha 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. Hamaguchi N, et al. **Biochemistry** 1996 Nov 12;35(45):14312–7

Pharmacophore development for antagonists at alpha 1 adrenergic receptor subtypes. Bremner JB, et al.
J Comput Aided Mol Des 1996 Dec;10(6):545–57

Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT uptake inhibiting and alpha2-antagonistic activities. Meyer MD, et al. **J Med Chem** 1997 Mar 28;40(7):1049–62

DIAGNOSTIC USE

Intravenous phentolamine test--an aid in the evaluation of patients with persistent pain after low-back surgery? Sörensen J, et al. **Acta Anaesthesiol Scand** 1997 May; 41(5):581–5

[Regitine test] Takasaki I, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:363–6 (12 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Chiral recognition in liquid chromatography utilising chargeable cyclodextrins for resolution of doxazosin enantiomers. Owens PK, et al. **Chirality** 1997;9(2):184–90

METABOLISM

Rat pineal alpha 1-adrenoceptor subtypes: studies using radioligand binding and reverse transcription-polymerase chain reaction analysis. Sugden D, et al.
Br J Pharmacol 1996 Jul;118(5):1246–52

Microbial models of mammalian metabolism. Fungal metabolism of phenolic and nonphenolic p-cymene-related drugs and prodrugs. I. Metabolites of thymoxamine. Moussa C, et al. **Drug Metab Dispos** 1997 Mar;25(3):301–10

Microbial models of mammalian metabolism. Fungal metabolism of phenolic and nonphenolic p-cymene-related drugs and prodrugs. II. Metabolites of nonphenolic derivatives. Moussa C, et al. **Drug Metab Dispos** 1997 Mar; 25(3):311–6

Polyclonal anti-idiotypic antibodies to idazoxan and their interaction with human brain imidazoline binding sites. Bennai F, et al. **Eur J Pharmacol** 1996 Jun 13; 306(1-3):211–8

Coexpression of alpha 1A- and alpha 1B-adrenoceptors in the liver of the rhesus monkey (Macaca mulatta). García-Sáinz JA, et al. **Eur J Pharmacol** 1996 Sep 12; 311(2-3):277–83

Alpha 2-adrenoceptor subtypes in the human brain: a pharmacological delineation of [3H]RX-821002 binding to membranes and tissue sections. Grijalba B, et al.
Eur J Pharmacol 1996 Aug 22;310(1):83–93

The alpha-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate. Hatano A, et al. **Eur J Pharmacol** 1996 Oct 10;313(1-2):135–43

[3H]R-terazosin binds selectively to alpha1-adrenoceptors over alpha2-adrenoceptors - comparison with racemic [3H]terazosin and [3H]prazosin. Ireland LM, et al.
Eur J Pharmacol 1997 May 26;327(1):79–86

Characterization of adrenoceptor types and subtypes in American bullfrogs acclimated to warm or cold temperature. Herman CA, et al. **Gen Comp Endocrinol** 1996 Nov;104(2):168–78

Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. Taguchi K, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):1–5

Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding. Zhao MM, et al. **Mol Pharmacol** 1996 Nov; 50(5):1118–26

Sustained increase in rat myocardial alpha 1A-adrenoceptors induced by 6-hydroxydopamine treatment involves a decelerated receptor turnover. Sallés J, et al.
Naunyn Schmiedebergs Arch Pharmacol 1996 Mar; 353(4):408–16

Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Richardson CD, et al. **Prostate** 1997 Sep 15;33(1):55–9

Alpha-1 adrenoceptor subtypes (high, low) in human benign prostatic hypertrophy tissue according to the affinities for prazosin. Takeda M, et al. **Prostate** 1997 Jun 1;31(4):216–22

PHARMACOKINETICS

Pharmacokinetics study of 14C-moxisylyte after percutaneous application to hairless rat. Neau B, et al.
Arzneimittelforschung 1995 Nov;45(11):1161–5

Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. Weidinger G. **Arzneimittelforschung** 1995 Nov; 45(11):1166–71 (66 ref.)

Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Bressolle F, et al. **Eur J Clin Pharmacol** 1996;49(5):411–5

Effects of yohimbine on autonomic measures are determined by individual values for area under the concentration-time curve. Grasing K, et al. **J Clin Pharmacol** 1996 Sep; 36(9):814–22

Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein. Koiso K, et al. **J Clin Pharmacol** 1996 Nov;36(11):1029–38

Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride. Samara EE, et al. **J Clin Pharmacol** 1996 Dec;36(12):1169–78

Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. Berman J, et al. **J Med Chem** 1997 Mar 14;40(6):827–9

Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Soeishi Y, et al. **Xenobiotica** 1996 Jun;26(6):637–45

[The concentration of Tamsulosin hydrochloride in the blood and prostatic tissue of the patients in benign prostatic hyperplasia] Morita M, et al.
Nippon Hinyokika Gakkai Zasshi 1997 May;88(5):535–40 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Mirtazapine: pharmacology in relation to adverse effects. Nutt D. **Acta Psychiatr Scand Suppl** 1997;391:31–7

Designing a new generation of antidepressant drugs. Pinder RM. **Acta Psychiatr Scand Suppl** 1997;391:7–13

Treatment and post-treatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension. Schobel HP, et al.
Am Heart J 1996 Nov;132(5):1004–9

A comparative study of the effects of alpha 1-adrenoceptor antagonists on sympathetic function in rats. Saito H, et al.
Am J Hypertens 1996 Nov;9(11):160S–169S (55 ref.)

Effects of alpha-adrenergic stimuli on mesenteric collecting lymphatics in the rate. Benoit JN. **Am J Physiol** 1997 Jul; 273(1 Pt 2):R331–6

Effect of alpha 1-adrenoceptor blockade on resting and hyperemic myocardial blood flow in normal humans. Lorenzoni R, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1302–6

Chronic alpha 1-adrenergic blockade stimulates terminal and arcade arteriolar development. Price RJ, et al.
Am J Physiol 1996 Aug;271(2 Pt 2):H752–9

Alpha-2 adrenoceptor blockade protects rats against lipopolysaccharide. Fessler HE, et al.
Am J Respir Crit Care Med 1996 Dec;154(6 Pt 1):1689–93

Toxicity and kinetics of amitraz in dogs. Hugnet C, et al.
Am J Vet Res 1996 Oct;57(10):1506–10

Functional study of the excitatory alpha-adrenoceptor in guinea pig ileum, in relation to the hypothesis of an atypical receptor. Bricola A, et al. **Ann N Y Acad Sci** 1997 May 30;812:189–92

Alpha-adrenergic mechanisms of thermoregulation in humans. Frank SM, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:101–10

ADRENERGIC ALPHA-ANTAGONISTS

Do cardiovascular mechanisms participate in thermoregulatory activity of alpha 2-adrenoceptor agonists and antagonists in rabbits? Szreder Z. **Ann N Y Acad Sci** 1997 Mar 15;813:512-25

Terazosin blockade of nicotine-induced skin flap necrosis in the rat. Karien RG, et al. **Arch Otolaryngol Head Neck Surg** 1997 Aug;123(8):837-40

Structure-activity relationships of some 1,4-benzodioxane aryl-piperazine derivatives as alpha-blocking agents. Corsano S, et al. **Arch Pharm (Weinheim)** 1996 Oct; 329(10):468-70

Search for new antiarrhythmic and hypotensive compounds. Synthesis, antiarrhythmic, antihypertensive, and alpha-adrenoceptor blocking activity of novel 1-[(2-hydroxy-3-amino)]-propylpyrrolidin-2-one derivatives. Filipek B, et al. **Arch Pharm (Weinheim)** 1997 Jul;330(7):225-31

Pharmacological evaluation of prazosin- and doxazosin-related compounds with modified piperazine ring. Giardinà D, et al. **Arzneimittelforschung** 1996 Nov; 46(11):1054-9

Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. Weidinger G. **Arzneimittelforschung** 1995 Nov; 45(11):1166-71 (66 ref.)

Enhancement of central noradrenaline release during development alters the packing density of neurons in the rat occipital cortex. Ruiz S, et al. **Biol Neonate** 1997; 71(2):119-25

The anti-anesthetic action of idazoxan. Majeed AB. **Biol Pharm Bull** 1996 Feb;19(2):203-8

In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine. Alarayyed NA, et al. **Br J Clin Pharmacol** 1997 Apr;43(4):415-20

Contribution of monoaminergic modulation to the analgesic effect of tramadol. Desmeules JA, et al. **Br J Clin Pharmacol** 1996 Jan;41(1):7-12

Effect of locally applied prazosin on the kinetics of the pupillary light reflex. Mortlock SA, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):236-8

The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man. Tham TC, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):251-6

Antagonism by idazoxan at low dose but not high dose, of the natriuretic action of moxonidine. Allan DR, et al. **Br J Pharmacol** 1996 Jan;117(1):29-34

The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor. Chess-Williams R, et al. **Br J Pharmacol** 1996 Nov;119(6):1093-100

The effect of S-(+)-boldine on the alpha 1-adrenoceptor of the guinea-pig aorta. Chuliá S, et al. **Br J Pharmacol** 1996 Dec;119(7):1305-12

Micturition in conscious rats with and without bladder outlet obstruction: role of spinal alpha 1-adrenoceptors. Ishizuka O, et al. **Br J Pharmacol** 1996 Mar;117(5):962-6

Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Kenny BA, et al. **Br J Pharmacol** 1996 Jun;118(4):871-8

Different subtypes of alpha 1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053. Marshall I, et al. **Br J Pharmacol** 1996 Sep;119(2):407-15

Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretion. Mourtada M, et al. **Br J Pharmacol** 1997 Jun;121(4):799-805

The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Noble AJ, et al. **Br J Pharmacol** 1997 Jan;120(2):231-8

Analysis of the effects of alpha 1-adrenoceptor antagonists on noradrenaline-mediated contraction of rat small mesenteric artery. Van der Graaf PH, et al. **Br J Pharmacol** 1996 Jul;118(5):1308-16

A comparative study of the reversal by different alpha 2-adrenoceptor antagonists of the central sympatho-inhibitory effect of clonidine. Vayssettes-Courchay C, et al. **Br J Pharmacol** 1996 Feb; 117(3):587-593

alpha 2-, alpha 2A-, alpha 2B/2C-Adrenoceptor subtype antagonists prevent lipopolysaccharide-induced fever response in rabbits. Bencsics A, et al. **Brain Res** 1995 Dec 24;705(1-2):302-6

Alpha1-adrenergic receptor blockade blocks LH secretion but not LHRH cFos activation. Le WW, et al. **Brain Res** 1997 Feb 7;747(2):236-45

The 'alpha 2 adrenoreceptor agonist clonidine suppresses seizures, whereas the alpha 2 adrenoreceptor antagonist idazoxan promotes seizures: pontine microinfusion studies of amygdala-kindled kittens. Shouse MN, et al. **Brain Res** 1996 Aug 26;731(1-2):203-7

Atipamezole-precipitated clonidine withdrawal induces c-Fos expression in rat central nervous system. Stornetta RL, et al. **Brain Res** 1997 Aug 1;764(1-2):81-92

Alpha-adrenergic receptor antagonism and N-methyl-D-aspartate (NMDA) induced luteinizing hormone release in female rhesus macaques. Urbanski HF, et al. **Brain Res** 1997 Jan 2;744(1):96-104

Synergistic interactions between noradrenaline and glutamate in cytosolic calcium influx in cultured visual cortical neurons. Yang B, et al. **Brain Res** 1996 May 20; 721(1-2):181-90

Role of different subtypes of adrenoceptors in pressor responses to catecholamines released from sympathetic nerve endings. Dóda M. **Brain Res Bull** 1997;42(1):51-7

Lack of relationship between thalamic oscillations and attention in rats: differential modulation by an alpha-2 antagonist. Puumala T, et al. **Brain Res Bull** 1997; 43(2):163-71

Antagonism of clonidine injected intracerebroventricularly in different models of salt intake. Sato MA, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1663-6

Expressed alpha 1-adrenoceptors in adult rat brown adipocytes are primarily of alpha 1A subtype. Costain WJ, et al. **Can J Physiol Pharmacol** 1996 Mar;74(3):234-40

An evaluation of the influence of medetomidine hydrochloride and atipamezole hydrochloride on the arrhythmogenic dose of epinephrine in dogs during halothane anesthesia. Pettifer GR, et al. **Can J Vet Res** 1996 Jan;60(1):1-6

No evidence for mediation of ischemic preconditioning by alpha 1-adrenergic signal transduction pathway or protein kinase C in the isolated rat heart. Moolman JA, et al. **Cardiovasc Drugs Ther** 1996 May;10(2):125-36

Doxazosin blocks the angiotensin II-induced smooth muscle cell DNA synthesis in the media, but not in the neointima of the rat carotid artery after balloon injury. van Kleef EM, et al. **Cardiovasc Res** 1996 Feb;31(2):324-30

Effects of alpha 2-adrenoceptor antagonists and imidazoline2-receptor ligands on neuronal damage in global ischaemia in the rat. Craven JA, et al. **Clin Exp Pharmacol Physiol** 1997 Feb;24(2):204-7

Effects of DC-015, a novel potent and selective alpha 1-adrenoceptor antagonist on plasma lipid and vascular reactivity in hyperlipidaemic rats. Sheu JR, et al. **Clin Exp Pharmacol Physiol** 1996 Mar;23(3):207-13

Effect of 5-methylurapidil, an alpha 1a-adrenergic antagonist and 5-hydroxytryptamine1a agonist, on aqueous humor dynamics in monkeys and rabbits. Wang RF, et al. **Curr Eye Res** 1997 Aug;16(8):769-75

Adrenoceptor antagonists, but not guanethidine, reduce glucopenia-induced glucagon secretion from perfused rat pancreas. Ito K, et al. **Diabetes Res Clin Pract** 1995 Dec; 30(3):173-80

Effects of atipamezole, an alpha 2-adrenergic antagonist, and somatostatin on xylazine-induced growth hormone release in calves. Kasuya E, et al. **Endocr J** 1996 Oct;43(5):551-6

Effect of clonidine and yohimbine on sleep in healthy men: a double-blind, randomized, controlled trial. Gentili A, et al. **Eur J Clin Pharmacol** 1996;50(6):463-5

Effect of alpha 1-adrenoceptor antagonists, prazosin and urapidil, on a finger skin vasoconstrictor response to cold stimulation. Harada K, et al. **Eur J Clin Pharmacol** 1996; 49(5):371-5

[3H]RX821002 (2-methoxyidazoxan) binds to alpha 2-adrenoceptor subtypes and a non-adrenoceptor imidazoline binding site in rat kidney. Callado LF, et al. **Eur J Pharmacol** 1996 Dec 5;316(2-3):359-68

Inhibition by tamsulosin of tension responses of human hyperplastic prostate to electrical field stimulation. Chueh SC, et al. **Eur J Pharmacol** 1996 Jun 3;305(1-3):177-80

Clotrimazole and efaroxan inhibit red cell Gardos channel independently of imidazoline I1 and I2 binding sites. Coupry I, et al. **Eur J Pharmacol** 1996 Jan 4;295(1):109-12

Effect of delequamine (RS15385) on female sexual behaviour in the rat. Gonzalez MI, et al. **Eur J Pharmacol** 1996 Sep 19;312(1):1-6

The subtype-selective alpha 2-adrenoceptor antagonists BRL 44408 and ARC 239 also recognize 5-HT1A receptors in the rat brain. Meana JJ, et al. **Eur J Pharmacol** 1996 Oct 3;312(3):385-8

KMD-3213, a novel alpha1A-adrenoceptor antagonist, potently inhibits the functional alpha1-adrenoceptor in human prostate. Moriyama N, et al. **Eur J Pharmacol** 1997 Jul 16;331(1):39-42

Pineal melatonin in rats: suppression by the selective alpha2-adrenoceptor agonist medetomidine. Mustanoja SM, et al. **Eur J Pharmacol** 1997 May 20;326(2-3):229-36

The alpha 1-adrenoceptor agonist, SDZ NVI-085, behaves as a potent, competitive antagonist of 5-hydroxytryptamine-induced contraction of rat aorta. Van der Graaf PH, et al. **Eur J Pharmacol** 1995 Dec 20; 287(3):309-12

Benextramine acts as an irreversible noncompetitive antagonist of U46619-mediated contraction of the rat small mesenteric artery. Van der Graaf PH, et al. **Eur J Pharmacol** 1996 Apr 11;300(3):211-4

Effect of KMD-3213, an alpha 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Yamagishi R, et al. **Eur J Pharmacol** 1996 Nov 7;315(1):73-9

(+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Yang HT, et al. **Eur J Pharmacol** 1996 Oct 3;312(3):281-91

Vascular alpha 1D-adrenoceptors have a role in the pressor response to phenylephrine in the pithed rat. Zhou L, et al. **Eur J Pharmacol** 1996 Jun 3;305(1-3):173-6

Characterization of subtype of alpha1-adrenoceptor mediating vasoconstriction in perfused rat hind limb. Zhu W, et al. **Eur J Pharmacol** 1997 Jun 18;329(1):55-61

Maldistribution of multidose blood cardioplegia: pharmacologic intervention to prevent subendocardial hypoperfusion by alpha-adrenergic blockade. Sakakibara Y. **Eur Surg Res** 1997;29(1):20-6

The alpha-adrenoceptor-mediated actions of chloroethylclonidine. Docherty JR, et al. **Gen Pharmacol** 1997 Feb;28(2):197-201 (36 ref.)

Effect of alpha 1-adrenoceptor antagonists on urinary bladder function in urethane-anesthetized rats. Sudoh K, et al. **Gen Pharmacol** 1997 Apr;28(4):521-4

Effect of buflomedil on the neutrophil-endothelial cell interaction under inflammatory and hypoxia conditions. Boisseau MR, et al. **Haemostasis** 1996 Oct;26 Suppl 4:182-8

Effect of alpha-blockers on epididymal sperm concentration, motility and testicular productivity in the rat. Hibi H, et al. **Hinyokika Kiyo** 1996 May;42(5):357-60

Phentolamine precludes inhibitory effect of the K+ channel opener pinacidil on insulin release. Links TP, et al. **Horm Metab Res** 1996 Jan;28(1):20-2

Endothelial modulation of contractile responses in arteries from hypertensive rats. Dohi Y, et al. **Hypertension** 1996 Nov;28(5):732-7

Stimulation of imidazoline receptors inhibits proliferation of human coronary artery vascular smooth muscle cells. Regunathan S, et al. **Hypertension** 1997 Aug;30(2 Pt 1):295-300

Effect of chronic treatment with atenolol and prazosin in streptozotocin induced diabetic rats. Goyal RK, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):220-4

Dose-response functions of apomorphine, SKF 38393, LY 171555, haloperidol and clonidine on the self-stimulation evoked from lateral hypothalamus and ventral tegmentum. Singh J, et al. **Indian J Physiol Pharmacol** 1996 Jan; 40(1):15-22

Effect of tamsulosin, a novel alpha 1-adrenoceptor antagonist, on urethral pressure profile in anaesthetized dogs. Sudoh K, et al. **J Auton Pharmacol** 1996 Jun; 16(3):147-54

Alpha 1D-adrenoceptors do not contribute to inotropic responses of neonatal rat myocardium. Deng XF, et al. **J Cardiovasc Pharmacol** 1997 Jan;29(1):57-60

Glucose tolerance and postprandial glucose and insulin kinetics in rats with short- and long-term alpha 1-adrenergic blockade. Fajardo N, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):402-8

Comparative effects of idazoxan, prazosin, and yohimbine on coronary ligation-induced arrhythmias in spontaneously hypertensive rats. Roegel JC, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):226-34

Electrical and mechanical effects of a novel antihypertensive quinazoline derivative, 3-[[4-(2-methoxyphenyl) piperazin-1-ly]methyl]-5-(methylthio)-2,3-dihydroimidazo [1,2-c]quinazoline, on guinea pig ventricular muscles. Yang JM, et al. **J Cardiovasc Pharmacol** 1997 Aug;30(2):229-34

Characterization of bunazosin-sensitive alpha1-adrenoceptors in human renal medulla. Yasuda G, et al. **J Cardiovasc Pharmacol** 1997 Aug;30(2):163-8

Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride. Samara EE, et al. **J Clin Pharmacol** 1996 Dec;36(12):1169-78

Pharmacophore development for antagonists at alpha 1 adrenergic receptor subtypes. Bremner JB, et al. **J Comput Aided Mol Des** 1996 Dec;10(6):545-57

Interaction between prolactin and catecholamines on hypothalamic GnRH release in vitro. Calogero AE, et al. **J Endocrinol** 1996 Nov;151(2):269-75

Influence of nifedipine on pressor responses induced by different alpha-adrenoceptor agonists and angiotensin II in pithed diabetic hypertensive rats. Beenen OH, et al. **J Hypertens** 1996 Jul;14(7):847-53

Sympathetic, parasympathetic and non-autonomic contributions to cardiovascular spectral powers in unanesthetized spontaneously hypertensive rats. Daffonchio A, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1636-42

LPS-induced blood neutrophilia is inhibited by alpha 1-adrenoceptor antagonists: a role for catecholamines. Altenburg SP, et al. **J Leukoc Biol** 1997 Jun;61(6):689-94

Alpha 1-adrenoceptor blockade increases behavioral deficits in traumatic brain injury. Dunn-Meynell AA, et al. **J Neurotrauma** 1997 Jan;14(1):43-52

Effects of doxazosin on functional alterations of isolated coronary arteries from cholesterol-fed rabbits. Simonsen U, et al. **J Pharm Pharmacol** 1996 Jun;48(6):607-14

Pharmacological activity of DC-015, a novel potent and selective alpha 1-adrenoceptor antagonist. Yen MH, et al. **J Pharm Pharmacol** 1996 Jan;48(1):90-5

Characterization of alpha-2D adrenergic receptor subtypes in bovine ocular tissue homogenates. Bylund DB, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1171-7

Alpha-adrenoceptor-mediated prejunctional effects of chloroethylclonidine in the canine saphenous vein. Guimarães S, et al. **J Pharmacol Exp Ther** 1997 Sep; 282(3):1326-30

Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. Leonardi A, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1272-83

Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. Martin DJ, et al. **J Pharmacol Exp Ther** 1997

Jul;282(1):228-35
In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045). Okuyama S, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):56-63
Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. Testa R, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1284-93
Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin. Witte DG, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):891-8
The effect of Yohimbine, an alpha2 adrenergic receptor antagonist, on the growth hormone response to apomorphine in normal subjects. Lal S, et al. **J Psychiatry Neurosci** 1996 Mar;21(2):96-100
Effects of chronic treatment with carvedilol on smooth muscle tone and endothelium-dependent relaxation of aorta in stroke-prone spontaneously hypertensive rats. Sunano S, et al. **J Smooth Muscle Res** 1997 Feb;33(1):23-35
Antagonistic effects of atipamezole on medetomidine-induced sedation in horses. Yamashita K, et al. **J Vet Med Sci** 1996 Oct;58(10):1049-52
Pharmacological evaluation of ocoteine, isolated from Cassytha filiformis, as an alpha 1-adrenoceptor antagonist in rat thoracic aorta. Chang CW, et al. **Jpn J Pharmacol** 1997 Mar;73(3):207-14
Alpha 1B-adrenoceptor subtype mediating the phenylephrine-induced contractile response in rabbit corpus cavernosum penis. Furukawa K, et al. **Jpn J Pharmacol** 1996 Aug;71(4):325-31
Drug receptor mechanisms in smooth muscle: beta-chloroethylamine-sensitive and -resistant receptor mechanisms. Takayanagi I, et al. **Jpn J Pharmacol** 1997 Jan;73(1):1-22 (89 ref.)
Are alpha-adrenergic antagonists potent tocolytics? In vivo experiments on postpartum rats. Zupkó I, et al. **Life Sci** 1997;61(11):PL 159-63
Effects of alpha 2-adrenergic agonism, imidazolines, and G-protein on insulin secretion in beta cells. Hirose H, et al. **Metabolism** 1997 Oct;46(10):1146-9
Alpha 2-autoreceptors and alpha 2-heteroreceptors modulating tyrosine and tryptophan hydroxylase activity in the rat brain in vivo: an investigation into the alpha 2-adrenoceptor subtypes. Esteban S, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Mar; 353(4):391-9
Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Haddjeri N, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jan; 355(1):20-9
Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular alpha 1-adrenoceptors in humans. Harada K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov;354(5):557-61
Stimulation of bladder activity by volume, L-dopa and capsaicin in normal conscious rats--effects of spinal alpha 1-adrenoceptor blockade. Ishizuka O, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jun; 355(6):787-93
Inhibition of centrally induced ventricular arrhythmias by rilmenidine and idazoxan in rabbits. Roegel JC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):598-605
Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyanine-type inhibitors of extraneuronal monoamine transport. Russ H, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug-Sep; 354(3):268-74
Influence of alpha- and beta-adrenoceptor antagonists on ventricular fibrillation in ischemic rat hearts. Tölg R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jul; 356(1):62-8
Analysis of the action of idazoxan calls into question the reliability of the rat isolated small mesenteric artery assay as a predictor for alpha 1-adrenoceptor-mediated pressor activity. Van der Graaf PH, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug-Sep; 354(3):389-92
Presynaptic alpha 2-autoreceptors in mouse heart atria: evidence for the alpha 2D subtype. Wahl CA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug-Sep; 354(3):253-61
Is alpha1D-adrenoceptor protein detectable in rat tissues? Yang M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Apr;355(4):438-46
Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients. Giordano M, et al. **Nephron** 1996;72(3):447-53
Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism. Hertel P, et al. **Neuropsychopharmacology** 1997 Jul;17(1):44-55
Gender differences in brain metabolic and plasma catecholamine responses to alpha 2-adrenoceptor blockade. Schmidt ME, et al. **Neuropsychopharmacology** 1997 Apr; 16(4):298-310
An I2 imidazoline ligand, RS 45041, potentiates hyperalgesia in acute arthritis. Houghton AK, et al. **Neuroreport** 1996 Jun 17;7(9):1497-501
Rauwolscine potentiates the effect of desipramine on limbic noradrenaline efflux. Palij P, et al. **Neuroreport** 1996 Apr 26;7(6):1121-4
Modulation of neurotransmitter release by opioid mu- and kappa-receptors from adrenergic terminals in the myenteric plexus of the guinea-pig colon: effect of alpha 2-autoreceptor blockade. Cosentino M, et al. **Neurosci Lett** 1997 Jan 31;222(2):75-8
Hippocampal type I and type II corticosteroid receptors are differentially regulated by chronic prazosin treatment. Kabbaj M, et al. **Neuroscience** 1996 Aug;73(4):963-70
Increased potency of neuropeptide Y to antagonize alpha2-adrenoceptor function in the nucleus tractus solitarii of the spontaneously hypertensive rat. Yang SN, et al. **Neuroscience** 1997 Jun;78(3):803-13
Cardiorespiratory effects of cocaine and procaine at the ventral brainstem. Dehkordi O, et al. **Neurotoxicology** 1996 Summer;17(2):387-95
Effects of spinal alpha 1-adrenoceptor antagonism on bladder activity induced by apomorphine in conscious rats with and without bladder outlet obstruction. Ishizuka O, et al. **Neurourol Urodyn** 1997;16(3):191-200
Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction. DORALI Study Group. Perrigot M, et al. **Neurourol Urodyn** 1996; 15(2):119-31
Monitoring adequacy of alpha-adrenoceptor blockade following systemic phentolamine administration. Raja SN, et al. **Pain** 1996 Jan;64(1):197-204
Effect of yohimbine on the development of morphine dependence in the rat: lack of involvement of cortical beta-adrenoceptor modifications. Ambrosio E, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):487-91
Effects of alpha 1-adrenoceptor and Ca2+ channel inhibition on norepinephrine-induced thermoregulatory behavior in the cold. Carlisle HJ, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):185-9
Effects of St-587 and prazosin on water maze and passive avoidance performance of scopolamine-treated rats. Puumala T, et al. **Pharmacol Biochem Behav** 1996 Sep; 55(1):107-15
Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Rämä P, et al. **Pharmacol Biochem Behav** 1996 Nov;55(3):415-22
Effects of the alpha 1a-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats. Wellman PJ, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):281-4
Effects of hypoxia on enzyme activities in skeletal muscle of rats of different ages. An attempt at pharmacological treatment. Pastoris O, et al. **Pharmacol Res** 1995 Dec; 32(6):375-81
Effects of naftopidil on some urodynamic parameters and arterial blood pressure in comparison with prazosin in conscious rats. Pescalli N, et al. **Pharmacol Res** 1996 Sep-Oct;34(3-4):121-4
Concentration-response relationship of alpha 1-adrenoceptor-stimulated increase of 86Rb+ efflux in rat heart. Andersen GO, et al. **Pharmacol Toxicol** 1996 Oct; 79(4):169-76
Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs. Brune ME, et al. **Pharmacology** 1996 Dec; 53(6):356-68
Evidence that prazosin disturbs isoprenaline positive inotropic action in the guinea pig heart papillary muscle. Kocić I. **Pol J Pharmacol** 1996 Jul-Aug;48(4):447-52
Thromboxane inhibition potentiates antihypertensive effects of alpha 1 adrenoceptor antagonists in the rat. Takada S, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Feb; 56(2):127-34
Prostatic alpha 1-adrenoceptors and uroselectivity. Andersson KE, et al. **Prostate** 1997 Feb 15;30(3):202-15 (132 ref.)
Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Richardson CD, et al. **Prostate** 1997 Sep 15;33(1):55-9
Pharmacological manipulation of ultrasound induced defence behaviour in the rat. Beckett SR, et al. **Psychopharmacology (Berl)** 1996 Oct;127(4):384-90
Alpha 2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Camacho F, et al. **Psychopharmacology (Berl)** 1996 Apr;124(4):347-54
Similarities in the pharmacology of spontaneous and DOI-induced head-shakes suggest 5HT2A receptors are active under physiological conditions. Dursun SM, et al. **Psychopharmacology (Berl)** 1996 Nov;128(2):198-205
Executive function and uptake of 99mTc-exametazime shown by single photon emission tomography after oral idazoxan in probable Alzheimer-type dementia. Goodwin GM, et al. **Psychopharmacology (Berl)** 1997 Jun; 131(4):371-8
The effect of alpha 2 adrenoceptor blockers on aggressive behavior in mice: implications for the actions of adrenoceptor agents. Haller J, et al. **Psychopharmacology (Berl)** 1996 Aug;126(4):345-50
Evidence of acoustic startle hyperreflexia in recently detoxified early onset male alcoholics: modulation by yohimbine and m-chlorophenylpiperazine (mCPP). Krystal JH, et al. **Psychopharmacology (Berl)** 1997 Jun; 131(3):207-15
Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Prinssen EP, et al. **Psychopharmacology (Berl)** 1996 Nov;128(2):191-7
Effects of phentolamine or yohimbine on naloxone's actions during endotoxin shock in rats. Law WR, et al. **Shock** 1997 Mar;7(3):217-24
Studies on the influence of enriched-environment housing combined with systemic administration of an alpha2-adrenergic antagonist on spatial learning and hyperactivity after global ischemia in rats. Puurunen K, et al. **Stroke** 1997 Mar;28(3):623-31
Participation of presynaptic noradrenergic fibers in the suppression of alpha 2-adrenoceptor activity by substance P at the nucleus reticularis gigantocellularis of the rat. Len WB, et al. **Synapse** 1995 Dec;21(4):357-63
Gene targeting--homing in on alpha 2-adrenoceptor-subtype function. MacDonald E, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):211-9 (48 ref.)
Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. Goepel M, et al. **Urol Res** 1997;25(3):199-206
Report of a unique meeting between the alpha-blocker subcommittee and the pharmaceutical industry. McGrath JC, et al. **Urology** 1996 Nov;48(5):665-7
The effect of detomidine and its antagonism with tolazoline on stress-related hormones, metabolites, physiologic responses, and behavior in awake ponies. Carroll GL, et al. **Vet Surg** 1997 Jan-Feb;26(1):69-77
Cytochrome P4501A (CYP1A) induction in rat and man by the benzodioxino derivative, fluparoxan. Beresford AP, et al. **Xenobiotica** 1997 Feb;27(2):159-73
Increased airway pressure in response to xylazine is inhibited by both atipamezole and atropine in sheep. Papazoglou L, et al. **Zentralbl Veterinarmed A** 1994 Sep;41(7):568-72
[Effects of (-) SPD and (-) THP on the firing of noradrenergic neurons in locus coeruleus] Wu JH, et al. **Sheng Li Hsueh Pao** 1995 Dec;47(6):601-4 (Eng. Abstr.) **(Chi)**
[Morphologic effect of adrenaline and insulin on bone capillaries after receptor blockade. Functional transmission electron microscopy analysis] Döhler JR, et al. **Langenbecks Arch Chir** 1997;382(3):164-6 (Eng. Abstr.) **(Ger)**
[Effect of nipradilol on aqueous flow in glaucoma patients treated with timolol] Nagataki S, et al. **Nippon Ganka Gakkai Zasshi** 1997 Mar;101(3):252-6 (Eng. Abstr.) **(Jpn)**
[Long-term effects of a selective alpha 1-adrenergic inhibitor on right and left ventricular masses in patients with chronic pulmonary disease] Nakamoto T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Jan;35(1):30-7 (Eng. Abstr.) **(Jpn)**
[The effect of guanfacine on the background and nociceptive stimulation-induced activity of spinal cord neurons in rats] Ivanov VE. **Eksp Klin Farmakol** 1997 May-Jun;60(3):12-5 (Eng. Abstr.) **(Rus)**
[The effect of alpha-adrenoblockaders on the lipid complex of the myocardium, liver and erythrocytes in dogs with pulmonary heart failure] Frantsuzova SB, et al. **Fiziol Zh** 1995 Sep-Dec;41(5-6):80-3 (Eng. Abstr.) **(Ukr)**

THERAPEUTIC USE

Clinical implications of alpha 1 adrenergic blockade and angiotensin converting enzyme inhibition 'cross talk' in heart failure in Nigerians [letter] Ajayi AA, et al. **Afr J Med Med Sci** 1996 Mar;25(1):95
Alpha blockers, diuretics and beta blockers for hypertension [letter; comment] Coutts LC. **Am Fam Physician** 1997 May 15;55(7):2431-2, 2434. Comment on: Am Fam Physician 1996 Jul;54(1):263-6, 269-70.
Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance. Jeng JR, et al. **Am Heart J** 1996 Oct;132(4):783-9
The alpha-1 adrenergic blocking agent urapidil counteracts postrotational atherectomy "elastic recoil" where nitrates have failed. Gregorini L, et al. **Am J Cardiol** 1997 Apr 15;79(8):1100-3
Dose dependent effects of yohimbine on methadone maintained patients. Hameedi FA, et al. **Am J Drug Alcohol Abuse** 1997 May;23(2):327-33
Yohimbine as an antidote for clonidine overdose. Roberge RJ, et al. **Am J Emerg Med** 1996 Nov;14(7):678-80
Study provides head-to-head comparison of terazosin, finasteride [news] **Am J Health Syst Pharm** 1996 Oct 15; 53(20):2380, 2382
Neural mechanisms in primary hypertension. Efficacy of alpha-blockade with doxazosin during stress. Lee D, et al. **Am J Hypertens** 1996 Jan;9(1):47-53
Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Lithell HO. **Am J Hypertens** 1996 Nov; 9(11):150S-154S (28 ref.)
Orthostatic hypotension: how to avoid it during antihypertensive therapy. Rieckert H. **Am J Hypertens** 1996 Nov;9(11):155S-159S

ADRENERGIC ALPHA-ANTAGONISTS

Overview of alpha 1-adrenoceptor antagonism and recent advances in hypertensive therapy. Veelken R, et al. **Am J Hypertens** 1996 Nov;9(11):139S-149S (76 ref.)

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Giugliano D, et al. **Ann Intern Med** 1997 Jun 15;126(12):955-9

Alternatives to estrogen for the treatment of hot flashes. Lucerno MA, et al. **Ann Pharmacother** 1997 Jul-Aug; 31(7-8):915-7

Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension. Sekiyama T, et al. **Arzneimittelforschung** 1997 Apr;47(4):353-5

Alpha-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility. Marshall HJ, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):507-9

Optimising the medical management of benign prostatic hyperplasia. McDermott T. **Br J Clin Pract** 1997 Mar; 51(2):116-8

The missing alpha blocker paper [editorial] **Br J Urol** 1997 Aug;80(2):1 p preceding 195

Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy. Kurita Y, et al. **Br J Urol** 1997 Jul;80(1):78-83

alpha-receptor blockade for benign prostatic hyperplasia: uses and problems in a developing country. Ogbonna BC, et al. **Br J Urol** 1997 Jan;79(1):32-5

What is the best medical treatment for benign prostate hyperplasia? Evans MF, et al. **Can Fam Physician** 1997 Jun;43:1073-4

Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension. Bönner G, et al. **Cardiovasc Drugs Ther** 1997 Mar; 11(1):21-6

Effect of nipradilol on silent myocardial ischemia, plasma beta-endorphin, and bradykinin in chronic stable angina. Takase B, et al. **Clin Cardiol** 1996 Jun;19(6):477-82

Complex regional pain syndrome (reflex sympathetic dystrophy and causalgia): management with the calcium channel blocker nifedipine and/or the alpha-sympathetic blocker phenoxybenzamine in 59 patients. Muizelaar JP, et al. **Clin Neurol Neurosurg** 1997 Feb;99(1):26-30

Mianserin, a 5-HT2a/2c and alpha 2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Aizenberg D, et al. **Clin Neuropharmacol** 1997 Jun;20(3):210-4

The impact of different therapies on symptoms of benign prostatic hyperplasia: a prospective study. Kawachi I, et al. **Clin Ther** 1996 Nov-Dec;18(6):1118-27

Efficacy and tolerability of doxazosin versus enalapril in the treatment of patients with mild-to-moderate hypertension. Tan KW, et al. **Clin Ther** 1997 May-Jun;19(3):459-70

Nicergoline: parallel evolution of clinical trial methodology and drug development in dementias. Crook TH. **Dement Geriatr Cogn Disord** 1997;8 Suppl 1:22-6

Altered neurotransmission and signal transduction: targets for nicergoline treatment. Winblad B. **Dement Geriatr Cogn Disord** 1997;8 Suppl 1:2-5

Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. Eri LM, et al. **Drugs Aging** 1997 Feb;10(2):107-18 (84 ref.)

Benign prostatic hyperplasia. Practical treatment guidelines. Tammela T. **Drugs Aging** 1997 May;10(5):349-66 (141 ref.)

Oral therapy with combined enalapril, prazosin and hydrochlorothiazide in the acute treatment of severe hypertension in Nigerians. Ajayi AA, et al. **Eur J Clin Pharmacol** 1996;51(1):45-8

A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs. Bagheri H, et al. **Eur J Clin Pharmacol** 1997;52(5):339-42

Metabolic effects of carvedilol in hypertensive patients. Lithell H, et al. **Eur J Clin Pharmacol** 1997;52(1):13-7

Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies. Abrams P. **Eur Urol** 1997;32(1):39-46

Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Buzelin JM, et al. **Eur Urol** 1997;31(2):190-8

The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group. Debruyne FM, et al. **Eur Urol** 1996;30(3):369-76

Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Lukacs B, et al. **Eur Urol** 1996;29(1):29-35

Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. Martorana G, et al. **Eur Urol** 1997;32(1):47-53

Dapiprazole for patients with night haloes after excimer keratectomy. Alster Y, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234 Suppl 1:S139-41

Alpha 1-adrenergic blockers: do they have a place in the prophylaxis of migraine? Vatz KA. **Headache** 1997 Feb; 37(2):107-8

Prostate disease in older men: 1. Benign hyperplasia. Albertsen PC. **Hosp Pract (Off Ed)** 1997 May 15;32(5):61-4, 67-8, 77 passim (6 ref.)

Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] Haddjeri N, et al. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:11-7 (30 ref.)

Concurrent alpha 1 adrenergic blockade and angiotensin converting enzyme inhibition in the treatment of congestive heart failure. Ajayi AA, et al. **Int J Cardiol** 1996 Dec 6; 57(2):173-6

Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction. Meinhardt W, et al. **Int J Impot Res** 1996 Mar;8(1):5-7

Oral treatments for erectile dysfunction. Riley A. **Int J STD AIDS** 1996;7 Suppl 3:16-8 (12 ref.)

Transition zone ratio and prostate-specific antigen density: the index of response of benign prostatic hypertrophy to an alpha blocker. Kurita Y, et al. **Int J Urol** 1996 Sep; 3(5):361-6

The effectiveness of dapiprazole in preventing exercise-induced IOP increase in patients with pigmentary dispersion syndrome. Mastropasqua L, et al. **Int Ophthalmol** 1995-96;19(6):359-62

Effect of the alpha-1 adrenoceptor blocker on tissue norepinephrine contents in human benign prostatic hyperplasia. Ishigooka M, et al. **Int Urol Nephrol** 1997; 29(2):195-200

A placebo controlled double blind study using perioperative prazosin in the prevention of urinary retention following inguinal hernia repair. Woo HH, et al. **Int Urol Nephrol** 1995;27(5):557-62

Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine. Burger DH, et al. **J Am Coll Surg** 1997 Sep;185(3):234-6

Microdialysis of adipose tissue during surgery: effect of local alpha- and beta-adrenoceptor blockade on blood flow and lipolysis. Felländer G, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2919-24

Terazosin vs finasteride for BPH. Zacks M. **J Fam Pract** 1996 Dec;43(6):533

Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). Oren S, et al. **J Hum Hypertens** 1996 Feb;10(2):123-7

Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients. Eriksson JW, et al. **J Hypertens** 1996 Dec; 14(12):1469-75

Chronic alpha-1-adrenergic blockade increases sympathoneural but not adrenomedullary activity in patients with essential hypertension. Jacobs MC, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1837-41

Pharmacological options in the treatment of benign prostatic hyperplasia. Kenny B, et al. **J Med Chem** 1997 Apr 25; 40(9):1293-315 (146 ref.)

Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia. Dutkiewicz S. **Mater Med Pol** 1996 Jul-Sep; 28(3):93-102

Serum PSA levels at 6 month after surgery, TURP or Doxazosin therapy for BPH. Dutkiewicz S, et al. **Mater Med Pol** 1996 Apr-Jun;28(2):69-70

A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia. Dutkiewicz S. **Mater Med Pol** 1995 Oct-Dec;27(4):151-2

Carvedilol for heart failure. **Med Lett Drugs Ther** 1997 Sep 26;39(1010):89-91

Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension. Haenni A, et al. **Metabolism** 1996 Oct;45(10):1221-9

Safety profile of selective alpha-1 adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Sciarra A, et al. **Minerva Urol Nefrol** 1997 Mar;49(1):21-8

Terazosin, finasteride, or both in benign prostatic hyperplasia [letter; comment] Kuchel GA, et al. **N Engl J Med** 1997 Jan 23;336(4):293-4; discussion 294. Comment on: N Engl J Med 1996 Aug 22;335(8):533-9.

The usefulness of dapiprazole, an alpha-adrenergic blocking agent, in pigmentary glaucoma. Mastropasqua L, et al. **Ophthalmic Surg Lasers** 1996 Sep;27(9):806-9

The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Hieble JP, et al. **Pharmacol Res** 1996 Mar;33(3):145-60 (158 ref.)

Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Gurguis GN, et al. **Psychiatry Res** 1997 Jun 16;71(1):27-39

The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type. Coull JT, et al. **Psychopharmacology (Berl)** 1996 Feb;123(3):239-49

Involvement of the alpha2-adrenergic system in polydipsia in schizophrenic patients: a pilot study. Hayashi T, et al. **Psychopharmacology (Berl)** 1997 Apr;130(4):382-6

Severe envenoming by the Indian red scorpion Mesobuthus tamulus: the use of prazosin therapy. Bawaskar HS, et al. **QJM** 1996 Sep;89(9):701-4

Failure of buflomedil to improve wound healing in ischaemic skin flaps. Quirinia A, et al. **Scand J Plast Reconstr Surg Hand Surg** 1996 Jun;30(2):81-7

Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group. Hansen BJ, et al. **Scand J Urol Nephrol** 1996 Apr;30(2):103-7

Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group. Hansen BJ, et al. **Scand J Urol Nephrol** 1996 Oct;30(5):373-7

Scorpion envenoming and the cardiovascular system. Bawaskar HS, et al. **Trop Doct** 1997 Jan;27(1):6-9

Prazosin: scorpion envenoming and the cardiovascular system [editorial] Warrell DA. **Trop Doct** 1997 Jan;27(1):1

Phentolamine mesylate can alleviate the nausea and vomiting associated with liver metastasis. McCleane GJ. **Ulster Med J** 1996 Nov;65(2):165-6

Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months. Gerber GS, et al. **Urology** 1997 Aug;50(2):229-33

Alpha-blockade: monotherapy for hypertension and benign prostatic hyperplasia. Kaplan SA, et al. **Urology** 1996 Oct; 48(4):541-50 (58 ref.)

Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Lepor H, et al. **Urology** 1997 Mar;49(3):476-80

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Lukacs B, et al. **Urology** 1996 Nov; 48(5):731-40

Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. Witjes WP, et al. **Urology** 1997 Feb;49(2):197-205; discussion 205-6

[Prolonged use of moxisylyte chlorhydrate (Icavex) by intracavernous self-injections in the treatment of impotence. Evaluation of long-term tolerance] Arvis G, et al. **J Urol (Paris)** 1996;102(4):151-6 (Eng. Abstr.) **(Fre)**

[Tamsulosin--the first selective alpha 1A-adrenergic receptor blocker in the treatment of BPH (benign prostatic hypertrophy)] **Dtsch Med Wochenschr** 1996 Aug;121(33 Suppl):1-5 **(Ger)**

[Drug therapy of benign prostatic hyperplasia] Vahlensieck W Jr, et al. **Fortschr Med** 1996 Nov 10;114(31):407-11 (0 ref.) (Eng. Abstr.) **(Ger)**

[In what sense are alpha 1-receptor blockers as first choice agents in treatment of hypertension suitable?] Düsing R. **Internist (Berl)** 1996 Sep;37(9):941 **(Ger)**

[Therapy of primary dementia based on modern concepts] **Nervenarzt** 1995 May;66(5 Suppl):1-4 **(Ger)**

[Treatment of benign prostatic hyperplasia with alpha 1-adrenoreceptor antagonists] Heimbach D, et al. **Urologe A** 1997 Jan;36(1):18-34 (157 ref.) (Eng. Abstr.) **(Ger)**

[Benign prostatic hyperplasia] Schulze H. **Urologe A** 1997 Jan;36(1):1-2 **(Ger)**

[Raynaud's phenomenon: effects of terazosin] Paterna S, et al. **Minerva Cardioangiol** 1997 May;45(5):215-21 (Eng. Abstr.) **(Ita)**

[Prevention of hypertensive crises in the perioperative period. Efficacy and safety of the use of urapidil] Mastronardi P, et al. **Minerva Chir** 1996 Apr;51(4):227-33 (Eng. Abstr.) **(Ita)**

[Urodynamic evaluation of alpha-1 blocker tamsulosin on benign prostatic hyperplasia using pressure-flow study] Miyatake R, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Aug;87(8):1048-55 (Eng. Abstr.) **(Jpn)**

[The effect of adrenoblockers on the ultrastructural changes in the epithelium and neural elements of the small intestine of suckling rabbits with experimental cholera] Lomov IuM, et al. **Arkh Patol** 1996 Nov-Dec;58(6):51-5 (Eng. Abstr.) **(Rus)**

[Randomized, comparative study to evaluate efficacy and safety of doxazosin versus nitrendipine in the treatment of mild to moderate hypertension] Sanz Guajardo D, et al. **An Med Interna** 1997 Jan;14(1):15-9 (Eng. Abstr.) **(Spa)**

[Alpha blockers in the treatment of benign hyperplasia of the prostate] Gómez Sancha F, et al. **Rev Clin Esp** 1997 May;197(5):358-62 (46 ref.) **(Spa)**

[An approach to the pharmacological treatment of autism] Ruggieri VL. **Rev Neurol** 1996 Nov;24(135):1451-5 (58 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Effect of prazosin on sperm transport in male rats. Solomon HM, et al. **Reprod Toxicol** 1997 Jul-Aug;11(4):627-31

URINE

High-performance liquid chromatographic determination of the conjugate metabolites of moxisylyte in human plasma and urine. Marquer C, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):389-96

ADRENERGIC ALPHA-RECEPTOR AGONISTS see **ADRENERGIC ALPHA-AGONISTS**

ADRENERGIC ALPHA-RECEPTOR BLOCKADERS see **ADRENERGIC ALPHA-ANTAGONISTS**

ADRENERGIC ALPHA-RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA**

ADRENERGIC ALPHA-1 RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA-1**

ADRENERGIC ALPHA-2 RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA-2**

ADRENERGIC ANTAGONISTS

see related
SYMPATHOLYTICS

PHARMACOLOGY

NE inhibits cerebrovascular mast cell exocytosis induced by cholinergic and peptidergic agonists. Reynier-Rebuffel AM, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R845-50

The acute cardiovascular actions of intravenous thyrotrophin releasing hormone (TRH) in man are mediated by non-catecholaminergic mechanisms. Bouloux PM, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):225-32

Effect of adrenergic and nitrergic blockade on experimental ileus in rats De Winter BY, et al. **Br J Pharmacol** 1997 Feb;120(3):464-8

Adrenoceptor antagonists block c-fos response to stress in the mouse brain. Stone EA, et al. **Brain Res** 1995 Oct 2; 694(1-2):279-86

Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms. Brunvand H, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):409-17

Mechanism of resistance to alpha-adrenergic receptor antagonists of renal nerve stimulation-induced vasoconstriction at low frequencies. Sehic E, et al. **J Cardiovasc Pharmacol** 1997 Jan;29(1):97-108

Stress increases plasma enzyme activity in rats: differential effects of adrenergic and cholinergic blockades. Arakawa H, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1296-303

Effects of adrenergic, cholinergic and ganglionic blockade on acute depressor responses to metformin in spontaneously hypertensive rats. Muntzel MS, et al. **J Pharmacol Exp Ther** 1997 May;281(2):618-23

Portal adrenergic blockade does not inhibit the gluconeogenic effects of circulating catecholamines on the liver. Chu CA, et al. **Metabolism** 1997 Apr;46(4):458-65

Influence of adrenoceptor and muscarinic receptor blockade on the cardiovascular effects of exogenous noradrenaline and of endogenous noradrenaline released by infused tyramine. Schäfers RF, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):239-49

Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Bymaster FP, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1-2):87-94

[Adrenergic dependence of hematopoietic precursors proliferation under cytostatic effect] Khlusov IA, et al. **Biull Eksp Biol Med** 1997 Jun;123(6):638-41 **(Rus)**

THERAPEUTIC USE

Recent advances in the medical management of prostate cancer [see comments] Kirby RS. **Br J Clin Pract** 1996 Mar;50(2):88-93 (57 ref.). Comment in: Br J Clin Pract 1996 Jul-Aug;50(5):287.

[Stress protection therapy in surgical patients] Nazarov IP, et al. **Anesteziol Reanimatol** 1996 Jul-Aug;(4):45-6 **(Rus)**

ADRENERGIC BETA-AGONISTS

A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients. Schreurs AJ, et al. **Eur Respir J** 1996 Aug;9(8):1678-83

L-type calcium current in catecholamine-induced cardiac hypertrophy in the rat. Mészáros J, et al. **Exp Physiol** 1997 Jan;82(1):71-83

Biphasic antagonisms by beta-blockers against positive inotropic response through beta1-adrenoceptors in isolated canine right ventricular muscles: possible involvement of two beta 1-adrenoceptor subtypes. Kurosawa H, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):262-8

[Prohibition of use of beta agonists in the feed of market animals] Ungemach FR. **Tierarztl Prax** 1997 May; 25(3):9-10 **(Ger)**

[Development of beta 2-selective, long-acting agonists] Inagaki N, et al. **Nippon Rinsho** 1996 Nov;54(11):3062-7 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Inhaled beta agonists as a bronchodilator are a mainstay of asthma therapy: focusing on inhaled beta agonists and oral theophylline] Nishimura K, et al. **Nippon Rinsho** 1996 Nov; 54(11):3073-7 (14 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Inaccuracy of portable peak flow meters: correction is not needed. Dutch CNSLD Study Group. Brand PL, et al. **Acta Paediatr** 1997 Aug;86(8):888-9

Prospective evaluation of high-dose or low-dose isoproterenol upright tilt protocol for unexplained syncope in young adults. Carlioz R, et al. **Am Heart J** 1997 Mar; 133(3):346-52

Should epinephrine be administered exclusively by the endotracheal route in respiratory arrest secondary to asthma? [letter] Leibman JB. **Am J Emerg Med** 1997 Jan; 15(1):106-7

Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels. Rodrigo G, et al. **Am J Emerg Med** 1996 Mar;14(2):144-50

Inhaled salmeterol or oral theophylline in nocturnal asthma? Selby C, et al. **Am J Respir Crit Care Med** 1997 Jan; 155(1):104-8

Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Weersink EJ, et al. **Am J Respir Crit Care Med** 1997 Apr; 155(4):1241-6

An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. Yates DH, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1603-7

Interpretation of positive results of a methacholine inhalation challenge and 1 week of inhaled bronchodilator use in diagnosing and treating cough-variant asthma. Irwin RS, et al. **Arch Intern Med** 1997 Sep 22;157(17):1981-7

Several studies have shown salmeterol to be more potent than salbutamol for systemic effects [letter; comment] Bennett J, et al. **BMJ** 1997 Jul 12;315(7100):121. Comment on: BMJ 1997 Apr 12;314(7087):1061-2.

Potentially hazardous co-prescribing of beta-adrenoceptor antagonists and agonists in the community. Evans JM, et al. **Br J Gen Pract** 1996 Jul;46(408):423-5

Terbutaline inhalation suppresses fentanyl-induced coughing. Lui PW, et al. **Can J Anaesth** 1996 Dec;43(12):1216-9

Spinal somatosensory evoked potentials after epidural isoproterenol in awake sheep. Marcus MA, et al. **Can J Anaesth** 1997 Jan;44(1):85-9

Effect of nebulized fenoterol on spirometry, dyspnea sensation changes during exercise in patients with chronic obstructive pulmonary disease. Chiang LL, et al. **Chang Keng I Hsueh** 1996 Jun;19(2):129-34

The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Coates AL, et al. **Chest** 1997 May;111(5):1206-12

Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered? Karpel JP, et al. **Chest** 1997 Aug;112(2):348-56

Aerosol delivery during continuous nebulization [see comments] McPeck M, et al. **Chest** 1997 May;111(5):1200-5 . Comment in: Chest 1997 May;111(5):1155-6.

Aerosols for the intubated: cultivating the rose [editorial; comment] Manthous CA. **Chest** 1997 Aug;112(2):303-4. Comment on: Chest 1997 Aug;112(2):484-90.

Efficacy of metered-dose inhaler administration of albuterol in intubated infants [see comments] Torres A Jr, et al. **Chest** 1997 Aug;112(2):484-90. Comment in: Chest 1997 Aug;112(2):303-4.

Effects of thyroid hormone on cardiac beta-adrenergic responsiveness in conscious baboons. Hoit BD, et al. **Circulation** 1997 Jul 15;96(2):592-8

Hypoxia, hypocapnia and spirometry at altitude. Pollard AJ, et al. **Clin Sci (Colch)** 1997 Jun;92(6):593-8

Does pharmacologic coronary flow reserve reflect vasodilator responsiveness to increased myocardial demand in humans? Rossen JD, et al. **Coron Artery Dis** 1996 Jun; 7(6):479-84

Use of a hand-held, metered-dose aerosol delivery device to administer pirbuterol acetate to horses with 'heaves' [comment] Derksen FJ, et al. **Equine Vet J** 1996 Jul; 28(4):306-10. Comment on: Equine Vet J 1996 Jul;28(4):250-2.

Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol. Hernández RM, et al. **Eur J Drug Metab Pharmacokinet** 1997 Apr-Jun; 22(2):145-50

Treatment of recurrent acute wheezing episodes in infancy with oral salbutamol and prednisolone. Fox GF, et al. **Eur J Pediatr** 1996 Jun;155(6):512-6

Effective treatment of acute hyperkalaemia in childhood by short-term infusion of salbutamol [see comments] Kemper MJ, et al. **Eur J Pediatr** 1996 Jun;155(6):495-7. Comment in: Eur J Pediatr 1997 May;156(5):420.

Continuous isoproterenol inhalation therapy in children with severe asthmatic attack. Iikura Y, et al. **Int Arch Allergy Immunol** 1997 May-Jul;113(1-3):370-2

Dobutamine stress-redistribution-reinjection versus rest-redistribution thallium-201 SPECT in the assessment of myocardial viability. Cornel JH, et al. **Int J Card Imaging** 1997 Feb;13(1):59-64

Hyperamylasemia in response to ritodrine or ephedrine administered to pregnant women. Takahashi T, et al. **J Am Coll Surg** 1997 Jan;184(1):31-6

Long-term isoprenaline administration and its effect on the revascularisation and regeneration of skeletal muscle transplants in mice. Roberts P, et al. **J Anat** 1996 Jun;188 (Pt 3):705-12

Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol. Scalabrin DM, et al. **J Asthma** 1996;33(6):407-15

Eosinophilic myocarditis in heart transplant candidates [letter; comment] Fernández-González AL, et al. **J Heart Lung Transplant** 1996 Aug;15(8):852-3. Comment on: J Heart Lung Transplant 1995 Jul-Aug;14(4):755-60.

Formulation and preparation of controlled release pellets of salbutamol by the air suspension technique. Govender T, et al. **J Microencapsul** 1997 Jul-Aug;14(4):445-55

Albuterol in mild asthma [letter; comment] Suissa S, et al. **N Engl J Med** 1997 Mar 6;336(10):729; discussion 730. Comment on: N Engl J Med 1996 Sep 19;335(12):841-7.

Albuterol in mild asthma [letter; comment] Zahger D. **N Engl J Med** 1997 Mar 6;336(10):729-30; discussion 730 . Comment on: N Engl J Med 1996 Sep 19;335(12):841-7.

Oral bronchodilators in the control of asthma [editorial; comment] Rees PJ. **Natl Med J India** 1996 Jul-Aug; 9(4):153-4. Comment on: Natl Med J India 1996 Jul-aug;9(4):159-62.

Cost-effectiveness of inhaled beta-agonists v. oral salbutamol in asthma: a randomized double-blind cross-over study [see comments] Thomas K, et al. **Natl Med J India** 1996 Jul-Aug;9(4):159-62. Comment in: Natl Med J India 1996 Jul-Aug;9(4):153-4. Comment in: Natl Med J India 1997 Jan-Feb;10(1):47-8.

Delivery of albuterol in a pediatric emergency department. Williams JR, et al. **Pediatr Emerg Care** 1996 Aug; 12(4):263-7

Beta 2-agonist metered dose inhaler overuse: psychological and demographic profiles. Beausoleil JL, et al. **Pediatrics** 1997 Jan;99(1):40-3

Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment [see comments] Simons FE, et al. **Pediatrics** 1997 May;99(5):655-9. Comment in: Pediatrics 1997 May;99(5):729-30.

Ineffectiveness of intravenous beta 2-agonists on improving exercise tolerance in patients with reversible chronic airway obstruction. Malerba M, et al. **Respiration** 1996; 63(1):8-16

The effect of inhaled salbutamol and salmeterol on lung function and endurance performance in healthy well-trained athletes. Carlsen KH, et al. **Scand J Med Sci Sports** 1997 Jun;7(3):160-5

Insufficient control of asthma: increase the dose of inhaled steroids or add long-acting beta 2-agonists? Aubert JD, et al. **Schweiz Med Wochenschr** 1997 Feb 1;127(5):176-81 (28 ref.)

Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic non-asthmatic subjects. Evans DW, et al. **Thorax** 1997 Feb;52(2):136-42

Asthma guidelines [letter; comment] Jack D. **Thorax** 1997 Jul;52(7):665; discussion 665-6. Comment on: Thorax 1997 Feb;52 Suppl 1:S2-8, S11-5, S20-1.

Nebulisers for chronic obstructive pulmonary disease. O'Driscoll BR. **Thorax** 1997 Apr;52 Suppl 2:S49-52

Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction [see comments] Zanen P, et al. **Thorax** 1996 Oct;51(10):977-80 . Comment in: Thorax 1997 Jun;52(6):586-7.

[Beta2-agonists and anticholinergic agents (letter; comment)] Madsen FF. **Ugeskr Laeger** 1997 Mar 3;159(10):1470-1. Comment on: Ugeskr Laeger 1996 Oct 14;158(42):5957-62. **(Dan)**

[Beta2 agonists and anticholinergics. Inhalation therapy in acute deterioriation of asthma and chronic obstructive pulmonary disease (see comments)] Ringbaek TJ, et al. **Ugeskr Laeger** 1996 Oct 14;158(42):5957-62 (40 ref.). Comment in: Ugeskr Laeger 1997 Mar 3;159(10):1470-1. **(Dan)**

[Formoterol as inhalation powder in the treatment of patients with reversible obstructive lung diseases. A 3-month placebo-controlled comparison of the effects of formoterol and salbutamol, followed by a 12-month period with formoterol alone] Steffensen IE, et al. **Ugeskr Laeger** 1996 Dec 2;158(49):7092-6 (Eng. Abstr.) **(Dan)**

[Recommendations for treatment of asthma in pregnancy] Worth H, et al. **Med Klin** 1996 Jul 15;91(7):435-7 **(Ger)**

[Re: Barandun J: Inhalation therapy in chronic obstructive bronchial diseases. Schweiz Med Wochenschr 1996; 126: 1693-1703 (letter; comment)] Kochen MM. **Schweiz Med Wochenschr** 1997 Mar 8;127(10):411. Comment on: Schweiz Med Wochenschr 1996 Oct 5;126(40):1693-703. **(Ger)**

[Relation between the sialic acid/fucose ratio in airway secretions and the degree of airway remodeling in bronchial asthma--reversibility of airflow limitation by beta-agonists and airway remodeling in bronchial asthma] Kobayashi H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:54-8 (Eng. Abstr.) **(Jpn)**

[Status asthmaticus treated with inhaled isoflurane and intravenous isoproterenol] Nakahara Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 May; 35(5):536-40 (Eng. Abstr.) **(Jpn)**

[Pharmacologic therapy for patients with stable chronic obstructive pulmonary disease--emphasis on inhaled agents] Nishimura K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:75-8 (18 ref.) (Eng. Abstr.) **(Jpn)**

[The management of chronic asthma with inhaled beta 2 agonists--regular use? symptomatic use?] Kitamura S, et al. **Nippon Rinsho** 1996 Nov;54(11):3078-80 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics] Ogawa C, et al. **Nippon Rinsho** 1996 Nov;54(11):3081-6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[The clinical usefulness of the combined use of inhaled beta 2-agonist and inhaled steroid in asthma] Yamamoto C, et

al. **Nippon Rinsho** 1996 Nov;54(11):3087–92 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Beta 2–mimetics—mechanism of action and their place in treatment of bronchospastic states] Chazan R. **Pol Merkuriusz Lek** 1997 Jan;2(7):36–9 (58 ref.) (Eng. Abstr.) **(Pol)**

[The inhalation administration of liposomes for the transport of broncholytic preparations in bronchial asthma] Nevzorova VA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Nov–Dec; (6):12–4 (Eng. Abstr.) **(Rus)**

[Adrenergic beta–2 agents and the Olympic Games (letter)] Drobnic F. **Med Clin (Barc)** 1996 Nov 23;107(18):717–8 **(Spa)**

ADVERSE EFFECTS

Confounding by indication and channeling over time: the risks of beta 2–agonists. Blais L, et al. **Am J Epidemiol** 1996 Dec 15;144(12):1161–9

Identifying patients at risk from the use of beta–adrenergic agonists [editorial; comment] Leff AR. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1593. Comment on: Am J Respir Crit Care Med 1996 Dec;154(6 Pt 1):1598–1602.

Bronchodilators and acute cardiac death [letter; comment] Sears MR. **Am J Respir Crit Care Med** 1997 Jul;156(1):333 . Comment on: Am J Respir Crit Care Med 1996 Dec;154(6 Pt 1):1598–602.

Bronchodilators and acute cardiac death [see comments] Suissa S, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1598–602. Comment in: Am J Respir Crit Care Med 1996 Dec;154(6 Pt 1):1593. Comment in: Am J Respir Crit Care Med 1997 Jul;156(1):333.

Beta2–agonist induced ventricular dysrhythmias secondary to hyperexcitable conduction system in the absence of a long QT syndrome. Finn AF Jr, et al. **Ann Allergy Asthma Immunol** 1997 Feb;78(2):230–2

Ritodrine–induced leukopenia: a case report and literature review. Wu CD, et al. **Chang Keng I Hsueh** 1996 Dec; 19(4):388–91 (7 ref.)

A paradoxical effect of bronchodilators. Maury E, et al. **Chest** 1997 Jun;111(6):1766–7 (6 ref.)

Steric aspects of formoterol and terbutaline: is there an adverse effect of the distomer on airway smooth muscle function? Källström BL, et al. **Chirality** 1996;8(8):567–73

Dobutamine–induced transmural myocardial ischemia in a patient with mild coronary lesions. Kardaras FG, et al. **Clin Cardiol** 1996 Feb;19(2):149–51

Concerns regarding the current use of beta–agonists in the therapy of asthma. Aberg G, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):3–6

Airway subsensitivity with long–acting beta 2–agonists. Is there cause for concern? Lipworth BJ. **Drug Saf** 1997 May; 16(5):295–308 (60 ref.)

Concentration–effect relationship of the positive chronotropic and hypokalaemic effects of fenoterol in healthy women of childbearing age. Bouillon T, et al. **Eur J Clin Pharmacol** 1996;51(2):153–60

A warning for the treatment of hyperkalaemia with salbutamol [letter; comment] Semmekrot BA, et al. **Eur J Pediatr** 1997 May;156(5):420. Comment on: Eur J Pediatr 1996 Jun;155(6):495–7.

Cardiac arrest during dobutamine stress echocardiography. Salustri A, et al. **G Ital Cardiol** 1997 Jan;27(1):69–71

Severe pulmonary edema associated with tocolytic therapy. Case report with hemodynamic study [letter] Leduc D, et al. **Intensive Care Med** 1996 Nov;22(11):1280–1

Evolution of dobutamine echocardiography protocols and indications: safety and side effects in 3,011 studies over 5 years. Secknus MA, et al. **J Am Coll Cardiol** 1997 May; 29(6):1234–40

International trends in sales of inhaled fenoterol, all inhaled beta–agonists, and asthma mortality, 1970–1992. Lanes SF, et al. **J Clin Epidemiol** 1997 Mar;50(3):321–8

Hypokalaemia following nebulized salbutamol in children with acute attack of bronchial asthma. Singhi SC, et al. **J Paediatr Child Health** 1996 Dec;32(6):495–7

Hypokalaemia in pregnant women treated with the beta 2–mimetic drug fenoterol—a concentration and time dependent effect. Hildebrandt R, et al. **J Perinat Med** 1997; 25(2):173–9

Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Haimovici R, et al. **Ophthalmology** 1997 Oct;104(10):1653–60

Risk of severe life threatening asthma [editorial] Barnes NC, et al. **Thorax** 1996 Nov;51(11):1073

Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity. Garrett JE, et al. **Thorax** 1996 Nov;51(11):1093–9

Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Meier CR, et al. **Thorax** 1997 Jul;52(7):612–7

[Maternal complications from tocolytic treatment with beta–mimetics. Three cases of pulmonary edema] Hourdequin P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(5):528–32 (21 ref.) (Eng. Abstr.) **(Fre)**

[Effect of the beta–2 mimetic drug terbutaline of growth hormone secretion in prepubertal asthmatic children] Baum WF, et al. **Pneumologie** 1997 May;51(5):513–6 (Eng. Abstr.) **(Ger)**

[New developments in predicting the arrhythmogenic effect of beta–adrenomimetics in chronic obstructive lung diseases] Andrianov VP, et al. **Voen Med Zh** 1996 Nov; 317(11):34–6 **(Rus)**

ANALYSIS

Detection of the anabolic beta 2–adrenoceptor agonist clenbuterol in human scalp hair by HPLC/EIA. Gleixner A, et al. **Clin Chem** 1996 Nov;42(11):1869–71

Beta–agonists in animal feed. II: Optimization of the extraction. Courtheyn D, et al. **Food Addit Contam** 1996 Jul;13(5):493–509

Beta–agonists in animal feed. IV: Intercomparison study of a candidate reference confirmatory method. Leyssens L, et al. **Food Addit Contam** 1996 Nov–Dec;13(8):883–95

beta–agonists in animal feed. III: Optimization of the clean–up and the end–determination step. Leyssens L, et al. **Food Addit Contam** 1996 Oct;13(7):795–810

Beta–agonists in animal feed. I: First intercomparison of methods of analysis for clenbuterol in animal feed materials. Schilt R, et al. **Food Addit Contam** 1996 Jul;13(5):477–92

Gas chromatographic–tandem mass spectrometric analysis of clenbuterol residues in faeces. Batjoens P, et al. **J Chromatogr A** 1996 Oct 25;750(1–2):133–9

Detection of clenbuterol in bovine retinal tissue by high–performance liquid chromatography with electrochemical detection. Lin LA, et al. **J Chromatogr A** 1997 Feb 21;762(1–2):275–80

Gas and liquid chromatography coupled to tandem mass spectrometry for the multiresidue analysis of beta–agonists in biological matrices. Van Vyncht G, et al. **J Chromatogr A** 1996 Oct 25;750(1–2):43–9

Determination of residues of the beta–agonist clenbuterol in liver of medicated farm animals by gas chromatography–mass spectrometry using diphasic dialysis as an extraction procedure. González P, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):321–6

Determination of beta 2–agonists in hair by gas chromatography/mass spectrometry. Polettini A, et al. **J Mass Spectrom** 1996 Jan;31(1):47–54

Quality control of pharmaceuticals containing clenbuterol by thermal lens spectrometry. Martin Biosca Y, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1037–41

BLOOD

Rapid pharmacokinetic screening of salbutamol in plasma samples by column–switching high–performance liquid chromatography–electrospray mass spectrometry. Schmeer K, et al. **J Chromatogr A** 1997 Aug 8;777(1):67–72

Gas chromatographic–mass spectrometric determination of beta 2–agonists in postmortem blood: application in forensic medicine. Couper FJ, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25;685(2):265–72

Determination of ractopamine in monkey plasma and swine serum by high–performance liquid chromatography with electrochemical detection. Turberg MP, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26;675(2):279–85

CHEMICAL SYNTHESIS

Synthesis and pharmacological properties of 1,2,3,4–tetrahydroisoquinoline derivatives. Brzezińska E. **Acta Pol Pharm** 1996 Jan–Feb;53(1):25–9

"Vinylogs" and "acetylenylogs" of beta–adrenergic agents. Nudelman A, et al. **Arch Pharm (Weinheim)** 1996 Mar; 329(3):125–32

Synthesis and evaluation of trimetoquinol derivatives: novel thromboxane A2/prostaglandin H2 antagonists with diminished beta–adrenergic agonist activity. Christoff JJ, et al. **J Med Chem** 1997 Jan 3;40(1):85–91

Iodinated analogs of trimetoquinol as highly potent and selective beta 2–adrenoceptor ligands. De Los Angeles JE, et al. **J Med Chem** 1996 Sep 13;39(19):3701–11

CHEMISTRY

Compatibility of nebulizer solution admixtures. Joseph JC. **Ann Pharmacother** 1997 Apr;31(4):487–9 (17 ref.)

Sustained activation of a G protein–coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2–adrenergic receptor. Green SA, et al. **J Biol Chem** 1996 Sep 27;271(39):24029–35

CONTRAINDICATIONS

[The systemic problems in the dental treatment of the elderly patients] Matsuura H. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):505–7 (0 ref.) **(Jpn)**

DIAGNOSTIC USE

Usefulness of isoproterenol in the induction of clinical sustained ventricular tachycardia during electrophysiological study. de Meester A, et al. **Acta Cardiol** 1997;52(1):67–74

Prospective evaluation of high–dose or low–dose isoproterenol upright tilt protocol for unexplained syncope in young adults. Carlioz R, et al. **Am Heart J** 1997 Mar; 133(3):346–52

Prognostic significance of systolic blood pressure changes during dobutamine–atropine stress technetium–99m sestamibi perfusion scintigraphy in patients with chest pain and known or suspected coronary artery disease. Geleijnse ML, et al. **Am J Cardiol** 1997 Apr 15;79(8):1031–5

Comparison of Tc–99m sestamibi perfusion imaging and echocardiography using an arbutamine infusion for the detection of coronary artery disease. Hendel RC, et al. **Am J Cardiol** 1997 Jun 1;79(11):1518–21

Early chronotropic incompetence predicts the need for atropine during dobutamine stress echocardiography. Hepner AM, et al. **Am J Cardiol** 1997 Feb 1;79(3):365–6

Quantitative evaluation of the segmental left ventricular response to dobutamine stress by tissue Doppler echocardiography. Katz WE, et al. **Am J Cardiol** 1997 Apr 15;79(8):1036–42

Comparison of the prognostic value of dipyridamole and dobutamine stress echocardiography in patients with known or suspected coronary artery disease. Schröder K, et al. **Am J Cardiol** 1997 Jun 1;79(11):1516–8

Isoproterenol tilt–table testing in patients with syncope and structural heart disease. Sheldon R, et al. **Am J Cardiol** 1996 Sep 15;78(6):700–3

Usefulness of dobutamine echocardiography in the hemodynamic assessment of mechanical prostheses in the aortic valve position. Zabalgoitia M, et al. **Am J Cardiol** 1997 Aug 15;80(4):523–6

Dobutamine stress echocardiography: angiographic correlates. Yeo TC, et al. **Ann Acad Med Singapore** 1996 Mar;25(2):196–9

Septal myectomy in hypertrophic obstructive cardiomyopathy: late results with stress echocardiography. Göl MK, et al. **Ann Thorac Surg** 1997 Sep;64(3):739–45

Observer bias in the interpretation of dobutamine stress echocardiography. Tighe JF Jr, et al. **Clin Cardiol** 1997 May;20(5):449–54

Arbutamine stress echocardiography. Ketteler T, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D24–30 (28 ref.)

Cardiac arrest during dobutamine stress echocardiography. Salustri A, et al. **G Ital Cardiol** 1997 Jan;27(1):69–71

Symptomatic and hemodynamic recovery following dobutamine stress echo: benefit of low–dose esmolol administration. Abdullah EE, et al. **Int J Card Imaging** 1997 Feb;13(1):53–7

Arbutamine vs. exercise stress testing in patients with coronary artery disease: evaluation by echocardiography and electrocardiography. Ginzton LE, et al. **Int J Cardiol** 1996 Nov 15;57(1):81–9

Evolution of dobutamine echocardiography protocols and indications: safety and side effects in 3,011 studies over 5 years. Secknus MA, et al. **J Am Coll Cardiol** 1997 May; 29(6):1234–40

Comparison of sensitivity and specificity of tilt protocols with and without isoproterenol in children with unexplained syncope. Alehan D, et al. **Pacing Clin Electrophysiol** 1997 Jul;20(7):1769–76

Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients [see comments] Tan KS, et al. **Thorax** 1997 Jul;52(7):608–11. Comment in: Thorax 1997 Jul;52(7):591–2.

Pretransplant dobutamine stress echocardiography is useful and cost–effective in renal transplant candidates. Brennan DC, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):233–4

[Whole body distribution of Tc–99m–sestamibi after pharmacological stress with arbutamine and dipyridamole compared with resting conditions] Kotzerke J, et al. **Nuklearmedizin** 1997 Jan;36(1):19–22 (Eng. Abstr.) **(Ger)**

[Unmasking an exclusively retrograde accessory pathway by catecholamines] Weismüller P, et al. **Z Kardiol** 1996 Dec; 85(12):949–52 (Eng. Abstr.) **(Ger)**

[Dobutamine stress–echocardiography] Roguin A, et al. **Harefuah** 1997 Jun 15;132(12):884–9 (46 ref.) **(Heb)**

[Stress echocardiography with dobutamine in the identification of coronary disease in patients with left bundle branch block] Scandura S, et al. **Cardiologia** 1997 Jun;42(6):619–25 (Eng. Abstr.) **(Ita)**

[Prognostic stratification after acute uncomplicated myocardial infarction: exercise test, echo–dobutamine test or both?] Greco CA, et al. **G Ital Cardiol** 1997 May; 27(5):450–7 (Eng. Abstr.) **(Ita)**

[Is reduced left ventricular volume related to mechanisms of dynamic mid–ventricular obstruction provoked by dobutamine infusion?] Murakami H, et al. **J Cardiol** 1997 Apr;29(4):203–8 (Eng. Abstr.) **(Jpn)**

[Assessment of coronary artery lesions and myocardial viability by pharmacological stress echocardiography] Senda S, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:615–8 (9 ref.) **(Jpn)**

ECONOMICS

International trends in sales of inhaled fenoterol, all inhaled beta–agonists, and asthma mortality, 1970–1992. Lanes SF, et al. **J Clin Epidemiol** 1997 Mar;50(3):321–8

IMMUNOLOGY

Agonistic effects of anti–peptide antibodies and autoantibodies directed against adrenergic and cholinergic receptors: absence of desensitization. Wallukat G, et al. **Blood Press Suppl** 1996;3:31–6

Effects of active immunization against clenbuterol on the growth–promoting effect of clenbuterol in rats. Kim YH, et al. **J Anim Sci** 1997 Feb;75(2):446–53

ISOLATION & PURIFICATION

Bioanalysis of beta 2–agonists by hyphenated

chromatographic and mass spectrometric techniques. Polettini A. **J Chromatogr B Biomed Appl** 1996 Dec 6; 687(1):27–42 (58 ref.)

Simultaneous determination of the elimination profiles of the individual enantiomers of racemic isoproterenol using capillary electrophoresis and microdialysis sampling. Hadwiger ME, et al. **J Pharm Biomed Anal** 1997 Feb; 15(5):621–9

Interaction of beta 2-adrenoceptor agonists with native cyclodextrins: application to the development of chiral assays for terbutaline. Boulton DW, et al. **Pharm Acta Helv** 1996 Oct;71(4):293–6

METABOLISM

Beta-adrenoceptor desensitization during the development of canine pacing-induced heart failure. Vatner DE, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):688–92

Characterization of the beta 2 adrenoceptors of dog liver. García-Sáinz JA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Sep;115(1):61–5

The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Manchee GR, et al. **Drug Metab Dispos** 1996 May;24(5):555–9

Interindividual variability in the rate of salbutamol sulphation in the human lung. Pacifici GM, et al. **Eur J Clin Pharmacol** 1996;49(4):299–303

In vitro toxicity and formation of early conjugates in Caco-2 cell line treated with clenbuterol, salbutamol and isoxsuprine. Stammati A, et al. **Eur J Drug Metab Pharmacokinet** 1997 Apr-Jun; 22(2):173–8

Triiodothyronine and amiodarone effects on beta 3-adrenoceptor density and lipolytic response to the beta 3-adrenergic agonist BRL 37344 in rat white adipocytes. Germack R, et al. **Fundam Clin Pharmacol** 1996; 10(3):289–97

Characteristics of [3H]CGP12177 binding sites at beta 2- and beta 3-adrenoceptors in the guinea pig taenia caecum. Koike K, et al. **Gen Pharmacol** 1997 Jan;28(1):73–6

Distribution, elimination, and residues of [14C]clenbuterol HCl in Holstein calves. Smith DJ, et al. **J Anim Sci** 1997 Feb;75(2):454–61

Characterization of a novel iodocyanopindolol and SM-11044 binding protein, which may mediate relaxation of depolarized rat colon tonus. Sugasawa T, et al. **J Biol Chem** 1997 Aug 22;272(34):21244–52

Three-dimensional models for agonist and antagonist complexes with beta 2 adrenergic receptor. Kontoyianni M, et al. **J Med Chem** 1996 Oct 25;39(22):4406–20

The stability of the agonist beta2-adrenergic receptor-Gs complex: evidence for agonist-specific states. Krumins AM, et al. **Mol Pharmacol** 1997 Jul;52(1):144–54

Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. Wieland K, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9276–81

PHARMACOKINETICS

Dobutamine pharmacokinetics during dobutamine stress echocardiography. Daly AL, et al. **Am J Cardiol** 1997 May 15;79(10):1381–6

Enantioselective disposition of salbutamol in man following oral and intravenous administration. Boulton DW, et al. **Br J Clin Pharmacol** 1996 Jan;41(1):35–40

Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Boulton DW, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):138–44

Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol. Hernández RM, et al. **Eur J Drug Metab Pharmacokinet** 1997 Apr-Jun; 22(2):145–50

Basis for dosing time-dependent changes in the ocular and systemic absorption of topically applied timolol. Lee VH, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):103–13

Simultaneous determination of the elimination profiles of the individual enantiomers of racemic isoproterenol using capillary electrophoresis and microdialysis sampling. Hadwiger ME, et al. **J Pharm Biomed Anal** 1997 Feb; 15(5):621–9

Systemic concentrations of salbutamol and HFA-134a after inhalation of salbutamol sulfate in a chlorofluorocarbon-free system. Harrison LI, et al. **Ther Drug Monit** 1996 Jun;18(3):240–4

(-)-salbutamol sulphation in the human liver and duodenal mucosa: interindividual variability. Pacifici GM, et al. **Xenobiotica** 1997 Mar;27(3):279–86

PHARMACOLOGY

Long-term ischaemic preconditioning of the heart induced by repeated beta-adrenergic stress. Kovanecz I, et al. **Acta Physiol Hung** 1996;84(3):297–8

beta-Adrenoceptor agonists-induced desensitization in rat trachea. Vassilev PP. **Acta Physiol Pharmacol Bulg** 1995; 21(3):57–62

Effect of treatment with beta-agonists on tissue and urinary taurine levels in rats. Mechanism and implications for protection. Waterfield CJ, et al. **Adv Exp Med Biol** 1996; 403:233–45

Review article: beta 3-adrenoceptor agonists--future anti-inflammatory drugs for the gastrointestinal tract? Anthony A. **Aliment Pharmacol Ther** 1996 Dec; 10(6):859–63 (45 ref.)

Effects of dobutamine on aortic valve indexes in asymptomatic patients with bileaflet mechanical prostheses in the aortic valve position. Tsai CH, et al. **Am J Cardiol** 1997 Jun 1;79(11):1546–9

Antitussive effect of herbal medicine bakumondo-to: a case report. Mizushima Y, et al. **Am J Chin Med** 1996; 24(3–4):321–5

Contraction inhibition by beta-agonists progressively decreases before labor in the rat myometrium. Yeagley C, et al. **Am J Obstet Gynecol** 1996 May;174(5):1637–42

Beta-adrenergic modulation of Na-K pump activity in young and adult canine cardiac Purkinje fibers. Charpentier F, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H706–12

PKA-mediated phosphorylation and inhibition of Na(+)-K(+)-ATPase in response to beta-adrenergic hormone. Cheng XJ, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C893–901

Tissue-specific regulation of lipoprotein lipase by isoproterenol in normal-weight humans. Eckel RH, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1280–6

TNF-alpha inhibits isoproterenol-stimulated adenylyl cyclase activity in cultured airway smooth muscle cells. Emala CW, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):L644–50

Insulin sensitizes beta-agonist and forskolin-stimulated lipolysis to inhibition by 2',5'-dideoxyadenosine. Gokmen-Polar Y, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):C562–9

Inhibition of nitric oxide synthase augments myocardial contractile responses to beta-adrenergic stimulation. Keaney JF Jr, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2646–52

Chronic effects of catecholamines on the beta 2-adrenoreceptor system in cultured human airway epithelial cells. Kelsen SG, et al. **Am J Physiol** 1997 May; 272(5 Pt 1):L916–24

Transgenic manipulation of beta-adrenergic receptor kinase modifies cardiac myocyte contraction to norepinephrine. Korzick DH, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H590–6

Inhibitory effects of Gs on desensitization of beta-adrenergic receptors in tracheal smooth muscle. Kume H, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):L556–64

beta 3-Adrenergic-mediated suppression of leptin gene expression in rats. Li H, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E1031–6

Troponin I phosphorylation in spontaneously hypertensive rat heart: effect of beta-adrenergic stimulation. McConnell BK, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1440–51

Beta-adrenergic agonists attenuate fibroblast-mediated contraction of released collagen gels. Mio T, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L829–35

Redistribution of intracellular Ca2+ stores after beta-adrenergic stimulation of rat tail artery SMC. Miyashita Y, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H244–55

Distinct cellular mechanisms of cholinergic and beta-adrenergic sweat secretion. Reddy MM, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C486–94

Clenbuterol, a beta2-adrenoceptor agonist, reduces scoliosis due to partial transection of rat spinal cord. Zeman RJ, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E712–5

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Baraniuk JN, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):704–10

Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Bolton PB, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1428–35

Broxaterol increases force output of fatigued canine diaphragm more than salbutamol. Derom E, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):181–5

Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilation. Díaz O, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):17–22

Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Dowling RB, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):327–36

In vivo quantification of human pulmonary beta-adrenoceptors: effect of beta-agonist therapy. Hayes MJ, et al. **Am J Respir Crit Care Med** 1996 Nov; 154(5):1277–83

Effect of the beta-agonist clenbuterol on dexamethasone-induced diaphragm dysfunction in rabbits. Jiang TX, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1778–83

Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Sakuma T, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):506–12

Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Tibayan FA, et al. **Am J Respir Crit Care Med** 1997 Aug;156(2 Pt 1):438–44

Inotropic effects of salbutamol on rat diaphragm contractility are potentiated by foreshortening. van der Heijden HF, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):1072–9

Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting. Berendes E, et al. **Anesth Analg** 1997 May;84(5):950–7

Dobutamine infusion modifies thermoregulation during general anesthesia. Shitara T, et al. **Anesth Analg** 1996 Dec; 83(6):1154–9

Effects of a dobutamine-induced increase in splanchnic blood flow on hepatic metabolic activity in patients with septic shock. Reinelt H, et al. **Anesthesiology** 1997 Apr; 86(4):818–24

Actions of phenylephrine, isoproterenol, and epinephrine with halothane on endocardial conduction and activation in canine left ventricular papillary muscles. Vodanovic S, et al. **Anesthesiology** 1997 Jul;87(1):117–26

Changes in the noradrenaline and acetylcholine content of three major salivary glands and in the salivation and protein component patterns of whole saliva in chronically isoprenaline-administered mice. Kawaguchi T, et al. **Arch Oral Biol** 1997 Mar;42(3):225–34

"Vinylogs" and "acetylenylogs" of beta-adrenergic agents. Nudelman A, et al. **Arch Pharm (Weinheim)** 1996 Mar; 329(3):125–32

Oxidation of nutrients in bull calves treated with beta-adrenergic agonists. Chwalibog A, et al. **Arch Tierernahr** 1996;49(4):255–61

Acceleration of contraction by beta-adrenoceptor stimulation is greater in ventricular myocytes from failing than non-failing human hearts. Harding SE, et al. **Basic Res Cardiol** 1996;91 Suppl 2:53–6

Rapid inhibition of ob gene expression and circulating leptin levels in lean mice by the beta 3-adrenoceptor agonists BRL 35135A and ZD2079. Trayhurn P, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):605–10

Improvement of metabolic disorders and visceral fat obesity by the beta 3-adrenoceptor agonist (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2 -(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents. Hashimoto K, et al. **Biochem Pharmacol** 1996 Nov 22; 52(10):1529–35

Stereoselective action of (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl)ethylamino] propyl]-phenoxyacetic acid (BRL37344) on beta-adrenoceptors and metabolic chiral inversion. Ida K, et al. **Biochem Pharmacol** 1996 Nov 22; 52(10):1521–7

Examination of the effects of increasing Gs protein on beta2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Krumins AM, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):61–72

Anabolic effects of a range of beta 2-adrenoceptor agonists in a clonal G8.P8 cell line. Blackburn SJ, et al. **Biochem Soc Trans** 1996 May;24(2):214S

Clenbuterol is not an agonist of Na+ dependent creatine transport. Thorpe KA, et al. **Biochem Soc Trans** 1996 May; 24(2):215S

Mechanism of beta-adrenergic agonist-induced transmural transport of glucose in rat small intestine. Regulation of phosphorylation of SGLT1 controls the function. Ishikawa Y, et al. **Biochim Biophys Acta** 1997 Jul 24;1357(3):306–18

Activation of a NADH dehydrogenase in the human erythrocyte by beta-adrenergic agonists: possible involvement of a G protein in enzyme activation. Marques F, et al. **Biol Signals** 1997 Mar-Apr;6(2):52–61

In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine. Alarayyed NA, et al. **Br J Clin Pharmacol** 1997 Apr;43(4):415–20

The acute effects of inhaled salbutamol on the beat-to-beat variability of heart rate and blood pressure assessed by spectral analysis. Jartti T, et al. **Br J Clin Pharmacol** 1997 Apr;43(4):421–8

Evaluation of partial beta-adrenoceptor agonist activity. Lipworth BJ, et al. **Br J Clin Pharmacol** 1997 Jan; 43(1):9–14 (32 ref.)

The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man. Tham TC, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):251–6

(--)-Timolol is a more potent antagonist of the positive inotropic effects of (--)-adrenaline than of those of (--)-noradrenaline in human atrium. Wang T, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):217–23

Effects of age on cardiovascular responses to adrenaline in man. White M, et al. **Br J Clin Pharmacol** 1997 Apr; 43(4):407–14

Comparison of the profiles of agonists as stimulants of the beta 3-adrenoceptor in vitro with their gastroprotective effects in the conscious rat. Bahl AK, et al. **Br J Pharmacol** 1996 Feb;117(3):580–586

In situ assessment of the role of the beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Barbe P, et al. **Br J Pharmacol** 1996 Mar;117(5):907–13

Extent of salmeterol-mediated reassertion of relaxation in guinea-pig trachea pretreated with aliphatic side chain structural analogues. Bergendal A, et al. **Br J Pharmacol** 1996 Mar;117(6):1009–15

The involvement of ATP-sensitive potassium channels in beta 2-adrenoceptor agonist-induced vasodilatation on rat diaphragmatic microcirculation. Chang HY. **Br J Pharmacol** 1997 Jul;121(5):1024–30

Protection by dexamethasone of the functional desensitization to beta 2-adrenoceptor-mediated responses in human lung

mast cells. Chong LK, et al. **Br J Pharmacol** 1997 Jun; 121(4):717–22

Differential contribution of two serine residues of wild type and constitutively active beta2-adrenoceptors to the interaction with beta2-selective agonists. Kikkawa H, et al. **Br J Pharmacol** 1997 Jul;121(6):1059–64

Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle. Liu YL, et al. **Br J Pharmacol** 1996 Mar;117(6):1355–61

Effects of (–)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors. Molenaar P, et al. **Br J Pharmacol** 1997 Jan;120(2):165–76

Beta 2-adrenoceptor agonist-mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of beta 2-adrenoceptor stimulation. Stewart AG, et al. **Br J Pharmacol** 1997 Jun;121(3):361–8

Noradrenaline modifies the spontaneous spiking activity of red nucleus neurons in the rat by activation of alpha 2- and beta-adrenoceptors. Ciranna L, et al. **Brain Res** 1996 Dec 16;743(1-2):284–93

Beta-adrenoceptor control of cardiac adenylyl cyclase during development: agonist pretreatment in the neonate uniquely causes heterologous sensitization, not desensitization. Giannuzzi CE, et al. **Brain Res** 1995 Oct 2;694(1-2):271–8

Down-regulation of rat beta-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [3H] CGP-12177 binding reveals rapid (24 hour) modulation. Newman-Tancredi A, et al. **Brain Res Bull** 1996;41(2):93–6

Reduction in post-intubation respiratory resistance by isoflurane and albuterol. Choi JH, et al. **Can J Anaesth** 1997 Jul;44(7):717–22

Expression of functional beta-adrenoceptors and polyploidy development in cultured vascular smooth muscle cells from spontaneously hypertensive rats. Conyers RB, et al. **Can J Physiol Pharmacol** 1997 May;75(5):375–82

Differentiation of binding sites of CGP12177, a beta 3-adrenoceptor partial agonist, and carteolol, a beta 1/beta 2-adrenoceptor partial agonist, to the beta-adrenoceptors in guinea-pig taenia caecum. Koike K, et al. **Can J Physiol Pharmacol** 1996 Aug;74(8):928–33

Effects of the beta 3-adrenoceptor agonist BRL 37344 on lipomobilization and plasma glucose levels in conscious fasted rabbits. Reverte M, et al. **Can J Physiol Pharmacol** 1996 Mar;74(3):251–6

Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth. Carbó N, et al. **Cancer Lett** 1997 May 1;115(1):113–8

Inhibition of beta- but not alpha 1-mediated adrenergic responses in isolated hearts and cardiomyocytes by nitric oxide and 8-bromo cyclic GMP. Ebihara Y, et al. **Cardiovasc Res** 1996 Sep;32(3):622–9

Mechanism of coronary microvascular responses to metabolic stimulation. Embrey RP, et al. **Cardiovasc Res** 1997 Jul; 35(1):148–57

Thyroid hormones increase the contractility but suppress the effects of beta-adrenergic agonist by decreasing phospholamban expression in rat atria. Kaasik A, et al. **Cardiovasc Res** 1997 Jul;35(1):106–12

Right and left ventricular geometry and myocyte contractile processes with dilated cardiomyopathy: myocyte growth and beta-adrenergic responsiveness. McMahon WS, et al. **Cardiovasc Res** 1996 Feb;31(2):314–23

Endogenous adenosine increases O2 utilisation efficiency in isoprenaline-stimulated canine myocardium. Mallet RT, et al. **Cardiovasc Res** 1996 Jan;31(1):102–16

Modulation of myocardial economy and efficiency in mammalian failing and non-failing myocardium by calcium channel activation and beta-adrenergic stimulation. Ruf T, et al. **Cardiovasc Res** 1996 Dec;32(6):1047–55

Acute L-triiodothyronine administration potentiates inotropic responses to beta-adrenergic stimulation in the isolated perfused rat heart. Tielens ET, et al. **Cardiovasc Res** 1996 Aug;32(2):306–10

Similarities between early and delayed afterdepolarizations induced by isoproterenol in canine ventricular myocytes. Volders PG, et al. **Cardiovasc Res** 1997 May;34(2):348–59

The different effect of salbutamol and aminophylline on platelet activating factor-induced plasma exudation into guinea pig tracheal wall and lumen. Liu CY, et al. **Chang Keng I Hsueh** 1996 Sep;19(3):211–6

The effect of regular salbutamol on lung function and bronchial hyperresponsiveness in normal subjects and nonasthmatic atopic subjects with allergic rhinitis. Boothman-Burrell D, et al. **Chest** 1997 Jul;112(1):12–8

Renal dose dopamine does not alter the response to beta-adrenergic stimulation by isoproterenol in healthy human volunteers. MacGregor DA, et al. **Chest** 1997 Jul; 112(1):40–4

The effect of nebulized albuterol on the activity of the renin-angiotensin system in asthma. Millar EA, et al. **Chest** 1997 Jan;111(1):71–4

Agonist regulation of beta-adrenergic receptors: immunoblotting and indirect immunofluorescence reveal agonist-induced lateral sequestration and loss of binding. Wang HY, et al. **Chin J Physiol** 1996;39(2):83–93

Dobutamine enhances cardiodepressant effects of receptor-mediated coronary endothelial stimulation. Bartunek J, et al. **Circulation** 1997 Jan 7;95(1):90–6

Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm. Dawes M, et al. **Circulation** 1997 May 6; 95(9):2293–7

Beta 2-adrenergic dilation of resistance coronary vessels involves KATP channels and nitric oxide in conscious dogs. Ming Z, et al. **Circulation** 1997 Mar 18;95(6):1568–76

Role of myocyte nitric oxide in beta-adrenergic hyporesponsiveness in heart failure. Yamamoto S, et al. **Circulation** 1997 Mar 4;95(5):1111–4

Efficacy and mechanisms of dopexamine in the prevention of ischemia-reperfusion induced organ damage: role of oxygen free radicals. Jacinto SM, et al. **Clin Exp Hypertens** 1997 Jan-Feb;19(1-2):181–90

Inhibitory effect of salmeterol on the respiratory burst of adherent human neutrophils. Ottonello L, et al. **Clin Exp Immunol** 1996 Oct;106(1):97–102

Decreased sensitivity to beta-adrenergic stimulation of the ventricular cells isolated from the spontaneously hypertensive rat heart. Habuchi Y, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S105–6

Is salmeterol ergogenic? Morton AR, et al. **Clin J Sport Med** 1996 Oct;6(4):220–5

Nasal mucociliary clearance and salmeterol. Tay HL, et al. **Clin Otolaryngol** 1997 Feb;22(1):68–70

Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Boulton DW, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):138–44

Fenoterol but not dobutamine increases erythropoietin production in humans. Gleiter CH, et al. **Clin Pharmacol Ther** 1997 Jun;61(6):669–76

Nonshivering thermogenesis in marsupials: absence of thermogenic response to beta 3-adrenergic agonists. Nicol SC, et al. **Comp Biochem Physiol A Physiol** 1997 Jul; 117(3):399–405

Effects of breed and adipose depot location on responsiveness and sensitivity to adrenergic stimulation in ovine adipose tissue. Gilson TL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Sep;115(1):19–26

Metabolic and calorigenic effects of dopexamine in healthy volunteers. Geisser W, et al. **Crit Care Med** 1997 Aug; 25(8):1332–7

Dopexamine improves liver oxygenation during crystalloid resuscitation from experimental hemorrhagic shock. Nordin A, et al. **Crit Care Med** 1997 Apr;25(4):663–8

CL-316,243, a beta3-specific adrenoceptor agonist, enhances insulin-stimulated glucose disposal in nonobese rats. de Souza CJ, et al. **Diabetes** 1997 Aug;48(8):1257–63

Functional responses of the left and right heart of diabetic rats to alpha- and beta-adrenergic receptor stimulation. Irlbeck M, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S79–86

Adipocyte lipolysis in normal weight subjects with obesity among first-degree relatives. Hellström L, et al. **Diabetologia** 1996 Aug;39(8):921–8

Effect of CL316,243, a highly specific beta(3)-adrenoceptor agonist, on lipolysis of epididymal, mesenteric and subcutaneous adipocytes in rats. Umekawa T, et al. **Endocr J** 1997 Feb;44(1):181–5

Strain-specific response to beta 3-adrenergic receptor agonist treatment of diet-induced obesity in mice. Collins S, et al. **Endocrinology** 1997 Jan;138(1):405–13

Targetting the use of beta 2-adrenoceptor agonists to meet physiological and rule book requirements [editorial; comment] Nolan A, et al. **Equine Vet J** 1996 Jul;28(4):250–2 . Comment on: Equine Vet J 1996 Jul;28(4):306–10. Comment on: Equine Vet J 1996 Jul;28(4):320–6.

Characterisation of beta-adrenoceptors in equine digital veins: implications of the modes of vasodilatory action of isoxsuprine. Elliott J, et al. **Equine Vet J Suppl** 1995 Sep; (19):101–7

Cardiovascular effects of dopexamine HCl in conscious and halothane-anaesthetised horses. Muir WW 3rd. **Equine Vet J Suppl** 1992 Feb;(11):24–9

Clenbuterol-induced fiber type transition in the soleus of adult rats. Criswell DS, et al. **Eur J Appl Physiol** 1996; 74(5):391–6

Clenbuterol has a greater influence on untrained than on previously trained skeletal muscle in rats. Murphy RJ, et al. **Eur J Appl Physiol** 1996;73(3-4):304–10

The effect of salbutamol on performance in endurance cyclists. Norris SR, et al. **Eur J Appl Physiol** 1996; 73(3-4):364–8

Effect of beta 2-adrenoceptor agonists on plasma potassium and cardiopulmonary responses on exercise in patients with chronic obstructive pulmonary disease. Yang CT, et al. **Eur J Clin Pharmacol** 1996;49(5):341–5

Regulation of obese mRNA expression by hormonal factors in primary cultures of rat adipocytes. Yoshida T, et al. **Eur J Endocrinol** 1996 Nov;135(5):619–25

Regulation of interleukin-10 production by beta-adrenergic agonists. Suberville S, et al. **Eur J Immunol** 1996 Nov; 26(11):2601–5

Beta-adrenergic receptor activation promotes process outgrowth in an embryonic rat basal forebrain cell line and in primary neurons. Kwon JH, et al. **Eur J Neurosci** 1996 Oct;8(10):2042–55

Interaction between alpha- and beta-adrenergic receptor agonists modulating the slow Ca(2+)-activated K+ current IAHP in hippocampal neurons. Pedarzani P, et al. **Eur J Neurosci** 1996 Oct;8(10):2098–110

Cell type-specific regulation of beta2-adrenoceptor mRNA by agonists. Danner S, et al. **Eur J Pharmacol** 1997 Jul 16;331(1):73–8

Local exposure to salbutamol or Bt2 cyclic AMP inhibits pleural exudation and leukocyte influx caused by antigen in rats. Diaz BL, et al. **Eur J Pharmacol** 1996 Jan 25; 296(2):173–80

Differences in isoproterenol stimulation of Ca2+ current of rat ventricular myocytes in neonatal compared to adult. Katsube Y, et al. **Eur J Pharmacol** 1996 Dec 19; 317(2-3):391–400

Density-dependent proliferation of adult rat hepatocytes in primary culture induced by epidermal growth factor is potentiated by cAMP-elevating agents. Kimura M, et al. **Eur J Pharmacol** 1997 Apr 18;324(2-3):267–76

Pharmacological activities of trimetoquinol and 1-benzyl halogen-substituted analogues on rat beta-adrenoceptor subtypes. Konkar AA, et al. **Eur J Pharmacol** 1996 Jun 3;305(1-3):63–71

Presynaptic modulation by VIP, secretin and isoproterenol of somatostatin release from enriched enteric synaptosomes: role of cAMP. Kurjak M, et al. **Eur J Pharmacol** 1996 Oct 24;314(1-2):165–73

Effects of K+ channel blockers and K+ ionophore on isoprenaline-induced secretion of amylase from rat parotid acini. Murayama T, et al. **Eur J Pharmacol** 1997 Mar 12; 322(1):21–5

Effect of short- and long-acting beta 2-adrenoceptor agonists on pulmonary beta 2-adrenoceptor expression in human lung. Nishikawa M, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):123–9

Cytokines and nitric oxide synthase inhibitor as mediators of adrenergic refractoriness in cardiac myocytes. Oddis CV, et al. **Eur J Pharmacol** 1997 Feb 12;320(2-3):167–74

Endothelium- and cytochrome P-450-dependent relaxation induced by isoproterenol in rat aortic rings. Satake N, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):37–41

Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors. Sato Y, et al. **Eur J Pharmacol** 1996 Nov 21;315(3):363–7

Depression of the inotropic action of isoprenaline by nitric oxide synthase induction in rat isolated hearts. Sun X, et al. **Eur J Pharmacol** 1997 Feb 5;320(1):29–35

Evidence that the eosinophil is a cellular target for the inhibitory action of salmeterol on eosinophil recruitment in vivo. Teixeira MM, et al. **Eur J Pharmacol** 1997 Apr 4;323(2-3):255–60

In vitro studies on the interactions of beta2-adrenoceptor agonists, methylxanthines, Ca2+-channel blockers, K+-channel openers and other airway smooth muscle relaxants in isolated guinea-pig trachea. Thirstrup S, et al. **Eur J Pharmacol** 1997 May 20;326(2-3):191–200

Interactions of glucocorticoids and beta 2-agonists. Adcock IM, et al. **Eur Respir J** 1996 Jan;9(1):160–8 (82 ref.)

Allergic responses reduce the relaxant effect of beta-agonists but not potassium channel openers in guinea-pig isolated trachea. Houjou S, et al. **Eur Respir J** 1996 Oct; 9(10):2050–6

Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. Yates DH, et al. **Eur Respir J** 1997 Jul;10(7):1483–8

The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils. Tool AT, et al. **Eur Respir J Suppl** 1996 Aug;22:141s–145s

Beta-agonist-induced activation of Na+ absorption and KCl release in rat fetal distal lung epithelium: a study of cell volume regulation. Nakahari T, et al. **Exp Physiol** 1997 May;82(3):521–36

The endogenous cardiac sarcoplasmic reticulum Ca2+/calmodulin-dependent kinase is activated in response to beta-adrenergic stimulation and becomes Ca2+-independent in intact beating hearts. Baltas LG, et al. **FEBS Lett** 1997 Jun 9;409(2):131–6

Suppression of insulin-stimulated phosphatidylinositol 3-kinase activity by the beta3-adrenoceptor agonist CL316243 in rat adipocytes. Ohsaka Y, et al. **FEBS Lett** 1997 Feb 3;402(2-3):246–50

Salbutamol potentiates the relaxant effects of selective phosphodiesterase inhibitors on guinea pig isolated trachea. Planquois JM, et al. **Fundam Clin Pharmacol** 1996; 10(4):356–67

Circadian melatonin rhythms in cultured zebrafish pineals are not affected by catecholamine receptor agonists. Cahill GM. **Gen Comp Endocrinol** 1997 Feb;105(2):270–5

Alteration of the cardiac effects of isoproterenol and propranolol by hypothermia in isolated rat atrium. Melnikov AL, et al. **Gen Pharmacol** 1996 Jun;27(4):665–8

Potentiation of the relaxing action of isoproterenol by forskolin in rabbit aortic rings: the involvement of beta 2-adrenoceptors. Satake N, et al. **Gen Pharmacol** 1997 May; 28(5):753–6

Modulation of Ca(2+)-activated K+ current by isoprenaline, carbachol, and phorbol ester in cultured (and fresh) rat aortic vascular smooth muscle cells. Satoh H. **Gen Pharmacol** 1996 Mar;27(2):319–24

Beta-adrenergic receptor and platelet inhibitory activities of a new series of trimetoquinol and related benzazepine analogs. Shams G, et al. **Gen Pharmacol** 1997 Feb; 28(2):323–30

Some pharmacodynamic aspects on long-acting beta-adrenoceptor agonists. Waldeck B. **Gen Pharmacol** 1996 Jun;27(4):575–80 (54 ref.)

Beta-adrenergic regulation of voltage-dependent calcium currents in cultured skeletal myocytes of the frog Rana temporaria. Lukyanenko V, et al. **Gen Physiol Biophys** 1995

Dec;14(6):515–23
Stimulation of beta-adrenoceptors with isoprenaline inhibits small intestinal activity fronts and induces a postprandial-like motility pattern in humans. Thollander M, et al. **Gut** 1997 Mar;40(3):376–80
Catecholamines stimulate steroid secretion of dispersed fowl adrenocortical cells, acting through the beta-receptor subtype. Mazzocchi G, et al. **Horm Metab Res** 1997 Apr; 29(4):190–2
Effect of CL316,243, a highly specific beta 3-adrenoceptor agonist, on lipolysis of human and rat adipocytes. Umekawa T, et al. **Horm Metab Res** 1996 Aug;28(8):394–6
Lack of correlation between arterial and venous beta-adrenergic receptor sensitivity. Stein CM, et al. **Hypertension** 1997 Jun;29(6):1273–7
Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia. Szabó C, et al. **Immunology** 1997 Jan;90(1):95–100
Beta-adrenoceptor desensitization despite cardiac denervation in human failing transplanted myocardium. Reithmann C, et al. **Int J Cardiol** 1996 Sep;56(1):11–5
Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol. Dottorini ML, et al. **Int J Clin Pharmacol Ther** 1996 Oct;34(10):438–43
Salmeterol inhibits interferon-gamma and interleukin-4 production by human peripheral blood mononuclear cells. Mohede IC, et al. **Int J Immunopharmacol** 1996 Mar; 18(3):193–201
Experimental allergic encephalomyelitis, beta-adrenergic receptors and interferon gamma-secreting cells in beta-adrenergic agonist-treated rats. Muthyala S, et al. **Int J Immunopharmacol** 1995 Nov;17(11):895–901
Lipolytic catecholamine resistance linked to alpha 2-adrenoceptor sensitivity--a metabolic predictor of weight loss in obese subjects. Hellström L, et al. **Int J Obes Relat Metab Disord** 1997 Apr;21(4):314–20
Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol. Tome MB, et al. **J Affect Disord** 1997 Jul;44(2-3):101–9
Safety and appropriate use of salmeterol in the treatment of asthma. AAAAI Committee on Drugs, American Academy of Allergy, Asthma and Immunology. **J Allergy Clin Immunol** 1996 Sep;98(3):475–80
Agonizing over long-acting beta-agonists [letter] Wolf BL, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):717–8
Characterization of dose-dependent metabolic responses to close arterial infusion of cimaterol in the hindlimb of steers. Byrem TM, et al. **J Anim Sci** 1996 Dec;74(12):2907–16
Effect of clenbuterol on growth and body composition during food restriction in rats. Cardoso LA, et al. **J Anim Sci** 1996 Sep;74(9):2245–52
Effects of somatotropin and salbutamol in three genotypes of finishing barrows: blood hormones and metabolites and muscle characteristics. Hansen JA, et al. **J Anim Sci** 1997 Jul;75(7):1810–21
Effects of active immunization against clenbuterol on the growth-promoting effect of clenbuterol in rats. Kim YH, et al. **J Anim Sci** 1997 Feb;75(2):446–53
Effects of vigorous exercise training and beta-agonist administration on bone response to hindlimb suspension. Bloomfield SA, et al. **J Appl Physiol** 1997 Jul;83(1):172–8
Terbutaline stimulates alveolar fluid resorption in hyperoxic lung injury. Lasnier JM, et al. **J Appl Physiol** 1996 Oct; 81(4):1723–9
Cardiovascular responses to beta-stimulation with isoproterenol in deep hypothermia. Lauri T. **J Appl Physiol** 1996 Aug;81(2):573–7
Effects of beta 2-agonist administration and exercise on contractile activation of skeletal muscle fibers. Lynch GS, et al. **J Appl Physiol** 1996 Oct;81(4):1610–8
Effects of salbutamol on intracellular calcium oscillations in porcine airway smooth muscle. Prakash YS, et al. **J Appl Physiol** 1997 Jun;82(6):1836–43
Exercise training improves lusitropy by isoproterenol in papillary muscles from aged rats. Taffet GE, et al. **J Appl Physiol** 1996 Oct;81(4):1488–94
Dobutamine as a countermeasure for reduced exercise performance of rats exposed to simulated microgravity. Tipton CM, et al. **J Appl Physiol** 1997 May;82(5):1607–15
Comparison of isoproterenol with BRL37344 in activation of beta 3-adrenoceptors to inhibit the uptake of [14C]deoxy-D-glucose and translocation of glucose transporter (GLUT4) to membrane fraction in rat adipocytes. Chang CJ, et al. **J Auton Nerv Syst** 1996 Nov 6;61(2):191–4
Changes in cardiovascular responsiveness to dopexamine and beta 1- and beta 2-adrenoceptor function after the chronic treatment of beta-adrenoceptor antagonists and agonists in anaesthetized dogs. Chang DH, et al. **J Auton Pharmacol** 1996 Oct;16(5):269–79
The effects of bromoacetylalprenololmenthane on the responses to isoprenaline of the left ventricle from normo-, prehyper- and hypertensive rats. Doggrell SA, et al. **J Auton Pharmacol** 1997 Jun;17(3):183–90
Effect of clenbuterol on the modulation of noradrenaline release in the rat tail artery. Encabo A, et al. **J Auton Pharmacol** 1996 Oct;16(5):243–50
Beta 3-adrenoceptors mediating relaxation of the oesophageal tunica muscularis mucosae and distal colon in the rat: comparative pharmacology and their desensitization by BRL 37344. Kelly J, et al. **J Auton Pharmacol** 1996 Aug;16(4):205–11
Expression of beta3-adrenoceptor and stimulation of glucose transport by beta3-agonists in brown adipocyte primary culture. Nikami H, et al. **J Biochem (Tokyo)** 1996 Jan; 119(1):120–5
Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. Gether U, et al. **J Biol Chem** 1997 Jan 31;272(5):2587–90
Beta3-adrenergic receptors on white and brown adipocytes mediate beta3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice. Grujic D, et al. **J Biol Chem** 1997 Jul 11;272(28):17686–93
beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. January B, et al. **J Biol Chem** 1997 Sep 19;272(38):23871–9
Beta-adrenergic receptor kinase (GRK2) colocalizes with beta-adrenergic receptors during agonist-induced receptor internalization. Ruiz-Gómez A, et al. **J Biol Chem** 1997 Apr 11;272(15):9601–4
A 20-nucleotide (A + U)-rich element of beta2-adrenergic receptor (beta2AR) mRNA mediates binding to beta2AR-binding protein and is obligate for agonist-induced destabilization of receptor mRNA. Tholanikunnel BG, et al. **J Biol Chem** 1997 Apr 25; 272(17):11471–8
Endothelin-1 inhibits L-type Ca2+ current enhanced by isoprenaline in rat atrial myocytes. Delpech N, et al. **J Cardiovasc Pharmacol** 1997 Jan;29(1):136–43
Influence of alpha-adrenergic-receptor activation on junctional conductance in heart cells: interaction with beta-adrenergic adrenergic agonists. De Mello WC. **J Cardiovasc Pharmacol** 1997 Feb;29(2):273–7
Effects of putative K+ channel blockers on beta-adrenoceptor-mediated vasorelaxation of rat mesenteric artery. Huang Y, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):515–9
Inhibition of nitric oxide synthesis reduces coronary blood flow response but does not increase cardiac contractile response to beta-adrenergic stimulation in normal dogs. Kaneko H, et al. **J Cardiovasc Pharmacol** 1996 Feb; 27(2):247–54
Beta-adrenoceptor stimulation-mediated preconditioning-like cardioprotection in perfused rat hearts. Nasa Y, et al. **J Cardiovasc Pharmacol** 1997 Apr; 29(4):436–43
Beta-adrenergic stimulation enhances left ventricular diastolic performance in normal subjects. Nixdorff U, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):476–84
Hemodynamic changes, plasma catecholamine responses, and echocardiographically detected contractile reserve during two different dobutamine-infusion protocols. Poldermans D, et al. **J Cardiovasc Pharmacol** 1997 Jun;29(6):808–13
Transcriptional and posttranscriptional mechanisms of glucocorticoid-mediated repression of phosphoenolpyruvate carboxykinase gene expression in adipocytes. Franckhauser-Vogel S, et al. **J Cell Biochem** 1997 Sep 1;66(3):386–93
Muscarinic receptor modulation of basal and beta-adrenergic stimulated function of the failing human left ventricle. Newton GE, et al. **J Clin Invest** 1996 Dec 15; 98(12):2756–63
Modification of feed intake response to a beta 2-agonist by bovine somatotropin in lactating or dry dairy cows. Bareille N, et al. **J Dairy Sci** 1997 Jan;80(1):52–66
Effect of pregnancy on rat myometrial beta 2-adrenoceptor mRNA and isoproterenol-induced relaxation of isolated uterine strips. Engstrøm T, et al. **J Endocrinol** 1997 Jun; 153(3):393–9
Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man. Arvat E, et al. **J Endocrinol Invest** 1996 Jan;19(1):25–9
Regulatory volume decrease of cardiac myocytes induced by beta-adrenergic activation of the Cl- channel in guinea pig. Wang Z, et al. **J Gen Physiol** 1997 Jul;110(1):73–82
Evidence from in vitro differentiating cells that adrenoceptor agonists can increase uncoupling protein mRNA level in adipocytes of adult humans: an RT-PCR study. Champigny O, et al. **J Lipid Res** 1996 Sep;37(9):1907–14
Effects of nebulized beta 2-adrenergic agonists on pulmonary mechanics in anesthetized patients with chronic obstructive pulmonary disease. Vichitvejpaisal P, et al. **J Med Assoc Thai** 1996 Dec;79(12):779–84
Agonist-independent tonic inhibitory influence of Gi on adenylate cyclase activity in rabbit ventricular myocardium and its removal by pertussis toxin: a role of empty receptor-mediated Gi activation. Akaishi Y, et al. **J Mol Cell Cardiol** 1997 Feb;29(2):765–75
The effect of alterations to action potential duration on beta-adrenoceptor-mediated aftercontractions in human and guinea-pig ventricular myocytes. Tweedie D, et al. **J Mol Cell Cardiol** 1997 May;29(5):1457–67
Neurotrophin-3- and norepinephrine-mediated adrenergic differentiation and the inhibitory action of desipramine and cocaine. Zhang JM, et al. **J Neurobiol** 1997 Mar; 32(3):262–80
Alpha 1D L-type Ca(2+)-channel currents: inhibition by a beta-adrenergic agonist and pituitary adenylate cyclase-activating polypeptide (PACAP) in rat pinealocytes. Chik CL, et al. **J Neurochem** 1997 Mar; 68(3):1078–87
beta-Adrenergic stimulation promotes homocysteic acid release from astrocyte cultures: evidence for a role of astrocytes in the modulation of synaptic transmission. Do KQ, et al. **J Neurochem** 1997 Jun;68(6):2386–94
Beta 2-adrenergic activation enhances interleukin-8 production by human monocytes. Kavelaars A, et al. **J Neuroimmunol** 1997 Aug;77(2):211–6
Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. Shen YT, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1435–43
Kinetic studies of desensitization and resensitization of the relaxation response to beta-2 adrenoceptor agonists in isolated guinea pig trachea. Wachsman DE, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):332–45
Agonist potency at the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay. Wilson S, et al. **J Pharmacol Exp Ther** 1996 Oct; 279(1):214–21
Sino-aortic denervation causes right atrial beta adrenoceptor down-regulation. Zanesco A, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):677–85
Continuous intraocular pressure measurement by telemetry in alpha-chymotrypsin-induced glaucoma model in the rabbit: effects of timolol, dorzolamide, and epinephrine. Percicot CL, et al. **J Pharmacol Toxicol Methods** 1996 Dec; 36(4):223–8
Salbutamol and chronic low-frequency stimulation of canine skeletal muscle. Hu P, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):221–7
Salbutamol changes the molecular and mechanical properties of canine skeletal muscle. Zhang KM, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):211–20
Anomalous behavior of CGP 12177A on beta 1-adrenergic receptors. Pak MD, et al. **J Recept Signal Transduct Res** 1996 Jan-Mar;16(1-2):1–23
Mechanisms of ionic currents involved in suppressive effect of isoprenaline on the action potential of guinea-pig vas deferens in normal Krebs solution. Mimata T, et al. **J Smooth Muscle Res** 1996 Dec;32(6):255–67
Beta-adrenergic stimulation down-regulates neutrophil priming for superoxide generation, but not elastase release. Barnett CC Jr, et al. **J Surg Res** 1997 Jul 1;70(2):166–70
Regional effects of dobutamine in endotoxic shock. De Backer D, et al. **J Surg Res** 1996 Oct;65(2):93–100
Changes in taurine levels in response to repeated administration of the beta 2-agonist salbutamol in lambs. Bastos ML, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):33–7
Effect of pharmacological agonists on contractile responses in aortic rings derived from endotoxaemic rats. Donaldson LL, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):389–96
Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogs. Main BW, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):225–32
Relaxation of equine tracheal muscle in vitro by different adrenoceptor drugs. Törneke K, et al. **J Vet Pharmacol Ther** 1997 Jun;20(3):216–9
Effects of adrenergic agents and phosphodiesterase inhibitors on outflow facility and cell shape of bovine trabecular meshwork. Suzuki R, et al. **Jpn J Ophthalmol** 1997 Jan-Feb;41(1):31–7
Relationship between desensitization and downregulation of beta-adrenoceptors in cardiac tissues after prolonged in vivo infusion of T-0509, a beta 1-adrenoceptor agonist. Sato Y, et al. **Jpn J Pharmacol** 1997 Apr;73(4):325–32
beta-Adrenoceptors and dexamethasone synergistically stimulate the expression of the angiotensinogen gene in opossum kidney cells. Ming M, et al. **Kidney Int** 1996 Jul; 50(1):94–101
Beta 2-agonist-elevated stress response in human bronchial epithelial cells in vivo and in vitro. Hastie AT, et al. **Lung** 1997;175(5):287–98
Myocardial signal response to dipyridamole and dobutamine: demonstration of the BOLD effect using a double-echo gradient-echo sequence. Li D, et al. **Magn Reson Med** 1996 Jul;36(1):16–20
Effects of clenbuterol on contractile and biochemical properties of skeletal muscle. Dodd SL, et al. **Med Sci Sports Exerc** 1996 Jun;28(6):669–76
Accentuated antagonism in canine subendocardium is not altered by chronic exercise. Hamra M, et al. **Med Sci Sports Exerc** 1997 Aug;29(8):1013–20
Effects of dopexamine hydrochloride on calcium channels in isolated guinea pig ventricular myocytes. Dun W, et al. **Methods Find Exp Clin Pharmacol** 1996 Jul-Aug; 18(6):353–7
Beta 2-adrenoceptor activation by zinterol causes protein phosphorylation, contractile effects and relaxant effects through a cAMP pathway in human atrium. Kaumann AJ, et al. **Mol Cell Biochem** 1996 Oct-Nov;163-164:113–23
Inhibition of rat parotid gland growth response induced by chronic isoproterenol following treatment with quinolone antibiotics. Kelentey B, et al. **Mol Cell Biochem** 1996 Dec 6;165(1):55–63
Beta-adrenergic modulation of FMLP- and zymosan-induced intracellular and extracellular oxidant production by polymorphonuclear leukocytes. Kopprasch S, et al. **Mol Cell Biochem** 1997 Mar;168(1-2):133–9
Heart glycogen content and isoprenaline-induced myocardial

lesions. Mráz M, et al. **Mol Cell Biochem** 1996 Oct–Nov; 163–164:145–9

Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor. Chidiac P, et al. **Mol Pharmacol** 1996 Sep;50(3):662–9

Beta-adrenoceptor activation-induced placental prorenin secretion is mediated by increased renin messenger RNA and protein synthesis. Downing GJ, et al. **Mol Pharmacol** 1997 Feb;51(2):201–8

Selective up-regulation of alpha1a-adrenergic receptor protein and mRNA in brown adipose tissue by neural and beta3-adrenergic stimulation. Granneman JG, et al. **Mol Pharmacol** 1997 Apr;51(4):644–50

Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution. Morrison KJ, et al. **Mol Pharmacol** 1996 Sep;50(3):692–9

Acute cardiovascular effects of salmeterol in subjects with stable bronchial asthma. Bagnato GF, et al. **Monaldi Arch Chest Dis** 1996 Aug;51(4):275–8

The beta3-adrenoceptor agonist SR58611A inhibits gastric acid secretion in the conscious cat. Coruzzi G, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Aug; 356(2):263–5

The influence of hyperthyroidism on beta-adrenoceptor-mediated relaxation of isolated small mesenteric arteries. Zwaveling J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Mar; 353(4):438–44

Isoproterenol stimulates tubular DNA replication in mice. Wolf G, et al. **Nephrol Dial Transplant** 1996 Nov; 11(11):2288–92

Inhibition of microglial superoxide anion production by isoproterenol and dexamethasone. Colton CA, et al. **Neurochem Int** 1996 Jul;29(1):43–53

Beta-adrenergic modulation of GABAergic inhibition in the deep cerebellar nuclei of F344 rats. Gould TJ, et al. **Neuropharmacology** 1997 Jan;36(1):75–81

The effects of aging on cerebellar beta-adrenergic receptor activation and motor learning in female F344 rats. Gould TJ, et al. **Neurosci Lett** 1996 Sep 20;216(1):53–6

Blockade of isoproterenol-induced synaptic potentiation by tetra-9-aminoacridine in the rat amygdala. Wang SJ, et al. **Neurosci Lett** 1996 Aug 23;214(2–3):87–90

Cell surface adrenergic receptor stimulation modifies the endothelial response to SIRS. Systemic Inflammatory Response Syndrome. Tighe D, et al. **New Horiz** 1996 Nov; 4(4):426–42 (104 ref.)

Effect of nipradilol, a beta-adrenergic blocker with vasodilating activity, on oxotremorine-induced tremor in mice. Iwata S, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Oct; 16(5):171–4

Influence of a sympathomimetic amine on masticatory and trapezius pain/pressure thresholds and electromyographic levels. Reid KI, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Nov;82(5):525–31

Ontogeny of beta-adrenergic desensitization in rabbit tracheal smooth muscle. Omlor GJ, et al. **Pediatr Pulmonol** 1996 Oct;22(4):255–62

Effect of beta 3-adrenergic agonist (Zeneca D7114) on thermoregulation in near-term lambs delivered by cesarean section. Clarke L, et al. **Pediatr Res** 1996 Aug;40(2):330–6

The effects of bronchodilators on spontaneous ventilation and oxygen consumption in rhesus monkeys. Newth CJ, et al. **Pediatr Res** 1997 Aug;42(2):157–62

Effects of clenbuterol and ICI118551, a selective beta 2-antagonist, on the growth of skeletal muscle of suckling rats. Morton RH, et al. **Pflugers Arch** 1995 Dec; 431(2):237–43

Salbutamol antagonizes insulin- and sodium mercaptoacetate-induced but not 2-deoxy-D-glucose-induced hyperphagia. Nisoli E, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):409–13

Role of medial preoptic area beta adrenoceptors in the regulation of sleep-wakefulness. Sood S, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):1–5

A match between binding to beta-adrenoceptors and stimulation of adenylyl cyclase parameters of (-)isoproterenol and salbutamol on rat brain. Garnier V, et al. **Pharmacol Res** 1997 Apr;35(4):303–12

Effect of trypan blue on the action of acetylcholine, histamine and salbutamol in the isolated guinea-pig ileum. Mahmoudian M, et al. **Pharmacol Toxicol** 1996 Jul; 79(1):29–31

Agonist and antagonist properties of beta 3-adrenoceptors in human omental and mouse 3T3-L1 adipocytes. Shimizu M, et al. **Pharmacol Toxicol** 1996 Apr;78(4):254–63

Pharmacological characteristics of BDTI, a new isoquinoline-derived beta 2-adrenoceptor agonist, in canine trachea and rat heart. Lin CH, et al. **Pharmacology** 1996 Jul;53(1):19–27

Vanidilol: a vanilloid-type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2-agonist activity. Sheu MM, et al. **Pharmacology** 1997 Apr;54(4):211–24

Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Yoshimura T, et al. **Pharmacology** 1997 Mar;54(3):144–52

Endothelium-dependent higenamine-induced aortic relaxation in isolated rat aorta. Wong KK, et al. **Planta Med** 1997 Apr;63(2):130–2

Evidence that prazosin disturbs isoprenaline positive inotropic action in the guinea pig heart papillary muscle. Kocić I. **Pol J Pharmacol** 1996 Jul–Aug;48(4):447–52

Histamine-and isoprenaline-evoked stimulation of cAMP formation in chick cerebral cortex. Nowak JZ, et al. **Pol J Pharmacol** 1995 Nov–Dec;47(6):541–4

Interaction of cholecystokinin (CCK-8) with agonist and antagonist of beta-adrenergic receptors in circulatory system of diabetic rats. Wiśniewska RJ, et al. **Pol J Pharmacol** 1996 May–Jun;48(3):293–7

G-proteins and beta-adrenergic stimulation of adenylate cyclase activity in the diabetic rat prostate. Carmena MJ, et al. **Prostate** 1997 Sep 15;33(1):46–54

Airway effects of salmeterol in healthy individuals. Bergendal A, et al. **Pulm Pharmacol** 1995 Dec;8(6):283–8

Isolated, electrically-stimulated airway preparations--their use in determining beta-adrenoceptor agonist activity. Coleman RA, et al. **Pulm Pharmacol** 1996 Apr;9(2):107–17

Granulocyte-macrophage colony stimulating factors (GM-CSF) and interleukin 8 (IL-8) production by human bronchial epithelial cells (HBEC) in asthmatics and controls. Lack of in vitro effect of salbutamol compared to sodium nedocromil. Gormand F, et al. **Pulm Pharmacol** 1995 Apr–Jun;8(2–3):107–13

A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Matera MG, et al. **Pulm Pharmacol** 1995 Dec;8(6):267–71

Inhaled albuterol does not inhibit cellular influx or lung injury produced by segmental antigen challenge in humans. O'Connor J, et al. **Pulm Pharmacol** 1995 Dec;8(6):237–43

Additive effect of nitroglycerine inhalation on beta2-agonist-induced bronchodilatation in asthmatics. Rolla G, et al. **Pulm Pharmacol** 1995 Apr–Jun; 8(2–3):137–41

Developmental changes in beta-adrenergic and muscarinic modulations of Ca2+ currents in fetal and neonatal ventricular cardiomyocytes of the rat. Masuda H, et al. **Reprod Fertil Dev** 1996;8(1):129–35

Discrepancy between inotropic response and cyclic AMP production induced by isoprenaline and forskolin in rat ventricle strips. Martinez E, et al. **Res Commun Mol Pathol Pharmacol** 1997 May;96(2):157–67

Beta-2-agonists have antioxidant function in vitro. 2. The effect of beta-2-agonists on oxidant-mediated cytotoxicity and on superoxide anion generated by human polymorphonuclear leukocytes. Gillissen A, et al. **Respiration** 1997;64(1):23–8

Beta-2-agonists have antioxidant function in vitro. 1. Inhibition of superoxide anion, hydrogen peroxide, hypochlorous acid and hydroxyl radical. Gillissen A, et al. **Respiration** 1997;64(1):16–22

Lipolytic effects of beta1, beta2 and beta3-adrenergic agonists in isolated human fat cells from omental and retroperitoneal adipose tissues. Portillo MP, et al. **Rev Esp Fisiol** 1995 Dec;51(4):193–200

Cardiovascular autonomic regulation in asthmatic children evidenced by spectral analysis of heart rate and blood pressure variability. Jartti TT, et al. **Scand J Clin Lab Invest** 1996 Oct;56(6):545–54

Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Bennett JA, et al. **Thorax** 1997 May;52(5):458–64

Beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol [letter; comment] Jonkers RE, et al. **Thorax** 1997 Mar;52(3):305. Comment on: Thorax 1996 Jan;51(1):54–8.

Histological and ultrastructural study of the effects of cholinergic and adrenergic agonists on salivary secretion from the lingual epithelium and the lingual gland of the Tokyo Daruma pond frog. Iwasaki S, et al. **Tissue Cell** 1997 Jun;29(3):323–38

Beta-adrenergic stimulation induces ST-segment elevation in dogs with healing myocardial infarction. Katori R, et al. **Tohoku J Exp Med** 1995 Nov;177(3):233–48

Pharmacological criteria for the detection of beta 3-adrenoceptors [letter; comment] De Ponti F. **Trends Pharmacol Sci** 1997 Feb;18(2):52–3 (14 ref.). Comment on: Trends Pharmacol Sci 1996 Oct;17(10):373–81.

Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. Giembycz MA. **Trends Pharmacol Sci** 1996 Sep;17(9):331–6 (62 ref.)

The interaction between salmeterol and the beta 2-adrenoceptor protein [letter; comment] Jack D. **Trends Pharmacol Sci** 1997 May;18(5):149–51. Comment on: Trends Pharmacol Sci 1996 Sep;17(9):324–30.

Pharmacological properties of beta 3-adrenoceptors [letter] Nisoli E, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):257–8 (9 ref.)

Effects of clenbuterol as a repartitioning agent on beta-adrenoceptor concentrations in heart, bronchi and brain of veal calves. Re G, et al. **Vet J** 1997 Jan; 153(1):63–70

[Hemodynamic and metabolic impairment during hepatectomy: effect of continuous dobutamine infusion] Finco G, et al. **Chir Ital** 1995;47(5):33–9 (Eng. Abstr.) **(Ita)**

[Effects of inhaled anticholinergic agents and beta 2-agonists on distilled water induced cough in patients with chronic cough] Tanaka S. **Arerugi** 1996 Jan;45(1):17–27 (Eng. Abstr.) **(Jpn)**

[Effects of beta-adrenergic agonists and phosphodiesterase inhibitors on the outflow facility of the eye] Suzuki R, et al. **Nippon Ganka Gakkai Zasshi** 1997 Jul;101(7):551–7 (Eng. Abstr.) **(Jpn)**

[Long-term effect of a beta-adrenergic agonist on Na+/K(+)-ATPase activity in rat lung explants] Suzuki S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34(12):1311–6 (Eng. Abstr.) **(Jpn)**

[Anti-allergic effects of beta-adrenoceptor agonists in the clinical pharmacological studies] Horikoshi S, et al. **Nippon Rinsho** 1996 Nov;54(11):3068–72 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of beta 2-adrenergic agonists on neurotoxic action of aminophyllines] Lupina T, et al. **Pneumonol Alergol Pol** 1996;64 Suppl 1:70–7 (Eng. Abstr.) **(Pol)**

[The effect of neurotensin and adrenaline on sinus arrhythmia during firing stimulation of the vagus nerve] Osadchiĭ OE, et al. **Biull Eksp Biol Med** 1997 May;123(5):494–7 **(Rus)**

[The effect of isoproterenol on protein extrusion from tissue explants of the mouse mamma] Markov AG, et al. **Tsitologiia** 1996;38(6):606–10 (Eng. Abstr.) **(Rus)**

[Laryngeal mucociliary clearance: influence of beta-2 agonists, beta antagonists, and alpha-agonists. An experimental study in rabbits] Armengot M, et al. **Acta Otorrinolaringol Esp** 1996 Nov–Dec;47(6):425–8 (Eng. Abstr.) **(Spa)**

[The adrenergic reactions to isopropylnoradrenaline in white rats during the development of experimental hyperthyroidism] Soboliev VI, et al. **Fiziol Zh** 1997; 43(3–4):93–100 (Eng. Abstr.) **(Ukr)**

POISONING

Food poisoning following consumption of clenbuterol-treated veal in Italy [letter] Brambilla G, et al. **JAMA** 1997 Aug 27;278(8):635

[Salbutamol intoxication] Danenberg HD. **Harefuah** 1997 Apr 15;132(8):549–51, 607 (Eng. Abstr.) **(Heb)**

[Clenbuterol poisoning. Clinical and analytical data on an outbreak in Móstoles, Madrid] Bilbao Garay J, et al. **Rev Clin Esp** 1997 Feb;197(2):92–5 (Eng. Abstr.) **(Spa)**

STANDARDS

Safety and appropriate use of salmeterol in the treatment of asthma. AAAAI Committee on Drugs, American Academy of Allergy, Asthma and Immunology. **J Allergy Clin Immunol** 1996 Sep;98(3):475–80

THERAPEUTIC USE

Efficacy of atropine sulfate in combination with albuterol in the treatment for acute asthma. Díaz JE, et al. **Acad Emerg Med** 1997 Feb;4(2):107–13

Efficacy of salmeterol in the treatment of childhood asthma. Tomaç N, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):489–94

Effects of local treatment with salmeterol and terbutaline on anti-IgE-induced wheal, flare, and late induration in human skin. Grönneberg R, et al. **Allergy** 1996 Oct; 51(10):685–92

Effects of salmeterol and terbutaline on IgE-mediated dermal reactions and inflammatory events in skin chambers in atopic patients. Grönneberg R, et al. **Allergy** 1996 Sep; 51(9):640–6

Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Allon M, et al. **Am J Kidney Dis** 1996 Oct;28(4):508–14

A placebo-controlled randomized trial of the terbutaline pump for prevention of preterm delivery. Wenstrom KD, et al. **Am J Perinatol** 1997 Feb;14(2):87–91

Quality of life changes in COPD patients treated with salmeterol. Jones PW, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1283–9

Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Tan KS, et al. **Am J Respir Crit Care Med** 1997 Jul; 156(1):28–35

Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin. Dockhorn RJ, et al. **Ann Allergy Asthma Immunol** 1997 Jul;79(1):85–8

Beta2-agonist induced ventricular dysrhythmias secondary to hyperexcitable conduction system in the absence of a long QT syndrome. Finn AF Jr, et al. **Ann Allergy Asthma Immunol** 1997 Feb;78(2):230–2

Salmeterol versus theophylline in the treatment of asthma. Pollard SJ, et al. **Ann Allergy Asthma Immunol** 1997 May; 78(5):457–64

Hypertrophy of brown adipocytes in brown and white adipose tissues and reversal of diet-induced obesity in rats treated with a beta3-adrenoceptor agonist. Ghorbani M, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):121–31

New guidelines on asthma management [editorial] Keeley D, et al. **BMJ** 1997 Feb 1;314(7077):315–6

Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. Wilding P, et al. **BMJ** 1997 May 17;314(7092):1441–6

Beta-adrenoceptor blockers in chronic heart failure--a review. Krum H. **Br J Clin Pharmacol** 1997 Aug; 44(2):111–8 (57 ref.)

Picumeterol: dissociation of improvement in lung function

and reduction of airways hyperresponsiveness in asthmatics. Weersink EJ, et al. **Br J Clin Pharmacol** 1997 Feb;43(2):169–76

The duration of action of inhaled formoterol dry powder. Quebe-Fehling E, et al. **Br J Clin Pract** 1996 Dec; 50(8):446–9

Treatment of hyperkalaemia [letter; comment] Wheatley EC. **Br J Hosp Med** 1997 Feb 19–Mar 4;57(4):171. Comment on: Br J Hosp Med 1996 Feb 21–Mar 5;55(4):167–70.

Partial beta 2-agonists and their impartial assessment [editorial] Dickey BF, et al. **Chest** 1996 Nov;110(5):1131–2

The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group. FitzGerald JM, et al. **Chest** 1997 Feb;111(2):311–5

Tolerance to the protective effect of salmeterol on allergen challenge. Giannini D, et al. **Chest** 1996 Dec;110(6):1452–7

Effect of inhaled salmeterol on sulfur dioxide-induced bronchoconstriction in asthmatic subjects. Gong H Jr, et al. **Chest** 1996 Nov;110(5):1229–35

The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Kraft M, et al. **Chest** 1997 May;111(5):1249–54

Salmeterol reduces dyspnea and improves lung function in patients with COPD. Ramirez-Venegas A, et al. **Chest** 1997 Aug;112(2):336–40

Effect of age on bronchodilator response in acute severe asthma treatment. Rodrigo G, et al. **Chest** 1997 Jul; 112(1):19–23

Hyperkalemia: therapeutic options in acute and chronic renal failure. Kemper MJ, et al. **Clin Nephrol** 1996 Jul;46(1):67–9 (15 ref.)

Dose-response of inhaled drugs in asthma. An update. Clark DJ, et al. **Clin Pharmacokinet** 1997 Jan;32(1):58–74 (78 ref.)

Concerns regarding the current use of beta-agonists in the therapy of asthma. Aberg G, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):3–6

Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM. Saleh TY, et al. **Diabetes Care** 1997 Aug;20(8):1231–6

Asthma treatment during pregnancy. What can be safely taken? Schatz M. **Drug Saf** 1997 May;16(5):342–50 (28 ref.)

Using beta 2-stimulants in asthma. **Drug Ther Bull** 1997 Jan; 35(1):1–4 (32 ref.)

Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat [see comments] Umekawa T, et al. **Eur J Endocrinol** 1997 Apr;136(4):429–37. Comment in: Eur J Endocrinol 1997 Apr;136(4):362–5.

Rapid fetal fibronectin swab-test in preterm labor patients treated by betamimetics. Benattar C, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Apr;72(2):131–5

Urinary trypsin inhibitor: a new drug to treat preterm labor: a comparative study with ritodrine. Kanayama N, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug;67(2):133–8

Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Compliance Working Group. Braunstein GL, et al. **Eur Respir J** 1996 May; 9(5):893–8

Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Tzelepis G, et al. **Eur Respir J** 1996 Jan;9(1):100–3

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. van Noord JA, et al. **Eur Respir J** 1996 Aug;9(8):1684–8

Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics. Wong AG, et al. **Eur Respir J** 1997 Feb;10(2):330–6

A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study. Boulet LP, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):13–21

Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. Garrett JE, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):165–70

Agonizing over long-acting beta-agonists [letter] Wolf BL, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):717–8

Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol. Scalabrin DM, et al. **J Asthma** 1996;33(6):407–15

Cardiopulmonary effects of enoximone or dobutamine and nitroglycerin on mitral valve regurgitation and pulmonary venous hypertension. Hachenberg T, et al. **J Cardiothorac Vasc Anesth** 1997 Jun;11(4):453–7

Acute therapy for hyperkalemia with the combined regimen of bicarbonate and beta(2)-adrenergic agonist (salbutamol) in chronic renal failure patients. Kim HJ. **J Korean Med Sci** 1997 Apr;12(2):111–6

Betamimetics in fetal distress: randomised controlled trial. Kulier R, et al. **J Perinat Med** 1997;25(1):97–100

Prolongation of the life span of cardiomyopathic hamster by the adrenergic beta 1-selective partial agonist denopamine. Kurosawa H, et al. **Jpn J Pharmacol** 1996 Dec;72(4):325–33

FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Yamamoto H, et al. **Jpn J Pharmacol** 1997 May;74(1):109–12

Shrinking lungs syndrome in systemic lupus erythematosus: improvement with inhaled beta-agonist therapy. Muñoz-Rodríguez FJ, et al. **Lupus** 1997;6(4):412–4

Interaction between corticosteroids and beta-agonists in asthma. Wilding PJ, et al. **Monaldi Arch Chest Dis** 1996 Feb;51(1):39–41 (24 ref.)

Prudent use of beta2-agonists in the treatment of asthma. Giangrasso T. **N J Med** 1996 Mar;93(3):171–4 (22 ref.)

Visaline in the treatment of age-related macular degeneration: a pilot study. Kaiser HJ, et al. **Ophthalmologica** 1995;209(6):302–5

Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler in children with mild to moderate asthma. Ståhl E, et al. **Pediatr Pulmonol** 1996 Aug;22(2):106–10

Are beta-adrenergic bronchodilators safe?[comment] Eggleston PA. **Pediatrics** 1997 May;99(5):729–30. Comment on: Pediatrics 1997 May;99(5):655–9.

Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis. Flores G, et al. **Pediatrics** 1997 Aug;100(2 Pt 1):233–9

Asthma compliance and psychological factors [letter] Levine DA. **Pediatrics** 1997 Oct;100(4):731–2

Speeds of action of single doses of formoterol and salbutamol compared with placebo in reversing methacholine-induced bronchoconstriction. Beach JR, et al. **Pulm Pharmacol** 1996 Aug;9(4):245–9

Comparative effects of dopexamine and dopamine on glycerol-induced acute renal failure in rats. Gómez-Garre DN, et al. **Ren Fail** 1996 Jan;18(1):59–68

A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Matera MG, et al. **Respir Med** 1996 Sep;90(8):497–9

Pharmacotherapy of respiratory muscles in chronic obstructive pulmonary disease. van der Heijden HF, et al. **Respir Med** 1996 Oct;90(9):513–22 (101 ref.)

Potential for tolerance, morbidity, and mortality resulting from regular use of beta 2-adrenergic agonists in asthma. Giangrasso T. **South Med J** 1997 Feb;90(2):173–9 (31 ref.)

The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Hedner J, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S111–5

Functional antagonism: tolerance produced by inhaled beta 2 agonists. Cockcroft DW, et al. **Thorax** 1996 Oct; 51(10):1051–6 (34 ref.)

Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis. Moretti M, et al. **Thorax** 1997 Feb;52(2):176–80

Effects of fenoterol on ventilatory response to hypercapnia and hypoxia in patients with chronic obstructive pulmonary disease. Suzuki S, et al. **Thorax** 1997 Feb;52(2):125–9

Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. van der Molen T, et al. **Thorax** 1997 Jun; 52(6):535–9

Effect of regular terbutaline on the airway response to inhaled budesonide. Wilding PJ, et al. **Thorax** 1996 Oct; 51(10):989–92

[Terminal heart failure; therapeutic strategies. Drug therapy in cases of absence of possibility of heart transplantation: dobutamine therapy, aspects of compassion?] Roul G, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89 Spec No 6:27–32 (41 ref.) (Eng. Abstr.) **(Fre)**

[Mucociliary clearance function and medicamentous modification] Konrad F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):404–8 (38 ref.) (Eng. Abstr.) **(Ger)**

[Beta-2 agonists in the therapy of obstructive airway diseases (editorial)] Solèr M. **Schweiz Rundsch Med Prax** 1996 Sep 17;85(38):1159–61 **(Ger)**

[The effect of formoterol on light or moderate bronchial asthma due to allergy to Parietaria officinalis] Pacor ML, et al. **Clin Ter** 1996 Nov;147(11):567–70 (Eng. Abstr.) **(Ita)**

[Involvement of G proteins between receptors and KCa channels in the regulation of airway tone by the autonomic nervous system] Kume H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:116–24 (Eng. Abstr.) **(Jpn)**

[Future aspects of new cardiotonic drugs] Hori M, et al. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):59–63 (5 ref.) **(Jpn)**

[Long-acting beta-2 adrenergic agents--a new therapeutic tool in COBP] Mihăiţan F, et al. **Pneumoftiziologia** 1996 Jul-Dec;45(3–4):183–4 **(Rum)**

[Serevent in the treatment of moderate bronchial asthma] Panghea P, et al. **Pneumoftiziologia** 1996 Jul–Dec; 45(3–4):145–8 (Eng. Abstr.) **(Rum)**

[The interrelation of autonomic homeostasis and the broncho-obstructive syndrome in patients with chronic bronchitis and the effect of broncholytic therapy with sal'tos] Sokolov AV, et al. **Ter Arkh** 1996;68(11):70–2 **(Rus)**

[Adrenergic beta-2 agonists and their impact on physical performance] Drobnic F. **Arch Bronconeumol** 1997 Mar; 33(3):136–42 (56 ref.) (Eng. Abstr.) **(Spa)**

[Beta-adrenergic agents in asthma (editorial)] Morales AM, et al. **Rev Alerg Mex** 1996 Jan-Feb;43(1):2–4 **(Spa)**

[Update on beta-adrenergic agonists and corticosteroid aerosols (editorial)] Spector S. **Rev Alerg Mex** 1993 Nov-Dec;40(6):i–iv **(Spa)**

[Treatment of irritable colon with lidamidine and support psychotherapy] Rodríguez Magallán A, et al. **Rev Gastroenterol Mex** 1997 Jan-Mar;62(1):7–13 (Eng. Abstr.) **(Spa)**

TOXICITY

Cardiotoxic effects of salmeterol in comparison with salbutamol on the isolated perfused Langendorff-heart of the rat. Prévost A, et al. **Arzneimittelforschung** 1997 Jan; 47(1):39–43

The role of myocardial glycogen content for the development of isoprenaline-induced myocardial lesions in different inbred strains of rats. Mráz M, et al. **Basic Res Cardiol** 1995 Nov-Dec;90(6):467–74

In vitro toxicity and formation of early conjugates in Caco-2 cell line treated with clenbuterol, salbutamol and isoxsuprine. Stammati A, et al. **Eur J Drug Metab Pharmacokinet** 1997 Apr-Jun; 22(2):173–8

An immunotoxicity screening study on salmeterol in rats. de Waal EJ, et al. **Int J Immunopharmacol** 1996 Aug-Sep; 18(8–9):523–8

Increased cardiac workload by adrenoceptor agonists for the estimation of potential antiischemic activity in a conscious rabbit model. Kovanecz I, et al. **J Pharmacol Toxicol Methods** 1997 Apr;37(3):149–59

Protective effect of stobadine on isoproterenol premedicated rabbits. Guzy J, et al. **Pharmazie** 1997 May;52(5):408

URINE

Probenecid, sulfinpyrazone and pyrazinamide do not inhibit urinary excretion of the beta 2-adrenoceptor agonist clenbuterol in cattle. Gleixner A, et al. **Food Addit Contam** 1996 Aug-Sep;13(6):603–8

Effects of drugs which influence renal transport systems on the urinary excretion of the beta 2-adrenoceptor agonist clenbuterol and the anabolic steroids ethinylestradiol and methyltestosterone. Gleixner A, et al. **Food Addit Contam** 1997 Feb-Mar;14(2):143–50

Quantitative multi-residue determination of beta-agonists in bovine urine using on-line immunoaffinity extraction-coupled column packed capillary liquid chromatography-tandem mass spectrometry. Cai J, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):357–70

Comparison and evaluation of the specificity and binding capacity of commercial and in house affinity columns used in sample preparation for analysis of growth-promoting drugs. Crooks SR, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):161–72

Application of a sequential analytical procedure for the detection of the beta-agonist brombuterol in bovine urine samples. Sangiorgi E, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):468–78

Design and applications of a self-aligning liquid junction-electrospray interface for capillary electrophoresis-mass spectrometry. Wachs T, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25;685(2):335–42

Ion trap high-performance liquid chromatography/multiple mass spectrometry in the determination of beta-agonists in bovine urines [letter] Biancotto G, et al. **J Mass Spectrom** 1997 Jul;32(7):781–4

Hyphenation of coupled-column liquid chromatography and thermospray tandem mass spectrometry for the rapid determination of beta 2-agonist residues in bovine urine using direct large-volume sample injection. Set-up of single-residue methods for clenbuterol and salbutamol. Hogendoorn EA, et al. **J Mass Spectrom** 1996 Apr; 31(4):418–26

ADRENERGIC BETA-ANTAGONISTS

Beyond hyperkalemia: beta-blocker-induced cardiac arrest for normothermic cardiac operations. Ede M, et al. **Ann Thorac Surg** 1997 Mar;63(3):721–7

Characterization of pulmonary and myocardial beta-adrenoceptors with S-1'-[fluorine-18]fluorocarazolol. Visser TI, et al. **J Nucl Med** 1997 Feb;38(2):169–74

Perioperative maintenance of normal temperature [letter; comment] Berry AJ. **JAMA** 1997 Aug 20;278(7):545; discussion 545–6. Comment on: JAMA 1997 Apr 9;277(14):1127–34.

[Clinical use of beta-blocker an as antiarrhythmic agent] Okazaki O, et al. **Nippon Rinsho** 1996 Aug;54(8):2117–24 (15 ref.) (Eng. Abstr.) **(Jpn)**

[The beta-adrenomimetic effect of human and animal blood serum] Tsirkin VI. **Fiziol Cheloveka** 1997 May-Jun; 23(3):88–96 **(Rus)**

[30 years of the clinical use of beta-adrenoblockers: achievements and prospectives (editorial)] Sidorenko BA, et al. **Ter Arkh** 1995;67(12):3–8 **(Rus)**

ADMINISTRATION & DOSAGE

Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people. Diggory P, et al. **Age Ageing** 1996 Nov;25(6):424–8

Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure [editorial] Eichhorn

EJ, et al. **Am J Cardiol** 1997 Mar 15;79(6):794–8 (55 ref.)

Comparison between metoprolol orally osmotic once daily and metoprolol two or three times daily in suppressing exercise–induced and daily myocardial ischemia. Tzivoni D, et al. **Am J Cardiol** 1996 Dec 15;78(12):1362–8

Reduction in drug requirements for hypertension by means of a cognitive–behavioral intervention. Shapiro D, et al. **Am J Hypertens** 1997 Jan;10(1):9–17

Evaluation of multiple doses of 4 and 6% timolol, and timolol combined with 2% pilocarpine in clinically normal beagles and beagles with glaucoma. Gelatt KN, et al. **Am J Vet Res** 1995 Oct;56(10):1325–31

Relationship between the amount of propranolol permeating through the stratum corneum of guinea pig skin after application of propranolol adhesive patches and skin irritation. Kobayashi I, et al. **Biol Pharm Bull** 1996 Jun; 19(6):839–44

Potentially hazardous co–prescribing of beta–adrenoceptor antagonists and agonists in the community. Evans JM, et al. **Br J Gen Pract** 1996 Jul;46(408):423–5

Use of ratings of perceived exertion for predicting maximal work rate and prescribing exercise intensity in patients taking atenolol [see comments] Eston RG, et al. **Br J Sports Med** 1997 Jun;31(2):114–9. Comment in: Br J Sports Med 1997 Jun;31(2):93.

Exercise metabolism in healthy volunteers taking celiprolol, atenolol, and placebo [see comments] Head A, et al. **Br J Sports Med** 1997 Jun;31(2):120–5. Comment in: Br J Sports Med 1997 Jun;31(2):93.

Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo–controlled, randomized trial. Basu S, et al. **Circulation** 1997 Jul 1; 96(1):183–91

Comparison of topical timolol gel to oral acetazolamide in the prophylaxis of viscoelastic–induced ocular hypertension after penetrating keratoplasty. Kanellopoulos AJ, et al. **Cornea** 1997 Jan;16(1):12–5

Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. Bakish D, et al. **Int Clin Psychopharmacol** 1997 Mar;12(2):91–7

Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Tome MB, et al. **Int Clin Psychopharmacol** 1997 Mar;12(2):81–9

Symptomatic and hemodynamic recovery following dobutamine stress echo: benefit of low–dose esmolol administration. Abdullah EE, et al. **Int J Card Imaging** 1997 Feb;13(1):53–7

Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration. Martins ML, et al. **Int J Clin Pharmacol Ther** 1997 Aug;35(8):324–8

The determination of additive effect and intraocular pressure lowering effects of 0.05% bromocriptine and 0.25% timolol. Elibol O, et al. **Int Ophthalmol** 1996–97; 20(1–3):53–5

Ocular hypotensive effect of sublingual administration of timolol. Quaranta L, et al. **Int Ophthalmol** 1996–97; 20(1–3):49–51

The effects of long–term topical glaucoma medication on conjunctival impression cytology. Turaçli E, et al. **Int Ophthalmol** 1997;21(1):27–33

Efficacy of silicone punctal plugs as adjuncts to topical pharmacotherapy of glaucoma--a pilot study. Punctal Plugs in Glaucoma Study Group. Bartlett JD, et al. **J Am Optom Assoc** 1996 Nov;67(11):664–8

Ocular tolerability of timolol in Gelrite in young glaucoma patients. Nelson MD, et al. **J Am Optom Assoc** 1996 Nov; 67(11):659–63

Application of ultra short acting beta blockade (esmolol) in pediatric open heart surgery: a trial in total anomalous pulmonary venous return. Matsuda H, et al. **J Card Surg** 1996 Nov–Dec;11(6):411–5; discussion 416

High–dose esmolol and cardiopulmonary bypass for mitral valve replacement in the beating heart. Pivalizza EG, et al. **J Cardiothorac Vasc Anesth** 1997 Jun;11(4):485–6

d–Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy. Dorian P, et al. **J Cardiovasc Electrophysiol** 1996 Oct;7(10):952–61

Pindolol augmentation of tranylcypromine in psychotic depression [letter] Kraus RP. **J Clin Psychopharmacol** 1997 Jun;17(3):225–6

Enhanced acute ocular hypotensive response to timolol with dexamethasone treatment. Rom M, et al. **J Glaucoma** 1997 Apr;6(2):111–6

Structure and function of resistance arteries of hypertensive patients treated with a beta–blocker or a calcium channel antagonist. Schiffrin EL, et al. **J Hypertens** 1996 Oct; 14(10):1247–55

Carboxymethylcellulose–sodium based transdermal drug delivery system for propranolol. Krishna R, et al. **J Pharm Pharmacol** 1996 Apr;48(4):367–70

Recovery of iodine–123 metaiodobenzylguanidine uptake associated with left ventricular functional recovery in a patient with dilated cardiomyopathy. Endomyocardial histological findings before and after the improvement of uptake. Ueda T, et al. **Jpn Heart J** 1997 Jan;38(1):145–50

Randomized trial of oxytocin alone and with propranolol in the management of dysfunctional labor. Sanchez–Ramos L, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):517–20

Efficacy of a novel hydrogel formulation in human volunteers. Mayer H, et al. **Ophthalmologica** 1996; 210(2):101–3

A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Heijl A, et al. **Ophthalmology** 1997 Jan;104(1):137–42

Lower total serum protein, albumin, and beta– and gamma–globulin in major and treatment–resistant depression: effects of antidepressant treatments. Van Hunsel F, et al. **Psychiatry Res** 1996 Dec 20;65(3):159–69

Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Schuman JS. **Surv Ophthalmol** 1996 Nov;41 Suppl 1:S27–37

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Serle JB. **Surv Ophthalmol** 1996 Nov;41 Suppl 1:S39–47

Effects of atenolol as add–on therapy to fosinopril in heart failure. Pacher R, et al. **Wien Klin Wochenschr** 1997 Apr 11;109(7):232–8

[Metoprolol prevents myocardial ischemia during endoscopic retrograde cholangiopancreatography] Rosenberg J, et al. **Ugeskr Laeger** 1997 Sep 8;159(37):5514–8 (Eng. Abstr.) **(Dan)**

[Protection of the heart with beta blockaders] **Internist (Berl)** 1996 Feb;37(2 Suppl):1–4 **(Ger)**

[Early treatment of acute myocardial infarct: implementation of therapy guidelines in routine clinical practice, MITRA pilot phase] Schuster S, et al. **Z Kardiol** 1997 Apr; 86(4):273–83 (Eng. Abstr.) **(Ger)**

[Ophthalmic mucoadhesive vehicles: preliminary study of ocular pharmacokinetics "in vivo"] Chetoni P, et al. **Boll Chim Farm** 1996 Feb;135(2):147–9 **(Ita)**

[The effects of chronic beta–blocker administration on respiratory sinus arrhythmia] Pitzalis MV, et al. **Cardiologia** 1997 Feb;42(2):201–4 (Eng. Abstr.) **(Ita)**

[Time–related effect of betapressin+ in patients with essential hypertension stage II] Zaslavskaia RM, et al. **Klin Med (Mosk)** 1996;74(9):43–5 (Eng. Abstr.) **(Rus)**

[The characteristics of the effect of obzidan on the cardiac hemodynamics in patients with an artificial pacemaker when used one time and over a course of treatment] Iskenderov BG, et al. **Ter Arkh** 1996;68(5):60–3 (Eng. Abstr.) **(Rus)**

[Efficacy of pilocarpine and timolol maleate combination in therapy of glaucoma] Egorov EA, et al. **Vestn Oftalmol** 1996 Jul–Aug;112(3):5–7 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

The effect of hypertonic sodium and dantrolene on propranolol cardiotoxicity. Kerns W 2nd, et al. **Acad Emerg Med** 1997 Jun;4(6):545–51

Glaucoma therapy may take your breath away. Diggory P, et al. **Age Ageing** 1997 Mar;26(2):63–7 (24 ref.)

Stevens–Johnson syndrome associated with carvedilol therapy. Kowalski BJ, et al. **Am J Cardiol** 1997 Sep 1; 80(5):669–70

Cancer risk with calcium–channel–blocker use examined [news] **Am J Health Syst Pharm** 1996 Sep 1;53(17):1999

Glucagon therapy in the treatment of symptomatic bradycardia. Love JN, et al. **Ann Emerg Med** 1997 Jan; 29(1):181–3

Uveitis associated with topical beta–blockers. Beck RW, et al. **Arch Ophthalmol** 1996 Oct;114(10):1181–2

Bilateral anterior uveitis associated with a brand of metipranolol [letter] Watanabe TM, et al. **Arch Ophthalmol** 1997 Mar;115(3):421–2

Cardiac conduction with diltiazem and beta–blockade combined. A review and report on cases. Kjeldsen SE, et al. **Blood Press** 1996 Sep;5(5):260–3 (29 ref.)

The asthma death problem revisited [letter; comment] Ernst P, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):339. Comment on: Br J Clin Pharmacol 1996 Jul;42(1):11–4.

Acute effects of beta blockade and exercise on mood and anxiety. Head A, et al. **Br J Sports Med** 1996 Sep; 30(3):238–42

Sotalol–induced torsades de pointes in patients with renal failure. Dancey D, et al. **Can J Cardiol** 1997 Jan;13(1):55–8

Torsade de pointes with amiodarone in a patient with previous torsade during beta–receptor blockade. Skanes AC, et al. **Can J Cardiol** 1997 Apr;13(4):383–6 (36 ref.)

Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta–blocker. Rosenthal J, et al. **Cardiology** 1996 Sep–Oct;87(5):409–14

Refractory anaphylactoid shock potentiated by beta–blockers. Javeed N, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):383–4 (8 ref.)

Nonselective beta–adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. Demopoulos L, et al. **Circulation** 1997 Apr 1;95(7):1764–7

Systemic side effects of topical beta–adrenergic blockers. Stewart WC, et al. **Clin Cardiol** 1996 Sep;19(9):691–7 (82 ref.)

Beta–blocker induced asthma: a role for sensory nerve hyperresponsiveness? [editorial; comment] Belvisi M. **Clin Exp Allergy** 1996 Dec;26(12):1343–6 (29 ref.). Comment on: Clin Exp Allergy 1996 Dec;26(12):1428–35.

Problem drugs for the patient with asthma. Craig T, et al. **Compr Ther** 1996 Jun;22(6):339–44 (21 ref.)

Contact dermatitis due to levobunolol in eyedrops. Garcia F, et al. **Contact Dermatitis** 1997 Apr;36(4):230

First report of sweating associated with topical beta–blocker therapy [letter] Schmutz JL, et al. **Dermatology** 1997; 194(2):197–8

Sudden cardiac death in patients with hypertension. An association with diuretics and beta–blockers? Hoes AW, et al. **Drug Saf** 1997 Apr;16(4):233–41 (44 ref.)

Involvement of PAF in postallergic propranolol–induced bronchoconstriction in guinea–pigs. Fujimura M, et al. **Eur Respir J** 1996 Oct;9(10):2064–9

Early conjunctival changes following treatment with metipranolol and preservatives are not reversible with dexamethasone. Mietz H, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Jul;235(7):452–9

Torsade de pointes in a patient using usual dose of beta agonist therapy [letter] Chao CL, et al. **Int J Cardiol** 1996 Dec 13;57(3):295–6

Painless Prinzmetal's ST elevation related to propranolol: a case report. Lin YJ, et al. **Int J Cardiol** 1997 Aug 8; 60(3):311–4

The effects of antiglaucomatous agents on conjunctiva used for various durations. Aritürk N, et al. **Int Ophthalmol** 1996–97;20(1–3):57–62

Atenolol–induced lupus erythematosus. McGuiness M, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):298–9 (16 ref.)

Cardiac arrest after esmolol administration: a review of acute beta–blocker toxicity. Litman RS, et al. **J Am Osteopath Assoc** 1996 Oct;96(10):616–8 (27 ref.)

Hemodynamic predictors of early intolerance and long–term effects of propranolol in dilated cardiomyopathy. Talwar KK, et al. **J Card Fail** 1996 Dec;2(4):273–7

Eye drops and lethargy. Vahidassr MD, et al. **J R Soc Med** 1997 Mar;90(3):155

Successful haemodialysis in sotalol–induced torsade de pointes in a patient with progressive renal failure. van Uum SH, et al. **Nephrol Dial Transplant** 1997 Feb;12(2):331–3

Validation of a questionnaire for comparing the tolerability of ophthalmic medications [published erratum appears in Ophthalmology 1997 May;104(5):736, 890–3] Barber BL, et al. **Ophthalmology** 1997 Feb;104(2):334–42

Cardiopulmonary compromise after use of topical and submucosal alpha–agonists: possible added complication by the use of beta–blocker therapy. Kalyanaraman M, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):56–61 (32 ref.)

Adverse CNS–effects of beta–adrenoceptor blockers. Gleiter CH, et al. **Pharmacopsychiatry** 1996 Nov;29(6):201–11 (142 ref.)

Atenolol induced memory impairment: a case report. Ramanathan M. **Singapore Med J** 1996 Apr;37(2):218–9

Xerostomia: prevalence and pharmacotherapy. With special reference to beta–adrenoceptor antagonists. Nederfors T. **Swed Dent J Suppl** 1996;116:1–70

[Bradycardia after beginning therapy with metoprolol and paroxetine] König F, et al. **Psychiatr Prax** 1996 Sep; 23(5):244–5 (Eng. Abstr.) **(Ger)**

[Beta–blocking eyedrops and adverse effects] Landmark K. **Tidsskr Nor Laegeforen** 1997 May 30;117(14):2018 **(Nor)**

[Adverse effects of local use of beta–blockaders in glaucoma. A literature review and a survey of reports to the adverse drug reaction authority 1986–95] Nygaard HA, et al. **Tidsskr Nor Laegeforen** 1997 May 30;117(14):2019–21 (31 ref.) (Eng. Abstr.) **(Nor)**

ANALYSIS

Performance of micellar mobile phases in reversed–phase chromatography for the analysis of pharmaceuticals containing beta–blockers and other antihypertensive drugs. Rapado–Martínez I, et al. **Analyst** 1996 Nov; 121(11):1677–82

Solid–phase extraction and derivatisation methods for beta–blockers in human post mortem whole blood, urine and equine urine. Black SB, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):67–80

Determination of sotalol in human cardiac tissue by high–performance liquid chromatography. Läer S, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):291–8

Liquid chromatographic sample cleanup coupled on–line with gas chromatography in the analysis of beta–blockers in human serum and urine. Hyötyläinen T, et al. **J Chromatogr Sci** 1997 Jun;35(6):280–6

Determination of the dihydropyridine aryloxypropanolamine Z6568 and its acidic metabolites in plasma, urine and tissues by solid phase extraction and liquid chromatography/negative–ion mass spectrometry. Gregori M, et al. **J Mass Spectrom** 1996 Sep;31(9):994–1002

Determination of beta–blocker drugs in pharmaceutical preparations by non–suppressed ion chromatography. Ghanem R, et al. **J Pharm Biomed Anal** 1996 Dec; 15(3):383–8

Development and validation of a capillary zone electrophoretic method for the determination of atenolol in presence of its related substances in bulk and tablet dosage form. Shafaati A, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1547–54

Enantioseparation of beta–blockers labelled with a chiral fluorescent reagent, R (–)–DBD–PyNCS, by reversed–phase liquid chromatography. Toyo'oka T, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1467–76

Densitometric determination of metoprolol tartrate in pharmaceutical dosage forms. Vujic Z, et al. **J Pharm Biomed Anal** 1997 Feb;15(5):581–5

BLOOD

Chiral assay of atenolol present in microdialysis and plasma samples of rats using chiral CBH as stationary phase. Fornstedt T, et al. **Chirality** 1997;9(4):329–34

Exercise increases plasma concentrations of (R)- and (S)-propranolol. Stoschitzky K, et al. **Eur J Clin Pharmacol** 1996;50(4):339–42

Efficient assay for the determination of atenolol in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Chiu FC, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):473–7

Comparison of the Hummel-Dreyer method in high-performance liquid chromatography and capillary electrophoresis conditions for study of the interaction of (RS)-, (R)- and (S)-carvedilol with isolated plasma proteins. Oravcova J, et al. **J Chromatogr B Biomed Appl** 1996 Jul 12;682(2):349–57

Liquid chromatographic determination of total celiprolol or (S)-celiprolol and (R)-celiprolol simultaneously in human plasma. Verbesselt R, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30;683(2):231–6

Stereoselective high-performance liquid chromatography determination of propranolol and 4-hydroxypropranolol in human plasma after pre-column derivatization. Wu ST, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25; 692(1):133–40

4-(6-methoxy-2-naphthyl)-2-butyl chloroformate enantiomers: new reagents for the enantiospecific analysis of amino compounds in biogenic matrices. Büschges R, et al. **J Pharm Biomed Anal** 1996 Nov;15(2):201–20

Enantioselective determination of oxprenolol in human plasma using dialysis coupled on-line to reversed-phase chiral liquid chromatography. Ceccato A, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1365–74

A fluorimetric liquid chromatographic method for the determination of propranolol in human serum/plasma. Rekhi GS, et al. **J Pharm Biomed Anal** 1995 Nov; 13(12):1499–505

CHEMICAL SYNTHESIS

"Vinylogs" and "acetylenylogs" of beta-adrenergic agents. Nudelman A, et al. **Arch Pharm (Weinheim)** 1996 Mar; 329(3):125–32

Studies on agents with vasodilator and beta-blocking activities. IV. Seki T, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2061–9

Synthesis and beta-adrenoreceptor blocking activity of [[3-(alkylamine)-2-hydroxypropyl]oximino]pyridines and O[3-(alkylamine)-2-hydroxypropyl]methylpyridine ketone oximes derivatives. Manna F, et al. **Farmaco** 1996 Aug–Sep; 51(8–9):579–87

Beta-adrenoreceptor blocking heterocyclic oximes and ethers. Manna F, et al. **Farmaco** 1996 Nov;51(11):699–706

Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma. Boder N, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):115–22

Synthesis and preliminary evaluation of (R,S)-1-[2-((carbamoyl-4-hydroxy)phenoxy)-ethylamino]-3-[4-(1-[11C]-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol ([11C]CGP 20712A) as a selective beta 1-adrenoceptor ligand for PET. Elsinga PH, et al. **Nucl Med Biol** 1994 Feb;21(2):211–7

Development of radioligands for the imaging of cardiac beta-adrenoceptors using SPECT. Part I: Asymmetric synthesis and structural characterization of five new iodine-containing beta-adrenoceptor antagonist derivatives. van den Bos JC, et al. **Nucl Med Biol** 1997 Jan;24(1):1–7

Comparative studies on beta-adrenolytic potencies of some new phenoxyaminopropanol derivatives and celiprolol. Mlynárová R, et al. **Pharmazie** 1997 Mar;52(3):234–7

CHEMISTRY

Preformulation studies of atenolol in oral liquid dosage form. I. Effect of pH and temperature. Hatem A, et al. **Acta Pharm Hung** 1996 Jul;66(4):177–80

Toxic doses of rac-, (-)-(S)- and (+)-(R)-propranolol in rats and rabbits. Toet AE, et al. **Chirality** 1996;8(6):411–7

Correlation of drug absorption with molecular surface properties. Palm K, et al. **J Pharm Sci** 1996 Jan;85(1):32–9

Tensioactivity and supramolecular organization of the palmitoyl prodrug of timolol. Pech B, et al. **Pharm Res** 1997 Jan;14(1):37–41

[Transdermal administration of drugs. XI. Formulation of polymeric matrices with metoprolol in transdermal therapeutic systems] Kučera J, et al. **Ceska Slov Farm** 1996 Jul;45(4):185–90 (Eng. Abstr.) **(Cze)**

[Chiral separation of seven beta-blockers in the French pharmacopoeia] Berthault F, et al. **Ann Pharm Fr** 1997; 55(1):12–9 (Eng. Abstr.) **(Fre)**

CONTRAINDICATIONS

Three rules of thumb [letter] Newcomb RD. **J Am Optom Assoc** 1996 Nov;67(11):645, 706

[The systemic problems in the dental treatment of the elderly patients] Matsuura H. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):505–7 (0 ref.) **(Jpn)**

DIAGNOSTIC USE

Comments on the study by Bono et al [letter; comment] Blankesteijn WM, et al. **Am J Hypertens** 1996 Jul;9(7):708–9 . Comment on: Am J Hypertens 1995 May;8(5 Pt 1):487–93.

Stress-induced ST-segment elevation after a recent myocardial infarction: myocardial necrosis, viability or both? [editorial; comment] Elhendy A, et al. **Eur Heart J** 1996 Jul;17(7):975–7. Comment on: Eur Heart J 1996 Jul;17(7):1008–14.

Dobutamine stress echocardiography. Krahwinkel W, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D9–15 (48 ref.)

Significance of ST-segment elevation during dobutamine-stress echocardiography in patients with acute myocardial infarction treated with thrombolysis [see comments] Lanzarini L, et al. **Eur Heart J** 1996 Jul; 17(7):1008–14. Comment in: Eur Heart J 1996 Jul;17(7):975–7.

Effects of combined beta-adrenergic and cholinergic blockade on the initial ventilatory response to exercise in humans. Ishida K, et al. **Eur J Appl Physiol** 1997; 76(3):230–5

Pharmacologic characterization in vitro and in vivo of iodine 123-labeled derivatives of the beta-adrenoceptor antagonist CGP12177, designed for the imaging of cardiac beta-receptors. Dubois EA, et al. **J Nucl Cardiol** 1996 May-Jun;3(3):242–52

Imaging beta-adrenoceptors in the human brain with (S)-1'-[18F]fluorocarazolol. van Waarde A, et al. **J Nucl Med** 1997 Jun;38(6):934–9

(S,S)- and (S,R)-1'-[18F]fluorocarazolol, ligands for the visualization of pulmonary beta-adrenergic receptors with PET. Elsinga PH, et al. **Nucl Med Biol** 1996 Feb; 23(2):159–67

ECONOMICS

Daily cost of beta-adrenergic blocker therapy [see comments] Stewart WC, et al. **Arch Ophthalmol** 1997 Jul;115(7):853–6 . Comment in: Arch Ophthalmol 1997 Jul;115(7):914.

Cost of beta-blocker therapy [editorial; comment] Zimmerman TJ. **Arch Ophthalmol** 1997 Jul;115(7):914. Comment on: Arch Ophthalmol 1997 Jul;115(7):853–6.

The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment. Johannesson M. **J Hum Hypertens** 1996 Feb;10 Suppl 2:S23–6

Budget cut for budget deficit versus beta-blocker for chronic heart failure [letter] Lee YC. **Md Med J** 1996 Feb;45(2):98

[Prescribing practice for beta blockers at patient discharge to ambulatory care. A health care economic evaluation in a cardiology patient sample with special reference to drug budgeting] Weltermann B, et al. **Gesundheitswesen** 1997 Apr;59(4):258–61 (Eng. Abstr.) **(Ger)**

[Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany] Schädlich PK, et al. **Med Klin** 1997 Aug 15;92(8):499–504 (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Three approaches to enantiomer separation of beta-adrenergic antagonists by capillary electrochromatography. Nilsson S, et al. **Electrophoresis** 1997 Jun;18(6):884–90

Enantiomeric separation of denopamine by capillary electrophoresis and high-performance liquid chromatography using cyclodextrins. Nishi H, et al. **J Pharm Biomed Anal** 1995 Nov;13(12):1483–92

[Endogenous blocker of beta-adrenoreceptors] Tsirkin VI, et al. **Biull Eksp Biol Med** 1997 Mar;123(3):248–52 **(Rus)**

METABOLISM

Relationship between amount of beta-blockers permeating through the stratum corneum and skin irritation after application of beta-blocker adhesive patches to guinea pig skin. Kobayashi I, et al. **Biol Pharm Bull** 1997 Apr; 20(4):421–7

Stereoselectivity in bunitrolol 4-hydroxylation in liver microsomes from marmosets and Japanese monkeys. Narimatsu S, et al. **Biol Pharm Bull** 1996 Nov; 19(11):1429–33

Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes. Rowland K, et al. **Br J Clin Pharmacol** 1996 Sep;42(3):390–3

Cytochrome P450 enzymes involved in the enhancement of propranolol N-desisopropylation after repeated administration of propranolol in rats. Narimatsu S, et al. **Chem Biol Interact** 1996 Sep 6;101(3):207–24

Covalent binding of a reactive metabolite derived from propranolol and its active metabolite 4-hydroxypropranolol to hepatic microsomal proteins of the rat. Narimatsu S, et al. **Chem Res Toxicol** 1997 Mar; 10(3):289–95

Characterization of the beta 2 adrenoceptors of dog liver. García-Sáinz JA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Sep;115(1):61–5

A sensitive method for determination of cytochrome P4502D6 activity in vitro using bupranolol as substrate. Appanna G, et al. **Drug Metab Dispos** 1996 Mar;24(3):303–6

Inhibition of metoprolol metabolism by amino acids in perfused rat livers. Insights into the food effect? Wang BO, et al. **Drug Metab Dispos** 1997 Mar;25(3):287–95

Triiodothyronine and amiodarone effects on beta 3-adrenoceptor density and lipolytic response to the beta 3-adrenergic agonist BRL 37344 in rat white adipocytes. Germack R, et al. **Fundam Clin Pharmacol** 1996; 10(3):289–97

Distribution of metoprolol enantiomers in a fatal overdose. Mozayani A, et al. **J Anal Toxicol** 1995 Oct;19(6):519–21

Cloning and functional characterization of the ornithokinin receptor. Recognition of the major kinin receptor antagonist, HOE140, as a full agonist. Schroeder C, et al. **J Biol Chem** 1997 May 9;272(19):12475–81

Direct high-performance liquid chromatography determination of diastereomeric oxprenolol glucuronides. Laethem ME, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26;675(2):251–5

Three-dimensional models for agonist and antagonist complexes with beta 2 adrenergic receptor. Kontoyianni M, et al. **J Med Chem** 1996 Oct 25;39(22):4406–20

Determination of the binding of a beta 2-blocker drug, frusemide and ceftriaxone to serum proteins by capillary zone electrophoresis. Quaglia MG, et al. **J Pharm Biomed Anal** 1997 May;15(8):1033–9

In-vitro metabolic interaction of bunitrolol enantiomers in rabbit liver microsomes. Narimatsu S, et al. **J Pharm Pharmacol** 1996 Nov;48(11):1185–9

Binding of beta 1-adrenoceptor antagonist [3H]CGP 26505 in rat cerebral cortex and sinus atrial node. Chiellini G, et al. **Neurochem Res** 1996 Oct;21(10):1149–53

Pharmacogenetics and heart failure: a convergence with carvedilol [editorial] Meadowcroft AM, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):637–9

PHARMACOKINETICS

Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. Jacobs G, et al. **Am J Vet Res** 1997 Apr;58(4):398–403

Pharmacokinetics of atenolol in clinically normal cats. Quiñones M, et al. **Am J Vet Res** 1996 Jul;57(7):1050–3

Disposition of human drug preparations in the horse. V. Orally administered oxprenolol. Delbeke FT. **Biomed Chromatogr** 1996 Jul–Aug;10(4):172–8

Renal, biliary and intestinal clearance of sotalol enantiomers in rat model: evidence of intestinal exsorption. Carr RA, et al. **Biopharm Drug Dispos** 1996 Nov;17(8):725–35

Influence of cimetidine coadministration on the pharmacokinetics of sotalol enantiomers in an anaesthetized rat model: evidence supporting active renal excretion of sotalol. Carr RA, et al. **Biopharm Drug Dispos** 1996 Jan; 17(1):55–69

Pharmacokinetics of acebutolol enantiomers after intravenous administration of racemate in a rat model: a dosing range comparison. Mostafavi SA, et al. **Biopharm Drug Dispos** 1997 Jul;18(5):397–408

Pharmacokinetics and multiple peaking of acebutolol enantiomers in rats. Piquette-Miller M, et al. **Biopharm Drug Dispos** 1997 Aug;18(6):543–56

Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Cheymol G, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):563–70

Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. Sowinski KM, et al. **Br J Clin Pharmacol** 1996 Sep; 42(3):339–46

Aging effects on the organic base transporter and stereoselective renal clearance. Ujhelyi MR, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):117–28

Permeability characteristics of primary cultured rabbit conjunctival epithelial cells to low molecular weight drugs. Saha P, et al. **Curr Eye Res** 1996 Dec;15(12):1170–4

In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Oldham HG, et al. **Drug Metab Dispos** 1997 Aug;25(8):970–7

Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Cheymol G, et al. **Eur J Clin Pharmacol** 1997;51(6):493–8

Increased sensitivity of propranolol clearance to reduced oxygen delivery in the isolated perfused cirrhotic rat liver. Hickey PL, et al. **Gastroenterology** 1996 Oct;111(4):1039–48

How can the bioavailability of timolol be enhanced? A pharmacokinetic pilot study of novel hydrogels. von der Ohe N, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jul; 234(7):452–6

Bioequivalence studies of celiprolol in healthy human volunteers. Iyer EK, et al. **Indian J Med Sci** 1996 Jul; 50(7):234–8

Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers. Deroubaix X, et al. **Int J Clin Pharmacol Ther** 1996 Feb; 34(2):61–70

Comparative pharmacokinetics of two brands of atenolol following a single oral administration. Irshaid YM, et al. **Int J Clin Pharmacol Ther** 1996 Oct;34(10):457–61

Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers. Koch HJ, et al. **Int J Clin Pharmacol Ther** 1996 Oct;34(10):420–3

Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose

administration. Martins ML, et al.
Int J Clin Pharmacol Ther 1997 Aug;35(8):324–8

Location of the hydroxyl functions in hydroxylated metabolites of nebivolol in different animal species and human subjects as determined by on-line high-performance liquid chromatography-diode-array detection. Hendrickx J, et al. **J Chromatogr A** 1996 Apr 5;729(1–2):341–54

Ocular mini-tablets for controlled release of timolol: evaluation in rabbits. Chetoni P, et al.
J Ocul Pharmacol Ther 1996 Fall;12(3):245–52

Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. Chiang CH, et al.
J Ocul Pharmacol Ther 1996 Winter;12(4):471–80

Bioavailability and in-vitro/in-vivo correlation for propranolol hydrochloride extended-release bead products prepared using aqueous polymeric dispersions. Rekhi GS, et al. **J Pharm Pharmacol** 1996 Dec;48(12):1276–84

In-situ ocular absorption of ophthalmic beta-blockers through ocular membranes in albino rabbits. Sasaki H, et al. **J Pharm Pharmacol** 1997 Feb;49(2):140–4

Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. Terao T, et al. **J Pharm Pharmacol** 1996 Oct; 48(10):1083–9

Stereoselective pharmacokinetics of bisoprolol after intravenous and oral administration in beagle dogs. Horikiri Y, et al. **J Pharm Sci** 1997 May;86(5):560–4

Correlation of drug absorption with molecular surface properties. Palm K, et al. **J Pharm Sci** 1996 Jan;85(1):32–9

In situ ocular absorption of tilisolol through ocular membranes in albino rabbits. Sasaki H, et al.
J Pharm Sci 1996 Sep;85(9):940–3

Unified model for the corneal permeability of related and diverse compounds with respect to their physicochemical properties. Yoshida F, et al. **J Pharm Sci** 1996 Aug; 85(8):819–23

Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. Lipka E, et al.
J Pharmacokinet Biopharm 1995 Jun;23(3):267–86

Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. Muir WW, et al. **J Vet Pharmacol Ther** 1996 Aug; 19(4):259–67

Specific in vivo binding in the rat brain of [18F]RP 62203: a selective 5-HT2A receptor radioligand for positron emission tomography. Besret L, et al. **Nucl Med Biol** 1996 Feb;23(2):169–71

Evaluation of stereoselective transdermal transport and concurrent cutaneous hydrolysis of several ester prodrugs of propranolol: mechanism of stereoselective permeation. Ahmed S, et al. **Pharm Res** 1996 Oct;13(10):1524–9

Bioequivalence of a highly variable drug: an experience with nadolol. Buice RG, et al. **Pharm Res** 1996 Jul;13(7):1109–15

Intracerebral penetration of carteolol hydrochloride in rats. Kudo S, et al. **Psychopharmacology (Berl)** 1997 Jun; 131(4):388–93

[Ophthalmic mucoadhesive vehicles: preliminary study of ocular pharmacokinetics "in vivo"] Chetoni P, et al.
Boll Chim Farm 1996 Feb;135(2):147–9 **(Ita)**

[The effect of phenobarbital and cimetidine on the elimination kinetics and distribution in the heart and liver of propranolol in rats with acute and chronic inflammations] Lutsevich AN, et al. **Eksp Klin Farmakol** 1996 May-Jun; 59(3):47–52 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Esmolol for hypotensive anesthesia in middle ear surgery. Pilli G, et al. **Acta Anaesthesiol Belg** 1996;47(2):85–91

Haemodynamic effects of high-dose vecuronium compared with pancuronium in beta-blocked patients with coronary artery disease during fentanyl-diazepam-nitrous oxide anaesthesia. Husby P, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):26–31

Effect of esmolol on the heart rate, arterial pressure and electrocardiographic changes during laryngomicroscopy. Korpinen R, et al. **Acta Anaesthesiol Scand** 1997 Mar; 41(3):371–5

A comparison of lidocaine, fentanyl, and esmolol for attenuation of cardiovascular response to laryngoscopy and tracheal intubation. Feng CK, et al.
Acta Anaesthesiol Sin 1996 Jun;34(2):61–7

No further improvement of ischaemic myocardial metabolism by combining preconditioning with beta-blockade: an in vivo experimental study in the pig heart using a microdialysis technique. Wikström BG, et al.
Acta Physiol Scand 1997 Jan;159(1):23–32

Synthesis of new 6,7-dichloro-3,4-dihydroisoquinoline derivatives and their actions at the adrenoreceptors. Glinka R, et al. **Acta Pol Pharm** 1995 May-Jun;52(3):241–4

Dexmedetomidine, diazepam, and propranolol in the treatment of ethanol withdrawal symptoms in the rat. Riihioja P, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):804–8

Heterogeneous aortic response to acute beta-adrenergic blockade in Marfan syndrome. Haouzi A, et al.
Am Heart J 1997 Jan;133(1):60–3

Treatment and post-treatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension. Schobel HP, et al.
Am Heart J 1996 Nov;132(5):1004–9

Metoprolol abolishes exercise-induced left ventricular dysfunction in patients with silent ischemia. Bech J, et al. **Am J Cardiol** 1996 Oct 15;78(8):871–5

Impact of metoprolol on heart rate, blood pressure, and contractility in normal subjects during dobutamine stress echocardiography. Marcovitz PA, et al. **Am J Cardiol** 1997 Aug 1;80(3):386–8

Neither physical exercise nor alpha 1- and beta-adrenergic blockade affect plasma endothelin concentrations. Cosenzi A, et al. **Am J Hypertens** 1996 Aug;9(8):819–22

Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade. Himmelmann A, et al. **Am J Hypertens** 1996 Sep;9(9):850–3

beta 1-and beta 2-adrenergic receptors exhibit differing susceptibility to muscarinic accentuated antagonism. Aprigliano O, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2726–35

Beta-blockade reduces effects of adenosine and carbachol by transregulation of inhibitory receptors and Gi proteins. Borst MM, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1672–9

Whole body and splanchnic metabolic and circulatory effects of glucose during beta-adrenergic receptor inhibition. Brundin T, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E678–87

Effects of ACE inhibition and beta-blockade on skeletal muscle fiber types in dogs with moderate heart failure. Sabbah HN, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H115–20

The cardiovascular responses to double lumen endobronchial intubation and the effect of esmolol. Thompson JP, et al. **Anaesthesia** 1997 Aug;52(8):790–4

Esmolol reduces anesthetic requirement for skin incision during propofol/nitrous oxide/morphine anesthesia. Johansen JW, et al. **Anesthesiology** 1997 Feb;86(2):364–71

Daily changes in sympathetic activity. The thermoregulatory effects of the beta blocker propranolol. Haim A, et al.
Ann N Y Acad Sci 1997 Mar 15;813:73–7

Arrhythmogenic effect of beta-adrenoceptor-blocking drugs in Purkinje fibres of guinea-pig hearts. Lemmens-Gruber R, et al. **Arch Int Pharmacodyn Ther** 1996 Jan-Feb; 331(1):46–58

Quantitative measurement of the effects of caffeine and propranolol on surgeon hand tremor. Humayun MU, et al. **Arch Ophthalmol** 1997 Mar;115(3):371–4

"Vinylogs" and "acetylenylogs" of beta-adrenergic agents. Nudelman A, et al. **Arch Pharm (Weinheim)** 1996 Mar; 329(3):125–32

Effects of acute cardioselective and non-selective beta-adrenergic blockade on plasma ammonia levels in exercising dogs. Matthys D, et al.
Arch Physiol Biochem 1996;104(1):14–9

Impact of a combination of a calcium antagonist and a beta-blocker on cell- and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells. Lesnik P, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):979–88

Effects of oxprenolol treatment on pseudocholinesterase and lipids in rats. Krnić Z, et al. **Arzneimittelforschung** 1997 Aug;47(8):910–3

Effect of Apafant on bronchial hyperresponsiveness and down-regulation of beta-adrenoceptors induced by endotoxin in guinea pigs. Sugimoto Y, et al.
Arzneimittelforschung 1997 Jul;47(7):837–41

Acquisition of a runway motor learning task is impaired by a beta adrenergic antagonist in F344 rats. Heron C, et al. **Behav Brain Res** 1996 Aug;78(2):235–41

Inhibitory avoidance impairments induced by intra-amygdala propranolol are reversed by glutamate but not glucose. Lennartz RC, et al. **Behav Neurosci** 1996 Oct;110(5):1033–9

Beneficial effect induced by a beta-adrenoceptor blocker on fetal growth in streptozotocin-diabetic rats. Clabaut M, et al. **Biol Neonate** 1997;71(3):171–80

Effects of chronic administration of bopindolol on the binding characteristics of cardiac alpha 1H-, alpha 1L-, beta 1- and beta 2-adrenoceptor subtypes in cardiac muscles of spontaneously hypertensive rats (SHR). Hosohata Y, et al. **Biol Pharm Bull** 1996 Jul;19(7):932–5

beta-Adrenoreceptor antagonistic actions and mutagenicities of R(+)- and S(-)-enantiomers of N-desisopropylpropranolol and its N-acetyl conjugate. Ono Y, et al. **Biol Pharm Bull** 1997 Jan;20(1):61–5

Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats. Shibasaki K, et al. **Biol Pharm Bull** 1997 Mar;20(3):230–6

Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs. Loan PB, et al. **Br J Anaesth** 1997 Jan;78(1):90–1

Effects of chronic beta-blockade on compensatory mechanisms during acute isovolaemic haemodilution in patients with coronary artery disease. Spahn DR, et al. **Br J Anaesth** 1997 Apr;78(4):381–5

Bisoprolol attenuates noradrenaline- and phenylephrine-evoked venoconstriction in man in vivo. Abdelmawla AH, et al. **Br J Clin Pharmacol** 1997 Jul; 44(1):61–8

The effects of combined treatment with beta 1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects. Eagles CJ, et al. **Br J Clin Pharmacol** 1997 Mar; 43(3):291–300

A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects. Ferro A, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):301–8

The effect of acute vs chronic treatment with beta-adrenoceptor blockade on exercise performance, haemodynamic and metabolic parameters in healthy men and women. Gullestad L, et al. **Br J Clin Pharmacol** 1996 Jan;41(1):57–67

(−)-Timolol is a more potent antagonist of the positive inotropic effects of (−)-adrenaline than of those of (−)-noradrenaline in human atrium. Wang T, et al.
Br J Clin Pharmacol 1996 Aug;42(2):217–23

Some effects of nipradilol, a beta-antagonist possessing a nitroxy group, on smooth muscle of the pig coronary artery. Abe S, et al. **Br J Pharmacol** 1996 Apr; 117(8):1707–15

Capsinolol: the first beta-adrenoceptor blocker with an associated calcitonin gene-related peptide releasing activity in the heart. Chen IJ, et al. **Br J Pharmacol** 1996 Sep; 119(1):7–14

Effects of beta-adrenoceptor antagonists on Ca(2+)-overload induced by lysophosphatidylcholine in rat isolated cardiomyocytes. Chen M, et al.
Br J Pharmacol 1996 Jun;118(4):865–70

Characteristics of cyanopindolol analogues active at the beta 3-adrenoceptor in rat ileum. Hoey AJ, et al.
Br J Pharmacol 1996 Oct;119(3):564–8

(-)-CGP 12177-induced increase of human atrial contraction through a putative third beta-adrenoceptor. Kaumann AJ.
Br J Pharmacol 1996 Jan;117(1):93–8

Differences between the third cardiac beta-adrenoceptor and the colonic beta 3-adrenoceptor in the rat. Kaumann AJ, et al. **Br J Pharmacol** 1996 Aug;118(8):2085–98

Mediation of the positive chronotropic effect of CGP 12177 and cyanopindolol in the pithed rat by atypical beta-adrenoceptors, different from beta 3-adrenoceptors. Malinowska B, et al. **Br J Pharmacol** 1996 Mar;117(5):943–9

Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Manara L, et al.
Br J Pharmacol 1996 Feb;117(3):435–442

Beta adrenergic blocking drugs and the Borg rating scale of perceived exertion [comment] Pedoe DT.
Br J Sports Med 1997 Jun;31(2):93. Comment on: Br J Sports Med 1997 Jun;31(2):120–5. Comment on: Br J Sports Med 1997 Jun;31(2):114–9.

Ca(2+)-antagonistic action of bevantolol on hypothalamic neurons in vitro: its comparison with those of other beta-adrenoceptor antagonists, a local anesthetic and a Ca(2+)-antagonist. Omura T, et al. **Brain Res** 1996 Jan 15;706(2):289–92

Human sleep EEG following the 5-HT1A antagonist pindolol: possible disinhibition of raphe neuron activity. Seifritz E, et al. **Brain Res** 1997 Jun 6;759(1):84–91

Comparison of nifedipine and metoprolol on collateral coronary blood flow in a swine model of chronic coronary obstruction and acute ischaemia during isoflurane anaesthesia. Cheng DC, et al. **Can J Anaesth** 1996 Feb; 43(2):160–8

Esmolol blunts the haemodynamic responses to tracheal intubation in treated hypertensive patients. Sharma S, et al. **Can J Anaesth** 1996 Aug;43(8):778–82

Differentiation of binding sites of CGP12177, a beta 3-adrenoceptor partial agonist, and carteolol, a beta 1/beta 2-adrenoceptor partial agonist, to the beta-adrenoceptors in guinea-pig taenia caecum. Koike K, et al.
Can J Physiol Pharmacol 1996 Aug;74(8):928–33

Effect of progressive incremental exercise and beta-adrenergic blockade on erythrocyte ion concentrations. McKelvie RS, et al.
Can J Physiol Pharmacol 1997 Jan;75(1):19–25

Synergism between prostaglandin E2 and isoproterenol in stimulating glucose oxidation in the heart. Olley PM, et al. **Can J Physiol Pharmacol** 1996 May;74(5):590–7

Beta-blockade prevents ventricular failure following aortic regurgitation in rabbits. Suzuki M, et al. **Cardiology** 1997 Sep-Oct;88(5):418–24

Acute effects of celiprolol on angiographically normal and stenotic coronary arteries. Jost S, et al.
Cardiovasc Drugs Ther 1997 Apr;11(2):133–8

Contrasting effects of betaxolol and propranolol on Ca(2+)-activated contractions in skinned fibers from canine coronary arteries and ventricular muscles. Kitada Y. **Cardiovasc Drugs Ther** 1996 Nov;10(5):581–6

1,4-Dihydropyridines versus beta-blockers for hypertension: are either safe for the heart? [editorial] Leenen FH.
Cardiovasc Drugs Ther 1996 Sep;10(4):397–402

Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Ruffolo RR Jr, et al. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:247–56 (77 ref.)

Contrasting actions of celiprolol and metoprolol on cardiac performance in normal volunteers. Silke B, et al.
Cardiovasc Drugs Ther 1997 Mar;11(1):57–61

Beta-blockers inhibit the modification of low-density lipoproteins by sodium hypochlorite in vitro. Seifert T, et al. **Chem Phys Lipids** 1997 Jan 17;85(1):13–21

Greater effects of fluoxetine and its combination with (-)-pindolol in elevating hypothalamic serotonin in rats

during dark hours. Dreshfield LJ, et al. **Chin J Physiol** 1997 Jun 30;40(2):57–61

Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Knight CJ, et al. **Circulation** 1997 Jan 7;95(1):125–32

Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Wollert KC, et al. **Circulation** 1997 Apr 1;95(7):1910–7

Negative chronotropic effect of beta-blockade therapy reduces myocardial oxygen expenditure for nonmechanical work. Yamakawa H, et al. **Circulation** 1996 Aug 1; 94(3):340–5

The effect of propranolol on sleep bruxism: hypothetical considerations based on a case study. Sjöholm TT, et al. **Clin Auton Res** 1996 Feb;6(1):37–40

Effects of ACE inhibition and beta-blockade on collagen remodelling in the heart of Bio 14.6 hamsters. Mansoor AM, et al. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):43–9

Improving effect of carteolol on bodyweight and carbohydrate and lipid metabolic responses in the OLETF rat. Saitoh Y, et al. **Clin Exp Pharmacol Physiol** 1997 May; 24(5):321–5

Effects of chronic treatment with carvedilol on abnormalities of endothelium-dependent relaxation and structure of endothelium in resistance arteries of SHRSP. Sasaki F, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S329–30

Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. Schmetterer L, et al. **Clin Pharmacol Ther** 1997 May;61(5):583–95

Effect of beta-blocking agents with and without intrinsic sympathomimetic activity on work efficiency in healthy men. Mäki T, et al. **Clin Physiol** 1996 Sep;16(5):543–50

Propranolol blocks the stimulatory effects of naloxone on ventilation and oxygen consumption in hamsters. Schlenker EH, et al. **Comp Biochem Physiol A Physiol** 1997 Jun; 117(2):177–82

Effect of one week of levobunolol HCl 0.5% on the human retinal circulation. Bloom AH, et al. **Curr Eye Res** 1997 Mar;16(3):191–6

Effect of a beta-adrenergic antagonist, propranolol, on induced HSV-1 ocular recurrence in latently infected rabbits. Garza HH Jr, et al. **Curr Eye Res** 1997 May; 16(5):453–8

No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects. Toft-Nielsen M, et al. **Diabet Med** 1996 Jun; 13(6):544–8

Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Dunn CJ, et al. **Drugs** 1997 Jul;54(1):161–85 (179 ref.)

Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Cheymol G, et al. **Eur J Clin Pharmacol** 1997;51(6):493–8

The differentiation of propafenone from other class Ic agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action. Faber TS, et al. **Eur J Clin Pharmacol** 1996;51(3-4):199–208 (103 ref.)

Effects of carvedilol and atenolol on arterial pulse curves (plethysmography) and finger temperature after hand cooling. Klemsdal TO, et al. **Eur J Clin Pharmacol** 1996; 50(6):483–9

Acute effects of celiprolol on muscle blood flow and insulin sensitivity: studies using [15O]-water, [18F]-fluorodeoxyglucose and positron emission tomography. Malminiemi K, et al. **Eur J Clin Pharmacol** 1997;52(1):19–26

Pharmacological properties of nebivolol in man. Van Bortel LM, et al. **Eur J Clin Pharmacol** 1997;51(5):379–84

Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. Brunvand H, et al. **Eur J Pharmacol** 1996 Oct 24; 314(1–2):99–107

A mechanistic study of beta-adrenoceptor antagonists on ethanol-induced gastric damage. Kaan SK, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):115–22

The antiaggressive potency of (-)-penbutolol involves both 5-HT1A and 5-HT1B receptors and beta-adrenoceptors. Sánchez C, et al. **Eur J Pharmacol** 1996 Feb 15;297(1–2):1–8

Effect of long-term topical betaxolol on tissue circulation in the iris and optic nerve head. Araie M, et al. **Exp Eye Res** 1997 Feb;64(2):167–72

Up-regulation of a constitutively active form of the beta2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. MacEwan DJ, et al. **FEBS Lett** 1996 Dec 9;399(1–2):108–12

The myocardial lesions produced by the potassium channel opener aprikalim in monkeys and rats are prevented by blockade of cardiac beta-adrenoceptors. Belin V, et al. **Fundam Appl Toxicol** 1996 Jun;31(2):259–67

Identification of viable myocardium early after acute myocardial infarction under beta-blockade by enoximone echocardiography. Natale E, et al. **G Ital Cardiol** 1997 Apr; 27(4):342–8

Modification of systemic and regional circulatory effects of intracerebroventricular administration of endothelin-1 by propranolol in anesthetized rats. Kumar A, et al. **Gen Pharmacol** 1996 Sep;27(6):1025–33

The effects of propranolol hydrochloride singularly or in conjunction with ethanol on clotting activity in the rat. Lox CD. **Gen Pharmacol** 1996 Mar;27(2):211–13

Alteration of the cardiac effects of isoproterenol and propranolol by hypothermia in isolated rat atrium. Melnikov AL, et al. **Gen Pharmacol** 1996 Jun;27(4):665–8

Influence of hypothermia on the cardiac effects of propranolol observed in isolated rat atria. Melnikov AL, et al. **Gen Pharmacol** 1997 Jan;28(1):55–9

Beta-adrenergic regulation of voltage-dependent calcium currents in cultured skeletal myocytes of the frog Rana temporaria. Lukyanenko V, et al. **Gen Physiol Biophys** 1995 Dec;14(6):515–23

Nipradilol, a new beta-adrenergic blocker, reduces left ventricular remodeling following myocardial infarction in spontaneously hypertensive rats. Sonoki H, et al. **Heart Vessels** 1997;12(1):19–26

Daily variation in portal blood flow and the effect of propranolol administration in a randomized study of patients with cirrhosis. Alvarez D, et al. **Hepatology** 1997 Mar;25(3):548–50

Catecholamines stimulate steroid secretion of dispersed fowl adrenocortical cells, acting through the beta-receptor subtype. Mazzocchi G, et al. **Horm Metab Res** 1997 Apr; 29(4):190–2

Chronic effect of beta-adrenoceptor blockade on plasma levels of brain natriuretic peptide during exercise in essential hypertension. Tanaka M, et al. **Hypertens Res** 1996 Dec;19(4):239–45

Effect of chronic treatment with atenolol and prazosin in streptozotocin induced diabetic rats. Goyal RK, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):220–4

A study of the antiulcer mechanisms of propranolol in rats. Kaan SK, et al. **Inflamm Res** 1996 Aug;45(8):370–5

The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. Middeke M, et al. **Int J Clin Pharmacol Ther** 1997 Jun;35(6):231–4

Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Levy B, et al. **Intensive Care Med** 1997 Mar;23(3):282–7

Timolol decreases aqueous humor flow but not Na+ movement from plasma to aqueous. Maren TH, et al. **Invest Ophthalmol Vis Sci** 1997 May;38(6):1274–7

Effects of beta-blockade and atropine on ischemic responses in left ventricular regions subtending coronary stenosis during dobutamine stress echocardiography. Chen L, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1866–76

Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Doughty RN, et al. **J Am Coll Cardiol** 1997 Apr;29(5):1060–6

Chronic beta-blockade increases skeletal muscle beta-adrenergic-receptor density and enhances contractile force. Murphy RJL, et al. **J Appl Physiol** 1997 Aug; 83(2):459–65

Altitude and beta-blockade augment glucose utilization during submaximal exercise. Roberts AC, et al. **J Appl Physiol** 1996 Feb;80(2):605–15

Changes in cardiovascular responsiveness to dopexamine and beta 1- and beta 2-adrenoceptor function after the chronic treatment of beta-adrenoceptor antagonists and agonists in anaesthetized dogs. Chang DH, et al. **J Auton Pharmacol** 1996 Oct;16(5):269–79

The effects of bromoacetylalprenololmenthane on the responses to isoprenaline of the left ventricle from normo-, prehyper- and hypertensive rats. Doggrell SA, et al. **J Auton Pharmacol** 1997 Jun;17(3):183–90

Effects of esmolol on 35 GHz microwave-induced lethal heat stress. Jauchem JR, et al. **J Auton Pharmacol** 1997 Jun; 17(3):165–73

Beta 3-adrenoceptors mediating relaxation of the oesophageal tunica muscularis mucosae and distal colon in the rat: comparative pharmacology and their desensitization by BRL 37344. Kelly J, et al. **J Auton Pharmacol** 1996 Aug;16(4):205–11

Propranolol stereoselectively inhibits alpha-adrenoceptor-mediated vasoconstriction in mesenteric arterial beds of rats. Stauber RE, et al. **J Auton Pharmacol** 1996 Jun;16(3):125–9

beta-Adrenoceptor regulation in rat heart, lung and skin after chronic treatment with (--)-tertatolol or (--)-propranolol. Tan YY, et al. **J Auton Pharmacol** 1995 Dec;15(6):421–36

Decreased inotropic but relatively preserved relaxation response to cyclic adenosine monophosphate-dependent agents in myopathic human myocardium. Gutstein DE, et al. **J Card Fail** 1996 Dec;2(4):285–92

Biphasic antagonisms by beta-blockers against positive inotropic response through beta1-adrenoceptors in isolated canine right ventricular muscles: possible involvement of two beta 1-adrenoceptor subtypes. Kurosawa H, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):262–8

Vasomolol: an ultra short-acting and vasorelaxant vanilloid type beta 1-adrenoceptor antagonist. Lin YT, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):149–57

Effects of tilisolol, a nonselective beta-adrenergic blocker, on the membrane currents of isolated guinea pig ventricular myocytes. Takagi S, et al. **J Cardiovasc Pharmacol** 1997 May;29(5):593–8

Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man. Arvat E, et al. **J Endocrinol Invest** 1996 Jan;19(1):25–9

Effects of dichloroisoproterenol on macromolecular synthesis and differentiation in Tetrahymena vorax. Ryals PE, et al. **J Eukaryot Microbiol** 1997 Jan-Feb;44(1):43–5

Beta-blockers and ocular blood flow: a perspective [editorial] Harris A, et al. **J Glaucoma** 1997 Jun;6(3):143–5

Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: comparison between acute and chronic effects. Bolognesi M, et al. **J Hepatol** 1997 Feb; 26(2):305–11

Effects of beta-adrenergic blockade on insulin-mediated glucose disposal in hypertensive and normotensive rats. Farrace S, et al. **J Hypertens** 1996 Sep;14(9):1087–92

Propranolol blocks the hypophosphaturia of acute respiratory alkalosis in human subjects. Tucker RR, et al. **J Lab Clin Med** 1996 Oct;128(4):423–8

Effect of beta 1 adrenergic receptor blockade on myocardial blood flow and vasodilatory capacity. Böttcher M, et al. **J Nucl Med** 1997 Mar;38(3):442–6

Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma. Boder N, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):115–22

The effect of 0.5% timolol maleate on the ocular perfusion of ocular hypertensive patients by scanning laser flowmetry. Wang TH, et al. **J Ocul Pharmacol Ther** 1997 Jun;13(3):225–33

Effects of pilocarpine and other antiglaucoma drugs on cultured human Tenon's fibroblast cells. Wu KY, et al. **J Ocul Pharmacol Ther** 1997 Feb;13(1):13–21

Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. Barone FC, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):948–55

Carvedilol retards sudden loss of contraction during early regional myocardial ischemia in feline hearts. Brunvand H, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):363–8

Continuous intraocular pressure measurement by telemetry in alpha-chymotrypsin-induced glaucoma model in the rabbit: effects of timolol, dorzolamide, and epinephrine. Percicot CL, et al. **J Pharmacol Toxicol Methods** 1996 Dec; 36(4):223–8

Relationship between beta adrenoceptor occupancy and receptor down-regulation induced by beta antagonists with intrinsic sympathomimetic activity. Lima JJ. **J Recept Signal Transduct Res** 1996 Sep-Nov; 16(5–6):357–72

Anomalous behavior of CGP 12177A on beta 1-adrenergic receptors. Pak MD, et al. **J Recept Signal Transduct Res** 1996 Jan-Mar;16(1–2):1–23

Effects of chronic treatment with carvedilol on smooth muscle tone and endothelium-dependent relaxation of aorta in stroke-prone spontaneously hypertensive rats. Sunano S, et al. **J Smooth Muscle Res** 1997 Feb;33(1):23–35

Hepatic denervation induces supersensitivity to terbutaline of the hepatic arterial system in conscious dogs. Akiyama H, et al. **J Surg Res** 1997 Feb 15;68(1):67–72

Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogs. Main BW, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):225–32

Atrial fibrillation following coronary artery bypass graft surgery [letter; comment] Khan SS. **JAMA** 1996 Dec 4; 276(21):1719; discussion 1719–20. Comment on: JAMA 1996 Jul 24–31;276(4):300–6.

Cardiovascular and renal effects of the combination of felodipine and metoprolol during a high-salt and a moderate-salt diet in spontaneously hypertensive rats. Mervaala EM, et al. **Jpn Circ J** 1997 May;61(5):421–31

Relationship between desensitization and downregulation of beta-adrenoceptors in cardiac tissues after prolonged in vivo infusion of T-0509, a beta 1-adrenoceptor agonist. Sato Y, et al. **Jpn J Pharmacol** 1997 Apr;73(4):325–32

Hypotensive effects of YM430, a 1,4-dihydropyridine derivative, in spontaneously hypertensive rats and renal hypertensive dogs. Shibasaki K, et al. **Jpn J Pharmacol** 1997 Feb;73(2):113–24

Effects of antiglaucoma drugs and corticosteroids on the cellular glucose uptake in cultured porcine corneal endothelial cells. Wu KY, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Aug; 13(8):480–6

The impact of beta-adrenergic blockade on daily rhythms of melatonin and body temperature of golden spiny mice Acomys russatus. Haim A, et al. **Life Sci** 1997;61(7):703–9

Beta 1-adrenoreceptors regulate resting metabolic rate. Lamont LS, et al. **Med Sci Sports Exerc** 1997 Jun; 29(6):769–74

Comparative antioxidant effects of beta-adrenoceptor blockers, calcium antagonists and U-74500A against iron-dependent lipid peroxidation in murine ventricular microsomal membranes. Reddy DS, et al. **Methods Find Exp Clin Pharmacol** 1996 Nov;18(9):559–67

Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor. Chidiac P, et al. **Mol Pharmacol** 1996 Sep;50(3):662–9

A complex interaction between topical verapamil and timolol on intraocular pressure in conscious rabbits. Santafé J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jul; 354(2):198–204

Influence of alpha- and beta-adrenoceptor antagonists on ventricular fibrillation in ischemic rat hearts. Tölg R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jul; 356(1):62–8

(-)-pindolol and (+/-)-tertatolol affect rat hippocampal 5-HT levels through mechanisms involving not only 5-HT1A, But also 5-HT1B receptors. Assie MB, et al. **Neuropharmacology** 1996 Feb;35(2):213–22

beta-adrenergic antagonism alters the behavioral and neurochemical responses to cocaine. Harris GC, et al. **Neuropsychopharmacology** 1996 Mar;14(3):195–204

Working memory failure by combined blockade of muscarinic and beta-adrenergic transmission in the rat hippocampus. Ohno M, et al. **Neuroreport** 1997 May 6; 8(7):1571–5

Cardiorespiratory effects of cocaine and procaine at the ventral brainstem. Dehkordi O, et al. **Neurotoxicology** 1996 Summer;17(2):387–95

Development of radioligands for the imaging of cardiac beta-adrenoceptors using SPECT. Part II: Pharmacological characterization in vitro and in vivo of new 123I-labeled beta-adrenoceptor antagonists. Dubois EA, et al. **Nucl Med Biol** 1997 Jan;24(1):9–13

Effect of timolol and UF-021 (a prostaglandin-related compound) on pulsatile ocular blood flow in normal volunteers. Kitaya N, et al. **Ophthalmic Res** 1997; 29(3):139–44

Effects of bradykinin receptor antagonist on the release of beta-endorphin and bradykinin and on hemodynamic changes in a canine model of experimental acute pancreatitis. Satake K, et al. **Pancreas** 1996 Jan;12(1):92–7

Effects of clenbuterol and ICI118551, a selective beta 2-antagonist, on the growth of skeletal muscle of suckling rats. Morton RH, et al. **Pflugers Arch** 1995 Dec; 431(2):237–43

Stressor-induced alterations of the splenic plaque-forming cell response: strain differences and modification by propranolol. Kerr L, et al. **Pharmacol Biochem Behav** 1996 Feb;53(2):235–41

Blockade of effect of stress on risk assessment behavior in mice by a beta-1 adrenoceptor antagonist. Stone EA, et al. **Pharmacol Biochem Behav** 1996 Oct;55(2):215–7

Delayed arousal from anesthesia: a further similarity between stress and beta-1 adrenoceptor blockade. Stone EA, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):131–3

Nadolol–glibenclamide interaction: relevance to carbohydrate metabolism in hyperglycaemic rats. Abdel Aziz AH, et al. **Pharmacol Res** 1996 Jul–Aug;34(1–2):11–5

Effects of beta-blockers association with pilocarpine on rabbit intraocular pressure and heart rate. Drago F, et al. **Pharmacol Res** 1997 Apr;35(4):299–302

Agonist and antagonist properties of beta 3-adrenoceptors in human omental and mouse 3T3-L1 adipocytes. Shimizu M, et al. **Pharmacol Toxicol** 1996 Apr;78(4):254–63

Vanidilol: a vanilloid-type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2-agonist activity. Sheu MM, et al. **Pharmacology** 1997 Apr;54(4):211–24

Comparative studies on beta-adrenolytic potencies of some new phenoxyaminopropanol derivatives and celiprolol. Mlynárová R, et al. **Pharmazie** 1997 Mar;52(3):234–7

Central propranolol and pindolol, but not atenolol nor metoprolol, inhibit sexual behavior in male rats. Smith ER, et al. **Physiol Behav** 1996 Feb;59(2):241–6

Effect of chronic treatment with propranolol on the cardiovascular responses to chronic cold exposure. Sun Z, et al. **Physiol Behav** 1997 Aug;62(2):379–84

Rapid down-regulation of beta-adrenergic receptors evoked by combined forced swimming test and CGP 37849—a competitive antagonist of NMDA receptors. Wędzony K, et al. **Pol J Pharmacol** 1995 Nov–Dec;47(6):537–40

Interaction of cholecystokinin (CCK-8) with agonist and antagonist of beta-adrenergic receptors in circulatory system of diabetic rats. Wiśniewska RJ, et al. **Pol J Pharmacol** 1996 May–Jun;48(3):293–7

Discriminative stimulus properties of cocaine: enhancement by beta-adrenergic receptor antagonists. Kieven MS, et al. **Psychopharmacology (Berl)** 1997 Jun;131(3):307–12

The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats. Kikuchi T, et al. **Psychopharmacology (Berl)** 1997 May;131(2):108–14

Antisense oligonucleotides fail to inhibit the expression of central beta adrenergic receptors. Zhang K, et al. **Res Commun Mol Pathol Pharmacol** 1997 Jan;95(1):21–32

Pharmacological criteria for the detection of beta 3-adrenoceptors [letter; comment] De Ponti F. **Trends Pharmacol Sci** 1997 Feb;18(2):52–3 (14 ref.). Comment on: Trends Pharmacol Sci 1996 Oct;17(10):373–81.

Pharmacological properties of beta 3-adrenoceptors [letter] Nisoli E, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):257–8 (9 ref.)

[Effect of local medications on intraocular pressure control following trabeculectomy] Detry-Morel M, et al. **Bull Soc Belge Ophtalmol** 1995;259:135–41 (Eng. Abstr.) **(Fre)**

[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors] Erley CM, et al. **Dtsch Med Wochenschr** 1997 Aug 1;122(31–32):953–8 (Eng. Abstr.) **(Ger)**

[The modification of the effects of calcium on the heart using beta-adrenergic blockers] Hapke HJ, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 May;103(5):170–4 (Eng. Abstr.) **(Ger)**

[Morphologic effect of adrenaline and insulin on bone capillaries after receptor blockade. Functional transmission electron microscopy analysis] Döhler JR, et al. **Langenbecks Arch Chir** 1997;382(3):164–6 (Eng. Abstr.) **(Ger)**

[Pharmacology of beta-receptor blockers] Schmitz W. **Z Kardiol** 1996;85 Suppl 7:5–9 (13 ref.) (Eng. Abstr.) **(Ger)**

[Effects of beta-adrenergic blockers on retinal circulation] Ishikawa Y, et al. **Nippon Ganka Gakkai Zasshi** 1996 Oct; 100(10):798–802 (Eng. Abstr.) **(Jpn)**

[Pharmacological characteristics of the long-acting beta-blocker "bopindolol"] Nagatomo T, et al. **Nippon Yakurigaku Zasshi** 1997 Jan;109(1):1–12 (51 ref.) (Eng. Abstr.) **(Jpn)**

[Doppler echocardiography in assessing the effect of the beta 1-selective adrenoblocker acebutolol on left-ventricular diastolic filling in hypertension patients] Alekhin MN, et al. **Ter Arkh** 1997;69(4):15–8 **(Rus)**

[The characteristics of the effect of obzidan on the cardiac hemodynamics in patients with an artificial pacemaker when used one time and over a course of treatment] Iskenderov BG, et al. **Ter Arkh** 1996;68(5):60–3 (Eng. Abstr.) **(Rus)**

[Laryngeal mucociliary clearance: influence of beta-2 agonists, beta antagonists, and alpha-agonists. An experimental study in rabbits] Armengot M, et al. **Acta Otorrinolaringol Esp** 1996 Nov–Dec;47(6):425–8 (Eng. Abstr.) **(Spa)**

[The neurophysiological effects of the beta-blocker obzidan in the modelling of emotional stress] Shever'ova VM. **Fiziol Zh** 1997;43(1–2):31–9 (Eng. Abstr.) **(Ukr)**

[The effect of obzidan on the central and hepatic portal hemodynamics in patients with liver cirrhosis] Rusyn VI, et al. **Klin Khir** 1995;(1):7–8 **(Ukr)**

POISONING

Insulin improves survival in a canine model of acute beta-blocker toxicity. Kerns W 2nd, et al. **Ann Emerg Med** 1997 Jun;29(6):748–57

Acebutolol overdose treated with hemodialysis and extracorporeal membrane oxygenation. Rooney M, et al. **J Clin Pharmacol** 1996 Aug;36(8):760–3

Characterization of fatal beta blocker ingestion: a review of the American Association of Poison Control Centers data from 1985 to 1995. Love JN, et al. **J Toxicol Clin Toxicol** 1997;35(4):353–9 (25 ref.)

Overdose of metoprolol treated with enoximone [letter] Hoeper MM, et al. **N Engl J Med** 1996 Nov 14;335(20):1538

Eye drops—the hidden poison. Jones AL, et al. **Scott Med J** 1996 Aug;41(4):110–2 (32 ref.)

THERAPEUTIC USE

The effects of nasolacrimal canal blockage on topical medications for glaucoma. Aritürk N, et al. **Acta Ophthalmol Scand** 1996 Aug;74(4):411–3

Safety of beta-adrenergic blocker washout period in clinical trials. Stroman GA, et al. **Acta Ophthalmol Scand** 1997 Feb; 75(1):94–5

Beta-blockers revisited: picking patients with alcoholic cirrhosis who will benefit. Bay MK, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):788–90 (33 ref.)

Alpha blockers, diuretics and beta blockers for hypertension [letter; comment] Coutts LC. **Am Fam Physician** 1997 May 15;55(7):2431–2, 2434. Comment on: Am Fam Physician 1996 Jul;54(1):263–6, 269–70.

Treatment of acute myocardial infarction today. Maggioni AP, et al. **Am Heart J** 1997 Aug;134(2 Pt 2):S9–14 (29 ref.)

Professor Peter Sleight's reflections on the use of beta-blocking agents after myocardial infarction. Sleight P. **Am Heart J** 1997 Aug;134(2 Pt 2):S15–20 (25 ref.)

Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Suwa M, et al. **Am Heart J** 1997 Mar;133(3):353–8

Atrial fibrillation follow-up investigation of rhythm management -- the AFFIRM study design. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. **Am J Cardiol** 1997 May 1;79(9):1198–202

Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris. Alpert JS, et al. **Am J Cardiol** 1997 Apr 15;79(8):1025–30

Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Aronow WS, et al. **Am J Cardiol** 1997 Jul 15;80(2):207–9

Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. The APSI Investigators. Acebutolol et Prévention Secondaire de l'Infarctus. Cucherat M, et al. **Am J Cardiol** 1997 Mar 1;79(5):587–9

Correlation between time-domain measures of heart rate variability and scatterplots in patients with healed myocardial infarcts and the influence of metoprolol. Keeley EC, et al. **Am J Cardiol** 1997 Feb 15;79(4):412–4

Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy [letter; comment] Lee YC. **Am J Cardiol** 1997 Apr 1;79(7):1001. Comment on: Am J Cardiol 1996 Oct 1;78(7):779–84.

Effect of atenolol on QT interval and dispersion in patients with syndrome X. Leonardo F, et al. **Am J Cardiol** 1997 Sep 15;80(6):789–90

Systolic blood pressure at rest, not the degree of beta blockade, predicts the result of follow-up tilt-table testing for vasovagal syncope. Lewis WR, et al. **Am J Cardiol** 1997 Aug 1;80(3):351–3

Relation between dynamic midventricular obstruction and unexplained chest pain in patients with normal echocardiograms at rest. Murakami H, et al. **Am J Cardiol** 1996 Nov 1;78(9):1063–5

Management of atrial fibrillation after coronary artery bypass graft. Olshansky B. **Am J Cardiol** 1996 Oct 17;78(8A):27–34 (57 ref.)

Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy [see comments] Quaife RA, et al. **Am J Cardiol** 1996 Oct 1;78(7):779–84. Comment in: Am J Cardiol 1997 Apr 1;79(7):1001.

Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring. Reiffel JA, et al. **Am J Cardiol** 1997 Apr 15; 79(8):1048–53

Beta blockers prevent cardiac death following a myocardial infarction: so why are so many infarct survivors discharged without beta blockers? [editorial] Viskin S, et al. **Am J Cardiol** 1996 Oct 1;78(7):821–2

Results of hypertension treatment with low-dose combinations of a beta-adrenergic blocker and a diuretic. Frishman WH. **Am J Hypertens** 1997 Mar;10(3):17S–23S (35 ref.)

Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Lithell HO. **Am J Hypertens** 1996 Nov; 9(11):150S–154S (28 ref.)

The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. Paran E, et al. **Am J Hypertens** 1996 Dec;9(12 Pt 1):1206–13

Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. Netland PA, et al. **Am J Ophthalmol** 1997 Apr; 123(4):465–77

A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels. Nicolela MT, et al. **Am J Ophthalmol** 1996 Dec;122(6):784–9

Surgical vs medical management of chronic open-angle glaucoma. Stewart WC, et al. **Am J Ophthalmol** 1996 Dec; 122(6):767–74

Beta blockade to prevent atrial dysrhythmias following coronary bypass surgery. Paull DL, et al. **Am J Surg** 1997 May;173(5):419–21

Use of esmolol during intraoperative atrioventricular rhythm. James MF, et al. **Anaesth Intensive Care** 1996 Aug; 24(4):492–5

Anaesthetic management of childhood thyrotoxicosis and the use of esmolol. Knighton JD, et al. **Anaesthesia** 1997 Jan; 52(1):67–70

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Giugliano D, et al. **Ann Intern Med** 1997 Jun 15;126(12):955–9

Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Gueyffier F, et al. **Ann Intern Med** 1997 May 15;126(10):761–7

Design of a trial to evaluate the effect of propranolol upon abdominal aortic aneurysm expansion. Ricci MA, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:252–3

Effects of hypertension and propranolol upon aneurysm expansion in the Anidjar/Dobrin aneurysm model. Ricci MA, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:89–96

Syncope: pathophysiology, diagnosis, and pharmacotherapy. Lazarus JC, et al. **Ann Pharmacother** 1996 Sep; 30(9):994–1005 (51 ref.)

Beta-adrenergic blocking agents in the treatment of congestive heart failure: mechanisms and clinical results. Doughty RN, et al. **Annu Rev Med** 1997;48:103–14 (70 ref.)

A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Kaniecki RG. **Arch Neurol** 1997 Sep;54(9):1141–5

Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Konstas AG, et al. **Arch Ophthalmol** 1997 Aug;115(8):975–9

Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension. Sekiyama T, et al. **Arzneimittelforschung** 1997 Apr;47(4):353–5

Beta-blockers for ventricular arrhythmias: have we underestimated their value? Campbell TJ. **Aust N Z J Med** 1996 Oct;26(5):689–96 (59 ref.)

Remodeling after myocardial infarction: an opportunity for early intervention. Amos DJ, et al. **Basic Res Cardiol** 1997 Apr;92(2):69–71 (10 ref.)

Improved recovery from laryngeal-stimulation-induced apnea by alpha-adrenergic blockade in adult rabbits.

Beyaert C, et al. **Biol Neonate** 1996;70(6):359–62
Cardiac conduction with diltiazem and beta-blockade combined. A review and report on cases. Kjeldsen SE, et al. **Blood Press** 1996 Sep;5(5):260–3 (29 ref.)
Proximal tubular function in essential hypertensives on beta-blocker therapy with atenolol. Krusell LR, et al. **Blood Press** 1997 May;6(3):166–70
Comparison of temocapril and atenolol in the long-term treatment of mild to moderate essential hypertension. Sierakowski B, et al. **Blood Press** 1997 Jul;6(4):229–34
A study to investigate the comparative efficacy and tolerability of nisoldipine coat-core and atenolol in the treatment of mild to moderate hypertension. Murray TS. **Br J Clin Pract** 1996 Oct-Nov;50(7):368–72
Effect of celiprolol therapy on arterial dilatation in experimental hypertension. Tolvanen JP, et al. **Br J Pharmacol** 1996 Nov;119(6):1137–44
PROTECT (Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial): a randomized, double-blind clinical trial of diltiazem versus atenolol in secondary prophylaxis post non-Q wave myocardial infarction [see comments] Goodman S, et al. **Can J Cardiol** 1996 Nov;12(11):1183–90. Comment in: Can J Cardiol 1997 Jul;13(7):693, 696.
Vasodepressor syncope. Diagnosis and management. Barbey JT. **Cardiol Clin** 1997 May;15(2):251–6 (41 ref.)
Pharmacologic control of heart rate in atrial fibrillation. Falk RH. **Cardiol Clin** 1996 Nov;14(4):521–36 (71 ref.)
Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. Angina Prognosis Study in Stockholm. Rehnqvist N, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):301
Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension. Bönner G, et al. **Cardiovasc Drugs Ther** 1997 Mar; 11(1):21–6
Second- and third-generation beta-blocking drugs in chronic heart failure. Bristow MR, et al. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:291–6
Combination drug therapy in chronic heart failure: is treatment part of the problem in heart failure? Cleland JG. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:297–303 (47 ref.)
Beta-blocking drugs and coronary heart disease. Goldstein S. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:219–25 (44 ref.)
Acute hemodynamic effects of amlodipine 15 days after a myocardial infarction in normotensive patients treated with atenolol. Rocha P, et al. **Cardiovasc Drugs Ther** 1997 Apr; 11(2):139–47
Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Weber K, et al. **Cardiovasc Drugs Ther** 1996 May;10(2):113–7
Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial. Wiklund I, et al. **Cardiovasc Drugs Ther** 1996 Jul;10(3):361–8
Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension. Chern MS, et al. **Chang Keng I Hsueh** 1997 Jun;20(2):86–93
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators [comment] Bristow MR, et al. **Circulation** 1996 Dec 1;94(11):2807–16. Comment on: Circulation 1996 Dec 1;94(11):2793–9. Comment on: Circulation 1996 Dec 1;94(11):2800–6. Comment on: Circulation 1996 Dec 1;94(11):2807–16.
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Colucci WS, et al. **Circulation** 1996 Dec 1; 94(11):2800–6
Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization [see comments] Davies RF, et al. **Circulation** 1997 Apr 15; 95(8):2037–43. Comment in: Circulation 1997 Apr 15;95(8):1992–3.
Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Gilbert EM, et al. **Circulation** 1996 Dec 1;94(11):2817–25
Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. Groenemeijer BE, et al. **Circulation** 1997 Jun 17;95(12):2628–35
Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. Held C, et al. **Circulation** 1997 May 20; 95(10):2380–6
Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Newton GE, et al. **Circulation** 1996 Aug 1;94(3):353–8
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Packer M, et al. **Circulation** 1996 Dec 1;94(11):2793–9
Effects of age on aortic blood velocity at rest and during exercise in patients with coronary artery disease. Salmasi AM, et al. **Clin Auton Res** 1996 Apr;6(2):99–106
Modification of the circadian pattern of ventricular tachyarrhythmias by beta-blocker therapy. Behrens S, et al. **Clin Cardiol** 1997 Mar;20(3):253–7
Atrial fibrillation in acute myocardial infarction: a prospective study based on data from a consecutive series of patients admitted to the coronary unit [letter; comment] Lemberg L. **Clin Cardiol** 1996 Aug;19(8):605, 619. Comment on: Clin Cardiol 1996 Mar;19(3):180–6.
Bruxism secondary to antipsychotic drug exposure: a positive response to propranolol. Amir I, et al. **Clin Neuropharmacol** 1997 Feb;20(1):86–9
The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension. Hartenbaum D. **Clin Ther** 1996 May-Jun; 18(3):460–5
Dorzolamide versus pilocarpine as adjunctive therapies to timolol: a comparison of patient preference and impact on daily life. Laibovitz R, et al. **Clin Ther** 1996 Sep-Oct; 18(5):821–32
Sudden cardiac death in ischemic heart disease. Chang D, et al. **Compr Ther** 1997 Feb;23(2):95–103 (38 ref.)
Carvedilol [Coreg]. Kukin M. **Compr Ther** 1997 Sep; 23(9):617–20 (13 ref.)
Post-myocardial infarction trials: beta blockers, antiarrhythmics, thrombolytics. Anderson JL. **Control Clin Trials** 1996 Jun;17(3 Suppl):17S–27S (35 ref.)
Beta-blocker therapy for heart failure. Slatton ML, et al. **Curr Opin Cardiol** 1996 May;11(3):263–8 (56 ref.)
Renal and metabolic effects of l-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Schnack C, et al. **Diabetologia** 1996 Dec;39(12):1611–6
Systemic and hepatic hemodynamics in hepatosplenic Manson's schistosomiasis with and without propranolol. Mies S, et al. **Dig Dis Sci** 1997 Apr;42(4):751–61
Recognition and treatment of unstable angina. Brunelli C, et al. **Drugs** 1996 Aug;52(2):196–208 (80 ref.)
Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Dunn CJ, et al. **Drugs** 1997 Jul;54(1):161–85 (179 ref.)
Current drug treatment and treatment patterns with antihypertensive drugs. Freis ED, et al. **Drugs** 1996 Jul; 52(1):1–16 (136 ref.)
Angina with normal coronary arteries: diagnosis, pathophysiology and treatment. Chierchia SL, et al. **Eur Heart J** 1996 Dec;17 Suppl G:14–9 (42 ref.)
Beta-blocking agents in heart failure. Should they be used and how? Cleland JG, et al. **Eur Heart J** 1996 Nov; 17(11):1629–39 (90 ref.)
Slowing the progression of heart failure [editorial] Cohn JN. **Eur Heart J** 1996 Nov;17(11):1609–11
Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Doughty RN, et al. **Eur Heart J** 1997 Apr;18(4):560–5 (32 ref.)
More favourable haemodynamic effects from metoprolol than from captopril in patients with dilated cardiomyopathy. Jansson K, et al. **Eur Heart J** 1997 Jul;18(7):1115–21
Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication. Results of the Augsburg Myocardial Infarction Follow-up Study 1985 to 1993 [see comments] Koenig W, et al. **Eur Heart J** 1996 Aug;17(8):1199–206. Comment in: Eur Heart J 1997 Jan;18(1):168–9.
Effects of beta receptor antagonists on left ventricular function in patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol. Echocardiographic results from the Metoprolol and Xamoterol Infarction Study (MEXIS). Persson H, et al. **Eur Heart J** 1996 May;17(5):741–9
Felodipine in addition to beta-adrenergic blockade for angina pectoris. a multicentre, randomized, placebo-controlled trial. Rønnevik PK, et al. **Eur Heart J** 1995 Nov; 16(11):1535–41
Beta-blocker effects on postoperative atrial fibrillation. Ali IM, et al. **Eur J Cardiothorac Surg** 1997 Jun;11(6):1154–7
Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Hauf-Zachariou U, et al. **Eur J Clin Pharmacol** 1997;52(2):95–100
Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Himmelmann A, et al. **Eur J Clin Pharmacol** 1996;51(3–4):259–64
Efficacy of an ultrashort-acting beta-adrenoceptor blocker (ONO-1101) in attenuating cardiovascular responses to endotracheal intubation. Kitamura A, et al. **Eur J Clin Pharmacol** 1997;51(6):467–71
Metabolic effects of carvedilol in hypertensive patients. Lithell H, et al. **Eur J Clin Pharmacol** 1997;52(1):13–7
Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension. Rangemark C, et al. **Eur J Clin Pharmacol** 1996;49(4):267–71
Effects of metoprolol on myocardial beta-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. Sigmund M, et al. **Eur J Clin Pharmacol** 1996;51(2):127–32
Medical prophylaxis of haemorrhage from oesophageal varices in patients with liver cirrhosis. Gross M, et al. **Eur J Gastroenterol Hepatol** 1997 Jun;9(6):603–12 (95 ref.)
Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy. Fukuoka S, et al. **Eur J Nucl Med** 1997 May;24(5):523–9
Effects on salivary flow rate and composition of withdrawal of and re-exposure to the beta 1-selective antagonist metoprolol in a hypertensive patient population. Nederfors T, et al. **Eur J Oral Sci** 1996 Jun;104(3):262–8
Propranolol as an adjunct therapy for hyperthyroid tremor. Henderson JM, et al. **Eur Neurol** 1997;37(3):182–5
Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group. Paggiaro PL, et al. **Eur Respir J** 1996 Aug;9(8):1689–95
A hydroxylated analog of the beta-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Kramer JH, et al. **Free Radic Biol Med** 1996;21(6):813–25
Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. **Fundam Clin Pharmacol** 1997;11(2):138–42
Propranolol therapy in experimental heart failure in rabbits improves cardiac response to catecholamines without beta-adrenoceptor up-regulation. Xiong L, et al. **Fundam Clin Pharmacol** 1995;9(6):522–30
Ocular hypotensive effect of topical ketanserin in timolol users. Mastropasqua L, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Mar;235(3):130–5
Atenolol prophylaxis in migraine secondary to an arteriovenous malformation. Kowacs PA, et al. **Headache** 1996 Nov-Dec;36(10):625–7
Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine. Biffi M, et al. **Heart** 1997 Mar; 77(3):268–72
Impaired left ventricular filling dynamics in patients with angina and angiographically normal coronary arteries: effect of beta adrenergic blockade. Fragasso G, et al. **Heart** 1997 Jan;77(1):32–9
Intractable recurrent ventricular tachycardia in dilated cardiomyopathy controlled by a vasodilating beta blocker. Wright DJ, et al. **Heart** 1997 Jun;77(6):581–2
Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Bernard B, et al. **Hepatology** 1997 Jan; 25(1):63–70
Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Merkel C, et al. **Hepatology** 1997 Jul;26(1):34–9
Effects of long-term antihypertensive therapy on physical fitness of men with mild hypertension. Tomiyama H, et al. **Hypertens Res** 1997 Jun;20(2):105–11
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Bakris GL, et al. **Hypertension** 1997 Mar;29(3):744–50
Comparison of anti-ischemic effects of isosorbide-5-mononitrate, metoprolol and diltiazem: a study based on serial treadmill exercise test. Gupta DK, et al. **Indian Heart J** 1995 Sep-Oct;47(5):485–8
A comparative evaluation of pilocarpine 1% and clonidine 0.125% versus timolol 0.5%. Sihota R, et al. **Indian J Ophthalmol** 1996 Jun;44(2):87–9
Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN). de Vries RJ, et al. **Int J Cardiol** 1996 Dec 6;57(2):143–50
Heart rate variability after acute myocardial infarction in patients treated with atenolol and metoprolol. Lurje L, et al. **Int J Cardiol** 1997 Jul 25;60(2):157–64
Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis. Erley CM, et al. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):504–9
Metabolic effects of spirapril and atenolol: results from a randomized, long-term study. Hakamäki T, et al. **Int J Clin Pharmacol Ther** 1997 Jun;35(6):227–30
Beta-adrenoceptor blocking agents for the treatment of heart failure. Heilbron BG, et al. **Int J Clin Pharmacol Ther** 1996 Jun;34(6):231–5 (35 ref.)
The use of esmolol in whole-body hyperthermia: cardiovascular effects. Berry JM, et al. **Int J Hyperthermia** 1997 May-Jun;13(3):261–8
Haemodynamic study as guideline for the use of beta blockers in acute theophylline poisoning. Kempf J, et al. **Intensive Care Med** 1996 Jun;22(6):585–7
Treatment of essential and parkinsonian tremor with nipradilol. Yoshii F, et al. **Intern Med** 1996 Nov; 35(11):861–5
A pilot study of nadolol for overt aggression in developmentally delayed individuals. Connor DF, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jun;36(6):826–34
Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS [see comments] Folland ED, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1505–11. Comment in: J Am Coll Cardiol 1997 Jun;29(7):1512–4.
Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. Heidenreich PA, et al. **J Am Coll Cardiol** 1997 Jul; 30(1):27–34

ADRENERGIC BETA-ANTAGONISTS

Beta-adrenergic blocking agents or angiotensin-converting enzyme inhibitors, or both, for postinfarction patients with left ventricular dysfunction [editorial] O'Rourke RA. **J Am Coll Cardiol** 1997 Feb;29(2):237-9

Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. Vantrimpont P, et al. **J Am Coll Cardiol** 1997 Feb;29(2):229-36

Short-term regular beta 2-adrenergic agonists treatment is safe in mild asthmatics taking low doses of inhaled steroids. Ganassini A, et al. **J Asthma** 1997;34(1):61-6

Prolonged use of propranolol safely decreases cardiac work in burned children. Baron PW, et al. **J Burn Care Rehabil** 1997 May-Jun;18(3):223-7

Metoprolol in dilated cardiomyopathy: is it possible to identify factors predictive of improvement? The Heart Muscle Disease Study Group. DiLenarda A, et al. **J Card Fail** 1996 Jun;2(2):87-102

Beta-blocker therapy in heart failure: myths or realities. Kelly DT. **J Card Fail** 1996 Dec;2(4 Suppl):S239-42 (10 ref.)

Direct effects of chronic beta-adrenergic receptor blockade on left ventricular and myocyte function in a model of tachycardia-induced congestive heart failure. Spinale FG, et al. **J Card Fail** 1996 Dec;2(4):311-8

Are patients chronically treated with beta 1-adrenoceptor antagonists in fact beta-blocked? Yndgaard S, et al. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):32-6

Changes in plasma epinephrine concentration and in heart rate during head-up tilt testing in patients with neurocardiogenic syncope: correlation with successful therapy with beta-receptor antagonists. Klingenheben T, et al. **J Cardiovasc Electrophysiol** 1996 Sep;7(9):802-8

Response to beta blockers in patients with neurocardiogenic syncope: how to predict beneficial effects. Natale A, et al. **J Cardiovasc Electrophysiol** 1996 Dec;7(12):1154-8

Spontaneous changes of heart rate, blood pressure, and ischemia-type ST-segment depressions in patients with hypertension without significant coronary artery disease: beneficial effects of beta-blockade [published erratum appears in J Cardiovasc Pharmacol 1997 Mar;29(3):427] Christ M, et al. **J Cardiovasc Pharmacol** 1996 Dec; 28(6):755-63

Long-term beta 1-adrenergic blockade restores adrenomedullary activity in primary hypertension. Jacobs MC, et al. **J Cardiovasc Pharmacol** 1997 Sep;30(3):338-42

Antifibrillatory effect of esmolol alone and in combination with lidocaine. Tisdale JE, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):376-82

Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects. Buitelaar JK, et al. **J Child Psychol Psychiatry** 1996 Jul;37(5):587-95

Effects of intravenous lidocaine and/or esmolol on hemodynamic responses to laryngoscopy and intubation: a double-blind, controlled clinical trial. Kindler CH, et al. **J Clin Anesth** 1996 Sep;8(6):491-6

Use of esmolol to control bleeding and heart rate during electroconvulsive therapy in a patient with an intracranial aneurysm. Kolano JE, et al. **J Clin Anesth** 1997 Sep; 9(6):493-5

Microdialysis of adipose tissue during surgery: effect of local alpha- and beta-adrenoceptor blockade on blood flow and lipolysis. Felländer G, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2919-24

On wisdom after the event [comment] [see comments] Senn S, et al. **J Clin Epidemiol** 1997 Jul;50(7):749-51. Comment on: J Clin Epidemiol 1996 Apr;49(4):395-400. Comment in: J Clin Epidemiol 1997 Jul;50(7):753-5.

Beta-blocker use in systolic heart failure and dilated cardiomyopathy. Hash TW 2nd, et al. **J Clin Pharmacol** 1997 Jan;37(1):7-19 (73 ref.)

Use of beta-adrenergic receptor blockers in blacks. Prisant LM, et al. **J Clin Pharmacol** 1996 Oct;36(10):867-73 (34 ref.)

Temporal variation in the effects of ophthalmic timolol on cardiovascular and respiratory functions in healthy men. Umetsuki MH, et al. **J Clin Pharmacol** 1997 Jan;37(1):58-63

Comments on "Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression" [letter; comment] Anderson GM. **J Clin Psychopharmacol** 1996 Jun;16(3):256-7. Comment on: J Clin Psychopharmacol 1995 Jun;15(3):217-22.

Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder? [letter] Koran LM, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):253-4

Recent developments in the psychopharmacology of anxiety disorders. Lydiard RB, et al. **J Consult Clin Psychol** 1996 Aug;64(4):660-8 (85 ref.)

Atenolol for prevention of postsurgical cardiovascular events. Shapley-Quinn K, et al. **J Fam Pract** 1997 Mar; 44(3):243, 247

Prevention of variceal rebleeding. Stevermer JJ, et al. **J Fam Pract** 1996 Sep;43(3):240-1

Safety and efficacy of first-line antihypertensives. Strickland C. **J Fam Pract** 1997 Jun;44(6):530-1

Ambulatory blood pressure monitoring for evaluation of long-acting beta-blockers in Taiwan. Tseng CD, et al. **J Formos Med Assoc** 1996 Apr;95(4):320-4

Racial differences in the medical treatment of elderly Medicare patients with acute myocardial infarction. Allison JJ, et al. **J Gen Intern Med** 1996 Dec;11(12):736-43

Current use of ophthalmic beta blockers. Gross RL, et al. **J Glaucoma** 1997 Jun;6(3):188-91 (29 ref.)

The effects of the beta-adrenergic-blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients. Yamamoto T, et al. **J Glaucoma** 1996 Aug;5(4):252-7

Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. Forrest EH, et al. **J Hepatol** 1996 Dec;25(6):909-15

Measurement of variceal pressure with an endoscopic pressure sensitive gauge: validation and effect of propranolol therapy in chronic conditions. Nevens F, et al. **J Hepatol** 1996 Jan;24(1):66-73

Commentary: calcium antagonist controversy, does the accusing finger also point to beta-blockers and methyldopa? Opie LH. **J Hum Hypertens** 1997 Apr; 11(4):201-4 (21 ref.)

Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients. Eriksson JW, et al. **J Hypertens** 1996 Dec; 14(12):1469-75

Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors. Kohzuki M, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1785-90

The control of oral secretions in bulbar ALS/MND. Newall AR, et al. **J Neurol Sci** 1996 Aug;139 Suppl:43-4

Effects of selective beta-adrenoceptor antagonists on gastric ulceration in the rat. Kaan SK, et al. **J Pharm Pharmacol** 1997 Feb;49(2):200-5

Adverse outcomes of underuse of beta-blockers in elderly patients [letter; comment] Gambassi G, et al. **JAMA** 1997 May 14;277(18):1433-4; discussion 1436-7. Comment on: JAMA 1997 Jan 8;277(2):115-21.

Adverse outcomes of underuse of beta-blockers in elderly patients [letter; comment] Hein HA. **JAMA** 1997 May 14; 277(18):1436; discussion 1436-7. Comment on: JAMA 1997 Jan 8;277(2):155-6.

Adverse outcomes of underuse of beta-blockers in elderly patients [letter; comment] Holt RJ. **JAMA** 1997 May 14; 277(18):1434; discussion 1436-7. Comment on: JAMA 1997 Jan 8;277(2):115-21.

Adverse outcomes of underuse of beta-blockers in elderly patients [letter; comment] Jay SJ. **JAMA** 1997 May 14; 277(18):1434-5; discussion 1436-7. Comment on: JAMA 1997 Jan 8;277(2):115-21.

Adverse outcomes of underuse of beta-blockers in elderly patients [letter; comment] Lapane KL, et al. **JAMA** 1997 May 14;277(18):1435; discussion 1436-7. Comment on: JAMA 1997 Jan 8;277(2):115-21.

Adverse outcomes of underuse of beta-blockers in elderly patients [letter; comment] Levinson D. **JAMA** 1997 May 14;277(18):1436; discussion 1436-7. Comment on: JAMA 1997 Jan 8;277(2):155-6.

Primary prevention of cardiovascular disease endpoints using beta-blockers [letter; comment] Michalewiz L, et al. **JAMA** 1997 Jun 11;277(22):1759-60. Comment on: JAMA 1997 Mar 5;277(9):739-45.

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis [see comments] Psaty BM, et al. **JAMA** 1997 Mar 5;277(9):739-45. Comment in: JAMA 1997 Jun 11;277(22):1759-60. Comment in: ACP J Club 1997 Sep-Oct;127(2):36.

Adverse outcomes of underuse of beta-blockers in elderly patients [letter; comment] Rumboldt Z, et al. **JAMA** 1997 May 14;277(18):1435-6; discussion 1436-7. Comment on: JAMA 1997 Jan 8;277(2):115-21.

Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction [see comments] Soumerai SB, et al. **JAMA** 1997 Jan 8;277(2):115-21. Comment in: JAMA 1997 May 14;277(18):1433-4; discussion 1436-7. Comment in: JAMA 1997 May 14;277(18):1434; discussion 1436-7. Comment in: JAMA 1997 May 14;277(18):1434-5; discussion 1436-7. Comment in: JAMA 1997 May 14;277(18):1435; discussion 1436-7. Comment in: JAMA 1997 May 14;277(18):1435-6; discussion 1436-7.

Comparison of the therapeutic effects of the beta-blocking agent bisoprolol and the calcium-blocking agent diltiazem in patients with heart failure due to dilated cardiomyopathy. Suwa M, et al. **Jpn Circ J** 1996 Oct; 60(10):767-73

Effect of a new beta-blocker, nipradilol, on cardiac function and neurohumoral factors in idiopathic dilated cardiomyopathy. Yoshikawa T, et al. **Jpn Circ J** 1996 May; 60(5):285-92

Chronic therapy with nipradilol, a beta-adrenergic blocker, attenuated left ventricular remodeling following myocardial infarction in rats. Sonoki H, et al. **Jpn J Pharmacol** 1997 Jun;74(2):171-8

Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group [see comments] **Lancet** 1997 Feb 8; 349(9049):375-80. Comment in: ACP J Club 1997 Jul-Aug;127(1):3.

Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP) [see comments] Merkel C, et al. **Lancet** 1996 Dec 21-28;348(9043):1677-81. Comment in: ACP J Club 1997 May-Jun;126(3):68.

Carvedilol for heart failure. **Med Lett Drugs Ther** 1997 Sep 26;39(1010):89-91

Digoxin in patients with heart failure [letter; comment] Böhm M. **N Engl J Med** 1997 Jul 10;337(2):129-30; discussion 130-1. Comment on: N Engl J Med 1997 Feb 20;336(8):525-33.

Adjunctive drug therapy for acute myocardial infarction [letter; comment] Bostom AG. **N Engl J Med** 1997 May 15;336(20):1455; discussion 1455-6. Comment on: N Engl J Med 1996 Nov 28;335(22):1660-7.

Implantable defibrillators in patients with coronary artery disease at high risk for ventricular arrhythmia [letter; comment] Clesham GJ, et al. **N Engl J Med** 1997 Jun 5; 336(23):1676; discussion 1677. Comment on: N Engl J Med 1996 Dec 26;335(26):1933-40.

Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery [letter; comment] Devereaux PJ, et al. **N Engl J Med** 1997 May 15;336(20):1452-3; discussion 1453-4. Comment on: N Engl J Med 1996 Dec 5;335(23):1713-20.

Reducing cardiovascular risk in patients undergoing noncardiac surgery [editorial; comment] Eagle KA, et al. **N Engl J Med** 1996 Dec 5;335(23):1761-3. Comment on: N Engl J Med 1996 Dec 5;335(23):1713-20.

Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group [see comments] [published erratum appears in N Engl J Med 1997 Apr 3;336(14):1039] Mangano DT, et al. **N Engl J Med** 1996 Dec 5;335(23):1713-20. Comment in: N Engl J Med 1996 Dec 5;335(23):1761-3. Comment in: N Engl J Med 1997 May 15;336(20):1452; discussion 1453-4. Comment in: N Engl J Med 1997 May 15;336(20):1452-3; discussion 1453-4. Comment in: N Engl J Med 1997 May 15;336(20):1453; discussion 1453-4. Comment in: ACP J Club 1997 May-Jun;126(3):58.

Carvedilol in patients with chronic heart failure [letter; comment] Moyé LA, et al. **N Engl J Med** 1996 Oct 24; 335(17):1318; discussion 1319-20. Comment on: N Engl J Med 1996 May 23;334(21):1349-55.

Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery [letter; comment] Petros JA. **N Engl J Med** 1997 May 15;336(20):1452; discussion 1453-4 . Comment on: N Engl J Med 1996 Dec 5;335(23):1713-20.

Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery [letter; comment] Reis SE, et al. **N Engl J Med** 1997 May 15;336(20):1453; discussion 1453-4 . Comment on: N Engl J Med 1996 Dec 5;335(23):1713-20.

Carvedilol in patients with chronic heart failure [letter; comment] von Olshausen K, et al. **N Engl J Med** 1996 Oct 24;335(17):1318-9; discussion 1319-20. Comment on: N Engl J Med 1996 May 23;334(21):1349-55.

Effect of dapiprazole, an alpha-adrenergic blocking agent, on aqueous humor dynamics in pigmentary glaucoma. Mastropasqua L, et al. **Ophthalmic Res** 1996;28(5):312-8

Clinical presentation and initial treatment patterns in patients with exfoliation glaucoma versus primary open-angle glaucoma. Konstas AG, et al. **Ophthalmic Surg Lasers** 1997 Feb;28(2):111-7

The usefulness of dapiprazole, an alpha-adrenergic blocking agent, in pigmentary glaucoma. Mastropasqua L, et al. **Ophthalmic Surg Lasers** 1996 Sep;27(9):806-9

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Alm A, et al. **Ophthalmology** 1995 Dec; 102(12):1743-52

Association of retinal capillary perfusion with visual status during chronic glaucoma therapy. Sponsel WE, et al. **Ophthalmology** 1997 Jun;104(6):1026-32

Response of neurocardiac syncope to beta-blocker therapy: interaction between age and parasympathetic tone. Slotwiner DJ, et al. **Pacing Clin Electrophysiol** 1997 Mar; 20(3 Pt 2):810-4

Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation. Wiesfeld AC, et al. **Pacing Clin Electrophysiol** 1996 Jul;19(7):1026-35 (77 ref.)

Long-term efficacy and safety of atenolol for supraventricular tachycardia in children. Mehta AV, et al. **Pediatr Cardiol** 1996 Jul-Aug;17(4):231-6

New antiarrhythmic drug in pediatric use: sotalol. Pfammatter JP, et al. **Pediatr Cardiol** 1997 Jan-Feb; 18(1):28-34 (62 ref.)

Carvedilol inhibits aortic lipid deposition in the hypercholesterolemic rat. Feuerstein GZ, et al. **Pharmacology** 1997 Jan;54(1):24-32

Pharmacologic prophylaxis of supraventricular tachyarrhythmias after coronary artery bypass. Dorovenis SA, et al. **Pharmacotherapy** 1996 Jul-Aug;16(4):615-8 (24 ref.)

Antianginal response to once-daily diltiazem CD in patients receiving concomitant beta-blockers, long-acting nitrates, or both. Diltiazem CD Study Group. Heller GV, et al. **Pharmacotherapy** 1997 Jul-Aug;17(4):760-6

Current approaches to stable angina. Jackson G. **Practitioner** 1996 Nov;240(1568):642-4, 647-8

Increased survival with beta-blockers: importance of

ancillary properties. Soriano JB, et al. **Prog Cardiovasc Dis** 1997 Mar–Apr;39(5):445–56

Psychopharmacologic treatment of pathologic aggression. Fava M. **Psychiatr Clin North Am** 1997 Jun;20(2):427–51 (176 ref.)

Beta–blockade in heart failure: a potential role. Kwasniewski R, et al. **S D J Med** 1997 Jan;50(1):25–6

Intravenous salbutamol treatment for penile erection arising during cystoscopy of cervical spinal cord injury patients. Vaidyanathan S, et al. **Spinal Cord** 1996 Nov;34(11):691–5

The use of ratings of perceived exertion for exercise prescription in patients receiving beta–blocker therapy. Eston R, et al. **Sports Med** 1996 Mar;21(3):176–90 (122 ref.)

Myocardial protection by pressure– and volume–controlled continuous hypothermic coronary perfusion (PVC–CONTHY–CAP) in combination with ultra–short beta–blockade and nitroglycerine. Borowski A, et al. **Thorac Cardiovasc Surg** 1997 Apr;45(2):51–4

Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine. Robin AL. **Trans Am Ophthalmol Soc** 1996;94:89–101; discussion 101–3

Beta–blockers and nitrates in patients with peripheral arterial occlusive disease: long–term findings. Schweizer J, et al. **Vasa** 1997;26(1):43–6

Use of beta–blockade to prevent death after noncardiac surgery. Wallace A, et al. **West J Med** 1997 Mar; 166(3):203–4

Successful treatment of a patient with chronic fatigue using head–up tilt guided therapy. Handa KK, et al. **Wis Med J** 1997 Mar;96(3):40–2

[Clinical effects of bisoprolol in congestive heart failure due to dilated cardiomyopathy] Li Z, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):683–6 (Eng. Abstr.) **(Chi)**

[Do beta–blockers have a role in the modern treatment of arterial hypertension?] Horký K. **Vnitr Lek** 1996 Jun; 42(6):420–5 (21 ref.) (Eng. Abstr.) **(Cze)**

[Secondary prevention after myocardial infarction; role of beta blockaders] Cohen–Solal A, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89 Spec No 3:43–6 (Eng. Abstr.) **(Fre)**

[Do diuretics and beta–blockers still have a role in the treatment of arterial hypertension in diabetic patients?] Passa P. **Diabetes Metab** 1997 Feb;23(1):109–11 (16 ref.) **(Fre)**

[Drug of the month. Maxsoten] Kulbertus H. **Rev Med Liege** 1996 May;51(5):382–4 **(Fre)**

[Treatment with a beta blocker and digitalis] Böhm M. **Anaesthesist** 1996 Sep;45(9):868 **(Ger)**

[Carvedilol] Antepohl W, et al. **Dtsch Med Wochenschr** 1997 Jun 20;122(25–26):833–4 **(Ger)**

[beta–Receptor blockers: a new principle in the therapy of heart failure? (editorial)] Schotten U, et al. **Dtsch Med Wochenschr** 1997 Mar 27;122(13):387–90 (14 ref.) **(Ger)**

[Therapy with beta blockers in heart failure. Recent studies of carvedilol] Böhm M, et al. **Fortschr Med** 1996 May 10; 114(13):167–8 (0 ref.) **(Ger)**

[Beta blocker for therapy of heart failure. Decreased mortality and fewer clinic admissions (news)] Pickl S. **Fortschr Med** 1997 Apr 20;115(11):22 **(Ger)**

[Beta blockers in chronic heart failure. Clinical position on the topic (interview)] Dominiak P, et al. **Internist (Berl)** 1996 Dec;37(12):1274–8; discussion 1279 **(Ger)**

[Beta blockers in heart failure (editorial)] Heinzl S. **Med Monatsschr Pharm** 1996 Feb;19(2):37 **(Ger)**

[Beta receptors and beta blockers in heart failure] Heinzl S. **Med Monatsschr Pharm** 1997 Jun;20(6):146–8 (4 ref.) **(Ger)**

[Beta receptor blockers: renaissance in therapy of heart failure (editorial)] Klein W. **Wien Klin Wochenschr** 1997 Apr 11;109(7):219–21 **(Ger)**

[Beta blockers—1997 update] Stoschitzky K, et al. **Wien Klin Wochenschr** 1997 Apr 11;109(7):222–31 (71 ref.) (Eng. Abstr.) **(Ger)**

[Angiotensin II antagonist for heart insufficiency] **Z Kardiol** 1997 Jun;86(6 Suppl):1–8 **(Ger)**

[Beta–blocker therapy in heart failure] Böhm M. **Z Kardiol** 1996;85 Suppl 7:IV–V **(Ger)**

[Therapy of chronic heart failure with beta–receptor blockers] Böhm M. **Z Kardiol** 1996;85 Suppl 7:11–21 (42 ref.) (Eng. Abstr.) **(Ger)**

[Beta–blockers and heart failure—a critical view] Erdmann E. **Z Kardiol** 1996;85 Suppl 7:35–8 (10 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of heart failure with beta–blockers?] Osterziel KJ, et al. **Z Kardiol** 1997 Jan;86(1):1–8 (63 ref.) (Eng. Abstr.) **(Ger)**

[New aspects of differential therapy of arterial hypertension with beta–blockers] Schwartzkopff B, et al. **Z Kardiol** 1996; 85 Suppl 7:31–4 (24 ref.) (Eng. Abstr.) **(Ger)**

[Renaissance of beta blocker therapy in myocardial infarct] Seidl K, et al. **Z Kardiol** 1996 Oct;85(10):737–44 (38 ref.) (Eng. Abstr.) **(Ger)**

[Value of beta–blocker therapy in treatment of coronary heart disease and sudden cardiac death with special reference to carvedilol] Zehender M, et al. **Z Kardiol** 1996;85 Suppl 7:23–9 (36 ref.) (Eng. Abstr.) **(Ger)**

[Comparative study of verapamil and bisoprolol in the secondary prevention of myocardial infarction] Sárosi I, et al. **Orv Hetil** 1997 Aug 3;138(31):1939–45 (40 ref.) (Eng. Abstr.) **(Hun)**

[Effectiveness and tolerability of bisoprolol vs. nifedipine in uremic patients with ischemic cardiopathy in dialysis treatment] Cice G, et al. **Cardiologia** 1997 Apr; 42(4):397–403 (Eng. Abstr.) **(Ita)**

[Abnormal vasomotor response of the forearm due to propranolol–induced loss of cardiopulmonary baroreflex sensitivity: experience with seven cases of recent myocardial infarct] De Vecchis R, et al. **Cardiologia** 1996 Aug;41(8):759–65 (Eng. Abstr.) **(Ita)**

[The effects of mid– and long–term administration (3–4 years) of carvedilol in patients with idiopathic dilated cardiomyopathy] Metra M, et al. **Cardiologia** 1997 May; 42(5):503–12 (Eng. Abstr.) **(Ita)**

[Prevention of sudden death in myocardial infarct: do experimental results help to understand the clinical reality? The case of the clinical trial SWORD (Survival With ORal D–sotalol)] Schwartz PJ. **Cardiologia** 1996 Aug; 41(8):739–45 **(Ita)**

[Beta–blocker therapy in tachycardic atrial fibrillation with heart failure (letter)] Misumi K. **J Cardiol** 1996 Nov; 28(5):301–3 **(Jpn)**

[How and to what extent has beta–blocker treatment been established for chronic heart failure?] Yokota Y. **J Cardiol** 1996 Aug;28(2):99–112 (113 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of nipradilol on aqueous flow in glaucoma patients treated with timolol] Nagataki S, et al. **Nippon Ganka Gakkai Zasshi** 1997 Mar;101(3):252–6 (Eng. Abstr.) **(Jpn)**

[Repair of total anomalous pulmonary venous return using an ultra–short acting beta blockade (esmolol)—case reports] Miyagawa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep;44(9):1814–7 (Eng. Abstr.) **(Jpn)**

[Case of dilated cardiomyopathy with marked improvement of the cardiac function with beta block treatment and exacerbation with the interruption of the treatment] Shimizu K, et al. **Nippon Naika Gakkai Zasshi** 1997 May 10;86(5):840–2 **(Jpn)**

[Adrenergic beta–antagonists: treatment of heart failure] Yokoyama M, et al. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):75–9 (5 ref.) **(Jpn)**

[Prevention of cardiac events by beta–blocking agents in elderly patients after myocardial infarction] Ishikawa K, et al. **Nippon Ronen Igakkai Zasshi** 1997 Apr;34(4):273–7 (Eng. Abstr.) **(Jpn)**

[The effect of ACE inhibitors, beta blockers and calcium antagonists on the responses to pressor stress tests in the elderly hypertensive patients] Suzuki Y, et al. **Nippon Ronen Igakkai Zasshi** 1996 Jan;33(1):27–32 (Eng. Abstr.) **(Jpn)**

[Treatment of elderly patients with hypertension—complications and current drug therapy] Takagawa Y, et al. **Nippon Ronen Igakkai Zasshi** 1997 Jan; 34(1):30–7 (Eng. Abstr.) **(Jpn)**

[Treatment of heart failure with beta–blockaders] Gundersen T, et al. **Tidsskr Nor Laegeforen** 1997 Feb 10;117(4):526–8 (30 ref.) (Eng. Abstr.) **(Nor)**

[Patients with diabetes mellitus—secodary prophylaxis after myocardial infarction] Gundersen T. **Tidsskr Nor Laegeforen** 1997 Jun 20;117(16):2335–6 (Eng. Abstr.) **(Nor)**

[Atenolol in treatment of patients with airway obstruction] Chazan R. **Pol Merkuriusz Lek** 1996 Dec;1(6):428–30 (44 ref.) (Eng. Abstr.) **(Pol)**

[Beta–adrenergic receptor blockers in the treatment of chronic heart failure] Mularek–Kubzdela T, et al. **Pol Merkuriusz Lek** 1996 Aug;1(2):120–3 (40 ref.) (Eng. Abstr.) **(Pol)**

[Left ventricular hypertrophy and cardiovascular risk. Critical analysis of the use of diuretics and adrenergic beta blockers] Albanesi Filho FM. **Arq Bras Cardiol** 1995 Dec; 65(6):549–54 **(Por)**

[Pharmacologic treatment of acute myocardial infarction: 2 large clinical trials at a central hospital] Fernando PB, et al. **Rev Port Cardiol** 1996 Sep;15(9):617–30, 611 (Eng. Abstr.) **(Por)**

[Differential combined drug therapy of phantom pain syndrome after amputation of extremity] Kukushkin ML, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):39–42 (Eng. Abstr.) **(Rus)**

[The effect of adrenoblockers on the ultrastructural changes in the epithelium and neural elements of the small intestine of suckling rabbits with experimental cholera] Lomov IuM, et al. **Arkh Patol** 1996 Nov–Dec;58(6):51–5 (Eng. Abstr.) **(Rus)**

[A comparative study of the membrane–protector efficacy of anaprilin and korinfar in hypertension patients] Gapon LI, et al. **Lik Sprava** 1996 Oct–Dec;(10–12):69–71 (Eng. Abstr.) **(Rus)**

[Beta–blockers in the treatment of open–angle glaucoma] Potocký M, et al. **Cesk Slov Oftalmol** 1996 Nov; 52(6):399–402 (Eng. Abstr.) **(Slo)**

[Carvedilol and heart failure: new findings (editorial)] Cosín Aguilar J. **Rev Esp Cardiol** 1996 Feb;49(2):85–7 **(Spa)**

[Beta–blockers in cardiac insufficiency: should they always be considered in the therapeutic strategy? Arguments in favor] de Teresa E. **Rev Esp Cardiol** 1997 May;50(5):300–3 (23 ref.) (Eng. Abstr.) **(Spa)**

[Beta–blockers in cardiac insufficiency: should they always be considered in the therapeutic strategy? Arguments against] Ortigosa Aso J, et al. **Rev Esp Cardiol** 1997 May; 50(5):304–7 (21 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Effect of propranolol on rat brain synaptosomal Na(+)–K(+)–ATPase, Mg(2+)–ATPase and Ca(2+)–ATPase. Gopalaswamy UV, et al. **Chem Biol Interact** 1997 Jan 24;103(1):51–8

Toxic doses of rac–, (–)–(S)– and (+)–(R)–propranolol in rats and rabbits. Toet AE, et al. **Chirality** 1996;8(6):411–7

Role of sensory neuropeptides in post–allergic propranolol–induced bronchoconstriction in guinea pigs in vivo [see comments] Fujimura M, et al. **Clin Exp Allergy** 1996 Dec;26(12):1428–35. Comment in: Clin Exp Allergy 1996 Dec;26(12):1343–6.

Experimental study of the detrimental effect of dopamine/glucagon combination in d,l–propranolol intoxication. Toet AE, et al. **Hum Exp Toxicol** 1996 May; 15(5):411–21

URINE

Efficient assay for the determination of atenolol in human plasma and urine by high–performance liquid chromatography with fluorescence detection. Chiu FC, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):473–7

Detection of beta–blockers in urine by solid–phase extraction–supercritical fluid extraction and gas chromatography–mass spectrometry. Hartonen K, et al. **J Chromatogr B Biomed Appl** 1996 Feb 9;676(1):45–52

Stimulants, narcotics and beta–blockers: 25 years of development in analytical techniques for doping control. Hemmersbach P, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6;687(1):221–38 (107 ref.)

High–performance liquid chromatography with amperometric detection applied to the screening of beta–blockers in human urine. Maguregui MI, et al. **J Chromatogr B Biomed Appl** 1995 Dec 1;674(1):85–91

Identification of talinolol metabolites in urine of man, dog, rat and mouse after oral administration by high–performance liquid chromatography–thermospray tandem mass spectrometry. Schupke H, et al. **J Mass Spectrom** 1996 Dec;31(12):1371–81

ADRENERGIC BETA–RECEPTOR AGONISTS see **ADRENERGIC BETA–AGONISTS**

ADRENERGIC BETA–RECEPTOR BLOCKADERS see **ADRENERGIC BETA–ANTAGONISTS**

ADRENERGIC BETA–RECEPTORS see **RECEPTORS, ADRENERGIC, BETA**

ADRENERGIC BETA–1 RECEPTORS see **RECEPTORS, ADRENERGIC, BETA–1**

ADRENERGIC BETA–2 RECEPTORS see **RECEPTORS, ADRENERGIC, BETA–2**

ADRENERGIC–BLOCKING AGENTS see **ADRENERGIC ANTAGONISTS**

ADRENERGIC FIBERS

Increased QT dispersion and cardiac adrenergic dysinnervation in diabetic patients with autonomic neuropathy. Shimabukuro M, et al. **Am J Cardiol** 1996 Nov 1;78(9):1057–9

CHEMISTRY

Postnatal changes in adrenergic and neuropeptide Y–containing nerve fibres in pineal gland of the pig. An immunohistochemical study. Przybylska–Gornowicz B, et al. **Folia Histochem Cytobiol** 1995;33(4):239–45

Prejunctional regulation by endogenous and exogenous acetylcholine of adrenergic nerve function in isolated canine mesenteric arteries. Zhang JX, et al. **Hypertens Res** 1997 Jun;20(2):119–25

CGRP–immunoreactive nerve fibers projecting to lumbar facet joints through the paravertebral sympathetic trunk in rats. Suseki K, et al. **Neurosci Lett** 1996 Dec 27; 221(1):41–4

Neurokinin–1 receptor–immunoreactive sympathetic preganglionic neurons: target specificity and ultrastructure. Llewellyn–Smith IJ, et al. **Neuroscience** 1997 Apr; 77(4):1137–49

DRUG EFFECTS

Long–latency responses of brain noradrenergic neurons to noxious stimuli are preferentially attenuated by intravenous morphine. Hirata H, et al. **Brain Res** 1996 Apr 1; 714(1–2):9–18

The depletion of monoamines blocks the sympathoinhibitory response to cocaine. Abrahams TP, et al. **J Auton Nerv Syst** 1996 May 6;58(3):170–6

Effect of sodium nitroprusside on norepinephrine overflow and antidiuresis induced by stimulation of renal nerves in anesthetized dogs. Maekawa H, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):211–7

Sympathetic, parasympathetic and non–autonomic contributions to cardiovascular spectral powers in unanesthetized spontaneously hypertensive rats. Daffonchio A, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1636–42

ADRENERGIC FIBERS

Changes in noradrenergic sensitivity to tumor necrosis factor-alpha in brains of rats administered clonidine. Ignatowski TA, et al. **J Neuroimmunol** 1996 Oct; 70(1):55–63

Neurochemical activity of noradrenergic neurons and pituitary-adrenal response after naloxone-induced withdrawal: the role of calcium channels. Vargas ML, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Apr; 355(4):501–6

Effects of potassium channel inhibitors on nitrergic and adrenergic neurotransmission in lamina propria of the female rabbit urethra. Zygmunt PK, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug–Sep; 354(3):336–42

Renal sympathetic nerve discharge mediated by the paraventricular nucleus is altered in STZ induced diabetic rats. Reynolds AY, et al. **Nebr Med J** 1996 Dec; 81(12):419–23

Electrophysiological and electrochemical responses of NMDA in the cerebellum: interactions with nonadrenergic pathway. Wang Y, et al. **Neuropharmacology** 1996 Jun; 35(6):671–8

ENZYMOLOGY

In sympathetic but not sensory neurones, phosphoinositide-3 kinase is important for NGF-dependent survival and the retrograde transport of 125I-betaNGF. Bartlett SE, et al. **Brain Res** 1997 Jul 4;761(2):257–62

Increased expression of nitric oxide synthase in a subpopulation of rat sympathetic neurons after axotomy – correlation with vasoactive intestinal peptide. Klimaschewski L, et al. **Cell Tissue Res** 1996 Sep; 285(3):419–25

METABOLISM

Expression of angiotensinogen mRNA and localization of angiotensin II and renin in peripheral adrenergic neurons in primary culture. Wang JM, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):876–81

ATP as a co-transmitter with noradrenaline in sympathetic nerves—function and fate. Kennedy C, et al. **Ciba Found Symp** 1996;198:223–35; discussion 235–8 (38 ref.)

The depletion of monoamines blocks the sympathoinhibitory response to cocaine. Abrahams TP, et al. **J Auton Nerv Syst** 1996 May 6;58(3):170–6

Distribution of immunoreactivity for the NK1 receptor on different subpopulations of sympathetic preganglionic neurons in the rat. Grkovic I, et al. **J Comp Neurol** 1996 Oct 21;374(3):376–86

Noradrenergic and dopaminergic systems in the central nervous system of the hedgehog (Erinaceus europaeus). Michaloudi HC, et al. **J Hirnforsch** 1996;37(3):319–50

Expression of RESP18 in peptidergic and catecholaminergic neurons. Darlington DN, et al. **J Histochem Cytochem** 1997 Sep;45(9):1265–77

Neurohistochemical evaluation of adrenergic innervation in fetal development of the white rat. Lotocki W, et al. **Rocz Akad Med Bialymst** 1996;41(2):390–6

PHYSIOLOGY

Sympathetic efferent pathways projecting bilaterally to the vas deferens in the rat. Kihara K, et al. **Anat Rec** 1997 Jun;248(2):291–9

Organization of NADPH-diaphorase-reactive neurons and catecholaminergic fibers in human intermediolateral cell column. Smithson IL, et al. **Brain Res** 1996 Jun 3; 723(1–2):218–22

The locus coeruleus noradrenergic system in the rat brain studied by dual-probe microdialysis. Van Gaalen M, et al. **Brain Res** 1997 Jul 18;763(1):56–62

Central noradrenergic lesioning using anti-DBH-saporin: anatomical findings. Wrenn CC, et al. **Brain Res** 1996 Nov 18;740(1–2):175–84

Reactions of the middle meningeal artery of the cat to neural and humoral stimulation. Michalicek J, et al. **Cephalalgia** 1996 Feb;16(1):27–36

Neuropeptide Y innervation of nitric oxide-synthesizing sympathetic preganglionic neurons in humans. Benarroch EE, et al. **Clin Auton Res** 1997 Feb;7(1):31–4

The neural correlates of the noradrenergic modulation of human attention, arousal and learning. Coull JT, et al. **Eur J Neurosci** 1997 Mar;9(3):589–98

Adrenergic innervation of the ovarian cortical structures in the sexual cycle of the white rat. Lotocki W. **Folia Histochem Cytobiol** 1996;34 Suppl 1:93–4

The mechanism of altered neural function in a rat model of acute colitis. Jacobson K, et al. **Gastroenterology** 1997 Jan;112(1):156–62

Attenuated inhibition of adrenergic contraction by nitric oxide in injured guinea pig femoral artery. Matsuda H, et al. **Heart Vessels** 1997;12(1):10–8

Effect of sciatic denervation on cell-mediated immunity. Kubera M, et al. **Int J Immunopharmacol** 1997 Jan; 19(1):25–9

Transplanted sweat glands from mature and aged donors determine cholinergic phenotype and altered density of host sympathetic nerves [corrected and republished article originally printed in J Auton Nerv Syst 1996 May 6;58(3):153–62] Cowen T, et al. **J Auton Nerv Syst** 1996 Sep 12;60(3):215–24

Transplanted sweat glands from mature and aged donors determine cholinergic phenotype and altered density of host sympathetic nerves [corrected and republished in J Auton Nerv Syst 1996 Sep 12;60(3):215–24] Cowen T, et al. **J Auton Nerv Syst** 1996 May 6;58(3):153–62

Two distinct mechanisms generate the respiratory modulation in fibre activity of the rat cervical sympathetic trunk. Häbler HJ, et al. **J Auton Nerv Syst** 1996 Nov 6; 61(2):116–22

Heme oxygenase and NO-synthase in the human prostate—relation to adrenergic, cholinergic and peptide-containing nerves. Hedlund P, et al. **J Auton Nerv Syst** 1997 Apr 14;63(3):115–26

Noradrenergic input to nociceptive modulatory neurons in the rat rostral ventromedial medulla. Meng XW, et al. **J Comp Neurol** 1997 Jan 20;377(3):381–91

Bulbospinal sympatho-excitatory neurons in the rat caudal raphe. Pilowsky PM, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1618–23

Sympathectomy induces adrenergic excitability of cutaneous C-fiber nociceptors. Bossut DF, et al. **J Neurophysiol** 1996 Jan;75(1):514–7

Vagal, sympathetic and somatic sensory inputs to upper cervical (C1–C3) spinothalamic tract neurons in monkeys. Chandler MJ, et al. **J Neurophysiol** 1996 Oct;76(4):2555–67

Stimulation within the rostral ventrolateral medulla can evoke monosynaptic GABAergic IPSPs in sympathetic preganglionic neurons in vitro. Deuchars SA, et al. **J Neurophysiol** 1997 Jan;77(1):229–35

Electrotonic coupling between rat sympathetic preganglionic neurones in vitro. Logan SD, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):491–502

Potentiation of IPSCs by nitric oxide in immature rat sympathetic preganglionic neurones in vitro. Wu SY, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):479–90

Scintigraphic detection of regional disruption of the adrenergic nervous system in sarcoid heart disease. Misumi I, et al. **Jpn Circ J** 1996 Oct;60(10):774–8

Adrenergic vascular control. Mano T. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S85–9

Inhibitory H3 receptors on sympathetic nerves of the pithed rat: activation by endogenous histamine and operation in spontaneously hypertensive rats. Godlewski G, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):261–6

Beta-adrenergic modulation of GABAergic inhibition in the deep cerebellar nuclei of F344 rats. Gould TJ, et al. **Neuropharmacology** 1997 Jan;36(1):75–81

Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Maldonado R. **Neurosci Biobehav Rev** 1997 Jan; 21(1):91–104 (137 ref.)

A- and C-reflexes elicited in cardiac sympathetic nerves by single shock to a somatic afferent nerve include spinal and supraspinal components in anesthetized rats. Kimura A, et al. **Neurosci Res** 1996 May;25(1):91–6

Nonadrenergic relaxation of the cat cervical trachea evoked by stimulation in the lateral hypothalamic area. Tatsuta H, et al. **Neurosci Res** 1996 Dec;26(4):315–22

Central noradrenergic neurons signal via ATP to elicit vasopressin responses to haemorrhage. Buller KM, et al. **Neuroscience** 1996 Aug;73(3):637–42

Maintenance of sympathetic innervation into the hippocampal formation requires a continuous local availability of nerve growth factor. Conner JM, et al. **Neuroscience** 1996 Jun;72(4):933–45

Stimulation of lumbar sympathetic nerves may produce hindlimb vasodilation via the release of pre-formed stores of nitrosyl factors. Davisson RL, et al. **Neuroscience** 1996 Jun;72(4):881–7

Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation. Jung M, et al. **Neuroscience** 1996 Sep;74(2):403–14

Effect of hippocampal sympathetic ingrowth and cholinergic denervation on hippocampal phospholipase C activity and G-protein function. Kolasa K, et al. **Neuroscience** 1997 Mar;77(1):111–20

Mechanisms in adrenergic dependent onset of torsades de pointes. Abildskov JA, et al. **Pacing Clin Electrophysiol** 1997 Jan;20(1 Pt 1):88–94

Consequences of selective blockade of septal noradrenergic afferents on anxiety and spatial working memory performance in mice. Belotti M, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):541–7

Adrenergic mechanisms in the control of gastrointestinal motility: from basic science to clinical applications. De Ponti F, et al. **Pharmacol Ther** 1996;69(1):59–78 (378 ref.)

Long-term inhibition of NO synthase induces cardiac hypertrophy with a decrease in adrenergic innervation. Gerová M, et al. **Physiol Res** 1996;45(4):339–44

Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Bremner JD, et al. **Synapse** 1996 May; 23(1):28–38 (138 ref.)

Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Bremner JD, et al. **Synapse** 1996 May;23(1):39–51 (118 ref.)

Noradrenergic neurons release both noradrenaline and neuropeptide Y from a single pool: the large dense cored vesicles. De Potter WP, et al. **Synapse** 1997 Jan;25(1):44–55

[Sympathetic skin responses and variability of the R-R interval: correlation with the severity stages of diabetic polyneuropathy] Chassande B, et al. **Rev Neurol (Paris)** 1996 Oct;152(10):623–9 (Eng. Abstr.) **(Fre)**

[Nonadrenergic noncholinergic regulation of gallstone containing and gallstone free human gallbladders] Sänger P, et al. **Zentralbl Chir** 1997;122(5):418–24 (Eng. Abstr.) **(Ger)**

[Mechanism of potentiation of duodenum contraction after stimulation of the sympathetic fibers] Smirnov VM, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):11–4 **(Rus)**

RADIONUCLIDE IMAGING

Use of [123I]MIBG to assess cardiac adrenergic innervation: experience in hypertensive cardiopathy and left ventricular aneurysms. Giordano A, et al. **Q J Nucl Med** 1995 Dec; 39(4 Suppl 1):44–8

ULTRASTRUCTURE

Ultrastructure of sympathetic axons and their structural relationship with vascular smooth muscle. Luff SE. **Anat Embryol (Berl)** 1996 Jun;193(6):515–31 (150 ref.)

The sensory branch of the pudendal nerve is the major route for adrenergic innervation of the penis in the rat. Galindo R, et al. **Anat Rec** 1997 Apr;247(4):479–85

Ultrastructural evidence for a separate, small synaptic vesicle (SSV) pathway in ligated bovine splenic nerves, incubated in vitro. Quatacker J, et al. **Brain Res** 1996 Aug 26; 731(1–2):101–7

Persistent correlation between expression of a sulfated carbohydrate antigen and adrenergic differentiation in cultures of quail trunk neural crest cells. Hennig AK, et al. **Differentiation** 1995 Dec;59(5):299–306

Ultrastructural relationships between noradrenergic nerve fibers and non-neuronal elements in the rat cerebral cortex. Paspalas CD, et al. **Glia** 1996 Jun;17(2):133–46

Ultrastructural localization of sympathetic axons in experimental rat sciatic nerve neuromas. Small JR, et al. **J Neurocytol** 1996 Oct;25(10):573–82

Arborization pattern of sympathetic preganglionic axons in the rat superior cervical and stellate ganglia. Asamoto K, et al. **Neurosci Res** 1997 Jul;28(3):235–41

[The effect of chemical sympathectomy on the adrenergic innervation of the blood vessels belonging to different organs in salt-sensitive and salt-resistant Dahl-strain rats] Leont'eva GR, et al. **Morfologiia** 1996;110(4):105–8 (Eng. Abstr.) **(Rus)**

[Changes in the cerebrovascular adrenergic innervation and the neurons of the locus coeruleus in the brain stem during action on the hypothalamus] Shustova TI, et al. **Morfologiia** 1995;108(3):15–20 (Eng. Abstr.) **(Rus)**

ADRENERGIC NEURON AGENTS see **ADRENERGIC AGENTS**

ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC**

ADRENERGIC RELEASE INHIBITORS see **ADRENERGIC AGENTS**

ADRENERGIC REUPTAKE INHIBITORS see **ADRENERGIC UPTAKE INHIBITORS**

ADRENERGIC SYNTHESIS INHIBITORS see **ADRENERGIC AGENTS**

ADRENERGIC UPTAKE INHIBITORS

see related
AMPHETAMINES
ANTIDEPRESSIVE AGENTS, TRICYCLIC
DOPAMINE UPTAKE INHIBITORS

ADMINISTRATION & DOSAGE

[Ultrastructural changes in various regions of rat brain after administration of amitriptyline] Bardakhch'ian EA, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):457–61 **(Rus)**

ADVERSE EFFECTS

Combined drug therapy debate (continued) [letter; comment] Zavodnick JM. **J Am Acad Child Adolesc Psychiatry** 1997 Jan;36(1):1–3. Comment on: J Am Acad Child Adolesc Psychiatry 1995 May;34(5):540. Comment on: J Am Acad Child Adolesc Psychiatry 1996 Jan;35(1):1–2.

DIAGNOSTIC USE

Assessment of noradrenergic functioning in patients with non-combat-related posttraumatic stress disorder: a study with desmethylimipramine and orthostatic challenges. Yatham LN, et al. **Psychiatry Res** 1996 Jun 26;63(1):1–6

PHARMACOKINETICS

Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods. Mehvar R, et al. **Clin Pharmacokinet** 1997 Aug;33(2):122–41 (88 ref.)

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Dostert P, et al. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S23–35; discussion S71–3 (80 ref.)

Pharmacokinetics of milnacipran in comparison with other

antidepressants. Puozzo C, et al.
Int Clin Psychopharmacol 1996 Sep;11 Suppl 4:15-27 (90 ref.)

Reserpine- and tetrabenazine-sensitive transport of (3)H-histamine by the neuronal isoform of the vesicular monoamine transporter. Erickson JD, et al.
J Mol Neurosci 1995;6(4):277-87

PHARMACOLOGY

Designing a new generation of antidepressant drugs. Pinder RM. **Acta Psychiatr Scand Suppl** 1997;391:7-13

Inhibitory effect of noradrenaline uptake inhibitors on contractions of rat aortic smooth muscle. Huang Y.
Br J Pharmacol 1996 Feb;117(3):533-539

Modelling the changes induced by chronic desipramine treatment on the factors governing the agonism at prejunctional alpha 2-adrenoceptors. Sallés J, et al.
Br J Pharmacol 1996 Mar;117(6):1286-92

REM sleep inhibition by desipramine: evidence for an alpha-1 adrenergic mechanism. Ross RJ, et al.
Brain Res 1995 Dec 1;701(1-2):129-34

omega-Conotoxin GVIA and desipramine insensitive norepinephrine efflux from cardiac sympathetic nerve terminal. Yamazaki T, et al. **Brain Res** 1997 Jul 4; 761(2):329-32

Down-regulation of rat beta-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [3H] CGP-12177 binding reveals rapid (24 hour) modulation. Newman-Tancredi A, et al. **Brain Res Bull** 1996;41(2):93-6

Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. Illi A, et al. **Eur J Clin Pharmacol** 1996; 51(3-4):273-6

NMDA receptor antagonists increase the release of dopamine in the substantia nigra of reserpine-treated rats. Biggs CS, et al. **Eur J Pharmacol** 1996 Mar 28;299(1-3):83-91

Behavioural responsiveness to picrotoxin and desipramine in adult rats prenatally exposed to different benzodiazepine receptor agonists. Cannizzaro C, et al.
Eur Neuropsychopharmacol 1995 Dec;5(4):523-6

Protriptyline, chronic tension-type headaches, and weight loss in women. Cohen GL. **Headache** 1997 Jul-Aug; 37(7):433-6

Preclinical pharmacology of milnacipran. Briley M, et al.
Int Clin Psychopharmacol 1996 Sep;11 Suppl 4:9-14 (24 ref.)

Effects of locally administered desipramine on myocardial interstitial norepinephrine levels. Yamazaki T, et al.
J Auton Nerv Syst 1996 Dec 14;61(3):264-8

Suppression of the rat micturition reflex by imipramine. Sohn UD, et al. **J Auton Pharmacol** 1997 Feb;17(1):35-41

Neurotrophin-3- and norepinephrine-mediated adrenergic differentiation and the inhibitory action of desipramine and cocaine. Zhang JM, et al. **J Neurobiol** 1997 Mar; 32(3):262-80

Effects of amitriptyline on rat plasma and brain content of monoamine precursors and other large neutral amino acids. Eriksson T, et al. **J Pharm Pharmacol** 1995 Dec; 47(12A):1007-14

Platelet I1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients. Piletz JE, et al. **J Psychiatr Res** 1996 May-Jun;30(3):169-84

Rauwolscine potentiates the effect of desipramine on limbic noradrenaline efflux. Palij P, et al. **Neuroreport** 1996 Apr 26;7(6):1121-4

Exposure to threshold doses of nicotine in utero: III. Augmentation of the prolactin and ACTH response to 8-OH DPAT by desipramine treatment is compromised in adult male offspring. Poland RE, et al.
Neurotoxicology 1996 Summer;17(2):351-8

Time-dependent recovery of in vivo binding sites after drug dosing: a method for radiotracer evaluation. Kilbourn MR. **Nucl Med Biol** 1997 Jan;24(1):115-8

Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline, and fluvoxamine. I. Social interactions. Cutler MG, et al. **Pharmacol Biochem Behav** 1997 May-Jun; 57(1-2):119-25

Effects of tetrabenazine on methamphetamine-induced hyperactivity in mice are dependent on order and time-course of administration. Kuribara H.
Pharmacol Biochem Behav 1997 Jan;56(1):9-14

Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze. Rodgers RJ, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):127-36

Effects of desipramine and fluvoxamine on timing behavior investigated with the fixed-interval peak procedure and the interval bisection task. Ho MY, et al.
Psychopharmacology (Berl) 1996 Jun;125(3):274-84

Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy [letter; comment] Boyeson MG. **Stroke** 1996 Nov; 27(11):2145-6. Comment on: Stroke 1996 Jul;27(7):1211-4.

[The effect of lithium chloride on the desynchronization of "reserpine-induced depression"] Zamoshchina TA, et al.
Eksp Klin Farmakol 1997 Jan-Feb;60(1):3-6 (Eng. Abstr.) **(Rus)**

POISONING

Orthostatic hypotension due to suppression of vasomotor outflow after amphetamine intoxication. Smit AA, et al.
Mayo Clin Proc 1996 Nov;71(11):1067-70

THERAPEUTIC USE

Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Barr LC, et al. **Am J Psychiatry** 1997 Sep;154(9):1293-5

Pharmacological options for the management of dyskinesias. Shale H, et al. **Drugs** 1996 Dec;52(6):849-60 (89 ref.)

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. Berzewski H, et al.
Eur Neuropsychopharmacol 1997 Apr;7 Suppl 1:S37-47; discussion S71-3

Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Bosc M, et al. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S57-70; discussion S71-3

Do noradrenaline and serotonin differentially affect social motivation and behaviour? Dubini A, et al.
Eur Neuropsychopharmacol 1997 Apr;7 Suppl 1:S49-55; discussion S71-3

The effects of antidepressants on psychomotor function with particular reference to reboxetine. Hindmarch I.
Eur Neuropsychopharmacol 1997 Apr;7 Suppl 1:S17-21; discussion S71-3 (31 ref.)

Noradrenaline in basic models of depression. Leonard BE.
Eur Neuropsychopharmacol 1997 Apr;7 Suppl 1:S11-6; discussion S71-3 (17 ref.)

Is there a role for a pure noradrenergic drug in the treatment of depression? Montgomery SA.
Eur Neuropsychopharmacol 1997 Apr;7 Suppl 1:S3-9; discussion S71-3 (40 ref.)

Managing the patient with atypical chest pain. Snape WJ Jr. **Hosp Pract (Off Ed)** 1997 Apr 15;32(4):159-73; discussion 173-4 passim

An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group. Berk M, et al.
Int Clin Psychopharmacol 1997 May;12(3):137-40

Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Fabre L, et al.
Int Clin Psychopharmacol 1996 Jun;11(2):119-27

Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Kasper S, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:35-9 (19 ref.)

Clinical efficacy of milnacipran: placebo-controlled trials. Lecrubier Y, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:29-33 (13 ref.)

Milnacipran and selective serotonin reuptake inhibitors in major depression. Lopez-Ibor J, et al.
Int Clin Psychopharmacol 1996 Sep;11 Suppl 4:41-6 (32 ref.)

Efficacy and tolerability of milnacipran: an overview. Montgomery SA, et al. **Int Clin Psychopharmacol** 1996 Sep; 11 Suppl 4:47-51 (24 ref.)

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Puech A, et al.
Int Clin Psychopharmacol 1997 Mar;12(2):99-108

Nortriptyline for the treatment of depression in progressive supranuclear palsy [letter] Tamai S, et al.
J Am Geriatr Soc 1997 Aug;45(8):1033-4

Spinal manipulation vs. amitriptyline for the treatment of chronic tension headache: a randomized clinical trial [letter; comment] Hobson WH, et al.
J Manipulative Physiol Ther 1996 May;19(4):278-9. Comment on: J Manipulative Physiol Ther 1995 Mar-Apr;18(3):148-54.

The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. Bowsher D.
J Pain Symptom Manage 1997 Jun;13(6):327-31

[Drug therapy of enuresis] von Gontard A, et al.
Z Kinder Jugenpsychiatr 1996 Mar;24(1):18-33 (65 ref.) **(Ger)**

ADRENOCEPTORS see **RECEPTORS, ADRENERGIC**

ADRENOCHROME

ANALOGS & DERIVATIVES

Effects of carbazochrome sodium sulfonate (AC-17) on oleic acid-induced lung injury. Moriuchi H, et al.
Pharmacol Toxicol 1995 Sep;77(3):238-40

ADRENOCORTICOTROPIC HORMONE see **CORTICOTROPIN**

ADRENOCORTICOTROPIC HORMONE RECEPTORS see **RECEPTORS, CORTICOTROPIN**

ADRENOCORTICOTROPIN see **CORTICOTROPIN**

ADRENODOXIN

ANALYSIS

Ontogeny of immunoreactive steroidogenic proteins (adrenodoxin and cytochrome p-450(21)) in the interrenals of the teleost Lates calcarifer. Sampath-Kumar R, et al.
Gen Comp Endocrinol 1996 Apr;102(1):147-55

BIOSYNTHESIS

Cloning and sequence analysis of a full-length cDNA of rat adrenodoxin. Sagara Y, et al. **Biol Pharm Bull** 1996 Jan; 19(1):39-41

[Synthesis in Escherichia coli and certain properties of hybrid protein consisting of a modified precursor of adrenodoxin reductase and shortened precursor of adrenodoxin] Isaeva LV, et al. **Biokhimiia** 1996 Aug;61(8):1448-59 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Langmuir-Blodgett films of cytochrome P450scc and its complex with adrenodoxin. Guryev OL, et al.
Biochemistry (Mosc) 1997 Jun;62(6):641-7

Identification of intermediates in the conversion of cholesterol to pregnenolone with a reconstituted cytochrome p-450scc system: accumulation of the intermediate modulated by the adrenodoxin level. Sugano S, et al. **J Biochem (Tokyo)** 1996 Oct;120(4):780-7

Conformational stability of adrenodoxin mutant proteins. Burova TV, et al. **Protein Sci** 1996 Sep;5(9):1890-7

Preparation and crystallization of a cross-linked complex of bovine adrenodoxin and adrenodoxin reductase. Lapko A, et al. **Proteins** 1997 Jun;28(2):289-92

[Crystallization of a covalently-linked complex of adrenodoxin and adrenodoxin reductase] Lapko AG, et al.
Biokhimiia 1996 Sep;61(9):1637-47 (Eng. Abstr.) **(Rus)**

GENETICS

Messenger RNAs encoding steroidogenic enzymes are expressed in rodent brain. Strömstedt M, et al.
Brain Res Mol Brain Res 1995 Dec 1;34(1):75-88

Developmental expression of placental trophoblast P-450 cholesterol side-chain cleavage, adrenodoxin and delta 5-3 beta-hydroxysteroid dehydrogenase/isomerase messenger ribonucleic acids during baboon pregnancy. Babischkin JS, et al. **Placenta** 1996 Nov;17(8):595-602

METABOLISM

Different effects of carboxy-terminal deletion in the adrenodoxin molecule on cytochrome c and acetylated cytochrome c reductions. Sagara Y, et al.
Biol Pharm Bull 1996 Nov;19(11):1401-6

Specific aspects of electron transfer from adrenodoxin to cytochromes p450scc and p45011beta. Beckert V, et al.
J Biol Chem 1997 Feb 21;272(8):4883-8

Association of Ad4BP/SF-1 transcription factor with steroidogenic activity in oncogene-transformed granulosa cells. Keren-Tal I, et al. **Mol Cell Endocrinol** 1997 Mar 14;127(1):49-57

Preimplantation mouse blastocysts fail to express CYP genes required for estrogen biosynthesis. Strömstedt M, et al.
Mol Reprod Dev 1996 Apr;43(4):428-36

ADRENODOXIN REDUCTASE see **FERREDOXIN-NADP REDUCTASE**

ADRENOGENITAL SYNDROME see **ADRENAL HYPERPLASIA, CONGENITAL**

ADRENOLEUKODYSTROPHY

Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Moser HW. **Brain** 1997 Aug;120 (Pt 8):1485-508 (173 ref.)

A mouse model for X-linked adrenoleukodystrophy. Lu JF, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9366-71

BLOOD

Effect of erucic acid on platelets in patients with adrenoleukodystrophy. Kickler TS, et al.
Biochem Mol Med 1996 Apr;57(2):125-33

Red blood cell ghosts are affected by adrenoleucodystrophy. Arienti G, et al. **Eur J Clin Invest** 1996 Oct;26(10):917-22

Decreased platelet membrane anisotropy in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides. Stöckler S, et al. **J Inherit Metab Dis** 1997 Mar;20(1):54-8

COMPLICATIONS

Cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy. Edwin D, et al. **Ann Neurol** 1996 Oct;40(4):675-8

Variability of endocrinological dysfunction in 55 patients with X-linked adrenoleucodystrophy: clinical, laboratory and genetic findings [see comments] Korenke GC, et al.
Eur J Endocrinol 1997 Jul;137(1):40-7. Comment in: Eur J Endocrinol 1997 Jul;137(1):10-2.

Adrenoleukodystrophy presenting as postperfusion syndrome [letter] Luciani GB, et al. **N Engl J Med** 1997 Mar 6; 336(10):731-2

Adrenomyeloneuropathy: a rare cause of Addison's disease? Hochstenbag MM, et al. **Neth J Med** 1996 Aug;49(2):77-81

[A case of adult type adrenoleukodystrophy with an acute onset and repeated episodes of ataxic dysarthria] Ochi H, et al. **Rinsho Shinkeigaku** 1996 Nov;36(11):1229-33 (Eng.

ADRENOLEUKODYSTROPHY

Abstr.) **(Jpn)**

[Late-onset adrenomyeloneuropathy perplexed with spondylosis. A case report] Sakai H, et al. **Rinsho Shinkeigaku** 1996 Feb;36(2):352-4 (Eng. Abstr.) **(Jpn)**

CONGENITAL see **PEROXISOMAL DISORDERS**

DIAGNOSIS

Adrenoleukodystrophy indicated by abnormal electro-encephalography. Wada N, et al. **Acta Paediatr Jpn** 1996 Aug;38(4):352-6

Location of pyramidal and spinothalamic tracts [letter; comment] Yagishita A, et al. **AJNR Am J Neuroradiol** 1997 Jan;18(1):195-6. Comment on: AJNR Am J Neuroradiol 1995 Jun-Jul;16(6):1227-37.

Localized proton magnetic resonance spectroscopy in patients with adult adrenoleukodystrophy. Increase of choline compounds in normal appearing white matter. Tourbah A, et al. **Arch Neurol** 1997 May;54(5):586-92

Central nervous system white matter diseases other than multiple sclerosis. O'Riordan JI. **Curr Opin Neurol** 1997 Jun;10(3):211-4 (41 ref.)

Adrenoleukodystrophy. Raja U, et al. **Indian Pediatr** 1995 Sep;32(9):1016-19 (10 ref.)

DNA diagnosis of X-linked adrenoleukodystrophy. Seneca S, et al. **J Inherit Metab Dis** 1995;18 Suppl 1:34-44 (60 ref.)

Unusual lateralization of adrenoleukodystrophy lesions on neuroimaging. Terakawa H, et al. **J Neuroimaging** 1997 Apr;7(2):121-3

26-year-old man with hyperpigmentation of skin and lower extremity spasticity. Crum BA, et al. **Mayo Clin Proc** 1997 May;72(5):479-82

Abnormalities of somatosensory and motor evoked potentials in adrenomyeloneuropathy: comparison with magnetic resonance imaging and clinical findings. Restuccia D, et al. **Muscle Nerve** 1997 Oct;20(10):1249-57

X-linked adrenoleukodystrophy [letter; comment] Bruyn RP. **Neurology** 1996 Apr;46(4):1192. Comment on: Neurology 1995 Jun;45(6):1101-4.

The value of new MRI techniques in adrenoleukodystrophy. Engelbrecht V, et al. **Pediatr Radiol** 1997 Mar;27(3):207-15

[Examination of very long chain fatty acids in diagnosis of x-linked adrenoleukodystrophy] Stradomska TJ, et al. **Pediatr Pol** 1996 Mar;71(3):197-201 (Eng. Abstr.) **(Pol)**

DIET THERAPY

Bleeding in a patient taking Lorenzo's oil: evidence for a vascular defect. Chai BC, et al. **Postgrad Med J** 1996 Feb; 72(844):113-4

DRUG THERAPY

Failure of beta interferon therapy in X-linked adrenoleukodystrophy [letter] Korenke GC, et al. **Eur J Pediatr** 1996 Sep;155(9):833

Progression of X-linked adrenoleukodystrophy under interferon-beta therapy. Korenke GC, et al. **J Inherit Metab Dis** 1997 Mar;20(1):59-66

Protease inhibitors suppress the degradation of mutant adrenoleukodystrophy proteins but do not correct impairment of very long chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. Yamada T, et al. **Neurochem Res** 1997 Mar;22(3):233-7

GENETICS

Mitochondrial abnormalities and intrafamilial variability of sural nerve biopsy findings in adrenomyeloneuropathy. Schröder JM, et al. **Acta Neuropathol (Berl)** 1996 Jul; 92(1):64-9

Proton MR spectroscopy of childhood adrenoleukodystrophy. Rajanayagam V, et al. **AJNR Am J Neuroradiol** 1996 Jun-Jul;17(6):1013-24

Mutational analysis of an X-linked adrenoleukodystrophy (ALD) patient with detectable ALD protein. Jorge P, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:756-9

Topology of ATP-binding domain of adrenoleukodystrophy gene product in peroxisomes. Contreras M, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):369-79

Two novel missense mutations in the ATP-binding domain of the adrenoleukodystrophy gene: immunoblotting and immunocytological study of two patients. Imamura A, et al. **Clin Genet** 1997 May;51(5):322-5

Variability of endocrinological dysfunction in 55 patients with X-linked adrenoleucodystrophy: clinical, laboratory and genetic findings [see comments] Korenke GC, et al. **Eur J Endocrinol** 1997 Jul;137(1):40-7. Comment in: Eur J Endocrinol 1997 Jul;137(1):10-2.

Chromosomal localization of the adrenoleukodystrophy-related gene in man and mice. Savary S, et al. **Eur J Hum Genet** 1997 Mar-Apr; 5(2):99-101

Structure and location of the murine adrenoleukodystrophy gene. Kennedy MA, et al. **Genomics** 1996 Mar 15; 32(3):395-400

Interchromosomal duplications of the adrenoleukodystrophy locus: a phenomenon of pericentromeric plasticity. Eichler EE, et al. **Hum Mol Genet** 1997 Jul;6(7):991-1002

Identification of two new nonsense mutations (Q311X and W326X) in Exon 2 of the adrenoleukodystrophy (ALD) gene. Barceló A, et al. **Hum Mutat** 1996;8(3):286-7

Mutations in the adrenoleukodystrophy gene. Dodd A, et al. **Hum Mutat** 1997;9(6):500-11 (57 ref.)

Assessment of adrenal function in women heterozygous for adrenoleukodystrophy. el-Deiry SS, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):856-60

ALDP expression in fibroblasts of patients with X-linked adrenoleukodystrophy. Kemp S, et al. **J Inherit Metab Dis** 1996;19(5):667-74

DNA diagnosis of X-linked adrenoleukodystrophy. Seneca S, et al. **J Inherit Metab Dis** 1995;18 Suppl 1:34-44 (60 ref.)

Novel missense and frameshift mutations in the adrenoleukodystrophy gene. Ueyama H, et al. **Jpn J Hum Genet** 1996 Dec;41(4):407-11

X-linked adrenoleukodystrophy [letter; comment] Bruyn RP. **Neurology** 1996 Apr;46(4):1192. Comment on: Neurology 1995 Jun;45(6):1101-4.

[Adrenoleukodystrophy] Kálmánchey R, et al. **Orv Hetil** 1997 Apr 6;138(14):867-71 (Eng. Abstr.) **(Hun)**

IMMUNOLOGY

Absence of circulating adrenal autoantibodies in adult-onset X-linked adrenoleukodystrophy. Laureti S, et al. **Horm Metab Res** 1996 Jul;28(7):319-22

Normal natural killer cell activity in a patient with adrenoleukodystrophy treated with Lorenzo's oil [letter] Tanaka M, et al. **Neurodegeneration** 1996 Jun;5(2):192-4

Immunohistochemical investigation of human leukocyte antigen (HLA)-DR-positive astrocytes in adrenoleukodystrophy brain. Katsuragi T, et al. **Neurosci Lett** 1996 Nov 29;219(3):207-10

METABOLISM

Topology of ATP-binding domain of adrenoleukodystrophy gene product in peroxisomes. Contreras M, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):369-79

Localized proton magnetic resonance spectroscopy in patients with adult adrenoleukodystrophy. Increase of choline compounds in normal appearing white matter. Tourbah A, et al. **Arch Neurol** 1997 May;54(5):586-92

Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Kobayashi T, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):631-6

Carrier identification of X-linked adrenoleukodystrophy by measurement of very long chain fatty acids and lignoceric acid oxidation. Inoue K, et al. **Clin Genet** 1996 Nov; 50(5):348-52

Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis. McGuinness MC, et al. **J Neuroimmunol** 1997 May;75(1-2):174-82

PATHOLOGY

Mitochondrial abnormalities and intrafamilial variability of sural nerve biopsy findings in adrenomyeloneuropathy. Schröder JM, et al. **Acta Neuropathol (Berl)** 1996 Jul; 92(1):64-9

MRI of adrenoleukodystrophy involving predominantly the cerebellum and brain stem. Waragai M, et al. **Neuroradiology** 1996 Nov;38(8):788-91

PHYSIOPATHOLOGY

X-linked adrenoleukodystrophy. Aubourg P, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:461-76 (75 ref.)

Targeted disruption of the peroxisomal fatty acyl-CoA oxidase gene: generation of a mouse model of pseudoneonatal adrenoleukodystrophy. Fan CY, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:530-41

Cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy. Edwin D, et al. **Ann Neurol** 1996 Oct;40(4):675-8

Neurophysiological abnormalities in adrenoleukodystrophy carriers. Evidence of different degrees of central nervous system involvement. Restuccia D, et al. **Brain** 1997 Jul;120 (Pt 7):1139-48

Transcranial magnetic stimulation in an adrenoleukodystrophy patient. Nezu A, et al. **Brain Dev** 1996 Jul-Aug;18(4):327-9

Testicular dysfunction in adrenomyeloneuropathy [see comments] Brennemann W, et al. **Eur J Endocrinol** 1997 Jul;137(1):34-9. Comment in: Eur J Endocrinol 1997 Jul;137(1):10-2.

Assessment of adrenal function in women heterozygous for adrenoleukodystrophy. el-Deiry SS, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):856-60

Abnormalities of somatosensory and motor evoked potentials in adrenomyeloneuropathy: comparison with magnetic resonance imaging and clinical findings. Restuccia D, et al. **Muscle Nerve** 1997 Oct;20(10):1249-57

Occurrence of adrenocortical insufficiency in adrenomyeloneuropathy. Brennemann W, et al. **Neurology** 1996 Aug;47(2):605

Somatosensory evoked potentials in adrenomyeloneuropathy. Kaplan PW, et al. **Neurology** 1997 Jun;48(6):1662-7

Urodynamic abnormalities in two brothers with adrenomyeloneuropathy. Walther MM, et al. **World J Urol** 1997;15(4):262-5 (11 ref.)

RADIONUCLIDE IMAGING

Single photon emission computed tomography in adrenoleukodystrophy. A case report. Dirik E, et al. **Turk J Pediatr** 1996 Jul-Sep;38(3):349-53

THERAPY

Temporary improvement of neurological symptoms with gammaglobulin therapy in a boy with adrenoleukodystrophy. Oka A, et al. **Brain Dev** 1996 Mar-Apr;18(2):119-21

26-year-old man with hyperpigmentation of skin and lower extremity spasticity. Crum BA, et al. **Mayo Clin Proc** 1997 May;72(5):479-82

Normal natural killer cell activity in a patient with adrenoleukodystrophy treated with Lorenzo's oil [letter] Tanaka M, et al. **Neurodegeneration** 1996 Jun;5(2):192-4

ADRENOLEUKODYSTROPHY, NEONATAL see **PEROXISOMAL DISORDERS**

ADRENOLYTICS see **ADRENERGIC AGENTS**

ADRENOMIMETICS see **ADRENERGIC AGENTS**

ADRENOMYELONEUROPATHY see **ADRENOLEUKODYSTROPHY**

ADRIAMYCIN see **DOXORUBICIN**

ADULT RESPIRATORY DISTRESS SYNDROME see **RESPIRATORY DISTRESS SYNDROME, ADULT**

ADULT T-CELL LEUKEMIA-LYMPHOMA VIRUS I see **HTLV-I**

ADVANCE DIRECTIVES

see related
RESUSCITATION ORDERS
RIGHT TO DIE

Playing with fire: advance directives in the emergency department [letter; comment] Thewes J. **Acad Emerg Med** 1997 Jan;4(1):83-4. Comment on: Acad Emerg Med 1996 Jan;3(1):54-7.

Factors influencing dialysis patients' completion of advance directives. Holley JL, et al. **Am J Kidney Dis** 1997 Sep; 30(3):356-60

Outcomes of advance directive education of pulmonary rehabilitation patients. Heffner JE, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):1055-9

Whose death is it, anyway? [letter; comment] Bohlmann BJ. **Ann Intern Med** 1997 Apr 1;126(7):586; discussion 588. Comment on: Ann Intern Med 1996 Jul 15;125(2):149-51.

Whose death is it, anyway? [letter; comment] Glick S. **Ann Intern Med** 1997 Apr 1;126(7):586-7; discussion 588 . Comment on: Ann Intern Med 1996 Jul 15;125(2):137-41. Comment on: Ann Intern Med 1996 Jul 15;125(2);149-51.

Whose death is it, anyway? [letter; comment] Griffin EA. **Ann Intern Med** 1997 Apr 1;126(7):587; discussion 588. Comment on: Ann Intern Med 1996 Jul 15;125(2):137-41. Comment on: Ann Intern Med 1996 Jul 15;125(2):149-51.

Whose death is it, anyway? [letter; comment] Harris RH Jr. **Ann Intern Med** 1997 Apr 1;126(7):586; discussion 588. Comment on: Ann Intern Med 1996 Jul 15;125(2):137-41. Comment on: Ann Intern Med 1996 Jul 15;125(2):149-51.

Whose death is it, anyway? [letter; comment] Lena PJ. **Ann Intern Med** 1997 Apr 1;126(7):584-5; discussion 588 . Comment on: Ann Intern Med 1996 Jul 15;125(2):149-51.

Validation of preferences for life-sustaining treatment: implications for advance care planning. Patrick DL, et al. **Ann Intern Med** 1997 Oct 1;127(7):509-17

Whose death is it, anyway? [letter; comment] Portnoi VA. **Ann Intern Med** 1997 Apr 1;126(7):587-8. Comment on: Ann Intern Med 1996 Jul 15;125(2):137-41.

Whose death is it, anyway? [letter; comment] Reich JS. **Ann Intern Med** 1997 Apr 1;126(7):587; discussion 588. Comment on: Ann Intern Med 1996 Jul 15;125(2):149-51.

Whose death is it, anyway? [letter; comment] Ringel E. **Ann Intern Med** 1997 Apr 1;126(7):585; discussion 588. Comment on: Ann Intern Med 1996 Jul 15;125(2):137-41. Comment on: Ann Intern Med 1996 Jul 15;125(2):149-51.

Whose death is it, anyway? [letter; comment] Rousseau P. **Ann Intern Med** 1997 Apr 1;126(7):585-6; discussion 588 . Comment on: Ann Intern Med 1996 Jul 15;125(2):149-51.

Whose death is it, anyway? [letter; comment] Routh CR. **Ann Intern Med** 1997 Apr 1;126(7):586; discussion 588. Comment on: Ann Intern Med 1996 Jul 15;125(2):137-41. Comment on: Ann Intern Med 1996 Jul 15;125(2):149-51.

Whose death is it, anyway? [letter; comment] Salon JE. **Ann Intern Med** 1997 Apr 1;126(7):585; discussion 588. Comment on: Ann Intern Med 1996 Jul 15;125(2):137-41. Comment on: Ann Intern Med 1996 Jul 15;125(2):149-51.

Impact of advance directive videotape on patient comprehension and treatment preferences [see comments] Siegert EA, et al. **Arch Fam Med** 1996 Apr;5(4):207-12. Comment in: Arch Fam Med 1996 Apr;5(4):213-4.

A multi-institutional study of care given to patients dying in hospitals. Ethical and practice implications. Faber-Langendoen K. **Arch Intern Med** 1996 Oct 14; 156(18):2130-6

Can goals of care be used to predict intervention preferences

in an advance directive? Fischer GS, et al. **Arch Intern Med** 1997 Apr 14;157(7):801–7

Beyond do-not-resusitate orders: a house staff mentoring and credentialing project on advance directives [letter] Harlow NC, et al. **Arch Intern Med** 1997 Jan 13;157(1):135

Reassessing the reliability of advance directives. May T. **Camb Q Healthc Ethics** 1997 Summer;6(3):325–38

Prospective autonomy and critical interests: a narrative defense of the moral authority of advance directives. Rich BA. **Camb Q Healthc Ethics** 1997 Spring;6(2):138–47 (24 ref.)

Do physicians' own preferences for life-sustaining treatment influence their perceptions of patients' preferences? A second look. Schneiderman LJ, et al. **Camb Q Healthc Ethics** 1997 Spring;6(2):131–7

Advance care planning [letter; comment] Ney PG. **Can Med Assoc J** 1997 Mar 15;156(6):767–8. Comment on: Can Med Assoc J 1996 Dec 15;155(12):1689–92.

Bioethics for clinicians: 6. Advance care planning [see comments] Singer PA, et al. **Can Med Assoc J** 1996 Dec 15;155(12):1689–92. Comment in: Can Med Assoc J 1997 Mar 15;156(6):767–8.

Advance directives, revisited [letter; comment] Gianakos D. **Chest** 1997 Apr;111(4):1144. Comment on: Chest 1996 Sep;110(3):816–22.

Anticipatory planning for psychiatric treatment is not quite the same as planning for end-of-life care. Backlar P. **Community Ment Health J** 1997 Aug;33(4):261–8

Advance directives: when, why, and how to start talking. Carney MT, et al. **Geriatrics** 1997 Apr;52(4):65–6, 69–73; quiz 74

Efficacy of advance directives in a general hospital. Heintz LL. **Hawaii Med J** 1997 Aug;56(8):203–6

An emergency physician's perspective on death with dignity. Holschuh FC. **Hawaii Med J** 1996 Dec;55(12):252–4

What SUPPORT really means. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments [editorial] Markson LJ, et al. **Hosp Pract (Off Ed)** 1996 Sep 15;31(9):11–3

Readability of advance directive documents. Ott BB, et al. **Image J Nurs Sch** 1997 Spring;29(1):53–7

Advance directives for research: ethical problems and responses. Moorhouse A, et al. **Int J Law Psychiatry** 1996 Spring;19(2):107–41 (55 ref.)

Assessing capacity to participate in discussions of advance directives in nursing homes: findings from a study of the Patient Self Determination Act. Bradley E, et al. **J Am Geriatr Soc** 1997 Jan;45(1):79–83

Advance directives and SUPPORT [editorial; comment] Fins JJ. **J Am Geriatr Soc** 1997 Apr;45(4):519–20. Comment on: J Am Geriatr Soc 1997 Apr;45(4):500–7. Comment on: J Am Geriatr Soc 1997 Apr;45(4):508–12. Comment on: J Am Geriatr Soc 1997 Apr;45(4):513–8.

Medical care in old age: what do nurses in long-term care consider appropriate? Gillick MR, et al. **J Am Geriatr Soc** 1996 Nov;44(11):1322–5

Advance directives [letter] Kaplan RS, et al. **J Am Geriatr Soc** 1997 Sep;45(9):1156–7

Hospitalization of nursing home residents: the right rate? [editorial; comment] Lynn J. **J Am Geriatr Soc** 1997 Mar; 45(3):378–9 (8 ref.). Comment on: J Am Geriatr Soc 1997 Mar;45(3):265–9.

The doctor's role in discussing advance preferences for end-of-life care: perceptions of physicians practicing in the VA. Markson L, et al. **J Am Geriatr Soc** 1997 Apr; 45(4):399–406

Implementation of the Patient Self-Determination Act (PSDA) in nursing homes in New York City [see comments] Mezey M, et al. **J Am Geriatr Soc** 1997 Jan; 45(1):43–9. Comment in: J Am Geriatr Soc 1997 Jan;45(1):114–6.

Advance directives for seriously ill hospitalized patients: effectiveness with the patient self-determination act and the SUPPORT intervention. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment [see comments] Teno J, et al. **J Am Geriatr Soc** 1997 Apr;45(4):500–7. Comment in: J Am Geriatr Soc 1997 Apr;45(4):519–20.

The illusion of end-of-life resource savings with advance directives. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment [see comments] Teno J, et al. **J Am Geriatr Soc** 1997 Apr;45(4):513–8. Comment in: J Am Geriatr Soc 1997 Apr;45(4):519–20.

Do advance directives provide instructions that direct care? SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment [see comments] Teno JM, et al. **J Am Geriatr Soc** 1997 Apr; 45(4):508–12. Comment in: J Am Geriatr Soc 1997 Apr;45(4):519–20.

Changes in advance care planning in nursing homes before and after the patient Self-Determination Act: report of a 10-state survey. Teno JM, et al. **J Am Geriatr Soc** 1997 Aug;45(8):939–44

Why is it difficult for staff to discuss advance directives with chronic dialysis patients? Perry E, et al. **J Am Soc Nephrol** 1996 Oct;7(10):2160–8

Putting advance-care planning into action. Teno JM, et al. **J Clin Ethics** 1996 Fall;7(3):205–13

The family physician and end-of-life care. Schneiderman LJ. **J Fam Pract** 1997 Sep;45(3):259–62 (6 ref.)

Preferences of physicians and their patients for end-of-life care. Gramelspacher GP, et al. **J Gen Intern Med** 1997 Jun;12(6):346–51

Tube feeding preferences among nursing home residents. O'Brien LA, et al. **J Gen Intern Med** 1997 Jun;12(6):364–71

Strategies to promote the use of advance directives in a residency outpatient practice. Sulmasy DP, et al. **J Gen Intern Med** 1996 Nov;11(11):657–63

Utilizing advanced healthcare directives: a true (for the most part) story. Berg RN. **J Med Assoc Ga** 1997 Apr; 86(2):145–7

The Patient Self-Determination Act. The chief nurse executive's perspective. Haynor PM. **J Nurs Adm** 1996 Oct; 26(10):47–55

Advance directives affecting medical treatment choices. Waddell C, et al. **J Palliat Care** 1997 Summer;13(2):5–8

Knowing when enough is enough [editorial] Hinds PS. **J Pediatr Oncol Nurs** 1996 Jan;13(1):1

Advance directives: from the perspective of the patient and the physician [published erratum appears in J R Soc Med 1997 Feb;90(2):120] Johnston SC, et al. **J R Soc Med** 1996 Oct;89(10):568–70 (31 ref.)

Advance directives and withdrawal of dialysis in the United States, Germany, and Japan. Sehgal AR, et al. **JAMA** 1996 Nov 27;276(20):1652–6

Improving the use of advance directives. Stafford DT. **Md Med J** 1997 Jan;46(1):25–7

Psychometric analysis of an advance directive. Alpert HR, et al. **Med Care** 1996 Oct;34(10):1057–65

Is experience a good teacher? How interns and attending physicians understand patients' choices for end-of-life care. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Wilson IB, et al. **Med Decis Making** 1997 Apr–Jun; 17(2):217–27

Advance medical planning [letter; comment] Sandy LG, et al. **N Engl J Med** 1997 Feb 27;336(9):662–3; discussion 663 . Comment on: N Engl J Med 1996 Sep 5;335(10):741–3.

The importance of advance directives in primary care. Arenson CA, et al. **Prim Care** 1996 Mar;23(1):67–82 (69 ref.)

Advance directive--a surgical viewpoint [editorial] Agasthian T. **Singapore Med J** 1997 Apr;38(4):143

The advance directive--a review. Hong CY, et al. **Singapore Med J** 1996 Aug;37(4):411–8 (85 ref.)

Advance directive: a study on the knowledge and attitudes among general practitioners in Singapore. Tee KH, et al. **Singapore Med J** 1997 Apr;38(4):145–8

Negotiating advance directives for persons with AIDS. Littrell J, et al. **Soc Work Health Care** 1996;23(2):43–65

Advance directives outside the USA: are they the best solution everywhere? Sanchez-Gonzalez MA. **Theor Med** 1997 Sep;18(3):283–301

ECONOMICS

Advance medical planning [letter; comment] Schneiderman LJ, et al. **N Engl J Med** 1997 Feb 27;336(9):663. Comment on: N Engl J Med 1996 Sep 5;335(10):741–3.

ETHNOLOGY

Minority populations and advance directives: insights from a focus group methodology. Hauser JM, et al. **Camb Q Healthc Ethics** 1997 Winter;6(1):58–71

Influence of ethnicity on advance directives and end-of-life decisions [letter] Romero LJ, et al. **JAMA** 1997 Jan 22–29; 277(4):298–9

LEGISLATION & JURISPRUDENCE

Durable power of attorney and informed consent with Alzheimer's disease patients: a clinical study. Dukoff R, et al. **Am J Psychiatry** 1997 Aug;154(8):1070–5

Ethical hazards of the substituted judgement test in decision making concerning the end of life of dementia patients [editorial] Berghmans RL. **Int J Geriatr Psychiatry** 1997 Mar;12(3):283–7

Forsaking the spirit for the letter of law: advance directives in nursing homes [editorial; comment] Ackerman TF. **J Am Geriatr Soc** 1997 Jan;45(1):114–6. Comment on: J Am Geriatr Soc 1997 Jan;45(1):43–9.

Ethics consultants and surrogates: can we do better? Fletcher JC. **J Clin Ethics** 1997 Spring;8(1):50–9

Presumed consent to organ donation: 10 years' experience in Belgium [see comments] Michielsen P. **J R Soc Med** 1996 Dec;89(12):663–6. Comment in: J R Soc Med 1996 Dec;89(12):663–6.

Therapeutic jurisprudence and end-of-life medical care: physician perceptions of a statute's impact. Kapp MB. **Med Law** 1996;15(2):201–17

Anticipatory decision making & incompetent patients. Recent developments in Europe. Nys H. **Med Law** 1997;16(1):1–7

Advanced directives and the Patient Self-Determination Act. Sill GM. **Mo Med** 1996 Jan;93(1):14–5

Achieving a sense of completion. O'Brien M. **N C Med J** 1996 Sep–Oct;57(5):299–301

A survey on use of advance directives for mental health treatment in Oregon. Backlar P, et al. **Psychiatr Serv** 1996 Dec;47(12):1387–9

Living, dying, death and advance directives [editorial] Lee KO, et al. **Singapore Med J** 1997 Apr;38(4):141–2

Advance directives for patients. Wencel S. **Wis Med J** 1997 Feb;96(2):51–5

Women's health and end-of-life decision making [comment] Grodin MA. **Womens Health Issues** 1996 Sep–Oct; 6(5):295–301. Comment on: Womens Health Issues 1996 Sep–Oct;6(5):287–94.

[Death as an agreement—a provocation or possible method for public consensus in the brain death discussion? (editorial)] Gubernatis G. **Med Klin** 1996 Jan 15;91(1):47–8 **(Ger)**

[Values anamnesis: a narrative approach to determining and interpreting advance directives] Kielstein R, et al. **Wien Med Wochenschr** 1997;147(6):125–9 (Eng. Abstr.) **(Ger)**

[Advance directives in Austria law] Memmer M. **Wien Med Wochenschr** 1997;147(6):135–8 (Eng. Abstr.) **(Ger)**

[Advance directives from the medical viewpoint] Meran JG. **Wien Med Wochenschr** 1997;147(6):117–20 (Eng. Abstr.) **(Ger)**

[Acceptance and validation of advanced directives—ethical and clinical considerations] Sass HM, et al. **Wien Med Wochenschr** 1997;147(6):121–4 (Eng. Abstr.) **(Ger)**

[Theological moral considerations of advance directives] Virt G. **Wien Med Wochenschr** 1997;147(6):130–4 (Eng. Abstr.) **(Ger)**

[General practice of advance directives in the USA] Zülicke F. **Wien Med Wochenschr** 1997;147(6):139–44 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Misgivings about advance directives [letter; comment] Smith UA. **Am J Nurs** 1996 Nov;96(11):15–6. Comment on: Am J Nurs 1996 Aug;96(8):24–8; quiz 29.

The values history as a nursing intervention to encourage use of advance directives among older adults. Schirm V, et al. **Appl Nurs Res** 1996 May;9(2):93–6

Fates worse than death: the role of valued life activities in health-state evaluations. Ditto PH, et al. **Health Psychol** 1996 Sep;15(5):332–43

Denying the dying. Advance directives and dialysis discontinuation. Cohen LM, et al. **Psychosomatics** 1997 Jan–Feb;38(1):27–34

[Managing life and death wishes of invasively ventilated amyotrophic lateral sclerosis patients] Winterholler M, et al. **Med Klin** 1997 Apr 28;92 Suppl 1:90–2 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Increasing the use of advance directives in medical outpatients. Landry FJ, et al. **J Gen Intern Med** 1997 Jul; 12(7):412–5

ADVERSE DRUG REACTION REPORTING SYSTEMS

Suspected adverse drug reactions in the Hungarian veterinary practice between 1982 and 1992. Bernáth S, et al. **Acta Vet Hung** 1996;44(4):451–6 (12 ref.)

Detection of adverse reactions to new medicines [editorial] Griffin JP. **Adverse Drug React Toxicol Rev** 1996 Jun; 15(2):77–8

The Welsh Adverse Drug Reactions Scheme: experience of a UK regional monitoring centre. Houghton JE, et al. **Adverse Drug React Toxicol Rev** 1996 Jun;15(2):93–107

Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Hunziker T, et al. **Allergy** 1997 Apr;52(4):388–93

FDA seeks help in evaluating consequences of therapeutic interchange [news] **Am J Health Syst Pharm** 1997 May 15;54(10):1149

Algorithms used in adverse drug event reports: a comparative study. Frick PA, et al. **Ann Pharmacother** 1997 Feb; 31(2):164–7

Reasons for stopping drugs are monitored in New Zealand [letter] Coulter DM. **BMJ** 1996 Sep 21;313(7059):756

Reporting of adverse drug reactions by hospital pharmacists: pilot scheme [see comments] Lee A, et al. **BMJ** 1997 Aug 30;315(7107):519. Comment in: BMJ 1997 Aug 30;315(7107):500.

Newly licensed drugs. Doctors should be encouraged to report adverse reactions [letter; comment] Tiner R. **BMJ** 1997 Feb 22;314(7080):605. Comment on: BMJ 1996 Nov 9;313(7066):1157–8.

Adverse events associated with mefloquine. Manufacturer should also give incidence of "severe" adverse events [letter; comment] Traer-Clark L. **BMJ** 1996 Dec 14; 313(7071):1553; discussion 1554. Comment on: BMJ 1996 Aug 31;313(7056):525–8.

Pharmacovigilance in the 1990s [comment] Lawson DH. **Br J Clin Pharmacol** 1997 Aug;44(2):109–10. Comment on: Br J Clin Pharmacol 1997 Aug;44(2):175–8.

Reporting of adverse drug reactions by hospital doctors and the response to intervention. McGettigan P, et al. **Br J Clin Pharmacol** 1997 Jul;44(1):98–100

Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Smith CC, et al. **Br J Clin Pharmacol** 1996 Oct; 42(4):423–9

Spontaneous reports of psychiatric adverse effects to mefloquine in the Netherlands [letter] van Riemsdijk MM, et al. **Br J Clin Pharmacol** 1997 Jul;44(1):105–6

Drug-associated anaphylaxis: 20 years of reporting in The

Netherlands (1974–1994) and review of the literature [see comments] van der Klauw MM, et al. **Clin Exp Allergy** 1996 Dec;26(12):1355–63 (55 ref.). Comment in: Clin Exp Allergy 1996 Dec;26(12):1341–2.

Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Pillans PI, et al. **Eur J Clin Pharmacol** 1996;51(2):123–6 (14 ref.)

A comparison of two cohort studies evaluating the safety of cisapride: Prescription–Event Monitoring and a large phase IV study. Wager E, et al. **Eur J Clin Pharmacol** 1997; 52(2):87–94

European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 1995. **Eur J Nucl Med** 1996 Dec;23(12):BP27–31

Adverse drug reaction monitoring in pediatric practice [editorial] Kshirsagar NA, et al. **Indian Pediatr** 1996 Dec; 33(12):993–8

Poison Information Service of the Nofer Institute of Occupational Medicine in Lódź. Types of toxicological inquiries 1991–1994. Jaraczewska W, et al. **Int J Occup Med Environ Health** 1997;10(2):167–75

Comparison of adverse drug reaction reporting in veterinary and human medicine [see comments] Bukowski JA, et al. **J Am Vet Med Assoc** 1996 Jul 1;209(1):40–5. Comment in: J Am Vet Med Assoc 1996 Nov 1;209(9):1546–7.

Progress in FDA pharmacosurveillance [letter; comment] Keller WC. **J Am Vet Med Assoc** 1996 Nov 1;209(9):1546–7 . Comment on: J Am Vet Med Assoc 1996 Jul 1;209(1):40–5.

Adverse reactions to radiopharmaceuticals: the SNM/RSNA USP Drug Product Problem Reporting Program. Society of Nuclear Medicine/Radiological Society of North America. United States Pharmacopeial Convention [news] Silberstein EB. **J Nucl Med** 1997 Sep;38(9):49N

Clinical cases and problems of delayed (tardive) reactions to drugs—for pharmaceuticals in general. Hama R. **J Toxicol Sci** 1996 Feb;21(1):81–91 (7 ref.)

From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin–converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada, and Israel, 1987–1995. **JAMA** 1997 Apr 16;277(15):1193–4

Secrets about drugs are not healthy [editorial] **Lancet** 1996 Sep 21;348(9030):765

EMEA and third–generation oral contraceptives [letter; comment] Alexandre JM, et al. **Lancet** 1997 Jul 26; 350(9073):290. Comment on: Lancet 1997 Apr 19;349(9059):1113–4.

Worldwide pharmacovigilance systems and tolrestat withdrawal [letter] Foppiano M, et al. **Lancet** 1997 Feb 8;349(9049):399–400

Citalopram toxicity [letter; comment] Personne M, et al. **Lancet** 1997 Aug 16;350(9076):518–9. Comment on: Lancet 1996 Aug 3;348(9023):339–40. Comment on: Lancet 1997 May 31;349(9065):1602.

Every defect a treasure: learning from adverse events in hospitals. James BC. **Med J Aust** 1997 May 5;166(9):484–7

The stock market is a source of information on the efficacy and side effects of drugs. Sénard JM. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:59–60

Postmarketing surveillance for angiotensin–converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada, and Israel, 1987–1995. **MMWR Morb Mortal Wkly Rep** 1997 Mar 21;46(11):240–2

Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Chen RT, et al. **Pediatrics** 1997 Jun;99(6):765–73

Attitudes to adverse drug reaction reporting by medical practitioners in a Northern Italian district. Cosentino M, et al. **Pharmacol Res** 1997 Feb;35(2):85–8

Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions. Spigset O, et al. **Pharmacotherapy** 1997 Mar–Apr; 17(2):348–52

Report every adverse drug reaction! We're all in this together [editorial; comment] Griffin GC, et al. **Postgrad Med** 1997 Apr;101(4):13–6. Comment on: Postgrad Med 1997 Jul;102(1):35–6.

A centralized system for monitoring clozapine use in British Columbia. Black LL, et al. **Psychiatr Serv** 1996 Jan; 47(1):81–3

The complicated task of monitoring vaccine safety. Ellenberg SS, et al. **Public Health Rep** 1997 Jan–Feb;112(1):10–20; discussion 21 (51 ref.)

Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. Bettmann MA, et al. **Radiology** 1997 Jun;203(3):611–20

Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. Lasser EC, et al. **Radiology** 1997 Jun;203(3):605–10

Adverse reactions to radiopharmaceuticals: the RSNA–SNM–USP Drug Product Problem Reporting Program. Silberstein EB. **Radiology** 1997 Aug;204(2):34A

Testing for adverse reactions using prescription event monitoring. Andrew JE, et al. **Stat Med** 1996 May 30; 15(10):987–1002

Therapeutic drug monitoring databases for postmarketing surveillance of drug–drug interactions: evaluation of a paired approach for psychotropic medication. Gex–Fabry M, et al. **Ther Drug Monit** 1997 Feb;19(1):1–10

Drug–induced autoimmunity: experience of the French pharmacovigilance system. Vial T, et al. **Toxicology** 1997 Apr 11;119(1):23–7 (26 ref.)

[Adverse effects of drugs—25 years later (editorial)] Poulsen HE. **Ugeskr Laeger** 1997 Aug 11;159(33):4964 **(Dan)**

[Good practices of publication of clinical cases of pharmacovigilance: comments, Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance: commentary] Auriche M, et al. **Therapie** 1997 Mar–Apr;52(2):123–7 (Eng. Abstr.) **(Fre)**

[Clostridium difficile associated diarrhea in cephalosporin administration: experiences of the Swiss Adverse Drug Reaction Reporting System 1981–1995] Werth B, et al. **Schweiz Med Wochenschr Suppl** 1997;89:5S–8S (Eng. Abstr.) **(Ger)**

[The seventeenth report on Survey of the Adverse Reaction to Radiopharmaceuticals (the 20th survey in 1994). Subcommittee of Safety Issue for the Radiopharmaceuticals Medical and Pharmaceutical Committee. Japan Radioisotope Association] **Kaku Igaku** 1996 Jun; 33(6):675–86 **(Jpn)**

[Adverse drug reactions and a program of voluntary notification: an opinion survey of primary care physicians] Serrano Cózar G, et al. **Aten Primaria** 1997 Apr 15; 19(6):307–12 (Eng. Abstr.) **(Spa)**

[Drug adverse reactions: a practical protocol] Gozalo Reques F, et al. **Rev Clin Esp** 1997 Feb;197(2):108–11 (12 ref.) **(Spa)**

ECONOMICS

Cost–effectiveness of clozapine monitoring after the first 6 months. Zhang M, et al. **Arch Gen Psychiatry** 1996 Oct; 53(10):954–8

HISTORY

[The recommendation by Menzel in 1877 for statistical assessment of anesthesia performance] Röse W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):432–3 **(Ger)**

LEGISLATION & JURISPRUDENCE

Two UK Government proposals bearing on drug safety [editorial] Griffin JP. **Adverse Drug React Toxicol Rev** 1997 Mar;16(1):1–7 (10 ref.)

NRA investigates drug reactions [news] **Aust Vet J** 1996 Sep; 74(3):193

Monitoring suspected adverse reactions [letter; comment] Davidson DL. **Vet Rec** 1997 Apr 12;140(15):407. Comment on: Vet Rec 1997 Feb 8;140(6):159–60.

[European drug agency and drug management (editorial)] Barfuss W. **Leber Magen Darm** 1996 Jul;26(4):191–2 **(Ger)**

ORGANIZATION & ADMINISTRATION

Adverse drug reaction monitoring in the HMO setting. Pepping J. **Am J Health Syst Pharm** 1996 Sep 1; 53(17):2027–8

Reporting vaccine–associated adverse events. Duclos P, et al. **Can Fam Physician** 1997 Sep;43:1551–6, 1559–60

Principles of signal detection in pharmacovigilance. Meyboom RH, et al. **Drug Saf** 1997 Jun;16(6):355–65 (22 ref.)

Adverse drug reactions in a medical ward. Wu FL, et al. **J Formos Med Assoc** 1996 Mar;95(3):241–6

Interaction between the Drug Information Centre and the Regional Centre for Adverse Drug Reaction Monitoring in northern Sweden [letter] Nordkvist Olsson T, et al. **Pharm World Sci** 1997 Apr;19(2):114–5

[Joint program of pharmacovigilance in Quebec: comparison with France, Aquitaine and the Basque region] Biron P, et al. **Therapie** 1996 Sep–Oct;51(5):578–81 (Eng. Abstr.) **(Fre)**

[Evaluation of declarations of severe adverse effects from the publication of the decree dated 13 March 1995 about the organisation of pharmacovigilance] Lelouet H, et al. **Therapie** 1996 Sep–Oct;51(5):555–6 **(Fre)**

STANDARDS

Adverse drug reactions: finding the needle in the haystack [editorial; comment] Edwards IR. **BMJ** 1997 Aug 30; 315(7107):500. Comment on: BMJ 1997 Aug 30;315(7107):519.

An open letter to the FDA regarding changes in reporting procedures for drugs and biologics proposed in the wake of the FIAU tragedy. Meinert CL. **Control Clin Trials** 1996 Aug;17(4):273–84

Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. de Boer WA, et al. **Eur J Gastroenterol Hepatol** 1996 Jul; 8(7):641–3

STATISTICS & NUMERICAL DATA

A 5–year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus–infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. O'Brien JG, et al. **Clin Infect Dis** 1997 May;24(5):854–9

Japanese and American reports of randomized trials: differences in the reporting of adverse effects. Hayashi K, et al. **Control Clin Trials** 1996 Apr;17(2):99–110

Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Honigfeld G. **Psychiatr Serv** 1996 Jan;47(1):52–6

Nonfatal adverse reactions to iodinated contrast media: spontaneous reporting to the U.S. Food and Drug Administration, 1978–1994. Spring DB, et al. **Radiology** 1997 Aug;204(2):325–32

Deaths related to iodinated contrast media reported spontaneously to the U.S. Food and Drug Administration, 1978–1994: effect of the availability of low–osmolality contrast media. Spring DB, et al. **Radiology** 1997 Aug; 204(2):333–7

Adverse Drug Reaction Project. Blustein JN, et al. **Wis Med J** 1997 Mar;96(3):48–9

[Periodic report of pharmacovigilance: new recommendations, results of a survey among 200 pharmaceutical laboratories] Castot A, et al. **Therapie** 1996 Sep–Oct;51(5):554–5 **(Fre)**

UTILIZATION

Under–reporting of adverse drug reactions in general practice. Moride Y, et al. **Br J Clin Pharmacol** 1997 Feb; 43(2):177–81

ADVERTISING

Alcohol advertising in France [letter; comment] Dubois G. **Addiction** 1996 Dec;91(12):1870. Comment on: Addiction 1996 Jan;91(1):5–9.

Advertisement for the Bard BTA test for bladder cancer [letter] Marshall KG. **Am Fam Physician** 1997 Mar; 55(4):1078, 1080, 1085–6 passim

WD–40 and arthritic pain: the squeaky joint gets the grease [letter] Ramratham B, et al. **Am Fam Physician** 1997 Apr; 55(5):1584

Health–related quality–of–life claims in prescription drug advertisements. Rothermich EA, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1565–9

No endorsement implied [letter; comment] Scura KW, et al. **Am J Nurs** 1997 May;97(5):16. Comment on: Am J Nurs 1997 Apr;97(4):36–43.

The extent of cigarette brand and company switching: results from the Adult Use–of–Tobacco Survey [see comments] Siegel M, et al. **Am J Prev Med** 1996 Jan–Feb;12(1):14–6 . Comment in: Am J Prev Med 1996 Jan–Feb;12(1):2–3.

Tobacco promotion and susceptibility to tobacco use among adolescents aged 12 through 17 years in a nationally representative sample. Altman DG, et al. **Am J Public Health** 1996 Nov;86(11):1590–3

Targeted tobacco markets: outdoor advertising in Los Angeles minority neighborhoods [letter] Stoddard JL, et al. **Am J Public Health** 1997 Jul;87(7):1232–3

The PDR: another view [letter; comment] Jones JV. **Arch Intern Med** 1997 Mar 10;157(5):576. Comment on: Arch Intern Med 1996 Jul 8;156(13):1375–80.

The treatment of obesity. A call for prudence and professionalism. Kushner R. **Arch Intern Med** 1997 Mar 24;157(6):602–4 (19 ref.)

UK specialists to be allowed to advertise [news] Beecham L. **BMJ** 1996 Nov 16;313(7067):1226–7

Advertisements in the BMJ. Advertisements for drugs used in disorders with a negative image never feature men [letter] Breimer L. **BMJ** 1996 Oct 5;313(7061):883

What information is available on request from drug advertisers in India? Dikshit RK, et al. **BMJ** 1996 Oct 5; 313(7061):855–6

Advertisements for donepezil (Aricept) in the BMJ. Advertisement suggests an unrealistic improvement in mental status [letter] Gray S. **BMJ** 1997 May 24; 314(7093):1555

Advertisements in the BMJ. BMJ should not carry advertisements for cars [letter] Salmon D. **BMJ** 1996 Oct 5;313(7061):883

Dutch anti–alcohol campaign is under attack [news] Sheldon T. **BMJ** 1996 Nov 30;313(7069):1349

Jewish paper forgoes tobacco advertising [news] Siegel–Itzkovich J. **BMJ** 1997 Jun 7;314(7095):1644

Passive smoking and health: should we believe Philip Morris's "experts"? [see comments] Smith GD, et al. **BMJ** 1996 Oct 12;313(7062):929–33. Comment in: BMJ 1997 Feb 1;314(7077):371.

Joe Camel beware as doctors strike back [news] Tanne JH. **BMJ** 1996 Nov 30;313(7069):1349

Advertisement for toremifene. Playing on women's fears is unethical [letter] Twelves C, et al. **BMJ** 1996 Oct 12; 313(7062):944–5

Cigarette deaths, cigarette advertisements, cigarette recruits, cigarette money [editorial] Jackson G. **Br J Clin Pract** 1996 Dec;50(8):422

The use of targeted and non–targeted advertising to enrich skin cancer screening samples. Katris P, et al. **Br J Dermatol** 1996 Aug;135(2):268–74

Concerns about formula advertising [letter] Gross MS. **Can Fam Physician** 1996 Feb;42:236, 238, 240

Breastfeeding still best [letter] Lent B. **Can Fam Physician** 1996 Sep;42:1669

Breastfeeding still the best [letter; comment] Lexchin J. **Can Fam Physician** 1996 Sep;42:1669, 1671. Comment on: Can Fam Physician 1996 May;42:850, 852.

Consequences of direct–to–consumer advertising of prescription drugs [editorial] [see comments] Lexchin J.

Can Fam Physician 1997 Apr;43:594–6, 602–5. Comment in: Can Fam Physician 1997 Jun;43:1041–2. **(Eng, Fre)**

Adopting the WHO international code of marketing of breast-milk substitutes [editorial] Reid AJ. **Can Fam Physician** 1996 Sep;42:1639–41, 1650–3 **(Eng, Fre)**

Advertising of therapies for cardiovascular patients [editorial] [see comments] Conti CR. **Clin Cardiol** 1997 Jan;20(1):1. Comment in: Clin Cardiol 1997 May;20(5):506–7.

Advertising of therapies for cardiovascular patients [letter; comment] Foster MC. **Clin Cardiol** 1997 May;20(5):506–7 . Comment on: Clin Cardiol 1997 Jan;20(1):1.

Tobacco abroad: infiltrating foreign markets [news] Holzman D. **Environ Health Perspect** 1997 Feb;105(2):178–83

Target marketing of tobacco and alcohol-related products to ethnic minority groups in the United States. Moore DJ, et al. **Ethn Dis** 1996 Winter-Spring;6(1–2):83–98 (56 ref.)

Tobacco free at the Indianapolis 500. Blom ED. **Indiana Med** 1996 Mar-Apr;89(2):207–9

Misleading information on environmental tobacco smoke in the French lay press [letter] Colin C, et al. **Int J Epidemiol** 1997 Feb;26(1):240–1

Ergogenic aids: evaluating sport nutrition products. Butterfield G. **Int J Sport Nutr** 1996 Jun;6(2):191–7

What can we learn from Madison Avenue? [editorial] Litt IF. **J Adolesc Health** 1996 Oct;19(4):245

Informing public, students will make profession 'visible' [letter; comment] Bahrami P. **J Am Osteopath Assoc** 1997 Jun;97(6):330. Comment on: J Am Osteopath Assoc 1997 Mar;97(3):168–70.

Critical evaluation of references in drug advertisements: an Indian experience. Lal A, et al. **J Assoc Physicians India** 1996 Nov;44(11):778–9

Wall of fame [letter] Reid JA, et al. **J Can Dent Assoc** 1996 Oct;62(10):765–6

Kids, cancer, and the Joe Camel connection [editorial; comment] Koh HK. **J Clin Oncol** 1997 Jun;15(6):2181–2. Comment on: J Clin Oncol 1997 Jun;15(6):2194–204.

BCRA 1 testing guidelines for high-risk patients [letter] Sorscher S, et al. **J Clin Oncol** 1997 Apr;15(4):1711

Responsible public communication: on how not to become a clown in the media circus [editorial] Barnett ML. **J Dent Res** 1996 Aug;75(8):1528–9

Adolescent counterarguing of TV beer advertisements: evidence for effectiveness of alcohol education and critical viewing discussions. Slater MD, et al. **J Drug Educ** 1996; 26(2):143–58

Informational and symbolic content of over-the-counter drug advertising on television. Tsao JC. **J Drug Educ** 1997; 27(2):173–97

The effect of homosexual imagery in advertising on attitude toward the ad. Bhat S, et al. **J Homosex** 1996; 31(1–2):161–76

Comparative evaluation of drug advertisements in Indian, British and American medical journals. Lal A, et al. **J Indian Med Assoc** 1997 Jan;95(1):19–20

Cigarette advertisement cites journal [letter] Crespo GG. **J Natl Cancer Inst** 1997 Feb 5;89(3):260

National Cancer Policy Board adds its voice to tobacco issues [news] Smigel K. **J Natl Cancer Inst** 1997 Aug 6; 89(15):1097–8

Nicotine addiction: a pediatric disease. Kessler DA, et al. **J Pediatr** 1997 Apr;130(4):518–24

The marketing of estrogens for menopausal and postmenopausal women. Palmlund I. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):158–64 (30 ref.)

Social marketing: a tool not a solution. Montazeri A. **J R Soc Health** 1997 Apr;117(2):115–8

Are images mirages? [editorial] Ferner RE. **J R Soc Med** 1997 Feb;90(2):62–3

Prostitution advertisements suggest association of transvestism and masochism. Chivers M, et al. **J Sex Marital Ther** 1996 Summer;22(2):97–102

Male adolescents' reactions to TV beer advertisements: the effects of sports content and programming context. Slater MD, et al. **J Stud Alcohol** 1996 Jul;57(4):425–33

Violence in television commercials during nonviolent programming. The 1996 Major League Baseball playoffs. Anderson C. **JAMA** 1997 Oct 1;278(13):1045–6

Regulating firearm advertisements [letter; comment] Blackman PH. **JAMA** 1997 Sep 3;278(9):702; discussion 703. Comment on: JAMA 1997 May 7;277(17):1391–7.

Recognition of cigarette advertisement product logos [letter] Fischer PM. **JAMA** 1997 Feb 19;277(7):532

Magazines containing tobacco advertisements: proscription not subscription [letter] Hurt RD, et al. **JAMA** 1997 Jul 9;278(2):117

Regulating firearm advertisements [letter; comment] Orr DL 2nd. **JAMA** 1997 Sep 3;278(9):701–2; discussion 703. Comment on: JAMA 1997 May 7;277(17):1391–7.

Regulating firearm advertisements [letter; comment] Paola FA. **JAMA** 1997 Sep 3;278(9):702; discussion 703. Comment on: JAMA 1997 May 7;277(17):1391–7.

Regulating firearm advertisements [letter; comment] Pipas JE. **JAMA** 1997 Sep 3;278(9):702; discussion 703. Comment on: JAMA 1997 May 7;277(17):1391–7.

FDA poster campaign targets teen smoking [news] Skolnick AA. **JAMA** 1997 Aug 27;278(8):616

Personal use of drug samples by physicians and office staff. Westfall JM, et al. **JAMA** 1997 Jul 9;278(2):141–3

Selling out [editorial] **Lancet** 1997 Aug 23;350(9077):529

Drug advertisements and prescribing [letter; comment] Angel JE. **Lancet** 1996 Nov 23;348(9039):1452–3. Comment on: Lancet 1996 Sep 7;348(9028):632.

Advertising, politicians, and delusions in the mentally vulnerable [letter] Kelly C. **Lancet** 1996 Nov 16; 348(9038):1385

Stop selling tobacco to children. Fulton JP. **Med Health R I** 1996 Feb;79(2):69–71

Gifts from the pharmaceutical industry [letter] Jorm AF. **Med J Aust** 1997 Apr 7;166(7):386–7

Columbia/HCA promotes Pepsi [letter; comment] Hirsch R. **N Engl J Med** 1996 Dec 19;335(25):1927. Comment on: N Engl J Med 1996 Aug 1;335(5):362–7. Comment on: N Engl J Med 1996 Aug 8;335(6):446–51.

A longitudinal study of the attitudes of the dental profession towards competition and advertising. Fay M, et al. **N Z Dent J** 1997 Mar;93(411):10–3

Doctor, "what about that article in the paper?" [editorial] Fitzgibbons TC. **Nebr Med J** 1996 Sep;81(9):301

Influencing advertisers. Hess KW. **Pediatr Ann** 1996 Feb; 25(2):63

Voice and advertising: effects of intonation and intensity of voice on source credibility, attitudes toward the advertised service and the intent to buy. Gélinas-Chebat C, et al. **Percept Mot Skills** 1996 Aug;83(1):243–62

What is wrong with advertising? [letter] Manstein CH. **Plast Reconstr Surg** 1996 Nov;98(6):1124–5

Are adolescents receptive to current sales promotion practices of the tobacco industry? Gilpin EA, et al. **Prev Med** 1997 Jan-Feb;26(1):14–21

Content analysis of gay male and lesbian personal advertisements. Hatala MN, et al. **Psychol Rep** 1996 Apr; 78(2):371–4

Disclosure of contextually hidden sexual images embedded in an advertisement. Simpson PM, et al. **Psychol Rep** 1997 Aug;81(1):333–4

Use of hospital discharge packs--1995. Position statement of the Texas Pediatric Society Committee on Fetus and Newborn. Speer ME. **Tex Med** 1996 Sep;92(9):56–7

Why did Swiss citizens refuse to ban tobacco advertising? Cornuz J, et al. **Tob Control** 1996 Summer;5(2):149–53

The tobacco industry's code of advertising in the United States: myth and reality. Richards JW Jr, et al. **Tob Control** 1996 Winter;5(4):295–311 (84 ref.)

The fight against tobacco [editorial] Doyle JE. **Wis Med J** 1996 Nov;95(11):755–6

The commodification and advertising of infertility treatment. **Womens Health Issues** 1997 May-Jun;7(3):149–50; discussion 150–2

Accountability in the advertising and marketing of assisted reproduction. **Womens Health Issues** 1997 May-Jun; 7(3):167–71

Ethics, advertising, and assisted reproduction: the goals and methods of advertising. Dyer AR. **Womens Health Issues** 1997 May-Jun;7(3):143–8

Panel two: reporting and advertising success rates--the Gordian Knot of assisted reproductive technology. The role of professional societies. Garcia JE. **Womens Health Issues** 1997 May-Jun;7(3):188–92; discussion 194–6

Assisted reproductive technologies, ads, and ethics: philosophical, ethical, and clinical perspectives on the use of advertising in reproductive medicine. A conference held by the National Advisory Board on Ethics in Reproduction. Macklin R, et al. **Womens Health Issues** 1997 May-Jun;7(3):127–31 (0 ref.)

Accountability, representation, and advertising. Sher G, et al. **Womens Health Issues** 1997 May-Jun;7(3):153–61

Panel one: marketing strategies and informing the patient/consumer. Infertility, advertising, and choice: a consumer advocate's perspective. Zieselman K. **Womens Health Issues** 1997 May-Jun;7(3):180–5; discussion 186–7

[The elderly in TV commercials: ridiculous or respectable?] van Selm M, et al. **Tijdschr Gerontol Geriatr** 1996 Dec; 27(6):237–42 (Eng. Abstr.) **(Dut)**

[Comprehension of food label claims by university undergraduate students] Grenier K, et al. **Can J Public Health** 1996 Sep-Oct;87(5):351–3 (Eng. Abstr.) **(Fre)**

[Advertising and tobacco (editorial)] Jiménez Ruiz CA. **Arch Bronconeumol** 1996 Dec;32(10):497–9 **(Spa)**

[Drug information: a company convicted for advertising without permission from the Medical Products Agency] **Lakartidningen** 1997 Feb 5;94(6):449 **(Swe)**

[Complain directly to the advertisers about the quality of paper! (letter)] Blomstrand S. **Lakartidningen** 1997 Mar 12; 94(11):934 **(Swe)**

[Careless risk estimation in an advertisement on osteoporosis (letter)] Englund L. **Lakartidningen** 1997 Mar 19; 94(12):1049, 1051 **(Swe)**

[Läkartidningen--a scientific journal or an advertisement rag? (letter)] Hedberg G. **Lakartidningen** 1997 Jan 29; 94(5):318 **(Swe)**

[Misleading facts in an advertisement of an antidepressive agent (letter)] Mattsson B. **Lakartidningen** 1997 Mar 19; 94(12):1051–2 **(Swe)**

[Alarmingly inadequate clinical evaluation and marketing of intrauterine devices (letter)] Odlind V, et al. **Lakartidningen** 1997 Jun 25;94(26–27):2445 **(Swe)**

[Marketing becoming more and more sophisticated. Physicians are questioned about their prescriptions by drug industry] Orn P. **Lakartidningen** 1996 Dec 11;93(50):4597 **(Swe)**

[Misleading marketing of the use of antibiotics (letter)] Sörberg M, et al. **Lakartidningen** 1996 Oct 9;93(41):3553–4 **(Swe)**

ECONOMICS

The effects of tobacco advertising: brand loyalty, brand switching, or market expansion? [editorial; comment] Davis RM. **Am J Prev Med** 1996 Jan-Feb;12(1):2–3. Comment on: Am J Prev Med 1996 Jan-Feb;12(1):14–6.

HISTORY

Bread and newspapers: the making of a revolution in the science of food'. Weatherall M. **Clio Med** 1995;32:179–212

Advertising dentistry. Curtis EK. **J Am Coll Dent** 1997 Summer;64(2):39–40

Recruiting women smokers: the engineering of consent. Brandt AM. **J Am Med Womens Assoc** 1996 Jan–Apr; 51(1–2):63–6

Deadly targeting of women in promoting cigarettes. O'Keefe AM, et al. **J Am Med Womens Assoc** 1996 Jan–Apr; 51(1–2):67–9

May 1846 and 1896. Colon GA. **J La State Med Soc** 1996 May;148(5):204–6

Advertisements in the Laryngoscope. Clinical confirmation. **Laryngoscope** 1997 Jan;107(1):6

[Tainted femininity--traces of traditional menstruation myths in product advertising of feminine hygiene products] Backe J. **Gynakol Geburtshilfliche Rundsch** 1997;37(1):30–8 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Criminal deception. Davis RM. **Alaska Med** 1996 Jan–Mar; 38(1):43–8

(If the regulators don't get you) your competitors will. Barker MO. **Am J Contact Dermat** 1997 Jun;8(2):127–9

Controlling tobacco advertising: the FDA regulations and the First Amendment. Glantz LH. **Am J Public Health** 1997 Mar;87(3):446–51 (24 ref.)

Tobacco marketing: shackling the pied piper [editorial] Hastings G, et al. **BMJ** 1997 Aug 23;315(7106):439–40

FDA tightens rules on advertising [news] Josefson D. **BMJ** 1997 Aug 23;315(7106):447

Hong Kong bans tobacco advertising [news] Mackay J, et al. **BMJ** 1997 Jul 5;315(7099):8

Alcohol advertising and violence against women: a media advocacy case study. Woodruff K. **Health Educ Q** 1996 Aug;23(3):330–45

Subjects and accomplices: regulation and the ethics of cigarette advertising. Cutler T, et al. **Int J Health Serv** 1997;27(2):329–46

Advertising, computers, and pharmacy liability. A Michigan court's decision has ramifications for pharmaceutical care. Cacciatore GG. **J Am Pharm Assoc (Wash)** 1996 Nov; NS36(11):651–4

Infant feeding and the law. Sobti JC, et al. **J Indian Med Assoc** 1996 Mar;94(3):108–10

FDA regulation of tobacco advertising and youth smoking. Historical, social, and constitutional perspectives. Gostin LO, et al. **JAMA** 1997 Feb 5;277(5):410–8

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Oct 9;276(14):1128

Regulating firearm advertisements that promise home protection. A public health intervention [see comments] Vernick JS, et al. **JAMA** 1997 May 7;277(17):1391–7. Comment in: JAMA 1997 Sep 3;278(9):701–2; discussion 703. Comment in: JAMA 1997 Sep 3;278(9):702; discussion 703.

Direct-to-consumer prescription drug advertising. Bradley LR, et al. **Med Care** 1997 Jan;35(1):86–92

Cowboys, camels, and the First Amendment--the FDA's restrictions on tobacco advertising [published erratum appears in N Engl J Med 1997 Feb 6;336(6):451] Annas GJ. **N Engl J Med** 1996 Dec 5;335(23):1779–83

The Food and Drug Administration's regulation of tobacco products [letter; comment] Nadarajan VS. **N Engl J Med** 1997 Mar 20;336(12):880–1. Comment on: N Engl J Med 1996 Sep 26;335(13):988–94.

New legislation in Turkey [letter] Emri S. **Tob Control** 1997 Spring;6(1):61

1995 tobacco control ordinances survey: Wisconsin counties, cities and villages. Brazin S, et al. **Wis Med J** 1996 Nov; 95(11):773–4

New FDA rule issued to reduce youth smoking rates, challenges to rule expected. McCollum C. **Wis Med J** 1996 Nov;95(11):760–2

Panel two: reporting and advertising success rates--the Gordian Knot of assisted reproductive technology. The role of a federal regulatory agency. Katz M. **Womens Health Issues** 1997 May-Jun;7(3):192–4; discussion 194–6

[The private outpatient clinic of the chief physician as a "private practice" qualified to be registered in the classified directory of the official telephone book?] Rieger HJ. **Dtsch Med Wochenschr** 1996 Oct 18;121(42):1309 **(Ger)**

[Effects of tobacco advertising regulations in various countries] Sone T. **Nippon Koshu Eisei Zasshi** 1995 Dec; 42(12):1017–28 (56 ref.) (Eng. Abstr.) **(Jpn)**

ADVERTISING

METHODS

Epidemiology and the Internet [letter; comment] Hadley J. **Epidemiology** 1997 Jul;8(4):464–5. Comment on: Epidemiology 1997 Mar;8(2):123–5.

Issues in recruitment and retention of minority nursing students. Dowell MA. **J Nurs Educ** 1996 Oct;35(7):293–7 (43 ref.)

The art of advertising for research subjects. Timmerman GM. **Nurs Res** 1996 Nov–Dec;45(6):339–40, 344

Anti-tobacco crusader educates youth on the facts of life of the tobacco industry. McCollum C. **Wis Med J** 1996 Nov;95(11):766–8

STANDARDS

Advertising wearout in the Transport Accident Commission road safety campaigns. Fry TR. **Accid Anal Prev** 1996 Jan; 28(1):123–9

Commentary: advertising adversities. Christo GG, et al. **BMJ** 1997 Aug 23;315(7106):460

Are drug advertisements in Indian edition of BMJ unethical? Gitanjali B, et al. **BMJ** 1997 Aug 23;315(7106):459

Recent progress in drug advertising [letter; comment] McElwain M. **Can Fam Physician** 1997 Jun;43:1041–2. Comment on: Can Fam Physician 1997 Apr;43:594–6, 602–5.

The PMAC code of marketing practices: time for improvement? Pharmaceutical Manufacturers Association of Canada [editorial; comment] [see comments] Desjardins JG. **Can Med Assoc J** 1997 Feb 1;156(3):363–4. Comment on: Can Med Assoc J 1997 Feb 1;156(3):351–6. Comment in: Can Med Assoc J 1997 Apr 1;156(7):982–3.

Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines? [see comments] Lexchin J. **Can Med Assoc J** 1997 Feb 1;156(3):351–6. Comment in: Can Med Assoc J 1997 Feb 1;156(3):359–61. Comment in: Can Med Assoc J 1997 Feb 1;156(3):351–6. Comment in: Can Med Assoc J 1997 Apr 1;156(7):982–3.

Can drug companies have it both ways? [letter; comment] Rapp MS. **Can Med Assoc J** 1997 Apr 1;156(7):982–3. Comment on: Can Med Assoc J 1997 Feb 1;156(3):351–6. Comment on: Can Med Assoc J 1997 Feb 1;156(3):359–61. Comment on: Can Med Assoc J 1997 Feb 1;156(3):363–4.

Regulating pharmaceutical advertising: what will work? [editorial; comment] [see comments] Shapiro MF. **Can Med Assoc J** 1997 Feb 1;156(3):359–61. Comment on: Can Med Assoc J 1997 Feb 1;156(3):351–6. Comment in: Can Med Assoc J 1997 Apr 1;156(7):982–3.

Should the federal trade commission allow dentistry to require its members to adhere to a high standard in advertising? Allamano BL. **J Am Coll Dent** 1996 Spring; 63(1):19–22

From the Food and Drug Administration. Nightingale SL. **JAMA** 1997 Oct 1;278(13):1054

STATISTICS & NUMERICAL DATA

A comparison of the numbers of pharmaceutical advertising pages in family medicine research journals and journals in other medical disciplines. Hueston WJ, et al. **Acad Med** 1997 Sep;72(9):804–6

Cancer coverage and tobacco advertising in African-American women's popular magazines. Hoffman-Goetz L, et al. **J Community Health** 1997 Aug; 22(4):261–70

Frequency of contact with cigarette advertising and smoking experience among young women in Japan. Sone T. **J Epidemiol** 1997 Mar;7(1):43–7

TRENDS

A comparison of the numbers of pharmaceutical advertising pages in family medicine research journals and journals in other medical disciplines. Hueston WJ, et al. **Acad Med** 1997 Sep;72(9):804–6

Communication of HIV serostatus between potential sex partners in personal ads. Hamers FF, et al. **AIDS Educ Prev** 1997 Feb;9(1):42–8

Subliminal manipulation of smoking. Frydman M. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):173–6 (8 ref.)

Does pharmaceutical marketing actually have real and proven value? [letter; comment] Muller D, et al. **J Gen Intern Med** 1997 Apr;12(4):258. Comment on: J Gen Intern Med 1996 Oct;11(10):635–6.

AEDES

Effect of ebastine on mosquito bites. Reunala T, et al. **Acta Derm Venereol** 1997 Jul;77(4):315–6

The discovery of the vector for "yellow jack". Thompson CS, et al. **Am Surg** 1997 May;63(5):462–3

Factors influencing the duration of blood-feeding by laboratory-reared and wild Aedes aegypti (Diptera: Culicidae) from Trinidad, West Indies. Chadee DD, et al. **Ann Trop Med Parasitol** 1997 Mar;91(2):199–207

The reemergence of Aedes aegypti in Arizona [letter] Engelthaler DM, et al. **Emerg Infect Dis** 1997 Apr–Jun; 3(2):241–2

Cell cycle parameters in Aedes albopictus mosquito cells. Gerenday A, et al. **In Vitro Cell Dev Biol Anim** 1996 May; 32(5):307–12

Laboratory evaluation of toxic baits for mosquito (Aedes aegypti) larvae. Vartak PH, et al. **Indian J Exp Biol** 1996 Mar;34(3):272–3

Effects of three larvicides on the production of Aedes albopictus based on removal of pupal exuviae. Becnel JJ, et al. **J Am Mosq Control Assoc** 1996 Sep;12(3 Pt 1):499–502

Efficacy of different ovitraps and binomial sampling in Aedes albopictus surveillance activity. Bellini R, et al. **J Am Mosq Control Assoc** 1996 Dec;12(4):632–6

Efficacy of carbon dioxide, 1-octen-3-ol, and lactic acid in modified Fay-Prince traps as compared to man-landing catch of Aedes aegypti. Canyon DV, et al. **J Am Mosq Control Assoc** 1997 Mar;13(1):66–70

Comparative susceptibility of larvae of three Aedes species to malathion and permethrin. Cilek JE, et al. **J Am Mosq Control Assoc** 1995 Dec;11(4):416–8

First record of Aedes albopictus from New Jersey. Crans WJ, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):307–9

Influence of ground ULV droplet spectra on adulticide efficacy for Aedes taeniorhynchus. Curtis GA, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 2):368–71

Attractant resting boxes for rapid collection and surveillance of Aedes aegypti (L.) inside houses. Edman J, et al. **J Am Mosq Control Assoc** 1997 Mar;13(1):24–7

Response of Anopheles farauti to permethrin-treated net and cloth fabrics in the laboratory. Frances SP, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):321–4

Aedes albopictus and Ae. triseriatus eggs survive waste tire processing. Hanson SM, et al. **J Am Mosq Control Assoc** 1996 Dec;12(4):728–9

Field evaluation of heat as an added attractant to traps baited with carbon dioxide and octenol for Aedes taeniorhynchus. Kline DL, et al. **J Am Mosq Control Assoc** 1995 Dec; 11(4):454–6

Occurrence and spread in Italy of Aedes albopictus, with implications for its introduction into other parts of Europe. Knudsen AB, et al. **J Am Mosq Control Assoc** 1996 Jun; 12(2 Pt 1):177–83

Reduction of Aedes dorsalis by enhancing tidal action in a northern California marsh. Kramer VL, et al. **J Am Mosq Control Assoc** 1995 Dec;11(4):389–95

Evaluation of the efficacy of 3% citronella candles and 5% citronella incense for protection against field populations of Aedes mosquitoes. Lindsay LR, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):293–4

Efficiency of Altosid (S-methoprene) liquid larvicide formulated on Biodac (granular carrier) against spring Aedes species in flooded woodlots. McCarry MJ. **J Am Mosq Control Assoc** 1996 Sep;12(3 Pt 1):497–8

Acoustical detection of Aedes taeniorhynchus swarms and emergence exoduses in remote salt marshes. Mankin RW. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 2):302–8

Newsletters as a channel for communication in a community-based Aedes aegypti control program in Marília, Brazil. Mazine CA, et al. **J Am Mosq Control Assoc** 1996 Dec;12(4):732–5

Evaluation of entomopathogenic bacteria against Aedes polynesiensis, the vector of lymphatic filariasis in French Polynesia. Mercer DR, et al. **J Am Mosq Control Assoc** 1995 Dec;11(4):485–8

Control of Aedes albopictus in waste tire piles with reduced rates of temephos-treated granules. Morris CD, et al. **J Am Mosq Control Assoc** 1996 Sep;12(3 Pt 1):472–6

Possible introduction of Aedes albopictus into Texas from Vietnam [letter] Nowell WR. **J Am Mosq Control Assoc** 1996 Dec;12(4):743–4

Discovery of Aedes albopictus in Guatemala. Ogata K, et al. **J Am Mosq Control Assoc** 1996 Sep;12(3 Pt 1):503–6

Evaluation of Caribbean strains of Macrocyclops and Mesocyclops (Cyclopoida:Cyclopidae) as biological control tools for the dengue vector Aedes aegypti. Rawlins SC, et al. **J Am Mosq Control Assoc** 1997 Mar;13(1):18–23

Acute and sublethal effects of (S)-methoprene on some Australian mosquitoes. Ritchie SA, et al. **J Am Mosq Control Assoc** 1997 Jun;13(2):153–5

Efficacy of ALTOSID pellets and granules against Aedes aegypti in ornamental bromeliads. Ritchie SA, et al. **J Am Mosq Control Assoc** 1997 Jun;13(2):201–2

Insecticide susceptibility of Aedes aegypti and Aedes albopictus in the Lower Rio Grande Valley of Texas and Mexico. Sames WJ 4th, et al. **J Am Mosq Control Assoc** 1996 Sep;12(3 Pt 1):487–90

A new serovar of Bacillus thuringiensis possessing 28a28c flagellar antigenic structure: Bacillus thuringiensis serovar jegathesan, selectively toxic against mosquito larvae. Seleena P, et al. **J Am Mosq Control Assoc** 1995 Dec; 11(4):471–3

Relationship between Breteau and House indices and cases of dengue/dengue hemorrhagic fever in Kuala Lumpur, Malaysia. Sulaiman S, et al. **J Am Mosq Control Assoc** 1996 Sep;12(3 Pt 1):494–6

Seasonal occurrence and abundance of Aedes triseriatus and other mosquitoes in a La Crosse virus-endemic area in western North Carolina. Szumlas DE, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):184–93

Test of a mosquito eggshell isolation method and subsampling procedure. Turner PA, et al. **J Am Mosq Control Assoc** 1997 Mar;13(1):43–6

Construction of a field trap for initiating an ovipositional response in Aedes taeniorhynchus. Wallace FL. **J Am Mosq Control Assoc** 1996 Sep;12(3 Pt 1):491–3

Parameters influencing potency of Bacillus thuringiensis var. israelensis products. Skovmand O, et al. **J Econ Entomol** 1997 Apr;90(2):361–9

Attraction and trapping of Aedes aegypti (Diptera: Culicidae) with host odors in the laboratory. McCall PJ, et al. **J Med Entomol** 1996 Jan;33(1):177–9

Occurrence of Aedes (Stegomyia) spp. mosquitoes (Diptera: Culicidae) in Halmahela villages, Indonesia. Mogi M, et al. **J Med Entomol** 1996 Jan;33(1):169–72

Inter- and intraspecific variation in resistance to desiccation by adult Aedes (Stegomyia) spp. (Diptera: Culicidae) from Indonesia. Mogi M, et al. **J Med Entomol** 1996 Jan; 33(1):53–7

Abundance, parity, and Japanese encephalitis virus infection of mosquitoes (Diptera:Culicidae) in Sepang District, Malaysia. Vythilingam I, et al. **J Med Entomol** 1997 May; 34(3):257–62

Larval competition in Aedes triseriatus (Diptera: Culicidae): effects of density on size, growth, sex ratio, and survival. Mahmood F, et al. **J Vector Ecol** 1997 Jun;22(1):90–4

Dispersal behavior of adult snow melt mosquitoes in the Upper Rhine Valley, Germany. Schäfer M, et al. **J Vector Ecol** 1997 Jun;22(1):1–5

Dengue in the Americas--time to talk [editorial] **Lancet** 1997 Aug 16;350(9076):455

Surveillance of the mosquito Aedes aegypti and its biocontrol with the copepod Mesocyclops aspericornis in Australian wells and gold mines. Russell BM, et al. **Med Vet Entomol** 1996 Apr;10(2):155–60

The feasibility of eradicating Aedes aegypti in the Americas. **Rev Panam Salud Publica** 1997 Jan;1(1):68–72

Fighting dengue in Cuba [letter; comment] Green MM. **Science** 1997 Aug 1;277(5326):623. Comment on: Science 1997 Jul 11;277(5323):174.

Resurgent mosquitoes, dengue in Cuba [news] [published erratum appears in Science 1997 Aug 1;277(5326):625] [see comments] Taubes G. **Science** 1997 Jul 11;277(5323):174. Comment in: Science 1997 Aug 1;277(5326):623.

Toxicity of insecticides to Toxorhynchites splendens and three vector mosquitos and their sublethal effect on biocontrol potential of the predator. Amalraj DD, et al. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):154–9

Insecticide impregnated cotton fabrics of different hydrophobicity against Aedes aegypti (Diptera:Culicidae). Amalraj DD, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):617–21

Microdroplet application of mosquitocidal Bacillus thuringiensis using ultra-low-volume generator for the control of mosquitos. Seleena P, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):628–32

Rapid and efficient removal of immature Aedes aegypti in metal drums by sweep net and modified sweeping method. Tun-Lin W, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):754–9

The biology and predatory potential of notonectid bug, Enithares indica (Fabr) against mosquito larvae. Wattal S, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):633–6

Community based dengue control in Columbia: people's knowledge and practice and the potential contribution of the biological larvicide Bti (Bacillus thuringiensis israelensis). Kroeger A, et al. **Trop Med Parasitol** 1995 Dec; 46(4):241–6

[Anti-Aedes aegypti campaign in French Guiana] Cebret A, et al. **Bull Soc Pathol Exot** 1996;89(2):148–52; discussion 153 (Eng. Abstr.) **(Fre)**

[The risk of urban yellow fever outbreaks in Brazil by dengue vectors. Aedes aegypti and Aedes albopictus] Mondet B, et al. **Bull Soc Pathol Exot** 1996;89(2):107–13; discussion 114 (11 ref.) (Eng. Abstr.) **(Fre)**

[Control of mosquitos in Martinique. A collective public health action and improvement of the quality of life] Yebakima A. **Bull Soc Pathol Exot** 1996;89(2):145–7 (4 ref.) (Eng. Abstr.) **(Fre)**

[Control of Aedes aegypti in Martinique. Contribution of entomology studies] Yébakima A. **Bull Soc Pathol Exot** 1996;89(2):161–2 (Eng. Abstr.) **(Fre)**

[A new culicid in Italy: Aedes (Ochlerotatus) annulipes (Diptera, Culicidae)] Zamburlini R. **Parassitologia** 1996 Dec;38(3):491–4 (Eng. Abstr.) **(Ita)**

[1st isolation of Aedes (Ochlerotatus) sticticus (Diptera, Culicidae) in the Po-Venetian valley] Zamburlini R. **Parassitologia** 1996 Dec;38(3):555–8 (Eng. Abstr.) **(Ita)**

[Occurrence of Aedes scapularis (Diptera:Culicidae) in artificial breeding area of southern Brazil] da Silva AM, et al. **Rev Saude Publica** 1996 Feb;30(1):103–4 (Eng. Abstr.) **(Por)**

[First recorded occurrence of Aedes (Stegomyia) albopictus (Skuse) in the southeastern region of Brazil] Sant'Ana AL. **Rev Saude Publica** 1996 Aug;30(4):392–3 (Eng. Abstr.) **(Por)**

[Description of the colonization of Aedes albopictus (Diptera: culicidae) in the region of Saõ José do Rio Preto, SP, 1991–1994] Chiaravalloti Neto F, et al. **Rev Soc Bras Med Trop** 1996 Nov–Dec;29(6):543–8 (Eng. Abstr.) **(Por)**

CLASSIFICATION

Aedes albopictus in Mexico. Ibáñez-Bernal S, et al.

J Am Mosq Control Assoc 1994 Jun;10(2 Pt 1):231–2
A larval mosquito survey in northeastern Arkansas including a new record for Aedes albopictus. Jamieson DH, et al. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 1):236–9
Operational and scientific notes. Mekuria Y, et al. **J Am Mosq Control Assoc** 1995 Dec;11(4):468–70
The mosquitoes of Yellowstone National Park (Diptera:Culicidae). Nielsen LT, et al. **J Am Mosq Control Assoc** 1996 Dec;12(4):695–700
Survey of container-inhabiting mosquitoes in Clemson, South Carolina, with emphasis on Aedes albopictus. Richardson JH, et al. **J Am Mosq Control Assoc** 1995 Dec;11(4):396–400
Revalidation and description of Aedes (Finlaya) Pallirostris from northeastern India (Diptera:Culicidae). Tewari SC, et al. **J Am Mosq Control Assoc** 1996 Dec;12(4):713–20
Regional molecular genetic key of thirteen snow pool Aedes species (Diptera:Culicidae) in northern Colorado. West DF, et al. **J Med Entomol** 1997 Jul;34(4):404–10
Culicine mosquitoes (Diptera: Culicidae) attracted to humans on Espiritu Santo, Vanuatu. Bryan JH, et al. **Med Vet Entomol** 1996 Jan;10(1):101–2
[Demonstration of two twin species A and B of the Aedes detritus (Haliday, 1833) complex from the Atlantic coast of France] Brutus L, et al. **Parasite** 1994 Jun;1(2):167–70 (Eng. Abstr.) **(Fre)**

CYTOLOGY

Evaluation of a heterologous metallothionein gene promoter in transfected mosquito cells. Wu CC, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Mar; 116(3):353–8
Synchronization of Aedes albopictus mosquito cells using hydroxyurea. Gerenday A, et al. **Insect Mol Biol** 1997 May; 6(2):191–6
In vitro cultivation of Wolbachia pipientis in an Aedes albopictus cell line. O'Neill SL, et al. **Insect Mol Biol** 1997 Feb;6(1):33–9
Characterization of the infection of Aedes albopictus cell clones by Sindbis virus. Karpf AR, et al. **Virus Res** 1997 Jul;50(1):1–13

DRUG EFFECTS

Inheritance of larval resistance to permethrin in Aedes aegypti and association with sex ratio distortion and life history variation. Mebrahtu YB, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):456–65
Evaluation of Methoprene (Altosid) and Diflubenzuron (Dimilin) for control of mosquito breeding in Tezpur (Assam). Baruah I, et al. **Indian J Malariol** 1996 Jun; 33(2):61–6
Effects of two insect growth regulators on the susceptibility of Aedes aegypti (Diptera:Culicidae) to Molinema dessetae (Nematoda:Filarioidea). Fournet F, et al. **J Am Mosq Control Assoc** 1997 Mar;13(1):40–2
Methoprene affects the rotation of the male terminalia of Aedes aegypti mosquitoes. O'Donnell PP, et al. **J Am Mosq Control Assoc** 1997 Mar;13(1):1–4
Purification and identification of a metabolite from Escherichia coli which is toxic to mosquito larvae. Thanabalu T, et al. **J Invertebr Pathol** 1996 May; 67(3):306–8
Larvicidal constituents of Melantheria albinervia. Slimestad R, et al. **Planta Med** 1995 Dec;61(6):562–3

ENZYMOLOGY

Apyrase and alpha-glucosidase in the salivary glands of Aedes albopictus. Marinotti O, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Apr; 113(4):675–9
Analysis of the mosquito lysosomal aspartic protease gene: an insect housekeeping gene with fat body–enhanced expression. Dittmer NT, et al. **Insect Biochem Mol Biol** 1997 Apr;27(4):323–35
cDNA cloning and pattern of expression of an adult, female-specific chymotrypsin from Aedes aegypti midgut. Jiang Q, et al. **Insect Biochem Mol Biol** 1997 Apr; 27(4):283–9
Involvement of peroxidase in chorion hardening in Aedes aegypti. Li J, et al. **Insect Biochem Mol Biol** 1996 Mar; 26(3):309–17
Early trypsin, a female-specific midgut protease in Aedes aegypti: isolation, aminoterminal sequence determination, and cloning and sequencing of the gene. Noriega FG, et al. **Insect Biochem Mol Biol** 1996 Feb;26(2):119–26
Biochemical, molecular, and phylogenetic analysis of pyruvate carboxylase in the yellow fever mosquito, Aedes aegypti. Tu Z, et al. **Insect Biochem Mol Biol** 1997 Feb; 27(2):133–47
Structural mapping of the dihydrofolate reductase amplicon in mosquito cells resistant to methotrexate. Wang ZH, et al. **Insect Biochem Mol Biol** 1997 Jan;27(1):79–92
Cloning and sequencing of the blood meal–induced late trypsin gene from the mosquito Aedes aegypti and characterization of the upstream regulatory region. Barillas-Mury C, et al. **Insect Mol Biol** 1993;2(1):7–12
Cloning and analysis of the locus for mosquito vitellogenic carboxypeptidase. Deitsch KW, et al. **Insect Mol Biol** 1993; 2(4):205–13
Isolation, sequencing and characterization of two cDNA clones coding for trypsin-like enzymes from the midgut of Aedes aegypti. Kalhok SE, et al. **Insect Mol Biol** 1993; 2(2):71–9
An amplified mosquito dihydrofolate reductase gene: amplicon size and chromosomal distribution. Shotkoski FA, et al. **Insect Mol Biol** 1993;2(3):155–61
Enzymatic variability in natural populations of Aedes aegypti (Diptera:Culicidae) from Brazil. Dinardo-Miranda LL, et al. **J Med Entomol** 1996 Sep;33(5):726–33
On the occurrence of thrombin-like enzymes in mosquitoes. Bark N, et al. **Thromb Res** 1996 Mar 15;81(6):623–34

GENETICS

Evaluation of a heterologous metallothionein gene promoter in transfected mosquito cells. Wu CC, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Mar; 116(3):353–8
Intensive linkage mapping in a wasp (Bracon hebetor) and a mosquito (Aedes aegypti) with single-strand conformation polymorphism analysis of random amplified polymorphic DNA markers. Antolin MF, et al. **Genetics** 1996 Aug;143(4):1727–38
Generation of expressed sequence tags and sequence-tagged sites as physical landmarks in the mosquito, Aedes aegypti, genome. Severson DW, et al. **Genome** 1996 Feb;39(1):224–9
Evidence for a DNA homologous pairing activity in nuclear extracts from mosquito cells. Baldridge GD, et al. **Insect Biochem Mol Biol** 1996 Jul;26(7):667–76
Molecular characterization of a defensin gene from the mosquito, Aedes aegypti. Cho WL, et al. **Insect Biochem Mol Biol** 1997 May;27(5):351–8
Transposition of the Hermes element in embryos of the vector mosquito, Aedes aegypti. Sarkar A, et al. **Insect Biochem Mol Biol** 1997 May;27(5):359–63
FISH landmarks for Aedes aegypti chromosomes. Brown SE, et al. **Insect Mol Biol** 1997 May;6(2):197–202
Insulin-mediated secretion of ecdysteroids from mosquito ovaries and molecular cloning of the insulin receptor homologue from ovaries of bloodfed Aedes aegypti. Graf R, et al. **Insect Mol Biol** 1997 May;6(2):151–63
Cloning and expression analysis of Aedes aegypti opsin: adaptation of an in situ hybridization protocol for mosquitoes. Graf R, et al. **Insect Mol Biol** 1996 Aug; 5(3):173–80
A comparison of three methods for isolating RNA from mosquitoes. Noriega FG, et al. **Insect Mol Biol** 1993; 2(1):21–4
Juvenile hormone controls early trypsin gene transcription in the midgut of Aedes aegypti. Noriega FG, et al. **Insect Mol Biol** 1997 Feb;6(1):63–6
Genetic differentiation of Aedes aegypti, the vector of dengue virus in French Polynesia. Failloux AB, et al. **J Am Mosq Control Assoc** 1995 Dec;11(4):457–62
Comparisons of genetic variability and genome structure among mosquito strains selected for refractoriness to a malaria parasite. Yan G, et al. **J Hered** 1997 May-Jun; 88(3):187–94
Gene flow in Aedes albifasciatus (Diptera:Culicidae) from central Argentina. De Sousa GB, et al. **J Med Entomol** 1996 Nov;33(6):894–900
Muscle actin gene from Aedes aegypti (Diptera:Culicidae). Ibrahim MS, et al. **J Med Entomol** 1996 Nov;33(6):955–62
Zebedee: a novel copia-Ty1 family of transposable elements in the genome of the medically important mosquito Aedes aegypti. Warren AM, et al. **Mol Gen Genet** 1997 May 20; 254(5):505–13
Molecular characterization of the mosquito vitellogenin receptor reveals unexpected high homology to the Drosophila yolk protein receptor. Sappington TW, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):8934–9
Three novel families of miniature inverted-repeat transposable elements are associated with genes of the yellow fever mosquito, Aedes aegypti. Tu Z. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7475–80
Phenotypic segregation of Aedes aegypti for immune antibacterial activity and resistance to filariae. Ham PJ, et al. **Proc R Soc Lond B Biol Sci** 1996 Sep 22; 263(1374):1205–10

GROWTH & DEVELOPMENT

Disposable containers as larval habitats for Aedes aegypti in a city with regular refuse collection: a study in Marília, São Paulo State, Brazil. Mazine CA, et al. **Acta Trop** 1996 Sep;62(1):1–13
Pupal survey: an epidemiologically significant surveillance method for Aedes aegypti: an example using data from Trinidad. Focks DA, et al. **Am J Trop Med Hyg** 1997 Feb; 56(2):159–67
Simulating development and survival of Aedes vexans (Diptera: Culicidae) preimaginal stages under field conditions. Fouque F, et al. **J Med Entomol** 1996 Jan; 33(1):32–8
Effects of developmental asynchrony between Aedes triseriatus (Diptera:Culicidae) and its predator Toxorhynchites rutilus (Diptera:Culicidae). Nannini MA, et al. **J Med Entomol** 1997 Jul;34(4):457–60
Biological control of Aedes albopictus (Diptera: Culicidae) larvae in trap tyres by Mesocyclops longisetus (Copepoda: Cyclopidae) in two field trials. Urbano Santos L, et al. **Mem Inst Oswaldo Cruz** 1996 Mar-Apr;91(2):161–2
Factors favoring houseplant container infestation with Aedes aegypti larvae in Marília, São Paulo, Brazil. Macoris ML, et al. **Rev Panam Salud Publica** 1997 Apr;1(4):280–6
[Aedes aegypti in French Guiana. Some aspects of history, general ecology and vertical transmission of the dengue virus] Fouque F, et al. **Bull Soc Pathol Exot** 1996; 89(2):115–9 (7 ref.) (Eng. Abstr.) **(Fre)**
[Epidemiology of arbovirus diseases: use and value of physiologic age determination of female mosquito vectors] Mondet B. **Bull Soc Pathol Exot** 1996;89(2):155–60 (Eng. Abstr.) **(Fre)**
[Oviposition and dispersion of Aedes aegypti in an urban environment] Reiter P. **Bull Soc Pathol Exot** 1996; 89(2):120–2 (Eng. Abstr.) **(Fre)**
[Problems posed by the spread of Aedes albopictus] Rodhain F. **Bull Soc Pathol Exot** 1996;89(2):137–40; discussion 140–1 (0 ref.) (Eng. Abstr.) **(Fre)**
[Ecology of Aedes aegypti in Africa and Asia] Rodhain F. **Bull Soc Pathol Exot** 1996;89(2):103–6 (0 ref.) (Eng. Abstr.) **(Fre)**
[Detection of Aedes aegypti and Aedes albopictus, in an urban zone of the municipality of Catanduva, SP, after control of a Dengue epidemic] Cardoso Júnior RP, et al. **Rev Soc Bras Med Trop** 1996 Jan-Feb;30(1):37–40 (Eng. Abstr.) **(Por)**
[A description of Aedes aegypti colonization in the region of São José do Rio Preto, São Paulo] Chiaravalloti Neto F. **Rev Soc Bras Med Trop** 1997 Jul-Aug;30(4):279–85 (Eng. Abstr.) **(Por)**

IMMUNOLOGY

Comparison of proteins, IgE, and IgG binding antigens, and skin reactivity in commercial and laboratory-made mosquito extracts. Peng Z, et al. **Ann Allergy Asthma Immunol** 1996 Nov;77(5):371–6
Characterization of Aedes communis, Aedes aegypti and Anopheles stephensi mosquito saliva antigens by immunoblotting. Brummer-Korvenkontio H, et al. **Int Arch Allergy Immunol** 1997 Feb;112(2):169–74
Cross-reactivity of skin and serum specific IgE responses and allergen analysis for three mosquito species with worldwide distribution. Peng Z, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):192–8
In vivo effect of a natural Aedes aegypti defensin on Brugia pahangi development. Albuquerque CM, et al. **Med Vet Entomol** 1996 Oct;10(4):397–9
Heritability of infection-induced humoral antibacterial activity in the immune response of the mosquito Aedes aegypti. Ham PJ, et al. **Med Vet Entomol** 1996 Jul; 10(3):299–300

METABOLISM

A fitness advantage for Aedes aegypti and the viruses it transmits when females feed only on human blood. Scott TW, et al. **Am J Trop Med Hyg** 1997 Aug;57(2):235–9
Changes in ribosomal protein rpL8 mRNA during the reproductive cycle of the mosquito, Aedes aegypti. Mazzacano CA, et al. **Insect Biochem Mol Biol** 1996 Jun; 26(6):563–70
Mosquito hexamerins: characterization during larval development. Korochkina SE, et al. **Insect Mol Biol** 1997 Feb;6(1):11–21
Peritrophic matrix proteins of Anopheles gambiae and Aedes aegypti. Moskalyk LA, et al. **Insect Mol Biol** 1996 Nov; 5(4):261–8
Lipid transfer from insect fat body to lipophorin: comparison between a mosquito triacylglycerol-rich lipophorin and a sphinx moth diacylglycerol-rich lipophorin. Pennington JE, et al. **J Lipid Res** 1996 May;37(5):1144–52
Reduced transfer of male accessory gland proteins and monandry in female Aedes aegypti mosquitoes. Dickinson JM, et al. **J Vector Ecol** 1997 Jun;22(1):95–8

MICROBIOLOGY

First record of genus Coelomomyces in Macau (China): Coelomomyces stegomyiae var. stegomyiae parasitizing Aedes albopictus. Ramos HC, et al. **J Am Mosq Control Assoc** 1996 Sep;12(3 Pt 1):507–9
Parasites of the Asian tiger mosquito and other container-inhabiting mosquitoes (Diptera:Culicidae) in northcentral Florida. Fukuda T, et al. **J Med Entomol** 1997 Mar;34(2):226–33
Analysis of LaCrosse virus S mRNA 5' termini in infected mosquito cells and Aedes triseriatus mosquitoes. Dobie DK, et al. **J Virol** 1997 Jun;71(6):4395–9

PARASITOLOGY

Country-wide prevalence of Ascogregarina culicis (apicomplexa: lecudinidae), a protozoan parasite of Aedes aegypti in Trinidad, West Indies. Beier JC, et al. **J Am Mosq Control Assoc** 1995 Dec;11(4):419–23
Ultrastructure of infection, development and gametocyst formation of Ascogregarina taiwanensis (Apicomplexa: Lecudinidae) in its mosquito host, Aedes albopictus (Diptera: Culicidae). Chen WJ, et al. **J Eukaryot Microbiol** 1997 Mar-Apr;44(2):101–8
The effect of chitin synthesis inhibitors on the development of Brugia malayi in Aedes aegypti. Mohapatra R, et al. **J Helminthol** 1996 Sep;70(3):269–70
Comparisons of genetic variability and genome structure among mosquito strains selected for refractoriness to a malaria parasite. Yan G, et al. **J Hered** 1997 May-Jun; 88(3):187–94

AEDES

Lambornella clarki (Ciliophora:Tetrahymenidae) resistance in Aedes sierrensis (Diptera:Culicidae):population differentiation in a quantitative trait and allozyme loci. Broberg LE, et al. **J Med Entomol** 1997 Jan;34(1):38–45

Developmental synchrony of Ascogregarina taiwanensis (Apicomplexa: Lecudinidae) within Aedes albopictus (Diptera: Cuclicidae). Chen WJ, et al. **J Med Entomol** 1996 Mar;33(2):212–5

Parasites of the Asian tiger mosquito and other container-inhabiting mosquitoes (Diptera:Culicidae) in northcentral Florida. Fukuda T, et al. **J Med Entomol** 1997 Mar;34(2):226–33

Infection and transmission of Plasmodium gallinaceum (Eucoccida: Plasmodiidae) in Aedes aegypti (Diptera: Culicidae): effect of preinfection sugar meals and postinfection blood meals. Kelly R, et al. **J Vector Ecol** 1997 Jun;22(1):36–42

The influence of microfilarial density of dog heartworm Dirofilaria immitis on infection rate and survival of Aedes notoscriptus and Culex annulirostris from Australia. Russell RC, et al. **Med Vet Entomol** 1996 Jan;10(1):29–34

An ultrastructural study on the early cellular response to Dirofilaria immitis (Nematoda) in the Malpighian tubules of Aedes aegypti (refractory strains). Vegni Talluri M, et al. **Parasite** 1994 Dec;1(4):343–8

Temperature thresholds and statistical modelling of larval Wuchereria bancrofti (Filariidea:Onchocercidae) developmental rates. Lardeux F, et al. **Parasitology** 1997 Feb;114 (Pt 2):123–34

PATHOGENICITY

Aedes albopictus in the United States: ten-year presence and public health implications. Moore CG, et al.
Emerg Infect Dis 1997 Jul-Sep;3(3):329–34 (28 ref.)

Virulence, parasite mode of transmission, and host fluctuating asymmetry. Agnew P, et al.
Proc R Soc Lond B Biol Sci 1997 Jan 22;264(1378):9–15

PHYSIOLOGY

Quiescent ovarioles in the mosquito Aedes aegypti (L.) (Diptera: Culicidae). Hoc TQ. **Ann Trop Med Parasitol** 1996 Feb;90(1):95–99

Ovulation and post-ovulation changes in the terminal region of the ovarioles of the mosquito Aedes aegypti (L.) (Diptera: Culicidae). Hoc TQ. **Ann Trop Med Parasitol** 1996 Feb;90(1):71–78

Lipophorin levels in the yellow fever mosquito, Aedes aegypti, and the effect of feeding. Van Heusden MC, et al. **Arch Insect Biochem Physiol** 1997;34(3):301–12

A search for components in human body odour that attract females of Aedes aegypti. Geier M, et al.
Ciba Found Symp 1996;200:132–44; discussion 144–8, 178–83 (35 ref.)

Responses of antennal olfactory receptors in the yellow fever mosquito Aedes aegypti to human body odours. Pappenberger B, et al. **Ciba Found Symp** 1996;200:254–63; discussion 263–6, 281–4

Repellency of Lantana camara (Verbenaceae) flowers against Aedes mosquitoes. Dua VK, et al.
J Am Mosq Control Assoc 1996 Sep;12(3 Pt 1):406–8

Endogenous regulation of the attraction of Aedes aegypti mosquitoes. Klowden MJ. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 2):326–32 (55 ref.)

Sensory bases of attractancy: morphology of mosquito olfactory sensilla-- a review. Sutcliffe JF.
J Am Mosq Control Assoc 1994 Jun;10(2 Pt 2):309–15 (54 ref.)

Diel patterns of pupation, emergence, and oviposition in a laboratory population of Aedes albopictus. Xue RD, et al.
J Am Mosq Control Assoc 1997 Jun;13(2):205–7

A single cDNA encodes all three Aedes leucokinins, which stimulate both fluid secretion by the malpighian tubules and hindgut contractions. Veenstra JA, et al.
J Biol Chem 1997 Apr 18;272(16):10402–7

Diel oviposition patterns of Aedes albopictus (Skuse) and Aedes triseriatus (Say) in the laboratory and the field. Trexler JD, et al. **J Vector Ecol** 1997 Jun;22(1):64–70

Effects of variations in a formulated protein meal on the fecundity and fertility of female mosquitoes. Cosgrove JB, et al. **Med Vet Entomol** 1996 Jul;10(3):260–4

Adaptive larval thermotolerance and induced cross-tolerance to propoxur insecticide in mosquitoes Anopheles stephensi and Aedes aegypti. Patil NS, et al. **Med Vet Entomol** 1996 Jul;10(3):277–82

[Oviposition and dispersion of Aedes aegypti in an urban environment] Reiter P. **Bull Soc Pathol Exot** 1996; 89(2):120–2 (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

SEM examination of the eggs of five British Aedes species. Service MW, et al. **J Am Mosq Control Assoc** 1997 Mar; 13(1):47–65

VIROLOGY

Failure of Aedes aegypti to become infected by feeding on dengue virus-infected immuno-comprised nude mice [letter] Mourya DT, et al. **Acta Virol** 1997 Feb;41(1):57–8

Venereal and vertical transmission of the Aedes albopictus parvovirus in Aedes aegypti mosquitoes. Barreau C, et al. **Am J Trop Med Hyg** 1997 Aug;57(2):126–31

Impact of dengue virus infection on feeding behavior of Aedes aegypti. Platt KB, et al. **Am J Trop Med Hyg** 1997 Aug;57(2):119–25

Aedes albopictus (Diptera:Culicidae) is incompetent as a vector of hepatitis C virus. Bellini R, et al. **APMIS** 1997 Apr;105(4):299–302

Aedes albopictus in the United States: ten-year presence and public health implications. Moore CG, et al.
Emerg Infect Dis 1997 Jul-Sep;3(3):329–34 (28 ref.)

Replication and expression of a recombinant Sindbis virus in mosquitoes. Rayms-Keller A, et al. **Insect Mol Biol** 1995 Nov;4(4):245–51

Stability of equine infectious anemia virus in Aedes aegypti (Diptera: Culicidae), Stomoxys calcitrans (Diptera:Muscidae), and Tabanus fuscicostatus (Diptera:Tabanidae) stored at -70 degrees C. Green BE, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):334–6

Pathogenicity of the Aedes albopictus parvovirus (AaPV), a denso-like virus, for Aedes aegypti mosquitoes. Barreau C, et al. **J Invertebr Pathol** 1996 Nov;68(3):299–309

Evidence of vertical transmission of Ross River and Sindbis viruses (Togaviridae: Alphavirus) by mosquitoes (Diptera: Culicidae) in southeastern Australia. Dhileepan K, et al. **J Med Entomol** 1996 Jan;33(1):180–2

Ross River virus in mosquitoes (Diptera:Culicidae) during the 1994 epidemic around Brisbane, Australia. Ritchie SA, et al. **J Med Entomol** 1997 Mar;34(2):156–9

Surveillance for yellow fever virus in eastern Senegal during 1993. Traoré-Lamizana M, et al. **J Med Entomol** 1996 Sep; 33(5):760–5

Analysis of La Crosse virus S-segment RNA and its positive-sense transcripts in persistently infected mosquito tissues. Chandler LJ, et al. **J Virol** 1996 Dec;70(12):8972–6

Dengue 3 virus distribution in the mosquito Aedes aegypti: an immunocytochemical study. Linthicum KJ, et al.
Med Vet Entomol 1996 Jan;10(1):87–92

Dengue vector mosquitos at a tourist attraction, Ko Samui, in 1995. Thavara U, et al.
Southeast Asian J Trop Med Public Health 1996 Mar; 27(1):160–3

Transovarial transmission of dengue 3 virus by Aedes aegypti. Joshi V, et al. **Trans R Soc Trop Med Hyg** 1996 Nov-Dec;90(6):643–4

Adsorptive endocytosis of California encephalitis virus into mosquito and mammalian cells: a role for G1. Hacker JK, et al. **Virology** 1997 Aug 18;235(1):40–7

Methyltransferase activity of the insect orbivirus JKT-7400: photoaffinity labeling of a minor virion protein, VP4, with S-adenosylmethionine. Liao HJ, et al. **Virology** 1997 Sep 1;235(2):235–40

Characterization of the infection of Aedes albopictus cell clones by Sindbis virus. Karpf AR, et al. **Virus Res** 1997 Jul;50(1):1–13

Identification of mayaro virus nucleocapsid protein in nucleus of Aedes albopictus cells. Mitchell C, et al. **Virus Res** 1997 Jan;47(1):67–77

AEQUORIN

Calibration of micropipets using the bioluminescent protein aequorin. Grosvenor AL, et al. **Anal Chem** 1997 Aug 1; 69(15):3115–8

Recombinant apoaequorin acting as a pseudo-luciferase reports micromolar changes in the endoplasmic reticulum free Ca2+ of intact cells. Kendall JM, et al.
Biochem J 1996 Sep 1;318 (Pt 2):383–7

ANALOGS & DERIVATIVES

Synthesis of coelenterazine. Gonzalez-Trueba G, et al.
Anal Biochem 1996 Sep 5;240(2):308–10

Coelenterazine analogs as chemiluminescent probe for superoxide anion. Teranishi K, et al. **Anal Biochem** 1997 Jun 15;249(1):37–43

The use of Renilla luciferase, Oplophorus luciferase, and apoaequorin as bioluminescent reporter protein in the presence of coelenterazine analogues as substrate. Inouye S, et al. **Biochem Biophys Res Commun** 1997 Apr 17; 233(2):349–53

Membrane permeability of coelenterazine analogues measured with fish eggs. Shimomura O. **Biochem J** 1997 Sep 1;326 (Pt 2):297–8

ANALYSIS

Generation of cell transfectants expressing cardiac calcium ion channel and calcium indicator protein aequorin. Maeda A, et al. **Anal Biochem** 1996 Nov 1;242(1):31–9

BIOSYNTHESIS

Construction of a full-length Ca2+-sensitive adenylyl cyclase/aequorin chimera. Nakahashi Y, et al.
J Biol Chem 1997 Jul 18;272(29):18093–7

Glucose-stimulated insulin secretion correlates with changes in mitochondrial and cytosolic Ca2+ in aequorin-expressing INS-1 cells. Kennedy ED, et al.
J Clin Invest 1996 Dec 1;98(11):2524–38

CHEMISTRY

Bioluminescence hybridization assays using recombinant aequorin. Application to the detection of prostate-specific antigen mRNA. Galvan B, et al. **Anal Chem** 1996 Oct 15; 68(20):3545–50

Regeneration and luminescence of aequorin in Chinese hamster ovary cells transformed with cDNA for apoaequorin. Sanchez-Bueno A, et al.
Int J Biochem Cell Biol 1996 Sep;28(9):1045–9

DIAGNOSTIC USE

Focal increases in [Ca2+]i may account for apparent low Ca2+ sensitivity in swine carotid artery. Van Riper DA, et al. **Cell Calcium** 1996 Jun;19(6):501–8

DRUG EFFECTS

Nuclear calcium flux in Trypanosoma brucei can be quantified with targeted aequorin. Xiong ZH, et al.
Mol Biochem Parasitol 1996 Dec 2;83(1):57–67

GENETICS

Regeneration and luminescence of aequorin in Chinese hamster ovary cells transformed with cDNA for apoaequorin. Sanchez-Bueno A, et al.
Int J Biochem Cell Biol 1996 Sep;28(9):1045–9

METABOLISM

The use of Renilla luciferase, Oplophorus luciferase, and apoaequorin as bioluminescent reporter protein in the presence of coelenterazine analogues as substrate. Inouye S, et al. **Biochem Biophys Res Commun** 1997 Apr 17; 233(2):349–53

Measurement of changes in sarcoplasmic reticulum [Ca2+] in rat tail artery with targeted apoaequorin delivered by an adenoviral vector. Rembold CM, et al. **Cell Calcium** 1997 Jan;21(1):69–79

Domains of high Ca2+ beneath the plasma membrane of living A7r5 cells. Marsault R, et al. **EMBO J** 1997 Apr 1;16(7):1575–81

Subcellular analysis of Ca2+ homeostasis in primary cultures of skeletal muscle myotubes. Brini M, et al.
Mol Biol Cell 1997 Jan;8(1):129–43

Aequorin targeted to the endoplasmic reticulum reveals heterogeneity in luminal Ca++ concentration and reports agonist- or IP3-induced release of Ca++. Button D, et al. **Mol Biol Cell** 1996 Mar;7(3):419–34

PHARMACOLOGY

Measurement of intracellular calcium in cell populations loaded with aequorin: neurokinin-1 responses in U373MG cells. Hedley L, et al. **Anal Biochem** 1996 May 1; 236(2):270–4

AEROBACTER see **ENTEROBACTER**

AEROBACTER AEROGENES see **KLEBSIELLA PNEUMONIAE**

AEROBIC BACTERIA see **BACTERIA, AEROBIC**

AEROBIC EXERCISE see **EXERCISE**

AEROCOCCUS see **STREPTOCOCCACEAE**

AEROMONAS

Experiences with different vaccines and vaccination procedures to control furunculosis in sea-reared Atlantic salmon. Lillehaug A. **Acta Vet Scand Suppl** 1996;90:57–62

Aeromonas and Plesiomonas species as bacterial agents of diarrhoea in urban and rural areas of Nigeria: antibiogram of isolates [see comments] Obi CL, et al.
Cent Afr J Med 1995 Dec;41(12):397–403. Comment in: Cent Afr J Med 1996 May;42(5):156–7.

Ecological relationship between Aeromonas and Vibrio spp. and planktonic copepods in the coastal marine environment in southern Italy. Dumontet S, et al.
Comp Immunol Microbiol Infect Dis 1996 Jun;19(3):245–54

Aeromonas bacteremia in patients with hematologic diseases. Funada H, et al. **Intern Med** 1997 Mar;36(3):171–4

Characterization of a type IV bundle-forming pilus (SFP) from a gastroenteritis-associated strain of Aeromonas veronii biovar sobria. Kirov SM, et al. **Microb Pathog** 1996 Jul;21(1):23–34

Multiple regulation of carp (Cyprinus carpio L.) macrophages and neutrophilic granulocytes by serum factors: influence of infection with atypical Aeromonas salmonicida. Verburg-van Kemenade BM, et al.
Vet Immunol Immunopathol 1996 May;51(1-2):189–200

Water quality parameters associated with Aeromonas spp-affected hatcheries. Ortega C, et al. **Vet Res** 1996; 27(6):553–60

Furunculosis control using a paraimmunization stimulant (Baypamun) in rainbow trout. Ortega C, et al. **Vet Res** 1996;27(6):561–8

[Severe acute gastroenteritis due to Aeromonas in a patient colectomized for Crohn's disease] de Sola Earle C, et al.
Rev Esp Enferm Dig 1997 Jan;89(1):48–50 (18 ref.) (Eng. Abstr.) **(Spa)**

[Bacteremia for Aeromonas sobria in a patient with cholecystitis (letter)] Torres L, et al.
Rev Esp Enferm Dig 1997 Apr;89(4):332 **(Spa)**

CHEMISTRY

Spectroscopically distinct cobalt(II) sites in heterodimetallic forms of the aminopeptidase from Aeromonas proteolytica: characterization of substrate binding. Bennett B, et al. **Biochemistry** 1997 Aug 12;36(32):9837–46

Structural studies of the O-antigenic polysaccharide from an Aeromonas caviae strain. Linnerborg M, et al. **Carbohydr Res** 1996 Sep 23;291:165–74

The role of the capsular polysaccharide of Aeromonas salmonicida in the adherence and invasion of fish cell lines. Merino S, et al. **FEMS Microbiol Lett** 1996 Sep 1; 142(2–3):185–9

Immunological analysis of extracellular products and cell surface components of motile Aeromonas isolated from fish. Santos Y, et al. **J Appl Bacteriol** 1996 Dec;81(6):585–93

CLASSIFICATION

The species composition of oligotrophic bacterial communities of Lake Balaton--a numerical analysis. Tóth E. **Acta Microbiol Immunol Hung** 1996;43(4):333–8

Haemolytic activity of Aeromonas species isolated in Libya. Ghenghesh KS, et al. **Arch Inst Pasteur Tunis** 1995 Jan–Apr;72(1–2):13–5

Differentiation of Aeromonas genomospecies using random amplified polymorphic DNA polymerase chain reaction (RAPD–PCR). Oakey HJ, et al. **J Appl Bacteriol** 1996 Apr; 80(4):402–10

Identification of Aeromonas clinical isolates by restriction fragment length polymorphism of PCR–amplified 16S rRNA genes. Borrell N, et al. **J Clin Microbiol** 1997 Jul; 35(7):1671–4

Further studies on biochemical characteristics and serologic properties of the genus Aeromonas. Janda JM, et al. **J Clin Microbiol** 1996 Aug;34(8):1930–3

Characterization of Aeromonas spp. isolated from humans with diarrhea, from healthy controls, and from surface water in Bangladesh. Kühn I, et al. **J Clin Microbiol** 1997 Feb;35(2):369–73

Molecular and phenotypic methods for the characterization of atypical Aeromonas salmonicida. Hänninen ML, et al. **Vet Microbiol** 1997 May;56(1–2):147–58

Evaluation of the synergistic haemolysis (CAMP-like) test in the identification of motile, mesophilic Aeromonas species. Gubash SM. **Zentralbl Bakteriol** 1997 Jun; 286(1):41–5

A biochemical protocol for the differentiation of current genomospecies of Aeromonas. Oakey HJ, et al. **Zentralbl Bakteriol** 1996 Jun;284(1):32–46

Computer aided assignment of motile Aeromonas strains to genospecies level by standard biochemical tests. Brunner B, et al. **Zentralbl Veterinarmed [B]** 1997 Jun;44(4):221–33

DRUG EFFECTS

Increasing antibiotic resistance in clinical isolates of Aeromonas strains in Taiwan. Ko WC, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1260–2

Application of a modified disc diffusion technique to antimicrobial susceptibility testing of Vibrio anguillarum and Aeromonas salmonicida clinical isolates. Guérin-Faublée V, et al. **Vet Microbiol** 1996 Jul; 51(1–2):137–49

ENZYMOLOGY

Spectroscopically distinct cobalt(II) sites in heterodimetallic forms of the aminopeptidase from Aeromonas proteolytica: characterization of substrate binding. Bennett B, et al. **Biochemistry** 1997 Aug 12;36(32):9837–46

Mechanistic studies on the aminopeptidase from Aeromonas proteolytica: a two-metal ion mechanism for peptide hydrolysis. Chen G, et al. **Biochemistry** 1997 Apr 8; 36(14):4278–86

Isolation and characterization of restriction endonuclease in Plesiomonas shigelloides and Aeromonas species. Miyahara M, et al. **Biol Pharm Bull** 1996 Nov;19(11):1506–7

In vivo production of A-protein, lipopolysaccharide, iron-regulated outer membrane proteins and 70-kDa serine protease by Aeromonas salmonicida subsp. salmonicida. Ellis AE, et al. **FEMS Microbiol Lett** 1997 Apr 15; 149(2):157–63

Purification and characterization of L-allo-threonine aldolase from Aeromonas jandaei DK-39. Kataoka M, et al. **FEMS Microbiol Lett** 1997 Jun 15;151(2):245–8

Secreted enzymes of Aeromonas. Pemberton JM, et al. **FEMS Microbiol Lett** 1997 Jul 1;152(1):1–10 (73 ref.)

Metabolism of proteins and glycoproteins in tumour bearing mice treated with Aeromonas L-asparaginase. Benny PJ, et al. **Indian J Biochem Biophys** 1996 Dec;33(6):527–30

Production of extracellular proteases and amylases by some acidophilic and alkalophilic bacteria. Sharma A, et al. **Indian J Exp Biol** 1996 Mar;34(3):232–4

Enzyme kinetics and biochemical analysis of ImiS, the metallo-beta-lactamase from Aeromonas sobria 163a. Walsh TR, et al. **J Antimicrob Chemother** 1996 Mar; 37(3):423–31

Cloning and analysis of the poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) biosynthesis genes of Aeromonas caviae. Fukui T, et al. **J Bacteriol** 1997 Aug;179(15):4821–30

The Aeromonas metallo-beta-lactamases: genetics, enzymology, and contribution to drug resistance. Rossolini GM, et al. **Microb Drug Resist** 1996 Summer;2(2):245–52 (34 ref.)

Polysaccharide lyases from gellan-producing Sphingomonas spp. Sutherland IW, et al. **Microbiology** 1996 Apr;142 (Pt 4):867–72

GENETICS

Cloning and nucleotide sequence of the DNA gyrase gyrA gene from the fish pathogen Aeromonas salmonicida. Oppegaard H, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1126–33

Identification of Aeromonas hydrophila hybridization group 1 by PCR assays. Cascón A, et al. **Appl Environ Microbiol** 1996 Apr;62(4):1167–70

Plasmids and Aeromonas virulence. Brown RL, et al. **FEMS Immunol Med Microbiol** 1997 Apr;17(4):217–23

Study of the intergenic exeF–exeG region and its application as a simple preliminary test for Aeromonas spp. Karlyshev AV, et al. **FEMS Microbiol Lett** 1996 Mar 15;137(1):37–44

An Aeromonas salmonicida gene required for the establishment of infection in rainbow trout (Oncorhynchus mykiss). Noonan B, et al. **Gene** 1996 Oct 10;175(1–2):127–31

Cloning, characterization and expression of the recA gene of Aeromonas salmonicida. Umelo E, et al. **Gene** 1996 Oct 10;175(1–2):133–6

Mesophilic Aeromonas sp. serogroup O:11 resistance to complement-mediated killing. Merino S, et al. **Infect Immun** 1996 Dec;64(12):5302–9

High-resolution genotypic analysis of the genus Aeromonas by AFLP fingerprinting. Huys G, et al. **Int J Syst Bacteriol** 1996 Apr;46(2):572–80

Expression of Aeromonas caviae bla genes in Escherichia coli. Sayeed S, et al. **J Antimicrob Chemother** 1996 Sep; 38(3):435–41

Survival of cells and DNA of Aeromonas salmonicida released into aquatic microcosms. Deere D, et al. **J Appl Bacteriol** 1996 Sep;81(3):309–18

Expression of the AsbA1, OXA-12, and AsbM1 beta-lactamases in Aeromonas jandaei AER 14 is coordinated by a two-component regulon. Alksne LE, et al. **J Bacteriol** 1997 Mar;179(6):2006–13

L-allo-threonine aldolase from Aeromonas jandaei DK-39: gene cloning, nucleotide sequencing, and identification of the pyridoxal 5'-phosphate-binding lysine residue by site-directed mutagenesis. Liu JQ, et al. **J Bacteriol** 1997 Jun;179(11):3555–60

Quorum sensing in Aeromonas hydrophila and Aeromonas salmonicida: identification of the LuxRI homologs AhyRI and AsaRI and their cognate N-acylhomoserine lactone signal molecules. Swift S, et al. **J Bacteriol** 1997 Sep; 179(17):5271–81

Identification and molecular characterization of two tandemly located flagellin genes from Aeromonas salmonicida A449. Umelo E, et al. **J Bacteriol** 1997 Sep; 179(17):5292–9

Characterization of cytotoxic, hemolytic Aeromonas caviae clinical isolates and their identification by determining presence of a unique hemolysin gene. Wang G, et al. **J Clin Microbiol** 1996 Dec;34(12):3203–5

The Aeromonas metallo-beta-lactamases: genetics, enzymology, and contribution to drug resistance. Rossolini GM, et al. **Microb Drug Resist** 1996 Summer;2(2):245–52 (34 ref.)

Molecular and phenotypic methods for the characterization of atypical Aeromonas salmonicida. Hänninen ML, et al. **Vet Microbiol** 1997 May;56(1–2):147–58

[Rapid detection of the hemolysin genes in Aeromonas sobria by the polymerase chain reaction] Shibata M, et al. **Kansenshogaku Zasshi** 1996 Dec;70(12):1266–70 (Eng. Abstr.) **(Jpn)**

[Isolation and characteristics of plasmids from Aeromonas] Kul'ba AM, et al. **Mol Gen Mikrobiol Virusol** 1997;(1):22–5 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Prevention of suicide phenomenon in aeromonads. Guimarães MS, et al. **Eur J Clin Microbiol Infect Dis** 1996 May; 15(5):420–2

Pril-ampicillin-dextrin-ethanol agar for the isolation and quantification of Aeromonas spp. from polluted environmental waters. Imziln B, et al. **J Appl Microbiol** 1997 May;82(5):557–66

IMMUNOLOGY

Immunization with bacterial antigens: infections with motile aeromonads. Karunasagar I, et al. **Dev Biol Stand** 1997; 90:135–41

Complement resistance of capsulated strains of Aeromonas salmonicida. Merino S, et al. **Microb Pathog** 1997 May; 22(5):315–20

The effect of temperature and water quality on antibody response to Aeromonas salmonicida in sunshine bass (Morone chrysops x Morone saxatilis). Hrubec TC, et al. **Vet Immunol Immunopathol** 1996 Mar;50(1–2):157–66

ISOLATION & PURIFICATION

A 4-year study of the diversity and persistence of coliforms and Aeromonas in the water of a Swedish drinking water well. Kühn I, et al. **Can J Microbiol** 1997 Jan;43(1):9–16

Prevention of suicide phenomenon in aeromonads. Guimarães MS, et al. **Eur J Clin Microbiol Infect Dis** 1996 May; 15(5):420–2

Application of a colorimetric DNA-DNA hybridization method for identification of Aeromonas genomic species, isolated from diarrheal stools. Kaznowski A. **Folia Microbiol (Praha)** 1996;41(6):505–9

Aeromonas species and Plesiomonas shigelloides in diarrhoea in Goa. Verenkar M, et al. **Indian J Pathol Microbiol** 1995 Apr;38(2):169–71

Aeromonas species in fish, fish-eggs, shrimp and freshwater. Hänninen ML, et al. **Int J Food Microbiol** 1997 Jan; 34(1):17–26

Survival of cells and DNA of Aeromonas salmonicida released into aquatic microcosms. Deere D, et al. **J Appl Bacteriol** 1996 Sep;81(3):309–18

Pril-ampicillin-dextrin-ethanol agar for the isolation and quantification of Aeromonas spp. from polluted environmental waters. Imziln B, et al. **J Appl Microbiol** 1997 May;82(5):557–66

Near-drowning-associated Aeromonas pneumonia. Ender PT, et al. **J Emerg Med** 1996 Nov–Dec;14(6):737–41

Indigenous bacterial flora of medicinal leeches and their susceptibilities to 15 antimicrobial agents. Nonomura H, et al. **J Med Microbiol** 1996 Dec;45(6):490–3

Infections after shark attacks in Australia. Royle JA, et al. **Pediatr Infect Dis J** 1997 May;16(5):531–2

Evaluation of the synergistic haemolysis (CAMP-like) test in the identification of motile, mesophilic Aeromonas species. Gubash SM. **Zentralbl Bakteriol** 1997 Jun; 286(1):41–5

Molecular and phenotypic features of aeromonads isolated from snails (Helix aspersa) affected with a new summer disease. Kodjo A, et al. **Zentralbl Veterinarmed [B]** 1997 Jun;44(4):245–52

[Endophthalmitis caused by Aeromonas sobria (letter)] Cánovas A, et al. **Enferm Infecc Microbiol Clin** 1996 Oct; 14(8):505–6 **(Spa)**

METABOLISM

Biochemical characterization of the carbapenem-hydrolyzing beta-lactamase AsbM1 from Aeromonas sobria AER 14M: a member of a novel subgroup of metallo-beta-lactamases. Yang Y, et al. **FEMS Microbiol Lett** 1996 Apr 1; 137(2–3):193–200

Studies on the energetics of proaerolysin secretion across the outer membrane of Aeromonas species. Evidence for a requirement for both the protonmotive force and ATP. Letellier L, et al. **J Biol Chem** 1997 Apr 25; 272(17):11109–13

Production of haemolysin and enterotoxin by Aeromonas jandaei and Aeromonas trota strains after animal passage. Singh DV, et al. **J Diarrhoeal Dis Res** 1996 Dec;14(4):274–9

Adherence of Aeromonas caviae to human cell lines Hep-2 and Caco-2. Thornley JP, et al. **J Med Microbiol** 1996 Dec;45(6):445–51

Behaviour of Aeromonas spp. after animal passage. Almeida VC, et al. **Mem Inst Oswaldo Cruz** 1996 Jul–Aug; 91(4):499–500

The cell surface of Aeromonas salmonicida determines in vitro survival in cultured brook trout (Salvelinus fontinalis) peritoneal macrophages. Daly JG, et al. **Microb Pathog** 1996 Dec;21(6):447–61

Polysaccharide lyases from gellan-producing Sphingomonas spp. Sutherland IW, et al. **Microbiology** 1996 Apr;142 (Pt 4):867–72

A biochemical protocol for the differentiation of current genomospecies of Aeromonas. Oakey HJ, et al. **Zentralbl Bakteriol** 1996 Jun;284(1):32–46

PATHOGENICITY

Adherence and invasion of Aeromonas caviae to monolayer cells. Adherence and invasion of Aeromonas caviae. Shaw J, et al. **Adv Exp Med Biol** 1997;412:217–9

Plasmids and Aeromonas virulence. Brown RL, et al. **FEMS Immunol Med Microbiol** 1997 Apr;17(4):217–23

Enteropathogenicity of Aeromonas jandaei and A. trota. Singh DV, et al. **FEMS Immunol Med Microbiol** 1997 Apr; 17(4):243–50

Measurement of virulence of aeromonads using a suckling mouse model of infection. Wong CY, et al. **FEMS Immunol Med Microbiol** 1996 Oct;15(4):233–41

Characterization of cytotoxic, hemolytic Aeromonas caviae clinical isolates and their identification by determining presence of a unique hemolysin gene. Wang G, et al. **J Clin Microbiol** 1996 Dec;34(12):3203–5

The cell surface of Aeromonas salmonicida determines in vitro survival in cultured brook trout (Salvelinus fontinalis) peritoneal macrophages. Daly JG, et al. **Microb Pathog** 1996 Dec;21(6):447–61

[Recent knowledge on fish pathogenic bacteria Aeromonas salmonicida, Listonella anguillara and Cytophaga columnaris, and their virulence factors] Nomura S. **Nippon Saikingaku Zasshi** 1997 Apr;52(2):393–416 (193 ref.) **(Jpn)**

PHYSIOLOGY

Aeromonas trota strains, which agglutinate with Vibrio cholerae O139 Bengal antiserum, possess a serologically distinct fimbrial colonization factor. Nakasone N, et al. **Microbiology** 1996 Feb;142 (Pt 2):309–13

AEROMONAS HYDROPHILA

Aeromonas hydrophila soft-tissue infection: a report of two cases [letter] Caudell MJ, et al. **Acad Emerg Med** 1997 Feb; 4(2):157–8

Early onset neonatal septicemia caused by Aeromonas hydrophilia [letter] Gupta P, et al. **Indian Pediatr** 1996 Aug; 33(8):703–4

Fulminant pneumonia and sepsis due to Aeromonas hydrophila in an alcohol abuser. Takano Y, et al. **Intern Med** 1996 May;35(5):410–2

A fresh water pathogen and its pedal manifestations [letter] Albreski DA, et al. **J Am Podiatr Med Assoc** 1996 Mar; 86(3):135–7

Exploring the use of the medicinal leech: a clinical risk–benefit analysis. de Chalain TM. **J Reconstr Microsurg** 1996 Apr;12(3):165–72

Aeromonas hydrophila necrotizing fasciitis and gas gangrene in a diabetic patient on haemodialysis. Furusu A, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1730–4

Fatal myofascial necrosis due to imipenem–resistant Aeromonas hydrophila. González–Barca E, et al. **Scand J Infect Dis** 1997;29(1):91–2

[Aeromonas hydrophila bone infection (letter)] Deghrar A, et al. **Presse Med** 1997 Mar 22;26(9):415 **(Fre)**

[A case of severe acute hepatorenal failure due to Aeromoas hydrophila septicemia] Yokoba M, et al. **Kansenshogaku Zasshi** 1996 Oct;70(10):1111–5 (Eng. Abstr.) **(Jpn)**

[Aeromonas hydrophila rapidly progressive myonecrosis (letter; comment)] Torres L, et al. **Enferm Infecc Microbiol Clin** 1996 Nov;14(9):572–3. Comment on: Enferm Infecc Microbiol Clin 1995 Oct;13(8):469–72. **(Spa)**

CHEMISTRY

[Purification and characterization of S–layer protein from Aeromonas hydrophila] Yan Y, et al. **Wei Sheng Wu Hsueh Pao** 1996 Apr;36(2):144–50 (Eng. Abstr.) **(Chi)**

CLASSIFICATION

Pulsed–field gel electrophoresis as an epidemiological tool for clonal identification of Aeromonas hydrophila. Talon D, et al. **J Appl Bacteriol** 1996 Mar;80(3):277–82

DRUG EFFECTS

Antibiotic–induced antimicrobial resistance in Aeromonas spp [letter] Paterson DL. **Med J Aust** 1997 Feb 3;166(3):165

ENZYMOLOGY

Sensitivity of Aeromonas hydrophila carbapenemase to delta3–cephems: comparative study with other metallo–beta–lactamases. Felici A, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):866–8

Zn(II) dependence of the Aeromonas hydrophila AE036 metallo–beta–lactamase activity and stability. Hernandez Valladares M, et al. **Biochemistry** 1997 Sep 23; 36(38):11534–41

The disulfide bond in the Aeromonas hydrophila lipase/acyltransferase stabilizes the structure but is not required for secretion or activity. Brumlik MJ, et al. **J Bacteriol** 1997 May;179(10):3116–21

Overproduction and purification of the Aeromonas hydrophila CphA metallo–beta–lactamase expressed in Escherichia coli. Hernandez Villadares M, et al. **Microb Drug Resist** 1996 Summer;2(2):253–6

GENETICS

Expression of chitinase–encoding genes from Aeromonas hydrophila and Pseudomonas maltophilia in Bacillus thuringiensis subsp. israelensis. Wiwat C, et al. **Gene** 1996 Nov 7;179(1):119–26

Quorum sensing in Aeromonas hydrophila and Aeromonas salmonicida: identification of the LuxRI homologs AhyRI and AsaRI and their cognate N–acylhomoserine lactone signal molecules. Swift S, et al. **J Bacteriol** 1997 Sep; 179(17):5271–81

Cloning and characterization of two immunophilin–like genes, ilpA and fkpA, on a single 3.9–kilobase fragment of Aeromonas hydrophila genomic DNA. Wong CY, et al. **J Bacteriol** 1997 Jun;179(11):3397–403

Overproduction and purification of the Aeromonas hydrophila CphA metallo–beta–lactamase expressed in Escherichia coli. Hernandez Villadares M, et al. **Microb Drug Resist** 1996 Summer;2(2):253–6

Molecular analysis and expression of the extracellular lipase of Aeromonas hydrophila MCC–2. Chuang YC, et al. **Microbiology** 1997 Mar;143 (Pt 3):803–12

Cloning of an Aeromonas hydrophila type IV pilus biogenesis gene cluster: complementation of pilus assembly functions and characterization of a type IV leader peptidase/N–methyltransferase required for extracellular protein secretion. Pepe CM, et al. **Mol Microbiol** 1996 Feb; 19(4):857–69

GROWTH & DEVELOPMENT

The aerobic growth of Aeromonas hydrophila and Listeria monocytogenes in broths and on pork. Gill CO, et al. **Int J Food Microbiol** 1997 Mar 18;35(1):67–74

Survival potential of Aeromonas hydrophila in freshwaters and nutrient–poor waters in comparison with other bacteria. Kersters I, et al. **J Appl Bacteriol** 1996 Mar; 80(3):266–76

Effects of modified atmosphere and vacuum packaging on the growth of spoilage and inoculated pathogenic bacteria on fresh poultry. Ozbaş ZY, et al. **Z Lebensm Unters Forsch** 1996 Oct;203(4):326–32

IMMUNOLOGY

Enhancement of the resistance of tilapia and grass carp to experimental Aeromonas hydrophila and Edwardsiella tarda infections by several polysaccharides. Wang WS, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jun; 20(3):261–70

The role of the O–antigen lipopolysaccharide on the colonization in vivo of the germfree chicken gut by Aeromonas hydrophila serogroup O:34. Merino S, et al. **Microb Pathog** 1996 Jun;20(6):325–33

ISOLATION & PURIFICATION

Pathogenic analysis of Aeromonas hydrophila septicemia. Chang CY, et al. **Ann Clin Lab Sci** 1997 Jul–Aug; 27(4):254–9

Aeromonas bacteraemia in burn patients. Barillo DJ, et al. **Burns** 1996 Feb;22(1):48–52 (33 ref.)

Successful treatment of Aeromonas hydrophila peritoneal dialysis–associated peritonitis using intermittent intraperitoneal gentamicin. Eisele G, et al. **Clin Nephrol** 1995 Dec;44(6):402

Incidence and toxigenicity of Aeromonas hydrophila in seafood. Tsai GJ, et al. **Int J Food Microbiol** 1996 Aug; 31(1–3):121–31

Characterization of Aeromonas hydrophila: a comparative study of strains isolated from diarrheal feces and the environment. Haque QM, et al. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):132–8

[Conjunctivitis caused by Aeromonas hydrophila (letter)] Agulla A, et al. **Enferm Infecc Microbiol Clin** 1997 Jan; 15(1):44–5 **(Spa)**

METABOLISM

Molecular and biochemical characterization of a heat–labile cytotonic enterotoxin from Aeromonas hydrophila. Chopra AK, et al. **Microb Pathog** 1996 Nov;21(5):357–77

A TonB–like protein and a novel membrane protein containing an ATP–binding cassette function together in exotoxin secretion. Howard SP, et al. **Mol Microbiol** 1996 Nov;22(4):595–604

PATHOGENICITY

Measurement of virulence of aeromonads using a suckling mouse model of infection. Wong CY, et al. **FEMS Immunol Med Microbiol** 1996 Oct;15(4):233–41

Influence of osmolarity on lipopolysaccharides and virulence of Aeromonas hydrophila serotype O:34 strains grown at 37 degrees C. Aguilar A, et al. **Infect Immun** 1997 Apr; 65(4):1245–50

Acid sensitivity as affected by physico–chemical stresses in Aeromonas hydrophila. Parvis A, et al. **Jpn J Med Sci Biol** 1996 Jun;49(3):95–102

Using a new inbred fish model and cultured fish tissue cells to study Aeromonas hydrophila and Yersinia ruckeri pathogenesis. Kawulz TH, et al. **Microb Pathog** 1996 Feb; 20(2):119–25

PHYSIOLOGY

The role of flagella and motility in the adherence and invasion to fish cell lines by Aeromonas hydrophila serogroup O:34 strains. Merino S, et al. **FEMS Microbiol Lett** 1997 Jun 15;151(2):213–7

Thermal and biological treatments to control psychrotrophic pathogens. Sheldon BW, et al. **Poult Sci** 1996 Sep; 75(9):1126–32 (45 ref.)

AEROSOL PROPELLANTS

Characterization of surfactant effect on aggregates in model aerosol propellent suspensions. Bower C, et al. **J Pharm Pharmacol** 1996 Apr;48(4):337–41

The effect of surfactant and solid phase concentration on drug aggregates in model aerosol propellent suspensions. Bower C, et al. **J Pharm Pharmacol** 1996 Apr;48(4):342–6

Influence of metering chamber volume and water level on the emitted dose of a suspension–based pMDI containing propellant 134a. Williams RO 3rd, et al. **Pharm Res** 1997 Apr;14(4):438–43

Therapeutic equivalence of a novel HFA134a–containing metered–dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double–blind placebo–controlled crossover study in patients with asthma. Maesen FP, et al. **Respiration** 1997; 64(4):273–80

Vaccinator device for delivering propellant–driven aerosols of Streptococcus suis bacterin into the respiratory tracts of swine. Brown AR, et al. **Vaccine** 1997 Aug; 15(11):1165–73

THERAPEUTIC USE

Equivalence of asthma control with new CFC–free formulation HFA–134a beclomethasone dipropionate and CFC–beclomethasone dipropionate [published erratum appears in Br J Clin Pract 1997 Mar;51(2):124] Dahl R, et al. **Br J Clin Pract** 1997 Jan–Feb;51(1):11–5

TOXICITY

Twenty–eight–day double–blind safety study of an HFA–134a inhalation aerosol system in healthy subjects. Harrison LI, et al. **J Pharm Pharmacol** 1996 Jun; 48(6):596–600

AEROSOLS

The effect of aerosolized furosemide in infants with chronic lung disease. Ohki Y, et al. **Acta Paediatr** 1997 Jun; 86(6):656–60

A field investigation of the acute respiratory effects of metal working fluids. I. Effects of aerosol exposures. Kriebel D, et al. **Am J Ind Med** 1997 Jun;31(6):756–66

Assessment of particle size distributions in workers' aerosol exposures. Ramachandran G, et al. **Analyst** 1996 Sep; 121(9):1225–32

Investigation into the impact of introducing workplace aerosol standards based on the inhalable fraction. Werner MA, et al. **Analyst** 1996 Sep;121(9):1207–14 (22 ref.)

Therapeutic aerosol delivery during mechanical ventilation. Coleman DM, et al. **Ann Pharmacother** 1996 Jun; 30(6):644–55 (54 ref.)

The effect of budesonide (Rhinocort) in the treatment of small and medium–sized nasal polyps. Vendelo Johansen L, et al. **Clin Otolaryngol** 1993 Dec;18(6):524–7

Aerosol bolus dispersion in healthy subjects. Brand P, et al. **Eur Respir J** 1997 Feb;10(2):460–7

An experimental study of aerosol penetration through horizontal tubes and Strom–type loops. Wong FS, et al. **Health Phys** 1996 Dec;71(6):886–95

Development of a new aerosol generating cell with an ultrasonic nebulizer. Serita F. **Ind Health** 1997 Jul; 35(3):433–9

Regional deposition of inhaled hygroscopic aerosols: in vivo SPECT compared with mathematical modeling. Finlay WH, et al. **J Appl Physiol** 1996 Jul;81(1):374–83

Approach to aerosol therapy in management of asthma at primary care level. Athavale AU, et al. **J Indian Med Assoc** 1997 Jan;95(1):12–3

Neural network computer simulation of medical aerosols. Richardson CJ, et al. **J Pharm Pharmacol** 1996 Jun; 48(6):581–91

Drugs by inhalatory route: an overview and upcoming clinical perspectives. Melillo EM, et al. **Monaldi Arch Chest Dis** 1996 Oct;51(5):405–12 (117 ref.)

Human cell mutagenicity of oxygenated, nitrated and unsubstituted polycyclic aromatic hydrocarbons associated with urban aerosols. Durant JL, et al. **Mutat Res** 1996 Dec 20;371(3–4):123–57

Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols. Hickey AJ, et al. **Pharm Acta Helv** 1996 Aug;71(3):185–90

Aerosol electrostatics. I: Properties of fine powders before and after aerosolization by dry powder inhalers. Byron PR, et al. **Pharm Res** 1997 Jun;14(6):698–705

Optimal particle size for aerosols [letter; comment] Chege JK, et al. **Thorax** 1997 Jun;52(6):586–7. Comment on: Thorax 1996 Oct;51(10):977–80.

Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction [see comments] Zanen P, et al. **Thorax** 1996 Oct;51(10):977–80 . Comment in: Thorax 1997 Jun;52(6):586–7.

[Aerosol therapy and cystic fibrosis: a national survey] Huet F, et al. **Rev Pneumol Clin** 1997;53(2):91–7 (42 ref.) (Eng. Abstr.) **(Fre)**

[Bacterial aerosol generated by mechanical ventilators: comparative study] Dias MD, et al. **Rev Assoc Med Bras** 1997 Jan–Mar;43(1):15–20 (Eng. Abstr.) **(Por)**

[Detection of minimal ammonia concentrations using the aerosol method] Korableva AA, et al. **Med Tr Prom Ekol** 1996;(10):31–4 (Eng. Abstr.) **(Rus)**

[Incorrect use of pressurized aerosols by health personnel] Domínguez Juncal LM, et al. **An Med Interna** 1996 Oct; 13(10):487–90 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

The construction and validation of a high containment nose–only rodent inhalation facility. Hoskins JA, et al. **Ann Occup Hyg** 1997 Jan;41(1):51–61

Respiratory drug delivery [editorial; comment] Anderson PJ. **Chest** 1997 May;111(5):1155–6. Comment on: Chest 1997 May;111(5):1200–5.

Measuring nebulizer output. Aerosol production vs gravimetric analysis. Tandon R, et al. **Chest** 1997 May; 111(5):1361–5

A simple device for the exposure of animals to infectious microorganisms by the airborne route. Phillpotts RJ, et al. **Epidemiol Infect** 1997 Feb;118(1):71–5

Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation. Harvey CJ, et al. **Eur Respir J** 1997 Apr;10(4):905–9

Comparison of the antiasthmatic, oropharyngeal, and

systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler. Toogood JH, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):186–93

An increase in laryngeal aerosol deposition by ultrasonic nebulizer therapy with intermittent vocalization. Kumazawa H, et al. **Laryngoscope** 1997 May;107(5):671–4

The AERX aerosol delivery system. Schuster J, et al. **Pharm Res** 1997 Mar;14(3):354–7

[Evaluation of the everyday use of a metered dose aerosol triggered by inhalation (the "Autohaler" system)] Le Cocguic Y, et al. **Rev Pneumol Clin** 1997;53(1):13–9 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Hot dog vapor–induced status asthmaticus. Polasani R, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):35–6

Health effects of acid aerosols on North American children: respiratory symptoms. Dockery DW, et al. **Environ Health Perspect** 1996 May;104(5):500–5

Health effects of acid aerosols on North American children: pulmonary function. Raizenne M, et al. **Environ Health Perspect** 1996 May;104(5):506–14

Health effects of acid aerosols on North American children: air pollution exposures. Spengler JD, et al. **Environ Health Perspect** 1996 May;104(5):492–9

Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. Nikolaizik WH, et al. **Eur J Pediatr** 1996 Jul;155(7):608–11

Aerosolized specific antibody protects mice from lung injury associated with aerosolized ricin exposure. Poli MA, et al. **Toxicon** 1996 Sep;34(9):1037–44

ANALYSIS

An experimental method for measuring aerosol deposition efficiency in the human oral airway. Cheng KH, et al. **Am Ind Hyg Assoc J** 1997 Mar;58(3):207–13

Developments in workplace aerosol sampling. A review. Kenny LC. **Analyst** 1996 Sep;121(9):1233–9 (28 ref.)

Deposition of inspired aerosol particles within the respiratory tract of patients with obstructive lung disease. Schiller–Scotland CF, et al. **Toxicol Lett** 1996 Nov; 88(1–3):255–61

Chemical mixtures in atmospheric aerosols and their correlation to lung diseases and lung cancer occurence in the general population. Spurny KR. **Toxicol Lett** 1996 Nov; 88(1–3):271–7 (34 ref.)

CHEMISTRY

Characteristics of winter and summer aerosol mass and light extinction on the Colorado plateau. Sisler JF, et al. **J Air Waste Manag Assoc** 1997 Mar;47(3):317–30

Residual solvents in biodegradable microparticles. Influence of process parameters on the residual solvent in microparticles produced by the aerosol solvent extraction system (ASES) process. Ruchatz F, et al. **J Pharm Sci** 1997 Jan;86(1):101–5

Model for moisture transport into inhalation aerosols. Reynolds JM, et al. **Pharm Res** 1996 May;13(5):809–11

Chlorofluorocarbon–free aerosol therapy in patients with pulmonary airflow obstruction. Matthys H. **Respiration** 1996;63(6):321–4 (17 ref.)

Physical characterization of incense aerosols. Mannix RC, et al. **Sci Total Environ** 1996 Dec 20;193(2):149–58

DIAGNOSTIC USE

Detection of impaired intrapulmonary convective mixing by aerosol bolus dispersion in patients with emphysema. Kohlhäufl M, et al. **Eur J Med Res** 1997 Mar 24;2(3):121–8

Thirty month variability of aerosol pulse dispersion and conventional lung function parameters in healthy middle aged smokers and nonsmokers. Siekmeier R, et al. **Toxicol Lett** 1996 Nov;88(1–3):263–70

METABOLISM

Two– and three–dimensional simulations of aerosol transport and deposition in alveolar zone of human lung. Darquenne C, et al. **J Appl Physiol** 1996 Apr;80(4):1401–14

Regional clearance of solute from the respiratory epithelia: 18–20 h postexposure to ozone. Foster WM, et al. **J Appl Physiol** 1996 Sep;81(3):1143–9

PHARMACOKINETICS

Comparison of theoretical and experimental particle diffusion data within human airway casts. Zhang Z, et al. **Cell Biochem Biophys** 1995–96;27(2):97–108

PHARMACOLOGY

Bronchiolar aerosol deposition and clearance [editorial; comment] Agnew JE. **Eur Respir J** 1996 Jun;9(6):1118–22 (43 ref.). Comment on: Eur Respir J 1996 Jun;9(6):1123–9.

Breathing volume and deposition in the respiratory tract. Legáth L, et al. **Exp Toxicol Pathol** 1997 Feb;49(1–2):71–4

THERAPEUTIC USE

Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Bellon G, et al. **Hum Gene Ther** 1997 Jan 1;8(1):15–25

[Evaluation of inhalation treatment in asthmatic infants] Gracia Antequera M, et al. **An Esp Pediatr** 1997 Jan; 46(1):13–9 (Eng. Abstr.) **(Spa)**

TOXICITY

Evaluation of the respiratory tract after acute exposure to a pyrotechnically generated aerosol fire suppressant. Smith EA, et al. **J Appl Toxicol** 1997 Mar–Apr;17(2):95–103

Influence of acid aerosol droplet size on structural changes in the rat lung caused by acute exposure to sulfuric acid and ozone. Kimmel TA, et al. **Toxicol Appl Pharmacol** 1997 Jun;144(2):348–55

AEROSPACE MEDICINE

see related
ACCIDENTS, AVIATION
ALTITUDE
DECOMPRESSION SICKNESS
SPACE FLIGHT

Alcohol and aviation. Cook CC. **Addiction** 1997 May; 92(5):539–55 (101 ref.)

Pharmacology in space: pharmacotherapy. Pavy–Le Traon A, et al. **Adv Space Biol Med** 1997;6:93–105

Effects of a single dose of loratadine on flying ability under conditions of simulated cabin pressure. Valk PJ, et al. **Am J Rhinol** 1997 Jan–Feb;11(1):27–33

Tolerance of mefloquine by SwissAir trainee pilots. Schlagenhauf P, et al. **Am J Trop Med Hyg** 1997 Feb; 56(2):235–40

Cardiovascular risk factors in commercial flight aircrew officers compared with those in the general population. Ekstrand K, et al. **Angiology** 1996 Nov;47(11):1089–94

Melatonin: a wonder drug for jet lag, daytime sleep, better sex, & longer life? **Aviat Space Environ Med** 1996 Aug; 67(8):792

Directory issue of the Aerospace Medical Association. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 2):A15–131

Echocardiographic findings in NATO pilots: do acceleration (+Gz) stresses damage the heart? AGARD, Neuilly–sur–Seine, France. **Aviat Space Environ Med** 1997 Jul;68(7):596–600

Medical guidelines for air travel. Aerospace Medical Association, Air Transport Medicine Committee, Alexandria, Va. **Aviat Space Environ Med** 1996 Oct;67(10 Suppl):B1–16 (62 ref.)

Directory issue of the Aerospace Medical Association. **Aviat Space Environ Med** 1996 Sep;67(9 Suppl):A1–128

New AsMA HIV policy [news] **Aviat Space Environ Med** 1997 Mar;68(3):279

An area of "blurry vision". Angle BN, et al. **Aviat Space Environ Med** 1997 Feb;68(2):163–4

Respiratory muscle fatigue during simulated air combat maneuvering (SACM). Bain B, et al. **Aviat Space Environ Med** 1997 Feb;68(2):118–25

Outcome from neurological decompression illness [letter] Ball R, et al. **Aviat Space Environ Med** 1997 Aug;68(8):756

Visual scanning and pilot expertise: the role of attentional flexibility and mental model development. Bellenkes AH, et al. **Aviat Space Environ Med** 1997 Jul;68(7):569–79

You're the flight surgeon: sickle cell trait and beta–thalassemia. Bendrick GA. **Aviat Space Environ Med** 1997 Mar;68(3):244–5

Is there a hypercoagulable state in military fighter pilots? Biondi G, et al. **Aviat Space Environ Med** 1996 Jun; 67(6):568–71

Grasping of virtual objects in changed gravity. Bock O. **Aviat Space Environ Med** 1996 Dec;67(12):1185–9

The British Army Air Corps in–flight spatial disorientation demonstration sortie. Braithwaite MG. **Aviat Space Environ Med** 1997 Apr;68(4):342–5

An aviator with an unusual gait: a rare disease teaches some everyday lessons. Brooks KE, et al. **Aviat Space Environ Med** 1997 Feb;68(2):147–50

Cervical intervertebral disc protrusion [letter; comment] Burton RR. **Aviat Space Environ Med** 1997 Apr;68(4):354 . Comment on: Aviat Space Environ Med 1996 Apr;67(4):351–3.

Cognitive assessment of USAF pilot training candidates. Callister JD, et al. **Aviat Space Environ Med** 1996 Dec; 67(12):1124–9

Male–female performance on U.S. Air Force pilot selection tests. Carretta TR. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):818–23

Role of metabolites in aviation forensic toxicology. Chaturvedi AK, et al. **Aviat Space Environ Med** 1997 Mar; 68(3):230–3 (30 ref.)

Melatonin efficacy in aviation missions requiring rapid deployment and night operations. Comperatore CA, et al. **Aviat Space Environ Med** 1996 Jun;67(6):520–4

Safety of commercial air travel following myocardial infarction. Cox GR, et al. **Aviat Space Environ Med** 1996 Oct;67(10):976–82

Application of USAF G–suit technology for clinical orthostatic hypotension: a case study. Elizondo LL, et al. **Aviat Space Environ Med** 1996 Apr;67(4):344–50

Cases from the aerospace medicine residents' teaching file. Case #66. A pilot with Falciparum malaria [clinical conference] Funke BJ, et al. **Aviat Space Environ Med** 1996 Sep;67(9):896–8

Coffee, tea, or frostbite? A case report of inflight freezing hazard from dry ice. Gamble WB, et al. **Aviat Space Environ Med** 1996 Sep;67(9):880–1

You're the flight surgeon: severe headache. Geyer DE. **Aviat Space Environ Med** 1996 Sep;67(9):899–900

You're the flight surgeon. Gilleran LG. **Aviat Space Environ Med** 1996 Jan;67(1):83–4

Brain cancer, flying, and socioeconomic status: a nested case–control study of USAF aircrew. Grayson JK, et al. **Aviat Space Environ Med** 1996 Dec;67(12):1152–4

Arm arterial occlusion cuffs as a means of alleviating high +Gz–associated arm pain. Green ND. **Aviat Space Environ Med** 1997 Aug;68(8):715–21

Retinal detachment in U.S. Air Force flyers. Green RP Jr, et al. **Aviat Space Environ Med** 1996 Sep;67(9):874–9

Aortic valve replacement in a United States Air Force pilot: case report and literature review. Hardy JC, et al. **Aviat Space Environ Med** 1997 Mar;68(3):221–4

Female acceleration tolerance: effects of menstrual state and physical condition. Heaps CL, et al. **Aviat Space Environ Med** 1997 Jun;68(6):525–30

Relationship of leg strength and power to ground reaction forces in both experienced and novice jump trained personnel. Hoffman JR, et al. **Aviat Space Environ Med** 1997 Aug;68(8):710–4

High resolution ECG changes among Finnish pilots. Hyvämäki EJ, et al. **Aviat Space Environ Med** 1996 Mar; 67(3):269–71

Photorefractive keratectomy (PRK) in the military aviator: an aeromedical perspective. Ivan DJ, et al. **Aviat Space Environ Med** 1996 Aug;67(8):770–6 (44 ref.)

You're the flight surgeon. Malaria chemoprophylaxis. Jex TT. **Aviat Space Environ Med** 1996 Jun;67(6):592–3

Sources of situation awareness errors in aviation. Jones DG, et al. **Aviat Space Environ Med** 1996 Jun;67(6):507–12

Saccade amplitude as a discriminator of flight types. Katoh Z. **Aviat Space Environ Med** 1997 Mar;68(3):205–8

Disorientation and postural ataxia following flight simulation. Kennedy RS, et al. **Aviat Space Environ Med** 1997 Jan; 68(1):13–7

Lipid lowering therapy and military aviators. Khan MA, et al. **Aviat Space Environ Med** 1996 Sep;67(9):867–71 (28 ref.)

Intracerebral bleed, retinal detachment, cataract removal, and intraocular lenses in an Army aviator. Knapp CJ. **Aviat Space Environ Med** 1996 Oct;67(10):997–1001

Sinus node arrest and asystole from vaso–vagal phenomena during lower body negative pressure in a healthy pilot. Kopka L, et al. **Aviat Space Environ Med** 1996 Jun; 67(6):572–5

The responsibility of aviation medicine [letter] Krakauer H. **Aviat Space Environ Med** 1996 Jul;67(7):665

Panic with a twist: an unusual presentation of combined psychiatric and neurologic symptoms in a tactical jet aviator. Krentz MJ, et al. **Aviat Space Environ Med** 1997 Mar;68(3):217–20

You're the flight surgeon: nasal congestion and increasing right–sided headaches. Little JR. **Aviat Space Environ Med** 1996 Oct;67(10):1002–4

Effects of hypovolemia and posture on responses to the Valsalva maneuver. Luster EA, et al. **Aviat Space Environ Med** 1996 Apr;67(4):308–13

Inflight incapacitation in the USAF [letter; comment] Lyons TJ. **Aviat Space Environ Med** 1997 Apr;68(4):354. Comment on: Aviat Space Environ Med 1983 Feb;54(2):161–4. Comment on: Aviat Space Environ Med 1996 Nov;67(11):1023–7.

Assessment of the anti–G straining maneuver (AGSM) skill performance and reinforcement program. Lyons TJ, et al. **Aviat Space Environ Med** 1997 Apr;68(4):322–4

Female United States Air Force (USAF) pilots: themes, challenges, and possible solutions. McGlohn SE, et al. **Aviat Space Environ Med** 1997 Feb;68(2):132–6

Neck injury after repeated flexions due to parachuting. Mäkelä JP, et al. **Aviat Space Environ Med** 1997 Mar; 68(3):228–9

The optokinetic cervical reflex in pilots of high–performance aircraft. Merryman RF, et al. **Aviat Space Environ Med** 1997 Jun;68(6):479–87

Chronic glomerulonephritis: medical and aeromedical disposition. Michaud VJ. **Aviat Space Environ Med** 1997 Mar;68(3):225–7

Guidelines for treatment of decompression illness. Moon RE, et al. **Aviat Space Environ Med** 1997 Mar;68(3):234–43 (88 ref.)

Percutaneous transluminal coronary angioplasty (PTCA): long–term outcome and aeromedical implications. Moorman DL, et al. **Aviat Space Environ Med** 1996 Oct; 67(10):990–6 (45 ref.)

+GZ–induced neck injuries in Royal Australian Air Force fighter pilots. Newman DG. **Aviat Space Environ Med** 1997 Jun;68(6):520–4

Head positioning for high +Gz loads: an analysis of the techniques used by F/A–18 pilots. Newman DG. **Aviat Space Environ Med** 1997 Aug;68(8):732–5

Effects of hypobaric–hypoxia on the salivary cortisol levels of aircraft pilots. Obmiński Z, et al. **Aviat Space Environ Med** 1997 Mar;68(3):183–6

Cases from the aerospace medicine resident's teaching file #65. Complicated diagnosis of left ear pain and facial weakness in an aviator [clinical conference] O'Brien DM. **Aviat Space Environ Med** 1996 Aug;67(8):787–9

Muscle strain during aerial combat maneuvering exercise. Oksa J, et al. **Aviat Space Environ Med** 1996 Dec; 67(12):1138–43

AEROSPACE MEDICINE

Aviation spatial orientation in relationship to head position and attitude interpretation. Patterson FR, et al. **Aviat Space Environ Med** 1997 Jun;68(6):463–71

Psychiatric syndromes associated with problems in aeronautical adaptation among military student pilots. Picano JJ, et al. **Aviat Space Environ Med** 1996 Dec; 67(12):1119–23

Incorporating occupational medicine methodology into military fitness for duty and readiness issues. Popper SE. **Aviat Space Environ Med** 1997 Aug;68(8):740–5 (28 ref.)

You're the flight surgeon: bicuspid aortic valve with mild aortic insufficiency and mild left ventricular enlargement. Ramsey CS. **Aviat Space Environ Med** 1996 Dec; 67(12):1204–5

The effect of positive pressure breathing for altitude protection on intraocular pressure. Ryles MT, et al. **Aviat Space Environ Med** 1996 Dec;67(12):1179–84

Two–crew operations: stress and fatigue during long–haul night flights. Samel A, et al. **Aviat Space Environ Med** 1997 Aug;68(8):679–87

Pregnancy and flying [letter; comment] Schenker EB. **Aviat Space Environ Med** 1996 Apr;67(4):389–90. Comment on: Aviat Space Environ Med 1995 Nov;66(11):1090–3.

Mefloquine versus doxycycline for malaria prophylaxis in intermittent exposure of Israeli Air Force aircrew in Rwanda. Shamiss A, et al. **Aviat Space Environ Med** 1996 Sep;67(9):872–3

Aviation spatial orientation in relationship to head position, altitude interpretation, and control. Smith DR, et al. **Aviat Space Environ Med** 1997 Jun;68(6):472–8

The effects of slow waves in the screening EEGs of pilot cadets on P300 ERP and memory scanning performance. Smyrnis N, et al. **Aviat Space Environ Med** 1997 Mar; 68(3):209–16

Drug and alcohol testing [letter; comment] Snyder QC. **Aviat Space Environ Med** 1996 Apr;67(4):391–2. Comment on: Aviat Space Environ Med 1995 Sep;66(9):837–40.

Aircrew fatigue monitoring during sustained flight operations from Souda Bay, Crete, Greece. Stoner JD. **Aviat Space Environ Med** 1996 Sep;67(9):863–6

Relationship between age and susceptibility to altitude decompression sickness. Sulaiman ZM, et al. **Aviat Space Environ Med** 1997 Aug;68(8):695–8

Cancer incidence in USAF aircrew [letter; comment] Ungs TJ. **Aviat Space Environ Med** 1996 Aug;67(8):794. Comment on: Aviat Space Environ Med 1996 Feb;67(2):101–4.

Survival at high altitudes: wheel–well passengers. Veronneau SJ, et al. **Aviat Space Environ Med** 1996 Aug;67(8):784–6 (6 ref.)

"Biospheric medicine" as viewed from the two–year first closure of Biosphere 2. Walford RL, et al. **Aviat Space Environ Med** 1996 Jul;67(7):609–17

Physiological training in Jordan. al–Wedyan IA, et al. **Aviat Space Environ Med** 1996 Sep;67(9):882–4

Pilot performance of the anti–G straining maneuver: respiratory demands and breathing system effects. Whitley PE. **Aviat Space Environ Med** 1997 Apr;68(4):312–6

Pilots' knowledge of the relationship between alcohol consumption and levels of blood alcohol concentration. Widders R, et al. **Aviat Space Environ Med** 1997 Jun; 68(6):531–7

Visual display delay effects on pilot performance. Wildzunas RM, et al. **Aviat Space Environ Med** 1996 Mar;67(3):214–21

The sleeping aviator––aeromedical disposition of Kleine–Levin syndrome. Wygnanski T, et al. **Aviat Space Environ Med** 1996 Jan;67(1):61–2

Heart rate responses to real and simulated BA Hawk MK 51 flight. Ylönen H, et al. **Aviat Space Environ Med** 1997 Jul;68(7):601–5

Research on the relationship between small heart syndrome and poor orthostatic endurance of aviators [letter] Yu CH, et al. **Aviat Space Environ Med** 1997 Mar;68(3):246

The psychophysiological assessment method for pilot's professional reliability. Zhang LM, et al. **Aviat Space Environ Med** 1997 May;68(5):368–72

Space doctor. Similarities of medicine and astronautics. Thirsk R. **Can Fam Physician** 1997 May;43:833–5, 836–8 **(Eng, Fre)**

An algorithm for pulmonary screening of military pilots in Israel. Schwarz YA, et al. **Chest** 1997 Apr;111(4):916–21

The efficiency of respiratory muscle strengthening training programs in pilots. Ji S, et al. **Chin Med J (Engl)** 1996 Dec;109(12):930–2

Interindividual differences in the flexibility of human temporal organization: pertinence to jet lag and shiftwork. Ashkenazi IE, et al. **Chronobiol Int** 1997 Mar;14(2):99–113 (35 ref.)

Bright light: a countermeasure for jet lag? Samel A, et al. **Chronobiol Int** 1997 Mar;14(2):173–83 (40 ref.)

Promoting sleep in shiftworkers and intercontinental travelers. Stone BM, et al. **Chronobiol Int** 1997 Mar; 14(2):133–43 (64 ref.)

Venous thromboembolism and air travel [letter; comment] Matarasso A. **Dermatol Surg** 1997 Jul;23(7):597. Comment on: Dermatol Surg 1996 Jul;22(7):637–41.

Medical emergencies in commercial air travel. Jagoda A, et al. **Emerg Med Clin North Am** 1997 Feb;15(1):251–60 (21 ref.)

Blunt trauma and operative care in microgravity: a review of microgravity physiology and surgical investigations with implications for critical care and operative treatment in space. Kirkpatrick AW, et al. **J Am Coll Surg** 1997 May; 184(5):441–53 (120 ref.)

Lest we forget the future... [editorial] Satava RM. **J Am Coll Surg** 1997 May;184(5):519–20

Barodontalgia among flyers: a review of seven cases. Holowatyj RE. **J Can Dent Assoc** 1996 Jul;62(7):578–84

Bilateral photorefractive keratectomy with intentional unilateral undercorrection performed on an aircraft pilot [editorial; comment] Mader TH. **J Cataract Refract Surg** 1997 Mar;23(2):145–7 (22 ref.). Comment on: J Cataract Refract Surg 1997 Mar;23(2):294–6.

Bilateral photorefractive keratectomy with intentional unilateral undercorrection in an aircraft pilot [see comments] Maguen E, et al. **J Cataract Refract Surg** 1997 Mar;23(2):294–6. Comment in: J Cataract Refract Surg 1997 Mar;23(2):145–7.

Crisis management training helps young anesthesiologist successfully manage mid–air passenger cardiac arrest [letter] Leith P. **J Clin Monit** 1997 Jan;13(1):69

Resuscitation of passengers on two TWA flights [letter] Statman SH. **J Clin Monit** 1997 Mar;13(2):136

Emergencies in the air: problems, management, and prevention. Rosenberg CA, et al. **J Emerg Med** 1997 Mar–Apr;15(2):159–64 (31 ref.)

A pilot suffering from Ménière's disease. A case report. Kortschot HW, et al. **ORL J Otorhinolaryngol Relat Spec** 1995 Nov–Dec; 57(6):316–8

Effect of long flights on the cognitive performance of air crew. Beh HC, et al. **Percept Mot Skills** 1997 Feb; 84(1):319–22

Flying and the bends [news] Zorpette G. **Sci Am** 1997 Sep; 277(3):22, 24

[Repatriation of patients via airplane: think before beginning (letter; comment)] Rietveld–Verboom JA. **Ned Tijdschr Geneeskd** 1996 Nov 23;140(47):2359–60. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1944–7. **(Dut)**

[Indicator of adrenoreceptors in cell membranes: reference values and informative validity in the assessment of the functional state of the cardiovascular system] Dlusskaia IG, et al. **Aviakosm Ekolog Med** 1996;30(4):46–51 (Eng. Abstr.) **(Rus)**

[Man, cosmos, medicine (35th anniversary of space flight by Iu. A. Gagarin) (editorial)] Giurdzhian AA. **Aviakosm Ekolog Med** 1996;30(2):4–5 **(Rus)**

[Immuno–physiological and hematological aspects of flight certification examination] Goranchuk VV, et al. **Aviakosm Ekolog Med** 1996;30(1):54–7 (12 ref.) (Eng. Abstr.) **(Rus)**

[Use of low–frequency electric field in the rehabilitation of flying personnel] Gvozdikov AV, et al. **Aviakosm Ekolog Med** 1997;31(3):44–6 **(Rus)**

[Experimental morphological studies of stress–inducing effects of weightlessness in rats flown aboard Spacelab–2] Kaplanskiĭ AS, et al. **Aviakosm Ekolog Med** 1996; 30(2):16–20 (Eng. Abstr.) **(Rus)**

[Psychophysiological aspects of joint activity of crew members in special flight situations] Kosolapov OA. **Aviakosm Ekolog Med** 1997;31(3):7–10 (Eng. Abstr.) **(Rus)**

[Tolerance of +Gz loads by space physician Poliakov VV during the active phases of his 438–days space mission] Kotovskaia AR, et al. **Aviakosm Ekolog Med** 1997; 31(1):29–34 (Eng. Abstr.) **(Rus)**

[Formation of a unified system of mental regulation of activities and functional state of the flyer during effects of piloting strain] Lapa VV, et al. **Aviakosm Ekolog Med** 1996;30(2):26–30 (Eng. Abstr.) **(Rus)**

[Effects of preliminary loading on dynamic strength of the spine] Moiseev IuB, et al. **Aviakosm Ekolog Med** 1996; 30(4):31–4 (Eng. Abstr.) **(Rus)**

[Biochemical evaluation of various respiration conditions during simulation of extended flight] Nagornev SN, et al. **Aviakosm Ekolog Med** 1996;30(2):20–6 (Eng. Abstr.) **(Rus)**

[Visual tests and their score for selection of candidates to higher aviation schools] Okovitov VV. **Aviakosm Ekolog Med** 1996;30(5):62–6 (Eng. Abstr.) **(Rus)**

[Effects of enduracin on the level of cholesterol in flying personnel] Preobrazhenskiĭ VN, et al. **Aviakosm Ekolog Med** 1997;31(3):43–4 **(Rus)**

[Characteristics of clinical course of myocardial infarct in pilots] Sinopal'nikov VI, et al. **Aviakosm Ekolog Med** 1996; 30(2):52–5 (Eng. Abstr.) **(Rus)**

[Medical aspects of prolongation of occupational longevity] Stupakov GP, et al. **Aviakosm Ekolog Med** 1997;31(3):4–7 (Eng. Abstr.) **(Rus)**

[Effect of alcohol intake on the ability to pilot aircraft] Ushakov IB, et al. **Aviakosm Ekolog Med** 1996;30(6):19–24 (Eng. Abstr.) **(Rus)**

[Improvement of protective and survival means as a current ecological–ergonomic problem in aviation] Ushakov IB, et al. **Aviakosm Ekolog Med** 1997;31(2):4–8 (Eng. Abstr.) **(Rus)**

[Possibilities of the use of static ergometric functional test in clinical practice] Vartbaronov RA, et al. **Aviakosm Ekolog Med** 1996;30(2):44–8 (Eng. Abstr.) **(Rus)**

[Radial methods of investigation in expert assessment of some liver disease in pilots] Vasil'ev AI. **Aviakosm Ekolog Med** 1996;30(5):48–51 (Eng. Abstr.) **(Rus)**

[Clinical and X–ray diagnosis of initial degenerative changes in the lumbar section of the spine in flight personnel] Vasil'ev AIu, et al. **Aviakosm Ekolog Med** 1996;30(2):55–8 (Eng. Abstr.) **(Rus)**

[Combined radiodiagnosis of urinary calculi in flying personnel] Vasil'ev AIu. **Aviakosm Ekolog Med** 1996; 30(4):44–6 (Eng. Abstr.) **(Rus)**

[Evaluation of the physical performance of flying personnel] Vlasov VV. **Aviakosm Ekolog Med** 1996;30(5):54–7 (15 ref.) (Eng. Abstr.) **(Rus)**

[Evaluation of the effectiveness of a universal pneumatic stimulating system as new therapeutic and rehabilitative means for flying personnel] Volkov AK, et al. **Aviakosm Ekolog Med** 1996;30(2):48–52 (Eng. Abstr.) **(Rus)**

[Changes in psychophysiologic parameters of test pilots under simulated conditions of time limitation] Gorbunov VV. **Fiziol Cheloveka** 1996 Nov–Dec;22(6):43–6 **(Rus)**

[Medico–biological aspects of a Mars expedition] Grigor'ev AI, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):88–92 (30 ref.) **(Rus)**

[Number of chronic diseases and future duration of pilot's work] Vlasov VV. **Med Tr Prom Ekol** 1996;(8):39–41 **(Rus)**

[Clinico–functional evaluation of the significance of mitral valve prolapse in flight personnel] Preobrazhenskiĭ VN, et al. **Ter Arkh** 1995;67(12):25–7 (Eng. Abstr.) **(Rus)**

[The diagnostic potentials for the consulting surgeon in a medical aviation department] Verushkin IuI, et al. **Vestn Khir Im I I Grek** 1996;155(3):86–8 **(Rus)**

[Developmental stages of inflight medical monitoring of space crew health status and medical studies] Bednenko VS, et al. **Vestn Ross Akad Med Nauk** 1996;(7):41–5 (Eng. Abstr.) **(Rus)**

[Problems in the use of alimentary agents to enhance body's resistance of flight personnel to unfavorable occupational factors] Bugrov SA, et al. **Vestn Ross Akad Med Nauk** 1996;(7):45–8 (Eng. Abstr.) **(Rus)**

[Psychophysiologic pattern of pilot's activity during flight as a basis for setting up his workplace] Frolov NI. **Vestn Ross Akad Med Nauk** 1997;(4):45–9 (Eng. Abstr.) **(Rus)**

[Aerospace toxicology: basic stages of formation and prospects of development] Kustov VV, et al. **Vestn Ross Akad Med Nauk** 1996;(7):37–40 (Eng. Abstr.) **(Rus)**

[Psychophysiological reserves of occupational health of man] Ponomarenko VA. **Vestn Ross Akad Med Nauk** 1997; (4):24–8 (Eng. Abstr.) **(Rus)**

[Methodological and organizational aspects of psychophysiologic care in the military training of aviation specialists] Stupakov GP, et al. **Vestn Ross Akad Med Nauk** 1997;(4):40–4 **(Rus)**

[Current problems of aviation medicine (the 60th anniversary of the State Research Institute of Aviation and Space Medicine)] Stupakov GP. **Vestn Ross Akad Med Nauk** 1996;(7):3–9 (Eng. Abstr.) **(Rus)**

[Current aspects of creation of expert systems in aviation medicine] Stupakov GP, et al. **Vestn Ross Akad Med Nauk** 1996;(7):31–7 (Eng. Abstr.) **(Rus)**

[Methodological aspects of pharmacological regulation of emotional stress in persons with dangerous occupations] Sytnik SI, et al. **Vestn Ross Akad Med Nauk** 1996;(7):60–4 (Eng. Abstr.) **(Rus)**

[Functional reliability and functional reserves of a flyer] Ushakov IB, et al. **Vestn Ross Akad Med Nauk** 1996; (7):26–31 (Eng. Abstr.) **(Rus)**

[Protection of occupational health as an ergonomic problem] Ushakov IB, et al. **Vestn Ross Akad Med Nauk** 1997; (4):37–9 (Eng. Abstr.) **(Rus)**

[Methodological problems of the impact of G–loads on the functional status and occupation health of the pilot] Vartbaronov RA, et al. **Vestn Ross Akad Med Nauk** 1996; (7):19–26 (Eng. Abstr.) **(Rus)**

[Intersensory interactions as the basis of methods in enhancing resistance to motion sickness] Vorob'ev OA, et al. **Vestn Ross Akad Med Nauk** 1996;(7):48–52 (Eng. Abstr.) **(Rus)**

[Current problems in the correction of functional states and rehabilitation in aerospace medicine] Egorov SV. **Voen Med Zh** 1997 Apr;318(4):77–8 **(Rus)**

EDUCATION

Predictors of students' success in the Medical Service Apprentice course. Porter RD, et al. **Mil Med** 1997 Jul; 162(7):495–500

HISTORY

The Lovelace Award presentation of the Society of NASA Flight Surgeons. White SC. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):863–5

Centenary year of scientific papers in the British Dental Journal. Richardson P. **Br Dent J** 1997 Jan 11;182(1):35–6

[Development of aviation medicine in Germany] Myshko VI. **Aviakosm Ekolog Med** 1997;31(2):49–53 **(Rus)**

[Contribution of Harald von Beckh to the development of

aerospace medicine] Von Beck-Widmanstetter de Viale M, et al. **Aviakosm Ekolog Med** 1996;30(4):52–4 **(Rus)**

[V. V. Strel'tsov: founder of the Institute and father of our country's aerospace medicine] Agadzhanian NA. **Vestn Ross Akad Med Nauk** 1996;(7):10–5 (Eng. Abstr.) **(Rus)**

[History of solving medical problems of safety provisions of altitude flights] Dvornikov MV, et al. **Vestn Ross Akad Med Nauk** 1996;(7):15–9 (Eng. Abstr.) **(Rus)**

[Aerospace radiobiology: 35 years (1960–1995)] Ushakov IB, et al. **Vestn Ross Akad Med Nauk** 1996;(7):64–6 (Eng. Abstr.) **(Rus)**

[The flagship of aerospace medicine (on the 55th anniversary of the Central Military Research Aviation Hospital of the Ministry of Defense of the Russian Federation)] Kokhan VE. **Voen Med Zh** 1997 Apr;318(4):63–6 **(Rus)**

LEGISLATION & JURISPRUDENCE

Policy improvements for prevention of alcohol misuse by airline pilots. McFadden KL. **Hum Factors** 1997 Mar; 39(1):1–8

[The indemnification of accidents in itinere in the military medicolegal field] Rotondo G. **Riv Med Aeronaut Spaz** 1975 Apr–Sep;38(2–3):317–26 (Eng. Abstr.) **(Ita)**

METHODS

Assessment of a portable clinical blood analyzer during space flight. Smith SM, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):1056–65

Laparoscopic surgery in weightlessness. Campbell MR, et al. **Surg Endosc** 1996 Feb;10(2):111–7

[The theory and practice of medical support of long-term space missions] Grigoriev AI, et al. **Aviakosm Ekolog Med** 1997;31(1):14–25 (21 ref.) (Eng. Abstr.) **(Rus)**

ORGANIZATION & ADMINISTRATION

The effect of occupational cultures on coordination of emergency medical service aircrew. Fonne VM, et al. **Aviat Space Environ Med** 1996 Jun;67(6):525–9

Forum for leadership in preventive medicine: impact on the specialty of aerospace medicine. Mork MR. **Aviat Space Environ Med** 1997 Jun;68(6):542–4

Role of the flight surgeon in fighter squadron Arctic deployments. Walker CM, et al. **Aviat Space Environ Med** 1997 Feb;68(2):137–41

STANDARDS

A case of "eating disorder NOS": aeromedical implications of DSM-IV diagnostic criteria. Berg JS, et al. **Aviat Space Environ Med** 1996 Feb;67(2):157–60

Meeting the vision care needs of aircraft pilots. Asmus TL, et al. **J Am Optom Assoc** 1997 Feb;68(2):116–24 (15 ref.)

Elderly pilots [letter] Devianne L, et al. **Lancet** 1997 May 31;349(9065):1629–30

[Advancement and goals of the aviation human engineering] Stupakov GP, et al. **Aviakosm Ekolog Med** 1997;31(1):26–8 (16 ref.) (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

The periodic medical examination in the Republic of Singapore Air Force--a review. Tan RH. **Ann Acad Med Singapore** 1997 Jan;26(1):46–53

Musculoskeletal injury review in the U.S. space program. Jennings RT, et al. **Aviat Space Environ Med** 1996 Aug; 67(8):762–6

Review of cardiac events in USAF aviators [see comments] Osswald S, et al. **Aviat Space Environ Med** 1996 Nov; 67(11):1023–7. Comment in: Aviat Space Environ Med 1997 Apr;68(4):354.

Army helicopter casualty evacuations in Belize in 1995 and 1996. Eke AJ. **J R Army Med Corps** 1997 Jun;143(2):93–6

TRENDS

Are human subject volunteers still players in aeromedical research as we enter the 21st century? Popper SE, et al. **Aviat Space Environ Med** 1997 Aug;68(8):746–50

AESCIN see **ESCIN**

AET

ADMINISTRATION & DOSAGE

Radioprotective efficacy of HT + AET in encapsulated form. Upadhyay SN, et al. **Indian J Exp Biol** 1996 May; 34(5):403–7

PHARMACOLOGY

Effect of radioprotectors on the aggregability, cAMP and thiol content of blood platelets. Horváth G, et al. **Acta Physiol Hung** 1995;83(4):389–402

The modulatory effect of aminothiols on the clastogenic activity of X-rays assayed by the vivo mouse micronucleus test. Mazur L. **Folia Biol (Krakow)** 1996;44(1–2):55–9

AFFECT

Instrumental or emotional evaluations: what determines preferences? Böhm G, et al. **Acta Psychol (Amst)** 1996 Sep; 93(1–3):135–48

The effect of low brain serotonin on mood and aggression in humans. Influence of baseline mood and genetic factors. Young SN, et al. **Adv Exp Med Biol** 1996;398:45–50 (24 ref.)

Mood, physical working capacity and cognitive performance in the elderly as related to physical activity. Hassmén P, et al. **Aging (Milano)** 1997 Feb–Apr;9(1–2):136–42

Advantages and safeguards in using the ideomotor signaling technique: a commentary of Walsh and clinical practice [comment] Hammond DC. **Am J Clin Hypn** 1997 Jul; 40(1):360–7. Comment on: Am J Clin Hypn 1997 Jul;40(1):349–59.

Goldfinger: a framework for resolving affect using ideomotor questioning [see comments] Walsh BJ. **Am J Clin Hypn** 1997 Jul;40(1):349–59. Comment in: Am J Clin Hypn 1997 Jul;40(1):360–7.

Proxy reporting in five areas of functional status. Comparison with self-reports and observations of performance. Magaziner J, et al. **Am J Epidemiol** 1997 Sep 1; 146(5):418–28

Belief systems and the analytic work. Horner AJ. **Am J Psychoanal** 1997 Mar;57(1):75–8

Effects of cognitive ability and affect on school mathematics performance and feelings of difficulty. Efklides A, et al. **Am J Psychol** 1997 Summer;110(2):225–58

Cross-cultural measurements of psychological well-being: the psychometric equivalence of Cantonese, Vietnamese, and Laotian translations of the Affect Balance Scale. Devins GM, et al. **Am J Public Health** 1997 May; 87(5):794–9

Vagal reactivity and affective adjustment in infants. Convergent response systems. Bazhenova OV, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:469–71

Acute effects on mood and cognitive performance of breakfasts differing in fat and carbohydrate content. Lloyd HM, et al. **Appetite** 1996 Oct;27(2):151–64

A comparison of structured versus guided preheart catheterization information on mood states and coping resources. Houston S, et al. **Appl Nurs Res** 1996 Nov; 9(4):189–94

Postural control and strength and mood among older adults. Topp R, et al. **Appl Nurs Res** 1997 Feb;10(1):11–8

Complex interaction of the sleep-wake cycle and circadian phase modulates mood in healthy subjects. Boivin DB, et al. **Arch Gen Psychiatry** 1997 Feb;54(2):145–52

The affective dimension of low-back pain: its influence on the outcome of back school. Bonaiuti D, et al. **Arch Phys Med Rehabil** 1996 Dec;77(12):1239–42

Jealousy, general creativity, and coping with social frustration during the menstrual cycle. Krug R, et al. **Arch Sex Behav** 1996 Apr;25(2):181–99

Measuring cognitive, affective, and behavioral components of homophobic reaction. Van de Ven P, et al. **Arch Sex Behav** 1996 Apr;25(2):155–79

Effects of group exercise on cognitive functioning and mood in older women. Williams P, et al. **Aust N Z J Public Health** 1997 Feb;21(1):45–52

A study of USAF air traffic controller shiftwork: sleep, fatigue, activity, and mood analyses. Luna TD, et al. **Aviat Space Environ Med** 1997 Jan;68(1):18–23

Short-term mood change, perceived funniness, and the effect of humor stimuli. Moran CC. **Behav Med** 1996 Spring; 22(1):32–8

A time series analysis of daily hassles and mood changes in the 3 days before the migraine attack. Sorbi MJ, et al. **Behav Med** 1996 Fall;22(3):103–13

Chronic emotional processing in survivors of the Herald of Free Enterprise disaster: the relationship of intrusion and avoidance at 3 years to distress at 5 years. Joseph S, et al. **Behav Res Ther** 1996 Apr;34(4):357–60

The psychological impact of negative TV news bulletins: the catastrophizing of personal worries. Johnston WM, et al. **Br J Psychol** 1997 Feb;88 (Pt 1):85–91

Asymmetric affective evaluation of words and faces. Raccuglia RA, et al. **Br J Psychol** 1997 Feb;88 (Pt 1):93–116

Cognitive performance and mood after a weekend on call in a surgical unit. Wesnes KA, et al. **Br J Surg** 1997 Apr; 84(4):493–5

The effects of hemispheric asymmetries and depression on the perception of emotion. Moretti MM, et al. **Brain Cogn** 1996 Oct;32(1):67–82

Asymmetrical hemispheric activation and emotion: the effects of unilateral forced nostril breathing. Schiff BB, et al. **Brain Cogn** 1995 Dec;29(3):217–31

The ability to perceive and comprehend intonation in linguistic and affective contexts by brain-damaged adults. Pell MD, et al. **Brain Lang** 1997 Mar;57(1):80–99

Lateralization of affective prosody in brain and the callosal integration of hemispheric language functions. Ross ED, et al. **Brain Lang** 1997 Jan;56(1):27–54

Traumatic childhood events, perceived availability of emotional support, and the development of dissociative tendencies. Irwin HJ. **Child Abuse Negl** 1996 Aug; 20(8):701–7

Temperament and parenting antecedents of individual differences in three-year-old boys' pride and shame reactions. Belsky J, et al. **Child Dev** 1997 Jun;68(3):456–66

Reciprocal negative affect in parent–child interactions and children's peer competency. Carson JL, et al. **Child Dev** 1996 Oct;67(5):2217–26

Preschoolers' emotional control in the disappointment paradigm and its relation to temperament, emotional knowledge, and family expressiveness. Garner PW, et al. **Child Dev** 1996 Aug;67(4):1406–19

Mutually responsive orientation between mothers and their young children: implications for early socialization. Kochanska G. **Child Dev** 1997 Feb;68(1):94–112

Behavioral, affective, and social correlates of involvement in cross-sex friendship in elementary school. Kovacs DM, et al. **Child Dev** 1996 Oct;67(5):2269–86

Adult perception of emotion intensity in human infant cries: effects of infant age and cry acoustics. Leger DW, et al. **Child Dev** 1996 Dec;67(6):3238–49

Patterns of change in early childhood aggressive–disruptive behavior: gender differences in predictions from early coercive and affectionate mother–child interactions. McFadyen-Ketchum SA, et al. **Child Dev** 1996 Oct; 67(5):2417–33

Infants' responses to facial and vocal emotional signals in a social referencing paradigm. Mumme DL, et al. **Child Dev** 1996 Dec;67(6):3219–37

Depressed mothers' touching increases infants' positive affect and attention in still-face interactions. Peláez-Nogueras M, et al. **Child Dev** 1996 Aug;67(4):1780–92

Circadian determinants of the postlunch dip in performance. Monk TH, et al. **Chronobiol Int** 1996 Jul;13(2):123–33

The effect of treatment variables on mood and social adjustment in adult patients with pituitary disease. Peace KA, et al. **Clin Endocrinol (Oxf)** 1997 Apr;46(4):445–50

Evaluative learning with "subliminally" presented stimuli. de Houwer J, et al. **Conscious Cogn** 1997 Mar;6(1):87–107

Assessment of mood state in patients undergoing electroconvulsive therapy: the utility of visual analog mood scales developed for cognitively impaired patients. Arruda JE, et al. **Convuls Ther** 1996 Dec;12(4):207–12

Preschoolers' understanding of mental and bodily reactions to contamination: what you don't know can hurt you, but cannot sadden you. Kalish C. **Dev Psychol** 1997 Jan; 33(1):79–91

Emotion regulation in mother–child narrative co-construction: associations with children's narratives and adaptation. Oppenheim D, et al. **Dev Psychol** 1997 Mar; 33(2):284–94

Infant emotionality, parenting, and 3-year inhibition: exploring stability and lawful discontinuity in a male sample. Park SY, et al. **Dev Psychol** 1997 Mar;33(2):218–27

Psychological effect of stereoscopic 3-D images with fragrances. Kawai T, et al. **Ergonomics** 1996 Nov; 39(11):1364–9

Neuropsychological impairments and deficits in theory of mind and emotion recognition in a non-autistic boy. Buitelaar JK, et al. **Eur Child Adolesc Psychiatry** 1996 Apr; 5(1):44–51

Family values, religiosity, and emotional reactions to schizophrenia in Mexican and Anglo-American cultures. Weisman AG, et al. **Fam Process** 1996 Jun;35(2):227–37

The serial measurement of mood in two brothers, renal transplant recipient and donor. Wilner A, et al. **Gen Hosp Psychiatry** 1996 Nov;18(6):426–30

Predicting the size and direction of sex differences in measures of emotion and personality. Whissell CM. **Genet Soc Gen Psychol Monogr** 1996 Aug;122(3):253–84

The Pleasant Events Schedule-AD: psychometric properties and relationship to depression and cognition in Alzheimer's disease patients. Logsdon RG, et al. **Gerontologist** 1997 Feb; 37(1):40–5

Mood and symptom reporting among middle-aged women: the relationship between menopausal status, hormone replacement therapy, and exercise participation. Slaven L, et al. **Health Psychol** 1997 May;16(3):203–8

Mood disturbance in patients with recurrent ventricular dysrhythmia before insertion of implantable cardioverter defibrillator. Dunbar SB, et al. **Heart Lung** 1996 Jul–Aug; 25(4):253–61

Effects of bright artificial light on subjective mood of shift work nurses. Iwata N, et al. **Ind Health** 1997;35(1):41–7

Effect of mood and food cues on body image in women with bulimia and controls. Carter FA, et al. **Int J Eat Disord** 1996 Jul;20(1):65–76

Restrained and unrestrained females' positive and negative associations with specific foods and body parts. Gattellari M, et al. **Int J Eat Disord** 1997 May;21(4):377–83

Affect and self-regulation in binge eaters: effects of activating family images. Villejo RE, et al. **Int J Eat Disord** 1997 Apr;21(3):237–49

Depression in dementia: a study of mood in a community sample and referrals to a community service. Allen H, et al. **Int J Geriatr Psychiatry** 1997 May;12(5):513–8

Cognitive estimation in traumatic brain injury: relationships with measures of intelligence, memory, and affect. Freeman MR, et al. **Int J Neurosci** 1995 Dec;83(3–4):269–73

Peripheral cuing of covert spatial attention before and after emotional conditioning of the cue. Stormark KM, et al. **Int J Neurosci** 1996 Sep;86(3–4):225–40

Mood-congruent vs. mood-incongruent psychotic symptoms in affective psychotic disorders. Fennig S, et al. **Isr J Psychiatry Relat Sci** 1996;33(4):238–45 (30 ref.)

Inconsistency of mothers' feedback and toddlers' misbehavior

and negative affect. Acker MM, et al. **J Abnorm Child Psychol** 1996 Dec;24(6):703–14

Fundamental frequency of phonation and perceived emotional stress. Protopapas A, et al. **J Acoust Soc Am** 1997 Apr;101(4):2267–77

Gender differences in affective reactions to first coitus. Guggino JM, et al. **J Adolesc** 1997 Apr;20(2):189–200

Prediction of acute and late responses to light therapy from vocal (pitch) and self–rated activation in seasonal affective disorder. Boenink AD, et al. **J Affect Disord** 1997 Feb; 42(2–3):117–26

Relationship between perception of facial emotions and anxiety in clinical depression: does anxiety–related perception predict persistence of depression? Bouhuys AL, et al. **J Affect Disord** 1997 May;43(3):213–23

Perception of airway obstruction in asthma: sequential daily analyses of symptoms, peak expiratory flow rate, and mood. Apter AJ, et al. **J Allergy Clin Immunol** 1997 May; 99(5):605–12

Borderline personality disorder in adolescents: affective and cognitive features. Pinto A, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Oct; 35(10):1338–43

Quality of life in patients with Alzheimer's disease as reported by patient proxies [see comments] Albert SM, et al. **J Am Geriatr Soc** 1996 Nov;44(11):1342–7. Comment in: J Am Geriatr Soc 1996 Nov;44(11):1400–2.

The synergy of memory, affects and metaphor. Modell AH. **J Anal Psychol** 1997 Jan;42(1):105–17

An investigation of attention and affect in children with autism and Down syndrome. Joseph RM, et al. **J Autism Dev Disord** 1997 Aug;27(4):385–96

Detection of major and minor depression in children and adolescents: evaluation of the Mood and Feelings Questionnaire. Kent L, et al. **J Child Psychol Psychiatry** 1997 Jul;38(5):565–73

An investigation of negative affectivity in Australian adolescents. Boyd CP, et al. **J Clin Child Psychol** 1997 Jun;26(2):190–7

Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. Wang C, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3578–83

Comparison of psychologic outcome in adult survivors of childhood acute lymphoblastic leukemia versus sibling controls: a cooperative Children's Cancer Group and National Institutes of Health study. Zeltzer LK, et al. **J Clin Oncol** 1997 Feb;15(2):547–56

Mood as a predictor of discharge from Air Force basic training. Lubin B, et al. **J Clin Psychol** 1996 Mar; 52(2):145–51

Behavior therapy and the transdermal nicotine patch: effects on cessation outcome, affect, and coping. Cinciripini PM, et al. **J Consult Clin Psychol** 1996 Apr;64(2):314–23

Affect regulation and affective experience: individual differences, group differences, and measurement using a Q–sort procedure. Westen D, et al. **J Consult Clin Psychol** 1997 Jun;65(3):429–39

Cognitive bias in spider fear and control children: assessment of emotional interference by a card format and a single–trial format of the stroop task. Kindt M, et al. **J Exp Child Psychol** 1997 Aug;66(2):163–79

Featural evaluation, integration, and judgment of facial affect. Ellison JW, et al. **J Exp Psychol Hum Percept Perform** 1997 Feb;23(1):213–26

Wisdom and life satisfaction in old age. Ardelt M. **J Gerontol B Psychol Sci Soc Sci** 1997 Jan;52(1):P15–27

The measurement of mood states in older adults. Gibson SJ. **J Gerontol B Psychol Sci Soc Sci** 1997 Jul;52(4):P167–74

Predictors of success in emotionally focused marital therapy. Johnson SM, et al. **J Marital Fam Ther** 1997 Apr; 23(2):135–52

Affective reactivity of symptoms as a process discriminator in schizophrenia. Docherty NM. **J Nerv Ment Dis** 1996 Sep;184(9):535–41 (46 ref.)

Testing the alexithymia hypothesis: physiological and subjective responses during relaxation and stress. Friedlander L, et al. **J Nerv Ment Dis** 1997 Apr; 185(4):233–9

On the interaction of hypnotizability and negative affect in chronic pain. Implications for the somatization of trauma. Wickramasekera I, et al. **J Nerv Ment Dis** 1996 Oct; 184(10):628–35

Differences in mood states, health status, and caregiver strain between family caregivers of oncology outpatients with and without cancer–related pain. Miaskowski C, et al. **J Pain Symptom Manage** 1997 Mar;13(3):138–47

Postoperative use of pediatric pain scales: children's self–report versus nurse assessment of pain intensity and affect. Colwell C, et al. **J Pediatr Nurs** 1996 Dec; 11(6):375–82

Effects of induced mood states on objective and projective dependency scores. Bornstein RF, et al. **J Pers Assess** 1996 Oct;67(2):324–40

Development and factor analytic validation of the SPANAS among women in Spain: (more) cross–cultural convergence in the structure of mood. Joiner TE Jr, et al. **J Pers Assess** 1997 Jun;68(3):600–15

Predicting three mood phenomena from factors and facets of the NEO–PI. Velting DM, et al. **J Pers Assess** 1997 Feb;68(1):165–72

Differential roles of neuroticism, extraversion, and event desirability for mood in daily life: an integrative model of top–down and bottom–up influences. David JP, et al. **J Pers Soc Psychol** 1997 Jul;73(1):149–59

Influence of overt head movements on memory for valenced words: a case of conceptual–motor compatibility. Förster J, et al. **J Pers Soc Psychol** 1996 Sep;71(3):421–30

Emotional responses to goal attainment: strength of regulatory focus as moderator. Higgins ET, et al. **J Pers Soc Psychol** 1997 Mar;72(3):515–25

Objective standards are not enough: affective, self–evaluative, and behavioral responses to social comparison information. Klein WM. **J Pers Soc Psychol** 1997 Apr;72(4):763–74

Mood and the correction of positive versus negative stereotypes. Lambert AJ, et al. **J Pers Soc Psychol** 1997 May;72(5):1002–16

Why do bad moods increase self–defeating behavior? Emotion, risk taking, and self–regulation. Leith KP, et al. **J Pers Soc Psychol** 1996 Dec;71(6):1250–67

Self–injurious behavior and mood regulation in borderline patients. Kemperman I, et al. **J Personal Disord** 1997 Summer;11(2):146–57

Beliefs about mood moderate the relationship of stress to illness and symptom reporting. Goldman SL, et al. **J Psychosom Res** 1996 Aug;41(2):115–28

The relation of sleep difficulties to fatigue, mood and disability in chronic fatigue syndrome. Morriss RK, et al. **J Psychosom Res** 1997 Jun;42(6):597–605

The effect of moderate exercise on mood in mildly hypertensive volunteers: a randomized controlled trial. Stanton JM, et al. **J Psychosom Res** 1996 Jun;40(6):637–42

Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self–report. Denburg SD, et al. **J Rheumatol** 1997 May;24(5):998–1003 (71 ref.)

Circadian rhythms in human performance and mood under constant conditions. Monk TH, et al. **J Sleep Res** 1997 Mar;6(1):9–18

The effects of cognitive and affective perspective taking on empathic concern and altruistic helping. Oswald PA. **J Soc Psychol** 1996 Oct;136(5):613–23

Nutritional, immunologic and psychological responses to a 7250 km run. Mertens DJ, et al. **J Sports Med Phys Fitness** 1996 Jun;36(2):132–8

Varying the intensity of acute exercise: implications for changes in affect. Tate AK, et al. **J Sports Med Phys Fitness** 1995 Dec;35(4):295–302

An affect–management group for women with posttraumatic stress disorder and histories of childhood sexual abuse. Zlotnick C, et al. **J Trauma Stress** 1997 Jul;10(3):425–36

Mood, neuromuscular function, and performance during training in female swimmers. Raglin JS, et al. **Med Sci Sports Exerc** 1996 Mar;28(3):372–7

Mood response to acute tryptophan depletion in healthy volunteers: sex differences and temporal stability. Ellenbogen MA, et al. **Neuropsychopharmacology** 1996 Nov;15(5):465–74

Treatment of depression in drug–dependent patients: effects on mood and drug use. Nunes EV, et al. **NIDA Res Monogr** 1997;172:61–85 (98 ref.)

Women, food, and mood. Kurzer MS. **Nutr Rev** 1997 Jul; 55(7):268–76 (96 ref.)

Concerns, affect, and cognitive disruption following completion of radiation treatment for localized breast or prostate cancer. Walker BL, et al. **Oncol Nurs Forum** 1996 Sep;23(8):1181–7

Relationship of swimming distance, expectancy, and performance to mood states of competitive athletes. Berger BG, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 2):1199–210

Induced mood and selective attention. Brand N, et al. **Percept Mot Skills** 1997 Apr;84(2):455–63

Attitude and enduring involvement of older adults in structured programs of physical activity. Gravelle F, et al. **Percept Mot Skills** 1997 Aug;85(1):67–71

Partial validation of the MAACL–R positive affect scales. Greenwald DF, et al. **Percept Mot Skills** 1996 Oct; 83(2):540–2

Effects of mood state and favorability of feedback on reactions to performance feedback. Hammer LB, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 1):923–34

Changes in scores on the profile of mood states following a single bout of physical activity: heart rate and changes in affect. McGowan RW, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 1):859–66

Correlations between mood scores and volleyball performance. Newby RW, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1153–4

Psychological affect at different ratings of perceived exertion in high– and low–active women: a study using a production protocol. Parfitt G, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):1035–42

Stroop and mood/memory measures in the study of unconscious "oneness". Sohlberg S, et al. **Percept Mot Skills** 1997 Aug;85(1):81–2

Effects of melody and lyrics on mood and memory. Sousou SD. **Percept Mot Skills** 1997 Aug;85(1):31–40

The effect of psychosocial nursing intervention on the mood state of patients with implantable cardioverter defibrillators and their caregivers. Sneed NV, et al. **Prog Cardiovasc Nurs** 1997 Spring;12(2):4–14

The mutual interactions of culture and emotion. Markus H, et al. **Psychiatr Serv** 1996 Mar;47(3):225–6 (9 ref.)

Affect recognition in schizophrenia: a function of global impairment or a specific cognitive deficit. Bryson G, et al. **Psychiatry Res** 1997 Jul 4;71(2):105–13

Prevalence of seasonal changes in mood and behavior during the winter months in central Texas. Hegde AL, et al. **Psychiatry Res** 1996 Jun 1;62(3):265–71

Relationship between sleep and mood in patients with rapid–cycling bipolar disorder. Leibenluft E, et al. **Psychiatry Res** 1996 Jul 31;63(2–3):161–8

A quantitative measure for expressed emotion. Lenior ME, et al. **Psychiatry Res** 1997 Mar 3;69(1):53–65

Object relations, affect management, and psychic structure formation. The concept of object constancy. Tyson P. **Psychoanal Study Child** 1996;51:172–89

A longitudinal study of the effects of pessimism, trait anxiety, and life stress on depressive symptoms in middle–aged women. Bromberger JT, et al. **Psychol Aging** 1996 Jun; 11(2):207–13

Structure and variation of mood in individuals with Parkinson's disease: a dynamic factor analysis. Shifren K, et al. **Psychol Aging** 1997 Jun;12(2):328–39

Beyond stress and arousal: a reconceptualization of alcohol–emotion relations with reference to psychophysiological methods. Stritzke WG, et al. **Psychol Bull** 1996 Nov;120(3):376–95 (183 ref.)

Inter–rater reliability of expressed emotion ratings based on the Camberwell Family Interview. Bentsen H, et al. **Psychol Med** 1996 Jul;26(4):821–8

How distinct is 'distinct quality' of mood? Parker G, et al. **Psychol Med** 1997 Mar;27(2):445–53

Effects of affective–semantic mode of item presentation in balanced self–report scales: biased construct validity of the Zung Self–rating Depression Scale. Schotte CK, et al. **Psychol Med** 1996 Nov;26(6):1161–8

Responses to Bortner's scale and the eight basic emotions by patients with acute coronary heart disease at hospital admission and discharge. Catipović–Veselica K, et al. **Psychol Rep** 1996 Aug;79(1):259–67

Affective Bicultural and Global–Human Identity Scales for Mexican–American adolescents. Der–Karabetian A, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):1027–39

Examination–related feedback, mood and helping: a correlational study. Feldt RC, et al. **Psychol Rep** 1997 Feb; 80(1):239–42

Friendships, femininity, and reaction to affective arousal. Jacobs MG, et al. **Psychol Rep** 1996 Aug;79(1):183–90

The role of emotional and socio–cognitive patterns in obesity: eating attitudes in obese adolescents before and after a dietary–behavioural therapy. Riva G. **Psychol Rep** 1996 Aug;79(1):35–46

The role of positive and negative affect in flashbulb memory [see comments] Scott D, et al. **Psychol Rep** 1996 Oct; 79(2):467–73. Comment in: Psychol Rep 1996 Dec;79(3 Pt 2):1169–70.

Comments on Scott and Ponsoda's (1996) positive and negative flashbulb memories [comment] Wright DB, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1169–70. Comment on: Psychol Rep 1996 Oct;79(2):467–73.

Affect and memory in depression: evidence of better delayed recall of positive than negative affect words. Calev A. **Psychopathology** 1996;29(2):71–6

Drama–induced affect and pain sensitivity. Zillmann D, et al. **Psychosom Med** 1996 Jul–Aug;58(4):333–41

Severe paroxysmal hypertension. An automatic syndrome and its relationship to repressed emotions. Mann SJ. **Psychosomatics** 1996 Sep–Oct;37(5):444–50

Decoding difficulties of facial expression of emotions in mothers of children suffering from developmental obesity. Baldaro B, et al. **Psychother Psychosom** 1996;65(5):258–61

Preliminary results of a differentiated emotion–stimulating interview in patients with essential hypertension as compared with inpatients of a psychosomatic unit and normal controls. Deter HC, et al. **Psychother Psychosom** 1996;65(5):262–71

Mood–state–dependent retrieval: the effects of induced mood on memory reconsidered. Kenealy PM. **Q J Exp Psychol A** 1997 May;50(2):290–317

Pathways to depressed mood for midlife women: observations from the Seattle Midlife Women's Health Study. Woods NF, et al. **Res Nurs Health** 1997 Apr; 20(2):119–29

Importance and attainment of life values among disabled and non–disabled people. Montgomery H, et al. **Scand J Rehabil Med** 1996 Dec;28(4):233–40

Cue availability and affect perception in schizophrenia. Bellack AS, et al. **Schizophr Bull** 1996;22(3):535–44

Facial–affect recognition and visual scanning behaviour in the course of schizophrenia. Streit M, et al. **Schizophr Res** 1997 Apr 11;24(3):311–7

Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4–5 hours per night. Dinges DF, et al. **Sleep** 1997 Apr;20(4):267–7

Spinal cord injuries: a shortened measure of function and mood. Lundqvist C, et al. **Spinal Cord** 1997 Jan;35(1):17–21

Relationship between quality of life and mood in long–term survivors of breast cancer treated with mastectomy. Weitzner MA, et al. **Support Care Cancer** 1997 May; 5(3):241–8

[Stability and predictive role of emotions, expressed by families in the development of a cohort of schizophrenic patients in the course of 5 years] Huguelet P, et al. **Ann Med Psychol (Paris)** 1995 Dec;153(10):687–95 (Eng. Abstr.) **(Fre)**

[Capacity to experience pleasure and displeasure by Cloninger and von Knorring in type I and II alcoholism] Nowaczkowski P, et al. **Encephale** 1997 May–Jun; 23(3):168–74 (Eng. Abstr.) **(Fre)**

[What are affects?] Solms M. **Psyche (Stuttg)** 1996 Jun; 50(6):485–522 (66 ref.) (Eng. Abstr.) **(Ger)**

[Validation of the Italian version of the Kjellberg and Iwanowski's Mood Scale] Camerino D, et al. **Med Lav** 1996 Mar–Apr;87(2):99–109 (Eng. Abstr.) **(Ita)**

CLASSIFICATION

The alternate forms of the Positive and Negative Mood Scales: reliability, validity, and equivalence in referred samples. Van Whitlock R, et al. **J Clin Psychol** 1997 Aug; 53(5):507–15

DRUG EFFECTS

Analgesic and psychomotor effects of thiopental at subanesthetic concentrations in human volunteers. Young CJ, et al. **Acta Anaesthesiol Scand** 1997 Aug;41(7):903–10

Mood and cognitive effects of +/–3,4–methylenedioxymethamphetamine (MDMA, 'ecstasy'): week–end 'high' followed by mid–week low. Curran HV, et al. **Addiction** 1997 Jul;92(7):821–31

Effect of valine on 5–HT neurotransmission and mood. Cowen PJ, et al. **Adv Exp Med Biol** 1996;398:67–71

The effects of midazolam on propofol–induced anesthesia: propofol dose requirements, mood profiles, and perioperative dreams. Oxorn DC, et al. **Anesth Analg** 1997 Sep;85(3):553–9

Hormonal and subjective responses to intravenous meta–chlorophenylpiperazine in bulimia nervosa. Levitan RD, et al. **Arch Gen Psychiatry** 1997 Jun;54(6):521–7

Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Schiavi RC, et al. **Arch Sex Behav** 1997 Jun;26(3):231–41

The effects of 600 mg of slow release caffeine on mood and alertness. Sicard BA, et al. **Aviat Space Environ Med** 1996 Sep;67(9):859–62

Rewarding affective properties of intra–nucleus accumbens injections of testosterone. Packard MG, et al. **Behav Neurosci** 1997 Feb;111(1):219–24

Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Barr LC, et al. **Biol Psychiatry** 1997 May 1;41(9):949–54

Lack of behavioral effects of monoamine depletion in healthy subjects. Salomon RM, et al. **Biol Psychiatry** 1997 Jan 1; 41(1):58–64

Enhanced response to repeated d–amphetamine challenge: evidence for behavioral sensitization in humans [see comments] Strakowski SM, et al. **Biol Psychiatry** 1996 Nov 1;40(9):872–80. Comment in: Biol Psychiatry 1997 Aug 1;42(3):230–1.

Acute effects of beta blockade and exercise on mood and anxiety. Head A, et al. **Br J Sports Med** 1996 Sep; 30(3):238–42

The effects of steroidal contraceptives on the well–being and sexuality of women: a double–blind, placebo–controlled, two–centre study of combined and progestogen–only methods. Graham CA, et al. **Contraception** 1995 Dec; 52(6):363–9

Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Katz MM, et al. **Depress Anxiety** 1996–97;4(6):257–67 (61 ref.)

Do patients use marijuana as an antidepressant? Gruber AJ, et al. **Depression** 1996;4(2):77–80 (34 ref.)

Mood and physiological effects of subcutaneous nicotine in smokers and never–smokers. Foulds J, et al. **Drug Alcohol Depend** 1997 Mar 14;44(2–3):105–15

Behavioral, neuroendocrine and biochemical effects of different doses of 5–HTP in panic disorder. van Vliet IM, et al. **Eur Neuropsychopharmacol** 1996 May;6(2):103–10

The effects of D– and L–fenfluramine (and their interactions with D–amphetamine) on psychomotor function and mood. Feeney S, et al. **Int Clin Psychopharmacol** 1996 Jun; 11(2):89–99

The effects of caffeine on ambulatory blood pressure, heart rate, and mood in coffee drinkers. Green PJ, et al. **J Behav Med** 1996 Apr;19(2):111–28

Effects of a two–week physiological dehydroepiandrosterone substitution on cognitive performance and well–being in healthy elderly women and men. Wolf OT, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2363–7

Effects of yohimbine on autonomic measures are determined by individual values for area under the concentration–time curve. Grasing K, et al. **J Clin Pharmacol** 1996 Sep; 36(9):814–22

A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician–rated measures of sleep in depressed patients: a double–blind, 8–week clinical trial [published erratum appears in J Clin Psychiatry 1997 Jun;58(6):275] Gillin JC, et al. **J Clin Psychiatry** 1997 May; 58(5):185–92

Acute tolerance to subjective but not cardiovascular effects of d–amphetamine in normal, healthy men. Brauer LH, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):72–6

Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo–controlled study. Hall SM, et al. **J Consult Clin Psychol** 1996 Oct;64(5):1003–9

Illustrating caffeine's pharmacological and expectancy effects utilizing a balanced placebo design. Lotshaw SC, et al. **J Drug Educ** 1996;26(1):13–24

Differential associations of P300 amplitude and latency with cognitive and psychiatric function in solvent–exposed adults. Morrow LA, et al. **J Neuropsychiatry Clin Neurosci** 1996 Fall;8(4):446–9

Effects of a specific CCK–A antagonist, Loxiglumide, on postprandial mood and sleepiness. Wells AS, et al. **J Psychopharmacol (Oxf)** 1997;11(3):241–6

Intravenous administration of haloperidol to healthy volunteers: lack of subjective effects but clear objective effects. Williams JH, et al. **J Psychopharmacol (Oxf)** 1997; 11(3):247–52

Mood effects of zolpidem versus phenobarbital combined with promethazine in an anesthesiological setting. Uhlig T, et al. **Neuropsychobiology** 1996;34(2):90–7

Seasonal variation in neuroendocrine and mood responses to i.v. L–tryptophan in depressed patients and healthy subjects. Cappiello A, et al. **Neuropsychopharmacology** 1996 Nov;15(5):475–83

Differential acute tolerance development to effects of nitrous oxide in humans. Zacny JP, et al. **Neurosci Lett** 1996 May 10;209(2):73–6

Comparative effects of alcohol and marijuana on mood, memory, and performance. Heishman SJ, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):93–101

Effects of brief caffeinated–beverage deprivation on mood, symptoms, and psychomotor performance. Lane JD. **Pharmacol Biochem Behav** 1997 Sep;58(1):203–8

Lack of acute tolerance development to the subjective, cognitive, and psychomotor effects of nitrous oxide in healthy volunteers. Yajnik S, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):501–8

Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory. Foltin RW, et al. **Physiol Behav** 1996 Feb;59(2):295–305

Effect of gabapentin (Neurontin) [corrected] on mood and well–being in patients with epilepsy [published erratum appears in Prog Neuropsychopharmacol Biol Psychiatry 1996 Aug;20(6):1081] Dimond KR, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Apr; 20(3):407–17

Biological and behavioral responses to D–amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers. Grady TA, et al. **Psychiatry Res** 1996 Aug 30;64(1):1–10

Individual differences in changes in mood and platelet monoamine oxidase (MAO) activity during hormonal replacement therapy in menopausal women. Klaiber EL, et al. **Psychoneuroendocrinology** 1996 Oct;21(7):575–92

Corticosteroid receptor mediated effects on mood in humans. Plihal W, et al. **Psychoneuroendocrinology** 1996 Aug; 21(6):515–23

The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles. Raven PW, et al. **Psychoneuroendocrinology** 1996 Apr;21(3):277–86

Androgens in the elderly: will androgen replacement therapy improve mood, cognition, and quality of life in aging men and women. Morrison MF. **Psychopharmacol Bull** 1997; 33(2):293–6

The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers. Anderson IM, et al. **Psychopharmacology (Berl)** 1996 Nov; 128(1):74–82

Thiamine supplementation mood and cognitive functioning. Benton D, et al. **Psychopharmacology (Berl)** 1997 Jan; 129(1):66–71

Does noise stress modulate effects of smoking/nicotine? Mood, vigilance, and EEG responses. Gilbert DG, et al. **Psychopharmacology (Berl)** 1997 Feb;129(4):382–9

Noise stress does not modulate effects of smoking/nicotine on beta–endorphin, cortisol, ACTH, glucose, and mood. Gilbert DG, et al. **Psychopharmacology (Berl)** 1997 Apr; 130(3):197–202

Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. Lukas SE, et al. **Psychopharmacology (Berl)** 1996 Jun; 125(4):346–54

Interaction of expectancy and the pharmacological effects of d–amphetamine: subjective effects and self–administration. Mitchell SH, et al. **Psychopharmacology (Berl)** 1996 Jun;125(4):371–8

The effects of vigabatrin on attention, concentration and mood: an investigation in healthy volunteers. Thomas L, et al. **Seizure** 1996 Sep;5(3):205–8

PHYSIOLOGY

Cognition and mood in systemic lupus erythematosus. Evaluation and pathogenesis. Denburg SD, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:44–59 (107 ref.)

Lack of relations of hostility, negative affect, and high–risk behavior with low plasma lipid levels in the Coronary Artery Risk Development in Young Adults Study. Markovitz JH, et al. **Arch Intern Med** 1997 Sep 22; 157(17):1953–9

Classical heart rate conditioning and affective behavior: the role of the cerebellar vermis. Ghelarducci B, et al. **Arch Ital Biol** 1997 Sep;135(4):369–84 (85 ref.)

Dissociative storage systems in human evaluative conditioning. Fulcher EP, et al. **Behav Res Ther** 1997 Jan; 35(1):1–10

Pessimistic attributional style: is it specific to depression versus anxiety versus negative affect? Luten AG, et al. **Behav Res Ther** 1997 Aug;35(8):703–19

Gender differences in regional cerebral blood flow during transient self–induced sadness or happiness. George MS, et al. **Biol Psychiatry** 1996 Nov 1;40(9):859–71

A brain imaging (single photon emission computerized tomography) study of semantic and affective processing in psychopaths. Intrator J, et al. **Biol Psychiatry** 1997 Jul 15;42(2):96–103

A preliminary study of tryptophan depletion on tics, obsessive–compulsive symptoms, and mood in Tourette's syndrome. Rasmusson AM, et al. **Biol Psychiatry** 1997 Jan 1;41(1):117–21

Hypothalamic–pituitary–ovarian axis and mood. Toren P, et al. **Biol Psychiatry** 1996 Nov 15;40(10):1051–5 (52 ref.)

Effects of menstrual cycle moods and symptoms on academic performance: a study of senior secondary school students. Boyle GJ. **Br J Educ Psychol** 1997 Mar;67 (Pt 1):37–49

Psychological effects of snacks and altered meal frequency. Kanarek R. **Br J Nutr** 1997 Apr;77 Suppl 1:S105–18; discussion 118–20 (26 ref.)

Exercise enhances creativity independently of mood. Steinberg H, et al. **Br J Sports Med** 1997 Sep;31(3):240–5

Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Fink G, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):325–44 (87 ref.)

Effects of nocturnal shiftwork on mood states of student nurses. Florida–James G, et al. **Chronobiol Int** 1996 May; 13(1):59–69

A preliminary investigation into individual differences in the circadian variation of meal tolerance: effects on mood and hunger. Owens DS, et al. **Chronobiol Int** 1996 Dec; 13(6):435–47

Effects of self–generated sad mood on regional cerebral activity: a PET study in normal subjects. Gemar MC, et al. **Depression** 1996;4(2):81–8

Behavioral and neuroendocrine responses in shy children. Schmidt LA, et al. **Dev Psychobiol** 1997 Mar;30(2):127–40

A naturalistic study of the impact of acute physical activity on feeling states and affect in women. Gauvin L, et al. **Health Psychol** 1996 Sep;15(5):391–7

Effects of guided imagery and music (GIM) therapy on mood and cortisol in healthy adults. McKinney CH, et al. **Health Psychol** 1997 Jul;16(4):390–400

Androgen–behavior correlations in hypogonadal men and eugonadal men. I. Mood and response to auditory sexual stimuli. Alexander GM, et al. **Horm Behav** 1997 Apr; 31(2):110–9

Prospective associations between lateralised brain function and immune status in HIV infection: analysis of EEG, cognition and mood over 30 months. Gruzelier J, et al. **Int J Psychophysiol** 1996 Oct;23(3):215–24

Preliminary evidence that daily changes in frontal alpha asymmetry correlate with changes in affect in therapy sessions. Rosenfeld JP, et al. **Int J Psychophysiol** 1996 Aug–Sep;23(1–2):137–41

Relationships between exhaustive mood state and changes in stress hormones following an ultraendurance race. Odagiri Y, et al. **Int J Sports Med** 1996 Jul;17(5):325–31

Optimism, social support, and premenstrual dysphoria. Fontaine KR, et al. **J Clin Psychol** 1997 Apr;53(3):243–7

The placebo effect on mood and behavior: the role of the endogenous opioid system. Sher L. **Med Hypotheses** 1997 Apr;48(4):347–9 (32 ref.)

Genetics of complex behavioral traits: obesity, dopamine, and mood [news] LaHoste GJ. **Mol Psychiatry** 1996 Sep; 1(4):302

Lateralized effects of self–induced sadness and happiness on corticospinal excitability. Tormos JM, et al. **Neurology** 1997 Aug;49(2):487–91

The effect of tryptophan depletion on mood in medication–free, former patients with major affective disorder. Leyton M, et al. **Neuropsychopharmacology** 1997 Apr;16(4):294–7

Functional neuroanatomy of robbery re–experience: affective memories studied with PET. Fischer H, et al. **Neuroreport** 1996 Sep 2;7(13):2081–6

Is craving mood–driven or self–propelled? Sensitization and "street" stimulant addiction. Gawin FH, et al. **NIDA Res Monogr** 1996;163:224–50 (37 ref.)

A prospective study of sleep, mood, and cognitive function in postpartum and nonpostpartum women. Swain AM, et al. **Obstet Gynecol** 1997 Sep;90(3):381–6

Assessing the stages of pain processing: a multivariate analytical approach. Wade JB, et al. **Pain** 1996 Nov; 68(1):157–67

Influences of fat, energy, and time of day on mood and performance. Wells AS, et al. **Physiol Behav** 1996 Jun; 59(6):1069–76

Influences of fat and carbohydrate on postprandial sleepiness, mood, and hormones. Wells AS, et al. **Physiol Behav** 1997 May;61(5):679–86

Involvement of the spino–parabrachio –amygdaloid and –hypothalamic pathways in the autonomic and affective emotional aspects of pain. Bernard JF, et al. **Prog Brain Res** 1996;107:243–55 (80 ref.)

Hemispheric specialization for emotions, affective aspects of language and communication and the cognitive control of display behaviors in humans. Ross ED. **Prog Brain Res** 1996;107:583–94 (131 ref.)

Affect, attachment, memory: contributions toward psychobiologic integration. Amini F, et al. **Psychiatry** 1996 Fall;59(3):213–39 (113 ref.)

AFFECT

Cerebral blood flow related to induction of a depressed mood within and out of the realm of attention in normal volunteers. De Raedt R, et al. **Psychiatry Res** 1997 Jul 4;74(3):159–71

The interaction between mood and cognitive function studied with PET. Baker SC, et al. **Psychol Med** 1997 May; 27(3):565–78

The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles. Raven PW, et al. **Psychoneuroendocrinology** 1996 Apr;21(3):277–86

Emotional expectancy: brain electrical activity associated with an emotional bias in interpreting life events. Chung G, et al. **Psychophysiology** 1996 May;33(3):218–33

Brain activation, affect, and aerobic exercise: an examination of both state-independent and state-dependent relationships. Petruzzello SJ, et al. **Psychophysiology** 1997 Sep;34(5):527–33

Daily mood states and ambulatory blood pressure. Shapiro D, et al. **Psychophysiology** 1997 Jul;34(4):399–405

The effects of perceived stress, traits, mood states, and stressful daily events on salivary cortisol. van Eck M, et al. **Psychosom Med** 1996 Sep–Oct;58(5):447–58

Pain affect encoded in human anterior cingulate but not somatosensory cortex. Rainville P, et al. **Science** 1997 Aug 15;277(5328):968–71

[The effects of mood and content on sentence memory in children] Tomiyama N. **Shinrigaku Kenkyu** 1995 Dec; 66(5):336–44 (Eng. Abstr.) **(Jpn)**

[Mood-congruency effects in self-relevant words] Tsutsui M. **Shinrigaku Kenkyu** 1997 Apr;68(1):25–32 (Eng. Abstr.) **(Jpn)**

AFFECTIVE DISORDERS

Can cocaine addicts with severe mental illness be treated along with singly diagnosed addicts? Galanter M, et al. **Am J Drug Alcohol Abuse** 1996 Nov;22(4):497–507

Ambivalent attachment in female adolescents: association with affective instability and eating disorders. Salzman JP. **Int J Eat Disord** 1997 Apr;21(3):251–9

Mood disorders in the female patient. Redmond G. **Int J Fertil Womens Med** 1997 Mar–Apr;42(2):67–72 (5 ref.)

BLOOD

Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. George MS, et al. **J Neuropsychiatry Clin Neurosci** 1996 Spring;8(2):172–80

Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. Bertschy G, et al. **Ther Drug Monit** 1996 Oct;18(5):570–2

[The study of the relationship between cholesterol and lipid concentration and suicidal behavior in patients with schizophrenia affective illness] Rybakowski J, et al. **Psychiatr Pol** 1996 Sep–Oct;30(5):699–712 (Eng. Abstr.) **(Pol)**

CHEMICALLY INDUCED

Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments. Gillham R, et al. **Epilepsy Res** 1996 May;24(1):47–55

CLASSIFICATION

Casemix and affective disorders: a comparison of private and public psychiatric systems. Goldney RD, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):511–5

COMPLICATIONS

Cognitive deficits and emotional disorders in HIV-1 infected individuals [see comments] Poutiainen E. **Acta Psychiatr Scand** 1995 Dec;92(6):429–35. Comment in: Acta Psychiatr Scand 1996 Nov;94(5):379–80.

Prediction, detection, and treatment of postnatal depression. Cooper P, et al. **Arch Dis Child** 1997 Aug;77(2):97–9

Affective instability and impulsivity in personality disorder. Results of an experimental study. Herpertz S, et al. **J Affect Disord** 1997 Jun;44(1):31–7

Feelings of exhaustion, emotional distress, and pituitary and adrenocortical hormones in borderline hypertension. Räikkönen K, et al. **J Hypertens** 1996 Jun;14(6):713–8

Communication, social-emotional development and parenting stress in Cornelia-de-Lange syndrome. Sarimski K. **J Intellect Disabil Res** 1997 Feb;41 (Pt 1):70–5

Alexithymia in essential hypertensive and psychiatric outpatients: a comparative study. Todarello O, et al. **J Psychosom Res** 1995 Nov;39(8):987–94

Behavioral and emotional aspects of Tourette syndrome. Coffey BJ, et al. **Neurol Clin** 1997 May;15(2):277–89 (84 ref.)

The relationship between symptoms of post-traumatic stress disorder and pain, affective disturbance and disability among patients with accident and non-accident related pain. Geisser ME, et al. **Pain** 1996 Aug;66(2–3):207–14

Relationship of borderline symptoms to histories of abuse and neglect: a pilot study. Oldham JM, et al. **Psychiatr Q** 1996 Winter;67(4):287–95

Dissociative symptoms in psychotic mood disorders: an example of symptom nonspecificity. Giese AA, et al. **Psychiatry** 1997 Spring;60(1):60–6

Mood disorder with manic features in a patient treated with granulocyte-monocyte colony stimulating factor [letter] Zdanowicz NH, et al. **Psychosomatics** 1996 May-Jun; 37(3):305–6

DIAGNOSIS

Contrasts in neuropsychological test profile between patients with first-episode schizophrenia and first-episode affective disorders. Albus M, et al. **Acta Psychiatr Scand** 1996 Aug; 94(2):87–93

MRI findings in patients with affective disorder: a meta-analysis. Videbech P. **Acta Psychiatr Scand** 1997 Sep; 96(3):157–68

Cognition and mood in systemic lupus erythematosus. Evaluation and pathogenesis. Denburg SD, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:44–59 (107 ref.)

Studies of ventricular enlargement [letter; comment] Persaud R. **Arch Gen Psychiatry** 1996 Dec;53(12):1165–7. Comment on: Arch Gen Psychiatry 1995 Sep;52(9):735–46.

Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Brown TA, et al. **Behav Res Ther** 1997 Jan;35(1):79–89

Detection of behavioural and emotional problems in deaf children and adolescents: comparison of two rating scales. Vostanis P, et al. **Child Care Health Dev** 1997 May; 23(3):233–46

Social-vocational adjustment in unipolar mood disorders: results of the DSM-IV field trial. Evans S, et al. **J Affect Disord** 1996 Jun 5;38(2–3):73–80

Hypomanic personality traits in a community sample of adolescents. Klein DN, et al. **J Affect Disord** 1996 Jun 5; 38(2–3):135–43

Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. Kaufman J, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jul;36(7):980–8

Consensus on minimal criteria of clinical and neuropathological diagnosis of schizophrenia and affective disorders for post mortem research. Report from the European Dementia and Schizophrenia Network (BIOMED I). Riederer P, et al. **J Neural Transm Gen Sect** 1995;102(3):255–64 (16 ref.)

Low-end specificity of childhood measures of emotional distress: differential effects for depression and anxiety. Joiner TE Jr, et al. **J Pers Assess** 1996 Oct;67(2):258–71

Homelessness, negative affect, and coping among veterans with gambling problems who misused substances. Castellani B, et al. **Psychiatr Serv** 1996 Mar;47(3):298–9

Mood (affective) disorders (F3). Results from the ICD-10 field trial of the Diagnostic Criteria for Research in German-speaking countries. Thiel A, et al. **Psychopathology** 1996;29(5):285–91

[Quantitative psychopathology of affect and emotion. Review of evaluation scales and emotion induction methods] Garcia C, et al. **Encephale** 1997 Mar–Apr;23(2):119–30 (129 ref.) (Eng. Abstr.) **(Fre)**

[Are there factors which maintain a subjective symptom-free psychological state? A study exemplified with HIV-infected subjects] Eich-Höchli D, et al. **Schweiz Med Wochenschr** 1996 Dec 28;126(51–52):2209–16 (Eng. Abstr.) **(Ger)**

[A scientific and practical conference on affective and obsessive-phobic disorders. Their clinical picture, therapy, neurophysiology and epidemiology] Efremova MD, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(4):77–8 **(Rus)**

DRUG THERAPY

Pathological crying and laughing: treatment with sertraline. Mukand J, et al. **Arch Phys Med Rehabil** 1996 Dec; 77(12):1309–11

The role of lithium in the affective disorders. Johnson G. **Aust N Z J Psychiatry** 1996 Dec;30(6):715–9 (19 ref.)

Instant lithium monitoring: a clinical revolution in the making. Srinivasan DP, et al. **Br J Clin Pract** 1996 Oct–Nov;50(7):386–8

Treatment-resistant affective disorders [letter; comment] Bowskill RJ, et al. **Br J Hosp Med** 1997 Feb 19–Mar 4; 57(4):171–2. Comment on: Br J Hosp Med 1995 Nov 15–Dec 12;54(10):501–6.

Advances in psychopharmacology: mood disorders and dementia. Cowen PJ. **Br Med Bull** 1996 Jul;52(3):539–55 (44 ref.)

Asterixis induced by psychotropic drug treatment. Rittmannsberger H. **Clin Neuropharmacol** 1996 Aug; 19(4):349–55

Pharmacotherapy of late life mood disorders. Herrmann N, et al. **Clin Neurosci** 1997;4(1):41–7 (81 ref.)

Prospects for the development of new treatments with a rapid onset of action in affective disorders. Soares JC, et al. **Drugs** 1996 Oct;52(4):477–82 (34 ref.)

Current Aspects in the Psychopharmacology of Mood Disorders. ECNP regional meeting. Istanbul, Turkey, 8–11 May 1996. Abstracts. **Eur Neuropsychopharmacol** 1996 Apr; 6 Suppl 1:S1–44

The expanding indications for clozapine. Young CR, et al. **Exp Clin Psychopharmacol** 1997 Aug;5(3):216–34 (235 ref.)

Case study: nefazodone for juvenile mood disorders. Wilens TE, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Apr; 36(4):481–5

Algorithms for the treatment of affective illness, primary disorder of vigilance, and task-dependent attention disorders (learning disabilities) in children and adolescents. Weinberg WA, et al. **J Child Neurol** 1996 May;11(3):220–7

Antidepressant and double antidepressant treatment for the affective disorder of epilepsy. Blumer D. **J Clin Psychiatry** 1997 Jan;58(1):3–11

Extreme mood lability associated with systemic lupus erythematosus and stroke successfully treated with valproic acid [letter] Himelhoch S, et al. **J Clin Psychopharmacol** 1996 Dec;16(6):469–70

Recent developments in the pharmacotherapy of mood disorders. Thase ME, et al. **J Consult Clin Psychol** 1996 Aug;64(4):646–59 (209 ref.)

Birth outcomes in pregnant women taking fluoxetine [letter; comment] Cohen LS, et al. **N Engl J Med** 1997 Mar 20; 336(12):872; discussion 873. Comment on: N Engl J Med 1996 Oct 3;335(14):1010–5.

Nephrogenic diabetes insipidus in a lethargic lithium-treated patient. Meinardi JR, et al. **Neth J Med** 1997 Mar; 50(3):105–9

Circadian rhythms and the pharmacology of affective illness. Duncan WC Jr. **Pharmacol Ther** 1996;71(3):253–312 (493 ref.)

On the problems of switching from intravenous to oral administration in drug treatment of endogenous depression--a placebo-controlled double-blind trial with doxepin. Adler L, et al. **Pharmacopsychiatry** 1997 Mar; 30(2):62–9

Mortality studies and the effectiveness of drugs in long-term treatment. Ahrens B. **Pharmacopsychiatry** 1997 Jan;30(1 Suppl):57–61

Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Michelini S, et al. **Pharmacopsychiatry** 1996 Jul; 29(4):127–34 (93 ref.)

Lithium side effects in relation to brain lithium concentration measured by lithium-7 magnetic resonance spectroscopy. Kato T, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jan; 20(1):87–97

Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Cavazzoni P, et al. **Psychiatry Res** 1996 Sep 27;64(2):91–6

Pharmacokinetic and pharmacodynamic drug interactions with polypharmacotherapy of treatment-resistant affective and obsessive-compulsive disorders. Carson SW. **Psychopharmacol Bull** 1996;32(4):555–68 (59 ref.)

An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Phillips KA. **Psychopharmacol Bull** 1996;32(1):175–80

Novel uses of thyroid hormones in patients with affective disorders. Prange AJ Jr. **Thyroid** 1996 Oct;6(5):537–43 (56 ref.)

[Therapy of affect incontinence with paroxetine] Erfurth A. **Psychiatr Prax** 1997 Jul;24(4):208–9 **(Ger)**

[The efficiency of alprazolam for seasonal affective disorder (SAD, autumn/winter type)] Yamadera H, et al. **Nippon Ika Daigaku Zasshi** 1997 Feb;64(1):53–6 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Temperament and personality features in panic disorder with or without comorbid mood disorders. Ampollini P, et al. **Acta Psychiatr Scand** 1997 May;95(5):420–3

Developmental precursors of affective illness in a general population birth cohort. van Os J, et al. **Arch Gen Psychiatry** 1997 Jul;54(7):625–31

A prospective study of childhood emotional and behavioural problems in Port Pirie, South Australia. Sawyer MG, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):781–7

Comorbidity and boundaries of affective disorders with anxiety disorders and substance misuse: results of an international task force. Merikangas KR, et al. **Br J Psychiatry Suppl** 1996 Jun;(30):58–67

Epidemiology of affective disorders: a review. Bland RC. **Can J Psychiatry** 1997 May;42(4):367–77 (106 ref.)

The age of misery: affective disorders on the rise [editorial] Grof P. **Can J Psychiatry** 1997 May;42(4):361–2

Epidemiologic questions on mood disorders in old age. Snowdon J. **Clin Neurosci** 1997;4(1):3–7 (40 ref.)

Childhood adversity and vulnerability to mood and anxiety disorders. Young EA, et al. **Depress Anxiety** 1997; 5(2):66–72

Comorbidity and social phobia: clinical and epidemiological issues. Lépine JP, et al. **Int Clin Psychopharmacol** 1996 Jun; 11 Suppl 3:35–41 (39 ref.)

The prevalence of affective and anxiety disorders in primary care practice in Hungary. Szádóczky E, et al. **J Affect Disord** 1997 May;43(3):239–44

Origins of comorbidity between conduct and affective disorders. Fergusson DM, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Apr;35(4):451–60

Increased prevalence and earlier onset of mood disorders among relatives of prepubertal versus adult probands. Neuman RJ, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Apr;36(4):466–73

The relationship of distress to mood disturbance in primary care and psychiatric populations. Coyne JC, et al. **J Consult Clin Psychol** 1997 Feb;65(1):161–8

Prevalence of mood and anxiety disorders in a working

population in Japan. Kawakami N, et al. **J Occup Environ Med** 1996 Sep;38(9):899–905

ETIOLOGY

Affect instability in adults with a borderline personality disorder. Stein KF. **Arch Psychiatr Nurs** 1996 Feb; 10(1):32–40

Information needs of the traumatic brain injury patient's family members regarding the consequences of the injury and associated perception of physical, cognitive, emotional and quality of life changes. Junqué C, et al. **Brain Inj** 1997 Apr;11(4):251–8

Mood disorders and menopause. Pearlstein T, et al. **Endocrinol Metab Clin North Am** 1997 Jun;26(2):279–94 (137 ref.)

Women's health. Depression and related disorders. Szewczyk M, et al. **Prim Care** 1997 Mar;24(1):83–101 (103 ref.)

Mood disorder with manic features in a patient treated with granulocyte–monocyte colony stimulating factor [letter] Zdanowicz NH, et al. **Psychosomatics** 1996 May–Jun; 37(3):305–6

Psychological and behavioural effects of endogenous testosterone and anabolic–androgenic steroids. An update. Bahrke MS, et al. **Sports Med** 1996 Dec;22(6):367–90 (157 ref.)

[Psycho–affective problems associated with retinitis pigmentosa] Strougo Z, et al. **J Fr Ophtalmol** 1997; 20(2):111–6 (Eng. Abstr.) **(Fre)**

GENETICS

A follow–up report of a genome search for affective disorder predisposition loci in the Old Order Amish. LaBuda MC, et al. **Am J Hum Genet** 1996 Dec;59(6):1343–62

Understanding the genetic basis of mood disorders: where do we stand? [comment] Reus VI, et al. **Am J Hum Genet** 1997 Jun;60(6):1283–8 (40 ref.). Comment on: Am J Hum Genet 1997 Jun;60(6):1265–75.

Comparison of the family history with the family study method: report from the Camberwell Collaborative Psychosis Study. Davies NJ, et al. **Am J Med Genet** 1997 Feb 21;74(1):12–7

An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders. Arinami T, et al. **Biol Psychiatry** 1996 Dec 1;40(11):1122–7

Relationship between prophylactic effect of lithium therapy and family history of affective disorders. Engström C, et al. **Biol Psychiatry** 1997 Sep 15;42(6):425–33

Quantitative analysis of leukocyte mitochondrial DNA deletion in affective disorders. Kato T, et al. **Biol Psychiatry** 1997 Sep 1;42(5):311–6

Cytogenetic abnormalities on chromosome 18 associated with bipolar affective disorder or schizophrenia. Mors O, et al. **Br J Psychiatry** 1997 Mar;170:278–80

The serotonin transporter gene and affective disorder. Harmar AJ, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:791–5

Autosomal recessive inheritance of affective disorders in families of responders to lithium prophylaxis? Alda M, et al. **J Affect Disord** 1997 Jul;44(2–3):153–7

Ring chromosome 22 and mood disorders. Sovner R, et al. **J Intellect Disabil Res** 1996 Feb;40 (Pt 1):82–6 (8 ref.)

Association between the serotonin transporter gene and affective disorder: the evidence so far. Ogilvie AD, et al. **Mol Med** 1997 Feb;3(2):90–3 (25 ref.)

Human catechol–O–methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Lachman HM, et al. **Pharmacogenetics** 1996 Jun;6(3):243–50

Lithium–responsive affective disorders: no association with the tyrosine hydroxylase gene. Cavazzoni P, et al. **Psychiatry Res** 1996 Sep 27;64(2):91–6

IMMUNOLOGY

HLA antigens in schizophrenia and mood disorders. Ozcan ME, et al. **Biol Psychiatry** 1996 May 15;39(10):891–5

METABOLISM

Enhanced calcium response to serotonin in platelets from patients with affective disorders. Yamawaki S, et al. **J Psychiatry Neurosci** 1996 Nov;21(5):321–4

The effect of tryptophan depletion on mood in medication–free, former patients with major affective disorder. Leyton M, et al. **Neuropsychopharmacology** 1997 Apr;16(4):294–7

[Affective disturbances and serotonin–2 receptor functions] Kuzumi I, et al. **Seishin Shinkeigaku Zasshi** 1996; 98(11):915–9 (22 ref.) **(Jpn)**

[Role of G protein in physiopathology and treatment of affective disturbances] Ozawa H, et al. **Seishin Shinkeigaku Zasshi** 1996;98(11):920–9 (16 ref.) **(Jpn)**

MORTALITY

Mortality studies and the effectiveness of drugs in long–term treatment. Ahrens B. **Pharmacopsychiatry** 1997 Jan;30(1 Suppl):57–61

Clinical course of affective disorders: were Emil Kraepelin and Jules Angst wrong? Grof P, et al. **Psychopathology** 1995;28 Suppl 1:73–80 (24 ref.)

PATHOLOGY

Neuroimaging in late–life mood disorders. Kumar A, et al. **Clin Neurosci** 1997;4(1):8–15 (64 ref.)

Consensus on minimal criteria of clinical and neuropathological diagnosis of schizophrenia and affective disorders for post mortem research. Report from the European Dementia and Schizophrenia Network (BIOMED I). Riederer P, et al. **J Neural Transm Gen Sect** 1995;102(3):255–64 (16 ref.)

PHYSIOPATHOLOGY

Temperature rhythm of patients with major affective disorders: reduced circadian period length. Bicakova–Rocher A, et al. **Chronobiol Int** 1996 May; 13(1):47–57

Affective disorders following stroke. Ghika–Schmid F, et al. **Eur Neurol** 1997;38(2):75–81 (86 ref.)

Topographical analysis of adolescent affective disorders. Defrance JF, et al. **Int J Neurosci** 1996 Jul;86(1–2):119–41

Neurologic and neurobehavioral effects of electric and lightning injuries. Janus TJ, et al. **J Burn Care Rehabil** 1996 Sep–Oct;17(5):409–15

Effect of interferon–alpha on DOI–induced wet–dog shakes in rats. Kugaya A, et al. **J Neural Transm** 1996; 103(8–9):947–55

Blunted left cingulate activation in mood disorder subjects during a response interference task (the Stroop). George MS, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter; 9(1):55–63

A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala–kindled seizures. Post RM, et al. **Mol Neurobiol** 1996 Aug; 13(1):33–60 (132 ref.)

A view on noradrenergic, hypothalamic–pituitary–adrenal axis and extrahypothalamic corticotrophin–releasing factor function in anxiety and affective disorders: the reduced growth hormone response to clonidine. Coplan JD, et al. **Psychopharmacol Bull** 1997;33(2):193–204 (93 ref.)

The treatment of posttraumatic stress disorder (PTSD) [letter; comment] Glover H. **Psychosom Med** 1997 Jan–Feb; 59(1):70–1. Comment on: Psychosom Med 1996 Mar–Apr;58(2):165–82.

The perimenopause and affective disorders. Schmidt PJ, et al. **Semin Reprod Endocrinol** 1997 Feb;15(1):91–100

PREVENTION & CONTROL

Relationship between prophylactic effect of lithium therapy and family history of affective disorders. Engström C, et al. **Biol Psychiatry** 1997 Sep 15;42(6):425–33

Single motherhood and mental health: implications for primary prevention [editorial; comment] Avison WR. **Can Med Assoc J** 1997 Mar 1;156(5):661–3 (9 ref.). Comment on: Can Med Assoc J 1997 Mar 1;156(5):639–45.

Autosomal recessive inheritance of affective disorders in families of responders to lithium prophylaxis? Alda M, et al. **J Affect Disord** 1997 Jul;44(2–3):153–7

Examination of children's responses to two preventive intervention strategies over time. Beardslee WR, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Feb; 36(2):196–204

PSYCHOLOGY

The risk for psychiatric illness in siblings of schizophrenics: the impact of psychotic and non–psychotic affective illness and alcoholism in parents. Kendler KS, et al. **Acta Psychiatr Scand** 1996 Jul;94(1):49–55

Cognitive impairment among the dually–diagnosed: substance use history and depressive symptom correlates. Carpenter KM, et al. **Addiction** 1997 Jun;92(6):747–59

Is decreased use of analgesics in Alzheimer disease due to a change in the affective component of pain? Scherder EJ, et al. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):171–4

School performance and emotional problems in refugee children. Rousseau C, et al. **Am J Orthopsychiatry** 1996 Apr;66(2):239–51

Pathological crying and laughing: treatment with sertraline. Mukand J, et al. **Arch Phys Med Rehabil** 1996 Dec; 77(12):1309–11

The aversiveness of specific emotional states associated with binge–eating in obese subjects. Kenardy J, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):839–44

Problem–solving style, stress and psychological illness: development of a multifactorial measure. Cassidy T, et al. **Br J Clin Psychol** 1996 May;35 (Pt 2):265–77

How does marriage protect women with histories of affective disorder from post–partum relapse? Marks M, et al. **Br J Med Psychol** 1996 Dec;69 (Pt 4):329–42

Impulsivity in disordered eating, affective disorder and substance use disorder. Bushnell JA, et al. **Br J Psychiatry** 1996 Sep;169(3):329–33

Life events and primary affective disorders. A one year prospective study. Pardoen D, et al. **Br J Psychiatry** 1996 Aug;169(2):160–6

Standardisation of a self–report questionnaire for use in evaluating cognitive, affective and behavioural side–effects of anti–epileptic drug treatments. Gillham R, et al. **Epilepsy Res** 1996 May;24(1):47–55

Impaired color naming of food and body shape words: weight phobia or distinct affective state? Green MW, et al. **Int J Eat Disord** 1997 Jan;21(1):77–82

1995 IPA/Bayer Research Awards in Psychogeriatrics. Late–life consequences of affective spectrum disorder. Vaillant GE, et al. **Int Psychogeriatr** 1996 Spring;8(1):13–32

Jews and their intraethnic vulnerability to affective disorders, fact or artifact? II: Evidence from a cohort study. Kohn R, et al. **Isr J Psychiatry Relat Sci** 1997;34(2):149–56

The differential effects of mood on patients' ratings of life quality and satisfaction with their care. Atkinson MJ, et al. **J Affect Disord** 1997 Jul;44(2–3):169–75

Atypical depressive symptoms in seasonal and non–seasonal mood disorders. Tam EM, et al. **J Affect Disord** 1997 Jun; 44(1):39–44

Prediction of adolescent affective disorder: effects of prior parental affective disorders and child psychopathology. Beardslee WR, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Mar;35(3):279–88

Child sexual abuse and emotional and behavioral problems in adolescence: gender differences. Garnefski N, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Mar;36(3):323–9

Affect regulation and suicide attempts in adolescent inpatients. Zlotnick C, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jun;36(6):793–8

Impact of exposure to community violence on violent behavior and emotional distress among urban adolescents. Farrell AD, et al. **J Clin Child Psychol** 1997 Mar;26(1):2–14

The Post–Stroke Depression Rating Scale: a test specifically devised to investigate affective disorders of stroke patients. Gainotti G, et al. **J Clin Exp Neuropsychol** 1997 Jun; 19(3):340–56

Contextual strategy instruction: socially/emotionally maladjusted adolescents with language impairments. Ward–Lonergan JM, et al. **J Commun Disord** 1996 Mar–Apr;29(2):107–24

Psychosocial factors related to emotional disturbances during pregnancy. Bernazzani O, et al. **J Psychosom Res** 1997 Apr; 42(4):391–402

The relationship between locus of control, tinnitus severity, and emotional distress in a group of tinnitus sufferers. Budd RJ, et al. **J Psychosom Res** 1995 Nov;39(8):1015–8

Greater emotional distress is associated with accelerated CD4+ cell decline in HIV infection. Vedhara K, et al. **J Psychosom Res** 1997 Apr;42(4):379–90

The effect of tryptophan depletion on mood in medication–free, former patients with major affective disorder. Leyton M, et al. **Neuropsychopharmacology** 1997 Apr;16(4):294–7

Light therapy in bulimia nervosa: a double–blind, placebo–controlled study. Blouin AG, et al. **Psychiatry Res** 1996 Feb 28;60(1):1–9

Increased prefrontal sulcal prominence in relatively young patients with unipolar major depression. Elkis H, et al. **Psychiatry Res** 1996 Jul 31;67(2):123–34

Age disorientation in chronically hospitalized patients with mood disorders. Lombardi J, et al. **Psychiatry Res** 1996 Feb 28;60(1):87–90

Maladaptive coping and affective disorders among cancer patients. Parle M, et al. **Psychol Med** 1996 Jul;26(4):735–44

Alexithymia, affective disorders and substance abuse: possible cross–relationships. Giannini AJ. **Psychol Rep** 1996 Jun; 78(3 Pt 2):1389–90

Cognitive impairments and mood disturbances in growth hormone deficient men. Deijen JB, et al. **Psychoneuroendocrinology** 1996 Apr;21(3):313–22

Personality patterns in subjects at risk for affective disorders. Maier W, et al. **Psychopathology** 1995;28 Suppl 1:59–72

Gender differences in risk factors for mood and anxiety disorders: implications for clinical treatment research. Blehar MC. **Psychopharmacol Bull** 1995;31(4):687–91 (30 ref.)

Preinjury psychiatric illness and postinjury adjustment in adult burn survivors. Fauerbach JA, et al. **Psychosomatics** 1996 Nov–Dec;37(6):547–55

[Stress reactivity and affective psychopathology in health care workers] De Las Cuevas Castresana C, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jan–Feb;24(1):19–24 (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Affective disorders: discovery and recovery [editorial] Grof P. **Can J Psychiatry** 1997 Jun;42(5):461–2

Quantitative regional cerebral flow measured by Tc–99M HMPAO SPECT in mood disorder. Iidaka T, et al. **Psychiatry Res** 1997 Feb 7;68(2–3):143–54

REHABILITATION

In search of effective programs to address students' emotional distress and behavioral problems part III: student assessment of school–based support groups. Wassef A, et al. **Adolescence** 1996 Spring;31(121):1–16

Negative affect and cognitive biases in suicidal and nonsuicidal hospitalized adolescents. Pinto A, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Feb;35(2):158–65

THERAPY

Emotional disorder in chronic illness: psychotherapeutic interventions. Guthrie E. **Br J Psychiatry** 1996 Mar; 168(3):265–73

The "half–age" stimulation strategy for ECT dosing [see comments] Petrides G, et al. **Convuls Ther** 1996 Sep; 12(3):138–46. Comment in: Convuls Ther 1997

AFFECTIVE DISORDERS

Mar;13(1):37–43.
"Speech after long silence": the use of narrative therapy in a preventive intervention for children of parents with affective disorder. Focht L, et al. **Fam Process** 1996 Dec; 35(4):407–22
Examination of children's responses to two preventive intervention strategies over time. Beardslee WR, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Feb; 36(2):196–204
Training and generalization of affective behavior displayed by youth with autism. Gena A, et al. **J Appl Behav Anal** 1996 Fall;29(3):291–304
Light therapy in bulimia nervosa: a double–blind, placebo–controlled study. Blouin AG, et al. **Psychiatry Res** 1996 Feb 28;60(1):1–9
The concept of recovery in affective disorders [editorial] Fava GA. **Psychother Psychosom** 1996;65(1):2–13 (160 ref.)
[Therapy of affective disorders] Leština J. **Cas Lek Cesk** 1997 May 7;136(9):271–5 (50 ref.) (Eng. Abstr.) **(Cze)**

AFFECTIVE DISORDERS, PSYCHOTIC

Postpartum mood disorders: clinical perspectives. Pariser SF, et al. **J Womens Health** 1997 Aug;6(4):421–34 (62 ref.)

CHEMICALLY INDUCED

Antidepressant–induced hypomania in obsessive–compulsive disorder. Rihmer Z, et al. **Int Clin Psychopharmacol** 1996 Sep;11(3):203–5
Protracted benzodiazepine withdrawal syndrome mimicking psychotic depression [letter] Modell JG. **Psychosomatics** 1997 Mar–Apr;38(2):160–1

COMPLICATIONS

Obsessive compulsive disorder and mood disorders: a family study. Sciuto G, et al. **Am J Med Genet** 1995 Dec 18; 60(6):475–9
Depressive mood disorders in patients with operable breast cancer. Aragona M, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):111–8
Abdominal pain of psychotic origin. Khan Z, et al. **J R Soc Med** 1997 Apr;90(4):221–2
Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Kovasznay B, et al. **Schizophr Bull** 1997;23(2):195–201
[Chronic pelvic pains] Shcheglova II. **Klin Med (Mosk)** 1996; 74(9):73–5 **(Rus)**

DIAGNOSIS

Comparison of patients with early–, typical–, and late–onset affective psychosis. Sax KW, et al. **Am J Psychiatry** 1997 Sep;154(9):1299–301
Mood–congruent vs. mood–incongruent psychotic symptoms in affective psychotic disorders. Fennig S, et al. **Isr J Psychiatry Relat Sci** 1996;33(4):238–45 (30 ref.)
Eye–tracking performance and adaptive functioning over the short–term course of first–episode psychosis. Katsanis J, et al. **Psychiatry Res** 1996 Aug 30;64(1):19–26
Clinical and psychosocial variables in different diagnostic groups: their interrelationships and value as predictors of course and outcome during a 14–year follow–up. Vetter P, et al. **Psychopathology** 1996;29(3):159–68
Diagnostic and therapeutic advances in treatment–resistant mood disorders. Blinder BJ, et al. **West J Med** 1996 Mar; 164(3):258–9
[Differential diagnosis of tuberculous meningoencephalitis, schizophrenic psychosis and severe conflict reaction] Lauer G, et al. **Psychiatr Prax** 1996 Nov;23(6):296–7 **(Ger)**

DRUG THERAPY

Current Aspects in the Psychopharmacology of Mood Disorders. ECNP regional meeting. Istanbul, Turkey, 8–11 May 1996. Abstracts. **Eur Neuropsychopharmacol** 1996 Apr; 6 Suppl 1:S1–44
Psychiatric patients' attitudes about medication and factors affecting noncompliance. Ruscher SM, et al. **Psychiatr Serv** 1997 Jan;48(1):82–5
Ethnic considerations in the pharmacotherapy of mood disorders. Risby ED. **Psychopharmacol Bull** 1996; 32(2):231–4

ETIOLOGY

Mood changes associated with isotretinoin and substance abuse [letter] Kovacs SO, et al. **Pediatr Dermatol** 1996 Jul–Aug;13(4):350
Psychobiology of postpartum mood disorders. Wisner KL, et al. **Semin Reprod Endocrinol** 1997 Feb;15(1):77–89
[Chronic psychotic delirium and infarction in the left posterior cerebral area: a case report] Luauté JP, et al. **Ann Med Psychol (Paris)** 1996 Jun;154(4):249–53 **(Fre)**

GENETICS

Elevated lymphocyte spiperone binding: a vulnerability factor for affective psychosis? Fartaçek R, et al. **Biol Psychiatry** 1997 Jan 1;41(1):107–10
Psychopathological syndromes and familial morbid risk of psychosis. Van Os J, et al. **Br J Psychiatry** 1997 Mar; 170:241–6
Analysis of case–control/family sampling design. Liang KY, et al. **Genet Epidemiol** 1996;13(3):253–70

PHYSIOPATHOLOGY

Differences in the prevalence of psychosensory features among schizophrenic, schizoaffective, and manic patients. Atre–Vaidya N, et al. **Compr Psychiatry** 1997 Mar–Apr; 38(2):88–92
Affective disorders following stroke. Ghika–Schmid F, et al. **Eur Neurol** 1997;38(2):75–81 (86 ref.)
Interictal mood and personality disorders in temporal lobe epilepsy and juvenile myoclonic epilepsy. Perini GI, et al. **J Neurol Neurosurg Psychiatry** 1996 Dec;61(6):601–5
The thyroid axis and mood disorders: overview and future prospects. Esposito S, et al. **Psychopharmacol Bull** 1997; 33(2):205–17 (186 ref.)

PSYCHOLOGY

Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Thies–Flechtner K, et al. **Pharmacopsychiatry** 1996 May;29(3):103–7

REHABILITATION

Clinical interpretation of "predictors of functional outcome among adolescents and young adults with psychotic disorders" [comment] Barrows C. **Am J Occup Ther** 1996 Mar;50(3):182–3. Comment on: Am J Occup Ther 1996 Mar;50(3):171–81.
Predictors of functional outcome among adolescents and young adults with psychotic disorders. Henry AD, et al. **Am J Occup Ther** 1996 Mar;50(3):171–81 (97 ref.)
Patient dynamics in early stages of vocational rehabilitation: a pilot study. Hoffmann H, et al. **Compr Psychiatry** 1996 May–Jun;37(3):216–21

THERAPY

Diagnosis, treatment, and six–month outcome status in first–admission psychosis. Craig TJ, et al. **Ann Clin Psychiatry** 1997 Jun;9(2):89–97
Diagnostic and therapeutic advances in treatment–resistant mood disorders. Blinder BJ, et al. **West J Med** 1996 Mar; 164(3):258–9
[Therapy of affective disorders] Leština J. **Cas Lek Cesk** 1997 May 7;136(9):271–5 (50 ref.) (Eng. Abstr.) **(Cze)**

VIROLOGY

First isolates of infectious human Borna disease virus from patients with mood disorders [see comments] Bode L, et al. **Mol Psychiatry** 1996 Jul;1(3):200–12. Comment in: Mol Psychiatry 1996 Jul;1(3):165–7.

AFFECTIVE PSYCHOSIS, BIPOLAR see **BIPOLAR DISORDER**

AFFECTIVE SYMPTOMS

Introducing alexithymia: a concept within the psychosomatic process. Stephenson R. **Disabil Rehabil** 1996 Apr; 18(4):209–14 (47 ref.)
Psychiatric consultations in obstetric inpatients. Tsai SJ, et al. **J Obstet Gynaecol Res** 1996 Dec;22(6):603–7
An emotional 13–year–old girl. Kanabar DJ, et al. **Lancet** 1996 Oct 12;348(9033):1000
Impaired verbal and nonverbal emotion recognition in alexithymia [published erratum appears in Psychosom Med 1996 Nov–Dec;58(6):581] Lane RD, et al. **Psychosom Med** 1996 May–Jun;58(3):203–10
Alexithymia: present, past—and future? [editorial] Nemiah JC. **Psychosom Med** 1996 May–Jun;58(3):217–8
[Multimodal iatrogenic apathy] Oliveira–Souza RD, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):216–21 (Eng. Abstr.) **(Por)**

CHEMICALLY INDUCED

Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. Voruganti LN, et al. **J Nerv Ment Dis** 1997 Jul;185(7):463–5
[Mental health deterioration in workers exposed to styrene] Sassine MP, et al. **Rev Epidemiol Sante Publique** 1996 Jan; 44(1):14–24 (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Alexithymia—a useful concept for all psychiatrists? [editorial] Shapiro CM. **J Psychosom Res** 1996 Dec;41(6):503–4

COMPLICATIONS

Alexithymia in anorexia nervosa: a controlled study using the 20–item Toronto Alexithymia Scale. Råstam M, et al. **Acta Psychiatr Scand** 1997 May;95(5):385–8
Secondary alexithymia as a state reaction in panic disorder and social phobia. Fukunishi I, et al. **Compr Psychiatry** 1997 May–Jun;38(3):166–70
Alexithymia in chronic pain patients. Lumley MA, et al. **Compr Psychiatry** 1997 May–Jun;38(3):160–5
Personality characteristics of patients with "white coat" hypertension. Muneta S, et al. **Hypertens Res** 1997 Jun; 20(2):99–104
Alexithymia and affect pathology among adult male alcoholics. Cecero JJ, et al. **J Clin Psychol** 1997 Apr; 53(3):201–8
Environmental illness and multiple chemical sensitivity [letter] Curtis L. **J Occup Environ Med** 1996 Jan;38(1):16
Environmental illness and multiple chemical sensitivity [letter] Fung F, et al. **J Occup Environ Med** 1996 Jan; 38(1):16–7
Burning mouth syndrome (BMS) and the concept of alexithymia—a preliminary study. Jerlang BB. **J Oral Pathol Med** 1997 Jul;26(6):249–53
Childhood abuse, alexithymia and personality disorder. Berenbaum H. **J Psychosom Res** 1996 Dec;41(6):585–95
How are alexithymia and physical illness linked? A review and critique of pathways. Lumley MA, et al. **J Psychosom Res** 1996 Dec;41(6):505–18 (101 ref.)
A longitudinal study of alexithymia and psychological distress in inflammatory bowel disease. Porcelli P, et al. **J Psychosom Res** 1996 Dec;41(6):569–73
Alexithymia in somatoform disorder and somatic disease: a comparative study. Bach M, et al. **Psychother Psychosom** 1996;65(3):150–2
[Dysphagia and emotional distress] Bretan O, et al. **Arq Gastroenterol** 1996 Apr–Jun;33(2):60–5 (Eng. Abstr.) **(Por)**
[Clinical and psychological characterization of children and adolescents with recurrent abdominal pain] Guiraldes E, et al. **Rev Med Chil** 1995 Nov;123(11):1341–8 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Emotional disorders in HIV infection [letter; comment] Bungener C, et al. **Acta Psychiatr Scand** 1996 Nov; 94(5):379–80. Comment on: Acta Psychiatr Scand 1995 Dec;92(6):429–35.
Foster care's youngest: a preliminary report. Klee L, et al. **Am J Orthopsychiatry** 1997 Apr;67(2):290–9
Neuropsychiatric consequences of stroke. Robinson RG. **Annu Rev Med** 1997;48:217–29 (56 ref.)
The Numbing Scale: psychometric properties, a preliminary report. Glover H, et al. **Anxiety** 1994;1(2):70–9
Courts and torts: the psychiatrist preparing for trial. Hoffman BF. **Can J Psychiatry** 1997 Jun;42(5):497–501 (11 ref.)
Maltreatment, conscience functioning and dopamine beta hydroxylase in emotionally disturbed boys. Galvin MR, et al. **Child Abuse Negl** 1997 Jan;21(1):83–92
The significance of emotions in the affective presentation of sexually abused girls. Carey TC, et al. **Child Psychiatry Hum Dev** 1996 Winter;27(2):115–24
Alexithymia in chronic pain patients. Lumley MA, et al. **Compr Psychiatry** 1997 May–Jun;38(3):160–5
The ability of teacher reports to identify child sexual abuse victims. Hildreth AJ, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(1):6–15
General principles in child liaison consultation service: a literature review. Ortiz P. **Eur Child Adolesc Psychiatry** 1997 Mar;6(1):1–6 (46 ref.)
Emotional lability, intrusiveness, and catastrophic reactions. Haupt M. **Int Psychogeriatr** 1996;8 Suppl 3:409–14
Development of a structured psychiatric interview for children: agreement between child and parent on individual symptoms. Herjanic B, et al. **J Abnorm Child Psychol** 1997 Feb;25(1):21–31
Accuracy of informants: do parents think that mother knows best? Phares V. **J Abnorm Child Psychol** 1997 Apr; 25(2):165–71
Individual differences in emotion regulation and behavior problems in preschool children. Cole PM, et al. **J Abnorm Psychol** 1996 Nov;105(4):518–29
Ego control, Ego resiliency, and the Five–Factor Model as predictors of behavioral and emotional problems in clinic–referred children and adolescents. Huey SJ Jr, et al. **J Abnorm Psychol** 1997 Aug;106(3):404–15
Scientific status of the concept of continuing emotional propensity for sexually aberrant acts. Lanyon RI. **J Am Acad Psychiatry Law** 1997;25(1):59–67 (36 ref.)
Long–term stability of individual differences in the emotional responsiveness of children with autism. Dissanayake C, et al. **J Child Psychol Psychiatry** 1996 May;37(4):461–7
Cross–cultural alexithymia: development and validation of a Hindi translation of the 20–Item Toronto Alexithymia Scale. Pandey R, et al. **J Clin Psychol** 1996 Mar;52(2):173–6
What does the Toronto Alexithymia Scale TAS–R measure? Rief W, et al. **J Clin Psychol** 1996 Jul;52(4):423–9
Testing the alexithymia hypothesis: physiological and subjective responses during relaxation and stress. Friedlander L, et al. **J Nerv Ment Dis** 1997 Apr; 185(4):233–9
Nonverbal behavior and alexithymic traits in normal subjects. Individual differences in encoding emotions. Troisi A, et al. **J Nerv Ment Dis** 1996 Sep;184(9):561–6
Impact of rater knowledge on sexually abused and nonabused girls' scores on the Draw–A–Person: Screening Procedure for Emotional Disturbance (DAP:SPED). Bruening CC, et al. **J Pers Assess** 1997 Jun;68(3):665–77
The long–term stability and predictive validity of trait measures of affect. Watson D, et al. **J Pers Soc Psychol** 1996 Mar;70(3):567–77
Cross validation of the factor structure of the 20–item Toronto Alexithymia Scale: an Italian multicenter study. Bressi C, et al. **J Psychosom Res** 1996 Dec;41(6):551–9
Relationship of swimming distance, expectancy, and performance to mood states of competitive athletes. Berger BG, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 2):1199–210
Anhedonia and alexithymia: distinct or overlapping constructs. Loas G, et al. **Percept Mot Skills** 1997 Apr;

84(2):415–25
Alexithymia in patients with eating disorders: an investigation using a new projective technique. Smith GJ, et al. **Percept Mot Skills** 1997 Aug;85(1):247–56
The Children's Affective Lability Scale: a psychometric evaluation of reliability. Gerson AC, et al. **Psychiatry Res** 1996 Dec 20;65(3):189–98
Scores on the Wechsler Intelligence Scale for Children–Third Edition and Woodcock–Johnson Tests of Achievement–Revised for a sample of children with emotional handicaps. Lavin C. **Psychol Rep** 1996 Dec;79(3 Pt 2):1291–5
Factor analysis of the French version of the 20–Item Toronto Alexithymia Scale (TAS–20). Loas G, et al. **Psychopathology** 1996;29(2):139–44
Does affective blunting in schizophrenia reflect affective deficit or neuromotor dysfunction? Dworkin RH, et al. **Schizophr Res** 1996 Jul 5;20(3):301–6
[Scales for assessing anhedonia. Response to questions by Dr. Pierson (letter)] Assouly–Besse F. **Encephale** 1996 Sep–Oct;22(5):393 **(Fre)**
[Quantitative psychopathology of affect and emotion. Review of evaluation scales and emotion induction methods] Garcia C, et al. **Encephale** 1997 Mar–Apr;23(2):119–30 (129 ref.) (Eng. Abstr.) **(Fre)**
[Detection of anhedonia in the normal subject. Determination of the validity of the Chapman and Chapman (1978) revised Physical Anhedonia Scale (letter)] Loas G, et al. **Encephale** 1996 Jul–Aug;22(4):301–2 **(Fre)**
[Clinical characteristics of chronic schizophrenic patients presenting with severe anhedonia] Loas G, et al. **Encephale** 1996 Sep–Oct;22(5):351–8 (Eng. Abstr.) **(Fre)**
[The emotional development of children] Fegert JM, et al. **Gesundheitswesen** 1997 Jan;59(1):1–9 (34 ref.) (Eng. Abstr.) **(Ger)**
[Validation of the German version of the 20–item Toronto Alexithymia Scale in normal persons and psychiatric patients] Bach M, et al. **Psychother Psychosom Med Psychol** 1996 Jan;46(1):23–8 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Rossi A, et al. **Acta Psychiatr Scand** 1997 Jan;95(1):40–3
Emotional incontinence: a dramatic response to paroxetine [letter] Tan I, et al. **Aust N Z J Med** 1996 Dec;26(6):844
Pharmacologic treatment of emotional lability. Iannaccone S, et al. **Clin Neuropharmacol** 1996 Dec;19(6):532–5
Long–term treatment of elderly individuals with emotional disturbances: an open study with citalopram. Ragneskog H, et al. **Int Psychogeriatr** 1996 Winter;8(4):659–68
[Clinical effects of clozapine: effect on negative symptoms] Llorca PM, et al. **Encephale** 1996 Jul–Aug;22(4):287–92 (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

The Great Smoky Mountains Study of Youth. Functional impairment and serious emotional disturbance. Costello EJ, et al. **Arch Gen Psychiatry** 1996 Dec;53(12):1137–43
Psychological distress among older adolescents and young adults in Australia. Rickwood D, et al. **Aust N Z J Public Health** 1996 Feb;20(1):83–6
Subjective ratings of emotional health as a risk factor for major depression in a community sample. Hoff RA, et al. **Br J Psychiatry** 1997 Feb;170:167–72
Emotional distress and substance abuse as risk factors for suicide attempts. Overholser JC, et al. **Can J Psychiatry** 1997 May;42(4):402–8
School–based mental health services in the United States: history, current models and needs. Flaherty LT, et al. **Community Ment Health J** 1996 Aug;32(4):341–52 (27 ref.)
Addressing the barriers to mental health services for inner city children and their caretakers. McKay MM, et al. **Community Ment Health J** 1996 Aug;32(4):353–61
Emotional distress in men with life–threatening illness. van Servellen G, et al. **Int J Nurs Stud** 1996 Oct;33(5):551–65
Adjustment of children facing the death of a parent due to cancer. Siegel K, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Apr;35(4):442–50
Sojourner readjustment: mental health of international students after one year's foreign sojourn and its psychosocial correlates. Furukawa T. **J Nerv Ment Dis** 1997 Apr;185(4):263–8
Gender and cross–cultural differences in somatic symptoms associated with emotional distress. An international study in primary care. Piccinelli M, et al. **Psychol Med** 1997 Mar; 27(2):433–44
Alexithymia and health care utilization. Lumley MA, et al. **Psychosom Med** 1996 May–Jun;58(3):197–202
Alexithymia and psychological distress among frequent attendance patients in health care. Joukamaa M, et al. **Psychother Psychosom** 1996;65(4):199–202
The deficit syndrome in the DSM–IV Field Trial: I. Alcohol and other drug abuse. Kirkpatrick B, et al. **Schizophr Res** 1996 May;20(1–2):69–77
The prevalence of self–reported problems in young adults from the general population. Ferdinand RF, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jan;31(1):10–20

ETHNOLOGY

Emotional health of Indonesian adoptees living in Australian families. Goldney RD, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):534–9
Ethnolinguistic correlates of alexithymia: toward a cultural perspective. Dion KL. **J Psychosom Res** 1996 Dec; 41(6):531–9
An investigation of the psychometric properties of the 26 item Toronto Alexithymia Scale in a Japanese culture. Fukunishi I, et al. **Psychol Rep** 1996 Oct;79(2):555–62

ETIOLOGY

Emotional aspects in burn patients: usage of a health state classification system. Pardo Mateu L, et al. **Burns** 1996 Aug;22(5):396–8
Cognitive and emotional deficits in early stages of HIV infection: an event–related potentials study. Bungener C, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov;20(8):1303–14

GENETICS

A prospective four–year follow–up study of children at risk for ADHD: psychiatric, neuropsychological, and psychosocial outcome. Faraone SV, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Nov; 35(11):1449–59

IMMUNOLOGY

Decreased cytotoxic lymphocyte counts in alexithymia. Dewaraja R, et al. **Psychother Psychosom** 1997;66(2):83–6
Alexithymia, immunity and cervical intraepithelial neoplasia: replication. Todarello O, et al. **Psychother Psychosom** 1997; 66(4):208–13

MORTALITY

Alexithymia and risk of death in middle–aged men. Kauhanen J, et al. **J Psychosom Res** 1996 Dec;41(6):541–9

NURSING

A randomised controlled trial and cost analysis of problem–solving treatment for emotional disorders given by community nurses in primary care. Mynors–Wallis L, et al. **Br J Psychiatry** 1997 Feb;170:113–9
Hopelessness in the myocardial infarction patient. Johnson LH, et al. **Prog Cardiovasc Nurs** 1996 Spring;11(2):19–32

PHYSIOPATHOLOGY

Alexithymia: a right hemisphere dysfunction specific to recognition of certain facial expressions? Jessimer M, et al. **Brain Cogn** 1997 Jul;34(2):246–58
Differences in the prevalence of psychosensory features among schizophrenic, schizoaffective, and manic patients. Atre–Vaidya N, et al. **Compr Psychiatry** 1997 Mar–Apr; 38(2):88–92
The outward expression of anger, the inward experience of anger and CVR: the role of vocal expression. Siegman AW, et al. **J Behav Med** 1997 Feb;20(1):29–45
The availability of social support reduces cardiovascular reactivity to acute psychological stress. Uchino BN, et al. **J Behav Med** 1997 Feb;20(1):15–27
Alexithymia, defensiveness and cardiovascular reactivity to stress. Linden W, et al. **J Psychosom Res** 1996 Dec; 41(6):575–83
Limbic processes and the affective dimension of pain. Chapman CR. **Prog Brain Res** 1996;110:63–81 (72 ref.)
Cognitive and emotional deficits in early stages of HIV infection: an event–related potentials study. Bungener C, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov;20(8):1303–14
[Brain biopotential mapping in emotional and cognitive pathology] Strelets VB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar–Apr; 47(2):226–42 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. Voruganti LN, et al. **J Nerv Ment Dis** 1997 Jul;185(7):463–5

PSYCHOLOGY

Alexithymia in suicide attempters. Taiminen TJ, et al. **Acta Psychiatr Scand** 1996 Mar;93(3):195–8
Confirmatory and disconfirmatory family communication as predictor of offspring socio–emotional functioning. A 10 to 14 year follow–up of children at risk. Wichstrom L, et al. **Acta Psychiatr Scand** 1996 Jan;93(1):49–56
Sexual assault in school, mental health and suicidal behaviors in adolescent women in Canada. Bagley C, et al. **Adolescence** 1997 Summer;32(126):361–6
Psychological aspects of hemiplegia. Goodman R. **Arch Dis Child** 1997 Mar;76(3):177–8
Modelling cognition in emotional disorder: the S–REF model. Wells A, et al. **Behav Res Ther** 1996 Nov–Dec; 34(11–12):881–8 (25 ref.)
Hypomania, anxiety and the emotional Stroop. French CC, et al. **Br J Clin Psychol** 1996 Nov;35 (Pt 4):617–26
Locus of control in behaviourally disordered children. Elliott J. **Br J Educ Psychol** 1996 Mar;66 (Pt 1):47–57
The spectrum of emotional distress and personality changes after minor head injury incurred in a motor vehicle accident. Parker RS. **Brain Inj** 1996 Apr;10(4):287–302
Miserable minority: emotional risk factors that influence the outcome of a mild traumatic brain injury. Ruff RM, et al. **Brain Inj** 1996 Aug;10(8):551–65
The socioemotional development of orphans in orphanages and traditional foster care in Iraqi Kurdistan. Ahmad A, et al. **Child Abuse Negl** 1996 Dec;20(12):1161–73
Children's emotional and behavioral reactions following the disclosure of extrafamilial sexual abuse: initial effects. Ligezinska M, et al. **Child Abuse Negl** 1996 Feb; 20(2):111–25
Secondary alexithymia as a state reaction in panic disorder and social phobia. Fukunishi I, et al. **Compr Psychiatry** 1997 May–Jun;38(3):166–70
Pragmatic difficulties and socio–emotional problems: a case study. Vedeler L. **Eur J Disord Commun** 1996;31(3):271–88
Alexithymic features do not predict compliance with psychotherapy in consultation–liaison patients. Aärelä E, et al. **Gen Hosp Psychiatry** 1997 May;19(3):229–33
Emotional disturbances in trauma patients during the rehabilitation phase: studies of posttraumatic stress disorder and alexithymia. Fukunishi I, et al. **Gen Hosp Psychiatry** 1996 Mar;18(2):121–7
Emotional expression during mid– to late–stage dementia. Magai C, et al. **Int Psychogeriatr** 1996 Fall;8(3):383–95
Comparative affective reactivity of different types of communication disturbances in schizophrenia. Docherty NM, et al. **J Abnorm Psychol** 1997 May;106(2):325–30
Coping strategies, drinking motives, and stressful life events among middle adolescents: associations with emotional and behavioral problems and with academic functioning. Windle M, et al. **J Abnorm Psychol** 1996 Nov;105(4):551–60
Adolescents from one parent, stepparent and intact families: emotional problems and suicide attempts. Garnefski N, et al. **J Adolesc** 1997 Apr;20(2):201–8
The outward expression of anger, the inward experience of anger and CVR: the role of vocal expression. Siegman AW, et al. **J Behav Med** 1997 Feb;20(1):29–45
The availability of social support reduces cardiovascular reactivity to acute psychological stress. Uchino BN, et al. **J Behav Med** 1997 Feb;20(1):15–27
Psychopathology in infancy. Zeanah CH, et al. **J Child Psychol Psychiatry** 1997 Jan;38(1):81–99 (200 ref.)
Cognitive complaints in closed–head injury: relationship to memory test performance and emotional disturbance. Gass CS, et al. **J Clin Exp Neuropsychol** 1997 Apr;19(2):290–9
Alexithymia and dissociative tendencies. Irwin HJ, et al. **J Clin Psychol** 1997 Feb;53(2):159–66
Foster home environments: a preliminary report. Simms MD, et al. **J Dev Behav Pediatr** 1996 Jun;17(3):170–5
School refusal and emotional lability in a 6–year–old boy. Stein MT, et al. **J Dev Behav Pediatr** 1996 Jun;17(3):187–90
Chronic pain and emotional distress in children and adolescents. Varni JW, et al. **J Dev Behav Pediatr** 1996 Jun;17(3):154–61
Affective states in normal and depressed older people. Lawton MP, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):P309–16
Testing the alexithymia hypothesis: physiological and subjective responses during relaxation and stress. Friedlander L, et al. **J Nerv Ment Dis** 1997 Apr; 185(4):233–9
Signs of emotional disturbance three years after early hospitalization. Fahrenfort JJ, et al. **J Pediatr Psychol** 1996 Jun;21(3):353–66
Childhood abuse, alexithymia and personality disorder. Berenbaum H. **J Psychosom Res** 1996 Dec;41(6):585–95
Pain sensitivity, alexithymia, and depression in patients with eating disorders: are they related? de Zwaan M, et al. **J Psychosom Res** 1996 Jul;41(1):65–70
A California Q–set alexithymia prototype and its relationship to ego–control and ego–resiliency. Haviland MG, et al. **J Psychosom Res** 1996 Dec;41(6):597–607
"Passing through life": alexithymia and attachment disorders [editorial] Kraemer S, et al. **J Psychosom Res** 1995 Nov; 39(8):937–41
Alexithymia, defensiveness and cardiovascular reactivity to stress. Linden W, et al. **J Psychosom Res** 1996 Dec; 41(6):575–83
Alexithymia, social support and health problems. Lumley MA, et al. **J Psychosom Res** 1996 Dec;41(6):519–30
Alexithymia and impoverished dream recall in asthmatic patients: evidence from self–report measures. Nielsen T, et al. **J Psychosom Res** 1997 Jan;42(1):53–9
Relationships between alexithymia and psychological characteristics associated with eating disorders. Taylor GJ, et al. **J Psychosom Res** 1996 Dec;41(6):561–8
Alexithymia in Holocaust survivors with and without PTSD. Yehuda R, et al. **J Trauma Stress** 1997 Jan;10(1):93–100
Alexithymia and visual perception. Duchesneau AP. **Percept Mot Skills** 1996 Aug;83(1):291–8
Sleep characteristics of Japanese working men who score alexithymic on the Toronto Alexithymia Scale. Fukunishi I, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):859–65
Interscorers' agreement of the human figure drawings with a referred group of children. Fuller GB, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):882
Elevated blood pressure and personality: a meta–analytic review. Jorgensen RS, et al. **Psychol Bull** 1996 Sep; 120(2):293–320

AFFECTIVE SYMPTOMS

Alexithymia in substance abuse: relationship to depression. Fukunishi I. **Psychol Rep** 1996 Apr;78(2):641–2

Influence of ego strength on associations of alexithymia and depression. Fukunishi I, et al. **Psychol Rep** 1996 Dec;79(3 Pt 1):999–1005

Is alexithymia a culture-bound construct? Validity and reliability of the Japanese versions of the 20-item Toronto Alexithymia Scale and modified Beth Israel Hospital Psychosomatic Questionnaire. Fukunishi I, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):787–99

Externally oriented thinking of obese men and women. Fukunishi I, et al. **Psychol Rep** 1997 Feb;80(1):219–24

Association of alexithymia with low utilization and perception on a measure of social support in patients on peritoneal dialysis. Fukunishi I, et al. **Psychol Rep** 1997 Feb;80(1):127–30

Mothers' low care in the development of alexithymia: a preliminary study in Japanese college students. Fukunishi I, et al. **Psychol Rep** 1997 Feb;80(1):143–6

Can scores on alexithymia distinguish patients with peptic ulcer and erosive gastritis? Fukunishi S, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):995–1004

Alexithymia, affective disorders and substance abuse: possible cross-relationships. Giannini AJ. **Psychol Rep** 1996 Jun; 78(3 Pt 2):1389–90

Defensive and affective-emotional reactions to war: the Abkhazian war as reflected in people's subjective reactions. Hentschel U, et al. **Psychol Rep** 1996 Feb;78(1):135–43

Emotional states and perceived family functioning of caregivers of chronically ill children. Labbé EE. **Psychol Rep** 1996 Dec;79(3 Pt 2):1233–4

Alexithymia in a clinical sample of obese women. Morosin A, et al. **Psychol Rep** 1997 Apr;80(2):387–94

Family factors related to alexithymia characteristics. Lumley MA, et al. **Psychosom Med** 1996 May-Jun;58(3):211–6

Independency of alexithymia and somatization. A factor analytic study. Bach M, et al. **Psychosomatics** 1996 Sep-Oct;37(5):451–8

Relationship of alexithymia and poor social support to ulcerative changes on gastrofiberscopy. Fukunishi I, et al. **Psychosomatics** 1997 Jan-Feb;38(1):20–6

Alexithymia, anger, and interpersonal behavior. Berenbaum H, et al. **Psychother Psychosom** 1996;65(4):203–8

[A training program for coping with maladaptive emotions of schizophrenic patients. Initial results and experiences] Hodel B, et al. **Nervenarzt** 1996 Jul;67(7):564–71 (Eng. Abstr.) **(Ger)**

[Alexithymia--psychometric phantom or psychophysiologic reality?] Franz M, et al. **Psychother Psychosom Med Psychol** 1996 Jan;46(1):1–10 (Eng. Abstr.) **(Ger)**

[Computer-assisted text analysis of psychiatric treatment sessions--comparison with psychoanalytically oriented initial interview, psychoanalytic sessions and visit interviews] Scheibe G. **Psychother Psychosom Med Psychol** 1996 Dec; 46(12):438–43 (Eng. Abstr.) **(Ger)**

[Emotional-personality condition of patients with some gastroenterological diseases] Solov'eva AD, et al. **Klin Med (Mosk)** 1997;75(1):27–8 (Eng. Abstr.) **(Rus)**

REHABILITATION

Driving quality through Hoshin planning. Hyde RS, et al. **Jt Comm J Qual Improv** 1996 Jan;22(1):27–35

The impact of legislation to improve coordination of services to children with serious emotional disturbance. Petti TA, et al. **Psychiatr Serv** 1996 Nov;47(11):1239–43

Promoting the full inclusion of emotionally disturbed students through "no fault" interactions between parents and professionals. Kelly EJ. **Psychol Rep** 1997 Aug;81(1):256–8

THERAPY

School-based wraparound planning: integrating services for students with emotional and behavioral needs. Eber L, et al. **Am J Orthopsychiatry** 1997 Jul;67(3):385–95

Outcome assessment of psychotherapy. VandenBos GR. **Am Psychol** 1996 Oct;51(10):1005–6

Psychological treatment of emotional problems by general practitioners. Cape JD. **Br J Med Psychol** 1996 Jun;69 (Pt 2):85–99

Skills training treatment for adaptive affect regulation in a woman with binge-eating disorder. Telch CF. **Int J Eat Disord** 1997 Jul;22(1):77–81

Patients' perspectives on the management of emotional distress in primary care settings [see comments] Brody DS, et al. **J Gen Intern Med** 1997 Jul;12(7):403–6. Comment in: J Gen Intern Med 1997 Jul;12(7):453–4.

Emotions and medicine. What do patients expect from their physicians? [editorial; comment] Gallo JJ. **J Gen Intern Med** 1997 Jul;12(7):453–4. Comment on: J Gen Intern Med 1997 Jul;12(7):403–6.

Comparison of changes in autonomic and respiratory parameters of girls after yoga and games at a community home. Telles S, et al. **Percept Mot Skills** 1997 Feb; 84(1):251–7

Changes in scores on alexithymia over a period of psychiatric treatment. Fukunishi I, et al. **Psychol Rep** 1997 Apr; 80(2):483–9

[The phototherapy of psycho-autonomic disorders] Solov'eva AD, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(3):67–71 (Eng. Abstr.) **(Rus)**

VIROLOGY

Borna disease virus antibodies and the deficit syndrome of schizophrenia. Waltrip RW 2nd, et al. **Schizophr Res** 1997 Feb 28;23(3):253–7

AFFERENT LOOP SYNDROME

ETIOLOGY

Afferent loop syndrome complicated by a duodenal phytobezoar after Billroth-II subtotal gastrectomy. Hui MS, et al. **Am J Gastroenterol** 1997 Sep;92(9):1550–2

AFFERENT PATHWAYS

Relative afferent pupillary defect and edge light pupil cycle time in the early differentiation of central retinal vein occlusion. Menon V, et al. **Indian J Ophthalmol** 1995 Sep; 43(3):127–30

[Pulmonary vagal afferents in man] Paleček F. **Cesk Fysiol** 1997 Jun;46(2):57–63 (90 ref.) (Eng. Abstr.) **(Cze)**

ANATOMY & HISTOLOGY

Anatomical relationship between vagal afferent fibers and CCK-immunoreactive entero-endocrine cells in the rat small intestinal mucosa. Berthoud HR, et al. **Acta Anat (Basel)** 1996;156(2):123–31

Evidence for divergent projections to the brain noradrenergic system and the spinal parasympathetic system from Barrington's nucleus. Valentino RJ, et al. **Brain Res** 1996 Sep 2;732(1–2):1–15

Afferents to the seizure-sensitive neurons in layer III of the medial entorhinal area: a tracing study in the rat. Eid T, et al. **Exp Brain Res** 1996 May;109(2):209–18

Topographical organisation within the lateral reticular nucleus mossy fibre projection to the c1 and c2 zones in the rostral paramedian lobule of the cat cerebellum. Apps R, et al. **J Comp Neurol** 1997 May 5;381(2):175–87

Spinal afferents to functionally distinct periaqueductal gray columns in the rat: an anterograde and retrograde tracing study. Keay KA, et al. **J Comp Neurol** 1997 Aug 25; 385(2):207–29

Organisation of the reticular thalamic projection to the intralaminar and midline nuclei in rats. Kolmac CI, et al. **J Comp Neurol** 1997 Jan 13;377(2):165–78

Simultaneous anterograde labeling of axonal layers from lateral superior olive and dorsal cochlear nucleus in the inferior colliculus of cat. Oliver DL, et al. **J Comp Neurol** 1997 Jun 2;382(2):215–29

Initial trajectories of sensory axons toward laminar targets in the developing mouse spinal cord. Ozaki S, et al. **J Comp Neurol** 1997 Apr 7;380(2):215–29

Reafferent thalamo- "cortical" loops in the song system of oscine songbirds. Vates GE, et al. **J Comp Neurol** 1997 Apr 7;380(2):275–90

Experimentally induced retinal projections to the ferret auditory thalamus: development of clustered eye-specific patterns in a novel target. Angelucci A, et al. **J Neurosci** 1997 Mar 15;17(6):2040–55

Cells in laminae III and IV of the rat spinal cord that possess the neurokinin-1 receptor and have dorsally directed dendrites receive a major synaptic input from tachykinin-containing primary afferents. Naim M, et al. **J Neurosci** 1997 Jul 15;17(14):5536–48

Synaptic contacts between cholinergic afferents and suprachiasmatic neurones of the rat. Kiss J, et al. **Neuroreport** 1996 Aug 12;7(12):1961–4

Afferent sources of substance P in the C1 area of the rat rostral ventrolateral medulla. Milner TA, et al. **Neurosci Lett** 1996 Feb 16;205(1):37–40

Afferent connections of the nucleus accumbens of the snake, Elaphe guttata, studied by means of in vitro and in vivo tracing techniques in combination with TH immunohistochemistry. Perez-Santana L, et al. **Neurosci Lett** 1997 Apr 4;225(2):101–4

Heterogeneity of the commissural projection to the rat dentate gyrus: a Phaseolus vulgaris leucoagglutinin tracing study. Deller T, et al. **Neuroscience** 1996 Nov;75(1):111–21

The lamellar organization of the rat substantia nigra pars reticulata: segregated patterns of striatal afferents and relationship to the topography of corticostriatal projections. Deniau JM, et al. **Neuroscience** 1996 Aug; 73(3):761–81

Peripheral cutaneous nerve distribution to the fingers. Stappaerts KH, et al. **Physiother Res Int** 1996;1(1):41–9

The fimbria-fornix/cingular bundle pathways: a review of neurochemical and behavioural approaches using lesions and transplantation techniques. Cassel JC, et al. **Prog Neurobiol** 1997 Apr;51(6):663–716 (556 ref.)

CYTOLOGY

Kappa opioid receptor-like immunoreactivity is present in substance P-containing subcortical afferents in guinea pig dentate gyrus. Drake CT, et al. **Hippocampus** 1997; 7(1):36–47

[The morphological organization of the afferent connections of the limbic cortex] Varlamova TI. **Morfologiia** 1995; 108(3):25–9 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

A comparison of the effects of two antispastic drugs, tizanidine and baclofen, on synaptic transmission from muscle spindle afferents to spinal interneurones in cats. Skoog B. **Acta Physiol Scand** 1996 Jan;156(1):81–90

Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Hoskin KL, et al. **Brain** 1996 Oct;119 (Pt 5):1419–28

Evidence that excitatory amino acids mediate afferent input to the primate somatosensory thalamus. Dougherty PM, et al. **Brain Res** 1996 Jul 29;728(2):267–73

Pharmacology of the skate electroretinogram indicates independent ON and OFF bipolar cell pathways. Chappell RL, et al. **J Gen Physiol** 1996 Apr;107(4):535–44

Serotonin 5-HT1A receptors modulate hippocampal reactivity to afferent stimulation. Levkovitz Y, et al. **J Neurosci** 1997 Jul 15;17(14):5591–8

A novel methodology for simultaneous assessment of the effects of 5-hydroxytryptamine on primary afferent polarisation and synaptic transmission in rat dorsal horn neurones in vitro. Lopez-Garcia JA, et al. **J Neurosci Methods** 1996 Sep;68(1):1–6

Renshaw cell responses to intra-arterial injection of muscle metabolites into cat calf muscles. Windhorst U, et al. **Neurosci Res** 1997 Mar;27(3):235–47

Presence of neuropeptide FF receptors on primary afferent fibres of the rat spinal cord. Gouardères C, et al. **Neuroscience** 1996 Sep;74(1):21–7

EMBRYOLOGY

Developmental dynamics of functionally specific primary sensory afferent projections in the chicken embryo. Eide AL, et al. **Anat Embryol (Berl)** 1997 Mar;195(3):237–50

GROWTH & DEVELOPMENT

The vestibular primary afferents and the vestibulospinal projections in the developing and adult opossum, Monodelphis domestica. Pflieger JF, et al. **Anat Embryol (Berl)** 1996 Jul;194(1):75–88

IMMUNOLOGY

Immunomodulation of afferent neurons in guinea-pig isolated airway. Riccio MM, et al. **J Physiol (Lond)** 1996 Mar 1; 491 (Pt 2):499–509

METABOLISM

Thalamocortical afferents in rat transiently express high-affinity serotonin uptake sites. Bennett-Clarke CA, et al. **Brain Res** 1996 Sep 16;733(2):301–6

Evidence for release of glutamic acid, aspartic acid and substance P but not gamma-aminobutyric acid from primary afferent fibres in rat spinal cord. Teoh H, et al. **Eur J Pharmacol** 1996 Apr 29;302(1–3):27–36

Neonatal damage to the rat's infraorbital nerve upregulates both galanin and neuropeptide Y in individual vibrissae-related primary afferent axons. Boylan CB, et al. **Exp Brain Res** 1996 Dec;112(3):475–84

The temporal and spatial development of corticotropin-releasing factor (CRF) binding sites and CRF afferents in the opossum cerebellum. Madtes PC Jr, et al. **J Chem Neuroanat** 1996 Oct;11(4):231–41

A population of nicotinic receptors is associated with thalamocortical afferents in the adult rat: laminal and areal analysis. Lavine N, et al. **J Comp Neurol** 1997 Apr 7; 380(2):175–90

Characterization of cholecystokininA and cholecystokininB receptors expressed by vagal afferent neurons. Moriarty P, et al. **Neuroscience** 1997 Aug;79(3):905–13

PATHOLOGY

Acute neuronal and vascular changes following unilateral cerebellar pedunculotomy in the neonatal rat. Sherrard RM, et al. **J Anat** 1997 Aug;191 (Pt 2):177–89

PHYSIOLOGY

Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Moran TH, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1245–51

Tuning of electroreceptors in the blind cave salamander, Proteus anguinus L. Schlegel PA, et al. **Brain Behav Evol** 1997;49(3):132–6

Synaptic terminals immunolabelled against glutamate in the lobus parolfactorius of domestic chicks (Gallus domesticus) in relation to afferents from the archistriatum. Csillag A, et al. **Brain Res** 1997 Mar 7;750(1–2):171–9

Fatigue-induced changes in group IV muscle afferent activity: differences between high- and low-frequency electrically induced fatigues. Darques JL, et al. **Brain Res** 1997 Mar 7;750(1–2):147–54

Ureteral ligation induces Fos expression in the dorsal horn. Fitch GK, et al. **Brain Res** 1996 Jun 3;723(1–2):199–205

Effects of extensor muscle afferents on the timing of locomotor activity during walking in adult rats. Fouad K, et al. **Brain Res** 1997 Feb 28;749(2):320–8

Examination of the afferent fiber responsible for the suppression of jaw-opening reflex in heat, cold, and manual acupuncture stimulation in rats. Okada K, et al. **Brain Res** 1996 Nov 18;740(1–2):201–7

Interaction of nociceptive and non-nociceptive cutaneous

afferents from foot sole in common reflex pathways to tibialis anterior motoneurones in humans. Rossi A, et al. **Brain Res** 1996 Apr 1;714(1–2):76–86

Deafferentiation–induced c–fos gene expression in subthalamic nucleus and substantia nigra reticulata is reduced by non–NMDA receptor antagonist. Saji M, et al. **Brain Res** 1995 Dec 12;703(1–2):165–74

The effects of peripheral deafferentation on spontaneously bursting neurons in the somatosensory cortex of waking cats. Webster HH, et al. **Brain Res** 1997 Mar 7; 750(1–2):109–21

Afferents originating from the dorsal penile nerve excite oxytocin cells in the hypothalamic paraventricular nucleus of the rat. Yanagimoto M, et al. **Brain Res** 1996 Sep 16; 733(2):292–6

Peripheral afferents with common function cluster in the median nerve and somatotopically innervate the human palm. Ekedahl R, et al. **Brain Res Bull** 1997;42(5):367–76

The columnar region of the ventral nucleus of the lateral lemniscus in the big brown bat (Eptesicus fuscus): synaptic arrangements and structural correlates of feedforward inhibitory function. Vater M, et al. **Cell Tissue Res** 1997 Aug;289(2):223–33

Task–dependence of muscle afferent monosynaptic inputs to human extensor carpi radialis motoneurones. Schmied A, et al. **Electroencephalogr Clin Neurophysiol** 1997 Jun; 105(3):220–34

Locomotor–related presynaptic modulation of primary afferents in the lamprey. El Manira A, et al. **Eur J Neurosci** 1997 Apr;9(4):696–705

Topography and dipole analysis of reafferent electrical brain activity following the Bereitschaftspotential. Bötzel K, et al. **Exp Brain Res** 1997 Apr;114(2):352–61

Short–term plasticity in primary somatosensory cortex of the rat: rapid changes in magnitudes and latencies of neuronal responses following digit denervation. Doetsch GS, et al. **Exp Brain Res** 1996 Dec;112(3):505–12

Selective cortical and segmental control of primary afferent depolarization of single muscle afferents in the cat spinal cord. Eguibar JR, et al. **Exp Brain Res** 1997 Mar; 113(3):411–30

Neuronal gagging activity patterns may be generated by neurons in the reticular area dorsomedial to the retrofacial nucleus in dogs. Fukuda H, et al. **Exp Brain Res** 1997 Mar; 113(3):394–401

Influence of afferent feedback on isometric fine force resolution in humans. Henningsen H, et al. **Exp Brain Res** 1997 Feb;113(2):207–13

Is human muscle spindle afference dependent on perceived size of error in visual tracking? Kakuda N, et al. **Exp Brain Res** 1997 Apr;114(2):246–54

Evidence for excitation of the human lower limb motoneurones by group II muscle afferents. Marque P, et al. **Exp Brain Res** 1996 May;109(2):357–60

The "size principle" and synaptic effectiveness of muscle afferent projections to human extensor carpi radialis motoneurones during wrist extension. Schmied A, et al. **Exp Brain Res** 1997 Feb;113(2):214–29

Changes in motor activity and biomechanics during balance recovery following cutaneous and muscular deafferentation. Thoumie P, et al. **Exp Brain Res** 1996 Jul; 110(2):289–97

Waveform complexity of unit activity recorded with concentric needle electrodes from human peripheral nerves. Wu G, et al. **Exp Brain Res** 1997 Apr;114(2):377–83

The role of NGF and afferent denervation in the process of sympathetic fiber ingrowth into the hippocampal formation. Scalapino K, et al. **Exp Neurol** 1996 Oct; 141(2):310–7

Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Sengupta JN, et al. **Gastroenterology** 1996 Oct; 111(4):968–80

Alteration of human cutaneous afferent discharges as the result of long–lasting vibration. Ribot–Ciscar E, et al. **J Appl Physiol** 1996 May;80(5):1708–1715

Putative projection of phrenic afferents to the limbic cortex in humans studied with cerebral–evoked potentials. Straus C, et al. **J Appl Physiol** 1997 Feb;82(2):480–90

Convergence of visceral and somatic afferents on single neurones in the reticular formation of the lower brain stem in dogs. Langhorst P, et al. **J Auton Nerv Syst** 1996 Mar 7;57(3):149–57

Cognitive impairments after lesions of the neostriatum caudolaterale and its thalamic afferent in pigeons: functional similarities to the mammalian prefrontal system? Güntürkün O. **J Hirnforsch** 1997;38(1):133–43

Role of presynaptic inputs to proprioceptive afferents in tuning sensorimotor pathways of an insect joint control network. Sauer AE, et al. **J Neurobiol** 1997 Apr; 32(4):359–76

The noradrenergic innervation of identified hypothalamic magnocellular somata and its contribution to lactation–induced synaptic plasticity. Michaloudi HC, et al. **J Neuroendocrinol** 1997 Jan;9(1):17–23

Postgeniculate afferent visual system and visual higher cortical function, 1994. Wall M. **J Neuroophthalmol** 1996 Mar;16(1):23–32 (52 ref.)

In vitro characterization of a peripheral afferent pathway of the rat after chronic sciatic nerve section. Babbedge RC, et al. **J Neurophysiol** 1996 Nov;76(5):3169–77

Active–sleep–related suppression of feline trigeminal sensory neurons: evidence implicating presynaptic inhibition via a process of primary afferent depolarization. Cairns BE, et al. **J Neurophysiol** 1996 Mar;75(3):1152–62

Stretch sensitivity of mechanoreceptor neurons in rat hairy skin. Grigg P. **J Neurophysiol** 1996 Nov;76(5):2886–95

Contribution of hind limb flexor muscle afferents to the timing of phase transitions in the cat step cycle. Hiebert GW, et al. **J Neurophysiol** 1996 Mar;75(3):1126–37

Uncrossed disynaptic inhibition of second–order vestibular neurons and its interaction with monosynaptic excitation from vestibular nerve afferent fibers in the frog. Straka H, et al. **J Neurophysiol** 1996 Nov;76(5):3087–101

Low–threshold mechanoreceptive afferents in the human lingual nerve. Trulsson M, et al. **J Neurophysiol** 1997 Feb; 77(2):737–48

Respiratory neurons mediating the Breuer–Hering reflex prolongation of expiration in rat. Hayashi F, et al. **J Neurosci** 1996 Oct 15;16(20):6526–36

Formation of specific monosynaptic connections between muscle spindle afferents and motoneurons in the mouse. Mears SC, et al. **J Neurosci** 1997 May 1;17(9):3128–35

Unit identification, sampling bias and technical issues in microneurographic recordings from muscle spindle afferents. Burke D. **J Neurosci Methods** 1997 Jun 27; 74(2):137–44 (39 ref.)

Assessing changes in presynaptic inhibition of Ia afferents during movement in humans. Pierrot–Deseilligny E. **J Neurosci Methods** 1997 Jun 27;74(2):189–99 (46 ref.)

Target and afferents interact to control developmental cell death in the mesencephalic parabigeminal nucleus of the rat. Piñón LG, et al. **J Neurosci Res** 1996 Jul 15; 45(2):174–82

Group I extensor afferents evoke disynaptic EPSPs in cat hindlimb extensor motorneurones during fictive locomotion. Angel MJ, et al. **J Physiol (Lond)** 1996 Aug 1;494 (Pt 3):851–61

Movement illusions evoked by ensemble cutaneous input from the dorsum of the human hand. Collins DF, et al. **J Physiol (Lond)** 1996 Nov 1;496 (Pt 3):857–71

Excitability changes in human cutaneous afferents induced by prolonged repetitive axonal activity. Kiernan MC, et al. **J Physiol (Lond)** 1997 Apr 1;500 (Pt 1):255–64

Pancreatic secretion evoked by cholecystokinin and non–cholecystokinin–dependent duodenal stimuli via vagal afferent fibres in the rat. Li Y, et al. **J Physiol (Lond)** 1996 Aug 1;494 (Pt 3):773–82

Tendon organ sensitivity to steady–state isotonic contraction of in–series motor units in feline peroneus tertius muscle. Petit J, et al. **J Physiol (Lond)** 1997 Apr 1;500 (Pt 1):227–33

High–frequency tuning properties of bullfrog lagenar vestibular afferent fibers. Cortopassi KA, et al. **J Vestib Res** 1996 Mar–Apr;6(2):105–19

Primary afferent nerves mediate in part beta–adrenoceptor stimulation–induced mesenteric hyperemia in rats. Seno K, et al. **Life Sci** 1996;59(15):1203–9

Somatosensory afferent inputs release 5–HT and NA from the spinal cord. Men D, et al. **Neurochem Res** 1996 Dec; 21(12):1515–9

Reciprocal talk between the auditory thalamus and the hypothalamus: an antidromic study. Cheng MF, et al. **Neuroreport** 1997 Feb 10;8(3):653–8

Intercellular communication between dorsal root ganglion cells and colonic smooth muscle cells in vitro. Ennes HS, et al. **Neuroreport** 1997 Feb 10;8(3):733–7

Corticofugal feedback improves the timing of retino–geniculate signal transmission. Funke K, et al. **Neuroreport** 1996 Sep 2;7(13):2130–4

How effective is integration of information from muscle afferents in spinal pathways? Jankowska E, et al. **Neuroreport** 1996 Oct 2;7(14):2337–40

The progressive tactile hyperalgesia induced by peripheral inflammation is nerve growth factor dependent. Ma QP, et al. **Neuroreport** 1997 Mar 3;8(4):807–10

Sprouting of A beta fibers into lamina II of the rat dorsal horn in peripheral neuropathy. Lekan HA, et al. **Neurosci Lett** 1996 Apr 26;208(3):147–50

Influences of laryngeal afferent inputs on intralaryngeal muscle activity during vocalization in the cat. Shiba K, et al. **Neurosci Res** 1997 Jan;27(1):85–92

Electrophysiological demonstration of N–methyl–D–aspartate receptors at the afferent synapse of catfish electroreceptor organs. Andrianov GN, et al. **Neuroscience** 1997 Aug;79(4):1231–7

Activity–dependent slowing of conduction velocity provides a method for identifying different functional classes of C–fibre in the rat saphenous nerve. Gee MD, et al. **Neuroscience** 1996 Aug;73(3):667–75

Effects of cutaneous afferent input on fatigue–induced changes in fusimotor activity of decerebrate cats. Ljubisavljević M, et al. **Neuroscience** 1997 Aug; 79(3):935–42

Differential c–fos expression in the nucleus of the solitary tract and spinal cord following noxious gastric distention in the rat. Traub RJ, et al. **Neuroscience** 1996 Oct; 74(3):873–84

Patterns of overlap and segregation between insular cortical, intermediodorsal thalamic and basal amygdaloid afferents in the nucleus accumbens of the rat. Wright CI, et al. **Neuroscience** 1996 Jul;73(2):359–73

Cholinergic innervation and receptors in the cerebellum. Jaarsma D, et al. **Prog Brain Res** 1997;114:67–96 (113 ref.)

Primary motor cortex influences on the descending and ascending systems. Canedo A. **Prog Neurobiol** 1997 Feb; 51(3):287–335 (531 ref.)

Role of laryngeal afferents in cough. Sant'Ambrogio G, et al. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):309–14

The immediate effects of peripheral deafferentation on neurons of the cuneate nucleus in raccoons. Northgrave SA, et al. **Somatosens Mot Res** 1996;13(2):103–13

[Spinal cord: afferent interactions] Pleshchinskii IN, et al. **Fiziol Cheloveka** 1996 Jan–Feb;22(1):123–30 (97 ref.) **(Rus)**

PHYSIOPATHOLOGY

Treatment of deafferentation pain by chronic stimulation of the motor cortex: report of a series of 20 cases. Nguyen JP, et al. **Acta Neurochir Suppl (Wien)** 1997;68:54–60

Spatiotemporal aspects of sympathetic C–fiber afferent activity in pressor reflex during abdominal ischemia. Pan HL, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1928–36

Cortical facilitatory action on centralis lateralis thalamic activity during the development of carrageenin–produced inflammation. Condés–Lara M, et al. **Arch Med Res** 1996 Autumn;27(3):265–73

Afferent mechanism of cortical myoclonus studied by proprioception–related SEPs. Mima T, et al. **Electroencephalogr Clin Neurophysiol** 1997 Jan;104(1):51–9

Stable analogues of cyclic AMP but not cyclic GMP sensitize unmyelinated primary afferents in rat skin to heat stimulation but not to inflammatory mediators, in vitro. Kress M, et al. **Neuroscience** 1996 Sep;74(2):609–17

[Changes in the somatosensory evoked potentials in patients with amputated limbs with and without phantom pain syndrome] Reshetniak VK, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):4–7 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Ultrastructural features of tyrosine–hydroxylase–immunoreactive afferents and their targets in the rat amygdala. Asan E. **Cell Tissue Res** 1997 Jun;288(3):449–69

Larval development of tectal efferents and afferents in Xenopus laevis (Amphibia Anura). Chahoud BH, et al. **J Hirnforsch** 1996;37(4):519–35

Striatal neuropeptide Y neurones are not a target for thalamic afferent fibres. Kachidian P, et al. **Neuroreport** 1996 Jul 8;7(10):1665–9

NMDA and AMPA receptors in the lateral nucleus of the amygdala are postsynaptic to auditory thalamic afferents. Farb CR, et al. **Synapse** 1997 Oct;27(2):106–21

AFFINITY, ANTIBODY see **ANTIBODY AFFINITY**

AFFINITY LABELING REAGENTS see **AFFINITY LABELS**

AFFINITY LABELS

Identification of the nonsubstrate steroid binding site of rat liver glutathione S–transferase, isozyme 1–1, by the steroid affinity label, 3beta–(iodoacetoxy)dehydroisoandrosterone. Barycki JJ, et al. **Arch Biochem Biophys** 1997 Sep 1; 345(1):16–31

Application of photoaffinity labeling with [11,12–3H]all–trans–retinoic acid to characterization of rat liver microsomal UDP–glucuronosyltransferase(s) with activity toward retinoic acid. Little JM, et al. **Biochem Biophys Res Commun** 1997 Jan 23;230(3):497–500

Photoaffinity labeling of peripheral benzodiazepine receptors in R–3327 Dunning prostatic tumors. Alenfall J, et al. **Biochem Pharmacol** 1996 Apr 26;51(8):1009–13

p–(4–Hydroxybenzoyl)phenylalanine: a photoreactive amino acid analog amenable to radioiodination for elucidation of peptide–protein interaction. Application to substance P receptor. Wilson CJ, et al. **Biochemistry** 1997 Apr 15; 36(15):4542–51

Improved targeting of an anti–epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N–succinimidyl 5–iodo–3–pyridinecarboxylate. Reist CJ, et al. **Cancer Res** 1997 Apr 15;57(8):1510–5

Affinity precipitation: a novel approach to protein purification. Irwin JA, et al. **Essays Biochem** 1995; 29:137–56 (41 ref.)

Chemical arrows for enzymatic targets. Colman RF. **FASEB J** 1997 Mar;11(4):217–26 (27 ref.)

Monoclonal antibodies against Nalpha–(5'–phosphopyridoxyl)–L–lysine. Screening and spectrum of pyridoxal 5'–phosphate–dependent activities toward amino acids. Gramatikova SI, et al. **J Biol Chem** 1997 Apr 11;272(15):9779–84

A procedure for in situ hybridization combined with retrograde labeling of neurons: application to the study of cell adhesion molecule expression in DiI–labeled rat pyramidal neurons. Fujimori KE, et al. **J Histochem Cytochem** 1997 Mar;45(3):455–9

Dye–affinity techniques for bioprocessing: recent developments. Garg N, et al. **J Mol Recognit** 1996 Jul–Aug; 9(4):259–74 (109 ref.)

Affinity labels for NAD(P)–specific sites. Colman RF. **Methods Enzymol** 1997;280:186–203

Covalent modification of G proteins by affinity labeling. Hohenegger M, et al. **Methods Mol Biol** 1997;83:179–90

AFFINITY LABELS

(12 ref.)
A simple method for 3'-labeling of RNA. Huang Z, et al. **Nucleic Acids Res** 1996 Nov 1;24(21):4360-1
A photolabile 2',3'-dideoxyuridylate analog bearing an aryl(trifluoromethyl)diazirine moiety: photoaffinity labeling of HIV-1 reverse transcriptase. Yamaguchi T, et al. **Nucleic Acids Res** 1996 Sep 1;24(17):3364-9
Quantitative approach for detection and characterization of formyl peptide receptor in solution using a photoaffinity ligand. Lala A, et al. **Pept Res** 1996 Mar-Apr;9(2):58-60

ANALYSIS

Insecticidal quinazoline derivatives with (trifluoromethyl)diazirinyl and azido substituents as NADH:ubiquinone oxidoreductase inhibitors and candidate photoaffinity probes. Latli B, et al. **Chem Res Toxicol** 1996 Mar;9(2):445-50

CHEMICAL SYNTHESIS

Synthesis of the photoaffinity label [1'-14C]-6C-(azimethyl)octylglucoside and its reaction with isolated renal brush border membranes. Kipp H, et al. **Anal Biochem** 1997 Feb 1;245(1):61-8
Synthesis and use of a biotinylated 3-azidophenothiazine to photolabel both amino- and carboxyl-terminal sites in calmodulin. DeLaLuz PJ, et al. **Bioconjug Chem** 1995 Sep-Oct;6(5):558-66
Synthesis and binding affinity of bidentate phenothiazines with two different photoactive groups. Golinski M, et al. **Bioconjug Chem** 1995 Sep-Oct;6(5):567-72
Synthesis of a novel [125I]neonicotinoid photoaffinity probe for the Drosophila nicotinic acetylcholine receptor. Latli B, et al. **Bioconjug Chem** 1997 Jan-Feb;8(1):7-14
A new method of synthesizing biopolymeric affinity ligands. Chaga GS, et al. **Biotechnol Appl Biochem** 1997 Aug;26 (Pt 1):7-14
Synthesis and characterization of a carbene-generating biotinylated N-acetylglucosamine for photoaffinity labeling of beta-(1-->4)-galactosyltransferase. Hatanka Y, et al. **Carbohydr Res** 1996 Nov 20;294:95-108
Synthesis and application of alpha-D-mannosyl clusters as photoaffinity ligands for mannose-binding proteins: concanavalin A as a model receptor. Lehmann J, et al. **Carbohydr Res** 1996 Nov 20;294:65-94
Synthesis of a photoaffinity labeling analogue of the inactivating peptide of the Shaker B potassium channel. Fernandez AM, et al. **FEBS Lett** 1996 Nov 25;398(1):81-6
Specific photoaffinity labelling of a ferripyoverdin outer membrane receptor of Pseudomonas aeruginosa. Ocaktan A, et al. **FEBS Lett** 1996 Nov 4;396(2-3):243-7
Detection of the receptor for the human urokinase-type plasminogen activator using fluoresceinated uPA. Ciccocioppo R, et al. **J Histochem Cytochem** 1997 Sep; 45(9):1307-13
Platinum porphyrins as phosphorescent label for time-resolved microscopy. de Haas RR, et al. **J Histochem Cytochem** 1997 Sep;45(9):1279-92
Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties. Lobaccaro C, et al. **J Med Chem** 1997 Jul 4;40(14):2217-27
Understanding the mechanism of sweet taste: synthesis of ultrapotent guanidinoacetic acid photoaffinity labeling reagents. Nagarajan S, et al. **J Med Chem** 1996 Oct 11; 39(21):4167-72
Irreversible inhibition of high-affinity [3H]kainate binding by a novel photoactivatable analogue: (2'S,3'S,4'R)-2'-carboxy-4'-(2-diazo-1-oxo-3, 3,3-trifluoropropyl)-3'-pyrrolidinyl acetate. Willis CL, et al. **J Neurochem** 1997 Apr;68(4):1503-10
Synthesis and characterization of a photoactivatable analog of corticotropin-releasing factor for specific receptor labeling. Rühmann A, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10609-13

CHEMISTRY

C-terminal incorporation of fluorogenic and affinity labels using wild-type and mutagenized carboxypeptidase Y. Stennicke HR, et al. **Anal Biochem** 1997 May 15; 248(1):141-8
High efficiency photolabeling of human serum albumin and human gamma-globulin with [14C]methyl 4-azido-2,3,5,6-tetrafluorobenzoate. Pandurangi RS, et al. **Bioconjug Chem** 1995 Sep-Oct;6(5):630-4
Location of two photoaffinity-labeled sites on the ligand-binding domain of retinoic acid receptor alpha. Sasaki T, et al. **Biol Pharm Bull** 1996 May;19(5):659-64
The synthesis and biological evaluation of 4-p-nitrobenzylthio-v-triazolo[4,5-d]pyridazine and imidazo[4,5-d]pyridazine ribosides as potential nucleoside transport inhibitors. Bussolari JC, et al. **Bioorg Med Chem** 1996 Oct;4(10):1725-31
Novel photoactivatable agonist of the nicotinic acetylcholine receptor of potential use for exploring the functional activated state. Kotzyba-Hibert F, et al. **J Neurochem** 1996 Dec;67(6):2557-65
Comparison of the photochemical behavior of four different photoactivatable probes. Weber PJ, et al. **J Pept Res** 1997 May;49(5):375-83
Benzophenone photoprobes for phosphoinositides, peptides and drugs. Prestwich GD, et al. **Photochem Photobiol** 1997 Feb;65(2):222-34 (95 ref.)
A new strategy for introducing photoactivatable 4-thiouridine ((4S)U) into specific positions in a long RNA molecule. Yu YT, et al. **RNA** 1997 Jul;3(7):807-10

METABOLISM

Effective non-radioactive method of surface labeling Cryptosporidium parvum sporozoites. Nesterenko MV, et al. **Acta Trop** 1997 Apr 30;65(1):53-7
Photoaffinity labeling of yeast farnesyl protein transferase and enzymatic synthesis of a Ras protein incorporating a photoactive isoprenoid. Edelstein RL, et al. **Biochem Biophys Res Commun** 1997 Jun 18;235(2):377-82
Photoaffinity labelling of human poly(ADP-ribose) polymerase catalytic domain. Kim H, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):469-75
Covalent labeling of muscarinic acetylcholine receptors by tritiated aryldiazonium photoprobes [published erratum appears in Biochem Pharmacol 1997 Jun 15;53(12):1945] Autelitano F, et al. **Biochem Pharmacol** 1997 Feb 21; 53(4):501-10
Synthesis of a radioactive azido derivative of thapsigargin and photolabeling of the sarcoplasmic reticulum ATPase. Hua S, et al. **Biochemistry** 1997 Sep 30;36(39):11865-72
[3H](azidophenyl)ureido taxoid photolabels peptide amino acids 281-304 of alpha-tubulin. Loeb C, et al. **Biochemistry** 1997 Apr 1;36(13):3820-5
Conformational changes and fusion activity of vesicular stomatitis virus glycoprotein: [125I]iodonaphthyl azide photolabeling studies in biological membranes. Pak CC, et al. **Biochemistry** 1997 Jul 22;36(29):8890-6
Affinity radiolabeling identifies peptides associated with the isomerase activity of human type I (placental) 3beta-hydroxysteroid dehydrogenase/isomerase. Thomas JL, et al. **Biochemistry** 1997 Jul 22;36(29):9029-34
FSBA modifies both alpha- and beta-subunits of F1 specifically and can be bound together with AXP at the same alpha-subunit. Hartog AF, et al. **Biochim Biophys Acta** 1997 Jan 16;1318(1-2):107-22
The anion transporter and a 28 kDa protein are selectively photolabeled by p-azidobenzylphlorizin under conditions that alter RBC morphology, flexibility, and volume. Hoefner DM, et al. **Biochim Biophys Acta** 1997 Jul 25; 1327(2):231-41
Modification of membrane-bound F1 by p-fluorosulfonylbenzoyl-5'-adenosine: sites of binding and effect on activity. van der Zwet-de Graaff I, et al. **Biochim Biophys Acta** 1997 Jan 16;1318(1-2):123-32
Woodchuck p-glycoprotein found in virus-induced hepatocellular carcinomas binds anticancer drugs. Dunn SE, et al. **Cancer Lett** 1996 Dec 20;110(1-2):177-80
Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Hu YP, et al. **Cancer Lett** 1996 Dec 3;109(1-2):203-9
Affinity labeling of Escherichia coli histidyl-tRNA synthetase with reactive ATP analogues. Identification of labeled amino acid residues by matrix assisted laser desorption-ionization mass spectrometry. Gillet S, et al. **Eur J Biochem** 1996 Oct 1;241(1):133-41
Affinity labeling of Escherichia coli glucosamine-6-phosphate synthase with a fructose 6-phosphate analog--evidence for proximity between the N-terminal cysteine and the fructose-6-phosphate-binding site. Leriche C, et al. **Eur J Biochem** 1997 Apr 15; 245(2):418-22
[3H]2-(2-benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors. Lione LA, et al. **Eur J Pharmacol** 1996 May 23;304(1-3):221-9
Molecular weight determination of the hepatic vasopressin receptor with a high-affinity photoprobe. Barbeau D, et al. **Int J Pept Protein Res** 1996 Oct;48(4):364-73
Determination of the affinity constants of pea lectin for neutral sugars by capillary affinophoresis with a monoligand affinophore. Shimura K, et al. **J Biochem (Tokyo)** 1996 Dec;120(6):1146-52
Modification of domains of alpha and beta subunits of F1-ATPase from the thermophylic bacterium PS3, in their isolated and associated forms, by 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate (BzATP). Bar-Zvi D, et al. **J Bioenerg Biomembr** 1996 Dec;28(6):471-81
Photoaffinity labeling of NAD(+)-linked enzymes. Ensor CM, et al. **Methods Enzymol** 1997;280:204-10
Synthesis and application of pyridoxal polyphosphoryl derivatives as active-site probes for nucleotide-binding enzymes. Fukui T, et al. **Methods Enzymol** 1997;280:41-50
Labelling of I2B-imidazoline receptors by [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes. Alemany R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jul; 356(1):39-47
Tyrosine 8 contributes to catalysis but is not required for activity of rat liver glutathione S-transferase, 1-1. Wang J, et al. **Protein Sci** 1996 Jun;5(6):1032-42

PHARMACOKINETICS

Measurement of nitrobenzylthioinosine in plasma and erythrocytes: a pharmacokinetic study in mice. Gati WP, et al. **Cancer Chemother Pharmacol** 1997;40(4):342-6

PHARMACOLOGY

Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine. Rahn JJ, et al. **Antimicrob Agents Chemother** 1997 May;41(5):918-23
FSBA modifies both alpha- and beta-subunits of F1 specifically and can be bound together with AXP at the same alpha-subunit. Hartog AF, et al. **Biochim Biophys Acta** 1997 Jan 16;1318(1-2):107-22
Modification of membrane-bound F1 by p-fluorosulfonylbenzoyl-5'-adenosine: sites of binding and effect on activity. van der Zwet-de Graaff I, et al. **Biochim Biophys Acta** 1997 Jan 16;1318(1-2):123-32
Characterization of a benzodiazepine receptor site with exceptionally high affinity for Ro 15-4513 in the rat CNS. Mehta AK, et al. **Brain Res** 1995 Dec 18;704(2):289-97
Development of kainate binding sites in chick cerebellum demonstrated with the photoaffinity ligand [3H]ABCPA. Voukelatou G, et al. **Int J Dev Neurosci** 1996 Oct; 14(6):779-83
Irreversible inhibition of hepatic fatty acid salt uptake by photoaffinity labeling with 11, 11-azistearate. Schmider W, et al. **J Lipid Res** 1996 Apr;37(4):739-53
A guinea pig ileum preparation devoid of functional kappa receptors: a new in vitro pharmacologic assay for mu-opioid ligands. Schwartz RW, et al. **Life Sci** 1997; 60(15):PL235-9

AFIBRINOGENEMIA

CHEMICALLY INDUCED

Hypofibrinogenemia induced by prednisolone therapy in a patient with chronic lymphocytic leukemia complicated with autoimmune hemolytic anemia [letter] Yokose N, et al. **Am J Hematol** 1997 Jul;55(3):166-7
[A study on the plasma fibrinogen decrease induced by danazol] Fukunaga T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jun;48(6):419-22 **(Jpn)**

COMPLICATIONS

Congenital afibrinogenemia: treatment of excessive menstrual bleeding with continuous oral contraceptive [letter] Rizk DE, et al. **Am J Hematol** 1996 Jul;52(3):237-8
Bilateral vertebral artery dissection in a patient with afibrinogenemia. García-Moncó JC, et al. **Stroke** 1996 Dec; 27(12):2325-7

CONGENITAL

Congenital afibrinogenemia: treatment of excessive menstrual bleeding with continuous oral contraceptive [letter] Rizk DE, et al. **Am J Hematol** 1996 Jul;52(3):237-8
Congenital dysfibrinogenemia. Martinez J. **Curr Opin Hematol** 1997 Sep;4(5):357-65 (91 ref.)
Successful pregnancy outcome in a patient with both congenital hypofibrinogenemia and protein S deficiency. Funai EF, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):858

DIAGNOSIS

[Comparison of coagulation screening test results in two cases having dysfibrinogen] Terasawa F, et al. **Rinsho Byori** 1996 Aug;44(8):791-6 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Congenital afibrinogenemia with successful delivery. Kobayashi T, et al. **Gynecol Obstet Invest** 1996;42(1):66-9

GENETICS

Fibrinogen Matsumoto II: gamma 308 Asn-->Lys (AAT-->AAG) mutation associated with bleeding tendency. Okumura N, et al. **Br J Haematol** 1996 Sep; 94(3):526-8
The structure-function relationship of hereditary dysfibrinogens. Matsuda M. **Int J Hematol** 1996 Oct; 64(3-4):167-79 (83 ref.)

HISTORY

William Hewson and the lady without the coagulable lymph. Ingram GI. **Br J Obstet Gynaecol** 1996 Oct;103(10):967

PHYSIOPATHOLOGY

Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Bugge TH, et al. **Cell** 1996 Nov 15;87(4):709-19

VETERINARY

Dysfibrinogenemia or afibrinogenemia in a Border Leicester lamb. Fecteau G, et al. **Can Vet J** 1997 Jul;38(7):443-4

AFLATOXIN B1

Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Kensler TW, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Aug;6(8):603-10
Correspondence re: C.V. Rao, et al., Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-

induced lymphoma formation by oltipraz. Cancer Res., 56: 3395–3398, 1996 [letter] Roebuck BD, et al. **Cancer Res** 1997 Jul 1;57(13):2806–7

Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Shen HM, et al. **Mutat Res** 1996 Oct;366(1):23–44 (167 ref.)

Inhibition of aflatoxin B1– and N–nitrosodiethylamine–induced liver preneoplastic foci in rats fed naturally occurring allyl sulfides. Haber–Mignard D, et al. **Nutr Cancer** 1996;25(1):61–70

An intercalation inhibitor altering the target selectivity of DNA damaging agents: synthesis of site–specific aflatoxin B1 adducts in a p53 mutational hotspot. Kobertz WR, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9579–84

ADMINISTRATION & DOSAGE

Dose–related increase in liver heme catabolism during rabbit aflatoxicosis. Guerre P, et al. **Toxicol Lett** 1997 Jul 21; 92(2):101–8

ANALOGS & DERIVATIVES

Conjugation of highly reactive aflatoxin B1 exo–8,9–epoxide catalyzed by rat and human glutathione transferases: estimation of kinetic parameters. Johnson WW, et al. **Biochemistry** 1997 Mar 18;36(11):3056–60

Effects of multiple risk factors for hepatocellular carcinoma on formation of aflatoxin B1–DNA adducts. Yu MW, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):613–9

Effect of aflatoxin B1–8,9–epoxide–DNA adducts on transcription of a supF gene fragment. Yu FL, et al. **Cancer Lett** 1996 Dec 3;109(1–2):77–83

Aflatoxin B1 8,9–epoxide hydrolysis in the presence of rat and human epoxide hydrolase. Johnson WW, et al. **Chem Res Toxicol** 1997 Jun;10(6):672–6

Binding of the aflatoxin–glutathione conjugate to mouse glutathione S–transferase A3–3 is saturated at only one ligand per dimer. McHugh TE, et al. **J Biol Chem** 1996 Nov 1;271(44):27470–4

Reaction of aflatoxin B1 exo–8,9–epoxide with DNA: kinetic analysis of covalent binding and DNA–induced hydrolysis. Johnson WW, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6121–5

Aflatoxin B1 activation in human lung. Kelly JD, et al. **Toxicol Appl Pharmacol** 1997 May;144(1):88–95

ANALYSIS

Determination of aflatoxin B1–DNA adduct in rat liver by enzyme immunoassay. Vidyasagar T, et al. **Analyst** 1997 Jun;122(6):609–13

Aflatoxin variability in pistachios. Mahoney NE, et al. **Appl Environ Microbiol** 1996 Apr;62(4):1197–202

p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Lunn RM, et al. **Cancer Res** 1997 Aug 15;57(16):3471–7

Aflatoxin B1–induced DNA adduct formation and p53 mutations in CYP450–expressing human liver cell lines. Macé K, et al. **Carcinogenesis** 1997 Jul;18(7):1291–7

Aflatoxin B1 contamination in maize samples collected from different geographical regions of India—a multicentre study. Bhat RV, et al. **Food Addit Contam** 1997 Feb–Mar; 14(2):151–6

Determination of aflatoxin B1 in pistachio kernels and shells. Scholten JM, et al. **J AOAC Int** 1996 Nov–Dec; 79(6):1360–4

Aflatoxin B1 in common Egyptian foods. Selim MI, et al. **J AOAC Int** 1996 Sep–Oct;79(5):1124–9

ANTAGONISTS & INHIBITORS

Inhibition of aflatoxin B1–induced initiation of hepatocarcinogenesis in the rat by green tea. Qin G, et al. **Cancer Lett** 1997 Jan 30;112(2):149–54

Protective effect of food additives on aflatoxin–induced mutagenicity and hepatocarcinogenicity. Soni KB, et al. **Cancer Lett** 1997 May 19;115(2):129–33

Anti–aflatoxigenic activity of Lactobacillus casei pseudoplantarum. Gourama H, et al. **Int J Food Microbiol** 1997 Feb;34(2):131–43

Effect of a lignan–enriched extract of Schisandra chinensis on aflatoxin B1 and cadmium chloride–induced hepatotoxicity in rats. Ip SP, et al. **Pharmacol Toxicol** 1996 Jun;78(6):413–6

BIOSYNTHESIS

Characterization of the function of the ver–1A and ver–1B genes, involved in aflatoxin biosynthesis in Aspergillus parasiticus. Liang SH, et al. **Appl Environ Microbiol** 1996 Dec;62(12):4568–75

Analysis of mechanisms regulating expression of the ver–1 gene, involved in aflatoxin biosynthesis. Liang SH, et al. **Appl Environ Microbiol** 1997 Mar;63(3):1058–65

Development of polyclonal antibodies for detection of aflatoxigenic molds involving culture filtrate and chimeric proteins expressed in Escherichia coli. Shapira R, et al. **Appl Environ Microbiol** 1997 Mar;63(3):990–5

Demonstration of the catalytic roles and evidence for the physical association of type I fatty acid synthases and a polyketide synthase in the biosynthesis of aflatoxin B1. Watanabe CM, et al. **Chem Biol** 1996 Jun;3(6):463–9

Heterologous expression, isolation, and characterization of versicolorin B synthase from Aspergillus parasiticus. A key enzyme in the aflatoxin B1 biosynthetic pathway. Silva JC, et al. **J Biol Chem** 1997 Jan 10;272(2):804–13

Influence of white light, near–UV irradiation and other environmental conditions on production of aflatoxin B1 by Aspergillus flavus and ochratoxin A by Aspergillus ochraceus. Aziz NH, et al. **Nahrung** 1997 Jun;41(3):150–4

BLOOD

Aflatoxin: is it a neglected threat for formula–fed infants? Akşit S, et al. **Acta Paediatr Jpn** 1997 Feb;39(1):34–6

Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin–albumin adducts and risk of liver cancer. Kensler TW, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Aug;6(8):603–10

IMMUNOLOGY

Preparation and characterization of monoclonal antibodies against aflatoxin B1. Lu G, et al. **Chin J Biotechnol** 1995; 11(4):253–8

Mucosal unresponsiveness to aflatoxin B1 is not broken by cholera toxin. Oliver AR, et al. **Immunol Cell Biol** 1997 Feb;75(1):47–53

METABOLISM

Activation of toxic chemicals by cytochrome P450 enzymes: regio– and stereoselective oxidation of aflatoxin B1. Guengerich FP, et al. **Adv Exp Med Biol** 1996;387:7–15 (38 ref.)

Metabolism of aflatoxin B1 by human hepatocytes in primary culture. Langouet S, et al. **Adv Exp Med Biol** 1996; 387:439–42

Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B1. Yanagimoto T, et al. **Arch Biochem Biophys** 1997 Apr 15;340(2):215–8

Modulation of aflatoxin B1 biotransformation by beta–naphthoflavone in isolated rabbit lung cells. Im SH, et al. **Arch Toxicol** 1996;71(1–2):72–9

Effects of multiple risk factors for hepatocellular carcinoma on formation of aflatoxin B1–DNA adducts. Yu MW, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):613–9

Comparison of the effect of low– and high–dose dietary butylated hydroxytoluene on microsome–mediated aflatoxin B1–DNA binding. Allameh A. **Cancer Lett** 1997 Mar 19;114(1–2):217–20

Mutational specificity of aflatoxin B1. Comparison of in vivo host–mediated assay with in vitro S9 metabolic activation. Prieto–Alamo MJ, et al. **Carcinogenesis** 1996 Sep; 17(9):1997–2002

Interaction of aflatoxin B1 with cytochrome P450 2A5 and its mutants: correlation with metabolic activation and toxicity. Pelkonen P, et al. **Chem Res Toxicol** 1997 Jan; 10(1):85–90

Involvement of cytochrome P450, glutathione S–transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. Guengerich FP, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:557–62

Growth and aflatoxin B1 production on olives and olive paste by moulds isolated from 'Turkish–style' natural black olives in brine. Eltem R. **Int J Food Microbiol** 1996 Sep; 32(1–2):217–23

ATP–dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Loe DW, et al. **Mol Pharmacol** 1997 Jun;51(6):1034–41

Bioactivation and inactivation of aflatoxin B1 by human, mouse and rat liver preparations: effect on SCE in human mononuclear leucocytes. Wilson AS, et al. **Mutat Res** 1997 Feb 3;373(2):257–64

In vitro microsome–mediated aflatoxin B1–DNA binding and its inhibition by cytosol of various organs of the hamster and quail. Kono M, et al. **Mycopathologia** 1995 Nov; 132(2):117–9

The kinetics of aflatoxin B1 oxidation by human cDNA–expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Gallagher EP, et al. **Toxicol Appl Pharmacol** 1996 Dec;141(2):595–606

Glutathione S–transferase–catalyzed conjugation of bioactivated aflatoxin B1 in rabbit lung and liver. Stewart RK, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):499–507

CYP1A induction by beta–naphthoflavone, Aroclor 1254, and 2,3,7,8–tetrachlorodibenzo–p–dioxin and its influence on aflatoxin B1 metabolism and DNA adduction in zebrafish. Troxel CM, et al. **Toxicol Appl Pharmacol** 1997 Sep;146(1):69–78

In vivo aflatoxin B1 metabolism and hepatic DNA adduction in zebrafish (Danio rerio). Troxel CM, et al. **Toxicol Appl Pharmacol** 1997 Mar;143(1):213–20

Dietary restriction modulated carcinogen–DNA adduct formation and the carcinogen–induced DNA strand breaks. Chou MW, et al. **Toxicol Lett** 1997 Jun 16;92(1):21–30

Aflatoxin B1 epoxidation catalysed by partially purified human liver lipoxygenase. Roy SK, et al. **Xenobiotica** 1997 Feb;27(2):231–41

PHARMACOKINETICS

A case of self–experimentation [editorial] London NL, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jul;6(7):475–6

In vivo activation of aflatoxin B1 in C57BL/6N mice carrying a human fetus–specific CYP3A7 gene. Li Y, et al. **Cancer Res** 1997 Feb 15;57(4):641–5

Biotransformation of aflatoxin B1 in human lung. Donnelly PJ, et al. **Carcinogenesis** 1996 Nov;17(11):2487–94

Bioactivation of aflatoxin B1 in the nasal and tracheal mucosa in swine. Larsson P, et al. **J Anim Sci** 1996 Jul; 74(7):1672–80

ATP–dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Loe DW, et al. **Mol Pharmacol** 1997 Jun;51(6):1034–41

Aflatoxin B1 activation in human lung. Kelly JD, et al. **Toxicol Appl Pharmacol** 1997 May;144(1):88–95

Glutathione S–transferase–catalyzed conjugation of bioactivated aflatoxin B1 in rabbit lung and liver. Stewart RK, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):499–507

PHARMACOLOGY

Chemoprevention of carcinogen–DNA binding: the relative role of different oxygenated substituents on 4–methylcoumarins in the inhibition of aflatoxin B1–DNA binding in vitro. Raj HG, et al. **Bioorg Med Chem** 1996 Dec;4(12):2225–8

Mutational specificity of aflatoxin B1. Comparison of in vivo host–mediated assay with in vitro S9 metabolic activation. Prieto–Alamo MJ, et al. **Carcinogenesis** 1996 Sep; 17(9):1997–2002

In vitro activation of the human Harvey–ras proto–oncogene by aflatoxin B1. Riley J, et al. **Carcinogenesis** 1997 May; 18(5):905–10

Detection of elevated reactive oxygen species level in cultured rat hepatocytes treated with aflatoxin B1. Shen HM, et al. **Free Radic Biol Med** 1996;21(2):139–46

Modulation by dietary copper of aflatoxin B1–induced activity of DNA repair enzymes poly (ADP–ribose) polymerase, DNA polymerase beta and DNA ligase. Webster RP, et al. **In Vivo** 1996 Sep–Oct;10(5):533–6

Mycotoxin T–2 and aflatoxin B1 as immunosuppressors in mice chronically infected with Toxoplasma gondii. Venturini MC, et al. **J Comp Pathol** 1996 Oct;115(3):229–37

Effects of aflatoxin B1 on the sensitivity of the rat central nervous system to pentobarbital–Na racemate. Stětinová V, et al. **Pol J Pharmacol** 1995 Sep–Oct;47(5):393–9

The effect of aflatoxin B1 on the expression of early response genes and transforming growth factor–alpha in CCl4 induced rat liver injury. Hong SW, et al. **Yonsei Med J** 1997 Jun;38(3):167–77

TOXICITY

The 1995 Pharmacological Society of Canada Merck Frosst Award. Cellular and molecular targets in pulmonary chemical carcinogenesis: studies with aflatoxin B1. Massey TE. **Can J Physiol Pharmacol** 1996 Jun;74(6):621–8 (58 ref.)

Modulation of aflatoxin B1 carcinogenicity, genotoxicity and metabolism in rat liver by dietary carotenoids: evidence for a protective effect of CYP1A inducers. Gradelet S, et al. **Cancer Lett** 1997 Mar 19;114(1–2):221–3

Inhibition of aflatoxin B1–induced initiation of hepatocarcinogenesis in the rat by green tea. Qin G, et al. **Cancer Lett** 1997 Jan 30;112(2):149–54

Protective effect of food additives on aflatoxin–induced mutagenicity and hepatocarcinogenicity. Soni KB, et al. **Cancer Lett** 1997 May 19;115(2):129–33

Genotoxicity of aflatoxin B1: evidence for a recombination–mediated mechanism in Saccharomyces cerevisiae [published erratum appears in Cancer Res 1997 Feb 15;57(4):793] Sengstag C, et al. **Cancer Res** 1996 Dec 1;56(23):5457–65

Species–specific differences in hepatic mutant frequency and mutational spectrum among lambda/lacI transgenic rats and mice following exposure to aflatoxin B1. Dycaico MJ, et al. **Carcinogenesis** 1996 Nov;17(11):2347–56

Effect of cell proliferation on initiation of aflatoxin B1–induced enzyme altered hepatic foci in rats and hamsters. Hiruma S, et al. **Carcinogenesis** 1996 Nov; 17(11):2495–9

Minisatellite rearrangements are increased in liver tumours induced by transplacental aflatoxin B1 treatment of hepatitis B virus transgenic mice, but not in spontaneously arising tumours. Kaplanski C, et al. **Carcinogenesis** 1997 Apr;18(4):633–9

Aflatoxin B1–induced DNA adduct formation and p53 mutations in CYP450–expressing human liver cell lines. Macé K, et al. **Carcinogenesis** 1997 Jul;18(7):1291–7

Absence of mutations in the p53 tumor suppressor gene in woodchuck hepatocellular carcinomas associated with hepadnavirus infection and intake of aflatoxin B1. Rivkina M, et al. **Carcinogenesis** 1996 Dec;17(12):2689–94

Chemoprevention by inducers of carcinogen detoxication enzymes. Kensler TW. **Environ Health Perspect** 1997 Jun; 105 Suppl 4:965–70 (55 ref.)

Protection against aflatoxin B1–induced hepatic toxicity as short–term screen of cancer chemopreventive dithiolethiones. Maxuitenko YY, et al. **Fundam Appl Toxicol** 1996 Aug;32(2):250–9

Comparison of the enhancing effects of dehydroepiandrosterone with the structural analog 16 alpha–fluoro–5–androsten–17–one on aflatoxin B1 hepatocarcinogenesis in rainbow trout. Orner GA, et al. **Fundam Appl Toxicol** 1996 Nov;34(1):132–40

Regulation of glutathione S–transferases and aldehyde reductase by chemoprotectors: studies of mechanisms

responsible for inducible resistance to aflatoxin B1. Hayes JD, et al. **IARC Sci Publ** 1996;(139):175–87 (75 ref.)
The effect of aflatoxin B1 on cytokine mRNA and corresponding protein levels in peritoneal macrophages and splenic lymphocytes. Dugyala RR, et al. **Int J Immunopharmacol** 1996 Oct;18(10):599–608
Alteration of energy-linked functions in rat hepatic mitochondria following aflatoxin B1 administration. Sajan MP, et al. **J Biochem Toxicol** 1996;11(5):235–41
Food restriction reduces aflatoxin B1 (AFB1)–DNA adduct formation, AFB1–glutathione conjugation, and DNA damage in AFB1–treated male F344 rats and B6C3F1 mice. Chou MW, et al. **J Nutr** 1997 Feb;127(2):210–7
The molecular mechanism of aflatoxin B1–induced liver cancer: is mitotic recombination involved? Sengstag C. **Mol Carcinog** 1997 Jul;19(3):147–52 (22 ref.)
Two-dimensional polyacrylamide gel electrophoresis of cancer–associated proteins. Wirth PJ, et al. **Recent Results Cancer Res** 1997;143:145–60
Ascorbic acid protects guinea pigs from acute aflatoxin toxicity. Netke SP, et al. **Toxicol Appl Pharmacol** 1997 Apr; 143(2):429–35
Overexpression of cytochrome P–450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Kirby GM, et al. **Toxicol Pathol** 1996 Jul–Aug;24(4):458–67
Urinary taurine as a non–invasive marker of aflatoxin B1–induced hepatotoxicity: success and failure. Maxuitenko YY, et al. **Toxicology** 1997 Mar 28;118(2–3):159–69
Immunosuppressant activity of aflatoxin ingestion in rabbits measured by response to Mycobacterium bovis antigen I. Cell mediated immune response measured by skin test reaction. Dimitri RA, et al. **Vet Hum Toxicol** 1996 Oct; 38(5):333–6
Immunomodulative effects of aflatoxins and selenium on human peripheral blood lymphocytes. Methenitou G, et al. **Vet Hum Toxicol** 1996 Aug;38(4):274–7

URINE

Plasma antioxidant vitamins, chronic hepatitis B virus infection and urinary aflatoxin B1–DNA adducts in healthy males. Yu MW, et al. **Carcinogenesis** 1997 Jun;18(6):1189–94

AFLATOXIN M1

ANALOGS & DERIVATIVES

Characterization of monoclonal antibodies to aflatoxin M1 and molecular modeling studies of related aflatoxins. Holtzapple CK, et al. **Mol Immunol** 1996 Aug; 33(11–12):939–46

ANALYSIS

Use of an improved method for analysis of urinary aflatoxin M1 in a survey of mainland China and Taiwan. Cheng Z, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jul; 6(7):523–9
Occurrence of aflatoxin M1 in milk and dairy products commercialized in Campinas, Brazil. de Sylos CM, et al. **Food Addit Contam** 1996 Feb–Mar;13(2):169–72
Immunochemical assessment of aflatoxin M1 in milk powder consumed by infants in São Paulo, Brazil. Oliveira CA, et al. **Food Addit Contam** 1997 Jan;14(1):7–10
Aflatoxin M1 occurrence in samples of Grana Padano cheese. Peitri A, et al. **Food Addit Contam** 1997 May–Jun; 14(4):341–4

IMMUNOLOGY

Characterization of monoclonal antibodies to aflatoxin M1 and molecular modeling studies of related aflatoxins. Holtzapple CK, et al. **Mol Immunol** 1996 Aug; 33(11–12):939–46

METABOLISM

Hydrated sodium calcium aluminosilicate (HSCAS), acidic HSCAS, and activated charcoal reduce urinary excretion of aflatoxin M1 in turkey poults. Lack of effect by activated charcoal on aflatoxicosis. Edrington TS, et al. **Toxicol Lett** 1996 Dec 16;89(2):115–22

PHARMACOKINETICS

A case of self–experimentation [editorial] London NL, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jul;6(7):475–6

AFLATOXINS

ADMINISTRATION & DOSAGE

Primary liver cancer is of multifactorial origin: importance of hepatitis B virus infection and dietary aflatoxin. Saracco G. **J Gastroenterol Hepatol** 1995 Sep–Oct;10(5):604–8 (38 ref.)

ADVERSE EFFECTS

Molecular biomarkers for aflatoxins: from adducts to gene mutations to human liver cancer. Groopman JD, et al. **Can J Physiol Pharmacol** 1996 Feb;74(2):203–9 (40 ref.)
Hepatocellular carcinoma p53 G > T transversions at codon 249: the fingerprint of aflatoxin exposure? Lasky T, et al. **Environ Health Perspect** 1997 Apr;105(4):392–7 (48 ref.)

ANALYSIS

Airborne aflatoxin in the grain processing industries in India. Ghosh SK, et al. **Am Ind Hyg Assoc J** 1997 Aug; 58(8):583–6
Aflatoxin–albumin adducts: a basis for comparative carcinogenesis between animals and humans. Wild CP, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Mar;5(3):179–89
Screening of aflatoxins in Shiro and ground red pepper in Addis Ababa. Fufa H, et al. **Ethiop Med J** 1996 Oct; 34(4):243–9
Anti–aflatoxin mutagenic factors in corn. Weng CY, et al. **Food Addit Contam** 1997 Apr;14(3):269–79
Occurrence of fumonisins and aflatoxins in corn from Thailand. Yoshizawa T, et al. **Food Addit Contam** 1996 Feb–Mar;13(2):163–8
Robotic automated analysis of foods for aflatoxin. Carman AS Jr, et al. **J AOAC Int** 1996 Mar–Apr;79(2):456–64
Comparison of three methods for determining aflatoxins in melon seeds. DiProssimo VP, et al. **J AOAC Int** 1996 Nov–Dec;79(6):1330–5
Variability associated with analytical methods used to measure aflatoxin in agricultural commodities. Whitaker T, et al. **J AOAC Int** 1996 Mar–Apr;79(2):476–85
Aflatoxins in the lungs of children with kwashiorkor and children with miscellaneous diseases in Nigeria. Oyelami OA, et al. **J Toxicol Environ Health** 1997 Aug 29; 51(6):623–8
Development of greenhouse screening for resistance to Aspergillus parasiticus infection and preharvest aflatoxin contamination in peanut. Anderson WF, et al. **Mycopathologia** 1996;135(2):115–8
Aflatoxin formation and varietal difference of cow pea (Vigna unguiculata (L.) Walp.) and garden pea (Pisum sativum L.) cultivars. El–Kady IA, et al. **Mycopathologia** 1996;133(3):185–8
Influence of sundrying on the chemical composition, aflatoxin content and fungal counts of two pepper varieties—Capsicum annum and Capsicum frutescens. Adegoke GO, et al. **Plant Foods Hum Nutr** 1996 Feb; 49(2):113–7
[Evaluation of a detection method for determination of aflatoxins in peanuts using immunoaffinity chromatography coupled fluorimetry detection] Postupolski J, et al. **Rocz Panstw Zakl Hig** 1996;47(3):277–83 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

Anti–aflatoxigenic activity of Lactobacillus casei pseudoplantarum. Gourama H, et al. **Int J Food Microbiol** 1997 Feb;34(2):131–43

BIOSYNTHESIS

Aflatoxin and cyclopiazonic acid production by a sclerotium–producing Aspergillus tamarii strain. Goto T, et al. **Appl Environ Microbiol** 1996 Nov;62(11):4036–8
Identification of aflatoxin biosynthesis genes by genetic complementation in an Aspergillus flavus mutant lacking the aflatoxin gene cluster. Prieto R, et al. **Appl Environ Microbiol** 1996 Oct;62(10):3567–71
avnA, a gene encoding a cytochrome P–450 monooxygenase, is involved in the conversion of averantin to averufin in aflatoxin biosynthesis in Aspergillus parasiticus. Yu J, et al. **Appl Environ Microbiol** 1997 Apr;63(4):1349–56
Purification and characterization of the esterases involved in aflatoxin biosynthesis in Aspergillus parasiticus. Kusumoto K, et al. **Can J Microbiol** 1996 Aug;42(8):804–10
Co–production of aflatoxins and cyclopiazonic acid in isolates of Aspergillus flavus. Gqaleni N, et al. **Food Addit Contam** 1996 Aug–Sep;13(6):677–85
Relationship between aflatoxin biosynthesis and sporulation in Aspergillus parasiticus. Guzmán–de–Peña D, et al. **Fungal Genet Biol** 1997 Apr;21(2):198–205
Detection of aflatoxinogenic fungi in figs by a PCR reaction. Färber P, et al. **Int J Food Microbiol** 1997 May 20; 36(2–3):215–20
Aflastatin A, a novel inhibitor of aflatoxin production by aflatoxigenic fungi. Ono M, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):111–8
Aspergillus nidulans stcL encodes a putative cytochrome P–450 monooxygenase required for bisfuran desaturation during aflatoxin/sterigmatocystin biosynthesis. Kelkar HS, et al. **J Biol Chem** 1997 Jan 17;272(3):1589–94
Growth and toxigenesis of Aspergillus flavus isolates on selected spices. Bartine H, et al. **J Environ Pathol Toxicol Oncol** 1997;16(1):61–5
High incidence of Aspergillus flavus and aflatoxins in stored groundnut in Ghana and the use of a microbial assay to assess the inhibitory effects of plant extracts on aflatoxin synthesis. Awuah RT, et al. **Mycopathologia** 1996; 134(2):109–14

IMMUNOLOGY

Serological serum protein fraction and responses to Brucella melitensis in lambs fed aflatoxins. Fernandez A, et al. **Vet Hum Toxicol** 1997 Jun;39(3):137–40

METABOLISM

ord1, an oxidoreductase gene responsible for conversion of O–methylsterigmatocystin to aflatoxin in Aspergillus flavus. Prieto R, et al. **Appl Environ Microbiol** 1997 May; 63(5):1661–6
Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. Yu MW, et al. **J Hepatol** 1997 Aug; 27(2):320–30

PHARMACOKINETICS

In situ absorption of aflatoxins in rat small intestine. Ramos AJ, et al. **Mycopathologia** 1996;134(1):27–30

PHARMACOLOGY

Mitogenic effects of mycotoxins on T4 lymphocytes. Griffiths BB, et al. **Microbios** 1996;86(347):127–34

POISONING

Suspected aflatoxicosis in breeding budgerigars [letter] Bastianello SS, et al. **J S Afr Vet Assoc** 1997 Mar;68(1):2–4
Aflatoxin and liver injury. Bhat RV. **Trop Gastroenterol** 1996 Jul–Sep;17(3):153–60 (75 ref.)

TOXICITY

Alterations in the performance, haematology and clinical biochemistry of growing lambs fed with aflatoxin in the diet. Fernández A, et al. **J Appl Toxicol** 1996 Jan–Feb; 16(1):85–91
Individual and combined effects of moniliformin present in Fusarium fujikuroi culture material and aflatoxin in broiler chicks. Kubena LF, et al. **Poult Sci** 1997 Feb;76(2):265–70

AFP see **ALPHA–FETOPROTEINS**

AFRICAN AMERICANS see **BLACKS**

AFRICAN GREEN MONKEY see **CERCOPITHECUS AETHIOPS**

AFRICAN HORSESICKNESS

DIAGNOSIS

Rapid diagnosis of African horse sickness. Adeyefa CA. **Rev Elev Med Vet Pays Trop** 1996;49(4):295–8

EPIDEMIOLOGY

Transmission and distribution of virus serotypes: African horse sickness in zebra. Lord CC, et al. **Epidemiol Infect** 1997 Feb;118(1):43–50
Vector–borne diseases and the basic reproduction number: a case study of African horse sickness. Lord CC, et al. **Med Vet Entomol** 1996 Jan;10(1):19–28

IMMUNOLOGY

Serologic markers in early stages of African horse sickness virus infection. Martínez–Torrecuadrada JL, et al. **J Clin Microbiol** 1997 Feb;35(2):531–5

PREVENTION & CONTROL

Recombinant baculovirus–synthesized African horsesickness virus (AHSV) outer–capsid protein VP2 provides protection against virulent AHSV challenge. Roy P, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2053–7
African horsesickness virus VP7 sub–unit vaccine protects mice against a lethal, heterologous serotype challenge. Wade–Evans AM, et al. **J Gen Virol** 1997 Jul;78 (Pt 7):1611–6
Simulation studies of vaccination strategies in African horse sickness. Lord CC, et al. **Vaccine** 1997 Apr;15(5):519–24

TRANSMISSION

Transmission and distribution of virus serotypes: African horse sickness in zebra. Lord CC, et al. **Epidemiol Infect** 1997 Feb;118(1):43–50

VIROLOGY

Role of dogs (Canis domesticus) as hosts for African horse sickness virus. Braverman Y, et al. **Vet Microbiol** 1996 Jul; 51(1–2):19–25

AFRICAN HORSESICKNESS VIRUS

Role of dogs (Canis domesticus) as hosts for African horse sickness virus. Braverman Y, et al. **Vet Microbiol** 1996 Jul; 51(1–2):19–25

GENETICS

Nucleotide sequence comparison of the segments S10 of the nine African horsesickness virus serotypes. Sailleau C, et al. **Arch Virol** 1997;142(5):965–78
Comparative sequence analysis and expression of the M6 gene, encoding the outer capsid protein VP5, of African horsesickness virus serotype nine. du Plessis M, et al. **Virus Res** 1997 Jan;47(1):41–9

IMMUNOLOGY

Transmission and distribution of virus serotypes: African horse sickness in zebra. Lord CC, et al. **Epidemiol Infect** 1997 Feb;118(1):43–50
Serologic markers in early stages of African horse sickness

virus infection. Martínez-Torrecuadrada JL, et al. **J Clin Microbiol** 1997 Feb;35(2):531-5

Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge. Roy P, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2053-7

African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge. Wade-Evans AM, et al. **J Gen Virol** 1997 Jul;78 (Pt 7):1611-6

METABOLISM

Characterization of tubular structures composed of nonstructural protein NS1 of African horsesickness virus expressed in insect cells. Maree FF, et al. **J Gen Virol** 1997 May;78 (Pt 5):1077-82

AFRICAN LYMPHOMA see **BURKITT'S LYMPHOMA**

AFRICAN MEDICINE, TRADITIONAL see **MEDICINE, AFRICAN TRADITIONAL**

AFRICAN SLEEPING SICKNESS see **TRYPANOSOMIASIS, AFRICAN**

AFRICAN SWINE FEVER

DIAGNOSIS

A solid-phase enzyme linked immunosorbent assay using monoclonal antibodies, for the detection of African swine fever virus antigens and antibodies. Vidal MI, et al. **J Virol Methods** 1997 Jul;66(2):211-8

ECONOMICS

African swine fever in Zambia: potential financial and production consequences for the commercial sector. Samui KL, et al. **Jpn J Vet Res** 1996 Aug;44(2):119-24

EPIDEMIOLOGY

A case study of an outbreak of African swine fever in Spain. Bech-Nielsen S, et al. **Br Vet J** 1995 Mar-Apr; 151(2):203-14

African swine fever in Zambia: potential financial and production consequences for the commercial sector. Samui KL, et al. **Jpn J Vet Res** 1996 Aug;44(2):119-24

ETIOLOGY

African swine fever virus infection of bone marrow: lesions and pathogenesis. Gómez-Villamandos JC, et al. **Vet Pathol** 1997 Mar;34(2):97-107

IMMUNOLOGY

Changes in swine macrophage phenotype after infection with African swine fever virus: cytokine production and responsiveness to interferon-gamma and lipopolysaccharide. Whittall JT, et al. **Immunology** 1997 Jul;91(3):444-9

Blocking antibodies inhibit complete African swine fever virus neutralization. Gómez-Puertas P, et al. **Virus Res** 1997 Jun;49(2):115-22

Modulation of immune cell populations and activation markers in the pathogenesis of African swine fever virus infection. Ramiro-Ibáñez F, et al. **Virus Res** 1997 Jan; 47(1):31-40

[A comparative analysis of humoral and cellular funcation activity indicators during in vivo viral infections] Makarov VV, et al. **Biull Eksp Biol Med** 1995 Dec;120(12):599-602 **(Rus)**

PATHOLOGY

Apoptosis in lymph nodes in acute African swine fever. Carrasco L, et al. **J Comp Pathol** 1996 Nov;115(4):415-28

Subcellular changes in platelets in acute and subacute African swine fever. Gómez-Villamandos JC, et al. **J Comp Pathol** 1996 Nov;115(4):327-41

Structural and ultrastructural study of glomerular changes in African swine fever. Hervás J, et al. **J Comp Pathol** 1996 Jul;115(1):61-75

Immunohistopathological study of African swine fever (strain E-75)-infected bone marrow. Rodríguez F, et al. **J Comp Pathol** 1996 May;114(4):399-406

Apoptosis: a mechanism of cell killing and lymphoid organ impairment during acute African swine fever virus infection. Ramiro-Ibáñez F, et al. **J Gen Virol** 1996 Sep; 77 (Pt 9):2209-19

The pathogenic role of pulmonary intravascular macrophages in acute African swine fever. Carrasco L, et al. **Res Vet Sci** 1996 Nov;61(3):193-8

African swine fever: morphopathology of a viral haemorrhagic disease. Rodríguez F, et al. **Vet Rec** 1996 Sep 14;139(11):249-54

Development of microscopic lesions in splenic cords of pigs infected with African swine fever virus. Carrasco L, et al. **Vet Res** 1997;28(1):93-9

Subcellular changes in the tonsils of pigs infected with acute African swine fever virus. Gómez-Villamandos JC, et al. **Vet Res** 1997;28(2):179-89

[Intercellular interactions in swine bone marrow cell culture and PPK-66B cell line infected with African swine fever virus] Shubina NG, et al. **Biull Eksp Biol Med** 1996 Oct; 122(10):418-24 **(Rus)**

VIROLOGY

Virus-host interactions in African swine fever: the attachment to cellular receptors. Angulo A, et al. **Arch Virol Suppl** 1993;7:169-83 (48 ref.)

Neutralizing antibodies to different proteins of African swine fever virus inhibit both virus attachment and internalization. Gómez-Puertas P, et al. **J Virol** 1996 Aug; 70(8):5689-94

High level expression of the major antigenic African swine fever virus proteins p54 and p30 in baculovirus and their potential use as diagnostic reagents. Oviedo JM, et al. **J Virol Methods** 1997 Feb;64(1):27-35

A BIR motif containing gene of African swine fever virus, 4CL, is nonessential for growth in vitro and viral virulence. Neilan JG, et al. **Virology** 1997 Apr 14;230(2):252-64

AFRICAN SWINE FEVER-LIKE VIRUSES

African swine fever: morphopathology of a viral haemorrhagic disease. Rodríguez F, et al. **Vet Rec** 1996 Sep 14;139(11):249-54

AFRICAN SWINE FEVER VIRUS

A case study of an outbreak of African swine fever in Spain. Bech-Nielsen S, et al. **Br Vet J** 1995 Mar-Apr; 151(2):203-14

[Intercellular interactions in swine bone marrow cell culture and PPK-66B cell line infected with African swine fever virus] Shubina NG, et al. **Biull Eksp Biol Med** 1996 Oct; 122(10):418-24 **(Rus)**

CHEMISTRY

Neutralization susceptibility of African swine fever virus is dependent on the phospholipid composition of viral particles. Gómez-Puertas P, et al. **Virology** 1997 Feb 17; 228(2):180-9

ENZYMOLOGY

African swine fever virus trans-prenyltransferase. Alejo A, et al. **J Biol Chem** 1997 Apr 4;272(14):9417-23

GENETICS

African swine fever virus genome content and variability. Dixon LK, et al. **Arch Virol Suppl** 1993;7:185-99 (72 ref.)

Characterisation of transcription factors in African swine fever virus. Baxter T, et al. **Biochem Soc Trans** 1996 Aug; 24(3):415S

A set of African swine fever virus tandem repeats shares similarities with SAR-like sequences. Almazán F, et al. **J Gen Virol** 1995 Apr;76 (Pt 4):729-40

Intermediate class of mRNAs in African swine fever virus. Rodríguez JM, et al. **J Virol** 1996 Dec;70(12):8584-9

An African swine fever virus virulence-associated gene NL-S with similarity to the herpes simplex virus ICP34.5 gene. Zsak L, et al. **J Virol** 1996 Dec;70(12):8865-71

High level expression of the major antigenic African swine fever virus proteins p54 and p30 in baculovirus and their potential use as diagnostic reagents. Oviedo JM, et al. **J Virol Methods** 1997 Feb;64(1):27-35

African swine fever virus gene A179L, a viral homologue of bcl-2, protects cells from programmed cell death. Brun A, et al. **Virology** 1996 Nov 1;225(1):227-30

A BIR motif containing gene of African swine fever virus, 4CL, is nonessential for growth in vitro and viral virulence. Neilan JG, et al. **Virology** 1997 Apr 14;230(2):252-64

GROWTH & DEVELOPMENT

A conserved African swine fever virus IkappaB homolog, 5EL, is nonessential for growth in vitro and virulence in domestic swine. Neilan JG, et al. **Virology** 1997 Sep 1; 235(2):377-85

IMMUNOLOGY

Neutralizing antibodies to different proteins of African swine fever virus inhibit both virus attachment and internalization. Gómez-Puertas P, et al. **J Virol** 1996 Aug; 70(8):5689-94

An IkappaB homolog encoded by African swine fever virus provides a novel mechanism for downregulation of proinflammatory cytokine responses in host macrophages. Powell PP, et al. **J Virol** 1996 Dec;70(12):8527-33

Application of linker-ligation-PCR for construction of phage display epitope libraries. Nagesha HS, et al. **J Virol Methods** 1996 Jul;60(2):147-54

A solid-phase enzyme linked immunosorbent assay using monoclonal antibodies, for the detection of African swine fever virus antigens and antibodies. Vidal MI, et al. **J Virol Methods** 1997 Jul;66(2):211-8

Neutralization susceptibility of African swine fever virus is dependent on the phospholipid composition of viral particles. Gómez-Puertas P, et al. **Virology** 1997 Feb 17; 228(2):180-9

African swine fever virus-specific cytotoxic T lymphocytes recognize the 32 kDa immediate early protein (vp32). Alonso F, et al. **Virus Res** 1997 Jun;49(2):123-30

Blocking antibodies inhibit complete African swine fever virus neutralization. Gómez-Puertas P, et al. **Virus Res** 1997 Jun;49(2):115-22

Modulation of immune cell populations and activation markers in the pathogenesis of African swine fever virus infection. Ramiro-Ibáñez F, et al. **Virus Res** 1997 Jan; 47(1):31-40

METABOLISM

Strong sequence conservation of African swine fever virus p72 protein provides the molecular basis for its antigenic stability. Yu M, et al. **Arch Virol** 1996;141(9):1795-802

Characterisation of transcription factors in African swine fever virus. Baxter T, et al. **Biochem Soc Trans** 1996 Aug; 24(3):415S

Proteolytic processing in African swine fever virus: evidence for a new structural polyprotein, pp62. Simón-Mateo C, et al. **J Virol** 1997 Aug;71(8):5799-804

Characterization of the African swine fever virus structural protein p14.5: a DNA binding protein. Martínez-Pomares L, et al. **Virology** 1997 Mar 3;229(1):201-11

Expression of ubiquitin, actin, and actin-like genes in African swine fever virus infected cells. Ferreira C. **Virus Res** 1996 Sep;44(1):11-21

Protein cell receptors mediate the saturable interaction of African swine fever virus attachment protein p12 with the surface of permissive cells. Galindo I, et al. **Virus Res** 1997 Jun;49(2):193-204

PATHOGENICITY

Granulocyte-macrophage colony stimulating factor promotes prolonged survival and the support of virulent infection by African swine fever virus of macrophages generated from porcine bone marrow and blood. Denham S, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2625-30

Apoptosis: a mechanism of cell killing and lymphoid organ impairment during acute African swine fever virus infection. Ramiro-Ibáñez F, et al. **J Gen Virol** 1996 Sep; 77 (Pt 9):2209-19

An African swine fever virus virulence-associated gene NL-S with similarity to the herpes simplex virus ICP34.5 gene. Zsak L, et al. **J Virol** 1996 Dec;70(12):8865-71

African swine fever virus infection of bone marrow: lesions and pathogenesis. Gómez-Villamandos JC, et al. **Vet Pathol** 1997 Mar;34(2):97-107

A BIR motif containing gene of African swine fever virus, 4CL, is nonessential for growth in vitro and viral virulence. Neilan JG, et al. **Virology** 1997 Apr 14;230(2):252-64

A conserved African swine fever virus IkappaB homolog, 5EL, is nonessential for growth in vitro and virulence in domestic swine. Neilan JG, et al. **Virology** 1997 Sep 1; 235(2):377-85

PHYSIOLOGY

Virus-host interactions in African swine fever: the attachment to cellular receptors. Angulo A, et al. **Arch Virol Suppl** 1993;7:169-83 (48 ref.)

Assembly of African swine fever virus: role of polyprotein pp220. Andrés G, et al. **J Virol** 1997 Mar;71(3):2331-41

Involvement of the endoplasmic reticulum in the assembly and envelopment of African swine fever virus. Cobbold C, et al. **J Virol** 1996 Dec;70(12):8382-90

Subcellular changes in the tonsils of pigs infected with acute African swine fever virus. Gómez-Villamandos JC, et al. **Vet Res** 1997;28(2):179-89

Assembly of African Swine fever virus: quantitative ultrastructural analysis in vitro and in vivo. Brookes SM, et al. **Virology** 1996 Oct 1;224(1):84-92

Inhibition of apoptosis by the African swine fever virus Bcl-2 homologue: role of the BH1 domain. Revilla Y, et al. **Virology** 1997 Feb 17;228(2):400-4

AFTERCARE

see related

HALFWAY HOUSES

Aftercare telephone contacts with problem drinkers can serve a clinical and research function. Breslin C, et al. **Addiction** 1996 Sep;91(9):1359-64

A controlled field trial of group versus individual cognitive-behavioural training for relapse prevention. Graham K, et al. **Addiction** 1996 Aug;91(8):1127-39

Casemix for inpatient care of elderly people: rehabilitation and post-acute care. Casemix for the Elderly Inpatient Working Group. Carpenter GI, et al. **Age Ageing** 1997 Mar; 26(2):123-31

A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Kabel DI, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):780-4

Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Brobeil A, et al. **Ann Surg Oncol** 1997 Jan;4(1):19-23

Patient-physician communication at hospital discharge and patients' understanding of the postdischarge treatment plan. Calkins DR, et al. **Arch Intern Med** 1997 May 12; 157(9):1026-30

The management of late fetal death: a guide to comprehensive care. Fox R, et al. **Br J Obstet Gynaecol** 1997 Jan; 104(1):4-10 (31 ref.)

AFTERCARE

Clinical usefulness of an aftercare worker for psychotic patients discharged from half-way houses in Hong Kong. Mak KY, et al. **Br J Psychiatry** 1996 Jun;168(6):757-61

Paths and impacts in the progressive independence model: a homelessness and substance abuse intervention in Chicago. Sosin MR, et al. **J Addict Dis** 1995;14(4):1-20

Strategies used by chronically ill older women and their caregiving daughters in managing posthospital care. Bull MJ, et al. **J Adv Nurs** 1997 Mar;25(3):541-7

Patients' perceptions of their education needs in the first six weeks following discharge after cardiac surgery. Goodman H. **J Adv Nurs** 1997 Jun;25(6):1241-51

The problems of elderly people at home one week after discharge from an acute care setting. Mistiaen P, et al. **J Adv Nurs** 1997 Jun;25(6):1233-40

Suicidal adolescents after hospitalization: parent and family impacts on treatment follow-through. King CA, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jan;36(1):85-93

Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. **J Stud Alcohol** 1997 Jan;58(1):7-29

A randomized trial of early discharge and nurse specialist transitional follow-up care of high-risk childbearing women. York R, et al. **Nurs Res** 1997 Sep-Oct;46(5):254-61

Predictors of receipt of aftercare and recidivism among persons with severe mental illness: a review. Klinkenberg WD, et al. **Psychiatr Serv** 1996 May;47(5):487-96 (117 ref.)

Mammographic findings after 14-gauge automated needle and 14-gauge directional, vacuum-assisted stereotactic breast biopsies. Burbank F. **Radiology** 1997 Jul;204(1):153-6

[Evaluation of the effectiveness of an ambulatory after-care rehabilitation program] Röseler S, et al. **Gesundheitswesen** 1997 Apr;59(4):236-41 (Eng. Abstr.) **(Ger)**

[After-care of colorectal carcinoma--value of tumor markers] Köhne CH, et al. **Internist (Berl)** 1997 Apr; 38(4):363-5 **(Ger)**

[The intracavitary administration of contrast medium in the aftercare of complicated thoracic empyema with long-term drainage: x-ray fluoroscopy compared to computed tomography] Düx M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jul;167(1):37-45 (Eng. Abstr.) **(Ger)**

[Some experiences with hospital-based psychiatric aftercare over ten years] Haugerud S. **Tidsskr Nor Laegeforen** 1997 Feb 10;117(4):545-6 **(Nor)**

ECONOMICS

Patterns and costs of post-acute care: a longitudinal study of people aged 60 and over in Dubbo. McCallum J, et al. **Aust N Z J Public Health** 1996 Feb;20(1):19-26

[After care of breast cancer: tips for medical charges] Grebe W. **Fortschr Med** 1996 Feb 20;114(5):44, 46 **(Ger)**

[After-care of gastrointestinal malignancies--an evaluation of costs and benefits] Zieren HU, et al. **Zentralbl Chir** 1996; 121(3):167-76 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Forensic psychiatric aftercare following hospital order treatment. Muller-Isberner JR. **Int J Law Psychiatry** 1996 Winter;19(1):81-6

Can the law serve as the solution to social ills? The case of the Mental Health (Patients in the Community) Act, 1995. Prins H. **Med Sci Law** 1996 Jul;36(3):217-20

METHODS

Posthospital setting, resource utilization, and self-care outcome in older women with hip fracture. Levi SJ. **Arch Phys Med Rehabil** 1997 Sep;78(9):973-9

The use of the telephone in cardiac and pulmonary rehabilitation [letter] Mack M. **J Cardiopulm Rehabil** 1997 Jul-Aug;17(4):288

A simple intervention for improving telephone contact of patients discharged from the emergency department. Isaacman DJ, et al. **Pediatr Emerg Care** 1997 Aug; 13(4):256-8

Effects of training in psychosocial interventions for community psychiatric nurses in England. Lancashire S, et al. **Psychiatr Serv** 1997 Jan;48(1):39-41

Recommendations on follow-up of breast cancer patients following primary therapy. Khandekar JD. **Semin Surg Oncol** 1996 Sep-Oct;12(5):346-51 (37 ref.)

[After care of breast carcinoma patients--recommendations from the Berlin consensus conference] Hellriegel KP, et al. **Fortschr Med** 1996 Feb 20;114(5):43-5 (0 ref.) **(Ger)**

[New after-care guidelines in breast carcinoma] Sauer H. **Geburtshilfe Frauenheilkd** 1996 Sep;56(9):M141-3 (14 ref.) **(Ger)**

[After care of acute myocardial infarct: what are the 4 most important points?] Kurz DJ, et al. **Schweiz Rundsch Med Prax** 1997 Jul 2;86(27-28):1116-9 (Eng. Abstr.) **(Ger)**

[Risk-guided after-care of testicular tumor] Schölermann KH, et al. **Urologe A** 1996 Jul;35(4):326-30 (Eng. Abstr.) **(Ger)**

[After-care and palliative therapeutic measures in ovarian carcinoma] Kurz C, et al. **Wien Med Wochenschr** 1996; 146(1-2):34-7 (12 ref.) (Eng. Abstr.) **(Ger)**

[Heart transplantation: after-care and rehabilitation. Current status and results of a survey by the German Transplantation Program. Thoracic Organ Transplantation Study Group of the German Society of Cardiology] Fleck E, et al. **Z Kardiol** 1996 Jan;85(1):67-77 **(Ger)**

ORGANIZATION & ADMINISTRATION

Community psychiatric nurse aftercare for alcoholics: a five-year follow-up study. Patterson DG, et al. **Addiction** 1997 Apr;92(4):459-68

The influence of posttreatment mutual help group participation on the friendship networks of substance abuse patients. Humphreys K, et al. **Am J Community Psychol** 1997 Feb;25(1):1-16

Patients discharged from emergency care after acute myocardial infarction was ruled out: early follow-up in relation to gender. Karlson BW, et al. **Eur J Emerg Med** 1997 Jun;4(2):72-80

Establishing good practices in continuing care: a descriptive study of community nursing services for people with HIV infection. Brocklehurst N, et al. **J Adv Nurs** 1996 Sep; 24(3):488-97

Discharge of elderly people from an accident and emergency department: evaluation of health visitor follow-up. Runciman P, et al. **J Adv Nurs** 1996 Oct;24(4):711-8

Clinical pathway across tertiary and community care after an interventional cardiology procedure. Doran K, et al. **J Cardiovasc Nurs** 1997 Jan;11(2):1-14

Domiciliary health counselling in patients with sexually transmitted diseases. Rathore AS, et al. **J Commun Dis** 1997 Mar;29(1):35-9

Bereavement follow-up: an opportunity to extend nursing care. Ruden BM. **J Pediatr Oncol Nurs** 1996 Oct; 13(4):219-25

PSYCHOLOGY

The aftercare of adolescents with deliberate self-harm. Brent DA. **J Child Psychol Psychiatry** 1997 Mar;38(3):277-86 (100 ref.)

Factors predictive of poor compliance with follow-up care after facial trauma: a prospective study. Stewart MG, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):72-5

Encouraging participation in aftercare group therapy among substance-dependent men. Lash SJ, et al. **Psychol Rep** 1996 Oct;79(2):585-6

[Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation] Gärtner U, et al. **Med Klin** 1996 Aug 15; 91(8):501-8 (Eng. Abstr.) **(Ger)**

STANDARDS

Posthospital setting, resource utilization, and self-care outcome in older women with hip fracture. Levi SJ. **Arch Phys Med Rehabil** 1997 Sep;78(9):973-9

Home visits by community nurses for cancer patients after discharge from hospital: an evaluation study of the continuity visit. van Harteveld JT, et al. **Cancer Nurs** 1997 Apr;20(2):105-14

One-year status of homeless mentally ill clients who completed a transitional residential program. Murray R, et al. **Community Ment Health J** 1997 Feb;33(1):43-50

Psychiatric rehospitalization following hospital discharge. Owen C, et al. **Community Ment Health J** 1997 Feb; 33(1):13-24

Preventive care for patients following myocardial infarction. The Wessex Research Network (WReN). Bradley F, et al. **Fam Pract** 1997 Jun;14(3):220-6

"Every defect is a treasure. **Int J Qual Health Care** 1996 Jun;8(3):297-8

Head injury instructions: a time to unify. Parsley J, et al. **J Accid Emerg Med** 1997 Jul;14(4):238-9

Effects of diagnosis, demographic characteristics, and case management on rehospitalization. D'Ercole A, et al. **Psychiatr Serv** 1997 May;48(5):682-8

Positive screening tests for gonorrhea and chlamydial infection fail to lead consistently to treatment of patients attending a sexually transmitted disease clinic. Schwebke JR, et al. **Sex Transm Dis** 1997 Apr;24(4):181-4

[Little benefit of medical specialist after-care for case-finding of recurrence following treatment of endometrial or cervix carcinoma (see comments)] Ansink AC. **Ned Tijdschr Geneeskd** 1996 Dec 14;140(50):2488-9. Comment in: Ned Tijdschr Geneeskd 1997 Feb 22;141(8):398. **(Dut)**

STATISTICS & NUMERICAL DATA

Noncompliance in psychiatric aftercare. Owen C, et al. **Community Ment Health J** 1997 Feb;33(1):25-34

Discharge destination and repeat hospitalizations. Camberg LC, et al. **Med Care** 1997 Aug;35(8):756-67

UTILIZATION

Effect of predischarge interventions on aftercare attendance: process and outcome. Sharma SB, et al. **Health Soc Work** 1995 Feb;20(1):15-20

Differences in follow-up visits between African American and white Medicaid children hospitalized with asthma. Ali S, et al. **J Health Care Poor Underserved** 1997 Feb; 8(1):83-98

[Utilization of ambulatory psychotherapy by patients with endogenous depression after inpatient psychiatric treatment] Backenstrass M, et al. **Psychother Psychosom Med Psychol** 1997 Jul;47(7):234-9 (Eng. Abstr.) **(Ger)**

AFTERIMAGE

Voluntary suppression of caloric nystagmus under fixation of imaginary or after-image target. Watabe H, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:155-7

Influence of foveal afterimage on non-visually induced pursuit eye movements. Watanabe N, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:163-6

Orthogonal motion after-effect illusion predicted by a model of cortical motion processing. Grunewald A, et al. **Nature** 1996 Nov 28;384(6607):358-60

Does local or global orientation determine the McCollough effect? Yoshioka T, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):723-7

The perceived direction of textured gratings and their motion aftereffects. Alais D, et al. **Perception** 1995;24(12):1383-96

DRUG EFFECTS

Resolution of palinopsia with carbamazepine [letter] Silva JA, et al. **J Clin Psychiatry** 1997 Jan;58(1):30

PHYSIOLOGY

Three-dimensional baselines for perceived self-motion during acceleration and deceleration in a centrifuge. Holly JE. **J Vestib Res** 1997 Jan-Feb;7(1):45-61

Psychophysical scaling of circular vection (CV) produced by optokinetic (OKN) motion: individual differences and effects of practice. Kennedy RS, et al. **J Vestib Res** 1996 Sep-Oct;6(5):331-41

Cortical dynamics of boundary segmentation and reset: persistence, afterimages, and residual traces. Francis G, et al. **Perception** 1996;25(5):543-67 (60 ref.)

A neural model of foveal light adaptation and afterimage formation. Wilson HR. **Vis Neurosci** 1997 May-Jun; 14(3):403-23 (82 ref.)

Temporal and spatial frequency tuning of the flicker motion aftereffect. Bex PJ, et al. **Vision Res** 1996 Sep;36(17):2721-7

A reduced motion aftereffect in strabismic amblyopia. Hess RF, et al. **Vision Res** 1997 May;37(10):1303-11

Linking lower and higher stages of motion processing? Mareschal I, et al. **Vision Res** 1997 Jul;37(13):1755-9

AGAMMAGLOBULINEMIA

CHEMICALLY INDUCED

[Effect of occupational lead exposure on immunoglobulin concentration and cellular immune function in man] Castillo Méndez A, et al. **Rev Alerg** 1993 Mar-Apr; 40(2):33-6 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Chest high resolution CT in adults with primary humoral immunodeficiency. Feydy A, et al. **Br J Radiol** 1996 Dec; 69(828):1108-16

Mycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients. Franz A, et al. **Br J Rheumatol** 1997 Jun; 36(6):661-8

An unusual case of refractory Campylobacter jejuni infection in a patient with X-linked agammaglobulinemia: successful combined therapy with maternal plasma and ciprofloxacin. Autenrieth IB, et al. **Clin Infect Dis** 1996 Sep;23(3):526-31

Mycoplasma felis septic arthritis in a patient with hypogammaglobulinemia. Bonilla HF, et al. **Clin Infect Dis** 1997 Feb;24(2):222-5

Use of amplification and sequencing of the 16S rRNA gene to diagnose Mycoplasma pneumoniae osteomyelitis in a patient with hypogammaglobulinemia. La Scola B, et al. **Clin Infect Dis** 1997 Jun;24(6):1161-3

Visceral leishmaniasis in a patient with hyper-IgM hypogammaglobulinemia. Martin JC, et al. **Clin Infect Dis** 1996 Nov;23(5):1188-9

B cell-deficient muMT mice as an experimental model for Mycoplasma infections in X-linked agammaglobulinemia. Berglöf A, et al. **Eur J Immunol** 1997 Aug;27(8):2118-21

Vitamin B12 deficiency and subclinical infection with Giardia lamblia in an adolescent with agammaglobulinemia of Bruton. Springer SC, et al. **J Adolesc Health** 1997 Jan; 20(1):58-61

Hypersensitivity pneumonitis in a patient with hypogammaglobulinemia. Schkade PA, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):710-2

Allergic bronchopulmonary aspergillosis and common variable hypogammaglobulinemia in an adult male patient: case report. Schwartz HJ, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):708-10

Consequences of hypogammaglobulinemia and steroid therapy in severe bronchopulmonary dysplasia. Wheeler W, et al. **Pediatr Pulmonol** 1996 Aug;22(2):96-100

Chronic diarrhea associated with thymoma and hypogammaglobulinemia (Good's syndrome). Verne GN, et al. **South Med J** 1997 Apr;90(4):444-6

[Encephalomyelitis secondary to variable common hypogammaglobulinemia (letter)] Ferreira A, et al. **Rev Neurol (Paris)** 1997 Mar;153(2):144-5 **(Fre)**

[A case of agammaglobulinemia with chronic enteroviral meningomyelitis] Ito N, et al. **Rinsho Shinkeigaku** 1996 Feb; 36(2):306-11 (Eng. Abstr.) **(Jpn)**

[Hepatic granulomas in a patient with acquired hypogammaglobulinemia] Artaza Varasa T, et al. **Gastroenterol Hepatol** 1996 Dec;19(10):517–8 (Eng. Abstr.) **(Spa)**

[Systemic amyloidosis associated with common variable hypogammaglobulinemia and intestinal lymphoid nodular hyperplasia] Sánchez-Pobre P, et al. **Gastroenterol Hepatol** 1996 Aug–Sep;19(7):351–5 (38 ref.) (Eng. Abstr.) **(Spa)**

[Radiologic digestive manifestations in patients with antibody deficiency] Alonso Falcón F, et al. **Rev Esp Enferm Dig** 1996 Sep;88(9):593–7 (Eng. Abstr.) **(Spa)**

CONGENITAL

Giardiasis as a cause of hypokalemic myopathy in congenital immunodeficiency. Genovese A, et al. **Int J Clin Lab Res** 1996;26(2):132–5

DIAGNOSIS

Response to minocycline of arthritis associated with agammaglobulinemia. A case-report. Soubrier M, et al. **Rev Rhum Engl Ed** 1997 Mar;64(3):195–7

X-linked agammaglobulinemia presenting as pseudomonas aeruginosa septicemia. Zenone T, et al. **Scand J Infect Dis** 1996;28(4):417–8

Chronic diarrhea associated with thymoma and hypogammaglobulinemia (Good's syndrome). Verne GN, et al. **South Med J** 1997 Apr;90(4):444–6

[Immunodeficiency with thymoma (Good's syndrome) similar to sino-bronchial syndrome] Akai M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul;34(7):829–32 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Natural recovery from acute hepatitis C virus infection by agammaglobulinemic twin children. Adams G, et al. **Pediatr Infect Dis J** 1997 May;16(5):533–4

ENZYMOLOGY

X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease. Mattsson PT, et al. **Bioessays** 1996 Oct;18(10):825–34 (84 ref.)

Identification of novel Bruton's tyrosine kinase mutations in 10 unrelated subjects with X linked agammaglobulinaemia. Brooimans RA, et al. **J Med Genet** 1997 Jun;34(6):484–8

EPIDEMIOLOGY

Consequences of hypogammaglobulinemia and steroid therapy in severe bronchopulmonary dysplasia. Wheeler W, et al. **Pediatr Pulmonol** 1996 Aug;22(2):96–100

ETIOLOGY

[Sarcoidosis with hematologic involvement and hypogammaglobulinemia] Bader-Meunier B, et al. **Arch Pediatr** 1996 Jun;3(6):576–9 (Eng. Abstr.) **(Fre)**

[Leishmaniasis with hypogammaglobulinemia and its relationship with T-cell lymphoma (letter)] Mendoza H, et al. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):226–7 **(Spa)**

GENETICS

Unusual patterns of exon skipping in Bruton tyrosine kinase are associated with mutations involving the intron 17 3' splice site. Haire RN, et al. **Am J Hum Genet** 1997 Apr; 60(4):798–807

Anemia in a patient with panhypogammaglobulinemia [clinical conference] Ruddell DN, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):17–20

A novel Tth111I restriction fragment length polymorphism (RFLP) allows tracing of X-chromosome inactivation in the (Xid) heterozygote. Shanmugam V, et al. **Biochem Genet** 1996 Feb;34(1–2):17–29

X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease. Mattsson PT, et al. **Bioessays** 1996 Oct;18(10):825–34 (84 ref.)

X-linked agammaglobulinemia: a case report. Chen CM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Dec; 56(6):427–31

Expression of Bruton's tyrosine kinase in B lymphoblastoid cell lines from X-linked agammaglobulinaemia patients. De Weers M, et al. **Clin Exp Immunol** 1997 Feb;107(2):235–40

Neutropenia in X-linked agammaglobulinemia. Farrar JE, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):271–6

Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. Hyvönen M, et al. **EMBO J** 1997 Jun;16(12):3396–404

B cell-deficient muMT mice as an experimental model for Mycoplasma infections in X-linked agammaglobulinemia. Berglöf A, et al. **Eur J Immunol** 1997 Aug;27(8):2118–21

Missense mutations affecting a conserved cysteine pair in the TH domain of Btk. Vihinen M, et al. **FEBS Lett** 1997 Aug 18;413(2):205–10

Mutations of the Btk gene in 12 unrelated families with X-linked agammaglobulinemia in Japan. Kobayashi S, et al. **Hum Genet** 1996 Apr;97(4):424–30

Mutation analysis in CD40 ligand deficiency leading to X-linked hypogammaglobulinemia with hyper IgM syndrome. Katz F, et al. **Hum Mutat** 1996;8(3):223–8

Mutation pattern in the Bruton's tyrosine kinase gene in 26 unrelated patients with X-linked agammaglobulinemia. Vořechovský I, et al. **Hum Mutat** 1997;9(5):418–25

BTKbase: XLA-mutation registry. Vihinen M. **Immunol Today** 1996 Nov;17(11):502–6

Symposium on gene abnormalities in medical diseases. 1. Immunological diseases: Bruton's agammaglobulinemia. Tsukada S. **Intern Med** 1997 Feb;36(2):148–50

A human non-XLA immunodeficiency disease characterized by blockage of B cell development at an early proB cell stage. Meffre E, et al. **J Clin Invest** 1996 Oct 1; 98(7):1519–26

Identification of novel Bruton's tyrosine kinase mutations in 10 unrelated subjects with X linked agammaglobulinaemia. Brooimans RA, et al. **J Med Genet** 1997 Jun;34(6):484–8

Bilateral chronic conjunctivitis and corneal scarring in a boy with X-linked hypogammaglobulinaemia. al Ghonaium A, et al. **J Paediatr Child Health** 1996 Oct;32(5):463–5

Primary immunodeficiency disease presenting in midlife [letter] Kornfeld SJ, et al. **JAMA** 1996 Dec 25; 276(24):1953–4

X-linked agammaglobulinemia. A clinical and molecular analysis. Ochs HD, et al. **Medicine (Baltimore)** 1996 Nov; 75(6):287–99 (134 ref.)

A novel mutation (Cys145-->Stop) in Bruton's tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male. Kornfeld SJ, et al. **Mol Med** 1996 Sep;2(5):619–23

Molecular and structural characterization of five novel mutations in the Bruton's tyrosine kinase gene from patients with X-linked agammaglobulinemia. Saha BK, et al. **Mol Med** 1997 Jul;3(7):477–85

Agammaglobulinemia and insights into B-cell differentiation [editorial; comment] Manis J, et al. **N Engl J Med** 1996 Nov 14;335(20):1523–5. Comment on: N Engl J Med 1996 Nov 14;335(20):1486–93.

Mutations in the mu heavy-chain gene in patients with agammaglobulinemia [see comments] Yel L, et al. **N Engl J Med** 1996 Nov 14;335(20):1486–93. Comment in: N Engl J Med 1996 Nov 14;335(20):1523–5.

BTKbase, mutation database for X-linked agammaglobulinemia (XLA) [published erratum appears in Nucleic Acids Res 1997 May 1;25(9):1874] Vihinen M, et al. **Nucleic Acids Res** 1997 Jan 1;25(1):166–71

[Diseases in the field of internal medicine and gene abnormalities. 1. Immunologic disease (Bruton's agammaglobulinemia)] Tsukada S. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1491–7 **(Jpn)**

IMMUNOLOGY

Clinical manifestations of IgE hypogammaglobulinemia. Smith JK, et al. **Ann Allergy Asthma Immunol** 1997 Mar; 78(3):313–8

Hypogammaglobulinaemia occurs in Fas-deficient MRL-lpr mice following deletion of MHC class II molecules. Anderson CC, et al. **Clin Exp Immunol** 1997 Sep; 109(3):473–9

Elevation of CD8+ CD11b+ Leu-8- T cells is associated with the humoral immunodeficiency in myeloma patients. Walchner M, et al. **Clin Exp Immunol** 1997 Aug; 109(2):310–6

Neutropenia in X-linked agammaglobulinemia. Farrar JE, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):271–6

A non-XLA primary deficiency causes the earliest known defect of B cell differentiation in humans: a comparison with an XLA case. Meffre E, et al. **Immunol Lett** 1997 Jun 1;57(1-3):93–9

T cell activity and cytokine production in X-linked agammaglobulinemia: implications for vaccination strategies. Plebani A, et al. **Int Arch Allergy Immunol** 1997 Sep;114(1):90–3

A human non-XLA immunodeficiency disease characterized by blockage of B cell development at an early proB cell stage. Meffre E, et al. **J Clin Invest** 1996 Oct 1; 98(7):1519–26

xid affects events leading to B cell cycle entry. Brorson K, et al. **J Immunol** 1997 Jul 1;159(1):135–43

Quantitative analysis of the influenza virus-specific CD4+ T cell memory in the absence of B cells and Ig. Topham DJ, et al. **J Immunol** 1996 Oct 1;157(7):2947–52

Humoral immunity in steroid-dependent children with asthma and hypogammaglobulinemia. Lack G, et al. **J Pediatr** 1996 Dec;129(6):898–903

Hyperimmunized agammaglobulinemic RAG mice develop accelerated rejection of skin allografts due to CD8+ T cell immunization. Chargui J, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):867

Strongyloidiasis in a patient with IgA deficiency. Leung VK, et al. **Trop Gastroenterol** 1995 Oct-Dec;16(4):27–30

METABOLISM

The identification of Bruton's tyrosine kinase and Wiskott-Aldrich syndrome protein associated proteins and signalling pathways. Kinnon C, et al. **Biochem Soc Trans** 1997 May;25(2):648–50 (27 ref.)

PATHOLOGY

Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Washington K, et al. **Am J Surg Pathol** 1996 Oct; 20(10):1240–52

Anemia in a patient with panhypogammaglobulinemia [clinical conference] Ruddell DN, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):17–20

PREVENTION & CONTROL

HCV and hypogammaglobulinemia [letter] Sierra FJ, et al. **J Hepatol** 1997 May;26(5):1158–9

THERAPY

T cell activity and cytokine production in X-linked agammaglobulinemia: implications for vaccination strategies. Plebani A, et al. **Int Arch Allergy Immunol** 1997 Sep;114(1):90–3

[Nebulization with human IGA in patients with hypogammaglobulinemia and airway infections secondary to lymphoproliferative diseases (letter)] Sánchez Avalos JC, et al. **Medicina (B Aires)** 1995;55(6):727–9 **(Spa)**

VIROLOGY

Hepatitis C virus infection in Italian patients with hypogammaglobulinemia. Quinti I, et al. **Clin Ther** 1996; 18 Suppl B:96–107

HCV and hypogammaglobulinemia [letter] Sierra FJ, et al. **J Hepatol** 1997 May;26(5):1158–9

Epstein-Barr virus (EBV)-induced CD30+ natural killer cell-type malignancy resembling malignant histiocytosis: malignant transformation in chronic active EBV infection associating hypogammaglobulinemia. Tsutsumi Y, et al. **Pathol Int** 1997 Jun;47(6):384–92

AGANGLIONOSIS, COLONIC see **HIRSCHSPRUNG DISEASE**

AGAR

Ceftazidime kinetics of diffusion in inoculated agar plates. Arcelloni C, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1280–1

Inexpensive 4-hour micro-agar dilution susceptibility determination method. Holloway Y, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2792–5

Isolation of thermophilic bacteria using bacteriological grade agar at temperatures above 80 degrees C. D'Souza DR, et al. **Biotechniques** 1997 Jun;22(6):1078

Evaluation of CPS ID 2 chromogenic agar as a single medium for urine culture. Reisner BS, et al. **Diagn Microbiol Infect Dis** 1997 Jul;28(3):113–7

Evaluation of CHROMagar Orientation for differentiation and presumptive identification of gram-negative bacilli and Enterococcus species [published erratum appears in J Clin Microbiol 1997 Aug;35(8):2190] Merlino J, et al. **J Clin Microbiol** 1996 Jul;34(7):1788–93

Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. Patterson TF, et al. **J Clin Microbiol** 1996 Jul;34(7):1794–7

[Comparison of the results of determining antibiotic sensitivity on AGV medium and on Mueller-Hinton and isosensitest agars] Kozlov RS, et al. **Antibiot Khimioter** 1996;41(10):22–7 (Eng. Abstr.) **(Rus)**

[Evaluation of chromogenic medium CPS ID2 (bioMérieux) in urine cultures (see comments)] Navarro F, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):215–9 (Eng. Abstr.). Comment in: Enferm Infecc Microbiol Clin 1996 Nov;14(9):570–1. Comment in: Enferm Infecc Microbiol Clin 1996 Nov;14(9):571. **(Spa)**

CHEMISTRY

Development of oral dosage form for elderly patients: use of agar as base of rapidly disintegrating oral tablets. Ito A, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2132–6

Two-day hydrophobic grid membrane filter method for yeast and mold enumeration in foods using YM-11 agar: collaborative study. Entis P. **J AOAC Int** 1996 Sep-Oct; 79(5):1069–82

Use of urease-bromothymol blue-agar method for large-scale testing of urine on grain and seeds. Valdes PA, et al. **J AOAC Int** 1996 Jul-Aug;79(4):866–73

DIAGNOSTIC USE

Comparison of agar gel (CLOtest) or reagent strip (PyloriTek) rapid urease tests for detection of Helicobacter pylori infection. Yousfi MM, et al. **Am J Gastroenterol** 1997 Jun;92(6):997–9

METABOLISM

Effects of a functional agar surface on in vitro dentinogenesis induced in proteolytically isolated, agar-coated dental papillae in rat mandibular incisors. Kikuchi H, et al. **Arch Oral Biol** 1996 Aug-Sep;41(8-9):871–83

PHARMACOLOGY

Antagonism of teicoplanin and vancomycin activity by chocolatized Mueller-Hinton agar. Traub WH, et al. **Chemotherapy** 1996 Sep-Oct;42(5):343–7

The effects of agar concentration on the growth and morphology of submerged colonies of motile and non-motile bacteria. Mitchell AJ, et al.

AGAR

J Appl Microbiol 1997 Jul;83(1):76–84

STANDARDS

Problems in detecting low–expression–class methicillin resistance in Staphylococcus aureus with batches of Oxoid Mueller–Hinton agar [letter] Coombs GW, et al. **J Antimicrob Chemother** 1996 Sep;38(3):551–3

AGAR DILUTION COUNT see **COLONY COUNT, MICROBIAL**

AGARICACEAE see **AGARICALES**

AGARICALES

Orellanine poisoning: rapid detection of the fungal toxin in renal biopsy material. Rohrmoser M, et al. **J Toxicol Clin Toxicol** 1997;35(1):63–6

CHEMISTRY

Polysaccharides in fungi. XXXVII. Immunomodulating activities of carboxymethylated derivatives of linear (1—>3)–alpha–D–glucans extracted from the fruiting bodies of Agrocybe cylindracea and Amanita muscaria. Yoshida I, et al. **Biol Pharm Bull** 1996 Jan;19(1):114–21

Determination of psilocybin in Psilocybe semilanceata by capillary zone electrophoresis. Pedersen–Bjergaard S, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):375–81

ENZYMOLOGY

Heterologous expression and reconstitution of fungal Mn peroxidase. Whitwam R, et al. **Arch Biochem Biophys** 1996 Sep 15;333(2):439–46

Glutathione S–transferases from the white–rot fungus, Phanerochaete chrysosporium. Dowd CA, et al. **Biochem J** 1997 May 15;324 (Pt 1):243–8

Co–expression of a Phanerochaete chrysosporium cellobiohydrolase gene and a Butyrivibrio fibrisolvens endo–beta–1,4–glucanase gene in Saccharomyces cerevisiae. van Rensburg P, et al. **Curr Genet** 1996 Aug; 30(3):246–50

GENETICS

Meiotic segregation and recombination of the intergenic spacer of the ribosomal DNA in the ectomycorrhizal basidiomycete Laccaria bicolor. Selosse MA, et al. **Curr Genet** 1996 Sep;30(4):332–7

METABOLISM

Degradation of polycyclic aromatic hydrocarbons by manganese peroxidase of Nematoloma frowardii. Sack U, et al. **FEMS Microbiol Lett** 1997 Jul 15;152(2):227–34

AGARICUS

Lack of carcinogenesis superfluous by the back mushroom Agaricus bisporus in mice: different feeding regimen. Toth B, et al. **In Vivo** 1997 May–Jun;11(3):227–31

NMR imaging of white button mushroom (Agaricus bisporis) at various magnetic fields. Donker HC, et al. **Magn Reson Imaging** 1996;14(10):1205–15

CHEMISTRY

Quantitative 1H–NMR imaging of water in white button mushrooms (Agaricus bisporus). Donker HC, et al. **Magn Reson Imaging** 1997;15(1):113–21

New contributions to the wall polysaccharide structure of vegetative mycelium and fruit body cell walls of Agaricus bisporus. Calonje M, et al. **Microbiologia** 1996 Dec; 12(4):599–606

ENZYMOLOGY

The Agaricus bisporus pruA gene encodes a cytosolic delta 1–pyrroline–5–carboxylate dehydrogenase which is expressed in fruit bodies but not in gill tissue. Schaap PJ, et al. **Appl Environ Microbiol** 1997 Jan;63(1):57–62

Pyranose 2–dehydrogenase, a novel sugar oxidoreductase from the basidiomycete fungus Agaricus bisporus. Volc J, et al. **Arch Microbiol** 1997 Feb–Mar;167(2–3):119–25

Triton X–114–aided purification of latent tyrosinase. Núñez–Delicado E, et al. **J Chromatogr B Biomed Appl** 1996 May 17;680(1–2):105–12

GENETICS

The Agaricus bisporus pruA gene encodes a cytosolic delta 1–pyrroline–5–carboxylate dehydrogenase which is expressed in fruit bodies but not in gill tissue. Schaap PJ, et al. **Appl Environ Microbiol** 1997 Jan;63(1):57–62

Isolation of expressed sequence tags of Agaricus bisporus and their assignment to chromosomes. Sonnenberg AS, et al. **Appl Environ Microbiol** 1996 Dec;62(12):4542–7

Cloning and sequencing of cDNA encoding 4–aminobenzoate hydroxylase from Agaricus bisporus. Tsuji H, et al. **Biochim Biophys Acta** 1996 Nov 11;1309(1–2):31–6

Conservation of genetic linkage with map expansion in distantly related crosses of Agaricus bisporus. Callac P, et al. **FEMS Microbiol Lett** 1997 Jan 15;146(2):235–40

Isolation of developmentally regulated genes from the edible mushroom Agaricus bisporus. De Groot PW, et al. **Microbiology** 1997 Jun;143 (Pt 6):1993–2001

Expression of CEL2 and CEL4, two proteins from Agaricus bisporus with similarity to fungal cellobiohydrolase I and beta–mannanase, respectively, is regulated by the carbon source. Yagüe E, et al. **Microbiology** 1997 Jan;143 (Pt 1):239–44

IMMUNOLOGY

A polysaccharide–peptide complex from cultured mycelia of the mushroom Tricholoma mongolicum with immunoenhancing and antitumor activities. Wang HX, et al. **Biochem Cell Biol** 1996;74(1):95–100

METABOLISM

15N–NMR study of ammonium assimilation in Agaricus bisporus. Baars JJ, et al. **Biochim Biophys Acta** 1997 Jan 10;1310(1):74–80

VIROLOGY

RT–PCR detection of dsRNAs associated with La France disease of the cultivated mushroom Agaricus bisporus (Lange) Imbach. Revill PA, et al. **J Virol Methods** 1997 Jan;63(1–2):17–26

AGARIN see **MUSCIMOL**

AGAROSE see **SEPHAROSE**

AGE DETERMINATION BY SKELETON

Can frontal sinus development be used for the prediction of skeletal maturity at puberty? Ruf S, et al. **Acta Odontol Scand** 1996 Aug;54(4):229–34

Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height. Haeusler G, et al. **Acta Paediatr** 1996 Dec; 85(12):1408–14

Appropriate use of significant figures [letter; comment] Mitchell CS. **AJR Am J Roentgenol** 1997 Aug;169(2):597–8 . Comment on: AJR Am J Roentgenol 1996 Dec;167(6):1395–8.

Bone age in children of diverse ethnicity [see comments] Ontell FK, et al. **AJR Am J Roentgenol** 1996 Dec; 167(6):1395–8. Comment in: AJR Am J Roentgenol 1997 Aug;169(2):597–8.

Ossification of the distal phalanx of the first digit as a maturity indicator for initiation of orthodontic treatment of Class III malocclusion in Japanese women. Goto S, et al. **Am J Orthod Dentofacial Orthop** 1996 Nov;110(5):490–501

Frontal sinus development as an indicator for somatic maturity at puberty? Ruf S, et al. **Am J Orthod Dentofacial Orthop** 1996 Nov;110(5):476–82

Developmental age and taxonomic affinity of the Mojokerto child, Java, Indonesia. Antón SC. **Am J Phys Anthropol** 1997 Apr;102(4):497–514

Sampling location in cortical bone histology. Drusini AG. **Am J Phys Anthropol** 1996 Aug;100(4):609–10

Problems in the aging of skeletal juveniles: perspectives from maturation assessments of living children. Lampl M, et al. **Am J Phys Anthropol** 1996 Nov;101(3):345–55

Assessing the reliability of paleodemographic fertility estimators using simulated skeletal distributions. Paine RR, et al. **Am J Phys Anthropol** 1996 Oct;101(2):151–9 (38 ref.)

Accuracy of leg length prediction in children younger than 10 years of age. Kasser JR, et al. **Clin Orthop** 1997 May; (338):9–13

Population biology of human aging: ethnic and climatic variation of bone age scores. Livshits G, et al. **Hum Biol** 1996 Apr;68(2):293–314

Rate of maturation during the teenage years: nutrient intake and physical activity between ages 12 and 22. Kemper HC, et al. **Int J Sport Nutr** 1997 Sep;7(3):229–40

Standard bone–age of infants and children in Korea. Yeon KM. **J Korean Med Sci** 1997 Feb;12(1):9–16

Skeletal immaturity, IGF–I and IGFBP–3 serum concentrations in Legg–Calvé–Perthes disease (skeletal immaturity, IGF–I and IGFBP–3 in LCPD). Grasemann H, et al. **Klin Padiatr** 1996 Nov–Dec;208(6):339–43

Skeletal age as a determinant of bone mass in preadolescent females. Ilich JZ, et al. **Skeletal Radiol** 1996 Jul;25(5):431–9

[Computerized tomography of the epiphyseal union of the medial clavicle: an auxiliary method of age determination during adolescence and the 3d decade of life?] Kreitner KF, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jun;166(6):481–6 (Eng. Abstr.) **(Ger)**

METHODS

Skeletal maturation of wrist and hand ossification centers in normal Spanish boys and girls: a study using the Greulich–Pyle method. Jiménez–Castellanos J, et al. **Acta Anat (Basel)** 1996;155(3):206–11

Brief communication: estimates of some demographic parameters in a Neolithic rock–cut chamber (approximately 2000 BC) using iterative techniques for aging and demographic estimators. Bocquet–Appel JP, et al. **Am J Phys Anthropol** 1997 Apr;102(4):569–75

Brief communication: a test and correction of the clavicle method of Stout and Paine for histological age estimation of skeletal remains. Stout SD, et al. **Am J Phys Anthropol** 1996 May;100(1):139–42

Age of epiphyseal closure in tamarins and marmosets. Kohn LA, et al. **Am J Primatol** 1997;41(2):129–39

Skeletal maturity of the hand and wrist of healthy Argentinian children aged 4–12 years, assessed by the TWII method. Lejarraga H, et al. **Ann Hum Biol** 1997 May–Jun; 24(3):257–61

Main problems associated with bone age and maturity evaluation. Benso L, et al. **Horm Res** 1996;45 Suppl 2:42–8

Tanner–Whitehouse method of assessing skeletal maturity: problems and common errors. Cox LA. **Horm Res** 1996; 45 Suppl 2:53–5 (13 ref.)

The assessment of skeletal maturation. Gilli G. **Horm Res** 1996;45 Suppl 2:49–52 (15 ref.)

The effect of alternate–day low dose prednisolone on bone age in children with steroid dependent nephrotic syndrome. Bircan Z, et al. **Int Urol Nephrol** 1997;29(3):357–61

Contribution of microscopic plant anatomy to postmortem bone dating. Quatrehomme G, et al. **J Forensic Sci** 1997 Jan;42(1):140–3

Tanner–Whitehouse versus Greulich–Pyle in bone age determinations [editorial; comment] Oestreich AE. **J Pediatr** 1997 Jul;131(1 Pt 1):5–6. Comment on: J Pediatr 1997 Jul;131(1 Pt 1):34–40.

Tanner–Whitehouse bone age reference values for North American children [see comments] Tanner J, et al. **J Pediatr** 1997 Jul;131(1 Pt 1):34–40. Comment in: J Pediatr 1997 Jul;131(1 Pt 1):5–6.

Estimation of sex and age by calcification pattern of costal cartilage in Japanese. Inoi T. **Nippon Hoigaku Zasshi** 1997 Apr;51(2):89–94

Computer–aided skeletal age scores in healthy children, girls with Turner syndrome, and in children with constitutionally tall stature. Van Teunenbroek A, et al. **Pediatr Res** 1996 Feb;39(2):360–7

[Determination of skeletal age using the Oxford Score in children with epiphyseolysis of the femur head] Vick S, et al. **Z Orthop Ihre Grenzgeb** 1996 Jul–Aug;134(4):305–8 (Eng. Abstr.) **(Ger)**

AGE DETERMINATION BY TEETH

T.F.J. Huda and J.E. Bowman, Age determination from dental microstructure in juveniles: American Journal of Physical Anthropology, 1995 vol. 97: 135–150 [letter; comment] Black SM, et al. **Am J Phys Anthropol** 1996 Oct; 101(2):305–6. Comment on: Am J Phys Anthropol 1995 Jun;97(2):135–50.

Problems in the aging of skeletal juveniles: perspectives from maturation assessments of living children. Lampl M, et al. **Am J Phys Anthropol** 1996 Nov;101(3):345–55

An adolescent female Neandertal mandible from Montgaudier Cave, Charente, France. Mann A, et al. **Am J Phys Anthropol** 1997 Aug;103(4):507–27

Individual variation of tooth development in Swedish children. Teivens A, et al. **Swed Dent J** 1996;20(3):87–93

[Present possibilities of age determination in forensic medicine with emphasis on the importance of measurement of D– and L– forms of aspartic acid. I. An overview] Pilin A, et al. **Soud Lek** 1997 Feb;42(1):9–11 (Eng. Abstr.) **(Cze)**

[Age determination by measurement of the ratio of D– and L– forms of aspartic acid. II. Chiral separation of amino acids from human dentin] Pilin A, et al. **Soud Lek** 1997 Feb;42(1):12–6 (Eng. Abstr.) **(Cze)**

METHODS

Dental emergence among urban Zambian school children: an assessment of the accuracy of three methods in assigning ages. Gillett RM. **Am J Phys Anthropol** 1997 Apr; 102(4):447–54

Some considerations regarding the use of amino acid racemization in human dentine as an indicator of age at death. Carolan VA, et al. **J Forensic Sci** 1997 Jan;42(1):10–6

A Bayesian approach to adult human age estimation from dental observations by Johanson's age changes. Lucy D, et al. **J Forensic Sci** 1996 Mar;41(2):189–94

Estimation of age from teeth by amino acid racemization: influence of fixative. Ohtani S, et al. **J Forensic Sci** 1997 Jan;42(1):137–9

Age estimation using third molar development. Phrabhakaran N. **Malays J Pathol** 1995 Jun;17(1):31–4

Intra– and inter–examiner variations in four dental methods for age estimation of children. Reventlid M, et al. **Swed Dent J** 1996;20(4):133–9

VETERINARY

Dental age determination in young bushbabies. Molez–Verrière N, et al. **Folia Primatol (Basel)** 1997; 68(2):106–9

Ageing draft and trotter horses by their dentition. Muylle S, et al. **Vet Rec** 1997 Jul 5;141(1):17–20

[Comparison of two methods of age determination in teeth of known age from wild carnivores] Thomé H, et al. **Anat Histol Embryol** 1997 Jun;26(2):81–4 (Eng. Abstr.) **(Ger)**

AGE DISTRIBUTION

Anaesthetists are younger than other doctors [letter;

comment] McMamus C. **BMJ** 1997 Aug 2;315(7103):314. Comment on: BMJ 1996 Dec 21-28;313(7072):1581-2. Comment on: BMJ 1997 Apr 12;314(7087):1132.
Cohort size and age-specific suicide rates: a contingent relationship. Pampel FC. **Demography** 1996 Aug; 33(3):341-55
Age and gender interactions in physiological functional capacity: insight from swimming performance. Tanaka H, et al. **J Appl Physiol** 1997 Mar;82(3):846-51
Cross pressures on middle-aged adults: a broader view [editorial] Soldo BJ. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):S271-3
Effects of age upon interhemispheric EEG coherence in normal adults. Duffy FH, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):587-99
The effect of age on susceptibility to hypoxic-ischemic brain damage. Yager JY, et al. **Neurosci Biobehav Rev** 1997 Mar; 21(2):167-74 (91 ref.)

AGE FACTORS

Age and life-sustaining treatment. Attitudes of intensive care unit professionals. Melltorp G, et al.
Acta Anaesthesiol Scand 1996 Sep;40(8 Pt 1):904-8
Effects of age at introduction of complementary foods to breast-fed infants on duration of lactational amenorrhea in Honduran women. Dewey KG, et al.
Am J Clin Nutr 1997 May;65(5):1403-9
Re: "Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale" [letter; comment] Ingram DD, et al. **Am J Epidemiol** 1997 Sep 15;146(6):528-9. Comment on: Am J Epidemiol 1997 Jan 1;145(1):72-80.
Decline in muscle insulin-dependent and -independent glucose uptake but not GLUT-4 in 21- vs. 28-day-old rats. Cartee GD, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):E446-52
Blunt hepatic injury in adolescents: age makes a difference. Shin H, et al. **Am Surg** 1997 Jan;63(1):29-36
Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands [see comments] de Rijke JM, et al. **Ann Oncol** 1996 Sep;7(7):677-85. Comment in: Ann Oncol 1996 Sep;7(7):657-8.
Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Metlay JP, et al.
Arch Intern Med 1997 Jul 14;157(13):1453-9
Do-not-resuscitate orders in the elderly: age discrimination or patient preference? [letter; comment] Rosenfeld KE, et al. **Arch Intern Med** 1997 May 12;157(9):1041, 1043. Comment on: Arch Intern Med 1996 Sep 9;156(16):1821-6.
Associations of age, adiposity, menopause, and alcohol intake with low-density lipoprotein subclasses. Williams PT, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1082-90
Seasonal variability in blood platelet 3H-imipramine binding in healthy controls: age and gender effects. Soria PR, et al. **Biol Psychiatry** 1996 Nov 15;40(10):981-5
Effect of age on outcome and epidemiology of infectious diseases. Miller E, et al. **Biologicals** 1997 Jun;25(2):137-42
Oral contraceptive use at a young age and the risk of breast cancer: an Icelandic, population-based cohort study of the effect of birth year. Tryggvadóttir L, et al.
Br J Cancer 1997;75(1):139-43
Are young age and insulin treatment enough to diagnose IDDM? [letter; comment] Maislos M, et al.
Diabetes Care 1997 Apr;20(4):675-6. Comment on: Diabetes Care 1996 Jul;19(7):689-97.
Insulin resistance shows selective metabolic and hormonal targets in the elderly. Pagano G, et al.
Eur J Clin Invest 1996 Aug;26(8):650-6
Mothers and daughters menopausal ages: is there a link? Torgerson DJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jul;74(1):63-6
The impact of age on cost-effectiveness ratios and its control in decision making. Baltussen R, et al. **Health Econ** 1996 May-Jun;5(3):227-39 (40 ref.)
The relationship between health expenditures and the age structure of the population in OECD countries. O'Connell JM. **Health Econ** 1996 Nov-Dec;5(6):573-8
Marriage: distance between birthplaces and age difference between mates. Bouckaert A, et al. **Hum Biol** 1997 Apr; 69(2):241-51
Female and male partner age and menotrophin requirements influence pregnancy rates with human menopausal gonadotrophin therapy in combination with intrauterine insemination. Brzechffa PR, et al. **Hum Reprod** 1997 Jan; 12(1):29-33
Psychological stress and depression in older patients with intravenous drug use and human immunodeficiency virus infection: implications for intervention. Singh N, et al.
Int J STD AIDS 1997 Apr;8(4):251-5
Acetylator phenotype in relation to age and gender in the Baltimore Longitudinal Study of Aging. Korrapati MR, et al. **J Clin Pharmacol** 1997 Feb;37(2):83-91
Preliminary normative data on the Geriatric Depression Scale-Short Form (GDS-SF) in a young adult sample. Ferraro FR, et al. **J Clin Psychol** 1996 Jul;52(4):443-7
Age at death of Gibraltar 2. Skinner M. **J Hum Evol** 1997 May;32(5):469-70; discussion 471-2
National Institutes of Health Consensus Development Conference Statement: Breast Cancer Screening for Women Ages 40-49, January 21-23, 1997. National Institutes of Health Consensus Development Panel.
J Natl Cancer Inst 1997 Jul 16;89(14):1015-26 (94 ref.)
ART in women 40 and over. Is the cost worth it? Legro RS, et al. **J Reprod Med** 1997 Feb;42(2):76-82
Person perception as a function of marital status and age. Stacy NL, et al. **J Soc Psychol** 1997 Jun;137(3):395-7
Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. Poynard T, et al.
J Viral Hepat 1997 May;4(3):199-208
Effect of age, gender, and platelet count on Sonoclot coagulation analysis in patients undergoing orthopedic operations. Horlocker TT, et al. **Mayo Clin Proc** 1997 Mar; 72(3):214-9
Maternal age effect on early human embryonic development and blastocyst formation. Janny L, et al.
Mol Reprod Dev 1996 Sep;45(1):31-7
Can age-based rationing of health care be morally justified? Rivlin MM. **Mt Sinai J Med** 1997 Mar;64(2):113-9
Sex, age, height, and weight as predictors of selected physiologic outcomes. Brown JK, et al. **Nurs Res** 1997 Mar-Apr;46(2):101-4
Prognostic importance of advanced age in aggressive non-Hodgkin's malignant lymphoma. Kovner F, et al.
Oncology 1996 Nov-Dec;53(6):435-40
In vitro cytokine production and phenotype expression by blood mononuclear cells from umbilical cords, children and adults. Müller K, et al. **Pediatr Allergy Immunol** 1996 Aug; 7(3):117-24
Ebola hemorrhagic fever: why were children spared? Dowell SF. **Pediatr Infect Dis J** 1996 Mar;15(3):189-91
Using the SF-36 and Euroqol on an elderly population. Brazier JE, et al. **Qual Life Res** 1996 Apr;5(2):195-204
Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Pignon T, et al. **Radiother Oncol** 1997 Feb; 42(2):107-20
Estimating age, period and cohort effects using the multistage model for cancer. Holford TR, et al. **Stat Med** 1994 Jan 15;13(1):23-41
Aging living donor: the best source for kidney transplantation? Berardinelli L, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):195-7
Discarding the older age kidney: establishing the need for innovative utilization. Delmonico FL. **Transplant Proc** 1997 Feb-Mar;29(1-2):130-1
Senior citizens pool for aged kidneys. Gjertson DW, et al.
Transplant Proc 1997 Feb-Mar;29(1-2):129
Short- and intermediate-term implications of using older donors for heart transplantation. Pierson RN 3rd, et al.
Transplant Proc 1997 Feb-Mar;29(1-2):593-4
Analysis of factors affecting the outcome of renal transplantation in older people. Sharma AK, et al.
Transplant Proc 1997 Feb-Mar;29(1-2):261
Association between serum gastrin levels, gastric acid secretion and age in early gastric cancer. Miyaji M, et al.
Tumour Biol 1997;18(5):311-20

AGE OF ONSET

Thalamic gliomas: a clinicopathologic analysis of 20 cases with reference to patient age. Nishio S, et al.
Acta Neurochir (Wien) 1997;139(4):336-42
Age at onset: the major determinant of outcome in Parkinson's disease. Hely MA, et al. **Acta Neurol Scand** 1995 Dec;92(6):455-63
Age of onset in familial and sporadic schizophrenia. Alda M, et al. **Acta Psychiatr Scand** 1996 Jun;93(6):447-50
Variable age at onset in insulin-dependent diabetes mellitus, by the marker-association-segregation-chi 2 method. Bonneuil N, et al. **Am J Hum Genet** 1997 Jul;61(1):223-7
Late-onset congenital adrenal hyperplasia. Panitsa-Faflia C, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:230-4 (06 ref.)
Semiparametric estimation of major gene and family-specific random effects for age of onset. Li H, et al. **Biometrics** 1997 Mar;53(1):282-93
Age at onset in schizophrenia and risk of illness in relatives. Results from the Roscommon Family Study. Kendler KS, et al. **Br J Psychiatry** 1996 Aug;169(2):213-8
Early onset cerebellar ataxia with retained tendon reflexes (EOCA): an electromyographic study. Pal PK, et al.
Electromyogr Clin Neurophysiol 1996 Jul-Aug;36(5):287-93
Mean age of tumor onset in hereditary nonpolyposis colorectal cancer (HNPCC) families correlates with the presence of mutations in DNA mismatch repair genes. Pensotti V, et al. **Genes Chromosomes Cancer** 1997 Jul; 19(3):135-42
Timing of menopause in relation to body size and weight change. Leidy LE. **Hum Biol** 1996 Dec;68(6):967-82
Truly late onset of eating disorders: a study of 11 cases averaging 60 years of age at presentation. Beck D, et al.
Int J Eat Disord 1996 Dec;20(4):389-95
Average age at first occurrence as an alternative occurrence parameter in epidemiology. Boshuizen HC, et al.
Int J Epidemiol 1997 Aug;26(4):867-72
Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers. Chang-Claude J, et al.
J Cancer Res Clin Oncol 1997;123(5):272-9
Adult onset of stuttering as a presenting sign in a parkinsonian-like syndrome: a case report. Leder SB.
J Commun Disord 1996 Nov-Dec;29(6):471-7; quiz 477-8
Variation on a theme of Creutzfeldt-Jakob disease: implications of new cases with a young age at onset. Ridley RM, et al. **J Gen Virol** 1996 Dec;77 (Pt 12):2895-904 (61 ref.)
Differential rates of age of seizure onset between sexes and between hemispheres? Strauss E, et al.
J Int Neuropsychol Soc 1997 Sep;3(5):428-34
Comparing the age at prostate cancer diagnosis in humans and dogs [letter] Waters DJ, et al. **J Natl Cancer Inst** 1996 Nov 20;88(22):1686-7
Trinucleotide repeats not the only cause of anticipation. Fraser FC. **Lancet** 1997 Aug 16;350(9076):459-60
Does Alzheimer's disease start early in life? Ohm TG.
Mol Psychiatry 1997 Jan;2(1):21-5
Polymorphism in AACT gene may lower age of onset of Alzheimer's disease. Talbot C, et al. **Neuroreport** 1996 Jan 31;7(2):534-6
The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. Minthon L, et al. **Neurosci Lett** 1997 Apr 18; 226(1):65-7
Late onset type I familial amyloidotic polyneuropathy: presentation of three autopsy cases in comparison with 19 autopsy cases of the ordinary type. Takahashi K, et al.
Pathol Int 1997 Jun;47(6):353-9
Late onset central hypoventilation syndrome. Del Carmen Sanchez M, et al. **Pediatr Pulmonol** 1996 Mar;21(3):189-91
Anticipation in multiplex schizophrenia pedigrees. Yaw J, et al. **Psychiatr Genet** 1996 Spring;6(1):7-11
Age at illness onset and left temporal lobe length in males with schizophrenia. Bartzokis G, et al. **Psychiatry Res** 1996 Oct 7;67(3):189-201
Quality of well-being in late-life psychosis. Patterson TL, et al. **Psychiatry Res** 1996 Jul 31;63(2-3):169-81
[Late onset schizophrenias: a case of chronic hallucinatory psychosis] Fabregat Navarro V, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1996 Nov-Dec;24(6):353-7 (Eng. Abstr.) **(Spa)**
[Late onset epilepsy] Alberca R, et al. **Neurologia** 1996 Dec; 11 Suppl 4:72-9 (57 ref.) (Eng. Abstr.) **(Spa)**

AGE-RELATED OSTEOPOROSIS see **OSTEOPOROSIS**

AGED

see related
HEALTH SERVICES FOR THE AGED
HOMES FOR THE AGED
HOUSING FOR THE ELDERLY
PENSIONS
RETIREMENT

Exposure and risk factors among elderly drivers: a case-control study. Lefrançois R, et al.
Accid Anal Prev 1997 May;29(3):267-75
Dens fractures in the elderly. Results of anterior screw fixation in 19 elderly patients. Berlemann U, et al.
Acta Orthop Scand 1997 Aug;68(4):319-24
Different kinds of services and informal support in the daily life activities in a community-based elderly population. Gosman-Hedström G, et al. **Aging (Milano)** 1995 Oct; 7(5):371-8
The use and effectiveness of assistive devices in an elderly urban population. Sonn U, et al. **Aging (Milano)** 1996 Jun; 8(3):176-83
Incidence of functional decline and improvement in a community-dwelling, very elderly population. Hébert R, et al. **Am J Epidemiol** 1997 May 15;145(10):935-44
Physician rationale for benzodiazepine prescriptions to elderly hospitalized patients. Zisselman MH, et al.
Am J Geriatr Psychiatry 1997 Spring;5(2):167-71
Common questions about sex and sexuality in elders. Mueller IW. **Am J Nurs** 1997 Jul;97(7):61-4
Six tips for caring for aging parents. Stocker S.
Am J Nurs 1996 Sep;96(9):32-3
Fat and carbohydrate metabolism during exercise in elderly and young subjects. Sial S, et al. **Am J Physiol** 1996 Dec; 271(6 Pt 1):E983-9
Modifying the environment: a community-based injury-reduction program for elderly residents. Plautz B, et al. **Am J Prev Med** 1996 Jul-Aug;12(4 Suppl):33-8
Myocardial protection in the elderly. Biology of the senescent heart. McCully JD, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:305-18 (51 ref.)
Reliability of a modified medication appropriateness index in ambulatory older persons [see comments] Fitzgerald LS, et al. **Ann Pharmacother** 1997 May;31(5):543-8. Comment in: Ann Pharmacother 1997 May;31(5):643-4.
Factors associated with suboptimal analgesic use in community-dwelling elderly. Hanlon JT, et al.
Ann Pharmacother 1996 Jul-Aug;30(7-8):739-44
Medication use characteristics in an ambulatory elderly population in Taiwan. Hsu RY, et al.
Ann Pharmacother 1997 Mar;31(3):308-14
Extent and variation of omeprazole prescribing in an elderly population of Ontario. McBride JE, et al.
Ann Pharmacother 1997 Apr;31(4):411-6
Medication appropriateness index: putting a number on an old problem in older patients [comment] Murray MD.
Ann Pharmacother 1997 May;31(5):643-4. Comment on: Ann Pharmacother 1997 May;31(5):529-33. Comment on: Ann Pharmacother 1997 May;31(5):533-42. Comment on: Ann Pharmacother 1997 May;31(5):543-8.
Drug use by the elderly in Italy. Nobili A, et al.

Ann Pharmacother 1997 Apr;31(4):416–22

Inappropriate prescribing and health outcomes in elderly veteran outpatients [see comments] Schmader KE, et al. **Ann Pharmacother** 1997 May;31(5):529–33. Comment in: Ann Pharmacother 1997 May;31(5):643–4.

Reliability of drug utilization evaluation as an assessment of medication appropriateness [see comments] Shelton PS, et al. **Ann Pharmacother** 1997 May;31(5):533–42. Comment in: Ann Pharmacother 1997 May;31(5):643–4.

Heart transplantation in patients 65 years of age and older: a comparative analysis of 40 patients. Blanche C, et al. **Ann Thorac Surg** 1996 Nov;62(5):1442–6; discussion 1447

Distribution and correlates of lipids and lipoproteins in elderly Japanese-American men. The Honolulu Heart Program. Burchfiel CM, et al.
Arterioscler Thromb Vasc Biol 1996 Nov;16(11):1356–64

Peripheral artery disease and cardiovascular risk factors in the elderly. The Honolulu Heart Program. Curb JD, et al. **Arterioscler Thromb Vasc Biol** 1996 Dec; 16(12):1495–500

Health status, life satisfaction and health practices: a study of Pacific Asian and Native Hawaiian elderly cohorts. Koseki LK, et al. **Asia Pac J Public Health** 1995; 8(2):95–101

Are older people living in the subtropics at risk of hypothermia? [letter] Kwok T, et al. **Aust N Z J Med** 1997 Feb;27(1):76

Competence and the elderly patient with cognitive impairments. Ryan SP. **Aust N Z J Psychiatry** 1996 Dec; 30(6):768–73 (30 ref.)

Professional responsibility in elder law: a synthesis of preventive law and therapeutic jurisprudence. Stolle DP. **Behav Sci Law** 1996 Autumn;14(4):459–78 (0 ref.)

Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Zinzani PL, et al. **Blood** 1997 Jun 1; 89(11):3974–9

Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Stamatoullas A, et al. **Bone Marrow Transplant** 1997 Jan;19(1):31–5

Prevalence of cancer in the elderly: discrepancies between self-reported and registry data. Berthier F, et al.
Br J Cancer 1997;75(3):445–7

Logistics of performing an ophthalmic assessment in elderly inpatients. Whittaker KW, et al. **Br J Clin Pract** 1997 Mar; 51(2):119–20

Ultrasound bone densitometry of os calcis in elderly Japanese women with hip fracture. Sakata S, et al.
Calcif Tissue Int 1997 Jan;60(1):2–7

Allocating healthcare by QALYs: the relevance of age. Mckie J, et al. **Camb Q Healthc Ethics** 1996 Fall;5(4):534–45

Safety and efficacy of physical restraints for the elderly. Review of the evidence. Frank C, et al.
Can Fam Physician 1996 Dec;42:2402–9 (42 ref.)

Double-edged sword. Anticoagulation therapy for the elderly [news] Kermode-Scott B. **Can Fam Physician** 1997 Apr;43:803–4

Cardiopulmonary resuscitation of elderly people in long-term care [editorial] [see comments] Nazerali N.
Can Fam Physician 1996 Dec;42:2320–2, 2330–2 (22 ref.) . Comment in: Can Fam Physician 1997 Apr;43:609, 611, 613. Comment in: Can Fam Physician 1997 Apr;43:613. **(Eng, Fre)**

Medication use and rural seniors. Who really knows what they are taking? Torrible SJ, et al. **Can Fam Physician** 1997 May;43:893–8

The STEPS Project: participatory action research to reduce falls in public places among seniors and persons with disabilities. Gallagher EM, et al. **Can J Public Health** 1997 Mar-Apr;88(2):129–33 (24 ref.)

Health of our elders. Perera B. **Ceylon Med J** 1997 Jun; 42(2):91–3

Shift in the incidence of rheumatoid arthritis toward elderly patients in Finland during 1975–1990. Kaipiainen-Seppänen O, et al. **Clin Exp Rheumatol** 1996 Sep-Oct;14(5):537–42

Cancer in the elderly. Epidemiologic and clinical implications. Balducci L, et al. **Clin Geriatr Med** 1997 Feb; 13(1):1–14 (48 ref.)

Life expectancy, comorbidity, and quality of life. A framework of reference for medical decisions. Bennahum DA, et al. **Clin Geriatr Med** 1997 Feb;13(1):33–53 (94 ref.)

Cancer surgery in the elderly. Berger DH, et al.
Clin Geriatr Med 1997 Feb;13(1):119–41 (84 ref.)

Prevalence of cancer in older persons living at home and in institutions. Caranasos GJ. **Clin Geriatr Med** 1997 Feb; 13(1):15–31 (33 ref.)

Barriers to cancer prevention in the older person. Fox SA, et al. **Clin Geriatr Med** 1997 Feb;13(1):79–95 (129 ref.)

Radiotherapy in the aged. Olmi P, et al.
Clin Geriatr Med 1997 Feb;13(1):143–68 (116 ref.)

Cancer screening in the older patient. Robinson B, et al.
Clin Geriatr Med 1997 Feb;13(1):97–118 (76 ref.)

Symptomatic management of the older person with cancer. Sheehan DC, et al. **Clin Geriatr Med** 1997 Feb;13(1):203–19 (66 ref.)

Preoperative and postoperative care of the elderly woman. Barber HR. **Clin Obstet Gynecol** 1996 Dec;39(4):902–5 (7 ref.)

Geriatric gynecologic care of minorities. Haynes MO.
Clin Obstet Gynecol 1996 Dec;39(4):946–58 (31 ref.)

Vulvovaginal disorders in the elderly woman. Nathan L.
Clin Obstet Gynecol 1996 Dec;39(4):933–45 (36 ref.)

Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence? Ozdemir V, et al.
Clin Pharmacokinet 1996 Nov;31(5):372–85 (144 ref.)

Setting handicap goals with elderly people: a pilot study of the Life Strengths Interview. Pomeroy VM, et al.
Clin Rehabil 1997 May;11(2):156–61

Aging and gerontology: a paradigm of transdisciplinary research. Crews DE. **Coll Antropol** 1997 Jun;21(1):83–92

Recruiting older adults for clinical trials. Adams J, et al.
Control Clin Trials 1997 Feb;18(1):14–26

Preventive cardiology in the elderly. Wenger NK.
Curr Opin Cardiol 1997 Mar;12(2):195–201 (39 ref.)

Dyslipoproteinemia in the elderly. Hazzard WR.
Curr Ther Endocrinol Metab 1997;6:650–7 (12 ref.)

Growth hormone deficiency in the elderly. Toogood AA, et al. **Curr Ther Endocrinol Metab** 1997;6:645–9 (11 ref.)

Group-living care: an alternative for the demented elderly. Annerstedt L. **Dement Geriatr Cogn Disord** 1997 Mar-Apr; 8(2):136–42

Services for older people with mental health problems: inequalities and strategies to help the 'have-nots'. Jolley D. **Dement Geriatr Cogn Disord** 1997 Mar-Apr;8(2):132–5

Project for the development of an ambulatory and semi-ambulatory community center for the third age. Tataru N. **Dement Geriatr Cogn Disord** 1997 Mar-Apr; 8(2):128–31

Psychogeriatric organization in the medico-social network: the experience of the canton of Vaud, Switzerland. Wertheimer J. **Dement Geriatr Cogn Disord** 1997 Mar-Apr; 8(2):143–5

Demographic and economic correlates of health in old age. Smith JP, et al. **Demography** 1997 Feb;34(1):159–70

Disability and cognitive impairment in the elderly. Barberger-Gateau P, et al. **Disabil Rehabil** 1997 May; 19(5):175–93 (173 ref.)

Planning a health education programme for the elderly visually impaired person--a focus group study. Ivanoff SD, et al. **Disabil Rehabil** 1996 Oct;18(10):515–22

An estimation of the functional disability burden in elderly Chinese age 70 years and over. Woo J, et al.
Disabil Rehabil 1996 Dec;18(12):609–12

Inflammatory bowel disease in the elderly. Practical treatment guidelines. Akerkar GA, et al. **Drugs Aging** 1997 Mar;10(3):199–208 (55 ref.)

Age as a basis for healthcare rationing. Arguments against agism. Scharf S, et al. **Drugs Aging** 1996 Dec;9(6):399–402

Age as a basis for healthcare rationing. Support for agist policies. Shaw AB. **Drugs Aging** 1996 Dec;9(6):403–5

Is anticoagulation therapy underused in elderly patients with atrial fibrillation? Turazza FM, et al. **Drugs Aging** 1997 Mar;10(3):174–84 (37 ref.)

Comparison of conventional amplification and an assistive listening device in elderly persons. Jerger J, et al.
Ear Hear 1996 Dec;17(6):490–504

The Jerusalem seventy year olds longitudinal study. II: Background results from the initial home interview. Cohen A, et al. **Eur J Epidemiol** 1995 Dec;11(6):685–92

The Jerusalem seventy-year-old longitudinal study. I: Description of the initial cross-sectional survey. Stessman J, et al. **Eur J Epidemiol** 1995 Dec;11(6):675–84

Selections from current literature: falls in the elderly. Trilling JS, et al. **Fam Pract** 1995 Dec;12(4):482–5 (17 ref.)

Electroconvulsive therapy in the very old. Casey DA, et al. **Gen Hosp Psychiatry** 1996 Nov;18(6):436–9

Keeping an eye on vision: new tools to preserve sight and quality of life. A roundtable discussion, Part 2. Butler RN, et al. **Geriatrics** 1997 Sep;52(9):48–50, 53–6

National Brown Bag Day. Annual reviews of older patients' medications would reduce the risk of reactions [editorial] Butler RN. **Geriatrics** 1996 Dec;51(12):9–10

When your patient is hospitalized: tips for primary care physicians. Palmer RM, et al. **Geriatrics** 1997 Sep; 52(9):36–42, 47

The 1996 election: older voters and implications for policies on aging. Binstock RH. **Gerontologist** 1997 Feb;37(1):15–9

Gender, the state, and constructing the old as dependent: lessons from the economic transition in Poland. Calasanti TM, et al. **Gerontologist** 1997 Aug;37(4):452–61 (34 ref.)

Human resource policies and older workers in Japan. Clark RL, et al. **Gerontologist** 1996 Oct;36(5):627–36 (26 ref.)

Missing links: the case for a social psychology of the life course. George LK. **Gerontologist** 1996 Apr;36(2):248–55

The meaning of heterogeneity: an introduction [comment] Grigsby JS. **Gerontologist** 1996 Apr;36(2):145–6. Comment on: Gerontologist 1996 Apr;36(2):147–56. Comment on: Gerontologist 1996 Apr;36(2):157–64. Comment on: Gerontologist 1996 Apr;36(2):165–73.

Distribution of informal and formal home help for elderly people in Sweden. Herlitz C. **Gerontologist** 1997 Feb; 37(1):117–24

The escape from poverty among rural and urban elders. Jensen L, et al. **Gerontologist** 1997 Aug;37(4):462–8

Gain in the caregiving experience: where are we? What next? Kramer BJ. **Gerontologist** 1997 Apr;37(2):218–32 (86 ref.)

Sexual activity and satisfaction among very old adults: results from a community-dwelling Medicare population survey. Matthias RE, et al. **Gerontologist** 1997 Feb;37(1):6–14

The precious and the precocious: understanding cumulative disadvantage and cumulative advantage over the life course. O'Rand AM. **Gerontologist** 1996 Apr;36(2):230–8

Religiosity and perceived rewards of black and white caregivers. Picot SJ, et al. **Gerontologist** 1997 Feb; 37(1):89–101

Internet resources on aging: increasing options and human factors. Post JA. **Gerontologist** 1997 Feb;37(1):125–9

Internet resources on aging: geriatrics, gerontological nursing, and related topics. Post JA. **Gerontologist** 1997 Apr;37(2):258–66

Internet resources on aging: parts of the Internet. Post JA.
Gerontologist 1996 Apr;36(2):137–40

Internet resources on aging: seniors on the net. Post JA.
Gerontologist 1996 Oct;36(5):565–9

The financial burden of prescription drug use among elderly persons. Rogowski J, et al. **Gerontologist** 1997 Aug; 37(4):475–82

Effects of a one-year physical activity intervention for older adults at congregate nutrition sites. Sharpe PA, et al.
Gerontologist 1997 Apr;37(2):208–15

Centenarians: human longevity outliers. Smith DW.
Gerontologist 1997 Apr;37(2):200–6

Lack of association between helicobacter pylori and gastric atrophy or intestinal metaplasia in elderly patients. Liston R, et al. **Gerontology** 1996;42(2):97–103

Is there a duty to die? Hardwig J. **Hastings Cent Rep** 1997 Mar-Apr;27(2):34–42 (9 ref.)

Age-related differences in perceptual learning. Gilbert DK, et al. **Hum Factors** 1996 Sep;38(3):417–24

Training older adults to use automatic teller machines. Rogers WA, et al. **Hum Factors** 1996 Sep;38(3):425–33

Left ventricular mass in the elderly. The Cardiovascular Health Study. Gardin JM, et al. **Hypertension** 1997 May; 29(5):1095–103

Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Sega R, et al. **Hypertension** 1997 Jul;30(1 Pt 1):1–6

The structural adjustment programme and the elderly in Nigeria. Ekpenyong S. **Int J Aging Hum Dev** 1995; 41(4):267–80

The meaning of work for older adults seeking employment: the generativity factor. Mor-Barak ME.
Int J Aging Hum Dev 1995;41(4):325–44

The meaning of grandparents as viewed by adolescent grandchildren: an empirical study in Belgium. Van Ranst N, et al. **Int J Aging Hum Dev** 1995;41(4):311–24

Women and the third and fourth age. Diczfalusy E, et al.
Int J Gynaecol Obstet 1997 Jul;58(1):177–88

Measuring the quality of life of older persons: a model with implications for community and public health nursing. Raphael D, et al. **Int J Nurs Stud** 1997 Jun;34(3):231–9

Physical performance measures for the elderly rehabilitated at home. Bohannon RW. **Int J Rehabil Res** 1997 Mar; 20(1):107–9

Emergency operations in the elderly: management and outcome. Karanikas ID, et al. **Int Surg** 1996 Apr-Jun; 81(2):158–62

Eye screening in the elderly. Keane EM, et al. **Ir Med J** 1997 Jun-Jul;90(4):141–2

Profile of Jerusalem's 70 year olds--social data. Cohen A, et al. **Isr J Med Sci** 1996 Aug;32(8):688–701

Factors predicting emergency room utilization in a 70-year-old population. Ginsberg G, et al.
Isr J Med Sci 1996 Aug;32(8):649–64

Gallopamil reduces the post-transplantation acute tubular necrosis in kidneys from aged donors. Lustig S, et al.
Isr J Med Sci 1996 Dec;32(12):1249–51

Profile of Jerusalem's 70 year olds--medical data. Stessman J, et al. **Isr J Med Sci** 1996 Aug;32(8):665–87

Teaching elderly patients how to use inhalers. A study to evaluate an education programme on inhaler technique, for elderly patients. Abley C. **J Adv Nurs** 1997 Apr; 25(4):699–708

Nursing attitudes to the care of elderly patients at risk of continuing hospital care. Carter H, et al. **J Adv Nurs** 1996 Sep;24(3):448–55

Promoting autonomy and independence for older people within nursing practice: a literature review. Davies S, et al. **J Adv Nurs** 1997 Aug;26(2):408–17 (89 ref.)

Functional status of the oldest-old in a home setting. Krach P, et al. **J Adv Nurs** 1996 Sep;24(3):456–64

Alcohol use amongst community-dwelling elderly people: a review of the literature. Lakhani N. **J Adv Nurs** 1997 Jun;25(6):1227–32 (36 ref.)

Snapshots of experience: vignettes from a nursing home. Running A. **J Adv Nurs** 1997 Jan;25(1):117–22

Hearing aid use, central auditory disorder, and hearing handicap in elderly persons. Chmiel R, et al.
J Am Acad Audiol 1996 Jun;7(3):190–202

Speech understanding in the elderly. Humes LE.
J Am Acad Audiol 1996 Jun;7(3):161–7

Assistive devices for the elderly. Kaplan H.
J Am Acad Audiol 1996 Jun;7(3):203–11

Communication Scale for Older Adults (CSOA). Kaplan H, et al. **J Am Acad Audiol** 1997 Jun;8(3):203–17

Rehabilitation of the older lower limb amputee: a brief review. Cutson TM, et al. **J Am Geriatr Soc** 1996 Nov; 44(11):1388–93 (60 ref.)

Use of the diagnosis "failure to thrive" in older veterans. Hildebrand JK, et al. **J Am Geriatr Soc** 1997 Sep; 45(9):1113–7

Viral hepatitis in older adults. Marcus EL, et al.
J Am Geriatr Soc 1997 Jun;45(6):755–63 (108 ref.)

Circumstances of falls resulting in hip fractures among older

people. Norton R, et al. **J Am Geriatr Soc** 1997 Sep; 45(9):1108–12

The clinical diagnosis of heart failure in older patients. Tresch DD. **J Am Geriatr Soc** 1997 Sep;45(9):1128–33 (38 ref.)

Chronic dialysis in patients over age 65 [editorial] Latos DL. **J Am Soc Nephrol** 1996 May;7(5):637–46

Effective communication with older clients. Turnwald GH, et al. **J Am Vet Med Assoc** 1996 Aug 15;209(4):725–6

Joining education and service in exploring discharge needs. Schultz AA, et al. **J Community Health Nurs** 1997; 14(3):141–53

The training of emergency medical technicians in geriatric emergency medicine [editorial; comment] Sanders AB. **J Emerg Med** 1996 Jul–Aug;14(4):499–500. Comment on: J Emerg Med 1996 Jul–Aug;14(4):439–44.

Transfer behavior within the family: results from the Asset and Health Dynamics Study. McGarry K, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52 Spec No:82–92

Asset and Health Dynamics Among the Oldest Old (AHEAD): initial results from the longitudinal study. Introduction. Myers GC, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52 Spec No:v–viii

Patterns of in-home care among elderly black and white Americans. Norgard TM, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52 Spec No:93–101

A comparative analysis of ADL questions in surveys of older people. Rodgers W, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52 Spec No:21–36

Race, socioeconomic status, and health: accounting for race differences in health. Schoenbaum M, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52 Spec No:61–73

Asking the age question in elderly populations: a reverse record check study. Smit JH, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Jul;52(4):P175–7

Wealth inequality among older Americans. Smith JP. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52 Spec No:74–81

Asset and Health Dynamics Among the Oldest Old: an overview of the AHEAD Study. Soldo BJ, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52 Spec No:1–20

The structure of health status among Hispanic, African American, and white older adults. Stump TE, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52 Spec No:49–60

The quality of health data obtained in a new survey of elderly Americans: a validation study of the proposed Medicare Beneficiary Health Status Registry (MBHSR). Turner CF, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Jan; 52(1):S49–58

Therapy in old patients with isolated systolic hypertension: fourth progress report on the Syst-Eur trial. Antikainen R, et al. **J Hum Hypertens** 1997 May;11(5):263–9

Doctors' attitudes towards the detection and treatment of hypertension in older people. Duggan S, et al. **J Hum Hypertens** 1997 May;11(5):271–6

Antihypertensive therapy and orthostatic responses in elderly hospital in-patients. Fotherby MD, et al. **J Hum Hypertens** 1997 May;11(5):291–4

Ethics and law in the field of medical care for the elderly in France. Gromb S, et al. **J Med Ethics** 1997 Aug; 23(4):233–8

Falls in the elderly. Abyad A. **J Med Liban** 1995;43(4):194–9 (25 ref.)

Caring for the older patient, Part I: The relationship of theory to practice. Dowd SB, et al. **J Nucl Med Technol** 1997 Mar;25(1):24–32; quiz 35 (58 ref.)

Caring for the older patient, Part II: Age-related anatomic and physiologic changes and pathologies. Steves AM, et al. **J Nucl Med Technol** 1997 Jun;25(2):86–97; quiz 103, 105 (44 ref.)

Baccalaureate student gerontological nursing experiences: raising consciousness levels and affecting attitudes. Fox SD, et al. **J Nurs Educ** 1996 Nov;35(8):348–55

Eyesight and the elderly [letter; comment] Schoeffler LE. **J Okla State Med Assoc** 1996 Oct;89(10):379. Comment on: J Okla State Med Assoc 1996 Aug;89(8):263.

Scapegoating the elderly: new voices, old theme [editorial] Minkler M. **J Public Health Policy** 1997;18(1):8–12

Medication for older people. Summary and recommendations of a report of a working party of The Royal College of Physicians. **J R Coll Physicians Lond** 1997 May–Jun; 31(3):254–7

Elderly patients excluded from resuscitation discussion [letter; comment] King D. **J R Coll Physicians Lond** 1996 Jul–Aug;30(4):398. Comment on: J R Coll Physicians Lond 1996 Mar–Apr;30(2):133–5.

Use of standardised assessment scales in elderly hip fracture patients. Shepherd SM, et al. **J R Coll Physicians Lond** 1996 Jul–Aug;30(4):335–43

Surgical treatment of abdominal aortic aneurysms in octogenarians. Sugawara Y, et al. **Jpn Circ J** 1996 Jun; 60(6):328–33

The age-associated decline in immune function of healthy individuals is not related to changes in plasma concentrations of beta-carotene, retinol, alpha-tocopherol or zinc. Gardner EM, et al. **Mech Ageing Dev** 1997 Mar; 94(1–3):55–69

The monitoring biomarker for immune function of lymphocytes in the elderly. Liu J, et al. **Mech Ageing Dev** 1997 Mar;94(1–3):177–82

Cytokines and impaired CD8+ CTL activity among elderly persons and the enhancing effect of IL-12. Mbawuike IN, et al. **Mech Ageing Dev** 1997 Mar;94(1–3):25–39

Attitudes to and knowledge about elderly people: a comparative analysis of students of medicine, English and Computer Science and their teachers. Edwards MJ, et al. **Med Educ** 1996 May;30(3):221–5

The epidemiology of physical activity and physical function in older people. DiPietro L. **Med Sci Sports Exerc** 1996 May;28(5):596–600

First-choice vascular access in patients over 65 years of age starting dialysis [letter] Gómez Campderá FJ, et al. **Nephron** 1996;73(2):342–3

An association between head circumference and Alzheimer's disease in a population-based study of aging and dementia. Schofield PW, et al. **Neurology** 1997 Jul;49(1):30–7

The influence of aging on auditory brainstem response and electrocochleography in the elderly. Oku T, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 May–Jun; 59(3):141–6

Dialyzing the elderly: benefit or burden? Oreopoulos DG. **Perit Dial Int** 1997;17 Suppl 2:S7–12

Predicting the probability for falls in community-dwelling older adults. Shumway-Cook A, et al. **Phys Ther** 1997 Aug; 77(8):812–9

Chronic disability trends in elderly United States populations: 1982–1994. Manton KG, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2593–8

Health and social support among older women in congregate housing. Lough MA, et al. **Public Health Nurs** 1996 Dec; 13(6):434–41

Breast cancer screening in older women. Caplan LS, et al. **Public Health Rev** 1996;24(2):193–204

Migration of persons with AIDS—a search for support from elderly parents? Ellis M, et al. **Soc Sci Med** 1996 Oct; 43(7):1109–18

Beyond single indicators of social networks: a LISREL analysis of social ties among the elderly. Glass TA, et al. **Soc Sci Med** 1997 May;44(10):1503–17

Cultural problems of ageing especially regarding gender and intergenerational equity. Henrard JC. **Soc Sci Med** 1996 Sep;43(5):667–80 (115 ref.)

Cultural aspects of ageing: gender and inter-generational issues. Jefferys M. **Soc Sci Med** 1996 Sep;43(5):681–7 (36 ref.)

Age, adjustment, and costs: a study of chronic illnesses. Watt S, et al. **Soc Sci Med** 1997 May;44(10):1483–90

The economics of retirement: a nontechnical guide. Leonesio MV. **Soc Secur Bull** 1996 Winter;59(4):29–50 (64 ref.)

Family unit incomes of the elderly and children, 1994. Radner DB. **Soc Secur Bull** 1996 Winter;59(4):12–28

Poverty among single elderly women under different systems of old-age security: a comparative review. Siegenthaler JK. **Soc Secur Bull** 1996 Fall;59(3):31–44 (59 ref.)

Pension benefits among the aged: conflicting measures, unequal distributions. Woods JR. **Soc Secur Bull** 1996 Fall; 59(3):3–30 (30 ref.)

Puerto Rican sons as primary caregivers of elderly parents. Delgado M, et al. **Soc Work** 1997 Mar;42(2):125–34

Shaping the policy practice agenda of social work in the field of aging. Greene RR, et al. **Soc Work** 1996 Sep; 41(5):553–60

Radiotherapy for carcinomas of the head and neck in elderly patients. Huguenin P, et al. **Strahlenther Onkol** 1996 Sep; 172(9):485–8

Haemostatic parameters and lifestyle factors in elderly men in Italy and The Netherlands. Bijnen FC, et al. **Thromb Haemost** 1996 Sep;76(3):411–6

Effects of long travels in sitting position in elderly volunteers on biological markers of coagulation activation and fibrinolysis. Tardy B, et al. **Thromb Res** 1996 Jul 15; 83(2):153–60

Factors affecting death at home in Japan. Sauvaget C, et al. **Tohoku J Exp Med** 1996 Oct;180(2):87–98

Transplantation in the elderly: changing philosophy. Santiago-Delpín EA. **Transplant Proc** 1996 Dec; 28(6):3408–9

Drugs for the elderly. Second edition. World Health Organization. Offerhaus L. **WHO Reg Publ Eur Ser** 1997; 71:1–145

Live better, live longer: a new attitude [editorial] Berger M. **Wis Med J** 1996 Oct;95(10):674

[The elderly poor and political slowness (editorial)] Braam GP. **Tijdschr Gerontol Geriatr** 1996 Dec;27(6):234–5 **(Dut)**

[The relative importance of independent living for the social functioning of the elderly] Broese van Groenou M, et al. **Tijdschr Gerontol Geriatr** 1996 Aug;27(4):150–8 (Eng. Abstr.) **(Dut)**

[Women of the middle generation and informal care for the elderly] Dautzenberg MG, et al. **Tijdschr Gerontol Geriatr** 1996 Aug;27(4):141–9 (Eng. Abstr.) **(Dut)**

[Hospital admission of nursing home patients considered but not carried out: role of the nursing home physician and the involved parties and various differences with realized hospital admissions] Konings JW, et al. **Tijdschr Gerontol Geriatr** 1996 Oct;27(5):197–205 (Eng. Abstr.) **(Dut)**

[The elderly in TV commercials: ridiculous or respectable?] van Selm M, et al. **Tijdschr Gerontol Geriatr** 1996 Dec; 27(6):237–42 (Eng. Abstr.) **(Dut)**

[Coronary surgery in patients 70 years and older. Report of 70 cases] el-Asmar B, et al. **J Med Liban** 1996; 44(4):195–9 (Eng. Abstr.) **(Fre)**

[Myocardial infarction in patients over 75 years of age. Hospital characteristics and long-term follow-up (see comments)] Jacquemin L, et al. **Presse Med** 1996 Oct 26; 25(32):1536–40 (Eng. Abstr.). Comment in: Presse Med 1997 Apr 12;26(12):566. **(Fre)**

[Predictive factors for institutionalization in the context of geriatric planning in the Gironde department (France)] Metzger MH, et al. **Rev Epidemiol Sante Publique** 1997 Jun;45(3):203–13 (Eng. Abstr.) **(Fre)**

[Still disease in the elderly (letter)] Bonnet F, et al. **Rev Med Interne** 1997;18(2):170–1 (13 ref.) **(Fre)**

[Confusion syndromes in hospitalized aged patients: polymorphism of symptoms and course. Prospective study of 183 patients] Dubos G, et al. **Rev Med Interne** 1996; 17(12):979–86 (Eng. Abstr.) **(Fre)**

[Bone and joint manifestations in the elderly patient] André B, et al. **Rev Med Liege** 1997 Apr;52(4):270–7 (12 ref.) **(Fre)**

[Depression in the elderly] Ansseau M. **Rev Med Liege** 1997 Apr;52(4):262–6 (7 ref.) **(Fre)**

[Therapeutic alternatives to systemic corticotherapy in severe and chronic dermatologic disorders in the elderly patient] de la Brassinne M. **Rev Med Liege** 1997 Apr;52(4):296–8 (0 ref.) **(Fre)**

[Cataracts due to age] Galand A. **Rev Med Liege** 1997 Apr; 52(4):299–303 (11 ref.) **(Fre)**

[Diabetes in the elderly patient] Lefèbvre P. **Rev Med Liege** 1997 Apr;52(4):205–8 (9 ref.) **(Fre)**

[Presbycusis] Lefebvre PP. **Rev Med Liege** 1997 Apr; 52(4):304–8 (14 ref.) **(Fre)**

[Anal incontinence (in the elderly)] Mohr E. **Rev Med Liege** 1997 Apr;52(4):251–4 (16 ref.) **(Fre)**

[Frequent skin tumors in geriatrics] Piérard-Franchimont C, et al. **Rev Med Liege** 1997 Apr;52(4):289–95 (20 ref.) **(Fre)**

[Total hip replacement in the elderly patient: indications and results] Rodriguez A, et al. **Rev Med Liege** 1997 Apr; 52(4):278–84 (27 ref.) **(Fre)**

[Dehydration in the elderly patient] Smitz S. **Rev Med Liege** 1997 Apr;52(4):215–20 (14 ref.) **(Fre)**

[Carotid surgery beyond 75 years old] Van Damme H, et al. **Rev Med Liege** 1997 Apr;52(4):237–44 (47 ref.) **(Fre)**

[Ketoprofen—a first-class nonsteroidal antirheumatic agent] Rass H. **Dtsch Med Wochenschr** 1997 Feb 28;122(9 Suppl):1–8 **(Ger)**

[Fosinopril in the cardiovascular management of elderly patients] **Fortschr Med Suppl** 1996;175:1–8 **(Ger)**

[Rehabilitation of deafness in the elderly: multidisciplinary intervention in experimental university center] Menozzi Tucci F, et al. **Acta Otorhinolaryngol Ital** 1996 Feb;16(1 Suppl 52):3–16 (Eng. Abstr.) **(Ita)**

[Biliary surgery in the aged] Catania G, et al. **Ann Ital Chir** 1997 Jan–Feb;68(1):73–8; discussion 79 (Eng. Abstr.) **(Ita)**

[Evaluation of the surgical risk and preparation to major surgical intervention in geriatric surgery] Roseano M, et al. **Ann Ital Chir** 1997 Jan–Feb;68(1):67–72 (Eng. Abstr.) **(Ita)**

[Characteristics of hospitalization of aged patients before and after introduction of the prospective payment (DRG-ROD system). Researchers of the Italian Group of Pharmaco-epidemiology in the Aged (GIFA)] **Ann Ital Med Int** 1996 Jul–Sep;11(3):220–7 (Eng. Abstr.) **(Ita)**

[Pharmacokinetics in a "special population": the aged] Zuccaro P, et al. **Boll Chim Farm** 1996 Feb;135(2):127–8 **(Ita)**

[Drug prescription in the elderly: epidemiological issues] Cerrone L, et al. **Epidemiol Prev** 1995 Dec;19(65):349–52 **(Ita)**

[Surgical strategy in gastric cancer in aged patients] Caporale A, et al. **G Chir** 1997 Jan–Feb;18(1–2):36–40 (Eng. Abstr.) **(Ita)**

[Clinical aspects and pathogenetic mechanisms of cognitive impairment in arterial hypertension] Puddu GM, et al. **Minerva Cardioangiol** 1996 Jun;44(6):285–97 (133 ref.) (Eng. Abstr.) **(Ita)**

[Laparoscopic surgery in patients over 75 years of age] Ballesta Lopez C, et al. **Minerva Chir** 1996 Dec; 51(12):1011–5 (Eng. Abstr.) **(Ita)**

[Risk indices in geriatric surgery: ASA index versus Reiss index] Leardi S, et al. **Minerva Chir** 1997 Mar;52(3):255–60 (Eng. Abstr.) **(Ita)**

[Emergency abdominal surgery in the aged] Monaco A, et al. **Minerva Chir** 1996 Dec;51(12):1043–7 (Eng. Abstr.) **(Ita)**

[Quality of life of geriatric patients after surgery. VII. Lung tumors] Pannella A, et al. **Minerva Chir** 1996 Dec; 51(12):1083–8 (Eng. Abstr.) **(Ita)**

[Preoperative evaluation of aged patients] Meguro K, et al. **Masui** 1996 Dec;45 Suppl:S143–6 (5 ref.) **(Jpn)**

[An examination of two reporting methods of falls among the elderly living in the community] Haga H, et al. **Nippon Koshu Eisei Zasshi** 1996 Nov;43(11):983–8 (Eng. Abstr.) **(Jpn)**

[Mortality in relation to disabilities, health, management and psycho-social conditions among the community-residing elderly people] Nakanishi N, et al. **Nippon Koshu Eisei Zasshi** 1997 Feb;44(2):89-101 (Eng. Abstr.) **(Jpn)**

[Quality of life in the elderly] Shibata H. **Nippon Koshu Eisei Zasshi** 1996 Nov;43(11):941-5 **(Jpn)**

[39th annual meeting of the Japan Geriatrics Society. Tokyo. June 18-20, 1997. Abstracts] **Nippon Ronen Igakkai Zasshi** 1997 May;34 Suppl:1-138 **(Jpn)**

[Cerebrovascular disease in the elderly-risk factor, treatment and prognosis] Fujishima M, et al. **Nippon Ronen Igakkai Zasshi** 1996 Sep;33(9):647-51 (8 ref.) **(Jpn)**

[Terminal care for the aged] Kashiwagi T. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):496-8 (5 ref.) **(Jpn)**

[Nutritional assessment in elderly] Muto Y, et al. **Nippon Ronen Igakkai Zasshi** 1996 Sep;33(9):652-6 (6 ref.) **(Jpn)**

[Control of Nosocomial infections: prevention of respiratory infections in the elderly] Nagatake T, et al. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):871-6 (14 ref.) **(Jpn)**

[Morbidity and mortality among the hospitalized aged. Identification of prognostic factors] Alonso Martinez JL, et al. **An Med Interna** 1995 Sep;12(9):420-4 (Eng. Abstr.) **(Spa)**

[Effects of chronic diseases on the use of primary care by the aged] López Navarrete E, et al. **Aten Primaria** 1997 Feb 15;19(2):92-5 (Eng. Abstr.) **(Spa)**

[Rational use of drugs for the aged] Prieto Lozano A, et al. **Aten Primaria** 1997 Feb 15;19(2):96-100 **(Spa)**

[Cognitive reconceptualization in the perception of sex activity in the aged: structural neoformation of attitudes to sexuality in old age] Nazario Serrano JA, et al. **Bol Asoc Med P R** 1996 Oct-Dec;88(10-12):94-8 **(Spa)**

[Social support and perceived health status in non-institutionalized population over 60 years of age] Ferrando J, et al. **Gac Sanit** 1996 Jul-Aug;10(55):174-82 (Eng. Abstr.) **(Spa)**

[Considerations on aging in Cuba] López Fernández R. **P R Health Sci J** 1996 Dec;15(4):279-82 (Eng. Abstr.) **(Spa)**

[Epidemiology of drugs intake in aged people] Aizpuru K. **Rev Neurol** 1997 Jul;25 Suppl 1:S73-5 **(Spa)**

[Preventive medicine for the aged] Calvo-Aguirre JJ. **Rev Neurol** 1997 Jul;25 Suppl 1:S104-7 **(Spa)**

[Minimal examination of mental functions in healthy Cuban old-aged people. Letter] Scherle CE, et al. **Rev Neurol** 1997 Feb;25(138):302-4 **(Spa)**

[Project of world objectives relating to the aged in the year 2001] **Salud Publica Mex** 1996 Nov-Dec;38(6):536-40 **(Spa)**

[Health conditions among the elderly] **Salud Publica Mex** 1996 Nov-Dec;38(6):533 **(Spa)**

[Principles of the United Nations in favor of the aged] **Salud Publica Mex** 1996 Nov-Dec;38(6):534-5 **(Spa)**

[Use of hospital services by the aged population of Mexico City] Borges-Yáñez SA, et al. **Salud Publica Mex** 1996 Nov-Dec;38(6):475-86 (Eng. Abstr.) **(Spa)**

[Financing of health care for the aged] Durán-Arenas L, et al. **Salud Publica Mex** 1996 Nov-Dec;38(6):501-12 (Eng. Abstr.) **(Spa)**

[Aging: a new dimension in health in Mexico] Ham-Chande R. **Salud Publica Mex** 1996 Nov-Dec;38(6):409-18 (Eng. Abstr.) **(Spa)**

[Epidemiologic aspects of the aged at the Mexican Institute of Social Security] Lara-Rodríguez MA, et al. **Salud Publica Mex** 1996 Nov-Dec;38(6):448-57 (Eng. Abstr.) **(Spa)**

[Burden of disease in the aged, Mexico, 1994] Lozano-Ascencio R, et al. **Salud Publica Mex** 1996 Nov-Dec;38(6):419-29 (Eng. Abstr.) **(Spa)**

[Morbidity characteristics among elderly Mexicans: an analysis of the 1988 National Health Survey] Ruiz-Arregui L, et al. **Salud Publica Mex** 1996 Nov-Dec;38(6):430-7 (Eng. Abstr.) **(Spa)**

[Successful aging: conceiving the aging process from a more positive perspective] Vellas P. **Salud Publica Mex** 1996 Nov-Dec;38(6):513-22 (Eng. Abstr.) **(Spa)**

[Care of the chronically ill aged person] Warren MW. **Salud Publica Mex** 1996 Nov-Dec;38(6):525-32 (Eng. Abstr.) **(Spa)**

[Increase of safety of surgical interventions in aged patients by application of geriatric measures] Zapadniuk VG, et al. **Klin Khir** 1996;(10):33-5 **(Ukr)**

PHYSIOLOGY

Relation between the instrumental activities of daily living and physical fitness tests in elderly women. Uchida H, et al. **Acta Med Okayama** 1996 Dec;50(6):325-33

Life-long endurance-trained elderly men have high aerobic power, but have similar muscle strength to non-active elderly men. Harridge S, et al. **Aging (Milano)** 1997 Feb-Apr;9(1-2):80-7

The reliability and validity of an obstacle course as a measure of gait and balance in older adults. Rubenstein LZ, et al. **Aging (Milano)** 1997 Feb-Apr;9(1-2):127-35

Muscle function of women aged 65-89 years meeting two sets of health criteria. Skelton DA, et al. **Aging (Milano)** 1997 Feb-Apr;9(1-2):106-11

One-leg standing balance and functional status in a population of 512 community-living elderly persons. Vellas BJ, et al. **Aging (Milano)** 1997 Feb-Apr;9(1-2):95-8

Emotional activation of limbic circuitry in elderly normal subjects in a PET study. Paradiso S, et al. **Am J Psychiatry** 1997 Mar;154(3):384-9

Anticardiolipin antibodies and physical disability in the elderly [letter] Cesbron JY, et al. **Ann Intern Med** 1997 Jun 15;126(12):1003

Assessment of medication management skills in older outpatients. Ruscin JM, et al. **Ann Pharmacother** 1996 Oct; 30(10):1083-8

General anesthesia and elderly surgical patients. Hazen SE, et al. **AORN J** 1997 Apr;65(4):815-9, 821-2

Interpreting laboratory values in elderly surgical patients. Martin JL, et al. **AORN J** 1997 Mar;65(3):621-6

Postural control and strength and mood among older adults. Topp R, et al. **Appl Nurs Res** 1997 Feb;10(1):11-8

Prestroke physical function predicts stroke outcomes in the elderly. Colantonio A, et al. **Arch Phys Med Rehabil** 1996 Jun;77(6):562-6

The relationship of postural sway to sensorimotor function, functional performance, and disability in the elderly. Hughes MA, et al. **Arch Phys Med Rehabil** 1996 Jun; 77(6):567-72

Blood pressure and mortality in healthy old people: the r shaped curve. Starr JM, et al. **BMJ** 1996 Nov 16; 313(7067):1243-4

Spirometry reference values for healthy elderly blacks. The Cardiovascular Health Study Research Group. Enright PL, et al. **Chest** 1996 Dec;110(6):1416-24

Effect of high-altitude exposure in the elderly: the Tenth Mountain Division study. Levine BD, et al. **Circulation** 1997 Aug 19;96(4):1224-32

Pharmacology of cancer chemotherapy in the older person. Baker SD, et al. **Clin Geriatr Med** 1997 Feb;13(1):169-83 (62 ref.)

Medications and falls. Causation, correlation, and prevention. Monane M, et al. **Clin Geriatr Med** 1996 Nov;12(4):847-58 (67 ref.)

Lipoprotein alterations and atherosclerosis in the elderly. Corti MC, et al. **Curr Opin Lipidol** 1997 Aug;8(4):236-41 (47 ref.)

Ergonomic data of elderly people and their application in rehabilitation design. Rogers N, et al. **Disabil Rehabil** 1996 Oct;18(10):487-96 (59 ref.)

Activities of daily living studied longitudinally between 70 and 76 years of age. Sonn U, et al. **Disabil Rehabil** 1996 Feb;18(2):91-100

The influence of age on length of stay, functional independence and discharge destination of rehabilitation inpatients in Italy. Tesio L, et al. **Disabil Rehabil** 1996 Oct; 18(10):502-8

Principles of antibiotic prescribing in the elderly. Borrego F, et al. **Drugs Aging** 1997 Jul;11(1):7-18 (47 ref.)

Age-related changes in male gonadal function. Implications for therapy. Maas D, et al. **Drugs Aging** 1997 Jul; 11(1):45-60 (128 ref.)

Successful aging. Rowe JW, et al. **Gerontologist** 1997 Aug; 37(4):433-40 (62 ref.)

Oral temperatures of the elderly in nursing homes in summer and winter in relation to activities of daily living. Nakamura K, et al. **Int J Biometeorol** 1997 Apr;40(2):103-6

The institutionalized elderly: dry to the bone! Armstrong-Esther CA, et al. **Int J Nurs Stud** 1996 Dec; 33(6):619-28

Laboratory reference values for the 70 year olds. Hammerman-Rozenberg R, et al. **Isr J Med Sci** 1996 Aug; 32(8):611-20

The significance of subnormal serum vitamin B12 concentration in older people: a case control study. Metz J, et al. **J Am Geriatr Soc** 1996 Nov;44(11):1355-61

Five-year performance trends for older exercisers: a hierarchical model of endurance, strength, and flexibility. Morey MC, et al. **J Am Geriatr Soc** 1996 Oct; 44(10):1226-31

Developmental care: the key to the emergence of the vital older woman. Pulliam LW, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Sep;25(7):623-8 (30 ref.)

Muscle strength and rising from a chair in older adults. Alexander NB, et al. **Muscle Nerve Suppl** 1997;5:S56-9 (19 ref.)

How do the elderly negotiate stairs? Cavanagh PR, et al. **Muscle Nerve Suppl** 1997;5:S52-5 (20 ref.)

Choosing the best strength measure in frail older persons: importance of task specificity. Chandler J, et al. **Muscle Nerve Suppl** 1997;5:S47-51 (34 ref.)

Excitation-Ca2+ release-contraction coupling in single aged human skeletal muscle fiber. Delbono O, et al. **Muscle Nerve Suppl** 1997;5:S88-92 (19 ref.)

Assessment of physical performance and disability in older persons. Guralnik JM. **Muscle Nerve Suppl** 1997;5:S14-6 (20 ref.)

A simple assessment of the renal function in geriatric patients [letter] Sanaka M, et al. **Nephron** 1997;76(2):243-4

Pharmacologic approaches to chronic pain in the older adult. Dellasega C, et al. **Nurse Pract** 1997 May;22(5):20-4, 26, 31-2 passim; quiz 36-7 (21 ref.)

What is the long term value of multiphasic health screening and the initial judgement of benefit? Allander E, et al. **Scand J Soc Med Suppl** 1997;51:1-20

Socio-economic status, health and life-style in two elderly cohorts in Jyväskylä. Pohjolainen P, et al. **Scand J Soc Med Suppl** 1997;52:1-65

Longitudinal changes in diary- and laboratory-based sleep measures in healthy "old old" and "young old" subjects: a three-year follow-up. Hoch CC, et al. **Sleep** 1997 Mar; 20(3):192-202

Effect of strenuous exercise on fibrinogen and fibrinolysis in healthy elderly men and women. Schuit AJ, et al. **Thromb Haemost** 1997 Aug;78(2):845-51

[Variations in reference biological parameters with age] Delwaide PA. **Rev Med Liege** 1997 Apr;52(4):197-200 (15 ref.) **(Fre)**

[Particulars about pharmacotherapy in the elderly patient] Scheen AJ. **Rev Med Liege** 1997 Apr;52(4):201-4 (17 ref.) **(Fre)**

[Evaluation of environmental stimulation and its relation to physical deterioration in the elderly after 3 years—a health-social longitudinal study] Anme T. **Nippon Koshu Eisei Zasshi** 1997 Mar;44(3):159-66 (Eng. Abstr.) **(Jpn)**

[Development of a functional fitness test for the elderly] Oida Y, et al. **Nippon Koshu Eisei Zasshi** 1996 Mar;43(3):196-208 (Eng. Abstr.) **(Jpn)**

[An analysis of the relationship among functional fitness tests, life style and bone density of the elderly in O town, Fukuoka Prefecture] Matsuda S, et al. **Sangyo Ika Daigaku Zasshi** 1996 Sep 1;18(3):213-21 (Eng. Abstr.) **(Jpn)**

[Methods of nutrient intake and nutritional status of the elderly in Poland on the basis of the literature from the years 1980-1996] Wierzbicka E, et al. **Rocz Panstw Zakl Hig** 1997;48(1):87-102 (62 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Neurological findings in the normal elderly: prevalence and relationships with memory performance. Cosi V, et al. **Aging (Milano)** 1996 Aug;8(4):243-9

Test-retest reliability of the WAIS-R Satz-Mogel short form in a normal elderly sample. Mitrushina M, et al. **Aging (Milano)** 1996 Aug;8(4):250-3

Application of a Spanish version of the "Informant Questionnaire on Cognitive Decline in the Elderly" in the clinical assessment of dementia. Del-Ser T, et al. **Alzheimer Dis Assoc Disord** 1997 Mar;11(1):3-8

How should a group living unit for demented elderly be designed to decrease psychiatric symptoms? Elmståhl S, et al. **Alzheimer Dis Assoc Disord** 1997 Mar;11(1):47-52

Adaptive responses among Dutch elderly: the impact of eight chronic medical conditions on health-related quality of life. Kempen GI, et al. **Am J Public Health** 1997 Jan;87(1):38-44

Relation of prescription nonsteroidal antiinflammatory drug use to cognitive function among community-dwelling elderly. Hanlon JT, et al. **Ann Epidemiol** 1997 Feb; 7(2):87-94

Association of symptoms of depression with diagnostic test charges among older adults. Callahan CM, et al. **Ann Intern Med** 1997 Mar 15;126(6):426-32

Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons [see comments] Covinsky KE, et al. **Ann Intern Med** 1997 Mar 15;126(6):417-25. Comment in: Ann Intern Med 1997 Mar 15;126(6):463-4.

Depression in the medically ill elderly: a focus on methylphenidate. Emptage RE, et al. **Ann Pharmacother** 1996 Feb;30(2):151-7 (43 ref.)

Assessment of medication management skills in older outpatients. Ruscin JM, et al. **Ann Pharmacother** 1996 Oct; 30(10):1083-8

Social support and physical health in the rural elderly. Johnson JE. **Appl Nurs Res** 1996 May;9(2):61-6

Postural control and strength and mood among older adults. Topp R, et al. **Appl Nurs Res** 1997 Feb;10(1):11-8

Factors contributing to hope among noninstitutionalized elderly. Zorn CR. **Appl Nurs Res** 1997 May;10(2):94-100

Attitudes of elderly patients and their families toward physician-assisted suicide. Koenig HG, et al. **Arch Intern Med** 1996 Oct 28;156(19):2240-8

Outcomes of enhanced physical and occupational therapy service in a nursing home setting. Przybylski BR, et al. **Arch Phys Med Rehabil** 1996 Jun;77(6):554-61

A phenomenological study of meaning in life in suicidal older adults. Moore SL. **Arch Psychiatr Nurs** 1997 Feb; 11(1):29-36

Transcendence: the meaning of great-grandmothering. Reese CG, et al. **Arch Psychiatr Nurs** 1996 Aug;10(4):245-51

The SIMA-project: effects of 1 year cognitive and psychomotor training on cognitive abilities of the elderly. Oswald WD, et al. **Behav Brain Res** 1996 Jun;78(1):67-72

Medical comorbidity in elderly psychiatric inpatients. Zubenko GS, et al. **Biol Psychiatry** 1997 Mar 15; 41(6):724-36

A psychometric analysis of a short device for assessing depression in elderly people. Richardson CA, et al. **Br J Clin Psychol** 1996 Nov;35 (Pt 4):543-51

Older people's perceptions about symptoms. Morgan R, et al. **Br J Gen Pract** 1997 Jul;47(420):427-30

Visuospatial ability of parkinsonians and elderly adults in location memory tasks. Giraudo MD, et al. **Brain Cogn** 1997 Jul;34(2):259-73

The diagnosis and treatment of mania in the elderly. McDonald WM, et al. **Bull Menninger Clin** 1996 Spring; 60(2):174–96 (136 ref.)

Suicide in old age: a tragedy of neglect [see comments] Duckworth G, et al. **Can J Psychiatry** 1996 May; 41(4):217–22. Comment in: Can J Psychiatry 1996 Oct;41(8):536–7.

Interaction between the physician and the older patient: the oncologist's perspective. Ganz PA. **Cancer** 1997 Oct 1; 80(7):1323–5

Determinants of happiness and life satisfaction in elderly Zimbabweans. Allain TJ, et al. **Cent Afr J Med** 1996 Nov; 42(11):308–11

Psychophysical and psychohedonic functions of four common food flavours in elderly subjects. de Graaf C, et al. **Chem Senses** 1996 Jun;21(3):293–302

A longitudinal study of pain: reported pain from middle age to old age. Brattberg G, et al. **Clin J Pain** 1997 Jun; 13(2):144–9

Prognosis and outcome studies in late-life depression. Baldwin RC, et al. **Clin Neurosci** 1997;4(1):16–22 (72 ref.)

Depressive dementia: a "transitional dementia"? Emery VO, et al. **Clin Neurosci** 1997;4(1):23–30 (89 ref.)

Epidemiology and comorbidity of anxiety disorders in later life: implications for treatment. Flint AJ. **Clin Neurosci** 1997;4(1):31–6 (60 ref.)

Pharmacotherapy of late life mood disorders. Herrmann N, et al. **Clin Neurosci** 1997;4(1):41–7 (81 ref.)

Neuroimaging in late-life mood disorders. Kumar A, et al. **Clin Neurosci** 1997;4(1):8–15 (64 ref.)

Neurologic comorbidity and mania in old age. Shulman KI. **Clin Neurosci** 1997;4(1):37–40 (48 ref.)

Epidemiologic questions on mood disorders in old age. Snowdon J. **Clin Neurosci** 1997;4(1):3–7 (40 ref.)

Suicide in the elderly—bias, infirmity, and suicide. Conwell Y. **Crisis** 1995;16(4):147–8

Suicide in late life at the end of the 1990s: a less neglected topic? De Leo D. **Crisis** 1997;18(2):51–2

Elderly suicides in Hong Kong: the role of volunteer befrienders. Law FY. **Crisis** 1997;18(2):55–6

Membership of the University of the Third Age (U3A) and perceived well-being. Mitchell RA, et al. **Disabil Rehabil** 1997 Jun;19(6):244–8

The pharmacoeconomics of dementia therapies. Bringing the clinical, research and economic perspectives together. Molnar FJ, et al. **Drugs Aging** 1997 Mar;10(3):219–33 (44 ref.)

Selective serotonin reuptake inhibitors in older patients. A tolerability perspective. Skerritt U, et al. **Drugs Aging** 1997 Mar;10(3):209–18 (74 ref.)

Selection bias during recruitment of elderly subjects from the general population for psychiatric interviews. Heun R, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(2):87–92

Attempted suicide by Chinese elderly in Hong Kong. Chiu HF, et al. **Gen Hosp Psychiatry** 1996 Nov;18(6):444–7

Social determinants of loneliness among older Americans. Mullins LC, et al. **Genet Soc Gen Psychol Monogr** 1996 Nov;122(4):453–73

Worrying about health: a uniquely American pastime? Anderson EG. **Geriatrics** 1996 Sep;51(9):56–7

Incorporating diversity: meaning, levels of research, and implications for theory [see comments] Calasanti TM. **Gerontologist** 1996 Apr;36(2):147–56 (60 ref.). Comment in: Gerontologist 1996 Apr;36(2):145–6. Comment in: Gerontologist 1996 Apr;36(2):174–7.

Age, socioeconomic status, and exercise self-efficacy [see comments] Clark DO. **Gerontologist** 1996 Apr;36(2):157–64 (53 ref.). Comment in: Gerontologist 1996 Apr;36(2):145–6. Comment in: Gerontologist 1996 Apr;36(2):174–7.

The search for new solutions. Hendricks J. **Gerontologist** 1996 Apr;36(2):141–4

Welfare participation and self-esteem in later life. Krause N. **Gerontologist** 1996 Oct;36(5):665–73

Aging and heterogeneity: genetics, social structure, and personality [see comments] Light JM, et al. **Gerontologist** 1996 Apr;36(2):165–73 (52 ref.). Comment in: Gerontologist 1996 Apr;36(2):145–6. Comment in: Gerontologist 1996 Apr;36(2):174–7.

Stress and the life course: a paradigmatic alliance. Pearlin LI, et al. **Gerontologist** 1996 Apr;36(2):239–47 (69 ref.)

Understanding the well-being of care receivers. Pruchno RA, et al. **Gerontologist** 1997 Feb;37(1):102–9

Typologies of caregiving families: family congruence and individual well-being. Pruchno RA, et al. **Gerontologist** 1997 Apr;37(2):157–67

Successful aging. Rowe JW, et al. **Gerontologist** 1997 Aug; 37(4):433–40 (62 ref.)

Elderly patients' satisfaction with the outcome of their health care complaints. Dolinsky AL. **Health Care Manage Rev** 1997 Spring;22(2):33–40

Relocation to a new environment: decisional control and the move to a nursing home. Reinardy JR. **Health Soc Work** 1995 Feb;20(1):31–8

Medication instruction design: younger and older adult schemas for taking medication. Morrow DG, et al. **Hum Factors** 1996 Dec;38(4):556–73

Older people and attachment to things, places, pets, and ideas. Cookman CA. **Image J Nurs Sch** 1996 Fall;28(3):227–31 (56 ref.)

A lifetime of events: age and gender variations in the life story. deVries B, et al. **Int J Aging Hum Dev** 1996; 42(2):81–102

Employee age and perceptions of work in self-managing and traditional work groups. Hayslip B Jr, et al. **Int J Aging Hum Dev** 1996;42(4):291–312

Risk factors associated with negative interactions between family caregivers and elderly care-receivers. Johnson JR. **Int J Aging Hum Dev** 1996;43(1):7–20

Social support and depression among elderly Korean immigrants in the United States. Lee MS, et al. **Int J Aging Hum Dev** 1996;42(4):313–27

Respect redefined: focus group insights from Singapore. Mehta K. **Int J Aging Hum Dev** 1997;44(3):205–19

Participation in leisure activities by older adults after a stressful life event: the loss of a spouse. Patterson I. **Int J Aging Hum Dev** 1996;42(2):123–42

Reasons for living and coping abilities among older adults. Range LM, et al. **Int J Aging Hum Dev** 1996;43(1):1–5

An outlook on subjective well-being in older Israeli adults: a unified formulation. Shmotkin D, et al. **Int J Aging Hum Dev** 1996;42(4):271–89

Worry among Canadian seniors. Skarborn M, et al. **Int J Aging Hum Dev** 1996;43(2):169–78

Aging and the aged in Aesopic fables. Wortley J. **Int J Aging Hum Dev** 1997;44(3):183–203

Correlations between subjective compliance, objective compliance, and factors determining compliance in geriatric hypertensive patients treated with triamterene and hydrochlorothiazide. Oelzner S, et al. **Int J Clin Pharmacol Ther** 1996 Jun;34(6):236–42

Determinants of non-compliance and attrition in the elderly. Slymen DJ, et al. **Int J Epidemiol** 1996 Apr;25(2):411–9

A study of the quality of life in elderly people using psychological testing. Nagatomo I, et al. **Int J Geriatr Psychiatry** 1997 Jun;12(6):599–608

Napping in the elderly and its association with night sleep and psychological status. Frisoni GB, et al. **Int Psychogeriatr** 1996 Fall;8(3):477–87

Adapting cognitive behavioral therapy for the frail elderly. Grant RW, et al. **Int Psychogeriatr** 1995 Winter;7(4):561–71 (25 ref.)

Determinants of loneliness in Jerusalem's 70-year-old population. Stessman J, et al. **Isr J Med Sci** 1996 Aug; 32(8):639–48

"Failure to thrive" in elderly depressed patients: a new concept or a different name for an old problem? Schreiber S, et al. **Isr J Psychiatry Relat Sci** 1997;34(2):108–14

The grief experience of older women whose husbands had hospice care. Jacob SR. **J Adv Nurs** 1996 Aug;24(2):280–6

Entry to care: positive choice or fait accompli? developing a more proactive nursing response to the needs of older people and their carers. Nolan M, et al. **J Adv Nurs** 1996 Aug;24(2):265–74

A predictive model for ADL dependence in community-living older adults based on a reduced set of cognitive status items. Gill TM, et al. **J Am Geriatr Soc** 1997 Apr;45(4):441–5

How older patient preferences are influenced by consideration of future health outcomes. Mazur DJ. **J Am Geriatr Soc** 1997 Jun;45(6):725–8

Subjective alertness rhythms in elderly people. Monk TH, et al. **J Biol Rhythms** 1996 Sep;11(3):268–76

Performance of elderly White and African American community residents on the abbreviated CERAD Boston Naming Test. Fillenbaum GG, et al. **J Clin Exp Neuropsychol** 1997 Apr;19(2):204–10

Expanded norms for the Controlled Oral Word Association Test. Sumerall SW, et al. **J Clin Psychol** 1997 Aug; 53(5):517–21

The geriatric obstacle course: a training session designed to help prehospital personnel recognize geriatric stereotypes and misconceptions [see comments] Fleisher FI, et al. **J Emerg Med** 1996 Jul-Aug;14(4):439–44. Comment in: J Emerg Med 1996 Jul-Aug;14(4):499–500.

Factors related to the desire to enter a nursing home among elderly Japanese. Sauvaget C, et al. **J Epidemiol** 1997 Jun; 7(2):77–83

Preferences for different life-sustaining treatments among elderly persons in Israel. Carmel S, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Mar;52(2):S97–102

The measurement of mood states in older adults. Gibson SJ. **J Gerontol B Psychol Sci Soc Sci** 1997 Jul;52(4):P167–74

Measures of cognitive functioning in the AHEAD Study. Herzog AR, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52 Spec No:37–48

The effect of dementia risk factors on comparative and diagnostic selective reminding norms. Sliwinski M, et al. **J Int Neuropsychol Soc** 1997 Jul;3(4):317–26

Developmental care: the key to the emergence of the vital older woman. Pulliam LW, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Sep;25(7):623–8 (30 ref.)

Still participating after all these years: a study of life task participation in later life. Harlow RE, et al. **J Pers Soc Psychol** 1996 Dec;71(6):1235–49

Improving memory in old age through implicit self-stereotyping. Levy B. **J Pers Soc Psychol** 1996 Dec; 71(6):1092–107

Validity of self-reported rheumatoid arthritis in elderly women. Star VL, et al. **J Rheumatol** 1996 Nov; 23(11):1862–5

Age, birthdays, and suicide in Taiwan. Chuang HL, et al. **J Soc Psychol** 1996 Oct;136(5):659–60

Issues of sexuality in older women. Loehr J, et al. **J Womens Health** 1997 Aug;6(4):451–7

Pet ownership and future health [letter] Anderson WP, et al. **Med J Aust** 1997 Aug 18;167(4):230; discussion 230–1

Impact of pet ownership on elderly Australians' use of medical services: an analysis using Medicare data. Jorm AF, et al. **Med J Aust** 1997 Apr 7;166(7):376–7

Pet ownership and future health [letter] Simons LA, et al. **Med J Aust** 1997 Aug 18;167(4):231–2

Pets helping to heal the elderly. Propsner N. **N J Med** 1997 Sep;94(9):32

Cross-national interrater reliability of dementia diagnosis in the elderly and factors associated with disagreement. O'Connor DW, et al. **Neurology** 1996 Nov;47(5):1194–9

Wellness spirituality in the older adult. Assessment and intervention protocol. Leetun MC. **Nurse Pract** 1996 Aug; 21(8):60, 65–70 (36 ref.)

Spiritual well-being, religiosity, hope, depression, and other mood states in elderly people coping with cancer. Fehring RJ, et al. **Oncol Nurs Forum** 1997 May;24(4):663–71

Attitude and enduring involvement of older adults in structured programs of physical activity. Gravelle F, et al. **Percept Mot Skills** 1997 Aug;85(1):67–71

Assumptions about fitness and exercise among elderly persons. Vitulli WF, et al. **Percept Mot Skills** 1997 Apr; 84(2):671–4

Disability and health: perceptions of a sample of elderly people. Partridge C, et al. **Physiother Res Int** 1996; 1(1):17–29

Maximizing drug compliance in the elderly. Tips for staying on top of your patients' medication use. Ennis KJ, et al. **Postgrad Med** 1997 Sep;102(3):211–3, 218, 223–4 (13 ref.)

Reaching midlife and older smokers: tailored interventions for routine medical care. Morgan GD, et al. **Prev Med** 1996 May-Jun;25(3):346–54

Successful coping, adaptation and resilience in the elderly: an interpretation of epidemiologic data. Foster JR. **Psychiatr Q** 1997 Fall;68(3):189–219 (96 ref.)

Alcoholism among elderly persons. Goldstein MZ, et al. **Psychiatr Serv** 1996 Sep;47(9):941–3 (23 ref.)

Prevention of late life suicide: when, where, why and how. Conwell Y, et al. **Psychiatry Clin Neurosci** 1995 May;49 Suppl 1:S79–83 (34 ref.)

Abnormal behavior of elderly people residing in institutions of medical and social welfare systems. Nagatomo I, et al. **Psychiatry Clin Neurosci** 1997 Apr;51(2):53–6

Relationship between odor perception and depression in the Japanese elderly. Satoh S, et al. **Psychiatry Clin Neurosci** 1996 Oct;50(5):271–5

A prospective study of cognitive function in the elderly. Korten AE, et al. **Psychol Med** 1997 Jul;27(4):919–30

Elements of behavioral health intervention in geriatric long-term care settings. Curtis JM. **Psychol Rep** 1996 Aug; 79(1):24–6

The Kogan Attitudes Toward Old People scale: is it time for a revision? Hilt ML. **Psychol Rep** 1997 Jun;80(3 Pt 2):1372–4

Instrumental measures in geriatric psychopharmacology. Lebowitz BD, et al. **Psychopharmacol Bull** 1995;31(4):641–9 (55 ref.)

Prolactin response to neuroleptic challenge in late-life psychosis. Sweet RA, et al. **Psychopharmacol Bull** 1995; 31(4):651–7

Health behaviors of an elderly Filipino group. DiPasquale-Davis J, et al. **Public Health Nurs** 1997 Apr; 14(2):118–22

Older adults' experience of health promotion: a theory for nursing practice. Frenn M. **Public Health Nurs** 1996 Feb; 13(1):65–71 (32 ref.)

Giving voice to elderly people: community-based long-term care. Krothe JS. **Public Health Nurs** 1997 Aug;14(4):217–26

Social support sources among older women with heart failure: continuity versus loss over time. Friedman MM. **Res Nurs Health** 1997 Aug;20(4):319–27

Depressed mood among the elderly in Jyväskylä. A five-year follow-up. Heikkinen RL. **Scand J Soc Med Suppl** 1997; 53:66–78

Patient satisfaction and the elderly. Owens DJ, et al. **Soc Sci Med** 1996 Jun;42(11):1483–91 (26 ref.)

Depression among elderly Chinese immigrants: an exploratory study. Mui AC. **Soc Work** 1996 Nov; 41(6):633–45

Social support and depression among older adults living alone: the importance of friends within and outside of a retirement community. Potts MK. **Soc Work** 1997 Jul; 42(4):348–62

Being suicidal and elderly in changing times: a case history. Richman J. **Suicide Life Threat Behav** 1997 Spring; 27(1):34–40

First-year Swedish nursing students' experiences with elderly patients. Fagerberg I, et al. **West J Nurs Res** 1997 Apr; 19(2):177–89

Gender differences in participation and responsiveness to a health intervention for older Americans. Gallagher RA, et al. **Women Health** 1997;25(3):63–81

[Depression in the elderly in family practice] van Marwijk HW. **Tijdschr Gerontol Geriatr** 1997 Apr;28(2):69–75 (Eng. Abstr.) **(Dut)**

[Vaccination against influenza in elderly persons: some current presumptions] Roy G, et al. **Can J Public Health** 1996 Sep–Oct;87(5):298–300 (Eng. Abstr.) **(Fre)**

[Anticonvulsant treatment in old age--principles and

differential indications] Hetzel W.
Fortschr Neurol Psychiatr 1997 Jun;65(6):261–77 (144 ref.) (Eng. Abstr.) **(Ger)**

[Cost reduction in long–term nursing thanks to a memory clinic––results of a case control study] Wettstein A, et al. **Schweiz Rundsch Med Prax** 1996 Sep 17;85(38):1175–9 (Eng. Abstr.) **(Ger)**

[Hypochondriasis in the elderly (editorial)] Yoffe A, et al. **Harefuah** 1996 Aug;131(3–4):94–6 (16 ref.) **(Heb)**

[Quality of life among aged people the lower limit of the age of elderly people in an epidemiological study in Shirahama–machi, Chiba Prefecture] Okuda M.
Nippon Ika Daigaku Zasshi 1996 Feb;63(1):48–55 (Eng. Abstr.) **(Jpn)**

[Evaluation of environmental stimulation and its relation to physical deterioration in the elderly after 3 years––a health–social longitudinal study] Anme T.
Nippon Koshu Eisei Zasshi 1997 Mar;44(3):159–66 (Eng. Abstr.) **(Jpn)**

[Social support exchange and quality of life among the Korean elderly in a rural area] Kim H, et al.
Nippon Koshu Eisei Zasshi 1996 Jan;43(1):37–49 (Eng. Abstr.) **(Jpn)**

[Relationship of 'sekentei' to utilization of health, social and nursing services by the elderly] Momose Y, et al.
Nippon Koshu Eisei Zasshi 1996 Mar;43(3):209–19 (Eng. Abstr.) **(Jpn)**

[Social factors related to awareness of public health care services among elderly adults] Sugisawa H, et al.
Nippon Koshu Eisei Zasshi 1996 Aug;43(8):624–31 (Eng. Abstr.) **(Jpn)**

[What is terminal care of the elderly?] Murai A, et al.
Nippon Ronen Igakkai Zasshi 1997 Jan;34(1):12–6 **(Jpn)**

[The quality of life for the elderly in long–term care––view point of social welfare] Ohkuni M.
Nippon Ronen Igakkai Zasshi 1996 Jul;33(7):508–11 (0 ref.) **(Jpn)**

[Serum lipid concentration and subjective evaluation of well–being in elderly persons living at home] Okamoto K.
Nippon Ronen Igakkai Zasshi 1996 Sep;33(9):676–80 (Eng. Abstr.) **(Jpn)**

[Development of a regimen comprehension scale] Shiomi T, et al. **Nippon Ronen Igakkai Zasshi** 1997 Mar;34(3):209–14 (Eng. Abstr.) **(Jpn)**

[Travel outside the home and perceived problems with such travel, among elderly people in a small town] Yoshimoto T, et al. **Nippon Ronen Igakkai Zasshi** 1996 Jun;33(6):430–9 (Eng. Abstr.) **(Jpn)**

[An preliminary study on Quality of Life Scale for Elderly: an examination in terms of psychological satisfaction] Hoshino K, et al. **Shinrigaku Kenkyu** 1996 Jun;67(2):134–40 (Eng. Abstr.) **(Jpn)**

[Treatment with tianeptine for depressive disorders in the elderly] Saiz Ruiz J, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997 Mar–Apr;25(2):79–83 (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

Weight, height and body mass index distributions in geographically and ethnically diverse samples of older persons. Ad Hoc Committee on the Statistics of Anthropometry and Aging. Launer LJ, et al.
Age Ageing 1996 Jul;25(4):300–6

Evaluation of validity of British anthropometric reference data for assessing nutritional state of elderly people in Edinburgh: cross sectional study. Bannerman E, et al.
BMJ 1997 Aug 9;315(7104):338–41

The demographic timebomb [editorial] Raleigh VS. **BMJ** 1997 Aug 23;315(7106):442–3

The elderly and disabled in Hawaii. McElrath AQ.
Hawaii Med J 1996 Dec;55(12):258–9

The demographic face of America's elderly. Waite LJ.
Inquiry 1996 Fall;33(3):220–4

Racial differences in the household composition of elders by age, gender, and area of residence. Coward RT, et al.
Int J Aging Hum Dev 1996;42(3):205–27

Effects of preventive health services on survival of the elderly living in a community in Osaka, Japan. Nakanishi N, et al. **J Epidemiol Community Health** 1997 Apr; 51(2):199–204

Population review: (5). The population aged 60 and over. Grundy EM. **Popul Trends** 1996 Summer;(84):14–20

Development of the health–promotion activities of older adults measure. Padula CA. **Public Health Nurs** 1997 Apr; 14(2):123–8

A comparative study of trends in mortality rates of the ageing population in Norway, Sweden, Denmark, and Finland, 1966–1986. Sverre JM. **Scand J Soc Med** 1995 Dec; 23(4):227–32

Percentage of elderly and the use of welfare services at city welfare offices in Japan. Ida O, et al. **Soc Sci Med** 1996 Dec;43(11):1527–32

[Aging of the population: demographics for the Liege region] Paul I, et al. **Rev Med Liege** 1997 Apr;52(4):190–2 **(Fre)**

[Family relations and informal social networks in the social structure and demographic change] Backes GM.
Z Gerontol Geriatr 1996 Jan–Feb;29(1):29–33 (Eng. Abstr.) **(Ger)**

[Regional aging in Germany] Bucher H.
Z Gerontol Geriatr 1996 Jan–Feb;29(1):3–10 (Eng. Abstr.) **(Ger)**

[Health and social problems in the aged] Grujić V, et al. **Med Pregl** 1997 Mar–Apr;50(3–4):115–9 (Eng. Abstr.) **(Scr)**

AGED ABUSE see **ELDER ABUSE**

AGED, 80 AND OVER

Safety and efficacy of electroconvulsive therapy in patients over age 85. Tomac TA, et al.
Am J Geriatr Psychiatry 1997 Spring;5(2):126–30

The oldest patient? [letter] Wraight WJ. **Anaesthesia** 1997 May;52(5):509

Perceptions by family members of the dying experience of older and seriously ill patients. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments [see comments] Lynn J, et al. **Ann Intern Med** 1997 Jan 15;126(2):97–106. Comment in: Ann Intern Med 1997 Jan 15;126(2):164–5. Comment in: Ann Intern Med 1997 Aug 1;127(3):242; discussion 243. Comment in: Ann Intern Med 1997 Aug 1;127(3):242–3. Comment in: Ann Intern Med 1997 Aug 1;127(3):243.

Factors associated with suboptimal analgesic use in community–dwelling elderly. Hanlon JT, et al.
Ann Pharmacother 1996 Jul–Aug;30(7–8):739–44

Drug use by the elderly in Italy. Nobili A, et al.
Ann Pharmacother 1997 Apr;31(4):416–22

Cardiac operations in patients 80 years old and older. Akins CW, et al. **Ann Thorac Surg** 1997 Sep;64(3):606–14; discussion 614–5

Reliability and validity of the FIM for persons aged 80 years and above from a multilevel continuing care retirement community. Pollak N, et al. **Arch Phys Med Rehabil** 1996 Oct;77(10):1056–61

Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. Mannucci PM, et al.
Arterioscler Thromb Vasc Biol 1997 Apr;17(4):755–9

Treatment of abdominal aortic aneurysm disease in the 9th and 10th decades of life. Robinson D, et al.
Aust N Z J Surg 1997 Sep;67(9):640–2

Anthropometric characteristics of healthy Italian nonagenarians and centenarians. Ravaglia G, et al.
Br J Nutr 1997 Jan;77(1):9–17

Surgical care in octogenarians. Bufalari A, et al.
Br J Surg 1996 Dec;83(12):1783–7

Surgical care and outcome for patients in their nineties. Burns–Cox N, et al. **Br J Surg** 1997 Apr;84(4):496–8

Cancer of the oldest old. What we have learned from autopsy studies. Stanta G, et al. **Clin Geriatr Med** 1997 Feb; 13(1):55–68 (18 ref.)

An assessment of the suitability of Mohs micrographic surgery in patients aged 90 years and older. MacFarlane DF, et al. **Dermatol Surg** 1997 May;23(5):389–92; discussion 392–3

Cardiovascular event classification in the very old: how accurate and how complete? [editorial; comment] Heckbert SR, et al. **Epidemiology** 1997 Sep;8(5):473–4. Comment on: Epidemiology 1997 Sep;8(5):495–500. Comment on: Epidemiology 1997 Sep;8(5):501–4.

Circulatory disease mortality in the very elderly [see comments] Smith DW. **Epidemiology** 1997 Sep;8(5):501–4 . Comment in: Epidemiology 1997 Sep;8(5):473–4.

Social and psychological resources in the oldest old. Martin P, et al. **Exp Aging Res** 1996 Apr–Jun;22(2):121–39

Unplanned readmissions of elderly patients. Gautam P, et al. **Health Bull (Edinb)** 1996 Nov;54(6):449–57

Acute care costs of the oldest old. Perls TT.
Hosp Pract (Off Ed) 1997 Jul 15;32(7):123–4, 129–32, 137 (12 ref.)

Early cognitive markers of the incidence of dementia and mortality: a longitudinal population–based study of the oldest old. Johansson B, et al. **Int J Geriatr Psychiatry** 1997 Jan;12(1):53–9

Surgical results in cardiac patients over the age of 80 years. Sahar G, et al. **Isr J Med Sci** 1996 Dec;32(12):1322–5

Causes of death in the very old [letter] Fogata ML, et al. **J Am Geriatr Soc** 1996 Nov;44(11):1412–3

End–of–life issues for very elderly women: incurable and terminal illness. Ahronheim JC.
J Am Med Womens Assoc 1997 Summer;52(3):147–51

The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine–metabolic parameters and functional status in the oldest–old. Results from an Italian study on healthy free–living over–ninety–year–olds. Ravaglia G, et al. **J Clin Endocrinol Metab** 1996 Mar; 81(3):1173–8

Prevalence of organ–specific and non organ–specific autoantibodies in healthy centenarians. Candore G, et al.
Mech Ageing Dev 1997 Mar;94(1–3):183–90

Is it worth performing kidney replacement therapy on patients Over 80? [news] Röhrich B, et al.
Nephrol Dial Transplant 1996 Dec;11(12):2412–3

The treatment of octogenarians [letter; comment] Caporale N. **Perit Dial Int** 1996 Nov–Dec;16(6):649. Comment on: Perit Dial Int 1996 May–Jun;16(3):241–2.

Gallstone disease in patients over the age of 80. Surgery or long–term medical treatment? González González JJ, et al. **Rev Esp Enferm Dig** 1997 Mar;89(3):196–205 **(Eng, Spa)**

Heart surgery in patients aged eighty years and above: determinants of morbidity and mortality. Deiwick M, et al. **Thorac Cardiovasc Surg** 1997 Jun;45(3):119–26

[The demography of centenarians in Denmark] Jeune B, et al. **Ugeskr Laeger** 1996 Dec 16;158(51):7392–6 (Eng. Abstr.) **(Dan)**

[Centenarians in the county of Funen. Morbidity and functional capacity] Olsen H, et al. **Ugeskr Laeger** 1996 Dec 16;158(51):7397–401 (Eng. Abstr.) **(Dan)**

[New special research data on over 100–year–old and older probands and problems (II)] Franke H.
Z Gerontol Geriatr 1997 Mar–Apr;30(2):130–55 (119 ref.) (Eng. Abstr.) **(Ger)**

[Longitudinal and comprehensive follow–up study of the oldest man in Japan] Akisaka M, et al.
Nippon Ronen Igakkai Zasshi 1997 Apr;34(4):312–23 (Eng. Abstr.) **(Jpn)**

[Carotid intima–media thickness and the occurrence of plaque in centenarians––data from the Tokyo Centenarian Study] Homma S, et al. **Nippon Ronen Igakkai Zasshi** 1997 Feb; 34(2):139–46 (Eng. Abstr.) **(Jpn)**

[Problems related to dispensing of generic drugs in primary care (letter)] Rodero Garduño I, et al. **Aten Primaria** 1997 Mar 15;19(4):216–7 **(Spa)**

PHYSIOLOGY

CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Agúndez JA, et al. **Age Ageing** 1997 Mar; 26(2):147–51

Muscle function of women aged 65–89 years meeting two sets of health criteria. Skelton DA, et al.
Aging (Milano) 1997 Feb–Apr;9(1–2):106–11

The pituitary–gonadal axis and health in elderly men: a study of men born in 1913. Tibblin G, et al. **Diabetes** 1996 Nov; 45(11):1605–9

Drug selection for optimal treatment of hypertension in the elderly. Shammas E, et al. **Drugs Aging** 1997 Jul;11(1):19–26 (43 ref.)

Five–year performance trends for older exercisers: a hierarchical model of endurance, strength, and flexibility. Morey MC, et al. **J Am Geriatr Soc** 1996 Oct; 44(10):1226–31

Serum levels of insulin–like growth factor–I (IGF–I) and IGF–binding protein–3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function. Paolisso G, et al.
J Clin Endocrinol Metab 1997 Jul;82(7):2204–9

Nutritional status of centenarians assessed by activity and anthropometric, hematological and biochemical characteristics. Chan YC, et al.
J Nutr Sci Vitaminol (Tokyo) 1997 Feb;43(1):73–81

The prevalence of pain among the oldest old in Sweden. Brattberg G, et al. **Pain** 1996 Sep;67(1):29–34

[Gait impairment in the oldest old] Bloem BR, et al.
Tijdschr Gerontol Geriatr 1997 Apr;28(2):76–81 (Eng. Abstr.) **(Dut)**

[Lipid and lipoprotein profile of Japanese centenarians––high prevalence of hypo beta lipoproteinemia] Arai Y, et al. **Nippon Ronen Igakkai Zasshi** 1997 Mar;34(3):202–8 (Eng. Abstr.) **(Jpn)**

[Tokyo Centenarian Study. 4. Apolipoprotein E phenotype in Japanese centenarians living in the Tokyo Metropolitan area] Hirose N, et al. **Nippon Ronen Igakkai Zasshi** 1997 Apr;34(4):267–72 (Eng. Abstr.) **(Jpn)**

[Tokyo Centenarian Study. 5. Nutritional status of Japanese centenarians] Hirose N, et al.
Nippon Ronen Igakkai Zasshi 1997 Apr;34(4):324–30 (Eng. Abstr.) **(Jpn)**

[Relationships between heart rate variabilities and psychosomatic activities of centenarians in Tokyo] Shimizu K, et al. **Nippon Ronen Igakkai Zasshi** 1996 Aug; 33(8):613–5 **(Jpn)**

[Prevalence of autoantibodies in serum of healthy persons over 85 years of age] Potocka–Płazak K, et al.
Przegl Lek 1995;52(11):544–6 (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Correlates of self–rated health in persons aged 85 and over: results from the Canadian Study of Health and Aging. Ebly EM, et al. **Can J Public Health** 1996 Jan–Feb;87(1):28–31

Incidence of depression in octo– and nonagenerians: results of an epidemiological follow–up community study. Meller I, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(2):93–9

Loneliness among the oldest old, a comparison between residents living in nursing homes and residents living in the community. Bondevik M, et al.
Int J Aging Hum Dev 1996;43(3):181–97

Personality, longevity, and successful aging among Tokyo metropolitan centenarians. Shimonaka Y, et al.
Int J Aging Hum Dev 1996;42(3):173–87

Suicidal thinking in community residents over eighty. Rao R, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):337–43

Transcending old age: creativity, development and psychoanalysis in the life of a centenarian. Settlage CF. **Int J Psychoanal** 1996 Jun;77 (Pt 3):549–64

Mini–Mental State Exam status of community–dwelling cognitively intact centenarians. Holtsberg PA, et al.
Int Psychogeriatr 1995 Fall;7(3):417–27

Episodic remembering in a population–based sample of nonagenarians: does major depression exacerbate the memory deficits seen in Alzheimer's disease? Bäckman L, et al. **Psychol Aging** 1996 Dec;11(4):649–57

Perceived continuity of self in very old age. Troll LE, et

al. **Psychol Aging** 1997 Mar;12(1):162–9
[Relationships between heart rate variabilities and psychosomatic activities of centenarians in Tokyo] Shimizu K, et al. **Nippon Ronen Igakkai Zasshi** 1996 Aug; 33(8):613–5 **(Jpn)**

STATISTICS & NUMERICAL DATA

Activities of daily living: changes in functional ability in three samples of elderly and very elderly people. Bowling A, et al. **Age Ageing** 1997 Mar;26(2):107–14
[Recent problems of advanced age in humans. I. General problems] Franke H. **Z Gerontol Geriatr** 1996 Jan–Feb; 29(1):51–64 (Eng. Abstr.) **(Ger)**

AGEISM see **PREJUDICE**

AGENCY FOR HEALTH CARE POLICY AND RESEARCH see **UNITED STATES AGENCY FOR HEALTH CARE POLICY AND RESEARCH**

AGEPC see **PLATELET ACTIVATING FACTOR**

AGEUSIA

CHEMICALLY INDUCED

[Damage to sense of smell and taste following xylocaine administration? Process before the expert evaluation committee for medical malpractice of the North Rhine Physicians Organization in 1995 (Az. 91/588)] Wienke A. **Laryngorhinootologie** 1996 Feb;75(2):109–10 **(Ger)**
[Acarbose-induced ageusia (letter)] Martín Bun M, et al. **Med Clin (Barc)** 1996 Sep 28;107(10):399 **(Spa)**

DIAGNOSIS

Clinical and physiological investigations in patients with taste abnormality. Osaki T, et al. **J Oral Pathol Med** 1996 Jan; 25(1):38–43
[Testing smell and taste] Jahnke V. **HNO** 1996 Oct;44(10):595 **(Ger)**

ETIOLOGY

Ataxic hemiparesis and hemiageusia from an isolated post-traumatic midbrain lesion. Johnson TM. **Neurology** 1996 Nov;47(5):1348–9
[Disorders of smell and taste sensations] Schilling V. **Internist (Berl)** 1997 Jan;38(1):95–104 (13 ref.) **(Ger)**

AGGLUTINATION

DRUG EFFECTS

A small peptide from durum wheat gliadin prevents cell agglutination induced by prolamin-peptides toxic in coeliac disease. De Vincenzi M, et al. **Toxicology** 1997 Jul 11; 120(3):207–13

IMMUNOLOGY

Serological identification of Shigella flexneri strains by the coagglutination reaction. Ciudin L, et al.
Roum Arch Microbiol Immunol 1995 Oct–Dec; 54(4):295–311

PHYSIOLOGY

Crowding stress induces changes in serum haemolytic and agglutinating activity in the gilthead sea bream Sparus aurata. Tort L, et al. **Vet Immunol Immunopathol** 1996 May; 51(1–2):179–88

AGGLUTINATION TESTS

Evaluation of latex agglutination test for rapid detection of goat poxvirus antigen and antibodies. Rao TV, et al.
Acta Virol 1996 Apr;40(2):95–7
Comparison of assay methods for benzodiazepines in urine. A receptor assay, two immunoassays, and gas chromatography–mass spectrometry. Nishikawa T, et al.
Am J Clin Pathol 1997 Mar;107(3):345–52
Serotyping of Streptococcus pneumoniae by agglutination assays: a cost-effective technique for developing countries. Lalitha MK, et al. **Bull World Health Organ** 1996; 74(4):387–90
The fat emulsion agglutination test: a reliable and cost effective alternative to the latex agglutination test for rapid bedside CRP measurement. Richter D, et al.
Clin Chim Acta 1997 May 28;261(2):141–8
Coagglutination with antisera to MyfA and PsaA to distinguish Yersinia enterocolitica from Yersinia pseudotuberculosis pathogenic isolates. Leiva J, et al.
Contrib Microbiol Immunol 1995;13:158–64
Agglutination of Yersinia strains by lectins. Martinez MB, et al. **Contrib Microbiol Immunol** 1995;13:145–9
Comparative evaluation of serological tests for diagnosis of visceral leishmaniasis. Agarwal M, et al.
Indian J Exp Biol 1996 Aug;34(8):734–8
Two hundred false Widal positive cases from eastern U.P. [letter] Singh PS. **J Assoc Physicians India** 1996 Nov; 44(11):842
Comparison of commercial slide agglutination kits with a tube coagulase test for the rapid identification of Staphylococcus aureus from blood culture. Cooke RP, et al. **J Clin Pathol** 1997 Feb;50(2):164–6
A particle agglutination assay for rapid identification of heparin binding to coagulase-negative staphylococci. Pascu C, et al. **J Med Microbiol** 1996 Oct;45(4):263–9

HISTORY

[The centenary of the discovery of Widal's agglutination reaction (the history of the development of serodiagnosis)] Tsyhanenko AIa, et al. **Mikrobiol Z** 1996 Sep–Oct; 58(5):107–9 **(Ukr)**

METHODS

Feasibility of Helicobacter pylori identification by a slide agglutination test. Maeland JA, et al. **APMIS** 1997 Feb; 105(2):157–60
Detection of methicillin-resistant Staphylococcus aureus: the evaluation of rapid agglutination methods. Davies S.
Br J Biomed Sci 1997 Mar;54(1):13–5
HIV-antibody detection in vitreous humor and serum by enzyme immunosorbent assay and particle agglutination test. Schor P, et al. **Cornea** 1997 Sep;16(5):541–4
Comparison of screening methods to identify methicillin-resistant Staphylococcus aureus. Kampf G, et al. **Eur J Clin Microbiol Infect Dis** 1997 Apr;16(4):301–7
Comparison of the indirect immunofluorescent antibody test and the direct agglutination test for serodiagnosis of visceral leishmaniasis in HIV-infected subjects. Nigro L, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):832–5
Dog-DAT: a direct agglutination test using stabilized, freeze-dried antigen for the serodiagnosis of canine visceral leishmaniasis. Oskam L, et al.
FEMS Immunol Med Microbiol 1996 Dec 31;16(3–4):235–9
Direct agglutination test for early diagnosis of Indian visceral leishmaniasis. Jha TK, et al. **J Assoc Physicians India** 1996 Sep;44(9):606–8
Simple, speedy, sensitive, and specific serodiagnosis of pertussis by using a particle agglutination test. Aoyama T, et al. **J Clin Microbiol** 1997 Jul;35(7):1859–61
Rapid method for detection of Coxiella burnetii antibodies using high-density particle agglutination. Nguyen SV, et al. **J Clin Microbiol** 1996 Dec;34(12):2947–51
Comparative performances of six agglutination kits assessed by using typical and atypical strains of Staphylococcus aureus. Personne P, et al. **J Clin Microbiol** 1997 May; 35(5):1138–40
A rapid serological detection method for squamous cell carcinoma. Yoshizawa H, et al. **J Obstet Gynaecol Res** 1996 Dec;22(6):575–83
A serologic Mycobacteria leprae gelatin particle agglutination (MLPA) in the diagnosis of leprosy: comparison with conventional enzyme-linked immunoassay and bacterial index. Agdamag AT, et al.
Nippon Rai Gakkai Zasshi 1996 Jul;65(2):100–5
Identification of Angiostrongylus cantonensis in infected rats with a coagglutination assay. Rojas Rivero L, et al.
Southeast Asian J Trop Med Public Health 1995 Dec; 26(4):716–8
[Diagnosis of legionellosis by microagglutination test—comparison to indirect immunofluorescent antibody method] Koide M, et al. **Kansenshogaku Zasshi** 1996 Dec; 70(12):1254–8 (Eng. Abstr.) **(Jpn)**

VETERINARY

A latex cryptococcal antigen agglutination test for diagnosis and monitoring of therapy for cryptococcosis. Malik R, et al. **Aust Vet J** 1996 Nov;74(5):358–64
Evaluation of diagnostic procedures to detect Mycoplasma synoviae in commercial multiplier-breeder farms and commercial hatcheries in Florida. Ewing ML, et al.
Avian Dis 1996 Oct–Dec;40(4):798–806
Serotyping of Actinobacillus pleuropneumoniae serotype 5 strains using a monoclonal-based polystyrene agglutination test. Dubreuil JD, et al. **Can J Vet Res** 1996 Jan;60(1):69–71
Detection of equine antisperm antibodies by indirect immunofluorescence and the tube-slide agglutination test. Day MJ. **Equine Vet J** 1996 Nov;28(6):494–6
Usefulness and limitations of three serologic methods for diagnosing or excluding chlamydiosis in birds. Grimes JE, et al. **J Am Vet Med Assoc** 1996 Aug 15;709(4):747–50
Detecting infections of chickens with recent Salmonella pullorum isolates using standard serological methods. Gast RK. **Poult Sci** 1997 Jan;76(1):17–23
Coagglutination test for rapid detection of infectious bursal disease virus antigen. Shakya S, et al.
Trop Anim Health Prod 1997 May;29(2):105–7
Validation of the specificity of the modified agglutination test for toxoplasmosis in pigs. Dubey JP. **Vet Parasitol** 1997 Aug;71(4):307–10

AGGLUTININS

ADVERSE EFFECTS

[Hemolytic anemia by cryoagglutinins, leukopenia and repetead infections (clinical conference)]
Medicina (B Aires) 1995;55(6):697–704 **(Spa)**

ANALYSIS

Affinity electrophoretic determination of oligosaccharide specificity of Butea monosperma agglutinin. Wongkham S, et al. **Electrophoresis** 1996 Jan;17(1):98–103
[Cold agglutinins and cryoglobulinemia in a patient with hepatitis C] Ruivard M, et al. **Presse Med** 1996 Oct 26; 25(32):1548–9 (Eng. Abstr.) **(Fre)**
[Autoimmune hemolytic anemia caused by cold agglutinins of the anti-Pr specificity after rubella infection] König AL, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:26–9 (Eng. Abstr.) **(Ger)**

BLOOD

Increased pressures in the retrograde blood cardioplegia line: an unusual presentation of cold agglutinins during cardiopulmonary bypass. Fischer GD, et al.
Anesth Analg 1997 Feb;84(2):454–6
Inverse correlation between IgG-antihinge region and antierythrocyte autoantibody in chronic benign and malignant cold agglutination. Terness P, et al.
J Clin Immunol 1997 May;17(3):220–7
A patient with fatal cold haemagglutinins. Mandigers CM, et al. **Neth J Med** 1996 Nov;49(5):209–11
Autoimmune hemolytic anemia with warm antibodies complicated with an intercurrent attack of hemolysis with cold agglutinins in a case of Waldenström disease. Gologan R, et al. **Rom J Intern Med** 1996 Jan–Jun;34(1–2):149–54 (30 ref.)
Do cold agglutinins have any impact on the outcome of liver transplantation? Marsman WA, et al. **Transplantation** 1996 Dec 15;62(11):1673–6
[The frequency of agglutinins for Leptospira seen in the inhabitants of Uberaba, Minas Gerais] Tavares-Neto J, et al. **Rev Soc Bras Med Trop** 1996 Jan–Feb;29(1):55–8 **(Por)**

GENETICS

Molecular cloning of the bark and seed lectins from the Japanese pagoda tree (Sophora japonica). Van Damme EJ, et al. **Plant Mol Biol** 1997 Feb;33(3):523–36

IMMUNOLOGY

Effect of low ionic strength on anti-Pr reactions. Leo A, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:22–5
Structure of antigens recognized by cold agglutinins. Stahl D, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:7–12
[Cold agglutinin disease and paroxysmal cold hemoglobinuria] Kannagi R, et al. **Nippon Rinsho** 1996 Sep; 54(9):2519–27 (29 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Anti-Sia-lb (anti-Gd) cold agglutinins bind the domain NeuNAc alpha2-3Gal in sialyl Lewis(x), sialyl Lewis(a), and related carbohydrates on nucleated cells and in soluble cancer-associated mucins. Gallart T, et al. **Blood** 1997 Aug 15;90(4):1576–87
Characterization of the binding specificity of Anguilla anguilla agglutinin (AAA) in comparison to Ulex europaeus agglutinin I (UEA-I). Baldus SE, et al. **Glycoconj J** 1996 Aug;13(4):585–90
Immobilized Lotus tetragonolobus agglutinin binds oligosaccharides containing the Le(x) determinant. Yan L, et al. **Glycoconj J** 1997 Jan;14(1):45–55
Distribution patterns of Wisteria floribunda agglutinin binding sites and parvalbumin-immunoreactive neurons in the human visual cortex: a double-labelling study. Seeger G, et al. **J Hirnforsch** 1996;37(3):351–66

PHARMACOLOGY

Immunomodulatory effects of Viscum album agglutinin-I on natural immunity. Hajto T, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S43–6
Induction of capacitation in human spermatozoa in vitro by an endometrial sialic acid-binding protein. Banerjee M, et al. **Hum Reprod** 1995 Dec;10(12):3147–53
Mitogenic activity of high molecular weight mannose specific agglutinin. Gupta A, et al. **Indian J Biochem Biophys** 1996 Aug;33(4):325–7

AGGLUTININS, PLANT see **LECTINS**

AGGLUTININS, WHEAT GERM see **WHEAT GERM AGGLUTININS**

AGGREGATION BIAS see **BIAS (EPIDEMIOLOGY)**

AGGREGATION, RECEPTOR see **RECEPTOR AGGREGATION**

AGGRESSION

The effect of low brain serotonin on mood and aggression in humans. Influence of baseline mood and genetic factors. Young SN, et al. **Adv Exp Med Biol** 1996;398:45–50 (24 ref.)
Characteristics of children and adolescents with mental retardation and frequent outwardly directed aggressive behavior. Davidson PW, et al. **Am J Ment Retard** 1996 Nov;101(3):244–55
Intervention with excessively aggressive children. Conceptual and ethical issues. Blustein J.
Ann N Y Acad Sci 1996 Sep 20;794:308–17

AGGRESSION

A clinical approach to the pharmacotherapy of aggression in children and adolescents. Connor DF, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:290–307 (132 ref.)

Hypothalamic paraventricular nucleus, oxytocin, and maternal aggression in rats. Giovenardi M, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:606–9

Ethopharmacology of aggression: impact on autonomic and mesocorticolimbic activity. Miczek KA, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:60–77 (108 ref.)

Gonadal and adrenal hormones. Developmental transitions and aggressive behavior. Susman EJ, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:18–30

Aggressive youth: healing biology with relationship. Vance JE. **Ann N Y Acad Sci** 1997 Jan 15;807:587–9

Pharmacotherapy of aggressive behavior. Pabis DJ, et al. **Ann Pharmacother** 1996 Mar;30(3):278–87 (106 ref.)

Interventions for cognitive impairment and neurobehavioral disturbances of older adults. Cronin-Stubbs D. **Annu Rev Nurs Res** 1997;15:35–56 (98 ref.)

Abusive behavior in the perioperative setting. Fortunato N. **AORN J** 1996 Sep;64(3):451–3

A pathological cause for aggression. Kerr CD. **Aust Fam Physician** 1996 Dec;25(12):1881

The efficacy of a response cost-based treatment package for managing aggressive behavior in preschoolers. Reynolds LK, et al. **Behav Modif** 1997 Apr;21(2):216–30

Psychometric evaluation of the Dutch version of the Aggression Questionnaire. Meesters C, et al. **Behav Res Ther** 1996 Oct;34(10):839–43

Manipulation of serotonergic status related to subjective and behavioral measures of aggression [letter; comment] Bond AJ, et al. **Biol Psychiatry** 1997 Jun 1;41(11):1147. Comment on: Biol Psychiatry 1996 Aug 1;40(3):157–64.

Relationship of prolactin response to d-fenfluramine to behavioral and questionnaire assessments of aggression in personality-disordered men [see comments] Coccaro EF, et al. **Biol Psychiatry** 1996 Aug 1;40(3):157–64. Comment in: Biol Psychiatry 1997 Jun 1;41(11):1147.

Aggressive, socially disruptive and antisocial behaviour associated with fronto-temporal dementia. Miller BL, et al. **Br J Psychiatry** 1997 Feb;170:150–4

The use of seclusion and emergency medication in a hospital for people with learning disability. Rangecroft ME, et al. **Br J Psychiatry** 1997 Mar;170:273–7

Comparison of food intake, rate of consumption, pecking activity and behaviour in layer and broiler breeder males. Hocking PM, et al. **Br Poult Sci** 1997 Jul;38(3):237–40

Agonistic interactions affect brain serotonergic activity in an acanthopterygiian fish: the bicolor damselfish (Pomacentrus partitus). Winberg S, et al. **Brain Behav Evol** 1996;48(4):213–20

Use of a modified version of the Overt Aggression Scale in the measurement and assessment of aggressive behaviours following brain injury. Alderman N, et al. **Brain Inj** 1997 Jul;11(7):503–23

Enhanced 5-HT1A receptor expression in forebrain regions of aggressive house mice. Korte SM, et al. **Brain Res** 1996 Oct 14;736(1–2):338–43

Comparison of cerebrospinal fluid monoamine metabolite levels in dominant-aggressive and non-aggressive dogs. Reisner IR, et al. **Brain Res** 1996 Apr 1;714(1–2):57–64

Territorial aggression, body weight, carbohydrate metabolism and testosterone levels of wild rats maintained in laboratory colonies. Lucion AB, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1657–62

Clinician's views on sexually aggressive children and their families: a theoretical exploration. Burton DL, et al. **Child Abuse Negl** 1997 Feb;21(2):157–70

Do mitigating circumstances influence family reactions to physical aggression? Martin JL, et al. **Child Dev** 1996 Aug; 67(4):1455–66

Aggression from a developmental perspective: genes, environments and interactions. Cairns RB. **Ciba Found Symp** 1996;194:45–56; discussion 57–60 (31 ref.)

Safety in Canadian junior ice hockey: the association between ice surface size and injuries and aggressive penalties in the Ontario Hockey League. Watson RC, et al. **Clin J Sport Med** 1997 Jul;7(3):192–5

Optimal management of behavioural disorders associated with dementia. Class CA, et al. **Drugs Aging** 1997 Feb; 10(2):95–106 (70 ref.)

Effect of repeated experience of victory and defeat in daily agonistic confrontations on brain tryptophan hydroxylase activity. Amstislavskaya TG, et al. **FEBS Lett** 1997 Apr 7;406(1–2):106–8

Conspecific aggression and predation: costs for a solitary mantled howler monkey. Cuarón AD. **Folia Primatol (Basel)** 1997;68(2):100–5

Prevalence and correlates of aggressive behaviours occurring in patients with Alzheimer's disease. Eastley R, et al. **Int J Geriatr Psychiatry** 1997 Apr;12(4):484–7

Aggressive behaviour in the Chinese elderly—validation of the Chinese version of the rating scale for aggressive behaviour in the elderly (RAGE) in hospital and nursing home settings. Lam LC, et al. **Int J Geriatr Psychiatry** 1997 Jun;12(6):678–81

The relationship between two scales measuring aggressive behaviour among elderly nursing home residents. Shah A, et al. **Int J Geriatr Psychiatry** 1997 Jun;12(6):628–31

Family enhancement of cognitive style in anxious and aggressive children. Barrett PM, et al. **J Abnorm Child Psychol** 1996 Apr;24(2):187–203

The moderating effects of children's fear and activity level on relations between parenting practices and childhood symptomatology. Colder CR, et al. **J Abnorm Child Psychol** 1997 Jun;25(3):251–63

The course of aggression in first-grade children with and without comorbid anxious symptoms. Ialongo N, et al. **J Abnorm Child Psychol** 1996 Aug;24(4):445–56

What they want and what they get: the social goals of boys with ADHD and comparison boys. Melnick SM, et al. **J Abnorm Child Psychol** 1996 Apr;24(2):169–85

Levels of analysis in cognitive bases of maternal disciplinary dysfunction. Strassberg Z. **J Abnorm Child Psychol** 1997 Jun;25(3):209–15

Aggression and environmental risk among low-income African-American youth. Fitzpatrick KM. **J Adolesc Health** 1997 Sep;21(3):172–8

Aggression in clinical settings: nurses' views. Farrell GA. **J Adv Nurs** 1997 Mar;25(3):501–8

Cholesterol and aggression [letter] Goodman J, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Mar;36(3):303–4

Comorbidity in ADHD: implications for research, practice, and DSM-V. Jensen PS, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Aug; 36(8):1065–79 (69 ref.)

Clonidine side effect [letter] McCracken JT, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Feb;36(2):160–1

Nonpharmacological response in hospitalized children with conduct disorder. Malone RP, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Feb;36(2):242–7

Effect of concentration problems on the malleability of children's aggressive and shy behaviors. Rebok GW, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Feb; 35(2):193–203

Influence of owner personality type on expression and treatment outcome of dominance aggression in dogs. Dodman NH, et al. **J Am Vet Med Assoc** 1996 Sep 15; 209(6):1107–9

Selecting, raising, and caring for dogs to avoid problem aggression. Hart BL, et al. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1129–34 (17 ref.)

Effects of aggressive behavior on canine welfare. Hunthausen W. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1134–6 (8 ref.)

Dog bite prevention from animal control's perspective. Rieck D. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1145–6 (1 ref.)

AVMA forum focuses on aggressive dogs [news] Suzik HA. **J Am Vet Med Assoc** 1997 Feb 1;210(3):305–6, 308

Animal behavior case of the month. Aggressive attacks by a cat against its owner. Taliaferro L, et al. **J Am Vet Med Assoc** 1996 Jul 1;209(1):66–8

A preliminary analysis of the effects of prior classroom conditions on performance under analogue analysis conditions. O'Reilly MF, et al. **J Appl Behav Anal** 1996 Winter;29(4):581–4

The use of buspirone with aggressive behavior [letter] Hillbrand M, et al. **J Autism Dev Disord** 1995 Dec; 25(6):663–4

Aggressiveness, dominance, developmental factors, and serum cholesterol level in college males. Greene RE Jr, et al. **J Behav Med** 1995 Dec;18(6):569–80

As through a glass darkly: the case for qualitative research on violence [editorial; comment] Prothrow-Smith D. **J Gen Intern Med** 1996 Feb;11(2):128–9. Comment on: J Gen Intern Med 1996 Feb;11(2):77–82.

The experience of violent injury for young African-American men: the meaning of being a "sucker" [see comments] Rich JA, et al. **J Gen Intern Med** 1996 Feb;11(2):77–82. Comment in: J Gen Intern Med 1996 Feb;11(2):128–9. Comment in: J Gen Intern Med 1996 Jun;11(6):381; discussion 382.

Hostility, aggression and the association with hypertension in post-menopausal women. Lahad A, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S115–21

Behaviour disorder in an adolescent with terminal deletion of chromosome 3. Davies JL, et al. **J Intellect Disabil Res** 1997 Jun;41 (Pt 3):278–80

Assessment of children with the overt aggression scale. Kafantaris V, et al. **J Neuropsychiatry Clin Neurosci** 1996 Spring;8(2):186–93

Reducing high-risk interventions for managing aggression in psychiatric settings. Visalli H, et al. **J Nurs Care Qual** 1997 Feb;11(3):54–61

Verbal abuse of staff nurses by physicians. Manderino MA, et al. **J Prof Nurs** 1997 Jan–Feb;13(1):48–55

Platelet abnormalities in aggressive subjects with mental deficiency. Marazziti D, et al. **J Psychiatry Neurosci** 1996 Mar;21(2):109–13

Aggression and violence in sport: an ISSP position stand. Tenenbaum G, et al. **J Sports Med Phys Fitness** 1997 Jun; 37(2):146–50

Characterization and treatment of 20 canine dominance aggression cases. Uchida Y, et al. **J Vet Med Sci** 1997 May; 59(5):397–9

Harassment in medical profession--myth or reality in Pakistan. Shaikh MA. **JPMA J Pak Med Assoc** 1996 Jun; 46(6):131–2

Genes for Prader Willi syndrome/Angelman syndrome and fragile X syndrome are homologous, with genetic imprinting and unstable trinucleotide repeats causing mental retardation, autism and aggression. Fischer KM. **Med Hypotheses** 1996 Oct;47(4):289–98

Homeostatic disturbances and human aggression. Naisberg Y. **Med Hypotheses** 1997 Apr;48(4):331–6

Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. König M, et al. **Nature** 1996 Oct 10; 383(6600):535–8

Attack priming in female Syrian golden hamsters is associated with a c-fos-coupled process within the corticomedial amygdala. Potegal M, et al. **Neuroscience** 1996 Dec; 75(3):869–80

Micro- and macrosocial conditions of adolescents' aggressiveness and antiforeigner attitudes. Klein-Allermann E, et al. **New Dir Child Dev** 1995 Winter; (70):71–83

Psychotherapeutic approaches to aggressive and violent patients. Alpert JE, et al. **Psychiatr Clin North Am** 1997 Jun;20(2):453–72 (122 ref.)

Genetics of aggressive and violent behavior. Cadoret RJ, et al. **Psychiatr Clin North Am** 1997 Jun;20(2):301–22

Psychopharmacologic treatment of pathologic aggression. Fava M. **Psychiatr Clin North Am** 1997 Jun;20(2):427–51 (176 ref.)

The neurobiology of impulsive aggression. Kavoussi R, et al. **Psychiatr Clin North Am** 1997 Jun;20(2):395–403

The developmental course of violence and aggression. Mechanisms of family and peer influence. Pettit GS. **Psychiatr Clin North Am** 1997 Jun;20(2):283–99 (47 ref.)

A positive correlation between self-ratings of depression and laboratory-measured aggression. Bjork JM, et al. **Psychiatry Res** 1997 Mar 3;69(1):33–8

Neurotransmitter-neuroendocrine responses to experimentally induced aggression in humans: influence of personality variable. Gerra G, et al. **Psychiatry Res** 1997 Jan 15;66(1):33–43

Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Strous RD, et al. **Psychiatry Res** 1997 Mar 24;69(2–3):71–7

Female gang members: a profile of aggression and victimization. Molidor CE. **Soc Work** 1996 May; 41(3):251–7

Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update. Bahrke MS, et al. **Sports Med** 1996 Dec;22(6):367–90 (157 ref.)

Aggressive behaviour in English cocker spaniels and the personality of their owners. Podberscek AL, et al. **Vet Rec** 1997 Jul 19;141(3):73–6

[Characteristics of dementia patients with aggressive behaviors] Tsai SJ, et al. **Chang Keng I Hsueh** 1995 Dec; 18(4):361–4 (Eng. Abstr.) **(Chi)**

[Aggression in children and adolescents] Malá E. **Ceska Slov Psychiatr** 1996 May;92 Suppl 1:58–67 (Eng. Abstr.) **(Cze)**

[Case report of sodium valproate treatment of aggression associated with Alzheimer's disease] Takahashi M, et al. **No To Shinkei** 1996 Aug;48(8):757–60 (Eng. Abstr.) **(Jpn)**

[Changes in immunological reactivity of C57Bl/6 mice during the zoosocial conflict] Al'perina EA, et al. **Biull Eksp Biol Med** 1996 Nov;122(11):541–3 **(Rus)**

[Aggression and group dependence in asthmatic children and a control group] de Hinojosa Vallejo P, et al. **Rev Alerg Mex** 1996 May-Jun;43(3):62–5 (Eng. Abstr.) **(Spa)**

[When does alcohol trigger violence? "Emotional blindness" and impulsiveness are important links] Heilig M. **Lakartidningen** 1997 Mar 5;94(10):841–4 (37 ref.) **(Swe)**

CLASSIFICATION

A revised teacher rating scale for reactive and proactive aggression. Brown K, et al. **J Abnorm Child Psychol** 1996 Aug;24(4):473–80

Reactive and proactive aggression in school children and psychiatrically impaired chronically assaultive youth. Dodge KA, et al. **J Abnorm Psychol** 1997 Feb;106(1):37–51

Subtypes of aggression and their relevance to child psychiatry. Vitiello B, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Mar;36(3):307–15 (62 ref.)

Expressive communicative ability, symptoms of mental illness and aggressive behavior. Dura J. **J Clin Psychol** 1997 Jun; 53(4):307–18

DRUG EFFECTS

Differential effects of ethanol on feline rage and predatory attack behavior: an underlying neural mechanism. Schubert K, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):882–9

Effects of vasotocin on aggressive behavior in male Japanese quail. Riters LV, et al. **Ann N Y Acad Sci** 1997 Jan 15; 807:478–80

Behavioral changes in Anolis carolinensis following injection with fluoxetine. Deckel AW. **Behav Brain Res** 1996 Aug; 78(2):175–82

The use of lithium in the treatment of aggressive behaviours with two brain-injured individuals in a state psychiatric hospital. Bellus SB, et al. **Brain Inj** 1996 Nov;10(11):849–60

Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Wroblewski BA, et al. **Brain Inj** 1997 Jan;11(1):37–47

Aggression in children treated with clobazam for epilepsy. Sheth RD, et al. **Clin Neuropharmacol** 1994 Aug; 17(4):332–7

Effects of short- and long-term withdrawal from gestational cocaine treatment on maternal behavior and aggression in Sprague-Dawley rats. Johns JM, et al. **Dev Neurosci** 1997; 19(4):368-74

The antiaggressive potency of (-)-penbutolol involves both 5-HT1A and 5-HT1B receptors and beta-adrenoceptors. Sánchez C, et al. **Eur J Pharmacol** 1996 Feb 15;297(1-2):1-8

Chronic treatment with eltoprazine does not lead to tolerance in its anti-aggressive action, in contrast to haloperidol. Mos J, et al. **Eur Neuropsychopharmacol** 1996 Mar;6(1):1-7

Progesterone does not inhibit aggression induced by testosterone metabolites in castrated male mice. Gravance CG, et al. **Horm Behav** 1996 Mar;30(1):22-5

Effects of testosterone and 7 alpha-methyl-19-nortestosterone (MENT) on sexual and aggressive behaviors in two inbred strains of male mice. Ogawa S, et al. **Horm Behav** 1996 Mar;30(1):74-84

Aggressive behaviour and extrapyramidal side effects of neuroleptics in schizophrenia. Cheung P, et al. **Int Clin Psychopharmacol** 1996 Dec;11(4):237-40

Adverse effects of clomipramine [letter] Brasić JR, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Sep;36(9):1165-6

Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. Cueva JE, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Apr; 35(4):480-90

Aggression and schizophrenia: efficacy of risperidone. Buckley PF, et al. **J Am Acad Psychiatry Law** 1997; 25(2):173-81

Use of fluoxetine to treat dominance aggression in dogs. Dodman NH, et al. **J Am Vet Med Assoc** 1996 Nov 1; 209(9):1585-7

Rare, idiosyncratic reaction to acepromazine in dogs. Meyer EK. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1114-5

Risperidone and explosive aggressive autism. Horrigan JP, et al. **J Autism Dev Disord** 1997 Jun;27(3):313-23

Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. Khan BU. **J Autism Dev Disord** 1997 Aug;27(4):479-89

Effects of serotonin reuptake inhibitors on aggressive behavior in psychiatrically hospitalized adolescents: results of an open trial. Constantino JN, et al. **J Child Adolesc Psychopharmacol** 1997 Spring;7(1):31-44

Estrogen or testosterone increases self-reported aggressive behaviors in hypogonadal adolescents. Finkelstein JW, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2433-8

Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. Allan ER, et al. **J Clin Psychiatry** 1996 Oct;57(10):455-9

Inhibitory role of opioid peptides in the regulation of aggressive and sexual behaviors in male Japanese quails. Kotegawa T, et al. **J Exp Zool** 1997 Feb 1;277(2):146-54

Antiandrogen treatment of aggressivity in men suffering from dementia. Amadeo M. **J Geriatr Psychiatry Neurol** 1996 Jul;9(3):142-5

Sertraline in the treatment of severe aggressiveness in Huntington's disease. Ranen NG, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):338-40

Vasopressin/serotonin interactions in the anterior hypothalamus control aggressive behavior in golden hamsters. Ferris CF, et al. **J Neurosci** 1997 Jun 1; 17(11):4331-40

The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats. Ossowska G, et al. **J Physiol Pharmacol** 1997 Mar;48(1):127-35

Nitric oxide: a brake for bad behavior [news] Dawson TM. **Mol Psychiatry** 1996 Mar;1(1):9-10

The influence of fluoxetine on aggressive behavior [see comments] Fuller RW. **Neuropsychopharmacology** 1996 Feb;14(2):77-81 (36 ref.). Comment in: Neuropsychopharmacology 1997 May;16(5):373-4.

Fluoxetine and aggression [letter; comment] Troisi A. **Neuropsychopharmacology** 1997 May;16(5):373-4. Comment on: Neuropsychopharmacology 1996 Feb;14(2):77-81.

Physiologic characterization of novel aggressotropic neuropeptides. Sherstnev VV, et al. **Neurosci Behav Physiol** 1996 Sep-Dec;26(5):460-7

Acute and subchronic effects of tiapride on isolation-induced aggression in male mice. Navarro JF, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):255-9

Prior cocaine exposure in different environments affects the behavioral responses of mouse dams. Petruzzi S, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):541-7

PCPA increases aggression in male firemouth cichlids. Adams CF, et al. **Pharmacology** 1996 Nov;53(5):328-30

Comparing different forms of male and female aggression in wild and laboratory mice: an ethopharmacological study. Ferrari PF, et al. **Physiol Behav** 1996 Aug;60(2):549-53

Anabolic-androgenic steroid exposure during adolescence and aggressive behavior in golden hamsters. Melloni RH Jr, et al. **Physiol Behav** 1997 Mar;61(3):359-64

Acute effect of dopamine agonists and some antidepressants in stress-induced deficit of fighting behavior. Ossowska G, et al. **Pol J Pharmacol** 1996 Jul-Aug;48(4):403-8

Serotonin and aggressive motivation in crustaceans: altering the decision to retreat. Huber R, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5939-42

The effects of cocaine and nandrolone co-administration on aggression in male rats. Long SF, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jul; 20(5):839-56

Trazodone for aggression in an adolescent with hydrocephalus. Mashiko H, et al. **Psychiatry Clin Neurosci** 1996 Jun;50(3):133-6 (16 ref.)

The effect of alpha 2 adrenoceptor blockers on aggressive behavior in mice: implications for the actions of adrenoceptor agents. Haller J, et al. **Psychopharmacology (Berl)** 1996 Aug;126(4):345-50

Increased aggression after ethanol self-administration in male resident rats. van Erp AM, et al. **Psychopharmacology (Berl)** 1997 Jun;131(3):287-95

Effects of alcohol on human aggression. Validity of proposed explanations. Bushman BJ. **Recent Dev Alcohol** 1997; 13:227-43

Alcohol, GABAA-benzodiazepine receptor complex, and aggression. Miczek KA, et al. **Recent Dev Alcohol** 1997; 13:139-71 (164 ref.)

Emerging themes in preclinical research on alcohol and aggression. Yudko E, et al. **Recent Dev Alcohol** 1997; 13:123-38 (90 ref.)

Effect of clozapine on physical and verbal aggression. Rabinowitz J, et al. **Schizophr Res** 1996 Dec 15; 22(3):249-55

The rules of drug taking: wine and poppy derivatives in the ancient world. III. Wine as an instrument of aggressive behavior and of ritual madness. Nencini P. **Subst Use Misuse** 1997 Feb;32(3):361-7

Assessment, management, and prognosis of canine dominance-related aggression. Reisner IR. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):479-95 (75 ref.)

[The effect of 5-HT1 and 5-HT2 serotonin receptor agonists and antagonists on predator aggression in wild Norway rats] Popova NK, et al. **Biull Eksp Biol Med** 1996 Jun; 121(6):687-9 **(Rus)**

[The effect of lithium oxybutyrate on aggressive animal behavior] Zamoshchina TA, et al. **Eksp Klin Farmakol** 1996 May-Jun;59(3):16-9 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

A nonhuman primate model of type II alcoholism? Part 2. Diminished social competence and excessive aggression correlates with low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations. Higley JD, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):643-50

Physical aggression and associated factors in probable Alzheimer disease. Tsai SJ, et al. **Alzheimer Dis Assoc Disord** 1996 Summer;10(2):82-5

Labeling and discrimination of facial expressions by aggressive and nonaggressive men with mental retardation. Walz NC, et al. **Am J Ment Retard** 1996 Nov;101(3):282-91

Styles of male social behavior and their endocrine correlates among low-ranking baboons. Virgin CE Jr, et al. **Am J Primatol** 1997;42(1):25-39

Central serotonin activity and aggression: inverse relationship with prolactin response to d-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Coccaro EF, et al. **Am J Psychiatry** 1997 Oct;154(10):1430-5

Brain SPECT findings and aggressiveness. Amen DG, et al. **Ann Clin Psychiatry** 1996 Sep;8(3):129-37

Adolescent stress alters ethanol ingestion and agonistic behavior in the male golden hamster. Ferris CF, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:348-51

Development and expression of hormonal systems regulating aggression. Simon NG, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:8-17 (48 ref.)

Physically aggressive boys from age 6 to 12 years. Their biopsychosocial status at puberty. Tremblay RE, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:192-207

Behavioral characteristics of defense and vigilance reactions elicited by electrical stimulation of the hypothalamus in rabbits. Duan YF, et al. **Behav Brain Res** 1996 Nov; 81(1-2):33-41

Neurotransmitter and endocrine modulation of aggressive behavior and its components in normal humans. Gerra G, et al. **Behav Brain Res** 1996 Nov;81(1-2):19-24

The neurobehavioral genetics of aggression. Crusio WE. **Behav Genet** 1996 Sep;26(5):459-61

Olfaction, GABAergic neurotransmission in the olfactory bulb, and intermale aggression in mice: modulation by steroids. Guillot PV, et al. **Behav Genet** 1996 Sep; 26(5):497-504 (65 ref.)

Issues in the genetics of social behavior: revisited. Hahn ME, et al. **Behav Genet** 1996 Sep;26(5):463-70 (24 ref.)

Searching for candidate genes with effects on an agonistic behavior, offense, in mice. Maxson SC. **Behav Genet** 1996 Sep;26(5):471-6 (70 ref.)

Selective breeding for isolation-induced intermale aggression in mice: associated responses and environmental influences. Sandnabba NK. **Behav Genet** 1996 Sep;26(5):477-88 (100 ref.)

Aggression in wild house mice: current state of affairs. Sluyter F, et al. **Behav Genet** 1996 Sep;26(5):489-96 (55 ref.)

Studies on wild house mice. VII. Prenatal maternal environment and aggression. Sluyter F, et al. **Behav Genet** 1996 Sep;26(5):513-8

First-order projections activated by stimulation of hypothalamic sites eliciting attack and flight in rats. Roberts WW, et al. **Behav Neurosci** 1996 Jun;110(3):509-27

D2 dopamine receptor involvement in the rough-and-tumble play behavior of juvenile rats. Siviy SM, et al. **Behav Neurosci** 1996 Oct;110(5):1168-76

Neuropsychological and cognitive psychophysiological substrates of impulsive aggression. Barratt ES, et al. **Biol Psychiatry** 1997 May 15;41(10):1045-61

Heritability of aggression and irritability: a twin study of the Buss-Durkee aggression scales in adult male subjects. Coccaro EF, et al. **Biol Psychiatry** 1997 Feb 1;41(3):273-84

CSF testosterone and 5-HIAA correlate with different types of aggressive behaviors. Higley JD, et al. **Biol Psychiatry** 1996 Dec 1;40(11):1067-82

Biogenic amines and aggression: experimental approaches in crustaceans. Huber R, et al. **Brain Behav Evol** 1997;50 Suppl 1:60-8 (45 ref.)

Effects of alcohol consumption on lateralized aggression in Anolis carolinensis. Deckel AW. **Brain Res** 1997 May 9; 756(1-2):96-105

Sexual dimorphism of GABAA receptor levels in subcortical brain regions of a woodland rodent (Apodemus sylvaticus). Canonaco M, et al. **Brain Res Bull** 1996;40(3):187-94

Issues in the search for candidate genes in mice as potential animal models of human aggression. Maxson SC. **Ciba Found Symp** 1996;194:21-30; discussion 30-5 (47 ref.)

Brain monoamines in aggression and sleep. Reis DJ. **Clin Neurosurg** 1971;18:471-502

Genes and aggressiveness. Behavioral genetics. Tecott LH, et al. **Curr Biol** 1996 Mar 1;6(3):238-40 (9 ref.)

Is the behaviour of hyperactive children disorganized and chaotic? An information-theoretical approach. Willemsen-Swinkels SH, et al. **Eur Child Adolesc Psychiatry** 1996 Sep;5(3):139-46

Increased intermale aggression and neuroendocrine response in mice deficient for the neural cell adhesion molecule (NCAM). Stork O, et al. **Eur J Neurosci** 1997 Jun; 9(6):1117-25

Differential lateral septal vasopressin in wild-type rats: correlation with aggression. Everts HG, et al. **Horm Behav** 1997 Apr;31(2):136-44

Male testosterone linked to high social dominance but low physical aggression in early adolescence. Schaal B, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Oct; 35(10):1322-30

Plasma cortisol and aggression in boys with ADHD. Schulz KP, et al. **J Am Acad Child Adolesc Psychiatry** 1997 May; 36(5):605-9

Pain sensitivity and stability of physical aggression in boys. Séguin JR, et al. **J Child Psychol Psychiatry** 1996 Oct; 37(7):823-34

Reduced aggressive behaviour in mice with targeted disruption of the oxytocin gene. DeVries AC, et al. **J Neuroendocrinol** 1997 May;9(5):363-8

Compression of the pituitary stalk elicits chronic increases in CSF vasopressin, oxytocin as well as in social investigation and aggressiveness. Haller J, et al. **J Neuroendocrinol** 1996 May;8(5):361-5

Genetic and environmental architecture of human aggression. Miles DR, et al. **J Pers Soc Psychol** 1997 Jan;72(1):207-17

Impulsive aggression in personality disorder correlates with platelet 5-HT2A receptor binding. Coccaro EF, et al. **Neuropsychopharmacology** 1997 Mar;16(3):211-6

Suppression of synaptic input of defense behavior command neurons by stimulation of neurons of the mesocerebrum in a preparation of the isolated CNS of the common snail. Maksimova OA. **Neurosci Behav Physiol** 1996 May-Jun; 26(3):259-65

Creation of a defense dominant during the functioning of a blink dominant in the rabbit. Roshchina GYa. **Neurosci Behav Physiol** 1996 Jul-Aug;26(4):349-56

Corticotropin-releasing factor receptor antagonist infused into the locus coeruleus attenuates immobilization stress-induced defensive withdrawal in rats. Smagin GN, et al. **Neurosci Lett** 1996 Dec 20;220(3):167-70

Behavioral characterization of mice packing the 5-HT1B receptor. Ramboz S, et al. **NIDA Res Monogr** 1996; 161:39-57 (32 ref.)

Prevention of ACTH- and adrenalectomy-induced muricidal behavior: by benzodiazepinic ligands. Miachon S, et al. **Peptides** 1997;18(2):185-9

Lateralization of displays during aggressive and courtship behaviour in the Siamese fighting fish (Betta splendens). Cantalupo C, et al. **Physiol Behav** 1996 Jul;60(1):249-52

Testosterone facilitates aggression by modulating vasopressin receptors in the hypothalamus. Delville Y, et al. **Physiol Behav** 1996 Jul;60(1):25-9

The influence of menstrual-cycle phase on the relationship between testosterone and aggression. Dougherty DM, et al. **Physiol Behav** 1997 Aug;62(2):431-5

Modulation of the baroreceptor reflex by stimulation of the hypothalamic defense and vigilance areas. Duan YF, et al. **Physiol Behav** 1996 Jun;59(6):1093-8

Comparing different forms of male and female aggression in wild and laboratory mice: an ethopharmacological study. Ferrari PF, et al. **Physiol Behav** 1996 Aug;60(2):549-53

Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states: a factor analytic study. Griebel G, et al. **Physiol Behav** 1996 Nov; 60(5):1255-60

Social organization and aggression in a group of olfactory bulbectomized male mice. Liebenauer LL, et al. **Physiol Behav** 1996 Aug;60(2):403-9

Sympathetic mediation of stress and aggressive competition: plasma catecholamines in free-living male tree lizards. Matt KS, et al. **Physiol Behav** 1997 May;61(5):639-47

Effects of small amygdala lesions on fear, but not aggression,

in the rat. Oakes ME, et al. **Physiol Behav** 1997 Jan; 61(1):45–55

Behavioral and adrenocortical responses to open-field test in rats selected for reduced aggressiveness toward humans. Plyusnina I, et al. **Physiol Behav** 1997 Mar;61(3):381–5

Social confrontation in male guinea pigs: behavior, experience, and complement activity [published erratum appears in Physiol Behav 1996 Nov;60(5):1391] Stefanski V, et al. **Physiol Behav** 1996 Jul;60(1):235–41

Elevated blood copper/zinc ratios in assaultive young males. Walsh WJ, et al. **Physiol Behav** 1997 Aug;62(2):327–9

Acute effect of dopamine agonists and some antidepressants in stress-induced deficit of fighting behavior. Ossowska G, et al. **Pol J Pharmacol** 1996 Jul–Aug;48(4):403–8

Investigating the role of lipids in mood, aggression, and schizophrenia. Hillbrand M, et al. **Psychiatr Serv** 1997 Jul; 48(7):875–6, 882

Does central serotonergic function correlate inversely with aggression? A study using D-fenfluramine in healthy subjects. Cleare AJ, et al. **Psychiatry Res** 1997 Mar 24; 69(2–3):89–95

Tryptophan depletion and aggressive responding in healthy males. Moeller FG, et al. **Psychopharmacology (Berl)** 1996 Jul;126(2):97–103

Serotonin in early-onset alcoholism. Virkkunen M, et al. **Recent Dev Alcohol** 1997;13:173–89 (117 ref.)

Aggressive behaviour and platelet 3H-paroxetine binding in schizophrenia. Maguire K, et al. **Schizophr Res** 1997 Jan 17;23(1):61–7

NOS and aggression [letter] Morris R, et al. **Trends Neurosci** 1996 Jul;19(7):277–8

Social behavior and aggressive problems of cats. Crowell-Davis SL, et al. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):549–68 (31 ref.)

Assessment, management, and prognosis of canine dominance-related aggression. Reisner IR. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):479–95 (75 ref.)

[The effect of the repeated experience of aggression in daily confrontations on the individual and social behavior of male mice] Kudriavtseva NN, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Jan–Feb; 47(1):86–97 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Personal and familial characteristics of resilient sons of male alcoholics. Vitaro F, et al. **Addiction** 1996 Aug; 91(8):1161–77

Adolescent aggression and imagery: contributions from object relations and social cognitive theory. Lennings CJ. **Adolescence** 1996 Winter;31(124):831–40

Executive cognitive functioning predicts reactive aggression in boys at high risk for substance abuse: a prospective study. Giancola PR, et al. **Alcohol Clin Exp Res** 1996 Jun; 20(4):740–4

Attributional bias and reactive aggression. Hudley C, et al. **Am J Prev Med** 1996 Sep–Oct;12(5 Suppl):75–81

Evaluating a cognitive/ecological program for the prevention of aggression among urban children. Huesmann LR, et al. **Am J Prev Med** 1996 Sep–Oct;12(5 Suppl):120–8

Inhibition of social behavior in chimpanzees under high-density conditions. Aureli F, et al. **Am J Primatol** 1997;41(3):213–28

Prevention of sexual aggression: Sociocultural risk and protective factors. Hall GC, et al. **Am Psychol** 1997 Jan; 52(1):5–14 (70 ref.)

Preliminary findings of an early intervention program with aggressive hyperactive children. Barkley RA, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:277–89

Neurotransmitter correlates of impulsive aggression in humans. Coccaro EF. **Ann N Y Acad Sci** 1996 Sep 20; 794:82–9 (55 ref.)

Peer perceptions of aggression and bullying behavior in primary schools in Northern Ireland. Collins K, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:336–8

Effects of serotonergic1A and 1B agonists in androgenic versus estrogenic systems for aggression. Cologer-Clifford A, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:339–42

Stress hormones, genotype, and brain organization. Implications for aggression. De Kloet ER, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:179–91 (65 ref.)

Aggression, attachment, and depression among school-age children at high social risk. Easterbrooks MA, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:346–7

Discussion: biological correlates of aggression. Eichelman B, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:78–81

Serotonin diminishes aggression by suppressing the activity of the vasopressin system. Ferris CF. **Ann N Y Acad Sci** 1996 Sep 20;794:98–103

Cultivating violence. Ferris CF. **Ann N Y Acad Sci** 1996 Sep 20;794:318–28

Cholesterol, serotonin, and behavior in young monkeys. Fontenot MB, et al. **Ann N Y Acad Sci** 1996 Sep 20; 794:352–4

Fluoxetine effects on serotonin function and aggressive behavior. Fuller RW. **Ann N Y Acad Sci** 1996 Sep 20; 794:90–7

Developmental factors influencing aggression. Animal models and clinical correlates. Gartner J, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:113–20

Disruptiveness, inhibition, and withdrawal as predictors of boys' delinquency and depression. Kerr M, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:367–8

Social attachment, brain function, and aggression. Kraemer GW, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:121–35

Aggressive symptoms and salivary cortisol in clinic-referred boys with conduct disorder. McBurnett K, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:169–78

Considerations regarding biosocial foundations of personality and aggression. McCord J. **Ann N Y Acad Sci** 1996 Sep 20;794:253–5

Adolescent anabolic steroid use and aggressive behavior in golden hamsters. Melloni RH Jr, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:372–5

Relationship of aggression and anxiety to autonomic regulation of heart rate variability in adolescent males. Mezzacappa E, et al. **Ann N Y Acad Sci** 1996 Sep 20; 794:376–9

Television violence viewing and aggression in females. Moise JF, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:380–3

Aggressive behaviors of transgenic estrogen-receptor knockout male mice. Ogawa S, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:384–5

Characteristics and putative mechanisms in boys at risk for drug abuse and aggression. Pihl RO, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:238–52 (81 ref.)

Serotonergic and cardiac correlates of aggression in children. Pine DS, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:391–3

Outcomes of childhood aggression in women. Podolski CL, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:394–8

The time course of angry behavior in the temper tantrums of young children. Potegal M, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:31–45

Disordered views of aggressive children. A late twentieth century perspective. Richters JE. **Ann N Y Acad Sci** 1996 Sep 20;794:208–23 (65 ref.)

Aggression in physically abused children. The role of distress proneness. Scarpa A, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:405–7

Low pain sensitivity and stability of physical aggression in boys. Séguin JR, et al. **Ann N Y Acad Sci** 1996 Sep 20; 794:408–10

Persistence of aggressive and nonaggressive delinquency in relation to neuropsychological functioning. White HR, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:413–6

Key issues in the development of aggression and violence from childhood to early adulthood. Loeber R, et al. **Annu Rev Psychol** 1997;48:371–410 (240 ref.)

Toward a developmental-contextual model of the effects of parental spanking on children's aggression [see comments] Gunnoe ML, et al. **Arch Pediatr Adolesc Med** 1997 Aug; 151(8):768–75. Comment in: Arch Pediatr Adolesc Med 1997 Aug;151(8):758–60.

A prospective study of aggression among psychiatric patients in rehabilitation wards. Cheung P, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):257–62

Aggressive behaviour in schizophrenia: the role of psychopathology. Cheung P, et al. **Aust N Z J Psychiatry** 1997 Feb;31(1):62–7

Intermale aggression and dark/light preference in ten inbred mouse strains. Guillot PV, et al. **Behav Brain Res** 1996 May;77(1–2):211–3

On the dimensionality of the Buss/Perry Aggression Questionnaire. Bernstein IH, et al. **Behav Res Ther** 1997 Jun;35(6):563–8

Studies of violent and nonviolent male parolees: I. Laboratory and psychometric measurements of aggression. Cherek DR, et al. **Biol Psychiatry** 1997 Mar 1;41(5):514–22

Studies of violent and nonviolent male parolees: II. Laboratory and psychometric measurements of impulsivity. Cherek DR, et al. **Biol Psychiatry** 1997 Mar 1;41(5):523–9

Age-related changes in the association between serotonergic function and aggression in boys with ADHD. Halperin JM, et al. **Biol Psychiatry** 1997 Mar 15;41(6):682–9

Do beliefs about aggressive feelings and actions predict reported levels of aggression? Archer J, et al. **Br J Soc Psychol** 1997 Mar;36 (Pt 1):83–105

Sex differences in aggression: does social representation mediate form of aggression? Campbell A, et al. **Br J Soc Psychol** 1997 Jun;36 (Pt 2):161–71

Are pedophiles with aggressive tendencies more sexually violent? Greenberg DM, et al. **Bull Am Acad Psychiatry Law** 1996;24(2):225–35

Is Mr Pac Man eating our children? A review of the effect of video games on children. Emes CE. **Can J Psychiatry** 1997 May;42(4):409–14 (38 ref.)

Long-term psychological adjustment to witnessing interparental physical conflict during childhood. Henning K, et al. **Child Abuse Negl** 1997 Jun;21(6):501–15

Parental abusive versus supportive behaviors and their relation to hostility and aggression in young adults. Nicholas KB, et al. **Child Abuse Negl** 1996 Dec; 20(12):1195–211

The role of overt aggression, relational aggression, and prosocial behavior in the prediction of children's future social adjustment. Crick NR. **Child Dev** 1996 Oct; 67(5):2317–27

Relational aggression, overt aggression, and friendship. Grotpeter JK, et al. **Child Dev** 1996 Oct;67(5):2328–38

Patterns of change in early childhood aggressive-disruptive behavior: gender differences in predictions from early coercive and affectionate mother-child interactions. McFadyen-Ketchum SA, et al. **Child Dev** 1996 Oct; 67(5):2417–33

The early socialization of aggressive victims of bullying. Schwartz D, et al. **Child Dev** 1997 Aug;68(4):665–75

Disruptiveness, friends' characteristics, and delinquency in early adolescence: a test of two competing models of development. Vitaro F, et al. **Child Dev** 1997 Aug; 68(4):676–89

Engagement in gender normative versus nonnormative forms of aggression: links to social-psychological adjustment. Crick NR. **Dev Psychol** 1997 Jul;33(4):610–7

Relational and overt aggression in preschool. Crick NR, et al. **Dev Psychol** 1997 Jul;33(4):579–88

A developmental investigation of social aggression among children. Galen BR, et al. **Dev Psychol** 1997 Jul; 33(4):589–600

Relational aggression, gender, and peer acceptance: invariance across culture, stability over time, and concordance among informants. Tomada G, et al. **Dev Psychol** 1997 Jul;33(4):601–9

A positive view of self: risk or protection for aggressive children? Hughes JN, et al. **Dev Psychopathol** 1997 Winter; 9(1):75–94

Victimized children's responses to peers' aggression: behaviors associated with reduced versus continued victimization. Kochenderfer BJ, et al. **Dev Psychopathol** 1997 Winter;9(1):59–73

Accelerated longitudinal comparisons of aggressive versus delinquent syndromes. Stanger C, et al. **Dev Psychopathol** 1997 Winter;9(1):43–58

Subjects with a history of drug dependence are more aggressive than subjects with no drug use history. Allen TJ, et al. **Drug Alcohol Depend** 1997 Jun 6;46(1–2):95–103

Antisocial personality disorder and aggression in recently abstinent cocaine dependent subjects. Moeller FG, et al. **Drug Alcohol Depend** 1997 Mar 14;44(2–3):175–82

Analysis of primary care staff language about aggression at work using concordancing techniques to identify themes. Carter YH, et al. **Fam Pract** 1997 Apr;14(2):136–41

Modifying repetitive verbalizations of community-dwelling patients with AD. Bourgeois MS, et al. **Gerontologist** 1997 Feb;37(1):30–9

Maternal behavior in male rats: effects of medial preoptic area lesions and presence of maternal aggression. Rosenblatt JS, et al. **Horm Behav** 1996 Sep;30(3):201–15

A study of aggression among referrals to a community-based psychiatry of old age service. Gibbons P, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):384–8

Attributional styles of aggressive boys and their mothers. Bickett LR, et al. **J Abnorm Child Psychol** 1996 Aug; 24(4):457–72

Family process and child anxiety and aggression: an observational analysis. Dadds MR, et al. **J Abnorm Child Psychol** 1996 Dec;24(6):715–34

Short-term stability of aggression, peer rejection, and depressive symptoms in middle childhood. Dumas JE, et al. **J Abnorm Child Psychol** 1996 Feb;24(1):105–19

Inhibition in ADHD, aggressive, and anxious children: a biologically based model of child psychopathology. Oosterlaan J, et al. **J Abnorm Child Psychol** 1996 Feb; 24(1):19–36

Sexual arousal to erotic and aggressive stimuli in sexually coercive and noncoercive men. Lohr BA, et al. **J Abnorm Psychol** 1997 May;106(2):230–42

Longitudinal study of early childhood injuries and acute illnesses in the offspring of adolescent mothers who were aggressive, withdrawn, or aggressive-withdrawn in childhood. Serbin LA, et al. **J Abnorm Psychol** 1996 Nov; 105(4):500–7

Adolescents' exposure to community and school violence: prevalence and behavioral correlates. O'Keefe M. **J Adolesc Health** 1997 May;20(5):368–76

A pilot study of nadolol for overt aggression in developmentally delayed individuals. Connor DF, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jun;36(6):826–34

Subtypes of aggression and their relevance to child psychiatry. Vitiello B, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Mar;36(3):307–15 (62 ref.)

Psychotic symptoms and physically aggressive behavior in Alzheimer's disease. Gilley DW, et al. **J Am Geriatr Soc** 1997 Sep;45(9):1074–9

Effects of equal and unequal reinforcer duration during functional analysis. Fisher WW, et al. **J Appl Behav Anal** 1996 Spring;29(1):117–20

Sleep deprivation, allergy symptoms, and negatively reinforced problem behavior. Kennedy CH, et al. **J Appl Behav Anal** 1996 Spring;29(1):133–5

Noncontingent reinforcement as treatment for severe problem behavior: some procedural variations. Lalli JS, et al. **J Appl Behav Anal** 1997 Spring;30(1):127–36; quiz 136–7

Negative side effects of noncontingent reinforcement. Vollmer TR, et al. **J Appl Behav Anal** 1997 Spring; 30(1):161–4

Functional assessment and treatment of aggressive and destructive behaviors in a child victim of physical abuse. Luiselli JK. **J Behav Ther Exp Psychiatry** 1996 Mar; 27(1):41–9

Social problem solving in hyperactive-aggressive children: how and what they think in conditions of automatic and controlled processing. Bloomquist ML, et al. **J Clin Child Psychol** 1997 Jun;26(2):172–80

Peer relationships of young children: affiliative choices and the shaping of aggressive behavior. Snyder J, et al. **J Clin Child Psychol** 1997 Jun;26(2):145–56

Impact of a smoking ban on a locked psychiatric unit [letter; comment] Pearlman T. **J Clin Psychiatry** 1997 Apr; 58(4):179. Comment on: J Clin Psychiatry 1996 Aug;57(8):329–32.

Parent ratings of children's depression, anxiety, and aggression: a cross-sample analysis of agreement and differences with child and teacher ratings. Epkins CC. **J Clin Psychol** 1996 Nov;52(6):599–608

Psychometric properties of family members' reports of parental physical aggression toward clinic-referred children. Jouriles EN, et al. **J Consult Clin Psychol** 1997 Apr;65(2):309–18

Attachment relationships among children with aggressive behavior problems: the role of disorganized early attachment patterns. Lyons-Ruth K. **J Consult Clin Psychol** 1996 Feb;64(1):64–73 (92 ref.)

Patterns of psychopathology among urban poor children: comorbidity and aggression effects. Tolan PH, et al. **J Consult Clin Psychol** 1996 Oct;64(5):1094–9

Intergenerational aspects of the development of aggression: a preliminary report. Constantino JN. **J Dev Behav Pediatr** 1996 Jun;17(3):176–82

Predatory violence during mass murder. Meloy JR. **J Forensic Sci** 1997 Mar;42(2):326–9

A new variant of "subjective" delusional misidentification associated with aggression. Silva JA, et al. **J Forensic Sci** 1997 May;42(3):406–10

Fighting among America's youth: a risk and protective factors approach. Fitzpatrick KM. **J Health Soc Behav** 1997 Jun;38(2):131–48

Cynicism, hostility, and suicidal ideation in depressed outpatients. Nierenberg AA, et al. **J Nerv Ment Dis** 1996 Oct;184(10):607–10

Correlation of testosterone with aggression in demented elderly men. Orengo CA, et al. **J Nerv Ment Dis** 1997 May; 185(5):349–51

Self-reported aggressive behavior in patients with stroke. Paradiso S, et al. **J Nerv Ment Dis** 1996 Dec;184(12):746–53

Role of the midbrain periaqueductal gray in maternal nurturance and aggression: c-fos and electrolytic lesion studies in lactating rats. Lonstein JS, et al. **J Neurosci** 1997 May 1;17(9):3364–78

Television violence and its effect on children. Johnson MO. **J Pediatr Nurs** 1996 Apr;11(2):94–9 (31 ref.)

Characteristics of men who aggress sexually and of men who imagine aggressing: risk and moderating variables. Dean KE, et al. **J Pers Soc Psychol** 1997 Feb;72(2):449–55

Children's normative beliefs about aggression and aggressive behavior. Huesmann LR, et al. **J Pers Soc Psychol** 1997 Feb;72(2):408–19

Escalation in response to persistent annoyance: groups versus individuals and gender effects. Mikolic JM, et al. **J Pers Soc Psychol** 1997 Jan;72(1):151–63

Managing threatening behavior. The role of talk down and talk up. Maier GJ. **J Psychosoc Nurs Ment Health Serv** 1996 Jun;34(6):25–30 (17 ref.)

Social status and aggression: a field study analyzed by survival analysis. Diekmann A, et al. **J Soc Psychol** 1996 Dec;136(6):761–8

Executive cognitive functioning and aggressive behavior in preadolescent boys at high risk for substance abuse/dependence. Giancola PR, et al. **J Stud Alcohol** 1996 Jul;57(4):352–9

Report form for aggressive episodes: preliminary report. Bjørkly S. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1139–52

Sex-related coping responses in mice selectively bred for aggression. Ewalds-Kvist SB, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):911–4

Comparison of aggressive behavior between men and women in sport. Lenzi A, et al. **Percept Mot Skills** 1997 Feb; 84(1):139–45

Fluoxetine and aggressive behaviour [letter] Friedman EH. **Pharmacopsychiatry** 1996 May;29(3):121

Characterization of sensorimotor performance, reproductive and aggressive behaviors in segmental trisomic 16 (Ts65Dn) mice. Klein SL, et al. **Physiol Behav** 1996 Oct;60(4):1159–64

Long-term changes in open field behaviour following a single social defeat in rats can be reversed by sleep deprivation. Meerlo P, et al. **Physiol Behav** 1996 Jul;60(1):115–9

Individual differences in plasma catecholamine and corticosterone stress responses of wild-type rats: relationship with aggression. Sgoifo A, et al. **Physiol Behav** 1996 Dec;60(6):1403–7

Severe aggression and related conduct problems among runaway and homeless adolescents. Booth RE, et al. **Psychiatr Serv** 1996 Jan;47(1):75–80

Epilepsy, aggression, and criminal responsibility. Borum R, et al. **Psychiatr Serv** 1996 Jul;47(7):762–3

Physical aggression against psychiatric inpatients by family members and partners. Cascardi M, et al. **Psychiatr Serv** 1996 May;47(5):531–3

Measurement of aggression in psychiatric patients. Gothelf D, et al. **Psychiatry Res** 1997 Jul 4;71(2):83–95 (90 ref.)

A survey of fears associated with Iraqi aggression among Kuwaiti children and adolescents: a factorial study 5.7 years after the Gulf War. Abdel-Khalek AM. **Psychol Rep** 1997 Aug;81(1):247–55

Scores on locus of control and aggression for drug addicts, users, and controls. De Mojà CA. **Psychol Rep** 1997 Feb; 80(1):40–2

College women who initiate assaults on their male partners and the reasons offered for such behavior. Fiebert MS, et al. **Psychol Rep** 1997 Apr;80(2):583–90

Long-term outcomes of early victimization by peers among Japanese male university students: model of a vicious cycle. Matsui T, et al. **Psychol Rep** 1996 Dec;79(3 Pt 1):711–20

Psychological abuse in dating, locus of control, depression, and suicidal preoccupation. Migeot M, et al. **Psychol Rep** 1996 Oct;79(2):682

Associations among rock music videos, locus of control, and aggression. Wann DL, et al. **Psychol Rep** 1996 Oct; 79(2):642

Aggression among psychiatric inpatients in Greece. Oulis P, et al. **Psychopathology** 1996;29(3):174–80

Alcohol and cocaine interactions and aggressive behaviors. Denison ME, et al. **Recent Dev Alcohol** 1997;13:283–303 (31 ref.)

Longitudinal perspective on alcohol use and aggression during adolescence. White HR. **Recent Dev Alcohol** 1997; 13:81–103 (82 ref.)

Changing care staff approaches to the prevention and management of aggressive behaviour in a residential treatment unit for persons with mental retardation and challenging behaviour. Allen D, et al. **Res Dev Disabil** 1997 Mar-Apr;18(2):101–12

Analysis and intervention with two topographies of challenging behavior exhibited by a young woman with autism. Kern L, et al. **Res Dev Disabil** 1997 Jul-Aug; 18(4):275–87

Comparing the emotional reactions and behavioral intentions of violent and nonviolent husbands to aggressive, distressed, and other wife behaviors. Holtzworth-Munroe A, et al. **Violence Vict** 1996 Winter;11(4):319–39

Desistance of husband aggression in the early years of marriage. Quigley BM, et al. **Violence Vict** 1996 Winter; 11(4):355–70

[Controlled study of outcome after 6 months to early intervention of bus driver victims of aggression] André C, et al. **Encephale** 1997 Jan-Feb;23(1):65–71 (Eng. Abstr.) **(Fre)**

[Anxiety, aggression, agitation and depression: psychopathologic aspects] Braconnier A, et al. **Encephale** 1997 Jun;23 Spec No 3:43–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[The phenomenon of aggressive behavior and potential violence in children and adolescents (editorial)] Cierpka M. **Prax Kinderpsychol Kinderpsychiatr** 1997 Mar; 46(3):141–2 **(Ger)**

[Aggression, inanimate objects and fantasy of invulnerability] Göbel S. **Prax Kinderpsychol Kinderpsychiatr** 1997 Mar; 46(3):206–14 (Eng. Abstr.) **(Ger)**

[2 forms of identification with the aggressor—according to Ferenczi and Anna Freud] Hirsch M. **Prax Kinderpsychol Kinderpsychiatr** 1996 Jul-Aug; 45(6):198–205 (Eng. Abstr.) **(Ger)**

[The status of aggressive children and victims of aggression in school] Klicpera C, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Jan;45(1):2–9 (Eng. Abstr.) **(Ger)**

[FAUSTLOS—a curriculum for promoting social competence and preventing aggressive and violent behavior in children] Krannich S, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Mar;46(3):236–47 (Eng. Abstr.) **(Ger)**

[Decreasing violence in the school: study of a cooperative intervention] Nolting HP, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Mar; 46(3):195–205 (Eng. Abstr.) **(Ger)**

[Behavior therapy with aggressive children] Petermann F, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Mar; 46(3):228–35 (Eng. Abstr.) **(Ger)**

[Aggression and violence in children in different contexts] Ratzke K, et al. **Prax Kinderpsychol Kinderpsychiatr** 1997 Mar;46(3):153–68 (Eng. Abstr.) **(Ger)**

[Psychoanalytic considerations of right extremist orientation of male adolescents] Schmidt B. **Prax Kinderpsychol Kinderpsychiatr** 1996 Dec;45(10):370–4 (Eng. Abstr.) **(Ger)**

RADIATION EFFECTS

Head-portion exposure to low-level X-rays reduces isolation-induced aggression of mouse, and involvement of the olfactory carnosine in modulation of the radiation effects. Miyachi Y, et al. **Behav Brain Res** 1996 Nov; 81(1–2):135–40

AGING

Preservation into old age of synaptic number and size in the supragranular layer of the dentate gyrus in rhesus monkeys. Tigges J, et al. **Acta Anat (Basel)** 1996;157(1):63–72

Quantified-EEG in normal aging and dementias. d'Onofrio F, et al. **Acta Neurol Scand** 1996 May;93(5):336–45

A newly discovered age-related synaptic change in the human locus ceruleus: morphometric and ultrastructural studies. Iwanaga K, et al. **Acta Neuropathol (Berl)** 1996; 91(4):337–42

Progressive changes in secondary conformation and composition of the senile cataractous human lens capsules. Lee SM, et al. **Acta Ophthalmol Scand** 1996 Dec; 74(6):542–6

Age comparisons of serial position effects in short-term memory. Korsnes MS, et al. **Acta Psychol (Amst)** 1996 Nov; 94(2):133–43

Reproductive health before and after the childbearing age: the Japanese scene. Aso T. **Adv Contracept** 1996 Dec; 12(4):305–8 (0 ref.)

Adolescence and senescence: new challenges for the Formerly Socialist Economies of Europe (FSE). Balogh A. **Adv Contracept** 1996 Dec;12(4):315–8 (13 ref.)

Reproductive health of the young and the elderly in the USA. Brenner PF. **Adv Contracept** 1996 Dec;12(4):297–303 (27 ref.)

Contraceptive provision for the older woman. Kirkman R. **Adv Contracept** 1996 Sep;12(3):173–7 (11 ref.)

CHD in the elderly: knowledge for clinicians and researchers [editorial; comment] Glynn RJ, et al. **Aging (Milano)** 1996 Apr;8(2):73–4. Comment on: Aging (Milano) 1996 Apr;8(2):75–89—.

Brief cognitive screening in a field survey of the oldest old. Parker MG, et al. **Aging (Milano)** 1996 Oct;8(5):354–9

Immunological correlates of disease severity in pediatric slow progressors with human immunodeficiency virus type 1 infection. Patarca R, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):1063–8

Effects of early weaning and social isolation on subsequent alcohol intake in rats. Fahlke C, et al. **Alcohol** 1997 Mar-Apr;14(2):175–80

The discrimination and durability of an ethanol cue in young and mid-aged female mice. Groseclose CH, et al. **Alcohol** 1997 Mar-Apr;14(2):191–7

Evidence for the incompatibility of age-neutral overweight and age-neutral physical activity standards from runners. Williams PT. **Am J Clin Nutr** 1997 May;65(5):1391–6

Age and race as prognostic factors in endometrial carcinoma. Aziz H, et al. **Am J Clin Oncol** 1996 Dec;19(6):595–600

Colorectal carcinoma in different age groups: a population-based investigation. Fante R, et al. **Am J Gastroenterol** 1997 Sep;92(9):1505–9

Delivering occupational therapy's fullest promise: clinical interpretation of "life domains and adaptive strategies of a group of low-income, well older adults". Wood W. **Am J Occup Ther** 1996 Feb;50(2):109–12

Cardiovascular disease, selected cardiovascular disease risk factors, and age-related cataracts: the Beaver Dam Eye Study. Klein BE, et al. **Am J Ophthalmol** 1997 Mar; 123(3):338–46

Aging accelerates but life-long dietary restriction suppresses apoptosis-related Fas expression on hepatocytes. Higami Y, et al. **Am J Pathol** 1997 Sep;151(3):659–63

Brief communication: estimates of some demographic parameters in a Neolithic rock-cut chamber (approximately 2000 BC) using iterative techniques for aging and demographic estimators. Bocquet-Appel JP, et al. **Am J Phys Anthropol** 1997 Apr;102(4):569–75

Impact of aging on adenosine levels, A1/A2 responses, arrhythmogenesis, and energy metabolism in rat heart. Headrick JP. **Am J Physiol** 1996 Mar;270(3 Pt 2):H897–906

Age-dependent neutrophil and blood flow responsiveness in acute pulmonary inflammation in rabbits. Hyde DM, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):L471–8

Age-related enhancement of 5-lipoxygenase metabolic capacity in cattle alveolar macrophages. Lu MC, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):L547–54

Effects of aging on sarcoplasmic reticulum function and contraction duration in skeletal muscles of the rat. Narayanan N, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1032–40

Sensitivity of lungs of aging Fischer 344 rats to ozone: assessment by bronchoalveolar lavage. Vincent R, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):L555–65

Acute exercise attenuates age-associated resistance to insulin-like growth factor I. Willis PE, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):E397–404

Current research in the epidemiology and public health of aging—the need for more diverse strategies [editorial; comment] Kasl SV. **Am J Public Health** 1997 Mar; 87(3):333–4. Comment on: Am J Public Health 1997 Mar;87(3):371–7. Comment on: Am J Public Health 1997 Mar;87(3):438–40. Comment on: Am J Public Health 1997 Mar;87(3):440–2.

The disabilities of aging—looking to the physical environment [editorial; comment] Satariano WA. **Am J Public Health** 1997 Mar;87(3):331–2. Comment on: Am J Public Health 1997 Mar;87(3):384–92. Comment on: Am J Public Health 1997 Mar;87(3):393–7.

Heavy habitual marijuana smoking does not cause an accelerated decline in FEV1 with age. Tashkin DP, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):141–8

Age-related changes in the localization of glycosaminoglycans in condylar cartilage of the mandible in rats. Takahashi I, et al. **Anat Embryol (Berl)** 1996 Nov; 194(5):489–500

Effects of aging on numbers and sizes of neurons in histochemically defined subregions of monkey striate cortex. Kim CB, et al. **Anat Rec** 1997 Jan;247(1):119–28

Light microscopic quantification of morphological changes during aging in neurons and glia of the rat parietal cortex. Peinado MA, et al. **Anat Rec** 1997 Mar;247(3):420–5

Laboratory markers as an index of aging. Narayanan S. **Ann Clin Lab Sci** 1996 Jan-Feb;26(1):50–9 (41 ref.)

Socioemotional behavior in adult rhesus monkeys after early versus late lesions of the medial temporal lobe. Málková

L, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:538–40
Thermoregulation with age: role of beta-adrenergic signal transduction. Scarpace PJ. **Ann N Y Acad Sci** 1997 Mar 15;813:111–6
Age-related changes in thermoregulation of mice. Talan M. **Ann N Y Acad Sci** 1997 Mar 15;813:95–100
Hazard ratio for thyroid carcinoma [letter] Spencer RP. **Ann Nucl Med** 1996 Aug;10(3):367
Aging rat vestibular ganglion: II. Quantitative electron microscopic evaluation. Lyon MJ, et al. **Ann Otol Rhinol Laryngol** 1997 Sep;106(9):753–8
Some features of the internal structure of the brachial plexus trunks in man. Urbanowicz Z. **Ann Univ Mariae Curie Sklodowska [Med]** 1995;50:19–25
Nutrition screening in old people: its place in a coherent practice of preventive health care. Rush D. **Annu Rev Nutr** 1997;17:101–25 (126 ref.)
Antimicrobial resistance of fecal aerobic gram-negative bacilli in different age groups in a community. Leistevuo T, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1931–4
Lack of evidence for an association between Helicobacter pylori infection and the anorexia of aging [letter; comment] Howden CW. **Arch Intern Med** 1997 Aug 11–25; 157(15):1771–3. Comment on: Arch Intern Med 1997 Feb 10;157(3):269–72.
Helicobacter pylori infection and anorexia of aging [see comments] Portnoi VA. **Arch Intern Med** 1997 Feb 10; 157(3):269–72. Comment in: Arch Intern Med 1997 Aug 11–25;157(15):1771–3.
P3 latency change in aging and Parkinson disease. Tachibana H, et al. **Arch Neurol** 1997 Mar;54(3):296–302
Changes in the chemical composition of the bovine temporomandibular joint disc with age. Nakano T, et al. **Arch Oral Biol** 1996 Aug–Sep;41(8–9):845–53
Assessment of sexual beliefs and information in aging couples with sexual dysfunction. Adams SG Jr, et al. **Arch Sex Behav** 1996 Jun;25(3):249–60
Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Tracy RP, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun; 17(6):1121–7
Bronchial responsiveness of aged asthmatic patients to bronchodilator and methacholine. Chuang CC, et al. **Asian Pac J Allergy Immunol** 1996 Jun;14(1):1–4
Aging of the vascular wall: serum concentration of elastin peptides and elastase inhibitors in relation to cardiovascular risk factors. The EVA study. Bizbiz L, et al. **Atherosclerosis** 1997 May;131(1):73–8
New indices of ischemic heart disease and aging: studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease. Morisaki N, et al. **Atherosclerosis** 1997 May;131(1):43–8
Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Horie K, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):327–32
Gender specific alterations in antioxidant status of aging Zaprionus paravittiger fed on propyl gallate. Bains JS, et al. **Biochem Mol Biol Int** 1996 Nov;40(4):731–40
Alterations in eighteen-carbon saturated, monounsaturated and polyunsaturated fatty acid peroxisomal oxidation in mouse brain during development and aging. Bourre JM, et al. **Biochem Mol Biol Int** 1997 Mar;41(3):461–8
Ageing-associated large-scale deletions of mitochondrial DNA in human hair follicles. Kao SH, et al. **Biochem Mol Biol Int** 1997 Jun;42(2):285–98
Distribution of and age-related changes in ciliary neurotrophic factor protein in rat tissues. Ohta M, et al. **Biochem Mol Biol Int** 1996 Nov;40(4):671–8
Changes in metabolism of inorganic polyphosphate in rat tissues and human cells during development and apoptosis. Lorenz B, et al. **Biochim Biophys Acta** 1997 Apr 17; 1335(1–2):51–60
The urgency of research on ageing [editorial] Holliday R. **Bioessays** 1996 Feb;18(2):89–90
Characterization and developmental aspects of anoxia-induced gasping in the rat. Gozal D, et al. **Biol Neonate** 1996;70(5):280–8
Reticuloendothelial system uptake of infused 125I-trypsin in newborn and adult rats. Levine JJ, et al. **Biol Neonate** 1997; 71(2):111–8
Age-related differences in the glomerular and renal tubular effects of amikacin in the rat. Meléndez E, et al. **Biol Neonate** 1996;70(4):229–34
Is the age-complexity effect mediated by reductions in a general processing resource? Bashore TR, et al. **Biol Psychol** 1997 Mar 21;45(1–3):263–82
Neonatal exposure of rats to recombinant follicle stimulating hormone increases adult Sertoli and spermatogenic cell numbers. Meachem SJ, et al. **Biol Reprod** 1996 Jan; 54(1):36–44
Age and hormonal dependence of acquisition of oocyte competence for embryogenesis in prepubertal calves. Presicce GA, et al. **Biol Reprod** 1997 Feb;56(2):386–92
Reinitiation of spermatogonial mitotic differentiation in inactive old BDF1 mouse seminiferous tubules transplanted to W/Wv mouse testis. Tanemura K, et al. **Biol Reprod** 1996 Dec;55(6):1237–42
Informed consent in biomedical studies on aging: survey of four journals [see comments] Olde Rikkert MG, et al. **BMJ** 1996 Nov 2;313(7065):1117. Comment in: BMJ 1997 Apr 12;314(7087):1127–8.
Aging: a global theme issue [editorial] Rochon P, et al. **BMJ** 1996 Dec 14;313(7071):1502
Aging and matrix microdamage accumulation in human compact bone. Schaffler MB, et al. **Bone** 1995 Dec; 17(6):521–25
The lumbar extradural structure changes with increasing age. Igarashi T, et al. **Br J Anaesth** 1997 Feb;78(2):149–52
Elective surgery for colorectal cancer in the aged: a clinical-economical evaluation. Audisio RA, et al. **Br J Cancer** 1997;76(3):382–4
Physical and psychosocial outcomes in cancer patients: a comparison of different age groups. Greimel ER, et al. **Br J Cancer** 1997;76(2):251–5
Longitudinal cognitive, electroencephalographic and morphological brain changes in ageing and Alzheimer's disease. Forstl H, et al. **Br J Psychiatry** 1996 Mar; 168(3):280–6
Vertical temperature profiles at bird level in broiler houses. Boshouwers FM, et al. **Br Poult Sci** 1996 Mar;37(1):55–62
Age and hemisphere effects on dendritic structure. Anderson B, et al. **Brain** 1996 Dec;119 (Pt 6):1983–90
Controlling for variability in research on normal aging and neuropsychological populations discourse analysis and applications: studies in adult clinical populations. Kahn HJ. **Brain Lang** 1996 Jun;53(3):408–16 (8 ref.)
Lexical priming by pictures and words in normal aging and in dementia of the Alzheimer's type. Margolin DI, et al. **Brain Lang** 1996 Aug;54(2):275–301
On the nature of naming errors in aging and dementia: a study of semantic relatedness. Nicholas M, et al. **Brain Lang** 1996 Aug;54(2):184–95
Pathological aging in Africans: a benign form of cerebral amyloidosis vs. pre-clinical Alzheimer's disease? [editorial; comment] Dickson DW. **Brain Pathol** 1996 Apr;6(2):107–8 . Comment on: Brain Pathol 1996 Apr;6(2):101–7.
Cerebral amyloid beta protein deposits and other Alzheimer lesions in non-demented elderly east Africans [see comments] Ogeng'o JA, et al. **Brain Pathol** 1996 Apr; 6(2):101–7. Comment in: Brain Pathol 1996 Apr;6(2):107–8.
Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts. Emerich DF, et al. **Brain Res** 1996 Oct 14;736(1–2):99–110
Factors associated with cortical and trabecular bone loss as quantified by peripheral computed tomography (pQCT) at the ultradistal radius in aging women. Boonen S, et al. **Calcif Tissue Int** 1997 Feb;60(2):164–70
Occurrence and effects of personality disorders in depression: are they the same in the old and young? [see comments] Agbayewa MO. **Can J Psychiatry** 1996 May;41(4):223–6. Comment in: Can J Psychiatry 1996 Nov;41(9):602.
Age dependence of the development of ventricular arrhythmias in a canine model of sudden cardiac death. Moïse NS, et al. **Cardiovasc Res** 1997 Jun;34(3):483–92
Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. Mbawuike IN, et al. **Cell Immunol** 1996 Oct 10;173(1):64–78
Early steps in T cell development are affected by aging. Thoman ML. **Cell Immunol** 1997 Jun 15;178(2):117–23
Age-associated decrease in inositol 1,4,5-trisphosphate and diacylglycerol generation by 1,25(OH)2-vitamin D3 in rat intestine. de Boland AR, et al. **Cell Signal** 1996 Mar; 8(3):153–7
Effect of aging and dietary restriction on hepatocyte proliferation and death in male F344 rats. Higami Y, et al. **Cell Tissue Res** 1997 Apr;288(1):69–77
Detection of tastes in mixture with other tastes: issues of masking and aging. Stevens JC. **Chem Senses** 1996 Apr; 21(2):211–21
Changes in taste threshold over the life span of the Sprague-Dawley rat. Thaw AK. **Chem Senses** 1996 Apr; 21(2):189–93
Detection and quantification of dysfunctional myocardium by magnetic resonance imaging. A new three-dimensional method for quantitative wall-thickening analysis. Holman ER, et al. **Circulation** 1997 Feb 18;95(4):924–31
Plasma thiols, cognitive function and ageing. Welsh SW, et al. **Clin Chim Acta** 1996 May 30;249(1–2):183–7
Postoperative pain management in the frail elderly. Egbert AM. **Clin Geriatr Med** 1996 Aug;12(3):583–99 (120 ref.)
Geriatric pain. Pain perceptions in the old. Harkins SW. **Clin Geriatr Med** 1996 Aug;12(3):435–59 (64 ref.)
Family and caregiver involvement in pain management. Juarez G, et al. **Clin Geriatr Med** 1996 Aug;12(3):531–47 (48 ref.)
Analgesic drugs for neuropathic and sympathetically maintained pain. Lipman AG. **Clin Geriatr Med** 1996 Aug; 12(3):501–15 (30 ref.)
The behavioral-cognitive model of pain. Manetto C, et al. **Clin Geriatr Med** 1996 Aug;12(3):461–71 (41 ref.)
The role of physical medicine and rehabilitation in pain management. Nguyen DM. **Clin Geriatr Med** 1996 Aug; 12(3):517–29 (59 ref.)
Pain in cognitively impaired older persons. Parmelee PA. **Clin Geriatr Med** 1996 Aug;12(3):473–87 (56 ref.)
Invasive modalities for the diagnosis and treatment of pain in the elderly [published erratum appears in Clin Geriatr Med 1996 Nov;12(4):X] Prager JP. **Clin Geriatr Med** 1996 Aug;12(3):549–61 (18 ref.)
Heart transplantation for patients over age 60. Everett JE, et al. **Clin Transplant** 1996 Dec;10(6 Pt 1):478–81
The aging process—an analysis of the latent structure of body morphology (in males). Živičnjak M, et al. **Coll Antropol** 1997 Jun;21(1):117–26
Coronary revascularization in the elderly: Florida multicenter consecutive case experience with coronary revascularization in patients age 75 years and older. The Program Committee Florida Chapter American College of Cardiology. Safford RE. **Compr Ther** 1996 Aug; 22(8):477–84
Collagen fibril diameter distributions in ligaments and tendons of the carpal region of the horse. Davankar SP, et al. **Connect Tissue Res** 1996;34(1):11–21
The influence of age on the results of reoperative coronary artery bypass grafting. Christenson JT, et al. **Coron Artery Dis** 1997 Feb;8(2):91–6
Ageing: levelling of the grim reaper. Charlesworth B, et al. **Curr Biol** 1997 Jul 1;7(7):R440–2 (19 ref.)
Age- and sex-related changes in lymphocyte subpopulations of healthy Asian subjects: from birth to adulthood. Lee BW, et al. **Cytometry** 1996 Mar 15;26(1):8–15
Ever since Gompertz. Olshansky SJ, et al. **Demography** 1997 Feb;34(1):1–15
Age-associated mitochondrial DNA deletions in mouse skeletal muscle: comparison of different regions of the mitochondrial genome. Eimon PM, et al. **Dev Genet** 1996; 18(2):107–13
Senescence: in search of causality. Orr WC. **Dev Genet** 1996; 18(2):93–8 (54 ref.)
Age-dependent expression of the androgen receptor gene in the prostate and its implication in glandular differentiation and hyperplasia. Prins GS, et al. **Dev Genet** 1996;18(2):99–106
Age-related differences in the chronic and acute response to cocaine in the rat. Bowman BP, et al. **Dev Psychobiol** 1996 Nov;29(7):597–611
Chronic activation of protein kinase C in soleus muscles and other tissues of insulin-resistant type II diabetic Goto-Kakizaki (GK), obese/aged, and obese/Zucker rats. A mechanism for inhibiting glycogen synthesis. Avignon A, et al. **Diabetes** 1996 Oct;45(10):1396–404
Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study. Bingley PJ. **Diabetes** 1996 Dec;45(12):1720–8
Insulin-like growth factor I (IGF-I) delays the onset of diabetes in non-obese diabetic (NOD) mice. Kaino Y, et al. **Diabetes Res Clin Pract** 1996 Sep;34(1):7–11
Cognition enhancers in age-related cognitive decline. Riedel WJ, et al. **Drugs Aging** 1996 Apr;8(4):245–74 (219 ref.)
Aging effects in multifrequency tympanometry. Holte L. **Ear Hear** 1996 Feb;17(1):12–8
Growth in weight, recumbent length, and head circumference for preterm low-birthweight infants during the first three years of life using gestation-adjusted ages. Guo SS, et al. **Early Hum Dev** 1997 Feb 20;47(3):305–25
Neonatal sucking behaviour and its development until 14 months. Iwayama K, et al. **Early Hum Dev** 1997 Jan 3; 47(1):1–9
Urinary excretion of adrenocortical steroid metabolites by pre-term human infants: trends from birth until 3 months post term. Taylor N, et al. **Endocr Res** 1996 Nov; 22(4):741–9
The importance of age and smoking in evaluating adverse cytogenetic effects of exposure to environmental agents. Tucker JD, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:489–92
Validation of a physical activity questionnaire in the elderly. Bonnefoy M, et al. **Eur J Appl Physiol** 1996;74(6):528–33
Time and frequency domain analysis of electromyogram and sound myogram in the elderly. Esposito F, et al. **Eur J Appl Physiol** 1996;73(6):503–10
Muscle strength and soft tissue composition as measured by dual energy x-ray absorptiometry in women aged 18–87 years. Madsen OR, et al. **Eur J Appl Physiol** 1997; 75(3):239–45
High resolution view of the true cytosolic membrane surface of phagosomes of known ages purified from Paramecium. Fok AK, et al. **Eur J Cell Biol** 1996 Nov;71(3):259–69
Age-dependent variations of lactate dehydrogenase and creatine kinase activities in water buffalo calf serum. Avallone L, et al. **Eur J Clin Chem Clin Biochem** 1996 Dec;34(12):961–4
SENECA. Nutrition and the elderly in Europe. Follow-up study and longitudinal analysis. **Eur J Clin Nutr** 1996 Jul; 50 Suppl 2:S1–127
Summary and conclusions of the report on the second data collection period and longitudinal analyses of the SENECA Study. de Groot CP, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S123–4
Longitudinal changes in anthropometric characteristics of elderly Europeans. SENECA Investigators. de Groot CP, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S9–15
The state of dentition in relation to nutrition in elderly Europeans in the SENECA Study of 1993. Fontijn-Tekamp FA, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S117–22
Variation in nutrient intake with dental status, age and odour

perception. Griep MI, et al. **Eur J Clin Nutr** 1996 Dec; 50(12):816–25

Mental health: minimental state examination and geriatric depression score of elderly Europeans in the SENECA study of 1993. Haller J, et al. **Eur J Clin Nutr** 1996 Jul; 50 Suppl 2:S112–6

Longitudinal changes in iron and protein status of elderly Europeans. SENECA Investigators. Lesourd B, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S16–24

Longitudinal changes in the intake of energy and macronutrients of elderly Europeans. SENECA Investigators. Moreiras O, et al. **Eur J Clin Nutr** 1996 Jul; 50 Suppl 2:S67–76

Folate and vitamin B12 status of the elderly. Quinn K, et al. **Eur J Clin Nutr** 1996 Jun;50(6):340–2

Anthropometric measurements from a cross-sectional survey of community dwelling subjects aged over 90 years of age. Rea IM, et al. **Eur J Clin Nutr** 1997 Feb;51(2):102–6

Longitudinal changes in dietary habits and attitudes of elderly Europeans. SENECA Investigators. Schlettwein-Gsell, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S56–66

Food patterns of elderly Europeans. SENECA Investigators. Schroll K, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S86–100

Health and physical performance of elderly Europeans. SENECA Investigators. Schroll M, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S105–11

Consumption of unfiltered coffee brews in elderly Europeans. SENECA Investigators. Urgert R, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S101–4

Evaluation of the dietary history method used in the SENECA Study. van Staveren WA, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S47–55

Assessment of bias in the SENECA study. van't Hof MA, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S4–8

Intake and sources of alpha-linolenic acid in Dutch elderly men. Voskuil DW, et al. **Eur J Clin Nutr** 1996 Dec; 50(12):784–7

Age and reproductive status affect basal venous tone in the rat. Hohmann M, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Sep;68(1-2):185–9

I. Aging of the human endometrium: a basic morphological and immunohistochemical study. Noci I, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Dec;63(2):181–5

Age-dependent changes in insulin-like immunoreactivity in rat submandibular salivary glands. Deville de Périère D, et al. **Eur J Oral Sci** 1996 Oct–Dec;104(5–6):630–3

Mandibular growth during initial treatment with the Bass orthopaedic appliance in relation to age and growth periods. Omblus J, et al. **Eur J Orthod** 1997 Feb;19(1):47–56

IQI/Jic mice have thymic B cells. Saegusa J, et al. **Exp Anim** 1996 Oct;45(4):353–60

Age-related appearance of dystrophic axon terminals in cerebellar and vestibular nuclei of Mongolian gerbils. Takeuchi YK, et al. **Exp Anim** 1997 Jan;46(1):59–65

Hyaluronic acid in the normal and glaucomatous optic nerve. Gong H, et al. **Exp Eye Res** 1997 Apr;64(4):587–95

Atropine reduces but does not eliminate the age-related decline in perfusion outflow facility in monkeys. Kiland JA, et al. **Exp Eye Res** 1997 May;64(5):831–5

Age-dependent lens changes in galactose-fed dogs. Lackner PA, et al. **Exp Eye Res** 1997 Mar;64(3):431–6

Age-related decline in ubiquitin conjugation in response to oxidative stress in the lens. Shang F, et al. **Exp Eye Res** 1997 Jan;64(1):21–30

Age-related changes in trabecular cells in vitro. Tripathi BJ, et al. **Exp Eye Res** 1997 Jan;64(1):57–66

Proceedings of the 2nd International Conference on Animal Models for Aging Research. Kyoto, Japan, May 12–19, 1995. **Exp Gerontol** 1997 Jan–Apr;32(1–2):1–242

Age-related changes in gene expression in the rat brain revealed by differential display. Salehi M, et al. **Experientia** 1996 Sep 15;52(9):888–91

A simple view of age-related changes in the shape of the lens of the human eye. Wyatt HJ, et al. **Eye** 1995;9 (Pt 6):772–5 (27 ref.)

The impact of an egg donor's age and her prior fertility on recipient pregnancy outcome. Faber BM, et al. **Fertil Steril** 1997 Aug;68(2):370–2

Chronobiologic evolution of luteinizing hormone secretion in adolescence: developmental patterns and speculations on the onset of the polycystic ovary syndrome. Porcu E, et al. **Fertil Steril** 1997 May;67(5):842–8

Age-dependent decrease in embryo implantation rate after in vitro fertilization. van Kooij RJ, et al. **Fertil Steril** 1996 Nov;66(5):769–75

Loss of neurons in the claustrum of aging brain. Moryś J, et al. **Folia Neuropathol** 1996;34(2):97–101

Effects of age, density, and geometry on the bending strength of human metatarsals. Courtney AC, et al. **Foot Ankle Int** 1997 Apr;18(4):216–21

Biochemical basis of lipofuscin, ceroid, and age pigment-like fluorophores. Yin D. **Free Radic Biol Med** 1996; 21(6):871–88 (187 ref.)

Changes in superoxide dismutase activity in liver and lung of old rats. Santa María C, et al. **Free Radic Res** 1996 Nov; 25(5):401–5

Findings of computerized nuclear morphometry of papillary thyroid carcinoma in correlation with the age of the patients. Tseleni S, et al. **Gen Diagn Pathol** 1997 Jul; 143(1):23–7

Preventing heat-related illness [editorial] Butler RN. **Geriatrics** 1997 Jun;52(6):7–8

Is Bob Dole too old to be President [editorial] Butler RN. **Geriatrics** 1996 Sep;51(9):8–9

Progress and pitfalls in gerontological theorizing. Bengtson VL, et al. **Gerontologist** 1996 Dec;36(6):768–72

Missing links: the case for a social psychology of the life course. George LK. **Gerontologist** 1996 Apr;36(2):248–55

Introduction: the many faces of aging: challenges for the future. Gutheil IA. **Gerontologist** 1996 Feb;36(1):13–4

Tracing the course of theoretical development in the sociology of aging. Lynott RJ, et al. **Gerontologist** 1996 Dec;36(6):749–60

Internet resources on aging: ten top Web sites. Post JA. **Gerontologist** 1996 Dec;36(6):728–33

Internet resources on aging: data sets and statistics. Post JA. **Gerontologist** 1996 Aug;36(4):425–9

Internet resources on aging: seniors on the net. Post JA. **Gerontologist** 1996 Oct;36(5):565–9

A postmodern perspective on feminist gerontology. Ray RE. **Gerontologist** 1996 Oct;36(5):674–80 (64 ref.)

Discussion: what does it all mean? Riley MW. **Gerontologist** 1996 Apr;36(2):256–8

Successful aging. Rowe JW, et al. **Gerontologist** 1997 Aug; 37(4):433–40 (62 ref.)

What's the latest? II. Cultural age deadlines for educational and work transitions. Settersten RA Jr, et al. **Gerontologist** 1996 Oct;36(5):602–13

The burden of aging: a theoretical framework for understanding the shifting balance of caregiving and care receiving as cohorts age. Uhlenberg P. **Gerontologist** 1996 Dec;36(6):761–7

Lipofuscin accumulation in neurons with restraint stress. Chaudhary A, et al. **Gerontology** 1995;41 Suppl 2:229–37

Age-related changes in elastic fibers of human heart. de Carvalho Filho ET, et al. **Gerontology** 1996;42(4):211–7

Decline in glucose metabolism in the brain in neuronal ceroid lipofuscinosis (NCL) in English setter--evidence by positron emission tomography (PET). Kitani K, et al. **Gerontology** 1995;41 Suppl 2:249–57

Lipofuscin accumulation and ageing of fibroblasts. von Zglinicki T, et al. **Gerontology** 1995;41 Suppl 2:95–108

Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Anglade P, et al. **Histol Histopathol** 1997 Jul;12(3):603–10

The neuropathological changes associated with normal brain aging. Hof PR, et al. **Histol Histopathol** 1996 Oct; 11(4):1075–88 (70 ref.)

Effects of nutritional status and aging on leptin gene expression in mice: importance of glucose. Mizuno T, et al. **Horm Metab Res** 1996 Dec;28(12):679–84

Seven rules for successful aging: a physician's advice to elderly patients. Stollerman GH. **Hosp Pract (Off Ed)** 1997 Mar 15;32(3):235–6, 238

Population biology of human aging: ethnic and climatic variation of bone age scores. Livshits G, et al. **Hum Biol** 1996 Apr;68(2):293–314

Methioninase: a therapeutic for diseases related to altered methionine metabolism and transmethylation: cancer, heart disease, obesity, aging, and Parkinson's disease. Hoffman RM. **Hum Cell** 1997 Mar;10(1):69–80 (117 ref.)

Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Feero WG, et al. **Hum Gene Ther** 1997 Mar 1;8(4):371–80

Somatic mutations are frequent and increase with age in human kidney epithelial cells. Martin GM, et al. **Hum Mol Genet** 1996 Feb;5(2):215–21

Ovulation induction and IUI in older women [letter; comment] Dickey RP, et al. **Hum Reprod** 1997 Jan; 12(1):199. Comment on: Hum Reprod 1996 May;11(5):1109–12.

Influence of aging on progression of cardiovascular complications associated with insulin resistance in patients with essential hypertension. Kamide K, et al. **Hypertens Res** 1997 Jun;20(2):127–32

The effect of age on glucose tolerance and plasma insulin level in hypertensive and normotensive subjects. Nakamura Y, et al. **Hypertens Res** 1996 Jun;19 Suppl 1:S23–6

Thymic involution with ageing: obsolescence or good housekeeping? [see comments] George AJ, et al. **Immunol Today** 1996 Jun;17(6):267–72 (60 ref.). Comment in: Immunol Today 1996 Oct;17(10):492–3.

Effect of age on the induction of endometrial lesions by a single intra-uterine administration of N-ethyl-N'-nitro-N-nitrosoguanidine in F344 rats. Kitamura T, et al. **In Vivo** 1995 Sep–Oct;9(5):489–94

Changes of IgE production in senescence-accelerated mice SAMP8. Oaki K, et al. **In Vivo** 1996 Jul–Aug;10(4):417–20

Effects of estrone with or without medroxyprogesterone acetate on the femur in aged rats. Sassa S, et al. **In Vivo** 1996 Jul–Aug;10(4):455–7

Age-related changes in ventilatory and heart rate responses to acute ozone exposure in the conscious rat. Arito H, et al. **Ind Health** 1997;35(1):78–86

Stage-specific alterations in murine B lymphopoiesis with age. Stephan RP, et al. **Int Immunol** 1996 Apr;8(4):509–18

Country-specific constancy by age in cagA+ proportion of Helicobacter pylori infections. Pérez-Pérez GI, et al. **Int J Cancer** 1997 Jul 29;72(3):453–6

Epidemiology of type II diabetes mellitus and ageing of the population: health policy implications and recommendations for epidemiological research. Casparie A. **Int J Epidemiol** 1991;20 Suppl 1:S25–9 (20 ref.)

Epidemiological research on ageing: an orientation. Miettenen OS. **Int J Epidemiol** 1991;20 Suppl 1:S2–7

An age-related change in susceptibility of rat brain to encephalomyocarditis virus infection. Ikegami H, et al. **Int J Exp Pathol** 1997 Apr;78(2):101–7

Observations on the brains of demented old people. B.E. Tomlinson, G. Blessed and M. Roth, Journal of the Neurological Sciences (1970) 11, 205–242 and Observations on the brains of non-demented old people. B.E. Tomlinson, G. Blessed and M. Roth, Journal of Neurological Sciences (1968) 7, 331–356. Burns A, et al. **Int J Geriatr Psychiatry** 1997 Aug;12(8):785–90

Spontaneous language production and aging: sex and educational effects. Ardila A, et al. **Int J Neurosci** 1996 Oct;87(1-2):71–8

Body mass index and all-cause mortality among people age 70 and over: the Longitudinal Study of Aging. Allison DB, et al. **Int J Obes Relat Metab Disord** 1997 Jun;21(6):424–31

Weight variability and incident disease in older women: the Iowa Women's Health Study. French SA, et al. **Int J Obes Relat Metab Disord** 1997 Mar;21(3):217–23

Preventing weight gain in adults: design, methods and one year results from the Pound of Prevention study. Jeffery RW, et al. **Int J Obes Relat Metab Disord** 1997 Jun; 21(6):457–64

Women's reproductive health: the role of body mass index in early and adult life. Lake JK, et al. **Int J Obes Relat Metab Disord** 1997 Jun;21(6):432–8

Anthropometric correlates to changes in visceral adipose tissue over 7 years in women. Lemieux S, et al. **Int J Obes Relat Metab Disord** 1996 Jul;20(7):618–24

The reallocation of body fat toward the abdomen persists to very old age, while body mass index declines after middle age in Chinese. Teh BH, et al. **Int J Obes Relat Metab Disord** 1996 Jul;20(7):683–7

Body mass index variations by age and sex, and prevalence of overweight in Japanese adults. Yanai M, et al. **Int J Obes Relat Metab Disord** 1997 Jun;21(6):484–8

Describing the natural heterogeneity of aging using multilevel regression models. Brant LJ, et al. **Int J Sports Med** 1997 Jul;18 Suppl 3:S225–31

A comprehensive assessment of visual impairment in a population of older Americans. The SEE Study. Salisbury Eye Evaluation Project. Rubin GS, et al. **Invest Ophthalmol Vis Sci** 1997 Mar;38(3):557–68

General practitioner and public health nurse views of nutritional risk factors in the elderly. Browne JP, et al. **Ir J Med Sci** 1997 Jan–Mar;166(1):23–5

Old age in Biblical and Talmudic lore. Kottek SS. **Isr J Med Sci** 1996 Aug;32(8):702–3

Findings from longitudinal cohort studies: Gothenburg and Jerusalem. Stessman J, et al. **Isr J Med Sci** 1996 Aug; 32(8):607–10

Age-related changes in temporal gap detection. Snell KB. **J Acoust Soc Am** 1997 Apr;101(4):2214–20

Stimulus variability and spoken word recognition. II. The effects of age and hearing impairment. Sommers MS. **J Acoust Soc Am** 1997 Apr;101(4):2278–88

Unsuccessful use of binaural amplification by an elderly person. Chmiel R, et al. **J Am Acad Audiol** 1997 Feb; 8(1):1–10

Evaluation of the use of a new compact disc for auditory perceptual assessment in the elderly. Humes LE, et al. **J Am Acad Audiol** 1996 Dec;7(6):419–27

Comprehension of time-compressed speech: effects of age and speech complexity. Letowski T, et al. **J Am Acad Audiol** 1996 Dec;7(6):447–57

Intelligibility of clear and conversational speech of young and elderly talkers. Schum DJ. **J Am Acad Audiol** 1996 Jun;7(3):212–8

Evidence against the influence of aging on distortion-product otoacoustic emissions. Strouse AL, et al. **J Am Acad Audiol** 1996 Oct;7(5):339–45

The old-old dental patient: the challenge of clinical decision-making. Berkey DB, et al. **J Am Dent Assoc** 1996 Mar;127(3):321–32 (37 ref.)

Common health problems among minority elders. Bernard MA, et al. **J Am Diet Assoc** 1997 Jul;97(7):771–6 (39 ref.)

The effect of DHEAS on influenza vaccination in aging adults. Degelau J, et al. **J Am Geriatr Soc** 1997 Jun; 45(6):747–51

Correlates of kyphosis in older women. The Fracture Intervention Trial Research Group. Ensrud KE, et al. **J Am Geriatr Soc** 1997 Jun;45(6):682–7

The impact of aging and chronic disease on use of hospital and outpatient services in a large HMO: 1971–1991 [see comments] Haan MN, et al. **J Am Geriatr Soc** 1997 Jun; 45(6):667–74. Comment in: J Am Geriatr Soc 1997 Jun;45(6):768–9.

The impact of disability in older women [see comments] Guralnik JM, et al. **J Am Med Womens Assoc** 1997 Summer;52(3):113–20. Comment in: J Am Med Womens Assoc 1997 Summer;52(3):98, 106.

An economic profile of American older women. Lewis MI. **J Am Med Womens Assoc** 1997 Summer;52(3):107–12

Demographic trends for the aging female population. Manton KG. **J Am Med Womens Assoc** 1997 Summer;52(3):99–105

Aging is a women's issue [editorial; comment] Wetle T. **J Am Med Womens Assoc** 1997 Summer;52(3):98, 106. Comment on: J Am Med Womens Assoc 1997 Summer;52(3):113–20.

MRI appearance of the articular cartilage in the knee according to age. Dalla Palma L, et al. **J Belge Radiol** 1997 Feb;80(1):17–20

Characterization of two age-induced intracisternal A-particle-related transcripts in the mouse liver. Transcriptional read-through into an open reading frame with similarities to the yeast ccr4 transcription factor. Puech A, et al. **J Biol Chem** 1997 Feb 28;272(9):5995–6003

Cardiac surgery in nonagenarians. Samuels LE, et al. **J Card Surg** 1996 Mar–Apr;11(2):121–7

Prevalence and surgical complications of pseudoexfoliation syndrome in Portuguese patients with senile cataract. Alfaiate M, et al. **J Cataract Refract Surg** 1996 Sep; 22(7):972–6

Age-related changes of the ciliary sulcus: implications for implanting sulcus-fixated lenses. Blum M, et al. **J Cataract Refract Surg** 1997 Jan–Feb;23(1):91–6

The minimum alveolar concentration (MAC) of sevoflurane with and without nitrous oxide in elderly versus young adults. Fragen RJ, et al. **J Clin Anesth** 1996 Aug;8(5):352–6

Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. Attanasio AF, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):82–8

Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1–29)-NH2 in age-advanced men and women. Khorram O, et al. **J Clin Endocrinol Metab** 1997 May; 82(5):1472–9

Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. Khosla S, et al. **J Clin Endocrinol Metab** 1997 May;82(5):1522–7

Dehydroepiandrosterone sulfate: a biomarker of primate aging slowed by calorie restriction. Lane MA, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2093–6

The pathogenesis of age-related osteoporotic fracture: effects of dietary calcium deprivation. Prince RL, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):260–4

Changes in diameter of the abdominal aorta with age: an epidemiological study. Grimshaw GM, et al. **J Clin Ultrasound** 1997 Jan;25(1):7–13

Utilization of supplemental triglycerides or free fatty acids by calves from 4 to 10 weeks of age. Spanski NA, et al. **J Dairy Sci** 1997 Mar;80(3):573–85

Is the persistence of isolated GH deficiency in adulthood predicted by anatomical hypothalamic-pituitary alterations? Vannelli S, et al. **J Endocrinol Invest** 1997 Jun; 20(6):312–8

Maintaining excellence: deliberate practice and elite performance in young and older pianists. Krampe RT, et al. **J Exp Psychol Gen** 1996 Dec;125(4):331–59

Selective attention in a reaching task: effect of normal aging and Alzheimer's disease. Simone PM, et al. **J Exp Psychol Hum Percept Perform** 1997 Jun; 23(3):595–608

Effect of ageing on pancreatic hyperplasia after 90% proximal small bowel resection. Sasaki M, et al. **J Gastroenterol Hepatol** 1997 May;12(5):376–81

Aging in AIDS; AIDS and aging [editorial; comment] Justice AC, et al. **J Gen Intern Med** 1996 Oct;11(10):645–7. Comment on: J Gen Intern Med 1996 Oct;11(10):591–6.

AIDS-related Pneumocystis carinii pneumonia in older patients [see comments] Keitz SA, et al. **J Gen Intern Med** 1996 Oct;11(10):591–6. Comment in: J Gen Intern Med 1996 Oct;11(10):645–7.

Hypothesis: interventions that increase the response to stress offer the potential for effective life prolongation and increased health. Johnson TE, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov;51(6):B392–5

Self-report versus state records for identifying crashes among older drivers. Marottoli RA, et al. **J Gerontol A Biol Sci Med Sci** 1997 May;52(3):M184–7

The evolution of the antiaging action of dietary restriction: a hypothesis. Masoro EJ, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov;51(6):B387–91

Predicting mortality from community surveys of older adults: the importance of self-rated functional ability. Bernard SL, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May; 52(3):S155–63

Patterns of motor impairement in normal aging, mild cognitive decline, and early Alzheimer's disease. Kluger A, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Jan; 52(1):P28–39

Loss to folow-up in a sample of Americans 70 years of age and older: The LSOA 1984–1990. Mihelic AH, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Jan;52(1):S37–48

Social relations and health assessments among older people: do the effects of integration and social contributions vary cross-culturally? Su YP, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Jan;52(1):S27–36

Age-related differences in movement control: adjusting submovement structure to optimize performance. Walker N, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Jan; 52(1):P40–52

Effects of age and long-term caloric restriction on the aqueous collecting channel in the mouse eye. Li Y, et al. **J Glaucoma** 1997 Feb;6(1):18–22

Aortic valve replacement in elderly women with small aortic roots: comparing sorin pericardial and St.Jude Medical mechanical valves. Mahon BD, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S324–8

Accumulation of advanced glycation endproducts in the rat nephron: link with circulating AGEs during aging. Verbeke P, et al. **J Histochem Cytochem** 1997 Aug;45(8):1059–68

Medical aspects of ageing in a population with intellectual disability: III. Mobility, internal conditions and cancer [published erratum appears in J Intellect Disabil Res 1997 Jun;41(Pt 3):283] Evenhuis HM. **J Intellect Disabil Res** 1997 Feb;41 (Pt 1):8–18

The natural history of dementia in ageing people with intellectual disability. Evenhuis HM. **J Intellect Disabil Res** 1997 Feb;41 (Pt 1):92–6

Intellectual disability and ageing: ecological perspectives from recent research. Hogg J. **J Intellect Disabil Res** 1997 Apr;41 (Pt 2):136–43

Immunohistochemical characteristics of the constituents of senile plaques and amyloid angiopathy in aged cynomolgus monkeys. Nakamura S, et al. **J Med Primatol** 1996 Aug; 25(4):294–300

Aging, cardiac hypertrophy and ischemic cardiomyopathy do not affect the proportion of mononucleated and multinucleated myocytes in the human heart. Olivetti G, et al. **J Mol Cell Cardiol** 1996 Jul;28(7):1463–77

Two-dimensional characterization of paired helical filament-tau from Alzheimer's disease: demonstration of an additional 74-kDa component and age-related biochemical modifications. Sergeant N, et al. **J Neurochem** 1997 Aug;69(2):834–44

Calcitonin gene-related peptide and alpha-CGRP mRNA expression in cranial motoneurons after hypoglossal nerve injury during postnatal development. Blake-Bruzzini KM, et al. **J Neurocytol** 1997 Mar;26(3):163–79

The involvement of dopaminergic and opioidergic neuronal systems in the control of the early rise in LH secretion in bull calves. Chandolia RK, et al. **J Neuroendocrinol** 1997 Feb;9(2):121–7

Age related cognitive decline: a clinical entity? A longitudinal study of cerebral blood flow and memory performance. Celsis P, et al. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):601–8

Mucolipidosis III (pseudo-Hurler polydystrophy); clinical studies in aged patients in one family. Umehara F, et al. **J Neurol Sci** 1997 Mar 10;146(2):167–72

Gender differences in cortical glucose metabolism in Alzheimer's disease and normal aging. Siegel BV Jr, et al. **J Neuropsychiatry Clin Neurosci** 1996 Spring;8(2):211–4

Significance of sarcopenia in the elderly. Dutta C. **J Nutr** 1997 May;127(5 Suppl):992S–993S (23 ref.)

Poison prevention for the elderly. McGoodwin L. **J Okla State Med Assoc** 1996 May;89(5):173–6 (35 ref.)

The soft tissue cover of the mandibular condyle: age-related changes in high buoyant density proteoglycans, free tissue water and remodelling activity. Müller K, et al. **J Orofac Orthop** 1996 Oct;57(5):310–21 **(Eng, Ger)**

A new technique for complex fibula fracture fixation in the elderly: a clinical and biomechanical evaluation. Koval KJ, et al. **J Orthop Trauma** 1997 Jan;11(1):28–33

Mobility in older patients with hip fractures: examining prefracture status, complications, and outcomes at discharge from the acute-care hospital. Myers AH, et al. **J Orthop Trauma** 1996;10(2):99–107

Vitamin A concentration in the liver decreases with age in patients with cystic fibrosis. Lindblad A, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):264–70

Fecal bacterial enzyme activities in infants increase with age and adoption of adult-type diet. Mykkänen H, et al. **J Pediatr Gastroenterol Nutr** 1997 Sep;25(3):312–6

Aging and drug interactions. III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. Loi CM, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):627–37

Changes in acromial morphology with age. Wang JC, et al. **J Shoulder Elbow Surg** 1997 Jan–Feb;6(1):55–9

Effects of age and Alzheimer's disease on recognition of gated spoken words. Marshall NB, et al. **J Speech Hear Res** 1996 Aug;39(4):724–33

Inverse relation between vertebral body deformity and intervertebral disk narrowing in lumbar spine of elderly women. Okawa A, et al. **J Spinal Disord** 1996 Feb; 9(1):23–31

Age-related differences in elastic properties of the upper arm vascular bed in healthy adults. Muntinga JH, et al. **J Vasc Res** 1997 Mar–Apr;34(2):137–47

Aging and the human vestibular nucleus. Lopez I, et al. **J Vestib Res** 1997 Jan–Feb;7(1):77–85

The aging adult voice. Sataloff RT, et al. **J Voice** 1997 Jun; 11(2):156–60

Malnutrition in the elderly. Swagerty DL Jr. **Kans Med** 1995 Winter;96(4):182–4

Para-chloroamphetamine (PCA)-induced ejaculation in aged rats, semen analysis and artificial insemination. Saito TR, et al. **Lab Anim** 1996 Oct;30(4):332–6

Mouse strain and age affect susceptibility to experimentally induced genital trichomoniasis. Hook RR Jr, et al. **Lab Anim Sci** 1997 Jun;47(3):324–6

Birth of normal young by microinsemination with frozen-thawed round spermatids collected from aged azoospermic mice. Tanemura K, et al. **Lab Anim Sci** 1997 Apr;47(2):203–4

Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Robert V, et al. **Lab Invest** 1997 May;76(5):729–38

Effects of dietary nucleoside-nucleotide mixture on memory in aged and young memory deficient mice. Chen TH, et al. **Life Sci** 1996;59(21):PL325–30

Cocaine abusers do not show loss of dopamine transporters with age. Wang GJ, et al. **Life Sci** 1997;61(11):1059–65

Expression of laminin alpha 1, alpha 5 and beta 2 chains during embryogenesis of the kidney and vasculature. Durbeej M, et al. **Matrix Biol** 1996 Dec;15(6):397–413

Structural and functional implications of age-related abnormal modifications in collagen II from intervertebral disc. Yang C, et al. **Matrix Biol** 1995 Oct;14(8):643–51

Creating knowledge relevant for public health applications in immunology and aging. Dean K. **Mech Ageing Dev** 1997 Mar;94(1-3):251–62 (64 ref.)

Diminished activation of the MAP kinase pathway in CD3-stimulated T lymphocytes from old mice. Gorgas G, et al. **Mech Ageing Dev** 1997 Mar;94(1-3):71–83

Increased apoptosis of CD45RO- T cells with aging. Herndon FJ, et al. **Mech Ageing Dev** 1997 Mar; 94(1-3):123–34

HLA and longevity or aging among Shanghai Chinese. Ma YX, et al. **Mech Ageing Dev** 1997 Mar;94(1-3):191–8

Altered expression of various receptors on T cells in young and old mice after mitogenic stimulation: a flow cytometric analysis. Wakikawa A, et al. **Mech Ageing Dev** 1997 Mar; 94(1-3):113–22

Thymocyte progenitors and T cell development in aging. Yu S, et al. **Mech Ageing Dev** 1997 Mar;94(1-3):103–11

Organ weight: a new tissue parameter to assess water proton spin-lattice relaxation time. Akber SF. **Med Hypotheses** 1997 Jan;48(1):71–5

Normalizing strength for body size differences in older adults. Davies MJ, et al. **Med Sci Sports Exerc** 1997 May; 29(5):713–7

Autonomic nervous system as a model of neuronal aging: the role of target tissues and neurotrophic factors. Andrews TJ. **Microsc Res Tech** 1996 Sep 1;35(1):2–19

Histochemical detection of age- and injury-related changes in signal transduction in the superior cervical ganglion. Roivainen R, et al. **Microsc Res Tech** 1996 Sep 1; 35(1):20–31

Mg(2+)-dependent and Ca2+, Mg(2+)-dependent ATPase activities in the harderian gland of rodents: age and sex influences. Vaughan MK, et al. **Microsc Res Tech** 1996 Jun 1;34(2):144–8

Aging and cancer: the role of stromal interactions with epithelial cells. Rinehart CA, et al. **Mol Carcinog** 1997 Apr; 18(4):187–92 (21 ref.)

Effects of chronically elevated growth hormone levels on polyamine metabolism in elderly transgenic mice. Gritli-Linde A, et al. **Mol Cell Endocrinol** 1997 Jan 3; 126(1):49–58

On the role of aging in carcinogenesis. Benson D, et al. **Mutat Res** 1996 Sep 23;356(2):209–16

Susceptibility of hepatocytes to cell death induced by single administration of cycloheximide in young and old F344 rats. Effect of dietary restriction. Higami Y, et al. **Mutat Res** 1996 Oct 25;357(1-2):225–30

Older adults in North Carolina. A demographic and health status profile. Blazer DG. **N C Med J** 1996 Nov-Dec; 57(6):344–7

The graying of dialysis in America [see comments] Jones FS. **N C Med J** 1996 Nov-Dec;57(6):359–62. Comment in: N C Med J 1997 May-Jun;58(3):165.

Worldwide ageing programme needed [letter; comment] Azzi A. **Nature** 1997 Mar 27;386(6623):320. Comment on: Nature 1997 Jan 30;385(6615):379.

Attenuating effect of castration on glomerular injury is age-dependent in unilaterally nephrectomized male Sprague-Dawley rats. Sakemi T, et al. **Nephron** 1997; 75(3):342–9

Renal replacement therapy in the elderly. Mandigers CM, et al. **Neth J Med** 1996 Oct;49(4):135–42

Effects of aging on the densities, numbers, and sizes of retinal ganglion cells in rhesus monkey. Kim CB, et al. **Neurobiol Aging** 1996 May-Jun;17(3):431–8

Astrocytes, brain aging, and neurodegeneration. Schipper HM. **Neurobiol Aging** 1996 May-Jun;17(3):467–80 (109 ref.)

Age dependent sensitivity of the rat retina to the excitotoxic action of N-methyl-D-aspartate. Izumi Y, et al. **Neurobiol Dis** 1995 Jun;2(3):139–44

The effects of selective cholinergic basal forebrain lesions and aging upon expectancy in the rat. Stoehr JD, et al. **Neurobiol Learn Mem** 1997 May;67(3):214–27

Alterations in the turnover rate of dopamine D1 but not D2 receptors in the adult rat neostriatum after a neonatal dopamine denervation. Dewar KM, et al. **Neurochem Int** 1997 Jun;30(6):613–21

Impaired adaptation of the hypothalamic-pituitary-adrenal axis to chronic ethanol stress in aged rats. Spencer RL, et al. **Neuroendocrinology** 1997 May;65(5):353–9

Effects of sequential neuropsychological testing of an elderly community-based sample. Frank R, et al. **Neuroepidemiology** 1996;15(5):257–68

Standardization of the diagnosis of dementia in the Canadian Study of Health and Aging. Graham JE, et al. **Neuroepidemiology** 1996;15(5):246–56

A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Kawas C, et al. **Neurology** 1997 Jun;48(6):1517–21

Dietary retinoic acid inhibits mouse skin carcinogenesis irrespective of age at initiation. De Luca LM, et al. **Nutr Cancer** 1996;25(3):249–57

Diet, age, and the immune system. Bradley J, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S43–50 (19 ref.)

Low-protein intakes and protein turnover in elderly women. de Groot LC, et al. **Nutr Rev** 1996 Feb;54(2 Pt 1):58–60 (12 ref.)

Body mass index at different ages and its association with height at age 14 and with the whole growing process. Amador M, et al. **Nutrition** 1996 Jun;12(6):416–22

Supplementation of oral nutrition with pancreatic enzymes improves the nutritional status of aged endotoxemic rats. Farges MC, et al. **Nutrition** 1996 Mar;12(3):189–94

Muscle mass, survival, and the elderly ICU patient. Griffiths RD. **Nutrition** 1996 Jun;12(6):456–8 (28 ref.)

A comparison of body fat estimates using anthropometry and bioelectrical impedance analysis with distinct prediction equations in elderly persons in the Republic of Guatemala. Mazariegos M, et al. **Nutrition** 1996 Mar;12(3):168–75

Trace elements in the elderly [editorial] Mertz W. **Nutrition** 1996 Jul–Aug;12(7–8):549–50

Special requirements for nutrition assessment in the aged [editorial] van Staveren WA, et al. **Nutrition** 1996 Sep; 12(9):645–6

The psychiatric disorders of aging in the work organization. Brodsky CM, et al. **Occup Med** 1996 Oct–Dec;11(4):739–46

Age-related macular degeneration. Oshinskie LJ. **Optom Clin** 1996;5(1):25–53 (102 ref.)

The influence of aging on auditory brainstem response and electrocochleography in the elderly. Oku T, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 May–Jun; 59(3):141–6

Age and sex related changes in heart rate to ventilation coupling: implications for rate adaptive pacemaker algorithms. Rickli H, et al. **Pacing Clin Electrophysiol** 1997 Jan;20(1 Pt 1):104–11

Etiology and age have only a limited influence on the course of acute pancreatitis. Lankisch PG, et al. **Pancreas** 1996 Nov;13(4):344–9

Hyalomma ticks: bovine resistance under field conditions as related to host age and breed. Sahibi H, et al. **Parasite** 1997 Jun;4(2):159–65

Age might influence the frequency distribution of metoprolol hydroxylation polymorphism in a Chinese population. Wan J, et al. **Pharmacol Toxicol** 1997 Apr;80(4):167–70

Male menopause. How to define it, how to treat it. Schow DA, et al. **Postgrad Med** 1997 Mar;101(3):62–4, 67–8, 71–4 passim (47 ref.)

Genetics of growth and reproduction in the turkey. 13. Effects of repeated backcrossing of an egg line to two sire lines. Nestor KE, et al. **Poult Sci** 1997 Feb;76(2):227–35

Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-alpha-phenylnitrone. Butterfield DA, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21;94(2):674–8

Effect of aging on the gastrointestinal tract and the pancreas. Majumdar AP, et al. **Proc Soc Exp Biol Med** 1997 Jun; 215(2):134–44 (138 ref.)

Age-related changes in IGFBP-4 and IGFBP-5 levels in human serum and bone: implications for bone loss with aging. Mohan S, et al. **Prog Growth Factor Res** 1995; 6(2–4):465–73 (27 ref.)

Focal cerebral perfusion defects demonstrated by 99mTc-hexamethylpropyleneamine oxime SPECT in elderly depressed patients. Vasile RG, et al. **Psychiatry Res** 1996 May 31;67(1):59–70

Measuring age-related changes in dopamine D2 receptors with 11C-raclopride and 18F-N-methylspiroperidol. Volkow ND, et al. **Psychiatry Res** 1996 May 31;67(1):11–6

Personality traits and states as predictors of subjective well-being in centenarians, octogenarians, and sexagenarians. Adkins G, et al. **Psychol Aging** 1996 Sep; 11(3):408–16

Aging and inhibitory control in text comprehension. Dywan J, et al. **Psychol Aging** 1996 Jun;11(2):199–206

Age and forgetfulness: confidence in ability and attribution for memory failures. Erber JT, et al. **Psychol Aging** 1996 Jun;11(2):310–5

Age and working memory: the role of perceptual speed, the central executive, and the phonological loop. Fisk JE, et al. **Psychol Aging** 1996 Jun;11(2):316–23

Effects of aging and musical experience on the representation of tonal hierarchies. Halpern AR, et al. **Psychol Aging** 1996 Jun;11(2):235–46

Aging and individual differences in the development of skilled memory search performance. Hertzog C, et al. **Psychol Aging** 1996 Sep;11(3):497–520

Adult age differences in the use of distractor homogeneity during visual search. Madden DJ, et al. **Psychol Aging** 1996 Sep;11(3):454–74

Self-efficacy beliefs and change in cognitive performance: MacArthur Studies of Successful Aging. Seeman T, et al. **Psychol Aging** 1996 Sep;11(3):538–51

Visual cues and the handwriting of older adults: a kinematic analysis. Slavin MJ, et al. **Psychol Aging** 1996 Sep; 11(3):521–6

Projections of aging: impact of generational differences and the aging process on perceptions of adults. Slotterback CS. **Psychol Aging** 1996 Sep;11(3):552–9

The structural organization of the mental lexicon and its contribution to age-related declines in spoken-word recognition. Sommers MS. **Psychol Aging** 1996 Jun; 11(2):333–41

Resource allocation in on-line reading by younger and older adults. Stine-Morrow EA, et al. **Psychol Aging** 1996 Sep; 11(3):475–86

Curiosity and mortality in aging adults: a 5-year follow-up of the Western Collaborative Group Study. Swan GE, et al. **Psychol Aging** 1996 Sep;11(3):449–53

Effects of age and gender on discrete and reciprocal aiming movements. Teeken JC, et al. **Psychol Aging** 1996 Jun; 11(2):195–8

Effects of serum vitamin B12 and folate status on episodic memory performance in very old age: a population-based study. Wahlin A, et al. **Psychol Aging** 1996 Sep;11(3):487–96

Comparison of four health-care disciplines on the Facts on Aging and Mental Health Quiz. Cole E, et al. **Psychol Rep** 1996 Aug;79(1):350

Effects of aging on implicit sequence learning: accounting for sequence structure and explicit knowledge. Curran T. **Psychol Res** 1997;60(1–2):24–41

Effects of perceptual and conceptual processing on memory for words and voice: different patterns for young and old. Naveh-Benjamin M, et al. **Q J Exp Psychol A** 1996 Aug; 49(3):780–96

GAPO syndrome (Radiographic clues to early diagnosis). Baxova A, et al. **Radiol Med (Torino)** 1997 Mar; 93(3):289–91

Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast [published erratum appears in Radiology 1997 Aug;204(2):583] Müller-Schimpfle M, et al. **Radiology** 1997 Apr;203(1):145–9

Aging of the female reproductive system: a window into brain aging. Wise PM, et al. **Recent Prog Horm Res** 1997; 52:279–303; discussion 303–5 (104 ref.)

Developmental capacity, energy metabolism and ultrastructure of mature oocytes from prepubertal and adult sheep. O'Brien JK, et al. **Reprod Fertil Dev** 1996; 8(7):1029–37

Insulin receptors: the binding capacity and localization in the digestive tract during the rabbits neonatal period. Nowak JW, et al. **Reprod Nutr Dev** 1996;36(5):513–21

Physical activity and functional independence in aging. Fiatarone MA. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S70

Pharmacokinetics of propofol as an induction agent in geriatric dogs. Reid J, et al. **Res Vet Sci** 1996 Sep; 61(2):169–71

Synovial effusions at the knee as the inaugural manifestation of stress fracture of the proximal tibia. Lassoued S, et al. **Rev Rhum Engl Ed** 1996 Jan;63(1):65–8

Age and gender differences in perceived accident likelihood and driver competences. Glendon AI, et al. **Risk Anal** 1996 Dec;16(6):755–62

Rate of characteristics for osteoporotic fractures in the elderly population of Kaunas region, Lithuania. Lashas L, et al. **Scand J Rheumatol Suppl** 1996;103:16–20; discussion 21–3

Aging--a potential pitfall of continent urinary diversions. Haupt G, et al. **Scand J Urol Nephrol** 1996 Aug;30(4):323–4

Is schizophrenia a lifetime disorder of brain plasticity, growth and aging? DeLisi LE. **Schizophr Res** 1997 Feb 7; 23(2):119–29 (101 ref.)

Schizophrenia throughout life: sex differences in severity and profile of symptoms. Gur RE, et al. **Schizophr Res** 1996 Jul;21(1):1–12

Hippocampal age-related changes in schizophrenia: a proton magnetic resonance spectroscopy study. Maier M, et al. **Schizophr Res** 1996 Oct 18;22(1):5–17

Hippocampal neurodegeneration in aging [letter; comment] Gallagher M, et al. **Science** 1996 Oct 25;274(5287):484–5. Comment on: Science 1996 Mar 1;271(5253):1229–30. Comment on: Science 1996 Jul 5;273(5271):48–50.

Syncope in an elderly. Sick sinus syndrome. Ardian JS, et al. **Singapore Med J** 1996 Apr;37(2):205, 236–7

Influence of age on optimal daily levothyroxine dosage in patients with primary hypothyroidism grouped according to etiology. Kabadi UM. **South Med J** 1997 Sep;90(9):920–4

The Canadian Study of Health and Aging: risk factors for vascular dementia. Lindsay J, et al. **Stroke** 1997 Mar; 28(3):526–30

Anatomic basis of micturition and urinary continence. Muscle systems in urinary bladder neck during ageing. Rother P, et al. **Surg Radiol Anat** 1996;18(3):173–7

Tobacco and aging: a call for papers for the global coordinated theme issues of 1997 [editorial] Davis RM. **Tob Control** 1996 Winter;5(4):257–8 (18 ref.)

5th Asia/Oceania Regional Congress of gerontology. November 19–23rd 1995. Sharma MP. **Trop Gastroenterol** 1995 Oct–Dec;16(4):34–7

Age dependence of ultrasonically induced lung hemorrhage in mice. Dalecki D, et al. **Ultrasound Med Biol** 1997; 23(5):767–76

Psychophysical evidence for losses in rod sensitivity in the aging visual system. Sturr JF, et al. **Vision Res** 1997 Feb; 37(4):475–81

Older women in an aging world: achieving health across the life course. Bonita R, et al. **World Health Stat Q** 1996; 49(2):134–41

Long-term follow-up of kidneys transplanted from elderly cadaveric donors. Wyner LM, et al. **World J Urol** 1996; 14(4):265–7

Formation of morphological traits of the quadriceps femoris muscle (QFM) before and after birth. Part I. Rectus femoris muscle (RFM). Lewandowski J. **Z Morphol Anthropol** 1996 Sep;81(2):189–203

[Epidemiology of arbovirus diseases: use and value of physiologic age determination of female mosquito vectors] Mondet B. **Bull Soc Pathol Exot** 1996;89(2):155–60 (Eng. Abstr.) **(Fre)**

[Information on the disabled and dependent people in France] Mormiche P. **Cah Sociol Demogr Med** 1996 Oct–Dec; 36(4):317–55 (Eng. Abstr.) **(Fre)**

[Radiotherapy and age-related macular degeneration: a review of the literature] Schwartz LH, et al. **Cancer Radiother** 1997;1(3):208–12 (38 ref.) (Eng. Abstr.) **(Fre)**

[Health in the third age. Preventing handicaps related to aging] Svanborg A, et al. **J Med Liban** 1995;43(2):102–6 (13 ref.) **(Fre)**

[Late onset myasthenia: 34 cases in patients over 65 years of age] Billé-Turc F, et al. **Rev Neurol (Paris)** 1997 Mar; 153(2):129–34 (24 ref.) (Eng. Abstr.) **(Fre)**

[Biomorphosis of the kidney boundary interstitium and intrarenal arteries] Strauch G. **Frankf Z Pathol** 1966; 75(4):336–41 **(Ger)**

[Age-dependent MR imaging of the tibia in children up to 2 years old. The findings in children without bone marrow-relevant diseases or therapies] Kujat C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):470–4 (Eng. Abstr.) **(Ger)**

[Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities] Klivényi P, et al. **Orv Hetil** 1997 Feb 9; 138(6):331–5 (43 ref.) (Eng. Abstr.) **(Hun)**

[Classification of age groups] Magyar LA. **Orv Hetil** 1997 Feb 9;138(6):363–5 **(Hun)**

[Letters by László Németh on aging] Vértes L. **Orv Hetil** 1996 Jul 28;137(30):1651 **(Hun)**

[Variations in the anatomy and physiology of the thyroid gland in old age] Messina G, et al. **Recenti Prog Med** 1997 Jun;88(6):281–6 (32 ref.) (Eng. Abstr.) **(Ita)**

[Aging brains and the dementias] Fukatsu R, et al. **Hokkaido Igaku Zasshi** 1996 May;71(3):297–301 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Aging of brain and the maintenance of the function] Mano Y. **Hokkaido Igaku Zasshi** 1996 May;71(3):321–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

[What is brain's senility?] Tashiro K, et al. **Hokkaido Igaku Zasshi** 1996 May;71(3):295–6 (2 ref.) (Eng. Abstr.) **(Jpn)**

[Changes in the elastic system fibers with aging (published erratum appears in Rev Assoc Med Bras 1996 Jul–Sep;42(3):IX)] de Carvalho Filho ET, et al. **Rev Assoc Med Bras** 1996 Jan–Mar;42(1):25–30 (49 ref.) **(Por)**

[Aging-related changes in the intraorganic lymphatic bed of the human stomach] Balashev VN. **Arkh Anat Gistol Embriol** 1968 Nov;55(11):11–6 (Eng. Abstr.) **(Rus)**

[Morphometric characteristics of the brain of 2-month-old rats depending upon the body weight at 1 month of age] Ryzhavskiĭ BIa. **Biull Eksp Biol Med** 1997 Jul;124(7):115–7 **(Rus)**

[Changes in the size of the stomach and its sections in human early postnatal ontogeny] Kernesiuk NL, et al. **Morfologiia** 1997;111(1):81–4 (Eng. Abstr.) **(Rus)**

[Age-related changes in the goniometric indices of the pelvic bones in children] Kil'diushov EM. **Morfologiia** 1997; 111(2):105–7 (Eng. Abstr.) **(Rus)**

[The morphological and age-related prerequisites for distinguishing the structural-functional myocardial units, the "myocardioangion" and the "myocardiohistion"] Mishalov VD. **Morfologiia** 1995;108(3):49–52 (Eng. Abstr.) **(Rus)**

[Age-related changes in the cytoarchitectonics of the human sensorimotor cortex] Shumeiko NS. **Morfologiia** 1997; 111(2):31–4 (Eng. Abstr.) **(Rus)**

[Age-related changes in the weight of the body and of the extremity muscles in boys 7 to 17 years old] Tambovtseva RV. **Morfologiia** 1995;108(3):45–8 (Eng. Abstr.) **(Rus)**

[Age-related changes in the intervertebral disks based on magnetic resonance tomographic data] Tiutin LA, et al. **Morfologiia** 1996;109(3):55–8 (Eng. Abstr.) **(Rus)**

[The structural transformations of the human cerebellar cortex from birth to 3 years] Tsekhmistrenko TA. **Morfologiia** 1995;108(3):21–4 (Eng. Abstr.) **(Rus)**

[Biological age: the forensic medical aspects] Nekliudov IuA. **Sud Med Ekspert** 1997 Apr–Jun;40(2):10–3 (Eng. Abstr.) **(Rus)**

[The x-ray morphometric characteristics of the spine in persons 50 and older] Belosel'skiĭ NN, et al. **Ter Arkh** 1997; 69(5):55–8 (Eng. Abstr.) **(Rus)**

[The surgery of peptic ulcer in middle-aged and elderly patients] Iarema IV, et al. **Vestn Khir Im I I Grek** 1996; 155(4):84–8; discussion 88–9 **(Rus)**

[Biomedical aspects of health preservation strategy: role of catecholaminergic neuronal populations] Iarygin VN, et al. **Vestn Ross Akad Med Nauk** 1997;(4):60–2 (Eng. Abstr.) **(Rus)**

[Presbyphonia: a study of acoustic parameters of normalcy] Carbonell J, et al. **Acta Otorrinolaringol Esp** 1996 Jul–Aug; 47(4):295–9 (Eng. Abstr.) **(Spa)**

[Prevalence of age-related hearing loss in a primary care

clinic] Melgarejo Moreno PJ, et al. **Acta Otorrinolaringol Esp** 1996 May-Jun;47(3):213-5 (Eng. Abstr.) **(Spa)**

[Aging and geriatric medicine] Morales-Virgen JJ. **Gac Med Mex** 1996 May-Jun;132(3):343-5 **(Spa)**

[Clinical and molecular pathology in brain aging] Coria F, et al. **Rev Neurol** 1997 Jul;25 Suppl 1:S14-7 (35 ref.) **(Spa)**

[Demographic perspectives of Communidad Autonoma Vasca and the OCDE's countries] Gabiña JJ. **Rev Neurol** 1997 Jul;25 Suppl 1:S86-96 **(Spa)**

The pharmaceutical industry faced with the double challenge of aging] García-Alvarez C. **Rev Neurol** 1997 Jul;25 Suppl 1:S76-82 **(Spa)**

[Drug-related motor disorders in aged people] Martí-Massó JF. **Rev Neurol** 1997 Jul;25 Suppl 1:S37-43 (35 ref.) **(Spa)**

[Introduction: cerebral diseases in aging] Martí-Massó JF, et al. **Rev Neurol** 1997 Jul;25 Suppl 1:S7-8 **(Spa)**

[Cerebral vascular pathology in aging] Martí-Massó JF. **Rev Neurol** 1997 Jul;25 Suppl 1:S18-22 (13 ref.) **(Spa)**

[Follow-up study of the evolution of the quantitative EEG in intraventricular infusion of nerve growth factor in an aged baboon] Morales-Chacón L, et al. **Rev Neurol** 1997 Jun;25(142):850-5 (Eng. Abstr.) **(Spa)**

[Receptors localization in human brain: contribution to neurochemistry of normal aging and neurodegenerative diseases] Pazos A. **Rev Neurol** 1997 Jul;25 Suppl 1:S28-32 (28 ref.) **(Spa)**

[Motor disorders of vascular origin in aged people] Zarranz JJ. **Rev Neurol** 1997 Jul;25 Suppl 1:S33-6 (25 ref.) **(Spa)**

[Morphological and neurochemical dysfunctions in normal cerebral aging] Zarranz JJ. **Rev Neurol** 1997 Jul;25 Suppl 1:S9-13 (23 ref.) **(Spa)**

[Successful aging: conceiving the aging process from a more positive perspective] Vellas P. **Salud Publica Mex** 1996 Nov-Dec;38(6):513-22 (Eng. Abstr.) **(Spa)**

[New height and weight standards for the middle aged and aged. Weight increases more than height] Björkelund C, et al. **Lakartidningen** 1997 Jan 29;94(5):332-5 (Eng. Abstr.) **(Swe)**

BLOOD

Age-dependent variation in the serum concentration of mannan-binding protein. Aittoniemi J, et al. **Acta Paediatr** 1996 Aug;85(8):906-9

Age-related changes of serum progastrin-releasing peptide levels during childhood. Adachi N, et al. **Acta Paediatr Jpn** 1997 Jun;39(3):336-8

Age dependence of large neutral amino acid levels in plasma. Focus on Tryptophan. Demling J, et al. **Adv Exp Med Biol** 1996;398:579-82

Seasonal variation in 25-hydroxyvitamin D and parathyroid hormone concentrations in healthy elderly people. Hegarty V, et al. **Age Ageing** 1994 Nov;23(6):478-82

Function of GH/IGF-I axis in aging: multicenter study in 152 healthy elderly subjects with different degrees of physical activity. Italian Association for Research on Brain Aging (AIRIC) Multicenter Study Group. **Aging (Milano)** 1997 Jun;9(3):185-92

Postprandial triglyceride-rich lipoprotein changes in elderly and young subjects. Cassader M, et al. **Aging (Milano)** 1996 Dec;8(6):421-8

Lipoprotein(a) plasma levels and apo(a) isoforms are not associated with longevity or disability in a sample of Italian octo-nonagenarians. Associazione Medica Sabin. Zuliani G, et al. **Aging (Milano)** 1995 Oct;7(5):385-91

Hormone replacement therapy and cobalamin status in elderly women. Carmel R, et al. **Am J Clin Nutr** 1996 Dec; 64(6):856-9

Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Dawson-Hughes B, et al. **Am J Clin Nutr** 1997 Jan; 65(1):67-71

Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Goodman-Gruen D, et al. **Am J Epidemiol** 1997 Jun 1; 145(11):970-6

Plasma renin activity and plasma prorenin are not suppressed in hypertensives surviving to old age. Trenkwalder P, et al. **Am J Hypertens** 1996 Jul;9(7):621-7

Regulation of plasma leptin in mice: influence of age, high-fat diet, and fasting. Ahrén B, et al. **Am J Physiol** 1997 Jul; 273(1 Pt 2):R113-20

Effect of age on blood acid-base composition in adult humans: role of age-related renal functional decline. Frassetto LA, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):F1114-22

Age-related changes in the responsiveness of apolipoprotein A1 to thyroid hormone. Mooradian AD, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1602-7

Aging alters calcium regulation of serum concentration of parathyroid hormone in healthy men. Portale AA, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E139-46

Insulin-stimulated amino acid utilization during glucose and amino acid clamps decreases with development. Wray-Cahen D, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):E305-14

GRO-alpha in human serum: differences related to age and sex. Kanda Y, et al. **Am J Reprod Immunol** 1997 Jul; 38(1):33-8

Temporal variation and factors affecting measurement of canine von Willebrand factor. Moser J, et al. **Am J Vet Res** 1996 Sep;57(9):1288-93

Cross-sectional and longitudinal changes in total and high-density-lipoprotein cholesterol levels over a 20-year period in elderly men: the Honolulu Heart Program. Abbott RD, et al. **Ann Epidemiol** 1997 Aug;7(6):417-24 (32 ref.)

Effects of malnutrition and atherosclerosis on the fatty acid composition of plasma phospholipids in the elderly. Bamberg T, et al. **Ann Nutr Metab** 1997;41(3):166-72

Low-density lipoprotein ability to generate lipoperoxides in healthy subjects: variations according to age. Tronel H, et al. **Ann Nutr Metab** 1997;41(3):160-5

Growth hormone bioactivity and levels of growth hormone, growth hormone-binding protein, insulinlike growth factor I, and insulinlike growth factor-binding proteins in premature and full-term newborns during the first month of life. Radetti G, et al. **Arch Pediatr Adolesc Med** 1997 Feb;151(2):170-5

Calcium ionophore (A23187) differential effect on red cells from pre and postnatal haemopoiesis. Corchs JL, et al. **Arch Physiol Biochem** 1996;104(2):148-51

Properties of low density lipoproteins relevant to oxidative modifications change paradoxically during aging. Stulnig TM, et al. **Atherosclerosis** 1996 Sep 27;126(1):85-94

Lipoprotein(a) and peripheral atherosclerosis in older adults. Sutton-Tyrrell K, et al. **Atherosclerosis** 1996 Apr 26; 122(1):11-9

The role of insulin in age-related sex differences of cardiovascular risk profile and morbidity. Willeit J, et al. **Atherosclerosis** 1997 Apr;130(1-2):183-9

Relationship of blood corticosterone, immunoglobulin and haematological values in young crocodiles (Crocodylus porosus) to water temperature, clutch of origin and body weight. Turton JA, et al. **Aust Vet J** 1997 Feb;75(2):114-9

Selenium and antioxidant vitamin and lipidoperoxidation levels in preaging French population. EVA Study Group. Edude de vieillissement artériel. Coudray C, et al. **Biol Trace Elem Res** 1997 May;57(2):183-90

Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: correlation between lifespan and cycling activity. de Haan G, et al. **Blood** 1997 Mar 1;89(5):1543-50

The effect of age on plasma MEGX concentrations. Orlando R, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):206-8

Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Lowe GD, et al. **Br J Haematol** 1997 Jun;97(4):775-84

Plasma viscosity values and the relationship with age and sex in normal commercial broiler and layer strains of chickens. Robertson GW, et al. **Br Poult Sci** 1996 May; 37(2):309-16

Increase in hydroxy fatty acids in human low density lipoproteins with age. Jira W, et al. **Chem Phys Lipids** 1996 Dec 20;84(2):165-73

Development of cardiovascular risk factors from ages 8 to 18 in Project HeartBeat! Study design and patterns of change in plasma total cholesterol concentration. Labarthe DR, et al. **Circulation** 1997 Jun 17;95(12):2636-42

Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women > or = 55 years of age. Sunayama S, et al. **Circulation** 1996 Sep 15;94(6):1263-8

High homocysteine levels are independently related to isolated systolic hypertension in older adults. Sutton-Tyrrell K, et al. **Circulation** 1997 Sep 16; 96(6):1745-9

Highly sensitive ELISA for soluble Fas in serum: increased soluble Fas in the elderly. Seishima M, et al. **Clin Chem** 1996 Dec;42(12):1911-4

Free triiodothyronine concentration in serum of 1050 euthyroid children is inversely related to their age. Verheecke P. **Clin Chem** 1997 Jun;43(6 Pt 1):963-7

Post-menopausal and chronological age have divergent effects on pituitary and hypothalamic function in episodic gonadotrophin secretion. Lambalk CB, et al. **Clin Endocrinol (Oxf)** 1997 Apr;46(4):439-43

Lymphocyte cAMP and ageing: significance of subset composition, plasma noradrenaline, regular physical training and long-term smoking. Knudsen JH, et al. **Clin Sci (Colch)** 1996 Nov;91(5):621-6

Increased low-density lipoprotein peroxidation in elderly men. Napoli C, et al. **Coron Artery Dis** 1997 Mar-Apr; 8(3-4):129-36

Age related changes in glycated haemoglobin in patients with insulin-dependent diabetes mellitus. Pound N, et al. **Diabet Med** 1996 Jun;13(6):510-3

Management of lipid disorders in the elderly. Playford DA, et al. **Drugs Aging** 1997 Jun;10(6):444-62 (146 ref.)

Incomplete testicular feminization syndrome: studies on androgen receptor(AR) function, AR gene analysis, and aromatase activities at puberty and long-term observations of clinical and hormonal features from infancy to puberty. Isurugi K, et al. **Endocr J** 1996 Oct;43(5):557-64

Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology. Risma KA, et al. **Endocrinology** 1997 Aug;138(8):3540-7

Age and sex related alterations in serum and platelet monoamine oxidase. Veral A, et al. **Eur J Clin Chem Clin Biochem** 1997 Apr;35(4):265-8

Plasma noradrenaline and ageing: effects of smoking habits. Jensen EW, et al. **Eur J Clin Invest** 1996 Oct;26(10):839-46

Diabetes mellitus and subjects' ageing: a study on the ATP content and ATP-related enzyme activities in human erythrocytes. Rabini RA, et al. **Eur J Clin Invest** 1997 Apr; 27(4):327-32

Longitudinal changes in serum lipids of elderly Europeans. SENECA Investigators. Grunenberger F, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S25-31

Changes in the vitamin status of elderly Europeans: plasma vitamins A, E, B-6, B-12, folic acid and carotenoids. SENECA Investigators. Haller J, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S32-46

Cerebrospinal fluid and plasma disposition of yohimbine and 11-hydroxy-yohimbine in young and older healthy subjects, and Alzheimer's disease patients. Le Corre PA, et al. **Eur J Clin Pharmacol** 1997;52(2):135-8

Pulsatile gonadotrophin secretion in hypothyroid women of reproductive age. Tomasi PA, et al. **Eur J Endocrinol** 1997 Apr;136(4):406-9

Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. Valetto MR, et al. **Eur J Endocrinol** 1996 Nov;135(5):568-72

Are different reference intervals for methylmalonic acid and total homocysteine necessary in elderly people? Joosten E, et al. **Eur J Haematol** 1996 Sep;57(3):222-6

(-)-Deprenyl treatment restores serum insulin-like growth factor-I (IGF-I) levels in aged rats to young rat level. De la Cruz CP, et al. **Eur J Pharmacol** 1997 May 30; 327(2-3):215-20

Psychoneuroendocrinological indicators of stress and intellectual performance among older adults: an exploratory study. Kelly KS, et al. **Exp Aging Res** 1996 Oct-Dec;22(4):393-401

Cystine levels, cystine flux, and protein catabolism in cancer cachexia, HIV/SIV infection, and senescence. Hack V, et al. **FASEB J** 1997 Jan;11(1):84-92

Relationships between insulin-like growth hormone factor-I and estradiol in reproductive aging. Blake EJ, et al. **Fertil Steril** 1997 Apr;67(4):697-701

Age-related changes in the peroxyl radical scavenging capacity of human plasma. Aejmelaeus RT, et al. **Free Radic Biol Med** 1997;23(1):69-75

Developmental changes in insulin-like growth factor-I (IGF-I) receptor levels and plasma IGF-I concentrations in large white and Meishan pigs. Louveau I, et al. **Gen Comp Endocrinol** 1996 Oct;104(1):29-36

3,5,3'-L-Triiodo-L-thyronine and L-thyroxine uptake into red blood cells of rainbow trout, Oncorhynchus mykiss. McLeese JM, et al. **Gen Comp Endocrinol** 1996 Apr; 102(1):47-55

Ontogeny of insulin-like growth factors (IGF-I and IGF-II) and IGF-binding proteins in the chicken following hatching. Radecki SV, et al. **Gen Comp Endocrinol** 1997 Jul;107(1):109-17

Effect of aging and sodium deprivation on plasma concentration of aldosterone and on plasma renin activity in the rat. Brudieux R, et al. **Gerontology** 1996;42(4):229-34

Changes in lymphocyte subsets, interleukin 2, and soluble interleukin 2 receptor in old and very old age. Rea IM, et al. **Gerontology** 1996;42(2):69-78

Utility of follicle stimulating hormone (FSH), luteinizing hormone (LH), oestradiol and FSH:LH ratio in predicting reproductive age in normal women. Kim YK, et al. **Hum Reprod** 1997 Jun;12(6):1152-5

Age-related changes of platelet arachidonic acid metabolism in normal subjects [letter] Tomo K, et al. **Int J Hematol** 1997 Aug;66(2):249-51

Laboratory reference values for the 70 year olds. Hammerman-Rozenberg R, et al. **Isr J Med Sci** 1996 Aug; 32(8):611-20

Circadian variation of plasma cobalamin, transcobalamin-bound cobalamin and unsaturated binding capacity of transcobalamin and haptocorrin in healthy elderly. Björkstén KS, et al. **J Affect Disord** 1995 Dec 24; 36(1-2):37-42

Negative relationship between blood concentrations of follicle-stimulating hormone and testicular size in mature boars. Ford JJ, et al. **J Anim Sci** 1997 Mar;75(3):790-5

Effect of selection for lifetime production of lamb weaned on hormonal factors that affect growth in Targhee ewes and lambs. Head WA Jr, et al. **J Anim Sci** 1996 Sep; 74(9):2152-7

Age and breed differences in thyroid hormones, insulin-like growth factor (IGF)-I and IGF binding proteins in female horses. Malinowski K, et al. **J Anim Sci** 1996 Aug; 74(8):1936-42

Vitamin E nutritional status and serum lipid pattern in normal weanling rabbits. Oriani G, et al. **J Anim Sci** 1997 Feb; 75(2):402-8

Fibrinolytic responses to acute physical activity in older hypertensive men. DeSouza CA, et al. **J Appl Physiol** 1997 Jun;82(6):1765-70

The renal clearance of free and conjugated pyridinium cross-links of collagen. Colwell A, et al. **J Bone Miner Res** 1996 Dec;11(12):1976-80

Low thyrotropin levels are not associated with bone loss in older women: a prospective study. Bauer DC, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2931-6

Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels

and anthropometric measures. Benbassat CA, et al. **J Clin Endocrinol Metab** 1997 May;82(5):1484–91

Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. Blum WF, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2904–10

Serum leptin levels in normal children: relationship to age, gender, body mass index, pituitary–gonadal hormones, and pubertal stage. Garcia–Mayor RV, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2849–55

Free insulin–like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. Juul A, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2497–502

Circadian cortisol rhythms in healthy boys and girls: relationship with age, growth, body composition, and pubertal development. Knutsson U, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):536–40

Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. Labrie F, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2396–402

Decline of plasma growth hormone binding protein in old age. Maheshwari H, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):995–7

The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine–metabolic parameters and functional status in the oldest–old. Results from an Italian study on healthy free–living over–ninety–year–olds. Ravaglia G, et al. **J Clin Endocrinol Metab** 1996 Mar; 81(3):1173–8

Epidemiological evidence for the disruption of ionized calcium homeostasis in the elderly. Watson JB, et al. **J Clin Epidemiol** 1997 Jul;50(7):845–9

Peripheral blood leukocyte populations in the elderly with and without periodontal disease. McArthur WP, et al. **J Clin Periodontol** 1996 Sep;23(9):846–52

Age and sex related differences in serum levels of unconjugated dehydroepiandrosterone and its sulphate in normal subjects. Sulcová J, et al. **J Endocrinol** 1997 Jul; 154(1):57–62

Relation between the longitudinal development of lipoprotein levels and biological parameters during adolescence and young adulthood in Amsterdam, The Netherlands. Twisk JW, et al. **J Epidemiol Community Health** 1996 Oct; 50(5):505–11

Is metabolic evidence for vitamin B–12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? Joosten E, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar; 52(2):M76–9

Circulating antioxidants as determinants of the rate of biological aging in pigtailed macaques (Macaca nemestrina). Short R, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):B26–38

Successful 6–month endurance training does not alter insulin–like growth factor–I in healthy older men and women. Vitiello MV, et al. **J Gerontol A Biol Sci Med Sci** 1997 May;52(3):M149–54

Apoprotein E phenotype determines serum cholesterol in infants during both high–cholesterol breast feeding and low–cholesterol formula feeding. Kallio MJ, et al. **J Lipid Res** 1997 Apr;38(4):759–64

Docosahexaenoic acid–rich fish oil does not affect serum lipid concentrations of normolipidemic young adults. Hamazaki T, et al. **J Nutr** 1996 Nov;126(11):2784–9

Developmental changes of tetrahydrobiopterin in rat and human erythrocytes. Azumagawa K, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Dec;41(6):607–17

5–Methoxytryptophol and melatonin in children: differences due to age and sex. Molina–Carballo A, et al. **J Pineal Res** 1996 Sep;21(2):73–9

Reference values for the trace elements copper, manganese, selenium, and zinc in the serum/plasma of children, adolescents, and adults. Rükgauer M, et al. **J Trace Elem Med Biol** 1997 Jun;11(2):92–8

Statistical review and analysis of the relationship between serum prostate specific antigen and age. Kirollos MM. **J Urol** 1997 Jul;158(1):143–5 (13 ref.)

Environmental, age, and sex effects on cotton rat (Sigmodon hispidus) hematology. Robel GL, et al. **J Wildl Dis** 1996 Apr;32(2):390–4

Reproductive performance and changes in blood lipids in breeding females and in growing Watanabe heritable hyperlipidaemic and New Zealand White rabbits. Mortensen A, et al. **Lab Anim** 1996 Jul;30(3):252–9

Effect of lithium on superoxide production and intracellular free calcium mobilization in elastin peptide (kappa–elastin) and FMLP stimulated human PMNS. Effect of age. Fülöp T Jr, et al. **Life Sci** 1997;60(22):PL 325–32

Glucocorticoid receptors in human peripheral blood mononuclear cells in relation to age and to sport activity. Grasso G, et al. **Life Sci** 1997;61(3):301–8

Blood cholinesterase levels in the elderly and newborn. Chan L. **Malays J Pathol** 1995 Dec;17(2):87–9

Difference of LH and FSH secretory characteristics and degree of concordance between postmenopausal and aging women. Genazzani AD, et al. **Maturitas** 1997 Mar; 26(2):133–8

Influence of the age and sex on respiratory burst of human monocytes. Alvarez E, et al. **Mech Ageing Dev** 1996 Sep 18;90(2):157–61

Age– and strain–related changes in tissue transglutaminase activity in murine macrophages: the effects of inflammation and induction by retinol. Lavie L, et al. **Mech Ageing Dev** 1996 Sep 18;90(2):129–43

Food restriction increases the protection of erythrocytes against the hemolysis induced by peroxyl radicals. Pieri C, et al. **Mech Ageing Dev** 1996 May 24;87(1):15–23

The effect of donor age on human erythrocyte density distribution. Pinkofsky HB. **Mech Ageing Dev** 1997 Jul; 97(1):73–9

Age–related tyrosine–specific protein phosphorylation defect in human T lymphocytes activated through CD3, CD4, CD8 or the IL–2 receptor. Quadri RA, et al. **Mech Ageing Dev** 1996 Jul 17;88(3):125–38

Effects of aging on dehydroepiandrosterone sulfate in relation to fasting insulin levels and body composition assessed by bioimpedance analysis. Denti L, et al. **Metabolism** 1997 Jul; 46(7):826–32

Sialic acid, diabetes, and aging: a study on the erythrocyte membrane. Mazzanti L, et al. **Metabolism** 1997 Jan; 46(1):59–61

Exercise increases serum testosterone and sex hormone–binding globulin levels in older men. Zmuda JM, et al. **Metabolism** 1996 Aug;45(8):935–9

Elevated prostate–specific antigen levels in black men and white men. Sawyer R, et al. **Mod Pathol** 1996 Nov; 9(11):1029–32

Lymphocyte content of amyloid precursor protein is increased in Down's syndrome and aging. Pallister C, et al. **Neurobiol Aging** 1997 Jan–Feb;18(1):97–103

Acute phase response and plasma carotenoid concentrations in older women: findings from the nun study. Boosalis MG, et al. **Nutrition** 1996 Jul–Aug;12(7–8):475–8

Antioxidants in healthy elderly Parisians [editorial; comment] Thurnham DI. **Nutrition** 1997 Apr;13(4):377–8. Comment on: Nutrition 1997 Apr;13(4):319–26.

Effect of tactile stimulation on serum lactate in the newborn rat. Alasmi MM, et al. **Pediatr Res** 1997 Jun;41(6):857–61

Plasma somatostatin and cholecystokinin levels in preterm infants during their first two years of life. Törnhage CJ, et al. **Pediatr Res** 1997 Jun;41(6):902–8

The ratio of amount of haemoglobin to total surface area of erythrocytes in birds in relation to body mass, age of nestlings, and season of the year. Kostelecka–Myrcha A. **Physiol Zool** 1997 May–Jun;70(3):278–82

Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin–like growth factor 1 to growth hormone. Morley JE, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8; 94(14):7537–42

The influence of aging on the plasma concentration and renal clearance of homovanillic acid. Lambert GW, et al. **Psychoneuroendocrinology** 1994;19(1):33–41

Influence of age of the donor sheep on the phagocytosis of Staphylococcus aureus subspecies anaerobius and S aureus by neutrophils. Quiteria JA, et al. **Res Vet Sci** 1996 Nov; 61(3):231–3

Contribution to the study of the multidimensional variational network of the human gerontogenesis. Acălugăriţei G, et al. **Rom J Physiol** 1995 Jan–Dec;32(1–4):119–24

Variation of correlation coefficient among aging and certain biological variables in man. Galaftion S, et al. **Rom J Physiol** 1995 Jan–Dec;32(1–4):111–7

The influence of age on the thermal transition of serum albumine in rats. Petec G, et al. **Rom J Physiol** 1995 Jan–Dec;32(1–4):107–10

Age–specific reference values for serum prostate–specific antigen in a community–based population of healthy Swedish men. Löfman O, et al. **Scand J Clin Lab Invest** 1997 May;57(3):225–32

Serum copper in institutionalized elderly subjects: relations with dietary intake of energy, specific nutrients and haematological parameters. Gámez C, et al. **Sci Total Environ** 1997 Aug 1;201(1):31–8

The effects of age and menopause on erythrocyte aggregation [letter] Demiroğlu H, et al. **Thromb Haemost** 1997 Feb; 77(2):404

Parameters of haemostasis in the elderly people. Sushko EA. **Ukr Biokhim Zh** 1996 Jul–Aug;68(4):21

Age–specific reference ranges for serum prostate–specific antigen. Richardson TD, et al. **Urol Clin North Am** 1997 May;24(2):339–51

The effects of age and reproductive status on serum and blood parameters in merino breed sheep. Alonso AJ, et al. **Zentralbl Veterinarmed A** 1997 Jun;44(4):223–31

Serum protein electrophoresis: potential test for use in geriatric companion animal health programmes. Batamuzi EK, et al. **Zentralbl Veterinarmed A** 1996 Oct;43(8):501–8

[Variations in reference biological parameters with age] Delwaide PA. **Rev Med Liege** 1997 Apr;52(4):197–200 (15 ref.) **(Fre)**

[Course of blood levels of calcium, inorganic phosphate, alkaline phosphatase, parathyroid hormone and calcidiol (25–OH–D3) in one and two year old thoroughbred horses] Enbergs H, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Dec;103(12):491–3 (Eng. Abstr.) **(Ger)**

[The effect of the albumin concentration on the relation between the concentration of ionized calcium and total calcium in the blood of dogs] Mischke R, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jun;103(6):199–204 (Eng. Abstr.) **(Ger)**

[Examination of the total protein concentration and gamma–glutamyltransferase (gamma–GT) in calves during the first 14 days of life and their significance for predictions of health status in the first two postnatal weeks] Steffen S, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug; 104(8):272–6 (Eng. Abstr.) **(Ger)**

[Hemoglobin derivatives in blood of cattle during during winter housing. Effect of age as well as developmental and functional conditions] Steinhardt M, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Mar;104(3):99–103 (Eng. Abstr.) **(Ger)**

[Lipoprotein(a) and plasma lipids in 429 elderly and very old subjects: significance as risk factor, effect of nutrition and life style] Heinimann K, et al. **Schweiz Med Wochenschr** 1996 Aug 31;126(35):1487 (Eng. Abstr.) **(Ger)**

[Age–dependence of laboratory values in dogs and cats. III. Bilirubin, creatinine and proteins in serum] Kraft W, et al. **Tierarztl Prax** 1996 Dec;24(6):610–5 (Eng. Abstr.) **(Ger)**

[Measurement of selected enzymes in blood plasma of cats in the first six months of life] Mähler M, et al. **Tierarztl Prax** 1996 Aug;24(4):406–10 (Eng. Abstr.) **(Ger)**

[Reference ranges in geriatrics: a review of age–dependence of selected blood components] Harm K. **Z Gerontol Geriatr** 1997 May–Jun;30(3):185–92 (25 ref.) (Eng. Abstr.) **(Ger)**

[The epidemiological aspects of cholesterol in some chronological age classes. 1] Zardi O, et al. **Riv Med Aeronaut Spaz** 1975 Apr–Sep;38(2–3):247–79 (147 ref.) (Eng. Abstr.) **(Ita)**

[Changes in the level of thrombomodulin with aging] Komatsumoto S, et al. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):512–7 (Eng. Abstr.) **(Jpn)**

[Age–related changes in concentrations of ferritin, glyeosylated ferritin, and non–glycosylated ferritin] Yamashita N, et al. **Nippon Ronen Igakkai Zasshi** 1996 Oct; 33(10):754–60 (Eng. Abstr.) **(Jpn)**

[Serum lipids in persons over 90 years of age] Potocka–Plazak K, et al. **Przegl Lek** 1996;53(9):680–2 (Eng. Abstr.) **(Pol)**

[Age–related dynamics of the blood clinical picture and acid hemolysis according to data of automated rapid–analysis in Kemerovo] Ivanov VI, et al. **Fiziol Cheloveka** 1996 Nov–Dec;22(6):76–81 **(Rus)**

[The effect of age, sex and prenatal exposure to glucocorticoids on the corticosterone level of the blood in rats] Dygalo NN, et al. **Fiziol Zh Im I M Sechenova** 1995 Oct;81(10):83–8 (Eng. Abstr.) **(Rus)**

[Lipid metabolism, iron metabolic indices and the rates of aging in welders with occupational diseases of the respiratory organs] Kucheruk TK, et al. **Lik Sprava** 1995 Mar–Apr;(3–4):135–8 (Eng. Abstr.) **(Rus)**

[Lymphogranulomatosis: a systems analysis of the age– and sex–related characteristics of hemopoiesis and metabolism] Genkin AA, et al. **Ter Arkh** 1997;69(2):37–45 (Eng. Abstr.) **(Rus)**

[The aggregation indices in the bulbar vessels of persons of different ages] Polunin GS, et al. **Vestn Oftalmol** 1996 Apr–Jun;112(2):43–5 (Eng. Abstr.) **(Rus)**

[The early diagnosis of prostate cancer in a selected population. The usefulness of PSAD, PSAD ad. and age–adjusted PSA in patients with a PSA between 4–10 ngr./ml.] Allepuz Losa CA, et al. **Actas Urol Esp** 1997 Apr;21(4):344–53 (Eng. Abstr.) **(Spa)**

[The age–related changes in the antioxidant system enzymes of the erythroid cells of swine at the early stages of postnatal development] Snityns'kyi VV, et al. **Fiziol Zh** 1996;42(5–6):19–2[illegible] (Eng. Abstr.) **(Ukr)**

[The level of gastrin, insulin and glucagon in the blood and the morphometric characteristics of the gastric mucosa in peptic ulcer patients of different ages] Haidychuk VS, et al. **Lik Sprava** 1996 Oct–Dec;(10–12):80–4 (Eng. Abstr.) **(Ukr)**

CEREBROSPINAL FLUID

Cerebrospinal fluid and plasma disposition of yohimbine and 11–hydroxy–yohimbine in young and older healthy subjects, and Alzheimer's disease patients. Le Corre PA, et al. **Eur J Clin Pharmacol** 1997;52(2):135–8

Somatostatin–like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease––effect of L–Dopa. Strittmatter M, et al. **J Neural Transm Gen Sect** 1996;103(5):591–602

Aging and superoxide dismutase activity in cerebrospinal fluid. Okabe T, et al. **J Neurol Sci** 1996 Sep 15; 141(1–2):100–4

Metabolism of dynorphin A1–13 in human CSF. Müller S, et al. **Neurochem Res** 1996 Oct;21(10):1213–9

DRUG EFFECTS

Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6–hydroxydopamine–induced neurotoxicity. Salonen T, et al. **Acta Neuropathol (Berl)** 1996;91(5):466–74

Vitamins and analgesics in the prevention of collagen ageing. Malik NS, et al. **Age Ageing** 1996 Jul;25(4):279–84

Inotropic agents in older patients with chronic heart failure––current perspectives. Carbonin PU, et al. **Aging (Milano)** 1996 Apr;8(2):90–8 (74 ref.)

Sex- and age-related antihypertensive effects of amlodipine [letter; comment] Spratt KA. **Am J Cardiol** 1997 Mar 15; 79(6):843-4. Comment on: Am J Cardiol 1996 Apr 1;77(9):713-22.

Effects of chronic administration of cytidine-5'-diphosphate choline (CDP choline) on the aged female mouse Harderian gland. Verduga R, et al. **Anat Embryol (Berl)** 1997 Feb; 195(2):209-14

GM1 ganglioside improves spatial learning and memory of aged rats. Fong TG, et al. **Behav Brain Res** 1997 May; 85(2):203-11

Effects of clozapine and haloperidol on baseline levels of vacuous jaw movements in aged rats. Steinpreis RE, et al. **Behav Brain Res** 1997 Jul;86(2):165-9

Effect of "beta CATECHIN" on the life span of senescence accelerated mice (SAM-P8 strain). Kumari MV, et al. **Biochem Mol Biol Int** 1997 Apr;41(5):1005-11

Increased longevity of kinetin-fed Zaprionus fruitflies is accompanied by their reduced fecundity and enhanced catalase activity. Sharma SP, et al. **Biochem Mol Biol Int** 1997 Apr;41(5):869-75

Effects of intraseptal injection of 192-IgG-saporin in mature and aged Long-Evans rats. Bannon AW, et al. **Brain Res** 1996 Apr 29;718(1-2):25-36

Alterations in opiate receptor binding in the hippocampus of aged Long-Evans rats. Nagahara AH, et al. **Brain Res** 1996 Jan 22;707(1):22-30

Effects of nicergoline on age-related decrements in radial maze performance and acetylcholine levels. McArthur RA, et al. **Brain Res Bull** 1997;43(3):305-11

Alterations in the estrogen sensitivity of hypothalamic proenkephalin mRNA expression with age and prenatal exposure to alcohol. Li Y, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1-2):215-22

Effects of oestrogen and progesterone on age-related changes in arteries of postmenopausal women. Liang YL, et al. **Clin Exp Pharmacol Physiol** 1997 Jun;24(6):457-9

Anti-ageing effect of aged garlic extract in the inbred brain atrophy mouse model. Moriguchi T, et al. **Clin Exp Pharmacol Physiol** 1997 Mar-Apr;24(3-4):235-42

Lack of effect of age on the cardiovascular response to neuropeptide Y injection in the rat nucleus tractus solitarius. Morris MJ, et al. **Clin Exp Pharmacol Physiol** 1997 Feb;24(2):162-5

Opioid analgesic drugs in the elderly. Forman WB. **Clin Geriatr Med** 1996 Aug;12(3):489-500 (44 ref.)

Age-dependent differences in the rat's conditioned defensive burying behavior: effect of 5-HT1A compounds. Lopez-Rubalcava C, et al. **Dev Psychobiol** 1996 Mar; 29(2):157-69

A kinematic comparison of L-DOPA-induced air-stepping and swimming in developing rats. McEwen ML, et al. **Dev Psychobiol** 1997 May;30(4):313-27

Sensitivity to the motoric effects of a dopamine receptor antagonist differs as a function of age at the time of dopamine depletion. Sandstrom MI, et al. **Dev Psychobiol** 1997 May;30(4):293-300

Visual attention in infant monkeys: effects of dietary fatty acids and age. Reisbick S, et al. **Dev Psychol** 1997 May; 33(3):387-95

Can estrogens prevent neurodegeneration? Schneider LS, et al. **Drugs Aging** 1997 Aug;11(2):87-95 (65 ref.)

The synergism between ACPD and arachidonic acid on glutamate release in hippocampus is age-dependent. McGahon B, et al. **Eur J Pharmacol** 1996 Aug 15; 309(3):323-6

Itasetron (DAU 6215) prevents age-related memory deficits in the rat in a multiple choice avoidance task. Pitsikas N, et al. **Eur J Pharmacol** 1996 Sep 12;311(2-3):115-9

Herbal medicine and the study of aging in senescence-accelerated mice (SAMP1TA/Ngs). Kishikawa M, et al. **Exp Gerontol** 1997 Jan-Apr;32(1-2):229-42

Beneficial effects of aged garlic extract on learning and memory impairment in the senescence-accelerated mouse. Nishiyama N, et al. **Exp Gerontol** 1997 Jan-Apr; 32(1-2):149-60

Myocardium-protective effects of Ginkgo biloba extract (EGb 761) in old rats against acute isobaric hypoxia. An electron microscopic morphometric study. I. Protection of cardiomyocytes. Fitzl G, et al. **Exp Toxicol Pathol** 1996 Jan;48(1):33-9

Myocardium-protective effects of Ginkgo biloba extract (EGb 761) in old rats against acute isobaric hypoxia. An electron microscopic morphometric study. II. Protection of microvascular endothelium. Welt K, et al. **Exp Toxicol Pathol** 1996 Jan;48(1):81-6

Super hype for super hormones [editorial] Butler RN. **Geriatrics** 1997 Feb;52(2):13-4

Effect of vitamin E on life span, malondialdehyde content and antioxidant enzymes in aging Zaprionus paravittiger. Kakkar R, et al. **Gerontology** 1996;42(6):312-21

The role of coenzyme Q-10 in aging: a follow-up study on life-long oral supplementation Q-10 in rats. Lönnrot K, et al. **Gerontology** 1995;41 Suppl 2:109-20

In vivo anti-influenza virus activity of Kampo (Japanese herbal) medicine "Sho-seiryu-to"--effects on aged mice, against subtypes of a viruses and B virus, and therapeutic effect. Nagai T, et al. **Immunopharmacol Immunotoxicol** 1996 May;18(2):193-208

Retardation of the age-related increase in spontaneous cortical spike-wave discharges (SWD) in rats after a 28-day inhalation (SWD) in rats after a 28-day inhalation exposure to an industrial solvent, pseudocumene (1,2,4-trimethylbenzene). Gralewicz S, et al. **Int J Occup Med Environ Health** 1997;10(2):213-22

Effects of vitamin E on the blastogenic response of splenocytes and lipofuscin contents in the hearts and brains of aged mice. Ma XY, et al. **J Environ Pathol Toxicol Oncol** 1996;15(1):51-3

L-deprenyl treatment in aged mice slightly increases life spans, and greatly reduces fecundity by aged males. Archer JR, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov; 51(6):B448-53

Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects. Bertz RJ, et al. **J Pharmacol Exp Ther** 1997 Jun; 281(3):1317-29

Recombinant human growth hormone in children with chronic renal insufficiency--clinical update: 1995. Fine RN. **Kidney Int Suppl** 1996 Jan;53:S115-8 (22 ref.)

Long-term melatonin supplementation does not recover the impairment of natural killer cell activity and lymphocyte proliferation in aging mice. Provinciali M, et al. **Life Sci** 1997;61(9):857-64

The use of anti-aging hormones. Melatonin, growth hormone, testosterone, and dehydroepiandrosterone: consumer enthusiasm for unproven therapies. Shomali ME. **Md Med J** 1997 Apr;46(4):181-6 (45 ref.)

Termination by early deletion of V beta 8 + T cells of aged mice in response to staphylococcal enterotoxin B. Hosono M, et al. **Mech Ageing Dev** 1996 Jun 7;87(2):99-114

Geroprotector efficiency depends on viability of control population: life span investigation in D. melanogaster. Izmaylov DM, et al. **Mech Ageing Dev** 1996 Nov 13; 91(3):155-64

The aging retarding effect of 'Long-Life CiLi'. Ma YX, et al. **Mech Ageing Dev** 1997 Jun;96(1-3):171-80

Effect of melatonin and pineal grafting on thymocyte apoptosis in aging mice. Provinciali M, et al. **Mech Ageing Dev** 1996 Sep 9;90(1):1-19

Effect of 1,25-dihydroxyvitamin D3 on proliferation in senescent IMR-90 human fibroblasts. Stio M, et al. **Mech Ageing Dev** 1996 Oct 4;91(1):23-36

"Grow dumb along with me". Misuse of DHEA (dehydroepiandrosterone). Mack RB. **N C Med J** 1997 Mar-Apr;58(2):144-6

Effect of glucose and peripheral glucose regulation on memory in the elderly. Messier C, et al. **Neurobiol Aging** 1997 May-Jun;18(3):297-304

Interleukin-1 beta inhibits glutamate release in hippocampus of young, but not aged, rats. Murray CA, et al. **Neurobiol Aging** 1997 May-Jun;18(3):343-8

Effect of ganglioside (GM1) on memory in senescent rats. Silva RH, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):583-6

Estrogen increases GAP-43 (neuromodulin) mRNA in the preoptic area of aged rats. Singer CA, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):661-3

Age-related decreases in mRNA for brain nuclear receptors and target genes are reversed by retinoic acid treatment. Enderlin V, et al. **Neurosci Lett** 1997 Jun 27;229(2):125-9

The histamine H1-antagonist chlorpheniramine facilitates learning in aged rats. Frisch C, et al. **Neurosci Lett** 1997 Jun 27;229(2):89-92

Antioxidant treatment with phenyl-alpha-tert-butyl nitrone (PBN) improves the cognitive performance and survival of aging rats. Sack CA, et al. **Neurosci Lett** 1996 Mar 1; 205(3):181-4

Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats. Vannucchi MG, et al. **Neuroscience** 1997 Aug;79(3):837-46

Melatonin: media hype or therapeutic breakthrough? Kendler BS. **Nurse Pract** 1997 Feb;22(2):66-7, 71-2, 77 (75 ref.)

Vestibular compensation in aged rats with unilateral labyrinthectomy treated with dopaminergic drugs. Drago F, et al. **Pharmacol Res** 1996 Feb;33(2):135-40

A review of phosphatidylserine pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing brain? Pepeu G, et al. **Pharmacol Res** 1996 Feb;33(2):73-80 (71 ref.)

The effects of L-deprenyl on spatial short term memory in young and aged dogs. Head E, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Apr; 20(3):515-30

Effect of L-alpha glycerylphosphorylcholine on muscarinic receptors and membrane microviscosity of aged rat brain. Muccioli G, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Feb; 20(2):323-39

Effects of stimulation of alpha 1-adrenergic and NMDA/glycine-B receptors on learning defects in aged rats. Riekkinen M, et al. **Psychopharmacology (Berl)** 1997 May;131(1):49-56

Chronic nimodipine and acute metrifonate treatment decreases age-related cortical high voltage spindles in rats. Riekkinen P Jr, et al. **Psychopharmacology (Berl)** 1997 Jan; 129(1):91-5

Age-related decline in central cholinergic function demonstrated with scopolamine. Tariot PN, et al. **Psychopharmacology (Berl)** 1996 May;125(1):50-6

Comparative evaluation of ultrastructural changes in articular cartilage of ofloxacin-treated and magnesium-deficient immature rats. Shakibaei M, et al. **Toxicol Pathol** 1996 Sep-Oct;24(5):580-7

[Review on the research of reinforcing body resistance and removing stasis compound kangshou yin in postponing senility] Li SC, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Apr; 16(4):244-5 **(Chi)**

[Clinical study on anti-senility effect of kuangquan 851 oral liquor type R and type Y] Lin QC, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Mar; 16(3):149-52 (Eng. Abstr.) **(Chi)**

[Juvenile hormones, reality or myth?] Vermeulen A. **Verh K Acad Geneeskd Belg** 1997;59(1):19-33 (Eng. Abstr.) **(Dut)**

[Aging of the vitreous body. Role of glycation and free radicals] Deguine V, et al. **Pathol Biol (Paris)** 1997 Apr; 45(4):321-30 (69 ref.) (Eng. Abstr.) **(Fre)**

[Calcitonin and bone aging] Reginster JY. **Pathol Biol (Paris)** 1997 Jan;45(1):52-6 (37 ref.) (Eng. Abstr.) **(Fre)**

["Strengthening injections"] Mitznegg P. **Dtsch Med Wochenschr** 1996 Oct 4;121(40):1243 **(Ger)**

[Clinical value of dehydroepiandrosterone and its sulfate ester] Fehér T. **Orv Hetil** 1996 Sep 15;137(37):2029-34 (Eng. Abstr.) **(Hun)**

[The effect of polymeric materials on the animal organism in ontogeny] Aksenova LP, et al. **Gig Sanit** 1997 Mar-Apr; (2):41-3 **(Rus)**

[The late sequelae of exposure to solvents (the gonadotropic, embryotropic, mutagenic and gerontogenic actions)] Sanotskiĭ IV. **Med Tr Prom Ekol** 1997;(3):17-20 (Eng. Abstr.) **(Rus)**

[Age-related changes in the effect of catecholamines on spontaneous periodic motor activity in rat pups] Bursian AV. **Zh Evol Biokhim Fiziol** 1996 May-Jun;32(3):292-301 (38 ref.) (Eng. Abstr.) **(Rus)**

[The effect of olivomycin on the spontaneous regression of experimental atherosclerosis in rabbits of different ages] Frol'kis VV, et al. **Fiziol Zh** 1997;43(3-4):3-10 (Eng. Abstr.) **(Ukr)**

ETHNOLOGY

Ageing in black and ethnic minorities: a challenge to service provision. Askham J. **Br J Hosp Med** 1996 Dec 11-1997 Jan 14;56(11):602-4 (14 ref.)

Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. Han ZH, et al. **J Bone Miner Res** 1997 Apr; 12(4):498-508

Odds ratios for different types of age-related cataract: ethnicity and environment. Pierscionek BK, et al. **Ophthalmic Res** 1996;28(2):88-92

Dementia in old age: an anthropological perspective. Pollitt PA. **Psychol Med** 1996 Sep;26(5):1061-74 (127 ref.)

GENETICS

Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males: a longitudinal analysis. Jarvik GP, et al. **Am J Hum Genet** 1997 Jul;61(1):171-81

The age dependency of gene expression for plasma lipids, lipoproteins, and apolipoproteins. Snieder H, et al. **Am J Hum Genet** 1997 Mar;60(3):638-50

Analysis of loss of inactive X chromosomes in interphase cells. Surrallés J, et al. **Am J Hum Genet** 1996 Nov; 59(5):1091-6

Increased low-level chromosome 21 mosaicism in older individuals with Down syndrome. Jenkins EC, et al. **Am J Med Genet** 1997 Jan 20;68(2):147-51

Age-related 4,977 bp deletion in human lung mitochondrial DNA. Fahn HJ, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):1141-5

Genetic variation and aging. Curtsinger JW, et al. **Annu Rev Genet** 1995;29:553-75 (156 ref.)

D2 dopamine receptor A1 allele in Alzheimer disease and aging. Small GW, et al. **Arch Neurol** 1997 Mar;54(3):281-5

Alterations in acetylcholine, NMDA, benzodiazepine receptors and protein kinase C in the brain of the senescence-accelerated mouse: an animal model useful for studies on cognitive enhancers. Nomura Y, et al. **Behav Brain Res** 1997 Feb;83(1-2):51-5

Age changes in the causes of individual differences in conservatism. Eaves L, et al. **Behav Genet** 1997 Mar; 27(2):121-4

Varied prevalence of age-associated mitochondrial DNA deletions in different species and tissues: a comparison between human and rat. Zhang C, et al. **Biochem Biophys Res Commun** 1997 Jan 23;230(3):630-5

Age-related analysis of EcoRI generated satellite DNA-containing chromatin of rat liver. Chaurasia P, et al. **Biochem Mol Biol Int** 1996 Dec;40(6):1261-70

Somatic mutations and aging: cause or effect? Barnett YA. **Biochem Soc Trans** 1997 Feb;25(1):332-5 (36 ref.)

Invertebrate gerontology: the age mutations of Caenorhabditis elegans. Lithgow GJ. **Bioessays** 1996 Oct; 18(10):809-15 (71 ref.)

Aging mechanisms in fruit files. Tower J. **Bioessays** 1996 Oct;18(10):799-807 (70 ref.)

Age associated changes in the distribution of lpr gene-induced B220-positive T cells in lymphoid organs of MRL/Mp-lpr/lpr mice using dual exposure microphotographs of double immunofluorescence staining. Usui T, et al. **Biotech Histochem** 1996 Jul;71(4):182-9

How can we live forever? [editorial] Kirkwood T. **BMJ** 1996

Dec 21–28;313(7072):1571

Age-dependent spatial memory deficits in transgenic mice expressing the human mid-sized neurofilament gene: I. Haroutunian V, et al. **Brain Res Mol Brain Res** 1996 Nov; 42(1):62–70

Age-related increase of baseline frequencies of sister chromatid exchanges, chromosome aberrations, and micronuclei in human lymphocytes. Bolognesi C, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Apr;6(4):249–56 (112 ref.)

Impaired induction of c-fos/c-jun genes and of transcriptional regulatory proteins binding distinct c-fos/c-jun promoter elements in activated human T cells during aging. Whisler RL, et al. **Cell Immunol** 1997 Jan 10;175(1):41–50

Extreme intrauterine growth retardation, hydrocephalus and aged facial appearance: a previously unrecognized autosomal recessive disorder? Winter RM, et al. **Clin Dysmorphol** 1996 Oct;5(4):313–9

Molecular interactions of aging and cancer. Lee SW, et al. **Clin Geriatr Med** 1997 Feb;13(1):69–77 (64 ref.)

Evolution of senescence: Alzheimer's disease and evolution. Charlesworth B. **Curr Biol** 1996 Jan 1;6(1):20–2 (14 ref.)

Contribution of various classes of defective mitochondrial DNA molecules to senescence in Podospora anserina. Jamet-Vierny C, et al. **Curr Genet** 1997 Feb;31(2):171–8

Genetic analysis of mechanisms of aging. Rose MR, et al. **Curr Opin Genet Dev** 1996 Jun;6(3):366–70 (51 ref.)

A longitudinal study of human age-related chromosomal analysis in skin fibroblasts. Mukherjee AB, et al. **Exp Cell Res** 1997 Aug 25;235(1):161–9

Issues in the choice of genetic configuration for animal aging models. Austad SN. **Exp Gerontol** 1997 Jan-Apr; 32(1–2):55–63 (25 ref.)

Selection for maximum longevity in mice. Harrison DE, et al. **Exp Gerontol** 1997 Jan-Apr;32(1–2):65–78 (52 ref.)

Genetic characterization of senescence-accelerated mouse (SAM). Higuchi K. **Exp Gerontol** 1997 Jan-Apr; 32(1–2):129–38 (39 ref.)

Management and design of the maintenance of SAM mouse strains: an animal model for accelerated senescence and age-associated disorders. Hosokawa M, et al. **Exp Gerontol** 1997 Jan-Apr;32(1–2):111–6 (12 ref.)

Genetic influences on aging. Johnson TE. **Exp Gerontol** 1997 Jan-Apr;32(1–2):11–22 (83 ref.)

Prospects for quantitative trait locus methodology in gerontology. McClearn GE. **Exp Gerontol** 1997 Jan-Apr; 32(1–2):49–54 (14 ref.)

Mouse and rat genotype choices. Sprott RL. **Exp Gerontol** 1997 Jan-Apr;32(1–2):79–86 (15 ref.)

Senescence-accelerated mouse (SAM): a novel murine model of senescence. Takeda T, et al. **Exp Gerontol** 1997 Jan-Apr; 32(1–2):105–9 (17 ref.)

Aging processes, DNA damage, and repair. Gilchrest BA, et al. **FASEB J** 1997 Apr;11(5):322–30 (95 ref.)

Age-associated alterations of the mitochondrial genome. Lee CM, et al. **Free Radic Biol Med** 1997;22(7):1259–69 (118 ref.)

Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels. Georges JL, et al. **Genet Epidemiol** 1996;13(2):179–92

Role of transposable elements in age-related genomic instability. Nikitin AG, et al. **Genet Res** 1997 Jun; 69(3):183–95 (173 ref.)

Age-specific patterns of genetic variance in Drosophila melanogaster. I. Mortality. Promislow DE, et al. **Genetics** 1996 Jun;143(2):839–48

Sex and death in the mouse: genetically delayed reproduction and senescence. Biddle FG, et al. **Genome** 1997 Apr; 40(2):229–35

Reduction of the activity of ribosomal genes with age in Down's syndrome. Borsatto B, et al. **Gerontology** 1996; 42(3):147–54

HLA phenotypes in healthy aged subjects. Papasteriades C, et al. **Gerontology** 1997;43(3):176–81

Insulin exposure and aging theory. Parr T. **Gerontology** 1997; 43(3):182–200 (165 ref.)

Expression of the APP gene family in brain cells, brain development and aging. Sandbrink R, et al. **Gerontology** 1997;43(1–2):119–31

Changes in the expression of genes involved in protein synthesis during Drosophila aging. Shikama N, et al. **Gerontology** 1996;42(3):123–36

The genetics of aging. Martin GM. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):47–50, 55–6, 59–61 passim (8 ref.)

Population-based, genetically informative sample for studies of physical frailty and aging: black elderly twin study. Miles TP. **Hum Biol** 1997 Feb;69(1):107–20

Reflections on telomeres, growth, aging, and essential hypertension. Aviv A, et al. **Hypertension** 1997 May; 29(5):1067–72 (69 ref.)

Analysis of quantitative trait loci for blood pressure on rat chromosomes 2 and 13. Age-related differences in effect. Samani NJ, et al. **Hypertension** 1996 Dec;28(6):1118–22

Telomere (telomerase) hypothesis of aging and immortalization. Rao KS. **Indian J Biochem Biophys** 1996 Apr;33(2):88–92 (47 ref.)

5-methylcytosine is present in the 5' flanking region of Ha-ras in mouse liver and increases with ageing. Counts JL, et al. **Int J Cancer** 1997 Jul 29;72(3):491–7

Old dog, new tricks? [editorial; comment] Miles TP. **J Am Geriatr Soc** 1996 Oct;44(10):1261–2. Comment on: J Am Geriatr Soc 1996 Oct;44(10):1242–50.

Systematic error in genetic evaluation of miles city line 1 hereford cattle resulting from preadjustment for age of dam. MacNeil MD, et al. **J Anim Sci** 1996 Aug; 74(8):1794–800

Estimation of direct and maternal breed effects for prediction of expected progeny differences for birth and weaning weights in three multibreed populations. Rodríguez-Almeida FA, et al. **J Anim Sci** 1997 May; 75(5):1203–12

Direct and maternal genetic covariances by age of dam for weaning weight. Van Vleck LD, et al. **J Anim Sci** 1996 Aug;74(8):1801–5

Change in the expression of hypopharyngeal-gland proteins of the worker honeybees (Apis mellifera L.) with age and/or role. Kubo T, et al. **J Biochem (Tokyo)** 1996 Feb; 119(2):291–5

Characterization of the 1B promoter of fibroblast growth factor 1 and its expression in the adult and developing mouse brain. Alam KY, et al. **J Biol Chem** 1996 Nov 22; 271(47):30263–71

Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis [see comments] Cooper GS, et al. **J Bone Miner Res** 1996 Dec;11(12):1841–9. Comment in: J Bone Miner Res 1996 Dec;11(12):1835–40.

Regional and age-related differences in mRNA composition of intracellular Ca(2+)-release channels of rat cardiac myocytes. Gorza L, et al. **J Mol Cell Cardiol** 1997 Mar; 29(3):1023–36

Identification of a rat brain gene associated with aging by PCR differential display method. Wu HC, et al. **J Mol Neurosci** 1997 Feb;8(1):13–8

Mutation, ageing, and ovarian cancer [letter] Pieretti M, et al. **Lancet** 1997 Mar 8;349(9053):700–1

Nucleosomal organization of the rat liver satellite DNA-containing chromatin during aging. Chaurasia P, et al. **Mech Ageing Dev** 1997 Apr;95(1–2):63–70

There is substantial agreement among interspecies estimates of DNA repair activity. Cortopassi GA, et al. **Mech Ageing Dev** 1996 Nov 13;91(3):211–8

Genetic control of immune responsiveness, aging and tumor incidence. Doria G, et al. **Mech Ageing Dev** 1997 Jun; 96(1–3):1–13 (50 ref.)

Mitochondrial electron transport chain activities and DNA deletions in regions of the rat brain. Filburn CR, et al. **Mech Ageing Dev** 1996 May 24;87(1):35–46

Gene regulation of senescence marker protein-30 (SMP30): coordinated up-regulation with tissue maturation and gradual down-regulation with aging. Fujita T, et al. **Mech Ageing Dev** 1996 Jun 25;87(3):219–29

Telomere shortening, ageing, and chromosome damage. Kormann-Bortolotto MH, et al. **Mech Ageing Dev** 1996 Jul 31;89(1):45–9

Age-related aneuploidy analysis of human blood cells in vivo by fluorescence in situ hybridization (FISH). Mukherjee AB, et al. **Mech Ageing Dev** 1996 Sep 18;90(2):145–56

The limit to human longevity: an approach through a stress theory of ageing. Parsons PA. **Mech Ageing Dev** 1996 Jun 25;87(3):211–8 (46 ref.)

Differential survival and natural selection: their impact upon aging and cancer mortality. Riggs JE. **Mech Ageing Dev** 1996 Dec 20;92(2–3):111–20

A longitudinal study of human age-related ribosomal RNA gene activity as detected by silver-stained NORs. Thomas S, et al. **Mech Ageing Dev** 1996 Dec 20;92(2–3):101–9

DNA status in brain and heart as prominent co-determinant for life span? Assessing the different degrees of DNA damage, damage susceptibility, and repair capability in different organs of young and old mice. Zahn RK, et al. **Mech Ageing Dev** 1996 Aug 15;89(2):79–94

A hypothesis that aging results from defects in genetically produced proteins. Secerbegovic S. **Med Hypotheses** 1997 Jun;48(6):531–3

Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mecocci P, et al. **Mol Chem Neuropathol** 1997 May;31(1):53–64

The Werner mutation: does it lead to a "public" or "private" mechanism of aging? Martin GM. **Mol Med** 1997 Jun; 3(6):356–8 (20 ref.)

Clonal chromosome aberrations accumulate with age in upper aerodigestive tract mucosa. Jin C, et al. **Mutat Res** 1997 Mar 4;374(1):63–72

Dwarf mice and the ageing process [letter] Brown-Borg HM, et al. **Nature** 1996 Nov 7;384(6604):33

APP gene family: unique age-associated changes in splicing of Alzheimer's betaA4-amyloid protein precursor. Sandbrink R, et al. **Neurobiol Dis** 1994 Nov;1(1–2):13–24

Age-related changes in the DNA and RNA content of the brain in spontaneously hypertensive rats. Nakane H, et al. **Neurochem Res** 1997 Mar;22(3):253–6

Effects of apolipoprotein E on dementia and aging in the Shanghai Survey of Dementia. Katzman R, et al. **Neurology** 1997 Sep;49(3):779–85

Evidence for DNA fragmentation in the CNS of aged Fischer-344 rats. Taglialatela G, et al. **Neuroreport** 1996 Apr 10;7(5):977–80

Apolipoprotein-E genotype in normal aging, age-associated memory impairment, Alzheimer's disease and vascular dementia patients. Palumbo B, et al. **Neurosci Lett** 1997 Aug 1;231(1):59–61

Telomere length regulation during postnatal development and ageing in Mus spretus. Coviello-McLaughlin GM, et al. **Nucleic Acids Res** 1997 Aug 1;25(15):3051–8

Multi-organ characterization of mitochondrial genomic rearrangements in ad libitum and caloric restricted mice show striking somatic mitochondrial DNA rearrangements with age. Melov S, et al. **Nucleic Acids Res** 1997 Mar 1; 25(5):974–82

Genetics of ageing. Macieira-Coelho A. **Pathol Biol (Paris)** 1997 Jun;45(6):500–5 (46 ref.)

Behavioral differences between outbred Wistar, inbred Fischer 344, brown Norway, and hybrid Fischer 344 x brown Norway rats. van der Staay FJ, et al. **Physiol Behav** 1996 Jul;60(1):97–109

Novel molecular markers for late phases of the growth cycle of Arabidopsis thaliana cell-suspension cultures are expressed during organ senescence. Callard D, et al. **Plant Physiol** 1996 Oct;112(2):705–15

Short-term selection for four-week body weight in Japanese quail. Anthony NB, et al. **Poult Sci** 1996 Oct;75(10):1192–7 (17 ref.)

Long-term divergent selection for eight-week body weight in white Plymouth rock chickens. Dunnington EA, et al. **Poult Sci** 1996 Oct;75(10):1168–79 (106 ref.)

Estimates of heritabilities and genetic correlations between tibial dyschondroplasia expression and body weight at two ages in broilers. Kuhlers DL, et al. **Poult Sci** 1996 Aug; 75(8):959–61

Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Issa JP, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11757–62

Dwarfism and age-associated spinal degeneration of heterozygote cmd mice defective in aggrecan. Watanabe H, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24; 94(13):6943–7

Mitochondrial DNA in aging and disease. Wallace DC. **Sci Am** 1997 Aug;277(2):40–7

Males mutate more, bird study shows [news] Dickman S. **Science** 1997 Oct 3;278(5335):34

Aging. What makes us tick? [comment] Guarente L. **Science** 1997 Feb 14;275(5302):943–4 (11 ref.). Comment on: Science 1997 Feb 14;275(5302):980–3.

Arg506Gln factor V mutation and cerebral ischemia in the young [letter] [see comments] Landi G, et al. **Stroke** 1996 Sep;27(9):1697–8. Comment in: Stroke 1997 Mar;28(3):672.

Age and sex dependent regulation of the factor IX gene in mice. Kurachi S, et al. **Thromb Haemost** 1996 Dec; 76(6):965–9

Heterozygote for plasmin inhibitor deficiency developing hemorrhagic tendency with advancing age. Ikematsu S, et al. **Thromb Res** 1996 Apr 15;82(2):129–16

Lifespan and lesions in genetically heterogeneous (four-way cross) mice: a new model for aging research. Chrisp CE, et al. **Vet Pathol** 1996 Nov;33(6):735–43

[Living in injury time out?] Bonneux L, et al. **Ned Tijdschr Geneeskd** 1996 Dec 28;140(52):2636–9 **(Dut)**

[Epigenetic mechanisms of aging: relations between Maillard reactions and radical generation] Deguine-Delay V, et al. **C R Seances Soc Biol Fil** 1997;191(2):247–52 (Eng. Abstr.) **(Fre)**

[The mechanisms of aging and perspective for elimination of deleterious effects] Fujiwara Y. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):499–502 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Human senescence, cancer and telomerase] Ide T, et al. **Tanpakushitsu Kakusan Koso** 1997 Jul;42(9):1351–74 (104 ref.) **(Jpn)**

[Oxidative damage of mitochondrial DNA associated with degenerative diseases and aging] Jurgowiak M, et al. **Postepy Biochem** 1997;43(1):30–40 (97 ref.) **(Pol)**

[Evaluation of the heritability of basic parameters of aging in Drosophila melanogaster] Myl'nikov SV, et al. **Genetika** 1997 May;33(5):616–22 (Eng. Abstr.) **(Rus)**

[Characterization of the genetic apparatus of cell nuclei and mitochondria of mouse liver during aging] Mozzhukhina TG, et al. **Ukr Biokhim Zh** 1996 Jul-Aug;68(4):84–90 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Inconstant apolipoprotein E (ApoE)-like immunoreactivity in amyloid beta protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease. Uchihara T, et al. **Acta Neuropathol (Berl)** 1996 Aug;92(2):180–5

Aging, immunity and neuroendocrine hormones. Mosley RL. **Adv Neuroimmunol** 1996;6(4):419–32 (117 ref.)

Early T-cell activation in elderly humans. Serra JA, et al. **Age Ageing** 1996 Nov;25(6):470–8

Dexamethasone suppression test: corticosteroid receptors regulation in mononuclear leukocytes of young and aged subjects. Zovato S, et al. **Aging (Milano)** 1996 Oct; 8(5):360–4

Effect of early vitamin A supplementation on cell-mediated immunity in infants younger than 6 mo. Rahman MM, et al. **Am J Clin Nutr** 1997 Jan;65(1):144–8

Patch testing in an aged population without dermatitis: high prevalence of patch test positivity. Mangelsdorf HC, et al. **Am J Contact Dermat** 1996 Sep;7(3):155–7

Is irregular regression of corpora lutea in climacteric women caused by age-induced alterations in the "tissue control system"? Bukovský A, et al. **Am J Reprod Immunol** 1996 Dec;36(6):327–41

Impact of age on reproductive outcome in women with recurrent spontaneous abortions and infertility of immune

etiology. Ruiz AM, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):408–14

Assessment of age-dependent immunity to malaria in transmigrants. Andersen E, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):647–9

Serum from normal elderly individuals contains anti-basement membrane zone antibodies. Hachisuka H, et al. **Arch Dermatol** 1996 Oct;132(10):1201–5

Age-related changes in the immunoreactivity of the monocyte/macrophage system in rat molar pulp. Okiji T, et al. **Arch Oral Biol** 1996 May;41(5):453–60

Age-dependent sensitivity to streptozotocin of pancreatic islets isolated from female NOD mice. Reddy S, et al. **Autoimmunity** 1995;22(2):121–6

Subchronic and chronic exposure to d-fenfluramine dose-dependently enhances splenic immune functions in young and old male Fischer-344 rats. Clancy J Jr, et al. **Behav Brain Res** 1996;73(1–2):355–8

Membrane phosphatidylcholine composition of human lymphocytes in neonates. Mander A, et al. **Biochem Soc Trans** 1997 May;25(2):346S

Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Small TN, et al. **Biol Blood Marrow Transplant** 1997 Jun;3(2):65–75

Age-dependent effect of pituitary transplants on immune responses in rat spleen: modulatory effect of cyclosporine. Arce A, et al. **Biol Signals** 1997 Jan-Feb;6(1):11–20

Changes in the aging immune system. Grubeck-Loebenstein B. **Biologicals** 1997 Jun;25(2):205–8 (23 ref.)

Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Martin JT. **Biologicals** 1997 Jun;25(2):209–13 (12 ref.)

Immunity aging. I. The chronic perduration of the thymus acute involution at puberty? Or the participation of the lymphoid organs and cells in fatal physiologic decline? [editorial] Mathé G. **Biomed Pharmacother** 1997;51(2):49–57

Restoration of aging reduced immunity is possible with immunomodulators and is applicable to cancer treatment and prevention [editorial] Mathé G, et al. **Biomed Pharmacother** 1997;51(5):193–9 (58 ref.)

The influence of age on transfer factor treatment of cellular immunodeficiency, chronic fatigue syndrome and/or chronic viral infections. Hana I, et al. **Biotherapy** 1996; 9(1–3):91–5

Quantitative assessment of feline epidermal Langerhans cells. Saint-André Marchal I, et al. **Br J Dermatol** 1997 Jun; 136(6):961–5

Changes in blood and spleen lymphocyte populations following antigen challenge in immature male chickens. Trout JM, et al. **Br Poult Sci** 1996 Sep;37(4):819–27

Ontogency of the responses of human peripheral blood T cells to glucocorticoids. Kavelaars A, et al. **Brain Behav Immun** 1996 Sep;10(3):288–97

Natural cytotoxicity toward K562 cells by macaque lymphocytes from infancy through puberty: effects of early social challenge. Laudenslager ML, et al. **Brain Behav Immun** 1996 Sep;10(3):275–87

Differential tyrosine phosphorylation of zeta chain dimers in mouse CD4 T lymphocytes: effect of age. Garcia GG, et al. **Cell Immunol** 1997 Jan 10;175(1):51–7

Involvement of cytokine gene expression in the age-dependent decline of NK cell response. Hsueh CM, et al. **Cell Immunol** 1996 Nov 1;173(2):221–9

Activation of NK1.1+ T cells in vitro and their possible role in age-associated changes in inducible IL-4 production. Poynter ME, et al. **Cell Immunol** 1997 Jul 10; 179(1):22–9

Impaired induction of c-fos/c-jun genes and of transcriptional regulatory proteins binding distinct c-fos/c-jun promoter elements in activated human T cells during aging. Whisler RL, et al. **Cell Immunol** 1997 Jan 10;175(1):41–50

Abnormality in the early signal transduction pathway is responsible for the impaired proliferative response and low K+ current in a T-cell clone by stimulation with anti-CD3 antibody. Zeng YX, et al. **Cell Signal** 1996 Jun;8(4):263–7

Analysis of different glycosylation states in IgG subclasses. Keusch J, et al. **Clin Chim Acta** 1996 Aug 30;252(2):147–58

Sensitization to Alternaria and Cladosporium by the age of 4 years. Tariq SM, et al. **Clin Exp Allergy** 1996 Jul; 26(7):794–8

Sex and parity modulate cytokine production during murine ageing. Barrat F, et al. **Clin Exp Immunol** 1997 Sep; 109(3):562–8

Surface antigen expression in spleen cells of C57B1/6 mice during ageing: influence of sex and parity. Barrat F, et al. **Clin Exp Immunol** 1997 Mar;107(3):593–600

Lower serum concentrations of cytokines in elderly patients with pneumonia and the impaired production of cytokines by peripheral blood monocytes in the elderly. Gon Y, et al. **Clin Exp Immunol** 1996 Oct;106(1):120–6

Morphologically and functionally intact dendritic cells can be derived from the peripheral blood of aged individuals. Steger MM, et al. **Clin Exp Immunol** 1996 Sep; 105(3):544–50

The lack of association between aging and postvaccination levels of IgG antibody to capsular polysaccharides of Streptococcus pneumoniae. Musher DM, et al. **Clin Infect Dis** 1996 Jan;22(1):165–7

Patch test reactions in children, adults and the elderly. A comparative study in patients with suspected allergic contact dermatitis. Wantke F, et al. **Contact Dermatitis** 1996 May;34(5):316–9

Cytometric analysis of immunosenescence. Cossarizza A, et al. **Cytometry** 1997 Apr 1;27(4):297–313 (192 ref.)

Age-dependent changes in peripheral blood lymphocyte subpopulations in cattle: a longitudinal study. Ayoub IA, et al. **Dev Comp Immunol** 1996 Sep-Oct;20(5):353–63

Plaque-forming cell responses and antibody titers following injection of sheep red blood cells in nonstressed, acute, and/or chronically stressed handled and nonhandled animals. Bhatnagar S, et al. **Dev Psychobiol** 1996 Mar; 29(2):171–81

Aging and gastrointestinal immunity [letter; comment] Freda BJ. **Dig Dis Sci** 1997 Mar;42(3):694–5. Comment on: Dig Dis Sci 1996 Jun;41(6):1183–93.

Immunosenescence revisited. Does it have any clinical significance? Voets AJ, et al. **Drugs Aging** 1997 Jul; 11(1):1–6 (84 ref.)

Islet cell-specific autoantibodies in children with insulin-dependent diabetes mellitus and their siblings at clinical manifestation of the disease. Childhood Diabetes in Finland Study Group [see comments] Vähäsalo P, et al. **Eur J Endocrinol** 1996 Dec;135(6):689–95. Comment in: Eur J Endocrinol 1996 Dec;135(6):643–4.

Age-related impaired affinity maturation and differential D-JH gene usage in human VH6-expressing B lymphocytes from healthy individuals. van Dijk-Härd I, et al. **Eur J Immunol** 1997 Jun;27(6):1381–6

Aging, exercise, training, and the immune system. Shinkai S, et al. **Exerc Immunol Rev** 1997;3:68–95 (162 ref.)

Age-related changes in susceptibility of mice to low-virulent mouse hepatitis virus (MHV-2-CC) infection. Suzuki H, et al. **Exp Anim** 1997 Jul;46(3):211–8

Immune abnormality in relation to nonimmune diseases in SAM mice. Hosono M, et al. **Exp Gerontol** 1997 Jan-Apr; 32(1–2):181–95 (49 ref.)

The correlation between NK cytotoxic activity and the production of the proinflammatory cytokines during the ageing process. Bryl E, et al. **Folia Histochem Cytobiol** 1997;35(2):75–6

Evidence for lowered induction of nuclear factor kappa B in activated human T lymphocytes during aging. Trebilcock GU, et al. **Gerontology** 1996;42(3):137–46

Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. Van Hoecke C, et al. **Gerontology** 1996;42(4):190–8

Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Yamada E, et al. **Glycoconj J** 1997 Apr;14(3):401–5

Mouse liver T cells: their change with aging and in comparison with peripheral T cells. Tsukahara A, et al. **Hepatology** 1997 Aug;26(2):301–9

Oligoclonality of CD8+ T cells in health and disease: aging, infection, or immune regulation? Batliwalla F, et al. **Hum Immunol** 1996 Jun-Jul;48(1–2):68–76 (37 ref.)

Neutrophil function in elderly persons assessed by flow cytometry. Esparza B, et al. **Immunol Invest** 1996 May; 25(3):185–90

Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehydroepiandrosterone sulphate (DHEAS). Araghi-Niknam M, et al. **Immunology** 1997 Mar;90(3):344–9

Expansion of cytotoxic CD8+ CD28- T cells in healthy ageing people, including centenarians. Fagnoni FF, et al. **Immunology** 1996 Aug;88(4):501–7

Cord blood CD4+ CD45RA+ T cells achieve a lower magnitude of activation when compared with their adult counterparts. Hassan J, et al. **Immunology** 1997 Mar; 90(3):397–401

Recipient age determines the success of intraperitoneal transplantation of peritoneal cavity B cells. Julius P Jr, et al. **Immunology** 1997 Jul;91(3):383–90

Differential effects of osteopontin on the cytotoxic activity of macrophages from young and old mice. Rollo EE, et al. **Immunology** 1996 Aug;88(4):642–7

In vitro effects of melatonin on mitogen-induced lymphocyte proliferation and cytokine expression in young and old rats. Pahlavani MA, et al. **Immunopharmacol Immunotoxicol** 1997 Aug;19(3):327–37

The immunosenescent phenotype in mice and humans can be defined by alterations in the natural immunity reversal by immunomodulation with oral AM3. Villarrubia VG, et al. **Immunopharmacol Immunotoxicol** 1997 Feb; 19(1):53–74

Cellular basis of decreased immune responses to pneumococcal vaccines in aged mice. Garg M, et al. **Infect Immun** 1996 Nov;64(11):4456–62

Neutrophil migration, oxidative metabolism, and adhesion in elderly and young subjects. Biasi D, et al. **Inflammation** 1996 Dec;20(6):673–81

Cytokine production in response to stimulation with tetanus toxoid, Mycobacterium tuberculosis and influenza antigens in peripheral blood mononuclear cells and T cell lines from healthy elderlies. Bodnár Z, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):323–30

Development of VH81X transgene-bearing B cells in fetus and adult: sites for expansion and deletion in conventional and CD5/B1 cells. Martin F, et al. **Int Immunol** 1997 Apr; 9(4):493–505

Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Nishimura H, et al. **Int Immunol** 1996 May; 8(5):773–80

IL-12 directly stimulates expression of IL-10 by CD5+ B cells and IL-6 by both CD5+ and CD5- B cells: possible involvement in age-associated cytokine dysregulation. Spencer NF, et al. **Int Immunol** 1997 May;9(5):745–54

Relationship of aging and cytokines to the immunomodulation by delta-9-tetrahydrocannabinol on murine lymphoid cells. Snella E, et al. **Int J Immunopharmacol** 1995 Dec;17(12):1045–54

Some relationships between age, immune responsiveness and resistance to parasites in ruminants. Colditz IG, et al. **Int J Parasitol** 1996 Aug-Sep;26(8–9):869–77 (30 ref.)

Associations of age, immunosuppression, and AIDS among homosexual men in the Tricontinental Seroconverter Study. Veugelers PJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 15;14(5):435–41

Failure of aged rats to accumulate eosinophils in allergic inflammation of the airway. Yagi T, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):38–47

The association between human leucocyte antigens (HLA) and mortality in community residents aged 85 and older. Izaks GJ, et al. **J Am Geriatr Soc** 1997 Jan;45(1):56–60

Effect of hemoglobin and immunization status on energy metabolism of weanling pigs. Gentry JL, et al. **J Anim Sci** 1997 Apr;75(4):1032–40

Effects of immune challenge, dietary energy density, and source of energy on performance and immunity in weanling pigs. van Heugten E, et al. **J Anim Sci** 1996 Oct; 74(10):2431–40

Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects. Danenberg HD, et al. **J Clin Endocrinol Metab** 1997 Sep; 82(9):2911–4

Effect of food restriction on life span and immune functions in long-lived Fischer-344 x Brown Norway F1 rats. Fernandes G, et al. **J Clin Immunol** 1997 Jan;17(1):85–95

Antigen-independent changes in naive CD4 T cells with aging. Linton PJ, et al. **J Exp Med** 1996 Nov 1; 184(5):1891–900

HIV and aging as a model for immunosenescence. Bender BS. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):M261–3 (29 ref.)

Age-associated thymic atrophy in the mouse is due to a deficiency affecting rearrangement of the TCR during intrathymic T cell development. Aspinall R. **J Immunol** 1997 Apr 1;158(7):3037–45

T cell regulation in adult transplantation tolerance. Davies JD, et al. **J Immunol** 1996 Jul 15;157(2):529–33

Increased acute-phase response and renal amyloidosis in aged CD2-fas-transgenic mice. Hsu HC, et al. **J Immunol** 1997 Jun 15;158(12):5988–96

Protein kinase C alpha-mediated chronic signal transduction for immunosenescence. Ohkusu K, et al. **J Immunol** 1997 Sep 1;159(5):2082–4

Development of B cells in aged mice: decline in the ability of pro-B cells to respond to IL-7 but not to other growth factors. Stephan RP, et al. **J Immunol** 1997 Feb 15; 158(4):1598–609

Influenza infection of beta 2-microglobulin-deficient (beta 2m-/-) mice reveals a loss of CD4+ T cell functions with aging. Taylor SF, et al. **J Immunol** 1997 Oct 1; 159(7):3453–9

Aging, immunity, and cardiopulmonary bypass surgery: adding insult to injury [editorial; comment] Peterson PK. **J Lab Clin Med** 1997 Jun;129(6):578–9 (9 ref.). Comment on: J Lab Clin Med 1997 Jun;129(6):592–602.

Lymphocyte and monocyte subset changes during cardiopulmonary bypass: effects of aging and gender [see comments] Rinder CS, et al. **J Lab Clin Med** 1997 Jun; 129(6):592–602. Comment in: J Lab Clin Med 1997 Jun;129(6):578–9.

Induction of thymic hyperplasia and suppression of splenic T cells by lesioning of the anterior hypothalamus in aging Wistar rats. Utsuyama M, et al. **J Neuroimmunol** 1997 Aug; 77(2):174–80

Dual action of a carbohydrate epitope on afferent and efferent axons in cortical development. Henke-Fahle S, et al. **J Neurosci** 1996 Jul 1;16(13):4195–206

C58 and AKR mice of all ages develop motor neuron disease after lactate dehydrogenase-elevating virus infection but only if antiviral immune responses are blocked by chemical or genetic means or as a result of old age. Anderson GW, et al. **J Neurovirol** 1995 Sep;1(3–4):244–52

Long-term feeding of high vitamin E diet improves the decreased mitogen response of rat splenic lymphocytes with aging. Sakai S, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Feb;43(1):113–22

Combined suppressive effect of cardiopulmonary bypass and aging on cell-mediated immunity. Hisatomi K, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):140–1

An immunohistochemical analysis of T-cell subsets in the chicken bursa of Fabricius during postnatal stages of development. Khan MZ, et al. **J Vet Med Sci** 1996 Dec; 58(12):1231–4

Autoimmune enteropathy in adults [letter] Mirakian R, et al. **Lancet** 1997 Sep 27;350(9082):959–60

Long-term melatonin supplementation does not recover the impairment of natural killer cell activity and lymphocyte proliferation in aging mice. Provinciali M, et al. **Life Sci** 1997;61(9):857–64

Proceedings of the 1st International Conference on

Immunology and Aging. Bethesda, Maryland, June 16–19, 1996. **Mech Ageing Dev** 1997 Feb;93(1–3):1–222

Proceedings of the 1st International Conference on Immunology and Aging. Bethesda, Maryland, June 16–19, 1996. **Mech Ageing Dev** 1997 Mar;94(1–3):1–262

Macrophage prostaglandin production contributes to the age-associated decrease in T cell function which is reversed by the dietary antioxidant vitamin E. Beharka AA, et al. **Mech Ageing Dev** 1997 Feb;93(1–3):59–77

Economic and political implications of immunology and aging on tomorrow's society. Butler RN. **Mech Ageing Dev** 1997 Feb;93(1–3):7–13

Prevalence of organ-specific and non organ-specific autoantibodies in healthy centenarians. Candore G, et al. **Mech Ageing Dev** 1997 Mar;94(1–3):183–90

Evidence of enhanced type 2 immune response and impaired upregulation of a type 1 response in frail elderly nursing home residents. Castle S, et al. **Mech Ageing Dev** 1997 Mar; 94(1–3):7–16

CD45 isoforms expression on CD4+ and CD8+ T cells throughout life, from newborns to centenarians: implications for T cell memory. Cossarizza A, et al. **Mech Ageing Dev** 1996 Mar 29;86(3):173–95

Age- and training-related events in active T subpopulation. Changes in polyphosphoinositide metabolism during mitogenic stimulation. Di Pietro R, et al. **Mech Ageing Dev** 1996 Sep 18;90(2):103–9

Aging of the recipients but not of the bone marrow donors enhances autoimmunity in syngeneic radiation chimeras. Doria G, et al. **Mech Ageing Dev** 1997 Apr;95(1–2):131–42

Regulation of cytokine production in aging: use of recombinant cytokines to upregulate mitogen-stimulated spleen cells. Frasca D, et al. **Mech Ageing Dev** 1997 Feb; 93(1–3):157–69

Changes in apoptosis of human polymorphonuclear granulocytes with aging. Fülöp T Jr, et al. **Mech Ageing Dev** 1997 Jun;96(1–3):15–34

Long-term exercise patterns and immune function in healthy older women. A report of preliminary findings. Gueldner SH, et al. **Mech Ageing Dev** 1997 Feb;93(1–3):215–22

Age-related changes in CD4 T cells of T cell receptor transgenic mice. Haynes L, et al. **Mech Ageing Dev** 1997 Feb;93(1–3):95–105 (44 ref.)

Reversing and restoring immune functions. Hirokawa K. **Mech Ageing Dev** 1997 Feb;93(1–3):119–24 (29 ref.)

Accelerated onset of age-related autoimmune lesions in MRL/+ mice by ovariectomy. Ishimaru N, et al. **Mech Ageing Dev** 1997 Feb;93(1–3):145–56

Effect of restraint stress on immune system and experimental B16 melanoma metastasis in aged mice. Kanno J, et al. **Mech Ageing Dev** 1997 Feb;93(1–3):107–17

Senescence and cytokines modulate the NK cell expression. Krishnaraj R. **Mech Ageing Dev** 1997 Jun;96(1–3):89–101

Age-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples. Kutza J, et al. **Mech Ageing Dev** 1996 Sep 30;90(3):209–22

Feedback regulation of T cell development: manifestations in aging. Mehr R, et al. **Mech Ageing Dev** 1996 Nov 13; 91(3):195–210

Age-related changes in T cell surface markers: a longitudinal analysis in genetically heterogeneous mice. Miller RA. **Mech Ageing Dev** 1997 Jun;96(1–3):181–96

The T cell in the ageing individual. Pawelec G, et al. **Mech Ageing Dev** 1997 Feb;93(1–3):35–45 (51 ref.)

Susceptibility to apoptosis of T lymphocytes from elderly humans is associated with increased in vivo expression of functional Fas receptors. Pheloux at MA, et al. **Mech Ageing Dev** 1997 Jun;96(1–3):35–46

Differential immunologic modulatory effects of tetrahydrocannabinol as a function of age. Ramarathinam L, et al. **Mech Ageing Dev** 1997 Jun;96(1–3):117–26

Influenza (H1N1)-ISCOMs enhance immune responses and protection in aged mice. Sambhara S, et al. **Mech Ageing Dev** 1997 Jun;96(1–3):157–69

T lymphocyte proliferative capability to defined stimuli and costimulatory CD28 pathway is not impaired in healthy centenarians. Sansoni P, et al. **Mech Ageing Dev** 1997 Jun; 96(1–3):127–36

Th1/Th2 changes in aging. Shearer GM. **Mech Ageing Dev** 1997 Mar;94(1–3):1–5 (14 ref.)

The accumulation of non-replicative, non-functional, senescent T cells with age is avoided in calorically restricted mice by an enhancement of T cell apoptosis. Spaulding CC, et al. **Mech Ageing Dev** 1997 Feb; 93(1–3):25–33

Calorie restriction inhibits the age-related dysregulation of the cytokines TNF-alpha and IL-6 in C3B10RF1 mice. Spaulding CC, et al. **Mech Ageing Dev** 1997 Feb; 93(1–3):87–94

Peripheral blood dendritic cells reinduce proliferation in in vitro aged T cell populations. Steger MM, et al. **Mech Ageing Dev** 1997 Feb;93(1–3):125–30

The effect of aging on the immune response: influence of phosphatidylcholine-containing lipid on IgD-receptor expression and antibody formation. Swenson CD, et al. **Mech Ageing Dev** 1997 May;95(3):167–86

Retardation of the age-associated decline of immune functions in aging rats under dietary restriction and daily physical exercise. Utsuyama M, et al. **Mech Ageing Dev** 1996 Nov 13;91(3):219–28

Impairment of signal transduction in T cells from old mice. Utsuyama M, et al. **Mech Ageing Dev** 1997 Feb; 93(1–3):131–44

Immunology and the elderly: an historical perspective for future international action. Weksler ME. **Mech Ageing Dev** 1997 Feb;93(1–3):1–6

Promotion of interleukin-2 activity as a strategy for 'rejuvenating' geriatric immune function. McCarty MF. **Med Hypotheses** 1997 Jan;48(1):47–54 (120 ref.)

Age-related susceptibility to experimental autoimmune myasthenia gravis: immunological and electrophysiological aspects. Hoedemaekers AC, et al. **Muscle Nerve** 1997 Sep; 20(9):1091–101

Evaluation of lymphokine-activated killer cell development in young and old healthy humans. Provinciali M, et al. **Nat Immun** 1995;14(3):134–44

Successful immunosenescence and the remodelling of immune responses with ageing. Franceschi C, et al. **Nephrol Dial Transplant** 1996;11 Suppl 9:18–25 (91 ref.)

Chemotherapy and immunomodulation in the elderly. Fraschini F, et al. **Nephrol Dial Transplant** 1996;11 Suppl 9:31–3 (38 ref.)

Selective breeding for high serum IgA levels from noninbred ddY mice: isolation of a strain with an early onset of glomerular IgA deposition. Miyawaki S, et al. **Nephron** 1997;76(2):201–7

Is hypothalamic GABA involved in immune function in relation to dietary protein during aging? Bandyopadhyay BC, et al. **Neurochem Res** 1997 Sep;22(9):1135–44

Induction of major histocompatibility class II antigen on microglial cells in postnatal and adult rats following intraperitoneal injections of lipopolysaccharide. Ng YK, et al. **Neurosci Res** 1997 Jun;28(2):111–8

Salivary IgA secretion rate in young and elderly persons. Miletic ID, et al. **Physiol Behav** 1996 Jul;60(1):243–8

Deletion of the mouse T-cell receptor beta gene enhancer blocks alphabeta T-cell development. Bouvier G, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7877–81

The absence of gut flora, the doses of antigen ingested and aging affect the long-term peripheral tolerance induced by ovalbumin feeding in mice. Moreau MC, et al. **Res Immunol** 1996 Jan;147(1):49–59

Survey on some aspects of immunologic reactivity in old age. Negru T, et al. **Rom J Physiol** 1995 Jan-Dec; 32(1–4):125–36

Autoantibody production in healthy elderly people is not promoted by interleukin-10 although this cytokine is expressed in them by a peculiar CD8+CD3+ large granular cell subpopulation. Llorente L, et al. **Scand J Immunol** 1997 Apr;45(4):401–7

Age-associated changes in the cellular composition of the human adenoid. Mattila PS, et al. **Scand J Immunol** 1997 Apr;45(4):423–7

Regulation of newborn and adult monocytes by PGE2: evidence of comparable differentiation status. Murphy FJ, et al. **Scand J Immunol** 1996 Oct;44(4):415–20

The age-associated increase in autoreactive immunoglobulins reflects a quantitative increase in specificities detectable at lower concentrations in young mice. Nobrega A, et al. **Scand J Immunol** 1996 Nov;44(5):437–43

The effect of age on the transendothelial migration of human T lymphocytes. Stohlawetz P, et al. **Scand J Immunol** 1996 Nov;44(5):530–4

Immaturity, ageing and oral tolerance. Vaz N, et al. **Scand J Immunol** 1997 Sep;46(3):225–9 (75 ref.)

Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Beyer WE, et al. **Vaccine** 1996 Oct;14(14):1331–9

MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Higgins DA, et al. **Vaccine** 1996 Apr;14(6):478–84

The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age. Hirota Y, et al. **Vaccine** 1996 Dec; 14(17–18):1597–602

The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination coverage in the elderly population. Honkanen PO, et al. **Vaccine** 1997 Feb;15(3):317–20

Phase I study of the immunogenicity and safety of conjugated Hemophilus influenzae type b vaccines in the elderly. Kantor E, et al. **Vaccine** 1997 Feb;15(2):129–32

Helper and cytotoxic T lymphocyte responses to influenza vaccination in healthy compared to diabetic elderly. McElhaney JE, et al. **Vaccine** 1996 Apr;14(6):539–44

Correlation between the antibody response to influenza vaccine and helper T cell subsets in healthy aging. Remarque EJ, et al. **Vaccine** 1996 Feb;14(2):127–30

The influence of age on the canine immune system. Greeley EH, et al. **Vet Immunol Immunopathol** 1996 Dec; 55(1–3):1–10

Postnatal development of lymphocyte subpopulations in the intestinal mucosa in goat. Navarro JA, et al. **Vet Immunol Immunopathol** 1997 Mar;55(4):303–11

Changes in lymphocyte subsets with age in perinatal cats: late gestation through eight weeks. Sellon RK, et al. **Vet Immunol Immunopathol** 1996 Sep;53(1–2):105–13

T-cell subsets in blood and lymphoid tissues obtained from fetal calves, maturing calves, and adult bovine. Wilson RA, et al. **Vet Immunol Immunopathol** 1996 Sep;53(1–2):49–60

Immunophenotypic analysis of foal bronchoalveolar lavage lymphocytes. Balson GA, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):237–46

[Characteristics of immunologic test values in the elderly] Rink L, et al. **Z Gerontol Geriatr** 1997 May-Jun;30(3):220–5 (22 ref.) (Eng. Abstr.) **(Ger)**

[The effect of herbal medicines on the immunodeficient animals by injecting cancer chemotherapeutic agent-special reference to age related recovery of the function] Li AL, et al. **Kansenshogaku Zasshi** 1996 Jul;70(7):717–26 (Eng. Abstr.) **(Jpn)**

[Sarcoidosis in an 82-year-old woman who presented with ocular symptoms] Kawano H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34(12):1375–9 (Eng. Abstr.) **(Jpn)**

[Expression of decay-accelerating factor on CD8-positive lymphocytes as an index of aging and of host defense function] Fuchino Y, et al. **Nippon Ronen Igakkai Zasshi** 1996 Aug;33(8):580–5 (Eng. Abstr.) **(Jpn)**

[Prevalence of autoantibodies in serum of healthy persons over 85 years of age] Potocka-Płazak K, et al. **Przegl Lek** 1995;52(11):544–6 (Eng. Abstr.) **(Pol)**

[Count of major lymphocyte subsets and their mitogenic response after lethal irradiation and transplantation of syngeneic bone marrow from young and old donors] Butenko GM, et al. **Biull Eksp Biol Med** 1996 Sep; 122(9):301–4 **(Rus)**

[Increase in the number of antibody-producing cells to syngeneic erythrocytes in the spleen of C57Bl/6 mice due to heterochronous parabiosis] Gubrii IB, et al. **Biull Eksp Biol Med** 1996 Jul;122(7):71–4 **(Rus)**

[Stress and changes in immune response in elderly subjects] Castillo Méndez A, et al. **Rev Alerg Mex** 1993 Sep-Oct; 40(5):114–8 (Eng. Abstr.) **(Spa)**

[The immune status of cattle at critical age periods] Haranovych II. **Fiziol Zh** 1997;43(3–4):19–24 (Eng. Abstr.) **(Ukr)**

METABOLISM

Age-dependent development of acute tolerance to propofol and its distribution in a pharmacokinetic compartment-independent rat model. Larsson JE, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):734–40

Regulation of collagen expression by interleukin-1 beta is dependent on donor age. Jarisch A, et al. **Acta Derm Venereol** 1996 Jul;76(4):287–90

Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia. Arnold SE, et al. **Acta Neuropathol (Berl)** 1996;91(3):269–77

Dense microspheres in normal horse brain. Furuoka H, et al. **Acta Neuropathol (Berl)** 1996;91(4):440–3

Senile plaques in very aged cats. Nakamura S, et al. **Acta Neuropathol (Berl)** 1996;91(4):437–9

Age-related changes in the brain transfer of blood-borne horseradish peroxidase in the hippocampus of senescence-accelerated mouse. Ueno M, et al. **Acta Neuropathol (Berl)** 1997 Mar;93(3):233–40

Vasopressin- and oxytocin-immunoreactive nerve cells in the aging rat hypothalamus. Lolova IS, et al. **Acta Physiol Pharmacol Bulg** 1996;22(1):7–16

Gender-related differences in the regulatory influence of thyroid hormone on the expression of myosin isoforms in young and old rats. Larsson L, et al. **Acta Physiol Scand** 1997 Jan;159(1):81–9

Glutathione status and reactive oxygen generation in tissues of young and old exercised rats. Ohkuwa T, et al. **Acta Physiol Scand** 1997 Mar;159(3):237–44

Distributions of taurine, glutamate, and glutamate receptors during post-natal development and plasticity in the rat brain. Magnusson KR. **Adv Exp Med Biol** 1996;403:435–44

Ontogenesis and expression of ALDH activity in the skin and the eye of the rat. Pappas P, et al. **Adv Exp Med Biol** 1997;414:73–80

Age-related changes in brain metabolism and vulnerability to anoxia. Roberts EL Jr, et al. **Adv Exp Med Biol** 1997; 411:83–9 (23 ref.)

Taurine and neural cell damage. Transport of taurine in adult and developing mice. Saransaari P, et al. **Adv Exp Med Biol** 1996;403:481–90

Kynurenine metabolism in the rat brain in vivo. Effect of acute excitotoxic insults. Schwarcz R, et al. **Adv Exp Med Biol** 1996;398:211–9

Potentiation of the age-dependent Ca uptake into coronary arteries of rats by the risk factor genetic hypertension. Thimm F, et al. **Adv Exp Med Biol** 1996;388:489–93

Responses of circulating urea cycle and branched-chain amino acids to feeding in adult and aged Fischer-344 rats. Hartman WJ, et al. **Aging (Milano)** 1997 Jun;9(3):198–206

Age and sex differences in body size and composition during rhesus monkey adulthood. Hudson JC, et al. **Aging (Milano)** 1996 Jun;8(3):197–204

Influence of age, exercise, and dietary restriction on oxidative stress in rats. Kim JD, et al. **Aging (Milano)** 1996 Apr; 8(2):123–9

Study of aging rat tail collagen using atomic force microscope. Odetti P, et al. **Aging (Milano)** 1995 Oct; 7(5):352–7

Enzymes involved in guanine monophosphate metabolism of aging chicken heart. Pane G, et al. **Aging (Milano)** 1996 Dec;8(6):396–9

The effect of aging and dietary restriction on the retinoylation of nuclear matrix proteins in rats. Pipkin JL, et al. **Aging (Milano)** 1996 Aug;8(4):263–70

Oxygen radical detoxification processes during aging: the

functional importance of melatonin. Reiter RJ. **Aging (Milano)** 1995 Oct;7(5):340–51 (98 ref.)
Altered oxidative stress in healthy old subjects. Rondanelli M, et al. **Aging (Milano)** 1997 Jun;9(3):221–3
A new outlook for anti-oxidant defense system [editorial] Yu BP. **Aging (Milano)** 1995 Oct;7(5):338–9
Splanchnic and whole-body leucine kinetics in young and elderly men. Boirie Y, et al. **Am J Clin Nutr** 1997 Feb; 65(2):489–95
Combined effects of lipid peroxidation and antioxidant status on carotid atherosclerosis in a population aged 59–71 y: The EVA Study. Etude sur le Vieillissement Artériel. Bonithon-Kopp C, et al. **Am J Clin Nutr** 1997 Jan; 65(1):121–7
Adolescent growth and maturation in zinc-deprived rhesus monkeys [see comment] Golub MS, et al. **Am J Clin Nutr** 1996 Sep;64(3):274–82. Comment on: Am J Clin Nutr 1996 Sep;64(3):375–6.
Serum vitamin D metabolites and calcium absorption in normal young and elderly free-living women and in women living in nursing homes. Kinyamu HK, et al. **Am J Clin Nutr** 1997 Mar;65(3):790–7
The association of dietary fat and fiber with coagulation factor VII in the elderly: the Rotterdam Study. Mennen LI, et al. **Am J Clin Nutr** 1997 Mar;65(3):732–6
Total and exogenous carbohydrate oxidation in obese prepubertal children. Rueda-Maza CM, et al. **Am J Clin Nutr** 1996 Dec;64(6):844–9
Aging, gastric acid secretion, and carotene status [editorial] Solomons NW. **Am J Clin Nutr** 1996 Oct;64(4):648–9
Effects of age on body fat distribution and cardiovascular risk factors in women. Zamboni M, et al. **Am J Clin Nutr** 1997 Jul;66(1):111–5
Age and secular trends in bone lead levels in middle-aged and elderly men: three-year longitudinal follow-up in the Normative Aging Study. Kim R, et al. **Am J Epidemiol** 1997 Oct 1;146(7):586–91
Prolactin-derived amyloid in the aging pituitary gland. Westermark P, et al. **Am J Pathol** 1997 Jan;150(1):67–73
Rates of local cerebral protein synthesis in fetal and neonatal sheep. Abrams RM, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1235–44
Ontogeny of K+ transport in rat distal colon. Aizman RI, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G268–74
Monoclonal antibodies for high-resolution localization of NHE3 in adult and neonatal rat kidney. Biemesderfer D, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F289–99
Expression of insulin receptors and of 60-kDa receptor substrate in rat mature and immature enterocytes. Buts JP, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):G217–26
Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Butterfield GE, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E94–9
Beta-adrenergic modulation of Na-K pump activity in young and adult canine cardiac Purkinje fibers. Charpentier F, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H706–12
Ontogeny of the extracellular calcium-sensing receptor in rat kidney. Chattopadhyay N, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F736–43
Regulation of AE2 Cl-/HCO3- exchanger during intestinal development. Chow A, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G330–7
Comparative analysis of the ontogeny of a sodium-dependent bile acid transporter in rat kidney and ileum. Christie DM, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G377–85
Influence of aging on protein import into cardiac mitochondria. Craig EE, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2983–8
Impairment of vascular function is associated with an age-related increase of lipid peroxidation in rats. Davidge ST, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1625–31
Developmental regulation of CFTR expression during human nephrogenesis. Devuyst O, et al. **Am J Physiol** 1996 Sep; 271(3 Pt 2):F723–35
Alterations of adenylyl cyclase-linked G proteins in rat liver during aging. Eakes AT, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):E126–32
Distribution and developmentally regulated expression of murine polycystin. Geng L, et al. **Am J Physiol** 1997 Apr; 272(4 Pt 2):F451–9
Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. Gerhart DZ, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E207–13
Lactate production by swine adipocytes: effects of age, nutritional status, glucose concentration, and insulin. Heckler BK, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E957–66
Developmental regulation of Na, K-ATPase in rat lung. Ingbar DH, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L619–29
Vasopressin V2 receptor mRNA expression and cAMP accumulation in aging rat kidney. Klingler C, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1775–82
Effect of aging on rat skeletal muscle beta-AR function in male Fischer 344 x brown Norway rats. Larkin LM, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):R462–8
Insulin secretion in adult rats that had experienced different underfeeding patterns during their development. Martín MA, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E634–40
Glutamine synthetase induction by glucocorticoids is preserved in skeletal muscle of aged rats. Meynial-Denis D, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):E1061–6
Gender differences in energy expended during activities and in daily energy expenditure of elderly people. Morio B, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):E321–7
Developmental differences in the IGF-I system response to severe and chronic calorie malnutrition. Oster MH, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):E646–53
Changes in P2Y1 nucleotide receptor activity during the development of rat salivary glands. Park MK, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1388–93
Developmental regulation of cytochrome oxidase subunit VIa isoforms in cardiac and skeletal muscle. Parsons WJ, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):H567–74
Hormonal regulation of hepatic gluconeogenesis: influence of age and training. Podolin DA, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):R365–72
Developmental changes in ATP utilization during graded hypoxia and reoxygenation in the heart in vivo. Portman MA, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H216–23
Developmental changes in rabbit juxtamedullary proximal convoluted tubule water permeability. Quigley R, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):F871–6
Postnatal development of the ob gene system: elevated leptin levels in suckling fa/fa rats. Rayner DV, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R446–50
Expression of adenylyl cyclase mRNAs in the adult, in developing, and in the Brattleboro rat kidney. Shen T, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C323–30
Ontogeny of blood-brain barrier function in ovine fetuses, lambs, and adults. Stonestreet BS, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1594–601
Posttranscriptional mechanisms regulate ontogenic changes in rat renal sodium-phosphate transporter. Taufiq S, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R134–41
Effect of nitric oxide synthase inhibitors on bone metabolism in growing rats. Tsukahara H, et al. **Am J Physiol** 1996 May;270(5 Pt 1):E840–5
Increased expression of EGFR in gastric mucosa of aged rats. Tureaud J, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):G389–98
Polyadenylated RNA, actin mRNA, and myosin heavy chain mRNA in young and old human skeletal muscle. Welle S, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):E224–9
Insulin receptor mRNA splicing and altered metabolic control in aged and mildly insulin-deficient rats. Wiersma MM, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E607–15
Synthesis of citrulline and arginine from proline in enterocytes of postnatal pigs. Wu G. **Am J Physiol** 1997 Jun;272(6 Pt 1):G1382–90
Arginine degradation in developing porcine enterocytes. Wu G, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):G913–9
Expression of AQP family in rat kidneys during development and maturation. Yamamoto T, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):F198–204
Na-K-ATPase alpha-isoform expression in heart and vascular endothelia: cellular and developmental regulation. Zahler R, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C361–71
Ins(1,4,5)P3 receptors in cerebral arteries: changes with development and high-altitude hypoxia. Zhou L, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1954–9
Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. Gottlieb DJ, et al. **Am J Respir Crit Care Med** 1996 Nov; 154(5):1290–5
Characterization of polypeptides synthesized and secreted by oviductal epithelial cell explants obtained from young, fertile and aged, subfertile mares. Brinsko SP, et al. **Am J Vet Res** 1996 Sep;57(9):1346–53
Age-related changes in the pharmacokinetic disposition of diazepam in foals. Norman WM, et al. **Am J Vet Res** 1997 Aug;58(8):878–80
Expression of carbonic anhydrase isozymes (CA-I, CA-II, CA-III) during postnatal development of the rat gastrointestinal tract. Igarashi S, et al. **Anat Anz** 1996 Aug; 178(4):369–73
Distribution of the neural cell adhesion molecule (NCAM) during pre- and postnatal development of mouse incisors. Obara N, et al. **Anat Embryol (Berl)** 1997 Feb; 195(2):193–202
Development of the hypothalamic vasopressin system and nephrons in Meriones shawi during ontogenesis. Rabhi M, et al. **Anat Embryol (Berl)** 1996 Mar;193(3):281–96
The epididymis of the prepubertal swamp buffalo (Bubalus bubalis): histochemistry of phosphatases. Ariyaratna HB, et al. **Anat Histol Embryol** 1996 Sep;25(3):161–5
Architecture, elastic fiber, and collagen in the distal air portion of the lung of the 18-month-old rat. Escolar JD, et al. **Anat Rec** 1997 May;248(1):63–9
Localization of proliferating cell nuclear antigen in the developing and mature rat heart cell. Marino TA, et al. **Anat Rec** 1996 Aug;245(4):677–84
Maturation decreases ethanol minimum alveolar anesthetic concentration in mice as previously demonstrated in rats: there is no species difference. Fang Z, et al. **Anesth Analg** 1997 Jul;85(1):160–3
Age-related changes in lipid peroxidation and antioxidant defense in Fischer 344 rats. Bagchi M, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:449–52
Immunohistochemical localization of metabotropic and ionotropic glutamate receptors in the mouse brain. Ryo Y, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:554–6
Developmental changes in forebrain vasopressin receptor binding in prairie voles (Microtus ochrogaster) and montane voles (Microtus montanus). Wang Z, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:510–3
Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Frey KA, et al. **Ann Neurol** 1996 Dec; 40(6):873–84
Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Chien SC, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1562–5
Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants [published erratum appears in Antimicrob Agents Chemother 1996 Jul;40(7):1757] Hayton WL, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):567–74
Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects. Kozawa O, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2824–8
Developmental control of cathepsin B expression in bovine fetal muscles. Béchet DM, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):362–8
Influences of age and dietary restriction on gastrocnemius electron transport system activities in mice. Desai VG, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):145–51
Effect of age and caloric intake on protein oxidation in different brain regions and on behavioral functions of the mouse. Dubey A, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):189–97
Age-related and dexamethasone-induced changes in cathepsins E and D in rat thymic and splenic cells. Nishishita K, et al. **Arch Biochem Biophys** 1996 Sep 15; 333(2):349–58
Age-associated increase in ferritin content of male rat liver: implication for diquat-mediated oxidative injury. Rikans LE, et al. **Arch Biochem Biophys** 1997 Aug 1;344(1):85–93
Stratum corneum lipids: the effect of ageing and the seasons. Rogers J, et al. **Arch Dermatol Res** 1996 Nov; 288(12):765–70
Muscarinic signalling in submandibular salivary acinar cells of ageing rats. Seagrave J, et al. **Arch Oral Biol** 1996 May; 41(5):425–30
Aging effect on inductive capacity of human demineralized bone matrix. Nyssen-Behets C, et al. **Arch Orthop Trauma Surg** 1996;115(6):303–6
Effect of age on the exocrine pancreatic secretion of the preruminant milk-fed goat. Naranjo JA, et al. **Arch Physiol Biochem** 1997 Apr;105(2):144–50
Contributions to senescence: non-enzymatic glycosylation of proteins. Sullivan R. **Arch Physiol Biochem** 1996 Dec; 104(7):797–806 (76 ref.)
Transglutaminase activity in aging articular chondrocytes and articular cartilage vesicles. Rosenthal AK, et al. **Arthritis Rheum** 1997 May;40(5):966–70
Scavenger receptor activity and expression of apolipoprotein E mRNA in monocyte-derived macrophages of young and old healthy men. Friedman G, et al. **Atherosclerosis** 1997 Jan 3;128(1):67–73
Heparan sulfate isomers in cerebral arteries of Japanese women with aging and with atherosclerosis--heparitinase and high-performance liquid chromatography determinations. Murata K, et al. **Atherosclerosis** 1997 Jul 11;132(1):9–17
Theoretical considerations concerning the effect of relativistic velocities on the rate of biological processes. Heneine IF. **Aviat Space Environ Med** 1997 Jun; 68(6):538–41
Expression and function of the cardiac Na+/Ca2+ exchanger in postnatal development of the rat, in experimental-induced cardiac hypertrophy and in the failing human heart. Studer R, et al. **Basic Res Cardiol** 1997; 92 Suppl 1:53–8 (34 ref.)
Chronic stimulation increases acetylcholinesterase activity in old Aplysia. Peretz B, et al. **Behav Brain Res** 1996 Oct; 80(1–2):203–10
Absence of relationship between the level of electron transport chain activities and aging in human skeletal muscle. Barrientos A, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):536–9
Pancreatic GAPDH gene expression during ontogeny and acute pancreatitis induced by caerulein. Calvo EL, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):636–40
Cleavage of amino acid residue(s) from the N-terminal region of alpha A- and alpha B-crystallins in human crystalline lens during aging. Kamei A, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):373–8
Sphingomyelinase activity is enhanced in cerebral cortex of senescence-accelerated mouse-P/10 with advancing age. Kim SS, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):583–7
Perinatal expression and inducibility of human CYP3A7 in C57BL/6N transgenic mice. Li Y, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):312–7
The glycoproteins that occur in the colloids of senescent porcine pituitary glands are clusterin and glycosylated albumin fragments. Ogawa S, et al. **Biochem Biophys Res Commun** 1997 May 29;234(3):712–8
Chronic high-fat feeding and middle-aging reduce in an additive fashion Glut4 expression in skeletal muscle and adipose tissue. Sevilla L, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):89–93
Effects of aging and diet on the accumulation of dolichol in rat tissues. Ishinaga M. **Biochem Cell Biol** 1996;

74(2):265–70

N–epsilon–(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Ahmed MU, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):565–70

Quantification of aggrecan and link–protein mRNA in human articular cartilage of different ages by competitive reverse transcriptase–PCR. Bolton MC, et al. **Biochem J** 1996 Oct 15;319 (Pt 2):489–98

Age–related changes in effects of insulin–like growth factor I on human osteoblast–like cells. D'avis PY, et al. **Biochem J** 1997 Jun 15;324 (Pt 3):753–60

Changes associated with aging and replicative senescence in the regulation of transcription factor nuclear factor–kappa B. Helenius M, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):603–8

Modulation of muscarinic receptor–stimulated phosphoinositide breakdown by sulfhydryl group modification is a general response in different rat brain regions and depends on the stage of brain development. Balduini W, et al. **Biochem Mol Biol Int** 1996 Oct; 40(2):427–32

Effects of short–chain acyl–CoA dehydrogenase deficiency on development expression of metabolic enzyme genes in the mouse. Hinsdale ME, et al. **Biochem Mol Med** 1996 Apr;57(2):106–15

Effect of aging on mixed–function oxidation and conjugation by isolated perfused rat livers. Handler JA, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):159–64

Biochemical analysis of mucin glycoproteins in paediatric colonic mucus. Aslam A, et al. **Biochem Soc Trans** 1997 Feb;25(1):347; replaces 7S

UDP–glucuronyl transferase enzyme family in both human and Balb/c mouse lung. Conner CE, et al. **Biochem Soc Trans** 1997 May;25(2):181S

Is there an optimal membrane protein content determined by membrane stability to lipid peroxidation? Disease and ageing consideration. Wiseman A, et al. **Biochem Soc Trans** 1996 Aug;24(3):376S

Aging and polyamine acetylation in rat kidney. Ferioli ME, et al. **Biochim Biophys Acta** 1996 Oct 7;1317(1):15–8

Quantitative decrease of human cytochrome c oxidase during development: evidences for a post–transcriptional regulation. Lefai E, et al. **Biochim Biophys Acta** 1997 Jan 16;1318(1–2):191–201

Bile acid concentrations in serum and duodenal aspirates of healthy preterm infants: effects of gestational and postnatal age. Boehm G, et al. **Biol Neonate** 1997;71(4):207–14

Fatty acid profiles of rat renal phospholipids during development. D'Antuono CL, et al. **Biol Neonate** 1997; 71(3):162–70

Properties of partially purified esterase in human crystalline lens and variation in its enzyme activity during aging and with advance of senile cataract. Kamei A. **Biol Pharm Bull** 1996 Sep;19(9):1223–6

The preventive effect of ginseng with du–zhong leaf on protein metabolism in aging. Metori K, et al. **Biol Pharm Bull** 1997 Mar;20(3):237–42

Influence of aging on rolipram–sensitive phosphodiesterase activity and [3H]rolipram binding in the rat brain. Tohda M, et al. **Biol Pharm Bull** 1996 Feb;19(2):300–2

Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction. Garbán H, et al. **Biol Reprod** 1997 Apr; 56(4):954–63

Ontogeny of androgen receptor–like immunoreactivity in the reproductive tract of male Monodelphis domestica. Sonea IM, et al. **Biol Reprod** 1997 Apr;56(4):852–60

Selenium, zinc, and thyroid hormones in healthy subjects: low T3/T4 ratio in the elderly is related to impaired selenium status. Olivieri O, et al. **Biol Trace Elem Res** 1996 Jan;51(1):31–41

Effect of acetaldehyde on oxidoreductases in tissues of rats at different ages. Devi GU, et al. **Biomed Environ Sci** 1996 Dec;9(4):430–6

Age–related metabolic effects of acetaldehyde on rats with reference to detoxification enzymes and sulfhydryl groups. Devi GU, et al. **Biomed Environ Sci** 1996 Dec;9(4):380–5

The effects of high energy and micronutrient supplementation on iron status in nutritionally at risk infants. Husaini MA, et al. **Biomed Environ Sci** 1996 Sep; 9(2–3):325–40

Antioxidant status in persons with and without senile lens changes. Xue AN, et al. **Biomed Environ Sci** 1996 Sep; 9(2–3):144–8

Alprazolam hydroxylation by mouse liver microsomes in vitro: the effect of age and phenobarbital induction. Charpentier KP, et al. **Biopharm Drug Dispos** 1997 Mar; 18(2):139–49

Changes of glycosaminoglycan composition in aging chicken brain. A preliminary investigation. Pane G, et al. **Boll Soc Ital Biol Sper** 1996 Nov–Dec;72(11–12):309–15

A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril. Macdonald NJ, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):201–4

The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. Macdonald NJ, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):205–9

Changes in the concentration of fructose in the blood of piglets of different ages after doses of fructose, fructose plus glucose, and sucrose. Bird PH, et al. **Br J Nutr** 1996 Sep;76(3):399–407

The sizes of the exchangeable pools of selenium in elderly women and their relation to institutionalization. Ducros V, et al. **Br J Nutr** 1997 Sep;78(3):379–96

The age–related decline of androgen levels in men: clinically significant? Gooren LI. **Br J Urol** 1996 Nov;78(5):763–8 (49 ref.)

Post–natal changes in biliary lipids in suckling goat kids. Fernández JI, et al. **Br Vet J** 1996 Nov;152(6):673–82

Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains. Arai Y, et al. **Brain Dev** 1997 Jun;19(4):290–4

Age–related changes in bindings of second messengers in the rat brain. Araki T, et al. **Brain Res** 1995 Dec 18; 704(2):227–32

Effects of aging on N–methyl–D–aspartate (NMDA)–induced GnRH and LH release in female rats. Arias P, et al. **Brain Res** 1996 Nov 18;740(1–2):234–8

N–acetylcysteine protects against age–related increase in oxidized proteins in mouse synaptic mitochondria. Banaclocha MM, et al. **Brain Res** 1997 Jul 11; 762(1–2):256–8

Thalamocortical afferents in rat transiently express high–affinity serotonin uptake sites. Bennett–Clarke CA, et al. **Brain Res** 1996 Sep 16;733(2):301–6

Age–dependent increases in protein kinase C–alpha beta immunoreactivity and activity in the human brain: possible in vivo modulatory effects on guanine nucleotide regulatory G(i) proteins. Busquets X, et al. **Brain Res** 1996 Feb 26;710(1–2):28–34

Neuronal plasticity in aging: a quantitative immunohistochemical study of GAP–43 distribution in discrete regions of the rat brain. Casoli T, et al. **Brain Res** 1996 Apr 1;714(1–2):111–7

Age–related changes of VIP, NPY and somatostatin–immunoreactive neurons in the cerebral cortex of aged rats. Cha CI, et al. **Brain Res** 1997 Apr 11;753(2):235–44

Caloric restriction enhances evoked DA overflow in striatum and nucleus accumbens of aged Fischer 344 rats. Diao LH, et al. **Brain Res** 1997 Jul 25;763(2):276–80

V+ fibronectin mRNA is increased in the brains of aged rats: effect of food restriction. Dorner H, et al. **Brain Res** 1996 Jul 8;726(1–2):198–206

Glycogen phosphorylase activity in the cerebral cortex of rats during development: effect of homocysteine–induced seizures. Folbergrová J. **Brain Res** 1995 Oct 2; 694(1–2):128–32

Beta–adrenoceptor control of cardiac adenylyl cyclase during development: agonist pretreatment in the neonate uniquely causes heterologous sensitization, not desensitization. Giannuzzi CE, et al. **Brain Res** 1995 Oct 2;694(1–2):271–8

Differential expression of MAG, MBP and L1 in the developing lateral superior olive. Hafidi A, et al. **Brain Res** 1996 Oct 14;736(1–2):35–43

Co–localization of beta–amyloid peptides, apolipoprotein E and glial markers in senile plaques in the prefrontal cortex of old rhesus monkeys. Härtig W, et al. **Brain Res** 1997 Mar 21;751(2):315–22

Somatostatin and brain–derived neurotrophic factor mRNA expression in the primate brain: decreased levels of mRNAs during aging. Hayashi M, et al. **Brain Res** 1997 Feb 28; 749(2):283–9

Astrocytes in the aged rat spinal cord fail to increase GFAP mRNA following sciatic nerve axotomy. Kane CJ, et al. **Brain Res** 1997 Jun 6;759(1):163–5

Age–related assessment of central 5–HT1A receptors following irreversible inactivation by N–ethoxycarbonyl–2–ethoxy–1,2–dihydroquinoline (EEDQ). Keck J, et al. **Brain Res** 1996 Jul 22;728(1):130–4

Effects of ethanol and nomifensine on NE clearance in the cerebellum of young and aged Fischer 344 rats. Lin AM, et al. **Brain Res** 1997 May 9;756(1–2):287–92

Age–related increase in oxidized proteins in mouse synaptic mitochondria. Martinez M, et al. **Brain Res** 1996 Aug 26; 731(1–2):246–8

Distinct cellular compartment of cyclin–dependent kinase 5 (Cdk5) and neuron–specific Cdk5 activator protein (p35nck5a) in the developing rat cerebellum. Matsushita M, et al. **Brain Res** 1996 Sep 23;734(1–2):319–22

SC1, a brain extracellular matrix glycoprotein related to SPARC and follistatin, is expressed by rat cerebellar astrocytes following injury and during development. Mendis DB, et al. **Brain Res** 1996 Aug 19;730(1–2):95–106

The maturation of GABA(A) receptor–mediated control of luteinizing hormone secretion in immature male rats. Mitsushima D, et al. **Brain Res** 1997 Feb 14;748(1–2):258–62

Localization and developmental changes of the expression of two inward rectifying K(+)–channel proteins in the rat brain. Miyashita T, et al. **Brain Res** 1997 Mar 7; 750(1–2):251–63

Thyroid hormone–induced GLUT–1 expression in rat cerebral tissue: effect of age. Mooradian AD, et al. **Brain Res** 1997 Jan 30;747(1):144–6

Transganglionic response of GAP–43 in the gracile nucleus to sciatic nerve injury in young and aged rats. Ohara S, et al. **Brain Res** 1995 Dec 24;705(1–2):325–31

Apparent absence of aging and gender effects on serotonin 1A receptors in human neocortex and hippocampus. Palego L, et al. **Brain Res** 1997 May 30;758(1–2):26–32

Aging impairs regulation of intracellular pH in rat hippocampal slices. Roberts EL Jr, et al. **Brain Res** 1996 Oct 7;735(2):339–42

Age–related modifications on the GABAA receptor binding properties from Wistar rat prefrontal cortex. Ruano D, et al. **Brain Res** 1996 Oct 28;738(1):103–8

Age–related changes of oxygen free radical production in the rat brain slice after hypoxia: on–line measurement using enhanced chemiluminescence. Schreiber SJ, et al. **Brain Res** 1995 Dec 12;703(1–2):227–30

The dephosphorylation of glial fibrillary acidic protein (GFAP) in the immature rat hippocampus is catalyzed mainly by a type 1 protein phosphatase. Vinadé L, et al. **Brain Res** 1996 Sep 2;732(1–2):195–200

Chronic nicotine treatment delays the developmental increase in brain muscarinic receptors in rat neonate. Zhu J, et al. **Brain Res** 1996 Sep 2;732(1–2):257–60

Advanced glycation endproducts in ageing and Alzheimer's disease. Münch G, et al. **Brain Res Brain Res Rev** 1997 Feb;23(1–2):134–43 (78 ref.)

The effects of aging on spinal neurochemistry in the rat. Ko ML, et al. **Brain Res Bull** 1997;42(2):95–8

Tyrosine hydroxylase and DOPA decarboxylase activities in the medical preoptic area and arcuate nucleus during the estrous cycle: effects of aging. Mohankumar PS, et al. **Brain Res Bull** 1997;42(4):265–71

Synaptophysin immunoreactivity in the aging rat pituitary gland. Saland LC, et al. **Brain Res Bull** 1997;43(6):561–4

Different responses of gonadotropin–releasing hormone (GnRH) release to glutamate receptor agonists during aging. Sortino MA, et al. **Brain Res Bull** 1996;41(6):359–62

Nerve growth factor, central nervous system apoptosis, and adrenocortical activity in aged Fischer–344/brown Norway F1 hybrid rats. Taglialatela G, et al. **Brain Res Bull** 1997;43(2):229–33

Excitotoxic lesions of the rat striatum: different responses of kynurenine pathway enzymes during ontogeny. Ceresoli G, et al. **Brain Res Dev Brain Res** 1996 Mar 29;92(1):61–9

Ontogeny of heme oxygenase activity in the hippocampus, frontal cerebral cortex, and cerebellum of the guinea pig. Cook MN, et al. **Brain Res Dev Brain Res** 1996 Mar 29; 92(1):18–23

Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. Court JA, et al. **Brain Res Dev Brain Res** 1997 Jul 18;101(1–2):93–105

Age–related changes in calcitonin gene–related peptide and substance P in renal afferent nerve soma in the rat. Association with afferent renal nerve activity. Doutova EA, et al. **Brain Res Dev Brain Res** 1996 Dec 23;97(2):260–8

The effects of bupropion in vivo in the neostriatum of 5–day–old and adult rats. Gazzara RA, et al. **Brain Res Dev Brain Res** 1997 May 20;100(1):139–42

Synaptophysin–like immunoreactivity in the rat olfactory bulb during postnatal development and after restricted early olfactory experience. Johnson BA, et al. **Brain Res Dev Brain Res** 1996 Mar 29;92(1):24–30

Development and activity–dependent expression of neuronal marker proteins in organotypic cultures of rat visual cortex. Kierstein G, et al. **Brain Res Dev Brain Res** 1996 Mar 29; 92(1):39–48

Prostaglandin uptake and catabolism by the choroid plexus during development in sheep. Krunic N, et al. **Brain Res Dev Brain Res** 1997 May 20;100(1):82–9

Ontogeny of NMDA R1 subunit protein expression in five regions of rat brain. Luo J, et al. **Brain Res Dev Brain Res** 1996 Mar 29;92(1):10–7

Calretinin immunoreactivity in the developing olfactory system of the rainbow trout. Porteros A, et al. **Brain Res Dev Brain Res** 1997 May 20;100(1):101–9

Distribution of muscarinic receptor subtypes in rat brain from postnatal to old age. Tice MA, et al. **Brain Res Dev Brain Res** 1996 Mar 29;92(1):70–6

Alpha2B adrenoceptor mRNA expression during rat brain development. Winzer–Serhan UH, et al. **Brain Res Dev Brain Res** 1997 May 20;100(1):90–100

Alterations of cAMP response element–binding activity in the aged rat brain in response to administration of rolipram, a cAMP–specific phosphodiesterase inhibitor. Asanuma M, et al. **Brain Res Mol Brain Res** 1996 Sep 5;41(1–2):210–5

Age–related changes in the expression of corticotropin–releasing hormone receptor mRNA in the rat pituitary. Ceccatelli S, et al. **Brain Res Mol Brain Res** 1996 Apr;37(1–2):175–80

Sodium channel alpha–subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): different expression patterns in developing rat nervous system. Felts PA, et al. **Brain Res Mol Brain Res** 1997 Apr;45(1):71–82

GABAA receptor subunit expression changes in the rat cerebellum and cerebral cortex during aging. Gutiérrez A, et al. **Brain Res Mol Brain Res** 1997 Apr;45(1):59–70

Decreased NGFI–A gene expression in the hippocampus of cognitively impaired aged rats. Yau JL, et al. **Brain Res Mol Brain Res** 1996 Dec;42(2):354–7

Age–associated decline in human femoral neck cortical and trabecular content of insulin–like growth factor I: potential implications for age–related (type II) osteoporotic fracture occurrence. Boonen S, et al. **Calcif Tissue Int** 1997 Sep; 61(3):173–8

Influence of ovariectomy on bone metabolism in very old rats. Gaumet N, et al. **Calcif Tissue Int** 1996 Apr; 58(4):256–62

Effects of acute and long–term administration of prolactin

on bone 45Ca uptake, calcium deposit, and calcium resorption in weaned, young, and mature rats. Krishnamra N, et al. **Can J Physiol Pharmacol** 1996 Oct;74(10):1157–65

Aging exaggerates the blood glucose response to total parenteral nutrition. Watters JM, et al. **Can J Surg** 1996 Dec;39(6):481–5

Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Balducci L, et al. **Cancer** 1997 Oct 1;80(7):1317–22 (51 ref.)

Aging and pharmacology. Vestal RE. **Cancer** 1997 Oct 1; 80(7):1302–10 (49 ref.)

Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat. Cusack BJ, et al. **Cancer Chemother Pharmacol** 1997;39(6):505–12

Beta-adrenoceptor function changes with age of subject in myocytes from non-failing human ventricle. Davies CH, et al. **Cardiovasc Res** 1996 Jan;31(1):152–6

Light microscopic radioautographic study on DNA synthesis of nerve cells in the cerebella of aging mice. Cui H. **Cell Mol Biol (Noisy-le-grand)** 1995 Dec;41(8):1139–54

Posttranslational modifications of brain and erythrocyte band 3 during aging and disease [published erratum appears in Cell Mol Biol (Noisy-le-grand) 1997 May;43(3):469] Kay MM, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Nov; 42(7):919–44

Age-related changes of RNA synthesis in the lungs of aging mice by light and electron microscopic radioautography. Sun L. **Cell Mol Biol (Noisy-le-grand)** 1995 Dec; 41(8):1061–72

Subcellular distribution of soluble and membrane-bound Arg-beta-naphthylamide hydrolyzing activities in the developing and aged rat brain. Arechaga G, et al. **Cell Mol Biol Res** 1995;41(5):369–75

Diminished heat shock response in the aged myocardium. Locke M, et al. **Cell Stress Chaperones** 1996 Dec; 1(4):251–60

Light-microscopical investigation of the distribution of extracellular matrix molecules and calcifications in human dental pulps of various ages. Hillmann G, et al. **Cell Tissue Res** 1997 Jul;289(1):145–54

Type II collagen and TGF-betas in developing and aging porcine mandibular condylar cartilage: immunohistochemical studies. Moroco JR, et al. **Cell Tissue Res** 1997 Jul;289(1):119–24

Variation in nitric oxide synthase-immunoreactive nerve fibres with age and along the length of the vas deferens in the rat. Ventura S, et al. **Cell Tissue Res** 1996 Sep; 285(3):427–34

Increase of aldehydic compounds derived from plasmalogens in the brain of aged cattle. Weisser M, et al. **Chem Phys Lipids** 1996 Aug 19;82(2):173–8

Reactive oxygen-mediated protein oxidation in aging and disease. Stadtman ER, et al. **Chem Res Toxicol** 1997 May; 10(5):485–94 (154 ref.)

Nutritional influences in early life upon obesity and body proportions. Jackson AA, et al. **Ciba Found Symp** 1996; 201:118–29; discussion 129–37, 188–93 (54 ref.)

Alterations of mRNA levels of alpha 1-adrenoceptor subtypes with maturation and ageing in different rat blood vessels. Xu KM, et al. **Clin Exp Pharmacol Physiol** 1997 Jun;24(6):415–7

Age-related changes in cerebral and peripheral monoamine contents in stroke-prone spontaneously hypertensive rats. Uchida T, et al. **Clin Exp Pharmacol Physiol Suppl** 1995; 1:S80–2

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Sotaniemi EA, et al. **Clin Pharmacol Ther** 1997 Mar;61(3):331–9

Aging effects on the organic base transporter and stereoselective renal clearance. Ujhelyi MR, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):117–28

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Wong SL, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):157–64

Age influence on intestinal taurine transport in mice. Barada KA, et al. **Comp Biochem Physiol A Physiol** 1997 Sep; 118(1):159–63

Intestinal lipid esterification and aging in mice and rats. Poirier H, et al. **Comp Biochem Physiol A Physiol** 1997 Mar;116(3):253–60

Pathways of adenine nucleotide metabolism: degradation and resynthesis of IMP in ageing chicken heart. Wegelin I, et al. **Comp Biochem Physiol A Physiol** 1996 Jun;114(2):99–104

Comparison of age-related differences in expression of phospholipid hydroperoxide glutathione peroxidase mRNA and activity in various tissues of pigs. Lei XG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):109–14

The patterning and onset of opsin expression in vertebrate retinae. Cepko CL. **Curr Opin Neurobiol** 1996 Aug; 6(4):542–6 (32 ref.)

Species-specific expression of type II TGF-beta receptor isoforms by articular chondrocytes: effect of proteoglycan depletion and aging. Glansbeek HL, et al. **Cytokine** 1997 May;9(5):347–51

Acetylcholinesterase activity of synaptic plasma membranes during ageing: effect of L-acetylcarnitine. Gorini A, et al. **Dementia** 1996 May-Jun;7(3):147–54

Alterations in tau protein metabolism during normal aging. Mukaetova-Ladinska EB, et al. **Dementia** 1996 Mar-Apr; 7(2):95–103

Platelet-activating factor acetylhydrolase expression and activity suggest a link between neuronal migration and platelet-activating factor. Albrecht U, et al. **Dev Biol** 1996 Dec 15;180(2):579–93

Developmental expression of laminin-5 and HD1 in the intestine: epithelial to mesenchymal shift for the laminin gamma-2 chain subunit deposition. Orian-Rousseau V, et al. **Dev Dyn** 1996 May;206(1):12–23

Troponin I isoform expression is developmentally regulated in differentiating embryonic stem cell-derived cardiac myocytes. Westfall MV, et al. **Dev Dyn** 1996 May; 206(1):24–38

Localization of mRNA for UDP-galactose: ceramide galactosyltransferase in the brain during mouse development. Kagawa T, et al. **Dev Neurosci** 1996; 18(4):309–18

Regulation of myelin oligodendrocyte glycoprotein in different species throughout development. Slavin AJ, et al. **Dev Neurosci** 1997;19(1):69–78

Low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of Zucker diabetic fatty rats. MacDonald MJ, et al. **Diabetes** 1996 Nov; 45(11):1626–30

Islet amyloid polypeptide/amylin contents in pancreas change with increasing age in genetically obese and diabetic mice. Takada K, et al. **Diabetes Res Clin Pract** 1996 Aug; 33(3):153–8

Malondialdehyde and glutathione in rat gastric mucosa and effects of exogenous melatonin [letter] Akbulut H, et al. **Dig Dis Sci** 1997 Jul;42(7):1381–2

Distribution of beta-adrenoceptor subtypes in gastrointestinal tract of nondiabetic and diabetic BB rats. A longitudinal study. Yu O, et al. **Dig Dis Sci** 1997 Jun;42(6):1146–53

Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats. Taljanski W, et al. **Drug Metab Dispos** 1997 Aug; 25(8):917–20

Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations. Bernus I, et al. **Drugs Aging** 1997 Apr;10(4):278–89 (71 ref.)

A medication capture and analysis system for use in epidemiology. Thomson WM. **Drugs Aging** 1997 Apr; 10(4):290–8 (16 ref.)

Role of the Maillard reaction in diabetes mellitus and diseases of aging. Thorpe SR, et al. **Drugs Aging** 1996 Aug; 9(2):69–77 (47 ref.)

Dehydroepiandrosterone and diseases of aging. Watson RR, et al. **Drugs Aging** 1996 Oct;9(4):274–91 (141 ref.)

Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Wimalawansa SJ. **Endocr Rev** 1996 Oct; 17(5):533–85 (655 ref.)

Expression of 17beta-hydroxysteroid dehydrogenase type 1 and type 2, P450 aromatase, and 20alpha-hydroxysteroid dehydrogenase enzymes in immature, mature, and pregnant rats. Akinola LA, et al. **Endocrinology** 1997 Jul; 138(7):2886–92

In vivo insulin-dependent glucose uptake of specific tissues is decreased during aging of mature Wistar rats. Escriva F, et al. **Endocrinology** 1997 Jan;138(1):49–54

Effect of 3,5,3'-triiodothyronine on maturation of rat renal phosphate transport: kinetic characteristics and phosphate transporter messenger ribonucleic acid and protein abundance. Euzet S, et al. **Endocrinology** 1996 Aug; 137(8):3522–30

Pre- and postnatal low protein diet affect pancreatic islet blood flow and insulin release in adult rats. Iglésias-Barreira V, et al. **Endocrinology** 1996 Sep; 137(9):3797–801

Developmental expression of proprotein-processing endoprotease furin in rat pancreatic islets. Kayo T, et al. **Endocrinology** 1996 Nov;137(11):5126–34

Ontogenic changes in the expression of cytochrome c oxidase subunit I gene in the cerebellar cortex of the perinatal hypothyroid rat. Koibuchi N, et al. **Endocrinology** 1996 Nov;137(11):5096–108

Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1. Sonntag WE, et al. **Endocrinology** 1997 Aug;138(8):3515–20

Human pancreatic beta-cell deoxyribonucleic acid-synthesis in islet grafts decreases with increasing organ donor age but increases in response to glucose stimulation in vitro. Tyrberg B, et al. **Endocrinology** 1996 Dec;137(12):5694–9

Localization of cellular retinoic acid-binding protein (CRABP) II and CRABP in developing rat testis. Zheng WL, et al. **Endocrinology** 1996 Nov;137(11):5028–35

Brain creatine kinase reaction rates and reactant concentrations during seizures in developing rats. Holtzman D, et al. **Epilepsy Res** 1997 Apr;27(1):7–11

Expressions of a calcium-binding protein (spot35/calbindin-D28K) in mouse olfactory cells: possible relationship to neuronal differentiation. Fujiwara M, et al. **Eur Arch Otorhinolaryngol** 1997;254(2):105–9

Influence of age on the production of interleukin-8-like chemokine (GRO/CINC-1) in rat nasal mucosa. Himi T, et al. **Eur Arch Otorhinolaryngol** 1997;254(2):101–4

Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Lacroix D, et al. **Eur J Biochem** 1997 Jul 15; 247(2):625–34

Variations in serum cholinesterase activity in different age and sex groups. Genç S, et al. **Eur J Clin Chem Clin Biochem** 1997 Mar;35(3):239–40

Human low-density lipoproteins: oxidative modification and its relation to age, gender, menopausal status and cholesterol concentrations. Mosinger BJ. **Eur J Clin Chem Clin Biochem** 1997 Mar;35(3):207–14

Serum and urine markers of type I collagen metabolism in elderly women with high and low bone mineral density. Cheng S, et al. **Eur J Clin Invest** 1996 Mar;26(3):186–91

Relationship between feeding pattern and body mass index in 220 free-living people in four age groups. Summerbell CD, et al. **Eur J Clin Nutr** 1996 Aug;50(8):513–9

Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. Russmann S, et al. **Eur J Clin Pharmacol** 1997;52(1):31–5

Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. Zeeh J, et al. **Eur J Clin Pharmacol** 1996;49(5):387–91

Developmental changes and differential regulation by testosterone and estradiol of growth hormone receptor expression in the rabbit. Yu YM, et al. **Eur J Endocrinol** 1996 Nov;135(5):583–90

Contrasts in the gonadotropin-releasing hormone dose-response relationships for luteinizing hormone, follicle-stimulating hormone and alpha-subunit release in young versus older men: appraisal with high-specificity immunoradiometric assay and deconvolution analysis. Zwart AD, et al. **Eur J Endocrinol** 1996 Oct;135(4):399–406

Ontogenetic development of 5-HT1D receptors in human brain: an autoradiographic study. del Olmo E, et al. **Eur J Neurosci** 1996 Jan;8(1):53–60

Decreased expression of TrkB and TrkC mRNAs in spinal motoneurons of aged rats. Johnson H, et al. **Eur J Neurosci** 1996 Mar;8(3):494–9

Role of thyroid hormone in the morphological differentiation and maturation of astrocytes: temporal correlation with synthesis and organization of actin. Paul S, et al. **Eur J Neurosci** 1996 Nov;8(11):2361–70

The G-protein gamma-subunit G gamma 8 is expressed in the developing axons of olfactory and vomeronasal neurons. Tirindelli R, et al. **Eur J Neurosci** 1996 Nov; 8(11):2388–98

Evidence for an age-dependent functional expression of alpha 1D-adrenoceptors in the rat vasculature. Ibarra M, et al. **Eur J Pharmacol** 1997 Mar 19;322(2-3):221–4

Differences in isoproterenol stimulation of Ca2+ current of rat ventricular myocytes in neonatal compared to adult. Katsube Y, et al. **Eur J Pharmacol** 1996 Dec 19; 317(2-3):391–400

Ageing is associated with changes in glutamate release, protein tyrosine kinase and Ca2+/calmodulin-dependent protein kinase II in rat hippocampus. Mullany P, et al. **Eur J Pharmacol** 1996 Aug 15;309(3):311–5

Depletion of serotonin, dopamine and noradrenaline in aged rats decreases the therapeutic effect of nicotine, but not of tetrahydroaminoacridine. Riekkinen M, et al. **Eur J Pharmacol** 1996 Jul 25;308(3):243–50

Induction of tyrosine hydroxylase by forskolin: modulation with age. Tümer N, et al. **Eur J Pharmacol** 1997 Apr 11; 324(1):57–62

Dopamine D3 receptor density elevation in aged Fischer-344 x Brown-Norway (F1) rats. Wallace DR, et al. **Eur J Pharmacol** 1996 Jul 25;308(3):283–5

The effects of hydergine on the MAO activity of the aged and adult rat brain. Büyüköztürk A, et al. **Eur Neuropsychopharmacol** 1995 Dec;5(4):527–9

Neutral endopeptidase activity in newborn and adult rabbit tracheas. Haver K, et al. **Eur Respir J** 1997 Aug; 10(8):1844–9

Age-associated changes in basal c-fos transcription factor binding activity in rat hearts. Tsou H, et al. **Exp Cell Res** 1996 Dec 15;229(2):432–7

Age-related changes in bovine alpha-crystallin and high-molecular-weight protein. Carver JA, et al. **Exp Eye Res** 1996 Dec;63(6):639–47

Age-related accumulation of 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3- carboxylic acid in human lens. Manabe S, et al. **Exp Eye Res** 1996 Aug;63(2):179–86

Increase in the intramolecular disulfide bonding of alpha-A crystallin during aging of the human lens. Takemoto L. **Exp Eye Res** 1996 Nov;63(5):585–90

Age-related postreceptor mechanisms: changes in adenylate cyclase but not phosphodiesterase in isolated mouse renal medullary collecting ducts. Davidson YS, et al. **Exp Gerontol** 1995 Nov-Dec;30(6):594–604

The error catastrophe theory of aging. Point counterpoint [letter] Gallant J, et al. **Exp Gerontol** 1997 May-Jun; 32(3):333–46 (28 ref.)

No effect of age on the dose requirement of thiopental in the rat. Harashima H, et al. **Exp Gerontol** 1997 May-Jun; 32(3):315–24

Effect of aging on lipid peroxide levels induced by L-glutamic acid and estimated by means of a thiobarbituric acid test in rat brain tissue. Krištofiková Z, et al. **Exp Gerontol** 1995 Nov-Dec;30(6):645–57

Expression of endothelin, fibronectin, and mortalin as aging and mortality markers. Kumazaki T, et al. **Exp Gerontol** 1997 Jan-Apr;32(1-2):95–103 (35 ref.)

The influence of age and some inducers on UDP-glucuronyltransferase activity. Plewka A, et al.

Exp Gerontol 1997 May-Jun;32(3):305-13
Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates. Kordower JH, et al. **Exp Neurol** 1997 Jun;145(2 Pt 1):586-91
Age-dependent expression of the apamin-sensitive calcium-activated K+ channel in fast and slow rat skeletal muscle. Vergara C, et al. **Exp Neurol** 1997 Jul;146(1):282-5
Aging decreases the abundance of retinoic acid (RAR) and triiodothyronine (TR) nuclear receptor mRNA in rat brain: effect of the administration of retinoids. Enderlin V, et al. **FEBS Lett** 1997 Aug 4;412(3):629-32
Decrease of rotenone inhibition is a sensitive parameter of complex I damage in brain non-synaptic mitochondria of aged rats. Genova ML, et al. **FEBS Lett** 1997 Jun 30; 410(2-3):467-9
Excess formation of lysophosphatidic acid with age inhibits myristic acid-induced superoxide anion generation in intact human neutrophils. Ito Y, et al. **FEBS Lett** 1996 Sep 30; 394(2):149-52
Age-dependent decline in the cytochrome c oxidase activity in rat heart mitochondria: role of cardiolipin. Paradies G, et al. **FEBS Lett** 1997 Apr 7;406(1-2):136-8
Characterization and localization of leptin receptors in the rat kidney. Serradeil-Le Gal C, et al. **FEBS Lett** 1997 Mar 10;404(2-3):185-91
Comparison of 5-hydroxy-2-amino valeric acid with carbonyl group content as a marker of oxidized protein in human and mouse liver tissues. Ayala A, et al. **Free Radic Biol Med** 1996;21(4):551-8
Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rat. De La Cruz CP, et al. **Free Radic Biol Med** 1996;20(1):53-61
Aging and caloric restriction affect mitochondrial respiration and lipid membrane status: an electron paramagnetic resonance investigation. Gabbita SP, et al. **Free Radic Biol Med** 1997;23(2):191-201
Age differences in sensitivity to H2O2- or NO-induced reductions in K(+)-evoked dopamine release from superfused striatal slices: reversals by PBN or Trolox. Joseph JA, et al. **Free Radic Biol Med** 1996;20(6):821-30
Retarding effect of dietary restriction on the accumulation of 8-hydroxy-2'-deoxyguanosine in organs of Fischer 344 rats during aging. Kaneko T, et al. **Free Radic Biol Med** 1997;23(1):76-81
Increased transcription of the astrocyte gene GFAP during middle-age is attenuated by food restriction: implications for the role of oxidative stress. Morgan TE, et al. **Free Radic Biol Med** 1997;23(3):524-8
Aging and oxidative stress: modulation by dietary restriction. Yu BP. **Free Radic Biol Med** 1996;21(5):651-68 (164 ref.)
Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease. Mansouri A, et al. **Gastroenterology** 1997 Aug;113(2):599-605
Androgen biosynthesis and secretion in developing Xenopus laevis. Kang L, et al. **Gen Comp Endocrinol** 1995 Dec; 100(3):293-307
Localization of insulin-like growth factor-I immunoreactivity in larval and juvenile barramundi (Lates calcarifer). Richardson NA, et al. **Gen Comp Endocrinol** 1995 Dec;100(3):282-92
Expression of MCH and POMC genes in rainbow trout (Oncorhynchus mykiss) during ontogeny and in response to early physiological challenges. Suzuki M, et al. **Gen Comp Endocrinol** 1997 Sep;107(3):341-50
Obesity and diabetes: research points to genetic connection [interview by Mark E. Weksler] Shuldiner AR. **Geriatrics** 1997 Feb;52(2):57-60, 63-4
Variation in intervertebral disc serine proteinase inhibitory proteins with ageing in a chondrodystrophoid (beagle) and a non-chondrodystrophoid (greyhound) canine breed. Melrose J, et al. **Gerontology** 1996;42(6):322-9
Age-related changes in secretion and metabolic effects of a trial natriuretic factor in rats. Rakotondrazafy J, et al. **Gerontology** 1996;42(2):79-86
Nitric oxide-mediated cGMP synthesis in oligodendrocytes in the developing rat brain. Tanaka J, et al. **Glia** 1997 Apr; 19(4):286-97
Stage-specific expression of fuco-neolacto- (Lewis X) and ganglio-series neutral glycosphingolipids during brain development: characterization of Lewis X and related glycosphingolipids in bovine, human and rat brain. Dasgupta S, et al. **Glycoconj J** 1996 Jun;13(3):367-75
Growth hormone as a function of age and dietary protein: energy ratio in a marine teleost, the gilthead sea bream (Sparus aurata). Martí-Palanca H, et al. **Growth Regul** 1996 Dec;6(4):253-9
Postnatal age and food intake alter insulin-like growth factor-II/mannose-6-phosphate receptors in ovine skeletal muscles. Oldham JM, et al. **Growth Regul** 1996 Jun; 6(2):88-95
Premenopause-dependent changes. de Aloysio D, et al. **Gynecol Obstet Invest** 1996;42(2):120-7
Age-related changes in GFAP-immunoreactive astrocytes in the rat ventral cochlear nucleus. Jalenques I, et al. **Hear Res** 1997 May;107(1-2):113-24
The cochlear place-frequency map of the adult and developing Mongolian gerbil. Müller M. **Hear Res** 1996 May;94(1-2):148-56
Defects of the respiratory chain in the normal human liver and in cirrhosis during aging. Müller-Höcker J, et al. **Hepatology** 1997 Sep;26(3):709-19
Aging of the liver: age-associated mitochondrial damage in intact hepatocytes. Sastre J, et al. **Hepatology** 1996 Nov; 24(5):1199-205
Changes in the content of the fibrillar collagens and the expression of their mRNAs in the menisci of the rabbit knee joint during development and ageing. Bland YS, et al. **Histochem J** 1996 Apr;28(4):265-74
DNA fragmentation of oocytes in aged mice. Fujino Y, et al. **Hum Reprod** 1996 Jul;11(7):1480-3
Contrasting autonomic and hemodynamic effects of insulin in healthy elderly versus young subjects. Hausberg M, et al. **Hypertension** 1997 Mar;29(3):700-5
Hypertension causes premature aging of endothelial function in humans. Taddei S, et al. **Hypertension** 1997 Mar; 29(3):736-43
Altered regulation of inducible nitric oxide synthase expression in macrophages from senescent mice. Chen LC, et al. **Infect Immun** 1996 Oct;64(10):4288-98
Tissue-specific and developmental stage-dependent expression of a novel rat Dopa/tyrosine sulfotransferase. Araki Y, et al. **Int J Biochem Cell Biol** 1997 May; 29(5):801-6
Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Paul RG, et al. **Int J Biochem Cell Biol** 1996 Dec;28(12):1297-310 (98 ref.)
Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age. Bianchetti G, et al. **Int J Clin Pharmacol Ther** 1996 May;34(5):195-201
The influence of age on the pharmacokinetics of nimodipine. Mück W, et al. **Int J Clin Pharmacol Ther** 1996 Jul; 34(7):293-8
Postnatal changes of brain monoamine levels in prenatally malnourished and control rats. Chen JC, et al. **Int J Dev Neurosci** 1997 Apr;15(2):257-63
Stimulation of glutamine synthetase activity by excitatory amino acids in astrocyte cultures derived from aged mouse cerebral hemispheres may be associated with non-N-methyl-D-aspartate receptor activation. Fleischer-Lambropoulos E, et al. **Int J Dev Neurosci** 1996 Jul;14(4):523-30
Localisation and expression of metallothionein immunoreactivity in the developing sheep brain. Holloway AF, et al. **Int J Dev Neurosci** 1997 Apr;15(2):195-203
DNA polymerases delta and epsilon in developing and aging rat brain. Prapurna DR, et al. **Int J Dev Neurosci** 1997 Feb;15(1):67-73
Non-insulin dependent diabetes mellitus: a phenomenon of ageing? Heine RJ. **Int J Epidemiol** 1991;20 Suppl 1:S18-24 (38 ref.)
Androgen replacement therapy in women: myths and realities. Casson PR, et al. **Int J Fertil Menopausal Stud** 1996 Jul-Aug;41(4):412-22 (79 ref.)
Effects of maternal vitamin E and selenium status during the perinatal period on age-related changes in tissue concentration of vitamin E in rat pups. Pazak HE, et al. **Int J Vitam Nutr Res** 1996;66(2):126-33
Effects of maternal vitamin E and selenium status during the perinatal period on age-related changes in heart, lung and liver microsomal lipid peroxidation in rat pups. Pazak HE, et al. **Int J Vitam Nutr Res** 1996;66(2):134-40
Localization of the site of major resistance to fluid transport in Bruch's membrane. Starita C, et al. **Invest Ophthalmol Vis Sci** 1997 Mar;38(3):762-7
Decreased ratio of fat to carbohydrate oxidation with increasing age in Pima Indians. Rising R, et al. **J Am Coll Nutr** 1996 Jun;15(3):309-12
Relationship between baseline insulin-like growth factor-I (IGF-I) and femoral bone density in women aged over 70 years: potential implications for the prevention of age-related bone loss. Boonen S, et al. **J Am Geriatr Soc** 1996 Nov;44(11):1301-6
Structural modifications of proteins during aging. Gafni A. **J Am Geriatr Soc** 1997 Jul;45(7):871-80 (133 ref.)
Glucose metabolism in older adults: a study including subjects more than 80 years of age. Garcia GV, et al. **J Am Geriatr Soc** 1997 Jul;45(7):813-7
Pharmacotherapy for elderly women. Noyes MA. **J Am Med Womens Assoc** 1997 Summer;52(3):138-41, 158
Are Leydig cell steroidogenic enzymes differentially regulated with aging? Luo L, et al. **J Androl** 1996 Sep-Oct; 17(5):509-15
Metabolic changes during the transition from the fed to the acute feed-deprived state in prepuberal and mature gilts. Barb CR, et al. **J Anim Sci** 1997 Mar;75(3):781-9
Influence of lipopolysaccharide-induced immune challenge and diet complexity on growth performance and acute-phase protein production in segregated early-weaned pigs. Dritz SS, et al. **J Anim Sci** 1996 Jul; 74(7):1620-8
Duodenal flow of microbial nitrogen estimated from urinary excretion of purine derivatives in calves after early weaning. Funaba M, et al. **J Anim Sci** 1997 Jul; 75(7):1965-73
Effect of hemoglobin and immunization status on energy metabolism of weanling pigs. Gentry JL, et al. **J Anim Sci** 1997 Apr;75(4):1032-40
Effect of protein and protein-free energy intake on protein and fat deposition rates in preruminant calves of 80 to 240 kg live weight. Gerrits WJ, et al. **J Anim Sci** 1996 Sep; 74(9):2129-39
Growth performance and enzyme development in weanling pigs injected with dexamethasone. Gómez S, et al. **J Anim Sci** 1997 Apr;75(4):993-1000
Supplemental phytases of microbial and cereal sources improve dietary phytate phosphorus utilization by pigs from weaning through finishing. Han YM, et al. **J Anim Sci** 1997 Apr;75(4):1017-25
Fatty acid composition of subcutaneous adipose tissue from male calves at different stages of growth. Huerta-Leidenz NO, et al. **J Anim Sci** 1996 Jun;74(6):1256-64
Insulin resistance, hyperglycemia, glucosuria, and galactosuria in intensively milk-fed calves: dependency on age and effects of high lactose intake. Hugi D, et al. **J Anim Sci** 1997 Feb;75(2):469-82
Influence of galactosyl lactose on energy and protein digestibility, enteric microflora, and performance of weanling pigs. Mathew AG, et al. **J Anim Sci** 1997 Apr; 75(4):1009-16
Pancreatic exocrine secretion during the first days after weaning in pigs. Rantzer D, et al. **J Anim Sci** 1997 May; 75(5):1324-31
Influence of prepubertal feeding level on milk yield potential of dairy heifers: a review. Sejrsen K, et al. **J Anim Sci** 1997 Mar;75(3):828-35 (63 ref.)
mRNA levels of the calpain system in longissimus muscle of young pigs during prolonged feeding of a protein-free diet. van den Hemel-Grooten HN, et al. **J Anim Sci** 1997 Apr;75(4):968-74
Muscle capillarization O2 diffusion distance, and VO2 kinetics in old and young individuals. Chilibeck PD, et al. **J Appl Physiol** 1997 Jan;82(1):63-9
Differential effects of exercise and heat stress on liver HSP70 accumulation with aging. Kregel KC, et al. **J Appl Physiol** 1996 Feb;80(2):547-51
Norepinephrine spillover at rest and during submaximal exercise in young and old subjects. Mazzeo RS, et al. **J Appl Physiol** 1997 Jun;82(6):1869-74
Effects of aging and obesity on respiratory muscle phenotype in Zucker rats. Powers SK, et al. **J Appl Physiol** 1996 Sep; 81(3):1347-54
Rates of free fatty acid appearance and fat oxidation in healthy younger and older men. Toth MJ, et al. **J Appl Physiol** 1996 Feb;80(2):506-11
Endurance exercise training decreases capillary basement membrane width in older nondiabetic and diabetic adults. Williamson JR, et al. **J Appl Physiol** 1996 Mar;80(3):747-53
Age-related changes in lipid secretion of perfused livers from male Wistar rats donors. Bravo E, et al. **J Biochem (Tokyo)** 1996 Feb;119(2):240-5
Chronic fenfluramine treatment of rats with different ages: effects on brain oxidative stress-related parameters. D'Almeida V, et al. **J Biochem Toxicol** 1996;11(4):197-201
Development and age-associated differences in electron transport potential and consequences for oxidant generation. Allen RG, et al. **J Biol Chem** 1997 Oct 3; 272(40):24805-12
Protein oxidation in aging, disease, and oxidative stress. Berlett BS, et al. **J Biol Chem** 1997 Aug 15;272(33):20313-6 (49 ref.)
Interleukin-1-induced ether-linked diglycerides inhibit calcium-insensitive protein kinase C isotypes. Implications for growth senescence. Mandal A, et al. **J Biol Chem** 1997 Aug 8;272(32):20306-11
The effect of aging on bone formation in porous hydroxyapatite: biochemical and histological analysis. Inoue K, et al. **J Bone Miner Res** 1997 Jun;12(6):989-94
Association between intestinal vitamin D receptor, calcium absorption, and serum 1,25 dihydroxyvitamin D in normal young and elderly women. Kinyamu HK, et al. **J Bone Miner Res** 1997 Jun;12(6):922-8
Evidence of a correlation of estrogen receptor level and avian osteoclast estrogen responsiveness. Pederson L, et al. **J Bone Miner Res** 1997 May;12(5):742-52
Keratin 19 as a biochemical marker of skin stem cells in vivo and in vitro: keratin 19 expressing cells are differentially localized in function of anatomic sites, and their number varies with donor age and culture stage. Michel M, et al. **J Cell Sci** 1996 May;109 (Pt 5):1017-28
Quantification of neuroreceptors in the living human brain: III. D2-like dopamine receptors: theory, validation, and changes during normal aging. Wong DF, et al. **J Cereb Blood Flow Metab** 1997 Mar;17(3):316-30
Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. Wong WF, et al. **J Cereb Blood Flow Metab** 1997 Mar;17(3):331-42
Autoradiographic mapping of serotonin 5-HT1A, 5-HT1D, 5-HT2A and 5-HT3 receptors in the aged human spinal cord. Laporte AM, et al. **J Chem Neuroanat** 1996 Jul; 11(1):67-75
Effect of ageing on human plasma glutathione concentrations as determined by high-performance liquid chromatography with fluorimetric detection. Yang CS, et al. **J Chromatogr B Biomed Appl** 1995 Dec 1;674(1):23-30
Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. Bellantoni MF, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2848-53
Comparison of pulsatile luteinizing hormone secretion between prepubertal children and young adults: evidence for a mass/amplitude-dependent difference without gender

or day/night contrasts. Clark PA, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2950–5

Defective hypothalamic growth hormone (GH)–releasing hormone activity may contribute to declining GH secretion with age in man. degli Uberti EC, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2885–8

Ovarian angiotensin–converting enzyme activity in humans: relationship to estradiol, age, and uterine pathology. Erman A, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1104–7

Aging and bone metabolism in African American and Caucasian women. Perry HM 3rd, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1108–17

Ontogeny of growth hormone receptors in human tissues: an immunohistochemical study. Simard M, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):3097–102

Differential sex steroid negative feedback regulation of pulsatile follicle-stimulating hormone secretion in healthy older men: deconvolution analysis and steady-state sex-steroid hormone infusions in frequently sampled healthy older individuals. Veldhuis JD, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1248–54

Endogenous glucose production following injury increases with age. Watters JM, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3005–10

Procollagen propeptide and pyridinium cross-links as markers of type I collagen turnover: sex- and age-related changes in healthy children. Zanze M, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2971–7

Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. Schleicher ED, et al. **J Clin Invest** 1997 Feb 1;99(3):457–68

Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. Wada J, et al. **J Clin Invest** 1997 May 15;99(10):2452–61

A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. Barbhaiya RH, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):19–25

Neuropeptides and neurotrophin receptor mRNAs in primary sensory neurons of aged rats. Bergman E, et al. **J Comp Neurol** 1996 Nov 11;375(2):303–19

Alterations of GABAA receptor subunit mRNA levels in the aging Fischer 344 rat inferior colliculus. Milbrandt JC, et al. **J Comp Neurol** 1997 Mar 17;379(3):455–65

Nerve growth factor receptor TrkA is down-regulated during postnatal development by a subset of dorsal root ganglion neurons. Molliver DC, et al. **J Comp Neurol** 1997 May 19;381(4):428–38

Species differences in vasopressin receptor binding are evident early in development: comparative anatomic studies in prairie and montane voles. Wang Z, et al. **J Comp Neurol** 1997 Feb 24;378(4):535–46

Stratification and age-related differences in blubber fatty acids of the male harbour porpoise (Phocoena phocoena). Koopman HN, et al. **J Comp Physiol [B]** 1996;165(8):628–39

Analysis of connective tissue macromolecular components in Ishibashi rat skin: role of collagen and elastin in cutaneous aging. Sakuraoka K, et al. **J Dermatol Sci** 1996 Sep;12(3):232–7

Ca2+ receptor mRNA and protein increase in the rat parathyroid gland with advancing age. Autry CP, et al. **J Endocrinol** 1997 Jun;153(3):437–44

Regulation by nutrition and age of insulin-like growth factor binding sites in ovine kidney. Martyn JA, et al. **J Exp Zool** 1997 Apr 1;277(5):382–9

Overload-induced C-Myc oncoprotein is reduced in aged skeletal muscle. Alway SE. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):B203–11

Vitamin E levels and susceptibility to lipid peroxidation increase with aging in heart plasma membrane from miniature swine. Banks MA, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov;51(6):B409–16

The stable, inactive but reactivatable, unfolding intermediate of rat muscle sarcoplasmic reticulum Ca(2+)-ATPase differs from the age-modified form of this protein. Bergenhem NC, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):B240–4

Effects of aging and food restriction on alpha 1-adrenergic receptors and G-protein in the rat parotid gland. Chen C, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar; 52(2):B103–10

The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test. De Ore K, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):B245–9

Bone mineral density and biochemical markers of bone turnover in healthy elderly men and women. Krall EA, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar;52(2):M61–7

Nitric oxide synthase in rat brain: age comparisons quantitated with NADPH-diaphorase histochemistry. Kuo H, et al. **J Gerontol A Biol Sci Med Sci** 1997 May; 52(3):B146–51

Aging impairs release of central and peripheral cholecystokinin (CCK) in male but not in female rats. Miyasaka K, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):M14–8

Adipose tissue-derived tumor necrosis factor-alpha activity is elevated in older rats. Morin CL, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):B190–5

Salivary cortisol levels and stress reactivity in human aging. Nicolson N, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar;52(2):M68–75

Validation of multifrequency bioelectrical impedance analysis in monitoring fluid balance in healthy elderly subjects. Olde Rikkert MG, et al. **J Gerontol A Biol Sci Med Sci** 1997 May;52(3):M137–41

Modulation by food restriction of intracellular calcium signaling in parotid acinar cells of aging Fischer 344 rats. Olsen JG, et al. **J Gerontol A Biol Sci Med Sci** 1997 May; 52(3):B152–8

Altered cellular heterogeneity as a possible mechanism for the maintenance of organ function in senescent animals. Ruhe RC, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan; 52(1):B53–8

Age-related association of tail tendon break time with tissue pentosidine in DBA/2 vs C57BL/6 mice: the effect of dietary restriction. Sell DR, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):B277–84

Effects of lifelong dietary restriction on somatotropes: immunohistochemical and functional aspects. Shimokawa I, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov; 51(6):B396–402

Exercise training reverses the age-related decline in tyrosine hydroxylase expression in rat hypothalamus. Tümer N, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):B255–9

Effect of aging on erythropoietin secretion in male rats. Wang RY, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov; 51(6):B434–8

The effect of aging on ANP levels in the plasma, heart, and brain of rats. Wu SQ, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):B250–4

Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholic patients. Mansouri A, et al. **J Hepatol** 1997 Jul;27(1):96–102

Changes in CD44 and ApoE immunoreactivities due to retinal pathology of man and rat. Kuhrt H, et al. **J Hirnforsch** 1997;38(2):223–9

Circulating angiotensin converting enzyme levels are increased in concentric, but not eccentric, left ventricular hypertrophy in elderly men. Reneland R, et al. **J Hypertens** 1997 Aug;15(8):885–90

Enhanced expression of inducible cyclooxygenase with age in murine macrophages. Hayek MG, et al. **J Immunol** 1997 Sep 1;159(5):2445–51

Aging is associated with reduced deposition of specific extracellular matrix components, an upregulation of angiogenesis, and an altered inflammatory response in a murine incisional wound healing model. Ashcroft GS, et al. **J Invest Dermatol** 1997 Apr;108(4):430–7

Transforming growth factor-beta receptor type I and type II expression during murine hair follicle development and cycling. Paus R, et al. **J Invest Dermatol** 1997 Oct; 109(4):518–26

Age-related changes in phospholipid fatty acid composition and monoaminergic neurotransmission in the hippocampus of rats fed a balanced or an n-3 polyunsaturated fatty acid-deficient diet. Delion S, et al. **J Lipid Res** 1997 Apr; 38(4):680–9

Characterization of a human cardiac gene which encodes for a LIM domain protein and is developmentally expressed in myocardial development. Fung YW, et al. **J Mol Cell Cardiol** 1996 Jun;28(6):1203–10

beta-Adrenergic and muscarinic receptor expression are regulated in opposite ways during senescence in rat left ventricle. Hardouin S, et al. **J Mol Cell Cardiol** 1997 Jan; 29(1):309–19

Aging-induced up-regulation of nuclear binding activities of oxidative stress responsive NF-kB transcription factor in mouse cardiac muscle. Helenius M, et al. **J Mol Cell Cardiol** 1996 Mar;28(3):487–98

The expression of parathyroid hormone and parathyroid hormone-related protein in developing rat parathyroid glands. Tucci J, et al. **J Mol Endocrinol** 1996 Oct; 17(2):149–57

Four repeat high-mol-wt MAP2 forms in rat dorsal root ganglia. Forleo P, et al. **J Mol Neurosci** 1996 Fall; 7(3):193–201

Quantitative analysis of low molecular weight G-actin-binding proteins, cofilin, ADF and profilin, expressed in developing and degenerating chicken skeletal muscles. Nagaoka R, et al. **J Muscle Res Cell Motil** 1996 Aug;17(4):463–73

Age-related changes of sodium-dependent D-[3H]aspartate and [3H]FK506 binding in rat brain. Araki T, et al. **J Neural Transm** 1997;104(2–3):259–67

Brain monoaminergic and neuropeptidergic variations in human aging. Arranz B, et al. **J Neural Transm** 1996; 103(1–2):101–15

Synaptophysin in spinal anterior horn in aging and ALS: an immunohistological study. Cruz-Sánchez FF, et al. **J Neural Transm** 1996;103(11):1317–29

Effects of chronic treatment with a cyclic AMP-selective phosphodiesterase inhibitor, rolipram, on excitatory amino acid neurotransmission systems in young and aged rat brains. Kato H, et al. **J Neural Transm** 1997;104(2–3):269–80

Effect of age on synthesis of the GABAergic steroids 5-alpha-pregnane-3,20-dione and 5-alpha-pregnane-3-alpha-ol-20-one in rat cortex in vitro. Stuerenburg HJ, et al. **J Neural Transm** 1997; 104(2–3):249–57

Expression of neuronal acetylcholine nicotinic receptor alpha 4 and beta 2 subunits during postnatal development of the rat brain. Cimino M, et al. **J Neural Transm Gen Sect** 1995; 100(2):77–92

Effects of (-)-sulpiride on dopamine release in striatum of developing rats: degree of depolarization influences responsiveness. Andersen SL, et al. **J Neurochem** 1996 Nov; 67(5):1931–7

Changes in brain protease activity in aging. Benuck M, et al. **J Neurochem** 1996 Nov;67(5):2019–29

Novel endogenous protein kinase C substrate proteins, neutrinins, in brain synaptic membranes of maturing rat. Chen XF, et al. **J Neurochem** 1996 May;66(5):2067–73

Functional impairment in protein kinase C by RACK1 (receptor for activated C kinase 1) deficiency in aged rat brain cortex. Pascale A, et al. **J Neurochem** 1996 Dec; 67(6):2471–7

Structure of the C-terminal tail of alpha-tubulin: increase of heterogeneity from newborn to adult. Redeker V, et al. **J Neurochem** 1996 Nov;67(5):2104–14

A globular, not asymmetric, form of acetylcholinesterase is expressed in chick motor neurons: down-regulation toward maturity and after denervation. Tsim KW, et al. **J Neurochem** 1997 Feb;68(2):479–87

Developmental and regional expression of NMDA receptor subtypes containing the NR2D subunit in rat brain. Wenzel A, et al. **J Neurochem** 1996 Mar;66(3):1240–8

Effects of chronic ethanol consumption and aging on dopamine, serotonin, and metabolites. Woods JM, et al. **J Neurochem** 1996 May;66(5):2168–78

Glial organization and chondroitin sulfate proteoglycan expression in the developing thalamus. Mitrofanis J, et al. **J Neurocytol** 1997 Feb;26(2):83–100

Unchanged amounts of vasopressin mRNA in the supraoptic and paraventricular nucleus during aging and in Alzheimer's disease. Lucassen PJ, et al. **J Neuroendocrinol** 1997 Apr;9(4):297–305

Amyloid beta-protein (A beta) accumulation in the leptomeninges during aging and in Alzheimer disease. Hamano T, et al. **J Neuropathol Exp Neurol** 1997 Aug; 56(8):922–32

Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. Ii K, et al. **J Neuropathol Exp Neurol** 1997 Feb;56(2):125–31

APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. Irizarry MC, et al. **J Neuropathol Exp Neurol** 1997 Sep; 56(9):965–73

Distinct neurodevelopmental patterns of bcl-2 and bcl-x expression are altered in glioneuronal hamartias of the human temporal lobe. Yachnis AT, et al. **J Neuropathol Exp Neurol** 1997 Feb;56(2):186–98

Developmental regulation of synaptotagmin I, II, III, and IV mRNAs in the rat CNS. Berton F, et al. **J Neurosci** 1997 Feb 15;17(4):1206–16

Changing patterns of expression and subcellular localization of TrkB in the developing visual system. Cabelli RJ, et al. **J Neurosci** 1996 Dec 15;16(24):7965–80

Expression and distribution of IGF-1 receptors containing a beta-subunit variant (betagc) in developing neurons. Mascotti F, et al. **J Neurosci** 1997 Feb 15;17(4):1447–59

Developmental expression of platelet-derived growth factor alpha-receptor in neurons and glial cells of the mouse CNS. Oumesmar BN, et al. **J Neurosci** 1997 Jan 1;17(1):125–39

Emergence of activity-dependent, bidirectional control of microtubule-associated protein MAP2 phosphorylation during postnatal development. Quinlan EM, et al. **J Neurosci** 1996 Dec 1;16(23):7627–37

Thyroid hormone-responsive genes in developing cerebellum include a novel synaptotagmin and a hairless homolog. Thompson CC. **J Neurosci** 1996 Dec 15;16(24):7832–40

Ganglioside GD3 in radial glia and astrocytes in situ in brains of young and adult mice. Cammer W, et al. **J Neurosci Res** 1996 Oct 1;46(1):18–23

Expression of the chicken cysteine-rich fibroblast growth factor receptor (CFR) during embryogenesis and retina development. Fayein NA, et al. **J Neurosci Res** 1996 Mar 1;43(5):602–12

Age-associated alterations in hippocampal and basal forebrain nuclear factor kappa B activity. Toliver-Kinsky T, et al. **J Neurosci Res** 1997 Jun 15;48(6):580–7

Age-related diminution of dopamine antagonist-stimulated vesamicol receptor binding. Efange SM, et al. **J Nucl Med** 1996 Jul;37(7):1192–7

Age-related change of technetium-99m-HMDP distribution in the skeleton. Kigami Y, et al. **J Nucl Med** 1996 May; 37(5):815–8

Iodine-123-IPT SPECT imaging of CNS dopamine transporters: nonlinear effects of normal aging on striatal uptake values. Mozley PD, et al. **J Nucl Med** 1996 Dec; 37(12):1965–70

Sodium excretion influences calcium homeostasis in elderly men and women. Dawson-Hughes B, et al. **J Nutr** 1996 Sep;126(9):2107–12

Glucocorticoids play an important role in mediating the enhanced metabolism of arginine and glutamine in enterocytes of postweaning pigs. Flynn NE, et al. **J Nutr** 1997 May;127(5):732–7

Total intestinal lactase and sucrase activities are reduced in aged rats. Lee MF, et al. **J Nutr** 1997 Jul;127(7):1382–7

Expression of heat shock protein 70 in rat spleen lymphocytes is affected by age but not by food restriction. Pahlavani MA, et al. **J Nutr** 1996 Sep;126(9):2069–75

Intestinal hydrolytic activity in young mink (Mustela vison)

develops slowly postnatally and exhibits late sensitivity to glucocorticoids. Sangild PT, et al. **J Nutr** 1996 Sep; 126(9):2061–8

Vitamin K status influences brain sulfatide metabolism in young mice and rats. Sundaram KS, et al. **J Nutr** 1996 Nov;126(11):2746–51

Taurine in gerbil retina: changes during ischemia reperfusion/insult (I.R.I.) and aging. Delbarre B, et al. **J Ocul Pharmacol Ther** 1996 Spring;12(1):65–73

Age changes in the rat temporomandibular joint articular disc: a biochemical study on glycosaminoglycan content. Okazaki J, et al. **J Oral Rehabil** 1996 Aug;23(8):536–40

Hyaluronic acid of wound fluid in adult and fetal rabbits. Sawai T, et al. **J Pediatr Surg** 1997 Jan;32(1):41–3

Levels of cytokines and collagen type I and type III as a function of age in human gingivitis. Yakovlev E, et al. **J Periodontol** 1996 Aug;67(8):788–93

Pharmacokinetic and pharmacodynamic study of imidaprilat, an active metabolite of imidapril, a new angiotensin–converting enzyme inhibitor, in spontaneously hypertensive rats. Yamanaka K, et al. **J Pharm Biomed Anal** 1997 Aug;15(12):1851–9

Age–related deficits in the cerebellar beta adrenergic signal transduction cascade in Fischer 344 rats. Gould TJ, et al. **J Pharmacol Exp Ther** 1997 May;281(2):965–71

Developmental changes in isolated rat type I carotid body cell K+ currents and their modulation by hypoxia. Hatton CJ, et al. **J Physiol (Lond)** 1997 May 15;501 (Pt 1):49–58

Melatonin enhances cortisol levels in aged women: reversible by estrogens. Cagnacci A, et al. **J Pineal Res** 1997 Mar; 22(2):81–5

Ovarian carbonyl reductase activity in rats at persistent oestrus. Inazu N, et al. **J Reprod Fertil** 1996 Sep; 108(1):123–30

Lipid and antioxidant changes in spermatozoa and seminal plasma throughout the reproductive period of bulls. Kelso KA, et al. **J Reprod Fertil** 1997 Jan;109(1):1–6

Age decreases nitric oxide synthase–containing nerve fibers in the rat penis. Carrier S, et al. **J Urol** 1997 Mar; 157(3):1088–92

Relationship between age–dependent changes of bovine neutrophil functions and their intracellular Ca2+ concentrations. Higuchi H, et al. **J Vet Med Sci** 1997 Apr; 59(4):271–6

Effects of age on the pharmacokinetics of single dose ceftiofur sodium administered intramuscularly or intravenously to cattle. Brown SA, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):32–8

Ontogeny of angiotensin II receptors, types 1 and 2, in ovine mesonephros and metanephros. Butkus A, et al. **Kidney Int** 1997 Sep;52(3):628–36

The hypothalamo–pituitary–growth hormone insulin–like growth factor 1 axis in children with chronic renal failure. Rees L, et al. **Kidney Int Suppl** 1996 Jan;53:S109–14 (16 ref.)

Effect of aging on thyroidal and pituitary T4–5'–deiodinase activity in female rats. Correa da Costa VM, et al. **Life Sci** 1996;59(18):1515–20

The effect of age and sex on the expression of prolactin binding activity in the chicken bursa of Fabricius. Di Carlo R, et al. **Life Sci** 1996;59(21):1803–8

Reduced anesthetic requirements in aged rats: association with altered brain synaptic plasma membrane Ca(2+)–ATPase pump and phospholipid methyltransferase I activities. Horn JL, et al. **Life Sci** 1996;59(17):PL263–8

Aging and acute stress decrease corticotropin releasing hormone in the ovary of the Fischer 344/N rat. Mastorakos G, et al. **Life Sci** 1995 Feb 17;56(13):1065–71

Effects of aging on the activities of pyruvate dehydrogenase complex and its kinase in rat heart. Nakai N, et al. **Life Sci** 1997;60(25):2309–14

Effect of endotoxin on gentamicin pharmacokinetics in old and young adult rats. Tanira MO, et al. **Life Sci** 1997; 60(6):413–24

Interleukin–6, tumor necrosis factor and corticosterone induction by central lipopolysaccharide in aged rats. Terrazzino S, et al. **Life Sci** 1997;61(7):695–701

Postnatal changes in activation of polyunsaturated fatty acid, acylation of lysophosphoglyceride, and phosphorylation of diacylglycerol in cortical gray matter of rat cerebrum. Kanazawa A, et al. **Lipids** 1996 Apr;31(4):437–40

Age–related changes in catalytic activity, enzyme mass, mRNA, and subcellular distribution of hepatic neutral cholesterol ester hydrolase in female rats. Natarajan R, et al. **Lipids** 1997 May;32(5):463–70

Bile acid metabolism in young–old parabiotic rats. Uchida K, et al. **Lipids** 1997 Apr;32(4):383–90

MR evaluation of age–related increase of brain iron in young adult and older normal males. Bartzokis G, et al. **Magn Reson Imaging** 1997;15(1):29–35

Estimating NAA in cortical gray matter with applications for measuring changes due to aging. Lim KO, et al. **Magn Reson Med** 1997 Mar;37(3):372–7

Morning magnesiuria: relation to age and sex. Simeková A, et al. **Magnes Res** 1996 Mar;9(1):41–5

Magnesium and antioxidant vitamin status and risk of complications of ageing in an elderly urban population. Singh RB, et al. **Magnes Res** 1996 Dec;9(4):299–306

Intravenous magnesium load test in elderly patients with protein–energy malnutrition. Toral Revuelta JR, et al. **Magnes Res** 1996 Dec;9(4):293–8

Aging and protein oxidative damage. Agarwal S, et al. **Mech Ageing Dev** 1994 Jul;75(1):11–9

Age–related responses of right ventricle in swim–trained rats: changes in lactate and pyruvate contents and lactate dehydrogenase activity. Anitha V, et al. **Mech Ageing Dev** 1996 Sep 18;90(2):91–102

Effects of vinconate on age–related alterations in [3H]MK–801, [3H]glycine, sodium–dependent D–[3H]aspartate, [3H]FK–506 and [3H]PN200–110 binding in rats. Araki T, et al. **Mech Ageing Dev** 1997 Apr; 95(1–2):13–29

Regional age–related alterations in cholinergic and GABAergic receptors in the rat brain. Araki T, et al. **Mech Ageing Dev** 1996 Jul 5;88(1–2):49–60

Plasma renin activity and metabolic clearance rate of angiotensin II in the unstressed aging rat. Baylis C, et al. **Mech Ageing Dev** 1997 Aug;97(2):163–72

Age–dependent decrease in the activity of succinic dehydrogenase in rat CA1 pyramidal cells: a quantitative cytochemical study. Bertoni–Freddari C, et al. **Mech Ageing Dev** 1996 Sep 9;90(1):53–62

Effects of transforming growth factor–beta 1 and interleukin–1 alpha on matrix synthesis in osteoarthritic cartilage of the temporo–mandibular joint in aged mice. Blumenfeld I, et al. **Mech Ageing Dev** 1997 Apr; 95(1–2):101–11

Age–related differences in the metabolism of sulphite to sulphate and in the identification of sulphur trioxide radical in human polymorphonuclear leukocytes. Constantin D, et al. **Mech Ageing Dev** 1996 Jul 5;88(1–2):95–109

CD45 isoforms expression on CD4+ and CD8+ T cells throughout life, from newborns to centenarians: implications for T cell memory. Cossarizza A, et al. **Mech Ageing Dev** 1996 Mar 29;86(3):173–95

The effect of age on calcium dynamics in rat brain in vivo. Das N, et al. **Mech Ageing Dev** 1996 Jul 5;88(1–2):17–24

The effects of age on rabbit MCL fibroblast matrix synthesis in response to TGF–beta 1 or EGF. Deie M, et al. **Mech Ageing Dev** 1997 Aug;97(2):121–30

Quantitative histochemical study of cytochrome oxidase in the dLGN of aging rats. Díaz F, et al. **Mech Ageing Dev** 1996 Oct 4;91(1):47–54

Age–related changes in the binding and uptake of Cu, Zn superoxide dismutase in rat liver cells. Dini L, et al. **Mech Ageing Dev** 1996 Sep 9;90(1):21–33

Age–related changes in monoamines within the olfactory bulbs of the Fischer 344 male rat. Dluzen DE. **Mech Ageing Dev** 1996 Oct 4;91(1):37–45

Relationship of age and calcitonin gene–related peptide to postprandial hypotension. Edwards BJ, et al. **Mech Ageing Dev** 1996 Jun 7;87(2):61–73

Age–related changes in amylin secretion. Edwards BJ, et al. **Mech Ageing Dev** 1996 Jan 5;86(1):39–51

Changes with aging, sex and physical exercise in murine natural killer activity and antibody–dependent cellular cytotoxicity. Ferrández MD, et al. **Mech Ageing Dev** 1996 Feb 24;86(2):83–94

Mitochondrial electron transport chain activities and DNA deletions in regions of the rat brain. Filburn CR, et al. **Mech Ageing Dev** 1996 May 24;87(1):35–46

Invertors mechanism of the influence of insulin on the condition of plasma membranes of myocardiocytes in animals of different age. Frolkis VV, et al. **Mech Ageing Dev** 1996 Jul 5;88(1–2):67–73

Abundance of alpha 1(I) and alpha 1(III) procollagen and p21 mRNAs in fibroblasts cultured from fetal and postnatal dermis. Furth JJ, et al. **Mech Ageing Dev** 1997 Aug; 97(2):131–42

Levels and activity of brain protein kinase C alpha and zeta during the aging of the medfly. Galve–Roperh I, et al. **Mech Ageing Dev** 1996 Nov 29;92(1):21–9

NOR activity in hippocampal areas during the postnatal development and ageing. García Moreno LM, et al. **Mech Ageing Dev** 1997 Aug;97(2):173–81

Age–related increase in nitric oxide synthase activity in senescence accelerated mouse brain and the effect of long–term administration of superoxide radical scavenger. Inada K, et al. **Mech Ageing Dev** 1996 Aug 15;89(2):95–102

Effects of aging on Na(+)–pump current in rat ventricular myocytes. Kennedy RH, et al. **Mech Ageing Dev** 1996 Aug 15;89(2):59–66

Effects of cellular aging on the induction of c–fos by antioxidant treatments. Keogh BP, et al. **Mech Ageing Dev** 1996 Mar 29;86(3):151–60

Age–related patterns of lectin–binding nuclear glycoproteins of hamster liver. Krześlak A, et al. **Mech Ageing Dev** 1996 Sep 30;90(3):223–33

Rapid decrease of glycogen concentration in the hearts of senescence–accelerated mice during aging. Kurokawa T, et al. **Mech Ageing Dev** 1997 Sep;97(3):227–36

cAMP signalling mechanisms with aging in the Ceratitis capitata brain. Laviada ID, et al. **Mech Ageing Dev** 1997 Jul;97(1):45–53

In K562 and HL60 cells membrane ageing during cell growth is associated with changes in cholesterol concentration. Levi M, et al. **Mech Ageing Dev** 1997 Aug;97(2):109–19

Changes in NADPH–diaphorase neurons of the rat laterodorsal and pedunculopontine tegmental nuclei in aging. Lolova IS, et al. **Mech Ageing Dev** 1996 Sep 18; 90(2):111–28

Perforins in human cytolytic cells: the effect of age. Mariani E, et al. **Mech Ageing Dev** 1996 Dec 20;92(2–3):195–209

The cytoskeleton in ATP–depleted erythrocytes: the effect of shape transformation [published erratum appears in Mech Ageing Dev 1996 Nov 13;91(3):229] Marikovsky Y. **Mech Ageing Dev** 1996 Feb 24;86(2):137–44

Expression of alpha 1 adrenergic receptor subtype mRNAs in the rat cardiovascular system with aging. Miller JW, et al. **Mech Ageing Dev** 1996 Jun 7;87(2):75–89

Age–related change of phosphatidylcholine hydroperoxide and phosphatidylethanolamine hydroperoxide levels in normal human red blood cells. Miyazawa T, et al. **Mech Ageing Dev** 1996 Mar 29;86(3):145–50

Enzymatic defenses of the rat heart against lipid peroxidation. Molina H, et al. **Mech Ageing Dev** 1997 Jul;97(1):1–7

Defects of the respiratory chain in various tissues of old monkeys: a cytochemical–immunocytochemical study. Müller–Höcker J, et al. **Mech Ageing Dev** 1996 Mar 29; 86(3):197–213

Age–related changes in the metabolism of neurotransmitters in rat striatum: a microdialysis study. Nakano M, et al. **Mech Ageing Dev** 1996 Feb 24;86(2):95–104

Effects of age on levels of cysteine, glutathione and related enzyme activities in livers of mice and rats and an attempt to replenish hepatic glutathione level of mouse with cysteine derivatives. Nakata K, et al. **Mech Ageing Dev** 1996 Sep 30;90(3):195–207

Early changes in the expression of GLUT4 protein in the heart of senescence–accelerated mouse. Ozaki N, et al. **Mech Ageing Dev** 1996 Jul 17;88(3):149–58

The effect of age on the expression of interleukin–2. Pahlavani MA, et al. **Mech Ageing Dev** 1996 Aug 29; 89(3):125–54 (188 ref.)

Age–related changes in carboxyl methylation of proteins in the kidney. Pelletier J, et al. **Mech Ageing Dev** 1996 Feb 24;86(2):115–35

Aging–related decrease in liver peroxisomal fatty acid oxidation in control and clofibrate–treated mice. A biochemical study and mechanistic approach. Périchon R, et al. **Mech Ageing Dev** 1996 Jun 7;87(2):115–26

P53 synthesis and phosphorylation in the aging diet–restricted rat following retinoic acid administration. Pipkin JL, et al. **Mech Ageing Dev** 1997 Jul;97(1):15–34

Influence of endurance training on the age–related decline in hepatic glyconeogenesis. Podolin DA, et al. **Mech Ageing Dev** 1994 Jul;75(1):81–93

Long–term effects of caloric restriction initiated at different ages on DNA polymerases in rat brain. Prapurna DR, et al. **Mech Ageing Dev** 1996 Dec 20;92(2–3):133–42

ATP catabolism and adenosine generation during ischemia in the aging heart. Ramani K, et al. **Mech Ageing Dev** 1996 Aug 15;89(2):113–24

Age and gender differences in hepatic ascorbic acid concentrations and NADPH–dehydroascorbic acid reductase activity. Rikans LE, et al. **Mech Ageing Dev** 1996 Nov 13;91(3):165–9

Ageing increases growth factor–induced inorganic pyrophosphate elaboration by articular cartilage. Rosenthal AK, et al. **Mech Ageing Dev** 1994 Jul;75(1):35–44

Early appearance of abnormality of microperoxisomal enzymes in the cerebral cortex of senescence–accelerated mouse. Sato E, et al. **Mech Ageing Dev** 1996 Dec 20; 92(2–3):175–84

Early and transient increase in oxidative stress in the cerebral cortex of senescence–accelerated mouse. Sato E, et al. **Mech Ageing Dev** 1996 Feb 24;86(2):105–14

Effect of aging on cytokine production in normal and experimental systemic lupus erythematosus afflicted mice. Segal R, et al. **Mech Ageing Dev** 1997 Jun;96(1–3):47–58

Ageing promotes the increase of early glycation Amadori product as assessed by epsilon–N–(2–furoylmethyl)–L–lysine (furosine) levels in rodent skin collagen. The relationship to dietary restriction and glycoxidation. Sell DR. **Mech Ageing Dev** 1997 Apr; 95(1–2):81–99

Expression of mRNAs of pancreatic and L type RNase inhibitors as a function of age in different tissues of SAMP8 and BDF1 mice. Semsei I, et al. **Mech Ageing Dev** 1997 Sep;97(3):249–61

Changes in N–acetyl–beta–D–glucosaminidase binding system in rat liver during growth. Sosa MA, et al. **Mech Ageing Dev** 1996 Feb 24;86(2):75–81

Age–associated changes in the template–reading fidelity of DNA polymerase alpha from regenerating rat liver. Taguchi T, et al. **Mech Ageing Dev** 1996 Dec 20; 92(2–3):143–57

Mitogenic activity but not phenotype expression of rat osteoprogenitor cells in response to IGF–I is impaired in aged rats. Tanaka H, et al. **Mech Ageing Dev** 1996 Nov 29;92(1):1–10

Age–related changes in proliferating cell nuclear antigen levels. Tanno M, et al. **Mech Ageing Dev** 1996 Nov 29; 92(1):53–66

Change of the lipid hydroperoxide level in mouse organs on ageing. Tokumaru S, et al. **Mech Ageing Dev** 1996 Jan 5;86(1):67–74

Desensitization of alpha 1–, beta– and glucagon receptors in rat hepatocytes: influence of ageing. Van Ermen A, et al. **Mech Ageing Dev** 1994 Jul;75(1):45–58

Effect of age on the activity of phosphoenolpyruvate carboxykinase in the kidney following fasting and refeeding. Van Remmen H, et al. **Mech Ageing Dev** 1997 Sep;97(3):237–48

Influence of physical exercise on aging rats: II. Life–long exercise delays aging of tail tendon collagen. Viidik A,

et al. **Mech Ageing Dev** 1996 Jul 17;88(3):139–48

Expression and catalytic activities of protein tyrosine kinases (PTKs) Fyn and Lck in peripheral blood T cells from elderly humans stimulated through the T cell receptor (TCR)/CD3 complex. Whisler RL, et al. **Mech Ageing Dev** 1997 Oct;98(1):57–73

Insulin receptors in mouse brain: age-related modifications are corrected by thymus graft. Zaia A, et al. **Mech Ageing Dev** 1997 Oct;98(1):37–46

Age-related decreases in chromium levels in 51,665 hair, sweat, and serum samples from 40,872 patients--implications for the prevention of cardiovascular disease and type II diabetes mellitus. Davies S, et al. **Metabolism** 1997 May;46(5):469–73

B cells of aging rats: impaired stimulus-secretion coupling but normal susceptibility to adverse effects of a diabetic state. Inoue K, et al. **Metabolism** 1997 Mar;46(3):242–6

Mitochondrial diseases and aging. Papa S, et al. **Mol Aspects Med** 1996 Dec;17(6):513–63 (254 ref.)

Androgen treatment protects mouse liver chromatin from cleavage by endogenous nucleases during aging. Androgen and nuclease activity. Mukherjee S, et al. **Mol Biol Rep** 1995–96;22(1):59–61

Age-dependent changes in particulate and soluble guanylyl cyclase activities in urinary tract smooth muscle. Wheeler MA, et al. **Mol Cell Biochem** 1997 Apr;169(1–2):115–24

Cellular distribution of EGF, TGFalpha and their receptor during postnatal development and spermatogenesis of the boar testis. Caussanel V, et al. **Mol Cell Endocrinol** 1996 Oct 14;123(1):61–9

Heterogeneity of growth hormone (GH)-producing cells in aging male rats: ultrastructure and GH gene expression in somatotrope subpopulations. Dobado-Berrios PM, et al. **Mol Cell Endocrinol** 1996 Apr 19;118(1–2):181–91

Chick muscle expresses various ARIA isoforms: regulation during development, denervation, and regeneration. Ng YP, et al. **Mol Cell Neurosci** 1997;9(2):132–43

Pharmacokinetics of intracerebroventricular tBuOOH in young adult and mature mice. Chang ML, et al. **Mol Chem Neuropathol** 1997 May;31(1):73–84

The effects of oxidative stress on in vivo brain GSH turnover in young and mature mice. Chang ML, et al. **Mol Chem Neuropathol** 1997 Apr;30(3):187–97

Cortical cathepsin D activity and immunolocalization in Alzheimer disease, critical coronary artery disease, and aging. Haas U, et al. **Mol Chem Neuropathol** 1996 Sep; 29(1):1–14

Laminins in the adult and aged brain. Jucker M, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1–3):209–18 (44 ref.)

Ontogeny and hormonal basis of male-dominant rat hepatic sulfotransferases. Liu L, et al. **Mol Pharmacol** 1996 Sep; 50(3):565–72

Age-related alterations of the N-methyl-D-aspartate receptor in the dentate gyrus [news] Morrison JH, et al. **Mol Psychiatry** 1996 Nov;1(5):356–8

Novel modalities for appraising individual and coordinate pulsatile hormone secretion: the paradigm of luteinizing hormone and testosterone release in the aging male. Veldhuis JD. **Mol Psychiatry** 1997 Jan;2(1):70–80 (56 ref.)

An accessory protein of DNA polymerase alpha declines in function with increasing age. Miller SD, et al. **Mutat Res** 1997 Mar 4;374(1):125–38

Pernicious anaemia patients should be screened for iron deficiency during follow up. Demiroğlu H, et al. **N Z Med J** 1997 Apr 25;110(1042):147–8

Some sodium, potassium and water changes in the elderly and their treatment. Andreucci VE, et al. **Nephrol Dial Transplant** 1996;11 Suppl 9:9–17 (113 ref.)

Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Filler G, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1668–71

Sodium profiling in elderly haemodialysis patients. Raja RM. **Nephrol Dial Transplant** 1996;11 Suppl 8:42–5 (16 ref.)

Neurochemical changes in the hippocampus of the brown Norway rat during aging. Bhatnagar M, et al. **Neurobiol Aging** 1997 May-Jun;18(3):319–27

Expression of alpha 4-1 and alpha 5 nicotinic cholinoceptor mRNA in the aging rat cerebral cortex. Birtsch C, et al. **Neurobiol Aging** 1997 May-Jun;18(3):335–42

Erythrocyte aging characteristics in elderly individuals with beginning dementia. Bosman GJ, et al. **Neurobiol Aging** 1997 May-Jun;18(3):291–5

In vivo amino acid release from the striatum of aging rats: adenosine modulation. Corsi C, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):243–50

Age-related loss of calcium binding proteins in rabbit hippocampus. de Jong GI, et al. **Neurobiol Aging** 1996 May-Jun;17(3):459–65

Effect of aging on the basal expression of c-Fos, c-Jun, and Egr-1 proteins in the hippocampus. Desjardins S, et al. **Neurobiol Aging** 1997 Jan-Feb;18(1):37–44

Amelioration of age-related deficits in the stimulation of synapsin phosphorylation. Eckles KE, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):213–7

beta-Amyloid (A beta) deposition in the brains of aged orangutans. Gearing M, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):139–46

Region-specific downregulation of free intracellular calcium in the aged rat brain. Hartmann H, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):557–63

Nigrostriatal monoamine oxidase A and B in aging squirrel monkeys and C57BL/6 mice. Irwin I, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):235–41

Glutamate receptor binding in the human hippocampus and adjacent cortex during development and aging. Johnson M, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):639–51

Neurotrophin receptor and tyrosine hydroxylase gene expression in aged sympathetic neurons. Kuchel GA, et al. **Neurobiol Aging** 1997 Jan-Feb;18(1):67–79

Effects of aging and chronic nimodipine on hippocampal binding of [3H]CGS 19755. Kusztos RD, et al. **Neurobiol Aging** 1996 May-Jun;17(3):453–7

Role of estrogen and iron in neurodegeneration: open peer commentary to "Astrocytes, brain aging, and neurodegeneration" by H. Schipper. Liehr JG. **Neurobiol Aging** 1996 May-Jun;17(3):481–2; discussion 488–90

Potassium, but not atropine-stimulated cortical acetylcholine efflux, is reduced in aged rats. Moore H, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):565–71

Age-related changes in c-fos mRNA induction after open-field exposure in the rat brain. Nagahara AH, et al. **Neurobiol Aging** 1997 Jan-Feb;18(1):45–55

Human brain S100 beta and S100 beta mRNA expression increases with age: pathogenic implications for Alzheimer's disease. Sheng JG, et al. **Neurobiol Aging** 1996 May-Jun; 17(3):359–63

N-methyl-D-aspartate receptor binding in brains of rats at different ages. Shimada A, et al. **Neurobiol Aging** 1997 May-Jun;18(3):329–33

APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Trieb K, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):541–7

Intracellular calcium buffering declines in aging adrenergic nerves. Tsai H, et al. **Neurobiol Aging** 1997 Mar-Apr; 18(2):229–33

The effect of aging on rat striatal D1 receptor mRNA-containing neurons. Zhang L, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):251–5

Cerebral ischemia in young and adult gerbils: effects on cholinergic metabolism. Bertrand N, et al. **Neurochem Int** 1996 Mar;28(3):293–7

Neurosteroid modulation of GABAA receptors in the developing rat brain cortex. Borodinsky LN, et al. **Neurochem Int** 1997 Aug;31(2):313–7

A developmental study of protein phosphorylating systems stimulated by phorbol dibutyrate in micro-slices of rat brain. Salbego C, et al. **Neurochem Int** 1996 Apr;28(4):431–8

Age-related changes of the ganglioside long-chain base composition in rat cerebellum. Valsecchi M, et al. **Neurochem Int** 1996 Feb;28(2):183–7

Age-dependent organotypic expression of microtubule-associated proteins (MAP1, MAP2, and MAP5) in rat brain. Chauhan N, et al. **Neurochem Res** 1997 Jun;22(6):713–9

Regional and developmental variations in metabolite concentration in the rat brain and eye: a study using 1H NMR spectroscopy and high performance liquid chromatography. Florian CL, et al. **Neurochem Res** 1996 Sep;21(9):1065–74

Specific [3H]glutamate binding in the cerebral cortex and hippocampus of rats during development: effect of homocysteine-induced seizures. Folbergrová J, et al. **Neurochem Res** 1997 May;22(5):637–46

Nitric oxide and antioxidant status in glucose and oxygen deprived neonatal and adult rat brain synaptosomes. Keelan J, et al. **Neurochem Res** 1996 Aug;21(8):923–7

Developmental analysis of factors binding to the mouse 68-kDa neurofilament promoter. Kure R, et al. **Neurochem Res** 1997 May;22(5):555–62

Age does not alter Protein kinase C isozymes mRNA expression in rat brain. Narang N, et al. **Neurochem Res** 1995 Oct;20(10):1119–26

Age and gender influence basal and stress-modulated hypothalamic-pituitary-thyroidal function in Fischer 344/N rats. Cizza G, et al. **Neuroendocrinology** 1996 Dec; 64(6):440–8

Hypophysiotropic somatostatin expression during postnatal development in growth hormone-deficient Ames dwarf mice: mRNA in situ hybridization. Hurley DL, et al. **Neuroendocrinology** 1997 Feb;65(2):98–106

Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Bannon MJ, et al. **Neurology** 1997 Apr;48(4):969–77

Neuropeptide Y- and peptide YY-containing colonic cells increase with ageing in male rats. Sweet MA, et al. **Neuropeptides** 1996 Aug;30(4):385–90

Changes in protein synthesis and synthesis of the synaptic vesicle protein, synaptophysin, in entorhinal cortex following induction of long-term potentiation in dentate gyrus: an age-related study in the rat. Mullany P, et al. **Neuropharmacology** 1997 Jul;36(7):973–80

Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients--effects of phosphatidylserine therapy. Brambilla F, et al. **Neuropsychobiology** 1996;34(1):18–21

Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. Ghilardi JR, et al. **Neuroreport** 1996 Nov 4;7(15–17):2607–11

Age-related changes in the expression of Alzheimer's beta APP in the brain of senescence accelerated mouse (SAM)-P/10. Jeong SJ, et al. **Neuroreport** 1997 May 6; 8(7):1733–7

Decreased neurofilament gene expression is an index of selective axonal hypotrophy in ageing. Kuchel GA, et al. **Neuroreport** 1996 May 31;7(8):1353–9

Seizure-induced glutamate release in mature and immature animals: an in vivo microdialysis study. Liu Z, et al. **Neuroreport** 1997 May 27;8(8):2019–23

Reduction of vesicular acetylcholine transporter mRNA in the rat septum following lead exposure. Sun X, et al. **Neuroreport** 1997 Mar 3;8(4):891–4

Age-related loss of calbindin from human basal forebrain cholinergic neurons. Wu CK, et al. **Neuroreport** 1997 Jul 7;8(9–10):2209–13

Age-related change of neuropeptide Y-immunoreactive neurons in the cerebral cortex of aged rats. Cha CI, et al. **Neurosci Lett** 1996 Aug 16;214(1):37–40

Decrease of immunoreactive catalase protein in specific areas of ageing rat brain. Ciriolo MR, et al. **Neurosci Lett** 1997 May 30;228(1):21–4

Age-related decreases in mRNA for brain nuclear receptors and target genes are reversed by retinoic acid treatment. Enderlin V, et al. **Neurosci Lett** 1997 Jun 27;229(2):125–9

Age-related change in the neuropeptide Y and NADPH-diaphorase-positive neurons in the cerebral cortex and striatum of aged rats. Huh Y, et al. **Neurosci Lett** 1997 Feb 28;223(3):157–60

Expression of neuronal nitric oxide synthase in spinal motoneurons in aged rats. Kanda K. **Neurosci Lett** 1996 Nov 15;219(1):41–4

Comparable amyloid beta-protein (A beta) 42(43) and A beta 40 deposition in the aged monkey brain. Kanemaru K, et al. **Neurosci Lett** 1996 Aug 23;214(2–3):196–8

Age-related changes in the regulation of transcription factor NF-kappa B in rat brain. Korhonen P, et al. **Neurosci Lett** 1997 Mar 28;225(1):61–4

Evidence that glucose metabolism is decreased in the cerebrum of aged female senescence-accelerated mouse; possible involvement of a low hexokinase activity. Kurokawa T, et al. **Neurosci Lett** 1996 Aug 16;214(1):45–8

Attenuated stress response of hippocampal acetylcholine release and adrenocortical secretion in aged rats. Mizuno T, et al. **Neurosci Lett** 1997 Jan 24;222(1):49–52

Reduction in number of dopamine uptake sites but unchanged number of piperazine-acceptor/CYP450IID6 binding sites in the human caudate nucleus in aging. Norlén M, et al. **Neurosci Lett** 1996 May 17;209(3):161–4

Relationship of impaired brain glucose metabolism to learning deficit in the senescence-accelerated mouse. Ohta H, et al. **Neurosci Lett** 1996 Oct 11;217(1):37–40

Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease. Schneider C, et al. **Neurosci Lett** 1997 Feb 7;222(3):183–6

Preservation of autoreceptor-mediated increases in dopamine synthesis in aged mice with experimentally-induced parkinsonism. Schneider JS. **Neurosci Lett** 1997 Jan 31; 222(2):138–40

Ontogeny of dopamine D3 receptors in the nucleus accumbens of the rat. Stanwood GD, et al. **Neurosci Lett** 1997 Feb 14;223(1):13–6

Arachidonate transport through the blood-retina and blood-brain barrier of the rat during aging. Strosznajder J, et al. **Neurosci Lett** 1996 May 17;209(3):145–8

Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Takedo A, et al. **Neurosci Lett** 1996 Dec 27;221(1):17–20

Changes in the expression of novel Cdk5 activator messenger RNA (p39nck5ai mRNA) during rat brain development. Cai XH, et al. **Neurosci Res** 1997 Aug;28(4):355–60

Prominent expression of nuclear hormone receptor ROR alpha in Purkinje cells from early development. Nakagawa S, et al. **Neurosci Res** 1997 Jun;28(2):177–84

Neurogranin in the development of the rat telencephalon. Alvarez-Bolado G, et al. **Neuroscience** 1996 Jul; 73(2):565–80

mCD24 expression in the developing mouse brain and in zones of secondary neurogenesis in the adult. Calaora V, et al. **Neuroscience** 1996 Jul;73(2):581–94

Regional distribution of iron, transferrin, ferritin, and oxidatively-modified proteins in young and aged Fischer 344 rat brains. Focht SJ, et al. **Neuroscience** 1997 Jul; 79(1):255–61

Aging-related subunit expression changes of the GABAA receptor in the rat hippocampus. Gutiérrez A, et al. **Neuroscience** 1996 Sep;74(2):341–8

Distribution and postnatal ontogeny of adenosine A2A receptors in rat brain: comparison with dopamine receptors. Johansson B, et al. **Neuroscience** 1997 Oct;80(4):1187–207

Ionotropic glutamate receptor subtypes in the aged memory-impaired and unimpaired Long-Evans rat. Le Jeune H, et al. **Neuroscience** 1996 Sep;74(2):349–63

Agrin gene expression in mouse somatosensory cortical neurons during development in vivo and in cell culture. Li Z, et al. **Neuroscience** 1997 Jul;79(1):191–201

Increased expression of nitric oxide synthase in the gracile nucleus of aged rats. Ma SX, et al. **Neuroscience** 1997 Feb; 76(3):659–63

GABAA receptor binding in the aging rat inferior colliculus. Milbrandt JC, et al. **Neuroscience** 1996 Jul;73(2):449–58

Galanin messenger RNA during postnatal development of the rat brain: expression patterns in Purkinje cells differentiate anterior and posterior lobes of cerebellum. Ryan MC, et al. **Neuroscience** 1997 Jun;78(4):1113–27

Enhanced taurine release in cell-damaging conditions in the

developing and ageing mouse hippocampus. Saransaari P, et al. **Neuroscience** 1997 Aug;79(3):847–54

Increased level of neurokinin–1 tachykinin receptor gene expression during early postnatal development of rat brain. Taoka M, et al. **Neuroscience** 1996 Oct;74(3):845–53

The regulation of hippocampal dynorphin by neural/neuroendocrine pathways: models for effects of aging on an opioid peptide system. Thai L, et al. **Neuroscience** 1996 Feb;70(3):661–71

Transient expression of alpha–1B adrenoceptor messenger ribonucleic acids in the rat superior cervical ganglion during postnatal development. Vidovic M, et al. **Neuroscience** 1997 Apr;77(3):841–8

Expression of alpha 2 adrenoceptors during rat brain development—I. Alpha 2A messenger RNA expression. Winzer-Serhan UH, et al. **Neuroscience** 1997 Jan; 76(1):241–60

Symmetry of bone mineral density in the hips is not affected by age. Yang RS, et al. **Nucl Med Commun** 1996 Aug; 17(8):711–6

Effect of aging on norepinephrine and phenylephrine stimulated lactate production by white adipocytes. Faintrenie G, et al. **Obes Res** 1997 Mar;5(2):100–4

Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Zindy F, et al. **Oncogene** 1997 Jul 10;15(2):203–11

The further metabolism of sorbitol–3–phosphate and fructose–3–phosphate in the mature rat lens. Cheng HM, et al. **Ophthalmic Res** 1996;28(1):57–63

Protein changes during aging and the effects of long–term cortisol treatment in macaque monkey lens. Matsushima H, et al. **Optom Vis Sci** 1997 Apr;74(4):190–7

The effect of a short course of calcium and vitamin D on bone turnover in older women. Prestwood KM, et al. **Osteoporos Int** 1996;6(4):314–9

The effect of old age on the disposition and antinociceptive response of morphine and morphine–6 beta–glucuronide in the rat. Van Crugten JT, et al. **Pain** 1997 Jun; 71(2):199–205

D1 and D2 dopamine receptors in perinatal and adult basal ganglia. Boyson SJ, et al. **Pediatr Res** 1997 Jun;41(6):822–31

Hyperoxic regulation of lung heme oxygenase in neonatal rats. Dennery PA, et al. **Pediatr Res** 1996 Dec;40(6):815–21

Cytokine production differs in children and adults. Lilic D, et al. **Pediatr Res** 1997 Aug;42(2):237–40

The renal phosphate threshold decreases with increasing postmenstrual age in very low birth weight infants. Mihatsch WA, et al. **Pediatr Res** 1996 Aug;40(2):300–3

Ontogeny of proopiomelanocortin posttranslational processing in the ovine fetal pituitary. Saoud CJ, et al. **Peptides** 1996;17(4):649–53

Brevican: a major proteoglycan in adult brain. Yamaguchi Y. **Perspect Dev Neurobiol** 1996;3(4):307–17 (54 ref.)

Responses to novelty stress in female F344 rats: effects of age and d–fenfluramine treatment. Handa RJ, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):641–7

Sex– or age–related differences were not detected in the activity of dihydropyrimidine dehydrogenase from rat liver. Tateishi T, et al. **Pharmacol Res** 1997 Feb;35(2):103–6

Elimination of recently absorbed methyl mercury depends on age and gender. Nielsen JB, et al. **Pharmacol Toxicol** 1996 Aug;79(2):60–4

Effects of aluminium on the mineral metabolism of rats in relation to age. Sánchez DJ, et al. **Pharmacol Toxicol** 1997 Jan;80(1):11–7

Glutamine metabolism is changed in lymphocytes from aged rats. Almeida AF, et al. **Physiol Behav** 1996 Sep;60(3):973–8

Effect of repeated stress on a number of plasma amino acids and related compounds in young and old rats. Milakofsky L, et al. **Physiol Behav** 1996 Sep;60(3):969–71

Developmental aspects of lipid metabolism. Koldovský O, et al. **Physiol Res** 1995;44(6):353–6 (40 ref.)

Uptake capacity in vitro for glucose and methionine and in situ for oleic acid in the proximal small intestine of posthatch chicks. Noy Y, et al. **Poult Sci** 1996 Aug; 75(8):998–1002

Changes in gonadal weights, serum lipids, and glucose during maturation in the juvenile northern bobwhite quail (Colinus virginianus). Peebles ED, et al. **Poult Sci** 1996 Nov; 75(11):1411–6

Digestible threonine requirement of broiler chickens during the period three to six and six to eight weeks posthatching. Webel DM, et al. **Poult Sci** 1996 Oct;75(10):1253–7

Effect of age on in vivo rates of mitochondrial protein synthesis in human skeletal muscle. Rooyackers OE, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15364–9

Molecular characterization of Br–cadherin, a developmentally regulated, brain–specific cadherin. Selig S, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18; 94(6):2398–403

Age–related variations in hepatic biosynthesis of phosphatidylcholine: a study of choline metabolism with perfused rat liver. Ortu G, et al. **Proc Soc Exp Biol Med** 1997 Oct;216(1):44–51

Alterations in apolipoprotein E expression during aging and neurodegeneration. Masliah E, et al. **Prog Neurobiol** 1996 Dec;50(5–6):493–503 (80 ref.)

Age–related changes in essential fatty acid metabolism in cultured rat heart myocytes. Lorenzini A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Aug; 57(2):143–7

PSA–based screening for prostate cancer in asymptomatic younger males: pilot study in blood donors. Reissigl A, et al. **Prostate** 1997 Jan 1;30(1):20–5

Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Yan Y, et al. **Prostate** 1997 Jul 1;32(2):129–39

Age–specific prostate–specific antigen: a reassessment. Etzioni R, et al. **Prostate Suppl** 1996;7:70–7

Hypertension in Japanese Americans: the Seattle Japanese–American Community Diabetes Study. Fujimoto W, et al. **Public Health Rep** 1996;111 Suppl 2:56–8

Increased salt retention and hypertension from non–steroidal agents in the elderly. Mulkerrin EC, et al. **QJM** 1997 Jun; 90(6):411–5

Variation of intrarenal angiotensin II and angiotensin II receptors by acute renal ischemia in the aged rat. Lü X, et al. **Ren Fail** 1996 Jan;18(1):19–29

Age–related changes in the soluble and the membrane–bound Tyr–aminopeptidase activities in several areas of the male and female rat brain. de Gandarias JM, et al. **Reprod Fertil Dev** 1996;8(3):465–9

Aldosterone release from adrenal cells is inhibited by reduced oxygen levels in vitro during maturation in rabbits. Papanek PE, et al. **Reprod Fertil Dev** 1996;8(8):1131–6

Morphological changes in the oesophagus of newborn pigs: effects of age, diet and oral insulin–like growth factor I (IGF–I) or IGF–II. Xu RJ, et al. **Reprod Fertil Dev** 1996; 8(5):903–9

Effect of swimming training on antioxidant enzymes in kidney of young and old mice. Toshinai K, et al. **Res Commun Mol Pathol Pharmacol** 1997 Mar;95(3):259–74

Effect of age on the pharmacokinetics of antipyrine in calves. Janus K, et al. **Res Vet Sci** 1996 May;60(3):234–7

Effects of aging and/or training on antioxidant enzyme system in diaphragm of mice. Oh–ishi S, et al. **Respir Physiol** 1996 Sep;105(3):195–202

Effect of aging on the rate of muscle protein turnover in rat. Frühbeck G, et al. **Rev Esp Fisiol** 1996 Dec; 52(4):207–14

Abnormalities of water metabolism in the elderly. Ayus JC, et al. **Semin Nephrol** 1996 Jul;16(4):277–88 (105 ref.)

The human lumbar endplate. Evidence of changes in biosynthesis and denaturation of the extracellular matrix with growth, maturation, aging, and degeneration. Antoniou J, et al. **Spine** 1996 May 15;21(10):1153–61

Expression of plasminogen activator inhibitor 2 in the adult and embryonic mouse tissues. Kawata Y, et al. **Thromb Haemost** 1996 Oct;76(4):569–76

The effect of hormone replacement therapy of the age–related rise of factor VIIc, and its activity state. Wright D, et al. **Thromb Res** 1997 Mar 15;85(6):455–64

The effect of age on aluminum retention in rats. Gómez M, et al. **Toxicology** 1997 Jan 15;116(1–3):1–8

Sex– and age–related composition of 10 617 calculi analyzed by infrared spectroscopy. Daudon M, et al. **Urol Res** 1995; 23(5):319–26

Pharmacological basis for hepatic drug metabolism in sheep. Galtier P, et al. **Vet Res** 1996;27(4–5):363–72 (30 ref.)

Characterization of aldehyde dehydrogenase–positive amacrine cells restricted in distribution to the dorsal retina. Milam AH, et al. **Vis Neurosci** 1997 May–Jun;14(3):601–8

Age–related increase in an advanced glycation end product in penile tissue. Jiaan DB, et al. **World J Urol** 1995; 13(6):369–75

[Effect of er–xian decoction and its disassembled prescription on enzyme activities and their gene expression of antioxidant enzymes in aging rat] Shen XH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Nov; 15(11):672–4 (Eng. Abstr.) **(Chi)**

[Present possibilities of age determination in forensic medicine with emphasis on the importance of measurement of D– and L– forms of aspartic acid. I. An overview] Pilin A, et al. **Soud Lek** 1997 Feb;42(1):9–11 (Eng. Abstr.) **(Cze)**

[Age determination by measurement of the ratio of D– and L– forms of aspartic acid. II. Chiral separation of amino acids from human dentin] Pilin A, et al. **Soud Lek** 1997 Feb;42(1):12–6 (Eng. Abstr.) **(Cze)**

[Sequential and ultrastructural study of lactotroph response to stress in rats as a function of age] el Feki A, et al. **Arch Physiol Biochem** 1997 Feb;105(1):92–5 (Eng. Abstr.) **(Fre)**

[Poly–medication and drug interaction in geriatrics] Sternon J, et al. **Rev Med Brux** 1996 Dec;17(6):389–96 (Eng. Abstr.) **(Fre)**

[Thyroid hormones in dairy calves after birth and in the first days of life. Amplitude of variation, maternal–fetal relationships and reaction patterns specific to the individual] Steinhardt M, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Apr;103(4):136–41 (Eng. Abstr.) **(Ger)**

[Changes of magnetization transfer ratio according to rat brain development] Bai LS, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Nov; 56(13):955–60 (Eng. Abstr.) **(Jpn)**

[Glucose tolerance and insulin resistance in the elderly] Ikegami H, et al. **Nippon Ronen Igakkai Zasshi** 1997 May; 34(5):365–8 (Eng. Abstr.) **(Jpn)**

[Simultaneous stereoinversion, racemization and isomerization at specific amino acid residues in the proteins during aging] Fujii N. **Seikagaku** 1996 Oct;68(10):1641–5 (12 ref.) **(Jpn)**

[Activity of basic arginine– and lysine–residue cleaving carboxypeptidase in rats of various ages] Vernigora AN, et al. **Biokhimiia** 1996 Oct;61(10):1848–56 (Eng. Abstr.) **(Rus)**

[Invertory mechanism of the changes in Na,K–ATPase activity in myocardium cytoplasmatic membranes during critical stage of compensatory hyperfunction of the heart in adult and aged rats] Frol'kis VV, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):631–3 **(Rus)**

[The effect of mu–opioid receptor agonist tetrapeptide A10 on the DNA synthesis in the myocardium and liver of albino rats during early stages of postnatal ontogenesis] Goncharova EN, et al. **Biull Eksp Biol Med** 1997 Feb; 123(2):212–5 **(Rus)**

[Prolactin receptors in bile duct cells during rat ontogenesis] Petrashchuk OM, et al. **Biull Eksp Biol Med** 1996 Dec; 122(12):669–72 **(Rus)**

[Melatonin biosynthesis in the epiphysis during early postnatal ontogenesis in healthy persons and in patients with hereditary retinal degeneration] Pozdeev NV, et al. **Biull Eksp Biol Med** 1997 Feb;123(2):131–4 **(Rus)**

[Age–related characteristics of the changes in the activity of the enzymes that implement cavity and membrane carbohydrate hydrolysis in stress] Rakhimova KR, et al. **Fiziol Zh Im I M Sechenova** 1996 Mar;82(3):89–94 (Eng. Abstr.) **(Rus)**

[Carbohydrate hydrolysis and absorption in the human small intestine in aging] Valenkevich LN, et al. **Fiziol Zh Im I M Sechenova** 1996 Mar;82(3):111–6 (Eng. Abstr.) **(Rus)**

[Telomerase, aging, cancer] Egorov EE. **Mol Biol (Mosk)** 1997 Jan–Feb;31(1):16–24 (97 ref.) **(Rus)**

[Changes in the oxytocinergic neurosecretory cells in the accessory magnocellular neuroendocrine nuclei of the rat hypothalamus during aging] Bazhanova ED, et al. **Morfologiia** 1997;111(2):44–6 (Eng. Abstr.) **(Rus)**

[Effect of sodium nitrate on oxidative phosphorylation in liver mitochondria of newborn and adult rats] Lavrushenko LF, et al. **Ukr Biokhim Zh** 1996 Jan–Feb;68(1):104–7 (Eng. Abstr.) **(Rus)**

[Effect of paracetamol on the microsomal oxidation, oxidative phosphorylation and liver mitochondria swelling in rats of various ages] Padalko VI, et al. **Ukr Biokhim Zh** 1996 Nov–Dec;68(6):92–8 (Eng. Abstr.) **(Rus)**

[Effect of stress on lipid peroxidation and physico–chemical status of endoplasmic reticulum membranes in liver of adult and old rats] Paramonova GI, et al. **Ukr Biokhim Zh** 1996 Sep–Oct;68(5):47–53 (Eng. Abstr.) **(Rus)**

[Age differences in topic concentrations and activity of H2– and B2–receptors in the larynx and trachea] Aslanian GG. **Vestn Otorinolaringol** 1997;(1):36–9 (Eng. Abstr.) **(Rus)**

[Lipoprotein lipase: properties, change in activity with age and in some noninfectious human diseases] Kovalenko IG, et al. **Vopr Med Khim** 1996 Jan–Mar;42(1):3–9 (53 ref.) **(Rus)**

[Status of bioenergetic processes in brain of immature rats during the dynamics of cranio–cerebral trauma] Novikov VE, et al. **Vopr Med Khim** 1996 Oct–Dec;42(4):309–11 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Cholinergic fibre loss associated with diffuse plaques in the non–demented elderly: the preclinical stage of Alzheimer's disease? Beach TG, et al. **Acta Neuropathol (Berl)** 1997 Feb;93(2):146–53

Apoptosis in the aged dog brain. Kiatipattanasakul W, et al. **Acta Neuropathol (Berl)** 1996 Sep;92(3):242–8

Age–dependent susceptibility in mumps–associated hydrocephalus: neuropathologic features and brain barriers. Uno M, et al. **Acta Neuropathol (Berl)** 1997 Sep; 94(3):207–15

Distribution of amyloid bodies in the aged human vestibulocochlear nerve. Fujii M, et al. **Acta Otolaryngol (Stockh)** 1996 Jul;116(4):566–71

The anti–aging effect of moxibustion and moxibustion combined with skin allograft evaluated from optic and electron microscopy study of thymus and pituitary glands. Zhang L, et al. **Acupunct Electrother Res** 1996 Apr–Jun; 21(2):93–104

The macular pigment: a possible role in protection from age–related macular degeneration. Landrum JT, et al. **Adv Pharmacol** 1997;38:537–56

Photoaging of the connective tissue of skin: its prevention and therapy. Scharffetter–Kochanek K. **Adv Pharmacol** 1997;38:639–55 (116 ref.)

Atherosclerosis and the vascular biology of aging. Bilato C, et al. **Aging (Milano)** 1996 Aug;8(4):221–34 (131 ref.)

Differences in body composition between female geriatric hip fracture patients and healthy controls: body fat is more important as explanatory factor for the fracture than body weight and lean body mass. Galvard H, et al. **Aging (Milano)** 1996 Aug;8(4):282–6

Age and sex differences in body size and composition during rhesus monkey adulthood. Hudson JC, et al. **Aging (Milano)** 1996 Jun;8(3):197–204

Effect of age on marrow macrophage number and function. Wang CQ, et al. **Aging (Milano)** 1995 Oct;7(5):379–84

T2 shortening in the visual cortex: effect of aging and cerebrovascular disease. Korogi Y, et al. **AJNR Am J Neuroradiol** 1997 Apr;18(4):711–4

Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non–amyloid

precursor to senile plaques? Dickson DW. **Am J Pathol** 1997 Jul;151(1):7–11 (33 ref.)
Pi-class glutathione-S-transferase-positive hepatocytes in aging B6C3F1 mice undergo apoptosis induced by dietary restriction. Muskhelishvili L, et al. **Am J Pathol** 1996 Nov; 149(5):1585–91
Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Tompkins MM, et al. **Am J Pathol** 1997 Jan;150(1):119–31
Longitudinal study of dental development in chimpanzees of known chronological age: implications for understanding the age at death of Plio-Pleistocene hominids. Anemone RL, et al. **Am J Phys Anthropol** 1996 Jan;99(1):119–33
Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer's type. Bertoni-Freddari C, et al. **Anal Quant Cytol Histol** 1996 Jun;18(3):209–13
Architecture, elastic fiber, and collagen in the distal air portion of the lung of the 18-month-old rat. Escolar JD, et al. **Anat Rec** 1997 May;248(1):63–9
Quantitative morphological changes in neurons from the dorsal lateral geniculate nucleus of young and old rats. Villena A, et al. **Anat Rec** 1997 May;248(1):137–41
Changes in the dental arches and dentition between 25 and 45 years of age [see comments] Bishara SE, et al. **Angle Orthod** 1996;66(6):417–22. Comment in: Angle Orthod 1996 ;66(6):403.
Influences of aging changes in proliferative rate of PDL cells during experimental tooth movement in rats. Kyomen S, et al. **Angle Orthod** 1997;67(1):67–72
Postnatal change in angle between the tympanic annulus and surrounding structures. Computer-aided three-dimensional reconstruction study. Ikui A, et al. **Ann Otol Rhinol Laryngol** 1997 Jan;106(1):33–6
Ultrastructural study of odontoblasts of dental pulp in the cells aging process. Grajewska I, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1995;50:61–5
Skinfold thickness can predict elastosis in hairless mice. Malmusi M, et al. **Arch Dermatol Res** 1996 Oct; 288(11):722–4
Racial variations in the extent of tooth root translucency in ageing individuals. Whittaker DK, et al. **Arch Oral Biol** 1996 Jan;41(1):15–9
Histological analysis of the coracoacromial arch: correlation between age-related changes and rotator cuff tears. Panni AS, et al. **Arthroscopy** 1996 Oct;12(5):531–40
Studies of the incidence of spontaneous pancreatic tumours in ageing CD rats. Majeed SK. **Arzneimittelforschung** 1997 Jul;47(7):879–84
Aging of the vascular wall and atherogenesis: role of the elastin-laminin receptor [published erratum appears in Atherosclerosis 1996 Sep 27;126(1):173] Robert L. **Atherosclerosis** 1996 Jun;123(1–2):169–79 (56 ref.)
Coronal displacement of cementum: correlation between age and coronal movement of cementum in impacted teeth. Bocutoğlu O, et al. **Aust Dent J** 1997 Jun;42(3):185–8
Hippocampal vulnerability to stress and aging: possible role of neurotrophic factors. Smith MA. **Behav Brain Res** 1996 Jun;78(1):25–36 (116 ref.)
Obstetric complications and age-related changes in brain morphology in schizophrenia. Smith GN, et al. **Biol Psychiatry** 1996 Dec 15;40(12):1200–8
Effect of age and dietary protein level on tissue mineral levels in female rats. Takeda T, et al. **Biol Trace Elem Res** 1996 Jul;54(1):55–74
Age-related change of mineral content in the human thoracic aorta and in the human cerebral artery. Tohno Y, et al. **Biol Trace Elem Res** 1996 Jul;54(1):23–31
The effect of advancing age on bone mineral content of female rhesus monkeys. Champ JE, et al. **Bone** 1996 Nov; 19(5):485–92
Relative contributions of age and menopause to the vertebral bone density of healthy Japanese women. Iki M, et al. **Bone** 1996 Jun;18(6):617–20
Osteocyte density changes in aging and osteoporosis. Mullender MG, et al. **Bone** 1996 Feb;18(2):109–13
Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Oxlund H, et al. **Bone** 1996 Nov;19(5):479–84
Modeling the mechanical behavior of vertebral trabecular bone: effects of age-related changes in microstructure. Silva MJ, et al. **Bone** 1997 Aug;21(2):191–9
Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study [published erratum appears in Bone 1996 Nov;19(5):566] Stolk RP, et al. **Bone** 1996 Jun;18(6):545–9
In vivo trabecular microcracks in human vertebral bone. Wenzel TE, et al. **Bone** 1996 Aug;19(2):89–95
Effects of xerosis and ageing on epidermal proliferation and differentiation. Engelke M, et al. **Br J Dermatol** 1997 Aug; 137(2):219–25
Structural alterations in the tunica albuginea of the penis: impact of Peyronie's disease, ageing and impotence [see comments] Akkus E, et al. **Br J Urol** 1997 Jan;79(1):47–53 . Comment in: Br J Urol 1997 Jul;80(1):190.
Distribution of AMPA receptor subunits in the nucleus basalis of Meynert in aged humans: implications for selective neuronal degeneration. Ikonomovic MD, et al. **Brain Res** 1996 Apr 15;716(1–2):229–32
Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Su JH, et al. **Brain Res** 1996 Nov 11;739(1–2):79–87
Age-related differences in mouse Schwann cell response to cyclic AMP. Yamada H, et al. **Brain Res** 1996 May 6; 719(1–2):187–93
Age-dependent effects of glutamate toxicity in the hippocampus. Liu Z, et al. **Brain Res Dev Brain Res** 1996 Dec 23;97(2):178–84
Ventrolateral medullary neurons show age-dependent depolarizations to hypoxia in vitro. Nolan PC, et al. **Brain Res Dev Brain Res** 1996 Jan 22;91(1):111–20
Age-related change in rat testicular ATPase activities in response to HCH treatment. Roy A, et al. **Bull Environ Contam Toxicol** 1996 Jan;56(1):165–70
Comparison of in vitro response to growth hormone by chondrocytes from mandibular condyle cartilage of young and old mice. Livne E, et al. **Calcif Tissue Int** 1997 Jul; 61(1):62–7
Effect of aging on the amide group of bone matrix, measured by FTIR spectrophotometry, in adult subjects deceased as a result of violent death. Very JM, et al. **Calcif Tissue Int** 1997 Mar;60(3):271–5
Immunohistochemical identification of B and T lymphocytes in formalin-fixed, paraffin-embedded feline lymphosarcomas: relation to feline leukemia virus status, tumor site, and patient age. Jackson ML, et al. **Can J Vet Res** 1996 Jul;60(3):199–204
The microcirculation in experimental hypertension and aging. Hutchins PM, et al. **Cardiovasc Res** 1996 Oct;32(4):772–80 (53 ref.)
Changes in endocrine circadian rhythms as markers of physiological and pathological brain aging. Magri F, et al. **Chronobiol Int** 1997 Jul;14(4):385–96
Flow-induced vascular remodeling in the rat carotid artery diminishes with age. Miyashiro JK, et al. **Circ Res** 1997 Sep;81(3):311–9
Maxillary and mandibular dental-arch dimensions and occlusion in bilateral cleft lip and palate patients form 3 to 17 years of age. Heidbuchel KL, et al. **Cleft Palate Craniofac J** 1997 Jan;34(1):21–6
Aging and regulation of apoptosis. Warner HR. **Curr Top Cell Regul** 1997;35:107–21 (88 ref.)
Optimal management of chronic leg ulcers in the elderly. Goodfield M. **Drugs Aging** 1997 May;10(5):341–8 (25 ref.)
Effects of age and coion (K+ and Na+) on the toxicity of thiocyanate to rainbow trout (Oncorhynchus mykiss) during pulse or continuous exposure. Kevan SD, et al. **Ecotoxicol Environ Saf** 1996 Dec;35(3):288–93
Echocardiographic measurements of cardiac dimensions in normal ponies and horses. Slater JD, et al. **Equine Vet J Suppl** 1995 Sep;(19):28–32
Medullary injury in the ageing rat kidney: functional-morphometric correlations. Greenfeld Z, et al. **Eur J Clin Invest** 1997 Apr;27(4):346–51
Does old age contraindicate TURP. Balslev Jørgensen J, et al. **Eur Urol** 1997;31(3):281–5
Modification of bladder structure in response to outflow obstruction and ageing. Gosling JA. **Eur Urol** 1997;32 Suppl 1:9–14
Age and racial distribution of prostatic intraepithelial neoplasia. Sakr WA, et al. **Eur Urol** 1996;30(2):138–44 (26 ref.)
In vitro study of the mechanisms of senescence acceleration. Hosokawa M, et al. **Exp Gerontol** 1997 Jan-Apr; 32(1–2):197–203
Neuropathological studies on strains of senescence-accelerated mice (SAM) with age-related deficits in learning and memory. Kawamata T, et al. **Exp Gerontol** 1997 Jan-Apr;32(1–2):161–9 (45 ref.)
Pathobiology of aging rodents: inbred and hybrid models. Lipman RD. **Exp Gerontol** 1997 Jan-Apr;32(1–2):215–28 (27 ref.)
Pathobiology of the senescence-accelerated mouse (SAM). Takeda T, et al. **Exp Gerontol** 1997 Jan-Apr;32(1–2):117–27 (41 ref.)
Effect of acidic fibroblast growth factor on basal forebrain cholinergic neurons in senescence-accelerated mice. Tooyama I, et al. **Exp Gerontol** 1997 Jan-Apr;32(1–2):171–9
Amyloid load and neural elements in Alzheimer's disease and nondemented individuals with high amyloid plaque density. Mochizuki A, et al. **Exp Neurol** 1996 Nov;142(1):89–102
Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques. Wallace MN, et al. **Exp Neurol** 1997 Apr;144(2):266–72
Spontaneous lesions of nasal cavity in aging F344 rats and BDF1 mice. Nagano K, et al. **Exp Toxicol Pathol** 1997 Feb;49(1–2):97–104
Age related changes in the motoneurons of the spinal cord of the rat. Karmańska W, et al. **Folia Morphol (Warsz)** 1996; 55(4):309–11
On development and clinical aspects of human supratentorial bridge veins. Kędzia A, et al. **Folia Morphol (Warsz)** 1996; 55(4):327–9
Morphological features of the patella and its ligament before and after birth. Lewandowski J. **Folia Morphol (Warsz)** 1996;55(4):373–4
Age related changes in the density of blood vessels in the human sciatic nerve. Mikusek J, et al. **Folia Morphol (Warsz)** 1996;55(4):398–400
Growth hormone therapy in elderly people: an age-delaying drug? Bouillanne O, et al. **Fundam Clin Pharmacol** 1996; 10(5):416–30 (168 ref.)
Utilization of the rat as a model of mammalian aging: impact of pathology on behavior. Spangler EL, et al. **Gerontology** 1996;42(6):301–11
Histopathologic observations of the aging gerbil cochlea. Adams JC, et al. **Hear Res** 1997 Feb;104(1–2):101–11
Auditory evoked potentials in aged gerbils: responses elicited by noises separated by a silent gap. Boettcher FA, et al. **Hear Res** 1996 Dec 1;102(1–2):167–78
Cochlear spiral ganglion cell degeneration in wild-caught mice as a function of age. Dazert S, et al. **Hear Res** 1996 Oct;100(1–2):101–6
Functional changes in the aging mouse middle ear. Doan DE, et al. **Hear Res** 1996 Aug;97(1–2):174–7
Central tinnitus and lateral inhibition: an auditory brainstem model. Gerken GM. **Hear Res** 1996 Aug;97(1–2):75–83 (57 ref.)
Age-related decreases in endocochlear potential are associated with vascular abnormalities in the stria vascularis. Gratton MA, et al. **Hear Res** 1996 May; 94(1–2):116–24
Age-related decreases in endocochlear potential are associated with vascular abnormalities in the stria vascularis. Gratton MA, et al. **Hear Res** 1996 Dec 1; 102(1–2):181–90
Age-related changes in GFAP-immunoreactive astrocytes in the rat ventral cochlear nucleus. Jalenques I, et al. **Hear Res** 1997 May;107(1–2):113–24
Correlative evidence of hypertension and altered cochlear microhomeostasis: electrophysiological changes in the spontaneously hypertensive rat. Rarey KE, et al. **Hear Res** 1996 Dec 1;102(1–2):63–9
Effects of aging on potassium homeostasis and the endocochlear potential in the gerbil cochlea. Schmiedt RA. **Hear Res** 1996 Dec 1;102(1–2):125–32
Gastric mucosal injury and repair: effect of aging. Majumdar AP, et al. **Histol Histopathol** 1997 Apr;12(2):491–501 (81 ref.)
A model conforming the decline in follicle numbers to the age of menopause in women. Faddy MJ, et al. **Hum Reprod** 1996 Jul;11(7):1484–6
Histopathological & immunohistochemical evaluation of ageing changes in normal human brain. Yasha TC, et al. **Indian J Med Res** 1997 Mar;105:141–50
Loss of granule neurons in the aging human cerebellar cortex. Renovell A, et al. **Int J Dev Biol** 1996;Suppl 1:193S–194S
The aging olfactory epithelium: neurogenesis, response to damage, and odorant-induced activity. Loo AT, et al. **Int J Dev Neurosci** 1996 Nov;14(7–8):881–900
The prostate: decreasing cost-effectiveness of biopsy with advancing age. Gottlieb RH, et al. **Invest Radiol** 1996 Feb; 31(2):84–90
Relationship between baseline insulin-like growth factor-I (IGF-I) and femoral bone density in women aged over 70 years: potential implications for the prevention of age-related bone loss. Boonen S, et al. **J Am Geriatr Soc** 1996 Nov;44(11):1301–6
Preadipocyte function and aging: links between age-related changes in cell dynamics and altered fat tissue function. Kirkland JL, et al. **J Am Geriatr Soc** 1997 Aug;45(8):959–67 (60 ref.)
Renal interstitial sclerosis in aging: effects of enalapril and nifedipine. Inserra F, et al. **J Am Soc Nephrol** 1996 May; 7(5):676–80
The effect of age on residual strain in the rat aorta. Badreck-Amoudi A, et al. **J Biomech Eng** 1996 Nov; 118(4):440–4
Heterogeneity of the skeleton: comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. Amling M, et al. **J Bone Miner Res** 1996 Jan;11(1):36–45
The influence of growth hormone on cancellous and cortical bone of the vertebral body in aged rats. Andreassen TT, et al. **J Bone Miner Res** 1996 Aug;11(8):1094–102
Demineralized bone matrix mediates differentiation of bone marrow stromal cells in vitro: effect of age of cell donor. Becerra J, et al. **J Bone Miner Res** 1996 Nov;11(11):1703–14
Effect of ethnicity and age or menopause on the structure and geometry of iliac bone [published erratum appears in J Bone Miner Res 1997 May;12(5):867] Han ZH, et al. **J Bone Miner Res** 1996 Dec;11(12):1967–75
The effect of aging on bone formation in porous hydroxyapatite: biochemical and histological analysis. Inoue K, et al. **J Bone Miner Res** 1997 Jun;12(6):989–94
The thickness of human vertebral cortical bone and its changes in aging and osteoporosis: a histomorphometric analysis of the complete spinal column from thirty-seven autopsy specimens. Ritzel H, et al. **J Bone Miner Res** 1997 Jan;12(1):89–95
Predictors of ankle and foot fractures in older women. The Study of Osteoporotic Fractures Research Group. Seeley DG, et al. **J Bone Miner Res** 1996 Sep;11(9):1347–55
A documentation of an age related increase in neuronal and axonal numbers in the stingray, Dasyatis sabina, Leseuer. Leonard RB, et al. **J Comp Neurol** 1978 May 1;179(1):13–21
Age-related changes in oligodendrocytes in monkey cerebral cortex. Peters A. **J Comp Neurol** 1996 Jul 15;371(1):153–63
Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. Simić G, et al. **J Comp Neurol** 1997 Mar 24;379(4):482–94
Structural plasticity of identified glomeruli in the antennal lobes of the adult worker honey bee. Winnington AP, et al. **J Comp Neurol** 1996 Feb 12;365(3):479–90
Sudden unexpected death in young adult due to right ventricular dysplasia. Lane CD. **J Forensic Sci** 1997 Jan;

42(1):148–50

Effect of age on muscle hypertrophy induced by resistance training. Welle S, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov;51(6):M270–5

Terminal dUTP nick end labeling (TUNEL) positive cells in the different regions of the brain in normal aging and Alzheimer patients. Li WP, et al. **J Mol Neurosci** 1997 Apr;8(2):75–82

Induction of thymic hyperplasia and suppression of splenic T cells by lesioning of the anterior hypothalamus in aging Wistar rats. Utsuyama M, et al. **J Neuroimmunol** 1997 Aug; 77(2):174–80

Age-related ubiquitin-positive granular structures in non-demented subjects and neurodegenerative disorders. Iseki E, et al. **J Neurol Sci** 1996 Oct;142(1–2):25–9

Alzheimer's disease, Lewy body disease and aging: a comparative study of the perforant pathway. Lippa CF, et al. **J Neurol Sci** 1997 Apr 15;147(2):161–6

Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. Sparks DL, et al. **J Neurol Sci** 1996 Jun;138(1–2):97–104

The acromion: morphologic condition and age-related changes. A study of 420 scapulas. Nicholson GP, et al. **J Shoulder Elbow Surg** 1996 Jan–Feb;5(1):1–11

Morphological and morphometrical study of human lens in senile cataract. Shaikh MR, et al. **JPMA J Pak Med Assoc** 1997 May;47(5):141–4

Are breast cancers in young women qualitatively distinct? [see comments] Henderson IC, et al. **Lancet** 1997 May 24; 349(9064):1488–9. Comment in: Lancet 1997 May 24;349(9064):1505–10.

Age-related changes of the globular substance in the otoconial membrane of mice. Suzuki H, et al. **Laryngoscope** 1997 Mar;107(3):378–81

MRI in successful aging, a 5-year follow-up study from the eighth to ninth decade of life. Wahlund LO, et al. **Magn Reson Imaging** 1996;14(6):601–8

HIV infection and aging: mechanisms to explain the accelerated rate of progression in the older patient. Adler WH, et al. **Mech Ageing Dev** 1997 Jun;96(1–3):137–55

Age-related morphological changes in the hippocampus in two mouse strains. Barkats M, et al. **Mech Ageing Dev** 1996 Jun 25;87(3):155–64

Effect of treatment with L-deprenyl on age-dependent microanatomical changes in the rat kidney. Battisti A, et al. **Mech Ageing Dev** 1996 Jul 31;89(1):1–10

Adaptations of myonuclei to hypertrophy in patagialis muscle fibers from aged quail. Lee J, et al. **Mech Ageing Dev** 1996 Jul 17;88(3):185–97

Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Parnetti L, et al. **Mech Ageing Dev** 1997 Jul;97(1):9–14

The effect of ageing on neurones in the visual sector of the thalamic reticular nucleus. Requena V, et al. **Mech Ageing Dev** 1996 Aug 29;89(3):185–93

"Aging bull'. Geelhoed GW. **Med Hypotheses** 1996 Dec; 47(6):471–9 (9 ref.)

Effect of age on the structure of Meissner corpuscles in murine digital pads. Nava PB, et al. **Microsc Res Tech** 1996 Jul 1;34(4):376–89

Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. Cummings BJ, et al. **Neurobiol Aging** 1996 Jul–Aug;17(4):653–9

Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. De Leon MJ, et al. **Neurobiol Aging** 1997 Jan–Feb;18(1):1–11

Topography of brain atrophy during normal aging and Alzheimer's disease. Double KL, et al. **Neurobiol Aging** 1996 Jul–Aug;17(4):513–21

Differential susceptibility of senile and lesion-induced astrogliosis to phosphatidylserine. Jegliński W, et al. **Neurobiol Aging** 1997 Jan–Feb;18(1):81–6

Premature aging in Werner's syndrome spares the central nervous system. Postiglione A, et al. **Neurobiol Aging** 1996 May–Jun;17(3):325–30

Sex differences in the corpus callosum with aging. Salat D, et al. **Neurobiol Aging** 1997 Mar–Apr;18(2):191–7

Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Troncoso JC, et al. **Neurobiol Aging** 1996 May–Jun;17(3):365–71

Direct intracerebral nerve growth factor gene transfer using a recombinant adenovirus: effect on basal forebrain cholinergic neurons during aging. Castel-Barthe MN, et al. **Neurobiol Dis** 1996 Feb;3(1):76–86

Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Jack CR Jr, et al. **Neurology** 1997 Sep;49(3):786–94

Increased vulnerability of septal cholinergic neurons to partial loss of target neurons in aged rats. Cooper JD, et al. **Neuroscience** 1996 Nov;75(1):29–35

Reduced retrograde labelling with fluorescent tracer accompanies neuronal atrophy of basal forebrain cholinergic neurons in aged rats. De Lacalle S, et al. **Neuroscience** 1996 Nov;75(1):19–27

Morphometric analyses and aging process of nerve fibers in the human spinal posterior funiculus. Zhang C, et al. **Okajimas Folia Anat Jpn** 1995 Dec;72(5):259–64

Ocular conditions associated with posterior vitreous detachment in young patients. Hikichi T, et al. **Ophthalmic Surg Lasers** 1996 Sep;27(9):782–6

Cartilage swelling and loss in a spontaneous model of osteoarthritis visualized by magnetic resonance imaging. Watson PJ, et al. **Osteoarthritis Cartilage** 1996 Sep; 4(3):197–207

Effect of aging on trabecular and compact bone components of proximal and ultradistal radius. Gatti D, et al. **Osteoporos Int** 1996;6(5):355–60

Age-related changes in vertebral height ratios and vertebral fracture. Sone T, et al. **Osteoporos Int** 1997;7(2):113–8

Ultrasound velocity changes at the proximal phalanxes of the hand in pre-, peri- and postmenopausal women. Ventura V, et al. **Osteoporos Int** 1996;6(5):368–75

Wheat kernel ingestion protects from progression of muscle weakness in mdx mice, an animal model of Duchenne muscular dystrophy. Hübner C, et al. **Pediatr Res** 1996 Sep;40(3):444–9

Examination of telomere lengths in muscle tissue casts doubt on replicative aging as cause of progression in Duchenne muscular dystrophy. Oexle K, et al. **Pediatr Res** 1997 Aug; 42(2):226–31

Peptide T prevents NBM lesion-induced cortical atrophy in aged rats. Socci DJ, et al. **Peptides** 1996;17(5):831–7

Decline in isokinetic force with age: muscle cross-sectional area and specific force. Jubrias SA, et al. **Pflugers Arch** 1997 Jul;434(3):246–53

Age-related changes in alpha-adrenoceptor-mediated blood pressure in the rat: relationship between the potency for phenylephrine and the maximum number of binding sites. Koike K, et al. **Pharmacology** 1996 Jan;52(1):16–24

Sulcal, ventricular, and white matter changes at MR imaging in the aging brain: data from the cardiovascular health study [see comments] Yue NC, et al. **Radiology** 1997 Jan; 202(1):33–9. Comment in: Radiology 1997 Jan;202(1):17–9.

MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration. Baur A, et al. **Skeletal Radiol** 1997 Jul;26(7):414–8

Interactive effects of age and hypertension on volumes of brain structures. Strassburger TL, et al. **Stroke** 1997 Jul; 28(7):1410–7

A topographical study of cartilaginous lesions to the elbow. Debouck C, et al. **Surg Radiol Anat** 1995;17(4):301–5

Neurons and microvessels of the nodose (vagal sensory) ganglion in young adult and aged rats: morphometric and enzyme histochemical studies. Soltanpour N, et al. **Tissue Cell** 1996 Oct;28(5):593–602

Spontaneous lesions in aging FVB/N mice. Mahler JF, et al. **Toxicol Pathol** 1996 Nov–Dec;24(6):710–6

Appearance of eosinophilic granule cells as pathological changes in the uteri of two aged virgin Donryu rats. Yoshida M, et al. **Toxicol Pathol** 1997 May–Jun;25(3):321–5

Lifespan and lesions in genetically heterogeneous (four-way cross) mice: a new model for aging research. Chrisp CE, et al. **Vet Pathol** 1996 Nov;33(6):735–43

Immunohistochemical and morphological characterization of spontaneously occurring pheochromocytomas in the aging mouse. Tischler AS, et al. **Vet Pathol** 1996 Sep;33(5):512–20

Ageing draft and trotter horses by their dentition. Muylle S, et al. **Vet Rec** 1997 Jul 5;141(1):17–20

Relationship between numbers of retinal ganglion cells and lateral geniculate neurons in the rhesus monkey. Spear PD, et al. **Vis Neurosci** 1996 Jan–Feb;13(1):199–203

[Potential role for family physicians in pushing back age-related impairment: hearing and vision disorders, incontinence and arthrosis (see comments)] Eekhof JA, et al. **Ned Tijdschr Geneeskd** 1996 Nov 30;140(48):2402–6 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1997 Feb 1;141(5):256. **(Dut)**

[Volumetric examination of senile brain involution in dogs] Reifinger M. **Anat Histol Embryol** 1997 Jun;26(2):141–6 (Eng. Abstr.) **(Ger)**

[Comparison of two methods of age determination in teeth of known age from wild carnivores] Thomé H, et al. **Anat Histol Embryol** 1997 Jun;26(2):81–4 (Eng. Abstr.) **(Ger)**

[Senescence-accelerated mouse (SAM): with special reference to age-associated pathologies and their modulation] Takeda T. **Nippon Eiseigaku Zasshi** 1996 Jul; 51(2):569–78 (86 ref.) (Eng. Abstr.) **(Jpn)**

[MR images of bone marrow in aplastic anemia and correlation between MR findings and age] Amano Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jul; 56(8):546–9 (Eng. Abstr.) **(Jpn)**

[Age-related changes in morphological studies in rat and human kidney] Takeda T, et al. **Nippon Jinzo Gakkai Shi** 1996 Dec;38(12):555–62 (Eng. Abstr.) **(Jpn)**

[Pathological study of age-related vascular changes in the spinal cord] Wang Y, et al. **Nippon Ronen Igakkai Zasshi** 1996 Aug;33(8):563–8 (Eng. Abstr.) **(Jpn)**

[Age-related changes of diffusional anisotropy in the cerebral white matter in normal subjects] Hanyu H, et al. **No To Shinkei** 1997 Apr;49(4):331–6 (Eng. Abstr.) **(Jpn)**

[Mineral changes in the intervertebral disc and facet joints during aging] Niedźwiedzki T, et al. **Chir Narzadow Ruchu Ortop Pol** 1997;62(1):39–45 (Eng. Abstr.) **(Pol)**

[Age-related features of cardiomyocyte ultrastructure of the effluent region of the right ventricle in patients with Fallot's tetralogy] Egorova IF, et al. **Arkh Patol** 1996 May–Jun;58(3):58–61 (Eng. Abstr.) **(Rus)**

[Morphologic and functional changers in B-cells and vessels of the islands of Langerhans in patients with insulin-dependent diabetes mellitus] Severgina ES, et al. **Arkh Patol** 1996 Sep–Oct;58(5):40–7 (Eng. Abstr.) **(Rus)**

[Age-related changes in the autonomic ganglia] Sosunov AA, et al. **Arkh Patol** 1997 Mar–Apr;59(2):32–7 (Eng. Abstr.) **(Rus)**

[A new cyto-biophysical index of biological age and the physiological state of the human body] Shakhbazov VG, et al. **Fiziol Cheloveka** 1996 Nov–Dec;22(6):71–5 **(Rus)**

[The reaction to stress of the nonapeptidergic hypothalamic centers in old and young rats] Bazhanova ED, et al. **Morfologiia** 1996;110(5):30–3 (Eng. Abstr.) **(Rus)**

[Involutional ophthalmic endotoxicosis as the cause of the involutional vitroretinal syndrome] Vodovozov AM. **Vestn Oftalmol** 1996 Apr–Jun;112(2):35–8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

The age-related risk of occupational accidents: the case of Swedish iron-ore miners. Laflamme L, et al. **Accid Anal Prev** 1996 May;28(3):349–57

The different responses of the female mouse thymus to estrogen after treatment of neonatal, prepubertal, and adult animals. Forsberg JG. **Acta Anat (Basel)** 1996;157(4):275–90

Hypertrophic Z-line observed in aged one-humped camel (Camelus dromedarius). Karkoura A, et al. **Acta Anat (Basel)** 1995;153(3):220–5

Cardiac rod body: hypertrophic Z-line in an aged pony. Tangkawattana P, et al. **Acta Anat (Basel)** 1996; 155(4):266–73

Sex and strain differences of acoustic startle reaction development in adolescent albino Wistar and hooded rats. Błaszczyk J, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(4):919–25

The effect of pinealectomy and foetal pineal transplantation of collagen ageing in rats. Berker M, et al. **Acta Neurochir (Wien)** 1996;138(10):1224–8; discussion 1228–9

Aging, disease and death of nerve cells. Agid Y, et al. **Acta Neurol Belg** 1996 Sep;96(3):219–23

Functional uncertainty, aging and memory processes during sleep. Salzarulo P, et al. **Acta Neurol Belg** 1997 Jun; 97(2):118–22 (31 ref.)

Age-related neuronal loss in the nucleus centralis superior of the rhesus monkey. Kemper TL, et al. **Acta Neuropathol (Berl)** 1997 Aug;94(2):124–30

Age, weight, body mass index and endometrial thickness in postmenopausal women [letter; comment] Andolf E, et al. **Acta Obstet Gynecol Scand** 1996 Oct;75(9):867–8. Comment on: Acta Obstet Gynecol Scand 1996 Feb;75(2):181–2.

Visual development in healthy eyes from 24 months to four years of age. Lithander J. **Acta Ophthalmol Scand** 1997 Jun;75(3):275–6

Age-related macular degeneration. An epidemiological study of 1000 elderly individuals. With reference to prevalence, funduscopic findings, visual impairment and risk factors. Vinding T. **Acta Ophthalmol Scand Suppl** 1995;(217):1–32 (126 ref.)

Changes in vestibulo-ocular reflex of elderly people. Hirvonen TP, et al. **Acta Otolaryngol Suppl (Stockh)** 1997; 529:108–10

The ageing voice: changes in fundamental frequency, waveform stability and spectrum. Decoster W, et al. **Acta Otorhinolaryngol Belg** 1997;51(2):105–12

Morphological evidence for effects of the aging on the serotoninergic neurons in the rat brainstem nuclei. Lolova IS. **Acta Physiol Pharmacol Bulg** 1996;22(1):17–25

Ageing is associated with reduced basal and stimulated release of nitric oxide by the coronary endothelium. Amrani M, et al. **Acta Physiol Scand** 1996 May;157(1):79–84

Alpha-adrenoceptor activation induces rhythmic contractile activity in carotid arteries from young, not adult, rats. Eddinger TJ, et al. **Acta Physiol Scand** 1997 Feb; 159(2):123–9

Heart rate variability in healthy subjects is related to age and gender. Jensen-Urstad K, et al. **Acta Physiol Scand** 1997 Jul;160(3):235–41

Ageing reduces sympatho-suppressive response to head-out water immersion in humans. Miwa C, et al. **Acta Physiol Scand** 1996 Sep;158(1):15–20

Effects of strength and endurance training on isometric muscle strength and walking speed in elderly women. Sipilä S, et al. **Acta Physiol Scand** 1996 Apr;156(4):457–64

Effects of treadmill training on the arteriolar and venular portions of capillary in soleus muscle of young and middle-aged rats. Suzuki J, et al. **Acta Physiol Scand** 1997 Feb;159(2):113–21

General lexical slowing and the semantic priming effect: the roles of age and ability. Myerson J, et al. **Acta Psychol (Amst)** 1997 Jun;96(1–2):83–101

Measurement of the total body fat content of growing rabbits by X-ray computerised tomography and direct chemical analysis. Romvári R, et al. **Acta Vet Hung** 1996; 44(2):145–51

Age-related changes in scrotal circumference of Hungarian Simmental bulls in self-performance test. Tözsér J, et al. **Acta Vet Hung** 1996;44(3):263–7

The effects of taurine in a rodent model of aging. Dawson R Jr, et al. **Adv Exp Med Biol** 1996;403:37–50

Effects of chronic taurine treatment on the electrical and contractile properties of skeletal muscle fibers of aged rats. Pierno S, et al. **Adv Exp Med Biol** 1996;403:249–55

AGING

Sex differences in endogenous retinoid release in the post-embryonic spinal cord of the western mosquitofish, Gambusia affinis affinis. Rosa-Molinar E, et al. **Adv Exp Med Biol** 1997;414:95-108

Advanced glycosylation in nephropathy of diabetes and aging. Vlassara H. **Adv Nephrol Necker Hosp** 1996; 25:303-15 (58 ref.)

Changes in autonomic function with age: a study of pupillary kinetics in healthy young and old people. Bitsios P, et al. **Age Ageing** 1996 Nov;25(6):432-8

Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Bohannon RW. **Age Ageing** 1997 Jan;26(1):15-9

Determinants of age-associated changes in os calcis ultrasonic indices in elderly women: potential involvement of geriatric hyposomatotropism in bone fragility. Boonen S, et al. **Age Ageing** 1997 Mar;26(2):139-46

Evidence for a non-linear relationship between leg strength and gait speed. Buchner DM, et al. **Age Ageing** 1996 Sep; 25(5):386-91

Dispersion measures in biomedical research on ageing: nuances in the meaning of variability. Olde Rikkert MG, et al. **Age Ageing** 1997 Jan;26(1):45-52

Aspartame pharmacokinetics: the effect of ageing [letter; comment] Sayer AP. **Age Ageing** 1996 Sep;25(5):413. Comment on: Age Ageing 1996 May;25(3):217-20.

Age-related changes in O-deethylase and aldrin epoxidase activity in mouse skin and liver microsomes. Williams D, et al. **Age Ageing** 1996 Sep;25(5):377-80

Atherosclerosis and the vascular biology of aging. Bilato C, et al. **Aging (Milano)** 1996 Aug;8(4):221-34 (131 ref.)

Age-related bone loss and senile osteoporosis: evidence for both secondary hyperparathyroidism and skeletal growth factor deficiency in the elderly. Boonen S, et al. **Aging (Milano)** 1995 Dec;7(6):414-22 (90 ref.)

Differential effects of reduced muscle use (hindlimb unweighting) on skeletal muscle with aging. Brown M, et al. **Aging (Milano)** 1996 Apr;8(2):99-105

Aging, fat oxidation and exercise. Calles-Escandón J, et al. **Aging (Milano)** 1997 Feb-Apr;9(1-2):57-63 (35 ref.)

Detoxification of reactive aldehydes in mitochondria: effects of age and dietary restriction. Chen JJ, et al. **Aging (Milano)** 1996 Oct;8(5):334-40

Coronary heart disease risk factors in older persons [see comments] Corti MC, et al. **Aging (Milano)** 1996 Apr; 8(2):75-89 (154 ref.). Comment in: Aging (Milano) 1996 Apr;8(2):73-4.

Neurological findings in the normal elderly: prevalence and relationships with memory performance. Cosi V, et al. **Aging (Milano)** 1996 Aug;8(4):243-9

Swallowing and the duration of the hyoid movement in normal adults of different ages. Dejaeger E, et al. **Aging (Milano)** 1996 Apr;8(2):130-4

A method for scoring the pain map of the McGill Pain Questionnaire for use in epidemiologic studies. Escalante A, et al. **Aging (Milano)** 1995 Oct;7(5):358-66

Uncoupling of changes in skeletal muscle beta-adrenergic receptor density and aerobic capacity during the aging process. Farrar RP, et al. **Aging (Milano)** 1997 Feb-Apr; 9(1-2):153-8

Chrono-neuroendocrine markers of the aging brain. Ferrari E, et al. **Aging (Milano)** 1996 Oct;8(5):320-7

Exercise, free radical generation, and aging. Fielding RA, et al. **Aging (Milano)** 1997 Feb-Apr;9(1-2):12-8 (64 ref.)

Physical activity as a factor in the action of dietary restriction on aging: effects in Fischer 344 rats. McCarter RJ, et al. **Aging (Milano)** 1997 Feb-Apr;9(1-2):73-9

Tilt test results in young and elderly patients with syncope of unknown origin. Marangoni E, et al. **Aging (Milano)** 1996 Dec;8(6):409-16

Glucocorticoids and aging. Masoro EJ. **Aging (Milano)** 1995 Dec;7(6):407-13 (75 ref.)

Presence of a DNA-4236 bp deletion and 8-hydroxy-deoxyguanosine in mouse cardiac mitochondrial DNA during aging. Muscari C, et al. **Aging (Milano)** 1996 Dec;8(6):429-33

The structure underlying physical performance measures for older adults in the community. Nagasaki H, et al. **Aging (Milano)** 1995 Dec;7(6):451-8

A physical fitness model of older adults. Nagasaki H, et al. **Aging (Milano)** 1995 Oct;7(5):392-7

Aspects of cognitive status as predictors of mobility following geriatric rehabilitation. Patrick L, et al. **Aging (Milano)** 1996 Oct;8(5):328-33

P48: a novel nuclear protein possibly associated with aging and mortality. Pipkin JL, et al. **Aging (Milano)** 1996 Oct; 8(5):311-9

Synovial fluid levels of proinflammatory interleukins and their inter-relationships in elderly vs younger onset rheumatoid arthritis. Punzi L, et al. **Aging (Milano)** 1996 Aug;8(4):277-81

Aging and the respiratory system. Rossi A, et al. **Aging (Milano)** 1996 Jun;8(3):143-61 (136 ref.)

Effects of energy imbalance on energy expenditure and respiratory quotient in young and older men: a summary of data from two metabolic studies. Saltzman E, et al. **Aging (Milano)** 1996 Dec;8(6):370-8

Exercise, immunity and aging. Venjatraman JT, et al. **Aging (Milano)** 1997 Feb-Apr;9(1-2):42-56 (122 ref.)

Reasons for poor detection of frequent falls in elderly people by general practitioners. Vetter NJ, et al. **Aging (Milano)** 1995 Dec;7(6):430-2

Influence of physical exercise on old rats: changes in patterns of spontaneous activity and connective tissues. Viidik A, et al. **Aging (Milano)** 1997 Feb-Apr;9(1-2):64-72

Nutritional support and functional status in undernourished geriatric patients during hospitalization and 6-month follow-up. Volkert D, et al. **Aging (Milano)** 1996 Dec; 8(6):386-95

Effect of age on marrow macrophage number and function. Wang CQ, et al. **Aging (Milano)** 1995 Oct;7(5):379-84

MR methods of measuring changes in brain and cerebrospinal fluid volume with age and menstrual cycle [letter; comment] Condon B, et al. **AJNR Am J Neuroradiol** 1996 Jun-Jul;17(6):1199-200. Comment on: AJNR Am J Neuroradiol 1995 Feb;16(2):241-51.

Age and sex do not affect cerebellar volume in humans [letter] Luft AR, et al. **AJNR Am J Neuroradiol** 1997 Mar; 18(3):593-6

Premature aging in persons with Down syndrome: MR findings. Roth GM, et al. **AJNR Am J Neuroradiol** 1996 Aug;17(7):1283-9

Effects of lifelong ethanol consumption on rat locus coeruleus. Lu W, et al. **Alcohol Alcohol** 1997 Jul-Aug; 32(4):463-70

Full-information models for multiple psychometric tests: annualized rates of change in normal aging and dementia. McCleary R, et al. **Alzheimer Dis Assoc Disord** 1996 Winter;10(4):216-23

Clinical and research issues on older drivers: future directions. Owsley. **Alzheimer Dis Assoc Disord** 1997 Jun; 11 Suppl 1:3-7 (34 ref.)

Cognitive change, medical illness, and crash risk among older drivers: an epidemiological consideration. Wallace RB. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:31-7 (18 ref.)

Age and referral to coronary angiography after an abnormal treadmill thallium test. Lauer MS, et al. **Am Heart J** 1997 Feb;133(2):139-46

Serum albumin is associated with skeletal muscle in elderly men and women. Baumgartner RN, et al. **Am J Clin Nutr** 1996 Oct;64(4):552-8

Body composition of a young, multiethnic female population. Ellis KJ, et al. **Am J Clin Nutr** 1997 Mar;65(3):724-31

Activity and attention in zinc-deprived adolescent monkeys. Golub MS, et al. **Am J Clin Nutr** 1996 Dec;64(6):908-15

Regional body fat distribution in relation to pubertal stage: a dual-energy X-ray absorptiometry study of New Zealand girls and young women. Goulding A, et al. **Am J Clin Nutr** 1996 Oct;64(4):546-51

Age and sex effects on energy expenditure. Klausen B, et al. **Am J Clin Nutr** 1997 Apr;65(4):895-907

Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment [see comments] La Rue A, et al. **Am J Clin Nutr** 1997 Jan;65(1):20-9. Comment in: Am J Clin Nutr 1997 Aug;66(2):449-50.

Comparison of ground-based and space flight energy expenditure and water turnover in middle-aged healthy male US astronauts. Lane HW, et al. **Am J Clin Nutr** 1997 Jan;65(1):4-12

Nutrition and immunity in the elderly: modification of immune responses with nutritional treatments. Lesourd BM. **Am J Clin Nutr** 1997 Aug;66(2):478S-484S (88 ref.)

Specificity of indexes of malnutrition when applied to apparently healthy people: the effect of age. Naber TH, et al. **Am J Clin Nutr** 1997 Jun;65(6):1721-5

Pupillary threshold as an index of population vitamin A status among children in India. Sanchez AM, et al. **Am J Clin Nutr** 1997 Jan;65(1):61-6

A 5-year longitudinal study of the Mini-Mental State Examination in normal aging. Jacqmin-Gadda H, et al. **Am J Epidemiol** 1997 Mar 15;145(6):498-506

Families and natural history of lipids in childhood: an 18-year follow-up study. Uiterwaal CS, et al. **Am J Epidemiol** 1997 May 1;145(9):777-85

A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype. Payami H, et al. **Am J Hum Genet** 1997 Apr;60(4):948-56

Autonomic nervous function in essential hypertension in the elderly. Evaluation by power spectral analysis of heart rate variability. Kohara K, et al. **Am J Hypertens** 1996 Nov; 9(11):1084-9

Mechanisms mediating postprandial blood pressure reduction in young and elderly subjects. Masuo K, et al. **Am J Hypertens** 1996 Jun;9(6):536-44

Developmental studies demonstrate age-dependent elevation of renin activity in TGR(mRen2)27 rats. Véniant M, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 1):1167-76

Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. Naessen T, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):115-9

Relative influence of age and menopause on total and regional body composition changes in postmenopausal women. Trémollieres FA, et al. **Am J Obstet Gynecol** 1996 Dec; 175(6):1594-600

Life domains and adaptive strategies of a group of low-income, well older adults. Clark F, et al. **Am J Occup Ther** 1996 Feb;50(2):99-108 (35 ref.)

Age-related factors in the pathogenesis of senile (Type II) femoral neck fractures. Boonen S, et al. **Am J Orthop** 1996 Mar;25(3):198-204 (107 ref.)

Pubertal weight gain in female rhesus macaques. Blackwelder TL, et al. **Am J Phys Anthropol** 1996 Mar;99(3):449-54

Menarche age, fatness, and fat distribution in Hawaiian adolescents. Brown DE, et al. **Am J Phys Anthropol** 1996 Feb;99(2):239-47

Gender-related factors affecting primate social behavior: grooming, rank, age, and kinship in heterosexual and all-male groups of stumptail macaques. Butovskaya ML, et al. **Am J Phys Anthropol** 1996 Sep;101(1):39-54

Dental indicators of stress and reduced age at death in prehistoric Native Americans. Duray SM. **Am J Phys Anthropol** 1996 Feb;99(2):275-86

Physical growth of children under five years of age in Nchelenge, Zambia: results from a district survey. Gernaat HB, et al. **Am J Phys Anthropol** 1996 Aug;100(4):473-85

Regulation of prostanoid vasomotor effects and receptors in choroidal vessels of newborn pigs. Abran D, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R995-1001

Properties and modulation of If in newborn versus adult cardiac SA node. Accili EA, et al. **Am J Physiol** 1997 Mar; 272(3 Pt 2):H1549-52

Brown fat thermogenesis and cardiac rate regulation during cold challenge in infant rats. Blumberg MS, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1308-13

Adrenal vasoactive intestinal peptide participates in neonatal corticosteroid production in the rat. Bodnar M, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1163-72

Maximal metabolic rate and the balance of substrate utilization in aging [letter] Brooks GA. **Am J Physiol** 1997 Sep;273(3 Pt 1):E655-6

Age-related changes in the diurnal rhythm of CRH gene expression in the paraventricular nuclei. Cai A, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):E238-43

Stretch overload-induced satellite cell activation in slow tonic muscle from adult and aged Japanese quail. Carson JA, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):C578-84

Age-related differences in beta-adrenergic regulation of repolarization in canine epicardial myocytes. Charpentier F, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1174-81

Patterns of gastric myoelectrical activity in human subjects of different ages. Chen JD, et al. **Am J Physiol** 1997 May; 272(5 Pt 1):G1022-7

Impaired cAMP-mediated gene expression and decreased cAMP response element binding protein in senescent cells. Chin JH, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C362-71

Evidence for the anorexia of aging: gastrointestinal transit and hunger in healthy elderly vs. young adults. Clarkston WK, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R243-8

Effects of small intestinal nutrient infusion on appetite and pyloric motility are modified by age. Cook CG, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R755-61

Cryptdin gene expression in developing mouse small intestine. Darmoul D, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):G197-206

Influence of age on the sympathetic neural adjustments to alterations in systemic oxygen levels in humans. Davy KP, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R690-5

Electrical properties of diaphragm and EDL muscles during the life of dystrophic mice. De Luca A, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):C333-40

Persistent glucose production and greater peripheral sensitivity to insulin in the neonate vs. the adult. Farrag HM, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E86-93

Alterations in the cardiovascular control by the chemoreflex and the baroreflex in old rats. Franchini KG, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):R310-3

Development of REM and slow wave sleep in the rat. Frank MG, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1792-9

Development of diurnal organization of EEG slow-wave activity and slow-wave sleep in the rat. Frank MG, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R472-8

Effect of age on blood acid-base composition in adult humans: role of age-related renal functional decline. Frassetto LA, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):F1114-22

Basal and stimulated nitric oxide in control of kidney function in the aging rat. Hill C, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1747-53

Aging affects development and persistence of feeding-associated circadian rhythm in rat plasma corticosterone. Honma S, et al. **Am J Physiol** 1996 Dec; 271(6 Pt 2):R1514-20

Systemic hemodynamic determinants of blood pressure in women: age, physical activity, and hormone replacement. Hunt BE, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H777-85

Age-related alterations in the fractal scaling of cardiac interbeat interval dynamics. Iyengar N, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R1078-84

Role of endogenous NO in modulating airway contraction mediated by muscarinic receptors during development. Jakupaj M, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):L531-6

Absence of age-related decline in total blood volume in physically active females. Jones PP, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2534-40

Age-related increase in muscle sympathetic nerve activity is associated with abdominal adiposity. Jones PP, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E976-80

Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Kajstura J, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1215-28

Alterations in dopamine DA1 receptor and G proteins in renal proximal tubules of old rats. Kansra V, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):F53-9

Age-dependent augmentation of cardiac endothelial NOS in a genetic rat model of heart failure. Khadour FH, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1223–30

Role of apoptotic and nonapoptotic cell death in removal of intercalated cells from developing rat kidney. Kim J, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):F575–92

Effects of aging on shortening velocity and myosin isoform composition in single human skeletal muscle cells. Larsson L, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C638–49

Evidence for diminished visceral pain with aging: studies using graded intraesophageal balloon distension. Lasch H, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):G1–3

Effect of oxidant challenge on contractile function of the aging rat diaphragm. Lawler JM, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):E201–7

Hyperplasia and hypertrophy of chicken cardiac myocytes during posthatching development. Li F, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R518–26

Maximum shortening velocity and myosin isoforms in single muscle fibers from young and old rats. Li X, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C352–60

Developmental changes in alpha 1-adrenergic receptors, IP3 responses, and NE-induced contraction in cerebral arteries. Longo LD, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2313–9

Contractile properties of diaphragm muscle segments from old mdx and old transgenic mdx mice. Lynch GS, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):C2063–8

Relationship between cold-induced thermoregulation and spontaneous rapid body weight loss of aging F344 rats. McDonald RB, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1115–22

Postischemic cardiac performance in the insulin-resistant JCR:LA-cp rat. Maddaford TG, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1187–92

Association of insulin-like growth factor mRNA expressions with muscle regeneration in young, adult, and old rats. Marsh DR, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R353–8

Integration of vascular, contractile and metabolic responses to hypoxia: effects of maturation and adenosine. Matherne GP, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):R895–905

Raising at thermoneutrality prevents obesity and hyperphagia in BAT-ablated transgenic mice. Melnyk A, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1088–93

Distribution of alveolar type II cells in neonatal and adult rat lung revealed by RT-PCR in situ. Mensah EA, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):L178–85

Differentiation and cell polarity during renal cyst formation in the Han:SPRD (cy/+) rat, a model for ADPKD. Obermüller N, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):F357–71

Glucose tolerance and insulin action in healty centenarians. Paolisso G, et al. **Am J Physiol** 1996 May;270(5 Pt 1):E890–4

Aging alters the serotonergic modulation of light-induced phase advances in golden hamsters. Penev PD, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R509–13

Aging alters calcium regulation of serum concentration of parathyroid hormone in healthy men. Portale AA, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E139–46

Effect of exposure to hypoxia from birth on aldosterone in rabbits: role of unesterified fatty acids. Raff H, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1084–7

Long-term dietary supplementation with L-arginine prevents age-related reduction in renal function. Reckelhoff JF, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1768–74

Age-related changes in renal hemodynamics in female rats: role of multiple pregnancy and NO. Reckelhoff JF. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1985–9

A cross-sectional study on body composition and energy expenditure in women athletes during aging. Ryan AS, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):E916–21

Apical K+ conductance in maturing rabbit principal cell. Satlin LM, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):F397–404

Impairment of Kit-dependent development of interstitial cells alters contractile responses of murine intestinal tract. Sato D, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):G762–71

Aging and photoperiod affect entrainment and quantitative aspects of locomotor behavior in Syrian hamsters. Scarbrough K, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1219–25

Fat and carbohydrate metabolism during exercise in elderly and young subjects. Sial S, et al. **Am J Physiol** 1996 Dec; 271(6 Pt 1):E983–9

Hypertrophy of colonic smooth muscle: structural remodeling, chemical composition, and force output. Siegman MJ, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):G1560–70

A putative growth-related renal Na(+)-Pi cotransporter. Silverstein DM, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R928–33

Exercise training enhances cardiac function in response to an afterload stress in older mer.. Spina RJ, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H995–1000

Thirst and fluid regulatory responses to hypertonicity in older adults. Stachenfeld NS, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R757–65

Mechanism of attenuated thirst in aging: role of central volume receptors. Stachenfeld NS, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R148–57

Age and autonomic effects on interrelationships between lung volume and heart rate. Stanley G, et al. **Am J Physiol** 1996 May;270(5 Pt 2):H1833–40

Aging is not accompanied by sympathetic hyperresponsiveness to air-jet stress. Stauss HM, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H768–75

Modulation of baroreflex sensitivity and spectral power of blood pressure by heat stress and aging. Stauss HM, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H776–84

New perspectives in a gustatory physiology: transduction, development, and plasticity. Stewart RE, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):C1–26 (203 ref.)

In vivo adaptive responses of the aorta to hypertension and aging. Sumitani M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H96–103

Effect of aging on vasopressin and aquaporin responses to dehydration in Fischer 344-brown-Norway F1 rats. Swenson KL, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R35–40

Development of muscarinic potassium current in fetal and neonatal rat heart. Takano M, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1188–95

Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Tsai CH, et al. **Am J Physiol** 1997 Jul; 273(1 Pt 1):E77–84

Amelioration of ischemic calcium overload correlates with high-energy phosphates in senescent myocardium. Tsukube T, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H418–25

Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Vahl N, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E1108–16

Age-related changes in the pressure diuresis and natriuresis response. Vargas F, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R578–82

Developmental changes in glucose transport, lipid composition, and fluidity of jejunal BBM. Vázquez CM, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1086–93

Density of fat-free body mass: relationship with race, age, and level of body fatness. Visser M, et al. **Am J Physiol** 1997 May;272(5 Pt 1):E781–7

Changes in electrical and mechanical activity during ontogeny of the canine proximal colon. Ward SM. **Am J Physiol** 1996 Jul;271(1 Pt 1):G184–91

Frequency of gastroesophageal reflux events induced by pharyngeal water stimulation in young and elderly subjects. Xie P, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):G233–7

Growth hormone-induced nuclear translocation of Stat-3 decreases with age: modulation by caloric restriction. Xu X, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):E903–9

Development of urinary concentrating capacity: role of aquaporin-2. Yasui M, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F461–8

Age and regulation of fluid and electrolyte balance during repeated exercise sessions. Zappe DH, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):R71–9

Age dependence of cerebrovascular response mechanisms in domestic pigs. Zuckerman SL, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H535–40

Increase in pulmonary ventilation-perfusion inequality with age in healthy individuals. Cardús J, et al. **Am J Respir Crit Care Med** 1997 Aug;156(2 Pt 1):648–53

Nitric oxide modulates ventilatory responses to hypoxia in the developing rat. Gozal D, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1755–62

Age, period, and cohort effects. Influences on differences between cross-sectional and longitudinal pulmonary function results. Lebowitz MD. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 2):S273–7

The contractile properties of the elderly human diaphragm. Polkey MI, et al. **Am J Respir Crit Care Med** 1997 May; 155(5):1560–4

Volume history effects and airway responsiveness in middle-aged and older men. The Normative Aging Study. Sparrow D, et al. **Am J Respir Crit Care Med** 1997 Mar; 155(3):888–92

Effect of maturation and aging on the histomorphometric and biochemical characteristics of equine superficial digital flexor tendon. Gillis C, et al. **Am J Vet Res** 1997 Apr; 58(4):425–30

Effect of maturation and aging on material and ultrasonographic properties of equine superficial digital flexor tendon. Gillis C, et al. **Am J Vet Res** 1995 Oct; 56(10):1345–50

Evaluation of the catabolic activity of cartilage by measurement of serum keratan sulfate concentration in foals. Okumura M, et al. **Am J Vet Res** 1997 Aug; 58(8):925–9

Intraocular pressure variation associated with body length in young American alligators (Alligator mississippiensis). Whittaker CJ, et al. **Am J Vet Res** 1995 Oct;56(10):1380–3

End-tidal oxygraphy and safe duration of apnoea in young adults and elderly patients [see comments] Bhatia PK, et al. **Anaesthesia** 1997 Feb;52(2):175–8. Comment in: Anaesthesia 1997 Jun;52(6):606–7.

Morphologic changes in cerebellar mitochondria during aging. Fattoretti P, et al. **Anal Quant Cytol Histol** 1996 Jun;18(3):205–8

Behavior of carbonate and magnesium ions in the initial crystallites at the early developmental stages of the rat calvaria. Kakei M, et al. **Anat Anz** 1997 Aug;179(4):311–6

Development and ageing of the articular cartilage of the rabbit knee joint: distribution of the fibrillar collagens. Bland YS, et al. **Anat Embryol (Berl)** 1996 Dec; 194(6):607–19

Differential expression of placental (P)-cadherin in sertoli cells and peritubular myoid cells during postnatal development of the mouse testis. Lin LH, et al. **Anat Rec** 1996 Feb;244(2):155–64

Postnatal development of the lung parenchyma in a marsupial: the tammar wallaby. Runciman SI, et al. **Anat Rec** 1996 Feb;244(2):193–206

The threshold for thermoregulatory vasoconstriction during nitrous oxide/sevoflurane anesthesia is reduced in the elderly. Ozaki M, et al. **Anesth Analg** 1997 May; 84(5):1029–33

Age-related propofol effects on electrophysiological properties of isolated hearts. Wu MH, et al. **Anesth Analg** 1997 May;84(5):964–71

Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease. Wagner ML, et al. **Ann Clin Lab Sci** 1996 Sep–Oct; 26(5):389–95

Growth hormone and function in elderly persons [letter; comment] Feller AG, et al. **Ann Intern Med** 1997 Apr 1; 126(7):583–4. Comment on: Ann Intern Med 1996 Apr 15;124(8):708–16.

Patch-clamp study of developmental changes in voltage-dependent ion channels of mouse skeletal muscle fibers. Gonoi T. **Ann N Y Acad Sci** 1993 Dec 20;707:352–5

Myocardial protection in the elderly. Biology of the senescent heart. McCully JD, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:305–18 (51 ref.)

Ovarian aging. Maroulis GB. **Ann N Y Acad Sci** 1997 Jun 17;816:22–6 (28 ref.)

Immunohistochemical analysis of signal transduction system in developing rat Purkinje cell by using antibodies for signaling molecules. Miyazawa A, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:533–5

Development of inhibitory synaptic currents in rat spinal neurons. Momiyama A, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:447–8

Aging and blood pressure rhythms. O'Brien E. **Ann N Y Acad Sci** 1996 Aug 15;783:186–203 (81 ref.)

The t-ACPD-induced current response in rat cerebellum. Takagi H, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:518–20

Mitochondrial function in muscle from elderly athletes [published erratum appears in Ann Neurol 1997 May;41(5):698] Brierly EJ, et al. **Ann Neurol** 1997 Jan; 41(1):114–6

In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Kuhl DE, et al. **Ann Neurol** 1996 Sep;40(3):399–410

Comparison of the body composition of age-matched Italian, Ukrainian, and Dutch children. De Lorenzo A, et al. **Ann Nutr Metab** 1996;40(3):123–8

Age-related response of the small intestine to severe starvation and refeeding in rats. Ortega MA, et al. **Ann Nutr Metab** 1996;40(6):351–8

The assessment of 24-hour energy expenditure in elderly women by minute-by-minute heart rate monitoring. Rutgers CJ, et al. **Ann Nutr Metab** 1997;41(2):83–8

Age-related changes of elastic fibers in the superficial layer of the lamina propria of vocal folds. Sato K, et al. **Ann Otol Rhinol Laryngol** 1997 Jan;106(1):44–8

Functional asymmetries in the auditory system. Jerger J. **Ann Otol Rhinol Laryngol Suppl** 1997 May;168:23–30

The use of animal models to study the effects of aging on cognition. Gallagher M, et al. **Annu Rev Psychol** 1997; 48:339–70 (160 ref.)

The effects of race, living standards, and exercise on the degree of motor development: comparison between schoolchildren in the Republic of Honduras and Japan. Sekiya T, et al. **Appl Human Sci** 1996 Sep;15(5):211–8

Cardiorespiratory responses to cycling exercise in trained and untrained healthy elderly: with special reference to the lactate threshold. Takeshima N, et al. **Appl Human Sci** 1996 Nov;15(6):267–73

Oronasal distribution of ventilation at different ages. James DS, et al. **Arch Environ Health** 1997 Mar–Apr;52(2):118–23

Age-related changes in Meissner corpuscles in the mouse palate: a histochemical and ultrastructural study. Iida S, et al. **Arch Histol Cytol** 1996 Aug;59(3):281–90

Balance in the healthy elderly: posturography and clinical assessment. Camicioli R, et al. **Arch Neurol** 1997 Aug; 54(8):976–81

Saliva mediated adherence, aggregation and prevalence in dental plaque of Streptococcus mutans, Streptococcus sanguis and Actinomyces spp, in young and elderly humans. Carlén A, et al. **Arch Oral Biol** 1996 Dec; 41(12):1133–40

Normal masticatory performance in young adults and children. Julien KC, et al. **Arch Oral Biol** 1996 Jan; 41(1):69–75

The distribution of fibronectin and laminin in the murine periodontal membrane, indicating possible functional roles in the apical migration of the junctional epithelium. Sakai T, et al. **Arch Oral Biol** 1996 Aug–Sep;41(8–9):885–91

Latency of the jaw-opening reflex in the premature, preweaning and adolescent pig (hanford strain miniature pig, Sus scrofa). Thexton AJ, et al. **Arch Oral Biol** 1995 Dec;40(12):1133–5

Age-related magnetic resonance imaging morphology of the menisci in asymptomatic individuals. Jerosch J, et al. **Arch Orthop Trauma Surg** 1996;115(3–4):199–202

Influence of simulated bed rest and intermittent weight bearing on single skeletal muscle fiber function in aged rats. Alley KA, et al. **Arch Phys Med Rehabil** 1997 Jan; 78(1):19–25

Reference values for extremity muscle strength obtained by hand–held dynamometry from adults aged 20 to 79 years. Bohannon RW. **Arch Phys Med Rehabil** 1997 Jan; 78(1):26–32

Age–dependent effects of muscle vibration and the Jendrassik maneuver on the patellar tendon reflex response. Burke JR, et al. **Arch Phys Med Rehabil** 1996 Jun;77(6):600–4

Increased gait unsteadiness in community–dwelling elderly fallers. Hausdorff JM, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3):278–83

Effect of a 6–week endurance training programme and branched–chain amino acid supplementation on histomorphometric characteristics of aged human muscle. Freyssenet D, et al. **Arch Physiol Biochem** 1996; 104(2):157–62

The effect of feeding piglets up to the 100th day of their life with peat preparation on their growth and physiological and biochemical indices. Fuchs B, et al. **Arch Vet Pol** 1995; 35(1–2):97–107

Differential effects of aging on human chondrocyte responses to transforming growth factor beta: increased pyrophosphate production and decreased cell proliferation. Rosen F, et al. **Arthritis Rheum** 1997 Jul;40(7):1275–81

Changes in biomechanical properties, composition of collagen and elastin, and advanced glycation endproducts of the rat aorta in relation to age. Brüel A, et al. **Atherosclerosis** 1996 Dec 20;127(2):155–65

Cerebral palsy and ageing. A personal account. Lo Surdo P. **Aust Fam Physician** 1997 Apr;26(4):404–7

Changes in the interpupillary distance with age and its effect on the near fusion free position. Chen AH, et al. **Aust N Z J Ophthalmol** 1997 May;25 Suppl 1:S6–8

The population of nitric oxide synthase–containing neurons persist in the ageing human retina. Roufail E, et al. **Aust N Z J Ophthalmol** 1996 May;24(2 Suppl):64–6

Age–related differences in collagen crimp patterns in the superficial digital flexor tendon core region of untrained horses. Patterson–Kane JC, et al. **Aust Vet J** 1997 Jan; 75(1):39–44

Grazing and anthelmintic treatments to increase growth of Cashmere and Angora weaner goats [published erratum appears in Aust Vet J 1996 Nov;74(5):400] Robertson JA, et al. **Aust Vet J** 1996 Sep;74(3):246–8

Relationship of blood corticosterone, immunoglobulin and haematological values in young crocodiles (Crocodylus porosus) to water temperature, clutch of origin and body weight. Turton JA, et al. **Aust Vet J** 1997 Feb;75(2):114–9

Survey of doses in screening mammography. Heggie JC. **Australas Phys Eng Sci Med** 1996 Dec;19(4):207–16

The effects of early vestibular deprivation on the motor development in the rat. Geisler HC, et al. **Behav Brain Res** 1997 Jun;86(1):89–96

Hippocampal volume in migratory and non–migratory warblers: effects of age and experience. Healy SD, et al. **Behav Brain Res** 1996 Nov;81(1–2):61–8

Development of vicarious trial–and–error behavior in odor discrimination learning in the rat: relation to hippocampal function? Hu D, et al. **Behav Brain Res** 1997 Jun; 86(1):67–70

Murine models of brain aging and age–related neurodegenerative diseases. Jucker M, et al. **Behav Brain Res** 1997 Apr;85(1):1–26 (261 ref.)

Recovery from early cortical damage in rats, VII. Comparison of the behavioural and anatomical effects of medial prefrontal lesions at different ages of neural maturation. Kolb B, et al. **Behav Brain Res** 1996 Sep; 79(1–2):1–14

Is brain plasticity preserved during aging and in Alzheimer's disease? Mirmiran M, et al. **Behav Brain Res** 1996 Jun; 78(1):43–8 (77 ref.)

Lesion of the habenular efferent pathway produces anxiety and locomotor hyperactivity in rats: a comparison of the effects of neonatal and adult lesions. Murphy CA, et al. **Behav Brain Res** 1996 Nov;81(1–2):43–52

Alterations in acetylcholine, NMDA, benzodiazepine receptors and protein kinase C in the brain of the senescence–accelerated mouse: an animal model useful for studies on cognitive enhancers. Nomura Y, et al. **Behav Brain Res** 1997 Feb;83(1–2):51–5

Effects of neonatal stimulation on later cognitive function and hippocampal nerve growth factor. Pham TM, et al. **Behav Brain Res** 1997 Jun;86(1):113–20

Effect of acetylcholinesterase inhibition on behavior is age–dependent in freely moving Aplysia. Srivatsan M, et al. **Behav Brain Res** 1996 May;77(1–2):115–24

Redistribution of spatial representation in the hippocampus of aged rats performing a spatial memory task. Mizumori SJ, et al. **Behav Neurosci** 1996 Oct;110(5):1006–16

Learning and memory for hierarchical relationships in the monkey: effects of aging. Rapp PR, et al. **Behav Neurosci** 1996 Oct;110(5):887–97

Body composition of Italian children. Bellù R, et al. **Bibl Nutr Dieta** 1996;(53):103–8 (10 ref.)

Relationship of nutritional status and functional development in preschool age children. Pařízková J. **Bibl Nutr Dieta** 1996;(53):109–15

Linear growth in children. Waterlow JC. **Bibl Nutr Dieta** 1996;(53):45–54 (29 ref.)

Fat nutrition during infancy and childhood. Widhalm K. **Bibl Nutr Dieta** 1996;(53):116–28 (24 ref.)

Calcium waves in unstimulated left ventricular cardiomyocytes isolated from aged spontaneously hypertensive and normotensive rats. Failli P, et al. **Biochem Biophys Res Commun** 1997 Aug 8;237(1):103–6

Autocrine growth regulation in fetal and adult human fibroblasts. Pratsinis H, et al. **Biochem Biophys Res Commun** 1997 Aug 18;237(2):348–53

L–type Ca2+ channel–insulin–like growth factor–1 receptor signaling impairment in aging rat skeletal muscle. Renganathan M, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):784–9

The effects of chronic administration of nimodipine on age–related changes in nitric oxide and its synthase in senescence–accelerated mouse brain. Inada K, et al. **Biochem Mol Biol Int** 1997 Apr;41(4):753–65

Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Müller WE, et al. **Biochem Pharmacol** 1997 Jan 24;53(2):135–40

Intracellular protein synthesis, modifications and aging. Rattan SI, et al. **Biochem Soc Trans** 1996 Nov;24(4):1043–9 (58 ref.)

The effects of ageing on the chaperone–like function of rabbit alpha–crystallin, comparing three methods of assay. Derham BK, et al. **Biochim Biophys Acta** 1997 Aug 29; 1336(2):187–94

Mitochondrial oxidative phosphorylation changes in the life span. Molecular aspects and physiopathological implications. Papa S. **Biochim Biophys Acta** 1996 Sep 12; 1276(2):87–105 (243 ref.)

A proposed refinement of the mitochondrial free radical theory of aging. de Grey AD. **Bioessays** 1997 Feb; 19(2):161–6 (32 ref.)

Human senescence. Kirkwood TB. **Bioessays** 1996 Dec; 18(12):1009–16 (58 ref.)

Is the alpha rhythm a control parameter for brain responses? Başar E, et al. **Biol Cybern** 1997 Jun;76(6):471–80

Heart rate biorhythm changes during the first three months of life. Ardura J, et al. **Biol Neonate** 1997;72(2):94–101

Effect of age, sex steroids, brain region, and genetic strain on brain inositol monophosphatase activity. Patishi Y, et al. **Biol Psychiatry** 1996 Oct 1;40(7):656–9

Serotonin transporter expression in rat brain regions and blood platelets: aging and glucocorticoid effects. Slotkin TA, et al. **Biol Psychiatry** 1997 Jan 15;41(2):172–83

The effect of stimulus–response incompatibility on P3 latency depends on the task but not on age. Christensen CA, et al. **Biol Psychol** 1996 Oct 31;44(2):121–41

Aging, stimulus identification and the effect of probability: an event–related potential study. Czigler I, et al. **Biol Psychol** 1996 Mar 8;43(1):27–40

Focussing on aging: an electrophysiological exploration of spatial and attentional processing during reading. Gunter TC, et al. **Biol Psychol** 1996 Apr 12;43(2):103–45

Age–related changes in the photoperiodic response of Siberian hamsters. Bernard DJ, et al. **Biol Reprod** 1997 Jul; 57(1):172–7

Heat shock response, heat shock transcription factor and cell aging. Lee YK, et al. **Biol Signals** 1996 May–Jun; 5(3):180–91

Somatostatin–positive neurons in the different parts of the brain in normal aging and Alzheimer's disease. Li WP, et al. **Biol Signals** 1996 Nov–Dec;5(6):343–8

Role of transcription factors in the age–dependent regulation of the androgen receptor gene in rat liver. Supakar PC, et al. **Biol Signals** 1996 May–Jun;5(3):170–9 (37 ref.)

The influence of aging on renal response to cadmium in Syrian hamsters. Shibasaki T, et al. **Biol Trace Elem Res** 1996 Jul;54(1):87–95

The effect of aging and pressure on the specific hydraulic conductivity of the aortic wall. Whale MD, et al. **Biorheology** 1996 Jan–Feb;33(1):17–44

Increased granulocyte–macrophage colony–stimulating factor mRNA instability in cord versus adult mononuclear cells is translation–dependent and associated with increased levels of A + U–rich element binding factor. Buzby JS, et al. **Blood** 1996 Oct 15;88(8):2889–97

Pharmacokinetics of digoxin–specific Fab: effects of decreased renal function and age. Renard C, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):135–8

Effects of age on cardiovascular responses to adrenaline in man. White M, et al. **Br J Clin Pharmacol** 1997 Apr; 43(4):407–14

Asthma in the elderly [see comments] Luce PJ. **Br J Hosp Med** 1996 Feb 7–20;55(3):118–20 (21 ref.). Comment in: Br J Hosp Med 1996 Nov 6–19;56(9):488.

Modulation of age–related changes in immune functions of protein–deficient senescence–accelerated mice by dietary nucleoside–nucleotide mixture supplementation. Ameho CK, et al. **Br J Nutr** 1997 May;77(5):795–804

Protein requirements and ageing: metabolic demand and efficiency of utilization. Fereday A, et al. **Br J Nutr** 1997 May;77(5):685–702

Calcium excretion, apparent calcium absorption and calcium balance in young and elderly subjects: influence of protein intake. Pannemans DL, et al. **Br J Nutr** 1997 May; 77(5):721–9

Urogenital ageing and its effect on sexual health in older British women. Barlow DH, et al. **Br J Obstet Gynaecol** 1997 Jan;104(1):87–91

Protection of the aged substantia nigra of the rat against oxidative damage by (–)–deprenyl. de la Cruz CP, et al. **Br J Pharmacol** 1996 Apr;117(8):1756–60

Effects of chronic growth hormone treatment in aged rats on the biophysical and pharmacological properties of skeletal muscle chloride channels. De Luca A, et al. **Br J Pharmacol** 1997 Jun;121(3):369–74

Alpha 1–adrenoceptor vasoconstriction in the tail artery during ageing. Vila E, et al. **Br J Pharmacol** 1997 Jul; 121(5):1017–23

Uncoupling learning from initial recall: the relationship between speed and memory deficits in old age. Nettelbeck T, et al. **Br J Psychol** 1996 Nov;87 (Pt 4):593–607

Ontogenetic development of proline intestinal transport in the domestic fowl. Gonzalez E, et al. **Br Poult Sci** 1996 May;37(2):383–94

Dexamethasone–induced alterations in glucose tolerance and, insulin, glucagon and adrenaline responses during the first month in White Leghorn chicks. Joseph J, et al. **Br Poult Sci** 1996 Jul;37(3):665–76

Effect of constant and of changing photoperiods on age at first egg and related traits in pullets. Lewis PD, et al. **Br Poult Sci** 1996 Dec;37(5):885–94

Effect of size and timing of photoperiod increase on age at first egg and subsequent performance of two breeds of laying hen. Lewis PD, et al. **Br Poult Sci** 1997 May; 38(2):142–50

Effect of age of donor on the responsiveness of dispersed and cultured chicken anterior pituitary cells to GnRH–I. Liu RC, et al. **Br Poult Sci** 1996 May;37(2):451–63

Effects of ambient temperature, age and wind speed on the thermal balance of layer–strain fowls. Tzschentke B, et al. **Br Poult Sci** 1996 Jul;37(3):501–20

Decrease in highly polysialylated neuronal cell adhesion molecules and in spatial learning during ageing are not correlated. Abrous DN, et al. **Brain Res** 1997 Jan 9; 744(2):285–92

Effects of dark–rearing on the vascularization of the developmental rat visual cortex. Argandoña EG, et al. **Brain Res** 1996 Sep 2;732(1–2):43–51

The clustered cell system is present before formation of the ACh patches in the intermediate gray layer of the cat superior colliculus. Banfro FT, et al. **Brain Res** 1996 Sep 16;733(2):273–83

Central acetylcholine synthesis and catabolism activities in the cuttlefish during aging. Bellanger C, et al. **Brain Res** 1997 Jul 11;762(1–2):219–22

Light–induced phase shifts of circadian activity rhythms and immediate early gene expression in the suprachiasmatic nucleus are attenuated in old C3H/HeN mice. Benloucif S, et al. **Brain Res** 1997 Jan 30;747(1):34–42

MPP(+)–induced neurotoxicity in mouse is age–dependent: evidenced by the selective inhibition of complexes of electron transport. Desai VG, et al. **Brain Res** 1996 Apr 9;715(1–2):1–8

On the development of voluntary and reflexive components in human saccade generation. Fischer B, et al. **Brain Res** 1997 Apr 18;754(1–2):285–97

Coordinate reduction in cell proliferation and cell death in mouse olfactory epithelium from birth to maturity. Fung KM, et al. **Brain Res** 1997 Jul 4;761(2):347–51

DA1 and DA2 receptor regulation in the striatum of young and old rats after peripheral vestibular lesion. Giardino L, et al. **Brain Res** 1996 Oct 14;736(1–2):111–7

Right–left asymmetry of D1– and D2–receptor density is lost in the basal ganglia of old rats. Giardino L. **Brain Res** 1996 May 13;720(1–2):235–8

Calcium channel types mediating synaptic transmission during aging. Hall SC, et al. **Brain Res** 1997 Jan 16; 745(1–2):339–42

Neuropeptide Y and [Leu31,Pro34]neuropeptide Y potentiate potassium–induced noradrenaline release in the paraventricular nucleus of the aged rat. Hastings JA, et al. **Brain Res** 1997 Mar 7;750(1–2):301–4

Hypothyroidism coordinately and transiently affects myelin protein gene expression in most rat brain regions during postnatal development. Ibarrola N, et al. **Brain Res** 1997 Mar 28;752(1–2):285–93

Mechanisms underlying the vascular activity of beta–amyloid protein fragment (beta A(4)25–35) at the level of skin microvasculature. Khalil Z, et al. **Brain Res** 1996 Oct 14; 736(1–2):206–16

Effect of age on the sleep EEG: slow–wave activity and spindle frequency activity in young and middle–aged men. Landolt HP, et al. **Brain Res** 1996 Nov 4;738(2):205–12

The effects of raphe grafts on hippocampal electrophysiology in aged rats. Levkovitz Y, et al. **Brain Res** 1996 May 6; 719(1–2):234–8

Cell size and geometry of spinal cord motoneurons in the adult cat following the intramuscular injection of adriamycin: comparison with data from aged cats. Liu RH, et al. **Brain Res** 1996 Oct 28;738(1):121–30

Changes in Fos–like immunoreactivity evoked by maturation of the sneeze reflex triggered by nasal air puff stimulation in kittens. Masmoudi K, et al. **Brain Res** 1997 May 16; 757(1):102–10

Late development of Zif268 ocular dominance columns in primary visual cortex of primates [published erratum appears in Brain Res 1997 May 16;757(1):164–5] Silveira LC, et al. **Brain Res** 1996 Sep 2;732(1–2):237–41

An age–dependent novel hyperinnervation of circumvallate papillae by tyrosine hydroxylase–containing nerve fibers in NGF–overexpressing transgenic mice. Takami S, et al.

Brain Res 1996 Jan 29;707(2):303–7

Delayed development of spontaneous seizures and prolonged convulsive state in rats after massed stimulation of the anterior piriform cortex. Timofeeva OA, et al. **Brain Res** 1997 Apr 18;754(1–2):227–38

Cell death in the inner ear associated with aging is apoptosis? Usami S, et al. **Brain Res** 1997 Jan 30;747(1):147–50

Cholinergic deficits in aged rat spinal cord: restoration by GM1 ganglioside. Vogelsberg V, et al. **Brain Res** 1997 Jul 4;761(2):250–6

The origin of amyloid in cerebral vessels of aged dogs. Wegiel J, et al. **Brain Res** 1995 Dec 24;705(1–2):225–34

Hippocampus in delay eyeblink classical conditioning: essential for nefiracetam amelioration of learning in older rabbits. Woodruff-Pak DS, et al. **Brain Res** 1997 Feb 7; 747(2):207–18

Effect of aging on vulnerability of striatal D1 and D2 dopamine receptor-containing neurons to kainic acid. Zhang L, et al. **Brain Res** 1997 Jul 25;763(2):264–6

Plasticity of astrocytes derived from aged mouse cerebral hemispheres: changes with cell passage and immortalization. Grove J, et al. **Brain Res Bull** 1996; 39(4):211–7

Dissimilar age influences on two ERP waveforms (LPC and N400) reflecting semantic context effect. Juottonen K, et al. **Brain Res Cogn Brain Res** 1996 Sep;4(2):99–107

Febrile seizures: an appropriate-aged model suitable for long-term studies. Baram TZ, et al. **Brain Res Dev Brain Res** 1997 Feb 20;98(2):265–70

Metabolism of [5-(3)H]kynurenine in the developing rat brain in vivo: effect of intrastriatal ibotenate injections. Ceresoli G, et al. **Brain Res Dev Brain Res** 1997 May 20;100(1):73–81

Ontogenetic development of the response to anandamide and delta 9-tetrahydrocannabinol in mice. Fride E, et al. **Brain Res Dev Brain Res** 1996 Aug 20;95(1):131–4

Purkinje cell loss in heterozygous staggerer mutant mice during aging. Hadj-Sahraoui N, et al. **Brain Res Dev Brain Res** 1997 Jan 2;98(1):1–8

Decreased receptivity of pathway connective tissue to sympathetic nerve ingrowth in the developing rat. Hiebert JM, et al. **Brain Res Dev Brain Res** 1997 May 20; 100(1):35–42

Dextromethorphan ameliorates effects of neonatal hypoxia on brain morphology and seizure threshold in rats. Laroia N, et al. **Brain Res Dev Brain Res** 1997 May 20;100(1):29–34

Neurobehavioral evaluation of lurcher mutant mice during ontogeny. Thullier F, et al. **Brain Res Dev Brain Res** 1997 May 20;100(1):22–8

Influence of age on the cerebral lesions in an immature rat model of cerebral hypoxia-ischemia: a light microscopic study. Towfighi J, et al. **Brain Res Dev Brain Res** 1997 Jun 18;100(2):149–60

Behavioral changes in rats with early ventral hippocampal damage vary with age at damage. Wood GK, et al. **Brain Res Dev Brain Res** 1997 Jul 18;101(1–2):17–25

The effect of age on susceptibility to brain damage in a model of global hemispheric hypoxia-ischemia. Yager JY, et al. **Brain Res Dev Brain Res** 1996 May 31;93(1–2):143–54

Aging-related regulation of myo-inositol 1,4,5-trisphosphate signal transduction pathway in the rat striatum. Igwe OJ, et al. **Brain Res Mol Brain Res** 1997 Jun;46(1–2):39–53

Beta activity in aging and dementia. Holschneider DP, et al. **Brain Topogr** 1995 Winter;8(2):169–80

Effect of aging on cortical spreading depression. Guedes RC, et al. **Braz J Med Biol Res** 1996 Oct;29(10):1407–12

Age-related cortical bone loss at the metacarpal. Maggio D, et al. **Calcif Tissue Int** 1997 Jan;60(1):94–7

Influence of body mass index on the age-related slope of total and regional bone mineral content. Revilla M, et al. **Calcif Tissue Int** 1997 Aug;61(2):134–8

Sexual differences in bone markers and bone mineral density of normal Chinese. Tsai KS, et al. **Calcif Tissue Int** 1996 Dec;59(6):454–60

Cerebrovascular CO2 reactivity in elderly and younger adult patients during sevoflurane anaesthesia. Nishiyama T, et al. **Can J Anaesth** 1997 Feb;44(2):160–4

Aging and cardiovascular autonomic regulation [letter; comment] Török T, et al. **Can J Anaesth** 1997 Jun; 44(6):677–8. Comment on: Can J Anaesth 1996 Sep;43(9):972–4.

The influence of age and cardiorespiratory fitness on kinetics of oxygen uptake. Chilibeck PD, et al. **Can J Appl Physiol** 1996 Jun;21(3):185–96

Dynamics of the ventilatory response to step changes in end-tidal PCO2 in older humans. Poulin MJ, et al. **Can J Appl Physiol** 1997 Aug;22(4):368–83

Arterial stiffening: opposing effects of age- and hypertension-associated structural changes. Laurent S, et al. **Can J Physiol Pharmacol** 1996 Jul;74(7):842–9 (30 ref.)

Water intoxication in weaned beef calves. Gilchrist F. **Can Vet J** 1996 Aug;37(8):490–1

An agenda for clinical research in geriatrics. Cohen HJ. **Cancer** 1997 Oct 1;80(7):1294–301

The biology of aging: the current research agenda. Ershler WB, et al. **Cancer** 1997 Oct 1;80(7):1284–93 (103 ref.)

Comparison of growth rate of two B16 melanomas differing in metastatic potential in young versus middle-aged mice. Donin N, et al. **Cancer Invest** 1997;15(5):416–21

Early and late effect of neonatal hypo- and hyperthyroidism on coronary capillary geometry and long-term heart function in rat. Heron MI, et al. **Cardiovasc Res** 1997 Jan; 33(1):230–40

Effect of age on long-term heart rate variability. Yeragani VK, et al. **Cardiovasc Res** 1997 Jul;35(1):35–42

Plasticity of neuro-endocrine-thymus interactions during aging—a minireview. Fabris N, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Jun;43(4):529–41 (59 ref.)

A possible role of collagen fibrils in the process of calcification observed in the capsule of the pineal gland in aging rats. Humbert W, et al. **Cell Tissue Res** 1997 Jun; 288(3):435–9

Gene expression and immunolocalisation of amelogenins in developing embryonic and neonatal hamster teeth. Karg HA, et al. **Cell Tissue Res** 1997 Jun;288(3):545–55

Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. Raz N, et al. **Cereb Cortex** 1997 Apr-May;7(3):268–82

Aging effects on swallowing reflex [letter] Kobayashi H, et al. **Chest** 1997 May;111(5):1466

Effects of obesity and fat distribution on ventilatory function: the normative aging study [see comments] Lazarus R, et al. **Chest** 1997 Apr;111(4):891–8. Comment in: Chest 1997 Apr;111(4):844–5.

Inhibitory effect of estrogen on vascular contraction from male rats of different ages. Sun YF, et al. **Chin J Physiol** 1997 Jun 30;40(2):79–83

Changes in endocrine circadian rhythms as markers of physiological and pathological brain aging. Magri F, et al. **Chronobiol Int** 1997 Jul;14(4):385–96

Aging lengthens TauDD in C57BL/6J, DBA/2J, and outbred SWR male mice (Mus musculus). Mayeda AR, et al. **Chronobiol Int** 1997 Jan;14(1):19–23

Age-related differences of blood pressure profile in essential hypertension. Scorzoni D, et al. **Chronobiol Int** 1997 Jul; 14(4):397–407

The liver biochemical tests and serological markers of hepatitis B virus in the very old-aged population in Taiwan. Hsu SH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jan;57(1):16–21

Ageing and amyloid fibrillogenesis: lessons from apolipoprotein AI, transthyretin and islet amyloid polypeptide. Westermark P, et al. **Ciba Found Symp** 1996; 199:205–18; discussion 218–22

Flow-induced vascular remodeling in the rat carotid artery diminishes with age. Miyashiro JK, et al. **Circ Res** 1997 Sep;81(3):311–9

Developmental changes in the delayed rectifier K+ channels in mouse heart. Wang L, et al. **Circ Res** 1996 Jul;79(1):79–85

Skeletal muscle and cardiovascular adaptations to exercise conditioning in older coronary patients. Ades PA, et al. **Circulation** 1996 Aug 1;94(3):323–30

Occurrence and properties of the hyperpolarization-activated current If in ventricular myocytes from normotensive and hypertensive rats during aging. Cerbai E, et al. **Circulation** 1996 Oct 1;94(7):1674–81

Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984–1994. Ferrara A, et al. **Circulation** 1997 Jul 1;96(1):37–43

Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Franklin SS, et al. **Circulation** 1997 Jul 1;96(1):308–15

Coronary heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly Program. Frost PH, et al. **Circulation** 1996 Jul 1;94(1):26–34

A prospective study of anger and coronary heart disease. The Normative Aging Study. Kawachi I, et al. **Circulation** 1996 Nov 1;94(9):2090–5

Age and thrombolytic therapy [editorial; comment] Ridker PM, et al. **Circulation** 1996 Oct 15;94(8):1807–8. Comment on: Circulation 1996 Oct 15;94(8):1826–33.

Continuum of cardiovascular performance across a broad range of fitness levels in healthy older men. Schulman SP, et al. **Circulation** 1996 Aug 1;94(3):359–67

Myocardial ultrasonic tissue characterization in pediatric and adult patients with hypertrophic cardiomyopathy. Vitale DF, et al. **Circulation** 1996 Dec 1;94(11):2826–30

Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial [see comments] White HD, et al. **Circulation** 1996 Oct 15; 94(8):1826–33. Comment in: Circulation 1996 Oct 15;94(8):1807–8.

Effects of aging on left ventricular relaxation in humans. Analysis of left ventricular isovolumic pressure decay. Yamakado T, et al. **Circulation** 1997 Feb 18;95(4):917–23

Malformations of the liver: some prenatal and postnatal developmental aspects. Parke WW, et al. **Clin Anat** 1996; 9(5):309–16

Effects of age on aortic blood velocity at rest and during exercise in patients with coronary artery disease. Salmasi AM, et al. **Clin Auton Res** 1996 Apr;6(2):99–106

QT interval change with age in an overtly healthy older population. Reardon M, et al. **Clin Cardiol** 1996 Dec; 19(12):949–52

The premature aging syndromes. Pesce K, et al. **Clin Dermatol** 1996 Mar-Apr;14(2):161–70 (70 ref.)

Quantitative EEG correlates of normal aging in the elderly. Koyama K, et al. **Clin Electroencephalogr** 1997 Jul; 28(3):160–5

Growth hormone and the maintenance of adult bone mineral density. Inzucchi SE, et al. **Clin Endocrinol (Oxf)** 1996 Dec; 45(6):665–73 (80 ref.)

Characteristics of the pituitary gland in elderly subjects from magnetic resonance images: relationship to pituitary hormone secretion. Terano T, et al. **Clin Endocrinol (Oxf)** 1996 Sep;45(3):273–9

Skeletal muscle resting metabolism in cold-acclimated rats: effect of age, noradrenaline and hyperosmolarity. Cox JP, et al. **Clin Exp Pharmacol Physiol** 1997 Jun;24(6):403–7

Influence of ageing on ciliary beat frequency and on ciliary response to leukotriene D4 in guinea-pig tracheal epithelium. Joki S, et al. **Clin Exp Pharmacol Physiol** 1997 Feb;24(2):166–9

Arterial wall remodelling and stiffness in hypertension: heterogeneous aspects. London GM, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):S1–5 (38 ref.)

Lack of effect of age on the cardiovascular response to neuropeptide Y injection in the rat nucleus tractus solitarius. Morris MJ, et al. **Clin Exp Pharmacol Physiol** 1997 Feb;24(2):162–5

Alterations of mRNA levels of alpha 1-adrenoceptor subtypes with maturation and ageing in different rat blood vessels. Xu KM, et al. **Clin Exp Pharmacol Physiol** 1997 Jun;24(6):415–7

Role of nitric oxide in the control of blood pressure in young and adult spontaneously hypertensive rats. Akiba Y, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S142–3

Blood pressure-related changes of endothelium-dependent relaxation in the aorta from SHRSP at developmental ages of hypertension. Tomita T, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S139–41

Effects of age on the biomechanics and physiology of gait. Judge JO, et al. **Clin Geriatr Med** 1996 Nov;12(4):659–78 (45 ref.)

Postural control in the older adult. Maki BE, et al. **Clin Geriatr Med** 1996 Nov;12(4):635–58 (78 ref.)

Natural killer cells in the late decades of human life. Ogata K, et al. **Clin Immunol Immunopathol** 1997 Sep;84(3):269–75

Frequency of clonal dominance in the specific antibody response to DNP-HSA in CBA and C57BL mice reflects their susceptibility to age-associated development of monoclonal gammopathies. van Arkel C, et al. **Clin Immunol Immunopathol** 1997 Jun;83(3):272–80

Celiac disease is a lifelong disorder. Chartrand LJ, et al. **Clin Invest Med** 1996 Oct;19(5):357–61 (23 ref.)

Is celiac disease a lifelong disorder? Schmitz J. **Clin Invest Med** 1996 Oct;19(5):352–6 (28 ref.)

A longitudinal study of pain: reported pain from middle age to old age. Brattberg G, et al. **Clin J Pain** 1997 Jun; 13(2):144–9

Sexuality and the art of arousal in the geriatric woman. Barber HR. **Clin Obstet Gynecol** 1996 Dec;39(4):970–3 (9 ref.)

Age as a prognostic factor in open tibial fractures in children. Blasier RD, et al. **Clin Orthop** 1996 Oct;(331):261–4

Comparative effects of high- and low-intensity resistance training on thigh muscle strength, fiber area, and tissue composition in elderly women. Taaffe DR, et al. **Clin Physiol** 1996 Jul;16(4):381–92

Management of the older person after MI. Aronow WS. **Compr Ther** 1997 Apr;23(4):259–68 (68 ref.)

Normal aging and patterns of hematologic disease. Freedman ML. **Compr Ther** 1996 May;22(5):304–10 (24 ref.)

Menstrual bleeding patterns in untreated women. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Belsey EM, et al. **Contraception** 1997 Feb;55(2):57–65

Tear film changes associated with normal aging. Mathers WD, et al. **Cornea** 1996 May;15(3):229–34

A comparative study of human corneal keratocyte and endothelial cell density during aging. Møller-Pedersen T. **Cornea** 1997 May;16(3):333–8

The effects of age, gender, and fluid dynamics on the concentration of tear film epidermal growth factor. Nava A, et al. **Cornea** 1997 Jul;16(4):430–8

Cortical development: a role for spontaneous activity? Thompson I. **Curr Biol** 1997 May 1;7(5):R324–6 (25 ref.)

Quasielastic light scattering study of the living human lens as a function of age. Thurston GM, et al. **Curr Eye Res** 1997 Mar;16(3):197–207

Genetics of kidney development. Ekblom P. **Curr Opin Nephrol Hypertens** 1996 May;5(3):282–7 (37 ref.)

Pregnancy wastage and reproductive aging: the oocyte donation model. Sauer MV. **Curr Opin Obstet Gynecol** 1996 Jun;8(3):226–9 (42 ref.)

General principles of endocrine function after the sixth decade. Kowal J, et al. **Curr Ther Endocrinol Metab** 1997; 6:615–21 (13 ref.)

Tracking of risk factors for coronary heart disease from adolescence to young adulthood with special emphasis on physical activity and fitness. A longitudinal study. Andersen LB. **Dan Med Bull** 1996 Dec;43(5):407–18

Postural hypotension and EEG variables predict cognitive decline: results from a 5-year follow-up of healthy elderly women. Elmståhl S, et al. **Dement Geriatr Cogn Disord** 1997 May-Jun;8(3):180–7

Age vs. aging in the pathogenesis of senile dementia of the Alzheimer type: electrophysiological evidence. Politoff AL, et al. **Dement Geriatr Cogn Disord** 1997 Jan-Feb; 8(1):18–25

Diagnosing Alzheimer's disease in community-dwelling elderly: a comparison of EEG and MRI. Strijers RL, et al. **Dement Geriatr Cogn Disord** 1997 May-Jun;8(3):198–202

The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction

in Down syndrome. Arvat E, et al. **Dementia** 1996 Sep–Oct; 7(5):288–92

Sleep–related breathing and movement disorders in healthy elderly and demented subjects. Bader GG, et al. **Dementia** 1996 Sep–Oct;7(5):279–87

Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. Liu X, et al. **Dementia** 1996 May–Jun;7(3):128–34

Persistence of multipotential progenitors in the juvenile rat subventricular zone. Young GM, et al. **Dev Neurosci** 1996; 18(4):255–65

Aging changes of lens transparency in subjects with noncataractous eyes. Sasaki H, et al. **Dev Ophthalmol** 1997; 27:102–8

Expression of Sonic hedgehog and its putative role as a precursor cell mitogen in the developing mouse retina. Jensen AM, et al. **Development** 1997 Jan;124(2):363–71

Bax promotes neuronal cell death and is downregulated during the development of the nervous system. Vekrellis K, et al. **Development** 1997 Mar;124(6):1239–49

Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Matyka K, et al. **Diabetes Care** 1997 Feb;20(2):135–41

Relationship between weight change in young adulthood and the risk of NIDDM. The Sotetsu Study. Sakurai Y, et al. **Diabetes Care** 1997 Jun;20(6):978–82

New challenges in ageing: home care. Hermanova H. **Disabil Rehabil** 1997 Apr;19(4):142–6

The elderly: the single greatest achievement of mankind. Steel K. **Disabil Rehabil** 1997 Apr;19(4):130–3

Nonsteroidal anti–inflammatory drugs and acute renal failure in the elderly. A risk–benefit assessment. Ailabouni W, et al. **Drugs Aging** 1996 Nov;9(5):341–51 (74 ref.)

Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Burrell LM, et al. **Drugs Aging** 1997 Jun;10(6):421–34 (65 ref.)

Clinical trials in the elderly. Should we do more? Cameron HJ, et al. **Drugs Aging** 1996 Nov;9(5):307–10 (30 ref.)

Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors. Chatta GS, et al. **Drugs Aging** 1996 Jul;9(1):37–47 (101 ref.)

Analgesia in the elderly. Practical treatment recommendations. Drage MP, et al. **Drugs Aging** 1996 Nov; 9(5):311–8 (42 ref.)

Anaesthesia in the elderly. Special considerations. Jones AG, et al. **Drugs Aging** 1996 Nov;9(5):319–31 (73 ref.)

Age–related changes in male gonadal function. Implications for therapy. Maas D, et al. **Drugs Aging** 1997 Jul; 11(1):45–60 (128 ref.)

Management of acute renal failure in the elderly. Treatment options. Mandal AK, et al. **Drugs Aging** 1996 Oct; 9(4):226–50 (82 ref.)

Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations. Mörike K, et al. **Drugs Aging** 1997 Apr;10(4):259–77 (192 ref.)

Age–related changes in cardiac physiology. Can they be postponed or treated by drugs? Svanborg A. **Drugs Aging** 1997 Jun;10(6):463–72 (75 ref.)

Optimal dosage of ACE inhibitors in older patients. Tomlinson B. **Drugs Aging** 1996 Oct;9(4):262–73 (105 ref.)

Optimal treatment of urinary tract infections in elderly patients [see comments] Wood CA, et al. **Drugs Aging** 1996 Nov;9(5):352–62 (64 ref.). Comment in: Drugs Aging 1997 Feb;10(2):167.

Clinical multisegmental posturography: age–related changes in stance control. Accornero N, et al. **Electroencephalogr Clin Neurophysiol** 1997 Jun; 105(3):213–9

Multichannel auditory event–related brain potentials: effects of normal aging on the scalp distribution of N1, P2, N2 and P300 latencies and amplitudes. Anderer P, et al. **Electroencephalogr Clin Neurophysiol** 1996 Nov; 99(5):458–72

Discrimination of Alzheimer's disease and normal aging by EEG data. Besthorn C, et al. **Electroencephalogr Clin Neurophysiol** 1997 Aug; 103(2):241–8

Event–related brain potentials during semantic categorization in normal aging and senile dementia of the Alzheimer's type. Iragui V, et al. **Electroencephalogr Clin Neurophysiol** 1996 Sep; 100(5):392–406

Olfactory event–related potentials: older males demonstrate the greatest deficits. Morgan CD, et al. **Electroencephalogr Clin Neurophysiol** 1997 Jul;104(4):351–8

EEG and ERP assessment of normal aging. Polich J. **Electroencephalogr Clin Neurophysiol** 1997 May; 104(3):244–56

Enhanced amplitude reduction of somatosensory evoked potentials by voluntary movement in the elderly. Touge T, et al. **Electroencephalogr Clin Neurophysiol** 1997 Mar; 104(2):108–14

Somatosensory cortical and dermatome evoked potentials: a study conducted on 60 normal subjects. Results and their correlation relative to height and age. Gagnard–Landra C. **Electromyogr Clin Neurophysiol** 1996 Apr–May; 36(3):131–44

Muscle activation and force production during bilateral and unilateral concentric and isometric contractions of the knee extensors in men and women at different ages. Häkkinen K, et al. **Electromyogr Clin Neurophysiol** 1997 Apr–May; 37(3):131–42

Clinical epidemiology of endocrine disorders in the elderly. Hornick TR, et al. **Endocrinol Metab Clin North Am** 1997 Mar;26(1):145–63 (134 ref.)

Depletion and repopulation of Leydig cells in the testes of aging brown Norway rats. Chen H, et al. **Endocrinology** 1996 Aug;137(8):3447–52

The effects of aging on the bone inductive activity of recombinant human bone morphogenetic protein–2. Fleet JC, et al. **Endocrinology** 1996 Nov;137(11):4605–10

Fasting–induced increases in food intake and neuropeptide Y gene expression are attenuated in aging male brown Norway rats. Gruenewald DA, et al. **Endocrinology** 1996 Oct;137(10):4460–7

In vivo antisense antagonism of vasoactive intestinal peptide in the suprachiasmatic nuclei causes aging–like changes in the estradiol–induced luteinizing hormone and prolactin surges. Harney JP, et al. **Endocrinology** 1996 Sep; 137(9):3696–701

Growth hormone induces somatostatin and insulin–like growth factor I gene expression in the cerebral hemispheres of aging rats. López–Fernández J, et al. **Endocrinology** 1996 Oct;137(10):4384–91

Biosynthetic human parathyroid hormone (1–34) effects on bone quality in aged ovariectomized rats. Sato M, et al. **Endocrinology** 1997 Oct;138(10):4330–7

Differential effect of age on transforming growth factor–beta 1 inhibition of prolactin gene expression versus secretion in rat anterior pituitary cells. Tan SK, et al. **Endocrinology** 1997 Mar;138(3):878–85

Parathyroid cell proliferation in the rat: effect of age and of phosphate administration and recovery. Wang Q, et al. **Endocrinology** 1996 Nov;137(11):4558–62

Age–related effects of heat stress on protective enzymes for peroxides and microsomal monooxygenase in rat liver. Ando M, et al. **Environ Health Perspect** 1997 Jul; 105(7):726–33

The physiologic, neurologic, and behavioral effects of caloric restriction related to aging, disease, and environmental factors. Duffy PH, et al. **Environ Res** 1997;73(1–2):242–8

Comparison of age, sex, breed, history and management in 229 horses with colic. Morris DD, et al. **Equine Vet J Suppl** 1989 Jun;(7):129–32

Regional gastric pH measurement in horses and foals. Murray MJ, et al. **Equine Vet J Suppl** 1989 Jun;(7):73–6

The hock as a potential site for non–invasive bone measurement. Scotti E, et al. **Equine Vet J Suppl** 1988 Sep; (6):93–8

Age–related changes in structure and relative collagen content of the human and feline sinoatrial node. A comparative study [see comments] Alings AM, et al. **Eur Heart J** 1995 Nov;16(11):1655–67. Comment in: Eur Heart J 1996 Nov;17(11):1758–9.

Pulmonary venous flow velocity patterns in 143 normal subjects aged 20 to 80 years old. An echo 2D colour Doppler cooperative study. Gentile F, et al. **Eur Heart J** 1997 Jan;18(1):148–64

Blood pressure and mortality in an older population. A 5–year follow–up of the Helsinki Ageing Study [see comments] Hakala SM, et al. **Eur Heart J** 1997 Jun; 18(6):1019–23. Comment in: Eur Heart J 1997 Jun;18(6):889–90.

Blood pressure, ageing and mortality [editorial; comment] Parati G, et al. **Eur Heart J** 1997 Jun;18(6):889–90. Comment on: Eur Heart J 1997 Jun;18(6):1019–23.

Physical work capacity in dynamic exercise with differing muscle masses in healthy young and older men. Aminoff T, et al. **Eur J Appl Physiol** 1996;73(1–2):180–5

Passive temperature lability in the elderly. Anderson GS, et al. **Eur J Appl Physiol** 1996;73(3–4):278–86

The longitudinal development of running economy in males and females aged between 13 and 27 years: the Amsterdam Growth and Health Study. Ariëns GA, et al. **Eur J Appl Physiol** 1997;76(3):214–20

Decreased pulmonary diffusing capacity of divers over a 6–year period. Bermon S, et al. **Eur J Appl Physiol** 1997; 76(2):170–3

Haemodynamic response to exercise in healthy young and elderly subjects. Bogaard HJ, et al. **Eur J Appl Physiol** 1997;75(5):435–42

Influence of age on the immediate cardiovascular response to orthostatic manoeuvre. Cybulski G. **Eur J Appl Physiol** 1996;73(6):563–72

Influence of age on concentric isokinetic torque and passive extensibility variables of the calf muscles of women. Gajdosik RL, et al. **Eur J Appl Physiol** 1996;74(3):279–86

Regional differences in age–related decrements of the cutaneous vascular and sweating responses to passive heating. Inoue Y, et al. **Eur J Appl Physiol** 1996; 74(1–2):78–84

Longitudinal effects of age on heat–activated sweat gland density and output in healthy active older men. Inoue Y. **Eur J Appl Physiol** 1996;74(1–2):72–7

The mechanical properties of the heel pad in elderly adults. Kinoshita H, et al. **Eur J Appl Physiol** 1996;73(5):404–9

A comparison of prehension force control in young and elderly individuals. Kinoshita H, et al. **Eur J Appl Physiol** 1996;74(5):450–60

Habitual physical activity and peak anaerobic power in elderly women. Kostka T, et al. **Eur J Appl Physiol** 1997; 76(1):81–7

Breath–by–breath determinations of airway occlusion pressure in the developing lamb. Milerad J, et al. **Eur J Appl Physiol** 1996;74(1–2):44–51

Age–related changes in biomechanical properties of the Achilles tendon in rabbits. Nakagawa Y, et al. **Eur J Appl Physiol** 1996;73(1–2):7–10

Effects of habitual physical exercise on physiological age in men aged 20–85 years as estimated using principal component analysis. Nakamura E, et al. **Eur J Appl Physiol** 1996;73(5):410–8

Standing strength training of the ankle plantar and dorsiflexors in older women, using concentric and eccentric contractions. Porter MM, et al. **Eur J Appl Physiol** 1997; 76(1):62–8

Free radicals, atherosclerosis, ageing and related dysmetabolic pathologies: biochemical and molecular aspects. Cestaro B, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S25–30 (33 ref.)

High–risk subjects for vitamin deficiency. Filiberti R, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S37–42 (51 ref.)

Cloning of sheep: a possible technique for reprogramming ageing mechanisms. Gilbert C. **Eur J Cancer Prev** 1997 Jun;6(3):303–4

Free radicals, atherosclerosis, ageing, and related dysmetabolic pathologies: pathological and clinical aspects. Scarfiotti C, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S31–6 (31 ref.)

Gender differences in resting metabolic rate and noradrenaline kinetics in older individuals. Poehlman ET, et al. **Eur J Clin Invest** 1997 Jan;27(1):23–8

Short–term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Ghigo E, et al. **Eur J Endocrinol** 1996 Oct;135(4):407–12

Brain natriuretic peptide versus atrial natriuretic peptide—physiological and pathophysiological significance in children and adults: a review. Yoshibayashi M, et al. **Eur J Endocrinol** 1996 Sep;135(3):265–8 (22 ref.)

The influence of ageing on oesophageal motility after ingestion of liquids with different viscosities. Ferriolli E, et al. **Eur J Gastroenterol Hepatol** 1996 Aug;8(8):793–8

Coordination of deglutitive vocal cord closure and oral–pharyngeal swallowing events in the elderly. Zamir Z, et al. **Eur J Gastroenterol Hepatol** 1996 May;8(5):425–9

Identification of cells secreting a thymostimulin–like substance and examination of some histoenzymatic pathways in aging avian primary lymphatic organs: I. thymus. Aita M, et al. **Eur J Histochem** 1995;39(4):289–300

Correlations between water maze performance and cortical somatostatin mRNA and high–affinity binding sites during ageing in rats. Dournaud P, et al. **Eur J Neurosci** 1996 Mar;8(3):476–85

Neuronal precursors in the postnatal mouse cerebellum are fully committed cells: evidence from heterochronic transplantations. Jankovski A, et al. **Eur J Neurosci** 1996 Nov;8(11):2308–19

Evidence that spinal interneurons undergo programmed cell death postnatally in the rat. Lawson SJ, et al. **Eur J Neurosci** 1997 Apr;9(4):794–9

Age–related changes in excitability and recurrent inhibition in the rat CA1 hippocampal region. Papatheodoropoulos C, et al. **Eur J Neurosci** 1996 Mar;8(3):510–20

Developmental study of N–methyl–D–aspartate–induced firing activity and whole–cell currents in nucleus tractus solitarii neurons. Vincent A, et al. **Eur J Neurosci** 1996 Dec;8(12):2748–52

Age–related changes in the global skeletal uptake of technetium–99m methylene diphosphonate in healthy women. Carnevale V, et al. **Eur J Nucl Med** 1996 Nov; 23(11):1473–7

Effects of aging on the cerebral distribution of technetium–99m hexamethylpropylene amine oxime in healthy humans. Mozley PD, et al. **Eur J Nucl Med** 1997 Jul;24(7):754–61

In search of human dignity: reproductive health and healthy aging. Diczfalusy E. **Eur J Obstet Gynecol Reprod Biol** 1997 Feb;71(2):123–33

The role of patient's age in regression of holmium:YAG thermokeratoplasty–induced correction of hyperopia. Gezer A. **Eur J Ophthalmol** 1997 Apr–Jun;7(2):139–43

Development of the frontal sinus in relation to somatic and skeletal maturity. A cephalometric roentgenographic study at puberty. Ruf S, et al. **Eur J Orthod** 1996 Oct;18(5):491–7

Age–related differences and roles of endothelial nitric oxide and prostanoids in angiotensin II responses of isolated, perfused mesenteric arteries and veins of rats. Konishi C, et al. **Eur J Pharmacol** 1997 Feb 12;320(2–3):175–81

Metrifonate improves spatial navigation and avoidance behavior in scopolamine–treated, medial septum–lesioned and aged rats. Riekkinen P Jr, et al. **Eur J Pharmacol** 1996 Aug 8;309(2):121–30

Effects of ginsenosides on maze performance and brain choline acetyltransferase activity in scopolamine–treated young rats and aged rats. Yamaguchi Y, et al. **Eur J Pharmacol** 1997 Jun 18;329(1):37–41

Effect of ageing on peak expiratory flow variability and nocturnal exacerbations in bronchial asthma. Bellia V, et al. **Eur Respir J** 1997 Aug;10(8):1803–8

Pulmonary gas exchange in elderly subjects. Guénard H, et al. **Eur Respir J** 1996 Dec;9(12):2573–7

Peak expiratory flow from maximum expiratory flow volume curves in a community population: cross–sectional and longitudinal analyses. Lebowitz MD, et al. **Eur Respir J Suppl** 1997 Feb;24:29S–38S

The relationship between the magnetic resonance imaging appearance of the lumbar spine and low back pain, age and occupation in males. Savage RA, et al. **Eur Spine J** 1997;6(2):106–14

Different fibrinolytic potentials between human umbilical vein endothelial cells and human adult vein endothelial cells. Rydholm H, et al. **Eur Surg Res** 1996;28(5):380–7

Age-related changes of histological composition in established benign prostatic hyperplasia. Ishigooka M, et al. **Eur Urol** 1996;29(1):85–9

The uroflowmetry in normal men and after prostatectomy. Kuo HC. **Eur Urol** 1997;31(4):447–52

Measuring human functional age: a review of empirical findings. Anstey KJ, et al. **Exp Aging Res** 1996 Jul–Sep; 22(3):245–66 (44 ref.)

The representation of semantic categories in aging. Brosseau J, et al. **Exp Aging Res** 1996 Oct–Dec;22(4):381–91

Psychoneuroendocrinological indicators of stress and intellectual performance among older adults: an exploratory study. Kelly KS, et al. **Exp Aging Res** 1996 Oct–Dec;22(4):393–401

Upright standing and gait: are there changes in attentional requirements related to normal aging? Lajoie Y, et al. **Exp Aging Res** 1996 Apr–Jun;22(2):185–98

Isometric pinch force control and learning in older adults. Lazarus JA, et al. **Exp Aging Res** 1997 Apr–Jun; 23(2):179–99

Remembering what the doctor said: organization and adults' memory for medical information. McGuire LC. **Exp Aging Res** 1996 Oct–Dec;22(4):403–28

Multidimensional patterns of aging: a cluster-analytic approach. Maxson PJ, et al. **Exp Aging Res** 1997 Jan–Mar; 23(1):13–31

Aging and human heat tolerance. Pandolf KB. **Exp Aging Res** 1997 Jan–Mar;23(1):69–105 (73 ref.)

Memory scores in middle-aged rats predict later deficits in memory, paradoxical sleep, and blood glucose regulation in old age. Stone WS, et al. **Exp Aging Res** 1997 Jul–Sep; 23(3):287–300

Self-reported physical activity, subjective health, and cognitive performance in older adults. van Boxtel MP, et al. **Exp Aging Res** 1996 Oct–Dec;22(4):363–79

Aging and human cold tolerance. Young AJ, et al. **Exp Aging Res** 1997 Jan–Mar;23(1):45–67 (65 ref.)

Age-related histochemical and ultrastructural changes in renal glomerular mesangium of APA hamsters. Nishida E, et al. **Exp Anim** 1996 Oct;45(4):339–45

Effects of early cerebellar removal on the classically conditioned bradycardia of adult rabbits. Ghelarducci B, et al. **Exp Brain Res** 1996 Oct;111(3):417–23

Reciprocal changes in expression of mRNA for nerve growth factor and its receptors TrkA and LNGFR in brain of aged rats in relation to maze learning deficits. Hasenöhrl RU, et al. **Exp Brain Res** 1997 Apr;114(2):205–13

Development of contrast sensitivity and temporal-frequency selectivity in primate lateral geniculate nucleus. Hawken MJ, et al. **Exp Brain Res** 1997 Mar;114(1):86–98

Availability of visual and proprioceptive afferent messages and postural control in elderly adults. Hay L, et al. **Exp Brain Res** 1996 Feb;108(1):129–39

Development in neonatal rats of the sensory resetting of the locomotor rhythm induced by NMDA and 5-HT. Iizuka M, et al. **Exp Brain Res** 1997 Apr;114(2):193–204

Age-related changes in cerebral blood flow activation during a Card Sorting Test. Nagahama Y, et al. **Exp Brain Res** 1997 May;114(3):571–7

Stochastic processes in postural center-of-pressure profiles. Newell KM, et al. **Exp Brain Res** 1997 Jan;113(1):158–64

Aging decreases rebound synaptic excitation produced by removal of NMDA receptor block in the striatum. Ou X, et al. **Exp Brain Res** 1997 May;114(3):590–4

Endosteal human bone cells (EBC) show age-related activity in vitro. Battmann A, et al. **Exp Clin Endocrinol Diabetes** 1997;105(2):98–102

Müller and RPE cell response to photoreceptor cell degeneration in aging Fischer rats. Fan W, et al. **Exp Eye Res** 1996 Jul;63(1):9–18

The generation of superoxide anion by the UVA irradiation of human lens proteins. Linetsky M, et al. **Exp Eye Res** 1996 Jul;63(1):67–74

Comparative aging and life histories in mammals. Austad SN. **Exp Gerontol** 1997 Jan–Apr;32(1–2):23–38 (115 ref.)

Relationship between pituitary hormones, antioxidant enzymes, and histopathological changes in the mammary gland of senescent rats. Bolzán AD, et al. **Exp Gerontol** 1997 May–Jun;32(3):297–304

The role of obesity and cardiovascular fitness in the impaired glucose tolerance of aging. Colman E, et al. **Exp Gerontol** 1995 Nov–Dec;30(6):571–80

Age and gender effects on 1,25-dihydroxyvitamin D3-regulated gene expression. Johnson JA, et al. **Exp Gerontol** 1995 Nov–Dec;30(6):631–43

Biogerontologic theories. McClearn GE. **Exp Gerontol** 1997 Jan–Apr;32(1–2):3–10 (25 ref.)

Biomarkers of age and aging. McClearn GE. **Exp Gerontol** 1997 Jan–Apr;32(1–2):87–94 (14 ref.)

Life history evolution in guppies (Poecilia reticulata): guppies as a model for studying the evolutionary biology of aging [editorial] Reznick DN. **Exp Gerontol** 1997 May–Jun; 32(3):245–58 (49 ref.)

Change in heat loss as a part of adaptation to repeated cold exposures in adult and aged male C57BL/6J mice. Shefer VI, et al. **Exp Gerontol** 1997 May–Jun;32(3):325–32

Early appearance of age-associated deterioration in mitochondrial function of diaphragm and heart in rats treated with doxorubicin. Yamada K, et al. **Exp Gerontol** 1995 Nov–Dec;30(6):581–93

Maturational changes in Na(+)-K+ pump activity in guinea pig airway smooth muscle. Rhoden KJ, et al. **Exp Lung Res** 1997 Jul–Aug;23(4):333–45

Enhanced proliferation and migration and altered cytoskeletal proteins in early passage smooth muscle cells from young and old rat aortic explants. Li Z, et al. **Exp Mol Pathol** 1997 Feb;64(1):1–11

Localization of advanced glycation end products of Maillard reaction in bovine tissues and their endocytosis by macrophage scavenger receptors. Mori T, et al. **Exp Mol Pathol** 1995 Oct;63(2):135–52

Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats. Figueredo-Cardenas G, et al. **Exp Neurol** 1997 Aug; 146(2):444–57

Aging, metabolism, and Alzheimer disease: review and hypotheses. Finch CE, et al. **Exp Neurol** 1997 Jan; 143(1):82–102 (218 ref.)

Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Lynch G, et al. **Exp Neurol** 1997 May;145(1):89–92

Dystrophic neurite formation associated with age-related beta amyloid deposition in the neocortex: clues to the genesis of neurofibrillary pathology. Vickers JC, et al. **Exp Neurol** 1996 Sep;141(1):1–11

The influence of age on the assessment of motor unit activation in a human hand muscle. Spiegel KM, et al. **Exp Physiol** 1996 Sep;81(5):805–19

Attenuated heat shock transcriptional response in aging: molecular mechanism and implication in the biology of aging. Liu AY, et al. **EXS** 1996;77:393–408 (74 ref.)

Binocularity in infancy. Braddick O. **Eye** 1996;10 (Pt 2):182–8 (41 ref.)

Caloric restriction reduces fiber loss and mitochondrial abnormalities in aged rat muscle. Aspnes LE, et al. **FASEB J** 1997 Jun;11(7):573–81

Basal estradiol and follicle-stimulating hormone predict fecundity in women of advanced reproductive age undergoing ovulation induction therapy. Buyalos RP, et al. **Fertil Steril** 1997 Aug;68(2):272–7

Differential age of the endometrium [letter] Check JH. **Fertil Steril** 1996 Jul;66(1):174–5

Age-related decline in fertility: a link to degenerative oocytes? Lim AS, et al. **Fertil Steril** 1997 Aug;68(2):265–71

Correlation of reproductive aging with function in selected organ systems. Miller PB, et al. **Fertil Steril** 1997 Sep; 68(3):443–8

The impact of the woman's age on the success of standard and donor in vitro fertilization. Stolwijk AM, et al. **Fertil Steril** 1997 Apr;67(4):702–10

A quantitative immunocytochemical study of blood-brain barrier to endogenous albumin in cerebral cortex and hippocampus of senescence-accelerated mice (SAM). Vorbrodt AW, et al. **Folia Histochem Cytobiol** 1995; 33(4):229–37

False tendons in the left ventricle of the heart in humans during pre- and postnatal periods. Grzybiak M, et al. **Folia Morphol (Warsz)** 1996;55(2):89–99

The infrapatellar adipose body in humans of various age groups. Jędrzejczyk T, et al. **Folia Morphol (Warsz)** 1996; 55(1):51–5

Evaluation of human dura mater resistance in MTS Mini Bionix 85802 System. Kędzia A, et al. **Folia Morphol (Warsz)** 1996;55(4):332–4

The interossei muscles of manus and pes in rabbit. Wojnar T. **Folia Morphol (Warsz)** 1996;55(1):57–63

Formant frequency characteristics of elderly speakers in contextual speech. Rastatter MP, et al. **Folia Phoniatr Logop** 1997;49(1):1–8

Age-related differences in acoustical aspects of contrastive stress in women. Scukanec GP, et al. **Folia Phoniatr Logop** 1996;48(5):231–9

Ontogenetic variation in small-bodied New World primates: implications for patterns of reproduction and infant care. Garber PA, et al. **Folia Primatol (Basel)** 1997;68(1):1–22

Handwriting changes due to aging and Parkinson's syndrome. Walton J. **Forensic Sci Int** 1997 Aug 22;88(3):197–214

Cholesterol: a two-edged sword in brain aging. Joseph JA, et al. **Free Radic Biol Med** 1997;22(3):455–62

Influence of age on the release of reactive oxygen species by phagocytes as measured by a whole blood chemiluminescence assay. Kukovetz EM, et al. **Free Radic Biol Med** 1997;22(3):433–8

Chronic inhibition of the high-affinity dopamine uptake system increases oxidative damage to proteins in the aged rat substantia nigra. Romero-Ramos M, et al. **Free Radic Biol Med** 1997;23(1):1–7

Decreased local cerebral blood flow in young and aged spontaneously hypertensive rats. Katsuta T. **Fukuoka Igaku Zasshi** 1997 Mar;88(3):65–74

New trends in neurogeriatrics: from research to intervention in aging subjects with dementia. Proceedings and abstracts of the 7th National Congress of the Italian Society of Neurogeriatrics. Ville Ponti, Italy, 27–28 June 1997. **Funct Neurol** 1997 May–Aug;12(3–4):141–241

Drug metabolic enzymes in developmental toxicology. Miller MS, et al. **Fundam Appl Toxicol** 1996 Dec;34(2):165–75 (67 ref.)

Age limits for heart transplantation: medical aspects. Opasich C, et al. **G Ital Cardiol** 1997 Jun;27(6):557–62

Signal transduction pathways associated with contraction during development of the feline gastric antrum. Hillemeier AC, et al. **Gastroenterology** 1997 Aug;113(2):507–13

Plasma thyroxine concentrations in farmed ostriches in relation to age, body weight, and growth hormone. Dawson A, et al. **Gen Comp Endocrinol** 1996 Sep; 103(3):308–15

Age-related changes in nociception, behavior, and monoamine levels in rats. Goicoechea C, et al. **Gen Pharmacol** 1997 Feb;28(2):331–6

Abnormal renal vascular reactivity to acetylcholine and nitroprusside in aging rats. Vargas F, et al. **Gen Pharmacol** 1997 Jan;28(1):133–7

Sleep problems in older adults: putting myths to bed. Ancoli-Israel S. **Geriatrics** 1997 Jan;52(1):20–30 (30 ref.)

Older astronauts: next giant leap for mankind [editorial] Butler RN. **Geriatrics** 1997 Apr;52(4):14, 16

Preventive maintenance for the midlife patient. Sherman FT. **Geriatrics** 1997 Jan;52(1):32

Ten years later: what have we learned about human aging from studies of cell cultures? Cristofalo VJ. **Gerontologist** 1996 Dec;36(6):737–41

Proceedings of the 5th International Symposium on Lipofuscin and Ceroid Pigments. State of the Art 1995. Part 2 of the International Gerontology Week. Tokyo, 1995. **Gerontology** 1995;41 Suppl 2:1–330

Undernutrition and aging. Aihie Sayer A, et al. **Gerontology** 1997;43(4):203–5 (22 ref.)

Synaptic structural dynamics and aging. Bertoni-Freddari C, et al. **Gerontology** 1996;42(3):170–80 (51 ref.)

Deficiency of the growth hormone-insulin-like growth factor-I axis potentially involved in age-related alterations in body composition. Boonen S, et al. **Gerontology** 1996; 42(6):330–8

Accumulation of lipofuscin within retinal pigment epithelial cells results in enhanced sensitivity to photo-oxidation. Brunk UT, et al. **Gerontology** 1995;41 Suppl 2:201–12

Diet-induced residual formation in pigs. de Gritz BG, et al. **Gerontology** 1995;41 Suppl 2:305–17

Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. de la Torre JC. **Gerontology** 1997;43(1–2):26–43 (154 ref.)

Alzheimer's, ageing and amyloid: an absurd allegory? Fowler CJ, et al. **Gerontology** 1997;43(1–2):132–42 (97 ref.)

A preliminary investigation of the effects of aging on the nerve cell number in the myenteric ganglia of the human colon. Gomes OA, et al. **Gerontology** 1997;43(4):210–7

Melatonin as an antiaging drug: between facts and fantasy. Huether G. **Gerontology** 1996;42(2):87–96 (67 ref.)

Management of urinary incontinence in the elderly. Iqbal P, et al. **Gerontology** 1997;43(3):151–7 (41 ref.)

Lipofuscin in bovine muscle and brain: a model for studying age pigment. Jolly RD, et al. **Gerontology** 1995;41 Suppl 2:283–95

Extraction and purification of yellow-fluorescent lipofuscin in rat kidney. Klikugawa K, et al. **Gerontology** 1995;41 Suppl 2:1–14

Hypergravity and aging in Drosophila melanogaster. 8. Proboscis-extension-response threshold to sucrose. Le Bourg E. **Gerontology** 1996;42(4):235–40

Age-related changes in gastric blood flow in rats. Lee M. **Gerontology** 1996;42(5):289–93

Simple physiological and clinical tests for the accurate prediction of falling in older people. Lord SR, et al. **Gerontology** 1996;42(4):199–203

The effect of caloric restriction on lipofuscin accumulation in mouse brain with age. Moore WA, et al. **Gerontology** 1995;41 Suppl 2:173–85

Implications of increased intercellular variability of lipofuscin content with age in dentate gyrus granule cells in the mouse. Moore WA, et al. **Gerontology** 1995;41 Suppl 2:187–99

Overactivity of tumor necrosis factor-alpha but not interleukin 6 is associated with low natural killer cytotoxic activity in the elderly. Myśliwska J, et al. **Gerontology** 1997; 43(3):158–67

Age-related changes in the lipofuscin accumulation of brain and heart. Nakano M, et al. **Gerontology** 1995;41 Suppl 2:69–79

The age-related rise of plasma cholesterol in humans is not caused by a cell removal defect of LDL particles: 'in vitro' studies in peripheral mononuclear blood cells. Neves MQ, et al. **Gerontology** 1997;43(4):232–41

No influence of aging on the circadian rhythm of erythropoietin in healthy subjects. Pasqualetti P, et al. **Gerontology** 1997;43(4):206–9

Influence of visual control, conduction, and central integration on static and dynamic balance in healthy older adults. Perrin PP, et al. **Gerontology** 1997;43(4):223–31

Theoretical considerations on the nature of the pineal 'ageing clock'. Pierpaoli W, et al. **Gerontology** 1997;43(1–2):20–5 (15 ref.)

Risk factors and ocular senescence. Pierscionek BK, et al. **Gerontology** 1996;42(5):257–69 (55 ref.)

Changes in cathepsin B and lipofuscin during development and aging in rat brain and heart. Porta E, et al. **Gerontology** 1995;41 Suppl 2:81–93

Brain lipofuscinolysis and ceroidolysis--to be or not to be. Riga D, et al. **Gerontology** 1995;41 Suppl 2:271–81 (42 ref.)
Effects of aging on muscle fibers and collagen content of the diaphragm: a comparison with the rectus abdominis muscle. Rodrigues CJ, et al. **Gerontology** 1996;42(4):218–28
Dementia-free life expectancy among elderly Japanese. Sauvaget C, et al. **Gerontology** 1997;43(3):168–75
Effect of land-based and water-based fitness programs on the cardiovascular fitness, strength and flexibility of women aged 65–75 years. Taunton JE, et al. **Gerontology** 1996; 42(4):204–10
The effect of age on formation and elimination of autophagic vacuoles in mouse hepatocytes. Terman A. **Gerontology** 1995;41 Suppl 2:319–26
Studies on age pigments evolving into a new theory of biological aging. Yin D. **Gerontology** 1995;41 Suppl 2:159–72 (99 ref.)
Transplantation of RPE in age-related macular degeneration: observations in disciform lesions and dry RPE atrophy. Algvere PV, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Mar;235(3):149–58
Normal heterophoric changes: 20 years' follow-up. Spierer A, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Jun; 235(6):345–8
A mathematical approach for estimating reference values for weight-for-age, weight-for-height and height-for-age. Martins SJ, et al. **Growth Dev Aging** 1997 Spring;61(1):3–10
Sex differences in bone growth of broiler chickens. Rose N, et al. **Growth Dev Aging** 1996 Summer;60(2):49–59
The new model of age-dependent changes in bone mineral density. Xu SZ, et al. **Growth Dev Aging** 1997 Spring; 61(1):19–26
Divergent selection for high or low growth rate modifies the response of muscle cells to serum or insulin-like growth factor-I in vitro. Duclos MJ, et al. **Growth Regul** 1996 Sep; 6(3):176–84
Age-related decrease in the opioid control of LH secretion during reproductive years in normal women. Coiro V, et al. **Gynecol Obstet Invest** 1997;43(3):162–5
Speech recognition in noise and presbycusis: relations to possible neural mechanisms. Frisina DR, et al. **Hear Res** 1997 Apr;106(1–2):95–104
Decline in the endocochlear potential corresponds to decreased Na,K-ATPase activity in the lateral wall of quiet-aged gerbils. Gratton MA, et al. **Hear Res** 1997 Jun; 108(1–2):9–16
Effect of maternal cholestasis on biliary lipid and bile acid secretion in the infant rat. El-Mir MY, et al. **Hepatology** 1997 Sep;26(3):527–36
Age-related modifications in the regulation of the hypothalamic-pituitary-thyroid axis. Monzani F, et al. **Horm Res** 1996;46(3):107–12
Regulation factors of corticosteroid-binding globulin: lesson from ontogenesis. Séralini GE. **Horm Res** 1996; 45(3–5):192–6 (37 ref.)
Quantitative allele-specific PCR: demonstration of age-associated accumulation in human tissues of the A-->G mutation at nucleotide 3243 in mitochondrial DNA. Liu VW, et al. **Hum Mutat** 1997;9(3):265–71
Application of image analysis cytometry in follicular fluid cells obtained from in-vitro fertilization cycles: relationships to patient's age, oocyte maturity, fertilizability and in-vitro fertilization outcome. Agorastos T, et al. **Hum Reprod** 1996 Oct;11(10):2200–7
Cumulative pregnancy rate following in-vitro fertilization: the significance of age and infertility aetiology. Dor J, et al. **Hum Reprod** 1996 Feb;11(2):425–8
A model conforming the decline in follicle numbers to the age of menopause in women. Faddy MJ, et al. **Hum Reprod** 1996 Jul;11(7):1484–6
Utility of follicle stimulating hormone (FSH), luteinizing hormone (LH), oestradiol and FSH:LH ratio in predicting reproductive age in normal women. Kim YK, et al. **Hum Reprod** 1997 Jun;12(6):1152–5
Morphological and functional aspects of the endometrium of asymptomatic post-menopausal women: does the endometrium really age? Noci I, et al. **Hum Reprod** 1996 Oct;11(10):2246–50
Cumulative conception and live birth rates after oocyte donation: implications regarding endometrial receptivity. Paulson RJ, et al. **Hum Reprod** 1997 Apr;12(4):833–9
Senescent heart compared with pressure overload-induced hypertrophy. Assayag P, et al. **Hypertension** 1997 Jan;29(1 Pt 1):15–21
Exercise training in aging: hemodynamic, metabolic, and oxidative stress evaluations. De Angelis KL, et al. **Hypertension** 1997 Sep;30(3 Pt 2):767–71
Age-related changes in total arterial capacitance from birth to maturity in a normotensive population. de Simone G, et al. **Hypertension** 1997 Jun;29(6):1213–7
Aging and severity of hypertension attenuate endothelium-dependent renal vascular relaxation in humans. Higashi Y, et al. **Hypertension** 1997 Aug;30(2 Pt 1):252–8
Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hollenberg NK, et al. **Hypertension** 1997 Jan;29(1 Pt 2):171–6
Effects of age on Ca2+ currents in small mesenteric artery myocytes from Wistar-Kyoto and spontaneously hypertensive rats. Lozinskaya IM, et al. **Hypertension** 1997 Jun;29(6):1329–36
Aging and lymphocyte subsets in the spleen and peripheral blood of the Sprague-Dawley rat. Flaherty DK, et al. **Immunopharmacol Immunotoxicol** 1997 May;19(2):185–95
Exposure of mice to pulsed magnetic fields: long-term observations. Bellossi A, et al. **In Vivo** 1996 May-Jun; 10(3):357–60
Acceleration of renal dysfunction with ageing by the use of androgen in Wistar/Tw rats. Tanaka A, et al. **In Vivo** 1995 Sep-Oct;9(5):495–502
Age and intrinsic left ventricular myocardial contractility. Gajra A, et al. **Indian Heart J** 1997 Mar-Apr;49(2):155–8
Age-related decline in multiple unit action potentials of cerebral cortex correlates with the number of lipofuscin-containing neurons. Sharma D, et al. **Indian J Exp Biol** 1996 Aug;34(8):776–81
Proinflammatory cytokine deficiency and pathogenesis of Pseudomonas aeruginosa keratitis in aged mice. Hobden JA, et al. **Infect Immun** 1997 Jul;65(7):2754–8
Maintaining and restoring mobility in middle and old age: the importance of the soft tissues. Buckwalter JA. **Instr Course Lect** 1997;46:459–69 (80 ref.)
Youthful and older biases as special cases of a self-age optimization bias. Staats S. **Int J Aging Hum Dev** 1996; 43(4):267–76
Homeleaving age norms: conflict or consensus? Veevers JE, et al. **Int J Aging Hum Dev** 1996;43(4):277–95
Reproductive parameters of older compared to younger men of infertile couples. Rolf C, et al. **Int J Androl** 1996 Jun; 19(3):135–42
Triglyceride expression. Krishnaswami S, et al. **Int J Cardiol** 1996 Dec 6;57(2):167–71
Age related dilatation of the right ventricle in arrhythmogenic right ventricular dysplasia-cardiomyopathy. Peters S. **Int J Cardiol** 1996 Oct 11;56(2):163–7
Effects of age on anal function in normal women. Ryhammer AM, et al. **Int J Colorectal Dis** 1997;12(4):225–9
Properties of developing lateral geniculate neurones in the mouse. MacLeod N, et al. **Int J Dev Neurosci** 1997 Apr; 15(2):205–24
Evaluation of two sympathetic cutaneous vasomotor reflexes using laser Doppler fluxmetry. Netten PM, et al. **Int J Microcirc Clin Exp** 1996 May-Jun;16(3):124–8
Functional brain asymmetry, handedness and age characteristics of climacterium in women. Nikolova P, et al. **Int J Neurosci** 1996 Jul;86(1–2):143–9
Melatonin supplements for aging. Sandyk R. **Int J Neurosci** 1996 Nov;87(3–4):219–24 (45 ref.)
Age differences in hemispheric activation to sensory condition. Shapiro DM, et al. **Int J Neurosci** 1996 Nov; 87(3–4):249–56
The effect of aging on spectral parameters of event-related potentials. Yargicoglu P, et al. **Int J Neurosci** 1995 Nov; 83(1–2):135–43
Adiposity and regional body fat distribution in physically active young and middle-aged women. Davy KP, et al. **Int J Obes Relat Metab Disord** 1996 Aug;20(8):777–83
The influences of height and age on waist circumference as an index of adiposity in adults. Han TS, et al. **Int J Obes Relat Metab Disord** 1997 Jan;21(1):83–9
Childhood obesity elevates blood pressure and total cholesterol independent of physical activity. McMurray RG, et al. **Int J Obes Relat Metab Disord** 1995 Dec; 19(12):881–6
Changes in body weight in relation to mortality in 6441 European middle-aged men: the Seven Countries Study. Peters ET, et al. **Int J Obes Relat Metab Disord** 1995 Dec; 19(12):862–8
Use of weight-for-height indices in children to predict adult overweight: the Bogalusa Heart Study. Valdez R, et al. **Int J Obes Relat Metab Disord** 1996 Aug;20(8):715–21
Age-related changes in child and adolescent event-related potential component morphology, amplitude and latency to standard and target stimuli in an auditory oddball task. Johnstone SJ, et al. **Int J Psychophysiol** 1996 Dec; 24(3):223–38
The association between P300 and age from preadolescence to early adulthood. Katsanis J, et al. **Int J Psychophysiol** 1996 Dec;24(3):213–21
On the relationship between EEG and P300: individual differences, aging, and ultradian rhythms. Polich J. **Int J Psychophysiol** 1997 Jun;26(1–3):299–317
Alpha response system in children: changes with age. Yordanova J, et al. **Int J Psychophysiol** 1997 Jun; 26(1–3):411–30
Aging and the acute phase response to exercise: implications for the role of systemic factors on skeletal muscle protein turnover. Fielding RA, et al. **Int J Sports Med** 1997 Mar; 18 Suppl 1:S22–7 (59 ref.)
Acute hormonal responses to heavy resistance exercise in men and women at different ages. Häkkinen K, et al. **Int J Sports Med** 1995 Nov;16(8):507–13
Muscle cell and oxidative damage in aging: a century of hypothesis and personal contribution. Montanari G, et al. **Int J Tissue React** 1996;18(1):33–41 (55 ref.)
Health and dietary characteristics of supplement users in an elderly population. Houston DK, et al. **Int J Vitam Nutr Res** 1997;67(3):183–91
Influence of the number of meals taken per day on cardiovascular risk factors and the energy and nutrient intakes of a group of elderly people. Redondo MR, et al. **Int J Vitam Nutr Res** 1997;67(3):176–82
Normal aging and cognitive impairment revisited [editorial] Bergener M. **Int Psychogeriatr** 1995 Winter;7(4):475–7
Prevalence and course of depression among elderly residential home admissions in Mannheim and Camden, London. Weyerer S, et al. **Int Psychogeriatr** 1995 Winter; 7(4):479–93
Age-associated changes in detrusor sensory function in women with lower urinary tract symptoms. Collas DM, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(1):24–9
Morphometry of the aging female rat urethra. Russell B, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(1):30–6
Exclusion of TIMP3 as a candidate locus in age-related macular degeneration. De La Paz MA, et al. **Invest Ophthalmol Vis Sci** 1997 May;38(6):1060–5
On the Stiles-Crawford effect with age. DeLint PJ, et al. **Invest Ophthalmol Vis Sci** 1997 May;38(6):1271–4
Development and aging of cell topography in the human retinal pigment epithelium. Harman AM, et al. **Invest Ophthalmol Vis Sci** 1997 Sep;38(10):2016–26
Accommodation and presbyopia in the human eye. Changes in the anterior segment and crystalline lens with focus. Koretz JF, et al. **Invest Ophthalmol Vis Sci** 1997 Mar; 38(3):569–78
Biomechanical characteristics of the human anterior lens capsule in relation to age. Krag S, et al. **Invest Ophthalmol Vis Sci** 1997 Feb;38(2):357–63
Long-term caloric restriction delays age-related decline in proliferation capacity of murine lens epithelial cells in vitro and in vivo. Li Y, et al. **Invest Ophthalmol Vis Sci** 1997 Jan;38(1):100–7
Age-related ocular blood flow changes. Ravalico G, et al. **Invest Ophthalmol Vis Sci** 1996 Dec;37(13):2645–50
Age-related changes in human blinks. Passive and active changes in eyelid kinematics. Sun WS, et al. **Invest Ophthalmol Vis Sci** 1997 Jan;38(1):92–9
Function and visual impairment in a population-based study of older adults. The SEE project. Salisbury Eye Evaluation. West SK, et al. **Invest Ophthalmol Vis Sci** 1997 Jan;38(1):72–82
Age-related changes in human anterior cruciate ligament (ACL) collagen fibrils. Strocchi R, et al. **Ital J Anat Embryol** 1996 Oct-Dec;101(4):213–20
Age affects glutathione content and glutathione-transferase activity in human gastric mucosa. Loguercio C, et al. **Ital J Gastroenterol** 1996 Dec;28(9):477–81
Vibrotactile threshold in young and old observers: the effects of spatial summation and the presence of a rigid surround. Goble AK, et al. **J Acoust Soc Am** 1996 Apr;99(4 Pt 1):2256–69
Measures of tuning and suppression in single-fiber and whole-nerve responses in young and quiet-aged gerbils. Hellstrom LI, et al. **J Acoust Soc Am** 1996 Nov; 100(5):3275–85
Influences of age, viral load, and CD4+ count on the rate of progression of HIV-1 infection to AIDS. Transfusion Safety Study Group [letter] Operskalski EA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jul 1;15(3):243–4
Risk factors related to age-associated hearing loss in the speech frequencies. Brant LJ, et al. **J Am Acad Audiol** 1996 Jun;7(3):152–60
Auditory temporal processing in elderly listeners. Fitzgibbons PJ, et al. **J Am Acad Audiol** 1996 Jun;7(3):183–9
Binaural performance and aging. Grose JH. **J Am Acad Audiol** 1996 Jun;7(3):168–74
Speech understanding in the elderly. Humes LE. **J Am Acad Audiol** 1996 Jun;7(3):161–7
Anatomic and physiologic aging: a behavioral neuroscience perspective. Willott JF. **J Am Acad Audiol** 1996 Jun; 7(3):141–51 (60 ref.)
Cognitive factors in auditory performance: context, speed of processing, and constraints of memory. Wingfield A. **J Am Acad Audiol** 1996 Jun;7(3):175–82
Aging-associated endothelial dysfunction in humans is reversed by L-arginine. Chauhan A, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1796–804
Influence of age on the effect of bidirectional cavopulmonary anastomosis on left ventricular volume, mass and ejection fraction. Forbes TJ, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1301–7
Age-dependent changes in cardiac muscarinic receptor function in healthy volunteers. Poller U, et al. **J Am Coll Cardiol** 1997 Jan;29(1):187–93
Age dependency of left ventricular diastolic function in pressure overload hypertrophy. Villari B, et al. **J Am Coll Cardiol** 1997 Jan;29(1):181–6
Age considerations in nutrient needs for bone health: older adults. Heaney RP. **J Am Coll Nutr** 1996 Dec;15(6):575–8 (19 ref.)
Age considerations in nutrient needs for bone health. Miller GD, et al. **J Am Coll Nutr** 1996 Dec;15(6):553–5 (23 ref.)
The impact of advanced age on the results of carotid endarterectomy: an outcome analysis. Perler BA. **J Am Coll Surg** 1996 Dec;183(6):559–64
The effect of color on perceived flavor intensity and acceptance of foods by young adults and elderly adults. Chan MM, et al. **J Am Diet Assoc** 1997 Jun;97(6):657–9
The Dietary Variety Score: assessing diet quality in healthy young and older adults. Drewnowski A, et al. **J Am Diet Assoc** 1997 Mar;97(3):266–71
Nutrition, exercise, and healthy aging. Evans WJ, et al. **J Am Diet Assoc** 1997 Jun;97(6):632–8 (44 ref.)
Position of the American Dietetic Association: nutrition,

aging, and the continuum of care. Weddle D, et al. **J Am Diet Assoc** 1996 Oct;96(10):1048–52 (46 ref.)

Aging and cancer: the double-edged sword of replicative senescence. Campisi J. **J Am Geriatr Soc** 1997 Apr; 45(4):482–8 (52 ref.)

Predictors of decline in manual performance in older adults. Hughes S, et al. **J Am Geriatr Soc** 1997 Aug;45(8):905–10

Gait changes in older adults: predictors of falls or indicators of fear? Maki BE. **J Am Geriatr Soc** 1997 Mar;45(3):313–20

Renal response to acute dietary protein loading in young and old people [letter] Mulkerrin E, et al. **J Am Geriatr Soc** 1997 Mar;45(3):389–91

"Senility" redefined as age-associated frontal system impairment? [letter; comment] Polk MS. **J Am Geriatr Soc** 1997 Mar;45(3):386–8. Comment on: J Am Geriatr Soc 1996 Jun;44(6):671–4.

Foot position awareness in younger and older men: the influence of footwear sole properties. Robbins S, et al. **J Am Geriatr Soc** 1997 Jan;45(1):61–6

What does cell death have to do with aging? Warner HR, et al. **J Am Geriatr Soc** 1997 Sep;45(9):1140–6 (104 ref.)

Pupillary dilation and funduscopy with 1.0% hydroxyamphetamine plus 0.25% tropicamide (Paremyd) versus tropicamide (0.5 or 1.0%) as a function of iris and skin pigmentation, and age. Cooper J, et al. **J Am Optom Assoc** 1996 Nov;67(11):669–75

Pharmacotherapy problems in the elderly. Steiner JF. **J Am Pharm Assoc (Wash)** 1996 Jul;NS36(7):431–7, 467

The age of the patient should be taken into account when interpreting Doppler assessed pulmonary artery pressures. Dib JC, et al. **J Am Soc Echocardiogr** 1997 Jan–Feb; 10(1):72–3

Influence of aging on left atrial appendage flow velocity patterns in normal subjects. Tabata T, et al. **J Am Soc Echocardiogr** 1996 May–Jun;9(3):274–80

Postnatal maturation of the Kallikrein–kinin system in the rat kidney: from enzyme activity to receptor gene expression. Bascands JL, et al. **J Am Soc Nephrol** 1996 Jan;7(1):81–9

Aging and the kidney. Epstein M. **J Am Soc Nephrol** 1996 Aug;7(8):1106–22 (135 ref.)

Effects of age on the role of atrial natriuretic factor in renal adaptation to physiologic variations of dietary salt intake. Leosco D, et al. **J Am Soc Nephrol** 1996 Jul;7(7):1045–51

The effects of ageing on wound healing: immunolocalisation of growth factors and their receptors in a murine incisional model. Ashcroft GS, et al. **J Anat** 1997 Apr;190 (Pt 3):351–65

Localised degeneration occurs in aged mouse olfactory epithelium [letter] Breckenridge LJ, et al. **J Anat** 1997 Jul; 191 (Pt 1):151–4

Blood supply to the human femoral diaphysis in youth and senescence. Bridgeman G, et al. **J Anat** 1996 Jun;188 (Pt 3):611–21

Histomorphometric study of age-related changes in remodelling activity of human desmodontal bone. Jäger A. **J Anat** 1996 Oct;189 (Pt 2):257–64

The influence of age and particle number on absorption of polystyrene particles from the rat gut. Seifert J, et al. **J Anat** 1996 Dec;189 (Pt 3):483–6

The hypogastric and thirteenth thoracic ganglia of the rat: effects of age on the neurons and their extracellular environment. Warburton AL, et al. **J Anat** 1997 Jan;190 (Pt 1):115–24

In the male brown–Norway (BN) male rat, reproductive aging is associated with decreased LH–pulse amplitude and area. Bonavera JJ, et al. **J Androl** 1997 Jul–Aug; 18(4):359–65

Effects of a 5 alpha-reductase inhibitor, finasteride, on the developing prostate and testis of a marsupial. Ryhorchuk AR, et al. **J Androl** 1997 Mar–Apr;18(2):123–30

Impaired germ cell development in the testes of immature rats with neonatal hypothyroidism. Simorangkir DR, et al. **J Androl** 1997 Mar–Apr;18(2):186–93

Testosterone and the aging male. Tenover JL. **J Androl** 1997 Mar–Apr;18(2):103–6 (14 ref.)

Metabolic changes during the transition from the fed to the acute feed–deprived state in prepuberal and mature gilts. Barb CR, et al. **J Anim Sci** 1997 Mar;75(3):781–9

Influence of realimentation of mature cows on maturity, color, collagen solubility, and sensory characteristics. Boleman SJ, et al. **J Anim Sci** 1996 Sep;74(9):2187–94

Growth, reproductive performance, mammary development, and milk production of beef heifers as influenced by prepubertal dietary energy and administration of bovine somatotropin. Buskirk DD, et al. **J Anim Sci** 1996 Nov; 74(11):2649–62

Effects of individual vs group penning on the performance of weanling pigs. Bustamante M, et al. **J Anim Sci** 1996 Jul;74(7):1457–61

Effects of dietary energy on scrotal surface temperature, seminal quality, and sperm production in young beef bulls. Coulter GH, et al. **J Anim Sci** 1997 Apr;75(4):1048–52

Influence of weaning age and nursery diet complexity on growth performance and carcass characteristics and composition of high-health status pigs from weaning to 109 kilograms. Dritz SS, et al. **J Anim Sci** 1996 Dec; 74(12):2975–84

Preweaning variables' influence on market traits in rabbits. Ferguson FA, et al. **J Anim Sci** 1997 Mar;75(3):611–21

Tenderness variation among loin steaks from A and C maturity carcasses of heifers similar in chronological age. Field R, et al. **J Anim Sci** 1997 Mar;75(3):693–9

Effect of age and pattern of gain on induction of puberty with a progestin in beef heifers. Hall JB, et al. **J Anim Sci** 1997 Jun;75(6):1606–11

Live animal performance, carcass traits, and meat palatability of calf- and yearling-fed cloned steers. Harris JJ, et al. **J Anim Sci** 1997 Apr;75(4):986–92

Insulin resistance, hyperglycemia, glucosuria, and galactosuria in intensively milk-fed calves: dependency on age and effects of high lactose intake. Hugi D, et al. **J Anim Sci** 1997 Feb;75(2):469–82

Lifetime lamb and wool production of targhee or Finn-Dorset-Targhee ewes managed as farm or range flock: I. Average annual ewe performance. Iman NY, et al. **J Anim Sci** 1996 Aug;74(8):1757–64

Predicting the yield and composition of mature cow carcasses. Johnson DD, et al. **J Anim Sci** 1997 Jul; 75(7):1831–6

Feed intake, body weight, body condition score, musculation, and immunocompetence in aged mares given equine somatotropin. Malinowski K, et al. **J Anim Sci** 1997 Mar; 75(3):755–60

Effect of L-carnitine and soybean oil on growth performance and body composition of early-weaned pigs. Owen KQ, et al. **J Anim Sci** 1996 Jul;74(7):1612–9

Influence of prepubertal feeding level on milk yield potential of dairy heifers: a review. Sejrsen K, et al. **J Anim Sci** 1997 Mar;75(3):828–35 (63 ref.)

Effects of time of weaning, supplement, and sire breed of calf during the fall grazing period on cow and calf performance. Short RE, et al. **J Anim Sci** 1996 Jul; 74(7):1701–10

Fertility in estrus-cycling and noncycling virgin heifers and suckled beef cows after induced ovulation. Stevenson JS, et al. **J Anim Sci** 1997 May;75(5):1343–50

The use of urea dilution for estimation of carcass composition of Holstein steers at 3, 6, 9, and 12 months of age. Velazco J, et al. **J Anim Sci** 1997 Jan;75(1):139–47

Food preference and acceptance of novel foods by lambs depend on the composition of the basal diet. Wang J, et al. **J Anim Sci** 1996 Oct;74(10):2349–54

Incidence of precocious puberty in developing beef heifers. Wehrman ME, et al. **J Anim Sci** 1996 Oct;74(10):2462–7

Pattern of feed intake and associated metabolic and endocrine changes differentially affect postweaning fertility in primiparous lactating sows. Zak LJ, et al. **J Anim Sci** 1997 Jan;75(1):208–16

Effect of feeding a milk replacer to early-weaned pigs on growth, body composition, and small intestinal morphology, compared with suckled littermates. Zijlstra RT, et al. **J Anim Sci** 1996 Dec;74(12):2948–59

Hypercapnic and hypoxic ventilatory responses [letter; comment] Abraham K, et al. **J Appl Physiol** 1996 Aug; 81(2):1033–4. Comment on: J Appl Physiol 1994 Jan;76(1):314–20.

Role of aerobic capacity and body mass index in the age-associated decline in heart rate variability. Byrne EA, et al. **J Appl Physiol** 1996 Aug;81(2):743–50

Fibrinolytic responses to acute physical activity in older hypertensive men. DeSouza CA, et al. **J Appl Physiol** 1997 Jun;82(6):1765–70

Age-related changes in the twitch contractile properties of human thenar motor units. Doherty TJ, et al. **J Appl Physiol** 1997 Jan;82(1):93–101

Maturational changes in responses of tissue and airway resistance to histamine. Dreshaj IA, et al. **J Appl Physiol** 1996 Oct;81(4):1785–91

Endurance exercise modulates neuromuscular junction of C57BL/6NNia aging mice. Fahim MA. **J Appl Physiol** 1997 Jul;83(1):59–66

Autonomic and behavioral thermoregulation in guinea pigs during postnatal maturation. Fewell JE, et al. **J Appl Physiol** 1997 Sep;83(3):830–6

Age-related declines in maximal aerobic capacity in regularly exercising vs. sedentary women: a meta-analysis. Fitzgerald MD, et al. **J Appl Physiol** 1997 Jul;83(1):160–5

Appendicular skeletal muscle mass: effects of age, gender, and ethnicity. Gallagher D, et al. **J Appl Physiol** 1997 Jul; 83(1):229–39

Altered fractal dynamics of gait: reduced stride-interval correlations with aging and Huntington's disease. Hausdorff JM, et al. **J Appl Physiol** 1997 Jan;82(1):262–9

Age, fitness, and regional blood flow during exercise in the heat. Ho CW, et al. **J Appl Physiol** 1997 Apr;82(4):1126–35

Reflex peripheral vasoconstriction is diminished in older men. Kenney WL, et al. **J Appl Physiol** 1996 Feb;80(2):512–5

Alterations in autonomic adjustments to acute hypoxia in conscious rats with aging. Kregel KC. **J Appl Physiol** 1996 Feb;80(2):540–6

Norepinephrine spillover at rest and during submaximal exercise in young and old subjects. Mazzeo RS, et al. **J Appl Physiol** 1997 Jun;82(6):1869–74

Body-mass dependence of age-related deterioration in human muscular function. Meltzer DE. **J Appl Physiol** 1996 Apr;80(4):1149–55

Twenty-year follow-up of aerobic power and body composition of older track athletes. Pollock ML, et al. **J Appl Physiol** 1997 May;82(5):1508–16

Age-related increases in diaphragmatic maximal shortening velocity. Powers SK, et al. **J Appl Physiol** 1996 Feb; 80(2):445–51

Skeletal muscle mass and the reduction of VO2max in trained older subjects. Proctor DN, et al. **J Appl Physiol** 1997 May; 82(5):1411–5

Weight loss and wrestling training: effects on nutrition, growth, maturation, body composition, and strength. Roemmich JN, et al. **J Appl Physiol** 1997 Jun;82(6):1751–9

Arterial and cardiopulmonary baroreflexes in 60- to 69- vs. 18- to 36-yr-old humans [see comments] Shi X, et al. **J Appl Physiol** 1996 Jun;80(6):1903–10. Comment in: J Appl Physiol 1997 Feb;82(2):716–8.

Muscle adaptations to hindlimb suspension in mature and old Fischer 344 rats. Stump CS, et al. **J Appl Physiol** 1997 Jun;82(6):1875–81

Delayed and diminished pressor response to muscle sympathetic nerve activity in the elderly. Sugiyama Y, et al. **J Appl Physiol** 1996 Mar;80(3):869–75

Exercise training improves lusitropy by isoproterenol in papillary muscles from aged rats. Taffet GE, et al. **J Appl Physiol** 1996 Oct;81(4):1488–94

Age and gender interactions in physiological functional capacity: insight from swimming performance. Tanaka H, et al. **J Appl Physiol** 1997 Mar;82(3):846–51

Cardiovascular responses to treadmill and cycle ergometer exercise in children and adults. Turley KR, et al. **J Appl Physiol** 1997 Sep;83(3):948–57

Curtailed respiration by repeated vs. isolated hypoxia in maturing piglets is unrelated to NTS ME or SP levels. Waters KA, et al. **J Appl Physiol** 1997 Aug;83(2):522–9

Aging, hyaluronidase removal of the cumulus, and microinjection do not affect the sperm binding potential of human oocytes. Barros A, et al. **J Assist Reprod Genet** 1997 Feb;14(2):97–101

Differences in ovarian stimulation among older and younger women with a diminished gonadal reserve. Lindheim SR, et al. **J Assist Reprod Genet** 1997 Apr;14(4):235–7

Effect of age on P300 wave. Jha S, et al. **J Assoc Physicians India** 1995 Jan;43(1):21–3

Transplanted sweat glands from mature and aged donors determine cholinergic phenotype and altered density of host sympathetic nerves [corrected and republished article originally printed in J Auton Nerv Syst 1996 May 6;58(3):153–62] Cowen T, et al. **J Auton Nerv Syst** 1996 Sep 12;60(3):215–24

Transplanted sweat glands from mature and aged donors determine cholinergic phenotype and altered density of host sympathetic nerves [corrected and republished in J Auton Nerv Syst 1996 Sep 12;60(3):215–24] Cowen T, et al. **J Auton Nerv Syst** 1996 May 6;58(3):153–62

Age-related changes in baroreflex control of heart rate and sympathetic nerve activity in healthy humans. Matsukawa T, et al. **J Auton Nerv Syst** 1996 Sep 12;60(3):209–12

Effects of aging and of chronic obstructive pulmonary disease on RR interval variability. Pagani M, et al. **J Auton Nerv Syst** 1996 Jul 5;59(3):125–32

Preservation of the cervical vagus nerve in aged rats: morphometric and enzyme histochemical evidence. Soltanpour N, et al. **J Auton Nerv Syst** 1996 Aug 27; 60(1–2):93–101

Age-related changes in the reactivity of postsynaptic adrenoceptors in the rat vas deferens: differences between the epididymal and prostatic portion. Markus RP, et al. **J Auton Pharmacol** 1997 Jun;17(3):147–54

Distribution of deaths from ischemic heart disease and stroke. Environmental and aging influences in men and women. Stoupel E, et al. **J Basic Clin Physiol Pharmacol** 1996; 7(4):303–19

Maturational differences in chlorpyrifos-oxonase activity may contribute to age-related sensitivity to chlorpyrifos. Mortensen SR, et al. **J Biochem Toxicol** 1996;11(6):279–87

Des-(27–31)C-peptide. A novel secretory product of the rat pancreatic beta cell produced by truncation of proinsulin connecting peptide in secretory granules. Verchere CB, et al. **J Biol Chem** 1996 Nov 1;271(44):27475–81

Age-related changes in light-induced Jun-B and Jun-D expression: effects of transplantation of fetal tissue containing the suprachiasmatic nucleus. Cai A, et al. **J Biol Rhythms** 1996 Dec;11(4):284–90

Estimating the endogenous circadian temperature rhythm without keeping people awake. Carrier J, et al. **J Biol Rhythms** 1997 Jun;12(3):266–77

Photoperiod nonresponsive Siberian hamsters: effect of age on the probability of nonresponsiveness. Freeman DA, et al. **J Biol Rhythms** 1997 Apr;12(2):110–21

Long-term fitness training improves the circadian rest-activity rhythm in healthy elderly males. Van Someren EJ, et al. **J Biol Rhythms** 1997 Apr;12(2):146–56

Age-related differences in post-yield damage in human cortical bone. Experiment and model. Courtney AC, et al. **J Biomech** 1996 Nov;29(11):1463–71

The effects of ageing and changes in mineral content in degrading the toughness of human femora. Currey JD, et al. **J Biomech** 1996 Feb;29(2):257–60

Postural control in young and elderly adults when stance is perturbed: dynamics. Gu MJ, et al. **J Biomech** 1996 Mar; 29(3):319–29

Effects of aging on titanium implants inserted into the tibiae of female rats using light microscopy, SEM, and image processing. Takeshita F, et al. **J Biomed Mater Res** 1997 Jan;34(1):1–8

Age-related changes in the compressive strength of cancellous bone. The relative importance of changes in density and trabecular architecture. McCalden RW, et al. **J Bone Joint Surg Am** 1997 Mar;79(3):421–7

'Stress' distributions inside intervertebral discs. The effects of age and degeneration. Adams MA, et al. **J Bone Joint Surg Br** 1996 Nov;78(6):965–72

Age-related changes in osteogenic stem cells in mice. Bergman RJ, et al. **J Bone Miner Res** 1996 May; 11(5):568–77

Correlation of trabecular bone structure with age, bone mineral density, and osteoporotic status: in vivo studies in the distal radius using high resolution magnetic resonance imaging. Majumdar S, et al. **J Bone Miner Res** 1997 Jan;12(1):111–8

Bone density in Type 1 Gaucher disease. Pastores GM, et al. **J Bone Miner Res** 1996 Nov;11(11):1801–7

From density to structure: growing up and growing old on the surfaces of bone. Seeman E. **J Bone Miner Res** 1997 Apr;12(4):509–21 (88 ref.)

Influence of physical activity on vertebral deformity in men and women: results from the European Vertebral Osteoporosis Study. Silman AJ, et al. **J Bone Miner Res** 1997 May;12(5):813–9

Nonuniform anisotropy is responsible for age-related slowing of atrioventricular nodal reentrant tachycardia. Anselme F, et al. **J Cardiovasc Electrophysiol** 1996 Dec; 7(12):1145–53

Effect of aging on arteriolar dilatation induced by prostaglandin E(1) incorporated in lipid microspheres. Hirose M, et al. **J Cardiovasc Pharmacol** 1996 May; 27(5):749–51

Aging and refractive surgery [editorial; comment] Rosen ES. **J Cataract Refract Surg** 1996 Jul–Aug;22(6):641–2. Comment on: J Cataract Refract Surg 1996 Jul–Aug;22(6):686–9.

Expression of epidermal growth factor-related proteins in the aged adult mouse mammary gland and their relationship to tumorigenesis. Herrington EE, et al. **J Cell Physiol** 1997 Jan;170(1):47–56

From newborn to adult: phenotypic and functional properties of skin equivalent and human skin as a function of donor age. Michel M, et al. **J Cell Physiol** 1997 May;171(2):179–89

The influence of age of pH regulation in hippocampal slices before, during, and after anoxia. Roberts EL Jr, et al. **J Cereb Blood Flow Metab** 1997 May;17(5):560–6

Effect of aging on regulation of brain stem circulation during hypotension. Toyoda K, et al. **J Cereb Blood Flow Metab** 1997 Jun;17(6):680–5

The temporal and spatial development of corticotropin-releasing factor (CRF) binding sites and CRF afferents in the opossum cerebellum. Madtes PC Jr, et al. **J Chem Neuroanat** 1996 Oct;11(4):231–41

Selective decline of 5-HT1A receptor binding sites in rat cortex, hippocampus and cholinergic basal forebrain nuclei during aging. Nyakas C, et al. **J Chem Neuroanat** 1997 Jun;13(1):53–61

Pipecuronium revisited: dose-response and maintenance requirement in infants, children, and adults. Meretoja OA, et al. **J Clin Anesth** 1997 Mar;9(2):125–9

Age-associated sarcopenia--issues in the use of testosterone as an anabolic agent in older men [editorial; comment] Bhasin S, et al. **J Clin Endocrinol Metab** 1997 Jun; 82(6):1659–60. Comment on: J Clin Endocrinol Metab 1997 Jun;82(6):1661–7.

Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback. Chapman IM, et al. **J Clin Endocrinol Metab** 1997 Sep; 82(9):2996–3004

Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. Chapuy MC, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1129–33

Changes in quantitative bone histomorphometry in aging healthy men. Clarke BL, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2264–70

Lack of relationship between vitamin D receptor genotype and forearm bone gain in healthy children, adolescents, and young adults. Gunnes M, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):851–5

Aging and renal responsiveness to parathyroid hormone in healthy men. Halloran BP, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2192–7

Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. Klein NA, et al. **J Clin Endocrinol Metab** 1996 Mar; 81(3):1038–45

Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins. Meikle AW, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):571–5

Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids. Pontiroli AE, et al. **J Clin Endocrinol Metab** 1996 Nov; 81(11):3998–4001

Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated GH secretion in healthy adults. Vahl N, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2209–15

Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study [see comments] Vergnaud P, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):719–24. Comment in: J Clin Endocrinol Metab 1997 Mar;82(3):717–8.

Effect of age and severity of disability on short-term variation in walking speed: the Women's Health and Aging Study. Ferrucci L, et al. **J Clin Epidemiol** 1996 Oct; 49(10):1089–96

Effect of test duration on age-related differences in Stroop interference. Klein M, et al. **J Clin Exp Neuropsychol** 1997 Feb;19(1):77–82

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. Wang Y, et al. **J Clin Invest** 1997 Jun 15;99(12):2883–9

Development of adult-type inhibitory glycine receptors in the central auditory system of rats. Friauf E, et al. **J Comp Neurol** 1997 Aug 18;385(1):117–34

Postnatal development of GAP-43 immunoreactivity in the auditory brainstem of the rat. Horváth M, et al. **J Comp Neurol** 1997 May 26;382(1):104–15

Plasticity of the auditory brainstem: effects of cochlear ablation on GAP-43 immunoreactivity in the rat. Illing RB, et al. **J Comp Neurol** 1997 May 26;382(1):116–38

Neurogenesis in juvenile and adult ring doves. Ling C, et al. **J Comp Neurol** 1997 Mar 10;379(2):300–12

Relationship of gonadotropin-releasing hormone (GnRH) neurons to the olfactory system in developing lamprey (Petromyzon marinus). Tobet SA, et al. **J Comp Neurol** 1996 Dec 2;376(1):97–111

Effects of age on milk yield: time trends and method of adjustment. Khan MS, et al. **J Dairy Sci** 1996 Jun; 79(6):1057–64

Microvascular luminal volume changes in aged mouse periodontal ligament. Sims MR, et al. **J Dent Res** 1996 Jul;75(7):1503–11

Age-related discontinuous changes in the in vivo fluorescence of human facial skin. Takema Y, et al. **J Dermatol Sci** 1997 May;15(1):55–8

Postnatal maturation of autonomic modulation of heart rate. Assessments of parasympathetic and sympathetic efferent function in the developing canine heart. Pickoff AS, et al. **J Electrocardiol** 1996;29 Suppl:215–22

Role of the neuronal histaminergic system in the regulation of somatotropic function: comparison between the neonatal and the adult rat. Grilli R, et al. **J Endocrinol** 1996 Nov; 151(2):195–201

Event-related potentials differentiate the effects of aging on word and nonword repetition in explicit and implicit memory tasks. Swick D, et al. **J Exp Psychol Learn Mem Cogn** 1997 Jan;23(1):123–42

Development of hearing and vocalization in a marsupial, the Northern Quoll, Dasyurus hallucatus. Aitkin L, et al. **J Exp Zool** 1996 Dec 15;276(6):394–402

Achalasia in patients over 65. Simmons DB, et al. **J Fla Med Assoc** 1997 Feb;84(2):101–3

Relationship between age and clinical characteristics of patients with gastric cancer. Lo SS, et al. **J Gastroenterol Hepatol** 1996 Jun;11(6):511–4

Measuring prognosis and case mix in hospitalized elders. The importance of functional status [see comments] Covinsky KE, et al. **J Gen Intern Med** 1997 Apr;12(4):203–8. Comment in: J Gen Intern Med 1997 Apr;12(4):254–5.

Ethnic differences in insulin resistance and its consequences in older Mexican American and non-Hispanic white women. Aguirre MA, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):M56–60

Fidelity assurance mechanisms of the brain with special reference to its immunogenic CNS compartment: their role in aging and aging-associated neurological disease. Blumenthal HT. **J Gerontol A Biol Sci Med Sci** 1997 Jan; 52(1):B1–9 (96 ref.)

Abilities to turn suddenly while walking: effects of age, gender, and available response time. Cao C, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar;52(2):M88–93

Cytokine antagonists in aged subjects and their relation with cellular immunity. Catania A, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar;52(2):B93–7

A study of caloric restriction and cardiovascular aging in cynomolgus monkeys (Macaca fascicularis): a potential model for aging research. Cefalu WT, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):B10–9

Altered neuroendocrine control of GH secretion in normal women of advanced reproductive age. Coiro V, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):M254–8

Correlates of performance-based measures of muscle function in the elderly: the Cardiovascular Health Study. Hirsch CH, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul; 52(4):M192–200

Age patterns of the life table aging rate for major causes of death in Japan, 1951–1990. Horiuchi S, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):B67–77

Postmenopausal acceleration of age-related mortality increase. Horiuchi S. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):B78–92

Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. Khorram O, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):M1–7

Changes in neural modulation and motor control during voluntary movement of older individuals. Leonard CT, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):M320–5

The influence of age on isometric and isotonic rat detrusor contractions. Lieu PK, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar;52(2):M94–6

Skeletal muscle fatigue and endurance in young and old men and women. Lindström B, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):B59–66

Age-related changes in compensatory stepping in response to unpredictable perturbations. McIlroy WE, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov;51(6):M289–96

Age-associated loss of power and strength in the upper extremities in women and men. Metter EJ, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):B267–76

Candidate biomarkers of aging: age-sensitive indices of immune and muscle function covary in genetically heterogeneous mice. Miller RA, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):B39–47

Balance and skeletal alignment in a group of elderly female fallers and nonfallers. O'Brien K, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):B221–6

Age-associated changes in blood pressure in a longitudinal study of healthy men and women. Pearson JD, et al. **J Gerontol A Biol Sci Med Sci** 1997 May;52(3):M177–83

Alterations in atrial natriuretic peptide (ANP) secretion and renal effects in aging. Pollack JA, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):B196–202

Eccentric peak torque of the plantar and dorsiflexors is maintained in older women. Porter MM, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar;52(2):B125–31

Leg extension power and walking speed in very old people living independently. Rantanen T, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):M225–31

Self-paced resistance training and walking exercise in community-dwelling older adults: effects on neuromotor performance. Rooks DS, et al. **J Gerontol A Biol Sci Med Sci** 1997 May;52(3):M161–8

Effect of age and caloric restriction on cutaneous wound closure in rats and monkeys. Roth GS, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar;52(2):B98–102

Application of bioelectrical impedance analysis to elderly populations. Roubenoff R, et al. **J Gerontol A Biol Sci Med Sci** 1997 May;52(3):M129–36

Influence of fat intake and caloric restriction on bone in aging male rats. Sanderson JP, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):B20–5

Dopaminergic responses in the Fischer 344 rat heart: preserved chronotropic and dromotropic responses with aging. Schwartz JB. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):M36–43

Differences in muscle endurance and recovery between fallers and nonfallers, and between young and older women. Schwendner KI, et al. **J Gerontol A Biol Sci Med Sci** 1997 May;52(3):M155–60

The relationship between dehydration and parotid salivary gland function in young and older healthy adults. Ship JA, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):M310–9

The effects of two types of cognitive tasks on postural stability in older adults with and without a history of falls. Shumway-Cook A, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):M232–40

Age differences in using a rapid step to regain balance during a forward fall. Thelen DG, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):M8–13

Sleep disorders and aging: understanding the causes. Vitiello MV. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):M189–91 (23 ref.)

Same-sex and cross-sex relationships. Akiyama H, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):P374–82

Aging and motor control. Chaput S, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):P346–55

Adult age differences in source recall: a population-based study. Erngrund K, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):P335–45

Double jeopardy, aging as leveler, or persistent health inequality? A longitudinal analysis of white and black Americans. Ferraro KF, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):S319–28

The relation of religious preference and practice to depressive symptoms among 1,855 older adults. Kennedy GJ, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):P301–8

The interactive effect of perceived control and functional status on health and mortality among young-old and old-old adults. Menec VH, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52(3):P118–26

Irrelevant speech effect in aging: an assessment of inhibitory processes in working memory. Rouleau N, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):P356–63

Interrelations of age, visual acuity, and cognitive functioning. Salthouse TA, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):P317–30

Controlled and automatic forms of memory and attention: process purity and the uniqueness of age-related influences. Salthouse TA, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Sep;52(5):P216–28

Baseline performance and learning rate of procedural and declarative memory tasks: younger versus older adults. Vakil E, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Sep; 52(5):P229–34

Enzymes protective of oxidative damage present in all decades of life in the trabecular meshwork, as detected by two-dimensional gel electrophoresis protein maps. Russell P, et al. **J Glaucoma** 1996 Oct;5(5):317–24

Ulnar variance and age. Sanderson PL, et al. **J Hand Surg [Br]** 1997 Feb;22(1):21–4

Double jeopardy to health hypothesis for African Americans: analysis and critique. Ferraro KF, et al. **J Health Soc Behav** 1996 Mar;37(1):27–43

Education, age, and the cumulative advantage in health. Ross CE, et al. **J Health Soc Behav** 1996 Mar;37(1):104–20

Corpus callosum axons in the developing visual cortex of the gerbil revealed by DiI and Fluorogold. Hilbig H, et al. **J Hirnforsch** 1997;38(1):119–23

Ontogeny of locomotion in mountain gorillas and chimpanzees. Doran DM. **J Hum Evol** 1997 Apr; 32(4):323–44

Effects of aging on left ventricular–arterial coupling in man: assessment by means of arterial effective and left ventricular elastances. Cohen-Solal A, et al. **J Hum Hypertens** 1996 Feb;10(2):111–6

Electrolytes are associated with blood pressure at old age: the Rotterdam Study. Geleijnse JM, et al. **J Hum Hypertens** 1997 Jul;11(7):421–3

I/D polymorphism of the angiotensin–converting enzyme gene does not predict isolated systolic or systolic–diastolic hypertension in the elderly. Johnson AG, et al. **J Hum Hypertens** 1996 Mar;10(3):167–9

Ambulatory daytime blood pressure in relation to age and gender compared to previous population studies based on office blood pressure. The Danish Study Group on Ambulatory Blood Pressure. Nielsen PE, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S55–8

White–coat hypertension and cardiac organ damage in elderly subjects. Rizzo V, et al. **J Hum Hypertens** 1996 May;10(5):293–8

Ageing induces left ventricular concentric remodelling in normotensive subjects. Ganau A, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1818–22

Dietary electrolyte intake and blood pressure in older subjects: the Rotterdam Study [see comments] Geleijnse JM, et al. **J Hypertens** 1996 Jun;14(6):737–41. Comment in: J Hypertens 1996 Dec;14(12):1491.

Methodological aspects in the assessment of circadian blood pressure variation in the elderly--authors' reply [letter; comment] James MA, et al. **J Hypertens** 1996 Jun; 14(6):807–8. Comment on: J Hypertens 1996 Mar;14(3):411–2.

Postprandial hypotension and orthostatic blood pressure responses in elderly Parkinson's disease patients. Loew F, et al. **J Hypertens** 1995 Nov;13(11):1291–7

Effect of ageing and hypertension on endothelial modulation of ouabain–induced contraction and sodium pump activity in the rat aorta. Ponte A, et al. **J Hypertens** 1996 Jun; 14(6):705–12

Developmental regulation of transforming growth factor–beta 1 responses and vascular smooth muscle growth in spontaneously hypertensive rats. Saltis J, et al. **J Hypertens** 1995 Dec;13(12 Pt 1):1441–8

Vascular network changes in the retina with age and hypertension. Stanton AV, et al. **J Hypertens** 1995 Dec; 13(12 Pt 2):1724–8

Hypertension in the elderly. Hansson L. **J Hypertens Suppl** 1996 Oct;14(3):S17–21 (31 ref.)

Concomitant diseases in elderly hypertensives: the position of nicardipine. Zannad F. **J Hypertens Suppl** 1996 Oct; 14(3):S37–40 (34 ref.)

Daytime sleepiness and napping amongst the elderly in relation to somatic health and medical treatment. Asplund R. **J Intern Med** 1996 Mar;239(3):261–7

Calcific degeneration of the aortic valve in old age: is the development of flow obstruction predictable? [see comments] Iivanainen AM, et al. **J Intern Med** 1996 Mar; 239(3):269–73. Comment in: J Intern Med 1996 Jul;240(1):43–4.

Developmental susceptibility to intestinal injury by platelet–activating factor in the newborn rat. Bhatia AM, et al. **J Invest Surg** 1996 Sep–Oct;9(5):351–8

Non–heme (Fe3+) in the lung increases with age in both humans and rats. Ghio AJ, et al. **J Lab Clin Med** 1997 Jan;129(1):53–61

Pierre Robin syndrome: characteristics of hearing loss, effect of age on hearing level and possibilities in therapy planning. Handžić–Cuk J, et al. **J Laryngol Otol** 1996 Sep; 110(9):830–5

Correlation between steady–state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters. Woo J, et al. **J Med** 1995; 26(5–6):279–94

Cortical elasticity in aging rats with and without growth hormone treatments. Kohles SS, et al. **J Med Eng Technol** 1996 Jul–Oct;20(4–5):157–63

Excitation–calcium release uncoupling in aged single human skeletal muscle fibers. Delbono O, et al. **J Membr Biol** 1995 Dec;148(3):211–22

Dihydropyridine receptor–ryanodine receptor uncoupling in aged skeletal muscle. Renganathan M, et al. **J Membr Biol** 1997 Jun 1;157(3):247–53

Effects of caffeine and cyclopiazonic acid on contractile proteins of adult and newborn ferret cardiac fibres. Bonnet V, et al. **J Mol Cell Cardiol** 1996 Jun;28(6):1287–95

Differential effects of hypothyroidism on Na–K–ATPase mRNA alpha isoforms in the developing rat brain. Chaudhury S, et al. **J Mol Neurosci** 1996 Fall;7(3):229–34

Spatial and temporal patterns of myosin heavy chain expression in developing rat extraocular muscle. Brueckner JK, et al. **J Muscle Res Cell Motil** 1996 Jun;17(3):297–312

Simultaneously evoked primary and cognitive visual evoked potentials distinguish younger and older patients with Parkinson's disease. Antal A, et al. **J Neural Transm** 1996; 103(8–9):1053–67

Age–related decrease in responsiveness to L–DOPA is not due to changes in dopamine receptor mRNAs or G protein mRNAs. Murata M, et al. **J Neural Transm** 1996; 103(3):343–8

Regional differences of serotonin–mediated synaptic plasticity in the chicken spinal cord with development and aging. Chen L, et al. **J Neural Transplant Plast** 1997 Jan–Mar;6(1):41–8

Morphometric analysis of hippocampal pyramidal neurons in situ and in grafts developing in the anterior eye chambers of young and aged Wistar rats. Zhuravleva ZN, et al. **J Neural Transplant Plast** 1997 Jan–Mar;6(1):49–57

Neuronal precursors of the adult rat subependymal zone persist into senescence, with no decline in spatial extent or response to BDNF. Goldman SA, et al. **J Neurobiol** 1997 Jun 5;32(6):554–66

Specificity and development of innervation pattern of Xenopus pectoralis muscle. Grinnell AD, et al. **J Neurobiol** 1996 Dec;31(4):415–32

Male–male courtship behavior induced by ectopic expression of the Drosophila white gene: role of sensory function and age. Hing AL, et al. **J Neurobiol** 1996 Aug;30(4):454–64

Atrophy and degeneration of peptidergic neurons and cessation of egg laying in the aging pond snail Lymnaea stagnalis. Janse C, et al. **J Neurobiol** 1996 Feb;29(2):202–12

Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons. Andersen JK, et al. **J Neurochem** 1996 Nov; 67(5):2164–71

Oxidant injury in PC12 cells--a possible model of calcium "dysregulation" in aging: II. Interactions with membrane lipids. Denisova NA, et al. **J Neurochem** 1997 Sep; 69(3):1259–66

Differential expression of ciliary neurotrophic factor receptor in skeletal muscle of chick and rat after nerve injury. Ip FC, et al. **J Neurochem** 1996 Oct;67(4):1607–12

Evidence that glyceraldehyde–3–phosphate dehydrogenase is involved in age–induced apoptosis in mature cerebellar neurons in culture. Ishitani R, et al. **J Neurochem** 1996 Mar;66(3):928–35

Oxidant injury in PC12 cells--a possible model of calcium "dysregulation" in aging: I. Selectivity of protection against oxidative stress. Joseph JA, et al. **J Neurochem** 1997 Sep; 69(3):1252–8

Accumulation of DNA damage in aging neurons occurs through a mechanism other than apoptosis. Mandavilli BS, et al. **J Neurochem** 1996 Oct;67(4):1559–65

Glutamate uptake impairment and neuronal damage in young and aged rats in vivo. Massieu L, et al. **J Neurochem** 1997 Sep;69(3):1151–60

Developmental regulation of interstitial cell density in bullfrog skeletal muscle. Connor EA. **J Neurocytol** 1997 Jan;26(1):23–32

Age–related changes in the morphology of preganglionic neurons projecting to the rat hypogastric ganglion. Dering MA, et al. **J Neurocytol** 1996 Oct;25(10):555–63

Functional consequences of changes in NMDA receptor subunit expression during development. Feldmeyer D, et al. **J Neurocytol** 1996 Dec;25(12):857–67 (80 ref.)

Axon–glial relationships in early CNS–PNS transitional zone development: an ultrastructural study. Fraher JP. **J Neurocytol** 1997 Jan;26(1):41–52

Gonadotropin–releasing hormone (GnRH) neurons of the developing tectum of the mouse. Wu TJ, et al. **J Neuroendocrinol** 1995 Dec;7(12):899–902

Macrophage infiltration at the neuromuscular junction does not contribute to AChR loss and age–related resistance to EAMG. Hoedemaekers A, et al. **J Neuroimmunol** 1997 May;75(1–2):147–55

Effect of aging on dopaminergic receptors and uptake sites in the rat brain studied by receptor autoradiography. Araki T, et al. **J Neurol Sci** 1997 May 29;148(2):131–7

Brain aging in a sample of normal Egyptians cognition, education, addiction and smoking. Elwan O, et al. **J Neurol Sci** 1997 May 1;148(1):79–86

Parkinson's disease, cognition and aging. Clinical, neuropsychological, electrophysiological and cranial computerized tomographic assessment. Elwan OH, et al. **J Neurol Sci** 1996 Nov;143(1–2):64–71

Auditory and inspiratory gasp–evoked sympathetic skin response: age effects. Hay JE, et al. **J Neurol Sci** 1997 May 1;148(1):19–23

Age–related changes in cerebral MR angiography. Kajiya Y, et al. **J Neurol Sci** 1997 Feb 12;145(2):195–203

The pathogenesis of senile plaques. Dickson DW. **J Neuropathol Exp Neurol** 1997 Apr;56(4):321–39 (166 ref.)

Microglial cell activation in aging and Alzheimer disease: partial linkage with neurofibrillary tangle burden in the hippocampus. DiPatre PL, et al. **J Neuropathol Exp Neurol** 1997 Feb;56(2):143–9

DNA damage distribution in the human brain as shown by in situ end labeling; area–specific differences in aging and Alzheimer disease in the absence of apoptotic morphology. Lucassen PJ, et al. **J Neuropathol Exp Neurol** 1997 Aug; 56(8):887–900

Dystrophic axonal swellings develop as a function of age and diabetes in human dorsal root ganglia. Schmidt RE, et al. **J Neuropathol Exp Neurol** 1997 Sep;56(9):1028–43

In situ labeling of dying cortical neurons in normal aging and in Alzheimer's disease: correlations with senile plaques and disease progression. Troncoso JC, et al. **J Neuropathol Exp Neurol** 1996 Nov;55(11):1134–42

Electrophysiological correlates of seizure sensitivity in the dentate gyrus of epileptic juvenile and adult gerbils. Buckmaster PS, et al. **J Neurophysiol** 1996 Oct; 76(4):2169–80

Age–related impaired reflex sensitivity in a human hand muscle. Corden DM, et al. **J Neurophysiol** 1996 Oct; 76(4):2701–6

Glycine at the NMDA receptor in cat visual cortex: saturation and changes with age. Czepita D, et al. **J Neurophysiol** 1996 Jan;75(1):311–7

Different mechanisms regulate IPSC kinetics in early postnatal and juvenile hippocampal granule cells. Draguhn A, et al. **J Neurophysiol** 1996 Dec;76(6):3983–93

Decreased duration of Ca(2+)–mediated plateau potentials in striatal neurons from aged rats. Dunia R, et al. **J Neurophysiol** 1996 Oct;76(4):2353–63

Stimulation at 1–5 Hz does not produce long–term depression or depotentiation in the hippocampus of the adult rat in vivo. Errington ML, et al. **J Neurophysiol** 1995 Oct; 74(4):1793–9

GABAA receptor function in developing rat thalamic reticular neurons: whole cell recordings of GABA–mediated currents and modulation by clonazepam. Gibbs JW 3rd, et al. **J Neurophysiol** 1996 Oct;76(4):2568–79

Synaptically evoked prolonged depolarizations in the developing auditory system. Kotak VC, et al. **J Neurophysiol** 1995 Oct;74(4):1611–20

High–voltage–activated calcium currents in basal forebrain neurons during aging. Murchison D, et al. **J Neurophysiol** 1996 Jul;76(1):158–74

Physiology of the aged Fischer 344 rat inferior colliculus: responses to contralateral monaural stimuli. Palombi PS, et al. **J Neurophysiol** 1996 Nov;76(5):3114–25

Age–related loss of activity of auditory–nerve fibers. Schmiedt RA, et al. **J Neurophysiol** 1996 Oct; 76(4):2799–803

Age–related differences in neural activity during memory encoding and retrieval: a positron emission tomography study. Cabeza R, et al. **J Neurosci** 1997 Jan 1;17(1):391–400

Aging changes in voltage–gated calcium currents in hippocampal CA1 neurons. Campbell LW, et al. **J Neurosci** 1996 Oct 1;16(19):6286–95

Role of Olf–1 and Pax–6 transcription factors in neurodevelopment. Davis JA, et al. **J Neurosci** 1996 Aug 15;16(16):5082–94

The generation of neuronal heterogeneity in a rat sensory ganglion. Hall AK, et al. **J Neurosci** 1997 Apr 15; 17(8):2775–84

Slow kinetics of miniature IPSCs during early postnatal development in granule cells of the dentate gyrus. Hollrigel GS, et al. **J Neurosci** 1997 Jul 1;17(13):5119–28

An adult–like pattern of ocular dominance columns in striate cortex of newborn monkeys prior to visual experience. Horton JC, et al. **J Neurosci** 1996 Mar 1;16(5):1791–807

Developmental influence of glycinergic transmission: regulation of NMDA receptor–mediated EPSPs. Kotak VC, et al. **J Neurosci** 1996 Mar 1;16(5):1836–43

Selective alteration of long–term potentiation–induced transcriptional response in hippocampus of aged, memory–impaired rats. Lanahan A, et al. **J Neurosci** 1997 Apr 15;17(8):2876–85

Fetal transplants alter the development of function after spinal cord transection in newborn rats. Miya D, et al. **J Neurosci** 1997 Jun 15;17(12):4856–72

Increased susceptibility to induction of long–term depression and long–term potentiation reversal during aging. Norris CM, et al. **J Neurosci** 1996 Sep 1;16(17):5382–92

Developing neonatal rat sympathetic and sensory neurons differ in their regulation of 5–HT3 receptor expression. Rosenberg M, et al. **J Neurosci** 1997 Sep 1;17(17):6629–38

Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. Sánchez I, et al. **J Neurosci** 1996 Aug 15;16(16):5095–105

The effect of aging on experience–dependent plasticity of hippocampal place cells. Shen J, et al. **J Neurosci** 1997 Sep 1;17(17):6769–82

Three–dimensional organization of smooth endoplasmic reticulum in hippocampal CA1 dendrites and dendritic spines of the immature and mature rat. Spacek J, et al. **J Neurosci** 1997 Jan 1;17(1):190–203

A pacemaker current in dye–coupled hilar interneurons contributes to the generation of giant GABAergic potentials in developing hippocampus. Strata F, et al. **J Neurosci** 1997 Feb 15;17(4):1435–46

Brain aging: changes in the nature of information coding by the hippocampus. Tanila H, et al. **J Neurosci** 1997 Jul 1; 17(13):5155–66

Brain aging: impaired coding of novel environmental cues. Tanila H, et al. **J Neurosci** 1997 Jul 1;17(13):5167–74

Transforming growth factor–alpha null and senescent mice show decreased neural progenitor cell proliferation in the forebrain subependyma. Tropepe V, et al. **J Neurosci** 1997 Oct 15;17(20):7850–9

The clustering of axonal sodium channels during development of the peripheral nervous system. Vabnick I, et al. **J Neurosci** 1996 Aug 15;16(16):4914–22

Maturation of neuronal form and function in a mouse thalamo–cortical circuit. Warren RA, et al. **J Neurosci** 1997 Jan 1;17(1):277–95

Insensitivity of the hippocampus to environmental stimulation during postnatal development. Waters NS, et al. **J Neurosci** 1997 Oct 15;17(20):7967–73

Proliferation in the rat olfactory epithelium: age-dependent changes. Weiler E, et al. **J Neurosci** 1997 May 15; 17(10):3610–22

CaM I mRNA is localized to apical dendrites during postnatal development of neurons in the rat brain. Berry FB, et al. **J Neurosci Res** 1996 Mar 1;43(5):565–75

Differential expression of Na,K-ATPase alpha-isoform mRNAs in aging rat cerebellum. Chauhan N, et al. **J Neurosci Res** 1997 Feb 1;47(3):287–99

Serotonergic function of aging hippocampal CA3 pyramidal neurons: electrophysiological assessment following administration of 5,7-dihydroxytryptamine in the fimbria-fornix and cingulum bundle. Dugar A, et al. **J Neurosci Res** 1997 Jan 1;47(1):58–67

Gene localization and developmental expression of light chain 3: a common subunit of microtubule-associated protein 1A(MAP1A) and MAP1B. Mann SS, et al. **J Neurosci Res** 1996 Mar 1;43(5):535–44

Target and afferents interact to control developmental cell death in the mesencephalic parabigeminal nucleus of the rat. Piñón LG, et al. **J Neurosci Res** 1996 Jul 15; 45(2):174–82

Impaired synaptic functions with aging as characterized by decreased calcium influx and acetylcholine release. Tanaka Y, et al. **J Neurosci Res** 1996 Jan 1;43(1):63–76

Mortality rates, hospital length of stay, and the cost of treating subarachnoid hemorrhage in older patients: institutional and geographical differences. Taylor CL, et al. **J Neurosurg** 1997 Apr;86(4):583–8

Posttraumatic hyperemia in immature, mature, and aged rats: autoradiographic determination of cerebral blood flow. Biagas KV, et al. **J Neurotrauma** 1996 Apr;13(4):189–200

Age-specific determinants of stunting in Filipino children. Adair LS, et al. **J Nutr** 1997 Feb;127(2):314–20

Evidence for nervous system degeneration with advancing age. Lexell J. **J Nutr** 1997 May;127(5 Suppl):1011S–1013S (34 ref.)

Sarcopenia: origins and clinical relevance. Rosenberg IH. **J Nutr** 1997 May;127(5 Suppl):990S–991S (2 ref.)

Funds for nutrition related research. Aging. Starke-Reed PE. **J Nutr** 1996 Oct;126(10):2593–4

Optical density of the human lens. Xu J, et al. **J Opt Soc Am A** 1997 May;14(5):953–60

Alterations in the mechanical behavior of the human lumbar nucleus pulposus with degeneration and aging. Iatridis JC, et al. **J Orthop Res** 1997 Mar;15(2):318–22

Relationship between bone growth rate and hypertrophic chondrocyte volume in New Zealand white rabbits of varying ages. Kuhn JL, et al. **J Orthop Res** 1996 Sep; 14(5):706–11

Walking speed: reference values and correlates for older adults. Bohannon RW, et al. **J Orthop Sports Phys Ther** 1996 Aug;24(2):86–90

Analysis of heart rate variability demonstrates effects of development on vagal modulation of heart rate in healthy children [see comments] Goto M, et al. **J Pediatr** 1997 May; 130(5):725–9. Comment in: J Pediatr 1997 May;130(5):691–3.

Maturation of motility and motor inhibition in rapid-eye-movement sleep. Kohyama J, et al. **J Pediatr** 1997 Jan;130(1):117–22

Human aging and the GH-IGF-I axis. Ghigo E, et al. **J Pediatr Endocrinol Metab** 1996 Jun;9 Suppl 3:271–8 (74 ref.)

The association of gut-associated lymphoid tissue and bacterial translocation in the newborn rabbit. Urao M, et al. **J Pediatr Surg** 1996 Nov;31(11):1482–7

The effect of age on the expression of mineralized tissue progenitors in the periodontium--the effect of bFGF. Pitaru S, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):179–82

Age-related changes of the cementogenesis in the senescence-accelerated mouse (SAM). Sashima M, et al. **J Periodontal Res** 1996 Oct;31(7):470–6

Age-related changes in [3H]nimodipine and [3H]rolipram binding in the rat brain. Araki T, et al. **J Pharm Pharmacol** 1997 Mar;49(3):310–4

Percutaneous absorption of salicylic acid after repeated (14-day) in vivo administration to normal, acnegenic or aged human skin. Davis DA, et al. **J Pharm Sci** 1997 Aug; 86(8):896–9

Aging and glucocorticoids: effects on cell signaling mediated through adenylyl cyclase. Slotkin TA, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):478–91

pH regulation in single CA1 neurons acutely isolated from the hippocampi of immature and mature rats. Bevensee MO, et al. **J Physiol (Lond)** 1996 Jul 15;494 (Pt 2):315–28

The magnitude of the initial injury induced by stretches of maximally activated muscle fibres of mice and rats increases in old age. Brooks SV, et al. **J Physiol (Lond)** 1996 Dec 1;497 (Pt 2):573–80

Development of carotid chemoreceptor dynamic and steady-state sensitivity to CO2 in the newborn lamb. Calder NA, et al. **J Physiol (Lond)** 1997 Aug 15;503 (Pt 1):187–94

Postnatal development of the pattern of respiratory and cardiovascular response to systemic hypoxia in the piglet: the roles of adenosine. Elnazir B, et al. **J Physiol (Lond)** 1996 Apr 15;492 (Pt 2):573–85

Properties of single motor units in medial gastrocnemius muscles of adult and old rats. Kadhiresan VA, et al. **J Physiol (Lond)** 1996 Jun 1;493 (Pt 2):543–52

Thyroid hormone effects on contractility and myosin composition of soleus muscle and single fibres from young and old rats. Li X, et al. **J Physiol (Lond)** 1996 Jul 15;494 (Pt 2):555–67

Invariance of the pattern electroretinogram evoked by psychophysically equivalent stimuli in human ageing. Muir JA, et al. **J Physiol (Lond)** 1996 Dec 15;497 (Pt 3):825–35

Thyroid hormone regulates postnatal expression of transient K+ channel isoforms in rat ventricle. Shimoni Y, et al. **J Physiol (Lond)** 1997 Apr 1;500 (Pt 1):65–73

Tongue motor skills and masticatory performance in adult dentates, elderly dentates, and complete denture wearers. Koshino H, et al. **J Prosthet Dent** 1997 Feb;77(2):147–52

Melatonin, sleep, aging, and the health protection branch [editorial] Young SN. **J Psychiatry Neurosci** 1996 May; 21(3):161–4 (34 ref.)

In response: senescence, cancer and endogenous parasites [letter] Charlton BG. **J R Coll Physicians Lond** 1996 May-Jun;30(3):270

Senescence, cancer and 'endogenous parasites': a salutogenic hypothesis. Charlton BG. **J R Coll Physicians Lond** 1996 Jan-Feb;30(1):10–2 (22 ref.)

Age-related refractive shifts in simple myopia [see comments] Ellingsen KL, et al. **J Refract Surg** 1997 May-Jun; 13(3):223–8. Comment in: J Refract Surg 1997 May-Jun;13(3):213–5.

An evolution of exercise physiology: effects of exercise on functional independence with aging and physical disabilities [editorial] Glaser RM. **J Rehabil Res Dev** 1997 Jul; 34(3):vi–viii

Immunocytochemical and quantitative study of actin, desmin and vimentin in the peritubular cells of the testes from elderly men. Arenas MI, et al. **J Reprod Fertil** 1997 May; 110(1):183–93

Prolongation of duration of ovulation in ageing mice. Ishikawa H, et al. **J Reprod Fertil** 1996 Nov;108(2):167–70

An international comparison of the estimated effect of the aging of the population on the major cause of disablement, musculoskeletal disorders. Badley EM, et al. **J Rheumatol** 1995 Oct;22(10):1934–40

Blood pressure and age-dependent changes of endothelium-dependent tension oscillations in different strains of spontaneously hypertensive rats. Shimamura K, et al. **J Smooth Muscle Res** 1996 Aug;32(4):145–54

Electrophysiological indices of lexical processing: the effects of verb complexity and age. Rubin SS, et al. **J Speech Hear Res** 1996 Oct;39(5):1071–80

Reflex responses of lip muscles in young and older women. Wohlert AB. **J Speech Hear Res** 1996 Jun;39(3):578–89

Perioral muscle activity in young and older adults during speech and nonspeech tasks. Wohlert AB. **J Speech Hear Res** 1996 Aug;39(4):761–70

Developmental changes in laryngeal and respiratory function with variations in sound pressure level. Stathopoulos ET, et al. **J Speech Lang Hear Res** 1997 Jun;40(3):595–614

Comparison of female geriatric lumbar-extension strength: asymptotic versus chronic low back pain patients and their response to active rehabilitation. Holmes B, et al. **J Spinal Disord** 1996 Feb;9(1):17–22

Low intensity physical training in older subjects. De Vito G, et al. **J Sports Med Phys Fitness** 1997 Mar;37(1):72–7

Blood platelet function in healthy individuals of different ages. Effects of exercise and exercise conditioning. Gonzales F, et al. **J Sports Med Phys Fitness** 1996 Jun; 36(2):112–6

Reliability concept as a trend in biophysics of aging. Koltover VK. **J Theor Biol** 1997 Jan 21;184(2):157–63 (44 ref.)

Mature pulmonary lobar transplants grow in an immature environment. Binns OA, et al. **J Thorac Cardiovasc Surg** 1997 Aug;114(2):186–94

Maturation alters the pulmonary arterial response to hypoxia and inhaled nitric oxide in the presence of endothelial dysfunction. Myers JL, et al. **J Thorac Cardiovasc Surg** 1997 Feb;113(2):270–7

The impact of aging on penile hemodynamics in normal responders to pharmacological injection: a Doppler sonographic study [see comments] Chung WS, et al. **J Urol** 1997 Jun;157(6):2129–31. Comment in: J Urol 1997 Jun;157(6):2139.

Urethral closure pressure changes with age in men. Hammerer P, et al. **J Urol** 1996 Nov;156(5):1741–3

Urodynamic analysis of age-related changes of alpha 1-adrenoceptor responsiveness in female beagle dogs. Takahashi S, et al. **J Urol** 1996 Oct;156(4):1485–8

Effect of age and outlet resistance on rabbit urinary bladder emptying. Yu HJ, et al. **J Urol** 1997 Sep;158(3 Pt 1):924–30

Relationship between age-dependent changes of bovine neutrophil functions and their intracellular Ca2+ concentrations. Higuchi H, et al. **J Vet Med Sci** 1997 Apr; 59(4):271–6

The possibility of early estimation for fertility in bovine heterosexual twin females. Satoh S, et al. **J Vet Med Sci** 1997 Mar;59(3):221–2

Speaking Fo and cepstral periodicity analysis of conversational speech in a 105-year-old woman: variability of aging effects. Max L, et al. **J Voice** 1996 Sep;10(3):245–51

Physical activity and quality of life in older adults [editorial; comment] [see comments] Buchner DM. **JAMA** 1997 Jan 1;277(1):64–6. Comment on: JAMA 1996 Jan 1;277(1):25–31. Comment on: JAMA 1996 Jan 1;277(1):32–7. Comment in: JAMA 1997 Apr 2;277(13):1034–5.

The mature stomach. Still pumping out acid? [editorial; comment] Feldman M. **JAMA** 1997 Aug 27;278(8):681–2 . Comment on: JAMA 1997 Aug 27;278(8):659–62.

Gastric acidity in older adults [see comments] Hurwitz A, et al. **JAMA** 1997 Aug 27;278(8):659–62. Comment in: JAMA 1997 Aug 27;278(8):681–2.

Age-related effects of norepinephrine on rat ventricular hypertrophy. Hamada H, et al. **Jpn Heart J** 1997 May; 38(3):433–43

Effects of bifemelane on muscarinic receptors and choline acetyltransferase in the brains of aged rats following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries. Egashira T, et al. **Jpn J Pharmacol** 1996 Sep;72(1):57–65

aFGF, endogenous satiety substance, facilitates learning, memory and immune function in aging. Oomura Y, et al. **Jpn J Physiol** 1997;47 Suppl 1:S52–4

Renal function in the elderly: impact of hypertension and cardiac function. Fliser D, et al. **Kidney Int** 1997 Apr; 51(4):1196–204

Cellular mechanisms of the age-related decrease in renal phosphate reabsorption. Sorribas V, et al. **Kidney Int** 1996 Sep;50(3):855–63

Protein glycation in the kidney: role in diabetes and aging. Vlassara H. **Kidney Int** 1996 Jun;49(6):1795–804 (69 ref.)

Aging abolishes the renal response to L-arginine infusion in essential hypertension. Campo C, et al. **Kidney Int Suppl** 1996 Jun;55:S126–8

A longitudinal study of the natural history of growth post-transplantation. Tejani A, et al. **Kidney Int Suppl** 1996 Jan;53:103–8

The prevalence of diabetic complication of elderly diabetics in Himeji. Asami M, et al. **Kobe J Med Sci** 1995 Dec; 41(6):187–95

Elderly pilots [letter] Devianne L, et al. **Lancet** 1997 May 31;349(9065):1629–30

Aging of the normal nose in adults. Edelstein DR. **Laryngoscope** 1996 Sep;106(9 Pt 2):1–25 (132 ref.)

Contemporary management of the aging brow and forehead. Koch RJ, et al. **Laryngoscope** 1997 Jun;107(6):710–5

Variation of nasal respiratory pattern with age during growth and development. Laine-Alava MT, et al. **Laryngoscope** 1997 Mar;107(3):386–90

Influence of age on the 'nasal cycle'. Mirza N, et al. **Laryngoscope** 1997 Jan;107(1):62–6

Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. Bassan R, et al. **Leuk Lymphoma** 1996 Jul;22(3-4):295–301

Unravelling of physiological functions of retinoic acid using a dominant-negative retinoic acid receptor. Kakizuka A. **Leukemia** 1997 Apr;11 Suppl 3:378–9

Zinc and metallothioneins on cellular immune effectiveness during liver regeneration in young and old mice. Mocchegiani E, et al. **Life Sci** 1997;61(12):1125–45

Phospholipid composition of neonatal guinea pig liver and plasma: effect of postnatal food restriction. Hunt AN, et al. **Lipids** 1996 May;31(5):489–95

Effect of age on alteration of glutathione metabolism following chronic cigarette smoke inhalation in mice. Teramoto S, et al. **Lung** 1996;174(2):119–26

Ageing and ovarian hormones. Proceedings of the International Menopause Symposium. Tampere, Finland, 23-24 March 1995. **Maturitas** 1996 May;23 Suppl:S1–90

Female voice changes around and after the menopause--an initial investigation. Boulet MJ, et al. **Maturitas** 1996 Feb; 23(1):15–21

Age-related changes in body composition of healthy and osteoporotic women. Martini G, et al. **Maturitas** 1997 May; 27(1):25–33

Aging and detoxifying enzymes responses to hypoxic or hyperoxic treatment. Amicarelli F, et al. **Mech Ageing Dev** 1997 Sep;97(3):215–26

Body temperature and nesting behavior following influenza challenge in mice: effects of age. Bender BS, et al. **Mech Ageing Dev** 1996 Jan 5;86(1):1–9

The prolongation of survival in mice by dietary antioxidants depends on their age by the start of feeding this diet. Bezlepkin VG, et al. **Mech Ageing Dev** 1996 Dec 20; 92(2-3):227–34

Age-dependent prolactin-releasing activity of nucleoproteins. Brown OA, et al. **Mech Ageing Dev** 1996 Aug 15;89(2):103–11

cAMP signaling mechanisms with aging in rats. Chin JH, et al. **Mech Ageing Dev** 1996 Jan 5;86(1):11–26

Short-term caloric restriction augments age-related decreases in gastrin content and release. Chu KU, et al. **Mech Ageing Dev** 1996 May 24;87(1):25–33

Sexual dimorphism in the age changes of the pituitary lactotrophs in rats. Cónsole GM, et al. **Mech Ageing Dev** 1997 May;95(3):157–66

Elevated frequency of the C2 allele of the ETS-1 oncogene in elderly subjects. Crossen PE, et al. **Mech Ageing Dev** 1996 Jul 5;88(1-2):61–5

Age and temperature related changes in behavioral and physiological performance in the Peromyscus leucopus mouse. Duffy PH, et al. **Mech Ageing Dev** 1997 Apr; 95(1-2):43–61

Effect of age on the vasodilatory action of elastin peptides. Faury G, et al. **Mech Ageing Dev** 1997 Apr;95(1-2):31–42

Glomerular capillary network of cortical nephrons is reduced in male but not in female aging rats. Francois V, et al. **Mech Ageing Dev** 1996 Oct 4;91(1):11–22

Blood lipoproteins and their effect on contractile function

of vessels in rats of different age. Frolkis VV, et al. **Mech Ageing Dev** 1997 Sep;97(3):207–14

IL–6, DHEA and the ageing process. James K, et al. **Mech Ageing Dev** 1997 Feb;93(1–3):15–24

Effects of age and gender on the AII–induced stimulation of prolactin release and inositol phosphate accumulation in rat anterior pituitary cells in vitro. Janik JM, et al. **Mech Ageing Dev** 1997 Apr;95(1–2):113–30

A tumor preventive effect of dietary restriction is antagonized by a high housing temperature through deprivation of torpor. Koizumi A, et al. **Mech Ageing Dev** 1996 Nov 29;92(1):67–82

Aging and the dendritic morphology of the rat laterodorsal and pedunculopontine tegmental nuclei. Lolova IS, et al. **Mech Ageing Dev** 1997 Sep;97(3):193–205

Influence of dietary restriction on ionotropic glutamate receptors during aging in C57B1 mice. Magnusson KR. **Mech Ageing Dev** 1997 May;95(3):187–202

Age–associated changes in lymphoid and antigen–presenting cell functions in mice immunized with Trypanosoma cruzi antigens. Maletto BA, et al. **Mech Ageing Dev** 1996 Jul 5;88(1–2):39–47

Effects of calorie restriction and aging on the expression of antioxidant enzymes and ubiquitin in the liver of Emory mice. Mura CV, et al. **Mech Ageing Dev** 1996 Oct 25; 91(2):115–29

Premature thymic involution, observed at the ultrastructural level, in two lineages of human–SOD–1 transgenic mice. Nabarra B, et al. **Mech Ageing Dev** 1997 Jun;96(1–3):59–73

The magnocellular neurosecretory system of the hamster hypothalamus: an ultrastructural and morphometric study during lifetime. Navarro A, et al. **Mech Ageing Dev** 1997 Aug;97(2):143–61

Ultrastructural and quantitative study of atypical age–related bodies in the hamster brain. Navarro A, et al. **Mech Ageing Dev** 1996 Sep 9;90(1):75–90

Swimming training improves brown–adipose–tissue activity in young and old mice. Oh–ishi S, et al. **Mech Ageing Dev** 1996 Aug 15;89(2):67–78

Insulin exposure controls the rate of mammalian aging. Parr T. **Mech Ageing Dev** 1996 Jul 5;88(1–2):75–82 (45 ref.)

Excessive apoptosis of mature T lymphocytes is a characteristic feature of human immune senescence. Phelouzat MA, et al. **Mech Ageing Dev** 1996 Jul 5; 88(1–2):25–38

Glycation mediated crosslinking between alpha–crystallin and MP26 in intact lens membranes. Prabhakaram M, et al. **Mech Ageing Dev** 1996 Oct 4;91(1):65–78

The impact of ischemia on wound healing is increased in old age but can be countered by hyperbaric oxygen therapy. Quirinia A, et al. **Mech Ageing Dev** 1996 Oct 25; 91(2):131–44

Enhanced cell proliferation and biosynthesis mediate improved wound repair in refed, caloric–restricted mice. Reed MJ, et al. **Mech Ageing Dev** 1996 Jul 31;89(1):21–43

Differential survival, natural selection, and the manifestation of senescence. Riggs JE. **Mech Ageing Dev** 1996 Jun 7; 87(2):91–8

Influence of physical exercise on aging rats: I. Life–long exercise preserves patterns of spontaneous activity. Skalicky M, et al. **Mech Ageing Dev** 1996 Jun 7;87(2):127–39

The effect of multiparity and lactation periods on the graft versus host reactivity of thymocytes and splenocytes from aging C57BL mice. Skowron–Cendrzak A, et al. **Mech Ageing Dev** 1996 Oct 4;91(1):1–10

In vitro study of gingival fibroblasts from normal and inflamed tissue: age–related responsiveness. Solmi R, et al. **Mech Ageing Dev** 1996 Nov 29;92(1):31–41

Evidence for senescent convergence during human aging. Spencer RP, et al. **Mech Ageing Dev** 1996 Nov 13; 91(3):185–94 (26 ref.)

Quantitative age–related changes in apical dendrites and dendritic spines of CA1 pyramidal neurons among senescence accelerated mice (SAMP1TA/Ngs). Wasowicz I, et al. **Mech Ageing Dev** 1996 Sep 9;90(1):63–73

Human biological decline and mortality rates. Weale RA. **Mech Ageing Dev** 1997 Jul;97(1):55–72

Sensitivity of the segmental renal arterioles to angiotensin II in the aging rat. Zhang XZ, et al. **Mech Ageing Dev** 1997 Aug;97(2):183–92

Hypertension, aging, and atherosclerosis. The endothelial interface. Susic D. **Med Clin North Am** 1997 Sep; 81(5):1231–40 (55 ref.)

Ageing as upregulation failure. MacGibbon MF. **Med Hypotheses** 1996 Jun;46(6):523–7

Premature ageing: the link between psychosocial risk factors and disease. Nilsson PM. **Med Hypotheses** 1996 Jul; 47(1):39–42

What good is it to get old? Nusbaum NJ. **Med Hypotheses** 1996 Aug;47(2):77–9

Deleterious network hypothesis of aging. Ying W. **Med Hypotheses** 1997 Feb;48(2):143–8 (71 ref.)

Motor neurone disease and the life of motor neurones [letter; comment] Vaux DL, et al. **Med J Aust** 1997 Jan 20; 166(2):109, discussion 109–10. Comment on: Med J Aust 1996 Aug 19;165(4):180–1.

Acceleration plethysmography to evaluate aging effect in cardiovascular system. Using new criteria of four wave patterns. Takada H, et al. **Med Prog Technol** 1996–97; 21(4):205–10

Isometric intermittent endurance of four muscle groups in men aged 20–74 yr. Bemben MG, et al. **Med Sci Sports Exerc** 1996 Jan;28(1):145–54

The reproducibility of the Bruce protocol exercise test for the determination of aerobic capacity in older women. Fielding RA, et al. **Med Sci Sports Exerc** 1997 Aug; 29(8):1109–13

Changes in aerobic power of women, ages 20–64 yr. Jackson AS, et al. **Med Sci Sports Exerc** 1996 Jul;28(7):884–91

Adrenergic vascular control. Mano T. **Med Sci Sports Exerc** 1996 Oct;28(10 Suppl):S85–9

Age and cardiac output during cycle exercise in thermoneutral and warm environments. Minson CT, et al. **Med Sci Sports Exerc** 1997 Jan;29(1):75–81

Inhibition of histamine release by nedocromil sodium reduces exercise–induced hypoxemia in master athletes. Préfaut C, et al. **Med Sci Sports Exerc** 1997 Jan;29(1):10–6

Cardiovascular and peak VO2 responses to supine exercise: effects of age and training status. Proctor DN, et al. **Med Sci Sports Exerc** 1996 Jul;28(7):892–9

Effects of progressive resistance training on immune response in aging and chronic inflammation. Rall LC, et al. **Med Sci Sports Exerc** 1996 Nov;28(11):1356–65

Age–related differences in episodic odour recognition: the role of access to specific odour names. Larsson M, et al. **Memory** 1997 May;5(3):361–78

Effect of nitric oxide synthase inhibitor on age–related changes in second messenger systems and calcium channels in rats. Araki T, et al. **Metab Brain Dis** 1996 Mar; 12(1):83–92

Lack of deterioration of insulin action with aging in the GK rat: a contrasted adaptation as compared with nondiabetic rats. Berthelier C, et al. **Metabolism** 1997 Aug;46(8):890–6

Effects of aging on dehydroepiandrosterone sulfate in relation to fasting insulin levels and body composition assessed by bioimpedance analysis. Denti L, et al. **Metabolism** 1997 Jul; 46(7):826–32

Metabolically active component of fat–free body mass: influences of age, adiposity, and gender. Gallagher D, et al. **Metabolism** 1996 Aug;45(8):992–7

Alterations in key gluconeogenic regulators with age and endurance training. Horn DB, et al. **Metabolism** 1997 Apr; 46(4):414–9

Decreased glucose tolerance, not decreased insulin sensitivity, is a maturational abnormality in the male offspring of a parent with early coronary artery disease. Slyper AH, et al. **Metabolism** 1997 May;46(5):504–12

Effects of single nightly injections of growth hormone–releasing hormone (GHRH 1–29) in healthy elderly men. Vittone J, et al. **Metabolism** 1997 Jan; 46(1):89–96

Citicoline improves memory performance in elderly subjects. Alvarez XA, et al. **Methods Find Exp Clin Pharmacol** 1997 Apr;19(3):201–10

Challenging the clock. Doctor's research may help prevent aging. Ward RD. **Mich Med** 1996 Sep;95(9):46–7

Age–related differences in intestinal arteriolar responses to venous pressure elevation in the rat. Gosche JR, et al. **Microcirculation** 1996 Dec;3(4):395–400

Laser Doppler flux characteristics at the skin of the dorsum of the foot in young and in elderly healthy human subjects. Van den Brande P, et al. **Microvasc Res** 1997 Mar; 53(2):156–62

Operative and postoperative evaluation and management in the elderly. Abyad A. **Middle East J Anesthesiol** 1995 Oct; 13(3):291–306 (33 ref.)

Age–dependent alterations of c–fos and growth regulation in human fibroblasts expressing the HPV16 E6 protein. Yan Y, et al. **Mol Biol Cell** 1996 Jun;7(6):975–83

Proteasome inactivation upon aging and on oxidation–effect of HSP 90. Conconi M, et al. **Mol Biol Rep** 1997 Mar; 24(1–2):45–50

Role of reactive oxygen species in cardiovascular aging. Muscari C, et al. **Mol Cell Biochem** 1996 Jul–Aug; 160–161:159–66 (72 ref.)

Heterogeneity of growth hormone (GH)–producing cells in aging male rats: in vitro GH releasing activity of somatotrope subpopulations. Dobado–Berrios PM, et al. **Mol Cell Endocrinol** 1996 Oct 30;123(2):127–37

Netrin and netrin receptor expression in the embryonic mammalian nervous system suggests roles in retinal, striatal, nigral, and cerebellar development. Livesey FJ, et al. **Mol Cell Neurosci** 1997;8(6):417–29

Oxidative stress and age–related neuronal deficits. Joseph JA, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):35–40

Chronic nicotine treatment prevents neuronal loss in neocortex resulting from nucleus basalis lesions in young adult and aged rats. Socci DJ, et al. **Mol Chem Neuropathol** 1996 Apr;27(3):285–305

Use of subunit–specific antisense oligodeoxynucleotides to define developmental changes in the properties of N–methyl–D–aspartate receptors. Zhong J, et al. **Mol Pharmacol** 1996 Sep;50(3):631–8

In vivo aging of oocytes influences the behavior of nuclei transferred to enucleated rabbit oocytes. Adenot PG, et al. **Mol Reprod Dev** 1997 Mar;46(3):325–36

Cytoskeletal alteration in aged porcine oocytes and parthenogenesis. Kim NH, et al. **Mol Reprod Dev** 1996 Apr; 43(4):513–8

Propagation velocity of muscle action potentials in the growing normal child. Malmström JE, et al. **Muscle Nerve** 1997 Apr;20(4):403–10

Age–related changes in muscle calcium content in dystrophin–deficient mdx mice. Reeve JL, et al. **Muscle Nerve** 1997 Mar;20(3):357–60

Age–related changes in motor unit function. Roos MR, et al. **Muscle Nerve** 1997 Jun;20(6):679–90 (128 ref.)

Sarcopenia and physical performance in old age. Proceedings of a workshop. Bethesda, Maryland, July 9–10, 1996. **Muscle Nerve Suppl** 1997;5:S1–120

Age–related changes in neuromuscular innervation. Balice–Gordon RJ. **Muscle Nerve Suppl** 1997;5:S83–7 (24 ref.)

Quantifying physical functional performance in older adults. Cress ME. **Muscle Nerve Suppl** 1997;5:S17–20 (5 ref.)

Sarcopenia and physical performance in old age: overview. Dutta C, et al. **Muscle Nerve Suppl** 1997;5:S5–9 (15 ref.)

Age–related changes in contractile properties and expression of myosin isoforms in single skeletal muscle cells. Larsson L, et al. **Muscle Nerve Suppl** 1997;5:S74–8

Blood flow and substrate exchange in skeletal muscle of man: techniques relevant for use in the study of the ageing process of muscle. Saltin B. **Muscle Nerve Suppl** 1997; 5:S107–9 (12 ref.)

What leads to age and gender differences in balance maintenance and recovery? Schultz AB, et al. **Muscle Nerve Suppl** 1997;5:S60–4 (15 ref.)

Sarcopenia and physical performance in old age: introduction. Schwartz RS. **Muscle Nerve Suppl** 1997; 5:S10–2 (3 ref.)

Targeting disabled and at risk older adults for inclusion in population based studies. Williamson JD, et al. **Muscle Nerve Suppl** 1997;5:S21–6 (12 ref.)

The effect of donor age on the processing of UV–damaged DNA by cultured human cells: reduced DNA repair capacity and increased DNA mutability. Moriwaki S, et al. **Mutat Res** 1996 Oct 18;364(2):117–23

Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. Weindruch R, et al. **N Engl J Med** 1997 Oct 2;337(14):986–94 (69 ref.)

Cognition in ageing [letter; comment] Pennington H. **N Z Med J** 1996 Sep 27;109(1030):368. Comment on: N Z Med J 1996 May 24;109(1022):195.

Multistability of cognitive maps in the hippocampus of old rats. Barnes CA, et al. **Nature** 1997 Jul 17;388(6639):272–5

Differences in acetylcholine– and bradykinin–induced vasorelaxation of the mesenteric vascular bed in spontaneously hypertensive rats of different ages. Wirth KJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jun; 354(1):38–43

Variations in steroid hormone receptor content throughout age and menopausal periods, and menstrual cycle in breast cancer patients. Nikolić–Vukosavljević D, et al. **Neoplasma** 1996;43(3):163–9

Renal Disease and Ageing. Proceedings of the 1st International Symposium. Modena, Italy, September 15–16, 1995. **Nephrol Dial Transplant** 1996;11 Suppl 9:1–112

Ageing and the renin–angiotensin system [editorial] Anderson S. **Nephrol Dial Transplant** 1997 Jun;12(6):1093–4

Renal haemodynamics in the elderly. Fliser D, et al. **Nephrol Dial Transplant** 1996;11 Suppl 9:2–8 (92 ref.)

Renal function in the elderly—is the dogma of an inexorable decline of renal function correct? [editorial] Fliser D, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1553–5

Prognostic markers in older patients starting renal replacement therapy. Jassal SV, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):1052–7

Nutrition, ageing and GFR: is age–associated decline inevitable? Kimmel PL, et al. **Nephrol Dial Transplant** 1996; 11 Suppl 9:85–8

Neurobiological substrates of behavioral decline: models and data analytic strategies for individual differences in aging. Baxter MG, et al. **Neurobiol Aging** 1996 May–Jun; 17(3):491–5

Age–related prefrontal alterations during auditory memory. Chao LL, et al. **Neurobiol Aging** 1997 Jan–Feb;18(1):87–95

Dopaminergic function in the neostriatum and nucleus accumbens of young and aged Fischer 344 rats. Crawford CA, et al. **Neurobiol Aging** 1997 Jan–Feb;18(1):57–66

Effects of age upon interhemispheric EEG coherence in normal adults. Duffy FH, et al. **Neurobiol Aging** 1996 Jul–Aug;17(4):587–99

A stereological study on the nuclear volume of cerebellar granule cells in aging rats. Henrique RM, et al. **Neurobiol Aging** 1997 Mar–Apr;18(2):199–203

Brain–behavior linkages in aged rodent models: strategies for examining individual differences. Ingram DK. **Neurobiol Aging** 1996 May–Jun;17(3):497–9; discussion 500

Overloading a muscle does not alter the rate of motoneuronal loss in aged rats. Kanda K, et al. **Neurobiol Aging** 1996 Jul–Aug;17(4):613–7

Astrocytes, brain aging, and neurodegeneration. Langston W. **Neurobiol Aging** 1996 May–Jun;17(3):483–5; discussion 488–90

A further evaluation of the effect of age on striate cortex of the rhesus monkey. Peters A, et al. **Neurobiol Aging** 1997 Jan–Feb;18(1):29–36

Increased dendritic extent in hippocampal CA1 neurons from aged F344 rats. Pyapali GK, et al. **Neurobiol Aging** 1996 Jul–Aug;17(4):601–11

Individual differences in aging: implications for stereological studies of neuron loss. Rapp PR, et al. **Neurobiol Aging** 1996 May–Jun;17(3):495–6; discussion 500

Age–related decrease in cholinergic synaptic transmission in three hippocampal subfields. Shen J, et al. **Neurobiol Aging** 1996 May–Jun;17(3):439–51

Trace eyeblink conditioning in rabbits demonstrates heterogeneity of learning ability both between and within age groups. Thompson LT, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):619-29

Inhibitory avoidance and appetitive learning in aged normal mice: comparison with transgenic mice having elevated plasma growth hormone levels. Meliska CJ, et al. **Neurobiol Learn Mem** 1997 Jul;68(1):1-12

Protein kinases selectively modulate apoptosis in the developing retina in vitro. Varella MH, et al. **Neurochem Int** 1997 Aug;31(2):217-27

Responses of mature and aged sympathetic neurons to laminin and NGF: an in vitro study. Cowen T, et al. **Neurochem Res** 1997 Aug;22(8):1003-11

Age-related ischemia in the brain following bilateral carotid artery occlusion--collateral blood flow and brain metabolism. He Z, et al. **Neurochem Res** 1997 Jan; 22(1):37-42

In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection. Stuiver BT, et al. **Neurodegeneration** 1996 Jun;5(2):153-9

Function of the GH/IGF-1 axis in healthy middle-aged male runners. Ambrosio MR, et al. **Neuroendocrinology** 1996 Jun; 63(6):498-503

Structural sexual dimorphisms in the anteroventral periventricular nucleus of the rat hypothalamus are sensitive to gonadal steroids perinatally, but develop peripubertally. Davis EC, et al. **Neuroendocrinology** 1996 Feb;63(2):142-8

Combined dexamethasone/CRH test in rats: hypothalamo-pituitary-adrenocortical system alterations in aging. Hatzinger M, et al. **Neuroendocrinology** 1996 Nov; 64(5):349-56

Age-dependent suppression of nocturnal growth hormone levels during sleep deprivation. Mullington J, et al. **Neuroendocrinology** 1996 Sep;64(3):233-41

Effect of somatostatin-28 on growth hormone response to growth hormone-releasing hormone--impact of aging and lifelong dietary restriction. Shimokawa I, et al. **Neuroendocrinology** 1997 May;65(5):369-76

Hexarelin stimulation of growth hormone release and mRNA levels in an infant and adult rat model of impaired GHRH function. Torsello A, et al. **Neuroendocrinology** 1997 Feb; 65(2):91-7

Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. Wilkinson CW, et al. **Neuroendocrinology** 1997 Jan;65(1):79-90

Talking while walking: the effect of a dual task in aging and Alzheimer's disease. Camicioli R, et al. **Neurology** 1997 Apr;48(4):955-8

Hippocampal formation size predicts declining memory performance in normal aging. Golomb J, et al. **Neurology** 1996 Sep;47(3):810-3

Ovarian steroids and the brain: implications for cognition and aging. McEwen BS, et al. **Neurology** 1997 May;48(5 Suppl 7):S8-15 (90 ref.)

Age-related reduction in functional MRI response to photic stimulation. Ross MH, et al. **Neurology** 1997 Jan;48(1):173-6

Tactile spatial acuity and roughness discrimination: impairments due to aging and Parkinson's disease. Sathian K, et al. **Neurology** 1997 Jul;49(1):168-77

Prevalence of headaches in a Chinese elderly population in Kinmen: age and gender effect and cross-cultural comparisons. Wang SJ, et al. **Neurology** 1997 Jul; 49(1):195-200

Persistent multiple climbing fiber innervation of cerebellar Purkinje cells in mice lacking mGluR1. Kano M, et al. **Neuron** 1997 Jan;18(1):71-9

Age-related changes in the olfactory system of dogs. Hirai T, et al. **Neuropathol Appl Neurobiol** 1996 Dec;22(6):531-9

Age-and height-dependent changes of amplitude and latency of somatosensory evoked potentials in children and young adults with Down's syndrome. Ferri R, et al. **Neurophysiol Clin** 1996;26(5):321-7

Scalp topographic mapping of middle-latency somatosensory evoked potentials in normal aging and dementia. Ferri R, et al. **Neurophysiol Clin** 1996;26(5):311-9

Assessing the topographic EEG changes associated with aging and acute/long-term effects of smoking. Knott VJ, et al. **Neuropsychobiology** 1996;33(4):210-22

Controlling the focus of spatial attention during visual search: effects of advanced aging and Alzheimer disease. Greenwood PM, et al. **Neuropsychology** 1997 Jan; 11(1):3-12

Effects of aging on conditional associative learning: process analyses and comparison with focal frontal lesions. Levine B, et al. **Neuropsychology** 1997 Jul;11(3):367-81

Odor learning, recall, and recognition memory in young and elderly adults. Murphy C, et al. **Neuropsychology** 1997 Jan; 11(1):126-37

Correlation between frontal lobe functions and explicit and implicit stem completion in healthy elderly. Nyberg L, et al. **Neuropsychology** 1997 Jan;11(1):70-6

Stroop color-word interference and electroencephalogram activation: evidence for age-related decline of the anterior attention system. West R, et al. **Neuropsychology** 1997 Jul; 11(3):421-7

MRI of the brain in neurologically healthy middle-aged and elderly individuals. Salonen O, et al. **Neuroradiology** 1997 Aug;39(8):537-45

Age-related changes in fibre composition of the human corpus callosum: sex differences. Aboitiz F, et al. **Neuroreport** 1996 Jul 29;7(11):1761-4

Relation of age and apolipoprotein E to cognitive function in Down syndrome adults. Alexander GE, et al. **Neuroreport** 1997 May 27;8(8):1835-40

Effects of animal age on the responses along the outer segment of retinal rod photoreceptors. Bandarchi J, et al. **Neuroreport** 1997 Feb 10;8(3):581-5

Ageing potentiates anaesthetic-induced synaptic depression in hippocampal slices. el-Beheiry H, et al. **Neuroreport** 1996 Jan 31;7(2):502-4

Expression of beta-amyloid precursor protein immunoreactivity in the retina of the rat during normal development and after neonatal optic tract lesion. Chen ST, et al. **Neuroreport** 1997 Feb 10;8(3):713-7

Levels of NGF protein do not correlate with changes in innervation of the rat iris in old age. Cowen T, et al. **Neuroreport** 1996 Sep 2;7(13):2216-20

Memory dysfunction of the frontal type in normal ageing. Daum I, et al. **Neuroreport** 1996 Nov 4;7(15-17):2625-8

Dual cerebral processing of elementary auditory input in children. Karhu J, et al. **Neuroreport** 1997 Apr 14; 8(6):1327-30

Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: an electromyographic study. Kennel PF, et al. **Neuroreport** 1996 May 31;7(8):1427-31

Decreased neurofilament gene expression is an index of selective axonal hypotrophy in ageing. Kuchel GA, et al. **Neuroreport** 1997 Feb 10;8(3):799-805

Nicotine and D-cycloserine enhance acquisition of water maze spatial navigation in aged rats. Riekkinen M, et al. **Neuroreport** 1997 Feb 10;8(3):699-703

Dorsal hippocampal muscarinic acetylcholine and NMDA receptors disrupt water maze navigation. Riekkinen M, et al. **Neuroreport** 1997 Feb 10;8(3):645-8

Reproductive senescence predicts cognitive decline in aged female monkeys. Roberts JA, et al. **Neuroreport** 1997 May 27;8(8):2047-51

The role of hippocampus and frontal cortex in age-related memory changes: a PET study. Schacter DL, et al. **Neuroreport** 1996 Apr 26;7(6):1165-9

Reduced ageing effects of striatal neuronal discharge rate by aged ventral mesencephalic grafts. Strömberg I, et al. **Neuroreport** 1996 Feb 29;7(3):693-6

Vagal activity predicts eyeblink conditioning in human subjects. Tapp W, et al. **Neuroreport** 1997 Mar 24; 8(5):1203-7

Similar age-related changes in two regions of muscle with different properties. Vanden Noven S, et al. **Neuroreport** 1996 Feb 29;7(3):767-72

Modulation of insulin secretion by feeding behavior and physical activity: possible beneficial effects on obese and aged rats. Carpinelli AR, et al. **Neurosci Biobehav Rev** 1996 Summer;20(2):183-8 (64 ref.)

Differential effects of bilateral dopamine depletion in neonatal and adult rats. Moy SS, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):425-35 (124 ref.)

Age-dependent differences in sensitivity to aconitine of rat hippocampal slices. Ameri A. **Neurosci Lett** 1996 Sep 20; 216(1):13-6

Early effect of ApoE-epsilon 4 allele on cognitive results in a group of highly performing subjects: the EVA study. Etude sur le Vieillissement Artériel. Berr C, et al. **Neurosci Lett** 1996 Oct 25;218(1):9-12

Glial cell line-derived neurotrophic factor reverses motor impairment in 16-17 month old rats. Bowenkamp KE, et al. **Neurosci Lett** 1996 Jun 21;211(2):81-4

Loss of basic fibroblast growth factor in the subcommissural organ of old spontaneously hypertensive rats. Cuevas P, et al. **Neurosci Lett** 1996 Dec 27;221(1):25-8

Reduced cytochrome oxidase and memory dysfunction after chronic brain ischemia in aged rats. de la Torre JC, et al. **Neurosci Lett** 1997 Feb 28;223(3):165-8

Behavioral and neurochemical alterations induced by reversible conductive hearing loss in aged male rats. Drago F, et al. **Neurosci Lett** 1996 Feb 16;205(1):1-4

Primary afferent-evoked synaptic plasticity in deep dorsal horn neurons from neonatal rat spinal cord in vitro. Garraway SM, et al. **Neurosci Lett** 1997 Jul 11;230(1):61-4

The effects of aging on cerebellar beta-adrenergic receptor activation and motor learning in female F344 rats. Gould TJ, et al. **Neurosci Lett** 1996 Sep 20;216(1):53-6

In vitro assessment of neurotrophic activity from the striatum of aging rats. Kaseloo PA, et al. **Neurosci Lett** 1996 Nov 8;218(3):157-60

Loss of day-night differences in VIP mRNA levels in the suprachiasmatic nucleus of aged rats. Kawakami F, et al. **Neurosci Lett** 1997 Jan 31;222(2):99-102

Glutamate affects the development of the thalamofugal visual projection of the chick. Khyentse MD, et al. **Neurosci Lett** 1997 Jul 11;230(1):65-8

Age-related changes in soma size of neurons in the spinal cord motor column of the cat. Liu RH, et al. **Neurosci Lett** 1996 Jun 28;211(3):163-6

p75 neurotrophin receptor immunoreactivity in the aged human hypothalamus. Moga MM, et al. **Neurosci Lett** 1997 Aug 1;231(1):9-12

Functional characterization of cutaneous mechanoreceptor properties in aged rats. Reinke H, et al. **Neurosci Lett** 1996 Oct 4;216(3):171-4

Pre/postnatal dopamine D1 receptor stimulation induces a differential reduction of serotonin levels in hippocampus and superior colliculus of puber rats. Sajnani GG, et al. **Neurosci Lett** 1997 Jul 18;230(2):121-4

Alterations in GAP-43-immunoreactive innervation in the aging rat pituitary. Saland LC, et al. **Neurosci Lett** 1996 Apr 19;208(2):138-42

Nuclear condensation and fragmentation following cerebral hypoxia-ischemia occurs more frequently in immature than older rats. Sidhu RS, et al. **Neurosci Lett** 1997 Feb 21; 223(2):129-32

Age-dependent effect of AF64A on cholinergic activity in the septo-hippocampal pathway of the rat brain: decreased responsiveness in aged rats. El Tamer A, et al. **Neurosci Lett** 1996 Jan 19;203(2):123-6

Effect of stimulation of nicotinic cholinergic receptors on cortical cerebral blood flow and changes in the effect during aging in anesthetized rats. Uchida S, et al. **Neurosci Lett** 1997 Jun 13;228(3):203-6

Transcription supports age-related increases of GFAP gene expression in the male rat brain. Yoshida T, et al. **Neurosci Lett** 1996 Sep 6;215(2):107-10

Reduction in the number of NADPH-diaphorase-positive cells in the cerebral cortex and striatum in aged rats. Yamada K, et al. **Neurosci Res** 1996 Mar;24(4):393-402

Aging reduces neostriatal responsiveness to N-methyl-D-aspartate and dopamine: an in vitro electrophysiological study. Cepeda C, et al. **Neuroscience** 1996 Aug;73(3):733-50

Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. Doré S, et al. **Neuroscience** 1997 Oct;80(4):1033-40

Influence of age and anti-nerve growth factor treatment on the sympathetic and sensory innervation of the rat iris. Gavazzi I, et al. **Neuroscience** 1996 Aug;73(4):1069-79

Similarities in the age-related hippocampal deposition of periodic acid-schiff-positive granules in the senescence-accelerated mouse P8 and C57BL/6 mouse strains. Kuo H, et al. **Neuroscience** 1996 Oct;74(3):733-40

Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats. Lapchak PA, et al. **Neuroscience** 1997 Apr;77(3):745-52

In vitro autoradiography of ionotropic glutamate receptors in hippocampus and striatum of aged Long-Evans rats: relationship to spatial learning. Nicolle MM, et al. **Neuroscience** 1996 Oct;74(3):741-56

Morphological and biochemical adaptations to unilateral dopamine denervation of the neostriatum in newborn rats. Penit-Soria J, et al. **Neuroscience** 1997 Apr;77(3):753-66

Age-dependent changes in the immunoreactivity for neurofilaments in rabbit hippocampus. Van der Zee EA, et al. **Neuroscience** 1997 Jul;79(1):103-16

Age-related muscle stiffness: predominance of non-reflex factors. Wolfarth S, et al. **Neuroscience** 1997 Jul; 79(2):617-28

Peripubertal refinement of the intrinsic and associational circuitry in monkey prefrontal cortex. Woo TU, et al. **Neuroscience** 1997 Oct;80(4):1149-58

Mast cell number and maturation in the central nervous system: influence of tissue type, location and exposure to steroid hormones. Zhuang X, et al. **Neuroscience** 1997 Oct; 80(4):1237-45

Age-related differential susceptibility to calcium channel blocker and low calcium medium in rat detrusor muscle: response to field stimulation. Yu HJ, et al. **Neurourol Urodyn** 1996;15(5):563-76

Age-related reduction in 99Tcm-DTPA alveolar-capillary clearance in normal humans. Braga FJ, et al. **Nucl Med Commun** 1996 Nov;17(11):971-4

Age-related normal uptake of 99mTc-MDP in the lower spine. Sundkvist GM, et al. **Nuklearmedizin** 1997 Mar; 36(2):52-5

Age-associated changes in the endocrine system. Winger JM, et al. **Nurs Clin North Am** 1996 Dec;31(4):827-44 (58 ref.)

Physical activity in the elderly: benefits and intervention strategies. Allison M, et al. **Nurse Pract** 1997 Aug; 22(8):53-4, 56, 58 passim (74 ref.)

The dwindles: failure to thrive in older patients. Egbert AM. **Nutr Rev** 1996 Jan;54(1 Pt 2):S25-30 (22 ref.)

Effects of aging and exercise on nutrition needs of the elderly. Evans WJ. **Nutr Rev** 1996 Jan;54(1 Pt 2):S35-9 (27 ref.)

Nutrition and senescence. Rosenberg IH. **Nutr Rev** 1997 Jan; 55(1 Pt 2):S69-73; discussion S74-7 (20 ref.)

Structural characteristics of the superior venae cavae wall at the intrapericardium segment in adults and aging individuals. Piffer CR, et al. **Okajimas Folia Anat Jpn** 1996 Aug;73(2-3):89-100

Age-related reductions in number and size of anterior horn cells at C6 level of the human spinal cord. Zhang C, et al. **Okajimas Folia Anat Jpn** 1996 Oct;73(4):171-7

Distributional change of alpha-tocopherol in the rat lens with age. Nagata M, et al. **Ophthalmic Res** 1996;28 Suppl 2:136-40

Retinal hemodynamics in middle-aged normal subjects. Yoshida A, et al. **Ophthalmic Res** 1996;28(6):343-50

Retinal photoreceptor density decreases with age. Panda-Jonas S, et al. **Ophthalmology** 1995 Dec; 102(12):1853-9

Monocular contrast sensitivity in 3- to 36-month-old human infants. Adams RJ, et al. **Optom Vis Sci** 1996 Aug; 73(8):546-51

Age-related changes in the accommodation mechanism.

Beers AP, et al. **Optom Vis Sci** 1996 Apr;73(4):235–42

Corneal changes in schoolchildren. Friedman NE, et al. **Optom Vis Sci** 1996 Aug;73(8):552–7

Relative effects of aging and age-related macular degeneration on peripheral visual function. Holopigian K, et al. **Optom Vis Sci** 1997 Mar;74(3):152–9

Excess of autorefraction over subjective refraction: dependence on age [see comments] Joubert L, et al. **Optom Vis Sci** 1997 Jun;74(6):439–44. Comment in: Optom Vis Sci 1997 Jun;74(6):339–41.

Clinical evaluation of back optic radius and power determination by age in pediatric aphakia due to congenital cataract fitted with a Silicone Elaster contact lens [published erratum appears in Optom Vis Sci 1996 May;73(5):352] Lightman JM, et al. **Optom Vis Sci** 1996 Jan;73(1):22–7

Changes with age in the structure of fibromodulin in human articular cartilage. Roughley PJ, et al. **Osteoarthritis Cartilage** 1996 Sep;4(3):153–61

The impact of mitigating the effect of age-related diseases, such as osteoporosis. Walton I. **Osteoporos Int** 1996;6 Suppl 2:11–2

Changes in heart rate variability with age. Reardon M, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1863–6

Aging and time-domain and spectral turbulence parameters of signal-averaged electrocardiograms. Reardon M, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 1):1588–94

Response of neurocardiac syncope to beta-blocker therapy: interaction between age and parasympathetic tone. Slotwiner DJ, et al. **Pacing Clin Electrophysiol** 1997 Mar; 20(3 Pt 2):810–4

The influence of the age of the rat on the neuromuscular response to mivacurium in vitro. Yang HS, et al. **Paediatr Anaesth** 1996;6(5):367–72

Development of thermal nociception in rats. Falcon M, et al. **Pain** 1996 Sep;67(1):203–8

Chronic pain in elderly people. Gagliese L, et al. **Pain** 1997 Mar;70(1):3–14 (82 ref.)

Severity of skin lesions of herpes zoster at the worst phase rather than age and involved region most influences the duration of acute herpetic pain. Higa K, et al. **Pain** 1997 Feb;69(3):245–53

The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat. Van Crugten JT, et al. **Pain** 1997 Jun; 71(2):199–205

Pain measurement in elders with chronic low back pain: traditional and alternative approaches. Weiner D, et al. **Pain** 1996 Oct;67(2–3):461–7

Effect of aging on B-cell function and replication in rat pancreas after 90% pancreatectomy. Tanigawa K, et al. **Pancreas** 1997 Jul;15(1):53–9

Aging of the cardiovascular system. Hauss W, et al. **Pathol Biol (Paris)** 1996 Apr;44(4):312–20 **(Eng, Fre)**

Role of DNA repair enzymes in the cellular resistance to oxidative stress. Laval J. **Pathol Biol (Paris)** 1996 Jan; 44(1):14–24 (92 ref.)

Angiogenesis in breast cancer is related to age but not to other prognostic parameters. Marinho A, et al. **Pathol Res Pract** 1997;193(4):267–73

Donor age and graft function. Gellert S, et al. **Pediatr Nephrol** 1996 Dec;10(6):716–9

Impact of age on renal graft survival in children after the first rejection episode. Ingulli E, et al. **Pediatr Nephrol** 1996 Aug;10(4):474–8

Early age-dependent growth impairment in chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. Karlberg J, et al. **Pediatr Nephrol** 1996 Jun;10(3):283–7

Normal developmental changes in carotid arterial blood flow measured by Doppler flowmetry in children. Kojo M, et al. **Pediatr Neurol** 1996 May;14(4):313–6

Changes in endothelial cell and smooth muscle cell integrin expression during closure of the ductus arteriosus: an immunohistochemical comparison of the fetal, preterm newborn, and full-term newborn rhesus monkey ductus. Clyman RI, et al. **Pediatr Res** 1996 Aug;40(2):198–208

Age of onset of streptozocin diabetes determines the renal structural response in the rat. Lane PH. **Pediatr Res** 1997 Jun;41(6):912–5

L-type calcium current in pediatric and adult human atrial myocytes: evidence for developmental changes in channel inactivation. Roca TP, et al. **Pediatr Res** 1996 Sep; 40(3):462–8

Postnatal changes in mechanisms mediating acetylcholine-induced relaxation in piglet femoral arteries. Stjen R, et al. **Pediatr Res** 1997 May;41(5):702–7

Acetylcholine relaxation of renal artery and nitric oxide synthase activity of renal cortex increase with fetal and postnatal age. Thompson LP, et al. **Pediatr Res** 1996 Aug; 40(2):192–7

Age-related effects of cardiac sympathetic denervation on the responses to cardiopulmonary receptor stimulation in piglets. Tong S, et al. **Pediatr Res** 1997 Jan;41(1):72–7

Sleep and signs of attention during 3 months of intranasal vasopressin: a pilot study in two elderly subjects. Perras B, et al. **Peptides** 1996;17(7):1253–5

Test-retest reliability of a battery of sensory motor and physiological measures of aging. Anstey KJ, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):831–4

Nature of age-related changes in muscle strength of the extremities of women. Bohannon RW. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1155–60

Aging and executive function skills: an examination of a community-dwelling older adult population. Brennan M, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 2):1187–97

Simple reaction times and timing of serial reactions of middle-aged and old men. Inui N. **Percept Mot Skills** 1997 Feb;84(1):219–25

Gender differences in physical fitness in old age. Netz Y, et al. **Percept Mot Skills** 1996 Aug;83(1):218

Life-span development of odor identification, learning, and olfactory sensitivity. Cain WS, et al. **Perception** 1995; 24(12):1457–72

Functions of brain chondroitin sulfate proteoglycans during developments: interactions with adhesion molecules. Grumet M, et al. **Perspect Dev Neurobiol** 1996;3(4):319–30 (67 ref.)

Do central nervous system neurons require target-derived neurotrophic support for survival throughout adult life and aging? Svendsen CN, et al. **Perspect Dev Neurobiol** 1996; 3(2):133–42 (91 ref.)

Quantitating the capillary supply and the response to resistance training in older men. Hepple RT, et al. **Pflugers Arch** 1997 Jan;433(3):238–44

Decline in isokinetic force with age: muscle cross-sectional area and specific force. Jubrias SA, et al. **Pflugers Arch** 1997 Jul;434(3):246–53

Changes in baroreceptor vagal reflex performance in the developing rat. Kasparov S, et al. **Pflugers Arch** 1997 Aug; 434(4):438–44

Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit. Booij LH. **Pharm World Sci** 1997 Feb;19(1):45–52 (11 ref.)

Effect of age on pentylenetetrazol-kindling and kindling-induced impairments of learning performance. Grecksch G, et al. **Pharmacol Biochem Behav** 1997 Apr; 56(4):595–601

Combined cholinergic and 5-HT2 receptor activation suppresses thalamocortical oscillations in aged rats. Jäkälä P, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):713–8

Acetylcholine, aging, and Alzheimer's disease. Muir JL. **Pharmacol Biochem Behav** 1997 Apr;56(4):687–96 (124 ref.)

Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Rämä P, et al. **Pharmacol Biochem Behav** 1996 Nov;55(3):415–22

Climatotherapy of psoriasis and hypertension in elderly patients at the Dead-Sea. Kushelevsky AP, et al. **Pharmacol Res** 1996 Jul-Aug;34(1-2):87–91

The effect of ageing and in vitro exposure to xylene and KCl on [Ca2+]i in synaptosomes from rats exposed prenatally to xylene. Edelfors S, et al. **Pharmacol Toxicol** 1996 Jun;78(6):409–12

Aging and the mechanisms underlying head and postural control during voluntary motion. Di Fabio RP, et al. **Phys Ther** 1997 May;77(5):458–75 (96 ref.)

The effect of Tai Chi Quan and computerized balance training on postural stability in older subjects. Atlanta FICSIT Group. Frailty and Injuries: Cooperative Studies on Intervention Techniques. Wolf SL, et al. **Phys Ther** 1997 Apr;77(4):371–81; discussion 382–4

Balance control during walking in the older adult: research and its implications. Woollacott MH, et al. **Phys Ther** 1997 Jun;77(6):646–60 (67 ref.)

Effects of a 2-day abstinence from smoking on dietary, cognitive, subjective, and physiologic parameters among younger and older female smokers. Kos J, et al. **Physiol Behav** 1997 May;61(5):671–8

Effect of temperature and food intake on metabolic rate and posture of preruminant calves. Roefs JP, et al. **Physiol Behav** 1996 Jul;60(1):203–9

Tail pinch induces fos immunoreactivity within several regions of the male rat brain: effects of age. Smith WJ, et al. **Physiol Behav** 1997 May;61(5):717–23

Entrainment of aged, dysrhythmic rats to a restricted feeding schedule. Walcott EC, et al. **Physiol Behav** 1996 Nov; 60(5):1205–8

Body fluid alterations and organ hypertrophy in age-dependent salt hypertension of Dahl rats. Dobešová Z, et al. **Physiol Res** 1995;44(6):377–87

The role of mitochondria in aging [editorial] Kalous M, et al. **Physiol Res** 1996;45(5):351–9 (77 ref.)

Elucidation of intestinal transport results as a function of age. Martí T, et al. **Physiol Res** 1996;45(1):31–7

Genetic and functional changes in mitochondria associated with aging. Ozawa T. **Physiol Rev** 1997 Apr;77(2):425–64 (440 ref.)

Age-related changes of plasma alkaline phosphatase and inorganic phosphorus, and late ossification of the cranial roof in the Spanish imperial eagle (Aquila adalberti C. L. Brehm, 1861). Dobado-Berrios PM, et al. **Physiol Zool** 1997 Jul-Aug;70(4):421–7

Differential effects of platelet-derived growth factor BB in accelerating wound healing in aged versus young animals: the impact of tissue hypoxia. Wu L, et al. **Plast Reconstr Surg** 1997 Mar;99(3):815–22; discussion 823–4

Effect of egg size and strain and age of hens on the solids content of chicken eggs. Ahn DU, et al. **Poult Sci** 1997 Jun;76(6):914–9

Independent effects of hen age and egg size on incubation and poult characteristics in commercial turkeys. Applegate TJ, et al. **Poult Sci** 1996 Oct;75(10):1210–6

The effect of broiler breeder flock age and length of egg storage on egg albumen during early incubation. Benton CE Jr, et al. **Poult Sci** 1996 Sep;75(9):1069–75

Physiological differences in late embryos from turkey breeders at different ages. Christensen VL, et al. **Poult Sci** 1996 Feb;75(2):172–8

Effects of dietary threonine in starting, growing, and finishing turkey toms. Lehmann D, et al. **Poult Sci** 1997 May; 76(5):696–702

Effects of consecutive thiouracil exposures in the juvenile and adult single comb White Leghorn chicken on body weight and reproductive performance. Peebles ED, et al. **Poult Sci** 1997 Feb;76(2):236–43

Changes in gonadal weights, serum lipids, and glucose during maturation in the juvenile northern bobwhite quail (Colinus virginianus). Peebles ED, et al. **Poult Sci** 1996 Nov; 75(11):1411–6

Stunting syndrome in broilers: effect of age and exogenous amylase and protease on performance, development of the digestive tract, digestive enzyme activity, and apparent digestibility. Shapiro F, et al. **Poult Sci** 1995 Dec; 74(12):2019–28

Effect of strain and age of the broiler breeder female on incubation time and chick weight. Suarez ME, et al. **Poult Sci** 1997 Jul;76(7):1029–36

Health status of preweaned dairy heifers in the United States. Wells SJ, et al. **Prev Vet Med** 1997 Jan;29(3):185–99

Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Berr C, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13410–5

Decreased probabiiity of neurotransmitter release underlies striatal long-term depression and postnatal development of corticostriatal synapses. Choi S, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2665–70

Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Holtzman DM, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13333–8

Age-dependent decrease of synaptic plasticity in the neocortex of alphaCaMKII mutant mice. Kirkwood A, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3380–3

Arrest of neuronal migration by excitatory amino acids in hamster developing brain. Marret S, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15463–8

Early mortality surge in protein-deprived females causes reversal of sex differential of life expectancy in Mediterranean fruit flies. Müller HG, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2762–5

Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. Pincus SM, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):14100–5

Starburst amacrine cells change from spiking to nonspiking neurons during retinal development. Zhou ZJ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8057–62

A theoretical link between lenticular absorbance and fluorescence. Weale RA. **Proc R Soc Lond B Biol Sci** 1996 Sep 22;263(1374):1111–6

The effects of age, gender, and season on serotonergic function in healthy subjects. Golden RN, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov; 20(8):1315–23

Dipole source analysis of P300 component of the auditory evoked potential: a methodological advance? Hegerl U, et al. **Psychiatry Res** 1997 May 16;74(2):109–18

Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Rosier A, et al. **Psychiatry Res** 1996 Nov 25;68(1):11–22

Magnetic resonance imaging changes in putamen nuclei iron content and distribution in normal subjects. Steffens DC, et al. **Psychiatry Res** 1996 Nov 25;68(1):55–61

Aging or disease? Cardiovascular reactivity in Finnish men over the middle years. Jennings JR, et al. **Psychol Aging** 1997 Jun;12(2):225–38

An application of prefrontal cortex function theory to cognitive aging. West RL. **Psychol Bull** 1996 Sep; 120(2):272–92 (130 ref.)

A prospective study of cognitive function in the elderly. Korten AE, et al. **Psychol Med** 1997 Jul;27(4):919–30

Normal ageing, impaired cognitive functioning and senile dementia--a mixture distribution analysis. Reischies FM, et al. **Psychol Med** 1996 Jul;26(4):785–90

Behavioral reactivity to novelty during youth as a predictive factor of stress-induced corticosterone secretion in the elderly--a life-span study in rats. Dellu F, et al. **Psychoneuroendocrinology** 1996 Jul;21(5):441–53

Behavioral and endocrine effects of growth hormone administration in aged female rats. Drago F, et al. **Psychoneuroendocrinology** 1996 May;21(4):401–10

Acute and chronic nicotine effects on working memory in aged rats. Levin ED, et al. **Psychopharmacology (Berl)** 1996 Jan;123(1):88–97

ERP repetition effects in indirect and direct tasks: effects of age and interitem lag. Rugg MD, et al. **Psychophysiology** 1997 Sep;34(5):572–86

Perceptual factors affecting age-related differences in focused attention: performance and psychophysiological analyses. Zeef EJ, et al. **Psychophysiology** 1996 Sep; 33(5):555–65

Benzodiazepines: tolerability in elderly patients. Lechin F, et al. **Psychother Psychosom** 1996;65(4):171–82 (202 ref.)
Potassium homoeostasis in the elderly. Biswas K, et al. **QJM** 1997 Jul;90(7):487–92 (58 ref.)
Growth hormone–releasing hormone and growth hormone–releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Thorner MO, et al. **Recent Prog Horm Res** 1997;52:215–44; discussion 244–6 (63 ref.)
Epidural anatomy examined by cryomicrotome section. Influence of age, vertebral level, and disease. Hogan QH. **Reg Anesth** 1996 Sep–Oct;21(5):395–406
Age–related decline in thirst and sodium appetite in rats related to kininase II inhibition. Rowland NE, et al. **Regul Pept** 1996 Oct 22;66(3):163–7
Reduction of hepatic acute phase response after partial hepatectomy in elderly patients. Kimura F, et al. **Res Exp Med (Berl)** 1996;196(5):281–90
Effects of chronic cigarette smoke inhalation on the development of senile lung in senescence–accelerated mouse. Teramoto S, et al. **Res Exp Med (Berl)** 1997; 197(1):1–11
The influence of summary knowledge of results and aging on motor learning. Carnahan H, et al. **Res Q Exerc Sport** 1996 Sep;67(3):280–7
Effects of sex and age on the ossification of the collateral cartilages of the distal phalanx of the Finnhorse and the relationships between ossification and body size and type of horse. Ruohoniemi M, et al. **Res Vet Sci** 1997 Jan–Feb; 62(1):34–8
The Hering–Breuer reflex in ventilated children. Giffin F, et al. **Respir Med** 1996 Sep;90(8):463–6
Mechanism of specific force deficit in the senescent rat diaphragm. Criswell DS, et al. **Respir Physiol** 1997 Feb; 107(2):149–55
Natural history of subfoveal subretinal hemorrhage in age–related macular degeneration. Avery RL, et al. **Retina** 1996;16(3):183–9
Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Spaide RF, et al. **Retina** 1996;16(3):203–13
Serotonin, aging and cognitive functions of the hippocampus. Richter–Levin G, et al. **Rev Neurosci** 1996 Apr–Jun; 7(2):103–13 (96 ref.)
Ultrasound velocity measured at the proximal phalanges: precision and age–related changes in normal females. Duboeuf F, et al. **Rev Rhum Engl Ed** 1996 Jun;63(6):427–34
Ergonomic approach in aging: experimental procedures to assess cognitive and balance impairments. Pinto MR, et al. **Riv Eur Sci Med Farmacol** 1996 Jul–Aug;18(4):153–6
Tentative age–related norms for high frequency electric bone conduction audiometry. Voogt GR, et al. **S Afr J Commun Disord** 1995;42:49–52
Influence of donor age on the cytotoxicity and mutagenicity of ethylnitrosourea in cultured human T–lymphocytes. Mei N, et al. **Sangyo Ika Daigaku Zasshi** 1997 Jun 1;19(2):133–45
Age and anorectal sensibility in normal women. Ryhammer AM, et al. **Scand J Gastroenterol** 1997 Mar;32(3):278–84
Development of muscular endurance and strength from adolescence to adulthood and level of physical capacity in men and women at the age of 34 years. Barnekow–Bergkvist M, et al. **Scand J Med Sci Sports** 1996 Jun;6(3):145–55
The relationship of sustained exercise training and bone mineral density in aging male runners. Goodpaster BH, et al. **Scand J Med Sci Sports** 1996 Aug;6(4):216–21
The aging tendon. Tuite DJ, et al. **Scand J Med Sci Sports** 1997 Apr;7(2):72–7 (56 ref.)
Aging effects in skeletal muscle recovery after reinnervation. Choi SJ, et al. **Scand J Plast Reconstr Surg Hand Surg** 1996 Jun;30(2):89–98
Maximal isometric knee extension strength and stair–mounting ability in 75– and 80–year–old men and women. Rantanen T, et al. **Scand J Rehabil Med** 1996 May; 28(2):89–93
Changes in physical capacity and sensory/psychomotor functions from 75 to 80 years of age and from 80 to 85 years of age—a longitudinal study. Era P, et al. **Scand J Soc Med Suppl** 1997;53:25–43
Functional capacity and health of elderly people—the Evergreen project. Background, design and methods of the project. Heikkinen E. **Scand J Soc Med Suppl** 1997;53:1–18
Morbidity and disability in 75– and 80–year–old men and women. A five–year follow–up. Laukkanen P, et al. **Scand J Soc Med Suppl** 1997;53:79–106
Changes in physical characteristics and body composition during 5–year follow–up in 75– and 80–year–old men and women. Suominen H. **Scand J Soc Med Suppl** 1997; 53:19–24
Residual urine in 75–year–old men and women. A normative population study. Bonde HV, et al. **Scand J Urol Nephrol** 1996 Apr;30(2):89–91
Changes in the work ability of active employees over an 11–year period. Ilmarinen J, et al. **Scand J Work Environ Health** 1997;23 Suppl 1:49–57
Summary of the Finnish research project (1981–1992) to promote the health and work ability of aging workers. Tuomi K, et al. **Scand J Work Environ Health** 1997;23 Suppl 1:66–71
Finnish research project on aging workers in 1981–1992. Tuomi K, et al. **Scand J Work Environ Health** 1997;23 Suppl 1:7–11 (33 ref.)
The aging glomerulus. Baylis C, et al. **Semin Nephrol** 1996 Jul;16(4):265–76 (106 ref.)
The effect of age on insulin resistance and secretion: a review. Muller DC, et al. **Semin Nephrol** 1996 Jul;16(4):289–98 (79 ref.)
Normal swallowing and aging. Robbins J. **Semin Neurol** 1996 Dec;16(4):309–17 (69 ref.)
Speech production of normally aging adults. Benjamin BJ. **Semin Speech Lang** 1997 May;18(2):135–41 (54 ref.)
Normal aging and human physiology. Chodzko–Zajko WJ. **Semin Speech Lang** 1997 May;18(2):95–104; quiz 104–5 (34 ref.)
The aging voice. Mueller PB. **Semin Speech Lang** 1997 May; 18(2):159–68; quiz 168–9 (50 ref.)
Age does not affect thermal and cardiorespiratory responses to microwave heating in calorically restricted rats. Ryan KL, et al. **Shock** 1997 Jul;8(1):55–60
Chronologic age, physiologic age and mortality in sleep apnea [editorial; comment] Bliwise DL. **Sleep** 1996 May; 19(4):275–6. Comment on: Sleep 1996 May;19(4):277–82.
Circadian characteristics of sleep propensity function in healthy elderly: a comparison with young adults. Haimov I, et al. **Sleep** 1997 Apr;20(4):294–300
The effects of aging on information–processing channels in the sense of touch: III. Differential sensitivity to changes in stimulus intensity. Gescheider GA, et al. **Somatosens Mot Res** 1996;13(1):73–80
Long–term age–related consequences of forelimb damage upon expression of primary afferent phenotypes in the cervical dorsal horn. Rhoades RW, et al. **Somatosens Mot Res** 1995;12(3–4):199–208
Spatial acuity of the body surface over the life span. Stevens JC, et al. **Somatosens Mot Res** 1996;13(2):153–66
How do geriatric patients recover from surgery? Nusbaum NJ. **South Med J** 1996 Oct;89(10):950–7 (28 ref.)
Intermediate–term outcome of cervical spinal cord–injured patients older than 50 years of age. Alander DH, et al. **Spine** 1997 Jun 1;22(11):1189–92
The effect of age on the change in deformity after anterior débridement surgery for tuberculosis of the spine. Upadhyay SS, et al. **Spine** 1996 Oct 15;21(20):2356–62
Reparametrization of autoregressive models with coefficients depending on covariables: application to EEG spectrum maturation. Clark I, et al. **Stat Med** 1997 Aug 15; 16(15):1745–52
Impairment of vasodilator function in basilar arteries from aged rats. Arribas SM, et al. **Stroke** 1997 Sep;28(9):1812–20
Mitral valve strands and the risk of ischemic stroke in elderly patients. The French Study of Aortic Plaques in Stroke (FAPS) Investigators. Cohen A, et al. **Stroke** 1997 Aug; 28(8):1574–8
Performance of the 'unaffected' upper extremity of elderly stroke patients [see comments] Desrosiers J, et al. **Stroke** 1996 Sep;27(9):1564–70. Comment in: Stroke 1997 Feb;28(2):464.
Does the association of risk factors and atherosclerosis change with age? An analysis of the combined ARIC and CHS cohorts. The Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health Study (CHS) investigators. Howard G, et al. **Stroke** 1997 Sep; 28(9):1693–701
Comparison of stroke features and disability in daily life in patients with ischemic stroke aged 55 to 70 and 71 to 85 years. Pohjasvaara T, et al. **Stroke** 1997 Apr;28(4):729–35
Effect of age in rodent models of focal and forebrain ischemia. Sutherland GR, et al. **Stroke** 1996 Sep; 27(9):1663–7; discussion 1668
Age–related changes in response of brain stem vessels to opening of ATP–sensitive potassium channels. Toyoda K, et al. **Stroke** 1997 Jan;28(1):171–5
Ascorbic acid and aging. Barja G. **Subcell Biochem** 1996; 25:157–88 (196 ref.)
Facilitation of glutamate receptors reverses an age–associated memory impairment in rats. Granger R, et al. **Synapse** 1996 Apr;22(4):332–7
Age–related change in short–term synaptic plasticity intrinsic to excitatory striatal synapses. Ou X, et al. **Synapse** 1997 Sep;27(1):57–68
Age–related reference values for activation markers of the coagulation and fibrinolytic systems in children. Ries M, et al. **Thromb Res** 1997 Feb 15;85(4):341–4
Age–related alteration of cross–linking amino acids of elastin in human aorta. Watanabe M, et al. **Tohoku J Exp Med** 1996 Oct;180(2):115–30
Kinetic analysis of the in vitro inhibition, aging, and reactivation of brain acetylcholinesterase from rat and channel catfish by paraoxon and chlorpyrifos–oxon. Carr RL, et al. **Toxicol Appl Pharmacol** 1996 Aug;139(2):365–73
Possible mechanisms underlying the antiaging actions of caloric restriction. Masoro EJ. **Toxicol Pathol** 1996 Nov–Dec;24(6):738–41 (39 ref.)
The retardation of aging by caloric restriction: studies in rodents and primates. Weindruch R. **Toxicol Pathol** 1996 Nov–Dec;24(6):742–5 (26 ref.)
Theodore R. Woodward Award. Age–related decline in growth hormone secretion: clinical significance and potential reversibility. Thorner MO. **Trans Am Clin Climatol Assoc** 1996;108:99–105; discussion 105–8
Effect of donor age on porcine insulin secretion. Jay TR, et al. **Transplant Proc** 1997 Jun;29(4):2023
Histologic study of beta cells in porcine pancreas aged 5, 12, and 24 weeks. Jay TR, et al. **Transplant Proc** 1997 Jun; 29(4):2024–5
Effect of gut–associated lymphoid tissue and bacterial translocation in newborn rabbits. Urao M, et al. **Transplant Proc** 1996 Oct;28(5):2674
The role of anchoring protein RACK1 in PKC activation in the ageing rat brain. Battaini F, et al. **Trends Neurosci** 1997 Sep;20(9):410–5 (72 ref.)
Maturation of the mammalian dorsal root entry zone—from entry to no entry. Golding J, et al. **Trends Neurosci** 1997 Jul;20(7):303–8 (53 ref.)
The ageing bladder in urinary tract disorders [letter; comment] Kuchel GA, et al. **Trends Pharmacol Sci** 1996 Sep;17(9):314–6. Comment on: Trends Pharmacol Sci 1996 Apr;17(4):161–5.
Effect of age and sex of egg strain chickens and of two stocking densities of broilers on voluntary water intake and performance in a sub–humid environment. Balogun TF, et al. **Trop Anim Health Prod** 1997 May;29(2):117–23
Note on age and body weight at puberty in Mehraban Iranian fat–tailed ewe lambs. Bathaei SS, et al. **Trop Anim Health Prod** 1997 Feb;29(1):55–9
Nonlinear transcranial Doppler analysis demonstrates age–related changes of cerebral hemodynamics. Keunen RW, et al. **Ultrasound Med Biol** 1996;22(4):383–90
Effects of ageing and X–irradiation on the diurnal rhythm of mouse urinary bladder capacity. Dörr W, et al. **Urol Int** 1997;58(3):153–9
Variability of post–void residual urine volume in the elderly. Griffiths DJ, et al. **Urol Res** 1996;24(1):23–6
Characterization of in vitro relaxant mechanisms in erectile tissue from rabbits of different ages. Ragazzi E, et al. **Urol Res** 1996;24(6):317–22
Old age does not affect shortening velocity or content of contractile and cytoskeletal proteins in the rat detrusor smooth muscle. Sjuve R, et al. **Urol Res** 1997;25(1):67–70
Evaluation of young or unproven horses for potential exercise intolerance. Hendrickson DA. **Vet Clin North Am Equine Pract** 1996 Dec;12(3):607–12 (15 ref.)
Studies on the age of puberty of male camels (Camelus dromedaries) in Saudi Arabia. Abdel Rahim SE. **Vet J** 1997 Jul;154(1):79–83
Effects of four analgesic treatments on the behavioural and cortisol responses of 3–week–old lambs to tail docking. Graham MJ, et al. **Vet J** 1997 Jan;153(1):87–97
Age and hourly related changes of serum testosterone and spermiogram of prepubertal bulls fed two levels of nutrition. Rekwot PI, et al. **Vet J** 1997 May;153(3):341–7
When to spay dogs and cats [letter] Gourley J. **Vet Rec** 1997 Jan 25;140(4):104
Effects on calves less than one month old of feeding or not feeding them during road transport of up to 24 hours. Knowles TG, et al. **Vet Rec** 1997 Feb 1;140(5):116–24
Intermediate filaments in the Sertoli cells of the ageing human testis. de Miguel MP, et al. **Virchows Arch** 1997 Aug; 431(2):131–8
Age dependent modification of cytochrome oxidase activity in the cat dorsal lateral geniculate nucleus following removal of primary visual cortex. Payne BR, et al. **Vis Neurosci** 1996 Sep–Oct;13(5):805–16
An alternative phototransduction model for human rod and cone ERG a–waves: normal parameters and variation with age. Cideciyan AV, et al. **Vision Res** 1996 Aug; 36(16):2609–21
Visual ageing: unspecific decline of the responses to luminance and colour. Fiorentini A, et al. **Vision Res** 1996 Nov;36(21):3557–66
Effects of ageing on spatial aspects of the pattern electroretinogram in male and female quail. Lee JY, et al. **Vision Res** 1997 Mar;37(5):505–14
Retinal dopamine depletion in young quail mimics some of the effects of ageing on visual function. Lee JY, et al. **Vision Res** 1997 May;37(9):1103–13
Cadaver kidney transplantation in patients more than 65 years old. Barry JM, et al. **World J Urol** 1996;14(4):243–8
A longitudinal study of biological changes with age among the Brahmins of Calcutta. Gangopadhyay S, et al. **Z Morphol Anthropol** 1996 Sep;81(2):157–66
[Apoptosis and aging] Yang DL, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):64–6 (10 ref.) **(Chi)**
[Potential role of family physicians in pushing back age–related impairment: hearing and vision disorders, incontinence and arthrosis (letter; comment)] de Haan HM. **Ned Tijdschr Geneeskd** 1997 Feb 1;141(5):256. Comment on: Ned Tijdschr Geneeskd 1996 Nov 30;140(48):2402–6. **(Dut)**
[Odor perception in relation to age, general health, nutritional status, and dental status] Griep MI, et al. **Tijdschr Gerontol Geriatr** 1997 Feb;28(1):11–7 (Eng. Abstr.) **(Dut)**
[Reference intervals and biological profile in a group of healthy elderly population in the Paris region] Cals MJ, et al. **Ann Biol Clin (Paris)** 1996;54(7):307–15 (Eng. Abstr.) **(Fre)**
[Arterial hypertension, aging and cardiac decompensation] Safar M, et al. **Ann Cardiol Angeiol (Paris)** 1996 Oct; 45(8):439–44 (22 ref.) (Eng. Abstr.) **(Fre)**
[Effects of aging on standing up and sitting down. Kinematic analysis] Mourey F, et al. **C R Seances Soc Biol Fil** 1996; 190(5–6):603–11 (Eng. Abstr.) **(Fre)**

[Aging and brain circulation. Role of the extracellular matrix of brain microvessels] Robert AM, et al. **C R Seances Soc Biol Fil** 1997;191(2):253–60 (18 ref.) (Eng. Abstr.) **(Fre)**

[Role of oxidative stress in aging] Remacle J, et al. **Pathol Biol (Paris)** 1996 Jan;44(1):65–76 (64 ref.) (Eng. Abstr.) **(Fre)**

[Chronobiological approach of aging] Touitou Y, et al. **Pathol Biol (Paris)** 1996 Jun;44(6):534–46 (64 ref.) (Eng. Abstr.) **(Fre)**

[Actions of dehydroepiandrosterone: possible links with aging] Barrou Z, et al. **Presse Med** 1996 Dec 7; 25(38):1885–9 (25 ref.) (Eng. Abstr.) **(Fre)**

[Is senile dementia "age-related" or "ageing-related"?] Alperovitch A. **Rev Epidemiol Sante Publique** 1996 Jan; 44(1):93–4 **(Fre)**

[Thyroid function and dysfunction in the elderly] Schlienger JL, et al. **Rev Med Interne** 1996;17(8):653–60 (41 ref.) (Eng. Abstr.) **(Fre)**

[Andrological data on male sexuality in the elderly] Andrianne R. **Rev Med Liege** 1997 Apr;52(4):221–3 (0 ref.) **(Fre)**

[Biological mechanisms of aging] Lapière CM. **Rev Med Liege** 1997 Apr;52(4):193–6 (16 ref.) **(Fre)**

[Is the hypothalamohypophyseal control system modified during human aging?] Legros JJ, et al. **Rev Med Liege** 1997 Apr;52(4):209–14 (36 ref.) **(Fre)**

[Pulmonary problems related to aging] Weber T, et al. **Rev Med Liege** 1997 Apr;52(4):245–50 (13 ref.) **(Fre)**

[Osteoporosis of the elderly person] Rivier E. **Rev Med Suisse Romande** 1996 Sep;116(9):743–50 (45 ref.) **(Fre)**

[Non-nosocomial pneumonias in the elderly: clinical findings, etiology, therapeutic approach] Janssens JP, et al. **Schweiz Med Wochenschr** 1996 Sep 7;126(36):1515–23 (64 ref.) (Eng. Abstr.) **(Fre)**

[The effects of age on onset and recovery from atracurium, rocuronium and vecuronium blockade] de Almeida MC, et al. **Anaesthesist** 1996 Oct;45(10):903–6 (Eng. Abstr.) **(Ger)**

[RO 48–6791—a short acting benzodiazepine. Pharmacokinetics and pharmacodynamics in young and old subjects in comparison to midazolam] Hering W, et al. **Anaesthesist** 1996 Dec;45(12):1211–4 (Eng. Abstr.) **(Ger)**

[Age-related correlation between EEG parameters and depth of anesthesia under propofol. Effect of fentanyl] Werry C, et al. **Anaesthesist** 1996 Aug;45(8):722–30 (Eng. Abstr.) **(Ger)**

[Food restriction and neuronal growth in the aging brain. Increase in a neuronal growth marker in the hippocampus and thalamus] Popa-Wagner A, et al. **Fortschr Med** 1996 Nov 30;114(33):456 **(Ger)**

[Texture discrimination and visual search: development, learning and plasticity] Sireteanu R, et al. **Klin Monatsbl Augenheilkd** 1996 Jan;208(1):3–10 (Eng. Abstr.) **(Ger)**

[Age dependence of the interaction between proprioception and vision—a posturographic study] Aust G. **Laryngorhinootologie** 1996 Jul;75(7):379–83 (Eng. Abstr.) **(Ger)**

[Age dependence of cerebral Tc-99m-ECD distribution between preschool and school-age children and adults] Barthel H, et al. **Nuklearmedizin** 1997 Jun;36(4):110–6 (Eng. Abstr.) **(Ger)**

[Physical fitness in the elderly] Zenker TK. **Rehabilitation (Stuttg)** 1996 Nov;35(4):233–6 (24 ref.) (Eng. Abstr.) **(Ger)**

[Lumbar pain in old age] Baumgartner H. **Schweiz Rundsch Med Prax** 1996 Oct 22;85(43):1347–53 (13 ref.) (Eng. Abstr.) **(Ger)**

[Cardiopulmonary normal values in geriatrics] Gassmann KG, et al. **Z Gerontol Geriatr** 1997 May-Jun;30(3):193–9 (55 ref.) (Eng. Abstr.) **(Ger)**

[The kidneys in aging] Niederstadt C, et al. **Z Gerontol Geriatr** 1997 May-Jun;30(3):200–7 (44 ref.) (Eng. Abstr.) **(Ger)**

[Age adjusted diagnosis/normal values in geriatrics—sense and nonsense (editorial)] Schütz RM. **Z Gerontol Geriatr** 1997 May-Jun;30(3):179 **(Ger)**

[Homeostasis and adaptability in the elderly] Schütz RM. **Z Gerontol Geriatr** 1997 May-Jun;30(3):180–4 **(Ger)**

[Isolated systolic hypertension, a malady related to age] Guazzi MD. **Cardiologia** 1997 Jun;42(6):557–8 **(Ita)**

[Aging and isomyosin pattern of the left ventricle in spontaneously hypertensive and Wistar Kyoto rats] Vulpis V, et al. **Cardiologia** 1996 Sep;41(9):877–82 (Eng. Abstr.) **(Ita)**

[Heart transplant over 55 years] Pederzolli C, et al. **G Ital Cardiol** 1997 Mar;27(3):263–9 (Eng. Abstr.) **(Ita)**

[The histologic study on chronological changes of bone trabeclae in human postnatal mandible] Oya Y, et al. **Fukuoka Igaku Zasshi** 1997 Apr;88(4):90–104 (Eng. Abstr.) **(Jpn)**

[Neurochemical aspect of brain aging—neuronal death and decreased synaptic functions] Nomura Y. **Hokkaido Igaku Zasshi** 1996 May;71(3):309–14 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of aging on alpha-1 receptor-mediated, phenylephrine-induced contraction and pressor response: relationship with the amount of receptors] Koike K, et al. **J Smooth Muscle Res** 1995 Dec;31(6):396–7 **(Jpn)**

[Aging and immunity] Hosokawa T. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):602–4 (11 ref.) **(Jpn)**

[Senescence-accelerated mouse (SAM): with special reference to age-associated pathologies and their modulation] Takeda T. **Nippon Eiseigaku Zasshi** 1996 Jul; 51(2):569–78 (86 ref.) (Eng. Abstr.) **(Jpn)**

[Aging and the focal macular electroretinogram] Hayashi H, et al. **Nippon Ganka Gakkai Zasshi** 1997 May;101(5):417–22 (Eng. Abstr.) **(Jpn)**

[Aging of the blue mechanism studied by measuring the increment threshold on flashed background] Hirose H, et al. **Nippon Ganka Gakkai Zasshi** 1997 Mar;101(3):237–42 (Eng. Abstr.) **(Jpn)**

[The effect of age on short-wavelength sensitive cone electroretinograms and long-and middle-wavelength sensitive cone electroretinograms] Suzuki S, et al. **Nippon Ganka Gakkai Zasshi** 1997 May;101(5):434–40 (Eng. Abstr.) **(Jpn)**

[Effect of aging on distortion product otoacoustic emissions] Takahashi S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Jul;99(7):978–84 (Eng. Abstr.) **(Jpn)**

[Age-related development of the arrangement of connective tissue fibers in the lamina propria of the human vocal folds—scanning electron microscopic examination with digestion method] Yamashita K. **Nippon Jibiinkoka Gakkai Kaiho** 1997 May;100(5):499–511 (Eng. Abstr.) **(Jpn)**

[Age-dependent changes in dynamic body balance as evaluated by the body tracking test (BTT)] Yoshida T. **Nippon Jibiinkoka Gakkai Kaiho** 1997 Jul;100(7):729–39 (Eng. Abstr.) **(Jpn)**

[Assessment of biological age and indices of aging] Iguchi A, et al. **Nippon Ronen Igakkai Zasshi** 1996 Nov; 33(11):806–10 (Eng. Abstr.) **(Jpn)**

[Age-related changes in movement-related cortical potentials] Ishizuka H, et al. **Nippon Ronen Igakkai Zasshi** 1996 Aug;33(8):586–91 (Eng. Abstr.) **(Jpn)**

[A neuropsychological index of aging—data from 9000 elderly people] Kaneko M. **Nippon Ronen Igakkai Zasshi** 1996 Nov;33(11):811–5 (Eng. Abstr.) **(Jpn)**

[Influence of social environments on brain aging] Kobayashi S, et al. **Nippon Ronen Igakkai Zasshi** 1996 Jan;33(1):22–6 (Eng. Abstr.) **(Jpn)**

[Obesity and insulin resistance in the elderly] Kushiro T, et al. **Nippon Ronen Igakkai Zasshi** 1997 May;34(5):375–8 **(Jpn)**

[Variability in gait among patients with Alzheimer-type dementia] Nakamura T. **Nippon Ronen Igakkai Zasshi** 1996 Nov;33(11):816–9 (Eng. Abstr.) **(Jpn)**

[Effect of aging on respiratory system] Nishimura S, et al. **Nippon Ronen Igakkai Zasshi** 1996 Nov;33(11):825–8 **(Jpn)**

[Insulin resistance and hyperlipidemia in the elderly] Ohni M, et al. **Nippon Ronen Igakkai Zasshi** 1997 May; 34(5):379–88 (Eng. Abstr.) **(Jpn)**

[Effects of atherogenic risk factors on asymptomatic brain infarct] Sawai N, et al. **Nippon Ronen Igakkai Zasshi** 1997 May;34(5):389–94 (Eng. Abstr.) **(Jpn)**

[Evaluation and index of age-related change in circulatory function] Shimada K. **Nippon Ronen Igakkai Zasshi** 1996 Nov;33(11):820–4 **(Jpn)**

[Insulin resistance in elderly patients with hypertension] Shimamoto K, et al. **Nippon Ronen Igakkai Zasshi** 1997 May;34(5):369–74 (Eng. Abstr.) **(Jpn)**

[A quantitative study of regional cerebral blood flow in childhood using 123I-IMP-SPECT: with emphasis on age-related changes] Kobayashi A, et al. **No To Hattatsu** 1996 Nov;28(6):501–7 (Eng. Abstr.) **(Jpn)**

[Median nerve somatosensory evoked potentials—studies on latency variability as a function of subject height and age] Kitamura K, et al. **Rinsho Byori** 1996 Mar;44(3):274–80 (Eng. Abstr.) **(Jpn)**

[Effects of age and skin temperature on peripheral nerve conduction velocity—a basic study for nerve conduction velocity measurement in worksite] Yuasa J, et al. **Sangyo Eiseigaku Zasshi** 1996 Jul;38(4):158–64 (Eng. Abstr.) **(Jpn)**

[Age-related alteration of inhibitory effects of isradipine on alpha 1-adrenoceptor mediated responses] Kanai S, et al. **Yakugaku Zasshi** 1996 Oct;116(10):792–802 (Eng. Abstr.) **(Jpn)**

[Anatomic and radiologic studies of of ovarian arteries in women of various ages] Czerwiński F, et al. **Ginekol Pol** 1996 Jun;67(6):296–300 (Eng. Abstr.) **(Pol)**

[The effect of age on glucose tolerance and B cell secretion] Dembe K, et al. **Pol Arch Med Wewn** 1997 Feb;97(2):112–9 (Eng. Abstr.) **(Pol)**

[Examination of the mechanical properties of bone] Mazurkiewicz S. **Przegl Lek** 1997;54(4):237–42 (16 ref.) (Eng. Abstr.) **(Pol)**

[Evaluation of elemental and mineral composition of larynx thyroid cartilage in the period of its involutional mineralization] Stręk P, et al. **Przegl Lek** 1995;52(10):504–8 (Eng. Abstr.) **(Pol)**

[Is chronic serotonin deficiency the basis of diabetic and age-related angiopathy?] Simonenkov AP, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):103–10 **(Rus)**

[Age-related vagal regulation features of chronotropic heart function in sympathectomized and intact rats] Zefirov TL, et al. **Biull Eksp Biol Med** 1997 Jun;123(6):703–6 **(Rus)**

[Adaptation of the cardiovascular system in adolescents] Agadzhanian NA, et al. **Fiziol Cheloveka** 1997 Jan-Feb; 23(1):93–7 **(Rus)**

[Adaptation reactions of the heart to local muscular work in preschool children] Alferova-Popova TV, et al. **Fiziol Cheloveka** 1996 Sep-Oct;22(5):118–22 **(Rus)**

[Electrophysiologic studies of auditory function in normal and hearing-impaired children] Alieva ZS, et al. **Fiziol Cheloveka** 1996 Sep-Oct;22(5):62–7 **(Rus)**

[Heterogeneity and age-related dynamics of the alpha-rhythm of the electroencephalogram] Farber DA, et al. **Fiziol Cheloveka** 1996 Sep-Oct;22(5):5–12 **(Rus)**

[Interaction of the nervous and immune systems during normal aging and in dementias of the Alzheimer's type] Fokin VF, et al. **Fiziol Cheloveka** 1996 Nov-Dec;22(6):55–9 **(Rus)**

[Interhemispheric asymmetry and neuroimmune modulation in normal aging and Alzheimer's-type dementias] Fokin VF, et al. **Fiziol Cheloveka** 1997 May-Jun;23(3):20–4 **(Rus)**

[Elastic properties of the lungs in middle and old age] Ivanov LA. **Fiziol Cheloveka** 1996 Nov-Dec;22(6):82–5 **(Rus)**

[Neurohumoral regulation of gastric secretion in middle-aged and old people] Korkushko OV, et al. **Fiziol Cheloveka** 1996 Nov-Dec;22(6):66–70 **(Rus)**

[Maximal oxygen consumption in men as a function of age and level of motor activity] Korkushko OV, et al. **Fiziol Cheloveka** 1996 Jul-Aug;22(4):100–3 **(Rus)**

[Correlation between energy exchange in skeletal muscles of 6–11 year-old boys and development of somatotypologic characteristics] Kornienko IA, et al. **Fiziol Cheloveka** 1996 Nov-Dec;22(6):10–6 **(Rus)**

[The age-related characteristics of the cerebral organization of verbal activity: an electrophysiological analysis] Kulakovskii IuV, et al. **Fiziol Cheloveka** 1997 May-Jun; 23(3):122–4 **(Rus)**

[Spatial organization of the EEG beta-rhythm during rhythmic movements in children] Kurganskaia ME. **Fiziol Cheloveka** 1996 Sep-Oct;22(5):132–4 **(Rus)**

[Oscillovasometric evaluation of the elastic properties and diameter of the main arterial vessels of the extremities in people of varying age] Mazhbich BI, et al. **Fiziol Cheloveka** 1996 Nov-Dec;22(6):86–9 **(Rus)**

[Age-dependent features of the readiness potential during performance of simple voluntary movement] Orekhova EV, et al. **Fiziol Cheloveka** 1997 Jul-Aug;23(4):21–7 **(Rus)**

[Rhythmic stimulation: its effect on periodic processes and on the functional status of the cortical neurons in the rabbit during aging] Kopytova FV, et al. **Fiziol Zh Im I M Sechenova** 1996 Oct-Nov;82(10–11):122–5 **(Rus)**

[Changes in functional motor asymmetry during aging and after irradiation] Obukhova LK, et al. **Izv Akad Nauk Ser Biol** 1997 May-Jun;(3):315–9 (Eng. Abstr.) **(Rus)**

[The recognition by European lynxes (Lynx lynx, Felidae, Carnivora) through urinary odor signals of the species, sex and age of conspecific, familiar and unfamiliar individuals] Sokolov VE, et al. **Izv Akad Nauk Ser Biol** 1996 Sep-Oct; (5):571–7 (Eng. Abstr.) **(Rus)**

[Changes in the indices of left ventricular filling in elderly patients with ischemic heart disease] Korkushko OV, et al. **Lik Sprava** 1996 Jan-Feb;(1–2):68–71 (Eng. Abstr.) **(Rus)**

[Early age-specific changes in the accommodation volume] Rosenblium IZ, et al. **Vestn Oftalmol** 1996 Sep-Oct; 112(4):16–8 (Eng. Abstr.) **(Rus)**

[Hierarchical thermodynamics and gerontology] Gladyshev GP, et al. **Vestn Ross Akad Med Nauk** 1996;(6):31–8 (28 ref.) (Eng. Abstr.) **(Rus)**

[The dependence of spontaneous excitation processes on the nature of the metabolic activity in early postnatal ontogeny] Kuznetsov SV. **Zh Evol Biokhim Fiziol** 1996 Jul-Aug; 32(4):416–27 (Eng. Abstr.) **(Rus)**

[Cerebral blood flow and cerebrovascular reactivity in the early postnatal ontogeny of rats] Vaĭnshtein GB, et al. **Zh Evol Biokhim Fiziol** 1996 Mar-Apr;32(2):160–6 (Eng. Abstr.) **(Rus)**

[Cerebrovascular reactivity in the pathogenesis of ischemic brain lesions in patients of different ages] Ivanov IuS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(5):19–22 (Eng. Abstr.) **(Rus)**

[Long-term effects of febrile seizures in early ontogeny on learning processes and memory in adult rats] Chepurnova NE, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 May-Jun;47(3):601–4 **(Rus)**

[The dynamic nature and age-related dependence of functional brain organization in attention] Dubrovinskaia NV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar-Apr;47(2):196–208 (Eng. Abstr.) **(Rus)**

[Sensory information—an important factor in ontogeny] Raevskiĭ VV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Mar-Apr; 47(2):299–307 (30 ref.) (Eng. Abstr.) **(Rus)**

[Signal reception, protein kinesis and aging] García de Jalón P. **An R Acad Nac Med (Madr)** 1996;113(3):593–610; discussion 610–3 (41 ref.) **(Spa)**

[Aging through P300 in a Mexican population] García-de la Cadena C, et al. **Gac Med Mex** 1996 May-Jun; 132(3):267–76 (Eng. Abstr.) **(Spa)**

[Minimal examination of mental functions in healthy Cuban old-aged people. Letter] Scherle CE, et al. **Rev Neurol** 1997 Feb;25(138):302–4 **(Spa)**

[The formation of immune system function in early postnatal ontogeny] Baieva OV. **Fiziol Zh** 1997;43(3–4):116–29 (85 ref.) (Eng. Abstr.) **(Ukr)**

[The age-related characteristics of neurodynamic functions in schoolchildren under long-term physical training] Ivaniura IO. **Fiziol Zh** 1996;42(5–6):81–9 (Eng. Abstr.) **(Ukr)**

[The characteristics of visual information processing in persons of different age.] Korobeĭnikov HV. **Fiziol Zh** 1996;42(1–2):99–103 (En. Abstr.) **(Ukr)**

[The correlation of the characteristics of basic nervous processes and memory in younger schoolchildren] Makarenko MV, et al. **Fiziol Zh** 1997;43(3–4):54–63 (Eng. Abstr.) **(Ukr)**

[A comparative analysis of the level of the main properties of nervous processes in youths of different age groups] Nykonenko OP. **Fiziol Zh** 1996;42(1–2):59–64 (Eng. Abstr.) **(Ukr)**

PSYCHOLOGY

Temperament development to 30 months of age in discordant twin pairs. Riese ML.
Acta Genet Med Gemellol (Roma) 1996;45(4):439–47

Functional uncertainty, aging and memory processes during sleep. Salzarulo P, et al. **Acta Neurol Belg** 1997 Jun; 97(2):118–22 (31 ref.)

Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: a population-based study. Helgason AR, et al.
Age Ageing 1996 Jul;25(4):285–91

Age-associated differences in sensori-motor function and balance in community dwelling women. Lord SR, et al.
Age Ageing 1994 Nov;23(6):452–60

Older and more moral?—age-related changes in performance on Piagetian moral reasoning tasks. McDonald L, et al.
Age Ageing 1996 Sep;25(5):402–4

Methodological challenges in measurements of functional ability in gerontological research. A review. Avlund K.
Aging (Milano) 1997 Jun;9(3):164–74 (123 ref.)

Neurological findings in the normal elderly: prevalence and relationships with memory performance. Cosi V, et al.
Aging (Milano) 1996 Aug;8(4):243–9

Life events and the quality of life in old age. Report from a medical-social intervention study. Grimby A, et al.
Aging (Milano) 1996 Jun;8(3):162–9

Therapeutic drama activity for the cognitively impaired elderly in a nursing home. Moriyama M, et al.
Aging (Milano) 1995 Dec;7(6):441–50

Responses of people of different ages to health problems. Vetter NJ, et al. **Aging (Milano)** 1995 Oct;7(5):367–70

Ontogenetic differences in the expression of olfactory-conditioned aversions resulting from a state of acute alcohol intoxication in the rat. Lopez MF, et al.
Alcohol 1996 Sep–Oct;13(5):473–81

Concerned Americans for responsible driving (CARD): a personal narrative. Suroff SE.
Alzheimer Dis Assoc Disord 1997 Jun;11 Suppl 1:81–3

Citizen Kane as senior citizen. A mental health perspective [editorial] Cohen GD. **Am J Geriatr Psychiatry** 1997 Spring;5(2):93–6

The emergence of affiliative behavior in infant spotted hyenas (Crocuta crocuta). Drea CM, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:498–500

Effect of age and caloric intake on protein oxidation in different brain regions and on behavioral functions of the mouse. Dubey A, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):189–97

Neuroanatomical substrates of late-life minor depression. A quantitative magnetic resonance imaging study. Kumar A, et al. **Arch Neurol** 1997 May;54(5):613–7

Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Yaffe K, et al. **Arch Neurol** 1997 Sep;54(9):1110–4

Oxotremorine infusions into the medial septal area of middle-aged rats affect spatial reference memory and ChAT activity. Frick KM, et al. **Behav Brain Res** 1996 Oct;80(1–2):99–109

Effects of the subacute administration of nefiracetam on abnormal behavior in aged rats. Hasegawa M, et al.
Behav Brain Res 1996 Aug;78(2):93–100

The effect of the loss of molar teeth on spatial memory and acetylcholine release from the parietal cortex in aged rats. Kato T, et al. **Behav Brain Res** 1997 Feb;83(1–2):239–42

Role of nitric oxide in the effect of aging on spatial memory in rats. Noda Y, et al. **Behav Brain Res** 1997 Feb; 83(1–2):153–8

Nefiracetam ameliorates learning deficits in older rabbits and may act via the hippocampus. Woodruff-Pak DS.
Behav Brain Res 1997 Feb;83(1–2):179–84

Elevation of plasma beta-endorphin levels of shy elderly in response to novel laboratory experiences. Bell IR, et al.
Behav Med 1997 Winter;22(4):168–73

Spatial orienting of attention in adult and aged rhesus monkeys. Baxter MG, et al. **Behav Neurosci** 1996 Oct; 110(5):898–904

An herbal prescription, S-113m, consisting of biota, ginseng and schizandra, improves learning performance in senescence accelerated mouse. Nishiyama N, et al.
Biol Pharm Bull 1996 Mar;19(3):388–93

Age-related changes in the association between serotonergic function and aggression in boys with ADHD. Halperin JM, et al. **Biol Psychiatry** 1997 Mar 15;41(6):682–9

Beneficial effects of sigma agonists on the age-related learning impairment in the senescence-accelerated mouse (SAM). Maurice T, et al. **Brain Res** 1996 Sep 16; 733(2):219–30

Ameliorating effects of SDZ ENA 713 on age-associated decreases in learning performance and brain choline acetyltransferase activity in rats. Ohara T, et al.
Brain Res Bull 1997;43(1):39–42

ERPs during study as a function of subsequent direct and indirect memory testing in young and old adults. Friedman D, et al. **Brain Res Cogn Brain Res** 1996 Jul;4(1):1–13

Behavioral changes in rats with early ventral hippocampal damage vary with age at damage. Wood GK, et al.
Brain Res Dev Brain Res 1997 Jul 18;101(1–2):17–25

Age-related changes in cognitive ERPs of attenuation. DeFrance JF, et al. **Brain Topogr** 1997 Summer;9(4):283–93

Age and handedness: patterns of change in the population and sex differences become visible with increased statistical power. Coren S. **Can J Exp Psychol** 1995 Sep;49(3):376–86

Prefrontal deficits in attention and inhibitory control with aging. Chao LL, et al. **Cereb Cortex** 1997 Jan–Feb;7(1):63–9

Differences over the life span in daily life-style regularity. Monk TH, et al. **Chronobiol Int** 1997 May;14(3):295–306

Psychologic aspects of aging and the skin. Koblenzer CS.
Clin Dermatol 1996 Mar–Apr;14(2):171–7 (65 ref.)

Ethical issues in pain management. Borneman T, et al.
Clin Geriatr Med 1996 Aug;12(3):615–28 (45 ref.)

Attitudes to malocclusion among 18- and 35-year-old Norwegians. Stenvik A, et al.
Community Dent Oral Epidemiol 1996 Dec;24(6):390–3

Guessing strategies, aging, and bias effects in perceptual identification [see comments] Light LL, et al.
Conscious Cogn 1996 Dec;5(4):463–99. Comment in: Conscious Cogn 1996 Dec;5(4):500–11.

Separating implicit from explicit retrieval processes in perceptual identification [see comments] McKoon G, et al. **Conscious Cogn** 1996 Dec;5(4):500–11; discussion 512–24 . Comment in: Conscious Cogn 1996 Dec;5(4):463–99.

Word-list forgetting in young and elderly subjects: evidence for age-related decline in transferring information from transitory to permanent memory condition. Carlesimo GA, et al. **Cortex** 1997 Mar;33(1):155–66

Egg phobia in retirement homes: health risk perceptions among elderly Chinese. Lew-Ting CY.
Cult Med Psychiatry 1997 Mar;21(1):27–51

Progressive formation of neuritic plaques and neurofibrillary tangles is exponentially related to age and neuronal size. A morphometric study of three geographically distinct series of aging people. Dani SU, et al.
Dement Geriatr Cogn Disord 1997 Jul–Aug;8(4):217–27

Tone duration discrimination in demented, memory-impaired, and healthy elderly. Hellström A, et al. **Dement Geriatr Cogn Disord** 1997 Jan–Feb;8(1):49–54

Effect of normal aging and of Alzheimer's disease on, episodic memory. Le Moal S, et al.
Dement Geriatr Cogn Disord 1997 Sep–Oct;8(5):281–7

Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. Brayne C, et al. **Dementia** 1996 May–Jun; 7(3):169–74 (37 ref.)

An atypical neuroleptic drug in the treatment of behavioural disturbances and psychotic symptoms in elderly people. Robertsson B, et al. **Dementia** 1996 May–Jun;7(3):142–6

Ontogenetic differences in retention of spatial learning tested with the Morris water maze. Brown RW, et al.
Dev Psychobiol 1997 May;30(4):329–41

Intersensory experience and early perceptual development: the role of spatial contiguity in Bobwhite quail chicks' responsiveness to multimodal maternal cues. Lickliter R, et al. **Dev Psychobiol** 1996 Jul;29(5):403–16

A developmental analysis of contextual fear conditioning. Pugh CR, et al. **Dev Psychobiol** 1996 Mar;29(2):87–100

Developmental regulation across adulthood: primary and secondary control of age-related challenges. Heckhausen J. **Dev Psychol** 1997 Jan;33(1):176–87

Inhibition of feeding by a nitric oxide synthase inhibitor: effects of aging. Morley JE, et al. **Eur J Pharmacol** 1996 Sep 5;311(1):15–9

Adult age differences in long-term semantic priming. Allen PA, et al. **Exp Aging Res** 1997 Apr–Jun;23(2):107–35

Using a memory handbook to improve everyday memory in community-dwelling older adults with memory complaints. Andrewes DG, et al. **Exp Aging Res** 1996 Jul–Sep;22(3):305–22

Memory enhancement program for community-based older adults: development and evaluation. Caprio-Prevette MD, et al. **Exp Aging Res** 1996 Jul–Sep;22(3):281–303 (41 ref.)

Adult age differences in the effects of environmental context on memory performance. Earles JL, et al.
Exp Aging Res 1996 Jul–Sep;22(3):267–80

Role of age, education, and gender on cognitive performance in the Framingham Heart Study: community-based norms. Elias MF, et al. **Exp Aging Res** 1997 Jul–Sep;23(3):201–35

Age and forgetfulness: the effect of implicit priming. Erber JT, et al. **Exp Aging Res** 1997 Jan–Mar;23(1):1–12

Sustained attention and aging: overcoming the decrement? Giambra LM. **Exp Aging Res** 1997 Apr–Jun;23(2):145–61

Age differences in performance awareness on a complex financial decision-making task. Hershey DA, et al.
Exp Aging Res 1997 Jul–Sep;23(3):257–73

Effectiveness of the number-consonant mnemonic for retention of numeric material in community-dwelling older adults. Hill RD, et al. **Exp Aging Res** 1997 Jul–Sep; 23(3):275–86

Individual differences in the voluntary use of a memory aid during decision making. Johnson MM. **Exp Aging Res** 1997 Jan–Mar;23(1):33–43

Effects of division of attention during encoding and retrieval on age differences in episodic memory. Nyberg L, et al.
Exp Aging Res 1997 Apr–Jun;23(2):137–43

Aging effects on auditory processing: an event-related potential study. Pekkonen E, et al. **Exp Aging Res** 1996 Apr–Jun;22(2):171–84

Older adults' strategic superiority with mental multiplication: a generation effect assessment. Pesta BJ, et al.
Exp Aging Res 1996 Apr–Jun;22(2):155–69

Age differences in the accuracy of confidence judgments. Pliske RM, et al. **Exp Aging Res** 1996 Apr–Jun; 22(2):199–216

Taking charge of remembering: locus of control and older adults' memory for speech. Riggs KM, et al.
Exp Aging Res 1997 Jul–Sep;23(3):237–56

Effects of retention interval length on young and elderly adults' memory for spatial information. Rutledge PC, et al. **Exp Aging Res** 1997 Apr–Jun;23(2):163–77

Memory scores in middle-aged rats predict later deficits in memory, paradoxical sleep, and blood glucose regulation in old age. Stone WS, et al. **Exp Aging Res** 1997 Jul–Sep; 23(3):287–300

Aging and cognition: methodological differences in outcome. Williams JD, et al. **Exp Aging Res** 1996 Jul–Sep; 22(3):219–44 (71 ref.)

Characteristics of age-related behavioral changes in senescence-accelerated mouse SAMP8 and SAMP10. Miyamoto M. **Exp Gerontol** 1997 Jan–Apr;32(1–2):139–48 (32 ref.)

Stability and change in personality across the life span: behavioral-genetic versus evolutionary approaches. Cipriani DC. **Genet Soc Gen Psychol Monogr** 1996 Feb; 122(1):55–74

Nativity, declining health, and preferences in living arrangements among elderly Mexican Americans: implications for long-term care. Angel JL, et al.
Gerontologist 1996 Aug;36(4):464–73

Age norms, the timing of family role transitions, and intergenerational caregiving among aging African American women. Burton LM. **Gerontologist** 1996 Apr; 36(2):199–208

Everyday problem solving in elderly women: contributions of residence, perceived control, and age. Collins K, et al.
Gerontologist 1997 Jun;37(3):293–302

The social organization of diversity, and the normative organization of age [comment] Dannefer D.
Gerontologist 1996 Apr;36(2):174–77. Comment on: Gerontologist 1996 Apr;36(2):147–56. Comment on: Gerontologist 1996 Apr;36(2):152–64. Comment on: Gerontologist 1996 Apr;36(2):174–7.

Age norms and the structure of consciousness: some final comments. Foner A. **Gerontologist** 1996 Apr;36(2):221–3

Introduction. Gold DT. **Gerontologist** 1996 Apr;36(2):224–5

Caregiving for parents and parents-in-law: is gender important? Ingersoll-Dayton B, et al. **Gerontologist** 1996 Aug;36(4):483–91

Older adults as a community resource: results from the National Survey of Self-Care and Aging. Kincade JE, et al. **Gerontologist** 1996 Aug;36(4):474–82

Promotional timetables: an exploratory investigation of age norms for promotional expectations and their association with job well-being. Lashbrook J. **Gerontologist** 1996 Apr; 36(2):189–98

Organizational age norms: why is it so hard to know one when you see one? Lawrence BS. **Gerontologist** 1996 Apr; 36(2):209–20

Religious attendance and psychological well-being in Mexican Americans: a panel analysis of three-generations data. Levin JS, et al. **Gerontologist** 1996 Aug;36(4):454–63

Children's views on aging: their attitudes and values. Newman S, et al. **Gerontologist** 1997 Jun;37(3):412–7

Theoretical developments in the psychology of aging. Schroots JJ. **Gerontologist** 1996 Dec;36(6):742–8 (51 ref.)

What's the latest? Cultural age deadlines for family transitions. Settersten RA Jr, et al. **Gerontologist** 1996 Apr; 36(2):178–88

Visual memory support: an effective mnemonic device for older adults. Sharps MJ, et al. **Gerontologist** 1996 Oct; 36(5):706–8

Gays and Lesbians Older and Wiser (GLOW): a support group for older gay people. Slusher MP, et al.
Gerontologist 1996 Feb;36(1):118–23

Mutual attraction: demography and life-course analysis. Uhlenberg P. **Gerontologist** 1996 Apr;36(2):226–9

Everyday cognitive competence in elderly persons: conceptual issues and empirical findings. Willis SL.
Gerontologist 1996 Oct;36(5):595–601

"The measure of my days" critiqued by the oldest old. Running AF. **Image J Nurs Sch** 1996 Spring;28(1):71–4

Attitude to aging among different groups in Nigeria. Baiyewu O, et al. **Int J Aging Hum Dev** 1997;44(4):283–92

Olfactory acuity as a function of age and gender: a comparison of African and American samples. Barber CE.
Int J Aging Hum Dev 1997;44(4):317–34

Self-concepts of low-income older women: not old or poor, but fortunate and blessed. Barusch AS.
Int J Aging Hum Dev 1997;44(4):269–82

Self-disclosure and marital satisfaction in mid-life and late-life remarriages. Bograd R, et al.
Int J Aging Hum Dev 1996;42(3):161–72

The relationship of aging to self-esteem: the relative effects of maturation and role accumulation. Dietz BE.
Int J Aging Hum Dev 1996;43(3):249–66

Perceiving wisdom: do age and gender play a part? Hira FJ, et al. **Int J Aging Hum Dev** 1997;44(2):85–101

Temperament and personality as functions of age. Mehrabian A, et al. **Int J Aging Hum Dev** 1996;42(4):251–69

Aged citizens in the warning phase of disasters: re-examining the evidence. Perry RW, et al. **Int J Aging Hum Dev** 1997; 44(4):257–67 (43 ref.)

The ticking of the social clock: adults' beliefs about the timing of transition events. Peterson CC.
Int J Aging Hum Dev 1996;42(3):189–203

Personality, longevity, and successful aging among Tokyo metropolitan centenarians. Shimonaka Y, et al.
Int J Aging Hum Dev 1996;42(3):173–87

Achievement domain and life expectancies in Japanese civilization. Simonton DK. **Int J Aging Hum Dev** 1997; 44(2):103–14

Grandparents in Taiwan: a three-generational study. Strom R, et al. **Int J Aging Hum Dev** 1996;42(1):1–19

Determinants of perceived family support and conflict: life-course variations among the physically disabled. Turner HA. **Int J Aging Hum Dev** 1996;42(1):21–41

The Reminiscence Functions Scale: a replication. Webster JD. **Int J Aging Hum Dev** 1997;44(2):137–48

Current awareness in geriatric psychiatry.
Int J Geriatr Psychiatry 1997 Jul;12(7):777–84

A comparison of older longstay psychiatric and learning disability inpatients using the Health of the Nation Outcome Scales. Ashaye O, et al.
Int J Geriatr Psychiatry 1997 May;12(5):548–52

Psychotropic drug use and cognitive decline among older men and women. Dealberto MJ, et al.
Int J Geriatr Psychiatry 1997 May;12(5):567–74

Psychiatric disturbances and the use of psychotropic drugs in a population of nonagenarians. Forsell Y, et al.
Int J Geriatr Psychiatry 1997 May;12(5):533–6

Ageing and senility: a major problem of psychiatry. Aubrey Lewis, Journal of Mental Science (1946), 92: 150–170 [classical article] Lewis A. **Int J Geriatr Psychiatry** 1997 Jul;12(7):708–9; discussion 709–11

The elderly in a period of transition in Sofia [letter] Petrov I, et al. **Int J Geriatr Psychiatry** 1997 Jul;12(7):773–4

Social relationships in later life: a review of the research literature [editorial] Phillipson C.
Int J Geriatr Psychiatry 1997 May;12(5):505–12 (61 ref.)

Developmental and sex differences in sensory and motor functioning. Arceneaux JM, et al. **Int J Neurosci** 1997 Feb; 89(3–4):253–63

Age, color processing and meaningfulness: an event-related potential study. Czigler I. **Int J Psychophysiol** 1996 Apr–May;22(1–2):25–34

Memory and attention test performance of young and elderly subjects after retest practice. Rockstroh S, et al.
Int Psychogeriatr 1995 Fall;7(3):377–84

Loneliness in elderly people: an important area for nursing research. Donaldson JM, et al. **J Adv Nurs** 1996 Nov; 24(5):952–9 (76 ref.)

Recognizing depression in older adults: the role of the dietitian. Ryan C, et al. **J Am Diet Assoc** 1996 Oct; 96(10):1042–4

Does aging mean a better life for women? Eronen MK, et al. **J Am Geriatr Soc** 1997 May;45(5):594–7

Characterization of older adults who attribute functional decrements to "old age". Williamson JD, et al.
J Am Geriatr Soc 1996 Dec;44(12):1429–34

The archetypal senex: an exploration of old age. Hubback J. **J Anal Psychol** 1996 Jan;41(1):3–18

Moderating effects of personal and contextual factors in age discrimination. Perry EL, et al. **J Appl Psychol** 1996 Dec; 81(6):628–47

Subjective alertness rhythms in elderly people. Monk TH, et al. **J Biol Rhythms** 1996 Sep;11(3):268–76

Assessment of verbal memory in Spanish-speaking elders: development of two frequency-matched list learning tests. Jacobs DM, et al. **J Clin Exp Neuropsychol** 1997 Feb; 19(1):119–25

Development and validation of a demographic correction system for neuropsychological measures used in the Canadian Study of Health and Aging. Tuokko H, et al.
J Clin Exp Neuropsychol 1996 Aug;18(4):479–616

Color-Word Stroop test performance across the adult life span. Uttl B, et al. **J Clin Exp Neuropsychol** 1997 Jun; 19(3):405–20

Ceruletide improves event-related potential indicators of cognitive processing in young but not in elderly humans. Dodt C, et al. **J Clin Psychopharmacol** 1996 Dec; 16(6):440–5

Liquid conservation in orangutans (Pongo pygmaeus) and humans (Homo sapiens): individual differences and perceptual strategies. Call J, et al. **J Comp Psychol** 1996 Sep;110(3):219–32

Age differences in the ability of chimpanzees to distinguish mirror-images of self from video images of others. Eddy TJ, et al. **J Comp Psychol** 1996 Mar;110(1):38–44

Transfers of food from adults to infants in tufted capuchins (Cebus apella). Fragaszy DM, et al. **J Comp Psychol** 1997 Jun;111(2):194–200

Developmental changes in manipulation in tufted capuchins (Cebus apella) from birth through 2 years and their relation to foraging and weaning. Fragaszy DM, et al.
J Comp Psychol 1997 Jun;111(2):201–11

Age differences in the response of California ground Squirrels (Spermophilus beecheyi) to avian and mammalian predators. Hanson MT, et al. **J Comp Psychol** 1997 Jun; 111(2):174–84

Development of stone tool use by wild chimpanzees (Pan troglodytes). Inoue-Nakamura N, et al. **J Comp Psychol** 1997 Jun;111(2):159–73

Factors influencing young chimpanzees' (Pan troglodytes) recognition of attention. Povinelli DJ, et al.
J Comp Psychol 1996 Dec;110(4):336–45

Social referencing by young chimpanzees (Pan troglodytes). Russell CL, et al. **J Comp Psychol** 1997 Jun;111(2):185–93

Older and younger adults' strategy choices in multiplication: testing predictions of ASCM using the choice/no-choice method. Siegler RS, et al. **J Exp Psychol Gen** 1997 Mar; 126(1):71–92

Preschool children's use of information about age and perceptual access to infer another person's knowledge. Pillow BH, et al. **J Genet Psychol** 1997 Sep;158(3):365–76

Visual and semantic support for paired-associates recall in young and older adults. Sharps MJ, et al.
J Genet Psychol 1997 Sep;158(3):347–55

Category superiority effects in young and elderly adults. Sharps MJ. **J Genet Psychol** 1997 Jun;158(2):165–71

Effects of normal aging on the performance of motor-vehicle operational skills. Perryman KM, et al.
J Geriatr Psychiatry Neurol 1996 Jul;9(3):136–41

Circadian rhythms and psychiatric disorders in the elderly. Sloan EP, et al. **J Geriatr Psychiatry Neurol** 1996 Oct; 9(4):164–70 (71 ref.)

Factors associated with changes in gait speed in older adults. Buchner DM, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov;51(6):M297–302

Step length reductions in advanced age: the role of ankle and hip kinetics. Judge JO, et al.
J Gerontol A Biol Sci Med Sci 1996 Nov;51(6):M303–12

Characteristics of depressive symptoms in elderly urban and rural African Americans. Okwumabua JO, et al.
J Gerontol A Biol Sci Med Sci 1997 Jul;52(4):M241–6

Self-paced resistance training and walking exercise in community-dwelling older adults: effects on neuromotor performance. Rooks DS, et al.
J Gerontol A Biol Sci Med Sci 1997 May;52(3):M161–8

The effects of two types of cognitive tasks on postural stability in older adults with and without a history of falls. Shumway-Cook A, et al.
J Gerontol A Biol Sci Med Sci 1997 Jul;52(4):M232–40

Adult age-group differences in recall for the literal and interpretive meanings of narrative text. Adams C, et al.
J Gerontol B Psychol Sci Soc Sci 1997 Jul;52(4):P187–95

Age differences in mental multiplication: evidence for peripheral but not central decrements. Allen PA, et al.
J Gerontol B Psychol Sci Soc Sci 1997 Mar;52(2):P81–90

Theory, explanation, and a third generation of theoretical development in social gerontology. Bengtson VL, et al.
J Gerontol B Psychol Sci Soc Sci 1997 Mar;52(2):S72–88 (154 ref.)

Environmental "white noise": an intervention for verbally agitated nursing home residents. Burgio L, et al.
J Gerontol B Psychol Sci Soc Sci 1996 Nov;51(6):P364–73

Age and stage of readiness for smoking cessation. Clark MA, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Jul; 52(4):S212–21

Later-life economic inequality in longitudinal perspective. Crystal S, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):S307–18

Older and younger adults use a functionally identical algorithm to select items for restudy during multitrial learning. Dunlosky J, et al.
J Gerontol B Psychol Sci Soc Sci 1997 Jul;52(4):P178–86

Automatic category search and its transfer: aging, type of search, and level of learning. Fisk AD, et al.
J Gerontol B Psychol Sci Soc Sci 1997 Mar;52(2):P91–102

The effects of positive and negative social exchanges on aging adults [see comments] Ingersoll-Dayton B, et al.
J Gerontol B Psychol Sci Soc Sci 1997 Jul;52(4):S190–9. Comment in: J Gerontol B Psychol Sci Soc Sci 1997 Jul;52(4):S167–9.

Self-reports on memory functioning in a longitudinal study of the oldest old: relation to current, prospective, and retrospective performance. Johansson B, et al.
J Gerontol B Psychol Sci Soc Sci 1997 May;52(3):P139–46

Metalinguistic judgments in normal aging and Alzheimer's disease. Kemper S. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52(3):P147–55

Affective states in normal and depressed older people. Lawton MP, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):P309–16

The interactive effect of perceived control and functional status on health and mortality among young-old and old-old adults. Menec VH, et al.
J Gerontol B Psychol Sci Soc Sci 1997 May;52(3):P118–26

Age, subjective life expectancy, and the sense of control: the horizon hypothesis. Mirowsky J.
J Gerontol B Psychol Sci Soc Sci 1997 May;52(3):S125–34

The role of reader age and focus of attention in creating situation models from narratives. Morrow DG, et al.
J Gerontol B Psychol Sci Soc Sci 1997 Mar;52(2):P73–80

Initiation and inhibition of saccadic eye movements in younger and older adults: an analysis of the gap effect. Pratt J, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Mar; 52(2):P103–7

Mental health of aging women with children who are chronically disabled: examination of a two-factor model. Pruchno RA, et al. **J Gerontol B Psychol Sci Soc Sci** 1996 Nov;51(6):S284–96

Positive and negative social exchanges: weighing their effects in later life [editorial; comment] Rook KS.
J Gerontol B Psychol Sci Soc Sci 1997 Jul;52(4):S167–9. Comment on: J Gerontol B Psychol Sci Soc Sci 1997 Jul;52(4):S190–9.

Psychological effects of hearing aid use in older adults. Tesch-Römer C. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52(3):P127–38

Social pressures have selected for an extended juvenile period in primates. Joffe TH. **J Hum Evol** 1997 Jun;32(6):593–605

The systemic administration of tacrine or selegiline facilitate spatial learning in aged fisher 344 rats. Yavich L, et al.
J Neural Transm Gen Sect 1996;103(5):619–26

Age- and behavior-related variation in volumes of song control nuclei in male European starlings. Bernard DJ, et al. **J Neurobiol** 1996 Jul;30(3):329–39

Neurobiological bases of age-related cognitive decline in the rhesus monkey. Peters A, et al.
J Neuropathol Exp Neurol 1996 Aug;55(8):861–74 (105 ref.)

Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy. Bäckman C, et al.
J Neurosci 1996 Sep 1;16(17):5437–42

Body image in adulthood: a projective approach. Hayslip B Jr, et al. **J Pers Assess** 1997 Jun;68(3):628–49

Predicting women's well-being in midlife: the importance of personality development and social role involvements. Vandewater EA, et al. **J Pers Soc Psychol** 1997 May; 72(5):1147–60

Stability in extraversion and aspects of social support at midlife. Von Dras DD, et al. **J Pers Soc Psychol** 1997 Jan; 72(1):233–41

A comparison of the effects of sacred and secular music on elderly people. Lowis MJ, et al. **J Psychol** 1997 Jan; 131(1):45–55

Some thoughts on the influence of attitude on health and ageing. Walker AR. **J R Soc Health** 1996 Oct;116(5):283–6

Medication-taking behavior of the elderly. Huang LH.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1996 Jul; 12(7):423–33

Global burden of disease [letter; comment] Matsubayashi K, et al. **Lancet** 1997 Jul 12;350(9071):144. Comment on: Lancet 1997 May 3;349(9061):1263. Comment on: Lancet 1997 May 3;349(9061):1269–76. Comment on: Lancet 1997 May 10;349(9062):1347–52. Comment on: Lancet 1997 May 17;349(9063):1436–42. Comment on: Lancet 1997 May 24;349(9064):1498–504.

Gender differences in sexual activity among mid-aged adults in Massachusetts. Johannes CB, et al. **Maturitas** 1997 Apr; 26(3):175–84

Age and temperature related changes in behavioral and physiological performance in the Peromyscus leucopus mouse. Duffy PH, et al. **Mech Ageing Dev** 1997 Apr; 95(1–2):43–61

Blood and nerves revisited: menopause and the privatization of the body in a Newfoundland postindustrial fishery. Davis DL. **Med Anthropol Q** 1997 Mar;11(1):3–20; discussion 21–5 (44 ref.)

Premature ageing: the link between psychosocial risk factors and disease. Nilsson PM. **Med Hypotheses** 1996 Jul; 47(1):39–42

Aging parents' residential plans for adult children with mental retardation. Freedman RI, et al. **Ment Retard** 1997 Apr;35(2):114–23

Self-perception of health and survival. A 10-year follow-up among Italians aged over sixty. Inchingolo GM.
Minerva Med 1997 Jan–Feb;88(1–2):15–23

The effects of intrahippocampal BDNF and NGF on spatial learning in aged Long Evans rats. Pelleymounter MA, et al. **Mol Chem Neuropathol** 1996 Oct–Dec;29(2–3):211–26

Laughing as we go. Humor and aging. Glasgow-McDowell MA. **N C Med J** 1996 Nov–Dec;57(6):401–5

The art of aging [editorial] [see comments] Meymandi A. **N C Med J** 1996 Nov–Dec;57(6):342. Comment in: N C Med J 1997 Jan–Feb;58(1):7.

The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Arnsten AF, et al.
Neurobiol Aging 1997 Jan–Feb;18(1):21–8

Motor function in young and aged hemiplegic rats: effects of a Ginkgo biloba extract. Brailowsky S, et al.
Neurobiol Aging 1997 Mar–Apr;18(2):219–27

Automatic and effortful processing in aging and dementia: event-related brain potentials. Ford JM, et al.
Neurobiol Aging 1997 Mar–Apr;18(2):169–80

Recognition memory span in rhesus monkeys of advanced age. Moss MB, et al. **Neurobiol Aging** 1997 Jan–Feb; 18(1):13–9

Facilitation of cognitive performance in aged rats by past experience depends on the type of information processing involved: a combined cross-sectional and longitudinal study. Dellu F, et al. **Neurobiol Learn Mem** 1997 Mar;

67(2):121–8
ApoE–4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Blacker D, et al. **Neurology** 1997 Jan; 48(1):139–47
Hippocampal sclerosis contributes to dementia in the elderly. Corey–Bloom J, et al. **Neurology** 1997 Jan;48(1):154–60
Decline of frontal lobe functions in subjects with age–associated memory impairment. Hänninen T, et al. **Neurology** 1997 Jan;48(1):148–53 (71 ref.)
Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Kaye JA, et al. **Neurology** 1997 May;48(5):1297–304
The Medical College of Georgia Complex Figures: reliability and preliminary normative data using an intentional learning paradigm in older adults. Ingram F, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr; 10(2):144–6
The effects of glucose on nonmemory cognitive functioning in the elderly. Allen JB, et al. **Neuropsychologia** 1996 May; 34(5):459–65
Examination of the working memory components in normal aging and in dementia of the Alzheimer type. Belleville S, et al. **Neuropsychologia** 1996 Mar;34(3):195–207
Dissociations between memory for temporal order and recognition memory in aging. Fabiani M, et al. **Neuropsychologia** 1997 Feb;35(2):129–41
Asymmetrical memory decline in normal aging and dementia. Janowsky JS, et al. **Neuropsychologia** 1996 Jun;34(6):527–35
Interhemispheric transfer time differences related to aging and gender. Jeeves MA, et al. **Neuropsychologia** 1996 Jul; 34(7):627–36
Inhibition of return and visuospatial attention in healthy older adults and individuals with dementia of the Alzheimer type. Faust ME, et al. **Neuropsychology** 1997 Jan;11(1):13–29
Perceptual priming of proper names in young and older normal adults and a patient with prosopanomia. Geva A, et al. **Neuropsychology** 1997 Apr;11(2):232–42
Factor structure and age effects with an aphasia test battery in normal Taiwanese adults. Hua MS, et al. **Neuropsychology** 1997 Jan;11(1):156–62
Clustering and switching as two components of verbal fluency: evidence from younger and older healthy adults. Troyer AK, et al. **Neuropsychology** 1997 Jan;11(1):138–46
Impaired spatial information processing in aged monkeys with preserved recognition memory. Rapp PR, et al. **Neuroreport** 1997 May 27;8(8):1923–8
Reproductive senescence predicts cognitive decline in aged female monkeys. Roberts JA, et al. **Neuroreport** 1997 May 27;8(8):2047–51
Inhibition by the pentapeptide YFRKD of complex conditioned reflex activity during the ontogenesis of white rats. Ryabchikova NA, et al. **Neurosci Behav Physiol** 1997 May–Jun;27(3):319–22
Reduced cytochrome oxidase and memory dysfunction after chronic brain ischemia in aged rats. de la Torre JC, et al. **Neurosci Lett** 1997 Feb 28;223(3):165–8
The effects of aging on cerebellar beta–adrenergic receptor activation and motor learning in female F344 rats. Gould TJ, et al. **Neurosci Lett** 1996 Sep 20;216(1):53–6
Neonatal cranial ultrasound abnormalities in low birth weight infants: relation to cognitive outcomes at six years of age. Whitaker AH, et al. **Pediatrics** 1996 Oct;98(4 Pt 1):719–29
Perception of body shape in elderly white and black men. Abadie BR, et al. **Percept Mot Skills** 1996 Oct;83(2):449–50
Long lasting blindness, availability of resources, and early aging. Bachar E, et al. **Percept Mot Skills** 1997 Apr; 84(2):675–88 (77 ref.)
Manual action in infant chimpanzees: a preliminary study. Itakura S. **Percept Mot Skills** 1996 Oct;83(2):611–4
Conversations between older men and women: turn–taking and topics. Martin M, et al. **Percept Mot Skills** 1996 Dec; 83(3 Pt 2):1330
Noise–limited detection in young and old observers. Speranza F, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):829–30
Contributions to the history of psychology: CVIII. On aging and intelligence: history teaches a different lesson. Thompson DN. **Percept Mot Skills** 1997 Aug;85(1):28–30
Effects of aging and reduced relative frequency of knowledge of results on learning a motor skill. Wishart LR, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):1107–22
Structuring of perceived interrelations among life events for college students. Yamashita T. **Percept Mot Skills** 1997 Jun; 84(3 Pt 1):809–10
The alpha–1 adrenergic agonist, cirazoline, impairs spatial working memory performance in aged monkeys. Arnsten AF, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):55–9
Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions. Bartolini L, et al. **Pharmacol Biochem Behav** 1996 Feb;53(2):277–83
Age–dependent effects of developmental lead exposure on performance in the Morris water maze. Jett DA, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):271–9
Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits. Kronforst–Collins MA, et al. **Pharmacol Biochem Behav** 1997 Jan;56(1):103–10
Effect of a novel prolyl endopeptidase inhibitor, JTP–4819, on spatial memory and central cholinergic neurons in aged rats. Toide K, et al. **Pharmacol Biochem Behav** 1997 Mar; 56(3):427–34
Prenatal effects of parity on behavioral ontogeny in mice. Crusio WE, et al. **Physiol Behav** 1996 Jun;59(6):1171–4
Effect of sucrose in breakfast items on pleasantness and food intake in the elderly. De Jong N, et al. **Physiol Behav** 1996 Dec;60(6):1453–62
Age–related differences for duration discrimination in rats. Leblanc P, et al. **Physiol Behav** 1996 Aug;60(2):555–8
Effects of aging and hypertension on learning, memory, and activity in rats. Meneses A, et al. **Physiol Behav** 1996 Aug; 60(2):341–5
Remote and proximal US preexposure and aging effects in taste aversion learning in rats. Misanin JR, et al. **Physiol Behav** 1997 Feb;61(2):221–4
Differential environmental modulations on locomotor activity, exploration and spatial behaviour in young and old rats. Van Waas M, et al. **Physiol Behav** 1996 Feb; 59(2):265–71
The effects of age on continuous learning in the radial maze. Winter JC. **Physiol Behav** 1997 Apr;61(4):609–12
Memory systems analyses of mnemonic disorders in aging and age–related diseases. Gabrieli JD. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13534–40 (57 ref.)
Effect of aging on the spatial learning deficit produced by diazepam in rats. McNamara RK, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jul; 20(5):873–81
The psychology of normal aging. Carman MB. **Psychiatr Clin North Am** 1997 Mar;20(1):15–24 (10 ref.)
Strength in the lower limbs, visual contrast sensitivity, and simple reaction time predict cognition in older women. Anstey KJ, et al. **Psychol Aging** 1997 Mar;12(1):137–44
A comparison of the factor structure of processing speed for younger and older adults: testing the assumption of measurement equivalence across age groups. Babcock RL, et al. **Psychol Aging** 1997 Jun;12(2):268–76
Emergence of a powerful connection between sensory and cognitive functions across the adult life span: a new window to the study of cognitive aging? Baltes PB, et al. **Psychol Aging** 1997 Mar;12(1):12–21
Aging and the use of perceptual and temporal information in source memory tasks. Bayen UJ, et al. **Psychol Aging** 1996 Jun;11(2):293–303
The moderating influence of physical fitness on age gradients in vigilance and serial choice responding tasks. Bunce DJ, et al. **Psychol Aging** 1996 Dec;11(4):671–82
Relationship of psychosocial and background variables to older adults' end–of–life decisions. Cicirelli VG. **Psychol Aging** 1997 Mar;12(1):72–83
Age–related differences in absolute but not relative metamemory accuracy. Connor LT, et al. **Psychol Aging** 1997 Mar;12(1):50–71
Effects of familiarity of task and choice on the functional performance of younger and older adults. Dickerson AE, et al. **Psychol Aging** 1997 Jun;12(2):247–54
Adult age differences in recall of performed and nonperformed items. Earles JL. **Psychol Aging** 1996 Dec; 11(4):638–48
Sources of tension in the aging mother and adult daughter relationship. Fingerman KL. **Psychol Aging** 1996 Dec; 11(4):591–606
More or less "me" in past, present, and future: perceived lifetime personality during adulthood. Fleeson W, et al. **Psychol Aging** 1997 Mar;12(1):125–36
Effects of memory training on the subjective memory functioning and mental health of older adults: a meta–analysis. Floyd M, et al. **Psychol Aging** 1997 Mar; 12(1):150–61
Stereotyping of older adults: the role of target facial cues and perceiver characteristics. Hummert ML, et al. **Psychol Aging** 1997 Mar;12(1):107–14
An opposition procedure for detecting age–related deficits in recollection: telling effects of repetition. Jennings JM, et al. **Psychol Aging** 1997 Jun;12(2):352–61
Younger and older adults' on–line processing of syntactically ambiguous sentences. Kemtes KA, et al. **Psychol Aging** 1997 Jun;12(2):362–71
Age–related equivalence of identity suppression in the Stroop color–word task. Kieley JM, et al. **Psychol Aging** 1997 Mar; 12(1):22–9
Aging, cognitive resources, and declarative learning. Kirasic KC, et al. **Psychol Aging** 1996 Dec;11(4):658–70
Distinctive late–life challenges: implications for coping and well–being. Kling KC, et al. **Psychol Aging** 1997 Jun; 12(2):288–95
Overcoming feelings of powerlessness in "aging" researchers: a primer on statistical power in analysis of variance designs. Levin JR. **Psychol Aging** 1997 Mar;12(1):84–106 (45 ref.)
Center for Epidemiologic Studies Depression Scale (CES–D) as a screening instrument for depression among community–residing older adults. Lewinsohn PM, et al. **Psychol Aging** 1997 Jun;12(2):277–87
Predicting episodic memory performance of very old men and women: contributions from age, depression, activity, cognitive ability, and speed. Luszcz MA, et al. **Psychol Aging** 1997 Jun;12(2):340–51
Mental illness in late life: socioeconomic conditions, psychiatric symptoms, and adjustment of long–term sufferers. Meeks S, et al. **Psychol Aging** 1997 Jun; 12(2):296–308
Effect of age on event–based and time–based prospective memory. Park DC, et al. **Psychol Aging** 1997 Jun; 12(2):314–27
Mediators of long–term memory performance across the life span. Park DC, et al. **Psychol Aging** 1996 Dec;11(4):621–37
False recollection induced by photographs: a comparison of older and younger adults. Schacter DL, et al. **Psychol Aging** 1997 Jun;12(2):203–15
State–dependent learning in older and younger adults. Schramke CJ, et al. **Psychol Aging** 1997 Jun;12(2):255–62
The ethic of care: stability over time, gender differences, and correlates in mid– to late adulthood. Skoe EE, et al. **Psychol Aging** 1996 Jun;11(2):280–92
Aging and counting speed: evidence for process–specific slowing. Sliwinski M. **Psychol Aging** 1997 Mar;12(1):38–49
Attitudes toward older adults reported by young adults: variation based on attitudinal task and attribute categories. Slotterback CS, et al. **Psychol Aging** 1996 Dec;11(4):563–71
Subjective memory complaints, psychological distress, and longitudinal change in objective memory performance. Smith GE, et al. **Psychol Aging** 1996 Jun;11(2):272–9
Characteristics of associative learning in younger and older adults: evidence from an episodic priming paradigm. Spieler DH, et al. **Psychol Aging** 1996 Dec;11(4):607–20
Are backward words special for older adults? Weir C, et al. **Psychol Aging** 1997 Mar;12(1):145–9
Differential age–related processing limitations in recall and recognition tasks. Whiting WL 4th, et al. **Psychol Aging** 1997 Jun;12(2):216–24
Age–related differences in an ecologically based study of route learning. Wilkniss SM, et al. **Psychol Aging** 1997 Jun; 12(2):372–5
Effect of infants on adult social relations in the squirrel monkey (Saimiri Sciureus). Aruguete MS, et al. **Psychol Rep** 1996 Oct;79(2):603–11
Aging and intellectual ability in young, middle–aged, and older educated adults: preliminary results from a sample of college faculty. Compton DM, et al. **Psychol Rep** 1997 Aug;81(1):79–90
Preliminary study of health value as a moderator of the link between age and life satisfaction. Fahey AL, et al. **Psychol Rep** 1996 Oct;79(2):443–6
Religion and psychological well–being in later life. Francis LJ, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):1050
Age and sex differences in health beliefs and behaviours. Furnham A, et al. **Psychol Rep** 1997 Feb;80(1):63–6
State versus trait loneliness in elderly New Zealanders. Hector–Taylor L, et al. **Psychol Rep** 1996 Jun;78(3 Pt 2):1329–30
Motivational and behavioral correlates of life satisfaction in an elderly sample. Jacob M, et al. **Psychol Rep** 1997 Jun; 80(3 Pt 1):811–8
Emotional control in adulthood. McConatha JT, et al. **Psychol Rep** 1997 Apr;80(2):499–507
Comments on "sense of humor and longevity" by Yoder and Haude [comment] Ridley DR, et al. **Psychol Rep** 1996 Feb; 78(1):254. Comment on: Psychol Rep 1995 Jun;76(3 Pt 1):945–6.
Elderly persons' perceptions of humor as a gender–linked characteristic. Vitulli WF, et al. **Psychol Rep** 1996 Feb; 78(1):83–9
Multilevel statistical models for psychosomatic research [editorial; comment] Berry CC. **Psychosom Med** 1997 Jul–Aug;59(4):350–1. Comment on: Psychosom Med 1997 Jul–Aug;59(4):339–47.
Marital conflict in older adults: endocrinological and immunological correlates [see comments] Kiecolt–Glaser JK, et al. **Psychosom Med** 1997 Jul–Aug;59(4):339–49. Comment in: Psychosom Med 1997 Jul–Aug;59(4):350–1.
The relationship of perceived benefits of and barriers to reported exercise in older African American women. Jones M, et al. **Public Health Nurs** 1996 Apr;13(2):151–8
Cognitive functioning of 75– and 80–year–old people and changes during a 5–year follow–up. Ruoppila I, et al. **Scand J Soc Med Suppl** 1997;53:44–65
Aging and work––coping with strengths and weaknesses [editorial] Ilmarinen J. **Scand J Work Environ Health** 1997; 23 Suppl 1:3–5
Perceived work changes between 1981 and 1992 among aging workers in Finland. Nygård CH, et al. **Scand J Work Environ Health** 1997;23 Suppl 1:12–9
Life–style, aging and work ability among active Finnish workers in 1981–1992. Seitsamo J, et al. **Scand J Work Environ Health** 1997;23 Suppl 1:20–6
Aging and changes in health. Seitsamo J, et al. **Scand J Work Environ Health** 1997;23 Suppl 1:27–35
Aging, work, life–style and work ability among Finnish municipal workers in 1981–1992. Tuomi K, et al. **Scand J Work Environ Health** 1997;23 Suppl 1:58–65
Normal aging and the multicultural population. Benjamin BJ. **Semin Speech Lang** 1997 May;18(2):127–34 (36 ref.)
Spatial acuity of touch: ubiquitous decline with aging revealed by repeated threshold testing. Stevens JC, et al. **Somatosens Mot Res** 1996;13(1):1–10
Puppy socialization classes. Seksel K. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):465–77 (48 ref.)
The meanings of home in the stories of older women. Moloney MF. **West J Nurs Res** 1997 Apr;19(2):166–76
[Changes in the concept of aging] Stelzner F. **Chirurg** 1996 Jul;67(7):694–6 **(Ger)**
[Bad fortune for elderly women. Demographic considerations complicate the search for new partners] Wagner B. **Fortschr Med** 1997 May 30;115(15):33–6 **(Ger)**
[Emotionality, age and aging––research perspectives, methodological approaches and empirical results] Kruse A, et al. **Ther Umsch** 1997 Jun;54(6):326–36 (43 ref.) (Eng.

Abstr.) (Ger)
[Aging, family relations and life course] Rosenmayr L. **Ther Umsch** 1996 Mar;53(3):179–86 (Eng. Abstr.) (Ger)
[Social networks of elderly migrants: on the relevance of familial and intra-ethnic support] Dietzel-Papakyriakou M, et al. **Z Gerontol Geriatr** 1996 Jan–Feb;29(1):34–41 (Eng. Abstr.) (Ger)
[Change in East Germany intergenerational relations in a large city. Results of the 4th survey phase of the Halle Longitudinal Study of participants of the 1994 senior college (HALSEKO)] Genz M. **Z Gerontol Geriatr** 1996 Sep–Oct;29(5):367–71 (Eng. Abstr.) (Ger)
[Multidisciplinary perspectives on the topic of age and aging (editorial)] Kruse A. **Z Gerontol Geriatr** 1997 Jan–Feb; 30(1):1–2 (Ger)
[Longevity as a developmental process: life history and individual perspectives] Martin P. **Z Gerontol Geriatr** 1997 Jan–Feb;30(1):3–9 (Eng. Abstr.) (Ger)
[Human-accessible environment design. Crossroads between persons and environment] Olbrich E. **Z Gerontol Geriatr** 1996 Jul–Aug;29(4):257–66 (Eng. Abstr.) (Ger)
[Aging and technology] Rudinger G. **Z Gerontol Geriatr** 1996 Jul–Aug;29(4):246–56 (49 ref.) (Eng. Abstr.) (Ger)
[Unmarried women of the war generation: an explorative study of their goals in life and personal satisfaction] Wilken B, et al. **Z Gerontol Geriatr** 1997 Jan–Feb;30(1):34–45 (Eng. Abstr.) (Ger)
[Aging and mental disorders] Nishimura T. **Nippon Ronen Igakkai Zasshi** 1996 Jan;33(1):1–3 (2 ref.) (Jpn)
[Age-related and sex-related features of retention and memory of a visual-spatial image in children of preschool age] Anurova IA, et al. **Fiziol Cheloveka** 1996 Jan–Feb; 22(1):50–4 (Rus)
[Age-related features of involuntary perception of visual stimuli] Beteleva TG. **Fiziol Cheloveka** 1996 Sep–Oct; 22(5):75–84 (Rus)
[Cerebral organization of cognitive processes at preschool age] Farber DA, et al. **Fiziol Cheloveka** 1997 Mar–Apr; 23(2):25–32 (Rus)
[Age-related features of training and retraining in a computer operation] Poliakov AA, et al. **Fiziol Cheloveka** 1996 Nov–Dec;22(6):60–5 (Rus)
[The syndrome of drive pathology in children and adolescents (the age-related and nosological aspects)] Luss LA. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(4):36–41 (Eng. Abstr.) (Rus)
[The age-related factor in the pathology of consciousness in craniocerebral trauma] Dobrokhotova TA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Jul–Sep;(3):22–5 (Eng. Abstr.) (Rus)
[The sensorimotor reaction time of preschool and young school-age children] Kiselev SIu, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 Jan–Feb; 47(1):159–62 (Rus)
[Sex and age differences in the subjective assessment of time by preschoolers] Surnina OE, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Mar–Apr; 46(2):260–6 (Eng. Abstr.) (Rus)

RADIATION EFFECTS

Normal aging changes of the scattering light intensity in human lens measuring with Scheimpflug photography. Shyn KH, et al. **Dev Ophthalmol** 1997;27:14–8
Somatic cell mutation as a radiation biodosimeter and predictor of cancer risk and aging. Mendelsohn ML. **Jpn J Cancer Res** 1996 Sep;87(9):inside front cover
[Changes in functional motor asymmetry during aging and after irradiation] Obukhova LK, et al. **Izv Akad Nauk Ser Biol** 1997 May–Jun;(3):315–9 (Eng. Abstr.) (Rus)

URINE

Urinary N-acetyl-beta-D-glucosaminidase changes in relation to age, sex, race, and diastolic and systolic blood pressure in a young adult biracial population. The Bogalusa Heart Study. Agirbasli M, et al. **Am J Hypertens** 1996 Feb; 9(2):157–61
Aging and urinary excretion of epidermal growth factor. Chou JS, et al. **Ann Clin Lab Sci** 1997 Mar–Apr; 27(2):116–22
Mucosal immunity in the urinary tract: changes in sIgA, FSC and total IgA with age and in urinary tract infection. James-Ellison MY, et al. **Clin Nephrol** 1997 Aug; 48(2):69–78
Age dependency of infradian rhythms in enzymuria of female volunteers. Gerasch A, et al. **Eur J Clin Chem Clin Biochem** 1997 Apr;35(4):281–6
Increase in urinary cortisol excretion and memory declines: MacArthur studies of successful aging. Seeman TE, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2458–65
Intra- and interindividual variation in urine osmolality and urine specific gravity in healthy pet dogs of various ages. van Vonderen IK, et al. **J Vet Intern Med** 1997 Jan–Feb; 11(1):30–5
Evaluation of patterns of urinary proteins by SDS-PAGE in rats of different ages. Calzada-García JA, et al. **Mech Ageing Dev** 1996 May 24;87(1):1–13
Age-related changes of urinary nitrite/nitrate excretion in normal children. Tsukahara H, et al. **Nephron** 1997; 76(3):307–9
[Variations in reference biological parameters with age] Delwaide PA. **Rev Med Liege** 1997 Apr;52(4):197–200 (15 ref.) (Fre)

AGING, CELL see **CELL AGING**

AGITATION, PSYCHOMOTOR see **PSYCHOMOTOR AGITATION**

AGKISTRODON

Study on the action mechanism of hemorrhagin I from Agkistrodon acutus venom. Xu X, et al. **Adv Exp Med Biol** 1996;391:361–6
Simultaneous isolation of protein C activator, fibrin clot promoting enzyme (fibrozyme) and phospholipase A2 from the venom of the southern copperhead snake. Fortová H, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20; 694(1):49–53
Effect of extract of Agkistrodon blomhoffii on acute gastric mucosal lesions induced by ischaemia-reperfusion in rats [letter] Wada K, et al. **J Pharm Pharmacol** 1997 Feb; 49(2):227–8
Capillary permeability-increasing enzyme-2 from the venom of Agkistrodon caliginosus (kankoku-mamushi): activity resulting from the release of peptides from fibrinogen. Shimokawa K, et al. **Toxicon** 1997 Apr;35(4):597–605
Preliminary X-ray crystallographic data for a myotoxin from Agkistrodon contortrix laticinctus (broad-banded copperhead) venom. Treharne AC, et al. **Toxicon** 1997 Apr; 35(4):613–5
LYS-49 phospholipase A2 homologs from venoms of Deinagkistrodon acutus and Trimeresurus mucrosquamatus have identical protein sequence. Wang YM, et al. **Toxicon** 1996 Apr;34(4):485–9
Purification, characterization and conformational analysis of a haemorrhagin from the venom of Agkistrodon acutus. Zhu Z, et al. **Toxicon** 1997 Feb;35(2):283–92

ANATOMY & HISTOLOGY

Ultrastructure of the crotaline snake infrared pit receptors: SEM confirmation of TEM findings. Amemiya F, et al. **Anat Rec** 1996 Sep;246(1):135–46

BLOOD

Purification and characterization of three distinct types of phospholipase A2 inhibitors from the blood plasma of the Chinese mamushi, Agkistrodon blomhoffii siniticus. Ohkura N, et al. **Biochem J** 1997 Jul 15;325 (Pt 2):527–31

METABOLISM

Specificity of two types of phospholipase A2 inhibitors from the plasma of venomous snakes. Inoue S, et al. **Biochem Mol Biol Int** 1997 Mar;41(3):529–37
Both the isomerase and chaperone activities of protein disulfide isomerase are required for the reactivation of reduced and denatured acidic phospholipase A2. Yao Y, et al. **EMBO J** 1997 Feb 3;16(3):651–8

PARASITOLOGY

Viper's blood and bile. Zhang QY, et al. **Lancet** 1997 Jan 25;349(9047):250

PHYSIOLOGY

Ultrastructure of the crotaline snake infrared pit receptors: SEM confirmation of TEM findings. Amemiya F, et al. **Anat Rec** 1996 Sep;246(1):135–46
Annual cycle of plasma testosterone in male copperheads, Agkistrodon contortrix (Serpentes, Viperidae): relationship to timing of spermatogenesis, mating, and agonistic behavior. Schuett GW, et al. **Gen Comp Endocrinol** 1997 Mar;105(3):417–24

AGKISTRODON RHODOSTOMA VENOM PROTEASE see **ANCROD**

AGKISTRODON SERINE PROTEINASE see **ANCROD**

AGMATINE

BLOOD

Determination of agmatine in brain and plasma using high-performance liquid chromatography with fluorescence detection. Feng Y, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):277–86

IMMUNOLOGY

An antiserum to idazoxan recognizes an immunoreactive substance in human serum and cerebral spinal fluid which is not agmatine. Wang H, et al. **Neurochem Int** 1997 Jan; 30(1):85–94

METABOLISM

Cryptosporidium parvum: polyamine biosynthesis from agmatine. Yarlett N, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):73S
Agmatinase activity in rat brain: a metabolic pathway for the degradation of agmatine. Sastre M, et al. **J Neurochem** 1996 Oct;67(4):1761–5
Metabolism of agmatine into urea but not into nitric oxide in rat brain. Gilad GM, et al. **Neuroreport** 1996 Jul 29; 7(11):1730–2
Agmatine does not have activity at alpha 2-adrenoceptors which modulate the firing rate of locus coeruleus neurones: an electrophysiological study in rat. Pineda J, et al. **Neurosci Lett** 1996 Nov 22;219(2):103–6

PHARMACOLOGY

Agmatine affects glomerular filtration via a nitric oxide synthase-dependent mechanism. Schwartz D, et al. **Am J Physiol** 1997 May;272(5 Pt 2):F597–601
Agmatine, an endogenous modulator of noradrenergic neurotransmission in the rat tail artery. González C, et al. **Br J Pharmacol** 1996 Oct;119(4):677–84
Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed. Berdeu D, et al. **Eur J Pharmacol** 1996 Jul 25;308(3):301–4
Functional properties of agmatine in rat vas deferens. Jurkiewicz NH, et al. **Eur J Pharmacol** 1996 Jul 4; 307(3):299–304
Modulation of opioid analgesia by agmatine. Kolesnikov Y, et al. **Eur J Pharmacol** 1996 Jan 18;296(1):17–22
Stimulation of imidazoline receptors inhibits proliferation of human coronary artery vascular smooth muscle cells. Regunathan S, et al. **Hypertension** 1997 Aug;30(2 Pt 1):295–300
Central cardiovascular actions of agmatine, a putative clonidine-displacing substance, in conscious rabbits. Head GA, et al. **Neurochem Int** 1997 Jan;30(1):37–45
Natriuresis following central and peripheral administration of agmatine in the rat. Penner SB, et al. **Pharmacology** 1996 Sep;53(3):160–9
Agmatine enhances caloric intake and dietary carbohydrate preference in satiated rats. Prasad A, et al. **Physiol Behav** 1996 Oct;60(4):1187–9
Agmatine activation of nitric oxide synthase in endothelial cells. Morrissey JJ, et al. **Proc Assoc Am Physicians** 1997 Jan;109(1):51–7

AGNOGENIC MYELOID METAPLASIA see **MYELOID METAPLASIA**

AGNOSIA

Literature update. Agnosia in Alzheimer disease. Gura C. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):180

CHEMICALLY INDUCED

[Hypoxic brain damage after carbon monoxide poisoning. Visual agnosia, reduced initiative and memory and delayed sequelae] Tvedt B, et al. **Tidsskr Nor Laegeforen** 1996 Oct 20;116(25):3005–8 (Eng. Abstr.) (Nor)

COMPLICATIONS

A case of concomitant impairment of operational signs and punctuation marks. Laiacona M, et al. **Neuropsychologia** 1997 Mar;35(3):325–32

DIAGNOSIS

Single-photon emission CT and MR findings in Klüver-Bucy syndrome after Reye syndrome. Ozawa H, et al. **AJNR Am J Neuroradiol** 1997 Mar;18(3):540–2
Object recognition difficulty in visual apperceptive agnosia. Grossman M, et al. **Brain Cogn** 1997 Apr;33(3):306–42
Electrophysiologic manifestations of impaired temporal lobe auditory processing in verbal auditory agnosia. Klein SK, et al. **Brain Lang** 1995 Dec;51(3):383–405
What is it like to be a patient with apperceptive agnosia? Vecera SP, et al. **Conscious Cogn** 1997 Jun–Sep; 6(2–3):237–66
Visual agnosia [letter] Grewal RP. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Jan; 10(1):64–6
Anosognosia and procedural learning in Alzheimer's disease. Starkstein SE, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr; 10(2):96–101
[Imaging diagnosis and function tests--auditory agnosia (cortical deafness)] Kaga K. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Aug;99(8):1144–7 (Jpn)
[Tests for aphasia, apraxia and agnosia] Hasegawa T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:318–21 (11 ref.) (Jpn)

EPIDEMIOLOGY

Hemineglect in acute stroke--incidence and prognostic implications. The Copenhagen Stroke Study. Pedersen PM, et al. **Am J Phys Med Rehabil** 1997 Mar–Apr;76(2):122–7

ETIOLOGY

Aphasia, apraxia, and agnosia in the diagnosis of dementia. Kramer JH, et al. **Dementia** 1996 Jan–Feb;7(1):23–6
Visual neglect associated with frontal lobe infarction. Husain M, et al. **J Neurol** 1996 Sep;243(9):652–7
Bilateral visual loss and simultagnosia after lumboperitoneal shunt for pseudotumor cerebri. Miller NR.

AGNOSIA

J Neuroophthalmol 1997 Mar;17(1):36–8

High level object recognition without an anterior inferior temporal lobe. Biederman I, et al. **Neuropsychologia** 1997 Mar;35(3):271–87 (64 ref.)

[A 36-year-old woman with acute onset left hemiplegia and anosognosia (clinical conference)] Goto K, et al. **No To Shinkei** 1997 Mar;49(3):291–300 (Eng. Abstr.) **(Jpn)**

["Associative" visual agnosia for objects, pictures, faces and letters with altitudinal hemianopia] Suzuki K, et al. **Rinsho Shinkeigaku** 1997 Jan;37(1):31–6 (Eng. Abstr.) **(Jpn)**

[Transient prosopagnosia and lasting topographical disorientation after the total removal of a right occipital arteriovenous malformation] Suzuki K, et al. **Rinsho Shinkeigaku** 1996 Sep;36(9):1114–7 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Tactile agnosia. Casuistic evidence and theoretical remarks on modality-specific meaning representations and sensorimotor integration. Platz T. **Brain** 1996 Oct;119 (Pt 5):1565–74

PHYSIOPATHOLOGY

Visual form agnosia in multiple sclerosis. Okuda B, et al. **Acta Neurol Scand** 1996 Jul;94(1):38–44

Tactile agnosia. Casuistic evidence and theoretical remarks on modality-specific meaning representations and sensorimotor integration. Platz T. **Brain** 1996 Oct;119 (Pt 5):1565–74

Electrophysiologic manifestations of impaired temporal lobe auditory processing in verbal auditory agnosia. Klein SK, et al. **Brain Lang** 1995 Dec;51(3):383–405

When is a view unusual? A single case study of orientation-dependent visual agnosia. Turnbull OH, et al. **Brain Res Bull** 1996;40(5–6):497–502; discussion 502–3

Alien hand syndrome: influence of neglect on the clinical presentation of frontal and callosal variants. Chan JL, et al. **Cortex** 1997 Jun;33(2):287–99

The perception and prehension of objects oriented in the depth plane. I. Effects of visual form agnosia. Dijkerman HC, et al. **Exp Brain Res** 1996 Dec;112(3):442–51

The removal of binocular cues disrupts the calibration of grasping in patients with visual form agnosia. Marotta JJ, et al. **Exp Brain Res** 1997 Aug;116(1):113–21

Can the recognition of living things really be selectively impaired? Kurbat MA. **Neuropsychologia** 1997 Jun; 35(6):813–27

Copying without perceiving: motor imagery in visual form agnosia. Dijkerman HC, et al. **Neuroreport** 1997 Feb 10; 8(3):729–32

Mirror agnosia. Ramachandran VS, et al. **Proc R Soc Lond B Biol Sci** 1997 May 22;264(1382):645–7

PSYCHOLOGY

Microsomatoagnosia: whole body schema illusion as part of an epileptic aura. Leker RR, et al. **Acta Neurol Scand** 1996 Dec;94(6):383–5

Congenital visual agnosia and prosopagnosia in a child: a case report. Ariel R, et al. **Cortex** 1996 Jun;32(2):221–40

Associative agnosia and optic aphasia: qualitative or quantitative difference? De Renzi E, et al. **Cortex** 1997 Mar; 33(1):115–30

Can we learn from the clinically significant face processing deficits, prosopagnosia and Capgras delusion? Wacholtz E. **Neuropsychol Rev** 1996 Dec;6(4):203–57 (182 ref.)

Visuomotor sensitivity for shape and orientation in a patient with visual form agnosia. Carey DP, et al. **Neuropsychologia** 1996 May;34(5):329–37

Selective loss of verbal imagery. Mehta Z, et al. **Neuropsychologia** 1996 May;34(5):441–7

Agnosia for object orientation: implications for theories of object recognition. Turnbull OH, et al. **Neuropsychologia** 1997 Feb;35(2):153–63

A double dissociation between knowledge of object identity and object orientation. Turnbull OH. **Neuropsychologia** 1997 Apr;35(4):567–70

Perceptual priming of proper names in young and older normal adults and a patient with prosopanomia. Geva A, et al. **Neuropsychology** 1997 Apr;11(2):232–42

Copying without perceiving: motor imagery in visual form agnosia. Dijkerman HC, et al. **Neuroreport** 1997 Feb 10; 8(3):729–32

Obstacle avoidance during locomotion is unaffected in a patient with visual form agnosia. Patla AE, et al. **Neuroreport** 1996 Dec 20;8(1):165–8

Mirror agnosia. Ramachandran VS, et al. **Proc R Soc Lond B Biol Sci** 1997 May 22;264(1382):645–7

RADIONUCLIDE IMAGING

Progressive visual agnosia with posterior cortical atrophy. Mizuno M, et al. **Clin Neurol Neurosurg** 1996 May; 98(2):176–8

REHABILITATION

Balint's syndrome arising from bilateral posterior cortical atrophy or infarction: rehabilitation strategies and their limitation. Perez FM, et al. **Disabil Rehabil** 1996 Jun; 18(6):300–4

AGONISTIC BEHAVIOR

Intermale aggression and dark/light preference in ten inbred mouse strains. Guillot PV, et al. **Behav Brain Res** 1996 May;77(1–2):211–3

Marital conflict and differential treatment of siblings. Deal JE. **Fam Process** 1996 Sep;35(3):333–46

Annual cycle of plasma testosterone in male copperheads, Agkistrodon contortrix (Serpentes, Viperidae): relationship to timing of spermatogenesis, mating, and agonistic behavior. Schuett GW, et al. **Gen Comp Endocrinol** 1997 Mar;105(3):417–24

Children's responding to live interadult conflict: the role of form of anger expression. el-Sheikh M, et al. **J Abnorm Child Psychol** 1996 Aug;24(4):401–15

Pavlovian conditioning of agonistic behavior in male threespine stickleback (Gasterosteus aculeatus). Jenkins JR, et al. **J Comp Psychol** 1996 Dec;110(4):396–401

Primate cognition and the bared-teeth display: a reevaluation of the concept of formal dominance. Maestripieri D. **J Comp Psychol** 1996 Dec;110(4):402–5 (26 ref.)

The development of a forgiveness scale. Hargrave TD, et al. **J Marital Fam Ther** 1997 Jan;23(1):41–63

The perception of an out-group after provocation by one of its members. Ruscher JB, et al. **J Soc Psychol** 1997 Feb; 137(1):5–9

Comparative analysis of anxiety-like behavior in partition and plus-maze tests after agonistic interactions in mice. Avgustinovich DF, et al. **Physiol Behav** 1997 Jan; 61(1):37–43

Long-term changes in open field behaviour following a single social defeat in rats can be reversed by sleep deprivation. Meerlo P, et al. **Physiol Behav** 1996 Jul;60(1):115–9

DRUG EFFECTS

Kainic acid versus carbachol induced emotional-defensive response in the cat. Eckersdorf B, et al. **Behav Brain Res** 1996 May;77(1–2):201–10

Early NMDA receptor blockade impairs defensive behavior and increases cell proliferation in the dentate gyrus of developing rats. Gould E, et al. **Behav Neurosci** 1997 Feb; 111(1):49–56

Changes in the structure of the agonistic behavior of mice produced by D-amphetamine. Moro M, et al. **Pharmacol Biochem Behav** 1997 Jan;56(1):47–54

Interaction of morphine and haloperidol on agonistic and motor behaviors of male mice. Rodríguez-Arias M, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):153–8

PHYSIOLOGY

Olfaction, GABAergic neurotransmission in the olfactory bulb, and intermale aggression in mice: modulation by steroids. Guillot PV, et al. **Behav Genet** 1996 Sep; 26(5):497–504 (65 ref.)

Issues in the genetics of social behavior: revisited. Hahn ME, et al. **Behav Genet** 1996 Sep;26(5):463–70 (24 ref.)

Searching for candidate genes with effects on an agonistic behavior, offense, in mice. Maxson SC. **Behav Genet** 1996 Sep;26(5):471–6 (70 ref.)

Executive function of the hippocampus in social behavior in the rat. Maaswinkel H, et al. **Behav Neurosci** 1997 Aug; 111(4):777–84

Testosterone facilitates aggression by modulating vasopressin receptors in the hypothalamus. Delville Y, et al. **Physiol Behav** 1996 Jul;60(1):25–9

Sympathetic mediation of stress and aggressive competition: plasma catecholamines in free-living male tree lizards. Matt KS, et al. **Physiol Behav** 1997 May;61(5):639–47

Social confrontation and tumor metastasis in rats: defeat and beta-adrenergic mechanisms. Stefanski V, et al. **Physiol Behav** 1996 Jul;60(1):277–82

Social confrontation in male guinea pigs: behavior, experience, and complement activity [published erratum appears in Physiol Behav 1996 Nov;60(5):1391] Stefanski V, et al. **Physiol Behav** 1996 Jul;60(1):235–41

Context-dependent behavioral effects of interleukin-1 in the rhesus monkey (Macaca mulatta). Friedman EM, et al. **Psychoneuroendocrinology** 1996 Jul;21(5):455–68

[Agonistic behavior during stress inhibits the development of learned helplessness in rats] Zhukov DA, et al. **Fiziol Zh Im I M Sechenova** 1996 Dec;82(12):6–11 (Eng. Abstr.) **(Rus)**

AGORAPHOBIA

Soft signs in children of parents with agoraphobia. Kaplan SL, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Apr; 35(4):516–22

CHEMICALLY INDUCED

Clinical features of cocaine-induced panic. Louie AK, et al. **Biol Psychiatry** 1996 Nov 1;40(9):938–40

COMPLICATIONS

Illumination perception in photophobic patients suffering from panic disorder with agoraphobia. Kellner M, et al. **Acta Psychiatr Scand** 1997 Jul;96(1):72–4

Comorbidity and its effects on panic disorder. Marshall JR. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A39–53 (63 ref.)

A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Bakish D, et al. **Psychopharmacol Bull** 1996;32(1):135–41

DIAGNOSIS

The panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms. Cassano GB, et al. **Am J Psychiatry** 1997 Jun;154(6 Suppl):27–38 (108 ref.)

Consistencies between recalled panic and lactate-induced panic. Goetz RR, et al. **Anxiety** 1994;1(1):31–6

Assessment instrument for panic disorder that includes fear of sensation-producing activities: the Albany Panic and Phobia Questionnaire. Rapee RM, et al. **Anxiety** 1994–95; 1(3):114–22

Validation of the spanish version of the Anxiety Sensitivity Index in a clinical sample. Sandin B, et al. **Behav Res Ther** 1996 Mar;34(3):283–90

Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients. Pols H, et al. **Biol Psychiatry** 1996 Nov 1;40(9):913–7

Predictors of remission in patients with panic with and without agoraphobia: prospective 5-year follow-up data. Warshaw MG, et al. **J Nerv Ment Dis** 1997 Aug; 185(8):517–9

Quantitative EEG correlates of panic disorder. Knott VJ, et al. **Psychiatry Res** 1996 Nov 25;68(1):31–9

Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder. Koszycki D, et al. **Psychiatry Res** 1996 May 17; 62(2):131–8

Electrodermal lability in anxiety disorders. Jensen HH, et al. **Scand J Psychol** 1996 Mar;37(1):103–8

DRUG THERAPY

Effect of pharmacotherapy on serum cholesterol levels in patients with panic disorder. Shioiri T, et al. **Acta Psychiatr Scand** 1996 Mar;93(3):164–7

Patient Stage of Change predicts outcome in a panic disorder medication trial. Beitman BD, et al. **Anxiety** 1994;1(2):64–9

Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics. Sheehan DV, et al. **Anxiety** 1996;2(1):40–6

Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Curtis GC, et al. **Biol Psychiatry** 1997 Jan 1;41(1):76–85

Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients. van Megen HJ, et al. **Biol Psychiatry** 1996 Oct 15;40(8):804–6

Predictors of outcome in panic disorder: a 5-year prospective follow-up study. Scheibe G, et al. **J Affect Disord** 1996 Nov 25;41(2):111–6

The treatment of panic disorder in a clinical setting: a 12-month naturalistic study. Marchesi C, et al. **Neuropsychobiology** 1997;36(1):25–31

Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment. Kiliç C, et al. **Psychother Psychosom** 1997;66(4):175–8

EPIDEMIOLOGY

Life events and panic disorder/agoraphobia: a comparison at two time periods. Lteif GN, et al. **Compr Psychiatry** 1996 Jul–Aug;37(4):241–4

Panic disorder and agoraphobia in consecutively referred children and adolescents. Biederman J, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Feb;36(2):214–23

ETIOLOGY

Single ion gas chromatographic/mass spectroscopic quantitative analysis of environmental CO2 in agoraphobic environments. Cox S, et al. **Anxiety** 1994–95;1(6):275–7

Case study: seizure disorder presenting as panic disorder with agoraphobia. Lee DO, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Sep;36(9):1295–8

Panic disorder with agoraphobia following tuberculous meningitis. Chand SP, et al. **Singapore Med J** 1996 Dec; 37(6):663–4

HISTORY

[Panic: attack and disorder. History of the word and concepts] Pichot P. **Encephale** 1996 Dec;22 Spec No 5:3–8 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

The psychoimmunological association of panic disorder and allergic reaction. Schmidt-Traub S, et al. **Br J Clin Psychol** 1997 Feb;36 (Pt 1):51–62

PHYSIOPATHOLOGY

The sleep of non-depressed patients with panic disorder: a comparison with normal controls. Arriaga F, et al. **Acta Psychiatr Scand** 1996 Mar;93(3):191–4

Relaxation-induced EEG alterations in panic disorder patients. Knott V, et al. **J Anxiety Disord** 1997 Jul–Aug; 11(4):365–76

Surface dependence: a balance control strategy in panic disorder with agoraphobia. Jacob RG, et al.

Psychosom Med 1997 May-Jun;59(3):323-30

PREVENTION & CONTROL

[The first panic attack: a missed chance for prevention of panic disorder and its complications] Amering M, et al. **Psychiatr Prax** 1997 Mar;24(2):65-8 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

The recollection of parental rearing styles in patients with panic disorder. Wiborg IM, et al. **Acta Psychiatr Scand** 1997 Jul;96(1):58-63

Social, blood/injury, and agoraphobic fears in patients with physically unexplained chronic pain: are they clinically significant? Asmundson GJ, et al. **Anxiety** 1996;2(1):28-33

Comparison of anxiety sensitivity in panic disorder and social phobia. Hazen AL, et al. **Anxiety** 1994-95;1(6):298-301

Embarrassment about the first panic attack predicts agoraphobia in panic disorder patients. Amering M, et al. **Behav Res Ther** 1997 Jun;35(6):517-21

Do agoraphobics interpret the environment in large shops and supermarkets differently? Jones RB, et al. **Br J Clin Psychol** 1996 Nov;35 (Pt 4):635-7

Interpersonal problems among patients suffering from panic disorder with agoraphobia before and after treatment. Hoffart A. **Br J Med Psychol** 1997 Jun;70 (Pt 2):149-57

Depersonalization and derealization during panic and hypnosis in low and highly hypnotizable agoraphobics. Van Dyck R, et al. **Int J Clin Exp Hypn** 1997 Jan;45(1):41-54

Opposite asymmetries in blind locomotor orientation of patients with panic agoraphobia compared to those with generalized anxiety. Kállai J, et al. **Int J Psychophysiol** 1996 Oct;23(3):155-61

Personality traits among panic disorder with agoraphobia patients before and after symptom-focused treatment. Hoffart A, et al. **J Anxiety Disord** 1997 Jan-Feb;11(1):77-87

Interpretive bias for benign sensations in panic disorder with agoraphobia. Kamieniecki GW, et al. **J Anxiety Disord** 1997 Mar-Apr;11(2):141-56

Space and motion discomfort in Brazilian versus American patients with anxiety disorders. Romas RT, et al. **J Anxiety Disord** 1997 Mar-Apr;11(2):131-9

Fear, anxiety and perceived control in children of agoraphobic parents. Capps L, et al. **J Child Psychol Psychiatry** 1996 May;37(4):445-52

My role as a consumer-provider: challenges and opportunities. Francell EG Jr. **J Psychosoc Nurs Ment Health Serv** 1996 Sep;34(9):29-31

RADIONUCLIDE IMAGING

Polycythaemia and agoraphobia. Haghighat R, et al. **J Behav Ther Exp Psychiatry** 1996 Jun;27(2):149-55

THERAPY

Does preference for type of treatment matter? A study of exposure in vivo with or without hypnosis in the treatment of panic disorder with agoraphobia. Van Dyck R, et al. **Behav Modif** 1997 Apr;21(2):172-86

Exposure versus cognitive restructuring in the treatment of panic disorder with agoraphobia. Bouchard S, et al. **Behav Res Ther** 1996 Mar;34(3):213-24

Discussion of "methodological controversies in the treatment of panic disorder". Klein DF. **Behav Res Ther** 1996 Nov-Dec;34(11-12):849-53; discussion 855-63

Cognitive and performance-based treatments for panic attacks in people with varying degrees of agoraphobic disability. Williams SL, et al. **Behav Res Ther** 1996 Mar; 34(3):253-64

Interoceptive exposure versus breathing retraining within cognitive-behavioural therapy for panic disorder with agoraphobia. Craske MG, et al. **Br J Clin Psychol** 1997 Feb;36 (Pt 1):85-99

Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care [see comments] Sharp DM, et al. **Br J Gen Pract** 1997 Mar;47(416):150-5 . Comment in: Br J Gen Pract 1997 Mar;47(416):136-7.

Personality traits among panic disorder with agoraphobia patients before and after symptom-focused treatment. Hoffart A, et al. **J Anxiety Disord** 1997 Jan-Feb;11(1):77-87

A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. van Balkom AJ, et al. **J Nerv Ment Dis** 1997 Aug;185(8):510-6

Two cases of panic disorder treated with autogenic training and in vivo exposure without medication. Sakai M, et al. **Psychiatry Clin Neurosci** 1996 Dec;50(6):335-6

Study and course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone. Bouvard M, et al. **Psychother Psychosom** 1997;66(1):27-32

Does exposure to internal cues enhance exposure to external cues in agoraphobia with panic? A pilot controlled study of self-exposure. Ito LM, et al. **Psychother Psychosom** 1996; 65(1):24-28

[The role of psychotherapy in managing panic disorder] Cottraux J. **Encephale** 1996 Dec;22 Spec No 5:54-60 (53 ref.) (Eng. Abstr.) **(Fre)**

AGRAMMATISM see **APHASIA, BROCA**

AGRANULOCYTOSIS

[Agranulocytosis] **Policlinico [Prat]** 1970 Dec 14; 77(50):1641-2 (00 ref.) **(Ita)**

BLOOD

The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Netea MG, et al. **Blood** 1997 Jan 15; 89(2):577-82

CHEMICALLY INDUCED

Treatment of drug-induced bone marrow suppression with recombinant human granulocyte/monocyte colony stimulating factor. Somogyi A, et al. **Adverse Drug React Toxicol Rev** 1996 Jun;15(2):119-24

Treatment of sulphasalazine-induced agranulocytosis with granulocyte macrophage-colony stimulating factor. Roddie P, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):711-2

Granulocyte colony-stimulating factor treatment of clozapine-induced agranulocytosis [letter] Pasquale D, et al. **Am J Psychiatry** 1996 Nov;153(11):1503-4

Agranulocytosis, plasmacytosis, and thrombocytosis followed by a leukemoid reaction due to acute acetaminophen toxicity. Gürsoy M, et al. **Ann Pharmacother** 1996 Jul-Aug;30(7-8):762-5

Comment: Pseudomonas bacteremia secondary to ticlopidine-induced agranulocytosis [letter] Johanning RJ, et al. **Ann Pharmacother** 1996 Oct;30(10):1201

Spironolactone-induced agranulocytosis. Whitling AM, et al. **Ann Pharmacother** 1997 May;31(5):582-5

Haematopoiesis in drug-induced agranulocytosis. Ruvidić R. **Biomed Pharmacother** 1996;50(6-7):275-8 (30 ref.)

Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). Castriota-Scanderbeg A, et al. **Br J Haematol** 1997 Feb; 96(2):254-5

Coexistence of eosinophilia and agranulocytosis in a clozapine-treated patient [letter] Amital D, et al. **Br J Psychiatry** 1997 Feb;170:194

Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Atkin K, et al. **Br J Psychiatry** 1996 Oct;169(4):483-8

Use of cytokines in clozapine-induced agranulocytosis [see comments] Chin-Yee I, et al. **Can J Psychiatry** 1996 Jun; 41(5):280-4 (42 ref.). Comment in: Can J Psychiatry 1996 Nov;41(9):603.

Re: Cytokines and agranulocytosis induced by clozapine [letter; comment] Malek-Ahmadi P. **Can J Psychiatry** 1996 Nov;41(9):603. Comment on: Can J Psychiatry 1996 Jun;41(5):280-4.

Structural features associated with reactive metabolite formation in clozapine analogues. Uetrecht J, et al. **Chem Biol Interact** 1997 May 2;104(2-3):117-29

Drug-induced agranulocytosis. **Drug Ther Bull** 1997 Jul; 35(7):49-52 (26 ref.)

Epidemiology. **Eur J Haematol Suppl** 1996;60:126-7

Drugs in the aetiology of agranulocytosis and aplastic anaemia. Kaufman DW, et al. **Eur J Haematol Suppl** 1996; 60:23-30

Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994. Wiholm BE, et al. **Eur J Haematol Suppl** 1996; 60:42-6

Comments on "Clozapine treatment after agranulocytosis induced by classic neuroleptics" [letter; comment] Mahmood T, et al. **J Clin Psychopharmacol** 1996 Jun; 16(3):262-3. Comment on: J Clin Psychopharmacol 1994 Feb;14(1):71-3.

Unsuccessful reexposure to clozapine [letter] Szarek BL, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):71-3

Case report: agranulocytosis induced by interferon-alpha therapy for chronic hepatitis C. Higashi Y, et al. **J Gastroenterol Hepatol** 1996 Nov;11(11):1012-5

Catastrophic consequences secondary to psychotropic drugs, Part 2. Keltner NL. **J Psychosoc Nurs Ment Health Serv** 1997 May;35(5):48-50

Dapsone agranulocytosis in a leprosy patient. Hiran S, et al. **Lepr Rev** 1994 Sep;65(3):279-81 (14 ref.)

Effect of recombinant human granulocyte colony stimulating factor on granulocytopenia induced by cytotoxic chemotherapy in patients with multiple myeloma. Pogłód R, et al. **Mater Med Pol** 1995 Jul-Sep;27(3):83-9

Oral ganciclovir as prophylaxis against cytomegalovirus [letter; comment] Nicklin D. **N Engl J Med** 1996 Oct 31; 335(18):1395; discussion 1396-7. Comment on: N Engl J Med 1996 Jun 6;334(23):1491-7.

Haematological side effects of clozapine: patient characteristics. Miller PR, et al. **N Z Med J** 1997 Apr 11; 110(1041):125-7

Colchicine agranulocytosis [letter] Ducloux D, et al. **Nephrol Dial Transplant** 1997 Jul;12(7):1541-2

Human leukocyte antigen system in clozapine-induced agranulocytosis. Theodoropoulou S, et al. **Neuropsychobiology** 1997;36(1):5-7

Thyrotoxicosis and antithyroid drugs. Monakier D, et al. **Postgrad Med J** 1997 Jun;73(860):335-6

Sertraline-induced agranulocytosis [letter] Trescoli-Serrano C, et al. **Postgrad Med J** 1996 Jul;72(849):446

Psychopharmacology. Clozapine and agranulocytosis. Feldman J. **Psychiatr Serv** 1996 Nov;47(11):1177-8

Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Honigfeld G. **Psychiatr Serv** 1996 Jan;47(1):52-6

The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF). Chengappa KN, et al. **Psychopharmacol Bull** 1996; 32(1):111-21

Agranulocytosis and bone marrow aplasia induced by second-line drugs for rheumatoid arthritis. Treatment with granulocyte colony-stimulating factor [letter; comment] Sayag-Boukris V, et al. **Rev Rhum Engl Ed** 1997 Jan; 64(1):66. Comment on: Rev Rhum Engl Ed 1995 Jul-Sep;62(7-8):477-86.

Successful treatment of a patient with Graves' disease on hemodialysis complicated by antithyroid drug-induced granulocytopenia and angina pectoris. Miyasaka Y, et al. **Thyroid** 1997 Aug;7(4):621-4

Usefulness of granulocyte count measurement four hours after injection of granulocyte colony-stimulating factor for detecting recovery from antithyroid drug-induced granulocytopenia. Tajiri J, et al. **Thyroid** 1997 Aug; 7(4):575-8

[Agranulocytosis caused by perindopril (letter)] Hamidou M, et al. **Ann Med Interne (Paris)** 1996;147(7):523-4 **(Fre)**

[Hematologic effects of clozapine: a review of the international experience] Lamarque V. **Encephale** 1996 Dec;22 Spec No 6:35-6 (Eng. Abstr.) **(Fre)**

[Agranulocytosis during a treatment with terbinafine (letter)] Barete S, et al. **Rev Med Interne** 1997;18(3):258-9 **(Fre)**

[Acute drug-induced agranulocytosis: experience of the Regional Center of Pharmacovigilance of Lyon over 7 years] Vial T, et al. **Therapie** 1996 Sep-Oct;51(5):508-15 (Eng. Abstr.) **(Fre)**

[Treatment of drug-induced agranulocytosis with granulocyte colony stimulating factor (G-CSF) in a surgical intensive care unit] Huss B, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):529-30 (Eng. Abstr.) **(Ger)**

[Effective administration of recombinant granulocyte colony-stimulating factor to prevent granulocytopenia due to combination chemotherapy for testicular germ cell tumors] Nonomura K, et al. **Hinyokika Kiyo** 1996 Sep; 42(9):699-704 (Eng. Abstr.) **(Jpn)**

[Drug induced hemolytic anemia associated with agranulocytosis] Satoh S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Oct; 19(5):498-504 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Comment: Pseudomonas bacteremia secondary to ticlopidine-induced agranulocytosis [letter] Johanning RJ, et al. **Ann Pharmacother** 1996 Oct;30(10):1201

Granulocytopenia in Cohen syndrome. Kivitie-Kallio S, et al. **Br J Haematol** 1997 Aug;98(2):308-11

Thymoma and agranulocytosis: two case reports and literature review. Yip D, et al. **Br J Haematol** 1996 Oct; 95(1):52-6 (10 ref.)

High-dose itraconazole for the treatment of cerebral aspergillosis [letter; comment] Verweij PE, et al. **Clin Infect Dis** 1996 Nov;23(5):1196-7. Comment on: Clin Infect Dis 1995 Dec;21(6):1485-7.

Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. Böhme A, et al. **J Antimicrob Chemother** 1996 Dec; 38(6):953-61

Ceftriaxone as a single agent in empirical therapy of unexplained fever in granulocytopenic children with solid tumors. Bartolozzi S, et al. **J Chemother** 1997 Jun; 9(3):227-31

Effective splenectomy in agranulocytosis associated with systemic lupus erythematosus [letter] Formiga F, et al. **J Rheumatol** 1997 Jan;24(1):234-5

A coincidence of disastrous accidents: Crohn's disease, agranulocytosis, and Clostridium septicum infection. Thalhammer F, et al. **J Trauma** 1997 Sep;43(3):556-7

[Effectiveness of piperacillin/tazobactam in the treatment of fever of unknown etiology in patients with granulocytopenia] Maschan AA, et al. **Antibiot Khimioter** 1997;42(2):38-40 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Chemotherapy and granulocyte-colony stimulating factor for non-Hodgkin's lymphoma of the head and neck. Tsuge I, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:129-34

Treatment of sulphasalazine-induced agranulocytosis with granulocyte macrophage-colony stimulating factor. Roddie P, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):711-2

Granulocyte colony-stimulating factor treatment of clozapine-induced agranulocytosis [letter] Pasquale D, et al. **Am J Psychiatry** 1996 Nov;153(11):1503-4

Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Avilés A, et al. **Anticancer Drugs** 1996 Jun;7(4):392-7

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Cometta A, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1108-15

AGRANULOCYTOSIS

Treatment of drug-induced agranulocytosis with colony stimulating factors (G-CSF or GM-CSF). Góra-Tybor J, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(4):255-8

Re: Cytokines and agranulocytosis induced by clozapine [letter; comment] Malek-Ahmadi P. **Can J Psychiatry** 1996 Nov;41(9):603. Comment on: Can J Psychiatry 1996 Jun;41(5):280-4.

Effect of recombinant human granulocyte colony stimulating factor on granulocytopenia induced by cytotoxic chemotherapy in patients with multiple myeloma. Poglód R, et al. **Mater Med Pol** 1995 Jul-Sep;27(3):83-9

Effects of polar glycopeptidolipids of Mycobacterium chelonae (pGPL-Mc) on haematopoietic regeneration and resistance to infection of sublethally irradiated mice. Neway T, et al. **Res Immunol** 1996 Jan;147(1):39-48

ENZYMOLOGY

Activation of CGS 12094 (prinomide metabolite) to 1,4-benzoquinone by myeloperoxidase: implications for human idiosyncratic agranulocytosis. Parrish DD, et al. **Fundam Appl Toxicol** 1997 Feb;35(2):197-204

ETIOLOGY

Agranulocytosis and thrombocytopenic purpura following measles infection in a living-related orthotopic liver transplantation recipient. Arakawa Y, et al. **Acta Paediatr Jpn** 1997 Apr;39(2):226-9

Clozapine-induced agranulocytosis [letter] Fenner S, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):874-5

Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. Böhme A, et al. **J Antimicrob Chemother** 1996 Dec; 38(6):953-61

[Agranulocytosis secondary to acute hepatitis B with a good response to G-CSF (letter)] Ulla Anes M, et al. **Sangre (Barc)** 1997 Feb;42(1):91-2 **(Spa)**

GENETICS

Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Turbay D, et al. **Blood** 1997 Jun 1;89(11):4167-74

METABOLISM

Reactive metabolites and agranulocytosis. Uetrecht JP. **Eur J Haematol Suppl** 1996;60:83-8 (38 ref.)

PREVENTION & CONTROL

Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma. Avilés A, et al. **Eur J Cancer** 1997 Jul;33(8):1323-5

SURGERY

Effective splenectomy in agranulocytosis associated with systemic lupus erythematosus [letter] Formiga F, et al. **J Rheumatol** 1997 Jan;24(1):234-5

THERAPY

Haploidentical bone marrow transplants for two patients with reticular dysgenesis. De Santes KB, et al. **Bone Marrow Transplant** 1996 Jun;17(6):1171-3

[Effective administration of recombinant granulocyte colony-stimulating factor to prevent granulocytopenia due to combination chemotherapy for testicular germ cell tumors] Nonomura K, et al. **Hinyokika Kiyo** 1996 Sep; 42(9):699-704 (Eng. Abstr.) **(Jpn)**

[Intensive care of myelotoxic agranulocytosis using nonselective plasmapheresis] Andriukhin VI, et al. **Anesteziol Reanimatol** 1996 Jul-Aug;(4):75-6 (Eng. Abstr.) **(Rus)**

[A case of the successful use of plasmapheresis in the combined treatment of a female patient with autoimmune agranulocytosis against a background of Schmidt's syndrome] Vlasenko AN, et al. **Ter Arkh** 1997;69(2):64-5 (10 ref.) **(Rus)**

AGRANULOCYTOSIS, FELINE see **FELINE PANLEUKOPENIA**

AGRAPHIA

COMPLICATIONS

Agraphia in Alzheimer's disease: an independent lexical impairment. Lambert J, et al. **Brain Lang** 1996 May; 53(2):222-33

DIAGNOSIS

Acquired dysgraphia in alphabetic and stenographic handwriting. Miceli G, et al. **Cortex** 1997 Jun;33(2):355-67

Instrument for locating students with suspected learning disabilities: a quantitative approach. Engel R. **Int J Rehabil Res** 1997 Jun;20(2):169-81

The continuum of deep/surface dyslexia. Nolan KA, et al. **J Psycholinguist Res** 1997 Jul;26(4):413-24

ETIOLOGY

Agraphia as the only symptom of migraine aura: a case report. Evers S, et al. **Cephalalgia** 1996 Dec;16(8):562-3

Acquired dysgraphia with selective damage to the graphemic buffer: a single case report. Cantagallo A, et al. **Ital J Neurol Sci** 1996 Jun;17(3):249-54

Spatial dysgraphia and cerebellar lesion: a case report. Silveri MC, et al. **Neurology** 1997 Jun;48(6):1529-32

[Neuro-cognitive models of spelling and Alzheimer disease: mutual clarification] Eustache F, et al. **Rev Neurol (Paris)** 1996 Nov;152(11):658-68 (60 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Alexia and agraphia in posterior cortical atrophy. Ardila A, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Jan; 10(1):52-9

[Developmental dyslexia and dysgraphia--a case report] Kaneko M, et al. **No To Hattatsu** 1997 May;29(3):249-53 (Eng. Abstr.) **(Jpn)**

THERAPY

Brief communication: electromagnetic fields improve visuospatial performance and reverse agraphia in a parkinsonian patient. Sandyk R. **Int J Neurosci** 1996 Nov; 87(3-4):209-17

AGRICULTURAL CHEMICALS see **AGROCHEMICALS**

AGRICULTURAL CROPS see **CROPS, AGRICULTURAL**

AGRICULTURAL WORKERS' DISEASES

Cancer-causing effects of pesticides [letter] Curtis L. **Arch Environ Health** 1996 Nov-Dec;51(6):473

Oestrus ovis (sheep nasal fly) infesting the eyes and the nose of a camel keeper family. Fekry AA, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):493-6

Musculoskeletal problems in the tomato growing industry: 'tomato trainer's shoulder'? Palmer KT. **Occup Med (Oxf)** 1996 Dec;46(6):428-31

Health problems of migrant farm workers. **Tex Med** 1996 Oct;92(10):25

[Mycetoma: report of 3 cases in Falcón State, Venezuela] Pérez-Blanco M, et al. **Invest Clin** 1996 Mar;37(1):61-73 (23 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Risk factors for systemic illnesses following agricultural exposures to restricted organophosphates in California, 1984-1988. Weinbaum Z, et al. **Am J Ind Med** 1997 May; 31(5):572-9

Cancer-causing effects of pesticides [letter] Curtis L. **Arch Environ Health** 1996 Nov-Dec;51(6):473

Dermatitis in Ecuadorean farm workers. Cole DC, et al. **Contact Dermatitis** 1997 Jul;37(1):1-8

An investigation into neurologic and neurobehavioral effects of long-term agrichemical use among deciduous fruit farm workers in the Western Cape, South Africa. London L, et al. **Environ Res** 1997;73(1-2):132-45

A systemic reaction following exposure to a pyrethroid insecticide. Box SA, et al. **Hum Exp Toxicol** 1996 May; 15(5):389-90

Abnormalities on neurological examination among sheep farmers exposed to organophosphorous pesticides. Beach JR, et al. **Occup Environ Med** 1996 Aug;53(8):520-5

The problems associated with pesticide use by irrigation workers in Ghana. Clarke EE, et al. **Occup Med (Oxf)** 1997 Jul;47(5):301-8

Farming, pesticide use and hairy-cell leukemia. Clavel J, et al. **Scand J Work Environ Health** 1996 Aug;22(4):285-93

A jaundiced farmer. Richards JM, et al. **Scott Med J** 1996 Dec;41(6):176-7

[Tumors of the hemolymphopoietic tract and employment in agriculture: a case-control study carried out in an epidemiologic area in southern Italy] Assennato G, et al. **G Ital Med Lav** 1995 Jan-Nov;17(1-6):91-7 (Eng. Abstr.) **(Ita)**

CLASSIFICATION

Type of prion protein in UK farmers with Creutzfeldt-Jakob disease [letter] Hill AF, et al. **Lancet** 1997 Jul 19; 350(9072):188

DIAGNOSIS

Occupational asthma in poultry-slaughterhouse workers. Perfetti L, et al. **Allergy** 1997 May;52(5):594-5

Effect of ambient ozone exposure on lung function in farm workers. Brauer M, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):981-7

Enlarging lesion on hand. Golledge CL. **Aust Fam Physician** 1996 May;25(5):787

Occupational allergic contact dermatitis and airborne contact dermatitis from 5 fungicides in a vineyard worker. Cross-reactions between fungicides of the dithiocarbamate group? Koch P. **Contact Dermatitis** 1996 May;34(5):324-9

EPIDEMIOLOGY

Representativeness of trauma center registries for farm injury surveillance. Layde PM, et al. **Accid Anal Prev** 1996 Sep; 28(5):581-6

Gestational age, birth weight, and perinatal death among births to Norwegian farmers, 1967-1991. Kristensen P, et al. **Am J Epidemiol** 1997 Aug 15;146(4):329-38

Association between female infertility and agricultural work history. Fuortes L, et al. **Am J Ind Med** 1997 Apr; 31(4):445-51

Estimating underreported pesticide poisonings in Nicaragua. Keifer M, et al. **Am J Ind Med** 1996 Aug;30(2):195-201

A meta-analysis of non-Hodgkin's lymphoma among farmers in the central United States. Keller-Byrne JE, et al. **Am J Ind Med** 1997 Apr;31(4):442-4

Cancer feasibility studies among migrant farmworkers. The Farmworker Epidemiology Research Group. Zahm SH, et al. **Am J Ind Med** 1997 Sep;32(3):301-2

Respiratory function in vineyard and orchard workers. Zuskin E, et al. **Am J Ind Med** 1997 Feb;31(2):250-5

Aplastic anemia in rural Thailand: its association with grain farming and agricultural pesticide exposure. Aplastic Anemia Study Group. Issaragrisil S, et al. **Am J Public Health** 1997 Sep;87(9):1551-4

Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96. Cousens SN, et al. **BMJ** 1997 Aug 16;315(7105):389-95

Commentary: age related exposure of patients to the agent of BSE should not be downplayed. Gore SM. **BMJ** 1997 Aug 16;315(7105):395-6

Children of farm laborers: utilization of services for mental health problems. Martin SL, et al. **Community Ment Health J** 1996 Aug;32(4):327-40

Psychiatric disorders among Egyptian pesticide applicators and formulators. Amr MM, et al. **Environ Res** 1997; 73(1-2):193-9

Meta-analysis of leukemia and farming. Keller-Byrne JE, et al. **Environ Res** 1995 Oct;71(1):1-10

Injury from dairy cattle activities. Boyle D, et al. **Epidemiology** 1997 Jan;8(1):37-41

Disinfectant use as a risk factor for atopic sensitization and symptoms consistent with asthma: an epidemiological study. Preller L, et al. **Eur Respir J** 1996 Jul;9(7):1407-13

Cancer in banana plantation workers in Costa Rica. Wesseling C, et al. **Int J Epidemiol** 1996 Dec;25(6):1125-31

Cancer incidence among Icelandic pesticide users. Zhong Y, et al. **Int J Epidemiol** 1996 Dec;25(6):1117-24

Outbreak of sporotrichosis among tree nursery workers. Hajjeh R, et al. **J Infect Dis** 1997 Aug;176(2):499-504

Pesticide poisonings in the lawn care and tree service industries. A review of cases in the New York State Pesticide Poisoning Registry [see comments] Gadon M. **J Occup Environ Med** 1996 Aug;38(8):794-9. Comment in: J Occup Environ Med 1997 Mar;39(3):193-4.

A population-based study of tractor-related injuries: Regional Rural Injury Study-I (RRIS-I). Lee TY, et al. **J Occup Environ Med** 1996 Aug;38(8):782-93

Spatial and temporal clustering of an occupational poisoning: the example of green tobacco sickness. McKnight RH, et al. **Stat Med** 1996 Apr 15-May 15;15(7-9):747-57

ETIOLOGY

Occupational allergy in saffron workers. Feo F, et al. **Allergy** 1997 Jun;52(6):633-41

Hypersensitivity pneumonitis induced by exposure to the legume algarroba. Franco-Vicario R, et al. **Allergy** 1997 Apr;52(4):478-9

Occupational type I allergy to Christmas cactus (Schlumbergera). Paulsen E, et al. **Allergy** 1997 Jun; 52(6):656-60

Association between female infertility and agricultural work history. Fuortes L, et al. **Am J Ind Med** 1997 Apr; 31(4):445-51

Meta-analyses of prostate cancer and farming. Keller-Byrne JE, et al. **Am J Ind Med** 1997 May;31(5):580-6

Respiratory morbidity in relationship to farm characteristics in swine confinement work: possible preventive measures. Vogelzang PF, et al. **Am J Ind Med** 1996 Aug;30(2):212-8

Allergic contact dermatitis from streptomycin in a cattle breede. Gauchía R, et al. **Contact Dermatitis** 1996 Dec; 35(6):374-5

Occupational allergic contact dermatitis caused by decorative plants. Lamminpää A, et al. **Contact Dermatitis** 1996 May; 34(5):330-5

Contact dermatitis in agricultural workers: rôle of common crops, fodder and weeds. Mahajan VK, et al. **Contact Dermatitis** 1996 Dec;35(6):373-4

The role of endotoxin in grain dust exposure and airway obstruction. Von Essen S. **Curr Opin Pulm Med** 1997 May; 3(3):198-202 (37 ref.)

Danger in the dust. Lang L. **Environ Health Perspect** 1996 Jan;104(1):26-30

Epidemiology of Lyme disease in France: Lyme borreliosis in the region of Berry sud: a six year retrospective. Christiann F, et al. **Eur J Epidemiol** 1996 Oct;12(5):479-83

Clinical and biochemical changes in greenhouse sprayers chronically exposed to pesticides. Parrón T, et al. **Hum Exp Toxicol** 1996 Dec;15(12):957-63

A health hazard for female adolescent farmers: scalp avulsion [letter] Borman H, et al. **J Adolesc Health** 1997 Jan;20(1):2

Cytogenetic biomonitoring of pesticide-exposed farmers in central Italy. Pasquini R, et al. **J Environ Pathol Toxicol Oncol** 1996;15(1):29-39

Green tobacco sickness (bradycardia in a young farmer). Edmonson WD. **J Tenn Med Assoc** 1996 Mar;89(3):85-6

Is working in greenhouses healthy? Evidence concerning the

toxic risks that might affect greenhouse workers. Illing HP. **Occup Med (Oxf)** 1997 Jul;47(5):281–93 (70 ref.)
Corneal ulcers in paddy workers in south India [letter] Kulshrestha M, et al. **Occup Med (Oxf)** 1996 Aug;46(4):320
Milking is a high–risk job for young females. Stål M, et al. **Scand J Rehabil Med** 1996 May;28(2):95–104
Modeling long–term average exposure in occupational exposure–response analysis. Preller L, et al. **Scand J Work Environ Health** 1995 Dec;21(6):504–12
[Chronic obstructive bronchitis in a fodder farming setting] Dalphin JC. **Rev Mal Respir** 1996 Dec;13(6):575–81 (22 ref.) (Eng. Abstr.) **(Fre)**
[Different threshold concentrations for sensitization by cattle hair allergen Bos d 2 in atopic and non–atopic farmers] Hinze S, et al. **Pneumologie** 1996 Feb;50(2):177–81 (Eng. Abstr.) **(Ger)**
[Exposure to organic dust and microorganisms as a factor affecting respiratory function of workers of purebred horse farms] Mackiewicz B, et al. **Pneumonol Alergol Pol** 1996; 64 Suppl 1:19–24 (Eng. Abstr.) **(Pol)**

GENETICS

Cytogenetic Monitoring of Farmers exposed to pesticides in Colombia. Hoyos LS, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:535–8
Butyrylcholinesterase variants (BCHE and CHE2 Loci) associated with erythrocyte acetylcholinesterase inhibition in farmers exposed to pesticides. Fontoura–da–Silva SE, et al. **Hum Hered** 1996 May–Jun;46(3):142–7

IMMUNOLOGY

Humoral responses to bovine dust in dairy farmers with allergic rhinitis. Rautiainen M, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;529:169–72
IgE–mediated allergy to spider mite, Panonychus citri in occupationally exposed individuals. Ashida T, et al. **Arerugi** 1995 Nov;44(11):1290–6
Immunological effects of grain dust. Gould JR, et al. **Biochem Soc Trans** 1997 May;25(2):159S
IgE response to fur animal allergens and domestic animal allergens in fur farmers and fur garment workers [see comments] Savolainen J, et al. **Clin Exp Allergy** 1997 May; 27(5):501–9. Comment in: Clin Exp Allergy 1997 May;27(5):479–81.
Immune reactivity of cow–asthmatic dairy farmers to the major allergen of cow (BDA20) and to other cow–derived proteins. The use of purified BDA20 increases the performance of diagnostic tests in respiratory cow allergy. Virtanen T, et al. **Clin Exp Allergy** 1996 Feb;26(2):188–96
High incidence of Coxiella burnetii markers in a rural population in France. Thibon M, et al. **Eur J Epidemiol** 1996 Oct;12(5):509–13

MICROBIOLOGY

Transmission of Trichophyton interdigitale via an intermediate plant host [letter] Weller R, et al. **Br J Dermatol** 1996 Oct;135(4):656–7
Tularemia: association with hunting and farming. Stewart SJ. **FEMS Immunol Med Microbiol** 1996 Mar;13(3):197–99
Vero–cytotoxin–producing Escherichia coli O157 in a farmer handling horses [letter] Chalmers RM, et al. **Lancet** 1997 Jun 21;349(9068):1816
Pasteurella aerogenes isolated from ulcers or wounds in humans with occupational exposure to pigs: a report of 7 Danish cases. Ejlertsen T, et al. **Scand J Infect Dis** 1996; 28(6):567–70
[Intestinal entomothoramycosis: report of a case] Carvalho FA, et al. **Rev Soc Bras Med Trop** 1996 Jan–Feb;30(1):65–8 (Eng. Abstr.) **(Por)**
[The causative agents of chlamydiosis in agricultural animals and their pathogenicity for man] Khamadeev RKh, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb; (1):99–101 (28 ref.) **(Rus)**

MORTALITY

Cancer mortality among rice growers in Novara Province, northern Italy. Gambini GF, et al. **Am J Ind Med** 1997 Apr;31(4):435–41
Fatal agricultural injuries in North Carolina by race and occupation, 1977–1991. Richardson D, et al. **Am J Ind Med** 1997 Apr;31(4):452–8
Mortality of farmers and farmers' wives in England and Wales 1979–80, 1982–90. Inskip H, et al. **Occup Environ Med** 1996 Nov;53(11):730–5
[Mortality by tumors and other causes in dairy cattle and other agricultural workers in Veneto] Mastrangelo G, et al. **G Ital Med Lav** 1995 Jan–Nov;17(1–6):19–21 (Eng. Abstr.) **(Ita)**

PARASITOLOGY

Occupational otitis externa in chicken catchers. Rossiter A. **J Laryngol Otol** 1997 Apr;111(4):366–7
Occupational asthma in greenhouse tomato growing. Erlam AR, et al. **Occup Med (Oxf)** 1996 Apr;46(2):163–4
[Primary calcified mediastinal hydatid cyst producing compression] Benzarti M, et al. **Rev Mal Respir** 1997 Jan; 14(1):53–4 (Eng. Abstr.) **(Fre)**
[Strongyloides stercoralis infection in a cortico–dependent patient with chronic airflow obstruction] Cremades Romero MJ, et al. **Arch Bronconeumol** 1996 Oct;32(8):430–1 (Eng. Abstr.) **(Spa)**

PATHOLOGY

Tularemia: association with hunting and farming. Stewart SJ. **FEMS Immunol Med Microbiol** 1996 Mar;13(3):197–99
Clinical and biochemical changes in greenhouse sprayers chronically exposed to pesticides. Parrón T, et al. **Hum Exp Toxicol** 1996 Dec;15(12):957–63
[Milker's nodules] Hansen SK, et al. **Ugeskr Laeger** 1997 Jan 20;159(4):436–7 (Eng. Abstr.) **(Dan)**

PREVENTION & CONTROL

Health care for pesticide applicators in a locust eradication campaign in Kuwait (1988–1989). Al–Shatti AK, et al. **Environ Res** 1997;73(1–2):219–26
Preventive medicine and health promotion are overdue in the agricultural workplace. Schenker MB. **J Public Health Policy** 1996;17(3):275–305 (95 ref.)
A clinical historical overview of pesticide health issues. Schuman SH, et al. **Occup Med** 1997 Apr–Jun;12(2):203–7 (15 ref.)

PSYCHOLOGY

Sense of coherence, negative affectivity, and general health in farm supervisors. Strümpfer DJ. **Psychol Rep** 1997 Jun; 80(3 Pt 1):963–6

THERAPY

Acute calcification of the peroneal tendons in a sheep shearer. Williams CR. **Foot Ankle Int** 1996 Jan;17(1):49–50

AGRICULTURE

Medications as risk factors for farm injury. Pickett W, et al. **Accid Anal Prev** 1996 Jul;28(4):453–62
A pre–intervention survey to determine understanding of HIV and AIDS in farm worker communities in Zimbabwe. Laver SM, et al. **AIDS Educ Prev** 1997 Feb;9(1):94–110
Individual, organizational, and societal empowerment: a study of the processes in a Nicaraguan agricultural cooperative. Kroeker CJ. **Am J Community Psychol** 1995 Oct;23(5):749–64
Environmental factors, reproductive history, and selective fertility in farmers' sibships. Kristensen P, et al. **Am J Epidemiol** 1997 May 1;145(9):817–25
The relation between subjective dust exposure estimates and quantitative dust exposure measurements in California agriculture. Nieuwenhuijsen MJ, et al. **Am J Ind Med** 1997 Oct;32(4):355–63
The Agricultural Health Study: factors affecting completion and return of self–administered questionnaires in a large prospective cohort study of pesticide applicators. Tarone RE, et al. **Am J Ind Med** 1997 Feb;31(2):233–42
Role of agriculture in creating values for the country and improving the quality of life for the people of Malaysia towards de year 2020. Daud SH. **Ann Acad Med Singapore** 1995 Nov;24(6):921–5
Hard work does not result in a decrease in meal quality: the case of a Japanese farming village. Nakatsuka H, et al. **Appetite** 1997 Apr;28(2):177–83
Is sustainable development a practical possibility given the continued use of plant protection products?—the scientific view. Herrchen M, et al. **Arch Toxicol Suppl** 1997;19:167–76 (17 ref.)
Cancer incidence among Finnish farmers, 1979–93. Pukkala E, et al. **Cancer Causes Control** 1997 Jan;8(1):25–33
Cryptosporidiosis in children who visited an open farm. Sayers GM, et al. **Commun Dis Rep CDR Rev** 1996 Sep 13;6(10):R140–4
Two outbreaks of Vero cytotoxin producing Escherichia coli O157 infection associated with farms. **Commun Dis Rep CDR Wkly** 1997 Jul 25;7(30):263, 266
Contact dermatitis caused by the insecticides omethoate and dimethoate. Haenen C, et al. **Contact Dermatitis** 1996 Jul; 35(1):54–5
Contact dermatitis due to rubber boots worn by Japanese farmers, with special attention to 6–ethoxy–2,2,4–trimethyl–1,2–dihydroquinoline (ETMDQ) sensitivity. Nishioka K, et al. **Contact Dermatitis** 1996 Oct; 35(4):241–5
Chlorothalonil, a possible cause of erythema dyschromicum perstans (ashy dermatitis). Penagos H, et al. **Contact Dermatitis** 1996 Oct;35(4):214–8
Allergic contact dermatitis from kiwi fruit vine (actinidia chinensis). Rademaker M. **Contact Dermatitis** 1996 Mar; 34(3):221–2
Local institutional development and relief in Ethiopia: a kire–based seed distribution programme in North Wollo. Pratten DT. **Disasters** 1997 Jun;21(2):138–54
Correlation of environmental carbaryl measurements with serum and urinary 1–naphthol measurements in a farmer applicator and his family. Shealy DB, et al. **Environ Health Perspect** 1997 May;105(5):510–3
Birth defects among offspring of Norwegian farmers, 1967–1991. Kristensen P, et al. **Epidemiology** 1997 Sep; 8(5):537–44
A comparative study of mortality in agricultural and industrial areas in Spain. Suarez Varela MM, et al. **Eur J Epidemiol** 1995 Dec;11(6):633–41
Reactive airways dysfunction syndrome (RADS) following exposure to toxic gases of a swine confinement building. Cormier Y, et al. **Eur Respir J** 1996 May;9(5):1090–1
Molecular mapping and tagging of genes in crop plants. Sharma RP, et al. **Genetica** 1996 May;97(3):313–20 (36 ref.)
Wheat threshing dust—a "new allergen" in April–May nasobronchial allergy. Lavasa S, et al. **Indian Pediatr** 1996 Jul;33(7):566–70
Use of psychotropic drugs and risk of myocardial infarction: a case–control study in Finnish farmers. Penttinen J, et al. **Int J Epidemiol** 1996 Aug;25(4):760–2
Nutrient composition and nutritional importance of green leaves and wild food resources in an agricultural district, Koutiala, in southern Mali. Nordeide MB, et al. **Int J Food Sci Nutr** 1996 Nov;47(6):455–68
Agricultural pesticide use in developing countries: health effects and research needs. Wesseling C, et al. **Int J Health Serv** 1997;27(2):273–308
Marketing strategies to enhance the value of food animal veterinarians. Clevenger J. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1386–7
The world's food supply and the role of food animal veterinarians [letter] Herrick JB. **J Am Vet Med Assoc** 1997 Mar 15;210(6):751–2
Challenges for food animal veterinarians in food animal production in the 21st century. Humble JA. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1106–8
The biologic production unit for food animal veterinarians. Humble JA. **J Am Vet Med Assoc** 1996 Nov 15; 209(10):1698–9
The role of industry in international animal agriculture. Peel CJ. **J Anim Sci** 1996 Jun;74(6):1382–5 (4 ref.)
Malaria epidemic in Lamta PHC of Balaghat district—a rice cultivating ecosystem. Chand G, et al. **J Commun Dis** 1997 Jun;29(2):179–81
Drug rehabilitation in a treatment farm setting: the Nitawgi farm experience, 1978–1990. Richardson DW. **J Dev Behav Pediatr** 1996 Aug;17(4):258–61
Dietary exposure from pesticide application on farms in the Agricultural Health Pilot Study. Melnyk LJ, et al. **J Expo Anal Environ Epidemiol** 1997 Jan–Mar;7(1):61–80
Acute Q fever as a cause of acute febrile illness of unknown origin in Taiwan: report of seven cases. Ko WC, et al. **J Formos Med Assoc** 1997 Apr;96(4):295–7
Physical workload during selected farm operations. Salokhe VM, et al. **J Hum Ergol (Tokyo)** 1995 Dec;24(2):161–9
Effects of rice culture practices on the abundance of Culex mosquitoes (Diptera:Culicidae) in northern Thailand. Takagi M, et al. **J Med Entomol** 1997 May;34(3):272–6
Agricultural safety and health: principles and possibilities for nursing education. Martin SR. **J Nurs Educ** 1997 Feb; 36(2):74–8
Micronutrient status of plantation workers in Sri Lanka during pregnancy and postpartum. de Silva LD, et al. **J Obstet Gynaecol Res** 1996 Jun;22(3):239–46
Cancer incidence among women living on farms: findings from the Iowa Women's Health Study. Folsom AR, et al. **J Occup Environ Med** 1996 Nov;38(11):1171–6
An epidemiological study of roadway fatalities related to farm vehicles: United States, 1988 to 1993. Gerberich SG, et al. **J Occup Environ Med** 1996 Nov;38(11):1135–40
Pesticide application and increased dioxin body burden in male and female agricultural workers in China. Schecter AJ, et al. **J Occup Environ Med** 1996 Sep;38(9):906–11
Tobacco prevention in tobacco–raising areas: lessons from the lion's den. Noland MP. **J Sch Health** 1996 Sep; 66(7):266–8
From the Centers for Disease Control and Prevention. Use of rollover protective structures—Iowa, Kentucky, New York, and Ohio, 1992–1997. **JAMA** 1997 Oct 8; 278(14):1144–5
Does organic gardening foster foodborne pathogens? [letter; comment] DiMatteo KT. **JAMA** 1997 Jun 4; 277(21):1679–80. Comment on: JAMA 1997 Jan 8;277(2):97–8.
Effect on infant mortality of iodination of irrigation water in a severely iodine–deficient area of China. DeLong GR, et al. **Lancet** 1997 Sep 13;350(9080):771–3
Occurrence of glycopeptide resistance among Enterococcus faecium isolates from conventional and ecological poultry farms. Aarestrup FM. **Microb Drug Resist** 1995 Fall; 1(3):255–7
Suffocations in grain bins—Minnesota, 1992–1995. **MMWR Morb Mortal Wkly Rep** 1996 Oct 4;45(39):837–41
Skid–steer loader–related fatalities in the workplace—United States, 1992–1995. **MMWR Morb Mortal Wkly Rep** 1996 Jul 26;45(29):624–8
Use of rollover protective structures -- Iowa, Kentucky, and Ohio, 1992–1997. **MMWR Morb Mortal Wkly Rep** 1997 Sep 12;46(36):842–5
Pros and cons of foreign genes in crops [letter; comment] Bengtsson BO. **Nature** 1997 Jan 23;385(6614):290. Comment on: Nature 1996 Oct 17;383(6601):559. Comment on: Nature 1996 Nov 28;384(6607):304.
Organophosphates: the relationship between chronic and acute exposure effects. Stephens R, et al. **Neurotoxicol Teratol** 1996 Jul–Aug;18(4):449–53
Immunological changes among farmers exposed to phenoxy herbicides: preliminary observations. Faustini A, et al. **Occup Environ Med** 1996 Sep;53(9):583–5
Accidents related to manure in eastern Switzerland: an epidemiological study. Knoblauch A, et al. **Occup Environ Med** 1996 Sep;53(9):577–82

AGRICULTURE

Erythrocyte cholinesterase activity levels in desert farm workers. Gomes J, et al. **Occup Med (Oxf)** 1997 Feb; 47(2):90–4

Work-related accidents of ophthalmologic interest in Italy during 1986–1991. Cruciani F, et al. **Ophthalmologica** 1997; 211(4):251–5

Induced intensification: agricultural change in Bangladesh with implications for Malthus and Boserup. Turner BL 2nd, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10; 93(25):14984–91

Limits and limitations to nitrogen use in farm animals. Oldham JD, et al. **Proc Nutr Soc** 1997 Jul;56(2):525–34 (40 ref.)

Consumption implications of agri-food policies. Traill B, et al. **Proc Nutr Soc** 1996 Jul;55(2):649–59 (14 ref.)

Agricultural safety efforts by county health departments in Wisconsin. Chapman LJ, et al. **Public Health Rep** 1996 Sep–Oct;111(5):437–43

Experts' subjective assessment of pesticide exposure in fruit growing. de Cock J, et al.
Scand J Work Environ Health 1996 Dec;22(6):425–32

Potential for respirable quartz exposure from North Carolina farm soils. Stopford CM, et al.
Scand J Work Environ Health 1995;21 Suppl 2:44–6

Alternative measures of pesticide use. Barnard C, et al.
Sci Total Environ 1997 Sep 15;203(3):229–44

Green revolution agriculture and chemical hazards. Pimentel D. **Sci Total Environ** 1996 Sep;188 Suppl 1:S86–98 (93 ref.)

Morbidity and mortality due to malaria in Tarajulie Tea Estate, Assam, India. Gogoi SC, et al.
Southeast Asian J Trop Med Public Health 1996 Sep; 27(3):526–9

Impact of guineaworm disease on agricultural productivity in Owo local government area, Ondo state. Adewale B, et al. **West Afr J Med** 1997 May–Jun;16(2):75–9

Changes in agriculture bring potential for new health and safety risks. Olenchock SA, et al. **Wis Med J** 1997 Aug; 96(8):10–1

University of Wisconsin agricultural safety and health activities. Purschwitz M. **Wis Med J** 1997 Aug;96(8):25–9

Farm injuries don't just involve farmers [editorial] Purschwitz MA. **Wis Med J** 1997 Aug;96(8):9

Talking about health and health care: experiences and perspectives of Latina women in a farmworking community. Farr KA, et al. **Women Health** 1997; 25(2):23–40

Water: where from, and for whom? Konradsen F, et al.
World Health Forum 1997;18(1):41–3

Tobacco in Africa. Yach D. **World Health Forum** 1996; 17(1):29–36

[Treatment of sludge from purification stations with the purpose of ameliorating soils intended for agriculture: parasitic contamination and model development with a view to managing the sanitation risk] Gaspard P, et al. **Bull Acad Natl Med** 1997 Jan;181(1):43–56; discussion 57 (Eng. Abstr.) **(Fre)**

[Introduction: soil pollution, agriculture and public health] Molina C. **Bull Acad Natl Med** 1997 Jan;181(1):17–9 **(Fre)**

[The effect of the multiyear agricultural use of animal husbandry wastes on the infectious morbidity of the local population] Prokopov VA, et al. **Lik Sprava** 1995 Mar–Apr; (3–4):127–32 (Eng. Abstr.) **(Rus)**

[The peculiarities of the health of women–mothers who work in the cattle breeding sector] Kamayev IA, et al.
Probl Sotsialnoi Gig Istor Med 1997 Jan–Feb;(1):17–20 (Eng. Abstr.) **(Rus)**

[The economic basis for the work of the dental service in an agricultural region] Opeshko VV.
Stomatologiia (Mosk) 1996;Spec No:29–30 **(Rus)**

[Agricultural and nutritional importance of legumes] Montilla JJ. **Arch Latinoam Nutr** 1996 Dec;44(4 Suppl 1):44S–47S (Eng. Abstr.) **(Spa)**

ECONOMICS

Who pays to clean up livestock waste? [news]
Environ Health Perspect 1996 Jun;104(6):600

A biocultural perspective on health and household economy in southern Peru [see comments] Leatherman TL.
Med Anthropol Q 1996 Dec;10(4):476–95. Comment in: Med Anthropol Q 1996 Dec;10(4):451–4. Comment in: Med Anthropol Q 1996 Dec;10(4):516–9. Comment in: Med Anthropol Q 1996 Dec;10(4):519–22.

The Yoruba farm market as a communication channel in guinea worm disease surveillance. Brieger WR, et al.
Soc Sci Med 1996 Jan;42(2):233–43

EDUCATION

United States should export knowledge [letter] Ebaugh JR.
J Am Vet Med Assoc 1997 Jun 1;210(11):1584

Global linkages in animal agriculture: new opportunities for United States agricultural universities. Johnson WL.
J Anim Sci 1996 Jun;74(6):1386–94 (13 ref.)

INSTRUMENTATION

Farm tractors, and the use of seat belts and roll-over protective structures. Kelsey TW, et al. **Am J Ind Med** 1996 Oct;30(4):447–51

Non-tractor, agricultural machinery injuries in Ontario. Hartling L, et al. **Can J Public Health** 1997 Jan–Feb; 88(1):32–5

A population-based study of tractor-related injuries: Regional Rural Injury Study-I (RRIS-I). Lee TY, et al.
J Occup Environ Med 1996 Aug;38(8):782–93

[Serious childhood accidents involving tractors] Rodríguez Núñez A, et al. **An Esp Pediatr** 1996 May;44(5):461–3 (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

California bans pesticides [news] **Environ Health Perspect** 1996 Nov;104(11):1146

MANPOWER

The role of mentors for women in animal science: perspectives from government. Glenn BP. **J Anim Sci** 1996 Nov;74(11):2855–9 (15 ref.)

A study of suicide in farmers in England and Wales. Malmberg A, et al. **J Psychosom Res** 1997 Jul;43(1):107–11

Tobacco farmers and diversification: opportunities and barriers. Altman DG, et al. **Tob Control** 1996 Autumn; 5(3):192–8

Diversification is the future for many tobacco farmers [editorial] Joossens L. **Tob Control** 1996 Autumn;5(3):177–8

METHODS

Subsurface losses of surface-applied metribuzin as influenced by yard waste compost amendments, no-tillage, and conventional-tillage. Malone RW, et al.
Bull Environ Contam Toxicol 1996 Nov;57(5):751–8

LMOs: treasure chest or Pandora's box? Baram M.
Environ Health Perspect 1996 Jul;104(7):704–7

Indicators of the sustainability of heavy-metal management in agro-ecosystems. Moolenaar SW, et al.
Sci Total Environ 1997 Aug 10;201(2):155–69

In-village studies of the use of work oxen in central Mali. Bartholomew PW, et al. **Trop Anim Health Prod** 1995 Nov; 27(4):241–8

Use of donkeys and their draught performance in smallholder farming in Zimbabwe. Hagmann J, et al.
Trop Anim Health Prod 1995 Nov;27(4):231–9

Health of dairy herds converting to organic farming [letter; comment] Day CE. **Vet Rec** 1996 Sep 14;139(11):267. Comment on: Vet Rec 1996 Aug 10;139(6):141–2.

STANDARDS

Community food systems: working toward a sustainable future. Peters J. **J Am Diet Assoc** 1997 Sep;97(9):955–6 (10 ref.)

NAFTA and GATT: the future of animal health and trade. Sheesley D, et al. **J Am Vet Med Assoc** 1996 Dec 15; 209(12):1998–2000

Agricultural policy and social returns to eradication programs: the case of Aujeszky's disease in Sweden. Andersson H, et al. **Prev Vet Med** 1997 Feb;29(4):311–28 (30 ref.)

STATISTICS & NUMERICAL DATA

Farm-related injury mortality in New Mexico, 1980–91. Crandall CS, et al. **Accid Anal Prev** 1997 Mar;29(2):257–61

Five years of work-related injuries and fatalities in Minnesota. Agriculture: a high-risk industry. Brown M, et al. **Minn Med** 1997 Aug;80(8):29–32

TRENDS

Agricultural and food policies. Some concerns regarding their nutritional relevance. Arroyave G.
Arch Latinoam Nutr 1995 Mar;45(1):12–8

Metabolic engineering: prospects for crop improvement through the genetic manipulation of phenylpropanoid biosynthesis and defense responses—a review. Dixon RA, et al. **Gene** 1996 Nov 7;179(1):61–71 (80 ref.)

Role of ruminant livestock in sustainable agricultural systems. Oltjen JW, et al. **J Anim Sci** 1996 Jun;74(6):1406–9 (13 ref.)

Agriculture is biotechnology's future in Europe. Burke JF, et al. **Nat Biotechnol** 1997 Aug;15(8):695–6

[Agribusiness and the consumer market: a continuation of crisis trends] Rubval'ter DA. **Vopr Pitan** 1996;(1):43–8 **(Rus)**

AGRIN

ANALYSIS

Agrin accumulates in the brain microvascular basal lamina during development of the blood–brain barrier. Barber AJ, et al. **Dev Dyn** 1997 Jan;208(1):62–74

Non-neural agrin codistributes with acetylcholine receptors during early differentiation of Torpedo electrocytes. Cartaud A, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1837–46

Anti-agrin staining is absent at abandoned synaptic sites of frog neuromuscular junctions. Werle MJ, et al.
J Neurobiol 1996 Jun;30(2):293–302

ANTAGONISTS & INHIBITORS

Inhibition of agrin-mediated acetylcholine receptor clustering by utrophin C-terminal peptides. Namba T, et al. **Genes Cells** 1996 Aug;1(8):755–64

BIOSYNTHESIS

The developing avian retina expresses agrin isoforms during synaptogenesis. Kröger S, et al. **J Neurobiol** 1996 Feb; 29(2):165–82

Expression of agrin in the developing and adult rat brain. Cohen NA, et al. **Neuroscience** 1997 Jan;76(2):581–96

Agrin gene expression in mouse somatosensory cortical neurons during development in vivo and in cell culture. Li Z, et al. **Neuroscience** 1997 Jul;79(1):191–201

Induction by agrin of ectopic and functional postsynaptic-like membrane in innervated muscle. Jones G, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18; 94(6):2654–9

CHEMISTRY

Agrin binds to the nerve-muscle basal lamina via laminin. Denzer AJ, et al. **J Cell Biol** 1997 May 5;137(3):671–83

Aggregation of sodium channels induced by a postnatally upregulated isoform of agrin. Sharp AA, et al.
J Neurosci 1996 Nov 1;16(21):6775–83

GENETICS

Selective regulation of agrin mRNA induction and alternative splicing in PC12 cells by Ras-dependent actions of nerve growth factor. Smith MA, et al. **J Biol Chem** 1997 Jun 20;272(25):15675–81

Scrambler, a new neurological mutation of the mouse with abnormalities of neuronal migration. Sweet HO, et al.
Mamm Genome 1996 Nov;7(11):798–802

Agrin mRNA expression in the developing chick Edinger-Westphal nucleus. McAvoy M, et al.
Vis Neurosci 1996 Mar–Apr;13(2):293–301

METABOLISM

NCAM-mediated adhesion of transfected cells to agrin. Storms SD, et al. **Cell Adhes Commun** 1996 Apr; 3(6):497–509

The receptor tyrosine kinase MuSK is required for neuromuscular junction formation and is a functional receptor for agrin. Glass DJ, et al.
Cold Spring Harb Symp Quant Biol 1996;61:435–44 (65 ref.)

Biochemical and functional characterization of basal lamina-bound agrin in the chick central nervous system. Kröger S, et al. **Eur J Neurosci** 1996 Mar;8(3):500–9

Agrin binds to the nerve-muscle basal lamina via laminin. Denzer AJ, et al. **J Cell Biol** 1997 May 5;137(3):671–83

Axonal targeting of agrin in cultured rat dorsal horn neurons. Escher G, et al. **J Cell Sci** 1996 Dec;109 (Pt 13):2959–66

Distribution and substrate properties of agrin, a heparan sulfate proteoglycan of developing axonal pathways. Halfter W, et al. **J Comp Neurol** 1997 Jun 23;383(1):1–17

Agrin is synthesized by retinal cells and colocalizes with gephyrin [corrected] [published erratum appears in Mol Cell Neurosci 1996;8(4):301] Mann S, et al.
Mol Cell Neurosci 1996;8(1):1–13

PHARMACOLOGY

Common molecular mechanisms in field- and agrin-induced acetylcholine receptor clustering. Sabrina F, et al.
Cell Mol Neurobiol 1997 Apr;17(2):207–25

Heparin inhibits acetylcholine receptor aggregation at two distinct steps in the agrin-induced pathway. Hopf C, et al. **Eur J Neurosci** 1997 Jun;9(6):1170–7

Laminin-induced clustering of dystroglycan on embryonic muscle cells: comparison with agrin-induced clustering. Cohen MW, et al. **J Cell Biol** 1997 Mar 10;136(5):1047–58

Agrin-induced postsynaptic-like apparatus in skeletal muscle fibers in vivo. Cohen I, et al. **Mol Cell Neurosci** 1997; 9(4):237–53

Full-length agrin isoform activities and binding site distributions on cultured Xenopus muscle cells. Daggett DF, et al. **Mol Cell Neurosci** 1996 Jan;7(1):75–88

gamma-AChR/epsilon-AChR switch at agrin-induced postsynaptic-like apparatus in skeletal muscle. Rimer M, et al. **Mol Cell Neurosci** 1997;9(4):254–63

PHYSIOLOGY

Sequential roles of agrin, MuSK and rapsyn during neuromuscular junction formation. Glass DJ, et al.
Curr Opin Neurobiol 1997 Jun;7(3):379–84 (45 ref.)

Agrin, laminin beta 2 (s-laminin) and ARIA: their role in neuromuscular development. Ruegg MA.
Curr Opin Neurobiol 1996 Feb;6(1):97–103 (58 ref.)

Agrin inhibits neurite outgrowth but promotes attachment of embryonic motor and sensory neurons. Chang D, et al.
Dev Biol 1997 Jan 1;181(1):21–35

Neural agrin induces ectopic postsynaptic specializations in innervated muscle fibers. Meier T, et al. **J Neurosci** 1997 Sep 1;17(17):6534–44

The role of an agrin-growth factor interaction in ACh receptor clustering. Daggett DF, et al.
Mol Cell Neurosci 1996;8(4):272–85

Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Cole GJ, et al. **Perspect Dev Neurobiol** 1996;3(4):359–71 (86 ref.)

AGROBACTERIUM

Agrobacterium radiobacter pneumonia in a patient with HIV infection [letter] Mastroianni A, et al.

Eur J Clin Microbiol Infect Dis 1996 Dec;15(12):960–3
Cellulitis and myositis caused by Agrobacterium radiobacter and Haemophilus parainfluenzae after influenza virus vaccination. Owensby JE, et al. **South Med J** 1997 Jul; 90(7):752–4

CHEMISTRY

Purification and characterization of an extracellular lectin (Lectin I) from Agrobacterium radiobacter NCIM 2443. Joshi B, et al. **Biochim Biophys Acta** 1997 Aug 29; 1336(2):218–24

ENZYMOLOGY

Characterization of the Agrobacterium vitis pehA gene and comparison of the encoded polygalacturonase with the homologous enzymes from Erwinia carotovora and Ralstonia solanacearum. Herlache TC, et al. **Appl Environ Microbiol** 1997 Jan;63(1):338–46
Tryptophan synthase from Agrobacterium tumefaciens 8628: isolation and properties. Rekoslavskaya NI, et al. **Biochemistry (Mosc)** 1997 Apr;62(4):433–9
Purification and characterization of D(+)-carnitine dehydrogenase from Agrobacterium sp.—a new enzyme of carnitine metabolism. Hanschmann H, et al. **Biochim Biophys Acta** 1997 Jan 4;1337(1):133–42
Identification, sequencing and mutagenesis of the gene for a D-carbamoylase from Agrobacterium radiobacter. Buson A, et al. **FEMS Microbiol Lett** 1996 Nov 15;145(1):55–62
In vitro characterization of astaxanthin biosynthetic enzymes. Fraser PD, et al. **J Biol Chem** 1997 Mar 7;272(10):6128–35
Primary structure and catalytic mechanism of the epoxide hydrolase from Agrobacterium radiobacter AD1. Rink R, et al. **J Biol Chem** 1997 Jun 6;272(23):14650–7

GENETICS

Characterization of the Agrobacterium vitis pehA gene and comparison of the encoded polygalacturonase with the homologous enzymes from Erwinia carotovora and Ralstonia solanacearum. Herlache TC, et al. **Appl Environ Microbiol** 1997 Jan;63(1):338–46
The plant oncogene rolD stimulates flowering in transgenic tobacco plants. Mauro ML, et al. **Dev Biol** 1996 Dec 15; 180(2):693–700
Identification, sequencing and mutagenesis of the gene for a D-carbamoylase from Agrobacterium radiobacter. Buson A, et al. **FEMS Microbiol Lett** 1996 Nov 15;145(1):55–62
Mutational analysis of the rolA gene of Agrobacterium rhizogenes in tobacco: function of the rolA pre-mRNA intron and rolA proteins defective in their biological activity. Spena A, et al. **Genet Res** 1997 Feb;69(1):11–5
A specific protease encoded by the conjugative DNA transfer systems of IncP and Ti plasmids is essential for pilus synthesis. Haase J, et al. **J Bacteriol** 1997 Sep; 179(18):5728–35
Transformation of the cereals using Agrobacterium. Gould J. **Methods Mol Biol** 1997;62:491–501
Expression of the exoY gene, required for exopolysaccharide synthesis in Agrobacterium, is activated by the regulatory ros gene. Tiburtius A, et al. **Microbiology** 1996 Sep;142 (Pt 9):2621–9
Wound-inducible and organ-specific expression of ORF13 from Agrobacterium rhizogenes 8196 T-DNA in transgenic tobacco plants. Hansen G, et al. **Mol Gen Genet** 1997 Apr 16;254(3):337–43
T-DNA integration patterns in co-transformed plant cells suggest that T-DNA repeats originate from co-integration of separate T-DNAs. De Neve M, et al. **Plant J** 1997 Jan; 11(1):15–29
Gene targeting and instability of Agrobacterium T-DNA loci in the plant genome. Risseeuw E, et al. **Plant J** 1997 Apr; 11(4):717–28
Expression of two heterologous promoters, Agrobacterium rhizogenes rolC and cauliflower mosaic virus 35S, in the stem of transgenic hybrid aspen plants during the annual cycle of growth and dormancy. Nilsson O, et al. **Plant Mol Biol** 1996 Jul;31(4):887–95
T-DNA integration into genomic DNA of rice following Agrobacterium inoculation of isolated shoot apices. Park SH, et al. **Plant Mol Biol** 1996 Dec;32(6):1135–48
Frequent collinear long transfer of DNA inclusive of the whole binary vector during Agrobacterium-mediated transformation. Wenck A, et al. **Plant Mol Biol** 1997 Aug; 34(6):913–22
[VirD2-independent, but MobA-dependent transfer of plasmid DNA from a broad circle of hosts from agrobacterium into the plant cell nucleus] Shadenkov AA, et al. **Mol Biol (Mosk)** 1996 Mar-Apr;30(2):454–60 **(Rus)**

ISOLATION & PURIFICATION

Agrobacterium radiobacter bacteremia in a patient with chronic obstructive pulmonary disease. Yu WL, et al. **J Formos Med Assoc** 1997 Aug;96(8):664–6

METABOLISM

A putative helical domain in the MalK subunit of the ATP-binding-cassette transport system for maltose of Salmonella typhimurium (MalFGK2) is crucial for interaction with MalF and MalG. A study using the LacK protein of Agrobacterium radiobacter as a tool. Wilken S, et al. **Mol Microbiol** 1996 Nov;22(4):655–66

PATHOGENICITY

Case of bacterial endophthalmitis caused by an Agrobacterium radiobacter-like organism. Miller JM, et al. **J Clin Microbiol** 1996 Dec;34(12):3212–3
Discrete regions of the sensor protein virA determine the strain-specific ability of Agrobacterium to agroinfect maize. Heath JD, et al. **Mol Plant Microbe Interact** 1997 Mar;10(2):221–7
Differences in susceptibility of Arabidopsis ecotypes to crown gall disease may result from a deficiency in T-DNA integration. Nam J, et al. **Plant Cell** 1997 Mar;9(3):317–33

PHYSIOLOGY

Agrobacterium-plant cell DNA transport: have virulence proteins, will travel. Sheng J, et al. **Plant Cell** 1996 Oct; 8(10):1699–710 (55 ref.)

AGROBACTERIUM TUMEFACIENS

Bacteremia due to Agrobacterium tumefaciens (radiobacter). Report of infection in a pregnant women and her stillborn fetus. Southern PM Jr. **Diagn Microbiol Infect Dis** 1996 Jan;24(1):43–5
Integration of an insertion-type transferred DNA vector from Agrobacterium tumefaciens into the Saccharomyces cerevisiae genome by gap repair. Risseeuw E, et al. **Mol Cell Biol** 1996 Oct;16(10):5924–32

CHEMISTRY

Purification of a protein from Agrobacterium tumefaciens strain A348 that binds phenolic compounds. Dyé F, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):319–24
The molecular structure of agrobacterium VirE2-single stranded DNA complexes involved in nuclear import. Citovsky V, et al. **J Mol Biol** 1997 Sep 5;271(5):718–27
Agrobacterium tumefaciens VirB7 and VirB9 form a disulfide-linked protein complex. Anderson LB, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):8889–94

CLASSIFICATION

A PCR-based DNA fingerprinting technique: AFLP for molecular typing of bacteria. Lin JJ, et al. **Nucleic Acids Res** 1996 Sep 15;24(18):3649–50

DRUG EFFECTS

Alkylsyringamides, new inducers of Agrobacterium tumefaciens virulence genes. Dyé F, et al. **Biochimie** 1997; 79(1):3–6

ENZYMOLOGY

The VirB4 ATPase of Agrobacterium tumefaciens is a cytoplasmic membrane protein exposed at the periplasmic surface. Dang TA, et al. **J Bacteriol** 1997 Jan;179(2):453–62
A T-DNA gene required for agropine biosynthesis by transformed plants is functionally and evolutionarily related to a Ti plasmid gene required for catabolism of agropine by Agrobacterium strains. Hong SB, et al. **J Bacteriol** 1997 Aug;179(15):4831–40
Characterization of membrane and protein interaction determinants of the Agrobacterium tumefaciens VirB11 ATPase. Rashkova S, et al. **J Bacteriol** 1997 Feb; 179(3):583–91

GENETICS

A simple method for the transformation of Agrobacterium tumefaciens by foreign DNA. Cui W, et al. **Chin J Biotechnol** 1995;11(4):267–74
Agrobacterium tumefaciens mediated transformation of Orychophragmus violaceus cotyledon and regeneration of transgenic plants. Zhou J, et al. **Chin J Biotechnol** 1996; 12(1):39–45
Isolation and characterisation of a linked cluster of genes from Agrobacterium tumefaciens encoding proteins involved in flagellar basal-body structure. Deakin WJ, et al. **Gene** 1997 Apr 11;189(1):135–7
The Agrobacterium tumefaciens motor gene, motA, is in a linked cluster with the flagellar switch protein genes, fliG, fliM and fliN. Deakin WJ, et al. **Gene** 1997 Apr 11; 189(1):139–41
The sensing of plant signal molecules by Agrobacterium: genetic evidence for direct recognition of phenolic inducers by the VirA protein. Lee YW, et al. **Gene** 1996 Nov 7; 179(1):83–8 (20 ref.)
Interactions between VirB9 and VirB10 membrane proteins involved in movement of DNA from Agrobacterium tumefaciens into plant cells. Beaupré CE, et al. **J Bacteriol** 1997 Jan;179(1):78–89
Variable efficiency of a Ti plasmid-encoded VirA protein in different agrobacterial hosts. Bélanger C, et al. **J Bacteriol** 1997 Apr;179(7):2305–13
Transcriptional regulation and locations of Agrobacterium tumefaciens genes required for complete catabolism of octopine. Cho K, et al. **J Bacteriol** 1997 Jan;179(1):1–8
Ti plasmid conjugation is independent of vir: reconstitution of the tra functions from pTiC58 as a binary system. Cook DM, et al. **J Bacteriol** 1997 Feb;179(4):1291–7
VirB2 is a processed pilin-like protein encoded by the Agrobacterium tumefaciens Ti plasmid. Jones AL, et al. **J Bacteriol** 1996 Oct;178(19):5706–11
The Agrobacterium tumefaciens virulence gene chvE is part of a putative ABC-type sugar transport operon. Kemner JM, et al. **J Bacteriol** 1997 Apr;179(7):2452–8
Requirement for genes with homology to ABC transport systems for attachment and virulence of Agrobacterium tumefaciens. Matthysse AG, et al. **J Bacteriol** 1996 Sep; 178(17):5302–8
Suppression of mutant phenotypes of the Agrobacterium tumefaciens VirB11 ATPase by overproduction of VirB proteins. Zhou XR, et al. **J Bacteriol** 1997 Sep; 179(18):5835–42
Manipulating photosynthesis. Knight JS, et al. **Mol Biotechnol** 1996 Dec;6(3):335–45
Characterization of flagella genes of Agrobacterium tumefaciens, and the effect of a bald strain on virulence. Chesnokova O, et al. **Mol Microbiol** 1997 Feb;23(3):579–90
The putA gene of Agrobacterium tumefaciens is transcriptionally activated in response to proline by an Lrp-like protein and is not autoregulated. Cho K, et al. **Mol Microbiol** 1996 Dec;22(5):1025–33
Integration of T-DNA binary vector 'backbone' sequences into the tobacco genome: evidence for multiple complex patterns of integration. Kononov ME, et al. **Plant J** 1997 May;11(5):945–57
Exogenous phytohormone-independent growth and regeneration of tobacco plants transgenic for the 6b gene of Agrobacterium tumefaciens AKE10. Wabiko H, et al. **Plant Physiol** 1996 Nov;112(3):939–51
Integration of Agrobacterium tumefaciens T-DNA in the Saccharomyces cerevisiae genome by illegitimate recombination. Bundock P, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15272–5
"Agrolistic" transformation of plant cells: integration of T-strands generated in planta. Hansen G, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14978–83
Identification of transferred DNA insertions within Arabidopsis genes involved in signal transduction and ion transport. Krysan PJ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8145–50
Effects of seed-specific expression of a cytokinin biosynthetic gene on canola and tobacco phenotypes. Roeckel P, et al. **Transgenic Res** 1997 Mar;6(2):133–41
[The genetic transformation of Lycopersicon peruvianum var. dentatum by using Agrobacterium tumefaciens carrying a plasmid with the human beta-interferon gene] Rudas VA, et al. **Tsitol Genet** 1997 Mar-Apr;31(2):17–22 (Eng. Abstr.) **(Rus)**

METABOLISM

Plant transformation: a pilus in Agrobacterium T-DNA transfer. Baron C, et al. **Curr Biol** 1996 Dec 1;6(12):1567–9 (12 ref.)
VirB1, a component of the T-complex transfer machinery of Agrobacterium tumefaciens, is processed to a C-terminal secreted product, VirB1. Baron C, et al. **J Bacteriol** 1997 Feb;179(4):1203–10
The lipoprotein VirB7 interacts with VirB9 in the membranes of Agrobacterium tumefaciens. Baron C, et al. **J Bacteriol** 1997 Feb;179(4):1211–8
Delineation of the interaction domains of Agrobacterium tumefaciens VirB7 and VirB9 by use of the yeast two-hybrid assay. Das A, et al. **J Bacteriol** 1997 Jun; 179(11):3404–9
Functional domains of Agrobacterium tumefaciens single-stranded DNA-binding protein VirE2. Dombek P, et al. **J Bacteriol** 1997 Feb;179(4):1165–73
Intermolecular disulfide bonds stabilize VirB7 homodimers and VirB7/VirB9 heterodimers during biogenesis of the Agrobacterium tumefaciens T-complex transport apparatus. Spudich GM, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7512–7

PATHOGENICITY

The Agrobacterium tumefaciens virulence gene chvE is part of a putative ABC-type sugar transport operon. Kemner JM, et al. **J Bacteriol** 1997 Apr;179(7):2452–8
Attachment of Agrobacterium tumefaciens to carrot cells and Arabidopsis wound sites is correlated with the presence of a cell-associated, acidic polysaccharide. Reuhs BL, et al. **J Bacteriol** 1997 Sep;179(17):5372–9
Characterization of flagella genes of Agrobacterium tumefaciens, and the effect of a bald strain on virulence. Chesnokova O, et al. **Mol Microbiol** 1997 Feb;23(3):579–90

PHYSIOLOGY

Agrobacterium tumefaciens T-complex transport apparatus: a paradigm for a new family of multifunctional transporters in eubacteria. Christie PJ. **J Bacteriol** 1997 May; 179(10):3085–94 (102 ref.)
Transformation of rice mediated by Agrobacterium tumefaciens. Hiei Y, et al. **Plant Mol Biol** 1997 Sep; 35(1-2):205–18 (119 ref.)

AGROCHEMICALS

see related

PESTICIDES

Alternative measures of pesticide use. Barnard C, et al. **Sci Total Environ** 1997 Sep 15;203(3):229–44

AGROCHEMICALS

[Chemicals in agriculture and problems of ecologically clean and biologically full-value food products] Ladonin VF. **Vopr Pitan** 1996;(4):19–23 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Photoallergic contact dermatitis from mancozeb, an agricultural fungicide. Higo A, et al. **Contact Dermatitis** 1996 Sep;35(3):183

The four county study of childhood cancer: clusters in context. Reynolds P, et al. **Stat Med** 1996 Apr 15–May 15;15(7–9):683–97

POISONING

Agricultural and horticultural chemical poisonings: mortality and morbidity in the United States. Klein-Schwartz W, et al. **Ann Emerg Med** 1997 Feb;29(2):232–8

Chemical exposures and Parkinson's disease in residents of three Negev kibbutzim. Kordysh EA, et al. **Environ Res** 1997;73(1–2):162–5

An investigation into neurologic and neurobehavioral effects of long-term agrichemical use among deciduous fruit farm workers in the Western Cape, South Africa. London L, et al. **Environ Res** 1997;73(1–2):132–45

[Effects of chemical factors on health of the population in various regions of Russia] Spirin VF, et al. **Med Tr Prom Ekol** 1997;(2):7–9 (Eng. Abstr.) **(Rus)**

TOXICITY

Comparative inhibition of enzymes of human erythrocytes and plasma in vitro by agricultural chemicals. Dowla HA, et al. **Arch Environ Contam Toxicol** 1996 Jul;31(1):107–14

Use of knowledge bases and QSARs to estimate the relative ecological risk of agrichemicals: a problem formulation exercise. Russom CL, et al. **SAR QSAR Environ Res** 1995; 4(2–3):83–95

[Agricultural antiparasitics evaluated for their potential cancerogenic, mutagenic and toxic reproductive effects] Petrelli G, et al. **Med Lav** 1996 Mar–Apr;87(2):110–21 (Eng. Abstr.) **(Ita)**

AH RECEPTORS see **RECEPTORS, ARYL HYDROCARBON**

AH-5158 see **LABETALOL**

AHG-CDC TESTS see **CYTOTOXICITY TESTS, IMMUNOLOGIC**

AHR-1911 see **ISOTHIURONIUM**

AI (ARTIFICIAL INTELLIGENCE) see **ARTIFICIAL INTELLIGENCE**

AID TO FAMILIES WITH DEPENDENT CHILDREN

Fathers of children on welfare: their impact on child well-being. Perloff JN, et al. **Am J Orthopsychiatry** 1996 Oct;66(4):557–71

Welfare reform and access to family-supportive benefits in the workplace. Piotrkowski CS, et al. **Am J Orthopsychiatry** 1996 Oct;66(4):538–47

The partners of welfare mothers: potential earnings and child support. Brien MJ, et al. **Future Child** 1997 Spring; 7(1):65–73 (29 ref.)

Turning job finders into job keepers. Hershey AM, et al. **Future Child** 1997 Spring;7(1):74–86 (39 ref.)

Arranging child care. Kisker EE, et al. **Future Child** 1997 Spring;7(1):99–109 (39 ref.)

Welfare to work: analysis and recommendations. Larner MB, et al. **Future Child** 1997 Spring;7(1):4–19 (57 ref.)

Health care coverage for children who are on and off welfare. Moffitt RA, et al. **Future Child** 1997 Spring; 7(1):87–98 (20 ref.)

Alternative strategies for increasing employment. Nightingale DS, et al. **Future Child** 1997 Spring;7(1):52–64 (30 ref.)

Income security for children [editorial] Ewalt PL. **Soc Work** 1997 May;42(3):221–2

Welfare reforms and services for children and families: setting a new practice, research, and policy agenda. Freeman EM. **Soc Work** 1996 Sep;41(5):521–32

HISTORY

"Why do they hate me so much?" A history of welfare and its abandonment in the United States. Withorn A. **Am J Orthopsychiatry** 1996 Oct;66(4):496–509

A brief history of work expectations for welfare mothers. Blank SW, et al. **Future Child** 1997 Spring;7(1):28–38

LEGISLATION & JURISPRUDENCE

The new politics of child and family policies. Kamerman SB. **Soc Work** 1996 Sep;41(5):453–65

ORGANIZATION & ADMINISTRATION

Infantile malnutrition redux? [editorial; comment] Finberg L. **Arch Pediatr Adolesc Med** 1997 Sep;151(9):870. Comment on: Arch Pediatr Adolesc Med 1997 Sep;151(9):871–5.

Welfare reform and food insecurity: influence on children [see comments] Willis E, et al. **Arch Pediatr Adolesc Med** 1997 Sep;151(9):871–5 (23 ref.) . Comment in: Arch Pediatr Adolesc Med 1997 Sep;151(9):870.

Welfare recipients' job skills and employment prospects. Burtless GT. **Future Child** 1997 Spring;7(1):39–51 (20 ref.)

Introduction to the AFDC program. Aid to Families with Dependent Children. Page SB, et al. **Future Child** 1997 Spring;7(1):20–7 (21 ref.)

The Medicaid managed care policy consensus for welfare recipients: a reflection of traditional welfare concerns [see comments] Grogan CM. **J Health Polit Policy Law** 1997 Jun;22(3):815–38 (17 ref.). Comment in: J Health Polit Policy Law 1997 Jun;22(3):879–96. Comment in: J Health Polit Policy Law 1997 Jun;22(3):897–906.

AID TO THE BLIND see **SOCIAL SECURITY**

AID TO THE TOTALLY DISABLED see **SOCIAL SECURITY**

AIDS see **ACQUIRED IMMUNODEFICIENCY SYNDROME**

AIDS ANTIBODIES see **HIV ANTIBODIES**

AIDS ANTIGENS see **HIV ANTIGENS**

AIDS-ASSOCIATED ENTEROPATHY see **HIV ENTEROPATHY**

AIDS-ASSOCIATED LYMPHOMA see **LYMPHOMA, AIDS-RELATED**

AIDS-ASSOCIATED NEPHROPATHY

Renal failure with large echogenic kidneys. Pouria S, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):610–1

[Tubulo-interstitial nephritis associated with abnormal immune system] Kawaguchi K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):281–3 (9 ref.) **(Jpn)**

DIAGNOSIS

[35-year-old patient with eyelid and ankle edema after foreign travel] Encke J, et al. **Internist (Berl)** 1997 May; 38(5):474–8 **(Ger)**

DRUG THERAPY

Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy. Briggs WA, et al. **Am J Kidney Dis** 1996 Oct;28(4):618–21

Clinical response to prolonged corticosteroids in a patient with human immunodeficiency virus-associated nephropathy. Watterson MK, et al. **Am J Kidney Dis** 1997 Apr;29(4):624–6

Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. Burns GC, et al. **J Am Soc Nephrol** 1997 Jul;8(7):1140–6

ETIOLOGY

[Kidney and AIDS (editorial)] González-Zárate Apiñániz P, et al. **Rev Clin Esp** 1996 Sep;196(9):575–6 **(Spa)**

IMMUNOLOGY

[HIV infection es IgA nephropathy] Nagy Z, et al. **Orv Hetil** 1996 Jun 2;137(22):1197–8 (Eng. Abstr.) **(Hun)**

[IgA nephropathy associated with human immunodeficiency virus infection. Description of a case (letter)] Nicolás Sánchez FJ, et al. **Med Clin (Barc)** 1997 Jun 7;109(2):77–8 **(Spa)**

PATHOLOGY

Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. Bruggeman LA, et al. **J Clin Invest** 1997 Jul 1;100(1):84–92

[Spectrum of the renal pathology in HIV infection: description of 85 autopsies and clinico-pathologic correlation] Martínez Hernández PL, et al. **Rev Clin Esp** 1996 Sep;196(9):577–83 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Renal complications in HIV disease. Rao TK. **Med Clin North Am** 1996 Nov;80(6):1437–51 (61 ref.)

THERAPY

Uremia therapy in patients with end-stage renal disease and human immunodeficiency virus infection: has the outcome changed in the 1990s? Ifudu O, et al. **Am J Kidney Dis** 1997 Apr;29(4):549–52

AIDS DEMENTIA COMPLEX

HIV-1 neuropathogenesis and abused drugs: current reviews, problems, and solutions. Shapshak P, et al. **Adv Exp Med Biol** 1996;402:171–86 (122 ref.)

HIV encephalitis and HIV leukoencephalopathy are associated with distinct clinical and radiological subtypes of the AIDS dementia complex [letter] Grassi MP, et al. **AIDS** 1997 Apr;11(5):690–1

Behavioral and psychiatric aspects of HIV infection. Searight HR, et al. **Am Fam Physician** 1997 Mar;55(4):1227–37, 1241–2 (57 ref.)

Neurological manifestations of human immunodeficiency virus infection and acquired immune deficiency syndrome: a review. Kwasa TO. **East Afr Med J** 1995 Oct; 72(10):664–8 (38 ref.)

Neuroscience of HIV infection. Basic research and clinical frontiers. Paris, France, March 6–9, 1996. Abstracts. **J Neurovirol** 1996 Feb;2(1):1–55

HIV in the brain: pathology and neurobehavioral consequences. Bloom FE, et al. **J Neurovirol** 1997 Apr; 3(2):102–9

Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy. López-Villegas D, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9854–9

[The brain in children and the human immunodeficiency virus (HIV-1) (editorial)] Tardieu M. **Arch Pediatr** 1996 Jun; 3(6):523–7 (33 ref.) **(Fre)**

[Pathogenesis of HIV-1-associated-neurologic diseases] Yoshioka M, et al. **Nippon Rinsho** 1997 Apr;55(4):897–903 (26 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Intrathecal reactivity for myelin components precedes development of neurological symptoms in AIDS patients. Silva AA, et al. **Arch Med Res** 1997 Autumn;28(3):391–6

Apolipoprotein A and biological half-life of prostaglandin I2 in HIV-1 infection. Pirich C, et al. **Thromb Res** 1996 Jan 15;81(2):213–18

CEREBROSPINAL FLUID

In vivo evidence of HIV-1 productive infection in cerebrospinal fluid of patients with HIV-1 encephalopathy [letter; comment] Di Stefano M, et al. **AIDS** 1997 Apr; 11(5):698–9. Comment on: AIDS 1996 Jul;10(8):843–7.

Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS. Akula SK, et al. **Am J Med Sci** 1997 Apr;313(4):244–6

Intrathecal reactivity for myelin components precedes development of neurological symptoms in AIDS patients. Silva AA, et al. **Arch Med Res** 1997 Autumn;28(3):391–6

Cerebrospinal fluid ferritin in HIV infected patients with acute neurological episodes. Deisenhammer F, et al. **Genitourin Med** 1997 Jun;73(3):181–3

Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. Brew BJ, et al. **J Infect Dis** 1997 Apr;175(4):963–6

Search for herpesvirus DNA in cerebrospinal fluid of HIV patients with brain disorders: prevalence of cytomegalovirus DNA findings. Portolani M, et al. **J Neurovirol** 1997 Jun;3(3):192–6

COMPLICATIONS

Dementia and pancytopenia in a patient who died of AIDS within one year of primary human immunodeficiency virus infection [see comments] Holland DJ, et al. **Clin Infect Dis** 1996 Jun;22(6):1121–2. Comment in: Clin Infect Dis 1997 Feb;24(2):282–3.

Obstructive renal failure requiring surgical intervention in an AIDS patient being treated with sulphadiazine. Mir N, et al. **Int J STD AIDS** 1997 Jan;8(1):61–2

CMV retinitis and dementia in an Indian with AIDS. Lehl SS, et al. **J Assoc Physicians India** 1995 Feb;43(2):136–7

AIDS dementia complex with generalized myoclonus. Maher J, et al. **Mov Disord** 1997 Jul;12(4):593–7

Mild cognitive impairment in HIV disease [news] Martin HP. **Nurse Pract** 1995 Aug;20(8):94–7

[Crusted scabies (Norwegian scabies) in a patient with neuroAIDS (letter)] Font A, et al. **Enferm Infecc Microbiol Clin** 1996 Dec;14(10):634–5 **(Spa)**

DIAGNOSIS

Longitudinal neuropsychological evaluation of HIV-infected intravenous drug users. Bono G, et al. **Addiction** 1996 Feb; 91(2):263–8

Neuroimaging findings in patients with AIDS. Walot I, et al. **Clin Infect Dis** 1996 Jun;22(6):906–19 (44 ref.)

Severe mental illness and HIV-related medical and neuropsychiatric sequelae. McDaniel JS, et al. **Clin Psychol Rev** 1997;17(3):311–25 (85 ref.)

Effects of HIV seropositivity and drug abuse on cognitive function. Grassi MP, et al. **Eur Neurol** 1997;37(1):48–52

HIV encephalopathy. Shroff RC, et al. **Indian Pediatr** 1996 Oct;33(10):863–5

The impact of primary central nervous system lymphoma in AIDS patients: a population-based autopsy study from Oslo. Goplen AK, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 1;14(4):351–4

Diagnosing HIV dementia: a retrospective analysis. Rosenberg DM, et al. **J Assoc Nurses AIDS Care** 1996 Nov-Dec;7(6):57–66

Brain atrophy in HIV infection is more strongly associated with CDC clinical stage than with cognitive impairment.

Di Sclafani V, et al. **J Int Neuropsychol Soc** 1997 May; 3(3):276–87

A comparison of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients. d'Arminio Monforte A, et al. **J Neurol** 1997 Jan;244(1):35–9

Utility of cerebral proton magnetic resonance spectroscopy in differential diagnosis of HIV-related dementia. Swindells S, et al. **J Neurovirol** 1995 Sep;1(3–4):268–74

Impairment of expressive behavior in pediatric HIV-infected patients with evidence of CNS disease. Moss HA, et al. **J Pediatr Psychol** 1996 Jun;21(3):379–400

Choreoathetosis in acquired immune deficiency syndrome patients with cerebral toxoplasmosis. Maggi P, et al. **Mov Disord** 1996 Jul;11(4):434–6

Imaging of pediatric central nervous system HIV infection. States LJ, et al. **Neuroimaging Clin N Am** 1997 May; 7(2):321–39 (87 ref.)

Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Antinori A, et al. **Neurology** 1997 Mar;48(3):687–94

High-signal lesions in the midbrain on T1-weighted MRI in an HIV-infected patient. Lüttmann S, et al. **Neuroradiology** 1997 Feb;39(2):136–8

Progressive multifocal leukoencephalopathy in an HIV-infected child. Morriss MC, et al. **Neuroradiology** 1997 Feb;39(2):142–4

[HIV-1 cognitive and motor syndrome] Mussa M, et al. **Sante** 1997 May-Jun;7(3):187–93 (30 ref.) (Eng. Abstr.) **(Fre)**

[Nervous system manifestations in HIV infected children] Funk M, et al. **Klin Padiatr** 1996 Sep–Oct;208(5):299–303 (Eng. Abstr.) **(Ger)**

[Psychosis in the early stage of HIV infection] Frei A, et al. **Psychiatr Prax** 1997 Mar;24(2):90–1 **(Ger)**

[A case from practice (356). HIV-encephalopathy and vacuolar myelopathy in stage CDC C3 HIV infection] Bassetti S. **Schweiz Rundsch Med Prax** 1996 Sep 3; 85(36):1096–7 **(Ger)**

DRUG THERAPY

Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex. Brew BJ, et al. **AIDS** 1996 Oct; 10(12):1357–60

Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens. Brouwers P, et al. **AIDS** 1997 Jan;11(1):59–66

Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: identification of evolving metabolic patterns in relation to dementia and therapy. Salvan AM, et al. **AIDS Res Hum Retroviruses** 1997 Aug 10;13(12):1055–66

Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS. Akula SK, et al. **Am J Med Sci** 1997 Apr;313(4):244–6

Pharmacotherapy of HIV dementia. Melton ST, et al. **Ann Pharmacother** 1997 Apr;31(4):457–73 (90 ref.)

Successful zidovudine (AZT) treatment in a case of human immunodeficiency virus (HIV)-1-associated dementia complex [letter] Sobanski T, et al. **Biol Psychiatry** 1996 Jun 15;39(12):1065–6

Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischemia: potential treatment with NMDA open-channel blockers and nitric oxide-related species. Lipton SA. **Brain Pathol** 1996 Oct;6(4):507–17 (117 ref.)

Dexamethasone therapy worsens the neuropathology of human immunodeficiency virus type 1 encephalitis in SCID mice. Limoges J, et al. **J Infect Dis** 1997 Jun;175(6):1368–81

Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. Sei S, et al. **J Infect Dis** 1996 Dec;174(6):1200–6

Peptide T and glucose metabolism in AIDS dementia complex. Villemagne VL, et al. **J Nucl Med** 1996 Jul; 37(7):1177–80

Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. **Neurology** 1997 Jul;49(1):142–6

Psychopharmacology in HIV-positive patients: research perspectives. Vitiello B, et al. **Psychopharmacol Bull** 1996; 32(3):293–7

Treating AIDS dementia [letter; comment] Lipton SA. **Science** 1997 Jun 13;276(5319):1629–30. Comment on: Science 1997 May 9;276(5314):898–9. Comment on: Science 1997 May 9;276(5314):960–4.

ENZYMOLOGY

Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Adamson DC, et al. **Science** 1996 Dec 13;274(5294):1917–21

EPIDEMIOLOGY

HIV-associated brain pathology in the United Kingdom: an epidemiological study. Davies J, et al. **AIDS** 1997 Jul 15; 11(9):1145–50

Nationwide survey of neurologic manifestations of acquired immunodeficiency syndrome in Japan [see comments] Nakagawa M, et al. **Intern Med** 1997 Mar;36(3):175–8. Comment in: Intern Med 1997 Mar;36(3):160–1.

AIDS dementia complex in the Italian National AIDS Registry: temporal trends (1987–93) and differential incidence according to mode of transmission of HIV-1 infection. Chiesi A, et al. **J Neurol Sci** 1996 Dec; 144(1–2):107–13

ETIOLOGY

A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Rho MB, et al. **Brain Behav Immun** 1995 Dec;9(4):366–77

Neuropathogenesis of acquired immunodeficiency syndrome dementia. Lipton SA. **Curr Opin Neurol** 1997 Jun; 10(3):247–53 (74 ref.)

Mitochondrial DNA levels in the brain of HIV-positive patients after zidovudine therapy. Davison FD, et al. **J Neurol** 1996 Sep;243(9):648–51

Identification of cytotoxic peptide as possible mechanism for neurotoxicity of HIV viral envelope and AIDS pathogenesis. Sangster B. **Med Hypotheses** 1997 Jun; 48(6):463–8 (25 ref.)

Bartonellosis and human immunodeficiency disease (AIDS): L-forms as persisters, activating factors, and mechanism of disease. Sood FH, et al. **Med Hypotheses** 1997 Jun; 48(6):511–5 (25 ref.)

Central nervous system damage during HIV infection. Lombardi VR, et al. **Methods Find Exp Clin Pharmacol** 1996 Dec;18(10):707–22 (121 ref.)

Neuronal damage and its relation to dementia in acquired immunodeficiency syndrome (AIDS). Trillo-Pazos G, et al. **Pathobiology** 1996;64(6):295–307 (126 ref.)

GENETICS

HIV dementia and apolipoprotein E. Dunlop O, et al. **Acta Neurol Scand** 1997 May;95(5):315–8

IMMUNOLOGY

Monokine products as predictors of AIDS dementia. Pulliam L, et al. **AIDS** 1996 Nov;10(13):1495–500

Alcohol and human immunodeficiency virus infection. Cook RT. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):210A–215A

MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. Sozzani S, et al. **J Leukoc Biol** 1997 Jul;62(1):30–3 (23 ref.)

The relationship between AIDS dementia complex and the presence of macrophage tropic and non-syncytium inducing isolates of human immunodeficiency virus type 1 in the cerebrospinal fluid. Brew BJ, et al. **J Neurovirol** 1996 Jun;2(3):152–7

Unique monocyte subset in patients with AIDS dementia. Pulliam L, et al. **Lancet** 1997 Mar 8;349(9053):692–5

AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines. Nuovo GJ, et al. **Mol Med** 1996 May;2(3):358–66

METABOLISM

Tumor necrosis factor-alpha, microglia and astrocytes in AIDS dementia complex. Seilhean D, et al. **Acta Neuropathol (Berl)** 1997 May;93(5):508–17

Localization of quinolinic acid in the murine AIDS model of retrovirus-induced immunodeficiency: implications for neurotoxicity and dendritic cell immunopathogenesis. Espey MG, et al. **AIDS** 1996 Feb;10(2):151–8

Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: identification of evolving metabolic patterns in relation to dementia and therapy. Salvan AM, et al. **AIDS Res Hum Retroviruses** 1997 Aug 10;13(12):1055–66

Chemokine expression in simian immunodeficiency virus-induced AIDS encephalitis. Sasseville VG, et al. **Am J Pathol** 1996 Nov;149(5):1459–67

Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities. Giometto B, et al. **Ann Neurol** 1997 Jul; 42(1):34–40

Elevated frontal lobe cytosolic choline levels in minimal or mild AIDS dementia complex patients: a proton magnetic resonance spectroscopy study. English CD, et al. **Biol Psychiatry** 1997 Feb 15;41(4):500–2

Nitric oxide and derived species as toxic agents in stroke, AIDS dementia, and chronic neurodegenerative disorders. Hensley K, et al. **Chem Res Toxicol** 1997 May;10(5):527–32 (64 ref.)

Cerebral metabolic alterations in human immunodeficiency virus-related encephalopathy detected by proton magnetic resonance spectroscopy. Comparison between sequences using short and long echo times. Salvan AM, et al. **Invest Radiol** 1997 Aug;32(8):485–95

Decreased plasma ratio of tryptophan to competing large neutral amino acids in human immunodeficiency virus type 1 infected subjects: possible implications for development of neuro-psychiatric disorders. Eriksson T, et al. **J Neural Transm** 1996;103(1–2):157–64

The regulation of quinolinic acid in human immunodeficiency virus-infected monocytes. Nottet HS, et al. **J Neurovirol** 1996 Apr;2(2):111–7

Quinolinic acid and neurodegeneration in AIDS [editorial; comment] Wiley CA. **J Neurovirol** 1995 Dec;1(5–6):328–9 . Comment on: J Neurovirol 1995 Dec;1(5–6):369–74. Comment on: J Neurovirol 1995 Dec;1(5–6):375–80.

Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. Rottenberg DA, et al. **J Nucl Med** 1996 Jul;37(7):1133–41

Elevated glutamate in the cerebrospinal fluid of patients with HIV dementia [letter] [see comments] Ferrarese C, et al. **JAMA** 1997 Feb 26;277(8):630. Comment in: JAMA 1997 Jun 25;277(24):1931.

Elevated cerebrospinal fluid glutamate in patients with HIV-related dementia [letter; comment] Gurwitz D, et al. **JAMA** 1997 Jun 25;277(24):1931. Comment on: JAMA 1997 Feb 26;277(8):630.

Astrocytic adhesion molecules are increased in HIV-1-associated cognitive/motor complex. Seilhean D, et al. **Neuropathol Appl Neurobiol** 1997 Apr;23(2):83–92

[Encephalopathy in AIDS—increased formation of beta-chemokines in monocytes after HIV-1 virus infection: mechanisms of CNS involvement] Mayer V, et al. **Bratisl Lek Listy** 1997 Jun;98(6):330–4 (Eng. Abstr.) **(Slo)**

MORTALITY

Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death. Sacktor NC, et al. **J Neurovirol** 1996 Dec;2(6):404–10

NURSING

Neuroscience nurses' intentions to care for persons with HIV/AIDS. DiIorio C. **J Neurosci Nurs** 1997 Feb; 29(1):50–5

PATHOLOGY

Tumor necrosis factor-alpha, microglia and astrocytes in AIDS dementia complex. Seilhean D, et al. **Acta Neuropathol (Berl)** 1997 May;93(5):508–17

HIV-associated brain pathology in the United Kingdom: an epidemiological study. Davies J, et al. **AIDS** 1997 Jul 15; 11(9):1145–50

Central brain atrophy in childhood AIDS encephalopathy. Scarmato V, et al. **AIDS** 1996 Sep;10(11):1227–31

Cerebral proton magnetic resonance spectroscopy in cytomegalovirus encephalitis and HIV leucoencephalopathy/encephalitis [letter] Wilkinson ID, et al. **AIDS** 1996 Oct;10(12):1443–4

Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities. Giometto B, et al. **Ann Neurol** 1997 Jul; 42(1):34–40

Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischemia: potential treatment with NMDA open-channel blockers and nitric oxide-related species. Lipton SA. **Brain Pathol** 1996 Oct;6(4):507–17 (117 ref.)

Pathologic correlations between ocular and cerebral lesions in 36 AIDS patients. Léger F, et al. **Clin Neuropathol** 1997 Jan-Feb;16(1):45–8

AIDS dementia complex: a complex, slow virus "model" of acquired genetic neurodegenerative disease. Price RW. **Cold Spring Harb Symp Quant Biol** 1996;61:759–70 (90 ref.)

The HIV-1 associated dementia complex: a metabolic encephalopathy fueled by viral replication in mononuclear phagocytes. Zheng J, et al. **Curr Opin Neurol** 1997 Aug; 10(4):319–25 (77 ref.)

Apoptosis induced by HIV-1 infection of the central nervous system. Shi B, et al. **J Clin Invest** 1996 Nov 1;98(9):1979–90

Cellular aspects of HIV-1 infection of macrophages leading to neuronal dysfunction in in vitro models for HIV-1 encephalitis. Nottet HS, et al. **J Leukoc Biol** 1997 Jul; 62(1):107–16 (112 ref.)

Development of laboratory and animal model systems for HIV-1 encephalitis and its associated dementia. Persidsky Y, et al. **J Leukoc Biol** 1997 Jul;62(1):100–6

A neuronal and neuroanatomical correlate of HIV-1 encephalopathy relative to HIV-1 encephalitis in HIV-1-infected children. da Cunha A, et al. **J Neuropathol Exp Neurol** 1997 Sep;56(9):974–87

Stereological analysis of cerebral atrophy in human immunodeficiency virus-associated dementia. Subbiah P, et al. **J Neuropathol Exp Neurol** 1996 Oct;55(10):1032–7

Pathogenic mechanisms of neuronal damage in the AIDS dementia complex. Swingler S. **Mol Pathol** 1997 Apr; 50(2):72–6 (72 ref.)

Progressive multifocal leukoencephalopathy presenting as human immunodeficiency virus type 1 (HIV)-associated dementia. Zunt JR, et al. **Neurology** 1997 Jul;49(1):263–5

Astrocytic adhesion molecules are increased in HIV-1-associated cognitive/motor complex. Seilhean D, et al. **Neuropathol Appl Neurobiol** 1997 Apr;23(2):83–92

Neuronal damage and its relation to dementia in acquired immunodeficiency syndrome (AIDS). Trillo-Pazos G, et al. **Pathobiology** 1996;64(6):295–307 (126 ref.)

Imaging in acquired immune deficiency syndrome dementia complex (AIDS dementia complex): a review. Kim DM, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Apr;20(3):349–70 (79 ref.)

[Pathobiology of AIDS in the central nervous system—an epidemic with an elusive pathobiology] Kristt D, et al. **Harefuah** 1996 Oct;131(7–8):285–8 (30 ref.) **(Heb)**

[Neurological manifestations associated with HIV-1

infection] Kishida S. **No To Shinkei** 1997 Jan;49(1):25–37 (90 ref.) **(Jpn)**
[Neuropathology of AIDS: opportunistic infections and HIV encephalopathy] Shintaku M. **No To Shinkei** 1997 Jan; 49(1):5–17 (118 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Multimodal evoked potentials in HIV-1-seropositive patients: relationship between the immune impairment and the neurophysiological function. Pierelli F, et al. **Acta Neurol Scand** 1996 Apr;93(4):266–71
Human immunodeficiency virus and the brain. Glass JD, et al. **Annu Rev Neurosci** 1996;19:1–26 (149 ref.)
Neuropathogenesis of acquired immunodeficiency syndrome dementia. Lipton SA. **Curr Opin Neurol** 1997 Jun; 10(3):247–53 (74 ref.)
HIV-1 encephalopathy in children. Gelbard HA, et al. **Curr Opin Pediatr** 1995 Dec;7(6):655–62 (78 ref.)
Alpha EEG activity and subcortical pathology in HIV infection. Baldeweg T, et al. **Int J Psychophysiol** 1997 Jun; 26(1–3):431–42
HIV infection of macrophages and pathogenesis of AIDS dementia complex: interaction of the host cell and viral genotype. Cunningham AL, et al. **J Leukoc Biol** 1997 Jul; 62(1):117–25
Cellular aspects of HIV-1 infection of macrophages leading to neuronal dysfunction in in vitro models for HIV-1 encephalitis. Nottet HS, et al. **J Leukoc Biol** 1997 Jul; 62(1):107–16 (112 ref.)
Development of laboratory and animal model systems for HIV-1 encephalitis and its associated dementia. Persidsky Y, et al. **J Leukoc Biol** 1997 Jul;62(1):100–6
Absence of the inducible form of nitric oxide synthase in the brains of patients with the acquired immunodeficiency syndrome. Bagasra O, et al. **J Neurovirol** 1997 Apr; 3(2):153–67
Neuroglial ATF/CREB factors interact with the human immunodeficiency virus type 1 long terminal repeat. Krebs FC, et al. **J Neurovirol** 1997 May;3 Suppl 1:S28–32 (28 ref.)
HIV neuropathogenesis. Levy JA. **J Neurovirol** 1997 May; 3 Suppl 1:S14–5
Neurological and developmental problems in pediatric HIV infection. Mintz M. **J Nutr** 1996 Oct;126(10 Suppl):2663S–2673S (95 ref.)
Mechanisms of HIV infection of the central nervous system and pathogenesis of AIDS-dementia complex. Dal Canto MC. **Neuroimaging Clin N Am** 1997 May;7(2):231–41 (87 ref.)
Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Sardar AM, et al. **Neuroreport** 1996 Mar 22;7(4):910–2
Endocrine modulation of the neurotoxicity of gp120: implications for AIDS-related dementia complex. Brooke S, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19; 94(17):9457–62
[Neurological impairment in children with HIV infection] Orejón de Luna G, et al. **Rev Neurol** 1996 Mar; 24(127):278–84 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Stable neurological function in subjects treated with 2'3'-dideoxyinosine. Sidtis JJ, et al. **J Neurovirol** 1997 Jun; 3(3):233–40

PSYCHOLOGY

A novel approach to the determination and characterization of HIV dementia. Brouwers P, et al. **Can J Neurol Sci** 1996 May;23(2):104–9
Memory for verbal information in individuals with HIV-associated dementia complex. HNRC Group. White DA, et al. **J Clin Exp Neuropsychol** 1997 Jun;19(3):357–66
Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. **Neurology** 1996 Nov;47(5):1247–53

RADIONUCLIDE IMAGING

Peptide T and glucose metabolism in AIDS dementia complex. Villemagne VL, et al. **J Nucl Med** 1996 Jul; 37(7):1177–80

REHABILITATION

HIV-related neurological disability and prospects for rehabilitation. O'Dell MW. **Disabil Rehabil** 1996 Jun; 18(6):285–92 (50 ref.)

THERAPY

Management of AIDS dementia complex and HIV-1 infection of the nervous system. Price RW. **AIDS** 1995;9 Suppl A:S221–36 (148 ref.)
[HIV-1 cognitive and motor syndrome] Mussa M, et al. **Sante** 1997 May–Jun;7(3):187–93 (30 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Genetic and biological analysis of variants derived from the cerebrospinal fluid of HIV type 1 subtype B- and D-infected patients with and without AIDS dementia complex. Brengel-Pesce K, et al. **AIDS Res Hum Retroviruses** 1996 Nov 20;12(17):1643–5
Region-specific changes, gene duplications, and random deletions in the nef gene from HIV type 1-infected brain tissues and blood of a demented patient. Saksena NK, et al. **AIDS Res Hum Retroviruses** 1997 Jan 1;13(1):111–6
The HIV-1 associated dementia complex: a metabolic encephalopathy fueled by viral replication in mononuclear phagocytes. Zheng J, et al. **Curr Opin Neurol** 1997 Aug; 10(4):319–25 (77 ref.)
Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. Sei S, et al. **J Infect Dis** 1996 Dec;174(6):1200–6
Quinolinic acid production is related to macrophage tropic isolates of HIV-1 [see comments] Brew BJ, et al. **J Neurovirol** 1995 Dec;1(5–6):369–74. Comment in: J Neurovirol 1995 Dec;1(5–6):328–9.
The relationship between AIDS dementia complex and the presence of macrophage tropic and non-syncytium inducing isolates of human immunodeficiency virus type 1 in the cerebrospinal fluid. Brew BJ, et al. **J Neurovirol** 1996 Jun;2(3):152–7
Human immunodeficiency virus type 1 DNA and RNA load in brains of demented and nondemented patients with acquired immunodeficiency syndrome. Lazarini F, et al. **J Neurovirol** 1997 Aug;3(4):299–303
Human herpesvirus 6 polymerase chain reaction findings in human immunodeficiency virus associated neurological disease and multiple sclerosis. Liedtke W, et al. **J Neurovirol** 1995 Sep;1(3–4):253–8
The development of animal model systems for HIV-1 encephalitis and its associated dementia. Persidsky Y, et al. **J Neurovirol** 1995 Sep;1(3–4):229–43 (95 ref.)
Search for herpesvirus DNA in cerebrospinal fluid of HIV patients with brain disorders: prevalence of cytomegalovirus DNA findings. Portolani M, et al. **J Neurovirol** 1997 Jun;3(3):192–6
Cellular localization of human herpesvirus-6 in the brains of children with AIDS encephalopathy [see comments] Saito Y, et al. **J Neurovirol** 1995 Mar;1(1):30–9. Comment in: J Neurovirol 1995 Sep;1(3–4):321.
Toxicity of TNF alpha and platelet activating factor for human NT2N neurons: a tissue culture model for human immunodeficiency virus dementia. Westmoreland SV, et al. **J Neurovirol** 1996 Apr;2(2):118–26
Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS. Teo I, et al. **J Virol** 1997 Apr;71(4):2928–33
AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines. Nuovo GJ, et al. **Mol Med** 1996 May;2(3):358–66
[Virology on AIDS and AIDS dementia complex] Hoshino H. **No To Shinkei** 1997 Jan;49(1):39–49 (23 ref.) **(Jpn)**

AIDS DRUGS see **ANTI-HIV AGENTS**

AIDS ENCEPHALOPATHY see **AIDS DEMENTIA COMPLEX**

AIDS ENTEROPATHY see **HIV ENTEROPATHY**

AIDS, FELINE see **FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME**

AIDS, MURINE see **MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME**

AIDS-RELATED COMPLEX

COMPLICATIONS

Is Kaposi sarcoma caused by new herpesvirus? [letter] Haverkos HW. **Biomed Pharmacother** 1996;50(6–7):318–9 (15 ref.)
Concurrent Sweet's syndrome and Löfgren's syndrome. Cuende Quintana E, et al. **J Rheumatol** 1996 Nov; 23(11):1995–8 (13 ref.)
Rhodococcus equi infection in HIV-positive subjects: a retrospective analysis of 24 cases. Arlotti M, et al. **Scand J Infect Dis** 1996;28(5):463–7

DIAGNOSIS

[Intraparotid lymphoepithelial cysts and the human immunodeficiency virus] Rivas Lacarte MP, et al. **Rev Clin Esp** 1997 Jun;197(6):417–9 (13 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. Li RC, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1397–402
Lymphangiographic study of pelvic adenopathy regression in a phase II trial of methyl-hydroxy-ellipticine in HIV1-AIDS complex [letter] Mathé G, et al. **Biomed Pharmacother** 1996;50(10):510–1

IMMUNOLOGY

A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex. Gries JM, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):70–82

METABOLISM

Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. Li RC, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1397–402

MICROBIOLOGY

Acute cervical lymphadenopathy [letter] Pasticci MB, et al. **Emerg Infect Dis** 1996 Jul–Sep;2(3):241

PHYSIOPATHOLOGY

Acute cervical lymphadenopathy [letter] Pasticci MB, et al. **Emerg Infect Dis** 1996 Jul–Sep;2(3):241

SURGERY

Surgical indications for HIV-infected patients. Eriguchi M, et al. **Biomed Pharmacother** 1996;50(10):500

THERAPY

Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine (ZDV). Raise E, et al. **Biotherapy** 1996;9(1–3):49–54

VIROLOGY

Predominance of HIV-1 among patients with AIDS and AIDS-related complex in Ghana. Brandful JA, et al. **East Afr Med J** 1997 Jan;74(1):17–20

AIDS-RELATED LYMPHOMA see **LYMPHOMA, AIDS-RELATED**

AIDS-RELATED OPPORTUNISTIC INFECTIONS

Chronic rhinosinusitis in patients with AIDS: potential role of microsporidia [letter] Franzen C, et al. **AIDS** 1996 Jun; 10(6):687–8
Molecular biology and epidemiology of Pneumocystis carinii infection in AIDS [editorial] Stringer JR, et al. **AIDS** 1996 Jun;10(6):561–71 (120 ref.)
Mucormycosis in a patient with acquired immunodeficiency syndrome [letter] Weinberg JM, et al. **Arch Dermatol** 1997 Feb;133(2):249–51
Tuberculous pericarditis in a woman infected with human immunodeficiency virus type 1, long-term nonprogressive [letter; comment] Buil E, et al. **Arch Intern Med** 1997 Jun 23;157(12):1391–2. Comment on: Arch Intern Med 1996 Apr 22;156(8):889–94.
Tuberculosis in the HIV-positive patient. Corbett EL, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):200–4 (24 ref.)
HIV in children. Bye MR. **Clin Chest Med** 1996 Dec; 17(4):787–96 (132 ref.)
Mycobacterial complications of HIV infection. Chin DP, et al. **Clin Chest Med** 1996 Dec;17(4):697–711 (155 ref.)
Fungal pulmonary complications. Davies SF, et al. **Clin Chest Med** 1996 Dec;17(4):725–44 (59 ref.)
Pneumocystis carinii. Levine SJ. **Clin Chest Med** 1996 Dec; 17(4):665–95 (342 ref.)
Bacterial pneumonia associated with HIV-1 infection. Noskin GA, et al. **Clin Chest Med** 1996 Dec;17(4):713–23 (57 ref.)
HIV in illicit drug users. O'Donnell AE. **Clin Chest Med** 1996 Dec;17(4):797–807 (90 ref.)
Overview of pulmonary complications. Rosen MJ. **Clin Chest Med** 1996 Dec;17(4):621–31 (79 ref.)
Approach to the patient with pulmonary disease. Vander Els NJ, et al. **Clin Chest Med** 1996 Dec;17(4):767–85 (119 ref.)
Viruses and other miscellaneous organisms. Wallace JM. **Clin Chest Med** 1996 Dec;17(4):745–54 (101 ref.)
Tuberculous rheumatism (Poncet's disease) in a patient infected with human immunodeficiency virus. Lesprit P, et al. **Clin Infect Dis** 1996 Nov;23(5):1179–80
Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Singh VR, et al. **Clin Infect Dis** 1996 Sep; 23(3):563–8
Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Zylberberg H, et al. **Clin Infect Dis** 1996 Nov;23(5):1117–25 (97 ref.)
Recent advances in the management of opportunistic fungal infections. Sanchez JL, et al. **Compr Ther** 1996 Nov; 22(11):703–12 (85 ref.)
Pleural disease in patients with AIDS. Hamm H, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):315–8 (22 ref.)
Pulmonary complications of HIV infection. Schneider RF, et al. **Curr Opin Pulm Med** 1997 Mar;3(2):151–8 (73 ref.)
AIDS-associated cerebral toxoplasmosis: an update on diagnosis and treatment. Ammassari A, et al. **Curr Top Microbiol Immunol** 1996;219:209–22 (63 ref.)
Cutaneous aspergillosis. Smith WF, et al. **Cutis** 1997 Mar; 59(3):138–40
Emerging disease issues and fungal pathogens associated with HIV infection. Ampel NM. **Emerg Infect Dis** 1996 Apr–Jun;2(2):109–16 (50 ref.)
Cytomegalovirus polyradiculopathy treated successfully with

foscarnet [letter] Corral I, et al.
Eur J Clin Microbiol Infect Dis 1996 May;15(5):428–9 (10 ref.)

Microsporidia: a new sexually transmissable cause of urethritis [letter] Birthistle K, et al. **Genitourin Med** 1996 Dec;72(6):445

Acute cytomegalovirus prostatitis in AIDS [letter] Mastroianni A, et al. **Genitourin Med** 1996 Dec;72(6):447–8

Crusted ("Norwegian") scabies in a specialist HIV unit [letter; comment] Nandwani R, et al. **Genitourin Med** 1996 Dec; 72(6):453. Comment on: Genitourin Med 1996 Apr;72(2):115–7.

Ocular toxoplasmosis in HIV infection [editorial] Rodgers CA, et al. **Int J STD AIDS** 1996 Aug–Sep;7(5):307–9 (21 ref.)

Progressive multifocal leukoencephalopathy in HIV [editorial] Sadler M, et al. **Int J STD AIDS** 1997 Jun; 8(6):351–7 (61 ref.)

Respiratory grey case. Seemungal B, et al.
Int J STD AIDS 1996 Aug–Sep;7(5):322

Central venous catheter infections in AIDS patients with cytomegalovirus. Ustianowski AP, et al.
Int J STD AIDS 1996 Aug–Sep;7(5):372–3

Granulomatous-ulcerative vulvar cryptococcosis in a patient with advanced HIV disease. Tomasini C, et al.
J Am Acad Dermatol 1997 Jul;37(1):116–7

Tubercular splenic abscesses in a patient with AIDS. Dubey SG, et al. **J Assoc Physicians India** 1996 Aug;44(8):575–7

Mycobacterium kansasii: its presentation, treatment and outcome in HIV infected patients. Rooney G, et al.
J Clin Pathol 1996 Oct;49(10):821–3

Concurrent cytomegalovirus, M. tuberculosis and M. avium-intracellulare cutaneous infection in an HIV patient. Núñez M, et al. **J Dermatol** 1997 Jun;24(6):401–4

Resistant herpes infection of the palm in a patient with acquired immunodeficiency syndrome: a case report. Dilley D, et al. **J Hand Surg [Am]** 1997 Jul;22(4):650–2

HIV and associated infections. Cybulska B.
J R Coll Physicians Lond 1997 Jan–Feb;31(1):100–2

HIV-related skin diseases. Geusau A, et al.
J R Coll Physicians Lond 1997 Jul–Aug;31(4):374–9 (38 ref.)

Research issues involving HIV-associated tuberculosis in resource-poor countries. De Cock KM, et al. **JAMA** 1996 Nov 13;276(18):1502–7

Smoking and risk of cryptococcosis in patients with AIDS [letter] Olson PE, et al. **JAMA** 1997 Feb 26;277(8):629–30

Tuberculosis research. Balancing the portfolio [editorial] Small PM. **JAMA** 1996 Nov 13;276(18):1512–3

HIV-associated respiratory disease [letter; comment] Antinori S, et al. **Lancet** 1996 Sep 28;348(9031):892–3. Comment on: Lancet 1996 Aug 3;348(9023):307–12.

AIDS and the eyes [letter; comment] Harindra V, et al.
Lancet 1996 Oct 5;348(9032):968–9. Comment on: Lancet 1996 Aug 24;348(9026):525–8.

AIDS and the eyes [letter; comment] Newton R. **Lancet** 1996 Oct 5;348(9032):968. Comment on: Lancet 1996 Aug 24;348(9026):525–8.

HIV-associated respiratory disease [letter; comment] Núñez MJ, et al. **Lancet** 1996 Sep 28;348(9031):893. Comment on: Lancet 1996 Aug 3;348(9023):307–12.

HIV-related skin diseases [letter; comment] Zeldis JB.
Lancet 1996 Nov 30;348(9040):1511–2. Comment on: Lancet 1996 Sep 7;348(9028):659–63.

HIV-associated respiratory disease [letter; comment] Zuckerman M, et al. **Lancet** 1996 Sep 28;348(9031):892. Comment on: Lancet 1996 Aug 3;348(9023):307–12.

Nontuberculous mycobacterial infections. French AL, et al.
Med Clin North Am 1997 Mar;81(2):361–79 (84 ref.)

Bacterial infections. Kovacs A, et al.
Med Clin North Am 1997 Mar;81(2):319–43 (261 ref.)

Fungal infections in patients with acquired immunodeficiency syndrome. Minamoto GY, et al. **Med Clin North Am** 1997 Mar;81(2):381–409 (194 ref.)

Dermatologic complications of HIV infection. Myskowski PL, et al. **Med Clin North Am** 1996 Nov;80(6):1415–35 (75 ref.)

Pneumocystis carinii pneumonia. Santamauro JT, et al.
Med Clin North Am 1997 Mar;81(2):299–318 (102 ref.)

Anergic disseminated toxoplasmosis in a patient with AIDS. Case report. Mastroianni A, et al. **Minerva Med** 1997 Mar; 88(3):101–4

Images in clinical medicine. Cutaneous cryptococcosis. Baker DJ, et al. **N Engl J Med** 1997 Apr 3;336(14):998

Congenital cytomegalovirus infection in infants infected with human immunodeficiency virus type 1. Doyle M, et al.
Pediatr Infect Dis J 1996 Dec;15(12):1102–6

Low risk of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus [letter] Dunn D, et al. **Pediatr Infect Dis J** 1997 Jan;16(1):84

Invasive aspergillosis in human immunodeficiency virus-infected children. Shetty D, et al.
Pediatr Infect Dis J 1997 Feb;16(2):216–21

Kaposi's sarcoma and its management in AIDS patients. Recommendations from a Scandinavian Study Group.
Scand J Infect Dis 1997;29(1):3–12 (76 ref.)

Features and outcome of Pneumocystis carinii pneumonia according to risk category for HIV infection. Laing R, et al. **Scand J Infect Dis** 1997;29(1):57–61

Clinical manifestations and treatment of mycobacterium avium-intracellulare complex infection in HIV-infected patients. Julander I. **Scand J Infect Dis Suppl** 1995;98:19–20

Nontuberculous mycobacteria in patients with human immunodeficiency virus infection. Benator DA, et al.
Semin Respir Infect 1996 Dec;11(4):285–300 (86 ref.)

Pulmonary toxoplasmosis. Campagna AC.
Semin Respir Infect 1997 Jun;12(2):98–105 (47 ref.)

Human immunodeficiency-virus-related pulmonary infections in children. McSherry GD.
Semin Respir Infect 1996 Sep;11(3):173–83 (42 ref.)

Epidemiology and control of coccidioidomycosis in California. Rutherford GW, et al. **West J Med** 1996 Oct; 165(4):221–2

[Review of 105 cases of isolation of Rhodococcus equi in humans] Votava M, et al. **Cas Lek Cesk** 1997 Jan 22; 136(2):51–3 (29 ref.) (Eng. Abstr.) **(Cze)**

[Prevention of herpes simplex and varicella zoster infections in patients of HIV infections] Caumes E, et al.
Ann Med Interne (Paris) 1997;148(3):255–7 (25 ref.) (Eng. Abstr.) **(Fre)**

[Extrapulmonary and disseminated pneumocystosis in AIDS. A review of the literature] Grasland A, et al.
Ann Med Interne (Paris) 1997;148(2):177–83 (54 ref.) (Eng. Abstr.) **(Fre)**

[Splenic pneumocystosis disclosing extrapulmonary pneumocystosis of fatal outcome (letter)] Grasland A, et al. **Ann Med Interne (Paris)** 1997;148(2):184–5 **(Fre)**

[Ophthalmologic manifestations observed in a pediatric HIV-seropositive population] Girard B, et al.
J Fr Ophtalmol 1997;20(1):49–60 (31 ref.) (Eng. Abstr.) **(Fre)**

[Absence of cerebral lymphoma in chronic Epstein-Barr virus encephalitis in a patient with HIV infection (letter)] Blanche P, et al. **Presse Med** 1997 Apr 19;26(13):611 **(Fre)**

[Pneumococcal infections in patients with HIV infections] Lesprit P, et al. **Presse Med** 1997 Feb 22;26(5):243–7 (37 ref.) (Eng. Abstr.) **(Fre)**

[Aspergillus niger osteitis of the middle ear in a patient with HIV infection (letter)] Lesueur A, et al. **Presse Med** 1997 Jul 5;26(23):1098 **(Fre)**

[Cytomegalovirus infections in HIV infection] Matheron S.
Presse Med 1997 Jan;26 Suppl 1:13–5 (13 ref.) **(Fre)**

[Streptococcus constellatus cerebral abscess in a patient with HIV infection (letter)] Passeron C, et al. **Presse Med** 1997 Jul 12;26(24):1145 **(Fre)**

[Generalized rhodococcosis of fatal outcome in a patient with AIDS (letter)] Steineur MP, et al. **Presse Med** 1996 Sep 7;25(25):1166 **(Fre)**

[Staphylococcus aureus purulent pericarditis in a patient with AIDS (letter)] Hadrami J, et al. **Rev Med Interne** 1997; 18(6):493–4 **(Fre)**

[Campylobacter jejuni septicemia with cutaneous sites in a patient with human immunodeficiency virus infection (letter)] Malbec D, et al. **Rev Med Interne** 1997;18(3):257–8 **(Fre)**

[Mechanism of neuronal damage in AIDS] Nagashima K.
Hokkaido Igaku Zasshi 1997 Jan;72(1):37–41 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Toxoplasmosis in patients with AIDS] Zieliński A.
Przegl Epidemiol 1995;49(4):343–52 (86 ref.) (Eng. Abstr.) **(Pol)**

[Parasitic infections in AIDS] Rogowska-Szadkowska D.
Wiad Parazytol 1996;42(2):145–57 (40 ref.) (Eng. Abstr.) **(Pol)**

[Molluscum contagiosum in immunodepressed patient] Caballero Alcántara J, et al. **Actas Urol Esp** 1997 Feb; 21(2):171–4 (Eng. Abstr.) **(Spa)**

[Tuberculous prostatic abscess in acquired immunodeficiency syndrome] Galbis Sanjuan F, et al. **Arch Esp Urol** 1997 May;50(4):393–5 (Eng. Abstr.) **(Spa)**

[Infections of the lower respiratory tract in patients with human immunodeficiency virus infection] Arzuaga JA, et al. **Enferm Infecc Microbiol Clin** 1997 Feb;15(2):91–106 (152 ref.) **(Spa)**

[Pneumonia caused by measles in a pregnant woman with HIV antibodies. Response to treatment with immunoglobulins (letter)] Carmena J, et al.
Enferm Infecc Microbiol Clin 1996 Aug–Sep;14(7):456–7 **(Spa)**

[Intestinal tuberculosis and AIDS (letter)] Llena J, et al.
Enferm Infecc Microbiol Clin 1995 Dec;13(10):635–7 **(Spa)**

[Cavitated pulmonary nodule due to infection by Pneumocystis carinii (letter)] Pérez-Canal C, et al.
Enferm Infecc Microbiol Clin 1996 Dec;14(10):633–4 **(Spa)**

[Disseminated Mycobacterium genavense infection in patients with HIV infection. Description of 5 cases and review of the literature] Rodríguez P, et al.
Enferm Infecc Microbiol Clin 1996 Apr;14(4):220–6 (35 ref.) (Eng. Abstr.) **(Spa)**

[Coinfection by mycobacteria in HIV-positive patients] von Wichmann MA, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):466–9 (Eng. Abstr.) **(Spa)**

[Hafnia alvei bacteremia in an AIDS patient (letter)] Ibáñez Pérez de la Blanca MA, et al. **Med Clin (Barc)** 1997 May 17;108(19):757–8 **(Spa)**

[The problems of Candida infection in the HIV-positive patient] Arrizabalaga Aguirreazaldegui J, et al.
Rev Clin Esp 1997 Apr;197 Suppl 1:44–8 (44 ref.) **(Spa)**

[Cryptococcus neoformans infections in patients infected and not infected with HIV] Miró Meda JM, et al.
Rev Clin Esp 1997 Apr;197 Suppl 1:49–59 (74 ref.) **(Spa)**

[Nodal nocardiosis in 2 patients with HIV infection treated with cotrimoxazole (letter)] Valencia Ortega ME, et al.
Rev Clin Esp 1997 Apr;197(4):298–9 **(Spa)**

[Polymicrobial endocarditis: a clinical and evolutive study of 12 cases diagnosed during a 10-year period] Valencia Ortega ME, et al. **Rev Clin Esp** 1997 Apr;197(4):245–7 (Eng. Abstr.) **(Spa)**

BLOOD

Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS. Klinker H, et al. **Antimicrob Agents Chemother** 1996 Jul; 40(7):1623–7

Beta-2-microglobulin, neopterin and monocyte Fc gamma receptors in opportunistic infections of HIV-positive patients. Dunne J, et al. **Br J Biomed Sci** 1996 Dec; 53(4):263–9

Increased plasma thiobarbituric acid-reactive substances (TBARS) before opportunistic infection symptoms in HIV infected individuals. Lopez O, et al. **Clin Chim Acta** 1996 Mar 29;247(1–2):181–7

Abnormal levels of circulating adhesion molecules in HIV-1 infection with characteristic alterations in opportunistic infections. Nordøy I, et al. **Clin Immunol Immunopathol** 1996 Oct;81(1):16–21

Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users. Brown LS, et al. **Drug Alcohol Depend** 1996 Dec 2; 43(1–2):71–7

Eosinophilia in patients infected with human immunodeficiency virus [letter; comment] Colebunders R, et al. **J Infect Dis** 1997 May;175(5):1283. Comment on: J Infect Dis 1996 Sep;174(3):615–8.

Zinc levels and infections in hospitalized patients with AIDS. Koch J, et al. **Nutrition** 1996 Jul–Aug;12(7–8):515–8

CEREBROSPINAL FLUID

The utility of direct acid-fast stain of cerebrospinal fluid for the rapid diagnosis of tuberculous meningitis in patients with and without AIDS [letter] Dural AT, et al.
J Gen Intern Med 1997 Apr;12(4):259

Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. Bernasconi S, et al.
J Infect Dis 1996 Nov;174(5):1098–101

Acute lumbosacral polyradiculopathy due to cytomegalovirus in advanced HIV disease: CSF findings in 17 patients. Miller RF, et al.
J Neurol Neurosurg Psychiatry 1996 Nov;61(5):456–60

Search for herpesvirus DNA in cerebrospinal fluid of HIV patients with brain disorders: prevalence of cytomegalovirus DNA findings. Portolani M, et al.
J Neurovirol 1997 Jun;3(3):192–6

CHEMICALLY INDUCED

Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma [letter] White RM. **AIDS** 1997 Sep;11(11):1412–3

Medicinal marijuana? [letter] Tashkin DP, et al.
N Engl J Med 1997 Apr 17;336(16):1186; discussion 1186–7

CLASSIFICATION

Redefining AIDS: towards a modification of the current AIDS case definition. Albrecht H. **Clin Infect Dis** 1997 Jan;24(1):64–74 (128 ref.)

Cardiac involvement in HIV infection. Patel RC, et al.
Med Clin North Am 1996 Nov;80(6):1493–512 (152 ref.)

COMPLICATIONS

Pneumocystis carinii pneumonia. Review of 32 cases in immunocompromised hosts. de Hoon JN, et al.
Acta Clin Belg 1997;52(1):19–26

A nasal septum perforation caused by a Varicella zoster infection in an AIDS patient. Colebunders R, et al.
Acta Otorhinolaryngol Belg 1997;51(1):49–50

Clinical significance of qualitative human cytomegalovirus (HCMV) detection in cell-free serum samples in HIV-infected patients at risk for HCMV disease [letter] Laue T, et al. **AIDS** 1997 Jul 15;11(9):1195–6

Confusing criteria for the diagnosis of toxoplasmic encephalitis in AIDS [letter; comment] Lijmer JG, et al. **AIDS** 1997 Jul 15;11(9):1188–9. Comment on: AIDS 1997 Feb;11(2):177–84.

Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: increasing incidence, unchanged prognosis. Low N, et al. **AIDS** 1997 Jul 15;11(9):1165–71

Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Côte d'Ivoire. Mukadi YD, et al. **AIDS** 1997 Jul 15;11(9):1151–8

Azithromycin for relapsing cerebral toxoplasmosis in AIDS [letter] Nasta P, et al. **AIDS** 1997 Jul 15;11(9):1188

Bacillary angiomatosis: a role for Phyllobacterium? [letter] Price DA, et al. **AIDS** 1997 Jul 15;11(9):1186–7

High frequency of non-Hodgkin's lymphoma in patients with HIV-associated Kaposi's sarcoma. Ridolfo AL, et al.
AIDS 1996 Feb;10(2):181–5

Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8 encephalitis in HIV-positive and -negative individuals. Said JW, et al. **AIDS** 1997 Jul 15;11(9):1119–22

Intravenous lidocaine for treatment-resistant pruritus. Fishman SM, et al. **Am J Med** 1997 Jun;102(6):584-5

Review: pneumothorax in patients with AIDS-related Pneumocystis carinii pneumonia. Pastores SM, et al. **Am J Med Sci** 1996 Nov;312(5):229-34

Symptomatology of HIV-related illness and community-acquired illness in an HIV-infected emergency department population. Hafner JW Jr, et al. **Ann Emerg Med** 1997 Jan;29(1):151-7

Management of AIDS-related pneumothorax [see comments] Trachiotis GD, et al. **Ann Thorac Surg** 1996 Dec; 62(6):1608-13. Comment in: Ann Thorac Surg 1997 Jul;64(1):290-1.

AIDS-related pneumothorax [letter; comment] Wait MA. **Ann Thorac Surg** 1997 Jul;64(1):290-1. Comment on: Ann Thorac Surg 1996 Dec;62(6):1608-13.

Pulmonary manifestations in HIV seropositivity and malnutrition in Zimbabwe. Ikeogu MO, et al. **Arch Dis Child** 1997 Feb;76(2):124-8

Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Jacobson MA, et al. **Arch Intern Med** 1997 Sep 8; 157(16):1825-31

Ocular manifestations of disseminated intravascular coagulation in a patient with the acquired immunodeficiency syndrome [letter] Lertsumitkul S, et al. **Arch Ophthalmol** 1997 May;115(5):676-7

Latent Epstein-Barr virus infection demonstrated in low-grade leiomyosarcomas of adults with acquired immunodeficiency syndrome, but not in adjacent Kaposi's lesion or smooth muscle tumors in immunocompetent patients. Boman F, et al. **Arch Pathol Lab Med** 1997 Aug; 121(8):834-8

Malignant tumors and AIDS. Nasti G, et al. **Biomed Pharmacother** 1997;51(6-7):243-51 (78 ref.)

Recent advances. HIV infection-II. Beiser C. **BMJ** 1997 Feb 22;314(7080):579-83 (56 ref.)

HIV associated tuberculosis [editorial] Coker R, et al. **BMJ** 1997 Jun 28;314(7098):1847

Isolated subcutaneous candidal abscess and HIV disease [letter] Manfredi R, et al. **Br J Dermatol** 1997 Apr; 136(4):647-9

Clinical utility of cytomegalovirus urine cultures for ophthalmic care in patients with HIV. Gellrich MM, et al. **Br J Ophthalmol** 1996 Sep;80(9):818-22

Association of progressive outer retinal necrosis and varicella zoster encephalitis in a patient with AIDS. van den Horn GJ, et al. **Br J Ophthalmol** 1996 Nov;80(11):982-5

Pseudomonas aeruginosa bronchopulmonary infection in patients with advanced human immunodeficiency virus disease. Traill ZC, et al. **Br J Radiol** 1996 Dec; 69(828):1099-103

Severe complications of perianal sepsis in patients with human immunodeficiency virus [letter] Sarela AI. **Br J Surg** 1996 Nov;83(11):1655-6

Cryptococcal meningitis and primary CNS lymphoma in a patient with acquired immunodeficiency syndrome: a case report. Wang JH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Jan;59(1):50-4

Reactive hemophagocytic syndrome: a new presentation of disseminated histoplasmosis in patients with AIDS. Koduri PR, et al. **Clin Infect Dis** 1995 Dec;21(6):1463-5

Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus. Maslo C, et al. **Clin Infect Dis** 1997 Mar;24(3):350-5

Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Moosa MY, et al. **Clin Infect Dis** 1997 Feb;24(2):131-4

Photo quiz. Choroidal lesions of disseminated cryptococcosis. Rajagopalan S, et al. **Clin Infect Dis** 1997 Jun;24(6):1079, 1239

Bronchoesophageal fistula due to Mycobacterium tuberculosis and cytomegalovirus in a patient with AIDS. Vartian CV, et al. **Clin Infect Dis** 1996 Mar;22(3):581

Bronchoesophageal fistula as a complication of cytomegalovirus esophagitis in AIDS. Chalasani N, et al. **Endoscopy** 1997 Jun;29(5):S28-9

Spinal cord compression due to concomitant primary lymphoma and Mycobacterium avium-intracellulare infection of the paravertebral muscles in an AIDS patient [letter] Moulignier A, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):891-3 (15 ref.)

Adult respiratory distress syndrome and pancytopenia associated with miliary tuberculosis in a HIV-infected patient. Mofredj A, et al. **Eur Respir J** 1996 Dec; 9(12):2685-7

Pneumothorax in HIV-infected patients: role of Pneumocystis carinii pneumonia and pulmonary tuberculosis. Tumbarello M, et al. **Eur Respir J** 1997 Jun; 10(6):1332-5

Management of viral retinitis-associated retinal detachment in AIDS. Hannouche D, et al. **Eye** 1997;11 (Pt 1):33-6

Rapid liver failure related to chronic C hepatitis in an HIV seropositive hemophilic patient with severe immunodepression. Dragoni F, et al. **Haematologica** 1996 Jul-Aug;81(4):335-8

Cytomegalovirus enteritis causing massive bleeding in a patient with AIDS. Lai IR, et al. **Hepatogastroenterology** 1996 Jul-Aug;43(10):987-91

Infections in HIV-infected patients with malignancy. Brown MA, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):401-12 (46 ref.)

Pyrexia of undetermined origin in patients with human immunodeficiency virus infection and AIDS. Miller RF, et al. **Int J STD AIDS** 1996 May-Jun;7(3):170-5 (32 ref.)

Hypercalcaemia in a patient with AIDS and Mycobacterium avium intracellulare infection. Newell A, et al. **Int J STD AIDS** 1997 Jun;8(6):405

Branch retinal artery occlusion (BRAO) combined with branch retinal vein occlusion (BRVO) and optic disc neovascularization associated with HIV and CMV retinitis. Conway MD, et al. **Int Ophthalmol** 1995-96;19(4):249-52

Respiratory distress syndrome and septic shock due to varicella in an HIV-infected adult [letter] Mofredj A, et al. **Intensive Care Med** 1996 Aug;22(8):835-6

Blastomycosis-like pyoderma in a man with AIDS. Crowley JJ, et al. **J Am Acad Dermatol** 1997 Apr;36(4):633-4

CMV retinitis and dementia in an Indian with AIDS. Lehl SS, et al. **J Assoc Physicians India** 1995 Feb;43(2):136-7

Pneumatosis cystoides intestinalis in AIDS-associated cryptosporidiosis. More than an incidental finding? Samson VE, et al. **J Clin Gastroenterol** 1996 Jun;22(4):311-2

Invasive amoebiasis in two patients with AIDS and cytomegalovirus colitis. Fätkenheuer G, et al. **J Clin Microbiol** 1997 Aug;35(8):2168-9

Persistence, replacement, and microevolution of Cryptococcus neoformans strains in recurrent meningitis in AIDS patients. Sullivan D, et al. **J Clin Microbiol** 1996 Jul;34(7):1739-44

Clinical features of tuberculosis associated with HIV infection in Taiwan. Hsieh SM, et al. **J Formos Med Assoc** 1996 Dec;95(12):923-8

Alopecia areata heralding cytomegalovirus reactivation in AIDS [letter] Piras MA, et al. **J Infect** 1997 Mar; 34(2):159-60

Treatment of pneumothorax in the patient with AIDS. Becker CE, et al. **J Ky Med Assoc** 1996 Feb;94(2):59-61

Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. Gordon M, et al. **J Med** 1997;28(1-2):108-28

Nontropical pyomyositis in patients with AIDS. Antony SJ, et al. **J Natl Med Assoc** 1996 Sep;88(9):565-9 (45 ref.)

Long-term survival of an AIDS patient with a tuberculous cerebral abscess. Gettler JF, et al. **J Natl Med Assoc** 1996 Sep;88(9):605-6

Acute lumbosacral polyradiculopathy due to cytomegalovirus in advanced HIV disease: CSF findings in 17 patients. Miller RF, et al. **J Neurol Neurosurg Psychiatry** 1996 Nov;61(5):456-60

Bartonellosis and human immunodeficiency disease (AIDS): L-forms as persisters, activating factors, and mechanism of disease. Sood FH, et al. **Med Hypotheses** 1997 Jun; 48(6):511-5 (25 ref.)

Central nervous system damage during HIV infection. Lombardi VR, et al. **Methods Find Exp Clin Pharmacol** 1996 Dec;18(10):707-22 (121 ref.)

Crescentic IgA nephropathy and acute renal failure in an HIV-positive patient with enteric salmonella infection. Hsieh WS, et al. **Nephrol Dial Transplant** 1996 Nov; 11(11):2320-3

Repair of retinal detachments due to herpes varicella-zoster virus retinitis in patients with acquired immune deficiency syndrome. Weinberg DV, et al. **Ophthalmology** 1997 Feb; 104(2):279-82

The seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus infections in paediatric oncology patients in Turkey. Berberoğlu S. **Postgrad Med J** 1996 Oct;72(852):609-11

Acute renal failure due to sulphadiazine crystalluria in AIDS patients. de Sequera P, et al. **Postgrad Med J** 1996 Sep; 72(851):557-8

Deafness and blindness in a HIV-positive patient with cryptococcal meningitis [letter] Prada JL, et al. **Postgrad Med J** 1996 Sep;72(851):575

Major blinding complication of acquired immune deficiency syndrome (AIDS) [letter] Akduman L, et al. **Retina** 1997; 17(2):167-8

Retinal vascular nonperfusion and retinal neovascularization as a consequence of cytomegalovirus retinitis and cryptococcal choroiditis. Saran BR, et al. **Retina** 1996; 16(6):510-2

Cystoid macular edema due to cytomegalovirus retinitis in a patient with acquired immune deficiency syndrome. Weinberg DV, et al. **Retina** 1996;16(4):343-4

Invasive Candida norvegensis infection in immunocompromised patients. Nielsen H, et al. **Scand J Infect Dis** 1996;28(3):311-2

Tuberculosis mortality and HIV infection [letter; comment] Kelly PM. **Trans R Soc Trop Med Hyg** 1996 Jan-Feb; 90(1):90. Comment on: Trans R Soc Trop Med Hyg 1995 Jan-Feb;89(1):78-82.

Clinical presentation of pulmonary tuberculosis in under 10s and differences in AIDS-related cases: a cohort study of 115 patients. Garay JE. **Trop Doct** 1997 Jul;27(3):139-42

Persistent cough in patients using an urban chest clinic in Malawi. Nwanyanwu O, et al. **Trop Doct** 1996 Oct; 26(4):165-7

Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosis. Wallis RS, et al. **Tuber Lung Dis** 1996 Dec;77(6):516-23

Cryptococcosis associated with HIV negative Indian patients and HIV positive Indian blood donors. Khan ZK, et al. **Zentralbl Bakteriol** 1996 Mar;283(3):360-74

On the development of mycobacterial infections II. Changing mycobacterial infection spectrum in the Cologne area 1983-1993. Schütt-Gerowitt H. **Zentralbl Bakteriol** 1995 Dec;283(2):225-38 (71 ref.)

[Perforation of cytomegalovirus appendicitis in a patient with human immunodeficiency virus infection (letter)] Mazza D, et al. **Gastroenterol Clin Biol** 1997;21(4):346-7 **(Fre)**

[Red fingers syndrome in the course of HIV infection. A new case] Lair G, et al. **J Mal Vasc** 1997;22(1):48-50 (Eng. Abstr.) **(Fre)**

[Antecubital herpes zoster in AIDS (letter)] Loembe PM, et al. **Med Trop (Mars)** 1997;57(2):207-8 **(Fre)**

[Treatment of cytomegalovirus infections in HIV infection] Breton G, et al. **Presse Med** 1996 Dec 14;25(39):1967-73 (39 ref.) (Eng. Abstr.) **(Fre)**

[Coincidence of Pneumocystis carinii pneumonia and lung carcinoma in AIDS] Klinker H, et al. **Pneumologie** 1996 Jul;50(7):496-501 (Eng. Abstr.) **(Ger)**

[What is your diagnosis? Septic pulmonary embolism, right-sided pleural effusion] Braunschweig M. **Schweiz Rundsch Med Prax** 1997 Apr 2;86(14):549-50 **(Ger)**

[Pancreatitis caused by Cryptosporidium parvum in patients with severe immunodeficiency related to HIV infection] Calzetti C, et al. **Ann Ital Med Int** 1997 Apr-Jun;12(2):63-6 (Eng. Abstr.) **(Ita)**

[Clinico-diagnostic and odonto-stomatologic therapeutic problems in patients with HIV infection and AIDS] Spadari F, et al. **Minerva Stomatol** 1997 Jun;46(6):307-28 (100 ref.) (Eng. Abstr.) **(Ita)**

[Thoracotomy as treatment for pneumothorax associated with pneumocystic carinii pneumonia in a patient with hemophilia A and the acquired immunodeficiency syndrome] Yoshida S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec; 33(12):1464-8 (Eng. Abstr.) **(Jpn)**

[Aids associated nervous system infections] Kishida S. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):725-30 (5 ref.) **(Jpn)**

[Histoplasmosis in immunodepressed patients: study of 18 cases seen in Uberlândia, MG] Borges AS, et al. **Rev Soc Bras Med Trop** 1997 Mar-Apr;30(2):119-24 (Eng. Abstr.) **(Por)**

[Adult respiratory distress syndrome caused by miliary tuberculosis in a patient with HIV infection (letter)] Arbol Linde F, et al. **An Med Interna** 1996 Oct;13(10):511 **(Spa)**

[Respiratory cryptosporidiosis as first manifestation of AIDS (letter) (see comments)] Martínez-Alvarez R, et al. **Enferm Infecc Microbiol Clin** 1996 May;14(5):336-7. Comment in: Enferm Infecc Microbiol Clin 1996 Dec;14(10):627. **(Spa)**

[Fever of unknown origin in patients with HIV infection] Riera M, et al. **Enferm Infecc Microbiol Clin** 1996 Dec; 14(10):581-5 (Eng. Abstr.) **(Spa)**

[Diarrhea due to microsporidia in a patient with AIDS] Bantar C, et al. **Medicina (B Aires)** 1995;55(6):685-8 (Eng. Abstr.) **(Spa)**

[Diarrhea in patients with AIDS] Monés J, et al. **Rev Esp Enferm Dig** 1996 Apr;88(4):280-6 (30 ref.) **(Spa)**

DIAGNOSIS

Ring-enhancing brain lesion in a 42-year-old man. Tomkovich K, et al. **Acad Radiol** 1996 Nov;3(11):968-70

Pulmonary sporotrichosis with hyphae in a human immunodeficiency virus-infected patient. A case report. Gori S, et al. **Acta Cytol** 1997 Mar-Apr;41(2):519-21

Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. Bowen EF, et al. **AIDS** 1997 Jun;11(7):889-93

Lessons from the natural history of cytomegalovirus. Bowen EF, et al. **AIDS** 1996 Nov;10 Suppl 1:S37-41 (14 ref.)

Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. Cinque P, et al. **AIDS** 1996 Aug;10(9):951-8

Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction [editorial] Cinque P, et al. **AIDS** 1997 Jan;11(1):1-17 (192 ref.)

Comparison of fluorescence and standard light microscopy for diagnosis of microsporidia in stools of patients with AIDS and chronic diarrhoea [letter] Conteas C, et al. **AIDS** 1997 Mar;11(3):386-7

Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. Dodt KK, et al. **AIDS** 1997 Mar;11(3):F21-8

Polymerase chain reaction for microsporidian DNA in gastrointestinal biopsy specimens of HIV-infected patients. Franzen C, et al. **AIDS** 1996 Jul;10(8):F23-7

Clinical significance of qualitative human cytomegalovirus (HCMV) detection in cell-free serum samples in HIV-infected patients at risk for HCMV disease [letter] Laue T, et al. **AIDS** 1997 Jul 15;11(9):1195-6

Confusing criteria for the diagnosis of toxoplasmic

encephalitis in AIDS [letter; comment] Lijmer JG, et al. **AIDS** 1997 Jul 15;11(9):1188–9. Comment on: AIDS 1997 Feb;11(2):177–84.

Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection [letter] Macías J, et al. **AIDS** 1997 Feb;11(2):253–4

Solitary cutaneous cryptococcosis resembling chickenpox: a case report [letter] Martinelli C, et al. **AIDS** 1997 Feb; 11(2):260–1

A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. The BIOTOXO Study Group [see comments] Raffi F, et al. **AIDS** 1997 Feb;11(2):177–84. Comment in: AIDS 1997 Jul 15;11(9):1188–9.

Strongyloides stercoralis hyperinfection diagnosed by gastric cytology in an AIDS patient [letter] Sarangarajan R, et al. **AIDS** 1997 Mar;11(3):394–6

Cryptococcal disease: implications of recent clinical trials on treatment and management. Aberg JA, et al. **AIDS Clin Rev** 1997–98;:229–48 (56 ref.)

Granulomatous amebic encephalitis caused by leptomyxid amebae in an HIV-infected patient. Zagardo MT, et al. **AJNR Am J Neuroradiol** 1997 May;18(5):903–8

Neuroradiology case of the day. CNS cryptococcal infection. Lanzieri CF, et al. **AJR Am J Roentgenol** 1997 Jul; 169(1):295, 299

Diagnostic yield of duodenal biopsy and aspirate in AIDS-associated diarrhea [see comments] Bown JW, et al. **Am J Gastroenterol** 1996 Nov;91(11):2289–92. Comment in: Am J Gastroenterol 1996 Nov;91(11):2261–2.

Diagnosis and treatment of esophageal diseases associated with HIV infection. Practice Parameters Committee of the American College of Gastroenterology. Dieterich DT, et al. **Am J Gastroenterol** 1996 Nov;91(11):2265–9 (76 ref.)

To scope or not to scope: the role of endoscopy in the evaluation of AIDS-related diarrhea [editorial; comment] Johanson JF. **Am J Gastroenterol** 1996 Nov;91(11):2261–2 . Comment on: Am J Gastroenterol 1996 Nov;91(11):2289–92.

The coexistence of primary esophageal lymphoma and Candida glabrata esophagitis presenting as dysphagia and odynophagia in a patient with acquired immunodeficiency syndrome. Marnejon T, et al. **Am J Gastroenterol** 1997 Feb; 92(2):354–6 (10 ref.)

Endoscopic appearance of cryptosporidial duodenitis. Papp JP Jr, et al. **Am J Gastroenterol** 1996 Oct;91(10):2235–6

Mycobacterium avium complex esophagitis. El-Serag HB, et al. **Am J Gastroenterol** 1997 Sep;92(9):1561–3

Utility of bone marrow culture and biopsy in the diagnosis of disseminated infections in AIDS. Keiser P, et al. **Am J Hematol** 1997 Sep;56(1):1–4

Tuberculous brain abscess in a patient with HIV infection: case report and review. Farrar DJ, et al. **Am J Med** 1997 Mar;102(3):297–301 (49 ref.)

Cytomegalovirus antigenemia in acquired immunodeficiency syndrome patients with untreated cytomegalovirus retinitis. Pannuti CS, et al. **Am J Ophthalmol** 1996 Dec; 122(6):847–52

Cytomegalovirus: the monster in the closet? [editorial] Baughman RP. **Am J Respir Crit Care Med** 1997 Jul; 156(1):1–2

Lack of association of induration size with HIV infection among drug users reacting to tuberculin [letter; comment] Daniel TM. **Am J Respir Crit Care Med** 1997 May; 155(5):1816–7. Comment on: Am J Respir Crit Care Med 1996 Oct;154(4 Pt 1):1029–33.

Lack of association of induration size with HIV infection among drug users reacting to tuberculin [see comments] Gourevitch MN, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):1029–33. Comment in: Am J Respir Crit Care Med 1997 May;155(5):1816–7.

Two-step tuberculin skin testing in HIV-infected persons in Uganda. Hecker MT, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):81–6

Lack of clinical utility of bronchoalveolar lavage cultures for cytomegalovirus in HIV infection. Mann M, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1723–8

Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Stansell JD, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):60–6

Oncological problems in AIDS—a review of the clinical features and management. Geh JI, et al. **Ann Acad Med Singapore** 1996 May;25(3):380–91 (74 ref.)

Outpatient management of HIV-related pneumonia [letter; comment] Becker SL. **Ann Intern Med** 1996 Dec 1; 125(11):938–9. Comment on: Ann Intern Med 1996 Feb 15;124(4):451–3.

Bone marrow biopsy in the diagnosis of fever of unknown origin in patients with acquired immunodeficiency syndrome. Benito N, et al. **Arch Intern Med** 1997 Jul 28; 157(14):1577–80

Association of tuberculosis risk with the degree of tuberculin reaction in HIV-infected patients. The Gruppo Italiano di Studio Tubercolosi e AIDS. Girardi E, et al. **Arch Intern Med** 1997 Apr 14;157(7):797–800

Central nervous system Mycobacterium avium complex infection [letter; comment] Baksh FK, et al. **Arch Pathol Lab Med** 1996 Jul;120(7):614–5. Comment on: Arch Pathol Lab Med 1995 Sep;119(9):836–9.

Pseudomonas pericarditis and tamponade in an infant with human immunodeficency virus infection. Tumaliuan JA, et al. **Arch Pediatr Adolesc Med** 1997 Feb;151(2):207–8 (9 ref.)

Leishmaniasis presenting as a psoriasiform eruption in AIDS [letter] Rubio FA, et al. **Br J Dermatol** 1997 May; 136(5):792–4

Molecular diagnosis of deep nodular bacillary angiomatosis and monitoring of therapeutic success. Schlüpen EM, et al. **Br J Dermatol** 1997 May;136(5):747–51

The eye in AIDS. Lightman S, et al. **Br J Hosp Med** 1996 Feb 7–20;55(3):95–99 (19 ref.)

Ophthaproblem. Cytomegalovirus retinitis. Sharma S. **Can Fam Physician** 1997 May;43:853, 861

Diagnosis and management of AIDS-related diarrhea. Johanson JF. **Can J Gastroenterol** 1996 Nov–Dec; 10(7):461–8 (61 ref.)

Pulmonary aspergilloma and AIDS. A comparison of HIV-infected and HIV-negative individuals. Addrizzo-Harris DJ, et al. **Chest** 1997 Mar;111(3):612–8

Empiric treatments impair the diagnostic yield of BAL in HIV-positive patients. Gracia JD, et al. **Chest** 1997 May; 111(5):1180–6

A 31-year-old man with a thick-walled cyst. Lando Y, et al. **Chest** 1997 Jun;111(6):1754–6 (9 ref.)

Cytomegalovirus as a pulmonary pathogen [letter] Numazaki K. **Chest** 1997 Sep;112(3):860–1

Development and application of genetic probes for detection of Enterocytozoon bieneusi in formalin-fixed stools and in intestinal biopsy specimens from infected patients. Carville A, et al. **Clin Diagn Lab Immunol** 1997 Jul; 4(4):405–8

Acute primary human immunodeficiency virus type 1 infection in a patient with concomitant cytomegalovirus encephalitis. Berger DS, et al. **Clin Infect Dis** 1996 Jul; 23(1):66–70

Markedly elevated serum lactate dehydrogenase levels are a clue to the diagnosis of disseminated histoplasmosis in patients with AIDS. Corcoran GR, et al. **Clin Infect Dis** 1997 May;24(5):942–4

Reliving a nightmare: a hard (and tragic) lesson in humility. DiNubile MJ. **Clin Infect Dis** 1996 Jul;23(1):160–5

Penicillium marneffei infection associated with AIDS [letter; comment] Dupouy-Camet J, et al. **Clin Infect Dis** 1997 May;24(5):1026. Comment on: Clin Infect Dis 1996 Jul;23(1):125–30.

Brucella melitensis osteitis following craniotomy in a patient with AIDS. Galle C, et al. **Clin Infect Dis** 1997 May; 24(5):1012

Cytomegalovirus (CMV) viremia and the CD4+ lymphocyte count as predictors of CMV disease in patients infected with human immunodeficiency virus [see comments] Gérard L, et al. **Clin Infect Dis** 1997 May;24(5):836–40. Comment in: Clin Infect Dis 1997 May;24(5):841–2.

Photo quiz. Syphilis of the skin (nodular syphilids). Glatt AE, et al. **Clin Infect Dis** 1996 Aug;23(2):231, 377

Rapid detection of cytomegalovirus in bronchoalveolar lavage fluid and serum samples by polymerase chain reaction: correlation of virus isolation and clinical outcome for patients with human immunodeficiency virus infection. Hansen KK, et al. **Clin Infect Dis** 1997 May;24(5):878–83

Pleural pseudotumoral mass revealing an extrapulmonary Pneumocystis carinii infection. Kaplanski G, et al. **Clin Infect Dis** 1996 Jul;23(1):199–200

Salmonella parotitis with abscess formation in a patient with human immunodeficiency virus infection. Knee TS, et al. **Clin Infect Dis** 1997 May;24(5):1009–10

Primary tuberculosis of the larynx in a patient infected with human immunodeficiency virus. Nasti G, et al. **Clin Infect Dis** 1996 Jul;23(1):183–4

Diagnosing and treating cytomegalovirus pneumonia in patients with AIDS. Rodriguez-Barradas MC, et al. **Clin Infect Dis** 1996 Jul;23(1):76–81

Remember Rocky Mountain spotted fever—a lesson in ethical principles [editorial] Woodward TE. **Clin Infect Dis** 1996 Jul;23(1):165–6

Severe mental illness and HIV-related medical and neuropsychiatric sequelae. McDaniel JS, et al. **Clin Psychol Rev** 1997;17(3):311–25 (85 ref.)

The spectrum of MRI findings in CNS cryptococcosis in AIDS. Miszkiel KA, et al. **Clin Radiol** 1996 Dec; 51(12):842–50

Salmonella osteomyelitis in a patient with human immunodeficiency virus infection [letter] Belzunegui J, et al. **Clin Rheumatol** 1997 May;16(3):319–20 (10 ref.)

Pyogenic arthritis caused by streptococcus equisimilis (group-C streptococcus) in a patient with AIDS. Steinfeld S, et al. **Clin Rheumatol** 1997 May;16(3):314–6 (20 ref.)

Diagnosis and treatment of infectious diseases in HIV-infected hosts. Castano-Molina C, et al. **Dermatol Clin** 1997 Apr;15(2):267–83 (197 ref.)

Chronic varicella presenting as disseminated pinpoint-sized papules in a man infected with the human immunodeficiency virus. Castanet J, et al. **Dermatology** 1996;192(1):84–6

Viral lesions of the mouth in HIV-infected patients. Itin PH, et al. **Dermatology** 1997;194(1):1–7 (85 ref.)

Diagnosis of Cryptosporidium parvum in patients with severe diarrhea and AIDS. Greenberg PD, et al. **Dig Dis Sci** 1996 Nov;41(11):2286–90

Tuberculous bronchoesophageal fistula in a patient infected with the HIV virus. Ravera M. **Endoscopy** 1997 Feb; 29(2):146

Cytomegalovirus ileocolitis: different manifestations of the same illness in the terminal ileum and colon. Sebastián JJ, et al. **Endoscopy** 1996 Oct;28(8):729

Acute myocarditis mimicking myocardial infarction in an HIV infected patient [letter] Monsuez JJ, et al. **Eur Heart J** 1996 Sep;17(9):1449

Lactobacillus casei infection in an AIDS patient [letter] Abgrall S, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb; 16(2):180–2 (7 ref.)

Acute mediastinitis due to Rhodococcus equi in a patient with human immunodeficiency virus infection. Casado JL, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):241–4

Species-specific identification of microsporidia in stool and intestinal biopsy specimens by the polymerase chain reaction. Kock NP, et al. **Eur J Clin Microbiol Infect Dis** 1997 May;16(5):369–76

Oerskovia turbata and Comamonas acidovorans bacteremia in a patient with AIDS [letter] Lair MI, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):424–6

Agrobacterium radiobacter pneumonia in a patient with HIV infection [letter] Mastroianni A, et al. **Eur J Clin Microbiol Infect Dis** 1996 Dec;15(12):960–3

Pleural and peritoneal leishmaniasis in an AIDS patient. Muñoz-Rodriguez FJ, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):246–8

Relevance of clinical and laboratory findings in the diagnosis of cytomegalovirus encephalitis in patients with AIDS. Mussini C, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jun; 16(6):437–44

Isolation of Bartonella quintana from an HIV-positive patient with bacillary angiomatosis. Schmidt HU, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep;15(9):736–41 (21 ref.)

Interferon-gamma in 388 immunocompromised and immunocompetent patients for diagnosing pleural tuberculosis. Villena V, et al. **Eur Respir J** 1996 Dec; 9(12):2635–9

Molecular diagnosis of gastrointestinal infections associated with HIV infection. Talal AH, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):417–44 (152 ref.)

Results of culture form colonoscopically obtained specimens for bacteria and fungi in HIV-infected patients with diarrhea. Beaugerie L, et al. **Gastrointest Endosc** 1996 Dec; 44(6):663–6

Rapidly progressive deafness in a young woman. Hariharan R, et al. **Hosp Pract (Off Ed)** 1996 Oct 15;31(10):159–60

Pneumocystis carinii pneumonia simulating as pulmonary tuberculosis in AIDS. Arora VK, et al. **Indian J Chest Dis Allied Sci** 1996 Oct–Dec;38(4):253–7

Disseminated cryptococcosis presenting as molluscum-like lesions as the first manifestation of AIDS. Muñoz-Pérez MA, et al. **Int J Dermatol** 1996 Sep;35(9):646–8

Neutrophilic eccrine hidradenitis in an HIV-infected patient. Sevila A, et al. **Int J Dermatol** 1996 Sep;35(9):651–2 (4 ref.)

Pyrexia of undetermined origin in patients with human immunodeficiency virus infection and AIDS. Miller RF, et al. **Int J STD AIDS** 1996 May–Jun;7(3):170–5 (32 ref.)

Morphological injury of the intestinal mucosa and infection in patients with AIDS. The role of combined tissue and stool examination. Dionisio D, et al. **Ital J Gastroenterol Hepatol** 1997 Feb;29(1):25–30

Cytomegalovirus retinitis: diagnosis and status of systemic therapy. Friedberg DN. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S1–6 (20 ref.)

Evaluation of a new self-screening chart for cytomegalovirus retinitis in patients with AIDS. Teich SA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 1;13(4):336–42

Chronic varicella zoster infection mimicking a basal cell carcinoma in an AIDS patient. Tsao H, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 2):831–3

Early bronchoscopic diagnosis of concomitant tuberculosis and Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. Albino JA, et al. **J Assoc Acad Minor Phys** 1996;7(4):99–103

Cryptococcal meningitis in AIDS—need for early diagnosis. Aquinas SR, et al. **J Assoc Physicians India** 1996 Mar; 44(3):178–80

HIV-associated staphylococcal pyomyositis. Hamide A, et al. **J Assoc Physicians India** 1995 Jan;43(1):63–5

Toxoplasma encephalitis in AIDS. Handa R, et al. **J Assoc Physicians India** 1996 Nov;44(11):838

Central nervous system toxoplasmosis in acquired immune deficiency syndrome. Venkatachalam S, et al. **J Assoc Physicians India** 1995 Jun;43(6):427–30

Criteria for classifying endocarditis [letter; comment] van der Meer JT. **J Clin Epidemiol** 1997 Jun;50(6):745. Comment on: J Clin Epidemiol 1996 Oct;49(10):1149–54.

PCR enzyme-linked immunosorbent assay for diagnosis of leishmaniasis in human immunodeficiency virus-infected patients. Costa JM, et al. **J Clin Microbiol** 1996 Jul; 34(7):1831–3

Antigen detection: the method of choice in comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in human immunodeficiency virus-infected patients. Dahl H, et al. **J Clin Microbiol** 1997 Feb; 35(2):347–9

A new acid-fast trichrome stain for simultaneous detection of Cryptosporidium parvum and microsporidial species in stool specimens. Ignatius R, et al. **J Clin Microbiol** 1997

Feb;35(2):446–9
Evaluation of the Digene Hybrid Capture System for detection and quantitation of human cytomegalovirus viremia in human immunodeficiency virus–infected patients. Mazzulli T, et al. **J Clin Microbiol** 1996 Dec; 34(12):2959–62
Interest of quantitative pp65 cytomegalovirus antigenemia assay for human immunodeficiency virus–positive patients [letter; comment] Ranger-Rogez S, et al. **J Clin Microbiol** 1996 Dec;34(12):3255–6. Comment on: J Clin Microbiol 1996 Feb;34(2):457–9.
Unusual pattern of enhancement in cryptococcal meningitis: in vivo findings with postmortem correlation. Arnder L, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):1023–6 (8 ref.)
Macronodular hepatic granulomas due to visceral leishmaniasis in an AIDS patient: imaging findings. Canalias J, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):677–9 (13 ref.)
Dentate nuclei involvement in AIDS patients with CNS cryptococcosis: imaging findings with pathologic correlation. Ruiz A, et al. **J Comput Assist Tomogr** 1997 Mar–Apr;21(2):175–82
Electron microscopy in AIDS-related infectious diseases. I. Acanthamoebiasis. Hashimoto K, et al. **J Dermatol** 1996 Nov;23(11):773–7 (11 ref.)
Pruritic papular eruptions and candidiasis due to HIV infection. Uchigasaki S, et al. **J Dermatol** 1996 Aug; 23(8):572–6
Evaluation of PCR technique for diagnosing Pneumocystis carinii pneumonia in HIV positive patients using oropharyngeal washings. Lundgren B, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):9S
Bacteremia caused by Helicobacter cinaedi in an AIDS patients. Hung CC, et al. **J Formos Med Assoc** 1997 Jul; 96(7):558–60
The utility of direct acid–fast stain of cerebrospinal fluid for the rapid diagnosis of tuberculous meningitis in patients with and without AIDS [letter] Dural AT, et al. **J Gen Intern Med** 1997 Apr;12(4):259
Proof of CMV neurological infection is problematic [letter; comment] Gluckman SJ. **J Gen Intern Med** 1996 Sep; 11(9):569. Comment on: J Gen Intern Med 1996 Jan;11(1):47–9.
Detection of HIV infection in pulmonary tuberculosis patients. Samuel NM, et al. **J Indian Med Assoc** 1996 Sep; 94(9):331–3
A comparison of two methods of gene amplification for the diagnosis of Toxoplasma gondii in AIDS. Nicoll S, et al. **J Infect** 1996 Nov;33(3):177–83
Cryptococcal dermatitis with negative antigenaemia heralding disseminated disease in HIV infection [letter] Soldani F, et al. **J Infect** 1996 Nov;33(3):240–1
PCR detection of Toxoplasma gondii DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions. Cingolani A, et al. **J Med Microbiol** 1996 Dec;45(6):472–6
Evaluation of different techniques in the diagnosis of Toxoplasma encephalitis. Rodriguez JC, et al. **J Med Microbiol** 1997 Jul;46(7):597–601
Infection caused by Cryptococcus neoformans var. gattii serotype B in an AIDS patient in India. Abraham M, et al. **J Med Vet Mycol** 1997 Jul–Aug;35(4):283–4
Fatal brain stem encephalitis due to herpes simplex virus type 1 in AIDS [letter] Moulignier A, et al. **J Neurol** 1996 Jun; 243(6):491–3
Diagnostic criteria and clinical procedures in HIV–1 associated progressive multifocal leukoencephalopathy. von Giesen HJ, et al. **J Neurol Sci** 1997 Mar 20;147(1):63–72
Magnetic resonance brain imaging lacks sensitivity for AIDS associated cytomegalovirus encephalitis. Clifford DB, et al. **J Neurovirol** 1996 Dec;2(6):397–403
Actinomycosis of the tongue associated with human immunodeficiency virus infection: case report. Vazquez AM, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):879–81 (18 ref.)
A rapid microwave–in situ hybridization method for the definitive diagnosis of oral hairy leukoplakia: comparison with immunohistochemistry. Mabruk MJ, et al. **J Oral Pathol Med** 1996 Apr;25(4):170–6
Alveolar echinococcosis of the liver in a six–year–old girl with acquired immunodeficiency syndrome. Sailer M, et al. **J Pediatr** 1997 Feb;130(2):320–3 (24 ref.)
Necrotizing external otitis in patients with AIDS. Ress BD, et al. **Laryngoscope** 1997 Apr;107(4):456–60
Neopterin, beta 2–microglobulin, and acute phase proteins in HIV–1–seropositive and –seronegative Zambian patients with tuberculosis. Hosp M, et al. **Lung** 1997;175(4):265–75
An unexpected clue: the peripheral blood smear in a patient with AIDS. Lacson EK Jr, et al. **Md Med J** 1996 Jun; 45(6):482–4
Pulmonary disease. Walker PA, et al. **Med Clin North Am** 1996 Nov;80(6):1337–62 (156 ref.)
Detection of Pneumocystis carinii in induced sputa from immunocompromised patients using a repetitive DNA probe. Graves DC, et al. **Mol Cell Probes** 1997 Feb; 11(1):1–9
Choreoathetosis in acquired immune deficiency syndrome patients with cerebral toxoplasmosis. Maggi P, et al. **Mov Disord** 1996 Jul;11(4):434–6
Human immunodeficiency virus–related progressive multifocal leukoencephalopathy presenting with an akinetic rigid syndrome. Werring DJ, et al. **Mov Disord** 1996 Nov; 11(6):758–61
Cryptosporidium, Isospora and Strongyloides in AIDS [letter; comment] Ghorpade MV, et al. **Natl Med J India** 1996 Jul–Aug;9(4):201. Comment on: Natl Med J India 1996 Jan–Feb;9(1):17–9.
Intracranial bacterial infections in patients with AIDS. Cohen WA. **Neuroimaging Clin N Am** 1997 May;7(2):223–9 (41 ref.)
Neuroimaging of AIDS. I. Fungal infections of the central nervous system. Harris DE, et al. **Neuroimaging Clin N Am** 1997 May;7(2):187–98 (60 ref.)
Neurosyphilis in patients with AIDS. Harris DE, et al. **Neuroimaging Clin N Am** 1997 May;7(2):215–21 (18 ref.)
Neuroimaging of AIDS. I. Viral infections. Lizerbram EK, et al. **Neuroimaging Clin N Am** 1997 May;7(2):261–80 (74 ref.)
Neuroimaging of AIDS. I. Central nervous system toxoplasmosis. Ramsey RG, et al. **Neuroimaging Clin N Am** 1997 May;7(2):171–86 (67 ref.)
Imaging of pediatric central nervous system HIV infection. States LJ, et al. **Neuroimaging Clin N Am** 1997 May; 7(2):321–39 (87 ref.)
Diagnostic imaging of infections and neoplasms affecting the spine in patients with AIDS. Thurnher MM, et al. **Neuroimaging Clin N Am** 1997 May;7(2):341–57 (86 ref.)
Neuroimaging of central nervous system tuberculosis in HIV–infected patients. Whiteman ML. **Neuroimaging Clin N Am** 1997 May;7(2):199–214 (79 ref.)
Diagnosis of AIDS–related focal brain lesions: a decision–making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Antinori A, et al. **Neurology** 1997 Mar;48(3):687–94
The "target sign": is it a specific sign of CNS tuberculoma? Bargalló J, et al. **Neuroradiology** 1996 Aug;38(6):547–50
Cytomegalovirus encephalitis and primary cerebral lymphoma mimicking Wernicke's encephalopathy. Brechtelsbauer DL, et al. **Neuroradiology** 1997 Jan; 39(1):19–22
Progressive multifocal leukoencephalopathy in an HIV–infected child. Morriss MC, et al. **Neuroradiology** 1997 Feb;39(2):142–4
Cytomegalovirus disease presenting as a focal brain mass: report of two cases. Huang PP, et al. **Neurosurgery** 1997 May;40(5):1074–8; discussion 1078–9
Bacillary angiomatosis of the cervix and vulva in a patient with AIDS. Long SR, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):709–11
Oral secondary syphilis in a patient with human immunodeficiency virus infection. Ramirez–Amador V, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jun;81(6):652–4
Bacteremia caused by Hafnia alvei in a human immunodeficiency virus–infected child [letter] Conte M, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):182–3
Tuberculin skin testing in a pediatric population exposed to human immunodeficiency virus. Nachman SA, et al. **Pediatr Infect Dis J** 1996 Nov;15(11):1041–2
Disseminated histoplasmosis in a human immunodeficiency virus–infected African child. Pillay T, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):417–8
Interventional procedures in the AIDS patient. Klein JS, et al. **Radiol Clin North Am** 1997 Sep;35(5):1223–43 (79 ref.)
Changing trends in the pulmonary manifestations of AIDS. McGuinness G. **Radiol Clin North Am** 1997 Sep; 35(5):1029–82 (153 ref.)
Musculoskeletal manifestations of AIDS. Major NM, et al. **Radiol Clin North Am** 1997 Sep;35(5):1167–89 (88 ref.)
Brain and spine imaging findings in AIDS patients. Provenzale JM, et al. **Radiol Clin North Am** 1997 Sep; 35(5):1127–66 (146 ref.)
Intra–abdominal manifestations of AIDS. Redvanly RD, et al. **Radiol Clin North Am** 1997 Sep;35(5):1083–125 (148 ref.)
Clinical versus fundus photographic evaluation of the status of cytomegalovirus retinitis in AIDS patients. Flores–Aguilar M, et al. **Retina** 1996;16(5):363–72
Fine–needle aspiration of lymph nodes [letter; comment] Parrish AG. **S Afr Med J** 1997 Mar;87(3):342, 344. Comment on: S Afr Med J 1996 Oct;86(10):1300.
pp65 antigenemia as a marker of future CMV disease and mortality in HIV–infected patients. Podzamczer D, et al. **Scand J Infect Dis** 1997;29(3):223–7
Helicobacter cinaedi bacteraemia: varied clinical manifestations in three homosexual males. Tee W, et al. **Scand J Infect Dis** 1996;28(2):199–203
Intestinal microsporidiosis. Croft SL, et al. **Semin Gastrointest Dis** 1997 Jan;8(1):45–55 (70 ref.)
Diagnostic strategies for Pneumocystis carinii pneumonia. Kroe DM, et al. **Semin Respir Infect** 1997 Jun;12(2):70–8 (97 ref.)
CMV colitis masquerading as colon cancer--an unusual presentation of acquired immunodeficiency syndrome. Chow PK, et al. **Singapore Med J** 1997 Jan;38(1):32–4
Salmonella as a cause of bacteremia and subdural empyema in a patient with HIV infection. Kanchanapongkul J, et al. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):196–9
Clinical presentation of pulmonary tuberculosis in under 10s and differences in AIDS–related cases: a cohort study of 115 patients. Garay JE. **Trop Doct** 1997 Jul;27(3):139–42
"Splenic abscess in a HIV patient". Swamy TK, et al. **Trop Gastroenterol** 1995 Jul–Sep;16(3):29–31
Splenic abscesses and abdominal tuberculosis in patients with AIDS. Reichel C, et al. **Z Gastroenterol** 1996 Aug; 34(8):494–6
[Penicillium marneffei infection: a pathology to be known] Grise G, et al. **Ann Biol Clin (Paris)** 1997 May–Jun; 55(3):241–2 **(Fre)**
[Early diagnosis and treatment of cytomegalovirus polyradiculoneuritis in a child infected by HIV] Quartier P, et al. **Arch Pediatr** 1996 Aug;3(8):792–5 (Eng. Abstr.) **(Fre)**
[Recurrent varicella and HIV infection. Apropos of 10 cases seen in Lomé] Pitche P, et al. **Med Trop (Mars)** 1997; 57(1):65–7 (Eng. Abstr.) **(Fre)**
[HIV infection manifesting as a pneumococcal spondylodiscitis] Touchard P, et al. **Med Trop (Mars)** 1996; 56(3):275–8 (Eng. Abstr.) **(Fre)**
[The AIDS patient, AIDS, the general practitioner] Piquard D. **Rev Med Brux** 1996 Sep;17(4):160–3 (Eng. Abstr.) **(Fre)**
[The eye and AIDS: ophthalmological consultation for AIDS screening, 1–year retrospective study] Lendi B, et al. **Rev Med Suisse Romande** 1996 Jan;116(1):59–64 **(Fre)**
[Tuberculous pleurisy followed by bronchial cancer in a patient with HIV infection] N'Gbesso RD, et al. **Rev Pneumol Clin** 1996;52(6):398–403 (35 ref.) (Eng. Abstr.) **(Fre)**
[HIV infection, tuberculosis and tuberculin test in Switzerland. The Swiss HIV Cohort Study] Sudre P, et al. **Schweiz Med Wochenschr** 1996 Nov 23;126(47):2007–12 (Eng. Abstr.) **(Fre)**
[Mycobacterioses: HIV patients depend on rapid diagnosis and therapy (interview by Dr. rer. nat. Anita Schweiger)] Poppinger J. **Fortschr Med** 1996 Jul 1;114(18–19):20–1, 24 **(Ger)**
[Molecular biology methods in detection of mycobacteria. Improved and newly developed test systems for the diagnosis of mycobacteria] Reischl U, et al. **Fortschr Med** 1996 Jul 1;114(18–19):237–41 (15 ref.) (Eng. Abstr.) **(Ger)**
[Illnesses caused by ubiquitous mycobacteria. Clinical, therapeutic and microbiological aspects] Schütt–Gerowitt H. **Fortschr Med** 1996 Jul 1;114(18–19):233–6 (10 ref.) (Eng. Abstr.) **(Ger)**
[Mollusca contagiosa in HIV infection. Clinical manifestation, relation to immune status and prognostic value in 39 patients] Husak R, et al. **Hautarzt** 1997 Feb; 48(2):103–9 (Eng. Abstr.) **(Ger)**
[Molluscum contagiosum–like papules within the scope of disseminated infection with Mycobacterium avium complex in an AIDS patient] Mohr C, et al. **Hautarzt** 1996 Aug; 47(8):634–7 (Eng. Abstr.) **(Ger)**
[HIV–associated skin diseases. 1: Follow–up and epidemiology of HIV infection, pathogen–induced HIV–associated dermatoses] Ramsauer J, et al. **Hautarzt** 1996 Oct;47(10):795–813 (73 ref.) **(Ger)**
[Management of atypical Mycobacterium infections in AIDS–patients] **Internist (Berl)** 1996 Apr;37(4 Suppl):1–8 **(Ger)**
[Intestinal and systemic infections caused by Microsporidia] Weber R, et al. **Internist (Berl)** 1996 Sep;37(9):912–8 (22 ref.) **(Ger)**
[Ubiquitous mycobacteria: clinical and microbiological aspects] Schütt–Gerowitt H. **Med Klin** 1996 Oct 15; 91(10):654–9 (32 ref.) **(Ger)**
[Invasive mold infections in the university clinics of Leipzig in the period from 1992–1994] Nenoff P, et al. **Mycoses** 1996;39 Suppl 1:107–12 (Eng. Abstr.) **(Ger)**
[Tuberculosis] Kirsten D. **Pneumologie** 1996 Sep;50 Suppl 2:595–8 (13 ref.) **(Ger)**
[Value of polymerase chain reaction (PCR) in diagnosis of tuberculosis and mycobacterium infections caused by ubiquitous mycobacteria] Rosenkranz S, et al. **Pneumologie** 1997 Feb;51(2):78–86 (Eng. Abstr.) **(Ger)**
[A solitary toxoplasmosis focus simulating a brain tumor as the first manifestation of AIDS] Röricht S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):201–3 (12 ref.) **(Ger)**
[Neurosyphilis 12 years after treatment of primary infection in a meanwhile HIV infected patient] Eriksson U, et al. **Schweiz Med Wochenschr** 1997 May 31;127(22):940–4 (Eng. Abstr.) **(Ger)**
[Disseminated mycobacteriosis with M. kansasii in a case of AIDS without HIV infection] Knoblauch A, et al. **Schweiz Med Wochenschr** 1997 Aug 5;127(31–32):1291–5 (Eng. Abstr.) **(Ger)**
[Oral ulcers in HIV infection] Bassetti S, et al. **Schweiz Rundsch Med Prax** 1997 May 21;86(21):912–3 **(Ger)**
[A case fom practice (368). Pulmonary tuberculosis in AIDS] Bassetti ST. **Schweiz Rundsch Med Prax** 1996 Dec 10; 85(50):1633–4 **(Ger)**
[HIV infection and opportunistic pathology: the etiopathogenetic considerations and clinico–diagnostic aspects in candidiasis of the oral mucosa] Spadari F, et al. **Minerva Stomatol** 1996 Mar;45(3):81–99 (100 ref.) (Eng. Abstr.) **(Ita)**
[Candidiasis of the oropharyngeal mucosa. The clinical and epidemiological aspects in a group of HIV–positive and AIDS patients] Zambellini Artini M, et al. **Minerva Stomatol** 1996 Dec;45(12):549–61 (60 ref.) (Eng. Abstr.) **(Ita)**
[Tuberculosis in patients with human immunodeficiency virus

infection] Nagai H, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1997 Mar; 35(3):267–72 (Eng. Abstr.) **(Jpn)**
[Diversity in the clinical course of toxoplasma encephalitis in two patients infected with human immunodeficiency virus (HIV)] Rogowska-Szadkowska D, et al.
Neurol Neurochir Pol 1997 Jan–Feb;31(1):161–8 (Eng. Abstr.) **(Pol)**
[Correlation of clinical and morphological diagnoses in 55 fatal AIDS cases] Walewska-Zielecka B.
Przegl Epidemiol 1995;49(4):353–9 (Eng. Abstr.) **(Pol)**
[Toxoplasmosis in patients with AIDS] Zieliński A.
Przegl Epidemiol 1995;49(4):343–52 (86 ref.) (Eng. Abstr.) **(Pol)**
[Verrucous herpes zoster in AIDS patients] Agusto V, et al. **Acta Med Port** 1997 Jun–Jul;10(6–7):497–501 (20 ref.) (Eng. Abstr.) **(Por)**
[Syphilis in an HIV-infected patient] Cunha HM, et al.
Acta Med Port 1997 Jun–Jul;10(6–7):503–7 (12 ref.) (Eng. Abstr.) **(Por)**
[Cutaneous infection with the cytomegalovirus virus in AIDS patients] Franca I, et al. **Acta Med Port** 1997 Jun–Jul; 10(6–7):479–84 (21 ref.) (Eng. Abstr.) **(Por)**
[Breast tuberculosis: case report and literature review] Mendes W da S, et al.
Rev Hosp Clin Fac Med Sao Paulo 1996 Jul–Aug; 51(4):136–7 (Eng. Abstr.) **(Por)**
[The clinico-epidemiological aspects of a case of Cryptococcus neoformans meningoencephalitis] Ruginã S, et al. **Bacteriol Virusol Parazitol Epidemiol** 1993 Jan–Jun; 38(1–2):36–8 **(Rum)**
[Tuberculosis in patients with HIV infection] Kravchenko AV, et al. **Ter Arkh** 1996;68(4):69–71 (Eng. Abstr.) **(Rus)**
[The diagnosis and clinical characteristics of cytomegalovirus infection in HIV-infected subjects] Shakhgil'dian VI, et al. **Ter Arkh** 1996;68(4):65–8 (Eng. Abstr.) **(Rus)**
[The lungs in human immunodeficiency virus type 1 infection] Barić D, et al. **Med Pregl** 1997 Mar–Apr; 50(3–4):128–33 (Eng. Abstr.) **(Scr)**
[Diarrhea and AIDS: more complex diagnostic techniques; better therapeutic results] Olmos M, et al.
Acta Gastroenterol Latinoam 1996;26(2):91–100 (Eng. Abstr.) **(Spa)**
[Efficiency of bone marrow aspirate for diagnosis of opportunistic infections in HIV infected patients] Supervía A, et al. **An Med Interna** 1996 Aug;13(8):374–7 (Eng. Abstr.) **(Spa)**
[Fever and inhabited pulmonary cavity in an AIDS patient] Aguirre A, et al. **Enferm Infecc Microbiol Clin** 1996 Dec; 14(10):621–2 **(Spa)**
[Fever and cavitated pulmonary infiltrates in a patient with AIDS] Gainzarain JC, et al.
Enferm Infecc Microbiol Clin 1997 Mar;15(3):165–6 **(Spa)**
[Respiratory cryptosporidiosis (letter; comment)] Turrientes MC, et al. **Enferm Infecc Microbiol Clin** 1996 Dec; 14(10):627. Comment on: Enferm Infecc Microbiol Clin 1996 May;14(5):336–7. **(Spa)**
[Tuberculous abscess of the pancreas as initial manifestation of AIDS (letter)] Molina M, et al.
Gastroenterol Hepatol 1997 Mar;20(3):165–6 **(Spa)**
[Sepsis caused bt Leuconostoc cremoris, neutropenia and human immunodeficiency virus infection (letter)] del Nozal-Nalda M, et al. **Med Clin (Barc)** 1997 May 24; 108(20):799 **(Spa)**
[Fever of unknown origin in HIV infection (letter; comment)] Knobel H. **Med Clin (Barc)** 1996 Jun 29;107(5):198. Comment on: Med Clin (Barc) 1995 Nov 11;105(16):615–6. **(Spa)**
[Hyperinfection by Strongyloides stercoralis as first manifestation of AIDS (letter)] Montero A, et al.
Medicina (B Aires) 1996;56(3):319–20 **(Spa)**
[Intestinal leishmaniasis in AIDS patients (letter)] García-Samaniego J, et al. **Rev Esp Enferm Dig** 1997 Feb; 89(2):145 **(Spa)**

DRUG THERAPY

Cryptococcosis. Aberg JA, et al. **Adv Pharmacol** 1997; 37:215–51 (117 ref.)
3rd International Congress on Drug Therapy in HIV Infection. Birmingham, United Kingdom, 3–7 November 1996. Abstracts. **AIDS** 1996 Nov;10 Suppl 2:S1–59
Trifluorothymidine 0.5% ointment in the treatment of aciclovir-resistant mucocutaneous herpes simplex in AIDS [letter] Amin AR, et al. **AIDS** 1996 Aug;10(9):1051–3
Low-dose dapsone, co-trimoxazole, and survival in Pneumocystis carinii primary prophylaxis [letter] Antinori A, et al. **AIDS** 1996 Aug;10(9):1046–7
Atovaquone is effective treatment for the symptoms of gastrointestinal microsporidiosis in HIV-1-infected patients. Anwar-Bruni DM, et al. **AIDS** 1996 Jun; 10(6):619–23
Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. Bowen EF, et al. **AIDS** 1996 Nov; 10(13):1515–20
Convenient twice daily foscarnet in induction therapy of AIDS-associated cytomegalovirus retinitis. The Foscarnet Italian Study Group [letter] Carosi G, et al. **AIDS** 1997 Feb;11(2):258–60
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. Chaisson RE, et al. **AIDS** 1997 Mar;11(3):311–7
Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir [letter] Conant MA, et al.
AIDS 1997 Aug;11(10):1300–1
Cytomegalovirus retinitis in AIDS patients: a comparative study of intravenous and oral ganciclovir as maintenance therapy. Danner SA, et al. **AIDS** 1996 Dec;10 Suppl 4:S7–11
A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis. De Wit S, et al. **AIDS** 1997 May;11(6):759–63
Rhodococcus equi infections: antibiotic therapy and relapses [letter; comment] Giacometti A, et al. **AIDS** 1997 Jan; 11(1):120–1. Comment on: AIDS 1996 Apr;10(4):359–62.
Ganciclovir evaluation in AIDS patients with cytomegalovirus retinitis: a European study of treatment patterns and resource utilization. Hardens M. **AIDS** 1996 Dec;10 Suppl 4:S25–30
Lessons learned from HIV pathogenesis and therapy: implications for better management of cytomegalovirus disease. Hardy WD. **AIDS** 1996 Nov;10 Suppl 1:S31–5 (17 ref.)
Antimony/interferon-gamma combination in the treatment of visceral leishmaniasis in AIDS [letter] Kaplanski G, et al. **AIDS** 1996 Sep;10(10):1172–4
Consequences for the management of cytomegalovirus. Katlama C. **AIDS** 1996 Nov;10 Suppl 1:S43–6 (15 ref.)
Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovir [letter] Mueller AJ, et al. **AIDS** 1997 Mar;11(3):397–9
Azithromycin for relapsing cerebral toxoplasmosis in AIDS [letter] Nasta P, et al. **AIDS** 1997 Jul 15;11(9):1188
Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. Phillips P, et al.
AIDS 1996 Oct;10(12):1369–76
Potential role for granulocyte-macrophage colony-stimulating factor in the treatment of HIV-associated cryptococcal meningitis [letter] Price DA, et al. **AIDS** 1997 Apr;11(5):693–4
Chemotherapy for AIDS-related malignancies does not increase HIV viraemia [letter] Rutschmann OT, et al.
AIDS 1997 Jun;11(7):944–5
Successful treatment of cytomegalovirus encephalitis in an AIDS patient using cidofovir [letter] Sadler M, et al.
AIDS 1997 Aug;11(10):1293–4
Early foscarnet failure in herpes simplex virus infection in a patient with AIDS [letter] Segal BH, et al. **AIDS** 1997 Mar 15;11(4):552–3
Oral ganciclovir for cytomegalovirus retinitis in patients with AIDS: results of two randomized studies. Squires KE.
AIDS 1996 Dec;10 Suppl 4:S13–8
Prior antimicrobials and staphylococcal bacteremia in HIV-infected patients. Styrt BA, et al. **AIDS** 1997 Aug; 11(10):1243–8
Cryptococcal disease: implications of recent clinical trials on treatment and management. Aberg JA, et al.
AIDS Clin Rev 1997–98;:229–48 (56 ref.)
Disseminated Mycobacterium avium complex infection: implications of recent clinical trials on prophylaxis and treatment. Benson CA. **AIDS Clin Rev** 1997–98;:271–87 (37 ref.)
Cytomegalovirus retinitis: new developments in prophylaxis and therapy. Jacobson MA. **AIDS Clin Rev** 1997–98; :249–69 (44 ref.)
Cidofovir for AIDS-related retinitis [news]
Am Fam Physician 1996 Nov 1;54(6):2124
Resolution of AIDS associated cryptosporidiosis after treatment with indinavir [letter] Grube H, et al.
Am J Gastroenterol 1997 Apr;92(4):726
Criteria for use of rifabutin in adult patients with human immunodeficiency virus (HIV)-associated disease. Fish N, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1598–9
Prevention and treatment of drug-resistant tuberculosis. Humma LM. **Am J Health Syst Pharm** 1996 Oct 1; 53(19):2291–8; quiz 2335–6
New trends in the drug therapy of localized and disseminated Mycobacterium avium complex infection [see comments] Sesin GP, et al. **Am J Health Syst Pharm** 1996 Nov 1; 53(21):2585–90 (29 ref.). Comment in: Am J Health Syst Pharm 1997 May 15;54(10):1208–9.
Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Wheat J, et al. **Am J Med** 1997 Sep;103(3):223–32
Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group (ACTG). **Am J Ophthalmol** 1997 Jul;124(1):61–70
Treatment of bilateral cytomegalovirus retinitis with sustained-release ganciclovir implants in a child. Malley DS, et al. **Am J Ophthalmol** 1996 Nov;122(5):731–2
Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Chaisson RE, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):1034–8
Selective malabsorption and the origin of mono-rifampin-resistant Mycobacterium tuberculosis [letter; comment] Perlman DC, et al.
Am J Respir Crit Care Med 1996 Oct;154(4 Pt 1):1213. Comment on: Am J Respir Crit Care Med 1996 Feb;153(2):837–40.
Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Doumbo O, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):637–9
Successful oral desensitization to trimethoprim-sulfamethoxazole in acquired immune deficiency syndrome. Kalanadhabhatta V, et al.
Ann Allergy Asthma Immunol 1996 Nov;77(5):394–400
Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group.
Ann Intern Med 1997 Feb 15;126(4):264–74
Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Benhamou Y, et al.
Ann Intern Med 1996 Nov 1;125(9):705–12
Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Lalezari JP, et al. **Ann Intern Med** 1997 Feb 15; 126(4):257–63
Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets [letter] Martins MD, et al.
Ann Intern Med 1997 Feb 15;126(4):332–3
Comparison of oral agents for treatment of Pneumocystis carinii pneumonia [letter; comment] Perazella MA.
Ann Intern Med 1997 Mar 1;126(5):407–8. Comment on: Ann Intern Med 1996 May 1;124(9):792–802.
Combination antiviral therapy for cytomegalovirus disease in patients with AIDS. Cline JJ, et al.
Ann Pharmacother 1997 Sep;31(9):1080–2 (14 ref.)
Azole resistance in yeasts [letter] Craig JM, et al.
Ann Pharmacother 1997 Feb;31(2):255
Intravitreal ganciclovir for cytomegalovirus retinitis in patients with AIDS. Montero MC, et al.
Ann Pharmacother 1996 Jul–Aug;30(7–8):717–23
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Balfour HH Jr, et al.
Antimicrob Agents Chemother 1996 Dec;40(12):2721–6
Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients. Dautzenberg B, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1722–5
Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. Dieterich DT, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1226–30
Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. Jacobson JM, et al.
Antimicrob Agents Chemother 1996 Jun;40(6):1360–5
Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS. Klinker H, et al. **Antimicrob Agents Chemother** 1996 Jul; 40(7):1623–7
Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors. Lacassin F, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1961–3
Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Wheat J, et al.
Antimicrob Agents Chemother 1997 Feb;41(2):410–4
Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. White TC.
Antimicrob Agents Chemother 1997 Jul;41(7):1482–7
Quantitative systemic and local evaluation of the antiviral effect of ganciclovir and foscarnet induction treatment on human cytomegalovirus gastrointestinal disease of patients with AIDS. Italian Foscarnet GID Study Group. Gerna G, et al. **Antiviral Res** 1997 Mar;34(1):39–50
Safety and efficacy of Virend for topical treatment of genital and anal herpes simplex lesions in patients with AIDS. Orozco-Topete R, et al. **Antiviral Res** 1997 Jul;35(2):91–103
Treatment of acyclovir-resistant perianal herpetic ulceration with intramuscular interferon alfa. Borrego L, et al.
Arch Dermatol 1996 Oct;132(10):1157–8
Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection [letter] Fournier S, et al. **Arch Dermatol** 1997 Jul; 133(7):918–9
Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Pulido F, et al.
Arch Intern Med 1997 Jan 27;157(2):227–32
Management of varicella zoster virus retinitis in AIDS. Moorthy RS, et al. **Br J Ophthalmol** 1997 Mar;81(3):189–94
Renal ultrasonic findings in sulphadiazine-induced renal failure. Kane D, et al. **Br J Radiol** 1996 Oct;69(826):925–8
Vinca alkaloids and macrolides in human immunodeficiency virus-related malignancies: a safe association [letter; comment] Torresin A, et al.
Cancer Chemother Pharmacol 1996;39(1–2):176–7. Comment on: Cancer Chemother Pharmacol

1995;35(3):188–90.
Pleural tuberculosis in patients infected with HIV in Addis Ababa. Aderaye AG, et al. **Cent Afr J Med** 1996 Dec; 42(12):337–40
Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis.Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group. de Repentigny L, et al. **Chemotherapy** 1996 Sep–Oct;42(5):374–83
Fluconazole vs itraconazole–flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group. Barbaro G, et al. **Chest** 1996 Dec;110(6):1507–14
Treatment of HIV infection and its complications. Polsky B. **Clin Chest Med** 1996 Dec;17(4):647–63 (68 ref.)
Tremors associated with trimethoprim–sulfamethoxazole therapy in a patient with AIDS: case report and review. Aboulafia DM. **Clin Infect Dis** 1996 Mar;22(3):598–600 (10 ref.)
Hypothermia following the intravenous administration of amphotericin B. Barlows TG 3rd, et al. **Clin Infect Dis** 1996 Nov;23(5):1187–8
A life-threatening adverse reaction during trimethoprim–sulfamethoxazole desensitization in a previously hypersensitive patient infected with human immunodeficiency virus. Caumes E, et al. **Clin Infect Dis** 1996 Dec;23(6):1313–4
Urethritis associated with disseminated microsporidiosis: clinical response to albendazole. Corcoran GD, et al. **Clin Infect Dis** 1996 Mar;22(3):592–3
Resolution of intractable molluscum contagiosum in a human immunodeficiency virus–infected patient after institution of antiretroviral therapy with ritonavir. Hicks CB, et al. **Clin Infect Dis** 1997 May;24(5):1023–5
Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Joly V, et al. **Clin Infect Dis** 1996 Sep;23(3):556–62
Pyrimethamine–clindamycin vs. pyrimethamine–sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Katlama C, et al. **Clin Infect Dis** 1996 Feb;22(2):268–75
Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus–infected patients with oropharyngeal candidiasis due to Candida albicans. Laguna F, et al. **Clin Infect Dis** 1997 Feb;24(2):124–30
Resistance to fluconazole and amphotericin B in a patient with AIDS who was being treated for candidal esophagitis. Le TP, et al. **Clin Infect Dis** 1996 Sep;23(3):649–50
Myelitis due to varicella–zoster virus in two patients with AIDS: successful treatment with acyclovir. Lionnet F, et al. **Clin Infect Dis** 1996 Jan;22(1):138–40
Rifampin-resistant Mycobacterium kansasii infection in a patient with AIDS who was receiving rifabutin. Meynard JL, et al. **Clin Infect Dis** 1997 Jun;24(6):1262–3
Cytarabine therapy for progressive multifocal leukoencephalopathy in patients with AIDS. Moreno S, et al. **Clin Infect Dis** 1996 Nov;23(5):1066–8
A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus–infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. O'Brien JG, et al. **Clin Infect Dis** 1997 May;24(5):854–9
A clarithromycin–induced myasthenic syndrome. Pijpers E, et al. **Clin Infect Dis** 1996 Jan;22(1):175–6
Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Pons V, et al. **Clin Infect Dis** 1997 Jun; 24(6):1204–7
Editorial response: management of cryptococcal meningitis—have we answered all the questions? [editorial; comment] Powderly WG. **Clin Infect Dis** 1996 Feb; 22(2):329–30. Comment on: Clin Infect Dis 1996 Feb;22(2):315–21. Comment on: Clin Infect Dis 1996 Feb;22(2):322–8.
Rifabutin prevents campylobacter infection in patients with AIDS [letter; comment] Pulik M, et al. **Clin Infect Dis** 1996 Nov;23(5):1197–8. Comment on: Clin Infect Dis 1996 Apr;22 Suppl 1:S61–6; discussion S66–9.
Diagnosing and treating cytomegalovirus pneumonia in patients with AIDS. Rodriguez-Barradas MC, et al. **Clin Infect Dis** 1996 Jul;23(1):76–81
Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS [see comments] Sharkey PK, et al. **Clin Infect Dis** 1996 Feb;22(2):315–21. Comment in: Clin Infect Dis 1996 Feb;22(2):329–30.
Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100/mm3: demonstration of efficacy in a positive, multicenter trial. Singh N, et al. **Clin Infect Dis** 1996 Dec;23(6):1282–6
Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. Torres RA, et al. **Clin Infect Dis** 1997 Mar;24(3):422–9
Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. Tseng AL, et al. **Clin Infect Dis** 1997 Jan;24(1):76–7
Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing [see comments] Witt MD, et al. **Clin Infect Dis** 1996 Feb; 22(2):322–8. Comment in: Clin Infect Dis 1996 Feb;22(2):329–30. Comment in: Clin Infect Dis 1996 Dec;23(6):1337–8.
Trimethoprim–sulfamethoxazole and hypouricemia. Chertow GM, et al. **Clin Nephrol** 1996 Sep;46(3):193–8
Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes. Peloquin CA. **Clin Pharmacokinet** 1997 Feb;32(2):132–44 (60 ref.)
Oral ganciclovir: role in maintenance therapy for CMV retinitis in AIDS patients. Owens RC Jr, et al. **Conn Med** 1996 Nov;60(11):663–5
Current clinical issues in the management of herpes simplex virus infections in patients with HIV. Conant M. **Dermatology** 1997;194(2):93–7
Remission of localized cutaneous leishmaniasis in a HIV-positive patient using systemic terbinafine [letter] González-Rupérez J, et al. **Dermatology** 1997;194(1):85–6
Drug treatment of HIV-related opportunistic infections. Klepser ME, et al. **Drugs** 1997 Jan;53(1):40–73 (178 ref.)
Mild rhabdomyolysis after high-dose trimethoprim–sulfamethoxazole in a patient with HIV infection. Anders HJ, et al. **Eur J Med Res** 1997 May 28; 2(5):198–200
Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis. Tognon MS, et al. **Eur J Ophthalmol** 1996 Apr–Jun;6(2):179–82
Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis. Barbaro G, et al. **Gastroenterology** 1996 Nov; 111(5):1169–77
Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients. Heylen R, et al. **Genitourin Med** 1996 Aug; 72(4):237–46 (71 ref.)
Management of CMV retinitis in HIV infected patients. Katlama C. **Genitourin Med** 1997 Jun;73(3):169–73 (32 ref.)
Rifabutin–associated anterior uveitis in patients infected with human immunodeficiency virus. Schimkat M, et al. **Ger J Ophthalmol** 1996 Jul;5(4):195–201
Of magic bullets and social justice: emerging challenges of recent advances in AIDS treatment. Linsk NL, et al. **Health Soc Work** 1997 Feb;22(1):70–4
The use of rifabutin in Europe for the treatment of mycobacterial infection in AIDS patients. Dautzenberg B. **Infection** 1997 Jan–Feb;25(1):63–6 (16 ref.)
Pyrimethamine alone as prophylaxis for cerebral toxoplasmosis in patients with advanced HIV infection. Klinker H, et al. **Infection** 1996 Jul–Aug;24(4):324–7
Antibiotic-associated diarrhea in HIV-infected patients receiving clindamycin [letter] Slevogt H, et al. **Infection** 1997 May–Jun;25(3):189
Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. Blanshard C, et al. **Int J STD AIDS** 1997 Feb;8(2):124–9
Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi's sarcoma. Bower M, et al. **Int J STD AIDS** 1997 Aug;8(8):518–21
Liposomal amphotericin B and recombinant human granulocyte–macrophage colony–stimulating factor (rHuGM–CSF) in the treatment of paediatric AIDS-related cryptococcosis. Manfredi R, et al. **Int J STD AIDS** 1997 Jun;8(6):406–8
Rationalizing prescribing for oral and oesophageal candidiasis. Taylor CB, et al. **Int J STD AIDS** 1996 Oct; 7(6):452
New therapies for cytomegalovirus retinitis. Schwartz DM. **Int Ophthalmol Clin** 1996 Spring;36(2):1–9 (35 ref.)
Use of natural surfactant in an HIV-infected infant with Pneumocystis carinii pneumonia [letter; comment] Marriage SC, et al. **Intensive Care Med** 1996 Jun; 22(6):611–2. Comment on: Intensive Care Med 1995 Mar;21(3):261–3.
New approaches to the treatment of cytomegalovirus retinitis. Proceedings of a roundtable meeting. Washington, D.C., January 26, 1996. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:vii, S1–38
Successful use of cidofovir in treating AIDS-related cytomegalovirus retinitis, encephalitis, and esophagitis [letter] Blick G, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 May 1;15(1):84–5
Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. Bucher HC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jun 1;15(2):104–14
Cytomegalovirus retinitis: diagnosis and status of systemic therapy. Friedberg DN. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S1–6 (20 ref.)
Management strategies for patients with cytomegalovirus retinitis. Hardy WD. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S7–12 (19 ref.)
Therapeutic options for resistant cytomegalovirus retinitis. Kuppermann BD. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S13–21 (40 ref.)
Cidofovir: a new therapy for cytomegalovirus retinitis. Lalezari JP. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S22–6 (25 ref.)
Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. Lalezari JP, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S27–31 (16 ref.)
Current therapeutic challenges in the treatment of cytomegalovirus retinitis. Spector SA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S32–5 (13 ref.)
Pharmacologic management of cytomegalovirus retinitis: review of current and future therapeutic modalities. Bright DC. **J Am Optom Assoc** 1997 Jan;68(1):11–30 (195 ref.)
Uveitis associated with rifabutin therapy: a clinical alert. Petrowski JT 3rd. **J Am Optom Assoc** 1996 Nov; 67(11):693–6 (17 ref.)
Clinical response to ketoconazole of HIV-related oral candidosis is predicted by Odds' relative growth method of susceptibility testing. Cartledge JD, et al. **J Antimicrob Chemother** 1997 Jul;40(1):117–9
Treatment of fungal infection in AIDS. Hood S, et al. **J Antimicrob Chemother** 1996 May;37 Suppl B:71–85 (62 ref.)
Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients. Jaruratanasirikul S, et al. **J Antimicrob Chemother** 1996 Nov;38(5):877–80
Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. Joly V, et al. **J Antimicrob Chemother** 1996 Jul;38(1):117–26
Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients [letter] Petit N, et al. **J Antimicrob Chemother** 1996 Jul; 38(1):154–7
In-vitro activity of antiviral agents used in AIDS against Salmonella typhi and non-typhoid salmonella [letter] Sanchez-Carrillo C, et al. **J Antimicrob Chemother** 1996 Jul;38(1):153–4
Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. Tumbarello M, et al. **J Antimicrob Chemother** 1996 Oct;38(4):691–9
Empirical treatment for PCP in HIV-infected patients—justified? [letter] Hamide A, et al. **J Assoc Physicians India** 1995 Jan;43(1):70–1
Adverse reactions to sulphonamides in patients with HIV infection. Federico G, et al. **J Chemother** 1995 Nov;7 Suppl 4:190–2
In vitro inhibitory activity of citreoviridin against HIV-1 and an HIV-associated opportunist: Candida albicans. Vieta I, et al. **J Chemother** 1996 Oct;8(5):351–7
Susceptibilities to co-trimoxazole of pathogens isolated from blood and stool specimens in Abidjan, Ivory Coast, 1994 to 1996 [letter] Anglaret X, et al. **J Clin Microbiol** 1997 Jul;35(7):1915
Faulty prescription—an avoidable cause of multidrug resistance tuberculosis. Jain RF. **J Indian Med Assoc** 1996 Oct;94(10):385–8
First report of Cryptococcus albidus septicaemia in an HIV patient. Loison J, et al. **J Infect** 1996 Sep;33(2):139–40
Treatment of non-meningeal cryptococcosis in patients with AIDS. Centre d'Informations et de Soins de l'Immunodéficience Humaine de l'Est Parisien. Meyohas MC, et al. **J Infect** 1996 Jul;33(1):7–10
Central venous line infections in AIDS. Moore DA, et al. **J Infect** 1997 Jan;34(1):35–40
Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS. Wiselka MJ, et al. **J Infect** 1996 Nov;33(3):227–9
Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. **J Infect Dis** 1997 Jul; 176(1):50–8
High-dose interferon–alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. Frissen PH, et al. **J Infect Dis** 1997 Sep;176(3):811–4
Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus–infected patients. Revankar SG, et al. **J Infect Dis** 1996 Oct;174(4):821–7
Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. Gordon M, et al. **J Med** 1997;28(1–2):108–28
Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and flucytosine in the treatment of cryptococcal meningitis in AIDS. Chotmongkol V, et al. **J Med Assoc Thai** 1997 Jul;80(7):416–25
Clinical efficacy of itraconazole with initial flucytosine in AIDS-related cryptococcal meningitis: a preliminary study. Riantawan P, et al. **J Med Assoc Thai** 1996 Jul; 79(7):429–33
Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis [letter] Whitcup SM, et al. **JAMA** 1997 May 21;277(19):1519–20
Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy [letter; comment] Baldeweg T,

et al. **Lancet** 1997 May 24;349(9064):1554–5. Comment on: Lancet 1997 Mar 22;349(9055):850.

Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy [letter; comment] Domingo P, et al. **Lancet** 1997 May 24;349(9064):1554–5. Comment on: Lancet 1997 Mar 22;349(9055):850.

M tuberculosis drug resistance in AIDS [letter; comment] Durrheim DN, et al. **Lancet** 1997 Jan 4;349(9044):61; discussion 61–2. Comment on: Lancet 1996 Oct 5;348(9032):928–31.

2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy [letter] [see comments] Elliot B, et al. **Lancet** 1997 Mar 22;349(9055):850. Comment in: Lancet 1997 May 24;349(9064):1554–5.

Pentoxifylline to treat Mycobacterium avium complex exacerbation in late-stage HIV infection [letter] Reeves GE, et al. **Med J Aust** 1997 Apr 21;166(8):446

Penicillin-resistant pneumococci in adult disease with special reference to AIDS patients. Bouza E, et al. **Microb Drug Resist** 1995 Spring;1(1):9–28 (241 ref.)

Tracheobronchial aspergillosis in a patient with AIDS treated with aerosolized amphotericin B combined with itraconazole. Dal Conte I, et al. **Mycoses** 1996 Sep–Oct; 39(9–10):371–4

Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Jacobson MA. **N Engl J Med** 1997 Jul 10;337(2):105–14 (94 ref.)

Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. Musch DC, et al. **N Engl J Med** 1997 Jul 10;337(2):83–90

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. van der Horst CM, et al. **N Engl J Med** 1997 Jul 3;337(1):15–21

Tremor caused by trimethoprim-sulfamethoxazole in a patient with AIDS. Van Gerpen JA. **Neurology** 1997 Feb; 48(2):537–8

Topical thymopentin therapy in HIV positive patients with recurrent oral candidiasis: a pilot study. Coppola S, et al. **New Microbiol** 1996 Oct;19(4):351–5

The maternal and fetal effects of tuberculosis therapy. Brost BC, et al. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):659–73 (80 ref.)

FDA clears new treatment for invasive aspergillosis. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):107

Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Baudouin C, et al. **Ophthalmologica** 1996; 210(6):329–35

Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention [published erratum appears in Ophthalmology 1997 Jul;104(7):1063] Chavez-de la Paz E, et al. **Ophthalmology** 1997 Mar;104(3):539–44

Ganciclovir intraocular implant [letter; comment] Morley MG, et al. **Ophthalmology** 1996 Oct;103(10):1517. Comment on: Ophthalmology 1996 Mar;103(3):416–21.

Cytomegalovirus papillitis in patients with acquired immune deficiency syndrome. Visual prognosis of patients treated with ganciclovir and/or foscarnet. Patel SS, et al. **Ophthalmology** 1996 Sep;103(9):1476–82

Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Taskintuna I, et al. **Ophthalmology** 1997 Jun;104(6):1049–57

Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis. Walton RC, et al. **Ophthalmology** 1995 Dec;102(12):1865–70

Ketoconazole resistant oral candidiasis in HIV-infected patients [letter] Diz Dios P, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):3–4

Clinical characteristics and management responses in 85 HIV-infected patients with oral candidiasis. Silverman S Jr, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Oct;82(4):402–7

Itraconazole responsive tinea capitis in an HIV-infected child. Smith RL, et al. **Pediatr Dermatol** 1996 Jul–Aug; 13(4):313–5

Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers. DeVincenzo JP, et al. **Pediatr Infect Dis J** 1996 May;15(5):465–7

Cryptococcosis in human immunodeficiency virus-infected children [see comments] Gonzalez CE, et al. **Pediatr Infect Dis J** 1996 Sep;15(9):796–800. Comment in: Pediatr Infect Dis J 1997 May;16(5):536–7.

Rapid oral desensitization to trimethoprim-sulfamethoxazole in infants and children. Palusci VJ, et al. **Pediatr Infect Dis J** 1996 May;15(5):456–60

Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review. Zaknun D, et al. **Pediatr Infect Dis J** 1997 Aug; 16(8):807–11

Therapeutic options for the management and prevention of Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome. Tartaglione TA. **Pharmacotherapy** 1996 Mar–Apr;16(2):171–82 (89 ref.)

Interferon found helpful in herpes genitalis case [letter] Dungwa N. **S Afr Med J** 1997 Apr;87(4):475

Serum polymerase chain reaction for cytomegalovirus DNA for monitoring ganciclovir treatment in AIDS patients. Marenzi R, et al. **Scand J Infect Dis** 1996;28(4):347–51

Clinical experience with rifabutin in the treatment of mycobacterial infections. De Cian W, et al. **Scand J Infect Dis Suppl** 1995;98:22–6 (28 ref.)

Treatment of Pneumocystis carinii pneumonia in adults with AIDS. Deresinski SC. **Semin Respir Infect** 1997 Jun; 12(2):79–97 (142 ref.)

Tetany in a child with AIDS receiving intravenous tobramycin. Slayton W, et al. **South Med J** 1996 Nov; 89(11):1108–10

Effects of the human immunodeficiency virus on tuberculosis in children. Jeena PM, et al. **Tuber Lung Dis** 1996 Oct; 77(5):437–43

Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso. Ledru S, et al. **Tuber Lung Dis** 1996 Oct;77(5):429–36

New therapies for cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Cunningham ET Jr. **West J Med** 1997 Feb;166(2):138–9

[Mycobacterium avium infection in HIV-infected patients: epidemiology, diagnosis, prevention and treatment (letter; comment)] Blaauwwiekel EE, et al. **Ned Tijdschr Geneeskd** 1997 Mar 22;141(12):602–3. Comment on: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):80–3. **(Dut)**

[Lymph node cryptococcosis in an AIDS patient on long-term fluconazole: relapse or cure? (letter)] Ginsburg C, et al. **Presse Med** 1997 Jun 28;26(22):1049 **(Fre)**

[Clinical fluconazole and itraconazole resistance of oro-gastrointestinal candidiasis in a patient with AIDS] Tebbe B, et al. **Hautarzt** 1996 Feb;47(2):136–9 (Eng. Abstr.) **(Ger)**

[Rifabutin-induced hypopyon iritis in HIV infection] Diemer PR, et al. **Klin Monatsbl Augenheilkd** 1996 Jul;209(1):40–2 (Eng. Abstr.) **(Ger)**

[Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis] Eichel M, et al. **Mycoses** 1996; 39 Suppl 1:102–6 (Eng. Abstr.) **(Ger)**

[Improved prognosis of first episode HIV associated Pneumocystis carinii pneumonia without preventive treatment: etiology and sequelae] Ewig S, et al. **Pneumologie** 1996 Jul;50(7):455–61 (Eng. Abstr.) **(Ger)**

[Fungi in feces, fungi in the intestines—therapeutic consequences?] Rösch W. **Versicherungsmedizin** 1996 Dec 1;48(6):215–7 (4 ref.) (Eng. Abstr.) **(Ger)**

[Role of clinical pharmacology in the monitoring of therapy of HIV-infected subjects] Villani P, et al. **Clin Ter** 1996 Jun;147(6):279–93 (57 ref.) (Eng. Abstr.) **(Ita)**

[Azithromycin combined with pyrimethamine in the treatment of neurotoxoplasmosis, in an AIDS patient] Trotta M, et al. **Minerva Med** 1997 Mar;88(3):117–9 (Eng. Abstr.) **(Ita)**

[A case of acquired immunodeficiency syndrome associated with cryptococcemia and cryptococcal meningitis] Inami T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun; 19(3):251–8 (Eng. Abstr.) **(Jpn)**

[Intravitreal injection of ganciclovir in AIDS patients with cytomegalovirus retinitis] Fujino Y, et al. **Nippon Ganka Gakkai Zasshi** 1996 Aug;100(8):634–40 (Eng. Abstr.) **(Jpn)**

[Systemic mycoses: therapy with a new antifungal drug diflucan] Barantsevich EP. **Klin Med (Mosk)** 1996; 74(4):52–4 (Eng. Abstr.) **(Rus)**

[Treatment of AIDS and associated diseases] Rytik PG. **Klin Med (Mosk)** 1997;75(1):5–10 (22 ref.) **(Rus)**

[Prophylaxis secondary to retinitis by CMV in patients with AIDS: the efficacy of an intermittent schedule of 3 days/week] Mallolas J, et al. **Enferm Infecc Microbiol Clin** 1997 Feb;15(2):61–4 (Eng. Abstr.) **(Spa)**

[Nosocomial infection with methicillin resistant Staphylococcus aureus in 14 human immunodeficiency virus infected patients] Eulalia Valencia M, et al. **Med Clin (Barc)** 1997 Sep 6;109(7):261–3 (Eng. Abstr.) **(Spa)**

[Rifabutin as a cause of curable visual alterations in patients with human immunodeficiency virus infection (letter)] Fernández Peña CM, et al. **Med Clin (Barc)** 1997 Jul 5; 109(6):239 **(Spa)**

ECONOMICS

An economic exploration of oral and intravenous ganciclovir in the induction and maintenance treatment of AIDS-related cytomegalovirus retinitis. Davies L, et al. **Int J STD AIDS** 1996 Oct;7(6):415–21

Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. Moore RD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Mar 1;14(3):223–31

The use and cost of hospital services by London AIDS patients with different AIDS defining conditions. Beck EJ, et al. **J Public Health Med** 1996 Dec;18(4):457–64

Managing HIV with limited medical resources. Stewart GJ, et al. **Med J Aust** 1996 Nov 4;165(9):499–503 (08 ref.)

ENZYMOLOGY

[Adenosine deaminase in the cerebrospinal fluid of patients with acquired immunodeficiency syndrome] Machado LD, et al. **Arq Neuropsiquiatr** 1995 Dec;53(4):755–9 (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY

Prevalence of HIV1 in leprosy patients in Rio de Janeiro, Brazil. Andrade VL, et al. **Acta Leprol** 1997;10(3):159–63

Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort. Dore GJ, et al. **AIDS** 1996 Oct; 10(12):1401–6

The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. International MAC Study Group. Fordham von Reyn C, et al. **AIDS** 1996 Aug;10(9):1025–32

Epidemiology of Mycobacterium avium infection in northern Italy [letter] Franzetti F, et al. **AIDS** 1997 Jul;11(8):1065–6

Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV-infected adults in Abidjan, Côte d'Ivoire. Grant AD, et al. **AIDS** 1997 Sep;11(11):1357–64

Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS in Europe Study Group. Hermans P, et al. **AIDS** 1996 Jul;10(8):911–7

Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends. The Adult/Adolescent Spectrum of Disease Group. Jones JL, et al. **AIDS** 1996 Oct; 10(12):1393–9

Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: increasing incidence, unchanged prognosis. Low N, et al. **AIDS** 1997 Jul 15;11(9):1165–71

The risks and benefits of childhood bacille Calmette-Guérin immunization among adults with AIDS. International MAC study groups. Marsh BJ, et al. **AIDS** 1997 Apr; 11(5):669–72

Frequency and risk factors of infectious complications in neutropenic patients infected with HIV. Meynard JL, et al. **AIDS** 1997 Jul;11(8):995–8

Incidence and factors associated with extrapulmonary cryptococcosis among persons with HIV infection in Los Angeles County. Sorvillo F, et al. **AIDS** 1997 Apr; 11(5):673–9

The epidemiology of HIV-associated Kaposi's sarcoma: the unraveling mystery. Strathdee SA, et al. **AIDS** 1996;10 Suppl A:S51–7 (112 ref.)

Factors associated with tuberculosis at AIDS diagnosis in France. Triol I, et al. **AIDS** 1996 Feb;10(2):223–8

The spread of AIDS and the re-emergence of tuberculosis in Catalonia, Spain. Vall Mayans M, et al. **AIDS** 1997 Mar 15;11(4):499–505

Gastric toxoplasmosis: case report and review of the literature. Kofman E, et al. **Am J Gastroenterol** 1996 Nov; 91(11):2436–8 (8 ref.)

Geographic and seasonal variation in Mycobacterium avium bacteremia among North American patients with AIDS. Horsburgh CR Jr, et al. **Am J Med Sci** 1997 Jun; 313(6):341–5

A nosocomial outbreak of multidrug-resistant tuberculosis. Kenyon TA, et al. **Ann Intern Med** 1997 Jul 1;127(1):32–6

Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. Markowitz N, et al. **Ann Intern Med** 1997 Jan 15;126(2):123–32

AIDS—associated Kaposi's sarcoma: a rare entity at Maharaj Nakorn Chiang Mai Hospital. Bhoopat SK, et al. **Asian Pac J Allergy Immunol** 1996 Dec;14(2):115–20

Oral lesions in Thai heterosexual AIDS patients: a preliminary study. Nittayananta W, et al. **Br Dent J** 1997 Mar 22;182(6):219–21

AIDS in Africa: face the facts [letter; comment] Squire SB. **Br J Hosp Med** 1997 Apr 16–May 6;57(8):412. Comment on: Br J Hosp Med 1996 Nov 6–19;56(9):442–3.

Tuberculous pleurisy is more common in AIDS than in non-AIDS patients with tuberculosis. Frye MD, et al. **Chest** 1997 Aug;112(2):393–7

Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Boschini A, et al. **Clin Infect Dis** 1996 Jul; 23(1):107–13

Prevalence of hepatitis G virus among intravenous drug abusers in Los Angeles. Fong TL, et al. **Clin Infect Dis** 1997 Jul;25(1):165–6

Major differences in the spectrum of gastrointestinal infections associated with AIDS in India versus the west: an autopsy study. Lanjewar DN, et al. **Clin Infect Dis** 1996 Sep;23(3):482–5

Pulmonary toxoplasmosis in patients infected with human immunodeficiency virus: a French National Survey. Rabaud C, et al. **Clin Infect Dis** 1996 Dec;23(6):1249–54

HIV-related tuberculosis in British Columbia: indications of a rise in prevalence and a change in risk groups. Blenkush MF, et al. **Clin Invest Med** 1996 Aug;19(4):271–8

Opportunist mycobacteria in England and Wales: 1982 to 1994. Lamden K, et al. **Commun Dis Rep CDR Rev** 1996 Oct 11;6(11):R147–51

Association between carriage of oral yeasts, malnutrition and HIV-1 infection among Tanzanian children aged 18 months to 5 years. Scheutz F, et al.

Community Dent Oral Epidemiol 1997 Jun;25(3):193–8

HIV infection and antituberculosis drug resistance among pulmonary tuberculosis patients in Harar Tuberculosis Centre, Ethiopia. Mitike G, et al. **East Afr Med J** 1997 Mar;74(3):154–7

Giardiasis in HIV: a possible role in patients with severe immune deficiency. Angarano G, et al. **Eur J Epidemiol** 1997 Jun;13(4):485–7

Multidrug resistant tuberculosis: practical lessons for HIV units [editorial] [see comments] Easterbrook P. **Genitourin Med** 1996 Oct;72(5):313–4. Comment in: Genitourin Med 1997 Feb;73(1):76–7.

Nosocomial infections in HIV-infected patients: preliminary results from a multicenter surveillance system (1989–1995). Stroud L, et al. **Infect Control Hosp Epidemiol** 1997 Jul; 18(7):479–85

High prevalence of opportunistic infections in the head and neck related to human immunodeficiency virus. A prospective study of the distribution of otorhinolaryngologic disorders in 250 patients. Riederer AP, et al. **Infection** 1996 Nov–Dec;24(6):440–6 (43 ref.)

Clinical features of AIDS in the Edinburgh City Hospital cohort. Brettle RP, et al. **Int J STD AIDS** 1996 May–Jun; 7(3):190–6

Cryptosporidiosis in patients with AIDS. Stuart RL, et al. **Int J STD AIDS** 1997 May;8(5):339–41

Nationwide survey of neurologic manifestations of acquired immunodeficiency syndrome in Japan [see comments] Nakagawa M, et al. **Intern Med** 1997 Mar;36(3):175–8. Comment in: Intern Med 1997 Mar;36(3):160–1.

CD8+ T lymphocyte counts as an adjunctive predictor of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Oka S, et al. **Intern Med** 1997 Jul;36(7):461–5

U.S. hospital care for HIV-infected persons and the role of public, private, and Veterans Administration hospitals. Bennett CL, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 15;13(5):416–21

Geographic variation in the management and outcome of patients with AIDS-related Pneumocystis carinii pneumonia. Cohn SE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 15;13(5):408–15

Impact of human immunodeficiency virus infection on abdominal tuberculosis in western India. Rathi PM, et al. **J Clin Gastroenterol** 1997 Jan;24(1):43–8

Molecular epidemiology of Mycobacterium tuberculosis strains isolated from patients in a human immunodeficiency virus cohort in Switzerland. Strässle A, et al. **J Clin Microbiol** 1997 Feb;35(2):374–8

Cryptosporidiosis in HIV infection. Anand L, et al. **J Commun Dis** 1996 Dec;28(4):241–4

Epidemiologic principles in studies of infectious disease outcomes: pediatric HIV as a model. Scott GS, et al. **J Commun Disord** 1997 Jul–Aug;30(4):303–22; quiz 322–4 (78 ref.)

Pneumocystis carinii pneumonia: evolution from 1981 to 1995 in two Paris hospitals. Poirot JL, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):58S–59S

Causes of chronic diarrhea in patients with AIDS in Thailand: a prospective clinical and microbiological study. Manatsathit S, et al. **J Gastroenterol** 1996 Aug;31(4):533–7

Cryptococcal infections of the central nervous system: an analysis of predisposing factors, laboratory findings and outcome in patients from South India with special reference to HIV infection. Khanna N, et al. **J Med Microbiol** 1996 Nov;45(5):376–9

Arthritis associated with HIV infection in Zimbabwe. Stein CM, et al. **J Rheumatol** 1996 Mar;23(3):506–11

The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA [see comments] Bradford WZ, et al. **Lancet** 1996 Oct 5;348(9032):928–31 . Comment in: Lancet 1997 Jan 4;349(9044):60–1; discussion 61–2. Comment in: Lancet 1997 Jan 4;349(9044):61; discussion 61–2.

Managing tuberculosis case-loads in African countries [letter] Wilkinson D. **Lancet** 1997 Mar 22;349(9055):882

Staphylococcal parotitis in AIDS: a case report [letter] Ong KR, et al. **Laryngoscope** 1996 Nov;106(11):1443

Modeling the impact of HIV on the spread of tuberculosis in the United States. West RW, et al. **Math Biosci** 1997 Jul 1;143(1):35–60

Update: trends in AIDS incidence -- United States, 1996. **MMWR Morb Mortal Wkly Rep** 1997 Sep 19;46(37):861–7

Cryptococcus neoformans var. gattii among patients with cryptococcal meningitis in Mexico. First observations. López-Martínez R, et al. **Mycopathologia** 1996;134(2):61–4

Immune compromise and prevalence of Candida vulvovaginitis in human immunodeficiency virus-infected women. Duerr A, et al. **Obstet Gynecol** 1997 Aug; 90(2):252–6

Viral resistance and CMV retinitis: design and methods of a prospective study. CRVR Research Groups. Cytomegalovirus Retinitis Viral Resistance Research Group. Enger C, et al. **Ophthalmic Epidemiol** 1997 Mar; 4(1):41–8

Herpes simplex virus keratitis among patients who are positive or negative for human immunodeficiency virus: an epidemiologic study. Hodge WG, et al. **Ophthalmology** 1997 Jan;104(1):120–4

Community-acquired bacteremia in human immunodeficiency virus-infected children in Harare, Zimbabwe [see comments] Nathoo KJ, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1092–7. Comment in: Pediatr Infect Dis J 1997 May;16(5):537–8.

Rarity of cryptococcal infection in children [letter; comment] Speed BR, et al. **Pediatr Infect Dis J** 1997 May;16(5):536–7 . Comment on: Pediatr Infect Dis J 1996 Sep;15(9):796–800.

AIDS pathology: infections and neoplasms in 55 fatal AIDS cases. A postmortem study. Walewska-Zielecka B, et al. **Pol J Pathol** 1996;47(4):163–70

Prevalence of Isospora belli in AIDS and immunocompetent patients in Uganda [letter] Ravera M, et al. **Presse Med** 1996 Sep 7;25(25):1170

The acquired immunodeficiency syndrome and endemic diseases in Brazil [editorial] Ferreira MS. **Rev Soc Bras Med Trop** 1996 Nov–Dec;29(6):531–5 **(Eng, Por)**

HIV-related tuberculosis [letter] van Bogaert LJ. **S Afr Med J** 1997 Aug;87(8):1019

HIV-related tuberculosis [letter] Wood R, et al. **S Afr Med J** 1997 Aug;87(8):1018–9

AIDS in Africa. O'Keefe EA, et al. **Scand J Gastroenterol Suppl** 1996;220:147–52 (63 ref.)

Using multiple decrement models to estimate risk and morbidity from specific AIDS illnesses. Multicenter AIDS Cohort Study (MACS). Hoover DR, et al. **Stat Med** 1996 Nov 15–30;15(21–22):2307–21; discussion 2337–40

Leishmania/HIV co-infection. Epidemiological analysis of 692 retrospective cases. **Wkly Epidemiol Rec** 1997 Feb 21; 72(8):49–54 **(Eng, Fre)**

[Tuberculosis and the HIV pandemic. Risk of nosocomial tuberculosis infection] Pedersen C, et al. **Ugeskr Laeger** 1997 Feb 24;159(9):1233–8 (40 ref.) (Eng. Abstr.) **(Dan)**

[Mycobacterium avium infection in HIV-infected patients: epidemiology, diagnosis, prevention and treatment (see comments)] Schneider MM, et al. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):80–3 (46 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1997 Mar 22;141(12):602–3. **(Dut)**

[Leprosy and infection by the human immunodeficiency virus (HIV) (editorial)] Flageul B. **Acta Leprol** 1997;10(3):129–30 **(Fre)**

[HIV seroprevalence in adults with pulmonary tuberculosis in Yaounde, Cameroon] Kuaban C, et al. **Med Trop (Mars)** 1996;56(4):357–60 (Eng. Abstr.) **(Fre)**

[Generalized Mycobacterium avium complex infections in patients with HIV infection: a decreasing incidence (letter)] Cambau E, et al. **Presse Med** 1997 Apr 5;26(11):513 **(Fre)**

[Tuberculin test, antitubercular chemoprophylaxis and incidence of tuberculosis in a Swiss HIV cohort study (news)] Sudre P, et al. **Rev Epidemiol Sante Publique** 1997 Apr;45(2):171–3 **(Fre)**

[Pulmonary complications of human immunodeficiency virus infection in sub-Saharan Africa] Domoua K, et al. **Rev Pneumol Clin** 1997;53(2):79–84 (47 ref.) (Eng. Abstr.) **(Fre)**

[Indications for eye examination of HIV patients--screening parameters for cytomegalovirus retinitis] Gellrich MM, et al. **Klin Monatsbl Augenheilkd** 1996 Aug–Sep;209(2–3):72–8 (Eng. Abstr.) **(Ger)**

[HIV-associated tuberculosis in Africa exemplified by Zimbabwe] Schoch OD. **Schweiz Med Wochenschr** 1997 Jul 22;127(29–30):1223–8 (61 ref.) (Eng. Abstr.) **(Ger)**

[Pulmonary tuberculosis and acquired immunodeficiency syndrome in Ukraine (first communication)] Feshchenko II, et al. **Probl Tuberk** 1997;(4):55–7 (8 ref.) (Eng. Abstr.) **(Rus)**

[Digestive cytomegalovirus disease in AIDS patients] Barberá JR, et al. **Enferm Infecc Microbiol Clin** 1996 Aug–Sep;14(7):411–5 (38 ref.) (Eng. Abstr.) **(Spa)**

[Resistant tuberculosis in Madrid. Coinfection of tuberculosis and AIDS (letter; comment)] de March Ayuela P. **Med Clin (Barc)** 1996 Sep 21;107(9):357–8. Comment on: Med Clin (Barc) 1996 Jan 13;106(1):1–6. **(Spa)**

[Resistant tuberculosis in Madrid. Coinfection of tuberculosis and AIDS (letter; comment)] García Rodríguez J, et al. **Med Clin (Barc)** 1996 Sep 21;107(9):358–9. Comment on: Med Clin (Barc) 1996 Jan 13;106(1):1–6. **(Spa)**

[Mycobacterium avium complex infection: a growing problem in our country] Blázquez R, et al. **Rev Clin Esp** 1997 Mar;197(3):158–62 (Eng. Abstr.) **(Spa)**

[Pneumocistis carinii pneumonia in patients with AIDS at the Saint Thomas Hospital] Rodríguez French A, et al. **Rev Med Panama** 1996 Jan–May;21(1–2):4–10 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Pneumocystis carinii Pneumonia in Asians and Pacific Islanders. Eckholdt H, et al. **Clin Infect Dis** 1997 Jun; 24(6):1265–7

ETIOLOGY

The association between cigarette smoking and selected HIV-related medical conditions. Conley LJ, et al. **AIDS** 1996 Sep;10(10):1121–6

Totally implantable venous access device infections in patients with AIDS [letter] Hellard M, et al. **AIDS** 1997 Apr;11(5):697–8

Varicella-zoster virus retrobulbar optic neuritis in a patient with human immunodeficiency virus. Shayegani A, et al. **Am J Ophthalmol** 1996 Oct;122(4):586–8

Optic neuropathy preceding acute retinal necrosis in acquired immunodeficiency syndrome. Friedlander SM, et al. **Arch Ophthalmol** 1996 Dec;114(12):1481–5

Orbital cellulitis in the acquired immunodeficiency syndrome [letter] Nash E, et al. **Arch Ophthalmol** 1997 May; 115(5):677–8

AIDS-related extrapulmonary Pneumocystis carinii infection presenting as a solitary rectal ulcer. Yoshida EM, et al. **Can J Gastroenterol** 1996 Oct;10(6):401–4

Causes of fever in patients infected with human immunodeficiency virus who were admitted to Boston City Hospital. Barat LM, et al. **Clin Infect Dis** 1996 Aug; 23(2):320–8

Microsporidia and AIDS-associated diarrhea. Cleveland KO, et al. **Clin Infect Dis** 1996 Mar;22(3):603–4, reply 604–5

Prednisone therapy is not associated with increased risk of herpetic infections in patients infected with human immunodeficiency virus. Keiser P, et al. **Clin Infect Dis** 1996 Jul;23(1):201–2

Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. McKinsey DS, et al. **Clin Infect Dis** 1997 Jun;24(6):1195–203

Increased risk for opportunistic infections during chemotherapy in HIV-infected patients with Kaposi's sarcoma. Plettenberg A, et al. **Dermatology** 1997; 194(3):234–7

Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients. Dronda F, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jun; 15(6):446–52

Clinical features of drug use and drug use related HIV [editorial] Brettle RP. **Int J STD AIDS** 1996 May–Jun; 7(3):151–65 (114 ref.)

Liver disease in HIV-infected patients: multifactorial or not? [letter] Philpot CR. **Int J STD AIDS** 1997 Aug;8(8):534–5

Intestinal microsporidiosis in Italian individuals with AIDS. Voglino MC, et al. **Ital J Gastroenterol** 1996 Sep; 28(7):381–6

Toxoplasma pneumonia in Africa [letter] Doherty JF, et al. **J Infect** 1996 Jan;32(1):70

Hepatic pneumocystosis without concomitant PCP in a patient with AIDS. Sarmento e Castro R, et al. **J Infect** 1997 May;34(3):257–9

Evolution of AIDS and AIDS related malignancies in pediatric patients in the United States. Parmley RT. **J Nihon Univ Sch Dent** 1997 Mar;39(1):8–11

Gastrointestinal manifestations. Tanowitz HB, et al. **Med Clin North Am** 1996 Nov;80(6):1395–414 (128 ref.)

Retinal findings and characteristics in AIDS patients with systemic Mycobacterium avium-intracellulare complex and toxoplasmic encephalitis. Arevalo JF, et al. **Ophthalmic Surg Lasers** 1997 Jan;28(1):50–4

Opportunistic infections of the eye in immunocompromised patients. Guembel HO, et al. **Ophthalmologica** 1997;211 Suppl 1:53–61 (55 ref.)

Orbital infections in patients with human immunodeficiency virus infection. Kronish JW, et al. **Ophthalmology** 1996 Sep; 103(9):1483–92 (39 ref.)

Clinical complications of HIV infection. Heald AE, et al. **Radiol Clin North Am** 1997 Sep;35(5):1007–27 (76 ref.)

[Musculoskeletal infections in HIV-positive patients] Melamed EA, et al. **Harefuah** 1996 Sep;131(5–6):181–4 (32 ref.) **(Heb)**

[HIV infection and opportunistic pathology: the etiopathogenetic considerations and clinico-diagnostic aspects in candidiasis of the oral mucosa] Spadari F, et al. **Minerva Stomatol** 1996 Mar;45(3):81–99 (100 ref.) (Eng. Abstr.) **(Ita)**

[Sepsis due to Pasteurella multocida in an HIV-positive patient (letter)] Garavelli PL. **Recenti Prog Med** 1997 May; 88(5):226 **(Ita)**

[Pulmonary complications during HIV infection in children] Murgoci G, et al. **Pneumoftiziologia** 1997 Jan–Mar; 46(1):39–44 (12 ref.) **(Rum)**

[Non-typhoid salmonellosis and human immunodeficiency virus (HIV) infection] Ramos JM, et al. **Med Clin (Barc)** 1997 Mar 8;108(9):349–55 (168 ref.) **(Spa)**

GENETICS

Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. Gaidano G, et al. **AIDS** 1996 Aug;10(9):941–9

Expression and mutation of the tumor suppressor gene p53 in AIDS-associated Kaposi's sarcoma. Li JJ, et al. **Am J Dermatopathol** 1997 Aug;19(4):373–8

Coinfection and genetic recombination between HIV-1 strains: possible biological implications in Australia and South East Asia. Saksena NK, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):121–7

The clinical course of human immunodeficiency virus infection in genetically identical children [see comments] Saulsbury FT. **Clin Infect Dis** 1997 May;24(5):971–4. Comment in: Clin Infect Dis 1997 May;24(5):975–6.

Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Masood R, et al. **Proc Natl Acad Sci U S A** 1997 Feb 4;94(3):979–84

IMMUNOLOGY

Antigen-specific oligoclonal IgG in AIDS-related cytomegalovirus and toxoplasma encephalitis. Franciotta D, et al. **Acta Neurol Scand** 1996 Sep;94(3):215–8

Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. Derouin F, et al. **AIDS** 1996 Nov;10(13):1521–7

The sex ratio of AIDS-associated Kaposi's sarcoma does not provide evidence that sex hormones play a role in pathogenesis [letter] Grulich AE, et al. **AIDS** 1996 Nov; 10(13):1595–6

Functionally relevant changes occur in HIV-infected individuals' alveolar macrophages prior to the onset of respiratory disease. Lipman MC, et al. **AIDS** 1997 May; 11(6):765–72

Chlamydia pneumoniae seroprevalence among HIV-1-infected and uninfected people with known HIV risk factor. Viscott Comandini U, et al. **AIDS** 1996 Nov; 10(13):1543–7

CD4 lymphocyte counts in HIV/AIDS patients with intercurrent illness [letter] Woolley I, et al. **AIDS** 1996 Jun; 10(6):680–1

Progression of human immunodeficiency virus infection in patients with tuberculosis disease. A cohort study in Bordeaux, France, 1988–1994. The Groupe d'Épidémiologie Clinique du Sida en Aquitaine (GECSA). Leroy V, et al. **Am J Epidemiol** 1997 Feb 15;145(4):293–300

Will killing the last HIV1 particle cure AIDS patients? Doesn't CMV activation and/or a graft-versus-host component of the disease, also have to be considered? I. First of two parts [editorial] Mathé G. **Biomed Pharmacother** 1996;50(5):185–206 (140 ref.)

CD8+ T lymphocytes in cytomegalovirus retinitis in a patient with AIDS [letter] Oka S, et al. **Br J Ophthalmol** 1996 Dec;80(12):1108–9

Unusually high seroprevalence of Borna disease virus in clade E human immunodeficiency virus type 1-infected patients with sexually transmitted diseases in Thailand. Auwanit W, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):590–3

Abnormal levels of circulating adhesion molecules in HIV-1 infection with characteristic alterations in opportunistic infections. Nordøy I, et al. **Clin Immunol Immunopathol** 1996 Oct;81(1):16–21

Cytokine profiles in bronchoalveolar lavage fluid and blood in HIV-seropositive patients with Pneumocystis carinii pneumonia. Perenboom RM, et al. **Eur J Clin Invest** 1997 Apr;27(4):333–9

High predictive value of Toxoplasma gondii IgG antibody levels in HIV-infected patients for diagnosis of cerebral toxoplasmosis. Hellerbrand C, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):869–72

Immunological findings in HIV-Leishmania coinfection. Preiser W, et al. **Intervirology** 1996;39(4):285–8

Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group. Phillips AN, et al. **J Clin Epidemiol** 1996 Nov;49(11):1253–8

Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. Kersten MJ, et al. **J Clin Invest** 1997 Apr 1;99(7):1525–33

Infrequent detection of lipoarabinomannan antibodies in human immunodeficiency virus-associated mycobacterial disease. Swiss HIV Cohort Study. Boggian K, et al. **J Clin Microbiol** 1996 Jul;34(7):1854–5

Increases in CD3+CD4-CD8- T lymphocytes in AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection. Moreau JF, et al. **J Infect Dis** 1996 Nov;174(5):969–76

T cell subsets and cytomegalovirus retinitis in human immunodeficiency virus-infected patients. Tay-Kearney ML, et al. **J Infect Dis** 1997 Sep;176(3):790–4

Immune stimulation and HIV-1 viral replication. Wahl SM, et al. **J Leukoc Biol** 1997 Jul;62(1):67–71 (60 ref.)

Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals. Yao QY, et al. **J Virol** 1996 Aug;70(8):4884–94

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor [letter] Carr A, et al. **Lancet** 1997 Apr 5;349(9057):995–6

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [letter; comment] Carr A, et al. **Lancet** 1997 Aug 23;350(9077):589; discussion 590. Comment on: Lancet 1997 May 17;349(9063):1443–5.

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [letter; comment] Mitchell SM, et al. **Lancet** 1997 Aug 23;350(9077):588; discussion 590. Comment on: Lancet 1996 May 17;349(9063):1443–5.

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [letter; comment] Stein DS. **Lancet** 1997 Aug 23;350(9077):589–90. Comment on: Lancet 1997 May 17;349(9063):1443–5.

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [letter; comment] Stricker RB, et al. **Lancet** 1997 Aug 23;350(9077):589; discussion 590. Comment on: Lancet 1997 May 17;349(9063):1443–5.

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [letter; comment] Uthayakumar S, et al. **Lancet** 1997 Aug 23;350(9077):588–9; discussion 590 . Comment on: Lancet 1997 May 17;349(9063):1443–5.

CD4+ and CD8+ T cell immune responses of immunocompetent and immunocompromised (AIDS) patients with American tegumentary leishmaniasis. Coutinho SG, et al. **Mem Inst Oswaldo Cruz** 1996 May-Jun; 91(3):381–4

Report on the 4th International Symposium of Ocular Inflammation [editorial] Wakefield D. **Ocul Immunol Inflamm** 1997 Mar;5(1):1–9

Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. Gibb D, et al. **Pediatr Infect Dis J** 1996 Dec; 15(12):1097–101

Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. King JC Jr, et al. **Pediatrics** 1997 Apr; 99(4):575–80

Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV. Cribier B, et al. **Res Virol** 1996 Sep-Oct;147(5):263–6

Immunological disorders of increased severity in children with AIDS associated with hepatitis B and C infections. Antipa C, et al. **Rom J Virol** 1995 Jan-Jun;46(1-2):3–8

Herpesviruses and AIDS. Griffiths PD. **Scand J Infect Dis Suppl** 1996;100:3–7 (46 ref.)

Survival benefits of pulmonary cellular activation in AIDS patients with Pneumocystis infection. Sharma R, et al. **South Med J** 1997 May;90(5):531–4

Toxoplasma infection in healthy persons and in patients with HIV or ocular disease. Wongkamchai S, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):655–8

Interactions between opportunistic micro-organisms and HIV in the lung [editorial] Clarke JR, et al. **Thorax** 1996 Sep;51(9):875–77

Prolonged Th2 cell activation and increased viral replication in HIV-Leishmania co-infected patients despite treatment. Cacopardo B, et al. **Trans R Soc Trop Med Hyg** 1996 Jul-Aug;90(4):434–5

Impaired antibody responses and loss of reactivity to Onchocerca volvulus antigens by HIV-seropositive onchocerciasis patients. Tawill SA, et al. **Trans R Soc Trop Med Hyg** 1996 Jan-Feb;90(1):85–9

Influence of microbial infections on the progression of HIV disease. Blanchard A, et al. **Trends Microbiol** 1997 Aug; 5(8):326–31 (72 ref.)

The interplay of herpesviruses in AIDS: superantigen sharing. Sutkowski N, et al. **Trends Microbiol** 1996 Mar; 4(3):89–91

Mycoplasmas and HIV infection, a possible interaction through immune activation. Blanchard A. **Wien Klin Wochenschr** 1997 Aug 8;109(14–15):590–3 (31 ref.)

Cryptococcosis in HIV infection of man: an epidemiological and immunological indicator? Arastéh K, et al. **Zentralbl Bakteriol** 1996 Jul;284(2-3):153–63

[Immunologic findings in HIV infected children with bacterial infections] Bunikowski R, et al. **Klin Padiatr** 1996 Sep-Oct;208(5):304–9 (Eng. Abstr.) **(Ger)**

[Induction of tumor necrosis factor alpha by Mycoplasma penetrans isolated from patients with AIDS] Iyama K. **Kansenshogaku Zasshi** 1996 Jan;70(1):11–8 (Eng. Abstr.) **(Jpn)**

[The immunological aspects in the HIV/AIDS-tuberculosis association in children] Murgoci G, et al. **Pneumoftiziologia** 1996 Jul-Dec;45(3-4):149–53 (Eng. Abstr.) **(Rum)**

[Clinical picture of some diseases in HIV-infected Ethiopians] Nemchinov EN. **Klin Med (Mosk)** 1997; 75(2):51–4 (Eng. Abstr.) **(Rus)**

METABOLISM

Marked activation of the tumour necrosis factor system in AIDS-associated cryptococcosis [letter] Mastroianni CM, et al. **AIDS** 1996 Oct;10(12):1436–8

The metabolic response to opportunistic infections in AIDS. Sharpstone DR, et al. **AIDS** 1996 Nov;10(13):1529–33

Faecal tumour necrosis factor-alpha in individuals with HIV-related diarrhoea. Sharpstone DR, et al. **AIDS** 1996 Aug;10(9):989–94

Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. Dieterich DT, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1226–30

Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Heald AE, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1514–9

Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. Owens RC Jr, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1508–11

AIDS-associated Kaposi's sarcoma cells secrete a neurotrophic growth factor(s). Weeks BS, et al. **Biochem Biophys Res Commun** 1997 Apr 17;233(2):408–12

Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Choudhri SH, et al. **Clin Infect Dis** 1997 Jul;25(1):104–11

Jejunal water and electrolyte transport in human cryptosporidiosis. Kelly P, et al. **Dig Dis Sci** 1996 Oct; 41(10):2095–9

Cytokine profiles in bronchoalveolar lavage fluid and blood in HIV-seronegative patients with Pneumocystis carinii pneumonia. Perenboom RM, et al. **Eur J Clin Invest** 1996 Feb;26(2):159–66

Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis. Castelli F, et al. **Eur J Clin Pharmacol** 1997;52(5):397–401

Expression of the alpha 5 beta 1 fibronectin receptor on T lymphocytes of patients with HIV-1 infection. Torre D, et al. **J Clin Pathol** 1996 Sep;49(9):733–6

Endocrinologic complications of HIV infection. Danoff A. **Med Clin North Am** 1996 Nov;80(6):1453–69 (134 ref.)

Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. Husain SR, et al. **Mol Med** 1997 May;3(5):327–38

A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods. Jelliffe RW, et al. **Ther Drug Monit** 1997 Aug;19(4):450–9

MICROBIOLOGY

Long survival of a patient with AIDS in spite of previous Rhodococcus equi infection [letter; comment] Schneider E, et al. **Acta Clin Belg** 1997;52(1):50. Comment on: Acta Clin Belg 1996;51(2):101–5.

Laboratory diagnosis of antibiotic resistant Mycobacterium bovis within 48 h: a qualitative change in the approach to mycobacterial diseases in AIDS patients [letter] Espinosa de los Monteros LE, et al. **AIDS** 1997 May;11(6):827–8

Source of Pneumocystis carinii in recurrent episodes of pneumonia in AIDS patients. Keely SP, et al. **AIDS** 1996 Jul;10(8):881–8

Pneumocystis carinii hominis sequencing to study hypothetical person-to-person transmission [letter] Latouche S, et al. **AIDS** 1997 Mar 15;11(4):549

Bacillary angiomatosis: a role for Phyllobacterium? [letter] Price DA, et al. **AIDS** 1997 Jul 15;11(9):1186–7

Disseminated Mycobacterium avium complex infection: implications of recent clinical trials on prophylaxis and treatment. Benson CA. **AIDS Clin Rev** 1997–98;:271–87 (37 ref.)

Molecular epidemiology of mucosal candidiasis in HIV-positive women. Dahl KM, et al. **AIDS Res Hum Retroviruses** 1997 Apr 10;13(6):485–91

Pityriasis rubra pilaris: an unusual cutaneous complication of AIDS. Bonomo RA, et al. **Am J Med Sci** 1997 Aug; 314(2):118–21

Similar serovar and drug susceptibility profiles among AIDS-related Mycobacterium avium isolates from diverse geographic locations. Jacobs NJ, et al. **Am J Med Sci** 1997 Jun;313(6):352–4

Invasive aspergillosis of the paranasal sinuses and orbit: can you save the eye? Adler SC, et al. **Am J Otolaryngol** 1997 Jul-Aug;18(4):230–4

Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Manfredi R, et al. **Arch Intern Med** 1997 Jan 13;157(1):64–9

Haemophilus species bacteremia in adults. The importance of the human immunodeficiency virus epidemic. Muñoz P, et al. **Arch Intern Med** 1997 Sep 8;157(16):1869–73

Colonic histoplasmosis associated with acquired immunodeficiency syndrome [letter] Warner D. **Arch Intern Med** 1997 Jun 23;157(12):1393

A case of gram negative pericarditis in a patient with the Acquired Immunodeficiency Syndrome. Manyemba JE, et al. **Cent Afr J Med** 1995 Nov;41(11):355–7

Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis [letter; comment] Armengou A, et al. **Clin Infect Dis** 1996 Dec;23(6):1337–8. Comment on: Clin Infect Dis 1996 Feb;22(2):322–8.

Pyomyositis caused by Morganella morganii in a patient with AIDS. Arranz-Caso JA, et al. **Clin Infect Dis** 1996 Feb; 22(2):372–3

Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus. Baily GG, et al. **Clin Infect Dis** 1997 Jul;25(1):161–3

Cryptococcus neoformans myositis in a patient with AIDS. Barber BA, et al. **Clin Infect Dis** 1995 Dec;21(6):1510–1

Central nervous system pneumocystosis in a patient with AIDS. Bartlett JA, et al. **Clin Infect Dis** 1997 Jul;25(1):82–5 (27 ref.)

Transmission of Mycobacterium tuberculosis among health care workers infected with human immunodeficiency virus. Blumberg HM, et al. **Clin Infect Dis** 1996 Mar;22(3):597–8

Xanthogranulomatous cholecystitis due to invasive Candida albicans in a patient with AIDS. Brown H, et al. **Clin Infect Dis** 1996 Jan;22(1):186–7

Isolation of a nutritionally aberrant strain of Cryptococcus neoformans from a patient with AIDS. Dunne WM Jr, et al. **Clin Infect Dis** 1995 Dec;21(6):1512–3

Community-acquired Hafnia alvei infection. Fazal BA, et al. **Clin Infect Dis** 1997 Mar;24(3):527–8

Nontuberculous mycobacterial meningitis: report of two cases and review. Flor A, et al. **Clin Infect Dis** 1996 Dec; 23(6):1266–73 (43 ref.)

Lung abscess in patients with AIDS. Furman AC, et al. **Clin Infect Dis** 1996 Jan;22(1):81–5

Cryptococcal choroiditis in a patient with AIDS: case report and review. Gandhi SA, et al. **Clin Infect Dis** 1996 Nov; 23(5):1193–4 (8 ref.)

Herpes simplex esophagitis in patients with AIDS: report

of 34 cases. The Cooperative Study Group on Herpetic Esophagitis in HIV Infection. Généreau T, et al. **Clin Infect Dis** 1996 Jun;22(6):926–31

Septic shock due to disseminated tuberculosis. George S, et al. **Clin Infect Dis** 1996 Jan;22(1):188–9

Hypertrophic osteoarthropathy associated with Pneumocystis carinii pneumonia and human immunodeficiency virus infection. Gunnarsson G, et al. **Clin Infect Dis** 1996 Mar;22(3):590–1 (9 ref.)

Isolation of Candida norvegensis from clinical specimens: four case reports. Hood SV, et al. **Clin Infect Dis** 1996 Nov;23(5):1185–7

Acalculous cholecystitis associated with microsporidial infection in a patient with AIDS [see comments] Knapp PE, et al. **Clin Infect Dis** 1996 Jan;22(1):195–6. Comment in: Clin Infect Dis 1996 Sep;23(3):664.

Polysaccharide antigen in brain tissue of AIDS patients with cryptococcal meningitis. Lee SC, et al. **Clin Infect Dis** 1996 Jul;23(1):194–5

Polymicrobial brain abscess in a patient infected with human immunodeficiency virus. Maniglia RJ, et al. **Clin Infect Dis** 1997 Mar;24(3):449–51 (12 ref.)

Staphylococcus cohnii: an unusual cause of primary septic arthritis in a patient with AIDS. Mastroianni A, et al. **Clin Infect Dis** 1996 Dec;23(6):1312–3

Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. Meynard JL, et al. **Clin Infect Dis** 1996 Mar;22(3):437–40

Invasive sinusitis due to Sporothrix schenckii in a patient with AIDS. Morgan M, et al. **Clin Infect Dis** 1996 Dec; 23(6):1319–20

Fatal Pasteurella bettyae pleuropneumonia in a patient infected with human immunodeficiency virus. Moritz F, et al. **Clin Infect Dis** 1996 Mar;22(3):591–2

Muscle abscess due to Aspergillus fumigatus in a patient with AIDS. Mylonakis E, et al. **Clin Infect Dis** 1996 Dec; 23(6):1323–4

Clostridium paraputrificum bacteremia in a patient with AIDS and Duodenal Kaposi's sarcoma. Nerad JL, et al. **Clin Infect Dis** 1996 Nov;23(5):1183–4

Paracoccidioidomycosis and AIDS [letter; comment] Nishioka S de A. **Clin Infect Dis** 1996 Jun;22(6):1132–3. Comment on: Clin Infect Dis 1995 Nov;21(5):1275–81.

Granulomatous Pneumocystis carinii myositis presenting as an intramuscular mass. Pearl GS, et al. **Clin Infect Dis** 1996 Mar;22(3):577–8

Liver biopsy is not useful in the diagnosis of mycobacterial infections in patients who are infected with human immunodeficiency virus. Roger PM, et al. **Clin Infect Dis** 1996 Dec;23(6):1302–4

Meningitis due to Pseudomonas stutzeri in a patient infected with human immunodeficiency virus. Roig P, et al. **Clin Infect Dis** 1996 Mar;22(3):587–8

Fluconazole-resistant Candida parapsilosis fungemia in a patient with AIDS. Tumbarello M, et al. **Clin Infect Dis** 1996 Jan;22(1):179–80

AIDS-associated infections in salivary glands: autopsy survey of 60 cases. Wagner RP, et al. **Clin Infect Dis** 1996 Feb;22(2):369–71

Prevalence of Bartonella henselae antibodies among human immunodeficiency virus-infected patients from Bahrain. Yousif A, et al. **Clin Infect Dis** 1996 Aug;23(2):398–9

Adrenal insufficiency, recurrent bacteremia, and disseminated abscesses caused by Nocardia asteroides in a patient with acquired immunodeficiency syndrome. Arabi Y, et al. **Diagn Microbiol Infect Dis** 1996 Jan;24(1):47–51

Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients. Barchiesi F, et al. **Diagn Microbiol Infect Dis** 1995 Nov;23(3):99–103

Comparison of BACTEC 12B vs solid media for the recovery of Mycobacterium avium complex from blood cultures in AIDS patients. Morgan MB, et al. **Diagn Microbiol Infect Dis** 1997 May;28(1):45–8

Bacteriology and sensitivity patterns of pyogenic meningitis at Kenyatta National Hospital, Nairobi, Kenya. Wanyoike MN, et al. **East Afr Med J** 1995 Oct;72(10):658–60

Systemic Penicillium marneffei infection in a German AIDS patient [letter] Sobottka I, et al. **Eur J Clin Microbiol Infect Dis** 1996 Mar;15(3):256–9

Simultaneous carriage of Candida albicans strains from HIV-infected patients with oral candidiasis: multilocus enzyme electrophoresis analysis. Reynes J, et al. **FEMS Microbiol Lett** 1996 Apr 1;137(2–3):269–73

Tumor necrosis factor-inducing activities of Cryptococcus neoformans components [published erratum appears in Infect Immun 1997 May;65(5):1991] Delfino D, et al. **Infect Immun** 1996 Dec;64(12):5199–204

Detection of Pneumocystis carinii with direct fluorescence antibody and calcofluor white stain. Aslanzadeh J, et al. **Infection** 1996 May–Jun;24(3):248–50

Mycobacterium simiae disseminated infection in a patient with acquired immunodeficiency syndrome. Vandercam B, et al. **Infection** 1996 Jan–Feb;24(1):49–51

Isolated cutaneous Mycobacterium avium complex infection in AIDS. Alfandari S, et al. **Int J Dermatol** 1997 Apr; 36(4):294–5

Bacterial infections in HIV: the extent and nature of the problem [editorial] Brettle RP. **Int J STD AIDS** 1997 Jan; 8(1):5–15 (105 ref.)

Recurrent Helicobacter cinaedi cellulitis and bacteraemia in a patient with HIV Infection. Sullivan AK, et al. **Int J STD AIDS** 1997 Jan;8(1):59–60

Infectious choroiditis in the acquired immune deficiency syndrome. Samy CN, et al. **Int Ophthalmol Clin** 1996 Summer;36(3):187–96 (33 ref.)

Fatal Aspergillus pericarditis in acquired immunodeficiency syndrome [letter] Dalhoff K, et al. **Intensive Care Med** 1996 Aug;22(8):831–3

Treatment of fungal infection in AIDS. Hood S, et al. **J Antimicrob Chemother** 1996 May;37 Suppl B:71–85 (62 ref.)

Type frequency and antimicrobial susceptibility of Mycobacterium avium–intracellulare complex strains isolated in Italy from AIDS and non–AIDS patients. Fattorini L, et al. **J Chemother** 1996 Feb;8(1):37–42

Recurrent CDC group IVc-2 bacteremia in a human with AIDS. Anderson RR, et al. **J Clin Microbiol** 1997 Mar; 35(3):780–2 (15 ref.)

Genetic dissimilarity of two fluconazole-resistant Candida albicans strains causing meningitis and oral candidiasis in the same AIDS patient. Berenguer J, et al. **J Clin Microbiol** 1996 Jun;34(6):1542–5

Genetic characterization of multidrug-resistant Mycobacterium bovis strains from a hospital outbreak involving human immunodeficiency virus–positive patients. Blázquez J, et al. **J Clin Microbiol** 1997 Jun;35(6):1390–3

Comparison of four molecular typing methods for evaluating genetic diversity among Candida albicans isolates from human immunodeficiency virus–positive patients with oral candidiasis. Díaz-Guerra TM, et al. **J Clin Microbiol** 1997 Apr;35(4):856–61

Study of internal transcribed spacer and mitochondrial large-subunit genes of Pneumocystis carinii hominis isolated by repeated bronchoalveolar lavage from human immunodeficiency virus–infected patients during one or several episodes of pneumonia. Latouche S, et al. **J Clin Microbiol** 1997 Jul;35(7):1687–90

Biodiversity of Pneumocystis carinii hominis: typing with different DNA regions. Latouche S, et al. **J Clin Microbiol** 1997 Feb;35(2):383–7

Rapid discrimination of Mycobacterium avium strains from AIDS patients by randomly amplified polymorphic DNA analysis. Matsiota-Bernard P, et al. **J Clin Microbiol** 1997 Jun;35(6):1585–8

Detection of Pneumocystis carinii in respiratory specimens by PCR–solution hybridization enzyme–linked immunoassay. Ortona E, et al. **J Clin Microbiol** 1997 Jun; 35(6):1589–91

Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection. Redding SW, et al. **J Clin Microbiol** 1997 Jul; 35(7):1761–5

Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus–infected individuals. Sullivan D, et al. **J Clin Microbiol** 1997 Apr;35(4):960–4

Helicobacter westmeadii sp. nov., a new species isolated from blood cultures of two AIDS patients. Trivett-Moore NL, et al. **J Clin Microbiol** 1997 May;35(5):1144–50

Spectrum of clinical and laboratory characteristics of HIV infection in northern India. Giri TK, et al. **J Commun Dis** 1995 Sep;27(3):131–41

P.carinii DNA detected by ITSs nested PCR in serum and PBMC of AIDS patients with PCP. Atzori C, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):42S

Biodiversity of French and Italian human Pneumocystis carinii. Latouche S, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):54S–55S

Usefulness of molecular biology for Pneumocystis carinii hominis pneumonia epidemiology. Latouche S, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):56S–57S

Comparison of two PCR methods for detection of Pneumocystis carinii in bronchoalveolar lavage fluid. Tamburrini E, et al. **J Eukaryot Microbiol** 1996 Sep–Oct; 43(5):20S

Detection of Pneumocystis carinii DNA in HIV patients with P. carinii pneumonia (PCP) and in animal models. Tamburrini E, et al. **J Eukaryot Microbiol** 1996 Sep–Oct; 43(5):18S–19S

Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus–associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group. Brandt ME, et al. **J Infect Dis** 1996 Oct;174(4):812–20

Infectious pseudomonas subglottic stenosis occurring in a patient with acquired immunodeficiency syndrome. Ghufoor K, et al. **J Laryngol Otol** 1997 Jan;111(1):70–2

Pulmonary infections in HIV infected patients. Mootsikapun P, et al. **J Med Assoc Thai** 1996 Aug;79(8):477–85

Cladophialophora bantiana isolated from an AIDS patient with pulmonary infiltrates. Brenner SA, et al. **J Med Vet Mycol** 1996 Nov–Dec;34(6):427–9

Crytococcus neoformans var. gattii in an AIDS patient: first observation in Mexico. Castanón-Olivares LR, et al. **J Med Vet Mycol** 1997 Jan–Feb;35(1):57–9

Meningitis caused by Rhodotorula rubra in an HIV-infected patient. Gyaurgieva OH, et al. **J Med Vet Mycol** 1996 Sep–Oct;34(5):357–9

Atypical strains of Candida albicans recovered from AIDS patients. Pujol C, et al. **J Med Vet Mycol** 1997 Mar–Apr; 35(2):115–21

Oral cryptococcosis: case report of salivary gland involvement in an AIDS patient. Monteil RA, et al. **J Oral Pathol Med** 1997 Jan;26(1):53–6

M tuberculosis drug resistance in AIDS [letter; comment] Di Perri G, et al. **Lancet** 1997 Jan 4;349(9044):60–1; discussion 61–2. Comment on: Lancet 1996 Oct 5;348(9032):928–31.

beta-Tubulin genes and the basis for benzimidazole sensitivity of the opportunistic fungus Cryptococcus neoformans. Cruz MC, et al. **Microbiology** 1997 Jun;143 (Pt 6):2003–8

Serotypes of Cryptococcus neoformans isolated from patients prior to and during the AIDS era in Thailand. Sukroongreung S, et al. **Mycopathologia** 1996;135(2):75–8

Phospholipase activity in Cryptococcus neoformans. Vidotto V, et al. **Mycopathologia** 1996–97;136(3):119–23

Disseminated mycosis due to Scedosporium prolificans in an AIDS patient with Burkitt lymphoma. Nenoff P, et al. **Mycoses** 1996 Nov–Dec;39(11–12):461–5

Increased prevalence of oral Candida albicans serotype B in homosexual men: a comparative and longitudinal study in HIV-infected and HIV-negative patients. Torssander J, et al. **Mycoses** 1996 Sep–Oct;39(9–10):353–6

Empyema with malakoplakic-like lesions by Rhodococcus equi as a presentation of HIV infection. Calore EE, et al. **Pathologica** 1995 Oct;87(5):525–27

Isolation of Ureaplasma urealyticum from nonneonatal respiratory tract specimens in a pediatric institution. Matlow AG, et al. **Pediatr Infect Dis J** 1996 Mar; 15(3):272–4

Gastrointestinal translocation as a possible source of candidemia in an AIDS patient. Colombo AL, et al. **Rev Inst Med Trop Sao Paulo** 1996 May–Jun;38(3):197–200

Penicillium marneffei infection in a Swedish HIV-infected immunodeficient narcotic addict. Julander I, et al. **Scand J Infect Dis** 1997;29(3):320–2

Invasive Candida norvegensis infection in immunocompromised patients. Nielsen H, et al. **Scand J Infect Dis** 1996;28(3):311–2

Cutaneous protothecosis in association with the acquired immunodeficiency syndrome. Polk P, et al. **South Med J** 1997 Aug;90(8):831–2

Detection of Mycoplasma sp. in bronchoalveolar lavage of AIDS patients with pulmonary infiltrates. Sloot N, et al. **Zentralbl Bakteriol** 1996 Jun;284(1):75–9

[Tsukamurella infections. Review of the literature apropos of a case] Rey D, et al. **Pathol Biol (Paris)** 1997 Jan; 45(1):60–5 (27 ref.) (Eng. Abstr.) **(Fre)**

[Salmonella typhimurium cerebral abscess in a patient with HIV infection (letter; comment)] Gueit I, et al. **Presse Med** 1996 Dec 21;25(40):2052. Comment on: Presse Med 1996 Mar 30;25(11):556. **(Fre)**

[Prospective study of pathogenic agents isolated from feces of patients with HIV infections] Meynard JL, et al. **Presse Med** 1997 May 17;26(16):748–51 (Eng. Abstr.) **(Fre)**

[Mycobacterium haemophilum infection in a patient with AIDS] Bachmann S, et al. **Dtsch Med Wochenschr** 1996 Sep 27;121(39):1189–92 (Eng. Abstr.) **(Ger)**

[A new problem: multiresistant fungi (news)] Wehr A. **Dtsch Med Wochenschr** 1997 Mar 14;122(11):A9 **(Ger)**

[Comparison of three antifungal susceptibility testing methods for the in vitro testing of Candida isolates from patients with HIV infection] Ruhnke M, et al. **Mycoses** 1996;39 Suppl 2:47–50 (Eng. Abstr.) **(Ger)**

[A case of acquired immunodeficiency syndrome with disseminated Mycobacterium avium complex infection in which M. avium was isolated from bone marrow] Ohse H, et al. **Kekkaku** 1997 Feb;72(2):73–7 (Eng. Abstr.) **(Jpn)**

[Bacteremia caused by Corynebacterium urealyticum in 2 patients co-infected with HIV and HBV (letter)] Aracil B, et al. **Enferm Infecc Microbiol Clin** 1997 Mar;15(3):172–3 **(Spa)**

[Disseminated infection by Mycobacterium scrofulaceum: apropos of 3 cases (see comments)] Campos-Herrero MI, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):258–60 (13 ref.) (Eng. Abstr.). Comment in: Enferm Infecc Microbiol Clin 1996 Dec;14(10):628. **(Spa)**

[Sinusitis caused by Mycobacterium avium–M. intracellulare in a patient with HIV infection (letter)] Cibrián F, et al. **Enferm Infecc Microbiol Clin** 1996 Jun–Jul;14(6):401–2 **(Spa)**

[Infection by Bordetella bronchiseptica in patients with AIDS (letter; comment)] Goenaga MA, et al. **Enferm Infecc Microbiol Clin** 1997 Jan;15(1):48–9. Comment on: Enferm Infecc Microbiol Clin 1996 Aug–Sep;14(7):458–9. **(Spa)**

[Pulmonary infection by Mycobacterium malmoense in a patient with AIDS (letter)] López R, et al. **Enferm Infecc Microbiol Clin** 1997 Jan;15(1):47–8 **(Spa)**

[Pulmonary nocardiosis in a HIV–positive patient (letter)] Lorente L, et al. **Enferm Infecc Microbiol Clin** 1997 Feb; 15(2):115–6 **(Spa)**

[Mycobacterium scrofulaceum and AIDS (letter; comment)] Lozano F, et al. **Enferm Infecc Microbiol Clin** 1996 Dec; 14(10):628. Comment on: Enferm Infecc Microbiol Clin 1996 Apr;14(4):258–60. **(Spa)**

[Otomastoiditis caused by Aspergillus in AIDS] Martínez-Berriotxoa A, et al. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):200–2 (Eng. Abstr.) **(Spa)**

[Histoplasmosis and AIDS (letter)] Santos J, et al.

Enferm Infecc Microbiol Clin 1997 Apr;15(4):229–30 **(Spa)**

[Yeast infections: causative agents and their antifungal resistance in hospitalized pediatric patients and HIV-positive adults] Rodero L, et al. **Rev Argent Microbiol** 1997 Jan–Mar;29(1):7–15 (Eng. Abstr.) **(Spa)**

[Pseudomonas aeruginosa: dreadful also in the AIDS patient editorial)] Bouza E. **Rev Clin Esp** 1996 Oct;196(10):670–1 **(Spa)**

[Bacteremia caused by Pseudomonas aeruginosa in patients with AIDS] Bouza Santiago E, et al. **Rev Clin Esp** 1996 Oct;196(10):698–702 (Eng. Abstr.) **(Spa)**

[Cholangitis with hepatosplenomegaly caused by Xanthomonas maltophilia in a patient with AIDS (letter)] Ortiz Cansado A, et al. **Rev Clin Esp** 1997 May;197(5):382–3 **(Spa)**

[Characterization of Cryptococcus neoformans strains isolated from patients with acquired immunodeficiency syndrome (AIDS)] Garza-Garza D, et al. **Rev Latinoam Microbiol** 1995 Jul–Sep;37(3):273–9 (Eng. Abstr.) **(Spa)**

[Cryptococcus neoformans meningitis in patients with AIDS at the Saint Thomas Hospital] Sierra LO, et al. **Rev Med Panama** 1996 Jan–May;21(1–2):46–50 (Eng. Abstr.) **(Spa)**

[Histoplasmosis of the central nervous system. Report of 2 cases and review of the literature] Sosa N, et al. **Rev Med Panama** 1996 Jan–May;21(1–2):18–29 (56 ref.) (Eng. Abstr.) **(Spa)**

[The validation of the possible use of monosugars and 6-azacytidine for the elimination of Mollicutes associated with HIV/AIDS from the human urogenital tract] Skrypal' IH, et al. **Mikrobiol Z** 1996 Sep–Oct;58(5):80–5 (Eng. Abstr.) **(Ukr)**

MORTALITY

Survival with AIDS in Ireland. Dunne MT, et al. **AIDS** 1997 Aug;11(10):1281–90

Survival of European patients with Kaposi's sarcoma as AIDS-defining condition during the first decade of AIDS. AIDS in Europe Study Group. Hermans P, et al. **AIDS** 1997 Mar 15;11(4):525–31

Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. Whalen C, et al. **AIDS** 1997 Mar 15;11(4):455–60

Re: "Cryptosporidiosis among patients infected with human immunodeficiency virus: factors related to symptomatic infection and survival" [letter; comment] Clark RA, et al. **Am J Epidemiol** 1997 Aug 15;146(4):358–9. Comment on: Am J Epidemiol 1996 Nov 1;144(9):807–16.

Cryptosporidiosis among patients infected with human immunodeficiency virus. Factors related to symptomatic infection and survival [see comments] Colford JM Jr, et al. **Am J Epidemiol** 1996 Nov 1;144(9):807–16. Comment in: Am J Epidemiol 1997 Aug 15;146(4):358–9.

Temporal trends and factors associated with survival after Pneumocystis carinii pneumonia in California, 1983–1992. Colford JM Jr, et al. **Am J Epidemiol** 1997 Jul 15; 146(2):115–27

Pneumocystis carinii and cytomegalovirus infections in severely ill, HIV-infected African infants. Jeena PM, et al. **Ann Trop Paediatr** 1996 Dec;16(4):361–8

Fatal Mycobacterium fortuitum meningitis in a patient with AIDS. Smith MB, et al. **Clin Infect Dis** 1996 Dec; 23(6):1327–8

Impact of disseminated Mycobacterium avium–complex infection on survival of HIV-infected patients. Brodt HR, et al. **Eur J Med Res** 1997 Mar 24;2(3):106–10

Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Mocroft AJ, et al. **Int J Epidemiol** 1997 Apr;26(2):400–7

Survival after AIDS-defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial Group. Pueyo S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 15;14(5):459–64

AIDS-related Pneumocystis carinii pneumonia in older patients [see comments] Keitz SA, et al. **J Gen Intern Med** 1996 Oct;11(10):591–6. Comment in: J Gen Intern Med 1996 Oct;11(10):645–7.

Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. Selik RM, et al. **J Infect Dis** 1997 Sep;176(3):632–6

Impact of pregnancy on maternal AIDS. Kumar RM, et al. **J Reprod Med** 1997 Jul;42(7):429–34

Comparison of changing autopsy trends in the Bronx population with acquired immunodeficiency syndrome. Concepcion L, et al. **Mod Pathol** 1996 Oct;9(10):1001–6

Survival benefits of pulmonary cellular activation in AIDS patients with Pneumocystis infection. Sharma R, et al. **South Med J** 1997 May;90(5):531–4

Analysis of multiple failure time data from an AIDS clinical trial. Finkelstein DM, et al. **Stat Med** 1997 Apr 30; 16(8):951–61

Predicting in-hospital mortality of patients with AIDS-related Pneumocystis carinii pneumonia: an example of hierarchically optimal classification tree analysis. Yarnold PR, et al. **Stat Med** 1997 Jul 15;16(13):1451–63

[Tuberculosis takes a large toll in human lives (news)] **Pneumologie** 1996 Jun;50(6):IX **(Ger)**

PARASITOLOGY

Leishmania infantum is clonal in AIDS patients too: epidemiological implications. Jiménez M, et al. **AIDS** 1997 Apr;11(5):569–73

Diagnosis of infections caused by Enterocytozoon bieneusi and Encephalitozoon intestinalis using polymerase chain reaction in stool specimens [see comments] Liguory O, et al. **AIDS** 1997 May;11(6):723–6. Comment in: AIDS 1997 May;11(6):817–8.

Disseminated microsporidiosis in AIDS: are any organs spared? [letter] Orenstein JM, et al. **AIDS** 1997 Mar; 11(3):385–6

Fulminant hepatic failure caused by microsporidial infection in a patient with AIDS [letter] Sheth SG, et al. **AIDS** 1997 Mar 15;11(4):553–4

Disseminated microsporidiosis especially infecting the brain, heart, and kidneys. Report of a newly recognized pansporoblastic species in two symptomatic AIDS patients. Yachnis AT, et al. **Am J Clin Pathol** 1996 Oct;106(4):535–43

Cryptosporidiosis in HIV-infected patients: diagnostic sensitivity of stool examination, based on number of specimens submitted. Blackman E, et al. **Am J Gastroenterol** 1997 Mar;92(3):451–3

Cutaneous infections due to Acanthamoeba in patients with acquired immunodeficiency syndrome. Chandrasekar PH, et al. **Arch Intern Med** 1997 Mar 10;157(5):569–72

Kala-azar comes to New York. Parkas V, et al. **Arch Intern Med** 1997 Apr 28;157(8):921–3 (20 ref.)

Foamy macrophages in acquired immunodeficiency syndrome cholangiopathy with Encephalitozoon intestinalis. Liberman E, et al. **Arch Pathol Lab Med** 1997 Sep;121(9):985–8

A patient with acquired immunodeficiency syndrome and untreated Encephalitozoon (Septata) intestinalis microsporidiosis leading to small bowel perforation. Response to albendazole. Soule JB, et al. **Arch Pathol Lab Med** 1997 Aug;121(8):880–7

Trypanosoma cruzi meningoencephalitis in AIDS mimicking cerebral metastases: case report. Pimentel PC, et al. **Arq Neuropsiquiatr** 1996 Mar;54(1):102–6

Protozoal colonization of the intestinal tract in institutionalized Romanian children. Brannan DK, et al. **Clin Infect Dis** 1996 Mar;22(3):456–61

Primary amebic meningoencephalitis in a patient with AIDS: unusual protozoological findings. Clavel A, et al. **Clin Infect Dis** 1996 Dec;23(6):1314–5

Prevalence of microsporidiosis due to Enterocytozoon bieneusi and Encephalitozoon (Septata) intestinalis among patients with AIDS-related diarrhea: determination by polymerase chain reaction to the microsporidian small-subunit rRNA gene. Coyle CM, et al. **Clin Infect Dis** 1996 Nov;23(5):1002–6

Immunologic and molecular characteristics of Encephalitozoon-like microsporidia isolated from humans and rabbits indicate that Encephalitozoon cuniculi is a zoonotic parasite. Deplazes P, et al. **Clin Infect Dis** 1996 Mar;22(3):557–9

Polyarthritis caused by Leishmania in a patient with AIDS. Perelló-Roso A, et al. **Clin Infect Dis** 1996 Jun;22(6):1113–4

Ocular toxoplasmosis as the presenting manifestation of human immunodeficiency virus infection [letter; comment] Pomeroy C, et al. **Clin Infect Dis** 1997 Apr;24(4):745–6. Comment on: Clin Infect Dis 1996 Aug;23(2):277–82.

Microsporidium-associated sinusitis. Moss RB, et al. **Ear Nose Throat J** 1997 Feb;76(2):95–101 (19 ref.)

Pleural and peritoneal leishmaniasis in an AIDS patient. Muñoz-Rodríguez FJ, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):246–8

Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. Ventura G, et al. **Eur J Gastroenterol Hepatol** 1997 Mar;9(3):307–10 (18 ref.)

Disseminated microsporidiosis in a patient with acquired immunodeficiency syndrome. Cowley GP, et al. **Histopathology** 1997 Apr;30(4):386–9

Pulmonary cryptosporidiosis in the acquired immunodeficiency syndrome. Meynard JL, et al. **Infection** 1996 Jul–Aug;24(4):328–31

Scabies and leukocytoclastic vasculitis in an HIV-seropositive man [letter] Valks R, et al. **Int J Dermatol** 1996 Aug;35(8):605–6

Quantitative light microscopic detection of Enterocytozoon bieneusi in stool specimens: a longitudinal study of human immunodeficiency virus-infected microsporidiosis patients. Clarridge JE 3rd, et al. **J Clin Microbiol** 1996 Mar; 34(3):520–3

Identification of Enterocytozoon bieneusi spores in respiratory samples from an AIDS patient with a 2-year history of intestinal microsporidiosis. del Aguila C, et al. **J Clin Microbiol** 1997 Jul;35(7):1862–6

A microsporidian isolated from an AIDS patient corresponds to Encephalitozoon cuniculi III, originally isolated from domestic dogs. Didier ES, et al. **J Clin Microbiol** 1996 Nov; 34(11):2835–7

Myositis associated with a newly described microsporidian, Trachipleistophora hominis, in a patient with AIDS. Field AS, et al. **J Clin Microbiol** 1996 Nov;34(11):2803–11

Multiplex PCR for diagnosis of AIDS-related central nervous system lymphoma and toxoplasmosis. Roberts TC, et al. **J Clin Microbiol** 1997 Jan;35(1):268–9

Detection of the microsporidian parasite Enterocytozoon bieneusi in specimens from patients with AIDS by PCR. Velásquez JN, et al. **J Clin Microbiol** 1996 Dec; 34(12):3230–2

Cryptosporidium in AIDS patients in south India: a laboratory investigation. Ananthasubramanian M, et al. **J Commun Dis** 1997 Mar;29(1):29–33

Detection of T.gondii-DNA by PCR in AIDS-related toxoplasmic encephalitis. Cingolani A, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):118S–119S

Cutaneous lesions due to Acanthamoeba sp in a patient with AIDS. Deluol AM, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):130S–131S

Broncho-pulmonary cryptosporidiosis in four HIV-infected patients. Poirot JL, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):78S–79S

Comparative rDNA analysis of Microsporidia including AIDS related species. Vossbrinck CR, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):110S

Pulmonary microsporidiosis due to Encephalitozoon hellem in a patient with AIDS. Scaglia M, et al. **J Infect** 1997 Mar;34(2):119–26

Detection and species identification of intestinal microsporidia by polymerase chain reaction in duodenal biopsies from human immunodeficiency virus-infected patients. David F, et al. **J Infect Dis** 1996 Oct;174(4):874–7

Pulmonary infections in HIV infected patients. Mootsikapun P, et al. **J Med Assoc Thai** 1996 Aug;79(8):477–85

Disseminated cerebral hemorrhages as unusual manifestation of toxoplasmic encephalitis in AIDS. Berlit P, et al. **J Neurol Sci** 1996 Nov;143(1–2):187–9

Microsporidiosis of the mandible in a patient with acquired immunodeficiency syndrome. Belcher JW Jr, et al. **J Oral Maxillofac Surg** 1997 Apr;55(4):424–6

Protozoal infection of the gut in patients with HIV infection [letter; comment] Harries AD, et al. **Lancet** 1996 Nov 2; 348(9036):1248–9. Comment on: Lancet 1996 Aug 10;348(9024):379–83.

Tubulin genes from AIDS-associated microsporidia and implications for phylogeny and benzimidazole sensitivity. Li J, et al. **Mol Biochem Parasitol** 1996 Jun;78(1–2):289–95

Disseminated Encephalitozoon (Septata) intestinalis infection in a patient with AIDS [letter] Franzen C, et al. **N Engl J Med** 1996 Nov 21;335(21):1610–1

Cerebral microsporidiosis due to Encephalitozoon cuniculi [letter; comment] Guntinas-Lichius O. **N Engl J Med** 1997 Aug 28;337(9):640–1. Comment on: N Engl J Med 1997 Feb 13;336(7):474–8.

Cerebral microsporidiosis due to Encephalitozoon cuniculi in a patient with human immunodeficiency virus infection [see comments] Weber R, et al. **N Engl J Med** 1997 Feb 13;336(7):474–8. Comment in: N Engl J Med 1997 Aug 28;337(9):640–1.

Microsporidiosis in New Zealand [letter] Everts R, et al. **N Z Med J** 1997 Mar 14;110(1039):83

Cryptosporidium, isospora and strongyloides in AIDS [see comments] Lanjewar DN, et al. **Natl Med J India** 1996 Jan–Feb;9(1):17–9. Comment in: Natl Med J India 1996 Jul–Aug;9(4):201.

Deadly human parasite discovered. **Oncology (Huntingt)** 1996 Aug;10(8):1133, 1139

Factors associated with microsporidial and cryptosporidial diarrhea in HIV infected patients. Cornet M, et al. **Parasite** 1996 Dec;3(4):397–401

Pathogenicity of Cyclospora sp [letter] Garavelli PL. **Parasite** 1994 Mar;1(1):94

Intestinal co-infection by Cyclospora sp. and Cryptosporidium parvum: first report in an AIDS patient. Scaglia M, et al. **Parasite** 1994 Dec;1(4):387–90

Microsporidium and Cyclospora in human stools in Chiang Mai, Thailand. Morakote N, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):799–800

Cyclospora cayetanensis in an asymptomatic patient infected with HIV and HTLV-1. Schubach TM, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):175

[PCR for detection and characterization of parasites (Leishmania, Echinococcus, Microsporodia, Giardia)] Mathis A, et al. **Schweiz Arch Tierheilkd** 1996;138(3):133–8 (Eng. Abstr.) **(Ger)**

[Oocysts of Cryptosporidium sp in feces: comparison of the modified Kinyoun and Heine methods] Amato Neto V, et al. **Rev Soc Bras Med Trop** 1996 Nov–Dec;29(6):575–8 (Eng. Abstr.) **(Por)**

[The usefulness of the isolation of Cryptosporidium in the respiratory secretions of HIV-infected patients (letter)] Cervero M, et al. **Arch Bronconeumol** 1997 May;33(5):259 **(Spa)**

[Watery diarrhea and weight loss in a patient with HIV infection] Elcuaz R, et al. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):219–20 **(Spa)**

PATHOLOGY

Cytologic diagnosis of Cryptococcus neoformans in HIV-positive patients. Kanjanavirojkul N, et al. **Acta Cytol** 1997 Mar–Apr;41(2):493–6

Pulmonary malacoplakia associated with Rhodococcus equi infection in an AIDS patient. Report of a case with diagnosis by fine needle aspiration. Sughayer M, et al. **Acta Cytol** 1997 Mar–Apr;41(2):507–12

Clinical features and outcomes of HIV-related cytomegalovirus pneumonia. Salomon N, et al. **AIDS** 1997 Mar;11(3):319–24

Encephalitozoon (Septata) intestinalis: cytologic, histologic, and electron microscopic features of a systemic intestinal

pathogen. Chu P, et al. **Am J Clin Pathol** 1996 Nov; 106(5):606–14

Bacillary angiomatosis associated with extensive esophageal polyposis: a new mucocutaneous manifestation of acquired immunodeficiency disease (AIDS). Chang AD, et al. **Am J Gastroenterol** 1996 Oct;91(10):2220–3

Pneumocystis carinii and cytomegalovirus infections in severely ill, HIV-infected African infants. Jeena PM, et al. **Ann Trop Paediatr** 1996 Dec;16(4):361–8

Cutaneous infections due to Acanthamoeba in patients with acquired immunodeficiency syndrome. Chandrasekar PH, et al. **Arch Intern Med** 1997 Mar 10;157(5):569–72

Pathologic quiz case 1. Pneumocystic lymphadenitis. Reisacher WR, et al. **Arch Otolaryngol Head Neck Surg** 1997 Aug;123(8):880, 882–3

Pathology of Penicillium marneffei. An emerging acquired immunodeficiency syndrome-related pathogen. Cooper CR Jr, et al. **Arch Pathol Lab Med** 1997 Aug;121(8):798–804 (44 ref.)

Coinfection with Giardia lamblia and Enterocytozoon bieneusi in a patient with acquired immunodeficiency syndrome and chronic diarrhea. Hewan-Lowe K, et al. **Arch Pathol Lab Med** 1997 Apr;121(4):417–22

Oral histoplasmosis associated with candidiasis in HIV-infected patients: a report of two cases. Nittayananta W, et al. **Br Dent J** 1997 Apr 26;182(8):309–12

Bacillary angiomatosis: presentation of six patients, some with unusual features. Schwartz RA, et al. **Br J Dermatol** 1997 Jan;136(1):60–5

'Creeping' cytomegalovirus retinitis in AIDS [letter] Dhillon B, et al. **Br J Ophthalmol** 1996 Aug;80(8):771–2

Alveolar damage in AIDS-related Pneumocystis carinii pneumonia. Benfield TL, et al. **Chest** 1997 May; 111(5):1193–9

Localized cutaneous infection caused by Mycobacterium avium complex in an AIDS patient. Esteban J, et al. **Clin Exp Dermatol** 1996 May;21(3):230–1

Isolated cutaneous non-tuberculous mycobacterial infection as a manifestation of AIDS [published erratum appears in Clin Exp Dermatol 1996 Nov;21(6):468] Paige DG, et al. **Clin Exp Dermatol** 1996 May;21(3):226–9

Recrudescence of initial cutaneous lesions after crusting of chickenpox in an adult with advanced AIDS suggests prolonged local viral persistence. Baran J Jr, et al. **Clin Infect Dis** 1997 Apr;24(4):741–2

Botryomycosis. Fain O, et al. **Clin Infect Dis** 1997 Apr; 24(4):557, 717

Changing patterns of infections in patients with AIDS: a study of 279 autopsies of prison inmates and nonincarcerated patients at a university hospital in eastern Texas, 1984–1993 [see comments] Lyon R, et al. **Clin Infect Dis** 1996 Aug;23(2):241–7. Comment in: Clin Infect Dis 1996 Aug;23(2):248–54.

Bacillary angiomatosis associated with myositis in a patient infected with human immunodeficiency virus. Whitfeld MJ, et al. **Clin Infect Dis** 1997 Apr;24(4):562–4

Microglial nodule encephalitis: limited CNS infection despite disseminated systemic cryptococcosis. Edelman M, et al. **Clin Neuropathol** 1996 Jan-Feb;15(1):30–3

Pathologic correlations between ocular and cerebral lesions in 36 AIDS patients. Léger F, et al. **Clin Neuropathol** 1997 Jan-Feb;16(1):45–8

Sites of tuberculous involvement in patients with AIDS. Autopsy findings and evaluation of gallium imaging. Abdel-Dayem HM, et al. **Clin Nucl Med** 1997 May; 22(5):310–4

Disseminated mycobacterium avium complex. Review of Ga-67 and Tl-201 scans and autopsy findings. Abdel-Dayem HM, et al. **Clin Nucl Med** 1996 Jul; 21(7):547–56

Perianal cytomegalovirus ulcer in an HIV-infected patient. Aloi F, et al. **Dermatology** 1996;192(1):81–3

Eruptive dermatofibromas in AIDS patients: a form of mycobacteriosis? [letter; comment] Silvestre JF, et al. **Dermatology** 1997;194(2):197. Comment on: Dermatology 1995;190(4):309–12. Comment on: Dermatology 1995;190(4):319.

Histological and ultrastructural study of one case of oral bacillary angiomatosis in HIV disease and review of the literature. Monteil RA, et al. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):65–71 (64 ref.)

Unusual endoscopic features of gastric and duodenal cryptosporidiosis in AIDS. Chalasani N, et al. **Gastrointest Endosc** 1997 Jun;45(6):525–7

Endoscopic features of gastroduodenal cryptococcosis in AIDS. Chalasani N, et al. **Gastrointest Endosc** 1997 Mar; 45(3):315–7

Colonic histoplasmosis in AIDS: unusual endoscopic findings in two cases. Halline AG, et al. **Gastrointest Endosc** 1997 Feb;45(2):199–204 (33 ref.)

Endoscopic appearance of Mycobacterium genavense: case report and review of the literature [see comments] Koehler M, et al. **Gastrointest Endosc** 1996 Sep;44(3):331–3. Comment in: Gastrointest Endosc 1997 Mar;45(3):334.

Pneumocystis carinii pneumonia in human immunodeficiency virus infected patients in Bombay: diagnosed by bronchoalveolar lavage cytology and transbronchial lung biopsy. Bijur S, et al. **Indian J Chest Dis Allied Sci** 1996 Oct-Dec;38(4):227–33

Toxic shock syndrome in AIDS [letter] Klinker H, et al. **Int J Dermatol** 1997 Jun;36(6):472–3

Giant molluscum contagiosum in AIDS. Vozmediano JM, et al. **Int J Dermatol** 1996 Jan;35(1):45–7

Massive salivary gland swelling due to primary cytomegalovirus infection in an AIDS patient. Smith NA, et al. **Int J STD AIDS** 1997 Aug;8(8):528–9

Autopsy findings in HIV-1-infected adults in Kenya [letter] Rana F, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jan 1;14(1):83–5

An atlas of HIV-associated oral lesions: a new classification and diagnostic criteria. Wiebe CB, et al. **J Can Dent Assoc** 1997 Apr;63(4):288–9, 292–4 (8 ref.)

Pneumocystis carinii pneumonia in four mammal species: histopathology and ultrastructure. Creusy C, et al. **J Eukaryot Microbiol** 1996 Sep-Oct;43(5):47S–48S

Prognostic value of oral candidosis and hairy leukoplakia in 111 Mexican HIV-infected patients. Ramírez-Amador VA, et al. **J Oral Pathol Med** 1996 May;25(5):206–11

Exfoliative cheilitis (EC) in AIDS: association with Candida infection. Reichart PA, et al. **J Oral Pathol Med** 1997 Jul; 26(6):290–3

Localised oral histoplasmosis lesions associated with HIV infection. Warnakulasuriya KA, et al. **J Oral Pathol Med** 1997 Jul;26(6):294–6

Apoptosis of human monocytes/macrophages in Mycobacterium tuberculosis infection. Placido R, et al. **J Pathol** 1997 Jan;181(1):31–8

Multilocular thymic cysts in children with human immunodeficiency virus infection: clinical and pathologic aspects. Kontny HU, et al. **J Pediatr** 1997 Aug; 131(2):264–70

Encephalitozoon cuniculi microsporidiosis: infection of the brain, heart, kidneys, trachea, adrenal glands, and urinary bladder in a patient with AIDS. Mertens RB, et al. **Mod Pathol** 1997 Jan;10(1):68–77

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 27-1997. A 38-year-old man with the acquired immunodeficiency syndrome and cavitary pulmonary lesions [clinical conference] **N Engl J Med** 1997 Aug 28;337(9):619–27

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-1996. A 37-year-old man with AIDS, neurologic deterioration, and multiple hemorrhagic cerebral lesions [clinical conference] **N Engl J Med** 1996 Nov 21;335(21):1587–95

Picture resembling hemicentral retinal vein occlusion in the acquired immunodeficiency syndrome: is it related to cytomegalovirus? Mansour AM, et al. **Ophthalmologica** 1996;210(2):108–11

Perioral and cutaneous umbilicated papular lesions in acquired immunodeficiency syndrome [clinical conference] Hicks MJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):189–91

Herpes simplex and cytomegalovirus coinfected oral ulcers in HIV-positive patients. Regezi JA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jan;81(1):55–62

Recent advances in the pulmonary pathology of human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS). Klassen MK, et al. **Pathology (Phila)** 1996;4(1):43–71 (149 ref.)

Opportunistic infections in pediatric HIV infection: a study of 74 autopsy cases from Latin America. The Latin American AIDS Pathology Study Group. Drut R, et al. **Pediatr Pathol Lab Med** 1997 Jul-Aug;17(4):569–76

Gastrointestinal manifestations in pediatric AIDS. Kahn E. **Pediatr Pathol Lab Med** 1997 Mar-Apr;17(2):171–208 (127 ref.)

Osseous manifestations of bacillary angiomatosis. Gomez-Jorge JT, et al. **Skeletal Radiol** 1996 Jul;25(5):505–8

Disseminated blastomycosis and acquired immunodeficiency syndrome: a case report and ultrastructural study. Guccion JG, et al. **Ultrastruct Pathol** 1996 Sep-Oct;20(5):429–35

Pathological and epidemiological aspects of skin lesions in histoplasmosis. Observations in an AIDS patient and badgers outside endemic areas of histoplasmosis. Grosse G, et al. **Zentralbl Bakteriol** 1997 Apr;285(4):531–9

[Anatomopathologic study of five cases of leprosy in HIV seropositive patients] Faye O, et al. **Acta Leprol** 1996; 10(2):93–9 (22 ref.) (Eng. Abstr.) **(Fre)**

[Role of guided fine needle punction in the diagnosis of deep-seated Aids-related infections. Report of a case of hepato-nodal histoplasmosis] Longchampt E, et al. **Ann Pathol** 1996 Sep;16(4):266–70 (12 ref.) (Eng. Abstr.) **(Fre)**

[Diffuse cutaneous leishmaniasis and acquired immunodeficiency syndrome in a Senegalese patient] Ndiaye PB, et al. **Bull Soc Pathol Exot** 1996;89(4):282–6 (22 ref.) (Eng. Abstr.) **(Fre)**

[Disseminated cryptococcosis with extensive cutaneous involvement in AIDS] Arastéh K, et al. **Med Klin** 1997 Jun 15;92(6):354–7 (Eng. Abstr.) **(Ger)**

[Diagnosis of cytomegalovirus disease in biopsy and surgical material. Methods and clinical relevance] Seifert G. **Pathologe** 1997 May;18(3):207–17 (163 ref.) (Eng. Abstr.) **(Ger)**

[Atypical morphologic lung manifestations of Pneumocystis carinii infection in AIDS patients] Wöckel W, et al. **Pathologe** 1997 May;18(3):246–51 (Eng. Abstr.) **(Ger)**

[Neuropathology of AIDS: opportunistic infections and HIV encephalopathy] Shintaku M. **No To Shinkei** 1997 Jan; 49(1):5–17 (118 ref.) **(Jpn)**

[Multiorgan changes in AIDS in a reported case] Rogowska-Szadkowska D, et al. **Pol Tyg Lek** 1996 Jun; 51(23–26):340–3 (Eng. Abstr.) **(Pol)**

[Oophoritis due to cytomegalovirus in a female AIDS patient (letter)] Ortiz-Rey JA, et al. **Med Clin (Barc)** 1997 Mar 8;108(9):357–8 (10 ref.) **(Spa)**

[Spontaneous bacterial peritonitis and primary hepatic lymphoma in a female patient with human immunodeficiency virus infection (letter)] Sancho JM, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):238 (7 ref.) **(Spa)**

PHYSIOPATHOLOGY

AIDS-related varicella zoster meningoencephalitis and radicular pain without cutaneous eruption [letter] Débat Zoguéreh D, et al. **AIDS** 1996 Nov;10(13):1604–6

Cytomegalovirus infection: a possible cause of recurrent transient neurological dysfunction in advanced HIV infection. Klein JL, et al. **AIDS** 1996 Mar;10(3):345–6

Funduscopy versus photographic assessment of cytomegalovirus retinitis progression: a clinician's perspective. Migdal C. **AIDS** 1996 Dec;10 Suppl 4:S19–23 (4 ref.)

Unperceived visual field defects [letter; comment] Safran AB. **Arch Ophthalmol** 1997 May;115(5):686–7. Comment on: Arch Ophthalmol 1996 Jul;114(7):841–7.

Signs and symptoms of prevalent and incident cases of gonorrhea and genital chlamydial infection among female prostitutes in Kinshasa, Zaire. Alary M, et al. **Clin Infect Dis** 1996 Mar;22(3):477–84

Herpes zoster and progression to AIDS in a cohort of individuals who seroconverted to human immunodeficiency virus. Italian HIV Seroconversion Study. Alliegro MB, et al. **Clin Infect Dis** 1996 Nov; 23(5):990–5

A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. Alpert PL, et al. **Clin Infect Dis** 1997 Apr;24(4):661–8

Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus. Darras-Joly C, et al. **Clin Infect Dis** 1996 Aug;23(2):369–76

Infection with human immunodeficiency virus does not influence the clinical severity of scrub typhus. Kantipong P, et al. **Clin Infect Dis** 1996 Nov;23(5):1168–70

Progression of human immunodeficiency virus infection in children is related to the interaction of the virus, the immune system, and then some [editorial; comment] Pizzo PA. **Clin Infect Dis** 1997 May;24(5):975–6. Comment on: Clin Infect Dis 1997 May;24(5):971–4.

Toxoplasmosis of the spinal cord in a patient with AIDS: case report and review. Vyas R, et al. **Clin Infect Dis** 1996 Nov;23(5):1061–5 (29 ref.)

Visual prognosis of AIDS patients with cytomegalovirus retinitis. Bloom PA, et al. **Eye** 1995;9 (Pt 6):697–702

Impact of HIV infection on leprosy. Thappa DM, et al. **Indian J Lepr** 1996 Jul-Sep;68(3):255–6

HIV and tuberculosis. Sahoo RC. **J Assoc Physicians India** 1995 Jan;43(1):49–53 (62 ref.)

Neurological and developmental problems in pediatric HIV infection. Mintz M. **J Nutr** 1996 Oct;126(10 Suppl):2663S–2673S (95 ref.)

Oral candidiasis in HIV infection: predictive value and comparison of findings in injecting drug users and homosexual men. Phelan JA, et al. **J Oral Pathol Med** 1997 May;26(5):237–43

Cardiac involvement in HIV infection. Patel RC, et al. **Med Clin North Am** 1996 Nov;80(6):1493–512 (152 ref.)

Gastrointestinal manifestations. Tanowitz HB, et al. **Med Clin North Am** 1996 Nov;80(6):1395–414 (128 ref.)

Ophthalmic complications of HIV infection. Tay-Kearney ML, et al. **Med Clin North Am** 1996 Nov;80(6):1471–92 (156 ref.)

Pulmonary disease. Walker PA, et al. **Med Clin North Am** 1996 Nov;80(6):1337–62 (156 ref.)

Pediatric HIV infection. Wiznia AA, et al. **Med Clin North Am** 1996 Nov;80(6):1309–36 (206 ref.)

Pediatric aspects of AIDS. Miller CR. **Radiol Clin North Am** 1997 Sep;35(5):1191–221 (59 ref.)

No increased prevalence of adrenocortical insufficiency in human immunodeficiency virus-associated tuberculosis. Hawken MP, et al. **Tuber Lung Dis** 1996 Oct;77(5):444–8

[Neuropathogenesis of HIV infection] Araújo AD, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):335–45 (72 ref.) (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL

Treatment and prevention of opportunistic infections in patients with human immunodeficiency virus infection. Walworth CM, et al. **Adv Intern Med** 1996;41:31–84 (224 ref.)

Changing care: evidence-based decisions in HIV and cytomegalovirus therapy. Proceedings of a satellite symposium to the XI International Conference on AIDS. Vancouver, Canada, 7 July 1996. **AIDS** 1996 Nov;10 Suppl 1:S1–49

Community-acquired bacteremia in HIV-positive patients: protective benefit of co-trimoxazole [see comments] Edge MD, et al. **AIDS** 1996 Dec;10(14):1635–9. Comment in: AIDS 1997 Jul;11(8):1070–1.

Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. Foster S, et al. **AIDS** 1997 Jun;11(7):919–25

Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. Hawken MP, et al. **AIDS** 1997 Jun;11(7):875–82

Consequences for the management of cytomegalovirus. Katlama C. **AIDS** 1996 Nov;10 Suppl 1:S43–6 (15 ref.)

Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand. Ngamvithayapong J, et al. **AIDS** 1997 Jan;11(1):107–12

Does dapsone increase mortality when given for prophylaxis of Pneumocystis carinii pneumonia? [letter; comment] Opravil M, et al. **AIDS** 1996 Aug;10(9):1045–6. Comment on: AIDS 1995 Dec;9(12):1343–50.

Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients [letter] Pérez-Molina JA, et al. **AIDS** 1996 Feb;10(2):237–8

Multiple opportunistic infection prophylaxis. Powderly WG. **AIDS** 1996;10 Suppl A:S165–71 (79 ref.)

Reducing the incidence of Pneumocystis carinii pneumonia: a persisting challenge [letter] Pradier C, et al. **AIDS** 1997 May;11(6):832–3

Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. Rose DN, et al. **AIDS** 1997 Jun;11(7):883–7

Toxoplasmosis in HIV-positive women: seroprevalence and the role of prophylaxis in preventing disease [letter; comment] Ruiz R, et al. **AIDS** 1997 Jan;11(1):119–20. Comment on: AIDS 1996 May;10(5):509–13.

Prevention of Pneumocystis carinii pneumonia: who are we missing? Schwarcz SK, et al. **AIDS** 1997 Aug;11(10):1263–8

Co-trimoxazole desensitization syndrome: delayed hematologic toxicity complicating prophylactic therapy in AIDS patients [letter] Stricker RB, et al. **AIDS** 1996 Jul; 10(8):927–9

Role of trimethoprim-sulphamethoxazole in preventing HIV-associated bacteraemia [letter; comment] Tumbarello M, et al. **AIDS** 1997 Jul;11(8):1070–1. Comment on: AIDS 1996 Dec;10(14):1635–9.

Secondary Pneumocystis carinii pneumonia prophylaxis with trimethoprim-sulphamethoxazole does not prevent bacterial pneumonia in HIV-infected persons [letter] Tumbarello M, et al. **AIDS** 1996 Nov;10(13):1603–4

Cytomegalovirus retinitis: new developments in prophylaxis and therapy. Jacobson MA. **AIDS Clin Rev** 1997–98; :249–69 (44 ref.)

1997 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV: Part II. Prevention of first episode of disease. **Am Fam Physician** 1997 Sep 15;56(4):1131–46

1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with HIV: Part I. Prevention of exposure. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention. **Am Fam Physician** 1997 Sep 1;56(3):823–34

Prophylaxis of opportunistic infections in HIV/AIDS [editorial] Goldschmidt RH. **Am Fam Physician** 1997 Sep 15;56(4):1039–40

Opportunistic infections and psychosocial stress in HIV [see comments] Montauk SL, et al. **Am Fam Physician** 1997 Jul;56(1):87–96 (24 ref.). Comment in: Am Fam Physician 1997 Jul;56(1):37, 40–2.

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients [letter; comment] Laguna-del-Estal P, et al. **Am J Med** 1997 Feb;102(2):222 . Comment on: Am J Med 1996 May;100(5):496–501.

Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals [letter; comment] Pérez-Molina JA, et al. **Am J Med** 1997 Jan;102(1):132. Comment on: Am J Med 1996 May;100(5):496–501.

Skin involvement with Pneumocystis despite dapsone prophylaxis: a rare cause of skin nodules in a patient with AIDS. Bundow DL, et al. **Am J Med Sci** 1997 Mar; 313(3):182–6 (25 ref.)

Immunization of HIV-infected adults with a three-dose series of inactivated Mycobacterium vaccae. Marsh BJ, et al. **Am J Med Sci** 1997 Jun;313(6):377–83

Maintenance of chemoprophylaxis against Pneumocystis carinii despite combination antiretroviral treatment associated CD4+ T-lymphocytosis [letter] Macher AM, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1491

Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Schuman P, et al. **Ann Intern Med** 1997 May 1; 126(9):689–96

Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. Gatti G, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2743–8

Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women. Geletko SM, et al. **Antimicrob Agents Chemother** 1996 Jun; 40(6):1338–41

Inmate access to postrelease medical care: public health implications [letter; comment] Macher AM, et al. **Arch Fam Med** 1997 Jul-Aug;6(4):318. Comment on: Arch Fam Med 1994 Oct;3(10):894–8.

Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Manfredi R, et al. **Arch Intern Med** 1997 Jan 13;157(1):64–9

Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival. Moreno S, et al. **Arch Intern Med** 1997 Aug 11–25;157(15):1729–34

The continued occurrence of primary Pneumocystis carinii pneumonia despite the availability of prophylaxis. Klein MB, et al. **Clin Infect Dis** 1997 Mar;24(3):522–3

Clinical and bacteriologic impact of rifabutin prophylaxis for Mycobacterium avium complex infection in patients with human immunodeficiency virus infection. Maslo C, et al. **Clin Infect Dis** 1997 Mar;24(3):344–9

Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials Group. Rousseau F, et al. **Clin Infect Dis** 1997 Mar; 24(3):396–402

Secondary prophylaxis for tuberculosis in patients infected with human immunodeficiency virus [letter] Shuter J, et al. **Clin Infect Dis** 1996 Feb;22(2):398–9

Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. Veenstra J, et al. **Clin Infect Dis** 1997 May;24(5):936–41

USPHS and IDSA collaborate on guidelines to prevent opportunistic infections in HIV-infected persons [news] Kaplan JE, et al. **Emerg Infect Dis** 1995 Jul-Sep;1(3):102–3

Effect of long-term primary aerosolized pentamidine prophylaxis on breakthrough Pneumocystis carinii pneumonia. Ewig S, et al. **Eur Respir J** 1996 May; 9(5):1006–12

Primary and secondary prophylaxis for Pneumocystis carinii related complications in HIV patients [editorial] Held M, et al. **Eur Respir J** 1996 May;9(5):868–71 (47 ref.)

Adherence to guidelines for the prevention of HIV-related respiratory diseases. Montaner JS, et al. **Eur Respir J** 1996 Nov;9(11):2318–22

How to interpret an overview: a meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Easterbrook PJ. **Genitourin Med** 1997 Apr; 73(2):139–43

Prevention and management of tuberculosis in HIV positive patients [letter; comment] Higgins SP, et al. **Genitourin Med** 1996 Oct;72(5):387. Comment on: Genitourin Med 1996 Apr;72(2):89–92.

Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis. Pozniak A, et al. **Genitourin Med** 1996 Aug;72(4):269–71 (14 ref.)

Is rifabutin prophylaxis against Mycobacterium avium complex infection in HIV infection worthwhile? The net impact on patients suggests not. Stephenson JM, et al. **Genitourin Med** 1996 Aug;72(4):272–6 (10 ref.)

Prophylaxis against Mycobacterium avium-intracellulare complex infections in human immunodeficiency virus-infected patients. Nightingale SD. **Infection** 1997 Jan-Feb;25(1):67–70 (9 ref.)

How successful are we in administering prophylaxis against Pneumocystis carinii pneumonia (PCP) in patients with HIV infection? Knowles C, et al. **Int J STD AIDS** 1997 May;8(5):345–6

Are we preventing Pneumocystis carinii pneumonia in regular clinic attenders with HIV. Richardson C, et al. **Int J STD AIDS** 1996 Aug-Sep;7(5):372

Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis. Freedberg KA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Aug 1;15(4):275–82

Impact of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in a cohort of 1000 patients with AIDS. Monforte AD, et al. **J Chemother** 1995 Nov;7 Suppl 4:184–6

Intrapulmonary and systemic pharmacokinetics of aerosolized pentamidine used for prophylaxis of pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus. Conte JE Jr, et al. **J Clin Pharmacol** 1995 Dec;35(12):1166–73

Effect of Lactobacillus reuteri on intestinal resistance to Cryptosporidium parvum infection in a murine model of acquired immunodeficiency syndrome. Alak JI, et al. **J Infect Dis** 1997 Jan;175(1):218–21

In vitro efficacy of a compound derived from garlic against Pneumocystis carinii [letter] Abdullah TH. **J Natl Med Assoc** 1996 Nov;88(11):694, 704

Preventing opportunistic infections in persons infected with HIV: 1997 guidelines [editorial] Kaplan JE, et al. **JAMA** 1997 Jul 23-30;278(4):337–8

Physicians face new contradictions in HIV care [news] Voelker R. **JAMA** 1997 May 21;277(19):1504–5

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [see comments] Jacobson MA, et al. **Lancet** 1997 May 17;349(9063):1443–5. Comment in: Lancet 1997 Aug 23;350(9077):588; discussion 590. Comment in: Lancet 1997 Aug 23;350(9077):588–9; discussion 590. Comment in: Lancet 1997 Aug 23;350(9077):589; discussion 590. Comment in: Lancet 1997 Aug 23;350(9077):589–90.

Keep guard up against HIV-1-related lung infections, say experts [news] McCarthy M. **Lancet** 1997 May 31; 349(9065):1607

Strategies for control of tuberculosis [letter; comment] Marshall BG, et al. **Lancet** 1997 Mar 22;349(9055):882–3. Comment on: Lancet 1997 Jan 11;349(9045):71–2.

1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. **MMWR Morb Mortal Wkly Rep** 1997 Jun 27; 46(RR-12):1–46

Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. Centers for Disease Control and Prevention. **MMWR Morb Mortal Wkly Rep** 1997 Sep 5; 46(RR-15):1–10

A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. Gordin FM, et al. **N Engl J Med** 1997 Jul 31;337(5):315–20

The double burden of HIV infection and tuberculosis in sub-Saharan Africa [editorial; comment] Msamanga GI, et al. **N Engl J Med** 1997 Sep 18;337(12):849–51. Comment on: N Engl J Med 1997 Sep 18;337(12):801–8.

Oral ganciclovir as prophylaxis against cytomegalovirus [letter; comment] Nicklin D. **N Engl J Med** 1996 Oct 31; 335(18):1395; discussion 1396–7. Comment on: N Engl J Med 1996 Jun 6;334(23):1491–7.

Oral ganciclovir as prophylaxis against cytomegalovirus [letter; comment] Pulido F, et al. **N Engl J Med** 1996 Oct 31;335(18):1396; discussion 1396–7. Comment on: N Engl J Med 1996 Jun 6;334(23):1491–7.

A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration [see comments] Whalen CC, et al. **N Engl J Med** 1997 Sep 18;337(12):801–8. Comment in: N Engl J Med 1997 Sep 18;337(12):847–9. Comment in: N Engl J Med 1997 Sep 18;337(12):849–51.

Oral ganciclovir as prophylaxis against cytomegalovirus [letter; comment] Wood CA. **N Engl J Med** 1996 Oct 31; 335(18):1395; discussion 1396–7. Comment on: N Engl J Med 1996 Jun 6;334(23):1491–7.

Patterns of morbidity and mortality in AIDS patients on Pneumocystis carinii prophylaxis who died during hospital admission: a report of 50 diseased patients. Hentzen BT, et al. **Neth J Med** 1996 Sep;49(3):101–5

Penetration of dapsone into lung of human immunodeficiency virus-infected children. Gatti G, et al. **Pediatr Infect Dis J** 1997 May;16(5):523–4

Alternative dapsone dosage regimen for prophylaxis of Pneumocystis carinii pneumonia [letter] Gatti G, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):183–4

Preventing Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children: new guidelines for prophylaxis. CDC, US Public Health Service, and the Infectious Disease Society of America. Grubman S, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):165–8 (19 ref.)

Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. King JC Jr, et al. **Pediatr Infect Dis J** 1996 Mar;15(3):192–6

Active immunization in HIV-infected patients. Pau AK, et al. **Pharmacotherapy** 1996 Mar-Apr;16(2):163–70 (60 ref.)

Therapeutic options for the management and prevention of Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome. Tartaglione TA. **Pharmacotherapy** 1996 Mar-Apr;16(2):171–82 (89 ref.)

Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia. Warnock AC, et al. **Pharmacotherapy** 1996 Nov-Dec;16(6):1030–8

Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. Zeind CS, et al. **Pharmacotherapy** 1996 Jul-Aug;16(4):547–61 (127 ref.)

Prevention and treatment of common HIV-associated opportunistic complications. Carmichael C. **Prim Care** 1997 Sep;24(3):561–74 (46 ref.)

Risk of toxoplasmic encephalitis in AIDS patients: indications for prophylaxis. Dunlop O, et al. **Scand J Infect Dis** 1996; 28(1):71–3

Nebulisers for patients with HIV infection and AIDS. Miller RF, et al. **Thorax** 1997 Apr;52 Suppl 2:S60–3

Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus. Cheever LW, et al. **West J Med** 1996 Jul-Aug;165(1-2):67–73 (71 ref.)

[Prevention of herpes simplex and varicella zoster infections in patients of HIV infections] Caumes E, et al. **Ann Med Interne (Paris)** 1997;148(3):255–7 (25 ref.) (Eng. Abstr.) **(Fre)**

[Current status in the prevention of Mycobacterium avium complex infections in patients with HIV infection] Doco-Lecompte T, et al. **Ann Med Interne (Paris)** 1997; 148(2):167–71 (21 ref.) (Eng. Abstr.) **(Fre)**

[Risk factors of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention] Leport C, et al. **Ann Med Interne (Paris)** 1996;147(5):331–2 (8 ref.) (Eng. Abstr.) **(Fre)**

[Why does cerebral toxoplasmosis still occur in patients with immunodeficiency virus infection? (letter)] Bachmeyer C,

et al. **Presse Med** 1997 Mar 29;26(10):464 **(Fre)**
[Prevention of opportunistic infections in HIV seropositive patients. Prevention of parasitic infections] Casassus P, et al. **Presse Med** 1997 Mar 8;26(7):334–9 (55 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of opportunistic infections in HIV seropositive patients. Prevention of bacterial infections] Casassus P, et al. **Presse Med** 1997 Mar 8;26(7):340–3 (29 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of opportunistic infections in HIV seropositive patients. Prevention of viral infections and mycoses] Casassus P, et al. **Presse Med** 1997 Mar 8;26(7):344–7 (25 ref.) (Eng. Abstr.) **(Fre)**
[Efficacy of pyrimethamine in monotherapy for preventing toxoplasmosis in AIDS (letter)] De Truchis P, et al. **Presse Med** 1996 Jul 6–13;25(24):1125 **(Fre)**
[Management of HIV infected patients. Report of recommendations] **Rev Pneumol Clin** 1996;52(5):277–360 **(Fre)**
[Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries] Anglaret X, et al. **Sante** 1997 Mar–Apr;7(2):89–94 (38 ref.) (Eng. Abstr.) **(Fre)**
[Sex differences in disease course: analysis of the Swiss HIV cohort study] Schmid M, et al. **Schweiz Med Wochenschr** 1996 Dec 28;126(51–52):2234–6 (Eng. Abstr.) **(Ger)**
[Dapsone in the prevention of HIV-related parasitosis] Garavelli PL. **Recenti Prog Med** 1996 Jun;87(6):279 **(Ita)**
[Guidelines for the prevention of opportunistic infections in persons with HIV or AIDS in Latin America and the Caribbean. USPHS/IDSA] **Bol Oficina Sanit Panam** 1996 Nov;121(5):377–415 **(Spa)**

PSYCHOLOGY

Reasons for HIV antibody test refusal in a heterosexual sexually transmitted disease clinic population. Simon PA, et al. **AIDS** 1996 Nov;10(13):1549–53
Opportunistic infections and psychosocial stress in HIV [see comments] Montauk SL, et al. **Am Fam Physician** 1997 Jul;56(1):87–96 (24 ref.). Comment in: Am Fam Physician 1997 Jul;56(1):37, 40–2.

RADIOGRAPHY

High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. Gruden JF, et al. **AJR Am J Roentgenol** 1997 Oct; 169(4):967–75
AIDS-related airway disease. McGuinness G, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):67–77 (61 ref.)
Radiology of pulmonary tuberculosis. Rottenberg GT, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):195–9 (18 ref.)
Pleural tuberculosis in patients infected with HIV in Addis Ababa. Aderaye AG, et al. **Cent Afr J Med** 1996 Dec; 42(12):337–40
Utility of lactate dehydrogenase vs radiographic severity in the differential diagnosis of Pneumocystis carinii pneumonia. Boldt MJ, et al. **Chest** 1997 May;111(5):1187–92
Neuroimaging findings in patients with AIDS. Walot I, et al. **Clin Infect Dis** 1996 Jun;22(6):906–19 (44 ref.)
Lobar or segmental consolidation on chest radiographs of patients with HIV infection. Amin Z, et al. **Clin Radiol** 1997 Jul;52(7):541–5
High resolution computed tomography in HIV patients with suspected Pneumocystis carinii pneumonia and a normal chest radiograph. Richards PJ, et al. **Clin Radiol** 1996 Oct; 51(10):689–93
Case report: fulminant Toxoplasma gondii pneumonia in a patient with AIDS. Rottenberg GT, et al. **Clin Radiol** 1997 Jun;52(6):472–4
Management protocol for an enhancing cerebral lesion in HIV infection. Finelli PF. **Conn Med** 1996 Nov; 60(11):649–51
Cavitary cryptococcoma of the lungs and meningitis by Cryptococcus neoformans in a patient with AIDS. Schubert S, et al. **Eur J Med Res** 1997 Apr 21;2(4):173–6
Radiological findings in nine AIDS patients with Rhodococcus equi pneumonia. Wicky S, et al. **Eur Radiol** 1996;6(6):826–30
Radiology of pulmonary turberculosis and human immunodeficiency virus infection in Gulu, Uganda. Awil PO, et al. **Eur Respir J** 1997 Mar;10(3):615–8
Condyloma acuminatum of the bladder in a patient with AIDS: radiological findings. Jimenez Lasanta JA, et al. **J Clin Ultrasound** 1997 Jul–Aug;25(6):338–40
Mycobacterium tuberculosis versus nontuberculous mycobacterial infection of the lung in AIDS patients: CT and HRCT patterns. Laissy JP, et al. **J Comput Assist Tomogr** 1997 Mar–Apr;21(2):312–7
Aspergillus mastoiditis in a patient with acquired immunodeficiency syndrome. Yates PD, et al. **J Laryngol Otol** 1997 Jun;111(6):560–1
Chest radiograph interpretation of Pneumocystis carinii pneumonia, bacterial pneumonia, and pulmonary tuberculosis in HIV-positive patients: accuracy, distinguishing features, and mimics. Boiselle PM, et al. **J Thorac Imaging** 1997 Jan;12(1):47–53
Dense Rhodococcus cerebral abscesses in an HIV-positive patient. Perrymore WD, et al. **Neuroradiology** 1997 Aug; 39(8):581–2
Tuberculosis in children with acquired immunodeficiency syndrome. Haller JO, et al. **Pediatr Radiol** 1997 Feb; 27(2):186–8 (12 ref.)
Interpretation of chest radiographs in AIDS patients: usefulness of CD4 lymphocyte counts [published erratum appears in Radiographics 1997 May-Jun;17(3):804] Shah RM, et al. **Radiographics** 1997 Jan–Feb;17(1):47–58; discussion 59–61
Mycobacterium kansasii pulmonary infection in patients with AIDS: spectrum of chest radiographic findings. Fishman JE, et al. **Radiology** 1997 Jul;204(1):171–5
Cytomegalovirus pneumonia manifesting as a focal mass in acquired immunodeficiency syndrome. Fishman JE, et al. **South Med J** 1996 Nov;89(11):1121–2
[AIDS-associated illnesses in radiologic diagnosis: overview and differential diagnosis] Rademaker J, et al. **Aktuelle Radiol** 1997 Mar;7(2):69–73 (30 ref.) **(Ger)**
[Computerized tomography of AIDS associated thoracic diseases] Bankier AA, et al. **Radiologe** 1996 Jul;36(7):543–9 (16 ref.) (Eng. Abstr.) **(Ger)**
[Fever and pulmonary nodules in patients with HIV infection] Roig R, et al. **Enferm Infecc Microbiol Clin** 1997 Jan;15(1):41–2 **(Spa)**

RADIONUCLIDE IMAGING

The role of nuclear medicine in the investigation of patients with AIDS. Prvulovich EM, et al. **Br J Hosp Med** 1996 May 1–14;55(9):549–53 (19 ref.)
Thallium-201 single photon emission computed tomography in the management of contrast-enhancing brain lesions in a patient with AIDS. Gianotti N, et al. **Clin Infect Dis** 1996 Jul;23(1):185–6
Disseminated mycobacterium avium complex. Review of Ga-67 and TI-201 scans and autopsy findings. Abdel-Dayem HM, et al. **Clin Nucl Med** 1996 Jul; 21(7):547–56
Radioactively labelled diethylene triamine penta acetate lung scan in Pneumocystis carinii pneumonia and asymptomatic HIV-positive patients. Dimian CO, et al. **Int J STD AIDS** 1997 Aug;8(8):482–8
Evaluation of sequential thallium and gallium scans of the chest in AIDS patients. Abdel-Dayem HM, et al. **J Nucl Med** 1996 Oct;37(10):1662–7
Thallium-201 uptake in cytomegalovirus encephalitis. Gorniak RJ, et al. **J Nucl Med** 1997 Sep;38(9):1386–8
Rapid differential diagnosis of cerebral toxoplasmosis and primary central nervous system lymphoma by thallium-201 SPECT. Lorberboym M, et al. **J Nucl Med** 1996 Jul; 37(7):1150–4
[Cerebral SPECT with thallium-201 in the differential diagnosis of focal cerebral lesions in patients with AIDS] Sanjaume M, et al. **Enferm Infecc Microbiol Clin** 1997 Jan; 15(1):28–31 (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Radiation therapy in AIDS-related cutaneous Kaposi's sarcoma. Conill C, et al. **Dermatology** 1997;195(1):40–2

REHABILITATION

Transtibial prosthesis for a patient with Kaposi's sarcoma lesions on the residual limb. Ethans KD, et al. **Arch Phys Med Rehabil** 1997 Jan;78(1):106–8

SURGERY

Transtibial prosthesis for a patient with Kaposi's sarcoma lesions on the residual limb. Ethans KD, et al. **Arch Phys Med Rehabil** 1997 Jan;78(1):106–8
Surgery for tuberculosis before and after human immunodeficiency virus infection: a tropical perspective. Watters DA. **Br J Surg** 1997 Jan;84(1):8–14 (94 ref.)
Actinomycetoma of the phalanx in an immunocompromised patient: a case report. Kocher MS, et al. **J Hand Surg [Am]** 1996 May;21(3):515–7
Thoracoscopy in acquired immunodeficiency syndrome. Flum DR, et al. **J Thorac Cardiovasc Surg** 1997 Sep; 114(3):361–6

THERAPY

Treatment and prevention of opportunistic infections in patients with human immunodeficiency virus infection. Walworth CM, et al. **Adv Intern Med** 1996;41:31–84 (224 ref.)
Diagnosis and treatment of esophageal diseases associated with HIV infection. Practice Parameters Committee of the American College of Gastroenterology. Dieterich DT, et al. **Am J Gastroenterol** 1996 Nov;91(11):2265–9 (76 ref.)
Ophthalmology: the role of the non-specialist [editorial] Davey CC. **Br J Hosp Med** 1996 Feb 7–20;55(3):84
The eye in AIDS. Lightman S, et al. **Br J Hosp Med** 1996 Feb 7–20;55(3):95–99 (19 ref.)
Variations in medical care for HIV-related Pneumocystis carinii pneumonia: a comparison of process and outcome at two hospitals. Curtis JR, et al. **Chest** 1997 Aug; 112(2):398–405
Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. Campo RE, et al. **Clin Infect Dis** 1997 Jun;24(6):1233–8
Catheter-related bacteremia due to Mycobacterium avium complex. Dubé MP, et al. **Clin Infect Dis** 1996 Aug; 23(2):405–6
Destructive mucocutaneous phagedenic herpes simplex virus infection in an HIV-infected patient who had a partial response to interferon and ultraviolet rays. Giani G, et al. **Clin Infect Dis** 1996 Feb;22(2):381–2
Diagnosis and treatment of infectious diseases in HIV-infected hosts. Castano-Molina C, et al. **Dermatol Clin** 1997 Apr;15(2):267–83 (197 ref.)
Uptake of medical interventions in women with HIV infection in Britain and Ireland. Study Group for the MRC Collaborative Study of HIV Infection in Women. Mercey D, et al. **Genitourin Med** 1996 Aug;72(4):281–2
Management of HIV-related diarrhoea. Neild PJ, et al. **Int J STD AIDS** 1997 May;8(5):286–96; quiz 296–7 (71 ref.)
Chronic and aggressive plantar verrucae in a patient with HIV. Soltani SK, et al. **J Am Podiatr Med Assoc** 1996 Nov;86(11):555–8
Interferon alfa treatment of a patient with eosinophilic cellulitis and HIV infection [letter] Husak R, et al. **N Engl J Med** 1997 Aug 28;337(9):641–2
Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection [letter] Power C, et al. **N Engl J Med** 1997 Feb 27;336(9):661–2
Hyperfocal cryotherapy of multiple Molluscum contagiosum lesions in patients with the acquired immune deficiency syndrome. Bardenstein DS, et al. **Ophthalmology** 1995 Jul; 102(7):1031–4
[Focusing on therapy of systemic mycoses] **Internist (Berl)** 1995 Dec;36(12 Suppl):1–12 **(Ger)**
[The use of hyperimmune anti-cytomegalovirus immunoglobulins in HIV infection] Mancuso S, et al. **Recenti Prog Med** 1996 Jun;87(6):267–70 (Eng. Abstr.) **(Ita)**
[A case of AIDS with intractable cryptococcal meningitis] Konishi M, et al. **Kansenshogaku Zasshi** 1996 Jul; 70(7):752–6 (Eng. Abstr.) **(Jpn)**
[Clinical course of HIV-infected tuberculosis patients who admitted to the tuberculosis isolation ward: current problems of medical care] Fujita A, et al. **Kekkaku** 1997 Feb;72(2):67–72 (Eng. Abstr.) **(Jpn)**
[The treatment of chronic hepatitis C with interferon in patients infected with the human immunodeficiency virus. The Spanish Group for the Study of Viral Hepatitis in HIV+ Patients] Soriano V, et al. **Med Clin (Barc)** 1996 Apr 6;106(13):486–90 (64 ref.) (Eng. Abstr.) **(Spa)**
[Proposal of a rule for deciding the therapeutic option in chronic hepatitis C in HIV-infected patients. Spanish Group for the Study of Viral Hepatitis in HIV-infected Patients] Soriano V, et al. **Rev Clin Esp** 1996 Jul; 196(7):488–91 **(Spa)**

TRANSMISSION

The influence of intravenous drug use and HIV infection in the transmission of tuberculosis [letter] Caylà JA, et al. **AIDS** 1996 Oct;10(12):1446–7
The influence of intravenous drug use and HIV infection in the transmission of tuberculosis [letter; comment] Collazos J, et al. **AIDS** 1996 Oct;10(12):1445–6. Comment on: AIDS 1996 Jan;10(1):95–100.
Oral transmission of Candida albicans between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates. Dromer F, et al. **AIDS** 1997 Jul 15;11(9):1095–101
Recent transmission of tuberculosis in a cohort of HIV-1-infected female sex workers in Nairobi, Kenya. Gilks CF, et al. **AIDS** 1997 Jun;11(7):911–8
Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room [letter; comment] Singh G. **AIDS** 1996 Nov;10(13):1609. Comment on: AIDS 1996 May;10(5):521–5.
Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain. Rullán JV, et al. **Emerg Infect Dis** 1996 Apr–Jun;2(2):125–9
Injecting drug use as risk factor for visceral leishmaniasis in AIDS patients. Amela C, et al. **Eur J Epidemiol** 1996 Feb;12(1):91–2
Simian immunodeficiency virus-inoculated macaques acquire Mycobacterium avium from potable water during AIDS. Mansfield KG, et al. **J Infect Dis** 1997 Jan;175(1):184–7
Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires [see comments] Ritacco V, et al. **J Infect Dis** 1997 Sep;176(3):637–42. Comment in: J Infect Dis 1997 Sep;176(3):748–51.
Tuberculosis and HIV infection in southern Africa. Blumberg L. **Natl Med J India** 1996 Jul–Aug;9(4):189–90
No evidence of nosocomial Pneumocystis carinii infection via health care personnel. Lidman C, et al. **Scand J Infect Dis** 1997;29(1):63–4
Social scientists and the new tuberculosis. Farmer P. **Soc Sci Med** 1997 Feb;44(3):347–58
[Atypical mycoses--also a sequela of medical progress (interview by Dr. rer. nat. Anita Schweiger)] Mayser P. **Fortschr Med** 1996 Aug 20;114(22–23):14–5 **(Ger)**
[Sexually transmitted diseases in HIV infection] Hartmann M, et al. **Hautarzt** 1997 Mar;48(3):206–13; quiz 213 (90 ref.) **(Ger)**

ULTRASONOGRAPHY

Cardiovascular involvement during HIV infection [letter]

Valdes EF, et al. **Eur Heart J** 1996 Oct;17(10):1605

Splenic pneumocystosis in AIDS: unusual ultrasound appearances. Harvey CJ, et al. **Int J STD AIDS** 1997 May; 8(5):342–4

Abdominal ultrasound findings of disseminated tuberculosis in AIDS. Monill-Serra JM, et al. **J Clin Ultrasound** 1997 Jan;25(1):1–6

[Subcutaneous and soft tissue involvement associated with AIDS: ultrasonographic aspects. Apropos of 3 cases] N'Gbesso RD, et al. **Sante** 1996 Jul–Aug;6(4):245–8 (Eng. Abstr.) **(Fre)**

VIROLOGY

Coinfection of the central nervous system by cytomegalovirus and herpes simplex virus type 1 or 2 in AIDS patients: autopsy study on 82 cases by immunohistochemistry and polymerase chain reaction. Vago L, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):404–8

A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS: longitudinal molecular analysis of the CMV viral load and viral mutations in blood compartments. Boivin G, et al. **AIDS** 1997 Jun;11(7):867–73

Risk factors associated with Epstein-Barr virus replication in oral epithelial cells of HIV-infected individuals. Boulter AW, et al. **AIDS** 1996 Aug;10(9):935–40

Predictors of cytomegalovirus disease, natural history and autopsy findings in a cohort of patients with AIDS. d'Arminio Monforte A, et al. **AIDS** 1997 Mar 15; 11(4):517–24

Detection of Kaposi's sarcoma herpesvirus DNA in semen of homosexual men with Kaposi's sarcoma [letter] Gupta P, et al. **AIDS** 1996 Nov;10(13):1596–8

Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. Moore PS, et al. **AIDS** 1996 Feb;10(2):175–80

Corrected prevalence of Kaposi's sarcoma (KS)-associated herpesvirus infection prior to onset of KS [letter] Parry JP, et al. **AIDS** 1997 Jan;11(1):127–8

Human herpesvirus type 8 DNA sequences in biological samples of HIV-positive and negative individuals in Sicily. Viviano E, et al. **AIDS** 1997 Apr;11(5):607–12

Asymptomatic shedding of HSV in patients with AIDS. Apgar B. **Am Fam Physician** 1997 Sep 1;56(3):910

Kaposi's sarcoma-associated herpesvirus and human herpesvirus 8 (KSHV/HHV8)-associated lymphoma of the bowel. Report of two cases in HIV-positive men with secondary effusion lymphomas. DePond W, et al. **Am J Surg Pathol** 1997 Jun;21(6):719–24

Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Ometto L, et al. **Blood** 1997 Jul 1; 90(1):313–22

Cytomegalovirus as a primary pulmonary pathogen in AIDS. Waxman AB, et al. **Chest** 1997 Jan;111(1):128–34

Kaposi's sarcoma herpesvirus-like DNA sequences in the saliva of individuals infected with human immunodeficiency virus. Boldogh I, et al. **Clin Infect Dis** 1996 Aug;23(2):406–7

Polyvisceral cytomegalovirus (CMV) disease revealed by CMV-induced necrotizing bronchitis in a patient with AIDS. Cabié A, et al. **Clin Infect Dis** 1996 Jan;22(1):181–2

Rapidly progressive outer retinal necrosis caused by varicella zoster virus in a patient infected with human immunodeficiency virus. Galindez OA, et al. **Clin Infect Dis** 1996 Jan;22(1):149–51

Human immunodeficiency virus infection is a major risk factor for detection of human papillomavirus DNA in esophageal brushings. Trottier AM, et al. **Clin Infect Dis** 1997 Apr;24(4):565–9

Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus. van Elsacker-Neile AM, et al. **Clin Infect Dis** 1996 Dec;23(6):1255–60 (28 ref.)

Inoculation herpes simplex virus infections in patients with AIDS: unusual appearance and location of lesions. Weaver G, et al. **Clin Infect Dis** 1996 Jan;22(1):141–2

Focal epithelial hyperplasia (Heck disease) associated with AIDS. Viraben R, et al. **Dermatology** 1996;193(3):261–2

Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS. Chang Y, et al. **Infect Agents Dis** 1996 Oct; 5(4):215–22 (71 ref.)

High prevalence of opportunistic infections in the head and neck related to human immunodeficiency virus. A prospective study of the distribution of otorhinolaryngologic disorders in 250 patients. Riederer AP, et al. **Infection** 1996 Nov-Dec;24(6):440–6 (43 ref.)

Quantitation of cytomegalovirus (CMV) DNA in leukocytes of human immunodeficiency virus-infected subjects with and without CMV disease by using PCR and the SHARP Signal Detection System. Boivin G, et al. **J Clin Microbiol** 1997 Feb;35(2):525–6

Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. Dubois V, et al. **J Clin Microbiol** 1997 Sep;35(9):2288–92

Detection of human Betaherpesvirinae in saliva and urine from immunocompromised and immunocompetent subjects. Gautheret-Dejean A, et al. **J Clin Microbiol** 1997 Jun;35(6):1600–3

Evaluation of the Digene Hybrid Capture System for detection and quantitation of human cytomegalovirus viremia in human immunodeficiency virus-infected patients. Mazzulli T, et al. **J Clin Microbiol** 1996 Dec; 34(12):2959–62

Herpetic syringitis associated with eccrine squamous syringometaplasia in HIV-positive patients. Muñoz E, et al. **J Cutan Pathol** 1997 Aug;24(7):425–8

Quantification of human herpesvirus 6 in immunocompetent persons and post-mortem tissues from AIDS patients by PCR. Clark DA, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2271–5

Infection with AIDS-related herpesviruses in human immunodeficiency virus-negative infants and endemic childhood Kaposi's sarcoma in Africa. Kasolo FC, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):847–55

Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. Chou S, et al. **J Infect Dis** 1997 Sep;176(3):786–9

Absence of detectable human herpesvirus 8 in the semen of human immunodeficiency virus-infected men without Kaposi's sarcoma. Diamond C, et al. **J Infect Dis** 1997 Sep; 176(3):775–7

Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. Erice A, et al. **J Infect Dis** 1997 May;175(5):1087–92

Analysis of human herpesvirus type 8 infection in AIDS-related and AIDS-unrelated primary central nervous system lymphoma. Gaidano G, et al. **J Infect Dis** 1997 May;175(5):1193–7

Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. Hagensee ME, et al. **J Infect Dis** 1997 Sep;176(3):625–31

The impact of active herpes simplex virus infection on human immunodeficiency virus load. Mole L, et al. **J Infect Dis** 1997 Sep;176(3):766–70

Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients. Rasmussen L, et al. **J Infect Dis** 1997 Jan;175(1):179–84

Human herpesvirus 8 DNA sequences in CD8+ T cells [letter; comment] Sirianni MC, et al. **J Infect Dis** 1997 Aug; 176(2):541. Comment on: J Infect Dis 1996 Nov;174(5):1101–5.

Epstein-Barr virus and human herpesvirus 8 prevalence in human immunodeficiency virus-associated oral mucosal lesions. Webster-Cyriaque J, et al. **J Infect Dis** 1997 Jun; 175(6):1324–32

JC virus detection in the cerebrospinal fluid of AIDS patients with progressive multifocal leucoencephalopathy and monitoring of the antiviral treatment by a PCR method. Matsiota-Bernard P, et al. **J Med Microbiol** 1997 Mar; 46(3):256–9

Coinfection of individual leukocytes with human cytomegalovirus and human immunodeficiency virus is a rare event in vivo. Bertram S, et al. **J Med Virol** 1996 Aug;49(4):283–8

Seroepidemiology of new AIDS-associated adenoviruses among the San Francisco Men's Health Study. Crawford-Miksza L, et al. **J Med Virol** 1996 Nov; 50(3):230–6

Comprehensive investigation of the presence of JC virus in AIDS patients with and without progressive multifocal leukoencephalopathy. Ferrante P, et al. **J Med Virol** 1997 Jul;52(3):235–42

Detection of human herpes virus 6 in AIDS-associated retinitis by means of in situ hybridization, polymerase chain reaction and immunohistochemistry. Fillet AM, et al. **J Med Virol** 1996 Aug;49(4):289–95

Human herpesvirus-6 reactivation in a longitudinal study of two HIV-1 infected patients. Iuliano R, et al. **J Med Virol** 1997 Apr;51(4):259–64

Molecular analysis of mixed infection with hepatitis C virus and human immunodeficiency virus in a patient infected simultaneously. Mazza C, et al. **J Med Virol** 1996 Nov; 50(3):276–82

Significance of cytomegalovirus (CMV)-pp65 antigenemia in the diagnosis of CMV disease in human immunodeficiency virus-infected patients. Reynes J, et al. **J Med Virol** 1996 Jul;49(3):195–8

Human herpesvirus 6 polymerase chain reaction findings in human immunodeficiency virus associated neurological disease and multiple sclerosis. Liedtke W, et al. **J Neurovirol** 1995 Sep;1(3-4):253–8

Cellular localization of human herpesvirus-6 in the brains of children with AIDS encephalopathy [see comments] Saito Y, et al. **J Neurovirol** 1995 Mar;1(1):30–9. Comment in: J Neurovirol 1995 Sep;1(3-4):321.

Capsid protein VP1 deletions in JC virus from two AIDS patients with progressive multifocal leukoencephalopathy. Stoner GL, et al. **J Neurovirol** 1995 Jun;1(2):189–94

The expression of hepatitis B virus polymerase in hepatocytes during chronic HBV infection. McGarvey MJ, et al. **J Viral Hepat** 1996 Mar;3(2):67–73

Identification, expression, and immunogenicity of Kaposi's sarcoma-associated herpesvirus-encoded small viral capsid antigen. Lin SF, et al. **J Virol** 1997 Apr;71(4):3069–76

A single 13-kilobase divergent locus in the Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genome contains nine open reading frames that are homologous to or related to cellular proteins. Nicholas J, et al. **J Virol** 1997 Mar;71(3):1963–74

Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. Staskus KA, et al. **J Virol** 1997 Jan;71(1):715–9

Strain variability among Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genomes: evidence that a large cohort of United States AIDS patients may have been infected by a single common isolate. Zong JC, et al. **J Virol** 1997 Mar;71(3):2505–11

In situ detection of human cytomegalovirus DNA in gastrointestinal biopsies from AIDS patients by means of various PCR-derived methods. Musso O, et al. **J Virol Methods** 1996 Feb;56(2):125–37

Gastrointestinal manifestations of HIV infection [letter; comment] Cunliffe NA, et al. **Lancet** 1996 Oct 12; 348(9033):1037. Comment on: Lancet 1996 Aug 10;348(9024):379–83.

Antibodies to human herpesvirus 8 in women and infants born in Haiti and the USA [letter] Goedert JJ, et al. **Lancet** 1997 May 10;349(9062):1368

Viral infections in human immunodeficiency virus disease. Cavert W. **Med Clin North Am** 1997 Mar;81(2):411–26 (85 ref.)

Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial neoplasia in women infected with the human immunodeficiency virus. Chiasson MA, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):690–4

Kaposi's sarcoma-associated herpesvirus-like DNA sequences (KSHV/HHV-8) in oral AIDS-Kaposi's sarcoma: a PCR and clinicopathologic study. Flaitz CM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):259–64

Relationship of cytomegalovirus to salivary gland dysfunction in HIV-infected patients. Greenberg MS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Mar;83(3):334–9

Cytomegalovirus myelitis in a child infected with human immunodeficiency virus type 1. Marriage SC, et al. **Pediatr Infect Dis J** 1996 Jun;15(6):549–51

Polymerase chain reaction to monitor repair of the HBV genome, the first step in viral replication. Maillard P, et al. **Res Virol** 1996 Jan-Feb;147(1):5–16

Polymerase chain reaction detection of cytomegalovirus and human immunodeficiency virus-1 in the retina of patients with acquired immune deficiency syndrome with and without cotton-wool spots. González CR, et al. **Retina** 1996;16(4):305–11

Human herpes virus-8 DNA in bronchoalveolar lavage samples from patients with AIDS-associated pulmonary Kaposi's sarcoma. Benfield TL, et al. **Scand J Infect Dis** 1997;29(1):13–6

Chronic intestinal infection due to subgenus F type 40 adenovirus in a patient with AIDS. Dionisio D, et al. **Scand J Infect Dis** 1997;29(3):305–7

Macrophages as a source of HIV during opportunistic infections. Orenstein JM, et al. **Science** 1997 Jun 20; 276(5320):1857–61

HHV-8: a new herpesvirus associated with Kaposi's sarcoma. Offermann MK. **Trends Microbiol** 1996 Oct;4(10):383–6 (51 ref.)

Characterization of a chemokine receptor-related gene in human herpesvirus 8 and its expression in Kaposi's sarcoma. Guo HG, et al. **Virology** 1997 Feb 17;228(2):371–8

Kaposi's sarcoma-associated herpesvirus (KSHV): a new viral pathogen associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Said J. **West J Med** 1997 Jul;167(1):37–8

[Herpes simplex virus and varicella-zoster virus infections in HIV-infected patients] Leport C, et al. **Presse Med** 1997 Jan;26 Suppl 1:10–2 (19 ref.) **(Fre)**

[Cytomegalovirus colitis in AIDS] Bassetti S. **Schweiz Rundsch Med Prax** 1997 Apr 9;86(15):630–1 **(Ger)**

[Kaposi sarcoma-associated herpesvirus; human herpesvirus 8] Kemény L, et al. **Orv Hetil** 1997 Apr 20;138(16):979–83 (49 ref.) (Eng. Abstr.) **(Hun)**

[Incidence of HPV and CIN in HIV positive women] Zarcone R, et al. **Minerva Ginecol** 1995 Nov;47(11):477–80 (Eng. Abstr.) **(Ita)**

[Management of viral hepatitis in patients with HIV infection] Soriano V, et al. **Rev Clin Esp** 1996 Jul;196(7):479–87 (183 ref.) **(Spa)**

AIDS SEROCONVERSION see **HIV SEROPOSITIVITY**

AIDS SERODIAGNOSIS

see related
HIV SEROPREVALENCE

The future of prenatal HIV testing. Minkoff H, et al. **Acta Paediatr Suppl** 1997 Jun;421:72–7 (36 ref.)

Identification of HIV infection in pregnancy: another era. Saba J. **Acta Paediatr Suppl** 1997 Jun;421:65–6

Promoting HIV prevention: a problem identification approach to interventions in post-HIV test counselling. Norton J, et al. **AIDS Care** 1997 Jun;9(3):345–53

The role of HIV counseling and testing in the developing world. Campbell CH Jr, et al. **AIDS Educ Prev** 1997 Jun; 9(3 Suppl):92–104 (44 ref.)

Concepts, goals, and techniques of counseling: review and implications for HIV counseling and testing. Sikkema KJ, et al. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):14–26 (55 ref.)

Partner notification for HIV prevention: a critical reexamination. West GR, et al. **AIDS Educ Prev** 1997 Jun; 9(3 Suppl):68–78 (60 ref.)

A balancing act: the tension between case-finding and

primary prevention strategies in New York State's voluntary HIV counseling and testing program in women's health care settings. Healton C, et al. **Am J Prev Med** 1996 Jul–Aug;12(4 Suppl):53–60

Prevalence of human immunodeficiency virus in the trauma emergency room. Fröschle G, et al. **Arch Orthop Trauma Surg** 1996;115(6):337–8

HIV risk behaviour and HIV testing of psychiatric patients in Melbourne. Thompson SC, et al. **Aust N Z J Psychiatry** 1997 Aug;31(4):566–76

Testing for HIV without specific consent: a short review. Magnusson RS. **Aust N Z J Public Health** 1996 Feb; 20(1):57–60 (33 ref.)

False negative ELISA in an Indian truck driver with AIDS. Varma S, et al. **J Assoc Physicians India** 1996 Apr; 44(4):281–2

CDA approves HIV testing guidelines [news] **J Can Dent Assoc** 1997 May;63(5):332

HIV testing in developing countries [letter; comment] Colebunders R, et al. **Lancet** 1997 Apr 26;349(9060):1258 . Comment on: Lancet 1997 Mar 1;349(9052):650.

Preoperative testing for HIV: a survey of surgeons' attitudes and practices [letter] Danziger R, et al. **Lancet** 1996 Oct 12;348(9033):1036–7

Evaluation of enzyme-linked immunosorbent assay for the serodiagnosis of tuberculosis in patients with AIDS in Cuba. Montoro E, et al. **Mem Inst Oswaldo Cruz** 1996 Mar–Apr;91(2):191

The times they are a-changin' [editorial] Slobodien HD. **N J Med** 1996 Sep;93(9):19–20

Factors associated with HIV testing among sexually active adolescents: a Massachusetts survey. Samet JH, et al. **Pediatrics** 1997 Sep;100(3 Pt 1):371–7

Characterization of the epidemiological process of HIV infection using some immunological markers. Neguţ EA, et al. **Roum Arch Microbiol Immunol** 1996 Apr–Jun; 55(2):89–106

HIV confirmation and counselling in the insurance industry [letter; comment] Barker EM. **S Afr Med J** 1997 Feb; 87(2):173–4. Comment on: S Afr Med J 1996 Nov;86(11):1430.

HIV confirmation and counselling in the insurance industry [letter] Lockyer IK. **S Afr Med J** 1997 Feb;87(2):174

Predictors of condom use and human immunodeficiency virus test seeking among women living in inner-city public housing developments. Heckman TG, et al. **Sex Transm Dis** 1996 Sep–Oct;23(5):357–65

Hepatitis B markers in men seeking human immunodeficiency virus antibody testing in Mexico City. Juárez-Figueroa LA, et al. **Sex Transm Dis** 1997 Apr;24(4):211–7

Patterns and trends of sexual behavior, HIV testing, and HIV prevalence among all sexually transmitted disease clinic attenders in Denmark. Smith E, et al. **Sex Transm Dis** 1994 Mar–Apr;21(2):97–102

HIV testing history among gay/bisexual men recruited in Barcelona: evidence of high levels of risk behavior among self-reported HIV + men. Wang J, et al. **Soc Sci Med** 1997 Feb;44(4):469–77

[Results of screening for HIV antibodies in pregnant women in Amsterdam reference stations, 1988–1995] Bindels PJ, et al. **Ned Tijdschr Geneeskd** 1996 Nov 16;140(46):2296–8 (Eng. Abstr.) **(Dut)**

[Specificity of a new test for detection of antibodies to HIV-1/-2 in blood donors] Saadé C, et al. **Infusionsther Transfusionsmed** 1996 Jun;23(3):133–7 (Eng. Abstr.) **(Ger)**

[Five hospitals and one patient in need for hip surgery] Hjort H. **Tidsskr Nor Laegeforen** 1996 Aug 30;116(20):2485–6 **(Nor)**

[AIDS and immigration (letter)] Wessel I. **Tidsskr Nor Laegeforen** 1997 May 30;117(14):2073 **(Nor)**

[The serological diagnosis of HIV/AIDS in children] Leshchinskaia NP. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov–Dec;(6):86–90 (50 ref.) **(Rus)**

ECONOMICS

On-site HIV testing in resource-poor settings: is one rapid test enough? Wilkinson D, et al. **AIDS** 1997 Mar; 11(3):377–81

Publicly funded HIV counseling and testing in the United States, 1992–1995. Weber JT, et al. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):79–91

A cost-benefit analysis of voluntary routine HIV-antibody testing for hospital patients. La Croix SJ, et al. **Soc Sci Med** 1996 May;42(9):1259–72

HISTORY

10th anniversary of the National Reference Laboratory on AIDS in the Czech Republic. Bruckova M, et al. **Cent Eur J Public Health** 1995 Nov;3(4):202–4

INSTRUMENTATION

Advances in HIV testing technology and their potential impact on prevention. Kassler WJ. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):27–40 (40 ref.)

LEGISLATION & JURISPRUDENCE

Testing testing. Schneider CE. **Hastings Cent Rep** 1997 Jul–Aug;27(4):22–3

Home test system for HIV approved by FDA [news] **J Psychosoc Nurs Ment Health Serv** 1996 Aug;34(8):9

Informed consent is required for HIV testing [news] **Minn Med** 1996 Nov;79(11):36

METHODS

Detection of HIV infection during window period using polyclonal B-cell activation test [letter] Jehuda-Cohen T, et al. **AIDS** 1997 Jan;11(1):124–5

Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras. Stetler HC, et al. **AIDS** 1997 Mar;11(3):369–75

Home screening kit for HIV approved [news] **AORN J** 1996 Oct;64(4):587

Screening for HIV seropositive blood - a critical evaluation. Verma A, et al. **Indian J Pathol Microbiol** 1995 Apr; 38(2):163–8

Performance of a rapid, on-site human immunodeficiency virus antibody assay in public health settings [letter; comment] Arya SC. **J Clin Microbiol** 1996 Jun;34(6):1600 . Comment on: J Clin Microbiol 1995 Nov;33(11):2899–902.

Flow cytometric immunofluorescence assay for detection of antibodies to human immunodeficiency virus type 1 using insoluble precursor forms of recombinant polyproteins as carriers and antigens. Hu YW, et al. **J Clin Microbiol** 1996 Jun;34(6):1412–9

Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assay. Kline RL, et al. **J Clin Microbiol** 1996 Nov;34(11):2650–3

Further evaluation of alternative strategy for HIV testing in India. Chattopadhya D, et al. **J Commun Dis** 1996 Sep; 28(3):158–62

HIV testing in the home [news] **J Community Health Nurs** 1997;14(1):67

Evaluation of a new third generation anti-HIV-1/anti-HIV-2 assay with increased sensitivity for HIV-1 group O. van Binsbergen J, et al. **J Virol Methods** 1996 Jul;60(2):131–7

Low-tech HIV-1 test introduced in Kenya [news] Kigotho AW. **Lancet** 1997 Sep 13;350(9080):789

IgE-based assay for early detection of HIV-1 infection in infants [letter] Miguez-Burbano MJ, et al. **Lancet** 1997 Sep 13;350(9080):782–3

Indeterminate results of HIV testing: explanation and clinical management. Elliot BC, et al. **Med Health R I** 1996 Oct; 79(10):360–2

Dried blood spots collected on filter paper: an international resource for the diagnosis and genetic characterization of human immunodeficiency virus type-1. Cassol SA, et al. **Mem Inst Oswaldo Cruz** 1996 May-Jun;91(3):351–8

Advantage of dimeric peptide antigens in serodiagnosis of HIV-1 infection. Gokulan K, et al. **Microbiol Immunol** 1997;41(3):215–20

The use of radioimmune western blotting to evaluate indeterminate western blotting results in blood donor HIV serodiagnosis. Portincasa P, et al. **New Microbiol** 1997 Jul; 20(3):277–81

Use of human immunodeficiency virus (HIV) type 1 and 2 recombinant strip immunoblot assay to resolve enzyme immunoassay anti-HIV-2-repeatably reactive samples after anti-HIV-1/2 combination enzyme immunoassay screening. Tobler LH, et al. **Transfusion** 1997 Sep; 37(9):921–5

False negative anti-HIV-1/HIV-2 ELISAs in acute HIV-2 infection. Christiansen CB, et al. **Vox Sang** 1996;70(3):144–7

PSYCHOLOGY

On returning for one's HIV test result: demographic, behavioral and psychological predictors [letter] Bell RA, et al. **AIDS** 1997 Feb;11(2):263–4

HIV-positive patient's choice of a significant other to be informed about the HIV-test result: findings from an HIV/AIDS counselling programme in the regional hospitals of Arusha and Kilimanjaro, Tanzania. Lie GT, et al. **AIDS Care** 1996 Jun;8(3):285–96

Sexual risk and HIV-testing behaviour by gay and bisexual men in Canada. Myers T, et al. **AIDS Care** 1996 Jun; 8(3):297–309

Understanding the intention of gay and bisexual men to take the HIV antibody test. Godin G, et al. **AIDS Educ Prev** 1997 Feb;9(1):31–41

It's like a regular part of gay life: repeat HIV antibody testing among gay and bisexual men. Kalichman SC, et al. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):41–51

Behavioral risks for HIV infection associated with HIV-testing decisions. Miller KS, et al. **AIDS Educ Prev** 1996 Oct;8(5):394–402

The effects of HIV counseling and testing on risk-related practices and help-seeking behavior. Wolitski RJ, et al. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):52–67 (45 ref.)

Predictors of follow-through on plans to be tested for HIV. Phillips KA, et al. **Am J Prev Med** 1997 May-Jun; 13(3):193–8

HIV-positive women living in the metropolitan Toronto area: their experiences and perceptions related to HIV testing. The HIV Women's Study Group. Jackson LA, et al. **Can J Public Health** 1997 Jan–Feb;88(1):18–22

HIV testing, behaviors, and knowledge among adolescents at high risk. Rotheram-Borus MJ, et al. **J Adolesc Health** 1997 Mar;20(3):216–25

Decision making in HIV testing among a group with low HIV risk. Coyle A, et al. **J Eval Clin Pract** 1996 Aug; 2(3):223–30

Does HIV test result influence methadone maintenance treatment retention? Wimbush J, et al. **J Subst Abuse** 1996; 8(2):263–9

To be or not to be tested for the AIDS virus. Harris RM. **Nurs Res** 1997 Sep–Oct;46(5):293–4

Predictors of human immunodeficiency virus counseling and testing among sexually transmitted disease clinic patients. Schwarcz SK, et al. **Sex Transm Dis** 1997 Jul;24(6):347–52

[Screening for notification of seropositivity: ethical and psychological aspects] De Wit S, et al. **Rev Med Brux** 1996 Sep;17(4):167–70 (Eng. Abstr.) **(Fre)**

STANDARDS

Risk of iatrogenic human immunodeficiency virus infection through transfusion of blood tested by inappropriately stored or expired rapid antibody assays in a Zambian hospital. Consten EC, et al. **Transfusion** 1997 Sep; 37(9):930–4

STATISTICS & NUMERICAL DATA

Retesting of sera for antibodies to HIV-1/HIV-2. **Commun Dis Rep CDR Wkly** 1996 May 3;6(18):153

Laboratory-based HIV surveillance with information on exposure: importance of discriminating person-based from test-based results. van Duynhoven YT, et al. **Int J STD AIDS** 1996 Mar–Apr;7(2):117–22

TRENDS

The evaluation of HIV counseling-and-testing services: making the most of limited resources. Holtgrave DR, et al. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):105–18

HIV counseling and testing: its evolving role in HIV prevention. Valdiserri RO. **AIDS Educ Prev** 1997 Jun;9(3 Suppl):2–13 (42 ref.)

UTILIZATION

Diagnostic HIV antibody testing in the United States: the role of private providers and public programs. Anderson JE, et al. **AIDS** 1996 Mar;10(3):342–3

HIV testing among low-income African-American mothers. Battle RS, et al. **AIDS Educ Prev** 1996 Apr;8(2):165–75

Testing for human immunodeficiency virus infection among tuberculosis patients in Los Angeles. Asch SM, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):378–81

A profile of HIV testing in Victoria to the end of 1993. Victorian Collaborative Group on HIV and AIDS Surveillance (VCGHAS). Thompson SC, et al. **Aust N Z J Public Health** 1996 Apr;20(2):165–71

AIDS SEROLOGY see **AIDS SERODIAGNOSIS**

AIDS SEROPOSITIVITY see **HIV SEROPOSITIVITY**

AIDS, SIMIAN see **SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME**

AIDS VACCINES

HIV-peplotion vaccine. A novel approach to vaccination against AIDS by transepithelial transport of viral peptides and antigens to Langerhans cells for induction of cytolytic T cells by HLA class I and CD1 molecules for long term protection. Becker Y. **Adv Exp Med Biol** 1996;397:97–104 (22 ref.)

Complexed HIV envelope as a target for an AIDS vaccine. Gershoni JM, et al. **Adv Exp Med Biol** 1996;397:91–6

Changing paradigms for an HIV vaccine. Schultz AM. **Adv Exp Med Biol** 1996;397:79–90 (61 ref.)

HIV vaccine development: from basic research to human trials. Esparza J, et al. **AIDS** 1996;10 Suppl A:S123–32 (134 ref.)

Social and behavioral issues in phase III HIV preventive vaccine trials. Grinstead OA. **AIDS** 1995;9 Suppl A:S245–50 (32 ref.)

Primate models for AIDS vaccine development. Heeney JL. **AIDS** 1996;10 Suppl A:S115–22 (67 ref.)

The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: Project ACHIEVE. AIDS Community Health Initiative Enroute to the Vaccine EFfort. Koblin BA, et al. **AIDS** 1996 Nov;10(13):1555–61

AIDS 1995. Vaccines and immunology: overview. Montelaro RC, et al. **AIDS** 1995;9 Suppl A:S111–2

Comparative Approach to Retroviral Vaccines. Workshop proceedings. Les Pensières, Veyrier-du-Lac, France, June 23–24, 1995. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):355–467

Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. Ahlers JD, et al. **AIDS Res Hum Retroviruses** 1996 Mar 1;12(4):259–72

Retroviral vaccines: challenges for the developing world. Essex M. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):361–3 (26 ref.)

Resistance to immunodeficiency viruses and its relevance to vaccine development. Jeffs SA. **AIDS Res Hum Retroviruses** 1997 Jul 20;13(11):909–12

HIV type 1 coreceptors, neutralization serotypes, and vaccine development. Moore J, et al.

AIDS Res Hum Retroviruses 1997 Jun 10;13(9):733–6 (35 ref.)

Titration of a vaccine stock preparation of human immunodeficiency virus type 1SF2 in cultured lymphocytes and in chimpanzees. Murthy KK, et al. **AIDS Res Hum Retroviruses** 1996 Sep 20;12(14):1341–8

Update on the issues of HIV vaccine development. Haynes BF, et al. **Ann Med** 1996 Feb;28(1):39–41

Development and applications of vaccines and gene therapy in AIDS. Proceedings of an international workshop. Naples, Italy, June 15–16, 1995. **Antibiot Chemother** 1996; 48:IX–X, 1–246

Overview of HIV vaccine development. Bolognesi DP. **Antibiot Chemother** 1996;48:63–7 (16 ref.)

Establishment of WHO-sponsored field sites for HIV vaccine evaluation in developing countries. Heyward WL, et al. **Antibiot Chemother** 1996;48:139–44

Relative importance and functional role of genetic elements targeted for a live attenuated AIDS vaccine. Lang SM, et al. **Antibiot Chemother** 1996;48:92–9 (37 ref.)

HIV-1 genetic variability: implications for the development of HIV vaccines. Osmanov S, et al. **Antibiot Chemother** 1996;48:30–8 (51 ref.)

A recombinant HIV-1 virus-like particle vaccine: from concepts to a field study. Wagner R, et al. **Antibiot Chemother** 1996;48:68–83 (42 ref.)

Enhancement of immunogenicity of recombinant antigens by production of a cytokine-antigen fusion protein for vaccination. McCormick AL, et al. **Biochem Soc Trans** 1997 May;25(2):297S

A factorial survey study to assess the acceptability of HIV vaccine trial designs. Hennessy M, et al. **Control Clin Trials** 1996 Jun;17(3):209–20

Potential of chimaeric plant virus particles as novel, stable vaccines. Xu F, et al. **Dev Biol Stand** 1996;87:201–5

HIV vaccines: problems and prospects. Johnston MI. **Hosp Pract (Off Ed)** 1997 May 15;32(5):125–8, 131–40 (6 ref.)

Proceedings of the 1st International summit meeting on Immunological Correlates of Protection from HIV Infection and Disease. Mont Pelerin, Switzerland, 27–30 May 1995. **Immunol Lett** 1996 Jun;51(1–2):1–135

Health beliefs and intention to get immunized for HIV. Zimet GD, et al. **J Adolesc Health** 1997 May;20(5):354–9

Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm? Koff WC, et al. **J Clin Immunol** 1996 May;16(3):127–33 (63 ref.)

Risk behaviours and comprehension among intravenous drug users volunteered for HIV vaccine trial. Pitisuttithum P, et al. **J Med Assoc Thai** 1997 Jan;80(1):47–50

Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees. Bagarazzi ML, et al. **J Med Primatol** 1997 Feb–Apr; 26(1–2):27–33

In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. Boyer JD, et al. **J Med Primatol** 1996 Jun;25(3):242–50

Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination. Fuller DH, et al. **J Med Primatol** 1996 Jun;25(3):236–41

Collaboration needed for HIV vaccine success [news] [published erratum appears in JAMA 1997 Apr 2;277(13):1038] Voelker R. **JAMA** 1997 Jan 1;277(1):9

Low-efficacy HIV vaccines: potential for community-based intervention programmes [see comments] Anderson RM, et al. **Lancet** 1996 Oct 12;348(9033):1010–3. Comment in: Lancet 1997 Feb 1;349(9048):361.

Future vaccines for HIV [letter; comment] Blanchard T, et al. **Lancet** 1996 Dec 21–28;348(9043):1741. Comment on: Lancet 1996 Oct 5;348(9032):933–7.

HIV vaccines [letter; comment] Ellenberg SS, et al. **Lancet** 1997 Feb 1;349(9048):361. Comment on: Lancet 1996 Oct 12;348(9033):1010–3.

Getting the vaccine strategy right in HIV-1 disease [news] Rowe PM. **Lancet** 1997 May 17;349(9063):1454

Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR [see comments] Schwartz DH, et al. **Lancet** 1997 Jul 26; 350(9073):256–9. Comment in: Lancet 1997 Jul 26;350(9073):230–1.

SIV/HIV-1 chimeric viruses having HIV-1 env gene: a new animal model and a candidate for attenuated live vaccine. Hayami M, et al. **Leukemia** 1997 Apr;11 Suppl 3:95–7

Trick and treat: toward peptide mimic vaccines [news; comment] Shikhman AR, et al. **Nat Biotechnol** 1997 Jun; 15(6):512–3. Comment on: Nat Biotechnol 1997 Jun;15(6):547–51.

Who is really behind Clinton's AIDS vaccine crusade? [news] Culliton BJ. **Nat Med** 1997 Jul;3(7):711

Advances encourage Nobel winner to head AIDS vaccine effort [news] Wadman M. **Nature** 1996 Dec 19–26; 384(6610):604

An HIV vaccine: breaking the paradigms. Fauci AS. **Proc Assoc Am Physicians** 1996 Jan;108(1):6–13 (47 ref.)

A vaccine for HIV type 1: the antibody perspective. Burton DR. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10018–23 (76 ref.)

Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Letvin NL, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9378–83

Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Yusibov V, et al. **Proc Natl Acad Sci U S A** 1997 May 27; 94(11):5784–8

Should South Africa be preparing for HIV-1 vaccine efficacy trials? [editorial] Morris L, et al. **S Afr Med J** 1997 Mar; 87(3):285–90 (64 ref.)

Promoting HIV vaccine research and development in southern Africa [letter] van der Ryst E, et al. **S Afr Med J** 1997 Aug;87(8):1015–6

Shot in the arm for AIDS vaccine [news] **Science** 1997 Mar 14;275(5306):1573

Russia steps into AIDS research arena [news] **Science** 1997 Apr 4;276(5309):23

UNAIDS to weigh vaccine ethics [news] **Science** 1997 Sep 19;277(5333):1751

Planned tests in Thailand spark debate [news] Cohen J. **Science** 1997 May 23;276(5316):1197

Baltimore to head new vaccine panel [news] Cohen J. **Science** 1996 Dec 20;274(5295):2005

Weakened SIV vaccine still kills [news] Cohen J. **Science** 1997 Oct 3;278(5335):24–5

Exploiting the HIV-chemokine nexus [news] Cohen J. **Science** 1997 Feb 28;275(5304):1261–4

Novel campaign to test live HIV vaccine [news] Cohen J. **Science** 1997 Aug 22;277(5329):1035

A deadline for an AIDS vaccine [news] Lawler A, et al. **Science** 1997 May 23;276(5316):1184–5

Curtailing the AIDS pandemic [letter] Mullins JI. **Science** 1997 Jun 27;276(5321):1955–7

High-powered support for AIDS vaccine [news] Vogel G. **Science** 1997 Feb 21;275(5303):1055

Feasibility of northern Thai factory workers as participants in HIV vaccine trials. Natpratan C, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):457–62

A control-conditional test for assessing HIV vaccine efficacy in small sample preclinical studies. Albert JM. **Stat Med** 1996 Nov 15–30;15(21–22):2371–8; discussion 2405–12

Comparing methods for calculating confidence intervals for vaccine efficacy. Ewell M. **Stat Med** 1996 Nov 15–30; 15(21–22):2379–92

Assessing the effect of HIV vaccination on infectiousness. Rida WN. **Stat Med** 1996 Nov 15–30;15(21–22):2393–404; discussion 2405–12

New scientific developments towards an AIDS vaccine: report on a workshop organized by EU programme EVA entitled Novel approaches to AIDS vaccine development held at the Institut Pasteur, Paris. 16–17 November 1995. Oxford JS, et al. **Vaccine** 1996 Dec;14(17–18):1712–7

[The therapeutic strategy in controlling HIV infection, its hindrances and by-products] Frottier J, et al. **Bull Acad Natl Med** 1996 May;180(5):1053–78 (15 ref.) **(Fre)**

[Search for a HIV vaccine] Sicard D, et al. **Presse Med** 1997 Feb 22;26(5):248–54 (30 ref.) (Eng. Abstr.) **(Fre)**

[Recent topics on AIDS research— study of AIDS viruses and the application for development of prevention and therapeutic methods of AIDS] Honda M. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):606–7 (0 ref.) **(Jpn)**

[Analysis of the principal neutralization site of HIV-1 and vaccine research] Okamoto Y, et al. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1201–8 (20 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. Staats HF, et al. **AIDS Res Hum Retroviruses** 1997 Jul 20;13(11):945–52

HIV-2 vaccine trials in cynomolgus monkeys. Biberfeld G, et al. **Antibiot Chemother** 1996;48:113–20

Vaccination of chimpanzees against HIV-1. Girard M, et al. **Antibiot Chemother** 1996;48:121–4 (16 ref.)

Immunological aspects of patients with HIV-1 disease following immunization with recombinant gp160 (VaxSyn). Guerra E, et al. **Antibiot Chemother** 1996;48:147–54

Strategies for the achievement of prophylactic vaccination against HIV. Hilleman MR. **Antibiot Chemother** 1996; 48:161–72 (54 ref.)

Combination strategies for vaccination against HIV. Plotkin SA. **Antibiot Chemother** 1996;48:145–6

International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Phanuphak P, et al. **Asian Pac J Allergy Immunol** 1997 Mar;15(1):41–8

So far so good for HIV vaccine [news] **CMAJ** 1997 Jun 15;156(12):1692

Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. Cleland JL, et al. **J Pharm Sci** 1996 Dec; 85(12):1350–7

Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response. Cleland JL, et al. **J Pharm Sci** 1996 Dec;85(12):1346–9

US dispute over live AIDS vaccine trials [news] Wadman M. **Nature** 1997 Oct 2;389(6650):426

Mucosal immunization with DNA-liposome complexes. Klavinskis LS, et al. **Vaccine** 1997 Jun;15(8):818–20

DNA vaccination followed by macromolecular multicomponent peptide vaccination against HIV-1 induces strong antigen-specific immunity. Okuda K, et al. **Vaccine** 1997 Jul;15(10):1049–56

ADVERSE EFFECTS

Live HIV vaccines—how safe? [letter; comment] Dittmer U, et al. **Nat Med** 1997 Aug;3(8):816. Comment on: Nat Med 1997 Jan;3(1):32–6.

Live-attenuated HIV vaccines: how safe is safe enough? [news; comment] Murphey-Corb M. **Nat Med** 1997 Jan; 3(1):17–8. Comment on: Nat Med 1997 Jan;3(1):32–6.

Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120. Veljković V, et al. **Vaccine** 1997 Apr; 15(5):473–4

ANTAGONISTS & INHIBITORS

Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure. Kent SJ, et al. **J Immunol** 1997 Jan 15; 158(2):807–15

BIOSYNTHESIS

Macaque models for AIDS vaccine development. Johnson RP. **Curr Opin Immunol** 1996 Aug;8(4):554–60 (42 ref.)

The development of cowpea mosaic virus as a potential source of novel vaccines. Porta C, et al. **Intervirology** 1996; 39(1–2):79–84 (24 ref.)

CHEMICAL SYNTHESIS

Peptomer aluminum oxide nanoparticle conjugates as systemic and mucosal vaccine candidates: synthesis and characterization of a conjugate derived from the C4 domain of HIV-1MN gp120. Frey A, et al. **Bioconjug Chem** 1997 May-Jun;8(3):424–33

CHEMISTRY

Antigenicity of HIV-derived T helper determinants in the context of carrier recombinant proteins: effect on T helper cell repertoire selection. Manca F, et al. **Eur J Immunol** 1996 Oct;26(10):2461–9

ECONOMICS

Funds earmarked for AIDS vaccine centre [news] **Nature** 1997 Aug 7;388(6642):510

GENETICS

HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. Choi DJ, et al. **AIDS Res Hum Retroviruses** 1997 Mar 1; 13(4):357–61

IMMUNOLOGY

Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994–1995. Berzofsky JA, et al. **AIDS** 1995;9 Suppl A:S143–57 (178 ref.)

Human trials of experimental HIV vaccines. Burke DS. **AIDS** 1995;9 Suppl A:S171–80 (112 ref.)

Non-human primate models for AIDS vaccines. Desrosiers RC. **AIDS** 1995;9 Suppl A:S137–41 (40 ref.)

Vaccines and immunology. Norrby E, et al. **AIDS** 1996;10 Suppl A:S83–4

Nucleic acid-based immunization against HIV-1: induction of protective in vivo immune responses. Wang B, et al. **AIDS** 1995;9 Suppl A:S159–70 (66 ref.)

HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy. Ada GL, et al. **AIDS Res Hum Retroviruses** 1997 Feb 10;13(3):205–10 (83 ref.)

Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2. Biberfeld G, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20; 12(5):443–6 (22 ref.)

An approach to vaccines against human immunodeficiency virus. Girard M, et al. **AIDS Res Hum Retroviruses** 1996 Mar 20;12(5):461–3 (22 ref.)

Relationship between antigenicity and immunogenicity of chimeric hepatitis B virus core particles carrying HIV type 1 epitopes. Grene E, et al. **AIDS Res Hum Retroviruses** 1997 Jan 1;13(1):41–51

Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. Kelleher AD, et al. **AIDS Res Hum Retroviruses** 1997 Jan 1;13(1):29–32

Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals. Klein MR, et al. **AIDS Res Hum Retroviruses** 1997 Mar 20;13(5):393–9

HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. McElrath MJ, et al. **AIDS Res Hum Retroviruses** 1997 Feb 10;13(3):211–6 (34 ref.)

Environmental pathogenesis of human retroviruses. Montagnier L. **AIDS Res Hum Retroviruses** 1996 Mar 20;

12(5):357–9
Role of adjuvants in HIV vaccine design. Vogel FR. **Antibiot Chemother** 1996;48:84–91 (48 ref.)
Lymphoproliferative response to synthetic V3 loop P18 peptide and HIV–1 envelope glycoprotein among individuals immunized with gp160 candidate vaccines. Moukrim Z, et al. **Biomed Pharmacother** 1996;50(10):494–9
A live–virus "suicide" vaccine for human immunodeficiency virus. Kestler HW, et al. **Cleve Clin J Med** 1997 May; 64(5):269–74 (32 ref.)
Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group. Gorse GJ, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):378–86
Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group. Gorse GJ, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):769–73
Expansion of restricted cellular immune responses to HIV–1 envelope by vaccination: IL–7 and IL–12 differentially augment cellular proliferative responses to HIV–1. Kim JH, et al. **Clin Exp Immunol** 1997 May;108(2):243–50
Immunogenicity of HIV–1LAI gp160 and env peptides in squirrel monkey Saimiri sciureus using alumine and experimental adjuvants. Perraut R, et al. **Clin Exp Immunol** 1996 Dec;106(3):434–41
Strong augment effect of IL–12 expression plasmid on the induction of HIV–specific cytotoxic T lymphocyte activity by a peptide vaccine candidate. Hamajima K, et al. **Clin Immunol Immunopathol** 1997 May;83(2):179–84
Immunomodulatory effects of a plasmid expressing B7–2 on human immunodeficiency virus–1–specific cell–mediated immunity induced by a plasmid encoding the viral antigen. Tsuji T, et al. **Eur J Immunol** 1997 Mar;27(3):782–7
Correlates of protective immunity against HIV–1 infection in immunized chimpanzees. Murthy KK, et al. **Immunol Lett** 1996 Jun;51(1–2):121–4 (27 ref.)
Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design" [corrected and republished article originally printed in Immunol Lett 1997 Jun 1;57(1–3):105–12] Parren PW, et al. **Immunol Lett** 1997 Jul;58(2):125–32 (87 ref.)
Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Parren PW, et al. **Immunol Lett** 1997 Jun 1;57(1–3):105–12 (87 ref.)
Improvements in live–attenuated HIV vaccines? **Immunol Today** 1996 Sep;17(9):401
HIV–1–specific cell–mediated immunity is enhanced by co–inoculation of TCA3 expression plasmid with DNA vaccine. Tsuji T, et al. **Immunology** 1997 Jan;90(1):1–6
Monophosphoryl lipid A enhances both humoral and cell–mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Sasaki S, et al. **Infect Immun** 1997 Sep;65(9):3520–8
Viral load, CD4 percentage, and delayed–type hypersensitivity in subjects receiving the HIV–1 immunogen and antiviral drug therapy. Moss RB, et al. **J Clin Immunol** 1996 Sep;16(5):266–71
Targeting of HIV–1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. Tobery TW, et al. **J Exp Med** 1997 Mar 3;185(5):909–20
Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. Eckhart L, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2001–8
Protection of monkeys vaccinated with vpr– and/or nef–defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live–attenuated human AIDS vaccine. Igarashi T, et al. **J Gen Virol** 1997 May;78 (Pt 5):985–9
Cytokine–in–adjuvant steering of the immune response phenotype to HIV–1 vaccine constructs: granulocyte–macrophage colony–stimulating factor and TNF–alpha synergize with IL–12 to enhance induction of cytotoxic T lymphocytes. Ahlers JD, et al. **J Immunol** 1997 Apr 15;158(8):3947–58
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. Garrity RR, et al. **J Immunol** 1997 Jul 1;159(1):279–89
Adsorption to aluminum hydroxide promotes the activity of IL–12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV–1 gp120. Jankovic D, et al. **J Immunol** 1997 Sep 1;159(5):2409–17
HIV–1 env DNA vaccine administered to rhesus monkeys elicits MHC class II–restricted CD4+ T helper cells that secrete IFN–gamma and TNF–alpha. Lekutis C, et al. **J Immunol** 1997 May 1;158(9):4471–7
Vaccine–specific antibody responses induced by HIV–1 envelope subunit vaccines. Pincus SH, et al. **J Immunol** 1997 Apr 1;158(7):3511–20
Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3–like superfamily: implications for vaccine development. Threlkeld SC, et al. **J Immunol** 1997 Aug 15;159(4):1648–57
Enhancement of cell–mediated immunity against HIV–1 induced by coinnoculation of plasmid–encoded HIV–1 antigen with plasmid expressing IL–12. Tsuji T, et al. **J Immunol** 1997 Apr 15;158(8):4008–13
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. Andersson S, et al. **J Infect Dis** 1996 Nov;174(5):977–85
Genetic and immunologic characterization of viruses infecting MN–rgp120–vaccinated volunteers. Berman PW, et al. **J Infect Dis** 1997 Aug;176(2):384–97
Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. Buchbinder SP, et al. **J Infect Dis** 1996 Nov;174(5):954–61
Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV–1)–negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV–1 and boosted with a recombinant gp160. Fleury B, et al. **J Infect Dis** 1996 Oct; 174(4):734–8
Maternal monoclonal antibody to the V3 loop alters specificity of the response to a human immunodeficiency virus vaccine. Jelonek MT, et al. **J Infect Dis** 1996 Oct; 174(4):866–9
Immunization with recombinant p17/p24:Ty virus–like particles in human immunodeficiency virus–infected persons. Veenstra J, et al. **J Infect Dis** 1996 Oct; 174(4):862–6
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus–uninfected recipients of candidate AIDS vaccines. Zolla–Pazner S, et al. **J Infect Dis** 1997 Apr;175(4):764–74
Mechanisms of protection induced by attenuated simian immunodeficiency virus. IV. Protection against challenge with virus grown in autologous simian cells. Almond N, et al. **J Med Primatol** 1997 Feb–Apr;26(1–2):34–43
A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys. Cole KS, et al. **J Med Primatol** 1997 Feb–Apr; 26(1–2):51–8
Preclinical AIDS vaccine development: formal survey of global HIV, SIV, and SHIV in vivo challenge studies in vaccinated nonhuman primates. Warren JT, et al. **J Med Primatol** 1997 Feb–Apr;26(1–2):63–81
Humoral and cellular immunities elicited by HIV–1 vaccination. Shiver JW, et al. **J Pharm Sci** 1996 Dec; 85(12):1317–24
Induction of anti–gp160 cytotoxic T cells cross–reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope–immunized individuals. Achour A, et al. **J Virol** 1996 Oct;70(10):6741–50
Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. Caley IJ, et al. **J Virol** 1997 Apr; 71(4):3031–8
Failure of a human immunodeficiency virus type 1 (HIV–1) subtype B–derived vaccine to prevent infection of chimpanzees by an HIV–1 subtype E strain. Girard M, et al. **J Virol** 1996 Nov;70(11):8229–33
Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. Hinkula J, et al. **J Virol** 1997 Jul; 71(7):5528–39
In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope. Parren PW, et al. **J Virol** 1996 Dec; 70(12):9046–50
Randomised trial of MNrgp120 HIV–1 vaccine in symptomless HIV–1 infection [see comments] Eron JJ Jr, et al. **Lancet** 1996 Dec 7;348(9041):1547–51. Comment in: Lancet 1996 Dec 7;348(9041):1531–2.
HIV vaccines: where we are and where we are going [see comments] Haynes BF. **Lancet** 1996 Oct 5;348(9032):933–7 (47 ref.). Comment in: Lancet 1996 Dec 21–28;348(9043):1741.
Distinguishing between response to HIV vaccine and response to HIV [comment] Weber J. **Lancet** 1997 Jul 26; 350(9073):230–1. Comment on: Lancet 1997 Jul 26;350(9073):256–9.
Genetic control of immune responses to HIV–1 env DNA vaccine. Ishii N, et al. **Microbiol Immunol** 1997;41(5):421–5
Clade B–based HIV–1 vaccines elicit cross–clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Ferrari G, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18; 94(4):1396–401
Viral quasispecies and the problem of vaccine–escape and drug–resistant mutants. Domingo E, et al. **Prog Drug Res** 1997;48:99–128 (201 ref.)
HIV vaccine and genital secretory immune response. Stefanache–Guihard AI. **Rom J Virol** 1995 Jan–Jun; 46(1–2):85–98 (24 ref.)
Looking for leads in HIV's battle with immune system [news] Cohen J. **Science** 1997 May 23;276(5316):1196–7
Vaccination with HIV–1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Barnett SW, et al. **Vaccine** 1997 Jun;15(8):869–73
Enhancement of immunodeficiency virus–specific immune responses in DNA–immunized rhesus macaques. Fuller DH, et al. **Vaccine** 1997 Jun;15(8):924–6
Nucleic acid vaccination with HIV regulatory genes: a combination of HIV–1 genes in separate plasmids induces strong immune responses. Hinkula J, et al. **Vaccine** 1997 Jun;15(8):874–8
Development of a multicomponent candidate vaccine for HIV–1. Kim JJ, et al. **Vaccine** 1997 Jun;15(8):879–83
Induction of cross–reactive cytotoxic T–lymphocyte responses specific for HIV–1 gp120 using saponin adjuvant (QS–21) supplemented subunit vaccine formulations. Newman MJ, et al. **Vaccine** 1997 Jun;15(9):1001–7
Manipulation of HIV–1 gp120–specific immune responses elicited via gene gun–based DNA immunization. Prayaga SK, et al. **Vaccine** 1997 Aug–Sep;15(12–13):1349–52
Eliciting HIV–1 envelope–specific antibodies with mixed vaccinia virus recombinants. Rencher SD, et al. **Vaccine** 1997 Feb;15(3):265–72
Anti–HIV env immunities elicited by nucleic acid vaccines. Shiver JW, et al. **Vaccine** 1997 Jun;15(8):884–7
Mucosal immunization with a DNA vaccine induces immune responses against HIV–1 at a mucosal site. Wang B, et al. **Vaccine** 1997 Jun;15(8):821–5
The organization of human leucocyte antigen class I epitopes in HIV genome products: implications for HIV evolution and vaccine design. Zhang C, et al. **Vaccine** 1997 Aug–Sep; 15(12–13):1291–302
Challenge of chimpanzees immunized with a recombinant canarypox–HIV–1 virus. Girard M, et al. **Virology** 1997 May 26;232(1):98–104
Screening of HIV–1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Richmond JF, et al. **Virology** 1997 Apr 14;230(2):265–74
Complement–activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35). Zhou J, et al. **Virology** 1996 Dec 1;226(1):13–21

ISOLATION & PURIFICATION

The Maginot Line and AIDS vaccines. Stricker RB, et al. **Med Hypotheses** 1997 Jun;48(6):527–9 (24 ref.)

PHARMACOLOGY

Antibody to human immunodeficiency virus type 1 (HIV–1) gp160 in mucosal specimens of asymptomatic HIV–1–infected volunteers parenterally immunized with an experimental recombinant HIV–1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases–sponsored AIDS Vaccine Evaluation Group. Lambert JS, et al. **Clin Diagn Lab Immunol** 1997 May; 4(3):302–8

SUPPLY & DISTRIBUTION

[A vaccine against HIV—status after ten years of research] Schønning K, et al. **Ugeskr Laeger** 1996 Dec 2; 158(49):7047–50 **(Dan)**

THERAPEUTIC USE

A placebo–controlled clinical phase I trial with combined anti–HIV–1 and anti–interferon–alpha immunization [letter] Coulaud IP, et al. **AIDS** 1997 Jun;11(7):937–8
Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. Myagkikh M, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):985–92
Preparation for HIV vaccine efficacy trials. Hoff R, et al. **Antibiot Chemother** 1996;48:155–60
A live–virus "suicide" vaccine for human immunodeficiency virus. Kestler HW, et al. **Cleve Clin J Med** 1997 May; 64(5):269–74 (32 ref.)
Effect of therapeutic immunization with recombinant gp160 HIV–1 vaccine on HIV–1 proviral DNA and plasma RNA: relationship to cellular immune responses. Kundu SK, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Aug 1;15(4):269–74
Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV–1 vaccines. Longini IM Jr, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 15;13(5):440–7
Strategies for AIDS vaccines. Stott EJ, et al. **J Antimicrob Chemother** 1996 May;37 Suppl B:185–98 (67 ref.)
Protection against experimental nervous system autoimmune diseases by a human immunodeficiency virus–1 Tat peptide–based polyvalent vaccine. Schluesener HJ. **J Neurosci Res** 1996 Oct 15;46(2):258–62
Protection of chimpanzees from high–dose heterologous HIV–1 challenge by DNA vaccination [see comments] Boyer JD, et al. **Nat Med** 1997 May;3(5):526–32. Comment in: Nat Med 1997 May;3(5):473.
DNA vaccination for HIV [news] Kennedy RC. **Nat Med** 1997 May;3(5):501–2
Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV–1: prelude to a clinical trial. Ugen KE, et al. **Vaccine** 1997 Jun;15(8):927–30
[Stride for stride with AIDS vaccination (news)] Eibl I. **Pharm Unserer Zeit** 1996 Jul;25(4):211 **(Ger)**
[A modern approach to developing anti–HIV vaccines] Sergeev OV. **Vopr Virusol** 1997 Mar–Apr;42(2):50–3 **(Rus)**

AIDS VIRUS see **HIV–1**

AIDS VIRUS RECEPTORS see RECEPTORS, HIV

AIDS WASTING SYNDROME see HIV WASTING SYNDROME

AIKIDO see MARTIAL ARTS

AINHUM

DIAGNOSIS

A case of atypical localized scleroderma presenting with pseudoainhum: treatment with tranilast, an anti-fibrotic agent [letter] Tajima S, et al. **Acta Derm Venereol** 1996 Mar;76(2):162

ETIOLOGY

Pseudoainhum associated with linear scleroderma [letter] Park BS, et al. **Arch Dermatol** 1996 Dec;132(12):1520-1

AIR

Impact of reoxygenation with oxygen and air on the extent of the brain damage after hypoxia–ischaemia in neonatal rats. Bågenholm R, et al. **Acta Paediatr** 1996 Oct; 85(10):1228–31

Incidence of recurrent intussusception following barium versus air enema. Eshel G, et al. **Acta Paediatr** 1997 May; 86(5):545–6

Time to abandon loss of resistance to air [letter] Yentis SM. **Anaesthesia** 1997 Feb;52(2):184

Intraalveolar bubbles and bubble films: III. Vulnerability and preservation in the laboratory. Scarpelli EM, et al. **Anat Rec** 1997 Aug;248(4):498–520

Technique of right heart protection and deairing during heartmate vented electric LVAD implantation. Van Meter CH Jr, et al. **Ann Thorac Surg** 1997 Apr;63(4):1191–2

Pupillary block, angle-closure glaucoma produced by an anterior chamber air bubble in a nanophthalmic [corrected] eye [letter; comment] [published erratum appears in Arch Ophthalmol 1997 Sep;115(9):1112] Shugar JK. **Arch Ophthalmol** 1997 Mar;115(3):432. Comment on: Arch Ophthalmol 1996 Sep;114(9):1145–6.

The effects of air cavities on X-ray dose distribution at 6 and 25 MV. Wong TP, et al. **Australas Phys Eng Sci Med** 1996 Dec;19(4):237–47

A study of the combined effects of shelf ageing following irradiation in air and counterface roughness on the wear of UHMWPE. Besong AA, et al. **Biomed Mater Eng** 1997; 7(1):59–65

Volumetric analysis of aeration in the lungs during general anaesthesia [letter; comment] Drummond GB. **Br J Anaesth** 1996 Nov;77(5):697–8. Comment on: Br J Anaesth 1996 Jun;76(6):760–6.

The test–retest variability of the caloric test: a comparison of a modified air irrigation with the conventional water technique. Munro KJ, et al. **Br J Audiol** 1996 Oct; 30(5):303–6

Air, by any other name...[letter; comment] Kirsch CM. **Chest** 1997 Jun;111(6):1786. Comment on: Chest 1997 Feb;111(2):503–5.

Air or CO2 as an insufflation agent for double contrast barium enema [letter; comment] Matson MB, et al. **Clin Radiol** 1996 Oct;51(10):741–2. Comment on: Clin Radiol 1995 Aug;50(8):558–61. Comment on: Clin Radiol 1996 May;51(5):382.

Air–trapping in extrinsic allergic alveolitis on computed tomography. Small JH, et al. **Clin Radiol** 1996 Oct; 51(10):684–8

Recent developments in air–conduction hearing aids. Arlinger S. **Ear Nose Throat J** 1997 May;76(5):310–5 (7 ref.)

Radiological appearance of air introduced during equine regional limb anaesthesia. Kirberger RM, et al. **Equine Vet J** 1996 Jul;28(4):298–305

Effects of water and ambient air temperatures on human diving bradycardia. Schagatay E, et al. **Eur J Appl Physiol** 1996;73(1–2):1–6

The importance of air quality in human biometeorology. Flemming G. **Int J Biometeorol** 1996 Nov;39(4):192–6

Treatment with hot, humid air reduces the nasal response to allergen challenge. Desrosiers M, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):77–86

The degradation of glycosphingolipids by air. Jennemann R, et al. **J Biochem (Tokyo)** 1997 Jan;121(1):150–4

Gas in the spinal canal associated with injury of the cervical spinal cord: a diagnostic dilemma. A case report. Abraham DJ, et al. **J Bone Joint Surg Am** 1997 Apr;79(4):591–3

Effect of oxygen and air inhalation during cataract surgery on blood gas parameters. Cummings AB, et al. **J Cataract Refract Surg** 1996 Nov;22(9):1236–9

Limits to flight energetics of hummingbirds hovering in hypodense and hypoxic gas mixtures. Chai P, et al. **J Exp Biol** 1996 Oct;199 (Pt 10):2285–95

Room air challenge: prediction for successful weaning of oxygen–dependent infants. Simoes EA, et al. **J Perinatol** 1997 Mar–Apr;17(2):125–9

Time–resolved observations of shock waves and cavitation bubbles generated by femtosecond laser pulses in corneal tissue and water. Juhasz T, et al. **Lasers Surg Med** 1996; 19(1):23–31

Disruption of the rat mesenteric arterial bed endothelial function by air perfusion. Tatchum–Talom R, et al. **Life Sci** 1997;60(26):2407–16

Effects of air and oxygen on parenteral nutrition admixtures—an underrated risk? Allwood MC, et al. **Nutrition** 1996 Mar;12(3):222–3 (19 ref.)

"Pneumofornix" (air under the eyelid): a normal finding. Patel BC, et al. **Ophthalmic Surg Lasers** 1997 Jun;28(6):520–2

The appearance of inverted Meckel diverticulum with intussusception on air enema. Kim G, et al. **Pediatr Radiol** 1997 Aug;27(8):647–50

Acceleration of barrier ontogenesis in vitro through air exposure. Hanley K, et al. **Pediatr Res** 1997 Feb;41(2):293–9

Airway blood flow responses to temperature and humidity of inhaled air. Le Merre C, et al. **Respir Physiol** 1996 Sep; 105(3):235–9

Retinal detachment after noncontact pneumatic tonometry. Axer–Siegel R, et al. **Retina** 1996;16(1):80–1

The microbiologic effect of gas filtration. Schneider TL, et al. **Retina** 1996;16(2):125–8

Anti gravity. Body blow [news] Mirsky S. **Sci Am** 1997 Mar; 276(3):25

The influence of laparotomy and laparoscopy on tumor growth in a rat model. Jacobi CA, et al. **Surg Endosc** 1997 Jun;11(6):618–21

Pneumomediastinum following Politzer's manoeuvre [letter; comment] Carbognani P, et al. **Thorax** 1996 Nov; 51(11):1169. Comment on: Thorax 1996 Mar;51(3):339–40; discussion 340–1.

[Remarks on the work of J. Rathgeber et al. Warming and humidification for acclimatization of intubated inspiratory air in patients in intensive care. Anaesthesist (1995) 44:274–83] Tontschev G, et al. **Anaesthesist** 1996 Mar; 45(3):284–7 **(Ger)**

[Stimulating conditions of cold air caloric test] Mano H, et al. **Rinsho Byori** 1997 Mar;45(3):271–6 (Eng. Abstr.) **(Jpn)**

[Dry air–gas baths as a method of pathogenetic therapy in hypertension at the sanatorium stage] Kliachkin LM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Nov–Dec; (6):3–5 **(Rus)**

ANALYSIS

Gas composition of the human nose and nasopharyngeal space. Harell M, et al. **Acta Otolaryngol (Stockh)** 1996 Jan; 116(1):82–4

Identification of pentachloronitrobenzene in ambient air extracts. Thompson TS, et al. **Bull Environ Contam Toxicol** 1997 Jun;58(6):939–44

Contamination of hospital compressed air with nitric oxide: unwitting replacement therapy. Pinsky MR, et al. **Chest** 1997 Jun;111(6):1759–63

Is nitric oxide in exhaled air produced at airway or alveolar level? Byrnes CA, et al. **Eur Respir J** 1997 May; 10(5):1021–5

Anomaly in atmospheric radon concentration: a possible precursor of the 1995 Kobe, Japan, earthquake. Yasuoka Y, et al. **Health Phys** 1997 May;72(5):759–61

Modeling indoor air concentrations near emission sources in imperfectly mixed rooms. Furtaw EJ Jr, et al. **J Air Waste Manag Assoc** 1996 Sep;46(9):861–8

Quantitative echocardiographic analysis of retained intracardiac air in pooled form: an experimental study. Orihashi K, et al. **J Am Soc Echocardiogr** 1996 Jul–Aug; 9(4):567–72

Separation and identification of metals in human bones, placenta and milk and in air by adsorption and ion–exchange thin–layer chromatography. Baranowska I, et al. **J Chromatogr A** 1996 Feb 19;725(1):199–202

Exposure to environmental tobacco smoke in sixteen cities in the United States as determined by personal breathing zone air sampling. Jenkins RA, et al. **J Expo Anal Environ Epidemiol** 1996 Oct–Dec;6(4):473–502

Pathophysiology of dysbaric osteonecrosis: a magnetic resonance imaging study [letter] Coulthard A, et al. **Undersea Hyperb Med** 1996 Jun;23(2):119–20

Is atmospheric superoxide vitally necessary? Accelerated death of animals in a quasi–neutral electric atmosphere. Goldstein N, et al. **Z Naturforsch [C]** 1997 May–Jun; 52(5–6):396–404

[Gas chromatographic determination of the disinfectant agent glutaraldehyde in hospital air] Wliszczak W, et al. **Mikrochim Acta** 1977;(3–4 Pt 2):139–48 **(Ger)**

[Rapid method of the determination of carbon dioxide in the air of premises] Karelin ON, et al. **Gig Sanit** 1996 Jul–Aug; (4):56 **(Rus)**

MICROBIOLOGY see AIR MICROBIOLOGY

STANDARDS

Trends in air quality in the UK. Ayres JG. **Allergy** 1997;52(38 Suppl):7–13 (14 ref.)

Scientific basis for an air quality standard on benzene. Tordoir WF. **Cent Eur J Public Health** 1996;4 Suppl:46–7

Air quality and public health [editorial] Walker B Jr, et al. **J Natl Med Assoc** 1997 Jun;89(6):378–80

Market turkey performance, air quality, and energy consumption affected by partial slotted flooring. Noll SL, et al. **Poult Sci** 1997 Feb;76(2):271–9

Proposed air pollutant standards [editorial] [published erratum appears in Science 1997 Aug 8;277(5327):753] Abelson PH. **Science** 1997 Jul 4;277(5322):15

Showdown over clean air science [news] Kaiser J. **Science** 1997 Jul 25;277(5325):466–9

VIROLOGY see AIR MICROBIOLOGY

AIR AMBULANCES

Risks and safety standards of flying intensive care units. Kroesen GA. **Acta Anaesthesiol Scand Suppl** 1996; 109:108–9

Air force helicopters for transport of intensive care patients. Mittermair HG. **Acta Anaesthesiol Scand Suppl** 1996; 109:113–4

Interhospital aeromedical transports: air medical activation intervals in adult and pediatric trauma patients. Harrison T, et al. **Am J Emerg Med** 1997 Mar;15(2):122–4

An airborne intensive care facility (fixed wing). Gilligan JE, et al. **Anaesth Intensive Care** 1996 Apr;24(2):245–53

Military and civilian emergency aeromedical services: common goals and different approaches. De Lorenzo RA. **Aviat Space Environ Med** 1997 Jan;68(1):56–60

Effect of upright and supine posture on hypoxemia during air transport. Knutson SW, et al. **Aviat Space Environ Med** 1996 Jan;67(1):14–8

Evaluation of repatriation parameters: an analysis of patient data of the German Air Rescue. Kramer W, et al. **Aviat Space Environ Med** 1996 Sep;67(9):885–9

The care of patients and transport by air [letter; comment] Shirley PJ. **Br J Anaesth** 1996 Sep;77(3):435. Comment on: Br J Anaesth 1996 May;76(5):726–30.

Changes in cardiac output during air ambulance repatriation. Malagon I, et al. **Intensive Care Med** 1996 Dec; 22(12):1396–9

Pressure–controlled ventilation for the long–range aeromedical transport of patients with burns. Barillo DJ, et al. **J Burn Care Rehabil** 1997 May–Jun;18(3):200–5

Helicopter transport of patients with marginal respiratory function/status [letter; comment] Benumof JL. **J Clin Anesth** 1996 Nov;8(7):621. Comment on: J Clin Anesth 1995 Dec;7(8):689–90.

Army helicopter casualty evacuations in Belize in 1995 and 1996. Eke AJ. **J R Army Med Corps** 1997 Jun;143(2):93–6

Efficacy of urgent thoracotomy for trauma in patients attended by a helicopter emergency medical service [letter] [see comments] Haji–Michael PG, et al. **J R Coll Surg Edinb** 1996 Feb;41(1):61. Comment in: J R Coll Surg Edinb 1996 Dec;41(6):423.

Aeromedical evacuation in Bosnia. Dashfield AK, et al. **J R Nav Med Serv** 1997;83(1):8–13

Are scene flights for penetrating trauma justified? Cocanour CS, et al. **J Trauma** 1997 Jul;43(1):83–6; discussion 86–8

Response after out–of–hospital cardiac arrest in the trauma patient should determine aeromedical transport to a trauma center. Margolin DA, et al. **J Trauma** 1996 Oct;41(4):721–5

Laryngeal mask airway in air transport when intubation fails: case report. Martin SE, et al. **J Trauma** 1997 Feb; 42(2):333–6

Appropriate helicopter transport of urban trauma patients. Norton R, et al. **J Trauma** 1996 Nov;41(5):886–91

Helping the helpers after the bombing in Dhahran: critical–incident stress services for an air rescue squadron. Budd MF. **Mil Med** 1997 Aug;162(8):515–20

Air medical transport services in North Carolina. Gibbs MA, et al. **N C Med J** 1997 Jul–Aug;58(4):254–8

Transport case 1: a time to fly? A dilemma in pediatric transport. Lavelle J. **Pediatr Emerg Care** 1996 Apr; 12(2):122–5

Pediatric prehospital care provided by a physician–staffed emergency medical helicopter unit in Finland. Suominen P, et al. **Pediatr Emerg Care** 1996 Jun;12(3):169–72

The Red Cross Air Ambulance—flight of fancy or not? [editorial] Ruttmann T. **S Afr Med J** 1997 Jun;87(6):713–4

[The organization of helicopter emergency services for the rescue of aircraft crash victims in the topical forest] Lemaire M. **Med Trop (Mars)** 1997;57(1):91–5 (Eng. Abstr.) **(Fre)**

HISTORY

Helicopter ambulances in critical care. Andrew DR. **J R Army Med Corps** 1994 Feb;140(1):22–5

STANDARDS

Helicopter emergency medical services: their role in integrated trauma care. Zalstein S, et al. **Aust N Z J Surg** 1997 Sep;67(9):593–8 (56 ref.)

Helicopter transport of injured children: system effectiveness and triage criteria. Moront ML, et al. **J Pediatr Surg** 1996 Aug;31(8):1183–6; discussion 1187–8

AIR BAGS

see related
SEAT BELTS

An investigation of behavioural adaptation to airbags and antilock brakes among taxi drivers. Sagberg F, et al. **Accid Anal Prev** 1997 May;29(3):293–302

Reactive airway dysfunction syndrome due to sodium azide inhalation. Weiss JS. **Int Arch Occup Environ Health** 1996; 68(6):469–71

An unusual cause of rib fracture following a road traffic accident. Daniels RJ, et al. **J Accid Emerg Med** 1997 Mar;

14(2):113–4
Airbag protection versus compartment intrusion effect determines the pattern of injuries in multiple trauma motor vehicle crashes. Loo GT, et al. **J Trauma** 1996 Dec; 41(6):935–51
From the Centers for Disease Control and Prevention. Update: fatal air bag–related injuries to children—United States, 1993–1996 [published erratum appears in JAMA 1997 Feb 5;277(5):372] **JAMA** 1997 Jan 1;277(1):11–2
Update: fatal air bag–related injuries to children—United States, 1993–1996 [published erratum appears in MMWR Morb Mortal Wkly Rep 1997 Jan 17;46(2):40] **MMWR Morb Mortal Wkly Rep** 1996 Dec 13; 45(49):1073–6
Airbag deployment following a motor vehicle accident in pregnancy. Sims CJ, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):726
Fatal air bag mediated craniocervical trauma in a child. Willis BK, et al. **Pediatr Neurosurg** 1996 Jun;24(6):323–7
Air bags alone compared with the combination of mechanical restraints and air bags: implications for the emergency evaluation of crash victims. Sutyak JP, et al. **South Med J** 1997 Sep;90(9):915–9
[Safety equipment and automobile accidents] Lereim I. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2436 **(Nor)**

ADVERSE EFFECTS

Injury with spontaneous deployment of an automobile air bag [letter] Adams SL, et al. **Acad Emerg Med** 1996 Feb; 3(2):179–80
Air bag–related ocular trauma. Ghafouri A, et al. **Am J Emerg Med** 1997 Jul;15(4):389–92
Bilateral hyphemas as a result of air bag deployment [letter] Zacovic JW, et al. **Am J Emerg Med** 1997 May;15(3):323–4
Air bag–related fatality in a short, forward–positioned driver [see comments] Perez J, et al. **Ann Emerg Med** 1996 Dec; 28(6):722–4. Comment in: Ann Emerg Med 1996 Dec;28(6):709–10.
Mechanisms of burn injury secondary to airbag deployment. Hallock GG. **Ann Plast Surg** 1997 Aug;39(2):111–3
Formation and treatment of a traumatic macular hole. Madreperla SA, et al. **Arch Ophthalmol** 1997 Sep; 115(9):1210–1
Corneoscleral laceration associated with passenger–side airbag inflation [letter] Bhavsar AR, et al. **Br J Ophthalmol** 1997 Jun;81(6):514–5
Blow–out fracture of the orbit associated with inflation of an airbag: a case report. Cacciatori M, et al. **Br J Oral Maxillofac Surg** 1997 Aug;35(4):241–2
Driver's airbags and facial injuries [letter] Newman L, et al. **Br J Oral Maxillofac Surg** 1996 Oct;34(5):480
Case report: retinal tear as a consequence of air bag inflation. Dubinsky I, et al. **Can Fam Physician** 1997 Sep;43:1576–7
Irreversible bullous keratopathy after air bag trauma. Geggel HS, et al. **CLAO J** 1996 Apr;22(2):148–50
An unusual mechanism of airbag injury. Walter DP, et al. **Injury** 1996 Sep;27(7):523–4
Mechanisms of thoracic injury in frontal impact. Yoganandan N, et al. **J Biomech Eng** 1996 Nov;118(4):595–7
Facial nerve paresis involving passenger airbag deployment: a case report. Bedell JR, et al. **J Emerg Med** 1997 Jul–Aug; 15(4):475–6
Severe head injury caused by airbag deployment. Hollands CM, et al. **J Trauma** 1996 Nov;41(5):920–2
Airbag–induced lethal cervical trauma. Maxeiner H, et al. **J Trauma** 1997 Jun;42(6):1148–51
Renal injury in a child with airbag deployment. Smith DP, et al. **J Trauma** 1997 Feb;42(2):341–2
"React, not over–react" [editorial] Thomas JR. **Mo Med** 1997 May;94(5):200
Aortic transection following air–bag deployment [letter] deGuzman BJ, et al. **N Engl J Med** 1997 Aug 21; 337(8):573–4
Traumatic hearing loss following air–bag inflation [letter] Kramer MB, et al. **N Engl J Med** 1997 Aug 21;337(8):574–5
Reflex sympathetic dystrophy syndrome following air–bag inflation [letter] Shah N, et al. **N Engl J Med** 1997 Aug 21;337(8):574
Air bag–related ocular injuries. Manche EE, et al. **Ophthalmic Surg Lasers** 1997 Mar;28(3):246–50
Airbag–associated injury producing cyclodialysis cleft and ocular hypotony. Scott IU, et al. **Ophthalmic Surg Lasers** 1996 Nov;27(11):955–7
Lethal airbag injury in an infant. Hollands CM, et al. **Pediatr Emerg Care** 1996 Jun;12(3):201–2
Aortic valve injury secondary to blunt trauma from an air bag [see comments] Hanna KM, et al. **Tenn Med** 1997 May; 90(5):195–6. Comment in: Tenn Med 1997 Aug;90(8):332.
Airbags and trauma [letter; comment] Lee LH. **Tenn Med** 1997 Aug;90(3):332. Comment on: Tenn Med 1997 May;90(5):195–6.
[Air bags influence the pattern of injury in severe thoracic trauma] Pillgram–Larsen J, et al. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2437–9 (Eng. Abstr.) **(Nor)**

STANDARDS

Improving air bags [editorial; comment] Martinez R. **Ann Emerg Med** 1996 Dec;28(6):709–10. Comment on: Ann Emerg Med 1996 Dec;28(6):627–34. Comment on: Ann Emerg Med 1996 Dec;28(6):722–4.
A parametric study of a side airbag system to meet deflection based criteria. Håland Y, et al. **J Biomech Eng** 1996 Aug; 118(3):412–9

TRENDS

Motor vehicle occupant protection: have we become too complacent? Rivara FP. **Inj Prev** 1997 Jun;3(2):78

AIR BLADDER see **AIR SACS**

AIR–BLOOD BARRIER see **BLOOD–AIR BARRIER**

AIR CONDITIONING

[The effect of anesthetic method on enflurane air pollution in non–air conditioned operating rooms] Marx T, et al. **Anaesthesist** 1996 Dec;45(12):1167–70 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Sanitary impact of air conditioning: what is the relation to sick building syndrome?] Vincent D, et al. **Rev Med Interne** 1997;18(6):460–9 (37 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

A lightweight ambient air–cooling unit for use in hazardous environments. Chen YT, et al. **Am Ind Hyg Assoc J** 1997 Jan;58(1):10–4
The risks associated with HVAC drip pans. **Health Devices** 1996 Jan;25(1):43

STANDARDS

Cabin air quality. Aerospace Medical Association. Thibeault C. **Aviat Space Environ Med** 1997 Jan;68(1):80–2

AIR EMBOLISM see **EMBOLISM, AIR**

AIR IONIZATION

Physical effects of negative air ions in a wet sauna. Watanabe I, et al. **Int J Biometeorol** 1997 Apr;40(2):107–12
[The prophylactic effect of negatively charged air ions in acute stress in rats with different typological behavioral characteristics] Livanova LM, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 May–Jun; 46(3):564–70 (Eng. Abstr.) **(Rus)**

AIR MICROBIOLOGY

Coagulase–negative staphylococci in air samples from operating theatres. Kiss L, et al. **Acta Microbiol Immunol Hung** 1996;43(1):39–46
The medical and epidemiologic effects on workers of the levels of airborne Thermoactinomyces Spp. spores present in Australian raw sugar mills. Dawson MW, et al. **Am Ind Hyg Assoc J** 1996 Nov;57(11):1002–12
The use of ergosterol to measure exposure to fungal propagules in indoor air. Miller JD, et al. **Am Ind Hyg Assoc J** 1997 Jan;58(1):39–43
Exposure to airborne microbes during the repair of moldy buildings. Rautiala S, et al. **Am Ind Hyg Assoc J** 1996 Mar; 57(3):279–84
Penetration of airborne microorganisms through a surgical mask and a dust/mist respirator. Willeke K, et al. **Am Ind Hyg Assoc J** 1996 Apr;57(4):348–55
Exposure assessment for a field investigation of the acute respiratory effects of metalworking fluids. I. Summary of findings. Woskie SR, et al. **Am Ind Hyg Assoc J** 1996 Dec; 57(12):1154–62
Respiratory symptoms and lung function abnormalities among machine operators in automobile production. Sprince NL, et al. **Am J Ind Med** 1997 Apr;31(4):403–13
Aerosolization of infectious virus by excimer laser. Moreira LB, et al. **Am J Ophthalmol** 1997 Mar;123(3):297–302
Measurement methods and strategies for non–infectious microbial components in bioaerosols at the workplace. Eduard W. **Analyst** 1996 Sep;121(9):1197–201 (34 ref.)
Microbial volatile organic compounds—what substances can be found in sick buildings? Wessén B, et al. **Analyst** 1996 Sep;121(9):1203–5
Evaluation of four bioaerosol samplers in the outdoor environment. Cage BR, et al. **Ann Allergy Asthma Immunol** 1996 Nov;77(5):401–6
Exposure assessment of airborne microorganisms by fluorescence microscopy and image processing. Kildesø J, et al. **Ann Occup Hyg** 1997 Apr;41(2):201–16
Assessment of indoor climate in an apartment by use of a fungal index. Abe K, et al. **Appl Environ Microbiol** 1996 Mar;62(3):959–63
Effect of aerosolization on culturability and viability of gram–negative bacteria. Heidelberg JF, et al. **Appl Environ Microbiol** 1997 Sep;63(9):3585–8
The sea to air bacteria transfer from the coastal waters. Marks R, et al. **Bull Inst Marit Trop Med Gdynia** 1996; 47(1–4):93–103
Environmental sampling to detect Burkholderia cepacia in a cystic fibrosis outpatient clinic [letter] Humphreys H, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jun;15(6):523–5
The risks associated with HVAC drip pans. **Health Devices** 1996 Jan;25(1):43
The effect of a portable HEPA–filtered body exhaust system on airborne microbial contamination in a conventional operating room. Bohn WW, et al. **Infect Control Hosp Epidemiol** 1996 Jul;17(7):419–22
Food–borne and air–borne streptococcal pharyngitis—a clinical comparison. Bar–Dayan Y, et al. **Infection** 1997 Jan–Feb;25(1):12–5
Health and immunology study following exposure to toxigenic fungi (Stachybotrys chartarum) in a water–damaged office environment. Johanning E, et al. **Int Arch Occup Environ Health** 1996;68(4):207–18
Review of quantitative standards and guidelines for fungi in indoor air. Rao CY, et al. **J Air Waste Manag Assoc** 1996 Sep;46(9):899–908 (76 ref.)
An assessment of the Sartorius MD8 microbiological air sampler. Parks SR, et al. **J Appl Bacteriol** 1996 May; 80(5):529–34
Efficacy of the Steri–Shield filtered exhaust helmet in limiting bacterial counts in the operating room during total joint arthroplasty. Shaw JA, et al. **J Arthroplasty** 1996 Jun; 11(4):469–73
Air contamination during skin preparation and draping in joint replacement surgery. Brown AR, et al. **J Bone Joint Surg Br** 1996 Jan;78(1):92–4
Optimisation of ultraclean air. The role of instrument preparation. Chosky SA, et al. **J Bone Joint Surg Br** 1996 Sep;78(5):835–7
DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora. Wakefield AE. **J Clin Microbiol** 1996 Jul; 34(7):1754–9
Types of Pneumocystis carinii detected in air samples. Bartlett MS, et al. **J Eukaryot Microbiol** 1996 Sep–Oct; 43(5):44S
Inefficiency of upward displacement operating theatre ventilation. Friberg B, et al. **J Hosp Infect** 1996 Aug; 33(4):263–72
Aspergillus wound infection following laparostomy. Carlson GL, et al. **J Infect** 1996 Sep;33(2):119–21
Assignment and serotyping of Trichosporon species: the causative agents of summer–type hypersensitivity pneumonitis. Nishiura Y, et al. **J Med Vet Mycol** 1997 Jan–Feb;35(1):45–52
The effectiveness of an aerosol reduction device for ultrasonic scalers. King TB, et al. **J Periodontol** 1997 Jan; 68(1):45–9
Fungal biodiversity in the air of Turin. Airaudi D, et al. **Mycopathologia** 1996–97;136(2):95–102
In support of settle plates. Whyte W. **PDA J Pharm Sci Technol** 1996 Jul–Aug;50(4):201–4
The microbiologic effect of gas filtration. Schneider TL, et al. **Retina** 1996;16(2):125–8
TB breakthrough in sight [news] Jones JS. **S Afr Med J** 1996 Oct;86(10):1234, 1239
Detection of Pneumocystis carinii DNA by filtration of air. Olsson M, et al. **Scand J Infect Dis** 1996;28(3):279–82
Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice. Hart MK, et al. **Vaccine** 1997 Mar;15(4):363–9
Simulated airborne spread of Aujeszky's disease and foot–and–mouth disease. Casal J, et al. **Vet Rec** 1997 Jun 28;140(26):672–6
[A membrane filter sampling method for determining microbial air pollution] Cherneva P, et al. **Probl Khig** 1996; 21:116–22 (Eng. Abstr.) **(Bul)**
[Influence of local air suction on the density of air–borne bacteria during cementation of alloplasties] Enggaard TP, et al. **Ugeskr Laeger** 1997 Feb 10;159(7):952–5 (Eng. Abstr.) **(Dan)**
[Contribution of air mycological control for the prevention of invasive nosocomial aspergillosis] Paugam A, et al. **Pathol Biol (Paris)** 1997 May;45(5):410–3 (Eng. Abstr.) **(Fre)**
[Airborne microorganisms in animal stables. 1. Anaerobic airborne bacteria in a calf stable with special regard to Clostridium perfringens] Chai T, et al. **Berl Munch Tierarztl Wochenschr** 1997 Jan;110(1):1–4 (Eng. Abstr.) **(Ger)**
[Microbiological studies of a nasal positive pressure respirator with and without a humidifier system] Hetzel J, et al. **Wien Med Wochenschr** 1996;146(13–14):354–6 (Eng. Abstr.) **(Ger)**
[Quality of indoor air in nursery schools with different building characteristics] Leoni E, et al. **Ann Ig** 1997 Mar–Apr;9(2):133–42 **(Ita)**
[The measurement of microbial contamination of the air. I] Pitzurra M, et al. **Ann Ig** 1996 May–Jun;8(3):349–59 (Eng. Abstr.) **(Ita)**
[Measurement of microbial air pollution: cfu/m3 A.M.I. (Air Microbial Index). 2] Pitzurra M, et al. **Ann Ig** 1996 Jul–Aug; 8(4):441–52 **(Ita)**
[Pollution by mites and/or mold spores in work environments and the risk of occupational respiratory pathology] Palmas F, et al. **Med Lav** 1996 Sep–Oct;87(5):411–22 (Eng. Abstr.) **(Ita)**
[Microflora of the air in sawmills as a potential occupational hazard: concentration and composition of microflora and immunologic reactivity of workers to microbial aeroallergens] Dutkiewicz J, et al. **Pneumonol Alergol Pol** 1996;64 Suppl 1:25–31 (Eng. Abstr.) **(Pol)**

[Microflora of the in furniture factors as a potential occupational hazard: concentration and composition of microflora and immunologic reactivity of workers to microbial aeroallergens] Krysińska-Traczyk E, et al. **Pneumonol Alergol Pol** 1996;64 Suppl 1:38-44 (Eng. Abstr.) **(Pol)**

[Exposure to organic dust and microorganisms as a factor affecting respiratory function of workers of purebred horse farms] Mackiewicz B, et al. **Pneumonol Alergol Pol** 1996; 64 Suppl 1:19-24 (Eng. Abstr.) **(Pol)**

[The influence of organic dust on the chemotaxis of lung cells. Experimental studies] Milanowski J. **Pneumonol Alergol Pol** 1996;64 Suppl 1:78-89 (Eng. Abstr.) **(Pol)**

[The prevalence of bacterial and fungal aerosol in homes, offices and ambient air of Upper Silesia. Preliminary results] Lis DO, et al. **Rocz Panstw Zakl Hig** 1997;48(1):59-68 (Eng. Abstr.) **(Pol)**

[Bacterial aerosol generated by mechanical ventilators: comparative study] Dias MD, et al. **Rev Assoc Med Bras** 1997 Jan-Mar;43(1):15-20 (Eng. Abstr.) **(Por)**

[Results of integrated tests of the facility to disinfect gaseous environment of orbital stations] Balashov EV, et al. **Aviakosm Ekolog Med** 1996;30(6):37-42 (Eng. Abstr.) **(Rus)**

[Sanitizing effect of volatile isolates from the intact common Myrtle (Myrtus communis L.) plant in an interior location] Tsybulia NV, et al. **Biull Eksp Biol Med** 1996 May; 121(5):597-600 **(Rus)**

[Improvement of a portable device for isolation of bacteria from the air under study] Kotenok IaF, et al. **Gig Sanit** 1996 Jul-Aug;(4):50-2 **(Rus)**

[Methods for controlling colonization of air and laboratory surfaces by pathogens of certain especially dangerous viral infections] Chepurnov AA, et al. **Vopr Virusol** 1997 Jul-Aug;42(4):189-91 (Eng. Abstr.) **(Rus)**

AIR MOVEMENTS

Air movement around a worker in a low-speed flow field. Johnson AE, et al. **Ann Occup Hyg** 1996 Feb;40(1):57-64

The effect of contaminant source location on worker exposure in the near-wake region. Kulmala I, et al. **Ann Occup Hyg** 1996 Oct;40(5):511-23

Influence of air flow on the behavior of thoron and its progeny in a traditional Japanese house. Ma J, et al. **Health Phys** 1997 Jan;72(1):86-91

Identification of coherent structures in turbulent shear flows with a fuzzy artmap neural network. Ferre-Gine J, et al. **Int J Neural Syst** 1996 Nov;7(5):559-68

Effects of drafting during short-track speed skating. Rundell KW. **Med Sci Sports Exerc** 1996 Jun;28(6):765-71

AIR POLLUTANTS

Gaseous pollutants and plant defence mechanisms. Wellburn AR, et al. **Biochem Soc Trans** 1996 May;24(2):461-4 (15 ref.)

Impact of major air pollutants on human health. Proceedings of the EUROTOX-IUTOX satellite symposium to EUROTOX 95. Pilsen, Czech Republic, August 31-September 1, 1995. **Cent Eur J Public Health** 1996;4 Suppl:1-59

Allergen reduction measures in houses of allergic asthmatic patients: effects of air-cleaners and allergen-impermeable mattress covers [see comments] van der Heide S, et al. **Eur Respir J** 1997 Jun;10(6):1217-23. Comment in: Eur Respir J 1997 Jun;10(6):1203-4.

Atmospheric degradation of HFCs and HCFCs: chemistry and noxiousness. Carassiti V, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2-3):85-91

Human lead absorption -- Texas. **MMWR Morb Mortal Wkly Rep** 1997 Sep 19;46(37):871-7

The influence of retained mass (lung burden) on the results of intratracheal tests [letter] Jensen SL, et al. **Occup Environ Med** 1997 May;54(5):358-9

Ozone pollution in the rural United States and the new NAAQS. Chameides WL, et al. **Science** 1997 May 9; 276(5314):916

Tropospheric air pollution: ozone, airborne toxics, polycyclic aromatic hydrocarbons, and particles. Finlayson-Pitts BJ, et al. **Science** 1997 May 16;276(5315):1045-52 (193 ref.)

Getting a handle on air pollution's tiny killers [news; comment] Kaiser J. **Science** 1997 Apr 4;276(5309):33. Comment on: Science 1997 Apr 4;276(5309):96-9.

The atmospheric aerosol-forming potential of whole gasoline vapor [see comments] Odum JR, et al. **Science** 1997 Apr 4;276(5309):96-9. Comment in: Science 1997 Apr 4;276(5309):33.

[Principles of validating maximum allowable concentrations of atmospheric pollution in large tonnage release of waste] Styrikovich MA, et al. **Gig Sanit** 1996 Nov-Dec;(6):50-2 **(Rus)**

ADMINISTRATION & DOSAGE

Risk assessment of inhaled chloroform based on its mode of action. Wolf DC, et al. **Toxicol Pathol** 1997 Jan-Feb; 25(1):49-52 (36 ref.)

ADVERSE EFFECTS

Pulmonary effects of machining fluids in guinea pigs and mice. Thorne PS, et al. **Am Ind Hyg Assoc J** 1996 Dec; 57(12):1168-72

Airborne allergic contact dermatitis from pine dust. Watsky KL. **Am J Contact Dermat** 1997 Jun;8(2):118-20

Airborne dust antigen exposure and specific IgG response in the potato processing industry. Zock JP, et al. **Clin Exp Allergy** 1996 May;26(5):542-8

Health effects of outdoor air pollution. Linn WS, et al. **Compr Ther** 1996 Oct;22(10):673-9 (17 ref.)

Airborne contact dermatitis from unexpected exposure to rosin (colophony). Rosin sources revealed with chemical analyses. Karlberg AT, et al. **Contact Dermatitis** 1996 Nov; 35(5):272-8

Airborne contact dermatitis from propacetamol. Mathelier-Fusade P, et al. **Contact Dermatitis** 1997 May; 36(5):267-8

Airborne contact dermatitis due to methylchloro- and methylisothiazolinone (MCI/MI). Schubert H. **Contact Dermatitis** 1997 May;36(5):274

Air pollution and lung cancer in Trieste, Italy: spatial analysis of risk as a function of distance from sources. Biggeri A, et al. **Environ Health Perspect** 1996 Jul;104(7):750-4

Particulate air pollution and mortality [letter; comment] Moolgavkar SH, et al. **Epidemiology** 1996 Mar;7(2):212-14 . Comment on: Epidemiology 1995 Nov;6(6):629-32.

Respiratory symptoms in children of Upper Silesia, Poland cross-sectional study in two towns of different air pollution levels. Zejda JE, et al. **Eur J Epidemiol** 1996 Feb; 12(1):115-20

Short-term effects of particulate air pollution on respiratory morbidity in asthmatic children. Peters A, et al. **Eur Respir J** 1997 Apr;10(4):872-9

Noise stress and airway toxicity: a prospect for experimental analysis. Van Raaij MT, et al. **Food Chem Toxicol** 1996 Nov-Dec;34(11-12):1159-61 (15 ref.)

Individual susceptibility to inhaled pollutants--identification, mechanisms and public health policy implications. Jedrychowski W, et al. **G Ital Med Lav Ergon** 1996 Jan-May;18(1-3):63-72

The role of allergy in the pathogenesis of atopic dermatitis [letter; comment] Langeveld-Wildschut A, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):280-1. Comment on: J Am Acad Dermatol 1995 Dec;33(6):1008-18.

Radiographic small lung opacities and pleural abnormalities in relation to smoking, urbanization status, and occupational asbestos exposure in Finland. Zitting AJ, et al. **J Occup Environ Med** 1996 Jun;38(6):602-9

Symptoms and cholinesterase activity among rural residents living near cotton fields in Nicaragua. Keifer M, et al. **Occup Environ Med** 1996 Nov;53(11):726-9

Chamber challenges: the necessity of objective observation. Selner JC. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 2):S87-95

SAPALDIA: methods and participation in the cross-sectional part of the Swiss Study on Air Pollution and Lung Diseases in Adults. Martin BW, et al. **Soz Praventivmed** 1997;42(2):67-84

Climate and aeroallergen levels in asthma: a 12 month prospective study. Epton MJ, et al. **Thorax** 1997 Jun; 52(6):528-34

Free radical activity and pro-inflammatory effects of particulate air pollution (PM10) in vivo and in vitro. Li XY, et al. **Thorax** 1996 Dec;51(12):1216-22

Estimation of recent exposures to volatile organic chemicals using alveolar air measurements. Raymer JH, et al. **Toxicol Ind Health** 1996 Mar-Apr;12(2):201-10

Sister chromatid exchanges in rodent tracheal epithelium exposed in vitro to environmental pollutants. Hornberg C, et al. **Toxicol Lett** 1996 Nov;88(1-3):45-53

Chemical mixtures in atmospheric aerosols and their correlation to lung diseases and lung cancer occurence in the general population. Spurny KR. **Toxicol Lett** 1996 Nov; 88(1-3):271-7 (34 ref.)

[Cancer incidence in the Schiphol area in 1988-1993] Visser O, et al. **Ned Tijdschr Geneeskd** 1997 Mar 8;141(10):468-73 (Eng. Abstr.) **(Dut)**

[Are inhaled dust particles harmful for our lungs?] Brändli O. **Schweiz Med Wochenschr** 1996 Dec 14;126(50):2165-74 (50 ref.) (Eng. Abstr.) **(Ger)**

[Reduced lung function parameters after physical exertion in Austrian Alps in ozone concentrations below the legal warning limit] Wittels P, et al. **Wien Klin Wochenschr** 1997 May 9;109(9):321-6 (Eng. Abstr.) **(Ger)**

[Pneumological aspects of environmental medicine. Medical relevance of environmental pollution of outdoor air (1)] Hüttemann U. **Z Arztl Fortbild Qualitatssich** 1997 Feb; 91(1):27-30 (Eng. Abstr.) **(Ger)**

[Evaluation of the prevalence sensitization to common inhaled allergens in children of school age using skin tests] Brębborowicz A, et al. **Pediatr Pol** 1996 Jan;71(1):11-4 (Eng. Abstr.) **(Pol)**

[Variability of respiratory system reactions to air pollutants. Epidemiologic study of children in Cracow] Jędrychowski W, et al. **Pneumonol Alergol Pol** 1996;64(5-6):267-75 (Eng. Abstr.) **(Pol)**

ANALYSIS

Ozone increases group 5 allergen content of Lolium perenne. Masuch GI, et al. **Allergy** 1997 Aug;52(8):874-5

An experimental method for measuring aerosol deposition efficiency in the human oral airway. Cheng KH, et al. **Am Ind Hyg Assoc J** 1997 Mar;58(3):207-13

Workers exposed to thermal degradation products of TDI- and MDI-based polyurethane: biomonitoring of 2,4-TDA, 2,6-TDA, and 4,4'-MDA in hydrolyzed urine and plasma. Dalene M, et al. **Am Ind Hyg Assoc J** 1997 Aug; 58(8):587-91

Comparison of measures of exposure to asbestos in former crocidolite workers from Wittenoom Gorge, W. Australia. de Klerk NH, et al. **Am J Ind Med** 1996 Nov;30(5):579-87

Human lung parenchyma retains PM2.5. Churg A, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):2109-11

Assessment of particle size distributions in workers' aerosol exposures. Ramachandran G, et al. **Analyst** 1996 Sep; 121(9):1225-32

Microbial volatile organic compounds--what substances can be found in sick buildings? Wessén B, et al. **Analyst** 1996 Sep;121(9):1203-5

Mapping air contaminants indoors using a prototype computed tomography system. Samanta A, et al. **Ann Occup Hyg** 1996 Dec;40(6):675-91

Polychlorinated dibenzofurans and dibenzo-p-dioxins in subsurface soil, superficial dust, and air extracts from a contaminated landfill. Hansen LG, et al. **Arch Environ Contam Toxicol** 1996 Aug;31(2):271-6

Diffusive sampling and biological monitoring of 2-bromopropane. Kawai T, et al. **Arch Environ Contam Toxicol** 1997 Jul;33(1):23-8

Determination of atmospheric contamination by pentachlorophenol using pine needles located near treated utility pole storage sites. Thompson TS, et al. **Bull Environ Contam Toxicol** 1997 Oct;59(4):548-55

Scientific basis for an air quality standard on benzene. Tordoir WF. **Cent Eur J Public Health** 1996;4 Suppl:46-7

PCDD/PCDF from emission sources and ambient air in northeast Spain. Abad E, et al. **Chemosphere** 1997 Aug; 35(3):453-63

Concentrations of selected contaminants in cabin air of airbus aircrafts. Dechow M, et al. **Chemosphere** 1997 Jul; 35(1-2):21-31

Urinary excretion of dimethylhippuric acids in humans after exposure to trimethylbenzenes. Järnberg J, et al. **Int Arch Occup Environ Health** 1997;69(6):491-7

Evaluation of the TEOM method for measurement of ambient particulate mass in urban areas. Allen G, et al. **J Air Waste Manag Assoc** 1997 Jun;47(6):682-9

Characteristics of winter and summer aerosol mass and light extinction on the Colorado plateau. Sisler JF, et al. **J Air Waste Manag Assoc** 1997 Mar;47(3):317-30

Ambient air concentrations of fine (PM2.5) manganese in U.S. national parks and in California and Canadian cities: the possible impact of adding MMT to unleaded gasoline. Wallace L, et al. **J Air Waste Manag Assoc** 1997 Jun; 47(6):642-52

Evaluation of different techniques for washing cats: quantitation of allergen removed from the cat and the effect on airborne Fel d 1 [see comments] Avner DB, et al. **J Allergy Clin Immunol** 1997 Sep;100(3):307-12. Comment in: J Allergy Clin Immunol 1997 Sep;100(3):290-2.

Impinger sampling coupled to high-performance liquid chromatography by a modified autoinjector interface. Schlitt H. **J Chromatogr A** 1997 Feb 21;762(1-2):187-92

Chemical characterization of the PM10 fraction of airborne particulate matter in the urban atmosphere. Bagnoli P, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2-3):219-25

Mutagenicity and chemical analysis of airborne particulate matter collected in Pisa. Bronzetti G, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2-3):147-56

Ozone measurements in the urban and extra-urban areas of Pisa during the summer of 1995. Ciacchini G, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2-3):111-7

Aerobiologia 2.0: a software program for processing aeropollen data. Mercuri AM, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2-3):191-4

Chemical analysis and biological activity of airborne particulate matter. Morozzi G, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2-3):133-46

A study of airborne Ulmaceae pollen in Modena (northern Italy). Torri P, et al. **J Environ Pathol Toxicol Oncol** 1997; 16(2-3):227-30

Comparative evaluation of methods for estimating potential human exposure to ozone: photochemical modeling and ambient monitoring. Georgopoulos PG, et al. **J Expo Anal Environ Epidemiol** 1997 Apr-Jun;7(2):191-215

Carinal and tubular airway particle concentrations in the large airways of non-smokers in the general population: evidence for high particle concentration at airway carinas. Churg A, et al. **Occup Environ Med** 1996 Aug;53(8):553-8

Methods for assessing the extent of exposure and effects of air pollution. Krzyzanowski M. **Occup Environ Med** 1997 Mar;54(3):145-51 (46 ref.)

Asbestos exposure of building maintenance personnel. Mlynarek S, et al. **Regul Toxicol Pharmacol** 1996 Jun; 23(3):213-24

Ubiquitous fiber exposure in selected sampling sites in Europe. Schneider T, et al. **Scand J Work Environ Health** 1996 Aug;22(4):274-84

Proposed air pollutant standards [editorial] [published erratum appears in Science 1997 Aug 8;277(5327):753] Abelson PH. **Science** 1997 Jul 4;277(5322):15

Indoor air pollution by different heating systems: coal

burning, open fireplace and central heating. Moriske HJ, et al. **Toxicol Lett** 1996 Nov;88(1–3):349–54

[Blood PCDD/F levels in blood of residents of a former cable incineration facility] Ewers U, et al. **Gesundheitswesen** 1996 Aug–Sep;58(8–9):465–9 (Eng. Abstr.) **(Ger)**

[NO2 concentration in outdoor air and ambulatory physician consultations by children with asthma. Collaboration with the Lower Saxony and Saxony–Anhalt district health offices] Seidler A, et al. **Pneumologie** 1996 Dec; 50(12):889–94 (Eng. Abstr.) **(Ger)**

[Urban air pollutant exposure among traffic policemen] Priante E, et al. **Med Lav** 1996 Jul–Aug;87(4):314–22 (Eng. Abstr.) **(Ita)**

[Analysis of aromatic DNA adducts in inhabitants of Upper Silesia] Grzybowska E. **Postepy Hig Med Dosw** 1997; 51(2):185–203 (58 ref.) (Eng. Abstr.) **(Pol)**

[Mutagenic activity of atmospheric dust in Warsaw] Krogulski A, et al. **Rocz Panstw Zakl Hig** 1997;48(1):31–5 (Eng. Abstr.) **(Pol)**

[Exposure of inhabitants of Poznan to fluorides. I. Fluorides in atmospheric air, tap water and selected additional fluids] Oporowska–Moszyk K, et al. **Rocz Panstw Zakl Hig** 1997; 48(1):47–52 (Eng. Abstr.) **(Pol)**

[Exposure of Poznan inhabitants to fluorides. II. Fluorides in urine and hair of school children] Oporowska–Moszyk K, et al. **Rocz Panstw Zakl Hig** 1997;48(1):53–8 (Eng. Abstr.) **(Pol)**

[Heavy metal content of the hair of children in industrial cities] Cherniaeva TK, et al. **Gig Sanit** 1997 May–Jun; (3):26–8 (Eng. Abstr.) **(Rus)**

[Comparative characterization of heat electric power plants as the source of atmospheric pollution by benz(a)pyrenes] Kireev GV, et al. **Gig Sanit** 1996 Nov–Dec;(6):38–9 **(Rus)**

[Photochemical oxidants in Novi Sad 1992–1995] Kristoforović–Ilić M. **Med Pregl** 1996;49(9–10):398–400 (Eng. Abstr.) **(Scr)**

BLOOD

Removing the smoking confounder from blood volatile organic compounds measurements. Ashley DL, et al. **Environ Res** 1995 Oct;71(1):39–45

IMMUNOLOGY

Analysis of the allergenic composition of rat dust. Gordon S, et al. **Clin Exp Allergy** 1996 May;26(5):533–41

Airborne dust antigen exposure and specific IgG response in the potato processing industry. Zock JP, et al. **Clin Exp Allergy** 1996 May;26(5):542–8

[Specific IgE against inhaled allergens in dystreptic children with food allergy] Bujniewicz E, et al. **Pol Merkuriusz Lek** 1996 Jul;1(1):28–9 (Eng. Abstr.) **(Pol)**

ISOLATION & PURIFICATION

Atmospheric particulate pollutants and environmental health [editorial] Spurny KR. **Arch Environ Health** 1996 Nov–Dec;51(6):415–6

METABOLISM

Metabolism of hexachlorobenzene in humans: association between serum levels and urinary metabolites in a highly exposed population. To–Figueras J, et al. **Environ Health Perspect** 1997 Jan;105(1):78–83

Background exposure of urban populations to lead and cadmium: comparison between China and Japan. Zhang ZW, et al. **Int Arch Occup Environ Health** 1997; 69(4):273–81

PHARMACOKINETICS

Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease. Kim CS, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):899–905

A lung retention model based on Michaelis–Menten–like kinetics. Yu RC, et al. **Environ Health Perspect** 1997 May; 105(5):496–503

Uptake and decay of volatile organic compounds at environmental concentrations: application of a four–compartment model to a chamber study of five human subjects. Wallace LA, et al. **J Expo Anal Environ Epidemiol** 1997 Apr–Jun;7(2):141–63

Serum concentrations of methanol after inhalation at 200 ppm. Osterloh JD, et al. **J Occup Environ Med** 1996 Jun; 38(6):571–6

PHARMACOLOGY

Changes in human serum antioxidant capacity and peroxidation after four months of exposure to air pollutants. Medina–Navarro R, et al. **Arch Med Res** 1997 Summer; 28(2):205–8

Effect of airborne particulate extracts on monocyte oxidative metabolism. Fabiani R, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2–3):195–9

Pre–activating wounding response in tobacco prior to high–level ozone exposure prevents necrotic injury. Orvar BL, et al. **Plant J** 1997 Feb;11(2):203–12

Airway response of asthmatic subjects to inhaled allergen after exposure to pollutants. Rusznak C, et al. **Thorax** 1996 Nov;51(11):1105–8

Induction of prostaglandin H synthase 2 in human airway epithelial cells exposed to residual oil fly ash. Samet JM, et al. **Toxicol Appl Pharmacol** 1996 Nov;141(1):159–68

POISONING

Environmental surveys conducted in the Gulf region following the Gulf War to identify possible neurobehavioral consequences. Osman Y. **Environ Res** 1997;73(1–2):207–10

TOXICITY

Effects of air pollution on hematological and plasma parameters in Apodemus sylvaticus and Mus musculus. Gorriz A, et al. **Arch Environ Contam Toxicol** 1996 Jul; 31(1):153–8

Effects of air pollution on hematological parameters in passerine birds. Llacuna S, et al. **Arch Environ Contam Toxicol** 1996 Jul;31(1):148–52

An attempt to define a just detectable effect for airborne chemicals on the respiratory tract in mice. Boylstein LA, et al. **Arch Toxicol** 1996;70(9):567–78

Assessing the estrogenic and dioxin–like activities of chemicals and complex mixtures using in vitro recombinant receptor–reporter gene assays. Balaguer P, et al. **Can J Physiol Pharmacol** 1996 Feb;74(2):216–22

Human bronchial smooth muscle responsiveness after in vitro exposure to oxidizing pollutants. Marthan R, et al. **Cell Biol Toxicol** 1996 Dec;12(4–6):245–9

Toxicological considerations in evaluating indoor air quality and human health: impact of new carpet emissions. Dietert RR, et al. **Crit Rev Toxicol** 1996 Nov;26(6):633–707 (416 ref.)

Environmental quality objectives for 10 polycyclic aromatic hydrocarbons (PAHs). Kalf DF, et al. **Ecotoxicol Environ Saf** 1997 Feb;36(1):89–97 (46 ref.)

Role of endotoxin in tumor necrosis factor alpha expression from alveolar macrophages treated with urban air particles. Dong W, et al. **Exp Lung Res** 1996 Sep–Oct;22(5):577–92

Assessment of health effects of fluctuating concentrations using simplified pharmacokinetic algorithms. Saltzman BE. **J Air Waste Manag Assoc** 1996 Nov;46(11):1022–34

Assessment of respiratory effect of air pollution: study design on general population samples. Baldacci S, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2–3):77–83

Mutagenicity and chemical analysis of airborne particulate matter collected in Pisa. Bronzetti G, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2–3):147–56

Biological activity of particle exhaust emissions from light–duty diesel engines. Carraro E, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2–3):101–9

Airborne levels of polycyclic aromatic hydrocarbons: 32P–postlabeling DNA adducts and micronuclei in white blood cells from traffic police workers and urban residents. Merlo F, et al. **J Environ Pathol Toxicol Oncol** 1997; 16(2–3):157–62

Chemical analysis and biological activity of airborne particulate matter. Morozzi G, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2–3):133–46

Comparison of inducible nitric oxide synthase gene expression and lung inflammation following intratracheal instillation of silica, coal, carbonyl iron, or titanium dioxide in rats. Blackford JA Jr, et al. **J Toxicol Environ Health** 1997 Jun 27;51(3):203–18

Soluble transition metals mediate residual oil fly ash induced acute lung injury. Dreher KL, et al. **J Toxicol Environ Health** 1997 Feb 21;50(3):285–305

The use of a urine mutagenicity assay in the monitoring of environmental exposure to genotoxins. Cerná M, et al. **Mutat Res** 1997 Jun 13;391(1–2):99–110

Human cell mutagenicity of oxygenated, nitrated and unsubstituted polycyclic aromatic hydrocarbons associated with urban aerosols. Durant JL, et al. **Mutat Res** 1996 Dec 20;371(3–4):123–57

Exposure of organic extracts of air particulates to sunlight leads to metabolic activation independence for mutagenicity. al–Khodairy F, et al. **Mutat Res** 1997 Jun 13;391(1–2):71–7

SCE analysis in peripheral blood lymphocytes of a group of filling station attendants. Pitarque M, et al. **Mutat Res** 1997 Apr 24;390(1–2):153–9

Dairy cattle as a bioindicator of exposure to genotoxic substances in a heavily polluted area in northern Bohemia. Rubeš J, et al. **Mutat Res** 1997 Jun 13;391(1–2):57–70

DNA adducts in human placenta as related to air pollution and to GSTM1 genotype. Topinka J, et al. **Mutat Res** 1997 Apr 24;390(1–2):59–68

Pharmacokinetics of methanol and formate in female cynomolgus monkeys exposed to methanol vapors. Medinsky MA, et al. **Res Rep Health Eff Inst** 1997 Jun; (77):1–30; discussion 31–8

Pneumotoxicity and pulmonary clearance of different welding fumes after intratracheal instillation in the rat. Antonini JM, et al. **Toxicol Appl Pharmacol** 1996 Sep; 140(1):188–99

Inhalation of high concentrations of low toxicity dusts in rats results in impaired pulmonary clearance mechanisms and persistent inflammation. Warheit DB, et al. **Toxicol Appl Pharmacol** 1997 Jul;145(1):10–22

Particles, inflammation and respiratory tract carcinogenesis. Borm PJ, et al. **Toxicol Lett** 1996 Nov;88(1–3):109–13 (16 ref.)

Carcinogenicity study of outdoor airborne particulate matter in newborn male NMRI mice. Heussen GA, et al. **Toxicol Lett** 1996 Nov;88(1–3):23–8

Development of an in vitro human nasal epithelial (HNE) cell model. Schmidt D, et al. **Toxicol Lett** 1996 Nov; 88(1–3):75–9

Risk assessment of inhaled chloroform based on its mode of action. Wolf DC, et al. **Toxicol Pathol** 1997 Jan–Feb; 25(1):49–52 (36 ref.)

A review of the toxicology of air pollutants: toxicology of chemical mixtures. Oehme FW, et al. **Vet Hum Toxicol** 1996 Oct;38(5):371–7 (47 ref.)

[Tracheal normal mucin secretion and morphology and after SO2 and NO2–induced tracheobronchitis in the rat model] Wagner U. **Pneumologie** 1997 May;51(5):493–4 **(Ger)**

[Genotoxicity of urban air particulate matter] Clonfero E. **Med Lav** 1997 Jan–Feb;88(1):13–23 (81 ref.) (Eng. Abstr.) **(Ita)**

URINE

Urinary cobalt as a measure of exposure in the wet sharpening of hard metal and stellite blades. Linnainmaa M, et al. **Int Arch Occup Environ Health** 1997;69(3):193–200

The use of a urine mutagenicity assay in the monitoring of environmental exposure to genotoxins. Cerná M, et al. **Mutat Res** 1997 Jun 13;391(1–2):99–110

AIR POLLUTANTS, ENVIRONMENTAL

DNA adducts in environmental, occupational and life–style studies in human biomonitoring. Hemminki K, et al. **Acta Biochim Pol** 1996;43(2):305–12 (38 ref.)

A test chamber for experimental hydrogen fluoride exposure in humans. Søstrand P, et al. **Am Ind Hyg Assoc J** 1997 Jul;58(7):521–5

Respiratory health and long–term exposure to air pollutants in Swiss schoolchildren. SCARPOL Team. Swiss Study on Childhood Allergy and Respiratory Symptoms with Respect to Air Pollution, Climate and Pollen. Braun–Fahrländer C, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):1042–9

Respiratory tract lining fluid antioxidants: the first line of defence against gaseous pollutants. Kelly FJ, et al. **Cent Eur J Public Health** 1996;4 Suppl:11–4

Mechanisms of action of some air pollutants on the airways. Višňovský P, et al. **Cent Eur J Public Health** 1996;4 Suppl:15–6

Human exposure to air pollutants. Ashmore M. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:12–21 (0 ref.)

Aeroallergen contact dermatitis. Taïeb A, et al. **Clin Rev Allergy Immunol** 1996 Summer;14(2):209–23 (64 ref.)

New laws on landfills [news] **Environ Health Perspect** 1996 Jul;104(7):685–6

Nowhere to hide [news] **Environ Health Perspect** 1996 Jan; 104(1):13–4

Air toxics: biomarkers in environmental applications. Houston, Texas, April 27–28, 1995. Proceedings. **Environ Health Perspect** 1996 Oct;104 Suppl 5:849–932

The link between silica dust levels, risk assessments, and regulations. Goldsmith DF. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep;7(3):385–95 (58 ref.)

A practical device for histological fixative procedures that limits formaldehyde deleterious effects in laboratory environments. Nogueira MI, et al. **J Neurosci Methods** 1997 Mar;72(1):65–70

A new shade of green. Deavenport E. **Regul Toxicol Pharmacol** 1997 Apr;25(2):91–3

Personal exposure to elements in Mexico City air. Riveros–Rosas H, et al. **Sci Total Environ** 1997 May 9; 198(1):79–96

Prevalence of pathogenic Acanthamoeba (Protozoa:Amoebidae) in the atmosphere of the city of San Luis Potosi, Mexico. Rodriguez–Zaragoza S, et al. **Toxicol Ind Health** 1997 Jul–Aug;13(4):519–26

ADMINISTRATION & DOSAGE

The construction and validation of a high containment nose–only rodent inhalation facility. Hoskins JA, et al. **Ann Occup Hyg** 1997 Jan;41(1):51–61

ADVERSE EFFECTS

Connection between NO(x) and SO(x) collected from the Japanese cedar tree and Pollinosis. Ito H, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:79–84

Trends in air quality in the UK. Ayres JG. **Allergy** 1997;52(38 Suppl):7–13 (14 ref.)

Epidemiology of pollution–induced airway disease in Scandinavia and Eastern Europe. Björkstén B. **Allergy** 1997;52(38 Suppl):23–5; discussion 35–6 (11 ref.)

Epidemiology of pollution–induced airway disease in Japan. Miyamoto T. **Allergy** 1997;52(38 Suppl):30–4; discussion 35–6 (13 ref.)

Epidemiology of pollution–induced airway disease: urban/rural differences in East and West Germany. Nicolai T. **Allergy** 1997;52(38 Suppl):26–9; discussion 35–6 (18 ref.)

Mechanisms of pollution-induced airway disease: in vivo studies. Peden DB. **Allergy** 1997;52(38 Suppl):37–44; discussion 57–8 (64 ref.)

Allergen sensitization and exposure to irritants in infancy. Søyseth V, et al. **Allergy** 1996 Oct;51(10):719–23

Is the increase in asthma prevalence linked to increase in allergen load? Woolcock AJ, et al. **Allergy** 1995 Dec; 50(12):935–40 (64 ref.)

Particulate air pollution: possible relevance in asthma. Glovsky MM, et al. **Allergy Asthma Proc** 1997 May–Jun; 18(3):163–6

Reexamination of epidemic asthma in New Orleans, Louisiana, in relation to the presence of soy at the harbor. White MC, et al. **Am J Epidemiol** 1997 Mar 1;145(5):432–8

Genetic variability in combustion particle-induced chronic lung injury. Kodavanti UP, et al. **Am J Physiol** 1997 Mar; 272(3 Pt 1):L521–32

Lung function and long term exposure to air pollutants in Switzerland. Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) Team. Ackermann-Liebrich U, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):122–9

Effect of ambient ozone exposure on lung function in farm workers. Brauer M, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):981–7

Effects of air pollution on emergency room visits for respiratory illnesses in Montreal, Quebec. Delfino RJ, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):568–76

Biomarkers of lung inflammation in recreational joggers exposed to ozone. Kinney PL, et al.
Am J Respir Crit Care Med 1996 Nov;154(5):1430–5

Respiratory effects are associated with the number of ultrafine particles. Peters A, et al.
Am J Respir Crit Care Med 1997 Apr;155(4):1376–83

Summertime haze air pollution and children with asthma. Thurston GD, et al. **Am J Respir Crit Care Med** 1997 Feb; 155(2):654–60

Urinary levels of 1-hydroxypyrene, 1-, 2-, 3-, and 4-hydroxyphenanthrene in females living in an industrial area of Germany. Gündel J, et al.
Arch Environ Contam Toxicol 1996 Nov;31(4):585–90

Nitrogen dioxide, the oxides of nitrogen, and infants' health symptoms. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Farrow A, et al.
Arch Environ Health 1997 May–Jun;52(3):189–94

Responses of older men with and without chronic obstructive pulmonary disease to prolonged ozone exposure. Gong H Jr, et al. **Arch Environ Health** 1997 Jan–Feb;52(1):18–25

Pulmonary functions of school children in highly polluted northern Bohemia. Horstman D, et al.
Arch Environ Health 1997 Jan–Feb;52(1):56–62

Chamber exposures of children to mixed ozone, sulfur dioxide, and sulfuric acid. Linn WS, et al.
Arch Environ Health 1997 May–Jun;52(3):179–87

Respiratory health of children at schools near a fertilizer plant. Gomzi M. **Arh Hig Rada Toksikol** 1996 Jun; 47(2):145–55

Respiratory morbidity 10 years after the Union Carbide gas leak at Bhopal: a cross sectional survey. The International Medical Commission on Bhopal [see comments] Cullinan P, et al. **BMJ** 1997 Feb 1;314(7077):338–42. Comment in: BMJ 1997 Feb 1;314(7077):342. Comment in: BMJ 1997 Feb 1;314(7077):343.

Commentary: industry can damage your health [comment] Garner P. **BMJ** 1997 Feb 1;314(7077):342. Comment on: BMJ 1997 Feb 1;314(7077):338–42.

Short-term effects of ambient sulphur dioxide and particulate matter on mortality in 12 European cities: results from time series data from the APHEA project. Air Pollution and Health: a European Approach. Katsouyanni K, et al.
BMJ 1997 Jun 7;314(7095):1658–63

Commentary: assessing the effects of environmental pollution when people know that they have been exposed [comment] Mayon-White RT. **BMJ** 1997 Feb 1;314(7077):343. Comment on: BMJ 1997 Feb 1;314(7077):338–42.

Allergen avoidance in the primary prevention of atopy. Tariq SM. **Br J Clin Pract** 1996 Mar;50(2):99–102 (47 ref.)

Executive summary and future research. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:9–11 (0 ref.)

Epidemiology of the effects of air pollutants on allergic disease in adults. Ayres JG. **Clin Exp Allergy** 1995 Nov; 25 Suppl 3:47–51 (0 ref.)

Comparative degree and type of sensitization to common indoor and outdoor allergens in subjects with allergic rhinitis and/or asthma. Boulet LP, et al.
Clin Exp Allergy 1997 Jan;27(1):52–9

Cupressaceae pollinosis in the Madrid area. Caballero T, et al. **Clin Exp Allergy** 1996 Feb;26(2):197–201

Epidemiology of the effects of air pollutants on allergic disease in children. Carswell F. **Clin Exp Allergy** 1995 Nov; 25 Suppl 3:52–5 (0 ref.)

Ozone, airways and allergic airways disease. Krishna MT, et al. **Clin Exp Allergy** 1995 Dec;25(12):1150–8 (82 ref.)

Impact of the environment on allergic lung diseases. Rusznak C, et al. **Clin Exp Allergy** 1997 May;27 Suppl 1:26–35 (80 ref.)

Human laboratory studies of the health effects of air pollutants. Wardlaw AJ, et al. **Clin Exp Allergy** 1995 Nov; 25 Suppl 3:44–6 (0 ref.)

Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Kim PE, et al. **Clin Infect Dis** 1996 Jan;22(1):100–6

Contact allergy to aeroallergens in children with atopic dermatitis: comparison with allergic contact dermatitis. Cabon N, et al. **Contact Dermatitis** 1996 Jul;35(1):27–32

Airborne eczema due to mould allergy. Kanny G, et al.
Contact Dermatitis 1996 Dec;35(6):378

Natural rubber latex as an aeroallergen in the general environment. Ruëff F, et al. **Contact Dermatitis** 1996 Jul; 35(1):46–7

Turning CFCs into salt [news] **Environ Health Perspect** 1996 May;104(5):468–9

Health effects of acid aerosols on North American children: respiratory symptoms. Dockery DW, et al.
Environ Health Perspect 1996 May;104(5):500–5

The attack of asthma. Friebele E.
Environ Health Perspect 1996 Jan;104(1):22–5

Health and respirable particulate (PM10) air pollution: a causal or statistical association? Gamble JF, et al.
Environ Health Perspect 1996 Aug;104(8):838–50 (97 ref.)

Particulate air pollution and respiratory disease in Anchorage, Alaska. Gordian ME, et al.
Environ Health Perspect 1996 Mar;104(3):290–7

MTBE toxicity [letter] Mehlman MA.
Environ Health Perspect 1996 Aug;104(8):808

Medication use modifies the health effects of particulate sulfate air pollution in children with asthma. Peters A, et al. **Environ Health Perspect** 1997 Apr;105(4):430–5

Health effects of acid aerosols on North American children: pulmonary function. Raizenne M, et al.
Environ Health Perspect 1996 May;104(5):506–14

Health effects of acid aerosols on North American children: air pollution exposures. Spengler JD, et al.
Environ Health Perspect 1996 May;104(5):492–9

Association between ozone and asthma emergency department visits in Saint John, New Brunswick, Canada. Stieb DM, et al. **Environ Health Perspect** 1996 Dec; 104(12):1354–60

Association between ambient carbon monoxide levels and hospitalizations for congestive heart failure in the elderly in 10 Canadian cities. Burnett RT, et al. **Epidemiology** 1997 Mar;8(2):162–7

Damage to the nasopharyngeal mucosa induced by current levels of urban air pollution: a field study in lambs. Gulisano M, et al. **Eur Respir J** 1997 Mar;10(3):567–72

Epidemiological studies of the respiratory effects of air pollution. Lebowitz MD. **Eur Respir J** 1996 May; 9(5):1029–54 (306 ref.)

Effect of nitrogen dioxide and other combustion products on asthmatic subjects in a home-like environment. Salome CM, et al. **Eur Respir J** 1996 May;9(5):910–8

Environmental factors in PEF variability. Paoletti P, et al. **Eur Respir J Suppl** 1997 Feb;24:64S–66S

Aromatic hydroxylation in nasal lavage fluid following ambient ozone exposure. Frischer T, et al.
Free Radic Biol Med 1997;22(1–2):201–7

Emergency department visits and hospitalizations for respiratory disease on the island of Hawaii, 1981 to 1991. Mannino DM, et al. **Hawaii Med J** 1996 Mar;55(3):48–54

Trend of air pollution and its effect on human health in Hiroshima Prefecture—a retrospective study in the cities of Otake, Kure, Mihara, Takehara, Fukuyama and Kaita Town, 1977–1992. Setiani O. **Hiroshima J Med Sci** 1996 Jun;45(2):43–50

Acute hydrogen selenide gas poisoning admissions in one of the hospitals in Delhi, India: case report. Banerjee BD, et al. **Hum Exp Toxicol** 1997 May;16(5):276–8

An international registry for toxic inhalation and pulmonary edema: notes from work in progress. Guidotti TL.
Int Arch Occup Environ Health 1996;68(6):380–6 (28 ref.)

Frequency of patients with acute asthma in relation to ozone, nitrogen dioxide, other pollutants of ambient air and meteorological observations. Holmén A, et al.
Int Arch Occup Environ Health 1997;69(5):317–22

"Lung cancer due to diesel soot particles in ambient air?" by W. Stöber and U. Abel [editorial; comment] Kentner M, et al. **Int Arch Occup Environ Health** 1996;68 Suppl:S1–2. Comment on: Int Arch Occup Environ Health 1996;68 Suppl:S3–61.

Exposure to urban and rural air pollution: DNA and protein adducts and effect of glutathione-S-transferase genotype on adduct levels. Nielsen PS, et al.
Int Arch Occup Environ Health 1996;68(3):170–6

Lung cancer due to diesel soot particles in ambient air? A critical appraisal of epidemiological studies addressing this question [see comments] Stöber W, et al.
Int Arch Occup Environ Health 1996;68 Suppl:S3–61 (292 ref.). Comment in: Int Arch Occup Environ Health 1996;68 Suppl:S1–2.

Asthma and the indoor environment: the significance of emission of formaldehyde and volatile organic compounds from newly painted indoor surfaces. Wieslander G, et al.
Int Arch Occup Environ Health 1997;69(2):115–24

Air pollution involving nitrogen dioxide exposure and wheezing bronchitis in children. Pershagen G, et al.
Int J Epidemiol 1995 Dec;24(6):1147–53

Asthma presentations to emergency departments in western Sydney during the January 1994 Bushfires. Smith MA, et al. **Int J Epidemiol** 1996 Dec;25(6):1227–36

Methyl tertiary-butyl ether (MTBE): use as an oxygenate in fuels. Stern BR, et al. **J Appl Toxicol** 1997 May;17 Suppl 1:S1–2

An epidemiological study in an Anatolian village in Turkey environmentally exposed to tremolite asbestos. Cöplü L, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):177–82

Environment, cancer, and molecular epidemiology: air pollution. Moran EM. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):97–104 (81 ref.)

Cancer risk assessment for crystalline silica. Collins JF, et al. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep; 7(3):359–65

Noncancer inhalation toxicology of crystalline silica: exposure–response assessment. Gift JS, et al.
J Expo Anal Environ Epidemiol 1997 Jul–Sep;7(3):345–58 (42 ref.)

Criteria for conducting quantitative risk assessments for silica. Goldsmith DF, et al. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep;7(3):367–75

Initiating the risk assessment process for inhaled particulate materials: development of short term inhalation bioassays. Warheit DB, et al. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep;7(3):313–25

Ozone-exposure depletes vitamin E and induces lipid peroxidation in murine stratum corneum. Thiele JJ, et al.
J Invest Dermatol 1997 May;108(5):753–7

A discussion of the environmental influences on asthma and the role of Environmental Health Officers in combating it. Griffiths SD. **J R Soc Health** 1996 Aug;116(4):223–9

Particles in the air: the enigma of urban air pollution [published erratum appears in J R Soc Med 1997 Jan;90(1):60] Seaton A. **J R Soc Med** 1996 Nov; 89(11):604–7

Health effects due to inhalation of oilseed rape emissions. Antó JM. **Lancet** 1997 Aug 16;350(9076):458–9

Air pollution exposure-DNA adduct dosimetry in humans and rodents: evidence for non-linearity at high doses. Lewtas J, et al. **Mutat Res** 1997 Aug 1;378(1–2):51–63

Adverse health effects of PM10 particles: involvement of iron in generation of hydroxyl radical. Gilmour PS, et al.
Occup Environ Med 1996 Dec;53(12):817–22

Daily time series for cardiovascular hospital admissions and previous day's air pollution in London, UK. Poloniecki JD, et al. **Occup Environ Med** 1997 Aug;54(8):535–40

Short term variations in hospital admissions and mortality and particulate air pollution. Wordley J, et al.
Occup Environ Med 1997 Feb;54(2):108–16

Effects of ambient ozone exposures during the spring and summer of 1994 on pulmonary function of schoolchildren. Ulmer C, et al. **Pediatr Pulmonol** 1997 May;23(5):344–53

How energy policies affect public health. Romm JJ, et al.
Public Health Rep 1996 Sep–Oct;111(5):390–9 (44 ref.)

Ozone exposure and daily mortality in Mexico City: a time-series analysis. Loomis DP, et al.
Res Rep Health Eff Inst 1996 Oct;(75):1–37; discussion 39–45

Health risks from exposure to metals in household dusts. Lemus R, et al. **Rev Environ Health** 1996 Oct–Dec; 11(4):179–89

Adverse health impacts of air pollution—continuing problems. Bates DV. **Scand J Work Environ Health** 1995 Dec;21(6):405–11 (52 ref.)

Controlled human studies of ozone exposure. Bylin G.
Scand J Work Environ Health 1996;22 Suppl 3:52–71 (113 ref.)

Epidemiologic studies on ozone. Nyberg F, et al.
Scand J Work Environ Health 1996;22 Suppl 3:72–98 (144 ref.)

Lung cancer incidence among an Icelandic cohort exposed to diatomaceous earth and cristobalite. Rafnsson V, et al.
Scand J Work Environ Health 1997 Jun;23(3):187–92

Ozone and other photochemical oxidants in ambient and indoor air—properties, sources and concentrations. Sundell J, et al. **Scand J Work Environ Health** 1996;22 Suppl 3:5–14

Suspended particulate matter and health: new light on an old problem [editorial] Maynard RL, et al. **Thorax** 1996 Dec;51(12):1174–6

Dangerous and cancer-causing properties of products and chemicals in the oil-refining and petrochemical industry—Part XXII: Health hazards from exposure to gasoline containing methyl tertiary butyl ether: study of New Jersey residents. Mehlman MA.
Toxicol Ind Health 1996 Sep–Oct;12(5):613–27 (56 ref.)

Immunological alterations in sera of persons living in areas with different air pollution. Hadnagy W, et al.
Toxicol Lett 1996 Nov;88(1–3):147–53

A cohort study with children living in an air-polluted region—a model for public health. Marth E, et al.
Toxicol Lett 1996 Nov;88(1–3):155–9

Assessment of cancer hazard from environmental pollution in Silesia. Motykiewicz G, et al. **Toxicol Lett** 1996 Nov; 88(1–3):169–73

Immunological findings in groups of children after compensatory measures. Richter J, et al. **Toxicol Lett** 1996 Nov;88(1–3):165–8

Total serum IgE concentration of children from air-polluted regions. Schaffler K, et al. **Toxicol Lett** 1996 Nov; 88(1–3):161–4

Hepatic enzyme induction and mutagenicity of airborne particulate matter from Santiago, Chile in the nourished and malnourished rat. Adonis M, et al. **Xenobiotica** 1997 May;27(5):527–36

[Airborne small particles as a cause of pulmonary diseases and excessive mortality? (see comments)] Frøsig CA, et al. **Ugeskr Laeger** 1996 Oct 14;158(42):5915–9 (34 ref.) (Eng. Abstr.). Comment in: Ugeskr Laeger 1996 Dec 16;158(51):7429–30. **(Dan)**

[Air pollution, disease and death (letter; comment)] Jensen AO. **Ugeskr Laeger** 1996 Dec 16;158(51):7429–30. Comment on: Ugeskr Laeger 1996 Oct 14;158(42):5915–9. **(Dan)**

[Exposure to endotoxins in the environment. Occurrence and health hazards] Rix BA. **Ugeskr Laeger** 1997 Apr 21; 159(17):2529–33 (36 ref.) (Eng. Abstr.) **(Dan)**

[Air pollution (letter)] Wilson K. **Ugeskr Laeger** 1997 Mar 17;159(12):1779 **(Dan)**

[Urban atmospheric pollution and human public health] **Allerg Immunol (Paris)** 1997 Jun;29(6):171–9 **(Fre)**

[Urban atmospheric pollution: sources, pollutants and evolution] Festy B. **Bull Acad Natl Med** 1997 Mar 18; 181(3):461–74; discussion 474–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Asbestos and protection of the population exposed to inhalation of asbestos fibers in public and private buildings] Fournier E. **Bull Acad Natl Med** 1996 Apr;180(4):887–905 **(Fre)**

[Atmospheric pollution, mechanisms of action of inhaled toxicants] Masse R. **Bull Acad Natl Med** 1997 Mar 18; 181(3):477–88 (36 ref.) (Eng. Abstr.) **(Fre)**

[Health effects of ozone in the environment] Låg M, et al. **Tidsskr Nor Laegeforen** 1997 Jan 10;117(1):57–60 (Eng. Abstr.) **(Nor)**

[Assessment of lung cancer risk due to environmental asbestos dust exposure in the general population] Szeszenia-Dąbrowska N, et al. **Przegl Epidemiol** 1995; 49(4):407–16 (Eng. Abstr.) **(Pol)**

[Consequences of exposure to asbestos dust] Kotela I, et al. **Przegl Lek** 1996;53(8):631–3 (Eng. Abstr.) **(Pol)**

[The screening assessment indices of body immunological reactivity in young people living in the Donetsk region] Raksha-Sliusareva EA, et al. **Lik Sprava** 1996 Jul–Sep; (7–9):47–9 (Eng. Abstr.) **(Rus)**

[Artificial mineral fibers and respiratory disease. Scientific Committee on Airbone Insulating Mineral Fibers] **Arch Bronconeumol** 1996 Oct;32(8):403–9 **(Spa)**

[Asthma in a population of children and its relation to airborne environmental pollutants in Mexico City. A cohort study. Mexico, 1991. Experimental design] Meneses González F, et al. **Rev Alerg Mex** 1996 May–Jun; 43(3):66–72 (Eng. Abstr.) **(Spa)**

ANALYSIS

Ozone, suspended particulates, and daily mortality in Mexico City. Borja-Aburto VH, et al. **Am J Epidemiol** 1997 Feb 1;145(3):258–68

Measurements of indoor and outdoor nitrogen dioxide concentrations using a diffusive sampler. Hagenbjörk-Gustafsson A, et al. **Analyst** 1996 Sep; 121(9):1261–4

Spatial and temporal visualization of gases and vapours in air using computed tomography. Numerical studies. Bhattacharyya R, et al. **Ann Occup Hyg** 1997 Jan; 41(1):105–22

Asbestos bodies in the sputum of workers exposed to environmental pollution. Alderisio M, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2965–8

A multiresidue method for determination of trace levels of pesticides in air and water. Millet M, et al. **Arch Environ Contam Toxicol** 1996 Nov;31(4):543–56

Airborne (1—>3)-beta-D-glucan and airway disease in a day-care center before and after renovation. Rylander R. **Arch Environ Health** 1997 Jul–Aug;52(4):281–5

Monitoring pesticides in ambient air [letter] [see comments] Short K. **Aust N Z J Public Health** 1996 Apr;20(2):219–20 . Comment in: Aust N Z J Public Health 1996 Jun;20(3):325–6.

Trace metal biomonitoring in the soil and the leaves of Quercus ilex in the urban area of Naples. Alfani A, et al. **Biol Trace Elem Res** 1996 Jan;51(1):117–31

Concentrations of pentachlorophenol in atmospheric samples from three Canadian locations, 1994. Cessna AJ, et al. **Bull Environ Contam Toxicol** 1997 Apr;58(4):651–8

Personal sample measurements of airborne lead during abatement procedures. Lange JH, et al. **Bull Environ Contam Toxicol** 1997 Apr;58(4):659–66

Identification of pentachloronitrobenzene in ambient air extracts. Thompson TS, et al. **Bull Environ Contam Toxicol** 1997 Jun;58(6):939–44

Chemical and mutagenic analysis of volatile organic compounds in Raleigh air samples at three different elevations before, during, and after Hurricane Gordon. de Pollok FS, et al. **Chemosphere** 1997 Aug;35(4):879–93

Long-term decline of atmospheric and marine pollution by polycyclic aromatic hydrocarbons (PAHS) in Germany. Jacob J, et al. **Chemosphere** 1997 May;34(9–10):2099–108

Contamination of hospital compressed air with nitric oxide: unwitting replacement therapy. Pinsky MR, et al. **Chest** 1997 Jun;111(6):1759–63

Concentrations of air pollutants in the U.K. Maynard RL. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:22–32 (0 ref.)

Toxic gas exposures in ice arenas. Pribyl CR, et al. **Clin J Sport Med** 1996 Oct;6(4):232–6

New model for ozone transport [news] **Environ Health Perspect** 1997 Apr;105(4):368–9

Fueling the gas debate [news] [published erratum appears in Environ Health Perspect 1996 Sep;104(9):920] **Environ Health Perspect** 1996 Jul;104(7):687–9

Latex allergens in tire dust and airborne particles. Miguel AG, et al. **Environ Health Perspect** 1996 Nov; 104(11):1180–6

Possible relevance of pigeons as an indicator species for monitoring air pollution. Schilderman PA, et al. **Environ Health Perspect** 1997 Mar;105(3):322–30

Occurrence of polychlorinated terphenyls (PCTs) in indoor particulate matter. Seidel U, et al. **Environ Health Perspect** 1996 Nov;104(11):1172–9

Trend of air pollution and its effect on human health in Hiroshima Prefecture--a retrospective study in the cities of Otake, Kure, Mihara, Takehara, Fukuyama and Kaita Town, 1977–1992. Setiani O. **Hiroshima J Med Sci** 1996 Jun;45(2):43–50

Airborne emissions at skin surfaces: a potential biological exposure index. Batterman SA, et al. **Int Arch Occup Environ Health** 1996;68(4):268–74

On-line monitoring of benzene air concentrations while driving in traffic by means of isotopic dilution gas chromatography/mass spectrometry. Davoli E, et al. **Int Arch Occup Environ Health** 1996;68(4):262–7

Airborne hexavalent chromium in southwestern Ontario. Bell RW, et al. **J Air Waste Manag Assoc** 1997 Aug;47(8):905–10

Body burden measurements and models to assess inhalation exposure to methyl tertiary butyl ether (MTBE). Buckley TJ, et al. **J Air Waste Manag Assoc** 1997 Jul;47(7):739–52

Effects of grades and other loads on on-road emissions of hydrocarbons and carbon monoxide. Cicero-Fernández P, et al. **J Air Waste Manag Assoc** 1997 Aug;47(8):898–904

Alveolar breath sampling and analysis to assess exposures to methyl tertiary butyl ether (MTBE) during motor vehicle refueling. Lindstrom AB, et al. **J Air Waste Manag Assoc** 1996 Jul;46:676–82

Atmospheric pollution originating from the interaction of different gaseous effluents. Bartùli C, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2–3):245–52

Air pollution profile of Bursa. Ozer U, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):129–33

Atmospheric pollutants in Uludağ National Park. Tuncel SG, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):115–27

Use of residence time distribution for evaluation of gaseous pollutant volatilization from stored swine manure. Liao CM. **J Environ Sci Health B** 1997 Jan;32(1):127–45

Combination of direct and indirect approaches for exposure assessment. Duan N, et al. **J Expo Anal Environ Epidemiol** 1997 Oct–Dec;7(4):439–70

Sulfate concentrations as an indicator of ambient particulate matter air pollution for health risk evaluations. Lippmann M, et al. **J Expo Anal Environ Epidemiol** 1996 Apr–Jun; 6(2):123–46 (51 ref.)

Ambient PM10 emissions: contributions and impact on silica emissions. Ruble R, et al. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep;7(3):327–44 (54 ref.)

Determination of PAH in airborne particulate: comparison between off-line sampling techniques and an automatic analyser based on a photoelectric aerosol sensor. Agnesod G, et al. **Sci Total Environ** 1996 Oct 28;189–190:443–9

Occurrence of organochlorines (PCBs, pesticides) and herbicides (triazines, phenylureas) in the atmosphere and in the fallout from urban and rural stations of the Paris area. Chevreuil M, et al. **Sci Total Environ** 1996 Apr 5; 182(1–3):25–37

Turbulence effects upon the NO2/NO conversion in the vicinity of an urban area. Fraigneau Y, et al. **Sci Total Environ** 1996 Oct 28;189–190:293–300

The German heavy metal survey by means of mosses. Markert B, et al. **Sci Total Environ** 1996 Apr 5; 182(1–3):159–68

Determination of environmental reference concentration of six PAHs in urban areas (Pavia, Italy). Minoia C, et al. **Sci Total Environ** 1997 May 9;198(1):33–41

Atmospheric lead pollution in KwaZulu/Natal, South Africa. Nriagu J, et al. **Sci Total Environ** 1996 Nov 18; 191(1–2):69–76

Exposure of Danish children to traffic exhaust fumes. Raaschou-Nielsen O, et al. **Sci Total Environ** 1996 Oct 28; 189–190:51–5

Airborne platinum concentrations in Munich city buses. Schierl R, et al. **Sci Total Environ** 1996 Apr 5;182(1–3):21–3

Verification of expected trends in urban traffic NOx emissions from long-term measurements of ambient NO2 concentrations in urban air. Sjödin A, et al. **Sci Total Environ** 1996 Oct 28;189–190:213–20

Quantifying individual residential exposure to smelter emissions in four Arizona copper smelter communities: exposure estimation procedures and results. Esmen NA, et al. **Toxicol Ind Health** 1997 Mar–Jun;13(2–3):247–58

Using measured contaminant concentrations versus modeling for CERCLA-related air pathway risk assessments. Smith SA, et al. **Toxicol Ind Health** 1997 Mar–Jun;13(2–3):231–45

Free radical activity associated with the surface of particles: a unifying factor in determining biological activity? Donaldson K, et al. **Toxicol Lett** 1996 Nov;88(1–3):293–8

Pentachlorophenol in the indoor environment: evidence for a correlation between pentachlorophenol in passively deposited suspended particulate and in urine of exposed persons. Meissner T, et al. **Toxicol Lett** 1996 Nov; 88(1–3):237–42

[Association of air pollution with unscheduled outpatient visits in Beijing Longfu Hospital, 1991] Dong JW, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Feb; 17(1):13–6 (Eng. Abstr.) **(Chi)**

[Association between air pollen concentrations and seasonal allergies: synthesis of epidemiological studies published between 1978 and 1995] Quénel P, et al. **Rev Epidemiol Sante Publique** 1997 Jun;45(3):224–36 (41 ref.) (Eng. Abstr.) **(Fre)**

[Quality of indoor air in nursery schools with different building characteristics] Leoni E, et al. **Ann Ig** 1997 Mar–Apr;9(2):133–42 **(Ita)**

[The requirements for the reproducibility of an analysis of background environmental pollution by fibrous particulates (letter)] Maddalon G. **Med Lav** 1996 Sep–Oct;87(5):437–8 **(Ita)**

[Particle numbers in classified sizes of roadside dust caused by studded tires in the air at different heights from the pavement surface] Sato T, et al. **Nippon Eiseigaku Zasshi** 1996 Jul;51(2):588–98 (Eng. Abstr.) **(Jpn)**

[Reliability of routine measurements of the atmospheric air pollutant nitrogen dioxide] Matczak W, et al. **Med Pr** 1997; 48(2):145–52 (Eng. Abstr.) **(Pol)**

[Methods of extrapolating risk from from high to low doses and their effect on determining MAC values] Szymczak W. **Med Pr** 1996;47(5):501–9 (Eng. Abstr.) **(Pol)**

[Reliability of routine measurements of atmospheric air pollution using sulfur dioxide as an example] Wróblewska-Jakubowska KA, et al. **Med Pr** 1996; 47(5):467–73 (Eng. Abstr.) **(Pol)**

[Contemporary problems of exposure to lead with special consideration to the situation in Poland] Andrzejak R, et al. **Postepy Hig Med Dosw** 1996;50(6):581–95 (Eng. Abstr.) **(Pol)**

[Usefulness of immunologic and protein determinations for assessment of exposure to mercury] Moszczyński P, et al. **Przegl Lek** 1996;53(3):143–6 (Eng. Abstr.) **(Pol)**

[The prevalence of bacterial and fungal aerosol in homes, offices and ambient air of Upper Silesia. Preliminary results] Lis DO, et al. **Rocz Panstw Zakl Hig** 1997;48(1):59–68 (Eng. Abstr.) **(Pol)**

[Determination of lead, cadmium, copper and zinc in hair of children from Lublin as a test of environmental pollution] Zaborowska W, et al. **Rocz Panstw Zakl Hig** 1996;47(2):217–22 (Eng. Abstr.) **(Pol)**

[Comparative characterization of heat electric power plants as the source of atmospheric pollution by benz(a)pyrenes] Kireev GV, et al. **Gig Sanit** 1996 Nov–Dec;(6):38–9 **(Rus)**

[Regularities of transformation of organic compounds in the environment] Malysheva AG. **Gig Sanit** 1997 May–Jun; (3):5–10 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

The changing risk assessments for crystalline silica. Goldsmith DF, et al. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep;7(3):265–6

IMMUNOLOGY

Pollinosis due to Australian pine (Casuarina): an aerobiologic and clinical study in southern Spain. García JJ, et al. **Allergy** 1997 Jan;52(1):11–7

Predominant tree aeroallergens of the Washington, DC area: a six year survey (1989–1994). Kosisky SE, et al. **Ann Allergy Asthma Immunol** 1997 Apr;78(4):381–92

Sensitization and enhanced allergen responsiveness. Wardlaw AJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:56–9 (0 ref.)

Annual and diurnal incidence of Cladosporium conidia in the atmosphere of Córdoba, Spain. Mediavilla Molina A, et al. **J Investig Allergol Clin Immunol** 1997 May–Jun; 7(3):179–82

Respiratory syncytial virus infection: its role in aeroallergen sensitization during the first two years of life. Forster J, et al. **Pediatr Allergy Immunol** 1996 May;7(2):55–60

Month of birth, atopic disease, and sensitization to common aeroallergens in Greece. Karachaliou FH, et al. **Pediatr Allergy Immunol** 1995 Nov;6(4):216–9

Impact of pollution and place of residence on atopic diseases among schoolchildren in Telemark County, Norway. Steen-Johnsen J, et al. **Pediatr Allergy Immunol** 1995 Nov; 6(4):192–9

[Sensitization to industrial chemical allergens in bronchial asthma in children in environmental pollution] Dueva LA, et al. **Med Tr Prom Ekol** 1997;(2):41–5 (Eng. Abstr.) **(Rus)**

METABOLISM

Biological waste air treatment in biofilters. Deshusses MA. **Curr Opin Biotechnol** 1997 Jun;8(3):335–9 (28 ref.)

Lung epithelial cell (A549) interaction with unopsonized environmental particulates: quantitation of particle-specific binding and IL-8 production. Stringer B, et al. **Exp Lung Res** 1996 Sep–Oct;22(5):495–508

Growth and neutralization of sulfate aerosols in human airways. Sarangapani R, et al. **J Appl Physiol** 1996 Jul; 81(1):480–90

PHARMACOKINETICS

Longitudinal distribution of O3 absorption in the lung: gender differences and intersubject variability. Bush ML, et al. **J Appl Physiol** 1996 Oct;81(4):1651–7

Pharmacokinetics and disposition of methyl t-butyl ether in Fischer-344 rats. Miller MJ, et al. **J Appl Toxicol** 1997

May;17 Suppl 1:S3-12
An indoor air quality-pharmacokinetic simulation of passive inhalation of marijuana smoke and the resultant buildup of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in urine. Giardino NJ. **J Forensic Sci** 1997 Mar;42(2):323-5
Relation between pulmonary clearance and particle burden: a Michaelis-Menten-like kinetic model. Yu RC, et al. **Occup Environ Med** 1996 Aug;53(8):567-72
Environmental and urinary reference values as markers of exposure to hydrocarbons in urban areas. Minoia C, et al. **Sci Total Environ** 1996 Dec 2;192(2):163-82
In vitro uptake of methyl tert-butyl ether in male rat kidney: use of a two-compartment model to describe protein interactions. Poet TS, et al. **Toxicol Appl Pharmacol** 1997 Aug;145(2):340-8

PHARMACOLOGY

Effect of inhaled salmeterol on sulfur dioxide-induced bronchoconstriction in asthmatic subjects. Gong H Jr, et al. **Chest** 1996 Nov;110(5):1229-35
Interaction between air pollutants and aeroallergens. Emberlin J. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:33-9 (0 ref.)
Mutagenicity of the atmospheric transformation products 2-nitrofluoranthene and 2-nitrodibenzopyranone in Salmonella and human cell forward mutation assays. Busby WF Jr, et al. **Mutat Res** 1997 Mar 17;389(2-3):261-70
Acute effects of summer air pollution on respiratory function in primary school children in southern England. Scarlett JF, et al. **Thorax** 1996 Nov;51(11):1109-14
CS2-mediated cross-linking of erythrocyte spectrin and neurofilament protein: dose response and temporal relationship to the formation of axonal swellings. Valentine WM, et al. **Toxicol Appl Pharmacol** 1997 Jan;142(1):95-105
[The genetic activity of superlow doses of antitumor antibiotics and 2-nitrofluorene: the ecological aspects of the problem] Vasil'eva SV, et al. **Izv Akad Nauk Ser Biol** 1996 Nov-Dec;(6):676-80 (Eng. Abstr.) **(Rus)**

POISONING

Mortality in the elderly and ambient ozone concentration during the hot summer, 1994, in Belgium. Sartor F, et al. **Environ Res** 1997 Feb;72(2):109-17

TOXICITY

Mechanisms of pollution-induced airway disease: in vitro studies in the upper and lower airways. Devalia JL, et al. **Allergy** 1997;52(38 Suppl):45-51; discussion 57-8 (37 ref.)
Disruption of protein tyrosine phosphate homeostasis in bronchial epithelial cells exposed to oil fly ash. Samet JM, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):L426-32
Longitudinal distribution of ozone absorption in the lung: effects of nitrogen dioxide, sulfur dioxide, and ozone exposures. Rigas ML, et al. **Arch Environ Health** 1997 May-Jun;52(3):173-8
Some consequences of ozone exposure on health. Paz C. **Arch Med Res** 1997 Summer;28(2):163-70 (96 ref.)
Acute and subacute inhalation toxicity of dichlorosilane in male ICR mice. Nakashima H, et al. **Arch Toxicol** 1996; 70(3-4):218-23
Lack of evidence for the involvement of formaldehyde in the hepatocarcinogenicity of methyl tertiary-butyl ether in CD-1 mice. Casanova M, et al. **Chem Biol Interact** 1997 Jul 11;105(2):131-43
Toxicology of air pollutants (animal studies). Wardlaw AJ. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:40-3 (0 ref.)
Multiple chemical sensitivity multiorgan dysesthesia, multiple symptom complex, and multiple confusion: problems in diagnosing the patient presenting with unexplained multisystemic symptoms. Salvaggio JE, et al. **Crit Rev Toxicol** 1996 Nov;26(6):617-31 (77 ref.)
Utilization of biomarker data for clinical and environmental intervention. Christiani DC. **Environ Health Perspect** 1996 Oct;104 Suppl 5:921-5 (36 ref.)
Geographical distribution of benzene in air in northwestern Italy and personal exposure. Gilli G, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1137-40
Air toxics: biomarkers in environmental applications--overview and summary of recommendations. Holian A. **Environ Health Perspect** 1996 Oct;104 Suppl 5:851-5 (7 ref.)
Enzyme induction and acute endocrine effects in prepubertal female rats receiving environmental PCB/PCDF/PCDD mixtures. Li MH, et al. **Environ Health Perspect** 1996 Jul; 104(7):712-22
Air toxics regulatory issues facing urban settings. Olden K, et al. **Environ Health Perspect** 1996 Oct;104 Suppl 5:857-60
Biomarkers of environmental benzene exposure. Weisel C, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1141-6
Pulmonary endocrine cell hyperplasia and papilloma in rats induced by intratracheal injections of extract from particulate air pollutants. Ito T, et al. **Exp Toxicol Pathol** 1997 Feb;49(1-2):65-70
Evaluation of a novel assay of potential toxicity/neurotoxicity of carpet emissions (VOCs) in mice. Stott WT, et al. **Food Chem Toxicol** 1997 Feb;35(2):241-54
Increased immune and inflammatory responses to dust mite antigen in rats exposed to 5 ppm NO2. Gilmour MI, et al. **Fundam Appl Toxicol** 1996 May;31(1):65-70
Air pollution and allergy: experimental studies on modulation of allergen release from pollen by air pollutants. Behrendt H, et al. **Int Arch Allergy Immunol** 1997 May-Jul; 113(1-3):69-74 (26 ref.)
Altered skin prick test reactivity and histamine release with extracts from pollen exposed to pollutants. Thomas P, et al. **Int Arch Allergy Immunol** 1997 May-Jul;113(1-3):264-5
In vivo exposure to ozone produces an increase in a 72-kDa heat shock protein in guinea pigs. Su WY, et al. **J Appl Physiol** 1997 Sep;83(3):707-11
Ozone toxicity in the rat. III. Effect of changes in ambient temperature on pulmonary parameters. Wiester MJ, et al. **J Appl Physiol** 1996 Oct;81(4):1691-700
Developmental toxicity evaluation of methyl tertiary-butyl ether (MTBE) by inhalation in mice and rabbits. Bevan C, et al. **J Appl Toxicol** 1997 May;17 Suppl 1:S21-9
Two-generation reproductive toxicity study of methyl tertiary-butyl ether (MTBE) in rats. Bevan C, et al. **J Appl Toxicol** 1997 May;17 Suppl 1:S13-9
Oncogenicity studies of inhaled methyl tertiary-butyl ether (MTBE) in CD-1 mice and F-344 rats. Bird MG, et al. **J Appl Toxicol** 1997 May;17 Suppl 1:S45-55
Neurotoxicological evaluation of methyl tertiary-butyl ether in rats. Daughtrey WC, et al. **J Appl Toxicol** 1997 May; 17 Suppl 1:S57-64
Neurotoxicological evaluation of ethyl tertiary-butyl ether following subchronic (90-day) inhalation in the Fischer 344 rat. Dorman DC, et al. **J Appl Toxicol** 1997 Jul-Aug; 17(4):235-42
Evaluation of 13-week inhalation toxicity study on methyl t-butyl ether (MTBE) in Fischer 344 rats. Lington AW, et al. **J Appl Toxicol** 1997 May;17 Suppl 1:S37-44
Assessment of the in vivo mutagenic potential of methyl tertiary-butyl ether. McKee RH, et al. **J Appl Toxicol** 1997 May;17 Suppl 1:S31-6
Sulfur dioxide. Von Burg R. **J Appl Toxicol** 1996 Jul-Aug; 16(4):365-71 (96 ref.)
Temporal expression and cellular distribution of pulmonary fibronectin gene induction following exposure to an emission source particle. Su WY, et al. **J Environ Pathol Toxicol Oncol** 1995;14(3-4):215-25
Fetal exposure to low protein maternal diet alters the susceptibility of young adult rats to sulfur dioxide-induced lung injury. Langley-Evans SC, et al. **J Nutr** 1997 Feb; 127(2):202-9
Mutagenicity of scooter exhaust particulate matter. Zhou W, et al. **J Toxicol Environ Health** 1997 Sep;52(1):35-44
Atmospheric and potable water exposures to methyl tert-butyl ether (MTBE). Brown SL. **Regul Toxicol Pharmacol** 1997 Jun;25(3):256-76
Potential health risks related to carcinogens in the atmospheric environment in India. Gurjar BR, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 1):141-8
Chronic inhalation toxicity and carcinogenicity testing of respirable fibrous particles. Workshop report. Vu V, et al. **Regul Toxicol Pharmacol** 1996 Dec;24(3):202-12 (5 ref.)
Exposure-response functions for health effects of air pollutants based on epidemiological findings. Aunan K. **Risk Anal** 1996 Oct;16(5):693-709 (97 ref.)
Stimulation of human and rat alveolar macrophages by urban air particulates: effects on oxidant radical generation and cytokine production. Becker S, et al. **Toxicol Appl Pharmacol** 1996 Dec;141(2):637-48
Methyl tert-butyl ether causes alpha2u-globulin nephropathy and enhanced renal cell proliferation in male Fischer-344 rats. Prescott-Mathews JS, et al. **Toxicol Appl Pharmacol** 1997 Apr;143(2):301-14
Risk assessment of butadiene in ambient air; the approach used in the UK. Fielder RJ. **Toxicology** 1996 Oct 28; 113(1-3):221-5
Airborne particulate matter modulates the production of reactive oxygen species in human polymorphonuclear granulocytes. Hitzfeld B, et al. **Toxicology** 1997 Jul 11; 120(3):185-95
A morphometric and functional study of the toxicity of atmospheric ammonia in the extrathoracic airways in pigs. Urbain B, et al. **Vet Res Commun** 1996;20(4):381-99
[A method of mutagenic activity testing for coal tar in atmospheric dust] Krogulski A, et al. **Rocz Panstw Zakl Hig** 1996;47(2):175-80 (Eng. Abstr.) **(Pol)**
[The hygienic regulation of 3-phenoxybenzaldehyde in the atmosphere] Iskandarova ShT. **Gig Sanit** 1996 May-Jun; (3):6-8 (Eng. Abstr.) **(Rus)**

URINE

An indoor air quality-pharmacokinetic simulation of passive inhalation of marijuana smoke and the resultant buildup of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in urine. Giardino NJ. **J Forensic Sci** 1997 Mar;42(2):323-5

AIR POLLUTANTS, OCCUPATIONAL

see related

GAS SCAVENGERS

DNA adducts in environmental, occupational and life-style studies in human biomonitoring. Hemminki K, et al. **Acta Biochim Pol** 1996;43(2):305-12 (38 ref.)
Local ventilation for powder handling--combination of local supply and exhaust air. Heinonen K, et al. **Am Ind Hyg Assoc J** 1996 Apr;57(4):356-64
Penetration of airborne microorganisms through a surgical mask and a dust/mist respirator. Willeke K, et al. **Am Ind Hyg Assoc J** 1996 Apr;57(4):348-55
A field investigation of the acute respiratory effects of metal working fluids. I. Effects of aerosol exposures. Kriebel D, et al. **Am J Ind Med** 1997 Jun;31(6):756-66
Assessment of past exposure to man-made vitreous fibers in the Swedish prefabricated house industry. Plato N, et al. **Am J Ind Med** 1997 Oct;32(4):349-54
A field investigation of the acute respiratory effects of metal working fluids. II. Effects of airborne sulfur exposures. Sama SR, et al. **Am J Ind Med** 1997 Jun;31(6):767-76
Gas leakage and the laryngeal mask airway. A comparison with the tracheal tube and facemask during spontaneous ventilation using a circle breathing system. Cameron AE, et al. **Anaesthesia** 1996 Dec;51(12):1117-9
Exposure assessment of airborne microorganisms by fluorescence microscopy and image processing. Kildesø J, et al. **Ann Occup Hyg** 1997 Apr;41(2):201-16
The effect of contaminant source location on worker exposure in the near-wake region. Kulmala I, et al. **Ann Occup Hyg** 1996 Oct;40(5):511-23
Occupational exposure to desflurane and isoflurane during cardiopulmonary bypass: is the gas outlet of the membrane oxygenator an operating theatre pollution hazard? Hoerauf K, et al. **Br J Anaesth** 1997 Apr;78(4):378-80
Laryngeal cancer incidence among workers exposed to acid mists (United States). Steenland K. **Cancer Causes Control** 1997 Jan;8(1):34-8
Clinical perspective of inorganic dusts, metals, and fumes exposures. Skarote SJ, et al. **Curr Opin Pulm Med** 1997 May;3(3):209-14 (53 ref.)
The influence of atmospheric chromium on selenium content and glutathione peroxidase activity in blood of tannery workers. Gromadzińska J, et al. **Environ Health Perspect** 1996 Dec;104(12):1312-6
South Karelia Air Pollution Study: daily symptom intensity in relation to exposure levels of malodorous sulfur compounds from pulp mills. Marttila O, et al. **Environ Res** 1995 Nov;71(2):122-7
Cancer incidence around an oil refinery as an example of a small area study based on map coordinates. Pekkanen J, et al. **Environ Res** 1995 Nov;71(2):128-34
Evaluation of an activated carbon felt passive sampler in monitoring organic vapors. Byeon SH, et al. **Ind Health** 1997 Jul;35(3):404-14
Exposure of anesthesiologists to nitrous oxide during pediatric anesthesia. Chang WP, et al. **Ind Health** 1997; 35(1):112-8
Thymus-directed immunotoxicity of airborne dust particles from Upper Silesia (Poland) under acute extrapulmonary studies in mice. Kozłowska E, et al. **J Toxicol Environ Health** 1996 Dec 27;49(6):563-79
Combustion products and other firefighter exposures. Lees PS. **Occup Med** 1995 Oct-Dec;10(4):691-706 (43 ref.)
Urinary 1-naphthol excretion in the assessment of exposure to creosote in an impregnation facility. Heikkilä PR, et al. **Scand J Work Environ Health** 1997 Jun;23(3):199-205
Effect of exposure to swine dust on levels of IL-8 in airway lavage fluid. Larsson BM, et al. **Thorax** 1997 Jul; 52(7):638-42
[Staphylococcal contamination of the upper respiratory tract mucosa in children exposed to air pollution] Bukharin OV, et al. **Gig Sanit** 1996 Nov-Dec;(6):6-8 (Eng. Abstr.) **(Rus)**
[Hygienic characterization of air pollution in Cheboksary] Dimitriev DA. **Gig Sanit** 1997 Jan-Feb;(1):6-8 **(Rus)**
[Comparative characterization of waste from petrochemical and oil processing industries in the environmental air] Suleimanov RA. **Gig Sanit** 1997 Jan-Feb;(1):8-10 (Eng. Abstr.) **(Rus)**
[Substantiation of MAC of crotonaldehyde in environmental air] Tepikina LA, et al. **Gig Sanit** 1997 May-Jun;(3):3-5 (Eng. Abstr.) **(Rus)**
[Experimental data on substantiation of MAC of methyl dioxide in the workplace air] Bogachuk GP, et al. **Med Tr Prom Ekol** 1996;(11):45-7 **(Rus)**
[Dust and gas factors in extraction of polymetallic ore in Arctic conditions and their hygienic assessment] Borisenkova RV, et al. **Med Tr Prom Ekol** 1996;(7):9-13 (Eng. Abstr.) **(Rus)**
[An experimental study determining MAC in the workplace air for alkylophosphonic acids: pesticides camposan and zyod] Iskandarova GT. **Med Tr Prom Ekol** 1996;(10):41-2 **(Rus)**
[Hygienic evaluation of an enameled bathtub and washer plant] Novoselova TA, et al. **Med Tr Prom Ekol** 1997; (4):38-41 **(Rus)**

ADVERSE EFFECTS

The medical and epidemiologic effects on workers of the levels of airborne Thermoactinomyces Spp. spores present in Australian raw sugar mills. Dawson MW, et al. **Am Ind Hyg Assoc J** 1996 Nov;57(11):1002-12
Control of ethyl methacrylate exposures during the application of artificial fingernails. Spencer AB, et al. **Am Ind Hyg Assoc J** 1997 Mar;58(3):214-8
Exposure assessment for a field investigation of the acute respiratory effects of metalworking fluids. I. Summary of findings. Woskie SR, et al. **Am Ind Hyg Assoc J** 1996 Dec; 57(12):1154-62
Respirator cartridge service-life: exposure to mixtures. Yoon YH, et al. **Am Ind Hyg Assoc J** 1996 Sep;57(9):809-19
Risk of cancer and exposure to gasoline vapors. Lynge E,

et al. **Am J Epidemiol** 1997 Mar 1;145(5):449–58
Chronic lung disease secondary to ammonia inhalation injury: a report on three cases. de la Hoz RE, et al.
Am J Ind Med 1996 Feb;29(2):209–14
What to do about softwood? A review of respiratory effects and recommendations regarding exposure limits. Demers PA, et al. **Am J Ind Med** 1997 Apr;31(4):385–98 (72 ref.)
Liver function alterations in synthetic leather workers exposed to dimethylformamide. Fiorito A, et al.
Am J Ind Med 1997 Sep;32(3):255–60
A cohort mortality study of foundry workers. Hansen ES.
Am J Ind Med 1997 Sep;32(3):223–33
A meta-analysis of non-Hodgkin's lymphoma among farmers in the central United States. Keller-Byrne JE, et al.
Am J Ind Med 1997 Apr;31(4):442–4
Screening for asbestos-induced diseases in Finland. Koskinen K, et al. **Am J Ind Med** 1996 Sep;30(3):241–51
Respiratory symptoms and pulmonary function in mill workers exposed to wood dust. Liou SH, et al.
Am J Ind Med 1996 Sep;30(3):293–9
Genotoxic effects in workers exposed to low levels of benzene from gasoline. Nilsson RI, et al.
Am J Ind Med 1996 Sep;30(3):317–24
Case-control study of exposure to carbon black in the occupational setting and risk of lung cancer. Parent ME, et al. **Am J Ind Med** 1996 Sep;30(3):285–92
Colorectal cancer in asbestos cement workers in Denmark. Raffn E, et al. **Am J Ind Med** 1996 Sep;30(3):267–72
Work-related asthma and respiratory symptoms among workers exposed to metal-working fluids. Rosenman KD, et al. **Am J Ind Med** 1997 Oct;32(4):325–31
Occupational laryngitis caused by formaldehyde: a case report. Roto P, et al. **Am J Ind Med** 1996 Mar;29(3):275–77 (13 ref.)
Mortality among workers at two triazine herbicide manufacturing plants. Sathiakumar N, et al.
Am J Ind Med 1996 Feb;29(2):143–51
Chrysotile asbestos is the main cause of pleural mesothelioma. Smith AH, et al. **Am J Ind Med** 1996 Sep;30(3):252–66 (113 ref.)
Respiratory symptoms and lung function abnormalities among machine operators in automobile production. Sprince NL, et al. **Am J Ind Med** 1997 Apr;31(4):403–13
Health effects of working in pulp and paper mills: exposure, obstructive airways diseases, hypersensitivity reactions, and cardiovascular diseases. Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):111–22 (75 ref.)
Health effects of working in pulp and paper mills: malignant diseases [see comments] Torén K, et al. **Am J Ind Med** 1996 Feb;29(2):123–30 (48 ref.). Comment in: Am J Ind Med 1996 Nov;30(5):641.
Bronchial reactivity in oil-mist exposed automobile workers revisited [letter] Wild P, et al. **Am J Ind Med** 1997 Oct; 32(4):421–2
Glass bottle workers exposed to low-dose irritant fumes cough but do not wheeze. Gordon SB, et al.
Am J Respir Crit Care Med 1997 Jul;156(1):206–10
Diagnostic implications of p53 protein reactivity in nasal mucosa of nickel workers. Zhang Z, et al.
Anal Quant Cytol Histol 1997 Aug;19(4):345–50
The 1891–1920 birth cohort of Quebec chrysotile miners and millers: development from 1904 and mortality to 1992 [see comments] Liddell FD, et al. **Ann Occup Hyg** 1997 Jan; 41(1):13–36. Comment in: Ann Occup Hyg 1997 Jan;41(1):3–12.
Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Sessink PJ, et al. **Arch Environ Health** 1997 May-Jun;52(3):240–4
An investigation of multiple biomarkers among workers exposed to styrene and styrene-7,8-oxide. Rappaport SM, et al. **Cancer Res** 1996 Dec 1;56(23):5410–6
Carbon-fibre-induced airborne irritant contact dermatitis. Eedy DJ. **Contact Dermatitis** 1996 Dec;35(6):362–3
Airborne contact dermatitis from east Indian rosewood (Dalbergia latifolia Roxb). Gallo R, et al.
Contact Dermatitis 1996 Jul;35(1):60–1
Airborne irritant contact dermatitis from benzalkonium chloride. Krogsrud NE, et al. **Contact Dermatitis** 1997 Feb; 36(2):112
New clinic for chemically related illnesses [news]
Environ Health Perspect 1996 Jan;104(1):14
Biological monitoring of workers exposed to emissions from petroleum plants. Anderson D, et al.
Environ Health Perspect 1996 May;104 Suppl 3:609–13
Polycyclic aromatic hydrocarbons and cancer in man. Mastrangelo G, et al. **Environ Health Perspect** 1996 Nov; 104(11):1166–70 (33 ref.)
Effects of repeated swine building exposures on normal naive subjects. Cormier Y, et al. **Eur Respir J** 1997 Jul; 10(7):1516–22
Fatal acute pulmonary oedema after inhalation of fumes from polytetrafluoroethylene (PTFE). Lee CH, et al.
Eur Respir J 1997 Jun;10(6):1408–11
Short-term ventilatory effects in workers exposed to fumes containing zinc oxide: comparison of forced oscillation technique with spirometry. Pasker HG, et al.
Eur Respir J 1997 Jul;10(7):1523–9
Allergic alveolitis following exposure to epoxy polyester powder paint containing low amounts (<1%) of acid anhydrides. Piirilä P, et al. **Eur Respir J** 1997 Apr; 10(4):948–51
Inhalation of swine dust induces cytokine release in the upper and lower airways. Wang Z, et al. **Eur Respir J** 1997 Feb; 10(2):381–7
Environmental factors in PEF variability. Paoletti P, et al. **Eur Respir J Suppl** 1997 Feb;24:64S–66S
Genotoxic effects in workers exposed to benzene: with special reference to exposure biomarkers and confounding factors. Bogadi-Sare A, et al. **Ind Health** 1997 Jul; 35(3):367–73
Estimation of CO exposure of road construction workers in tunnel. Kamei M, et al. **Ind Health** 1997;35(1):119–25
Occupational exposure and chronic respiratory symptoms--a population based study in Vietnam. Matsuda S, et al.
Ind Health 1997 Apr;35(2):271–7
Increases of thrombomodulin activity and antigen level on human umbilical vein endothelial cells treated with asbestos and man-made mineral fibers. Urano H, et al.
Ind Health 1997 Jul;35(3):359–66
A study on the beryllium lymphocyte transformation test and the beryllium levels in working environment. Yoshida T, et al. **Ind Health** 1997 Jul;35(3):374–9
The influence of cognitive bias on the perceived odor, irritation and health symptoms from chemical exposure. Dalton P, et al. **Int Arch Occup Environ Health** 1997; 69(6):407–17
Acute effects of 1,1,1-trichloroethane inhalation on the human central nervous system. Laine A, et al.
Int Arch Occup Environ Health 1996;69(1):53–61
Neurotoxicity of long-term low-level exposure to carbon disulphide: results of questionnaire, clinical neurological examination and neuropsychological testing. Reinhardt F, et al. **Int Arch Occup Environ Health** 1997;69(5):332–8
Relationship between acetone exposure concentration and health effects in acetate fiber plant workers. Satoh T, et al. **Int Arch Occup Environ Health** 1996;68(3):147–53
Pulmonary function and symptoms of welders. Wolf C, et al. **Int Arch Occup Environ Health** 1997;69(5):350–3
Ambient particles and health: lines that divide. Vedal S.
J Air Waste Manag Assoc 1997 May;47(5):551–81 (173 ref.)
Evidence for silica's neoplastic risk among workers and derivation of cancer risk assessment. Goldsmith DF.
J Expo Anal Environ Epidemiol 1997 Jul-Sep;7(3):291–301 (46 ref.)
Neurobehavioural changes in workshop painters of a public transport network. Tripathi SR, et al.
J Hum Ergol (Tokyo) 1995 Dec;24(2):153–60
Neuropsychological performance of journeymen painters under acute solvent exposure and exposure-free conditions. Morrow LA, et al. **J Int Neuropsychol Soc** 1997 May; 3(3):269–75
Effects of prolonged low exposure to methyl isocyanate. Avashia B, et al. **J Occup Environ Med** 1996 Jun; 38(6):625–30
Mortality in carbon black workers in the United States. Robertson JM, et al. **J Occup Environ Med** 1996 Jun; 38(6):569–70
Respiratory disease as a result of talc inhalation. Scancarello G, et al. **J Occup Environ Med** 1996 Jun;38(6):610–4
Effect of chronic low-level exposure to jet fuel on postural balance of US Air Force personnel. Smith LB, et al.
J Occup Environ Med 1997 Jul;39(7):623–32
Evaluation of genotoxic potential of styrene in furniture workers using unsaturated polyester resins. Karakaya AE, et al. **Mutat Res** 1997 Aug 14;392(3):261–8
Air pollution exposure-DNA adduct dosimetry in humans and rodents: evidence for non-linearity at high doses. Lewtas J, et al. **Mutat Res** 1997 Aug 1;378(1-2):51–63
Survey of the use of personal protective equipment and prevalence of work related symptoms among dental staff. Allsopp J, et al. **Occup Environ Med** 1997 Feb;54(2):125–34
Acute effects of exposure to air contaminants in a sawmill on healthy volunteers. Dahlqvist M, et al.
Occup Environ Med 1996 Sep;53(9):586–90
Airway responsiveness, respiratory symptoms, and exposures to soluble oil mist in mechanical workers. Massin N, et al. **Occup Environ Med** 1996 Nov;53(11):748–52
Comparison of dust related respiratory effects in Dutch and Canadian grain handling industries: a pooled analysis. Peelen SJ, et al. **Occup Environ Med** 1996 Aug;53(8):559–66
Episode of toxic gas exposure in sewer workers. Watt MM, et al. **Occup Environ Med** 1997 Apr;54(4):277–80
Sick of the system? Laird R. **Occup Health Saf** 1994 Sep; 63(9):65–8
The risk of cancer in firefighters. Golden AL, et al.
Occup Med 1995 Oct-Dec;10(4):803–20 (73 ref.)
Are textile formaldehyde regulations reasonable? Experiences from the Finnish textile and clothing industries. Priha E.
Regul Toxicol Pharmacol 1995 Dec;22(3):243–9
Exposure of contractors to chemical pollutants during the maintenance shut-down of a chemical plant. Hery M, et al. **Risk Anal** 1996 Oct;16(5):645–55
Terpene exposure and respiratory effects among sawmill workers. Eriksson KA, et al.
Scand J Work Environ Health 1996 Jun;22(3):182–90
Bronchial asthma and air pollution at workplaces. Flodin U, et al. **Scand J Work Environ Health** 1996 Dec;22(6):451–6
Transient increase in DNA strand breaks in car refinishing spray painters. Fuchs J, et al.
Scand J Work Environ Health 1996 Dec;22(6):438–43
A thirteen-year follow-up of respiratory effects of acute exposure to sulfur dioxide. Piirilä PL, et al.
Scand J Work Environ Health 1996 Jun;22(3):191–6
Airway isocyanate-adducts in asthma induced by exposure to hexamethylene diisocyanate. Redlich CA, et al.
Scand J Work Environ Health 1997 Jun;23(3):227–31
Coronary heart disease mortality among Newfoundland fluorspar miners. Villeneuve PJ, et al.
Scand J Work Environ Health 1997 Jun;23(3):221–6
Exposure to styrene and mortality from nonmalignant diseases of the genitourinary system. Welp E, et al.
Scand J Work Environ Health 1996 Jun;22(3):223–6
[Changes in the humoral immune response in occupational exposure to metal aerosols] Altünkova I, et al.
Probl Khig 1996;21:122–30 (Eng. Abstr.) **(Bul)**
[Exposure to endotoxins in the environment. Occurrence and health hazards] Rix BA. **Ugeskr Laeger** 1997 Apr 21; 159(17):2529–33 (36 ref.) (Eng. Abstr.) **(Dan)**
[Air pollution (letter)] Wilson K. **Ugeskr Laeger** 1997 Mar 17;159(12):1779 **(Dan)**
[Bronchial irritation syndrome following inhalation or urea. Histologic and immunohistochemical evaluation] Lemière C, et al. **Rev Mal Respir** 1996 Dec;13(6):595–7 (Eng. Abstr.) **(Fre)**
[Environmental and work site contamination in anesthesia] Marx T.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Jan; 32(1):44–6 **(Ger)**
[Behm's T-piece for reducing anesthesia gas pollution at the anesthesia work site] Salomon F, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Sep; 31(7):425–6 (Eng. Abstr.) **(Ger)**
[Different threshold concentrations for sensitization by cattle hair allergen Bos d 2 in atopic and non-atopic farmers] Hinze S, et al. **Pneumologie** 1996 Feb;50(2):177–81 (Eng. Abstr.) **(Ger)**
[Absence of association of specific and nonspecific bronchial hyperreactivity in occupational asthma caused by platinum salts] Merget R, et al. **Pneumologie** 1997 Apr;51(4):345–50 (Eng. Abstr.) **(Ger)**
[A case of hepatocellular carcinoma related with exposure to vinyl chloride monomers] Makita O, et al.
Nippon Shokakibyo Gakkai Zasshi 1997 Mar;94(3):215–9 **(Jpn)**
[Incidence and physicians' registration of assumed occupational lung cancer in Norway] Hilt B, et al.
Tidsskr Nor Laegeforen 1997 Jan 20;117(2):203–7 (Eng. Abstr.) **(Nor)**
[Effect of cigarette smoking on T and NK cell count in blood of persons occupationally exposed to organic solvents] Moszczyński P, et al. **Med Pr** 1995;46(6):541–7 (Eng. Abstr.) **(Pol)**
[Kinetics of cell division in peripheral blood lymphocytes of stainless steel welders] Myślak M, et al. **Med Pr** 1997; 48(3):261–4 (Eng. Abstr.) **(Pol)**
[Neurologic diagnosis and certification in persons chronically exposed to certain organic solvents in light of personal cases] Sińczuk-Walczak H. **Med Pr** 1995;46(6):557–61 (Eng. Abstr.) **(Pol)**
[Occupational neoplasms in Poland in the years 1971–1994] Szeszenia-Dąbrowska N, et al. **Med Pr** 1997;48(1):1–14 (Eng. Abstr.) **(Pol)**
[Mortality from malignant neoplasms in men occupationally exposed to asbestos dust] Wilczyńska U, et al. **Med Pr** 1996; 47(5):437–43 (Eng. Abstr.) **(Pol)**
[Microflora of the air in sawmills as a potential occupational hazard: concentration and composition of microflora and immunologic reactivity of workers to microbial aeroallergens] Dutkiewicz J, et al.
Pneumonol Alergol Pol 1996;64 Suppl 1:25–31 (Eng. Abstr.) **(Pol)**
[Microflora of the in furniture factors as a potential occupational hazard: concentration and composition of microflora and immunologic reactivity of workers to microbial aeroallergens] Krysińska-Traczyk E, et al.
Pneumonol Alergol Pol 1996;64 Suppl 1:38–44 (Eng. Abstr.) **(Pol)**
[Exposure to organic dust and microorganisms as a factor affecting respiratory function of workers of purebred horse farms] Mackiewicz B, et al. **Pneumonol Alergol Pol** 1996; 64 Suppl 1:19–24 (Eng. Abstr.) **(Pol)**
[The effect of wood dust on the respiratory system. Medical examination of furniture factory workers] Milanowski J, et al. **Pneumonol Alergol Pol** 1996;64 Suppl 1:32–7 (Eng. Abstr.) **(Pol)**
[Respiratory system function in workers from the Mechanical Petrochemical Plant in Płock--influence of the workplace environment] Martusewicz M, et al.
Pol Merkuriusz Lek 1996 Jul;1(1):25–7 (Eng. Abstr.) **(Pol)**
[Clinical and biochemical manifestations of the effects of nitro esters on workers] Davletshin RA, et al.
Med Tr Prom Ekol 1997;(2):47–8 **(Rus)**
[Hygienic and immuno-allergologic aspects of the effects of formaldehyde and wood dust in furniture production] Dueva LA, et al. **Med Tr Prom Ekol** 1996;(11):13–7 (Eng. Abstr.) **(Rus)**
[Occupational bronchial asthma due to organic solvents] Ozhiganova VN, et al. **Med Tr Prom Ekol** 1997;(3):24–6 (Eng. Abstr.) **(Rus)**
[Clinical aspects of stomach and duodenal ulcer in workers exposed to phenol and formaldehyde] Pomytkina TE.
Med Tr Prom Ekol 1996;(11):40–2 **(Rus)**
[Diagnostic signs of technogenic effects of the environment in inhabitants of Bashkortostan industrial cities] Simonova NI. **Med Tr Prom Ekol** 1996;(11):8–13 (Eng. Abstr.) **(Rus)**

[The effect of organic solvents on the child-bearing function of women painters (an epidemiological hygiene study] Tikhonova GI, et al. **Med Tr Prom Ekol** 1997;(3):20-4 (Eng. Abstr.) **(Rus)**

[Optimization of the diagnosis and treatment of anemias under exposure to aromatic-type organic solvents] Shpagina LA, et al. **Ter Arkh** 1996;68(12):15-9 (Eng. Abstr.) **(Rus)**

[Mechanisms in the onset of nonspecific respiratory diseases caused by air pollutants in the work environment] Zuškin E, et al. **Arh Hig Rada Toksikol** 1996 Dec;47(4):405-11 (Eng. Abstr.) **(Scr)**

[Occupational asthma. Occupational environment may be the cause of asthma debut in adults] Torén K, et al. **Lakartidningen** 1997 Mar 12;94(11):949-52 **(Swe)**

ANALYSIS

Field precision of formaldehyde sampling and analysis using NIOSH method 3500. Akbar-Khanzadeh F, et al. **Am Ind Hyg Assoc J** 1997 Sep;58(9):657-60

Retrospective beryllium exposure assessment at the Rocky Flats Environmental Technology Site. Barnard AE, et al. **Am Ind Hyg Assoc J** 1996 Sep;57(9):804-8

Application of the thoracic sampling definition to fiber measurement. Baron PA. **Am Ind Hyg Assoc J** 1996 Sep; 57(9):820-4

Relation between in-mask and ambient concentration [letter; comment] Cherrie JW, et al. **Am Ind Hyg Assoc J** 1996 Apr;57(4):396-7, 399. Comment on: Am Ind Hyg Assoc J 1995 Mar;56(3):280-3.

Inorganic particles in the lungs of five aluminum smelter workers with pleuro-pulmonary cancer. Dufresne A, et al. **Am Ind Hyg Assoc J** 1996 Apr;57(4):370-5

Uptake of polycyclic aromatic hydrocarbons among trainers in a fire-fighting training facility. Feunekes FD, et al. **Am Ind Hyg Assoc J** 1997 Jan;58(1):23-8

Development and evaluation of an inhalable bioaerosol manifold sampler. Gao P, et al. **Am Ind Hyg Assoc J** 1997 Mar;58(3):196-206

Factors associated with exposure in Occupational Safety and Health Administration data. Gómez MR. **Am Ind Hyg Assoc J** 1997 Mar;58(3):186-95

Comparison of metalworking fluid mist exposures from machining with different levels of machine enclosure. Hands D, et al. **Am Ind Hyg Assoc J** 1996 Dec; 57(12):1173-8

Experience in the use of the NIOSH diffusive sampler evaluation protocol. Harper M, et al. **Am Ind Hyg Assoc J** 1996 Dec;57(12):1115-23 (38 ref.)

Potential health hazards from lead shielding. Klein RC, et al. **Am Ind Hyg Assoc J** 1996 Dec;57(12):1124-6

Cobalt exposure level and variability in the hard metal industry of Japan. Kumagai S, et al. **Am Ind Hyg Assoc J** 1996 Apr;57(4):365-9

Concentration and size distribution of airborne hexavalent chromium in electroplating factories. Kuo HW, et al. **Am Ind Hyg Assoc J** 1997 Jan;58(1):29-32

Laboratory measurements of oil mist concentrations using filters and an electrostatic precipitator. Leith D, et al. **Am Ind Hyg Assoc J** 1996 Dec;57(12):1137-41

Direct measurement of hexahydrophthalic anhydride in workplace air with a transportable Fourier transform infrared spectrometer. Lindh CH, et al. **Am Ind Hyg Assoc J** 1996 Sep;57(9):832-6

Silica article clarification [letter] McCully R, et al. **Am Ind Hyg Assoc J** 1996 Sep;57(9):860

Biological monitoring results for cadmium exposed workers. McDiarmid MA, et al. **Am Ind Hyg Assoc J** 1996 Nov; 57(11):1019-23

Exposure of coke-oven workers to polycyclic aromatic hydrocarbons based on biological monitoring results. Mielyńska D, et al. **Am Ind Hyg Assoc J** 1997 Sep; 58(9):661-6

Worker exposure to endotoxin, phenolic compounds, and formaldehyde in a fiberglass insulation manufacturing plant. Milton DK, et al. **Am Ind Hyg Assoc J** 1996 Oct; 57(10):889-96

Evaluation of real-time techniques to measure hydrogen peroxide in air at the permissible exposure limit. Puskar MA, et al. **Am Ind Hyg Assoc J** 1996 Sep;57(9):843-8

Evaluation of two inversion techniques for retrieving health-related aerosol fractions from personal cascade impactor measurements. Ramachandran G, et al. **Am Ind Hyg Assoc J** 1997 Jan;58(1):15-22

Worker exposures to nitrosamines in a rubber vehicle sealing plant. Reh BD, et al. **Am Ind Hyg Assoc J** 1996 Oct; 57(10):918-23

Evaluation of 1-(9-anthracenylmethyl) piperazine for the analysis of isocyanates in spray-painting operations. Rudzinski WE, et al. **Am Ind Hyg Assoc J** 1996 Oct; 57(10):914-7

Development of a novel derivatization reagent for the sampling and analysis of total isocyanate group in air and comparison of its performance with that of several established reagents. Streicher RP, et al. **Am Ind Hyg Assoc J** 1996 Oct;57(10):905-13

Air and biological monitoring of toluene diisocyanate in a flexible foam plant. Tinnerberg H, et al. **Am Ind Hyg Assoc J** 1997 Mar;58(3):229-35

Characteristics of lead aerosols in different work environments. Tsai CJ, et al. **Am Ind Hyg Assoc J** 1997 Sep;58(9):650-6

Exposures to inhalable and "total" oil mist aerosol by metal machining shop workers. Wilsey PW, et al. **Am Ind Hyg Assoc J** 1996 Dec;57(12):1149-53

Exposure of taxi drivers and office workers to total and respirable manganese in an urban environment. Zayed J, et al. **Am Ind Hyg Assoc J** 1996 Apr;57(4):376-80

A task-based approach to assessing lead exposure among iron workers engaged in bridge rehabilitation. Goldberg M, et al. **Am J Ind Med** 1997 Mar;31(3):310-8

Occupational exposure to sevoflurane, halothane and nitrous oxide during paediatric anaesthesia. Waste gas exposure during paediatric anaesthesia [see comments] Hoerauf K, et al. **Anaesthesia** 1997 Mar;52(3):215-9. Comment in: Anaesthesia 1997 Jul;52(7):714.

Elemental carbon-based method for occupational monitoring of particulate diesel exhaust: methodology and exposure issues. Birch ME, et al. **Analyst** 1996 Sep;121(9):1183-90

Electret-based passive dust sampler: sampling of organic dusts. Brown RC, et al. **Analyst** 1996 Sep;121(9):1241-6

Measurement methods and strategies for non-infectious microbial components in bioaerosols at the workplace. Eduard W. **Analyst** 1996 Sep;121(9):1197-201 (34 ref.)

Sampling intercomparisons for aldehydes in simulated workplace air. Goelen E, et al. **Analyst** 1997 May; 122(5):411-9

Summary of the NIOSH guidelines for air sampling and analytical method development and evaluation. Kennedy ER, et al. **Analyst** 1996 Sep;121(9):1163-9

Developments in workplace aerosol sampling. A review. Kenny LC. **Analyst** 1996 Sep;121(9):1233-9 (28 ref.)

Comparative study of an inhalable and a total dust sampler for personal sampling of dust and polycyclic aromatic hydrocarbons in the gas and particulate phase. Notø H, et al. **Analyst** 1996 Sep;121(9):1191-6

Effect of sampling on measurement errors. Olsen E. **Analyst** 1996 Sep;121(9):1155-61

Determination of complex mixtures of airborne isocyanates and amines. Part 3. Methylenediphenyl diisocyanate, methylenediphenylamino isocyanate and methylenediphenyldiamine and structural analogues after thermal degradation of polyurethane. Tinnerberg H, et al. **Analyst** 1997 Mar;122(3):275-8

Application of tryptamine as a derivatizing agent for the determination of airborne isocyanates. Part 7. Selection of impinger solvents and the evaluation against dimethyl sulfoxide used in US NIOSH Regulatory Method 5522. Wu WS, et al. **Analyst** 1997 Apr;122(4):321-3

The effects of welding parameters on ultra-violet light emissions, ozone and CrVI formation in MIG welding. Dennis JH, et al. **Ann Occup Hyg** 1997 Jan;41(1):95-104

Occupational exposure to carbon black in its manufacture: data from 1987 to 1992. Gardiner K, et al. **Ann Occup Hyg** 1996 Feb;40(1):65-77

A lognormal distribution-based exposure assessment method for unbalanced data. Lyles RH, et al. **Ann Occup Hyg** 1997 Jan;41(1):63-76

Scanning electron microscope sizing of airborne fibre samples: a preliminary investigation into the effects of the variable inclination of fibres to filter surfaces. McIntosh C, et al. **Ann Occup Hyg** 1996 Feb;40(1):45-55

Measurement of short-term exposure to airborne soluble platinum in the platinum industry. Maynard AD, et al. **Ann Occup Hyg** 1997 Jan;41(1):77-94

Airborne inorganic fibre level monitoring by transmission electron microscope (TEM): comparison of direct and indirect sample transfer methods. Sahle W, et al. **Ann Occup Hyg** 1996 Feb;40(1):29-44

Mapping air contaminants indoors using a prototype computed tomography system. Samanta A, et al. **Ann Occup Hyg** 1996 Dec;40(6):675-91

Semi-empirical model for the aspiration efficiencies of personal aerosol samplers of the type widely used in occupational hygiene. Tsai PJ, et al. **Ann Occup Hyg** 1996 Feb;40(1):93-113

Monitoring and modelling of exposure to ethanol in hairdressing salons. van Muiswinkel WJ, et al. **Ann Occup Hyg** 1997 Apr;41(2):235-47

Asbestos bodies in the sputum of workers exposed to environmental pollution. Alderisio M, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2965-8

N-nitroso compounds in the ambient air of metal factories using metal-working fluids. Fadlallah S, et al. **Bull Environ Contam Toxicol** 1996 Dec;57(6):867-74 (22 ref.)

Estimate of methane emissions from the U.S. natural gas industry. Kirchgessner DA, et al. **Chemosphere** 1997 Sep; 35(6):1365-90

Reduction of exposure to laboratory animal allergens in the workplace. Gordon S, et al. **Clin Exp Allergy** 1997 Jul; 27(7):744-51

Wheat antigen exposure assessment for epidemiological studies in bakeries using personal dust sampling and inhibition ELISA [see comments] Houba R, et al. **Clin Exp Allergy** 1996 Feb;26(2):154-63. Comment in: Clin Exp Allergy 1996 Feb;26(2):128-31.

Detection of snow-crab antigens by air sampling of a snow-crab production plant. Malo JL, et al. **Clin Exp Allergy** 1997 Jan;27(1):75-8

Correlation of environmental carbaryl measurements with serum and urinary 1-naphthol measurements in a farmer applicator and his family. Shealy DB, et al. **Environ Health Perspect** 1997 May;105(5):510-3

Airborne particles from latex gloves in the hospital environment. Newsom SW, et al. **Eur J Surg Suppl** 1997; (579):31-3

Drosophila melanogaster, Vicia faba and Arabidopsis thaliana short-term bioassays in genotoxicity evaluation of air and soil samples from sites surrounding two industrial factories in the Czech Republic. Chroust K, et al. **Folia Biol (Praha)** 1997;43(2):71-8

Size-selective sampling of oil mist in air and subjective symptoms among machine workers. Kira S, et al. **Ind Health** 1997 Jul;35(3):394-8

Occupational exposure to sevoflurane and nitrous oxide in operating room personnel. Hoerauf KH, et al. **Int Arch Occup Environ Health** 1997;69(2):134-8

Biological monitoring of vehicle mechanics and other workers exposed to low concentrations of benzene. Hotz P, et al. **Int Arch Occup Environ Health** 1997;70(1):29-40

Occupational exposure to Cr(VI): comparison between chromium levels in lymphocytes, erythrocytes, and urine. Lukanova A, et al. **Int Arch Occup Environ Health** 1996; 69(1):39-44

Urinary hexane diamine as an indicator of occupational exposure to hexamethylene diisocyanate. Maître A, et al. **Int Arch Occup Environ Health** 1996;69(1):65-8

Occupational exposure in Polish paint and lacquer industry. Wesołowski W, et al. **Int J Occup Med Environ Health** 1997;10(1):79-88

Occupational exposure during nitric oxide inhalational therapy in a pediatric intensive care setting. Markhorst DG, et al. **Intensive Care Med** 1996 Sep;22(9):954-8

"Air emissions from the manufacture of printing inks," (Journal of the Air & Waste Management Association, Vol. 46, July 1996, pp. 683-685), by J.B. Phillips, G.R. Mysore, J.F. Griffiths, and R.V. Bailey, Engineering Development Institute [letter] Grimes SD. **J Air Waste Manag Assoc** 1996 Dec;46(12):1118-9

"Air emissions from the manufacture of printing inks," (Journal of the Air & Waste Management Association, Vol. 46, July 1996, pp. 683-685), by J.B Phillips, G.R. Mysore, J.F. Griffiths, and R.V. Bailey, Engineering Development Institute [letter] Sutphin JH. **J Air Waste Manag Assoc** 1996 Dec;46(12):1119

Airborne levels of alpha-amylase allergens in bakeries. Houba R, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):286-92

Evaluation of environmental levels of aromatic hydrocarbons in gasoline service stations by gas chromatography. Periago JF, et al. **J Chromatogr A** 1997 Aug 22;778(1-2):263-8

The response of anesthetic agent monitors to trifluoromethane warns of the presence of carbon monoxide from anesthetic breakdown. Woehlck HJ, et al. **J Clin Monit** 1997 May;13(3):149-55

Industrial hygiene sampling and applications to ambient silica monitoring. Hearl FJ. **J Expo Anal Environ Epidemiol** 1997 Jul-Sep;7(3):279-89

Confined space hazards and fiberglass exposure [letter; comment] Bender JR. **J Occup Environ Med** 1996 Jul; 38(7):658. Comment on: J Occup Environ Med 1995 Feb;37(2):185-8.

Respiratory findings in workers not exposed to air pollutants. Zuskin E, et al. **J Occup Environ Med** 1996 Sep;38(9):912-9

Measurement of exposure to mouse urinary proteins in an epidemiological study. Gordon S, et al. **Occup Environ Med** 1997 Feb;54(2):135-40

Airway responsiveness, respiratory symptoms, and exposures to soluble oil mist in mechanical workers. Massin N, et al. **Occup Environ Med** 1996 Nov;53(11):748-52

Mortality of workers exposed to toluene diisocyanate in the polyurethane foam industry. Schnorr TM, et al. **Occup Environ Med** 1996 Oct;53(10):703-7

Contractors cited in lead exposure [news] **Occup Health Saf** 1994 May;63(5):26

Colorimetric tubes: cost-effective gear in the IH toolbox. Breeding DC. **Occup Health Saf** 1996 Apr;65(4):65-8

Alarming readings. Rekus J. **Occup Health Saf** 1994 Oct; 63(10):59-62, 64, 66-7

A survey of starch particle counts in the hospital environment in relation to the use of powdered latex gloves. Newsom SW, et al. **Occup Med (Oxf)** 1997 Apr;47(3):155-8

Pentamidine aerosols and environmental contamination: health-care workers at risk. Ros JJ, et al. **Pharm World Sci** 1996 Aug;18(4):148-52

An assessment of heavy metals and boron contamination in workplace atmospheres from ceramic factories. Roig-Navarro AF, et al. **Sci Total Environ** 1997 Aug 18; 201(3):225-34

[A chemical hygiene assessment of point emitters and of an unorganized source of air pollution from copper smelting at Nipkitoks in the city of Pernik] Gülübova V, et al. **Probl Khig** 1996;21:112-5 (Eng. Abstr.) **(Bul)**

[Carbon monoxide exposure in automobile garages: evaluation of mechanics] Gourdeau P, et al. **Can J Public Health** 1995 Nov-Dec;86(6):414-7 (Eng. Abstr.) **(Fre)**

[Reclaiming volatile and gaseous anesthetics] Bäder S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):46-8 **(Ger)**

[Effectiveness of anesthetic gas scavengers fulfilling EN 740 requirements with reference to equipment leakage and fresh gas flow] Marx T, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):101-4 (Eng. Abstr.) **(Ger)**

[Exposure of operating room personnel to anesthetic gases during ENT interventions (see comments)] Hoerauf K, et

al. **HNO** 1996 Oct;44(10):567–71 (Eng. Abstr.). Comment in: HNO 1996 Oct;44(10):554–5. **(Ger)**

[An example for stepwise reduction of work site–induced formaldehyde exposure in pathology] Binding N, et al. **Pathologe** 1996 Sep;17(5):380–4 (Eng. Abstr.) **(Ger)**

[The determination of asbestos fiber concentration by scanning electron microscopy: a comparison of the results obtained by different laboratories] Paoletti L, et al. **Med Lav** 1996 Sep–Oct;87(5):386–93 (Eng. Abstr.) **(Ita)**

[Evaluation of a protocol of health surveillance for the personnel exposed to inhalation anesthetics in a sample of 3 operating rooms] Domenegati E, et al. **Minerva Anestesiol** 1996 Sep;62(9):297–305 (Eng. Abstr.) **(Ita)**

[A study of waste anesthetic gases monitoring and working environmental controls in hospital operating rooms] Koda S, et al. **Sangyo Eiseigaku Zasshi** 1997 Jan;39(1):38–45 (Eng. Abstr.) **(Jpn)**

[Determination of polycyclic aromatic hydrocarbons in the working environment during aluminum production] Brzeźnicki S, et al. **Med Pr** 1996;47(1):1–8 (Eng. Abstr.) **(Pol)**

[Use of biological monitoring for evaluating occupational exposure in the paint and varnish industry] Kostrzewski P. **Med Pr** 1995;46(6):549–55 (Eng. Abstr.) **(Pol)**

[Evaluation of exposure to toxic factors occurring in the cellulose and paper industry] Szadkowska–Stańczyk I, et al. **Med Pr** 1995;46(6):563–74 (Eng. Abstr.) **(Pol)**

[A quantitative evaluation of risk associated with occupational inhalation exposure to polycyclic aromatic hydrocarbons in Polish production plants] Szymczak W. **Med Pr** 1996;47(6):547–57 (Eng. Abstr.) **(Pol)**

[Quantitative evaluation of health risk associated with occupational inhalation exposure to vinyl chloride at production plants in Poland] Szymczak W. **Med Pr** 1997; 48(2):153–9 (Eng. Abstr.) **(Pol)**

[Occupational exposure to organic solvent vapors among workers in industrial enterprises of Estonia] Veimer S, et al. **Med Pr** 1996;47(5):455–60 (Eng. Abstr.) **(Pol)**

[Prognosis after exposure to engine fuel vapours] Wesołowski W, et al. **Med Pr** 1996;47(1):19–29 (Eng. Abstr.) **(Pol)**

[Exposure to ceramic fibers in the work environment. III. occupational exposure to ceramic fibers in plants which produce and apply insulation materials made of ceramic fibers] Wojtczak J, et al. **Med Pr** 1997;48(1):51–60 (Eng. Abstr.) **(Pol)**

[Silicon carbide, occupational exposure, proposed MAC values] Woźniak H, et al. **Med Pr** 1997;48(2):129–37 (Eng. Abstr.) **(Pol)**

[Microflora of the air in sawmills as a potential occupational hazard: concentration and composition of microflora and immunologic reactivity of workers to microbial aeroallergens] Dutkiewicz J, et al. **Pneumonol Alergol Pol** 1996;64 Suppl 1:25–31 (Eng. Abstr.) **(Pol)**

[Microflora of the in furniture factors as a potential occupational hazard: concentration and composition of microflora and immunologic reactivity of workers to microbial aeroallergens] Krysińska–Traczyk E, et al. **Pneumonol Alergol Pol** 1996;64 Suppl 1:38–44 (Eng. Abstr.) **(Pol)**

[The prevalence of bacterial and fungal aerosol in homes, offices and ambient air of Upper Silesia. Preliminary results] Lis DO, et al. **Rocz Panstw Zakl Hig** 1997;48(1):59–68 (Eng. Abstr.) **(Pol)**

[Gas chromatographic determination of dicyclohexyl ethers of succinic, glutaric and adipic acids in the workplace air] Guglia EB. **Gig Sanit** 1996 Jul–Aug;(4):52–3 **(Rus)**

[The control of the level of nitrogen oxides in the air of mines when using diesel–drive machines] Chebotarev AG, et al. **Med Tr Prom Ekol** 1997;(3):30–4 (Eng. Abstr.) **(Rus)**

[Determination of orthophosphoric and orthophosphorous acids in the workplace air using ion chromatography] Guglia EB. **Med Tr Prom Ekol** 1996;(10):34–6 (Eng. Abstr.) **(Rus)**

[Detection of minimal ammonia concentrations using the aerosol method] Korableva AA, et al. **Med Tr Prom Ekol** 1996;(10):31–4 (Eng. Abstr.) **(Rus)**

[Elaboration and improvement of biochemical methods in early diagnosis and prognostication of the development of occupational diseases] Pavlovskaia NA, et al. **Med Tr Prom Ekol** 1997;(2):45–7 (Eng. Abstr.) **(Rus)**

BLOOD

A study of the relationship between ambient lead and blood lead among lead battery workers. Lai JS, et al. **Int Arch Occup Environ Health** 1997;69(4):295–300

[Determination of methyl sulfide compounds in biological fluids] Taranenko NA, et al. **Gig Sanit** 1997 May–Jun; (3):57–9 **(Rus)**

IMMUNOLOGY

[Incidence of cutaneous sensitization to environmental allergens in obstructive sleep apnea syndrome] Duchna HW, et al. **Pneumologie** 1997 Aug;51 Suppl 3:763–6 (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

[Pollution by mites and/or mold spores in work environments and the risk of occupational respiratory pathology] Palmas F, et al. **Med Lav** 1996 Sep–Oct;87(5):411–22 (Eng. Abstr.) **(Ita)**

METABOLISM

Role of alveolar macrophages in the dissolution of two different industrial uranium oxides. Hengé–Napoli MH, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 May;42(3):413–20

PHARMACOKINETICS

The use of toxic equivalency factors in assessing occupational and environmental health risk associated with exposure to airborne mixtures of polycyclic aromatic hydrocarbons (PAHs). Petry T, et al. **Chemosphere** 1996 Feb;32(4):639–48

[Evaluation of the absorption of polycyclic aromatic hydrocarbons by analysing 1–hydroxypyrene in the urine of the workers in a factory of graphite electrodes] Marchionna G, et al. **Med Lav** 1996 Mar–Apr;87(2):162–70 (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Profound effects of the weak environmental estrogen–like chemical bisphenol A on the growth of the mammary gland of Noble rats. Colerangle JB, et al. **J Steroid Biochem Mol Biol** 1997 Jan;60(1–2):153–60

[Acid resistance of erythrocytes in workers of the Astrakhan gas processing plant] Balashov VI, et al. **Med Tr Prom Ekol** 1996;(11):38–40 **(Rus)**

POISONING

Acute arsine intoxication as a consequence of metal burnishing operations. Romeo L, et al. **Am J Ind Med** 1997 Sep;32(3):211–6

Social and economic impact of neurotoxicity in hazardous waste workers in Lenoir, North Carolina. Callender TJ, et al. **Environ Res** 1997;73(1–2):166–74

Motor function, olfactory threshold, and hematological indices in manganese–exposed ferroalloy workers. Lucchini R, et al. **Environ Res** 1997;73(1–2):175–80

Solvent exposure and ratings of well–being: dose–effect relationships and consistency of data. Seeber A, et al. **Environ Res** 1997;73(1–2):81–91

The usefulness of thiosulfate as an indicator of hydrogen sulfide poisoning: three cases. Kage S, et al. **Int J Legal Med** 1997;110(4):220–2

Fatal gassing due to methylene chloride – a case report. Tay P, et al. **Singapore Med J** 1995 Aug;36(4):444–5

[The toxicological, hygienic and clinical aspects of the action of low levels of organic solvents] Ulanova IP, et al. **Med Tr Prom Ekol** 1997;(3):11–7 (Eng. Abstr.) **(Rus)**

STANDARDS

What to do about softwood? A review of respiratory effects and recommendations regarding exposure limits. Demers PA, et al. **Am J Ind Med** 1997 Apr;31(4):385–98 (72 ref.)

Recommendations for reducing the effect of grain dust on the lungs. Canadian Thoracic Society Standards Committee. Becklake M, et al. **Can Med Assoc J** 1996 Nov 15;155(10):1399–403

Review of international criteria and mixture rules for health hazard classification. Ignatowski AJ, et al. **Regul Toxicol Pharmacol** 1995 Dec;22(3):231–42

TOXICITY

Toxicity in vitro of some silicon carbides and silicon nitrides: whiskers and powders. Svensson I, et al. **Am J Ind Med** 1997 Mar;31(3):335–43

Respiratory effects of a synthetic metalworking fluid and its components. Detwiler–Okabayashi KA, et al. **Arch Toxicol** 1996;70(3–4):195–201

The use of toxic equivalency factors in assessing occupational and environmental health risk associated with exposure to airborne mixtures of polycyclic aromatic hydrocarbons (PAHs). Petry T, et al. **Chemosphere** 1996 Feb;32(4):639–48

Sensitivity of mouse lymphoid and nonlymphoid organs to Silesian air pollutants. Kozlowska E, et al. **Ecotoxicol Environ Saf** 1997 Jun;37(1):10–6

Bisphenol A in food cans: an update [letter] Hoyle WC, et al. **Environ Health Perspect** 1997 Jun;105(6):570–2

Responses to welding fumes: lung injury, inflammation, and the release of tumor necrosis factor–alpha and interleukin–1 beta. Antonini JM, et al. **Exp Lung Res** 1997 May–Jun; 23(3):205–27

Superoxide anion release by alveolar macrophages exposed to respirable industrial fibres: modifying effect of fibre opsonisation. Donaldson K, et al. **Exp Toxicol Pathol** 1995 Sep;47(4):229–31

Induction of sister chromatid exchanges in rodent tracheal epithelial cells as a sensitive bioassay for detection of genotoxic activity of airborne particulates. Hornberg C, et al. **Exp Toxicol Pathol** 1995 Sep;47(4):241–3

Pulmonary immunotoxicity of inhaled ammonium metavanadate in Fisher 344 rats. Cohen MD, et al. **Fundam Appl Toxicol** 1996 Oct;33(2):254–63

Sequence of toxic events in arsine–induced hemolysis in vitro: implications for the mechanism of toxicity in human erythrocytes. Winski SL, et al. **Fundam Appl Toxicol** 1997 Aug;38(2):123–8

Laboratory studies on silica induced toxicity and relationship to carcinogenicity. Rabovsky J. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep;7(3):267–78 (51 ref.)

Ketone potentiation of intrahepatic cholestasis: effect of two aliphatic isomers. Duguay AB, et al. **J Toxicol Environ Health** 1997 Jan;50(1):41–52

Reactive oxygen species do not cause arsine–induced hemoglobin damage. Hatlelid KM, et al. **J Toxicol Environ Health** 1997 Apr 11;50(5):463–74

Reproductive hazards and firefighters. McDiarmid MA, et al. **Occup Med** 1995 Oct–Dec;10(4):829–41 (84 ref.)

Exposure to methylmethacrylate in an orthopaedic operating theatre [letter] Williams S, et al. **Occup Med (Oxf)** 1996 Aug;46(4):322–3

Application of beryllium antibodies in risk assessment and health surveillance: two case studies. Clarke SM, et al. **Toxicol Ind Health** 1995 Jul–Aug;11(4):399–411

[Environmental and biological monitoring of occupational exposure to perchloroethylene in dry cleaning shops] Gobba F, et al. **Med Lav** 1997 Jan–Feb;88(1):24–36 (Eng. Abstr.) **(Ita)**

[The behavior of rat progeny after prenatal benzene exposure in an iron–deficiency state of the mother] Senichenkova IN, et al. **Fiziol Zh Im I M Sechenova** 1996 May–Jun; 82(5–6):95–101 (Eng. Abstr.) **(Rus)**

[A method of integral evaluation of the toxicity industrial ferrous alloy waste] Kazachenok NN, et al. **Gig Sanit** 1996 Sep–Oct;(5):49–50 **(Rus)**

[The establishment of the maximum permissible concentration of orlok in the air of a work area when used in agriculture] Nakariakova MV, et al. **Gig Sanit** 1996 May–Jun;(3):15–7 (Eng. Abstr.) **(Rus)**

[The validation of the maximum permissible concentration of pyromellitic dianhydride in the atmosphere] Sokolov SM, et al. **Gig Sanit** 1997 Mar–Apr;(2):6–8 (Eng. Abstr.) **(Rus)**

[Effects of highly dispersed aerosol of silicon nitride modified by yttrium oxide] Baranov VI, et al. **Med Tr Prom Ekol** 1996;(7):41–3 **(Rus)**

[Occupational hygiene in production and use of multicomponent metal compounds] Fadeev AI. **Med Tr Prom Ekol** 1996;(10):4–6 (Eng. Abstr.) **(Rus)**

[Clinical and psychological criteria of early detection of hazardous effects of components of synthetic hydrocarbon fuel] Kiselev DB, et al. **Med Tr Prom Ekol** 1997;(6):34–7 (Eng. Abstr.) **(Rus)**

[Hygienic evaluation of the effects of vibration and arsenic in miners engaged in extraction of arsenic–containing ore] Remizov IuA, et al. **Med Tr Prom Ekol** 1996;(12):25–8 (Eng. Abstr.) **(Rus)**

[Anion–produced surface active agents, derivatives of alkylbenzyl sulfonic acid: toxicity and hazards] Sidorin GI, et al. **Med Tr Prom Ekol** 1996;(11):42–5 **(Rus)**

[The toxicological, hygienic and clinical aspects of the action of low levels of organic solvents] Ulanova IP, et al. **Med Tr Prom Ekol** 1997;(3):11–7 (Eng. Abstr.) **(Rus)**

[An evaluation of the mutagenic activity of the air pollutants in the area of a plant for the manufacture of synthetic rubber by using Tradescantia (clone 02) as the test object] Atoiants AL, et al. **Tsitol Genet** 1996 May–Jun;30(3):26–31 (Eng. Abstr.) **(Rus)**

URINE

Analysis of some metabolites of organic solvents in urine by high–performance liquid chromatography with beta–cyclodextrin. Moon DH, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):367–74

Adjustment of urinary mercury in health risk assessment of mercury. Lee E, et al. **J Korean Med Sci** 1996 Aug; 11(4):319–25

Epidemiologic assessment of measures used to indicate low–level exposure to mercury vapor (Hg). Cianciola ME, et al. **J Toxicol Environ Health** 1997 Sep;52(1):19–33

AIR POLLUTANTS, RADIOACTIVE

Solubility characterization of airborne uranium from an in situ uranium processing plant. Metzger R, et al. **Health Phys** 1997 Mar;72(3):418–22

NESHAP risk assessment [letter] Weinstock LG. **Health Phys** 1997 Feb;72(2):321

Regulatory issues are primary focus for nuclear medicine groups [news] Nichols D. **J Nucl Med** 1997 Feb;38(2):17N

ADMINISTRATION & DOSAGE

Deposition of monodisperse particles in hollow models representing adult and child–size tracheobronchial airways. Oldham MJ, et al. **Health Phys** 1997 Jun;72(6):827–34

Intake of 226Ra, 210Pb and 210Po with food in Poland. Pietrzak–Flis Z, et al. **Sci Total Environ** 1997 Sep 6; 203(2):157–65

ADVERSE EFFECTS

A case–control study of cancer risk factors in the Alaskan Arctic: responding to village concern about environmental radiation. Bowerman RJ. **Arctic Med Res** 1996 Jul; 55(3):129–34

Radiotoxicity of tritiated water and tritiated hydrogen. Franić Z. **Arh Hig Rada Toksikol** 1996 Dec;47(4):359–67

Radon exposure and incidence of paediatric malignancies [letter; comment] Thorne R, et al. **Eur J Cancer** 1996 Dec; 32A(13):2371–2. Comment on: Eur J Cancer 1996

Feb;32A(2):201–4.
Radon and cancer. Bochicchio F. **Eur J Cancer Prev** 1996 Oct;5(5):383–4 (12 ref.)
Response to Cohen's plea for help [letter] Archer VE. **Health Phys** 1997 Sep;73(3):530–2
Questionnaire study of the lung cancer risk from radon in homes. Cohen BL. **Health Phys** 1997 Apr;72(4):615–22
Problems in the radon vs lung cancer test of the linear no–threshold theory and a procedure for resolving them. Cohen BL. **Health Phys** 1997 Apr;72(4):623–8
Deposition of monodisperse particles in hollow models representing adult and child–size tracheobronchial airways. Oldham MJ, et al. **Health Phys** 1997 Jun;72(6):827–34
Case–control study of possible risk factors for cancer among residents of a small village in Alaska [letter] Beller M, et al. **Int J Circumpolar Health** 1997 Apr;56(1–2):54–9
Quantification of FISH–painted chromosome aberrations after domestic radon exposure. Bauchinger M, et al. **Int J Radiat Biol** 1996 Dec;70(6):657–63
Lung cancer risk from indoor radon [letter] Auvinen A. **Lancet** 1996 Dec 14;348(9042):1662–3
Clinical measures, smoking, radon exposure, and risk of lung cancer in uranium miners. Finkelstein MM. **Occup Environ Med** 1996 Oct;53(10):697–702
Radon, your home or mine? [comment] Boice JD Jr. **Radiat Res** 1997 Feb;147(2):135–7. Comment on: Radiat Res 1997 Feb;147(2):126–34.
Estimating lung cancer mortality from residential radon using data for low exposures of miners [see comments] Lubin JH, et al. **Radiat Res** 1997 Feb;147(2):126–34. Comment in: Radiat Res 1997 Feb;147(2):135–7.
Coronary heart disease mortality among Newfoundland fluorspar miners. Villeneuve PJ, et al. **Scand J Work Environ Health** 1997 Jun;23(3):221–6
[A health status study of the population subjected to combined exposures to ionizing and nonionizing radiation factors] Paskalev Z, et al. **Probl Khig** 1996;21:131–4 (Eng. Abstr.) **(Bul)**
[Carcinogenic effects of radon in humans (literature review)] Averkina NA. **Med Tr Prom Ekol** 1996;(9):32–6 (20 ref.) (Eng. Abstr.) **(Rus)**
[Ways to reduce radiation doses caused by radon during exploration of gas and oil fields in the North] Chepenko BA, et al. **Med Tr Prom Ekol** 1996;(9):8–13 (Eng. Abstr.) **(Rus)**
[The aftereffects of the accident at the Chernobyl Atomic Electric Power Station for hydrobionts (1986–1996)] Polikarpov GG, et al. **Radiats Biol Radioecol** 1996 Jul–Aug; 36(4):460–8 (Eng. Abstr.) **(Rus)**
[The results of the cytogenetic monitoring of the species of angiosperm plants growing in the area of the radionuclide contamination after the accident at the Chernobyl Atomic Electric Power Station] Kordium EL, et al. **Tsitol Genet** 1997 May–Jun;31(3):39–46 (Eng. Abstr.) **(Rus)**

ANALYSIS

A survey of radon properties in underground shopping centers in Hong Kong. Yu KN, et al. **Appl Radiat Isot** 1997 Jun;48(6):863–6
Determination of MDA for a two count method for stripping short–lived activity out of an air sample. Allen DE. **Health Phys** 1997 Sep;73(3):512–7
Developing historical food production and consumption data for 131I dose estimates: the Hanford experience. Anderson DM, et al. **Health Phys** 1996 Oct;71(4):578–87
Radon measurements in the Gran Sasso Underground Laboratory. Arpesella C, et al. **Health Phys** 1997 Apr; 72(4):629–32
Six methods to assess potential radioactive air emissions from a stack. Barnett JM, et al. **Health Phys** 1996 Nov; 71(5):773–8
Radiation doses from Hanford Site releases to the atmosphere and the Columbia River. Farris WT, et al. **Health Phys** 1996 Oct;71(4):588–601
210Pb in indoor air by total alpha measurement. Fisenne IM, et al. **Health Phys** 1996 Nov;71(5):723–6
Radon retesting and mitigation behavior among the U.S. population. Ford ES, et al. **Health Phys** 1997 Apr; 72(4):611–4
Reconstruction of radionuclide releases from the Hanford Site, 1944–1972. Heeb CM, et al. **Health Phys** 1996 Oct; 71(4):545–55
Radon in residences: influences of geological and housing characteristics. Lévesque B, et al. **Health Phys** 1997 Jun; 72(6):907–14
Overview of the Fernald Dosimetry Reconstruction Project and source term estimates for 1951–1988. Meyer KR, et al. **Health Phys** 1996 Oct;71(4):425–37
Plutonium releases from the 1957 fire at Rocky Flats. Mongan TR, et al. **Health Phys** 1996 Oct;71(4):510–21
Plutonium release from the 903 pad at Rocky Flats. Mongan TR, et al. **Health Phys** 1996 Oct;71(4):522–31
An estimate by two methods of thyroid absorbed doses due to BRAVO fallout in several Northern Marshall Islands. Musolino SV, et al. **Health Phys** 1997 Oct;73(4):651–62
Modeling the resuspension of radionuclides in Ukrainian regions impacted by Chernobyl fallout. Nair SK, et al. **Health Phys** 1997 Jan;72(1):77–85
Measurement of radon decay products and thoron decay products in air by beta counting using end–window Geiger–Muller counter. Papp Z, et al. **Health Phys** 1997 Apr;72(4):601–10
Ambient air sampling for tritium—determination of breakthrough volumes and collection efficiencies for silica gel adsorbent. Patton GW, et al. **Health Phys** 1997 Mar; 72(3):397–407
Predictions and maps of county mean indoor radon concentrations in the mid–Atlantic states. Price PN. **Health Phys** 1997 Jun;72(6):893–906
Atmospheric dispersion and deposition of 131I released from the Hanford Site. Ramsdell JV Jr, et al. **Health Phys** 1996 Oct;71(4):568–77
Past radionuclide releases from routine operations at Rocky Flats. Ripple SR, et al. **Health Phys** 1996 Oct;71(4):502–9
Hanford Environmental Dose Reconstruction Project—an overview. Shipler DB, et al. **Health Phys** 1996 Oct; 71(4):532–44
Predicted versus measured tritium oxide concentrations at the Savannah River Site. Simpkins AA, et al. **Health Phys** 1997 Feb;72(2):179–85
A new device to measure the activity size distribution of radon progeny in a low level environment. Tokonami S, et al. **Health Phys** 1997 Sep;73(3):494–7
Carbon cartridge standards for 125I and suggested applications. Tries MA, et al. **Health Phys** 1997 Sep; 73(3):502–11
Identification and screening evaluation of key historical materials and emission sources at the Oak Ridge Reservation. Widner TE, et al. **Health Phys** 1996 Oct; 71(4):457–69
Calibration of a portable tritium–in–air monitor for various radioactive gases. Wood MJ, et al. **Health Phys** 1997 Mar; 72(3):423–30
A novel portable grab sampler for tritiated water vapor. Zaromb S, et al. **Health Phys** 1997 Mar;72(3):481–5
Factors affecting use of CR–39 surface monitor technology to estimate past exposure to indoor radon. Mahaffey JA, et al. **J Expo Anal Environ Epidemiol** 1996 Oct–Dec; 6(4):425–37
Indoor radon in Thailand: a study with particular reference to its sources. Ausoodkij B, et al. **J Med Assoc Thai** 1996 Aug;79(8):519–25
Radioactivity in municipal sewage and sludge. Martin JE, et al. **Public Health Rep** 1997 Jul–Aug;112(4):308–16; discussion 317–8
The ratio of long–lived to short–lived radon–222 progeny concentrations in ground–level air. Hötzl H, et al. **Sci Total Environ** 1996 Mar 29;181(3):249–55
Perturbation in the 240Pu/239Pu global fallout ratio in local sediments following the nuclear accidents at Thule (Greenland) and Palomares (Spain). Mitchell PI, et al. **Sci Total Environ** 1997 Aug 25;202(1–3):147–53
[A set of devices for monitoring radon and thoron in various media] Kotliarov AA, et al. **Med Tekh** 1997 Jan–Feb; (1):25–7 (Eng. Abstr.) **(Rus)**
[Radon and its decay products in the air of preschool institutions of Serpukhov] Eremeeva TN. **Med Tr Prom Ekol** 1996;(9):13–7 (Eng. Abstr.) **(Rus)**
[Atmospheric contamination by 137Cs during forest fires in the Chernobyl area] Azarov SI. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):506–15 (Eng. Abstr.) **(Rus)**

TOXICITY

Chromosome analysis of peripheral lymphocytes from persons exposed to radioactive fallout in Norway from the Chernobyl accident. Brøgger A, et al. **Mutat Res** 1996 Dec 12;361(2–3):73–9
Micronucleus test of erythrocytes and lymphocytes in the blood of the people living in the radiation pollution zone as a result of the accident at the Siberian chemical plant on April 6, 1993. Ilyinskikh NN, et al. **Mutat Res** 1996 Dec 12;361(2–3):173–8
[The effect of incorporation of various doses of 131I on the immunological reactions] Solov'ev AS, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):664–6 **(Rus)**

AIR POLLUTION

Air pollution, temperature, and regional differences in lung cancer mortality in Japan. Choi KS, et al. **Arch Environ Health** 1997 May–Jun;52(3):160–8
Analytical microscopy and environment. Current developments using bioindicators of pollution by stable and radioactive elements. Chassard–Bouchaud C. **Cell Mol Biol (Noisy–le–grand)** 1996 May;42(3):361–83
Impact of major air pollutants on human health. Proceedings of the EUROTOX–IUTOX satellite symposium to EUROTOX 95. Pilsen, Czech Republic, August 31–September 1, 1995. **Cent Eur J Public Health** 1996;4 Suppl:1–59
Air pollution and childrens' respiratory morbidity in the Tata area, Hungary. Pintér A, et al. **Cent Eur J Public Health** 1996;4 Suppl:17–20
Air pollution and trends in asthma. Anderson HR. **Ciba Found Symp** 1997;206:190–202; discussion 203–7 (50 ref.)
Air pollution and allergic disease. Report of a Working Party of the British Society for Allergy and Clinical Immunology. Wardlaw AJ. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:6–8 (0 ref.)
Airing the word on pollution [news] **Environ Health Perspect** 1996 Jun;104(6):598
Teplice program--the impact of air pollution on human health. Srám RJ, et al. **Environ Health Perspect** 1996 Aug; 104 Suppl 4:699–714 (54 ref.)
Human visual sensitivity to plumes with a Gaussian luminance distribution: experiments to develop an empirical probability of detection model. Ross DM, et al. **J Air Waste Manag Assoc** 1997 Mar;47(3):370–82
Air Quality '95--Interdisciplinary Opportunities in the Environmental Evaluation International Conference. Pisa, Italy, October 19–21, 1995. **J Environ Pathol Toxicol Oncol** 1997;16(2–3):73–257
Air pollution and the deterioration of historic monuments. Lorusso S, et al. **J Environ Pathol Toxicol Oncol** 1997; 16(2–3):171–3
Lichens and moss as bioindicators and bioaccumulators in air pollution monitoring. Palmieri F, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2–3):175–90
Mediators of inflammation in response to air pollution: a focus on ozone and nitrogen dioxide. Krishna MT, et al. **J R Coll Physicians Lond** 1996 Jan–Feb;30(1):61–6 (62 ref.)
Air pollution and health. Krishna MT, et al. **J R Coll Physicians Lond** 1996 Sep–Oct;30(5):448–52
The lung and the world about it. The Tudor Edwards Lecture 1996. Seaton A. **J R Coll Physicians Lond** 1996 May–Jun;30(3):232–7 (33 ref.)
Mutagen in cigarettes and foggy air [letter] [see comments] Middleton G. **Lancet** 1996 Dec 21–28;348(9043):1744. Comment in: Lancet 1997 Mar 1;349(9052):652.
Climate, health and medicine in a changing world [editorial] Jackson EK, et al. **Med J Aust** 1996 Dec 2–16; 165(11–12):597–8
The cloud over Sarawak [editorial] **Nature** 1997 Sep 25; 389(6649):315
Forest fires cause pollution crisis in Asia [news] Swinbanks D. **Nature** 1997 Sep 25;389(6649):321
Methods for assessing the extent of exposure and effects of air pollution. Krzyzanowski M. **Occup Environ Med** 1997 Mar;54(3):145–51 (46 ref.)
Environmental auditing programme in India. Mahwar RS, et al. **Sci Total Environ** 1997 Sep 19;204(1):11–26
City air pollution of polycyclic aromatic hydrocarbons and other mutagens: occurrence, sources and health effects. Nielsen T, et al. **Sci Total Environ** 1996 Oct 28; 189–190:41–9
Tropospheric air pollution: ozone, airborne toxics, polycyclic aromatic hydrocarbons, and particles. Finlayson–Pitts BJ, et al. **Science** 1997 May 16;276(5315):1045–52 (193 ref.)
[Urban atmospheric pollution: sources, pollutants and evolution] Festy B. **Bull Acad Natl Med** 1997 Mar 18; 181(3):461–74; discussion 474–6 (11 ref.) (Eng. Abstr.) **(Fre)**
[Thematic meeting: "Urban atmospheric pollution and public health"] Rochemaure J. **Bull Acad Natl Med** 1997 Mar 18; 181(3):455–9 **(Fre)**
[The measurement of microbial contamination of the air. I] Pitzurra M, et al. **Ann Ig** 1996 May–Jun;8(3):349–59 (Eng. Abstr.) **(Ita)**
[Acute–phase proteins in children from industrially polluted regions: influence of treatment] Sojka L, et al. **Pediatr Pol** 1996 Feb;71(2):111–6 (Eng. Abstr.) **(Pol)**
[Staphylococcal contamination of the upper respiratory tract mucosa in children exposed to air pollution] Bukharin OV, et al. **Gig Sanit** 1996 Nov–Dec;(6):6–8 (Eng. Abstr.) **(Rus)**
[Hygienic characterization of air pollution in Cheboksary] Dimitriev DA. **Gig Sanit** 1997 Jan–Feb;(1):6–8 **(Rus)**
[Hygienic aspects of health of children living in areas with developed gas chemical industries (review)] Savin VP, et al. **Gig Sanit** 1996 Jul–Aug;(4):24–7 (45 ref.) **(Rus)**
[Cytological status of mucous membranes as a criterion of ecological risk] Sidorenko GI, et al. **Gig Sanit** 1997 May–Jun;(3):56–7 **(Rus)**

ADVERSE EFFECTS

Trends in air quality in the UK. Ayres JG. **Allergy** 1997;52(38 Suppl):7–13 (14 ref.)
Lactational transfer of volatile chemicals in breast milk. Fisher J, et al. **Am Ind Hyg Assoc J** 1997 Jun;58(6):425–31
Exposure to varying levels of contaminants and symptoms among workers in two office buildings. Menzres D, et al. **Am J Public Health** 1996 Nov;86(11):1629–33
Longitudinal studies of air pollution effects on lung function. Dockery DW, et al. **Am J Respir Crit Care Med** 1996 Dec; 154(6 Pt 2):S250–6 (50 ref.)
Acute effects of summer air pollution on respiratory health of asthmatic children. Gielen MH, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):2105–8
Respiratory effects are associated with the number of ultrafine particles. Peters A, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1376–83
Air pollution and respiratory health among children with asthmatic or cough symptoms. Timonen KL, et al. **Am J Respir Crit Care Med** 1997 Aug;156(2 Pt 1):546–52
Associations between respiratory illness and PM10 air pollution. Choudhury AH, et al. **Arch Environ Health** 1997 Mar–Apr;52(2):113–7
Associations between health and air pollution in time–series analyses. Goldsmith JR, et al. **Arch Environ Health** 1996 Sep–Oct;51(5):359–67
Air pollution in relation to allergic and nonallergic rhinitis. Samir M, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jul;123(7):746–8
Pollution and the development of allergy: the East and West

Germany story. Nicolai T, et al. **Arch Toxicol Suppl** 1997; 19:201–6

Nasal lavage biomarkers in air pollution epidemiology. Steerenberg PA, et al. **Arch Toxicol Suppl** 1997;19:207–16 (35 ref.)

Short-term effects of ambient sulphur dioxide and particulate matter on mortality in 12 European cities: results from time series data from the APHEA project. Air Pollution and Health: a European Approach. Katsouyanni K, et al. **BMJ** 1997 Jun 7;314(7095):1658–63

Association between ambient air concentrations of nitrogen dioxide and respiratory symptoms in children in Prague, Czech Republic. Preliminary results from the Czech part of the SAVIAH Study. Small Area Variation in Air Pollution and Health. Pikhart H, et al. **Cent Eur J Public Health** 1997 Jun;5(2):82–5

Lung function in children of upper Silesian industrial zone, Poland: results of the cross-sectional study in two towns of different ambient air pollution levels. Zejda JE, et al. **Cent Eur J Public Health** 1996 Dec;4(4):252–6

Air pollution and allergic disease. Report of a working party of the British Society for Allergy and Clinical Immunology. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:1–72

Diesel exhaust particles and respiratory allergy [editorial] Frew AJ, et al. **Clin Exp Allergy** 1997 Mar;27(3):237–9

Major grass pollen allergen Lol p 1 binds to diesel exhaust particles: implications for asthma and air pollution. Knox RB, et al. **Clin Exp Allergy** 1997 Mar;27(3):246–51

The urban/rural divide in head and neck cancer—the effect of atmospheric pollution. Wake M. **Clin Otolaryngol** 1993 Aug;18(4):298–302

Health effects of outdoor air pollution. Linn WS, et al. **Compr Ther** 1996 Oct;22(10):673–9 (17 ref.)

The role of particulate size and chemistry in the association between summertime ambient air pollution and hospitalization for cardiorespiratory diseases. Burnett RT, et al. **Environ Health Perspect** 1997 Jun;105(6):614–20

The effect of outdoor fungal spore concentrations on daily asthma severity. Delfino RJ, et al. **Environ Health Perspect** 1997 Jun;105(6):622–35

Air pollution and emergency room visits for asthma in Santa Clara County, California. Lipsett M, et al. **Environ Health Perspect** 1997 Feb;105(2):216–22

Association between air pollution and low birth weight: a community-based study. Wang X, et al. **Environ Health Perspect** 1997 May;105(5):514–20

The relationship between selected causes of postneonatal infant mortality and particulate air pollution in the United States. Woodruff TJ, et al. **Environ Health Perspect** 1997 Jun;105(6):608–12

DNA damage in nasal respiratory epithelium from children exposed to urban pollution. Calderón-Garcidueñas L, et al. **Environ Mol Mutagen** 1997;30(1):11–20

A critical review of the evidence on particulate air pollution and mortality. Moolgavkar SH, et al. **Epidemiology** 1996 Jul;7(4):420–8 (44 ref.)

Air pollution and hospital admissions for respiratory causes in Minneapolis-St. Paul and Birmingham [see comments] Moolgavkar SH, et al. **Epidemiology** 1997 Jul;8(4):364–70 . Comment in: Epidemiology 1997 Jul;8(4):341–3.

Air pollution and hospital admissions for cardiovascular disease in Tucson [see comments] Schwartz J. **Epidemiology** 1997 Jul;8(4):371–7. Comment in: Epidemiology 1997 Jul;8(4):341–3.

Air pollution and daily mortality in Amsterdam. Verhoeff AP, et al. **Epidemiology** 1996 May;7(3):225–30

Damage to the nasopharyngeal mucosa induced by current levels of urban air pollution: a field study in lambs. Gulisano M, et al. **Eur Respir J** 1997 Mar;10(3):567–72

Asthmatic bronchial hyperresponsiveness varies with ambient levels of summertime air pollution. Taggart SC, et al. **Eur Respir J** 1996 Jun;9(6):1146–54

Biomarkers in nasal lavage as a tool for the assessment of health effects of photochemical air pollution. A feasibility study with volunteers. Steerenberg PA, et al. **Exp Toxicol Pathol** 1995 Sep;47(4):232–4

Effects of an ambient air pollution intervention and environmental tobacco smoke on children's respiratory health in Hong Kong. Peters J, et al. **Int J Epidemiol** 1996 Aug;25(4):821–8

Air population and mortality in East Berlin during the winters of 1981–1989. Rahlenbeck SI, et al. **Int J Epidemiol** 1996 Dec;25(6):1220–6

Asthma presentations to emergency departments in western Sydney during the January 1994 Bushfires. Smith MA, et al. **Int J Epidemiol** 1996 Dec;25(6):1227–36

Air pollution and mortality: the implications of uncertainties in regression modeling and exposure measurement. Lipfert FW, et al. **J Air Waste Manag Assoc** 1997 Apr;47(4):517–23

Is daily mortality associated specifically with fine particles? Schwartz J, et al. **J Air Waste Manag Assoc** 1996 Oct; 46(10):927–39

Air pollution and mortality in Valencia, Spain: a study using the APHEA methodology. Ballester F, et al. **J Epidemiol Community Health** 1996 Oct;50(5):527–33

Respiratory health effects of industrial air pollution: a study in east Lancashire, UK. Ginns SE, et al. **J Epidemiol Community Health** 1996 Dec;50(6):631–5

Reliability of lifetime residential history and activity measures as elements of cumulative ambient ozone exposure assessment. Künzli N, et al. **J Expo Anal Environ Epidemiol** 1996 Jul–Sep;6(3):289–310

Short-term air pollution exposures and responses in Los Angeles area schoolchildren. Linn WS, et al. **J Expo Anal Environ Epidemiol** 1996 Oct–Dec;6(4):449–72

Predictive pulmonary function of school children in an area of low air pollution in Taiwan. Tang FC, et al. **J Formos Med Assoc** 1997 Jun;96(6):397–404

Ambient air quality and asthma: a northern perspective. Guidotti TL. **J Investig Allergol Clin Immunol** 1997 Jan–Feb;7(1):7–13 (55 ref.)

Airway reactivity in welders: a controlled prospective cohort study. Beckett WS, et al. **J Occup Environ Med** 1996 Dec; 38(12):1229–38

Air pollution and respiratory health in Mexico City. Hernández-Garduño E, et al. **J Occup Environ Med** 1997 Apr;39(4):299–307

Epidemiologic evidence of an association between air quality and asthma. Leaderer BP, et al. **J Pharm Pharmacol** 1997 May;49 Suppl 3:39–44 (54 ref.)

Occupational asthma—a lawyer's view. Evans W. **J R Soc Health** 1996 Aug;116(4):229–30

Particles in the air: the enigma of urban air pollution [published erratum appears in J R Soc Med 1997 Jan;90(1):60] Seaton A. **J R Soc Med** 1996 Nov; 89(11):604–7

Inhaled nitric oxide [letter; comment] Adisesh A, et al. **Lancet** 1996 Nov 23;348(9039):1447–8. Comment on: Lancet 1996 Sep 7;348(9028):629–30.

Increased plasma viscosity during an air pollution episode: a link to mortality? Peters A, et al. **Lancet** 1997 May 31; 349(9065):1582–7

Air pollution and respiratory disease. Nardini S. **Monaldi Arch Chest Dis** 1996 Feb;51(1):50–1

Lichens, air pollution and lung cancer [letter] Cislaghi C, et al. **Nature** 1997 May 29;387(6632):463–4

Air pollution and sudden infant death syndrome [letter; comment] Koehler SA. **Pediatrics** 1996 Oct;98(4 Pt 1):796–8. Comment on: Pediatrics 1995 Dec;96(6):1106–10.

Is there a relationship between proximity to industry and the occurrence of otitis media with effusion in school entrant children? Holtby I, et al. **Public Health** 1997 Mar; 111(2):89–91

Introduction to the workshop on air pollution and health in the new Middle East. Goren A, et al. **Public Health Rev** 1997;25(1):3–6

Short-term effects of air pollution on health: a European approach using epidemiologic time series data. The APHEA Project. Air Pollution Health Effects—A European Approach. Katsouyanni K, et al. **Public Health Rev** 1997;25(1):7–18; discussion 19–28

Potential health risks related to carcinogens in the atmospheric environment in India. Gurjar BR, et al. **Regul Toxicol Pharmacol** 1996 Oct;24(2 Pt 1):141–8

Comparing estimates of the effects of air pollution on human mortality obtained using different regression methodologies. Baxter LA, et al. **Risk Anal** 1997 Jun; 17(3):273–8

Air pollution and human health: perspectives for the '90s and beyond. Lipfert FW. **Risk Anal** 1997 Apr;17(2):137–46 (19 ref.)

Showdown over clean air science [news] Kaiser J. **Science** 1997 Jul 25;277(5325):466–9

Clean air skepticism [letter] Lipfert FW. **Science** 1997 Oct 3;278(5335):19–20

A longitudinal study of emergency room visits and air pollution for Prince George, British Columbia. Jørgensen B, et al. **Stat Med** 1996 Apr 15–May 15;15(7–9):823–36

Particulate air pollution. Bates DV. **Thorax** 1996 Aug;51 Suppl 2:S3–8 (42 ref.)

Acute effects of summer air pollution on respiratory function in primary school children in southern England. Scarlett JF, et al. **Thorax** 1996 Nov;51(11):1109–14

Reactions to particles in smoke. Hill IR. **Toxicology** 1996 Dec 31;115(1–3):119–22 (17 ref.)

Long-term effects of air pollution. Berglund D, et al. **West J Med** 1996 Sep;165(3):140

Endemic fluorosis in Guizhou Province, China [letter] Dasheng L, et al. **World Health Forum** 1996;17(2):173–4

[Air pollution and its health effects on residents in Taiwanese communities] Ko YC. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Dec; 12(12):657–69 (76 ref.) (Eng. Abstr.) **(Chi)**

[Urban atmospheric pollution and public health: epidemiologic data] Aubier M. **Bull Acad Natl Med** 1997 Mar 18;181(3):489–97 (21 ref.) (Eng. Abstr.) **(Fre)**

[Susceptible populations and urban atmospheric pollution. Development of a policy of protection] Voisin C. **Bull Acad Natl Med** 1997 Mar 18;181(3):499–509; discussion 509–23 (Eng. Abstr.) **(Fre)**

[Environmental and occupational diseases] Baur X, et al. **Pneumologie** 1996 Sep;50 Suppl 2:604–6 (15 ref.) **(Ger)**

[Vehicular traffic pollution and risks to health] De Luca d'Alessandro E, et al. **Ann Ig** 1996 Nov–Dec;8(6):675–80 (29 ref.) **(Ita)**

[Atmospheric air pollution as a factor potentiating the risk of asthma in school children. Epidemiologic studies in Krakow] Jędrychowski W, et al. **Przegl Lek** 1997; 54(3):158–62 (Eng. Abstr.) **(Pol)**

[Influence of energy expenditure and other factors on the incidence of arterial hypertension in employees with some types of employment in Tychy] Marcisz C, et al. **Przegl Lek** 1996;53(8):604–9 (Eng. Abstr.) **(Pol)**

[The relationship of cancer morbidity to air pollution] Kireev GV, et al. **Gig Sanit** 1997 Mar–Apr;(2):3–5 (Eng. Abstr.) **(Rus)**

[Course of a specific process in high risk ecological areas] Khudzik LB, et al. **Probl Tuberk** 1997;(1):46–8 (0 ref.) (Eng. Abstr.) **(Rus)**

[Pollution and indoor allergens in respiratory allergy (editorial)] Peréz-Martín J. **Rev Alerg Mex** 1993 Sep–Oct; 40(5):107–9 **(Spa)**

ANALYSIS

Comparison of direct immunostaining and electroimmunoassay for analysis of airborne grass-pollen antigens. Yli-Panula E, et al. **Allergy** 1997 May;52(5):541–6

Airborne aflatoxin in the grain processing industries in India. Ghosh SK, et al. **Am Ind Hyg Assoc J** 1997 Aug; 58(8):583–6

A field deployable gas chromatograph/mass spectrometer for industrial hygiene applications. Piltingsrud HV. **Am Ind Hyg Assoc J** 1997 Aug;58(8):564–77

Monte Carlo uncertainty analysis of a diffusion model for the assessment of halogen gas exposure during dosing of brominators. Shade WD, et al. **Am Ind Hyg Assoc J** 1997 Jun;58(6):418–24

A comparison of pollen recovery by three models of the Rotorod sampler. Frenz DA, et al. **Ann Allergy Asthma Immunol** 1997 Sep;79(3):256–8

Aeroallergen-specific IgE changes in individuals with rapid human immunodeficiency virus disease progression. Goetz DW, et al. **Ann Allergy Asthma Immunol** 1997 Mar; 78(3):301–6

The variability of exposure over time: a prospective longitudinal study. Peretz C, et al. **Ann Occup Hyg** 1997 Aug;41(4):485–500

Blood lead concentrations and associated factors in residents of Monterrey, Mexico. Junco-Muñoz P, et al. **Arch Med Res** 1996 Winter;27(4):547–51

Interaction between air pollutants and aeroallergens. Emberlin J. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:33–9 (0 ref.)

Increased prevalence of sensitization against aeroallergens in adults in West compared with East Germany. Nicolai T, et al. **Clin Exp Allergy** 1997 Aug;27(8):886–92

Comparison of outdoor and classroom ozone exposures for school children in Mexico City [published erratum appears in J Air Waste Manag Assoc 1996 Jun;46(6):593] Gold DR, et al. **J Air Waste Manag Assoc** 1996 Apr;46(4):335–42

Background air concentrations of Cr(VI) in Hudson County, New Jersey: implications for setting health-based standards for Cr(VI) in soil. Scott PK, et al. **J Air Waste Manag Assoc** 1997 May;47(5):592–600

Applications and limitations of air dispersion modeling in environmental epidemiology. Esmen NA, et al. **J Expo Anal Environ Epidemiol** 1996 Jul–Sep;6(3):339–53

Assessment of human inhalation exposure to polycyclic aromatic hydrocarbons. Sišović, et al. **J Expo Anal Environ Epidemiol** 1996 Oct–Dec;6(4):439–47

Atmospheric lead pollution in KwaZulu/Natal, South Africa. Nriagu J, et al. **Sci Total Environ** 1996 Nov 18; 191(1–2):69–76

Exposure of Danish children to traffic exhaust fumes. Raaschou-Nielsen O, et al. **Sci Total Environ** 1996 Oct 28; 189–190:51–5

Urban air pollution is still a public health problem in Paris. Medina S, et al. **World Health Forum** 1996;17(2):187–93

[A membrane filter sampling method for determining microbial air pollution] Cherneva P, et al. **Probl Khig** 1996; 21:116–22 (Eng. Abstr.) **(Bul)**

[Measurement of microbial air pollution: cfu/m3 A.M.I. (Air Microbial Index). 2] Pitzurra M, et al. **Ann Ig** 1996 Jul–Aug; 8(4):441–52 **(Ita)**

[Effects of global climate change on Japanese cedar pollen concentration in air—estimated results obtained from Yamagata City and its surrounding area] Takahashi Y, et al. **Arerugi** 1996 Dec;45(12):1270–6 (Eng. Abstr.) **(Jpn)**

[The assessment of population exposure to atmospheric air pollution] Goryński P, et al. **Rocz Panstw Zakl Hig** 1997; 48(1):37–46 (Eng. Abstr.) **(Pol)**

ECONOMICS

Adverse health impacts of air pollution—continuing problems. Bates DV. **Scand J Work Environ Health** 1995 Dec;21(6):405–11 (52 ref.)

Economic reduction of acidifying deposition in Finland by decreasing emissions in Finland, Estonia and Russia. Tähtinen M, et al. **Sci Total Environ** 1997 Sep 26; 204(2):177–92

HISTORY

Air pollution and other local factors in respiratory disease. 1959 [classical article] Fairbairn AS, et al. **J Epidemiol Community Health** 1997 Jun;51(3):216–22; discussion 223

LEGISLATION & JURISPRUDENCE

Car makers like tobacco producers? [news] **Ann Oncol** 1997 Jan;8(1):2

A decent proposal? EPA's new clean air standards. Brown KS. **Environ Health Perspect** 1997 Apr;105(4):378–83

The regulation of crystalline silica: an industry perspective. Elzea JM. **J Expo Anal Environ Epidemiol** 1997 Jul–Sep;

7(3):377–84
US air pollution rules stir up a stink about research [news] Reichhardt T. **Nature** 1997 Jul 3;388(6637):5
The interface of environmental regulation and public health. Klees AA. **Occup Med** 1996 Jan–Mar;11(1):173–92
Impacts of water and air quality legislation on the poultry industry. Morse D. **Poult Sci** 1996 Jul;75(7):857–61 (6 ref.)

PREVENTION & CONTROL

Enhancing contaminant control to mitigate aeroallergies. Frey AH. **Ann Allergy Asthma Immunol** 1996 Dec; 77(6):460–6
Mexican brickmaking [news] **Environ Health Perspect** 1996 May;104(5):470–2
A decent proposal? EPA's new clean air standards. Brown KS. **Environ Health Perspect** 1997 Apr;105(4):378–83
VOC removal at low contaminant concentrations using granular activated carbon. VanOsdell DW, et al. **J Air Waste Manag Assoc** 1996 Sep;46(9):883–90
Disposal of bio–medical wastes [letter] Bhattacharyya TK. **J Indian Med Assoc** 1996 Dec;94(12):458–9
Dioxin data contested [letter; comment] Howlett CT. **Public Health Rep** 1996 Nov–Dec;111(6):473–5. Comment on: Public Health Rep 1996 Jul–Aug;111(4):299–313.
Introduction to the workshop on air pollution and health in the new Middle East. Goren A, et al. **Public Health Rev** 1997;25(1):3–6
Economic reduction of acidifying deposition in Finland by decreasing emissions in Finland, Estonia and Russia. Tähtinen M, et al. **Sci Total Environ** 1997 Sep 26; 204(2):177–92
Safe air in the workplace? Chinni A, et al. **World Health Forum** 1997;18(1):39–40
[Sanitary protection zones in major gas chemical enterprises] Kuznetsov IE, et al. **Med Tr Prom Ekol** 1996;(6):7–10 (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Olea europaea airborne pollen in southern Spain. González Minero FJ, et al. **Ann Allergy Asthma Immunol** 1997 Mar; 78(3):278–84
Replication [editorial; comment] Cohen AJ. **Epidemiology** 1997 Jul;8(4):341–3. Comment on: Epidemiology 1997 Jul;8(4):364–70. Comment on: Epidemiology 1997 Jul;8(4):371–7.
Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Anderson HR, et al. **Eur Respir J** 1997 May;10(5):1064–71
Childhood asthma in four regions in Scandinavia: risk factors and avoidance effects. Forsberg B, et al. **Int J Epidemiol** 1997 Jun;26(3):610–9
Epidemiologic evidence of an association between air quality and asthma. Leaderer BP, et al. **J Pharm Pharmacol** 1997 May;49 Suppl 3:39–44 (54 ref.)
A hazardous environment and city suicide rates. Lester D. **Percept Mot Skills** 1996 Jun;82(3 Pt 2):1330
Ozone and other photochemical oxidants in ambient and indoor air—properties, sources and concentrations. Sundell J, et al. **Scand J Work Environ Health** 1996;22 Suppl 3:5–14
Determination of environmental reference concentration of six PAHs in urban areas (Pavia, Italy). Minoia C, et al. **Sci Total Environ** 1997 May 9;198(1):33–41
[The SAPALDIA Study—no results? (editorial)] Künzli N. **Soz Praventivmed** 1997;42(3):131–2 **(Ger)**

AIR POLLUTION, INDOOR

see related

ENVIRONMENTAL ILLNESS

Achieving healthy indoor air. Report of the ATS Workshop: Santa Fe, New Mexico, November 16–19, 1995. **Am J Respir Crit Care Med** 1997 Sep;156(3 Pt 2):S31–64
Measurements of indoor and outdoor nitrogen dioxide concentrations using a diffusive sampler. Hagenbjörk–Gustafsson A, et al. **Analyst** 1996 Sep; 121(9):1261–4
Microbial volatile organic compounds—what substances can be found in sick buildings? Wessén B, et al. **Analyst** 1996 Sep;121(9):1203–5
Mapping air contaminants indoors using a prototype computed tomography system. Samanta A, et al. **Ann Occup Hyg** 1996 Dec;40(6):675–91
Assessment of indoor climate in an apartment by use of a fungal index. Abe K, et al. **Appl Environ Microbiol** 1996 Mar;62(3):959–63
Nitrogen dioxide, the oxides of nitrogen, and infants' health symptoms. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Farrow A, et al. **Arch Environ Health** 1997 May–Jun;52(3):189–94
Indoor pollution and sick building syndrome symptoms among workers in day–care centers. Li CS, et al. **Arch Environ Health** 1997 May–Jun;52(3):200–7
Human exposure to elemental mercury in a contaminated residential building. Orloff KG, et al. **Arch Environ Health** 1997 May–Jun;52(3):169–72
Evaluation of indoor air quality using the decibel concept. Part I—proposal of new units. Jokl MV. **Cent Eur J Public Health** 1997 Mar;5(1):3–8 (22 ref.)
Evaluation of indoor air quality using the decibel concept. Part II–ventilation for acceptable indoor air quality. Jokl MV. **Cent Eur J Public Health** 1997 Mar;5(1):9–12 (7 ref.)
Levels of selected organic compounds in materials for candle production and human exposure to candle emissions. Lau C, et al. **Chemosphere** 1997 Mar–Apr;34(5–7):1623–30
The use of toxic equivalency factors in assessing occupational and environmental health risk associated with exposure to airborne mixtures of polycyclic aromatic hydrocarbons (PAHs). Petry T, et al. **Chemosphere** 1996 Feb;32(4):639–48
Toxicological considerations in evaluating indoor air quality and human health: impact of new carpet emissions. Dietert RR, et al. **Crit Rev Toxicol** 1996 Nov;26(6):633–707 (416 ref.)
Airing the word on pollution [news] **Environ Health Perspect** 1996 Jun;104(6):598
Log–additive versus log–linear analysis of lead–contaminated house dust and children's blood–lead levels. Implications for residential dust–lead standards. Rust SW, et al. **Environ Res** 1997 Feb;72(2):173–84
Home dampness, moulds and their influence on respiratory infections and symptoms in adults in Finland. Pirhonen I, et al. **Eur Respir J** 1996 Dec;9(12):2618–22
Residential radon and lung cancer in Sweden: risk analysis accounting for random error in the exposure assessment [see comments] Lagarde F, et al. **Health Phys** 1997 Feb; 72(2):269–76. Comment in: Health Phys 1997 Jul;73(1):272–3. Comment in: Health Phys 1997 Aug;73(2):393. Comment in: Health Phys 1997 Aug;73(2):394–5.
Bayesian prediction of mean indoor radon concentrations for Minnesota counties. Price PN, et al. **Health Phys** 1996 Dec; 71(6):922–36
Diffusive transport of radon in a homogeneous column of dry sand. van der Spoel WH, et al. **Health Phys** 1997 May; 72(5):766–77; appendix 778
Ambient air pollution & respiratory symptoms complex in preschool children. Awasthi S, et al. **Indian J Med Res** 1996 Oct;104:257–62
Experimental asthma developed by room air contamination with cockroach allergen. Kang BC, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):299–306
Radon daughter deposition on surfaces carrying alternating electric fields. Mayya YS, et al. **Int J Radiat Biol** 1997 Jan;71(1):69–74
Dust and airborne exposure to allergens derived from cockroach (Blattella germanica) in low–cost public housing in Strasbourg (France). de Blay F, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):107–12
From the Centers for Disease Control and Prevention. Legionnaires disease associated with a whirlpool spa display—Virginia, September–October 1996. **JAMA** 1997 Mar 5;277(9):705–6
Environmental allergen analyses. Hamilton RG, et al. **Methods** 1997 Sep;13(1):53–60
Legionnaires disease associated with a whirlpool spa display—Virginia, September–October, 1996 [published erratum appears in MMWR Morb Mortal Wkly Rep 1997 Apr 18;46(15):336] **MMWR Morb Mortal Wkly Rep** 1997 Jan 31;46(4):83–6
Humidification and perceived indoor air quality in the office environment. Reinikainen LM, et al. **Occup Environ Med** 1997 May;54(5):322–7
Viable fungi in indoor air in homes and schools in the Sør–Varanger community during winter. Dotterud LK, et al. **Pediatr Allergy Immunol** 1995 Nov;6(4):181–6
Childhood asthma and exposure to indoor allergens: low mite levels are associated with sensitivity. Warner AM, et al. **Pediatr Allergy Immunol** 1996 May;7(2):61–7
Wood–burning stoves and lower respiratory illnesses in Navajo children. Robin LF, et al. **Pediatr Infect Dis J** 1996 Oct;15(10):859–65
A critical examination of OSHA's assessment of risk associated with workplace exposure to environmental tobacco smoke. Rosenbaum WL, et al. **Regul Toxicol Pharmacol** 1996 Jun;23(3):233–40 (29 ref.)
Estimating the sensory irritating potency of airborne nonreactive volatile organic chemicals and their mixtures. Alarie Y, et al. **SAR QSAR Environ Res** 1996;5(3):151–65
Indoor air pollution by different heating systems: coal burning, open fireplace and central heating. Moriske HJ, et al. **Toxicol Lett** 1996 Nov;88(1–3):349–54
[Influence of local air suction on the density of air–borne bacteria during cementation of alloplasties] Enggaard TP, et al. **Ugeskr Laeger** 1997 Feb 10;159(7):952–5 (Eng. Abstr.) **(Dan)**
[Indoor chemical pollutants and their effects on health] De Luca D'Alessandro E, et al. **Ann Ig** 1996 Sep–Oct; 8(5):593–5 (Eng. Abstr.) **(Ita)**
[A review of epidemiologic studies on the health effects of indoor environments] Nakai S. **Nippon Koshu Eisei Zasshi** 1996 Mar;43(3):183–95 (52 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Indoor allergy to spathe flower (Spathiphyllum floribundum). Cahen YD, et al. **Allergy** 1997 Jan;52(1):114–5
Human performance during exposure to toluene. Rahill AA, et al. **Aviat Space Environ Med** 1996 Jul;67(7):640–7
The effect of moderately increased CO2 concentration on perception of coherent motion. Yang Y, et al. **Aviat Space Environ Med** 1997 Mar;68(3):187–91
Adult and infant abamectin exposures following Avert 310 and pressurized gel crack and crevice treatment. Krieger RI, et al. **Bull Environ Contam Toxicol** 1997 May; 58(5):681–7
Bronchiolitis obliterans and wood–burning stoves [editorial; comment] Hogg JC. **Can Med Assoc J** 1997 Apr 15; 156(8):1147–8. Comment on: Can Med Assoc J 1997 Apr 15;156(8):1171–3.
Bronchiolitis obliterans in a man who used his wood–burning stove to burn synthetic construction materials [see comments] Janigan DT, et al. **Can Med Assoc J** 1997 Apr 15;156(8):1171–3. Comment in: Can Med Assoc J 1997 Apr 15;156(8):1147–8.
Health aspects of formaldehyde in the indoor environment. Czech and Slovak experience. Holcátová I, et al. **Cent Eur J Public Health** 1997 Mar;5(1):38–42 (46 ref.)
Occupational allergic contact dermatitis from epoxy resin on chipboard. Goulden V, et al. **Contact Dermatitis** 1996 Oct;35(4):262–3
An unusual case of mercurial baboon syndrome. Le Coz CJ, et al. **Contact Dermatitis** 1996 Aug;35(2):112
Airborne dermatitis in a painter. Raccagni AA, et al. **Contact Dermatitis** 1996 Aug;35(2):119–20
Methyl parathion comes inside [news] **Environ Health Perspect** 1997 Jul;105(7):690–1
Sick days at work. Brown KS. **Environ Health Perspect** 1996 Oct;104(10):1032–5
Indoor risk factors for asthma and wheezing among Seattle school children. Maier WC, et al. **Environ Health Perspect** 1997 Feb;105(2):208–14
Childhood exposure to magnetic fields: residential area measurements compared to personal dosimetry. Friedman DR, et al. **Epidemiology** 1996 Mar;7(2):151–5
The indoor air and children's health study: methods and incidence rates. Marbury MC, et al. **Epidemiology** 1996 Mar;7(2):166–74
Infant respiratory symptoms in relation to mite allergen exposure. van Strien RT, et al. **Eur Respir J** 1996 May; 9(5):926–31
Environmental factors in PEF variability. Paoletti P, et al. **Eur Respir J Suppl** 1997 Feb;24:64S–66S
Indoor air pollution and acute lower respiratory infections in young Gambian children. Campbell H. **Health Bull (Edinb)** 1997 Jan;55(1):20–31
Residential radon and lung cancer in Sweden [letter; comment] Archer VE. **Health Phys** 1997 Aug;73(2):394–5. Comment on: Health Phys 1997 Feb;72(2):269–76.
Problems in the radon vs lung cancer test of the linear no–threshold theory and a procedure for resolving them. Cohen BL. **Health Phys** 1997 Apr;72(4):623–8
Questionnaire study of the lung cancer risk from radon in homes. Cohen BL. **Health Phys** 1997 Apr;72(4):615–22
Residential radon and lung cancer in Sweden [letter; comment] Tsoulfanidis N. **Health Phys** 1997 Aug;73(2):393. Comment on: Health Phys 1997 Feb;72(2):269–76.
Bronchial responsiveness of non–smoking women exposed to environmental tobacco smoke or biomass fuel combustion. Jindal SK, et al. **Indian J Med Res** 1996 Dec; 104:359–64
Control of construction–associated nosocomial aspergillosis in an antiquated hematology unit. Loo VG, et al. **Infect Control Hosp Epidemiol** 1996 Jun;17(6):360–4
Respiratory effects associated with indoor nitrogen dioxide exposure in children. Pilotto LS, et al. **Int J Epidemiol** 1997 Aug;26(4):788–96
Quantification of FISH–painted chromosome aberrations after domestic radon exposure. Bauchinger M, et al. **Int J Radiat Biol** 1996 Dec;70(6):657–63
A strategy for the evaluation of sensory and pulmonary irritation due to chemical emissions from indoor sources. Muller WJ, et al. **J Air Waste Manag Assoc** 1996 Sep; 46(9):808–12
Exposure to indoor allergens in early infancy and sensitization. Munir AK, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):177–81
Indoor allergen exposure is a risk factor for sensitization during the first three years of life. Wahn U, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):763–9
Epidemic carbon monoxide poisoning following a winter storm [see comments] Houck PM, et al. **J Emerg Med** 1997 Jul–Aug;15(4):469–73. Comment in: J Emerg Med 1997 Jul–Aug;15(4):531–2.
Carbon monoxide poisoning during ice storms: a tale of two cities [see comments] Wrenn K, et al. **J Emerg Med** 1997 Jul–Aug;15(4):465–7. Comment in: J Emerg Med 1997 Jul–Aug;15(4):531–2.
Lung cancer risk from residential radon: meta–analysis of eight epidemiologic studies [letter; comment] Cohen BL. **J Natl Cancer Inst** 1997 May 7;89(9):664; discussion 664–5. Comment on: J Natl Cancer Inst 1997 Jan 1;89(1):4–6. Comment on: J Natl Cancer Inst 1997 Jan 1;89(1):49–57.
Re: indoor radon exposure and risk of lung cancer: a nested case–control study in Finland [letter; comment] Lagarde F, et al. **J Natl Cancer Inst** 1997 Apr 16;89(8):584–5. Comment on: J Natl Cancer Inst 1996 Jul 17;88(14):966–72.
Lung cancer risk from residential radon: meta–analysis of eight epidemiologic studies [see comments] Lubin JH, et al. **J Natl Cancer Inst** 1997 Jan 1;89(1):49–57. Comment in: J Natl Cancer Inst 1997 Jan 1;89(1):4–6. Comment in: J Natl Cancer Inst 1997 May 7;89(9):663–4; discussion 664–5. Comment in: J Natl Cancer Inst 1997 May 7;89(9):664; discussion 664–5.
Lung cancer risk from residential radon: meta–analysis of eight epidemiologic studies [letter; comment] Neuberger

J, et al. **J Natl Cancer Inst** 1997 May 7;89(9):663–4; discussion 664–5. Comment on: J Natl Cancer Inst 1997 Jan 1;89(1):49–57.

Indoor radon exposure and lung cancer: risky or not?—all over again [editorial; comment] [see comments] Samet JM. **J Natl Cancer Inst** 1997 Jan 1;89(1):4–6. Comment on: J Natl Cancer Inst 1997 Jan 1;89(1):49–57. Comment in: J Natl Cancer Inst 1997 May 7;89(9):664; discussion 664–5.

Lung cancer in chromate-exposed aerospace workers. Alexander BH, et al. **J Occup Environ Med** 1996 Dec; 38(12):1253–8

Effects of 10-ppm hydrogen sulfide inhalation on pulmonary function in healthy men and women. Bhambhani Y, et al. **J Occup Environ Med** 1996 Oct;38(10):1012–7

Mercury toxicity awareness in the nursery. Thigpen J, et al. **J Perinatol** 1997 Mar–Apr;17(2):140–2

Lung cancer risk from indoor radon [letter] Auvinen A. **Lancet** 1996 Dec 14;348(9042):1662–3

Nitrogen dioxide, gas heating and respiratory illness [editorial] Pilotto LS, et al. **Med J Aust** 1997 Sep 15; 167(6):295–6

Health and social concerns of restaurant/bar workers exposed to environmental tobacco smoke. Akbar-Khanzadeh F, et al. **Med Lav** 1996 Mar–Apr;87(2):122–32

Possible role of indoor environment and coal combustion emission in lung carcinogenesis in Fuyuan County, China. Nakanishi Y, et al. **Neoplasma** 1997;44(1):69–72

Health risks from exposure to metals in household dusts. Lemus R, et al. **Rev Environ Health** 1996 Oct–Dec; 11(4):179–89

Pleural mesothelioma and household asbestos exposure. Schneider J, et al. **Rev Environ Health** 1996 Jan–Jun; 11(1–2):65–70 (68 ref.)

Terpene exposure and respiratory effects among workers in Swedish joinery shops. Eriksson KA, et al. **Scand J Work Environ Health** 1997 Apr;23(2):114–20

Allergic alveolitis in a school environment. Thörn A, et al. **Scand J Work Environ Health** 1996 Aug;22(4):311–4

Risk assessment of pyrethroids following indoor use. Pauluhn J. **Toxicol Lett** 1996 Nov;88(1–3):339–48

Man-made mineral fibre boards in buildings—health risks caused by quality deficiencies. Thriene B, et al. **Toxicol Lett** 1996 Nov;88(1–3):299–303

Acute inhalant toxicoses of cagebirds [letter] Duff P. **Vet Rec** 1997 Jul 26;141(4):107

Chronic exposure of pigs to airborne dust and endotoxins in an environmental chamber: technical note. Urbain B, et al. **Vet Res** 1996;27(6):569–78

[Effects of renovation measures on the health status of persons, exposed to pyrethroids through carpets and flooring] Böge KP, et al. **Gesundheitswesen** 1996 Dec; 58(12):673–81 (Eng. Abstr.) **(Ger)**

[Exposure: environmental medicine considerations before measurements] Behrends HB. **Z Arztl Fortbild Qualitatssich** 1997 Feb;91(1):51–7 (Eng. Abstr.) **(Ger)**

[Ventilation of ice-skating rinks should be improved (letter)] Lorentzon R. **Lakartidningen** 1996 Dec 11;93(50):4611 **(Swe)**

ANALYSIS

Carbon monoxide hazards in rural Alaskan homes. Howell J, et al. **Alaska Med** 1997 Jan–Mar;39(1):8–11

Measurement of mite allergen in the environment. Kuehr J. **Allergy** 1997 Apr;52(4):380–2 (22 ref.)

Indoor mite allergens in patients with respiratory allergy living in Porto, Portugal. Plácido JL, et al. **Allergy** 1996 Sep;51(9):633–9

Cockroach allergen in house dust. van Wijnen JH, et al. **Allergy** 1997 Apr;52(4):460–4

An evaluation of a local exhaust ventilation control system for a foundry casting-cleaning operation. Gressel MG. **Am Ind Hyg Assoc J** 1997 May;58(5):354–8

The use of ergosterol to measure exposure to fungal propagules in indoor air. Miller JD, et al. **Am Ind Hyg Assoc J** 1997 Jan;58(1):39–43

Lead-contaminated house dust and urban children's blood lead levels. Lanphear BP, et al. **Am J Public Health** 1996 Oct;86(10):1416–21

Aerodynamic properties of the major dog allergen Can f 1: distribution in homes, concentration, and particle size of allergen in the air. Custovic A, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):94–8

Single ion gas chromatographic/mass spectroscopic quantitative analysis of environmental CO2 in agoraphobic environments. Cox S, et al. **Anxiety** 1994–95;1(6):275–7

Mercury exposure in high school chemistry teachers. Crump C, et al. **Arch Environ Contam Toxicol** 1996 Aug; 31(2):206–9

You're the flight surgeon. Stoner PS Jr. **Aviat Space Environ Med** 1996 Apr;67(4):382–3

Concentrations and emission rates of aerial ammonia, nitrous oxide, methane, carbon dioxide, dust and endotoxin in UK broiler and layer houses. Wathes CM, et al. **Br Poult Sci** 1997 Mar;38(1):14–28

Concentrations of selected contaminants in cabin air of airbus aircrafts. Dechow M, et al. **Chemosphere** 1997 Jul; 35(1–2):21–31

Domestic allergens in public places. II: Dog (Can f1) and cockroach (Bla g 2) allergens in dust and mite, cat, dog and cockroach allergens in the air in public buildings [see comments] Custovic A, et al. **Clin Exp Allergy** 1996 Nov; 26(11):1246–52. Comment in: Clin Exp Allergy 1996 Nov;26(11):1225–7.

The importance of domestic allergens in a tropical environment [editorial; comment] Leung R, et al. **Clin Exp Allergy** 1997 Aug;27(8):856–9. Comment on: Clin Exp Allergy 1997 Aug;27(8):876–85.

Prevalence and distribution of indoor allergens in Singapore [see comments] Zhang L, et al. **Clin Exp Allergy** 1997 Aug; 27(8):876–85. Comment in: Clin Exp Allergy 1997 Aug;27(8):856–9.

Toxic gas exposures in ice arenas. Pribyl CR, et al. **Clin J Sport Med** 1996 Oct;6(4):232–6

Occurrence of polychlorinated terphenyls (PCTs) in indoor particulate matter. Seidel U, et al. **Environ Health Perspect** 1996 Nov;104(11):1172–9

Measurement error and its impact on the estimated relationship between dust lead and children's blood lead: Members of the Rochester Lead-in-Dust Study Group. Emond MJ, et al. **Environ Res** 1997 Jan;72(1):82–92

Radon measurements in the Gran Sasso Underground Laboratory. Arpesella C, et al. **Health Phys** 1997 Apr; 72(4):629–32

Radon retesting and mitigation behavior among the U.S. population. Ford ES, et al. **Health Phys** 1997 Apr; 72(4):611–4

Radon in residences: influences of geological and housing characteristics. Lévesque B, et al. **Health Phys** 1997 Jun; 72(6):907–14

Influence of air flow on the behavior of thoron and its progeny in a traditional Japanese house. Ma J, et al. **Health Phys** 1997 Jan;72(1):86–91

State-of-the-art instruments for measuring radon/thoron and their progeny in dwellings—a review [letter] Moridi R. **Health Phys** 1996 Dec;71(6):973–4

Predictions and maps of county mean indoor radon concentrations in the mid-Atlantic states. Price PN. **Health Phys** 1997 Jun;72(6):893–906

Evaluation of continuous air monitor placement in a plutonium facility. Whicker JJ, et al. **Health Phys** 1997 May;72(5):734–43

Blood mercury in workers exposed to the preparation of mercury cadmium telluride layers on cadmium telluride base. Gupta M, et al. **Ind Health** 1996;34(4):421–5

Indoor/outdoor concentrations of ozone and peroxyacetyl nitrate (PAN). Jakobi G, et al. **Int J Biometeorol** 1997 May; 40(3):162–5

Indoor air quality and health: validity and determinants of reported home dampness and moulds. Dales RE, et al. **Int J Epidemiol** 1997 Feb;26(1):120–5

Airborne hexavalent chromium in southwestern Ontario. Bell RW, et al. **J Air Waste Manag Assoc** 1997 Aug;47(8):905–10

Modeling indoor air concentrations near emission sources in imperfectly mixed rooms. Furtaw EJ Jr, et al. **J Air Waste Manag Assoc** 1996 Sep;46(9):861–8

Volatilization of chemicals from drinking water to indoor air: role of the kitchen sink. Howard C, et al. **J Air Waste Manag Assoc** 1996 Sep;46(9):830–7

A methodological approach for exposure assessment studies in residences using volatile organic compound-contaminated water. Lindstrom AB, et al. **J Air Waste Manag Assoc** 1996 Nov;46(11):1058–66

Causes and consequences of backdrafting of vented gas appliances. Nagda NL, et al. **J Air Waste Manag Assoc** 1996 Sep;46(9):838–46

Evaluation of virtual source beam configurations for rapid tomographic reconstruction of gas and vapor concentrations in workplaces. Park DY, et al. **J Air Waste Manag Assoc** 1997 May;47(5):582–91

Analysis of sampling strategies for estimating annual average indoor NO2 concentrations in residences with gas ranges. Wilkes CR, et al. **J Air Waste Manag Assoc** 1996 Sep; 46(9):853–60

Effects of gas flow management on postintubation end-tidal anesthetic concentration and operating room pollution. Siker D, et al. **J Clin Anesth** 1997 May;9(3):228–32

Air quality inside the passenger compartment of a bus. Conceição EZ, et al. **J Expo Anal Environ Epidemiol** 1997 Oct–Dec;7(4):521–34

Association between indoor residential contamination with methyl parathion and urinary para-nitrophenol. Esteban E, et al. **J Expo Anal Environ Epidemiol** 1996 Jul–Sep; 6(3):375–87

Exposure of commuters to carbon monoxide in Mexico City II. Comparison of in-vehicle and fixed-site concentrations. Fernandez-Bremauntz AA, et al. **J Expo Anal Environ Epidemiol** 1995 Oct–Dec;5(4):497–510

Residential radon-222 exposure and lung cancer: exposure assessment methodology. Field RW, et al. **J Expo Anal Environ Epidemiol** 1996 Apr–Jun;6(2):181–95

Assessment of airborne hexavalent chromium in the home following use of contaminated tapwater. Finley BL, et al. **J Expo Anal Environ Epidemiol** 1996 Apr–Jun;6(2):229–45

Long-term trends in United States highway emissions, ambient concentrations, and in-vehicle exposure to carbon monoxide in traffic. Flachsbart PG. **J Expo Anal Environ Epidemiol** 1995 Oct–Dec;5(4):473–95 (51 ref.)

Characterization of the emissions of trichloroethylene, chloroform, and 1,2-dibromo-3-chloropropane in a full-size, experimental shower. Giardino NJ, et al. **J Expo Anal Environ Epidemiol** 1996 Oct–Dec;6(4):413–23

Exposure to volatile organic compounds in the passenger compartment of automobiles during periods of normal and malfunctioning operation. Lawryk NJ, et al. **J Expo Anal Environ Epidemiol** 1995 Oct–Dec;5(4):511–31

A validity analysis of residential magnetic fields estimated from high-voltage transmission lines. Li CY, et al. **J Expo Anal Environ Epidemiol** 1997 Oct–Dec;7(4):493–504

California residential air exchange rates and residence volumes. Wilson AL, et al. **J Expo Anal Environ Epidemiol** 1996 Jul–Sep;6(3):311–26

Hydrocarbon emissions and health risks from cookstoves in developing countries. Zhang J, et al. **J Expo Anal Environ Epidemiol** 1996 Apr–Jun;6(2):147–61

An indoor air quality-pharmacokinetic simulation of passive inhalation of marijuana smoke and the resultant buildup of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in urine. Giardino NJ. **J Forensic Sci** 1997 Mar;42(2):323–5

Indoor radon in Thailand: a study with particular reference to its sources. Ausoodkij B, et al. **J Med Assoc Thai** 1996 Aug;79(8):519–25

Exposure in a household using gasoline-contaminated water. Beavers JD, et al. **J Occup Environ Med** 1996 Jan; 38(1):35–8

Nitrogen dioxide and respiratory illness in children. Part IV: Effects of housing and meteorologic factors on indoor nitrogen dioxide concentrations. Spengler JD, et al. **Res Rep Health Eff Inst** 1996 Dec;(58):1–29; discussion 31–6

Potential health risks from indoor exposure to chlorpyrifos (O,O-diethyl O-[3,5,6-trichloro-2-pyridyl] phosphorothioate). Lemus R, et al. **Rev Environ Health** 1997 Apr–Jun;12(2):91–7

Assessment of air quality in Stockholm by personal monitoring of nonsmokers for respirable suspended particles and environmental tobacco smoke. Phillips K, et al. **Scand J Work Environ Health** 1996;22 Suppl 1:1–24

Ubiquitous fiber exposure in selected sampling sites in Europe. Schneider T, et al. **Scand J Work Environ Health** 1996 Aug;22(4):274–84

Physical characterization of incense aerosols. Mannix RC, et al. **Sci Total Environ** 1996 Dec 20;193(2):149–58

Nicotine levels in indoor athletic centres. Michael CM, et al. **Sci Total Environ** 1996 Dec 2;192(2):213–6

Airborne platinum concentrations in Munich city buses. Schierl R, et al. **Sci Total Environ** 1996 Apr 5;182(1–3):21–3

Basement gas: issues related to the migration of potentially toxic chemicals into house basements from distant sources. Foster SJ, et al. **Toxicol Ind Health** 1996 Mar–Apr; 12(2):165–77

Assessing the indoor air impact from a hazardous waste site: a case study. Underwood MC. **Toxicol Ind Health** 1996 Mar–Apr;12(2):179–88

Improper use of an insecticide at a kindergarten. Fischer AB, et al. **Toxicol Lett** 1996 Nov;88(1–3):359–64

Pentachlorophenol in the indoor environment: evidence for a correlation between pentachlorophenol in passively deposited suspended particulate and in urine of exposed persons. Meissner T, et al. **Toxicol Lett** 1996 Nov; 88(1–3):237–42

Sanitation programmes for living spaces and health risks involved. Sobottka A, et al. **Toxicol Lett** 1996 Nov; 88(1–3):365–8

[The effect of anesthetic method on enflurane air pollution in non-air conditioned operating rooms] Marx T, et al. **Anaesthesist** 1996 Dec;45(12):1167–70 (Eng. Abstr.) **(Ger)**

[Polychlorinated biphenyls (PCB) in caulking compounds of buildings—assessment of current status in Berlin and new indoor air sources] Fromme H, et al. **Gesundheitswesen** 1996 Dec;58(12):666–72 (Eng. Abstr.) **(Ger)**

[Toxicologic evaluation of pyrethroids in indoor air: demonstrated with the example of cyfluthrin and permethrin] Pauluhn J, et al. **Gesundheitswesen** 1996 Oct; 58(10):551–6 (Eng. Abstr.) **(Ger)**

[Polychlorinated biphenyls indoors: attempt at an assessment] Sagunski H, et al. **Gesundheitswesen** 1997 Jun;59(6):391–9 (45 ref.) (Eng. Abstr.) **(Ger)**

[Gas chromatographic determination of the disinfectant agent glutaraldehyde in hospital air] Wliszczak W, et al. **Mikrochim Acta** 1977;(3-4 Pt 2):139–48 **(Ger)**

[Room air allergens: clinical significance, detection and prevention] Müsken H. **Pneumologie** 1996 Feb;50(2):168–76 (119 ref.) **(Ger)**

[Quality of indoor air in nursery schools with different building characteristics] Leoni E, et al. **Ann Ig** 1997 Mar–Apr;9(2):133–42 **(Ita)**

[A study of waste anesthetic gases monitoring and working environmental controls in hospital operating rooms] Koda S, et al. **Sangyo Eiseigaku Zasshi** 1997 Jan;39(1):38–45 (Eng. Abstr.) **(Jpn)**

[Estimation and control measures for environmental tobacco smoke in an office] Seto T, et al. **Sangyo Ika Daigaku Zasshi** 1996 Dec 1;18(4):273–9 (Eng. Abstr.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

OSHA publishes proposed indoor air rule [news] **Occup Health Saf** 1994 May;63(5):12, 14

[Allergen decontamination and public sector] Madsen FF. **Ugeskr Laeger** 1997 Jan 6;159(2):180–2 (Eng. Abstr.) **(Dan)**

[Development of minimal requirements for site assessment and monitoring to estimate exposure in environmental

medicine—the Hamburg approach] Hentschel S, et al. **Gesundheitswesen** 1996 Nov;58(11):618–21 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Effects of a dietary and environmental prevention programme on the incidence of allergic symptoms in high atopic risk infants: three years' follow-up. Marini A, et al. **Acta Paediatr Suppl** 1996 May;414:1–21

Positive human health effects of dust suppression with canola oil in swine barns. Senthilselvan A, et al. **Am J Respir Crit Care Med** 1997 Aug;156(2 Pt 1):410–7

Building a healthy house [editorial] Schoenwetter WF. **Ann Allergy Asthma Immunol** 1997 Jul;79(1):1–4

Government agency issues surgical smoke hazard control. **AORN J** 1996 Dec;64(6):1045

Cabin air quality. Aerospace Medical Association. Thibeault C. **Aviat Space Environ Med** 1997 Jan;68(1):80–2

Methyl parathion comes inside [news] **Environ Health Perspect** 1997 Jul;105(7):690–1

Green houses. Tibbetts J. **Environ Health Perspect** 1996 Oct; 104(10):1036–9

The risks associated with HVAC drip pans. **Health Devices** 1996 Jan;25(1):43

Nitrous oxide (N2O) cryosurgical units must be scavenged. **Health Devices** 1996 Aug;25(8):306–9

Nitrous oxide in the dental office. ADA Council on Scientific Affairs; ADA Council on Dental Practice. **J Am Dent Assoc** 1997 Mar;128(3):364–5

Nitrous oxide in the dental environment: assessing the risk, reducing the exposure [published erratum appears in J Am Dent Assoc 1997 Jun;128(6):700] Howard WR. **J Am Dent Assoc** 1997 Mar;128(3):356–60 (22 ref.)

Optimisation of ultraclean air. The role of instrument preparation. Chosky SA, et al. **J Bone Joint Surg Br** 1996 Sep;78(5):835–7

Air sampling for aspergillus spp. during building activity in a paediatric hospital ward [letter] Kennedy HF, et al. **J Hosp Infect** 1995 Dec;31(4):322–5

Measurement and reduction of nitrous oxide in operating rooms. Schuyt HC, et al. **J Occup Environ Med** 1996 Oct; 38(10):1036–40

Inadequate air distribution and poor mixing cause IAQ problems. Moving partitions, walls, and furniture may change the air flow, often for the worse. Burton DJ. **Occup Health Saf** 1996 Mar;65(3):20–1

Well-designed air control systems diminish exposure to lead and acid. Minor C. **Occup Health Saf** 1994 May; 63(5):109–11, 115

Indoor air pollutants and sick building syndrome: a case study and implications for the community health nurse. Tsacoyianis R. **Public Health Nurs** 1997 Feb;14(1):58–75 (19 ref.)

[Improvement of a filter and the effect on the TECHNEGAS leakage] Komatani A, et al. **Kaku Igaku** 1997 Jun; 34(6):385–8 (Eng. Abstr.) **(Jpn)**

[Results of integrated tests of the facility to disinfect gaseous environment of orbital stations] Balashov EV, et al. **Aviakosm Ekolog Med** 1996;30(6):37–42 (Eng. Abstr.) **(Rus)**

[The development of a methodological approach to evaluating the operating efficiency of a system for purifying the atmosphere of harmful trace contaminants] Zlotopol'skiĭ VM. **Aviakosm Ekolog Med** 1996;30(3):51–4 (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Health risk assessment of fungi in home environments. Verhoeff AP, et al. **Ann Allergy Asthma Immunol** 1997 Jun; 78(6):544–54; quiz 555–6 (67 ref.)

Modeling the effects of water usage and co-behavior on inhalation exposures to contaminants volatilized from household water. Wilkes CR, et al. **J Expo Anal Environ Epidemiol** 1996 Oct–Dec;6(4):393–412

AIR POLLUTION, RADIOACTIVE

Impact of the 235U series on doses from intakes of natural uranium and decay progeny. Lowe LM. **Health Phys** 1997 Oct;73(4):694–5

Reconstruction of doses and deposition in the western trace from the Chernobyl accident. Sikkeland T, et al. **Health Phys** 1997 May;72(5):750–8

Radiation risk estimation in human populations: lessons from the radiological accident in Brazil. da Cruz AD, et al. **Mutat Res** 1997 Feb 3;373(2):207–14

Variations in the concentration of plutonium, strontium-90 and total alpha-emitters in human teeth collected within the British Isles. O'Donnell RG, et al. **Sci Total Environ** 1997 Aug 18;201(3):235–43

[Health evaluation of radioactive pollution of the environment] Mikhalev VP, et al. **Gig Sanit** 1997 May–Jun; (3):36–41 **(Rus)**

ADVERSE EFFECTS

Influence of environmental factors on development of Bialystok newborns born in 1987. Litwiejko-Pietryńczak E. **Rocz Akad Med Bialymst** 1996;41(2):457–62

[The genetic sequelae for plant populations of radioactive environmental pollution in connection with the Chernobyl accident] Shevchenko VA, et al. **Radiats Biol Radioecol** 1996 Jul–Aug;36(4):531–45 (Eng. Abstr.) **(Rus)**

[The function of the hypothalamo-hypophyseal-adrenal system in participants in the cleanup of the aftereffects of the accident at the Chernobyl Atomic Electric Power Station who have a neurocirculatory dystonia syndrome] Kovalenko AN, et al. **Ter Arkh** 1993;65(2):58–62 **(Rus)**

[The genetic sequelae of the Chelyabinsk and Chernobyl radioactive contaminations] Bochkov NP, et al. **Vestn Ross Akad Med Nauk** 1996;(6):64–72 (Eng. Abstr.) **(Rus)**

[The results of medical and dosimetric research on the population and on those who worked in cleanup subjected to radiation exposure as a result of the Chernobyl catastrophe] Tsyb AF, et al. **Vestn Ross Akad Med Nauk** 1996;(6):58–64 (Eng. Abstr.) **(Rus)**

ANALYSIS

Measurement of airborne 218Po—a Bayesian approach. Groer PG, et al. **Health Phys** 1996 Dec;71(6):951–5

The variations in long term TLD measurements of environmental background radiation at locations in southeastern New York state and northern New Jersey. Maiello ML. **Health Phys** 1997 Jun;72(6):915–22

Raetrad model extensions for radon entry into multi-level buildings with basements or crawl spaces. Nielson KK, et al. **Health Phys** 1997 Oct;73(4):696–9

A constant flow filter air sampler for workplace environments. Parulian A, et al. **Health Phys** 1996 Dec; 71(6):870–8

Bayesian prediction of mean indoor radon concentrations for Minnesota counties. Price PN, et al. **Health Phys** 1996 Dec; 71(6):922–36

Calculation procedure of potential alpha energy concentration with continuous air sampling. Tokonami S, et al. **Health Phys** 1996 Dec;71(6):937–43

Evaluation of continuous air monitor placement in a plutonium facility. Whicker JJ, et al. **Health Phys** 1997 May;72(5):734–43

PREVENTION & CONTROL

Airborne contamination and the use of aerosol ventilation systems. Hart G, et al. **Nucl Med Commun** 1996 Jul; 17(7):551–3

[Improvement of a filter and the effect on the TECHNEGAS leakage] Komatani A, et al. **Kaku Igaku** 1997 Jun; 34(6):385–8 (Eng. Abstr.) **(Jpn)**

AIR POLLUTION, TOBACCO SMOKE see **TOBACCO SMOKE POLLUTION**

AIR PRESSURE

Mechanism for changes in vasopressin during acute exposure at 3 atm abs air. Torii R, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R259–64

Suicide with an air rifle. Pottker TI, et al. **Ann Emerg Med** 1997 Jun;29(6):818–20

Effect of negative middle-ear pressure on transient-evoked otoacoustic emissions. Marshall L, et al. **Ear Hear** 1997 Jun;18(3):218–26

Interaction of cross-sectional area, driving pressure, and airflow of passive velopharynx. Isono S, et al. **J Appl Physiol** 1997 Sep;83(3):851–9

Initial use of Browne Pneumatic Impactor. Tawfiek ER, et al. **J Endourol** 1997 Apr;11(2):121–4

A new system analysis of motor and locomotor activities associated with a microdialysis study of pressure-induced dopamine increase in rats. Darbin O, et al. **Physiol Behav** 1997 Aug;62(2):367–71

Effect of gas density variations on respiratory input impedance in humans. Calvet JH, et al. **Respir Physiol** 1996 Jul;104(2–3):241–50

Lung morphometric changes after exposure to hypobaria and/or hypoxia and undernutrition. Sekhon HS, et al. **Respir Physiol** 1996 Oct;106(1):99–107

Visual system degeneration induced by blast overpressure. Petras JM, et al. **Toxicology** 1997 Jul 25;121(1):41–9

Biological response to blast overpressure: a summary of modeling. Stuhmiller JH. **Toxicology** 1997 Jul 25; 121(1):91–103 (45 ref.)

[Biodynamic response to the windblast in expulsions with an ejection seat: the pathogenetic mechanism, analysis and prevention of lesions due to aerodynamic wind pressure] Rotondo G. **Riv Med Aeronaut Spaz** 1975 Apr–Sep; 38(2–3):209–34 (Eng. Abstr.) **(Ita)**

[Changes in liver structures of animals subjected to repeated prolonged hyperbaria] Kostkin VB, et al. **Dokl Akad Nauk** 1996 Oct;350(6):842–4 **(Rus)**

AIR QUALITY, INDOOR see **AIR POLLUTION, INDOOR**

AIR RADIOGRAPHY see **PNEUMORADIOGRAPHY**

AIR REVITALIZATION see **AIR CONDITIONING**

AIR SACS

BLOOD SUPPLY

Transport of insulin and albumin by the microvascular endothelium of the rete mirabile. Bendayan M, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1857–64

Evidence of a tubular system for transendothelial transport in arterial capillaries of the rete mirabile. Bendayan M, et al. **J Histochem Cytochem** 1997 Oct;45(10):1365–78

DRUG EFFECTS

Influence of flumequine and oxytetracycline on the resistance of the European eel against the parasitic swimbladder nematode Anguillicola crassus. van der Heijden MH, et al. **Vet Immunol Immunopathol** 1996 Jun 15;52(1–2):127–34

METABOLISM

Control of acid secretion in cultured gas gland cells of the European eel Anguilla anguilla. Pelster B, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):R578–84

Blood acidification in the swimbladder: mechanisms and metabolic pathways. Pelster B. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1133–8

PARASITOLOGY

Influence of flumequine and oxytetracycline on the resistance of the European eel against the parasitic swimbladder nematode Anguillicola crassus. van der Heijden MH, et al. **Vet Immunol Immunopathol** 1996 Jun 15;52(1–2):127–34

ULTRASTRUCTURE

Modification of a technique for support of thin, flexible tissues for microscopic examination: application to turkey air sac membranes. Kunkle RA. **Avian Dis** 1996 Jul–Sep; 40(3):729–35

VIROLOGY

Enhanced neuropathogenicity of avian influenza A virus by passages through air sac and brain of chicks. Silvano FD, et al. **J Vet Med Sci** 1997 Mar;59(3):143–8

AIRCRAFT

Aircrew fatigue in long-haul operations. Samel A, et al. **Accid Anal Prev** 1997 Jul;29(4):439–52

Air force helicopters for transport of intensive care patients. Mittermair HG. **Acta Anaesthesiol Scand Suppl** 1996; 109:113–4

Fear of flying—a Singapore perspective. Chew PH. **Ann Acad Med Singapore** 1997 Jan;26(1):40–5

An overview of the physiological effects of sustained high +Gz forces on human being. Fong KL, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):94–103 (61 ref.)

Simulation of human thermoregulation during water immersion: application to an aircraft cabin water-spray system. Wolf MB, et al. **Ann Biomed Eng** 1997 Jul–Aug; 25(4):620–34

Operation Blessing International's Flying Hospital takes flight to new surgical frontiers on its first medical mission to El Salvador, Saturday, June 29, to Sunday, July 7, 1996. West JS. **AORN J** 1996 Nov;64(5):704–8

Auditory effects of aircraft noise on people living near an airport. Chen TJ, et al. **Arch Environ Health** 1997 Jan–Feb; 52(1):45–50

The Royal Flying Doctor Service. The South Australian operation (central section)—past and present. Cooter R. **Aust Fam Physician** 1997 Jan;26(1):58–61

A review of health effects of aircraft noise. Morrell S, et al. **Aust N Z J Public Health** 1997 Apr;21(2):221–36 (129 ref.)

Liferaft evacuation from a ditched helicopter: dry shod vs. swim away method. Brooks CJ, et al. **Aviat Space Environ Med** 1997 Jan;68(1):35–40

Analysis of workload predictions generated by multiple resource theory. Cohen D, et al. **Aviat Space Environ Med** 1996 Feb;67(2):139–45

Anthropometric measurements and ejection injuries. Edwards M. **Aviat Space Environ Med** 1996 Dec; 67(12):1144–7

Pneumomediastinum during flight secondary to facial fractures—a case report. Kourtidou-Papadeli C, et al. **Aviat Space Environ Med** 1996 Dec;67(12):1201–3

Collision avoidance: a helicopter simulator study. Kruk R, et al. **Aviat Space Environ Med** 1996 Feb;67(2):111–14

First, do no harm: the role of defibrillators and advanced medical care in commercial aviation [editorial] McKenas DK. **Aviat Space Environ Med** 1997 May;68(5):365–7

The optokinetic cervical reflex in pilots of high-performance aircraft. Merryman RF, et al. **Aviat Space Environ Med** 1997 Jun;68(6):479–87

A passenger with pulmonary/laryngeal tuberculosis: no evidence of transmission on two short flights. Moore M, et al. **Aviat Space Environ Med** 1996 Nov;67(11):1097–100

Vertebral fracture after aircraft ejection during Operation Desert Storm. Osborne RG, et al. **Aviat Space Environ Med** 1997 Apr;68(4):337–41

Passenger safety, health, and comfort: a review. Rayman RB. **Aviat Space Environ Med** 1997 May;68(5):432–40 (43 ref.)

Using outdoor exercise to decrease jet lag in airline crewmembers. Shiota M, et al. **Aviat Space Environ Med** 1996 Dec;67(12):1155–60

The Dynamic Aviation Data System (DADS). Soman S, et al. **Aviat Space Environ Med** 1997 Aug;68(8):736–9

Cabin air quality. Aerospace Medical Association. Thibeault

C. **Aviat Space Environ Med** 1997 Jan;68(1):80–2
Survival at high altitudes: wheel–well passengers. Veronneau SJ, et al. **Aviat Space Environ Med** 1996 Aug;67(8):784–6 (6 ref.)
Concentrations of selected contaminants in cabin air of airbus aircrafts. Dechow M, et al. **Chemosphere** 1997 Jul; 35(1–2):21–31
Medical emergencies in commercial air travel. Jagoda A, et al. **Emerg Med Clin North Am** 1997 Feb;15(1):251–60 (21 ref.)
Planes and pollution [news] **Environ Health Perspect** 1997 Feb;105(2):172
Overhead headaches: overhead hazards on commercial airplanes [letter] Evans RW. **Headache** 1997 Feb; 37(2):114–5
Visual scene properties relevant for simulating low–altitude flight: a multidimensional scaling approach. Kleiss JA. **Hum Factors** 1995 Dec;37(4):711–34
Oculomotor responses with aviator helmet–mounted displays and their relation to in–flight symptoms. Kotulak JC, et al. **Hum Factors** 1995 Dec;37(4):699–710
Performance during positive pressure breathing after rapid decompression up to 72,000 feet. Lindeis AE, et al. **Hum Factors** 1997 Mar;39(1):102–10
Level of operator control and changes in heart rate variability during simulated flight maintenance. Tattersall AJ, et al. **Hum Factors** 1995 Dec;37(4):682–98
Effects of aircraft overflights on wilderness recreationists. Fidell S, et al. **J Acoust Soc Am** 1996 Nov;100(5):2909–18
Corneal response and vision with the Softperm lens in simulated aircraft conditions. Apsey DA, et al. **J Am Optom Assoc** 1996 Mar;67(3):151–9
Clinical characteristics of flight phobia. Wilhelm FH, et al. **J Anxiety Disord** 1997 May–Jun;11(3):241–61
Atlanto–axial dislocation without fracture: case report of an ejection injury. Boos N, et al. **J Bone Joint Surg Br** 1997 Mar;79(2):204–5 (8 ref.)
Travel fatigue and jet–lag. Reilly T, et al. **J Sports Sci** 1997 Jun;15(3):365–9
Venous thromboembolism and air travel. **J Vasc Interv Radiol** 1996 Sep–Oct;7(5):713
A pilot with an itchy rash. Piletta PA, et al. **Lancet** 1996 Oct 26;348(9035):1142
Do not go flying in short sleeves [letter] Rasmuson T. **Lancet** 1997 May 31;349(9065):1630
Jet flight leg and hypobaric pressure [letter; comment] Shuster S. **Lancet** 1996 Oct 5;348(9032):970. Comment on: Lancet 1996 Jun 15;347(9016):1697.
Airport malaria in Cairns. Jenkin GA, et al. **Med J Aust** 1997 Mar 17;166(6):307–8
Aircraft accessibility; communicable diseases. **Ment Phys Disabil Law Rep** 1997 Jan–Feb;21(1):129
Communication survey of CH–47D crewmembers. Ribera JE, et al. **Mil Med** 1996 Jul;161(7):387–91
Surviving the "air evac": medical and logistical issues of evacuating psychiatric patients by air from Korea to the United States. Ritchie EC, et al. **Mil Med** 1996 May; 161(5):298–302
Women in combat: concerns of U.S. Air Force and U.S. Army rated male and female aircrew. Voge VM, et al. **Mil Med** 1997 Feb;162(2):79–81
Identification by DNA analysis of the victims of the August 1996 Spitsbergen civil aircraft disaster [see comments] Olaisen B, et al. **Nat Genet** 1997 Apr;15(4):402–5. Comment in: Nat Genet 1997 Apr;15(4):329–31.
The limits of human performance: project Daedalus. Nadel ER. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S71–2
Evaluation of the i–STAT portable clinical analyzer for use in a helicopter. Burritt MF, et al. **Scand J Clin Lab Invest Suppl** 1996;224:121–8
In–flight cabin smoke control. Eklund TI. **Toxicology** 1996 Dec 31;115(1–3):135–44
[Repatriation of patients via airplane: think before beginning (letter; comment)] Griffioen RW. **Ned Tijdschr Geneeskd** 1996 Nov 23;140(47):2359. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1944–7. **(Dut)**
[Repatriation of patients via airplane: think before beginning (letter; comment)] Rietveld–Verboom JA. **Ned Tijdschr Geneeskd** 1996 Nov 23;140(47):2359–60. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1944–7. **(Dut)**
[Cerebral ischemic complication after a transatlantic flight (letter)] Masson C, et al. **Presse Med** 1997 Mar 1; 26(6):269–70 **(Fre)**
[Intraosseous puncture in preclincal emergency medicine. Experiences of an air rescue service] Helm M, et al. **Anaesthesist** 1996 Dec;45(12):1196–202 (Eng. Abstr.) **(Ger)**
[Glaucoma and aircraft pilot fitness] Schwartz R, et al. **Ophthalmologe** 1996 Feb;93(1):76–9 (18 ref.) (Eng. Abstr.) **(Ger)**
[Damaging health effects on children caused by low flying aircraft and other environmental stresses. Autonomic reactions and psychological symptoms in the developmental stage] Poustka F, et al. **Schriftenr Ver Wasser Boden Lufthyg** 1996;97:1–171 **(Ger)**
[Helicopter use in the Swiss air rescue service for children. Inland transport in 1992] Ummenhofer W, et al. **Schweiz Med Wochenschr** 1996 Oct 19;126(42):1785–91 (Eng. Abstr.) **(Ger)**
[Stress and fatigue in long distance 2–man cockpit crew] Samel A, et al. **Wien Med Wochenschr** 1996; 146(13–14):272–6 (Eng. Abstr.) **(Ger)**
[Chronic noise exposure and the cardiovascular system in aircraft pilots] Tomei F, et al. **Med Lav** 1996 Sep–Oct; 87(5):394–410 (Eng. Abstr.) **(Ita)**
[The effect of noise on catecholamine excretion] Paolucci G. **Riv Med Aeronaut Spaz** 1975 Apr–Sep;38(2–3):242–6 (Eng. Abstr.) **(Ita)**
[Psychophysical efficiency after prolonged exposure to intense noises in military aviation specialist personnel] Ramacci CA, et al. **Riv Med Aeronaut Spaz** 1975 Apr–Sep; 38(2–3):235–41 (Eng. Abstr.) **(Ita)**
[Biodynamic response to the windblast in expulsions with an ejection seat: the pathogenetic mechanism, analysis and prevention of lesions due to aerodynamic wind pressure] Rotondo G. **Riv Med Aeronaut Spaz** 1975 Apr–Sep; 38(2–3):209–34 (Eng. Abstr.) **(Ita)**
[Vertebral lesions due to being expelled with an ejection seat. The mechanism, diagnosis and prevention results and means] Rotondo G. **Riv Med Aeronaut Spaz** 1975 Jan–Mar; 38(1):62–77 concl (Eng. Abstr.) **(Ita)**
[Use of fast–acting adaptogens and symptomatic means during evacuation of trauma victims by air transportation] Grechko AT, et al. **Aviakosm Ekolog Med** 1997;31(2):47–9 **(Rus)**
[Prediction of tolerance of longitudinal linear head–to–tail accelerations of short duration (up to 5 seconds)] Mazurin IuV, et al. **Aviakosm Ekolog Med** 1997;31(3):10–4 (Eng. Abstr.) **(Rus)**
[The enhancement of the adaptive resistance of wounded patients to the action of the factors in air transport evacuation] Grechko AT, et al. **Voen Med Zh** 1996 Nov; 317(11):11–3 **(Rus)**
[Air crash on Svalbard. An effective disaster planning at a Norwegian hospital] Ivert T, et al. **Lakartidningen** 1997 Feb 12;94(7):508–9 **(Swe)**

CLASSIFICATION

Echocardiographic findings in NATO pilots: do acceleration (+Gz) stresses damage the heart? AGARD, Neuilly–sur–Seine, France. **Aviat Space Environ Med** 1997 Jul;68(7):596–600

HISTORY

The "automatic stabilizer" and angle of attack assessor: human factors contributions of the Wright brothers. Mohler SR. **Aviat Space Environ Med** 1996 Jun;67(6):585–8

INSTRUMENTATION

Visual scanning and pilot expertise: the role of attentional flexibility and mental model development. Bellenkes AH, et al. **Aviat Space Environ Med** 1997 Jul;68(7):569–79
The effect of a headset leakage on speech intelligibility in helicopter noise. Wagstaff AS, et al. **Aviat Space Environ Med** 1996 Nov;67(11):1034–8
Helicopter engine protection. Stallard P. **Perfusion** 1997 Jul; 12(4):263–7

LEGISLATION & JURISPRUDENCE

[Effect of hot–air balloon crossings on animals in the open air] Stephan E. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb; 104(2):79–82 (Eng. Abstr.) **(Ger)**

STANDARDS

Helicopter door and window jettison mechanisms for underwater escape: ergonomic confusion! Brooks CJ, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):844–57

STATISTICS & NUMERICAL DATA

F–16 Class A mishaps in the U.S. Air Force, 1975–93. Knapp CJ, et al. **Aviat Space Environ Med** 1996 Aug;67(8):777–83

AIRSICKNESS see **MOTION SICKNESS**

AIRWAY OBSTRUCTION

Changes in nasal and oral respiratory resistance before and after uvulopalatopharyngoplasty. Kawano K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:236–8
Bronchial casts in children: a proposed classification based on nine cases and a review of the literature. Seear M, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):364–70 (26 ref.)
The difficult airway: propofol infusion as an alternative to gaseous induction. Ludbrook GL, et al. **Anaesth Intensive Care** 1997 Feb;25(1):71–3
Obstruction due to retained carbon dioxide absorber canister wrapping [letter; comment] Ransom ES, et al. **Anesth Analg** 1997 Mar;84(3):703. Comment on: Anesth Analg 1996 Aug;83(2):425–6.
A choking hazard during nasal end–tidal CO2 monitoring [letter] Pan PH. **Anesthesiology** 1997 Aug;87(2):451
Acute macroglossia causing upper–airway obstruction. Tytherleigh MG. **J Otolaryngol** 1996 Aug;25(4):271–2
Factors influencing acquired upper airway obstruction in newborn infants receiving assisted ventilation because of respiratory failure: an overview. da Silva OP. **J Perinatol** 1996 Jul–Aug;16(4):272–5 (35 ref.)

BLOOD

Circulating endothelin–1 in obstructive sleep apnea. Saarelainen S, et al. **Endothelium** 1997;5(2):115–8

CHEMICALLY INDUCED

8–Epi–PGF2alpha induces airflow obstruction and airway plasma exudation in vivo. Okazawa A, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):436–41
Delayed upper airway obstruction. A life–threatening complication of Dettol poisoning. Joynt GM, et al. **Anaesthesia** 1997 Mar;52(3):261–3
Airway obstruction after oral midazolam [letter] Litman RS. **Anesthesiology** 1996 Nov;85(5):1217–8
[Angioedema of the mucous membranes of the upper aerodigestive tract after administration of ACE inhibitors] Tisch M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):122–3 (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Split Mallampati scores [letter] Dean VS. **Anaesth Intensive Care** 1997 Feb;25(1):91–2

COMPLICATIONS

End–tidal oxygraphy and safe duration of apnoea in young adults and elderly patients [letter; comment] Snowdon SL. **Anaesthesia** 1997 Jun;52(6):606–7. Comment on: Anaesthesia 1997 Feb;52(2):175–8.
Acute airway obstruction following facial scalding: differential diagnosis between a thermal and infective cause. Watts AM, et al. **Burns** 1996 Nov;22(7):570–3
Coexistent asthma and functional upper airway obstruction. Case reports and review of the literature. Elshami AA, et al. **Chest** 1996 Nov;110(5):1358–61 (16 ref.)
Negative–pressure pulmonary edema: a cautionary tale. Eid AA, et al. **Cleve Clin J Med** 1997 Mar;64(3):151–4
Late–onset life–threatening angioedema and upper airway obstruction caused by angiotensin–converting enzyme inhibitor: report of a case. Weng PK, et al. **Ear Nose Throat J** 1997 Jun;76(6):404–7
Airway obstruction and rheumatoid arthritis. Vergnenègre A, et al. **Eur Respir J** 1997 May;10(5):1072–8
Visceral fat accumulation as an important risk factor for obstructive sleep apnoea syndrome in obese subjects. Shinohara E, et al. **J Intern Med** 1997 Jan;241(1):11–8
Negative–pressure pulmonary edema in the otolaryngology patient. Goldenberg JD, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):62–6 (21 ref.)
Stridor in neonates. Mancuso RF. **Pediatr Clin North Am** 1996 Dec;43(6):1339–56 (40 ref.)
Polysomnographic studies in children with adenotonsillar hypertrophy and suspected obstructive sleep apnea. Sanchez–Armengol A, et al. **Pediatr Pulmonol** 1996 Aug; 22(2):101–5
Airways reactivity, atopy and bronchoalveolar lavage in male smokers with airflow obstruction. García–García JM, et al. **Respiration** 1996;63(4):199–204
Should everyone be monitored for upper–airway resistance and how? Guilleminault C, et al. **Sleep** 1996 Dec;19(10 Suppl):S260–2
Cardiogenic oscillations and airway patency [letter; comment] Pennock BE. **Sleep** 1996 Apr;19(3):255–7. Comment on: Sleep 1995 Oct;18(8):651–8.
Airway obstruction in ulcerative colitis. Cross DL, et al. **South Med J** 1997 Feb;90(2):249–50
[Post–obstructive pulmonary edema following extubation––report of two cases] Jiang CY, et al. **Acta Anaesthesiol Sin** 1996 Jun;34(2):97–102 (Eng. Abstr.) **(Chi)**

CONGENITAL

Upper airway obstruction caused by vascular anomalies in children. Wu JM, et al. **Acta Paediatr Sin** 1996 Mar–Apr; 37(2):122–7

DIAGNOSIS

Thymus hyperplasia, differential diagnosis in the wheezing infant. Pedroza Meléndez A, et al. **Allergol Immunopathol (Madr)** 1997 Mar–Apr;25(2):59–62
Acute supraglottitis in adults: early indicators of airway obstruction. Deeb ZE. **Am J Otolaryngol** 1997 Mar–Apr; 18(2):112–5
Inspiratory dynamic obstruction detected by forced oscillation during CPAP. A model study. Farré R, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):952–6
Anaesthesia for a patient with a mediastinal mass presenting with acute stridor. Lewer BM, et al. **Anaesth Intensive Care** 1996 Oct;24(5):605–8
Tumour fragment in the airway detected by intraoperative fibreoptic examination. Sakura S, et al. **Anaesth Intensive Care** 1996 Apr;24(2):265–6
Diagnosis of laryngomalacia is not enough! [letter; comment] Bluestone CD, et al. **Arch Otolaryngol Head Neck Surg** 1996 Dec;122(12):1417–8. Comment on: Arch Otolaryngol Head Neck Surg 1996 Mar;122(3):302–6.
MRI of the pharynx in young patients with sleep disordered breathing. Suto Y, et al. **Br J Radiol** 1996 Nov; 69(827):1000–4
Postesophagectomy mediastinal chylothorax causing upper

airway obstruction misdiagnosed as asthma: a report of two cases. Theaker NJ, et al. **Chest** 1997 Apr;111(4):1126–8
Respiratory resistance by the forced oscillation technique in asthmatic children and cystic fibrosis patients. Lebecque P, et al. **Eur Respir J** 1997 Apr;10(4):891–5
Otolaryngologic manifestations of Kabuki syndrome. Peterson–Falzone SJ, et al.
Int J Pediatr Otorhinolaryngol 1997 Jan 3;38(3):227–36
Capnography for monitoring non–intubated spontaneously breathing patients in an emergency room setting. Egleston CV, et al. **J Accid Emerg Med** 1997 Jul;14(4):222–4
FEF25–75 as a marker of airway obstruction in asthmatic children during reduced mite exposure at high altitude. Valletta EA, et al. **J Asthma** 1997;34(2):127–31
Bronchoscopic evaluation of pediatric airway pathology. McQueen CT, et al. **N C Med J** 1997 May–Jun;58(3):210–3
Changes in respiratory rate affect tidal expiratory flow indices in infants with airway obstruction. Rusconi F, et al. **Pediatr Pulmonol** 1996 Apr;21(4):236–40
Extrinsic airway compression secondary to pulmonary arterial conduits: MR findings. Donnelly LF, et al.
Pediatr Radiol 1997 Mar;27(3):268–70
Left pulmonary artery sling: diagnosis and delineation of associated tracheobronchial anomalies with MR. Newman B, et al. **Pediatr Radiol** 1996 Sep;26(9):661–8
Ultra–low–field magnetic resonance imaging in upper airways obstruction in sleep apnea syndrome. Okada T, et al. **Psychiatry Clin Neurosci** 1996 Oct;50(5):285–9
Analysis of variability in interpretation of spirometric tests. Quadrelli SA, et al. **Respiration** 1996;63(3):131–6 (28 ref.)
Obstructive sleep apnea in children. Marcus CL, et al.
Semin Pediatr Neurol 1996 Mar;3(1):23–8 (21 ref.)
[How to get evidence of the bronchial obstruction in a child?] Malmberg P, et al. **Duodecim** 1995;111(16):1623–9 **(Fin)**
[Predictive value of laryngoscopy with reference to the severity of obstructive sleep apnea] Geibel M, et al.
Pneumologie 1997 Aug;51 Suppl 3:809–10 (Eng. Abstr.) **(Ger)**
[Image diagnosis and function tests—obstructive sleep apnea syndromes] Asakura K, et al.
Nippon Jibiinkoka Gakkai Kaiho 1997 Jan;100(1):68–71 **(Jpn)**

DRUG THERAPY

Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Bullard MJ, et al.
Am J Emerg Med 1996 Mar;14(2):139–43
Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Emerman CL, et al. **Ann Emerg Med** 1997 Apr; 29(4):474–8
Bronchodilator delivery in acute airflow obstruction. A meta–analysis. Turner MO, et al. **Arch Intern Med** 1997 Aug 11–25;157(15):1736–44
Steroids for anything that swells: dexamethasone and postextubation airway obstruction [editorial; comment] Shemie S. **Crit Care Med** 1996 Oct;24(10):1613–4. Comment on: Crit Care Med 1996 Oct;24(10):1666–9.
Comparative efficacy and potency of ipratropium via Turbuhaler and pressurized metered–dose inhaler in reversible airflow obstruction. Böllert FG, et al.
Eur Respir J 1997 Aug;10(8):1824–8
Heliox in children with airway obstruction. Tobias JD.
Pediatr Emerg Care 1997 Feb;13(1):29–32 (14 ref.)
Direct injection of anti–cancer drugs into endobronchial tumours for palliation of major airway obstruction. Celikoğlu SI, et al. **Postgrad Med J** 1997 Mar; 73(857):159–62
Analysis of variability in interpretation of spirometric tests. Quadrelli SA, et al. **Respiration** 1996;63(3):131–6 (28 ref.)
[Atenolol in treatment of patients with airway obstruction] Chazan R. **Pol Merkuriusz Lek** 1996 Dec;1(6):428–30 (44 ref.) (Eng. Abstr.) **(Pol)**
[Reduction of upper airway obstruction in a patient with acromegaly treated with octreotide (letter)] Rojas I, et al.
Med Clin (Barc) 1996 Feb 3;106(4):158 **(Spa)**

ECONOMICS

Costs that would be incurred in establishing "difficult airway register" could be better spent [letter; comment] Morris E, et al. **BMJ** 1996 Nov 30;313(7069):1399. Comment on: BMJ 1996 Aug 17;313(7054):425.

EMBRYOLOGY

Effect of gestational age on the increase in fetal lung growth following tracheal obstruction. Keramidaris E, et al.
Exp Lung Res 1996 May–Jun;22(3):283–98

EPIDEMIOLOGY

Choking incidents among psychiatric patients: retrospective analysis of thirty–one cases from the west Bologna psychiatric wards. Fioritti A, et al. **Can J Psychiatry** 1997 Jun;42(5):515–20
Airway obstruction and rheumatoid arthritis. Vergnenègre A, et al. **Eur Respir J** 1997 May;10(5):1072–8
Effects of a hydrochloric acid spill on neurobehavioral and pulmonary function. Kilburn KH.
J Occup Environ Med 1996 Oct;38(10):1018–25

ETIOLOGY

Clinical pearls. Difficulty breathing. Mallon WK, et al.
Acad Emerg Med 1996 Nov;3(11):1064, 1069–70, 1076–9
Nasal turbinate dislocation caused by nasotracheal intubation. Dost P, et al. **Acta Anaesthesiol Scand** 1997 Jun;41(6):795–6
Intermittent airway obstruction in a child caused by a cervical lipoblastoma. Rasmussen IS, et al.
Acta Anaesthesiol Scand 1997 Aug;41(7):945–6
Complete obstruction of a naso–endotracheal tube. A case report. Politis C, et al. **Acta Stomatol Belg** 1996 Mar; 93(1):13–6
Acute pulmonary edema in a child with spasmodic croup [letter] Garyfallou GT, et al. **Am J Emerg Med** 1997 Mar; 15(2):211–3
Upper airway obstruction caused by brown recluse spider envenomization of the neck. Goto CS, et al.
Am J Emerg Med 1996 Nov;14(7):660–2
Laryngeal obstruction caused by lingual thyroglossal duct cyst presenting at birth. Kuint J, et al. **Am J Perinatol** 1997 Jul;14(6):353–6 (11 ref.)
Pulmonary involvement in Fabry disease. Brown LK, et al.
Am J Respir Crit Care Med 1997 Mar;155(3):1004–10
Integrin upregulation on sputum neutrophils in smokers with chronic airway obstruction. Maestrelli P, et al.
Am J Respir Crit Care Med 1996 Nov;154(5):1296–300
Morphologic determinants of airway responsiveness in chronic smokers. Riess A, et al.
Am J Respir Crit Care Med 1996 Nov;154(5):1444–9
Neck haematoma and airway obstruction in a pre–eclamptic patient: a complication of internal jugular vein cannulation. Lo WK, et al. **Anaesth Intensive Care** 1997 Aug;25(4):423–5
A simple manoeuvre to aid inhalation induction in a patient with a supraglottic mass [letter] Riley RH, et al.
Anaesth Intensive Care 1996 Dec;24(6):727–8
LMA obstruction [letter] Schwab C, et al.
Anaesth Intensive Care 1997 Feb;25(1):89
Life–threatening airway obstruction from nitrous oxide induced frostbite of the oral cavity. Svartling N, et al.
Anaesth Intensive Care 1996 Dec;24(6):717–20
Digital exploration and the laryngeal mask [letter; comment] Charters P. **Anaesthesia** 1996 Oct;51(10):990. Comment on: Anaesthesia 1996 Jun;51(6):604.
Airway obstruction following internal jugular vein cannulation. Kua JS, et al. **Anaesthesia** 1997 Aug; 52(8):776–80
Central airway compression. Anaesthetic and intensive care consequences. McMahon CC, et al. **Anaesthesia** 1997 Feb; 52(2):158–62
Acquired laryngomalacia as a cause of airway obstruction immediately after unilateral mouth floor surgery. Mima H, et al. **Anaesthesia** 1996 Dec;51(12):1152–4
Complete airway obstruction during awake fibreoptic intubation. Shaw IC, et al. **Anaesthesia** 1997 Jun;52(6):582–5
Glossopharyngeal nerve block for pain relief after pediatric tonsillectomy: retrospective analysis and two cases of life–threatening upper airway obstruction from an interrupted trial. Bean–Lijewski JD. **Anesth Analg** 1997 Jun;84(6):1232–8
Juvenile papillomatosis and airway obstruction [letter; comment] Berry FA. **Anesth Analg** 1997 Jun;84(6):1395–6 . Comment on: Anesth Analg 1996 Dec;83(6):1332–4.
Acute intraoperative endotracheal tube obstruction associated with a heat and moisture exchanger in an infant [letter] Casta A, et al. **Anesth Analg** 1997 Apr;84(4):939–40
Total airway obstruction by papillomas during induction of general anesthesia [see comments] Dalmeida RE, et al.
Anesth Analg 1996 Dec;83(6):1332–4. Comment in: Anesth Analg 1997 Jun;84(6):1395–6.
Airway obstruction after ventriculoperitoneal shunt insertion in a patient with neurofibromatosis. Davidson E, et al.
Anesth Analg 1997 Jan;84(1):223–4
Acute upper–airway obstruction in a patient with achalasia. Turkot S, et al. **Ann Emerg Med** 1997 May;29(5):687–9
Posttransplant lymphoproliferative disease presenting as sudden respiratory arrest in a three–year–old child. Hague K, et al. **Ann Otol Rhinol Laryngol** 1997 Mar;106(3):244–7
Upper airway obstruction after pharyngeal flap surgery. Lesavoy MA, et al. **Ann Plast Surg** 1996 Jan;36(1):26–30; Discussion 31–2
Diagnosis of laryngomalacia is not enough! [letter; comment] Bluestone CD, et al. **Arch Otolaryngol Head Neck Surg** 1996 Dec;122(12):1417–8. Comment on: Arch Otolaryngol Head Neck Surg 1996 Mar;122(3):302–6.
Airway problems after carotid endarterectomy [letter; comment] Beamish D. **Br J Anaesth** 1997 Jun;78(6):776. Comment on: Br J Anaesth 1996 Jan;76(1):156–9.
Cutting paediatric tracheal tubes—a potential cause of morbidity [letter] Gupta K, et al. **Br J Anaesth** 1997 May; 78(5):627–8
Obstructive sleep apnoea syndrome: is this an overlooked cause of desaturation in the immediate postoperative period? Vidhani K, et al. **Br J Anaesth** 1997 Apr; 78(4):442–3
An unusual thyroglossal cyst causing upper airway obstruction. Strachan D, et al. **Br J Clin Pract** 1996 Dec; 50(8):472–3
Upper airway obstruction complicating SLE [letter] Dell R, et al. **Can J Anaesth** 1997 Feb;44(2):229–30
Fatal asphyxiations in children involving drawstrings on clothing [see comments] Petruk J, et al.
Can Med Assoc J 1996 Nov 15;155(10):1417–9. Comment in: Can Med Assoc J 1996 Nov 15;155(10):1429–31.
Upper airway obstruction secondary to acinic cell carcinoma of the trachea. Use of Nd:YAG laser. Ansari MA, et al.
Chest 1996 Oct;110(4):1120–2
Effect of posture on the flow–volume loop in two patients with euthyroid goiter. Meysman M, et al. **Chest** 1996 Dec; 110(6):1615–8
Airway obstruction with percutaneous tracheostomy [letter; comment] Sakabu SA, et al. **Chest** 1997 May;111(5):1468 . Comment on: Chest 1996 Aug;110(2):480–5.
Postesophagectomy mediastinal chylothorax causing upper airway obstruction misdiagnosed as asthma: a report of two cases. Theaker NJ, et al. **Chest** 1997 Apr;111(4):1126–8
Tracheostomy tube occlusion protocol predicts significant tracheal obstruction to air flow in patients requiring prolonged mechanical ventilation. Rumbak MJ, et al.
Crit Care Med 1997 Mar;25(3):413–7
Late–onset life–threatening angioedema and upper airway obstruction caused by angiotensin–converting enzyme inhibitor: report of a case. Weng PK, et al.
Ear Nose Throat J 1997 Jun;76(6):404–7
Left main bronchus compression after aortic reconstruction for interruption of aortic arch. Sakai T, et al.
Eur J Cardiothorac Surg 1995;9(11):667–9
Sticker causing airway obstruction [letter] Mayr J, et al.
Eur J Pediatr 1996 Mar;155(3):254–5
Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. Nikolaizik WH, et al. **Eur J Pediatr** 1996 Jul;155(7):608–11
Fatal ball–valve airway obstruction by an extensive blood clot during mechanical ventilation. Foucher P, et al.
Eur Respir J 1996 Oct;9(10):2181–2
Endotracheal intubation–induced upper airway obstruction. Warshawsky ME, et al. **Heart Lung** 1996 Jan–Feb; 25(1):69–71
Intermittent airway obstruction by a floppy blood clot. Stanislas JM, et al. **Injury** 1996 Jul;27(6):452–3
Effect of maturation on allergen–induced airflow obstruction and airway plasma exudation in sensitized guinea pigs. Arakawa H, et al. **Int Arch Allergy Immunol** 1997 Feb; 112(2):196–202
Heterotopic brain in the parapharyngeal space. Forte V, et al. **Int J Pediatr Otorhinolaryngol** 1996 Nov;37(3):253–60
Unusual laryngeal cysts in the newborn. Forte V, et al.
Int J Pediatr Otorhinolaryngol 1996 Nov;37(3):261–7
A nasopharyngeal dermoid causing neonatal airway obstruction. Kayhan FT, et al.
Int J Pediatr Otorhinolaryngol 1997 Jun 20;40(2–3):195–201
Innominate artery compression of the trachea in infants [see comments] Mahboubi S, et al.
Int J Pediatr Otorhinolaryngol 1996 May;35(3):197–205. Comment in: Int J Pediatr Otorhinolaryngol 1997 Jan 3;38(3):281–4.
Wegener's granulomatosis, acute laryngotracheal airway obstruction and death in a 17–year–old female: case report and review of the literature. Matt BH.
Int J Pediatr Otorhinolaryngol 1996 Oct;37(2):163–72 (19 ref.)
Clear plastic cups: a childhood choking hazard. Weiss RL, et al. **Int J Pediatr Otorhinolaryngol** 1996 Nov;37(3):243–51
Near asphyxiation with a child's dummy. Macnamara AF, et al. **J Accid Emerg Med** 1995 Dec;12(4):291–2
Airway obstruction with a minitracheotomy tube. Rozenberg B, et al. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):613–4
Thyroid carcinoma causing fatal laryngeal occlusion. Carter N, et al. **J Laryngol Otol** 1996 Dec;110(12):1176–8
Airway obstruction in children due to plexiform neurofibroma of the larynx. Ejnell H, et al.
J Laryngol Otol 1996 Nov;110(11):1065–68
Isolated laryngeal lymphangioma: a rare cause of airway obstruction in infants. Papsin BC, et al.
J Laryngol Otol 1996 Oct;110(10):969–72
Obstructive atelectasis associated with nasotracheal intubation: a case report. Vikari CA, et al.
J Oral Maxillofac Surg 1997 Sep;55(9):992–6 (15 ref.)
Safe feeding practices for infants and young children. Byard RW, et al. **J Paediatr Child Health** 1996 Aug;32(4):327–9
Sand aspiration: a case report. Choy IO, et al.
J Pediatr Surg 1996 Oct;31(10):1448–50 (5 ref.)
Pulmonary artery band migration producing endobronchial obstruction. Parry RL, et al. **J Pediatr Surg** 1997 Jan; 32(1):48–9
Unique case presentations of acute epiglottic swelling and a protocol for acute airway compromise. Parsons DS, et al. **Laryngoscope** 1996 Oct;106(10):1287–91
Chronic lymphocytic leukaemia with upper airway obstruction. Dean MG, et al. **Leuk Lymphoma** 1996 Feb; 20(5–6):505–7
Allergic fungal sinusitis in children. Muntz HR.
Otolaryngol Clin North Am 1996 Feb;29(1):185–22
Relationship of tonsil size on an airway blockage maneuver in children during sedation. Fishbaugh DF, et al.
Pediatr Dent 1997 May–Jun;19(4):277–81
Choking on crayon. Swischuk LE. **Pediatr Emerg Care** 1997 Aug;13(4):285–6
A pedunculated papilloma causing ball valve obstruction of the larynx in a two–year–old child. Massie RJ, et al.
Pediatr Pulmonol 1997 Feb;23(2):117–9
Freeman Sheldon syndrome: severe upper airway obstruction requiring neonatal tracheostomy. Robinson PJ.
Pediatr Pulmonol 1997 Jun;23(6):457–9 (5 ref.)
Bronchial foreign body: should bronchoscopy be performed in all patients with a choking crisis? Barrios Fontoba JE,

et al. **Pediatr Surg Int** 1997 Feb;12(2–3):118–20

Tracheal obstruction in experimental diaphragmatic hernia: an endoscopic approach in the fetal lamb. Benachi A, et al. **Prenat Diagn** 1997 Jul;17(7):629–34

Inflammatory pseudotumour of the lung presenting as an airway obstructive syndrome. Calderazzo M, et al. **Respir Med** 1997 Jul;91(6):381–4

Functional upper airways obstruction: two patients with persistent symptoms. Warburton CJ, et al. **Thorax** 1996 Sep; 51(9):965–66

[Endoscopy of the respiratory tract in childhood] Nicolai T. **Fortschr Med** 1996 Sep 20;114(26):322–6 (17 ref.) (Eng. Abstr.) **(Ger)**

[Dangerous complication of transtracheal oxygen therapy with the SCOOP(R) system] Rothe TB, et al. **Pneumologie** 1996 Oct;50(10):700–2 (Eng. Abstr.) **(Ger)**

[Respiratory obstruction caused by retropharyngeal hematoma secondary to cervical spinal injury. Report of a case] Corbanese U, et al. **Minerva Anestesiol** 1995 Jul–Aug;61(7–8):339–42 (Eng. Abstr.) **(Ita)**

[Laryngeal diphtheria in a young woman causes diagnostic difficulties—case report] Garlicki A, et al. **Przegl Lek** 1996; 53(10):761–2 (Eng. Abstr.) **(Pol)**

[Upper airway obstruction in patients with chronic obstructive pulmonary disease (letter; comment)] García Pachón E, et al. **Arch Bronconeumol** 1997 Mar;33(3):157–8 . Comment on: Arch Bronconeumol 1996 May;32(5):216–21. **(Spa)**

[Use of a laryngeal mask in cricoarytenoid arthritis: risk of airway obstruction (letter; comment)] Gállego-Franco FJ, et al. **Rev Esp Anestesiol Reanim** 1996 Jun–Jul;43(6):228. Comment on: Rev Esp Anestesiol Reanim 1994 Sep–Oct;41(5):301–2. **(Spa)**

[Severe airway obstruction in 4 cases of postoperative obstructive hematoma (letter)] Ledesma M, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):39–40 (Eng. Abstr.) **(Spa)**

HISTORY

Clearing the airway—probangs. Westhorpe R. **Anaesth Intensive Care** 1997 Feb;25(1):3

Transport strangulation [letter; comment] Carson DO, et al. **Forensic Sci Int** 1996 Sep 30;82(2):191–2. Comment on: Forensic Sci Int 1996 Mar 5;78(1):7–11.

IMMUNOLOGY

The non-specific hypersensitivity of the upper and lower airways in Reinke's edema: preliminary results. Filiaci F, et al. **Allergol Immunopathol (Madr)** 1997 Jan–Feb; 25(1):18–22

Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Roquet A, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):1856–63

METABOLISM

[Correlation of ECP levels in sputum and blood with parameters of airflow obstruction and hyperreactivity in patients with irreversible bronchial obstruction due to chronic bronchitis] Chazan R, et al. **Pol Arch Med Wewn** 1995 Oct;94(4):300–6 (Eng. Abstr.) **(Pol)**

MORTALITY

Deaths due to foreign body aspiration in children: the continuing hazard of toy balloons. Lifschultz BD, et al. **J Forensic Sci** 1996 Mar;41(2):247–51

PATHOLOGY

Severe Hajdu–Cheney syndrome with upper airway obstruction. Crifasi PA, et al. **Am J Med Genet** 1997 Jun 13;70(3):261–6 (39 ref.)

Membranous bronchioles and connective tissue network of normal and emphysematous lungs. Verbeken EK, et al. **J Appl Physiol** 1996 Dec;81(6):2468–80

The effects of tracheal occlusion and release on type II pneumocytes in fetal lambs. Bin Saddiq W, et al. **J Pediatr Surg** 1997 Jun;32(6):834–8

Deleterious effect of tracheal obstruction on type II pneumocytes in fetal sheep. Piedboeuf B, et al. **Pediatr Res** 1997 Apr;41(4 Pt 1):473–9

[Intraoperative airway obstruction during use of a laryngeal mask. A case report and fiber optic findings] Rieger A, et al. **Anaesthesist** 1996 Mar;45(3):278–83 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Interaction between the bradycardic responses to upper airway negative pressure and carotid chemoreceptor stimulation in the anaesthetised rabbit. Nolan P, et al. **Adv Exp Med Biol** 1996;410:431–7

Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Bullard MJ, et al. **Am J Emerg Med** 1996 Mar;14(2):139–43

Effect of obstructive sleep apnea versus sleep fragmentation on responses to airway occlusion. Brooks D, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1609–17

Neuromuscular activity and upper airway collapsibility. Mechanisms of action in the decerebrate cat. Rowley JA, et al. **Am J Respir Crit Care Med** 1997 Aug;156(2 Pt 1):515–21

Characteristics of bronchial asthma with incomplete reversibility of airflow obstruction. Hudon C, et al. **Ann Allergy Asthma Immunol** 1997 Feb;78(2):195–202

Detection of inspiratory resistive loads after anaesthesia for minor surgery. Drummond GB, et al. **Br J Anaesth** 1997 Mar;78(3):308–10

Respiratory mechanics after abdominal surgery measured with continuous analysis of pressure, flow and volume signals. Nimmo AF, et al. **Br J Anaesth** 1996 Sep; 77(3):317–26

Role of endogenous nitric oxide in airflow obstruction in smokers. Kanazawa H, et al. **Chest** 1996 Oct;110(4):927–9

Granulocyte function in the airways of allergen-challenged pigs: effects of inhaled and systemic budesonide. Fornhem C, et al. **Clin Exp Allergy** 1996 Dec;26(12):1436–48

Thyroglossal duct cyst causing airway obstruction in an adult. Brown EG, et al. **Ear Nose Throat J** 1996 Aug; 75(8):530–2, 534

Mechanical coupling between the hemithoraces in humans. Johansen B, et al. **Eur Respir J** 1996 Jan;9(1):140–5

Gas exchange, expiratory flow obstruction and the clinical spectrum of asthma. Wagner PD, et al. **Eur Respir J** 1996 Jun;9(6):1278–82 (17 ref.)

Comparison of impedance and inductance ventilation sensors on adults during breathing, motion, and simulated airway obstruction. Cohen KP, et al. **IEEE Trans Biomed Eng** 1997 Jul;44(7):555–66

Habituation to prolonged airflow obstruction. Rietveld S. **J Asthma** 1997;34(2):133–9

Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction. Tang W, et al. **J Clin Invest** 1996 Dec 15;98(12):2845–53

Biophysics of airflow within the airway: a review. O'Grady K, et al. **J Otolaryngol** 1997 Apr;26(2):123–8 (28 ref.)

Sleep and upper airway obstruction in children with achondroplasia. Zucconi M, et al. **J Pediatr** 1996 Nov; 129(5):743–9

Arousal responses of the newborn piglet to airways obstruction and rebreathing during normothermia and hyperthermia. Galland BC, et al. **Reprod Fertil Dev** 1996; 8(3):365–71

Passive constriction of the upper airway during central apneas: fiberoptic and EMG investigations. Guilleminault C, et al. **Respir Physiol** 1997 Apr;108(1):11–22

Ineffectiveness of intravenous beta 2-agonists on improving exercise tolerance in patients with reversible chronic airway obstruction. Malerba M, et al. **Respiration** 1996; 63(1):8–16

Effect of modulators of hypoxic pulmonary vasoconstriction on the response to inhaled nitric oxide in a neonatal model of severe pulmonary atelectasis. Eyal FG, et al. **Semin Perinatol** 1996 Jun;20(3):186–93

Sleep fragmentation in obstructive sleep apnea. Kimoff RJ. **Sleep** 1996 Nov;19(9 Suppl):S61–6 (65 ref.)

[Comparative study of thoracic and abdominal effort, respiratory oscillatory impedance (ROI) and intrathoracic pressure in sleep apnea syndrome] Schlenker E, et al. **Pneumologie** 1997 Aug;51 Suppl 3:758–62 (Eng. Abstr.) **(Ger)**

[Bernoulli's law is of current interest during snoring. Mechanisms make the air flow easier] Ulfberg J. **Lakartidningen** 1996 Oct 23;93(43):3780–2 **(Swe)**

PREVENTION & CONTROL

Airway management of neonates with antenatally detected head and neck anomalies. Stocks RM, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jun;123(6):641–5

Pentoxifylline does not alter the response to inhaled grain dust. Jagielo PJ, et al. **Chest** 1997 May;111(5):1429–35

Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial [see comments] Anene O, et al. **Crit Care Med** 1996 Oct;24(10):1666–9. Comment in: Crit Care Med 1996 Oct;24(10):1613–4.

Safe feeding practices for infants and young children. Byard RW, et al. **J Paediatr Child Health** 1996 Aug;32(4):327–9

The use of the CO2 laser for airway maintenance in obstructive supraglottic carcinoma. Leontsinis TG, et al. **J R Coll Surg Edinb** 1996 Dec;41(6):414–5

Airway management for pediatric emergencies. Tobias JD. **Pediatr Ann** 1996 Jun;25(6):317–20, 323–8 (23 ref.)

Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Allegra L, et al. **Respiration** 1996;63(3):174–80

Role of thoracic surgery for childhood tuberculosis. Hewitson JP, et al. **World J Surg** 1997 Jun;21(5):468–74

PSYCHOLOGY

Perception of airway obstruction in asthma: sequential daily analyses of symptoms, peak expiratory flow rate, and mood. Apter AJ, et al. **J Allergy Clin Immunol** 1997 May; 99(5):605–12

Buspirone for the treatment of anxiety in patients with chronic obstructive airways disease [letter] Alderman CP, et al. **J Clin Psychopharmacol** 1996 Oct;16(5):410–1

Improving perception of air flow obstruction in asthma patients. Stout C, et al. **Psychosom Med** 1997 Mar–Apr; 59(2):201–6

Experimenter expectancy in resistance to respiratory air flow. Wigal JK, et al. **Psychosom Med** 1997 May–Jun; 59(3):318–22

RADIOGRAPHY

Obstructive lesions of the central airways: evaluation by using spiral CT with multiplanar and three-dimensional reformations. Remy-Jardin M, et al. **Eur Radiol** 1996; 6(6):807–16

Upper airway obstruction in infants and children: evaluation by tracheobronchography with a non-ionic contrast agent. Lee T, et al. **Pediatr Radiol** 1997 Mar;27(3):276–80

Airway obstruction in asthmatic and healthy individuals: inspiratory and expiratory thin-section CT findings. Park CS, et al. **Radiology** 1997 May;203(2):361–7

RADIOTHERAPY

Tracheostomy and radiotherapy in the management of laryngeal carcinoma causing airway obstruction. Dawes PJ, et al. **Clin Oncol (R Coll Radiol)** 1997;9(2):115–8

REHABILITATION

Laser bronchoscopy with transglottic/supraglottic ventilation to relieve dysphonia and subglottic obstruction. Gallivan GJ, et al. **J Voice** 1997 Mar;11(1):115–23

SURGERY

Prehospital cricothyroidotomy by physicians. Leibovici D, et al. **Am J Emerg Med** 1997 Jan;15(1):91–3

A survey of emergency airway management in the United Kingdom. Ratnayake B, et al. **Anaesthesia** 1996 Oct; 51(10):908–11

Subperiosteal release of the floor of the mouth in Pierre Robin sequence: experience with 12 cases. Caouette-Laberge L, et al. **Cleft Palate Craniofac J** 1996 Nov;33(6):468–72

Tracheostomy and radiotherapy in the management of laryngeal carcinoma causing airway obstruction. Dawes PJ, et al. **Clin Oncol (R Coll Radiol)** 1997;9(2):115–8

Thyroglossal duct cyst causing airway obstruction in an adult. Brown EG, et al. **Ear Nose Throat J** 1996 Aug; 75(8):530–2, 534

Cervical osteomyelitis after percutaneous transtracheal ventilation and tracheotomy. Newlands SD, et al. **Head Neck** 1996 May–Jun;18(3):295–8

Nager acrofacial dysostosis: management of a difficult airway. Friedman RA, et al. **Int J Pediatr Otorhinolaryngol** 1996 Mar;35(1):69–72 (14 ref.)

Early adenotonsillectomy for relief of acute upper airway obstruction due to acute tonsillitis in children. Sdralis T, et al. **Int J Pediatr Otorhinolaryngol** 1996 Mar;35(1):25–9

My first cricothyrotomy. Gates TJ. **J Fam Pract** 1996 Oct; 43(4):409–10

Paediatric Airway Clinic: an 18-month experience. Wiatrak BJ, et al. **J Otolaryngol** 1997 Jun;26(3):149–54

Operating on placental support: the ex utero intrapartum treatment procedure. Mychaliska GB, et al. **J Pediatr Surg** 1997 Feb;32(2):227–30; discussion 230–1

The OOPS procedure (operation on placental support): in utero airway management of the fetus with prenatally diagnosed tracheal obstruction. Skarsgard ED, et al. **J Pediatr Surg** 1996 Jun;31(6):826–8

Efficacy of prehospital surgical cricothyrotomy in trauma patients. Fortune JB, et al. **J Trauma** 1997 May;42(5):832–6; discussion 837–8

Laser bronchoscopy with transglottic/supraglottic ventilation to relieve dysphonia and subglottic obstruction. Gallivan GJ, et al. **J Voice** 1997 Mar;11(1):115–23

A cost-effective and rational surgical approach to patients with snoring, upper airway resistance syndrome, or obstructive sleep apnea syndrome. Utley DS, et al. **Laryngoscope** 1997 Jun;107(6):726–34

Limited septoplasty for endoscopic sinus surgery. Cantrell H. **Otolaryngol Head Neck Surg** 1997 Feb;116(2):274–7

Freeman Sheldon syndrome: severe upper airway obstruction requiring neonatal tracheostomy. Robinson PJ. **Pediatr Pulmonol** 1997 Jun;23(6):457–9 (5 ref.)

Improvement in excessive daytime sleepiness after surgical treatment for obstructive sleep apnea syndrome. Yamadera W. **Psychiatry Clin Neurosci** 1995 Aug;49(4):213–21

Craniofacial dysostosis: airway obstruction and craniofacial surgery. Järund M, et al. **Scand J Plast Reconstr Surg Hand Surg** 1996 Dec; 30(4):275–9

Management of simple snoring, upper airway resistance syndrome, and moderate sleep apnea syndrome. Lévy P, et al. **Sleep** 1996 Nov;19(9 Suppl):S101–10 (80 ref.)

Critical analysis of the results of surgery in the treatment of snoring, upper airway resistance syndrome (UARS), and obstructive sleep apnea (OSA). Pépin JL, et al. **Sleep** 1996 Nov;19(9 Suppl):S90–100 (92 ref.)

[Endonasal surgery of the paranasal sinuses—concepts, techniques, results, complications and revision interventions] Hosemann W. **Eur Arch Otorhinolaryngol Suppl** 1996;1:155–269 (894 ref.) **(Ger)**

[Functional palatoraphy and modified genioplasty in obstructive sleep apnea] Cohrs S, et al.

Wien Med Wochenschr 1996;146(13–14):366–8 (Eng. Abstr.) **(Ger)**

[Effect of adenotomy on mental performance of children with adenoid vegetations] Paditz E, et al. **Wien Med Wochenschr** 1996;146(13–14):327–8 (Eng. Abstr.) **(Ger)**

[Principles of surgical treatment of obstructive sleep apnea by interventions on the facial bones] Reinert S, et al. **Wien Med Wochenschr** 1996;146(13–14):368–72 (20 ref.) (Eng. Abstr.) **(Ger)**

[Functional palatoraphy and modified chin osteotomy in surgical therapy of sleep–related respiratory disorders with obstruction of the upper airways] Wiltfang J, et al. **Wien Med Wochenschr** 1996;146(13–14):363–5 (Eng. Abstr.) **(Ger)**

[Coniotomy: surgical airway management in trauma before hospitalization] Leibovici D, et al. **Harefuah** 1996 May 15; 130(10):719–21, 727 (Eng. Abstr.) **(Heb)**

[Nd–YAG laser in otorhinolaryngology: our experience] Amato G, et al. **Acta Otorhinolaryngol Ital** 1996 Apr; 16(2):114–21 (Eng. Abstr.) **(Ita)**

[Treatment via laser of airway obstructions] Cicconetti F, et al. **G Chir** 1996 Nov–Dec;17(11–12):614–9 (Eng. Abstr.) **(Ita)**

THERAPY

Treatment of malignant bronchial or mediastinal obstruction in comatose patients on life support. Ampil F. **Am J Crit Care** 1997 Mar;6(2):145–6

Airway management practices in emergency medicine [letter; comment] Tayal V. **Am J Emerg Med** 1997 Mar;15(2):211 . Comment on: Am J Emerg Med 1995 Sep;13(5):501–4.

Foreign body airway obstruction: when the Heimlich maneuver fails [letter] Westfal R. **Am J Emerg Med** 1997 Jan;15(1):103–5

Management of acute airway obstruction using extracorporeal membrane oxygenation. Morneault L, et al. **ASAIO J** 1996 Jul–Aug;42(4):321–3

Central anticholinergic syndrome complicating management of a difficult airway [letter] Ezri T, et al. **Can J Anaesth** 1996 Oct;43(10):1079–80

Airway and respiratory management following non–lethal hanging. Kaki A, et al. **Can J Anaesth** 1997 Apr; 44(4):445–50 (15 ref.)

Airway management in children with craniofacial anomalies. Perkins JA, et al. **Cleft Palate Craniofac J** 1997 Mar; 34(2):135–40

Cyclic alternating pattern sequences in non–apneic snorers with and without nasal dilation. Scharf MB, et al. **Ear Nose Throat J** 1996 Sep;75(9):617–9

Temporary tracheobronchial stenting in malignant stenoses. Witt C, et al. **Eur J Cancer** 1997 Feb;33(2):204–8

Prehospital management of the traumatized airway. Deakin CD. **Eur J Emerg Med** 1996 Dec;3(4):233–43 (62 ref.)

Severe endobronchial obstruction in a girl with relapsing polychondritis: treatment with Nd YAG laser and endobronchial silicon stent. Sacco O, et al. **Eur Respir J** 1997 Feb;10(2):494–6

A twenty year (1971–1990) review of tracheostomies in a major paediatric hospital. Donnelly MJ, et al. **Int J Pediatr Otorhinolaryngol** 1996 Mar;35(1):1–9

Bilateral bronchial balloon dilatation and Strecker stent implantation in a ventilated child with malignant carinal stenosis. Nicolai T, et al. **Intensive Care Med** 1996 May; 22(5):482–5

An analysis of dilemmas posed by prehospital DNR orders. Hall SA. **J Emerg Med** 1997 Jan–Feb;15(1):109–11

Airway management for pediatric emergencies. Tobias JD. **Pediatr Ann** 1996 Jun;25(6):317–20, 323–8 (23 ref.)

'Functional relaxation' reduces acute airway obstruction in asthmatics as effectively as inhaled terbutaline. Loew TH, et al. **Psychother Psychosom** 1996;65(3):124–8

Chlorofluorocarbon–free aerosol therapy in patients with pulmonary airflow obstruction. Matthys H. **Respiration** 1996;63(6):321–4 (17 ref.)

How and why should we stabilize the upper airway? Hoffstein V. **Sleep** 1996 Nov;19(9 Suppl):S57–60 (30 ref.)

Methods to stabilize the upper airway using positive pressure. Rapoport DM. **Sleep** 1996 Nov;19(9 Suppl):S123–30

Expandable metal stents for non–malignant bronchial obstruction. Fox RA, et al. **Thorax** 1996 Sep;51(9):963–4

[Respiratory emergencies in pediatrics: priority problems] Gehri M. **Rev Med Suisse Romande** 1996 Oct; 116(10):767–72 **(Fre)**

[Indications, technical implementation and results of endobronchial stent implantation] Thies J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:547–9 (Eng. Abstr.) **(Ger)**

[Flexible contra rigid bronchoscopy for implantation of tracheobronchial prostheses (stents). Pro flexible bronchoscopy] Becker HD. **Pneumologie** 1997 Mar; 51(3):258–61 **(Ger)**

[Stent implantation in severe tracheal and bronchial compression caused by aortic aneurysm] Ewert R, et al. **Pneumologie** 1997 Jan;51(1):19–23 (Eng. Abstr.) **(Ger)**

[Flexible contra rigid bronchoscopy for implantation of tracheobronchial prostheses (stents). Pro rigid bronchoscopy] Freitag L. **Pneumologie** 1997 Mar; 51(3):255–7 **(Ger)**

[Radiologic interventions in anastomosis complications after lung transplantation] Berger H, et al. **Radiologe** 1997 Mar; 37(3):220–4 (Eng. Abstr.) **(Ger)**

[Usefulness of Dumon–type endotracheal stent for left main bronchial obstruction caused by thoracic aortic aneurysm—a case report] Watanabe S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep;44(9):1776–80 (Eng. Abstr.) **(Jpn)**

[Airway stenosis and stents] Miyazawa T, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2086–90 (11 ref.) **(Jpn)**

[A device for realizing the permanent endoprosthesis of the respiratory tract in tumorous stenosis] Paĭkin AE, et al. **Klin Khir** 1995;(3):45 **(Rus)**

ULTRASONOGRAPHY

Airway management of neonates with antenatally detected head and neck anomalies. Stocks RM, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jun;123(6):641–5

Prenatal diagnosis of laryngeal atresia in two cases of congenital high airway obstruction syndrome (CHAOS). Kalache KD, et al. **Prenat Diagn** 1997 Jun;17(6):577–81

VETERINARY

Effects of airway obstruction on transmural pulmonary artery pressure in exercising horses. Jackson JA, et al. **Am J Vet Res** 1997 Aug;58(8):897–903

Pulmonary function measurements during repeated environmental challenge of horses with recurrent airway obstruction (heaves). Tesarowski DB, et al. **Am J Vet Res** 1996 Aug;57(8):1214–9

Complete upper airway obstruction and syncope caused by a subepiglottic cyst in a horse. Hay WP, et al. **Equine Vet J** 1997 Jan;29(1):75–6

Upper–airway obstruction and prolonged recovery from anesthesia following intranasal clotrimazole administration. Caulkett N, et al. **J Am Anim Hosp Assoc** 1997 May–Jun; 33(3):264–7

Tracheolaryngostomy as a treatment for laryngeal obstruction in cattle. West HJ. **Vet J** 1997 Jan;153(1):81–6

Negative pressure pulmonary edema as a post–anesthetic complication associated with upper airway obstruction in a horse. Tute AS, et al. **Vet Surg** 1996 Nov–Dec; 25(6):519–23

AIRWAY RESISTANCE

Changes in the amplitude of the nasal cycle associated with symptoms of acute upper respiratory tract infection. Eccles R, et al. **Acta Otolaryngol (Stockh)** 1996 Jan;116(1):77–81

Comparison of body surface and airway triggered ventilation in extremely premature infants. Laubscher B, et al. **Acta Paediatr** 1997 Jan;86(1):102–4

Objective and subjective nasal airflow. Yaniv E, et al. **Am J Otolaryngol** 1997 Jan–Feb;18(1):29–32

Effect of inspiratory training on mitochondrial DNA and cytochrome–c oxidase expression in the diaphragm. Akiyama Y, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):L320–5

Chronic, episodic, reversible airway obstruction after viral bronchiolitis in rats. Kumar A, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):130–4

Impaired respiratory response to resistive loading during sleep in healthy offspring of patients with obstructive sleep apnea. Pillar G, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1602–8

The effect of introducing fibreoptic bronchoscopes on gas flow in laryngeal masks and tracheal tubes. Brimacombe J, et al. **Anaesthesia** 1996 Oct;51(10):923–8

Measurement of respiratory resistance in the emergency department: feasibility in young children with acute asthma. Ducharme FM, et al. **Chest** 1997 Jun;111(6):1519–25

Post–operative nocturnal hypoxia in septoplasty: the value of nasal packing with airway tubes. Kristensen S, et al. **Clin Otolaryngol** 1996 Aug;21(4):331–4

Raising airway resistance in laryngectomees increases tissue oxygen saturation. McRae D, et al. **Clin Otolaryngol** 1996 Aug;21(4):366–8

New model–based indices for maximum expiratory flow–volume curve in patients with chronic obstructive pulmonary disease. Barnea O, et al. **Comput Biol Med** 1996 Mar;26(2):123–31

Effect of intensive swimming training on lung volumes, airway resistance and on the maximal expiratory flow–volume relationship in prepubertal girls. Courteix D, et al. **Eur J Appl Physiol** 1997;76(3):264–9

Nasal obstruction [letter; comment] Rubin RM. **Eur J Orthod** 1996 Dec;18(6):665; discussion 665–8. Comment on: Eur J Orthod 1995 Dec;17(6):491–5.

Estimation of random errors in respiratory resistance and reactance measured by the forced oscillation technique. Farré R, et al. **Eur Respir J** 1997 Mar;10(3):685–9

A system to generate simultaneous forced oscillation and continuous positive airway pressure. Farré R, et al. **Eur Respir J** 1997 Jun;10(6):1349–53

Measurement of the specific airway resistance by plethysmography in young children accompanied by an adult. Klug B, et al. **Eur Respir J** 1997 Jul;10(7):1599–605

Respiratory resistance by the forced oscillation technique in asthmatic children and cystic fibrosis patients. Lebecque P, et al. **Eur Respir J** 1997 Apr;10(4):891–5

The effect of a closed system suctioning on airway pressure in an experimental mode [letter] Van Hooser T, et al. **Intensive Care Med** 1996 Dec;22(12):1465–6

Enhanced ventilatory and exercise performance in athletes with slight expiratory resistive loading. Fee LL, et al. **J Appl Physiol** 1997 Aug;83(2):503–10

Effect of hypoxia on respiratory system impedance in dogs. Simon BA, et al. **J Appl Physiol** 1997 Aug;83(2):451–8

Snoring, apnea, and nasal resistance. Piché J, et al. **J Otolaryngol** 1996 Jun;25(3):150–4

Sources of error in estimation of laryngeal airway resistance in persons with spasmodic dysphonia. Finnegan EM, et al. **J Speech Hear Res** 1996 Feb;39(1):105–13

Effects of increasing airway pressure and PEEP on the assessment of cardiac preload. Diebel LN, et al. **J Trauma** 1997 Apr;42(4):585–90; discussion 590–1

Comparison of direct and indirect calculations of laryngeal airway resistance in connected speech. McHenry MA, et al. **J Voice** 1996 Sep;10(3):236–44

Recognition and surgical management of the upper airway resistance syndrome. Newman JP, et al. **Laryngoscope** 1996 Sep;106(9 Pt 1):1089–93

Lung function and airway responsiveness in infancy. Landau LI. **Monaldi Arch Chest Dis** 1996 Aug;51(4):303–5 (23 ref.)

Measurements of respiratory system resistance by the interrupter technique in healthy and asthmatic children. Oswald–Mammosser M, et al. **Pediatr Pulmonol** 1997 Aug; 24(2):78–85

Recognition of sleep–disordered breathing in children. Guilleminault C, et al. **Pediatrics** 1996 Nov;98(5):871–82

Improving perception of air flow obstruction in asthma patients. Stout C, et al. **Psychosom Med** 1997 Mar–Apr; 59(2):201–6

Experimenter expectancy in resistance to respiratory air flow. Wigal JK, et al. **Psychosom Med** 1997 May–Jun; 59(3):318–22

Use of the monofrequency forced oscillation technique to measure changes in upper airway resistance in Friesian and blue Belgian calves. Reinhold P, et al. **Res Vet Sci** 1996 Nov;61(3):227–30

Reduced nasal airway resistance following uvulopalatoplasty. Welinder R, et al. **Rhinology** 1997 Mar;35(1):16–8

Should everyone be monitored for upper–airway resistance and how? Guilleminault C, et al. **Sleep** 1996 Dec;19(10 Suppl):S260–2

Management of simple snoring, upper airway resistance syndrome, and moderate sleep apnea syndrome. Lévy P, et al. **Sleep** 1996 Nov;19(9 Suppl):S101–10 (80 ref.)

Critical analysis of the results of surgery in the treatment of snoring, upper airway resistance syndrome (UARS), and obstructive sleep apnea (OSA). Pépin JL, et al. **Sleep** 1996 Nov;19(9 Suppl):S90–100 (92 ref.)

Validation and clinical application of a continuous P0.1 measurement using standard respiratory equipment. Kuhlen R, et al. **Technol Health Care** 1996 Dec;4(4):415–24

Respiratory impedance estimated from airway and intrapleural pressure curves. Fukuyama H, et al. **Tokai J Exp Clin Med** 1996 Oct;21(3):147–56

[Increased resistance of the upper respiratory airways during sleep] Tuunainen A, et al. **Duodecim** 1995;111(12):1148–53 (25 ref.) **(Fin)**

[Respiratory disorders during sleep] Teculescu D, et al. **Rev Epidemiol Sante Publique** 1997 Mar;45(1):64–77 (114 ref.) (Eng. Abstr.) **(Fre)**

[Breathing disorders during sleep: current developments (editorial)] Gugger M. **Schweiz Med Wochenschr** 1997 Feb 8;127(6):204–7 (27 ref.) **(Ger)**

[Changes in ventilatory mechanics in emphysema] Wanke T. **Wien Med Wochenschr** 1996;146(23):585–7 (14 ref.) (Eng. Abstr.) **(Ger)**

[An automated system for determining tracheobronchial resistance] Ul'kin SV, et al. **Fiziol Zh Im I M Sechenova** 1996 Oct–Nov; 82(10–11):126–30 **(Rus)**

DRUG EFFECTS

Effect of bedtime alcohol on inspiratory resistance and respiratory drive in snoring and nonsnoring men. Dawson A, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):183–90

Human and rat airway smooth muscle responsiveness after ozone exposure in vitro. Roux E, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):L631–6

An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion. Morris S, et al. **Am J Rhinol** 1997 Mar–Apr; 11(2):109–15

The relaxant effect of ketamine on guinea pig airway smooth muscle is epithelium–independent. Sato T, et al. **Anesth Analg** 1997 Mar;84(3):641–7

The effect of L–menthol stimulation of the major palatine nerve on subjective and objective nasal patency. Naito K, et al. **Auris Nasus Larynx** 1997 Apr;24(2):159–62

The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Shlik J, et al. **Biol Psychiatry** 1997 Aug 1;42(3):206–12

Detection of inspiratory resistive loads after anaesthesia for minor surgery. Drummond GB, et al. **Br J Anaesth** 1997 Mar;78(3):308–10

Evaluation of partial beta–adrenoceptor agonist activity. Lipworth BJ, et al. **Br J Clin Pharmacol** 1997 Jan; 43(1):9–14 (32 ref.)

Intranasal administration of neuropeptide Y in man: systemic absorption and functional effects. Lacroix JS, et al. **Br J Pharmacol** 1996 Aug;118(8):2079–84

Reduction in post–intubation respiratory resistance by

isoflurane and albuterol. Choi JH, et al. **Can J Anaesth** 1997 Jul;44(7):717–22

Histamine and the nasal vasculature: the influence of H1 and H2–histamine receptor antagonism. Wood–Baker R, et al. **Clin Otolaryngol** 1996 Aug;21(4):348–52

Combined effects of hypocapnia and nicardipine on airway resistance: a pilot study. Combes P, et al. **Eur J Clin Pharmacol** 1997;51(5):385–8

The impact of surfactant replacement therapy on cerebral and systemic circulation and lung function. Schipper JA, et al. **Eur J Pediatr** 1997 Mar;156(3):224–7

A portable device based on the interrupter technique to measure bronchodilator response in schoolchildren [see comments] Bridge PD, et al. **Eur Respir J** 1996 Jul; 9(7):1368–73. Comment in: Eur Respir J 1997 Jun;10(6):1428–9.

Evaluation of a new interrupter device for measuring bronchial responsiveness and the response to bronchodilator in 3 year old children [see comments] Phagoo SB, et al. **Eur Respir J** 1996 Jul;9(7):1374–80. Comment in: Eur Respir J 1997 Jun;10(6):1428–9.

Effect of cessation of short–term therapy with ipratropium bromide on lung function and airway responsiveness. Wilding PJ, et al. **Eur Respir J** 1996 Aug;9(8):1627–31

Reduction by a kallikrein inhibitor of the increased nasal airway resistance of allergic patients after antigen challenge. Katori M, et al. **Immunopharmacology** 1996 Jun; 33(1–3):308–10

Effects of a cysteinyl leukotriene antagonist, ONO–1078 (pranlukast), on total airway resistance after antigen challenge in sensitized guinea pigs. Narita S, et al. **Inflamm Res** 1997 Apr;46(4):143–6

Effect of T–440, a novel type IV phosphodiesterase inhibitor, on allergen–induced immediate and late asthmatic reaction and leukocyte infiltration into the airways of guinea pigs. Kaminuma O, et al. **Int Arch Allergy Immunol** 1997 Apr; 112(4):406–11

Effect of furosemide on hyperpnea–induced airway obstruction, injury, and microvascular leakage. Freed AN, et al. **J Appl Physiol** 1996 Dec;81(6):2461–7

Role of tachykinins in sulfur dioxide–induced bronchoconstriction in anesthetized guinea pigs. Hajj AM, et al. **J Appl Physiol** 1996 Jun;80(6):2044–50

Effects of neonatal immunization and repeated allergen exposure on airway responsiveness in the rabbit. Minshall E, et al. **J Appl Physiol** 1996 Jun;80(6):2108–19

Effects of lung volume on airway resistance during induced constriction in papain–treated rabbits. Nagase T, et al. **J Appl Physiol** 1996 Jun;80(6):1872–9

Lung tissue behavior in the mouse during constriction induced by methacholine and endothelin–1. Nagase T, et al. **J Appl Physiol** 1996 Dec;81(6):2373–8

Greater airway narrowing in immature than in mature rabbits during methacholine challenge. Shen X, et al. **J Appl Physiol** 1996 Dec;81(6):2637–43

Acute histamine–induced flux of airway liquid: role of neuropeptides. Yager D, et al. **J Appl Physiol** 1996 Apr; 80(4):1285–95

Eosinophilia–induced vascular and airway remodeling and hyperresponsiveness in rat lungs. Yoshikawa S, et al. **J Appl Physiol** 1996 Sep;81(3):1279–87

Role of substance P and neurokinin A in toluene diisocyanate–induced increased airway responsiveness in rabbits. Marek W, et al. **Lung** 1996;174(2):83–97

Nitric oxide in chronic obstructive pulmonary disease. Barberà JA. **Monaldi Arch Chest Dis** 1996 Dec;51(6):528–32 (28 ref.)

Effect of capsaicin on airway responsiveness to hypertonic saline challenge in asthmatic and non–asthmatic children. Chang AB, et al. **Pediatr Pulmonol** 1997 Jun;23(6):412–6

Different effects of a thromboxane mimetic on blood flow and plasma exudation in guinea pig airways and skeletal muscle. Cui ZH, et al. **Prostaglandins** 1997 Apr; 53(4):263–77

Lack of effect of nitric oxide inhibition on bronchial tone and methacholine–induced bronchoconstriction in man. Maniscalco M, et al. **Respir Med** 1997 Jul;91(6):335–40

Temporal response of lung impedance after i.v. oleic acid in dogs. Mishima M, et al. **Respir Physiol** 1996 Feb; 103(2):177–85

Relationship between respiratory mechanics and postinspiratory muscle activity during muscarinic challenge in rabbits. Romero PV, et al. **Respir Physiol** 1996 Dec; 106(3):285–92

Airway and tissue constrictions are greater in closed than in open–chest conditions. Suki B, et al. **Respir Physiol** 1997 May;108(2):129–41

[Decongestant nasal spray. Results of a rhinomanometric double–blind study (published erratum appears in Schweiz Med Wochenschr 1996 Nov 30;126(48):2104)] Maranta CA, et al. **Schweiz Med Wochenschr** 1996 Nov 2;126(44):1875–80 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The effect of sympathetic nerve stimulation on ventilation and upper airway resistance in the anaesthetized rat. O'Halloran KD, et al. **Adv Exp Med Biol** 1996;410:443–7

Airway hyperreactivity produced by short–term exposure to hyperoxia in neonatal guinea pigs. Schulman SR, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):L1211–6

A comparison of nasal resistance in white Caucasians and blacks. Canbay EI, et al. **Am J Rhinol** 1997 Jan–Feb; 11(1):73–5

Biofeedback–induced voluntary reduction of respiratory resistance in severe bronchial asthma. Mass R, et al. **Behav Res Ther** 1996 Oct;34(10):815–9

Detection of small airway dysfunction using specific airway conductance. Bassiri AG, et al. **Chest** 1997 Jun; 111(6):1533–5

Influence of maxillary constriction on nasal resistance and sleep apnea severity in patients with Marfan's syndrome. Cistulli PA, et al. **Chest** 1996 Nov;110(5):1184–8

Effect of septal perforations on measures of nasal resistance. Guyette TW, et al. **Cleft Palate Craniofac J** 1997 Mar; 34(2):129–34

Variations in congestion of the nasal mucosa in man. Hallén H, et al. **Clin Otolaryngol** 1996 Oct;21(5):396–9

Analysis of rhinomanometric data based upon a model of nasal airflow and logarithmic transformation of the data. O'Neill G, et al. **Clin Otolaryngol** 1996 Dec;21(6):524–7

Sensation of nasal airflow compared with nasal airway resistance in patients with rhinitis. Simola M, et al. **Clin Otolaryngol** 1997 Jun;22(3):260–2

The nasal response to axillary pressure. Wilde AD, et al. **Clin Otolaryngol** 1996 Oct;21(5):442–4

The nasal response to axillary pressure in non–eosinophilic intrinsic rhinitis. Wilde D, et al. **Clin Otolaryngol** 1997 Jun; 22(3):219–21

The role of the temperature of the nasal lining in the sensation of nasal patency. Willatt DJ, et al. **Clin Otolaryngol** 1996 Dec;21(6):519–23

Estimation of pulmonary diffusion resistance and shunt in an oxygen status model. Andreassen S, et al. **Comput Methods Programs Biomed** 1996 Oct; 51(1–2):95–105

Mucociliary function of the maxillary sinuses after restoring ventilation: a radioisotopic study of the maxillary sinus. Dal T, et al. **Eur Arch Otorhinolaryngol** 1997;254(4):205–7

Effect of exercise–induced hyperventilation on airway resistance and cycling endurance. Kohl J, et al. **Eur J Appl Physiol** 1997;75(4):305–11

Breath–by–breath determinations of airway occlusion pressure in the developing lamb. Milerad J, et al. **Eur J Appl Physiol** 1996;74(1–2):44–51

Upper airway patency and nocturnal desaturation in habitual snoring and obstructive sleep apnea: pathogenesis of sleep–related breathing disorders. Boot H, et al. **Eur Neurol** 1996;36(4):206–10

Respiratory resistive impedance in obstructive patients: linear regression analysis vs viscoelastic modelling. Lorino AM, et al. **Eur Respir J** 1997 Jan;10(1):150–5

Short–term variations in oscillatory and spirometric lung function indices among school children. Timonen KL, et al. **Eur Respir J** 1997 Jan;10(1):82–7

Physiological outcomes. Tepper R, et al. **Eur Respir J Suppl** 1996 Apr;21:12s–15s (44 ref.)

Effects of resistive load on the phase difference between chest and mouth flow in patients with chronic obstructive pulmonary disease. Mishima M, et al. **Front Med Biol Eng** 1997;8(1):1–18

Reduction by a kallikrein inhibitor of the increased nasal airway resistance of allergic patients after antigen challenge. Katori M, et al. **Immunopharmacology** 1996 Jun; 33(1–3):308–10

Respiratory impedances and acinar gas transfer in a canine model for emphysema. Barnas GM, et al. **J Appl Physiol** 1997 Jul;83(1):179–88

Effect of topical upper airway anesthesia on apnea duration through the night in obstructive sleep apnea. Cala SJ, et al. **J Appl Physiol** 1996 Dec;81(6):2618–26

Maturational changes in responses of tissue and airway resistance to histamine. Dreshaj IA, et al. **J Appl Physiol** 1996 Oct;81(4):1785–91

Changes in airway resistance induced by nasal inhalation of cold dry, dry, or moist air in normal individuals. Fontanari P, et al. **J Appl Physiol** 1996 Oct;81(4):1739–43

Effects of N2O narcosis on breathing and effort sensations during exercise and inspiratory resistive loading. Fothergill DM, et al. **J Appl Physiol** 1996 Oct;81(4):1562–71

Friction in airway smooth muscle: mechanism, latch, and implications in asthma. Fredberg JJ, et al. **J Appl Physiol** 1996 Dec;81(6):2703–12

Effect of chronic resistive loading on hypoxic ventilatory responsiveness. Greenberg HE, et al. **J Appl Physiol** 1997 Feb;82(2):500–7

Effects of surface tension and intraluminal fluid on mechanics of small airways. Hill MJ, et al. **J Appl Physiol** 1997 Jan; 82(1):233–9

Phrenic motoneuron discharge during sustained inspiratory resistive loading. Iscoe S. **J Appl Physiol** 1996 Nov; 81(5):2260–6

Partitioning airway and lung tissue resistances in humans: effects of bronchoconstriction. Kaczka DW, et al. **J Appl Physiol** 1997 May;82(5):1531–41

Progressive changes in airway resistance during sleep. Kay A, et al. **J Appl Physiol** 1996 Jul;81(1):282–92

Relationship between resistive loads and P1 peak of respiratory–related evoked potential. Knafelc M, et al. **J Appl Physiol** 1997 Sep;83(3):918–26

How inhomogeneities and airway walls affect frequency dependence and separation of airway and tissue properties. Lutchen KR, et al. **J Appl Physiol** 1996 May;80(5):1696–707

Airway inhomogeneities contribute to apparent lung tissue mechanics during constriction. Lutchen KR, et al. **J Appl Physiol** 1996 May;80(5):1841–9

Mechanism of lobar alveolar pressure decline during forced deflation in canine regional emphysema. Mink SN. **J Appl Physiol** 1997 Feb;82(2):632–43

Assessment of local lung impedance by the alveolar capsule oscillator in dogs: a model analysis. Mishima M, et al. **J Appl Physiol** 1996 Apr;80(4):1165–72

Blockade of glutamate receptors in CVLM and NTS attenuates airway dilation evoked from parabrachial region. Motekaitis AM, et al. **J Appl Physiol** 1996 Jul;81(1):400–7

Airway closure and reopening assessed by the alveolar capsule oscillation technique. Otis DR Jr, et al. **J Appl Physiol** 1996 Jun;80(6):2077–84

Correction of thermal artifacts in plethysmographic airway resistance measurements. Peslin R, et al. **J Appl Physiol** 1996 Jun;80(6):2198–203

Phrenic motoneuron firing rates before, during, and after prolonged inspiratory resistive loading. Road JD, et al. **J Appl Physiol** 1997 Sep;83(3):776–83

Effect of tracheal and tongue displacement on upper airway airflow dynamics. Rowley JA, et al. **J Appl Physiol** 1996 Jun;80(6):2171–8

Respiratory transfer impedance between 8 and 384 Hz in guinea pigs before and after bronchial challenge. Sobh JF, et al. **J Appl Physiol** 1997 Jan;82(1):172–81

Effect of stochastic heterogeneity on lung impedance during acute bronchoconstriction: a model analysis. Thorpe CW, et al. **J Appl Physiol** 1997 May;82(5):1616–25

Frequency dependence of forced oscillatory respiratory mechanics in horses with heaves. Young SS, et al. **J Appl Physiol** 1997 Mar;82(3):983–7

Pulmonary airway reopening: effects of non–Newtonian fluid viscosity. Low HT, et al. **J Biomech Eng** 1997 Aug; 119(3):298–308

Physiologic effects of an external nasal dilator. Griffin JW, et al. **Laryngoscope** 1997 Sep;107(9):1235–8

Resistive loaded breathing changes the motor drive to arm and leg muscles in man. Fontanari P, et al. **Neurosci Lett** 1996 May 31;210(2):130–4

Increased nasal mucosal blood flow, airway resistance and secretion induced by electrical stimulation of the superior salivatory nucleus in cats. Yoshida K, et al. **Neurosci Res** 1996 Aug;25(4):371–7

Interpretation of respiratory input impedance in healthy infants. Jackson AC, et al. **Pediatr Pulmonol** 1996 Dec; 22(6):364–75

Resistive–load detection in healthy school–aged children. McQuaid EL, et al. **Pediatr Pulmonol** 1996 Dec; 22(6):357–63

Effect of exogenous and endogenous nitric oxide on the airway and tissue components of lung resistance in the newborn piglet. Potter CF, et al. **Pediatr Res** 1997 Jun; 41(6):886–91

Deflation–related variability of breathing pattern persists with intact upper airway. Bruce EN. **Respir Physiol** 1996 Dec;106(3):273–83

Effect of gas density variations on respiratory input impedance in humans. Calvet JH, et al. **Respir Physiol** 1996 Jul;104(2–3):241–50

Influence of thoracoabdominal pattern of breathing on respiratory resistance. Gallego J, et al. **Respir Physiol** 1997 May;108(2):143–52

Dry gas hyperpnea changes airway reactivity and ion content of rabbit tracheal wall. Högman M, et al. **Respir Physiol** 1997 Jul;109(1):65–72

Stimulation of the mesencephalic locomotor region constricts the airways of cats. Motekaitis AM, et al. **Respir Physiol** 1996 Dec;106(3):263–71

Negative–impedance ventilation and pressure support ventilation: a comparative study. Poon CS, et al. **Respir Physiol** 1997 May;108(2):117–27

Airway and tissue constrictions are greater in closed than in open–chest conditions. Suki B, et al. **Respir Physiol** 1997 May;108(2):129–41

Bronchodilator response in pulmonary disease at two different states of respiratory mechanics. Ahmad HR, et al. **Respiration** 1996;63(5):288–91

Thirty month variability of aerosol pulse dispersion and conventional lung function parameters in healthy middle aged smokers and nonsmokers. Siekmeier R, et al. **Toxicol Lett** 1996 Nov;88(1–3):263–70

[Reproducibility of inspiratory mouth occlusion pressure with a mobile computer–assisted measuring system] Neumeister W, et al. **Med Klin** 1997 Apr 28;92 Suppl 1:18–21 (Eng. Abstr.) **(Ger)**

[A simple method for improvement of the measurement of respiratory impedance in humans by increasing oropharyngeal impedance using cheek and mouth floor clamps] Barnikol WK, et al. **Pneumologie** 1997 Apr;51 Suppl 2:474–7 (Eng. Abstr.) **(Ger)**

[Impulse oscillometry and body position] Drews D, et al. **Pneumologie** 1997 Apr;51 Suppl 2:478–82 (Eng. Abstr.) **(Ger)**

[Extent of variations in minimal CPAP pressure requirements during a single night] Hein H, et al. **Pneumologie** 1997 Aug; 51 Suppl 3:786–8 (Eng. Abstr.) **(Ger)**

[Pneumologic diagnosis with model aerosols—1: Intrapulmonary morphometry. Principles and initial results of clinical research] Kohlhäufl M, et al. **Pneumologie** 1997 Jan;51(1):40–6 (41 ref.) **(Ger)**

[Predictability of model size in impulse oscillometric airway resistance measurements in animals (calf)] Reinhold P, et

al. **Pneumologie** 1997 Apr;51 Suppl 2:483–5 (Eng. Abstr.) **(Ger)**

[Comparative study of thoracic and abdominal effort, respiratory oscillatory impedance (ROI) and intrathoracic pressure in sleep apnea syndrome] Schlenker E, et al. **Pneumologie** 1997 Aug;51 Suppl 3:758–62 (Eng. Abstr.) **(Ger)**

[Diurnal profile of impulse oscillometric impedance in healthy subjects] Vogel J, et al. **Pneumologie** 1997 Apr;51 Suppl 2:486–9 (Eng. Abstr.) **(Ger)**

[Significance of oscillatory impedance in etiological determination of arousal in sleep related respiratory disorders] Schlenker E, et al. **Wien Med Wochenschr** 1996; 146(13–14):379–81 (Eng. Abstr.) **(Ger)**

[Long-term analysis of respiration in sleep] Schüttler F, et al. **Wien Med Wochenschr** 1996;146(13–14):382–4 (Eng. Abstr.) **(Ger)**

[Ultradian rhythms in the nasal cycle as measured by a new method] Fukuhara H. **Shinrigaku Kenkyu** 1996 Feb; 66(6):437–42 (Eng. Abstr.) **(Jpn)**

[The effect of increasing and decreasing physical loading on the breathing changes under additional resistance] Pogodin Ma, et al. **Fiziol Cheloveka** 1997 May–Jun;23(3):44–7 **(Rus)**

AIVR see **ACCELERATED IDIOVENTRICULAR RHYTHM**

AJMALINE

ADMINISTRATION & DOSAGE

[Pharmacological correction of impaired tolerance to strophanthin in a model of cardiac decompensation] Galenko-Iaroshevskii PA, et al. **Biull Eksp Biol Med** 1994 May;117(5):487–90 **(Rus)**

PHARMACOLOGY

Rate-dependent effects of ajmaline and propafenone on atrioventricular conduction. Stark G, et al. **Eur J Pharmacol** 1996 Aug 22;310(1):29–35

TOXICITY

Effects of lidocaine, ajmaline, and diltiazem on ventricular defibrillation energy requirements in isolated rabbit heart. Anvari A, et al. **J Cardiovasc Pharmacol** 1997 Apr; 29(4):429–35

AKATHISIA see **PSYCHOMOTOR AGITATION**

AKATHISIA, DRUG-INDUCED

see related
DYSKINESIA, DRUG-INDUCED

A case of paroxetine-induced akathisia. [letter] Olivera AA. **Biol Psychiatry** 1996 May 15;39(10):910

Adverse effects of clomipramine [letter] Brasić JR, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Sep;36(9):1165–6

DIAGNOSIS

Akathisia in adults with mental retardation: development of the Akathisia Ratings of Movement Scale (ARMS). Bodfish JW, et al. **Am J Ment Retard** 1997 Jan;101(4):413–23

Antipsychotic drug-induced dysphoria [letter; comment] Lynch G, et al. **Br J Psychiatry** 1996 Oct;169(4):524. Comment on: Br J Psychiatry 1995 Oct;167(4):480–2. Comment on: Br J Psychiatry 1996 May;168(5):655–6.

A case of neuroleptic malignant syndrome and serotonin disturbance [letter] Young C. **J Clin Psychopharmacol** 1997 Feb;17(1):65–6

Monoamine oxidase inhibitor overdose. Thorp M, et al. **West J Med** 1997 Apr;166(4):275–7

[Chorea-like motor restlessness in clozapine] Garcí a C, et al. **Fortschr Neurol Psychiatr** 1996 Oct;64(10):418–21 (26 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Propranolol treatment of olanzapine-induced akathisia [letter] Kurzthaler I, et al. **Am J Psychiatry** 1997 Sep; 154(9):1316

Treatment of a paradoxical reaction to midazolam with haloperidol. Khan LC, et al. **Anesth Analg** 1997 Jul; 85(1):213–5

Flumazenil reversal of psychomotor impairment due to midazolam or diazepam for conscious sedation for upper endoscopy. Kankaria A, et al. **Gastrointest Endosc** 1996 Oct;44(4):416–21

Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. Spivak B, et al. **J Clin Psychiatry** 1997 Jul;58(7):318–22

Successful treatment of the toxic serotonin syndrome with chlorpromazine [letter; comment] Graham PM. **Med J Aust** 1997 Feb 3;166(3):166–7. Comment on: Med J Aust 1996 Sep 16;165(6):345–6.

[Nicotine in neuropsychiatric movement disorders] Erdmann R. **Fortschr Neurol Psychiatr** 1996 Sep;64(9):362–6 (42 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Risk factors for the development of neuroleptic induced akathisia. Miller CH, et al. **Eur Neuropsychopharmacol** 1997 Feb;7(1):51–5

The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curaçao Extrapyramidal Syndromes Study: I. van Harten PN, et al. **Schizophr Res** 1996 May;19(2–3):195–203

ETIOLOGY

Protracted akathisia after risperidone withdrawal [letter] Rosebush PI, et al. **Am J Psychiatry** 1997 Mar;154(3):437–8

Akathisia associated with prochlorperazine as an antiemetic: a case report [letter] Dukoff R, et al. **Ann Oncol** 1996 Jan; 7(1):103

Beta 2-receptor density on mononuclear blood cells in patients suffering from neuroleptic-induced akathisia (NIA). Botschev C, et al. **Biol Psychiatry** 1996 Aug 1; 40(3):203–7

Nefazodone and akathisia. Eberstein S, et al. **Biol Psychiatry** 1996 Oct 15;40(8):798–9

Sertraline and akathisia: spontaneous resolution. Olivera AO. **Biol Psychiatry** 1997 Jan 15;41(2):241–2

Antipsychotic drug-induced dysphoria [letter] Hollistar LE. **Br J Psychiatry** 1997 Apr;170:387

Psychomotor agitation following gabapentin use in brain injury. Childers MK, et al. **Brain Inj** 1997 Jul;11(7):537–40

Tardive akathisia due to sulpiride. López de Munain A, et al. **Clin Neuropharmacol** 1994 Oct;17(5):481–3

Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine. Tollefson GD, et al. **Depress Anxiety** 1996–97;4(6):294–311 (55 ref.)

Zolpidem-induced agitation and disorganization [letter] Hoyler CL, et al. **Gen Hosp Psychiatry** 1996 Nov; 18(6):452–3

Desmopressin side effects [letter] von Gontard A, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Feb;35(2):129–30

Fluoxetine-induced akathisia does not reappear after switch to paroxetine [letter] Bauer M, et al. **J Clin Psychiatry** 1996 Dec;57(12):593–4

Movement disorders associated with the serotonin selective reuptake inhibitors. Leo RJ. **J Clin Psychiatry** 1996 Oct; 57(10):449–54 (86 ref.)

Fluvoxamine and akathisia [letter] Chong SA, et al. **J Clin Psychopharmacol** 1996 Aug;16(4):334–5

Akathisia and acute dystonia induced by sumatriptan [letter] López-Alemany M, et al. **J Neurol** 1997 Feb;244(2):131–2

Combined pharmacotherapy or polypharmacy? Levy F, et al. **J Paediatr Child Health** 1996 Jun;32(3):265–6

[Fluoxetine, akathisia and suicide] Lançon C, et al. **Encephale** 1997 May–Jun;23(3):218–23 (46 ref.) (Eng. Abstr.) **(Fre)**

[Acute agitation after poisoning to viloxazine (letter)] Py P, et al. **Therapie** 1996 May–Jun;51(3):327 **(Fre)**

GENETICS

Familial akathisia and depression treated with nefazodone [letter] Simpson JS. **Can J Psychiatry** 1996 Oct; 41(8):539–40

PHYSIOPATHOLOGY

Restlessness: the anatomy of a neuropsychiatric symptom. Sachdev P, et al. **Aust N Z J Psychiatry** 1996 Feb; 30(1):38–53 (100 ref.)

Prospective study of FK506 side effects: anxiety or akathisia? DiMartini AF, et al. **Biol Psychiatry** 1996 Sep 1; 40(5):407–11

Development of an animal model of fluoxetine akathisia. Teicher MH, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Dec; 19(8):1305–19

[The symptomology of akathisia] Dech H, et al. **Fortschr Neurol Psychiatr** 1997 May;65(5):232–6 (59 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia. Sachdev P, et al. **Acta Psychiatr Scand** 1996 Jun;93(6):451–9

Akathisia as violence [letter] Galynker II, et al. **J Clin Psychiatry** 1997 Jan;58(1):31–2

AKATHISIA, TARDIVE see **AKATHISIA, DRUG-INDUCED**

AKINETIC MUTISM

CHEMICALLY INDUCED

Eighteen cases exposed to sarin in Matsumoto, Japan [see comments] Suzuki J, et al. **Intern Med** 1997 Jul;36(7):466–70 . Comment in: Intern Med 1997 Jul;36(7):447.

DIAGNOSIS

Human immunodeficiency virus-related progressive multifocal leukoencephalopathy presenting with an akinetic rigid syndrome. Werring DJ, et al. **Mov Disord** 1996 Nov; 11(6):758–61

The many faces of acquired neurologic mutism in childhood. van Mourik M, et al. **Pediatr Neurol** 1996 Nov;15(4):352–7

ETIOLOGY

Epileptic akinetic mutism: following temporal lobectomy for Rasmussen's syndrome. Aylett SE, et al. **Eur Child Adolesc Psychiatry** 1996 Dec;5(4):222–5

Role of cavum septum pellucidum in akinetic mutism of hydrocephalic children. Lin KL, et al. **Pediatr Neurol** 1997 Feb;16(2):156–9

AKINETIC PETIT MAL see **EPILEPSY, ABSENCE**

AKR VIRUS

IMMUNOLOGY

Impaired generation of anti-AKR/Gross murine leukemia virus cytotoxic T lymphocytes in mice experimentally infected with MuLV. Coppola MA, et al. **Viral Immunol** 1996;9(2):107–19

D-ALA(2)-D-LEU(5)-ENKEPHALIN see **ENKEPHALIN, LEUCINE-2-ALANINE**

ALAGILLE SYNDROME

Alagille syndrome today. Alagille D. **Clin Invest Med** 1996 Oct;19(5):325–30 (18 ref.)

Alagille syndrome. Krantz ID, et al. **J Med Genet** 1997 Feb; 34(2):152–7 (47 ref.)

[Alagille syndrome] Matsuo K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):236–7 (7 ref.) **(Jpn)**

[Arteriohepatic dysplasia (AHD)] Yokoyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):211–3 (12 ref.) **(Jpn)**

BLOOD

Abnormal lipoprotein pattern in patients with Alagille syndrome depends on Icterus severity. Davit-Spraul A, et al. **Gastroenterology** 1996 Oct;111(4):1023–32

COMPLICATIONS

Paucity of intrahepatic bile ducts, solitary kidney and atrophic pancreas with diabetes mellitus: atypical Alagille syndrome? Devriendt K, et al. **Eur J Pediatr** 1996 Feb; 155(2):87–90

Papular umbilicated granuloma annulare in association with Alagille syndrome. Kibarian MA, et al. **Int J Dermatol** 1997 Mar;36(3):207–9

Ocular ultrasound in Alagille syndrome: a new sign. Nischal KK, et al. **Ophthalmology** 1997 Jan;104(1):79–85

DIAGNOSIS

[Arteriohepatic dysplasia (Alagille syndrome). A case report] Fiedler E, et al. **Rontgenpraxis** 1996 Nov;49(11):281–2 **(Ger)**

[Severe protracted cholestasis after general anesthesia in a patient with Alagille syndrome] Müller C, et al. **Z Gastroenterol** 1996 Dec;34(12):809–12 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Use of ursodeoxycholic acid in the treatment of arteriohepatic dysplasia. Kay MH, et al. **Clin Pediatr (Phila)** 1996 Nov;35(11):593–6

GENETICS

Deletions of 20p12 in Alagille syndrome: frequency and molecular characterization. Krantz ID, et al. **Am J Med Genet** 1997 May 2;70(1):80–6

Alagille syndrome with interstitial 20p deletion derived from maternal ins(7;20). Li PH, et al. **Am J Med Genet** 1996 Jun 28;63(4):537–41

Alagille syndrome in a family with duplication 20p11. Moog U, et al. **Clin Dysmorphol** 1996 Oct;5(4):279–88

Construction of an integrated physical and gene map of human chromosome 20p12 providing candidate genes for Alagille syndrome. Pollet N, et al. **Genomics** 1997 Jun 15; 42(3):489–98

Alagille syndrome--a notch up for the Notch receptor [news; comment] Artavanis-Tsakonas S. **Nat Genet** 1997 Jul; 16(3):212–3. Comment on: Nat Genet 1997 Jul;16(3):235–42. Comment on: Nat Genet 1997 Jul;16(3):243–51.

Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1 [see comments] Li L, et al. **Nat Genet** 1997 Jul;16(3):243–51. Comment in: Nat Genet 1997 Jul;16(3):212–3.

Mutations in the human Jagged1 gene are responsible for Alagille syndrome [see comments] Oda T, et al. **Nat Genet** 1997 Jul;16(3):235–42. Comment in: Nat Genet 1997 Jul;16(3):212–3.

Middle aortic syndrome in a boy with arteriohepatic dysplasia (Alagille syndrome). Shefler AG, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):232–4

RADIOGRAPHY

Syndrome of Asagille: radiological and sonographic findings.

ALAGILLE SYNDROME

A review of 37 cases. Berrocal T, et al. **Eur Radiol** 1997; 7(1):115–8

RADIONUCLIDE IMAGING

Outcome of hepatobiliary scanning in neonatal hepatitis syndrome. Gilmour SM, et al. **J Nucl Med** 1997 Aug; 38(8):1279–82

SURGERY

10 years of pediatric liver transplantation. Andrews W, et al. **J Pediatr Surg** 1996 May;31(5):619–24

Cholecystoappendicostomy in a child with Alagille syndrome. Gauderer MW, et al. **J Pediatr Surg** 1997 Feb; 32(2):166–7

ULTRASONOGRAPHY

Syndrome of Asagille: radiological and sonographic findings. A review of 37 cases. Berrocal T, et al. **Eur Radiol** 1997; 7(1):115–8

ALAMETHICIN

ANALOGS & DERIVATIVES

Ferrocenoyl derivatives of alamethicin: redox–sensitive ion channels. Schmitt JD, et al. **Biochemistry** 1997 Feb 4; 36(5):1115–22

Ion–channels formed by hypelcins, antibiotic peptides, in planar bilayer lipid membranes. Koide N, et al. **Biochim Biophys Acta** 1997 May 22;1326(1):47–53

Studies on metabolites of mycoparasitic fungi. V. Ion–spray ionization mass spectrometric analysis of trichokonin–II, a peptaibol mixture obtained from the culture broth of Trichoderma koningii. Huang Q, et al. **Chem Pharm Bull (Tokyo)** 1996 Mar;44(3):590–3

CHEMISTRY

Ferrocenoyl derivatives of alamethicin: redox–sensitive ion channels. Schmitt JD, et al. **Biochemistry** 1997 Feb 4; 36(5):1115–22

Alamethicin channels – modelling via restrained molecular dynamics simulations. Breed J, et al. **Biochim Biophys Acta** 1997 Apr 26;1325(2):235–49

Simulation studies of alamethicin–bilayer interactions. Biggin PC, et al. **Biophys J** 1997 Feb;72(2 Pt 1):627–36

Helix bending in alamethicin: molecular dynamics simulations and amide hydrogen exchange in methanol. Gibbs N, et al. **Biophys J** 1997 Jun;72(6):2490–5

Neutron scattering in the plane of membranes: structure of alamethicin pores. He K, et al. **Biophys J** 1996 Jun; 70(6):2659–66

Mechanism of alamethicin insertion into lipid bilayers. He K, et al. **Biophys J** 1996 Nov;71(5):2669–79

Effect of changing the size of lipid headgroup on peptide insertion into membranes. Heller WT, et al. **Biophys J** 1997 Jul;73(1):239–44

Influence of proline position upon the ion channel activity of alamethicin. Kaduk C, et al. **Biophys J** 1997 May; 72(5):2151–9

Intrinsic rectification of ion flux in alamethicin channels: studies with an alamethicin dimer. Woolley GA, et al. **Biophys J** 1997 Aug;73(2):770–8

The interactions with solvent, heat stability, and 13C–labelling of alamethicin, an ion–channel–forming peptide. Yee AA, et al. **Eur J Biochem** 1997 Jan 15; 243(1–2):283–91

Molecular dynamics simulation of conformational flexibility of alamethicin fragments in aqueous and membranous environment. Kothekar V, et al. **J Biomol Struct Dyn** 1996 Dec;14(3):303–16

Structure and functions of channel–forming peptides: magainins, cecropins, melittin and alamethicin. Bechinger B. **J Membr Biol** 1997 Apr 1;156(3):197–211 (262 ref.)

METABOLISM

Simulation studies of alamethicin–bilayer interactions. Biggin PC, et al. **Biophys J** 1997 Feb;72(2 Pt 1):627–36

PHARMACOLOGY

Glucuronidation of all–trans–retinoic acid and 5,6–epoxy–all–trans–retinoic acid. Activation of rat liver microsomal UDP–glucuronosyltransferase activity by alamethicin. Little JM, et al. **Drug Metab Dispos** 1997 Jan; 25(1):5–11

ALANINE

Scanning alanine mutagenesis of the second Ig domain of Fc gamma RI indicates critical residues for ligand recognition. McCarthy–Troke MH, et al. **Biochem Soc Trans** 1997 May;25(2):361S

Disrupted collagen architecture in the crystal structure of a triple–helical peptide with a Gly—>Ala substitution. Bella J, et al. **Connect Tissue Res** 1996;35(1–4):401–6

Effect of mutations on the sensitivity of human beta–cell glucokinase to liver regulatory protein. Veiga–da–Cunha M, et al. **Diabetologia** 1996 Oct;39(10):1173–9

Association between Ala54Thr substitution of the fatty acid–binding protein 2 gene with insulin resistance and intra–abdominal fat thickness in Japanese men. Yamada K, et al. **Diabetologia** 1997 Jun;40(6):706–10

New amino acid polymorphism, Ala/Val4058, in exon 45 of the polycystic kidney disease 1 gene: evolution of alleles. Constantinides R, et al. **Hum Genet** 1997 May;99(5):644–7

The pathogenicity of the Pro1148Ala substitution in the FBN1 gene: causing or predisposing to Marfan syndrome and aortic aneurysm, or clinically innocent? Schrijver I, et al. **Hum Genet** 1997 May;99(5):607–11

Structure–function relationships among wild–type variants of Staphylococcus aureus beta–lactamase: importance of amino acids 128 and 216. Voladri RK, et al. **J Bacteriol** 1996 Dec;178(24):7248–53

Functional interaction of transmembrane helices 3 and 6 in rhodopsin. Replacement of phenylalanine 261 by alanine causes reversion of phenotype of a glycine 121 replacement mutant. Han M, et al. **J Biol Chem** 1996 Dec 13; 271(50):32337–42

Alanine–scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity. Harlow GR, et al. **J Biol Chem** 1997 Feb 28; 272(9):5396–402

Scanning alanine mutagenesis and de–peptidization of a Candida albicans myristoyl–CoA:protein N–myristoyltransferase octapeptide substrate reveals three elements critical for molecular recognition. McWherter CA, et al. **J Biol Chem** 1997 May 2;272(18):11874–80

Exploring subunit–subunit interactions in the Escherichia coli bo–type ubiquinol oxidase by extragenic suppressor mutation analysis. Saiki K, et al. **J Biol Chem** 1997 Jun 6;272(23):14721–6

Effects of the phi[NHCO] retromodification on dehydroalanine dipeptide. Alemán C. **J Biomol Struct Dyn** 1996 Oct;14(2):193–9

Characterization of herpes simplex virus type 1 recombinants with mutations in the cytoplasmic tail of glycoprotein H. Browne HM, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2569–73

Alanine–scanning mutagenesis of Bacillus subtilis trp RNA–binding attenuation protein (TRAP) reveals residues involved in tryptophan binding and RNA binding. Yang M, et al. **J Mol Biol** 1997 Aug 1;270(5):696–710

Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha–helical/leucine zipper–like sequence. Poumbourios P, et al. **J Virol** 1997 Mar;71(3):2041–9

Identification of a cytoplasmic Tyr–X–X–Leu motif essential for down regulation of the human cell receptor CD46 in persistent measles virus infection. Yant S, et al. **J Virol** 1997 Jan;71(1):766–70

Spontaneous multivessel cervical artery dissection in a patient with a substitution of alanine for glycine (G13A) in the alpha 1 (I) chain of type I collagen [see comments] Mayer SA, et al. **Neurology** 1996 Aug;47(2):552–6. Comment in: Neurology 1997 May;48(5):1475.

Cysteine–to–alanine replacements in the Escherichia coli SoxR protein and the role of the [2Fe–2S] centers in transcriptional activation. Bradley TM, et al. **Nucleic Acids Res** 1997 Apr 15;25(8):1469–75

On the choice of reference mutant states in the application of the double–mutant cycle method [letter] Faiman GA, et al. **Protein Eng** 1996 Mar;9(3):315–6

ADMINISTRATION & DOSAGE

Alanyl–glutamine–supplemented total parenteral nutrition improves survival and protein metabolism in rat protracted bacterial peritonitis model. Naka S, et al. **JPEN J Parenter Enteral Nutr** 1996 Nov–Dec;20(6):417–23

ANALOGS & DERIVATIVES

A comparative study of tissue distribution and excretion among three substances implicated in eosinophilia–myalgia syndrome. Adachi J, et al. **Adv Exp Med Biol** 1996; 398:365–70

Benzoylalanine analogues as inhibitors of rat brain kynureninase and kynurenine 3–hydroxylase. Giordani A, et al. **Adv Exp Med Biol** 1996;398:499–505

Enantiospecific synthesis and in vitro activity of selective inhibitors of rat brain kynureninase and kynurenine–3–hydroxylase. Giordani A, et al. **Adv Exp Med Biol** 1996;398:531–4

Synthesis and analysis of contaminants in ems–related tryptophan. Steinhart H, et al. **Adv Exp Med Biol** 1996; 398:667–75

Effects of rebamipide on bile acid–induced inhibition of gastric epithelial repair in a rabbit cell culture model. Watanabe S, et al. **Aliment Pharmacol Ther** 1996 Dec; 10(6):927–32

Proceedings of the 2nd International Workshop on Lantibiotics. Arnhem, The Netherlands, 20–23 November 1994. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):87–202

Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. Naito Y, et al. **Arzneimittelforschung** 1996 Jul; 46(7):698–700

Enzymatic synthesis of two isoxazolylalanine isomers by cysteine synthases in Lathyrus species. Ikegami F, et al. **Biol Pharm Bull** 1996 Sep;19(9):1214–5

Effects of betamipron on cisplatin nephrotoxicity and its pharmacokinetics in rats. Tokunaga J, et al. **Biol Pharm Bull** 1997 Apr;20(4):386–91

Protective effects of N–benzoyl amino acids on cisplatin nephrotoxicity in rats. Tokunaga J, et al. **Biol Pharm Bull** 1996 Nov;19(11):1451–6

Stimulatory effects of the putative metabotropic glutamate receptor antagonist L–AP3 on phosphoinositide turnover in neonatal rat cerebral cortex. Mistry R, et al. **Br J Pharmacol** 1996 Mar;117(6):1309–17

Anti–epileptogenic and anticonvulsant activity of L–2–amino–4–phosphonobutyrate, a presynaptic glutamate receptor agonist. Abdul–Ghani AS, et al. **Brain Res** 1997 May 2;755(2):202–12

Effect on prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction. Marie C, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):593–8

Rebamipide attenuates indomethacin–induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Murakami K, et al. **Dig Dis Sci** 1997 Feb;42(2):319–25

Absorption and degradation of metalaxyl in mustard plant (Brassica juncea). Mehta N, et al. **Ecotoxicol Environ Saf** 1997 Jul;37(2):119–24

Separation of fungicides by micellar electrokinetic capillary chromatography. Penmetsa KV, et al. **Electrophoresis** 1997 Feb;18(2):235–40

Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. Bruno V, et al. **Eur J Pharmacol** 1996 Aug 22;310(1):61–6

The metabotropic glutamate receptor antagonist L–2–amino–3–phosphonopropionic acid inhibits phosphoserine phosphatase. Hawkinson JE, et al. **Eur J Pharmacol** 1996 Jun 27;307(2):219–25

Effects of thiocyanate and AMPA receptor ligands on (S)–5–fluorowillardiine, (S)–AMPA and (R,S)–AMPA binding. Hawkinson JE, et al. **Eur J Pharmacol** 1997 Jun 25;329(2–3):213–21

(S)–5–fluorowillardiine–mediated neurotoxicity in cultured murine cortical neurones occurs via AMPA and kainate receptors. Larm JA, et al. **Eur J Pharmacol** 1996 Oct 24; 314(1–2):249–54

Rebamipide ameliorates hepatic dysfunction induced by ischemia/reperfusion in rats. Lee SM, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):41–6

Conversion of 2',3'–dideoxyadenosine (ddA) and 2',3'–didehydro–2',3'–dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. Balzarini J, et al. **FEBS Lett** 1997 Jun 30;410(2–3):324–8

Role of rebamipide on induction of heat–shock proteins and protection against reactive oxygen metabolite–mediated cell damage in cultured gastric mucosal cells. Hahm KB, et al. **Free Radic Biol Med** 1997;22(4):711–6

The effect of rebamipide on gastric xanthine oxidase activity and type conversion in ethanol–treated rats. Huh K, et al. **Free Radic Biol Med** 1996;20(7):967–71

Swelling of Müller cells induced by AP3 and glutamate transport substrates in rat retina. Izumi Y, et al. **Glia** 1996 Aug;17(4):285–93

Selective loss of binding sites for the glutamate receptor ligands [3H]kainate and (S)–[3H]5–fluorowillardiine in the brains of rats with acute liver failure. Michalak A, et al. **Hepatology** 1997 Mar;25(3):631–5

Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene. Wegner M, et al. **Hypertens Res** 1996 Sep;19(3):151–9

Conformational investigation of alpha,beta–dehydropeptides. VII. Conformation of Ac–Pro–deltaAla–NHCH3 and Ac–Pro–(E)–deltaAbu–NHCH3: comparison with (Z)–substituted alpha,beta–dehydropeptides. Pietrzyński G, et al. **Int J Pept Protein Res** 1996 Oct;48(4):347–56

Amidepsine E, an inhibitor of diacylglycerol acyltransferase produced by Humicola sp. FO–5969. Tomoda H, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):929–31

The bimodular G57–V577 polypeptide chain of the class B penicillin–binding protein 3 of Escherichia coli catalyzes peptide bond formation from thiolesters and does not catalyze glycan chain polymerization from the lipid II intermediate. Adam M, et al. **J Bacteriol** 1997 Oct; 179(19):6005–9

Substitution of pyridoxal 5'–phosphate in the O–acetylserine sulfhydrylase from Salmonella typhimurium by cofactor analogs provides a test of the mechanism proposed for formation of the alpha–aminoacrylate intermediate. Cook PF, et al. **J Biol Chem** 1996 Oct 18;271(42):25842–9

D–Alanyl–D–lactate and D–alanyl–D–alanine synthesis by D–alanyl–D–alanine ligase from vancomycin–resistant Leuconostoc mesenteroides. Effects of a phenylalanine 261 to tyrosine mutation. Park IS, et al. **J Biol Chem** 1997 Apr 4;272(14):9210–4

Renal and depressor activity of C–natriuretic peptide in conscious monkeys: effects of enzyme inhibitors. Seymour AA, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):397–401

High–performance liquid chromatographic determination of the imino acids (opines) meso–alanopine and D–strombine in muscle extract of invertebrates. Sandee B, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):176–80

A refined model for the somatostatin pharmacophore: conformational analysis of lanthionine–sandostatin analogs. Melacini G, et al. **J Med Chem** 1997 Jul 4;40(14):2252–8

Lanthionine–somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies. Osapay G, et al. **J Med Chem** 1997 Jul 4;

40(14):2241–51
Crystal structures of the even and odd bolaform amino acid derivatives (11–N–[benzyloxycarbonyl–L–alanyl]aminoundecanoyl)–L–alanyl benzyl ester and (12–N–[benzyloxycarbonyl–L–alanyl]aminododecanoyl)–L–alanyl benzyl ester. Schade B, et al. **J Pept Res** 1997 Apr;49(4):363–8
Effects of rebamipide in a model of experimental diabetes and on the synthesis of transforming growth factor–beta and fibronectin, and lipid peroxidation induced by high glucose in cultured mesangial cells. Ha H, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1457–62
Preventive effect of rebamipide on gastric mucosal cell damage evoked by activation of formyl–methionyl–leucyl–phenylalanine receptors of rabbit neutrophils. Kim CD, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):478–83
Comparative histopathologic evaluation of animal studies: murine studies with L–tryptophan and constitutents. Brown WR. **J Rheumatol Suppl** 1996 Oct;46:99–108; discussion 108–10
Antiretrovirus specificity and intracellular metabolism of 2',3'–didehydro–2',3'–dideoxythymidine (stavudine) and its 5'–monophosphate triester prodrug So324. Balzarini J, et al. **Mol Pharmacol** 1996 Nov;50(5):1207–13
Biomarkers of effect in evaluating metalaxyl cocarcinogenesis. Selective induction of murine CYP 3A isoform. Paolini M, et al. **Mutat Res** 1996 Dec 12; 361(2–3):157–64
beta–Cyano–L–alanine toxicity: evidence for the involvement of an excitotoxic mechanism. Roy DN, et al. **Nat Toxins** 1996;4(6):247–53
Antagonism of the presumed presynaptic action of L–AP4 on GABAergic transmission in the ventrobasal thalamus by the novel mGluR antagonist MPPG. Salt TE, et al. **Neuropharmacology** 1996 Feb;35(2):239–41
Effects of rebamipide on gastric cell damage by Helicobacter pylori–stimulated human neutrophils. Han BG, et al. **Pharmacol Res** 1995 Oct;32(4):201–7
NMDA receptor–mediated increase in cyclic GMP in the rat cerebellum in vivo is blocked by alaproclate and GEA–857. Hu PS, et al. **Pharmacol Toxicol** 1997 Feb; 80(2):97–102
Synthesis and anticonvulsant activity of some amino acid derivatives. Part 1: alanine derivatives. Paruszewski R, et al. **Pharmazie** 1996 Mar;51(3):145–8
Betamipron reduces cisplatin nephrotoxicity in rodents without modifying its antileukemic activity in mice. Tokunaga J, et al. **Ren Fail** 1997 May;19(3):425–38
Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene sulphonic acid–induced colitis rats. Protective effect of rebamipide. Zea–Iriarte WL, et al. **Scand J Gastroenterol** 1996 Oct;31(10):985–92
Study of apoptosis in human lymphocytes by toxic substances implicated in toxic oil syndrome. Gallardo S, et al. **Toxicology** 1997 Mar 14;118(1):71–82
Effects of the lantibiotic mersacidin on the morphology of staphylococci. Molitor E, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):318–28
[Protection of cultured mammalian cells by rebamipide] Antoku S, et al. **Fukuoka Igaku Zasshi** 1997 Jun; 88(6):247–52 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Molecular cloning of cDNA encoding the c–kit receptor of Shiba goats and a novel alanine insertion specific to goats and sheep in the kinase insert region. Tanaka S, et al. **Biochim Biophys Acta** 1997 May 30;1352(2):151–5
Binding of ALA–substituted analogs of HA306–320 to DR1101, DR1301, and DR0402 molecules: correlation of DR–peptide interactions with recognition by a single TCR. Zeliszewski D, et al. **Hum Immunol** 1996 Sep 15;50(1):61–9

ANTAGONISTS & INHIBITORS

Acute and neonatal capsaicin treatment inhibit jejunal amino acid absorption through a Na+–dependent mechanism. Barada KA, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):G815–21

BIOSYNTHESIS

Alanine as an end product during fermentation of monosaccharides by Clostridium strain P2. Orlygsson J, et al. **Antonie Van Leeuwenhoek** 1995 Nov;68(4):273–80

BLOOD

Very low calorie diet (VLCD): a useful alternative in the treatment of the obese NIDDM patient. Capstick F, et al. **Diabetes Res Clin Pract** 1997 May;36(2):105–11

CHEMICAL SYNTHESIS

Enantiospecific synthesis and in vitro activity of selective inhibitors of rat brain kynureninase and kynurenine–3–hydroxylase. Giordani A, et al. **Adv Exp Med Biol** 1996;398:531–4
Synthesis of alanine and leucine by reductive amination of 2–oxoic acid with combination of hydrogenase and dehydrogenase. Hasumi F, et al. **Appl Biochem Biotechnol** 1996 Mar;56(3):341–4
Potential antimelanomic drugs. I. Synthesis and antimelanomic effect of a spin labelled D,L–amino acid containing a 2–chloroethylnitrosocarbamoyl group. Zheleva A, et al. **Pharmazie** 1996 Aug;51(8):602–4

CHEMISTRY

The mannose–binding protein A region of glutamic acid185–alanine221 can functionally replace the surfactant protein A region of glutamic acid195–phenylalanine228 without loss of interaction with lipids and alveolar type II cells. Honma T, et al. **Biochemistry** 1997 Jun 10; 36(23):7176–84
Laser temperature jump study of the helix<==>coil kinetics of an alanine peptide interpreted with a 'kinetic zipper' model. Thompson PA, et al. **Biochemistry** 1997 Jul 29;36(30):9200–10
A site–directed mutagenesis study on the conserved alanine residue in the distal third intracellular loops of cholecystokininB and neurotensin receptors. Wang HL. **Br J Pharmacol** 1997 May;121(2):310–6
Alanine exchanges of polar amino acids in the transmembrane domains of a platelet–activating factor receptor generate both constitutively active and inactive mutants. Ishii I, et al. **J Biol Chem** 1997 Mar 21;272(12):7846–54
Analysis of the dihydropyridine receptor site of L–type calcium channels by alanine–scanning mutagenesis. Peterson BZ, et al. **J Biol Chem** 1997 Jul 25;272(30):18752–8
An alanine residue in the M3–M4 linker lines the glycine binding pocket of the N–methyl–D–aspartate receptor. Wood MW, et al. **J Biol Chem** 1997 Feb 7;272(6):3532–7
Gas–phase reactions of glycine, alanine, valine and their N–methyl derivatives with the nitrosonium ion, NO+. Freitas MA, et al. **J Mass Spectrom** 1996 Oct; 31(10):1086–92
Estimating the relative populations of 3(10)–helix and alpha–helix in Ala–rich peptides: a hydrogen exchange and high field NMR study. Millhauser GL, et al. **J Mol Biol** 1997 Apr 11;267(4):963–74
Aza–peptides. II. X–ray structures of aza–alanine and aza–asparagine–containing peptides. André F, et al. **J Pept Res** 1997 Jun;49(6):556–62
Effect of replacing helical glycine residues with alanines on reversible and irreversible stability and production of Aspergillus awamori glucoamylase. Chen HM, et al. **Protein Eng** 1996 Jun;9(6):499–505
Helical preferences of alanine, glycine, and aminoisobutyric homopeptides. Alemán C, et al. **Proteins** 1997 May; 28(1):83–93
The magnitude of the backbone conformational entropy change in protein folding. D'Aquino JA, et al. **Proteins** 1996 Jun;25(2):143–56
Curious structure in "canonical" alanine–based peptides. Shirley WA, et al. **Proteins** 1997 May;28(1):59–71
Molecular dynamics simulations of synthetic peptide folding. Sung SS, et al. **Proteins** 1996 Jun;25(2):202–14
The use of differential transverse relaxation to detect mobile species in solids. Gerstein BC, et al. **Solid State Nucl Magn Reson** 1996 Feb;6(1):63–71
A 2H NMR spin–lattice relaxation study of –NH+3 group dynamics in polycrystalline L–alanine. Williams MA, et al. **Solid State Nucl Magn Reson** 1996 Feb;6(1):47–53
A novel missense mutation in two families with congenital plasminogen deficiency: identification of an Ala675 to Thr675 substitution. Mima N, et al. **Thromb Haemost** 1996 Jan;75(1):96–100
Genetic diagnosis of dysplasminogenemia: detection of an Ala601–Thr mutation in 118 out of 125 families and identification of a new Asp676–Asn mutation. Tsutsumi S, et al. **Thromb Haemost** 1996 Aug;76(2):135–8

GENETICS

Alanine–scanning mutagenesis along membrane segment 4 of the yeast plasma membrane H+–ATPase. Effects on structure and function. Ambesi A, et al. **J Biol Chem** 1996 Sep 20;271(38):22999–3005
Substitution of glutamic 779 with alanine in the Na,K–ATPase alpha subunit removes voltage dependence of ion transport. Argüello JM, et al. **J Biol Chem** 1996 Oct 4;271(40):24610–6
Alanine scanning mutagenesis of insulin. Kristensen C, et al. **J Biol Chem** 1997 May 16;272(20):12978–83
Rescue of His–42 –> Ala horseradish peroxidase by a Phe–41 –> His mutation. Engineering of a surrogate catalytic histidine. Savenkova MI, et al. **J Biol Chem** 1996 Oct 4;271(40):24598–603
CTLA4 alanine–17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. Donner H, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):143–6
Ala–insertion scanning mutagenesis of the glycophorin A transmembrane helix: a rapid way to map helix–helix interactions in integral membrane proteins. Mingarro I, et al. **Protein Sci** 1996 Jul;5(7):1339–41
Temperature sensitive mutants of influenza A virus generated by reverse genetics and clustered charged to alanine mutagenesis. Parkin NT, et al. **Virus Res** 1996 Dec; 46(1–2):31–44

METABOLISM

Effect of combined alanine and glutamine administration on the inhibition of liver regeneration caused by long–term administration of alcohol. Tanaka T, et al. **Alcohol Alcohol** 1994;29 Suppl 1:125–32
Binding of cationic (+4) alanine– and glycine–containing oligopeptides to double–stranded DNA: thermodynamic analysis of effects of coulombic interactions and alpha–helix induction. Padmanabhan S, et al. **Biochemistry** 1997 Apr 29;36(17):5193–206
In vivo assessment of metabolic perturbations following alanine and glucagon administration using 31P–MRS in the rat. Changani KK, et al. **Biochim Biophys Acta** 1997 Jun 6;1335(3):290–304
Increased alanine uptake and lipid synthesis from alanine in isolated hepatocytes of Wistar–Kyoto fatty rats: an inhibitory effect of biguanides. Mori K, et al. **Can J Physiol Pharmacol** 1997 Mar;75(3):179–84
Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM. Perriello G, et al. **Diabetes** 1997 Jun;46(6):1010–6
Ala217 is important for the catalytic function and autoactivation of prostate–specific human kallikrein 2. Mikolajczyk SD, et al. **Eur J Biochem** 1997 Jun 1; 246(2):440–6
Neutral amino acid transport in placental plasma membrane vesicles in the late pregnant rat. Evidence for a B0–like transport system. Carbó N, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jan;71(1):85–90
Activation of LA–N–2 cell phospholipases by single alanine substitution analogs of amyloid beta peptide (25–35). Singh IN, et al. **FEBS Lett** 1997 Mar 17;405(1):65–7
Free alanine, aspartic acid, or glutamic acid reduce the glycation of human lens proteins. Ramakrishnan S, et al. **Glycoconj J** 1996 Aug;13(4):519–23
Effects of ruminally degradable nitrogen intake and in vitro addition of ammonia and propionate on the metabolic fate of L–[1–14C]alanine and L–[15N]alanine in isolated sheep hepatocytes. Mutsvangwa T, et al. **J Anim Sci** 1997 Apr; 75(4):1149–59
Topographical and functional investigation of Escherichia coli penicillin–binding protein 1b by alanine stretch scanning mutagenesis. Lefèvre F, et al. **J Bacteriol** 1997 Aug;179(15):4761–7
Identification of four amino acids in the gastrin–releasing peptide receptor that are required for high affinity agonist binding. Akeson M, et al. **J Biol Chem** 1997 Jul 11; 272(28):17405–9
Novel insights into the chemical mechanism of ATP synthase. Evidence that in the transition state the gamma–phosphate of ATP is near the conserved alanine within the P–loop of the beta–subunit. Ko YH, et al. **J Biol Chem** 1997 Jul 25;272(30):18875–81
The involvement of serine 175 and alanine 185 of cytochrome b of Rhodobacter sphaeroides cytochrome bc1 complex in interaction with iron–sulfur protein. Tian H, et al. **J Biol Chem** 1997 Sep 19;272(38):23722–8
Differential localization of putative amino acid receptors in taste buds of the channel catfish, Ictalurus punctatus. Finger TE, et al. **J Comp Neurol** 1996 Sep 9;373(1):129–38
rBAT is an amino acid exchanger with variable stoichiometry. Coady MJ, et al. **J Membr Biol** 1996 Jan; 149(1):1–8
In vitro trans translation mediated by alanine–charged 10Sa RNA. Himeno H, et al. **J Mol Biol** 1997 May 23; 268(5):803–8
Mutagenesis of ser41 to ala inhibits the association of GAP–43 with the membrane skeleton of GAP–43–deficient PC12B cells: effects on cell adhesion and the composition of neurite cytoskeleton and membrane. Meiri KF, et al. **J Neurobiol** 1996 Feb;29(2):213–32
D–alanine deprivation of Bacillus subtilis teichoic acids is without effect on cell growth and morphology but affects the autolytic activity. Wecke J, et al. **Microb Drug Resist** 1996 Spring;2(1):123–9
Amino acid metabolism in rat hippocampus during the period of brain growth spurt. Govinatzki MT, et al. **Neurochem Res** 1997 Jan;22(1):23–6
Alanine–stretch scanning mutagenesis: a simple and efficient method to probe protein structure and function. Lefèvre F, et al. **Nucleic Acids Res** 1997 Jan 15;25(2):447–8
Hepatic glucose production from L–alanine is absent in perfused liver of diabetic rats. Ferraz M, et al. **Res Commun Mol Pathol Pharmacol** 1997 Feb;95(2):147–55

PHARMACOKINETICS

Stimulation of [3H] GABA and beta–[3H] alanine release from rat brain slices by cis–4–aminocrotonic acid. Chebib M, et al. **J Neurochem** 1997 Feb;68(2):786–94
Blood–endothelial cell and blood–brain transport of L–proline, alpha–aminoisobutyric acid, and L–alanine. Benrabh H, et al. **Neurochem Res** 1996 Oct;21(10):1227–35

PHARMACOLOGY

Effect of combined alanine and glutamine administration on the inhibition of liver regeneration caused by long–term administration of alcohol. Tanaka T, et al. **Alcohol Alcohol** 1994;29 Suppl 1:125–32
Synergistic effect of alanine and glycine on bovine embryos cultured in a chemically defined medium and amino acid uptake by vitro–produced bovine morulae and blastocysts. Lee ES, et al. **Biol Reprod** 1996 Dec;55(6):1383–9
Chemotaxis of the unicellular green alga Dunaliella salina and the ciliated Tetrahymena pyriformis—effects of glycine, lysine, and alanine, and their oligopeptides. Kóhidai L, et al. **Biosci Rep** 1996 Dec;16(6):467–76

ALANINE

Fluid recirculation in Necturus intestine and the effect of alanine. Hill AE, et al. **J Membr Biol** 1997 Jul 15; 158(2):119–26

Ion, fluid and charge transport across Necturus intestinal epithelium in response to alanine. Shachar-Hill B, et al. **J Membr Biol** 1997 Jul 15;158(2):109–18

The influence of alanine infusion on glucose production in 'malnourished' African children with falciparum malaria. Dekker E, et al. **QJM** 1997 Jul;90(7):455–60

PHYSIOLOGY

Alteration of a single serine in the basic domain of the Epstein-Barr virus ZEBRA protein separates its functions of transcriptional activation and disruption of latency. Francis AL, et al. **J Virol** 1997 Apr;71(4):3054–61

RADIATION EFFECTS

Alanine EPR dosimeter response in proton therapy beams. Gall K, et al. **Appl Radiat Isot** 1996 Nov-Dec; 47(11–12):1197–9

The extension of the range of NIM alanine/ESR dosimetric system to therapy level. Gao J, et al. **Appl Radiat Isot** 1996 Nov-Dec;47(11–12):1193–6

Multifrequency electron paramagnetic resonance of irradiated L-alanine. Ghim BT, et al. **Appl Radiat Isot** 1996 Nov-Dec;47(11–12):1235–9

Alanine-ESR in vivo dosimetry: a feasibility study and possible applications. Kuntz F, et al. **Appl Radiat Isot** 1996 Nov-Dec;47(11–12):1183–8

Alanine-ESR dosimetry for radiotherapy. IAEA experience. Mehta K, et al. **Appl Radiat Isot** 1996 Nov-Dec; 47(11–12):1189–91

Numerical signal treatment for optimized alanine/ESR dosimetry in the therapy-level dose range. Ruckerbauer F, et al. **Appl Radiat Isot** 1996 Nov-Dec;47(11–12):1263–8

One year of experience with alanine dosimetry in radiotherapy. Schaeken B, et al. **Appl Radiat Isot** 1996 Nov-Dec;47(11–12):1177–82

Progress towards an alanine/ESR therapy level reference dosimetry service at NPL. Sharpe PH, et al. **Appl Radiat Isot** 1996 Nov-Dec;47(11–12):1171–5

A response of L-alpha-alanine and standard bone powder on 3.4 MeV/amu 59Co ion beams. Stuglik Z, et al. **Appl Radiat Isot** 1996 Nov-Dec;47(11–12):1219–22

Alanine dosimetry of proton therapy beams. Onori S, et al. **Med Phys** 1997 Mar;24(3):447–53

THERAPEUTIC USE

Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM. Saleh TY, et al. **Diabetes Care** 1997 Aug;20(8):1231–6

Effect of alanine on D-galactosamine-induced acute liver failure in rats. Maezono K, et al. **Hepatology** 1996 Nov; 24(5):1211–6

Beneficial effect of alanine on metabolic recovery of fasted livers submitted to cold ischemia. Patry J, et al. **NMR Biomed** 1996 Sep;9(6):249–60

URINE

Urinary biotinidase and alanine excretion in patients with insulin-dependent diabetes mellitus. Terentyeva EA, et al. **Eur J Clin Chem Clin Biochem** 1997 Jan;35(1):21–4

ALANINE AMINOTRANSFERASE

ADMINISTRATION & DOSAGE

Targeting of alanine: glyoxylate aminotransferase in normal individuals and its mistargeting in patients with primary hyperoxaluria type 1. Danpure CJ, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:477–90

ANALYSIS

Relationship between the serum alanine aminotransferase level at the end of interferon treatment and histologic changes in wild-type and precore mutant hepatitis B virus infections. Bayraktar Y, et al. **J Viral Hepat** 1996 May; 3(3):137–42

Declining value of alanine aminotransferase in screening blood donors: missed opportunities [letter; comment] Bettigole R. **Transfusion** 1996 Sep;36(9):847–8. Comment on: Transfusion 1995 Nov-Dec;35(11):903–10.

[Pathogenesis-screening tests for liver dysfunction in the asymptomatic patients with elevated ALT values and their diagnostic efficacies in primary care medicine] Takemura Y, et al. **Rinsho Byori** 1996 Mar;44(3):261–6 (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Vigabatrin causes profound reduction in serum alanine transaminase activity. Ryan MF, et al. **Ann Clin Biochem** 1996 May;33 (Pt 3):257–8

In vitro effects of the novel anti-epileptic agent vigabatrin on alanine aminotransferase and aspartate aminotransferase activities in rat serum. Okumura H, et al. **Arzneimittelforschung** 1996 May;46(5):459–62

Structure-activity studies of L-canaline-mediated inhibition of porcine alanine aminotransferase. Worthen DR, et al. **Chem Res Toxicol** 1996 Dec;9(8):1293–7

BLOOD

Serum aminotransferase levels and histological disease in chronic hepatitis C. Michielsen PP, et al. **Acta Gastroenterol Belg** 1997 Jan-Mar;60(1):11–4

Serum alanine aminotransferase activity in obese children. Tazawa Y, et al. **Acta Paediatr** 1997 Mar;86(3):238–41

Effect of weight changes on serum transaminase activities in obese children. Tazawa Y, et al. **Acta Paediatr Jpn** 1997 Apr;39(2):210–4

Effects of histamine on gizzard erosions and on the activity of selected enzymes in chickens. Džaja P, et al. **Acta Vet Hung** 1995;43(4):431–41

Comparison of some blood parameters of captured and farmed red deer (Cervus elaphus) hinds. Zomborszky Z, et al. **Acta Vet Hung** 1996;44(4):433–41

New 'state' markers for the detection of alcoholism. Lesch OM, et al. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:59–62 (30 ref.)

Nitric oxide and liver injury in alcohol-fed rats after lipopolysaccharide administration. Chamulitrat W, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1065–70

Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Meltzer AA, et al. **Am J Epidemiol** 1997 Oct 1; 146(7):565–71

The effects of cigarette smoking and alcohol consumption on serum liver enzyme activities: a dose-related study in men. Whitehead TP, et al. **Ann Clin Biochem** 1996 Nov; 33 (Pt 6):530–5

Comparison of effect of cafetière and filtered coffee on serum concentrations of liver aminotransferases and lipids: six month randomised controlled trial [see comments] Urgert R, et al. **BMJ** 1996 Nov 30;313(7069):1362–6. Comment in: BMJ 1997 Mar 1;314(7081):680.

Evidence for both in vivo and in vitro interaction between vigabatrin and alanine transaminase. Richens A, et al. **Br J Clin Pharmacol** 1997 Feb;43(2):163–8

Correlation between the severity of acute hepatic necrosis induced by acetaminophen and serum aminotransferase levels in fasted and sucrose-fed rats. Hessel G, et al. **Braz J Med Biol Res** 1996 Jun;29(6):793–6

Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Tarao K, et al. **Cancer** 1997 Feb 15;79(4):688–94

Serum enzymes in heat stroke: prognostic implication. Alzeer AH, et al. **Clin Chem** 1997 Jul;43(7):1182–7

Absence of serum alanine aminotransferase activity in a neonate. Delanghe J, et al. **Clin Chem** 1997 Sep; 43(9):1665–7

Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study. Flichman D, et al. **Clin Diagn Virol** 1997 May;8(1):63–70

Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection. Ghany MG, et al. **Dig Dis Sci** 1996 Nov;41(11):2213–8

Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases. Montalto G, et al. **Dig Dis Sci** 1997 Aug;42(8):1703–7

Importance of pyridoxal-5'-phosphate addition to the assay medium for the measurement of catalytic concentrations of plasma aspartate and alanine aminotransferases in patients undergoing antineoplastic chemotherapy. Mastroianni A, et al. **Eur J Clin Chem Clin Biochem** 1996 Jun;34(6):507–10

Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hayashi J, et al. **Hepatology** 1997 Mar;25(3):697–701

Therapy of hepatitis C: patients with normal aminotransferase levels. Marcellin P, et al. **Hepatology** 1997 Sep;26(3 Suppl 1):133S–136S (19 ref.)

Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Mihm S, et al. **Hepatology** 1997 Mar;25(3):735–9

Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Rossini A, et al. **Hepatology** 1997 Oct; 26(4):1012–7

Changes in serum protease inhibitors and liver specific enzymes in experimental jaundice. Mishra JP, et al. **Indian J Med Sci** 1996 Jul;50(7):221–7

Effect of ursodeoxycholic acid on hypertransaminasaemia and bile acid composition in patients undergoing bone marrow transplantation--a double-blind randomized control study. Clerici C, et al. **Ital J Gastroenterol** 1996 May;28(4):191–8

Incidence of hepatitis C in patients with chronic elevations of aminotransferases [see comments] Salazar AE, et al. **J Am Board Fam Pract** 1996 May-Jun;9(3):157–61. Comment in: J Am Board Fam Pract 1996 Sep-Oct;9(5):391.

Divergent concentrations of plasma metabolites in swine selected for seven generations for high or low plasma total cholesterol. Pond WG, et al. **J Anim Sci** 1997 Feb; 75(2):311–6

Alanine aminotransferase assay to detect anti-HCV positive subjects in non-selected populations [letter] Guadagnino V, et al. **J Clin Pathol** 1997 Aug;50(8):709

Abnormal serum biochemistries in association with arterial gas embolism. Smith RM, et al. **J Emerg Med** 1997 May-Jun;15(3):285–9

A randomized, double-blind, controlled trial of natural interferon-beta therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels. Arase Y, et al. **J Gastroenterol** 1996 Aug;31(4):559–64

Cyclosporine therapy affects aminotransferase activity but not hepatitis C virus RNA levels in chronic hepatitis C. Kakumu S, et al. **J Gastroenterol Hepatol** 1997 Jan; 12(1):62–6

Antibodies to hepatitis C virus and elevated transaminase levels in a town of hyperendemicity in Iwate, Japan. Koyama T, et al. **J Gastroenterol Hepatol** 1997 Jan; 12(1):67–72

Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment. Orito E, et al. **J Gastroenterol Hepatol** 1997 Jan;12(1):58–61

Relationship between sustained elevation of serum alanine aminotransferase and progression from cirrhosis to hepatocellular carcinoma: comparison in patients with hepatitis B virus- and hepatitis C virus-associated cirrhosis [see comments] Sato A, et al. **J Gastroenterol Hepatol** 1996 Oct;11(10):944–8. Comment in: J Gastroenterol Hepatol 1996 Oct;11(10):942–3.

Diagnostic approach to liver enzyme elevation. Craxì A, et al. **J Hepatol** 1996;25 Suppl 1:47–51 (13 ref.)

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. Dusheiko G, et al. **J Hepatol** 1996 Nov;25(5):591–8

HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy). Magrin S, et al. **J Hepatol** 1996 Nov;25(5):583–90

Elevated serum liver enzymes in coke oven and by-product workers. Wu MT, et al. **J Occup Environ Med** 1997 Jun; 39(6):527–33

Virological characterization and liver histology in HCV positive subjects with normal and elevated ALT levels. Rossini A, et al. **Liver** 1997 Jun;17(3):133–8

Serum alanine aminotransferase level in relation to hepatitis B and C virus infections among blood donors. Tsai JF, et al. **Liver** 1997 Feb;17(1):24–9

Liver failure due to metastatic small-cell carcinoma of the lung [letter; comment] Galus M. **Mayo Clin Proc** 1997 Aug; 72(8):791. Comment on: Mayo Clin Proc 1997 Feb;72(2):133–9.

Hepatitis C virus infection-associated markers in sera from blood donors in Surabaya, Indonesia. Darmadi S, et al. **Microbiol Immunol** 1996;40(5):401–5

Relationships between plasma ferritin and aminotransferase profile in haemodialysis patients with hepatitis C virus. Caramelo C, et al. **Nephrol Dial Transplant** 1996 Sep; 11(9):1792–6

Epidemiology of HCV infection: disease and renal transplantation. Cisterne JM, et al. **Nephrol Dial Transplant** 1996;11 Suppl 4:46–7

Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Fabrizi F, et al. **Nephrol Dial Transplant** 1997 Jul; 12(7):1394–8

HCV liver disease in renal transplantation: a clinical and histological study. Haem J, et al. **Nephrol Dial Transplant** 1996;11 Suppl 4:48–51

Revised cutoff values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, an endemic area for hepatitis B. Hung KY, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):180–3

Plasma enzymic changes in insulin-induced hypoglycemia in experimental rabbits. Jiang ZL, et al. **Tohoku J Exp Med** 1996 Jul;179(3):219–22

Limited utility of alanine aminotransferase screening of hepatitis C antibody-screened blood donors. Cable R, et al. **Transfusion** 1997 Feb;37(2):206–10

A search for hepatitis C virus polymerase chain reaction-positive but seronegative subjects among blood donors with elevated alanine aminotransferase. Prince AM, et al. **Transfusion** 1997 Feb;37(2):211–4

Transaminitis and thrombocytopenia following non-heart-beating renal transplantation. Andrews PA, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1384–5

High preoperative serum alanine transferase levels: effect on the risk of liver resection in Child grade A cirrhotic patients. Noun R, et al. **World J Surg** 1997 May;21(4):390–4; discussion 395

[Should hepatitis C be screened? Hepatitis C: screening tools] Lunel F. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S11–24 (86 ref.) **(Fre)**

[The effect of blood AST, ALT and lactate after short and middle distance exercise training] Chuang CC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Sep; 12(9):544–8 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

The role of dimerization of alanine:glyoxylate aminotransferase 1 in its peroxisomal and mitochondrial import. Leiper JM, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:765–7

In vitro association with peroxisomes and conformational change of peroxisomal serine:pyruvate/alanine:glyoxylate aminotransferase in rat and human livers. Oda T, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):341–6

Microheterogeneity and intrahepatic localization of human and rat liver cytosolic alanine aminotransferase. Matsuzawa T, et al. **Biochim Biophys Acta** 1997 Jun 20;1340(1):115–22

Site-directed mutagenesis of the amino acid residues in beta-strand III [Val30-Val36] of D-amino acid aminotransferase of Bacillus sp. YM-1. Ro HS, et al. **FEBS Lett** 1996 Dec 2;398(2-3):141-5

DEFICIENCY

Absence of serum alanine aminotransferase activity in a neonate. Delanghe J, et al. **Clin Chem** 1997 Sep; 43(9):1665-7

DRUG EFFECTS

Late-onset alanine aminotransferase increase with tacrine [letter] Terrell PS, et al. **Ann Pharmacother** 1996 Mar; 30(3):301

Effect of naklofen, alcohol and naklofen administered simultaneously with alcohol on transaminase levels. Łąkowska H, et al. **Folia Morphol (Warsz)** 1996;55(4):380-1

GENETICS

A vertical (pseudodominant) pattern of inheritance in the autosomal recessive disease primary hyperoxaluria type 1: lack of relationship between genotype, enzymic phenotype, and disease severity. Hoppe B, et al. **Am J Kidney Dis** 1997 Jan;29(1):36-44 (27 ref.)

Human glutamate pyruvate transaminase (GPT): localization to 8q24.3, cDNA and genomic sequences, and polymorphic sites. Sohocki MM, et al. **Genomics** 1997 Mar 1;40(2):247-52

Inhibition of alanine:glyoxylate aminotransferase 1 dimerization is a prerequisite for its peroxisome-to-mitochondrion mistargeting in primary hyperoxaluria type 1. Leiper JM, et al. **J Cell Biol** 1996 Nov;135(4):939-51

Primary hyperoxaluria type 1: a cluster of new mutations in exon 7 of the AGXT gene. von Schnakenburg C, et al. **J Med Genet** 1997 Jun;34(6):489-92

Primary hyperoxaluria type 1 caused by peroxisome-to-mitochondrion mistargeting of alanine: glyoxylate aminotransferase. Lhotta K, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2296-8

A low-CO2-inducible gene encoding an alanine: alpha-ketoglutarate aminotransferase in Chlamydomonas reinhardtii. Chen ZY, et al. **Plant Physiol** 1996 Oct; 112(2):677-84

ISOLATION & PURIFICATION

Microheterogeneity and intrahepatic localization of human and rat liver cytosolic alanine aminotransferase. Matsuzawa T, et al. **Biochim Biophys Acta** 1997 Jun 20;1340(1):115-22

Purification and partial structural and kinetic characterization of an alanine aminotransferase from epimastigotes of Trypanosoma cruzi. Zelada C, et al. **Mol Biochem Parasitol** 1996 Aug;79(2):225-8

METABOLISM

Pre-operative time course changes in liver function tests in biliary atresia: its usefulness in the discrimination of biliary atresia in early infancy. Yamagiwa I, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):506-12

Liver specific kynurenine(alanine):glyoxylate aminotransferase was expressed in kidney cell line. Minatogawa Y, et al. **Adv Exp Med Biol** 1996;398:471-6

A semiautomated alanine:glyoxylate aminotransferase assay for the tissue diagnosis of primary hyperoxaluria type 1. Rumsby G, et al. **Ann Clin Biochem** 1997 Jul;34 (Pt 4):400-4

Alanine aminotransferase activity in mammary tissue, muscle and liver of dam rat during lactation and weaning. Desantiago S, et al. **Arch Med Res** 1996 Winter;27(4):443-8

In vitro association with peroxisomes and conformational change of peroxisomal serine:pyruvate/alanine:glyoxylate aminotransferase in rat and human livers. Oda T, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):341-6

Variable peroxisomal and mitochondrial targeting of alanine: glyoxylate aminotransferase in mammalian evolution and disease. Danpure CJ. **Bioessays** 1997 Apr;19(4):317-26 (69 ref.)

Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment. Palmberg C, et al. **Br J Urol** 1997 May;79(5):808-9

Molecular basis of the variable mitochondrial and peroxisomal localisation of alanine-glyoxylate aminotransferase. Oatey PB, et al. **Eur J Biochem** 1996 Oct 15;241(2):374-85

Assessment of liver histology in patients with hepatitis C and normal transaminase levels. Stanley AJ, et al. **Eur J Gastroenterol Hepatol** 1996 Sep;8(9):869-72

3-hydroxykynurenine transamination leads to the formation of the fluorescent substances in human lenses. Malina HZ, et al. **Eur J Ophthalmol** 1996 Jul-Sep;6(3):250-6

Abnormal liver enzymes in outpatients with eating disorders. Mickley D, et al. **Int J Eat Disord** 1996 Nov;20(3):325-9

Alcohol consumption and serum liver-derived enzymes in a Danish population aged 30-50 years. Steffensen FH, et al. **Int J Epidemiol** 1997 Feb;26(1):92-9

Pyridoxal 5'-phosphate binding of a recombinant rat serine: pyruvate/alanine:glyoxylate aminotransferase. Ishikawa K, et al. **J Biochem (Tokyo)** 1996 May;119(5):970-8

Inhibition of alanine:glyoxylate aminotransferase 1 dimerization is a prerequisite for its peroxisome-to-mitochondrion mistargeting in primary hyperoxaluria type 1. Leiper JM, et al. **J Cell Biol** 1996 Nov;135(4):939-51

Dual-enzyme assay of glutamate in single cells based on capillary electrophoresis. Wang Z, et al. **J Chromatogr B Biomed Appl** 1997 Jul 18;695(1):59-65

Persistent glycolic aciduria in a healthy child with normal alanine-glyoxylate aminotransferase activity. Craigen WJ. **J Inherit Metab Dis** 1996;19(6):793-4

Novel sources of mammalian C-S lyase activity. Adcock HJ, et al. **J Pharm Pharmacol** 1996 Feb;48(2):150-3

Hyperoxaluria with hyperglycoluria not due to alanine:glyoxylate aminotransferase defect: a novel type of primary hyperoxaluria. Van Acker KJ, et al. **Kidney Int** 1996 Nov;50(5):1747-52

[The effect of alimentary vitamin B6 supply during pregnancy and lactation on the activity of specific transaminases of lactating rats] Roth-Maier DA, et al. **Z Ernahrungswiss** 1996 Sep;35(3):282-7 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Energy-dependent degradation of a mutant serine: pyruvate/alanin: glyoxylate aminotransferase in a primary hyperoxaluria type 1 case. Suzuki T, et al. **Adv Exp Med Biol** 1996;389:137-40 (12 ref.)

STANDARDS

[Normal values of the de Ritis coefficient] Ivanov DE. **Klin Lab Diagn** 1997 Apr;(4):42-3 **(Rus)**

D-ALANINE CARBOXYPEPTIDASE see **MURAMOYLPENTAPEPTIDE CARBOXYPEPTIDASE**

ALANINE RACEMASE

CHEMISTRY

Determination of the structure of alanine racemase from Bacillus stearothermophilus at 1.9-A resolution. Shaw JP, et al. **Biochemistry** 1997 Feb 11;36(6):1329-42

GENETICS

Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. Cáceres NE, et al. **J Bacteriol** 1997 Aug;179(16):5046-55

The alanine racemase gene is essential for growth of Lactobacillus plantarum. Hols P, et al. **J Bacteriol** 1997 Jun;179(11):3804-7

ALANINE-SPECIFIC TRNA see **RNA, TRANSFER, ALA**

2-ALANYL-LEUCINE ENKEPHALIN see **ENKEPHALIN, LEUCINE-2-ALANINE**

ALANYL T RNA SYNTHETASE

GENETICS

Alanyl-tRNA synthetase gene of the extreme acidophilic chemolithoautotrophic Thiobacillus ferrooxidans is highly homologous to alaS genes from all living kingdoms but cannot be transcribed from its promoter in Escherichia coli. Guiliani N, et al. **Microbiology** 1997 Jul;143 (Pt 7):2179-87

IMMUNOLOGY

[Two cases of interstitial pneumonia with anti-PL-12 (alanyl tRNA synthetase) antibodies] Satoh S, et al. **Ryumachi** 1996 Dec;36(6):862-8 (Eng. Abstr.) **(Jpn)**

METABOLISM

A biologically active 53 kDa fragment of overproduced alanyl-tRNA synthetase from Thermus thermophilus HB8 specifically interacts with tRNA Ala acceptor helix. Lechler A, et al. **Nucleic Acids Res** 1997 Jul 15; 25(14):2737-44

Structure of the acceptor stem of Escherichia coli tRNA Ala: role of the G3.U70 base pair in synthetase recognition. Ramos A, et al. **Nucleic Acids Res** 1997 Jun 1; 25(11):2083-90

Specific atomic groups and RNA helix geometry in acceptor stem recognition by a tRNA synthetase. Beuning PJ, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10150-4

ALASTRIM see **SMALLPOX**

ALBENDAZOLE

ADMINISTRATION & DOSAGE

Cutaneous larva migrans: the case for routine oral treatment [letter] Loughrey MB, et al. **Br J Dermatol** 1997 Jul; 137(1):155-6

[E. Multilocularis infection under treatment with albendazole for very long durations (letter)] Ilias I, et al. **Presse Med** 1997 Apr 26;26(14):667 **(Fre)**

ADVERSE EFFECTS

Aplastic anemia during treatment with albendazole [letter] Fernández FJ, et al. **Am J Hematol** 1996 Sep;53(1):53-4

Development of bone marrow toxicosis after albendazole administration in a dog and cat. Stokol T, et al. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1753-6

[Polyradiculoneuritis and neurocysticercosis: report of a case] Agapejev S, et al. **Arq Neuropsiquiatr** 1996 Mar; 54(1):107-13 (Eng. Abstr.) **(Por)**

ANALOGS & DERIVATIVES

Determination of concentration of albendazole sulfoxide in plasma and uterine fluid of heifers. Piscopo SE, et al. **Am J Vet Res** 1997 Jan;58(1):62-5

Comparison of effects of albendazole sulfoxide on in vitro produced bovine embryos and rat embryos. Piscopo SE, et al. **Am J Vet Res** 1997 Sep;58(9):1038-42

Albendazole versus ricobendazole (albendazole-sulphoxide) against enteral and parenteral stages of Trichinella spiralis in mice. Lopez-Garcia ML, et al. **Int J Parasitol** 1997 Jul; 27(7):781-5

Study of the distribution of albendazole-sulphoxide (ABZ-SO) in fertilized egg compartments. Navarro M, et al. **J Pharmacol Toxicol Methods** 1997 Jun;37(4):191-6

Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Takayanagui OM, et al. **Ther Drug Monit** 1997 Feb;19(1):51-5

Enhanced plasma availability of the metabolites of albendazole in fasted adult sheep. Lifschitz A, et al. **Vet Res Commun** 1997 Apr;21(3):201-11

ANALYSIS

Trace analysis of albendazole and its sulphoxide and sulphone metabolites in milk by liquid chromatography. Fletouris DJ, et al. **J Chromatogr B Biomed Appl** 1996 Dec 13; 687(2):427-35

Sulfamethazine, sulfothiazole and albendazole residue dosage in food products determined by liquid chromatography/tandem mass spectrometry. Casetta B, et al. **Rapid Commun Mass Spectrom** 1996;10(12):1497-503

BLOOD

Enhanced plasma availability of the metabolites of albendazole in fasted adult sheep. Lifschitz A, et al. **Vet Res Commun** 1997 Apr;21(3):201-11

PHARMACOKINETICS

Distribution of the anthelmintic drug albendazole and its major metabolites in ovine milk and milk products after a single oral dose. De Liguoro M, et al. **J Dairy Res** 1996 Nov;63(4):533-42

Metabolism and pharmacokinetics of albendazole after oral administration to chickens. Csikó GY, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):322-5

Fasting-induced changes to the pharmacokinetic behaviour of albendazole and its metabolites in calves. Sánchez SF, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):38-47

Disposition kinetics of albendazole in buffalo and cattle. Sanyal PK. **J Vet Pharmacol Ther** 1997 Jun;20(3):240-2

Disposition of netobimin, albendazole, and its metabolites in the pregnant rat: developmental toxicity. Cristòfol C, et al. **Toxicol Appl Pharmacol** 1997 May;144(1):56-61

PHARMACOLOGY

Increases in the effects of albendazole on Echinococcus multilocularis metacestodes by the dipeptide methyl ester (Phe-Phe-OMe). Sarciron ME, et al. **Am J Trop Med Hyg** 1997 Feb;56(2):226-30

Development of chemotherapeutic model for the in vitro screening of drugs against Echinoccus granulosus cysts: the effects of an albendazole-albendazole sulphoxide combination. Casado N, et al. **Int J Parasitol** 1996 Jan; 26(1):59-65

Evolutionary origins of Microsporidia and basis for benzimidazole sensitivity: an update. Edlind T, et al. **J Eukaryot Microbiol** 1996 Sep-Oct;43(5):109S

Discrepancy between in vitro and in vivo antifungal activity of albendazole. Hardin TC, et al. **J Med Vet Mycol** 1997 May-Jun;35(3):153-8

Induction of albendazole resistance in Giardia lamblia. Lindquist HD. **Microb Drug Resist** 1996 Winter;2(4):433-4

Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in beta-tubulin. Upcroft J, et al. **Microb Drug Resist** 1996 Fall;2(3):303-8

Effect of sub-lethal doses of albendazole on the fecundity of Dictyocaulus viviparus. Osman AM, et al. **Res Vet Sci** 1996 Jul;61(1):92-3

THERAPEUTIC USE

Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Horton RJ. **Acta Trop** 1997 Apr 1;64(1-2):79-93 (36 ref.)

Treatment of isosporiasis with combined albendazole and ornidazole in patients with AIDS [letter] Dionisio D, et al. **AIDS** 1996 Sep;10(11):1301-2

Reduction of abdominal hydatid disease with prolonged treatment. Jover R, et al. **Am J Gastroenterol** 1997 Jul; 92(7):1231-2

Intraductal administration of albendazole for biliary ascariasis. van den Bogaerde JB, et al.

Am J Gastroenterol 1997 Sep;92(9):1531–3
Albendazole monitoring [letter] Smith AL, et al. **Am J Health Syst Pharm** 1997 Feb 1;54(3):319–20
Ocular and sinus microsporidial infection cured with systemic albendazole. Gritz DC, et al. **Am J Ophthalmol** 1997 Aug; 124(2):241–3
Clinical improvement of asthma after anthelminthic treatment in a tropical situation. Lynch NR, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):50–4
A comparative trial of a single–dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil–transmitted helminth infections in children. Marti H, et al. **Am J Trop Med Hyg** 1996 Nov; 55(5):477–81
Albendazole as a treatment for Giardia infection. Pungpak S, et al. **Ann Trop Med Parasitol** 1996 Oct;90(5):563–5
Severe forms of neurocysticercosis: treatment with albendazole. Agapejev S, et al. **Arq Neuropsiquiatr** 1996 Mar;54(1):82–93
Albendazole versus thiabendazole as therapy for trichinosis: a retrospective study. Cabié A, et al. **Clin Infect Dis** 1996 Jun;22(6):1033–5
Primary hydatidosis of the peripheral muscles: treatment with albendazole. Carpintero P, et al. **Clin Infect Dis** 1997 Jan; 24(1):85–6
Urethritis associated with disseminated microsporidiosis: clinical response to albendazole. Corcoran GD, et al. **Clin Infect Dis** 1996 Mar;22(3):592–3
Preoperative albendazole treatment for liver hydatid disease decreases the viability of the cyst. Aktan AO, et al. **Eur J Gastroenterol Hepatol** 1996 Sep;8(9):877–9
Cavernous sinus syndrome associated with neurocysticercosis [letter] Whitefield L, et al. **Eye** 1996;10 (Pt 5):642–3
Complete heart block caused by cardiac echinococcosis and successfully treated with albendazole. Ozdemir M, et al. **Heart** 1997 Jan;77(1):84–5
Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery. Ishizu H, et al. **Hepatology** 1997 Mar;25(3):528–31
Albendazole therapy in orbital cysticercosis. Srivastava VK, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):265–6
Albendazole therapy in liver hydatidosis. Singh H, et al. **Indian Pediatr** 1995 Oct;32(10):1105–6
Albendazole versus ricobendazole (albendazole–sulphoxide) against enteral and parenteral stages of Trichinella spiralis in mice. Lopez–Garcia ML, et al. **Int J Parasitol** 1997 Jul; 27(7):781–5
Albendazole treatment and serological follow–up in hydatid disease of bone. Bonifacino R, et al. **Int Orthop** 1997; 21(2):127–32
Abdominal cystic hydatid disease (CHD): classification of sonographic appearance and response to treatment. Caremani M, et al. **J Clin Ultrasound** 1996 Nov–Dec; 24(9):491–500
Serologic evolution of neurocysticercosis patients after antiparasitic therapy. Cysticercosis Working Group in Peru. Garcia HH, et al. **J Infect Dis** 1997 Feb;175(2):486–9
Discrepancy between in vitro and in vivo antifungal activity of albendazole. Hardin TC, et al. **J Med Vet Mycol** 1997 May–Jun;35(3):153–8
Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients. Del Brutto OH. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):659–61
Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle. Proaño JV, et al. **J Neurosurg** 1997 Jul;87(1):29–33
Neurocysticercosis treated with albendazole long term follow–up of a case. Maddalena G, et al. **J Neurosurg Sci** 1995 Sep;39(3):171–5
Effects of albendazole on growth of primary school children and the prevalence and intensity of soil–transmitted helminths in Sierra Leone [letter] Koroma MM, et al. **J Trop Pediatr** 1996 Dec;42(6):371–2
Randomised placebo–controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Addiss DG, et al. **Lancet** 1997 Aug 16;350(9076):480–4
Albendazole therapy for neurocysticercosis: a prospective double–blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru. Garcia HH, et al. **Neurology** 1997 May;48(5):1421–7
Activity of albendazole–ivermectin combination and other filaricidal drugs against infective larvae, preadult, microfilariae and adult worms of Molinema dessetae in the rodent Proechimys oris. Duarte Z, et al. **Parasite** 1994 Mar; 1(1):57–64
Ascariasis in the subdistrict of Cavacos, municipality of alterosa (MG), Brazil: effect of mass treatment with albendazole on the intensity of infection. Machado MT, et al. **Rev Inst Med Trop Sao Paulo** 1996 Jul–Aug; 38(4):265–71
Albendazole treatment of human hydatid tissue. Luchi S, et al. **Scand J Infect Dis** 1997;29(2):165–7
A randomized comparative study of albendazole and thiabendazole in chronic strongyloidiasis. Pitisuttithum P, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):735–8
Intramedullary cysticercosis cured with drug treatment. A case report. Corral I, et al. **Spine** 1996 Oct 1;21(19):2284–7
Medical decompression of vertebral hydatidosis. Lam KS, et al. **Spine** 1997 Sep 1;22(17):2050–5
Albendazole for the treatment of Mansonella perstans filariasis. Lipani F, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):221
The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole. Awadzi K, et al. **Trop Med Parasitol** 1995 Dec;46(4):213–20
Efficacy of an albendazole slow–release capsule for the control of susceptible or resistant nematode parasites of dairy goats. Chartier C, et al. **Vet Parasitol** 1996 Dec 31; 67(3–4):197–206
Effects of three nematode anthelmintic treatment regimes on flock performance of sheep and goats under extensive management in semi–arid Kenya. Gatongi PM, et al. **Vet Parasitol** 1997 Mar;68(4):323–36
Anthelmintic resistance in India. Gill BS. **Vet Parasitol** 1996 May;63(1–2):173–6
The effects of a controlled–release albendazole capsule (Proftril–Captec) on parasitism in grazing Corriedale ewes in the Nyandarua district of Kenya [published erratum appears in Vet Res Commun 1997 Jul;21(5):324] Munyua WK, et al. **Vet Res Commun** 1997 Feb;21(2):85–99
The efficacy of an albendazole–medicated block in controlling sheep nematodes in Xinjiang province, north–west China. Tan LX, et al. **Vet Res Commun** 1996; 20(5):427–35
[Results of sequential prolonged courses of albendazole and praziquantel in recurrent neurocysticercosis (letter)] Alla P, et al. **Med Trop (Mars)** 1996;56(3):308 **(Fre)**
[Advances of medical treatment of human hydatidosis] De Rosa F, et al. **Recenti Prog Med** 1996 Jul–Aug; 87(7–8):346–52 (48 ref.) (Eng. Abstr.) **(Ita)**
[Treatment of intra–abdominal hydatidosis with albendazole (letter)] Martínez G, et al. **Gastroenterol Hepatol** 1996 Dec; 19(10):542–3 **(Spa)**
[Randomized study comparing the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children] Romero–Cabello R, et al. **Rev Latinoam Microbiol** 1995 Oct–Dec;37(4):315–23 (Eng. Abstr.) **(Spa)**

ALBERS–SCHOENBERG DISEASE see **OSTEOPETROSIS**

ALBINISM

see related
CHEDIAK–HIGASHI SYNDROME
Albinism: an update. Orlow SJ. **Semin Cutan Med Surg** 1997 Mar;16(1):24–9 (47 ref.)

BLOOD

[Thrombocyte dysfunction in children with albinism] Pap Z, et al. **Orv Hetil** 1997 Feb 23;138(8):467–71 (Eng. Abstr.) **(Hun)**

COMPLICATIONS

Angle–closure glaucoma in a 10–year–old girl. Fivgas GD, et al. **Am J Ophthalmol** 1997 Aug;124(2):251–3

GENETICS

Base substitution at different alternative splice donor sites of the tyrosinase gene in murine albinism. Le Fur N, et al. **Genomics** 1996 Oct 15;37(2):245–8
Polygenic disease and retinitis pigmentosa: albinism exacerbates photoreceptor degeneration induced by the expression of a mutant opsin in transgenic mice. Naash MI, et al. **J Neurosci** 1996 Dec 15;16(24):7853–8
Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin–Va gene. Pastural E, et al. **Nat Genet** 1997 Jul;16(3):289–92
[Albinism. Current clinical and molecular genetic aspects of an important differential congenital nystagmus diagnosis] Lorenz B. **Ophthalmologe** 1997 Jul;94(7):534–44 (46 ref.) **(Ger)**

METABOLISM

The uptake of gamma–aminobutyric acid and glutamate by synaptosomes from the visual cortex of albino and pigmented rabbits. Burbridge T, et al. **J Neural Transm** 1996;103(3):299–305
Effect of hemilabyrinthectomy on monoamine metabolism in the medial vestibular nucleus, locus coeruleus, and other brainstem nuclei of albino and pigmented rats. Cransac H, et al. **J Vestib Res** 1996 Jul–Aug;6(4):243–53

PATHOLOGY

The cause of the decreased number of primordial germ cells in albino Xenopus resides not in the micro–environment but in the presumptive PGC. Ikenishi K, et al. **Dev Growth Differ** 1997 Jun;39(3):345–9
Polygenic disease and retinitis pigmentosa: albinism exacerbates photoreceptor degeneration induced by the expression of a mutant opsin in transgenic mice. Naash MI, et al. **J Neurosci** 1996 Dec 15;16(24):7853–8
Morphological alterations of the visual system in white zebra finches. Leminski S, et al. **Neuroreport** 1996 Jan 31; 7(2):557–61

PHYSIOPATHOLOGY

Brain monoamines and optokinetic performances in pigmented and albino rats. Cransac H, et al. **Comp Biochem Physiol A Physiol** 1997 Apr;116(4):341–9
Chiasmal crossing defects in disorders of binocular vision. Apkarian P. **Eye** 1996;10 (Pt 2):222–32 (73 ref.)

SURGERY

Treatment of extensive hypomelanosis with autologous cultured epithelium. Kumagai N, et al. **Ann Plast Surg** 1997 Jul;39(1):68–73

VETERINARY

YAC transgenesis in farm animals: rescue of albinism in rabbits. Brem G, et al. **Mol Reprod Dev** 1996 May; 44(1):56–62
Utilization of the sex–linked gene for imperfect albinism (S*ALS). 1. Effect of early weight loss on chick metabolism. Santos GA, et al. **Poult Sci** 1996 Nov; 75(11):1321–9
Utilization of the sex–linked gene for imperfect albinism (S*ALS). 2. Yolk sac lipid utilization. Santos GA, et al. **Poult Sci** 1996 Dec;75(12):1455–62

ALBINISM, CUTANEOUS see **PIEBALDISM**

ALBINISM, OCULAR

GENETICS

Utility of linked markers in genetic counseling: estimation of carrier risks in X–linked ocular albinism. Rebbeck TR, et al. **Am J Med Genet** 1997 May 2;70(1):58–66
Correction of retinal abnormalities found in albinism by introduction of a functional tyrosinase gene in transgenic mice and rabbits. Jeffery G, et al. **Brain Res Dev Brain Res** 1997 Mar 17;99(1):95–102
Cloning of the murine homolog of the ocular albinism type 1 (OA1) gene: sequence, genomic structure, and expression analysis in pigment cells [letter] Bassi MT, et al. **Genome Res** 1996 Sep;6(9):880–5
Isolation and characterization of a mouse homolog of the X–linked ocular albinism (OA1) gene. Newton JM, et al. **Genomics** 1996 Oct 15;37(2):219–25
Apparent digenic inheritance of Waardenburg syndrome type 2 (WS2) and autosomal recessive ocular albinism (AROA). Morell R, et al. **Hum Mol Genet** 1997 May;6(5):659–64

METABOLISM

The ocular albinism type 1 gene product is a membrane glycoprotein localized to melanosomes. Schiaffino MV, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9055–60

PHYSIOPATHOLOGY

Effects of yellow optical filters on contrast sensitivity function of albino patients. Provines WF, et al. **J Am Optom Assoc** 1997 Jun;68(6):353–9
Differential effect of ischemia/reperfusion on pigmented and albino rabbit retina. Muller A, et al. **J Ocul Pharmacol Ther** 1996 Fall;12(3):337–42
Vision in albinism. Summers CG. **Trans Am Ophthalmol Soc** 1996;94:1095–155
Solar pruning of retinal rods in albino rainbow trout. Allen DM, et al. **Vis Neurosci** 1997 May–Jun;14(3):589–600
Overrepresentation of the central visual field in the superior colliculus of the pigmented and albino ferret. Quevedo C, et al. **Vis Neurosci** 1996 Jul–Aug;13(4):627–38

ALBINISM, OCULOCUTANEOUS

Pigment, platelets, and Hermansky–Pudlak in human and mouse. Erickson RP. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):8924–5 (31 ref.)

BLOOD

The lysosomal granule membrane protein, LAMP–2, is also present in platelet dense granule membranes. Israels SJ, et al. **Thromb Haemost** 1996 Apr;75(4):623–9

COMPLICATIONS

Choroidal melanoma in an African–American albino. Kheterpal S, et al. **Am J Ophthalmol** 1996 Dec;122(6):901–3

DIAGNOSIS

Technical advances in prenatal diagnosis of tyrosinase–negative oculocutaneous albinism. Shimizu H. **Acta Derm Venereol** 1997 Jan;77(1):10–3

ENZYMOLOGY

R278TER and P431L mutations of the tyrosinase gene exist in Japanese patients with tyrosinase–negative oculocutaneous albinism. Matsunaga J, et al. **J Dermatol Sci** 1996 Nov;13(2):134–9
Mutations of the tyrosinase gene in three Korean patients with type I oculocutaneous albinism. Park KC, et al. **Jpn J Hum Genet** 1996 Sep;41(3):299–305
Prevalent and novel mutations of the tyrosinase gene in Korean patients with tyrosinase–deficient oculocutaneous albinism. Park SK, et al. **Mol Cells** 1997 Apr 30;7(2):187–91
Sequence analysis of the human tyrosinase promoter from a patient with tyrosinase–negative oculocutaneous albinism.

Matsunaga J, et al. **Pigment Cell Res** 1997 Feb-Apr; 10(1-2):64-7

EPIDEMIOLOGY

Distribution of oculocutaneous albinism in Zimbabwe. Lund PM. **J Med Genet** 1996 Aug;33(8):641-4

GENETICS

Oculocutaneous albinism (OCA2) in sub-Saharan Africa: distribution of the common 2.7-kb P gene deletion mutation. Stevens G, et al. **Hum Genet** 1997 Apr; 99(4):523-7

Mouse pale ear (ep) is homologous to human Hermansky-Pudlak syndrome and contains a rare 'AT-AC' intron. Feng GH, et al. **Hum Mol Genet** 1997 May; 6(5):793-7

Novel mutations of the P gene in type II oculocutaneous albinism (OCA2). Spritz RA, et al. **Hum Mutat** 1997; 10(2):175-7

Novel mutations of the tyrosinase (TYR) gene in type I oculocutaneous albinism (OCA1). Spritz RA, et al. **Hum Mutat** 1997;10(2):171-4

R278TER and P431L mutations of the tyrosinase gene exist in Japanese patients with tyrosinase-negative oculocutaneous albinism. Matsunaga J, et al. **J Dermatol Sci** 1996 Nov;13(2):134-9

Organization and nucleotide sequence of the human Hermansky-Pudlak syndrome (HPS) gene. Bailin T, et al. **J Invest Dermatol** 1997 Jun;108(6):923-7

Complementation of hypopigmentation in p-mutant (pink-eyed dilution) mouse melanocytes by normal human P cDNA, and defective complementation by OCA2 mutant sequences. Sviderskaya EV, et al. **J Invest Dermatol** 1997 Jan;108(1):30-4

Prevalent and novel mutations of the tyrosinase gene in Korean patients with tyrosinase-deficient oculocutaneous albinism. Park SK, et al. **Mol Cells** 1997 Apr 30;7(2):187-91

The clinical spectrum of albinism in humans. Oetting WS, et al. **Mol Med Today** 1996 Aug;2(8):330-5 (38 ref.)

Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles [see comments] Oh J, et al. **Nat Genet** 1996 Nov;14(3):300-6. Comment in: Nat Genet 1996 Nov;14(3):242-5.

Protein trafficking violations [news; comment] Ramsay M. **Nat Genet** 1996 Nov;14(3):242-5. Comment on: Nat Genet 1996 Nov;14(3):300-6. Comment on: Nat Genet 1996 Nov;14(3):307-11.

The mouse pale ear (ep) mutation is the homologue of human Hermansky-Pudlak syndrome. Gardner JM, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9238-43

[Albinism, thrombopathy, ceroid storage disease--Hermansky-Pudlak syndrome. Overview and description with immunodeficiency] Berz F, et al. **Klin Padiatr** 1996 Mar-Apr;208(2):83-7 (50 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

The clinical spectrum of albinism in humans. Oetting WS, et al. **Mol Med Today** 1996 Aug;2(8):330-5 (38 ref.)

PATHOLOGY

Oculocutaneous albinism. Sethi R, et al. **Cutis** 1996 Jun; 57(6):397-401 (65 ref.)

Hermansky-Pudlak syndrome; a case report with analysis of auto-fluorescent ceroid-like pigments. Ohbayashi C, et al. **Gerontology** 1995;41 Suppl 2:297-303

PHYSIOPATHOLOGY

Modified ERG-jet contact lens electrodes for use in infants and toddlers. Brodie S, et al. **Doc Ophthalmol** 1995-96; 91(2):141-6

Vision in albinism. Summers CG. **Trans Am Ophthalmol Soc** 1996;94:1095-155

ALBINISM, PARTIAL see **PIEBALDISM**

ALBINISM, TYROSINASE-NEGATIVE see **ALBINISM, OCULOCUTANEOUS**

ALBINISM, TYROSINASE-POSITIVE see **ALBINISM, OCULOCUTANEOUS**

ALBINISM, YELLOW-MUTANT see **ALBINISM, OCULOCUTANEOUS**

ALBRIGHT'S SYNDROME see **FIBROUS DYSPLASIA, POLYOSTOTIC**

ALBUMIN RECEPTORS see **RECEPTORS, ALBUMIN**

ALBUMINS

see related
PREALBUMIN
RECEPTORS, ALBUMIN

Albumin-impregnated polyester vascular prosthesis for abdominal aortic surgery: an improvement? Chakfe N, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):346-53

Ultrasound-guided fallopian tube cannulation using Albunex. Session DR, et al. **Fertil Steril** 1997 May;67(5):972-4

Effect of static pressure on acoustic transmittance of Albunex microbubble suspensions. Brayman AA, et al. **J Acoust Soc Am** 1996 Apr;99(4 Pt 1):2403-8

Albumin microbubble adherence to human coronary endothelium: implications for assessment of endothelial function using myocardial contrast echocardiography. Villanueva FS, et al. **J Am Coll Cardiol** 1997 Sep; 30(3):689-93

Mechanism of adsorption of human albumin to titanium in vitro. Klinger A, et al. **J Biomed Mater Res** 1997 Sep 5; 36(3):387-92

Human albumin solder supplemented with TGF-beta 1 accelerates healing following laser welded wound closure. Poppas DP, et al. **Lasers Surg Med** 1996;19(3):360-8

Platelets isolated by albumin gradient retain normal activation pathways. Vecino AM, et al. **Rev Esp Fisiol** 1996 Mar; 52(1):45-8

Effect of crystalloid and colloid solutions on blood rheology in sepsis. Castro VJ, et al. **Shock** 1997 Aug;8(2):104-7

Hemolysis of albunex-supplemented, 40% hematocrit human erythrocytes in vitro by 1-MHz pulsed ultrasound: acoustic pressure and pulse length dependence. Brayman AA, et al. **Ultrasound Med Biol** 1996;22(7):927-38

Acoustic cavitation nuclei survive the apparent ultrasonic destruction of Albunex microspheres. Brayman AA, et al. **Ultrasound Med Biol** 1997;23(5):793-6

[Effect of hemodilution with dextran and albumin on activated clotting time (ACT)] Inoue M, et al. **Masui** 1997 Jun;46(6):809-12 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Opacification of the thoracic aorta after venous injection of sonicated albumin microbubbles. Implications for aortic dissection. Voci P. **Cardiologia** 1997 Mar;42(3):299-304

Contrast echocardiography in coronary artery diseased patients: effect of systemic and pulmonary artery pressures on left heart opacification after intravenous injection of Albunex. Geny B, et al. **Coron Artery Dis** 1997 Feb; 8(2):77-81

Albumin bolus administration versus continuous infusion in critically ill hypoalbuminemic pediatric patients. Greissman A, et al. **Intensive Care Med** 1996 May;22(5):495-9

Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second-generation echocardiographic contrast agent capable of producing myocardial opacification from a venous injection. Skyba DM, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1292-300

Physiologic hypoalbuminemia is well tolerated by severely burned children. Sheridan RL, et al. **J Trauma** 1997 Sep; 43(3):448-52

Enhanced methionine levels and increased nutritive value of seeds of transgenic lupins (Lupinus angustifolius L.) expressing a sunflower seed albumin gene. Molvig L, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8393-8

Some considerations on the measurements of mean frequency shift and integrated backscatter following administration of Albunex. Wang SH, et al. **Ultrasound Med Biol** 1996; 22(4):441-51

[Consensus conference. Use of human albumin solutions in surgical anesthesia and surgical intensive care of adults. Saint-Mandé, France, 15 December 1995] **Ann Fr Anesth Reanim** 1996;15(4):407-568 (0 ref.) **(Fre)**

[Use of human albumin solutions in surgical anesthesia and critical care in adults] **Ann Fr Anesth Reanim** 1996; 15(4):414-23 **(Fre)**

[Indications and role of albumin for vascular loading during postoperative intensive care] Blanloeil Y, et al. **Ann Fr Anesth Reanim** 1996;15(4):497-506 (40 ref.) (Eng. Abstr.) **(Fre)**

[Indications and role of albumin for vascular loading during prehospital care] Carli P. **Ann Fr Anesth Reanim** 1996; 15(4):470-2 (Eng. Abstr.) **(Fre)**

[Indications and role of albumin for vascular loading in the operating room] Gérard JL, et al. **Ann Fr Anesth Reanim** 1996;15(4):481-90 (69 ref.) (Eng. Abstr.) **(Fre)**

[Is albumin administration useful in critical care for burnt patients?] Manelli JC. **Ann Fr Anesth Reanim** 1996; 15(4):507-13 (66 ref.) (Eng. Abstr.) **(Fre)**

[At what concentration should albumin be prescribed?] Mantz J. **Ann Fr Anesth Reanim** 1996;15(4):543-6 (Eng. Abstr.) **(Fre)**

[Indications of albumin for vascular loading during pregnancy] Palot M, et al. **Ann Fr Anesth Reanim** 1996; 15(4):491-6 (Eng. Abstr.) **(Fre)**

[A study of practice patterns of albumin administration in surgical patients by anesthetists] Pazart L, et al. **Ann Fr Anesth Reanim** 1996;15(4):424-7 (Eng. Abstr.) **(Fre)**

[Role of albumins in burnt patients: its efficacy during intensive care. Addendum to the expert guidelines of the Consensus Conference, Paris December 15th 1995] Sanchez R. **Ann Fr Anesth Reanim** 1996;15(7):1124-9 (Eng. Abstr.) **(Fre)**

[The generous administration of albumin (letter; comment)] Bergqvist D, et al. **Lakartidningen** 1997 Jun 18;94(25):2355 . Comment on: Lakartidningen 1997 Feb 26;94(9):711-3. **(Swe)**

[Albumin is still administered on doubtful indications. The results are not better than those of common salt or colloid solutions (see comments)] Zetterström H. **Lakartidningen** 1997 Feb 26;94(9):711-3. Comment in: Lakartidningen 1997 Jun 18;94(25):2355. **(Swe)**

ADVERSE EFFECTS

Renal failure associated with unrecognized hyperoncotic states after pediatric heart surgery. Bartels C, et al. **Intensive Care Med** 1996 May;22(5):492-4

Assessing myocardial perfusion with Albunex during coronary artery bypass surgery: technical considerations and safety of aortic root injections. Aronson S, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):713-8

[Evaluation of transmission of unconventional agents by human albumin] Dormont D. **Ann Fr Anesth Reanim** 1996; 15(4):560-8 (Eng. Abstr.) **(Fre)**

[Immediate and late complications of human albumin use] Quaranta JF. **Ann Fr Anesth Reanim** 1996;15(4):553-9 (Eng. Abstr.) **(Fre)**

ANALYSIS

Effects of cyclic and continuous parenteral nutrition on albumin gene transcription in rat liver [see comments] Morimoto T, et al. **Am J Clin Nutr** 1997 Apr;65(4):994-9 . Comment in: Am J Clin Nutr 1997 Apr;65(4):1078-9.

Interpretation of the TDx-FLM fluorescence polarization assay in pregnancies complicated by diabetes mellitus. Del Valle GO, et al. **Am J Perinatol** 1997 May;14(5):241-4

Immunospecificity of albumin detected in 1.6 million-year-old fossils from Venta Micena in Orce, Granada, Spain. Borja C, et al. **Am J Phys Anthropol** 1997 Aug;103(4):433-41

Albumin blue 580 fluorescence assay for albumin. Kessler MA, et al. **Anal Biochem** 1997 May 15;248(1):180-2

Salivary albumin of edentulous patients. Terrapon B, et al. **Arch Oral Biol** 1996 Dec;41(12):1183-5

Microalbuminuria and borderline-increased albumin excretion determined with a centrifugal analyzer and the Albumin Blue 580 fluorescence assay. Kessler MA, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):996-1002

Kinetic nephelometric determination of albumin produced by rat hepatocytes in culture. Pernet P, et al. **Clin Chim Acta** 1996 May 30;249(1-2):141-7

The effects of a kinin antagonist on changes in lung function and plasma extravasation into the airways following challenge of sensitized guinea-pigs. Featherstone RL, et al. **Clin Exp Allergy** 1996 Feb;26(2):235-40

Identification and characterization of wheat grain albumin/globulin allergens. Weiss W, et al. **Electrophoresis** 1997 May;18(5):826-33

Relationship between in vitro Fe and Zn dialysability and peptide composition of albumin and globulins extracted from cooked bean (Phaseolus vulgaris L.). Lombardi-Boccia G, et al. **Int J Food Sci Nutr** 1996 Nov; 47(6):485-92

Protein concentration of subcutaneous interstitial fluid in the human leg. A comparison between the wick technique and the blister suction technique. Haaverstad R, et al. **Int J Microcirc Clin Exp** 1996 May-Jun;16(3):111-7

Development and validation of a flow-injection method for the determination of albumin tannate, the active component of a pharmaceutical preparation. Gámiz Gracia L, et al. **J Pharm Biomed Anal** 1997 Jan;15(4):447-52

Transient increases in albumin and hyaluronan in bronchoalveolar lavage fluid after quitting smoking: possible signs of reparative mechanisms. Sköld CM, et al. **Respir Med** 1996 Oct;90(9):523-9

Quantitative measurements of second harmonic Doppler using ultrasound contrast agents. Chang PH, et al. **Ultrasound Med Biol** 1996;22(9):1205-14

[Sero-ascitic gradient of albumin: usefulness and diagnostic limitations] Alba D, et al. **An Med Interna** 1995 Aug; 12(8):404-7 (51 ref.) (Eng. Abstr.) **(Spa)**

[Echographic parameters in the evaluation of the degree of portal hypertension] Torres E, et al. **Rev Gastroenterol Peru** 1996 May-Aug;16(2):125-32 (Eng. Abstr.) **(Spa)**

[Urinary albumin excretion in non-insulin-dependent diabetic patients. Effects of an angiotensin-converting enzyme inhibitor] Durruty P, et al. **Rev Med Chil** 1996 Sep; 124(9):1036-44 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Detection of albumin messenger RNA in hepatic and extrahepatic neoplasms. A marker of hepatocellular differentiation. Krishna M, et al. **Am J Surg Pathol** 1997 Feb;21(2):147-52

Translational and pretranslational regulation of protein synthesis by amino acid availability in primary cultures of rat hepatocytes. Kimball SR, et al. **Int J Biochem Cell Biol** 1996 Mar;28(3):285-94

Synthesis of secretory protein in regenerating liver of rat after partial hepatectomy. Iwai M, et al. **J Gastroenterol Hepatol** 1996 Dec;11(12):1137-42

The vacuolar targeting signal of the 2S albumin from Brazil nut resides at the C terminus and involves the C-terminal propeptide as an essential element. Saalbach G, et al. **Plant Physiol** 1996 Nov;112(3):975-85

Elevated levels of albumin in soleus and diaphragm muscles of mdx mice. Dupont-Versteegden EE, et al. **Proc Soc Exp Biol Med** 1996 Dec;213(3):281-6

Stimulation of albumin synthesis in rat hepatocytes by ascites from patients with cirrhosis. Escobar E, et al. **Tokushima J Exp Med** 1996 Dec;43(3-4):159-66

ALBUMINS

BLOOD see SERUM ALBUMIN

CHEMISTRY

alpha-Amylase and salivary albumin adsorption onto titanium, enamel and dentin: an in vivo study. Kohavi D, et al. **Biomaterials** 1997 Jul;18(13):903–6

An albumin–coated polyester arterial graft: in vivo assessment of biocompatibility and healing characteristics. Marois Y, et al. **Biomaterials** 1996 Jan;17(1):3–14

Comparative studies of recombinant human albumin and human serum albumin derived by blood fractionation. Dodsworth N, et al. **Biotechnol Appl Biochem** 1996 Oct; 24 (Pt 2):171–6

Structure and organization of albumin molecules forming the shell of air–filled microspheres: evidence for a monolayer of albumin molecules of multiple orientations stabilizing the enclosed air. Myrset AH, et al. **Biotechnol Appl Biochem** 1996 Oct;24 (Pt 2):145–53

Amphiphilic networks. X. Diffusion of glucose and insulin (and nondiffusion of albumin) through amphiphilic membranes. Shamlou S, et al. **J Biomed Mater Res** 1997 May;35(2):157–63

The 1.8 A crystal structure of winged bean albumin 1, the major albumin from Psophocarpus tetragonolobus (L.) DC. McCoy AJ, et al. **J Mol Biol** 1997 Jun 27;269(5):881–91

Large scale procedure for fractionation of albumins and globulins from pea seeds. Créviеu I, et al. **Nahrung** 1996 Oct;40(5):237–44

[Quality control of human albumin solutions] Flan B. **Ann Fr Anesth Reanim** 1996;15(4):547–52 (Eng. Abstr.) **(Fre)**

DIAGNOSTIC USE

Definition of peritumoral vessels with contrast–enhanced magnetic resonance imaging: comparison of gadopentetate dimeglumine and a blood–pool macromolecular contrast medium. Brasch RC, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S464–5

Improving the sonographic contrast produced by Albunex during the inhalation of gases other than air. Wible JH Jr, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S317–9

Contrast enhancement of mitral regurgitation to estimate left ventricular systolic pressure. Donovan CL, et al. **Am Heart J** 1996 Oct;132(4):884–6

Myocardial contrast echocardiography: reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent. Meza M, et al. **Am Heart J** 1996 Oct;132(4):871–81

Improved Doppler echocardiographic assessment of the left atrial appendage by peripheral vein injection of sonicated albumin microbubbles. Yao SS, et al. **Am Heart J** 1997 Apr;133(4):400–5

Optimal Albunex dosing for enhancement of Doppler tricuspid regurgitation spectra. Kemp WE Jr, et al. **Am J Cardiol** 1997 Jan 15;79(2):232–4

Enhancement of left ventricular cavity opacification by harmonic imaging after venous injection of Albunex. Lindner JR, et al. **Am J Cardiol** 1997 Jun 15;79(12):1657–62

Doppler estimation of pulmonary artery end–diastolic pressure using contrast enhancement of pulmonary regurgitant signals. Tanabe K, et al. **Am J Cardiol** 1996 Nov 15;78(10):1145–8

Relation between air–filled albumin microbubble and red blood cell rheology in the human myocardium. Influence of echocardiographic systems and chest wall attenuation. Ismail S, et al. **Circulation** 1996 Aug 1;94(3):445–51

Safety of a new transpulmonary echocontrast agent (Albunex) in repeated echocardiographic studies in patients. Geny B, et al. **Clin Cardiol** 1997 Feb;20(2):111–5

Usefulness of contrast–enhanced endoscopic ultrasonography with intravenous injection of sonicated serum albumin. Hirooka Y, et al. **Gastrointest Endosc** 1997 Aug;46(2):166–9

Loss of contrast intensity during systole in the left ventricular cavity with the use of the contrast agent Albunex. An analysis of its correlation with pressure and velocity. Tiukinhoy S, et al. **Invest Radiol** 1996 Jul;31(7):415–22

Optimizing albunex in the left ventricle: an analysis of the technical parameters of four ultrasound systems in canines and humans. Block RJ, et al. **J Am Soc Echocardiogr** 1996 Nov–Dec;9(6):787–94

Benefits of reducing the cardiac cycle–triggering frequency of ultrasound imaging to increase myocardial opacification with FSO69 during fundamental and second harmonic imaging. Colon PJ 3rd, et al. **J Am Soc Echocardiogr** 1997 Jul–Aug;10(6):602–7

Reduced forward output states affect the left ventricular opacification of intravenously administered Albunex. Gandhok NK, et al. **J Am Soc Echocardiogr** 1997 Jan–Feb; 10(1):25–30

Contrast echocardiographic quantification of regional myocardial perfusion: validation with an isolated rabbit heart model. Mor–Avi V, et al. **J Am Soc Echocardiogr** 1996 Mar–Apr;9(2):156–65

Improved transvalvular continuous–wave Doppler signal intensity after intravenous Albunex injection in patients with prosthetic aortic valves. Okura H, et al. **J Am Soc Echocardiogr** 1997 Jul–Aug;10(6):608–12

Contrast echocardiography: influence of ultrasonic machine settings, mixing conditions, and pressurization on pixel intensity and microsphere size of Albunex solutions in vitro. Ota T, et al. **J Am Soc Echocardiogr** 1997 Jan–Feb; 10(1):31–40

Inhaled gases affect the ultrasound contrast produced by Albunex in anesthetized dogs. Wible JH Jr, et al. **J Am Soc Echocardiogr** 1996 Jul–Aug;9(4):442–51

Sonicated albumin in exercise echocardiography: technique and feasibility to enhance endocardial visualization. Yvorchuk KJ, et al. **J Am Soc Echocardiogr** 1996 Jul–Aug; 9(4):462–9

Sonicated albumin for evaluating midventricular obstruction in hypertrophic cardiomyopathy. Shimizu M, et al. **J Cardiol** 1996 Feb;27(2):57–63

Arthritic temporomandibular joint: correlation of macromolecular contrast–enhanced MR imaging parameters and histopathologic findings. van Dijke CF, et al. **Radiology** 1997 Sep;204(3):825–32

Gray scale second harmonic imaging of the liver: a preliminary animal study. Kono Y, et al. **Ultrasound Med Biol** 1997;23(5):719–26

Second harmonic characteristics of the ultrasound contrast agents albunex and FSO69. Krishna PD, et al. **Ultrasound Med Biol** 1997;23(3):453–9

[The preparation of hepatic receptor imaging agent 99mTc–DTPA–NGA] Li Y, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1996 Mar;27(1):54–8 (Eng. Abstr.) **(Chi)**

ECONOMICS

European hydroxyethyl starch: a safe and inexpensive alternative to albumin [letter] Treib J, et al. **Anesth Analg** 1997 Sep;85(3):709

GENETICS

Effects of cyclic and continuous parenteral nutrition on albumin gene transcription in rat liver [see comments] Morimoto T, et al. **Am J Clin Nutr** 1997 Apr;65(4):994–9 . Comment in: Am J Clin Nutr 1997 Apr;65(4):1078–9.

The same nuclear proteins bind to the 5'–flanking regions of genes for the rice seed storage protein: 16 kDa albumin, 13 kDa prolamin and type II glutelin. Nakase M, et al. **Plant Mol Biol** 1996 Nov;32(4):621–30

Complete structure of the human alpha–albumin gene, a new member of the serum albumin multigene family. Nishio H, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7557–61

IMMUNOLOGY

A comparison of the anti–idiotypic responses generated by antibodies to a protein and a hapten: a common interspecies idiotype on antibodies against human albumin induces an idiotypic network in rabbits. Comacchio RM, et al. **Immunol Cell Biol** 1996 Feb;74(1):72–80

METABOLISM

Impaired glomerular permselectivity for albumin in chemically medullectomized WKY rats. Bergström G, et al. **Acta Physiol Scand** 1996 Jan;156(1):61–7

Albumin endocytosis in OK cells: dependence on actin and microtubules and regulation by protein kinases. Gekle M, et al. **Am J Physiol** 1997 May;272(5 Pt 2):F668–77

The glycoproteins that occur in the colloids of senescent porcine pituitary glands are clusterin and glycosylated albumin fragments. Ogawa S, et al. **Biochem Biophys Res Commun** 1997 May 29;234(3):712–8

Coordination of copperpolyamine complex with imidazoles potentiates it superoxide dismutase mimicking activity and abolishes its interaction with albumin. Athar M, et al. **Biochem Mol Biol Int** 1996 Jul;39(4):813–21

Hydrogen peroxide–mediated degradation of protein: different oxidation modes of copper– and iron–dependent hydroxyl radicals on the degradation of albumin. Kocha T, et al. **Biochim Biophys Acta** 1997 Feb 8;1337(2):319–26

Identification of albumin–binding proteins of thymocyte plasmalemma [published erratum appears in: Biosci Rep 1996 Dec;16(6):529] Dobrila L, et al. **Biosci Rep** 1996 Oct; 16(5):425–38

Comparative studies of recombinant human albumin and human serum albumin derived by blood fractionation. Dodsworth N, et al. **Biotechnol Appl Biochem** 1996 Oct; 24 (Pt 2):171–6

Diabetic damage of selective renal reabsorption assessed by albumin negative charge. Kunika K, et al. **Diabetes Res Clin Pract** 1996 Aug;33(3):181–9

Effect of chronic dietary protein intake on the renal function in healthy subjects. Brändle E, et al. **Eur J Clin Nutr** 1996 Nov;50(11):734–40

The concentration of high molecular weight compounds in interstitial tissue fluid: a study in patients with post–reconstructive leg oedema. Haaverstad R, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):355–60

Description of an albumin binding activity for Streptococcus suis serotype 2. Quessy S, et al. **FEMS Microbiol Lett** 1997 Feb 15;147(2):245–50

A quantitative immunocytochemical study of blood–brain barrier to endogenous albumin in cerebral cortex and hippocampus of senescence–accelerated mice (SAM). Vorbrodt AW, et al. **Folia Histochem Cytobiol** 1995; 33(4):229–37

Early albumin leakage in pulmonary endothelial monolayers exposed to varying levels of hyperoxia. Payne DK, et al. **Free Radic Res** 1996 Sep;25(3):229–38

The oval–shaped cell as a candidate for a liver stem cell in embryonic, neonatal and precancerous liver: identification based on morphology and immunohistochemical staining for albumin and pyruvate kinase isoenzyme expression. Tian YW, et al. **Histochem Cell Biol** 1997 Mar;107(3):243–50

Acute alveolar hypoxia increases blood–to–tissue albumin transport: role of atrial natriuretic peptide. Albert TS, et al. **J Appl Physiol** 1997 Jan;82(1):111–7

Accumulation of pyrraline–modified albumin in phagocytes due to reduced degradation by lysosomal enzymes. Miyata S, et al. **J Biol Chem** 1997 Feb 14;272(7):4037–42

Transport of insulin and albumin by the microvascular endothelium of the rete mirabile. Bendayan M, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1857–64

Effusion cytology of hepatocellular carcinoma with in situ hybridisation for human albumin. Stephen MR, et al. **J Clin Pathol** 1997 May;50(5):442–4

Fibrinogen and the albumin–globulin ratio in essential hypertension: relations to plasma renin system activity. Allikmets K, et al. **J Hum Hypertens** 1996 Feb;10(2):105–9

Ontogenetic development of diffusional restriction to protein at the pial surface of the rat brain: an electron microscopical study. Balslev Y, et al. **J Neurocytol** 1997 Mar;26(3):133–48

Molecular biological analysis of the effects of ginsenoside–Rb2 on albumin mRNA in streptozotocin–induced diabetic rats. Yokozawa T, et al. **J Pharm Pharmacol** 1996 Jul;48(7):763–7

Albumin transfer across the choroid plexus of South American opossum (Monodelphis domestica). Knott GW, et al. **J Physiol (Lond)** 1997 Feb 15;499 (Pt 1):179–94

A new method of measuring albumin permeability in isolated glomeruli. Godfrin Y, et al. **Kidney Int** 1996 Oct; 50(4):1352–7

Serum–ascitic fluid albumin gradient, portal hypertension, and ascites [letter; comment] Rubin E. **Mayo Clin Proc** 1997 May;72(5):487. Comment on: Mayo Clin Proc 1996 Sep;71(9):874–81.

Shot–gun phage display mapping of two streptococcal cell–surface proteins. Jacobsson K, et al. **Microbiol Res** 1997 Jul;152(2):121–8

Diffusion of albumins in rat cortical slices and relevance to volume transmission. Tao L, et al. **Neuroscience** 1996 Dec; 75(3):839–47

Proteinuria and albumin homeostasis in the nephrotic syndrome: effect of dietary protein intake. Rodrigo R, et al. **Nutr Rev** 1996 Nov;54(11 Pt 1):337–47 (107 ref.)

Discrepancy between measured and PD ADEQUEST–calculated albumin loss [letter] Goffin E, et al. **Perit Dial Int** 1997 Jul–Aug;17(4):407–9

Interaction between nitric oxide and prostaglandin synthesis in the acute phase of allergic conjunctivitis. Meijer F, et al. **Prostaglandins** 1996 Dec;52(6):431–46

[Effect of erythropoietin on protein permeability of rats abdominal aortic wall] Timoshenko TE, et al. **Biull Eksp Biol Med** 1997 Jun;123(6):614–6 **(Rus)**

PHARMACOKINETICS

Transmission measurements of Albunex attenuation and phase velocity at concentrations approaching in vivo doses. Adams M, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S182–4

Spatial mapping of microvascular permeability and tissue blood volume using magnetic resonance imaging. Demsar F, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S344–6

Time and dose dependency of radiation–induced changes in tumor microvascular characteristics using contrast–enhanced magnetic resonance imaging: impact on the delivery of chemotherapeutic agents. Schmidt HC, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S347–8

Albumin kinetics in edematous and nonedematous protein–energy malnourished children. Morlese JF, et al. **Am J Clin Nutr** 1996 Dec;64(6):952–9

Gastrointestinal absorption, tissue retention, and urinary excretion of dietary aluminum in rats determined by using 26Al. Jouhanneau P, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):1023–8

Effect of beraprost sodium on the increased transendothelial permeation of albumin induced by high concentration of glucose. Kobayashi K, et al. **Fukuoka Igaku Zasshi** 1997 Mar;88(3):44–8

Intracarotid tumor necrosis factor–alpha administration increases the blood–brain barrier permeability in cerebral cortex of the newborn pig: quantitative aspects of double–labelling studies and confocal laser scanning analysis. Abraham CS, et al. **Neurosci Lett** 1996 Apr 19; 208(2):85–8

Indirect labeling of macroaggregated albumin with indium–111 via diethylenetriaminepentaacetic acid. Watanabe N, et al. **Nucl Med Biol** 1996 Jul;23(5):595–8

Pharmacokinetic studies of different echo–contrast agents in the cerebral circulation of dogs. Seidel G, et al. **Ultrasound Med Biol** 1996;22(8):1037–42

PHARMACOLOGY

The effect of intraventricular albumin in experimental brain oedema. Onal C, et al. **Acta Neurochir (Wien)** 1997; 139(7):661–8; discussion 668–9

A model of rod outer segment derived lipofuscin. Hiramitsu T, et al. **Gerontology** 1995;41 Suppl 2:121–30

Echocardiographic contrast agents and left ventricular contractility: evaluation using an isolated rabbit heart model. Mor–Avi V, et al. **J Am Soc Echocardiogr** 1996

Jul-Aug;9(4):452-61
Effects of Albunex infusion on left ventricular inflow velocity in dogs. Tomita M, et al. **J Cardiol** 1997 May;29(5):283-91
Maleylated-BSA induces hydrolysis of PIP2, fluxes of Ca2+, NF-kappaB binding, and transcription of the TNF-alpha gene in murine macrophages. Misra UK, et al. **J Leukoc Biol** 1996 Dec;60(6):784-92
Macroaggregated albumin potentiates the hypoglycemic effect of microencapsulated islets in the fed state of streptozotocin-induced diabetic mice. Hsu BR, et al. **J Microencapsul** 1997 Jan-Feb;14(1):27-34
Characteristics of albumin binding to opossum kidney cells and identification of potential receptors. Brunskill NJ, et al. **Pflugers Arch** 1997 Feb;433(4):497-504
Effect of inflation on interstitial cuff and pressure in liquid-filled rabbit lung. Liang J, et al. **Respir Physiol** 1996 Dec;106(3):293-305
Contrast-agent gas bodies enhance hemolysis induced by lithotripter shock waves and high-intensity focused ultrasound in whole blood. Miller DL, et al. **Ultrasound Med Biol** 1996;22(8):1089-95
The effects of physical and chemical agents on the secretion and stability of a Fusobacterium necrophorum hemolysin. Amoako KK, et al. **Vet Microbiol** 1996 Jul;51(1-2):115-24
[A comparative study of the effectiveness of 5% human albumin and 10% hydroxyethyl starch (HAES-steril) for correcting hemodynamics and O2 transport in surgical interventions] Hankeln K, et al. **Anesteziol Reanimatol** 1997 Jan-Feb;(1):23-6 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

The role of albumin in the release of platelet-activating factor by mouse preimplantation embryos in vitro. Ammit AJ, et al. **J Reprod Fertil** 1997 Mar;109(2):309-18

SECRETION

Long-term performance of albumin secretion of hepatocytes cultured in a packed-bed reactor utilizing porous resin. Miyoshi H, et al. **Artif Organs** 1996 Jul;20(7):803-7

THERAPEUTIC USE

Effect of increasing serum albumin on serum lipoprotein(a) concentration in patients receiving CAPD. Yang WS, et al. **Am J Kidney Dis** 1997 Oct;30(4):507-13
Fluid compartments in hemorrhaged rats after hyperosmotic crystalloid and hyperoncotic colloid resuscitation. Moon PF, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):F1-8
Randomised controlled trial of colloid or crystalloid in hypotensive preterm infants. So KW, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Jan;76(1):F43-6
Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study. Isik AZ, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec 27; 70(2):179-83
Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. Chen CD, et al. **Fertil Steril** 1997 Aug;68(2):287-91
Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis [see comments] Ginès A, et al. **Gastroenterology** 1996 Oct;111(4):1002-10. Comment in: ACP J Club 1996 May-Jun;126(3):69.
Human albumin solders for clinical application during laser tissue welding. Poppas DP, et al. **Lasers Surg Med** 1996; 19(1):2-8
Prognostic factors to predict outcome following the administration of hypertonic/hyperoncotic solution in hypovolemic patients. Younes RN, et al. **Shock** 1997 Feb; 7(2):79-83
[Role of albumin in pulmonary edema and septic shock, plasma volume expansion excluded] Guidet B. **Ann Fr Anesth Reanim** 1996;15(4):525-31 (Eng. Abstr.) **(Fre)**
[Indications and role of albumin for vascular loading in trauma patients and during preoperative period] Sztark F. **Ann Fr Anesth Reanim** 1996;15(4):473-80 (34 ref.) (Eng. Abstr.) **(Fre)**

URINE see ALBUMINURIA

ALBUMINURIA

Proximal tubular reabsorption of growth hormone and sodium/fluid in normo- and microalbuminuric insulin-dependent diabetes mellitus. Turner G, et al. **Acta Diabetol** 1997 Mar;34(1):27-32
The reliability of urinary albumin assay by immunonephelometry in the clinical practice. The critical role of medical surveillance on laboratory routine. Vangelisti S, et al. **Acta Diabetol** 1997 Mar;34(1):22-6
Fibrinogen and albuminuria are related to the presence and severity of peripheral arterial disease in women with type 2 diabetes mellitus. Tkáč I, et al. **Angiology** 1997 Aug; 48(8):715-9
The effect of an angiotensin converting enzyme inhibitor on skin microvascular hyperaemia in microalbuminuric insulin-dependent diabetes mellitus. Yosipovitch G, et al. **Diabet Med** 1997 Mar;14(3):235-41
Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Rossing P, et al. **Diabetes** 1997 Mar; 46(3):481-7
Utility of untimed urinary albumin measurements in assessing albuminuria in black NIDDM subjects. Chaiken RL, et al. **Diabetes Care** 1997 May;20(5):709-13
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. Gerstein HC, et al. **Diabetes Care** 1996 Nov;19(11):1225-8
Erythrocyte sodium-hydrogen exchange and microalbuminuria in type I diabetes. Giampietro O, et al. **Diabetes Care** 1996 Sep;19(9):995-7
Is ACE gene polymorphism a useful marker for diabetic albuminuria in Japanese NIDDM patients? Nakajima S, et al. **Diabetes Care** 1996 Dec;19(12):1420-2
Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Savage S, et al. **Diabetes Care** 1996 Nov; 19(11):1243-8
The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Zelmanovitz T, et al. **Diabetes Care** 1997 Apr; 20(4):516-9
Comparison of urinary excretion of albumin, alpha 1-microglobulin and retinol-binding protein in diabetic patients [published erratum appears in Diabetes Metab 1997 Feb;23(1):118] Galanti LM, et al. **Diabetes Metab** 1996 Oct; 22(5):324-30
The prognostic value of albuminuria for the development of cardiovascular disease and retinopathy: a 5-year follow-up of 451 patients with type 2 diabetes mellitus. Agardh CD, et al. **Diabetes Res Clin Pract** 1996 Apr; 32(1-2):35-44
Raised erythrocyte polyamine levels in non-insulin-dependent diabetes mellitus with great vessel disease and albuminuria. Seghieri G, et al. **Diabetes Res Clin Pract** 1997 Jul;37(1):15-20
Microalbuminuria as a marker of silent myocardial ischaemia in IDDM patients. Earle KA, et al. **Diabetologia** 1996 Jul; 39(7):854-6
Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study. Greaves M, et al. **Diabetologia** 1997 Jun;40(6):698-705
24-h blood pressure and autonomic function is related to albumin excretion within the normoalbuminuric range in IDDM patients. Poulsen PL, et al. **Diabetologia** 1997 Jun; 40(6):718-25
Urinary microalbumin as a marker for intermittent claudication [letter; comment] Tisi PV, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):253. Comment on: Eur J Vasc Endovasc Surg 1996 May;11(4):421-4.
Relationships among microalbuminuria, insulin resistance and renal-cardiac complications in insulin dependent and non insulin dependent diabetes. Nosadini R, et al. **Exp Clin Endocrinol Diabetes** 1997;105 Suppl 2:1-7 (72 ref.)
Correlates of abnormal urinary albumin excretion rates among primary care patients with essential hypertension. Spangler JG, et al. **J Am Board Fam Pract** 1997 May-Jun; 10(3):180-4
Microalbuminuria in essential hypertension and diabetes mellitus. Parving HH. **J Hypertens Suppl** 1996 Sep; 14(2):S89-93; discussion S93-4 (50 ref.)
Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group [see comments] **Lancet** 1997 Jun 21; 349(9068):1787-92. Comment in: Lancet 1997 Jun 21;349(9068):1782-3.
Microalbuminuria as risk in essential hypertension. Ruilope LM. **Nephrol Dial Transplant** 1997;12 Suppl 2:2-5 (51 ref.)
Screening for microalbuminuria by RIA in 131I-treated thyroid cancer patients. Bhatkar SV, et al. **Nucl Med Commun** 1996 Jun;17(6):536-9
[Decrease of nocturnal blood pressure in type II diabetic subjects with microalbuminuria] Berrut G, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89(8):1041-4 (Eng. Abstr.) **(Fre)**

BLOOD

Increased soluble fibrin monomer and soluble thrombomodulin levels in non-insulin-dependent diabetes mellitus. Sumida Y, et al. **Blood Coagul Fibrinolysis** 1997 Jul;8(5):303-7
Lipoprotein(a) is not elevated in non-diabetic microalbuminuric subjects. A longitudinal study of lipoprotein(a) concentrations and apolipoprotein(a) size isoforms. Yudkin JS, et al. **Int J Clin Lab Res** 1996; 26(1):43-50
Increased basic fibroblast growth factor-like substance in plasma from a subset of middle-aged or elderly male diabetic patients with microalbuminuria or proteinuria. Zimering MB, et al. **J Clin Endocrinol Metab** 1996 Dec; 81(12):4446-52
Serum total renin is increased before microalbuminuria in diabetes. Allen TJ, et al. **Kidney Int** 1996 Sep;50(3):902-7
Altered platelet magnesium and plasma and urinary soluble form of intercellular adhesion molecule I (sICAM-1) concentrations in insulin dependent diabetes mellitus (IDDM) patients with microalbuminuria. Corica F, et al. **Magnes Res** 1996 Dec;9(4):307-12
Apolipoprotein (a) levels and phenotypes in NIDDM patients with microalbuminuria and albuminuria. Lam KS, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2229-36

CHEMICALLY INDUCED

Replay to Sasaki et al [letter; comment] Trachtman H. **Clin Nephrol** 1997 Mar;47(3):210. Comment on: Clin Nephrol 1996 Jul;46(1):6-9.
Inorganic components of drinking water and microalbuminuria. Mao Y, et al. **Environ Res** 1995 Nov; 71(2):135-40

COMPLICATIONS

Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Agewall S, et al. **Am J Cardiol** 1997 Jul 15;80(2):164-9
Microalbuminuria in type 2 diabetic patients: a prospective follow-up study. Friis T, et al. **Ann Clin Biochem** 1997 May;34 (Pt 3):247-51
Microalbuminuria in type 2 diabetes: an independent predictor of cardiovascular mortality. Beilin J, et al. **Aust N Z J Med** 1996 Aug;26(4):519-25
Are glomerular lesions alternatives to microalbuminuria in predicting later progression of diabetic nephropathy? Shoji T, et al. **Clin Nephrol** 1996 Jun;45(6):367-71
Urinary albumin excretion and atherosclerosis in essential hypertension. Pedrinelli R, et al. **Clin Sci (Colch)** 1997 Jan; 92(1):45-50
Hypertension, hyperlipidemia and microalbuminuria. Campese VM, et al. **Contrib Nephrol** 1997;120:11-21 (70 ref.)
Relationship between microalbuminuria, blood pressure and cardiovascular changes in essential hypertension. Cerasola G, et al. **Contrib Nephrol** 1996;119:130-34
Microalbuminuria in hypertension. Pedrinelli R. **Contrib Nephrol** 1996;119:103-9 (42 ref.)
Microalbuminuria is associated with a worse cardiovascular risk profile and target organ damage in essential hypertension. Pontremoli R, et al. **Contrib Nephrol** 1996; 119:115-20
Diurnal variation in blood pressure in insulin-dependent diabetic smokers and non-smokers with and without microalbuminuria. Sinha RN, et al. **Diabet Med** 1997 Apr; 14(4):291-5
Microalbuminuria is not associated with cardiovascular death in Japanese NIDDM. Araki S, et al. **Diabetes Res Clin Pract** 1997 Feb;35(1):35-40
Urinary albumin excretion rate and cardiovascular disease in Spaniard type 2 diabetic patients. Relimpio F, et al. **Diabetes Res Clin Pract** 1997 May;36(2):127-34
Colour vision and persistent microalbuminuria in children with type-1 (insulin-dependent) diabetes mellitus: a longitudinal study. Verrotti A, et al. **Diabetes Res Clin Pract** 1995 Nov;30(2):125-30
Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. Cerasola G, et al. **J Hypertens** 1996 Jul;14(7):915-20
Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. Redon J, et al. **J Hypertens** 1997 Jan;15(1):79-86
Hypertension and renal disease: role of microalbuminuria. Janssen WM, et al. **J Hypertens Suppl** 1996 Dec; 14(5):S173-7 (42 ref.)
Diabetic retinopathy and urinary albumin excretion rate in type II (non-insulin-dependent) diabetic patients. Migdalis IN, et al. **J Med** 1996;27(5-6):341-50
Prediction of posttraumatic adult respiratory distress syndrome by albumin excretion rate eight hours after admission. Pallister I, et al. **J Trauma** 1997 Jun; 42(6):1056-61
Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. Hansen HP, et al. **Kidney Int** 1996 Aug;50(2):579-85
Intracellular calcium handling by fibroblasts from non-insulin dependent diabetic patients with and without hypertension and microalbuminuria. Solini A, et al. **Kidney Int** 1996 Aug; 50(2):618-26
Decreasing glomerular filtration rate--an indicator of more advanced diabetic glomerulopathy in the early course of microalbuminuria in IDDM adolescents? Rudberg S, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1149-54
The relationship between microalbuminuria in first generation diabetic and non-diabetic subjects and microalbuminuria and hypertension in the second generation (a population based study). Vestbo E, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:32-6
Proteinuria and progressive renal disease: birth weight and microalbuminuria. Yudkin JS, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:10-3
Difference of serum levels of type IV collagen 7S between early or overt nephropathy and nondiabetic renal disease in diabetic patients with micro- or macroalbuminuria. Inomata S, et al. **Nephron** 1996;73(4):601-5
Microalbuminuria in Hypertension [editorial] Pedrinelli R. **Nephron** 1996;73(4):499-505 (103 ref.)
Incidence of microalbuminuria in children with pyelonephritic scarring. Karlén J, et al. **Pediatr Nephrol**

1996 Dec;10(6):705–8

DIAGNOSIS

Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy. Alli C, et al. **Am J Hypertens** 1996 Nov;9(11):1068–76

Serum and urine albumin: a progress report on their measurement and clinical significance. Doumas BT, et al. **Clin Chim Acta** 1997 Feb 3;258(1):3–20 (105 ref.)

The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus. Ruggenenti P, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):141–5 (20 ref.)

Detection of microalbuminuria in diabetic patients by urinary dipstick. Gilbert RE, et al. **Diabetes Res Clin Pract** 1997 Feb;35(1):57–60

The use of the Micral-Test strip to identify the presence of microalbuminuria in people with insulin dependent diabetes mellitus (IDDM) participating in the EUCLID study. Webb DJ, et al. **Diabetes Res Clin Pract** 1996 Mar; 31(1–3):93–102

How to diagnose and how to interpret microalbuminuria in the diabetic patient [editorial] Czekalski S. **Nephrol Dial Transplant** 1996 Aug;11(8):1509–11

Accuracy of the urinary albumin titrator stick 'Micral-Test' in kidney-disease patients. Minetti EE, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):78–80

The MICRAL test for diabetic microalbuminuria: predictive values as a function of prevalence. Jensen JE, et al. **Scand J Clin Lab Invest** 1996 Apr;56(2):117–22

[Microalbuminuria as predictor of atherosclerotic cardiovascular disease in IDDM] Deckert T, et al. **Ugeskr Laeger** 1997 May 12;159(20):3010–4 (Eng. Abstr.) **(Dan)**

[Albuminuria and glycemic control. The significance for mortality in non-insulin-dependent diabetes mellitus] Gall MA, et al. **Ugeskr Laeger** 1996 Nov 25;158(48):6907–11 (Eng. Abstr.) **(Dan)**

[What decisions to make in view of microalbuminuria in a diabetic?] Marre M, et al. **Journ Annu Diabetol Hotel Dieu** 1996;:193–7 (13 ref.) **(Fre)**

[Screening for microalbuminuria in diabetic patients in the primary health care system] Farkas K, et al. **Orv Hetil** 1997 Feb 23;138(8):459–65 (46 ref.) (Eng. Abstr.) **(Hun)**

[The significance of diagnosing microalbuminuria and microglobulinuria in diabetes mellitus and arterial hypertension] Kasprowicz B, et al. **Przegl Lek** 1997; 54(3):180–4 (70 ref.) (Eng. Abstr.) **(Pol)**

[Albumin excretion with urine in a population of healthy individuals] Strojek K, et al. **Przegl Lek** 1996;53(12):862–5 (Eng. Abstr.) **(Pol)**

[The detection of microalbuminuria by using a recombinant albumin receptor] Gupalova TV, et al. **Klin Lab Diagn** 1997 Feb;(2):14–6 (Eng. Abstr.) **(Rus)**

[Microalbuminuria as one of the early diagnostic signs of kidney involvement in patients with a purine metabolic disorder] Lebedeva MV, et al. **Ter Arkh** 1996;68(6):40–3 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. Multicenter Study Group. Larochelle P. **Am J Hypertens** 1996 Jun; 9(6):551–9

Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Chan JC, et al. **Am J Nephrol** 1997;17(1):72–80

Short-term clinical trial of 1-(1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl)-3, 4-dihydro-2(1H)-quinolinone in patients with diabetic nephropathy. Possible effectiveness of the specific vasopressin V1 receptor antagonist for reducing albuminuria in patients with non-insulin dependent diabetes mellitus. Nishikawa T, et al. **Arzneimittelforschung** 1996 Sep;46(9):875–8

Effects of antihypertensive drugs on various aspects of renal function. de Leeuw PW, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):803–8 (27 ref.)

Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes. De Cesaris R, et al. **Clin Pharmacol Ther** 1996 Oct; 60(4):472–8

A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Szelanowska M, et al. **Curr Med Res Opin** 1997; 13(9):539–45

Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Schnack C, et al. **Diabetologia** 1996 Dec;39(12):1611–6

Effects of enalapril and nitrendipine on exercise albuminuria in normotensive type I diabetic patients with incipient nephropathy. Heinemann L, et al. **Horm Metab Res** 1996 Oct;28(10):549–52

Indapamide is as effective as captopril in the control of microalbuminuria in diabetes. Molyneaux LM, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):424–7

Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. Agrawal B, et al. **J Hum Hypertens** 1996 Aug;10(8):551–5

Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients. Cooper ME. **J Hypertens Suppl** 1996 Dec; 14(6):S11–4 (47 ref.)

Glycosaminoglycans as a possible tool for micro- and macroalbuminuria in diabetic patients. A pilot study. Sorrenti G, et al. **J Int Med Res** 1997 Mar-Apr;25(2):81–6

Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Mosconi L, et al. **Kidney Int Suppl** 1996 Jun;55:S91–3

Early closure of European Pimagedine trial. Steering Committee. Safety Committee [letter] Viberti G, et al. **Lancet** 1997 Jul 19;350(9072):214–5

Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Fujii M, et al. **Metabolism** 1997 Sep;46(9):981–3

Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nielsen S, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:19–23

Over 11 years of stable renal function after remission of nephrotic-range proteinuria in type I diabetics treated with an ACE inhibitor. McGregor D, et al. **Nephron** 1997; 76(3):270–5

[The efficacy of Sulodexide—a low-molecular heparin—in the therapy of diabetic nephropathy] Shestakova MV, et al. **Ter Arkh** 1997;69(6):34–7 (Eng. Abstr.) **(Rus)**

[Effect of enalapril on microalbuminuria and lipid profile of normotensive type I diabetes mellitus patients] Hernández Mijares A, et al. **Rev Clin Esp** 1996 Jun;196(6):354–8 (Eng. Abstr.) **(Spa)**

[Urinary albumin excretion in non-insulin-dependent diabetic patients. Effects of an angiotensin-converting enzyme inhibitor] Durruty P, et al. **Rev Med Chil** 1996 Sep; 124(9):1036–44 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Skeletal muscle lipoprotein-lipase activity in insulin-dependent diabetic patients with and without albuminuria. Hansen PM, et al. **J Diabetes Complications** 1997 Jul-Aug;11(4):230–5

EPIDEMIOLOGY

Epidemiology of microalbuminuria in type 1 diabetic patients (IDDM) in the Antwerp University Hospital. Bouten A, et al. **Acta Clin Belg** 1996;51(4):231–6

Low prevalence of microalbuminuria in young Italian insulin-dependent diabetic patients with short duration of disease: a population-based study. Piedmont Study Group for Diabetes Epidemiology. Bruno G, et al. **Diabet Med** 1996 Oct;13(10):889–93

Microalbuminuria and associated clinical features among Brazilians with insulin dependent diabetes mellitus. Gomes MB, et al. **Diabetes Res Clin Pract** 1997 Mar;35(2–3):143–7

Effect of smoking on the prevalence of albuminuria in Japanese men with non-insulin-dependent diabetes mellitus. Ikeda Y, et al. **Diabetes Res Clin Pract** 1997 Apr; 36(1):57–61

Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. The Italian NIDDM Nephropathy Study Group. Faronato PP, et al. **Diabetologia** 1997 Jul;40(7):816–23

Elevated sodium-lithium countertransport activity in erythrocytes is predictive of the development of microalbuminuria in IDDM. Monciotti CG, et al. **Diabetologia** 1997 Jun;40(6):654–61

Increased prevalence of elevated urinary albumin excretion rate in type 2 diabetic patients suffering from ischemic foot lesions. Zander E, et al. **Exp Clin Endocrinol Diabetes** 1997; 105 Suppl 2:51–3

Regional differences in albuminuria among American Indians: an epidemic of renal disease. Robbins DC, et al. **Kidney Int** 1996 Feb;49(2):557–63

Incidence of microalbuminuria in children with pyelonephritic scarring. Karlén J, et al. **Pediatr Nephrol** 1996 Dec;10(6):705–8

The MICRAL test for diabetic microalbuminuria: predictive values as a function of prevalence. Jensen JE, et al. **Scand J Clin Lab Invest** 1996 Apr;56(2):117–22

[Nephropathy and microalbuminuria in type-2 diabetes (letter; comment)] Franch Nadal J, et al. **Aten Primaria** 1997 Jul-Aug;20(3):155–6. Comment on: Aten Primaria 1995 Nov 30;16(9):516–24. **(Spa)**

[Diastolic dysfunction, left ventricular hypertrophy, and microalbuminuria in mild to moderate essential arterial hypertension] de Mora Martín M, et al. **Rev Esp Cardiol** 1997 Apr;50(4):233–8 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Markers for cardiovascular and renal morbidity: expectations for an intervention programme in an Australian aboriginal community. Hoy WE, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):S33–7

ETIOLOGY

Risk factors that predict development of microalbuminuria in treated hypertensive men. The Risk Factor Intervention Study Group. Agewall S, et al. **Angiology** 1996 Oct; 47(10):963–72

Urinary albumin excretion in patients with systemic lupus erythematosus without renal disease. Batlle-Gualda E, et al. **Ann Rheum Dis** 1997 Jun;56(6):386–9

The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Dinneen SF, et al. **Arch Intern Med** 1997 Jul 14;157(13):1413–8 (33 ref.)

What happens to women with preeclampsia? Microalbuminuria and hypertension following preeclampsia. North RA, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):233–8

Hypertension, atherosclerosis and microalbuminuria in ELSA. European Lacidipine Study of Atherosclerosis. Ruilope LM, et al. **Blood Press Suppl** 1996;4:48–52 (60 ref.)

Microalbuminuria in essential hypertension. Mimran A. **Clin Exp Hypertens** 1997 Jul-Aug;19(5–6):753–67 (38 ref.)

Diabetic damage of selective renal reabsorption assessed by albumin negative charge. Kunika K, et al. **Diabetes Res Clin Pract** 1996 Aug;33(3):181–9

Microalbuminuria is associated with salt sensitivity in hypertensive patients. Nešović M, et al. **J Hum Hypertens** 1996 Sep;10(9):573–6

The clinical course of renal function in NIDDM patients with normo- and microalbuminuria. Nielsen S, et al. **J Intern Med** 1997 Feb;241(2):133–41

Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Fujii M, et al. **Metabolism** 1997 Sep;46(9):981–3

Inhibition of aminopeptidase A activity causes an acute albuminuria in mice: an angiotensin II-mediated effect? Mentzel S, et al. **Nephrol Dial Transplant** 1996 Nov; 11(11):2163–9

Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nielsen S, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:19–23

The relationship between microalbuminuria in first generation diabetic and non-diabetic subjects and microalbuminuria and hypertension in the second generation (a population based study). Vestbo E, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:32–6

Elevated albumin excretion in nonmodulating essential hypertensive patients. Baldoncini R, et al. **Nephron** 1997; 76(3):264–9

Postexercise albuminuria in children with different duration of type-1 diabetes mellitus. Krüger M, et al. **Pediatr Nephrol** 1996 Oct;10(5):594–7

High altitude-induced albuminuria in normal man is enhanced by infusion of low-dose dopamine. Hansen JM, et al. **Scand J Clin Lab Invest** 1996 Jul;56(4):367–72

[The effect of captopril therapy on the degree of microalbuminuria in diabetic children and adolescents with incipient nephropathy] Barkai L, et al. **Orv Hetil** 1996 Nov 17;137(46):2565–8 (35 ref.) (Eng. Abstr.) **(Hun)**

[Microalbuminuria in patients with systemic lupus erythematosus] Koseda-Dragan M, et al. **Pol Arch Med Wewn** 1996 Aug;96(2):124–31 (Eng. Abstr.) **(Pol)**

[Microalbuminuria in essential hypertension] Styczyński G, et al. **Pol Arch Med Wewn** 1995 Nov;94(5):451–5 (40 ref.) **(Pol)**

GENETICS

Familial factors determine the development of diabetic nephropathy in patients with IDDM. Quinn M, et al. **Diabetologia** 1996 Aug;39(8):940–5

METABOLISM

Effects of erythropoietin administration on blood pressure and urinary albumin excretion in rats. Panzacchi G, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 1):772–8

Insulin sensitivity in clinically healthy individuals with microalbuminuria. Jensen JS, et al. **Atherosclerosis** 1996 Jan 5;119(1):69–76

Protein degradation during renal passage in normal kidneys is inhibited in experimental albuminuria. Osicka TM, et al. **Clin Sci (Colch)** 1997 Jul;93(1):65–72

Enhanced effects of insulin and angiotensin II on intracellular pH and free cytosolic calcium in fibroblasts from microalbuminuric patients with non-insulin-dependent diabetes mellitus. Trevisan R, et al. **Clin Sci (Colch)** 1996 Dec;91(6):703–10

Erythrocyte cation transport systems, plasma-inactive renin and albuminuria in insulin-dependent diabetics. Lijnen P, et al. **Contrib Nephrol** 1996;119:125–29

Effect of insulin on systemic and renal handling of albumin in nondiabetic and NIDDM subjects. Catalano C, et al. **Diabetes** 1997 May;46(5):868–75

Abnormal $Na+/H+$ antiport activity in cultured fibroblasts from NIDDM patients with hypertension and microalbuminuria. Trevisan R, et al. **Diabetologia** 1996 Jun; 39(6):717–24

Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. Vora JP, et al. **J Am Soc Nephrol** 1996 Jan;7(1):113–7

Albuminuria in untreated patients with primary aldosteronism or essential hypertension. Halimi JM, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1801–2

Tubulointerstitial responses in the progression of glomerular diseases: albuminuria modulates alpha v beta 5 integrin. Peruzzi L, et al. **Kidney Int** 1996 Oct;50(4):1310–20

Intracellular calcium handling by fibroblasts from non-insulin

dependent diabetic patients with and without hypertension and microalbuminuria. Solini A, et al. **Kidney Int** 1996 Aug; 50(2):618–26

Arginine reduces kidney collagen accumulation, cross-linking, lipid peroxidation, glycoxidation, kidney weight and albuminuria in the diabetic kk mouse. Lubec B, et al. **Nephron** 1997;75(2):213–8

Effect of interleukin-8 on glomerular sulfated compounds and albuminuria. Garin EH, et al. **Pediatr Nephrol** 1997 Jun;11(3):274–9

The acute effect of smoking on systemic haemodynamics, kidney and endothelial functions in insulin-dependent diabetic patients with microalbuminuria. Hansen HP, et al. **Scand J Clin Lab Invest** 1996 Aug;56(5):393–9

MORTALITY

The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Dinneen SF, et al. **Arch Intern Med** 1997 Jul 14;157(13):1413–8 (33 ref.)

Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. Rossing P, et al. **BMJ** 1996 Sep 28;313(7060):779–84

PATHOLOGY

Glomerular changes in normo- and microalbuminuric patients with long-standing insulin-dependent diabetes mellitus. Fioretto P, et al. **Adv Nephrol Necker Hosp** 1997; 26:247–63 (60 ref.)

Is microalbuminuria progressive? [letter; comment] Salardi S, et al. **Arch Dis Child** 1996 Sep;75(3):266. Comment on: Arch Dis Child 1995 Dec;73(6):512–4.

Predictors of renal morphological changes in the early stage of microalbuminuria in adolescents with IDDM. Rudberg S, et al. **Diabetes Care** 1997 Mar;20(3):265–71

PHYSIOPATHOLOGY

Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type 2 diabetes mellitus. Equiluz-Bruck S, et al. **Am J Hypertens** 1996 Nov; 9(11):1139–43

The relationship of hyperinsulinemic state to left ventricular hypertrophy, microalbuminuria, and physical fitness in borderline and mild hypertension. Tomiyama H, et al. **Am J Hypertens** 1997 Jun;10(6):587–91

Albuminuria in diabetes mellitus: relation to ambulatory versus office blood pressure and effects of cilazapril. Waeber B, et al. **Am J Hypertens** 1996 Dec;9(12 Pt 1):1220–7

Ambulatory blood pressure monitoring editing criteria: is standardization needed? Hypertension and Ambulatory Recording Venetia Study (HARVEST) Group, Italy. Winnicki M, et al. **Am J Hypertens** 1997 Apr;10(4 Pt 1):419–27

Insulin resistance in patients with essential hypertension can occur in the absence of microalbuminuria. Yip JW, et al. **Am J Hypertens** 1996 Oct;9(10 Pt 1):959–63

Microalbuminuria in patients with non-insulin-dependent diabetes mellitus relates to nocturnal systolic blood pressure. Mitchell TH, et al. **Am J Med** 1997 Jun; 102(6):531–5

Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. Yudkin JS. **Ann Med** 1996 Oct;28(5):433–8 (40 ref.)

Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension. Berrut G, et al. **Clin Nephrol** 1997 Aug;48(2):92–7

Subpressor doses of angiotensin II do not increase albumin excretion in humans. Erley CM, et al. **Clin Nephrol** 1996 Nov;46(5):312–8

Microalbuminuria: prognostic implications. Bakris GL. **Curr Opin Nephrol Hypertens** 1996 May;5(3):219–23 (44 ref.)

Stable glomerular filtration rate in normotensive IDDM patients with stable microalbuminuria. A 5-year prospective study. Mathiesen ER, et al. **Diabetes Care** 1997 Mar;20(3):286–9

Transcapillary escape rate of albumin in type II diabetic patients. The relationship with microalbuminuria and hypertension. Nannipieri M, et al. **Diabetes Care** 1997 Jun; 20(6):1019–26

Elevated ambulatory blood pressure in microalbuminuric IDDM patients is inversely associated with renal plasma flow. A compensatory mechanism? Poulsen PL, et al. **Diabetes Care** 1997 Mar;20(3):429–32

Determinants of progression of microalbuminuria in patients with NIDDM.A prospective study. Smulders YM, et al. **Diabetes Care** 1997 Jun;20(6):999–1005

Urinary albumin excretion rate is related to insulin resistance in normotensive subjects with impaired glucose tolerance. Wasada T, et al. **Diabetes Res Clin Pract** 1997 Jan; 34(3):157–62

Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: a light microscopy study. Bertani T, et al. **Diabetologia** 1996 Dec;39(12):1625–8

Patterns of renal injury in NIDDM patients with microalbuminuria. Fioretto P, et al. **Diabetologia** 1996 Dec; 39(12):1569–76

Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. Schrier RW, et al. **Diabetologia** 1996 Dec; 39(12):1646–54

Glomerular hyperfiltration in microalbuminuric NIDDM patients. Vedel P, et al. **Diabetologia** 1996 Dec; 39(12):1584–9

Associations between body morphology and microalbuminuria in healthy middle-aged European, Maori and Pacific Island New Zealanders. Metcalf PA, et al. **Int J Obes Relat Metab Disord** 1997 Mar;21(3):203–10

Glycemic control in patients with type I diabetes and normoalbuminuria after long diabetes duration. Kullberg CE, et al. **J Diabetes Complications** 1997 May-Jun; 11(3):151–7

Relationships among glomerular filtration rate, albuminuria, and autonomic nerve function in insulin-dependent and non-insulin-dependent diabetes mellitus. Sterner NG, et al. **J Diabetes Complications** 1997 May-Jun;11(3):188–93

Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. Agardh CD, et al. **J Hum Hypertens** 1996 Mar;10(3):185–92

The influence of exercise on albumin excretion rate in borderline hypertensives and in offspring of hypertensive parents. Purzycki Z, et al. **J Hum Hypertens** 1997 Feb; 11(2):119–23

The clinical course of renal function in NIDDM patients with normo- and microalbuminuria. Nielsen S, et al. **J Intern Med** 1997 Feb;241(2):133–41

Dissociation between urinary albumin excretion and variables associated with insulin resistance in a healthy population. Zavaroni I, et al. **J Intern Med** 1996 Sep;240(3):151–6

Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. Hansen HP, et al. **Kidney Int** 1996 Aug;50(2):579–85

Microalbuminuria, left ventricular mass and ambulatory blood pressure in essential hypertension. Redon J, et al. **Kidney Int Suppl** 1996 Jun;55:S81–4

Microalbuminuria in essential hypertension. A marker of systemic vascular damage? [editorial] Pedrinelli R. **Nephrol Dial Transplant** 1997 Mar;12(3):379–81

Microalbuminuria in essential hypertension--its relation to cardiovascular risk factors [editorial] Pontremoli R. **Nephrol Dial Transplant** 1996 Nov;11(11):2113–5 (12 ref.)

Relationships between beta-cell function and diabetic duration and albuminuria in type 2 diabetes mellitus. Shin SJ, et al. **Pancreas** 1997 Mar;14(2):192–8

[Development of blood pressure level over a three years period in non-insulin dependent diabetic subjects according to their microalbuminuria] Mayaudon H, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89(8):1045–9 (Eng. Abstr.) **(Fre)**

[Effect of hypercholesteremia on vascular endothelial function and albumin excretion rate in patients with diabetes mellitus] Nakano H, et al. **Nippon Jinzo Gakkai Shi** 1996 Nov;38(11):507–12 (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes. Allen TJ, et al. **Diabetes** 1997 Jan;46(1): 19–24

Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats. Yamauchi A, et al. **Diabetes Res Clin Pract** 1997 Jan;34(3):127–33

Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension. Rangemark C, et al. **Eur J Clin Pharmacol** 1996;49(4):267–71

Lisinopril and albumin excretion in diabetes [letter] Williams B. **Lancet** 1997 Aug 30;350(9078):662; discussion 663–4

Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Jensen JS, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:6–9

An inhibition of urinary albumin excretion by protease inhibitor in streptozotocin-diabetic rats. Ikeda T, et al. **Nephron** 1996;74(4):709–12

Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus. Beyer-Mears A, et al. **Pharmacology** 1996 May;52(5):292–302

URINE

Measurement of albumin and low molecular weight proteins in the urine of newborn infants using a cotton wool ball collection method. Fell JM, et al. **Acta Paedistr** 1997 May; 86(5):518–22

Urinary albumin excretion--a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Ljungman S, et al. **Am J Hypertens** 1996 Aug;9(8):770–8

Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension. Siewert-Delle A, et al. **Am J Hypertens** 1996 Sep;9(9):841–9

Characterization of proteinuria in primary glomerulonephritides: urinary polymers of albumin. Bazzi C, et al. **Am J Kidney Dis** 1997 Sep;30(3):404–12

Sodium-lithium countertransport is associated with insulin resistance and urinary albumin excretion in young African-Americans. Falkner B, et al. **Am J Kidney Dis** 1997 Jan;29(1):45–53

Effects of heparin on renal morphology and albuminuria in experimental diabetes. Marshall SM, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):E326–32

Comparison of urinary albumin, retinol-binding protein and N-acetyl beta-glucosaminidase as predictors of progression of low level albuminuria in diabetes. O'Brien SF, et al. **Ann Clin Biochem** 1997 Mar;34 (Pt 2):202–4

Different urinary albumin responses to submaximal exercise by normoalbuminuric diabetic children and controls. Cesarini PR, et al. **Braz J Med Biol Res** 1996 Dec; 29(12):1603–10

Microalbumin and freezing [letter] Innanen VT, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):1093–4

Gastrointestinal absorption, tissue retention, and urinary excretion of dietary aluminum in rats determined by using 26Al. Jouhanneau P, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):1023–8

Microalbuminuria and borderline-increased albumin excretion determined with a centrifugal analyzer and the Albumin Blue 580 fluorescence assay. Kessler MA, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):996–1002

Development and validation of a particle-enhanced turbidimetric inhibition assay for urine albumin on the Dade aca analyzer. Thakkar H, et al. **Clin Chem** 1997 Jan; 43(1):109–13

Serum and urine albumin: a progress report on their measurement and clinical significance. Doumas BT, et al. **Clin Chim Acta** 1997 Feb 3;258(1):3–20 (105 ref.)

Urinary microalbumin and retinol-binding protein assay for verifying children's nephron development and maturation. Hua MJ, et al. **Clin Chim Acta** 1997 Aug 8;264(1):127–32

Factors influencing the estimation of the albumin excretion rate in subjects with diabetes mellitus. Ross SA, et al. **Clin Invest Med** 1997 Jun;20(3):152–61

Urinary albumin excretion in short children treated with recombinant human growth hormone [see comments] Sasaki H, et al. **Clin Nephrol** 1996 Jul;46(1):6–9. Comment in: Clin Nephrol 1997 Mar;47(3):210.

Microalbuminuria screening in the UK: are we meeting European standards? Gazis A, et al. **Diabet Med** 1996 Aug; 13(8):764–7

Increased urinary IgG/albumin index in normoalbuminuric insulin-dependent diabetic patients: a laboratory artefact. Hoogenberg K, et al. **Diabet Med** 1996 Jul;13(7):651–5

Urinary glycosaminoglycan excretion in NIDDM subjects: its relationship to albuminura. McAuliffe AV, et al. **Diabet Med** 1996 Aug;13(8):758–63

Urinary infection and albumin excretion in insulin-dependent diabetes mellitus: implications for the measurement of microalbuminuria. Watts GF, et al. **Diabet Med** 1996 Jun; 13(6):520–4

Increased urinary albumin and retinol-binding protein in type I diabetes. A study of identical twins. Dubrey SW, et al. **Diabetes Care** 1997 Jan;20(1):84–9

Glomerular hyperfiltration is associated with blood pressure abnormalities in normotensive normoalbuminuric IDDM patients. Pecis M, et al. **Diabetes Care** 1997 Aug; 20(8):1329–33

The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care. Agardh CD, et al. **Diabetes Res Clin Pract** 1997 Mar;35(2–3):113–21

Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Hirano T, et al. **Diabetes Res Clin Pract** 1997 Apr;36(1):11–8

Relationship between kidney volume, microalbuminuria and duration of diabetes mellitus [letter] Bognetti E, et al. **Diabetologia** 1996 Nov;39(11):1409

Relationship between lipoprotein(a) phenotypes and albumin excretion rate in non-insulin-dependent diabetes mellitus: protective effect of 'null' phenotype? Hernández C, et al. **Eur J Clin Invest** 1997 Jun;27(6):497–502

Capillary filtration coefficient and urinary albumin leak at altitude. Lewis DM, et al. **Eur J Clin Invest** 1997 Jan; 27(1):64–8

Micro-albuminuria analysis and pregnancy. An approach to detect placentary insufficiency? Gaucherand P, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec;70(1):49–52

Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. Warram JH, et al. **J Am Soc Nephrol** 1996 Jun;7(6):930–7

Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. Agrawal B, et al. **J Hum Hypertens** 1996 Aug;10(8):551–5

Microalbuminuria in essential hypertension. Mimran A, et al. **J Hum Hypertens** 1996 Oct;10(10):657–61 (35 ref.)

Albuminuria predicts renal functional outcome after intervention in atheromatous renovascular disease. Halimi JM, et al. **J Hypertens** 1995 Nov;13(11):1335–42

Relationship between albumin excretion rate, ambulatory blood pressure and left ventricular hypertrophy in mild hypertension. Palatini P, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1796–800

Effect of the calcium channel blocker nilvadipine on urinary albumin excretion in hypertensive microalbuminuric patients with non-insulin-dependent diabetes mellitus. Sumida Y, et al. **J Int Med Res** 1997 May-Jun;25(3):117–26

Use of urine specific gravity to improve screening for albuminuria. Moore RR Jr, et al. **Kidney Int** 1997 Jul; 52(1):240–3

Urinary albumin excretion rate during angiotensin II infusion

ALBUMINURIA

in microalbuminuric patients with insulin and non-insulin-dependent diabetes mellitus. Spooren PF, et al. **Nephrol Dial Transplant** 1997 Feb;12(2):281-5

Urinary leucine aminopeptidase is a more sensitive indicator of early renal damage in non-insulin-dependent diabetics than microalbuminuria. Bedir A, et al. **Nephron** 1996; 74(1):110-3

Analysis of proteinuria: reference limits for urine excretion of albumin, protein HC, immunoglobulin G, kappa- and lambda-immunoreactivity, orosomucoid and alpha 1-antitrypsin. Tencer J, et al. **Scand J Clin Lab Invest** 1996 Dec;56(8):691-700

Long-term stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain-immunoreactivity, orosomucoid and alpha 1-antitrypsin in urine stored at -20 degrees C. Tencer J, et al. **Scand J Urol Nephrol** 1997 Feb; 31(1):67-71

Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. The Insulin Resistance Atherosclerosis Study (IRAS). Mykkänen L, et al. **Stroke** 1997 Sep;28(9):1710-6

Elevated levels of plasma endothelin-1, von Willebrand factor, and urinary albumin excretion in three relatives with pseudoxanthoma elasticum [letter] Piccoli A, et al. **Thromb Haemost** 1996 Aug;76(2):278-9

[Microalbuminuria in diabetic patients] Forsblom C, et al. **Duodecim** 1995;111(15):1463-9 (45 ref.) **(Fin)**

ALBUTEROL

An outbreak of Burkholderia cepacia lower respiratory tract infection associated with contaminated albuterol nebulization solution [see comments] Reboli AC, et al. **Infect Control Hosp Epidemiol** 1996 Nov;17(11):741-3. Comment in: Infect Control Hosp Epidemiol 1996 Nov;17(11):718-20.

ADMINISTRATION & DOSAGE

Continuous vs intermittent nebulized albuterol for emergency management of asthma. Khine H, et al. **Acad Emerg Med** 1996 Nov;3(11):1019-24

Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels. Rodrigo G, et al. **Am J Emerg Med** 1996 Mar;14(2):144-50

Albuterol via Turbuhaler versus albuterol via pressurized metered-dose inhaler in asthma. Chapman KR, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):59-63

Elevation of creatine kinase from skeletal muscle associated with inhaled albuterol. Craig TJ, et al. **Ann Allergy Asthma Immunol** 1996 Dec;77(6):488-90

A comparison of bronchodilator responses to albuterol delivered by ultrasonic versus jet nebulization in moderate to severe asthma. Pallares DE, et al. **Ann Allergy Asthma Immunol** 1996 Oct;77(4):292-7

Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Emerman CL, et al. **Ann Emerg Med** 1997 Apr; 29(4):474-8

Efficacy of nebulized ipratropium in severely asthmatic children. Qureshi F, et al. **Ann Emerg Med** 1997 Feb; 29(2):205-11

Comparison of bronchodilating effects of two salbutamol dry powder inhalers in asthmatic patients. Laurikainen K, et al. **Arzneimittelforschung** 1997 Jan;47(1):44-6

Several studies have shown salmeterol to be more potent than salbutamol for systemic effects [letter; comment] Bennett J, et al. **BMJ** 1997 Jul 12;315(7100):121. Comment on: BMJ 1997 Apr 12;314(7087):1061-2.

Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol [letter; comment] Chrystyn H. **Br J Clin Pharmacol** 1996 Aug;42(2):257-8. Comment on: Br J Clin Pharmacol 1996 Mar;41(3):247-9.

The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Coates AL, et al. **Chest** 1997 May;111(5):1206-12

Effects of inhaled albuterol and ipratropium bromide on autonomic control of the cardiovascular system. Dagnone AJ, et al. **Chest** 1997 Jun;111(6):1514-8

Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered? Karpel JP, et al. **Chest** 1997 Aug;112(2):348-56

Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children. Nakanishi AK, et al. **Chest** 1997 Jun;111(6):1505-8

Treatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder. Raimondi AC, et al. **Chest** 1997 Jul;112(1):24-8

Efficacy of metered-dose inhaler administration of albuterol in intubated infants [see comments] Torres A Jr, et al. **Chest** 1997 Aug;112(2):484-90. Comment in: Chest 1997 Aug;112(2):303-4.

Hypoxia, hypocapnia and spirometry at altitude. Pollard AJ, et al. **Clin Sci (Colch)** 1997 Jun;92(6):593-8

Relative efficacy of three different inhalers containing salbutamol in patients with asthma. Mahadewsingh JV, et al. **Eur J Clin Pharmacol** 1996;50(6):467-9

Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol. Hernández RM, et al. **Eur J Drug Metab Pharmacokinet** 1997 Apr-Jun; 22(2):145-50

Treatment of recurrent acute wheezing episodes in infancy with oral salbutamol and prednisolone. Fox GF, et al. **Eur J Pediatr** 1996 Jun;155(6):512-6

Effective treatment of acute hyperkalaemia in childhood by short-term infusion of salbutamol [see comments] Kemper MJ, et al. **Eur J Pediatr** 1996 Jun;155(6):495-7. Comment in: Eur J Pediatr 1997 May;156(5):420.

In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices. Barry PW, et al. **Eur Respir J** 1997 Jun;10(6):1345-8

Lung delivery of salbutamol by dry powder inhaler (Turbuhaler) and small volume antistatic metal spacer (Airomir CFC-free MDI plus NebuChamber). Lipworth BJ, et al. **Eur Respir J** 1997 Aug;10(8):1820-3

Electrostatic charge on a plastic spacer device influences the delivery of salbutamol. Wildhaber JH, et al. **Eur Respir J** 1996 Sep;9(9):1943-6

Equivalence of pharmacokinetic characteristics and bronchodilating effect between two combined formulations of nedocromil sodium and salbutamol: MDI and nebulizer solution. Reggio S, et al. **Int J Clin Pharmacol Res** 1996; 16(1):19-27

A comparison of drug delivery from a metered-dose inhaler plus an inspiratory flow control device with a metered-dose inhaler plus a spacer device. Kanner RE, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):853-4

Health beliefs of adults with asthma: toward an understanding of the difference between symptomatic and preventive use of inhaler treatment. Hand CH, et al. **J Asthma** 1996; 33(5):331-8

Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol. Scalabrin DM, et al. **J Asthma** 1996;33(6):407-15

Treating acute asthma in adults. Forsch R. **J Fam Pract** 1996 Oct;43(4):339-40

Is driving oxygen flow rate clinically important for nebulizer therapy in patients with COPD? Charoenratanakul S, et al. **J Med Assoc Thai** 1995 Dec;78(12):670-6

Formulation and preparation of controlled release pellets of salbutamol by the air suspension technique. Govender T, et al. **J Microencapsul** 1997 Jul-Aug;14(4):445-55

Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial [see comments] Klassen TP, et al. **J Pediatr** 1997 Feb;130(2):191-6. Comment in: J Pediatr 1997 Feb;130(2):170-2.

Efficacy of epinephrine with salbutamol in treatment of acute bronchiolitis [letter; comment] Rusconi F, et al. **J Pediatr** 1996 Mar;128(3):441-3. Comment on: J Pediatr 1995 Jun;126(6):1004-7.

What is continuous nebulized albuterol? Hageman JR. **J Perinatol** 1996 Nov-Dec;16(6):481-2

Early management of acute severe asthma [letter; comment] Robertson C. **Lancet** 1997 Apr 5;349(9057):1030. Comment on: Lancet 1997 Feb 1;349(9048):301-5.

Albuterol in mild asthma [letter; comment] Zahger D. **N Engl J Med** 1997 Mar 6;336(10):729-30; discussion 730 . Comment on: N Engl J Med 1996 Sep 19;335(12):841-7.

Oral bronchodilators in the control of asthma [editorial; comment] Rees PJ. **Natl Med J India** 1996 Jul-Aug; 9(4):153-4. Comment on: Natl Med J India 1996 Jul-aug;9(4):159-62.

Cost-effectiveness of inhaled beta-agonists v. oral salbutamol in asthma: a randomized double-blind cross-over study [see comments] Thomas K, et al. **Natl Med J India** 1996 Jul-Aug;9(4):159-62. Comment in: Natl Med J India 1996 Jul-Aug;9(4):153-4. Comment in: Natl Med J India 1997 Jan-Feb;10(1):47-8.

Delivery of albuterol in a pediatric emergency department. Williams JR, et al. **Pediatr Emerg Care** 1996 Aug; 12(4):263-7

Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Fok TF, et al. **Pediatr Pulmonol** 1996 May;21(5):301-9

Effects of salbutamol delivery from a metered dose inhaler versus jet nebulizer on dynamic lung mechanics in very preterm infants with chronic lung disease. Gappa M, et al. **Pediatr Pulmonol** 1997 Jun;23(6):442-8

Hospitalization patterns in severe acute asthma in children. Schuh S, et al. **Pediatr Pulmonol** 1997 Mar;23(3):184-92

Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers. Wildhaber JH, et al. **Pediatr Pulmonol** 1997 Mar;23(3):212-6

Generic inhaled salbutamol versus branded salbutamol. A randomised double-blind study. Williamson IJ, et al. **Postgrad Med J** 1997 Mar;73(857):156-8

The Spacehaler for delivery of salbutamol: a comparison with the standard metered-dose inhaler plus Volumatic spacer device. Gunawardena KA, et al. **Respir Med** 1997 May; 91(5):311-6

Ineffectiveness of intravenous beta 2-agonists on improving exercise tolerance in patients with reversible chronic airway obstruction. Malerba M, et al. **Respiration** 1996; 63(1):8-16

The effect of inhaled salbutamol and salmeterol on lung function and endurance performance in healthy well-trained athletes. Carlsen KH, et al. **Scand J Med Sci Sports** 1997 Jun;7(3):160-5

Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic non-asthmatic subjects. Evans DW, et al. **Thorax** 1997 Feb;52(2):136-42

Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Wildhaber JH, et al. **Thorax** 1996 Oct;51(10):985-8

Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction [see comments] Zanen P, et al. **Thorax** 1996 Oct;51(10):977-80 . Comment in: Thorax 1997 Jun;52(6):586-7.

[Formoterol as inhalation powder in the treatment of patients with reversible obstructive lung diseases. A 3-month placebo-controlled comparison of the effects of formoterol and salbutamol, followed by a 12-month period with formoterol alone] Steffensen IE, et al. **Ugeskr Laeger** 1996 Dec 2;158(49):7092-6 (Eng. Abstr.) **(Dan)**

[Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics] Ogawa C, et al. **Nippon Rinsho** 1996 Nov;54(11):3081-6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Sympathomimetics and theophylline: combined use?] Alvarez Sintes R, et al. **An Med Interna** 1995 Sep; 12(9):438-41 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Confounding by indication and channeling over time: the risks of beta 2-agonists. Blais L, et al. **Am J Epidemiol** 1996 Dec 15;144(12):1161-9

Beta2-agonist induced ventricular dysrhythmias secondary to hyperexcitable conduction system in the absence of a long QT syndrome. Finn AF Jr, et al. **Ann Allergy Asthma Immunol** 1997 Feb;78(2):230-2

Unilateral pharmacologic mydriasis in a patient with respiratory compromise [letter] Goldstein JB, et al. **Arch Ophthalmol** 1997 Jun;115(6):806

Asthma in the elderly [letter; comment] Jolobe OM. **Br J Hosp Med** 1996 Nov 6-19;56(9):488. Comment on: Br J Hosp Med 1996 Feb 7-20;55(3):118-20.

A paradoxical effect of bronchodilators. Maury E, et al. **Chest** 1997 Jun;111(6):1766-7 (6 ref.)

Anomalous effects of albuterol and other sympathomimetics in the guinea pig. Morley J. **Clin Rev Allergy Immunol** 1996 Spring;14(1):65-89 (57 ref.)

A warning for the treatment of hyperkalaemia with salbutamol [letter; comment] Semmekrot BA, et al. **Eur J Pediatr** 1997 May;156(5):420. Comment on: Eur J Pediatr 1996 Jun;155(6):495-7.

Successful treatment of salbutamol-induced panic disorder with citalopram. Rihmer Z. **Eur Neuropsychopharmacol** 1997 Aug;7(3):241-2

Hypokalaemia following nebulized salbutamol in children with acute attack of bronchial asthma. Singhi SC, et al. **J Paediatr Child Health** 1996 Dec;32(6):495-7

Fetal atrial flutter associated with maternal beta-sympathomimetic drug exposure. Baker ER, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):861

ANALOGS & DERIVATIVES

Efficacy of salmeterol in the treatment of childhood asthma. Tomaç N, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):489-94

Effects of salmeterol and terbutaline on IgE-mediated dermal reactions and inflammatory events in skin chambers in atopic patients. Grönneberg R, et al. **Allergy** 1996 Sep; 51(9):640-6

Effects of local treatment with salmeterol and terbutaline on anti-IgE-induced wheal, flare, and late induration in human skin. Grönneberg R, et al. **Allergy** 1996 Oct; 51(10):685-92

Salmeterol in the treatment of chronic asthma. D'Alonzo GE, et al. **Am Fam Physician** 1997 Aug;56(2):558-62 (30 ref.)

Asthma group issues guidelines for safe use of salmeterol [news] **Am J Health Syst Pharm** 1996 Dec 15;53(24):2943-4

Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Bolton PB, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1428-35

Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Dowling RB, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):327-36

Quality of life changes in COPD patients treated with salmeterol. Jones PW, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1283-9

Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Sakuma T, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):506-12

Inhaled salmeterol or oral theophylline in nocturnal asthma? Selby C, et al. **Am J Respir Crit Care Med** 1997 Jan; 155(1):104-8

Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Weersink EJ, et al. **Am J Respir Crit Care Med** 1997 Apr; 155(4):1241-6

Salmeterol versus theophylline in the treatment of asthma. Pollard SJ, et al. **Ann Allergy Asthma Immunol** 1997 May; 78(5):457-64

Cardiotoxic effects of salmeterol in comparison with salbutamol on the isolated perfused Langendorff-heart of the rat. Prévost A, et al. **Arzneimittelforschung** 1997 Jan; 47(1):39-43

Several studies have shown salmeterol to be more potent

than salbutamol for systemic effects [letter; comment] Bennett J, et al. **BMJ** 1997 Jul 12;315(7100):121. Comment on: **BMJ** 1997 Apr 12;314(7087):1061-2.

Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. Wilding P, et al. **BMJ** 1997 May 17;314(7092):1441-6

Extent of salmeterol-mediated reassertion of relaxation in guinea-pig trachea pretreated with aliphatic side chain structural analogues. Bergendal A, et al. **Br J Pharmacol** 1996 Mar;117(6):1009-15

The duration of action of non-beta 2-adrenoceptor mediated responses to salmeterol. Nials AT, et al. **Br J Pharmacol** 1997 Mar;120(5):961-7

Doping taboos [letter; comment] Wolstenholme RJ. **Br J Sports Med** 1995 Dec;29(4):279. Comment on: Br J Sports Med 1995 Jun;29(2):75.

Tolerance to the protective effect of salmeterol on allergen challenge. Giannini D, et al. **Chest** 1996 Dec;110(6):1452-7

Effect of inhaled salmeterol on sulfur dioxide-induced bronchoconstriction in asthmatic subjects. Gong H Jr, et al. **Chest** 1996 Nov;110(5):1229-35

The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Kraft M, et al. **Chest** 1997 May;111(5):1249-54

Salmeterol reduces dyspnea and improves lung function in patients with COPD. Ramirez-Venegas A, et al. **Chest** 1997 Aug;112(2):336-40

Inhibitory effect of salmeterol on the respiratory burst of adherent human neutrophils. Ottonello L, et al. **Clin Exp Immunol** 1996 Oct;106(1):97-102

Is salmeterol ergogenic? Morton AR, et al. **Clin J Sport Med** 1996 Oct;6(4):220-5

Nasal mucociliary clearance and salmeterol. Tay HL, et al. **Clin Otolaryngol** 1997 Feb;22(1):68-70

Enantioselective disposition of albuterol in humans. Boulton DW, et al. **Clin Rev Allergy Immunol** 1996 Spring; 14(1):115-38 (91 ref.)

Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma. Perrin-Fayolle M, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):139-47

The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Manchee GR, et al. **Drug Metab Dispos** 1996 May;24(5):555-9

Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern? Lipworth BJ. **Drug Saf** 1997 May; 16(5):295-308 (60 ref.)

Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma. Adkins JC, et al. **Drugs** 1997 Aug;54(2):331-54 (172 ref.)

Evidence that the eosinophil is a cellular target for the inhibitory action of salmeterol on eosinophil recruitment in vivo. Teixeira MM, et al. **Eur J Pharmacol** 1997 Apr 4;323(2-3):255-60

An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) [published erratum appears in Eur Respir J 1997 Jul;10(7):1696] Boyd G, et al. **Eur Respir J** 1997 Apr;10(4):815-21

Salmeterol in exercise-induced bronchoconstriction in asthmatic children: comparison of two doses [published erratum appears in Eur Respir J 1997 Jan;10(1):256] de Benedictis FM, et al. **Eur Respir J** 1996 Oct;9(10):2099-103

Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group. Faurschou P, et al. **Eur Respir J** 1996 Sep;9(9):1885-90

Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group. Paggiaro PL, et al. **Eur Respir J** 1996 Aug;9(8):1689-95

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. van Noord JA, et al. **Eur Respir J** 1996 Aug;9(8):1684-8

Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. Yates DH, et al. **Eur Respir J** 1997 Jul;10(7):1483-8

The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils. Tool AT, et al. **Eur Respir J Suppl** 1996 Aug;22:141s-145s

Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol. Dottorini ML, et al. **Int J Clin Pharmacol Ther** 1996 Oct;34(10):438-43

An immunotoxicity screening study on salmeterol in rats. de Waal EJ, et al. **Int J Immunopharmacol** 1996 Aug-Sep; 18(8-9):523-8

Salmeterol inhibits interferon-gamma and interleukin-4 production by human peripheral blood mononuclear cells. Mohede IC, et al. **Int J Immunopharmacol** 1996 Mar; 18(3):193-201

Safety and appropriate use of salmeterol in the treatment of asthma. AAAAI Committee on Drugs, American Academy of Allergy, Asthma and Immunology. **J Allergy Clin Immunol** 1996 Sep;98(3):475-80

Salmeterol does not cause tolerance during long-term asthma therapy. Arledge TE, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1116-9

A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study. Boulet LP, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):13-21

The effects of salmeterol on power output in nonasthmatic athletes. McDowell SL, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):443-9

Differential effects of salmeterol on lung endothelial and epithelial leakage in sheep. Peterson BT, et al. **J Appl Physiol** 1996 May;80(5):1666-73

A one-week dose-ranging study of inhaled salmeterol in children with asthma. Weinstein S, et al. **J Asthma** 1997; 34(1):43-52

Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. Green SA, et al. **J Biol Chem** 1996 Sep 27;271(39):24029-35

Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment [see comments] Simons FE, et al. **Pediatrics** 1997 May;99(5):655-9. Comment in: Pediatrics 1997 May;99(5):729-30.

Airway effects of salmeterol in healthy individuals. Bergendal A, et al. **Pulm Pharmacol** 1995 Dec;8(6):283-8

A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Matera MG, et al. **Pulm Pharmacol** 1995 Dec;8(6):267-71

A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Matera MG, et al. **Respir Med** 1996 Sep;90(8):497-9

The effect of inhaled salbutamol and salmeterol on lung function and endurance performance in healthy well-trained athletes. Carlsen KH, et al. **Scand J Med Sci Sports** 1997 Jun;7(3):160-5

Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Booth H, et al. **Thorax** 1996 Nov;51(11):1100-4

Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Grove A, et al. **Thorax** 1996 Jul;51(7):689-93

Asthma guidelines [letter; comment] Jack D. **Thorax** 1997 Jul;52(7):665; discussion 665-6. Comment on: Thorax 1997 Feb;52 Suppl 1:S2-8, S11-5, S20-1.

Beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol [letter; comment] Jonkers RE, et al. **Thorax** 1997 Mar;52(3):305. Comment on: Thorax 1996 Jan;51(1):54-8.

The interaction between salmeterol and the beta 2-adrenoceptor protein [letter; comment] Jack D. **Trends Pharmacol Sci** 1997 May;18(5):149-51. Comment on: Trends Pharmacol Sci 1996 Sep;17(9):324-30.

[Therapy of nocturnal asthma: salmeterol versus nocturnal administration of retard theophylline--comparison of effectiveness and tolerance] Ukena D, et al. **Pneumologie** 1997 Mar;51(3):317-23 (Eng. Abstr.) **(Ger)**

[Anti-allergic effects of beta-adrenoceptor agonists in the clinical pharmacological studies] Horikoshi S, et al. **Nippon Rinsho** 1996 Nov;54(11):3068-72 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Serevent in the treatment of moderate bronchial asthma] Panghea P, et al. **Pneumoftiziologia** 1996 Jul-Dec; 45(3-4):145-8 (Eng. Abstr.) **(Rum)**

ANALYSIS

beta-agonists in animal feed. III: Optimization of the clean-up and the end-determination step. Leyssens L, et al. **Food Addit Contam** 1996 Oct;13(7):795-810

Beta-agonists in animal feed. IV: Intercomparison study of a candidate reference confirmatory method. Leyssens L, et al. **Food Addit Contam** 1996 Nov-Dec;13(8):883-95

Determination of beta 2-agonists in hair by gas chromatography/mass spectrometry. Polettini A, et al. **J Mass Spectrom** 1996 Jan;31(1):47-54

Spectrophotometric determination of salbutamol sulphate using chlorinated quinones in the presence or absence of acetaldehyde. Bakry RS, et al. **J Pharm Biomed Anal** 1996 Jan;14(3):357-62

BLOOD

Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered-dose inhaler administration. Duarte AG, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1658-63

Evaluation of plasma and urinary salbutamol levels in COPD. Clark DJ, et al. **Eur J Clin Pharmacol** 1996;51(1):91-3

Rapid pharmacokinetic screening of salbutamol in plasma samples by column-switching high-performance liquid chromatography-electrospray mass spectrometry. Schmeer K, et al. **J Chromatogr A** 1997 Aug 8;777(1):67-72

Determination of albuterol in plasma after aerosol inhalation by gas chromatography-mass spectrometry with selected-ion monitoring. Logsdon TW, et al. **J Chromatogr B Biomed Appl** 1997 May 9;692(2):472-7

CHEMISTRY

Albuterol. A pharmaceutical chemistry review of R-, S-, and RS-albuterol. Bakale RP, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):7-35 (81 ref.)

Effects of albuterol enantiomers on in vitro bronchial reactivity. Johansson F, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):57-64

Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Penn RB, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):37-45

Stereoselective metabolism of RS-albuterol in humans. Walle T, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):101-13

Permeation behavior of salbutamol sulfate through hydrophilic and hydrophobic membranes embedded by thermo-responsive cholesteryl oleyl carbonate. Lin SY, et al. **Pharm Res** 1996 Jun;13(6):914-9

DIAGNOSTIC USE

A portable device based on the interrupter technique to measure bronchodilator response in schoolchildren [see comments] Bridge PD, et al. **Eur Respir J** 1996 Jul; 9(7):1368-73. Comment in: Eur Respir J 1997 Jun;10(6):1428-9.

Evaluation of a new interrupter device for measuring bronchial responsiveness and the response to bronchodilator in 3 year old children [see comments] Phagoo SB, et al. **Eur Respir J** 1996 Jul;9(7):1374-80. Comment in: Eur Respir J 1997 Jun;10(6):1428-9.

Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients [see comments] Tan KS, et al. **Thorax** 1997 Jul;52(7):608-11. Comment in: Thorax 1997 Jul;52(7):591-2.

METABOLISM

Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Eaton EA, et al. **Br J Clin Pharmacol** 1996 Mar;41(3):201-6

Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Penn RB, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):37-45

Delivery of metered dose inhaler aerosols to paralyzed and nonparalyzed rabbits. Fok TF, et al. **Crit Care Med** 1997 Jan;25(1):140-4

Interindividual variability in the rate of salbutamol sulphation in the human lung. Pacifici GM, et al. **Eur J Clin Pharmacol** 1996;49(4):299-303

PHARMACOKINETICS

Isoetherine or albuterol for acute asthma [letter; comment] Finkelstein F. **Am J Med** 1997 Jan;102(1):130. Comment on: Am J Med 1996 Mar;100(3):323-7.

Enantioselective disposition of salbutamol in man following oral and intravenous administration. Boulton DW, et al. **Br J Clin Pharmacol** 1996 Jan;41(1):35-40

Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol [see comments] Clark DJ, et al. **Br J Clin Pharmacol** 1996 Mar;41(3):247-9. Comment in: Br J Clin Pharmacol 1996 Aug;42(2):257-8.

Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler. Hindle M, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):336-8

Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Boulton DW, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):138-44

Enantioselective disposition of albuterol in humans. Boulton DW, et al. **Clin Rev Allergy Immunol** 1996 Spring; 14(1):115-38 (91 ref.)

Stereoselective metabolism of RS-albuterol in humans. Walle T, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):101-13

Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol. Hernández RM, et al. **Eur J Drug Metab Pharmacokinet** 1997 Apr-Jun; 22(2):145-50

Equivalence of pharmacokinetic characteristics and bronchodilating effect between two combined formulations of nedocromil sodium and salbutamol: MDI and nebulizer solution. Reggio S, et al. **Int J Clin Pharmacol Res** 1996; 16(1):19-27

Systemic concentrations of salbutamol and HFA-134a after inhalation of salbutamol sulfate in a chlorofluorocarbon-free system. Harrison LI, et al. **Ther Drug Monit** 1996 Jun;18(3):240-4

Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Clark DJ, et al. **Thorax** 1996 Oct; 51(10):981-4

(-)-salbutamol sulphation in the human liver and duodenal mucosa: interindividual variability. Pacifici GM, et al. **Xenobiotica** 1997 Mar;27(3):279-86

PHARMACOLOGY

Effect of treatment with beta-agonists on tissue and urinary taurine levels in rats. Mechanism and implications for protection. Waterfield CJ, et al. **Adv Exp Med Biol** 1996; 403:233-45

Role of nitric oxide in vasodilator response induced by salbutamol in rat diaphragmatic microcirculation. Chang HY. **Am J Physiol** 1997 May;272(5 Pt 2):H2173-9

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Baraniuk JN, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):704-10

Broxaterol increases force output of fatigued canine diaphragm more than salbutamol. Derom E, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):181-5

Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilation. Díaz O, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):17-22

In vivo quantification of human pulmonary beta-adrenoceptors: effect of beta-agonist therapy. Hayes MJ, et al. **Am J Respir Crit Care Med** 1996 Nov; 154(5):1277-83

Inotropic effects of salbutamol on rat diaphragm contractility are potentiated by foreshortening. van der Heijden HF, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):1072-9

Safety of one method of sputum induction in asthmatic subjects. Wong HH, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):299-303

The acute effects of inhaled salbutamol on the beat-to-beat variability of heart rate and blood pressure assessed by spectral analysis. Jartti T, et al. **Br J Clin Pharmacol** 1997 Apr;43(4):421-8

Anti-inflammatory effects of theophylline, cromolyn and salbutamol in a murine model of pleurisy. Saleh TS, et al. **Br J Pharmacol** 1996 Jun;118(3):811-9

Beta 2-adrenoceptor agonist-mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of beta 2-adrenoceptor stimulation. Stewart AG, et al. **Br J Pharmacol** 1997 Jun;121(3):361-8

Block of the endplate acetylcholine receptor channel by the sympathomimetic agents ephedrine, pseudoephedrine, and albuterol. Milone M, et al. **Brain Res** 1996 Nov 18; 740(1-2):346-52

Reduction in post-intubation respiratory resistance by isoflurane and albuterol. Choi JH, et al. **Can J Anaesth** 1997 Jul;44(7):717-22

The different effect of salbutamol and aminophylline on platelet activating factor-induced plasma exudation into guinea pig tracheal wall and lumen. Liu CY, et al. **Chang Keng I Hsueh** 1996 Sep;19(3):211-6

The effect of regular salbutamol on lung function and bronchial hyperresponsiveness in normal subjects and nonasthmatic atopic subjects with allergic rhinitis. Boothman-Burrell D, et al. **Chest** 1997 Jul;112(1):12-8

A comparison of pulmonary availability between Ventolin (albuterol) nebules and Ventolin (albuterol) Respirator Solution. MacNeish CF, et al. **Chest** 1997 Jan;111(1):204-8

The effect of nebulized albuterol on the activity of the renin-angiotensin system in asthma. Millar EA, et al. **Chest** 1997 Jan;111(1):71-4

Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Boulton DW, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):138-44

Albuterol. A pharmaceutical chemistry review of R-, S-, and RS-albuterol. Bakale RP, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):7-35 (81 ref.)

R-albuterol. Preclinical and clinical pharmacology of R-albuterol. From molecule to man. Handley DA. **Clin Rev Allergy Immunol** 1996 Spring;14(1):1-2

Effects of RS-albuterol on the development of antigen-mediated airway hyperreactivity in guinea pigs. Jafarian A, et al. **Clin Rev Allergy Immunol** 1996 Spring; 14(1):91-100

Effects of albuterol enantiomers on in vitro bronchial reactivity. Johansson F, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):57-64

Anomalous effects of albuterol and other sympathomimetics in the guinea pig. Morley J. **Clin Rev Allergy Immunol** 1996 Spring;14(1):65-89 (57 ref.)

Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma. Perrin-Fayolle M, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):139-47

S-albuterol exacerbates calcium responses to carbachol in airway smooth muscle cells. Yamaguchi H, et al. **Clin Rev Allergy Immunol** 1996 Spring;14(1):47-55

Effects of nedocromil sodium on the oxidative burst of polymorphonuclear leukocytes: comparison with salbutamol. Braga PC, et al. **Drugs Exp Clin Res** 1997; 23(1):33-8

The effect of salbutamol on performance in endurance cyclists. Norris SR, et al. **Eur J Appl Physiol** 1996; 73(3-4):364-8

Effect of beta 2-adrenoceptor agonists on plasma potassium and cardiopulmonary responses on exercise in patients with chronic obstructive pulmonary disease. Yang CT, et al. **Eur J Clin Pharmacol** 1996;49(5):341-5

Local exposure to salbutamol or Bt2 cyclic AMP inhibits pleural exudation and leukocyte influx caused by antigen in rats. Diaz BL, et al. **Eur J Pharmacol** 1996 Jan 25; 296(2):173-80

Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. Yates DH, et al. **Eur Respir J** 1997 Jul;10(7):1483-8

Salbutamol potentiates the relaxant effects of selective phosphodiesterase inhibitors on guinea pig isolated trachea. Planquois JM, et al. **Fundam Clin Pharmacol** 1996; 10(4):356-67

Effect of regular nedocromil sodium or albuterol on bronchial inflammation in chronic asthma. Altraja A, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 2):S58-64; discussion S64-6

Effects of somatotropin and salbutamol in three genotypes of finishing barrows: growth, carcass, and calorimeter criteria. Hansen JA, et al. **J Anim Sci** 1997 Jul; 75(7):1798-809

Effects of somatotropin and salbutamol in three genotypes of finishing barrows: blood hormones and metabolites and muscle characteristics. Hansen JA, et al. **J Anim Sci** 1997 Jul;75(7):1810-21

Effects of salbutamol on intracellular calcium oscillations in porcine airway smooth muscle. Prakash YS, et al. **J Appl Physiol** 1997 Jun;82(6):1836-43

Effects of salbutamol on rat diaphragm contractility. Van der Heijden HF, et al. **J Appl Physiol** 1996 Sep; 81(3):1103-10

A minimal response to albuterol challenge does not exclude a diagnosis of asthma. Plaut TF, et al. **J Asthma** 1997; 34(3):255-6

Effects of nebulized beta 2-adrenergic agonists on pulmonary mechanics in anesthetized patients with chronic obstructive pulmonary disease. Vichitvejpaisal P, et al. **J Med Assoc Thai** 1996 Dec;79(12):779-84

Salbutamol and chronic low-frequency stimulation of canine skeletal muscle. Hu P, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):221-7

Salbutamol changes the molecular and mechanical properties of canine skeletal muscle. Zhang KM, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):211-20

Changes in taurine levels in response to repeated administration of the beta 2-agonist salbutamol in lambs. Bastos ML, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):33-7

Beta 2-agonist-elevated stress response in human bronchial epithelial cells in vivo and in vitro. Hastie AT, et al. **Lung** 1997;175(5):287-98

Acute cardiovascular effects of salmeterol in subjects with stable bronchial asthma. Bagnato GF, et al. **Monaldi Arch Chest Dis** 1996 Aug;51(4):275-8

The influence of hyperthyroidism on beta-adrenoceptor-mediated relaxation of isolated small mesenteric arteries. Zwaveling J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Mar; 353(4):438-44

The effects of bronchodilators on spontaneous ventilation and oxygen consumption in rhesus monkeys. Newth CJ, et al. **Pediatr Res** 1997 Aug;42(2):157-62

The equivalent bronchodilator effects of salbutamol formulated in chlorofluorocarbon and hydrofluoroalkane-134a metered dose inhalers on the histamine-induced pulmonary response in dogs. Nogami-Itoh M, et al. **Pharm Res** 1997 Feb;14(2):208-12

Salbutamol antagonizes insulin- and sodium mercaptoacetate-induced but not 2-deoxy-D-glucose-induced hyperphagia. Nisoli E, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):409-13

A match between binding to beta-adrenoceptors and stimulation of adenylyl cyclase parameters of (-)isoproterenol and salbutamol on rat brain. Garnier V, et al. **Pharmacol Res** 1997 Apr;35(4):303-12

Airway effects of salmeterol in healthy individuals. Bergendal A, et al. **Pulm Pharmacol** 1995 Dec;8(6):283-8

Granulocyte-macrophage colony stimulating factors (GM-CSF) and interleukin 8 (IL-8) production by human bronchial epithelial cells (HBEC) in asthmatics and controls. Lack of in vitro effect of salbutamol compared to sodium nedocromil. Gormand F, et al. **Pulm Pharmacol** 1995 Apr-Jun;8(2-3):107-13

A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Matera MG, et al. **Pulm Pharmacol** 1995 Dec;8(6):267-71

Inhaled albuterol does not inhibit cellular influx or lung injury produced by segmental antigen challenge in humans. O'Connor J, et al. **Pulm Pharmacol** 1995 Dec;8(6):237-43

Additive effect of nitroglycerine inhalation on beta2-agonist-induced bronchodilatation in asthmatics. Rolla G, et al. **Pulm Pharmacol** 1995 Apr-Jun; 8(2-3):137-41

Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Bennett JA, et al. **Thorax** 1997 May;52(5):458-64

[Laryngeal mucociliary clearance: influence of beta-2 agonists, beta antagonists, and alpha-agonists. An experimental study in rabbits] Armengot M, et al. **Acta Otorrinolaringol Esp** 1996 Nov-Dec;47(6):425-8 (Eng. Abstr.) **(Spa)**

POISONING

[Salbutamol intoxication] Danenberg HD. **Harefuah** 1997 Apr 15;132(8):549-51, 607 (Eng. Abstr.) **(Heb)**

RADIATION EFFECTS

The effect of gamma radiation on the degradation of salbutamol. Basly JP, et al. **J Pharm Biomed Anal** 1997 May;15(8):1137-41

THERAPEUTIC USE

Efficacy of atropine sulfate in combination with albuterol in the treatment for acute asthma. Díaz JE, et al. **Acad Emerg Med** 1997 Feb;4(2):107-13

Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children. Daugbjerg P, et al. **Acta Paediatr** 1996 Jun; 85(6):684-7

Effect of oral and inhaled salbutamol in infants with bronchiolitis. Cengizlier R, et al. **Acta Paediatr Jpn** 1997 Feb;39(1):61-3

Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Allon M, et al. **Am J Kidney Dis** 1996 Oct;28(4):508-14

The influence of parasympatholytics on the resolution of acute attacks of asthma. McFadden ER Jr, et al. **Am J Med** 1997 Jan;102(1):7-13

Observations on the effects of aerosolized albuterol in acute asthma. Strauss L, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):454-8

Albuterol via Turbuhaler versus albuterol via pressurized metered-dose inhaler in asthma. Chapman KR, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):59-63

Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin. Dockhorn RJ, et al. **Ann Allergy Asthma Immunol** 1997 Jul;79(1):85-8

Beta2-agonist induced ventricular dysrhythmias secondary to hyperexcitable conduction system in the absence of a long QT syndrome. Finn AF Jr, et al. **Ann Allergy Asthma Immunol** 1997 Feb;78(2):230-2

A comparison of bronchodilator responses to albuterol delivered by ultrasonic versus jet nebulization in moderate to severe asthma. Pallares DE, et al. **Ann Allergy Asthma Immunol** 1996 Oct;77(4):292-7

Comparison of bronchodilating effects of two salbutamol dry powder inhalers in asthmatic patients. Laurikainen K, et al. **Arzneimittelforschung** 1997 Jan;47(1):44-6

Treatment of hyperkalaemia [letter; comment] Wheatley EC. **Br J Hosp Med** 1997 Feb 19-Mar 4;57(4):171. Comment on: Br J Hosp Med 1996 Feb 21-Mar 5;55(4):167-70.

The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group. FitzGerald JM, et al. **Chest** 1997 Feb;111(2):311-5

Effect of age on bronchodilator response in acute severe asthma treatment. Rodrigo G, et al. **Chest** 1997 Jul; 112(1):19-23

Hyperkalemia: therapeutic options in acute and chronic renal failure. Kemper MJ, et al. **Clin Nephrol** 1996 Jul;46(1):67-9 (15 ref.)

R-albuterol. Preclinical and clinical pharmacology of R-albuterol. From molecule to man. Handley DA. **Clin Rev Allergy Immunol** 1996 Spring;14(1):1-2

Nicardipine versus salbutamol in the treatment of premature labor. A prospective randomized study. Jannet D, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 May;73(1):11-6

Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Compliance Working Group. Braunstein GL, et al. **Eur Respir J** 1996 May; 9(5):893-8

Exhaled nitric oxide during acute changes of airways calibre in asthma. Garnier P, et al. **Eur Respir J** 1996 Jun; 9(6):1134-8

The asthmatic athlete: metabolic and ventilatory responses to exercise with and without pre-exercise medication. Ienna TM, et al. **Int J Sports Med** 1997 Feb;18(2):142-8

Effects of nebulized salbutamol on respiratory mechanics in adult respiratory distress syndrome. Moriña P, et al. **Intensive Care Med** 1997 Jan;23(1):58-64

A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study. Boulet LP, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):13-21

Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. Garrett JE, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):165-70

Acute therapy for hyperkalemia with the combined regimen of bicarbonate and beta(2)-adrenergic agonist (salbutamol) in chronic renal failure patients. Kim HJ. **J Korean Med Sci** 1997 Apr;12(2):111-6

Randomised trial of intravenous salbutamol in early management of acute severe asthma in children [see comments] Browne GJ, et al. **Lancet** 1997 Feb 1; 349(9048):301-5. Comment in: Lancet 1997 Apr 5;349(9057):1030.

Shrinking lungs syndrome in systemic lupus erythematosus: improvement with inhaled beta-agonist therapy. Muñoz-Rodríguez FJ, et al. **Lupus** 1997;6(4):412-4

Speeds of action of single doses of formoterol and salbutamol compared with placebo in reversing methacholine-induced bronchoconstriction. Beach JR, et al. **Pulm Pharmacol** 1996 Aug;9(4):245-9

Intravenous salbutamol treatment for penile erection arising during cystoscopy of cervical spinal cord injury patients. Vaidyanathan S, et al. **Spinal Cord** 1996 Nov;34(11):691-5

The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Hedner J, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S111-5

Thermogenic effect of bronchodilators in patients with chronic obstructive pulmonary disease. Burdet L, et al. **Thorax** 1997 Feb;52(2):130-5

Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Reiss TF, et al. **Thorax** 1997 Jan;52(1):45-8

Salbutamol inhalation for delivery of a retained second twin [letter] Gupta S, et al. **Trop Doct** 1996 Jul;26(3):141-2

TOXICITY

Cardiotoxic effects of salmeterol in comparison with

salbutamol on the isolated perfused Langendorff-heart of the rat. Prévost A, et al. **Arzneimittelforschung** 1997 Jan; 47(1):39–43

URINE

Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol [letter; comment] Chrystyn H.
Br J Clin Pharmacol 1996 Aug;42(2):257–8. Comment on: Br J Clin Pharmacol 1996 Mar;41(3):247–9.

Evaluation of plasma and urinary salbutamol levels in COPD. Clark DJ, et al. **Eur J Clin Pharmacol** 1996;51(1):91–3

Hyphenation of coupled-column liquid chromatography and thermospray tandem mass spectrometry for the rapid determination of beta 2-agonist residues in bovine urine using direct large-volume sample injection. Set-up of single-residue methods for clenbuterol and salbutamol. Hogendoorn EA, et al. **J Mass Spectrom** 1996 Apr; 31(4):418–26

ALCALIGENES

Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Duggan JM, et al.
Clin Infect Dis 1996 Sep;23(3):569–76 (64 ref.)

Keratitis caused by alcaligenes denitrificans subsp. xylosoxidans [letter] Vogel M, et al. **Cornea** 1996 Jul; 15(4):437–9

Bacteremia due to glucose non-fermenting gram-negative bacilli in patients with hematological neoplasias and solid tumors. Martino R, et al.
Eur J Clin Microbiol Infect Dis 1996 Jul;15(7):610–5

Recurrent septicaemia due to "Achromobacter group B". Jenks PJ, et al. **J Infect** 1997 Mar;34(2):143–5

[Neonatal meningitis caused by Alcaligenes xylosoxydans] Bruel H, et al. **Arch Pediatr** 1997 Mar;4(3):260–2 (Eng. Abstr.) **(Fre)**

[Bacterial endotoxins produced by Alcaligenes faecalis and Erwinia herbicola as potential occupational hazards for agricultural workers] Skórska C, et al.
Pneumonol Alergol Pol 1996;64 Suppl 1:9–18 (Eng. Abstr.) **(Pol)**

[Bacteremia by Alcaligenes xylosoxidans: report of a case (letter)] Torres L, et al. **Med Clin (Barc)** 1997 Jun 21; 109(4):158–9 **(Spa)**

CHEMISTRY

The mutation Met121—>His creates a type-1.5 copper site in Alcaligenes denitrificans azurin. Kroes SJ, et al.
Eur J Biochem 1996 Sep 1;240(2):342–51

A putative monofunctional glycosyltransferase is expressed in Ralstonia eutropha. Paik J, et al. **J Bacteriol** 1997 Jun; 179(12):4061–5

CLASSIFICATION

Bordetella trematum sp. nov., isolated from wounds and ear infections in humans, and reassessment of Alcaligenes denitrificans Rüger and Tan 1983. Vandamme P, et al.
Int J Syst Bacteriol 1996 Oct;46(4):849–58

ENZYMOLOGY

Microbial dehalogenation of halogenated alkanoic acids, alcohols and alkanes. Slater JH, et al.
Adv Microb Physiol 1997;38:133–76 (170 ref.)

Microbial D-amino acid oxidases (EC .4.3.3). Fischer L, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:683–8

Molecular cloning and analysis of the gene encoding the thermostable penicillin G acylase from Alcaligenes faecalis. Verhaert RM, et al. **Appl Environ Microbiol** 1997 Sep; 63(9):3412–8

Characterization of the gene encoding catechol 2,3-dioxygenase of Alcaligenes sp. KF711: overexpression, enzyme purification, and nucleotide sequencing. Moon J, et al. **Arch Biochem Biophys** 1996 Aug 15;332(2):248–54

Location, catalytic activity, and subunit composition of NAD-reducing hydrogenases of some Alcaligenes strains and Rhodococcus opacus MR22. Grzeszik C, et al.
Arch Microbiol 1997 Feb-Mar;167(2-3):172–6

Evidence for an isomeric muconolactone isomerase involved in the metabolism of 4-methylmuconolactone by Alcaligenes eutrophus JMP134. Prucha M, et al.
Arch Microbiol 1997 Jul;168(1):33–8

A fatty acid alpha-ketol, a product of the plant lipoxygenase pathway, is oxidized to 3(Z)-dodecendioic acid by a bacterial monooxygenase. Schneider C, et al.
Biochem Biophys Res Commun 1997 Mar 17;232(2):364–6

pH-dependence for binding a single nitrite ion to each type-2 copper centre in the copper-containing nitrite reductase of Alcaligenes xylosoxidans. Abraham ZH, et al.
Biochem J 1997 Jun 1;324 (Pt 2):511–6

Nitrite reductase from Achromobacter xylosoxidans forms stable trimers in dilute solution. Morgan PJ, et al.
Biochem Soc Trans 1997 Feb;25(1):40S

Subunit structure of L-aspartate beta-decarboxylase from Alcaligenes faecalis. Bowers WF, et al. **Biochemistry** 1970 Jun 23;9(13):2620–5

FMN cofactor dissociation from the soluble hydrogenase of Alcaligenes eutrophus H16. Axley MJ, et al. **Biofactors** 1995-96;5(2):87–92

The 2,4-dichlorophenol hydroxylase of Alcaligenes eutrophus JMP134 is a homotetramer. Farhana L, et al.
Can J Microbiol 1997 Feb;43(2):202–5

C-terminal extension of the H2-activating subunit, HoxH, directs maturation of the NAD-reducing hydrogenase in Alcaligenes eutrophus. Massanz C, et al.
Eur J Biochem 1997 Apr 15;245(2):441–8

Site-directed mutagenesis of azurin from Pseudomonas aeruginosa enhances the formation of an electron-transfer complex with a copper-containing nitrite reductase from Alcaligenes faecalis S-6. Kukimoto M, et al. **FEBS Lett** 1996 Sep 23;394(1):87–90

Polycaprolactone depolymerase produced by the bacterium Alcaligenes faecalis. Oda Y, et al.
FEMS Microbiol Lett 1997 Jul 15;152(2):339–43

Determination of the active sites serine of the poly (3-hydroxybutyrate) depolymerases of Pseudomonas lemoignei (PhaZ5) and of Alcaligenes faecalis. Shinohe T, et al. **FEMS Microbiol Lett** 1996 Jul 15;141(1):103–9

Catechol dioxygenases from Escherichia coli (MhpB) and Alcaligenes eutrophus (MpcI): sequence analysis and biochemical properties of a third family of extradiol dioxygenases. Spence EL, et al. **J Bacteriol** 1996 Sep; 178(17):5249–56

Overproduction of D-aminoacylase from Alcaligenes xylosoxydans subsp. xylosoxydans A-6 in Escherichia coli and its purification. Wakayama M, et al.
Protein Expr Purif 1996 Jun;7(4):395–9

Expression and analysis of a bacterial poly(hydroxyalkanoate) synthase in insect cells using a baculovirus system. Williams MD, et al. **Protein Expr Purif** 1996 Mar;7(2):203–11

[Bacterial cell membrane ATPase in assessing heavy metal toxicity] Gruzina TG, et al. **Mikrobiologiia** 1997 Jan-Feb; 66(1):14–8 (Eng. Abstr.) **(Rus)**

GENETICS

Identification and modification of biphenyl dioxygenase sequences that determine the specificity of polychlorinated biphenyl degradation. Mondello FJ, et al.
Appl Environ Microbiol 1997 Aug;63(8):3096–103

Structural gene (nirS) for the cytochrome cd1 nitrite reductase of Alcaligenes eutrophus H16. Rees E, et al.
Appl Environ Microbiol 1997 Feb;63(2):800–2

Molecular cloning and analysis of the gene encoding the thermostable penicillin G acylase from Alcaligenes faecalis. Verhaert RM, et al. **Appl Environ Microbiol** 1997 Sep; 63(9):3412–8

Characterization of the gene encoding catechol 2,3-dioxygenase of Alcaligenes sp. KF711: overexpression, enzyme purification, and nucleotide sequencing. Moon J, et al. **Arch Biochem Biophys** 1996 Aug 15;332(2):248–54

Identification of cbbBc as an additional distal gene of the chromosomal cbb CO2 fixation operon from Ralstonia eutropha. Bömmer D, et al. **Arch Microbiol** 1996 Oct; 166(4):245–51

Characterization of the gene encoding catechol 2,3-dioxygenase from Achromobacter xylosoxidans KF701. Moon J, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):430–5

Cloning of poly(3-hydroxybutyrate) depolymerase from a marine bacterium, Alcaligenes faecalis AE122, and characterization of its gene product. Kita K, et al.
Biochim Biophys Acta 1997 May 2;1352(1):113–22

Cloning and characterization of the Alcaligenes eutrophus 2-oxoglutarate dehydrogenase complex. Hein S, et al.
FEMS Microbiol Lett 1996 Mar 1;136(3):231–8

Evidence for the genetic unrelatedness of nosocomial Alcaligenes xylosoxidans strains in a pediatric hospital. Benaoudia F, et al. **Infect Control Hosp Epidemiol** 1997 Feb;18(2):132–4

A hydrogen-sensing system in transcriptional regulation of hydrogenase gene expression in Alcaligenes species. Lenz O, et al. **J Bacteriol** 1997 Mar;179(5):1655–63

Two-component regulatory system involved in transcriptional control of heavy-metal homoeostasis in Alcaligenes eutrophus. van der Lelie D, et al.
Mol Microbiol 1997 Feb;23(3):493–503

Genetic and physical maps of the Alcaligenes eutrophus CH34 megaplasmid pMOL28 and its derivative pMOL50 obtained after temperature-induced mutagenesis and mortality. Taghavi S, et al. **Plasmid** 1997;37(1):22–34

GROWTH & DEVELOPMENT

Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center. Vu-Thien H, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):876–9

ISOLATION & PURIFICATION

Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. Moissenet D, et al. **Clin Infect Dis** 1997 Feb;24(2):274–5

Chronic postoperative gram-negative endophthalmitis. Aaberg TM Jr, et al. **Retina** 1997;17(3):260–2

[Cerebral abscess of otic origin caused conjointly by Proteus mirabilis and Alcaligenes faecalis (letter)] Ojeda-Vargas M, et al. **Enferm Infecc Microbiol Clin** 1995 Dec;13(10):635 **(Spa)**

[Bacteremia caused by Alcaligenes (Achromobacter) xylosoxidans. Description of 3 cases and review of the literature] Ramos JM, et al.
Enferm Infecc Microbiol Clin 1996 Aug-Sep;14(7):436–40 (38 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Microbial dehalogenation of halogenated alkanoic acids, alcohols and alkanes. Slater JH, et al.
Adv Microb Physiol 1997;38:133–76 (170 ref.)

Benzoate degradation via the ortho pathway in Alcaligenes eutrophus is perturbed by succinate. Ampe F, et al.
Appl Environ Microbiol 1997 Jul;63(7):2765–70

Functional and structural role of the cytochrome b subunit of the membrane-bound hydrogenase complex of Alcaligenes eutrophus H16. Bernhard M, et al.
Eur J Biochem 1997 Aug 15;248(1):179–86

Degradation of crude oil by Acinetobacter calcoaceticus and Alcaligenes odorans. Lal B, et al. **J Appl Bacteriol** 1996 Oct;81(4):355–62

Siderophore-mediated iron uptake in Alcaligenes eutrophus CH34 and identification of aleB encoding the ferric iron-alcaligin E receptor. Gilis A, et al. **J Bacteriol** 1996 Sep;178(18):5499–507

PHYSIOLOGY

[Growth and substrate utilization by bacterial lawn on the agar surface: experiment and one-dimensional distributed model] Belova SE, et al. **Mikrobiologiia** 1996 Nov-Dec; 65(6):790–5 (Eng. Abstr.) **(Rus)**

ALCIAN BLUE

Quantitation of urinary glycosaminoglycans with Alcian blue: evaluation of the interference by Tamm-Horsfall glycoprotein. Bhavanandan VP, et al. **Clin Chim Acta** 1996 Jul 30;251(2):207–14

CHEMISTRY

The importance of standardization of carboxymethylchitin concentration by the dye-binding capacity of alcian blue before adsorption on liposomes. Mobed M, et al.
Artif Cells Blood Substit Immobil Biotechnol 1996 Mar; 24(2):107–20

ALCOHOL ABUSE see **ALCOHOLISM**

ALCOHOL AMNESTIC DISORDER

COMPLICATIONS

[Pyloric stenosis complicated by Wernicke-Korsakoff syndrome] Bataller R, et al. **Gastroenterol Hepatol** 1997 Mar;20(3):131–3 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Fine motor speed deficits in alcoholic Korsakoff's syndrome. Welch LW, et al. **Alcohol Clin Exp Res** 1997 Feb; 21(1):134–9

Monitoring the source of memory in detoxified alcoholics. Weingartner HJ, et al. **Biol Psychiatry** 1996 Jul 1; 40(1):43–53

The relationship between retrograde and anterograde amnesia in patients with typical global amnesia. Mayes AR, et al. **Cortex** 1997 Jun;33(2):197–217

DRUG THERAPY

The performance of amnesic subjects on tests of delayed matching-to-sample and delayed matching-to-position. Holdstock JS, et al. **Neuropsychologia** 1995 Dec; 33(12):1583–96

ENZYMOLOGY

A transketolase assembly defect in a Wernicke-Korsakoff syndrome patient. Wang JJ, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):576–80

EPIDEMIOLOGY

Increasing incidence of Korsakoff's psychosis in the east end of Glasgow. Ramayya A, et al. **Alcohol Alcohol** 1997 May-Jun;32(3):281–5

ETIOLOGY

Brain pyruvate oxidation in experimental thiamin-deficiency encephalopathy. Munujos P, et al. **Clin Chim Acta** 1996 Nov 15;255(1):13–25

Wernicke-Korsakoff syndrome in a liver transplant recipient [published erratum appears in Psychosomatics 1997 May-Jun;38(3):302] DiMartini A. **Psychosomatics** 1996 Nov-Dec;37(6):564–7

[The Korsakoff syndrome in a female patient operated on for an aneurysm of the anterior cerebral-anterior communicating arteries (a case report)] Dzhebrailbekov ESh, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct-Dec;(4):37–9 (17 ref.) **(Rus)**

HISTORY

Medico-psychological study of a memory disorder. 1889 [classical article] Korsakoff SS, et al. **Conscious Cogn** 1996 Mar-Jun;5(1-2):2–21

ALCOHOL AMNESTIC DISORDER

PATHOLOGY

Magnetic resonance imaging in alcoholic Korsakoff's syndrome: evidence for an association with alcoholic dementia. Emsley R, et al. **Alcohol Alcohol** 1996 Sep; 31(5):479–86

Neuropathological correlates of memory dysfunction in the Wernicke–Korsakoff syndrome. Halliday G, et al. **Alcohol Alcohol Suppl** 1994;2:245–51

Mammillary body and cerebellar shrinkage in chronic alcoholics with and without amnesia. Shear PK, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1489–95

Chronic alcohol consumption does not cause hippocampal neuron loss in humans. Harding AJ, et al. **Hippocampus** 1997;7(1):78–87

PHYSIOPATHOLOGY

Regional cerebral blood flow and oxygen metabolism in a patient with Korsakoff syndrome. Matsuda K, et al. **Ann Nucl Med** 1997 Feb;11(1):33–5

Korsakoff and amnesia. Banks WP. **Conscious Cogn** 1996 Mar–Jun;5(1–2):22–6

Preserved verb generation priming in global amnesia. Seger CA, et al. **Neuropsychologia** 1997 Aug;35(8):1069–74

Wernicke–Korsakoff syndrome. Zubaran C, et al. **Postgrad Med J** 1997 Jan;73(855):27–31 (55 ref.)

[Neurological complications associated with vitamin B1 deficiency (thiamine)] Moltó JM. **Rev Neurol** 1996 Apr; 24(128):389–91 **(Spa)**

PREVENTION & CONTROL

Preventing the Wernicke–Korsakoff syndrome in Australia: cost–effectiveness of thiamin–supplementation alternatives. Connelly L, et al. **Aust N Z J Public Health** 1996 Apr; 20(2):181–7

PSYCHOLOGY

Neuropathological correlates of memory dysfunction in the Wernicke–Korsakoff syndrome. Halliday G, et al. **Alcohol Alcohol Suppl** 1994;2:245–51

Spatial location memory in amnesia: binding item and location information under incidental and intentional encoding conditions. Chalfonte BL, et al. **Memory** 1996 Nov;4(6):591–614

Word priming with brief multiple presentation technique: preservation in amnesia. Beauregard M, et al. **Neuropsychologia** 1997 May;35(5):611–21

A comparison of implicit memory tasks in Korsakoff and alcoholic patients. Brunfaut E, et al. **Neuropsychologia** 1996 Dec;34(12):1143–50

Unconscious influences on amnesics' word–stem completion. Cermak LS, et al. **Neuropsychologia** 1997 May;35(5):605–10

Association learning and recognition memory in alcoholic Korsakoff patients. Oscar–Berman M, et al. **Neuropsychology** 1997 Apr;11(2):282–9

RADIONUCLIDE IMAGING

Regional cerebral blood flow and oxygen metabolism in a patient with Korsakoff syndrome. Matsuda K, et al. **Ann Nucl Med** 1997 Feb;11(1):33–5

REHABILITATION

Thiamine pyrophosphate effect and normalized erythrocyte transketolase activity ratio in Wernicke–Korsakoff patients and acute alcoholics undergoing detoxification. Rooprai HK, et al. **Alcohol Alcohol** 1996 Sep;31(5):493–501

ALCOHOL CONSUMPTION see **ALCOHOL DRINKING**

ALCOHOL DEHYDROGENASE

ANALYSIS

Localization of class I and class IV alcohol dehydrogenases in mouse testis and epididymis: potential retinol dehydrogenases for endogenous retinoic acid synthesis. Deltour L, et al. **Biol Reprod** 1997 Jan;56(1):102–9

Alcohol dehydrogenase of human and rat blood vessels. Role in ethanol metabolism. Allali–Hassani A, et al. **FEBS Lett** 1997 Mar 17;405(1):26–30

Alcohol dehydrogenase in human tissues: localisation of transcripts coding for five classes of the enzyme. Estonius M, et al. **FEBS Lett** 1996 Nov 18;397(2–3):338–42

ANTAGONISTS & INHIBITORS

Kinetic interactions between 4–methylpyrazole and ethanol in healthy humans. Jacobsen D, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):804–9

Kinetics of irreversible inhibition of yeast alcohol dehydrogenase during modification by 4,4'–dithiodipyridine. Zheng SY, et al. **Int J Biol Macromol** 1997 Jul;20(4):307–13

Safety and efficacy of 4–methylpyrazole for treatment of suspected or confirmed ethylene glycol intoxication in dogs: 107 cases (1983–1995). Connally HE, et al. **J Am Vet Med Assoc** 1996 Dec 1;209(11):1880–3

High–performance liquid chromatographic determination of 4–methylpyrazole in plasma and in dialysate. Jobard E, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1; 695(2):444–7

Kinetics of the course of inactivation of yeast alcohol dehydrogenase by 4–(2–pyridylazo)–resorcinol. Zhang YX, et al. **J Enzyme Inhib** 1996;10(4):239–250

[Lipid spectrum of rat liver and brain after administration of pyrazole] Selevich MI, et al. **Patol Fiziol Eksp Ter** 1997 Jan–Mar;(1):15–7 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Regulation of the seven human alcohol dehydrogenase genes. Edenberg HJ, et al. **Adv Exp Med Biol** 1997;414:339–45

Cosuppression in Drosophila: gene silencing of Alcohol dehydrogenase by white–Adh transgenes is Polycomb dependent [see comments] Pal–Bhadra M, et al. **Cell** 1997 Aug 8;90(3):479–90. Comment in: Cell 1997 Aug 8;90(3):385–7.

Role of NAD in regulating the adhE gene of Escherichia coli. Leonardo MR, et al. **J Bacteriol** 1996 Oct; 178(20):6013–8

BLOOD

Activity of class I and II isoenzymes of alcohol dehydrogenase measured by a fluorometric method in the sera of patients with obstructive jaundice. Chrostek L, et al. **Clin Chim Acta** 1997 Jul 4;263(1):117–22

Human alcohol dehydrogenase isoenzyme activity in the sera of non–alcoholic liver cirrhotic patients. Chrostek L, et al. **Eur J Clin Chem Clin Biochem** 1996 Oct;34(10):801–4

Human serum alcohol dehydrogenase isoenzymes as a markers of liver injury during viral hepatitis. Chrostek L, et al. **Rocz Akad Med Bialymst** 1996;41(2):268–76

[The accuracy of blood alcohol determination with head–space GC, ADH and REA ethanol assay for the AXSYM system––a comparison of the methods] Alt A, et al. **Blutalkohol** 1996 Jul;33(4):209–14 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Mammalian class II alcohol dehydrogenase. A highly variable enzyme. Höög JO, et al. **Adv Exp Med Biol** 1997; 414:303–11

Three–dimensional structures of human alcohol dehydrogenase isoenzymes reveal the molecular basis for their functional diversity. Hurley TD, et al. **Adv Exp Med Biol** 1997;414:291–302

Alcohol dehydrogenase variability. Evolutionary and functional conclusions from characterization of further variants. Jörnvall H, et al. **Adv Exp Med Biol** 1997; 414:281–9

Role of alcohol dehydrogenases in steroid and retinoid metabolism. Kedishvili NY, et al. **Adv Exp Med Biol** 1997; 414:321–9

Alcohol dehydrogenases. Persson B. **Adv Exp Med Biol** 1997; 414:591–4

Activity of liver alcohol dehydrogenases on steroids. Strasser F, et al. **Adv Exp Med Biol** 1997;414:313–20

Expression of the alcohol dehydrogenase (ADH) domain of Entamoeba histolytica EhADH2 enzyme. Espinosa A, et al. **Arch Med Res** 1997;28 Spec No:78–80

Model molecules for the active centre of alcoholdehydrogenases––an FT–IR study. Brzezinski B, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):473–6

Differential alcohol dehydrogenase and malate dehydrogenase isozyme expression in long–term callus tissue cultures of Cereus peruvianus (Cactaceae). Torquato EF, et al. **Biochem Genet** 1995 Dec;33(11–12):389–99

Flexibility of liver alcohol dehydrogenase in stereoselective binding of 3–butylthiolane 1–oxides. Cho H, et al. **Biochemistry** 1997 Jan 14;36(2):382–9

Thermodynamic analysis of the effects of small inert cosolutes in the ultracentrifugation of noninteracting proteins. Jacobsen MP, et al. **Biochemistry** 1996 Oct 8; 35(40):13173–9

The cloning and sequencing of the alcB gene, coding for alcohol dehydrogenase II, in Aspergillus nidulans. Hunter GD, et al. **Curr Genet** 1996 Jan;29(2):122–9

Tetrazolium–dye–linked alcohol dehydrogenase of the methylotrophic actinomycete Amycolatopsis methanolica is a three–component complex. Bystrykh LV, et al. **Eur J Biochem** 1997 Jul 1;247(1):280–7

The protein conformation of Cd–substituted horse liver alcohol dehydrogenase and its metal–site coordination geometry in binary and ternary inhibitor complexes. Hemmingsen L, et al. **Eur J Biochem** 1996 Oct 15; 241(2):546–51

Fourier transform infrared spectroscopic studies of proton transfer processes and the dissociation of Zn2+–bound water in alcohol dehydrogenases. Nadolny C, et al. **Eur J Biochem** 1997 Aug 1;247(3):914–9

Molecular modelling of human gastric alcohol dehydrogenase (class IV) and substrate docking: differences towards the classical liver enzyme (class I). Moreno A, et al. **FEBS Lett** 1996 Oct 21;395(2–3):99–102

Use of pH studies to determine the kinetic and chemical mechanism of yeast alcohol dehydrogenase with primary aliphatic alcohols and aldehydes. Leskovac V, et al. **Indian J Biochem Biophys** 1996 Jun;33(3):177–83

Comparison of inactivation and unfolding of yeast alcohol dehydrogenase during denaturation in urea solutions. Zhang T, et al. **Int J Biol Macromol** 1996 Aug;19(2):113–9

Yeast alcohol dehydrogenase catalyzed reduction of p–nitroso–N, N–dimethylaniline by NADH. Leskovac V, et al. **Ital J Biochem** 1996 Mar;45(1):9–18

X–ray structure of human class IV sigmasigma alcohol dehydrogenase. Structural basis for substrate specificity. Xie P, et al. **J Biol Chem** 1997 Jul 25;272(30):18558–63

Enzyme purification with aqueous two–phase systems: comparison between systems composed of pure polymers and systems composed of crude polymers. Venâncio A, et al. **J Chromatogr B Biomed Appl** 1996 May 17; 680(1–2):131–6

Pressure effects on the structure of oligomeric proteins prior to subunit dissociation. Cioni P, et al. **J Mol Biol** 1996 Nov 15;263(5):789–99

Modulation of the chaperone–like activity of bovine alpha–crystallin. Clark JI, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15185–9

Thermoanaerobacter brockii alcohol dehydrogenase: characterization of the active site metal and its ligand amino acids. Bogin O, et al. **Protein Sci** 1997 Feb;6(2):450–8

Cysteine reactivity in Thermoanaerobacter brockii alcohol dehydrogenase. Peretz M, et al. **Protein Sci** 1997 May; 6(5):1074–83

DRUG EFFECTS

In vitro stabilization and in vivo solubilization of foreign proteins by the beta subunit of a chaperonin from the hyperthermophilic archaeon Pyrococcus sp. strain KOD1. Yan Z, et al. **Appl Environ Microbiol** 1997 Feb;63(2):785–9

GENETICS

Study of the alcohol dehydrogenase–1 (Adh1) gene in tetraploid corn: expression in the pollen grains and restriction fragment length polymorphism. Hajós–Novák M, et al. **Acta Biol Hung** 1997;48(1):87–94

Regulation of the seven human alcohol dehydrogenase genes. Edenberg HJ, et al. **Adv Exp Med Biol** 1997;414:339–45

Alcohol dehydrogenase variability. Evolutionary and functional conclusions from characterization of further variants. Jörnvall H, et al. **Adv Exp Med Biol** 1997; 414:281–9

Alcohol dehydrogenases. Persson B. **Adv Exp Med Biol** 1997; 414:591–4

Effect of acetaldehyde generated from ethanol by ADH–transfected CHO cells on their membrane fatty acid profiles [published erratum appears in Alcohol 1997 Mar–Apr;14(2):203] Meskar A, et al. **Alcohol** 1996 Nov–Dec;13(6):611–6

Allele frequency of ADH2 and ALDH2 among Brazilians of different ethnic groups. Santos BR, et al. **Alcohol** 1997 May–Jun;14(3):205–7

Alcohol dehydrogenase polymorphisms in Native Americans: identification of the ADH2*3 allele. Wall TL, et al. **Alcohol Alcohol** 1997 Mar–Apr;32(2):129–32

Alcohol and aldehyde dehydrogenase genotypes, alcoholism and alcohol related disease. Couzigou P, et al. **Alcohol Alcohol Suppl** 1994;2:21–7 (47 ref.)

Alcohol dehydrogenases: molecular biology and gene regulation. Edenberg HJ, et al. **Alcohol Alcohol Suppl** 1994; 2:121–5 (28 ref.)

Polymorphisms of ethanol metabolizing enzyme genes and alcoholism. Higuchi S. **Alcohol Alcohol Suppl** 1994;2:29–34

ADH and ALDH genotypes in relation to alcohol metabolic rate and sensitivity. Whitfield JB. **Alcohol Alcohol Suppl** 1994;2:59–65 (15 ref.)

Expression patterns of class I and class IV alcohol dehydrogenase genes in developing epithelia suggest a role for alcohol dehydrogenase in local retinoic acid synthesis. Ang HL, et al. **Alcohol Clin Exp Res** 1996 Sep; 20(6):1050–64

Failure to find exon 7 polymorphism of the ADH7 gene in Chinese, Japanese, African–Americans, and Caucasians. Carr LG, et al. **Alcohol Clin Exp Res** 1996 May;20(3):418–9

Gene regulation of alcohol metabolizing enzymes. Crabb DW. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):113A–116A

Alcohol and aldehyde dehydrogenase genotypes and drinking behavior in Japanese. Higuchi S, et al. **Alcohol Clin Exp Res** 1996 May;20(3):493–7

Genotypes of alcohol–metabolizing enzymes and the risk for alcoholic chronic pancreatitis in Japanese alcoholics. Matsumoto M, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):289A–292A

Polymorphism of alcohol–metabolizing genes affects drinking behavior and alcoholic liver disease in Japanese men. Tanaka F, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):596–601

Stabilization of pet operon plasmids and ethanol production in Escherichia coli strains lacking lactate dehydrogenase and pyruvate formate–lyase activities. Hespell RB, et al. **Appl Environ Microbiol** 1996 Dec;62(12):4594–7

Characterization of the genes encoding the three–component membrane–bound alcohol dehydrogenase from Gluconobacter suboxydans and their expression in Acetobacter pasteurianus. Kondo K, et al. **Appl Environ Microbiol** 1997 Mar;63(3):1131–8

Characterization of an insertion sequence, IS12528, from Gluconobacter suboxydans. Kondo K, et al. **Appl Environ Microbiol** 1997 Mar;63(3):1139–42

Expression of the alcohol dehydrogenase (ADH) domain of Entamoeba histolytica EhADH2 enzyme. Espinosa A, et al. **Arch Med Res** 1997;28 Spec No:78–80

Genetic mapping of a possible new alcohol dehydrogenase

sequence to mouse chromosome 3 at the Adh-1/Adh-3 complex. Zheng YW, et al. **Biochem Genet** 1997 Apr; 35(3-4):105-17

Alcohol dehydrogenase and aldehyde dehydrogenase genotypes and alcoholism among Taiwanese aborigines. Chen WJ, et al. **Biol Psychiatry** 1997 Mar 15;41(6):703-9

Alcohol-metabolising genes and alcoholism among Taiwanese Han men: independent effect of ADH2, ADH3 and ALDH2. Chen WJ, et al. **Br J Psychiatry** 1996 Jun; 168(6):762-7

CYP2E1, ALDH2 and ADH2 genotypes and blood ethanol elimination kinetics [letter] Iwahashi K, et al. **Clin Chim Acta** 1996 Nov 15;255(1):85-7

The cloning and sequencing of the alcB gene, coding for alcohol dehydrogenase II, in Aspergillus nidulans. Hunter GD, et al. **Curr Genet** 1996 Jan;29(2):122-9

Initiation of retinoid signaling in primitive streak mouse embryos: spatiotemporal expression patterns of receptors and metabolic enzymes for ligand synthesis. Ang HL, et al. **Dev Dyn** 1997 Apr;208(4):536-43

The Adh-related gene of Drosophila melanogaster is expressed as a functional dicistronic messenger RNA: multigenic transcription in higher organisms. Brogna S, et al. **EMBO J** 1997 Apr 15;16(8):2023-31

Molecular organization of the alcohol dehydrogenase loci of Drosophila grimshawi and Drosophila hawaiiensis. Brennan MD, et al. **Gene** 1996 Nov 28;181(1-2):51-5

Molecular cloning of fish alcohol dehydrogenase cDNA. Funkenstein B, et al. **Gene** 1996 Sep 26;174(1):159-64

Ten kilobases of 5'-flanking region confers proper regulation of the mouse alcohol dehydrogenase-1 (Adh-1) gene in kidney and adrenal of transgenic mice. Xie D, et al. **Gene** 1996 Nov 28;181(1-2):173-8

Insertion of the retroposable element, jockey, near the Adh gene of Drosophila melanogaster is associated with altered gene expression. White LD, et al. **Genet Res** 1996 Dec; 68(3):203-9

Interactions between the regulatory regions of two Adh alleles. Freidman R, et al. **Genetics** 1996 Jan;97(1):1-14

Origin and evolution of a new gene descended from alcohol dehydrogenase in Drosophila. Begun DJ. **Genetics** 1997 Feb;145(2):375-82

Isolation and identification of genes activating UAS2-dependent ADH2 expression in Saccharomyces cerevisiae. Donoviel MS, et al. **Genetics** 1996 Jul; 143(3):1137-48

Selection on X-linked genes during speciation in the Drosophila athabasca complex. Ford MJ, et al. **Genetics** 1996 Oct;144(2):689-703

Intragenic recombination in the Adh locus of the wild plant Arabidopsis thaliana. Innan H, et al. **Genetics** 1996 Aug; 143(4):1761-70

The alcohol dehydrogenase gene is nested in the outspread locus of Drosophila melanogaster. McNabb S, et al. **Genetics** 1996 Jun;143(2):897-911

Molecular dissection of a major gene effect on a quantitative trait: the level of alcohol dehydrogenase expression in Drosophila melanogaster. Stam LF, et al. **Genetics** 1996 Dec;144(4):1559-64

Molecular cloning and chromosomal localization of the ADH7 gene encoding human class IV (sigma) ADH. Yokoyama H, et al. **Genomics** 1996 Jan 15;31(2):243-5

Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in Chinese patients. Chao YC, et al. **Hepatology** 1997 Jan;25(1):112-7

Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Coutelle C, et al. **Hum Genet** 1997 Mar; 99(3):319-25

The contribution of polymorphism in the alcohol dehydrogenase beta subunit to alcohol sensitivity in a Japanese population. Takeshita T, et al. **Hum Genet** 1996 Apr;97(4):409-13

Molecular analysis of a spontaneous insertion mutation near the alcohol dehydrogenase gene of Drosophila melanogaster. White LD, et al. **Insect Biochem Mol Biol** 1996 Jun;26(6):593-8

Synthesis of the osmoprotectant glycine betaine in Bacillus subtilis: characterization of the gbsAB genes. Boch J, et al. **J Bacteriol** 1996 Sep;178(17):5121-9

Evidence for the bacterial origin of genes encoding fermentation enzymes of the amitochondriate protozoan parasite Entamoeba histolytica. Rosenthal B, et al. **J Bacteriol** 1997 Jun;179(11):3736-45

cDNA sequence and catalytic properties of a chick embryo alcohol dehydrogenase that oxidizes retinol and 3beta,5alpha-hydroxysteroids. Kedishvili NY, et al. **J Biol Chem** 1997 Mar 14;272(11):7494-500

A gene correlate of geotaxis near Adh (2-50.1) in Drosophila melanogaster. Stoltenberg SF, et al. **J Comp Psychol** 1996 Sep;110(3):252-9

Adh nucleotide variation in Drosophila willistoni: high replacement polymorphism in an electrophoretically monomorphic protein. Griffith EC, et al. **J Mol Evol** 1997 Sep;45(3):232-7

Selection and methionine accumulation in the fat body protein 2 gene (FBP2), a duplicate of the Drosophila alcohol dehydrogenase (ADH) gene. Meghlaoui GK, et al. **J Mol Evol** 1997 Jan;44(1):23-32

Genotypes of aldehyde dehydrogenase and alcohol dehydrogenase polymorphisms in patients with Leber's hereditary optic neuropathy. Isashiki Y, et al. **Jpn J Hum Genet** 1997 Mar;42(1):187-91

Inducible expression cassettes in yeast: ADH2. Price VL. **Methods Mol Biol** 1997;62:149-57

A new insertion sequence IS1452 from Acetobacter pasteurianus. Kondo K, et al. **Microbiology** 1997 Feb;143 (Pt 2):539-46

Molecular population genetics of the alcohol dehydrogenase locus in the Hawaiian drosophilid D. mimica. Ayala FJ, et al. **Mol Biol Evol** 1996 Dec;13(10):1363-7

Cyclic AMP-dependent protein kinase inhibits ADH2 expression in part by decreasing expression of the transcription factor gene ADR1. Dombek KM, et al. **Mol Cell Biol** 1997 Mar;17(3):1450-8

bli-4, a gene that is rapidly induced by blue light, encodes a novel mitochondrial, short-chain alcohol dehydrogenase-like protein in Neurospora crassa. Bruchez JJ, et al. **Mol Gen Genet** 1996 Sep 13;252(3):223-9

Enhancement of Ty transposition at the ADH4 and ADH2 loci in meiotic yeast cells. Ribeiro-dos-Santos G, et al. **Mol Gen Genet** 1997 May 20;254(5):555-61

The two small introns of the Drosophila affinidisjuncta Adh gene are required for normal transcription. McKenzie RW, et al. **Nucleic Acids Res** 1996 Sep 15;24(18):3635-42

Evidence for the existence of a sheep and a goat line of Teladorsagia circumcincta (Nematoda). Gasnier N, et al. **Parasitol Res** 1996;82(6):546-50

The alcohol dehydrogenase genes of cotton. Millar AA, et al. **Plant Mol Biol** 1996 Jul;31(4):897-904

Both 5' and 3' sequences of maize adh1 mRNA are required for enhanced translation under low-oxygen conditions. Bailey-Serres J, et al. **Plant Physiol** 1996 Oct;112(2):685-95

Substitution rate comparisons between grasses and palms: synonymous rate differences at the nuclear gene Adh parallel rate differences at the plastid gene rbcL. Gaut BS, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10274-9

Evolution of alcohol dehydrogenase genes in the palm and grass families. Morton BR, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11735-9

Site-directed mutations reveal long-range compensatory interactions in the Adh gene of Drosophila melanogaster. Parsch J, et al. **Proc Natl Acad Sci U S A** 1997 Feb 4; 94(3):928-33

Pinus banksiana has at least seven expressed alcohol dehydrogenase genes in two linked groups. Perry DJ, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13020-3

[Molecular cloning of ADH7 encoding human class IV (sigma) ADH and its clinical significance] Yokoyama H, et al. **Tanpakushitsu Kakusan Koso** 1997 Jan;42(1):42-9 (49 ref.) **(Jpn)**

[Gene-enzyme alcohol dehydrogenase system and adaptability in Drosophila melanogaster] Tots'kiĭ VM, et al. **Ukr Biokhim Zh** 1996 May-Jun;68(3):62-9 (Eng. Abstr.) **(Ukr)**

IMMUNOLOGY

Alcohol dehydrogenase: a target of humoral autoimmune response in liver disease. Ma Y, et al. **Gastroenterology** 1997 Feb;112(2):483-92

ISOLATION & PURIFICATION

Structural and biochemical studies of alcohol dehydrogenase isozymes from Kluyveromyces lactis. Bozzi A, et al. **Biochim Biophys Acta** 1997 Apr 25;1339(1):133-42

Affinity chromatography of yeast alcohol dehydrogenase using immobilized monochlorotriazine colourless compounds. Li Y, et al. **Biomed Chromatogr** 1997 May-Jun; 11(3):180-4

A thermophilic alcohol dehydrogenase from Bacillus acidocaldarius not reactive towards ketones. D'Auria S, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):498-504

Enzyme purification with aqueous two-phase systems: comparison between systems composed of pure polymers and systems composed of crude polymers. Venâncio A, et al. **J Chromatogr B Biomed Appl** 1996 May 17; 680(1-2):131-6

Purification of alcohol dehydrogenase from Entamoeba histolytica and Saccharomyces cerevisiae using zinc-affinity chromatography. Cabrera N, et al. **Protein Expr Purif** 1997 Aug;10(3):340-4

METABOLISM

New alcohol dehydrogenases for the synthesis of chiral compounds. Hummel W. **Adv Biochem Eng Biotechnol** 1997;58:145-84 (252 ref.)

Evidence that class IV alcohol dehydrogenase may function in embryonic retinoic acid synthesis. Duester G, et al. **Adv Exp Med Biol** 1997;414:357-64 (25 ref.)

Mammalian class II alcohol dehydrogenase. A highly variable enzyme. Höög JO, et al. **Adv Exp Med Biol** 1997; 414:303-11

Role of alcohol dehydrogenases in steroid and retinoid metabolism. Kedishvili NY, et al. **Adv Exp Med Biol** 1997; 414:321-9

P. putida formaldehyde dehydrogenase. An alcohol dehydrogenase masquerading as an aldehyde dehydrogenase. Oppenheimer NJ, et al. **Adv Exp Med Biol** 1997;414:417-23

Mechanistic enzymology of liver alcohol dehydrogenase. Kinetic and stereochemical characterization of retinal oxidation and reduction. Pocker Y, et al. **Adv Exp Med Biol** 1997;414:331-8

Activity of liver alcohol dehydrogenases on steroids. Strasser F, et al. **Adv Exp Med Biol** 1997;414:313-20

Expression, activities, and kinetic mechanism of human stomach alcohol dehydrogenase. Inference for first-pass metabolism of ethanol in mammals. Yin SJ, et al. **Adv Exp Med Biol** 1997;414:347-55

Alcohol dehydrogenases: a family of isozymes with differential functions. Holmes RS. **Alcohol Alcohol Suppl** 1994;2:127-30 (43 ref.)

Alcohol dehydrogenase: enzymology and metabolism. Yin SJ. **Alcohol Alcohol Suppl** 1994;2:113-9 (37 ref.)

Ethnic differences in gastric sigma-alcohol dehydrogenase activity and ethanol first-pass metabolism. Dohmen K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1569-76

Characteristics of alcohol dehydrogenases of certain aerobic bacteria representing human colonic flora. Nosova T, et al. **Alcohol Clin Exp Res** 1997 May;21(3):489-94

Bivalent cations stabilize yeast alcohol dehydrogenase I. Bolle XD, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):409-13

Biophysical and mutagenic analysis of Thermoanaerobacter ethanolicus secondary-alcohol dehydrogenase activity and specificity. Burdette DS, et al. **Biochem J** 1997 Sep 15;326 (Pt 3):717-24

Activation of grass carp liver alcohol dehydrogenase by limited proteolysis. Lau KK, et al. **Biochem Mol Biol Int** 1996 Dec;40(6):1095-103

Electrostatic effects in the kinetics of coenzyme binding to isozymes of alcohol dehydrogenase from horse liver. Adolph HW, et al. **Biochemistry** 1997 Jul 22;36(29):8743-54

Flexibility of liver alcohol dehydrogenase in stereoselective binding of 3-butylthiolane 1-oxides. Cho H, et al. **Biochemistry** 1997 Jan 14;36(2):382-9

Involvement of alcohol dehydrogenase, short-chain dehydrogenase/reductase, aldehyde dehydrogenase, and cytochrome P450 in the control of retinoid signaling by activation of retinoic acid synthesis. Duester G. **Biochemistry** 1996 Sep 24;35(38):12221-7 (79 ref.)

Inhibition of the catalytic activity of alcohol dehydrogenase by nitric oxide is associated with S nitrosylation and the release of zinc. Gergel D, et al. **Biochemistry** 1996 Dec 17;35(50):16186-94

Binding of formamides to liver alcohol dehydrogenase. Ramaswamy S, et al. **Biochemistry** 1997 Mar 25; 36(12):3522-7

Strain-dependent variation in the NADH-dependent diacetyl reductase activities of larger- and alebrewing yeasts. Murphy CA, et al. **Biotechnol Appl Biochem** 1996 Feb;23 (Pt 1):19-22

Secondary alcohol dehydrogenase as a marker of the conversion between progestagens and androgens in the rat testis. de Oliveira JA, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 May;43(3):305-11

The effects of disulfiram and related compounds on equine hepatic alcohol dehydrogenase. Langeland BT, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 May;117(1):55-61

Class IV alcohol/retinol dehydrogenase localization in epidermal basal layer: potential site of retinoic acid synthesis during skin development. Haselbeck RJ, et al. **Dev Dyn** 1997 Apr;208(4):447-53

Retinoic acid and alcohol/retinol dehydrogenase in the mouse adrenal gland: a potential endocrine source of retinoic acid during development. Haselbeck RJ, et al. **Endocrinology** 1997 Jul;138(7):3035-41

Re-face stereospecificity at C4 of NAD(P) for alcohol dehydrogenase from Methanogenium organophilum and for (R)-2-hydroxyglutarate dehydrogenase from Acidaminococcus fermentans as determined by 1H-NMR spectroscopy. Berk H, et al. **FEBS Lett** 1996 Dec 9; 399(1-2):92-4

Drosophila alcohol dehydrogenase: evaluation of Ser139 site-directed mutants. Cols N, et al. **FEBS Lett** 1997 Aug 18;413(2):191-3

Molecular modelling of human gastric alcohol dehydrogenase (class IV) and substrate docking: differences towards the classical liver enzyme (class I). Moreno A, et al. **FEBS Lett** 1996 Oct 21;395(2-3):99-102

Aldehyde dismutase activity of human liver alcohol dehydrogenase. Svensson S, et al. **FEBS Lett** 1996 Sep 30; 394(2):217-20

Human stomach alcohol and aldehyde dehydrogenases: comparison of expression pattern and activities in alimentary tract. Yin SJ, et al. **Gastroenterology** 1997 Mar; 112(3):766-75

Use of pH studies to determine the kinetic and chemical mechanism of yeast alcohol dehydrogenase with primary aliphatic alcohols and aldehydes. Leskovac V, et al. **Indian J Biochem Biophys** 1996 Jun;33(3):177-83

Alcohol dehydrogenase activity in mouse brown adipose tissue. Muralidhara DV, et al. **Indian J Physiol Pharmacol** 1996 Apr;40(2):167-70

Differences in environmental temperature, ethanol and sucrose associated with enzyme activity and weight changes in Drosophila melanogaster. Pecsenye K, et al. **Insect Biochem Mol Biol** 1996 Feb;26(2):135-45

Comparison of inactivation and unfolding of yeast alcohol dehydrogenase during denaturation in urea solutions. Zhang T, et al. **Int J Biol Macromol** 1996 Aug;19(2):113-9

Alkaline unfolding and salt-induced folding of yeast alcohol dehydrogenase under high pH conditions. Le WP, et al. **Int J Pept Protein Res** 1996 Jun;47(6):484-90

Differential inactivation of alcohol dehydrogenase

ALCOHOL DEHYDROGENASE

isoenzymes in Zymomonas mobilis by oxygen. Tamarit J, et al. **J Bacteriol** 1997 Feb;179(4):1102–4

Alcohol dehydrogenase–catalyzed reduction of protein carbonyl derivatives. Kingu CS, et al.
J Biochem Biophys Methods 1997 Feb 1;34(1):61–8

A thermophilic alcohol dehydrogenase from Bacillus acidocaldarius not reactive towards ketones. D'Auria S, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):498–504

Reduction of methylglyoxal in Escherichia coli K12 by an aldehyde reductase and alcohol dehydrogenase. Misra K, et al. **Mol Cell Biochem** 1996 Mar 23;156(2):117–24

Spaceflight exposure effects on transcription, activity, and localization of alcohol dehydrogenase in the roots of Arabidopsis thaliana. Porterfield DM, et al.
Plant Physiol 1997 Mar;113(3):685–93

Alteration of substrate specificity of Zymomonas mobilis alcohol dehydrogenase–2 using in vitro random mutagenesis. Rellos P, et al. **Protein Expr Purif** 1997 Feb; 9(1):83–90

Cysteine reactivity in Thermoanaerobacter brockii alcohol dehydrogenase. Peretz M, et al. **Protein Sci** 1997 May; 6(5):1074–83

PHARMACOLOGY

Oxidation of 3–butene–1,2–diol by alcohol dehydrogenase. Kemper RA, et al. **Chem Res Toxicol** 1996 Oct–Nov; 9(7):1127–34

PHYSIOLOGY

A study on ADH2 and ALDH2 genotyping by PCR–RFLP and SSCP analyses with description of allele and genotype frequencies in Japanese, Finn and Lapp populations. Suzuki K, et al. **Alcohol Alcohol** 1994;29 Suppl 1:21–7

In vitro alcohol dehydrogenase–mediated acetaldehyde production by aerobic bacteria representing the normal colonic flora in man. Jokelainen K, et al.
Alcohol Clin Exp Res 1996 Sep;20(6):967–72

First–pass metabolism of ethanol is negligible in rat gastric mucosa. Levitt MD, et al. **Alcohol Clin Exp Res** 1997 Apr; 21(2):293–7

Human hepatic alcohol dehydrogenase and human erythrocyte catalase do not metabolize the cytochrome P–4502E1 substrate, chlorzoxazone. McCarver–May DG, et al. **Alcohol Clin Exp Res** 1996 May;20(3):533–7

Genetic and physiological analysis of the lethal effect of L–(+)–lactate dehydrogenase deficiency in Streptococcus mutans: complementation by alcohol dehydrogenase from Zymomonas mobilis. Hillman JD, et al. **Infect Immun** 1996 Oct;64(10):4319–23

RADIATION EFFECTS

[The possible role of the elements of protein secondary structure in adaptation to the action of ionizing radiation] Kharchenko LI, et al. **Izv Akad Nauk Ser Biol** 1997 Jan–Feb;(1):5–10 (Eng. Abstr.) **(Rus)**

ALCOHOL DETERRENTS

ADVERSE EFFECTS

Effects of disulfiram on positron emission tomography and neuropsychological studies in severe chronic alcoholism. Gilman S, et al. **Alcohol Clin Exp Res** 1996 Nov; 20(8):1456–61

Secondary contact sensitivity to TMTD in patients primarily positive to TETD. Rebandel P, et al.
Contact Dermatitis 1996 Jul;35(1):48

Drug eruption induced by cyanamide (carbimide): a clinical and histopathologic study of 7 patients. Kawana S.
Dermatology 1997;195(1):30–4

Psychosis during disulfiram therapy for alcoholism. Murthy KK. **J Indian Med Assoc** 1997 Mar;95(3):80–1

Yellow palms with disulfiram [letter] Santonastaso M, et al. **Lancet** 1997 Jul 26;350(9073):266

[Collateral effects of disulfiram on the central nervous system in alcoholics that have become totally abstemious. Description of 8 cases] Maccari S, et al.
Ann Ital Med Int 1996 Oct–Dec;11(4):279–83 (Eng. Abstr.) **(Ita)**

[In the zone between drug insurance and patient insurance. A case of liver damage, requiring transplantation, caused by antabuse] Schmidt D. **Lakartidningen** 1996 Sep 18; 93(38):3262, 3265 **(Swe)**

METABOLISM

S–methyl–N,N–diethylthiocarbamate sulfoxide and S–methyl–N,N–diethylthiocarbamate sulfone, two candidates for the active metabolite of disulfiram. Mays DC, et al. **Alcohol Clin Exp Res** 1996 May;20(3):595–600

PHARMACOKINETICS

Studies on the metabolic activation of disulfiram in rat. Evidence for electrophilic S–oxygenated metabolites as inhibitors of aldehyde dehydrogenase and precursors of urinary N–acetylcysteine conjugates. Hu P, et al.
J Pharmacol Exp Ther 1997 May;281(2):611–7

PHARMACOLOGY

Discriminative stimulus effects of ethanol: lack of antagonism with N–methyl–D–aspartate and D–cycloserine. Bienkowski P, et al. **Alcohol** 1997 Jul–Aug;14(4):345–50

The mixed 5–HT 1A/2A receptor drug FG5938 suppresses alcohol drinking while enhancing feeding in P rats. Piercy KT, et al. **Alcohol** 1996 Sep–Oct;13(5):521–7

Naltrexone persistently reduces rats' intake of a palatable alcoholic beverage. Gardell LR, et al.
Alcohol Clin Exp Res 1996 May;20(3):584–8

Daidzin decreases ethanol consumption in rats. Heyman GM, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1083–7

Time course of acamprosate action on operant ethanol self–administration after ethanol deprivation. Hölter SM, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):862–8

Isoflavonoid compounds extracted from Pueraria lobata suppress alcohol preference in a pharmacogenetic rat model of alcoholism. Lin RC, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):659–63

Interactions between ethanol and agents that act on the NMDA–type glutamate receptor. Lovinger DM.
Alcohol Clin Exp Res 1996 Nov;20(8 Suppl):187A–191A

Acamprosate (calcium acetylhomotaurinate) enhances the N–methyl–D–aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. Madamba SG, et al. **Alcohol Clin Exp Res** 1996 Jun; 20(4):651–8

Effect of bestatin, an aminopeptidase inhibitor, on alcohol intake in alcohol–preferring P rats. Szczepanska R, et al. **Alcohol Clin Exp Res** 1996 May;20(3):561–5

Stimulation of the Ca(2+)–ATPase of sarcoplasmic reticulum by disulfiram. Starling AP, et al. **Biochem J** 1996 Nov 15;320 (Pt 1):101–5

Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Wilde MI, et al. **Drugs** 1997 Jun; 53(6):1038–53 (62 ref.)

The anti–craving drug acamprosate reduces c–fos expression in rats undergoing ethanol withdrawal. Putzke J, et al.
Eur J Pharmacol 1996 Dec 12;317(1):39–48

Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat. Spanagel R, et al.
Eur J Pharmacol 1996 Jun 3;305(1–3):51–6

Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Spanagel R, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):39–44

Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Spanagel R, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):45–50

Suppression of alcohol preference in high alcohol drinking rats: efficacy of amperozide versus naltrexone. Myers RD, et al. **Neuropsychopharmacology** 1996 Feb;14(2):139–49

Disulfiram causes sustained behavioral and biochemical effects in rats. Rahman MA, et al.
Pharmacol Biochem Behav 1997 Mar;56(3):409–15

Daidzin inhibits mitochondrial aldehyde dehydrogenase and suppresses ethanol intake of Syrian golden hamsters. Keung WM, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4; 94(5):1675–9

[The effect of cholecystokinin octapeptide on ethanol–induced changes in motor activity and in dopamine metabolism in the nucleus accumbens of the rat brain] Medvedeva OF, et al. **Eksp Klin Farmakol** 1996 Nov–Dec; 59(6):44–7 (Eng. Abstr.) **(Rus)**

[Brain glycolipids in rats after disulfiram administration] Selevich MI, et al. **Eksp Klin Farmakol** 1996 Sep–Oct; 59(5):47–8 (Eng. Abstr.) **(Rus)**

POISONING

Methemoglobinemia in a fatal case of disulfiram–ethanol reaction [letter] Stransky G, et al. **J Anal Toxicol** 1997 Mar–Apr;21(2):178–9

THERAPEUTIC USE

The efficacy of disulfiram: a review of outcome studies. Hughes JC, et al. **Addiction** 1997 Apr;92(4):381–95 (81 ref.)

Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Anton RF.
Alcohol Alcohol 1996 Mar;31 Suppl 1:43–53 (70 ref.)

Review of neurotransmitters and their role in alcoholism treatment. Erickson CK. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:5–11 (35 ref.)

Alcohol reinforcement and neuropharmacological therapeutics. Lewis MJ. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:17–25 (36 ref.)

The pharmacological treatment of alcohol dependence: needs and possibilities. Mann K. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:55–8 (30 ref.)

Pharmacotherapy of alcoholism––10 years of progress. Anton RF. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):172A–175A

New methodologies for pharmacological treatment trials for alcohol dependence. Anton RF. **Alcohol Clin Exp Res** 1996 Oct;20(7 Suppl):3A–9A (56 ref.)

Carbohydrate–deficient transferrin and gamma–glutamyl transferase levels during disulfiram therapy. Helander A, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1202–5

International update: new findings on promising medications. Litten RZ. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):216A–218A

Psychotherapeutic considerations in pharmacological trials. O'Malley SS, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7 Suppl):17A–22A (49 ref.)

Alternatives to naltrexone in animal models. Overstreet DH. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):231A–235A

Recent developments in the pharmacotherapy of alcohol dependence. Schuckit MA. **J Consult Clin Psychol** 1996 Aug;64(4):669–76 (82 ref.)

Gadolinium chloride blocks alcohol–dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1. Koop DR, et al.
Mol Pharmacol 1997 Jun;51(6):944–50

Research strategies to assess pharmacotherapies for alcoholism. Naranjo CA, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1996 May; 20(4):543–59 (40 ref.)

Medications development for alcohol use disorders. Wright C. **Psychopharmacol Bull** 1995;31(4):681–6 (1 ref.)

The efficacy of treatments in reducing alcohol consumption: a meta–analysis [letter; comment] Chick J.
Subst Use Misuse 1996 Jul;31(9):1081. Comment on: Int J Addict 1995 Jun;30(8):1067–77.

[Pharmacotherapy of alcoholism] Soyka M, et al.
Med Monatsschr Pharm 1996 Dec;19(12):359–64 (21 ref.) **(Ger)**

[The efficacy and mechanisms of action of lerivon in alcoholism] Ivanets NN, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1996;96(5):52–8 (Eng. Abstr.) **(Rus)**

[Pharmacological treatment of alcohol dependence. Acamprosate and naltrexone offer new approach] Berglund M, et al. **Lakartidningen** 1997 Jul 23;94(30–31):2645–8 (19 ref.) **(Swe)**

ALCOHOL DRINKING

see related
ALCOHOLISM
TEMPERANCE

Alcohol use among injured patients aged 12 to 18 years. Mannenbach MS, et al. **Acad Emerg Med** 1997 Jan;4(1):40–4

Casual sex, extramarital sex, condom use and alcohol intake among heterosexual patients attending an STD clinic in Norway. Tveit KS, et al. **Acta Derm Venereol** 1996 Mar; 76(2):150–3

The development of a brief scale to measure outcome expectations of reduced consumption among excessive drinkers. Rollnick S, et al. **Addict Behav** 1996 May–Jun; 21(3):377–87

Alcohol policy and aviation safety. Cook CC. **Addiction** 1997 Jul;92(7):793–804 (36 ref.)

The role of non–governmental organizations. Craplet M.
Addiction 1997 Mar;92 Suppl 1:S103–8

Treating grouped data as continuous in alcohol consumption measures. de Burgh S, et al. **Addiction** 1997 Jun; 92(6):667–72 (10 ref.)

Are reconstructed self–reports of drinking reliable? Grant KA, et al. **Addiction** 1997 May;92(5):601–6

Alcohol and sexual victimization: a longitudinal study of Norwegian girls. Pedersen W, et al. **Addiction** 1996 Apr; 91(4):565–81

Shades of grey: some observations on Sobell & Sobell's "Controlled drinking after 25 years: how important was the great debate?" [letter] Ryder D. **Addiction** 1996 Apr; 91(4):603–4

Selection bias in national surveys due to screening: implications from a county general population survey. Tam TW, et al. **Addiction** 1996 Apr;91(4):557–64

Alcohol outlet policies and practices concerning sales to underage people. Wolfson M, et al. **Addiction** 1996 Apr; 91(4):589–602

Ethanol intake after chronic intoxication by inhalation of ethanol vapour in rats: behavioural dependence. Aufrère G, et al. **Alcohol** 1997 May–Jun;14(3):247–53

The regulation of alcohol consumption in rats: the role of alcohol–metabolizing enzymes–catalase and aldehyde dehydrogenase. Gill K, et al. **Alcohol** 1996 Jul–Aug; 13(4):347–53

Differential efficacy of serotonergic drugs FG5974, FG5893, and amperozide in reducing alcohol drinking in P rats. Lankford MF, et al. **Alcohol** 1996 Jul–Aug;13(4):399–404

Opiate and 5–HT2A receptors in alcohol drinking: preference in HAD rats is inhibited by combination treatment with naltrexone and amperozide. Lankford MF, et al.
Alcohol 1996 Jan–Feb;13(1):53–7

Effects of bromocriptine on the voluntary consumption of ethanol, water, and solid food by UChA and UChB rats. Mardones J, et al. **Alcohol** 1996 Jul–Aug;13(4):355–7

In vivo genotoxicity of alcohol consumption and lead exposure in printing press workers. Rajah TT, et al.
Alcohol 1996 Jan–Feb;13(1):65–8

Endogenous opioids and alcohol dependence: opioid alkaloids and the propensity to drink alcoholic beverages. Reid LD. **Alcohol** 1996 Jan–Feb;13(1):5–11 (52 ref.)

The GABAergic system of the dentate gyrus after withdrawal from chronic alcohol consumption: effects of intracerebral grafting and putative neuroprotective agents. Cadete–Leite A, et al. **Alcohol Alcohol** 1997 Jul–Aug; 32(4):471–84

Effects of 5–HT3 receptor agonists on voluntary ethanol intake in rats maintained on a limited access procedure. Dyr W, et al. **Alcohol Alcohol** 1997 Jul–Aug;32(4):455–62

Increased carbohydrate–deficient transferrin during pregnancy and relation to sex hormones: %CDT will not yield false positive results [letter] Grimsrud K.
Alcohol Alcohol 1997 Jul–Aug;32(4):537–8

Alcoholism: a long-term follow-up study of participants in an alcohol treatment programme. Shaw GK, et al. **Alcohol Alcohol** 1997 Jul-Aug;32(4):527-35

Voices of the afflicted. Erickson CK. **Alcohol Clin Exp Res** 1996 Dec;20(9):1592-3

Effect of chronic ethanol consumption on the atrial natriuretic system of spontaneously hypertensive rats. Guillaume P, et al. **Alcohol Clin Exp Res** 1996 Dec; 20(9):1653-61

Norepinephrine and serotonin receptors in the paraventricular nucleus interactively modulate ethanol consumption. Hodge CW, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1669-74

Alcohol and cytokine-inducible transcription factors. Zeldin G, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1639-45 (36 ref.)

Alcohol consumption, gamma-glutamyl transpeptidase (GGT), and pulmonary function: a cross-sectional and longitudinal study in working men. Zureik M, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1507-11

Women and alcohol abuse in primary care. Identification and intervention. Chang G, et al. **Am J Addict** 1997 Summer; 6(3):183-92

AHA Science Advisory. Alcohol and heart disease. Nutrition Committee of the American Heart Association. Pearson TA. **Am J Clin Nutr** 1997 May;65(5):1567-9

Relation of body mass and alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Stamler J, et al. **Am J Clin Nutr** 1997 Jan;65(1 Suppl):338S-365S

The formation of cocaethylene and clinical presentation of ED patients testing positive for the use of cocaine and ethanol. Signs SA, et al. **Am J Emerg Med** 1996 Nov; 14(7):665-70

Re: "Reliability of alcohol intake as recalled from 10 years in the past" [letter; comment] Guggenmoos-Holzmann I, et al. **Am J Epidemiol** 1996 Dec 1;144(11):1086-7; discussion 1087-8. Comment on: Am J Epidemiol 1996 Jan 15;143(2):177-86.

Alcohol consumption and coronary heart disease morbidity and mortality. Rehm JT, et al. **Am J Epidemiol** 1997 Sep 15;146(6):495-501

Re: "Reliability of alcohol intake as recalled from 10 years in the past" [letter; comment] Russell M, et al. **Am J Epidemiol** 1996 Dec 1;144(11):1087; discussion 1087-8. Comment on: Am J Epidemiol 1996 Jan 15;143(2):177-86.

Chronic ethanol feeding in a high-fat diet decreases insulin-stimulated glucose transport in rat adipocytes. Wilkes JJ, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E477-84

Along for the ride: the prevalence of motor vehicle passengers riding with drivers who have been drinking in an American Indian population. Oken E, et al. **Am J Prev Med** 1995 Nov-Dec;11(6):375-80

The firewater myth and response to alcohol in Mission Indians. Garcia-Andrade C, et al. **Am J Psychiatry** 1997 Jul;154(7):983-8

Dose-response analyses of women's alcohol use during pregnancy and children's cognitive functioning [letter; comment] Decouflé P, et al. **Am J Public Health** 1997 Feb; 87(2):299-300; discussion 300-1. Comment on: Am J Public Health 1995 Dec;85(12):1654-61.

The early use of alcohol and tobacco: its relation to children's competence and parents' behavior. Jackson C, et al. **Am J Public Health** 1997 Mar;87(3):359-64

The effects of cigarette smoking and alcohol consumption on serum liver enzyme activities: a dose-related study in men. Whitehead TP, et al. **Ann Clin Biochem** 1996 Nov; 33 (Pt 6):530-5

Recent thinking about the concept of alcohol dependence. Caetano R. **Ann Epidemiol** 1996 Sep;6(5):458-62 (39 ref.)

Alcohol consumption during pregnancy and infant birth weight [letter] Larroque B, et al. **Ann Epidemiol** 1996 Mar; 6(2):169-70

Relationship between serum ferritin, alcohol intake, and social status in 2235 Danish men and women. Milman N, et al. **Ann Hematol** 1996 Mar;72(3):145-51

Acute post-rape plasma cortisol, alcohol use, and PTSD symptom profile among recent rape victims. Resnick HS, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:433-6

Alcohol consumption and smoking habits as determinants of blood lead levels in a national population sample from Germany. Weyermann M, et al. **Arch Environ Health** 1997 May-Jun;52(3):233-9

Alcohol use after traumatic brain injury: concordance of patients' and relatives' reports. Sander AM, et al. **Arch Phys Med Rehabil** 1997 Feb;78(2):138-42

Associations of age, adiposity, menopause, and alcohol intake with low-density lipoprotein subclasses. Williams PT, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1082-90

Alcohol and survival in the elderly: the Dubbo Study [letter; comment] Emder P. **Aust N Z J Med** 1997 Apr;27(2):185. Comment on: Aust N Z J Med 1996 Oct;26(5):662-70.

Alcohol intake and survival in the elderly: a 77 month follow-up in the Dubbo study [see comments] Simons LA, et al. **Aust N Z J Med** 1996 Oct;26(5):662-70. Comment in: Aust N Z J Med 1997 Apr;27(2):185.

Changes in the public perceptions of the health benefits of alcohol use, 1989 to 1994. Hall W. **Aust N Z J Public Health** 1996 Feb;20(1):93-5

Alcohol and workload as factors affecting the detection of angular acceleration. Mughni WN, et al. **Aviat Space Environ Med** 1996 Dec;67(12):1148-51

Increased oxidative damage to mitochondrial DNA following chronic ethanol consumption. Cahill A, et al. **Biochem Biophys Res Commun** 1997 Jun 18;235(2):286-90

The effect of light drinking on HCV liver disease: the jury is still out. Sachithanandan S, et al. **Biomed Pharmacother** 1997;51(6-7):295-7

Alcohol consumption and blood pressure in recently hospitalised patients. Howes JB, et al. **Blood Press** 1997 Mar;6(2):109-11

Genotype of cytochrome P450 2E1 and alcohol-related blood pressure elevation in Japanese men. Yamada Y, et al. **Blood Press** 1997 Mar;6(2):112-6

ABC of mental health. Addiction and dependence--II: Alcohol. Ashworth M, et al. **BMJ** 1997 Aug 9; 315(7104):358-60 (0 ref.)

Young people, alcohol, and designer drinks. Conventional drinks are a much greater threat to health than designer drinks [letter; comment] Catterson P, et al. **BMJ** 1997 May 31;314(7094):1622-3. Comment on: BMJ 1997 Feb 8;314(7078):414-8.

Designer drinks and drunkenness among schoolchildren. Study left several questions unanswered [letter; comment] Crawford A, et al. **BMJ** 1996 Nov 30;313(7069):1397; discussion 1397-8. Comment on: BMJ 1996 Aug 17;313(7054):401.

Wine may prevent dementia [news] Dorozynski A. **BMJ** 1997 Apr 5;314(7086):997

More women drink at hazardous levels in England than Italy [letter; comment] Kaner EF, et al. **BMJ** 1997 May 10; 314(7091):1413. Comment on: BMJ 1997 Feb 8;314(7078):420-4.

Designer drinks and drunkenness among schoolchildren. More "alcopops" have come on marker since study was done [letter; comment] McKibben MA. **BMJ** 1996 Nov 30;313(7069):1397; discussion 1397-8. Comment on: BMJ 1996 Aug 17;313(7054):401.

Moderate alcohol consumption has been shown previously to improve insulin sensitivity in men [letter; comment] Razay G, et al. **BMJ** 1997 Feb 8;314(7078):443-4. Comment on: BMJ 1996 Oct 26;313(7064):1040-4.

Do GPs agree with 'old' sensible drinking limits? [letter] Strang J, et al. **Br J Gen Pract** 1997 Apr;47(417):253-4

Effects of alcohol consumption on lateralized aggression in Anolis carolinensis. Deckel AW. **Brain Res** 1997 May 9; 756(1-2):96-105

Effects of the benzodiazepine inverse agonist RO19-4603 alone and in combination with the benzodiazepine receptor antagonists flumazenil, ZK 93426 and CGS 8216, on ethanol intake in alcohol-preferring (P) rats. June HL, et al. **Brain Res** 1996 Sep 23;734(1-2):19-34

Ethanol-induced c-Fos expression in rat lines selected for low and high alcohol consumption. Thiele TE, et al. **Brain Res** 1997 May 9;756(1-2):278-82

Adolescent alcohol use: social determinants and the case for early family-centered prevention. Family-focused prevention of adolescent drinking. Schor EL. **Bull N Y Acad Med** 1996 Winter;73(2):335-56 (86 ref.)

Moderate drinking and health. Implications of recent evidence. Ashley MJ, et al. **Can Fam Physician** 1997 Apr; 43:687-94 (85 ref.)

Moderate drinking [editorial] Wilson L. **Can Fam Physician** 1997 Apr;43:592-4, 600-2 **(Eng, Fre)**

The effects of maternal alcohol consumption and cigarette smoking during pregnancy on acoustic cry analysis. Nugent JK, et al. **Child Dev** 1996 Aug;67(4):1806-15

Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. Camargo CA Jr, et al. **Circulation** 1997 Feb 4;95(3):577-80

Nicotine, caffeine and alcohol use in high- and low-dose benzodiazepine users. Lekka NP, et al. **Drug Alcohol Depend** 1997 May 2;45(3):207-12

Utility of the AUDIT for identification of hazardous or harmful drinking in drug-dependent patients. Skipsey K, et al. **Drug Alcohol Depend** 1997 May 2;45(3):157-63

Characterization of the decline in alcohol consumption by aminopeptidase inhibition. Szczepanska R, et al. **Drug Alcohol Depend** 1996 Dec 11;43(3):133-41

Target marketing of tobacco and alcohol-related products to ethnic minority groups in the United States. Moore DJ, et al. **Ethn Dis** 1996 Winter-Spring;6(1-2):83-98 (56 ref.)

Association of alcohol consumption with HDL subpopulations defined by apolipoprotein A-I and apolipoprotein A-II content. Branchi A, et al. **Eur J Clin Nutr** 1997 Jun;51(6):362-5

Cigarette smoking is associated with differences in nutritional habits and related to lipoprotein alterations independently of food and alcohol intake. Dallongeville J, et al. **Eur J Clin Nutr** 1996 Oct;50(10):647-54

Alcohol beverage drinking, diet and body mass index in a cross-sectional survey. Männistö S, et al. **Eur J Clin Nutr** 1997 May;51(5):326-32

Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Blomqvist O, et al. **Eur J Pharmacol** 1996 Oct 31;314(3):257-67

Alcohol drinking is reduced by a mu 1- but not by a delta-opioid receptor antagonist in alcohol-preferring rats. Honkanen A, et al. **Eur J Pharmacol** 1996 May 23; 304(1-3):7-13

Effects of a range of dopamine receptor agonists and antagonists on ethanol intake in the rat. Silvestre JS, et al. **Eur J Pharmacol** 1996 Dec 30;318(2-3):257-65

The effect of alcohol ingestion on exhaled nitric oxide. Yates DH, et al. **Eur Respir J** 1996 Jun;9(6):1130-3

New benzamide-derived 5-HT3 receptor antagonists which prevent the effects of ethanol on extracellular dopamine, and fail to reduce voluntary alcohol intake in rats. Iusco G, et al. **Farmaco** 1997 Mar;52(3):141-6

Determination of absorption time of ethanol in social drinkers. Winek CL, et al. **Forensic Sci Int** 1996 Feb 9; 77(3):169-77

Alcohol consumption and seroconversion from hepatitis B e antigen in the Okinawa Japanese. Nomura H, et al. **Fukuoka Igaku Zasshi** 1996 Nov;87(11):237-41

Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Luca A, et al. **Gastroenterology** 1997 Apr;112(4):1284-9

Influence of alcohol on gastrointestinal motility: lactulose breath hydrogen testing in orocecal transit time in chronic alcoholics, social drinkers and teetotaler subjects. Addolorato G, et al. **Hepatogastroenterology** 1997 Jul-Aug; 44(16):1076-81

Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Donato F, et al. **Hepatology** 1997 Sep; 26(3):579-84

Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation. Foster PF, et al. **Hepatology** 1997 Jun;25(6):1469-77

Alcohol use after liver transplantation in alcoholics: a clinical cohort follow-up study. Lucey MR, et al. **Hepatology** 1997 May;25(5):1223-7

Serum IgA, IgG, and IgM antibodies directed against acetaldehyde-derived epitopes: relationship to liver disease severity and alcohol consumption. Viitala K, et al. **Hepatology** 1997 Jun;25(6):1418-24

Coffee and alcohol intake, smoking and risk of multiple pregnancy. Parazzini F, et al. **Hum Reprod** 1996 Oct; 11(10):2306-9

Interactions between alcohol and other drugs. Adams WL. **Int J Addict** 1995 Nov-Dec;30(13-14):1903-23

Oesophageal cancer in France: potential importance of hot alcoholic drinks. Launoy G, et al. **Int J Cancer** 1997 Jun 11;71(6):917-23

Alcohol, fish, fibre and antioxidant vitamins intake do not explain population differences in coronary heart disease mortality. Kromhout D, et al. **Int J Epidemiol** 1996 Aug; 25(4):753-9

Outcome of nursing home care for residents with alcohol use disorders. Joseph CL, et al. **Int J Geriatr Psychiatry** 1997 Jul;12(7):767-72

Effect of alcohol on tumor growth of hepatocellular carcinoma with type C cirrhosis. Matsuhashi T, et al. **Intern Med** 1996 Jun;35(6):443-8

A case-control study on alcohol and seizures: study design, protocol, and data collection. The ALCE (Alcohol and Epilepsy) Study Group. Leone M, et al. **Ital J Neurol Sci** 1997 Apr;18(2):119-24

Does alcohol contribute to accident and emergency department attendance in elderly people? van der Pol V, et al. **J Accid Emerg Med** 1996 Jul;13(4):258-60

Influence of moderate daily wine consumption on body weight regulation and metabolism in healthy free-living males [see comments] Cordain L, et al. **J Am Coll Nutr** 1997 Apr;16(2):134-9. Comment in: J Am Coll Nutr 1997 Apr;16(2):105-6.

Let's not overlook nicotine [letter] Roll JM, et al. **J Anal Toxicol** 1996 Mar-Apr;20(2):143

The sure proof. Wine is sure proof that God loves us and wants us to be happy [editorial] Abel L. **J Ark Med Soc** 1996 Dec;93(7):316-8

The critical role of alcohol consumption in determining the risk of breast cancer with postmenopausal estrogen administration [editorial; comment] Zumoff B. **J Clin Endocrinol Metab** 1997 Jun;82(6):1656-8 (26 ref.). Comment on: J Clin Endocrinol Metab 1997 Jul;82(7):2378. "Conflicts of interest" and "political science". Seltzer CC. **J Clin Epidemiol** 1997 May;50(5):627-9

Insomnia, alcohol, and over-the-counter drug use in old-old urban women. Johnson JE. **J Community Health Nurs** 1997; 14(3):181-8

Gender differences in the relations between depressive symptoms and drinking behavior among problem drinkers: a three-wave study. Schutte KK, et al. **J Consult Clin Psychol** 1997 Jun;65(3):392-404

Smoking and alcohol consumption in Trent, UK: an analysis of item non-response. Dengler R. **J Epidemiol Community Health** 1996 Dec;50(6):687

Alcohol is not a dichotomous variable [editorial; comment] Vinson DC. **J Fam Pract** 1997 Feb;44(2):147-9. Comment on: J Fam Pract 1997 Feb;44(2):151-60.

Lack of interaction between hepatitis C virus and alcohol in the pathogenesis of cirrhosis. A statistical study. Alemy-Carreau M, et al. **J Hepatol** 1996 Nov;25(5):627-32

Alcohol and hypertension--kill or cure? Beilin LJ, et al. **J Hum Hypertens** 1996 Feb;10 Suppl 2:S1-5 (56 ref.)

Moderate beer consumption and the blood coagulation in patients with coronary artery disease. Gorinstein S, et al. **J Intern Med** 1997 Jan;241(1):47-51

Alcohol consumption, drinking pattern and acute myocardial infarction. A case referent study based on the Swedish Twin Register. Hammar N, et al. **J Intern Med** 1997 Feb; 241(2):125-31

Alcohol and coronary heart disease: the roles of HDL-cholesterol and smoking. Mänttäri M, et al. **J Intern Med** 1997 Feb;241(2):157-63

A 48-week natural history follow-up of alcoholics who do and do not engage in limited drinking after treatment. Watson CG, et al. **J Nerv Ment Dis** 1996 Oct;184(10):623-7

Effects of chronic ethanol consumption and aging on dopamine, serotonin, and metabolites. Woods JM, et al. **J Neurochem** 1996 May;66(5):2168-78

Platelets, alcohol consumption, and onset of brain infarction. Numminen H, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):376-80

Chronic alcohol consumption and withdrawal do not induce cell death in the suprachiasmatic nucleus, but lead to irreversible depression of peptide immunoreactivity and mRNA levels. Madeira MD, et al. **J Neurosci** 1997 Feb 15;17(4):1302-19

Tobacco, caffeine, alcohol, and carpal tunnel syndrome in American industry. A cross-sectional study of 1464 workers. Nathan PA, et al. **J Occup Environ Med** 1996 Mar;38(3):290-8

Alcohol consumption among Oklahoma women: before and during pregnancy. The PRAMS Working Group. Pregnancy Risk Assessment Monitoring System. Cloud SJ, et al. **J Okla State Med Assoc** 1997 Jan;90(1):10-7

Factors in adolescent drinking/driving: binge drinking, cigarette smoking, and gender. Copeland LA, et al. **J Sch Health** 1996 Sep;66(7):254-60

College students' high-risk sexual behavior following alcohol consumption. Anderson PB, et al. **J Sex Marital Ther** 1996 Winter;22(4):259-64

Drinking environment and sociodemographic factors among DWI offenders. Chang I, et al. **J Stud Alcohol** 1996 Nov; 57(6):659-69

Alcohol-related measures as factors in traffic fatalities. Mann RE, et al. **J Stud Alcohol** 1996 Nov;57(6):646-51

An alcohol involvement typology for adolescents: convergent validity and longitudinal stability. Windle M. **J Stud Alcohol** 1996 Nov;57(6):627-37

Controlled drinking as a treatment goal in Australian alcohol treatment agencies. Dawe S, et al. **J Subst Abuse Treat** 1997 Jan-Feb;14(1):81-6

Risk-taking behaviors among adolescent trauma patients. Spain DA, et al. **J Trauma** 1997 Sep;43(3):423-6

Breath alcohol concentrations in men 7-8 hours after prolonged, heavy drinking: influence of habitual alcohol intake [letter] Wright NR. **Lancet** 1997 Jan 18;349(9046):182

The visibility and effectiveness of standard drink labelling [letter] Chan MD, et al. **Med J Aust** 1997 Sep 15;167(6):344

Comparison of alcohol consumption patterns and social problems between women and men drink-drivers. Rogers DM, et al. **Med J Aust** 1997 Apr 7;166(7):358-61

Reported alcohol use and behavior in long-distance runners. Gutgesell ME, et al. **Med Sci Sports Exerc** 1996 Aug; 28(8):1063-70

Alcohol and minor trauma. Ryan CW. **Mil Med** 1997 Apr; 162(4):292-5

Alcohol involvement in fatal motor-vehicle crashes--United States, 1994-1995. **MMWR Morb Mortal Wkly Rep** 1996 Dec 6;45(48):1060, 1067

Public knowledge and attitudes towards the use of alcohol and drinking guidelines. Sellman JD, et al. **N Z Med J** 1996 Sep 13;109(1029):337-9

Death and the demon drink in Russia [news] Lincoln T. **Nature** 1997 Aug 21;388(6644):723

Effects of ethanol on the levels of brain 6R-L-erythro-5, 6, 7, 8-tetrahydrobiopterin in the inbred strains of mice. DBA/2J, C3H/HeJ and C57BL/6J with different alcohol preferences. Yoshimoto K, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1997 Apr; 32(2):139-48

Nutrient intake according to education, smoking, and alcohol in Italian women. D'Avanzo B, et al. **Nutr Cancer** 1997; 28(1):46-51

The saliva solution: new choices for alcohol testing. Wilson F, et al. **Occup Health Saf** 1997 Apr;66(4):40-3

The influence of alcohol consumption on the risk of vertebral deformity. European Vertebral Osteoporosis Study Group. Naves Diaz M, et al. **Osteoporos Int** 1997;7(1):65-71

The relationship between drinking status and serial changes of pancreatographic findings in patients with suspected early chronic alcoholic pancreatitis. Maejima S, et al. **Pancreas** 1996 Aug;13(2):209-14

Serotonergic receptors modify the voluntary intake of alcohol and morphine but not of cocaine and nicotine by rats. Mosner A, et al. **Pharmacology** 1997 Apr;54(4):186-92

Alcohol as a food: a commentary on Richter. Gill K, et al. **Physiol Behav** 1996 Dec;60(6):1485-90

Short-term effects of alcohol consumption on appetite and energy intake. Poppitt SD, et al. **Physiol Behav** 1996 Oct; 60(4):1063-70

Moderate alcohol consumption and vitamin C status in the guinea-pig and the rat. Zloch Z, et al. **Physiol Res** 1995; 44(3):173-8

The effects of alcohol on the heart: detrimental or beneficial? Figueredo VM. **Postgrad Med** 1997 Feb;101(2):165-8, 171-2, 175-6 (24 ref.)

Daidzin inhibits mitochondrial aldehyde dehydrogenase and suppresses ethanol intake of Syrian golden hamsters. Keung WM, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4; 94(5):1675-9

Regular alcohol consumption mimics cardiac preconditioning by protecting against ischemia-reperfusion injury. Miyamae M, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3235-9

Lesioning of midbrain raphe nuclei with 5,7-DHT fails to alter ethanol intake in the low alcohol drinking (LAD) rat. Adell A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Apr; 20(3):473-81

Preference for diazepam, but not buspirone, in moderate drinkers. Evans SM, et al. **Psychopharmacology (Berl)** 1996 Jan;123(2):154-63

Facilitation of ethanol consumption by intracerebroventricular infusions of corticosterone. Fahlke C, et al. **Psychopharmacology (Berl)** 1996 Sep;127(2):133-9

Neurotensin attenuates the reduction in alcohol drinking produced by angiotensin II. Grupp LA, et al. **Psychopharmacology (Berl)** 1996 May;125(1):57-64

Alcohol consumption modifies the total lung capacity in smokers. Ström K, et al. **Respiration** 1996;63(2):66-72

Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Orgogozo JM, et al. **Rev Neurol (Paris)** 1997 Apr;153(3):185-92

Sports, physical exercise and use of alcohol. Watten RG. **Scand J Med Sci Sports** 1995 Dec;5(6):364-8

Socioeconomic level, sedentary lifestyle, and wine consumption as possible explanations for geographic distribution of cerebrovascular disease mortality in Spain. Rodríguez Artalejo F, et al. **Stroke** 1997 May;28(5):922-8

Alcohol consumption by undergraduate students. Basten CJ, et al. **Subst Use Misuse** 1996 Aug;31(10):1379-99

Alcohol use following liver transplantation for alcoholic cirrhosis. Gerhardt TC, et al. **Transplantation** 1996 Oct 27; 62(8):1060-3

[How valid are self-reported intakes of beer, wine and spirits in population studies? (published erratum appears in Ugeskr Laeger 1997 Jul 7;159(28):4414)] Grønbaek MN, et al. **Ugeskr Laeger** 1997 May 19;159(21):3151-4 (Eng. Abstr.) **(Dan)**

[Alcohol consumption, S-LDL-cholesterol and risk of ischemic heart disease. 6-year follow-up in The Copenhagen Male Study] Hein HO, et al. **Ugeskr Laeger** 1997 Jun 23;159(26):4110-6 (Eng. Abstr.) **(Dan)**

[Alcohol and coronary disease (see comments)] van de Wiel A, et al. **Ned Tijdschr Geneeskd** 1996 Aug 31; 140(35):1755-9 (27 ref.). Comment in: Ned Tijdschr Geneeskd 1996 Oct 19;140(42):2102. **(Dut)**

[How much alcohol is good for health?] Poikolainen K. **Duodecim** 1995;111(14):1314-7 **(Fin)**

[Alcohol, wine and cardiovascular risk (editorial)] Richard JL. **Arch Mal Coeur Vaiss** 1996 Sep;89(9):1115-6 **(Fre)**

[Consumption, attitudes and knowledge on compared alcoholic beverages among high school and university students] Cocchioni M, et al. **Ann Ig** 1997 Jan-Feb; 9(1):89-97 **(Ita)**

[Is TLFB method applicable to Japanese drinking population?: a methodological study on measurement of alcohol consumption] Shimizu S, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1997 Jun; 32(3):163-81 (Eng. Abstr.) **(Jpn)**

[Behavioral pharmacological studies on the effects of cocaine on alcohol preference in inbred strain of mouse C57BL/6J] Uemura K. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1997 Feb;32(1):59-77 (Eng. Abstr.) **(Jpn)**

[A study on the relationship between sources of health information concerning smoking and drinking, and health behavior] Kubo N, et al. **Nippon Eiseigaku Zasshi** 1996 Jul;51(2):579-87 (Eng. Abstr.) **(Jpn)**

[Reduction of alcohol consumption and its effect on Na(+)-K(+)-ATPase activity of red blood cell membrane] Kurosawa Y, et al. **Nippon Eiseigaku Zasshi** 1997 Jan;51(4):749-54 (Eng. Abstr.) **(Jpn)**

[When should we start to drink? (letter)] Foss OP. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1184 **(Nor)**

[Perceived access to alcohol among lower secondary school students. A longitudinal study] Klepp KI, et al. **Tidsskr Nor Laegeforen** 1996 Oct 30;116(26):3132-5 (Eng. Abstr.) **(Nor)**

[Alcohol as a "heart drug". Beneficial for the individual? Harmful for the general population!] Riise G, et al. **Tidsskr Nor Laegeforen** 1997 Feb 20;117(5):713 **(Nor)**

[Alcohol and public health (letter)] Riise G, et al. **Tidsskr Nor Laegeforen** 1997 May 10;117(12):1810-1 **(Nor)**

[Alcohol as an agent against coronary heart disease--flippancy or fact? (see comments)] Skovenborg E, et al. **Tidsskr Nor Laegeforen** 1997 Feb 20;117(5):708-12 (40 ref.) . Comment in: Tidsskr Nor Laegeforen 1997 Mar 20;117(8):1184. **(Nor)**

[Norwegian policy on alcohol use and the Norwegian Medical Society (letter; comment)] Thorsby E. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1184. Comment on: Tidsskr Nor Laegeforen 1997 Feb 20;117(5):708-12. **(Nor)**

[Characteristics of tyrosine hydroxylase gene expression in the brain of rats with different ethanol consumption after chronic alcoholic intoxication] Anokhina IP, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):63-5 **(Rus)**

[Relation between the quantity, type and duration of alcohol drinking and the development of alcoholic liver cirrhosis] Hozo I, et al. **Med Arh** 1995;49(1-2):5-8 (Eng. Abstr.) **(Scr)**

[Alcohol consumption and adolescence: a descriptive epidemiological study] Alonso Hernández J, et al. **Aten Primaria** 1997 Mar 15;19(4):183-7 (Eng. Abstr.) **(Spa)**

[A multicenter primary care study on alcohol consumption] Bueno Ortiz JM, et al. **Aten Primaria** 1997 Feb 15; 19(2):80-3 (Eng. Abstr.) **(Spa)**

[Effectiveness of brief medical counseling to reduce drinkers' alcohol consumption] Fernández San Martín MI, et al. **Aten Primaria** 1997 Feb 28;19(3):127-32 (Eng. Abstr.) **(Spa)**

[Relationship between family perception and alcohol consumption (see comments)] Rodríguez Fernández E, et al. **Aten Primaria** 1997 Feb 28;19(3):117-21 (Eng. Abstr.) . Comment in: Aten Primaria 1997 Jun 30;20(2):110-2. **(Spa)**

[Alcohol, health and society: European charter on alcohol (letter)] Alvarez González FJ, et al. **Gac Sanit** 1996 Jul-Aug;10(55):197-9 **(Spa)**

[Mortality related to alcohol consumption in Spain: 1981-1990] Prada Puentes C, et al. **Gac Sanit** 1996 Jul-Aug; 10(55):161-8 (Eng. Abstr.) **(Spa)**

[Ecological correlation between consumption of alcoholic beverages and liver cirrhosis mortality in Mexico] Narro-Robles J, et al. **Salud Publica Mex** 1997 May-Jun; 39(3):217-20 (Eng. Abstr.) **(Spa)**

[When does alcohol trigger violence? "Emotional blindness" and impulsiveness are important links] Heilig M. **Lakartidningen** 1997 Mar 5;94(10):841-4 (37 ref.) **(Swe)**

[Increased pressure on health care services with liberal alcohol policy] Lind J. **Lakartidningen** 1996 Oct 9; 93(41):3532-3 **(Swe)**

ADVERSE EFFECTS

Alcohol use among pedestrians and the odds of surviving an injury: evidence from Florida law enforcement data. Miles-Doan R. **Accid Anal Prev** 1996 Jan;28(1):23-31

Alcohol and occupational injuries among older workers. Zwerling C, et al. **Accid Anal Prev** 1996 May;28(3):371-6

Conversation with Albert Tuyns [interview] **Addiction** 1996 Jan;91(1):17-33

Guidelines on sensible drinking. Anderson P, et al. **Addiction** 1996 Jan;91(1):25-33

Alcohol and aviation. Cook CC. **Addiction** 1997 May; 92(5):539-55 (101 ref.)

Lost productivity and costs to society. Godfrey C. **Addiction** 1997 Mar;92 Suppl 1:S49-54

Drinking and driving: drinking patterns and drinking problems. Gruenewald PJ, et al. **Addiction** 1996 Nov; 91(11):1637-49

The New Zealand Rugby Injury and Performance Project: alcohol use patterns within a cohort of rugby players. Quarrie KL, et al. **Addiction** 1996 Dec;91(12):1865-8

Alcohol and health: individual and population perspectives. Rehm J, et al. **Addiction** 1997 Mar;92 Suppl 1:S109-15

From research to policy: when cutting edge meets coalface. Richmond R. **Addiction** 1996 Jan;91(1):35-7

Place of work, communities and municipalities. Ritson B. **Addiction** 1997 Mar;92 Suppl 1:S127-32

The effects of alcohol on the heart. Patel VB, et al. **Adverse Drug React Toxicol Rev** 1997 Mar;16(1):15-43 (155 ref.)

Alcohol intake in a rural village: physical signs and biological markers predicting excessive consumption in apparently healthy people. Santolaria F, et al. **Alcohol** 1997 Jan-Feb; 14(1):9-19

Maternal alcohol consumption and spontaneous abortion. Abel EL. **Alcohol Alcohol** 1997 May-Jun;32(3):211-9 (45 ref.)

Mortality and morbidity related to alcohol. Andreasson S, et al. **Alcohol Alcohol** 1997 Mar-Apr;32(2):173-8

Alcohol-related diseases in general hospital patients. Gerke P, et al. **Alcohol Alcohol** 1997 Mar-Apr;32(2):179-84

The effects of alcohol on eye movements during reading. Watten RG, et al. **Alcohol Alcohol** 1997 May-Jun; 32(3):275-80

Israeli Arab and Jewish youth knowledge and opinion about alcohol warning labels: pre-intervention data. Weiss S. **Alcohol Alcohol** 1997 May-Jun;32(3):251-7

Increased susceptibility of experimental animals to infectious organisms as a consequence of ethanol consumption. Jerrells TR, et al. **Alcohol Alcohol Suppl** 1994;2:425-30 (36 ref.)

Drinking patterns and problems and drinking in the event: an analysis of injury by cause among casualty patients. Cherpitel CJ. **Alcohol Clin Exp Res** 1996 Sep;20(6):1130-7

Effect of bedtime alcohol on inspiratory resistance and respiratory drive in snoring and nonsnoring men. Dawson A, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):183-90

Relation between executive cognitive functioning and the adverse consequences of alcohol use in social drinkers. Giancola PR, et al. **Alcohol Clin Exp Res** 1996 Sep; 20(6):1094-8

Alcohol consumption by young actively growing rats: a study of cortical bone histomorphometry and mechanical properties. Hogan HA, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):809-16

Increased acetaldehyde production by mouthwashings from patients with oral cavity, laryngeal, or pharyngeal cancer. Jokelainen K, et al. **Alcohol Clin Exp Res** 1996 Oct; 20(7):1206-10

Alcohol, cytokines, and estrogen in the control of bone

remodeling. Kimble RB. **Alcohol Clin Exp Res** 1997 May; 21(3):385–91 (85 ref.)
Alcohol–induced bone disease: impact of ethanol on osteoblast proliferation. Klein RF.
Alcohol Clin Exp Res 1997 May;21(3):392–9 (112 ref.)
Effects of ethanol consumption on susceptibility to pulmonary and gastrointestinal factors. Mellencamp MA.
Alcohol Clin Exp Res 1996 Nov;20(8 Suppl):192A–195A
Effect of alcohol drinking on gene expression of hepatic O6–methylguanine DNA methyltransferase in chronic liver diseases. Miyakawa H, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):297A–300A
Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Mochida S, et al.
Alcohol Clin Exp Res 1996 Dec;20(9 Suppl):371A–377A
Does moderate alcohol intake reduce fecundability? A European multicenter study on infertility and subfecundity. European Study Group on Infertility and Subfecundity. Olsen J, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):206–12
Alcohol and the gastrointestinal tract. Preedy VR.
Alcohol Clin Exp Res 1996 Nov;20(8 Suppl):48A–50A
Alcohol consumption inhibits bone growth and development in young actively growing rats. Sampson HW, et al.
Alcohol Clin Exp Res 1996 Nov;20(8):1375–84
Alcohol, osteoporosis, and bone regulating hormones. Sampson HW. **Alcohol Clin Exp Res** 1997 May;21(3):400–3 (45 ref.)
Neuroendocrine–immune axis of alcoholics. Sarkar DK.
Alcohol Clin Exp Res 1996 Nov;20(8 Suppl):256A–259A
Alcohol and breast cancer: interactions between alcohol and other risk factors. Singletary KW.
Alcohol Clin Exp Res 1996 Nov;20(8 Suppl):57A–61A
Alcohol use disorders, consumption patterns, and health–related quality of life of primary care patients. Volk RJ, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):899–905
The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Whitfield RM, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):122–7
High alcohol–related premature mortality in France: concordant estimates from a prospective cohort study and national mortality statistics. Zureik M, et al.
Alcohol Clin Exp Res 1996 May;20(3):428–33
Smoking, alcohol consumption, and leukocyte counts. Parry H, et al. **Am J Clin Pathol** 1997 Jan;107(1):64–7
Effects of cigarette smoking, caffeine consumption, and alcohol intake on fecundability. Curtis KM, et al.
Am J Epidemiol 1997 Jul 1;146(1):32–41
Dietary calcium, alcohol, and incidence of treated hypertension in the NHANES I epidemiologic follow–up study. Dwyer JH, et al. **Am J Epidemiol** 1996 Nov 1; 144(9):828–38
Effects of maternal cigarette smoking and alcohol consumption on blood lead levels of newborns. Rhainds M, et al. **Am J Epidemiol** 1997 Feb 1;145(3):250–7
Nutritional deficiencies in chronic alcoholics: relation to dietary intake and alcohol consumption. Glória L, et al.
Am J Gastroenterol 1997 Mar;92(3):485–9
Safer sex behavior and alcohol consumption. Research Group of the Swiss HIV Prevention Study. Läuchli S, et al.
Ann Epidemiol 1996 Jul;6(4):357–64
Alcohol intake and cardiac hypertrophy in hypertensive patients [letter] Ishimitsu T. **Ann Intern Med** 1997 Apr 15; 126(8):666
Alcohol and the young. Graham P. **Arch Dis Child** 1996 Nov; 75(5):361–3 (20 ref.)
Short term and long term effects of alcohol on blood pressure, cardiovascular risk and all cause mortality. Sleight P. **Blood Press** 1996 Jul;5(4):201–5 (24 ref.)
Alcohol consumption may influence onset of the menopause [letter; comment] Torgerson DJ, et al. **BMJ** 1997 Jul 19; 315(7101):188. Comment on: BMJ 1997 Apr 19;314(7088):1159–64.
Alcohol, tobacco and oesophageal cancer: effects of the duration of consumption, mean intake and current and former consumption. Launoy G, et al. **Br J Cancer** 1997; 75(9):1389–96
Alcohol and the heart. Cowie MR. **Br J Hosp Med** 1997 May 7–20;57(9):457–60 (23 ref.)
Alcohol and the liver. Hills KS, et al. **Br J Hosp Med** 1997 May 21–Jun 3;57(10):517–21 (15 ref.)
Alcohol and the brain. Scheepers BD. **Br J Hosp Med** 1997 Jun 4–17;57(11):548–51 (16 ref.)
Long–term cognitive effects of drinking [letter] Kenny P. **Can Fam Physician** 1997 Aug;43:1341–3
Alcohol consumption in early pregnancy. How much will harm a fetus? Koren G. **Can Fam Physician** 1996 Nov; 42:2141–3
Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow–up. Malatjalian DA, et al. **Can J Gastroenterol** 1996 Oct;10(6):369–75
The influence of cigarette smoking, alcohol, and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai, China [letter; comment] Galanis DJ, et al. **Cancer** 1997 May 1;79(9):1840–1. Comment on: Cancer 1996 Jun 15;77(12):2449–57.
Multiple myeloma among Blacks and Whites in the United States: role of cigarettes and alcoholic beverages. Brown LM, et al. **Cancer Causes Control** 1997 Jul;8(4):610–4
Drinking practices and risk of squamous–cell esophageal cancer among Black and White men in the United States. Brown LM, et al. **Cancer Causes Control** 1997 Jul; 8(4):605–9
A nested case–control study on alcohol drinking, tobacco smoking, and cancer. Murata M, et al.
Cancer Detect Prev 1996;20(6):557–65
Alcohol, cigarette smoking, and the risk of breast cancer. Ranstam J, et al. **Cancer Detect Prev** 1995;19(6):487–93
Effects of diet and ethanol treatment on azoxymethane–induced liver and gastrointestinal neoplasia of male rats. Hakkak R, et al. **Cancer Lett** 1996 Oct 22; 107(2):257–64
Diet and heart disease. The role of fat, alcohol, and antioxidants. Gaziano JM, et al. **Cardiol Clin** 1996 Feb; 14(1):69–83 (130 ref.)
Red wine–induced release of [14C]5–hydroxytryptamine from platelets of migraine patients and controls. Jarman J, et al. **Cephalalgia** 1996 Feb;16(1):41–3
Adverse reactions to alcoholic beverages: a diagnostic guideline [letter; comment] Wantke F, et al.
Clin Exp Allergy 1997 Mar;27(3):343. Comment on: Clin Exp Allergy 1996 Sep;26(9):1089–91.
Maternal assessment of infant development: associations with alcohol and drug use in pregnancy. Seagull FN, et al.
Clin Pediatr (Phila) 1996 Dec;35(12):621–8
Alcohol ingestion and glycaemic control in patients with insulin–dependent diabetes mellitus. Meeking DR, et al.
Diabet Med 1997 Apr;14(4):279–83 (46 ref.)
A prospective study of alcohol, smoking, caffeine, and the risk of duodenal ulcer in men. Aldoori WH, et al.
Epidemiology 1997 Jul;8(4):420–4
The relation of alcohol intake to coronary heart disease and all–cause mortality in a beer–drinking population. Keil U, et al. **Epidemiology** 1997 Mar;8(2):150–6
The effect of maternal drinking before conception and in early pregnancy on infant birthweight. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood [see comments] Passaro KT, et al.
Epidemiology 1996 Jul;7(4):377–83. Comment in: Epidemiology 1997 Jan;8(1):112–3.
Increased cancer risk among Swedish female alcoholics. Sigvardsson S, et al. **Epidemiology** 1996 Mar;7(2):140–3
Alcohol consumption and breast cancer risk among women under age 45 years [see comments] Swanson CA, et al.
Epidemiology 1997 May;8(3):231–7. Comment in: Epidemiology 1997 May;8(3):225–7.
Sobering data on alcohol and breast cancer [editorial; comment] Willett WC, et al. **Epidemiology** 1997 May; 8(3):225–7. Comment on: Epidemiology 1997 May;8(3):231–7.
Moderate maternal alcohol consumption and risk of spontaneous abortion. Windham GC, et al. **Epidemiology** 1997 Sep;8(5):509–14
Moderate maternal drinking and infant birthweight [letter; comment] Windham GC, et al. **Epidemiology** 1997 Jan; 8(1):112–3. Comment on: Epidemiology 1996 Jul;7(4):377–83.
Lifestyle factors including diet and cancer of the gallbladder and bile duct: a population–based case–control study in The Netherlands. Moerman CJ, et al.
Eur J Cancer Prev 1997 Apr;6(2):139–42
Influence of dose and cessation of kiraiku, cigarettes and alcohol use on the risk of developing oral leukoplakia. Macigo FG, et al. **Eur J Oral Sci** 1996 Oct–Dec; 104(5–6):498–502
Influence of moderate alcohol consumption on obstructive sleep apnoea with and without AutoSet nasal CPAP therapy. Teschler H, et al. **Eur Respir J** 1996 Nov; 9(11):2371–7
Drinking habits and occupational exposure to xenobiotics: a review. Bisio S, et al. **G Ital Med Lav** 1995 Jan–Nov; 17(1–6):37–40 (32 ref.)
Alcohol and rhythm disturbance: the holiday heart syndrome. Menz V, et al. **Herz** 1996 Aug;21(4):227–31 (33 ref.)
Hypothermia, slow pulse, and an unusual QRS complex. Hancock EW. **Hosp Pract (Off Ed)** 1996 Nov 15; 31(11):25–6
Differentiation of visibility and alcohol as contributors to twilight road fatalities. Owens DA, et al. **Hum Factors** 1996 Dec;38(4):680–9
Nitrosamines, alcohol, and gastrointestinal tract cancer: recent epidemiology and experimentation. Chhabra SK, et al. **In Vivo** 1996 May–Jun;10(3):265–84 (221 ref.)
Ki–ras mutations in exocrine pancreatic cancer: association with clinico–pathological characteristics and with tobacco and alcohol consumption. PANK–ras I Project Investigators. Malats N, et al. **Int J Cancer** 1997 Mar 17; 70(6):661–7
Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma. Wu AH, et al. **Int J Cancer** 1997 Mar 4;70(5):512–7
Cancer screening of upper aerodigestive tract in Japanese alcoholics with reference to drinking and smoking habits and aldehyde dehydrogenase–2 genotype. Yokoyama A, et al. **Int J Cancer** 1996 Nov 4;68(3):313–6
Alcohol consumption and heart failure in hypertensives. Olubodun JO, et al. **Int J Cardiol** 1996 Jan;53(1):81–5
Drinking triples orally supplemented estrogen level [news] **Int J Fertil Womens Med** 1997 Jan–Feb;42(1):17
Acute renal failure and alcohol [editorial; comment] Kaizu K. **Intern Med** 1997 Feb;36(2):80. Comment on: Intern Med 1997 Feb;36(2):102–6.
Alcohol intake increases hepatitis C virus–induced hepatocellular injury. Katakami Y, et al. **Intern Med** 1995 Dec;34(12):1153–7
Acute renal failure after binge drinking of alcohol and nonsteroidal antiinflammatory drug ingestion [see comments] Tsuboi N, et al. **Intern Med** 1997 Feb; 36(2):102–6. Comment in: Intern Med 1997 Feb;36(2):80.
Alcoholic and non–alcoholic Wernicke's encephalopathy. Be alert to the preventable and treatable disease [editorial; comment] Yamamoto T. **Intern Med** 1996 Oct;35(10):754–5 . Comment on: Intern Med 1996 Oct;35(10):831–4.
Relationship of alcohol use and risky sexual behavior: a review and analysis of findings. Halpern–Felsher BL, et al. **J Adolesc Health** 1996 Nov;19(5):331–6 (42 ref.)
Alcohol availability and motor vehicle fatalities. Kelleher KJ, et al. **J Adolesc Health** 1996 Nov;19(5):325–30
Alcohol availability and motor vehicle fatalities [letter] Tonkin RS. **J Adolesc Health** 1997 Aug;21(2):74–5
Alcohol–induced asthma: not only in Asians [letter; comment] Zellweger JP. **J Allergy Clin Immunol** 1997 Jun; 99(6 Pt 1):860. Comment on: J Allergy Clin Immunol 1996 Jan;97(1 Pt 1):74–84.
Association of prenatal alcohol exposure with behavioral and learning problems in early adolescence. Olson HC, et al.
J Am Acad Child Adolesc Psychiatry 1997 Sep; 36(9):1187–94
The relationship between alcohol consumption, cognitive performance, and daily functioning in an urban sample of older black Americans. Hendrie HC, et al.
J Am Geriatr Soc 1996 Oct;44(10):1158–65
Smoking, alcohol and the risk of Dupuytren's contracture. Burge P, et al. **J Bone Joint Surg Br** 1997 Mar;79(2):206–10
Alcohol, estrogens, and breast cancer [letter; comment] Zumoff B. **J Clin Endocrinol Metab** 1997 Jul;82(7):2378. Comment on: J Clin Endocrinol Metab 1997 Jun;82(6):1656–8.
Flushing pattern and idiopathic avascular necrosis of the femoral head. Shibata A, et al. **J Epidemiol** 1996 Mar; 6(1):37–43
Tobacco smoking and alcohol consumption as risk factors for glioma: a case–control study in Melbourne, Australia. Hurley SF, et al. **J Epidemiol Community Health** 1996 Aug; 50(4):442–6
The influence of alcohol consumption on worldwide trends in mortality from upper aerodigestive tract cancers in men. Macfarlane GJ, et al. **J Epidemiol Community Health** 1996 Dec;50(6):636–9
Is an increased waist : hip ratio the cause of alcohol–induced hypertension? The AIR94 study. Suter PM, et al.
J Hypertens 1995 Dec;13(12 Pt 2):1857–62
Medical risk factors amongst drivers in single–car accidents. Gislason T, et al. **J Intern Med** 1997 Mar;241(3):213–9
Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia [see comments] Gammon MD, et al. **J Natl Cancer Inst** 1997 Sep 3;89(17):1277–84. Comment in: J Natl Cancer Inst 1997 Sep 3;89(17):1247–9.
Drug and alcohol use in orthopedic trauma patients: a prospective study. Levy RS, et al. **J Orthop Trauma** 1996; 10(1):21–7
Alcohol and other drugs: the scope of the problem among pregnant and parenting women in California. Young N.
J Psychoactive Drugs 1997 Jan–Mar;29(1):3–22 (122 ref.)
Effects of alcohol and other drugs on children. Young NK.
J Psychoactive Drugs 1997 Jan–Mar;29(1):23–42 (145 ref.)
Maternal use of alcohol during pregnancy is a risky lifestyle. Elhassani SB, et al. **J S C Med Assoc** 1996 Mar;92(3):128–32
The relationship of drinking and hangovers to workplace problems: an empirical study. Ames GM, et al.
J Stud Alcohol 1997 Jan;58(1):37–47
Individual differences in perceived riskiness of drinking in pregnancy: antecedents and consequences. Testa M, et al.
J Stud Alcohol 1996 Jul;57(4):360–7
Predicting academic problems in college from freshman alcohol involvement. Wood PK, et al. **J Stud Alcohol** 1997 Mar;58(2):200–10
Latent variable models of alcohol–related constructs. Lennox RD, et al. **J Subst Abuse** 1996;8(2):241–50
Effects of early adolescent drug use on cognitive efficacy in early–late adolescence: a developmental structural model [published erratum appears in J Subst Abuse 1996;8(2):271–3] Scheier LM, et al. **J Subst Abuse** 1995; 7(4):379–404
A serendipitous peek at tobacco. Hornsby RP.
J Tenn Med Assoc 1996 Mar;89(3):90–1
Alcohol and injury severity: reappraisal of the continuing controversy. Li G, et al. **J Trauma** 1997 Mar;42(3):562–9 (74 ref.)
Anal atresia: effect of smoking and drinking habits during pregnancy. Yuan P, et al. **Jpn J Hum Genet** 1995 Dec; 40(4):327–32
Consumption of alcohol and mortality in Russia [letter] Cleophas TJ, et al. **Lancet** 1997 Sep 27;350(9082):956–7
A case–control study of myelodysplastic syndromes among Japanese men and women. Ido M, et al. **Leuk Res** 1996 Sep;20(9):727–31
Alcohol involvement in motor vehicle fatalities, 1995. Buechner JS, et al. **Med Health R I** 1997 Jul;80(7):232–3
Alcohol use in Minnesota. Extent and cost. Kloehn D, et

al. **Minn Med** 1997 May;80(5):26–9

Alcohol use is a risk factor for a first generalized tonic–clonic seizure. The ALC.E. (Alcohol and Epilepsy) Study Group. Leone M, et al. **Neurology** 1997 Mar;48(3):614–20

Alcohol consumption and risk of pancreatic cancer. Tavani A, et al. **Nutr Cancer** 1997;27(2):157–61

Human cataract risk factors: significance of abstention from, and high consumption of, ethanol (U–curve) and non–significance of smoking. Phillips CI, et al. **Ophthalmic Res** 1996;28(4):237–47

Risk of tongue cancer associated with tobacco smoking and alcohol consumption: a case–control study. Zheng T, et al. **Oral Oncol** 1997 Mar;33(2):82–5

High fever and high lipids. Ballinger AB, et al. **Postgrad Med J** 1997 Jun;73(860):365–7

Early drinking onset and its association with alcohol use and problem behavior in late adolescence. Gruber E, et al. **Prev Med** 1996 May–Jun;25(3):293–300

Is alcohol a cofactor of HIV and AIDS? Evidence from immunological and behavioral studies. Dingle GA, et al. **Psychol Bull** 1997 Jul;122(1):56–71 (125 ref.)

Temperament, hostility, and consequences of alcohol use. Butryn MF, et al. **Psychol Rep** 1997 Apr;80(2):544–6

Effects of alcohol on human aggression. Validity of proposed explanations. Bushman BJ. **Recent Dev Alcohol** 1997; 13:227–43

Emerging themes in preclinical research on alcohol and aggression. Yudko E, et al. **Recent Dev Alcohol** 1997; 13:123–38 (90 ref.)

The role of heavy drinking in the risk of traffic fatalities. Kennedy BP, et al. **Risk Anal** 1996 Aug;16(4):565–9

Acute pancreatitis in Buskerud, Norway [letter; comment] Jacobsen CD. **Scand J Gastroenterol** 1996 Dec;31(12):1228 . Comment on: Scand J Gastroenterol 1996 Apr;31(4):411–4.

Alcohol–use–related problems in Puerto Rican and Irish–American males. Johnson PB. **Subst Use Misuse** 1997 Jan;32(2):169–79

Describing and predicting alcohol use–related harm: an analysis of the Yukon Alcohol and Drug Survey. Kellner F, et al. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1619–38

Direct and indirect effects of selected risk factors in producing adverse consequences of drug use. Thomas BS. **Subst Use Misuse** 1997 Mar;32(4):377–98

Maternal alcohol use and risk of orofacial cleft birth defects. Munger RG, et al. **Teratology** 1996 Jul;54(1):27–33

Road traffic injuries in developing countries: a comprehensive review of epidemiological studies. Odero W, et al. **Trop Med Int Health** 1997 May;2(5):445–60

Tobacco smoking, alcohol drinking and dietary factors as determinants of new primaries among male laryngeal cancer patients: a case–cohort study. Russo A, et al. **Tumori** 1996 Nov–Dec;82(6):519–25

[Alcohol intake and risk of liver disease––significance of gender. A population study] Becker PU, et al. **Ugeskr Laeger** 1997 Jun 9;159(24):3782–6 (Eng. Abstr.) **(Dan)**

[Is alcohol poisonous for the liver? (editorial)] Hardt F. **Ugeskr Laeger** 1997 Jun 23;159(26):4087–8 **(Dan)**

[Hypertension and alcohol: central and peripheral mechanisms] Rupp H, et al. **Herz** 1996 Aug;21(4):258–64 (41 ref.) (Eng. Abstr.) **(Ger)**

[Effects of chronic alcohol drinking on mouth mucosa. A morphometric study] Born IA, et al. **Laryngorhinootologie** 1996 Dec;75(12):754–8 (Eng. Abstr.) **(Ger)**

[Impaired vestibular diagnosis by the effect of alcohol] Lockemann U, et al. **Laryngorhinootologie** 1996 Nov; 75(11):646–8 (Eng. Abstr.) **(Ger)**

[Alcohol––protection or risk for the heart?] Wasielewski S. **Med Monatsschr Pharm** 1997 Mar;20(3):74–6 (6 ref.) **(Ger)**

[Effect of low alcohol concentrations on visual attention in street traffic] Buser A, et al. **Ophthalmologe** 1996 Aug; 93(4):371–6 (Eng. Abstr.) **(Ger)**

[Effect of alcohol on minimal effective nCPAP pressure] Wessendorf TE, et al. **Pneumologie** 1997 Aug;51 Suppl 3:783–5 (Eng. Abstr.) **(Ger)**

[Alcohol ingestion and hyperuricemia] Yamanaka H. **Nippon Rinsho** 1996 Dec;54(12):3369–73 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of alcohol intake on the ability to pilot aircraft] Ushakov IB, et al. **Aviakosm Ekolog Med** 1996;30(6):19–24 (Eng. Abstr.) **(Rus)**

[The early detection of young people with alcohol–related disorders in primary care] González García Y, et al. **Aten Primaria** 1997 Jul–Aug;20(3):133–6 (Eng. Abstr.) **(Spa)**

BLOOD

Carbohydrate–deficient transferrin as a marker of alcohol intake: a study with healthy subjects. Lesch OM, et al. **Alcohol Alcohol** 1996 May;31(3):265–71

Detection of relapses in alcohol dependent patients using serum carbohydrate deficient transferrin: improvement with individualized reference levels. Borg S, et al. **Alcohol Alcohol Suppl** 1994;2:493–6

The use of carbohydrate deficient transferrin as an indicator of alcohol consumption during treatment and follow–up. Anton RF. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):54A–56A

Ethyl palmitate and ethyl oleate are the predominant fatty acid ethyl esters in the blood after ethanol ingestion and their synthesis is differentially influenced by the extracellular concentrations of their corresponding fatty acids. Dan L, et al. **Alcohol Clin Exp Res** 1997 Apr; 21(2):286–92

Biological markers of alcohol consumption and effect of calcitonin in nonalcoholic men: a prospective, double–blind study. Elomaa VV, et al. **Alcohol Clin Exp Res** 1996 Aug; 20(5):830–5

Increased plasma atrial natriuretic peptide after ingestion of low doses of ethanol in humans. Gianoulakis C, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):162–70

The combined effect of alcohol and physical exercise on serum testosterone, luteinizing hormone, and cortisol in males. Heikkonen E, et al. **Alcohol Clin Exp Res** 1996 Jun; 20(4):711–6

Kinetic interactions between 4–methylpyrazole and ethanol in healthy humans. Jacobsen D, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):804–9

Serum and ascitic levels of soluble intercellular adhesion molecule–1 in patients with alcoholic liver cirrhosis: relation to biochemical markers of disease activity and alcohol intake. Nagy I, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):929–33

Effects of supplemental beta–carotene, cigarette smoking, and alcohol consumption on serum carotenoids in the Alpha–Tocopherol, Beta–Carotene Cancer Prevention Study. Albanes D, et al. **Am J Clin Nutr** 1997 Aug; 66(2):366–72

Blood alcohol concentration and driving. American College of Emergency Physicians. **Ann Emerg Med** 1997 Jun; 29(6):835

Alcohol and cardiovascular mortality in US physicians: is there a modifier effect by low–density lipoprotein? [letter] Enas EA. **Arch Intern Med** 1997 Aug 11–25; 157(15):1769–70

Pilots' knowledge of the relationship between alcohol consumption and levels of blood alcohol concentration. Widders R, et al. **Aviat Space Environ Med** 1997 Jun; 68(6):531–7

Traditional beer consumption and the iron status of spouse pairs from a rural community in Zimbabwe. Moyo VM, et al. **Blood** 1997 Mar 15;89(6):2159–66

Fatty acid ethyl esters: short–term and long–term serum markers of ethanol intake. Laposata M. **Clin Chem** 1997 Aug;43(8 Pt 2):1527–34 (53 ref.)

Higher high density lipoprotein cholesterol associated with moderate alcohol consumption is not related to altered plasma lecithin:cholesterol acyltransferase and lipid transfer protein activity levels. Riemens SC, et al. **Clin Chim Acta** 1997 Feb 3;258(1):105–15

Predictive value of MCV for hazardous drinking in the community. Peach HG, et al. **Clin Lab Haematol** 1997 Jun; 19(2):85–7

8–Hydroxydeoxyguanosine in human leukocyte DNA and daily health practice factors: effects of individual alcohol sensitivity. Nakajima M, et al. **Environ Health Perspect** 1996 Dec;104(12):1336–8

Drugs and alcohol among suspected impaired drivers in Canton de Vaud (Switzerland). Augsburger M, et al. **Forensic Sci Int** 1997 Feb 28;85(2):95–104

Alcohol and iron: one glass of red or more? Fletcher LM. **J Gastroenterol Hepatol** 1996 Nov;11(11):1039–41 (6 ref.)

Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre. Cromie SL, et al. **J Hepatol** 1996 Dec; 25(6):821–6

Cord blood carbohydrate–deficient transferrin levels are markedly higher than maternal. Whitty JE, et al. **J Matern Fetal Med** 1997 Jan–Feb;6(1):45–8

Alcohol use, driver, and crash characteristics among injured motorcycle drivers. Peek–Asa C, et al. **J Trauma** 1996 Dec; 41(6):989–93

Fatty acid ethyl esters in the blood as markers for ethanol intake [published erratum appears in JAMA 1997 Mar 12;227(10):792] Doyle KM, et al. **JAMA** 1996 Oct 9; 276(14):1152–6

Alcohol consumption and age of maternal menopause are associated with menopause onset. Torgerson DJ, et al. **Maturitas** 1997 Jan;26(1):21–5

Voluntary alcohol drinking and acetaldehyde metabolism in F2 hybrid crosses of AA and ANA rat lines. Koivisto T, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):441–6

Toxic effects of alcohol intake on prostate of rats. Novelli EL, et al. **Prostate** 1997 Apr 1;31(1):37–41

Validation of a measure of excessive drinking: frequency per year that BAL exceeds 0.08%. Conrod PJ, et al. **Subst Use Misuse** 1997 Apr;32(5):587–607

Stress, hormonal changes, alcohol, food constituents and drugs: factors that advance the incidence of tobacco smoke–related cancer? Maser E. **Trends Pharmacol Sci** 1997 Aug;18(8):270–5 (95 ref.)

[Blood alcohol concentrations after oral alcohol administration––effect of age and sex] Gärtner U, et al. **Z Gastroenterol** 1996 Oct;34(10):675–9 (Eng. Abstr.) **(Ger)**

[Effects of alcohol consumption, smoking, and dietary habits on blood concentrations of lead and cadmium] Roggi C, et al. **Ann Ig** 1996 Nov–Dec;8(6):657–65 **(Ita)**

[An investigation of the factors influencing serum pepsinogen levels––sex, age, smoking, drinking] Kitahara F, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Dec;93(12):867–75 (Eng. Abstr.) **(Jpn)**

[Asialotransferrin discriminating excessive, subacute and chronic active alcohol consumption. Clinical usefulness in hepatic disease] Peneda JA, et al. **Acta Med Port** 1996 Feb–Mar;9(2–3):103–11 (Eng. Abstr.) **(Por)**

[Diagnostic efficiency of biological markers of alcohol consumption for the detection of excessive drinkers] Rubio C, et al. **An Med Interna** 1996 Jun;13(6):274–8 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Spontaneous preference for ethanol in naive rats is influenced by cholecystokinin A receptor antagonism. Crespi F, et al. **Alcohol** 1997 Jul–Aug;14(4):327–32

Amphetamine and fenfluramine suppress ethanol intake in ethanol–dependent rats. Yu YL, et al. **Alcohol** 1997 Jan–Feb;14(1):45–8

Interaction between opiate and 5–HT3 receptor antagonists in the regulation of alcohol intake. Le AD, et al. **Alcohol Alcohol Suppl** 1994;2:545–9

Possible mechanism of action for the attenuation of ethanol intake induced by ritanserin in rats. Panocka I, et al. **Psychopharmacology (Berl)** 1996 Nov;128(2):181–90

ECONOMICS

The economics of alcohol. Lehto J. **Addiction** 1997 Mar;92 Suppl 1:S55–9

The relationship between alcohol consumption and earnings. Heien D. **J Stud Alcohol** 1996 Sep;57(5):536–42

EPIDEMIOLOGY

A longitudinal study of substance use and abuse in a single class of medical students. Croen LG, et al. **Acad Med** 1997 May;72(5):376–81

Alcohol use among injured sets of drivers and passengers. Soderstrom CA, et al. **Accid Anal Prev** 1996 Jan;28(1):111–4

Alcohol consumption and regular benzodiazepine use in 55–year–old female Malmö residents: results of a health screening. Osterling A, et al. **Acta Psychiatr Scand** 1996 Sep;94(3):141–8

Heavy drinking, alcohol–dependent vs. nondependent methadone–maintenance clients: a follow–up study. Chatham LR, et al. **Addict Behav** 1997 Jan–Feb;22(1):69–80

Addictive behavior of older adults. Graham K, et al. **Addict Behav** 1996 May–Jun;21(3):331–48

Overview of studies on drinking patterns and consequences. Bondy SJ. **Addiction** 1996 Nov;91(11):1663–74 (95 ref.)

Solitary drinking: a risk factor for alcohol–related problems? Bourgault C, et al. **Addiction** 1997 Mar;92(3):303–12

Temporal drinking patterns and variation in social consequences. Dawson DA. **Addiction** 1996 Nov; 91(11):1623–35

Changing society, changing drinking: solitary drinking as a non–pathological behaviour. Demers A, et al. **Addiction** 1996 Oct;91(10):1505–16

The epidemiology of alcohol use in Australian women: findings from a national survey of women's drinking. Fleming J. **Addiction** 1996 Sep;91(9):1325–34

Why has alcohol consumption declined in countries of southern Europe? Gual A, et al. **Addiction** 1997 Mar;92 Suppl 1:S21–31

Alcohol consumption in high school adolescents: frequency of use and dimensional structure of associated problems. Lewinsohn PM, et al. **Addiction** 1996 Mar;91(3):375–90

Inequality, deprivation and alcohol use. Marmot M. **Addiction** 1997 Mar;92 Suppl 1:S13–20

Educational approaches. Montonen M. **Addiction** 1997 Mar; 92 Suppl 1:S121–5

Alcohol consumption and community hospital admissions in the United States: a dynamic regression analysis, 1950–1992. Muller A. **Addiction** 1996 Feb;91(2):231–42

Gender differences in drinking behaviour in the Netherlands: convergence or stability? Neve RJ, et al. **Addiction** 1996 Mar;91(3):357–73

How does young people's alcohol consumption change during the transition to early adulthood? A longitudinal study of changes at aggregate and individual level. Pape H, et al. **Addiction** 1996 Sep;91(9):1345–57

Alcohol consumption in Switzerland 1987–93: adjusting for differential effect of assessment techniques on the analysis of trends. Rehm J, et al. **Addiction** 1996 Sep;91(9):1335–44

On the emerging paradigm of drinking patterns and their social and health consequences. Rehm J, et al. **Addiction** 1996 Nov;91(11):1615–21

The changes in the social class distribution of moderate and high alcohol consumption and of alcohol–related disabilities over time in Stockholm County and in Sweden. Romelsjö A, et al. **Addiction** 1996 Sep;91(9):1307–23

Alcohol, the individual and society: what history teaches us. Room R. **Addiction** 1997 Mar;92 Suppl 1:S7–11

Alcohol–related violence: the impact of drinking pattern and drinking context. Rossow I. **Addiction** 1996 Nov; 91(11):1651–61

Alcohol, Europe and the developing countries. Saxena S. **Addiction** 1997 Mar;92 Suppl 1:S43–8

Alcohol and European transformation. Simpura J. **Addiction** 1997 Mar;92 Suppl 1:S33–S41

Rural adolescent drinking behavior: three year follow–up in the New Hampshire substance abuse prevention study. Stevens MM, et al. **Adolescence** 1996 Spring;31(121):159–66

Utilizing culture and behaviour in epidemiological models of alcohol consumption and consequences for Western

nations. Peele S. **Alcohol Alcohol** 1997 Jan–Feb;32(1):51–64
The pattern of alcohol consumption of a general hospital population in north Belfast. Sharkey J, et al. **Alcohol Alcohol** 1996 May;31(3):279–85
Changes in alcohol use and alcohol-related problems among 7th to 12th grade students in New York State, 1983–1994. Barnes GM, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):916–22
Patterns of suicidality and alcohol use in alcoholics with major depression. Cornelius JR, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1451–5
The relationship between drinking and heart disease morbidity in the United States: results from the National Health Interview Survey. Hanna EZ, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):111–8
Relationships between depressive symptoms, anxiety, alcohol consumption, and blood pressure: results from the CARDIA Study. Coronary Artery Risk Development in Young Adults Study. Jones-Webb R, et al. **Alcohol Clin Exp Res** 1996 May;20(3):420–7
Polydrug use in adolescent drinkers with and without DSM–IV alcohol abuse and dependence. Martin CS, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1099–1108
Effects of early drinking and an antisocial orientation on the alcohol use of young Russians. Parker DA, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1179–83
Assessing alcohol problems in female DWI offenders. Parks KA, et al. **Alcohol Clin Exp Res** 1996 May;20(3):434–9
Subject–collateral reports of drinking in inpatient alcoholics with comorbid mental disorders. Stasiewicz PR, et al. **Alcohol Clin Exp Res** 1997 May;21(3):530–6
Combined use of cocaine with alcohol or cigarettes. Wiseman EJ, et al. **Am J Drug Alcohol Abuse** 1996 Nov;22(4):577–87
Tobacco, alcohol, and drug use increasing among women [news] **Am J Health Syst Pharm** 1996 Aug 15;53(16):1890, 1895
Alcohol intake and age-related maculopathy. Smith W, et al. **Am J Ophthalmol** 1996 Nov;122(5):743–5
Use of alcohol among lesbians: research and clinical implications. Hughes TL, et al. **Am J Orthopsychiatry** 1997 Jan;67(1):20–36 (98 ref.)
Detecting risk drinking during pregnancy: a comparison of four screening questionnaires. Russell M, et al. **Am J Public Health** 1996 Oct;86(10):1435–9
Alcohol-related health services use and identification of patients in the emergency department. Cherpitel CJ, et al. **Ann Emerg Med** 1996 Oct;28(4):418–23
Safer sex behavior and alcohol consumption. Research Group of the Swiss HIV Prevention Study. Läuchli S, et al. **Ann Epidemiol** 1996 Jul;6(4):357–64
The epidemiology of left-handedness in a hospital population [see comments] Stellman SD, et al. **Ann Epidemiol** 1997 Apr;7(3):167–71. Comment in: Ann Epidemiol 1997 Apr;7(3):165–6.
Moderate alcohol consumption and risk for angina pectoris or myocardial infarction in U.S. male physicians. Camargo CA Jr, et al. **Ann Intern Med** 1997 Mar 1;126(5):372–5
Alcohol and overall health outcomes. Poikolainen K. **Ann Med** 1996 Oct;28(5):381–4 (30 ref.)
Ecological analysis of collectivity of alcohol consumption in England: importance of average drinker [see comments] Colhoun H, et al. **BMJ** 1997 Apr 19;314(7088):1164–8. Comment in: BMJ 1997 Apr 19;314(7088):1142–3.
How much alcohol and how often? Population based case-control study of alcohol consumption and risk of a major coronary event [see comments] McElduff P, et al. **BMJ** 1997 Apr 19;314(7088):1159–64. Comment in: BMJ 1997 Jul 19;315(7101):188.
The use of medication and alcohol among the Spanish population. Del Río MC, et al. **Br J Clin Pharmacol** 1996 Mar;41(3):253–5
Introduction of high-alcohol beer in Ontario: preliminary observations on its use by underage drinkers. Mann RE, et al. **Can J Public Health** 1997 Mar–Apr;88(2):114–8
The 1993 General Social Survey I: alcohol use in Canada. Single EW, et al. **Can J Public Health** 1995 Nov–Dec; 86(6):397–401
Characteristics of pregnant women who engage in binge alcohol consumption [see comments] Gladstone J, et al. **Can Med Assoc J** 1997 Mar 15;156(6):789–94. Comment in: Can Med Assoc J 1997 Mar 15;156(6):807–8.
Alcohol, tobacco and cannabis use among Nova Scotia adolescents: implications for prevention and harm reduction [see comments] Poulin C, et al. **Can Med Assoc J** 1997 May 15;156(10):1387–93. Comment in: Can Med Assoc J 1997 May 15;156(10):1397–9.
Pancreas cancer, tobacco smoking and consumption of alcoholic beverages: a case-control study. Partanen TJ, et al. **Cancer Lett** 1997 Jun 3;116(1):27–32
Predictive value of MCV for hazardous drinking in the community. Peach HG, et al. **Clin Lab Haematol** 1997 Jun; 19(2):85–7
Israeli college student alcohol use: the association of background characteristics and regular drinking patterns. Isralowitz RE, et al. **Drug Alcohol Depend** 1996 Nov; 42(3):147–53
The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Sobell LC, et al. **Drug Alcohol Depend** 1996 Sep;42(1):49–54
Reliability of information on cigarette smoking and beverage consumption provided by hospital controls. D'Avanzo B, et al. **Epidemiology** 1996 May;7(3):312–5
Alcohol and smoking in relation to the prevalence of adenomatous colorectal polyps detected at sigmoidoscopy. Longnecker MP, et al. **Epidemiology** 1996 May;7(3):275–80
The effects of alcohol and smoking upon the age, anatomic sites and stage in the development of cancer of the oral cavity and oropharynx in females in the south west Netherlands. de Boer MF, et al. **Eur Arch Otorhinolaryngol** 1997;254(4):177–9
Validity of self-reported intakes of wine, beer and spirits in population studies. Grønbaek M, et al. **Eur J Clin Nutr** 1996 Jul;50(7):487–90
Relationships between childbearing and some food and alcohol habits: the Nordland Health Study. Jacobsen BK. **Eur J Epidemiol** 1996 Aug;12(4):327–30
Validity and reproducibility of alcohol consumption in Italy. Ferraroni M, et al. **Int J Epidemiol** 1996 Aug;25(4):775–82
Alcoholism in social classes and occupations in Sweden. Hemmingsson T, et al. **Int J Epidemiol** 1997 Jun; 26(3):584–91
Relationship of alcohol use, physical activity and dietary habits with serum carotenoids, retinol and alpha-tocopherol among male Japanese smokers. Kitamura Y, et al. **Int J Epidemiol** 1997 Apr;26(2):307–14
Self-reported alcohol intake using two different question formats in southeastern New England. Parker DR, et al. **Int J Epidemiol** 1996 Aug;25(4):770–4
Agreement between self and partner reports of paternal drinking and smoking. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Passaro KT, et al. **Int J Epidemiol** 1997 Apr;26(2):315–20
Lower consumption of wine and fish as a possible explanation for higher ischaemic heart disease mortality in Spain's Mediterranean region. Rodríguez Artalejo F, et al. **Int J Epidemiol** 1996 Dec;25(6):1196–201
Cluster versus individual randomization in adolescent tobacco and alcohol studies: illustrations for design decisions. Slymen DJ, et al. **Int J Epidemiol** 1997 Aug; 26(4):765–71
Alcohol consumption and serum liver-derived enzymes in a Danish population aged 30–50 years. Steffensen FH, et al. **Int J Epidemiol** 1997 Feb;26(1):92–9
Lifelong teetotallers, ex-drinkers and drinkers: mortality and the incidence of major coronary heart disease events in middle-aged British men. Wannamethee SG, et al. **Int J Epidemiol** 1997 Jun;26(3):523–31
Drinking and sexual experience on first dates among adolescents. Cooper ML, et al. **J Abnorm Psychol** 1997 May;106(2):191–202
Self-reported alcohol use patterns in a sample of male and female heavy smokers. Pomerleau CS, et al. **J Addict Dis** 1997;16(3):19–24
Adolescent drinking behaviour and the role of family life: a Scottish perspective. Shucksmith J, et al. **J Adolesc** 1997 Feb;20(1):85–101
The rate and pattern of alcohol consumption among Chinese adolescents. Li X, et al. **J Adolesc Health** 1996 Nov; 19(5):353–61
Alcohol use amongst community-dwelling elderly people: a review of the literature. Lakhani N. **J Adv Nurs** 1997 Jun;25(6):1227–32 (36 ref.)
Do fifth graders' attitudes and intentions toward alcohol use predict seventh-grade use? Webb JA, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Dec; 35(12):1611–7
Average weekly alcohol consumption: drinking percentiles for American college students. Meilman PW, et al. **J Am Coll Health** 1997 Mar;45(5):201–4
Binge drinking, tobacco, and illicit drug use and involvement in college athletics. A survey of students at 140 American colleges. Wechsler H, et al. **J Am Coll Health** 1997 Mar; 45(5):195–200
Binge drinking among college students: a comparison of California with other states. Wechsler H, et al. **J Am Coll Health** 1997 May;45(6):273–7
Nicotine: a gateway drug? Jessup M. **J Am Med Womens Assoc** 1996 Jan–Apr;51(1–2):21
Epidemiological features of first-visit outpatients in Japan: comparison with general population and variation by sex, age, and season. Inoue M, et al. **J Clin Epidemiol** 1997 Jan;50(1):69–77
Gender and patterns of alcohol problems: pretreatment responses of women and men to the comprehensive drinker profile. Miller WR, et al. **J Clin Psychol** 1997 Apr; 53(3):263–77
The relation between adolescent alcohol use and peer alcohol use: a longitudinal random coefficients model. Curran PJ, et al. **J Consult Clin Psychol** 1997 Feb;65(1):130–40
Intraclass correlation among measures related to alcohol use by school aged adolescents: estimates, correlates and applications in intervention studies. Murray DM, et al. **J Drug Educ** 1996;26(3):207–30
Students' self-reported substance use by grade level and gender. Nagel L, et al. **J Drug Educ** 1996;26(1):49–56
Drug and alcohol use by Canadian university athletes: a national survey. Spence JC, et al. **J Drug Educ** 1996; 26(3):275–87
School and neighborhood characteristics associated with school rates of alcohol, cigarette, and marijuana use. Ennett ST, et al. **J Health Soc Behav** 1997 Mar;38(1):55–71
Patterns of tobacco and alcohol use among sedentary, exercising, nonathletic, and athletic youth. Rainey CJ, et al. **J Sch Health** 1996 Jan;66(1):27–32
Adolescent gender differences in alcohol problem behaviors and the social contexts of drinking. Treiman KA, et al. **J Sch Health** 1996 Oct;66(8):299–304
Does allowing the sale of wine in Quebec grocery stores increase consumption? Adrian M, et al. **J Stud Alcohol** 1996 Jul;57(4):434–48
Suicide attempts and alcohol consumption in an emergency room sample. Borges G, et al. **J Stud Alcohol** 1996 Sep; 57(5):543–8
Correlates of alcohol, tobacco and marijuana use among Scottish postsecondary helping-profession students. Engs RC, et al. **J Stud Alcohol** 1997 Jul;58(4):435–44
Determinants of life-course variation in the frequency of alcohol consumption: meta-analysis of studies from the collaborative alcohol-related longitudinal project. Johnstone BM, et al. **J Stud Alcohol** 1996 Sep;57(5):494–506
Are women heavier drinkers than we thought they were? Lo CC. **J Stud Alcohol** 1996 Sep;57(5):531–5
What happened to wine consumption in Iowa following elimination of its retail wine monopoly? [letter; comment] Mulford HA, et al. **J Stud Alcohol** 1996 Sep;57(5):572–5 . Comment on: J Stud Alcohol 1993 Mar;54(2):251–3.
The scientific process works: seven replications now show significant wine sales increases after privatization [letter; comment] Wagenaar AC, et al. **J Stud Alcohol** 1996 Sep; 57(5):575–6. Comment on: J Stud Alcohol 1993 Mar;54(2):251–3.
Criterion variability in problem-drinking research on college students. Heck EJ, et al. **J Subst Abuse** 1995;7(4):437–47 (43 ref.)
Prevalences and related factors of substances use in female aborigines in southern Taiwan. Yang MS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Nov; 12(11):634–40
Alcohol and drug use in UK university students. Webb E, et al. **Lancet** 1996 Oct 5;348(9032):922–5
Patterns of alcohol use and misuse among adults in Rhode Island. Duncan DF. **Med Health R I** 1997 Mar;80(3):80–2
Alcohol consumption among pregnant and childbearing-aged women--United States, 1991 and 1995. **MMWR Morb Mortal Wkly Rep** 1997 Apr 25; 46(16):346–50
The relationship of drinking and birth outcome in a US national sample of expectant mothers. Faden VB, et al. **Paediatr Perinat Epidemiol** 1997 Apr;11(2):167–80
Substance use among patients with a psychotic disorder in a psychiatric emergency room. Claassen CA, et al. **Psychiatr Serv** 1997 Mar;48(3):353–8
Neuropsychological differences between alcohol-dependent and cocaine-dependent patients with or without problematic drinking. Easton C, et al. **Psychiatry Res** 1997 Jul 4;71(2):97–103
Drug and alcohol use in Spain: consumption habits, attitudes and opinions. Royo-Bordonada MA, et al. **Public Health** 1997 Sep;111(5):277–84
Drinking by adolescents in the European Community [letter] Van Reek J, et al. **Rev Epidemiol Sante Publique** 1997 Apr; 45(2):169–70
Risk-taking behaviour of Cape Peninsula high-school students. Part IX. Evidence for a syndrome of adolescent risk behaviour. Flisher AJ, et al. **S Afr Med J** 1996 Sep; 86(9):1090–3
Relationship of cigarette smoking, alcohol use, and dietary habits with Helicobacter pylori infection in Japanese men. Shinchi K, et al. **Scand J Gastroenterol** 1997 Jul;32(7):651–5
Alcohol consumption and ischemic heart disease mortality in Sweden. Messner T, et al. **Scand J Soc Med** 1996 Jun; 24(2):107–13
Alcohol consumption by undergraduate students. Basten CJ, et al. **Subst Use Misuse** 1996 Aug;31(10):1379–99
When anthropology meets epidemiology: using social representations to predict drinking patterns. Demers A, et al. **Subst Use Misuse** 1996 May;31(7):847–71
Tobacco, alcohol, and illicit drug use among Mexican-American and non-Hispanic white high school students. Grunbaum JA, et al. **Subst Use Misuse** 1996 Aug; 31(10):1279–310
Gender differences in alcohol and other drug use among young adults. Hughes TL, et al. **Subst Use Misuse** 1997 Feb;32(3):317–42
Alcohol-use-related problems in Puerto Rican and Irish-American males. Johnson PB. **Subst Use Misuse** 1997 Jan;32(2):169–79
Relationships among alcohol availability, drinking location, alcohol consumption, and drinking problems in adolescents. Jones-Webb R, et al. **Subst Use Misuse** 1997 Aug; 32(10):1261–85
Why and in what context adolescents obtain alcohol from adults: a pilot study. Jones-Webb R, et al. **Subst Use Misuse** 1997 Jan;32(2):219–28
Describing and predicting alcohol use-related harm: an analysis of the Yukon Alcohol and Drug Survey. Kellner F, et al. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1619–38
The drinking behaviors of a sample of university students in Nanning, Guangxi province, People's Republic of China. Lu ZP, et al. **Subst Use Misuse** 1997 Mar;32(4):495–506
Correlates of change in adolescent alcohol consumption in Ireland: implications for understanding influences and enhancing interventions. Morgan M, et al. **Subst Use Misuse** 1997 Apr;32(5):609–19
Does cessation of smoking cause a change in alcohol consumption? Evidence from the Lung Health Study.

Murray RP, et al. **Subst Use Misuse** 1996 Jan;31(2):141–56

Comorbidity of symptoms among junior and senior high school suicide attempters. Wagner BM, et al. **Suicide Life Threat Behav** 1996 Fall;26(3):300–7

Road traffic injuries in developing countries: a comprehensive review of epidemiological studies. Odero W, et al. **Trop Med Int Health** 1997 May;2(5):445–60

Lifestyle in Curaçao. Smoking, alcohol consumption, eating habits and exercise. Grol ME, et al. **West Indian Med J** 1997 Mar;46(1):8–14

Gender and ethnic differences in the prevalence of alcohol, cigarette, and illicit drug use over time in a cohort of young Hispanic adolescents in south Florida. Khoury EL, et al. **Women Health** 1996;24(1):21–40

[Drinking and driving] Peleg A, et al. **Harefuah** 1997 Feb 2;132(3):162–7, 240 (Eng. Abstr.) **(Heb)**

[Alcohol consumption in schoolchildren. Results of a questionnaire study] Modonutti GB, et al. **Minerva Pediatr** 1997 May;49(5):203–9 (Eng. Abstr.) **(Ita)**

[The relation of alcohol intake to constitutional and biochemical variables in Japanese populations] Kitamura A, et al. **Nippon Koshu Eisei Zasshi** 1996 Feb;43(2):86–101 (Eng. Abstr.) **(Jpn)**

[Characteristics of smoking, drinking, dietary habits, and physical exercise in health behavioral models] Ozasa K, et al. **Nippon Koshu Eisei Zasshi** 1995 Dec;42(12):1029–41 (Eng. Abstr.) **(Jpn)**

[The spread of harmful habits among medical students and their attitude to them] Vinogradov PB, et al. **Gig Sanit** 1996 May-Jun;(3):49–51 **(Rus)**

[Trends in alcohol consumption in relation to liver diseases in Slovakia 1973–1994] Szántová M, et al. **Bratisl Lek Listy** 1997 Jan;98(1):12–6 (Eng. Abstr.) **(Slo)**

[Young men and psychoactive substances] Pecci MC. **Acta Psiquiatr Psicol Am Lat** 1995 Dec;41(4):288–99 (Eng. Abstr.) **(Spa)**

[Prevalence of tobacco and alcohol consumption, attitudes and knowledge in high school students of the province of Tarragona (Spain)] Pérez Ollé R, et al. **An Esp Pediatr** 1996 Dec;45(6):583–90 (Eng. Abstr.) **(Spa)**

[Alcohol consumption (editorial)] Rico Irles J. **An Med Interna** 1995 Nov;12(11):521–3 **(Spa)**

[The consumption of alcohol, tobacco and drugs in adolescents] Martínez Alvarez J, et al. **Aten Primaria** 1996 Oct 31;18(7):383–5 (Eng. Abstr.) **(Spa)**

[Distribution of habits related to health in a female Canarian population] Navarro Rodríguez MC, et al. **Gac Sanit** 1997 May-Jun;11(3):131–5 (Eng. Abstr.) **(Spa)**

[The consumption of alcoholic drinks in Spain in the period of 1940–1987 (letter; comment)] Graciani MA, et al. **Med Clin (Barc)** 1996 Apr 6;106(13):517. Comment on: Med Clin (Barc) 1995 Apr 15;104(14):544–50. **(Spa)**

[Alcohol consumption in schoolchildren (letter; comment)] Valero Juan LF, et al. **Med Clin (Barc)** 1997 Mar 15; 108(10):399. Comment on: Med Clin (Barc) 1995 Apr 15;104(14):544–50. Comment on: Med Clin (Barc) 1995 Oct 21;105(13):481–6. **(Spa)**

[What, how much and when the university student drinks] Araneda JM, et al. **Rev Med Chil** 1996 Mar;124(3):377–88 (Eng. Abstr.) **(Spa)**

[Alcohol consumption and family: a descriptive study in adolescents] Mena M, et al. **Rev Med Chil** 1996 Jun; 124(6):749–55 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Ethnic differences in the association between behavior with a new partner: an event-based analysis. Graves KL, et al. **AIDS Educ Prev** 1997 Jun;9(3):219–37

Acculturation and alcohol consumption in the Mexican American population of the southwestern United States: findings from HHANES 1982–84. Markides KS, et al. **Am J Public Health** 1990 Dec;80 Suppl:42–6

Health risk behaviors of Hispanics in the United States: findings from HHANES, 1982–84. Marks G, et al. **Am J Public Health** 1990 Dec;80 Suppl:20–6

Alcohol consumption patterns among Mexican American mothers and among children from single- and dual-headed households: findings from HHANES 1982–84. Stroup-Benham CA, et al. **Am J Public Health** 1990 Dec; 80 Suppl:36–41

The use of tobacco, alcohol and other drugs by young Aboriginal people in Albany, Western Australia. Gray D, et al. **Aust N Z J Public Health** 1997 Feb;21(1):71–6

Problems related to alcohol use: a cross-cultural perspective. Gureje O, et al. **Cult Med Psychiatry** 1997 Jun; 21(2):199–211

Ethnic and religious identity and some age characteristics of alcohol use. Akabaliev V, et al. **Folia Med (Plovdiv)** 1996;38(3–4):5–10

Alcohol, drug use and consequences among Hispanics seeking treatment for alcohol-related problems. Arciniega LT, et al. **J Stud Alcohol** 1996 Nov;57(6):613–8

Aggregate-level predictors of the prevalence of selected drinking patterns in multiple studies: a research synthesis from the Collaborative Alcohol-Related Longitudinal Project. Ager CR, et al. **Subst Use Misuse** 1996 Sep–Oct; 31(11–12):1503–23

Drinking-related assessment instruments: cross-cultural studies. Annis HM, et al. **Subst Use Misuse** 1996 Sep–Oct; 31(11–12):1525–46

Modernization and geographical diffusion as explanations for regional differences in the consumption of wine and beer in the European Community. Knibbe RA, et al. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1639–55

The influence of acculturation on attitudes toward alcohol and alcohol use within the Punjabi community: an exploratory analysis. Weber TR. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1715–32

GENETICS

Neuropsychological functioning in sons of active alcoholic, recovering alcoholic, and social drinking fathers. Ozkaragoz T, et al. **Alcohol** 1997 Jan–Feb;14(1):31–7

The mixed 5-HT 1A/2A receptor drug FG5938 suppresses alcohol drinking while enhancing feeding in P rats. Piercy KT, et al. **Alcohol** 1996 Sep–Oct;13(5):521–7

Apomorphine and 7-OH DPAT reduce ethanol intake of P and HAD rats. Russell RN, et al. **Alcohol** 1996 Sep–Oct; 13(5):515–9

Effect of calcium channel blocker diltiazem on some depressant actions of ethanol in UChA and UChB rats. Tampier L, et al. **Alcohol** 1997 Jan–Feb;14(1):21–3

Constant absolute ethanol intake by Sardinian alcohol-preferring rats independent of ethanol concentrations. Lobina C, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):19–22

Genetic effects on alcohol consumption patterns and problems in women. Heath AC, et al. **Alcohol Alcohol Suppl** 1994;2:53–7 (27 ref.)

Genetically determined influences on voluntary ethanol consumption: extracellular levels of ethanol and monoamines in the nucleus accumbens of the alcohol preferring AA and alcohol avoiding ANA rat lines. Kiianmaa K, et al. **Alcohol Alcohol Suppl** 1994;2:73–8

Biphasic effects of alcohol on heart rate are influenced by alcoholic family history and rate of alcohol ingestion. Conrod PJ, et al. **Alcohol Clin Exp Res** 1997 Feb; 21(1):140–9

Characterization of the mu and delta opioid receptors in the brain of the C57BL/6 and DBA/2 mice, selected for their differences in voluntary ethanol consumption. de Waele JP, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):754–62

Manipulation of alcohol drinking by liver transplantation. Eriksson CJ, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):763–5

Ethanol-reinforced responding by AA and ANA rats following the sucrose-substitution initiation procedure. Files FJ, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):749–53

Initiation of ethanol self-administration by the sucrose-substitution method with HAS and LAS rats. Files FJ, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):677–81

Alcohol and aldehyde dehydrogenase genotypes and drinking behavior in Japanese. Higuchi S, et al. **Alcohol Clin Exp Res** 1996 May;20(3):493–7

Association between alcohol use and smoking in adolescent and young adult twins: a bivariate genetic analysis. Koopmans JR, et al. **Alcohol Clin Exp Res** 1997 May; 21(3):537–46

Effects of taste aversion training on the acquisition of alcohol drinking in adolescent P and HAD rat lines. McKinzie DL, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):682–7

Decreased measures of experimental anxiety in rats bred for high alcohol preference. Möller C, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):656–60

Behavioral similarities and differences among alcohol-preferring and -nonpreferring rats: confirmation by factor analysis and extension to additional groups. Overstreet DH, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):840–8

Serotonin2C receptors and serotonin2C receptor-mediated phosphoinositide hydrolysis in the brain of alcohol-preferring and alcohol-nonpreferring rats. Pandey SC, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1038–42

Correlated responses to selection in FAST and SLOW mice: effects of ethanol on ataxia, temperature, sedation, and withdrawal. Shen EH, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):688–96

High and low drinking rat lines: contributions to current understanding and future development. Sinclair JD. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):109A–112A

Alcohol effects on the heritability of EEG spectral power. Sorbel J, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1523–7

Polymorphism of alcohol-metabolizing genes affects drinking behavior and alcoholic liver disease in Japanese men. Tanaka F, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):596–601

Alcohol use disorder among adolescents: impact of paternal alcoholism on drinking behavior, drinking motivation, and consequences. Tarter RE, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):171–8

Absence of p53 mutations in squamous carcinomas of the tongue in nonsmoking and nondrinking patients younger than 40 years. Sorensen DM, et al. **Arch Otolaryngol Head Neck Surg** 1997 May;123(5):503–6

Intake of ethanol, sodium chloride, sucrose, citric acid, and quinine hydrochloride solutions by mice: a genetic analysis. Bachmanov AA, et al. **Behav Genet** 1996 Nov;26(6):563–73

Short-term selective breeding as a tool for QTL mapping: ethanol preference drinking in mice. Belknap JK, et al. **Behav Genet** 1997 Jan;27(1):55–66

Genetic and environmental contributions to the correlation between alcohol consumption and symptoms of anxiety and depression. Results from a bivariate analysis of Norwegian twin data. Tambs K, et al. **Behav Genet** 1997 May; 27(3):241–50

Interaction of the choiesteryl ester transfer protein I405V polymorphism with alcohol consumption in smoking and non-smoking healthy men, and the effect on plasma HDL cholesterol and apoAI concentration. Gudnason V, et al. **Clin Genet** 1997 Jan;51(1):15–21

Low Km aldehyde dehydrogenase (ALDH2) polymorphism, alcohol-drinking behavior, and chromosome alterations in peripheral lymphocytes. Morimoto K, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:563–7

Predictors of problem drinking and alcohol dependence in a population-based sample of female twins. Prescott CA, et al. **J Stud Alcohol** 1997 Mar;58(2):167–81

Heavy consumption of cigarettes, alcohol and coffee in male twins. Swan GE, et al. **J Stud Alcohol** 1997 Mar; 58(2):182–90

The consumption of tobacco, alcohol, and coffee in Caucasian male twins: a multivariate genetic analysis. Swan GE, et al. **J Subst Abuse** 1996;8(1):19–31

Linkage studies in alcohol-responsive myoclonic dystonia. Gasser T, et al. **Mov Disord** 1996 Jul;11(4):363–70

Genetic differences in alcohol drinking preference between inbred strains of mice. He XX, et al. **Pharmacogenetics** 1997 Jun;7(3):223–33

Genetic differences in tolerance and sensitization to the sedative/hypnotic effects of alcohol. Kurtz DL, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):585–91

Propofol-induced ataxia and hypnosis in rat lines selected for differential alcohol sensitivity. Yildirim Y, et al. **Pharmacol Toxicol** 1997 Jan;80(1):44–8

Odor of specific alcohol solutions selectively alters locomotor activity of alcohol-drinking P rats. Myers RD, et al. **Physiol Behav** 1997 Jan;61(1):71–5

[Children of Alcoholics Screening Test (CAST) and influence of parent's drinking on their children] Yamazaki S. **Nippon Koshu Eisei Zasshi** 1996 Dec;43(12):1045–54 (Eng. Abstr.) **(Jpn)**

HISTORY

Per capita alcohol consumption and total mortality: an analysis of historical data. Norström T. **Addiction** 1996 Mar; 91(3):339–44

American Indian and Alaska native aboriginal use of alcohol in the United States. Abbott PJ. **Am Indian Alsk Native Ment Health Res** 1996;7(2):1–13

Underground and under steam: liquor smuggling during Prohibition [letter; comment] Robinson GE. **Can Med Assoc J** 1997 Jan 1;156(1):19. Comment on: Can Med Assoc J 1996 Oct 1;155(7):860–1.

Social reform and violence: the case of the American prohibitionists. Hamm RF. **J Clin Pharm Ther** 1996 Jun; 21(3):131–3

Alcohol in American History. Musto DF. **Sci Am** 1996 Apr; 274(4):78–83

The rules of drug taking: wine and poppy derivatives in the ancient world. III. Wine as an instrument of aggressive behavior and of ritual madness. Nencini P. **Subst Use Misuse** 1997 Feb;32(3):361–7

The rules of drug taking: wine and poppy derivatives in the ancient world. I. General introduction. Nencini P. **Subst Use Misuse** 1997 Jan;32(1):89–96

The rules of drug taking: wine and poppy derivatives in the ancient world. V. Sobriety or postponement of drunkenness? Nencini P. **Subst Use Misuse** 1997 Apr; 32(5):629–33

The rules of drug taking: wine and poppy derivatives in the ancient world. IV. The rules of temperance. Nencini P. **Subst Use Misuse** 1997 Mar;32(4):475–83

IMMUNOLOGY

Anti-low-density lipoprotein antibodies in alcoholics without and with liver disease and in social drinkers. Wehr H, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):43–9

Factors involved in modulation of NK cell activity by ethanol consumption. Blank SE, et al. **Alcohol Alcohol Suppl** 1994;2:439–45 (27 ref.)

Increased susceptibility of experimental animals to infectious organisms as a consequence of ethanol consumption. Jerrells TR, et al. **Alcohol Alcohol Suppl** 1994;2:425–30 (36 ref.)

Ethanol suppresses endotoxin but not platelet activating factor-induced hypotension and nitric oxide. Greenberg SS, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1260–8

Distribution of peripheral blood lymphoid subsets in alcoholic liver cirrhosis: influence of ethanol intake. Laso FJ, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1564–8

Relationship between alcohol intake and immunoglobulin a immunoreactivity with acetaldehyde-modified bovine serum albumin. Worrall S, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):836–40

Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. Laso FJ, et al. **Hepatology** 1997 May;25(5):1096–100

LEGISLATION & JURISPRUDENCE

Are lower legal blood alcohol limits and a combination of sanctions desirable in reducing drunken driver-involved traffic fatalities and traffic accidents? Deshapriya EB, et

al. **Accid Anal Prev** 1996 Nov;28(6):721–31 (37 ref.)
Estimating blood alcohol level from observable signs. McKnight AJ, et al. **Accid Anal Prev** 1997 Mar; 29(2):247–55
License plate confiscation for persistent alcohol impaired drivers. Ross HL, et al. **Accid Anal Prev** 1996 Jan; 28(1):53–61
Drink–driving US style [news] **Addiction** 1996 Aug; 91(8):1239–40
Access to alcohol from licensed premises during adolescence: a longitudinal study. Casswell S, et al. **Addiction** 1997 Jun; 92(6):737–45
Alcohol policy and the public good: a good public debate [editorial] Edwards G, et al. **Addiction** 1996 Apr; 91(4):477–81
What does science have to say? Moskalewicz J. **Addiction** 1997 Mar;92 Suppl 1:S97–101
The analysis of policy: understanding the process of policy development. Ryder D. **Addiction** 1996 Sep;91(9):1265–70
Medical screening and medical–psychological assessment as prerequisites for regranting of licenses: summary of recommendations. Nickel WR. **Alcohol Alcohol** 1996 Nov; 31(6):605–7
Zero tolerance laws: effective public policy? Martin S. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):147A–150A
Motor vehicle safety. American College of Emergency Physicians. **Ann Emerg Med** 1997 Sep;30(3):363–4
Alcohol policy in the Nordic countries [editorial; comment] Chenet L, et al. **BMJ** 1997 Apr 19;314(7088):1142–3. Comment on: BMJ 1997 Apr 19;314(7088):1164–8.
Prohibition and the meaning of legislation [letter] [see comments] Latowsky M. **Can Med Assoc J** 1996 Oct 1; 155(7):860–1. Comment in: Can Med Assoc J 1997 Jan 1;156(1):19.
An impaired judicial system [letter; comment] Workman S. **CMAJ** 1997 Jun 15;156(12):1698. Comment on: Can Med Assoc J 1997 Mar 15;156(6):889–90.
MADD Massachusetts versus Senator Burke: a media advocacy case study. DeJong W. **Health Educ Q** 1996 Aug; 23(3):318–29
Policy improvements for prevention of alcohol misuse by airline pilots. McFadden KL. **Hum Factors** 1997 Mar; 39(1):1–8
Designing a survey of public opinions regarding alcohol control policies among African American and white adults. Jones–Webb R, et al. **J Health Care Poor Underserved** 1997 Feb;8(1):18–24
Drunk–driving recidivism: predicting factors from arrest context and case disposition [letter; comment] Marowitz L, et al. **J Stud Alcohol** 1996 Nov;57(6):679–80. Comment on: J Stud Alcohol 1995 Jan;56(1):60–6.
Procurement of alcohol and underage drinking among adolescents in Ontario. Smart RG, et al. **J Stud Alcohol** 1996 Jul;57(4):419–24
[Discrepancies between police breath alcohol measurements in a field trial and blood alcohol concentration according to BGA guidelines and possible consequences for citizens] Schütz H, et al. **Arch Kriminol** 1997 Mar–Apr; 199(3–4):103–8 (Eng. Abstr.) **(Ger)**
[The accuracy of blood alcohol determination with head–space GC, ADH and REA ethanol assay for the AXSYM system—a comparison of the methods] Alt A, et al. **Blutalkohol** 1996 Jul;33(4):209–14 (Eng. Abstr.) **(Ger)**
[The German promille law—overview and guideline for legal traffic applications] Grohmann P. **Blutalkohol** 1996 Jul; 33(4):177–200 (Eng. Abstr.) **(Ger)**
[Separation of therapy and diagnosis on the one hand—need for interprofessional cooperation on the other hand. Also a critical comment to the contribution of Pund and Kajan (letter)] Müller W. **Blutalkohol** 1996 Jul;33(4):215–20 **(Ger)**
[Alcohol and energy drink—can combined consumption of both beverages modify automobile driving fitness?] Riesselmann B, et al. **Blutalkohol** 1996 Jul;33(4):201–8 (Eng. Abstr.) **(Ger)**
[Alcohol at the wheel—medical psychological expert assessment. Laboratory data and abstinence—prognosis—responsibilities of the family physician] Müller–Wickop J, et al. **Fortschr Med** 1996 Oct 20;114(29):374–6 (4 ref.) **(Ger)**

METABOLISM

Genetically determined influences on voluntary ethanol consumption: extracellular levels of ethanol and monoamines in the nucleus accumbens of the alcohol preferring AA and alcohol avoiding ANA rat lines. Kiianmaa K, et al. **Alcohol Alcohol Suppl** 1994;2:73–8
Biological responses to administered interferon in alcoholics. Ono K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1560–3
Alcohol intake and insulin levels. The Normative Aging Study. Lazarus R, et al. **Am J Epidemiol** 1997 May 15; 145(10):909–16
Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study) [see comments] Kiechl S, et al. **BMJ** 1996 Oct 26; 313(7064):1040–4. Comment in: BMJ 1997 Feb 8;314(7078):443–4.
Elevated levels of hemoglobin–associated acetaldehyde related to alcohol drinking in the atypical genotype of low Km aldehyde dehydrogenase. Takeshita T, et al. **Cancer Res** 1997 Apr 1;57(7):1241–3
Smoking, alcohol and lipoprotein metabolism. Porkka KV, et al. **Curr Opin Lipidol** 1996 Jun;7(3):162–6 (47 ref.)
Composition of platelet phospholipids after moderate consumption of red wine in healthy volunteers. Pellegrini N, et al. **Eur J Clin Nutr** 1996 Aug;50(8):535–44
Effect of chronic moderate ethanol consumption on heart brain natriuretic peptide. Guillaume P, et al. **Eur J Pharmacol** 1996 Nov 28;316(1):49–58
Alterations in brain levels of atrial and C–type natriuretic peptides after chronic moderate ethanol consumption in spontaneously hypertensive rats. Guillaume P, et al. **Eur J Pharmacol** 1997 Jan 29;319(2–3):215–24
Chronic alcohol intoxication induces hepatic injury through enhanced macrophage inflammatory protein–2 production and intercellular adhesion molecule–1 expression in the liver. Bautista AP. **Hepatology** 1997 Feb;25(2):335–42
The influence of acute ethanol ingestion on phospholipase D activity in rat pancreas. An in vitro and in vivo study. Rydzewska G, et al. **Int J Pancreatol** 1996 Aug;20(1):59–68
Interfering substances identified in the breath of drinking drivers with Intoxilyzer 5000S. Jones AW. **J Anal Toxicol** 1996 Nov–Dec;20(7):522–7
Glutathione recycling is attenuated by acute ethanol feeding in rat liver. Oh SI, et al. **J Korean Med Sci** 1997 Aug; 12(4):316–21
Acute and chronic ethanol consumption effects on the immunolabeling of Gq/11 alpha subunit protein and phospholipase C isozymes in the rat brain. Pandey SC. **J Neurochem** 1996 Dec;67(6):2355–61
Altered dopamine transporter densities in alcohol–preferring vervet monkeys. Mash DC, et al. **Neuroreport** 1996 Jan 31;7(2):457–62
Quantitative comparison of mu opioid receptor mRNA in selected CNS regions of alcohol naive rats selectively bred for high and low alcohol drinking. Gong J, et al. **Neurosci Lett** 1997 May 9;227(1):9–12
The effect of beta–thia–iminoprostacyclin in taurocholate acute pancreatitis in rats: the role of antecedent acute ethanol abuse. Dlugosz JW, et al. **Pancreas** 1997 Jul; 15(1):91–8
Regional densities of benzodiazepine sites in the CNS of alcohol–naive P and NP rats. Thielen RJ, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):875–82
Metabolic mapping of the effects of chronic voluntary ethanol consumption in rats. Williams–Hemby L, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):415–23
Carbohydrate–deficient transferrin: an investigative biochemical marker of heavy alcohol consumption. Saini RS, et al. **Psychopharmacol Bull** 1997;33(1):171–5
Gender differences in ethanol oxidation and cytochrome P4502E1 content and functions in hepatic microsomes from alcohol–preferring and non–preferring rats. Nebbia C, et al. **Xenobiotica** 1996 Nov;26(11):1121–9

MORTALITY

WHO working group on population levels of alcohol consumption: Oslo, 14–16 December 1994. Anderson P. **Addiction** 1996 Feb;91(2):275–83
Public health consequences of the J–curve hypothesis of alcohol problems. Skog OJ. **Addiction** 1996 Mar; 91(3):325–37
Obesity, alcohol consumption, smoking, and mortality. Chyou PH, et al. **Ann Epidemiol** 1997 May;7(4):311–7
Prospective study of moderate alcohol consumption and mortality in US male physicians. Camargo CA Jr, et al. **Arch Intern Med** 1997 Jan 13;157(1):79–85
Alcohol and cardiovascular mortality in US physicians: is there a modifier effect by low–density lipoprotein? [letter] Enas EA. **Arch Intern Med** 1997 Aug 11–25; 157(15):1769–70
Contribution of deaths related to alcohol use of socioeconomic variation in mortality: register based follow up study. Mäkelä P, et al. **BMJ** 1997 Jul 26;315(7102):211–6
Follow up study of moderate alcohol intake and mortality among middle aged men in Shanghai, China. Yuan JM, et al. **BMJ** 1997 Jan 4;314(7073):18–23
Alcohol and coronary heart disease reduction among British doctors: confounding or causality? Doll R, et al. **Eur Heart J** 1997 Jan;18(1):23–5
The association between alcohol consumption and all–cause mortality in a cohort of male employees in the German construction industry. Brenner H, et al. **Int J Epidemiol** 1997 Feb;26(1):85–91
Trends of liver cirrhosis mortality in Europe, 1970–1989: age–period–cohort analysis and changing alcohol consumption. Corrao G, et al. **Int J Epidemiol** 1997 Feb; 26(1):100–9

PATHOLOGY

Chronic alcohol feeding in liquid diet or in drinking water has similar effects on electron microscopic appearance of the hepatic sinusoid in the rat. Sarphie TG, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):973–9
Use of artificial sweeteners to promote alcohol consumption by rats. Plummer JL, et al. **Pathology** 1997 Feb;29(1):57–9

PHYSIOPATHOLOGY

The effect of drink familiarity on tolerance to alcohol. Remington B, et al. **Addict Behav** 1997 Jan–Feb;22(1):45–53
Chronic ethanol ingestion produces cholinergic hypofunction in rat brain. Floyd EA, et al. **Alcohol** 1997 Jan–Feb; 14(1):93–8
The effect of ethanol drinking on opioid analgesia and receptors in mice. Shah S, et al. **Alcohol** 1997 Jul–Aug; 14(4):361–6
Circadian drinking pattern of Sardinian alcohol–preferring rats. Agabio R, et al. **Alcohol Alcohol** 1996 Jul;31(4):385–8
Buspirone as an inhibitor of voluntary ethanol intake in male rats. Hedlund L, et al. **Alcohol Alcohol** 1996 Mar; 31(2):149–56
A possible acetaldehyde–mediated cardioprotective mechanism [letter] Wickramasinghe SN, et al. **Alcohol Alcohol** 1996 May;31(3):309–11
Effect of dorsal raphe injections of the GABAA agonist, muscimol, on ethanol intake and measures of intoxication in Wistar rats. Tomkins DM, et al. **Alcohol Alcohol Suppl** 1994;2:551–8
Naltrexone blocks acquisition of voluntary ethanol intake in rats. Davidson D, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):677–83
Effects of 5,7–dihydroxytryptamine lesions of the prefrontal cortex on consumption of sucrose–ethanol solutions: relationship to prefrontal monoamines. Deckel AW, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):631–6
The portacaval–shunted rat: a new model for the study of the mechanisms controlling voluntary ethanol consumption and ethanol preference? de Waele JP, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):305–10
Liver regeneration attenuates increased voluntary alcohol intake evoked by the liver damage. Fogel WA, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):732–7
The neurobiology of ethanol–opioid interactions in ethanol reinforcement. Froehlich JC. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):181A–186A
Effects of time–of–day and photoperiod phase shifts on voluntary ethanol consumption in rats. Gauvin DV, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):817–25
Naltrexone treatment increases the aversiveness of alcohol for outbred rats. Hill KG, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):637–41
Effects of cholinergic agents on locomotor activity of P and NP rats. Katner SN, et al. **Alcohol Clin Exp Res** 1996 Sep; 20(6):1004–10
Sex differences in alcohol preference and drinking patterns emerge during the early postpubertal period. Lancaster FE, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1043–9
Isoflavonoid compounds extracted from Pueraria lobata suppress alcohol preference in a pharmacogenetic rat model of alcoholism. Lin RC, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):659–63
Ethanol–induced change in cardiac and endogenous opiate function and risk for alcoholism. Peterson JB, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1542–52
Naltrexone effects on ethanol drinking acquisition and on established ethanol consumption in C57BL/6J mice. Phillips TJ, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):691–702
Periodic naltrexone and propensity to take alcoholic beverage. Reid LD, et al. **Alcohol Clin Exp Res** 1996 Nov; 20(8):1329–34
Thyrotropin releasing hormone analog TA–0910 suppresses alcohol intake in alcohol drinking African green monkeys. Rezvani AH, et al. **Alcohol Clin Exp Res** 1997 Apr; 21(2):261–6
Strategies for revealing the multiple determinants of drinking: pharmacological and environmental manipulations. Tomkins DM. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):125A–127A
Central serotonergic lesions increase voluntary alcohol consumption in Sprague Dawley rats: moderation by long–term ethanol administration. Wang JY, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1252–9
Hemodynamic effects of acute ethanol in young adults. Kelly LF, et al. **Am J Cardiol** 1996 Oct 1;78(7):851–4
Ultrastructure of rat Purkinje neurons after chronic ethanol consumption and prolonged abstinence. Wenisch S, et al. **Anat Histol Embryol** 1997 Jun;26(2):93–8
Drinking habit as a base for blood pressure elevation—difference in epidemiological significance by beverage type. Takashima Y, et al. **Appl Human Sci** 1997 Mar;16(2):47–53
Serum gamma–glutamyl transferase levels and blood pressure falls after alcohol moderation. Yamada Y, et al. **Clin Exp Hypertens** 1997 Apr;19(3):249–68
Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Spanagel R, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):39–44
Effects of obesity, current smoking status, and alcohol consumption on heart rate variability in male white–collar workers. Kageyama T, et al. **Int Arch Occup Environ Health** 1997;69(6):447–54
Smooth pursuit in twins before and after alcohol ingestion. Blekher T, et al. **Invest Ophthalmol Vis Sci** 1997 Aug; 38(9):1768–73
Variability of the blood/breath alcohol ratio in drinking drivers. Jones AW, et al. **J Forensic Sci** 1996 Nov; 41(6):916–21
Effects of alcohol ingestion on estrogens in postmenopausal women. Ginsburg ES, et al. **JAMA** 1996 Dec 4; 276(21):1747–51
Effects of acute, chronic ethanol and withdrawal on dorsal raphe neurons: electrophysiological studies. Pistis M, et al. **Neuroscience** 1997 Jul;79(1):171–6

Effects of a low alcohol dose on static balance, fine motor activity, and mental performance. Mangold S, et al. **Neurotoxicol Teratol** 1996 Sep–Oct;18(5):547–54

Effects of ethanol consumption on brown adipose tissue thermogenic capacity in mice. Muralidhara DV, et al. **Physiol Behav** 1996 Aug;60(2):639–44

Acute thermogenic effects of nicotine and alcohol in healthy male and female smokers. Perkins KA, et al. **Physiol Behav** 1996 Jul;60(1):305–9

Role of taste aversion in calcium channel inhibitor–induced suppression of saccharin and alcohol drinking in rats. Pucilowski O, et al. **Physiol Behav** 1996 Feb;59(2):319–24

Inhibition of nitric oxide formation reduces voluntary ethanol consumption in the rat. Calapai G, et al. **Psychopharmacology (Berl)** 1996 Jun;125(4):398–401

Social drinking history, behavioral tolerance and the expectation of alcohol. Fillmore MT, et al. **Psychopharmacology (Berl)** 1996 Oct;127(4):359–64

Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. King AC, et al. **Psychopharmacology (Berl)** 1997 Jan; 129(1):15–22

[Alcohol, lipid metabolism and coronary heart disease] Schneider J, et al. **Herz** 1996 Aug;21(4):217–26 (66 ref.) (Eng. Abstr.) **(Ger)**

[Visual evoked potentials in low blood alcohol concentrations] Behrendt S, et al. **Ophthalmologe** 1996 Aug; 93(4):367–70 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Measurement of alcohol and tobacco availability to underage students. Klepp KI, et al. **Addict Behav** 1996 Sep–Oct; 21(5):585–95

Population level policies on alcohol: are they still appropriate given that "alcohol is good for the heart"? Casswell S. **Addiction** 1997 Mar;92 Suppl 1:S81–90

Alcohol policy and the public good. Edwards G. **Addiction** 1997 Mar;92 Suppl 1:S73–9

Alcohol misuse prevention for young people: a systematic review reveals methodological concerns and lack of reliable evidence of effectiveness. Foxcroft DR, et al. **Addiction** 1997 May;92(5):531–7 (45 ref.)

Preventing sales of alcohol to minors: results from a community trial. Grube JW. **Addiction** 1997 Jun;92 Suppl 2:S251–60

Where treatment and prevention merge: the need for a broader approach. Heather N. **Addiction** 1997 Mar;92 Suppl 1:S133–6

Media advocacy in community prevention: news as a means to advance policy change. Holder HD, et al. **Addiction** 1997 Jun;92 Suppl 2:S189–99

A community prevention trial to reduce alcohol-involved accidental injury and death: overview. Holder HD, et al. **Addiction** 1997 Jun;92 Suppl 2:S155–71

Summing up: lessons from a comprehensive community prevention trial. Holder HD, et al. **Addiction** 1997 Jun;92 Suppl 2:S293–301

Application of local policy to prevent alcohol problems: experiences from a community trial. Holder HD, et al. **Addiction** 1997 Jun;92 Suppl 2:S285–92

Use of spatial models for community program evaluation of changes in alcohol outlet distribution. Millar AB, et al. **Addiction** 1997 Jun;92 Suppl 2:S273–83

Community prevention and alcohol retail access. Reynolds RI, et al. **Addiction** 1997 Jun;92 Suppl 2:S261–72

Moderating drinking by correspondence: an evaluation of a new method of intervention. Sitharthan T, et al. **Addiction** 1996 Mar;91(3):345–55

Community mobilization: evaluation of an environmental approach to local action. Treno AJ, et al. **Addiction** 1997 Jun;92 Suppl 2:S173–87

Drinking and driving prevention in the community: program planning and implementation. Voas RB. **Addiction** 1997 Jun;92 Suppl 2:S201–19

The effect of drinking and driving interventions on alcohol-involved traffic crashes within a comprehensive community trial. Voas RB, et al. **Addiction** 1997 Jun;92 Suppl 2:S221–36

Treatment of alcohol dependence: experiences of using biological markers in monitoring and prevention of relapse. Borg S. **Alcohol Alcohol** 1996 Nov;31(6):621–4 (10 ref.)

Naltrexone persistently reduces rats' intake of a palatable alcoholic beverage. Gardell LR, et al. **Alcohol Clin Exp Res** 1996 May;20(3):584–8

Effectiveness of a high school alcohol misuse prevention program. Shope JT, et al. **Alcohol Clin Exp Res** 1996 Aug; 20(5):791–8

Protective factors and young adolescent tendency to abstain from alcohol use: a model using two waves of intervention study data. Spoth R, et al. **Am J Community Psychol** 1996 Dec;24(6):749–70

The effect of a community-supported alcohol ban on prenatal alcohol and other substance abuse [letter] Bowerman RJ. **Am J Public Health** 1997 Aug;87(8):1378–9

Health warning on alcoholic beverages [letter] Lovell J. **Aust Fam Physician** 1997 Feb;26(2):187

Dutch anti-alcohol campaign is under attack [news] Sheldon T. **BMJ** 1996 Nov 30;313(7069):1349

Early at-risk alcohol intake. Definitions and physicians' role in modifying behaviour. Herbert C, et al. **Can Fam Physician** 1997 Apr;43:639–44

Reducing the harm of adolescent substance use [editorial; comment] Erickson PG. **Can Med Assoc J** 1997 May 15; 156(10):1397–9 (15 ref.). Comment on: Can Med Assoc J 1997 May 15;156(10):1387–93.

Binge drinking during pregnancy: who are the women at risk? [editorial; comment] Nanson JL. **Can Med Assoc J** 1997 Mar 15;156(6):807–8. Comment on: Can Med Assoc J 1997 Mar 15;156(6):789–94.

Reducing alcohol-use disorders via decreased consumption: a comparison of population and high-risk strategies. Dawson DA, et al. **Drug Alcohol Depend** 1996 Sep; 42(1):39–47

Dopamine partial receptor agonists reduce ethanol intake in the rat. Bono G, et al. **Eur J Pharmacol** 1996 Feb 5; 296(3):233–8

Program: Minnesota Media Campaign to promote alcohol-free pregnancy. **Health Educ Q** 1996 Nov;23(4):418

Alcoholism and alcohol-related problems in Italy: an overview on recent developments in societal responses and treatment systems. Poldrugo F, et al. **J Addict Dis** 1996; 15(3):59–65 (5 ref.)

Embedded anti-alcohol messages on commercial television: what teenagers perceive. Borzekowski DL. **J Adolesc Health** 1996 Nov;19(5):345–52

Changing the perception of the norm: a strategy to decrease binge drinking among college students. Haines M, et al. **J Am Coll Health** 1996 Nov;45(3):134–40

Clinic nurses: confronting campus alcohol use on the frontline. Miller JB. **J Am Coll Health** 1997 Mar; 45(5):205–8

Behavioral Self-Control Program for Windows: results of a controlled clinical trial. Hester RK, et al. **J Consult Clin Psychol** 1997 Aug;65(4):686–93

Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. Jaffe AJ, et al. **J Consult Clin Psychol** 1996 Oct;64(5):1044–53

Behavior assessment and cross-validation by surrogate measures in drug prevention research. Duryea E, et al. **J Drug Educ** 1995;25(4):335–42

Evaluation of a dutch educational "Driving While Intoxicated (DWI)" prevention program for driving schools. Kayser RE, et al. **J Drug Educ** 1995;25(4):379–93

Responsible decision making regarding alcohol: a re-emerging prevention/education strategy for the 1990s. Milgram GG. **J Drug Educ** 1996;26(4):357–65 (11 ref.)

Intraclass correlation among measures related to alcohol use by school aged adolescents: estimates, correlates and applications in intervention studies. Murray DM, et al. **J Drug Educ** 1996;26(3):207–30

A three year outcome evaluation of a theory based drink driving education program. Sheehan M, et al. **J Drug Educ** 1996;26(3):295–312

Adolescent counterarguing of TV beer advertisements: evidence for effectiveness of alcohol education and critical viewing discussions. Slater MD, et al. **J Drug Educ** 1996; 26(2):143–58

Deaths from cirrhosis in Poland and Hungary: the impact of different alcohol policies during the 1980s. Varvasovsky Z, et al. **J Epidemiol Community Health** 1997 Apr; 51(2):167–71

Physician advice for problem alcohol drinkers. Van Meter RA. **J Fam Pract** 1997 Jul;45(1):17–8

Assessing substance abuse among health care students and the efficacy of educational interventions. Coleman EA, et al. **J Prof Nurs** 1997 Jan–Feb;13(1):28–37

Peer-planned social activities for preventing alcohol use among young adolescents. Komro KA, et al. **J Sch Health** 1996 Nov;66(9):328–34

Brief nurse consultations for preventing alcohol use among urban school youth. Werch CE, et al. **J Sch Health** 1996 Nov;66(9):335–8

Drinking careers of older male alcoholics in treatment as compared to younger alcoholics and to older social drinkers. Neve RJ, et al. **J Stud Alcohol** 1997 May; 58(3):303–11

Characteristics, policies and practices of alcohol outlets and sales to underage persons. Wolfson M, et al. **J Stud Alcohol** 1996 Nov;57(6):670–4

Operation Desert Shield/Storm performance of soldiers enrolled in the alcohol and drug abuse prevention and control program. Stagliano RF, et al. **Mil Med** 1995 Dec; 160(12):631–5

Charting WHO—goals for licit and illicit drugs for the year 2000: are we 'on track'? Fischer B, et al. **Public Health** 1997 Sep;111(5):271–5

The efficacy of treatments in reducing alcohol consumption: a meta-analysis [letter; comment] Chick J. **Subst Use Misuse** 1996 Jul;31(9):1081. Comment on: Int J Addict 1995 Jun;30(8):1067–77.

Harm reduction for alcohol-use-related problems among college students. Cronin C. **Subst Use Misuse** 1996 Dec; 31(14):2029–37

Need for a scientific basis for alcohol-involved problem prevention including a consideration of cost and effectiveness. Holder HD. **Subst Use Misuse** 1997 Jan; 32(2):203–9

Alcohol—less is better. **WHO Reg Publ Eur Ser** 1996;70:1–39 (39 ref.)

[Alcohol in Munich secondary school students—a study for dissemination of experiences, knowledge, attitude and behavior] Scherer K, et al. **Gesundheitswesen** 1996 Oct; 58(10):533–7 (Eng. Abstr.) **(Ger)**

[Availability of the Alcohol Use Disorders Identification Test (AUDIT) for a complete health examination in Japan] Hiro H, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Oct;31(5):437–50 (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

The relationship of social context of drinking, perceived social norms, and parental influence to various drinking patterns of adolescents. Beck KH, et al. **Addict Behav** 1996 Sep–Oct;21(5):633–44

The influence of gender, expectancy, and partner beverage selection on (meta)perceptions in a "blind" dating situation. Corcoran KJ. **Addict Behav** 1996 May–Jun;21(3):273–82

The utility of novelty seeking, harm avoidance, and expectancy in the prediction of drinking. Galen LW, et al. **Addict Behav** 1997 Jan–Feb;22(1):93–106

Predicting onset of drinking in a community sample of adolescents: the role of expectancy and temperament. Killen JD, et al. **Addict Behav** 1996 Jul–Aug;21(4):473–80

Alcohol effects on the facial expressions of anxiety patients undergoing a panic provocation. Kushner MG, et al. **Addict Behav** 1997 Mar–Apr;22(2):275–80

Drinking location and risk of alcohol-impaired driving among high school seniors. Lee JA, et al. **Addict Behav** 1997 May–Jun;22(3):387–93

Alcohol expectancies: effects of gender, age, and family history of alcoholism. Lundahl LH, et al. **Addict Behav** 1997 Jan–Feb;22(1):115–25

Decisional balance and stage of change for adolescent drinking. Migneault JP, et al. **Addict Behav** 1997 May–Jun; 22(3):339–51

The impact of behavior and addiction on psychological models of cigarette and alcohol use during pregnancy. Moore PJ, et al. **Addict Behav** 1996 Sep–Oct;21(5):645–68

The effect of drink familiarity on tolerance to alcohol. Remington B, et al. **Addict Behav** 1997 Jan–Feb;22(1):45–53

A comparison of factor structures of adolescent and adult alcohol effect expectancies. Schafer J, et al. **Addict Behav** 1996 May–Jun;21(3):403–8

Effects of alcohol and expectancy on self-disclosure and anxiety in male and female social drinkers. Schippers GM, et al. **Addict Behav** 1997 May–Jun;22(3):305–14

Perspectives on precipitants of relapse. **Addiction** 1996 Dec; 91 Suppl:S1–244

The effect of alcohol consumption on craving to smoke. Burton SM, et al. **Addiction** 1997 Jan;92(1):15–26

Predicting underage drinking and driving behaviors. Grube JW, et al. **Addiction** 1996 Dec;91(12):1843–57

A comparison of positive and negative alcohol expectancy and value and their multiplicative composite as predictors of post-treatment abstinence survivorship. Jones BT, et al. **Addiction** 1996 Jan;91(1):89–99

Prediction of results from correspondence treatment for controlled drinking. Kavanagh DJ, et al. **Addiction** 1996 Oct;91(10):1539–45

Drinking, the majority fallacy, cognitive dissonance and social pressure. Mäkelä K. **Addiction** 1997 Jun;92(6):729–36

The role of coping in relapse crisis outcome: a prospective study of treated alcoholics. Moser AE, et al. **Addiction** 1996 Aug;91(8):1101–13 (32 ref.)

High- and low-dose alcohol-related expectancies and the differential associations with drinking in male and female adolescents and young adults. Wiers RW, et al. **Addiction** 1997 Jul;92(7):871–88

Effects of sucrose-substitution initiation on patterns of drinking by Lewis rats during continuous alcohol access. Files FJ, et al. **Alcohol** 1997 Jul–Aug;14(4):379–87

Glucose and the insulin-releasing drug tolbutamide attenuate the effects of morphine and angiotensin on alcohol consumption. Grupp LA, et al. **Alcohol** 1997 Jan–Feb; 14(1):71–9

Acute alcohol tolerance in social drinkers: changes in subjective effects dependent on the alcohol dose and prior alcohol experience. Hiltunen AJ. **Alcohol** 1997 Jul–Aug; 14(4):373–8

The effects of single and repeated episodes of thiamin deficiency on memory in alcohol-consuming rats. Homewood J, et al. **Alcohol** 1997 Jan–Feb;14(1):81–91

The mixed 5-HT 1A/2A receptor drug FG5938 suppresses alcohol drinking while enhancing feeding in P rats. Piercy KT, et al. **Alcohol** 1996 Sep–Oct;13(5):521–7

Apomorphine and 7-OH DPAT reduce ethanol intake of P and HAD rats. Russell RN, et al. **Alcohol** 1996 Sep–Oct; 13(5):515–9

Morphine enhances selection of both sucrose and ethanol in a two-bottle test. Stromberg MF, et al. **Alcohol** 1997 Jan–Feb;14(1):55–62

The 5-HT1A receptor agonist 8-OH-DPAT reduces ethanol intake and maintained behavior in female Sprague-Dawley rats. Wilson AW, et al. **Alcohol** 1996 Sep–Oct;13(5):407–13

Are alcoholic women more likely to drink premenstrually? Allen D. **Alcohol Alcohol** 1996 Mar;31(2):145–7

ESBRA-Nordmann 1996 Award Lecture: ethanol drinking behaviour in Sardinian alcohol-preferring rats. Colombo G. **Alcohol Alcohol** 1997 Jul–Aug;32(4):443–53

Solitary drinking, social isolation, and escape drinking motives as predictors of high quantity drinking, among Anglo, African American and Mexican American males. Neff JA. **Alcohol Alcohol** 1997 Jan–Feb;32(1):33–41

Alcohol consumption and gustatory hedonic profiles in Wistar-Kyoto hyper- and normoactive rat strains. Razafimanalina R, et al. **Alcohol Alcohol** 1997 Jul–Aug; 32(4):485–91

Effects of naloxone on limited-access ethanol drinking in rats. Davidson D, et al. **Alcohol Clin Exp Res** 1996 Jun; 20(4):664-9

Naltrexone increases the latency to drink alcohol in social drinkers. Davidson D, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):732-9

Daidzin decreases ethanol consumption in rats. Heyman GM, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1083-7

Increased ethanol self-administration after a period of imposed ethanol deprivation in rats trained in a limited access paradigm. Heyser CJ, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):784-91

Thyrotropin-releasing hormone analog TA-0910 reduces voluntary alcohol intake of P rats subchronically in a limited scheduled access paradigm. Mason GA, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1000-3

Infants' suckling responses to the flavor of alcohol in mothers' milk. Mennella JA. **Alcohol Clin Exp Res** 1997 Jun; 21(4):581-5

Alcohol expectancies and drinking characteristics in parents of children with attention deficit hyperactivity disorder. Molina BS, et al. **Alcohol Clin Exp Res** 1997 May; 21(3):557-66

Current developments in the study of stress and alcohol consumption. Ragland DR. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):51A-53A

Effects of alcohol cues on smoking urges and topography among alcoholic men. Rohsenow DJ, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):101-7

Differential changes in sucrose/ethanol and sucrose maintained responding by independently altering ethanol or sucrose concentration. Slawecki CJ, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):250-60

Family characteristics as mediators of the influence of problem drinking and multiple risk status on child mental health. Roosa MW, et al. **Am J Community Psychol** 1996 Oct;24(5):607-24

Sex differences in the association between alcohol consumption and cognitive performance. EVA Study Group. Epidemiology of Vascular Aging. Dufouil C, et al. **Am J Epidemiol** 1997 Sep 1;146(5):405-12

Androgens and alcohol [letter] Wiseman EJ. **Am J Psychiatry** 1997 Jul;154(7):1040-1

A concept analysis of alcoholic denial and cultural accounts. Wing DM. **ANS Adv Nurs Sci** 1996 Dec;19(2):54-63

Response to alcohol in social phobia. Naftolowitz DF, et al. **Anxiety** 1994;1(2):96-9

Readiness to change alcohol drinking habits after traumatic brain injury. Bombardier CH, et al. **Arch Phys Med Rehabil** 1997 Jun;78(6):592-6

Effects of suppressing the urge to drink on the accessibility of alcohol outcome expectancies. Palfai TP, et al. **Behav Res Ther** 1997 Jan;35(1):59-65

Alcohol consumption and cognitive performance in a random sample of Australian soldiers who served in the Second World War. Dent OF, et al. **BMJ** 1997 Jun 7; 314(7095):1655-7

Young people, alcohol, and designer drinks: quantitative and qualitative study [see comments] Hughes K, et al. **BMJ** 1997 Feb 8;314(7078):414-8. Comment in: BMJ 1997 May 31;314(7094):1622-3.

Early at-risk alcohol intake. Definitions and physicians' role in modifying behaviour. Herbert C, et al. **Can Fam Physician** 1997 Apr;43:639-44

Alcohol problems among suicide attempters in the Nordic countries. Nielsen AS, et al. **Crisis** 1996;17(4):157-66

The effects of alcohol history on the reinforcing, subjective and psychomotor effects of nitrous oxide in healthy volunteers. Cho AM, et al. **Drug Alcohol Depend** 1997 Apr 14;45(1-2):63-70

Family structure, personality, drinking, smoking and illicit drug use: a study of UK teenagers. Miller P. **Drug Alcohol Depend** 1997 Apr 14;45(1-2):121-9

Excessive drinking situations in German alcoholics: replication of a three-factor model used for North Americans. Victorio-Estrada A, et al. **Drug Alcohol Depend** 1996 May;41(1):75-9

Forget "drinking to forget": enhanced consolidation of emotionally charged memory by alcohol. Bruce KR, et al. **Exp Clin Psychopharmacol** 1997 Aug;5(3):242-50

Does the repeated gambles procedure measure impulsivity in social drinkers. Vuchinich RE, et al. **Exp Clin Psychopharmacol** 1997 May;5(2):157-62

Let's party tonight: drinking patterns and breath alcohol values at high school parties. Schwartz RH, et al. **Fam Med** 1997 May;29(5):326-31

Attitudes towards alcohol use among Bulgarians-Christians and Turks-Muslims. Akabaliev V, et al. **Folia Med (Plovdiv)** 1997;39(1):7-12

Ethnic and religious identity and some age characteristics of alcohol use. Akabaliev V, et al. **Folia Med (Plovdiv)** 1996;38(3-4):5-10

Correlates of alcohol use and misuse in fourth-grade children: psychosocial, peer, parental, and family factors. Loveland-Cherry CJ, et al. **Health Educ Q** 1996 Nov; 23(4):497-511 (72 ref.)

Alcohol outcome expectancies and alcohol use: a latent variable cross-lagged panel study. Sher KJ, et al. **J Abnorm Psychol** 1996 Nov;105(4):561-74

Memory activation and expectancy as prospective predictors of alcohol and marijuana use. Stacy AW. **J Abnorm Psychol** 1997 Feb;106(1):61-73

Coping strategies, drinking motives, and stressful life events among middle adolescents: associations with emotional and behavioral problems and with academic functioning. Windle M, et al. **J Abnorm Psychol** 1996 Nov;105(4):551-60

Ego identity status and reported alcohol consumption: a study of first-year college students. Bishop DI, et al. **J Adolesc** 1997 Apr;20(2):209-18

Prevalence and effectiveness of self-regulatory techniques used to avoid drunk driving. Brown SL. **J Behav Med** 1997 Feb;20(1):55-66

Gender and patterns of alcohol problems: pretreatment responses of women and men to the comprehensive drinker profile. Miller WR, et al. **J Clin Psychol** 1997 Apr; 53(3):263-77

Environmental predictors of drinking and drinking-related problems in young adults. Jones-Webb R, et al. **J Drug Educ** 1997;27(1):67-82

Coping, drinking motives, goal attainment expectancies and family models in relation to alcohol use among college students. Karwacki SB, et al. **J Drug Educ** 1996; 26(3):243-55

Responsible decision making regarding alcohol: a re-emerging prevention/education strategy for the 1990s. Milgram GG. **J Drug Educ** 1996;26(4):357-65 (11 ref.)

Attitude and peer cross pressure: adolescent drug and alcohol use. Robin SS, et al. **J Drug Educ** 1996;26(1):69-99

Anxiety, alcohol, aphasia, and ums. Christenfeld N, et al. **J Pers Soc Psychol** 1996 Mar;70(3):451-60

Stress, social support and health-related behavior: a study of smoking, alcohol consumption and physical exercise. Steptoe A, et al. **J Psychosom Res** 1996 Aug;41(2):171-80

Adolescent gender differences in alcohol problem behaviors and the social contexts of drinking. Treiman KA, et al. **J Sch Health** 1996 Oct;66(8):299-304

Seminatural housing increases subsequent ethanol intake in male Maudsley Reactive rats. Adams N, et al. **J Stud Alcohol** 1996 Jul;57(4):349-51

A descriptive analysis of the structure and temporal pattern of voluntary ethanol intake within an acquisition paradigm. Boyle AE, et al. **J Stud Alcohol** 1997 Jul;58(4):382-91

Drinking motives predict alcohol-related problems in college students. Carey KB, et al. **J Stud Alcohol** 1997 Jan; 58(1):100-5

Drinking restraint and alcohol-related outcomes: exploring the contributions of beverage instructions, beverage content and self-monitoring. Collins RL, et al. **J Stud Alcohol** 1996 Sep;57(5):563-71

Acceptability of the controlled-drinking goal among alcohol treatment agencies in New South Wales, Australia. Donovan M, et al. **J Stud Alcohol** 1997 May;58(3):253-6

Drug-free behavioral history affects social drinkers' tolerance to a challenge dose of alcohol. Easdon CM, et al. **J Stud Alcohol** 1996 Nov;57(6):591-7

Evidence that expectancies mediate behavioral impairment under alcohol. Fillmore MT, et al. **J Stud Alcohol** 1996 Nov;57(6):598-603

Exploring the effects of age of alcohol use initiation and psychosocial risk factors on subsequent alcohol misuse. Hawkins JD, et al. **J Stud Alcohol** 1997 May;58(3):280-90

The Drinking-Related Locus of Control Scale: the factor structure with treatment-seeking outpatients. Hirsch LS, et al. **J Stud Alcohol** 1997 Mar;58(2):162-6

Substance use initiation among adolescent children of alcoholics: testing protective factors. Hussong AM, et al. **J Stud Alcohol** 1997 May;58(3):272-9

Eight-month predictive validity and covariance structure of the Alcohol Expectancy Questionnaire for Adolescents (AEQ-A) for junior high school students. Kline RB. **J Stud Alcohol** 1996 Jul;57(4):396-405

Individual differences in alcohol responsivity: physiological, psychomotor and subjective response domains. Mundt JC, et al. **J Stud Alcohol** 1997 Mar;58(2):130-40

Two varieties of helping in drunk-driving intervention: personal and situational factors. Newcomb MD, et al. **J Stud Alcohol** 1997 Mar;58(2):191-9

Acceptance of moderate drinking by alcoholism treatment services in Canada. Rosenberg H, et al. **J Stud Alcohol** 1996 Sep;57(5):559-62

The relationship between Self-Rating of the Effects of alcohol and alcohol challenge results in ninety-eight young men. Schuckit MA, et al. **J Stud Alcohol** 1997 Jul; 58(4):397-404

The relationship of gender balance at work, family responsibilities and workplace characteristics to drinking among male and female attorneys. Shore ER. **J Stud Alcohol** 1997 May;58(3):297-302

Factors affecting agreement between alcohol abusers' and their collaterals' reports. Sobell LC, et al. **J Stud Alcohol** 1997 Jul;58(4):405-13

Relationship between posttreatment drinking and alternative responses to high-risk situations proposed during treatment by problem drinkers. Breslin FC, et al. **J Subst Abuse** 1996; 8(4):479-86

Older adult controlled drinkers and abstainers. Chermack ST, et al. **J Subst Abuse** 1996;8(4):453-62

Dieting in sixth grade predicts alcohol use in ninth grade. Krahn D, et al. **J Subst Abuse** 1996;8(3):293-301

The temptation-coping questionnaire: development and validation. Myers MG, et al. **J Subst Abuse** 1995; 7(4):463-79

Alcohol consumption, brothel attendance, and condom use: normative expectations among Thai military conscripts. MacQueen KM, et al. **Med Anthropol Q** 1996 Sep; 10(3):402-23

Toward a (Dys)functional anthropology of drinking: ambivalence and the American Indian experience with alcohol. Spicer P. **Med Anthropol Q** 1997 Sep;11(3):306-23

Suppression of alcohol preference in high alcohol drinking rats: efficacy of amperozide versus naltrexone. Myers RD, et al. **Neuropsychopharmacology** 1996 Feb;14(2):139-49

Effects of a low alcohol dose on static balance, fine motor activity, and mental performance. Mangold S, et al. **Neurotoxicol Teratol** 1996 Sep-Oct;18(5):547-54

Fluoxetine reduces saccharin-induced elevation of fluid intake in alcohol-preferring Fawn-Hooded rats. Kampov-Polevoy AB, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):51-4

Investigation of the effects of moclobemide in chronic ethanol feeding rats. Uzbay IT, et al. **Pharmacol Res** 1995 Nov;32(5):287-92

Model for voluntary wine and alcohol consumption in rats. Arola L, et al. **Physiol Behav** 1997 Aug;62(2):353-7

The dipsogen angiotensin II does not stimulate ethanol intake in mice. Blair-West JR, et al. **Physiol Behav** 1996 Aug; 60(2):481-7

Alcohol, tobacco and illicit drug use among women. McGann KP, et al. **Prim Care** 1997 Mar;24(1):113-22 (43 ref.)

Beyond stress and arousal: a reconceptualization of alcohol-emotion relations with reference to psychophysiological methods. Stritzke WG, et al. **Psychol Bull** 1996 Nov;120(3):376-95 (183 ref.)

Family life satisfaction, age, length of residency: predicting alcohol and cigarette use among Korean adolescents in Australia. Hong SM, et al. **Psychol Rep** 1996 Feb; 78(1):187-93

Unemployment and alcohol consumption. Lester D. **Psychol Rep** 1996 Aug;79(1):150

Effects of alcohol on responsive laughter and amusement. Lowe G, et al. **Psychol Rep** 1997 Jun;80(3 Pt 2):1149-50

Habit-specific locus of control scales for drinking, smoking, and eating. Ludtke HA, et al. **Psychol Rep** 1996 Apr; 78(2):363-9

The "imaginary audience," self-handicapping, and drinking patterns among college students. Montgomery RL, et al. **Psychol Rep** 1996 Dec;79(3 Pt 1):783-6

Coping styles in abstainers from alcohol. Watten RG. **Psychopathology** 1996 Nov-Dec;29(6):340-6

Hostility, cigarette smoking and alcohol consumption in the general population. Whiteman MC, et al. **Soc Sci Med** 1997 Apr;44(8):1089-96

Reasons for drinking versus outcome expectancies in the prediction of college student drinking. Cronin C. **Subst Use Misuse** 1997 Aug;32(10):1287-311

When anthropology meets epidemiology: using social representations to predict drinking patterns. Demers A, et al. **Subst Use Misuse** 1996 May;31(7):847-71

Job dissatisfaction and substance use among employed high school students: the moderating influence of active and avoidant coping styles. Frone MR, et al. **Subst Use Misuse** 1997 Apr;32(5):571-85

The influence of religious affiliation on sociocultural predictors of drinking among Black and White Americans. Herd D. **Subst Use Misuse** 1996 Jan;31(1):35-63

The self-generated alcohol expectancies of Puerto Rican drinkers and abstainers. Johnson PB, et al. **Subst Use Misuse** 1996 Jul;31(9):1155-65

Differential perceptions of drinkers of alcoholic beverages by Mexican-Americans and non-Hispanic whites. Marin G, et al. **Subst Use Misuse** 1997 Aug;32(10):1369-84

Social influences: effects of the social environment on the use of alcohol and other drugs. Szalay LB, et al. **Subst Use Misuse** 1996 Feb;31(3):343-373

[Job strain and drinking behavior] Yang MJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Dec; 12(12):670-84 (Eng. Abstr.) **(Chi)**

[Analysis of flushing response to alcohol and drinking behavior in Japanese male students] Sobue I, et al. **Nippon Eiseigaku Zasshi** 1997 Jan;51(4):722-33 (Eng. Abstr.) **(Jpn)**

[Children of Alcoholics Screening Test (CAST) and influence of parent's drinking on their children] Yamazaki S. **Nippon Koshu Eisei Zasshi** 1996 Dec;43(12):1045-54 (Eng. Abstr.) **(Jpn)**

[Social drinking and adolescent parties] Míguez HA, et al. **Acta Psiquiatr Psicol Am Lat** 1995 Dec;41(4):282-7 (Eng. Abstr.) **(Spa)**

THERAPY

Where treatment and prevention merge: the need for a broader approach. Heather N. **Addiction** 1997 Mar;92 Suppl 1:S133-6

TRENDS

Situational norms for drinking and drunkenness: trends in the US adult population, 1979-1990. Greenfield TK, et al. **Addiction** 1997 Jan;92(1):33-47

Changes in alcohol consumption in a general population in The Netherlands: a 9-year follow-up study. Hajema KJ, et al. **Addiction** 1997 Jan;92(1):49-60

Alcohol and the future health of Europe. Lehto J. **Addiction** 1997 Mar;92 Suppl 1:S91-6

Trends in alcohol production, trade and consumption. Walsh B. **Addiction** 1997 Mar;92 Suppl 1:S61-6

ALCOHOL DRINKING

Predictors of increases in alcohol-related problems among black and white adults: results from the 1984 and 1992 National Alcohol Surveys. Jones-Webb R, et al. **Am J Drug Alcohol Abuse** 1997 May;23(2):281-99

Aboriginal drug and alcohol use: recent developments and trends [editorial] Brady M. **Aust N Z J Public Health** 1997 Feb;21(1):3-4

Consumption of alcohol and mortality in Russia [letter] Haaga JG, et al. **Lancet** 1997 Sep 27;350(9082):956

Huge variation in Russian mortality rates 1984-94: artefact, alcohol, or what? [see comments] Leon DA, et al. **Lancet** 1997 Aug 9;350(9075):383-8. Comment in: Lancet 1997 Aug 9;350(9075):379-80.

Consumption of alcohol and mortality in Russia [letter] Powles JW, et al. **Lancet** 1997 Sep 27;350(9082):956

Declining alcohol consumption in the U.S. and Rhode Island. Duncan DF. **Med Health R I** 1997 Mar;80(3):94-5

[Trends in alcohol consumption and predictors for increased alcohol consumption in former East Germany--analysis of the 1st and 2nd stages of the German Cardiovascular Prevention Study] Bloomfield K, et al. **Gesundheitswesen** 1997 Apr;59(4):283-8 (Eng. Abstr.) **(Ger)**

[Trends in alcohol intake among urban and rural Japanese populations] Kitamura A. **Nippon Koshu Eisei Zasshi** 1996 Feb;43(2):142-52 **(Jpn)**

[Pattern of alcohol consumption in young people and associated problems] Casas Anguita J, et al. **Med Clin (Barc)** 1996 Oct 26;107(14):544-8 **(Spa)**

URINE

Urinary excretion of tetrahydro-beta-carbolines relating to ingestion of alcoholic beverages. Tsuchiya H, et al. **Alcohol Alcohol** 1996 Mar;31(2):197-203

The use of 5-hydroxytryptophol as an alcohol intake marker. Helander A, et al. **Alcohol Alcohol Suppl** 1994;2:497-502 (30 ref.)

Disclosing recent drinking after alcohol has been cleared from the body [letter] Jones AW, et al. **J Anal Toxicol** 1996 Mar-Apr;20(2):141-2

Substance use among patients with a psychotic disorder in a psychiatric emergency room. Claassen CA, et al. **Psychiatr Serv** 1997 Mar;48(3):353-8

[Prevalence of porphyria cutanea tarda in Madrid and relationship between urine porphyrin and ethanol intake in a multiple linear regression model] Santos JL, et al. **Med Clin (Barc)** 1996 Nov 9;107(16):614-6 (Eng. Abstr.) **(Spa)**

ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION (U.S.) see **UNITED STATES SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION**

ALCOHOL, ETHYL

see related

ALCOHOLIC BEVERAGES

Alcohol policy and the public good: a good public debate [editorial] Edwards G, et al. **Addiction** 1996 Apr; 91(4):477-81

Selection bias in national surveys due to screening: implications from a county general population survey. Tam TW, et al. **Addiction** 1996 Apr;91(4):557-64

Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients [letter] Pol S, et al. **AIDS** 1996 Sep;10(11):1293-4

Correlation between the grade of tumoral invasion and pain relief in patients with celiac ganglia block. Akhan O, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1565-7

Fixation with Carnoy's fluid reduces the number of chymase-positive mast cells: not all chymase-positive mast cells are also positive for tryptase. KleinJan A, et al. **Allergy** 1996 Sep;51(9):614-20

Characteristics of pregnant substance abusers in two cities in the northeast. Bendersky M, et al. **Am J Drug Alcohol Abuse** 1996 Aug;22(3):349-62

Generalizability of the type A/type B distinction across different psychoactive substances. Feingold A, et al. **Am J Drug Alcohol Abuse** 1996 Aug;22(3):449-62

Characteristics associated with pregnant women's utilization of substance abuse treatment services. Messer K, et al. **Am J Drug Alcohol Abuse** 1996 Aug;22(3):403-22

Treatment of acute methanol intoxication with hemodialysis using an ethanol-enriched, bicarbonate-based dialysate. Chow MT, et al. **Am J Kidney Dis** 1997 Oct;30(4):568-70

TNF-alpha contributes to the pathogenesis of ethanol-induced gastric damage in cirrhotic rats. Ferraz JG, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):G809-14

Protective action of gastrin-17 against alcohol-induced gastric injury in the rat: role in mucosal defense. Mercer DW, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):G365-73

Alcohol increases plasma levels of cholesterol diet-induced atherogenic lipoproteins and aortic atherosclerosis in rabbits. Shaish A, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1091-7

The influence of 2-propanol and acetone on oviposition rate and oviposition site preference for acetic acid and ethanol of Drosophila melanogaster. Eisses KT. **Behav Genet** 1997 May;27(3):171-80

Mesoscopic gels at low agarose concentration: perturbation effects of ethanol. Bulone D, et al. **Biophys J** 1997 Jan; 72(1):388-94

Restricted motion of photoexcited bacteriorhodopsin in purple membrane containing ethanol. Kikukawa T, et al. **Biophys J** 1997 Jul;73(1):357-66

Increased yield of plasmid DNA during removal of CsCl by ethanol precipitation. Hildeman DA, et al. **Biotechniques** 1997 May;22(5):878-9

Abstaining and carousing: substance use among adolescents in the Western Isles of Scotland. Anderson K, et al. **Drug Alcohol Depend** 1996 Jul;41(3):189-96

Screening for alcohol problems in the emergency room: a rapid alcohol problems screen. Cherpitel CJ. **Drug Alcohol Depend** 1995 Dec;40(2):133-7

Comparison of formalin, ethanol, and Histochoice fixation on the PCR amplification from paraffin-embedded breast cancer tissue. Giannella C, et al. **Eur J Clin Chem Clin Biochem** 1997 Aug;35(8):633-5

Exhaled nitric oxide concentration is influenced by alcohol containing disinfectants [letter] Meijer RJ, et al. **Eur Respir J** 1996 May;9(5):1111

Endosonography-guided celiac plexus neurolysis. Wiersema MJ, et al. **Gastrointest Endosc** 1996 Dec;44(6):656-62

Recent developments in the pharmacotherapy of alcohol dependence. Schuckit MA. **J Consult Clin Psychol** 1996 Aug;64(4):669-76 (82 ref.)

Fixation affects morphometric characters of Psoroptes cuniculi mites (Acari:Psoroptidae). Reese NE, et al. **J Med Entomol** 1996 Sep;33(5):835-8

Effect of prenatal alcohol and cigarette exposure on two- and six-month-old infants' adrenocortical reactivity to stress. Ramsay DS, et al. **J Pediatr Psychol** 1996 Dec; 21(6):833-40

Effects of calcium channel antagonists on the reinforcing properties of morphine, ethanol and cocaine as measured by place conditioning. Biała G, et al. **J Physiol Pharmacol** 1996 Sep;47(3):497-502

Prevalence of depression and alcohol and other drug dependence in addictions treatment populations. Miller NS, et al. **J Psychoactive Drugs** 1996 Apr-Jun;28(2):111-24

DSM-V: there's work to be done [letter; comment] Martin CS. **J Stud Alcohol** 1997 May;58(3):334-5. Comment on: J Stud Alcohol 1996 Sep;57(5):469.

An intensive program for collegiate substance abusers. Progress six months after treatment entry. Bennett ME, et al. **J Subst Abuse Treat** 1996 May-Jun;13(3):219-25

Odor of specific alcohol solutions selectively alters locomotor activity of alcohol-drinking P rats. Myers RD, et al. **Physiol Behav** 1997 Jan;61(1):71-5

The biological, social and clinical bases of drug addiction: commentary and debate. Altman J, et al. **Psychopharmacology (Berl)** 1996 Jun;125(4):285-345

Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Worthington J, et al. **Psychosomatics** 1996 Nov-Dec;37(6):518-22

Report on the prevalence of drug/alcohol abuse and dependence in chronic pain patients (CPPs) [letter] Fishbain DA. **Subst Use Misuse** 1996 Jun;31(8):945-6

Ethanol ablation of lymphocele after renal transplantation: a minimally invasive approach. Kuzuhara K, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):147-50

["Inadvertent" use of alcohol-containing tonics in pregnancy] Hanck C, et al. **Med Klin** 1997 May 15;92(5):260 **(Ger)**

[The dependence of alcohol abuse and psychiatric comorbidity] Lastrico A, et al. **Minerva Psichiatr** 1996 Jun; 37(2):59-67 (Eng. Abstr.) **(Ita)**

[The 31st Conference of Japanese Medical Society of Alcohol and Drug Studies. September 13-14, 1996. Yokohama, Japan] **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Aug; 31(4):241-421 **(Jpn)**

[The 32nd conference of Japanese Medical Society of Alcohol and Drug Studies. September 11-13, 1997. Tokyo. Japan. Abstracts] **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1997 Aug; 32(4):203-465 **(Jpn)**

[The typological analysis of males with alcohol dependence disorder] Hauser J, et al. **Psychiatr Pol** 1996 Sep-Oct; 30(5):821-33 (Eng. Abstr.) **(Pol)**

[Competition of ethanol with endogenous digoxin-like natriuretic factor as a possible mechanism of addiction] Bagrov IaIu, et al. **Dokl Akad Nauk** 1996 May;348(2):268-9 **(Rus)**

ADMINISTRATION & DOSAGE

Magnetic resonance guidance of percutaneous ethanol injection in liver. Alexander AL, et al. **Acad Radiol** 1996 Jan;3(1):18-25

Effect of injection speed on the spread of ethanol during experimental liver ethanol injections. Tapani E, et al. **Acad Radiol** 1996 Dec;3(12):1025-9

Percutaneous ethanol sclerotherapy of postoperative lymphoceles. Zuckerman DA, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):433-7

Effects of prenatal alcohol exposure on birth weight in rats: is there an inverted U-shaped function? Abel EL. **Alcohol** 1996 Jan-Feb;13(1):99-102

Long-term ethanol treatment elicits changes in nicotinic receptor binding in only a few brain regions. Booker TK, et al. **Alcohol** 1997 Mar-Apr;14(2):131-40

Prenatal and postnatal ethanol exposure influences preweanling rats' behavioral and autonomic responding to ethanol odor. Chotro MG, et al. **Alcohol** 1996 Jul-Aug; 13(4):377-85

Heme oxygenase activity and acute and chronic ethanol exposure in the hippocampus, frontal cerebral cortex, and cerebellum of the near-term fetal guinea pig. Cook MN, et al. **Alcohol** 1997 Mar-Apr;14(2):117-24

There is not simple method to maintain a constant ethanol concentration in long-term cell culture: keys to a solution applied to the survey of astrocytic ethanol absorption. Eysseric H, et al. **Alcohol** 1997 Mar-Apr;14(2):111-5

Effects of early weaning and social isolation on subsequent alcohol intake in rats. Fahlke C, et al. **Alcohol** 1997 Mar-Apr;14(2):175-80

Alcohol utilization and dependence with special reference to protein level in a liquid diet for rats. Fisher H, et al. **Alcohol** 1997 Mar-Apr;14(2):199-202

Dose-related growth deficits in LS but not SS mice prenatally exposed to alcohol. Gilliam DM, et al. **Alcohol** 1996 Jan-Feb;13(1):47-51

The discrimination and durability of an ethanol cue in young and mid-aged female mice. Groseclose CH, et al. **Alcohol** 1997 Mar-Apr;14(2):191-7

Acute alcohol tolerance in cognitive and psychomotor performance: influence of the alcohol dose and prior alcohol experience. Hiltunen AJ. **Alcohol** 1997 Mar-Apr; 14(2):125-30

Angiotensin II reduces alcohol intake and choice in water- or food-restricted rats. Kulkosky PJ, et al. **Alcohol** 1996 Jul-Aug;13(4):359-63

Alterations in mouse Peyer's patch lymphocyte phenotype after ethanol consumption. Lopez MC, et al. **Alcohol** 1997 Mar-Apr;14(2):107-10

Effects of ethanol on energy balance of rats and the inappropriateness of intraperitoneal injection. Luz J, et al. **Alcohol** 1996 Nov-Dec;13(6):575-80

Regional CNS densities of monoamine receptors in alcohol-naive alcohol-preferring P and -nonpreferring NP rats. McBride WJ, et al. **Alcohol** 1997 Mar-Apr;14(2):141-8

The use of nonalcoholic beer as the vehicle for ethanol consumption in rats. Samson HH, et al. **Alcohol** 1996 Jul-Aug;13(4):365-8

Ethanol self-administration is genetically independent of locomotor stimulation in fast and slow mice. Sanchez FP, et al. **Alcohol** 1996 Jan-Feb;13(1):79-84

Dopaminergic and opiate agonists and antagonists differentially decrease multiple schedule responding maintained by sucrose/ethanol and sucrose. Slawecki CJ, et al. **Alcohol** 1997 May-Jun;14(3):281-94

Ethanol as an oral reinforcer in normal weight rhesus monkeys: dose-response functions. Stewart RB, et al. **Alcohol** 1996 Jul-Aug;13(4):341-6

Self-administration of ethanol: towards the location of predisposing polygenes in quasi-congenic animal models. Vadász C, et al. **Alcohol** 1996 Nov-Dec;13(6):617-20

Alcohol consumption alters cytokine release during murine AIDS. Wang JY, et al. **Alcohol** 1997 Mar-Apr;14(2):155-9 (38 ref.)

Constant absolute ethanol intake by Sardinian alcohol-preferring rats independent of ethanol concentrations. Lobina C, et al. **Alcohol Alcohol** 1997 Jan-Feb;32(1):19-22

Alcohol consumption and gustatory hedonic profiles in Wistar-Kyoto hyper- and normoactive rat strains. Razafimanalina R, et al. **Alcohol Alcohol** 1997 Jul-Aug; 32(4):485-91

Intravenous ethanol self-administration in C57BL/6J and DBA/2J mice. Grahame NJ, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):56-62

Dopamine receptors in the medial prefrontal cortex influence ethanol and sucrose-reinforced responding. Hodge CW, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1631-8

Effect of three different modes of alcohol administration on the activity of the rat hypothalamic-pituitary-adrenal axis. Ogilvie K, et al. **Alcohol Clin Exp Res** 1997 May; 21(3):467-76

Chronic alcohol feeding in liquid diet or in drinking water has similar effects on electron microscopic appearance of the hepatic sinusoid in the rat. Sarphie TG, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):973-9

Nutritional deficiencies in chronic alcoholics: relation to dietary intake and alcohol consumption. Glória L, et al. **Am J Gastroenterol** 1997 Mar;92(3):485-9

Brain impairment in well-nourished chronic alcoholics is related to ethanol intake. Nicolás JM, et al. **Ann Neurol** 1997 May;41(5):590-8

Treatment of radioiodine-negative bone metastasis from papillary thyroid carcinoma with percutaneous ethanol injection therapy. Nakada K, et al. **Ann Nucl Med** 1996 Nov;10(4):441-4

Drug self-administration viewed as ingestive behaviour. Wise RA. **Appetite** 1997 Feb;28(1):1-5 (37 ref.)

Increased oxidative damage to mitochondrial DNA following chronic ethanol consumption. Cahill A, et al. **Biochem Biophys Res Commun** 1997 Jun 18;235(2):286-90

Effects of moderate doses of ethyl alcohol on cerebral lateralization of language. II: a dichotic listening study. Clarici A, et al. **Boll Soc Ital Biol Sper** 1995 Sep-Oct; 71(9-10):241-8

Selective termination by intrahepatic vein alcohol injection of a monochorionic twin pregnancy discordant for fetal abnormality. Denbow ML, et al. **Br J Obstet Gynaecol** 1997 May;104(5):626-7

Dose-dependent effects of chronic ethanol on mouse adipose

tissue lipase activity and cyclic AMP accumulation. Shih MF, et al. **Br J Pharmacol** 1997 Feb;120(4):721–7

Persistent reduction of GABA(A) receptor–mediated inhibition in rat hippocampus after chronic intermittent ethanol treatment. Kang M, et al. **Brain Res** 1996 Feb 19; 709(2):221–8

Ethanol–induced hypothermia in rats is antagonized by dexamethasone. Carreño CF, et al. **Braz J Med Biol Res** 1997 Jan;30(1):69–72

Associations of alcohol, height, and reproductive factors with serum hormone concentrations in postmenopausal Japanese women. Steroid hormones in Japanese postmenopausal women. Nagata C, et al. **Breast Cancer Res Treat** 1997 Jul;44(3):235–41

Ablation of hepatocellular carcinoma by percutaneous ethanol injection: imaging findings. Becker CD, et al. **Cardiovasc Intervent Radiol** 1997 May–Jun;20(3):204–10

Successful repeat transcatheter ablation of a mediastinal parathyroid adenoma 6 years after alcohol embolization. Cook GJ, et al. **Cardiovasc Intervent Radiol** 1997 Jul–Aug; 20(4):314–6

Treatment of hepatocellular carcinoma: a single–center experience. Florio F, et al. **Cardiovasc Intervent Radiol** 1997 Jan–Feb;20(1):23–8

Transcatheter alcohol ablation of the septum in a patient of hypertrophic obstructive cardiomyopathy. Bhargava B, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):56–8

Alcohol, ischemic heart disease, and the French paradox. Constant J. **Clin Cardiol** 1997 May;20(5):420–4 (51 ref.)

Changes in serum apolipoprotein and lipoprotein profile induced by chronic alcohol consumption and withdrawal: determinant effect on heart disease? Lecomte E, et al. **Clin Chem** 1996 Oct;42(10):1666–75

Five–year follow–up of percutaneous ethanol injection for the treatment of hyperfunctioning thyroid nodules: a study of 117 patients. Monzani F, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):9–15

Transient liver accumulation of Tc–99m phytate in hepatocellular carcinoma after percutaneous ethanol injection. Shiomi S, et al. **Clin Nucl Med** 1997 Aug; 22(8):550–2

Elicitation thresholds for thiuram mix using petrolatum and ethanol/sweat as vehicles. Knudsen BB, et al. **Contact Dermatitis** 1996 Jun;34(6):410–3

Long–term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Witheiler DD, et al. **Dermatol Surg** 1997 Mar;23(3):191–6

Regulation of the hepatic CYP 2E1 gene during chronic alcohol exposure: lack of an ethanol response element in the proximal 5'–flanking sequence. McGehee RE Jr, et al. **DNA Cell Biol** 1997 Jun;16(6):725–36

Statistics and the dysphagia score [letter] Pal KM. **Endoscopy** 1996 Mar;28(3):327

Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases. Bennedbaek FN, et al. **Eur J Endocrinol** 1997 Mar;136(3):240–50 (71 ref.)

Role of adenosine in the ethanol–induced potentiation of the effects of general anesthetics in rats. Campisi P, et al. **Eur J Pharmacol** 1997 May 1;325(2–3):165–72

Comparison of the stimulus properties of ethanol and the Ca2+ channel antagonist nimodipine in rats. De Beun R, et al. **Eur J Pharmacol** 1996 Jun 13;306(1–3):5–13

Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat. Spanagel R, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):51–6

Percutaneous treatment of a congenital splenic cyst with alcohol: a new therapeutic approach. Akhan O, et al. **Eur Radiol** 1997;7(7):1067–70

Ethanol injection for the treatment of hepatic tumours. Bartolozzi C, et al. **Eur Radiol** 1996;6(5):682–96 (99 ref.)

Long–term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Lencioni R, et al. **Eur Radiol** 1997;7(4):514–9

Endosonography–guided celiac plexus neurolysis. Harada N, et al. **Gastrointest Endosc Clin N Am** 1997 Apr;7(2):237–45

The medical management of hepatocellular carcinoma (HCC) in Japan: a review with implications for HCC seen in the west. Ichida T, et al. **Hepatogastroenterology** 1996 Nov–Dec;43(12):1575–83 (37 ref.)

Predictive factors for recurrence after percutaneous ethanol injection for solitary hepatocellular carcinoma. Ishii H, et al. **Hepatogastroenterology** 1996 Jul–Aug;43(10):938–43

Chemoembolization and percutaneous ethanol injection for intrahepatic recurrence of hepatocellular carcinoma after hepatic resection. Sato M, et al. **Hepatogastroenterology** 1996 Nov–Dec;43(12):1421–6

Histological changes of parathyroid adenoma after percutaneous injection of ethanol. Chow LT, et al. **Histopathology** 1997 Jan;30(1):87–9

Different effects of alcohol and salt on 24–hour blood pressure and heart rate in hypertensive patients. Kawano Y, et al. **Hypertens Res** 1996 Dec;19(4):255–61

Septal coronary artery ablation for hypertrophic obstructive cardiomyopathy. Bahl VK, et al. **Indian Heart J** 1996 Nov–Dec;48(6):701–3

Transcatheter arterial renal and adrenal embolization with iohexol–ethanol solutions. Animal experimental study and clinical application. Miyazono N, et al. **Invest Radiol** 1996 Dec;31(12):755–60

How much do alcohol calories count? [editorial; comment] Suter PM. **J Am Coll Nutr** 1997 Apr;16(2):105–6. Comment on: J Am Coll Nutr 1997 Apr;16(2):134–9.

Dilute ethanol versus mechanical debridement before photorefractive keratectomy. Abad JC, et al. **J Cataract Refract Surg** 1996 Dec;22(10):1427–33

A large, nonfunctioning parathyroid cyst recurring after aspiration and subsequently cured by percutaneous ethanol injection. Zingrillo M, et al. **J Clin Ultrasound** 1996 Sep; 24(7):378–82

MR appearance and spectral features of injected ethanol in the liver: implication for fast MR–guided percutaneous ethanol injection therapy. Shinmoto H, et al. **J Comput Assist Tomogr** 1997 Jan–Feb;21(1):82–8

Experimental approaches for the treatment of murine B16 melanomas of various sizes. I: Local injection of ethanol with a combination of interleukin–2 or microwaval hyperthermia for B16 melanomas with a size of less than 7 mm in diameter. Nakayama J, et al. **J Dermatol Sci** 1997 Aug;15(2):75–81

Experimental approaches for the treatment of murine B16 melanomas of various sizes. II: Injection of ethanol with combinations of beta–interferon and microwaval hyperthermia for B16 melanomas with a size of greater than 10 mm in diameter. Nakayama J, et al. **J Dermatol Sci** 1997 Aug;15(2):82–8

An evaluation of five protocols for surgical handwashing in relation to skin condition and microbial counts. Pereira LJ, et al. **J Hosp Infect** 1997 May;36(1):49–65

MR–guided percutaneous ethanol ablation of liver tissue in a .2–T open MR system: preliminary study in porcine model. Lu DS, et al. **J Magn Reson Imaging** 1997 Mar–Apr; 7(2):303–8

Spin trapping studies of alcohol–initiated radicals in rat liver: influence of dietary fat. Reinke LA, et al. **J Nutr** 1997 May;127(5 Suppl):899S–902S

Effect of long–term alcohol administration on bone metabolism in rats. Yamamoto A, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Jun;43(3):369–75

Effects of gamma–aminobutyric acid agonists and N–methyl–D–aspartate antagonists on a multiple schedule of ethanol and saccharin self–administration in rats. Shelton KL, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1250–60

Red wine is less stress reducing than vodka; no differences in neuroendocrine challenge test. Jarrett N, et al. **J Psychopharmacol (Oxf)** 1997;11(3):283–6

Successful treatment of a bleeding renal tumor with ethanol [letter] Machan LS, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):152–3

Efficacy of direct injection of ethanol into the myocardium to control aconitine–induced ventricular tachycardia in anesthetized dogs. Kurita A, et al. **Jpn Heart J** 1996 Sep; 37(5):611–25

Beneficial effect of alcohol in hereditary cerebellar ataxia with myoclonus (progressive myoclonic ataxia): report of two siblings. Jain S, et al. **Mov Disord** 1996 Nov;11(6):751–2

The management of hypertrophic cardiomyopathy [letter; comment] Seggewiss H, et al. **N Engl J Med** 1997 Jul 31; 337(5):349–50. Comment on: N Engl J Med 1997 Mar 13;336(11):775–85.

Ethanol endovascular management of brain arteriovenous malformations: initial results. Yakes WF, et al. **Neurosurgery** 1997 Jun;40(6):1145–52; discussion 1152–4

Folate and alcohol intakes: related or independent roles in the adenoma–carcinoma sequence? Boutron–Ruault MC, et al. **Nutr Cancer** 1996;26(3):337–46

Alcohol concentration determines the type of atrial arrhythmia induced in a porcine model of acute alcoholic intoxication. Anadon MJ, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1962–7

Ethanol and cocaine intake by rats selectively bred for oral opioid acceptance. Carlson KR, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):309–13

Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Arnone M, et al. **Psychopharmacology (Berl)** 1997 Jul;132(1):104–6

The calcium channel agonist BAY k 8644 reduces ethanol intake and preference in alcohol–preferring AA rats. de Beun R, et al. **Psychopharmacology (Berl)** 1996 Oct; 127(4):302–10

Substitution of the selective serotonin reuptake inhibitors fluoxetine and paroxetine for the discriminative stimulus effects of ethanol in rats. Maurel S, et al. **Psychopharmacology (Berl)** 1997 Apr;130(4):404–6

Effects of bromocriptine on self–administration of sweetened ethanol solutions in rats. Nadal R, et al. **Psychopharmacology (Berl)** 1996 Nov;128(1):45–53

Long–term results of ethanol embolization of renal cell carcinoma. Saitoh H, et al. **Radiat Med** 1997 Mar–Apr; 15(2):99–102

Interventional radiologic procedures with CT guidance in cancer pain management. Gangi A, et al. **Radiographics** 1996 Nov;16(6):1289–304; discussion 1304–6

Medium–depth chemical peeling. Otley CC, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):145–54 (23 ref.)

Combination of transcatheter arterial embolization and percutaneous ethanol injection for hepatocellular carcinoma: comparison of efficacies of doxorubicin and epirubicin in transcatheter arterial embolization. Nakamura S, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6–46–S6–49

Appraisal of combination treatment for hepatocellular carcinoma: long–term follow–up and lipiodol–percutaneous ethanol injection therapy. Tateishi H, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6–81–S6–90

Evaluation of combined therapy with chemoembolization and ethanol injection for advanced hepatocellular carcinoma. Yamamoto K, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6–50–S6–55

Efficacy and safety of preoperative percutaneous transhepatic portal embolization with absolute ethanol: a clinical study. Shimamura T, et al. **Surgery** 1997 Feb;121(2):135–41

Percutaneous ethanol injection of large thyroid cystic nodules. Zingrillo M, et al. **Thyroid** 1996 Oct;6(5):403–8

Association between endothelial cell proliferation and pathologic changes in experimental alcoholic liver disease. Nanji AA, et al. **Toxicol Appl Pharmacol** 1996 Sep; 140(1):101–7

Effect of long–term ethanol pretreatment on the metabolism of dichloromethane to carbon monoxide in rats. Wirkner K, et al. **Toxicol Appl Pharmacol** 1997 Mar;143(1):83–8

Echogenicity of experimental liver ethanol injections. Vehmas T, et al. **Ultrasound Med Biol** 1995;21(9):1137–41

[Treatment of liver tumors with ethanol injection] Kaláb M. **Vnitr Lek** 1997 Mar;43(3):180–3 (Eng. Abstr.) **(Cze)**

[Percutaneous alcoholization of hepatocellular carcinoma complicated by acute endocarditis on aortic valvulopathy and cerebral abscess (letter)] Vuillemin E, et al. **Gastroenterol Clin Biol** 1997;21(5):441–2 **(Fre)**

[The curative therapy of primary hyperparathyroidism by percutaneous ethanol injections] Ackmann S, et al. **Dtsch Med Wochenschr** 1997 May 16;122(20):648–52 (24 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of osteoid osteoma with CT–guided drilling and ethanol instillation] Duda SH, et al. **Dtsch Med Wochenschr** 1997 Apr 18;122(16):507–10 (Eng. Abstr.) **(Ger)**

[Combined transarterial chemoembolization and percutaneous ethanol injection in hepatocellular carcinoma prior to transplantation] Hesse UJ, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:121–5 (Eng. Abstr.) **(Ger)**

[Elimination of thyroid cysts and controlling autonomous adenomas of the thyroid gland by local alcohol injection] Braun B, et al. **Med Klin** 1996 Feb 15;91 Suppl 1:1–2 **(Ger)**

[Percutaneous ethanol injection therapy of hepatocellular carcinoma] Reinwald H. **Med Klin** 1996 Nov 15; 91(11):729–34 **(Ger)**

[PET studies with C–11 ethanol in intratumoral therapy of hepatocellular carcinomas] Dimitrakopoulou–Strauss A, et al. **Radiologe** 1996 Sep;36(9):744–9 (Eng. Abstr.) **(Ger)**

[Percutaneous alcohol instillation therapy (PAI) and chemoembolization in extensive hepatocellular carcinoma] Adamus R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Feb;166(2):173–5 (10 ref.) **(Ger)**

[Nonsurgical therapy of focal liver lesions] Allgaier HP, et al. **Schweiz Rundsch Med Prax** 1997 Jan 21;86(4):86–90 (40 ref.) (Eng. Abstr.) **(Ger)**

[Assessment of the therapeutic effectiveness of alcohol administration in hepatocarcinoma: comparison of spiral computerized tomography and Doppler color ultrasonography] Basilico R, et al. **Radiol Med (Torino)** 1996 Jul–Aug;92(1–2):92–6 (Eng. Abstr.) **(Ita)**

[A patient with HCC successfully treated by ethanol injection therapy with etoposide] Sakon M, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1585–7 (Eng. Abstr.) **(Jpn)**

[Ethanol injection therapy to the lung cancer] Masaki Y, et al. **Kyobu Geka** 1997 May;50(5):384–8 (Eng. Abstr.) **(Jpn)**

[Effects of long–term ethanol administration (1). Effects of long–term ethanol administration on kidney studied at several periods of time during the administration] Omoto M, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1997 Feb;32(1):27–45 (Eng. Abstr.) **(Jpn)**

[Effect of long–term ethanol administration (2). Free type and bound type ethanol and related substances contents of the urine from ethanol administrated rats, indices in the serum, and renal tissues] Omoto M, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1997 Feb; 32(1):46–58 (Eng. Abstr.) **(Jpn)**

[Balloon–occluded ethanol ablation therapy: (BEAT) for hepatocellular carcinoma] Motohara T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Jun;57(7):433–5 (Eng. Abstr.) **(Jpn)**

[Selective segmental necrotizing therapy for hepatocellular carcinoma: an experimental study of an ethanol injection method] Usuki N. **Nippon Igaku Hoshasen Gakkai Zasshi** 1994 Oct 25; 54(12):1142–54 (Eng. Abstr.) **(Jpn)**

[Case of liver epithelioid hemangioendothelioma treated with percutaneous ethanol infusion] Shiro Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Jun 10;85(6):933–5 **(Jpn)**

[Percutaneous ethanol injection therapy for small hepatocellular carcinoma] Otsuka S. **Nippon Rinsho** 1996 May;54(5):1347–50 (14 ref.) (Eng. Abstr.) **(Jpn)**

[A case of hepatocellular carcinoma with direct invasion into the pleural cavity presenting as hemorrhage achieved hemostasis with intra–arterial injection of ethanol] Kanou S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Oct; 93(10):753–7 **(Jpn)**

[Effect of alcohol intake on the ability to pilot aircraft] Ushakov IB, et al. **Aviakosm Ekolog Med** 1996;30(6):19–24

(Eng. Abstr.) **(Rus)**

[Effect of a small dose of ethanol on activity of rat cerebellum Purkinje cells] Grigor'ian RA, et al. **Dokl Akad Nauk** 1992; 325(4):865–8 **(Rus)**

[Percutaneous treatment of hepatocellular carcinoma] Brú C. **Rev Gastroenterol Mex** 1996 Oct–Dec;61(4 Suppl 2):S90–3 **(Spa)**

[Palliative treatment of esophageal cancer with transendoscopic injection of alcohol] Güiitrón A, et al. **Rev Gastroenterol Mex** 1996 Jul–Sep;61(3):208–11 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Prolongation of the QTc interval during alcohol withdrawal syndrome. Otero-Antón E, et al. **Acta Cardiol** 1997; 52(3):285–94

Thioctic acid protection against ethanol and indomethacin induced gastric mucosal lesions in rats. Gutierrez-Cabano CA, et al. **Acta Gastroenterol Latinoam** 1996;26(3):167–71

Complications following high-dose percutaneous ethanol injection into hepatic tumors. Tapani E, et al. **Acta Radiol** 1996 Sep;37(5):655–9

Effects of prenatal alcohol exposure on birth weight in rats: is there an inverted U-shaped function? Abel EL. **Alcohol** 1996 Jan–Feb;13(1):99–102

Repeated ethanol withdrawal experience increases the severity and duration of subsequent withdrawal seizures in mice. Becker HC, et al. **Alcohol** 1997 Jul–Aug; 14(4):319–26

The paradoxical hedonic valence of acute ethanol withdrawal (hangover) states in rats: place and taste conditioning. Gauvin DV, et al. **Alcohol** 1997 May–Jun;14(3):261–8

A prospective study on hepatocellular carcinoma in liver cirrhosis: respective roles of alcohol and hepatitis C virus infection. Miyakawa H, et al. **Alcohol Alcohol** 1994;29 Suppl 1:75–9

Nature and healing of tibial shaft fractures in alcohol abusers. Nyquist F, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):91–5

Relative kindling effect of readmissions in alcoholics. Worner TM. **Alcohol Alcohol** 1996 Jul;31(4):375–80

Alcohol-induced bone disease: impact of ethanol on osteoblast proliferation. Klein RF. **Alcohol Clin Exp Res** 1997 May;21(3):392–9 (112 ref.)

Alcohol, osteoporosis, and bone regulating hormones. Sampson HW. **Alcohol Clin Exp Res** 1997 May;21(3):400–3 (45 ref.)

Medical consequences of alcohol abuse: is gender a factor? Schenker S. **Alcohol Clin Exp Res** 1997 Feb;21(1):179–81 (41 ref.)

Effect of chronic alcohol intake on energy metabolism in human muscle. Yazaki K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):360A–362A

Comparison of alcoholic cardiomyopathy in women versus men. Fernández-Solà J, et al. **Am J Cardiol** 1997 Aug 15; 80(4):481–5

Alcohol-containing mouthwashes and oropharyngeal cancer: a spurious association due to underascertainment of confounders? Shapiro S, et al. **Am J Epidemiol** 1996 Dec 15;144(12):1091–5 (19 ref.)

Sudden death due to metronidazole/ethanol interaction. Cina SJ, et al. **Am J Forensic Med Pathol** 1996 Dec;17(4):343–6

Treating acute alcohol withdrawal. Babel K. **Am J Nurs** 1997 Jan;97(1):22–3

Unexpected alcohol withdrawal. Brent MJ. **Am J Nurs** 1997 Jun;97(6):52–3

Hormone-specific alterations of T4, T3, and reverse T3 metabolism with recent ethanol abstinence in humans. Kaptein EM. **Am J Physiol** 1997 Feb;272(2 Pt 1):E191–200

Ethanol-induced anaphylaxis following ingestion of overripe rock melon, Cucumis melo. Mallon DF, et al. **Ann Allergy Asthma Immunol** 1997 Mar;78(3):285–6

Disulfiram–ethanol test reaction: significance of supervision [letter] Savas MC, et al. **Ann Pharmacother** 1997 Mar; 31(3):374–5

Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists. Palop D, et al. **Arzneimittelforschung** 1997 Apr;47(4A):450–4

Hangovers [editorial] [published erratum appears in BMJ 1997 Feb 15;314(7079):460] Calder I. **BMJ** 1997 Jan 4; 314(7073):2–3

Patients' reports of the effect of alcohol on tinnitus. Pugh R, et al. **Br J Audiol** 1995 Oct;29(5):279–83

Alcohol and the brain. Scheepers BD. **Br J Hosp Med** 1997 Jun 4–17;57(11):548–51 (16 ref.)

The acute impact of ethanol on glucose, insulin, triacylglycerol,and free fatty acid responses and insulin sensitivity in type 2 diabetes. Christiansen C, et al. **Br J Nutr** 1996 Nov;76(5):669–75

Decreased GABA effectiveness in the inferior colliculus neurons during ethanol withdrawal in rats susceptible to audiogenic seizures. N'Gouemo P, et al. **Brain Res** 1996 Jun 17;724(2):200–4

Another perspective on management of withdrawal [letter; comment] [see comments] Bates D. **Can Fam Physician** 1997 Mar;43:421–4. Comment on: Can Fam Physician 1996 Nov;42:2186–90. Comment in: Can Fam Physician 1997 Jul;43:1209, 1211–2.

Emergency management of acute alcohol problems. Part 1: Uncomplicated withdrawal [see comments] Etherington JM. **Can Fam Physician** 1996 Nov;42:2186–90 (14 ref.). Comment in: Can Fam Physician 1997 Mar;43:420–1. Comment in: Can Fam Physician 1997 Mar;43:421–4.

Article on alcohol withdrawal practical [letter; comment] McNeill CA. **Can Fam Physician** 1997 Mar;43:420–1. Comment on: Can Fam Physician 1996 Nov;42:2186–90.

Alcohol and the heart: biochemical alterations. Preedy VR, et al. **Cardiovasc Res** 1996 Jan;31(1):139–47 (83 ref.)

Ethanol metabolite acetic acid as causative agent for type-1 hypersensitivity-like reactions to alcoholic beverages [see comments] Boehncke WH, et al. **Clin Exp Allergy** 1996 Sep;26(9):1089–91. Comment in: Clin Exp Allergy 1997 Mar;27(3):343.

Adverse reactions to alcoholic beverages: a diagnostic guideline [letter; comment] Wantke F, et al. **Clin Exp Allergy** 1997 Mar;27(3):343. Comment on: Clin Exp Allergy 1996 Sep;26(9):1089–91.

Role of dopamine mesolimbic system in opioid action of psychotropic analgesic nitrous oxide in alcohol and drug withdrawal. Lichtigfeld FJ, et al. **Clin Neuropharmacol** 1996 Jun;19(3):246–51 (43 ref.)

Marked decrease of plasma neuroactive steroids during alcohol withdrawal. Romeo E, et al. **Clin Neuropharmacol** 1996 Aug;19(4):366–9

The complex interaction between ethanol and acetaminophen. Slattery JT, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):241–6 (49 ref.)

Alcohol & diabetes. Swade TF, et al. **Compr Ther** 1997 Feb; 23(2):135–40 (48 ref.)

Allergic contact dermatitis from benzalkonium chloride used as a denaturant of ethanol. Ortiz-Frutos FJ, et al. **Contact Dermatitis** 1996 Nov;35(5):302

Role of xanthine oxidase-derived oxidants and leukocytes in ethanol-induced jejunal mucosal injury. Dinda PK, et al. **Dig Dis Sci** 1996 Dec;41(12):2461–70

Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Wilde MI, et al. **Drugs** 1997 Jun; 53(6):1038–53 (62 ref.)

Disorders of brain development in the progeny of mothers who used alcohol during pregnancy. Konovalov HV, et al. **Early Hum Dev** 1997 Apr 25;48(1–2):153–66

Increased cancer risk among Swedish female alcoholics. Sigvardsson S, et al. **Epidemiology** 1996 Mar;7(2):140–3

Alcohol and breast cancer in the Swiss Canton of Vaud. Levi F, et al. **Eur J Cancer** 1996 Nov;32A(12):2108–13

Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Vnurman EF, et al. **Eur J Clin Pharmacol** 1996;50(6):475–82

The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal. Putzke J, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):39–48

Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Spanagel R, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):45–50

Acute pancreatic injury in asymptomatic individuals after heavy drinking over the long-term. Parent J, et al. **Gastrointest Endosc** 1996 Jun;43(6):637–8

Changes in the enterocyte cytoskeleton in newborn rats exposed to ethanol in utero. Montes JF, et al. **Gut** 1996 Jun;38(6):846–52

Prenatal alcohol exposure affects galactosyltransferase activity and glycoconjugates in the Golgi apparatus of fetal rat hepatocytes. Renau-Piqueras J, et al. **Hepatology** 1997 Feb;25(2):343–50

Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Janiri L, et al. **Int Clin Psychopharmacol** 1996 Jun;11(2):109–17

Effect of alcohol on tumor growth of hepatocellular carcinoma with type C cirrhosis. Matsuhashi T, et al. **Intern Med** 1996 Jun;35(6):443–8

Alcohol-induced bronchial asthma [letter; comment] Ayres JG. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):860. Comment on: J Allergy Clin Immunol 1996 Jan;97(1 Pt 1):74–84.

Laboratory validation study of drug evaluation and classification program: ethanol, cocaine, and marijuana. Heishman SJ, et al. **J Anal Toxicol** 1996 Oct;20(6):468–83

Effect of ethanol in Ice Drops on breath alcohol concentration [letter] Williams RD. **J Anal Toxicol** 1996 Jul–Aug;20(4):271

The antilesion actions of anticholinergic agents on ethanol-induced injury in rat stomachs: the importance of gastric vascular integrity and tonicity. Ko JK, et al. **J Auton Pharmacol** 1996 Jun;16(3):117–24

A validation study of the influence of alcohol on handwriting. Stinson MD. **J Forensic Sci** 1997 May;42(3):411–6

Can misoprostol and omeprazole reduce nicotine and ethanol induced gastric mucosal injury? A quantitative macroscopic and microscopic analysis in rats. Hui WM, et al. **J Gastroenterol Hepatol** 1997 Jan;12(1):7–12

Alcohol withdrawal treatment practices [letter; comment] Wartenberg AA. **J Gen Intern Med** 1996 May;11(5):315–6 . Comment on: J Gen Intern Med 1995 Sep;10(9):479–87.

Hepatic parenchymal changes after ethanol injection in rabbits: correlation of conventional and dynamic MR imaging with pathologic findings. Fujita T, et al. **J Magn Reson Imaging** 1996 Jan–Feb;6(1):156–61

Re: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy trial [letter; comment] Challem JJ. **J Natl Cancer Inst** 1997 Feb 19;89(4):325–6. Comment on: J Natl Cancer Inst 1996 Nov 6;88(21):1550–9.

Chronic alcohol consumption and withdrawal do not induce cell death in the suprachiasmatic nucleus, but lead to irreversible depression of peptide immunoreactivity and mRNA levels. Madeira MD, et al. **J Neurosci** 1997 Feb 15;17(4):1302–19

Gangliosides reduce the development of ethanol dependence without affecting ethanol tolerance. Snell LD, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):128–36

Impaired binocular depth inversion in patients with alcohol withdrawal. Schneider U, et al. **J Psychiatr Res** 1996 Nov–Dec;30(6):469–74

Effects of alcohol and other drugs on children. Young NK. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):23–42 (145 ref.)

Differences in sexual risk-taking behavior with state of inebriation in an aboriginal population in Ontario, Canada. Myers T, et al. **J Stud Alcohol** 1997 May;58(3):312–22

Visuospatial information processing in intoxicated, recently detoxified, and long-term abstinent alcoholics. Schandler SL, et al. **J Subst Abuse** 1996;8(3):321–33

Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. Mayo-Smith MF. **JAMA** 1997 Jul 9;278(2):144–51

Alcohol withdrawal syndrome [letter] Gillman MA, et al. **Lancet** 1997 Sep 6;350(9079):737

The alcohol withdrawal syndrome. Hall W, et al. **Lancet** 1997 Jun 28;349(9069):1897–900 (53 ref.)

Antioxidants and ischaemic heart disease [letter] Leo MA, et al. **Lancet** 1997 Aug 30;350(9078):667; discussion 668

Immune surveillance of the oral cavity and lymphocyte migration: relevance for alcohol abusers. Chiappelli F, et al. **Lymphology** 1995 Dec;28(4):196–207 (52 ref.)

Alcoholic liver disease. Fernández-Checa JC. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:27–31

Rhabdomyolysis with acute renal failure and disseminated intravascular coagulation: association with acetaminophen and ethanol. Riggs JE, et al. **Mil Med** 1996 Nov; 161(11):708–9

Ethanol and hypertrophic cardiomyopathy [letter; comment] Allan JJ. **N Engl J Med** 1997 Mar 20;336(12):878. Comment on: N Engl J Med 1996 Sep 26;335(13):938–41.

Alcohol, alcoholic brain damage, and GABAA receptor isoform gene expression. Lewohl JM, et al. **Neurochem Int** 1996 Dec;29(6):677–84

Persistent dyskinesia and obsessive-compulsive behavior following alcohol withdrawal [see comments] Cardoso F, et al. **Neurology** 1996 Sep;47(3):844. Comment in: Neurology 1997 May;48(5):1478–9.

Alcohol withdrawal and Tourette's syndrome [letter; comment] Muller-Vahl KR, et al. **Neurology** 1997 May; 48(5):1478–9. Comment on: Neurology 1996 Sep;47(3):844.

Mesolimbic dopaminergic reduction outlasts ethanol withdrawal syndrome: evidence of protracted abstinence. Diana M, et al. **Neuroscience** 1996 Mar;71(2):411–5

Effects of prenatal ethanol exposure and early experience on radial maze performance and conditioned taste aversion in mice. Opitz B, et al. **Neurotoxicol Teratol** 1997 May–Jun; 19(3):185–90

Human cataract risk factors: significance of abstention from, and high consumption of, ethanol (U-curve) and non-significance of smoking. Phillips CI, et al. **Ophthalmic Res** 1996;28(4):237–47

Ethanol consumption and susceptibility of the pancreas to cerulein-induced pancreatitis. Ponnappa BC, et al. **Pancreas** 1997 Mar;14(2):150–7

Cross-generalization of an EtOH "hangover" cue to endogenously and exogenously induced stimuli. Gauvin DV, et al. **Pharmacol Biochem Behav** 1997 May–Jun; 57(1–2):199–206

Risperidone in treatment-refractory chronic alcohol hallucinosis [letter] Soyka M, et al. **Pharmacopsychiatry** 1997 Jul;30(4):135–6

A copper-complex reduced gastric damage caused by acetylsalicylic acid and ethanol. Franco L, et al. **Prostaglandins** 1996 May;51(5):331–8

Toxic effects of alcohol intake on prostate of rats. Novelli EL, et al. **Prostate** 1997 Apr 1;31(1):37–41

Alcohol dementia and alcohol delirium in aged alcoholics. Kasahara H, et al. **Psychiatry Clin Neurosci** 1996 Jun; 50(3):115–23

Oral administration of glycine and polyamine receptor antagonists blocks ethanol withdrawal seizures. Kotlinska J, et al. **Psychopharmacology (Berl)** 1996 Oct;127(3):238–44

Glutamate and benzodiazepine receptor autoradiography in rat brain after repetition of alcohol dependence. Ulrichsen J, et al. **Psychopharmacology (Berl)** 1996 Jul;126(1):31–41

The course of alcohol withdrawal in a general hospital. Foy A, et al. **QJM** 1997 Apr;90(4):253–61

The course of alcohol withdrawal in a general hospital [letter] Green J, et al. **QJM** 1997 Aug;90(8):552

The effect of the neurolytic agent ethanol on cytoplasmic calcium in arterial smooth muscle and endothelium. Johnson ME, et al. **Reg Anesth** 1996 Jan–Feb;21(1):6–13

Deaths caused by alcohol [news] Doyle R. **Sci Am** 1996 Dec; 275(6):30–1

Exposure of embryonic cells to alcohol: contrasting effects during preimplantation and postimplantation development. Armant DR, et al. **Semin Perinatol** 1996 Apr;20(2):127–39 (115 ref.)

Effects of alcohol and prescription and over-the-counter drug use on liver enzyme profiles. Haley NJ. **Stat Bull Metrop Insur Co** 1995 Oct–Dec;76(4):2–9 (11 ref.)

Alcohol withdrawal. Murray TD, et al. **Va Med Q** 1997 Summer;124(3):184–7, 189 (35 ref.)

[Alcohol and smoking. The risk factors for the oral cavity] Weinstein RL, et al. **Minerva Stomatol** 1996 Sep; 45(9):405–13 (100 ref.) (Eng. Abstr.) **(Ita)**

[Effects of long–term ethanol administration (1). Effects of long–term ethanol administration on kidney studied at several periods of time during the administration] Omoto M, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1997 Feb;32(1):27–45 (Eng. Abstr.) **(Jpn)**

[Effect of long–term ethanol administration (2). Free type and bound type ethanol and related substances contents of the urine from ethanol administrated rats, indices in the serum, and renal tissues] Omoto M, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1997 Feb; 32(1):46–58 (Eng. Abstr.) **(Jpn)**

[Effects of chronic ethanol feeding on lipid composition of rat liver plasma membrane—changes of membrane by acute ethanol loading or its withdrawal in vivo] Yamashita T, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Jun; 31(3):215–25 (Eng. Abstr.) **(Jpn)**

[A case of cystic adenocarcinoma of the liver, appeared and developed a mural nodule after ethanol injection therapy] Dohchin A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Oct;93(10):763–8 **(Jpn)**

[Glucose intolerance after percutaneous ethanol injection therapy (PEI) in liver cirrhosis patients with hepatocellular carcinoma] Tamano M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb;93(2):90–5 (Eng. Abstr.) **(Jpn)**

[Ethanol and the gastrointestinal tract] Mincis M, et al. **Arq Gastroenterol** 1995 Jul–Sep;32(3):131–9 (96 ref.) (Eng. Abstr.) **(Por)**

[The significance of perinatal alcoholization and its withdrawal in the development of late cognitive disorders in rats] Trofimov SS, et al. **Eksp Klin Farmakol** 1996 Mar–Apr;59(2):44–6 (Eng. Abstr.) **(Rus)**

[Alcohol and bronchial asthma] Maevskii AA. **Klin Med (Mosk)** 1996;74(7):68–9 (14 ref.) **(Rus)**

[Alcohol and stomach] Makolkin VI, et al. **Klin Med (Mosk)** 1997;75(4):14–8 (39 ref.) **(Rus)**

[Administration of energostim in severe chronic cardiac failure due to alcoholic damage of heart] Paleev NR, et al. **Klin Med (Mosk)** 1997;75(4):35–41 **(Rus)**

[Reversible thrombopenia caused by alcohol. A condition to consider (letter)] Guilarte López–Mañas J, et al. **An Med Interna** 1996 Jul;13(7):354 **(Spa)**

[Chronic anemia protects against gastric damage by alcohol and aspirin. The role of the toxic radicals and lipid peroxidation] Marroni NP, et al. **Gastroenterol Hepatol** 1996 Dec;19(10):497–502 (Eng. Abstr.) **(Spa)**

ANALOGS & DERIVATIVES

Rapid in vivo hydrolysis of fatty acid ethyl esters, toxic nonoxidative ethanol metabolites. Saghir M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):G184–90

Increase of cytochrome b mRNA by bis(2–hydroxyethyl) trisulfide in J774A.1 cells. Kohama Y, et al. **Biol Pharm Bull** 1996 Jun;19(6):876–8

How to examine the antigen–damaging effect of sodium ethoxide on deplasticized epoxy sections. Brorson SH. **J Histochem Cytochem** 1997 Jan;45(1):143–6

The involvement of cytochrome P4502E1 in 2–bromoethanol–induced hepatocyte cytotoxicity. Khan S, et al. **Pharmacol Toxicol** 1996 Apr;78(4):241–8

ANALYSIS

Altering alcohol price by ethanol content: results from a Swedish tax policy in 1992. Ponicki W, et al. **Addiction** 1997 Jul;92(7):859–70

Expired breath ethanol measurement and toxicity of glycine solution in the mouse [letter; comment] Harrison RH. **Br J Urol** 1996 Nov;78(5):809–10. Comment on: Br J Urol 1996 Feb;77(2):198–202. Comment on: Br J Urol 1996 Feb;77(2):203–6.

A comparison of ethanol concentrations in the occipital lobe and cerebellum. Moore KA, et al. **Forensic Sci Int** 1997 Apr 18;86(1–2):127–34

Vapor–alcohol control tests with compressed ethanol–gas mixtures: scientific basis and actual performance. Dubowski KM, et al. **J Anal Toxicol** 1996 Oct;20(6):484–91

Unsuspected ethanol ingestion through soft drinks and flavored beverages [letter] Goldberger BA, et al. **J Anal Toxicol** 1996 Sep;20(5):332–3

Alcohol estimation at necropsy: epidemiology, economics, and the elderly. Cox DE, et al. **J Clin Pathol** 1997 Mar; 50(3):197–201

Breath alcohol concentrations in men 7–8 hours after prolonged, heavy drinking: influence of habitual alcohol intake [letter] Wright NR. **Lancet** 1997 Jan 18;349(9046):182

Blood alcohol level:– the law and the medicine. Marks P. **Med Leg J** 1996;64 (Pt 4):186–93

Ethanol in over–the–counter drugs. Khine H. **Pediatr Rev** 1996 Oct;17(10):342–3

The use of ethanol as a marker to detect and quantify the absorption of irrigation fluid during transurethral resection of the prostate. Hjertberg H. **Scand J Urol Nephrol Suppl** 1996;178:1–64 (180 ref.)

Estimation of fluid absorption by using the area under the curve for ethanol in expired air. Hahn RG. **Urol Int** 1997; 58(1):25–9

[Hidden alcohol in foods?] Greubel S. **Med Monatsschr Pharm** 1997 Aug;20(8):218–9 **(Ger)**

[Detection of the presence of ethyl alcohol in amniotic fluid drawn by trans–abdominal echo–guided amniocentesis] Del Borrello E, et al. **Boll Chim Farm** 1997 Apr;136(4):391–3 **(Ita)**

[The metrological assessment of the results of the quantitative determination of ethanol in biological fluids] Bataev GI. **Sud Med Ekspert** 1996 Oct–Dec;39(4):34–5 (Eng. Abstr.) **(Rus)**

[Uptake of the irrigating fluid during surgical endoscopy. Measure the absorption by ethanol indication] Hahn R. **Lakartidningen** 1997 Feb 5;94(6):440–3 (33 ref.) **(Swe)**

ANTAGONISTS & INHIBITORS

Forskolin delays the ethanol–induced desensitization of hypothalamic beta–endorphin neurons in primary cultures. Boyadjieva N, et al. **Alcohol Clin Exp Res** 1997 May; 21(3):477–82

Dantrolene sodium reduces the enhanced leakage of creatine kinase caused by ethanol, cocaine, and electrical stimulation in isolated fast and slow muscles of rat. Pagala M, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):63–7

New benzamide–derived 5–HT3 receptor antagonists which prevent the effects of ethanol on extracellular dopamine, and fail to reduce voluntary alcohol intake in rats. Iusco G, et al. **Farmaco** 1997 Mar;52(3):141–6

Natural honey prevents ethanol–induced increased vascular permeability changes in the rat stomach. Mobarok Ali AT, et al. **J Ethnopharmacol** 1997 Feb;55(3):231–8

Inhibition of ethanol production by Saccharomyces cerevisiae in human blood by sodium fluoride. Amick GD, et al. **J Forensic Sci** 1997 Jul;42(4):690–2

Gadolinium chloride blocks alcohol–dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1. Koop DR, et al. **Mol Pharmacol** 1997 Jun;51(6):944–50

Effects of 5–HT3, D1 and D2 receptor antagonists on ethanol– and cocaine–induced locomotion. Lê AD, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):325–32

Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. King AC, et al. **Psychopharmacology (Berl)** 1997 Jan; 129(1):15–22

[Bioactive constituents of Chinese natural medicines. III. Absolute stereostructures of new dihydroflavonols, hovenitins I, II, and III, isolated from hoveniae semen seu fructus, the seed and fruit of Hovenia dulcis THUNB. (Rhamnaceae): inhibitory effect on alcohol–induced muscular relaxation and hepatoprotective activity] Yoshikawa M, et al. **Yakugaku Zasshi** 1997 Feb; 117(2):108–18 (Eng. Abstr.) **(Jpn)**

BLOOD

Alcohol and endogenous nitric oxide in hepatic microcirculation. Oshita M, et al. **Alcohol Alcohol** 1994;29 Suppl 1:5–7

The firewater myth and response to alcohol in Mission Indians. Garcia–Andrade C, et al. **Am J Psychiatry** 1997 Jul;154(7):983–8

Concurrent use of cocaine and alcohol by patients treated in the emergency department. Vanek VW, et al. **Ann Emerg Med** 1996 Nov;28(5):508–14

Alcohol metabolism in Asian–American men with genetic polymorphisms of aldehyde dehydrogenase [see comments] Wall TL, et al. **Ann Intern Med** 1997 Sep 1;127(5):376–9 . Comment in: Ann Intern Med 1997 Sep 1;127(5):401–3.

Discrepancies in osmolal gaps and calculated alcohol concentrations [see comments] Osterloh JD, et al. **Arch Pathol Lab Med** 1996 Jul;120(7):637–41. Comment in: Arch Pathol Lab Med 1996 Jul;120(7):619–20.

Do discrepancies exist in serum osmolal gaps and calculated serum alcohol concentrations? The significance to the clinician and clinical pathologist [editorial; comment] Wolf PL. **Arch Pathol Lab Med** 1996 Jul;120(7):619–20. Comment on: Arch Pathol Lab Med 1996 Jul;120(7):637–41.

Pilots' knowledge of the relationship between alcohol consumption and levels of blood alcohol concentration. Widders R, et al. **Aviat Space Environ Med** 1997 Jun; 68(6):531–7

Prenatal alcohol and stress interact to attenuate ejaculatory behavior, but not serum testosterone or LH in adult male rats. Ward IL, et al. **Behav Neurosci** 1996 Dec; 110(6):1469–77

Highly sensitive gas chromatographic analysis of ethanol in whole blood, serum, urine, and fecal supernatants by the direct injection method. Tangerman A. **Clin Chem** 1997 Jun;43(6 Pt 1):1003–9

The effect of blood alcohol on the initial responses to cold water immersion in humans. Franks CM, et al. **Eur J Appl Physiol** 1997;75(3):279–81

Concerning the paper by Poklis et al., entitled: 'Gas chromatographic procedures for determination of ethanol in postmortem blood using t–butanol and methyl ethyl ketone as internal standards' (Forensic Sci. Int., 33 (1996)[correction of 1987] 31–38) [letter; comment] Machata G. **Forensic Sci Int** 1997 Apr 18;86(1–2):139–43 . Comment on: Forensic Sci Int 1996 Nov 11;83(1):31–8.

Gas chromatographic procedures for determination of ethanol in postmortem blood using t–butanol and methyl ethyl ketone as internal standards [see comments] O'Neal CL, et al. **Forensic Sci Int** 1996 Nov 11;83(1):31–8. Comment in: Forensic Sci Int 1997 Apr 18;86(1–2):139–43.

An accurate, automated, simultaneous gas chromatographic headspace measurement of whole blood ethanol and acetaldehyde for human in vivo studies. McCarver–May DG, et al. **J Anal Toxicol** 1997 Mar–Apr;21(2):134–41

Unusually high ethanol levels in two emergency medicine patients [letter] Wells DJ Jr, et al. **J Anal Toxicol** 1996 Jul–Aug;20(4):272

Inhibition of ethanol production by Saccharomyces cerevisiae in human blood by sodium fluoride. Amick GD, et al. **J Forensic Sci** 1997 Jul;42(4):690–2

Effect of alcohol on the utility of base deficit in trauma. Davis JW, et al. **J Trauma** 1997 Sep;43(3):507–10

Predictive model to identify trauma patients with blood alcohol concentrations > or = 50 mg/dl. Soderstrom CA, et al. **J Trauma** 1997 Jan;42(1):67–73

Fatty acid ethyl esters in the blood as markers for ethanol intake [published erratum appears in JAMA 1997 Mar 12;227(10):792] Doyle KM, et al. **JAMA** 1996 Oct 9; 276(14):1152–6

Analysis of 12 months of blood alcohol levels in patients in an urban emergency department [letter; comment] Davis AR. **Med J Aust** 1996 Sep 16;165(6):351–2. Comment on: Med J Aust 1996 Jun 3;164(11):699–700.

Legal issues concerning the taking of blood samples by a forensic medical examiner [letter; comment] Corre N. **Med Leg J** 1996;64 (Pt 4):198–9. Comment on: Med Leg J 1996;64 (Pt 1):43.

Investigation of the effects of moclobemide in chronic ethanol feeding rats. Uzbay IT, et al. **Pharmacol Res** 1995 Nov;32(5):287–92

Inhibition of nitric oxide formation reduces voluntary ethanol consumption in the rat. Calapai G, et al. **Psychopharmacology (Berl)** 1996 Jun;125(4):398–401

Blood alcohol and cardiac arrest. Parke T, et al. **Resuscitation** 1996 Oct;32(3):199–202

The effect of cimetidine on ethanol concentrations in fasting women and men after two different doses of alcohol. Clemmesen JO, et al. **Scand J Gastroenterol** 1997 Mar; 32(3):217–20

[The level of alcohol and titre of A and B group substances of the ABO system in blood samples infected by some strains of Escherichia coli] Kurzejamska–Parafiniuk M. **Ann Acad Med Stetin** 1996;42:85–104 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Ethanol binding to a model carbohydrate, glycogen. Channareddy S, et al. **Biochem Pharmacol** 1996 Dec 24; 52(12):1911–4

Determining ethanol distribution in phospholipid multilayers with MAS–NOESY spectra. Holte LL, et al. **Biochemistry** 1997 Apr 15;36(15):4669–74

Alcohol binding to liposomes by 2H NMR and radiolabel binding assays: does partitioning describe binding? Dubey AK, et al. **Biophys J** 1996 May;70(5):2307–15

l–Menthol, oleic acid and lauricidin in absorption enhancement of free and sodium salt of diclofenac using ethanol treated silicone membrane as model for skin. Maitani Y, et al. **Chem Pharm Bull (Tokyo)** 1996 Feb; 44(2):403–8

The dehydrofluorinated product of sevoflurane by soda lime reacts with ethanol to produce two products. Fujii K, et al. **Drug Metabol Drug Interact** 1996;13(2):137–44

Gas chromatographic determination of eugenol in ethanol extract of cloves. Myint S, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1–2):193–5

Photoisomerization of retinoic acids in ethanol under room light: a warning for cell biological study of geometrical isomers of retinoids. Murayama A, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Apr;43(2):167–76

In vitro effects of alcohol–containing and alcohol–free mouthrinses on microhardness of some restorative materials. Gürgan S, et al. **J Oral Rehabil** 1997 Mar; 24(3):244–6

[Effects of the number of carbon atoms of alcohols on the Ca(2+)–related functions of skinned skeletal muscle fibers from the guinea pigs] Nakajima T. **Masui** 1996 Nov; 45(11):1347–53 (Eng. Abstr.) **(Jpn)**

[The role of ethanol during gamma–irradiation of water–salt DNA solutions] Frisman EV, et al. **Biofizika** 1997 Jan–Feb; 42(1):117–24 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Ethanol resistive microbubble test: a modification of the stable microbubble test used to predict respiratory distress syndrome. Cho K, et al. **Acta Paediatr Jpn** 1996 Aug; 38(4):322–7

Cardiac output and ethanol monitoring of fluid absorption. Hahn RG, et al. **Eur J Anaesthesiol** 1997 Jul;14(4):406–11

Monitoring fluid absorption using 1% ethanol–tagged glycine during operative hysteroscopy. Molnar BG, et al. **J Am Assoc Gynecol Laparosc** 1997 May;4(3):357–62

Ethanol monitoring of the transurethral resection syndrome. Hahn RG, et al. **J Clin Anesth** 1996 Dec;8(8):652–5

[Calculation of lavage volume in transurethral prostate resection (TURP)] Zink M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Apr; 32(4):219–25 (Eng. Abstr.) **(Ger)**

ALCOHOL, ETHYL

[Addition of ethanol to the distension medium in surgical hysteroscopy as screening to prevent "fluid overload". A prospective randomized comparative study of ablative versus non-ablative surgical hysteroscopy and different ethanol concentration] Wallwiener D, et al. **Geburtshilfe Frauenheilkd** 1996 Sep;56(9):462-9 (Eng. Abstr.) **(Ger)**

HISTORY

The life and work of Erik M. P. Widmark. Andréasson R, et al. **Am J Forensic Med Pathol** 1996 Sep;17(3):177-90

METABOLISM

Terpene-enhanced transdermal permeation of water and ethanol in human epidermis. Magnusson BM, et al. **Acta Derm Venereol** 1997 Jul;77(4):264-7

Expression, activities, and kinetic mechanism of human stomach alcohol dehydrogenase. Inference for first-pass metabolism of ethanol in mammals. Yin SJ, et al. **Adv Exp Med Biol** 1997;414:347-55

There is not simple method to maintain a constant ethanol concentration in long-term cell culture: keys to a solution applied to the survey of astrocytic ethanol absorption. Eysseric H, et al. **Alcohol** 1997 Mar-Apr;14(2):111-5

The regulation of alcohol consumption in rats: the role of alcohol-metabolizing enzymes-catalase and aldehyde dehydrogenase. Gill K, et al. **Alcohol** 1996 Jul-Aug; 13(4):347-53

Effect of acetaldehyde generated from ethanol by ADH-transfected CHO cells on their membrane fatty acid profiles [published erratum appears in Alcohol 1997 Mar-Apr;14(2):203] Meskar A, et al. **Alcohol** 1996 Nov-Dec;13(6):611-6

Putative oxidative metabolites of 1-methyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline of potential relevance to the addictive and neurodegenerative consequences of ethanol abuse. Wrona MZ, et al. **Alcohol** 1997 May-Jun;14(3):213-23

A study on ADH2 and ALDH2 genotyping by PCR-RFLP and SSCP analyses with description of allele and genotype frequencies in Japanese, Finn and Lapp populations. Suzuki K, et al. **Alcohol Alcohol** 1994;29 Suppl 1:21-7

Hepatic messenger RNA contents of cytochrome P4502E1 in patients with different P4502E1 genotypes. Tsutsumi M, et al. **Alcohol Alcohol** 1994;29 Suppl 1:29-32

Polymorphisms of ethanol metabolizing enzyme genes and alcoholism. Higuchi S. **Alcohol Alcohol Suppl** 1994;2:29-34

Genetically determined influences on voluntary ethanol consumption: extracellular levels of ethanol and monoamines in the nucleus accumbens of the alcohol preferring AA and alcohol avoiding ANA rat lines. Kiianmaa K, et al. **Alcohol Alcohol Suppl** 1994;2:73-8

First pass metabolism of ethanol. Lieber CS, et al. **Alcohol Alcohol Suppl** 1994;2:163-9 (67 ref.)

Ethanol metabolism in the gastrointestinal tract and its possible consequences. Seitz HK, et al. **Alcohol Alcohol Suppl** 1994;2:157-62 (47 ref.)

ADH and ALDH genotypes in relation to alcohol metabolic rate and sensitivity. Whitfield JB. **Alcohol Alcohol Suppl** 1994;2:59-65 (15 ref.)

Alcohol dehydrogenase: enzymology and metabolism. Yin SJ. **Alcohol Alcohol Suppl** 1994;2:113-9 (37 ref.)

Ethnic differences in gastric sigma-alcohol dehydrogenase activity and ethanol first-pass metabolism. Dohmen K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1569-76

Effects of bezafibrate on ethanol oxidation in rats. Tsukamoto S, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1599-603

The energy value of ethanol [letter; comment] Jéquier E. **Am J Clin Nutr** 1996 Dec;64(6):978-9. Comment on: Am J Clin Nutr 1996 Jul;64(1):108-14.

Postmortem production of ethanol and factors that influence interpretation: a critical review. O'Neal CL, et al. **Am J Forensic Med Pathol** 1996 Mar;17(1):8-20 (48 ref.)

Bacteriocolonic pathway for ethanol oxidation: characteristics and implications. Salaspuro M. **Ann Med** 1996 Jun;28(3):195-200 (88 ref.)

Hybrid process for the conversion of lignocellulosic materials. Lee KC, et al. **Appl Biochem Biotechnol** 1997 Apr;66(1):1-23

Performance of coimmobilized yeast and amyloglucosidase in a fluidized bed reactor for fuel ethanol production. Sun MY, et al. **Appl Biochem Biotechnol** 1997 Spring; 63-65:483-93

Use of sulfite and hydrogen peroxide to control bacterial contamination in ethanol fermentation. Chang IS, et al. **Appl Environ Microbiol** 1997 Jan;63(1):1-6

Stabilization of pet operon plasmids and ethanol production in Escherichia coli strains lacking lactate dehydrogenase and pyruvate formate-lyase activities. Hespell RB, et al. **Appl Environ Microbiol** 1996 Dec;62(12):4594-7

Ethanolic fermentation of xylose with Saccharomyces cerevisiae harboring the Thermus thermophilus xylA gene, which expresses an active xylose (glucose) isomerase. Walfridsson M, et al. **Appl Environ Microbiol** 1996 Dec; 62(12):4648-51

Thermoanaerobacter mathranii sp. nov., an ethanol-producing, extremely thermophilic anaerobic bacterium from a hot spring in Iceland. Larsen L, et al. **Arch Microbiol** 1997 Aug;168(2):114-9

Modeling interpretation of microbe metabolism detected by nuclear magnetic resonance. Bastianoni S, et al. **Biochem Biophys Res Commun** 1996 Oct 3;227(1):53-8

Mitochondrial NADH dehydrogenase activity and ability to tolerate acetaldehyde determine faster ethanol production in Saccharomyces cerevisiae. Shankar CS, et al. **Biochem Mol Biol Int** 1996 Sep;40(1):145-50

Acceleration of the alcohol oxidation rate in rats with aloin, a quinone derivative of Aloe. Chung JH, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1461-8

Impairment of the asialoglycoprotein receptor by ethanol oxidation. Clemens DL, et al. **Biochem Pharmacol** 1996 Nov 22;52(10):1499-505

Coupling of ethanol metabolism to lipid biosynthesis: labelling of the glycerol moieties of sn-glycerol-3-phosphate, a phosphatidic acid and a phosphatidylcholine in liver of rats given [1,1-2H2]ethanol. Yu BY, et al. **Biochim Biophys Acta** 1997 Jan 21; 1344(2):165-70

Alcohol and the heart. Cowie MR. **Br J Hosp Med** 1997 May 7-20;57(9):457-60 (23 ref.)

Ethanol metabolism, cirrhosis and alcoholism. Lieber CS. **Clin Chim Acta** 1997 Jan 3;257(1):59-84 (165 ref.)

Effect of corn peptide on alcohol metabolism and plasma free amino acid concentrations in healthy men. Yamaguchi M, et al. **Eur J Clin Nutr** 1996 Oct;50(10):682-8

Muscarinic receptors and insulin concentration in the rat pancreas after chronic alcohol intake and cholinergic stimulation. Laine VJ, et al. **Exp Toxicol Pathol** 1996 Jan; 48(1):77-9

Alcohol dehydrogenase of human and rat blood vessels. Role in ethanol metabolism. Allali-Hassani A, et al. **FEBS Lett** 1997 Mar 17;405(1):26-30

Autonomous metabolic oscillation in continuous culture of Saccharomyces cerevisiae grown on ethanol. Keulers M, et al. **FEMS Microbiol Lett** 1996 Sep 1;142(2-3):253-8

Immobilization of Saccharomyces diastaticus on wood chips for ethanol production. Razmovski R, et al. **Folia Microbiol (Praha)** 1996;41(2):201-7

The kinetics of methanol elimination in alcoholics and the influence of ethanol. Haffner HT, et al. **Forensic Sci Int** 1997 Sep 19;89(1-2):129-36

Metabolism of alcohol by human gastric cells: relation to first-pass metabolism [see comments] Haber PS, et al. **Gastroenterology** 1996 Oct;111(4):863-70. Comment in: Gastroenterology 1996 Oct;111(4):1143-4.

First-pass metabolism of ethanol: an overview [editorial; comment] Sato N, et al. **Gastroenterology** 1996 Oct; 111(4):1143-4. Comment on: Gastroenterology 1996 Oct;111(4):863-70.

High intracolonic acetaldehyde values produced by a bacteriocolonic pathway for ethanol oxidation in piglets. Jokelainen K, et al. **Gut** 1996 Jul;39(1):100-4

First pass metabolism of ethanol: gastric or hepatic, mountain or molehill? Crabb DW. **Hepatology** 1997 May;25(5):1292-4

Production of ethanol by cultured insect cells. Takahashi M, et al. **In Vitro Cell Dev Biol Anim** 1995 Dec;31(11):876-9

Extracellular melibiose and fructose are intermediates in raffinose catabolism during fermentation to ethanol by engineered enteric bacteria. Moniruzzaman M, et al. **J Bacteriol** 1997 Mar;179(6):1880-6

Kinetic analysis of ethanol production from glucose fermentation by yeast cells immobilized onto ceramic supports. Zhang Y, et al. **J Biomater Sci Polym Ed** 1996; 7(12):1119-26

Binding of acetaldehyde to rat gastric mucosa during ethanol oxidation. Salmela KS, et al. **J Lab Clin Med** 1997 Jun; 129(6):627-33

Contribution of de novo fatty acid synthesis to very low density lipoprotein triacylglycerols: evidence from mass isotopomer distribution analysis of fatty acids synthesized from [2H6]ethanol. Yang LY, et al. **J Lipid Res** 1996 Feb; 37(2):262-74

Spin trapping studies of alcohol-initiated radicals in rat liver: influence of dietary fat. Reinke LA, et al. **J Nutr** 1997 May;127(5 Suppl):899S-902S

Preparation of corn peptide from corn gluten meal and its administration effect on alcohol metabolism in stroke-prone spontaneously hypertensive rats. Yamaguchi M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Jun;42(3):219-31

Effect of long-term 'corn peptide' ingestion on alcohol metabolism in stroke-prone spontaneously hypertensive rats with alcohol loading. Yamaguchi M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Dec;42(6):567-80

Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions. Yang SK. **J Pharm Sci** 1994 Jun;83(6):898-902

Interaction of ethanol with inducible nitric oxide synthase messenger RNA and protein: direct effects on autacoids and endotoxin in vivo. Greenberg SS, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):1044-54

Acetaldehyde as well as ethanol is metabolized by human CYP2E1. Kunitoh S, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):527-32

Phospholipase D mediated transphospatidylation as a possible new pathway of ethanol metabolism in isolated rat pancreatic acini. Rydzewska G, et al. **J Physiol Pharmacol** 1996 Jun;47(2):385-95

Acute interaction between ethanol and serotonin metabolism in the rat. Some M, et al. **Life Sci** 1997;61(5):577-83

Fatty acid ethyl ester synthesis by the isolated perfused rat heart. Chang W, et al. **Metabolism** 1997 Aug;46(8):926-9

Pullulan production by Aureobasidium pullulans grown on ethanol stillage as a nitrogen source. West TP, et al. **Microbios** 1996;88(354):7-18

Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat. Iimuro Y, et al. **Mol Pharmacol** 1996 Sep;50(3):656-61

Endogenous ethanol production in trauma victims associated with medical treatment. Moriya F, et al. **Nippon Hoigaku Zasshi** 1996 Aug;50(4):263-7

Molecular genetic aspects of alcohol metabolism and alcoholism. Agarwal DP. **Pharmacopsychiatry** 1997 May; 30(3):79-84 (55 ref.)

Ethanol oxidizing enzymes: roles in alcohol metabolism and alcoholic liver disease. Crabb DW. **Prog Liver Dis** 1995; 13:151-72 (158 ref.)

Gastric emptying and first-pass metabolism of ethanol in elderly subjects with and without atrophic gastritis. Pedrosa MC, et al. **Scand J Gastroenterol** 1996 Jul; 31(7):671-7

Alcohol plus cocaine: the whole is more than the sum of its parts. Jatlow P, et al. **Ther Drug Monit** 1996 Aug; 18(4):460-4

Gender differences in ethanol oxidation and cytochrome P4502E1 content and functions in hepatic microsomes from alcohol-preferring and non-preferring rats. Nebbia C, et al. **Xenobiotica** 1996 Nov;26(11):1121-9

Modulation of glycerol and ethanol yields during alcoholic fermentation in Saccharomyces cerevisiae strains overexpressed or disrupted for GPD1 encoding glycerol 3-phosphate dehydrogenase. Michnick S, et al. **Yeast** 1997 Jul;13(9):783-93

[Alcohol] Zima T. **Cas Lek Cesk** 1996 Jul 14;135(14):458-65 (Eng. Abstr.) **(Cze)**

[Death due to cold of a 63-year-old male associated with hepatocellular carcinoma--bibliographic consideration on alcohol metabolism of the patients with liver dysfunction] Kondo T, et al. **Nippon Hoigaku Zasshi** 1996 Aug; 50(4):276-80 (Eng. Abstr.) **(Jpn)**

[The status of the ethanol-oxidizing enzyme systems in fatal alcohol poisonings] Porodenko VA. **Sud Med Ekspert** 1997 Jul-Sep;40(3):15-8 (Eng. Abstr.) **(Rus)**

[Chronic consumption of alcohol and its damaging effects on the body] Petrović G, et al. **Srp Arh Celok Lek** 1996 Sep-Oct;124(9-10):260-6 (51 ref.) (Eng. Abstr.) **(Scc)**

PHARMACOKINETICS

Estimation of volumes of distribution and intratumoral ethanol concentrations by computed tomography scanning after percutaneous ethanol injection. Alexander DG, et al. **Acad Radiol** 1996 Jan;3(1):49-56

Are lower legal blood alcohol limits and a combination of sanctions desirable in reducing drunken driver-involved traffic fatalities and traffic accidents? Deshapriya EB, et al. **Accid Anal Prev** 1996 Nov;28(6):721-31 (37 ref.)

Estimating blood alcohol level from observable signs. McKnight AJ, et al. **Accid Anal Prev** 1997 Mar; 29(2):247-55

The "WAM" score: sensitivity and specificity of a user friendly biological screening test for alcohol problems in trauma patients. Nilssen O, et al. **Addiction** 1996 Feb; 91(2):255-62

Inhibitory effect of oleanene-type triterpene oligoglycosides on ethanol absorption: the structure-activity relationships. Yoshikawa M, et al. **Adv Exp Med Biol** 1996;404:207-18 (40 ref.)

Effect of alcohol on the endotoxin binding protein produced in the liver. Fukui H, et al. **Alcohol Alcohol** 1994;29 Suppl 1:87-91

Women, alcohol and the menstrual cycle. Gill J. **Alcohol Alcohol** 1997 Jul-Aug;32(4):435-41 (23 ref.)

Role of alcohol dehydrogenase in rat ethanol elimination kinetics. Matsumoto H, et al. **Alcohol Alcohol** 1994;29 Suppl 1:15-20

Estimation of ethanol first-pass effect in the perfused rat liver. Matsumoto H, et al. **Alcohol Alcohol** 1994;29 Suppl 1:9-13

Medical screening and medical-psychological assessment as prerequisites for regranting of licenses: summary of recommendations. Nickel WR. **Alcohol Alcohol** 1996 Nov; 31(6):605-7

Aldehyde dehydrogenase activity and acetate production by aerobic bacteria representing the normal flora of human large intestine. Nosova T, et al. **Alcohol Alcohol** 1996 Nov; 31(6):555-64

Development and application of a physiologically based pharmacokinetic model for ethanol in the mouse. Pastino GM, et al. **Alcohol Alcohol** 1996 Jul;31(4):365-74

Laboratory markers of alcohol abuse. Sillanaukee P. **Alcohol Alcohol** 1996 Nov;31(6):613-6 (29 ref.)

The distribution of fatty acid ethyl esters among lipoproteins and albumin in human serum. Bird DA, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):602-5

Gender and alcohol dosing: a procedure for producing comparable breath alcohol curves for men and women. Breslin FC, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):928-30

Biphasic effects of alcohol on heart rate are influenced by alcoholic family history and rate of alcohol ingestion. Conrod PJ, et al. **Alcohol Clin Exp Res** 1997 Feb; 21(1):140-9

Gene regulation of alcohol metabolizing enzymes. Crabb DW. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):113A-116A

Hepatic sinusoidal endothelial cell in alcoholemia and

endotoxemia. Deaciuc IV, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):607–14 (87 ref.)

The portacaval-shunted rat: a new model for the study of the mechanisms controlling voluntary ethanol consumption and ethanol preference? de Waele JP, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):305–10

Antipyrine and aminopyrine induce acetaldehyde accumulation from ethanol in isolated hepatocytes. Efthivoulou MA, et al. **Alcohol Clin Exp Res** 1997 Apr; 21(2):267–74

Noncompetitive-like inhibition of ethanol elimination by cyanamide treatment: pharmacokinetic study. Fujimiya T, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):278A–283A

Co-metabolism of ethanol, ethanol-derived acetaldehyde, and 4-hydroxynonenal in isolated rat hepatocytes. Hartley DP, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):298–304

Oxidative stress in alcoholic liver injury. Ishii H. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):162A–167A

Kinetic interactions between 4-methylpyrazole and ethanol in healthy humans. Jacobsen D, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):804–9

Inhibitory mechanism of intestinal ethanol absorption induced by high acetaldehyde concentrations: effect of intestinal blood flow and substance specificity. Kinoshita H, et al. **Alcohol Clin Exp Res** 1996 May;20(3):510–3

Ethanol and acetaldehyde metabolism: past, present, and future. Kitson KE. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):82A–92A

First-pass metabolism of ethanol is negligible in rat gastric mucosa. Levitt MD, et al. **Alcohol Clin Exp Res** 1997 Apr; 21(2):293–7

Endogenous production of methanol after the consumption of fruit. Lindinger W, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):939–43

Mitochondrial ALDH polymorphism affects ethanol-derived acetate disposition in Wistar rats. Matsumoto H, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):284A–288A

Genotypes of alcohol-metabolizing enzymes and the risk for alcoholic chronic pancreatitis in Japanese alcoholics. Matsumoto M, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):289A–292A

Infants' suckling responses to the flavor of alcohol in mothers' milk. Mennella JA. **Alcohol Clin Exp Res** 1997 Jun; 21(4):581–5

Evidence of multiple ethanol pools in the brain: an in vivo proton magnetization transfer study. Meyerhoff DJ, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1283–8

Characteristics of alcohol dehydrogenases of certain aerobic bacteria representing human colonic flora. Nosova T, et al. **Alcohol Clin Exp Res** 1997 May;21(3):489–94

Free radical formation in livers of rats treated acutely and chronically with alcohol. Reinke LA, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):642–6

Role of catalase in rat gastric mucosal ethanol metabolism in vitro. Salmela KS, et al. **Alcohol Clin Exp Res** 1996 Sep; 20(6):1011–5

Ethanol and polyamine metabolism: physiologic and pathologic implications: a review. Sessa A, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):318–25 (121 ref.)

Polymorphism of alcohol-metabolizing genes affects drinking behavior and alcoholic liver disease in Japanese men. Tanaka F, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):596–601

Alcohol elimination in Native American Mission Indians: an investigation of interindividual variation. Wall TL, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1159–64

Differences in the serum levels of acetaldehyde and cytotoxic acetaldehyde–albumin complexes after the consumption of red and white wine: in vitro effects of flavonoids, vitamin E, and other dietary antioxidants on cytotoxic complexes. Wickramasinghe SN, et al. **Alcohol Clin Exp Res** 1996 Aug; 20(5):799–803

Rapid in vivo hydrolysis of fatty acid ethyl esters, toxic nonoxidative ethanol metabolites. Saghir M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):G184–90

Maturation decreases ethanol minimum alveolar anesthetic concentration in mice as previously demonstrated in rats: there is no species difference. Fang Z, et al. **Anesth Analg** 1997 Jul;85(1):160–3

Maturation decreases ethanol minimum alveolar anesthetic concentration (MAC) more than desflurane MAC in rats. Fang Z, et al. **Anesth Analg** 1997 Apr;84(4):852–8

Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol. Antila S, et al. **Arzneimittelforschung** 1997 Jul;47(7):816–20

Ethanol monitoring during hysterectomy [letter; comment] Hahn RG. **Br J Anaesth** 1997 Apr;78(4):476–7. Comment on: Br J Anaesth 1996 Sep;77(3):305–8.

Effect of ranitidine hydrochloride (150 mg twice daily) on the pharmacokinetics of increasing doses of ethanol (0.15, 0.3, 0.6 g kg–1). Bye A, et al. **Br J Clin Pharmacol** 1996 Feb;41(2):129–33

Alcohol-metabolising genes and alcoholism among Taiwanese Han men: independent effect of ADH2, ADH3 and ALDH2. Chen WJ, et al. **Br J Psychiatry** 1996 Jun; 168(6):762–7

Ethanol elimination by rats as a function of reproductive state, gender and nutritional status. da-Silva VA, et al. **Braz J Med Biol Res** 1996 May;29(5):651–7

Bioactive saponins and glycosides. V. Acylated polyhydroxyolean-12-ene triterpene oligoglycosides, camelliasaponins A1, A2, B1, B2, C1, and C2, from the seeds of Camellia japonica L.: structures and inhibitory activity on alcohol absorption. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Oct;44(10):1899–907

Bioactive saponins and glycosides. VI. Elatosides A and B, potent inhibitors of ethanol absorption, from the bark of Aralia elata SEEM. (Araliaceae): the structure-requirement in oleanolic acid glucuronide-saponins for the inhibitory activity. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Oct;44(10):1915–22

Bioactive saponins and glycosides. III. Horse chestnut. (1): The structures, inhibitory effects on ethanol absorption, and hypoglycemic activity of escins Ia, Ib, IIa, IIb, and IIIa from the seeds of Aesculus hippocastanum L. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Aug; 44(8):1454–64

CYP2E1, ALDH2 and ADH2 genotypes and blood ethanol elimination kinetics [letter] Iwahashi K, et al. **Clin Chim Acta** 1996 Nov 15;255(1):85–7

Pharmacokinetic interactions between alcohol and other drugs. Fraser AG. **Clin Pharmacokinet** 1997 Aug; 33(2):79–90 (151 ref.)

A comparison of blood toxicology of heroin-related deaths and current heroin users in Sydney, Australia. Darke S, et al. **Drug Alcohol Depend** 1997 Jul 25;47(1):45–53

Cocaine and alcohol interactions in naive and alcohol-pretreated rats. Hedaya MA, et al. **Drug Metab Dispos** 1996 Jul;24(7):807–12

Pharmacodynamic response to Ro15–4513 in ethanol intoxicated dogs. Whitmire D, et al. **Drug Metabol Drug Interact** 1996;13(2):99–109

Statistical analysis of blood- to breath-alcohol ratio data in the logarithm-transformed and non-transformed modes. Labianca DA, et al. **Eur J Clin Chem Clin Biochem** 1996 Feb;34(2):111–7

Determination of absorption time of ethanol in social drinkers. Winek CL, et al. **Forensic Sci Int** 1996 Feb 9; 77(3):169–77

Determination of volume of distribution for ethanol in male and female subjects. Cowan JM Jr, et al. **J Anal Toxicol** 1996 Sep;20(5):287–90

Interfering substances identified in the breath of drinking drivers with Intoxilyzer 5000S. Jones AW. **J Anal Toxicol** 1996 Nov–Dec;20(7):522–7

Disclosing recent drinking after alcohol has been cleared from the body [letter] Jones AW, et al. **J Anal Toxicol** 1996 Mar–Apr;20(2):141–2

Dilution of blood collected for medicolegal alcohol analysis by intravenous fluids. Riley D, et al. **J Anal Toxicol** 1996 Sep;20(5):330–1

Variability of the blood/breath alcohol ratio in drinking drivers. Jones AW, et al. **J Forensic Sci** 1996 Nov; 41(6):916–21

Influence of age, gender, and blood-alcohol concentration on the disappearance rate of alcohol from blood in drinking drivers. Jones AW, et al. **J Forensic Sci** 1996 Nov; 41(6):922–6

Are women heavier drinkers than we thought they were? Lo CC. **J Stud Alcohol** 1996 Sep;57(5):531–5

Effects of opioids on the absorption of alcohol. Linseman MA, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):79–84

Validation of a measure of excessive drinking: frequency per year that BAL exceeds 0.08%. Conrod PJ, et al. **Subst Use Misuse** 1997 Apr;32(5):587–607

A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans. Pastino GM, et al. **Toxicol Appl Pharmacol** 1997 Jul;145(1):147–57

[Postoperative therapy of an alcoholic patient with an unusually high ethanol metabolic rate] Wilkens L, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):120–1 (Eng. Abstr.) **(Ger)**

[Discrepancies between police breath alcohol measurements in a field trial and blood alcohol concentration according to BGA guidelines and possible consequences for citizens] Schütz H, et al. **Arch Kriminol** 1997 Mar–Apr; 199(3–4):103–8 (Eng. Abstr.) **(Ger)**

[The accuracy of blood alcohol determination with head-space GC, ADH and REA ethanol assay for the AXSYM system--a comparison of the methods] Alt A, et al. **Blutalkohol** 1996 Jul;33(4):209–14 (Eng. Abstr.) **(Ger)**

[The German promille law--overview and guideline for legal traffic applications] Grohmann P. **Blutalkohol** 1996 Jul; 33(4):177–200 (Eng. Abstr.) **(Ger)**

[Alcohol and energy drink--can combined consumption of both beverages modify automobile driving fitness?] Riesselmann B, et al. **Blutalkohol** 1996 Jul;33(4):201–8 (Eng. Abstr.) **(Ger)**

[Visual evoked potentials in low blood alcohol concentrations] Behrendt S, et al. **Ophthalmologe** 1996 Aug; 93(4):367–70 (Eng. Abstr.) **(Ger)**

[Blood alcohol concentrations after oral alcohol administration--effect of age and sex] Gärtner U, et al. **Z Gastroenterol** 1996 Oct;34(10):675–9 (Eng. Abstr.) **(Ger)**

[H2-receptor antagonists and alcohol: clinical significance] Nemesánszky É, et al. **Orv Hetil** 1996 Jun 16; 137(24):1309–13 (43 ref.) (Eng. Abstr.) **(Hun)**

[The ethanol elimination pharmacokinetics--the effects of genotypes of ALDH2 and CYP2E1 on the ethanol metabolism] Iwahashi K, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Dec; 31(6):517–24 (Eng. Abstr.) **(Jpn)**

[Estimation of fast reversible effects of ethanol and pharmacokinetic prognosis] Zhuk MS, et al. **Biull Eksp Biol Med** 1997 Jun;123(6):673–6 **(Rus)**

[The dynamics of 14C-ethanol and 14C-acetaldehyde distribution in rat testes] Bozhko HKh, et al. **Fiziol Zh** 1996; 42(1–2):104–9 (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

Studies on the effect of ethanol on the Na+, and the Na+, K(+)-ATPase activities of plasma membranes of rat kidney proximal tubular cells. Rothman A, et al. **Acta Cient Venez** 1994;45(4):281–6

Ethanol enhances the mitogen-driven lymphocyte proliferation in patients with psoriasis. Schopf RE, et al. **Acta Derm Venereol** 1996 Jul;76(4):260–3

Comparison of various methods of assaying the cytotoxic effects of ethanol on human hepatoblastoma cells (HUH-6 line). Kosaka T, et al. **Acta Med Okayama** 1996 Jun; 50(3):151–6

Glutathione–glutathione reductase system and lipid peroxidation in Saccharomyces cerevisiae under alcohol stress. Gupta S, et al. **Acta Microbiol Immunol Hung** 1996; 43(1):33–8

Effect of ethanol on glycerolipid and fatty acid metabolism in Hep G2 human-hepatoma cells. Angeletti C, et al. **Acta Physiol Pharmacol Ther Latinoam** 1996;46(2):57–69

Mechanism of enhancement of renal (Na(+)+K+) ATPase activity following chronic ethanol exposure. Rodrigo R, et al. **Acta Physiol Pharmacol Ther Latinoam** 1996; 46(1):49–56

The influence of ethyl alcohol on the development of the chondrocranium of Gallus gallus. Heyns M. **Adv Anat Embryol Cell Biol** 1997;134:1–127 (90 ref.)

Tryptophan metabolism and disposition in relation to alcohol and alcoholism. Badawy AA. **Adv Exp Med Biol** 1996; 398:75–82 (28 ref.)

Prenatal high saturated fat diet modifies behavioral effects of prenatal alcohol exposure in rats. Abel EL, et al. **Alcohol** 1997 Jan–Feb;14(1):25–9

A study of the temporal effect of alcohol on human erythrocyte sodium–lithium countertransport in relation to membrane cholesterol and phospholipids. Adebayo GI, et al. **Alcohol** 1996 Nov–Dec;13(6):597–602

Beneficial vs. detrimental actions of ethanol on heart and coronary vascular muscle: roles of Mg2+ and Ca2+. Altura BM, et al. **Alcohol** 1996 Sep–Oct;13(5):499–513

Betaine effects on hepatic methionine metabolism elicited by short-term ethanol feeding. Barak AJ, et al. **Alcohol** 1996 Sep–Oct;13(5):483–6

Betaine, ethanol, and the liver: a review. Barak AJ, et al. **Alcohol** 1996 Jul–Aug;13(4):395–8 (27 ref.)

Opposite effects of GABAA and NMDA receptor antagonists on ethanol-induced behavioral sleep in rats. Beleslin DB, et al. **Alcohol** 1997 Mar–Apr;14(2):167–73

5-HT3 receptor antagonist, tropisetron, does not influence ethanol-induced conditioned taste aversion and conditioned place aversion. Bienkowski P, et al. **Alcohol** 1997 Jan–Feb;14(1):63–9

Discriminative stimulus effects of ethanol: lack of antagonism with N-methyl-D-aspartate and D-cycloserine. Bienkowski P, et al. **Alcohol** 1997 Jul–Aug;14(4):345–50

Serotonin-3 receptor and ethanol-stimulated somatodendritic dopamine release. Campbell AD, et al. **Alcohol** 1996 Nov–Dec;13(6):569–74

Effects of ethanol on the inner layers of chick retina during development. Chmielewski CE, et al. **Alcohol** 1997 Jul–Aug;14(4):313–7

Ethanol-induced oxidative stress and enzymatic defenses in cultured fetal rat hepatocytes. Devi BG, et al. **Alcohol** 1996 Jul–Aug;13(4):327–32

Ethanol as a neurochemical surrogate of conventional reinforcers: the dopamine–opioid link. Di Chiara G, et al. **Alcohol** 1996 Jan–Feb;13(1):13–7 (58 ref.)

Effects of ethanol intake on lipid metabolism in the lactating rat. do Carmo MG, et al. **Alcohol** 1996 Sep–Oct;13(5):443–8

Inhibition of platelet aggregation in whole blood after exposure of rats to alcohol by inhalation. Dong QS, et al. **Alcohol** 1997 Jan–Feb;14(1):49–54

Flow cytometric analysis of lymphocytes from rats following chronic ethanol treatment. Helm RM, et al. **Alcohol** 1996 Sep–Oct;13(5):467–71

Acute alcohol tolerance in social drinkers: changes in subjective effects dependent on the alcohol dose and prior alcohol experience. Hiltunen AJ. **Alcohol** 1997 Jul–Aug; 14(4):373–8

The effect of ethanol, beer, and wine on histamine release from the dog stomach. Intorre L, et al. **Alcohol** 1996 Nov–Dec;13(6):547–51

Characterization of the Phenomenon of rapid tolerance to ethanol. Khanna JM, et al. **Alcohol** 1996 Nov–Dec; 13(6):621–8

Taste reactivity in high-alcohol-sensitive and low-alcohol-sensitive rats. Kiefer SW, et al. **Alcohol** 1997 May–Jun;14(3):225–9

Effects of ethanol on energy balance of rats and the inappropriateness of intraperitoneal injection. Luz J, et al. **Alcohol** 1996 Nov–Dec;13(6):575–80

Modulation of tryptophan hydroxylase activity in vitro by

ethanol depends on biopterin cofactor concentration. Matsubara K, et al. **Alcohol** 1996 Sep–Oct;13(5):455–9
Chronic ethanol effects on the expression of phospholipase C isozymes and Gq/11-protein in primary cultures of astrocytes. Pandey SC, et al. **Alcohol** 1996 Sep–Oct; 13(5):487–92
The development of the blood–brain barrier in alcohol–exposed rats. Phillips DE, et al. **Alcohol** 1997 Jul–Aug;14(4):333–43
Effect of ethanol on folate binding by isolated rat renal brush border membranes. Ross DM, et al. **Alcohol** 1996 Sep–Oct; 13(5):449–54
Alcohol–induced changes in urinary aminolevulinic acid and porphyrins: unrelated to liver disease. Schoenfeld N, et al. **Alcohol** 1996 Jan–Feb;13(1):59–63 (18 ref.)
Effect of neonatal thyroid hormone alterations in CNS ethanol sensitivity in adult LS and SS mice. Segall MA, et al. **Alcohol** 1996 Nov–Dec;13(6):559–67
The effect of ethanol drinking on opioid analgesia and receptors in mice. Shah S, et al. **Alcohol** 1997 Jul–Aug; 14(4):361–6
Interaction of exercise and ethanol on antioxidant enzymes in brain regions of the rat. Somani SM, et al. **Alcohol** 1996 Nov–Dec;13(6):603–10
The effects of ethanol on a measure of conditioned fear in mice. Stromberg MF, et al. **Alcohol** 1997 Jul–Aug; 14(4):403–7
Effect of calcium channel blocker diltiazem on some depressant actions of ethanol in UChA and UChB rats. Tampier L, et al. **Alcohol** 1997 Jan–Feb;14(1):21–3
Ethanol impairs the induction of delayed hypersensitivity in C57BL/6 mice. Waltenbaugh C, et al. **Alcohol** 1997 Mar–Apr;14(2):149–53
Alcohol–induced thymocyte apoptosis is accompanied by impaired mitochondrial function. Wang JF, et al. **Alcohol** 1997 Jan–Feb;14(1):99–105
Chronic ethanol feeding alters the structure and function of the epidermal growth factor receptor in rat stomach. Wang SL, et al. **Alcohol** 1996 Sep–Oct;13(5):461–6
Ethanol affects hypothalamic neurons projecting to the hippocampus and inhibits dentate granule cell LTP. Wayner MJ, et al. **Alcohol** 1997 Jan–Feb;14(1):1–7
Intracellular mechanisms of constriction of rat aorta by ethanol. Werber AH, et al. **Alcohol** 1997 Jul–Aug; 14(4):351–60
Influence of long–term ethanol treatment on rat liver aniline and p–nitrophenol hydroxylation. Wirkner K, et al. **Alcohol** 1996 Jan–Feb;13(1):69–74
Chronic treatment of cultured cerebral vascular smooth cells with low concentration of ethanol elevates intracellular calcium and potentiates prostanoid–induced rises in [Ca2+]i: relation to etiology of alcohol–induced stroke. Zhang A, et al. **Alcohol** 1997 Jul–Aug;14(4):367–71
The GABAergic system of the dentate gyrus after withdrawal from chronic alcohol consumption: effects of intracerebral grafting and putative neuroprotective agents. Cadete–Leite A, et al. **Alcohol Alcohol** 1997 Jul–Aug; 32(4):471–84
ESBRA–Nordmann 1996 Award Lecture: ethanol drinking behaviour in Sardinian alcohol–preferring rats. Colombo G. **Alcohol Alcohol** 1997 Jul–Aug;32(4):443–53
Effects of 5–HT3 receptor agonists on voluntary ethanol intake in rats maintained on a limited access procedure. Dyr W, et al. **Alcohol Alcohol** 1997 Jul–Aug;32(4):455–62
'Overshoot' of ethanol in the blood after drinking on an empty stomach. Hahn RG, et al. **Alcohol Alcohol** 1997 Jul–Aug;32(4):501–5
Effects of ethanol on the function of G proteins in rat cerebral cortex membranes. Hatta S, et al. **Alcohol Alcohol** 1994;29 Suppl 1:45–51
Inhibition of ethanol–induced inositol phosphate formation and Ca(2+) mobilization by okadaic acid in rat hepatocytes: evidence for a role of protein phosphatases in the modulation of phospholipase C by ethanol. Higashi K, et al. **Alcohol Alcohol** 1994;29 Suppl 1:53–9
An anaesthetic dose of ethanol inhibits cyclic AMP formation by altering the function of GS protein. Ichida T, et al. **Alcohol Alcohol** 1997 Mar–Apr;32(2):153–60
Effects of lifelong ethanol consumption on rat locus coeruleus. Lu W, et al. **Alcohol Alcohol** 1997 Jul–Aug; 32(4):463–70
Ethanol induces transient arrest of cell division (G2 + M block) followed by G0/G1 block: dose effects of short– and longer–term ethanol exposure on cell cycle and cell functions. Mikami K, et al. **Alcohol Alcohol** 1997 Mar–Apr; 32(2):145–52
Effect of ethanol treatment on the activity and amount of stimulatory GTP–binding regulatory protein (Gs) in S49 murine lymphoma cells and human erythrocytes. Nakamura J. **Alcohol Alcohol** 1994;29 Suppl 1:61–5
Reduced sensitivity to ethanol of Gs alpha and Gi/o alpha in the cerebral cortex of alcoholic patients. Ozawa H, et al. **Alcohol Alcohol** 1994;29 Suppl 1:93–7
Influence of ethanol on insulin receptor substrate–1–mediated signal transduction during rat liver regeneration. Sasaki Y, et al. **Alcohol Alcohol** 1994;29 Suppl 1:99–106
Effect of combined alanine and glutamine administration on the inhibition of liver regeneration caused by long–term administration of alcohol. Tanaka T, et al. **Alcohol Alcohol** 1994;29 Suppl 1:125–32
Action of ethanol and some alcoholic beverages on gastric acid secretion in anaesthetized rats. Teyssen S, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):23–31
ADH and ALDH genotypes in relation to alcohol metabolic rate and sensitivity. Whitfield JB. **Alcohol Alcohol Suppl** 1994;2:59–65 (15 ref.)
Mechanism of ethanol inhibition of NMDA receptor function in primary cultures of cerebral cortical cells. Bhave SV, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):934–41
Ethanol modulates metastatic potential of B16BL6 melanoma and host responses. Blank SE, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):624–8
The role of cAMP in ethanol–regulated beta–endorphin release from hypothalamic neurons. Boyadjieva NI, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):728–31
Long–term ethanol and nicotine treatment elicit tolerance to ethanol. Collins AC, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):990–9
Acute hemodynamic, pituitary, and adrenocortical responses to alcohol in adult female sheep. Cudd TA, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1675–81
Effect of administered ethanol on protein kinase C in human platelets. Deitrich RA, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1503–6
The nitric oxide synthase inhibitor L–NAME (N omega–nitro–L–arginine methyl ester) does not produce discriminative stimulus effects similar to ethanol. Green KL, et al. **Alcohol Clin Exp Res** 1997 May;21(3):483–8
Ethanol suppresses endotoxin but not platelet activating factor–induced hypotension and nitric oxide. Greenberg SS, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1260–8
Effect of chronic ethanol consumption on the atrial natriuretic system of spontaneously hypertensive rats. Guillaume P, et al. **Alcohol Clin Exp Res** 1996 Dec; 20(9):1653–61
Ethanol, flunitrazepam, and pentobarbital modulation of GABAA receptors expressed in mammalian cells and Xenopus oocytes. Harris RA, et al. **Alcohol Clin Exp Res** 1997 May;21(3):444–51
Discriminative stimulus function of ethanol: role of GABAA receptors in the nucleus accumbens. Hodge CW, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1221–8
Ethanol ingestion impairs neutrophil bactericidal mechanisms against Streptococcus pneumoniae. Jareo PW, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1646–52
Ethanol and mitotic inhibitors promote differentiation of trophoblastic cells. Karl PI, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1269–74
The role of nitric oxide in ethanol–induced gastrointestinal dysfunction. Keshavarzian A, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1618–24
Interactions between ethanol and agents that act on the NMDA–type glutamate receptor. Lovinger DM. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):187A–191A
Contrasting effects of urethane, ketamine, and thiopental anesthesia on ethanol–clonidine hemodynamic interaction. el–Mas MM, et al. **Alcohol Clin Exp Res** 1997 Feb; 21(1):19–27
A PC–based software test for measuring alcohol and drug effects in human subjects. Mills KC, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1582–91
Effects of ethanol and temperature on NMDA receptor function in different mouse genotypes. Musleh W, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1299–304
Ethanol–induced change in cardiac and endogenous opiate function and risk for alcoholism. Peterson JB, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1542–52
Long–term effects of chronic ethanol on muscarinic receptor binding in rat brain. Rothberg BS, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1613–7
Sensitivity to ethanol–induced ataxia in HOT and COLD selected lines of mice. Schafer GL, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1604–12
Differential effects of ethanol on feline rage and predatory attack behavior: an underlying neural mechanism. Schubert K, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):882–9
Correlated responses to selection in FAST and SLOW mice: effects of ethanol on ataxia, temperature, sedation, and withdrawal. Shen EH, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):688–96
Alcohol effects on the heritability of EEG spectral power. Sorbel J, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1523–7
Effect of exogenous GM1 on ethanol sensitivity in selectively bred mouse lines. Ullman MD, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):661–5
Serotonin modulates ethanol–induced depression in cerebellar Purkinje neurons. Wang Y, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1229–36
Ethanol modulation of GABA–activated current responses in acutely dissociated retinal bipolar cells and ganglion cells. Yeh HH, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):647–55
Alcohol and cytokine–inducible transcription factors. Zeldin G, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1639–45 (36 ref.)
Alcohol consumption, gamma–glutamyl transpeptidase (GGT), and pulmonary function: a cross–sectional and longitudinal study in working men. Zureik M, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1507–11
Hemodynamic effects of acute ethanol in young adults. Kelly LF, et al. **Am J Cardiol** 1996 Oct 1;78(7):851–4
Effects of acute alcohol ingestion on heart rate variability in patients with documented coronary artery disease and stable angina pectoris. Rossinen J, et al. **Am J Cardiol** 1997 Feb 15;79(4):487–91
Sex differences in the association between alcohol consumption and cognitive performance. EVA Study Group. Epidemiology of Vascular Aging. Dufouil C, et al. **Am J Epidemiol** 1997 Sep 1;146(5):405–12
Ethanol disrupts and decreases the regulated body temperature differentially in C57BL/6J and DBA/2J mice. Crawshaw LI, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R696–702
GSH transport in mitochondria: defense against TNF–induced oxidative stress and alcohol–induced defect. Fernández–Checa JC, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):G7–17 (85 ref.)
Renal alterations of atrial natriuretic peptide receptors by chronic moderate ethanol treatment. Guillaume P, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):F107–16
Effect of ethanol on cholecystokinin–stimulated zymogen conversion in pancreatic acinar cells. Katz M, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):G171–5
Adenosine A2–receptor mediates ethanol–induced arteriolar dilation in rat stomach. Nagata H, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):G1028–33
Ethanol enhances caffeine–induced Ca2+–release channel activation in skeletal muscle sarcoplasmic reticulum. Oba T, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C622–7
Kupffer cell prostaglandin E2 stimulates parenchymal cell O2 consumption: alcohol and cell–cell communication. Qu W, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):G574–80
Effects of dietary polyunsaturated fat on ethanol–induced Ito cell activation. Tsukamoto H, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):G581–6
The firewater myth and response to alcohol in Mission Indians. Garcia–Andrade C, et al. **Am J Psychiatry** 1997 Jul;154(7):983–8
Polyurethane central venous catheters, hydrochloric acid and 70% ethanol: a safety evaluation. McHugh GJ, et al. **Anaesth Intensive Care** 1997 Aug;25(4):350–3
Quantitation of 5–lipoxygenase products by electrospray mass spectrometry: effect of ethanol on zymosan–stimulated production of 5–lipoxygenase products by human neutrophils. Wheelan P, et al. **Anal Biochem** 1997 Jan 1; 244(1):110–5
Ultrastructure of rat Purkinje neurons after chronic ethanol consumption and prolonged abstinence. Wenisch S, et al. **Anat Histol Embryol** 1997 Jun;26(2):93–8
Protection of ethanol–mediated acetaminophen hepatotoxicity by triacetyloleandomycin, a specific inhibitor of CYP3A. Kostrubsky VE, et al. **Ann Clin Lab Sci** 1997 Jan–Feb;27(1):57–62
Adolescent stress alters ethanol ingestion and agonistic behavior in the male golden hamster. Ferris CF, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:348–51
Acute ethanol treatment augments interleukin–12 production in activated human monocytes. Szabo G, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:422–5
Effect of ethanol on pancreatic interstitial pH and blood flow in cats with chronic pancreatitis. Toyama MT, et al. **Ann Surg** 1997 Feb;225(2):223–8
Salt–induced changes in lipid composition and ethanol tolerance in Saccharomyces cerevisiae. Sharma SC, et al. **Appl Biochem Biotechnol** 1996 Feb;56(2):189–95
Mitochondrial DNA loss caused by ethanol in Saccharomyces flor yeasts. Ibeas JI, et al. **Appl Environ Microbiol** 1997 Jan;63(1):7–12
Polyunsaturated fatty acid biosynthesis in Saccharomyces cerevisiae: expression of ethanol tolerance and the FAD2 gene from Arabidopsis thaliana. Kajiwara S, et al. **Appl Environ Microbiol** 1996 Dec;62(12):4309–13
Influence of ethanol on in vitro growth of human mammary carcinoma cell line MCF–7. Przylipiak A, et al. **Arch Gynecol Obstet** 1996;258(3):137–40
Inhibition by ethanol of the growth of biofilm and dispersed microcosm dental plaques. Sissons CH, et al. **Arch Oral Biol** 1996 Jan;41(1):27–34
Using a four–compartment closed model to describe inhalation of vaporised ethanol on 1–14C–pyruvate kinetics in mice. Wu G. **Arch Toxicol** 1997;71(8):501–7
N–acetyl cysteine attenuates ethanol induced hypertension in rats. Vasdev S, et al. **Artery** 1995;21(6):312–6
Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol. Antila S, et al. **Arzneimittelforschung** 1997 Jul;47(7):816–20
Local alcohol delivery may reduce phenotype conversion of smooth muscle cells and neointimal formation in rabbit iliac arteries after balloon injury. Liu MW, et al. **Atherosclerosis** 1996 Dec 20;127(2):221–7
Influence of sex, diabetes and ethanol on intrinsic contractile performance of isolated rat myocardium. Brown RA, et al. **Basic Res Cardiol** 1996 Sep–Oct;91(5):353–60
Modulation of serotonin2A/2C receptors and these receptor–linked phosphoinositide system by ethanol. Pandey SC, et al. **Behav Brain Res** 1996;73(1–2):235–8 (26 ref.)
Effects of ethanol on nonspatial working memory and attention in rats. Givens B, et al. **Behav Neurosci** 1997 Apr; 111(2):275–82
Prenatal alcohol and stress interact to attenuate ejaculatory behavior, but not serum testosterone or LH in adult male rats. Ward IL, et al. **Behav Neurosci** 1996 Dec; 110(6):1469–77
Genetic regulation of gene–specific mRNA by ethanol in

vivo and its possible role in ethanol preference in a cross with RI lines in mice. Tagliabracci CE, et al. **Biochem Genet** 1996 Jun;34(5–6):219–38

Over expression of inducible proteins in Escherichia coli by treatment with ethanol. Basu T, et al. **Biochem Mol Biol Int** 1997 May;41(6):1093–100

Decreased binding and autophosphorylation of the epidermal growth factor receptor in ethanol-fed rats. O'Rourke MF, et al. **Biochem Pharmacol** 1997 May 15;53(10):1445–50

The effect of starvation and ethanol on c-myc messenger RNA expression in the heart. Paice AG, et al. **Biochem Soc Trans** 1996 May;24(2):212S

Chronic ethanol administration decreases rat pancreatic GP2 content. Apte MV, et al. **Biochim Biophys Acta** 1997 Jul 19;1336(1):89–98

Ethanol represses thymidylate synthase and thymidine kinase at mRNA level in regenerating rat liver after partial hepatectomy. Yoshida Y, et al. **Biochim Biophys Acta** 1997 Aug 29;1336(2):180–6

Effects of ethanol on phospholipases in the mouse brain, heart and liver. Natsuki R, et al. **Biol Pharm Bull** 1996 Apr; 19(4):525–9

Effect of acute ethanol on auditory and visual event-related potentials: a review and reinterpretation. Jääskeläinen IP, et al. **Biol Psychiatry** 1996 Aug 15;40(4):284–91 (78 ref.)

Mismatch negativity subcomponents and ethyl alcohol. Jääskeläinen IP, et al. **Biol Psychol** 1996 Mar 8;43(1):13–25

The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance. Kerr JS, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):239–41

Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. van Steveninck AL, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):565–73

Ethanol enhances the IFN-gamma, TGF-alpha and IL-6 secretion in psoriatic co-cultures. Ockenfels HM, et al. **Br J Dermatol** 1996 Nov;135(5):746–51

Evidence of differential effects produced by ethanol on specific phospholipid biosynthetic pathways in rat hepatocytes. Carrasco MP, et al. **Br J Pharmacol** 1996 Sep; 119(2):233–8

Suppressive effect of melatonin administration on ethanol-induced gastroduodenal injury in rats in vivo. Melchiorri D, et al. **Br J Pharmacol** 1997 May; 121(2):264–70

Chemical ablation of the gallbladder. Majeed AW, et al. **Br J Surg** 1997 May;84(5):638–41

Discriminative stimulus properties of ethanol in the rat: effects of neurosteroids and picrotoxin. Bienkowski P, et al. **Brain Res** 1997 Apr 11;753(2):348–52

Effect of an NMDA receptor antagonist and a ganglioside GM1 derivative upon ethanol-induced modification of parameters of oxidative stress in several brain regions. Bondy SC, et al. **Brain Res** 1996 Apr 15;716(1–2):165–70

Microelectrophoretic application of SCH-23390 into the lateral septal nucleus blocks ethanol-induced suppression of LTP, in vivo, in the adult rodent hippocampus. Criado JR, et al. **Brain Res** 1996 Apr 15;716(1–2):192–6

Taurine increases in the nucleus accumbens microdialysate after acute ethanol administration to naive and chronically alcoholised rats. Dahchour A, et al. **Brain Res** 1996 Sep 30;735(1):9–19

Mouse cerebellar adenosinergic modulation of ethanol-induced motor incoordination: possible involvement of cAMP. Dar MS. **Brain Res** 1997 Feb 28; 749(2):263–74

Sensitivity of postsynaptic GABAB receptors on hippocampal CA1 and CA3 pyramidal neurons to ethanol. Frye GD, et al. **Brain Res** 1996 Oct 7;735(2):239–48

Ethanol effects on synaptic neurotransmission and tetanus-induced synaptic plasticity in hippocampal slices of chronic in vivo lead-exposed adult rats. Grover CA, et al. **Brain Res** 1996 Sep 23;734(1–2):61–71

Chronic alcohol reduces calcium signaling elicited by glutamate receptor stimulation in developing cerebellar neurons. Gruol DL, et al. **Brain Res** 1996 Jul 29; 728(2):166–74

Proliferation of astroglia from the adult human cerebrum is inhibited by ethanol in vitro. Kane CJ, et al. **Brain Res** 1996 Aug 26;731(1–2):39–44

Ethanol consumption following recovery from unilateral damage to the forelimb area of the sensorimotor cortex: reinstatement of deficits and prevention of dendritic pruning. Kozlowski DA, et al. **Brain Res** 1997 Jul 25; 763(2):159–66

Dynamics of ethanol-induced transmitter packet release in the frog neuromuscular junction. Kriebel ME, et al. **Brain Res** 1996 Aug 12;729(2):228–33

Acute and chronic actions of ethanol on CA1 hippocampal responses to serotonin. Lau AH, et al. **Brain Res** 1996 Aug 26;731(1–2):12–20

Effects of ethanol and nomifensine on NE clearance in the cerebellum of young and aged Fischer 344 rats. Lin AM, et al. **Brain Res** 1997 May 9;756(1–2):287–92

Ethanol exposure reduces the density of the low-affinity nerve growth factor receptor (p75) on pheochromocytoma (PC12) cells. Luo J, et al. **Brain Res** 1996 Oct 21; 737(1–2):34–44

Central corticotropin-releasing factor and benzodiazepine receptor systems are involved in the social isolation stress-induced decrease in ethanol sleep in mice. Matsumoto K, et al. **Brain Res** 1997 Apr 11;753(2):318–21

Ethanol actions on the mechanisms of Ca2+ mobilization in rat hippocampal cells are mediated by protein kinase C. Mironov SL, et al. **Brain Res** 1996 Apr 1;714(1–2):27–37

Effect of ethanol on extracellular dopamine in nucleus accumbens: comparison between Lewis and Fischer 344 rat strains. Mocsary Z, et al. **Brain Res** 1996 Jan 15; 706(2):194–8

Ethanol-induced state-dependent learning is mediated by 5-hydroxytryptamine3 receptors but not by N-methyl-D-aspartate receptor complex. Nakagawa Y, et al. **Brain Res** 1996 Jan 15;706(2):227–32

Role of arginine vasopressin and corticotropin-releasing factor in mediating alcohol-induced adrenocorticotropin and vasopressin secretion in male rats bearing lesions of the paraventricular nuclei. Ogilvie KM, et al. **Brain Res** 1997 Jan 2;744(1):83–95

Pretreatment with the protein kinase C activator phorbol 12,13-dibutyrate attenuates the ethanol-induced loss of the righting reflex in mice: modification by diabetes. Ohsawa M, et al. **Brain Res** 1997 Aug 1;764(1–2):244–8

Effects of acute prenatal ethanol exposure on Bergmann glia cells early postnatal development. Pérez-Torrero E, et al. **Brain Res** 1997 Jan 23;746(1–2):305–8

Acute alcohol blocks neurosteroid modulation of synaptic transmission and long-term potentiation in the rat hippocampal slice. Randall RD, et al. **Brain Res** 1995 Dec 1;701(1–2):238–48

Importance of pituitary and brain receptors for corticotrophin-releasing factor in modulating alcohol-induced ACTH secretion in the rat. Rivier C, et al. **Brain Res** 1996 May 20;721(1–2):83–90

Acute alcohol administration stimulates the activity of hypothalamic neurons that express corticotropin-releasing factor and vasopressin. Rivier C, et al. **Brain Res** 1996 Jul 8;726(1–2):1–10

Effect of ethanol on extracellular 5-HT and glutamate in the nucleus accumbens and prefrontal cortex: comparison between the Lewis and Fischer 344 rat strains. Selim M, et al. **Brain Res** 1996 Apr 15;716(1–2):157–64

Heat shock- and ethanol-induced ionic changes in C6 rat glioma cells determined by NMR and fluorescence spectroscopy. Skrandies S, et al. **Brain Res** 1997 Jan 23; 746(1–2):220–30

Ethanol inhibits chemoreflex excitation of reticulospinal vasomotor neurons. Sun MK, et al. **Brain Res** 1996 Aug 19;730(1–2):182–92

Ethanol-induced c-Fos expression in rat lines selected for low and high alcohol consumption. Thiele TE, et al. **Brain Res** 1997 May 9;756(1–2):278–82

Ethanol and nerve growth factor effects on calcium homeostasis in cultured embryonic rat medial septal neurons before and during depolarization. Webb B, et al. **Brain Res** 1995 Dec 1;701(1–2):61–74

Calcium homeostasis in cultured embryonic rat septohippocampal neurons is altered by ethanol and nerve growth factor before and during depolarization. Webb B, et al. **Brain Res** 1996 Aug 12;729(2):176–89

Single-channel and whole-cell analysis of ethanol inhibition of NMDA-activated currents in cultured mouse cortical and hippocampal neurons. Wright JM, et al. **Brain Res** 1996 Nov 4;738(2):249–56

FOS and JUN as markers for ethanol-sensitive pathways in the rat brain. Davidson M, et al. **Brain Res Bull** 1996; 39(3):177–84

Carbon monoxide formation in the guinea pig hippocampus: ontogeny and effect of in vitro ethanol exposure. Cook MN, et al. **Brain Res Dev Brain Res** 1997 Jul 18; 101(1–2):283–6

Protective effects of maternal buspirone treatment on serotonin reuptake sites in ethanol-exposed offspring. Kim JA, et al. **Brain Res Dev Brain Res** 1996 Apr 30;92(2):190–8

Deficiency of essential neurotrophic factors in conditioned media produced by ethanol-exposed cortical astrocytes. Kim JA, et al. **Brain Res Dev Brain Res** 1996 Oct 23; 96(1–2):1–10

Effects of ethanol on muscarinic receptor-stimulated c-fos expression in human neuroblastoma cells. Ding WQ, et al. **Brain Res Mol Brain Res** 1997 Jun;46(1–2):77–84

The 71 kDa glutamate-binding protein is increased in cerebellar granule cells after chronic ethanol treatment. Hoffman PL, et al. **Brain Res Mol Brain Res** 1996 Jul; 39(1–2):167–76

Chronic ethanol treatment produces a selective upregulation of the NMDA receptor subunit gene expression in mammalian cultured cortical neurons. Hu XJ, et al. **Brain Res Mol Brain Res** 1996 Mar;36(2):211–8

Activation of protein kinase A prevents the ethanol-induced up-regulation of delta-opioid receptor mRNA in NG108-15 cells. Jenab S, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1–2):44–8

Alterations in the estrogen sensitivity of hypothalamic proenkephalin mRNA expression with age and prenatal exposure to alcohol. Li Y, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1–2):215–22

Glucocorticoid interactions with ethanol effects on depolarization-induced calcium influx in brain synaptosomes. Sze PY. **Brain Res Mol Brain Res** 1996 Apr; 37(1–2):231–8

N-methyl-D-aspartate receptors, nitric oxide, and ethanol tolerance. Morato GS, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1415–26 (138 ref.)

Adaptive cytoprotection against ethanol-induced small intestinal mucosal injury. Dinda PK, et al. **Can J Physiol Pharmacol** 1996 May;74(5):598–602

Fetal breathing is not inhibited by ethanol exposure during prolonged reduced uterine blood flow. Watson CS, et al. **Can J Physiol Pharmacol** 1996 Sep;74(9):1016–24

Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Rubinstein M, et al. **Cell** 1997 Sep 19;90(6):991–1001

Inhibition of hepatic inositol 1,4,5-trisphosphate receptor function by ethanol and other short chain alcohols. Renard-Rooney DC, et al. **Cell Calcium** 1997 May; 21(5):387–98

Site-specificity of ethanol-induced dephosphorylation of rat hepatocyte keratins 8 and 18: A 31P NMR study. Eckert BS, et al. **Cell Motil Cytoskeleton** 1996;33(1):30–7

Prophylactic effects of sucralfate and geraniin on ethanol-induced gastric mucosal damage in rats [published erratum appears in Chin J Physiol 1996;39(1):63] Hung CR, et al. **Chin J Physiol** 1995;38(4):211–7

Alcohol and heart disease. Pearson TA. **Circulation** 1996 Dec 1;94(11):3023–5

Prevention of bioprosthetic heart valve calcification by ethanol preincubation. Efficacy and mechanisms [see comments] Vyavahare N, et al. **Circulation** 1997 Jan 21; 95(2):479–88. Comment in: Circulation 1997 Jan 21;95(2):297–8.

Impact of ethanol stress on components of the allantoic fluid of the chicken embryo. ten Busch M, et al. **Comp Biochem Physiol A Physiol** 1997 Feb;116(2):125–9

Ethanol alters brain phospholipid levels which correlate with altered brain morphology. Miller RR Jr, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Apr; 116(4):407–17

Effects of 50% ethanol and mechanical epithelial debridement on corneal structure before and after excimer photorefractive keratectomy. Helena MC, et al. **Cornea** 1997 Sep;16(5):571–9

Human monocyte IL-10 production is increased by acute ethanol treatment. Mandrekar P, et al. **Cytokine** 1996 Jul; 8(7):567–77

Long lasting immunological effects of ethanol after withdrawal. Laso FJ, et al. **Cytometry** 1996 Dec 15; 26(4):275–80

Effect of ethanol on adenosine triphosphate, cytosolic free calcium, and cell injury in rat hepatocytes. Time course and effect of nutritional status. Gasbarrini A, et al. **Dig Dis Sci** 1996 Nov;41(11):2204–12

Ethanol retards gastric epithelial restoration in monolayer cultures. Murai T, et al. **Dig Dis Sci** 1996 Oct;41(10):2062–9

Effect of ethanol on postprandial duodenojejunal motility in humans. Schmidt T, et al. **Dig Dis Sci** 1997 Aug; 42(8):1628–33

Enhanced interleukin-8 production by cultured Chang liver cells subjected to ethanol exposure and subsequent stimulation with tumor necrosis factor-alpha. Ohira H, et al. **Digestion** 1997;58(1):72–7

Alterations in serotonin1B (5HT1B) receptor subtypes in the brain of ethanol-treated rats. Pandey SC, et al. **Drug Alcohol Depend** 1996 Jul;41(3):219–25

Effect of alcohol coadministration on the plasma and brain concentrations of cocaine in rats. Hedaya MA, et al. **Drug Metab Dispos** 1997 May;25(5):647–50

Effects of ethanol and cocaethylene on cocaine pharmacokinetics in conscious dogs. Parker RB, et al. **Drug Metab Dispos** 1996 Aug;24(8):850–3

Induction of cytochrome P450 genes by ethanol in maize. Potter S, et al. **Drug Metabol Drug Interact** 1995; 12(3–4):317–27

Low concentrations of ethanol inhibits prolactin-induced mitogenesis and cytokine expression in cultured astrocytes. DeVito WJ, et al. **Endocrinology** 1997 Mar;138(3):922–8

Alcohol and its variable effect on human thermoregulatory response to exercise in a warm environment. Desruelle AV, et al. **Eur J Appl Physiol** 1996;74(6):572–4

Alcohol lowers the vasoconstriction threshold in humans without affecting core cooling rate during mild cold exposure. Johnston CE, et al. **Eur J Appl Physiol** 1996; 74(3):293–5

Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. Mattila MJ, et al. **Eur J Clin Pharmacol** 1996; 51(2):161–6

Effect of neuroleptics on ethanol-treated rats. Popović MR, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jul–Sep; 21(3):247–50

Differential reactivity of structural components of eosinophil leucocyte granules as revealed by ethanolic phosphotungstic acid. Tato A, et al. **Eur J Morphol** 1995 Nov;33(5):465–72

Exposure of piglet coronary arterial muscle cells to low alcohol results in elevation of intracellular free Ca2+: relevance to fetal alcohol syndrome. Altura MB, et al. **Eur J Pharmacol** 1996 Oct 31;314(3):R9–11

Chronic ethanol exposure selectively increases diazepam-insensitive [3H]RO15-4513 binding in mouse cerebellum. Becker HC, et al. **Eur J Pharmacol** 1996 Jan 18;296(1):43–6

Monosialoganglioside attenuates the excitatory and behavioural sensitization effects of ethanol. Bellot RG, et al. **Eur J Pharmacol** 1996 Oct 17;313(3):175–9

Competitive NMDA receptor antagonist, CGP 40116, substitutes for the discriminative stimulus effects of ethanol.

Bienkowski P, et al. **Eur J Pharmacol** 1996 Oct 31; 314(3):277–80

Acute and chronic effects of ethanol on papillary muscles from spontaneously hypertensive rats. Brown RA, et al. **Eur J Pharmacol** 1996 Apr 29;302(1–3):61–7

Effect of chronic moderate ethanol consumption on heart brain natriuretic peptide. Guillaume P, et al. **Eur J Pharmacol** 1996 Nov 28;316(1):49–58

N-Methyl-D-aspartate-induced enhancement of activator protein-1 DNA binding activity is blocked by ethanol in cerebellar granule cells. Hou YN, et al. **Eur J Pharmacol** 1996 Aug 15;309(3):307–10

Ethanol potentiates lipopolysaccharide- or interleukin-1 beta-induced nitric oxide generation in RBE4 cells. Naassila M, et al. **Eur J Pharmacol** 1996 Oct 17; 313(3):273–7

Inhibitory effect of ethanol on the 5-HT3 receptor-mediated tachycardia in isolated guinea-pig atrium. Nishio H, et al. **Eur J Pharmacol** 1997 Feb 19;321(1):27–31

Effect of prior ethanol experience on dopamine overflow in accumbens of AA and ANA rats. Nurmi M, et al. **Eur J Pharmacol** 1996 Nov 21;315(3):277–83

Intrastriatal adenosine A1 receptor antisense oligodeoxynucleotide blocks ethanol-induced motor incoordination. Phan TA, et al. **Eur J Pharmacol** 1997 Apr 4;323(2–3):R5–7

Ro 15-4513 potentiates, instead of antagonizes, ethanol-induced sleep in mice exposed to small platform stress. Pokk P, et al. **Eur J Pharmacol** 1996 Dec 12; 317(1):15–20

Insulin-like growth factor I expression alters acute sensitivity and tolerance to ethanol in transgenic mice. Pucilowski O, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):57–62

Piroxicam modifies the effects of ethanol on isolated rat hepatocytes. Saldaña-Balmori Y, et al. **Eur J Pharmacol** 1996 Dec 19;317(2–3):225–9

Discrimination of cocaethylene in rats trained to discriminate between its components. Schechter MD. **Eur J Pharmacol** 1997 Feb 5;320(1):1–7

Studies on the role of 5-HT3 receptors in the mediation of the ethanol interoceptive cue. Stefanski R, et al. **Eur J Pharmacol** 1996 Aug 8;309(2):141–7

Antisense oligonucleotide to c-fos blocks the ability of arginine vasopressin to maintain ethanol tolerance. Szabó G, et al. **Eur J Pharmacol** 1996 Jun 13;306(1–3):67–72

Ethanol inhibition of stress-related tachycardia involves medullary NMDA receptors. Varga K, et al. **Eur J Pharmacol** 1996 Aug 29;310(2–3):145–53

Ethanol alone or with dexamethasone alters the kinetics of choline acetyltransferase. Wattanathorn J, et al. **Eur J Pharmacol** 1996 Oct 10;313(1–2):69–72

Ethanol as a general anesthetic: actions in spinal cord. Wong SM, et al. **Eur J Pharmacol** 1997 Jun 25;329(2–3):121–7

Focal ethanol elevates extracellular dopamine and serotonin concentrations in the rat ventral tegmental area. Yan QS, et al. **Eur J Pharmacol** 1996 Apr 22;301(1–3):49–57

Resistance to cognitive impairment under alcohol: the role of environmental consequences. Fillmore MT, et al. **Exp Clin Psychopharmacol** 1997 Aug;5(3):251–5

Ethanol and pentobarbital: comparison of behavioral and subjective effects in sedative drug abusers. Mintzer MZ, et al. **Exp Clin Psychopharmacol** 1997 Aug;5(3):203–15

Benzodiazepine-GABA modulation of concurrent ethanol and sucrose reinforcement in the rat. Petry NM. **Exp Clin Psychopharmacol** 1997 Aug;5(3):183–94

Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Rush CR, et al. **Exp Clin Psychopharmacol** 1997 Feb;5(1):28–38

Ethanol depression of cerebellar Purkinje neuron firing involves nicotinic acetylcholine receptors. Freund RK, et al. **Exp Neurol** 1997 Feb;143(2):319–22

Immobilization and ethanol stress induce the same molecular response at the level of the cell wall in growing yeast. Parascandola P, et al. **FEMS Microbiol Lett** 1997 May 1; 150(1):121–6

A possible role of trehalose in osmotolerance and ethanol tolerance in Saccharomyces cerevisiae. Sharma SC. **FEMS Microbiol Lett** 1997 Jul 1;152(1):11–5

Enhancement of yeast ethanol tolerance by calcium and magnesium. Ciesarová Z, et al. **Folia Microbiol (Praha)** 1996;41(6):485–8

Effect of naklofen, alcohol and naklofen administered simultaneously with alcohol on transaminase levels. Łąkowska H, et al. **Folia Morphol (Warsz)** 1996;55(4):380–1

Methanol elimination in non-alcoholics: inter- and intraindividual variation. Haffner HT, et al. **Forensic Sci Int** 1997 Apr 18;86(1–2):69–76

Modulation of the development of humoral immunity by topically applied acetone, ethanol, and 12-O-tetradecanoylphorbol-13-acetate. Singh KP, et al. **Fundam Appl Toxicol** 1996 Sep;33(1):129–39

Modulation by alcohol and methadone of 2-deoxyglucose-stimulated pancreatic secretion in the rat. Nagain-Domaine C, et al. **Fundam Clin Pharmacol** 1996; 10(6):538–46

Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol [see comments] Clot P, et al. **Gastroenterology** 1997 Jul;113(1):265–76. Comment in: Gastroenterology 1997 Jul;113(1):353–5.

Antibodies against ethanol-derived protein adducts: pathogenic implications [editorial; comment] Israel Y. **Gastroenterology** 1997 Jul;113(1):353–5. Comment on: Gastroenterology 1997 Jul;113(1):265–76.

Oxidative stress on mitochondria and cell membrane of cultured rat hepatocytes and perfused liver exposed to ethanol. Kurose I, et al. **Gastroenterology** 1997 Apr; 112(4):1331–43

Differential inhibition of epidermal growth factor signaling pathways in rat hepatocytes by long-term ethanol treatment. Saso K, et al. **Gastroenterology** 1997 Jun; 112(6):2073–88

Ethanol perturbs receptor-operated cytosolic free calcium concentration signals in cultured rat hepatocytes. Zhang BH, et al. **Gastroenterology** 1997 Aug;113(2):641–8

The effects of propranolol hydrochloride singularly or in conjunction with ethanol on clotting activity in the rat. Lox CD. **Gen Pharmacol** 1996 Mar;27(2):211–13

Potentiation by ethanol of GABA-induced current and facilitation of its desensitization in cultured rat cortical neurons. Tsujiyama S, et al. **Gen Pharmacol** 1997 Mar; 28(3):375–80

Transcriptional regulation of tracheo-bronchial mucin (TBM) gene by ethanol. Verma M, et al. **Gene** 1997 Apr 11;189(1):9–12

Confirmation of quantitative trait loci for ethanol sensitivity in long-sleep and short-sleep mice. Markel PD, et al. **Genome Res** 1997 Feb;7(2):92–9

Studies on gastric mucosal microcirculation. 1. The nature of regional variations induced by ethanol injury. Kalia N, et al. **Gut** 1997 Jan;40(1):31–5

Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-L-methionine. Colell A, et al. **Hepatology** 1997 Sep;26(3):699–708

Effect of chronic ethanol feeding on lipid peroxidation and protein oxidation in relation to liver pathology. Rouach H, et al. **Hepatology** 1997 Feb;25(2):351–5

Long-term ethanol administration alters the degradation of acetaldehyde adducts by liver endothelial cells. Thiele GM, et al. **Hepatology** 1996 Sep;24(3):643–8

Blood glucose and plasma dopamine concentrations in ethanol-consuming rats. Fantidis P, et al. **Horm Metab Res** 1996 Mar;28(3):150–1

The contribution of polymorphism in the alcohol dehydrogenase beta subunit to alcohol sensitivity in a Japanese population. Takeshita T, et al. **Hum Genet** 1996 Apr;97(4):409–13

Influence of age on the inotropic response to acute ethanol exposure in spontaneously hypertensive rats. Brown RA, et al. **Hypertension** 1996 Nov;28(5):872–9

Role of cardiac output in ethanol-evoked attenuation of centrally mediated hypotension in conscious rats. El-Mas MM, et al. **Hypertension** 1997 Aug;30(2 Pt 1):288–94

Effects of alcohol on sympathetic activity, hemodynamics, and chemoreflex sensitivity. van de Borne P, et al. **Hypertension** 1997 Jun;29(6):1278–83

Role of lipids in ethanol tolerance of Candida lambica. el Dein MM. **Indian J Exp Biol** 1997 Jan;35(1):89–91

Differences in environmental temperature, ethanol and sucrose associated with enzyme activity and weight changes in Drosophila melanogaster. Pecsenye K, et al. **Insect Biochem Mol Biol** 1996 Feb;26(2):135–45

Interactions between alcohol and other drugs. Adams WL. **Int J Addict** 1995 Nov-Dec;30(13–14):1903–23

Sucrose administration to partially hepatectomized rats: a possible model to study ethanol-induced inhibition of liver regeneration. Gutiérrez-Salinas J, et al. **Int J Biochem Cell Biol** 1996 Sep;28(9):1007–16

Actions and interactions of ethanol and imipramine on the rat sinus node. Standen DJ, et al. **Int J Cardiol** 1997 Jul 25;60(2):165–70

Central and peripheral neurochemical alterations and immune effects of prenatal ethanol exposure in rats. Clausing P, et al. **Int J Dev Neurosci** 1996 Jul;14(4):461–9

Effects of low temperatures (9–33 degrees C) and pH (3.3–5.7) in the loss of Saccharomyces cerevisiae viability by combining lethal concentrations of ethanol with octanoic and decanoic acids. Viegas CA, et al. **Int J Food Microbiol** 1997 Mar 3;34(3):267–77

Effects of exogenous cytokines on the ethanol-mediated suppression of murine thymocyte proliferation. Yeh M, et al. **Int J Immunopharmacol** 1996 Mar;18(3):219–26

The influence of acute ethanol ingestion on phospholipase D activity in rat pancreas. An in vitro and in vivo study. Rydzewska G, et al. **Int J Pancreatol** 1996 Aug;20(1):59–68

Effects of metadoxine on cellular formation of fatty acid ethyl esters in ethanol treated rats. Calabrese V, et al. **Int J Tissue React** 1995;17(3):101–8

Alcohol liberates dye of syringes. Kayikcioğlu O, et al. **Int Ophthalmol** 1996–97;20(6):291–2

Effects of ethanol on ion channels. Crews FT, et al. **Int Rev Neurobiol** 1996;39:283–367 (520 ref.)

Neurochemical bases of locomotion and ethanol stimulant effects. Phillips TJ, et al. **Int Rev Neurobiol** 1996;39:243–82 (296 ref.)

Pril-ampicillin-dextrin-ethanol agar for the isolation and quantification of Aeromonas spp. from polluted environmental waters. Imziln B, et al. **J Appl Microbiol** 1997 May;82(5):557–66

Additive effect of alcohol and nicotine on lipid peroxidation and antioxidant defence mechanism in rats. Ashakumary L, et al. **J Appl Toxicol** 1996 Jul-Aug;16(4):305–8

Role of ethanol exposure on cocaine metabolism in rat hepatocytes. Figliomeni ML, et al. **J Appl Toxicol** 1997 Mar-Apr;17(2):105–12

Influence of insulin treatment on the mechanical properties and inotropic response to ethanol in diabetic myocardium. Brown RA, et al. **J Assoc Acad Minor Phys** 1996;7(1):25–30

Stress activation of Bacillus subtilis sigma B can occur in the absence of the sigma B negative regulator RsbX. Voelker U, et al. **J Bacteriol** 1997 Mar;179(6):1980–4

The role of protein kinase C in cellular tolerance to ethanol. Coe IR, et al. **J Biol Chem** 1996 Nov 15;271(46):29468–72

An inhibitory fragment derived from protein kinase Cepsilon prevents enhancement of nerve growth factor responses by ethanol and phorbol esters. Hundle B, et al. **J Biol Chem** 1997 Jun 6;272(23):15028–35

Effect of alcoholic drinks on surface quality and mechanical strength of denture base materials. Vlissidis D, et al. **J Biomed Mater Res** 1997 Fall;38(3):257–61

Moderate alcohol feeding attenuates postinjury vascular cell proliferation in rabbit angioplasty model. Merritt R, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):19–25

High doses of alcohol increase urinary testosterone-to-epitestosterone ratio in females. Karila T, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6; 687(1):109–16

Ethanol impairs insulin-mediated glucose uptake by an indirect mechanism. Avogaro A, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2285–90

Ethanol-induced retention of nascent proteins in rat hepatocytes is accompanied by altered distribution of the small GTP-binding protein rab2. Larkin JM, et al. **J Clin Invest** 1996 Nov 1;98(9):2146–57

Late-afternoon ethanol intake affects nocturnal sleep and the sleep EEG in middle-aged men. Landolt HP, et al. **J Clin Psychopharmacol** 1996 Dec;16(6):428–36

Effect of chronic ethanol on reproductive and growth hormones in the peripubertal male rat. Steiner JC, et al. **J Endocrinol** 1997 Aug;154(2):363–70

Ethanol, growth hormone and testosterone in peripubertal rats. Tentler JJ, et al. **J Endocrinol** 1997 Mar;152(3):477–87

Morphological changes in a hyperfunctioning thyroid adenoma after percutaneous ethanol injection: histological, enzymatic and sub-microscopical alterations. Crescenzi A, et al. **J Endocrinol Invest** 1996 Jun;19(6):371–6

Germination of Nosema algerae (Microspora) spores: conditional inhibition by D2O, ethanol and Hg2+ suggests dependence of water influxupon membrane hydration and specific transmembrane pathways. Frixione E, et al. **J Eukaryot Microbiol** 1997 Mar-Apr;44(2):109–16

Estimation of age from teeth by amino acid racemization: influence of fixative. Ohtani S, et al. **J Forensic Sci** 1997 Jan;42(1):137–9

Effects of ethanol on meal-stimulated secretion of pancreatic polypeptide and cholecystokinin: comparison of healthy volunteers, heavy drinkers, and patients with chronic pancreatitis. Hirano H, et al. **J Gastroenterol** 1996 Feb; 31(1):86–93

Effect of ethanol on mouse hepatitis virus-induced cytotoxicity. Saito H, et al. **J Gastroenterol** 1996 Oct; 31(5):679–83

Restoration of gap junctions in the regenerative process of ethanol-induced gastric mucosal injury. Endo K, et al. **J Gastroenterol Hepatol** 1995 Sep-Oct;10(5):589–94

Pressor and depressor hormones during alcohol-induced blood pressure reduction in hypertensive patients. Kawano Y, et al. **J Hum Hypertens** 1996 Sep;10(9):595–9

Moderate beer consumption and the blood coagulation in patients with coronary artery disease. Gorinstein S, et al. **J Intern Med** 1997 Jan;241(1):47–51

Effect of a single ethanol exposure on HIV replication in human lymphocytes. Cook RT, et al. **J Investig Med** 1997 Jun;45(5):265–71

Ethanol activates maxi Ca2+-activated K+ channels of clonal pituitary (GH3) cells. Jakab M, et al. **J Membr Biol** 1997 Jun 1;157(3):237–45

Alcohol exposure during development alters hypothalamic neurotransmitter concentrations. Kelly SJ. **J Neural Transm** 1996;103(1–2):55–67

Monoamine oxidase gene transcription in human cell lines: treatment with psychoactive drugs and ethanol. Ekblom J, et al. **J Neural Transm Gen Sect** 1996;103(6):681–92

Ethanol influences on the chick embryo spinal cord motor system. II. Effects of neuromuscular blockade and period of exposure. Bradley DM, et al. **J Neurobiol** 1997 Jun 20; 32(7):684–94

Ethanol promotes apoptosis in cerebellar granule cells by inhibiting the trophic effect of NMDA. Bhave SV, et al. **J Neurochem** 1997 Feb;68(2):578–86

Chronic ethanol administration regulates the expression of GABAA receptor alpha 1 and alpha 5 subunits in the ventral tegmental area and hippocampus. Charlton ME, et al. **J Neurochem** 1997 Jan;68(1):121–7

Calcium-activated neutral protease activity is decreased in PC12 cells after ethanol exposure. DePetrillo PB. **J Neurochem** 1997 May;68(5):1863–9

Bidirectional alterations of GABA(A) receptor subunit peptide levels in rat cortex during chronic ethanol consumption and withdrawal. Devaud LL, et al. **J Neurochem** 1997 Jul;69(1):126–30

Inhibition of muscarinic receptor-stimulated glial cell proliferation by ethanol. Guizzetti M, et al.

J Neurochem 1996 Dec;67(6):2236–45
Ethanol inhibits basic fibroblast growth factor–mediated proliferation of C6 astrocytoma cells. Luo J, et al. **J Neurochem** 1996 Oct;67(4):1448–56
Chronic intermittent ethanol treatment in rats increases GABA(A) receptor alpha4–subunit expression: possible relevance to alcohol dependence. Mahmoudi M, et al. **J Neurochem** 1997 Jun;68(6):2485–92
Glial fibrillary acidic protein expression in rat brain and in radial glia culture is delayed by prenatal ethanol exposure. Vallés S, et al. **J Neurochem** 1996 Dec;67(6):2425–33
Elevation of basal protein kinase C activity increases ethanol sensitivity of GABA(A) receptors in rat hippocampal CA1 pyramidal neurons. Weiner JL, et al. **J Neurochem** 1997 May;68(5):1949–59
Microtubule depolymerization inhibits ethanol–induced enhancement of GABAA responses in stably transfected cells. Whatley VJ, et al. **J Neurochem** 1996 Mar; 66(3):1318–21
Effect of ethanol on extracellular dopamine in rat striatum by direct perfusion with microdialysis. Yim HJ, et al. **J Neurochem** 1997 Apr;68(4):1527–33
Exposure to alcohol in utero blunts splenic sympathetic neural response to endotoxin and interleukin–1beta in the rat. Gottesfeld Z, et al. **J Neuroimmunol** 1997 Sep; 78(1–2):180–3
Differential ethanol sensitivity of subpopulations of GABAA synapses onto rat hippocampal CA1 pyramidal neurons. Weiner JL, et al. **J Neurophysiol** 1997 Mar;77(3):1306–12
BAPTA–AM and ethanol protect cerebellar granule neurons from the destructive effect of the weaver gene. Liesi P, et al. **J Neurosci Res** 1997 Jun 15;48(6):571–9
Ethanol alters the concentration of Met–enkephalin in brain by affecting peptide transport system–1 independent of preproenkephalin mRNA. Plotkin SR, et al. **J Neurosci Res** 1997 May 1;48(3):273–80
Effect of arachidonate on lipid metabolism in ethanol–treated rats fed with lard. Okita M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Jun;43(3):311–26
Effect of prenatal exposure to ethanol on intestinal development of rat fetuses. Camps L, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):302–11
Mutual hairless rat skin permeation–enhancing effect of ethanol/water system and oleic acid. Kim DD, et al. **J Pharm Sci** 1996 Nov;85(11):1191–5
Potentiation of the glycine–activated Cl– current by ethanol in cultured mouse spinal neurons. Aguayo LG, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1116–22
Ethanol–mediated transplacental induction of CYP2E1 in fetal rat liver. Carpenter SP, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):1028–36
Genetic selection and characterization of mouse lines for acute functional tolerance to ethanol. Erwin VG, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1310–7
Common quantitative trait loci for alcohol–related behaviors and central nervous system neurotensin measures: hypnotic and hypothermic effects. Erwin VG, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):911–8
Common quantitative trait loci for alcohol–related behaviors and central nervous system neurotensin measures: locomotor activation. Erwin VG, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):919–26
Beta adrenergic sensitization of gamma–aminobutyric acid receptors to ethanol involves a cyclic AMP/protein kinase A second–messenger mechanism. Freund RK, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1192–200
Enhancement of amphetamine– and cocaine–induced locomotor activity after chronic ethanol administration. Manley SJ, et al. **J Pharmacol Exp Ther** 1997 Jun; 281(3):1330–9
Synergistic behavioral interaction between ethanol and clonidine in rats: role of alpha–2 adrenoceptors. Mao L, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):443–9
Suppression by ethanol of inducible nitric oxide synthase expression in C6 glioma cells. Militante JD, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):558–65
Inhibition of 5–hydroxytryptamine type 2A receptor–induced currents by n–alcohols and anesthetics. Minami K, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1136–43
Protein kinase A regulates regulates inhibition of N– and P/Q–type calcium channels by ethanol in PC12 cells. Solem M, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1487–95
Suppression of splenic natural killer cell activity in a mouse model for binge drinking. I. Direct effects of ethanol and its major metabolites are not primarily responsible for decreased natural killer cell activity. Wu WJ, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1325–30
Contractile action of ethanol in guinea pig gastric smooth muscle: inhibition by tyrosine kinase inhibitors and comparison with the contractile action of epidermal growth factor–urogastrone. Zheng XL, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):485–95
Drug–free behavioral history affects social drinkers' tolerance to a challenge dose of alcohol. Easdon CM, et al. **J Stud Alcohol** 1996 Nov;57(6):591–7
Evidence that expectancies mediate behavioral impairment under alcohol. Fillmore MT, et al. **J Stud Alcohol** 1996 Nov;57(6):598–603
Individual differences in alcohol responsivity: physiological, psychomotor and subjective response domains. Mundt JC, et al. **J Stud Alcohol** 1997 Mar;58(2):130–40
The effect of ethanol on sphincter of Oddi motility in vitro. Cullen JJ, et al. **J Surg Res** 1997 Jan;67(1):58–61
Does concurrent acute ethanol ingestion during omeprazole therapy affect pituitary gonadal axis in male subjects? Mokshagundam SL, et al. **J Toxicol Clin Toxicol** 1997; 35(1):55–61
Ethanol potentiates the depressant effects of cocaine in human fetal myocardium in vitro. Richards IS. **J Toxicol Clin Toxicol** 1997;35(4):365–9
Percutaneous permeation of N,N–diethyl–m–toluamide (DEET) from commercial mosquito repellents and the effect of solvent. Stinecipher J, et al. **J Toxicol Environ Health** 1997 Oct 10;52(2):119–35
Effects of ethanol on in vivo cystometry and in vitro whole bladder contractility in the rat. Yokoi K, et al. **J Urol** 1996 Oct;156(4):1489–91
Effects of alcohol ingestion on estrogens in postmenopausal women. Ginsburg ES, et al. **JAMA** 1996 Dec 4; 276(21):1747–51
Hyposmolar medium and ethanol in isosmotic solution induce the release of thyrotropin–releasing hormone (TRH) by isolated rat pancreatic islets. Benický J, et al. **Life Sci** 1997; 60(11):865–72
Alcohol induces formation of morphine precursors in the striatum of rats. Haber H, et al. **Life Sci** 1997;60(2):79–89
Effects of ethanol on GLUT1 protein and gene expression in rat astrocytes. Singh LD, et al. **Metab Brain Dis** 1996 Dec;11(4):343–57
Ethanol exerts acute protein–sparing effects during postabsorptive but not during anabolic conditions in man. Berneis K, et al. **Metabolism** 1997 Jul;46(7):750–5
Studies on the site of ethanol action in inducing prolactin release in male rats. Sato F, et al. **Metabolism** 1996 Nov; 45(11):1330–4
Effect of ethanol and fructose on plasma uridine and purine bases. Yamamoto T, et al. **Metabolism** 1997 May; 46(5):544–7
Hepatic calcium–binding protein regucalcin concentration is decreased by streptozotocin–diabetic state and ethanol ingestion in rats. Isogai M, et al. **Mol Cell Biochem** 1997 Mar;168(1–2):67–72
Enzymatic responses of Drosophila melanogaster to long– and short–term exposures to ethanol. Pecsenye K, et al. **Mol Gen Genet** 1997 Jul;255(3):258–68
A two–gene ABC–type transport system that extrudes Na+ in Bacillus subtilis is induced by ethanol or protonophore. Cheng J, et al. **Mol Microbiol** 1997 Mar;23(6):1107–20
ERA, a novel cis–acting element required for autoregulation and ethanol repression of PDC1 transcription in Saccharomyces cerevisiae. Liesen T, et al. **Mol Microbiol** 1996 Aug;21(3):621–32
Chronic ethanol increases N–methyl–D–aspartate–stimulated nitric oxide formation but not receptor density in cultured cortical neurons. Chandler LJ, et al. **Mol Pharmacol** 1997 May;51(5):733–40
Gene knockout of the alpha6 subunit of the gamma–aminobutyric acid type A receptor: lack of effect on responses to ethanol, pentobarbital, and general anesthetics. Homanics GE, et al. **Mol Pharmacol** 1997 Apr; 51(4):588–96
The role of Src kinase in the potentiation by ethanol of cytokine– and endotoxin–mediated nitric oxide synthase expression in rat hepatocytes. Kuo ML, et al. **Mol Pharmacol** 1997 Sep;52(3):535–41
Ethanol inhibition of nicotinic acetylcholine type alpha 7 receptors involves the amino–terminal domain of the receptor. Yu D, et al. **Mol Pharmacol** 1996 Oct;50(4):1010–6
Where does alcohol act in the brain? [news] Crabbe JC. **Mol Psychiatry** 1997 Jan;2(1):17–20
Differential sensitivity of c–Fos expression in hippocampus and other brain regions to moderate and low doses of alcohol. Ryabinin AE, et al. **Mol Psychiatry** 1997 Jan; 2(1):32–43
Genotoxicity of industrial dyes under the inductive effect of ethanol on monooxygenase system in mice. Wrońska–Nofer T, et al. **Mutat Res** 1997 Aug 14; 392(3):229–35
Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors [see comments] Mihic SJ, et al. **Nature** 1997 Sep 25;389(6649):385–9. Comment in: Nature 1997 Sep 25;389(6649):384–5.
Glycine does not reverse the inhibitory actions of ethanol on NMDA receptor functions in cerebellar granule cells. Cebers G, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Dec;354(6):736–45
Both ethanol and ifenprodil inhibit NMDA–evoked release of various neurotransmitters at different, yet proportional potency: potential relation to NMDA receptor subunit composition. Fink K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug–Sep; 354(3):312–9
Perinatal responsiveness to alcohol's chemosensory cues as a function of prenatal alcohol administration during gestational days 17–20 in the rat. Dominguez HD, et al. **Neurobiol Learn Mem** 1996 Mar;65(2):103–12
Alcohol–mediated tactile conditioned aversions in infant rats: devaluation of conditioning through alcohol–sucrose associations. Molina JC, et al. **Neurobiol Learn Mem** 1996 Sep;66(2):121–32
Effects of ethanol on the incorporation of free fatty acids into cerebral membrane phospholipids. Zheng Z, et al. **Neurochem Int** 1996 May–Jun;28(5–6):551–5
Neuronal differentiation in PC12 cells is accompanied by diminished inducibility of Hsp70 and Hsp60 in response to heat and ethanol. Dwyer DS, et al. **Neurochem Res** 1996 Jun;21(6):659–66
Effect of ethanol on nuclear casein kinase II activity in brain. Haviryaji KS, et al. **Neurochem Res** 1997 Jun;22(6):699–704
Ethanol potentiates the uptake of [14C]serine into phosphatidylserine by base–exchange reaction in NG 108–15 cells. Rodríguez FD, et al. **Neurochem Res** 1996 Mar;21(3):305–11
Blunted furosemide action on cerebellar GABAA receptors in ANT rats selectively bred for high alcohol sensitivity. Mäkelä R, et al. **Neuropharmacology** 1996; 35(9–10):1493–502
Effects of chronic ethanol treatment on inositol 1,4,5–trisphosphate receptors and inositol 1,3,4,5–tetrakisphosphate receptors in rat brain. Saito H, et al. **Neuropsychobiology** 1996;33(2):60–5
The effects of ethanol on striatal dopamine and frontal cortical D–[3H]aspartate efflux oscillate with repeated treatment. Relevance to individual differences in drug responsiveness. Caggiula AR, et al. **Neuropsychopharmacology** 1996 Aug;15(2):125–32
Chronic ethanol enhances NMDA–induced AP–1 activity in cultured rat cerebellar granule cells. Cebers G, et al. **Neuroreport** 1996 Dec 20;8(1):217–20
Ethanol exposure increases expression of c–jun and junD in human neuroblastoma cells. Ding WQ, et al. **Neuroreport** 1996 Sep 2;7(13):2191–5
NGF level in the rat sciatic nerve is decreased after long–term consumption of ethanol. Hellweg R, et al. **Neuroreport** 1996 Feb 29;7(3):777–80
Alcohol intake decreases brain Zonisamide concentration in inbred EL mice. Nagatomo I, et al. **Neuroreport** 1997 Jan 20;8(2):391–4
Anxiolytics by ethanol, diazepam and buspirone in a novel murine behavioral assay. Seale TW, et al. **Neuroreport** 1996 Jul 29;7(11):1803–8
Chronic ethanol retards kindling of hippocampal area CA3. Veatch LM, et al. **Neuroreport** 1997 May 27;8(8):1903–6
Increased agonist and antagonist sensitivity of N–methyl–D–aspartate stimulated calcium flux in cultured neurons following chronic ethanol exposure. Blevins T, et al. **Neurosci Lett** 1995 Nov 24;200(3):214–8
Activation of pertussis toxin–sensitive G–proteins in membranes of SH–SY5Y human neuroblastoma cells and bovine transducin by ethanol. Klinker JF, et al. **Neurosci Lett** 1996 Jul 26;213(1):25–8
Ethanol microinjection into the area postrema selectively attenuates baroreflex sensitivity measured by vasopressin in conscious rats. Mao L, et al. **Neurosci Lett** 1996 Dec 6;220(1):13–6
Potent modulation of neuronal nicotinic acetylcholine receptor–channel by ethanol. Nagata K, et al. **Neurosci Lett** 1996 Oct 18;217(2–3):189–93
Increased Na(+)–dependent high affinity uptake of glutamate in astrocytes chronically exposed to ethanol. Smith TL, et al. **Neurosci Lett** 1996 Nov 1;218(2):142–4
Reduction of regional brain glucose metabolism following different durations of chronic ethanol consumption in mice: a selective effect on diencephalic structures. Bontempi B, et al. **Neuroscience** 1996 Jun;72(4):1141–53
Behavioral correlates of single units in the medial septal area: the effect of ethanol. Givens B. **Neuroscience** 1996 Mar; 71(2):417–27
Loss of vasopressin–immunoreactive neurons in alcoholics is dose–related and time–dependent. Harding AJ, et al. **Neuroscience** 1996 Jun;72(3):699–708
Hippocampal–dependent learning and experience–dependent activation of the hippocampus are preferentially disrupted by ethanol. Melia KR, et al. **Neuroscience** 1996 Sep; 74(2):313–22
Chronic ethanol consumption in rats: correlation between memory performance and hippocampal acetylcholine release in vivo. Melis F, et al. **Neuroscience** 1996 Sep; 74(1):155–9
Both iso– and hyperosmotic ethanol stimulate release of hypothalamic thyrotropin–releasing hormone despite opposite effect on neuron volume. Nikodémová M, et al. **Neuroscience** 1997 Oct;80(4):1263–9
Effects of acute, chronic ethanol and withdrawal on dorsal raphe neurons: electrophysiological studies. Pistis M, et al. **Neuroscience** 1997 Jul;79(1):171–6
Neonatal cocaine and/or ethanol exposure: effects on a runway task with suckling reward. Hansen–Trench LS, et al. **Neurotoxicol Teratol** 1996 Nov–Dec;18(6):651–7
Ethanol inhibition of reduced frequency–dependent rundown of calcium currents in acutely dissociated MS/nDB neurons from chronic in vivo lead–exposed adult rats. Grover CA, et al. **Neurotoxicology** 1997;18(1):179–90
Effects of ethanol on cocaine metabolism and disposition in the rat. Dean RA, et al. **NIDA Res Monogr** 1997;173:35–47 (49 ref.)
Effects of ethanol on the levels of brain 6R–L–erythro–5, 6, 7, 8–tetrahydrobiopterin in the inbred strains of mice. DBA/2J, C3H/HeJ and C57BL/6J with different alcohol preferences. Yoshimoto K, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1997 Apr; 32(2):139–48
Ethanol upregulates the expression of p21 WAF1/CIP1 and prolongs G1 transition via a p53–independent pathway in human epithelial cells. Guo W, et al. **Oncogene** 1997 Sep 4;15(10):1143–9

Visual functions and acute ingestion of alcohol. Watten RG, et al. **Ophthalmic Physiol Opt** 1996 Nov;16(6):460–6

Ocular hemodynamic effects of acute ethanol ingestion. Harris A, et al. **Ophthalmic Res** 1996;28(3):193–200

The effect of beta–thia–iminoprostacyclin in taurocholate acute pancreatitis in rats: the role of antecedent acute ethanol abuse. Dlugosz JW, et al. **Pancreas** 1997 Jul; 15(1):91–8

Ethanol inhibits CCK–induced enzyme secretion by affecting calcium–pump activity in isolated rat pancreatic acini. Tachibana I, et al. **Pancreas** 1996 Oct;13(3):316–23

Quantitative reverse transcription polymerase chain reaction shows that ethanol enhances interleukin–6 mRNA expression in cultured mesangial cells. Meleg–Smith S, et al. **Pathobiology** 1995;63(5):265–9

Esophageal carcinogenesis in the rat: zinc deficiency and alcohol effects on tumor induction. Newberne PM, et al. **Pathobiology** 1997;65(1):39–45

Desflurane, enflurane, isoflurane and ether produce ethanol–like discriminative stimulus effects in mice. Bowen SE, et al. **Pharmacol Biochem Behav** 1997 May–Jun; 57(1–2):191–8

Ethanol anapyrexia in rats. Briese E, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):399–402

Reduced tolerance to certain pharmacological effects of ethanol after chronic administration in perinatally undernourished rats. Cordoba NE, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):659–63

Phenobarbital sensitivity in HAS and LAS rats before and after chronic administration of ethanol. Draski LJ, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):651–7

Neurotensin levels and receptors in HAS and LAS rat brains: effects of ethanol. Erwin VG, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):525–32

Cumulative vs. acute dose–response procedures produce differential BAC and behavioral functions for ethanol. Gauvin DV, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):397–403

Chronic ethanol ingestion–induced changes in open–field behavior and oxidative stress in the rat. Harkany T, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):195–201

Comparative effects of alcohol and marijuana on mood, memory, and performance. Heishman SJ, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):93–101

Nutritional factors modify the inhibition of CNS development by combined exposure to methadone and ethanol in neonatal rats. Kane CM, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):399–407

Effect of lipid solubility on the development of chronic cross–tolerance between ethanol and different alcohols and barbiturates. Khanna JM, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):101–10

Effect of NMDA antagonists on rapid tolerance to ethanol under two different testing paradigms. Khanna JM, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):693–7

Genetic differences in tolerance and sensitization to the sedative/hypnotic effects of alcohol. Kurtz DL, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):585–91

Ethanol preference, metabolism, blood pressure, and conditioned taste aversion in experimental cholestasis. Lane JR, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):755–66

Decreased severity of ethanol withdrawal behaviors in kainic acid–treated rats. Matsumoto I, et al. **Pharmacol Biochem Behav** 1996 Nov;55(3):371–8

Oral intake of sweetened or sweetened alcoholic beverages and open–field behavior. Nadal RA, et al. **Pharmacol Biochem Behav** 1996 Aug;54(4):739–43

Behavioral sensitization to ethanol: genetics and the effects of stress. Phillips TJ, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):487–93 (120 ref.)

Dose– and conditioning trial–dependent ethanol–induced conditioned place preference in Swiss–Webster mice. Risinger FO, et al. **Pharmacol Biochem Behav** 1996 Sep; 55(1):117–23

Ethanol– and diazepam–induced cytochrome oxidase activity in mammillary bodies. Rubio S, et al. **Pharmacol Biochem Behav** 1996 Oct;55(2):309–14

Learned tolerance to the corticosterone–increasing action of ethanol in rats. Seeley RJ, et al. **Pharmacol Biochem Behav** 1996 Oct;55(2):268–73

The effect of intragastric ethanol on meal size in the rat. Seeley RJ, et al. **Pharmacol Biochem Behav** 1997 Mar; 56(3):379–82

Disruption of tolerance to the ataxic effect of ethanol by an extraneous stimulus. Siegel S, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):125–30

The influence of opioid antagonists on the discriminative stimulus effects of ethanol. Spanagel R. **Pharmacol Biochem Behav** 1996 Aug;54(4):645–9

Place conditioning with alcohol in alcohol–preferring and –nonpreferring rats. Stewart RB, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):487–91

The interaction of dopamine, cocaine, and cocaethylene with ethanol on central nervous system depression in mice. Wilson DM, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):73–80

Pharmacologic actions of subtype–selective and novel GABAergic ligands in rat lines with differential sensitivity to ethanol. Wong G, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):723–30

Alcohol pretreatment does not affect bupivacaine pharmacokinetics in the pig. Mets B, et al. **Pharmacol Res** 1996 Apr–May;33(4–5):291–5

Minor pain inducers modulate membrane current in cultured neuronal cells. Inoue K, et al. **Pharmacol Toxicol** 1995 Dec; 77(6):417–20

Opposite effect of ethanol on recombinant membrane–bound and soluble activities of catechol–O–methyltransferase. Reenilä I, et al. **Pharmacol Toxicol** 1995 Dec;77(6):414–6

Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental model. Xu BQ, et al. **Pharmacol Toxicol** 1997 Apr;80(4):171–81

Increase of adenosine release by adenosine antagonists in hearts with coronary occlusion and reperfusion. Bernauer W. **Pharmacology** 1996 Nov;53(5):311–9

Estradiol alters ethanol–induced effects on beta–endorphin and met–enkephalin levels in specific brain regions of ovariectomized rats. Carter A, et al. **Pharmacology** 1996 Sep;53(3):143–50

Alcohol as a food: a commentary on Richter. Gill K, et al. **Physiol Behav** 1996 Dec;60(6):1485–90

Acute thermogenic effects of nicotine and alcohol in healthy male and female smokers. Perkins KA, et al. **Physiol Behav** 1996 Jul;60(1):305–9

Short–term effects of alcohol consumption on appetite and energy intake. Poppitt SD, et al. **Physiol Behav** 1996 Oct; 60(4):1063–70

Inhibitory effect of ethanol on the Na(+)–ATPase activity of rat kidney proximal tubular cell plasma membranes. Rothman A, et al. **Physiol Res** 1996;45(3):205–11

Cellular and molecular neuroscience of alcoholism. Diamond I, et al. **Physiol Rev** 1997 Jan;77(1):1–20 (375 ref.)

Effect of ethanol on human placental transport and metabolism of adenosine. Acevedo CG, et al. **Placenta** 1997 Jul–Aug;18(5–6):387–92

5–HT3 receptors and central effects of ethanol. Kostowski W. **Pol J Pharmacol** 1996 May–Jun;48(3):243–54 (108 ref.)

The effects of alcohol on the heart: detrimental or beneficial? Figueredo VM. **Postgrad Med** 1997 Feb;101(2):165–8, 171–2, 175–6 (24 ref.)

Tyrosine kinase inhibitor–sensitive contractile action of ethanol in gastric smooth muscle: comparison with the action of epidermal growth factor. Zheng XL, et al. **Proc Assoc Am Physicians** 1997 Jan;109(1):78–83

Ethanol causes translocation of cAMP–dependent protein kinase catalytic subunit to the nucleus. Dohrman DP, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10217–21

Regular alcohol consumption mimics cardiac preconditioning by protecting against ischemia–reperfusion injury. Miyamae M, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3235–9

Piroxicam and tenoxicam effects on ethanol–induced lipid peroxidation in brains of CD–1 male mice. Pérez–Tapia E, et al. **Proc West Pharmacol Soc** 1996;39:77–9

Influence of exercise and ethanol on cholinesterase activity and lipid peroxidation in blood and brain regions of rat. Husain K, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 May; 21(4):659–70

Individual and combined effects of ethanol and cocaine on intracellular signals and gene expression. Torres G, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 May; 20(4):561–96 (154 ref.)

Transient elevation of nerve growth factor content in the rat hippocampus and frontal cortex by chronic ethanol treatment. Nakano T, et al. **Psychiatry Clin Neurosci** 1996 Jun;50(3):157–60

Ethanol effects on self–administration of alfentanil, cocaine, and nomifensine in rhesus monkeys. Aspen JM, et al. **Psychopharmacology (Berl)** 1997 Apr;130(3):222–7

Genetic differences in naloxone enhancement of ethanol–induced conditioned taste aversion. Broadbent J, et al. **Psychopharmacology (Berl)** 1996 Jul;126(2):147–55

Social drinking history, behavioral tolerance and the expectation of alcohol. Fillmore MT, et al. **Psychopharmacology (Berl)** 1996 Oct;127(4):359–64

Analysis of the biphasic locomotor response to ethanol in high and low responders to novelty: a study in Nijmegen Wistar rats. Gingras MA, et al. **Psychopharmacology (Berl)** 1996 Jun;125(3):258–64

Effect of ethanol on sustained attention in rats. Givens B. **Psychopharmacology (Berl)** 1997 Jan;129(2):135–40

Ethanol–like discriminative stimulus effects of the neurosteroid 3 alpha–hydroxy–5 alpha–pregnan–20–one in female Macaca fascicularis monkeys. Grant KA, et al. **Psychopharmacology (Berl)** 1996 Apr;124(4):340–6

Discriminative stimulus effects of ethanol and 3 alpha–hydroxy–5 alpha–pregnan–20–one in relation to menstrual cycle phase in cynomolgus monkeys (Macaca fascicularis). Grant KA, et al. **Psychopharmacology (Berl)** 1997 Mar;130(1):59–68

Endogenous opioid systems and alcohol addiction. Herz A. **Psychopharmacology (Berl)** 1997 Jan;129(2):99–111 (150 ref.)

Preference for saccharin–sweetened alcohol relative to isocaloric sucrose. Heyman GM. **Psychopharmacology (Berl)** 1997 Jan;129(1):72–8

Alcohol pretreatment increases preference for cocaine over monetary reinforcement. Higgins ST, et al. **Psychopharmacology (Berl)** 1996 Jan;123(1):1–8

Intravenous heroin and ethanol self–administration by alcohol–preferring AA and alcohol–avoiding ANA rats. Hyytiä P, et al. **Psychopharmacology (Berl)** 1996 Jun; 125(3):248–54

Flumazenil blockade of anxiety following ethanol withdrawal in rats. Moy SS, et al. **Psychopharmacology (Berl)** 1997 Jun; 131(4):354–60

Dizocilpine prevents the development of tolerance to ethanol–induced error on a circular maze test. Rafi–Tari S, et al. **Psychopharmacology (Berl)** 1996 May;125(1):23–32

Progressive ratio and behavioral economic evaluation of the reinforcing efficacy of orally delivered phencyclidine and ethanol in monkeys: effects of feeding conditions. Rodefer JS, et al. **Psychopharmacology (Berl)** 1996 Dec; 128(3):265–73

The interaction of cocaine and alcohol on schedule–controlled responding. Sobel BF, et al. **Psychopharmacology (Berl)** 1997 Jan;129(2):128–34

Combined effects of ethanol and cocaine on FOS–like protein and cocaethylene biosynthesis in the rat. Torres G, et al. **Psychopharmacology (Berl)** 1996 Nov;128(1):105–14

Increased aggression after ethanol self–administration in male resident rats. van Erp AM, et al. **Psychopharmacology (Berl)** 1997 Jun;131(3):287–95

Primate vocalizations during social separation and aggression: effects of alcohol and benzodiazepines. Weerts EM, et al. **Psychopharmacology (Berl)** 1996 Oct;127(3):255–64

The effects of recent food, alcohol, and tobacco intake and the temporal scheduling of testing on cardiovascular activity at rest and during psychological stress. Sheffield D, et al. **Psychophysiology** 1997 Mar;34(2):204–12

Alcohol, GABAA–benzodiazepine receptor complex, and aggression. Miczek KA, et al. **Recent Dev Alcohol** 1997; 13:139–71 (164 ref.)

Effect of culture conditions on artificial activation of porcine oocytes matured in vitro. Yamauchi N, et al. **Reprod Fertil Dev** 1996;8(8):1153–6

Combined effects of caffeine and alcohol during pregnancy on bones in newborn rats. Case TS, et al. **Res Exp Med (Berl)** 1996;196(3):179–85

Ethanol ingestion decreases superoxide dismutase activity and diminishes –SH compounds in the liver and red blood cells in rats. Farbiszewski R, et al. **Rocz Akad Med Bialymst** 1995;40(2):243–9

Effects of alcohol on sleep parameters of sleep–deprived healthy volunteers. Lobo LL, et al. **Sleep** 1997 Jan; 20(1):52–9

Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. Ortiz J, et al. **Synapse** 1995 Dec;21(4):289–98

Role of CYP3A in ethanol–mediated increases in acetaminophen hepatotoxicity. Kostrubsky VE, et al. **Toxicol Appl Pharmacol** 1997 Apr;143(2):315–23

Dose– and route–dependent alterations in metabolism and toxicity of chemical compounds in ethanol–treated rats: difference between highly (chloroform) and poorly (carbon tetrachloride) metabolized hepatotoxic compounds. Wang PY, et al. **Toxicol Appl Pharmacol** 1997 Jan;142(1):13–21

Effect of ethanol pretreatment on mercury distribution in organs of fetal guinea pigs following in utero exposure to mercury vapor. Yoshida M, et al. **Toxicology** 1997 May 16;119(3):193–201

[Alcohol and coronary disease (letter; comment)] Cleophas TJ. **Ned Tijdschr Geneeskd** 1996 Oct 19;140(42):2102. Comment on: Ned Tijdschr Geneeskd 1996 aug 31;140(35):1755–9. **(Dut)**

[Potentiating effect of ethanol on alpha 1 adrenergic receptor mediated contraction of thoracic aorta from guinea pig] Masui H, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1997 Apr; 32(2):107–21 (Eng. Abstr.) **(Jpn)**

[Tissue basophils of the thyroid gland in separate and combined exposure to ionizing radiation and ethanol] Vorontsova ZA, et al. **Aviakosm Ekolog Med** 1997; 31(3):39–43 (Eng. Abstr.) **(Rus)**

[Optimization of a method of infusion of reverse agonists of GABA–receptor complex in analysis of rapidly reversible effects of tranquilizers and ethanol] Golovenko NIa, et al. **Biull Eksp Biol Med** 1997 May;123(5):551–4 **(Rus)**

[The effect of calcium channel blockers on the effects of ethanol in the immobilization of mice] Kozlovskiĭ VL, et al. **Eksp Klin Farmakol** 1996 Jul–Aug;59(4):55–7 (Eng. Abstr.) **(Rus)**

[The contrary effects of ethanol on the behavior of short– and long–sleep C57BL/6 mice in a dark–light chamber] Lapin IP, et al. **Eksp Klin Farmakol** 1996 Mar–Apr; 59(2):50–2 (Eng. Abstr.) **(Rus)**

[The effect of cholecystokinin octapeptide on ethanol–induced changes in motor activity and in dopamine metabolism in the nucleus accumbens of the rat brain] Medvedeva OF, et al. **Eksp Klin Farmakol** 1996 Nov–Dec; 59(6):44–7 (Eng. Abstr.) **(Rus)**

[The paradoxical effect of ethanol on the protein status of a primary chick embryo myoblast culture] Matiushichev VB, et al. **Tsitologiia** 1996;38(11):1174–8 (Eng. Abstr.) **(Rus)**

[Steroidogenesis in rat testes in chronic alcoholic intoxication and addition of ethanol in vitro] Kashko MF, et al. **Ukr Biokhim Zh** 1996 Nov–Dec;68(6):98–103 (Eng. Abstr.) **(Rus)**

[Effect of ethanol, diazepam, and reserpine on the activity of angiotensin–converting enzyme and carboxypeptidase in normal state and during stress] Vernigora AN, et al. **Vopr Med Khim** 1996 Apr–Jun;42(2):127–30 (Eng. Abstr.)

(Rus)

POISONING

Paclitaxel formulation as a cause of ethanol intoxication. Wilson DB, et al. **Ann Pharmacother** 1997 Jul–Aug; 31(7–8):873–5

Alcohol and infection. MacGregor RR, et al. **Curr Clin Top Infect Dis** 1997;17:291–315 (208 ref.)

Oxidative stress–mediated apoptosis of hepatocytes exposed to acute ethanol intoxication. Kurose I, et al. **Hepatology** 1997 Feb;25(2):368–78

Acute renal failure and alcohol [editorial; comment] Kaizu K. **Intern Med** 1997 Feb;36(2):80. Comment on: Intern Med 1997 Feb;36(2):102–6.

Acute renal failure after binge drinking of alcohol and nonsteroidal antiinflammatory drug ingestion [see comments] Tsuboi N, et al. **Intern Med** 1997 Feb; 36(2):102–6. Comment in: Intern Med 1997 Feb;36(2):80.

Binge drinking among college students: a comparison of California with other states. Wechsler H, et al. **J Am Coll Health** 1997 May;45(6):273–7

Acute renal failure after binge drinking and NSAID use [letter] Spital A. **J Am Soc Nephrol** 1995 Dec;6(6):1682–5

Methemoglobinemia in a fatal case of disulfiram–ethanol reaction [letter] Stransky G, et al. **J Anal Toxicol** 1997 Mar–Apr;21(2):178–9

Combined toxicity due to alcohol and aluminium phosphide [letter] Gupta MS, et al. **J Assoc Physicians India** 1995 Jan;43(1):74

Impairment of metabolic hepatic nerve action by chronic but not acute ethanol intoxication studied in isolated perfused rat liver. Kucera T, et al. **J Hepatol** 1997 Jan; 26(1):183–90

A perspective on the IPCS methanol and ethylene glycol document [editorial; comment] Goldfrank L. **J Toxicol Clin Toxicol** 1997;35(2):145–6. Comment on: J Toxicol Clin Toxicol 1997 ;35(2):127–43.

Prenatal alcohol treatment attenuated postnatal cocaine–induced elevation of dopamine concentration in nucleus accumbens: a preliminary study. Chen WJ, et al. **Neurotoxicol Teratol** 1997 Jan–Feb;19(1):39–46

A fatal case of drinking and cyanamide intake. Kojima T, et al. **Nippon Hoigaku Zasshi** 1997 Apr;51(2):111–5

Alcohol concentration determines the type of atrial arrhythmia induced in a porcine model of acute alcoholic intoxication. Anadon MJ, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1962–7

[Tubular necrosis after non–steroidal anti–inflammatory agents and acute alcoholic intoxication] Galzin M, et al. **Nephrologie** 1997;18(3):113–5 (Eng. Abstr.) (Fre)

[Naloxone in ethanol overdose after alcoholization of hepatic metastasis] Iannarone C, et al. **Minerva Chir** 1996 Jul–Aug; 51(7–8):621–3 (Eng. Abstr.) (Ita)

[Discussion on the figure–description in the author's case with "acute alcoholic scenic complex hallucination"—against the criticism of HENRY Ey in his "Traité des hallucinations"] Konuma M. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Jun; 31(3):226–34 (Eng. Abstr.) (Jpn)

[Application of operant conditioning techniques to forensic toxicology: experimental studies on alcohol and abusable drugs] Hishida S. **Nippon Hoigaku Zasshi** 1996 Oct; 50(5):292–319 (Eng. Abstr.) (Jpn)

[Alcohol and suicide attempts] Kołaciński Z, et al. **Przegl Lek** 1997;54(6):438–40 (11 ref.) (Eng. Abstr.) (Pol)

[Acute poisoning with psychoactive substances among adult abusers of the Krakow population] Pach J, et al. **Przegl Lek** 1997;54(6):392–8 (Eng. Abstr.) (Pol)

[The death of a newborn infant from ethanol poisoning] Barinov EKh, et al. **Sud Med Ekspert** 1997 Apr–Jun; 40(2):45 (Rus)

[The status of the ethanol–oxidizing enzyme systems in fatal alcohol poisonings] Porodenko VA. **Sud Med Ekspert** 1997 Jul–Sep;40(3):15–8 (Eng. Abstr.) (Rus)

[The ultrastructure of the neurons and interneuronal contacts of the hypothalamus in acute ethanol poisoning] Mkheidze EG, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(3):105–6 (Rus)

THERAPEUTIC USE

Intraperitoneal seeding from hepatocellular carcinoma following percutaneous ethanol ablation therapy. Kurl S, et al. **Abdom Imaging** 1997 May–Jun;22(3):261–3

Complications following high–dose percutaneous ethanol injection into hepatic tumors. Tapani E, et al. **Acta Radiol** 1996 Sep;37(5):655–9

Transcatheter arterial ablation of aldosteronomas with high–concentration ethanol: preliminary and long–term results. Inoue H, et al. **AJR Am J Roentgenol** 1997 May; 168(5):1241–5

Percutaneous ethanol injection therapy: use of a directable needle guide. Ishizaka H, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1563–4

Human skin flora as a potential source of epidural abscess. Sato S, et al. **Anesthesiology** 1996 Dec;85(6):1276–82

Specificity of ethanol in essential tremor [letter; comment] Rajput AH. **Ann Neurol** 1996 Dec;40(6):950–1. Comment on: Ann Neurol 1996 May;39(5):650–8.

Percutaneous ethanol injection therapy for autonomously functioning thyroid nodule. Nakada K, et al. **Ann Nucl Med** 1996 May;10(2):171–6

Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Pompili M, et al. **Cancer** 1997 Apr 15; 79(8):1501–8

Venous malformations: sclerotherapy with a mixture of ethanol and lipiodol. Suh JS, et al. **Cardiovasc Intervent Radiol** 1997 Jul–Aug;20(4):268–73

Ethanol sclerosis can be a safe and useful treatment for pericardial cyst. Kinoshita Y, et al. **Clin Cardiol** 1996 Oct; 19(10):833–5

Sclerotherapy in noncirrhotic portal fibrosis. Chawla YK, et al. **Dig Dis Sci** 1997 Jul;42(7):1449–53

Epinephrine or epinephrine plus alcohol for injection of bleeding ulcers: a prospective randomized trial. Chung SC, et al. **Gastrointest Endosc** 1996 Jun;43(6):591–5

Effect of percutaneous ethanol injection for postoperative recurrence of hepatocellular carcinoma in combination with transcatheter arterial embolization. Ishii H, et al. **Hepatogastroenterology** 1996 May–Jun;43(9):644–50

The effects of a mouthrinse containing sodium benzoate and alcohol on the quantity and metabolism of dental plaque. Danielsen B, et al. **Int Dent J** 1996 Apr;46(2):91–6

Treatment of melasma with Jessner's solution versus glycolic acid: a comparison of clinical efficacy and evaluation of the predictive ability of Wood's light examination. Lawrence N, et al. **J Am Acad Dermatol** 1997 Apr; 36(4):589–93

Rapid destruction of murine and human melanomas by local injection of absolute ethanol: augmentation of the anti–proliferative effects with a combination of biological response modifiers. Nakayama J, et al. **J Dermatol** 1996 Mar;23(3):156–64

Significance of tumor vascularity as a predictor of long–term prognosis in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection therapy. Toyoda H, et al. **J Hepatol** 1997 May;26(5):1055–62

A randomized trial of alcohol 70% versus alcoholic iodine 2% in skin disinfection before insertion of peripheral infusion catheters. de Vries JH, et al. **J Hosp Infect** 1997 Aug;36(4):317–20

Percutaneous transcatheter renal ablation with absolute ethanol for uncontrolled hypertension or nephrotic syndrome: results in 11 patients with end–stage renal disease. Golwyn DH Jr, et al. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):527–33

Treatment of postoperative lymphoceles with percutaneous drainage and alcohol sclerotherapy. Sawhney R, et al. **J Vasc Interv Radiol** 1996 Mar–Apr;7(2):241–5

Treatment of symptomatic congenital hepatic cysts with single–session percutaneous drainage and ethanol sclerosis: technique and outcome. Tikkakoski T, et al. **J Vasc Interv Radiol** 1996 Mar–Apr;7(2):235–9

Inhibition of MNNG–induced gastroduodenal carcinoma in rats by synchronous application of wine or 11% ethanol. Cerar A, et al. **Nutr Cancer** 1996;26(3):347–52

A prospective evaluation of alcohol–assisted versus mechanical epithelial removal before photorefractive keratectomy. Abad JC, et al. **Ophthalmology** 1997 Oct; 104(10):1566–74; discussion 1574–5

Randomized trial of endoscopic injection sclerosis with ethanolamine oleate and ethanol for bleeding peptic ulcer. Mäkelä JT, et al. **Scand J Gastroenterol** 1996 Nov; 31(11):1059–62

Treatment of small hepatocellular carcinoma associated with cirrhosis by percutaneous ethanol injection. A trial with a comparison group. Orlando A, et al. **Scand J Gastroenterol** 1997 Jun;32(6):598–603

Ultrasound–guided alcoholization of celiac plexus for pain control in oncology. Caratozzolo M, et al. **Surg Endosc** 1997 Mar;11(3):239–44

Endoscopic injection treatment of gastrointestinal bleeding in hemophiliacs. Ziemski JM, et al. **World J Surg** 1996 Nov–Dec;20(9):1166–70

[Ethanol sclerotherapy in superficial bladder tumors] Damyanov C. **Ann Urol (Paris)** 1996;30(5):244–6 (Eng. Abstr.) (Fre)

[The role of percutaneous puncture alcohol sclerotherapy in the treatment of symptomatic kidney cysts] Pfister C, et al. **Prog Urol** 1996 Aug–Sep;6(4):543–7 (Eng. Abstr.) (Fre)

[Treatment of a solitary renal cyst using percutaneous drainage and repeat alcoholization] Porpiglia F, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):197–9 (Eng. Abstr.) (Ita)

[Ethanol in acute ischemic heart disease (letter)] Lagerlöf H, et al. **Lakartidningen** 1997 Feb 26;94(9):710 (Swe)

TOXICITY

Toxicity of ethanol in low concentrations. Experimental evaluation in cell culture. Tapani E, et al. **Acta Radiol** 1996 Nov;37(6):923–6

Acute treatment of paternal alcohol exposure produces malformations in offspring. Bielawski DM, et al. **Alcohol** 1997 Jul–Aug;14(4):397–401

Ethanol teratogenesis in the C57BL/6J, DBA/2J, and A/J inbred mouse strains. Boehm SL 2nd, et al. **Alcohol** 1997 Jul–Aug;14(4):389–95

Naltrexone prevents ethanol–induced changes in rat thymus. Budeč M, et al. **Alcohol** 1996 Nov–Dec;13(6):533–7

The membrane disordering effect of ethanol on neural crest cells in vitro and the protective role of GM1 ganglioside. Chen SY, et al. **Alcohol** 1996 Nov–Dec;13(6):589–95

Effects of prenatal ethanol exposure on hippocampal theta activity in the rat. Cortese BM, et al. **Alcohol** 1997 May–Jun;14(3):231–5

Effects of chronic ethanol ingestion on mid–latency auditory evoked potentials depend on length of exposure. Floyd EA, et al. **Alcohol** 1997 May–Jun;14(3):269–79

Response of cardiac antioxidant system to alcohol and exercise training in the rat. Husain K, et al. **Alcohol** 1997 May–Jun;14(3):301–7

Ethanol exposure alters the development of serotonergic neurons in chick spinal cord. Mendelson B, et al. **Alcohol** 1996 Sep–Oct;13(5):431–41

Biphasic in vivo immune function after low– versus high–dose alcohol consumption. Mendenhall CL, et al. **Alcohol** 1997 May–Jun;14(3):255–60

Effect of acute ethanol and cocaine administration on gestation days 14–17 in mice. Salo AL, et al. **Alcohol** 1996 Jul–Aug;13(4):369–75

The effect of acute ethanol (EtOH) exposure on protein kinase C (PKC) activity in anterior pituitary. Steiner J, et al. **Alcohol** 1997 May–Jun;14(3):209–11

Morphometric evidence that the total number of synapses on Purkinje neurons of old F344 rats is reduced after long–term ethanol treatment and restored to control levels after recovery. Dlugos CA, et al. **Alcohol Alcohol** 1997 Mar–Apr;32(2):161–72

Relative and combined effects of propylthiouracil, ethanol and protein deficiency on liver histology and hepatic iron, zinc, manganese and copper contents. Gonzalez–Reimers E, et al. **Alcohol Alcohol** 1996 Nov;31(6):535–45

Ethanol–mediated promotion of oesophageal carcinogenesis: association with lipid peroxidation and changes in phospholipid fatty acid profile of the target tissue. Mufti SI, et al. **Alcohol Alcohol** 1997 May–Jun;32(3):221–31

Relative and combined effects of propylthiouracil, ethanol and protein deficiency on muscle. Perez–Labajos J, et al. **Alcohol Alcohol** 1996 Mar;31(2):157–65

Ethanol withdrawal hyperexcitability in vivo and in isolated mouse hippocampal slices. Ripley TL, et al. **Alcohol Alcohol** 1996 Jul;31(4):347–57

Ethanol and phosphatidylethanol reduce the binding of [3H]inositol 1,4,5–trisphosphate to rat cerebellar membranes. Rodríguez FD, et al. **Alcohol Alcohol** 1996 Sep; 31(5):453–61

Metabolic and mitotic changes associated with the fetal alcohol syndrome. Shibley IA Jr, et al. **Alcohol Alcohol** 1997 Jul–Aug;32(4):423–34 (146 ref.)

Ethanol induced acinar cell injury. Apte MV, et al. **Alcohol Alcohol Suppl** 1994;2:365–8 (39 ref.)

Elevated AP–1 DNA–binding activity in rat brain during ethanol withdrawal. Beckmann AM, et al. **Alcohol Alcohol Suppl** 1994;2:223–7

Mapping quantitative trait loci for ethanol–induced anesthesia in LSxSS recombinant inbred and F2 mice: methodology and results. Bennett B, et al. **Alcohol Alcohol Suppl** 1994; 2:79–86

Use of recombinant inbred strains for studying genetic determinants of responses to alcohol. Crabbe JC, et al. **Alcohol Alcohol Suppl** 1994;2:67–71 (22 ref.)

Acute and chronic alcohol injections increase taurine in the nucleus accumbens. De Witte P, et al. **Alcohol Alcohol Suppl** 1994;2:229–33

An introduction to alcohol–induced brain damage and its causes. Harper C, et al. **Alcohol Alcohol Suppl** 1994; 2:237–43 (26 ref.)

Ethanol inhibition of NMDA receptor function in primary cultures of rat cerebellar granule cells and cerebral cortical cells. Hoffman PL, et al. **Alcohol Alcohol Suppl** 1994; 2:199–204 (34 ref.)

Ethanol–inducible cytochrome P4502E1: regulation, enzymology and molecular biology. Ingelman–Sundberg M, et al. **Alcohol Alcohol Suppl** 1994;2:131–9 (50 ref.)

Alcoholic pancreatic injury: alterations of pancreatic autonomic nerves and microcirculation. Ishii H, et al. **Alcohol Alcohol Suppl** 1994;2:369–75

Susceptibility to alcohol–related liver injury. Lieber CS. **Alcohol Alcohol Suppl** 1994;2:315–26 (122 ref.)

Role of nitric oxide in ethanol–induced perturbation of hepatic microcirculation in rat liver. Oshita M, et al. **Alcohol Alcohol Suppl** 1994;2:353–6

5–HT receptors: implications for the neuropharmacology of alcohol and alcoholism. Overstreet DH, et al. **Alcohol Alcohol Suppl** 1994;2:205–10 (49 ref.)

A brief review of immunomodulation caused by acute administration of ethanol: involvement of neuroendocrine pathways. Pruett SB, et al. **Alcohol Alcohol Suppl** 1994; 2:431–7 (44 ref.)

The possible role of voltage–operated calcium channels in the enhancement of excitatory amino acid toxicity following chronic ethanol exposure in vitro. Ruhe CA, et al. **Alcohol Alcohol Suppl** 1994;2:217–21

Alcohol and cancer. Watson RR, et al. **Alcohol Alcohol Suppl** 1994;2:453–5 (9 ref.)

Recent studies on the effects of fetal alcohol exposure on the endocrine and immune systems. Weinberg J. **Alcohol Alcohol Suppl** 1994;2:401–9 (96 ref.)

Recent findings on the mechanisms by which alcohol damages the developing nervous system. West JR. **Alcohol Alcohol Suppl** 1994;2:395–9 (40 ref.)

Gene expression during ethanol withdrawal. Wilce P, et al. **Alcohol Alcohol Suppl** 1994;2:97–102

The alcohol withdrawal "kindling" phenomenon: clinical and experimental findings. Becker HC.
Alcohol Clin Exp Res 1996 Nov;20(8 Suppl):121A–124A

New insight into the mechanisms of ethanol effects on GABAA receptor function and expression, and their relevance to behavior. Buck KJ. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):198A–202A

Differential effects of chronic ethanol consumption on hepatic mitochondrial and cytoplasmic ribosomes. Cahill A, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1362–7

Zonal differences in ethanol-induced impairments in fluid-phase endocytosis in rat hepatocytes. Camacho KB, et al. **Alcohol Clin Exp Res** 1996 May;20(3):589–94

Direct effects of ethanol on signaling proteins. Charness ME. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):157A–161A

Free radicals and ethanol-induced cytotoxicity in neural crest cells. Chen SY, et al. **Alcohol Clin Exp Res** 1996 Sep; 20(6):1071–6

Repeated exposure to moderate doses of alcohol in the rat fetus: evidence of sensitization to toxic and chemosensory aspects of alcohol. Chotro MG, et al.
Alcohol Clin Exp Res 1997 Apr;21(2):360–7

Effects of prenatal and early postnatal ethanol exposure on [3H]MK-801 binding in rat cortex and hippocampus. Diaz-Granados JL, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):874–81

Neural mechanisms of adaptation in chronic ethanol exposure and alcoholism. Dodd P. **Alcohol Clin Exp Res** 1996 Nov; 20(8 Suppl):151A–156A

Ethanol reduces expression of the nerve growth factor receptor, but not nerve growth factor protein levels in the neonatal rat cerebellum. Dohrman DP, et al.
Alcohol Clin Exp Res 1997 Aug;21(5):882–93

In vivo links between neurochemistry and behavioral effects of ethanol. Gonzales R. **Alcohol Clin Exp Res** 1996 Nov; 20(8 Suppl):203A–209A

Increased ethanol self-administration after a period of imposed ethanol deprivation in rats trained in a limited access paradigm. Heyser CJ, et al.
Alcohol Clin Exp Res 1997 Aug;21(5):784–91

Interaction of protein phosphatases and ethanol on phospholipase C-mediated intracellular signal transduction processes in rat hepatocytes: role of protein kinase A. Higashi K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):320A–324A

Ethanol-induced apoptosis and oxidative stress in hepatocytes. Higuchi H, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):340A–346A (65 ref.)

Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation. Hölter SM, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):862–8

Effect of maternal ethanol consumption on maternal and fetal calcium metabolism. Keiver K, et al.
Alcohol Clin Exp Res 1996 Oct;20(7):1305–12

Ethanol inhibits human osteoblastic cell proliferation. Klein RF, et al. **Alcohol Clin Exp Res** 1996 May;20(3):572–8

Effects of alcohols on murine preimplantation development: relationship to relative membrane disordering potency. Kowalczyk CL, et al. **Alcohol Clin Exp Res** 1996 May; 20(3):566–71

Differential effects of ethanol in adolescent and adult rats. Little PJ, et al. **Alcohol Clin Exp Res** 1996 Nov; 20(8):1346–51

Effects of ethanol on intestinal absorption of drugs. I. In situ studies with ciprofloxacin analogs in normal and chronic alcohol-fed rats. Merino V, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):326–33

Mechanisms of ethanol induced neuronal death during development: from the molecule to behavior. Miller MW. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):128A–132A

Supporting cells as targets of ethanol toxicity: altered regulation of growth factors and extracellular matrix. Miller MW. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):260A–264A

Effects of prenatal ethanol exposure on parvalbumin-expressing GABAergic neurons in the adult rat medial septum. Moore DB, et al.
Alcohol Clin Exp Res 1997 Aug;21(5):849–56

Ethanol and cocaine cause additive inhibitory effects on the calcium transients and contraction in single cardiomyocytes. Nicolás JM, et al.
Alcohol Clin Exp Res 1996 Sep;20(6):1077–82

Prenatal alcohol exposure results in hyperactivity of the hypothalamic-pituitary-adrenal axis of the offspring: modulation by fostering at birth and postnatal handling. Ogilvie KM, et al. **Alcohol Clin Exp Res** 1997 May; 21(3):424–9

Increase in vasoactive prostaglandin E production after perfusion in human placental cotyledons. Randall CL, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1321–8

Feeding patterns of rats chronically ingesting an ethanol-containing liquid diet. Reidelberger RD, et al.
Alcohol Clin Exp Res 1996 Oct;20(7):1275–82

Ethanol-induced inhibition of cell proliferation is modulated by insulin-like growth factor-I receptor levels. Resnicoff M, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):961–6

Dexmedetomidine, diazepam, and propranolol in the treatment of ethanol withdrawal symptoms in the rat. Riihioja P, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):804–8

Alcohol consumption by young actively growing rats: a histomorphometric study of cancellous bone. Sampson HW, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):352–9

Inhibitory effect of ethanol on hepatocyte growth factor-induced DNA synthesis and Ca2+ mobilization in rat hepatocytes. Saso K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):330A–334A

Ethanol ingestion inhibits cell-mediated immune responses of unprimed T-cell receptor transgenic mice. Schodde H, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):890–9

Ethanol's inhibition of LTP may not be mediated solely via direct effects on the NMDA receptor. Schummers J, et al. **Alcohol Clin Exp Res** 1997 May;21(3):404–8

Ethanol differentially affects metabolic and mitotic processes in chick embryonic cells. Shibley IA Jr, et al.
Alcohol Clin Exp Res 1997 May;21(3):460–6

Ethanol and experimental breast cancer: a review. Singletary K. **Alcohol Clin Exp Res** 1997 Apr;21(2):334–9 (61 ref.)

Effect of ethanol on gastric mucus glycoprotein synthesis, translocation, transport, glycosylation, and secretion. Slomiany A, et al. **Alcohol Clin Exp Res** 1997 May; 21(3):417–23

Ethanol-inducible cytochrome P450 (CYP2E1): biochemistry, molecular biology and clinical relevance: 1996 update. Song BJ. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):138A–146A

Sustained effects of a single injection of ethanol on the hypothalamic-pituitary-gonadal axis in the male rat. Steiner JC, et al. **Alcohol Clin Exp Res** 1996 Nov; 20(8):1368–74

Evaluation of lactational parameters after alcohol administration for four days during early or midlactation in the rat. Subramanian MG. **Alcohol Clin Exp Res** 1997 Aug;21(5):799–803

Regulation of human monocyte functions by acute ethanol treatment: decreased tumor necrosis factor-alpha, interleukin-1 beta and elevated interleukin-10, and transforming growth factor-beta production. Szabo G, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):900–7

c-Fos induction in rat brainstem in response to ethanol- and lithium chloride-induced conditioned taste aversions. Thiele TE, et al. **Alcohol Clin Exp Res** 1996 Sep; 20(6):1023–8

Behavioral sensitivity and ethanol potentiation of the N-methyl-D-aspartate receptor antagonist MK-801 in a rat line selected for high ethanol sensitivity. Toropainen M, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):666–71

The use of electrophysiological techniques in alcohol research. Treistman SN. **Alcohol Clin Exp Res** 1996 Nov; 20(8 Suppl):62A–66A

Effects of chronic ethanol administration on the endocytosis of cytokines by rat hepatocytes. Tuma DJ, et al.
Alcohol Clin Exp Res 1996 May;20(3):579–83

Ethanol-induced alterations in the posttranslational processing, but not secretion of luteinizing hormone-releasing hormone in vitro. Uddin S, et al.
Alcohol Clin Exp Res 1996 May;20(3):556–60

Cultured postnatal rat medial septal neurons respond to acute ethanol treatment and nerve growth factor by changing intracellular calcium levels. Webb B, et al.
Alcohol Clin Exp Res 1996 Nov;20(8):1385–94

Chronic ethanol inhibits inositol metabolism in specific brain regions. Zhang JP, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):716–20

Acute ethanol effects on focal cerebral ischemia in nonfasted rats. Zhao YJ, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):745–8

Binge ethanol-induced brain damage in rats: effect of inhibitors of nitric oxide synthase. Zou JY, et al.
Alcohol Clin Exp Res 1996 Nov;20(8):1406–11

Morphologic changes in offspring of female mice exposed to ethanol before conception. Soltes BA, et al.
Am J Obstet Gynecol 1996 Nov;175(5):1158–62

Acute alcohol produces hypoxia directly in rat liver tissue in vivo: role of Kupffer cells. Arteel GE, et al.
Am J Physiol 1996 Sep;271(3 Pt 1):G494–500

Adaptation to sublethal environmental stresses protects Listeria monocytogenes against lethal preservation factors. Lou Y, et al. **Appl Environ Microbiol** 1997 Apr;63(4):1252–5

Urinary mercapturic acid diastereoisomers in rats subchronically exposed to styrene and ethanol. Coccini T, et al. **Arch Toxicol** 1996;70(11):736–41

Influences of gender, development, pregnancy and ethanol consumption on the hematotoxicity of inhaled 10 ppm benzene. Corti M, et al. **Arch Toxicol** 1996;70(3–4):209–17

Enhancement of alcohol-induced hypoglycaemia by H2-receptor antagonists. Czyżyk A, et al.
Arzneimittelforschung 1997 Jun;47(6):746–9

Gastric mucosal apoptosis induced by ethanol: effect of antiulcer agents. Piotrowski J, et al.
Biochem Mol Biol Int 1997 Jun;42(2):247–54

Changes in some pro- and antioxidants in rat cerebellum after chronic alcohol intake [published erratum appears in Biochem Pharmacol 1997 Jun 15;53(12):1945] Rouach H, et al. **Biochem Pharmacol** 1997 Feb 21;53(4):539–45

Mouse cerebellar GABAB participation in the expression of acute ethanol-induced ataxia and in its modulation by the cerebellar adenosinergic A1 system. Dar MS.
Brain Res Bull 1996;41(1):53–9

Acute effects of ethanol on mineral metabolism and trabecular bone in Sprague-Dawley rats. Diez A, et al.
Calcif Tissue Int 1997 Aug;61(2):168–71

Combined effects of ethanol and cigarette smoke on hepatic and pulmonary xenobiotic metabolizing enzymes in rats. Eke BC, et al. **Chem Biol Interact** 1996 Dec 20; 102(3):155–67

Cytoprotective effects of 4,6-bis(1H-pyrazol-1-yl)pyrimidine and related compounds on HCl.ethanol-induced gastric lesions in rats. Ikeda M, et al. **Chem Pharm Bull (Tokyo)** 1997 Mar; 45(3):549–51

Alcohol inhibits lipopolysaccharide-induced tumor necrosis factor alpha gene expression by peripheral blood mononuclear cells as measured by reverse transcriptase PCR in situ hybridization. Nair MP, et al.
Clin Diagn Lab Immunol 1996 Jul;3(4):392–8

Behavioral deficits induced by bingelike exposure to alcohol in neonatal rats: importance of developmental timing and number of episodes. Thomas JD, et al. **Dev Psychobiol** 1996 Jul;29(5):433–52

Suramin enhances ethanol-induced injury to gastric mucosa in rats. Blandizzi C, et al. **Dig Dis Sci** 1997 Jun; 42(6):1233–41

Histological effect of (R)-alpha-methylhistamine on ethanol damage in rat gastric mucosa: influence on mucus production. Morini G, et al. **Dig Dis Sci** 1997 May; 42(5):1020–8

Developmental toxicity of Exell, a surfactant mixture, in rats and rabbits. Munley SM, et al. **Drug Chem Toxicol** 1996 Nov;19(4):279–300

Investigating the effect of maternal alcohol intake on human fetal breathing rate using adaptive time-frequency analysis methods. Akay M, et al. **Early Hum Dev** 1996 Sep 20; 46(1–2):153–64

Corticotropin-releasing hormone and proopiomelanocortin gene expression is altered selectively in the male rat fetal thymus by maternal alcohol consumption. Revskoy S, et al. **Endocrinology** 1997 Jan;138(1):389–96

Reproductive toxicology. Ethanol.
Environ Health Perspect 1997 Feb;105 Suppl 1:309–10

Enhancement of the clastogenicity of N-nitrosodialkylamines plus near-ultraviolet irradiation by ethanol in Chinese hamster lung fibroblasts [published erratum appears in Environ Mol Mutagen 1997;29(4):440] Yamashita Y, et al. **Environ Mol Mutagen** 1997;29(3):296–302

A mechanistic study of beta-adrenoceptor antagonists on ethanol-induced gastric damage. Kaan SK, et al.
Eur J Pharmacol 1996 Dec 12;317(1):115–22

Muscarinic receptors and insulin concentration in the rat pancreas after chronic alcohol intake and cholinergic stimulation. Laine VJ, et al. **Exp Toxicol Pathol** 1996 Jan; 48(1):77–9

Toxicity of chronic ethanol ingestion and superoxide radical formation on seminal vesicle of rats. Novelli EL, et al.
Food Chem Toxicol 1996 Oct;34(10):1003–7

Oxidative stress and the fetotoxicity of alcohol consumption during pregnancy. Amini SA, et al.
Free Radic Biol Med 1996;21(3):357–65

Effect of ethanol on DNA synthesis and c-met induction in Chang liver cells with long-term culture. Ohira H, et al. **Fukushima J Med Sci** 1995 Dec;41(2):103–10

The potentiating actions of cigarette smoking on ethanol-induced gastric mucosal damage in rats. Chow JY, et al. **Gastroenterology** 1997 Oct;113(4):1188–97

Pancreatic injury in rats induced by fatty acid ethyl ester, a nonoxidative metabolite of alcohol [see comments] Werner J, et al. **Gastroenterology** 1997 Jul;113(1):286–94. Comment in: Gastroenterology 1997 Jul;113(1):355–8.

The drinker's pancreas: molecular mechanisms emerge [editorial; comment] Wilson JS, et al. **Gastroenterology** 1997 Jul;113(1):355–8. Comment on: Gastroenterology 1997 Jul;113(1):286–94.

Mechanisms of alcohol impairment of recovery from mechanically denuded areas made within cultured rat hepatocytes. Anderson RJ, et al. **Hepatology** 1997 Jan; 25(1):128–32

Chronic enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. Arteel GE, et al. **Hepatology** 1997 Apr; 25(4):920–6

4-hydroxynonenal levels are enhanced in fetal liver mitochondria by in utero ethanol exposure. Chen JJ, et al. **Hepatology** 1997 Jan;25(1):142–7

Flow cytometric analysis of vesicular pH in rat hepatocytes after ethanol administration. Kharbanda KK, et al.
Hepatology 1997 Oct;26(4):929–34

Long-term alcohol intake enhances ADP-ribosylation of the multifunctional enzyme, phosphoglucomutase, in rat liver. Nomura F, et al. **Hepatology** 1996 Nov;24(5):1246–9

Prenatal exposure to moderate levels of ethanol can have long-lasting effects on hippocampal synaptic plasticity in adult offspring. Sutherland RJ, et al. **Hippocampus** 1997; 7(2):232–8

Developmental immunotoxicity of cocaine and ethanol in postnatal Lewis rats. Figliomeni ML, et al.
Immunopharmacology 1997 Apr;36(1):41–8

Glutathione S-transferase-M1 'null' genotype and alcohol-induced disorders of human spermatogenesis. Pajarinen J, et al. **Int J Androl** 1996 Jun;19(3):155–63

Polymorphism in the cytochrome P450 2E1 gene and alcohol-induced disorders of human spermatogenesis. Pajarinen J, et al. **Int J Androl** 1996 Oct;19(5):314–22

Enhancement by ethyl alcohol of experimental hepatocarcinogenesis induced by N-nitrosomorpholine. Tatsuta M, et al. **Int J Cancer** 1997 Jun 11;71(6):1045–8

Gestational ethanol-induced changes in protein expression during the morphogenesis of the rat optic nerve.

Pinazo-Duran MD, et al. **Int J Dev Biol** 1996;Suppl 1:141S-142S

Alcohol consumption during pregnancy alters glycoconjugates, galactosyltransferase activity and beta-COP proteins in the Golgi apparatus of hepatocytes in developing liver. Seguí JM, et al. **Int J Dev Biol** 1996; Suppl 1:285S-286S

Effects of nerve growth factor on splenic norepinephrine and pineal N-acetyl-transferase in neonate rats exposed to alcohol in utero: neuroimmune correlates. Gottesfeld Z, et al. **Int J Dev Neurosci** 1996 Aug;14(5):655-62

Effect of ethanol and cocaine treatment of the immune system of v-Ha-ras-transgenic mice. Chen G, et al. **Int J Immunopharmacol** 1996 Apr;18(4):251-8

Degeneration of intrapancreatic nerve fibers after chronic alcohol administration in mice. Berger Z, et al. **Int J Pancreatol** 1997 Apr;21(2):165-71

Ethanol intake may modify gossypol toxicosis in the rat. Akingbemi BT, et al. **J Appl Toxicol** 1996 Sep-Oct; 16(5):375-80

Interaction of exercise training and chronic ethanol ingestion on hepatic and plasma antioxidant system in rat. Husain K, et al. **J Appl Toxicol** 1997 May-Jun;17(3):189-94

Ethanol cytotoxicity to a transfected HepG2 cell line expressing human cytochrome P4502E1. Wu D, et al. **J Biol Chem** 1996 Sep 27;271(39):23914-9

Effect of ethanol on esophageal cell proliferation and the development of N-methyl-N'-nitro-N-nitrosoguanidine induced-esophageal carcinoma in shrews. Shikata N, et al. **J Cancer Res Clin Oncol** 1996;122(10):613-8

Effect of ethanol, haloperidol, and lorazepam on cardiac conduction and contraction. Medlin RP Jr, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):792-8

A cholecystokinin-releasing factor mediates ethanol-induced stimulation of rat pancreatic secretion. Saluja AK, et al. **J Clin Invest** 1997 Feb 1;99(3):506-12

Ethanol feeding enhances inflammatory cytokine expression in lipopolysaccharide-induced hepatitis. Pennington HL, et al. **J Gastroenterol Hepatol** 1997 Apr;12(4):305-13

Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. Fromenty B, et al. **J Hepatol** 1997;26 Suppl 2:43-53 (35 ref.)

Effects of acute and chronic ethanol administration on hepatic hemodynamics and hepatic oxygen consumption in awake rats. Souda K, et al. **J Hepatol** 1996 Jan; 24(1):101-8

Hepatotoxicity induced by iron overload and alcohol. Studies on the role of chelatable iron, cytochrome P450 2E1 and lipid peroxidation. Stål P, et al. **J Hepatol** 1996 Oct; 25(4):538-46

Neuroprotective effects of thiamine-megadoses after long-term ethanol application in the rat brain. A structural investigation of hippocampal CA1 pyramidal and cerebellar Purkinje neurons. Wenisch S, et al. **J Hirnforsch** 1996; 37(3):377-87

Effect of ethanol on the synthesis and secretion of apoA-I- and apoB-containing lipoproteins in HepG2 cells. Dashti N, et al. **J Lipid Res** 1996 Apr;37(4):810-24

Ethanol neurotoxicity in culture: selective loss of cholinergic neurons. Kentroti S, et al. **J Neurosci Res** 1996 Jun 15; 44(6):577-85

Ethanol-exposed central neurons fail to migrate and undergo apoptosis. Liesi P. **J Neurosci Res** 1997 Jun 1;48(5):439-48

Role of GABAA receptors in the GABA attenuation of ethanol neurotoxicity. Spoerri PE, et al. **J Neurosci Res** 1996 Jun 1;44(5):499-506

The influence of acute and chronic alcohol treatment on brain edema, cerebral infarct volume and neurological outcome following experimental head trauma in rats. Shapira Y, et al. **J Neurosurg Anesthesiol** 1997 Apr;9(2):118-27

Differential development and characterization of rapid acute neuronal tolerance to the depressant effects of ethanol on cerebellar Purkinje neurons of low-alcohol-sensitive and high-alcohol-sensitive rats. Pearson BJ, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):739-46

Effect of a single dose of ethanol on granulopoiesis in female rats: relationship to phase of estrous cycle. Stojanović N, et al. **J Stud Alcohol** 1996 Jul;57(4):344-8

Gastric antigen challenge releases gastrin and eicosanoids and protects against ethanol. Bacha EA, et al. **J Surg Res** 1997 Jun;70(1):69-74

Protective effects of buprenorphine against amplified cocaine and ethanol lethality in mice: role of cocaethylene. Hayase T, et al. **J Toxicol Sci** 1996 May;21(2):143-56

Low activity of aldehyde dehydrogenase (ALDH) in liver of Suncus murinus: possible explanation for high sensitivity to alcohol. Itoh S, et al. **J Toxicol Sci** 1997 May;22(2):111-5

Delayed effects of ethanol, caffeine and nicotine assessed by wheel-running and drinking in mice. Kuribara H, et al. **J Toxicol Sci** 1995 Nov;20(5):595-602

Intracisternal injection of basic fibroblast growth factor reduces the severity of gastric mucosal lesions evoked by ethanol in rats. Watanabe Y, et al. **Jpn J Physiol** 1997 Apr; 47(2):231-3

Ethanol-induced emesis in the house musk shrew, Suncus murinus. Chen Y, et al. **Life Sci** 1997;60(4-5):253-61

Hepatotoxicity of ethanol: protective effect of calcium channel blockers in isolated hepatocytes. Cobreros A, et al. **Liver** 1997 Apr;17(2):76-82

Effects of dietary restriction on experimental gastric mucosal injury in Fischer 344 rats. Lee M, et al. **Mech Ageing Dev** 1996 Jul 31;89(1):11-20

Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1. Koop DR, et al. **Mol Pharmacol** 1997 Jun;51(6):944-50

Development of glial cells cultured from prenatally alcohol treated rat brain: effect of supplementation of the maternal alcohol diet with a grape extract. Ledig M, et al. **Neurochem Res** 1996 Mar;21(3):313-7

Effects of chronic ethanol treatment and ethanol withdrawal on [3H]SCH23390 binding to rat striatal membranes. Gili-Martín E, et al. **Neuropharmacology** 1997 Jan; 36(1):101-6

alpha-Tocopherol attenuates alcohol-induced cerebral vascular damage in rats: possible role of oxidants in alcohol brain pathology and stroke. Altura BM, et al. **Neurosci Lett** 1996 Dec 20;220(3):207-10

Intracerebral grafts promote recovery of the cholinergic innervation of the hippocampal formation in rats withdrawn from chronic alcohol intake. An immunocytochemical study. Cadete-Leite A, et al. **Neuroscience** 1997 Jul;79(2):383-97

The cerebral cortex is damaged in chronic alcoholics. Kril JJ, et al. **Neuroscience** 1997 Aug;79(4):983-98

Functional observational battery comparing effects of ethanol, 1,1,1-trichloroethane, ether, and flurothyl. Bowen SE, et al. **Neurotoxicol Teratol** 1996 Sep-Oct;18(5):577-85

Ethanol-induced cell death in cultured rat astroglia. Holownia A, et al. **Neurotoxicol Teratol** 1997 Mar-Apr; 19(2):141-6

Characterization of the morphological variations of astrocytes in culture following ethanol exposure. Barret L, et al. **Neurotoxicology** 1996 Summer;17(2):497-507

Assessment of the effects of developmental toxicants: pharmacological and stress vulnerability of offspring. Spear LP. **NIDA Res Monogr** 1996;164:125-45 (42 ref.)

Forebrain hypoplasia following acute prenatal ethanol exposure: quantitative analysis of effects on specific forebrain nuclei. Ashwell KW, et al. **Pathology** 1996 May; 28(2):161-6

Newborn cerebrovascular responses after first trimester moderate maternal ethanol exposure in sheep. Gleason CA, et al. **Pediatr Res** 1997 Jul;42(1):39-45

Teratogenic actions of ethanol in the mouse: a minireview. Becker HC, et al. **Pharmacol Biochem Behav** 1996 Dec; 55(4):501-13 (129 ref.)

Temporal determinants of neonatal alcohol-induced cerebellar damage and motor performance deficits. Goodlett CR, et al. **Pharmacol Biochem Behav** 1996 Dec; 55(4):531-40

What research with animals is telling us about alcohol-related neurodevelopmental disorder. Hannigan JH. **Pharmacol Biochem Behav** 1996 Dec;55(4):489-99 (207 ref.)

Ethanol self-administration and motor deficits in adults C57BL/6J mice exposed prenatally to cocaine. Kelley BM, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):575-84

Gestational cocaine and ethanol exposure alter spontaneous and cocaine-induced behavior in weanling rats. Kunko PM, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):559-64

Prenatal binge-like alcohol exposure alters neurochemical profiles in fetal rat brain. Maier SE, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):521-9

Effects of prenatal alcohol exposure on activity and learning in Sprague-Dawley rats. Westergren S, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):515-20

Prenatal alcohol exposure influences the effects of neuroactive steroids on separation-induced ultrasonic vocalizations in rat pups. Zimmerberg B, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):541-7

Ethanol interference with morphine metabolism in isolated guinea pig hepatocytes. Aasmundstad TA, et al. **Pharmacol Toxicol** 1996 Sep;79(3):114-9

Effects of ethanol and acetate on adenosine production in rat hippocampal slices. Fredholm BB, et al. **Pharmacol Toxicol** 1996 Sep;79(3):120-3

Cinitapride protects against ethanol-induced gastric mucosal injury in rats: role of 5-hydroxytryptamine, prostaglandins and sulfhydryl compounds. Alarcón-de-la-Lastra Romero C, et al. **Pharmacology** 1997 Apr;54(4):193-202

Ethanol-induced alterations in beta-endorphin levels in specific rat brain regions: modulation by adenosine agonist and antagonist. Anwer J, et al. **Pharmacology** 1995 Dec; 51(6):364-9

Felodipine- and ethanol-induced gastric mucosal damage in rats. Liu XG, et al. **Pharmacology** 1995 Dec;51(6):391-7

Early postnatal alcohol exposure in rats: maternal behavior and estradiol levels. Wilson JH, et al. **Physiol Behav** 1996 Feb;59(2):287-93

Influence of adenosinergic drugs on ethanol withdrawal syndrome in rats. Malec D, et al. **Pol J Pharmacol** 1996 Nov-Dec;48(6):583-8

Gestational exposure to ethanol suppresses msx2 expression in developing mouse embryos. Rifas L, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7549-54

Effects of methyl beta-carboline-3-carboxylate on memory impairments induced by chronic alcohol consumption in mice. Borde N, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov; 20(8):1377-87

Cytoprotective activity of cisapride on experimental gastric mucosal lesions induced by ethanol. Role of endogenous prostaglandins. Motilva V, et al. **Prostaglandins** 1996 Jul; 52(1):63-74

Serotonin1A receptor autoradiography during alcohol-withdrawal kindling. Ulrichsen J, et al. **Psychopharmacology (Berl)** 1997 Jul;132(1):19-26

Emerging themes in preclinical research on alcohol and aggression. Yudko E, et al. **Recent Dev Alcohol** 1997; 13:123-38 (90 ref.)

The effect of ethanol upon early development in mice and rats. XXIII. The effect of indomethacin on beer-induced disturbances of preimplantation development in rats. Fazakas-Todea I, et al. **Rom J Morphol Embryol** 1996 Jan-Jun;42(1-2):33-40

Purkinje cell deficits in nonhuman primates following weekly exposure to ethanol during gestation. Bonthius DJ, et al. **Teratology** 1996 Apr;53(4):230-6

Interactive dysmorphogenic effects of all-trans-retinol and ethanol on cultured whole rat embryos during organogenesis. Chen H, et al. **Teratology** 1996 Jul; 54(1):12-9

Ethanol in utero induces epithelial cell damage and altered kinetics in the developing rat intestine. Estrada G, et al. **Teratology** 1996 Nov;54(5):245-54

Time-dependent alteration of epidermal growth factor receptor in rat stomach by ethanol feeding. Wang SL, et al. **Toxicol Lett** 1997 Feb 7;90(2-3):115-23

Protection against cocaine and combined cocaine-ethanol toxicities in mice by imidazobenzodiazepine Ro 15-4513. Hayase T, et al. **Toxicology** 1997 Feb 28;117(2-3):171-82

Comparative study of the damage produced by acute ethanol and acetaldehyde treatment in a human fetal hepatic cell line. Olivares IP, et al. **Toxicology** 1997 Jun 27; 120(2):133-44

Can megadoses of thiamine prevent ethanol-induced damages of rat hippocampal CA1 pyramidal neurones? Wenisch S, et al. **Z Ernahrungswiss** 1996 Sep;35(3):266-72

[The effect of selected cytoprotective drugs on alcohol-induced injury of isolated gastric mucosa cells] Mach T. **Folia Med Cracov** 1995;36(1-4):76-95 (Eng. Abstr.) **(Pol)**

[Study of ultrastructural alterations in gastrocnemius muscle of C57 BL10 mice after prolonged ethanol ingestion] Silva JB, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):260-72 (Eng. Abstr.) **(Por)**

[The corrective action of limontar in metabolic disorders in the mother-fetus system caused by ethanol exposure during pregnancy] Sheveleva GA, et al. **Eksp Klin Farmakol** 1996 Nov-Dec;59(6):41-3 (Eng. Abstr.) **(Rus)**

[Dystrophic and reparative changes in the cortical neurons of rat progeny in moderate prenatal alcoholization] Popova EN. **Morfologiia** 1996;109(2):23-7 (Eng. Abstr.) **(Rus)**

[Testicular changes produced by alcohol] Calleja Escudero J, et al. **Actas Urol Esp** 1997 Apr;21(4):337-42 (Eng. Abstr.) **(Spa)**

URINE

Highly sensitive gas chromatographic analysis of ethanol in whole blood, serum, urine, and fecal supernatants by the direct injection method. Tangerman A. **Clin Chem** 1997 Jun;43(6 Pt 1):1003-9

The confirmation of volatiles by solid-phase microextraction and GC-MS in the investigation of two traffic fatalities. Brewer WE, et al. **J Anal Toxicol** 1997 Jul-Aug; 21(4):286-90

ALCOHOL, METHYL

Solid-phase extraction in malondialdehyde analysis. Suttnar J, et al. **Anal Biochem** 1997 Jun 15;249(1):20-3

Estimating diffusion coefficients for alkylbenzenes and alkylphenones in aqueous mixtures with acetonitrile and methanol. Li J, et al. **Anal Chem** 1997 Jul 1;69(13):2550-3

Acid-induced unfolding of cytochrome c at different methanol concentrations: electrospray ionization mass spectrometry specifically monitors changes in the tertiary structure. Konermann L, et al. **Biochemistry** 1997 Oct 7; 36(40):12296-302

Heterodisulfide reductase from methanol-grown cells of Methanosarcina barkeri is not a flavoenzyme. Künkel A, et al. **Eur J Biochem** 1997 Feb 15;244(1):226-34

Methanol-precipitated, detergent-treated Newcastle disease virus as an agar-gel precipitation test antigen. Roy P, et al. **Trop Anim Health Prod** 1997 Feb;29(1):25-8

[First drafts of the Environmental Health Criteria (EHC) circulated for comments by IPCS in 1995-1996] Ohtake C. **Eisei Shikenjo Hokoku** 1996;(114):95-8 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Hangovers [editorial] [published erratum appears in BMJ 1997 Feb 15;314(7079):460] Calder I. **BMJ** 1997 Jan 4; 314(7073):2-3

Neurobehavioral effects of low-level methanol vapor exposure in healthy human volunteers. Chuwers P, et al. **Environ Res** 1995 Nov;71(2):141-50

Methanol-induced health disturbance in a worker engaged in antimold spraying. Kudo Y, et al. **Int Arch Occup Environ Health** 1996;68(6):513-5

ANALOGS & DERIVATIVES

1,8-bis(hydroxymethyl)anthracene. Aumiller WD, et al. **Acta Crystallogr C** 1997 Jun 15;53 (Pt 6):769-71

ALCOHOL, METHYL

Diphenylethanediamine (DPEDA) as chiral selector: VII. Efficient HPLC resolution of a series of underivatized diarylcarbinols on a chiral stationary phase based on C5-amide-bonded N-3,5-dinitrobenzyl-DPEDA. Maier NM, et al. **Chirality** 1996;8(7):490–93

ANALYSIS

Airborne emissions at skin surfaces: a potential biological exposure index. Batterman SA, et al. **Int Arch Occup Environ Health** 1996;68(4):268–74

CHEMISTRY

Bay-region distortions in a methanol adduct of a bay-region diol epoxide of the carcinogen 5-methylchrysene. Afshar CE, et al. **Carcinogenesis** 1996 Nov;17(11):2507–11

A kinetic study of the methanolysis of the sulfonylureas bensulfuron methyl and sulfometuron methyl using capillary electrophoresis. Matchett WH, et al. **Electrophoresis** 1997 Feb;18(2):205–13

Relationship between stationary and mobile phase composition and its influence on retention factors of aromatic hydrocarbons in reversed-phase high-performance liquid chromatography. Nasuto R, et al. **J Chromatogr A** 1997 Feb 21;762(1–2):27–33

Chromatographic behaviour in reversed-phase high-performance liquid chromatography with micellar and submicellar mobile phases: effects of the organic modifier. Fischer J, et al. **J Chromatogr B Biomed Appl** 1996 May 31;681(1):3–19

METABOLISM

Regulation of ammonia assimilation in an obligate methylotroph Methylobacillus flagellatum under steady-state and transient growth conditions. Baev MV, et al. **Antonie Van Leeuwenhoek** 1997 May;71(4):353–61

The methanol oxidation genes mxaFJGIR (S) ACKLD in Methylobacterium extorquens [published erratum appears in FEMS Microbiol Lett 1997 May 1;150(1):175–7] Amaratunga K, et al. **FEMS Microbiol Lett** 1997 Jan 1; 146(1):31–8

Cloning and analysis of methanol oxidation genes in the methylotroph Hyphomicrobium methylovorum GM2. Tanaka Y, et al. **FEMS Microbiol Lett** 1997 Sep 15; 154(2):397–401

The kinetics of methanol elimination in alcoholics and the influence of ethanol. Haffner HT, et al. **Forensic Sci Int** 1997 Sep 19;89(1–2):129–36

Increased endobiotic fatty acid methyl esters following exposure to methanol. Kaphalia BS, et al. **Fundam Appl Toxicol** 1995 Dec;28(2):264–73

Dihydroxyacetone synthase from a methanol-utilizing carboxydobacterium, Acinetobacter sp. strain JC1 DSM 3803. Ro YT, et al. **J Bacteriol** 1997 Oct;179(19):6041–7

Regulation of the formate dehydrogenase gene, FDH1, in the methylotrophic yeast Candida boidinii and growth characteristics of an FDH1-disrupted strain on methanol, methylamine, and choline. Sakai Y, et al. **J Bacteriol** 1997 Jul;179(14):4480–5

Molecular analysis of mxbD and mxbM, a putative sensor-regulator pair required for oxidation of methanol in Methylobacterium extorquens AM1. Springer AL, et al. **Microbiology** 1997 May;143 (Pt 5):1737–44

Methanol production during chemotaxis to amino acids in Bacillus subtilis. Kirby JR, et al. **Mol Microbiol** 1997 May; 24(4):869–78

PHARMACOKINETICS

New ways to use biochemical indicators of alcohol abuse to regrant licences in a fairer manner after drunken driving in Germany. Iffland R. **Alcohol Alcohol** 1996 Nov; 31(6):619–20

Endogenous production of methanol after the consumption of fruit. Lindinger W, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):939–43

Comparative toxicokinetics of methanol in pregnant and nonpregnant rodents. Ward KW, et al. **Drug Metab Dispos** 1996 Oct;24(10):1062–70

Methanol elimination in non-alcoholics: inter- and intraindividual variation. Haffner HT, et al. **Forensic Sci Int** 1997 Apr 18;86(1–2):69–76

Comparative toxicokinetics of inhaled methanol in the female CD-1 mouse and Sprague-Dawley rat. Perkins RA, et al. **Fundam Appl Toxicol** 1995 Dec;28(2):245–54

Serum concentrations of methanol after inhalation at 200 ppm. Osterloh JD, et al. **J Occup Environ Med** 1996 Jun; 38(6):571–6

Methanol inhalation: site and other factors influencing absorption, and an inhalation toxicokinetic model for the rat. Perkins RA, et al. **Pharm Res** 1996 May;13(5):749–55

Development of a physiologically based pharmacokinetic model to describe the disposition of methanol in pregnant rats and mice. Ward KW, et al. **Toxicol Appl Pharmacol** 1997 Aug;145(2):311–22

PHARMACOLOGY

Changes in spleen and thymus cell phenotypes in mice vaccinated with the Coxiella burnetii phase I whole-cell vaccine or the chloroform-methanol residue subunit vaccine. Waag DM, et al. **Acta Virol** 1996 Apr;40(2):87–94

POISONING

Liver and serum antioxidant status after methanol intoxication in rats. Skrzydlewska E, et al. **Acta Biochim Pol** 1997;44(1):139–45

Treatment of acute methanol intoxication with hemodialysis using an ethanol-enriched, bicarbonate-based dialysate. Chow MT, et al. **Am J Kidney Dis** 1997 Oct;30(4):568–70

Acute ocular methanol toxicity: clinical and electrophysiological features. McKellar MJ, et al. **Aust N Z J Ophthalmol** 1997 Aug;25(3):225–30 (22 ref.)

Sterilising anaesthetic cartridges [letter] [see comments] Gordon P. **Br Dent J** 1997 Feb 8;182(3):87. Comment in: Br Dent J 1997 May 24;182(10):370.

Late treatment of methanol blindness [letter] Rotenstreich Y, et al. **Br J Ophthalmol** 1997 May;81(5):416–7

Putaminal necrosis after methanol intoxication [letter] Moral AR, et al. **Intensive Care Med** 1997 Feb;23(2):234–5

Bilateral basal ganglia haemorrhage--uncommon manifestation of methanol poisoning. Ganguly G, et al. **J Assoc Physicians India** 1996 Nov;44(11):834–5

MR enhancing brain lesions in methanol intoxication. Anderson CA, et al. **J Comput Assist Tomogr** 1997 Sep–Oct;21(5):834–6

Antidotes for methanol and ethylene glycol poisoning--a REAL challenge! [editorial; comment] Becker C. **J Toxicol Clin Toxicol** 1997;35(2):147–8. Comment on: J Toxicol Clin Toxicol 1997 ;35(2):127–43.

Methanol and ethylene glycol toxicity [editorial; comment] Burkhart K. **J Toxicol Clin Toxicol** 1997;35(2):149–50. Comment on: J Toxicol Clin Toxicol 1997 ;35(2):127–43.

Neurotoxicity to the basal ganglia shown by magnetic resonance imaging (MRI) following poisoning by methanol and other substances. Hantson P, et al. **J Toxicol Clin Toxicol** 1997;35(2):151–61

Methanol poisoning during late pregnancy [see comments] Hantson P, et al. **J Toxicol Clin Toxicol** 1997;35(2):187–91 . Comment in: J Toxicol Clin Toxicol 1997 ;35(2):193–4.

Antidotes for methanol and ethylene glycol poisoning [see comments] Jacobsen D, et al. **J Toxicol Clin Toxicol** 1997; 35(2):127–43 (80 ref.). Comment in: J Toxicol Clin Toxicol 1997 ;35(2):145–6. Comment in: J Toxicol Clin Toxicol 1997 ;35(2):147–8. Comment in: J Toxicol Clin Toxicol 1997 ;35(2):149–50.

Methanol poisoning during pregnancy--prediction of risk and suggestions for management [editorial; comment] Tenenbein M. **J Toxicol Clin Toxicol** 1997;35(2):193–4. Comment on: J Toxicol Clin Toxicol 1997 ;35(2):187–91.

Optic atrophy and cerebral infarcts caused by methanol intoxication: MRI. Hsu HH, et al. **Neuroradiology** 1997 Mar;39(3):192–4

Decreased antioxidant status and increased lipid peroxidation in rats after methanol intoxication. Skrzydlewska E. **Rocz Akad Med Bialymst** 1996;41(2):397–404

Mass methanol poisoning: a clinico-biochemical analysis of 10 cases. Teo SK, et al. **Singapore Med J** 1996 Oct; 37(5):485–7

Formate-induced alterations in retinal function in methanol-intoxicated rats. Eells JT, et al. **Toxicol Appl Pharmacol** 1996 Sep;140(1):58–69

Successful liver transplantation with a graft from a methanol-poisoned donor [letter] Hantson P, et al. **Transpl Int** 1996;9(4):437

Diminished antioxidant defense potential of liver, erythrocytes and serum from rats with subacute methanol intoxication. Skrzydlewska E, et al. **Vet Hum Toxicol** 1996 Dec;38(6):429–33

[Methanol poisoning with bilateral necrosis of the putamen and additional involvement of the globus pallidus] Penndorf-Wehner F, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jul;167(1):99–100 (10 ref.) **(Ger)**

[Methanol poisoning in the Tarnów region in the years 1982–1992] Sydor A, et al. **Przegl Lek** 1996;53(3):135–7 (Eng. Abstr.) **(Pol)**

TOXICITY

Influence of methanol and its metabolites on the activity of alpha1-antitrypsin. Skrzydlewska E, et al. **Alcohol** 1997 May–Jun;14(3):295–9

Cytotoxic activity of a methanol extract of Phallusia nigra (Tunicata, Ascidiacea). Costa LV, et al. **Braz J Med Biol Res** 1996 Mar;29(3):367–73

Simple neurobehavioral functional observational battery and objective gait analysis validation by the use of acrylamide and methanol with a built-in recovery period. Youssef AF, et al. **Environ Res** 1997;73(1–2):52–62

Increased endobiotic fatty acid methyl esters following exposure to methanol. Kaphalia BS, et al. **Fundam Appl Toxicol** 1995 Dec;28(2):264–73

Comparative toxicokinetics of inhaled methanol in the female CD-1 mouse and Sprague-Dawley rat. Perkins RA, et al. **Fundam Appl Toxicol** 1995 Dec;28(2):245–54

Perinatal methanol exposure in the rat. I. Blood methanol concentration and neural cell adhesion molecules. Stern S, et al. **Fundam Appl Toxicol** 1996 Nov;34(1):36–46

Perinatal methanol exposure in the rat. II. Behavioral effects in neonates and adults. Stern S, et al. **Fundam Appl Toxicol** 1997 Apr;36(2):163–76

Influence of dietary folic acid on the developmental toxicity of methanol and the frequency of chromosomal breakage in the CD-1 mouse. Fu SS, et al. **Reprod Toxicol** 1996 Nov-Dec;10(6):455–63

Teratogenicity of methanol following a single oral dose in Long-Evans rats. Youssef AF, et al. **Reprod Toxicol** 1997 Jul–Aug;11(4):503–10

Pharmacokinetics of methanol and formate in female cynomolgus monkeys exposed to methanol vapors. Medinsky MA, et al. **Res Rep Health Eff Inst** 1997 Jun; (77):1–30; discussion 31–8

In vitro assessment of the effect of methanol and the metabolite, formic acid, on embryonic development of the rat. Brown-Woodman PD, et al. **Teratology** 1995 Oct; 52(4):233–43

Methanol causes posteriorization of cervical vertebrae in mice. Connelly LE, et al. **Teratology** 1997 Feb;55(2):138–44

Critical periods of sensitivity to the developmental toxicity of inhaled methanol in the CD-1 mouse. Rogers JM, et al. **Teratology** 1997 Jun;55(6):364–72

Influence of maternal folate status on the developmental toxicity of methanol in the CD-1 mouse. Sakanashi TM, et al. **Teratology** 1996 Oct;54(4):198–206

Physiologically based pharmacokinetic estimated metabolic constants and hepatotoxicity of carbon tetrachloride after methanol pretreatment in rats. Evans MV, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):245–53

Folate and 10-formyltetrahydrofolate dehydrogenase in human and rat retina: relation to methanol toxicity. Martinasevic MK, et al. **Toxicol Appl Pharmacol** 1996 Dec; 141(2):373–81

Use of intrauterine microdialysis to investigate methanol-induced alterations in uteroplacental blood flow. Ward KW, et al. **Toxicol Appl Pharmacol** 1996 Oct; 140(2):203–10

ALCOHOL OXIDOREDUCTASES

A new nomenclature for the aldo-keto reductase superfamily. Jez JM, et al. **Biochem Pharmacol** 1997 Sep 15;54(6):639–47

Cloning, sequencing, and enzymatic activity of an inducible aldo-keto reductase from Chinese hamster ovary cells. Hyndman DJ, et al. **J Biol Chem** 1997 May 16; 272(20):13286–91

ANALYSIS

Purification and characterization of sulochrin oxidase from Penicillium frequentans. Huang K, et al. **Biol Pharm Bull** 1996 Jan;19(1):42–6

Differential localization of Mox-1 and Mox-2 proteins indicates distinct roles during development. Candia AF, et al. **Int J Dev Biol** 1996 Dec;40(6):1179–84

High-performance liquid chromatographic methods for the quantification of tetrahydrobiopterin biosynthetic enzymes. Werner ER, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):51–8 (65 ref.)

ANTAGONISTS & INHIBITORS

Tetrahydrobiopterin synthesis inhibitors induce nitric oxide synthesis in rat aorta. Joly GA, et al. **Gen Pharmacol** 1997 Mar;28(3):475–80

Characterization of acetohexamide reductases purified from rabbit liver, kidney, and heart: structural requirements for substrates and inhibitors. Imamura Y, et al. **J Biochem (Tokyo)** 1997 Apr;121(4):705–10

Inhibitory effect of drugs with a ketone group on reduction of acetohexamide catalyzed by carbonyl reductase from rabbit kidney. Imamura Y, et al. **J Enzyme Inhib** 1997 Feb; 11(4):285–92

Three-dimensional structures of glycolate oxidase with bound active-site inhibitors. Stenberg K, et al. **Protein Sci** 1997 May;6(5):1009–15

BIOSYNTHESIS

Identification of two closely related genes, inducible and noninducible carbonyl reductases in the rat ovary. Aoki H, et al. **Biochem Biophys Res Commun** 1997 Jan 23; 230(3):518–23

Heterologous expression of alkaloid biosynthetic genes--a review. Kutchan TM. **Gene** 1996 Nov 7;179(1):73–81

Engineering Pichia pastoris for biocatalysis: co-production of two active enzymes. Payne MS, et al. **Gene** 1997 Jul 31;194(2):179–82

Transformation of Arabidopsis thaliana with the codA gene for choline oxidase; accumulation of glycinebetaine and enhanced tolerance to salt and cold stress. Hayashi H, et al. **Plant J** 1997 Jul;12(1):133–42

High-level expression, purification, and crystallization of recombinant spinach glycolate oxidase in Escherichia coli. Stenberg K, et al. **Protein Expr Purif** 1996 Nov;8(3):295–8

Flavin adenine dinucleotide binding is the crucial step in alcohol oxidase assembly in the yeast Hansenula polymorpha. Evers ME, et al. **Yeast** 1996 Aug; 12(10):917–23

CHEMISTRY

Characterization of a novel murine aldo-keto reductase. Bohren KM, et al. **Adv Exp Med Biol** 1997;414:455–64

Site-directed mutagenesis of residues in coenzyme-binding domain and active site of mouse lung carbonyl reductase. Nakanishi M, et al. **Adv Exp Med Biol** 1997;414:555–61

An essential cysteine (Cys-227) in human carbonyl reductase is involved in glutathione binding. Tinguely J, et al.

Adv Exp Med Biol 1997;414:563–8

Towards engineering an improved morphine dehydrogenase. Walker EH, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:6–10

Purification, characterization and partial primary structure of morphine 6-dehydrogenase from rabbit liver cytosol. Yamano S, et al. **Arch Biochem Biophys** 1997 May 1; 341(1):81–8

Reconstitution of the quinoprotein methanol dehydrogenase from inactive Ca(2+)-free enzyme with Ca2+, Sr2+ or Ba2+. Goodwin MG, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):839–42

Characterization of a novel methanol dehydrogenase containing a Ba2+ ion at the active site. Goodwin MG, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):673–9

Comparative anatomy of the aldo-keto reductase superfamily. Jez JM, et al. **Biochem J** 1997 Sep 15;326 (Pt 3):625–36 (101 ref.)

Properties of diacetyl (acetoin) reductase from Bacillus stearothermophilus. Giovannini PP, et al. **Bioorg Med Chem** 1996 Aug;4(8):1197–201

The crystal structure of plant acetohydroxy acid isomeroreductase complexed with NADPH, two magnesium ions and a herbicidal transition state analog determined at 1.65 A resolution. Biou V, et al. **EMBO J** 1997 Jun;16(12):3405–15

D-2-hydroxy-4-methylvalerate dehydrogenase from Lactobacillus delbrueckii subsp. bulgaricus. I. Kinetic mechanism and pH dependence of kinetic parameters, coenzyme binding and substrate inhibition. Alvarez JA, et al. **Eur J Biochem** 1997 Feb 15;244(1):203–12

Properties of an NAD(H)-containing methanol dehydrogenase and its activator protein from Bacillus methanolicus. Arfman N, et al. **Eur J Biochem** 1997 Mar 1;244(2):426–33

Effect of polar side chains at position 172 on thermal stability of 3-isopropylmalate dehydrogenase from Thermus thermophilus. Akanuma S, et al. **FEBS Lett** 1997 Jun 30; 410(2-3):141–4

Mercuration of vanillyl-alcohol oxidase from Penicillium simplicissimum generates inactive dimers. Fraaije MW, et al. **FEBS Lett** 1997 Jan 27;402(1):33–5

Molecular and phylogenetic characterization of isopropylmalate dehydrogenase of a thermoacidophilic archaeon, Sulfolobus sp. strain 7. Suzuki T, et al. **J Bacteriol** 1997 Feb;179(4):1174–9

Substrate activating mechanism of short-chain acyl-CoA, medium-chain acyl-CoA, long-chain acyl-CoA, and isovaleryl-CoA dehydrogenases from bovine liver: a resonance Raman study on the 3-ketoacyl-CoA complexes. Hazekawa I, et al. **J Biochem (Tokyo)** 1995 Nov; 118(5):900–10

Involvement of two basic residues (Lys-17 and Arg-39) of mouse lung carbonyl reductase in NADP(H)-binding and fatty acid activation: site-directed mutagenesis and kinetic analyses. Nakanishi M, et al. **J Biochem (Tokyo)** 1996 Aug; 120(2):257–63

Crystallization of mouse lung carbonyl reductase complexed with NADPH and analysis of symmetry of its tetrameric molecule. Tanaka N, et al. **J Biochem (Tokyo)** 1995 Nov; 118(5):871–3

ATP-, K+-dependent heptamer exchange reaction produces hybrids between GroEL and chaperonin from Thermus thermophilus. Taguchi H, et al. **J Biol Chem** 1997 Jul 18; 272(29):18155–60

Crystal structure of a ternary complex of D-2-hydroxyisocaproate dehydrogenase from Lactobacillus casei, NAD+ and 2-oxoisocaproate at 1.9 A resolution. Dengler U, et al. **J Mol Biol** 1997 Apr 4; 267(3):640–60

Crystal structures of Escherichia coli and Salmonella typhimurium 3-isopropylmalate dehydrogenase and comparison with their thermophilic counterpart from Thermus thermophilus. Wallon G, et al. **J Mol Biol** 1997 Mar 14;266(5):1016–31

Purification and characterisation of a novel iso-propanol dehydrogenase from Phytomonas sp. Uttaro AD, et al. **Mol Biochem Parasitol** 1997 Apr;85(2):213–9

Kinetic and structural evidence for the identification of 11-hydroxythromboxane B2 dehydrogenase as cytosolic aldehyde dehydrogenase. Fylling AC, et al. **Prostaglandins** 1995 Nov-Dec;50(5-6):287–99

Stabilization of Escherichia coli isopropylmalate dehydrogenase by single amino acid substitution. Aoshima M, et al. **Protein Eng** 1997 Mar;10(3):249–54

Relationship between thermal stability and 3-D structure in a homology model of 3-isopropylmalate dehydrogenase from Escherichia coli. Magyar C, et al. **Protein Eng** 1996 Aug;9(8):663–70

Sequence and homology model of 3-isopropylmalate dehydrogenase from the psychrotrophic bacterium Vibrio sp. I5 suggest reasons for thermal instability. Wallon G, et al. **Protein Eng** 1997 Jun;10(6):665–72

A stable intermediate in the thermal unfolding process of a chimeric 3-isopropylmalate dehydrogenase between a thermophilic and a mesophilic enzymes. Hayashi-Iwasaki Y, et al. **Protein Sci** 1996 Mar;5(3):511–6

Three-dimensional structures of glycolate oxidase with bound active-site inhibitors. Stenberg K, et al. **Protein Sci** 1997 May;6(5):1009–15

Crystallization and preliminary X-ray analysis of the flavoenzyme vanillyl-alcohol oxidase from Penicillium simplicissimum. Mattevi A, et al. **Proteins** 1997 Apr; 27(4):601–3

Structure and function of 3 alpha-hydroxysteroid dehydrogenase. Penning TM, et al. **Steroids** 1997 Jan; 62(1):101–11

Crystal structure of the ternary complex of mouse lung carbonyl reductase at 1.8 A resolution: the structural origin of coenzyme specificity in the short-chain dehydrogenase/reductase family. Tanaka N, et al. **Structure** 1996 Jan 15;4(1):33–45

DEFICIENCY

Tetrahydrobiopterin induced neonatal tyrosinaemia [letter] Blau N, et al. **Eur J Pediatr** 1996 Sep;155(9):832

Identification of mutations causing 6-pyruvoyl-tetrahydropterin synthase deficiency in four Italian families. Oppliger T, et al. **Hum Mutat** 1997; 10(1):25–35

6-Pyruvoyl-tetrahydropterin synthase deficiency with generalized dystonia and diurnal fluctuation of symptoms: a clinical and molecular study. Hanihara T, et al. **Mov Disord** 1997 May;12(3):408–11

GENETICS

Engineering pathways in Escherichia coli for the synthesis of morphine alkaloid analgesics and antitussives. Hailes AM, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:391–6

The methanol dehydrogenase structural gene mxaF and its use as a functional gene probe for methanotrophs and methylotrophs. McDonald IR, et al. **Appl Environ Microbiol** 1997 Aug;63(8):3218–24

Reversal of the nucleotide specificity of ketol acid reductoisomerase by site-directed mutagenesis identifies the NADPH binding site. Rane MJ, et al. **Arch Biochem Biophys** 1997 Feb 1;338(1):83–9

Identification of two closely related genes, inducible and noninducible carbonyl reductases in the rat ovary. Aoki H, et al. **Biochem Biophys Res Commun** 1997 Jan 23; 230(3):518–23

Molecular characterization of the gene coding for threonine dehydrogenase in Xanthomonas campestris. Liu YS, et al. **Biochem Biophys Res Commun** 1997 Jun 18;235(2):300–5

Comparative anatomy of the aldo-keto reductase superfamily. Jez JM, et al. **Biochem J** 1997 Sep 15;326 (Pt 3):625–36 (101 ref.)

Molecular cloning of the leuB genes from Mycobacterium bovis BCG and Mycobacterium tuberculosis. Han MY, et al. **Biochem Mol Biol Int** 1997 Apr;41(4):657–63

Direct PCR screening of Pichia pastoris clones. Linder S, et al. **Biotechniques** 1996 Jun;20(6):980–2

Isolation by genetic complementation of two differentially expressed genes for beta-isopropylmalate dehydrogenase from Aspergillus niger. Williams BA, et al. **Curr Genet** 1996 Sep;30(4):305–11

D-2-hydroxy-4-methylvalerate dehydrogenase from Lactobacillus delbrueckii subsp. bulgaricus. II. Mutagenic analysis of catalytically important residues. Bernard N, et al. **Eur J Biochem** 1997 Feb 15;244(1):213–9

Chromosomal localization, genomic structure and characterization of the human gene and a retropseudogene for 6-pyruvoyltetrahydropterin synthase [published erratum appears in Eur J Biochem 1996 Oct 15;241(2):697] Kluge C, et al. **Eur J Biochem** 1996 Sep 1;240(2):477–84

Transgenic mice for the establishment of histidinol-resistant embryonic fibroblast feeder layers. Tucker RM, et al. **FASEB J** 1996 Dec;10(14):1641–5

Use of phage display for isolation and characterization of single-chain variable fragments against dihydroflavonol 4-reductase from Petunia hybrida. De Jaeger G, et al. **FEBS Lett** 1997 Feb 17;403(2):116–22

Glycerol conversion to 1,3-propanediol by Clostridium pasteurianum: cloning and expression of the gene encoding 1,3-propanediol dehydrogenase. Luers F, et al. **FEMS Microbiol Lett** 1997 Sep 15;154(2):337–45

Cloning and analysis of methanol oxidation genes in the methylotroph Hyphomicrobium methylovorum GM2. Tanaka Y, et al. **FEMS Microbiol Lett** 1997 Sep 15; 154(2):397–401

Cloning and sequencing of the ilvBNC gene cluster from Mycobacterium avium. Gusberti L, et al. **Gene** 1996 Oct 24;177(1-2):83–5

Inducible expression of a heterologous protein in Hansenula polymorpha using the alcohol oxidase 1 promoter of Pichia pastoris. Raschke WC, et al. **Gene** 1996 Oct 24; 177(1-2):163–7

Primary structure of human 11-cis retinol dehydrogenase and organization and chromosomal localization of the corresponding gene. Simon A, et al. **Genomics** 1996 Sep 15;36(3):424–30

Cloning a cDNA for carbonyl reductase (Cbr) from mouse cerebellum: murine genes that express cbr map to chromosomes 16 and 11. Wei J, et al. **Genomics** 1996 May 15;34(1):147–8

Gene structure and promoter for Adh3 encoding mouse class IV alcohol dehydrogenase (retinol dehydrogenase). Zgombić-Knight M, et al. **Genomics** 1997 Apr 1; 41(1):105–9

Identification of mutations causing 6-pyruvoyl-tetrahydropterin synthase deficiency in four Italian families. Oppliger T, et al. **Hum Mutat** 1997; 10(1):25–35

Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin synthase genes. Thöny B, et al. **Hum Mutat** 1997;10(1):11–20 (54 ref.)

Spontaneous tandem sequence duplications reverse the thermal stability of carboxyl-terminal modified 3-isopropylmalate dehydrogenase. Akanuma S, et al. **J Bacteriol** 1996 Nov;178(21):6300–4

The rkpGHI and -J genes are involved in capsular polysaccharide production by Rhizobium meliloti. Kiss E, et al. **J Bacteriol** 1997 Apr;179(7):2132–40

Purification and sequence analysis of a novel NADP(H)-dependent type III alcohol dehydrogenase from Thermococcus strain AN1. Li D, et al. **J Bacteriol** 1997 Jul;179(13):4433–7

Hexose oxidase from the red alga Chondrus crispus. Purification, molecular cloning, and expression in Pichia pastoris. Hansen OC, et al. **J Biol Chem** 1997 Apr 25; 272(17):11581–7

Coexpression of the mRNAs encoding retinol dehydrogenase isozymes and cellular retinol-binding protein. Zhai Y, et al. **J Cell Physiol** 1997 Oct;173(1):36–43

A high level of accumulation of 2-hydroxymuconic 6-semialdehyde from aniline by the transpositional mutant Y-2 of Pseudomonas species AW-2. Aoki K, et al. **Microbiol Res** 1997 Jul;152(2):129–35

Molecular analysis of mxbD and mxbM, a putative sensor-regulator pair required for oxidation of methanol in Methylobacterium extorquens AM1. Springer AL, et al. **Microbiology** 1997 May;143 (Pt 5):1737–44

Reversion rates in a leuB auxotroph of Escherichia coli K-12 correlate with ppGpp levels during exponential growth. Wright BE, et al. **Microbiology** 1997 Mar;143 (Pt 3):847–54

Genetic regulation of the qa gene cluster of Neurospora crassa: induction of qa messenger ribonucleic acid and dependency on qa-1 function. Reinert WR, et al. **Mol Cell Biol** 1981 Sep;1(9):829–35

Genetic complementation of the Saccharomyces cerevisiae leu2 gene by the Escherichia coli leuB gene. Storms RK, et al. **Mol Cell Biol** 1981 Sep;1(9):836–42

Identification and genetic characterization of the Pseudomonas aeruginosa leuB gene encoding 3-isopropylmalate dehydrogenase. Hoang TT, et al. **Mol Gen Genet** 1997 Mar 26;254(2):166–70

Hydroxypyruvate reductase with a carboxy-terminal targeting signal to microbodies is expressed in Arabidopsis. Mano S, et al. **Plant Cell Physiol** 1997 Apr;38(4):449–55

Molecular and biochemical characterization of three anthocyanin synthetic enzymes from Gentiana triflora. Tanaka Y, et al. **Plant Cell Physiol** 1996 Jul;37(5):711–6

Transformation of Arabidopsis thaliana with the codA gene for choline oxidase; accumulation of glycinebetaine and enhanced tolerance to salt and cold stress. Hayashi H, et al. **Plant J** 1997 Jul;12(1):133–42

Changes in the activity and mRNA of cinnamyl alcohol dehydrogenase during tracheary element differentiation in zinnia. Sato Y, et al. **Plant Physiol** 1997 Feb;113(2):425–30

Gene targeting by linear duplex DNA frequently occurs by assimilation of a single strand that is subject to preferential mismatch correction. Leung W, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6851–6

Inheritance, gene expression, and lignin characterization in a mutant pine deficient in cinnamyl alcohol dehydrogenase. MacKay JJ, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8255–60

A mutation at the interface between domains causes rearrangement of domains in 3-isopropylmalate dehydrogenase. Qu C, et al. **Protein Eng** 1997 Jan; 10(1):45–52

Sequence and homology model of 3-isopropylmalate dehydrogenase from the psychrotrophic bacterium Vibrio sp. I5 suggest reasons for thermal instability. Wallon G, et al. **Protein Eng** 1997 Jun;10(6):665–72

ISOLATION & PURIFICATION

Purification and characterization of limonoate dehydrogenase from Rhodococcus fascians. Humanes L, et al. **Appl Environ Microbiol** 1997 Sep;63(9):3385–9

Purification and properties of methyl formate synthase, a mitochondrial alcohol dehydrogenase, participating in formaldehyde oxidation in methylotrophic yeasts. Murdanoto AP, et al. **Appl Environ Microbiol** 1997 May; 63(5):1715–20

Purification, characterization and partial primary structure of morphine 6-dehydrogenase from rabbit liver cytosol. Yamano S, et al. **Arch Biochem Biophys** 1997 May 1; 341(1):81–8

Purification and characterization of D(+)-carnitine dehydrogenase from Agrobacterium sp.—a new enzyme of carnitine metabolism. Hanschmann H, et al. **Biochim Biophys Acta** 1997 Jan 4;1337(1):133–42

Purification and characterization of a novel cytosolic NADP(H)-dependent retinol oxidoreductase from rabbit liver. Huang DY, et al. **Biochim Biophys Acta** 1997 Mar 7;1338(1):47–59

Characterization of hexose oxidase from the red seaweed Chondrus crispus. Groen BW, et al. **Eur J Biochem** 1997 Mar 15;244(3):858–61

Riboflavin 5'-hydroxymethyl oxidation. Molecular cloning, expression, and glycoprotein nature of the 5'-aldehyde-forming enzyme from Schizophyllum commune. Chen H, et al. **J Biol Chem** 1997 Aug 8; 272(32):20077–81

Purification and characterisation of a novel iso-propanol

dehydrogenase from Phytomonas sp. Uttaro AD, et al. **Mol Biochem Parasitol** 1997 Apr;85(2):213–9

Identification of hydroxypyruvate reductase from parsley by peptide sequence comparison after a two-step purification. Julliard JH, et al. **Protein Expr Purif** 1997 Feb;9(1):10–4

METABOLISM

Characterization of a novel murine aldo-keto reductase. Bohren KM, et al. **Adv Exp Med Biol** 1997;414:455–64

Cloning, sequencing, and enzymatic activity of an inducible aldo-keto reductase from Chinese hamster ovary cells. Flynn TG, et al. **Adv Exp Med Biol** 1997;414:521–8

Site-directed mutagenesis of residues in coenzyme-binding domain and active site of mouse lung carbonyl reductase. Nakanishi M, et al. **Adv Exp Med Biol** 1997;414:555–61

Nicotinoprotein alcohol/aldehyde oxidoreductases. Enzymes with bound NAD(P) as cofactor. Piersma SR, et al. **Adv Exp Med Biol** 1997;414:425–34 (29 ref.)

Carbonyl reducing 17 beta-hydroxysteroid dehydrogenase from the filamentous fungus Cochliobolus lunatus. Rižner TL, et al. **Adv Exp Med Biol** 1997;414:569–77

Metabolic inactivation and efflux of daunorubicin as complementary mechanisms in tumor cell resistance. Soldan M, et al. **Adv Exp Med Biol** 1997;414:537–44

An essential cysteine (Cys-227) in human carbonyl reductase is involved in glutathione binding. Tinguely J, et al. **Adv Exp Med Biol** 1997;414:563–8

Purification and properties of methyl formate synthase, a mitochondrial alcohol dehydrogenase, participating in formaldehyde oxidation in methylotrophic yeasts. Murdanoto AP, et al. **Appl Environ Microbiol** 1997 May; 63(5):1715–20

Reversal of the nucleotide specificity of ketol acid reductoisomerase by site-directed mutagenesis identifies the NADPH binding site. Rane MJ, et al. **Arch Biochem Biophys** 1997 Feb 1;338(1):83–9

Sensitivity to pH, product inhibition, and inhibition by NAD+ of 1,3-propanediol dehydrogenase purified from Enterobacter agglomerans CNCM 1210. Barbirato F, et al. **Arch Microbiol** 1997 Aug;168(2):160–3

Reconstitution of the quinoprotein methanol dehydrogenase from inactive Ca(2+)-free enzyme with Ca2+, Sr2+ or Ba2+. Goodwin MG, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):839–42

Characterization of a novel methanol dehydrogenase containing a Ba2+ ion at the active site. Goodwin MG, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):673–9

Effects of psychotropic drugs on aldo-keto reductase activity in rat ovary and adrenal gland. Inazu N, et al. **Biochem Pharmacol** 1996 Nov 22;52(10):1585–91

Involvement of alcohol dehydrogenase, short-chain dehydrogenase/reductase, aldehyde dehydrogenase, and cytochrome P450 in the control of retinoid signaling by activation of retinoic acid synthesis. Duester G. **Biochemistry** 1996 Sep 24;35(38):12221–7 (79 ref.)

Purification and characterization of a novel cytosolic NADP(H)-dependent retinol oxidoreductase from rabbit liver. Huang DY, et al. **Biochim Biophys Acta** 1997 Mar 7;1338(1):47–59

Purification, catalytic properties and thermostability of 3-isopropylmalate dehydrogenase from Escherichia coli. Wallon G, et al. **Biochim Biophys Acta** 1997 Jan 4; 1337(1):105–12

The pathway from GTP to tetrahydrobiopterin: three-dimensional structures of GTP cyclohydrolase I and 6-pyruvoyl tetrahydropterin synthase. Auerbach G, et al. **Biol Chem** 1997 Mar-Apr;378(3-4):185–92 (39 ref.)

Determination of choline dehydrogenase activity along the rat nephron. Miller B, et al. **Biol Chem Hoppe Seyler** 1996 Feb;377(2):129–37

Localization of class I and class IV alcohol dehydrogenases in mouse testis and epididymis: potential retinol dehydrogenases for endogenous retinoic acid synthesis. Deltour L, et al. **Biol Reprod** 1997 Jan;56(1):102–9

Strain-dependent variation in the NADH-dependent diacetyl reductase activities of larger- and alebrewing yeasts. Murphy CA, et al. **Biotechnol Appl Biochem** 1996 Feb;23 (Pt 1):19–22

Tissue localization of threonine oxidation in pigs. Le Floc'h N, et al. **Br J Nutr** 1997 Apr;77(4):593–603

Iterative type II polyketide synthases, cyclases and ketoreductases exhibit context-dependent behavior in the biosynthesis of linear and angular decapolyketides. Meurer G, et al. **Chem Biol** 1997 Jun;4(6):433–43

Characterization of sepiapterin reductase activity from Drosophila melanogaster. Ruiz-Vázquez P, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):131–6

Biochemical characterization of cell specific enzymes in light-exposed rat retinas: oxidative loss of all-trans retinol dehydrogenase activity. Darrow RA, et al. **Curr Eye Res** 1997 Feb;16(2):144–51

Class IV alcohol/retinol dehydrogenase localization in epidermal basal layer: potential site of retinoic acid synthesis during skin development. Haselbeck RJ, et al. **Dev Dyn** 1997 Apr;208(4):447–53

Retinoic acid and alcohol/retinol dehydrogenase in the mouse adrenal gland: a potential endocrine source of retinoic acid during development. Haselbeck RJ, et al. **Endocrinology** 1997 Jul;138(7):3035–41

D-2-hydroxy-4-methylvalerate dehydrogenase from Lactobacillus delbrueckii subsp. bulgaricus. I. Kinetic mechanism and pH dependence of kinetic parameters, coenzyme binding and substrate inhibition. Alvarez JA, et al. **Eur J Biochem** 1997 Feb 15;244(1):203–12

Properties of an NAD(H)-containing methanol dehydrogenase and its activator protein from Bacillus methanolicus. Arfman N, et al. **Eur J Biochem** 1997 Mar 1;244(2):426–33

D-2-hydroxy-4-methylvalerate dehydrogenase from Lactobacillus delbrueckii subsp. bulgaricus. II. Mutagenic analysis of catalytically important residues. Bernard N, et al. **Eur J Biochem** 1997 Feb 15;244(1):213–9

Substrate specificity of chlorophyll(ide) b reductase in etioplasts of barley (Hordeum vulgare L.). Scheumann V, et al. **Eur J Biochem** 1996 Nov 15;242(1):163–70

Re-face stereospecificity at C4 of NAD(P) for alcohol dehydrogenase from Methanogenium organophilum and for (R)-2-hydroxyglutarate dehydrogenase from Acidaminococcus fermentans as determined by 1H-NMR spectroscopy. Berk H, et al. **FEBS Lett** 1996 Dec 9; 399(1-2):92–4

Mercuration of vanillyl-alcohol oxidase from Penicillium simplicissimum generates inactive dimers. Fraaije MW, et al. **FEBS Lett** 1997 Jan 27;402(1):33–5

Effect of excess cadmium ion on the metal binding site of cabbage histidinol dehydrogenase studied by 113Cd-NMR spectroscopy. Kanaori K, et al. **FEBS Lett** 1997 Jul 28; 412(2):301–4

Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase corrects tetrahydrobiopterin deficiency in fibroblasts from hyperphenylalaninemic patients. Thöny B, et al. **Hum Gene Ther** 1996 Aug 20;7(13):1587–93

Differences in environmental temperature, ethanol and sucrose associated with enzyme activity and weight changes in Drosophila melanogaster. Pecsenye K, et al. **Insect Biochem Mol Biol** 1996 Feb;26(2):135–45

Enzymology of oxidation of tropic acid to phenylacetic acid in metabolism of atropine by Pseudomonas sp. strain AT3. Long MT, et al. **J Bacteriol** 1997 Feb;179(4):1044–50

Characterization of acetohexamide reductases purified from rabbit liver, kidney, and heart: structural requirements for substrates and inhibitors. Imamura Y, et al. **J Biochem (Tokyo)** 1997 Apr;121(4):705–10

Substrate recognition of isocitrate dehydrogenase and 3-isopropylmalate dehydrogenase from Thermus thermophilus HB8. Yaoi T, et al. **J Biochem (Tokyo)** 1997 Jan;121(1):77–81

Catalytic mechanism of the oxidative demethylation of 4-(methoxymethyl)phenol by vanillyl-alcohol oxidase. Evidence for formation of a p-quinone methide intermediate. Fraaije MW, et al. **J Biol Chem** 1997 Jul 18; 272(29):18111–6

Characterization of the substrate binding site in rat liver 3alpha-hydroxysteroid/dihydrodiol dehydrogenase. The roles of tryptophans in ligand binding and protein fluorescence. Jez JM, et al. **J Biol Chem** 1996 Nov 22; 271(47):30190–8

Identification and characterization of a stereospecific human enzyme that catalyzes 9-cis-retinol oxidation. A possible role in 9-cis-retinoic acid formation. Mertz JR, et al. **J Biol Chem** 1997 May 2;272(18):11744–9

Switch of coenzyme specificity of mouse lung carbonyl reductase by substitution of threonine 38 with aspartic acid. Nakanishi M, et al. **J Biol Chem** 1997 Jan 24;272(4):2218–22

Conversion of L-lactate oxidase to a long chain alpha-hydroxyacid oxidase by site-directed mutagenesis of alanine 95 to glycine. Yorita K, et al. **J Biol Chem** 1996 Nov 8;271(45):28300–5

Glyoxylate oxidoreductase activity and glyoxylate-like molecules in the motor, somatosensory, cyngulate and olfactory areas of the rat frontoparietal cortex. Histoenzymological and immunohistochemical study. Martínez-Rodríguez R, et al. **J Hirnforsch** 1997;38(1):61–70

Dietary protein and amino acid levels alter threonine dehydrogenase activity in hepatic mitochondria of Gallus domesticus. Davis AJ, et al. **J Nutr** 1997 May;127(5):738–44

Threonine is catabolized by L-threonine 3-dehydrogenase and threonine dehydratase in hepatocytes from domestic cats (Felis domestica). Hammer VA, et al. **J Nutr** 1996 Sep;126(9):2218–26

Inheritance of acetohexamide reductase activities in liver microsomes and cytosol of rats. Imamura Y, et al. **Life Sci** 1996;59(25-26):2201–8

Determination of tetrahydrobiopterin biosynthetic activities by high-performance liquid chromatography with fluorescence detection. Werner ER, et al. **Methods Enzymol** 1997;281:53–61

The effect of the stringent response on mutation rates in Escherichia coli K-12. Wright BE. **Mol Microbiol** 1996 Jan;19(2):213–9

Onchocerca fasciata: enzyme histochemistry and tissue distribution of various dehydrogenases in the adult female worm. Omar MS, et al. **Parasitol Res** 1996;82(1):32–7

Protein transport into higher plant peroxisomes. In vitro import assay provides evidence for receptor involvement. Brickner DG, et al. **Plant Physiol** 1997 Apr;113(4):1213–21

Redesigning secondary structure to invert coenzyme specificity in isopropylmalate dehydrogenase. Chen R, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12171–6

Modified substrate specificity of L-hydroxyisocaproate dehydrogenase derived from structure-based protein engineering. Feil IK, et al. **Protein Eng** 1997 Mar; 10(3):255–62

Acetohexamide reductase activities in liver microsomes and cytosol of cisplatin-treated male rats: cisplatin indirectly modulates the microsomal enzyme activity. Imamura Y, et al. **Res Commun Mol Pathol Pharmacol** 1996 Nov; 94(2):203–10

Abnormal lignin in a loblolly pine mutant. Ralph J, et al. **Science** 1997 Jul 11;277(5323):235–9

PHARMACOLOGY

Metyrapone reductase purified partially from liver microsomes of male rats: the enzyme differs from acetohexamide reductase. Imamura Y, et al. **Res Commun Mol Pathol Pharmacol** 1997 May;96(2):219–26

RADIATION EFFECTS

Time-resolved and steady-state fluorescence measurements of beta-nicotinamide adenine dinucleotide-alcohol dehydrogenase complex during UVA exposure. König K, et al. **J Photochem Photobiol B** 1997 Jan;37(1-2):91–5

ALCOHOL, PROPYL

Rapid clinical evaluation of anosmia. The alcohol sniff test. Davidson TM, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jun;123(6):591–4

ADMINISTRATION & DOSAGE

An evaluation of five protocols for surgical handwashing in relation to skin condition and microbial counts. Pereira LJ, et al. **J Hosp Infect** 1997 May;36(1):49–65

ADVERSE EFFECTS

Allergic contact dermatitis from Steret swab [see comments] Tan BB, et al. **Contact Dermatitis** 1996 Jan;34(1):62–3. Comment in: Contact Dermatitis 1996 Jul;35(1):66.

ANALOGS & DERIVATIVES

Enrichment and isolation of a nitropropanol-metabolizing bacterium from the rumen. Anderson RC, et al. **Appl Environ Microbiol** 1996 Oct;62(10):3885–6

Sensory irritation mechanisms investigated from model compounds: trifluoroethanol, hexafluoroisopropanol and methyl hexafluoroisopropyl ether. Nielsen GD, et al. **Arch Toxicol** 1996;70(6):319–28

Comparison of the toxicity of allyl alcohol, coumarin and menadione in precision-cut rat, guinea-pig, cynomolgus monkey and human liver slices. Price RJ, et al. **Arch Toxicol** 1996;71(1-2):107–11

Independent antioxidant action of vitamins E and C in cultured rat hepatocytes intoxicated with allyl alcohol. Glascott PA Jr, et al. **Biochem Pharmacol** 1996 Oct 25; 52(8):1245–52

Trout liver slices for metabolism and toxicity studies. Singh Y, et al. **Drug Metab Dispos** 1996 Jan;24(1):7–14

Effect of verapamil on allyl alcohol hepatotoxicity. Atzori L, et al. **Drug Metabol Drug Interact** 1996;13(2):87–98

Carcinogenicity of glycidol in F344 rats and B6C3F1 mice. Irwin RD, et al. **J Appl Toxicol** 1996 May-Jun;16(3):201–9

Expression of liver functions following sub-lethal and non-lethal doses of allyl alcohol and acetaminophen in the rat. Tygstrup N, et al. **J Hepatol** 1997 Jul;27(1):156–62

Pharmacological studies of 1-(p-chlorophenyl)propanol and 2-(1-hydroxy-3-butenyl)phenol: two new non-narcotic analgesics designed by molecular connectivity. García-March FJ, et al. **J Pharm Pharmacol** 1997 Jan; 49(1):10–5

Cooperative alpha-helix formation of beta-lactoglobulin and melittin induced by hexafluoroisopropanol. Hirota N, et al. **Protein Sci** 1997 Feb;6(2):416–21

Toxicity of allyl alcohol in primary cultures of freshly isolated and cryopreserved hepatocytes maintained on hydrated collagen gels. Pang JM, et al. **Toxicol Appl Pharmacol** 1997 Jan;142(1):87–94

Bacterial endotoxin enhances the hepatotoxicity of allyl alcohol. Sneed RA, et al. **Toxicol Appl Pharmacol** 1997 May;144(1):77–87

ANALYSIS

Acetone in urine as biological index of occupational exposure to isopropyl alcohol. Ghittori S, et al. **Ind Health** 1996; 34(4):409–14

ANTAGONISTS & INHIBITORS

Stimulated tissue repair prevents lethality in isopropanol-induced potentiation of carbon tetrachloride hepatotoxicity. Rao PS, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):235–44

CHEMICAL SYNTHESIS

Comparative studies on beta-adrenolytic potencies of some new phenoxyaminopropanol derivatives and celiprolol. Mlynárová R, et al. **Pharmazie** 1997 Mar;52(3):234–7

METABOLISM

Metal-catalyzed oxidation of histidine in human growth hormone. Mechanism, isotope effects, and inhibition by a mild denaturing alcohol. Zhao F, et al. **J Biol Chem** 1997

Apr 4;272(14):9019–29

PHARMACOKINETICS

New ways to use biochemical indicators of alcohol abuse to regrant licences in a fairer manner after drunken driving in Germany. Iffland R. **Alcohol Alcohol** 1996 Nov; 31(6):619–20

PHARMACOLOGY

The influence of 2-propanol and acetone on oviposition rate and oviposition site preference for acetic acid and ethanol of Drosophila melanogaster. Eisses KT. **Behav Genet** 1997 May;27(3):171–80

Nutritional value for swine of soybean meal produced by isopropyl alcohol extraction. O'Quinn PR, et al. **J Anim Sci** 1997 Mar;75(3):714–9

[Effectiveness of alcoholic hand disinfectants against methicillin resistant Staphylococcus aureus] Kampf G, et al. **Chirurg** 1997 Mar;68(3):264–8; discussion 269–70 (Eng. Abstr.) **(Ger)**

[Preparation and pharmacologic characteristics of aryloxyaminopropanol derivatives with an assumed cardiovascular effect] Mlynárová R, et al. **Ceska Slov Farm** 1996 Sep;45(5):260–4 (Eng. Abstr.) **(Slo)**

POISONING

[Acute oral poisoning with isopropyl alcohol in alcoholics] Wiernikowski A, et al. **Przegl Lek** 1997;54(6):459–63 (Eng. Abstr.) **(Pol)**

TOXICITY

Isopropanol vapor inhalation oncogenicity study in Fischer 344 rats and CD-1 mice. Burleigh-Flayer H, et al. **Fundam Appl Toxicol** 1997 Apr;36(2):95–111

Isopropanol: summary of TSCA test rule studies and relevance to hazard identification. Kapp RW Jr, et al. **Regul Toxicol Pharmacol** 1996 Jun;23(3):183–92 (54 ref.)

Stimulated tissue repair prevents lethality in isopropanol-induced potentiation of carbon tetrachloride hepatotoxicity. Rao PS, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):235–44

ALCOHOL WITHDRAWAL DELIRIUM

Risk factors for delirium tremens development. Ferguson JA, et al. **J Gen Intern Med** 1996 Jul;11(7):410–4

BLOOD

Elevated tryptophan levels in post-withdrawal alcoholics. Farren CK, et al. **Acta Psychiatr Scand** 1996 Dec; 94(6):465–70

Changes in human plasma nerve growth factor level after chronic alcohol consumption and withdrawal. Aloe L, et al. **Alcohol Clin Exp Res** 1996 May;20(3):462–5

[Postoperative therapy of an alcoholic patient with an unusually high ethanol metabolic rate] Wilkens L, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):120–1 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Blood phosphatidylethanol as a marker of alcohol abuse: levels in alcoholic males during withdrawal. Hansson P, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):108–10

Persistent delirium following cessation of heavy alcohol consumption: diagnostic and treatment implications [clinical conference] Hersh D, et al. **Am J Psychiatry** 1997 Jun;154(6):846–51

Alcohol dementia and alcohol delirium in aged alcoholics. Kasahara H, et al. **Psychiatry Clin Neurosci** 1996 Jun; 50(3):115–23

DRUG THERAPY

Assessment of diazepam loading dose therapy of delirium tremens. Wasilewski D, et al. **Alcohol Alcohol** 1996 May; 31(3):273–8

Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991 [see comments] Litten RZ, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):859–76 (247 ref.). Comment in: Alcohol Clin Exp Res 1997 Apr;21(2):380.

Persistent delirium following cessation of heavy alcohol consumption: diagnostic and treatment implications [clinical conference] Hersh D, et al. **Am J Psychiatry** 1997 Jun;154(6):846–51

Acute colonic pseudoobstruction (Ogilvie's syndrome) in two patients receiving high dose clonidine for delirium tremens. Stieger DS, et al. **Intensive Care Med** 1997 Jul;23(7):780–2

Alcohol withdrawal syndrome [letter] Matz R. **Lancet** 1997 Sep 6;350(9079):737

Clomethiazole treatment of alcohol withdrawal delirium in a patient under methadone maintenance [letter] Gross A, et al. **Pharmacopsychiatry** 1996 Nov;29(6):229–30

[Pharmacopsychiatric guidelines for treatment of alcohol withdrawal syndrome] Schröder-Rosenstock K, et al. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):301–6 (29 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Effects of chronic administration and subsequent withdrawal of ethanol-containing liquid diet on rat liver tryptophan pyrrolase and tryptophan metabolism. Bano S, et al. **Alcohol Alcohol** 1996 Mar;31(2):205–15

GENETICS

The 1996 RSA Distinguished Research Award Lecture. A genetic animal model of alcohol withdrawal. Crabbe JC. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):96A–100A

Correlated responses to selection in FAST and SLOW mice: effects of ethanol on ataxia, temperature, sedation, and withdrawal. Shen EH, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):688–96

Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium. Sander T, et al. **Biol Psychiatry** 1997 Feb 1;41(3):299–304

HISTORY

[Historical study of delirium tremens in Spain in the second half of the 19th century] Conde Lopez VJ, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jan-Feb;24(1):33–48 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Abnormalities of peripheral blood T lymphocytes and natural killer cells in alcoholic hepatitis persist after a 3-month withdrawal period. Laso FJ, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):672–6

METABOLISM

Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium. Sander T, et al. **Biol Psychiatry** 1997 Feb 1;41(3):299–304

AP-1 and Egr DNA-binding activities are increased in rat brain during ethanol withdrawal. Beckmann AM, et al. **J Neurochem** 1997 Jul;69(1):306–14

Bidirectional alterations of GABA(A) receptor subunit peptide levels in rat cortex during chronic ethanol consumption and withdrawal. Devaud LL, et al. **J Neurochem** 1997 Jul;69(1):126–30

Thiamine absorption in alcoholic delirium patients. Holzbach E. **J Stud Alcohol** 1996 Nov;57(6):581–4

MORTALITY

[Fatal post-traumatic alcohol delirium--compensation responsibility in private accident insurance?] Madea B, et al. **Versicherungsmedizin** 1997 Apr 1;49(2):45–7 (Eng. Abstr.) **(Ger)**

[Comment on B. Madea and P. Schmidt: Fatal post-traumatic alcohol delirium--right to compensation in private accident insurance (letter)] Wehking E. **Versicherungsmedizin** 1997 Aug 1;49(4):136–7 **(Ger)**

PATHOLOGY

Glutamate receptors in the frontal cortex of alcoholics. Freund G, et al. **Alcohol Clin Exp Res** 1996 Oct; 20(7):1165–72

PHYSIOPATHOLOGY

ST-segment changes and catecholamine-related myocardial enzyme release during alcohol withdrawal. Denison H, et al. **Alcohol Alcohol** 1997 Mar-Apr;32(2):185–94

Adrenalectomy protects ethanol-withdrawn rats from harmine-induced tremor. Lamblin F, et al. **Alcohol Alcohol** 1996 Mar;31(2):175–81

Prevention by cycloheximide of the audiogenic seizures and tryptophan metabolic disturbances of ethanol withdrawal in rats. Oretti R, et al. **Alcohol Alcohol** 1996 May; 31(3):243–7

Ethanol withdrawal hyperexcitability in vivo and in isolated mouse hippocampal slices. Ripley TL, et al. **Alcohol Alcohol** 1996 Jul;31(4):347–57

No loss of somatostatin-immunoreactive neurons in the hippocampal dentate hilus of alcohol-withdrawal-kindled rats. Ulrichsen J, et al. **Alcohol Alcohol** 1996 Jul;31(4):411–9

Relative kindling effect of readmissions in alcoholics. Worner TM. **Alcohol Alcohol** 1996 Jul;31(4):375–80

The alcohol withdrawal "kindling" phenomenon: clinical and experimental findings. Becker HC. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):121A–124A

Protein kinase C: molecular and cellular targets for the action of ethanol. Pandey SC. **Alcohol Clin Exp Res** 1996 Nov; 20(8 Suppl):67A–71A

Dexmedetomidine, diazepam, and propranolol in the treatment of ethanol withdrawal symptoms in the rat. Riihioja P, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):804–8

Free radical production during ethanol intoxication, dependence, and withdrawal. Vallett M, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):275–85

Effects of dihydropyridines on the components of the ethanol withdrawal syndrome: possible evidence for involvement of potassium, as well as calcium? Watson WP, et al. **Alcohol Clin Exp Res** 1997 May;21(3):409–16

Functional EEG mapping and SPECT in detoxified male alcoholics. Günther W, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(3):128–36

Influence of dopaminergic transmission on severity of withdrawal syndrome in alcoholism. Heinz A, et al. **J Stud Alcohol** 1996 Sep;57(5):471–4

Renal effects of alcohol withdrawal in five-week alcohol-treated rats. Ishigami M, et al. **J Stud Alcohol** 1997 Jul;58(4):392–6

Alteration in dopaminergic function in abstinent alcoholics. Marchesi C, et al. **Neuropsychobiology** 1997;36(1):1–4

Corticosteroids enhance convulsion susceptibility via central mineralocorticoid receptors. Roberts AJ, et al. **Psychoneuroendocrinology** 1995;20(8):891–902 (52 ref.)

PSYCHOLOGY

Impaired binocular depth inversion in patients with alcohol withdrawal. Schneider U, et al. **J Psychiatr Res** 1996 Nov-Dec;30(6):469–74

REHABILITATION

[Dependency outcome of alcohol-dependent patients after inpatient detoxification and motivation treatment] Stetter F, et al. **Nervenarzt** 1997 Jul;68(7):574–81 (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of alcohol withdrawal [letter] Travis CB. **Am Fam Physician** 1997 Feb 15;55(3):786, 788

Emergency management of acute alcohol problems. Part 2: Alcohol-related seizures, delirium tremens, and toxic alcohol ingestion. Etherington JM. **Can Fam Physician** 1996 Dec;42:2423–31 (17 ref.)

[Psychiatric hospitalization for delirium in Israel] Heinik J. **Harefuah** 1996 May 1;130(9):594–8, 655 (Eng. Abstr.) **(Heb)**

URINE

Excretion of beta-carbolines harman and norharman in 24-hour urine of chronic alcoholics during withdrawal and controlled abstinence. Wodarz N, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):706–10

ALCOHOLIC BEVERAGES

Alcohol advertising in France [letter; comment] Dubois G. **Addiction** 1996 Dec;91(12):1870. Comment on: Addiction 1996 Jan;91(1):5–9.

Political and economic influences on alcohol-related science: some considerations [letter] Fillmore KM. **Addiction** 1996 Dec;91(12):1872–5

Preventing sales of alcohol to minors: results from a community trial. Grube JW. **Addiction** 1997 Jun;92 Suppl 2:S251–60

What place for alcoholic beverage container labels? A view from the United States [editorial] Mosher JF. **Addiction** 1997 Jul;92(7):789–92

Alcohol and European transformation. Simpura J. **Addiction** 1997 Mar;92 Suppl 1:S33–S41

Urinary excretion of tetrahydro-beta-carbolines relating to ingestion of alcoholic beverages. Tsuchiya H, et al. **Alcohol Alcohol** 1996 Mar;31(2):197–203

Red wine, white wine, liquor, beer, and risk for coronary artery disease hospitalization. Klatsky AL, et al. **Am J Cardiol** 1997 Aug 15;80(4):416–20

"Flaming Dr. Pepper"--another cause of recreational burn injury [letter] Gear AJ, et al. **Am J Emerg Med** 1997 Jan; 15(1):108–11

Tobacco and alcohol use behaviors portrayed in music videos: a content analysis. DuRant RH, et al. **Am J Public Health** 1997 Jul;87(7):1131–5

An unusual mechanism of burn injury due to flaming drinks. Still J, et al. **Am Surg** 1997 Mar;63(3):252–4

Drinking habit as a base for blood pressure elevation--difference in epidemiological significance by beverage type. Takashima Y, et al. **Appl Human Sci** 1997 Mar;16(2):47–53

Young people, alcohol, and designer drinks. Conventional drinks are a much greater threat to health than designer drinks [letter; comment] Catterson P, et al. **BMJ** 1997 May 31;314(7094):1622–3. Comment on: BMJ 1997 Feb 8;314(7078):414–8.

Designer drinks and drunkenness among schoolchildren. Study left several questions unanswered [letter; comment] Crawford A, et al. **BMJ** 1996 Nov 30;313(7069):1397; discussion 1397–8. Comment on: BMJ 1996 Aug 17;313(7054):401.

Young people, alcohol, and designer drinks: quantitative and qualitative study [see comments] Hughes K, et al. **BMJ** 1997 Feb 8;314(7078):414–8. Comment in: BMJ 1997 May 31;314(7094):1622–3.

Designer drinks and drunkenness among schoolchildren. More "alcopops" have come on marker since study was done [letter; comment] McKibben MA. **BMJ** 1996 Nov 30;313(7069):1397; discussion 1397–8. Comment on: BMJ 1996 Aug 17;313(7054):401.

Validity of self-reported intakes of wine, beer and spirits in population studies. Grønbaek M, et al. **Eur J Clin Nutr** 1996 Jul;50(7):487–90

Alcoholic beverages produced by alcoholic fermentation but not by distillation are powerful stimulants of gastric acid secretion in humans. Teyssen S, et al. **Gut** 1997 Jan;

40(1):49–56
Program: Responsible Alcohol and Tobacco Sales Training (RATS). **Health Educ Q** 1996 Nov;23(4):416–7
Alcohol advertising and violence against women: a media advocacy case study. Woodruff K. **Health Educ Q** 1996 Aug;23(3):330–45
Alcohol cue reactivity, negative-mood reactivity, and relapse in treated alcoholic men. Cooney NL, et al. **J Abnorm Psychol** 1997 May;106(2):243–50
Evaluating the effects of a community coalition's efforts to reduce illegal sales of alcohol and tobacco products to minors. Lewis RK, et al. **J Community Health** 1996 Dec; 21(6):429–36
Red wine is less stress reducing than vodka; no differences in neuroendocrine challenge test. Jarrett N, et al. **J Psychopharmacol (Oxf)** 1997;11(3):283–6
Content analysis of coverage of alcohol control policy issues in black-oriented and mainstream newspapers in the U.S. Jones-Webb R, et al. **J Public Health Policy** 1997; 18(1):49–66
The merchants, not the customers: resisting the alcohol and tobacco industries' strategy to blame young people for illegal alcohol and tobacco sales. Mosher JF. **J Public Health Policy** 1995;16(4):412–32 (47 ref.)
Drinking restraint and alcohol-related outcomes: exploring the contributions of beverage instructions, beverage content and self-monitoring. Collins RL, et al. **J Stud Alcohol** 1996 Sep;57(5):563–71
The visibility and effectiveness of standard drink labelling [letter] Chan MD, et al. **Med J Aust** 1997 Sep 15;167(6):344
Rural Substance Abuse: State of Knowledge and Issues. Proceedings of a meeting. April 26–27, 1994. **NIDA Res Monogr** 1997;168:1–533
Oral intake of sweetened or sweetened alcoholic beverages and open-field behavior. Nadal RA, et al. **Pharmacol Biochem Behav** 1996 Aug;54(4):739–43
Differential perceptions of drinkers of alcoholic beverages by Mexican-Americans and non-Hispanic whites. Marín G, et al. **Subst Use Misuse** 1997 Aug;32(10):1369–84
[Consumption, attitudes and knowledge on compared alcoholic beverages among high school and university students] Cocchioni M, et al. **Ann Ig** 1997 Jan–Feb; 9(1):89–97 **(Ita)**
[Relation between the quantity, type and duration of alcohol drinking and the development of alcoholic liver cirrhosis] Hozo I, et al. **Med Arh** 1995;49(1–2):5–8 (Eng. Abstr.) **(Scr)**
[Outbreak of Salmonella enteritidis food poisoning. Potential protective effect of alcoholic beverages (see comments)] Bellido Blasco JB, et al. **Med Clin (Barc)** 1996 Nov 16; 107(17):641–4 (Eng. Abstr.). Comment in: Med Clin (Barc) 1996 Nov 16;107(17):655–6. **(Spa)**
[Has alcohol any beneficial effect? (editorial; comment)] San Molina L. **Med Clin (Barc)** 1996 Nov 16;107(17):655–6. Comment on: Med Clin (Barc) 1996 Nov 16;107(17):641–4. **(Spa)**

ADVERSE EFFECTS

Health, Society and Alcohol [editorial] Anderson P. **Addiction** 1997 Mar;92 Suppl 1:S3–6
Guidelines on sensible drinking. Anderson P, et al. **Addiction** 1996 Jan;91(1):25–33
Science and the drinks industry: cause for concern [editorial] [see comments] Babor TF, et al. **Addiction** 1996 Jan; 91(1):5–9. Comment in: Addiction 1996 Dec;91(12):1869. Comment in: Addiction 1996 Dec;91(12):1870. Comment in: Addiction 1996 Dec;91(12):1870–1. Comment in: Addiction 1996 Dec;91(12):1871–2. Comment in: Addiction 1996 Dec;91(12):1875–6. Comment in: Addiction 1996 Dec;91(12):1876–7.
How does one write satire in Rome? A reply from the editors [letter] Babor TF, et al. **Addiction** 1996 Dec;91(12):1877–9
"Good guys" versus "bad guys" in scientific inquiry [letter; comment] Chafetz ME. **Addiction** 1996 Dec;91(12):1875–6 . Comment on: Addiction 1996 Jan;91(1):5–9.
The drinks industry dilemma [letter; comment] Hawks D. **Addiction** 1996 Dec;91(12):1869. Comment on: Addiction 1996 Jan;91(1):5–9.
Liquorspeak and the developing world [letter; comment] Laranjeira R. **Addiction** 1996 Dec;91(12):1870–1. Comment on: Addiction 1996 Jan;91(1):5–9.
The drinks industry and alcohol research [letter; comment] Mosher JF. **Addiction** 1996 Dec;91(12):1871–2. Comment on: Addiction 1996 Jan;91(1):5–9.
From research to policy: when cutting edge meets coalface. Richmond R. **Addiction** 1996 Jan;91(1):35–7
A personal note from a retiring president [letter; comment] Turner TB. **Addiction** 1996 Dec;91(12):1876–7. Comment on: Addiction 1996 Jan;91(1):5–9.
Medical consequences of alcohol consumption—United States, 1992. Chou SP, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1423–9
Has awareness of the alcohol warning label reached its upper limit? Hankin JR, et al. **Alcohol Clin Exp Res** 1996 May; 20(3):440–4
Pharmacotherapy debate on alcohol withdrawal syndrome [letter; comment] Gawthrop P. **Can Fam Physician** 1997 Jul;43:1209, 1211–2. Comment on: Can Fam Physician 1997 Mar;43:421–4.
Changes in reported awareness of product warning labels and messages in cohorts of California Hispanics and non-Hispanic whites. Marín G, et al. **Health Educ Behav** 1997 Apr;24(2):230–44
Lichenoid dermatitis after consumption of gold-containing liquor. Russell MA, et al. **J Am Acad Dermatol** 1997 May; 36(5 Pt 2):841–4
Effects of alcohol on energy metabolism and body weight regulation: is alcohol a risk factor for obesity? Suter PM, et al. **Nutr Rev** 1997 May;55(5):157–71 (179 ref.)
Human sperm morphometry and smoking, caffeine, and alcohol consumption. Vine MF, et al. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):179–84
[Pseudo-allergies are due to histamine intolerance] Götz M. **Wien Med Wochenschr** 1996;146(15):426–30 (27 ref.) (Eng. Abstr.) **(Ger)**

ANALYSIS

Effect of ethanol in Ice Drops on breath alcohol concentration [letter] Williams RD. **J Anal Toxicol** 1996 Jul–Aug;20(4):271
Polycyclic aromatic hydrocarbons in whiskies [letter] Kleinjans JC, et al. **Lancet** 1996 Dec 21–28;348(9043):1731
Cadmium levels in wine, beer and other alcoholic beverages: possible sources of contamination. Mena C, et al. **Sci Total Environ** 1996 Mar 29;181(3):201–8

CLASSIFICATION

Drinking practices and risk of squamous-cell esophageal cancer among Black and White men in the United States. Brown LM, et al. **Cancer Causes Control** 1997 Jul; 8(4):605–9

ECONOMICS

Altering alcohol price by ethanol content: results from a Swedish tax policy in 1992. Ponicki W, et al. **Addiction** 1997 Jul;92(7):859–70
Regulating unregulated markets. Swiątkiewicz G. **Addiction** 1997 Mar;92 Suppl 1:S67–71
Trends in alcohol production, trade and consumption. Walsh B. **Addiction** 1997 Mar;92 Suppl 1:S61–6

HISTORY

American Indian and Alaska native aboriginal use of alcohol in the United States. Abbott PJ. **Am Indian Alsk Native Ment Health Res** 1996;7(2):1–13
Sylvius and the corner saloon. Aronson SM. **Med Health R I** 1997 Jul;80(7):215–6
Alcohol in American History. Musto DF. **Sci Am** 1996 Apr; 274(4):78–83

POISONING

[Lead poisoning associated with brandy consumption (letter)] Criado Alvarez JJ, et al. **Rev Clin Esp** 1997 Jun; 197(6):466–7 **(Spa)**

SUPPLY & DISTRIBUTION

Access to alcohol from licensed premises during adolescence: a longitudinal study. Casswell S, et al. **Addiction** 1997 Jun; 92(6):737–45
The effects of physical attractiveness on gaining access to alcohol: when social policy meets social decision making. McCall M. **Addiction** 1997 May;92(5):597–600
Use of spatial models for community program evaluation of changes in alcohol outlet distribution. Millar AB, et al. **Addiction** 1997 Jun;92 Suppl 2:S273–83
Community prevention and alcohol retail access. Reynolds RI, et al. **Addiction** 1997 Jun;92 Suppl 2:S261–72
A community-wide Responsible Beverage Service program in three communities: early findings. Saltz RF, et al. **Addiction** 1997 Jun;92 Suppl 2:S237–49
Alcohol availability and motor vehicle fatalities. Kelleher KJ, et al. **J Adolesc Health** 1996 Nov;19(5):325–30
Alcohol availability and motor vehicle fatalities [letter] Tonkin RS. **J Adolesc Health** 1997 Aug;21(2):74–5
Procurement of alcohol and underage drinking among adolescents in Ontario. Smart RG, et al. **J Stud Alcohol** 1996 Jul;57(4):419–24
Characteristics, policies and practices of alcohol outlets and sales to underage persons. Wolfson M, et al. **J Stud Alcohol** 1996 Nov;57(6):670–4
The use of alcohol home delivery services by male problem drinkers: a preliminary report. Fletcher LA, et al. **J Subst Abuse** 1996;8(2):251–61
Relationships among alcohol availability, drinking location, alcohol consumption, and drinking problems in adolescents. Jones-Webb R, et al. **Subst Use Misuse** 1997 Aug; 32(10):1261–85
Why and in what context adolescents obtain alcohol from adults: a pilot study. Jones-Webb R, et al. **Subst Use Misuse** 1997 Jan;32(2):219–28

TOXICITY

Action of ethanol and some alcoholic beverages on gastric acid secretion in anaesthetized rats. Teyssen S, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):23–31
Synaptonemal complex damage in mouse spermatocytes exposed to tequila and brandy. Piña-Calva A, et al. **Cancer Detect Prev** 1997;21(2):196–200

ALCOHOLIC CARDIOMYOPATHY see **CARDIOMYOPATHY, ALCOHOLIC**

ALCOHOLIC CIRRHOSIS see **LIVER CIRRHOSIS, ALCOHOLIC**

ALCOHOLIC FATTY LIVER see **FATTY LIVER, ALCOHOLIC**

ALCOHOLIC HEPATITIS see **HEPATITIS, ALCOHOLIC**

ALCOHOLIC INTOXICATION

Alcohol, drug intoxication, or both at the time of burn injury as a predictor of complications and mortality in hospitalized patients with burns. Grobmyer SR, et al. **J Burn Care Rehabil** 1996 Nov–Dec;17(6 Pt 1):532–9
Alcohol-related measures as factors in traffic fatalities. Mann RE, et al. **J Stud Alcohol** 1996 Nov;57(6):646–51
Prevalence of alcohol-impaired driving. Results from a national self-reported survey of health behaviors [see comments] Liu S, et al. **JAMA** 1997 Jan 8;277(2):122–5. Comment in: JAMA 1997 Apr 23–30;277(16):1279; discussion 1280. Comment in: JAMA 1997 Apr 23–30;277(16);1279–80; discussion 1280.
Alcohol-impaired driving: the family's tragedy and the public's health [letter; comment] Robberstad MK. **JAMA** 1997 Apr 23–30;277(16):1279–80; discussion 1280. Comment on: JAMA 1997 Jan 8;277(2):122–5.
Alcohol-impaired driving: the family's tragedy and the public's health [letter; comment] Templeton B. **JAMA** 1997 Apr 23–30;277(16):1279; discussion 1280. Comment on: JAMA 1997 Jan 8;277(2):122–5.
Alcohol intoxication and homicide. Artigues M, et al. **Med Law** 1996;15(3):485–91
Sentencing diversion programs for A&D—improving their imperiled future. Solursh LP, et al. **Med Law** 1996; 15(2):325–8
Drink driving legislation. Letter from Drs. Stark and Rogers [letter] Green PG. **Med Leg J** 1996;64 (Pt 1):43
Rural Substance Abuse: State of Knowledge and Issues. Proceedings of a meeting. April 26–27, 1994. **NIDA Res Monogr** 1997;168:1–533
Injured pedestrians in Cape Town—the role of alcohol. Peden MM, et al. **S Afr Med J** 1996 Sep;86(9):1103–5

BLOOD

Estimating blood alcohol level from observable signs. McKnight AJ, et al. **Accid Anal Prev** 1997 Mar; 29(2):247–55
The distribution of fatty acid ethyl esters among lipoproteins and albumin in human serum. Bird DA, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):602–5
Estrogen-related acetaldehyde elevation in women during alcohol intoxication. Eriksson CJ, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1192–5
Predictive value of MCV for hazardous drinking in the community. Peach HG, et al. **Clin Lab Haematol** 1997 Jun; 19(2):85–7
Human monocyte IL-10 production is increased by acute ethanol treatment. Mandrekar P, et al. **Cytokine** 1996 Jul; 8(7):567–77
Serum and intracellular magnesium concentrations in intoxicated chronic alcoholic and control subjects. Princi T, et al. **Drug Alcohol Depend** 1997 Jun 6;46(1–2):119–22
Dilution of blood collected for medicolegal alcohol analysis by intravenous fluids. Riley D, et al. **J Anal Toxicol** 1996 Sep;20(5):330–1
Validation of a measure of excessive drinking: frequency per year that BAL exceeds 0.08%. Conrod PJ, et al. **Subst Use Misuse** 1997 Apr;32(5):587–607

COMPLICATIONS

Alcoholic ketoacidosis presenting with extreme hypoglycemia. Marinella MA. **Am J Emerg Med** 1997 May; 15(3):280–1
Hangovers [editorial] [published erratum appears in BMJ 1997 Feb 15;314(7079):460] Calder I. **BMJ** 1997 Jan 4; 314(7073):2–3
Frequent hangovers and cardiovascular mortality in middle-aged men. Kauhanen J, et al. **Epidemiology** 1997 May;8(3):310–4
Exacerbation of ethanol withdrawal seizures in mice with a history of multiple withdrawal experience. Becker HC, et al. **Pharmacol Biochem Behav** 1997 May–Jun; 57(1–2):179–83
Alcohol level at head injury and subsequent psychotropic treatment during trauma critical care. Chatham-Showalter PE, et al. **Psychosomatics** 1996 May–Jun;37(3):285–8
[Tubular necrosis after non-steroidal anti-inflammatory agents and acute alcoholic intoxication] Galzin M, et al. **Nephrologie** 1997;18(3):113–5 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Diagnosing ethanol toxicity [letter; comment] Watson WA, et al. **Acad Emerg Med** 1996 Jul;3(7):728–9. Comment on: Acad Emerg Med 1996 Jan;3(1):85–7.
The validity of police assessment of driver intoxication in motor vehicle crashes leading to hospitalization. Grossman DC, et al. **Accid Anal Prev** 1996 Jul;28(4):435–42
Gender and alcohol dosing: a procedure for producing comparable breath alcohol curves for men and women. Breslin FC, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):928–30

The relationship between alcohol symptoms and consumption among older drinkers. Chermack ST, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1153–8

A PC–based software test for measuring alcohol and drug effects in human subjects. Mills KC, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1582–91

Variability of the blood/breath alcohol ratio in drinking drivers. Jones AW, et al. **J Forensic Sci** 1996 Nov; 41(6):916–21

Alcohol level at head injury and subsequent psychotropic treatment during trauma critical care. Chatham–Showalter PE, et al. **Psychosomatics** 1996 May–Jun;37(3):285–8

[Discrepancies between police breath alcohol measurements in a field trial and blood alcohol concentration according to BGA guidelines and possible consequences for citizens] Schütz H, et al. **Arch Kriminol** 1997 Mar–Apr; 199(3–4):103–8 (Eng. Abstr.) **(Ger)**

[The German promille law—overview and guideline for legal traffic applications] Grohmann P. **Blutalkohol** 1996 Jul; 33(4):177–200 (Eng. Abstr.) **(Ger)**

[Intoxication or psychosis? Expert assessment of a crime] Schröter A. **Psychiatr Prax** 1997 Jan;24(1):43–4 **(Ger)**

DRUG THERAPY

Ondansetron alters human alcohol intoxication. Swift RM, et al. **Biol Psychiatry** 1996 Sep 15;40(6):514–21

Effects of Metadoxine on cellular status of glutathione and of enzymatic defence system following acute ethanol intoxication in rats. Calabrese V, et al. **Drugs Exp Clin Res** 1996;22(1):17–24

[The effect of lithium oxybutyrate on the development of the fetus and progeny in alcoholic intoxication of male rats] Nemova EP, et al. **Eksp Klin Farmakol** 1996 Nov–Dec; 59(6):48–50 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

The frequency of unsuspected minor illness or injury in intoxicated patients. Biros MH. **Acad Emerg Med** 1996 Sep; 3(9):853–8

Alcohol abuse/dependence in motor vehicle crash victims presenting to the emergency department. Maio RF, et al. **Acad Emerg Med** 1997 Apr;4(4):256–62

Alcohol–related predictors of adolescent driving: gender differences in crashes and offenses. Shope JT, et al. **Accid Anal Prev** 1996 Nov;28(6):755–64

Overview of studies on drinking patterns and consequences. Bondy SJ. **Addiction** 1996 Nov;91(11):1663–74 (95 ref.)

Teenagers and alcohol misuse in the United States: by any definition, it's a big problem. Ellickson PL, et al. **Addiction** 1996 Oct;91(10):1489–503

Drinking and driving: drinking patterns and drinking problems. Gruenewald PJ, et al. **Addiction** 1996 Nov; 91(11):1637–49

Alcohol use and a safe environment. Holder HD. **Addiction** 1997 Mar;92 Suppl 1:S117–20

The New Zealand Rugby Injury and Performance Project: alcohol use patterns within a cohort of rugby players. Quarrie KL, et al. **Addiction** 1996 Dec;91(12):1865–8

Validity of self–reported criminal offences and traffic violations in screening of driving–while–intoxicated offenders. Chang I, et al. **Alcohol Alcohol** 1996 Nov; 31(6):583–90

Identifying hazardous or harmful alcohol use in medical admissions: a comparison of audit, cage and brief mast. MacKenzie D, et al. **Alcohol Alcohol** 1996 Nov;31(6):591–9

Factors in childhood and youth predicting alcohol dependence and abuse in Swedish women: findings from a general population study. Spak L, et al. **Alcohol Alcohol** 1997 May–Jun;32(3):267–74

Drinking patterns and problems and drinking in the event: an analysis of injury by cause among casualty patients. Cherpitel CJ. **Alcohol Clin Exp Res** 1996 Sep;20(6):1130–7

Application of decision theory to DUI assessment. Leshowitz B, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1148–52

A comparative analysis of alcohol in fatal and nonfatal bicycling injuries. Li G, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1553–9

Alcohol, central nervous system injury, and time to death in fatal motor vehicle crashes. Zink BJ, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1518–22

Ecological analysis of collectivity of alcohol consumption in England: importance of average drinker [see comments] Colhoun H, et al. **BMJ** 1997 Apr 19;314(7088):1164–8. Comment in: BMJ 1997 Apr 19;314(7088):1142–3.

Alcohol and injuries resulting from violence: a comparison of emergency room samples from two regions of the U.S. Cherpitel CJ. **J Addict Dis** 1997;16(1):25–40

Prevalence and effectiveness of self–regulatory techniques used to avoid drunk driving. Brown SL. **J Behav Med** 1997 Feb;20(1):55–66

The relationship of drinking and hangovers to workplace problems: an empirical study. Ames GM, et al. **J Stud Alcohol** 1997 Jan;58(1):37–47

Suicide attempts and alcohol consumption in an emergency room sample. Borges G, et al. **J Stud Alcohol** 1996 Sep; 57(5):543–8

Alcohol and injury: a comparison of three emergency room samples in two regions. Cherpitel CJ. **J Stud Alcohol** 1997 May;58(3):323–31

The contribution of drinking patterns to the relative risk of injury in six communities: a self–report based probability approach. Treno AJ, et al. **J Stud Alcohol** 1997 Jul; 58(4):372–81

Chronic drinking, binge drinking and drunk driving. Duncan DF. **Psychol Rep** 1997 Apr;80(2):681–2

Alcohol and violence–related injuries in the emergency room. Cherpitel CJ. **Recent Dev Alcohol** 1997;13:105–18 (51 ref.)

Alcohol and cocaine interactions and aggressive behaviors. Denison ME, et al. **Recent Dev Alcohol** 1997;13:283–303 (31 ref.)

Is there a causal relationship between alcohol use and violence? A synthesis of evidence. Lipsey MW, et al. **Recent Dev Alcohol** 1997;13:245–82 (84 ref.)

The relationship of alcohol to injury in assault cases. Martin SE, et al. **Recent Dev Alcohol** 1997;13:41–56

Longitudinal perspective on alcohol use and aggression during adolescence. White HR. **Recent Dev Alcohol** 1997; 13:81–103 (82 ref.)

Correlates of change in adolescent alcohol consumption in Ireland: implications for understanding influences and enhancing interventions. Morgan M, et al. **Subst Use Misuse** 1997 Apr;32(5):609–19

Expectancies for driving under the influence of alcohol among Hispanics and non–Hispanic Whites. Posner SF, et al. **Subst Use Misuse** 1996 Mar;31(4):409–21

[Alcohol, street drugs and therapeutic drugs in street traffic] Schöch H. **Fortschr Med** 1997 Mar 10;115(7):39–42 (Eng. Abstr.) **(Ger)**

ETHNOLOGY

Alcohol expectancies in a Native American population. Garcia–Andrade C, et al. **Alcohol Clin Exp Res** 1996 Nov; 20(8):1438–42

Purim syncope [letter] Kohn M, et al. **J Adolesc Health** 1996 Apr;18(4):245

Alcohol and spouse abuse ethnic differences. Kantor GK. **Recent Dev Alcohol** 1997;13:57–79 (88 ref.)

ETIOLOGY

The firewater myth and response to alcohol in Mission Indians. Garcia–Andrade C, et al. **Am J Psychiatry** 1997 Jul;154(7):983–8

GENETICS

Alcohol challenges in young men from alcoholic pedigrees and control families: a report from the COGA project. Schuckit MA, et al. **J Stud Alcohol** 1996 Jul;57(4):368–77

HISTORY

The life and work of Erik M. P. Widmark. Andréasson R, et al. **Am J Forensic Med Pathol** 1996 Sep;17(3):177–90

The rules of drug taking: wine and poppy derivatives in the ancient world. III. Wine as an instrument of aggressive behavior and of ritual madness. Nencini P. **Subst Use Misuse** 1997 Feb;32(3):361–7

The rules of drug taking: wine and poppy derivatives in the ancient world. II. Wine–induced loss of control and vigilance. Nencini P. **Subst Use Misuse** 1997 Jan; 32(2):211–7

The rules of drug taking: wine and poppy derivatives in the ancient world. V. Sobriety or postponement of drunkenness? Nencini P. **Subst Use Misuse** 1997 Apr; 32(5):629–33

IMMUNOLOGY

Cross–tolerance between acute alcohol intoxication and endotoxemia. Bautista AP, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1395–400

Gender differences in phagocytic responses in the blood and liver, and the generation of cytokine–induced neutrophil chemoattractant in the liver of acutely ethanol–intoxicated rats. Spitzer JA, et al. **Alcohol Clin Exp Res** 1996 Aug; 20(5):914–20

Regulation of human monocyte functions by acute ethanol treatment: decreased tumor necrosis factor–alpha, interleukin–1 beta and elevated interleukin–10, and transforming growth factor–beta production. Szabo G, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):900–7

Acute ethanol intoxication suppresses the pulmonary inflammatory response in rats challenged with intrapulmonary endotoxin. Zhang P, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):773–8

Acute ethanol administration modulates leukocyte actin polymerization in endotoxic rats. Zhang P, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):779–83

METABOLISM

Liver and serum antioxidant status after methanol intoxication in rats. Skrzydlewska E, et al. **Acta Biochim Pol** 1997;44(1):139–45

Pharmacodynamic response to Ro15–4513 in ethanol intoxicated dogs. Whitmire D, et al. **Drug Metabol Drug Interact** 1996;13(2):99–109

The kinetics of methanol elimination in alcoholics and the influence of ethanol. Haffner HT, et al. **Forensic Sci Int** 1997 Sep 19;89(1–2):129–36

MORTALITY

Natural disease and alcohol intoxication amongst drivers of motor vehicles in Singapore from 1989 to 1993: a study of 140 necropsies. Lau G. **Ann Acad Med Singapore** 1996 Jul;25(4):516–21

Alcohol and drugs in suicides [see comments] Ohberg A, et al. **Br J Psychiatry** 1996 Jul;169(1):75–80. Comment in: Br J Psychiatry 1996 Oct;169(4):526.

[Geographic variability of alcohol–related mortality in Italy in the period 1980–1990] Cipriani F, et al. **Epidemiol Prev** 1996 Oct–Dec;20(4):328–38 (Eng. Abstr.) **(Ita)**

PATHOLOGY

Postbinge effects of acute alcohol intoxication on hepatic free radical formation. Bautista AP, et al. **Alcohol Clin Exp Res** 1996 May;20(3):502–9

PHYSIOPATHOLOGY

The effect of drink familiarity on tolerance to alcohol. Remington B, et al. **Addict Behav** 1997 Jan–Feb;22(1):45–53

Comparison between subjective feelings to alcohol and nitrogen narcosis: a pilot study. Monteiro MG, et al. **Alcohol** 1996 Jan–Feb;13(1):75–8

Acetylcholinesterase and choline uptake in striatum from rats with varying sleeping times. Chumakova OV, et al. **Alcohol Alcohol** 1996 Mar;31(2):217–20

Development and application of a physiologically based pharmacokinetic model for ethanol in the mouse. Pastino GM, et al. **Alcohol Alcohol** 1996 Jul;31(4):365–74

Effect of dorsal raphe injections of the GABAA agonist, muscimol, on ethanol intake and measures of intoxication in Wistar rats. Tomkins DM, et al. **Alcohol Alcohol Suppl** 1994;2:551–8

Ethanol inhibits single–unit responses in the nucleus accumbens evoked by stimulation of the basolateral nucleus of the amygdala. Criado JR, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):368–74

Free radical formation in livers of rats treated acutely and chronically with alcohol. Reinke LA, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):642–6

Ethanol and polyamine metabolism: physiologic and pathologic implications: a review. Sessa A, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):318–25 (121 ref.)

Free radical production during ethanol intoxication, dependence, and withdrawal. Vallett M, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):275–85

Acute ethanol effects on focal cerebral ischemia in nonfasted rats. Zhao YJ, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):745–8

Binge ethanol–induced brain damage in rats: effect of inhibitors of nitric oxide synthase. Zou JY, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1406–11

Effect of ethanol, haloperidol, and lorazepam on cardiac conduction and contraction. Medlin RP Jr, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):792–8

Influence of age, gender, and blood–alcohol concentration on the disappearance rate of alcohol from blood in drinking drivers. Jones AW, et al. **J Forensic Sci** 1996 Nov; 41(6):922–6

Paradoxical effects of acute ethanolism in experimental brain injury. Kelly DF, et al. **J Neurosurg** 1997 May;86(5):876–82

Fatigue, alcohol and performance impairment [letter] Dawson D, et al. **Nature** 1997 Jul 17;388(6639):235

Serotonergic ethanol effects and auditory evoked dipole activity in alcoholic and healthy subjects. Hegerl U, et al. **Psychiatry Res** 1996 Jun 26;63(1):47–55

A nonhuman primate model of excessive alcohol intake. Personality and neurobiological parallels of type I– and type II–like alcoholism. Higley JD, et al. **Recent Dev Alcohol** 1997;13:191–219 (177 ref.)

Decreased antioxidant status and increased lipid peroxidation in rats after methanol intoxication. Skrzydlewska E. **Rocz Akad Med Bialymst** 1996;41(2):397–404

[Visual evoked potentials in low blood alcohol concentrations] Behrendt S, et al. **Ophthalmologe** 1996 Aug; 93(4):367–70 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Are lower legal blood alcohol limits and a combination of sanctions desirable in reducing drunken driver–involved traffic fatalities and traffic accidents? Deshapriya EB, et al. **Accid Anal Prev** 1996 Nov;28(6):721–31 (37 ref.)

What do Israeli Jewish and Arab adolescents know about drinking and driving? Weiss S. **Accid Anal Prev** 1996 Nov; 28(6):765–9

Alcohol misuse prevention for young people: a systematic review reveals methodological concerns and lack of reliable evidence of effectiveness. Foxcroft DR, et al. **Addiction** 1997 May;92(5):531–7 (45 ref.)

A community–wide Responsible Beverage Service program in three communities: early findings. Saltz RF, et al. **Addiction** 1997 Jun;92 Suppl 2:S237–49

Moderating binge drinking: it is possible to change behaviour if you plan it in advance. Murgraff V, et al. **Alcohol Alcohol** 1996 Nov;31(6):577–82

Policy improvements for prevention of alcohol misuse by airline pilots. McFadden KL. **Hum Factors** 1997 Mar; 39(1):1–8

Employee attitudes toward work–site alcohol testing. Howland J, et al. **J Occup Environ Med** 1996 Oct; 38(10):1041–6

Incentives for general practitioners to provide brief

interventions for alcohol problems. Adams PJ, et al. **N Z Med J** 1997 Aug 8;110(1049):291–4

Ready for the road. Schmitt D. **Occup Health Saf** 1996 Mar; 65(3):51–4

[Evaluation of a health education program for preventing alcohol and tobacco abuse in a health unit in Lombardi, Italy] Donato F, et al. **Epidemiol Prev** 1996 Jan–Mar; 20(1):24–30 (Eng. Abstr.) **(Ita)**

PSYCHOLOGY

Expectancies for drinking and excessive drinking among Mexican Americans and non–Hispanic whites. Marín G. Addict **Behav** 1996 Jul–Aug;21(4):491–507

The effect of drink familiarity on tolerance to alcohol. Remington B, et al. **Addict Behav** 1997 Jan–Feb;22(1):45–53

A longitudinal study of social, psychological and behavioural factors associated with drunken driving and public drunkenness. Karlsson G, et al. **Addiction** 1997 Apr; 92(4):447–57

Ontogenetic differences in the expression of olfactory–conditioned aversions resulting from a state of acute alcohol intoxication in the rat. Lopez MF, et al. **Alcohol** 1996 Sep–Oct;13(5):473–81

Behavioral deficits induced by bingelike exposure to alcohol in neonatal rats: importance of developmental timing and number of episodes. Thomas JD, et al. **Dev Psychobiol** 1996 Jul;29(5):433–52

Effects of alcohol intoxication on the perceived consequences of risk taking. Fromme K, et al. **Exp Clin Psychopharmacol** 1997 Feb;5(1):14–23

Differences in sexual risk–taking behavior with state of inebriation in an aboriginal population in Ontario, Canada. Myers T, et al. **J Stud Alcohol** 1997 May;58(3):312–22

Two varieties of helping in drunk–driving intervention: personal and situational factors. Newcomb MD, et al. **J Stud Alcohol** 1997 Mar;58(2):191–9

The relationship between Self–Rating of the Effects of alcohol and alcohol challenge results in ninety–eight young men. Schuckit MA, et al. **J Stud Alcohol** 1997 Jul; 58(4):397–404

Alcoholics' perceptions of cues to intoxication. Burroughs WJ, et al. **J Subst Abuse** 1996;8(4):471–7

Visuospatial information processing in intoxicated, recently detoxified, and long–term abstinent alcoholics. Schandler SL, et al. **J Subst Abuse** 1996;8(3):321–33

"About last night": the social ecology of sexual behavior relative to alcohol use among adolescents and young adults in substance abuse treatment. Tubman JG, et al. **J Subst Abuse** 1995;7(4):449–61

Spatial learning in rats exposed to acute ethanol intoxication on gestational day 8. Minetti A, et al. **Pharmacol Biochem Behav** 1996 Feb;53(2):361–7

Substance use during sex and unsafe sexual behaviors among acute psychiatric inpatients. Menon AS, et al. **Psychiatr Serv** 1997 Aug;48(8):1070–2

Attribution of responsibility for alcohol–related offenses. Kelly KT, et al. **Psychol Rep** 1997 Jun;80(3 Pt 2):1159–65

Effects of alcohol on human aggression. Validity of proposed explanations. Bushman BJ. **Recent Dev Alcohol** 1997; 13:227–43

When women are under the influence. Does drinking or drug use by women provoke beatings by men? Kantor GK, et al. **Recent Dev Alcohol** 1997;13:315–36 (91 ref.)

Sober adolescence––predictor of psychosocial maladjustment in young adulthood? Pape H, et al. **Scand J Psychol** 1996 Dec;37(4):362–77

[Discussion on the figure–description in the author's case with "acute alcoholic scenic complex hallucination"––against the criticism of HENRY Ey in his "Traité des hallucinations"] Konuma M. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Jun; 31(3):226–34 (Eng. Abstr.) **(Jpn)**

[Legal approaches to the forensic psychiatric expertise of persons who have committed socially dangerous actions in a state of intoxication with alcohol and other psychoactive substances] Igonin AL, et al. **Sud Med Ekspert** 1997 Jul–Sep;40(3):35–8 **(Rus)**

REHABILITATION

[Conservative management of alcohol intoxicated patients] Kaden M. **Fortschr Med** 1997 Feb 28;115(6):54–7 **(Ger)**

THERAPY

Alcohol use and medical care utilization among health maintenance organization patients in the emergency department [see comments] Cherpitel CJ, et al. **Acad Emerg Med** 1996 Feb;3(2):106–13. Comment in: Acad Emerg Med 1996 Feb;3(2):95–7.

Emergency management of acute alcohol problems. Part 2: Alcohol–related seizures, delirium tremens, and toxic alcohol ingestion. Etherington JM. **Can Fam Physician** 1996 Dec;42:2423–31 (17 ref.)

Practical guidelines for performing alcohol interventions in trauma centers. Dunn CW, et al. **J Trauma** 1997 Feb; 42(2):299–304

URINE

Urinary 5–hydroxytryptophol following acute ethanol consumption: clinical evaluation and potential aviation applications. Hagan RL, et al. **Aviat Space Environ Med** 1997 Jan;68(1):30–4

ALCOHOLIC LIVER DISEASES see **LIVER DISEASES, ALCOHOLIC**

ALCOHOLIC PANCREATITIS see **PANCREATITIS, ALCOHOLIC**

ALCOHOLICS ANONYMOUS

Predictors of adolescent A. A. affiliation. Hohman M, et al. **Adolescence** 1996 Summer;31(122):339–52

Voice of the afflicted. Erickson CK. **Alcohol Clin Exp Res** 1996 Aug;20(5):877

Occupational meanings and spirituality: the quest for sobriety. Moyers PA. **Am J Occup Ther** 1997 Mar;51(3):207–14

A comparative outcome study of frequent, moderate, occasional, and nonattenders of Alcoholics Anonymous. Watson CG, et al. **J Clin Psychol** 1997 Apr;53(3):209–14

Help–seeking for alcohol–related problems: social contexts surrounding entry into alcoholism treatment or Alcoholics Anonymous. George AA, et al. **J Stud Alcohol** 1996 Jul; 57(4):449–57

Issues in the implementation of a randomized clinical trial that includes Alcoholics Anonymous: studying AA–related behaviors during treatment. McCrady BS, et al. **J Stud Alcohol** 1996 Nov;57(6):604–12

Alcohol–related measures as factors in traffic fatalities. Mann RE, et al. **J Stud Alcohol** 1996 Nov;57(6):646–51

Modeling therapeutic response to 12–step treatment: optimal responders, nonresponders, and partial responders. Morgenstern J, et al. **J Subst Abuse** 1996;8(1):45–59

Life stories and shared experience. Steffen V. **Soc Sci Med** 1997 Jul;45(1):99–111

Recovery: with and without self–help. Godlaski TM, et al. **Subst Use Misuse** 1997 Apr;32(5):621–7

ECONOMICS

Reduced substance–abuse–related health care costs among voluntary participants in Alcoholics Anonymous. Humphreys K, et al. **Psychiatr Serv** 1996 Jul;47(7):709–13

ALCOHOLISM

see related
ALCOHOL DETERRENTS
ALCOHOLICS ANONYMOUS
FETAL ALCOHOL SYNDROME
PSYCHOSES, ALCOHOLIC
TEMPERANCE

Alcohol use and the emergency department: lessons in heterogeneity and homogeneity [editorial; comment] Zink BJ. **Acad Emerg Med** 1996 Feb;3(2):95–7. Comment on: Acad Emerg Med 1996 Feb;3(2):106–13.

Paediatric and ophthalmologic observations in offspring of alcohol abusing mothers. Strömland K, et al. **Acta Paediatr** 1996 Dec;85(12):1463–8

The substance use–delinquency nexus. Adlaf E, et al. **Addiction** 1996 Apr;91(4):504–6

Explaining the link between problem drinking and delinquency. Farrington DP. **Addiction** 1996 Apr; 91(4):498–500

Alcohol misuse and juvenile offending in adolescence: a response to the commentaries. Fergusson DM, et al. **Addiction** 1996 Apr;91(4):506–10

'Unraveling juvenile delinquency' revisited––cohort studies at risk. Klingemann HK. **Addiction** 1996 Apr;91(4):502–4

Contemplating the Stages of Change [news] Mason P. **Addiction** 1996 Apr;91(4):605–8

Comments on Fergusson et al.'s "Alcohol misuse and juvenile offending in adolescence". Rutter M. **Addiction** 1996 Apr; 91(4):495–8

Significant connections. Shepherd J. **Addiction** 1996 Apr; 91(4):501–2

Predictors of adolescent A. A. affiliation. Hohman M, et al. **Adolescence** 1996 Summer;31(122):339–52

Alcohol utilization and dependence with special reference to protein level in a liquid diet for rats. Fisher H, et al. **Alcohol** 1997 Mar–Apr;14(2):199–202

Implication of the endogenous opioid system in excessive ethanol consumption. Gianoulakis C, et al. **Alcohol** 1996 Jan–Feb;13(1):19–23 (33 ref.)

Endogenous opioids and alcohol dependence: opioid alkaloids and the propensity to drink alcoholic beverages. Reid LD. **Alcohol** 1996 Jan–Feb;13(1):5–11 (52 ref.)

Alcohol addiction (alcoholism) and the opioid system. Terenius L. **Alcohol** 1996 Jan–Feb;13(1):31–4 (19 ref.)

BAR 1996. XXIV annual Nordic meeting on biological alcohol research. Imatra, Finland, 24–26 May 1996. Abstracts. **Alcohol Alcohol** 1996 May;31(3):313–28

10th International Conference on Alcohol. Liverpool, United Kingdom, 14–17 April 1996. Abstracts. **Alcohol Alcohol** 1996 Sep;31(5):505–29

1996 Joint Meeting of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism. Washington, D.C., June 22–27, 1996. Abstracts. **Alcohol Clin Exp Res** 1996 Apr;20(2 Suppl):1A–155A

1997 Annual Scientific Meeting of the Research Society on Alcoholism. San Francisco, California, July 19–24, 1997. Abstracts. **Alcohol Clin Exp Res** 1997 May;21(3 Suppl):3A–145A

Alcohol research: celebrating the past, building the future. Gordis E. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):32A–37A

Cost of comorbid alcohol and drug problems. Pirzada SR, et al. **Am J Addict** 1997 Summer;6(3):193–204

Putting the brakes on drunk drivers. Bonnono C. **Am J Nurs** 1997 Sep;97(9):80

The early use of alcohol and tobacco: its relation to children's competence and parents' behavior. Jackson C, et al. **Am J Public Health** 1997 Mar;87(3):359–64

Chronic alcohol abuse in elderly surgical patients. Bailes BK. **AORN J** 1997 May;65(5):963–71

Alcoholism in the elderly [letter; comment] Lisi DM. **Arch Intern Med** 1997 Jan 27;157(2):242–3. Comment on: Arch Intern Med 1996 Jun 10;156(11):1150–6.

Normalization of immune response and phosphoinositide fatty acid composition of peripheral blood lymphocytes in an alcoholic patient after alcohol abstinence. Stefanini GF, et al. **Biochem Mol Biol Int** 1996 May;39(2):359–67

ABC of mental health. Addiction and dependence––II: Alcohol. Ashworth M, et al. **BMJ** 1997 Aug 9; 315(7104):358–60 (0 ref.)

Co–occurrence and contransmission of affective disorders and alcoholism in families. Maier W, et al. **Br J Psychiatry Suppl** 1996 Jun;(30):93–100

Predisposition to criminality: Swedish adoption studies in retrospect. Bohman M. **Ciba Found Symp** 1996;194:99–109; discussion 109–14 (21 ref.) (Eng. Abstr.)

High alcohol intake and slow progression to AIDS [letter] Soriano V, et al. **Genitourin Med** 1996 Oct;72(5):382

Laryngeal carcinoma in patients without a history of tobacco and alcohol use. Agudelo D, et al. **Head Neck** 1997 May; 19(3):200–4

Intimacy, loneliness, and openness to feelings in adult children of alcoholics. Martin JI. **Health Soc Work** 1995 Feb;20(1):52–9

Resilience in adult children of alcoholics: a nonpathological approach to social work practice. Palmer N. **Health Soc Work** 1997 Aug;22(3):201–9

Death due to alcoholic complications in a young woman with a severe eating disorder: a case report. Catterson ML, et al. **Int J Eat Disord** 1997 Apr;21(3):303–5

Heterogeneity in the families of sons of alcoholics: the impact of familial vulnerability type on offspring characteristics. Finn PR, et al. **J Abnorm Psychol** 1997 Feb;106(1):26–36

Cognitive and behavioral deficits associated with parental alcohol use. Weinberg NZ. **J Am Acad Child Adolesc Psychiatry** 1997 Sep; 36(9):1177–86 (73 ref.)

Substance abuse in victims of fire. Barillo DJ, et al. **J Burn Care Rehabil** 1996 Jan–Feb;17(1):71–6

Alcohol disorders in young adulthood: effects of transitions into adult roles. Chilcoat HD, et al. **J Health Soc Behav** 1996 Dec;37(4):339–49

The use of multiple outcomes in stress research: a case study of gender differences in responses to marital dissolution. Horwitz AV, et al. **J Health Soc Behav** 1996 Sep; 37(3):278–91

Alcoholism and African–American women: a medical sociocultural perspective. Carter JH, et al. **J Natl Med Assoc** 1996 Feb;88(2):81–6

Impairment in the medical and legal professions. Brooke D. **J Psychosom Res** 1997 Jul;43(1):27–34

Alcohol and illicit drug abuse and the risk of violent death in the home. Rivara FP, et al. **JAMA** 1997 Aug 20; 278(7):569–75

Immune surveillance of the oral cavity and lymphocyte migration: relevance for alcohol abusers. Chiappelli F, et al. **Lymphology** 1995 Dec;28(4):196–207 (52 ref.)

Physician impairment by substance abuse. O'Connor PG, et al. **Med Clin North Am** 1997 Jul;81(4):1037–52 (49 ref.)

Geriatric substance use disorders. Reid MC, et al. **Med Clin North Am** 1997 Jul;81(4):999–1016 (104 ref.)

Women and substance abuse. Stein MD, et al. **Med Clin North Am** 1997 Jul;81(4):979–98 (125 ref.)

"Sobering facts" [editorial] Thomas JR. **Mo Med** 1997 Feb; 94(2):57–8

A review of the treatment of alcoholism. McLellan AS. **N J Med** 1996 Aug;93(8):39–42 (14 ref.)

Lunch with Dr. Kerr: Nathan B. Eddy Award Lecture. Edwards G. **NIDA Res Monogr** 1997;174:17–27

Alcohol abuse. Takahashi A, et al. **Pediatr Rev** 1996 Feb; 17(2):39–45

Alcoholism in women. More common––and serious––than you might think. North CS. **Postgrad Med** 1996 Oct; 100(4):221–4, 230, 232–3 (25 ref.)

Reproductive risks of binge drinking during pregnancy. Gladstone J, et al. **Reprod Toxicol** 1996 Jan–Feb;10(1):3–13 (95 ref.)

Patients presenting with fresh trauma after interpersonal violence. Part I. Alcohol and substance abuse. Stein DJ, et al. **S Afr Med J** 1997 Aug;87(8):996–8

Faecal bile acid excretion during detoxification in patients with alcohol abuse. Ackehed G, et al. **Scand J Gastroenterol** 1996 Dec;31(12):1205–10

Subtypes of alcohol involvement and their relationships to exits from homelessness. Gregoire TK. **Subst Use Misuse** 1996 Aug;31(10):1333–57

[Awareness of ovulation time and sex determination in Biblical times] Ben–Noun L. **Harefuah** 1997 May 15; 132(10):726–7 (18 ref.) **(Heb)**

[Characteristics of hospitalized alcoholics] Marchevsky S, et

al. **Harefuah** 1997 Apr 15;132(8):586–90, 606 (Eng. Abstr.) **(Heb)**

[The role of the obstetrician–gynecologist in the prevention of alcohol–related problems] Weiss S. **Harefuah** 1996 May 15;130(10):714–8 **(Heb)**

[Substance abuse and pregnancy: alcohol] Wilczyński J, et al. **Ginekol Pol** 1996 Dec;67(12):620–5 (57 ref.) (Eng. Abstr.) **(Pol)**

[Internist's aspects of alcoholism] Kuczerowski R. **Pol Tyg Lek** 1996 Apr;51(14–18):249–55 (46 ref.) **(Pol)**

[Multicenter studies of primary care: the experience of the EIBAL study (letter)] Córdoba R, et al. **Aten Primaria** 1997 Mar 31;19(5):272–3 **(Spa)**

[Alcohol consumption and family dysfunction (letter; comment)] Sierra Manzano JM. **Aten Primaria** 1997 Jun 30;20(2):110–2. Comment on: Aten Primaria 1997 Feb 28;19(3):117–21. **(Spa)**

[Lymphoblastic stimulation in cirrhotic and non–cirrhotic chronic alcoholics] Palomo Gil S, et al. **Rev Clin Esp** 1996 Jul;196(7):451–4 (Eng. Abstr.) **(Spa)**

[When does alcohol trigger violence? "Emotional blindness" and impulsiveness are important links] Heilig M. **Lakartidningen** 1997 Mar 5;94(10):841–4 (37 ref.) **(Swe)**

BLOOD

Factors affecting the discriminant function analysis of blood chemistry profiles. Welte JW, et al. **Alcohol** 1997 Mar–Apr; 14(2):161–6

Isoforms of transferrin in psoriasis patients abusing alcohol. Hoefkens P, et al. **Alcohol Alcohol** 1997 Mar–Apr; 32(2):195–9

Aromatic and branched–chain amino acid levels in alcoholics. Saito T, et al. **Alcohol Alcohol** 1994;29 Suppl 1:133–5

Detection of relapses in alcohol dependent patients using serum carbohydrate deficient transferrin: improvement with individualized reference levels. Borg S, et al. **Alcohol Alcohol Suppl** 1994;2:493–6

The separation of hemoglobin–acetaldehyde adducts by cation exchange chromatography: a brief history. Itälä L, et al. **Alcohol Alcohol Suppl** 1994;2:509–13 (38 ref.)

Studies on the usefulness of acetaldehyde–modified proteins and associated antibodies as markers of alcohol abuse. Worrall S, et al. **Alcohol Alcohol Suppl** 1994;2:503–7

Changes in human plasma nerve growth factor level after chronic alcohol consumption and withdrawal. Aloe L, et al. **Alcohol Clin Exp Res** 1996 May;20(3):462–5

The distribution of fatty acid ethyl esters among lipoproteins and albumin in human serum. Bird DA, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):602–5

Stable acetaldehyde adducts: structural characterization of acetaldehyde adducts of human hemoglobin N–terminal beta–globin chain peptides. Braun KP, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):40–3

Oxidative susceptibility of low–density lipoproteins—influence of regular alcohol use. Croft KD, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):980–4

Biological responses to administered interferon in alcoholics. Ono K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1560–3

Alcohol mediates increases in hepatic and serum nonheme iron stores in a rat model for alcohol–induced liver injury. Valerio LG Jr, et al. **Alcohol Clin Exp Res** 1996 Nov; 20(8):1352–61

Origin of homovanillic acid in plasma [letter; comment] Lambert G, et al. **Am J Psychiatry** 1997 Jan;154(1):138–9 . Comment on: Am J Psychiatry 1995 Dec;152(12):1819–20.

Neopterin levels in alcohol–dependent patients. O'Hanlon M, et al. **Ann Clin Biochem** 1996 Nov;33 (Pt 6):536–9

Response of dehydroepiandrosterone to corticotropin–releasing hormone stimulation in alcohol–dependent subjects. Adinoff B, et al. **Biol Psychiatry** 1996 Dec 15;40(12):1305–7

Decreased inositol 1,4,5–trisphosphate–specific binding in platelets from alcoholic subjects. Saito H, et al. **Biol Psychiatry** 1996 Nov 1;40(9):886–91

Detection of DNA adducts of acetaldehyde in peripheral white blood cells of alcohol abusers. Fang JL, et al. **Carcinogenesis** 1997 Apr;18(4):627–32

Isoelectric focusing (IEF) and immunofixation for determination of disialotransferrin. Dumon MF, et al. **Clin Biochem** 1996 Dec;29(6):549–53

Semiautomated procedures for evaluation of carbohydrate–deficient transferrin in the diagnosis of alcohol abuse. Bean P, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):983–9

Serum ionized magnesium in chronic alcoholism: is it really decreased? Hristova EN, et al. **Clin Chem** 1997 Feb; 43(2):394–9

Changes in serum apolipoprotein and lipoprotein profile induced by chronic alcohol consumption and withdrawal: determinant effect on heart disease? Lecomte E, et al. **Clin Chem** 1996 Oct;42(10):1666–75

Quantification of carbohydrate–deficient transferrin by ion–exchange chromatography with an enzymatically prepared calibrator. Renner F, et al. **Clin Chem** 1997 Mar; 43(3):485–90

Clinical utility of carbohydrate–deficient transferrin to detect alcohol abuse in a general population [letter] Vermes I, et al. **Clin Chem** 1996 Dec;42(12):2048–50

Predictive value of MCV for hazardous drinking in the community. Peach HG, et al. **Clin Lab Haematol** 1997 Jun; 19(2):85–7

Diagnostic tests for alcoholism in primary health care: compared efficacy of different instruments. Escobar F, et al. **Drug Alcohol Depend** 1995 Dec;40(2):151–8

Serum and intracellular magnesium concentrations in intoxicated chronic alcoholic and control subjects. Princi T, et al. **Drug Alcohol Depend** 1997 Jun 6;46(1–2):119–22

Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Parés A, et al. **Hepatology** 1996 Dec;24(6):1399–403

The independent association of smoking and drinking with serum beta–carotene levels among males in Miyagi, Japan. Fukao A, et al. **Int J Epidemiol** 1996 Apr;25(2):300–6

Protection against cardiovascular collapse in an alcoholic patient with thiamine deficiency by concomitant alcoholic ketoacidosis. Bakker SJ, et al. **J Intern Med** 1997 Aug; 242(2):179–83

Biochemical markers of alcohol abuse. Sharpe PC, et al. **QJM** 1996 Feb;89(2):137–44

[Carbohydrate–deficient transferrin: a new biochemical marker for chronic excessive alcohol consumption] van Pelt J. **Ned Tijdschr Geneeskd** 1997 Apr 19;141(16):773–7 (Eng. Abstr.) **(Dut)**

[Asialotransferrin discriminating excessive, subacute and chronic active alcohol consumption. Clinical usefulness in hepatic disease] Peneda JA, et al. **Acta Med Port** 1996 Feb–Mar;9(2–3):103–11 (Eng. Abstr.) **(Por)**

[Class I and II histocompatibility antigens and severity of the alcoholic liver lesion] Caballería L, et al. **Gastroenterol Hepatol** 1997 Apr;20(4):167–71 (Eng. Abstr.) **(Spa)**

[The acid–base status of chronic alcoholics undergoing a bicycle ergometry test] Kyshko MM. **Lik Sprava** 1996 Mar–Apr;(3–4):87–8 **(Ukr)**

CEREBROSPINAL FLUID

Cerebrospinal fluid concentrations of corticotropin–releasing hormone (CRH) and diazepam–binding inhibitor (DBI) during alcohol withdrawal and abstinence. Adinoff B, et al. **Neuropsychopharmacology** 1996 Sep;15(3):288–95

CLASSIFICATION

Subtypes of alcoholism and their role in therapy. Lesch OM, et al. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:63–7 (20 ref.)

DSM–IV: was it worth all the fuss? Schuckit MA. **Alcohol Alcohol Suppl** 1994;2:459–69 (52 ref.)

Can we subtype alcoholism? A latent class analysis of data from relatives of alcoholics in a multicenter family study of alcoholism. Bucholz KK, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1462–71

Subtypes of alcohol–dependent men: a typology based on relative genetic and environmental loading. Johnson EO, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1472–80

Alcoholic epilepsy: a unified and dynamic classification. Bartolomei F, et al. **Eur Neurol** 1997;37(1):13–7

Validation of the Addiction Severity Index in French–speaking alcoholic patients. Daeppen JB, et al. **J Stud Alcohol** 1996 Nov;57(6):585–90

[Capacity to experience pleasure and displeasure by Cloninger and von Knorring in type I and II alcoholism] Nowaczkowski P, et al. **Encephale** 1997 May–Jun; 23(3):168–74 (Eng. Abstr.) **(Fre)**

[Alcohol dependence and depression. Classification, comorbidity, genetic and neurobiological aspects] Soyka M, et al. **Nervenarzt** 1996 Nov;67(11):896–904 (104 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Alcohol abuse and postoperative complications. Do we ask the right questions? [editorial; comment] Eklund J. **Acta Anaesthesiol Scand** 1996 Jul;40(6):647–8. Comment on: Acta Anaesthesiol Scand 1996 Jul;40(6):649–56.

Intensive care unit stay is prolonged in chronic alcoholic men following tumor resection of the upper digestive tract [see comments] Spies CD, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):649–56. Comment in: Acta Anaesthesiol Scand 1996 Jul;40(6):647–8.

Vibrameter testing facilitates the diagnosis of uremic and alcoholic polyneuropathy. Hilz MJ, et al. **Acta Neurol Scand** 1995 Dec;92(6):486–90

Presenilin–1 polymorphism in patients with Alzheimer's disease, vascular dementia and alcohol–associated dementia in Japanese population. Isoe K, et al. **Acta Neurol Scand** 1996 Nov;94(5):326–8

Heavy drinking, alcohol–dependent vs. nondependent methadone–maintenance clients: a follow–up study. Chatham LR, et al. **Addict Behav** 1997 Jan–Feb;22(1):69–80

Hemodynamic alterations in alcohol–related transitory hypertension. King AC, et al. **Alcohol** 1996 Jul–Aug; 13(4):387–93

Putative oxidative metabolites of 1–methyl–6–hydroxy–1,2,3,4–tetrahydro–beta–carboline of potential relevance to the addictive and neurodegenerative consequences of ethanol abuse. Wrona MZ, et al. **Alcohol** 1997 May–Jun;14(3):213–23

The significance of coronary death for the excess mortality in alcohol–dependent men. Denison H, et al. **Alcohol Alcohol** 1997 Jul–Aug;32(4):517–26

Ethanol–mediated promotion of oesophageal carcinogenesis: association with lipid peroxidation and changes in phospholipid fatty acid profile of the target tissue. Mufti SI, et al. **Alcohol Alcohol** 1997 May–Jun;32(3):221–31

Alcohol, thiamin deficiency, and neuropsychological disorders. Bowden S, et al. **Alcohol Alcohol Suppl** 1994; 2:267–72

Alcoholism and subtypes of antisocial personality disorder. Hesselbrock VM, et al. **Alcohol Alcohol Suppl** 1994; 2:479–84

Thiamine utilization in the pathogenesis of alcohol–induced brain damage. Martin PR, et al. **Alcohol Alcohol Suppl** 1994; 2:273–9 (35 ref.)

Alcohol dependence and schizophrenia: what are the interrelationships? Soyka M. **Alcohol Alcohol Suppl** 1994; 2:473–8 (58 ref.)

Impairments in reflective cognitive functions in alcoholics: a neuropharmacological model. Weingartner HJ, et al. **Alcohol Alcohol Suppl** 1994;2:291–8

Medical consequences of alcohol consumption—United States, 1992. Chou SP, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1423–9

Splenic function and alcohol addiction. Corazza GR, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):197–200

Two survival cases of alcoholic lactic acidosis complicated with diabetes mellitus and alcoholic liver disease. Ishii K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):387A–390A

The formation and measurement of DNA neuroadduction in alcoholism. Case report. Steinberg JJ, et al. **Am J Forensic Med Pathol** 1997 Mar;18(1):84–91

Nutritional deficiencies in chronic alcoholics: relation to dietary intake and alcohol consumption. Glória L, et al. **Am J Gastroenterol** 1997 Mar;92(3):485–9

Dietary and nutritional abnormalities in alcoholic liver disease: a comparison with chronic alcoholics without liver disease [see comments] Sarin SK, et al. **Am J Gastroenterol** 1997 May;92(5):777–83. Comment in: Am J Gastroenterol 1997 May;92(5):734–8.

Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Rosman AS, et al. **Am J Med** 1997 Sep;103(3):217–22

Alcohol abuse and psychopathic deviance in noncustodial parents as predictors of child–support payment and visitation. Dion MR, et al. **Am J Orthopsychiatry** 1997 Jan; 67(1):70–9

Brain impairment in well–nourished chronic alcoholics is related to ethanol intake. Nicolás JM, et al. **Ann Neurol** 1997 May;41(5):590–8

Alcohol–associated diabetes mellitus. A review of the impact of alcohol consumption on carbohydrate metabolism. Greenhouse L, et al. **Arch Fam Med** 1996 Apr;5(4):229–33 (29 ref.)

Case of the month. Autopsy Committee of the College of American Pathologists. Hanzlick R. **Arch Intern Med** 1997 Sep 8;157(16):1798

The impact of alcohol–related diagnoses on pneumonia outcomes. Saitz R, et al. **Arch Intern Med** 1997 Jul 14; 157(13):1446–52

Alcohol and the brain. Scheepers BD. **Br J Hosp Med** 1997 Jun 4–17;57(11):548–51 (16 ref.)

Substance abuse, traumatic brain injury and neuropsychological outcome. Kelly MP, et al. **Brain Inj** 1997 Jun;11(6):391–402

Comorbidity and its effects on panic disorder. Marshall JR. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A39–53 (63 ref.)

Withdrawal strategies for outpatients. Alcohol, benzodiazepine, barbiturate, and opiate addictions. Mezciems PE. **Can Fam Physician** 1996 Sep;42:1745–52 (27 ref.)

The 1993 General Social Survey II: alcohol problems in Canada. Single EW, et al. **Can J Public Health** 1995 Nov–Dec;86(6):402–7

Ketoacidosis with hyperglycemia in heavy drinkers: a report of 12 cases. Lu WT, et al. **Chang Keng I Hsueh** 1997 Mar; 20(1):34–8

Corneal melting in a chronic alcoholic contact lens wearer. Reisin I, et al. **CLAO J** 1996 Apr;22(2):146–7

Autonomic cardiac abnormalities in alcohol–dependent patients admitted to a psychiatric department. Rechlin T, et al. **Clin Auton Res** 1996 Apr;6(2):119–22

Substance use disorder exacerbates brain electrophysiological abnormalities in a psychiatrically–ill population [published erratum appears in Clin Electroencephalogr 1997 Jan;28(1):63] Braverman ER, et al. **Clin Electroencephalogr** 1996;27(4 Suppl):5–27

Methylobacterium mesophilicum synovitis in an alcoholic. Liu JW, et al. **Clin Infect Dis** 1997 May;24(5):1008–9

Osmolal gap in alcoholic ketoacidosis. Almaghamsi AM, et al. **Clin Nephrol** 1997 Jul;48(1):52–3

Gender differences in patients with schizophrenia and substance abuse. Brunette MF, et al. **Compr Psychiatry** 1997 Mar–Apr;38(2):109–16

Age effects on the clinical presentation of alcoholics at a psychiatric hospital. Cornelius JR, et al. **Compr Psychiatry** 1997 Jul–Aug;38(4):213–7

Alcoholic myopathies. Fernández–Solà J, et al. **Curr Opin Neurol** 1996 Oct;9(5):400–5 (28 ref.)

Cutaneous amebiasis in an Iranian immunodeficient alcoholic: immunochemical and histological study [letter] Loschiavo F, et al. **Dermatology** 1997;194(4):370–1 (16 ref.)

On the mechanism of alcohol–induced pseudo–Cushing's syndrome. Groote Veldman R, et al. **Endocr Rev** 1996 Jun; 17(3):262–8 (83 ref.)

Marked increase in serum CA 19–9 level in patients with alcoholic cirrhosis: report of four cases. Mathurin P, et

al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1129–31 (17 ref.)

Determinants of oral health in a group of Danish alcoholics. Hede B. **Eur J Oral Sci** 1996 Aug;104(4 (Pt 1)):403–8

A comparative study of isokinetic dynamometry and manual muscle testing of ankle dorsal and plantar flexors and knee extensors and flexors. Andersen H, et al. **Eur Neurol** 1997; 37(4):239–42

Reversible corpus callosum lesions in a patient with Marchiafava–Bignami disease: serial changes on MRI. Yamashita K, et al. **Eur Neurol** 1997;37(3):192–3

Acute pancreatic injury in asymptomatic individuals after heavy drinking over the long–term. Parent J, et al. **Gastrointest Endosc** 1996 Jun;43(6):637–8

RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. Ladero JM, et al. **Gut** 1996 Aug;39(2):330–3

Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in Chinese patients. Chao YC, et al. **Hepatology** 1997 Jan;25(1):112–7

Hepatitis C and alcohol. Schiff ER. **Hepatology** 1997 Sep;26(3 Suppl 1):39S–42S (24 ref.)

Alcohol and the heart [editorial] Maisch B. **Herz** 1996 Aug; 21(4):207–12 (25 ref.) **(Eng, Ger)**

Severe metabolic acidosis in the alcoholic: differential diagnosis and management. Höjer J. **Hum Exp Toxicol** 1996 Jun;15(6):482–8 (45 ref.)

Alcoholism and dementia. Smith DM, et al. **Int J Addict** 1995 Nov–Dec;30(13–14):1843–69 (80 ref.)

Cancer screening of upper aerodigestive tract in Japanese alcoholics with reference to drinking and smoking habits and aldehyde dehydrogenase–2 genotype. Yokoyama A, et al. **Int J Cancer** 1996 Nov 4;68(3):313–6

E. coli endotoxin enhances cardiomyopathy in rats with chronic alcohol consumption. Kita T, et al. **Int J Legal Med** 1996;109(1):37–41

Acute metabolic acidosis in chronic alcoholism: ketoacidosis as differential diagnosis [letter] Fumeaux T, et al. **Intensive Care Med** 1996 Dec;22(12):1462–3

Fulminant pneumonia and sepsis due to Aeromonas hydrophila in an alcohol abuser. Takano Y, et al. **Intern Med** 1996 May;35(5):410–2

A case–control study on alcohol and seizures: study design, protocol, and data collection. The ALCE (Alcohol and Epilepsy) Study Group. Leone M, et al. **Ital J Neurol Sci** 1997 Apr;18(2):119–24

The relationship between DSM–IV alcohol use disorders and DSM–IV major depression: examination of the primary–secondary distinction in a general population sample. Grant BF, et al. **J Affect Disord** 1996 Jun 5; 38(2–3):113–28

Five–year course of major depression: effects of comorbid alcoholism. Hasin DS, et al. **J Affect Disord** 1996 Nov 4; 41(1):63–70

Abnormalities in the bone marrow of the iliac crest in patients who have osteonecrosis secondary to corticosteroid therapy or alcohol abuse. Hernigou P, et al. **J Bone Joint Surg Am** 1997 Jul;79(7):1047–53

Accuracy of clinical diagnosis of cirrhosis among alcohol–abusing men. Hamberg KJ, et al. **J Clin Epidemiol** 1996 Nov;49(11):1295–301

Alexithymia and affect pathology among adult male alcoholics. Cecero JJ, et al. **J Clin Psychol** 1997 Apr; 53(3):201–8

Assessment of prose recall performance in chronic alcoholics: recall of essential versus detail propositions. Tivis LJ, et al. **J Clin Psychol** 1997 Apr;53(3):233–42

Prospective evaluation of three smoking interventions in 205 recovering alcoholics: one–year results of Project SCRAP–Tobacco. Martin JE, et al. **J Consult Clin Psychol** 1997 Feb;65(1):190–4

Alcoholic hepatic impairment complicating treatment with hepatotoxic antituberculosis drugs. Tiwari VK. **J Indian Med Assoc** 1996 Sep;94(9):347–8

Platelets, alcohol consumption, and onset of brain infarction. Numminen H, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):376–80

Visual pathway hemorrhage associated with alcohol–induced coagulopathy. Friedman DI, et al. **J Neuroophthalmol** 1996 Jun;16(2):124–33

Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. Lawlor P, et al. **J Pain Symptom Manage** 1997 Jun;13(6):356–61

Coexisting mental illness and alcohol and other drug dependencies in pregnant and parenting women [editorial] Jessup M. **J Psychoactive Drugs** 1996 Oct–Dec;28(4):311–7

The effects of dual diagnosis on pregnancy and parenting. Mallouh C. **J Psychoactive Drugs** 1996 Oct–Dec; 28(4):367–80 (98 ref.)

Psychiatric problems among alcohol and other drug dependent women. Zweben JE. **J Psychoactive Drugs** 1996 Oct–Dec;28(4):345–66 (69 ref.)

Screening cognitive impairment in alcohol abusers. Taylor J, et al. **J Psychosoc Nurs Ment Health Serv** 1997 Jul; 35(7):29–38

Maternal use of alcohol during pregnancy is a risky lifestyle. Elhassani SB, et al. **J S C Med Assoc** 1996 Mar;92(3):128–32

Neurogenic impotence and lower urinary tract symptoms due to vitamin B1 deficiency in chronic alcoholism. Tjandra BS, et al. **J Urol** 1997 Mar;157(3):954–5

The effect of tilsuprost on the liver mitochondria in taurocholate pancreatitis in rats with antecedent acute ethanol abuse. Dlugosz JW, et al. **Life Sci** 1996; 59(16):1297–306

Medical consequences of alcoholism. Stein MD. **Med Health R I** 1997 Mar;80(3):83–6

Overdose of venlafaxine––a new antidepressant [letter] Adesanya A, et al. **Med J Aust** 1997 Jul 7;167(1):54

Diseases of the airways and lungs in forensic autopsy material of alcoholics. Thomsen JL. **Med Sci Law** 1997 Jan; 37(1):23–6

Evaluation of suspected dementia [letter; comment] Charness ME. **N Engl J Med** 1996 Dec 26;335(26):1996–7; discussion 1997–8. Comment on: N Engl J Med 1996 Aug 1;335(5):330–6.

Dental treatment and the alcoholic. McDiarmid M. **N Z Dent J** 1996 Sep;92(409):83–5

Alcoholic ketoacidosis [letter] Harper JP. **N Z Med J** 1997 Jan 24;110(1036):18

Ethyleneglycol intoxication in a dipsomaniac patient. Kaiser N, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1753–4

Alcohol use is a risk factor for a first generalized tonic–clonic seizure. The ALC.E. (Alcohol and Epilepsy) Study Group. Leone M, et al. **Neurology** 1997 Mar;48(3):614–20

Health consequences of alcohol use in rural America. Brody GH, et al. **NIDA Res Monogr** 1997;168:137–74 (86 ref.)

Is urban frostbite a psychiatric disorder? Pinzur MS, et al. **Orthopedics** 1997 Jan;20(1):43–5

Dementia pugilistica in an alcoholic achondroplastic dwarf. Williams DJ, et al. **Pathology** 1996 Jan;28(1):102–4

Auditory brainwave stimulation in treating alcoholic depression. Waldkoetter RO, et al. **Percept Mot Skills** 1997 Feb;84(1):226

Early drinking onset and its association with alcohol use and problem behavior in late adolescence. Gruber E, et al. **Prev Med** 1996 May–Jun;25(3):293–300

Relation of denial of alcohol problems to neurocognitive impairment and depression. Wiseman EJ, et al. **Psychiatr Serv** 1996 Mar;47(3):306–8

Alcohol–induced organic cerebral psychosyndromes: partial reversal of cognitive impairments assisted by dihydroergocristine. Rainer M, et al. **Psychopharmacology (Berl)** 1996 Oct;127(4):365–9

Drinking patterns in liver transplant recipients. Tripp LE, et al. **Psychosomatics** 1996 May–Jun;37(3):249–53

Cigarette use, drinking and voiding in schizophrenic patients with polydipsia and hyponatremia. Shutty MS Jr. **Schizophr Res** 1996 Sep 18;21(3):195–7

Describing and predicting alcohol use–related harm: an analysis of the Yukon Alcohol and Drug Survey. Kellner F, et al. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1619–38

High malignancy of hepatocellular carcinoma in alcoholic patients with hepatitis C virus. Kubo S, et al. **Surgery** 1997 Apr;121(4):425–9

Chronic alcoholism decreases polyunsaturated fatty acid levels in human plasma, erythrocytes, and platelets––influence of chronic liver disease. Pita ML, et al. **Thromb Haemost** 1997 Aug;78(2):808–12

A case of Marchiafava–Bignami disease with complete recovery: sequential imaging documenting improvement of callosal lesions. Tobita M, et al. **Tohoku J Exp Med** 1997 Jun;182(2):175–9

Complication of acute pancreatitis: management of a haemorrhagic pancreatic pseudocyst. Garg P, et al. **Trop Doct** 1997 Jul;27(3):184

Disordered eating behaviors and bone–mineral density in women who misuse alcohol. Clark K. **West J Nurs Res** 1997 Feb;19(1):32–45; discussion 45–55

[Is alcohol poisonous for the liver? (editorial)] Hardt F. **Ugeskr Laeger** 1997 Jun 23;159(26):4087–8 **(Dan)**

[Pancytopenia with hemolysis of undetermined mechanism related to alcoholism [letter]] Menecier P, et al. **Presse Med** 1996 Oct 26;25(32):1563 **(Fre)**

[Lactic acidosis in alcoholic patients: to think of beriberi (letter; comment)] Schleinitz N, et al. **Presse Med** 1996 Nov 30;25(37):1848. Comment on: Presse Med 1996 Jun 8;25(20):924–8. **(Fre)**

[Mutilating acrodystrophic neuropathy of alcoholic origin in the French West Indies] Virevialle MH, et al. **Rev Med Interne** 1996;17(9):727–31 (Eng. Abstr.) **(Fre)**

[Emergency medicine for the practitioner: emergencies in the alcoholic patient and the drug addict] Perrin J, et al. **Rev Med Suisse Romande** 1997 Apr;117(4):305–7 **(Fre)**

[Marchiafava–Bignami disease: development with flare–up] Moreaud O, et al. **Rev Neurol (Paris)** 1996 Aug–Sep; 152(8–9):560–2 (Eng. Abstr.) **(Fre)**

[Medicamentous therapy of alcoholic polyneuropathy. Randomized double–blind study comparing 2 vitamin B preparations and a nucleotide preparation] Kretschmar C, et al. **Fortschr Med** 1996 Nov 20;114(32):439–43 (Eng. Abstr.) **(Ger)**

[Alcohol–induced hallucinosis. Clinical aspects, pathophysiology and therapy] Soyka M. **Nervenarzt** 1996 Nov;67(11):891–5 (52 ref.) (Eng. Abstr.) **(Ger)**

[Bilateral acetabulum fractures of the anterior column and vertebral body fracture after alcohol–induced seizure] Rommens PM, et al. **Unfallchirurg** 1996 Sep;99(9):704–7 (Eng. Abstr.) **(Ger)**

[Pathogenesis of glucose intolerance in alcoholics] Ishii H, et al. **Nippon Rinsho** 1996 Oct;54(10):2733–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[A heavy drinker case of HCV–Ab positive porphyria cutanea tarda, followed by primary hepatocellular carcinoma] Oguma T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jul;93(7):501–5 **(Jpn)**

[A patient under the influence of alcohol under acute care in the emergency department] Frańczuk B, et al. **Folia Med Cracov** 1996;37(3–4):35–9 (Eng. Abstr.) **(Pol)**

[Analysis of observations in the admissions room of the Krakow Clinical Toxicology Department of substance dependent persons in relation to changes in central nervous system metabolism caused by substances of abuse] Chrostek Maj J, et al. **Przegl Lek** 1997;54(6):420–5 (Eng. Abstr.) **(Pol)**

[Alcohol and cancer] Sofia C, et al. **Acta Med Port** 1997 May;10(5):373–9 (12 ref.) (Eng. Abstr.) **(Por)**

[Ethanol and the gastrointestinal tract] Mincis M, et al. **Arq Gastroenterol** 1995 Jul–Sep;32(3):131–9 (96 ref.) (Eng. Abstr.) **(Por)**

[Capillaroscopy in patients with chronic alcoholic pancreatitis] Teixeira GP, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 May–Jun; 51(3):81–4 (Eng. Abstr.) **(Por)**

[Administration of energostim in severe chronic cardiac failure due to alcoholic damage of heart] Paleev NR, et al. **Klin Med (Mosk)** 1997;75(4):35–41 **(Rus)**

[Acute pneumonia in alcoholics: onset and course] Tkachikhin VS, et al. **Klin Med (Mosk)** 1997;75(6):36–8 (26 ref.) (Eng. Abstr.) **(Rus)**

[Alcoholic arterial hypertension] Gromov VL, et al. **Ter Arkh** 1996;68(6):75–7 (36 ref.) **(Rus)**

[Variants in the course of chronic alcoholic gastritis] Kochegurov VN, et al. **Ter Arkh** 1996;68(2):18–21 (Eng. Abstr.) **(Rus)**

[Visceral lesions in alcoholism] Makhov VM, et al. **Ter Arkh** 1996;68(8):53–6 (Eng. Abstr.) **(Rus)**

[Alcohol abuse in HIV infection] Ruchkina EV, et al. **Ter Arkh** 1996;68(11):51–3 (Eng. Abstr.) **(Rus)**

[Acute nephritic syndrome in alcoholic nephritis] Tsineva LA, et al. **Ter Arkh** 1996;68(6):16–8 **(Rus)**

[Chronic consumption of alcohol and its damaging effects on the body] Petrović G, et al. **Srp Arh Celok Lek** 1996 Sep–Oct;124(9–10):260–6 (51 ref.) (Eng. Abstr.) **(Scc)**

[Alcohol dependence and psychiatric comorbidity. I. Epidemiology and etiopathogenic involvement] Cuadrado Callejo P. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Sep–Oct;24(5):231–44 (162 ref.) (Eng. Abstr.) **(Spa)**

[Alcohol dependence and psychiatric comorbidity. II. Clinical and therapeutic implications] Cuadrado Callejo P. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Jan–Feb;25(1):34–44 (150 ref.) (Eng. Abstr.) **(Spa)**

[Reversible thrombopenia caused by alcohol. A condition to consider (letter)] Guilarte López–Mañas J, et al. **An Med Interna** 1996 Jul;13(7):354 **(Spa)**

[Pellagra in alcoholic patients (letter)] Martín Alvarez R, et al. **Aten Primaria** 1996 Oct 15;18(6):341, 343 **(Spa)**

[Community–acquired pneumonia in an alcoholic patient] Piret MV, et al. **Enferm Infecc Microbiol Clin** 1997 Feb; 15(2):109–10 **(Spa)**

[Rhabdomyolysis and acute kidney failure in alcoholics (letter)] Alegre S, et al. **Med Clin (Barc)** 1996 Jun 22; 107(4):155 **(Spa)**

[Massive pleural effusion secondary to pancreatic–pleural fistula as first manifestation of chronic pancreatitis. Report of three cases] Molinuevo JL, et al. **Med Clin (Barc)** 1997 Jul 5;109(6):222–4 (Eng. Abstr.) **(Spa)**

[Shock of rapidly catastrophic course in a chronically alcoholic and diabetic 49–year–old male (clinical conference)] Sabrià M, et al. **Med Clin (Barc)** 1997 May 3;108(17):669–76 **(Spa)**

[Viral hepatitis and alcohol: a synergistic relationship] Kershenobich D. **Rev Gastroenterol Mex** 1995 Oct–Dec; 60(4 Suppl 2):S56 **(Spa)**

CONGENITAL see FETAL ALCOHOL SYNDROME

DIAGNOSIS

Agreement between DSM–III, DSM–III–R, DSM–IV and ICD–10 alcohol diagnoses in US community–sample heavy drinkers. Hasin D, et al. **Addiction** 1996 Oct;91(10):1517–27

The Alcohol Use Disorders Identification Test (AUDIT) as a screen for at–risk drinking in primary care patients of different racial/ethnic backgrounds. Volk RJ, et al. **Addiction** 1997 Feb;92(2):197–206

What is adolescent alcohol misuse in the United States according to the experts? Hays RD, et al. **Alcohol Alcohol** 1996 May;31(3):297–303

Should tri–sialo–transferrins be included when calculating carbohydrate–deficient transferrin for diagnosing elevated alcohol intake? Heggli DE, et al. **Alcohol Alcohol** 1996 Jul; 31(4):381–4

New 'state' markers for the detection of alcoholism. Lesch OM, et al. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:59–62 (30 ref.)

Carbohydrate–deficient transferrin as a marker of alcohol intake: a study with healthy subjects. Lesch OM, et al. **Alcohol Alcohol** 1996 May;31(3):265–71

Alcohol dependence: is carbohydrate–deficient transferrin a marker for alcohol intake? Lesch OM, et al. **Alcohol Alcohol** 1996 May;31(3):257–64

Comparative sensitivity of carbohydrate–deficient transferrin and gamma–glutamyltransferase [letter; comment] Rosalki SB. **Alcohol Alcohol** 1996 May;31(3):305–6. Comment on:

Alcohol Alcohol 1995 Mar;30(2):171–6.
Laboratory markers of alcohol abuse. Sillanaukee P. **Alcohol Alcohol** 1996 Nov;31(6):613–6 (29 ref.)
Carbohydrate-deficient transferrin measured by high-performance liquid chromatography and CDTect immunoassay. Simonsson P, et al. **Alcohol Alcohol** 1996 Jul;31(4):397–402
Urinary excretion of tetrahydro-beta-carbolines relating to ingestion of alcoholic beverages. Tsuchiya H, et al. **Alcohol Alcohol** 1996 Mar;31(2):197–203
High-performance liquid chromatography improves diagnostic efficiency of carbohydrate-deficient transferrin. Werle E, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):71–7
DSM-IV: was it worth all the fuss? Schuckit MA. **Alcohol Alcohol Suppl** 1994;2:459–69 (52 ref.)
A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Allen JP, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):613–9 (31 ref.)
Proposed recommendations for research on biochemical markers for problematic drinking. Allen JP, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):244–7 (11 ref.)
Comparison of the Alcohol Dependence Scale and diagnostic interview schedule in homeless women. Chantarujikapong SI, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):586–95
The relationship between alcohol symptoms and consumption among older drinkers. Chermack ST, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1153–8
Biological markers of alcohol consumption and effect of calcitonin in nonalcoholic men: a prospective, double-blind study. Elomaa VV, et al. **Alcohol Clin Exp Res** 1996 Aug; 20(5):830–5
DSM-IV, DSM-III-R, and ICD-10 alcohol and drug abuse/harmful use and dependence, United States, 1992: a nosological comparison. Grant BF. **Alcohol Clin Exp Res** 1996 Nov;20(8):1481–8
Blood phosphatidylethanol as a marker of alcohol abuse: levels in alcoholic males during withdrawal. Hansson P, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):108–10
Alcohol dependence and abuse diagnoses: validity in community sample heavy drinkers. Hasin D, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):213–9
Carbohydrate-deficient transferrin and alcohol dependency: variation in response to alcohol intake among different groups of patients. Huseby NE, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):201–5
Microheterogeneity with concanavalin A affinity of serum transferrin in patients with alcoholic liver disease. Inoue T, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):363A–365A
Alcohol abuse: adding content to category. Lagenbucher JW. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):270A–275A
Personality and substance use disorders: I. Effects of gender and alcoholism subtype. McGue M, et al. **Alcohol Clin Exp Res** 1997 May;21(3):513–20
Frontal lobe volume loss observed with magnetic resonance imaging in older chronic alcoholics. Pfefferbaum A, et al. **Alcohol Clin Exp Res** 1997 May;21(3):521–9
Sensitivity and specificity of carbohydrate-deficient transferrin as a marker of alcohol abuse are significantly influenced by alterations in serum transferrin: comparison of two methods. Sorvajärvi K, et al. **Alcohol Clin Exp Res** 1996 May;20(3):449–54
Models of treatment seeking for alcoholism: the role of genes and environment. True WR, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1577–81
Women and alcohol abuse in primary care. Identification and intervention. Chang G, et al. **Am J Addict** 1997 Summer; 6(3):183–92
Physician unawareness of serious substance abuse. Saitz R, et al. **Am J Drug Alcohol Abuse** 1997 Aug;23(3):343–54
Detecting alcohol problems in drug-dependent women of childbearing age. Svikis DS, et al. **Am J Drug Alcohol Abuse** 1996 Nov;22(4):563–75
When alcoholism hits home. Ianelli J. **Am J Nurs** 1997 Jul; 97(7):68–9
Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects. George DT, et al. **Am J Psychiatry** 1997 Jan;154(1):81–7
Superiority of carbohydrate-deficient transferrin to gamma-glutamyltransferase in detecting relapse in alcoholism. Schmidt LG, et al. **Am J Psychiatry** 1997 Jan; 154(1):75–80
Informative morphogenetic variants in patients with schizophrenia and alcohol-dependent patients: beyond the Waldrop Scale. Trixler M, et al. **Am J Psychiatry** 1997 May;154(5):691–3
Detecting risk drinking during pregnancy: a comparison of four screening questionnaires. Russell M, et al. **Am J Public Health** 1996 Oct;86(10):1435–9
Recent thinking about the concept of alcohol dependence. Caetano R. **Ann Epidemiol** 1996 Sep;6(5):458–62 (39 ref.)
Alcohol-related trauma [letter] Meehan AJ. **AORN J** 1996 Sep;64(3):353
The utility of the Brief MAST and the CAGE in identifying alcohol problems: results from national high-risk and community samples [see comments] Crowe RR, et al. **Arch Fam Med** 1997 Sep–Oct;6(5):477–83. Comment in: Arch Fam Med 1997 Sep–Oct;6(5):484–5.
Screening for alcohol problems [editorial; comment] McGann KP. **Arch Fam Med** 1997 Sep–Oct;6(5):484–5. Comment on: Arch Fam Med 1997 Sep–Oct;6(5):477–83.
Psychiatric assessment and confirmation of dual disorders in rural substance abusing women. Boyd MR, et al. **Arch Psychiatr Nurs** 1997 Apr;11(2):74–81
The dopamine D4 receptor gene (DRD4) is not associated with alcoholism in three Taiwanese populations: six polymorphisms tested separately and as haplotypes. Chang FM, et al. **Biol Psychiatry** 1997 Feb 15;41(4):394–405
Efficacy of the alcohol use disorders identification test as a screening tool for hazardous alcohol intake and related disorders in primary care: a validity study [see comments] Piccinelli M, et al. **BMJ** 1997 Feb 8;314(7078):420–4. Comment in: BMJ 1997 May 10;314(7091):1413.
Semiautomated procedures for evaluation of carbohydrate-deficient transferrin in the diagnosis of alcohol abuse. Bean P, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):983–9
Conceptualizing and scaling the developmental structure of behavior disorder: the Lifetime Alcohol Problems Score as an example. Zucker RA, et al. **Dev Psychopathol** 1997 Spring;9(2):453–71
Estimating measurement error in alcohol dependence symptomatology: findings from a multisite study. Babor TF, et al. **Drug Alcohol Depend** 1997 Apr 14;45(1–2):13–20
DSM-IV alcohol dependence and drug abuse/dependence in a treatment sample of whites, blacks and Mexican Americans. Caetano R, et al. **Drug Alcohol Depend** 1996 Dec 2;43(1–2):93–101
Quantitative electroencephalographic differences associated with alcohol, cocaine, heroin and dual-substance dependence. Costa L, et al. **Drug Alcohol Depend** 1997 Jun 6;46(1–2):87–93
Diagnostic tests for alcoholism in primary health care: compared efficacy of different instruments. Escobar F, et al. **Drug Alcohol Depend** 1995 Dec;40(2):151–8
Cross-system agreement among demographic subgroups: DSM-III, DSM-III-R, DSM-IV and ICD-10 diagnoses of alcohol use disorders. Hasin D, et al. **Drug Alcohol Depend** 1996 Jun;41(2):127–35
Psychometric evaluation of diagnostic criteria: application to a two-dimensional model of alcohol abuse and dependence. Muthén BO. **Drug Alcohol Depend** 1996 Jun; 41(2):101–12
Identification of fatty acid methyl esters (FAMEs) in postmortem tissue. A new marker of alcohol abuse? Emrich J, et al. **Forensic Sci Int** 1997 Feb 7;85(1):41–9
Post mortem markers of chronic alcoholism. Sadler DW, et al. **Forensic Sci Int** 1996 Sep 30;82(2):153–63
The feasibility of a new intake routine to assess substance use disorders by means of a structured interview. Jonasson B, et al. **Gen Hosp Psychiatry** 1997 Jan;19(1):36–41
Treating alcoholism: an age-specific intervention that works for older patients. Peterson M, et al. **Geriatrics** 1996 Oct; 51(10):45–9; quiz 50
Recognition and treatment of ethanol abuse in trauma patients. Erstad BL, et al. **Heart Lung** 1996 Jul–Aug; 25(4):330–6
Alcoholism in the elderly: physicians can make a difference. Lewis DC. **Hosp Pract (Off Ed)** 1997 Mar 15;32(3):211–4, 219–20
Milky ascites in a former whiskey runner. Matfin G, et al. **Hosp Pract (Off Ed)** 1997 Aug 15;32(8):39–40, 43
Screening and diagnosis of "alcohol abuse and dependence" in older adults. DeHart SS, et al. **Int J Addict** 1995 Nov–Dec;30(13–14):1717–47 (80 ref.)
Medical manifestations of alcoholism in the elderly. Smith JW. **Int J Addict** 1995 Nov–Dec;30(13–14):1749–98 (240 ref.)
Dual diagnosis in elders discharged from a psychiatric hospital. Blixen CE, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):307–13
Alcohol-history taking by nurses and doctors—how accurate are they really? Burns L, et al. **J Adv Nurs** 1997 Mar; 25(3):509–13
A logical functional analysis of reinforcement-based disorders: alcoholism and pedophilia. Wulfert E, et al. **J Consult Clin Psychol** 1996 Dec;64(6):1140–51
Dissociative experiences scale and MMPI-2 scores in video poker gamblers, other gamblers, and alcoholic controls. Kofoed L, et al. **J Nerv Ment Dis** 1997 Jan;185(1):58–60
Cerebral blood flow and cerebrovascular response to acetazolamide in patients with chronic alcoholism. Oishi M, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul; 63(1):100–2
Frontal cortical atrophy and negative symptoms in patients with chronic alcohol dependence. Rosse RB, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):280–2
The structure of problem drinking in adulthood: a confirmatory approach. DeCourville NH, et al. **J Stud Alcohol** 1997 Mar;58(2):146–54
Abuse vs dependence vs alcoholism [letter; comment] Erickson CK. **J Stud Alcohol** 1997 May;58(3):334. Comment on: J Stud Alcohol 1996 Sep;57(5):469.
Physiological alcohol dependence as a "specifier" of risk for medical problems and relapse liability in DSM-IV. Langenbucher J, et al. **J Stud Alcohol** 1997 Jul;58(4):341–50
Identification of the motor vehicle accident victim who abuses alcohol: an opportunity to reduce trauma. Mancino M, et al. **J Stud Alcohol** 1996 Nov;57(6):652–8
Staging in the onset of DSM-IV alcohol symptoms in adolescents: survival/ hazard analyses. Martin CS, et al. **J Stud Alcohol** 1996 Sep;57(5):549–58
DSM-V: there's work to be done [letter; comment] Martin CS. **J Stud Alcohol** 1997 May;58(3):334–5. Comment on: J Stud Alcohol 1996 Sep;57(5):469.
DSM-V: there's work to be done [editorial] [see comments] Schuckit MA. **J Stud Alcohol** 1996 Sep;57(5):469. Comment in: J Stud Alcohol 1997 May;58(3):334. Comment in: J Stud Alcohol 1997 May;58(3):334–5.
Factors affecting agreement between alcohol abusers' and their collaterals' reports. Sobell LC, et al. **J Stud Alcohol** 1997 Jul;58(4):405–13
Agreement in alcohol consumption levels as measured by two different questionnaires. Witte JS, et al. **J Stud Alcohol** 1996 Jul;57(4):406–9
Screening for alcohol and drug abuse. Schorling JB, et al. **Med Clin North Am** 1997 Jul;81(4):845–65 (97 ref.)
Detecting young adults with alcohol use disorder in a general practice. McMenamin JP. **N Z Med J** 1997 Apr 11; 110(1041):127–8
Intermanual differences on motor and psychomotor tests in alcoholics: no evidence for selective right-hemisphere dysfunction. Kwon LM, et al. **Percept Mot Skills** 1997 Apr; 84(2):403–14
Concurrent validity of clinicians' ratings of substance abuse among psychiatric outpatients [see comments] Carey KB, et al. **Psychiatr Serv** 1996 Aug;47(8):842–7. Comment in: Psychiatr Serv 1997 Jan;48(1):105–6.
Single photon emission computed tomography with iodoamphetamine-123 and neuropsychological studies in long-term abstinent alcoholics. Dupont RM, et al. **Psychiatry Res** 1996 Jul 31;67(2):99–111
Neuropsychological differences between alcohol-dependent and cocaine-dependent patients with or without problematic drinking. Easton C, et al. **Psychiatry Res** 1997 Jul 4;71(2):97–103
Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients. Nixon SJ, et al. **Psychiatry Res** 1996 Aug 30;64(1):35–45
Alcoholism—treating the disease. Lee A. **Singapore Med J** 1997 May;38(5):214–6 (11 ref.)
Drinking-related assessment instruments: cross-cultural studies. Annis HM, et al. **Subst Use Misuse** 1996 Sep–Oct; 31(11–12):1525–46
Validation of a measure of excessive drinking: frequency per year that BAL exceeds 0.08%. Conrod PJ, et al. **Subst Use Misuse** 1997 Apr;32(5):587–607
[Descriptive studies of the use of the Addiction Severity Index in France] Martin C, et al. **Encephale** 1996 Sep–Oct; 22(5):359–63 (Eng. Abstr.) **(Fre)**
[Screening for problem alcohol drinking in the Swiss population: comparison between an ISPA-developed instrument and the CAGE questionnaire. The Swiss Institute for the Prevention of Alcoholism] Truan P, et al. **Schweiz Med Wochenschr** 1997 May 3;127(18):753–61 (Eng. Abstr.) **(Fre)**
[Alcoholism as an illness] Feuerlein W. **Herz** 1996 Aug; 21(4):213–6 (4 ref.) (Eng. Abstr.) **(Ger)**
[Legal family assessment in the case of alcoholic parents] Siefen RG, et al. **Prax Kinderpsychol Kinderpsychiatr** 1996 Nov;45(9):343–9 (Eng. Abstr.) **(Ger)**
[Diagnosis and treatment of alcoholism] Fisch HU. **Ther Umsch** 1997 Jul;54(7):390–2 (Eng. Abstr.) **(Ger)**
[Specificity of alcoholism and resulting methods of therapeutic practice] Nowobilska-Stanios M, et al. **Przegl Lek** 1997;54(6):446–8 (5 ref.) (Eng. Abstr.) **(Pol)**
[Co-dependence—diagnosis and therapy] Sękowska M. **Przegl Lek** 1997;54(6):441–5 (3 ref.) (Eng. Abstr.) **(Pol)**
[Acute oral poisoning with isopropyl alcohol in alcoholics] Wiernikowski A, et al. **Przegl Lek** 1997;54(6):459–63 (Eng. Abstr.) **(Pol)**
[Diagnostic efficiency of biological markers of alcohol consumption for the detection of excessive drinkers] Rubio C, et al. **An Med Interna** 1996 Jun;13(6):274–8 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

The efficacy of disulfiram: a review of outcome studies. Hughes JC, et al. **Addiction** 1997 Apr;92(4):381–95 (81 ref.)
Naltrexone in the treatment of alcoholism: a clinical review. O'Brien CP, et al. **Alcohol** 1996 Jan–Feb;13(1):35–9 (25 ref.)
Consensus conference on the neuropharmacology of alcohol dependence and the role of pharmacotherapy in its treatment. Amsterdam, The Netherlands, September 16–17, 1994. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:1–87 (0 ref.)
Pharmacotherapy in alcoholism treatment: integrating and understanding the use of serotonin reuptake inhibitors. George FR. **Alcohol Alcohol Suppl** 1994;2:537–43 (38 ref.)
Ritanserin and alcohol abuse and dependence. Meert TF. **Alcohol Alcohol Suppl** 1994;2:523–30 (33 ref.)
Biobehavioural basis of pharmacologic treatment of alcohol dependence. Sellers EM. **Alcohol Alcohol Suppl** 1994; 2:517–21 (29 ref.)
Acamprosate: a new pharmacotherapeutic approach to relapse prevention in alcoholism—preliminary data. Soyka M, et al. **Alcohol Alcohol Suppl** 1994;2:531–6
Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Kranzler HR, et al. **Alcohol Clin Exp Res** 1996 Dec; 20(9):1534–41
Biological responses to administered interferon in alcoholics. Ono K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1560–3
Naltrexone for the treatment of alcoholism. Ciraulo AM, et al. **Am Fam Physician** 1997 Sep 1;56(3):803–6 (29 ref.)
Naltrexone in alcohol dependence. Hartmann PM.

ALCOHOLISM

Am Fam Physician 1997 Apr;55(5):1877–9, 1883–4 (31 ref.)
Tolerability of naltrexone in treating older, alcohol–dependent patients. Oslin D, et al. **Am J Addict** 1997 Summer;6(3):266–70
Sequential use of naltrexone in the treatment of relapsing alcoholism [letter] Farren CK, et al. **Am J Psychiatry** 1997 May;154(5):714
Naltrexone for alcoholic adolescents [letter] Lifrak PD, et al. **Am J Psychiatry** 1997 Mar;154(3):439–41
Disulfiram–ethanol test reaction: significance of supervision [letter] Savas MC, et al. **Ann Pharmacother** 1997 Mar; 31(3):374–5
Fluoxetine in depressed alcoholics. A double–blind, placebo–controlled trial [see comments] Cornelius JR, et al. **Arch Gen Psychiatry** 1997 Aug;54(8):700–5. Comment in: Arch Gen Psychiatry 1997 Aug;54(8):691–4.
Naltrexone and alcohol dependence. Role of subject compliance [see comments] Volpicelli JR, et al. **Arch Gen Psychiatry** 1997 Aug;54(8):737–42. Comment in: Arch Gen Psychiatry 1997 Aug;54(8):691–4.
Using fuzzy logic to predict response to citalopram in alcohol dependence. Naranjo CA, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):209–24
A risk–benefit assessment of naltrexone in the treatment of alcohol dependence. Berg BJ, et al. **Drug Saf** 1996 Oct; 15(4):274–82 (44 ref.)
Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Wilde MI, et al. **Drugs** 1997 Jun; 53(6):1038–53 (62 ref.)
Evidence for alcohol anti–craving properties of memantine. Hölter SM, et al. **Eur J Pharmacol** 1996 Oct 31;314(3):R1–2
Effects of fluoxetine at antidepressant doses on short–term outcome of detoxified alcoholics. Janiri L, et al. **Int Clin Psychopharmacol** 1996 Jun;11(2):109–17
Naltrexone for alcohol abuse [letter] Wold M, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jan;36(1):6–7
Misuse of naltrexone [letter] Measom MO. **J Clin Psychiatry** 1996 Oct;57(10):488–9
Alcohol withdrawal treatment practices [letter; comment] Wartenberg AA. **J Gen Intern Med** 1996 May;11(5):315–6 . Comment on: J Gen Intern Med 1995 Sep;10(9):479–87.
Psychosis during disulfiram therapy for alcoholism. Murthy KK. **J Indian Med Assoc** 1997 Mar;95(3):80–1
Naltrexone: a controversial therapy for alcohol dependence. Freed PE, et al. **J Psychosoc Nurs Ment Health Serv** 1997 Jul;35(7):24–8
Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Saitz R, et al. **Med Clin North Am** 1997 Jul; 81(4):881–907 (176 ref.)
The pharmacological treatment of alcohol dependence. Swift RM. **Med Health R I** 1997 Mar;80(3):91–3 (20 ref.)
Citalopram in the treatment of alcoholism: a double–blind placebo–controlled study. Tiihonen J, et al. **Pharmacopsychiatry** 1996 Jan;29(1):27–9
Research strategies to assess pharmacotherapies for alcoholism. Naranjo CA, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 May; 20(4):543–59 (40 ref.)
Closing the gap between alcoholism research and practice: the case for pharmacotherapy. Meza E, et al. **Psychiatr Serv** 1996 Sep;47(9):917–20 (49 ref.)
Medications development for alcohol use disorders. Wright C. **Psychopharmacol Bull** 1995;31(4):681–6 (1 ref.)
A double–blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal. Anton RF, et al. **Psychopharmacology (Berl)** 1997 May; 131(2):123–9
Ritanserin in the treatment of alcohol dependence--a multi–center clinical trial. Ritanserin Study Group. Johnson BA, et al. **Psychopharmacology (Berl)** 1996 Nov; 128(2):206–15
Alcohol treatment: measurement of effectiveness by global outcome. Thevos AK, et al. **Soc Work Health Care** 1996; 23(3):57–71
Anti–craving compounds for ethanol: new pharmacological tools to study addictive processes. Spanagel R, et al. **Trends Pharmacol Sci** 1997 Feb;18(2):54–9 (76 ref.)
Pharmacotherapy of alcohol dependence. Zernig G, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):229–31 (42 ref.)
Naltrexone hydrochloride use in the treatment of alcoholism. Ey SR. **West J Med** 1996 Oct;165(4):227
[Pharmacotherapy of alcoholism] **Nervenarzt** 1996 Jan;67(1 Suppl):1–8 **(Ger)**
[Collateral effects of disulfiram on the central nervous system in alcoholics that have become totally abstemious. Description of 8 cases] Maccari S, et al. **Ann Ital Med Int** 1996 Oct–Dec;11(4):279–83 (Eng. Abstr.) **(Ita)**
[The evaluation of the effect of zinc sulfate on primary immune response indices under alcoholic intoxication] Proskuriakova TV, et al. **Eksp Klin Farmakol** 1996 Mar–Apr;59(2):47–9 (Eng. Abstr.) **(Rus)**
[The efficacy and mechanisms of action of lerivon in alcoholism] Ivanets NN, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(5):52–8 (Eng. Abstr.) **(Rus)**
[Pharmacological treatment of alcohol dependence. Acamprosate and naltrexone offer new approach] Berglund M, et al. **Lakartidningen** 1997 Jul 23;94(30–31):2645–8 (19 ref.) **(Swe)**

ECONOMICS

An historical error in the tribute to the late Mark Keller [letter] Roizen R. **Addiction** 1997 Feb;92(2):221
The SECCAT survey: I. The costs and consequences of alcoholism. McKenna M, et al. **Alcohol Alcohol** 1996 Nov; 31(6):565–76
Savings on nutritional supplements administered to patients with chronic alcoholism [letter] Markowitz JS, et al. **Am J Health Syst Pharm** 1996 Jun 1;53(11):1336
The relationship between alcohol consumption and earnings. Heien D. **J Stud Alcohol** 1996 Sep;57(5):536–42
The relationship of public support payments to substance abuse among homeless veterans with mental illness. Frisman LK, et al. **Psychiatr Serv** 1997 Jun;48(6):792–5
Reduced substance–abuse–related health care costs among voluntary participants in Alcoholics Anonymous. Humphreys K, et al. **Psychiatr Serv** 1996 Jul;47(7):709–13
Measuring the human cost of a weak economy: does unemployment lead to alcohol abuse? Ettner SL. **Soc Sci Med** 1997 Jan;44(2):251–60

ENZYMOLOGY

A hypothesis linking hypoglycemia, hyperuricemia, lactic acidemia, and reduced gluconeogenesis in alcoholics to inactivation of glucose–6–phosphatase activity by acetaldehyde. Brecher AS, et al. **Alcohol** 1996 Nov–Dec; 13(6):553–7
Effects of chronic administration and subsequent withdrawal of ethanol–containing liquid diet on rat liver tryptophan pyrrolase and tryptophan metabolism. Bano S, et al. **Alcohol Alcohol** 1996 Mar;31(2):205–15
Prevention of ethanol–induced changes in reactive oxygen parameters by alpha–tocopherol. Bondy SC, et al. **Alcohol Alcohol** 1996 Jul;31(4):403–10
Regulation of rat neuronal nitric oxide synthase activity by chronic alcoholization. Naassila M, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):13–7
Increased concentrations of manganese superoxide dismutase in serum of alcohol–dependent patients. Thome J, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):65–9
Effect of methionine on the fatty acid composition of cellular membranes in rats with chronic ethanol consumption and jejunoileal bypass. Waladkhani AR, et al. **Alcohol Alcohol** 1996 Sep;31(5):463–9
Alcohol and aldehyde dehydrogenase genotypes, alcoholism and alcohol related disease. Couzigou P, et al. **Alcohol Alcohol Suppl** 1994;2:21–7 (47 ref.)
Monoamine oxidases and alcoholism: studies in unrelated alcoholics, normal controls and alcoholic families. Parsian A, et al. **Alcohol Alcohol Suppl** 1994;2:45–9
Alcohol dehydrogenase: enzymology and metabolism. Yin SJ. **Alcohol Alcohol Suppl** 1994;2:113–9 (37 ref.)
Gene regulation of alcohol metabolizing enzymes. Crabb DW. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):113A–116A
Ethanol and acetaldehyde metabolism: past, present, and future. Kitson KE. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):82A–92A
Alcohol and tyrosine kinase/phosphatase mediated processes. Nagy LE. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):106A–108A
Platelet adenylyl cyclase activity in alcoholics and subtypes of alcoholics. WHO/ISBRA Study Clinical Centers. Parsian A, et al. **Alcohol Clin Exp Res** 1996 Jun; 20(4):745–51
Chronic ethanol downregulates Gal–beta–1,4GlcNAc alpha 2,6–sialyltransferase and Gal–beta–1,3GlcNAc alpha 2,3–sialyltransferase mRNAs in rat liver. Rao MN, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):348–51
Ethanol–inducible cytochrome P450 (CYP2E1): biochemistry, molecular biology and clinical relevance: 1996 update. Song BJ. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):138A–146A
The 1996 James B. Isaacson Award Lecture. Platelet MAO activity in type 1/type 2 alcoholics. von Knorring L. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):224A–230A (82 ref.)
Mitochondrial aspartate aminotransferase isoenzyme: a biochemical marker for the clinical management of alcoholics? Macchia T, et al. **Clin Chim Acta** 1997 Jul 4; 263(1):79–96
Enhanced (Na+K)–ATPase activity and expression in mouse brain after chronic ethanol administration. Chen Y, et al. **Neurochem Res** 1997 May;22(5):583–8

EPIDEMIOLOGY

Alcohol abuse/dependence in motor vehicle crash victims presenting to the emergency department. Maio RF, et al. **Acad Emerg Med** 1997 Apr;4(4):256–62
Alcohol consumption and regular benzodiazepine use in 55–year–old female Malmö residents: results of a health screening. Osterling A, et al. **Acta Psychiatr Scand** 1996 Sep;94(3):141–8
Gender differences in the risk of alcohol dependence: United States, 1992. Dawson D. **Addiction** 1996 Dec; 91(12):1831–42
Temporal drinking patterns and variation in social consequences. Dawson DA. **Addiction** 1996 Nov; 91(11):1623–35
Teenagers and alcohol misuse in the United States: by any definition, it's a big problem. Ellickson PL, et al. **Addiction** 1996 Oct;91(10):1489–503
The epidemiology of alcohol use in Australian women: findings from a national survey of women's drinking. Fleming J. **Addiction** 1996 Sep;91(9):1325–34
Drug use in the high intensity drug trafficking area of the US Southwest border. Harrison LD, et al. **Addiction** 1996 Jan;91(1):47–61
The social impact of Life Education: estimating drug use prevalence among Victorian primary school students and the statewide effect of the Life Education programme. Hawthorne G. **Addiction** 1996 Aug;91(8):1151–9
Alcohol consumption in high school adolescents: frequency of use and dimensional structure of associated problems. Lewinsohn PM, et al. **Addiction** 1996 Mar;91(3):375–90
Risk functions for alcohol–related problems in a 1988 US national sample. Midanik LT, et al. **Addiction** 1996 Oct; 91(10):1427–37; discussion 1439–56
Irish descent, religion, and alcohol and tobacco use. Mullen K, et al. **Addiction** 1996 Feb;91(2):243–54
Alcohol consumption and community hospital admissions in the United States: a dynamic regression analysis, 1950–1992. Muller A. **Addiction** 1996 Feb;91(2):231–42
Gender differences in drinking behaviour in the Netherlands: convergence or stability? Neve RJ, et al. **Addiction** 1996 Mar;91(3):357–73
The "WAM" score: sensitivity and specificity of a user friendly biological screening test for alcohol problems in trauma patients. Nilssen O, et al. **Addiction** 1996 Feb; 91(2):255–62
How does young people's alcohol consumption change during the transition to early adulthood? A longitudinal study of changes at aggregate and individual level. Pape H, et al. **Addiction** 1996 Sep;91(9):1345–57
Alcohol consumption in Switzerland 1987–93: adjusting for differential effect of assessment techniques on the analysis of trends. Rehm J, et al. **Addiction** 1996 Sep;91(9):1335–44
On the emerging paradigm of drinking patterns and their social and health consequences. Rehm J, et al. **Addiction** 1996 Nov;91(11):1615–21
The changes in the social class distribution of moderate and high alcohol consumption and of alcohol–related disabilities over time in Stockholm County and in Sweden. Romelsjö A, et al. **Addiction** 1996 Sep;91(9):1307–23
Life–time problem drinking and psychiatric co–morbidity among Ontario women. Ross H, et al. **Addiction** 1997 Feb; 92(2):183–96
Alcohol–related violence: the impact of drinking pattern and drinking context. Rossow I. **Addiction** 1996 Nov; 91(11):1651–61
Characteristics of women with alcohol and other drug problems: findings of an Australian national survey. Swift W, et al. **Addiction** 1996 Aug;91(8):1141–50
Drug use and violent crime among adolescents. Dawkins MP. **Adolescence** 1997 Summer;32(126):395–405
Recidivism among drunken and drugged drivers in Norway. Christophersen AS, et al. **Alcohol Alcohol** 1996 Nov; 31(6):609–11
Predictors for hidden problem drinkers in general practice. Cornel M, et al. **Alcohol Alcohol** 1996 May;31(3):287–96
Alcohol–related diseases in general hospital patients. Gerke P, et al. **Alcohol Alcohol** 1997 Mar–Apr;32(2):179–84
Carbohydrate–deficient transferrin as a screening marker for drinking in a general hospital population. Lesch OM, et al. **Alcohol Alcohol** 1996 May;31(3):249–56
Identifying hazardous or harmful alcohol use in medical admissions: a comparison of audit, cage and brief mast. MacKenzie D, et al. **Alcohol Alcohol** 1996 Nov;31(6):591–9
Alcohol–related admissions to an inner city hospital intensive care unit. Marik P, et al. **Alcohol Alcohol** 1996 Jul; 31(4):393–6
Thoughts on 'alcohol problems into the next century'. Paton A. **Alcohol Alcohol** 1996 May;31(3):231–4
Utilizing culture and behaviour in epidemiological models of alcohol consumption and consequences for Western nations. Peele S. **Alcohol Alcohol** 1997 Jan–Feb;32(1):51–64
Prevalence of alcohol problems in general practice: an experience from southern Italy. Rambaldi A, et al. **Alcohol Alcohol** 1996 Mar;31(2):191–6
The pattern of alcohol consumption of a general hospital population in north Belfast. Sharkey J, et al. **Alcohol Alcohol** 1996 May;31(3):279–85
Factors in childhood and youth predicting alcohol dependence and abuse in Swedish women: findings from a general population study. Spak L, et al. **Alcohol Alcohol** 1997 May–Jun;32(3):267–74
Alcohol and indigenous populations. Hwu HG, et al. **Alcohol Alcohol Suppl** 1994;2:559–60
Psychiatric referrals associated with substance use disorders: prevalence and gender differences. European Consultation–Liaison Workgroup. Alaja R, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):620–6
Changes in alcohol use and alcohol–related problems among 7th to 12th grade students in New York State, 1983–1994. Barnes GM, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):916–22
Patterns of suicidality and alcohol use in alcoholics with major depression. Cornelius JR, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1451–5
Voice of the victims. Erickson CK. **Alcohol Clin Exp Res** 1996 Jun;20(4):785
The relationship between drinking and heart disease morbidity in the United States: results from the National

Health Interview Survey. Hanna EZ, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):111–8

Female alcoholism: new perspectives–findings from the COGA Study. Collaborative Study on the Genetics of Alcoholism. Hesselbrock V. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):168A–171A

Evaluating three reading tests for use with alcohol and other drug–abusing populations. Johnson ME, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1125–9

Effects of gender and comorbidity on problem drinking in a community sample. Lewis CE, et al. **Alcohol Clin Exp Res** 1996 May;20(3):466–76

Polydrug use in an inpatient treatment sample of problem drinkers. Martin CS, et al. **Alcohol Clin Exp Res** 1996 May; 20(3):413–7

Polydrug use in adolescent drinkers with and without DSM–IV alcohol abuse and dependence. Martin CS, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1099–1108

Assessing alcohol problems in female DWI offenders. Parks KA, et al. **Alcohol Clin Exp Res** 1996 May;20(3):434–9

Development of a screening questionnaire for the general hospital and general practices. Rumpf HJ, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):894–8

A prospective, high–risk study of the relationship between tobacco dependence and alcohol use disorders. Sher KJ, et al. **Alcohol Clin Exp Res** 1996 May;20(3):485–92

Eating pathology among women with alcoholism and/or anxiety disorders. Sinha R, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1184–91

Screening for alcohol dependence and abuse in women: description, validation, and psychometric properties of a new screening instrument, SWAG, in a population study. Spak F, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):723–31

Subject–collateral reports of drinking in inpatient alcoholics with comorbid mental disorders. Stasiewicz PR, et al. **Alcohol Clin Exp Res** 1997 May;21(3):530–6

Alcohol use disorders, consumption patterns, and health–related quality of life of primary care patients. Volk RJ, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):899–905

Longitudinal research on alcohol problems: the flow of risk, problems, and disorder over time. Zucker RA. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):93A–95A

Alcohol and drug abuse in patients with physical disabilities. Hubbard JR, et al. **Am J Drug Alcohol Abuse** 1996 May; 22(2):215–31 (41 ref.)

Drug use history and criminal behavior among 133 incarcerated men. Kouri EM, et al. **Am J Drug Alcohol Abuse** 1997 Aug;23(3):413–9

Gender differences in the relationship of alcohol and drug use to criminal behavior in a sample of arrestees. Nunes–Dinis MC, et al. **Am J Drug Alcohol Abuse** 1997 Feb;23(1):129–41

Effects of age on perinatal substance abuse among whites and African Americans. Vega WA, et al. **Am J Drug Alcohol Abuse** 1997 Aug;23(3):431–51

A descriptive study of elderly community–dwelling alcoholic patients in the rural south. Holroyd S, et al. **Am J Geriatr Psychiatry** 1997 Summer;5(3):221–8

Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Schuckit MA, et al. **Am J Psychiatry** 1997 Jul;154(7):948–57

Alcohol, tobacco, and other drug use among rural/small town and urban youth: a secondary analysis of the monitoring the future data set. Cronk CE, et al. **Am J Public Health** 1997 May;87(5):760–4

Alcohol and drug use, abuse, and dependence among welfare recipients. Grant BF, et al. **Am J Public Health** 1996 Oct; 86(10):1450–4

Substance use among runaway and homeless youth in three national samples. Greene JM, et al. **Am J Public Health** 1997 Feb;87(2):229–35

Drug detection in a suburban psychiatric emergency room. Dhossche D, et al. **Ann Clin Psychiatry** 1996 Jun;8(2):59–69

Alcohol–related health services use and identification of patients in the emergency department. Cherpitel CJ, et al. **Ann Emerg Med** 1996 Oct;28(4):418–23

Temperance board registration for alcohol abuse in a national sample of Swedish male twins, born 1902 to 1949. Kendler KS, et al. **Arch Gen Psychiatry** 1997 Feb;54(2):178–84

Lifetime co–occurrence of DSM–III–R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Kessler RC, et al. **Arch Gen Psychiatry** 1997 Apr;54(4):313–21

Substance use disorders among men in prison: a New Zealand study. Bushnell JA, et al. **Aust N Z J Psychiatry** 1997 Aug; 31(4):577–81

Phobic disorders are associated with temperament in alcoholic men. Sellman JD, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):110–3

Drug abuse: a significant variable in schizophrenia research. Boutros N, et al. **Biol Psychiatry** 1996 Jun 15;39(12):1053–4

Substance use in remand prisoners: a consecutive case study. Mason D, et al. **BMJ** 1997 Jul 5;315(7099):18–21

Sexual abuse in people with alcohol problems. A study of the prevalence of sexual abuse and its relationship to drinking behaviour [see comments] Moncrieff J, et al. **Br J Psychiatry** 1996 Sep;169(3):355–60. Comment in: Br J Psychiatry 1997 Feb;170:193.

Suicide in Avon. Life stress, alcohol misuse and use of services. Vassilas CA, et al. **Br J Psychiatry** 1997 May; 170:453–5

Impulsivity or comorbidity in bulimia nervosa. A controlled study of deliberate self–harm and alcohol and drug misuse in a community sample. Welch SL, et al. **Br J Psychiatry** 1996 Oct;169(4):451–8

Alcohol, drugs and gambling in the Ontario adult population, 1994. Smart RG, et al. **Can J Psychiatry** 1996 Feb; 41(1):36–45

The 1993 General Social Survey I: alcohol use in Canada. Single EW, et al. **Can J Public Health** 1995 Nov–Dec; 86(6):397–401

Oral health in alcohol misusers. Harris CK, et al. **Community Dent Health** 1996 Dec;13(4):199–203

Characteristics of injection drug users derived from a large family study of alcoholism. Dinwiddie SH. **Compr Psychiatry** 1997 Jul–Aug;38(4):218–29

Gender differences in DSM–IV alcohol use disorders and major depression as distributed in the general population: clinical implications. Hanna EZ, et al. **Compr Psychiatry** 1997 Jul–Aug;38(4):202–12

Detection of alcohol problems in primary care outpatients under different conditions. Chan AW, et al. **Drug Alcohol Depend** 1996 Jun;41(2):151–5

Development of substance use and psychiatric comorbidity in an epidemiologic study of white and American Indian young adolescents the Great Smoky Mountains Study. Federman EB, et al. **Drug Alcohol Depend** 1997 Mar 14; 44(2–3):69–78

The alcohol use disorder and associated disabilities interview schedule (AUDADIS): reliability of alcohol and drug modules in a clinical sample. Hasin D, et al. **Drug Alcohol Depend** 1997 Mar 14;44(2–3):133–41

Israeli college student alcohol use: the association of background characteristics and regular drinking patterns. Isralowitz RE, et al. **Drug Alcohol Depend** 1996 Nov; 42(3):147–53

Comorbidity of drug dependence and other mental disorders: a two–phase study of prevalence at outpatient treatment centres in Italy. Pozzi G, et al. **Drug Alcohol Depend** 1997 Jun 6;46(1–2):69–77

Treatment needs and experiences of Australian women with alcohol and other drug problems. Swift W, et al. **Drug Alcohol Depend** 1996 Mar;40(3):211–9

Increased cancer risk among Swedish female alcoholics. Sigvardsson S, et al. **Epidemiology** 1996 Mar;7(2):140–3

Alcoholism and psychiatric comorbidity in general hospital inpatients. Arolt V, et al. **Gen Hosp Psychiatry** 1996 Jul; 18(4):271–7

Epidemiology of problem drinking among elderly people. Adams WL, et al. **Int J Addict** 1995 Nov–Dec; 30(13–14):1693–716 (65 ref.)

Alcohol use, drug use, and well–being in older adults in Toronto. Adlaf EM, et al. **Int J Addict** 1995 Nov–Dec; 30(13–14):1985–2016

Special issue on drugs and the elderly: use and misuse of drugs, medicines, alcohol, and tobacco, Introduction. Gurnack AM. **Int J Addict** 1995 Nov–Dec; 30(13–14):1685–8

Early versus late onset of alcoholism in the elderly. Liberto JG, et al. **Int J Addict** 1995 Nov–Dec;30(13–14):1799–818 (35 ref.)

Alcoholism in social classes and occupations in Sweden. Hemmingsson T, et al. **Int J Epidemiol** 1997 Jun; 26(3):584–91

Alcohol dependence a growing problem for women. Treating depression in alcoholic patients helps to prevent relapse [news] **Int J Fertil Menopausal Stud** 1996 May–Jun; 41(3):273–4

Alcohol abuse: a source of reversible functional disability among residents of a VA nursing home. Oslin DW, et al. **Int J Geriatr Psychiatry** 1997 Aug;12(8):825–32

The prevalence of chemical substance and alcohol abuse in an obstetric population in Dublin. Bosio P, et al. **Ir Med J** 1997 Jun–Jul;90(4):149–50

The comorbidity of alcoholism and personality disorders in a clinical population: prevalence rates and relation to alcohol typology variables. Morgenstern J, et al. **J Abnorm Psychol** 1997 Feb;106(1):74–84

Alcohol use amongst community–dwelling elderly people: a review of the literature. Lakhani N. **J Adv Nurs** 1997 Jun;25(6):1227–32 (36 ref.)

Gender and comorbid psychopathology in adolescents with alcohol dependence. Clark DB, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Sep; 36(9):1195–203

Criminal recidivism and family histories of schizophrenic and nonschizophrenic fire setters: comorbid alcohol dependence in schizophrenic fire setters. Repo E, et al. **J Am Acad Psychiatry Law** 1997;25(2):207–15

Alcohol and substance abuse in panic disorder. Marshall JR. **J Clin Psychiatry** 1997;58 Suppl 2:46–9; discussion 49–50 (38 ref.)

Gender and drug differences in antisocial personality disorder. Brown JM, et al. **J Clin Psychol** 1997 Jun; 53(4):301–5

Co–morbidity of alcoholism and the paraphilias. Allnutt SH, et al. **J Forensic Sci** 1996 Mar;41(2):234–9

Familial aggregation of DSM–IV alcohol use disorders: examination of the primary–secondary distinction in a general population sample. Grant BF, et al. **J Nerv Ment Dis** 1997 May;185(5):335–43

A comparison of the symptoms associated with early and late onset alcohol dependence. Watson CG, et al. **J Nerv Ment Dis** 1997 Aug;185(8):507–9

Research accumulating on teenage alcohol abuse [news] **J Psychosoc Nurs Ment Health Serv** 1996 Sep;34(9):8–9

Problem drinking in the Naval Service: a study of personnel identified as alcohol abusers. Micklewright S. **J R Nav Med Serv** 1996 Spring;82(1):34–40

Alcohol and injury: a comparison of three emergency room samples in two regions. Cherpitel CJ. **J Stud Alcohol** 1997 May;58(3):323–31

The relation between heavy alcohol use and bar patronage: a latent growth model. Curran PJ, et al. **J Stud Alcohol** 1996 Jul;57(4):410–8

Determinants of life–course variation in the frequency of alcohol consumption: meta–analysis of studies from the collaborative alcohol–related longitudinal project. Johnstone BM, et al. **J Stud Alcohol** 1996 Sep;57(5):494–506

Are women heavier drinkers than we thought they were? Lo CC. **J Stud Alcohol** 1996 Sep;57(5):531–5

Childhood sexual abuse and women's substance abuse: national survey findings. Wilsnack SC, et al. **J Stud Alcohol** 1997 May;58(3):264–71

Predictors of HIV–related risk behaviors among heterosexuals in alcoholism treatment. Woods WJ, et al. **J Stud Alcohol** 1996 Sep;57(5):486–93

Nicotine and alcohol abuse in African American women who smoke crack cocaine. Boyd CJ, et al. **J Subst Abuse** 1996; 8(4):463–9

Cigarette smoking in alcohol and cocaine abusers. Burling TA, et al. **J Subst Abuse** 1996;8(4):445–52

The use of alcohol home delivery services by male problem drinkers: a preliminary report. Fletcher LA, et al. **J Subst Abuse** 1996;8(2):251–61

The relationships of substance abuse to illegal and violent behavior, in a community sample of young adult African American men and women (gender differences). Friedman AS, et al. **J Subst Abuse** 1996;8(4):379–402

Prevalence and correlates of drug use and DSM–IV drug dependence in the United States: results of the National Longitudinal Alcohol Epidemiologic Survey. Grant BF. **J Subst Abuse** 1996;8(2):195–210

Comorbidity between DSM–IV drug use disorders and major depression: results of a national survey of adults. Grant BF. **J Subst Abuse** 1995;7(4):481–97

Criterion variability in problem–drinking research on college students. Heck EJ, et al. **J Subst Abuse** 1995;7(4):437–47 (43 ref.)

Characteristics of posttraumatic stress disorder–alcohol abuse comorbidity in women. Ouimette PC, et al. **J Subst Abuse** 1996;8(3):335–46

Assessing substance abuse treatment provider training needs: screening skills. Vander Bilt J, et al. **J Subst Abuse Treat** 1997 Mar–Apr;14(2):163–71

Patterns of alcohol use and misuse among adults in Rhode Island. Duncan DF. **Med Health R I** 1997 Mar;80(3):80–2

Drug and alcohol use among youth in rural communities. Edwards RW. **NIDA Res Monogr** 1997;168:53–78 (14 ref.)

The influence of comorbid major depression and substance use disorders on alcohol and drug treatment: results of a national survey. Grant BF. **NIDA Res Monogr** 1997; 172:4–15

Validity of integrity tests for predicting drug and alcohol abuse: a meta–analysis. Schmidt FL, et al. **NIDA Res Monogr** 1997;170:69–95

Alcohol and drug abuse by migrant farmworkers: past research and future priorities. Watson JM. **NIDA Res Monogr** 1997;168:443–58 (22 ref.)

Alcoholism among elderly persons. Goldstein MZ, et al. **Psychiatr Serv** 1996 Sep;47(9):941–3 (23 ref.)

Mental illness among homeless individuals in a suburban county. Haugland G, et al. **Psychiatr Serv** 1997 Apr; 48(4):504–9

Effects of substance abuse on housing stability of homeless mentally Ill persons in supported housing. Hurlburt MS, et al. **Psychiatr Serv** 1996 Jul;47(7):731–6

Characteristics of patients with substance abuse diagnoses on a general psychiatry unit in a VA Medical Center. Lambert MT, et al. **Psychiatr Serv** 1996 Oct;47(10):1104–7

Prevalence and predictors of depressive, anxiety and substance use disorders in HIV–infected and uninfected men: a longitudinal evaluation. Dew MA, et al. **Psychol Med** 1997 Mar;27(2):395–409

Chronic drinking, binge drinking and drunk driving. Duncan DF. **Psychol Rep** 1997 Apr;80(2):681–2

Alcohol and violence–related injuries in the emergency room. Cherpitel CJ. **Recent Dev Alcohol** 1997;13:105–18 (51 ref.)

How far have we come? A critical review of the research on men who batter. Lee WV, et al. **Recent Dev Alcohol** 1997;13:337–56 (75 ref.)

Is there a causal relationship between alcohol use and violence? A synthesis of evidence. Lipsey MW, et al. **Recent Dev Alcohol** 1997;13:245–82 (84 ref.)

The relationship of alcohol to injury in assault cases. Martin SE, et al. **Recent Dev Alcohol** 1997;13:41–56

Epidemiological issues in alcohol–related violence. Roizen J. **Recent Dev Alcohol** 1997;13:7–40 (60 ref.)

The deficit syndrome in the DSM–IV Field Trial: I. Alcohol and other drug abuse. Kirkpatrick B, et al. **Schizophr Res** 1996 May;20(1–2):69–77

Sensitivity of MCMI–III Scales T (drugs) and B (alcohol) in detecting substance abuse. Craig RJ. **Subst Use Misuse** 1997 Aug;32(10):1385–93

Southeast Asians: Asian–Pacific Americans at risk for

substance misuse. D'Avanzo CE. **Subst Use Misuse** 1997 Jun;32(7–8):829–48 (65 ref.)
Substance use among homeless, immigrant, and refugee populations: an international perspective. Introduction. Johnson TP. **Subst Use Misuse** 1997 Jun;32(7–8):793–803
Relationships among alcohol availability, drinking location, alcohol consumption, and drinking problems in adolescents. Jones-Webb R, et al. **Subst Use Misuse** 1997 Aug; 32(10):1261–85
Describing and predicting alcohol use–related harm: an analysis of the Yukon Alcohol and Drug Survey. Kellner F, et al. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1619–38
"Substance abuse" disorders among runaway and homeless youth. Kipke MD, et al. **Subst Use Misuse** 1997 Jun; 32(7–8):969–86
Validity of self-reported drug use in high risk populations: a meta-analytical review. Magura S, et al. **Subst Use Misuse** 1996 Jul;31(9):1131–53
Reliability of adolescent self-reported pretreatment alcohol and other drug use. Stinchfield R. **Subst Use Misuse** 1997 Mar;32(4):425–34
Substance use patterns among homeless migrants and nonmigrants in Chicago. VanGeest JB, et al. **Subst Use Misuse** 1997 Jun;32(7–8):877–907
[Alcohol and drug abuse: a retrospective analysis of incidence in a regional hospital 1993–1994] Gabutti L, et al. **Schweiz Med Wochenschr** 1996 Dec 7;126(49):2130–5 (Eng. Abstr.) **(Fre)**
[Alcohol drinking by elderly patients in general practice] Weiss A. **Fortschr Med** 1996 Feb 28;114(6):26–9 **(Ger)**
[Physicians as patients—on the problem of the mentally ill physician] Loevenich A, et al. **Fortschr Neurol Psychiatr** 1996 Sep;64(9):344–52 (47 ref.) (Eng. Abstr.) **(Ger)**
[Trends in alcohol consumption and predictors for increased alcohol consumption in former East Germany—analysis of the 1st and 2nd stages of the German Cardiovascular Prevention Study] Bloomfield K, et al. **Gesundheitswesen** 1997 Apr;59(4):283–8 (Eng. Abstr.) **(Ger)**
[Status of the management of addicted patients—results of an expert survey as the basis for health policy decisions] Fleischmann H, et al. **Gesundheitswesen** 1996 Oct; 58(10):538–42 (Eng. Abstr.) **(Ger)**
[Social medicine aspects of addiction medicine] Tretter F. **Gesundheitswesen** 1996 Oct;58 Suppl 3:211–8 **(Ger)**
[Alcohol dependence in homeless men. Incidence, development and determinants] Dufeu P, et al. **Nervenarzt** 1996 Nov;67(11):930–4 (Eng. Abstr.) **(Ger)**
[Consumption patterns and motivation for use of addictive drugs in schizophrenic patients] Lambert M, et al. **Psychiatr Prax** 1997 Jul;24(4):185–9 (Eng. Abstr.) **(Ger)**
[Employment and alcohol: analysis of a clinical casuistic] Biscaldi G, et al. **G Ital Med Lav** 1995 Jan–Nov; 17(1–6):77–82 (Eng. Abstr.) **(Ita)**
[Alcohol and suicide attempts] Kołaciński Z, et al. **Przegl Lek** 1997;54(6):438–40 (11 ref.) (Eng. Abstr.) **(Pol)**
[Application of the Michigan Alcoholism Screening Test in heads of the family] Fuentealba Herrera R, et al. **Acta Psiquiatr Psicol Am Lat** 1995 Sep;41(3):206–13 (Eng. Abstr.) **(Spa)**
[Alcohol dependence and psychiatric comorbidity. I. Epidemiology and etiopathogenic involvement] Cuadrado Callejo P. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Sep–Oct;24(5):231–44 (162 ref.) (Eng. Abstr.) **(Spa)**
[An epidemiologic study of the prevalence of alcohol consumption in the Council of Tineo (Asturias)] Bousquets Toral L, et al. **An Med Interna** 1995 Nov;12(11):530–7 (Eng. Abstr.) **(Spa)**
[An epidemiologic study on the prevalence of alcohol consumption in a rural area of Asturias (council of Somiedo)] Fuentes Alvarez MD, et al. **An Med Interna** 1995 Nov;12(11):524–9 (Eng. Abstr.) **(Spa)**
[Relationship between family perception and alcohol consumption (see comments)] Rodríguez Fernández E, et al. **Aten Primaria** 1997 Feb 28;19(3):117–21 (Eng. Abstr.) . Comment in: Aten Primaria 1997 Jun 30;20(2):110–2. **(Spa)**

ETHNOLOGY

Comparisons of alcohol and other drugs: experience from the WHO Collaborative Cross-Cultural Applicability Research (CAR) Study. Gureje O, et al. **Addiction** 1996 Oct;91(10):1529–38
Ethnic and multicultural factor in alcohol research methods. Caetano R. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):117A–120A
Alcohol expectancies in a Native American population. Garcia-Andrade C, et al. **Alcohol Clin Exp Res** 1996 Nov; 20(8):1438–42
Alcohol research in Latin America. Monteiro MG. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):176A–180A
Epidemiology of alcohol use in a group of older American Indians. Lowe LP, et al. **Ann Epidemiol** 1997 May; 7(4):241–8
Cultural formulation of psychiatric diagnosis. Case No. 01. An American Indian woman suffering from depression, alcoholism and childhood trauma. Fleming CM. **Cult Med Psychiatry** 1996 Jun;20(2):145–54
Problems related to alcohol use: a cross-cultural perspective. Gureje O, et al. **Cult Med Psychiatry** 1997 Jun; 21(2):199–211
Alcohol, drug use and consequences among Hispanics seeking treatment for alcohol-related problems. Arciniega LT, et al. **J Stud Alcohol** 1996 Nov;57(6):613–8
Demographic and psychosocial risk for alcohol use: ethnic differences. Keefe K, et al. **J Stud Alcohol** 1996 Sep; 57(5):521–30
Drug and alcohol use among rural Mexican-Americans. Castro FG, et al. **NIDA Res Monogr** 1997;168:498–530 (90 ref.)
Alcohol and spouse abuse ethnic differences. Kantor GK. **Recent Dev Alcohol** 1997;13:57–79 (88 ref.)
Women, alcohol and work: interactions of gender, ethnicity and occupational culture. Ames GM, et al. **Soc Sci Med** 1996 Dec;43(11):1649–63 (100 ref.)
Aggregate-level predictors of the prevalence of selected drinking patterns in multiple studies: a research synthesis from the Collaborative Alcohol-Related Longitudinal Project. Ager CR, et al. **Subst Use Misuse** 1996 Sep–Oct; 31(11–12):1503–23
Drinking-related assessment instruments: cross-cultural studies. Annis HM, et al. **Subst Use Misuse** 1996 Sep–Oct; 31(11–12):1525–46
Changes in drinking problems among whites, blacks, and Hispanics: 1984–1992. Caetano R, et al. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1547–71
Ethnic differences in substance use and alcohol-use-related mortality among first generation migrants to England and Wales. Harrison L, et al. **Subst Use Misuse** 1997 Jun; 32(7–8):849–76
The influence of acculturation on attitudes toward alcohol and alcohol use within the Punjabi community: an exploratory analysis. Weber TR. **Subst Use Misuse** 1996 Sep–Oct;31(11–12):1715–32
[Search for biochemical factors implicated in the pathogenesis of alcoholism in different ethnic populations] Semke VIa, et al. **Vestn Ross Akad Med Nauk** 1996; (12):49–56 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Voices of the afflicted. Erickson CK. **Alcohol Clin Exp Res** 1996 Oct;20(7):1211
Ecological analysis of collectivity of alcohol consumption in England: importance of average drinker [see comments] Colhoun H, et al. **BMJ** 1997 Apr 19;314(7088):1164–8. Comment in: BMJ 1997 Apr 19;314(7088):1142–3.
Sexual abuse in people with alcohol problems [letter; comment] Kinzl JF, et al. **Br J Psychiatry** 1997 Feb;170:193 . Comment on: Br J Psychiatry 1996 Sep;169(3):355–60.
Serotonin in alcoholic violent offenders. Virkkunen M, et al. **Ciba Found Symp** 1996;194:168–77; discussion 177–82 (47 ref.)
Increased cancer risk among Swedish female alcoholics. Sigvardsson S, et al. **Epidemiology** 1996 Mar;7(2):140–3
Alcoholism in a geriatric outpatient clinic of São Paulo–Brazil. Hirata ES, et al. **Int Psychogeriatr** 1997 Mar; 9(1):95–103
[Attention deficit hyperactivity disorder, facilitating alcohol and drug abuse in an adult] Durst R, et al. **Harefuah** 1997 May 1;132(9):618–22, 680 (Eng. Abstr.) **(Heb)**

GENETICS

Severity of alcohol dependence and its relationship to neurological soft signs, neuropsychological impairment and family history. Keenan E, et al. **Acta Psychiatr Scand** 1997 Apr;95(4):272–6
Neuropsychological functioning in sons of active alcoholic, recovering alcoholic, and social drinking fathers. Ozkaragoz T, et al. **Alcohol** 1997 Jan–Feb;14(1):31–7
Biochemical markers of alcohol use and abuse: experiences from the Pilot Study of the WHO/ISBRA Collaborative Project on state and trait markers of alcohol. International Society for Biomedical Research on Alcoholism. Helander A, et al. **Alcohol Alcohol** 1997 Mar–Apr;32(2):133–44
The effects of family history, sobriety length, and drinking history in younger alcoholics on P300 auditory–evoked potentials. Keenan JP, et al. **Alcohol Alcohol** 1997 May–Jun; 32(3):233–9
Alcohol dehydrogenase polymorphisms in Native Americans: identification of the ADH2*3 allele. Wall TL, et al. **Alcohol Alcohol** 1997 Mar–Apr;32(2):129–32
Thiamine deficiency as predisposition to, and consequence of, increased alcohol consumption. Zimatkin SM, et al. **Alcohol Alcohol** 1996 Jul;31(4):421–7
Alcohol and aldehyde dehydrogenase genotypes, alcoholism and alcohol related disease. Couzigou P, et al. **Alcohol Alcohol Suppl** 1994;2:21–7 (47 ref.)
Genetic effects on alcohol consumption patterns and problems in women. Heath AC, et al. **Alcohol Alcohol Suppl** 1994;2:53–7 (27 ref.)
Polymorphisms of ethanol metabolizing enzyme genes and alcoholism. Higuchi S. **Alcohol Alcohol Suppl** 1994;2:29–34
GABAA and NMDA receptor subunit mRNA expression in ethanol dependent rats. Morrow AL, et al. **Alcohol Alcohol Suppl** 1994;2:89–95
Polymorphisms of the D2 dopamine receptor gene and alcoholism and other substance use disorders. Noble EP. **Alcohol Alcohol Suppl** 1994;2:35–43 (61 ref.)
Monoamine oxidases and alcoholism: studies in unrelated alcoholics, normal controls and alcoholic families. Parsian A, et al. **Alcohol Alcohol Suppl** 1994;2:45–9
The 1994 Isaacson Award Lecture: a prospective study of sons of alcoholics. Schuckit MA. **Alcohol Alcohol Suppl** 1994;2:1–6 (25 ref.)
Smooth pursuit eye movement dysfunction in abstinent cocaine abusers: effects of a paternal history of alcoholism. Bauer LO. **Alcohol Clin Exp Res** 1997 Aug;21(5):910–5
Quick method for confirmation of quantitative trait loci. Bennett B, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):767–72
Biphasic effects of alcohol on heart rate are influenced by alcoholic family history and rate of alcohol ingestion. Conrod PJ, et al. **Alcohol Clin Exp Res** 1997 Feb; 21(1):140–9
The 1996 RSA Distinguished Research Award Lecture. A genetic animal model of alcohol withdrawal. Crabbe JC. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):96A–100A
Alcohol feeding impedes early atherosclerosis in low-density lipoprotein receptor knockout mice: factors in addition to high-density lipoprotein-apolipoprotein A1 are involved. Dai J, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):11–8
Behavioral and cognitive measurements predict scores on the MAST: a 3-year prospective study. Deckel AW, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1173–8
Manipulation of alcohol drinking by liver transplantation. Eriksson CJ, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):763–5
Ethanol-reinforced responding by AA and ANA rats following the sucrose-substitution initiation procedure. Files FJ, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):749–53
Initiation of ethanol self-administration by the sucrose-substitution method with HAS and LAS rats. Files FJ, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):677–81
No association of the structural dopamine D2 receptor (DRD2) variant 311Cys with alcoholism. Finckh U, et al. **Alcohol Clin Exp Res** 1996 May;20(3):528–32
Chromosomal aberrations in peripheral lymphocytes of abstinent alcoholics. Gattás GJ, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):238–43
Tyrosine hydroxylase and dopamine D4 receptor allelic distribution in Scandinavian chronic alcoholics. Geijer T, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):35–9
Executive cognitive functioning predicts reactive aggression in boys at high risk for substance abuse: a prospective study. Giancola PR, et al. **Alcohol Clin Exp Res** 1996 Jun; 20(4):740–4
Intravenous ethanol self-administration in C57BL/6J and DBA/2J mice. Grahame NJ, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):56–62
Genetics of alcoholism: an international perspective. Grau C. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):78A–81A
Investigation of genetic risk factors associated with alcoholism. Harada S, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):293A–296A
Lack of allelic association of dopamine D1 and D2 (TaqIA) receptor gene polymorphisms with reduced dopaminergic sensitivity to alcoholism. Heinz A, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1109–13
Alcohol and aldehyde dehydrogenase genotypes and drinking behavior in Japanese. Higuchi S, et al. **Alcohol Clin Exp Res** 1996 May;20(3):493–7
Tridimensional personality traits in sons of alcoholic and nonalcoholic fathers. Howard MO, et al. **Alcohol Clin Exp Res** 1996 May;20(3):445–8
Bulimia nervosa and substance dependence: association and family transmission. Kaye WH, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):878–81
DRD2 haplotypes containing the TaqI A1 allele: implications for alcoholism research. Kidd KK, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):697–705
No association of PROP taster status and paternal history of alcohol dependence. Kranzler HR, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1496–500
Effect of apolipoprotein E phenotype on plasma lipids and lipoproteins in alcohol abusers. Liinamaa MJ, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):606–12
Cytochromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis or upper aerodigestive tract cancer in alcoholic caucasians. Lucas D, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1033–7
Genotypes of alcohol-metabolizing enzymes and the risk for alcoholic chronic pancreatitis in Japanese alcoholics. Matsumoto M, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):289A–292A
Decreased measures of experimental anxiety in rats bred for high alcohol preference. Möller C, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):656–60
Effects of ethanol and temperature on NMDA receptor function in different mouse genotypes. Musleh W, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1299–304
Serotonin2C receptors and serotonin2C receptor-mediated phosphoinositide hydrolysis in the brain of alcohol-preferring and alcohol-nonpreferring rats. Pandey SC, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1038–42
Human GABAA receptor alpha 1 and alpha 3 subunits genes and alcoholism. Parsian A, et al. **Alcohol Clin Exp Res** 1997 May;21(3):430–3
Issues in genetic testing for susceptibility to alcoholism: lessons from Alzheimer's disease and Huntington's disease. Quaid KA, et al. **Alcohol Clin Exp Res** 1996 Nov; 20(8):1430–7 (72 ref.)
Genetic predisposition to organ-specific endpoints of

alcoholism. Reed T, et al. **Alcohol Clin Exp Res** 1996 Dec; 20(9):1528–33

NAS–NRC Twin Registry Survey [letter] Reed T, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):381

A genomic survey of alcohol dependence and related phenotypes: results from the Collaborative Study on the Genetics of Alcoholism (COGA). Reich T. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):133A–137A

Reduced sensitivity to ethanol reward, but not ethanol aversion, in mice lacking 5-HT1B receptors. Risinger FO, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1401–5

Glutathione–S–transferase GST M1 "null" genotype and the risk of alcoholic liver disease. Savolainen VT, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1340–5

High and low drinking rat lines: contributions to current understanding and future development. Sinclair JD. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):109A–112A

The WHO/ISBRA study on state and trait markers in alcoholism: progress report. Tabakoff B. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):243A–247A

Polymorphism of alcohol–metabolizing genes affects drinking behavior and alcoholic liver disease in Japanese men. Tanaka F, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):596–601

Alcohol use disorder among adolescents: impact of paternal alcoholism on drinking behavior, drinking motivation, and consequences. Tarter RE, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):171–8

Behavioral sensitivity and ethanol potentiation of the N–methyl–D–aspartate receptor antagonist MK–801 in a rat line selected for high ethanol sensitivity. Toropainen M, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):666–71

Models of treatment seeking for alcoholism: the role of genes and environment. True WR, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1577–81

No electrocortical evidence of automatic mismatch dysfunction in children of alcoholics. van der Stelt O, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):569–75

Alcohol elimination in Native American Mission Indians: an investigation of interindividual variation. Wall TL, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1159–64

NF–kappa B, a prototypical cytokine–regulated transcription factor: implications for alcohol–mediated responses. Zakhari S. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):236A–242A

The transmission of parent/adult–child drinking patterns: testing a gender–specific structural model. Yu J, et al. **Am J Drug Alcohol Abuse** 1997 Feb;23(1):143–65

Lack of association between TaqI A1 allele of dopamine D2 receptor gene and alcohol–use disorders in atayal natives of Taiwan. Chen CH, et al. **Am J Med Genet** 1996 Sep 20;67(5):488–90

Dopamine D2 receptor gene and alcoholism among four aboriginal groups and Han in Taiwan. Chen WJ, et al. **Am J Med Genet** 1997 Apr 18;74(2):129–36

Lack of association between alcohol–dependence and D3 dopamine receptor gene in three independent samples. Gorwood P, et al. **Am J Med Genet** 1995 Dec 18; 60(6):529–31

Human adenylyl cyclase type 7 contains polymorphic repeats in the 3' untranslated region: investigations of association with alcoholism. Hellevuo K, et al. **Am J Med Genet** 1997 Feb 21;74(1):95–8

No evidence of association between structural polymorphism at the dopamine D3 receptor locus and alcoholism in the Japanese. Higuchi S, et al. **Am J Med Genet** 1996 Jul 26; 67(4):412–4

Association between early–onset alcoholism and the dopamine D2 receptor gene. Kono Y, et al. **Am J Med Genet** 1997 Apr 18;74(2):179–82

Cladistic analysis of disease association with tyrosine hydroxylase: application to manic–depressive disease and alcoholism. Lobos EA, et al. **Am J Med Genet** 1997 May 31;74(3):289–95

No association between polymorphisms in the human dopamine D3 and D4 receptors genes and alcoholism. Parsian A, et al. **Am J Med Genet** 1997 May 31;74(3):281–5

The familial aggregation of depressive symptoms, antisocial behavior, and alcohol abuse. Stallings MC, et al. **Am J Med Genet** 1997 Apr 18;74(2):183–91

The firewater myth and response to alcohol in Mission Indians. Garcia–Andrade C, et al. **Am J Psychiatry** 1997 Jul;154(7):983–8

Genetics, alcohol, and cirrhosis [letter] Ceni E, et al. **Ann Intern Med** 1997 Jun 15;126(12):1000

Dopamine D2 receptor (DRD2) genotype differentiates intravenous drug abusers from alcoholics and non–abusers. Foley PF, et al. **Ann N Y Acad Sci** 1996 Oct 31;801:409–14

Temperance board registration for alcohol abuse in a national sample of Swedish male twins, born 1902 to 1949. Kendler KS, et al. **Arch Gen Psychiatry** 1997 Feb;54(2):178–84

TPH replication study: not! [letter; comment] Nielsen DA, et al. **Arch Gen Psychiatry** 1996 Oct;53(10):964–5. Comment on: Arch Gen Psychiatry 1995 Oct;52(10):846–9.

The D2 dopamine receptor (DRD2) gene and family stress; interactive effects on cognitive functions in children. Berman SM, et al. **Behav Genet** 1997 Jan;27(1):33–43

The dopamine D4 receptor gene (DRD4) is not associated with alcoholism in three Taiwanese populations: six polymorphisms tested separately and as haplotypes. Chang FM, et al. **Biol Psychiatry** 1997 Feb 15;41(4):394–405

Alcohol dehydrogenase and aldehyde dehydrogenase genotypes and alcoholism among Taiwanese aborigines. Chen WJ, et al. **Biol Psychiatry** 1997 Mar 15;41(6):703–9

Neuroelectric correlates of response production and inhibition in individuals at risk to develop alcoholism. Cohen HL, et al. **Biol Psychiatry** 1997 Jul 1;42(1):57–67

Association of the D2 dopamine receptor A1 allele with alcoholism: medical severity of alcoholism and type of controls. Lawford BR, et al. **Biol Psychiatry** 1997 Feb 15; 41(4):386–93

Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium. Sander T, et al. **Biol Psychiatry** 1997 Feb 1;41(3):299–304

Alcohol–metabolising genes and alcoholism among Taiwanese Han men: independent effect of ADH2, ADH3 and ALDH2. Chen WJ, et al. **Br J Psychiatry** 1996 Jun; 168(6):762–7

A genetic linkage study of the D2 dopamine receptor locus in heavy drinking and alcoholism. Cook CC, et al. **Br J Psychiatry** 1996 Aug;169(2):243–8

Genetic markers of alcohol abuse. Ferguson RA, et al. **Clin Chim Acta** 1997 Jan 17;257(2):199–250 (232 ref.)

Indicators of genetic and environmental influences in drug abusing individuals. Johnson EO, et al. **Drug Alcohol Depend** 1996 May;41(1):17–23

Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the U.S. population. Kandel D, et al. **Drug Alcohol Depend** 1997 Jan 10;44(1):11–29

The influence of familial and non–familial factors on the association between major depression and substance abuse/dependence in 1874 monozygotic male twin pairs. Lin N, et al. **Drug Alcohol Depend** 1996 Dec 2; 43(1–2):49–55

Mating assortment and the liability to substance abuse. Vanyukov MM, et al. **Drug Alcohol Depend** 1996 Sep; 42(1):1–10 (100 ref.)

An adoption study of DSM–IIIR alcohol and drug dependence severity. Yates WR, et al. **Drug Alcohol Depend** 1996 May;41(1):9–15

Risk of alcoholism and parental history: gender differences and a possible reporting bias. Crum RM, et al. **Genet Epidemiol** 1996;13(4):329–41

Polymorphisms of ethanol–oxidizing enzymes in alcoholics with inactive ALDH2. Higuchi S, et al. **Hum Genet** 1996 Apr;97(4):431–4

The contribution of polymorphism in the alcohol dehydrogenase beta subunit to alcohol sensitivity in a Japanese population. Takeshita T, et al. **Hum Genet** 1996 Apr;97(4):409–13

Alcohol outcome expectancies and alcohol use: a latent variable cross–lagged panel study. Sher KJ, et al. **J Abnorm Psychol** 1996 Nov;105(4):561–74

Startle modulation in children at risk for anxiety disorders and/or alcoholism. Grillon C, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jul;36(7):925–32

Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholic patients. Mansouri A, et al. **J Hepatol** 1997 Jul;27(1):96–102

Association between alcoholism and the dopamine D4 receptor gene. Muramatsu T, et al. **J Med Genet** 1996 Feb; 33(2):113–5

Quantitative trait loci involved in genetic predisposition to acute alcohol withdrawal in mice. Buck KJ, et al. **J Neurosci** 1997 May 15;17(10):3946–55

Common quantitative trait loci for alcohol–related behaviors and central nervous system neurotensin measures: locomotor activation. Erwin VG, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):919–26

Common quantitative trait loci for alcohol–related behaviors and central nervous system neurotensin measures: hypnotic and hypothermic effects. Erwin VG, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):911–8

Fibromyalgia, depression, and alcoholism: a family history study. Katz RS, et al. **J Rheumatol** 1996 Jan;23(1):149–54

Executive cognitive functioning and aggressive behavior in preadolescent boys at high risk for substance abuse/dependence. Giancola PR, et al. **J Stud Alcohol** 1996 Jul;57(4):352–9

Estimating genetic and environmental effects of alcohol use and dependence from a national survey: a "quasi–adoption" study. Light JM, et al. **J Stud Alcohol** 1996 Sep; 57(5):507–20 (45 ref.)

Predictors of problem drinking and alcohol dependence in a population–based sample of female twins. Prescott CA, et al. **J Stud Alcohol** 1997 Mar;58(2):167–81

Assessing the risk for alcoholism among sons of alcoholics. Schuckit MA, et al. **J Stud Alcohol** 1997 Mar;58(2):141–5

Alcohol challenges in young men from alcoholic pedigrees and control families: a report from the COGA project. Schuckit MA, et al. **J Stud Alcohol** 1996 Jul;57(4):368–77

The role of childhood stressors in the intergenerational transmission of alcohol use disorders. Sher KJ, et al. **J Stud Alcohol** 1997 Jul;58(4):414–27

Reliability and reporting biases for perceived parental history of alcohol–related problems: agreement between twins and differences between discordant pairs. Slutske WS, et al. **J Stud Alcohol** 1996 Jul;57(4):387–95

Vigilance and iconic memory in children at high risk for alcoholism. Steinhauer SR, et al. **J Stud Alcohol** 1997 Jul; 58(4):428–34

Heavy consumption of cigarettes, alcohol and coffee in male twins. Swan GE, et al. **J Stud Alcohol** 1997 Mar; 58(2):182–90

On the discriminative validity of a family history of problem drinking index with a national sample of young adults. Windle M. **J Stud Alcohol** 1996 Jul;57(4):378–86

Are there two types of alcoholism? Hall W, et al. **Lancet** 1996 Nov 9;348(9037):1258

CYP2E1 genotypes and serum LAP in Japanese alcoholics. Miyatake R, et al. **Life Sci** 1995 Feb 17;56(13):1121–6

Rsa I polymorphism at the cytochrome P4502E1 locus is not related to the risk of alcohol–related severe liver disease. Agúndez J, et al. **Liver** 1996 Dec;16(6):380–3

Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Comings DE, et al. **Mol Psychiatry** 1997 Jan;2(1):44–56

Genes and the environment in complex diseases: a focus on alcoholism [news] Gordis E. **Mol Psychiatry** 1997 Jul; 2(4):282–6

Influence of the dopamine D2 receptor (DRD2) genotype on neuroadaptive effects of alcohol and the clinical outcome of alcoholism. Finckh U, et al. **Pharmacogenetics** 1997 Aug;7(4):271–81

Molecular genetic aspects of alcohol metabolism and alcoholism. Agarwal DP. **Pharmacopsychiatry** 1997 May; 30(3):79–84 (55 ref.)

Alcoholism and gene polymorphisms related to central dopaminergic transmission in the Japanese population. Dobashi I, et al. **Psychiatr Genet** 1997 Summer;7(2):87–91

No association between the dopamine D2 receptor gene and Korean alcoholism. Lee MS, et al. **Psychiatr Genet** 1997 Summer;7(2):93–5

Associations of beta–endorphin with HVA and MHPG in the plasma of prepubertal boys: effects of familial drug abuse and antisocial personality disorder liability. Moss HB, et al. **Psychiatry Res** 1996 Jun 1;62(3):203–11

[Alcoholism: value of a search for familial antecedents] Limosin F, et al. **Presse Med** 1996 Oct 26;25(32):1550–4 (27 ref.) (Eng. Abstr.) **(Fre)**

[Characteristics of tyrosine hydroxylase gene expression in the brain of rats with different ethanol consumption after chronic alcoholic intoxication] Anokhina IP, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):63–5 **(Rus)**

HISTORY

The history of alcoholism: Brühl–Cramer's concepts and observations. Kielhorn FW. **Addiction** 1996 Jan;91(1):121–8

The state's "sharp line between the sexes": women, alcohol and the law in the United States, 1850–1980. Nicolaides BM. **Addiction** 1996 Aug;91(8):1211–29

Per capita alcohol consumption and total mortality: an analysis of historical data. Norström T. **Addiction** 1996 Mar; 91(3):339–44

The treatment of Philadelphia inebriates. From temperance reform to "secret cure". Leonard EC Jr. **Am J Addict** 1997 Winter;6(1):1–10

A 39–year–old man with mental status change [clinical conference] [see comments] Benitez RM. **Md Med J** 1996 Sep;45(9):765–9. Comment in: Md Med J 1996 Dec;45(12):1009; discussion 1010.

Poe's death remains a mystery [letter; comment] Drewer D. **Md Med J** 1996 Dec;45(12):1009; discussion 1010. Comment on: Md Med J 1996 Sep;45(9):765–9.

Women alcoholics at Bellevue, 1918–1919 [letter] Roizen R. **Science** 1996 Nov 29;274(5292):1450–1

IMMUNOLOGY

Improvement of the CD4 cell count after alcohol withdrawal in HIV–positive alcoholic patients [letter] Pol S, et al. **AIDS** 1996 Sep;10(11):1293–4

Anti–low–density lipoprotein antibodies in alcoholics without and with liver disease and in social drinkers. Wehr H, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):43–9

Studies on the usefulness of acetaldehyde–modified proteins and associated antibodies as markers of alcohol abuse. Worrall S, et al. **Alcohol Alcohol Suppl** 1994;2:503–7

The effect of chronic ethanol feeding on cytokines in a rat model of alcoholic liver disease. Worrall S, et al. **Alcohol Alcohol Suppl** 1994;2:447–51

Alcohol and human immunodeficiency virus infection. Cook RT. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):210A–215A

Protective mechanism of high–density lipoprotein against endotoxemia in chronic alcohol ingestion. Kitano H, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):356A–359A

Effects of ethanol consumption on susceptibility to pulmonary and gastrointestinal factors. Mellencamp MA. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):192A–195A

Neuroendocrine–immune axis of alcoholics. Sarkar DK. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):256A–259A

Ethanol ingestion inhibits cell–mediated immune responses of unprimed T–cell receptor transgenic mice. Schodde H, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):890–9

Defective calcium increase and inositol phosphate production in anti–CD3–stimulated lymphocytes of alcoholics without progressive liver disease. Stefanini GF, et al. **Alcohol Clin Exp Res** 1996 May;20(3):523–7

Relationship between alcohol intake and immunoglobulin a immunoreactivity with acetaldehyde–modified bovine serum albumin. Worrall S, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):836–40

Alcohol and infection. MacGregor RR, et al.

Curr Clin Top Infect Dis 1997;17:291–315 (208 ref.)

Long lasting immunological effects of ethanol after withdrawal. Laso FJ, et al. **Cytometry** 1996 Dec 15; 26(4):275–80

Increased serum concentration of IgA2 subclass and IgA2/IgA1 ratio: specific markers of chronic alcoholic abuse? Meillet D, et al. **Eur J Clin Chem Clin Biochem** 1997 Apr;35(4):275–9

Chronic ethanol effects on cellular immune responses to hepatitis B virus envelope protein: an immunologic mechanism for induction of persistent viral infection in alcoholics. Geissler M, et al. **Hepatology** 1997 Sep; 26(3):764–70

Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. Laso FJ, et al. **Hepatology** 1997 May;25(5):1096–100

Is there a link between nutritional status, immune response and phosphinositide fatty acid composition of peripheral blood lymphocytes in alcoholics? [letter] Stefanini GF, et al. **Ital J Gastroenterol** 1996 Feb–Mar;28(2):123

Suppression of splenic natural killer cell activity in a mouse model for binge drinking. I. Direct effects of ethanol and its major metabolites are not primarily responsible for decreased natural killer cell activity. Wu WJ, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1325–30

Suppression of splenic natural killer cell activity in a mouse model for binge drinking. II. Role of the neuroendocrine system. Wu WJ, et al. **J Pharmacol Exp Ther** 1996 Sep; 278(3):1331–9

Is alcohol a cofactor of HIV and AIDS? Evidence from immunological and behavioral studies. Dingle GA, et al. **Psychol Bull** 1997 Jul;122(1):56–71 (125 ref.)

[Alcohol and free radicals: from basic research to clinical prospects] Nordmann R, et al.
Ann Gastroenterol Hepatol (Paris) 1996 May–Jun; 32(3):128–33; discussion 133–4 (41 ref.) (Eng. Abstr.) **(Fre)**

[Anti-HCV antibody and hemolytic complement activity in sera from alcoholic patients] Koyama I, et al.
Rinsho Byori 1997 Jun;45(6):585–9 (Eng. Abstr.) **(Jpn)**

[The evaluation of the effect of zinc sulfate on primary immune response indices under alcoholic intoxication] Proskuriakova TV, et al. **Eksp Klin Farmakol** 1996 Mar–Apr;59(2):47–9 (Eng. Abstr.) **(Rus)**

METABOLISM

Tryptophan metabolism and disposition in relation to alcohol and alcoholism. Badawy AA. **Adv Exp Med Biol** 1996; 398:75–82 (28 ref.)

Brain nucleic acid composition and fractional rates of protein synthesis in response to chronic ethanol feeding: comparison with skeletal muscle. Bonner AB, et al.
Alcohol 1996 Nov–Dec;13(6):581–7

GABAA receptors in damaged cerebral cortex areas in human chronic alcoholics. Dodd PR.
Alcohol Alcohol Suppl 1994;2:187–91

Polymorphisms of ethanol metabolizing enzyme genes and alcoholism. Higuchi S. **Alcohol Alcohol Suppl** 1994;2:29–34

Alteration in cerebral GABAB receptor functions during formation of alcohol dependence. Kuriyama K, et al.
Alcohol Alcohol Suppl 1994;2:193–7

Thiamine utilization in the pathogenesis of alcohol-induced brain damage. Martin PR, et al. **Alcohol Alcohol Suppl** 1994; 2:273–9 (35 ref.)

GABAA and NMDA receptor subunit mRNA expression in ethanol dependent rats. Morrow AL, et al.
Alcohol Alcohol Suppl 1994;2:89–95

5-HT receptors: implications for the neuropharmacology of alcohol and alcoholism. Overstreet DH, et al.
Alcohol Alcohol Suppl 1994;2:205–10 (49 ref.)

Alterations of receptor-G protein–adenylyl cyclase coupling in alcoholics. Saito T, et al. **Alcohol Alcohol Suppl** 1994; 2:211–5

Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Volkow ND, et al.
Alcohol Clin Exp Res 1996 Dec;20(9):1594–8

Folate absorption in the jejunum of chronic ethanol-fed rats: in vivo studies. Fernandez-Borrachero O, et al.
Ann Nutr Metab 1996;40(5):277–82

Folate absorption in the caecum of chronic ethanol-fed rats: in vivo studies. Fernandez-Borrachero O, et al.
Ann Nutr Metab 1996;40(5):283–6

Prevalence of high serotonin uptake in lymphocytes of abstinent alcoholics. Faraj BA, et al.
Biochem Pharmacol 1997 Jan 10;53(1):53–7

Altered myosin heavy chain in hearts of ethanol exposed rats. Sandhu GS, et al. **Biochem Soc Trans** 1996 May; 24(2):261S

Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium. Sander T, et al. **Biol Psychiatry** 1997 Feb 1;41(3):299–304

Lanthanum and zinc sensitivity of GABAA-activated currents in adult medial septum/diagonal band neurons from ethanol dependent rats. Frye GD, et al.
Brain Res 1996 May 13;720(1–2):101–10

Expression of the alpha 1, alpha 2 and alpha 3 isoforms of the GABAA receptor in human alcoholic brain. Lewohl JM, et al. **Brain Res** 1997 Mar 14;751(1):102–12

[3H]naloxone binding in the human brain: alcoholism and the TaqI A D2 dopamine receptor polymorphism. Ritchie T, et al. **Brain Res** 1996 Apr 29;718(1–2):193–7

Up-regulation of high-affinity neurotrophin receptor, trk B-like protein on western blots of rat cortex after chronic ethanol treatment. Baek JK, et al.
Brain Res Mol Brain Res 1996 Aug;40(1):161–4

Regional and subunit specific changes in NMDA receptor mRNA and immunoreactivity in mouse brain following chronic ethanol ingestion. Snell LD, et al.
Brain Res Mol Brain Res 1996 Aug;40(1):71–8

Ethanol metabolism, cirrhosis and alcoholism. Lieber CS. **Clin Chim Acta** 1997 Jan 3;257(1):59–84 (165 ref.)

Effects of thyrotropin-releasing hormone and metoclopramide on PRL secretion in normally cycling and amenorrheic alcoholic women. Vescovi PP, et al.
Drug Alcohol Depend 1997 Apr 14;45(1–2):115–9

Zolpidem binding sites on the GABA(A) receptor in brain from human cirrhotic and non-cirrhotic alcoholics. Lewohl JM, et al. **Eur J Pharmacol** 1997 May 20;326(2–3):265–72

CD18/ICAM-1-dependent nitric oxide production of Kupffer cells as a cause of mitochondrial dysfunction in hepatoma cells: influence of chronic alcohol feeding. Kurose I, et al. **Free Radic Biol Med** 1997;22(1–2):229–39

Prostaglandin E2 and prostaglandin F2 alpha biosynthesis in human gastric mucosa: effect of chronic alcohol misuse. Bode C, et al. **Gut** 1996 Sep;39(3):348–52

Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-L-methionine. Colell A, et al. **Hepatology** 1997 Sep;26(3):699–708

High-performance liquid chromatography method with light-scattering detection for measurements of lipid class composition: analysis of brains from alcoholics. Olsson NU, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):213–8

Effects of abstinence and relapse upon neuropsychological function and cerebral glucose metabolism in severe chronic alcoholism. Johnson-Greene D, et al.
J Clin Exp Neuropsychol 1997 Jun;19(3):378–85

A cholecystokinin-releasing factor mediates ethanol-induced stimulation of rat pancreatic secretion. Saluja AK, et al.
J Clin Invest 1997 Feb 1;99(3):506–12

Chronic ethanol administration to rats decreases receptor-operated mobilization of intracellular ionic calcium in cultured hepatocytes and inhibits 1,4,5-inositol trisphosphate production: relevance to impaired liver regeneration. Zhang BH, et al. **J Clin Invest** 1996 Sep 1; 98(5):1237–44

Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. Ciraulo DA, et al. **J Clin Pharmacol** 1997 Jan;37(1):64–73

Effects of ethanol on meal-stimulated secretion of pancreatic polypeptide and cholecystokinin: comparison of healthy volunteers, heavy drinkers, and patients with chronic pancreatitis. Hirano H, et al. **J Gastroenterol** 1996 Feb; 31(1):86–93

Alcohol and iron: one glass of red or more? Fletcher LM.
J Gastroenterol Hepatol 1996 Nov;11(11):1039–41 (6 ref.)

Oxidation of circulating proteins in alcoholics: role of acetaldehyde and xanthine oxidase. Grattagliano I, et al.
J Hepatol 1996 Jul;25(1):28–36

Impairment of metabolic hepatic nerve action by chronic but not acute ethanol intoxication studied in isolated perfused rat liver. Kucera T, et al. **J Hepatol** 1997 Jan; 26(1):183–90

Effects of m-chlorophenylpiperazine on regional brain glucose utilization: a positron emission tomographic comparison of alcoholic and control subjects. Hommer D, et al. **J Neurosci** 1997 Apr 15;17(8):2796–806

Studies on phospholipid biosynthesis in hepatocytes from alcoholic rats by using radiolabeled exogenous precursors. Carrasco MP, et al. **Lipids** 1996 Apr;31(4):393–7

Brain metabolite changes in alcoholism: an in vivo proton magnetic resonance spectroscopy (MRS) study.
Jagannathan NR, et al. **Magn Reson Imaging** 1996; 14(5):553–7

Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat. Iimuro Y, et al. **Mol Pharmacol** 1996 Sep;50(3):656–61

Alcohol, alcoholic brain damage, and GABAA receptor isoform gene expression. Lewohl JM, et al.
Neurochem Int 1996 Dec;29(6):677–84

Lipid peroxidation and antioxidant systems in rat brain: effect of chronic alcohol consumption. Omodeo-Sale F, et al. **Neurochem Res** 1997 May;22(5):577–82

Beta-adrenoreceptor coupling to GS protein in alcohol dependence, panic disorder, and patients with both conditions. Gurguis GN, et al.
Neuropsychopharmacology 1997 Jan;16(1):69–76

Chronic ethanol on mRNA levels of IP3R1, IP3 3-kinase and mGluR1 in mouse Purkinje neurons. Simonyi A, et al. **Neuroreport** 1996 Sep 2;7(13):2115–8

Thyroid hormone metabolism in the rat brain in an animal model of 'behavioral dependence' on ethanol. Baumgartner A, et al. **Neurosci Lett** 1997 May 9;227(1):25–8

Loss of vasopressin-immunoreactive neurons in alcoholics is dose-related and time-dependent. Harding AJ, et al.
Neuroscience 1996 Jun;72(3):699–708

Chronic ethanol intoxication enhances [3H]CCPA binding and does not reduce A1 adenosine receptor function in rat cerebellum. Concas A, et al.
Pharmacol Biochem Behav 1996 Feb;53(2):249–55

Cellular and molecular neuroscience of alcoholism. Diamond I, et al. **Physiol Rev** 1997 Jan;77(1):1–20 (375 ref.)

Disrupted melatonin-secretion during alcohol withdrawal. Schmitz MM, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1996 Aug; 20(6):983–95

Alcohol withdrawal and dopamine receptor sensitivity after prolonged abstinence. Wiesbeck GA, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1996 Oct; 20(7):1171–80

Carbohydrate-deficient transferrin: an investigative biochemical marker of heavy alcohol consumption. Saini RS, et al. **Psychopharmacol Bull** 1997;33(1):171–5

Endogenous opioid systems and alcohol addiction. Herz A. **Psychopharmacology (Berl)** 1997 Jan;129(2):99–111 (150 ref.)

Effect of alcohol abuse and glutathione administration on the circulating levels of glutathione and on antipyrine metabolism in patients with alcoholic liver cirrhosis. Loguercio C, et al. **Scand J Clin Lab Invest** 1996 Aug; 56(5):441–7

[Alcohol and free radicals: from basic research to clinical prospects] Nordmann R, et al.
Ann Gastroenterol Hepatol (Paris) 1996 May–Jun; 32(3):128–33; discussion 133–4 (41 ref.) (Eng. Abstr.) **(Fre)**

[Effects of chronic ethanol feeding on lipid composition of rat liver plasma membrane—changes of membrane by acute ethanol loading or its withdrawal in vivo] Yamashita T, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Jun; 31(3):215–25 (Eng. Abstr.) **(Jpn)**

[Steroidogenesis in rat testes in chronic alcoholic intoxication and addition of ethanol in vitro] Kashko MF, et al.
Ukr Biokhim Zh 1996 Nov–Dec;68(6):98–103 (Eng. Abstr.) **(Rus)**

[Search for biochemical factors implicated in the pathogenesis of alcoholism in different ethnic populations] Semke VIa, et al. **Vestn Ross Akad Med Nauk** 1996; (12):49–56 (Eng. Abstr.) **(Rus)**

[Assessment of bone status in intermittent and continuous alcoholics, without evidence of liver damage] Pumarino H, et al. **Rev Med Chil** 1996 Apr;124(4):423–30 (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Cokeromyces recurvatus isolated from pleural and peritoneal fluid: case report. Munipalli B, et al. **J Clin Microbiol** 1996 Oct;34(10):2601–3

MORTALITY

WHO working group on population levels of alcohol consumption: Oslo, 14–16 December 1994. Anderson P. **Addiction** 1996 Feb;91(2):275–83

Alcohol consumption and suicide mortality by age among Finnish men, 1950–1991. Mäkelä P. **Addiction** 1996 Jan; 91(1):101–12

Biased cohort studies on alcohol abuse and mortality [letter] Poikolainen K. **Addiction** 1997 Jul;92(7):903–4

The disadvantage of being advantaged?—on a social gradient in excess mortality among alcohol abusers. Rossow I, et al. **Addiction** 1996 Dec;91(12):1821–9

Alcohol and suicide—beyond the link at the individual level [editorial] Rossow I. **Addiction** 1996 Oct;91(10):1413–6

Public health consequences of the J-curve hypothesis of alcohol problems. Skog OJ. **Addiction** 1996 Mar; 91(3):325–37

Mortality and morbidity related to alcohol. Andreasson S, et al. **Alcohol Alcohol** 1997 Mar–Apr;32(2):173–8

High alcohol-related premature mortality in France: concordant estimates from a prospective cohort study and national mortality statistics. Zureik M, et al.
Alcohol Clin Exp Res 1996 May;20(3):428–33

Premature mortality in aboriginal adults in the Northern Territory, 1979–1991 [letter; comment] Wilson GC.
Med J Aust 1997 Mar 3;166(5):278–9. Comment on: Med J Aust 1996 Sep 16;165(6):309–12.

Chronic alcoholism in a forensic material. 1. Social parameters in alcoholics. Thomsen JL. **Med Sci Law** 1996 Jul;36(3):199–208

Chronic alcoholism in a forensic material. 2. Causes and manners of death in alcoholics. Thomsen JL.
Med Sci Law 1996 Jul;36(3):209–16

Alcohol use in Minnesota. Extent and cost. Kloehn D, et al. **Minn Med** 1997 May;80(5):26–9

Deaths caused by alcohol [news] Doyle R. **Sci Am** 1996 Dec; 275(6):30–1

Alcohol abuse and mortality: a 40-year prospective study of Norwegian conscripts. Rossow I, et al. **Soc Sci Med** 1997 Jan;44(2):261–7

[Geographic variability of alcohol-related mortality in Italy in the period 1980–1990] Cipriani F, et al.
Epidemiol Prev 1996 Oct–Dec;20(4):328–38 (Eng. Abstr.) **(Ita)**

[Mortality related to alcohol consumption in Spain: 1981–1990] Prada Puentes C, et al. **Gac Sanit** 1996 Jul–Aug; 10(55):161–8 (Eng. Abstr.) **(Spa)**

NURSING

Community psychiatric nurse aftercare for alcoholics: a five-year follow-up study. Patterson DG, et al.

Addiction 1997 Apr;92(4):459–68 **(Ger)**

Starting recovery. Gorman M. **Am J Nurs** 1996 Sep;96(9):15

When death comes to the alcoholic family. Raymer M. **Am J Nurs** 1996 Dec;96(12):58–60

Enhancing nursing competence with substance abusing clients. Marcus MT, et al. **J Nurs Educ** 1996 Nov; 35(8):361–6

PATHOLOGY

Morphometric evidence that the total number of synapses on Purkinje neurons of old F344 rats is reduced after long-term ethanol treatment and restored to control levels after recovery. Dlugos CA, et al. **Alcohol Alcohol** 1997 Mar-Apr;32(2):161–72

Magnetic resonance imaging in alcoholic Korsakoff's syndrome: evidence for an association with alcoholic dementia. Emsley R, et al. **Alcohol Alcohol** 1996 Sep; 31(5):479–86

Age-related effects of chronic ethanol intake on physical properties, lipid composition and galactosyltransferase activity of rat small intestine microsomes. Lindi C, et al. **Alcohol Alcohol** 1996 Mar;31(2):183–9

Chronic alcoholics have substantial glial pathology in the forebrain and diencephalon. Cullen KM, et al. **Alcohol Alcohol Suppl** 1994;2:253–7

Differential age-related loss of pigmented locus coeruleus neurons in suicides, alcoholics, and alcoholic suicides. Arango V, et al. **Alcohol Clin Exp Res** 1996 Oct; 20(7):1141–7

Ethanol modulates metastatic potential of B16BL6 melanoma and host responses. Blank SE, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):624–8

Fatty acid composition of liver total lipids in alcoholic patients with and without liver damage. de la Maza MP, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1418–22

Glutamate receptors in the frontal cortex of alcoholics. Freund G, et al. **Alcohol Clin Exp Res** 1996 Oct; 20(7):1165–72

Cortical and subcortical white matter damage without Wernicke's encephalopathy after recovery from thiamine deficiency in the rat. Langlais PJ, et al. **Alcohol Clin Exp Res** 1997 May;21(3):434–43

Thinning of the corpus callosum in older alcoholic men: a magnetic resonance imaging study. Pfefferbaum A, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):752–7

Effects of lifelong ethanol consumption on cerebellar layer volumes in AA and ANA rats. Rintala J, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):311–7

Alcohol consumption by young actively growing rats: a histomorphometric study of cancellous bone. Sampson HW, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):352–9

Chronic alcohol feeding in liquid diet or in drinking water has similar effects on electron microscopic appearance of the hepatic sinusoid in the rat. Sarphie TG, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):973–9

Mammillary body and cerebellar shrinkage in chronic alcoholics with and without amnesia. Shear PK, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1489–95

Do noradrenergic locus coeruleus neurons degenerate in alcoholics? [letter; comment] Underwood MD, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):786–7. Comment on: Alcohol Clin Exp Res 1996 Feb;20(1):191–2.

Decreased corpus callosum size among alcoholic women. Hommer D, et al. **Arch Neurol** 1996 Apr;53(4):359–63

Morphometrical study of the rat liver sinusoids in chronic ethanol intoxication. Foryś M, et al. **Folia Morphol (Warsz)** 1996;55(4):233–5

Chronic alcohol consumption does not cause hippocampal neuron loss in humans. Harding AJ, et al. **Hippocampus** 1997;7(1):78–87

Degeneration of intrapancreatic nerve fibers after chronic alcohol administration in mice. Berger Z, et al. **Int J Pancreatol** 1997 Apr;21(2):165–71

Atrophy of the corpus callosum in chronic alcoholism. Estruch R, et al. **J Neurol Sci** 1997 Mar 10;146(2):145–51

Morphologic changes in the vesical transition epithelium of alcoholic rats. Mello Júnior W, et al. **J Submicrosc Cytol Pathol** 1997 Jul;29(3):393–9

Brain metabolite changes in alcoholism: an in vivo proton magnetic resonance spectroscopy (MRS) study. Jagannathan NR, et al. **Magn Reson Imaging** 1996; 14(5):553–7

Chronic alcoholism in the absence of Wernicke-Korsakoff syndrome and cirrhosis does not result in the loss of serotonergic neurons from the median raphe nucleus. Baker KG, et al. **Metab Brain Dis** 1996 Sep;11(3):217–27

Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat. Iimuro Y, et al. **Mol Pharmacol** 1996 Sep;50(3):656–61

Letter to the editor. Jellinger K, et al. **Neuropathol Appl Neurobiol** 1996 Feb;22(1):84–5

The cerebral cortex is damaged in chronic alcoholics. Kril JJ, et al. **Neuroscience** 1997 Aug;79(4):983–98

Plasma cells with iron inclusions in two non-alcoholic Chinese women. Tsoi WC, et al. **Pathology** 1996 May; 28(2):125–7

[Atherosclerosis in alcoholics] Thomsen JL. **Ugeskr Laeger** 1997 Feb 3;159(6):757–60 (Eng. Abstr.) **(Dan)**

[Effects of chronic alcohol drinking on mouth mucosa. A morphometric study] Born IA, et al. **Laryngorhinootologie** 1996 Dec;75(12):754–8 (Eng. Abstr.) **(Ger)**

[Patho- and morphogenesis of alcoholism] Paukov VS. **Biull Eksp Biol Med** 1996 Dec;122(12):604–10 (34 ref.) **(Rus)**

[Changes in neurons of the caudate nucleus in experimental alcoholism] Popova EN. **Biull Eksp Biol Med** 1997 Jul; 124(7):66–9 **(Rus)**

[Changes in cortical neurons and their dendrites after chronic alcoholic intoxication] Popova EN. **Biull Eksp Biol Med** 1996 Oct;122(10):467–70 **(Rus)**

[Class I and II histocompatibility antigens and severity of the alcoholic liver lesion] Caballería L, et al. **Gastroenterol Hepatol** 1997 Apr;20(4):167–71 (Eng. Abstr.) **(Spa)**

[Histopathological study of minor salivary glands in alcoholics] Smith P, et al. **Rev Med Chil** 1995 Nov; 123(11):1387–93 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Vibrameter testing facilitates the diagnosis of uremic and alcoholic polyneuropathy. Hilz MJ, et al. **Acta Neurol Scand** 1995 Dec;92(6):486–90

Long-term observation of the hypothalamic-pituitary-thyroid (HPT) axis in alcohol-dependent patients. Heinz A, et al. **Acta Psychiatr Scand** 1996 Jun;93(6):470–6

Temporal recovery of auditory evoked potentials in individuals at risk for alcoholism. Cohen HL, et al. **Alcohol** 1996 Jul-Aug;13(4):333–9

ERP responses to target and nontarget visual stimuli in alcoholics from VA and community treatment programs. Glenn SW, et al. **Alcohol** 1996 Jan-Feb;13(1):85–92

Circadian drinking pattern of Sardinian alcohol-preferring rats. Agabio R, et al. **Alcohol Alcohol** 1996 Jul;31(4):385–8

The role of neurotransmitters in alcohol dependence: animal research. De Witte P. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:13–6 (33 ref.)

Platelet monoamine oxidase-B activity in alcoholics with lowered dopamine D2 receptor activity [letter] Farren CK, et al. **Alcohol Alcohol** 1996 May;31(3):307–8

Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Gianoulakis C. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:33–42

Buspirone as an inhibitor of voluntary ethanol intake in male rats. Hedlund L, et al. **Alcohol Alcohol** 1996 Mar; 31(2):149–56

Alcohol dependence: a commentary on mechanisms. Hoffman PL, et al. **Alcohol Alcohol** 1996 Jul;31(4):333–40 (60 ref.)

Adrenalectomy protects ethanol-withdrawn rats from harmine-induced tremor. Lamblin F, et al. **Alcohol Alcohol** 1996 Mar;31(2):175–81

Nature and healing of tibial shaft fractures in alcohol abusers. Nyquist F, et al. **Alcohol Alcohol** 1997 Jan-Feb;32(1):91–5

A possible acetaldehyde-mediated cardioprotective mechanism [letter] Wickramasinghe SN, et al. **Alcohol Alcohol** 1996 May;31(3):309–11

Cerebral dysfunction in chronic alcoholism: role of alcoholic liver disease. Butterworth RF. **Alcohol Alcohol Suppl** 1994; 2:259–65 (40 ref.)

A comparative neuropsychological approach to alcoholism and the brain. Oscar-Berman M. **Alcohol Alcohol Suppl** 1994;2:281–9 (58 ref.)

Interactions between alcohol- and opioid-induced suppression of rat testicular steroidogenesis in vivo. Adams ML, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):684–90

New insight into the mechanisms of ethanol effects on GABAA receptor function and expression, and their relevance to behavior. Buck KJ. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):198A–202A

Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics. Buydens-Branchey L, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):220–6

Direct effects of ethanol on signaling proteins. Charness ME. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):157A–161A

Effects of 5,7-dihydroxytryptamine lesions of the prefrontal cortex on consumption of sucrose-ethanol solutions: relationship to prefrontal monoamines. Deckel AW, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):631–6

Neural mechanisms of adaptation in chronic ethanol exposure and alcoholism. Dodd P. **Alcohol Clin Exp Res** 1996 Nov; 20(8 Suppl):151A–156A

The neurobiology of ethanol-opioid interactions in ethanol reinforcement. Froehlich JC. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):181A–186A

Dose-response studies with thyrotropin-releasing hormone: evidence for differential pituitary responses in men with major depression, alcoholism, or no psychopathology. Garbutt JC, et al. **Alcohol Clin Exp Res** 1996 Jun; 20(4):717–22

In vivo links between neurochemistry and behavioral effects of ethanol. Gonzales R. **Alcohol Clin Exp Res** 1996 Nov; 20(8 Suppl):203A–209A

NIAAA 25th anniversary: advances in the neuroscience of alcohol. Gordis E. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):38A–44A

A nonhuman primate model of type II excessive alcohol consumption? Part 1. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations and diminished social competence correlate with excessive alcohol consumption. Higley JD, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):629–42

A nonhuman primate model of type II alcoholism? Part 2. Diminished social competence and excessive aggression correlates with low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations. Higley JD, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):643–50

Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Lieber CS, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):375–9

Isoflavonoid compounds extracted from Pueraria lobata suppress alcohol preference in a pharmacogenetic rat model of alcoholism. Lin RC, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):659–63

Interactions between ethanol and agents that act on the NMDA-type glutamate receptor. Lovinger DM. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):187A–191A

Effect of chronic alcohol consumption on responses of cerebral arterioles. Mayhan WG, et al. **Alcohol Clin Exp Res** 1996 May;20(3):538–42

Effects of recombinant human insulin-like growth factor-1 and recombinant human growth hormone on anabolism and immunity in calorie-restricted alcoholic rats. Mendenhall CL, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):1–10

Effects of ethanol on intestinal absorption of drugs. I. In situ studies with ciprofloxacin analogs in normal and chronic alcohol-fed rats. Merino V, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):326–33

Supporting cells as targets of ethanol toxicity: altered regulation of growth factors and extracellular matrix. Miller MW. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):260A–264A

Tetrahydroisoquinolines and alcoholism: where are we today? Myers RD. **Alcohol Clin Exp Res** 1996 May; 20(3):498–500 (11 ref.)

Craving for alcohol and cocaine: from inside the brain to the clinic. Newlin DB. **Alcohol Clin Exp Res** 1996 Nov; 20(8 Suppl):45A–47A

Effect of glutathione on inositol 1,4,5-triphosphate-induced Ca2+ release in permeabilized hepatocytes from control and chronic ethanol-fed rats. Nomura T, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):325A–329A

Protein kinase C: molecular and cellular targets for the action of ethanol. Pandey SC. **Alcohol Clin Exp Res** 1996 Nov; 20(8 Suppl):67A–71A

Ethanol-induced change in cardiac and endogenous opiate function and risk for alcoholism. Peterson JB, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1542–52

Naltrexone effects on ethanol drinking acquisition and on established ethanol consumption in C57BL/6J mice. Phillips TJ, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):691–702

Alcohol and the gastrointestinal tract. Preedy VR. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):48A–50A

Periodic naltrexone and propensity to take alcoholic beverage. Reid LD, et al. **Alcohol Clin Exp Res** 1996 Nov; 20(8):1329–34

Feeding patterns of rats chronically ingesting an ethanol-containing liquid diet. Reidelberger RD, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1275–82

Free radical formation in livers of rats treated acutely and chronically with alcohol. Reinke LA, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):642–6

Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats. Roberts AJ, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1289–98

Glycine: the other inhibitory neurotransmitter. Schofield P. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):219A–223A

Ethanol and polyamine metabolism: physiologic and pathologic implications: a review. Sessa A, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):318–25 (121 ref.)

Ethanol and experimental breast cancer: a review. Singletary K. **Alcohol Clin Exp Res** 1997 Apr;21(2):334–9 (61 ref.)

Alcohol and breast cancer: interactions between alcohol and other risk factors. Singletary KW. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):57A–61A

Evidence for increased oxidative stress in alcohol-dependent patients provided by quantification of in vivo salicylate hydroxylation products. Thome J, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):82–5

Strategies for revealing the multiple determinants of drinking: pharmacological and environmental manipulations. Tomkins DM. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):125A–127A

The use of electrophysiological techniques in alcohol research. Treistman SN. **Alcohol Clin Exp Res** 1996 Nov; 20(8 Suppl):62A–66A

Free radical production during ethanol intoxication, dependence, and withdrawal. Vallett M, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):275–85

Testicular function in asymptomatic chronic alcoholics: relation to ethanol intake. Villalta J, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):128–33

Central serotonergic lesions increase voluntary alcohol consumption in Sprague Dawley rats: moderation by long-term ethanol administration. Wang JY, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1252–9

Chronic ethanol feeding impairs glucose tolerance but does not produce skeletal muscle insulin resistance in rat epitrochlearis muscle. Wilkes JJ, et al. **Alcohol Clin Exp Res** 1996 Sep;20(6):1016–22

Behavioral neurophysiology: neuronal spike train activity in alcohol research. Woodward DJ. **Alcohol Clin Exp Res**

1996 Nov;20(8 Suppl):101A–105A

Effect of chronic alcohol intake on energy metabolism in human muscle. Yazaki K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):360A–362A

Possibility of 5-HT3 receptor involvement in alcohol dependence: a microdialysis study of nucleus accumbens dopamine and serotonin release in rats with chronic alcohol consumption. Yoshimoto K, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):311A–319A

Chronic ethanol inhibits inositol metabolism in specific brain regions. Zhang JP, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):716–20

The role of neurosteroids in alcohol-related behaviors: new studies from the laboratory and clinic. Zimmerberg B. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):250A–255A

Chronic ethanol treatment reduces the responsiveness of the hypothalamic-pituitary-thyroid axis to central stimulation. Zoeller RT, et al. **Alcohol Clin Exp Res** 1996 Aug; 20(5):954–60

Chronic ethanol intake may delay the onset of gossypol-induced infertility in the male rat. Akingbemi BT, et al. **Andrologia** 1997 Jul–Aug;29(4):201–7

Impaired upper limb coordination in alcoholic cerebellar degeneration. Johnson–Greene D, et al. **Arch Neurol** 1997 Apr;54(4):436–9

Complex reaction time and EEG characteristics in alcoholics. Bobić J, et al. **Arh Hig Rada Toksikol** 1996 Dec;47(4):351–7

The involvement of catecholamines, in hypertension, alcohol and ACE-inhibition. Patel VB, et al. **Biochem Soc Trans** 1996 May;24(2):262S

Reduced dopaminergic function in alcoholics is related to severe dependence. Schmidt LG, et al. **Biol Psychiatry** 1996 Feb 1;39(3):193–8

Biochemical markers of bone metabolism after short and long time ethanol withdrawal in alcoholics. Nyquist F, et al. **Bone** 1996 Jul;19(1):51–4

Receptor binding sites and uptake activities mediating GABA neurotransmission in chronic alcoholics with Wernicke encephalopathy. Dodd PR, et al. **Brain Res** 1996 Feb 26; 710(1–2):215–28

Differential effects of cocaine, alcohol, and nicotine dependence on olfactory evoked potentials. Bauer LO, et al. **Drug Alcohol Depend** 1996 Sep;42(1):21–6

Pattern shift visual evoked potentials in abstinent cocaine-dependent, alcohol-dependent, and cross-dependent patients. Bauer LO, et al. **Drug Alcohol Depend** 1996 Mar;40(3):203–9

Basic aspects of GABA-transmission in alcoholism, with particular reference to GABA-transaminase. Sherif FM, et al. **Eur Neuropsychopharmacol** 1997 Feb;7(1):1–7 (61 ref.)

Late ventricular potentials and heavy drinking. Pochmalicki G, et al. **Heart** 1997 Aug;78(2):163–5

Influence of alcohol on gastrointestinal motility: lactulose breath hydrogen testing in orocecal transit time in chronic alcoholics, social drinkers and teetotaler subjects. Addolorato G, et al. **Hepatogastroenterology** 1997 Jul–Aug; 44(16):1076–81

Changes in cardiac signal transduction systems in chronic ethanol treatment preceding the development of alcoholic cardiomyopathy. Strasser RH, et al. **Herz** 1996 Aug; 21(4):232–40

The influence of acute and chronic alcohol treatment on brain edema, cerebral infarct volume and neurological outcome following experimental head trauma in rats. Shapira Y, et al. **J Neurosurg Anesthesiol** 1997 Apr;9(2):118–27

Propensity for alcoholism [letter; comment] Kubacki A. **J Psychiatry Neurosci** 1996 May;21(3):212. Comment on: J Psychiatry Neurosci 1995 Nov;20(5):372–96.

The effects of hypoxia on the bioenergetics of liver in situ in chronic ethanol-treated rats: a noninvasive in vivo 31P magnetic resonance spectroscopy study. Brauer M, et al. **J Stud Alcohol** 1997 Mar;58(2):119–29

Renal effects of alcohol withdrawal in five-week alcohol-treated rats. Ishigami M, et al. **J Stud Alcohol** 1997 Jul;58(4):392–6

Enhanced hepatotoxicity of acetaminophen in the alcoholic patient. Two case reports and a review of the literature. Johnston SC, et al. **Medicine (Baltimore)** 1997 May; 76(3):185–91 (40 ref.)

Genes and the environment in complex diseases: a focus on alcoholism [news] Gordis E. **Mol Psychiatry** 1997 Jul; 2(4):282–6

Effects of acute, chronic ethanol and withdrawal on dorsal raphe neurons: electrophysiological studies. Pistis M, et al. **Neuroscience** 1997 Jul;79(1):171–6

Influence of the dopamine D2 receptor (DRD2) genotype on neuroadaptive effects of alcohol and the clinical outcome of alcoholism. Finckh U, et al. **Pharmacogenetics** 1997 Aug;7(4):271–81

Early recurrence of withdrawal symptoms under phenytoin and chronic alcohol use. Knoll B, et al. **Pharmacopsychiatry** 1997 Mar;30(2):72–3

An animal model for type 2 alcoholism? Alcohol consumption and aggressive behavior following lesions in the raphe nuclei, medial hypothalamus, or ventral striatum-septal area. Bergvall AH, et al. **Physiol Behav** 1996 Oct;60(4):1125–35

Serotonergic ethanol effects and auditory evoked dipole activity in alcoholic and healthy subjects. Hegerl U, et al. **Psychiatry Res** 1996 Jun 26;63(1):47–55

An assessment of hypothalamo-pituitary-adrenal axis functioning in non-depressed, early abstinent alcoholics. Costa A, et al. **Psychoneuroendocrinology** 1996 Apr; 21(3):263–75

Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. King AC, et al. **Psychopharmacology (Berl)** 1997 Jan; 129(1):15–22

Evidence of acoustic startle hyperreflexia in recently detoxified early onset male alcoholics: modulation by yohimbine and m-chlorophenylpiperazine (mCPP). Krystal JH, et al. **Psychopharmacology (Berl)** 1997 Jun; 131(3):207–15

A nonhuman primate model of excessive alcohol intake. Personality and neurobiological parallels of type I- and type II-like alcoholism. Higley JD, et al. **Recent Dev Alcohol** 1997;13:191–219 (177 ref.)

Serotonin in early-onset alcoholism. Virkkunen M, et al. **Recent Dev Alcohol** 1997;13:173–89 (117 ref.)

Effect of alcohol abuse and glutathione administration on the circulating levels of glutathione and on antipyrine metabolism in patients with alcoholic liver cirrhosis. Loguercio C, et al. **Scand J Clin Lab Invest** 1996 Aug; 56(5):441–7

Alcohol withdrawal. Murray TD, et al. **Va Med Q** 1997 Summer;124(3):184–7, 189 (35 ref.)

[Clinical case of the month, apropos of a case of central pontine myelinolysis in a patient with chronic alcoholism] Lebrun F, et al. **Rev Med Liege** 1997;52(1):7–11 (18 ref.) **(Fre)**

[Hypertension and alcohol: central and peripheral mechanisms] Rupp H, et al. **Herz** 1996 Aug;21(4):258–64 (41 ref.) (Eng. Abstr.) **(Ger)**

[Alcohol and myocarditis] Wilke A, et al. **Herz** 1996 Aug; 21(4):248–57 (70 ref.) (Eng. Abstr.) **(Ger)**

[Neurotological examination of patients with alcohol dependency] Itoh A, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Aug;99(8):1110–8 (Eng. Abstr.) **(Jpn)**

[The effect of verbal reinforcement on visual-space perception in chronic alcoholism] Tsagareli MG. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(4):105–6 **(Rus)**

[The spatial organization of the electrical processes of the cerebral cortex in a pathological attraction to alcohol] Sviderskaia NE, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Nov–Dec; 46(6):999–1007 (Eng. Abstr.) **(Rus)**

[The hypophyseal-adrenal axis in chronic alcoholism] Somer L, et al. **Med Pregl** 1996;49(9–10):349–55 (Eng. Abstr.) **(Scr)**

PREVENTION & CONTROL

Feasibility of routine screening of patients for alcohol abuse [letter] Krishel S, et al. **Acad Emerg Med** 1996 Sep; 3(9):903–5

Prevention and treatment of alcohol-related problems: an international medical education model. Murray M, et al. **Acad Med** 1996 Nov;71(11):1204–10

Predicting problem drinking in college students: gender differences and the CAGE questionnaire. O'Hare T, et al. **Addict Behav** 1997 Jan–Feb;22(1):13–21

"Good guys" versus "bad guys" in scientific inquiry [letter; comment] Chafetz ME. **Addiction** 1996 Dec;91(12):1875–6 . Comment on: Addiction 1996 Jan;91(1):5–9.

Can individually directed interventions reduce population-level alcohol-involved problems? [editorial] Holder HD. **Addiction** 1997 Jan;92(1):5–7

Journal interview—39. Conversation with Senator Harold Hughes [interview] Hughes H. **Addiction** 1997 Feb; 92(2):137–49

Liquorspeak and the developing world [letter; comment] Laranjeira R. **Addiction** 1996 Dec;91(12):1870–1. Comment on: Addiction 1996 Jan;91(1):5–9.

Moderating drinking by correspondence: an evaluation of a new method of intervention. Sitharthan T, et al. **Addiction** 1996 Mar;91(3):345–55

Determining the effects of media portrayals of alcohol: going beyond short term influence. Baillie RK. **Alcohol Alcohol** 1996 May;31(3):235–42

Training general practitioners. McAvoy BR. **Alcohol Alcohol** 1997 Jan–Feb;32(1):9–12

Community organizing, public policy and the prevention of alcohol problems. Howard J. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):265A–269A

Screening for problem drinking and counseling by the primary care physician-nurse team. Israel Y, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1443–50

Effectiveness of a high school alcohol misuse prevention program. Shope JT, et al. **Alcohol Clin Exp Res** 1996 Aug; 20(5):791–8

Empowerment praxis in community coalitions. McMillan B, et al. **Am J Community Psychol** 1995 Oct;23(5):699–727

What is the psychiatrist's role in drugs and alcohol? Pols RG, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):540–8; discussion 548–9 (99 ref.)

Establishment and evaluation of a statewide drug and alcohol specialist advisory service. Crocker C, et al. **Aust N Z J Public Health** 1996 Aug;20(4):428–30

Managing alcohol and drug problems in general practice: a survey of trainees' knowledge, attitudes and educational requirements. Roche AM, et al. **Aust N Z J Public Health** 1996 Aug;20(4):401–8

More women drink at hazardous levels in England than Italy [letter; comment] Kaner EF, et al. **BMJ** 1997 May 10; 314(7091):1413. Comment on: BMJ 1997 Feb 8;314(7078):420–4.

Suicide prevention versus alcohol promotion [letter; comment] Ewbank J, et al. **Br J Psychiatry** 1996 Oct; 169(4):526. Comment on: Br J Psychiatry 1996 Jul;169(1):75–80.

Problems of alcohol- and drug abuse amongst seafarers. Searching for a wider approach. van Damme J. **Bull Inst Marit Trop Med Gdynia** 1996;47(1–4):53–60

Reducing alcohol-use disorders via decreased consumption: a comparison of population and high-risk strategies. Dawson DA, et al. **Drug Alcohol Depend** 1996 Sep; 42(1):39–47

Implementation of CAGE alcohol screening in a primary care practice. Lawner K, et al. **Fam Med** 1997 May; 29(5):332–5

Why is it so difficult for general practitioners to discuss alcohol with patients? Arborelius E, et al. **Fam Pract** 1995 Dec;12(4):419–22

Community coalitions for prevention and health promotion: factors predicting satisfaction, participation, and planning. Butterfoss FD, et al. **Health Educ Q** 1996 Feb;23(1):65–79

The detection of alcohol misuse in accident and emergency departments--grasping the opportunity [comment] Paton A. **J Accid Emerg Med** 1996 Sep;13(5):306–8 (22 ref.). Comment on: J Accid Emerg Med 1996 Sep;13(5):308–12.

Detection of alcohol misusing patients in accident and emergency departments: the Paddington alcohol test (PAT) [see comments] Smith SG, et al. **J Accid Emerg Med** 1996 Sep;13(5):308–12. Comment in: J Accid Emerg Med 1996 Sep;13(5):306–8.

Alcoholism and alcohol-related problems in Italy: an overview on recent developments in societal responses and treatment systems. Poldrugo F, et al. **J Addict Dis** 1996; 15(3):59–65 (5 ref.)

Concurrent and prospective screening for problem drinking among college students. Werner MJ, et al. **J Adolesc Health** 1996 Apr;18(4):276–85

Life after funding: a strategy for survival of a program to prevent substance abuse. Clapp JD, et al. **J Am Coll Health** 1996 Sep;45(2):79–81

Substance-free residence halls: the promise and the practice. Finn P. **J Am Coll Health** 1996 Sep;45(2):51–8

Experimental evaluation of "The Images Within": an alcohol education and prevention program. Woodside M, et al. **J Drug Educ** 1997;27(1):53–65

A two-item screening test for alcohol and other drug problems [see comments] Brown RL, et al. **J Fam Pract** 1997 Feb;44(2):151–60. Comment in: J Fam Pract 1997 Feb;44(2):147–9.

Physician advice for problem alcohol drinkers. Van Meter RA. **J Fam Pract** 1997 Jul;45(1):17–8

Alcohol is not a dichotomous variable [editorial; comment] Vinson DC. **J Fam Pract** 1997 Feb;44(2):147–9. Comment on: J Fam Pract 1997 Feb;44(2):151–60.

The practicality of using the SMAST and AUDIT to screen for alcoholism among adolescents in an urban private family practice. Foster AI, et al. **J Ky Med Assoc** 1997 Mar;95(3):105–7

Trauma history may shed light on elusive alcoholics [news] **J Psychosoc Nurs Ment Health Serv** 1997 Jul;35(7):8

Toward the assessment of psychological empowerment in health promotion: initial tests of validity and reliability. Rissel C, et al. **J R Soc Health** 1996 Aug;116(4):211–8

Substance use in an inner-city family planning population. Harwell TS, et al. **J Reprod Med** 1996 Sep;41(9):704–10

Screening for problem drinking in older primary care patients. Adams WL, et al. **JAMA** 1996 Dec 25; 276(24):1964–7

Brief physician advice for problem drinkers [letter] Bradley KA. **JAMA** 1997 Oct 1;278(13):1059; discussion 1060

Brief physician advice for problem alcohol drinkers. A randomized controlled trial in community-based primary care practices [see comments] Fleming MF, et al. **JAMA** 1997 Apr 2;277(13):1039–45. Comment in: JAMA 1997 Apr 2;277(13):1079–80.

Brief physician advice for problem drinkers [letter] Guarnieri M. **JAMA** 1997 Oct 1;278(13):1059–60; discussion 1060

Another indication for screening and early intervention: problem drinking [editorial; comment] Parish DC. **JAMA** 1997 Apr 2;277(13):1079–80. Comment on: JAMA 1997 Apr 2;277(13):1039–45.

Adolescents and alcohol: preventive opportunities for health care providers. Colby SM, et al. **Med Health R I** 1997 Jul;80(7):223–6 (21 ref.)

An imperative for all practicing physicians: screen and intervene for alcohol problems. Lewis DC. **Med Health R I** 1997 Mar;80(3):74–5

The prevention of alcohol use by rural youth. D'Onofrio CN. **NIDA Res Monogr** 1997;168:250–363 (293 ref.)

Preventing alcohol use problems among blue-collar workers: a field test of the Working People program. Cook RF, et al. **Subst Use Misuse** 1996 Feb;31(3):255–275

Perceived effectiveness of community-based measures against alcohol misuse among "problem" and "nonproblem" drinkers. Goldstein RB, et al. **Subst Use Misuse** 1997 Apr; 32(5):507–54

Prevention research for alcohol and other drugs: a look ahead to what is needed. Jansen MA. **Subst Use Misuse** 1996 Jul; 31(9):1217–22

Alcohol--less is better. **WHO Reg Publ Eur Ser** 1996;70:1–39

(39 ref.)
Alcohol and primary health care. Anderson P.
WHO Reg Publ Eur Ser 1996;64:1–90 (72 ref.)
Alcohol and the workplace. Henderson M, et al.
WHO Reg Publ Eur Ser 1996;67:1–100 (233 ref.)
Alcohol and the media. Montonen M.
WHO Reg Publ Eur Ser 1996;62:1–165 (289 ref.)
[Medical update of diverse Codes comprising anti-alcoholism measures] Sournia JC. **Bull Acad Natl Med** 1997 Feb; 181(2):355–60 **(Fre)**
[Therapeutic networks] Bonjour M.
Rev Med Suisse Romande 1997 Aug;117(8):613–9 **(Fre)**
[Approaches for the prevention of alcohol abuse] Watzl H. **Gesundheitswesen** 1996 Jul;58(1 Suppl):63–7 (Eng. Abstr.) **(Ger)**
[A study of the abuse of alcoholic beverage among college students by using the Adolescent Alcohol Involvement Scale (AAIS)] Fukuda T.
Nihon Arukoru Yakubutsu Igakkai Zasshi 1996 Oct; 31(5):462–74 (Eng. Abstr.) **(Jpn)**
[Availability of the Alcohol Use Disorders Identification Test (AUDIT) for a complete health examination in Japan] Hiro H, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Oct;31(5):437–50 (Eng. Abstr.) **(Jpn)**
[State and local administration, alcoholism and narcotic addiction] Lach U, et al. **Przegl Lek** 1997;54(6):456–8 (12 ref.) (Eng. Abstr.) **(Pol)**
[A multicenter primary care study on alcohol consumption] Bueno Ortiz JM, et al. **Aten Primaria** 1997 Feb 15; 19(2):80–3 (Eng. Abstr.) **(Spa)**
[Effectiveness of brief medical counseling to reduce drinkers' alcohol consumption] Fernández San Martín MI, et al.
Aten Primaria 1997 Feb 28;19(3):127–32 (Eng. Abstr.) **(Spa)**
[Alcohol, health and society: European charter on alcohol (letter)] Alvarez González FJ, et al. **Gac Sanit** 1996 Jul–Aug;10(55):197–9 **(Spa)**
[Multicenter study on the efficacy of advice for the prevention of alcoholism in primary health care] Altisent R, et al. **Med Clin (Barc)** 1997 Jun 21;109(4):121–4 (Eng. Abstr.) **(Spa)**
[Detection is not prevention (letter)] Guali Solé A, et al. **Med Clin (Barc)** 1996 Jun 29;107(5):197 **(Spa)**
[Detection in not prevention (letter)] Segura A.
Med Clin (Barc) 1997 Jan 11;108(1):37–8 **(Spa)**

PSYCHOLOGY

The risk for psychiatric illness in siblings of schizophrenics: the impact of psychotic and non-psychotic affective illness and alcoholism in parents. Kendler KS, et al.
Acta Psychiatr Scand 1996 Jul;94(1):49–55
Pathological gamblers and alcoholics: do they share the same addictions? Briggs JR, et al. **Addict Behav** 1996 Jul–Aug; 21(4):515–9
The utility of novelty seeking, harm avoidance, and expectancy in the prediction of drinking. Galen LW, et al. **Addict Behav** 1997 Jan–Feb;22(1):93–106
Disruption of family rituals as a mediator of the relationship between parental drinking and adult adjustment in offspring. Hawkins CA. **Addict Behav** 1997 Mar–Apr; 22(2):219–31
Illness severity and self-efficacy as course predictors of DSM-IV alcohol dependence in a multisite clinical sample. Langenbucher J, et al. **Addict Behav** 1996 Sep–Oct; 21(5):543–53
Alcohol expectancies: effects of gender, age, and family history of alcoholism. Lundahl LH, et al. **Addict Behav** 1997 Jan–Feb;22(1):115–25
Expectancies for drinking and excessive drinking among Mexican Americans and non-Hispanic whites. Marín G. **Addict Behav** 1996 Jul–Aug;21(4):491–507
The development of a brief scale to measure outcome expectations of reduced consumption among excessive drinkers. Rollnick S, et al. **Addict Behav** 1996 May–Jun; 21(3):377–87
A trial of relapse prevention with severely dependent male problem drinkers. Allsop S, et al. **Addiction** 1997 Jan; 92(1):61–73
Why do some doctors become addicted? [editorial] Brooke D. **Addiction** 1996 Mar;91(3):317–9
Cognitive impairment among the dually-diagnosed: substance use history and depressive symptom correlates. Carpenter KM, et al. **Addiction** 1997 Jun;92(6):747–59
End-of-treatment self-efficacy: a predictor of abstinence. Goldbeck R, et al. **Addiction** 1997 Mar;92(3):313–24
Situational norms for drinking and drunkenness: trends in the US adult population, 1979–1990. Greenfield TK, et al. **Addiction** 1997 Jan;92(1):33–47
Adulthood functioning: the joint effects of parental alcoholism, gender and childhood socio-economic stress. Hill EM, et al. **Addiction** 1997 May;92(5):583–96
Perceived workplace harassment experiences and problem drinking among physicians: broadening the stress/alienation paradigm. Richman JA, et al. **Addiction** 1996 Mar;91(3):391–403
Personal and familial characteristics of resilient sons of male alcoholics. Vitaro F, et al. **Addiction** 1996 Aug; 91(8):1161–77
Children of alcoholics and adolescence: individuation, development, and family systems. Crespi TD, et al.
Adolescence 1997 Summer;32(126):407–17
Ethanol intake after chronic intoxication by inhalation of ethanol vapour in rats: behavioural dependence. Aufrère G, et al. **Alcohol** 1997 May–Jun;14(3):247–53
Altered cortisol response in sober alcoholics: an examination of contributing factors. Bernardy NC, et al. **Alcohol** 1996 Sep–Oct;13(5):493–8
Toward a definition of a valid model of alcoholism: multiple animal models for multiple diseases. McMillen BA.
Alcohol 1997 Jul–Aug;14(4):409–19 (104 ref.)
Effects of long-term abstinence on psychological functioning: a prospective longitudinal analysis comparing alcohol-dependent patients and healthy volunteers. Voltaire-Carlsson A, et al. **Alcohol** 1996 Sep–Oct; 13(5):415–21
Amphetamine and fenfluramine suppress ethanol intake in ethanol-dependent rats. Yu YL, et al. **Alcohol** 1997 Jan–Feb;14(1):45–8
Are alcoholic women more likely to drink premenstrually? Allen D. **Alcohol Alcohol** 1996 Mar;31(2):145–7
Adaptation to repeated restraint stress in rats: failure of ethanol-treated rats to adapt in the stress schedule. Haleem DJ. **Alcohol Alcohol** 1996 Sep;31(5):471–7
Sub-populations of alcohol-dependent patients: differences in psychological functioning between high- and low-frequency alcohol consumers. Hiltunen AJ, et al.
Alcohol Alcohol 1996 Jul;31(4):429–38
Solitary drinking, social isolation, and escape drinking motives as predictors of high quantity drinking, among Anglo, African American and Mexican American males. Neff JA. **Alcohol Alcohol** 1997 Jan–Feb;32(1):33–41
Alcoholism and subtypes of antisocial personality disorder. Hesselbrock VM, et al. **Alcohol Alcohol Suppl** 1994; 2:479–84
A comparative neuropsychological approach to alcoholism and the brain. Oscar-Berman M. **Alcohol Alcohol Suppl** 1994;2:281–9 (58 ref.)
Biobehavioural basis of pharmacologic treatment of alcohol dependence. Sellers EM. **Alcohol Alcohol Suppl** 1994; 2:517–21 (29 ref.)
Impairments in reflective cognitive functions in alcoholics: a neuropharmacological model. Weingartner HJ, et al.
Alcohol Alcohol Suppl 1994;2:291–8
Adolescent risk factors and the prediction of persistent alcohol and drug use into adulthood. Bates ME, et al.
Alcohol Clin Exp Res 1997 Aug;21(5):944–50
Psychometric properties and validity of the obsessive-compulsive drinking scale. Bohn MJ, et al.
Alcohol Clin Exp Res 1996 Aug;20(5):817–23
Marital functioning in early versus late-onset alcoholic couples. Epstein EE, et al. **Alcohol Clin Exp Res** 1997 May; 21(3):547–56
Voice of the afflicted. Erickson CK.
Alcohol Clin Exp Res 1996 Aug;20(5):877
Voices of the afflicted. Erickson CK.
Alcohol Clin Exp Res 1997 Aug;21(5):951
Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation. Hölter SM, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):862–8
Alcohol expectancies and drinking characteristics in parents of children with attention deficit hyperactivity disorder. Molina BS, et al. **Alcohol Clin Exp Res** 1997 May; 21(3):557–66
Current developments in the study of stress and alcohol consumption. Ragland DR. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):51A–53A
Effects of alcohol cues on smoking urges and topography among alcoholic men. Rohsenow DJ, et al.
Alcohol Clin Exp Res 1997 Feb;21(1):101–7
A prospective study of self-esteem and alcohol use disorders in early adulthood: evidence for gender differences. Walitzer KS, et al. **Alcohol Clin Exp Res** 1996 Sep; 20(6):1118–24
Multivariate typology of adolescents with alcohol use disorder. Tarter RE, et al. **Am J Addict** 1997 Spring; 6(2):150–8
Relationship of hardiness to alcohol and drug use in adolescents. Maddi SR, et al.
Am J Drug Alcohol Abuse 1996 May;22(2):247–57
Sources of motivation in a couples outpatient alcoholism treatment program. Steinberg ML, et al.
Am J Drug Alcohol Abuse 1997 May;23(2):191–205
The Drug Use Screening Inventory for adults: psychometric structure and discriminative sensitivity. Tarter RE, et al. **Am J Drug Alcohol Abuse** 1997 May;23(2):207–19
A comparison of alcohol, drugs, and aggressive crime among Mexican-American, black, and white male arrestees in Texas. Valdez A, et al. **Am J Drug Alcohol Abuse** 1997 May;23(2):249–65
Starting recovery. Gorman M. **Am J Nurs** 1996 Sep;96(9):15
When alcoholism hits home. Ianelli J. **Am J Nurs** 1997 Jul; 97(7):68–9
When death comes to the alcoholic family. Raymer M.
Am J Nurs 1996 Dec;96(12):58–60
Impact of maternal alcoholism on separation of children from their mothers: findings from a sample of incarcerated women. Goldberg ME, et al. **Am J Orthopsychiatry** 1996 Apr;66(2):228–38
Homicidal behavior in drug abusing psychiatric patients [letter; comment] Dhossche D, et al. **Am J Psychiatry** 1997 Jun;154(6):888–9. Comment on: Am J Psychiatry 1996 Jul;153(7):953–5.
Evidence of preference for a high-concentration sucrose solution in alcoholic men. Kampov-Polevoy A, et al.
Am J Psychiatry 1997 Feb;154(2):269–70
A concept analysis of alcoholic denial and cultural accounts. Wing DM. **ANS Adv Nurs Sci** 1996 Dec;19(2):54–63
Posttraumatic stress disorder, depression, alcohol use disorders and quality of life in adolescents. Clark DB, et al. **Anxiety** 1996;2(5):226–33
Readiness to change alcohol drinking habits after traumatic brain injury. Bombardier CH, et al.
Arch Phys Med Rehabil 1997 Jun;78(6):592–6
Cocaine abusers have reduced auditory P50 amplitude and suppression compared to both normal controls and alcoholics. Fein G, et al. **Biol Psychiatry** 1996 Jun 1; 39(11):955–65
Alcohol misuse among doctors. Eliminating stress is the way forward [letter] Jowett NI. **BMJ** 1997 Jun 21; 314(7097):1834
Creativity [letter; comment] Crichton P. **Br J Psychiatry** 1996 Sep;169(3):379. Comment on: Br J Psychiatry 1996 May;168(5):545–55.
Alcoholism, a contagious disease. A contribution towards an anthropological definition of contagion. Fainzang S.
Cult Med Psychiatry 1996 Dec;20(4):473–87
Spatial cognition in alcoholics: influence of concurrent abuse of other drugs. Beatty WW, et al.
Drug Alcohol Depend 1997 Mar 14;44(2–3):167–74
The relationship between risk networks' patterns of crack cocaine and alcohol consumption and HIV-related sexual behaviors among adult injection drug users: a prospective study. Latkin CA, et al. **Drug Alcohol Depend** 1996 Nov; 42(3):175–81
Excessive drinking situations in German alcoholics: replication of a three-factor model used for North Americans. Victorio-Estrada A, et al.
Drug Alcohol Depend 1996 May;41(1):75–9
Alcohol use disorders and neuropsychological functioning in first-year undergraduates. Sher KJ, et al.
Exp Clin Psychopharmacol 1997 Aug;5(3):304–15
Family climate and expressed emotion in the course of alcoholism. Fichter MM, et al. **Fam Process** 1997 Jun; 36(2):203–21
Attitudes towards alcohol use among Bulgarians-Christians and Turks-Muslims. Akabaliev V, et al.
Folia Med (Plovdiv) 1997;39(1):7–12
Assessment and follow-up of alcohol-dependent liver transplantation patients. A clinical cohort. Tringali RA, et al. **Gen Hosp Psychiatry** 1996 Nov;18(6 Suppl):70S–77S
Alcohol abuse: medical effects of heavy drinking in late life. Gambert SR. **Geriatrics** 1997 Jun;52(6):30–7
World view change in adult children of Alcoholics/Al-Anon self-help groups: reconstructing the alcoholic family. Humphreys K. **Int J Group Psychother** 1996 Apr; 46(2):255–63
Is self-organized criticality relevant to alcoholism? Campbell WG. **J Addict Dis** 1997;16(1):41–50
Psychosocial predictors and consequences of drug use: a developmental perspective within a prospective study. Newcomb MD. **J Addict Dis** 1997;16(1):51–89
Five-year course of major depression: effects of comorbid alcoholism. Hasin DS, et al. **J Affect Disord** 1996 Nov 4; 41(1):63–70
Coping resources and self-perceived well-being of college students who report a parental drinking problem. Hall AE.
J Am Coll Health 1997 Jan;45(4):159–64
Effects of abstinence and relapse upon neuropsychological function and cerebral glucose metabolism in severe chronic alcoholism. Johnson-Greene D, et al.
J Clin Exp Neuropsychol 1997 Jun;19(3):378–85
Investigation of Cloninger's subtypes in a male alcoholic sample: applications and implications. Glenn SW, et al.
J Clin Psychol 1996 Mar;52(2):219–30
Articulating subtype differences in self and relational experience among alcoholic men using structural analysis of social behavior. Ichiyama MA, et al.
J Consult Clin Psychol 1996 Dec;64(6):1245–54
Gender differences in the relations between depressive symptoms and drinking behavior among problem drinkers: a three-wave study. Schutte KK, et al.
J Consult Clin Psychol 1997 Jun;65(3):392–404
Environmental predictors of drinking and drinking-related problems in young adults. Jones-Webb R, et al.
J Drug Educ 1997;27(1):67–82
Salience of alcohol expectancies and drinking outcomes. Reese FL. **J Drug Educ** 1997;27(1):43–51
Precursors, mediators and problem drinking: path analytic models for men and women. Woldt BD, et al.
J Drug Educ 1996;26(1):1–12
Effects of parent drug use and personality on toddler adjustment. Brook JS, et al. **J Genet Psychol** 1996 Mar; 157(1):19–35
Family cohesion as a buffer against the effects of problem-drinking fathers on psychological distress, deviant behavior, and heavy drinking in adolescents. Farrell MP, et al. **J Health Soc Behav** 1995 Dec;36(4):377–85
Word association profiles of alcoholics. Cecero JJ, et al.
J Pers Assess 1997 Aug;69(1):199–204
Drinking motives predict alcohol-related problems in college students. Carey KB, et al. **J Stud Alcohol** 1997 Jan; 58(1):100–5
Organization of psychological functions in alcoholics and nonalcoholics: a test of the compensatory hypothesis. Ham HP, et al. **J Stud Alcohol** 1997 Jan;58(1):67–74
Exploring the effects of age of alcohol use initiation and

psychosocial risk factors on subsequent alcohol misuse. Hawkins JD, et al. **J Stud Alcohol** 1997 May;58(3):280–90

Sex ratios of drinking patterns and problems among blacks and whites: results from a national survey. Herd D. **J Stud Alcohol** 1997 Jan;58(1):75–82

Cloninger's tridimensional theory of personality and psychopathology: applications to substance use disorders. Howard MO, et al. **J Stud Alcohol** 1997 Jan;58(1):48–66 (55 ref.)

Substance use initiation among adolescent children of alcoholics: testing protective factors. Hussong AM, et al. **J Stud Alcohol** 1997 May;58(3):272–9

Issues in the implementation of a randomized clinical trial that includes Alcoholics Anonymous: studying AA-related behaviors during treatment. McCrady BS, et al. **J Stud Alcohol** 1996 Nov;57(6):604–12

Couple communication patterns of maritally aggressive and nonaggressive male alcoholics. Murphy CM, et al. **J Stud Alcohol** 1997 Jan;58(1):83–90

Sexual satisfaction and dysfunction in marriages of male alcoholics: comparison with nonalcoholic maritally conflicted and nonconflicted couples. O'Farrell TJ, et al. **J Stud Alcohol** 1997 Jan;58(1):91–9

Global, behavioral and self ratings of interpersonal skills among adult children of alcoholic, divorced and control parents. Senchak M, et al. **J Stud Alcohol** 1996 Nov; 57(6):638–45

Predicting academic problems in college from freshman alcohol involvement. Wood PK, et al. **J Stud Alcohol** 1997 Mar;58(2):200–10

Late-life problem drinking: personal and environmental risk factors for 4-year functioning outcomes and treatment seeking. Brennan PL, et al. **J Subst Abuse** 1996;8(2):167–80

Alcoholics' perceptions of cues to intoxication. Burroughs WJ, et al. **J Subst Abuse** 1996;8(4):471–7

Latent variable models of alcohol-related constructs. Lennox RD, et al. **J Subst Abuse** 1996;8(2):241–50

Gender roles and interactions in drinking and drug use. Room R. **J Subst Abuse** 1996;8(2):227–39 (46 ref.)

The coping styles of alcoholics with axis II disorders. Smyth NJ, et al. **J Subst Abuse** 1995;7(4):425–35

The correlates of addiction concern among adolescents at high risk for drug abuse. Sussman S, et al. **J Subst Abuse** 1996;8(3):361–70

Feasibility of smoking cessation counseling by phone with alcohol treatment center graduates. Leed-Kelly A, et al. **J Subst Abuse Treat** 1996 May-Jun;13(3):203–10

Toward a (Dys)functional anthropology of drinking: ambivalence and the American Indian experience with alcohol. Spicer P. **Med Anthropol Q** 1997 Sep;11(3):306–23

A comparison of implicit memory tasks in Korsakoff and alcoholic patients. Brunfaut E, et al. **Neuropsychologia** 1996 Dec;34(12):1143–50

Patterns of content, contextual, and working memory impairments in schizophrenia and nonamnesic alcoholism. Sullivan EV, et al. **Neuropsychology** 1997 Apr; 11(2):195–206

Social and economic consequences of rural alcohol use. Kelleher KJ, et al. **NIDA Res Monogr** 1997;168:196–219 (76 ref.)

Cognitive functions in alcoholics and success in treatment: how are they related? Saarnio P. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Jun; 31(3):205–14

Self-recognition of alcohol and cigarette dependency among high school seniors. Daughton JM, et al. **Percept Mot Skills** 1997 Aug;85(1):115–20

How do nonalcoholics view alcoholics? Groettum G, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 2):1202

Prevalence of parental substance-abuse among child psychiatric inpatients. Pillay AL, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):947–53

Physician objectivity. Stuart S. **Pharos** 1997 Summer;60(3):46

A replication and elaboration of the esteem-enhancement model. Vega WA, et al. **Psychiatry** 1996 Summer; 59(2):128–44

Twin closeness and co-twin risk for substance use disorders: assessing the impact of the equal environment assumption. LaBuda MC, et al. **Psychiatry Res** 1997 May 30; 70(3):155–64

Depression and anxiety in young children of substance abusers. Drucker PM, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):723–32

Psychometric assessment of motives for using cocaine in men with substance use disorders. Ward LC, et al. **Psychol Rep** 1997 Feb;80(1):189–90

Double-blind fluoxetine in depressed alcoholic smokers. Cornelius JR, et al. **Psychopharmacol Bull** 1997; 33(1):165–70

Preinjury psychiatric illness and postinjury adjustment in adult burn survivors. Fauerbach JA, et al. **Psychosomatics** 1996 Nov-Dec;37(6):547–55

Alcohol, drugs, and violence in children's lives. Miller BA, et al. **Recent Dev Alcohol** 1997;13:357–85 (120 ref.)

Psychiatric and alcohol disorders as risk factors for drug abuse. A case-control study among adults in Rio de Janeiro, Brazil. Lopes CS, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Nov;31(6):355–63

Women, alcohol and work: interactions of gender, ethnicity and occupational culture. Ames GM, et al. **Soc Sci Med** 1996 Dec;43(11):1649–63 (100 ref.)

Measuring the human cost of a weak economy: does unemployment lead to alcohol abuse? Ettner SL. **Soc Sci Med** 1997 Jan;44(2):251–60

Unilateral interventions for women living with heavy drinkers. Barber JG, et al. **Soc Work** 1997 Jan;42(1):69–78 (38 ref.)

Coping with a partner who drinks too much: does anything work? Barber JG, et al. **Subst Use Misuse** 1997 Mar; 32(4):485–94

Personal and environmental factors in relation to adjustment of offspring of alcoholics. Chang JK, et al. **Subst Use Misuse** 1996 Aug;31(10):1401–12

The self-generated alcohol expectancies of Puerto Rican drinkers and abstainers. Johnson PB, et al. **Subst Use Misuse** 1996 Jul;31(9):1155–65

Homelessness and vulnerability among adults with and without alcohol problems. Sosin MR, et al. **Subst Use Misuse** 1997 Jun;32(7–8):939–68

[Therapeutic networks] Bonjour M. **Rev Med Suisse Romande** 1997 Aug;117(8):613–9 **(Fre)**

[Is drug dependence an occupational risk for physicians?] Schifferdecker M, et al. **Fortschr Med** 1996 Oct 20; 114(29):372–3, 376 (20 ref.) (Eng. Abstr.) **(Ger)**

[Alcohol abuse: ever earlier, ever more frequent. A study shows correlation with early childhood anxiety disorders] Schweiger A. **Fortschr Med** 1996 Oct 20;114(29):24 **(Ger)**

[Anxiety in alcohol-dependent patients] Baving L, et al. **Fortschr Neurol Psychiatr** 1996 Mar;64(3):83–9 (66 ref.) (Eng. Abstr.) **(Ger)**

[Typological analysis in male alcoholics: one-year-long follow-up study] Hauser J. **Psychiatr Pol** 1996 Sep-Oct; 30(5):835–46 (Eng. Abstr.) **(Pol)**

RADIONUCLIDE IMAGING

Effects of disulfiram on positron emission tomography and neuropsychological studies in severe chronic alcoholism. Gilman S, et al. **Alcohol Clin Exp Res** 1996 Nov; 20(8):1456–61

Single photon emission computerised tomography in chronic alcoholism. Antisocial personality disorder may be associated with decreased frontal perfusion. Kuruoğlu AC, et al. **Br J Psychiatry** 1996 Sep;169(3):348–54

REHABILITATION

Elevated tryptophan levels in post-withdrawal alcoholics. Farren CK, et al. **Acta Psychiatr Scand** 1996 Dec; 94(6):465–70

Alcohol treatment outcome methodology: state of the art 1989–1993. Breslin FC, et al. **Addict Behav** 1997 Mar-Apr; 22(2):145–55 (75 ref.)

Alcoholism treatment outcome studies, 1980–1992: the nature of the research. Floyd AS, et al. **Addict Behav** 1996 Jul-Aug;21(4):413–28 (16 ref.)

The public health and brief interventions for excessive alcohol consumption: the British experience. Heather N. **Addict Behav** 1996 Nov-Dec;21(6):857–68 (41 ref.)

Drinking goal selection in behavioral self-management treatment of chronic alcoholics. Hodgins DC, et al. **Addict Behav** 1997 Mar-Apr;22(2):247–55

Targeted naltrexone treatment of early problem drinkers. Kranzler HR, et al. **Addict Behav** 1997 May-Jun; 22(3):431–6

Stress among males recovering from substance abuse. Lamon BC, et al. **Addict Behav** 1997 Mar-Apr;22(2):195–205

Motivational interviewing: research, practice, and puzzles. Miller WR. **Addict Behav** 1996 Nov-Dec;21(6):835–42 (35 ref.)

Alcoholism treatment outcome studies, 1980–1992: methodological characteristics and quality. Morley JA, et al. **Addict Behav** 1996 Jul-Aug;21(4):429–43

Relapse revisited: a critique of current concepts and clinical practice in the management of alcohol problems. Saunders B, et al. **Addict Behav** 1996 Nov-Dec;21(6):843–55 (45 ref.)

Fostering self-change among problem drinkers: a proactive community intervention. Sobell LC, et al. **Addict Behav** 1996 Nov-Dec;21(6):817–33

Social identities and response to treatment for alcohol and cocaine abuse. Weisz C. **Addict Behav** 1996 Jul-Aug; 21(4):445–58

Neuropsychological function and psychosocial status of alcohol rehabilitation program residents. Zlotnick C, et al. **Addict Behav** 1997 Mar-Apr;22(2):183–94

Perspectives on precipitants of relapse. **Addiction** 1996 Dec; 91 Suppl:S1–244

Aftercare telephone contacts with problem drinkers can serve a clinical and research function. Breslin C, et al. **Addiction** 1996 Sep;91(9):1359–64

Understanding relapse in the broader context of post-treatment functioning. Connors GJ, et al. **Addiction** 1996 Dec;91 Suppl:S173–89

Looking forward and back to relapse: implications for research and practice. Connors GJ, et al. **Addiction** 1996 Dec;91 Suppl:S191–6

Conceptualizations of relapse: a summary of psychological and psychobiological models. Connors GJ, et al. **Addiction** 1996 Dec;91 Suppl:S5–13 (28 ref.)

Establishing and using a community inter-agency client monitoring system to develop addictions treatment programs. DeVillaer M. **Addiction** 1996 May;91(5):701–9

Assessment issues and domains in the prediction of relapse. Donovan DM. **Addiction** 1996 Dec;91 Suppl:S29–36 (22 ref.)

Marlatt's classification of relapse precipitants: is the Emperor still wearing clothes? Donovan DM. **Addiction** 1996 Dec; 91 Suppl:S131–7

The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Finney JW, et al. **Addiction** 1996 Dec;91(12):1773–96; discussion 1803–20 (72 ref.)

A controlled field trial of group versus individual cognitive-behavioural training for relapse prevention. Graham K, et al. **Addiction** 1996 Aug;91(8):1127–39

The development of patient profiles for Minnesota's treatment outcomes monitoring system. Harrison PA, et al. **Addiction** 1996 May;91(5):687–99

Waiting for a match: the future of psychosocial treatment for alcohol problems [editorial] Heather N. **Addiction** 1996 Apr;91(4):469–72

Application of random-effects regression models in relapse research. Hedeker D, et al. **Addiction** 1996 Dec;91 Suppl:S211–29

A comparison of positive and negative alcohol expectancy and value and their multiplicative composite as predictors of post-treatment abstinence survivorship. Jones BT, et al. **Addiction** 1996 Jan;91(1):89–99

Is Marlatt's relapse taxonomy reliable or valid? Kadden RM. **Addiction** 1996 Dec;91 Suppl:S139–45

Prediction of results from correspondence treatment for controlled drinking. Kavanagh DJ, et al. **Addiction** 1996 Oct;91(10):1539–45

The reliability of Marlatt's taxonomy for classifying relapses. Longabaugh R, et al. **Addiction** 1996 Dec;91 Suppl:S73–88

Replication and extension of Marlatt's taxonomy of relapse precipitants: overview of procedures and results. The Relapse Research Group. Lowman C, et al. **Addiction** 1996 Dec;91 Suppl:S51–71

Construct validation analyses on the Marlatt typology of relapse precipitants. Maisto SA, et al. **Addiction** 1996 Dec; 91 Suppl:S89–97

Taxonomy of high-risk situations for alcohol relapse: evolution and development of a cognitive-behavioral model. Marlatt GA. **Addiction** 1996 Dec;91 Suppl:S37–49 (30 ref.)

Lest taxonomy become taxidermy: a comment on the relapse replication and extension project. Marlatt GA. **Addiction** 1996 Dec;91 Suppl:S147–53

What is a relapse? Fifty ways to leave the wagon. Miller WR. **Addiction** 1996 Dec;91 Suppl:S15–27 (33 ref.)

What predicts relapse? Prospective testing of antecedent models. Miller WR, et al. **Addiction** 1996 Dec;91 Suppl:S155–72

The role of coping in relapse crisis outcome: a prospective study of treated alcoholics. Moser AE, et al. **Addiction** 1996 Aug;91(8):1101–13 (32 ref.)

Determinants of suggestions for alcohol treatment. Room R, et al. **Addiction** 1996 May;91(5):643–55

Gender differences in relapse situations. Rubin A, et al. **Addiction** 1996 Dec;91 Suppl:S111–20

Substance abuse treatment for Ontario residents in the United States. Rush B, et al. **Addiction** 1996 May;91(5):671–85

Alcohol and other drug problems and treatment systems: a framework for research and development [editorial] Rush B. **Addiction** 1996 May;91(5):629–42

Predictive validity of Marlatt's relapse taxonomy versus a more general relapse code. Stout RL, et al. **Addiction** 1996 Dec;91 Suppl:S99–110

Patterns in the institutional encounters of problem drinkers in a community human services network. Tam TW, et al. **Addiction** 1996 May;91(5):657–69

Latent transition analysis for longitudinal data. Velicer WF, et al. **Addiction** 1996 Dec;91 Suppl:S197–209

Relapse research and the Reasons for Drinking Questionnaire: a factor analysis of Marlatt's relapse taxonomy. Zywiak WH, et al. **Addiction** 1996 Dec;91 Suppl:S121–30

An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Addolorato G, et al. **Alcohol Alcohol** 1996 Jul;31(4):341–5

Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Anton RF. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:43–53 (70 ref.)

Treatment of alcohol dependence: experiences of using biological markers in monitoring and prevention of relapse. Borg S. **Alcohol Alcohol** 1996 Nov;31(6):621–4 (10 ref.)

Review of neurotransmitters and their role in alcoholism treatment. Erickson CK. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:5–11 (35 ref.)

New ways to use biochemical indicators of alcohol abuse to regrant licences in a fairer manner after drunken driving in Germany. Iffland R. **Alcohol Alcohol** 1996 Nov; 31(6):619–20

Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence: an overview of the preclinical data. Lê AD, et al. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:27–32 (55 ref.)

Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Lejoyeux M. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:69–75 (40 ref.)

Alcohol reinforcement and neuropharmacological therapeutics. Lewis MJ. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:17–25 (36 ref.)

The pharmacological treatment of alcohol dependence: needs and possibilities. Mann K. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:55–8 (30 ref.)

Evaluation of alcohol consumption level in drivers when regranting licences after driving while intoxicated in France. Mercier-Guyon C. **Alcohol Alcohol** 1996 Nov; 31(6):617–8

Alcohol-related seizures and the kindling effect of repeated detoxifications: the influence of cocaine. Moak DH, et al. **Alcohol Alcohol** 1996 Mar;31(2):135–43

The use of serum carbohydrate-deficient transferrin in the assessment of 'high risk offenders' in Great Britain. Morgan MY, et al. **Alcohol Alcohol** 1996 Nov;31(6):625–8

Medical screening and medical-psychological assessment as prerequisites for regranting of licenses: summary of recommendations. Nickel WR. **Alcohol Alcohol** 1996 Nov; 31(6):605–7

The relationship between helping alliance and outcome in outpatient treatment of alcoholics: a comparative study of psychiatric treatment and multimodal behavioural therapy. Ojehagen A, et al. **Alcohol Alcohol** 1997 May–Jun; 32(3):241–9

Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. O'Malley SS. **Alcohol Alcohol** 1996 Mar;31 Suppl 1:77–81 (20 ref.)

Voice of the victims—the key to consensus and support for alcoholism research. O'Neill JT. **Alcohol Alcohol** 1996 Mar; 31 Suppl 1:83–7

The SECCAT Survey: II. The Alcohol Related Problems Questionnaire as a proxy for resource costs and quality of life in alcoholism treatment. Study of Socio-Economic Consequences and Costs of Alcoholism and Treatment. Patience D, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):79–84

Alcoholism: a long-term follow-up study of participants in an alcohol treatment programme. Shaw GK, et al. **Alcohol Alcohol** 1997 Jul–Aug;32(4):527–35

Does increased spending on alcoholism treatment lead to lower cirrhosis death rates? Smart RG, et al. **Alcohol Alcohol** 1996 Sep;31(5):487–91

Persistence of defective serotonergic and GABAergic controls of growth hormone secretion in long-term abstinent alcoholics. Vescovi PP, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):85–90

Does liver dysfunction explain neuropsychological status in recently detoxified alcohol-dependent clients? Walton NH, et al. **Alcohol Alcohol** 1997 May–Jun;32(3):287–95

Relative kindling effect of readmissions in alcoholics. Worner TM. **Alcohol Alcohol** 1996 Jul;31(4):375–80

A comparison of two techniques to reach relatives of alcoholics for information of available support. Zetterlind U, et al. **Alcohol Alcohol** 1996 Jul;31(4):359–63

Manageability and tolerability of gamma-hydroxybutyric acid in the medium term outpatient treatment of alcoholism [letter; comment] Addolorato G, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):380. Comment on: Alcohol Clin Exp Res 1996 Aug;20(5):859–76.

Carbohydrate-deficient transferrin as an indicator of drinking status during a treatment outcome study. Anton RF, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):841–6

New methodologies for pharmacological treatment trials for alcohol dependence. Anton RF. **Alcohol Clin Exp Res** 1996 Oct;20(7 Suppl):3A–9A (56 ref.)

Pharmacotherapy of alcoholism—10 years of progress. Anton RF. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):172A–175A

The use of carbohydrate deficient transferrin as an indicator of alcohol consumption during treatment and follow-up. Anton RF. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):54A–56A

Resting hand tremor in abstinent cocaine-dependent, alcohol-dependent, and polydrug-dependent patients. Bauer LO. **Alcohol Clin Exp Res** 1996 Oct;20(7):1196–201

Correlates of past-year status among treated and untreated persons with former alcohol dependence: United States, 1992. Dawson DA. **Alcohol Clin Exp Res** 1996 Jun; 20(4):771–9

Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Del Boca FK, et al. **Alcohol Clin Exp Res** 1996 Nov;20(8):1412–7

Voices of the afflicted. Erickson CK. **Alcohol Clin Exp Res** 1996 Nov;20(8):1501–2

Voices of the afflicted. Erickson CK. **Alcohol Clin Exp Res** 1996 Sep;20(6):1138–9

Voices of the afflicted. Erickson CK. **Alcohol Clin Exp Res** 1997 May;21(3):567–8

Voices of the afflicted. Erickson CK. **Alcohol Clin Exp Res** 1997 Apr;21(2):248–9

Voices of the afflicted. Erickson CK. **Alcohol Clin Exp Res** 1996 Dec;20(9):1592–3

Voice of the victims. Erickson CK. **Alcohol Clin Exp Res** 1996 May;20(3):501

Naltrexone persistently reduces rats' intake of a palatable alcoholic beverage. Gardell LR, et al. **Alcohol Clin Exp Res** 1996 May;20(3):584–8

Cost and usage impacts of treatment initiation: a comparison of alcoholism and drug abuse treatments. Goodman AC, et al. **Alcohol Clin Exp Res** 1997 Aug;21(5):931–8

Hostility is associated with a low prolactin response to meta-chlorophenylpiperazine in abstinent alcoholics. Handelsman L, et al. **Alcohol Clin Exp Res** 1996 Aug; 20(5):824–9

Carbohydrate-deficient transferrin and gamma-glutamyl transferase levels during disulfiram therapy. Helander A, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1202–5

A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Kabel DI, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):780–4

Project MATCH: treatment main effects and matching results. Kadden RM. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):196A–197A

The effect of anonymous vs. nonanonymous rating conditions on patient satisfaction and motivation ratings in a population of substance abuse patients. Leonhard C, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):627–30

Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991 [see comments] Litten RZ, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):859–76 (247 ref.). Comment in: Alcohol Clin Exp Res 1997 Apr;21(2):380.

International update: new findings on promising medications. Litten RZ. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):216A–218A

Matching relational vs. individual treatment focus to patients. Longabaugh R. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):248A–249A

Efficacy of buspirone in alcohol dependence: a review. Malec TS, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):853–8 (39 ref.)

Zero tolerance laws: effective public policy? Martin S. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):147A–150A

Dosing issues in the pharmacotherapy of alcoholism. Mason BJ. **Alcohol Clin Exp Res** 1996 Oct;20(7 Suppl):10A–16A (45 ref.)

A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Mueller TI, et al. **Alcohol Clin Exp Res** 1997 Feb; 21(1):86–92

Psychotherapeutic considerations in pharmacological trials. O'Malley SS, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7 Suppl):17A–22A (49 ref.)

Alternatives to naltrexone in animal models. Overstreet DH. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):231A–235A

Pharmacological treatment for antisocial personality disorder alcoholics: a preliminary study. Penick EC, et al. **Alcohol Clin Exp Res** 1996 May;20(3):477–84

The natural history of outpatient alcohol and drug abuse treatment in a private healthcare setting. Pettinati HM, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):847–52

Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. Pettinati HM. **Alcohol Clin Exp Res** 1996 Oct;20(7 Suppl):23A–29A (46 ref.)

Effect of bestatin, an aminopeptidase inhibitor, on alcohol intake in alcohol-preferring P rats. Szczepanska R, et al. **Alcohol Clin Exp Res** 1996 May;20(3):561–5

Excretion of beta-carbolines harman and norharman in 24-hour urine of chronic alcoholics during withdrawal and controlled abstinence. Wodarz N, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):706–10

Special commentary. Bowman BJ. **Am Indian Alsk Native Ment Health Res** 1996;7(2):42–50; discussion 51–2

A survey of vocational rehabilitation counselors concerning American Indian and Alaska Native clients with alcohol and other drug abuse disorders. Schacht RM, et al. **Am Indian Alsk Native Ment Health Res** 1997;7(3):50–67

Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Guillo P, et al. **Am J Cardiol** 1997 May 1; 79(9):1276–8

A grounded theory of protecting recovery during transition to motherhood. Brudenell I. **Am J Drug Alcohol Abuse** 1997 Aug;23(3):453–66

Characteristics of participants in secular organizations for sobriety (SOS). Connors GJ, et al. **Am J Drug Alcohol Abuse** 1996 May;22(2):281–95

Linking substance abuse services with general medical care: integrated, brief interventions with hospitalized patients. Dunn CW, et al. **Am J Drug Alcohol Abuse** 1997 Feb; 23(1):1–13

Pathways to self-help among women for sobriety. Kaskutas LA. **Am J Drug Alcohol Abuse** 1996 May;22(2):259–80

A comparison of the Johnson Intervention with four other methods of referral to outpatient treatment. Loneck B, et al. **Am J Drug Alcohol Abuse** 1996 May;22(2):233–46

Occupational meanings and spirituality: the quest for sobriety. Moyers PA. **Am J Occup Ther** 1997 Mar;51(3):207–14

Naltrexone in the treatment of alcoholism. Weinrieb RM, et al. **Annu Rev Med** 1997;48:477–87 (27 ref.)

Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol-dependent patients. Heinz A, et al. **Arch Gen Psychiatry** 1996 Dec; 53(12):1123–8

Substance abuse disorders: psychiatric trainees' knowledge, diagnostic skills and attitudes. Roche AM, et al. **Aust N Z J Psychiatry** 1995 Dec;29(4):645–52

Does depression predict relapse in the 6 months following treatment for men with alcohol dependence? Sellman JD, et al. **Aust N Z J Psychiatry** 1996 Oct;30(5):573–8

ERP changes in alcoholics with and without alcohol psychosis. Kathmann N, et al. **Biol Psychiatry** 1996 May 15;39(10):873–81

Monitoring the source of memory in detoxified alcoholics. Weingartner HJ, et al. **Biol Psychiatry** 1996 Jul 1; 40(1):43–53

Changes in alcohol expectancies during treatment relate to subsequent abstinence survivorship. Jones BT, et al. **Br J Clin Psychol** 1996 May;35 (Pt 2):221–34

Aetiology of secondary depression in male alcoholics. Roy A. **Br J Psychiatry** 1996 Dec;169(6):753–7

Treatment of the mentally ill physician. Myers MF. **Can J Psychiatry** 1997 Aug;42(6):12 p. (43 ref.) **(Eng, Fre)**

Treating depression among alcoholics [letter] Roy A. **Can J Psychiatry** 1996 Apr;41(3):194–5

Attitudes and beliefs of the general public about treatment for alcohol problems. Rush BR, et al. **Can J Public Health** 1997 Jan–Feb;88(1):41–3

Prediction of recovery after abstinence in alcoholic cardiomyopathy: role of hemodynamic and morphometric parameters. La Vecchia LL, et al. **Clin Cardiol** 1996 Jan; 19(1):45–50

Treating sexual abuse trauma with dually diagnosed women. Harris M. **Community Ment Health J** 1996 Aug; 32(4):371–85

Changes in HIV-related behaviors among heterosexual alcoholics following addiction treatment. Avins AL, et al. **Drug Alcohol Depend** 1997 Jan 10;44(1):47–55

Sufficient conditions for effective treatment of substance abusing homeless persons. Milby JB, et al. **Drug Alcohol Depend** 1996 Dec 2;43(1–2):39–47

German mental health legislation and alcoholism treatment: results of a retrospective long-term study in a Berlin state mental health hospital. Oberlaender FA, et al. **Drug Alcohol Depend** 1995 Dec;40(2):165–71

Treatment outcome of cocaine-alcohol dependent patients. Schmitz JM, et al. **Drug Alcohol Depend** 1997 Jul 25; 47(1):55–61

Time course of manganese superoxide dismutase concentrations in serum of alcohol-dependent patients during abstinence. Thome J, et al. **Drug Alcohol Depend** 1997 Mar 14;44(2–3):151–5

OLITA: an alternative in the treatment of therapy-resistant chronic alcoholics. First evaluation of a new approach. Ehrenreich H, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(1):51–4

Functional EEG mapping and SPECT in detoxified male alcoholics. Günther W, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(3):128–36

Interest in a stepped approach model (SAM): identification of recruitment strategies for university alcohol programs. Black DR, et al. **Health Educ Q** 1996 Feb;23(1):98–114

Engaging and retaining women in outpatient alcohol and other drug treatment: the effect of referral intensity. Loneck B, et al. **Health Soc Work** 1997 Feb;22(1):38–46

Alcohol cue reactivity, negative-mood reactivity, and relapse in treated alcoholic men. Cooney NL, et al. **J Abnorm Psychol** 1997 May;106(2):243–50

Effective services for homeless substance abusers. Braucht GN, et al. **J Addict Dis** 1995;14(4):87–109

Willingness for treatment as a predictor of retention and outcomes. Erickson JR, et al. **J Addict Dis** 1995; 14(4):135–50

Homelessness and substance use among alcohol abusers following participation in project H&ART. Lapham SC, et al. **J Addict Dis** 1995;14(4):41–55

Six- and twelve-month abstinence rates in inpatient alcoholics treated with either faradic aversion or chemical aversion compared with matched inpatients from a treatment registry. Smith JW, et al. **J Addict Dis** 1997; 16(1):5–24

Evaluating alternative treatments for homeless substance-abusing men: outcomes and predictors of success. Stahler GJ, et al. **J Addict Dis** 1995;14(4):151–67

Factors that interact with treatment to predict outcomes in substance abuse programs for the homeless. Wright JD, et al. **J Addict Dis** 1995;14(4):169–81

Cross-validation of MMPI and MMPI-2 predictor scales. Aaronson AL, et al. **J Clin Psychol** 1996 May;52(3):311–5

MMPI-2 critical item norms in chemically dependent inpatients. Ladd JS. **J Clin Psychol** 1996 May;52(3):367–72

Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. Jaffe AJ, et al. **J Consult Clin Psychol** 1996 Oct;64(5):1044–53

A self-help approach for high-risk drinking: effect of an initial assessment. Sanchez-Craig M, et al. **J Consult Clin Psychol** 1996 Aug;64(4):694–700

A logical functional analysis of reinforcement-based disorders: alcoholism and pedophilia. Wulfert E, et al. **J Consult Clin Psychol** 1996 Dec;64(6):1140–51

Drug rehabilitation in a treatment farm setting: the Nitawgi farm experience, 1978–1990. Richardson DW. **J Dev Behav Pediatr** 1996 Aug;17(4):258–61

Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers. Wilk AI, et al. **J Gen Intern Med** 1997 May;12(5):274–83

A 48-week natural history follow-up of alcoholics who do and do not engage in limited drinking after treatment. Watson CG, et al. **J Nerv Ment Dis** 1996 Oct;184(10):623–7

Worksite barriers to the effective management of alcohol problems. Bell NS, et al. **J Occup Environ Med** 1996 Dec; 38(12):1213–9

Afterword. Future directions for perinatal alcohol and drug treatment services. Wellisch J, et al. **J Psychoactive Drugs** 1997 Jan–Mar;29(1):123–5

ALCOHOLISM

Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes. **J Stud Alcohol** 1997 Jan;58(1):7–29

Drinking restraint and alcohol-related outcomes: exploring the contributions of beverage instructions, beverage content and self-monitoring. Collins RL, et al. **J Stud Alcohol** 1996 Sep;57(5):563–71

Acceptability of the controlled-drinking goal among alcohol treatment agencies in New South Wales, Australia. Donovan M, et al. **J Stud Alcohol** 1997 May;58(3):253–6

Pain control in recovering alcoholics: effects of local anesthesia. Fiset L, et al. **J Stud Alcohol** 1997 May; 58(3):291–6

Help-seeking for alcohol-related problems: social contexts surrounding entry into alcoholism treatment or Alcoholics Anonymous. George AA, et al. **J Stud Alcohol** 1996 Jul; 57(4):449–57

Barriers to alcoholism treatment: reasons for not seeking treatment in a general population sample. Grant BF. **J Stud Alcohol** 1997 Jul;58(4):365–71

The Drinking-Related Locus of Control Scale: the factor structure with treatment-seeking outpatients. Hirsch LS, et al. **J Stud Alcohol** 1997 Mar;58(2):162–6

Social and community resources and long-term recovery from treated and untreated alcoholism. Humphreys K, et al. **J Stud Alcohol** 1997 May;58(3):231–8

Pretreatment readiness for change in male alcohol dependent subjects: predictors of one-year follow-up status. Isenhart CE. **J Stud Alcohol** 1997 Jul;58(4):351–7

Predictors of help seeking among a longitudinal sample of the general population, 1984–1992. Kaskutas LA, et al. **J Stud Alcohol** 1997 Mar;58(2):155–61

Self-insurance and worksite alcohol programs: an econometric analysis. Kenkel DS. **J Stud Alcohol** 1997 Mar; 58(2):211–9

Sleep in detoxified alcoholics: impairment of most standard sleep parameters and increased risk for sleep apnea, but not for myoclonias—a controlled study. Le Bon O, et al. **J Stud Alcohol** 1997 Jan;58(1):30–6

An initial evaluation of the psychosocial dimensions of the American Society of Addiction Medicine criteria for inpatient versus intensive outpatient substance abuse rehabilitation. McKay JR, et al. **J Stud Alcohol** 1997 May; 58(3):239–52

Drinking careers of older male alcoholics in treatment as compared to younger alcoholics and to older social drinkers. Neve RJ, et al. **J Stud Alcohol** 1997 May; 58(3):303–11

Longitudinal changes in alcohol and drug use among men seen at a gay-specific substance abuse treatment agency. Paul JP, et al. **J Stud Alcohol** 1996 Sep;57(5):475–85

Acceptance of moderate drinking by alcoholism treatment services in Canada. Rosenberg H, et al. **J Stud Alcohol** 1996 Sep;57(5):559–62

Low persistence predicts relapse in alcohol dependence following treatment. Sellman JD, et al. **J Stud Alcohol** 1997 May;58(3):257–63

The reliability of Form 90: an instrument for assessing alcohol treatment outcome. Tonigan JS, et al. **J Stud Alcohol** 1997 Jul;58(4):358–64

Predictors of tobacco quit attempts among recovering alcoholics. Bobo JK, et al. **J Subst Abuse** 1996;8(4):431–43

Relationship between posttreatment drinking and alternative responses to high-risk situations proposed during treatment by problem drinkers. Breslin FC, et al. **J Subst Abuse** 1996; 8(4):479–86

Older adult controlled drinkers and abstainers. Chermack ST, et al. **J Subst Abuse** 1996;8(4):453–62

Gender differences in the probability of alcohol treatment. Dawson DA. **J Subst Abuse** 1996;8(2):211–25

Diagnostic and referral reliability in an alcoholism treatment network. Mather DB, et al. **J Subst Abuse** 1996;8(1):81–91

Modeling therapeutic response to 12-step treatment: optimal responders, nonresponders, and partial responders. Morgenstern J, et al. **J Subst Abuse** 1996;8(1):45–59

Cost-benefit and cost-effectiveness analyses of behavioral marital therapy as an addition to outpatient alcoholism treatment. O'Farrell TJ, et al. **J Subst Abuse** 1996; 8(2):145–66

Visuospatial information processing in intoxicated, recently detoxified, and long-term abstinent alcoholics. Schandler SL, et al. **J Subst Abuse** 1996;8(3):321–33

Spouse enabling of alcohol abuse: conception, assessment, and modification. Thomas EJ, et al. **J Subst Abuse** 1996; 8(1):61–80

"About last night": the social ecology of sexual behavior relative to alcohol use among adolescents and young adults in substance abuse treatment. Tubman JG, et al. **J Subst Abuse** 1995;7(4):449–61

Construct validity and predictive utility of the stages of change scale for alcoholics. Willoughby FW, et al. **J Subst Abuse** 1996;8(3):275–91

A qualitative study of barriers to formal treatment among women who self-managed change in addictive behaviours. Copeland J. **J Subst Abuse Treat** 1997 Mar-Apr; 14(2):183–90

Controlled drinking as a treatment goal in Australian alcohol treatment agencies. Dawe S, et al. **J Subst Abuse Treat** 1997 Jan-Feb;14(1):81–6

Alcoholic patients' decisions about halfway houses. What they say, what they do. Fischer EH. **J Subst Abuse Treat** 1996 Mar-Apr;13(2):159–64

Training in substance abuse: still a stepchild in psychiatry residencies? [editorial] Katz JL. **J Subst Abuse Treat** 1997 Mar-Apr;14(2):197–8

Substance abuse treatment and HIV services: Massachusetts' policies and programs. McCarty D, et al. **J Subst Abuse Treat** 1996 Sep-Oct;13(5):429–38; discussion 439

Shelter-based treatment of the homeless alcoholic. Miescher A, et al. **J Subst Abuse Treat** 1996 Mar-Apr;13(2):135–40

Facilitation of internal locus of control in adolescent alcoholics through a brief biofeedback-assisted autogenic relaxation training procedure. Sharp C, et al. **J Subst Abuse Treat** 1997 Jan-Feb;14(1):55–60

Intervention in alcohol use disorder in a general practice. McMenamin JP. **N Z Med J** 1997 May 9;110(1043):173–4

Alteration in dopaminergic function in abstinent alcoholics. Marchesi C, et al. **Neuropsychobiology** 1997;36(1):1–4

Cognitive rehabilitation of chronic alcohol abusers. Allen DN, et al. **Neuropsychol Rev** 1997 Mar;7(1):21–39 (106 ref.)

A controlled trial of educational strategies to teach medical students brief intervention skills for alcohol problems. Roche AM, et al. **Prev Med** 1997 Jan-Feb;26(1):78–85

Federally funded drug and alcohol programs found effective in reducing drug use, crime, homelessness [news] **Psychiatr Serv** 1996 Nov;47(11):1280–1

Unanimous vote for parity coverage of mental illness in U.S. senate is followed by heated debate over costs [news] **Psychiatr Serv** 1996 Jul;47(7):779–80

Two group therapy models for clients with a dual diagnosis of substance abuse and personality disorder. Fisher MS Sr, et al. **Psychiatr Serv** 1996 Nov;47(11):1244–50

Physician health programs and the potentially impaired physician with a substance use disorder. Mansky PA. **Psychiatr Serv** 1996 May;47(5):465–7

Representative payee practices of community mental health centers in Washington State. Ries RK, et al. **Psychiatr Serv** 1997 Jun;48(6):811–4

Effect of centralized intake on outcomes of substance abuse treatment [see comments] Rohrer JE, et al. **Psychiatr Serv** 1996 Nov;47(11):1233–8. Comment in: Psychiatr Serv 1997 Mar;48(3):401–2.

Impact of representative payees on substance use by homeless persons with serious mental illness. Rosenheck R, et al. **Psychiatr Serv** 1997 Jun;48(6):800–6

Influence of retroactive disability payments on recipients' compliance with substance abuse treatment. Satel S, et al. **Psychiatr Serv** 1997 Jun;48(6):796–9

Outcomes of patients in a VA ambulatory detoxification program. Wiseman EJ, et al. **Psychiatr Serv** 1997 Feb; 48(2):200–3

Antisocial personality traits and patients' satisfaction with treatment for addiction. Cernovsky ZZ, et al. **Psychol Rep** 1997 Feb;80(1):275–82

Encouraging participation in aftercare group therapy among substance-dependent men. Lash SJ, et al. **Psychol Rep** 1996 Oct;79(2):585–6

Sustained elevation of vasopressin plasma levels in healthy young men, but not in abstinent alcoholics, upon expectation of novelty. Ehrenreich H, et al. **Psychoneuroendocrinology** 1997 Jan;22(1):13–24

Issues in the linkage of alcohol and domestic violence services. Collins JJ, et al. **Recent Dev Alcohol** 1997; 13:387–405 (91 ref.)

Nicotine dependence and intentions to quit smoking in three samples of male and female recovering alcoholics and problem drinkers. Bobo JK, et al. **Subst Use Misuse** 1996 Jan;31(1):17–33

The efficacy of treatments in reducing alcohol consumption: a meta-analysis [letter; comment] Chick J. **Subst Use Misuse** 1996 Jul;31(9):1081. Comment on: Int J Addict 1995 Jun;30(8):1067–77.

Educational lectures and films in the clinical treatment of alcoholism: a critique. Conner KR, et al. **Subst Use Misuse** 1996 Jul;31(9):1117–29

A prison-based alcohol use education program: evaluation of a pilot study. Crundall I, et al. **Subst Use Misuse** 1997 May;32(6):767–77

Drug and alcohol user treatment/intervention services in Russia—a Western perspective. Fleming PM. **Subst Use Misuse** 1996 Jan;31(1):103–14

Recovery: with and without self-help. Godlaski TM, et al. **Subst Use Misuse** 1997 Apr;32(5):621–7

Pervasive effects of childhood sexual abuse in lesbians' recovery from alcohol problems. Hall JM. **Subst Use Misuse** 1996 Jan;31(2):225–39

The use of bibliometric data in evaluating research on therapeutic community for addictions and in psychiatry. Nieminen P, et al. **Subst Use Misuse** 1997 Apr;32(5):555–70

Evaluating the impact of a clinical training program in the addictions. Scotch FL, et al. **Subst Use Misuse** 1997 Aug; 32(10):1331–48

Cultural linkage: treating Maori with alcohol and drug problems in dedicated Maori treatment programs. Sellman JD, et al. **Subst Use Misuse** 1997 Mar;32(4):415–24

The effect of an orientation-to-treatment group on the retention of alcoholics in outpatient treatment. Verinis JS. **Subst Use Misuse** 1996 Aug;31(10):1423–31

Liver transplantation for patients with alcoholic cirrhosis. Fabrega F, et al. **Transplant Proc** 1997 Feb-Mar; 29(1-2):465–6

[Work disability and alcohol problems] Holopainen A, et al. **Duodecim** 1995;111(17):1683–4 **(Fin)**

[Separation of therapy and diagnosis on the one hand—need for interprofessional cooperation on the other hand. Also a critical comment to the contribution of Pund and Kajan (letter)] Müller W. **Blutalkohol** 1996 Jul;33(4):215–20 **(Ger)**

[Without the family physician drug treatment is not feasible (interview by Dr. rer. nat. Anita Schweiger)] Fleischmann H. **Fortschr Med** 1996 Oct 20;114(29):20, 22 **(Ger)**

[Alcoholism as chronic disease: a challenge for the physician] Kruse G. **Fortschr Med** 1996 Oct 20;114(29):369–71 (0 ref.) (Eng. Abstr.) **(Ger)**

[Naltrexone—prevention of recurrence in narcotic dependence and in alcoholism] Poser W, et al. **Internist (Berl)** 1996 Oct;37(10):1061–7; discussion 1067 (61 ref.) **(Ger)**

[Hidden alcohol in foods?] Greubel S. **Med Monatsschr Pharm** 1997 Aug;20(8):218–9 **(Ger)**

[Pharmacotherapy of alcoholism] Soyka M, et al. **Med Monatsschr Pharm** 1996 Dec;19(12):359–64 (21 ref.) **(Ger)**

[Dependency outcome of alcohol-dependent patients after inpatient detoxification and motivation treatment] Stetter F, et al. **Nervenarzt** 1997 Jul;68(7):574–81 (Eng. Abstr.) **(Ger)**

[Harm reduction—on the paradigm changes in drug dependence treatment (editorial)] Kuhlmann T. **Psychiatr Prax** 1996 Jul;23(4):157–60 (Eng. Abstr.) **(Ger)**

[Is the new guardianship law regarding alcoholic patients therapeutically useful? A case example] Mundle G, et al. **Psychiatr Prax** 1996 Nov;23(6):300–1 (Eng. Abstr.) **(Ger)**

[Harm reduction—truly a paradigm change? Some sociological comments on the contribution by Thomas Kuhlmann] Tasseit S. **Psychiatr Prax** 1997 Jul;24(4):205–6 **(Ger)**

[Changes in the self-concept of alcohol dependent women and men during inpatient psychotherapy] Mann K, et al. **Psychother Psychosom Med Psychol** 1996 Sep-Oct; 46(9-10):350–5 (Eng. Abstr.) **(Ger)**

[Pharmacopsychiatric guidelines for treatment of alcohol withdrawal syndrome] Schröder-Rosenstock K, et al. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):301–6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Rehabilitation of the elderly alcoholic] Santonastaso M, et al. **Recenti Prog Med** 1996 Sep;87(9):412–5 (Eng. Abstr.) **(Ita)**

[Experience in treating tuberculosis patients suffering from alcoholism at a sanatorium] Sysoev VD, et al. **Probl Tuberk** 1996;(4):56–7 **(Rus)**

[Potable mineral waters as the correctors of the hormonal and motor-evacuatory disorders in chronic alcoholic intoxication] Polushina ND, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 May-Jun; (3):37–9 (Eng. Abstr.) **(Rus)**

[Health fitness of professional drivers and recurrence of alcoholism] Rossi-Gašparović D, et al. **Arh Hig Rada Toksikol** 1996 Jun;47(2):177–88 (Eng. Abstr.) **(Scr)**

[Alcohol dependence and psychiatric comorbidity. II. Clinical and therapeutic implications] Cuadrado Callejo P. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Jan-Feb;25(1):34–44 (150 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy. Caine D, et al. **J Neurol Neurosurg Psychiatry** 1997 Jan; 62(1):51–60

THERAPY

Prevention and treatment of alcohol-related problems: an international medical education model. Murray M, et al. **Acad Med** 1996 Nov;71(11):1204–10

Alcohol interventions: do the best things come in small packages? Drummond DC. **Addiction** 1997 Apr;92(4):375–9 (20 ref.)

How to have a high success rate in treatment [letter; comment] Mattick RP. **Addiction** 1997 Apr;92(4):484–5. Comment on: Addiction 1996 Jun;91(6):779–85.

How to become a true scientist: a guide to minimizing pesky treatment effects [letter; comment] Moos RH. **Addiction** 1997 Apr;92(4):481–2, 485. Comment on: Addiction 1996 Jun;91(6):779–85.

Use binary, not continuous measures [letter] Poikolainen K. **Addiction** 1997 Jul;92(7):904

How to measure outcome in alcoholism treatment studies? [letter; comment] Salaspuro M, et al. **Addiction** 1997 Apr; 92(4):483–4. Comment on: Addiction 1996 Jun;91(6):779–85.

Interventions into alcohol problems: what works? Smart RG, et al. **Addiction** 1997 Jan;92(1):9–13

Endogenous opioids in the treatment of alcohol dependence. XIXth Collegium Internationale Neuro-Psycopharmacologium Congress. Washington, D.C., June 24, 1994. **Alcohol** 1996 Jan-Feb;13(1):1–106

Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Kranzler HR, et al. **Alcohol Clin Exp Res** 1996 Dec; 20(9):1534–41

Predictors of successful vs. unsuccessful outcome of a 12-step inpatient alcohol rehabilitation program. Craig TJ, et al.

Am J Addict 1997 Summer;6(3):232–6

Recovery rates after treatment for alcohol/drug dependence. Tobacco users vs. non-tobacco users. Stuyt EB.
Am J Addict 1997 Spring;6(2):159–67

Influence of acupuncture and pharmacotherapy on sensitivity of sensory systems to alcohol irritants in patients with alcoholism. Timofeev MF. **Am J Chin Med** 1996; 24(2):177–84

Sources of motivation in a couples outpatient alcoholism treatment program. Steinberg ML, et al.
Am J Drug Alcohol Abuse 1997 May;23(2):191–205

Intervention for a homeless alcoholic [letter; comment] Kupkowski MJ. **Am J Nurs** 1996 Nov;96(11):15. Comment on: Am J Nurs 1996 Jul;96(7):48–50.

An intervention with high-risk mothers who abuse alcohol and drugs: the Seattle Advocacy Model. Grant TM, et al. **Am J Public Health** 1996 Dec;86(12):1816–7

Alcohol misuse among doctors. Treatment should be offered [letter] Cunningham GM. **BMJ** 1997 Jun 21; 314(7097):1833–4

Fetal alcohol syndrome. Duerbeck NB. **Compr Ther** 1997 Mar;23(3):179–83 (21 ref.)

Family climate and expressed emotion in the course of alcoholism. Fichter MM, et al. **Fam Process** 1997 Jun; 36(2):203–21

Treating alcoholism: an age-specific intervention that works for older patients. Peterson M, et al. **Geriatrics** 1996 Oct; 51(10):45–9; quiz 50

Alcohol use after liver transplantation in alcoholics: a clinical cohort follow-up study. Lucey MR, et al. **Hepatology** 1997 May;25(5):1223–7

Treatment approaches for older problem drinkers. Schonfeld L, et al. **Int J Addict** 1995 Nov–Dec;30(13–14):1819–42 (60 ref.)

Alcohol dependence a growing problem for women. Treating depression in alcoholic patients helps to prevent relapse [news] **Int J Fertil Menopausal Stud** 1996 May–Jun; 41(3):273–4

Outcome of nursing home care for residents with alcohol use disorders. Joseph CL, et al.
Int J Geriatr Psychiatry 1997 Jul;12(7):767–72

A comparative outcome study of frequent, moderate, occasional, and nonattenders of Alcoholics Anonymous. Watson CG, et al. **J Clin Psychol** 1997 Apr;53(3):209–14

The therapeutic alliance and its relationship to alcoholism treatment participation and outcome. Connors GJ, et al. **J Consult Clin Psychol** 1997 Aug;65(4):588–98

Utilization of acute inpatient services for alcohol detoxification. Booth BM, et al. **J Ment Health Adm** 1996 Fall;23(4):366–74

Treatment participation and outcome among problem drinkers in a managed care alcohol outpatient treatment program. Hu T, et al. **J Ment Health Adm** 1997 Winter; 24(1):23–34

Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. Krupitsky EM, et al.
J Psychoactive Drugs 1997 Apr–Jun;29(2):165–83 (55 ref.)

Impact of a body-mind treatment component on alcoholic inpatients. Ermalinski R, et al.
J Psychosoc Nurs Ment Health Serv 1997 Jul;35(7):39–45

Comorbid psychiatric diagnosis predicts three-year outcomes in alcoholics: a posttreatment natural history study. Kranzler HR, et al. **J Stud Alcohol** 1996 Nov;57(6):619–26

Alcohol-related measures as factors in traffic fatalities. Mann RE, et al. **J Stud Alcohol** 1996 Nov;57(6):646–51

Addiction medicine. O'Brien CP, et al. **JAMA** 1997 Jun 18; 277(23):1840–1

Cognitive functions in alcoholics and success in treatment: how are they related? Saarnio P.
Nihon Arukoru Yakubutsu Igakkai Zasshi 1996 Jun; 31(3):205–14

NIDA-NIAAA workshop: efficacy of therapies in drug and alcohol addiction. Strategies for treatment of alcohol problems. Allen JP, et al. **Psychopharmacol Bull** 1995; 31(4):665–9

Women and minorities representation in alcoholism treatment research. Williams LD, et al. **Psychopharmacol Bull** 1996; 32(2):201–4

Alcoholism—treating the disease. Lee A.
Singapore Med J 1997 May;38(5):214–6 (11 ref.)

Life stories and shared experience. Steffen V.
Soc Sci Med 1997 Jul;45(1):99–111

African-American women in an alcohol intervention group: addressing personal and political problems. Saulnier CF. **Subst Use Misuse** 1996 Aug;31(10):1259–78

Composite outcome measures in alcoholism treatment research: problems and potentialities. Zweben A, et al.
Subst Use Misuse 1996 Nov;31(13):1783–805 (36 ref.)

[Clinical study enabling improvement of inpatient psychotherapeutic treatment and after care of patients admitted in a specialized center] Neuberg P.
Bull Soc Sci Med Grand Duche Luxemb 1996;133(1):25–9 **(Fre)**

["Alcohol in the City". What does alcoholism specialty do in the Lausanne region and the canton of Vaud?] Schnyder C, et al. **Rev Med Suisse Romande** 1996 Sep;116(9):719–26 **(Fre)**

[Specificity of alcoholism and resulting methods of therapeutic practice] Nowobilska-Stanios M, et al.
Przegl Lek 1997;54(6):446–8 (5 ref.) (Eng. Abstr.) **(Pol)**

[Co-dependence—diagnosis and therapy] Sękowska M.
Przegl Lek 1997;54(6):441–5 (3 ref.) (Eng. Abstr.) **(Pol)**

[The use of holotropic breathing in the treatment of chronic alcoholism] Zaritskiĭ MG. **Lik Sprava** 1996 Mar–Apr; (3–4):134–6 (Eng. Abstr.) **(Rus)**

[The use of psychedelic agents in psychotherapy (apropos the article by Iu. P. Sivolap and V. A. Savchenkov "Experience in using ketamine preparations in the psychotherapy of alcoholism")] Krupitskiĭ EM, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1996;96(2):115–6 **(Rus)**

ULTRASONOGRAPHY

[Echocardiographic assessment of alcohol consumers in different clinical stages] Scafa F, et al. **Minerva Med** 1996 Sep;87(9):407–11 (Eng. Abstr.) **(Ita)**

URINE

Altered cortisol response in sober alcoholics: an examination of contributing factors. Bernardy NC, et al. **Alcohol** 1996 Sep–Oct;13(5):493–8

Alcohol-induced changes in urinary aminolevulinic acid and porphyrins: unrelated to liver disease. Schoenfeld N, et al. **Alcohol** 1996 Jan–Feb;13(1):59–63 (18 ref.)

The use of 5-hydroxytryptophol as an alcohol intake marker. Helander A, et al. **Alcohol Alcohol Suppl** 1994;2:497–502 (30 ref.)

Formaldehyde-derived tetrahydroisoquinolines and tetrahydro-beta-carbolines in human urine. Musshoff F, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30; 683(2):163–76

VIROLOGY

Ethanol and hepatocellular injury. French SW.
Clin Lab Med 1996 Jun;16(2):289–306 (110 ref.)

ALCOHOLS

The alcohol-drop solution: an aid in cytologic screening [letter] Dhimes P, et al. **Acta Cytol** 1996 Nov–Dec; 40(6):1328–9

Anesthetic potencies of n-alkanols: results of additivity and solubility studies suggest a mechanism of action similar to that for conventional inhaled anesthetics. Fang Z, et al. **Anesth Analg** 1997 May;84(5):1042–8

Non-specific helix-induction in charged homopolypeptides by alcohols. Arunkumar AI, et al.
Biochim Biophys Acta 1997 Mar 7;1338(1):69–76

No time for handwashing!? Handwashing versus alcoholic rub: can we afford 100% compliance? Voss A, et al.
Infect Control Hosp Epidemiol 1997 Mar;18(3):205–8

ADMINISTRATION & DOSAGE

Immunopathogenesis of HIV infection: role of alcohol and HIV peptides. Nair MP, et al. **Adv Exp Med Biol** 1996; 402:165–70

Terra firma-forme dermatosis. O'Brien TJ, et al.
Australas J Dermatol 1997 Aug;38(3):163–4

Effect of coronary perfusion of heptanol on conduction and ventricular arrhythmias in infarcted canine myocardium. Callans DJ, et al. **J Cardiovasc Electrophysiol** 1996 Dec; 7(12):1159–71

Histological assessment of combined chemoembolization and alcohol infusion for hepatocellular carcinoma in cirrhotic patients. Troisi R, et al. **Transplant Proc** 1997 Aug; 29(5):2412–3

ADVERSE EFFECTS

Localised pain following contact with liquids [letter] Misery L, et al. **Br J Dermatol** 1997 Jun;136(6):980–1

Evaluation of human skin irritation by carboxylic acids, alcohols, esters and aldehydes, with nitrocellulose-replica method and closed patch testing. Sato A, et al.
Contact Dermatitis 1996 Jan;34(1):12–6

ANALYSIS

Linear, steroidal, and triterpene esters, and steryl glycosides from Festuca argentina. Casabuono AC, et al. **Lipids** 1997 Feb;32(2):205–10

CHEMISTRY

Neural network classification and quantification of organic vapors based on fluorescence data from a fiber-optic sensor array. Sutter JM, et al. **Anal Chem** 1997 Mar 1;69(5):856–62

Effects of alcohols on the phase transition temperatures of mixed-chain phosphatidylcholines. Li S, et al.
Biophys J 1996 Jun;70(6):2784–94

Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols. Sturzebecher J, et al.
FEBS Lett 1997 Jul 28;412(2):295–300

Several polyhydroxymonoamide renin inhibitors assume similar conformations in the unbound and renin-bound states. Laplante SR, et al. **Int J Pept Protein Res** 1996 Nov; 48(5):401–10

Interaction of alcohols and anesthetics with protein kinase Calpha. Slater SJ, et al. **J Biol Chem** 1997 Mar 7; 272(10):6167–73

Effects of polyvalent alcohol solutions as dentine primers. Ohhashi M, et al. **J Dent** 1997 Mar;25(2):161–6

The hydrophobic propensity of water toward amphiprotic solutes: predicton and molecular origin of the aqueous solubility of aliphatic alcohols. Ruelle P, et al.
J Pharm Sci 1997 Feb;86(2):179–86

On the ozonization of cholesterol 3-acyl esters in protic media. Smith LL, et al. **Steroids** 1996 Jul;61(7):401–6

METABOLISM

The application of asymmetric bioreductions to the production of chiral pharmaceutical drugs. Chartrain M, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:612–19

Effect of aeration and unsaturated fatty acids on expression of the Saccharomyces cerevisiae alcohol acetyltransferase gene. Fujii T, et al. **Appl Environ Microbiol** 1997 Mar; 63(3):910–5

Utilization of alcohols by plant and mammalian phospholipase D. Ella KM, et al. **Biochem Mol Biol Int** 1997 Apr;41(4):715–24

The interaction of lower alcohols with apoB in spin labeled human plasma low density lipoproteins (LDL). Kveder M, et al. **Chem Phys Lipids** 1997 Jul 14;87(2):125–35

Influence of substrate structure on the catalytic efficiency of hydroxysteroid sulfotransferase STa in the sulfation of alcohols. Chen G, et al. **Chem Res Toxicol** 1996 Jan–Feb; 9(1):67–74

Use of pH studies to determine the kinetic and chemical mechanism of yeast alcohol dehydrogenase with primary aliphatic alcohols and aldehydes. Leskovac V, et al.
Indian J Biochem Biophys 1996 Jun;33(3):177–83

The yeast site-specific recombinase Flp mediates alcoholysis and hydrolysis of the strand cleavage product: mimicking the strand-joining reaction with non-DNA nucleophiles. Knudsen BR, et al. **J Mol Biol** 1997 Feb 14;266(1):93–107

Primary alcohols and phosphatidylcholine metabolism in rat brain synaptosomal membranes via phospholipase D. Seidler L, et al. **Pharmacol Toxicol** 1996 Apr;78(4):249–53

[Distribution of certain nonelectrolytes between intra- and extracellular parts of erythrocytes] Kucherenko IuV, et al.
Ukr Biokhim Zh 1995 Nov–Dec;67(6):98–102 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Modulation of GABAA receptor function by alcohols: effects of subunit composition and differential effects of ethanol. Whitten RJ, et al. **Alcohol Clin Exp Res** 1996 Oct; 20(7):1313–9

Interactive effect of combined exposure to glycol ethers and alcohols on toxicodynamic and toxicokinetic parameters. Morel G, et al. **Arch Toxicol** 1996;70(8):519–25

Effects of aliphatic alcohols on the ER calcium pumps and InsP3 receptors from porcine cerebellum. Mezna M, et al.
Biochem Soc Trans 1996 May;24(2):292S

Effect of n-alkanols on lipid bilayer hydration. Ho C, et al.
Biochemistry 1997 Sep 2;36(35):10630–7

The site for GTP hydrolysis on the archaeal elongation factor 2 is unmasked by aliphatic alcohols. Raimo G, et al.
Biochimie 1996;78(10):832–7

Synergetic cytotoxicity of bleomycin and polyhydric alcohols: DNA strand breakage evaluated by "comet assay". Kasamatsu T, et al. **Biol Pharm Bull** 1996 Apr;19(4):632–5

Homologous mutations on different subunits cause unequal but additive effects on n-alcohol block in the nicotinic receptor pore. Forman SA. **Biophys J** 1997 May; 72(5):2170–9

The site of general anaesthesia and cytochrome P450 oxygenases: similarities defined by straight chain and cyclic alcohols. LaBella FS, et al. **Br J Pharmacol** 1997 Mar; 120(6):1158–64

Effects of heptanol on electrical activity in the guinea-pig vas deferens. Manchanda R, et al. **Br J Pharmacol** 1997 Feb;120(3):367–70

Phosphatidic acid formation by phospholipase D is required for transport from the endoplasmic reticulum to the Golgi complex. Bi K, et al. **Curr Biol** 1997 May 1;7(5):301–7

Inhibition of nitric oxide synthase by straight chain and cyclic alcohols. Chen QM, et al. **Eur J Pharmacol** 1997 Mar 5; 321(3):355–60

Effect of heptanol on the short circuit currents of cornea and ciliary body demonstrates rate limiting role of heterocellular gap junctions in active ciliary body transport. Wolosin JM, et al. **Exp Eye Res** 1997 Jun; 64(6):945–52

Fatty acids stimulate activity and restore respiratory control in a proton channel mutant of cytochrome c oxidase. Fetter J, et al. **FEBS Lett** 1996 Sep 16;393(2–3):155–60

Neuroprotective potential of aromatic alcohols against oxidative cell death. Moosmann B, et al. **FEBS Lett** 1997 Aug 25;413(3):467–72

Synergetic inhibition of photophosphorylation and uncoupled electron transport by N,N'-dicyclohexylcarbodiimide and alcohols in pea chloroplasts. Zolotareva EK, et al.
FEBS Lett 1997 Jul 28;412(2):375–8

Strains of Drosophila melanogaster differ in alcohol tolerance. Bokor K, et al. **Hereditas** 1997;126(2):103–13

Vascular gap junctional communication and heptanol [letter; comment] Daniel EE. **Hypertension** 1997 Aug;30(2 Pt 1):306. Comment on: Hypertension 1996 Nov;28(5):888–93.

Heptanol but not fluoroacetate prevents the propagation of spreading depression in rat hippocampal slices. Largo C, et al. **J Neurophysiol** 1997 Jan;77(1):9–16

Effects of alcohols on A-type K+ currents in Lymnaea neurons. Alekseev SI, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):84–92

ALCOHOLS

Potentiation of GABA-induced Cl- current by a series of n-alcohols disappears at a cutoff point of a longer-chain n-alcohol in rat dorsal root ganglion neurons. Nakahiro M, et al. **Neurosci Lett** 1996 Feb 23;205(2):127-30

The enhancer effect of several phenyl alcohols on percutaneous penetration of 5-fluorouracil. López A, et al. **Pharm Res** 1997 May;14(5):681-5

Effect of lipid solubility on the development of chronic cross-tolerance between ethanol and different alcohols and barbiturates. Khanna JM, et al.
Pharmacol Biochem Behav 1997 May-Jun;57(1-2):101-10

Allosteric modulation of 5-HT3 receptors: focus on alcohols and anaesthetic agents. Parker RM, et al.
Trends Pharmacol Sci 1996 Mar;17(3):95-9 (38 ref.)

TOXICITY

The hepatic interaction of aliphatic alcohols with halogenated hydrocarbons. Simmons JE.
Drug Metab Rev 1997 Feb-May;29(1-2):123-36 (29 ref.)

Differential prenatal toxicity of one straight-chain and five branched-chain primary alcohols in rats. Hellwig J, et al. **Food Chem Toxicol** 1997 May;35(5):489-500

Correlation between hydrophobicity of short-chain aliphatic alcohols and their ability to alter plasma membrane integrity. McKarns SC, et al. **Fundam Appl Toxicol** 1997 Mar;36(1):62-70

[Structure-mutagenic activity relationships on the TA100 strain of Salmonella typhimurium exposed to a series of halogenated hydrocarbons and short-chain alcohols] Kharchevnikova NV, et al. **Genetika** 1997 May;33(5):710-3 (Eng. Abstr.) **(Rus)**

URINE

Analysis of bile acids and bile alcohols in urine by capillary column liquid chromatography-mass spectrometry using fast atom bombardment or electrospray ionization and collision-induced dissociation. Yang Y, et al.
Biomed Chromatogr 1997 Jul-Aug;11(4):240-55

ALCOHOLS, AMYL

PHARMACOLOGY

Olfactory event-related potentials to amyl acetate in congenital anosmia. Cui L, et al.
Electroencephalogr Clin Neurophysiol 1997 Apr; 102(4):303-6

Responses to odorants by the domestic chick. Burne TH, et al. **Physiol Behav** 1996 Dec;60(6):1441-7

Murine cytochrome P4503A is induced by 2-methyl-3-buten-2-ol, 3-methyl-1-pentyn-3-ol(meparfynol), and tert-amyl alcohol. Mannering GJ, et al. **Xenobiotica** 1996 May; 26(5):487-93

TOXICITY

A comparison of the acute behavioral effects of inhaled amyl, ethyl, and butyl acetate in mice. Bowen SE, et al.
Fundam Appl Toxicol 1997 Feb;35(2):189-96

ALCOHOLS, BUTYL

Gas chromatographic procedures for determination of ethanol in postmortem blood using t-butanol and methyl ethyl ketone as internal standards [see comments] O'Neal CL, et al. **Forensic Sci Int** 1996 Nov 11;83(1):31-8. Comment in: Forensic Sci Int 1997 Apr 18;86(1-2):139-43.

BLOOD

Toluene, 1-butanol, ethylbenzene and xylene from Sarstedt Monovette serum gel blood collection tubes. Dyne D, et al. **Ann Clin Biochem** 1996 Jul;33 (Pt 4):355-6

Kinetics of n-butyl alcohol and m-xylene in blood during single and combined inhalation exposure in rats. Swiercz R, et al. **Int J Occup Med Environ Health** 1995;8(4):361-5

CHEMISTRY

The enantiomeric purity of alcohols formed by enzymatic reduction of ketones can be improved by optimisation of the temperature and by using a high co-substrate concentration. Yang H, et al. **Biochim Biophys Acta** 1997 Jul 19;1336(1):51-8

Liquid/air partition coefficients of methyl and ethyl T-butyl ethers, T-amyl methyl ether, and T-butyl alcohol. Nihlen A, et al. **J Expo Anal Environ Epidemiol** 1995 Oct-Dec; 5(4):573-82

Reconstitution of the zone-block model of biomembranes. 3. Synthesis and investigation of the structure of phosphatidylcholine analog isobutyl-2-(trimethylammonia)ethyl phosphate in its monohydrate crystals and monohydrate complexes with isobutanol. Fundamensky VS, et al. **Membr Cell Biol** 1997; 11(1):137-56

DIAGNOSTIC USE

Quantitation of regional cerebral blood flow with 15O-butanol and positron emission tomography in humans. Herzog H, et al. **J Cereb Blood Flow Metab** 1996 Jul; 16(4):645-9

METABOLISM

The genes for butanol and acetone formation in Clostridium acetobutylicum ATCC 824 reside on a large plasmid whose loss leads to degeneration of the strain. Cornillot E, et al.
J Bacteriol 1997 Sep;179(17):5442-7

PHARMACOLOGY

Stress response of lysosomal cysteine proteinases in rat C6 glioma cells. Xu C, et al.
Comp Biochem Physiol B Biochem Mol Biol 1997 Jun; 117(2):169-78

TOXICITY

Environmental assessment of the alkanolamines. Davis JW, et al. **Rev Environ Contam Toxicol** 1997;149:87-137 (94 ref.)

URINE

Monitoring of occupational exposure to 1-butanol by diffusive sampling and urinalysis. Kawai T, et al.
Int Arch Occup Environ Health 1997;69(4):266-72

ALCOHOLS, HEXYL

CHEMISTRY

Alcohol binding to liposomes by 2H NMR and radiolabel binding assays: does partitioning describe binding? Dubey AK, et al. **Biophys J** 1996 May;70(5):2307-15

METABOLISM

Influence of monovalent cations on the binding of a charged and an uncharged ('carbo'-)muscarinic antagonist to muscarinic receptors. Hou X, et al. **Br J Pharmacol** 1996 Mar;117(5):955-61

TOXICITY

Effects of n-hexane and its metabolites on cloned voltage-operated neuronal potassium channels. Madeja M, et al. **Arch Toxicol** 1997;71(4):238-42

Oncogenicity testing of 2-ethylhexanol in Fischer 344 rats and B6C3F1 mice. Astill BD, et al.
Fundam Appl Toxicol 1996 May;31(1):29-41

Prechronic toxicity studies on 2-ethylhexanol in F334 rats and B6C3F1 mice. Astill BD, et al.
Fundam Appl Toxicol 1996 Jan;29(1):31-9

ALCOHOLS, OCTYL

Efficacy of carbon dioxide, 1-octen-3-ol, and lactic acid in modified Fay-Prince traps as compared to man-landing catch of Aedes aegypti. Canyon DV, et al.
J Am Mosq Control Assoc 1997 Mar;13(1):66-70

Olfactory attractants for mosquito surveillance and control: 1-octen-3-ol. Kline DL. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 2):280-7 (25 ref.)

Assessment of n-octanol/water partition coefficient: when is the assessment reliable? Gombar VK, et al.
J Chem Inf Comput Sci 1996 Nov-Dec;36(6):1127-34

Partition coefficients (n-octanol/water) of N-butyl-p-aminobenzoate and other local anesthetics measured by reversed-phase high-performance liquid chromatography. Grouls RJ, et al.
J Chromatogr B Biomed Appl 1997 Jul 4;694(2):421-5

Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates. Avdeef A, et al. **J Med Chem** 1996 Oct 25;39(22):4377-81

Responses of mosquitoes of the Anopheles farauti complex to 1-octen-3-ol and light in combination with carbon dioxide in northern Queensland, Australia. van den Hurk AF, et al. **Med Vet Entomol** 1997 Apr;11(2):177-80

CHEMISTRY

Micellar electrokinetic capillary chromatography as a method for determination of n-octanol/water partition coefficients of pesticides. Dinelli G, et al.
Electrophoresis 1997 Feb;18(2):214-9

Drug-phospholipid interactions. 2. Predicting the sites of drug distribution using n-octanol/water and membrane/water distribution coefficients. Barton P, et al.
J Pharm Sci 1997 Sep;86(9):1034-9

Lipophilicity determination of psoralens used in therapy through solubility and partitioning: comparison of theoretical and experimental approaches. Said A, et al.
J Pharm Sci 1996 Apr;85(4):387-92

METABOLISM

Biological spin trapping methodology. III. Octanol-water partition coefficients of spin-trapping compounds. Janzen EG, et al. **J Biochem Biophys Methods** 1996 Jul 10; 32(3):183-90

PHARMACOLOGY

Triggered propagated contractions in rat cardiac trabeculae. Inhibition by octanol and heptanol. Zhang YM, et al.
Circ Res 1996 Dec;79(6):1077-85

ALCOHOLS, SUGAR see **SUGAR ALCOHOLS**

ALCURONIUM

PHARMACOLOGY

Opposite effects of alcuronium on agonist and on antagonist binding to muscarinic receptors. Maass A, et al.
Eur J Pharmacol 1996 Jun 3;305(1-3):231-4

ALCURONIUM CHLORIDE see **ALCURONIUM**

ALDEHYDE DEHYDROGENASE

ANALYSIS

Fluorimetric detection of aldehyde dehydrogenase activity in human blood, saliva, and organ biopsies and kinetic differentiation between class I and class III isozymes. Wierzchowski J, et al. **Anal Biochem** 1997 Feb 1; 245(1):69-78

Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Tanner B, et al.
Gynecol Oncol 1997 Apr;65(1):54-62

Characterization of aldehyde dehydrogenase-positive amacrine cells restricted in distribution to the dorsal retina. Milam AH, et al. **Vis Neurosci** 1997 May-Jun;14(3):601-8

ANTAGONISTS & INHIBITORS

Yeast aldehyde dehydrogenase sensitivity to inhibition by chlorpropamide analogues as an indicator of human aldehyde dehydrogenase sensitivity to these agents. Devaraj VR, et al. **Adv Exp Med Biol** 1997;414:155-69

Effect of substituted bromoacetanilides on cytosolic aldehyde dehydrogenase. Euston SE, et al. **Adv Exp Med Biol** 1997; 414:233-41

Phenethyl isothiocyanate as an inhibitor of aldehyde dehydrogenases. Koivusalo M, et al. **Adv Exp Med Biol** 1997;414:225-32

Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol. Rekha GK, et al.
Adv Exp Med Biol 1997;414:133-46

Inhibition of mouse and human class 1 aldehyde dehydrogenase by 4-(N,N-dialkylamino)benzaldehyde compounds. Russo JE. **Adv Exp Med Biol** 1997;414:217-24

Mechanism for the inhibition of aldehyde dehydrogenase by nitric oxide. DeMaster EG, et al. **Alcohol** 1997 Mar-Apr; 14(2):181-9

S-methyl-N,N-diethylthiocarbamate sulfoxide and S-methyl-N,N-diethylthiocarbamate sulfone, two candidates for the active metabolite of disulfiram. Mays DC, et al. **Alcohol Clin Exp Res** 1996 May;20(3):595-600

Allosteric inhibition of human liver aldehyde dehydrogenase by the isoflavone prunetin. Sheikh S, et al.
Biochem Pharmacol 1997 Feb 21;53(4):471-8

Inhibition of aldehyde dehydrogenase by disulfiram and its metabolite methyl diethylthiocarbamoyl-sulfoxide. Veverka KA, et al. **Biochem Pharmacol** 1997 Feb 21; 53(4):511-8

Novel prodrugs of cyanamide that inhibit aldehyde dehydrogenase in vivo. Shirota FN, et al. **J Med Chem** 1997 Jun 6;40(12):1870-5

Studies on the metabolic activation of disulfiram in rat. Evidence for electrophilic S-oxygenated metabolites as inhibitors of aldehyde dehydrogenase and precursors of urinary N-acetylcysteine conjugates. Hu P, et al.
J Pharmacol Exp Ther 1997 May;281(2):611-7

Cimetidine and other H2-receptor antagonists as inhibitors of human E3 aldehyde dehydrogenase. Kikonyogo A, et al. **Mol Pharmacol** 1997 Aug;52(2):267-71

Daidzin inhibits mitochondrial aldehyde dehydrogenase and suppresses ethanol intake of Syrian golden hamsters. Keung WM, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4; 94(5):1675-9

BIOSYNTHESIS

A preliminary report on the cloning of a constitutively expressed rat liver cytosolic ALDH cDNA by PCR. Kathmann EC, et al. **Adv Exp Med Biol** 1997;414:69-72

Class 3 aldehyde dehydrogenase. A view from the hills. Lindahl R, et al. **Adv Exp Med Biol** 1997;414:15-8

Expression of ALDH3 and NMO1 in human corneal epithelial and breast adenocarcinoma cells. Marks-Hull H, et al. **Adv Exp Med Biol** 1997;414:59-68

Changes in aldehyde dehydrogenase isozymes expression in long-term cultures of human hematopoietic progenitor cells. Meier-Tackmann D, et al. **Adv Exp Med Biol** 1997; 414:47-57

Ontogenesis and expression of ALDH activity in the skin and the eye of the rat. Pappas P, et al.
Adv Exp Med Biol 1997;414:73-80

Regulation of rat ALDH-3 by hepatic protein kinases and glucocorticoids. Prough RA, et al. **Adv Exp Med Biol** 1997; 414:29-36 (18 ref.)

Mouse dioxin-inducible Ahd4 gene. Structure of the 5' flanking region and transcriptional regulation. Vasiliou V, et al. **Adv Exp Med Biol** 1997;414:37-46

Saccharomyces cerevisiae aldehyde dehydrogenases. Identification and expression. Wang X, et al.
Adv Exp Med Biol 1997;414:277-80

The cytosolic aldehyde dehydrogenase gene (Aldh1) is developmentally expressed in Leydig cells. López-Fernández LA, et al. **FEBS Lett** 1997 Apr 28; 407(2):225–9

Formation of crystalloid endoplasmic reticulum in COS cells upon overexpression of microsomal aldehyde dehydrogenase by cDNA transfection. Yamamoto A, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1727–38

BLOOD

Aldehyde dehydrogenase–mediated metabolism of acetaldehyde and mafosfamide in blood of healthy subjects and patients with malignant lymphoma. Metzenthin M, et al. **Adv Exp Med Biol** 1997;414:147–53

CHEMISTRY

Laser light scattering and ultracentrifuge studies on sheep liver cytosolic aldehyde dehdyrogenase. Harvey JJ, et al. **Adv Exp Med Biol** 1997;414:171–9

Conserved residues in the aldehyde dehydrogenase family. Locations in the class 3 tertiary structure. Hempel J, et al. **Adv Exp Med Biol** 1997;414:9–13

Crystal structure of a class 3 aldehyde dehydrogenase at 2.6 A resolution. Liu ZJ, et al. **Adv Exp Med Biol** 1997;414:1–7

Structural and functional studies of a NADP(+)–specific aldehyde dehydrogenase from the luminescent marine bacterium Vibrio harveyi. Vedadi M, et al. **Adv Exp Med Biol** 1997;414:269–75

Saccharomyces cerevisiae aldehyde dehydrogenases. Identification and expression. Wang X, et al. **Adv Exp Med Biol** 1997;414:277–80

Subunit interactions in mammalian liver aldehyde dehydrogenases. Weiner H, et al. **Adv Exp Med Biol** 1997; 414:181–5

Purification and partial characterization of bovine kidney aldehyde dehydrogenase able to oxidize retinal to retinoic acid. Bhat PV, et al. **Biochem Cell Biol** 1996;74(5):695–700

Rat hepatic microsomal aldehyde dehydrogenase. Identification of 3– and 4–substituted aromatic aldehydes as substrates of the enzyme. Martini R, et al. **Chem Res Toxicol** 1996 Jan–Feb;9(1):268–76

Expression, purification, and properties of the aldehyde dehydrogenase homologous carboxyl–terminal domain of rat 10–formyltetrahydrofolate dehydrogenase. Krupenko SA, et al. **J Biol Chem** 1997 Apr 11;272(15):10266–72

Heterotetramers of human liver mitochondrial (class 2) aldehyde dehydrogenase expressed in Escherichia coli. A model to study the heterotetramers expected to be found in Oriental people. Wang X, et al. **J Biol Chem** 1996 Dec 6;271(49):31172–8

The first structure of an aldehyde dehydrogenase reveals novel interactions between NAD and the Rossmann fold. Liu ZJ, et al. **Nat Struct Biol** 1997 Apr;4(4):317–26

Kinetic and structural evidence for the identification of 11–hydroxythromboxane B2 dehydrogenase as cytosolic aldehyde dehydrogenase. Fylling AC, et al. **Prostaglandins** 1995 Nov–Dec;50(5–6):287–99

Crystallization and preliminary X–ray analysis of aldehyde dehydrogenase from Vibrio harveyi. Croteau N, et al. **Protein Sci** 1996 Oct;5(10):2130–2

Structure of mitochondrial aldehyde dehydrogenase: the genetic component of ethanol aversion. Steinmetz CG, et al. **Structure** 1997 May 15;5(5):701–11

GENETICS

Mouse dioxin–inducible Ahd4 gene. Structure of the 5' flanking region and transcriptional regulation. Vasiliou V, et al. **Adv Exp Med Biol** 1997;414:37–46

Aldehyde dehydrogenase genes. Vasiliou V. **Adv Exp Med Biol** 1997;414:595–600

Studies on the dominant negative effect of the ALDH2*2 allele. Xiao Q, et al. **Adv Exp Med Biol** 1997;414:187–94

Allele frequency of ADH2 and ALDH2 among Brazilians of different ethnic groups. Santos BR, et al. **Alcohol** 1997 May–Jun;14(3):205–7

Point mutation of aldehyde dehydrogenase–2 gene in mutant strains of Long–Evans rats. Nakajima M, et al. **Alcohol Alcohol** 1994;29 Suppl 1:39–43

Alcohol and aldehyde dehydrogenase genotypes, alcoholism and alcohol related disease. Couzigou P, et al. **Alcohol Alcohol Suppl** 1994;2:21–7 (47 ref.)

Polymorphisms of ethanol metabolizing enzyme genes and alcoholism. Higuchi S. **Alcohol Alcohol Suppl** 1994;2:29–34

Mammalian aldehyde dehydrogenases: regulation of gene expression. Lindahl R. **Alcohol Alcohol Suppl** 1994;2:147–54 (32 ref.)

ADH and ALDH genotypes in relation to alcohol metabolic rate and sensitivity. Whitfield JB. **Alcohol Alcohol Suppl** 1994;2:59–65 (15 ref.)

Gene regulation of alcohol metabolizing enzymes. Crabb DW. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):113A–116A

Alcohol and aldehyde dehydrogenase genotypes and drinking behavior in Japanese. Higuchi S, et al. **Alcohol Clin Exp Res** 1996 May;20(3):493–7

Mitochondrial ALDH polymorphism affects ethanol–derived acetate disposition in Wistar rats. Matsumoto H, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):284A–288A

Genotypes of alcohol–metabolizing enzymes and the risk for alcoholic chronic pancreatitis in Japanese alcoholics. Matsumoto M, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):289A–292A

Hepatocellular carcinoma associated with alcoholic liver disease: a clinicopathological study and genetic polymorphism of aldehyde dehydrogenase 2. Ohhira M, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):378A–382A

Polymorphism of alcohol–metabolizing genes affects drinking behavior and alcoholic liver disease in Japanese men. Tanaka F, et al. **Alcohol Clin Exp Res** 1997 Jun; 21(4):596–601

Mutations associated with Sjögren–Larsson syndrome. Tsukamoto N, et al. **Ann Hum Genet** 1997 May;61 (Pt 3):235–42

Alcohol metabolism in Asian–American men with genetic polymorphisms of aldehyde dehydrogenase [see comments] Wall TL, et al. **Ann Intern Med** 1997 Sep 1;127(5):376–9 . Comment in: Ann Intern Med 1997 Sep 1;127(5):401–3.

Over–expression of glutathione S–transferases, DT–diaphorase and an apparently tumour–specific cytosolic class–3 aldehyde dehydrogenase by Warthin tumours and mucoepidermoid carcinomas of the human parotid gland. Sreerama L, et al. **Arch Oral Biol** 1996 Jun; 41(6):597–605

Cloning of a cDNA encoding a constitutively expressed rat liver cytosolic aldehyde dehydrogenase. Kathmann EC, et al. **Biochem Biophys Res Commun** 1997 Jul 18; 236(2):527–31

Extrahepatic expression of NAD(P)H:menadione oxidoreductase, UDP glucuronosyltransferase–1A6, microsomal aldehyde dehydrogenase, and hepatic nuclear factor–1 alpha mRNAs in ch/ch and 14CoS/14CoS mice. Vasiliou V, et al. **Biochem Biophys Res Commun** 1997 Apr 28;233(3):631–6

Involvement of conserved glycine residues, 229 and 234, of Vibrio harveyi aldehyde dehydrogenase in activity and nucleotide binding. Vedadi M, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):448–51

Alcohol dehydrogenase and aldehyde dehydrogenase genotypes and alcoholism among Taiwanese aborigines. Chen WJ, et al. **Biol Psychiatry** 1997 Mar 15;41(6):703–9

Alcohol–metabolising genes and alcoholism among Taiwanese Han men: independent effect of ADH2, ADH3 and ALDH2. Chen WJ, et al. **Br J Psychiatry** 1996 Jun; 168(6):762–7

Esophageal cancer and aldehyde dehydrogenase–2 genotypes in Japanese males. Yokoyama A, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Feb;5(2):99–102

CYP2E1, ALDH2 and ADH2 genotypes and blood ethanol elimination kinetics [letter] Iwahashi K, et al. **Clin Chim Acta** 1996 Nov 15;255(1):85–7

Mitochondrial aldehyde dehydrogenase in diabetes associated with mitochondrial tRNA(Leu(UUR)) mutation at position 3243. Suzuki Y, et al. **Diabetes Care** 1996 Dec;19(12):1423–5

Association of aldehyde dehydrogenase with inheritance of NIDDM. Suzuki Y, et al. **Diabetologia** 1996 Sep; 39(9):1115–8

Low Km aldehyde dehydrogenase (ALDH2) polymorphism, alcohol–drinking behavior, and chromosome alterations in peripheral lymphocytes. Morimoto K, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:563–7

Hormonal regulation of hepatic enzymes involved in foreign compound metabolism. Prough RA, et al. **FASEB J** 1996 Oct;10(12):1369–77 (39 ref.)

Sequencing and expression of the human ALDH8 encoding a new member of the aldehyde dehydrogenase family. Hsu LC, et al. **Gene** 1996 Oct 3;174(2):319–22

Human aldehyde dehydrogenase genes, ALDH7 and ALDH8: genomic organization and gene structure comparison. Hsu LC, et al. **Gene** 1997 Apr 11;189(1):89–94

The role of nuclear factor NF–Y/CP1 in the transcriptional regulation of the human aldehyde dehydrogenase 2–encoding gene. Stewart MJ, et al. **Gene** 1996 Sep 16; 173(2):155–61

The human aldehyde dehydrogenase 3 gene (ALDH3): identification of a new exon and diverse mRNA isoforms, and functional analysis of the promoter. Hsu LC, et al. **Gene Expr** 1996;6(2):87–99

Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in Chinese patients. Chao YC, et al. **Hepatology** 1997 Jan;25(1):112–7

Polymorphisms of ethanol–oxidizing enzymes in alcoholics with inactive ALDH2. Higuchi S, et al. **Hum Genet** 1996 Apr;97(4):431–4

Cancer screening of upper aerodigestive tract in Japanese alcoholics with reference to drinking and smoking habits and aldehyde dehydrogenase–2 genotype. Yokoyama A, et al. **Int J Cancer** 1996 Nov 4;68(3):313–6

Synthesis of the osmoprotectant glycine betaine in Bacillus subtilis: characterization of the gbsAB genes. Boch J, et al. **J Bacteriol** 1996 Sep;178(17):5121–9

cAMP–dependent negative regulation of rat aldehyde dehydrogenase class 3 gene expression. Xiao Gh, et al. **J Biol Chem** 1997 Feb 7;272(6):3238–45

Application of capillary gel electrophoresis to the diagnosis of the aldehyde dehydrogenase 2 genotype. Tomita M, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):185–90

The mutation in the mitochondrial aldehyde dehydrogenase (ALDH2) gene responsible for alcohol–induced flushing increases turnover of the enzyme tetramers in a dominant fashion. Xiao Q, et al. **J Clin Invest** 1996 Nov 1; 98(9):2027–32

Genotypes of aldehyde dehydrogenase and alcohol dehydrogenase polymorphisms in patients with Leber's hereditary optic neuropathy. Isashiki Y, et al. **Jpn J Hum Genet** 1997 Mar;42(1):187–91

The aldA gene of Escherichia coli is under the control of at least three transcriptional regulators. Limón A, et al. **Microbiology** 1997 Jun;143 (Pt 6):2085–95

Liver cytosolic aldehyde dehydrogenase (ALDH1) polymorphism and its inheritance in Wistar rats. Negoro M, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1997 Jun;32(3):182–8

Characterization of the rat Class 3 aldehyde dehydrogenase gene promoter. Xie YQ, et al. **Nucleic Acids Res** 1996 Nov 1;24(21):4185–91

Exon/intron structure of aldehyde dehydrogenase genes supports the "introns–late" theory. Rzhetsky A, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6820–5

[The ethanol elimination pharmacokinetics––the effects of genotypes of ALDH2 and CYP2E1 on the ethanol metabolism] Iwahashi K, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Dec; 31(6):517–24 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Immunohistochemical study of hepatocellular carcinoma–specific aldehyde dehydrogenase. Shibuya A, et al. **Alcohol Alcohol** 1994;29 Suppl 1:119–23

ISOLATION & PURIFICATION

Purification and partial characterization of bovine kidney aldehyde dehydrogenase able to oxidize retinal to retinoic acid. Bhat PV, et al. **Biochem Cell Biol** 1996;74(5):695–700

Identification of a 54–kDa mitochondrial acetaminophen–binding protein as aldehyde dehydrogenase. Landin JS, et al. **Toxicol Appl Pharmacol** 1996 Nov;141(1):299–307

METABOLISM

Selective assay of the cytosolic forms of the aldehyde dehydrogenase in rat, with possible significance for the investigations of cyclophosphamide cytotoxicity. Wierzchowski J, et al. **Acta Pol Pharm** 1996 May–Jun; 53(3):203–8

In hepatoma cell lines restored lipid peroxidation affects cell viability inversely to aldehyde metabolizing enzyme activity. Canuto RA, et al. **Adv Exp Med Biol** 1997; 414:113–22

Human corneal and lens aldehyde dehydrogenases. Purification and properties of human lens ALDH1 and differential expression as major soluble proteins in human lens (ALDH1) and cornea (ALDH3). King G, et al. **Adv Exp Med Biol** 1997;414:19–27

The action of cytosolic aldehyde dehydrogenase on resorufin acetate. Kitson TM, et al. **Adv Exp Med Biol** 1997; 414:201–8

Inhibition of and interaction with human recombinant mitochondrial aldehyde dehydrogenase by methyl diethylthiocarbamate sulfoxide. Lipsky JJ, et al. **Adv Exp Med Biol** 1997;414:209–16

Human aldehyde dehydrogenase E3. Further characterization. Pietruszko R, et al. **Adv Exp Med Biol** 1997;414:243–52

Organ distribution of aldehyde dehydrogenase activity in the newt, Notophthalmus viridescens. Settles HE, et al. **Adv Exp Med Biol** 1997;414:109–12

Mutation of the conserved amino acids of mitochondria aldehyde dehydrogenase. Role of the conserved residues in the mechanism of reaction. Sheikh S, et al. **Adv Exp Med Biol** 1997;414:195–200

Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents. Sreerama L, et al. **Adv Exp Med Biol** 1997;414:81–94

Structural and functional studies of a NADP(+)–specific aldehyde dehydrogenase from the luminescent marine bacterium Vibrio harveyi. Vedadi M, et al. **Adv Exp Med Biol** 1997;414:269–75

Studies on the dominant negative effect of the ALDH2*2 allele. Xiao Q, et al. **Adv Exp Med Biol** 1997;414:187–94

The regulation of alcohol consumption in rats: the role of alcohol–metabolizing enzymes–catalase and aldehyde dehydrogenase. Gill K, et al. **Alcohol** 1996 Jul–Aug; 13(4):347–53

Aldehyde dehydrogenase activity and acetate production by aerobic bacteria representing the normal flora of human large intestine. Nosova T, et al. **Alcohol Alcohol** 1996 Nov; 31(6):555–64

Aldehyde dehydrogenase and acetaldehyde metabolism. Weiner H, et al. **Alcohol Alcohol Suppl** 1994;2:141–5 (27 ref.)

Aldehyde dehydrogenases of the rat colon: comparison with other tissues of the alimentary tract and the liver. Koivisto T, et al. **Alcohol Clin Exp Res** 1996 May;20(3):551–5

Bacteriocolonic pathway for ethanol oxidation: characteristics and implications. Salaspuro M. **Ann Med** 1996 Jun;28(3):195–200 (88 ref.)

Studies of the esterase activity of cytosolic aldehyde dehydrogenase with resorufin acetate as substrate. Kitson TM, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):701–8

Involvement of alcohol dehydrogenase, short–chain dehydrogenase/reductase, aldehyde dehydrogenase, and cytochrome P450 in the control of retinoid signaling by

ALDEHYDE DEHYDROGENASE

activation of retinoic acid synthesis. Duester G. **Biochemistry** 1996 Sep 24;35(38):12221–7 (79 ref.)

Elevated levels of hemoglobin-associated acetaldehyde related to alcohol drinking in the atypical genotype of low Km aldehyde dehydrogenase. Takeshita T, et al. **Cancer Res** 1997 Apr 1;57(7):1241–3

Localization of cytosolic aldehyde dehydrogenase in the developing chick retina: in situ hybridization and immunohistochemical analyses. Godbout R, et al. **Dev Dyn** 1996 Mar;205(3):319–31

Two potential indole-3-acetaldehyde dehydrogenases in the phytopathogenic fungus Ustilago maydis. Basse CW, et al. **Eur J Biochem** 1996 Dec 15;242(3):648–56

Critical glutamic acid residues affecting the mechanism and nucleotide specificity of Vibrio harveyi aldehyde dehydrogenase. Vedadi M, et al. **Eur J Biochem** 1997 Jun 15;246(3):698–704

Binding of thyroxine analogs to human liver aldehyde dehydrogenases. Zhou J, et al. **Eur J Biochem** 1997 Apr 1;245(1):123–8

Corneal aldehyde dehydrogenase displays antioxidant properties [letter] Uma L, et al. **Exp Eye Res** 1996 Jul; 63(1):117–20

Human stomach alcohol and aldehyde dehydrogenases: comparison of expression pattern and activities in alimentary tract. Yin SJ, et al. **Gastroenterology** 1997 Mar; 112(3):766–75

Involvement of glutamate 399 and lysine 192 in the mechanism of human liver mitochondrial aldehyde dehydrogenase. Ni L, et al. **J Biol Chem** 1997 Jul 25; 272(30):18823–6

The potential roles of the conserved amino acids in human liver mitochondrial aldehyde dehydrogenase. Sheikh S, et al. **J Biol Chem** 1997 Jul 25;272(30):18817–22

Haloenol lactones as inactivators and substrates of aldehyde dehydrogenase. Mukerjee N, et al. **J Protein Chem** 1996 Oct;15(7):639–48

Low activity of aldehyde dehydrogenase (ALDH) in liver of Suncus murinus: possible explanation for high sensitivity to alcohol. Itoh S, et al. **J Toxicol Sci** 1997 May;22(2):111–5

Regional and cellular distribution of mitochondrial high-affinity aldehyde dehydrogenase in the rat brain (immunocytochemical investigation). Zimatkin SM, et al. **Neurosci Behav Physiol** 1996 May-Jun;26(3):225–30

[Comparative characteristics of membrane forms of aldehyde dehydrogenase] Kislova OV, et al. **Ukr Biokhim Zh** 1995 Nov-Dec;67(6):38–45 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

A study on ADH2 and ALDH2 genotyping by PCR-RFLP and SSCP analyses with description of allele and genotype frequencies in Japanese, Finn and Lapp populations. Suzuki K, et al. **Alcohol Alcohol** 1994;29 Suppl 1:21–7

ALDEHYDE-LYASES

CHEMISTRY

Bell pepper fruit fatty acid hydroperoxide lyase is a cytochrome P450 (CYP74B). Matsui K, et al. **FEBS Lett** 1996 Sep 23;394(1):21–4

Hydroxynitrile lyase from Hevea brasiliensis: molecular characterization and mechanism of enzyme catalysis. Hasslacher M, et al. **Proteins** 1997 Mar;27(3):438–49

Mechanism of cyanogenesis: the crystal structure of hydroxynitrile lyase from Hevea brasiliensis. Wagner UG, et al. **Structure** 1996 Jul 15;4(7):811–22

GENETICS

Sequence analysis of the phnD gene encoding 2-hydroxymuconic semialdehyde hydrolase in Pseudomonas sp. strain DJ77. Shin HJ, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):288–91

Molecular cloning, sequence analysis and functional characterization of the gene kdsA, encoding 3-deoxy-D-manno-2-octulosonate-8-phosphate synthase of Chlamydia psittaci 6BC. Brabetz W, et al. **Eur J Biochem** 1997 Feb 15;244(1):66–73

Identification, characterization, and developmental regulation of Chlamydia trachomatis 3-deoxy-D-manno-octulosonate (KDO)-8-phosphate synthetase and CMP-KDO synthetase. Wylie JL, et al. **Infect Immun** 1997 Apr;65(4):1527–30

Molecular cloning of acetone cyanohydrin lyase from flax (Linum usitatissimum). Definition of a novel class of hydroxynitrile lyases. Trummler K, et al. **J Biol Chem** 1997 Feb 21;272(8):4770–4

Is the ribulose monophosphate pathway widely distributed in bacteria? Reizer J, et al. **Microbiology** 1997 Aug;143 (Pt 8):2519–20

ISOLATION & PURIFICATION

(S)-hydroxynitrile lyase from Hevea brasiliensis. Hasslacher M, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:707–12

METABOLISM

Enantioselective synthesis of aliphatic (S)-cyanohydrins in organic solvents using hydroxynitrile lyase from Manihot esculenta. Wajant H, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:771–6

Properties of alpha-hydroxynitrile lyase from the petiole of cassava (Manihot esculenta Crantz). Chueskul S, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):401–5

Re-investigation of glucose metabolism in Fibrobacter succinogenes, using NMR spectroscopy and enzymatic assays. Evidence for pentose phosphates phosphoketolase and pyruvate formate lyase activities. Matheron C, et al. **Biochim Biophys Acta** 1997 Jan 10;1355(1):50–60

Hydroxynitrile lyases of higher plants. Wajant H, et al. **Biol Chem** 1996 Oct;377(10):611–7 (52 ref.)

Channelling of deoxyribose moiety of exogenous DNA into carbohydrate metabolism: role of deoxyriboaldolase. Sgarrella F, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Jun; 117(2):253–7

Identification of potential active-site residues in the hydroxynitrile lyase from Manihot esculenta by site-directed mutagenesis. Wajant H, et al. **J Biol Chem** 1996 Oct 18;271(42):25830–4

Hydroxynitrile lyase from Hevea brasiliensis: molecular characterization and mechanism of enzyme catalysis. Hasslacher M, et al. **Proteins** 1997 Mar;27(3):438–49

ALDEHYDE OXIDOREDUCTASES

ANALYSIS

Distribution of glyoxylate dehydrogenase activity in cortical and subcortical regions of the rat brain. A light microscopic histoenzymological study. Martínez-Rodríguez R, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Sep;42(6):873–80

BIOSYNTHESIS

Molecular identification of a major retinoic-acid-synthesizing enzyme, a retinaldehyde-specific dehydrogenase. Zhao D, et al. **Eur J Biochem** 1996 Aug 15;240(1):15–22

Role of NAD in regulating the adhE gene of Escherichia coli. Leonardo MR, et al. **J Bacteriol** 1996 Oct; 178(20):6013–8

Isolation of mutants of Acinetobacter calcoaceticus deficient in wax ester synthesis and complementation of one mutation with a gene encoding a fatty acyl coenzyme A reductase. Reiser S, et al. **J Bacteriol** 1997 May;179(9):2969–75

Cinnamoyl CoA reductase, the first committed enzyme of the lignin branch biosynthetic pathway: cloning, expression and phylogenetic relationships. Lacombe E, et al. **Plant J** 1997 Mar;11(3):429–41

Expression of a betaine aldehyde dehydrogenase gene in rice, a glycinebetaine nonaccumulator, and possible localization of its protein in peroxisomes. Nakamura T, et al. **Plant J** 1997 May;11(5):1115–20

CHEMISTRY

Differences in aldehyde oxidase activity in cytosolic preparations of human and monkey liver. Sugihara K, et al. **Biochem Mol Biol Int** 1997 May;41(6):1153–60

Isozyme multiplicity with anomalous dimer patterns in a class III alcohol dehydrogenase. Effects on the activity and quaternary structure of residue exchanges at "nonfunctional" sites in a native protein. Danielsson O, et al. **Biochemistry** 1996 Nov 19;35(46):14561–8

Arabidopsis formaldehyde dehydrogenase. Molecular properties of plant class III alcohol dehydrogenase provide further insights into the origins, structure and function of plant class p and liver class I alcohol dehydrogenases. Martínez MC, et al. **Eur J Biochem** 1996 Nov 1; 241(3):849–57

Mycothiol, 1-O-(2'-[N-acetyl-L-cysteinyl]amido-2'-deoxy-alpha-D-glucopyranosyl)-D- myo-inositol, is the factor of NAD/factor-dependent formaldehyde dehydrogenase. Misset-Smits M, et al. **FEBS Lett** 1997 Jun 9;409(2):221–2

In vivo nickel insertion into the carbon monoxide dehydrogenase of Rhodospirillum rubrum: molecular and physiological characterization of cooCTJ. Kerby RL, et al. **J Bacteriol** 1997 Apr;179(7):2259–66

TAO1, a representative of the molybdenum cofactor containing hydroxylases from tomato. Ori N, et al. **J Biol Chem** 1997 Jan 10;272(2):1019–25

Structure of human chi chi alcohol dehydrogenase: a glutathione-dependent formaldehyde dehydrogenase. Yang ZN, et al. **J Mol Biol** 1997 Jan 24;265(3):330–43

CLASSIFICATION

Arabidopsis formaldehyde dehydrogenase. Molecular properties of plant class III alcohol dehydrogenase provide further insights into the origins, structure and function of plant class p and liver class I alcohol dehydrogenases. Martínez MC, et al. **Eur J Biochem** 1996 Nov 1; 241(3):849–57

DEFICIENCY

Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA). Matern D, et al. **J Inherit Metab Dis** 1996;19(3):313–8

Succinic semialdehyde dehydrogenase deficiency: low excretion of metabolites in a neonate. Pitt JJ, et al. **J Inherit Metab Dis** 1997 Mar;20(1):39–42

The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Gibson KM, et al. **Pediatrics** 1997 Apr;99(4):567–74

GENETICS

Human succinic semialdehyde dehydrogenase. Molecular cloning and chromosomal localization. Trettel F, et al. **Adv Exp Med Biol** 1997;414:253–60

Mutations associated with Sjögren-Larsson syndrome. Tsukamoto N, et al. **Ann Hum Genet** 1997 May;61 (Pt 3):235–42

Cloning of genes coding for L-sorbose and L-sorbosone dehydrogenases from Gluconobacter oxydans and microbial production of 2-keto-L-gulonate, a precursor of L-ascorbic acid, in a recombinant G. oxydans strain. Saito Y, et al. **Appl Environ Microbiol** 1997 Feb; 63(2):454–60

5-Aminolevulinate production by Escherichia coli containing the Rhodobacter sphaeroides hemA gene. van der Werf MJ, et al. **Appl Environ Microbiol** 1996 Oct;62(10):3560–6

Biochemical and genetic characterization of the acetaldehyde dehydrogenase complex from Acetobacter europaeus. Thurner C, et al. **Arch Microbiol** 1997 Aug;168(2):81–91

Expression of glutamyl-tRNA reductase in Escherichia coli. Chen W, et al. **Biochim Biophys Acta** 1996 Nov 11; 1309(1-2):109–21

The hemA gene encoding glutamyl-tRNA reductase from the archaeon Methanobacterium thermoautotrophicum strain Marburg. Hungerer C, et al. **Bioorg Med Chem** 1996 Jul;4(7):1089–95

The molybdenum formylmethanofuran dehydrogenase operon and the tungsten formylmethanofuran dehydrogenase operon from Methanobacterium thermoautotrophicum. Structures and transcriptional regulation. Hochheimer A, et al. **Eur J Biochem** 1996 Nov 15;242(1):156–62

Molecular characterization of PadA, a phenylacetaldehyde dehydrogenase from Escherichia coli. Ferrandez A, et al. **FEBS Lett** 1997 Apr 7;406(1-2):23–7

Cloning of a rat cDNA encoding retinal dehydrogenase isozyme type I and its expression in E. coli. Penzes P, et al. **Gene** 1997 Jun 3;191(2):167–72

Cloning of the Arabidopsis and rice formaldehyde dehydrogenase genes: implications for the origin of plant ADH enzymes. Dolferus R, et al. **Genetics** 1997 Jul; 146(3):1131–41

Human fatty aldehyde dehydrogenase gene (ALDH10): organization and tissue-dependent expression. Chang C, et al. **Genomics** 1997 Feb 15;40(1):80–5

Genomic organization and expression of the human fatty aldehyde dehydrogenase gene (FALDH). Rogers GR, et al. **Genomics** 1997 Jan 15;39(2):127–35

A missense mutation in the FALDH gene identified in Sjögren-Larsson syndrome patients originating from the northern part of Sweden. Sillén A, et al. **Hum Genet** 1997 Aug;100(2):201–3

Identification, sequencing, and enzymatic activity of the erythrose-4-phosphate dehydrogenase gene of Vibrio cholerae. Carroll PA, et al. **J Bacteriol** 1997 Jan; 179(1):293–6

Analysis of the CO dehydrogenase/acetyl-coenzyme A synthase operon of Methanosarcina thermophila. Maupin-Furlow JA, et al. **J Bacteriol** 1996 Dec; 178(23):6849–56

Molecular characterization of genes of Pseudomonas sp. strain HR199 involved in bioconversion of vanillin to protocatechuate. Priefert H, et al. **J Bacteriol** 1997 Apr; 179(8):2595–607

Isolation of mutants of Acinetobacter calcoaceticus deficient in wax ester synthesis and complementation of one mutation with a gene encoding a fatty acyl coenzyme A reductase. Reiser S, et al. **J Bacteriol** 1997 May;179(9):2969–75

Isolation of animal cell mutants defective in long-chain fatty aldehyde dehydrogenase. Sensitivity to fatty aldehydes and Schiff's base modification of phospholipids: implications for Sj-ogren-Larsson syndrome. James PF, et al. **J Biol Chem** 1997 Sep 19;272(38):23532–9

Cloning and molecular characterization of plant aldehyde oxidase. Sekimoto H, et al. **J Biol Chem** 1997 Jun 13; 272(24):15280–5

Restricted expression and retinoic acid-induced downregulation of the retinaldehyde dehydrogenase type 2 (RALDH-2) gene during mouse development. Niederreither K, et al. **Mech Dev** 1997 Feb;62(1):67–78

2-phenylethylamine catabolism by Escherichia coli K-12: gene organization and expression. Hanlon SP, et al. **Microbiology** 1997 Feb;143 (Pt 2):513–8

Cloning, analysis and one-step disruption of the ARG5,6 gene of Candida albicans. Negredo A, et al. **Microbiology** 1997 Feb;143 (Pt 2):297–302

Molecular characterization of the bet genes encoding glycine betaine synthesis in Sinorhizobium meliloti 102F34. Pocard JA, et al. **Microbiology** 1997 Apr;143 (Pt 4):1369–79

A selenium-dependent and a selenium-independent formylmethanofuran dehydrogenase and their transcriptional regulation in the hyperthermophilic Methanopyrus kandleri. Vorholt JA, et al. **Mol Microbiol** 1997 Mar;23(5):1033–42

Cinnamoyl CoA reductase, the first committed enzyme of the lignin branch biosynthetic pathway: cloning, expression and phylogenetic relationships. Lacombe E, et al. **Plant J** 1997 Mar;11(3):429–41

Maize glutathione-dependent formaldehyde dehydrogenase cDNA: a novel plant gene of detoxification. Fliegmann J, et al. **Plant Mol Biol** 1997 Aug;34(6):843-54

Differential expression of two hemA mRNAs encoding glutamyl-tRNA reductase proteins in greening cucumber seedlings. Tanaka R, et al. **Plant Physiol** 1996 Apr; 110(4):1223-30

Betaine aldehyde dehydrogenase in sorghum. Wood AJ, et al. **Plant Physiol** 1996 Apr;110(4):1301-8

Cloning of a polycistronic cDNA from tomato encoding gamma-glutamyl kinase and gamma-glutamyl phosphate reductase. García-Ríos M, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8249-54

IMMUNOLOGY

Immunohistochemical localization of aldehyde and xanthine oxidase in rat tissues using polyclonal antibodies. Moriwaki Y, et al. **Histochem Cell Biol** 1996 Jan;105(1):71-9

ISOLATION & PURIFICATION

Resolution and purification of an aldehyde-generating and an alcohol-generating fatty acyl-CoA reductase from pea leaves (Pisum sativum L.). Vioque J, et al. **Arch Biochem Biophys** 1997 Apr 1;340(1):64-72

Purification and characterization of hepatic aldehyde oxidase in male and female mice. Yoshihara S, et al. **Arch Biochem Biophys** 1997 Feb 1;338(1):29-34

Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization. Kelson TL, et al. **Biochim Biophys Acta** 1997 Apr 17; 1335(1-2):99-110

Purification, characterization, and properties of an aryl aldehyde oxidoreductase from Nocardia sp. strain NRRL 5646. Li T, et al. **J Bacteriol** 1997 Jun;179(11):3482-7

METABOLISM

Formaldehyde dehydrogenase from yeast and plant. Implications for the general functional and structural significance of class III alcohol dehydrogenase. Fernández MR, et al. **Adv Exp Med Biol** 1997;414:373-81

Effects of glycerol on the kinetic properties of betaine aldehyde dehydrogenase. Muñoz-Clares RA, et al. **Adv Exp Med Biol** 1997;414:261-8

P. putida formaldehyde dehydrogenase. An alcohol dehydrogenase masquerading as an aldehyde dehydrogenase. Oppenheimer NJ, et al. **Adv Exp Med Biol** 1997;414:417-23

Sex differences in endogenous retinoid release in the post-embryonic spinal cord of the western mosquitofish, Gambusia affinis affinis. Rosa-Molinar E, et al. **Adv Exp Med Biol** 1997;414:95-108

Expression of formaldehyde dehydrogenase and S-formylglutathione hydrolase activities in different rat tissues. Uotila L, et al. **Adv Exp Med Biol** 1997;414:365-71

Betaine-aldehyde dehydrogenase from amaranth leaves efficiently catalyzes the NAD-dependent oxidation of dimethylsulfoniopropionaldehyde to dimethylsulfoniopropionate. Vojtechová M, et al. **Arch Biochem Biophys** 1997 Jan 1;337(1):81-8

Ontogeny of GABA pathway in human fetal brains. Das SK, et al. **Biochem Biophys Res Commun** 1996 Nov 12; 228(2):544-8

S-(-)-nicotine-1'-N-oxide reductase activity of rat liver aldehyde oxidase. Sugihara K, et al. **Biochem Mol Biol Int** 1996 Oct;40(3):535-41

Involvement of growth hormone as a regulating factor in sex differences of mouse hepatic aldehyde oxidase. Yoshihara S, et al. **Biochem Pharmacol** 1997 Apr 25; 53(8):1099-105

Unleashing hydrogenase activity in carbon monoxide dehydrogenase/acetyl-CoA synthase and pyruvate:ferredoxin oxidoreductase. Menon S, et al. **Biochemistry** 1996 Dec 10;35(49):15814-21

Mechanism of carbon monoxide oxidation by the carbon monoxide dehydrogenase/acetyl-CoA synthase from Clostridium thermoaceticum: kinetic characterization of the intermediates. Seravalli J, et al. **Biochemistry** 1997 Sep 16; 36(37):11241-51

Cysteine-286 as the site of acylation of the Lux-specific fatty acyl-CoA reductase. Lee CY, et al. **Biochim Biophys Acta** 1997 Apr 4;1338(2):215-22

Substrate inhibition by betaine aldehyde of betaine aldehyde dehydrogenase from leaves of Amaranthus hypochondriacus L. Vojtechová M, et al. **Biochim Biophys Acta** 1997 Aug 15;1341(1):49-57

In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Rashidi MR, et al. **Drug Metab Dispos** 1997 Jul; 25(7):805-13

Two potential indole-3-acetaldehyde dehydrogenases in the phytopathogenic fungus Ustilago maydis. Basse CW, et al. **Eur J Biochem** 1996 Dec 15;242(3):648-56

Uptake of acetaldehyde vapor and aldehyde dehydrogenase levels in the upper respiratory tracts of the mouse, rat, hamster, and guinea pig. Morris JB. **Fundam Appl Toxicol** 1997 Jan;35(1):91-100

Control of the availability of exogenous 5-aminolevulinic acid in Escherichia coli. Nakayashiki T, et al. **Genes Genet Syst** 1996 Aug;71(4):237-41

Intracellular signal transduction of PBAN action in the silkworm, Bombyx mori: involvement of acyl CoA reductase. Ozawa R, et al. **Insect Biochem Mol Biol** 1996 Mar;26(3):259-65

Differences in environmental temperature, ethanol and sucrose associated with enzyme activity and weight changes in Drosophila melanogaster. Pecsenye K, et al. **Insect Biochem Mol Biol** 1996 Feb;26(2):135-45

Identification, sequencing, and enzymatic activity of the erythrose-4-phosphate dehydrogenase gene of Vibrio cholerae. Carroll PA, et al. **J Bacteriol** 1997 Jan; 179(1):293-6

Characterization of Escherichia coli strains with gapA and gapB genes deleted. Seta FD, et al. **J Bacteriol** 1997 Aug; 179(16):5218-21

Role of the hemA gene product and delta-aminolevulinic acid in regulation of Escherichia coli heme synthesis. Verderber E, et al. **J Bacteriol** 1997 Jul;179(14):4583-90

Regulation of heme biosynthesis in Salmonella typhimurium: activity of glutamyl-tRNA reductase (HemA) is greatly elevated during heme limitation by a mechanism which increases abundance of the protein. Wang LY, et al. **J Bacteriol** 1997 May;179(9):2907-14

Comparative enzymatic properties of GapB-encoded erythrose-4-phosphate dehydrogenase of Escherichia coli and phosphorylating glyceraldehyde-3-phosphate dehydrogenase. Boschi-Muller S, et al. **J Biol Chem** 1997 Jun 13;272(24):15106-12

In vitro import of proteins into mitochondria of Trypanosoma brucei and Leishmania tarentolae. Hauser R, et al. **J Cell Sci** 1996 Feb;109 (Pt 2):517-23

Structure of human chi chi alcohol dehydrogenase: a glutathione-dependent formaldehyde dehydrogenase. Yang ZN, et al. **J Mol Biol** 1997 Jan 24;265(3):330-43

Selective localization of mouse aldehyde oxidase mRNA in the choroid plexus and motor neurons. Bendotti C, et al. **Neuroreport** 1997 Jul 7;8(9-10):2343-9

A structure-based catalytic mechanism for the xanthine oxidase family of molybdenum enzymes. Huber R, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):8846-51

Expression of catalytically active barley glutamyl tRNAGlu reductase in Escherichia coli as a fusion protein with glutathione S-transferase. Vothknecht UC, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9287-91

ALDEHYDE REDUCTASE

ANTAGONISTS & INHIBITORS

Study of non-covalent enzyme-inhibitor complexes of aldose reductase by electrospray mass spectrometry. Potier N, et al. **Adv Exp Med Biol** 1997;414:453-4

Structural studies of aldo-keto reductase inhibition. Wilson DK, et al. **Adv Exp Med Biol** 1997;414:435-42

An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Frank RN, et al. **Arch Ophthalmol** 1997 Aug;115(8):1036-47

Hypoglycemic and aldose reductase activity of Polichia campestris. Miura T, et al. **Biol Pharm Bull** 1996 Jun; 19(6):852-4

Highly selective aldose reductase inhibitors. II. Optimization of the aryl part of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids. Kotani T, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb; 45(2):297-304

Synthesis and aldose reductase-inhibitory activity of imidazopyrroloquinoline esters. Urakami T, et al. **Chem Pharm Bull (Tokyo)** 1996 Aug;44(8):1493-7

Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: a preliminary study. Fujishima H, et al. **Cornea** 1996 Jul;15(4):368-75

Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats. Hosotani H, et al. **Curr Eye Res** 1996 Oct;15(10):1005-7

Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor. Obrosova I, et al. **Curr Eye Res** 1997 Jan;16(1):34-43

Effects of aldose reductase inhibitor CT-112 on the corneal epithelial barrier of galactose-fed rats. Yokoi N, et al. **Curr Eye Res** 1997 Jun;16(6):595-9

A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration [see comments] Nicolucci A, et al. **Diabet Med** 1996 Dec;13(12):1017-26. Comment in: Diabet Med 1996 Dec;13(12):1007-8.

Treatment for diabetic neuropathy [editorial; comment] Watkins PJ. **Diabet Med** 1996 Dec;13(12):1007-8. Comment on: Diabet Med 1996 Dec;13(12):1017-26.

Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats. Mizisin AP, et al. **Diabetes** 1997 Apr;46(4):647-52

Aldose reductase inhibitors: the end of an era or the need for different trial designs? Pfeifer MA, et al. **Diabetes** 1997 Sep;46 Suppl 2:S82-9 (59 ref.)

Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Ramasamy R, et al. **Diabetes** 1997 Feb;46(2):292-300

The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data. Nicolucci A, et al. **Diabetes Care** 1996 Oct; 19(10):1091-6

Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats. Isogai S, et al. **Diabetes Res Clin Pract** 1995 Nov;30(2):111-6

Effect of an aldose reductase inhibitor on type IV collagen production by human endothelial cells cultured in high glucose. Bakillah A, et al. **Diabetologia** 1996 Jun; 39(6):641-8

Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Cameron NE, et al. **Diabetologia** 1997 Mar;40(3):271-81

Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat. Forster HG, et al. **Diabetologia** 1996 Aug;39(8):907-14

Study of non-covalent enzyme-inhibitor complexes of aldose reductase by electrospray mass spectrometry. Potier N, et al. **Eur J Biochem** 1997 Jan 15;243(1-2):274-82

Effect of an aldose reductase inhibitor on abnormalities of electroretinogram and vascular factors in diabetic rats. Hotta N, et al. **Eur J Pharmacol** 1997 May 12;326(1):45-51

The aldose reductase inhibitor sorbinil does not prevent the impairment in nitric oxide-mediated neurotransmission in anococcygeus muscle from diabetic rats. Way KJ, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):101-8

Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle. Wegener JW, et al. **Eur J Pharmacol** 1997 Mar 26;323(1):89-91

Cardiac effects of isoliquiritigenin. Wegener JW, et al. **Eur J Pharmacol** 1997 May 12;326(1):37-44

The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats. Sasaki H, et al. **Exp Neurol** 1997 Aug;146(2):466-70

Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats. Hotta N, et al. **Exp Physiol** 1995 Nov;80(6):981-9

Activation of aldose reductase in rat lens and metal-ion chelation by aldose reductase inhibitors and lipoic acid. Ou P, et al. **Free Radic Res** 1996 Oct;25(4):337-46

Influence of aldose reductase inhibition on the microvascular reactivity in experimental diabetes. Fortes ZB, et al. **Gen Pharmacol** 1996 Jul;27(5):917-21

Effectiveness of aldose reductase inhibitors for diabetic gastroenteropathy with constipation. Nakamura T, et al. **Intern Med** 1997 Jul;36(7):479-83

Enteric neuropeptides in streptozotocin-diabetic rats; effects of insulin and aldose reductase inhibition. Belai A, et al. **J Auton Nerv Syst** 1996 May 6;58(3):163-9

Nodal Na(+)-channel displacement is associated with nerve-conduction slowing in the chronically diabetic BB/W rat: prevention by aldose reductase inhibition. Cherian PV, et al. **J Diabetes Complications** 1996 Jul-Aug; 10(4):192-200

Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. Hotta N, et al. **J Diabetes Complications** 1996 May-Jun; 10(3):168-72

Nerve fiber regeneration following axotomy in the diabetic biobreeding Worcester rat: the effect of ARI treatment. Kamijo M, et al. **J Diabetes Complications** 1996 Jul-Aug; 10(4):183-91

Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. Costantino L, et al. **J Med Chem** 1996 Oct 25; 39(22):4396-405

Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids. Kotani T, et al. **J Med Chem** 1997 Feb 28;40(5):684-94

Effects of seven days of galactose feeding and aldose reductase inhibition on mast cells and vessel morphometry in rat sciatic nerve. Brett FM, et al. **J Neurol Sci** 1996 Sep 15;141(1-2):6-12

Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. Ashizawa N, et al. **Jpn J Pharmacol** 1997 Feb;73(2):133-44

Effects of ONO-2235, an aldose reductase inhibitor, on muscarinic receptors and contractile response of the urinary bladder in rats with streptozotocin-induced diabetes. Kanda M, et al. **Jpn J Pharmacol** 1997 Mar;73(3):221-8

Worldwide pharmacovigilance systems and tolrestat withdrawal [letter] Foppiano M, et al. **Lancet** 1997 Feb 8;349(9049):399-400

Diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats: effect of an aldose reductase inhibitor, TAT. Nakamura J, et al. **Life Sci** 1997;60(21):1847-57

Restoration of nitric oxide production by aldose reductase inhibitor in human endothelial cells cultured in high-glucose medium. Okuda Y, et al. **Life Sci** 1997; 60(3):PL53-6

Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patients. Ihm SH, et al. **Metabolism** 1997 Jun;46(6):634-8

Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation. Keogh RJ, et al. **Metabolism** 1997 Jan;46(1):41-7

ALDEHYDE REDUCTASE

Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus. Beyer-Mears A, et al. **Pharmacology** 1996 May;52(5):292-302

Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx. Beyer-Mears A, et al. **Pharmacology** 1997 Feb;54(2):76-83

The Vanderbilt Classification System in the evaluation of diabetic retinopathy patients treated with Alredase. Feman SS, et al. **Trans Am Ophthalmol Soc** 1996;94:433-47; discussion 447-50

[Treatment of chronic complications of diabetes mellitus with aldose reductase inhibitors] Cattalini M, et al. **Rev Assoc Med Bras** 1996 Apr-Jun;42(2):109-14 (72 ref.) **(Por)**

[Treatment of chronic microvascular complications of diabetes mellitus with aldose reductase inhibitors (editorial)] Wajchenberg BL. **Rev Assoc Med Bras** 1996 Apr-Jun;42(2):63-5 **(Por)**

[Clinical trial of the effects of isodibut on several indicators of microcirculation in combined therapy of patients with diabetes mellitus] Kakhnovskiĭ IM, et al. **Klin Med (Mosk)** 1996;74(3):56-8 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Gene regulation of aldose reductase under osmotic stress. Iwata T, et al. **Adv Exp Med Biol** 1997;414:507-14

Characterization of an element resembling an androgen response element (ARE) in the human aldose reductase promoter. Ruepp BU, et al. **Adv Exp Med Biol** 1997; 414:515-9

Increased white cell aldose reductase mRNA levels in diabetic patients. Kicic E, et al. **Diabetes Res Clin Pract** 1996 Jun;33(1):31-6

Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells. Spycher SE, et al. **FASEB J** 1997 Feb;11(2):181-8

Regulation of aldose reductase expression in rat astrocytes in culture. Jacquin-Becker C, et al. **Glia** 1997 Jun; 20(2):135-44

Isolation of the mouse aldose reductase promoter and identification of a tonicity-responsive element. Daoudal S, et al. **J Biol Chem** 1997 Jan 31;272(5):2615-9

BLOOD

The level of erythrocyte aldose reductase: a risk factor for diabetic neuropathy? Ito T, et al. **Diabetes Res Clin Pract** 1997 Jun;36(3):161-7

CHEMISTRY

Aldehyde reductase. Catalytic mechanism and substrate recognition. Barski OA, et al. **Adv Exp Med Biol** 1997; 414:443-51

A potential role for aldose reductase in steroid metabolism. Petrash JM, et al. **Adv Exp Med Biol** 1997;414:465-73

Study of non-covalent enzyme-inhibitor complexes of aldose reductase by electrospray mass spectrometry. Potier N, et al. **Adv Exp Med Biol** 1997;414:453-4

Structural studies of aldo-keto reductase inhibition. Wilson DK, et al. **Adv Exp Med Biol** 1997;414:435-42

The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Barski OA, et al. **Biochemistry** 1996 Nov 12;35(45):14276-80

A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Urzhumtsev A, et al. **Structure** 1997 May 15;5(5):601-12

DRUG EFFECTS

Regulation of glutathione S-transferases and aldehyde reductase by chemoprotectors: studies of mechanisms responsible for inducible resistance to aflatoxin B1. Hayes JD, et al. **IARC Sci Publ** 1996;(139):175-87 (75 ref.)

GENETICS

Characterization of an element resembling an androgen response element (ARE) in the human aldose reductase promoter. Ruepp BU, et al. **Adv Exp Med Biol** 1997; 414:515-9

Influence of cosubstrate concentration on xylose conversion by recombinant, XYL1-expressing Saccharomyces cerevisiae: a comparison of different sugars and ethanol as cosubstrates. Meinander NQ, et al. **Appl Environ Microbiol** 1997 May;63(5):1959-64

Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Heesom AE, et al. **Diabetes** 1997 Feb;46(2):287-91

Site-directed mutagenesis of the cysteine residues in the Pichia stipitis xylose reductase. Zhang Y, et al. **FEMS Microbiol Lett** 1997 Feb 15;147(2):227-32

Isolation of the mouse aldose reductase promoter and identification of a tonicity-responsive element. Daoudal S, et al. **J Biol Chem** 1997 Jan 31;272(5):2615-9

Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene. Ko BCB, et al. **J Biol Chem** 1997 Jun 27;272(26):16431-7

Distinct regulation of osmoprotective genes in yeast and mammals. Aldose reductase osmotic response element is induced independent of p38 and stress-activated protein kinase/Jun N-terminal kinase in rabbit kidney cells. Kültz D, et al. **J Biol Chem** 1997 May 16;272(20):13165-70

Aldose reductase gene expression is increased in diabetic nephropathy. Shah VO, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2294-8

Potassium depletion modulates aldose reductase mRNA in rat renal inner medulla. Nakanishi T, et al. **Kidney Int** 1996 Sep;50(3):828-34

Aldose reductase and IGF-I gene expression in aortic and arteriolar smooth muscle during hypo- and hyperinsulinemic diabetes. Connors B, et al. **Microvasc Res** 1997 Jan;53(1):53-62

Sequence and analysis of an aldose (xylose) reductase gene from the xylose-fermenting yeast Pachysolen tannophilus. Bolen PL, et al. **Yeast** 1996 Oct;12(13):1367-75

ISOLATION & PURIFICATION

NAD(P)H-dependent aldose reductase from the xylose-assimilating yeast Candida tenuis. Isolation, characterization and biochemical properties of the enzyme. Neuhauser W, et al. **Biochem J** 1997 Sep 15;326 (Pt 3):683-92

NADPH-dependent reductases in dog thyroid: comparison of a third enzyme "glyceraldehyde reductase" to dog thyroid aldehyde reductase. Schaffhauser MA, et al. **Int J Biochem Cell Biol** 1996 Mar;28(3):275-84

METABOLISM

Aldehyde reductase. Catalytic mechanism and substrate recognition. Barski OA, et al. **Adv Exp Med Biol** 1997; 414:443-51

In hepatoma cell lines restored lipid peroxidation affects cell viability inversely to aldehyde metabolizing enzyme activity. Canuto RA, et al. **Adv Exp Med Biol** 1997; 414:113-22

D-fructose-mediated stimulation of bovine lens aldose reductase activation by UV-irradiation. Mizoguchi T, et al. **Adv Exp Med Biol** 1997;414:529-35

A potential role for aldose reductase in steroid metabolism. Petrash JM, et al. **Adv Exp Med Biol** 1997;414:465-73

Aldose reductase as dihydrodiol dehydrogenase. Naphthoquinone formation by rat lens aldose reductase. Sato S, et al. **Adv Exp Med Biol** 1997;414:499-505

Physiological substrates of human aldose and aldehyde reductases. Vander Jagt DL, et al. **Adv Exp Med Biol** 1997; 414:491-7

A glycerol-3-phosphate dehydrogenase-deficient mutant of Saccharomyces cerevisiae expressing the heterologous XYL1 gene. Lidén G, et al. **Appl Environ Microbiol** 1996 Oct;62(10):3894-6

Influence of cosubstrate concentration on xylose conversion by recombinant, XYL1-expressing Saccharomyces cerevisiae: a comparison of different sugars and ethanol as cosubstrates. Meinander NQ, et al. **Appl Environ Microbiol** 1997 May;63(5):1959-64

NAD(P)H-dependent aldose reductase from the xylose-assimilating yeast Candida tenuis. Isolation, characterization and biochemical properties of the enzyme. Neuhauser W, et al. **Biochem J** 1997 Sep 15;326 (Pt 3):683-92

Aldose reductase: monosaccharide autoxidation and NADPH binding. Crabbe MJ. **Biochem Soc Trans** 1996 Aug; 24(3):888-91 (40 ref.)

Products of aldose reductase catalysed reduction of aldosuloses ("osones"). Walton DJ, et al. **Biochem Soc Trans** 1996 Aug;24(3):458S

Conformation and microenvironment of the active site of xylose reductase inferred by fluorescent chemoaffinity labeling. Rawat UB, et al. **Eur J Biochem** 1997 Jun 1; 246(2):344-9

Further characterization of a rat hepatoma-derived aldose-reductase-like protein--organ distribution and modulation in vitro. Zeindl-Eberhart E, et al. **Eur J Biochem** 1997 Aug 1;247(3):792-800

Induction of aldose reductase and xylitol dehydrogenase activities in Candida tenuis CBS 4435. Kern M, et al. **FEMS Microbiol Lett** 1997 Apr 1;149(1):31-7

Activation of aldose reductase in rat lens and metal-ion chelation by aldose reductase inhibitors and lipoic acid. Ou P, et al. **Free Radic Res** 1996 Oct;25(4):337-46

Specifically targeted modification of human aldose reductase by physiological disulfides. Cappiello M, et al. **J Biol Chem** 1996 Dec 27;271(52):33539-44

Sensitive, selective gas chromatographic-mass spectrometric analysis with trifluoroacetyl derivatives and a stable isotope for studying tissue sorbitol-producing activity. Kishimoto M, et al. **J Chromatogr B Biomed Appl** 1997 Jan 10; 688(1):1-10

Studies on L-threose as substrate for aldose reductase: a possible role in preventing protein glycation. Devamanoharan PS, et al. **Mol Cell Biochem** 1996 Jun 21; 159(2):123-7

Reduction of methylglyoxal in Escherichia coli K12 by an aldehyde reductase and alcohol dehydrogenase. Misra K, et al. **Mol Cell Biochem** 1996 Mar 23;156(2):117-24

Aldose reductase and sorbitol dehydrogenase activities in diabetic brain: in vivo kinetic studies using 19F 3-FDG NMR in rats. Kwee IL, et al. **Neuroreport** 1996 Feb 29; 7(3):726-8

ALDEHYDES

Crotonaldehyde: a carcinogenic and mutagenic air, water and food pollutant. Eder E, et al. **Cent Eur J Public Health** 1996;4 Suppl:21-2

Crotonaldehyde. **IARC Monogr Eval Carcinog Risks Hum** 1995;63:373-91 (102 ref.)

[Substantiation of MAC of crotonaldehyde in environmental air] Tepikina LA, et al. **Gig Sanit** 1997 May-Jun;(3):3-5 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Curcumin protects against 4-hydroxy-2-trans-nonenal-induced cataract formation in rat lenses. Awasthi S, et al. **Am J Clin Nutr** 1996 Nov; 64(5):761-6

Role of lipid aldehydes in cataractogenesis: 4-hydroxynonenal-induced cataract. Ansari NH, et al. **Biochem Mol Med** 1996 Jun;58(1):25-30

Evaluation of human skin irritation by carboxylic acids, alcohols, esters and aldehydes, with nitrocellulose-replica method and closed patch testing. Sato A, et al. **Contact Dermatitis** 1996 Jan;34(1):12-6

ANALYSIS

Simultaneous determination of multiple aldehydes in biological tissues and fluids using gas chromatography/stable isotope dilution mass spectrometry. Bruenner BA, et al. **Anal Biochem** 1996 Oct 15;241(2):212-9

Sampling intercomparisons for aldehydes in simulated workplace air. Goelen E, et al. **Analyst** 1997 May; 122(5):411-9

Resolution of the phytanic acid alpha-oxidation pathway: identification of pristanal as product of the decarboxylation of 2-hydroxyphytanoyl-CoA. Verhoeven NM, et al. **Biochem Biophys Res Commun** 1997 Aug 8;237(1):33-6

High-performance liquid chromatography of long chain aliphatic aldehydes with peroxyoxalate chemiluminescence detection utilizing a fluorogenic reagent, 4-(N,N-dimethylaminosulphonyl)-7-hydrazino-2,1,3-benzoxadiazole. Nakashima K, et al. **Biomed Chromatogr** 1996 Mar-Apr;10(2):99-101

Gaseous aliphatic aldehydes in smoke from burning raw materials of Chinese joss sticks. Lee RS, et al. **Bull Environ Contam Toxicol** 1996 Sep;57(3):361-6

Previously unknown aldehydic lipid peroxidation compounds of arachidonic acid. Miakar A, et al. **Chem Phys Lipids** 1996 Jan 25;79(1):47-53

Instantaneous analysis of aldehydes in biological fluids using a spray interface coupled to a mass spectrometer. St-Germain F, et al. **Free Radic Biol Med** 1997;23(1):166-72

Detecting and identifying volatile aldehydes as dinitrophenylhydrazones using gas chromatography mass spectrometry. Thomas MJ, et al. **Free Radic Biol Med** 1995 Mar;18(3):553-7

2-Hydroxy-succinaldehyde, a lipid peroxidation product proving that polyunsaturated fatty acids are able to react with three molecules of oxygen. Mlakar A, et al. **Free Radic Res** 1997 Jan;26(1):57-62

Monoclonal antibodies for detection of 4-hydroxynonenal modified proteins. Waeg G, et al. **Free Radic Res** 1996 Aug; 25(2):149-59

Detection of aldehydes in bronchoalveolar lavage of rats exposed to ozone. Pryor WA, et al. **Fundam Appl Toxicol** 1996 Nov;34(1):148-56

Impinger sampling coupled to high-performance liquid chromatography by a modified autoinjector interface. Schlitt H. **J Chromatogr A** 1997 Feb 21;762(1-2):187-92

Gas chromatographic-electron impact mass spectrometric screening procedure for unknown hydroxyaldehydic lipid peroxidation products after pentafluorobenzyloxime derivatization. Loidl-Stahlhofen A, et al. **J Chromatogr B Biomed Appl** 1995 Nov 3;673(1):1-14

Determination of the lipid peroxidation product (E)-4-hydroxy-2-nonenal in clinical samples by gas chromatography--negative-ion chemical ionisation mass spectrometry of the O-pentafluorobenzyl oxime. Selley ML. **J Chromatogr B Biomed Appl** 1997 Apr 11; 691(2):263-8

Estimation of peroxidative damage. A critical review. Esterbauer H. **Pathol Biol (Paris)** 1996 Jan;44(1):25-8 (20 ref.)

Immunohistochemical localization of lipoperoxidation products in normal human placenta. Casasco A, et al. **Placenta** 1997 May;18(4):249-53

[Regularities of transformation of organic compounds in the environment] Malysheva AG. **Gig Sanit** 1997 May-Jun; (3):5-10 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Vitamin E decreases hepatic levels of aldehyde-derived peroxidation products in rats with iron overload. Parkkila S, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G376-84

BLOOD

Plasma lipoperoxidative markers in ischaemic stroke suggest brain embolism. Re G, et al. **Eur J Emerg Med** 1997 Mar; 4(1):5-9

Increased levels of 4-hydroxynonenal modified proteins in plasma of children with autoimmune diseases. Grune T,

et al. **Free Radic Biol Med** 1997;23(3):357–60

CHEMICAL SYNTHESIS

Mechanisms of formation of adducts from reactions of glycidaldehyde with 2'-deoxyguanosine and/or guanosine. Golding BT, et al. **Chem Res Toxicol** 1996 Jan–Feb; 9(1):147–57

Preparation of general proteinase substrates using 3,5–dinitrosalicylaldehyde. Gallegos NG, et al. **J Biochem Biophys Methods** 1996 Oct 15;33(1):31–41

Anticancer and antiviral effects and inactivation of S–adenosyl–L–homocysteine hydrolase with 5'–carboxaldehydes and oximes synthesized from adenosine and sugar–modified analogues. Wnuk SF, et al. **J Med Chem** 1997 May 23;40(11):1608–18

A synthesis of 4–hydroxy–2–trans–nonenal and 4–(3H) 4–hydroxy–2–trans–nonenal. Chandra A, et al. **Lipids** 1997 Jul;32(7):779–82

Facile and general method for preparation of (E)–4–hydroxy–2–alkenals. Sugamoto K, et al. **Lipids** 1997 Aug;32(8):903–5

CHEMISTRY

Retention of propanal and diacetyl in experimental resins. Peutzfeldt A. **Acta Odontol Scand** 1997 Apr;55(2):94–100

4–Hydroxynonenal interaction with rhodopsin. van Kuijk FJ. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):275–9

3–Amino–2–hydroxy–propionaldehyde and 3–amino–1–hydroxy–propan–2–one derivatives: new classes of aminopeptidase inhibitors. Tarnus C, et al. **Bioorg Med Chem** 1996 Aug;4(8):1287–97

ACAT inhibitors derived from hetero–Diels–Alder cycloadducts of thioaldehydes. Wilde RG, et al. **Bioorg Med Chem** 1996 Sep;4(9):1493–513

Epoxidation of trans–4–hydroxy–2–nonenal by fatty acid hydroperoxides and hydrogen peroxide. Chen HJ, et al. **Chem Res Toxicol** 1996 Jan–Feb;9(1):306–12

Synthesis and in vitro reactivity of 3–carbamoyl–2–phenylpropionaldehyde and 2–phenylpropenal: putative reactive metabolites of felbamate. Thompson CD, et al. **Chem Res Toxicol** 1996 Dec;9(8):1225–9

Chemistry of muconaldehydes of possible relevance to the toxicology of benzene. Bleasdale C, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1201–9

Effect of propanal and diacetyl on quantity of remaining double bonds of chemically cured BisGMA/TEGDMA resins. Peutzfeldt A, et al. **Eur J Oral Sci** 1996 Jun; 104(3):309–12

Determination of site–specific modifications of glucose–6–phosphate dehydrogenase by 4–hydroxy–2–nonenal using matrix assisted laser desorption time–of–flight mass spectrometry. Grace JM, et al. **Free Radic Res** 1996 Jul;25(1):23–9

Effect of peptide aldehydes with IL–1 beta converting enzyme inhibitory properties on IL–1 alpha and IL–1 beta production in vitro. Németh K, et al. **Int J Immunopharmacol** 1995 Dec;17(12):985–93

Isolation of animal cell mutants defective in long–chain fatty aldehyde dehydrogenase. Sensitivity to fatty aldehydes and Schiff's base modification of phospholipids: implications for Sj–ogren–Larsson syndrome. James PF, et al. **J Biol Chem** 1997 Sep 19;272(38):23532–9

Analytical derivatizations of volatile and hydrophilic carbonyls from aqueous matrix onto a solid phase of a polystyrene–divinylbenzene macroreticular resin. Breckenridge SM, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):289–96

Attachment of Metarhizium anisopliae to the southern green stink bug Nezara viridula cuticle and fungistatic effect of cuticular lipids and aldehydes. Sosa–Gomez DR, et al. **J Invertebr Pathol** 1997 Jan;69(1):31–9

Salicylaldehyde–metal–amino acid ternary complex: a new tool for immobilized metal affinity chromatography. Leibler D, et al. **J Mol Recognit** 1996 Sep–Dec; 9(5–6):375–82

[Operational stability of catalase and its conjugates with aldehyde dextrans and superoxide dismutase] Eremin AN, et al. **Biokhimiia** 1996 Apr;61(4):664–79 (Eng. Abstr.) **(Rus)**

METABOLISM

Profiles of hepatic cellular protein adduction by malondialdehyde and 4–hydroxynonenal. Studies with isolated hepatocytes. Hartley DP, et al. **Adv Exp Med Biol** 1997;414:123–31

Immunohistochemical detection of 4–hydroxy–2–nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Montine KS, et al. **Am J Pathol** 1997 Feb;150(2):437–43

Transfection of a 4–hydroxynonenal metabolizing glutathione S–transferase isozyme, mouse GSTA4–4, confers doxorubicin resistance to Chinese hamster ovary cells. He NG, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):214–20

Amino acid residue 104 in an alpha–class glutathione S–transferase is essential for the high selectivity and specificity of the enzyme for 4–hydroxynonenal. Nanduri B, et al. **Arch Biochem Biophys** 1996 Nov 15;335(2):305–10

Quantification of malondialdehyde and 4–hydroxynonenal adducts to lysine residues in native and oxidized human low–density lipoprotein. Requena JR, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):317–25

2–oxoaldehydes, glyoxalase I and oxidative stress. Cordeiro C, et al. **Biochem Soc Trans** 1996 Aug;24(3):472S

Purification and characterization of a 4–hydroxynonenal metabolizing glutathione S–transferase isozyme from bovine pulmonary microvessel endothelial cells. He NG, et al. **Biochim Biophys Acta** 1996 Dec 6;1291(3):182–8

Doxorubicin–induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat. Luo X, et al. **Biochim Biophys Acta** 1997 Feb 27;1360(1):45–52

Oxygenation of (3Z)–alkenal to (2E)–4–hydroxy–2–alkenal in soybean seed (Glycine max L.). Takamura H, et al. **Biochim Biophys Acta** 1996 Sep 27;1303(2):83–91

High metabolic rates of 4–hydroxynonenal in brain capillary endothelial cells during hypoxia/reoxygenation. Kunstmann S, et al. **Brain Res** 1996 Nov 18;740(1–2):353–5

AM1 calculations on inclusion complexes of cyclomaltoheptaose (beta–cyclodextrin) with 1,7–dioxaspiro[5.5]undecane and nonanal, and comparison with experimental results. Botsi A, et al. **Carbohydr Res** 1996 Mar 22;283:1–16

Focal nuclear hepatocyte response to oxidative damage following low dose thioacetamide intoxication. Clawson GA, et al. **Carcinogenesis** 1997 Aug;18(8):1663–8

Increase of aldehydic compounds derived from plasmalogens in the brain of aged cattle. Weisser M, et al. **Chem Phys Lipids** 1996 Aug 19;82(2):173–8

Efficient scavenging of fatty acid oxidation products by aminoguanidine. Al–Abed Y, et al. **Chem Res Toxicol** 1997 Aug;10(8):875–9

Characterization of amino acid and glutathione adducts of cis–2–butene–1,4–dial, a reactive metabolite of furan. Chen LJ, et al. **Chem Res Toxicol** 1997 Aug;10(8):866–74

Prooxidant–initiated lipid peroxidation in isolated rat hepatocytes: detection of 4–hydroxynonenal– and malondialdehyde–protein adducts. Hartley DP, et al. **Chem Res Toxicol** 1997 Aug;10(8):895–905

Destruction of rat pancreatic islet beta–cells by cytokines involves the production of cytotoxic aldehydes. Suarez–Pinzon WL, et al. **Endocrinology** 1996 Dec; 137(12):5290–6

Iodolactones and iodoaldehydes––mediators of iodine in thyroid autoregulation. Dugrillon A. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:41–5 (21 ref.)

A glutathione S–transferases isozyme (bGST 5.8) involved in the metabolism of 4–hydroxy–2–trans–nonenal is localized in bovine lens epithelium. Srivastava SK, et al. **Exp Eye Res** 1996 Sep;63(3):329–37

Formation of a 2–methyl–branched fatty aldehyde during peroxisomal alpha–oxidation. Croes K, et al. **FEBS Lett** 1997 Aug 4;412(3):643–5

Aldehyde dismutase activity of human liver alcohol dehydrogenase. Svensson S, et al. **FEBS Lett** 1996 Sep 30; 394(2):217–20

Simultaneous determination of acrolein, malonaldehyde and 4–hydroxy–2–nonenal produced from lipids oxidized with Fenton's reagent. Miyake T, et al. **Food Chem Toxicol** 1996 Oct;34(10):1009–11

Effect of oxidative stress by iron on 4–hydroxynonenal formation and proliferative activity in hepatomas of different degrees of differentiation. Hammer A, et al. **Free Radic Biol Med** 1997;23(1):26–33

Induction of a wide range of C(2–12) aldehydes and C(7–12) acyloins in the kidney of Wistar rats after treatment with a renal carcinogen, ferric nitrilotriacetate. Toyokuni S, et al. **Free Radic Biol Med** 1997;22(6):1019–27

Intracellular metabolism of 4–hydroxynonenal in primary cultures of rabbit synovial fibroblasts. Ullrich O, et al. **Free Radic Biol Med** 1997;22(7):1153–7

4–hydroxynonenal levels are enhanced in fetal liver mitochondria by in utero ethanol exposure. Chen JJ, et al. **Hepatology** 1997 Jan;25(1):142–7

Acetaldehyde–modified and 4–hydroxynonenal–modified proteins in the livers of rats with alcoholic liver disease. Li CJ, et al. **Hepatology** 1997 Sep;26(3):650–7

Use of pH studies to determine the kinetic and chemical mechanism of yeast alcohol dehydrogenase with primary aliphatic alcohols and aldehydes. Leskovac V, et al. **Indian J Biochem Biophys** 1996 Jun;33(3):177–83

Release of aldehydic products from glutamate or deoxyuridine by delta–aminolevulinic acid in presence of copper ions. Singh V, et al. **Indian J Exp Biol** 1996 Mar; 34(3):208–10

Liver hyperthermia and oxidative stress: role of iron and aldehyde production. Skibba JL, et al. **Int J Hyperthermia** 1997 Mar–Apr;13(2):215–26

Preparation of general proteinase substrates using 3,5–dinitrosalicylaldehyde. Gallegos NG, et al. **J Biochem Biophys Methods** 1996 Oct 15;33(1):31–41

Biosynthesis and metabolism of 2–iodohexadecanal in cultured dog thyroid cells. Panneels V, et al. **J Biol Chem** 1996 Sep 20;271(38):23006–14

Human neutrophils employ the myeloperoxidase–hydrogen peroxide–chloride system to convert hydroxy–amino acids into glycolaldehyde, 2–hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha–hydroxy and alpha,beta–unsaturated aldehydes by phagocytes at sites of inflammation. Anderson MM, et al. **J Clin Invest** 1997 Feb 1;99(3):424–32

Excessive formation of hydroxyl radicals and aldehydic lipid peroxidation products in cultured skin fibroblasts from patients with complex I deficiency. Luo X, et al. **J Clin Invest** 1997 Jun 15;99(12):2877–82

Metabolic fate of 4–hydroxynonenal in hepatocytes: 1,4–dihydroxynonene is not the main product. Siems WG, et al. **J Lipid Res** 1997 Mar;38(3):612–22

Matrix–assisted laser desorption/ionization time–of–flight mass spectrometry as a tool to probe the reactions of trans–Hex–2–enal with proteins [letter] Houston CT, et al. **J Mass Spectrom** 1997 Jun;32(6):662–5

Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta–peptide: role of the lipid peroxidation product 4–hydroxynonenal. Keller JN, et al. **J Neurochem** 1997 Jul;69(1):273–84

4–Hydroxynonenal–derived advanced lipid peroxidation end products are increased in Alzheimer's disease. Sayre LM, et al. **J Neurochem** 1997 May;68(5):2092–7

4–hydroxynonenal, a lipid peroxidation product, rapidly accumulates following traumatic spinal cord injury and inhibits glutamate uptake. Springer JE, et al. **J Neurochem** 1997 Jun;68(6):2469–76

4–hydroxy–2–nonenal pyrrole adducts in human neurodegenerative disease. Montine KS, et al. **J Neuropathol Exp Neurol** 1997 Aug;56(8):866–71

Evidence that 4–hydroxynonenal mediates oxidative stress–induced neuronal apoptosis. Kruman I, et al. **J Neurosci** 1997 Jul 1;17(13):5089–100

Kinetics of formation of fluorescent products from hexanal and L–lysine in a two–phase system. Stapelfeldt H, et al. **Lipids** 1996 Nov;31(11):1125–32

Increased levels of lipid peroxidation products malondialdehyde and 4–hydroxynonenal after perinatal hypoxia. Schmidt H, et al. **Pediatr Res** 1996 Jul;40(1):15–20

4–hydroxy–2–nonenal–protein adducts and apoptosis in murine lung cells after acute ozone exposure. Kirichenko A, et al. **Toxicol Appl Pharmacol** 1996 Dec;141(2):416–24

Expression of aldehydic lipid peroxidation products in rat kidneys during warm ischemia. Eschwège P, et al. **Transplant Proc** 1997 Aug;29(5):2437–8

PHARMACOKINETICS

Detoxification of reactive aldehydes in mitochondria: effects of age and dietary restriction. Chen JJ, et al. **Aging (Milano)** 1996 Oct;8(5):334–40

Co–metabolism of ethanol, ethanol–derived acetaldehyde, and 4–hydroxynonenal in isolated rat hepatocytes. Hartley DP, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):298–304

Metabolic activation of trans–4–hydroxy–2–nonenal, a toxic product of membrane lipid peroxidation and inhibitor of P450 cytochromes. Kuo CL, et al. **J Biol Chem** 1997 Sep 5;272(36):22611–6

Disposition in rat of [2–3H]–trans–4–hydroxy–2,3–nonenal, a product of lipid peroxidation. de Zwart LL, et al. **Xenobiotica** 1996 Oct;26(10):1087–100

PHARMACOLOGY

Chemiluminescence of oxygen radical scavengers such as DDMP saponins in the presence of radicals and aldehyde. Yoshiki Y, et al. **Adv Exp Med Biol** 1996;405:231–9 (16 ref.)

Phosphatase inhibitors potentiate 4–hydroxynonenal–induced phospholipase D activation in vascular endothelial cells. Natarajan V, et al. **Am J Respir Cell Mol Biol** 1997 Aug; 17(2):251–9

4–hydroxynonenal specifically inhibits c–myb but does not affect c–fos expressions in HL–60 cells. Barrera G, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):589–93

Cellular response to the redox active lipid peroxidation products: induction of glutathione S–transferase P by 4–hydroxy–2–nonenal. Fukuda A, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):505–9

Effects of 4–OH–2,3–trans–nonenal on human erythrocyte plasma membrane Ca2+ pump and passive Ca2+ permeability. Raess BU, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):451–4

Inactivation of glutathione reductase by 4–hydroxynonenal and other endogenous aldehydes. Vander Jagt DL, et al. **Biochem Pharmacol** 1997 Apr 25;53(8):1133–40

Mechanism–based inactivation of cytochrome P450 2B4 by aldehydes: relationship to aldehyde deformylation via a peroxyhemiacetal intermediate. Raner GM, et al. **Biochemistry** 1997 Apr 22;36(16):4895–902

Biogenic 4–hydroxy–2–nonenal activates transcription factor AP–1 but not NF–kappa B in cells of the macrophage lineage. Camandola S, et al. **Biofactors** 1997;6(2):173–9

Norepinephrine transmitter metabolite is a selective cell death messenger in differentiated rat pheochromocytoma cells. Burke WJ, et al. **Brain Res** 1996 May 25;722(1–2):232–5

Effect of 4–hydroxynonenal on superoxide anion production from primed human neutrophils. Dianzani C, et al. **Cell Biochem Funct** 1996 Sep;14(3):193–200

Inhibition of glutathione S–transferase activity in human melanoma cells by alpha,beta–unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans–2–hexenal. Iersel ML, et al. **Chem Biol Interact** 1996 Oct 21;102(2):117–32

Modification of horse heart cytochrome c with trans–2–hexenal. Zidek L, et al. **Chem Res Toxicol** 1997 Jun;10(6):702–10

The lipid peroxidation end product 4–hydroxy–2,3–nonenal

up-regulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. Leonarduzzi G, et al. **FASEB J** 1997 Sep;11(11):851-7

Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein. Friguet B, et al. **FEBS Lett** 1997 Mar 17;405(1):21-5

Increased stress parameter synthesis in the yeast Saccharomyces cerevisiae after treatment with 4-hydroxy-2-nonenal. Wonisch W, et al. **FEBS Lett** 1997 Mar 17;405(1):11-5

Glutathione consumption and glutathione peroxidase inactivation in fibroblast cell lines by 4-hydroxy-2-nonenal. Kinter M, et al. **Free Radic Biol Med** 1996;21(4):457-62

4-Hydroxy-2-nonenal hardly affects glycolysis. Miwa I, et al. **Free Radic Biol Med** 1997;23(4):610-5

4-hydroxynonenal-induced relaxation of human mesenteric arteries. Romero FJ, et al. **Free Radic Biol Med** 1997; 23(3):521-3

Interactions of malondialdehyde and 4-hydroxynonenal with rat liver plasma membranes and their effect on binding of prostaglandin E2 by specific receptors. Buko VU, et al. **Free Radic Res** 1996 Nov;25(5):415-20

The effect of the lipid peroxidation product 4-hydroxynonenal and of its metabolite 4-hydroxynonenoic acid on respiration of rat kidney cortex mitochondria. Ullrich O, et al. **Free Radic Res** 1996 Jun; 24(6):421-7

Effect of peptide aldehydes with IL-1 beta converting enzyme inhibitory properties on IL-1 alpha and IL-1 beta production in vitro. Németh K, et al. **Int J Immunopharmacol** 1995 Dec;17(12):985-93

4-Hydroxynonenal inhibits interleukin-1 beta converting enzyme. Davis DW, et al. **J Interferon Cytokine Res** 1997 Apr;17(4):205-10

4-Hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with muscarinic acetylcholine and metabotropic glutamate receptors: possible action on G alpha(q/11). Blanc EM, et al. **J Neurochem** 1997 Aug;69(2):570-80

A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. Mark RJ, et al. **J Neurochem** 1997 Jan;68(1):255-64

The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. Subramaniam R, et al. **J Neurochem** 1997 Sep; 69(3):1161-9

Effects of nonanal, trans-2-nonenal and 4-hydroxy-2,3-trans-nonenal on cyclooxygenase and 12-lipoxygenase metabolism of arachidonic acid in rabbit platelets. Sakuma S, et al. **J Pharm Pharmacol** 1997 Feb; 49(2):150-3

Modulation of human T lymphocyte proliferation by 4-hydroxynonenal, the bioactive product of neutrophil-dependent lipid peroxidation. Cambiaggi C, et al. **Life Sci** 1997;61(8):777-85

Interaction of aldehydes with glyoxalase I and the status of several aldehyde metabolizing enzymes of Ehrlich ascites carcinoma cells. Biswas S, et al. **Mol Cell Biochem** 1996 Dec 6;165(1):9-16

4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. Mattson MP, et al. **Neuroreport** 1997 Jul 7; 8(9-10):2275-81

Effect of urine-derived compounds on cAMP accumulation in mouse vomeronasal cells. Zhou A, et al. **Neuroreport** 1997 Jul 7;8(9-10):2173-7

Effects of 4-hydroxynonenal and N-acetyl-L-cysteine on Myc-induced apoptosis. Yildiz D, et al. **Toxicol Lett** 1996 Dec 31;89(3):215-21

TOXICITY

Cytotoxicity, pH, and glucose degradation products in four different brands of PD fluid. Wieslander A, et al. **Adv Perit Dial** 1996;12:57-60

4-Hydroxy-2-nonenal cytotoxicity in renal proximal tubular cells: protein modification and redox alteration. Fukuda A, et al. **Arch Biochem Biophys** 1996 Sep 15;333(2):419-26

Increased gene expression in human promyeloid leukemia cells exposed to trans,trans-muconaldehyde, a hematotoxic benzene metabolite. Ho TY, et al. **Carcinogenesis** 1997 Apr; 18(4):739-44

(E)-2-hexenal-induced DNA damage and formation of cyclic 1,N2-(1,3-propano)-2'-deoxyguanosine adducts in mammalian cells. Gölzer P, et al. **Chem Res Toxicol** 1996 Oct-Nov;9(7):1207-13

Immunochemical evidence supporting 2-pentylpyrrole formation on proteins exposed to 4-hydroxy-2-nonenal. Sayre LM, et al. **Chem Res Toxicol** 1996 Oct-Nov; 9(7):1194-201

Chemistry of muconaldehydes of possible relevance to the toxicology of benzene. Bleasdale C, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1201-9

DNA single and double strand breaks induced by aliphatic and aromatic aldehydes in combination with copper (II). Becker TW, et al. **Free Radic Res** 1996 May;24(5):325-32

Assessment of the tumor-initiating potential of alpha, beta-unsaturated carbonyl compounds by 32P postlabeling quantification of DNA adducts in vivo. Eder E, et al. **Recent Results Cancer Res** 1997;143:65-75

URINE

Simultaneous determination of eight lipid peroxidation degradation products in urine of rats treated with carbon tetrachloride using gas chromatography with electron-capture detection. De Zwart LL, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):277-87

ALDICARB

ADVERSE EFFECTS

Categorical regression of toxicity data: a case study using aldicarb. Dourson ML, et al. **Regul Toxicol Pharmacol** 1997 Apr;25(2):121-9

ANALYSIS

Loss of label during processing cotton oil grown with 14C-aldicarb. Tunçbilek AS, et al. **Bull Environ Contam Toxicol** 1997 Feb;58(2):213-8

METABOLISM

The use of cultured hepatocytes from goats and cattle to investigate xenobiotic oxidative metabolism. Montesissa C, et al. **Vet Res Commun** 1996;20(5):449-60

PHARMACOLOGY

A genetic selection for Caenorhabditis elegans synaptic transmission mutants. Miller KG, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12593-8

POISONING

Carbamate poisoning in early childhood and in adults. Lifshitz M, et al. **J Toxicol Clin Toxicol** 1997;35(1):25-7

TOXICITY

Assessment of the ability of propoxur, methomyl, and aldicarb, three carbamate insecticides, to induce micronuclei in vitro in cultured Chinese hamster ovary cells and in vivo in BALB/c mice. Wei LY, et al. **Environ Mol Mutagen** 1997;29(4):386-93

ALDOLASE see FRUCTOSEDIPHOSPHATE ALDOLASE

ALDOSE REDUCTASE see ALDEHYDE REDUCTASE

ALDOSTERONE

see related
HYPERALDOSTERONISM
HYPOALDOSTERONISM
PSEUDOHYPOALDOSTERONISM
RECEPTORS, ALDOSTERONE
RENIN-ANGIOTENSIN SYSTEM

High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Sato A, et al. **Endocrinology** 1996 Oct; 137(10):4145-53

ADMINISTRATION & DOSAGE

Aldosterone and insulin stimulate amiloride-sensitive sodium transport in A6 cells by additive mechanisms. Record RD, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1079-84

ADVERSE EFFECTS

Vascular remodeling and mineralocorticoids. Weber KT, et al. **J Endocrinol Invest** 1995 Jul-Aug;18(7):533-9 (62 ref.)

ANALOGS & DERIVATIVES

Urinary excretion of 19-noraldosterone in the spontaneously hypertensive rat and stroke-prone spontaneously hypertensive rat. Takeda Y, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S20-2

ANALYSIS

Hormonal modulation of inner ear fluids. Ferrary E, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):244-7

ANTAGONISTS & INHIBITORS see ALDOSTERONE ANTAGONISTS

BIOSYNTHESIS

Molecular analysis of CYP21 and C4 genes in Brazilian families with the classical form of steroid 21-hydroxylase deficiency. de-Araujo M, et al. **Braz J Med Biol Res** 1996 Jan;29(1):1-13 (37 ref.)

Effects of staurosporine on ACTH-mediated stimulation of aldosterone production. Pecci A, et al. **Cell Signal** 1996 Aug;8(5):381-6

PCR-SSCP analysis of the promoter region of the renin gene in patients with aldosterone-producing adenomas. Ballantine DM, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):584-6

Different allelic patterns at chromosome 11q13 in paired aldosterone-producing tumours and blood DNA. Gordon R, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul; 23(6-7):594-6

Potentiating effects of calcium chelators on basal and stimulated aldosterone production by bovine adrenal glomerulosa cells in vitro. Kigoshi T, et al. **Endocr J** 1997 Apr;44(2):335-9

A nitric oxide synthesis inhibitor prevents the ACTH-stimulated production of aldosterone in rat adrenal gland. Nakayama T, et al. **Endocr J** 1996 Apr;43(2):157-62

Ascorbate and alpha-tocopherol depletion inhibit aldosterone stimulation by sodium deficiency in the guinea pig. Bähr V, et al. **Endocr Res** 1996 Nov;22(4):595-600

ACTH angiotensin II and TGF beta participate in the regulation of steroidogenesis in bovine adrenal glomerulosa cells. Galtier A, et al. **Endocr Res** 1996 Nov;22(4):607-12

Sources and sites of action of calcium in the regulation of aldosterone biosynthesis. Rossier MF, et al. **Endocr Res** 1996 Nov;22(4):579-88

Comparative effect of pituitary adenylate cyclase-activating polypeptide on aldosterone secretion in normal bovine and human tumorous adrenal cells. Bodart V, et al. **Endocrinology** 1997 Feb;138(2):566-73

Effects of gestation on enzymes controlling aldosterone synthesis in the rat adrenal. Brochu M, et al. **Endocrinology** 1997 Jun;138(6):2354-8

Aldosterone biosynthesis in the rat brain. Gomez-Sanchez CE, et al. **Endocrinology** 1997 Aug;138(8):3369-73

Pituitary adenylate cyclase-activating peptide enhances steroid production by interrenal glands in fowls: evidence for an indirect mechanism of action. Mazzocchi G, et al. **Horm Metab Res** 1997 Feb;29(2):86-7

Opposite feedback control of renin and aldosterone biosynthesis in the adrenal cortex by angiotensin II AT1-subtype receptors. Gigante B, et al. **Hypertension** 1997 Sep;30(3 Pt 2):563-8

Vascular aldosterone in genetically hypertensive rats. Takeda Y, et al. **Hypertension** 1997 Jan;29(1 Pt 1):45-8

Hypoxia in vivo inhibits aldosterone synthesis and aldosterone synthase mRNA in rats. Raff H, et al. **J Appl Physiol** 1996 Aug;81(2):604-10

Aldosterone-producing adenomas do not contain glucocorticoid-remediable aldosteronism chimeric gene duplications. Carroll J, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4310-2

Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. Davies E, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):611-5

Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism. Litchfield WR, et al. **J Clin Endocrinol Metab** 1997 May;82(5):1507-10

Correction of the nomenclature and mechanism of the aldosterone biosynthetic defects [letter] Ulick S. **J Clin Endocrinol Metab** 1996 Mar;81(3):1299-300

Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. Gómez-Sánchez EP. **J Endocrinol Invest** 1995 Jul-Aug; 18(7):580-5 (22 ref.)

The biochemical phenotypes of two inborn errors in the biosynthesis of aldosterone. Pascoe L. **J Endocrinol Invest** 1995 Jul-Aug;18(7):571-5

Idiopathic hyperplasia of the adrenal gland behaving like an aldosterone producing adenoma. Rao A, et al. **J Endocrinol Invest** 1997 Jan;20(1):29-31

Glucocorticoid-remediable aldosteronism. Williams GH, et al. **J Endocrinol Invest** 1995 Jul-Aug;18(7):512-7 (24 ref.)

Adrenal-sparing laparoscopic surgery for aldosterone-producing adenoma. Janetschek G, et al. **J Endourol** 1997 Apr;11(2):145-8

Enhancement of potassium-, and angiotensin II-stimulated aldosterone production by the calcium chelator EGTA in bovine adrenal glomerulosa cells in vitro. Kigoshi T, et al. **J Steroid Biochem Mol Biol** 1997 Feb;60(3-4):215-20

The role of nitric oxide in the regulation of aldosterone synthesis by adrenal glomerulosa cells. Natarajan R, et al. **J Steroid Biochem Mol Biol** 1997 Apr;61(1-2):47-53

Role of calmodulin-dependent protein kinase II in the acute stimulation of aldosterone production. Pezzi V, et al. **J Steroid Biochem Mol Biol** 1996 Jul;58(4):417-24

Demonstration of an angiotensin II-induced negative feedback effect on aldosterone synthesis in isolated rat adrenal zona glomerulosa cells. Aptel HB, et al. **Mol Cell Endocrinol** 1996 May 17;119(1):105-11

The H295R human adrenocortical cell line contains functional atrial natriuretic peptide receptors that inhibit aldosterone biosynthesis. Bodart V, et al. **Mol Cell Endocrinol** 1996 Apr 19;118(1-2):137-44

The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme [letter] Curnow KM, et al. **Nat Struct Biol** 1997 Jan;4(1):32-5

Congenital hypoaldosteronism: the Visser-Cost syndrome revisited. Peter M, et al. **Pediatr Res** 1996 Mar;39(3):554-60

Bilateral aldosterone-producing adenomas in two patients diagnosed by immunohistochemical analysis of steroidogenic enzymes. Watanabe N, et al. **Tohoku J Exp Med** 1996 Jun;179(2):123-9

BLOOD

Transient elevation of aldosterone levels in perinatal asphyxia. Pereira DN, et al. **Acta Paediatr** 1997 Aug; 86(8):851-3

Aldosterone cord levels in preterm newborn infants. Procianoy RS, et al. **Acta Paediatr** 1996 May;85(5):611-3

Effect of sympathetic and angiotensin-aldosterone systems

on renal salt conservation in the rat. Honrath U, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):F538–44

Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease. Jensen J, et al. **Am J Vet Res** 1997 May;58(5):535–40

Factors and molecular mechanisms involved in the regulation of chicken colonic luminal membrane Na(+)-linked transport systems. Wood IS, et al. **Biochem Soc Trans** 1996 May;24(2):248S

Early prediction of pre-eclampsia by measurement of kallikrein and creatinine on a random urine sample [letter; comment] Stratta P, et al. **Br J Obstet Gynaecol** 1997 Jun; 104(6):759–60. Comment on: Br J Obstet Gynaecol 1996 May;103(5):421–6.

Incidence of nursing sickness and biochemical observations in lactating mink with and without dietary salt supplementation. Clausen TN, et al. **Can J Vet Res** 1996 Oct;60(4):271–6

Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects [see comments] Cargill RI, et al. **Chest** 1996 Nov;110(5):1220–5 . Comment in: Chest 1996 Nov;110(5):1136–8.

Aldosterone changes during angiotensin III and potassium infusions in patients with primary aldosteronism [letter; comment] Plouin PF, et al. **Clin Endocrinol (Oxf)** 1996 Aug; 45(2):243–4. Comment on: Clin Endocrinol (Oxf) 1995 Feb;42(2):111–9.

Effect of felodipine on blood pressure, body sodium, plasma renin activity and plasma aldosterone in hypertensive and normotensive rats. Ledingham JM, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S323–5

Regulation of aldosterone in the 7-day-old rat. Feuillan PP, et al. **Endocrinology** 1996 Sep;137(9):3992–8

Alterations in plasma volume, plasma constituents, renin activity and aldosterone induced by maximal exercise in the horse. Masri M, et al. **Equine Vet J Suppl** 1990 Jun; (9):72–7

Fluid balance and renal response following dehydrating exercise in well-trained men and women. Stachenfeld NS, et al. **Eur J Appl Physiol** 1996;72(5–6):468–77

Lack of effect of the serotonin4 receptor agonist zacopride on ACTH secretion in normal men. Lefebvre H, et al. **Eur J Clin Pharmacol** 1996;51(1):49–51

Effects of metoclopramide and tropisetron on aldosterone secretion possibly due to agonism and antagonism at the 5-HT4 receptor. Sommers DK, et al. **Eur J Clin Pharmacol** 1996;50(5):371–3

Effect of aging and sodium deprivation on plasma concentration of aldosterone and on plasma renin activity in the rat. Brudieux R, et al. **Gerontology** 1996;42(4):229–34

Associations between circulating components of the renin–angiotensin–aldosterone system and left ventricular mass. Schunkert H, et al. **Heart** 1997 Jan;77(1):24–31

Influence of hemodynamic changes on neuroendocrine response in acute heart failure. Pohar B, et al. **Int J Cardiol** 1997 Aug 8;60(3):263–71

Evaluation of plasma aldosterone to plasma renin activity ratio in patients with primary aldosteronism. Ignatowska-Switalska H, et al. **J Hum Hypertens** 1997 Jun; 11(6):373–8

Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I. Stowasser M, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1610–3

Hemodynamic, renal, and hormonal responses to lower body positive pressure in human subjects. Mannix ET, et al. **J Lab Clin Med** 1996 Dec;128(6):585–93

The minimum sodium requirement of growing kittens defined on the basis of plasma aldosterone concentration. Yu S, et al. **J Nutr** 1997 Mar;127(3):494–501

Elevated intra-abdominal pressure increases plasma renin activity and aldosterone levels. Bloomfield GL, et al. **J Trauma** 1997 Jun;42(6):997–1004; discussion 1004–5

Circadian rhythms of plasma atriopeptin, plasma renin activity and plasma aldosterone in patients with hepatorenal syndrome. Pasqualetti P, et al. **Life Sci** 1997;60(4–5):289–97

Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment. Zacharieva S, et al. **Methods Find Exp Clin Pharmacol** 1996 Nov;18(9):593–7

Effects of the intravenous magnesium administration on aldosterone and atrial natriuretic factor plasma concentrations [letter] Corica F, et al. **Nephron** 1996; 73(4):739–41

Regulation of plasma aldosterone levels by metoclopramide: a reappraisal of its mechanism from dopaminergic antagonism to serotonergic agonism. Rizzi CA, et al. **Neuropharmacology** 1997 Jun;36(6):763–8 (65 ref.)

Effects of corticotrophin-releasing factor and vasopressin on plasma adrenocorticotrophin molecular forms, aldosterone and corticosterone in young and adult rats and rabbits. Pradier P, et al. **Reprod Fertil Dev** 1996;8(1):111–6

Primary aldosteronism: adrenal venous sampling. Young WF Jr, et al. **Surgery** 1996 Dec;120(6):913–9; discussion 919–20

The influence of endocrine changes in donors and recipients on the immediate outcome of kidney transplantation. Rowiński W, et al. **Transplant Proc** 1996 Dec;28(6):3494–6

[Aldosterone precursors and hypertension with hypokalemia and adrenal module non caused by primary hyperaldosteronism] Chamontin B, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89(8):1055–8 (Eng. Abstr.) **(Fre)**

[Electrolyte metabolism and endocrine indices in the plasma and lymph of rats with hereditary arterial hypertension] Antonov AR, et al. **Biull Eksp Biol Med** 1997 Jul; 124(7):36–8 **(Rus)**

[Diurnal rhythm of cortisol and aldosterone plasma levels in patients with chronic renal insufficiency] Ivić MA, et al. **Srp Arh Celok Lek** 1996 May-Jun;124(5–6):115–9 (Eng. Abstr.) **(Scc)**

[Is the aldosterone-renin ratio useful in screening for primary aldosteronism?] Kreze A Jr, et al. **Vnitr Lek** 1996 Sep; 42(9):649–51 (Eng. Abstr.) **(Slo)**

METABOLISM

Effect of exposure to hypoxia from birth on aldosterone in rabbits: role of unesterified fatty acids. Raff H, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1084–7

Ouabain increases aldosterone release from bovine adrenal glomerulosa cells: role of renin-angiotensin system. Tamura M, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):E27–35

Characterization of adrenal hormone binding sites in the prairie vole. Hastings NB, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:525–9

The promiscuous receptor: a case for the guardian enzyme [comment] Weber KT. **Cardiovasc Res** 1995 Aug;30(2):176 . Comment on: Cardiovasc Res 1995 Aug;30(2):177–80.

Mineralocorticoid (type I) receptors in the olfactory mucosa of the mammal: studies with [3H]aldosterone and the anti-mineralocorticoid spironolactone. Kern RC, et al. **Chem Senses** 1997 Apr;22(2):141–8

Mineralocorticoid receptors and glucocorticoid receptors. Funder JW. **Clin Endocrinol (Oxf)** 1996 Dec;45(6):651–6 (43 ref.)

Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Funder J, et al. **Endocrinology** 1996 Dec;137(12):5264–8

Tetralogy of Fallot repair results in activation of the renin–angiotensin–aldosterone system. Mainwaring RD, et al. **Eur Heart J** 1996 Sep;17(9):1421–5

Hypothyroidism affects the expression of electrogenic amiloride-sensitive sodium transport in rat colon. Pácha J, et al. **Gastroenterology** 1996 Dec;111(6):1551–7

Catecholamines stimulate steroid secretion of dispersed fowl adrenocortical cells, acting through the beta-receptor subtype. Mazzocchi G, et al. **Horm Metab Res** 1997 Apr; 29(4):190–2

Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Gandhi SK, et al. **Hypertension** 1996 Dec;28(6):961–6

Fluid and electrolyte hormonal responses to exercise and acute plasma volume expansion. Grant SM, et al. **J Appl Physiol** 1996 Dec;81(6):2386–92

Effects of nifedipine treatment on the renin–angiotensin–aldosterone axis. Fiad TM, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):457–60

Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. Okubo S, et al. **J Clin Invest** 1997 Mar 1; 99(5):855–60

The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase. Funder JW. **J Endocrinol Invest** 1995 Jul-Aug;18(7):576–9

Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn. Pozzan GB, et al. **J Endocrinol Invest** 1997 Feb;20(2):86–9

The steroidogenic acute regulatory protein is induced by angiotensin II and K+ in H295R adrenocortical cells. Clark BJ, et al. **Mol Cell Endocrinol** 1995 Dec 29; 115(2):215–19

Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Oelkers WK. **Steroids** 1996 Apr;61(4):166–71 (50 ref.)

[Content of components of the renin-angiotensin-aldosterone system and prostaglandins series E, F in various organs after suturing of peripheral nerves during treatment with dehydrating agents] Nechipurenko NI, et al. **Patol Fiziol Eksp Ter** 1996 Oct-Dec;(4):44–6 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Effects of chronic treatments with adrenal steroids on acid-base homeostasis in the rat. Igarreta MP, et al. **Acta Physiol Pharmacol Ther Latinoam** 1996;46(3):149–58

Aldosterone-induced increase in the abundance of Na+ channel subunits. Asher C, et al. **Am J Physiol** 1996 Aug; 271(2 Pt 1):C605–11

Protein prenylation is required for aldosterone-stimulated Na+ transport. Blazer-Yost BL, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):C1928–35

Rapid effects of steroid hormones on free intracellular calcium in T84 colonic epithelial cells. Doolan CM, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):C1935–41

Corticosteroid receptor mRNA expression is unaffected by corticosteroids in rat kidney, heart, and colon. Escoubet B, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1343–53

Noncoordinate regulation of epithelial Na channel and Na pump subunit mRNAs in kidney and colon by aldosterone. Escoubet B, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1482–91

Separate regulation of Na+ and anion transport by IMCD: location, aldosterone, hypertonicity, TGF-beta 1, and cAMP. Husted RF, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F433–9

Differential regulation of putative K(+)-ATPase by low-K+ diet and corticosteroids in rat distal colon and kidney. Jaisser F, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):C679–87

FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells. Rokaw MD, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C194–202

Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells. Schneider M, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E616–20

Adrenal steroids stimulate thiazide-sensitive NaCl transport by rat renal distal tubules. Velázquez H, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):F211–9

Aldosterone induction and epithelial distribution of CHIF. Wald H, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F322–9

Aldosterone-induced proteins in primary cultures of rabbit renal cortical collecting system. Bindels RJ, et al. **Biochim Biophys Acta** 1996 Oct 2;1284(1):63–8

The effects of type I and type II corticosteroid receptor agonists on exploratory behavior and spatial memory in the Y-maze. Conrad CD, et al. **Brain Res** 1997 Jun 6; 759(1):76–83

Changes in the electrophysiological parameters of the posterior intestine of Anguilla anguilla (Pisces) induced by oxytocin, urotensin II and aldosterone. Baldisserotto B, et al. **Braz J Med Biol Res** 1997 Jan;30(1):35–9

Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Sun Y, et al. **Cardiovasc Res** 1997 Jul;35(1):138–47

The expression of neural cell sialoglycoproteins following glucocorticoid regulation of sialyltransferase activity in vivo. Coughlan CM, et al. **Cell Mol Neurobiol** 1996 Jun; 16(3):433–8

Aldosterone, salt and cardiac fibrosis. Funder JW. **Clin Exp Hypertens** 1997 Jul-Aug;19(5–6):885–99 (25 ref.)

Interaction of exogenous ouabain and chronic mineralocorticoid treatment in the kidney of the conscious sheep. Yates NA, et al. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):57–63

Aldosterone rapidly represses protein kinase C activity in neonatal rat cardiomyocytes in vitro. Sato A, et al. **Endocrinology** 1997 Aug;138(8):3410–6

The role of adrenocortical steroid hormones in the development of hearing. Freeman S, et al. **J Basic Clin Physiol Pharmacol** 1996;7(3):167–77

Impaired rapid mineralocorticoid action on free intracellular calcium in pseudohypoaldosteronism. Gamarra F, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):831–4

Nongenomic effects of aldosterone on phosphocreatine levels in human calf muscle during recovery from exercise. Zange J, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4296–300

Aldosterone and dexamethasone stimulate calcineurin activity through a transcription-independent mechanism involving steroid receptor-associated heat shock proteins. Tumlin JA, et al. **J Clin Invest** 1997 Mar 15;99(6):1217–23

ADH action on whole-cell currents by cytosolic Ca2+-dependent pathways in aldosterone-treated A6 cells. Nakahari T, et al. **J Membr Biol** 1996 Nov; 154(1):35–44

Role of de novo protein synthesis and calmodulin in rapid activation of Na(+)-H+ exchange of aldosterone in frog diluting segment. Cooper GJ, et al. **J Physiol (Lond)** 1996 Feb 15;491 (Pt 1):219–23

Rapid activation of KATP channels by aldosterone in principal cells of frog skin. Urbach V, et al. **J Physiol (Lond)** 1996 Feb 15;491 (Pt 1):111–20

Inhibition of mineralocorticoid activity by the beta-isoform of the human glucocorticoid receptor. Bamberger CM, et al. **J Steroid Biochem Mol Biol** 1997 Jan;60(1–2):43–50

Physiological requirement of aldosterone action on the Na+/K+ pump in ADH-stimulated Na+ absorption in renal epithelium. Marunaka Y. **Jpn J Physiol** 1996 Aug; 46(4):357–61

AVP and aldosterone at physiological concentrations have synergistic effects on Na+ transport in rat CCD. Hawk CT, et al. **Kidney Int Suppl** 1996 Dec;57:S35–41

Characterization of early aldosterone-induced RNAs identified in A6 kidney epithelia. Spindler B, et al. **Pflugers Arch** 1997 Jul;434(3):323–31

Effects of aldosterone and spironolactone on the isolated perfused rat heart. Moreau D, et al. **Pharmacology** 1996 Jul;53(1):28–36

Rapid activation of Na+/H+ exchange by aldosterone in renal epithelial cells requires Ca2+ and stimulation of a plasma membrane proton conductance. Gekle M, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10500–4

The memory-facilitating effects of the competitive NMDA-receptor antagonist CGP 37849 are steroid-sensitive, whereas its memory-impairing effects are not. Mondadori C, et al. **Psychopharmacology (Berl)** 1996 Apr;124(4):380–3

[Implication of type II glucocorticoid receptors in aldosterone induced apoptosis of rat thymocytes] Ben Rhouma K, et al. **Arch Physiol Biochem** 1997 Apr; 105(2):216–24 (Eng. Abstr.) **(Fre)**

[Aldosterone increases the activity level of Na+-conducting channels in chronic myeloid leukemia K562 cells] Neguliaev IuA, et al. **Dokl Akad Nauk** 1996 Aug;

349(5):701–3 **(Rus)**

PHYSIOLOGY

Aldosterone regulation of sodium channel gamma-subunit mRNA in cortical collecting duct cells. Denault DL, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C423–8

Differential regulation of CHIF mRNA by potassium intake and aldosterone. Wald H, et al. **Am J Physiol** 1997 May; 272(5 Pt 2):F617–23

Urinary kallikrein excretion in pregnant adrenalectomized rats. Croxatto HR, et al. **Arch Biol Med Exp (Santiago)** 1986;19(3–4):305–9

The renin-angiotensin-aldosterone system in pre-eclampsia. Brown MA, et al. **Clin Exp Hypertens** 1997 Jul–Aug; 19(5–6):713–26 (46 ref.)

A reappraisal of aldosterone effects on the kidney: new insights provided by epithelial sodium channel cloning. Gründer S, et al. **Curr Opin Nephrol Hypertens** 1997 Jan; 6(1):35–9 (50 ref.)

Inherited forms of mineralocorticoid hypertension. White PC. **Hypertension** 1996 Dec;28(6):927–36 (84 ref.)

Activity of the renin-angiotensin-aldosterone axis is dependent on the occurrence of edema in growth hormone (GH)-deficient adults treated with GH [letter] Hayes FJ, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):322–3

Vascular aldosterone. Biosynthesis and a link to angiotension II-induced hypertrophy of vascular smooth muscle cells. Gómez-Sánchez EP. **J Endocrinol Invest** 1995 Jul–Aug; 18(7):580–5 (22 ref.)

Regulation of Na+ reabsorption in aldosterone target epithelia. Verrey F, et al. **Kidney Blood Press Res** 1997; 20(3):148–50

Aldosterone and potassium homeostasis. Rabinowitz L. **Kidney Int** 1996 Jun;49(6):1738–42 (47 ref.)

Aldosterone and vasopressin responses in the heat: hydration level and exercise intensity effects. Montain SJ, et al. **Med Sci Sports Exerc** 1997 May;29(5):661–8

The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertensive rats. MacLeod AB, et al. **Stroke** 1997 Sep;28(9):1821–8; discussion 1829

SECRETION

Effects of dihydropyridines on aldosterone secretion in adrenal capsule preparations from pregnant rats. Brochu M, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E18–24

Potassium-induced aldosterone secretion involves a Cl(-)-dependent mechanism. Wang W, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R183–7

Endothelin-1 acts through ETA receptors to stimulate aldosterone secretion by the rat adrenal gland. Hinson JP, et al. **Biochem Soc Trans** 1997 Feb;25(1):116S

Angiotensin II and the adrenal. Giacchetti G, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S119–24 (49 ref.)

The role of L-aromatic amino acid decarboxylase in serotonin-stimulated aldosterone secretion in response to salt intake. Burns N, et al. **Endocr Res** 1996 Nov;22(4):577–8

Effects of ecstasy on aldosterone secretion in the rat in vivo and in vitro. Burns N, et al. **Endocr Res** 1996 Nov; 22(4):601–6

Vasoactive intestinal peptide is a local regulator of adrenocortical function. Hinson JP, et al. **Endocr Res** 1996 Nov;22(4):831–8

Stimulatory effect of the substance P antagonist spantide-II on aldosterone secretion of dispersed rat zona glomerulosa cells. Malendowicz LK, et al. **Endocr Res** 1997 Feb–May; 23(1–2):131–9

Effects of K+ channel blockers on K+ channels, membrane potential, and aldosterone secretion in rat adrenal zona glomerulosa cells. Lotshaw DP. **Endocrinology** 1997 Oct; 138(10):4167–75

Permissive role of alpha-tocopherol in the stimulation of aldosterone by sodium depletion in the guinea pig. Möbius K, et al. **Eur J Endocrinol** 1996 Jun;134(6):758–63

Recent progress in understanding aldosterone secretion. Foster RH, et al. **Gen Pharmacol** 1997 May;28(5):647–51 (67 ref.)

Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Laredo J, et al. **Hypertension** 1997 Jan;29(1 Pt 2):401–7

Aldosterone-producing adrenocortical carcinoma metastases found seven years after adrenalectomy. Sakai N, et al. **Int J Urol** 1997 Jan;4(1):79–82

Primary aldosteronism with bilateral multiple aldosterone-producing adrenal adenomas [see comments] Matsuda A, et al. **Intern Med** 1996 Dec;35(12):970–5. Comment in: Intern Med 1996 Dec;35(12):919–21.

Ouabain is a potent inhibitor of aldosterone secretion and angiotensin action in the human adrenal. Antonipillai I, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2335–7

Liddle's syndrome: prospective genetic screening and suppressed aldosterone secretion in an extended kindred. Findling JW, et al. **J Clin Endocrinol Metab** 1997 Apr; 82(4):1071–4

Effects of adrenomedullin and proadrenomedullin N-terminal 20 peptide on rat zona glomerulosa cells. Andreis PG, et al. **Life Sci** 1997;60(19):1693–7

Characteristics of ANP-binding sites in the adrenal capsules of term-pregnant rats. Forcier I, et al. **Mol Cell Endocrinol** 1996 Mar 25;117(2):189–94

Adrenomedullin stimulates steroid secretion by the isolated perfused rat adrenal gland in situ: comparison with calcitonin gene-related peptide effects. Mazzocchi G, et al. **Peptides** 1996;17(5):853–7

Aldosterone release from adrenal cells is inhibited by reduced oxygen levels in vitro during maturation in rabbits. Papanek PE, et al. **Reprod Fertil Dev** 1996;8(8):1131–6

Evidence that both ETA and ETB receptor subtypes are involved in the in vivo aldosterone secretagogue effect of endothelin-1 in rats. Mazzocchi G, et al. **Res Exp Med (Berl)** 1996;196(3):145–52

Does hormonal function of the tumor influence the outcome of laparoscopic adrenalectomy? Fernández-Cruz L, et al. **Surg Endosc** 1996 Nov;10(11):1088–91

[Evaluation of surgical treatment for patients with multiple aldosteronoma: analysis of 11 cases] Liu D, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Nov;33(11):681–3 (Eng. Abstr.) **(Chi)**

TOXICITY

The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Young MJ, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):E883–8

URINE

Diurnal urinary excretion of cortisol and aldosterone in kidney graft recipients. Stefanovic V, et al. **Pathol Biol (Paris)** 1995 Nov;43(9):766–71

ALDOSTERONE ANTAGONISTS

ADVERSE EFFECTS

Allergic contact dermatitis from spironolactone. Corazza M, et al. **Contact Dermatitis** 1996 Dec;35(6):365–6

CONTRAINDICATIONS

Heart failure in the elderly [letter; comment] Jolobe OM. **Postgrad Med J** 1997 Mar;73(857):189–90. Comment on: Postgrad Med J 1996 Oct;72(852):577–80.

METABOLISM

Mineralocorticoid (type I) receptors in the olfactory mucosa of the mammal: studies with [3H]aldosterone and the anti-mineralocorticoid spironolactone. Kern RC, et al. **Chem Senses** 1997 Apr;22(2):141–8

Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations. Vergin H, et al. **Int J Clin Pharmacol Ther** 1997 Aug;35(8):334–40

PHARMACOKINETICS

Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex. Abosehmah-Albidy AZ, et al. **Br J Clin Pharmacol** 1997 Jul;44(1):35–9

Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations. Vergin H, et al. **Int J Clin Pharmacol Ther** 1997 Aug;35(8):334–40

PHARMACOLOGY

Effect of intravenously applied canrenoate on ampullar endolymphatic potential. Yura K, et al. **Acta Otolaryngol (Stockh)** 1995 Sep;115(5):648–52

Spironolactone prevents Na+/H+ exchange enhancement in primary aldosteronism. Koren W, et al. **Am J Hypertens** 1997 Mar;10(3):341–5

FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells. Rokaw MD, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C194–202

Inhibition of cortisol production by aldosterone secretion-inhibitory factor and brain natriuretic peptides. Fang VS, et al. **Chin J Physiol** 1995;38(4):247–54

New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo. Klauber N, et al. **Circulation** 1996 Nov 15;94(10):2566–71

The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Fuhrmann U, et al. **Contraception** 1996 Oct; 54(4):243–51

Effect of fludrocortisone and spironolactone on sodium and potassium losses in secretory diarrhea. Wenzl HH, et al. **Dig Dis Sci** 1997 Jan;42(1):119–28

Effects of canrenoate potassium, an aldosterone antagonist on portal hemodynamics in patients with compensated liver cirrhosis. Koda M, et al. **Hepatogastroenterology** 1996 Jul–Aug;43(10):887–92

Ouabain is a potent inhibitor of aldosterone secretion and angiotensin action in the human adrenal. Antonipillai I, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2335–7

Interactions of aldosterone antagonist diuretics with human serum proteins. Takamura N, et al. **Pharm Res** 1997 Apr; 14(4):522–6

Effects of aldosterone and spironolactone on the isolated perfused rat heart. Moreau D, et al. **Pharmacology** 1996 Jul;53(1):28–36

The memory-facilitating effects of the competitive NMDA-receptor antagonist CGP 37849 are steroid-sensitive, whereas its memory-impairing effects are not. Mondadori C, et al. **Psychopharmacology (Berl)** 1996 Apr;124(4):380–3

THERAPEUTIC USE

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). **Am J Cardiol** 1996 Oct 15;78(8):902–7

Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Benetos A, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1152–6

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. MacFadyen RJ, et al. **Cardiovasc Res** 1997 Jul;35(1):30–4

Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gökmen O, et al. **Gynecol Endocrinol** 1996 Aug;10(4):249–55

[Treatment of refractory ascites with clonidine and spironolactone (letter)] Lenaerts A, et al. **Gastroenterol Clin Biol** 1997;21(6–7):524–5 **(Fre)**

[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?] Brilla CG, et al. **Schweiz Rundsch Med Prax** 1997 Apr 2;86(14):566–74 (38 ref.) (Eng. Abstr.) **(Ger)**

ALDOSTERONE RECEPTORS see **RECEPTORS, ALDOSTERONE**

ALDOSTERONE SYNTHASE see **CYTOCHROME P-450 CYP11B2**

ALDOSTERONISM see **HYPERALDOSTERONISM**

ALDRICH SYNDROME see **WISKOTT-ALDRICH SYNDROME**

ALDRIN

ANALYSIS

[Accumulation and depuration of aldrin in the oyster Crassostrea rhizophorae, of the Ciénaga Grande de Santa Marta (Colombian Caribbean)] Gómez LC, et al. **Rev Biol Trop** 1995 Apr–Dec;43(1–3):161–72 (Eng. Abstr.) **(Spa)**

BLOOD

Determination of HCH and DDT in finger-prick whole blood dried on filter paper and its field application for monitoring concentrations in blood. Dua VK, et al. **Bull Environ Contam Toxicol** 1996 Jan;56(1):50–7

ALENDRONATE

ADMINISTRATION & DOSAGE

Improper alendronate administration and a case of pill esophagitis [letter] Rimmer DE, et al. **Am J Gastroenterol** 1996 Dec;91(12):2648–9

Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Falcini F, et al. **Calcif Tissue Int** 1996 Mar;58(3):166–9

Effects of orally administered bisphosphonates on bone loss in a disuse osteopenia model involving the rat. Mian M, et al. **Clin Exp Rheumatol** 1996 Nov–Dec;14(6):619–24

Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared. Bettica P, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3034–9

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. Bone HG, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):265–74

Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy [published erratum appears in Proc Assoc Am Physicians 1996 Jul;108(4):following table of contente] Greenspan SL, et al. **Proc Assoc Am Physicians** 1996 May;108(3):230–8

ADVERSE EFFECTS

A new probable increasing cause of esophageal ulceration: alendronate. Colina RE, et al. **Am J Gastroenterol** 1997 Apr;92(4):704–6 (11 ref.)

Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin. Graham DY, et al. **Am J Gastroenterol** 1997 Aug;92(8):1322–5

Improper alendronate administration and a case of pill esophagitis [letter] Rimmer DE, et al. **Am J Gastroenterol** 1996 Dec;91(12):2648–9

Esophageal stricture associated with alendronate therapy. Levine J, et al. **Am J Med** 1997 May;102(5):489–91

Avoiding alendronate-related esophageal irritation. Lilley LL, et al. **Am J Nurs** 1997 Jul;97(7):12–4

Esophageal ulceration due to alendronate. Sorrentino D, et al. **Endoscopy** 1996 Aug;28(6):529

Oesophageal stricture associated with alendronic acid [letter] Naylor G, et al. **Lancet** 1996 Oct 12;348(9033):1030–1

Esophagitis associated with alendronate sodium. Pizzani E, et al. **Va Med Q** 1997 Summer;124(3):181–2
[Drug–induced esophagitis: can stringent indications help prevent this disease picture?] Weihrauch TR. **Z Gastroenterol** 1997 Jun;35(6):525–7 **(Ger)**
[Alendronate–induced esophagitis. A report of 2 cases] Girelli CM, et al. **Recenti Prog Med** 1997 May;88(5):223–5 (13 ref.) (Eng. Abstr.) **(Ita)**

ANALOGS & DERIVATIVES

Radiopharmacokinetic data for 99mTc–ABP––a new radiopharmaceutical for bone scanning: comparison with 99mTc–MDP. Arteaga de Murphy C, et al. **Nucl Med Biol** 1997 Jan;24(1):27–33

ANALYSIS

Comparison of the distribution of 3H–alendronate and 3H–etidronate in rat and mouse bones. Masarachia P, et al. **Bone** 1996 Sep;19(3):281–90

DIAGNOSTIC USE

Technetium–99m–alendronate: a new radiopharmaceutical for bone scanning. Arteaga de Murphy C, et al. **Arch Med Res** 1996 Winter;27(4):481–3

PHARMACOLOGY

Alendronate inhibition of protein–tyrosine–phosphatase–meg1. Opas EE, et al. **Biochem Pharmacol** 1997 Sep 15;54(6):721–7
Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs. Roschger P, et al. **Bone** 1997 May;20(5):393–7
Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. van Beek ER, et al. **Bone** 1997 Apr;20(4):335–40
Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Jeal W, et al. **Drugs** 1997 Mar;53(3):415–34 (70 ref.)
Effects of alendronate and taxol on PC–3 ML cell bone metastases in SCID mice. Stearns ME, et al. **Invasion Metastasis** 1996;16(3):116–31
How does alendronate inhibit protein–tyrosine phosphatases? Skorey K, et al. **J Biol Chem** 1997 Sep 5;272(36):22472–80
Effects of sodium fluoride and alendronate on the bone mineral in minipigs: a small–angle X–ray scattering and backscattered electron imaging study. Fratzl P, et al. **J Bone Miner Res** 1996 Feb;11(2):248–53
Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. Owens JM, et al. **J Cell Physiol** 1997 Jul;172(1):79–86
Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long–term dosing of ovariectomized rats. Sato M, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):298–305
Alendronate: preclinical studies. Rodan GA. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):50S–52S

THERAPEUTIC USE

Treatment of osteoporosis: brighter horizons [editorial; comment] Gloth FM 3rd. **Am Fam Physician** 1996 Nov 1;54(6):1880, 1887. Comment on: Am Fam Physician 1996 Nov 1;54(6):2053–6.
Alendronate: a bisphosphonate for treatment of osteoporosis [see comments] Kirk JK, et al. **Am Fam Physician** 1996 Nov 1;54(6):2053–60. Comment in: Am Fam Physician 1996 Nov 1;54(6):1880, 1887.
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo–controlled trial [see comments] [published erratum appears in Am J Med 1997 Mar;102(3):322] Reid IR, et al. **Am J Med** 1996 Oct;101(4):341–8. Comment in: Am J Med 1996 Oct;101(4):339–40.
A potent new bisphosphonate for Paget's disease of bone [editorial; comment] Siris ES. **Am J Med** 1996 Oct; 101(4):339–40. Comment on: Am J Med 1996 Oct;101(4):341–8.
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Tucci JR, et al. **Am J Med** 1996 Nov;101(5):488–501
Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Adami S, et al. **Ann Rheum Dis** 1997 Mar; 56(3):201–4
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Devogelaer JP, et al. **Bone** 1996 Feb;18(2):141–50
Alendronate in the treatment of Paget's disease of bone. Khan SA, et al. **Bone** 1997 Mar;20(3):263–71
Alendronate prevents cyclosporin A–induced osteopenia in the rat. Sass DA, et al. **Bone** 1997 Jul;21(1):65–70
Sustained response to intravenous alendronate in postmenopausal osteoporosis. Vasikaran SD, et al. **Bone** 1995 Dec;17(6):517–20
Osteoporosis prevention and treatment. Pharmacological management and treatment implications. Sankaran SK. **Drugs Aging** 1996 Dec;9(6):472–7 (31 ref.)
Effects of alendronate on bone loss in pre– and postmenopausal hyperthyroid women treated with methimazole. Lupoli G, et al. **Gynecol Endocrinol** 1996 Oct; 10(5):343–8
Alendronate useful in treating osteoporosis [letter] Rubin BR. **J Am Osteopath Assoc** 1997 Feb;97(2):77
Dose–response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. Bone HG, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):265–74
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. Siris E, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):961–7
Preventing osteoporotic fractures with alendronate. Maughan KL. **J Fam Pract** 1997 Apr;44(4):336
Prevention of nonvertebral fractures by alendronate. A meta–analysis. Alendronate Osteoporosis Treatment Study Groups [see comments] Karpf DB, et al. **JAMA** 1997 Apr 9;277(14):1159–64. Comment in: JAMA 1997 Aug 27;278(8):631; discussion 631–2.
Meta–analysis of prevention of nonvertebral fractures by alendronate [letter; comment] Prostko M. **JAMA** 1997 Aug 27;278(8):631; discussion 631–2. Comment on: JAMA 1997 Apr 9;277(14):1159–64.
Meta–analysis of prevention of nonvertebral fractures by alendronate [letter; comment] Ross SD. **JAMA** 1997 Aug 27;278(8):631; discussion 631–2. Comment on: JAMA 1997 Apr 9;277(14):1159–64.
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group [see comments] Black DM, et al. **Lancet** 1996 Dec 7;348(9041):1535–41. Comment in: Lancet 1997 Feb 15;349(9050):505–6. Comment in: ACP J Club 1997 May–Jun;126(3):73.
Update on pharmacologic therapies for osteoporosis. Kessenich CR. **Nurse Pract** 1996 Aug;21(8):19–24 (19 ref.)
Alendronate treatment for osteoporosis: a review of the clinical evidence. Selby P. **Osteoporos Int** 1996;6(6):419–26 (47 ref.)
Alendronate––a new bisphosphonate. Selby PL. **Osteoporos Int** 1996;6 Suppl 2:21–3 (7 ref.)
Bisphosphonates in the treatment of osteoporosis. Hochberg MC. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):53S–55S (13 ref.)
[Alendronate (Fosamax 10 mg). The first amino–bisphosphate for the therapy of osteoporosis in postmenopausal women] **Dtsch Med Wochenschr** 1996 Oct;121(41 Suppl):1–4 **(Ger)**
[Alendronate (Fosamax 10 mg). The first amino–biphosphate for the treatment of women with postmenopausal osteoporosis] **Geburtshilfe Frauenheilkd** 1996 Oct;56(10 Suppl):1–4 **(Ger)**
[Does alendronate reduce the risk of fractures in postmenopausal women with osteoporosis?] Häuselmann HJ. **Schweiz Rundsch Med Prax** 1997 Apr 9;86(15):613 **(Ger)**
[Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate] Buffo L, et al. **Minerva Ginecol** 1996 Jun;48(6):263–72 (32 ref.) (Eng. Abstr.) **(Ita)**
[Drugs for osteoporosis (letter)] Hambro S. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2529 **(Nor)**
[Use of alendronate in osteoporosis––is it cost–effective?] Kristiansen IS, et al. **Tidsskr Nor Laegeforen** 1997 Aug 10;117(18):2619–22 (Eng. Abstr.) **(Nor)**
[Alendronate––a new drug for treatment of osteoporosis] Pluskiewicz W, et al. **Chir Narzadow Ruchu Ortop Pol** 1997; 62(1):73–7 (17 ref.) (Eng. Abstr.) **(Pol)**

TOXICITY

Bisphosphonates induce apoptosis in mouse macrophage–like cells in vitro by a nitric oxide–independent mechanism. Rogers MJ, et al. **J Bone Miner Res** 1996 Oct; 11(10):1482–91

ALEUTIAN DISEASE VIRUS see **ALEUTIAN MINK DISEASE VIRUS**

ALEUTIAN MINK DISEASE

see related
CHEDIAK–HIGASHI SYNDROME

COMPLICATIONS

Prevalence of microorganisms in dead mink kits from Aleutian–disease–infected and non–infected farms. Martino PE, et al. **Vet Res** 1996;27(6):607–12

EPIDEMIOLOGY

Investigation of an outbreak of Aleutian disease on a commercial mink ranch. Jackson MK, et al. **Am J Vet Res** 1996 Dec;57(12):1706–10

IMMUNOLOGY

Aleutian mink disease parvovirus infection of K562 cells is antibody–dependent and is mediated via an Fc(gamma)RII receptor. Dworak LJ, et al. **Arch Virol** 1997;142(2):363–73

MORTALITY

Melatonin reduces mortality from Aleutian disease in mink (Mustela vison). Ellis LC. **J Pineal Res** 1996 Nov; 21(4):214–7

PHYSIOPATHOLOGY

Progression of Aleutian disease in natural and experimentally induced infections of mink. Jackson MK, et al. **Am J Vet Res** 1996 Dec;57(12):1753–8

PREVENTION & CONTROL

Melatonin reduces mortality from Aleutian disease in mink (Mustela vison). Ellis LC. **J Pineal Res** 1996 Nov; 21(4):214–7

VIROLOGY

S–phase–dependent cell cycle disturbances caused by Aleutian mink disease parvovirus. Oleksiewicz MB, et al. **J Virol** 1997 Feb;71(2):1386–96

ALEUTIAN MINK DISEASE VIRUS

Aleutian mink disease parvovirus infection of K562 cells is antibody–dependent and is mediated via an Fc(gamma)RII receptor. Dworak LJ, et al. **Arch Virol** 1997;142(2):363–73

GENETICS

Sequence analysis of the lymphotropic Aleutian disease parvovirus ADV–SL3. Schuierer S, et al. **Arch Virol** 1997; 142(1):157–66
Two parvoviruses that cause different diseases in mink have different transcription patterns: transcription analysis of mink enteritis virus and Aleutian mink disease parvovirus in the same cell line. Storgaard T, et al. **J Virol** 1997 Jul; 71(7):4990–6

IMMUNOLOGY

Expression of Aleutian mink disease parvovirus capsid proteins in defined segments: localization of immunoreactive sites and neutralizing epitopes to specific regions. Bloom ME, et al. **J Virol** 1997 Jan;71(1):705–14

ISOLATION & PURIFICATION

Progression of Aleutian disease in natural and experimentally induced infections of mink. Jackson MK, et al. **Am J Vet Res** 1996 Dec;57(12):1753–8

PHYSIOLOGY

S–phase–dependent cell cycle disturbances caused by Aleutian mink disease parvovirus. Oleksiewicz MB, et al. **J Virol** 1997 Feb;71(2):1386–96

ALEUTS see **ESKIMOS**

ALEXIA see **DYSLEXIA, ACQUIRED**

ALEXITHYMIA see **AFFECTIVE SYMPTOMS**

ALFALFA

Pancreatic and extra–pancreatic effects of the traditional anti–diabetic plant, Medicago sativa (lucerne). Gray AM, et al. **Br J Nutr** 1997 Aug;78(2):325–34
Chewing activities and milk production of dairy cows fed alfalfa as hay, silage, or dried cubes of hay or silage. Beauchemin KA, et al. **J Dairy Sci** 1997 Feb;80(2):324–33
Synthesis of microbial protein in ruminally cannulated cows fed alfalfa silage, alfalfa hay, or corn silage. Hristov AN, et al. **J Dairy Sci** 1996 Sep;79(9):1627–37
Kinetics of cell–wall digestion of orchardgrass and alfalfa silages treated with cellulase and formic acid. Nadeau EM, et al. **J Dairy Sci** 1996 Dec;79(12):2207–16
Components of growth in Holstein heifers fed either alfalfa or corn silage diets to produce two daily gains. Waldo DR, et al. **J Dairy Sci** 1997 Aug;80(8):1674–84
[The effect of wheat bran and green meal supplements on vitamin B6 metabolism of sows fed suboptimal vitamin B6 supply] Roth–Maier DA, et al. **Arch Tierernahr** 1997; 50(2):155–62 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Primary photosensitization related to ingestion of alfalfa silage by cattle. House JK, et al. **J Am Vet Med Assoc** 1996 Nov 1;209(9):1604–7
Histopathological changes in the reproductive organs of Manchego ewes grazing on lucerne. Cantero A, et al. **Zentralbl Veterinarmed A** 1996 Aug;43(6):325–30

CHEMISTRY

Antifungal and hemolytic activity of aerial parts of alfalfa (Medicago) species in relation to saponin composition. Jurzysta M, et al. **Adv Exp Med Biol** 1996;404:565–74
Saponins from alfalfa, clover, and mungbeans analyzed by electrospray ionization–mass spectrometry as compared with positive and negative FAB–mass spectrometry. Lee MK, et al. **Adv Exp Med Biol** 1996;405:353–64
Alfalfa saponins: structure, biological activity, and chemotaxonomy. Oleszek W. **Adv Exp Med Biol** 1996; 405:155–70 (85 ref.)
Saponins from Medicago Spp.: chemical characterization and biological activity against insects. Tava A, et al. **Adv Exp Med Biol** 1996;405:97–109 (42 ref.)
Chemistry and biological activity of triterpenoid glycosides

ALFALFA

from Medicago sativa. Timbekova AE, et al. **Adv Exp Med Biol** 1996;405:171–82 (19 ref.)

Liquid secondary ion mass spectrometry and linked scanning at constant B/ELSIMS/MS for structure confirmation of saponins in Medicago sativa (alfalfa). West PR, et al. **Adv Exp Med Biol** 1996;405:339–52

Effect of storage temperature and time on fiber content of fresh and ensiled alfalfa. Nelson ML, et al. **J Anim Sci** 1996 Jul;74(7):1689–93

Malate content of forage varieties commonly fed to cattle. Callaway TR, et al. **J Dairy Sci** 1997 Aug;80(8):1651–5

Purification and characterization of ferritin from alfalfa seeds. Barceló F, et al. **J Inorg Biochem** 1997 Apr;66(1):23–7

Stimulation of pancreatic lipase activity by saponins isolated from Medicago sativa L. Sroka Z, et al. **Z Naturforsch [C]** 1997 Mar–Apr;52(3–4):235–9

EMBRYOLOGY

Characterization of somatic embryogenesis–related cDNAs from alfalfa (Medicago sativa L.). Giroux RW, et al. **Plant Mol Biol** 1997 Feb;33(3):393–404

ENZYMOLOGY

Affinity chromatography, substrate/product specificity, and amino acid sequence analysis of an isoflavone O–methyltransferase from alfalfa (Medicago sativa L.). He XZ, et al. **Arch Biochem Biophys** 1996 Dec 1;336(1):121–9

Cell cycle phase specificity of putative cyclin–dependent kinase variants in synchronized alfalfa cells. Magyar Z, et al. **Plant Cell** 1997 Feb;9(2):223–35

A carbonic anhydrase gene is induced in the nodule primordium and its cell–specific expression is controlled by the presence of Rhizobium during development. Coba de la Peña T, et al. **Plant J** 1997 Mar;11(3):407–20

Analyses of phosphoenolpyruvate carboxylase gene structure and expression in alfalfa nodules. Pathirana MS, et al. **Plant J** 1997 Aug;12(2):293–304

GENETICS

A cell cycle–regulated histone H3 gene of alfalfa with an atypical promoter structure. Robertson AJ, et al. **DNA Seq** 1997;7(3–4):209–16

Metabolic engineering: prospects for crop improvement through the genetic manipulation of phenylpropanoid biosynthesis and defense responses—a review. Dixon RA, et al. **Gene** 1996 Nov 7;179(1):61–71 (80 ref.)

Genetic markers and quantitative genetic variation in Medicago truncatula (Leguminosae): a comparative analysis of population structure. Bonnin I, et al. **Genetics** 1996 Aug;143(4):1795–805

A moderately repetitive DNA sequence in alfalfa is transcribed in a floral–specific manner. Xia X, et al. **Genome** 1996 Feb;39(1):9–16

Evolutionary diversity of symbiotically induced nodule MADS box genes: characterization of nmhC5, a member of a novel subfamily. Heard J, et al. **Mol Plant Microbe Interact** 1997 Jul;10(5):665–76

Nitrogen assimilation in alfalfa: isolation and characterization of an asparagine synthetase gene showing enhanced expression in root nodules and dark–adapted leaves. Shi L, et al. **Plant Cell** 1997 Aug;9(8):1339–56

Analyses of phosphoenolpyruvate carboxylase gene structure and expression in alfalfa nodules. Pathirana MS, et al. **Plant J** 1997 Aug;12(2):293–304

A novel gene whose expression in Medicago truncatula roots is suppressed in response to colonization by vesicular–arbuscular mycorrhizal (VAM) fungi and to phosphate nutrition. Burleigh SH, et al. **Plant Mol Biol** 1997 May;34(2):199–208

Characterization of somatic embryogenesis–related cDNAs from alfalfa (Medicago sativa L.). Giroux RW, et al. **Plant Mol Biol** 1997 Feb;33(3):393–404

Expression of a novel–type small proline–rich protein gene of alfalfa is induced by 2,4–dichlorophenoxiacetic acid in dedifferentiated callus cells. Györgyey J, et al. **Plant Mol Biol** 1997 Jul;34(4):593–602

Cloning of a WD–repeat–containing gene from alfalfa (Medicago sativa): a role in hormone–mediated cell division? McKhann HI, et al. **Plant Mol Biol** 1997 Jul; 34(5):771–80

Isolation of pathogen/stress–inducible cDNAs from alfalfa by mRNA differential display. Truesdell GM, et al. **Plant Mol Biol** 1997 Mar;33(4):737–43

Cloning and characterization of PO22, a pollen–expressed gene in alfalfa. Wu Y, et al. **Plant Mol Biol** 1996 Dec; 32(6):1205–7

PO149, a new member of pollen pectate lyase–like gene family from alfalfa. Wu Y, et al. **Plant Mol Biol** 1996 Dec; 32(6):1037–42

Stress signaling in plants: a mitogen–activated protein kinase pathway is activated by cold and drought. Jonak C, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):11274–9

Half tetrad analysis in alfalfa using multiple restriction fragment length polymorphism markers. Tavoletti S, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10918–22

GROWTH & DEVELOPMENT

The Rhizobium meliloti PII protein, which controls bacterial nitrogen metabolism, affects alfalfa nodule development. Arcondéguy T, et al. **Genes Dev** 1997 May 1;11(9):1194–206

METABOLISM

Digestibility, apparent mineral absorption, and voluntary intake by horses fed alfalfa, tall fescue, and caucasian bluestem. Crozier JA, et al. **J Anim Sci** 1997 Jun; 75(6):1651–8

Use of green fluorescent protein to visualize the early events of symbiosis between Rhizobium meliloti and alfalfa (Medicago sativa). Gage DJ, et al. **J Bacteriol** 1996 Dec; 178(24):7159–66

Protein degradation in response to spontaneous heating in alfalfa hay by in situ and ficin methods. Coblentz WK, et al. **J Dairy Sci** 1997 Apr;80(4):700–13

Nitrogen assimilation in alfalfa: isolation and characterization of an asparagine synthetase gene showing enhanced expression in root nodules and dark–adapted leaves. Shi L, et al. **Plant Cell** 1997 Aug;9(8):1339–56

15N estimates of dinitrogen fixation in alfalfa–weeping lovegrass swards under field conditions. Lázzari MA, et al. **Rev Argent Microbiol** 1996 Oct–Dec;28(4):175–81

MICROBIOLOGY

Rhizobium meliloti exopolysaccharides: synthesis and symbiotic function. González JE, et al. **Gene** 1996 Nov 7;179(1):141–6 (50 ref.)

The Rhizobium meliloti PII protein, which controls bacterial nitrogen metabolism, affects alfalfa nodule development. Arcondéguy T, et al. **Genes Dev** 1997 May 1;11(9):1194–206

Comparison of chemical treatments to kill Salmonella on alfalfa seeds destined for sprout production. Beuchat LR. **Int J Food Microbiol** 1997 Mar 3;34(3):329–33

Effect of fungal biomass in alfalfa hay on intake and total tract digestion in growing beef calves. Bossuyt CV, et al. **J Anim Sci** 1996 Jun;74(6):1336–42

Effect of fungal biomass in moldy alfalfa hay on preference by dairy calves with no previous exposure to moldy feeds. Undi M, et al. **J Dairy Sci** 1996 Jul;79(7):1250–4

An international outbreak of Salmonella infections caused by alfalfa sprouts grown from contaminated seeds. Mahon BE, et al. **J Infect Dis** 1997 Apr;175(4):876–82

From the Centers for Disease Control and Prevention. Outbreaks of Escherichia coli O157:H7 infection associated with eating alfalfa sprouts—Michigan and Virginia, June–July 1997. **JAMA** 1997 Sep 10;278(10):809–10

The Rhizobium meliloti putA gene: its role in the establishment of the symbiotic interaction with alfalfa. Jiménez–Zurdo JI, et al. **Mol Microbiol** 1997 Jan; 23(1):85–93

Defense reaction in Medicago sativa: a gene encoding a class 10 PR protein is expressed in vascular bundles. Breda C, et al. **Mol Plant Microbe Interact** 1996 Nov;9(8):713–9

PHYSIOLOGY

Low temperature perception in plants: effects of cold on protein phosphorylation in cell–free extracts. Monroy AF, et al. **FEBS Lett** 1997 Jun 30;410(2–3):206–9

Defense reaction in Medicago sativa: a gene encoding a class 10 PR protein is expressed in vascular bundles. Breda C, et al. **Mol Plant Microbe Interact** 1996 Nov;9(8):713–9

Mechanosensors in plants [letter] Bögre L, et al. **Nature** 1996 Oct 10;383(6600):489–90

Differential accumulation of two glycine–rich proteins during cold–acclimation alfalfa. Ferullo JM, et al. **Plant Mol Biol** 1997 Mar;33(4):625–33

A synthetic cryIC gene, encoding a Bacillus thuringiensis delta–endotoxin, confers Spodoptera resistance in alfalfa and tobacco. Strizhov N, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15012–7

STANDARDS

Early–vegetative tall fescue hay vs alfalfa hay as a supplement for cattle consuming low–quality roughages. Horney MR, et al. **J Anim Sci** 1996 Aug;74(8):1959–66

Site and extent of mineral absorption in lactating cows fed whole–crop cereal grain silage of alfalfa silage. Khorasani GR, et al. **J Anim Sci** 1997 Jan;75(1):239–48

Replacement of alfalfa neutral detergent fiber with a combination of nonforage fiber sources. Clark PW, et al. **J Dairy Sci** 1997 Apr;80(4):675–80

ALFALFA MOSAIC VIRUS

GENETICS

Functional equivalence of common and unique sequences in the 3' untranslated regions of alfalfa mosaic virus RNAs 1, 2, and 3. van Rossum CM, et al. **J Virol** 1997 May; 71(5):3811–6

Accumulation of alfalfa mosaic virus RNAs 1 and 2 requires the encoded proteins in cis. van Rossum CM, et al. **J Virol** 1996 Aug;70(8):5100–5

Identification of a competitive translation determinant in the 3' untranslated region of alfalfa mosaic virus coat protein mRNA. Hann LE, et al. **Mol Cell Biol** 1997 Apr; 17(4):2005–13

Comparison of the role of 5' terminal sequences of alfalfa mosaic virus RNAs 1, 2, and 3 in viral RNA replication. Van Rossum CM, et al. **Virology** 1997 Sep 1;235(2):333–41

METABOLISM

Alfalfa mosaic virus strains T6 and 425 differ in their capsid protein. Subr Z, et al. **Acta Virol** 1996 Jun;40(3):147–9

In vitro genetic selection analysis of alfalfa mosaic virus coat protein binding to 3'–terminal AUGC repeats in the viral RNAs. Houser–Scott F, et al. **J Virol** 1997 Mar; 71(3):2310–9

ULTRASTRUCTURE

The structure of alfalfa mosaic virus capsid protein assembled as a T=1 icosahedral particle at 4.0–A resolution. Kumar A, et al. **J Virol** 1997 Oct;71(10):7911–6

ALFAMOVIRUS

GENETICS

Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV–1. Yusibov V, et al. **Proc Natl Acad Sci U S A** 1997 May 27; 94(11):5784–8

PHYSIOLOGY

Tubule–forming capacity of the movement proteins of alfalfa mosaic virus and brome mosaic virus. Kasteel DT, et al. **J Gen Virol** 1997 Aug;78 (Pt 8):2089–93

ALFENTANIL

The effect of topical lignocaine on intubating conditions after propofol–alfentanil induction. Bülow K, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):752–6

A comparison of remifentanil and alfentanil in patients undergoing major abdominal surgery [see comments] Schüttler J, et al. **Anaesthesia** 1997 Apr;52(4):307–17. Comment in: Anaesthesia 1997 Apr;52(4):291–3.

The effect of skin incision followed by alfentanil on catecholamine levels and on the T–wave amplitude of ECG during isoflurane anaesthesia. Annila PA, et al. **Int J Clin Monit Comput** 1995;12(4):205–11

Comparison of intubation conditions under propofol in children—alfentanil vs atracurium. Senel AC, et al. **Middle East J Anesthesiol** 1996 Oct;13(6):605–11

[The need for alfentanyl in total intravenous anesthesia. Comparison between laparoscopic cholecystectomy and subcostal laparotomy] Figueredo–Gaspari E, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):103–7 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Epidural vs. intravenous infusion of alfentanil in the management of postoperative pain following laparotomies. van den Nieuwenhuyzen MC, et al. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1112–8

Effectiveness of a manually controlled infusion scheme of propofol and alfentanil mixture for endotracheal intubation in hypertensive patients: in comparison with thiamylal and nifedipine plus thiamylal. Wei TT, et al. **Acta Anaesthesiol Sin** 1996 Mar;34(1):9–16

Intubation without muscle relaxant: an alternative technique for rapid tracheal intubation. Wong AK, et al. **Anaesth Intensive Care** 1996 Apr;24(2):224–30

Use of alfentanil and propofol for outpatient monitored anesthesia care: determining the optimal dosing regimen. Avramov MN, et al. **Anesth Analg** 1997 Sep;85(3):566–72

Propofol and alfentanil prevent the increase in intraocular pressure caused by succinylcholine and endotracheal intubation during a rapid sequence induction of anesthesia. Zimmerman AA, et al. **Anesth Analg** 1996 Oct;83(4):814–7

Effect of flumazenil on ventilatory drive during sedation with midazolam and alfentanil. Gross JB, et al. **Anesthesiology** 1996 Oct;85(4):713–20

Dose comparison of remifentanil and alfentanil for loss of consciousness. Jhaveri R, et al. **Anesthesiology** 1997 Aug; 87(2):253–9

Bone marrow harvesting using local anaesthesia and PCA–alfentanil: a feasible alternative to general or regional anaesthesia. Sim KM, et al. **Bone Marrow Transplant** 1996 Oct;18(4):787–90

Target–controlled infusion of alfentanil for postoperative analgesia: a feasibility study and pharmacodynamic evaluation in the early postoperative period. Van den Nieuwenhuyzen MC, et al. **Br J Anaesth** 1997 Jan; 78(1):17–23

Use of patient–controlled analgesia in extracorporeal shockwave lithotripsy. Chin CM, et al. **Br J Urol** 1997 Jun;79(6):848–51

Patient maintained alfentanil target–controlled infusion for analgesia during extracorporeal shock wave lithotripsy. Irwin MG, et al. **Can J Anaesth** 1996 Sep;43(9):919–24

Recall after total intravenous anaesthesia due to an equipment misuse [see comments] Tong D, et al. **Can J Anaesth** 1997 Jan;44(1):73–7. Comment in: Can J Anaesth 1997 Jan;44(1):4–8.

Intravenous sedation prior to peribulbar anaesthesia for cataract surgery in elderly patients. Wong DH, et al. **Can J Anaesth** 1996 Nov;43(11):1115–20

Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Scholz J, et al. **Clin Pharmacokinet** 1996 Oct;31(4):275–92 (136 ref.)

Propofol–alfentanil versus fentanyl–midazolam in coronary artery surgery. Collard E, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):869–76

A comparison of the effects of propofol-alfentanil versus isoflurane anesthesia on arterial oxygenation during one-lung ventilation. Reid CW, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):860-3

Propofol and alfentanil for sedation during placement of retrobulbar block for cataract surgery. Yee JB, et al. **J Clin Anesth** 1996 Dec;8(8):623-6

Patient-controlled sedation and analgesia during SWL. Uyar M, et al. **J Endourol** 1996 Oct;10(5):407-10

Ethanol effects on self-administration of alfentanil, cocaine, and nomifensine in rhesus monkeys. Aspen JM, et al. **Psychopharmacology (Berl)** 1997 Apr;130(3):222-7

ADVERSE EFFECTS

Alfentanil mediated activation of epileptiform activity in the electrocorticogram during resection of epileptogenic foci. Keene DL, et al. **Can J Neurol Sci** 1997 Feb;24(1):37-9

[The effect of total intravenous anesthesia with S-(+)-ketamine/propofol on hemodynamic, endocrine and metabolic stress reactions in comparison to alfentanil/propofol in laparotomy] Crozier TA, et al. **Anaesthesist** 1996 Nov;45(11):1015-23 (Eng. Abstr.) **(Ger)**

BLOOD

A sensitive assay for the simultaneous measurement of alfentanil and fentanyl in plasma. Kumar K, et al. **J Pharm Biomed Anal** 1996 Apr;14(6):667-73

METABOLISM

Fentanyl and alfentanil plasma protein binding in preterm and term neonates. Wilson AS, et al. **Anesth Analg** 1997 Feb;84(2):315-8

Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Guitton J, et al. **Biochem Pharmacol** 1997 Jun 1; 53(11):1613-9

PHARMACOKINETICS

Effect of midazolam on development of acute tolerance to alfentanil: the role of pharmacokinetic interactions. Kissin I, et al. **Anesth Analg** 1997 Jul;85(1):182-7

Hepatic disposition of alfentanil and sufentanil in patients undergoing orthotopic liver transplantation. Raucoules-Aimé M, et al. **Anesth Analg** 1997 May; 84(5):1019-24

Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Ahonen J, et al. **Anesthesiology** 1996 Dec;85(6):1246-52

Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Kharasch ED, et al. **Anesthesiology** 1997 Jul;87(1):26-35

The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Kharasch ED, et al. **Anesthesiology** 1997 Jul;87(1):36-50

The cerebral pharmacokinetics of meperidine and alfentanil in conscious sheep. Upton RN, et al. **Anesthesiology** 1997 Jun;86(6):1317-25

Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Scholz J, et al. **Clin Pharmacokinet** 1996 Oct;31(4):275-92 (136 ref.)

Influence of Escherichia coli endotoxin on the pharmacokinetics and respiratory depressant effect of alfentanil in rabbits. Björkman S, et al. **J Pharm Sci** 1996 Jul;85(7):680-4

Pulmonary distribution of alfentanil and sufentanil studied with system dynamics analysis. Boer F, et al. **J Pharmacokinet Biopharm** 1996 Apr;24(2):197-218

Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. Hoke JF, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):226-32

PHARMACOLOGY

Alfentanil, but not amitriptyline, reduces pain, hyperalgesia, and allodynia from intradermal injection of capsaicin in humans. Eisenach JC, et al. **Anesthesiology** 1997 Jun; 86(6):1279-87

Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane, and alfentanil in healthy volunteers. Glass PS, et al. **Anesthesiology** 1997 Apr; 86(4):836-47

The effect of opioids on thermoregulatory responses in humans and the special antishivering action of meperidine. Ikeda T, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:792-8

Synergistic interactions between midazolam and alfentanil in isolated neonatal rat spinal cord. Feng J, et al. **Br J Anaesth** 1996 Sep;77(3):375-80

Psychophysical and electrophysiological responses to experimental pain may be influenced by sedation: comparison of the effects of a hypnotic (propofol) and an analgesic (alfentanil). Petersen-Felix S, et al. **Br J Anaesth** 1996 Aug;77(2):165-71

Effects of alfentanil on cerebral haemodynamics in an experimental model of traumatic brain injury. Souter MJ, et al. **Br J Anaesth** 1997 Jul;79(1):97-102

Alfentanil-mediated analgesia during propofol injection: no evidence for a peripheral action. Wrench IJ, et al. **Br J Anaesth** 1996 Aug;77(2):162-4

A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect. Billard V, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):45-58

The effect of alfentanil on cerebrospinal fluid pressure in human volunteers. Pühringer F, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):211-4

Comparison of alfentanil and fentanyl for anesthesia in short gynecologic procedures. Tan PP, et al. **J Formos Med Assoc** 1996 Jul;95(7):540-4

Influence of Escherichia coli endotoxin on the pharmacokinetics and respiratory depressant effect of alfentanil in rabbits. Björkman S, et al. **J Pharm Sci** 1996 Jul;85(7):680-4

Enhancement of analgesia from systemic opioid in humans by spinal cholinesterase inhibition. Hood DD, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):86-92

Propofol potentiates the depressant effect of alfentanil in isolated neonatal rat spinal cord and blocks naloxone-precipitated hyperresponsiveness. Feng JQ, et al. **Neurosci Lett** 1997 Jun 20;229(1):9-12

THERAPEUTIC USE

Remifentanil compared with alfentanil for ambulatory surgery using total intravenous anesthesia. The Remifentanil/Alfentanil Outpatient TIVA Group. Philip BK, et al. **Anesth Analg** 1997 Mar;84(3):515-21

Tracheal intubation using alfentanil and no muscle relaxant: is the choice of hypnotic important? Stevens JB, et al. **Anesth Analg** 1997 Jun;84(6):1222-6

Alfentanil as procedural pain relief in newborn infants. Saarenmaa E, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Sep;75(2):F103-7

Use of patient-controlled analgesia with alfentanil for burns dressing procedures: a preliminary report of five patients. Sim KM, et al. **Burns** 1996 May;22(3):238-41

High dose alfentanil pre-empts pain after abdominal hysterectomy. Katz J, et al. **Pain** 1996 Nov;68(1):109-18

ALFENTANYL see **ALFENTANIL**

ALGAE

Selective antitumor activity in vitro from marine algae from Japan coasts. Harada H, et al. **Biol Pharm Bull** 1997 May; 20(5):541-6

Sargassum dermatitis. Burnett JW, et al. **Cutis** 1997 Jun; 59(6):303-4

Dietary marine algae promotes efficient deposition of n-3 fatty acids for the production of enriched shell eggs. Herber SM, et al. **Poult Sci** 1996 Dec;75(12):1501-7

CHEMISTRY

Microalgal metabolites: a new perspective. Shimizu Y. **Annu Rev Microbiol** 1996;50:431-65 (135 ref.)

The lifetimes and energies of the first excited singlet states of diadinoxanthin and diatoxanthin: the role of these molecules in excess energy dissipation in algae. Frank HA, et al. **Biochim Biophys Acta** 1996 Dec 18;1277(3):243-52

Sulfated galactans from Australian specimens of the red alga Phacelocarpus peperocarpos (Gigartinales, Rhodophyta). Liao ML, et al. **Carbohydr Res** 1996 Dec 24;296:237-47

Digestive fates of soluble polysaccharides from marine macroalgae: involvement of the colonic microflora and physiological consequences for the host. Michel C, et al. **J Appl Bacteriol** 1996 Apr;80(4):349-69 (170 ref.)

Sterol composition of phaeodactylum tricornutum as influenced by growth temperature and light spectral quality. Véron B, et al. **Lipids** 1996 Sep;31(9):989-94

Utilization of algal polysaccharides by human colonic bacteria, in axenic culture or in association with hydrogenotrophic microorganisms. Rochet V, et al. **Reprod Nutr Dev** 1997;37(2):221-9

Plutonium in fish, algae, and sediments in the Barents, Petshora and Kara Seas. Ikäheimonen TK, et al. **Sci Total Environ** 1997 Aug 25;202(1-3):79-87

First report of pectenotoxin-2 (PTX-2) in algae (Dinophysis fortii) related to seafood poisoning in Europe. Draisci R, et al. **Toxicon** 1996 Aug;34(8):923-35

CYTOLOGY

The role of the cytoskeleton in polarity and morphogenesis of algal cells. Menzel D. **Curr Opin Cell Biol** 1996 Feb; 8(1):38-42 (38 ref.)

DRUG EFFECTS

Effects of 2,4-dichlorophenoxyacetic acid on Kentucky algae: simultaneous laboratory and field toxicity testings. Kobraei ME, et al. **Arch Environ Contam Toxicol** 1996 Nov; 31(4):571-80

Differential toxicity of atrazine to selected freshwater algae. Tang J, et al. **Bull Environ Contam Toxicol** 1997 Oct; 59(4):631-7

Effect of organotin compounds on the growth of the freshwater alga Scenedesmus quadricauda. Fargasová A, et al. **Ecotoxicol Environ Saf** 1996 Jul;34(2):156-9

Effective concentrations of nitrophenolics toward growth yield of selected microalgae and cyanobacteria isolated from soil. Madhavi DR, et al. **Ecotoxicol Environ Saf** 1995 Dec;32(3):205-8

Regulations for combined effects of pollutants: consequences from risk assessment in aquatic toxicology. Altenburger R, et al. **Food Chem Toxicol** 1996 Nov-Dec; 34(11-12):1155-7 (19 ref.)

Halymecins, new antimicroalgal substances produced by fungi isolated from marine algae. Chen C, et al. **J Antibiot (Tokyo)** 1996 Oct;49(10):998-1005

ENZYMOLOGY

Characterization of the alpha and beta-subunits of the F0F1-ATPase from the alga Polytomella spp., a colorless relative of Chlamydomonas reinhardtii. Atteia A, et al. **Biochim Biophys Acta** 1997 Jul 4;1320(3):275-84

Partial purification and characterization of the DNA polymerase from the cyanelles of Cyanophora paradoxa. White MA, et al. **FEBS Lett** 1997 Jun 30;410(2-3):509-14

The D1 C-terminal processing protease of photosystem II from Scenedesmus obliquus. Protein purification and gene characterization in wild type and processing mutants. Trost JT, et al. **J Biol Chem** 1997 Aug 15;272(33):20348-56

GENETICS

The large ribosomal protein gene cluster of a cryptomonad plastid: gene organization, sequence and evolutionary implications. Wang SL, et al. **Biochem Mol Biol Int** 1997 Apr;41(5):1035-44

The actin gene of the glaucocystophyte Cyanophora paradoxa: analysis of the coding region and introns, and an actin phylogeny of eukaryotes. Bhattacharya D, et al. **Curr Genet** 1997 May;31(5):439-46

Ribonuclease-P RNA gene of the plastid chromosome from Cyanophora paradoxa. Shevelev EL, et al. **DNA Res** 1995 Oct 31;2(5):231-4

Use of a deviant mitochondrial genetic code in yellow-green algae as a landmark for segregating members within the phylum. Ehara M, et al. **J Mol Evol** 1997 Aug;45(2):119-24

Algae or protozoa: phylogenetic position of euglenophytes and dinoflagellates as inferred from mitochondrial sequences. Inagaki Y, et al. **J Mol Evol** 1997 Sep; 45(3):295-300

Evolutionary origin of cryptomonad microalgae: two novel chloroplast/cytosol-specific GAPDH genes as potential markers of ancestral endosymbiont and host cell components. Liaud MF, et al. **J Mol Evol** 1997;44 Suppl 1:S28-37

Complete large subunit ribosomal RNA sequences from the heterokont algae Ochromonas danica, Nannochloropsis salina, and Tribonema aequale, and phylogenetic analysis. Van der Auwera G, et al. **J Mol Evol** 1997 Jul;45(1):84-90

Deep-level diagnostic value of the rDNA-ITS region. Hershkovitz MA, et al. **Mol Biol Evol** 1996 Nov; 13(9):1276-95

The fucoxanthin-chlorophyll proteins from a chromophyte alga are part of a large multigene family: structural and evolutionary relationships to other light harvesting antennae. Durnford DG, et al. **Mol Gen Genet** 1996 Dec 13;253(3):377-86

DNA binding and bending by a chloroplast-encoded HU-like protein overexpressed in Escherichia coli. Wu H, et al. **Plant Mol Biol** 1997 May;34(2):339-43

GROWTH & DEVELOPMENT

Simulation of the clonal growth of Bostrychia radicans (Ceramiales-Rhodophyta) using Lindenmayer systems. Collado-Vides L, et al. **Biosystems** 1997;42(1):19-27

Literature review and analysis of biological complexity in model stream ecosystems: influence of size and experimental design. Belanger SE. **Ecotoxicol Environ Saf** 1997 Feb;36(1):1-16 (187 ref.)

ISOLATION & PURIFICATION

Effect of treated sewage on the water quality and phytoplankton populations of Lake Manzala (Egypt) with emphasis on biological assessment of water quality. el-Naggar ME, et al. **New Microbiol** 1997 Jul;20(3):253-76

METABOLISM

Microalgal metabolites: a new perspective. Shimizu Y. **Annu Rev Microbiol** 1996;50:431-65 (135 ref.)

Biodegradation of phenols by the alga Ochromonas danica. Semple KT, et al. **Appl Environ Microbiol** 1996 Apr; 62(4):1265-73

Fatty acid unsaturation in the red alga Porphyridium cruentum. Is the methylene interrupted nature of polyunsaturated fatty acids an intrinsic property of the desaturases? Cohen Z, et al. **Biochim Biophys Acta** 1997 Jan 7;1344(1):59-64

Uptake and elimination of 14C-phenanthrene by the blue mussel Mytilus edulis L. at different algal concentrations. Björk M, et al. **Bull Environ Contam Toxicol** 1996 Jan; 56(1):151-8

Heavy metals in marine algae of the Kuwait coast. Buo-Olayan A, et al. **Bull Environ Contam Toxicol** 1996 Nov;57(5):816-23

Holotranscobalamins in B12 and non B12 requiring prokaryotes and eukaryotes. Baker H, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Apr; 113(4):707-9

Effect of algal food concentration on toxicity of two agricultural pesticides to Daphnia carinata. Barry MJ, et

ALGAE

al. **Ecotoxicol Environ Saf** 1995 Dec;32(3):273–9
Influence of the energy relationships of organic compounds on their specificity toward aquatic organisms. Genoni GP. **Ecotoxicol Environ Saf** 1997 Mar;36(2):99–108
Incorporation of 1–deoxy–D–xylulose into isoprene and phytol by higher plants and algae. Schwender J, et al. **FEBS Lett** 1997 Sep 1;414(1):129–34
Epoxy allylic carbocations as conceptual intermediates in the biogenesis of diverse marine oxylipins. Gerwick WH. **Lipids** 1996 Dec;31(12):1215–31 (73 ref.)
Microorganisms as an alternative source of protein. Kuhad RC, et al. **Nutr Rev** 1997 Mar;55(3):65–75 (60 ref.)
Public health benefits of using algae for simultaneous multiple metal extraction from waters. Pascucci PR, et al. **Rev Environ Health** 1996 Oct–Dec;11(4):205–11 (16 ref.)
Paralytic shellfish poisoning in southern China. Anderson DM, et al. **Toxicon** 1996 May;34(5):579–90
Calcium influx, fertilisation potential and egg activation in Fucus serratus. Roberts S, et al. **Zygote** 1995 Aug; 3(3):191–7

MICROBIOLOGY

[The antilysosomal sign in the microbiological characterization of river algal–bacterial communities] Nemtseva NV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May–Jun; (3):93–6 (Eng. Abstr.) **(Rus)**

PATHOGENICITY

[Microphytic algae in the pathology of the cetaceans] Birkun AA Jr, et al. **Mikrobiol Z** 1997 Mar–Apr;59(2):96–105 (58 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Separate determination of the electrical properties of the tonoplast and the plasmalemma of the giant–celled alga Valonia utricularis: vacuolar perfusion of turgescent cells with nystatin and other agents. Wang J, et al. **J Membr Biol** 1997 Jun 1;157(3):311–21

ULTRASTRUCTURE

N–acetylputrescine as a characteristic constituent of cyanelle peptidoglycan in glaucocystophyte algae. Pfanzagl B, et al. **J Bacteriol** 1996 Dec;178(23):6994–7
Epibiotic microorganisms on copepods and other marine crustaceans. Carman KR, et al. **Microsc Res Tech** 1997 Apr 15;37(2):116–35 (137 ref.)

ALGAE, BLUE–GREEN see **CYANOBACTERIA**

ALGAE, BROWN

CHEMISTRY

Mussels and algae as bioindicators for long–term tendencies of element pollution in marine ecosystems. Ostapczuk P, et al. **Chemosphere** 1997 May;34(9–10):2049–58
Phlorotannins from the brown algae Cystophora torulosa and Sargassum spinuligerum. Glombitza KW, et al. **Nat Toxins** 1997;5(2):58–63
Enhancing effect of polysaccharides from an edible brown alga, Hijikia fusiforme (Hijiki), on release of tumor necrosis factor–alpha from macrophages of endotoxin–nonresponder C3H/HeJ mice. Okai Y, et al. **Nutr Cancer** 1997;27(1):74–9

CYTOLOGY

The role of targeted secretion in the establishment of cell polarity and the orientation of the division plane in Fucus zygotes. Shaw SL, et al. **Development** 1996 Sep; 122(9):2623–30

GENETICS

Putative sigma–70–like promoters in a brown algal mitochondrial genome. Delaroque N, et al. **C R Acad Sci III** 1996 Sep;319(9):763–7
Gene structure of a chlorophyll a/c–binding protein from a brown alga: presence of an intron and phylogenetic implications. Caron L, et al. **J Mol Evol** 1996 Sep; 43(3):270–80
The reverse–transcriptase–like proteins encoded by group II introns in the mitochondrial genome of the brown alga Pylaiella littoralis belong to two different lineages which apparently coevolved with the group II ribosyme lineages. Fontaine JM, et al. **J Mol Evol** 1997 Jan;44(1):33–42

METABOLISM

Polar localization of a dihydropyridine receptor on living Fucus zygotes. Shaw SL, et al. **J Cell Sci** 1996 Feb;109 (Pt 2):335–42

PHYSIOLOGY

The coupling of cyclic GMP and photopolarization of Pelvetia zygotes. Robinson KR, et al. **Dev Biol** 1997 Jul 1;187(1):125–30

VIROLOGY

Comparison of two DNA viruses infecting the marine brown algae Ectocarpus siliculosus and E. fasciculatus. Müller DG, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2329–33

ALGAE, GREEN

CHEMISTRY

A simple procedure for large–scale purification of 9–cis beta–carotene from Dunaliella bardawil. Suzuki T, et al. **Biochem Mol Biol Int** 1996 Aug;39(6):1077–84
Fatty acid composition and chilling resistance in the green alga Caulerpa prolifera (Forrskal) Lamouroux (Chlorophyta, Caulerpales). Terrados J, et al. **Biochem Mol Biol Int** 1996 Aug;39(5):863–9
Identification and characterization of a lower plant Ypt/Rab guanosine dissociation inhibitor (GDI). Beyser K, et al. **FEBS Lett** 1996 Nov 4;396(2–3):298–304
Effect of caulerpenyne, a toxin extracted from Caulerpa taxifolia on mechanisms regulating intracellular pH in sea urchin eggs and sea bream hepatocytes. Galgani I, et al. **J Biochem Toxicol** 1996;11(5):243–50
The cruciated microtubule–associated fibers of the green alga Dunaliella bioculata consist of a 31 kDa SF–assemblin. Lechtreck KF, et al. **J Cell Sci** 1996 Apr;109 (Pt 4):827–35

CYTOLOGY

Actin–based vesicle dynamics and exocytosis during wound wall formation in characean internodal cells. Foissner I, et al. **Cell Motil Cytoskeleton** 1996;35(1):35–48

DRUG EFFECTS

Comparative sensitivity of Selenastrum capricornutum and Lemna minor to sixteen herbicides. Fairchild JF, et al. **Arch Environ Contam Toxicol** 1997 May;32(4):353–7
Effects of organic solvents and solvent–atrazine interactions on two algae, Chlorella vulgaris and Selenastrum capricornutum. El Jay A. **Arch Environ Contam Toxicol** 1996 Jul;31(1):84–90
Environmental impact of land–based pollutants on Izmit Bay (Turkey): short–term algal bioassays and simulation of toxicity distribution in the marine environment. Okay OS, et al. **Arch Environ Contam Toxicol** 1996 Nov;31(4):459–65
Tolerance to mercury chloride in Scenedesmus strains. Capolino E, et al. **Biometals** 1997 Apr;10(2):85–94
Chemotaxis of the unicellular green alga Dunaliella salina and the ciliated Tetrahymena pyriformis—effects of glycine, lysine, and alanine, and their oligopeptides. Kóhidai L, et al. **Biosci Rep** 1996 Dec;16(6):467–76
Quantitative structure–activity relationship study for toxicity of organotin compounds on algae. Huang G, et al. **Bull Environ Contam Toxicol** 1997 Feb;58(2):299–304
Growth rate of Ankistrodesmus falcatus and Scenedesmus bijuga in mixed culture exposed to monocrotophos. Nayak S, et al. **Bull Environ Contam Toxicol** 1996 Sep;57(3):473–9
Effecs of chlorsulfuron on growth of three freshwater species of phytoplankton. Sabater C, et al. **Bull Environ Contam Toxicol** 1997 May;58(5):807–13
Paraquat toxicity to different green algae. Sáenz ME, et al. **Bull Environ Contam Toxicol** 1997 Jun;58(6):922–8
Effects of technical grade and a commercial formulation of glyphosate on algal population growth. Sáenz ME, et al. **Bull Environ Contam Toxicol** 1997 Oct;59(4):638–44
Chronic toxicity of fenitrothion to an algae (Nannochloris oculata), a rotifer (Brachionus calyciflorus), and the cladoceran (Daphnia magna). Ferrando MD, et al. **Ecotoxicol Environ Saf** 1996 Nov;35(2):112–20
Comparison between a normal and a Cr–tolerant strain of Scenedesmus acutus as a food source to Daphnia magna. Gorbi G, et al. **Ecotoxicol Environ Saf** 1996 Nov; 35(2):109–11

ENZYMOLOGY

Identification of a copper–sensitive ascorbate peroxidase in the unicellular green alga Selenastrum capricornutum. Sauser KR, et al. **Biometals** 1997 Jul;10(3):163–8
Biosynthesis of ketocarotenoids in transgenic cyanobacteria expressing the algal gene for beta–C–4–oxygenase, crtO. Harker M, et al. **FEBS Lett** 1997 Mar 10;404(2–3):129–34
A cDNA coding for glutathione S–transferase from the unicellular green algae Coccomyxa sp. Hiltonen T, et al. **Gene** 1996 Oct 17;176(1–2):263–4
An NADP–glutamate dehydrogenase from the green alga Bryopsis maxima. Purification and properties. Inokuchi R, et al. **Plant Cell Physiol** 1997 Mar;38(3):327–35
Primary structure and effect of pH on the expression of the plasma membrane H(+)–ATPase from Dunaliella acidophila and Dunaliella salina. Weiss M, et al. **Plant Physiol** 1996 Dec;112(4):1693–702

GENETICS

Expression of an exogenous isopentenyl diphosphate isomerase gene enhances isoprenoid biosynthesis in Escherichia coli. Kajiwara S, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):421–6
Cell–wall polysaccharides from the marine green alga Ulva "rigida" (Ulvales, Chlorophyta)—NMR analysis of ulvan oligosaccharides. Lahaye M, et al. **Carbohydr Res** 1996 Mar 22;283:161–73
Three abundant germ line–specific transcripts in Volvox carteri encode photosynthetic proteins. Choi G, et al. **Curr Genet** 1996 Sep;30(4):347–55
The apocytochrome–b gene in Chlorogonium elongatum (Chlamydomonadaceae): an intronic GIY–YIG ORF in green algal mitochondria. Kroymann J, et al. **Curr Genet** 1997 May;31(5):414–8
Intron sequences provide a tool for high–resolution phylogenetic analysis of volvocine algae. Liss M, et al. **Curr Genet** 1997 Mar;31(3):214–27
Evolution of the ITS sequences of ribosomal DNA in Enteromorpha (Chlorophyceae). Leskinen E, et al. **Hereditas** 1997;126(1):17–23
The internal transcribed spacer 2 exhibits a common secondary structure in green algae and flowering plants. Mai JC, et al. **J Mol Evol** 1997 Mar;44(3):258–71
Nuclear–encoded rDNA group I introns: origin and phylogenetic relationships of insertion site lineages in the green algae. Bhattacharya D, et al. **Mol Biol Evol** 1996 Sep;13(7):978–89
Fragmented and scrambled mitochondrial ribosomal RNA coding regions among green algae: a model for their origin and evolution. Nedelcu AM. **Mol Biol Evol** 1997 May; 14(5):506–17
Higher ribosomal RNA substitution rates in Bacillariophyceae and Dasycladales than in Mollusca, Echinodermata, and Actinistia–Tetrapoda. Sorhannus U. **Mol Biol Evol** 1996 Sep;13(7):1032–8
A novel homologue of the prokaryotic htrA gene is differentially expressed in the alga Haematococcus pluvialis following stress. Hershkovits G, et al. **Mol Gen Genet** 1997 Apr 28;254(4):345–50
Phytochrome of the green alga Mougeotia: cDNA sequence, autoregulation and phylogenetic position. Winands A, et al. **Plant Mol Biol** 1996 Nov;32(4):589–97
The miniaturized nuclear genome of eukaryotic endosymbiont contains genes that overlap, genes that are cotranscribed, and the smallest known spliceosomal introns. Gilson PR, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23; 93(15):7737–42
Gene replacement by homologous recombination in the multicellular green alga Volvox carteri. Hallmann A, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7469–74
Chloroplast genes are expressed during intracellular symbiotic association of Vaucheria litorea plastids with the sea slug Elysia chlorotica. Mujer CV, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12333–8
Substitution rate calibration of small subunit ribosomal RNA identifies chlorarachniophyte endosymbionts as remnants of green algae. Van de Peer Y, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7732–6

GROWTH & DEVELOPMENT

Effects of technical grade and a commercial formulation of glyphosate on algal population growth. Sáenz ME, et al. **Bull Environ Contam Toxicol** 1997 Oct;59(4):638–44

METABOLISM

Metal accumulation in a biological indicator (Ulva rigida) from the lagoon of Venice (Italy). Favero N, et al. **Arch Environ Contam Toxicol** 1996 Jul;31(1):9–18
Cadmium bioaccumulation in Tetraselmis suecica: an electron energy loss spectroscopy (EELS) study. Nassiri Y, et al. **Arch Environ Contam Toxicol** 1997 Aug;33(2):156–61
Biotransformation of 1–naphthalenesulfonic acid by the green alga Scenedesmus obliquus. Kneifel H, et al. **Arch Microbiol** 1997 Jan;167(1):32–7
Effect of heavy metals on lipids from the freshwater alga Selenastrum capricornutum. Riches CJ, et al. **Biochem Soc Trans** 1996 May;24(2):174S
Differential targeting of closely related ECM glycoproteins: the pherophorin family from Volvox. Godl K, et al. **EMBO J** 1997 Jan 2;16(1):25–34
Selective binding of Ca2+, Zn2+, Cu2+ and K+ by the physodes of the green alga Mougeotia scalaris. Tretyn A, et al. **Folia Histochem Cytobiol** 1996;34(2):103–8
Improved visualization of F–actin in the green alga Acetabularia by microwave–accelerated fixation and simultaneous FITC–Phalloidin staining. Sawitzky H, et al. **Histochem J** 1996 May;28(5):353–60
A structurally novel transferrin–like protein accumulates in the plasma membrane of the unicellular green alga Dunaliella salina grown in high salinities. Fisher M, et al. **J Biol Chem** 1997 Jan 17;272(3):1565–70
Modeling the current–voltage characteristics of Chara membranes: I. The effect of ATP removal and zero turgor. Beilby MJ, et al. **J Membr Biol** 1996 Jan;149(2):89–101
A new route for synthesis of dimethylsulphoniopropionate in marine algae. Gage DA, et al. **Nature** 1997 Jun 26; 387(6636):891–4
Fermentation of green alga sea–lettuce (Ulva sp) and metabolism of its sulphate by human colonic microbiota in a semi–continuous culture system. Durand M, et al. **Reprod Nutr Dev** 1997 May–Jun;37(3):267–83

PHYSIOLOGY

Fatty acid composition and chilling resistance in the green alga Caulerpa prolifera (Forrskal) Lamouroux (Chlorophyta, Caulerpales). Terrados J, et al. **Biochem Mol Biol Int** 1996 Aug;39(5):863–9
Ba2+ ions hyperpolarize algal cell membrane and enhance plasmalemma resistance without affecting ion and water contents. Metlička R, et al. **Gen Physiol Biophys** 1996 Apr;

15(2):175–9
[Mechanisms of calcification and molecular phylogeny of Rubisco genes in coccolithophorid algae] Fujiwara S. **Seikagaku** 1996 Aug;68(8):1445–8 (8 ref.) **(Jpn)**
[Pathogenic Listeria in the soil and in association with algae: a reversible transition into a nonculturable state] Pushkareva VI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 May–Jun;(3):3–6 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Purification and characterization of basal apparatuses from a flagellate green alga. Geimer S, et al. **Cell Motil Cytoskeleton** 1997;37(1):72–85
A plastid of probable green algal origin in Apicomplexan parasites [see comments] Köhler S, et al. **Science** 1997 Mar 7;275(5305):1485–9. Comment in: Science 1997 Mar 7;275(5305):1422.

ALGAE, RED

Health effects associated with algal toxins from seafood. Aune T. **Arch Toxicol Suppl** 1997;19:389–97 (25 ref.)
Two new isomers of domoic acid from a red alga, Chondria armata. Zaman L, et al. **Toxicon** 1997 Feb;35(2):205–12

CHEMISTRY

Extract of the marine alga Prymnesium patelliferum induces release of acetylcholine from cholinergic nerves in the rat bronchial smooth muscle. Meldahl AS, et al. **Acta Physiol Scand** 1996 Feb;156(2):99–107
Isolation of a non-steroidal contragestative agent from Sri Lankan marine red alga, Gelidiella acerosa. Premakumara GA, et al. **Contraception** 1996 Dec;54(6):379–83
Massetolides A–H, antimycobacterial cyclic depsipeptides produced by two pseudomonads isolated from marine habitats. Gerard J, et al. **J Nat Prod** 1997 Mar;60(3):223–9
Cytotoxic oxygenated desmosterols of the red alga Galaxaura marginata. Sheu JH, et al. **J Nat Prod** 1996 Jan;59(1):23–6
Novel oxylipins from the temperate red alga Polyneura latissima: evidence for an arachidonate 9(S)-lipoxygenase. Jiang ZD, et al. **Lipids** 1997 Mar;32(3):231–5
Antiviral activity of Porphyridium cruentum polysaccharide. Minkova K, et al. **Pharmazie** 1996 Mar;51(3):194
[Algae polysaccharides. 51. Study of sulfated galactan of red algae Laurencia coronopus J.Ag. (Rhodophyta, RLhodomelaceae using partially reductive hydrolysis] Usov AI, et al. **Bioorg Khim** 1997 Jun;23(6):505–11 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Red alga terminology [letter; comment] Takahashi H. **Science** 1996 Nov 15;274(5290):1067. Comment on: Science 1996 Jun 28;272(5270):1932–5.

CYTOLOGY

Origin and evolution of mitochondria: what have we learnt from red algae? Leblanc C, et al. **Curr Genet** 1997 Mar; 31(3):193–207 (100 ref.)
Aphidicolin uncouples the chloroplast division cycle from the mitotic cycle in the unicellular red alga Cyanidioschyzon merolae. Itoh R, et al. **Eur J Cell Biol** 1996 Nov;71(3):303–10

ENZYMOLOGY

Ribulose-1,5-bisphosphate carboxylase/oxygenase from thermophilic red algae with a strong specificity for CO2 fixation. Uemura K, et al. **Biochem Biophys Res Commun** 1997 Apr 17;233(2):568–71
Characterization of the substrate binding site of polyenoic fatty acid isomerase, a novel enzyme from the marine alga Ptilota filicina. Wise ML, et al. **Biochemistry** 1997 Mar 11; 36(10):2985–92
Genes for two subunits of succinate dehydrogenase form a cluster on the mitochondrial genome of Rhodophyta. Viehmann S, et al. **Curr Genet** 1996 Jan;29(2):199–201
DNA gyrase involvement in chloroplast-nucleoid division in Cyanidioschyzon merolae. Itoh R, et al. **Eur J Cell Biol** 1997 Jul;73(3):252–8
Amino acid sequence homology between N- and C-terminal halves of a carbonic anhydrase in Porphyridium purpureum, as deduced from the cloned cDNA. Mitsuhashi S, et al. **J Biol Chem** 1996 Nov 8;271(45):28703–9

GENETICS

Cloning and sequencing of the gene encoding the plasma membrane H(+)-ATPase from an acidophilic red alga, Cyanidium caldarium. Ohta H, et al. **Biochim Biophys Acta** 1997 Mar 28;1319(1):9–13
Genes for two subunits of succinate dehydrogenase form a cluster on the mitochondrial genome of Rhodophyta. Viehmann S, et al. **Curr Genet** 1996 Jan;29(2):199–201
Hexose oxidase from the red alga Chondrus crispus. Purification, molecular cloning, and expression in Pichia pastoris. Hansen OC, et al. **J Biol Chem** 1997 Apr 25; 272(17):11581–7
A 5 S rRNA gene is present in the mitochondrial genome of the protist Reclinomonas americana but is absent from red algal mitochondrial DNA. Lang BF, et al. **J Mol Biol** 1996 Sep 6;261(5):407–13
LhcaR1 of the red alga Porphyridium cruentum encodes a polypeptide of the LHCI complex with seven potential chlorophyll a-binding residues that are conserved in most LHCs. Tan S, et al. **Plant Mol Biol** 1997 Jan;33(1):157–67
A model for the evolution of the plastid sec apparatus inferred from secY gene phylogeny. Vogel H, et al. **Plant Mol Biol** 1996 Nov;32(4):685–92
The origin of red algae: implications for plastid evolution. Stiller JW, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29; 94(9):4520–5

METABOLISM

Biosynthesis of eicosapentaenoic acid in the microalga Porphyridium cruentum. I: The use of externally supplied fatty acids. Shiran D, et al. **Lipids** 1996 Dec;31(12):1277–82
LhcaR1 of the red alga Porphyridium cruentum encodes a polypeptide of the LHCI complex with seven potential chlorophyll a-binding residues that are conserved in most LHCs. Tan S, et al. **Plant Mol Biol** 1997 Jan;33(1):157–67
Aplysiatoxin and debromoaplysiatoxin as the causative agents of a red alga Gracilaria coronopifolia poisoning in Hawaii. Nagai H, et al. **Toxicon** 1996 Jul;34(7):753–61

PHYSIOLOGY

Eukaryotic interference with homoserine lactone-mediated prokaryotic signalling. Givskov M, et al. **J Bacteriol** 1996 Nov;178(22):6618–22

ALGAL VIRUSES see **PHYCODNAVIRIDAE**

ALGESTONE ACETOPHENIDE

ADMINISTRATION & DOSAGE

Dihydroxyprogesterone acetophenide 150 mg + estradiol enantate 10 mg as monthly injectable contraceptives. Jarquín González JD, et al. **Adv Contracept** 1996 Sep; 12(3):213–25

ADVERSE EFFECTS

Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate. Coutinho EM, et al. **Contraception** 1997 Mar;55(3):175–81

ALGINATES

see related
DENTAL IMPRESSION MATERIALS

Adult human chondrocytes cultured in alginate form a matrix similar to native human articular cartilage. Häuselmann HJ, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):C742–52
Oxygen diffusivity in calcium alginate gel beads containing Gluconobacter suboxydans. Mehmetoglu U, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1996 Mar; 24(2):91–106
Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor-bearing rats. Kitazawa H, et al. **Biol Pharm Bull** 1997 Mar; 20(3):278–81
Effect of the alginate composition on the biocompatibility of alginate-polylysine microcapsules. De Vos P, et al. **Biomaterials** 1997 Feb;18(3):273–8
Novel alginate sponges for cell culture and transplantation. Shapiro L, et al. **Biomaterials** 1997 Apr;18(8):583–90
Influence of carboxylate ions containing polymers on calcification: in vitro study. Smetana K Jr, et al. **Biomaterials** 1996 Aug;17(16):1563–6
Collagen-coated Ba(2+)-alginate microcarriers for the culture of anchorage-dependent mammalian cells. Gröhn P, et al. **Biotechniques** 1997 May;22(5):970–5
Application of alginate gel as a vehicle for liposomes. II. Erosion of alginate gel beads and the release of loaded liposomes. Takagi I, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb;45(2):389–93
Transplantation of parathyroid tissue in experimental hypoparathyroidism: in vitro and in vivo function of parathyroid tissue microencapsulated with a novel amitogenic alginate. Hasse C, et al. **Int J Artif Organs** 1996 Dec;19(12):735–41
Non-decay type fast-setting calcium phosphate cement: hydroxyapatite putty containing an increased amount of sodium alginate. Ishikawa K, et al. **J Biomed Mater Res** 1997 Sep 5;36(3):393–9
Development and characterization of an alginate-impregnated polyester vascular graft. Lee JH, et al. **J Biomed Mater Res** 1997 Aug;36(2):200–8
Retention of trypsin activity in spermine alginate microcapsules. Patil RT, et al. **J Microencapsul** 1997 Jul–Aug;14(4):469–74
Iloprost in alginate decreases the thrombogenicity of expanded polytetrafluoroethylene. Viscardi PJ, et al. **J Reconstr Microsurg** 1997 May;13(4):303–6
Acrylic cranioplasty with alginate molding: technical note. Yamamoto Y, et al. **Neurosurgery** 1997 Jul;41(1):305–6; discussion 306–9
Microencapsulation for cell implants into the central nervous system: the importance of alginate viscosity and related factors. Chen ZP, et al. **Stereotact Funct Neurosurg** 1996; 66(1–3):141–6
Effects of alginate/polyaminoacidic coherent microcapsule transplantation in adult pigs. Calafiore R, et al. **Transplant Proc** 1997 Jun;29(4):2126–7
15-Deoxyspergualin attenuates pericapsular cellular infiltration and prolongs survival of alginate-poly-L-lysine-alginate microencapsulated islets. Hsu BR, et al. **Transplant Proc** 1997 Jun;29(4):2158–60
The plasminogen-plasmin fibrinolytic system accelerates degradation of alginate-poly-L-lysine-alginate microcapsules in vitro. Hsu BR, et al. **Transplant Proc** 1997 May;29(3):1877–80
Development of biocompatible barium alginate microcapsules. Petruzzo P, et al. **Transplant Proc** 1997 Jun; 29(4):2129–30
Permeability characteristics of microencapsulated pancreatic islets. Woods EJ, et al. **Transplant Proc** 1997 Jun;29(4):2148
Assessment of the protective effect of uncoated alginate microspheres. Wu JX, et al. **Transplant Proc** 1997 Jun; 29(4):2146–7
Factors influencing the adequacy of microencapsulation of rat pancreatic islets. De Vos P, et al. **Transplantation** 1996 Oct 15;62(7):888–93
[Amitogenic alginate--the key to first clinical use of the microencapsulation technology] Hasse C, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:755–9 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Hoffmann J, et al. **Cancer Res** 1997 Sep 1;57(17):3847–51
Successful treatment of toxic epidermal necrolysis with calcium sodium alginate fiber [letter] Imamura Y, et al. **Int J Dermatol** 1996 Nov;35(11):834–5
Oral immunization of rabbits against Pasteurella multocida with an alginate microsphere delivery system. Suckow MA, et al. **J Biomater Sci Polym Ed** 1996;8(2):131–9

ANALYSIS

Distribution of DNA and alginate in purulent cystic fibrosis sputum: implications to pulmonary targeting strategies. Mrsny RJ, et al. **J Drug Target** 1996;4(4):233–43

CHEMISTRY

Characterisation of alginates from mucoid strains of Pseudomonas aeruginosa. Tatnell PJ, et al. **Biochem Soc Trans** 1996 Aug;24(3):404S
Colonisation of cystic fibrosis patients by non-mucoid Pseudomonas aeruginosa--characterisation of the alginate from mucoid variants. Tatnell PJ, et al. **Biochem Soc Trans** 1996 Aug;24(3):406S
Expression of the Klebsiella pneumoniae alginate lyase gene in Pseudomonas aeruginosa--effect on alginate structure. Tatnell PJ, et al. **Biochem Soc Trans** 1996 Aug;24(3):407S
NMR spectroscopy analysis of oligoguluronates and oligomannuronates prepared by acid or enzymatic hydrolysis of homopolymeric blocks of alginic acid. Application to the determination of the substrate specificity of Haliotis tuberculata alginate lyase. Heyraud A, et al. **Carbohydr Res** 1996 Aug 19;289:11–23
Application of alginate gel as a vehicle for liposomes. I. Factors affecting the loading of drug-containing liposomes and drug release. Takagi I, et al. **Chem Pharm Bull (Tokyo)** 1996 Oct;44(10):1941–7
X-ray diffraction study of crystalline phases of calcium sulphate in alginate impression materials. Anastassiadou V, et al. **Eur J Oral Sci** 1996 Oct-Dec;104(5–6):637–40
Utilization of DNA as functional materials: preparation of filters containing DNA insolubilized with alginic acid gel. Iwata K, et al. **Int J Biol Macromol** 1996 Feb; 18(1–2):149–50
Effect of cellulose derivatives on alginate microspheres prepared by emulsification. Chan LW, et al. **J Microencapsul** 1997 Sep–Oct;14(5):545–55
Prolonged retention of cross-linked trypsin in calcium alginate microspheres. Chui WK, et al. **J Microencapsul** 1997 Jan–Feb;14(1):51–61
Production of BCG alginate-PLL microcapsules by emulsification/internal gelation. Esquisabel A, et al. **J Microencapsul** 1997 Sep–Oct;14(5):627–38
Coating alginate beads with cross-linked biopolymers: a novel method based on a transacylation reaction. Levy MC, et al. **J Microencapsul** 1996 Mar–Apr;13(2):169–83
A method to attach lectins to the surface of spermine alginate microcapsules based on the avidin biotin interaction. Sultzbaugh KJ, et al. **J Microencapsul** 1996 Jul–Aug; 13(4):363–76
Alginate as a displacer for protein displacement chromatography. Chen G, et al. **J Mol Recognit** 1996 Sep–Dec;9(5–6):415–25
Effects of long-term storage on properties of an alginate impression material. Hondrum SO, et al. **J Prosthet Dent** 1997 Jun;77(6):601–6
Diffusion of solutes in agarose and alginate gels: 1H and 23Na PFGSE and 23Na TQF NMR studies. Lundberg P, et al. **Magn Reson Med** 1997 Jan;37(1):44–52
Thermodynamic approach to the selection of polyuronide sequestrants for preventive and medicinal nutrition. Braudo

ALGINATES

EE, et al. **Nahrung** 1996 Aug;40(4):205–8

Rheological characterization of cellulosic and alginate polymers. Duggirala S, et al.
PDA J Pharm Sci Technol 1996 Sep–Oct;50(5):290–6

Buffer uptake and mass loss characteristics of freeze-dried cellulosic and alginate devices. Duggirala S, et al.
PDA J Pharm Sci Technol 1996 Sep–Oct;50(5):297–305

Ion transport studies in calcium alginate gels by magnetic resonance microscopy. Potter K, et al.
Solid State Nucl Magn Reson 1996 Jul;6(4):323–31

DIAGNOSTIC USE

Quantitative microbiology in the management of burn patients. I. Correlation between quantitative and qualitative burn wound biopsy culture and surface alginate swab culture. Steer JA, et al. **Burns** 1996 May;22(3):173–6

Quantitative microbiology in the management of burn patients. II. Relationship between bacterial counts obtained by burn wound biopsy culture and surface alginate swab culture, with clinical outcome following burn surgery and change of dressings. Steer JA, et al. **Burns** 1996 May; 22(3):177–81

Removable prosthesis [letter; comment] Zakaria S.
J Am Dent Assoc 1997 Mar;128(3):271. Comment on: J Am Dent Assoc 1996 Dec;127(12):1786.

HISTORY

Centenary year of scientific papers in the British Dental Journal. Braden M. **Br Dent J** 1997 Feb 8;182(3):112–3

ISOLATION & PURIFICATION

Biocompatibility of mannuronic acid-rich alginates. Klöck G, et al. **Biomaterials** 1997 May;18(10):707–13

METABOLISM

HPLC analysis of saturated or unsaturated oligoguluronates and oligomannuronates. Application to the determination of the action pattern of Haliotis tuberculata alginate lyase. Heyraud A, et al. **Carbohydr Res** 1996 Sep 23;291:115–26

Glucose stimulates alginate production and algD transcription in Pseudomonas aeruginosa. Ma JF, et al.
FEMS Microbiol Lett 1997 Mar 15;148(2):217–21

Inhibition of Pseudomonas aeruginosa alginate expression by subinhibitory concentrations of antibiotics. Majtán V, et al. **Folia Microbiol (Praha)** 1996;41(1):61–4

Induction of tumor necrosis factor production from monocytes stimulated with mannuronic acid polymers and involvement of lipopolysaccharide-binding protein, CD14, and bactericidal/permeability-increasing factor. Jahr TG, et al. **Infect Immun** 1997 Jan;65(1):89–94

DNA–alginate complex recognized by autoantibodies against DNA. Kitamura H, et al. **Int J Biol Macromol** 1997 Feb; 20(1):75–7

Fumarase C activity is elevated in response to iron deprivation and in mucoid, alginate-producing Pseudomonas aeruginosa: cloning and characterization of fumC and purification of native fumC. Hassett DJ, et al.
J Bacteriol 1997 Mar;179(5):1442–51

An operon containing fumC and sodA encoding fumarase C and manganese superoxide dismutase is controlled by the ferric uptake regulator in Pseudomonas aeruginosa: fur mutants produce elevated alginate levels. Hassett DJ, et al. **J Bacteriol** 1997 Mar;179(5):1452–9

Anaerobic production of alginate by Pseudomonas aeruginosa: alginate restricts diffusion of oxygen. Hassett DJ. **J Bacteriol** 1996 Dec;178(24):7322–5

Characterization of the alginate biosynthetic gene cluster in Pseudomonas syringae pv. syringae. Peñaloza-Vázquez A, et al. **J Bacteriol** 1997 Jul;179(14):4464–72

Mutational analysis of nucleoside diphosphate kinase from Pseudomonas aeruginosa: characterization of critical amino acid residues involved in exopolysaccharide alginate synthesis. Sundin GW, et al. **J Bacteriol** 1996 Dec; 178(24):7120–8

Identification of the algZ gene upstream of the response regulator algR and its participation in control of alginate production in Pseudomonas aeruginosa. Yu H, et al.
J Bacteriol 1997 Jan;179(1):187–93

Effect of gelation conditions and dissolution media on the release of paracetamol from alginate gel beads. Aslani P, et al. **J Microencapsul** 1996 Sep–Oct;13(5):601–14

Chitosan/calcium alginate microcapsules for intestinal delivery of nitrofurantoin. Hari PR, et al.
J Microencapsul 1996 May–Jun;13(3):319–29

Modulation of protein release from chitosan–alginate microcapsules using the pH-sensitive polymer hydroxypropyl methylcellulose acetate succinate. Okhamafe AO, et al. **J Microencapsul** 1996 Sep–Oct; 13(5):497–508

A search for Pseudomonas alginate biosynthesis inhibitors from microbial metabolites [letter] Nakagawa A, et al.
Jpn J Antibiot 1997 Mar;50(3):286–8

Effect of nutrients on alginate synthesis in Azotobacter vinelandii and characterization of the produced alginate. Sabry SA, et al. **Microbiologia** 1996 Dec;12(4):593–8

A novel gene, algK, from the alginate biosynthesis cluster of Pseudomonas aeruginosa. Aarons SJ, et al.
Microbiology 1997 Feb;143 (Pt 2):641–52

The Azotobacter vinelandii gene algJ encodes an outer-membrane protein presumably involved in export of alginate. Rehm BH. **Microbiology** 1996 Apr;142 (Pt 4):873–80

Physiological and biochemical changes accompanying the loss of mucoidy by Pseudomonas aeruginosa. Williams SG, et al. **Microbiology** 1996 Apr;142 (Pt 4):881–8

Influence on Pseudomonas aeruginosa elastase, proteinase and alginate by supra-inhibitory and supra-subinhibitory concentrations of quinolones. Hoštacká A, et al.
Microbios 1996;87(352):141–7

Genetic analysis of the transcriptional arrangement of Azotobacter vinelandii alginate biosynthetic genes: identification of two independent promoters. Lloret L, et al. **Mol Microbiol** 1996 Aug;21(3):449–57

PHARMACOLOGY

Immunological studies of SK2 hybridoma cells microencapsulated with alginate-poly(L)lysine-alginate (APA) membrane following allogeneic transplantation. Okada N, et al. **Biochem Biophys Res Commun** 1997 Jan 23;230(3):524–7

Effect of the alginate composition on the biocompatibility of alginate-polylysine microcapsules. De Vos P, et al.
Biomaterials 1997 Feb;18(3):273–8

Limitations of alginate gels as a culture model for the study of the effects of UVA radiation on human dermal fibroblasts. Le Tallec LP, et al. **Cell Biol Toxicol** 1997 Feb; 13(2):95–102

Stimulation of human keratinocyte growth by alginate oligosaccharides, a possible co-factor for epidermal growth factor in cell culture. Kawada A, et al. **FEBS Lett** 1997 May 12;408(1):43–6

Implication of neutral polysaccharides associated to alginate in inhibition of murine macrophage response to Pseudomonas aeruginosa. Pasquier C, et al.
FEMS Microbiol Lett 1997 Feb 15;147(2):195–202

The alginate reduce the postprandial glycaemic response by forming a gel with dietary calcium in the stomach of the rat. Ohta A, et al. **Int J Vitam Nutr Res** 1997;67(1):55–61

Effects of soluble sodium alginate on cholesterol excretion and glucose tolerance in rats. Kimura Y, et al.
J Ethnopharmacol 1996 Oct;54(1):47–54

Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates. Imai T, et al. **J Pharm Sci** 1997 Feb; 86(2):244–7

Influence of alginate gel entrapment and cryopreservation on survival and xenobiotic metabolism capacity of rat hepatocytes. Guyomard C, et al.
Toxicol Appl Pharmacol 1996 Dec;141(2):349–56

In vitro activation of human lymphocytes by crude and purified alginates. Arita S, et al. **Transplant Proc** 1997 Jun; 29(4):2125

STANDARDS

Improved biocompatibility but limited graft survival after purification of alginate for microencapsulation of pancreatic islets. De Vos P, et al. **Diabetologia** 1997 Mar; 40(3):262–70

THERAPEUTIC USE

Calcium alginate dressings promote healing of split skin graft donor sites. O'Donoghue JM, et al. **Acta Chir Plast** 1997; 39(2):53–5

A dressing for 'road rash' [letter] La Hausse-Brown TP, et al. **Ann R Coll Surg Engl** 1997 Mar;79(2):154

The use of calcium alginate dressings in deep hand burns. Kneafsey B, et al. **Burns** 1996 Feb;22(1):40–3

Effects of calcium alginate on cellular wound healing processes modeled in vitro. Doyle JW, et al.
J Biomed Mater Res 1996 Dec;32(4):561–8

Calcium alginate as haemostatic swabs in hip fracture surgery. Davies MS, et al. **J R Coll Surg Edinb** 1997 Feb; 42(1):31–2

ULTRASTRUCTURE

Ultrastructural examination of pancreatic islet containing alginate/polyaminoacidic coherent microcapsules. Basta G, et al. **J Submicrosc Cytol Pathol** 1996 Apr;28(2):209–13

ALGODYSTROPHIC SYNDROME see **REFLEX SYMPATHETIC DYSTROPHY**

ALGOR MORTIS see **POSTMORTEM CHANGES**

ALGORITHMS

Emergency department authorization for health maintenance organizations? Just say no! [letter; comment] Bitterman RA.
Acad Emerg Med 1996 Dec;3(12):1172–6. Comment on: Acad Emerg Med 1996 Apr;3(4):338–44.

Acute myocardial infarction management flowsheet and performance [letter] Dubinsky I, et al.
Acad Emerg Med 1996 Nov;3(11):1073–5

Match algorithms revisited [letter; comment] [see comments] Colenbrander A. **Acad Med** 1996 May;71(5):414–6. Comment on: Acad Med 1996 Apr;71(4):309–12. Comment in: Acad Med 1996 Aug;71(8):814.

Analysis of match algorithms. Colenbrander A.
Acad Med 1996 Oct;71(10 Suppl):S94–6

Volume imaging in fluoroscopy. A clinical prototype system based on a generalized digital tomosynthesis technique. Kolitsi Z, et al. **Acta Radiol** 1996 Sep;37(5):741–8

Determining neutralization serotypes of HIV type 1 by neural networks. Kostrikis LG, et al.
AIDS Res Hum Retroviruses 1996 Dec 10;12(18):1667–9

Routine use of a higher order interpolator and bone algorithm in thoracic CT. Hopper KD, et al.
AJR Am J Roentgenol 1996 Oct;167(4):947–9

Comparison of two algorithms and their associated charges when evaluating adrenal masses in patients with malignancies. Schwartz LH, et al.
AJR Am J Roentgenol 1997 Jun;168(6):1575–8

Outcomes and cost implications of a clinical-based algorithm to guide the discriminate use of stress imaging before noncardiac surgery. Rubin DN, et al. **Am Heart J** 1997 Jul;134(1):83–92

Evaluation of two inversion techniques for retrieving health-related aerosol fractions from personal cascade impactor measurements. Ramachandran G, et al.
Am Ind Hyg Assoc J 1997 Jan;58(1):15–22

Optimal procedures for detecting analytic bias using patient samples. Smith FA, et al. **Am J Clin Pathol** 1997 Sep; 108(3):254–68

Sternal fractures in blunt chest trauma: a practical algorithm for management. Chiu WC, et al. **Am J Emerg Med** 1997 May;15(3):252–5

Development of a patient-focused, interdisciplinary antimicrobial management program involving staff pharmacists. Lacy MK, et al. **Am J Health Syst Pharm** 1997 Aug 15;54(16):1837–41

Development of algorithms for treating patients in the intensive care unit. Maloney M, et al.
Am J Health Syst Pharm 1997 Aug 15;54(16):1841–5

Therapeutic-interchange algorithm for multiple drug classes. Wall DS, et al. **Am J Health Syst Pharm** 1996 Jun 1; 53(11):1295–6

1996 William Allan Award Address. Algorithms and inferences: the challenge of multifactorial diseases. Elston RC. **Am J Hum Genet** 1997 Feb;60(2):255–62

Structural determinants associated with risk of human developmental toxicity. Ghanooni M, et al.
Am J Obstet Gynecol 1997 Apr;176(4):799–805; discussion 805–6

Management of the Zollinger-Ellison syndrome in pregnancy. Stewart CA, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):224–33

Time quantified detection of fetal movements using a new fetal movement algorithm. Lowery CL, et al.
Am J Perinatol 1997 Jan;14(1):7–12

Penetrating injuries of the neck: selective management evolving. Klyachkin ML, et al. **Am Surg** 1997 Feb; 63(2):189–94

The role of ultrasonography in blunt abdominal trauma: a prospective study. McElveen TS, et al. **Am Surg** 1997 Feb; 63(2):184–8

The impact of image-directed core biopsy on the practice of breast surgery: a new algorithm for a changing technology. Stolier AJ, et al. **Am Surg** 1997 Sep; 63(9):827–30

Potential sources of discrepancies between living tissue near infrared spectroscopy algorithms. Macnab AJ, et al.
Anal Biochem 1996 May 1;236(2):375–7

The computer-assisted microscope analysis of Feulgen-stained nuclei linked to a supervised learning algorithm as an aid to prognosis assessment in invasive transitional bladder cell carcinomas. Decaestecker C, et al. **Anal Cell Pathol** 1996 May;10(3):263–80

Comparison of different mathematical algorithms to correct DNA-histograms obtained by measurements on thin liver tissue sections. Mairinger T, et al. **Anal Cell Pathol** 1996 Aug;11(3):159–71

Genetic algorithm-based method for selecting wavelengths and model size for use with partial least-squares regression: application to near-infrared spectroscopy. Bangalore AS, et al. **Anal Chem** 1996 Dec 1;68(23):4200–12

Data-driven approaches to decision making in automated tumor grading. An example of astrocytoma grading. Kolles H, et al. **Anal Quant Cytol Histol** 1996 Aug;18(4):298–304

An algorithm for assessing intraoperative mean arterial pressure lability. Reich DL, et al. **Anesthesiology** 1997 Jul; 87(1):156–61

Compact and accurate linear and nonlinear autoregressive moving average model parameter estimation using laguerre functions. Chon KH, et al. **Ann Biomed Eng** 1997 Jul–Aug; 25(4):731–8

Diagnosis of ectopic pregnancy [letter; comment] Barnhart K, et al. **Ann Emerg Med** 1997 Feb;29(2):295–6. Comment on: Ann Emerg Med 1996 Jul;28(1):10–7.

A new decision rule for parameter delta in MAP EM (OSL) reconstruction with the Gibbs prior. Ogawa K, et al.
Ann Nucl Med 1996 Aug;10(3):299–305

Algorithms used in adverse drug event reports: a comparative study. Frick PA, et al. **Ann Pharmacother** 1997 Feb; 31(2):164–7

Quantitative antisense dose-response relationships: mathematical modeling of antisense action under steady-state conditions. Fennell DA.
Antisense Nucleic Acid Drug Dev 1997 Feb;7(1):49–53

Impact of an algorithm-guided nurse intervention on the use of immunization opportunities. Christy C, et al.
Arch Pediatr Adolesc Med 1997 Apr;151(4):384–91

Industrial rehabilitation medicine. 4. Strategies for disability management. Rondinelli RD, et al.

Arch Phys Med Rehabil 1997 Mar;78(3 Suppl):S21–8 (54 ref.)

Don't care values in induction. Diamantidis N, et al. **Artif Intell Med** 1996 Oct;8(5):505–14

Multiple von Neumann computers: an evolutionary approach to functional emergence. Suzuki H. **Artif Life** 1997 Spring; 3(2):121–42

Adaptation drift suppression in blood glucose self-tuning control. Casanova Domingo JF, et al. **Artif Organs** 1997 Apr;21(4):272–7

A review of electron beam dose calculation algorithms. Keall PJ, et al. **Australas Phys Eng Sci Med** 1996 Sep; 19(3):111–30 (120 ref.)

Visual computation of egomotion using an image interpolation technique. Chahl JS, et al. **Biol Cybern** 1996 May;74(5):405–11

Simulation of nonstationary EEG. Kaipio JP, et al. **Biol Cybern** 1997 May;76(5):349–56

Automatic external defibrillators for public access defibrillation: recommendations for specifying and reporting arrhythmia analysis algorithm performance, incorporating new waveforms, and enhancing safety. A statement for health professionals from the American Heart Association Task Force on Automatic External Defibrillation, Subcommittee on AED and Efficacy. **Biomed Instrum Technol** 1997 May–Jun;31(3):238–44

Critique of arrhythmia detectors based on heuristic rules. Elghazzawi Z, et al. **Biomed Instrum Technol** 1997 May–Jun;31(3):263–71

Dynamical control of the dialysis process. Part II: An improved algorithm for the solution of a tracking problem. Bachhiesl P, et al. **Biomed Tech (Berl)** 1996 Sep;41(9):228, 231–5

A computationally simpler algorithm for the UMVUE of a normal mean following a group sequential trial. Emerson SS, et al. **Biometrics** 1997 Mar;53(1):365–9

General formulas for obtaining the MLEs and the asymptotic variance–covariance matrix in mapping quantitative trait loci when using the EM algorithm. Kao CH, et al. **Biometries** 1997 Jun;53(2):653–65

Subset selection with additional order information. Pan G. **Biometrics** 1996 Dec;52(4):1363–74

A modified EM algorithm for estimation in generalized mixed models. Steele BM. **Biometrics** 1996 Dec;52(4):1295–310

Modeling conception as an aggregated Bernoulli outcome with latent variables via the EM algorithm. Zhou H, et al. **Biometrics** 1996 Sep;52(3):945–54

SIMS: computation of a smooth invariant molecular surface. Vorobjev YN, et al. **Biophys J** 1997 Aug;73(2):722–32

Determination of the secondary structure of isomeric forms of human serum albumin by a particular frequency deconvolution procedure applied to Fourier transform IR analysis. Bramanti E, et al. **Biopolymers** 1996 May; 38(5):639–53

An alternative explanation for the manner in which genetic algorithms operate. Beyer HG. **Biosystems** 1997;41(1):1–15

A self organizing map approach to image quality. Hauske G. **Biosystems** 1997;40(1–2):93–102

Re-evaluating genetic algorithm performance under coordinate rotation of benchmark functions. A survey of some theoretical and practical aspects of genetic algorithms. Salomon R. **Biosystems** 1996;39(3):263–78

The evolution of parallel cellular machines: toward evolware. Sipper M. **Biosystems** 1997;42(1):29–43

Optical design with the aid of a genetic algorithm. van Leijenhorst DC, et al. **Biosystems** 1996;37(3):177–87

Dynamic relationships of trabecular bone density, architecture, and strength in a computational model of osteopenia. Siffert RS, et al. **Bone** 1996 Feb;18(2):197–206

Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors. Paone G, et al. **Br J Cancer** 1997; 75(3):448–50

The ascending neuromodulatory systems in learning by reinforcement: comparing computational conjectures with experimental findings. Pennartz CM. **Brain Res Brain Res Rev** 1995 Nov;21(3):219–45 (235 ref.)

Computational study on the neural mechanism of sequential pattern memory. Morita M. **Brain Res Cogn Brain Res** 1996 Dec;5(1–2):137–46

A non-local gap-penalty for profile alignment. Taylor WR. **Bull Math Biol** 1996 Jan;58(1):1–18

Evaluation of an algorithm for the treatment of persistent diarrhoea: a multicentre study. International Working Group on Persistent Diarrhoea. **Bull World Health Organ** 1996;74(5):479–89

Simple algorithms for the management of genital ulcers: evaluation in a primary health care centre in Kigali, Rwanda. Bogaerts J, et al. **Bull World Health Organ** 1995; 73(6):761–7

A guide to interpreting discordant systematic reviews. Jadad AR, et al. **Can Med Assoc J** 1997 May 15;156(10):1411–6

Validation of a new UNIX-based quantitative coronary angiographic system for the measurement of coronary artery lesions. Bell MR, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):66–74

The lymphomas. Jacobs P, et al. **Cent Afr J Med** 1996 Sep; 42(9):273–80 (117 ref.)

An algorithm for pulmonary screening of military pilots in Israel. Schwarz YA, et al. **Chest** 1997 Apr;111(4):916–21

Practical issues in the management of the patient with small cell lung cancer [published erratum appears in Chest Surg Clin N Am 1997 Aug;7(3):447] Govindan R, et al. **Chest Surg Clin N Am** 1997 Feb;7(1):167–81 (74 ref.)

Future directions in the therapy of small cell lung cancer. Perry MC. **Chest Surg Clin N Am** 1997 Feb;7(1):183–94 (56 ref.)

Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Chen CH, et al. **Circulation** 1997 Apr 1;95(7):1827–36

Automatic external defibrillators for public access defibrillation: recommendations for specifying and reporting arrhythmia analysis algorithm performance, incorporating new waveforms, and enhancing safety. A statement for health professionals from the American Heart Association Task Force on Automatic External Defibrillation, Subcommittee on AED Safety and Efficacy. Kerber RE, et al. **Circulation** 1997 Mar 18;95(6):1677–82

The universal advanced life support algorithm: an advisory statement from the Advanced Life Support Working Group of the International Liaison Committee on Resuscitation. Kloeck W, et al. **Circulation** 1997 Apr 15; 95(8):2180–2

Is computer interpretation of the exercise electrocardiogram a reasonable surrogate for visual reading? Veterans Affairs ACME Investigators. Mickelson JK, et al. **Clin Cardiol** 1997 Apr;20(4):391–7

Diagnostic strategies and test algorithms in liver disease. Black ER. **Clin Chem** 1997 Aug;43(8 Pt 2):1555–60

Design and assessment of average of normals (AON) patient data algorithms to maximize run lengths for automatic process control. Westgard JO, et al. **Clin Chem** 1996 Oct; 42(10):1683–8

Approach to the patient with pulmonary disease. Vander Els NJ, et al. **Clin Chest Med** 1996 Dec;17(4):767–85 (119 ref.)

An algorithmic approach using kappa/lambda ratios to improve the diagnostic accuracy of urine protein electrophoresis and to reduce the volume required for immunoelectrophoresis. Levinson SS. **Clin Chim Acta** 1997 Jun 27;262(1–2):121–30

Investigation of hypoglycaemia. Marks V, et al. **Clin Endocrinol (Oxf)** 1996 Feb;44(2):133–6 (10 ref.)

Strategies for preventing pressure ulcers. Bergstrom NI. **Clin Geriatr Med** 1997 Aug;13(3):437–54 (55 ref.)

Management of vaginal discharge in women treated at a Jamaican sexually transmitted disease clinic: use of diagnostic algorithms versus laboratory testing. Behets FM, et al. **Clin Infect Dis** 1995 Dec;21(6):1450–5

Editorial: how should clinical algorithms be used for syndromic management of cervical and vaginal infections? [editorial] Ryan CA, et al. **Clin Infect Dis** 1995 Dec; 21(6):1456–8

SEOPF high-grade match algorithm: the effect of HLA matching with ROP trays in transplanting highly sensitized patients. Southern Organ Procurement Foundation. Tardif GN, et al. **Clin Transplant** 1996 Dec;10(6 Pt 2):594–7

Calculation of daylength. Amthor JS. **Comput Appl Biosci** 1997 Aug;13(4):479–80

PARODS--a study of parallel algorithms for ordering DNA sequences. Bhandarkar SM, et al. **Comput Appl Biosci** 1996 Aug;12(4):269–80

Sequential and parallel algorithms for DNA sequencing. Blazewicz J, et al. **Comput Appl Biosci** 1997 Apr; 13(2):151–8

Applicability of the multiple alignment algorithm for detection of weak patterns: periodically distributed DNA pattern as a study case. Bolshoy A, et al. **Comput Appl Biosci** 1996 Oct;12(5):383–9

An algorithm to analyse the hydrolysis pathway of peptides and proteins by sequence analyses of unfractionated digestion mixtures. Caporale C, et al. **Comput Appl Biosci** 1996 Apr;12(2):81–8

Correlating patterns in alignments of polymorphic sequences with experimental assays. Chelvanayagam G, et al. **Comput Appl Biosci** 1997 Feb;13(1):13–22

Constraining volume by matching the moments of a distance distribution. Chen CC, et al. **Comput Appl Biosci** 1996 Aug; 12(4):319–26

A probabilistic algorithm for interactive huge genome comparison. Courtois PR, et al. **Comput Appl Biosci** 1995 Dec;11(6):657–65

The role of long-range interactions in defining the secondary structure of proteins is overestimated. Fiser A, et al. **Comput Appl Biosci** 1997 Jun;13(3):297–301

Using a measure of structural variation to define a core for the globins. Gerstein M, et al. **Comput Appl Biosci** 1995 Dec;11(6):633–44

Reduced space sequence alignment. Grice JA, et al. **Comput Appl Biosci** 1997 Feb;13(1):45–53

CONRAD: a method for identification of variable and conserved regions within proteins by scale-space filtering. Herrmann G, et al. **Comput Appl Biosci** 1996 Jun; 12(3):197–203

Objectively judging the quality of a protein structure from a Ramachandran plot. Hooft RW, et al. **Comput Appl Biosci** 1997 Aug;13(4):425–30

A general algorithm to compute multilocus genotype frequencies under various mating systems. Hospital F, et al. **Comput Appl Biosci** 1996 Dec;12(6):455–62

The prediction of vertebrate promoter regions using differential hexamer frequency analysis. Hutchinson GB. **Comput Appl Biosci** 1996 Oct;12(5):391–8

Prediction of protein secondary structure using the 3D-1D compatibility algorithm. Ito M, et al. **Comput Appl Biosci** 1997 Aug;13(4):415–24

Alignment of possible secondary structures in multiple RNA sequences using simulated annealing. Kim J, et al. **Comput Appl Biosci** 1996 Aug;12(4):259–67

An iterative algorithm for converting a class II MHC binding motif into a quantitative predictive model. Mallios RR. **Comput Appl Biosci** 1997 Jun;13(3):211–5

Hamming-Clustering method for signals prediction in 5' and 3' regions of eukaryotic genes. Milanesi L, et al. **Comput Appl Biosci** 1996 Oct;12(5):399–404

Detection of significant patterns by compression algorithms: the case of approximate tandem repeats in DNA sequences. Rivals E, et al. **Comput Appl Biosci** 1997 Apr;13(2):131–6

An algorithm for the detection of surface-active alpha helices with the potential to anchor proteins at the membrane interface. Roberts MG, et al. **Comput Appl Biosci** 1997 Feb; 13(1):99–106

Syntactic recognition of regulatory regions in Escherichia coli. Rosenblueth DA, et al. **Comput Appl Biosci** 1996 Oct; 12(5):415–22

Recognition of 3'-processing sites of human mRNA precursors. Salamov AA, et al. **Comput Appl Biosci** 1997 Feb;13(1):23–8

Predicting RNA H-type pseudoknots with the massively parallel genetic algorithm. Shapiro BA, et al. **Comput Appl Biosci** 1997 Aug;13(4):459–71

An annealing mutation operator in the genetic algorithms for RNA folding. Shapiro BA, et al. **Comput Appl Biosci** 1996 Jun;12(3):171–80

Searching for protein loops in parallel. Sudarsanam S, et al. **Comput Appl Biosci** 1995 Dec;11(6):591–3

Introduction of a distance cut-off into structural alignment by the double dynamic programming algorithm. Toh H. **Comput Appl Biosci** 1997 Aug;13(4):387–96

Image and volume data rotation with 1- and 3-pass algorithms. Tosoni L, et al. **Comput Appl Biosci** 1996 Dec; 12(6):549–52

Protein secondary structure prediction by the analysis of variation and conservation in multiple alignments. Tuckwell DS, et al. **Comput Appl Biosci** 1995 Dec; 11(6):627–32

Elasticities in Metabolic Control Analysis: algebraic derivation of simplified expressions. Woods JH, et al. **Comput Appl Biosci** 1997 Apr;13(2):123–30

A polynomial-time algorithm for a class of protein threading problems. Xu Y, et al. **Comput Appl Biosci** 1996 Dec; 12(6):511–7

Multisolutional clustering and quantization algorithm (MCQ). Dvorchik I, et al. **Comput Biol Med** 1996 Sep;26(5):439–50

Signal processing methods for pulse oximetry. Rusch TL, et al. **Comput Biol Med** 1996 Mar;26(2):143–59

A neuro-fuzzy algorithm for diagnosis of coronary artery stenosis. Sztandera LM, et al. **Comput Biol Med** 1996 Mar; 26(2):97–111

Applying local statistics to detect subtle G-bands in chromosomes. van Bebber G, et al. **Comput Biol Med** 1997 Mar;27(2):169–75

Procedure for estimating the correlation dimension of optokinetic nystagmus signals. Aasen T, et al. **Comput Biomed Res** 1997 Apr;30(2):95–116

Hybrid ultrasonic computed tomography. Azhari H, et al. **Comput Biomed Res** 1997 Feb;30(1):35–48

A Bayesian formulation of the Kalman filter applied to the estimation of individual pharmacokinetic parameters. Botsman K, et al. **Comput Biomed Res** 1997 Apr;30(2):83–94

Probabilistic rule induction from a medical research study database. Clarke EJ, et al. **Comput Biomed Res** 1996 Aug; 29(4):271–83

Measures of uncertainty of pharmacokinetic and pharmacodynamic parameter estimates: a new computerized algorithm. Guzy S, et al. **Comput Biomed Res** 1996 Dec;29(6):466–81

A large-scale processing of kinetic data files with derivation of the inhibitory constant Ki: an application to proline isomerases. Galat A. **Comput Chem** 1996 Jun;20(2):279–81

Non-linear algorithms for processing biological signals. Cerutti S, et al. **Comput Methods Programs Biomed** 1996 Oct;51(1–2):51–73 (40 ref.)

Analysis of pressurized resistance vessel diameter changes with a low cost digital image processing device. Fischer JG, et al. **Comput Methods Programs Biomed** 1996 Jun; 50(1):23–30

Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Freeborough PA, et al. **Comput Methods Programs Biomed** 1997 May;53(1):15–25

A least squares algorithm for estimating epidemiological indices in case-control studies with non-differential misclassification. Marinos AT. **Comput Methods Programs Biomed** 1997 May;53(1):47–55

An algorithm for real-time vessel enhancement and detection. Poli R, et al. **Comput Methods Programs Biomed** 1997 Jan;52(1):1–22

Prediction of polypeptide secondary structures analysing the oscillation of the hydropathy profile. Rauch G, et al. **Comput Methods Programs Biomed** 1995 Dec;48(3):193–200

Add-in macros for rapid and versatile calculation of non-compartmental pharmacokinetic parameters on Microsoft Excel spreadsheets. Sato H, et al. **Comput Methods Programs Biomed** 1996 Jun;50(1):43–52

Implementation of OSPOP, an algorithm for the estimation

of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. Tod M, et al. **Comput Methods Programs Biomed** 1996 Jun;50(1):13–22
Estimation of endogenous glucose production after a glucose perturbation by nonparametric stochastic deconvolution. Vicini P, et al. **Comput Methods Programs Biomed** 1997 Mar;52(3):147–56
Management of paroxysmal atrioventricular nodal reentrant tachycardia in the critically ill surgical patient. Kirton OC, et al. **Crit Care Med** 1997 May;25(5):761–6
Bioelectrical impedance techniques in medicine. Part III: Impedance imaging. Second section: reconstruction algorithms. Morucci JP, et al. **Crit Rev Biomed Eng** 1996; 24(4–6):599–654 (108 ref.)
Proposal of an algorithm to help the choice of the best transfusion strategy. Mercuriali F, et al. **Curr Med Res Opin** 1996;13(8):465–78
Novel methods of sampling phase space in the simulation of biological systems. Berne BJ, et al. **Curr Opin Struct Biol** 1997 Apr;7(2):181–9 (76 ref.)
Sequences and topology challenges for algorithms and experts [editorial] Brutlag DL, et al. **Curr Opin Struct Biol** 1996 Jun;6(3):343–5 (11 ref.)
New method of nuclear grading of tissue sections by means of digital image analysis with prognostic significance for node–negative breast cancer patients. Albert R, et al. **Cytometry** 1996 Jun 1;24(2):140–50
Advances in automated 3–D image analyses of cell populations imaged by confocal microscopy. Ancin H, et al. **Cytometry** 1996 Nov 1;25(3):221–34
Automatic correction of the interfering effect of unsuppressed interspersed repetitive sequences in comparative genomic hybridization analysis. Kirchhoff M, et al. **Cytometry** 1997 Jun 1;28(2):130–4
Applying watershed algorithms to the segmentation of clustered nuclei. Malpica N, et al. **Cytometry** 1997 Aug 1;28(4):289–97
Automation of spot counting in interphase cytogenetics using brightfield microscopy. Vrolijk H, et al. **Cytometry** 1996 Jun 1;24(2):158–66
An algorithmic approach to the differential diagnosis of dementia. Graham JE, et al. **Dementia** 1996 Nov–Dec; 7(6):324–30
A novel algorithm for the search of 5S rRNA genes in DNA databases: comparison with other methods and identification of new potential 5S rRNA genes. Pavesi A, et al. **DNA Seq** 1997;7(3–4):165–77
A digital filterbank hearing aid: predicting user preference and performance for two signal processing algorithms. Lunner T, et al. **Ear Hear** 1997 Feb;18(1):12–25
Computer analysis of two–dimensional electrophoresis gels: a new segmentation and modeling algorithm. Bettens E, et al. **Electrophoresis** 1997 May;18(5):792–8
Evaluation of algorithms used for cross–species proteome characterisation. Cordwell SJ, et al. **Electrophoresis** 1997 Aug;18(8):1410–7
Statistical features in the lakes–straits model and the influence of hernias. Disch C, et al. **Electrophoresis** 1996 Jun; 17(6):1060–4
Data–adaptive algorithms for calling alleles in repeat polymorphisms. Stoughton R, et al. **Electrophoresis** 1997 Jan;18(1):1–5
Automatic matrix determination in four dye fluorescence–based DNA sequencing. Yin Z, et al. **Electrophoresis** 1996 Jun;17(6):1143–50
Using laboratory–based surveillance data for prevention: an algorithm for detecting Salmonella outbreaks. Hutwagner LC, et al. **Emerg Infect Dis** 1997 Jul–Sep;3(3):395–400
Setting exposure standards: a decision process. Tilson HA, et al. **Environ Health Perspect** 1996 Apr;104 Suppl 2:401–5 (23 ref.)
Comparison of 13 published cytochrome c oxidase near–infrared spectroscopy algorithms. Gagnon RE, et al. **Eur J Appl Physiol** 1996;74(6):487–95
An algorithm for the design of epidemiologic studies applied to drug surveillance. Figueiras A, et al. **Eur J Clin Pharmacol** 1997;51(6):445–8
Use of scanner characteristics in iterative image reconstruction for high–resolution positron emission tomography studies of small animals. Brix G, et al. **Eur J Nucl Med** 1997 Jul;24(7):779–86
Validation of a knowledge–based boundary detection algorithm: a multicenter study. Groch MW, et al. **Eur J Nucl Med** 1996 Jun;23(6):662–8
Transmission–based scatter correction of 180 degrees myocardial single–photon emission tomographic studies. Hutton BF, et al. **Eur J Nucl Med** 1996 Oct;23(10):1300–8
A clinical perspective of accelerated statistical reconstruction. Hutton BF, et al. **Eur J Nucl Med** 1997 Jul;24(7):797–808
A new iterative reconstruction technique for attenuation correction in high–resolution positron emission tomography. Knesaurek K, et al. **Eur J Nucl Med** 1996 Jun;23(6):656–61
High–performance computing and networking as tools for accurate emission computed tomography reconstruction. Passeri A, et al. **Eur J Nucl Med** 1997 Apr;24(4):390–7
A non–negative fast multiplicative algorithm in 3D scatter–compensated SPET reconstruction. Walrand SH, et al. **Eur J Nucl Med** 1996 Nov;23(11):1521–6
The oculomotor integrator: testing of a neural network model. Arnold DB, et al. **Exp Brain Res** 1997 Jan; 113(1):57–74
The algorithm of estimation of the Km values for primers in DNA synthesis catalyzed by human DNA polymerase alpha. Kolocheva TI, et al. **FEBS Lett** 1996 Dec 9; 399(1–2):113–6
Optimum superimposition of protein structures: ambiguities and implications. Feng ZK, et al. **Fold Des** 1996;1(2):123–32
Algorithm of diagnostic invasive sonography. Nedeva A. **Folia Med (Plovdiv)** 1996;38(1):9–15
Assessment and comparison of algorithms for in vivo ESR–CT imaging of bioradicals with L–band microwaves. Yuasa T, et al. **Front Med Biol Eng** 1996;7(4):311–30
Wilson's disease in patients presenting with liver disease: a diagnostic challenge [see comments] Steindl P, et al. **Gastroenterology** 1997 Jul;113(1):212–8. Comment in: Gastroenterology 1997 Jul;113(1):348–50. Comment in: Gastroenterology 1997 Jul;113(1):350–3.
Neutral genetic markers and conservation genetics: simulated germplasm collections. Bataillon TM, et al. **Genetics** 1996 Sep;144(1):409–17
Symbolic kinship program. Brenner CH. **Genetics** 1997 Feb; 145(2):535–42
Inferring coalescence times from DNA sequence data. Tavaré S, et al. **Genetics** 1997 Feb;145(2):505–18
Mapping–linked quantitative trait loci using Bayesian analysis and Markov chain Monte Carlo algorithms. Uimari P, et al. **Genetics** 1997 Jun;146(2):735–43
A graph theoretic approach to the analysis of DNA sequencing data. Berno AJ. **Genome Res** 1996 Feb; 6(2):80–91
Linkage map integration. Collins A, et al. **Genomics** 1996 Aug 15;36(1):157–62
Computer–assisted search for sites of nuclear matrix attachment [published erratum appears in Genomics 1996 Jul 1;35(1):273] Kramer JA, et al. **Genomics** 1996 Apr 15; 33(2):305–8
CONTIG EXPLORER: interactive marker–content map assembly. Nadkarni PM, et al. **Genomics** 1996 Feb 1; 31(3):301–10
Management of evolving map data: data structures and algorithms based on the framework map. Nadkarni PM. **Genomics** 1995 Dec 10;30(3):565–73
Verification and comparison of two different predictive equations in Hodgkin's disease. Bettini R, et al. **Haematologica** 1997 May–Jun;82(3):324–7
Apparently normal ankyrin content in unsplenectomized hereditary spherocytosis patients with the inactivation of one ankyrin (ANK1) allele. Miraglia del Giudice E, et al. **Haematologica** 1997 May–Jun;82(3):332–3
An evaluation of Oregon's Medicaid rationing algorithms [editorial] Tengs TO. **Health Econ** 1996 May–Jun; 5(3):171–81 (16 ref.)
Early dose assessment following severe radiation accidents. Goans RE, et al. **Health Phys** 1997 Apr;72(4):513–8
The development of an early extubation algorithm for patients after cardiac surgery. Maxam–Moore VA, et al. **Heart Lung** 1996 Jan–Feb;25(1):61–8
Methods in quantitative image analysis. Oberholzer M, et al. **Histochem Cell Biol** 1996 May;105(5):333–55 (58 ref.)
Management after exposure to tuberculosis. Jordan TJ, et al. **Hosp Pract (Off Ed)** 1997 Jul 15;32(7):73–6, 81–4, 86
Steps in the management of low back pain [see comments] Kuritzky L. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):109–24; discussion 124, 130 (5 ref.). Comment in: Hosp Pract (Off Ed) 1997 Mar 15;32(3):41.
Improving the odds in acute myocardial infarction. Ryan TJ. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):97–113; discussion 117–8, 121
Reduction of computational complexity in the butterfly search technique. Alam SK, et al. **IEEE Trans Biomed Eng** 1996 Jul;43(7):723–33
A novel family of compression algorithms for ECG and other semiperiodical, one–dimensional, biomedical signals. Barlas GD, et al. **IEEE Trans Biomed Eng** 1996 Aug;43(8):820–8
A robust sequential detection algorithm for cardiac arrhythmia classification. Chen SW, et al. **IEEE Trans Biomed Eng** 1996 Nov;43(11):1120–5
Determination of nerve conduction velocity distribution from sampled compound action potential signals. Gu D, et al. **IEEE Trans Biomed Eng** 1996 Aug;43(8):829–38
Estimation of single event–related potentials utilizing the Prony method. Hansson M, et al. **IEEE Trans Biomed Eng** 1996 Oct;43(10):973–81
Selective discrete Fourier transform algorithm for time–frequency analysis: method and application on simulated and cardiovascular signals. Keselbrener L, et al. **IEEE Trans Biomed Eng** 1996 Aug;43(8):789–802
A technique for identifying the total space or temperature dependent thermal parameters (TITP) of biological materials in vivo. Liu J, et al. **IEEE Trans Biomed Eng** 1996 Aug;43(8):847–50
A patient–specific algorithm for the detection of seizure onset in long–term EEG monitoring: possible use as a warning device. Qu H, et al. **IEEE Trans Biomed Eng** 1997 Feb; 44(2):115–22
Estimation of slowly changing components of physiological signals. Raifel M, et al. **IEEE Trans Biomed Eng** 1997 Mar; 44(3):215–20
A real–time microprocessor QRS detector system with a 1–ms timing accuracy for the measurement of ambulatory HRV. Ruha A, et al. **IEEE Trans Biomed Eng** 1997 Mar; 44(3):159–67
Noise covariance incorporated MEG–MUSIC algorithm: a method for multiple–dipole estimation tolerant of the influence of background brain activity. Sekihara K, et al. **IEEE Trans Biomed Eng** 1997 Sep;44(9):839–47
Designing better adaptive sampling algorithms for ECG Holter systems. Tai SC, et al. **IEEE Trans Biomed Eng** 1997 Sep;44(9):901–3
Closed–loop drug infusion for control of heart–rate trajectory in pharmacological stress tests. Valcke CP, et al. **IEEE Trans Biomed Eng** 1997 Mar;44(3):185–95
Efficient computation of amplitude and phase maps in nuclear medicine equilibrium–gated cardiac studies. Vaquero JJ, et al. **IEEE Trans Biomed Eng** 1997 Mar;44(3):213–5
A model for the design and evaluation of algorithms for closed–loop cardiovascular therapy. Woodruff EA, et al. **IEEE Trans Biomed Eng** 1997 Aug;44(8):694–705
A rapid and automatic image registration algorithm with subpixel accuracy. Althof RJ, et al. **IEEE Trans Med Imaging** 1997 Jun;16(3):308–16
Weighted least–squares reconstruction methods for positron emission tomography. Anderson JM, et al. **IEEE Trans Med Imaging** 1997 Apr;16(2):159–65
A general class of preconditioners for statistical iterative reconstruction of emission computed tomography. Chinn G, et al. **IEEE Trans Med Imaging** 1997 Feb;16(1):1–10
Exact and approximate rebinning algorithms for 3–D PET data. Defrise M, et al. **IEEE Trans Med Imaging** 1997 Apr; 16(2):145–58
Grouped–coordinate ascent algorithms for penalized–likelihood transmission image reconstruction. Fessler JA, et al. **IEEE Trans Med Imaging** 1997 Apr; 16(2):166–75
Sampling concerns in scanline algorithms. Fleury M, et al. **IEEE Trans Med Imaging** 1997 Jun;16(3):349–61
A focus–of–attention preprocessing scheme for EM–ML PET reconstruction [letter] Gregor J, et al. **IEEE Trans Med Imaging** 1997 Apr;16(2):218–23
Estimating the bias field of MR images. Guillemaud R, et al. **IEEE Trans Med Imaging** 1997 Jun;16(3):238–51
Expectation maximization reconstruction of positron emission tomography images using anatomical magnetic resonance information. Lipinski B, et al. **IEEE Trans Med Imaging** 1997 Apr;16(2):129–36
Multimodality image registration by maximization of mutual information. Maes F, et al. **IEEE Trans Med Imaging** 1997 Apr;16(2):187–98
The weighted–distance scheme: a globally optimizing projection ordering method for ART [letter] Mueller K, et al. **IEEE Trans Med Imaging** 1997 Apr;16(2):223–30
Statistical approach to segmentation of single–channel cerebral MR images. Rajapakse JC, et al. **IEEE Trans Med Imaging** 1997 Apr;16(2):176–86
A segmentation–based lossless image coding method for high–resolution medical image compression. Shen L, et al. **IEEE Trans Med Imaging** 1997 Jun;16(3):301–7
An optimal rotator for iterative reconstruction [letter] Wallis JW, et al. **IEEE Trans Med Imaging** 1997 Feb;16(1):118–23
A geometric snake model for segmentation of medical imagery. Yezzi A Jr, et al. **IEEE Trans Med Imaging** 1997 Apr;16(2):199–209
A wavelet–based multiresolution regularized least squares reconstruction approach for optical tomography. Zhu W, et al. **IEEE Trans Med Imaging** 1997 Apr;16(2):210–7
An enhanced feature extraction algorithm for EMG pattern classification. Lee SP, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):439–43
A methodology for definition of neuromuscular electrical stimulation sequences: an application toward overcoming small obstacles. Quevedo AA, et al. **IEEE Trans Rehabil Eng** 1997 Mar;5(1):30–9
An evaluation of the application of the genetic algorithm to the problem of ordering genetic loci on human chromosomes using radiation hybrid data. Bansal A, et al. **IMA J Math Appl Med Biol** 1997 Sep;14(3):161–87
Implementation and evaluation of an algorithm for isolation of patients with suspected pulmonary tuberculosis [see comments] Pegues CF, et al. **Infect Control Hosp Epidemiol** 1996 Jul;17(7):412–8. Comment in: Infect Control Hosp Epidemiol 1996 Jul;17(7):409–11.
Infusion rate control algorithms for pharmacokinetic model–driven drug infusion devices. Jacobs JR. **Int Anesthesiol Clin** 1995 Summer;33(3):65–82 (20 ref.)
The mathematical principles of automatic pharmacokinetic infusion controllers. Quill TJ. **Int Anesthesiol Clin** 1995 Summer;33(3):83–9
Prediction of response to acute neuroleptic treatment in schizophrenia. Gaebel W. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:47–54 (31 ref.)
Ab initio tertiary–fold prediction of helical and non–helical protein chains using a genetic algorithm. Dandekar T, et al. **Int J Biol Macromol** 1996 Feb;18(1–2):1–4
Algorithms for robust nonlinear regression with heteroscedastic errors. Tóthfalusi L, et al. **Int J Biomed Comput** 1996 Aug;42(3):181–90
A modified Trigg's Tracking Variable as an 'advisory' alarm during anaesthesia. Kennedy RR. **Int J Clin Monit Comput** 1995;12(4):197–204
Analysis of laser Doppler flux motion in man: comparison of autoregressive modelling and fast Fourier transformation. Weidenhagen R, et al. **Int J Microcirc Clin Exp** 1996 Mar–Apr;16(2):64–73

Using a feed-forward network to incorporate the relation between attractees and attractors in a generalized discrete Hopfield network. Brouwer RK. **Int J Neural Syst** 1996 Jul;7(3):273–86

A low-dimensional, time-resolved and adapting model neuron. Cartling B. **Int J Neural Syst** 1996 Jul;7(3):237–46 (54 ref.)

Probabilistic interpretation of feedforward network outputs, with relationships to statistical prediction of ordinal quantities. Costa M. **Int J Neural Syst** 1996 Nov;7(5):627–37

A neural network based artificial vision system for licence plate recognition. Draghici S. **Int J Neural Syst** 1997 Feb; 8(1):113–26

A regularization term to avoid the saturation of the sigmoids in multilayer neural networks. Garrido L, et al. **Int J Neural Syst** 1996 Jul;7(3):257–62

Analytical interpretation of feed-forward nets outputs after training. Garrido L, et al. **Int J Neural Syst** 1996 Mar; 7(1):19–27

Learning activation rules rather than connection weights. Grundstrom EL, et al. **Int J Neural Syst** 1996 May; 7(2):129–47 (28 ref.)

Determination of dependent and independent communication paths using neural networks. Hemminger TL, et al. **Int J Neural Syst** 1996 Jul;7(3):247–55

Using neural networks to solve the multicast routing problem in packet radio networks. Hemminger TL, et al. **Int J Neural Syst** 1996 Nov;7(5):617–26

Dynamic cell structures for the evaluation of keypoints in facial images. Herpers R, et al. **Int J Neural Syst** 1997 Feb; 8(1):27–39

Control of spatiotemporal chaos in neuronal networks. Lourenço C, et al. **Int J Neural Syst** 1996 Sep;7(4):507–17

An adaptive Boolean automation to model circadian cycles. Perazzo RP, et al. **Int J Neural Syst** 1996 Mar;7(1):83–99 (10 ref.)

Robust feedforward processing in synfire chains. Postma EO, et al. **Int J Neural Syst** 1996 Sep;7(4):537–42

Video sequence compression via supervised training on cellular neural networks. Rodriguez L, et al. **Int J Neural Syst** 1997 Feb;8(1):127–35

LIA: a location-independent transformation for ASOCS adaptive algorithm 2. Rudolph GL, et al. **Int J Neural Syst** 1996 Nov;7(5):639–53

A hybrid classifier for remote sensing applications. Ruppert GS, et al. **Int J Neural Syst** 1997 Feb;8(1):63–8

Growing 3D-SOMs with 2D-input layer as a classification tool in a motion detection system. Seiffert U, et al. **Int J Neural Syst** 1997 Feb;8(1):81–9

Prediction of arterial "burst" activity and transitions between chaotic attractors with a multilayer perceptron optimized by a new stopping criterion. Stamatis N, et al. **Int J Neural Syst** 1996 Sep;7(4):417–28

Neural networks in petroleum engineering: a case study [letter] Vukelic MA, et al. **Int J Neural Syst** 1996 May; 7(2):187–94 (11 ref.)

An automated procedure for cluster analysis of multivariate satellite data. Waldemark J. **Int J Neural Syst** 1997 Feb; 8(1):3–15

A unified neural bigradient algorithm for robust PCA and MCA. Wang L, et al. **Int J Neural Syst** 1996 Mar;7(1):53–67

CNN: a speaker recognition system using a cascaded neural network [letter] Zaki M, et al. **Int J Neural Syst** 1996 May; 7(2):203–12 (29 ref.)

Learning multiple causes by competition enhanced least mean square error reconstruction. Zhang BL, et al. **Int J Neural Syst** 1996 Jul;7(3):223–36

Prediction of conformational states of amino acids using a Ramachandran plot. Kolaskar AS, et al. **Int J Pept Protein Res** 1996 Jan–Feb;47(1–2):110–6

High-throughput purity estimation and characterisation of synthetic peptides by electrospray mass spectrometry. Smart SS, et al. **Int J Pept Protein Res** 1996 Jan–Feb; 47(1–2):47–55

Constructing algorithm flowcharts for clinical performance measurement. Banks NJ. **Int J Qual Health Care** 1996 Aug; 8(4):395–400

Automatic three-dimensional expansion of structures applied to determination of the clinical target volume in conformal radiotherapy. Belshi R, et al. **Int J Radiat Oncol Biol Phys** 1997 Feb 1;37(3):689–96

A numerical simulation of organ motion and daily setup uncertainties: implications for radiation therapy. Killoran JH, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 1; 37(1):213–21

Optimization of permanent 1251 prostate implants using fast simulated annealing. Pouliot J, et al. **Int J Radiat Oncol Biol Phys** 1996 Oct 1;36(3):711–20

Clinical treatment planning optimization by Powell's method for gamma unit treatment system. Yan Y, et al. **Int J Radiat Oncol Biol Phys** 1997 Aug 1;39(1):247–54

Endoscopic surgery teleconferencing. Go PM, et al. **Int Surg** 1996 Jan–Mar;81(1):18–20

Toward determining construct mechanical optimality for fibular bone grafting in femoral head osteonecrosis. Sakamoto J, et al. **Iowa Orthop J** 1996;16:79–87

The early diagnosis of acute myocardial infarction. Comparison of a simple algorithm with a computer program for electrocardiogram interpretation. Tighe M, et al. **Ir J Med Sci** 1996 Jul–Sep;165(3):159–63

A sequence similarity search algorithm based on a probabilistic interpretation of an alignment scoring system. Bucher P, et al. **Ismb** 1996;4:44–51 (25 ref.)

A grammar-based unification of several alignment and folding algorithms. Lefebvre F. **Ismb** 1996;4:143–54

Gene prediction by pattern recognition and homology search. Xu Y, et al. **Ismb** 1996;4:241–51

Failure of standard criteria to diagnose nonemergency ectopic pregnancies in a noninfertility patient population. Diamond MP, et al. **J Am Assoc Gynecol Laparosc** 1994 Feb;1(2):131–4

Use of algorithmic pathways to develop quality, cost-effective clinical care. Khare VK, et al. **J Am Assoc Gynecol Laparosc** 1995 Feb;2(2):169–74

Equations for normalized protein catabolic rate based on two-point modeling of hemodialysis urea kinetics. Depner TA, et al. **J Am Soc Nephrol** 1996 May;7(5):780–5

The utilization of multidimensional scaling to identify forage characteristics associated with preference in sheep. Buntinx SE, et al. **J Anim Sci** 1997 Jun;75(6):1641–50

Submicroscopic mathematical evaluation of spermatozoa in assisted reproduction. 2. In vitro fertilization. (Notulae seminologicae. 7) [published erratum appears in J Assist Reprod Genet 1997 Jan;14(1):65] Piomboni P, et al. **J Assist Reprod Genet** 1996 Sep;13(8):635–46

Numerical analysis of three-dimensional Björk-Shiley valvular flow in an aorta. Shim EB, et al. **J Biomech Eng** 1997 Feb;119(1):45–51

Application of a genetic algorithm in the conformational analysis of methylene-acetal-linked thymine dimers in DNA: comparison with distance geometry calculations. Beckers ML, et al. **J Biomol NMR** 1997 Jan;9(1):25–34

Phase labeling of C-H and C-C spin-system topologies: application in PFG-HACANH and PFG-HACA(CO)NH triple-resonance experiments for determining backbone resonance assignments in proteins. Feng W, et al. **J Biomol NMR** 1996 Jul;8(1):98–104

CICADA interface with AMBER. An application on oligonucleotides and their fragments. Fadrná E, et al. **J Biomol Struct Dyn** 1996 Aug;14(1):137–52

Pair-preferences: a quantitative measure of regularities in protein sequences. Rani M, et al. **J Biomol Struct Dyn** 1996 Jun;13(6):935–44

Improved algorithm for statistical batch-by-batch analysis of corneal topographic data. Vass C, et al. **J Cataract Refract Surg** 1997 Jul–Aug;23(6):903–12

GA strategy for variable selection in QSAR studies: GA-based PLS analysis of calcium channel antagonists. Hasegawa K, et al. **J Chem Inf Comput Sci** 1997 Mar–Apr; 37(2):306–10

META. 3. A genetic algorithm for metabolic transform priorities optimization. Klopman G, et al. **J Chem Inf Comput Sci** 1997 Mar–Apr;37(2):329–34

Automated resonance assignment of proteins using heteronuclear 3D NMR. 2. Side chain and sequence-specific assignment. Li KB, et al. **J Chem Inf Comput Sci** 1997 May–Jun;37(3):467–77

A simple algorithm for superimposing sets of NMR derived structures: its application to the conformational study of cephalomannine in lipophobic and lipophilic solution. Moyna G, et al. **J Chem Inf Comput Sci** 1996 Nov–Dec; 36(6):1224–7

Algorithms for the treatment of affective illness, primary disorder of vigilance, and task-dependent attention disorders (learning disabilities) in children and adolescents. Weinberg WA, et al. **J Child Neurol** 1996 May;11(3):220–7

An overnight insulin infusion algorithm provides morning normoglycemia and can be used to predict insulin requirements in noninsulin-dependent diabetes mellitus. Mao CS, et al. **J Clin Endocrinol Metab** 1997 Aug; 82(8):2466–70

Correction for respiration artifact in pulmonary blood pressure signals of ventilated patients. Hoeksel SA, et al. **J Clin Monit** 1996 Sep;12(5):397–403

An algorithm for real-time, continuous evaluation of left ventricular mechanics by single-beat estimation of arterial and ventricular elastance. Shih H, et al. **J Clin Monit** 1997 May;13(3):157–70

Proposal for classifying the acute emetogenicity of cancer chemotherapy. Hesketh PJ, et al. **J Clin Oncol** 1997 Jan; 15(1):103–9 (69 ref.)

A treatment algorithm for the management of anxiety in primary care practice. Hales RE, et al. **J Clin Psychiatry** 1997;58 Suppl 3:76–80 (24 ref.)

Evolutionary algorithms in computer-aided molecular design. Clark DE, et al. **J Comput Aided Mol Des** 1996 Aug;10(4):337–58 (226 ref.)

Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design. Todorov NP, et al. **J Comput Aided Mol Des** 1997 Mar;11(2):175–92

Optimizing doped libraries by using genetic algorithms. Tomandl D, et al. **J Comput Aided Mol Des** 1997 Jan; 11(1):29–38

A comparison of heuristic search algorithms for molecular docking. Westhead DR, et al. **J Comput Aided Mol Des** 1997 May;11(3):209–28

Genomics via optical mapping. II: Ordered restriction maps. Anantharaman TS, et al. **J Comput Biol** 1997 Summer; 4(2):91–118

ReAligner: a program for refining DNA sequence multi-alignments. Anson EL, et al. **J Comput Biol** 1997 Fall;4(3):369–83

Sequence alignment with tandem duplication. Benson G. **J Comput Biol** 1997 Fall;4(3):351–67

An iterative method for improved protein structural motif recognition. Berger B, et al. **J Comput Biol** 1997 Fall; 4(3):261–73

Parallel computing of physical maps—a comparative study in SIMD and MIMD parallelism. Bhandarkar SM, et al. **J Comput Biol** 1996 Winter;3(4):503–28

Hunting for trees in binary character sets: efficient algorithms for extraction, enumeration, and optimization. Bryant D. **J Comput Biol** 1996 Summer;3(2):275–88

Recent developments in linear-space alignment methods: a survey. Chao KM, et al. **J Comput Biol** 1994 Winter; 1(4):271–91

Statistical modeling, phylogenetic analysis and structure prediction of a protein splicing domain common to inteins and hedgehog proteins. Dalgaard JZ, et al. **J Comput Biol** 1997 Summer;4(2):193–214

Hardness of flip-cut problems from optical mapping. Dančík V, et al. **J Comput Biol** 1997 Summer;4(2):119–25

Protein structure and energy landscape dependence on sequence using a continuous energy function. Dill KA, et al. **J Comput Biol** 1997 Fall;4(3):227–39

Recognizing circular decomposable metrics. Farach M. **J Comput Biol** 1997 Summer;4(2):157–62

Lattice and off-lattice side chain models of protein folding: linear time structure prediction better than 86% of optimal. Hart WE, et al. **J Comput Biol** 1997 Fall;4(3):241–59

Finding genes in DNA with a Hidden Markov Model. Henderson J, et al. **J Comput Biol** 1997 Summer;4(2):127–41

Path costs in evolutionary tree reconstruction. Hochbaum DS, et al. **J Comput Biol** 1997 Summer;4(2):163–75

A six-point condition for ordinal matrices. Kearney PE. **J Comput Biol** 1997 Summer;4(2):143–56

An algorithm for finding maximal common subtopologies in a set of protein structures. Koch I, et al. **J Comput Biol** 1996 Summer;3(2):289–306

On near-optimal alignments of biological sequences. Naor D, et al. **J Comput Biol** 1994 Winter;1(4):349–66

An efficient statistic to detect over- and under-represented words in DNA sequences [comment] Schbath S. **J Comput Biol** 1997 Summer;4(2):189–92. Comment on: J Comput Biol 1996 Fall;3(3):345–60.

The deferred path heuristic for the generalized tree alignment problem. Schwikowski B, et al. **J Comput Biol** 1997 Fall; 4(3):415–31

New flexible approaches for multiple sequence alignment. Shibuya T, et al. **J Comput Biol** 1997 Fall;4(3):385–413

Las Vegas algorithms for gene recognition: suboptimal and error-tolerant spliced alignment. Sze SH, et al. **J Comput Biol** 1997 Fall;4(3):297–309

On the complexity of multiple sequence alignment. Wang L, et al. **J Comput Biol** 1994 Winter;1(4):337–48

A segment-based dynamic programming algorithm for predicting gene structure. Wu TD. **J Comput Biol** 1996 Fall;3(3):375–94

An iterative algorithm for correcting sequencing errors in DNA coding regions. Xu Y, et al. **J Comput Biol** 1996 Fall;3(3):333–44

On a Mirkin-Muchnik-Smith conjecture for comparing molecular phylogenies [comment] Zhang L. **J Comput Biol** 1997 Summer;4(2):177–87. Comment on: J Comput Biol 1995 Winter;2(4):493–507.

Aligning a DNA sequence with a protein sequence. Zhang Z, et al. **J Comput Biol** 1997 Fall;4(3):339–49

Image processing assessment of femoral osteopenia. Lee RL, et al. **J Digit Imaging** 1997 Aug;10(3 Suppl 1):218–21

A new ECG algorithm for the localization of accessory pathways using only the polarity of the QRS complex. Iturralde P, et al. **J Electrocardiol** 1996 Oct;29(4):289–99

Multiresolution decomposition of the signal-averaged ECG using the mallat approach for prediction of arrhythmic events after myocardial infarction. Sierra G, et al. **J Electrocardiol** 1996 Jul;29(3):223–34

CQI: improving the time to thrombolytic therapy for patients with acute myocardial infarction in the emergency department. Markel KN, et al. **J Emerg Med** 1996 Nov-Dec;14(6):685–9

Performance of two clinical decision rules for knee radiography. Richman PB, et al. **J Emerg Med** 1997 Jul–Aug;15(4):459–63

Digital radiographic imaging transfer: comparison with plain radiographs. Averch TD, et al. **J Endourol** 1997 Apr; 11(2):99–101

Recent advances in the estimation of population exposure to mobile source pollutants. Johnson TR. **J Expo Anal Environ Epidemiol** 1995 Oct-Dec;5(4):551–71 (39 ref.)

Data mining: sophisticated forms of managed care modeling through artificial intelligence. Borok LS. **J Health Care Finance** 1997 Spring;23(3):20–36 (0 ref.)

Automated instrument tracking in robotically assisted laparoscopic surgery. Uecker DR, et al. **J Image Guid Surg** 1995;1(6):308–25

Automatic identification of gray matter structures from MRI to improve the segmentation of white matter lesions. Warfield S, et al. **J Image Guid Surg** 1995;1(6):326–38

Practical steps in the management of adult head and neck masses. Bumpous JM, et al. **J Ky Med Assoc** 1996 Feb; 94(2):50–6

Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open heart surgery treated with epoetin beta. Sowade O, et al. **J Lab Clin Med** 1997 Jan;129(1):97–105

REDOR dephasing by multiple spins in the presence of molecular motion. Goetz JM, et al. **J Magn Reson** 1997 Aug;127(2):147–54

Modeling NMR lineshapes using logspline density functions. Raz J, et al. **J Magn Reson** 1997 Aug;127(2):173–83

Application of genetic algorithms to spectral quantification. Metzger GJ, et al. **J Magn Reson B** 1996 Mar;110(3):316–20

Limitations of the keyhole technique for quantitative dynamic contrast–enhanced breast MRI. Bishop JE, et al. **J Magn Reson Imaging** 1997 Jul–Aug;7(4):716–23

Correspondence of closest gradient voxels—a robust registration algorithm. Ostuni JL, et al. **J Magn Reson Imaging** 1997 Mar–Apr;7(2):410–5

Inadequacy of motion correction algorithms in functional MRI: role of susceptibility–induced artifacts. Wu DH, et al. **J Magn Reson Imaging** 1997 Mar–Apr;7(2):365–70

Adaptive filtering for high resolution magnetic resonance images. Ying K, et al. **J Magn Reson Imaging** 1996 Mar–Apr;6(2):367–77

Designing combinatorial library mixtures using a genetic algorithm. Brown RD, et al. **J Med Chem** 1997 Jul 18; 40(15):2304–13

Data management of a pneumonia screening algorithm in Veterans Affairs Medical Centers. Reed JF 3rd, et al. **J Med Syst** 1996 Dec;20(6):395–401

Prediction of protein side–chain rotamers from a backbone–dependent rotamer library: a new homology modeling tool. Bower MJ, et al. **J Mol Biol** 1997 Apr 18; 267(5):1268–82

Multiple sequence information for threading algorithms. Defay TR, et al. **J Mol Biol** 1996 Sep 20;262(2):314–23

A novel method to develop highly specific models for regulatory units detects a new LTR in GenBank which contains a functional promoter. Frech K, et al. **J Mol Biol** 1997 Aug 1;270(5):674–87

Modelling protein docking using shape complementarity, electrostatics and biochemical information. Gabb HA, et al. **J Mol Biol** 1997 Sep 12;272(1):106–20

The NMR solution structure of intestinal fatty acid–binding protein complexed with palmitate: application of a novel distance geometry algorithm. Hodsdon ME, et al. **J Mol Biol** 1996 Dec 6;264(3):585–602

Development and validation of a genetic algorithm for flexible docking. Jones G, et al. **J Mol Biol** 1997 Apr 4; 267(3):727–48

Protein folding simulations with genetic algorithms and a detailed molecular description. Pedersen JT, et al. **J Mol Biol** 1997 Jun 6;269(2):240–59

Predicting conserved water–mediated and polar ligand interactions in proteins using a K–nearest–neighbors genetic algorithm. Raymer ML, et al. **J Mol Biol** 1997 Jan 31;265(4):445–64

Protein secondary structure prediction using local alignments. Salamov AA, et al. **J Mol Biol** 1997 Apr 25; 268(1):31–6

MONSSTER: a method for folding globular proteins with a small number of distance restraints. Skolnick J, et al. **J Mol Biol** 1997 Jan 17;265(2):217–41

Multiple sequence threading: an analysis of alignment quality and stability. Taylor WR. **J Mol Biol** 1997 Jun 27; 269(5):902–43

Prediction of IgE(Lb4)–ligand complex structures by automated docking. Winger RH, et al. **J Mol Recognit** 1996 May–Jun;9(3):239–46

Algorithms vie for diagnostic role in prostate cancer [news] Holzman D. **J Natl Cancer Inst** 1997 Jan 1;89(1):13–5

Automatic sorting of multiple unit neuronal signals in the presence of anisotropic and non–Gaussian variability [published erratum appears in J Neurosci Methods 1997 Feb;71(2):233] Fee MS, et al. **J Neurosci Methods** 1996 Nov;69(2):175–88

Guidelines for minor head injured patients' management in adult age. The Study Group on Head Injury of the Italian Society for Neurosurgery. **J Neurosurg Sci** 1996 Mar; 40(1):11–5

Comparison of motion correction algorithms for cardiac SPECT. Leslie WD, et al. **J Nucl Med** 1997 May; 38(5):785–90

Three–dimensional correction for spillover and recovery of myocardial PET images. Nuyts H, et al. **J Nucl Med** 1996 May;37(5):767–74

Noise reduction in PET attenuation correction by maximum likelihood histogram sharpening of attenuation images. Price JC, et al. **J Nucl Med** 1996 May;37(5):786–94

Prognostic factors in hospitalized children with persistent diarrhea: implications for diet therapy. Bhatnagar S, et al. **J Pediatr Gastroenterol Nutr** 1996 Aug;23(2):151–8

Option–4 algorithm for automated disc probe: reduction in the variance of site–specific relative attachment level measurements. Breen HJ, et al. **J Periodontol** 1997 May; 68(5):456–66

A comparison of six deconvolution techniques. Madden FN, et al. **J Pharmacokinet Biopharm** 1996 Jun;24(3):283–99

Propagation of synchronous spiking activity in feedforward neural networks. Aertsen A, et al. **J Physiol Paris** 1996; 90(3–4):243–7 (19 ref.)

Mechanisms for regulating synaptic efficiency in the visual cortex. Friedlander MJ, et al. **J Physiol Paris** 1996; 90(3–4):179–84

Predicting differential antigen–antibody contact regions based on solvent accessibility. Lebeda FJ, et al. **J Protein Chem** 1997 Aug;16(6):607–18

A diagnostic algorithm for distinguishing the eosinophilia–myalgia syndrome from fibromyalgia and chronic myofascial pain. Taylor RM, et al. **J Rheumatol Suppl** 1996 Oct;46:13–8

Preoperative diagnosis of carcinoma of the breast: Is a "cost–cutter" algorithm tenable? Chandawarkar RY, et al. **J Surg Oncol** 1997 Feb;64(2):153–8

On the nearest neighbour interchange distance between evolutionary trees. Li M, et al. **J Theor Biol** 1996 Oct 21; 182(4):463–7

Escape from evolutionary stasis by transposon–mediated deleterious mutations. McFadden J, et al. **J Theor Biol** 1997 Jun 21;186(4):441–7

Addition of Darwin's third dimension to phyletic trees. Pinou T, et al. **J Theor Biol** 1996 Oct 21;182(4):505–12

Pancreatic trauma: a simplified management guideline. Patton JH Jr, et al. **J Trauma** 1997 Aug;43(2):234–9; discussion 239–41

An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. Badalament RA, et al. **J Urol** 1996 Oct;156(4):1375–80

An algorithm for the management of anterior urethral valves. Van Savage JG, et al. **J Urol** 1997 Sep;158(3 Pt 2):1030–2

Prognostic factors in meningococcal disease. Development of a bedside predictive model and scoring system. Barcelona Meningococcal Disease Surveillance Group. Barquet N, et al. **JAMA** 1997 Aug 13;278(6):491–6

Predicting time to nursing home care and death in individuals with Alzheimer disease [see comments] Stern Y, et al. **JAMA** 1997 Mar 12;277(10):806–12. Comment in: JAMA 1997 Jun 25;277(24):1933–4. Comment in: ACP J Club 1997 Sep–Oct;127(2):43.

New algorithms for real–time, 24 hr continuous and noise–adjusted power spectral analysis of heart rate and blood pressure fluctuations in conscious rats. Nagai R, et al. **Jpn J Pharmacol** 1996 Dec;72(4):355–64

Three teams improving thrombolytic therapy. Mitchell L, et al. **Jt Comm J Qual Improv** 1996 Jun;22(6):379–90

Measurement of QT interval and QT dispersion. Hill JA, et al. **Lancet** 1997 Mar 29;349(9056):894–5

Screening for obstructive sleep apnea in patients presenting for snoring surgery. Pradhan PS, et al. **Laryngoscope** 1996 Nov;106(11):1393–7

Development of a multivariate statistical algorithm to analyze human cervical tissue fluorescence spectra acquired in vivo. Ramanujam N, et al. **Lasers Surg Med** 1996;19(1):46–62

An improved robust hierarchical registration algorithm. Alexander ME, et al. **Magn Reson Imaging** 1997; 15(4):505–14

Studies on the performance of circular and elliptical Z–gradient coils using a simulated annealing algorithm. Du YP, et al. **Magn Reson Imaging** 1997;15(2):255–62

Correction for distortion of echo–planar images used to calculate the apparent diffusion coefficient. Haselgrove JC, et al. **Magn Reson Med** 1996 Dec;36(6):960–4

Decoupled automated rotational and translational registration for functional MRI time series data: the DART registration algorithm. Maas LC, et al. **Magn Reson Med** 1997 Jan; 37(1):131–9

Intensity correction of phased–array surface coil images. Murakami JW, et al. **Magn Reson Med** 1996 Apr; 35(4):585–90

Implementation of a fast gradient–echo SVD encoding technique for dynamic imaging. Panych LP, et al. **Magn Reson Med** 1996 Apr;35(4):554–62

An extended two–point Dixon algorithm for calculating separate water, fat, and B0 images. Skinner TE, et al. **Magn Reson Med** 1997 Apr;37(4):628–30

Algorithms for extracting motion information from navigator echoes. Wang Y, et al. **Magn Reson Med** 1996 Jul; 36(1):117–23

Fourier tracking of myocardial motion using cine–PC data. Zhu Y, et al. **Magn Reson Med** 1996 Apr;35(4):471–80

Use of the recursion formula of the Gompertz survival function to evaluate life–table data. Bassukas ID. **Mech Ageing Dev** 1996 Aug 29;89(3):155–63

Theoretical analysis of non–invasive oscillometric maximum amplitude algorithm for estimating mean blood pressure. Baker PD, et al. **Med Biol Eng Comput** 1997 May; 35(3):271–8

Resolving superimposed motor unit action potentials. Etawil H, et al. **Med Biol Eng Comput** 1996 Jan;34(1):33–40

Optimisation algorithms for ECG data compression. Haugland D, et al. **Med Biol Eng Comput** 1997 Jul; 35(4):420–4

Characterisation of structural changes in the arterial elastic matrix by a new fractal feature: directional fractal curve. Jiang CF, et al. **Med Biol Eng Comput** 1997 May; 35(3):246–52

On refraction in Monte–Carlo simulations of light transport through biological tissues. Kolinko VG, et al. **Med Biol Eng Comput** 1997 May;35(3):287–8

Computer–based lung sound simulation. Kompis M, et al. **Med Biol Eng Comput** 1997 May;35(3):231–8

Classification of normal and abnormal electrogastrograms using multilayer feedforward neural networks. Lin Z, et al. **Med Biol Eng Comput** 1997 May;35(3):199–206

Application of genetic algorithms to parameter estimation of bioprocesses. Park LJ, et al. **Med Biol Eng Comput** 1997 Jan;35(1):47–9

Standard algorithm for blood pressure measurement by sphygmo–oscillographic method. Sapinski A. **Med Biol Eng Comput** 1996 Jan;34(1):82–3

Matching of digitised brain atlas to magnetic resonance images. Sorlié C, et al. **Med Biol Eng Comput** 1997 May; 35(3):239–45

Adaptive motor unit action potential clustering using shape and temporal information. Stashuk D, et al. **Med Biol Eng Comput** 1996 Jan;34(1):41–9

Magnetic source imaging in the human heart: estimating cardiac electrical sources from simulated and measured magnetocardiogram data. Wach P, et al. **Med Biol Eng Comput** 1997 May;35(3):157–66

An examination of cross–specialty linkage applied to the resource–based relative value scale. Glickman ME, et al. **Med Care** 1997 Aug;35(8):843–66

The psychology of good judgment: frequency formats and simple algorithms [see comments] Gigerenzer G. **Med Decis Making** 1996 Jul–Sep;16(3):273–80 (32 ref.). Comment in: Med Decis Making 1997 Apr–Jun;17(2):233.

Representation and analysis of medical decision problems with influence diagrams [see comments] Owens DK, et al. **Med Decis Making** 1997 Jul–Sep;17(3):241–62. Comment in: Med Decis Making 1997 Jul–Sep;17(3):351–2.

A trend–detection algorithm for intraoperative EEG monitoring. Hinrichs H, et al. **Med Eng Phys** 1996 Dec; 18(8):626–31

Irreversible encryption method by generation of polynomials. Quantin C, et al. **Med Inf (Lond)** 1996 Apr–Jun; 21(2):113–21

A computer–based flowcharting system for clinical protocols. Todd BS, et al. **Med Inf (Lond)** 1995 Jul–Sep;20(3):177–98

3D electron dose calculation using a Voxel based Monte Carlo algorithm (VMC). Kawrakow I, et al. **Med Phys** 1996 Apr;23(4):445–57

Superposition dose calculation incorporating Monte Carlo generated electron track kernels. Keall PJ, et al. **Med Phys** 1996 Apr;23(4):479–85

Super–Monte Carlo: a 3–D electron beam dose calculation algorithm. Keall PJ, et al. **Med Phys** 1996 Dec; 23(12):2023–34

A generic genetic algorithm for generating beam weights. Langer M, et al. **Med Phys** 1996 Jun;23(6):965–71

A new source localization algorithm with no requirement of one–to–one source correspondence between biplane radiographs. Li S, et al. **Med Phys** 1996 Jun;23(6):921–7

An automatic six–degree–of–freedom image registration algorithm for image–guided frameless stereotaxic radiosurgery. Murphy MJ. **Med Phys** 1997 Jun; 24(6):857–66

A restoration algorithm for P–32 and Y–90 bremsstrahlung emission nuclear imaging: a wavelet–neural network approach. Qian W, et al. **Med Phys** 1996 Aug;23(8):1309–23

Extension of a numerical algorithm to proton dose calculations. I. Comparisons with Monte Carlo simulations. Sandison GA, et al. **Med Phys** 1997 Jun;24(6):841–9

A self–collimating convolution backprojection algorithm for optimizing dose distributions of I–125 prostate implants. Siochi RA, et al. **Med Phys** 1997 Feb;24(2):241–9

A genetic algorithm for the optimization of prostate implants. Yu Y, et al. **Med Phys** 1996 Dec;23(12):2085–91

A Fourier based algorithm for tracking SPAMM tags in gated magnetic resonance cardiac images. Zhang S, et al. **Med Phys** 1996 Aug;23(8):1359–69

A multiple wavelength algorithm in color image analysis and its applications in stain decomposition in microscopy images. Zhou R, et al. **Med Phys** 1996 Dec;23(12):1977–86

An automatic contour extraction algorithm for short–axis cardiac magnetic resonance images. Zimmer Y, et al. **Med Phys** 1996 Aug;23(8):1371–9

Substrate docking algorithms and the prediction of substrate specificity. De Voss JJ, et al. **Methods Enzymol** 1996; 272:336–47

Treatment of multiwavelength anomalous diffraction data as a special case of multiple isomorphous replacement. Ramakrishnan V, et al. **Methods Enzymol** 1997;276:538–57

Performance of multi–layer feedforward neural networks to predict liver transplantation outcome. Dvorchik I, et al. **Methods Inf Med** 1996 Mar;35(1):12–8

GeneAssist. Smith–Waterman and other database similarity searches and identification of motifs. Shpaer EG. **Methods Mol Biol** 1997;70:173–87

Confidence intervals of evolutionary distances between sequences and comparison with usual approaches including the bootstrap method. Andrieu G, et al. **Mol Biol Evol** 1997 Aug;14(8):875–82

Introns and reading frames: correlation between splicing sites and their codon positions. Tomita M, et al. **Mol Biol Evol** 1996 Nov;13(9):1219–23

Hadamard conjugations and modeling sequence evolution with unequal rates across sites. Waddell PJ, et al. **Mol Phylogenet Evol** 1997 Aug;8(1):33–50

Complexity measures in molecular psychiatry. Rapp PE, et al. **Mol Psychiatry** 1996 Nov;1(5):408–16 (83 ref.)

Inquiry into the diagnostic workup of patients with fever of unknown origin. de Kleijn EM, et al. **Neth J Med** 1997 Feb;50(2):69–74

Selecting optimal experiments for multiple output multilayer perceptrons. Belue LM, et al. **Neural Comput** 1997 Jan 1; 9(1):161–83

A simple neural network exhibiting selective activation of neuronal ensembles: from winner–take–all to winners–share–all. Fukai T, et al. **Neural Comput** 1997 Jan

1;9(1):77–97
Flat minima. Hochreiter S, et al. **Neural Comput** 1997 Jan 1;9(1):1–42
A neuro–mimetic dynamic scheduling algorithm for control: analysis and applications. Kwatra HS, et al. **Neural Comput** 1997 Apr 1;9(3):479–502
A sequential learning scheme for function approximation using minimal radial basis function neural networks. Lu Y, et al. **Neural Comput** 1997 Feb 15;9(2):461–78
Fast sigmoidal networks via spiking neurons. Maass W. **Neural Comput** 1997 Feb 15;9(2):279–304
Singular perturbation analysis of competitive neural networks with different time scales. Meyer–Bäse A, et al. **Neural Comput** 1996 Nov 15;8(8):1731–42
Neural networks for functional approximation and system identification. Mhaskar HN, et al. **Neural Comput** 1997 Jan 1;9(1):143–59
Partial BFGS update and efficient step–length calculation for three–layer neural networks. Saito K, et al. **Neural Comput** 1997 Jan 1;9(1):123–41
A penalty–function approach for pruning feedforward neural networks. Setiono R. **Neural Comput** 1997 Jan 1; 9(1):185–204
Extracting rules from neural networks by pruning and hidden–unit splitting. Setiono R. **Neural Comput** 1997 Jan 1;9(1):205–25
Around the WORLD backward: an algorithm for scoring the MMSE WORLD item. Beckett LA, et al. **Neurology** 1997 Jun;48(6):1733–4
Validation of the ACAS TIA/stroke algorithm. Karanjia PN, et al. **Neurology** 1997 Feb;48(2):346–51
Bilateral comparison of occipital lobe sulci: a sulcus identifying algorithm. Naor Z, et al. **Neuropsychol Rev** 1996 Jun;6(2):95–105
Simultaneous spike detection and topographic classification in pediatric surface EEGs. Feucht M, et al. **Neuroreport** 1997 Jul 7;8(9–10):2193–7
Optimal sampling time for single–sample (Christensen–Groth) 51Cr–EDTA estimation of glomerular filtration rate [letter] Watson WS. **Nucl Med Commun** 1996 Jun;17(6):542, 544
A coalescent approach to the polymerase chain reaction. Weiss G, et al. **Nucleic Acids Res** 1997 Aug 1;25(15):3082–7
Relieving nausea and vomiting in patients with cancer: a treatment algorithm. Johnson MH, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):51–7
Fastpac visual field screening. Young IM, et al. **Ophthalmic Epidemiol** 1995 Dec;2(3):117–21
Clinical experience with Thera DR rate–drop response pacing algorithm in carotid sinus syndrome and vasovagal syncope. The International Rate–Drop Investigators Group. Benditt DG, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):832–9
Evaluation of a new sensor–based algorithm to protect against atrial arrhythmias. Delay M, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1704–7
Rate–drop response programming. Gammage MD. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):841–3
Evaluation of a new pacing algorithm to prevent rapid tracking of atrial tachyarrhythmias. Kamalvand K, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1714–8
Delayed exercise rate response kinetics due to sensor cross–checking in a dual sensor rate adaptive pacing system: the importance of individual sensor programming. Lau CP, et al. **Pacing Clin Electrophysiol** 1996 Jul; 19(7):1021–5
Effect of varying atrial sensitivity, AV interval, and detection algorithm on automatic mode switching. Palma EC, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1735–9
Reliability of a new algorithm for automatic mode switching from DDDR to DDIR pacing mode in sinus node disease patients with chronotropic incompetence and recurrent paroxysmal atrial fibrillation. Ricci R, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1719–23
Age and sex related changes in heart rate to ventilation coupling: implications for rate adaptive pacemaker algorithms. Rickli H, et al. **Pacing Clin Electrophysiol** 1997 Jan;20(1 Pt 1):104–11
Limitations of tachycardia confirmation and rate classification algorithms in a third–generation implantable cardioverter defibrillator. Stambler BS, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 1):1618–28
First steps toward a pacing algorithm for vasovagal syncope. Sutton R, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 2):827–8
The role of laparoscopy in the management of impalpable testes. El–Gohary MA. **Pediatr Surg Int** 1997 Jul; 12(5–6):463–5
Evaluation of a simulation of human performance on random–digit generation: measures of concept and redundancy. Spatt J. **Percept Mot Skills** 1996 Aug; 83(1):319–22
Cervical precancer detection using a multivariate statistical algorithm based on laser–induced fluorescence spectra at multiple excitation wavelengths. Ramanujam N, et al. **Photochem Photobiol** 1996 Oct;64(4):720–35
Electron beam dose calculations with the VMC algorithm and the verification data of the NCI working group. Fippel M, et al. **Phys Med Biol** 1997 Mar;42(3):501–20
Evaluation of a technique for simulation of gamma camera images. Fleming JS. **Phys Med Biol** 1996 Sep;41(9):1855–61
A pencil beam algorithm for proton dose calculations. Hong L, et al. **Phys Med Biol** 1996 Aug;41(8):1305–30
Application of a new discreet form of Gauss' theorem for measuring volume. Hughes SW, et al. **Phys Med Biol** 1996 Sep;41(9):1809–21
The influence of a relaxation parameter on SPECT iterative reconstruction algorithms. Ros D, et al. **Phys Med Biol** 1996 May;41(5):925–37
Iterative reconstruction of PET images using a high–overrelaxation single–projection algorithm. Schmidlin P, et al. **Phys Med Biol** 1997 Mar;42(3):569–82
Iterative methods for inverse treatment planning. Xing L, et al. **Phys Med Biol** 1996 Oct;41(10):2107–23
Improvement of the positional accuracy of EIT images of the head using a Lagrange multiplier reconstruction algorithm with diametric excitation. Bayford RH, et al. **Physiol Meas** 1996 Nov;17 Suppl 4A:A49–57
An interleaved drive electrical impedance tomography image reconstruction algorithm. Eyüboğlu BM. **Physiol Meas** 1996 Nov;17 Suppl 4A:A59–71
Comparison of different algorithms for evaluation of respiratory sinus arrhytmia: cross–correlation function histogram analysis and regression analysis. Schmitz JM, et al. **Physiol Res** 1995;44(3):197–203
Expressiveness and query complexity in an electronic health record data model. Dolin RH. **Proc AMIA Annu Fall Symp** 1996;:522–6
Centromere attribute integration based chromosome polarity assignment. Stanley RJ, et al. **Proc AMIA Annu Fall Symp** 1996;:284–8
Replacing personally–identifying information in medical records, the Scrub system. Sweeney L. **Proc AMIA Annu Fall Symp** 1996;:333–7
An evaluation of statistical approaches to MEDLINE indexing. Yang Y. **Proc AMIA Annu Fall Symp** 1996; :358–62
The rational design and construction of a cuboidal iron–sulfur protein. Coldren CD, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6635–40
Gene recognition via spliced sequence alignment. Gelfand MS, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20; 93(17):9061–6
Detection of non–topological motifs in protein structures. Alesker V, et al. **Protein Eng** 1996 Dec;9(12):1103–19
Hydrophobic regions on protein surfaces: definition based on hydration shell structure and a quick method for their computation. Eisenhaber F, et al. **Protein Eng** 1996 Dec; 9(12):1121–33
Grafting of discontinuous sites: a protein modeling strategy. Hornischer K, et al. **Protein Eng** 1996 Nov;9(11):931–9
An automated approach for defining core atoms and domains in an ensemble of NMR–derived protein structures. Kelley LA, et al. **Protein Eng** 1997 Jun;10(6):737–41
Pairwise iterative superposition of distantly related proteins and assessment of the significance of 3–D structural similarity. May AC. **Protein Eng** 1996 Dec;9(12):1093–101
Searching for common sequence patterns among distantly related proteins. Suyama M, et al. **Protein Eng** 1995 Nov; 8(11):1075–80
The prediction of protein contacts from multiple sequence alignments. Thomas DJ, et al. **Protein Eng** 1996 Nov; 9(11):941–8
Protein fold recognition by threading: comparison of algorithms and analysis of results. Westhead DR, et al. **Protein Eng** 1995 Dec;8(12):1197–1204
A fast conformational search strategy for finding low energy structures of model proteins. Beutler TC, et al. **Protein Sci** 1996 Oct;5(10):2037–43
Automated design of the surface positions of protein helices. Dahiyat BI, et al. **Protein Sci** 1997 Jun;6(6):1333–7
Improved genetic algorithm for the protein folding problem by use of a Cartesian combination operator. Rabow AA, et al. **Protein Sci** 1996 Sep;5(9):1800–15
Hydrophobic folding units at protein–protein interfaces: implications to protein folding and to protein–protein association. Tsai CJ, et al. **Protein Sci** 1997 Jul;6(7):1426–37
High resolution fast quantitative docking using Fourier domain correlation techniques. Blom NS, et al. **Proteins** 1997 Apr;27(4):493–506
Seventy–five percent accuracy in protein secondary structure prediction. Frishman D, et al. **Proteins** 1997 Mar; 27(3):329–35
A predicted consensus structure for the N–terminal fragment of the heat shock protein HSP90 family. Gerloff DL, et al. **Proteins** 1997 Mar;27(3):450–8
A method for the prediction of surface "U"–turns and transglobular connections in small proteins. Kolinski A, et al. **Proteins** 1997 Feb;27(2):290–308
Simulation of protein crystal nucleation. Pellegrini M, et al. **Proteins** 1997 Aug;28(4):515–21
Prediction and evaluation of side–chain conformations for protein backbone structures. Shenkin PS, et al. **Proteins** 1996 Nov;26(3):323–52
Protein structure prediction force fields: parametrization with quasi–newtonian dynamics. Ulrich P, et al. **Proteins** 1997 Mar;27(3):367–84
Exploring the energy landscapes of molecular recognition by a genetic algorithm: analysis of the requirements for robust docking of HIV–1 protease and FKBP–12 complexes. Verkhivker GM, et al. **Proteins** 1996 Jul; 25(3):342–53
Protein domain movements: detection of rigid domains and visualization of hinges in comparisons of atomic coordinates. Wriggers W, et al. **Proteins** 1997 Sep; 29(1):1–14
Reasoning the fast and frugal way: models of bounded rationality. Gigerenzer G, et al. **Psychol Rev** 1996 Oct; 103(4):650–69
Coronary arteries: retrospective cardiac gating technique to reduce cardiac motion artifact at spiral CT. Woodhouse CE, et al. **Radiology** 1997 Aug;204(2):566–9
Test procedures for verification of an electron pencil beam algorithm implemented for treatment planning. Blomquist M, et al. **Radiother Oncol** 1996 Jun;39(3):271–86
A CT–aided PC–based physical treatment planning of TBI: a method for dose calculation. Sánchez–Nieto B, et al. **Radiother Oncol** 1997 Jan;42(1):77–85 (27 ref.)
Comparative assessment of shockable ECG rhythm detection algorithms in automated external defibrillators. Clifford AC. **Resuscitation** 1996 Oct;32(3):217–25
The Universal ALS algorithm. An advisory statement by the Advanced Life Support Working Group of the International Liaison Committee on Resuscitation. Kloeck W, et al. **Resuscitation** 1997 Apr;34(2):109–11
Chagas' disease: an algorithm for donor screening and positive donor counseling. Hamerschlak N, et al. **Rev Soc Bras Med Trop** 1997 May–Jun;30(3):205–9
Comparison and assessment of blood gas related quantities including base excess, the gas exchange indices, and temperature corrected pH/PO2/PCO2, as defined in approved NCCLS standard C12–A, using a computer simulation of input variables. Degen BR, et al. **Scand J Clin Lab Invest Suppl** 1996;224:89–106
The Oxygen Status Algorithm on–line with the pH–blood gas analyzer. Larsen VH, et al. **Scand J Clin Lab Invest Suppl** 1996;224:9–19
Local computed tomography via iterative deblurring. Wang G, et al. **Scanning** 1996 Nov;18(8):582–8
De novo protein design: fully automated sequence selection [see comments] Dahiyat BI, et al. **Science** 1997 Oct 3; 278(5335):82–7. Comment in: Science 1997 Oct 3;278(5335):80–1.
Proteins from scratch [comment] DeGrado WF. **Science** 1997 Oct 3;278(5335):80–1. Comment on: Science 1997 Oct 3;278(5335):82–7.
New approaches to syphilis control. Finding opportunities for syphilis treatment and congenital syphilis prevention in a women's correctional setting [see comments] Blank S, et al. **Sex Transm Dis** 1997 Apr;24(4):218–26. Comment in: Sex Transm Dis 1997 Apr;24(4):227–8.
Proposed algorithm to aid the diagnosis of cerebellopontine angle tumors. Astor FC, et al. **South Med J** 1997 May; 90(5):514–7
Spatial partitioning using multivariate cluster analysis and a contiguity algorithm. Carvalho MS, et al. **Stat Med** 1996 Sep 15–30;15(17–18):1885–94
Estimating asymptomatic duration in cancer: the AIDS connection. Etzioni R, et al. **Stat Med** 1997 Mar 30; 16(6):627–44
Modelling and design of cross–over trials. Jones B, et al. **Stat Med** 1996 Jul 15;15(13):1435–46
Group sequential monitoring of distribution–free analyses of repeated measures. Lachin JM. **Stat Med** 1997 Mar 30; 16(6):653–68
Sorting variables for each case: a new algorithm to calculate injury severity score (ISS) using SPSS–PC. Linn S. **Stat Med** 1996 Apr 15–May 15;15(7–9):933–7
A scan statistic with a variable window. Nagarwalla N. **Stat Med** 1996 Apr 15–May 15;15(7–9):845–50
Cluster analysis by testing the statistical hypothesis of uniformity. Saferis V, et al. **Stat Med** 1996 Apr 15–May 15;15(7–9):817–21
Cluster analysis with constraints: its use with breast cancer mortality rates in Argentina. Wojdyla D, et al. **Stat Med** 1996 Apr 15–May 15;15(7–9):741–6
EM algorithms without missing data. Becker MP, et al. **Stat Methods Med Res** 1997 Mar;6(1):38–54
Uses of the EM algorithm in the analysis of data on HIV/AIDS and other infectious diseases. Becker NG. **Stat Methods Med Res** 1997 Mar;6(1):24–37
The EM algorithm in medical imaging. Kay J. **Stat Methods Med Res** 1997 Mar;6(1):55–75
The impact of the EM algorithm on medical statistics [editorial] McLachlan G. **Stat Methods Med Res** 1997 Mar; 6(1):1–2
On the EM algorithm for overdispersed count data. McLachlan GJ. **Stat Methods Med Res** 1997 Mar; 6(1):76–98 (85 ref.)
The EM algorithm and medical studies: a historical link. Meng XL. **Stat Methods Med Res** 1997 Mar;6(1):3–23 (39 ref.)
Stereotactic dose computation and plan optimization using the convolution theorem. I. Dose computation. Wu X, et al. **Stereotact Funct Neurosurg** 1996;66 Suppl 1:302–8
An assessment of the nine–month lactational amenorrhea method (MAMA–9) in Rwanda. Cooney KA, et al. **Stud Fam Plann** 1996 May–Jun;27(3):102–71
Rule induction and instance–based learning applied in medical diagnosis. Džeroski S, et al. **Technol Health Care** 1996 Aug;4(2):203–21
Determination of the unit size of the corneal endothelial cell mosaic from Fourier component image analysis. Doughty MJ, et al. **Tissue Cell** 1997 Apr;29(2):229–38
Sequence alignment through pictures. Searls DB. **Trends Genet** 1996 Jan;12(1):35–7

ALGORITHMS

Improved common line-based icosahedral particle image orientation estimation algorithms. Thuman-Commike PA, et al. **Ultramicroscopy** 1997 Aug 1;68(4):231-55

A real-time scan conversion algorithm on commercially available microprocessors. Basoglu C, et al. **Ultrason Imaging** 1996 Oct;18(4):241-60

Variable density linear acoustic inverse problem. Moghaddam M, et al. **Ultrason Imaging** 1993 Jul; 15(3):255-66

Evaluation of an automated real-time spectral analysis technique. Rickey DW, et al. **Ultrasound Med Biol** 1996; 22(1):61-73

New methods for arterial diameter measurement from B-mode images. Stadler RW, et al. **Ultrasound Med Biol** 1996;22(1):25-34

The application of echo-tracking methods to endothelium-dependent vasoreactivity and arterial compliance measurements. Stadler RW, et al. **Ultrasound Med Biol** 1996;22(1):35-42

Characterization of echographic image texture by cooccurrence matrix parameters. Valckx FM, et al. **Ultrasound Med Biol** 1997;23(4):559-71

The utility of video-assisted thoracic surgery in the diagnosis of pulmonary metastases from renal cell carcinoma. Amos AM, et al. **Urology** 1997 Jan;49(1):123-7

Mast cells and nerve fibers in interstitial cystitis (IC): an algorithm for histologic diagnosis via quantitative image analysis and morphometry (QIAM). Hofmeister MA, et al. **Urology** 1997 May;49(5A Suppl):41-7

Diagnosis and treatment of right upper quadrant abdominal pain. Dill JE. **Va Med Q** 1996 Winter;123(1):27-9

Implementations of a novel algorithm for colour constancy. Martínez-Verdú F, et al. **Vision Res** 1997 Jul; 37(13):1829-44

The perception of motion and structure in structure-from-motion: comparisons of affine and Euclidean formulations. Pollick FE. **Vision Res** 1997 Feb; 37(4):447-66

A clinical algorithm for the management of abnormal mammograms. A community hospital's experience. Gist D, et al. **West J Med** 1997 Jan;166(1):21-8

[Clinical models and decisional algorithm in the management of erectile disorders] Virag R, et al. **Rev Med Interne** 1997; 18 Suppl 1:26s-30s (Eng. Abstr.) **(Fre)**

[How I explore.... an adult subject with suspected hypothyroidism] Scheen AJ. **Rev Med Liege** 1996 May; 51(5):376-8 **(Fre)**

[Solitary nodule of the thyroid: diagnostic tests and surgical treatment] Mir A, et al. **Rev Med Suisse Romande** 1997 Apr;117(4):353-5 **(Fre)**

[The use of diagnostic and therapeutic algorithms in the management of of sexually transmitted diseases in developing countries (news)] Lefait-Robin R. **Sante** 1996 Jul-Aug;6(4):260 **(Fre)**

[Familial adenomatous polyposis (FAP): integration of clinical and genetic parameters in the screening of subjects at risk. A one-family example] Chautems R, et al. **Swiss Surg** 1996;2(5):196-200 (Eng. Abstr.) **(Fre)**

[Adaptive lung ventilation (AVL). Evaluation of new closed loop regulated respiration algorithm for operation in the hyperextended lateral position] Weiler N, et al. **Anaesthesist** 1996 Oct;45(10):950-6 (Eng. Abstr.) **(Ger)**

[Guidelines/algorithms by the German Society of Otorhinolaryngology, Head and Neck Surgery] **HNO** 1997 Jun;45(6):427-31 **(Ger)**

[Diagnosis of osteoporosis] Schulte C, et al. **Med Klin** 1997 May 15;92(5):263-4 **(Ger)**

[CT subtraction angiography (CTSA). Results with an automated "elastic" subtraction algorithm] Luboldt W, et al. **Radiologe** 1997 Jan;37(1):89-93 (Eng. Abstr.) **(Ger)**

[Acute otitis media with effusion: an overview of the pathogenesis and recommendations for therapy] Linder T, et al. **Schweiz Med Wochenschr** 1996 Dec 28; 126(51-52):2223-33 (43 ref.) (Eng. Abstr.) **(Ger)**

[The comatose patient: initial considerations and measures] Osterwalder JJ. **Schweiz Rundsch Med Prax** 1996 Dec 10; 85(50):1626-9 (Eng. Abstr.) **(Ger)**

[Resuscitation] Wietlisbach M, et al. **Schweiz Rundsch Med Prax** 1997 Feb 4;86(6):182-8 (Eng. Abstr.) **(Ger)**

[The treatment of therapy-resistant lateral epicondylitis] Nagy L. **Swiss Surg** 1997;3(2):76-9; discussion 80 (20 ref.) (Eng. Abstr.) **(Ger)**

[Is there a renaissance of conservative therapy in plastic penile induration?] Schubert J, et al. **Wien Med Wochenschr** 1997;147(4-5):99-101 (24 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic value of auto-capture: detection of lead dislocation] Liebold A, et al. **Z Kardiol** 1997 Jul;86(7):521-3 (Eng. Abstr.) **(Ger)**

[Verification of accuracy of several algorithms to quantitate left ventricular regional wall motion: a study using cine MR imaging with myocardial tagging] Terashima M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Sep; 56(11):720-5 (Eng. Abstr.) **(Jpn)**

[The evaluation of three dimensional image distortion of helical scanning CT] Wada S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jul; 56(8):588-94 (Eng. Abstr.) **(Jpn)**

[Plasmid size determination using 3 methods] Darini AL, et al. **Rev Latinoam Microbiol** 1995 Jul-Sep;37(3):217-25 (Eng. Abstr.) **(Por)**

[Prognostication of complications in surgery of lung cancer] Skorniakov SN, et al. **Anesteziol Reanimatol** 1997 Jan-Feb; (1):64-6 (Eng. Abstr.) **(Rus)**

[Retrospective estimation of the frequency of heterozygous beta-thalassemia in the Crimean Tatar population. Estimation of gene frequency in the ancestral population based on mixed population data with a known admixture rate] Asanov AIu, et al. **Genetika** 1996 Dec;32(12):1687-9 (Eng. Abstr.) **(Rus)**

[A unified methodological approach in the algorithmic construction and design of expert systems of the health-pathology type in medicine] Belousov VA, et al. **Med Tekh** 1996 May-Jun;(3):6-7 (Eng. Abstr.) **(Rus)**

[Testing signal for checking measuring ECG algorithms in automatic systems] Lebedev VV, et al. **Med Tekh** 1997 May-Jun;(3):40-1 (Eng. Abstr.) **(Rus)**

[A combinatorial algorithm for highly specific recognition of protein-coding regions in DNA sequences from higher eukaryotes] Roitberg MA, et al. **Mol Biol (Mosk)** 1997 Jan-Feb;31(1):25-31 **(Rus)**

[An algorithm of neuroradiological examination of patients with acute craniocerebral injuries] Anan'eva NI, et al. **Vestn Rentgenol Radiol** 1996 Nov-Dec;(6):30 **(Rus)**

[Experience in the realization of diagnostic and treatment algorithms in ischemic heart disease and arterial hypertension] Fisun AIa. **Voen Med Zh** 1997 Jul; 318(7):56-8 **(Rus)**

[Comparative study of 3 algorithms to localize the accessory pathway in Wolff-Parkinson-White syndrome] Alvarez López M, et al. **Rev Esp Cardiol** 1996 Aug;49(8):589-97 (Eng. Abstr.) **(Spa)**

[Clinical protocols in digestive system hemorrhage caused by peptic ulcer] Ruiz del Arbol Olmos L, et al. **Rev Esp Enferm Dig** 1996 Nov;88(11):785-98 (137 ref.) **(Spa)**

[Algorithm management for detection of monoclonal gammopathies in serum. Experience of the Instituto Nacional de Cancerología in México] Guarner J, et al. **Rev Med Chil** 1995 Dec;123(12):1499-504 (Eng. Abstr.) **(Spa)**

[A patient with a bad stomach--is there anything we can do? (see comments)] Brun J. **Nord Med** 1996 Oct; 111(8):291-2. Comment in: Nord Med 1997 May;112(5):176-7. **(Swe)**

ALIENATION, SOCIAL see **SOCIAL ALIENATION**

ALIMEMAZINE see **TRIMEPRAZINE**

ALKADIENES

ANALYSIS

Genetics of a difference in cuticular hydrocarbons between Drosophila pseudoobscura and D. persimilis. Noor MA, et al. **Genet Res** 1996 Oct;68(2):117-23

CHEMISTRY

Structure of hexadienoyl-CoA bound to enoyl-CoA hydratase determined by transferred nuclear Overhauser effect measurements: mechanistic predictions based on the X-ray structure of 4-(chlorobenzoyl)-CoA dehalogenase. Wu WJ, et al. **Biochemistry** 1997 Feb 25;36(8):2211-20

Structure analysis of an allene-containing estolide tetraester triglyceride in the seed oil of Sebastiana commersoniana (Euphorbiaceae). Spitzer V, et al. **Lipids** 1997 May; 32(5):549-57

METABOLISM

Genetics of a pheromonal difference affecting sexual isolation between Drosophila mauritiana and D. sechellia. Coyne JA, et al. **Genetics** 1997 Apr;145(4):1015-30

ALKALESCENS-DISPAR GROUP see **ESCHERICHIA COLI**

ALKALI see **ALKALIES**

ALKALI METALS see **METALS, ALKALI**

ALKALIES

see related
HYPERCALCEMIA

A simple and rapid procedure for hydrolyzing minute amounts of proteins with alkali. Landry J, et al. **Anal Biochem** 1996 Dec 1;243(1):191-4

Cytokine expression in the alkali-burned cornea. Sotozono C, et al. **Curr Eye Res** 1997 Jul;16(7):670-6

ADVERSE EFFECTS

Preventing symblepharon formation with a gelatin sponge in the eye of a patient with an alkali burn. Yamada M, et al. **Am J Ophthalmol** 1997 Apr;123(4):552-4

A simple ocular irrigation system for alkaline burns of the eye. Terzidou C, et al. **Ophthalmic Surg Lasers** 1997 Mar; 28(3):255-7

ANALYSIS

Characterization of acid and alkaline reflux in patients with Barrett's esophagus. G.O.S.P.E. Operative Group for the study of Esophageal Precancer. D'Onofrio V, et al. **Dis Esophagus** 1997 Jan;10(1):16-22; discussion 22-3

pH gradient electrophoresis of basic ribonucleases in sealed slab polyacrylamide gels: detection and inhibition of enzyme activity in the gel. Nadano D, et al. **Electrophoresis** 1996 Jan;17(1):104-9

BLOOD

Alkalemia reduces recovery from global cerebral ischemia by NMDA receptor-mediated mechanism. Hurn PD, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2557-62

CHEMISTRY

General equation for calculating the dissociation constants of polyprotic acids and bases from measured retention factors in high-performance liquid chromatography. Jano I, et al. **J Chromatogr A** 1997 Feb 21;762(1-2):63-72

Mechanism of linoleic acid hydroperoxide reaction with alkali. Gardner HW, et al. **Lipids** 1996 Oct;31(10):1023-8

METABOLISM

Role of intracellular alkalinization in inhibition of acetylcholine-induced relaxation by FMLP in rat aorta. Ando K, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2405-10

Beta 2-adrenergic receptors enhance contractility by stimulating HCO3(-)-dependent intracellular alkalinization. Jiang T, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H1044-7

Potassium depletion and acid-base transporters in rat kidney: differential effect of hypophysectomy. Wang Z, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):F736-43

Roles of Ca2+ and PKC in regulation of acid/base transport in isolated proximal tubules. Yamada H, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):F1068-76

Bogoriella caseilytica gen. nov., sp. nov., a new alkaliphilic actinomycete from a soda lake in Africa. Groth I, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):788-94

Alkaline pH facilitates the exchange of guanine nucleotides: a possible mechanism for modulation of the kinetics of responses mediated by guanine nucleotide-binding proteins. Lipinsky D, et al. **J Cell Physiol** 1996 Oct;169(1):167-74

Glial alkalinization detected in vivo by 1H-15N heteronuclear multiple-quantum coherence-transfer NMR in severely hyperammonemic rat. Kanamori K, et al. **J Neurochem** 1997 Mar;68(3):1209-20

Temporal resolution of activity-dependent pH shifts in rat hippocampal slices. Gottfried JA, et al. **J Neurophysiol** 1996 Oct;76(4):2804-7

PHARMACOLOGY

Alkaline stress response in Enterococcus faecalis: adaptation, cross-protection, and changes in protein synthesis. Flahaut S, et al. **Appl Environ Microbiol** 1997 Feb;63(2):812-4

Performance of broiler chicks fed on alkali-treated neem (Azadirachta indica) kernel cake as a protein supplement. Nagalakshmi D, et al. **Br Poult Sci** 1996 Sep;37(4):809-18

Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. Schrader-Fischer G, et al. **Brain Res** 1996 Apr 15;716(1-2):91-100

An excess of topical calcium and magnesium reverses the therapeutic effect of citrate on the development of corneal ulcers after alkali injury. Haddox JL, et al. **Cornea** 1996 Mar;15(2):191-5

Appearance of immune cells and expression of MHC II DQ molecule by fibroblasts in alkali-burned corneas. Kao WW, et al. **Cornea** 1996 Jul;15(4):397-408

Effect of alkali metal cations on slow inactivation of cardiac Na+ channels. Townsend C, et al. **J Gen Physiol** 1997 Jul;110(1):23-33

Vacuolar H(+)-ATPase and weak base action in Dictyostelium. Davies L, et al. **Mol Microbiol** 1996 Oct; 22(1):119-26

Effect of alkalinization of cytosolic pH by amines on intracellular Ca2+ activity in HT29 cells. Benning N, et al. **Pflugers Arch** 1996 May;432(1):126-33

Effect of alkali treatments on the nutritive value of common bean (Phaseolus vulgaris). Jyothi V, et al. **Plant Foods Hum Nutr** 1995 Oct;48(3):193-200

THERAPEUTIC USE

Alkali therapy extends the period of survival during hypoxia: studies in rats. Halperin FA, et al. **Am J Physiol** 1996 Aug; 271(2 Pt 2):R381-7

TOXICITY

Role of G-->T transversions in the mutagenicity of alkylperoxyl radicals: induction of alkali-labile sites in bacteriophage M13mp19. Harkin LA, et al. **Chem Res Toxicol** 1997 May;10(5):575-81

Influence of alkaline ionized water on rat erythrocyte hexokinase activity and myocardium. Watanabe T, et al. **J Toxicol Sci** 1997 May;22(2):141-52

ALKALINE EARTH METALS see **METALS, ALKALINE EARTH**

ALKALINE PHOSPHATASE

see related
HYPOPHOSPHATASIA

ADMINISTRATION & DOSAGE

Net-shaped hydroxyapatite implants for release of agents modulating periodontal-like tissues. Denissen H, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 1):40-6

ANALYSIS

Histochemistry of therapeutically relevant enzymes in human tumours transplanted into severe combined immunodeficient (SCID) mice: nitric oxide synthase-associated diaphorase, beta-D-glucuronidase and non-specific alkaline phosphatase. Schumacher U, et al. **Acta Histochem** 1996 Nov;98(4):381-7

Interethnic variability in birth weight and genetic background: a study of placental alkaline phosphatase. Amante A, et al. **Am J Phys Anthropol** 1996 Dec; 101(4):449-53

Lung alkaline phosphatase as a marker of fibrosis in chronic interstitial disorders. Capelli A, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):249-53

Protein patterning with a photoactivatable derivative of biotin. Hengsakul M, et al. **Bioconjug Chem** 1996 Mar-Apr; 7(2):249-54

Simultaneous demonstration of alkaline and acid phosphatase activity in bone, at bone-implant interfaces and at the epiphyseal growth plate in plastic-embedded undemineralized tissues. Piattelli A, et al. **Biomaterials** 1997 Apr;18(7):545-9

Biochemical markers of bone metabolism after short and long time ethanol withdrawal in alcoholics. Nyquist F, et al. **Bone** 1996 Jul;19(1):51-4

Simultaneous detection of all four alkaline phosphatase isoenzymes in human germ cell tumors using reverse transcription-PCR. Schär BK, et al. **Cancer Res** 1997 Sep 1;57(17):3841-6

Pleural alkaline phosphatase in separation of transudative and exudative pleural effusions [letter; comment] Gazquez I, et al. **Chest** 1997 Aug;112(2):569-70. Comment on: Chest 1994 Jun;105(6):1912-3.

A variant alkaline phosphatase detected in a patient with lung cancer. Miyanaga M, et al. **Enzyme Protein** 1996; 49(5-6):313-20

Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques. Bansi DS, et al. **Eur J Gastroenterol Hepatol** 1997 Jun;9(6):575-80

Echinococcus multilocularis metacestodes: immunological and immunocytochemical analysis of the relationships between alkaline phosphatase and the Em2 antigen. Lawton P, et al. **Exp Parasitol** 1997 Oct;87(2):142-9

Immunolocalization of tissue non-specific alkaline phosphatase in mice. Hoshi K, et al. **Histochem Cell Biol** 1997 Mar;107(3):183-91

Osteogenesis by pulsing electromagnetic fields (PEMFs): optimum stimulation setting. Matsunaga S, et al. **In Vivo** 1996 May-Jun;10(3):351-6

Activity of alkaline phosphatase in water-in-oil microemulsions containing vegetable oil. Gupta S, et al. **Indian J Biochem Biophys** 1995 Oct;32(5):261-5

A neural precursor cell line derived from murine teratocarcinoma. Hasgekar N, et al. **Int J Dev Biol** 1996 Jun;40(3):591-7

Erythrocyte alkaline phosphatase in patients with myotonic muscle disorders. Goldemberg AL, et al. **Invest Clin** 1996 Dec;37(4):247-53

Ultrastructural, enzyme-, lectin, and immunohistochemical studies of the erosion zone in rat tibiae. Nakamura H, et al. **J Bone Miner Res** 1996 Aug;11(8):1158-64

Chemiluminescent assay of alkaline phosphatase in human gingival crevicular fluid: investigations with an experimental gingivitis model and studies on the source of the enzyme within crevicular fluid. Chapple IL, et al. **J Clin Periodontol** 1996 Jun;23(6):587-94

New fracture-labelling method: alkaline phosphatase in unstimulated human neutrophils. Takizawa T, et al. **J Electron Microsc (Tokyo)** 1997;46(1):85-91

Isolation of alkaline phosphatase-positive gingival fibroblasts from patients with chronic inflammatory periodontal disease. Abe T, et al. **J Periodontal Res** 1996 May; 31(4):285-93

Ultracytochemical localization of alkaline phosphatase (ALPase) activity in neutrophils of the rat lung following injection of lipopolysaccharide. Jiang X, et al. **Kaibogaku Zasshi** 1996 Jun;71(3):183-94

Enzyme-histochemical study on postnatal development of rat stomach lymphatic vessels. Ji RC, et al. **Microvasc Res** 1997 Jul;54(1):1-12

Developmental study of ultrastructural and biochemical changes in isolated chick brain microvessels. Nico B, et al. **Microvasc Res** 1997 Jan;53(1):79-91

Human placental ecto-enzymes: studies on the plasma membrane anchorage and effect of inhibitors of ATP-metabolizing enzymes. Chayet L, et al. **Res Commun Mol Pathol Pharmacol** 1997 Apr;96(1):14-24

[Measurement of aspecific alkaline phosphatase in the intraoperative histological examination of the breast] Vigliani R, et al. **Pathologica** 1997 Feb;89(1):44-53 (Eng. Abstr.) **(Ita)**

[Characteristics of alkaline and acid phosphatase in Spirometra erinacei] Kwak KH, et al. **Korean J Parasitol** 1996 Mar;34(1):69-77 (Eng. Abstr.) **(Kor)**

ANTAGONISTS & INHIBITORS

Inhibition by sodium thiophosphate and L-p-bromotetramisole of neutrophil alkaline phosphatase in normal and trisomy 21 pregnancies. Denier CJ, et al. **Ann Clin Biochem** 1996 May;33 (Pt 3):215-8

Kinetics of inhibition of green crab (Scylla serrata) alkaline phosphatase by phenylglyoxal. Xie WZ, et al. **Biochem Mol Biol Int** 1996 Nov;40(5):981-91

All-trans retinoic acid inhibits dexamethasone-induced ALP activity and mineralization in human osteoblastic cell line SV HFO. Nuka S, et al. **Cell Struct Funct** 1997 Feb; 22(1):27-32

Kinetics of inhibition of alkaline phosphatase from green crab (Scylla serrata) by N-bromosuccinimide. Chen QX, et al. **J Protein Chem** 1996 May;15(4):345-50

Comparison of inactivation and unfolding of green crab (Scylla serrata) alkaline phosphatase during denaturation by guanidinium chloride. Chen QX, et al. **J Protein Chem** 1996 May;15(4):359-65

BIOSYNTHESIS

Prenatal ethanol exposure alters the expression of intestinal hydrolase mRNAs in newborn rats. Estrada G, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9):1662-8

Interleukin-1 beta enhances and tumor necrosis factor-alpha inhibits bone morphogenetic protein-2-induced alkaline phosphatase activity in MC3T3-E1 osteoblastic cells. Nakase T, et al. **Bone** 1997 Jul;21(1):17-21

Alkaline phosphatase in osteoblasts is down-regulated by pulsatile fluid flow. Hillsley MV, et al. **Calcif Tissue Int** 1997 Jan;60(1):48-53

Stable transfection of nonosteogenic cell lines with tissue nonspecific alkaline phosphatase enhances mineral deposition both in the presence and absence of beta-glycerophosphate: possible role for alkaline phosphatase in pathological mineralization. Hui M, et al. **Calcif Tissue Int** 1997 May;60(5):467-72

Purification of primordial germ cells from TNAPbeta-geo mouse embryos using FACS-gal. Abe K, et al. **Dev Biol** 1996 Dec 15;180(2):468-72

Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. Vejlgaard T, et al. **Eur J Haematol** 1997 Feb;58(2):104-8

PKC-dependent long-term effect of PMA on protein cell surface expression in Caco-2 cells. Sapin C, et al. **Exp Cell Res** 1997 Mar 15;231(2):308-18

Regulation of phosphatase synthesis in Saccharomyces cerevisiae--a review. Oshima Y, et al. **Gene** 1996 Nov 7; 179(1):171-7 (50 ref.)

Expression of alkaline phosphatase by a B-cell hybridoma and its modulation during cell growth and apoptosis. Souvannavong V, et al. **Immunol Lett** 1995 Sep; 47(3):163-70

Constitutive expression of non-bone/liver/kidney alkaline phosphatase in human osteosarcoma cell lines. Ali NN, et al. **J Bone Miner Res** 1996 Apr;11(4):512-20

Expression of mRNA encoding intestinal type alkaline phosphatase in rat liver and its increase by fat-feeding. Goseki-Sone M, et al. **Liver** 1996 Dec;16(6):358-64

Gain-of-function mutation of sapB that affects formation of alkaline phosphatase by Bacillus subtilis in sporulation conditions. Whalen MB, et al. **Microbiology** 1997 Feb;143 (Pt 2):577-83

Lack of correlation between NADPH-oxidase priming and elevated alkaline phosphatase activity in cord blood neutrophils. Khalfan L, et al. **Pediatr Allergy Immunol** 1995 Aug;6(3):161-4

Similarities and differences among inner retinal neurons revealed by the expression of reporter transgenes controlled by Brn-3a, Brn-3b, and Brn-3c promotor sequences. Xiang M, et al. **Vis Neurosci** 1996 Sep-Oct;13(5):955-62

BLOOD

Hyperphosphatasemia in early diagnosed infantile GM1 gangliosidosis presenting as transient hydrops fetalis. Denis R, et al. **Acta Clin Belg** 1996;51(5):320-7

Comparison of total alkaline phosphatase and three assays for bone-specific alkaline phosphatase in childhood and adolescence. Rauch F, et al. **Acta Paediatr** 1997 Jun; 86(6):583-7

Evaluation of alkaline phosphatase immunoassay and comparison with other diagnostic methods in areas of low transmission of schistosomiasis. Alarcón de Noya BA, et al. **Acta Trop** 1997 Aug;66(2):69-78

CCK-8 infusion increases plasma LMW alkaline phosphatase coincident with enterohepatic circulation of bile acids. Solter PF, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):G381-8

Alendronate in the treatment of Paget's disease of bone. Khan SA, et al. **Bone** 1997 Mar;20(3):263-71

Dissociation of bone formation markers in bone metastasis of prostate cancer. Koizumi M, et al. **Br J Cancer** 1997; 75(11):1601-4

The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis. Chen SS, et al. **Br J Urol** 1997 Feb;79(2):217-20

The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer. Nguyen-Pamart M, et al. **Br J Urol** 1997 Sep;80(3):452-5

New developments in biochemical markers for osteoporosis. Garnero P, et al. **Calcif Tissue Int** 1996;59 Suppl 1:S2-9 (79 ref.)

Clinical observations with a new specific assay for bone alkaline phosphatase: a cross-sectional study in osteoporotic and pagetic subjects and a longitudinal evaluation of the response to ovariectomy, estrogens, and bisphosphonates. Pedrazzoni M, et al. **Calcif Tissue Int** 1996 Nov;59(5):334-8

Sexual differences in bone markers and bone mineral density of normal Chinese. Tsai KS, et al. **Calcif Tissue Int** 1996 Dec;59(6):454-60

Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Morote J, et al. **Cancer** 1996 Dec 1;78(11):2374-8

Immunoadsorption assay for bone alkaline phosphatase compared with wheat germ agglutinin precipitation assay in serum from (pre)pubertal girls. Bouman AA, et al. **Clin Chem** 1996 Dec;42(12):1970-4

Increased alkaline phosphatase isoforms in autoimmune diseases. Hanna AN, et al. **Clin Chem** 1997 Aug;43(8 Pt 1):1357-64

Different age-related trends of bone and nonbone forms of alkaline phosphatase in Chinese men and women. Hsu SH, et al. **Clin Chem** 1997 Jan;43(1):186-8

Relations between intestinal alkaline phosphatase activity and insulin secretion in obese patients [letter] Ognibene A, et al. **Clin Chem** 1997 Sep;43(9):1672-3

More on total and bone-specific alkaline phosphatase [letter] Withold W. **Clin Chem** 1997 Sep;43(9):1670-2

Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases. Woitge HW, et al. **Clin Chem** 1996 Nov; 42(11):1796-804

Diagnostic discrimination and cost effective assay strategy for leukocyte alkaline phosphatase. DePalma L, et al. **Clin Chim Acta** 1996 Jan 15;244(1):83-90

Assessment of the performance of a capture immunoassay for the bone isoform of alkaline phosphatase in serum. Milligan TP, et al. **Clin Chim Acta** 1997 Jul 25; 263(2):165-75

Serum alkaline phosphatase activity during zinc deficiency and long-term inflammatory stress. Naber TH, et al. **Clin Chim Acta** 1996 May 30;249(1-2):109-27

Serum bone alkaline phosphatase is superior to plasma levels of bone matrix proteins for assessment of bone metabolism in patients receiving renal transplants. Withold W, et al. **Clin Chim Acta** 1997 May 28;261(2):105-15

Benign familial hyperphosphatasemia: a report of two families and review of the literature. Crespo-Peña M, et al. **Clin Exp Rheumatol** 1997 Jul-Aug;15(4):425-31 (36 ref.)

Benign transient hyperphosphatasemia in children with leukemia and lymphoma [see comments] Massey GV, et al. **Clin Pediatr (Phila)** 1996 Oct;35(10):501-4. Comment in: Clin Pediatr (Phila) 1997 Aug;36(8):491-2.

Transient alkaline hyperphosphatasaemia in an adult: biochemical peculiarities. Schambeck CM, et al. **Eur J Clin Chem Clin Biochem** 1997 Jun;35(6):441-4

Isoforms of alkaline phosphatase determined by isoelectric focusing in patients with chronic liver disorders. Wallace BH, et al. **Eur J Clin Chem Clin Biochem** 1996 Sep; 34(9):711-20

The value of tumor markers in testicular seminomas. Results of a prospective multicenter study. Weissbach L, et al. **Eur Urol** 1997;32(1):16-22

Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer. Wolff JM, et al. **Eur Urol** 1996;30(3):302-6

Identification of rat serum alkaline phosphatase isoenzyme by means of wheat germ agglutinin. Wada H, et al. **Exp Anim** 1997 Jan;46(1):89-92

An automated image analysis method for the measurement of neutrophil alkaline phosphatase in the prenatal screening of Down syndrome. Tafas T, et al. **Fetal Diagn Ther** 1996 Jul-Aug;11(4):254-9

Different starting times of alpha-tocopherol and gamma-tocotrienol supplementation and tumor marker enzyme activities in the rat chemically induced with cancer. Makpol S, et al. **Gen Pharmacol** 1997 Apr;28(4):589-92

Changes in serum protease inhibitors and liver specific enzymes in experimental jaundice. Mishra JP, et al. **Indian J Med Sci** 1996 Jul;50(7):221-7

Management of primary idiopathic hyperphosphatasemia with calcitonin: a case report. Roth AJ, et al. **Int Orthop** 1996;20(1):58-60 (14 ref.)

Divergent concentrations of plasma metabolites in swine selected for seven generations for high or low plasma total cholesterol. Pond WG, et al. **J Anim Sci** 1997 Feb; 75(2):311-6

Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency. Magnusson P, et al. **J Bone Miner Res** 1997 Feb;12(2):210-20

Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and

response to GH therapy. Tobiume H, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2056–61

Diagnosis of primary liver cancer using lectin affinity chromatography of serum alkaline phosphatase. Lu Y, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):75–80

Plasma alkaline phosphatase and pregnancy outcome. Goldenberg RL, et al. **J Matern Fetal Med** 1997 May–Jun; 6(3):140–5

Changes of serum alkaline phosphatase isoenzymes in fasted rats. Wada H, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Oct;42(5):435–47

Transient hyperphosphatasaemia and malabsorption syndrome [letter] Bayer M, et al. **J Paediatr Child Health** 1996 Apr;32(2):197

Benign transient hyperphosphatasaemia associated with adenovirus infection. Ng PC, et al. **J Paediatr Child Health** 1995 Dec;31(6):561–2

Detection of maternofetal transfusion by placental alkaline phosphatase levels. Kaneda T, et al. **J Pediatr** 1997 May; 130(5):730–5

The role of gamma–glutamyl transpeptidase in the preoperative metastatic evaluation of renal cell carcinoma. Sandock DS, et al. **J Urol** 1997 Mar;157(3):798–9

Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate [see comments] Smith JA Jr, et al. **J Urol** 1997 Apr;157(4):1329–34. Comment in: J Urol 1997 Apr;157(4):1335–6.

Electrophoretic study of lactate dehydrogenase and alkaline phosphatase isoenzymes of the Mongolian gerbil (Meriones unguiculatus). Shimizu M, et al. **J Vet Med Sci** 1996 May; 58(5):401–6

A new hepatitis C virus–like flavivirus in patients with cryptogenic liver disease associated with elevated GGT and alkaline phosphatase serum levels. Colombatto P, et al. **J Viral Hepat** 1997;4 Suppl 1:55–60

Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease? [corrected] [published erratum appears in J Viral Hepat 1997 Mar;4(2):143] Colombatto P, et al. **J Viral Hepat** 1996 Nov;3(6):301–6

Prognostic value of the doubling time of serum C–reactive protein and alkaline phosphatase levels in primary bone and soft tissue tumors. Yudoh K, et al. **Jpn J Cancer Res** 1996 Dec;87(12):1288–95

Hospital prevalence of asymptomatic primary biliary cirrhosis: 4–year study based on analysis of 4468 consecutive in–patients. Magrini A, et al. **Liver** 1996 Dec; 16(6):377–9

Primary biliary cirrhosis [letter; comment] Caldwell SH. **N Engl J Med** 1997 May 8;336(19):1387; discussion 1388 . Comment on: N Engl J Med 1996 Nov 21;335(21):1570–80.

Leukocyte alkaline phosphatase and serum alkaline phosphatase in patients with metastatic breast and colon cancer. Walach N, et al. **Neoplasma** 1996;43(5):297–300

Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Couttenye MM, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):1065–72

Bone alkaline phosphatase isoenzyme in renal osteodystrophy. Jarava C, et al. **Nephrol Dial Transplant** 1996;11 Suppl 3:43–6

Transient hyperphosphatasaemia in a 4–year–old boy after successful kidney transplantation. Schwab M, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1745–9

Age–related changes of plasma alkaline phosphatase and inorganic phosphorus, and late ossification of the cranial roof in the Spanish imperial eagle (Aquila adalberti C. L. Brehm, 1861). Dobado–Berrios PM, et al. **Physiol Zool** 1997 Jul–Aug;70(4):421–7

Heat–stable and immunoreactive placental alkaline phosphatase in maternal serum from Down's syndrome and trisomy 18 pregnancies. Aitken DA, et al. **Prenat Diagn** 1996 Nov;16(11):1051–4

Measurement of bone specific alkaline phosphatase in the horse: a comparison of two techniques. Jackson B, et al. **Res Vet Sci** 1996 Sep;61(2):160–4

Biochemical markers of bone turnover in osteoporosis. Delmas PD, et al. **Rev Rhum Engl Ed** 1997 Jun 30;64(6 Suppl):31S–36S (70 ref.)

Serum lactate dehydrogenase and alkaline phosphatase activities and serum cholesterol level in bone marrow blood. Cucuianu A, et al. **Rom J Intern Med** 1996 Jul–Dec; 34(3–4):173–82

Clear–cell chondrosarcoma with elevated alkaline phosphatase, mistaken for osteosarcoma on biopsy. Brien EW, et al. **Skeletal Radiol** 1996 Nov;25(8):770–4

Transient hyperphosphatasemia after liver transplantation in infancy. Lachaux A, et al. **Transplant Proc** 1996 Oct; 28(5):2847

Skeletal alkaline phosphatase: a marker for individual follow–up in patients with advanced prostatic cancer. Wechsel HW, et al. **Urol Int** 1997;58(2):80–3

Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Seaman E, et al. **Urology** 1996 Nov;48(5):692–5

[Detection of liver metastases from digestive cancer. Value of alkaline phosphatases, their macromolecular isoenzyme and of ceruloplasmin] Piva MT, et al. **Ann Biol Clin (Paris)** 1997 May–Jun;55(3):209–14 (Eng. Abstr.) **(Fre)**

[Respective value of serum activity of alkaline phosphatase, gamma–glutamyl transpeptidase and 5'–nucleotidase in the diagnosis of intra– and extrahepatic cholestasis (letter)] Sapey T, et al. **Gastroenterol Clin Biol** 1997;21(4):339–40 **(Fre)**

[Alkaline phosphatase of bone origin in hemodialyzed patients. 110 assays] Ureña P, et al. **Presse Med** 1996 Oct 5;25(29):1320–5 (Eng. Abstr.) **(Fre)**

[Course of blood levels of calcium, inorganic phosphate, alkaline phosphatase, parathyroid hormone and calcidiol (25–OH–D3) in one and two year old thoroughbred horses] Enbergs H, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Dec;103(12):491–3 (Eng. Abstr.) **(Ger)**

[Multiple bone pain, significant weight loss, multiple enhanced uptake in bone scintigraphy and massively increased alkaline phosphatase in a patient after stomach resection 27 years previously (clinical conference)] Rzepka AH, et al. **Med Klin** 1996 Feb 15;91(2):72–5 **(Ger)**

[Transitory hyperphosphatasemia in childhood. Nine cases and revision of Spanish contributions] Diego Núñez MA, et al. **An Esp Pediatr** 1997 May;46(5):503–7 (57 ref.) **(Spa)**

[Isolated increased of blood alkaline phosphatases, induced by diphenylhydantoin. Clinical interest (letter)] Gil González I. **An Med Interna** 1995 Aug;12(8):409–10 **(Spa)**

[Diagnostic efficiency of biological markers of alcohol consumption for the detection of excessive drinkers] Rubio C, et al. **An Med Interna** 1996 Jun;13(6):274–8 (Eng. Abstr.) **(Spa)**

[Clinical meaning of increased alkaline phosphatase] Ponce A, et al. **Rev Clin Esp** 1997 Mar;197(3):176–9 (34 ref.) **(Spa)**

[Asymptomatic elevation of plasmatic alkaline phosphatases secondary to benign familial hyperphosphatasemia in a patient] González G, et al. **Rev Med Chil** 1996 Sep; 124(9):1107–10 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Characterization of fluorescent nucleoside triphosphates by capillary electrophoresis with laser–induced fluorescence detection: action of alkaline phosphatase and DNA polymerase. Evangelista RA, et al. **Anal Biochem** 1996 Mar 1;235(1):89–97

Human tissue non–specific alkaline phosphatases: sugar–moiety–induced enzymic and antigenic modulations and genetic aspects. Nosjean O, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):297–303

Interaction of alkaline phosphatase with cytochrome c. Dadák V, et al. **Biochim Biophys Acta** 1996 Sep 13; 1297(1):69–76

Physicochemical and pathophysiological factors in the release of membrane–bound alkaline phosphatase from cells. Moss DW. **Clin Chim Acta** 1997 Jan 3;257(1):133–40 (27 ref.)

Microheterogeneity of rat serum alkaline phosphatase in fasting state: characterization of two duodenal alkaline phosphatase glycoforms. Japundzic I, et al. **Digestion** 1997; 58(2):181–8

Biochemical evidence for membrane–bound endoderm–specific alkaline phosphatase in larvae of the ascidian, Halocynthia roretzi. Kumano G, et al. **Eur J Biochem** 1996 Sep 1;240(2):485–9

Kinetics of inactivation of green crab (Scylla Serrata) alkaline phosphatase during removal of zinc ions by ethylenediaminetetraacetic acid disodium. Chen QX, et al. **Int J Biol Macromol** 1996 Dec;19(4):257–61

Roles of disulfide bonds in bacterial alkaline phosphatase. Sone M, et al. **J Biol Chem** 1997 Mar 7;272(10):6174–8

Pressure effects on the structure of oligomeric proteins prior to subunit dissociation. Cioni P, et al. **J Mol Biol** 1996 Nov 15;263(5):789–99

A pig collagen peptide fraction. A unique material for maintaining biological activity during lyophilization and during storage in the liquid state. Gaffney PJ, et al. **J Pharm Pharmacol** 1996 Sep;48(9):896–8

Detection of human cytomegalovirus polymerase chain reaction products using oligonucleotide probes directly conjugated to alkaline phosphatase [published erratum appears in J Virol Methods 1996 Dec;62(2):185] Gor D, et al. **J Virol Methods** 1996 Sep;61(1–2):145–50

Trapping and visualization of a covalent enzyme–phosphate intermediate [letter] Murphy JE, et al. **Nat Struct Biol** 1997 Aug;4(8):618–22

[Analysis of the effect of replacing Lys(–20) in the alkaline phosphatase signal peptide on secretion of this enzyme] Karamysheva ZN, et al. **Biokhimiia** 1996 Apr;61(4):745–54 (Eng. Abstr.) **(Rus)**

DEFICIENCY

Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression–associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome I. Niedermayer I, et al. **J Neuropathol Exp Neurol** 1997 Aug;56(8):879–86

DIAGNOSTIC USE

A comparative study of digoxigenin, 2,4–dinitrophenyl, and alkaline phosphatase as deoxyoligonucleotide labels in non–radioisotopic in situ hybridisation. Harper SJ, et al. **J Clin Pathol** 1997 Aug;50(8):686–90

Enzyme immunoassay technique using alkaline phosphatase enzyme labels and a Nafion electrode as sensor. Degrand C, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1343–9

[Detection and identification method of three mycobacterium species and genus specific detection by polymerase chain reaction and DNA hybridization with alkaline phosphatase labeled oligonucleotide probe] Komatsu M, et al. **Kansenshogaku Zasshi** 1996 Feb;70(2):141–50 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged L–thyroxine therapy. Leger J, et al. **Acta Paediatr** 1997 Jul;86(7):704–10

Effects of triiodothyronine on the morphology of cells and matrix, the localization of alkaline phosphatase, and the frequency of apoptosis in long–term cultures of MC3T3–E1 cells. Fratzl–Zelman N, et al. **Bone** 1997 Mar;20(3):225–36

Blockade of the stimulatory effect of estrogens, OH–tamoxifen, OH–toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM–800 in human endometrial adenocarcinoma Ishikawa cells. Simard J, et al. **Cancer Res** 1997 Aug 15;57(16):3494–7

Different responses of bone alkaline phosphatase isoforms during recombinant insulin–like growth factor–I (IGF–I) and during growth hormone therapy in adults with growth hormone deficiency. Magnusson P, et al. **J Bone Miner Res** 1997 Feb;12(2):210–20

Effects of vitamin B12 on cell proliferation and cellular alkaline phosphatase activity in human bone marrow stromal osteoprogenitor cells and UMR106 osteoblastic cells. Kim GS, et al. **Metabolism** 1996 Dec;45(12):1443–6

ECONOMICS

Diagnostic discrimination and cost effective assay strategy for leukocyte alkaline phosphatase. DePalma L, et al. **Clin Chim Acta** 1996 Jan 15;244(1):83–90

GENETICS

Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Narisawa S, et al. **Dev Dyn** 1997 Mar;208(3):432–46

In situ investigation of vitamin D receptor, alkaline phosphatase, and osteocalcin gene expression in oro–facial mineralized tissues. Davideau JL, et al. **Endocrinology** 1996 Aug;137(8):3577–85

Rat intestinal alkaline phosphatase II messenger RNA is present in duodenal crypt and villus cells. Xie QM, et al. **Gastroenterology** 1997 Feb;112(2):376–86

Caste variation of two placental phosphatases. Kumari SA, et al. **Gene Geogr** 1996 Aug;10(2):75–7

Distribution of placental alkaline phosphatase (PLAP) gene frequencies in Andhra Pradesh (south India). Swamy TV, et al. **Gene Geogr** 1996 Aug;10(2):79–81

Detection of deletion 1154–1156 hypophosphatasia mutation using TNSALP exon amplification. Orimo H, et al. **Genomics** 1997 Jun 1;42(2):364–6

Targeted nucleotide exchange in the alkaline phosphatase gene of HuH–7 cells mediated by a chimeric RNA/DNA oligonucleotide. Kren BT, et al. **Hepatology** 1997 Jun; 25(6):1462–8

Defective export in Escherichia coli caused by DsbA'–PhoA hybrid proteins whose DsbA' domain cannot fold into a conformation resistant to periplasmic proteases. Guigueno A, et al. **J Bacteriol** 1997 May;179(10):3260–9

Alkaline phosphatase–Strep tag fusion protein binding to streptavidin: resonant mirror studies. Hengsakul M, et al. **J Mol Biol** 1997 Feb 28;266(3):621–32

Retinoic acid and methylation cis–regulatory elements control the mouse tissue non–specific alkaline phosphatase gene expression. Escalante–Alcalde D, et al. **Mech Dev** 1996 Jun;57(1):21–32

Human placental alkaline phosphatase as a marker for gene expression. Bates P, et al. **Methods Mol Biol** 1997;63:41–8

Use of secreted alkaline phosphatase as a reporter of gene expression in mammalian cells. Kain SR. **Methods Mol Biol** 1997;63:49–60

Amino–terminal charge affects the periplasmic accumulation of recombinant heregulin/EGF hybrids exported using the Escherichia coli alkaline phosphatase signal sequence. Campion SR, et al. **Protein Expr Purif** 1997 Aug; 10(3):331–9

Human placental alkaline phosphatase as a histochemical marker of gene expression in transgenic mice. DePrimo SE, et al. **Transgenic Res** 1996 Nov;5(6):459–66

IMMUNOLOGY

Human tissue non–specific alkaline phosphatases: sugar–moiety–induced enzymic and antigenic modulations and genetic aspects. Nosjean O, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):297–303

Detection of T cells reactive to intestinal alkaline phosphatase, an autoantigen in acute bacterial infections, and discrimination between autoantigen–specific CD5+ and CD5– B cells. Kolbus N, et al. **Clin Exp Immunol** 1997 Apr;108(1):19–25

Monoclonal antibodies recognize 2300 years aged alkaline phosphatase. Etspüler H, et al. **Immunol Lett** 1995 Dec; 48(3):187–91

A scFv–alkaline phosphatase fusion protein which detects

potato leafroll luteovirus in plant extracts by ELISA. Harper K, et al. **J Virol Methods** 1997 Jan;63(1-2):237-42

Antibodies against Echinococcus multilocularis alkaline phosphatase as markers for the specific diagnosis and the serological monitoring of alveolar echinococcosis. Sarciron EM, et al. **Parasite Immunol** 1997 Feb;19(2):61-8

Redesigned anti-human placental alkaline phosphatase single-chain Fv: soluble expression, characterization and in vivo tumour targeting. Deonarain MP, et al. **Protein Eng** 1997 Jan;10(1):89-98

[A patient showing increased T3 and T4 levels due to ALP-interfering substances and heterophilic antibody] Kawakita S. **Rinsho Byori** 1996 Sep;44(9):899-902 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Identification of human pulmonary alkaline phosphatase isoenzymes. Capelli A, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1448-52

Reversible and irreversible immobilization of enzymes on Graphite Fibrils. Dong L, et al. **J Mol Recognit** 1996 Sep-Dec;9(5-6):383-8

Purification and characterization of an extracellular alkaline phosphatase from Penicillium chrysogenum. Politino M, et al. **Prep Biochem Biotechnol** 1996 Aug-Nov; 26(3-4):171-81

[Immobilization of enzymes on carriers with magnetic properties: the search for optimum conditions for immobilization of alkaline phosphatase from the chicken gut] Surinenaĭte BR, et al. **Prikl Biokhim Mikrobiol** 1996 Nov-Dec;32(6):609-14 (Eng. Abstr.) **(Rus)**

METABOLISM

Alkaline phosphatase of cancerous larynx tissue in comparison with the placental enzyme. Biochemical and histochemical studies. al-Mudamgha ZA, et al. **Acta Oncol** 1997;36(2):213-8

Comparison of total alkaline phosphatase and three assays for bone-specific alkaline phosphatase in childhood and adolescence. Rauch F, et al. **Acta Paediatr** 1997 Jun; 86(6):583-7

1 alpha,25-dihydroxyvitamin D3 stimulated alkaline phosphatase activity in cultured pig kidney epithelial LLC-PK1 cells. Do Thanh X, et al. **Acta Physiol Scand** 1996 Sep;158(1):107-11

Different enzyme activities in coronary capillary endothelial cells. Koyama T, et al. **Adv Exp Med Biol** 1997;411:359-64

Hydrolysis of membrane-bound liver alkaline phosphatase by GPI-PLD requires bile salts. Deng JT, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):G655-63

Examining the specificity of Src homology 3 domain---ligand interactions with alkaline phosphatase fusion proteins. Yamabhai M, et al. **Anal Biochem** 1997 Apr 5;247(1):143-51

Serum osteocalcin, total and bone-specific alkaline phosphatase following isolated tibial shaft fracture. Bowles SA, et al. **Ann Clin Biochem** 1996 May;33 (Pt 3):196-200

Regulation and properties of bone alkaline phosphatase during vitamin C deficiency in guinea pigs. Mahmoodian F, et al. **Arch Biochem Biophys** 1996 Dec 1;336(1):86-96

Effect of a low-calcium environment on alkaline phosphatase activity in embryonic rat calvarial bone cells in culture. Yoshimura Y, et al. **Arch Oral Biol** 1996 Jan;41(1):41-5

An essential tryptophan residue of green crab (syclla serrata) alkaline phosphatase. Zheng WZ, et al. **Biochem Mol Biol Int** 1997 Apr;41(5):951-9

Effect of extracellular matrix and growth arrest on the alkaline phosphatase activity of F9 embryonal carcinoma cells. Fleming JV, et al. **Biochem Soc Trans** 1996 May; 24(2):221S

The effects of bile salts on the kinetic properties of enzymes used in the diagnosis of liver and kidney damage. Morgan WA, et al. **Biochem Soc Trans** 1997 Feb;25(1):76S

Interaction of the E. coli alkaline phosphatase precursor with model phospholipid membranes. Mikhaleva NI, et al. **Biochemistry (Mosc)** 1997 Feb;62(2):184-90

A new microassay for the determination of alkaline phosphatase activity in early mouse concepti. Ahumada A, et al. **Biol Res** 1994;27(3-4):241-6

Flow cytometry of leucocyte alkaline phosphatase in normal and pathologic leucocytes. Rambaldi A, et al. **Br J Haematol** 1997 Mar;96(4):815-22

A new approach using tissue alkaline phosphatase activity to identify early testicular cancer. Dabare AA, et al. **Br J Urol** 1997 Mar;79(3):455-60

Ultrastructure and cytochemical detection of alkaline phosphatase in long-term cultures of osteoblast-like cells from rat calvaria. Herbert B, et al. **Calcif Tissue Int** 1997 Feb;60(2):216-23

Alkaline phosphatase bone isoenzyme and osteocalcin in the serum of hyperthyroid cats. Archer FJ, et al. **Can Vet J** 1996 Dec;37(12):735-9

Comparison of bone and total alkaline phosphatase activity on bone turnover during menopause and in patients with established osteoporosis. Takahashi M, et al. **Clin Endocrinol (Oxf)** 1997 Aug;47(2):177-83

Adult hypophosphatasia in an aged patient [letter] Praet JP, et al. **Clin Exp Rheumatol** 1997 Jul-Aug;15(4):453

Modification of DNA topoisomerase I enzymatic activity with phosphotyrosyl protein phosphatase and alkaline phosphatase from the hepatopancreas of the shrimp Penaeus japonicus (Crustacea:Decapoda). Chuang NN, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jun; 114(2):145-51

Analysis of the temporal expression of endoderm-specific alkaline phosphatase during development of the ascidian Halocynthia roretzi. Nishida H, et al. **Dev Growth Differ** 1997 Apr;39(2):199-205

Evaluation of two markers of cell maturation and proliferation in cultured amniotic cells of trisomic 18 fetuses at the 15th week of gestation. Vergnes H, et al. **Early Hum Dev** 1997 Jul 24;49(1):1-5

Toxicology of cupric salts on honeybees. V. Gluconate and sulfate action on gut alkaline and acid phosphatases. Bounias M, et al. **Ecotoxicol Environ Saf** 1996 Oct; 35(1):67-76

Targeting of signal sequenceless proteins for export in Escherichia coli with altered protein translocase. Prinz WA, et al. **EMBO J** 1996 Oct 1;15(19):5209-17

Establishment and hormonal regulation of a conditionally transformed preosteocytic cell line from adult human bone. Bodine PV, et al. **Endocrinology** 1996 Nov; 137(11):4592-604

Room temperature phosphorescence study of phosphate binding in Escherichia coli alkaline phosphatase. Sun L, et al. **Eur J Biochem** 1997 Apr 1;245(1):32-9

Bone alkaline phosphatase measured with a new immunoradiometric assay in patients with metabolic bone diseases. Gonnelli S, et al. **Eur J Clin Invest** 1996 May; 26(5):391-6

Histochemical observations of alkaline phosphatase activity of Echinococcus multilocularis during in vivo development in golden hamsters, an alternative definitive host. Arsac C, et al. **Exp Anim** 1997 Jan;46(1):25-30

Positively charged lysine at the N-terminus of the signal peptide of the Escherichia coli alkaline phosphatase provides the secretion efficiency and is involved in the interaction with anionic phospholipids. Nesmeyanova MA, et al. **FEBS Lett** 1997 Feb 17;403(2):203-7

Cholesterol 7alpha-hydroxylase activities from human and rat liver are modulated in vitro posttranslationally by phosphorylation/dephosphorylation. Nguyen LB, et al. **Hepatology** 1996 Dec;24(6):1468-74

Hormonal influence on lipid-protein interactions in biological membranes. Lactation effects on alkaline phosphatase activity and intestinal brush border membrane properties in rat. Molina AS, et al. **Horm Metab Res** 1997 Apr; 29(4):159-63

Biochemical markers of bone turnover. Crofton PM, et al. **Horm Res** 1996;45 Suppl 1:55-8 (10 ref.)

Individual and combined effects of calciotropic hormones and growth factors on mineral metabolism in embryonic chick tibiae. Duvos C, et al. **In Vitro Cell Dev Biol Anim** 1997 Jun;33(6):473-8

Growth and propagation of normal rat intestinal epithelial cells. Odedra RM, et al. **In Vitro Cell Dev Biol Anim** 1996 Feb;32(2):107-115

Leucocyte alkaline phosphatase activity in patients with squamous cell carcinoma. Bisht D, et al. **Indian J Pathol Microbiol** 1997 Apr;40(2):147-51

Differential solubilization of osteoblastic alkaline phosphatase from human primary bone cell cultures. Radisson J, et al. **Int J Biochem Cell Biol** 1996 Apr;28(4):421-30

Kinetics of inactivation of green crab (Scylla Serrata) alkaline phosphatase during removal of zinc ions by ethylenediaminetetraacetic acid disodium. Chen QX, et al. **Int J Biol Macromol** 1996 Dec;19(4):257-61

Stage-specific expression patterns of alkaline phosphatase during development of the first arch skeleton in inbred C57BL/6 mouse embryos. Miyake T, et al. **J Anat** 1997 Feb;190 (Pt 2):239-60

Alkaline phosphatase activity of Escherichia coli starved in sterile lake water microcosms. Ozkanca R, et al. **J Appl Bacteriol** 1996 Mar;80(3):252-8

Competition between functional signal peptides demonstrates variation in affinity for the secretion pathway. Chen H, et al. **J Bacteriol** 1996 Dec;178(23):6658-64

Lectin-like characteristics of recombinant human interleukin-1beta recognizing glycans of the glycosylphosphatidylinositol anchor. Fukushima K, et al. **J Biol Chem** 1997 Apr 18;272(16):10579-84

Mammalian alkaline phosphatases are allosteric enzymes. Hoylaerts MF, et al. **J Biol Chem** 1997 Sep 5; 272(36):22781-7

Differential in vivo roles played by DsbA and DsbC in the formation of protein disulfide bonds. Sone M, et al. **J Biol Chem** 1997 Apr 18;272(16):10349-52

Single cell enzyme activity and proliferation in the growth plate: effects of growth hormone. Gevers EF, et al. **J Bone Miner Res** 1996 Aug;11(8):1103-11

Role of beta-GP-derived Pi in mineralization via ecto-alkaline phosphatase in cultured fetal calvaria cells. Anagnostou F, et al. **J Cell Biochem** 1996 Aug;62(2):262-74

Rapid chondrocyte maturation by serum-free culture with BMP-2 and ascorbic acid. Leboy PS, et al. **J Cell Biochem** 1997 Sep 1;66(3):394-403

The membrane protein alkaline phosphatase is delivered to the vacuole by a route that is distinct from the VPS-dependent pathway. Piper RC, et al. **J Cell Biol** 1997 Aug 11;138(3):531-45

Collagen phagocytosis and apoptosis are induced by high level alkaline phosphatase expression in rat fibroblasts. Hui MZ, et al. **J Cell Physiol** 1997 Sep;172(3):323-33

Growth hormone (GH) treatment of GH-deficient children increases serum levels of insulin-like growth factors (IGFs), IGF-binding protein-3 and -5, and bone alkaline phosphatase isoenzyme. Ono T, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2111-6

Hypophosphatasia: levels of bone alkaline phosphatase immunoreactivity in serum reflect disease severity. Whyte MP, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2142-8

Lymphocytes produce specific alkaline phosphatase after in vitro stimulation or after in vivo infection with HIV-1. Murthy VV. **J Clin Lab Anal** 1996;10(6):465-7

Endochondral and intramembranous fetal bone development: osteoblastic cell proliferation, and expression of alkaline phosphatase, m-twist, and histone H4. Alborzi A, et al. **J Craniofac Genet Dev Biol** 1996 Apr-Jun;16(2):94-106

The ELF-97 alkaline phosphatase substrate provides a bright, photostable, fluorescent signal amplification method for FISH. Paragas VB, et al. **J Histochem Cytochem** 1997 Mar; 45(3):345-57

Dependence of divalent metal ions on phosphotransferase activity of osseous plate alkaline phosphatase. Ciancaglini P, et al. **J Inorg Biochem** 1997 Apr;66(1):51-5

Endothelial cell surface alkaline phosphatase activity is induced by IL-6 released during wound repair. Gallo RL, et al. **J Invest Dermatol** 1997 Oct;109(4):597-603

Leukocyte alkaline phosphatase activity and peripheral changes of granulocyte following administration of granulocyte colony-stimulating factor. Charuruks N, et al. **J Med Assoc Thai** 1996 Dec;79(12):801-7

Extracellular alkaline phosphatase activity as a possible marker for wound healing: a preliminary report. Alpaslan G, et al. **J Oral Maxillofac Surg** 1997 Jan;55(1):56-62; discussion 62-3

Comparison of inactivation and unfolding of green crab (Scylla serrata) alkaline phosphatase during denaturation by guanidinium chloride. Chen QX, et al. **J Protein Chem** 1996 May;15(4):359-65

Bone alkaline phosphatase in rheumatoid arthritis: a longitudinal study. Beyeler C, et al. **J Rheumatol** 1996 Feb; 23(2):241-4

Maltol complexes of vanadium (IV) and (V) regulate in vitro alkaline phosphatase activity and osteoblast-like cell growth. Barrio DA, et al. **J Trace Elem Med Biol** 1997 Jun;11(2):110-5

A physiologic function for alkaline phosphatase: endotoxin detoxification. Poelstra K, et al. **Lab Invest** 1997 Mar; 76(3):319-27

Leukocyte alkaline phosphatase a specific marker for the post-mitotic neutrophilic granulocyte: regulation in acute promyelocytic leukemia. Garattini E, et al. **Leuk Lymphoma** 1996 Nov;23(5-6):493-503 (73 ref.)

Effects of in vitro cellular aging on alkaline phosphatase, cathepsin activities and collagen secretion of human periodontal ligament derived cells. Goseki T, et al. **Mech Ageing Dev** 1996 Nov 13;91(3):171-83

Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays. Markiewicz L, et al. **Methods Find Exp Clin Pharmacol** 1997 May;19(4):215-22

Osteoarthritis in the temporo-mandibular joint (TMJ) of aged mice and the in vitro effect of TGF-beta 1 on cell proliferation, matrix synthesis, and alkaline phosphatase activity. Livne E, et al. **Microsc Res Tech** 1997 May 15; 37(4):314-23

Synergistic effect of BMP-2 and ascorbate on the phenotypic expression of osteoblastic MC3T3-E1 cells. Torii Y, et al. **Mol Cell Biochem** 1996 Dec 6;165(1):25-9

Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Fletcher S, et al. **Nephron** 1997;75(4):412-9

A lipid lowering drug (bezafibrate) has a favorable effect on liver enzymes (Al-P and gamma-GTP). Fukuo Y, et al. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):424-30

Alkaline phosphatase activity in the theca of ovarian follicles of the hen throughout follicular development. Chapeau C, et al. **Poult Sci** 1996 Dec;75(12):1536-45

COOH-terminal processing of nascent polypeptides by the glycosylphosphatidylinositol transamidase in the presence of hydrazine is governed by the same parameters as glycosylphosphatidylinositol addition. Ramalingam S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7528-33

Effects of bisphosphonates on alkaline phosphatase activity, mineralization, and prostaglandin E2 synthesis in the clonal osteoblast-like cell line MC3T3-E1. Igarashi K, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Feb; 56(2):121-5

Okadaic acid enhances prostaglandin E1-induced alkaline phosphatase activity in osteoblast-like cells: regulation at a point downstream from protein kinase A. Ito Y, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Nov; 55(5):357-61

[Alkaline phosphatase levels in gingival crevicular fluid of periodontitis before and after periodontal treatment] Yan F, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Jul; 30(4):204-6, 255-6 (Eng. Abstr.) **(Chi)**

[Comparison of daily alkaline phosphatase activity of a cyanobacterium (Microcystis aeruginosa) and a diatom (Synedra capitata)] Giraudet H, et al. **C R Acad Sci III** 1997 Jun;320(6):451-8 (Eng. Abstr.) **(Fre)**

[Localization and activity of some hydrolases in larvae of tapeworms Neogryporhynchus cheilancristrotus and Triaenophorus nodulosus parasitizing fish] Niemczuk W,

ALKALINE PHOSPHATASE

et al. **Wiad Parazytol** 1996;42(4):415–20 (Eng. Abstr.) **(Pol)**

[Effect of adrenalectomy on alkaline phosphatase isoenzymes in intact and pregnant mice] Tsirel'nikov NI, et al. **Patol Fiziol Eksp Ter** 1996 Jul–Sep;(3):26–8 (Eng. Abstr.) **(Rus)**

[Diagnostic value of studying salivary enzymes in leukemia patients] Volchkova VM, et al. **Vopr Med Khim** 1996 Jan–Mar;42(1):46–53 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Degradable bisphosphonate–alkaline phosphatase–complexed hydroxyapatite implants in vitro. Denissen H, et al. **J Bone Miner Res** 1997 Feb;12(2):290–7

PHYSIOLOGY

Effects of alkaline phosphatase on bone healing around plasma-sprayed titanium implants: a pilot study in rabbits. Piattelli A, et al. **Biomaterials** 1996 Jul;17(14):1443–9

Demonstration of alkaline phosphatase participation in the mineralization of osteoblasts by antisense RNA approach. Torii Y, et al. **Cell Biol Int** 1996 Jul;20(7):459–64

Biochemical characteristics of a primary blood–brain barrier cell culture system as a function of the activity of the proteases used in tissue disaggregation. Ng KY, et al. **J Neurosci Methods** 1996 Sep;68(1):49–53

Intestinal alkaline phosphatase: role in the depressed gut lipid transport after trauma–hemorrhagic shock. Wang W, et al. **Shock** 1997 Jul;8(1):40–4

SECRETION

Physicochemical and pathophysiological factors in the release of membrane-bound alkaline phosphatase from cells. Moss DW. **Clin Chim Acta** 1997 Jan 3;257(1):133–40 (27 ref.)

A variant alkaline phosphatase–producing gastric carcinoma with super bone scan. Tokushima K, et al. **Dig Dis Sci** 1997 Jan;42(1):66–73

URINE

Clinical significance of urinary human tissue non-specific alkaline phosphatase (hTNAP) in pre-eclampsia and eclampsia. Shaarawy M, et al. **Ann Clin Biochem** 1997 Jul; 34 (Pt 4):405–11

Diuresis-dependent excretion of enzymes in rat urine. Obatomi DK, et al. **Biochem Soc Trans** 1997 Feb;25(1):67S

Clinical guidelines for the treatment of osteoporosis in Japan. Fujita T. **Calcif Tissue Int** 1996;59 Suppl 1:34–7 (15 ref.)

Some urinary enzymes in bilharziasis. el-Naggar MM, et al. **Int Urol Nephrol** 1996;28(2):167–73

Enzymuria as early marker of interstitial nephritis. Neimark A, et al. **Int Urol Nephrol** 1997;29(2):137–40

ALKALOIDS

Larvicidal activity of the naphthylisoquinoline alkaloid dioncophylline A against the malaria vector Anopheles stephensi. François G, et al. **J Ethnopharmacol** 1996 Nov; 54(2–3):125–30

ADMINISTRATION & DOSAGE

Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Shao RG, et al. **Cancer Res** 1997 Sep 15;57(18):4029–35

2 multi-center trials assessing the clinical efficacy of 5% sanguinarine in a biodegradable drug delivery system. Polson AM, et al. **J Clin Periodontol** 1996 Aug;23(8):782–8

Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. I. Study design, procedures, and management. Polson AM, et al. **J Periodontol** 1997 Feb; 68(2):110–8

Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results. Polson AM, et al. **J Periodontol** 1997 Feb;68(2):119–26

Marigenol-concentrates comprising Taxol and/or Taxan esters as active substances. Eugster C, et al. **Panminerva Med** 1996 Dec;38(4):234–42

[The initial experience of using the preparation Ukrain in treating cancer patients in Ukraine] Zemskov VS, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):158–61 (Eng. Abstr.) **(Ukr)**

ADVERSE EFFECTS

[Dermatitis bullosa striata pratensis caused by Dictamnus albus L. (burning bush)] Schempp CM, et al. **Hautarzt** 1996 Sep;47(9):708–10 (Eng. Abstr.) **(Ger)**

ANALYSIS

Chiral gas chromatographic determination of ephedrine-type alkaloids in dietary supplements containing Má Huáng. Betz JM, et al. **J AOAC Int** 1997 Mar–Apr;80(2):303–15

Evaluation of micellar electrokinetic capillary chromatography for the analysis of selected tobacco alkaloids. Yang SS, et al. **J Chromatogr A** 1996 Oct 4; 746(1):131–6

Alkaloids from endophyte-infected Festuca argentina. Casabuono AC, et al. **J Ethnopharmacol** 1997 Jun;57(1):1–9

Analysis of aporphine and quinolizidine alkaloids from Caulophyllum thalictroides by densitometry and HPLC. Woldemariam TZ, et al. **J Pharm Biomed Anal** 1997 Mar; 15(6):839–43

Effect of drying conditions on the taxane content of the needles of ornamental Taxus. el Sohly HN, et al. **Planta Med** 1997 Feb;63(1):83–5

Absence of skin alkaloids in captive-raised Madagascan mantelline frogs (Mantella) and sequestration of dietary alkaloids. Daly JW, et al. **Toxicon** 1997 Jul;35(7):1131–5

[Extraction technology of effervescent granules for arresting cold pain optimized by orthogonal tests] Sun X, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Mar;21(3):159–61, 190 (Eng. Abstr.) **(Chi)**

BIOSYNTHESIS

Biosynthesis of taxol: enzymatic acetylation of 10-deacetylbaccatin-III to baccatin-III in crude extracts from roots of Taxus baccata. Zocher R, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):16–20

Mechanism of alkaloid cyclopeptide synthesis in the ergot fungus Claviceps purpurea. Walzel B, et al. **Chem Biol** 1997 Mar;4(3):223–30

Heterologous expression of alkaloid biosynthetic genes—a review. Kutchan TM. **Gene** 1996 Nov 7;179(1):73–81

Enzymology of indole alkaloid biosynthesis in Catharanthus roseus. Misra N, et al. **Indian J Biochem Biophys** 1996 Aug; 33(4):261–73 (121 ref.)

The biosynthesis of plant alkaloids and nitrogenous microbial metabolites. Herbert RB. **Nat Prod Rep** 1996 Feb; 13(1):45–58 (117 ref.)

The biosynthesis of plant alkaloids and nitrogenous microbial metabolites. Herbert RB. **Nat Prod Rep** 1997 Aug; 14(4):359–72 (94 ref.)

Nature knows best: an amazing reaction cascade is uncovered by design and discovery. Heathcock CH. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14323–7

BLOOD

Certain biophysical properties of Ukrain. Susak YM, et al. **Drugs Exp Clin Res** 1996;22(3–5):185–7

Determination of Aconitum alkaloids in blood and urine samples. I. High-performance liquid chromatographic separation, solid-phase extraction and mass spectrometric confirmation. Ohta H, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):351–6

CHEMICAL SYNTHESIS

Synthesis and bronchodilatory activity of four new derivatives of deoxyvasicine. Ojo B, et al. **Drug Des Discov** 1996 Mar;14(1):1–14

Perhydrogenation of tabersonine, ans Aspidiosperma indole alkaloid. Lewin G, et al. **J Nat Prod** 1997 Apr;60(4):419–20

A synthesis of the Amaryllidaceae alkaloid pratosine. Pereira MM, et al. **J Nat Prod** 1996 Aug;59(8):744–7

[Highlights from 43 years of chemistry of naturally occurring nitrogen-containing heterocycles. (1). Syntheses and structure determinations of benzo[a]quinolizidine-type and indolo[2,3-a]quinolizidine-type alkaloids isolated from several plants] Fujii T. **Yakugaku Zasshi** 1996 May; 116(5):335–54 (76 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

(+)-Sparteine N-16-oxide, a lupin alkaloid from Lygos raetam var. sarcocarpa. Abdel-Halim OB, et al. **Acta Pharm Hung** 1997 Jan;67(1):9–12

Indole alkaloids and other constituents from the plant Securidaca longipedunculata fres. Wróbel JT, et al. **Adv Exp Med Biol** 1996;398:685–9 (7 ref.)

SRS-A antagonist pyranoquinolone alkaloids from east African Fagara plants and their synthesis. Kamikawa T, et al. **Bioorg Med Chem** 1996 Aug;4(8):1317–20

Thermodynamics of the interactions of sanguinarine with DNA: influence of ionic strength and base composition. Sen A, et al. **Biophys Chem** 1996 Mar 7;59(1–2):155–70

Calystegine B4, a novel trehalase inhibitor from Scopolia japonica. Asano N, et al. **Carbohydr Res** 1996 Oct 31; 293(2):195–204

Studies on the constituents of Broussonetia species. II. Six new pyrrolidine alkaloids, broussonetine A, B, E, F and broussonetinine A and B, as inhibitors of glycosidases from Broussonetia kazinoki Sieb. Shibano M, et al. **Chem Pharm Bull (Tokyo)** 1997 Apr;45(4):700–5

Certain biophysical properties of Ukrain. Susak YM, et al. **Drugs Exp Clin Res** 1996;22(3–5):185–7

Some examples of the analysis of complex samples by micellar electrokinetic capillary chromatography with photodiode array detection. Vandepeer J, et al. **Electrophoresis** 1996 Aug;17(8):1361–6

Study of the acid–catalyzed isomerization of dihydroveatchine. Desai HK, et al. **J Nat Prod** 1997 Jul; 60(7):684–7

Selective demethylation of some aconitine-type norditerpenoid alkaloids. Joshi BS, et al. **J Nat Prod** 1997 May;60(5):439–43

Prederivatization and high-performance liquid chromatographic analysis of alkaloids of bulbs of Fritillaria. Ding K, et al. **J Pharm Sci** 1996 Nov;85(11):1174–9

Diterpenoid and steroidal alkaloids. Atta-ur-Rahman, et al. **Nat Prod Rep** 1997 Apr;14(2):191–203 (53 ref.)

beta-Phenylethylamines and the isoquinoline alkaloids. Bentley KW. **Nat Prod Rep** 1997 Aug;14(4):387–411 (462 ref.)

Cyclopeptide alkaloids [published erratum appears in Nat Prod Rep 1997 Aug;14(4):432] Gournelis DC, et al. **Nat Prod Rep** 1997 Feb;14(1):75–82 (75 ref.)

Quinoline, quinazoline and acridone alkaloids. Michael JP. **Nat Prod Rep** 1997 Feb;14(1):11–20 (61 ref.)

Marigenol-concentrates comprising Taxol and/or Taxan esters as active substances. Eugster C, et al. **Panminerva Med** 1996 Dec;38(4):234–42

Pyrrolizidine alkaloids from Gynura divaricata. Roeder E, et al. **Planta Med** 1996 Aug;62(4):386

HISTORY

The discovery of alkaloids. Hosztafi S. **Pharmazie** 1997 Jul; 52(7):546–50

ISOLATION & PURIFICATION

Direct enantiomeric separation of cathinone and one major metabolite on cellobiohydrolase (CBH-I) chiral stationary phase. Aboul-Enein HY, et al. **Biomed Chromatogr** 1997 Jan–Feb;11(1):47–9

Direct chiral resolution of phenylalkylamines using a crown ether chiral stationary phase. Aboul-Enein HY, et al. **Biomed Chromatogr** 1997 Jan–Feb;11(1):7–10

Identification and quantitation of alkaloids in coca tea. Jenkins AJ, et al. **Forensic Sci Int** 1996 Feb 9;77(3):179–89

Antifungal diterpenoid alkaloids from Delphinium denudatum. Atta-ur-Rahman, et al. **J Nat Prod** 1997 May; 60(5):472–4

Bioactive alkaloids from Illigera luzonensis. Chen KS, et al. **J Nat Prod** 1997 Jun;60(6):645–7

Four new bioactive manzamine-type alkaloids from the Philippine marine sponge Xestospongia ashmorica. Edrada RA, et al. **J Nat Prod** 1996 Nov;59(11):1056–60

Metabolites from an Antarctic sponge-associated bacterium, Pseudomonas aeruginosa. Jayatilake GS, et al. **J Nat Prod** 1996 Mar;59(3):293–6

Brasilidine A, a new cytotoxic isonitrile-containing indole alkaloid from the actinomycete Nocardia brasiliensis. Kobayashi J, et al. **J Nat Prod** 1997 Jul;60(7):719–20

Three new naphthyldihydroisoquinoline alkaloids from Ancistrocladus tectorius. Manfredi KP, et al. **J Nat Prod** 1996 Sep;59(9):854–9

(2E,9E)-pyronaamidine 9-(N-methylimine), a new imidazole alkaloid from the northern Mariana islands sponge Leucetta sp. cf. chagosensis. Plubrukarn A, et al. **J Nat Prod** 1997 Jul;60(7):712–5

Pyrrolidinoöxazolidine alkaloids from two species of ladybird beetles. Radford P, et al. **J Nat Prod** 1997 Aug;60(8):755–9

New macrocyclic spermine (budmunchiamine) alkaloids from Albizia gummifera: with some observations on the structure—activity relationships of the budmunchiamines. Rukunga GM, et al. **J Nat Prod** 1996 Sep;59(9):850–3

Stellettamide B, a new indolizidine alkaloid from a sponge of the genus Stelletta. Shin J, et al. **J Nat Prod** 1997 Jun; 60(6):611–3

Pyridindolols K1 and K2, new alkaloids from Streptomyces sp. K93-0711. Kim YP, et al. **Jpn J Antibiot** 1997 Mar; 50(3):189–93

Medicinal alkaloid as a sex pheromone [letter] Leal WS, et al. **Nature** 1997 Jan 16;385(6613):213

New dimeric aporphine alkaloids and cytotoxic constituents of Hernandia nymphaeifolia. Chen JJ, et al. **Planta Med** 1996 Dec;62(6):528–33

Isolation and toxicity of Cylindrospermopsis raciborskii from an ornamental lake. Hawkins PR, et al. **Toxicon** 1997 Mar; 35(3):341–6

[Alkaloids in the flowers of Sophora viciifolia Hance] Yan Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Apr; 21(4):232–3, 256 (Eng. Abstr.) **(Chi)**

[Isolation and structure flucidation of alkaloids from the bulb of Fritillaria Wabuensis S.Y. Tang et S.C. Yueh] Wang H, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1996 Mar; 27(1):100–5 (Eng. Abstr.) **(Chi)**

METABOLISM

Identification of genes induced in alkaloid-producing cultures of Claviceps sp. Arntz C, et al. **Curr Genet** 1997 Apr;31(4):357–60

Ptilomycalin A, a novel Na+, K(+)- or Ca2(+)-ATPase inhibitor, competitively interacts with ATP at its binding site. Ohizumi Y, et al. **Eur J Pharmacol** 1996 Aug 22; 310(1):95–8

Interactions of delta-conotoxins with alkaloid neurotoxins reveal differences between the silent and effective binding sites on voltage-sensitive sodium channels. Shichor I, et al. **J Neurochem** 1996 Dec;67(6):2451–60

[Isolation and receptor binding properties of alkaloids and lignans from Valeriana officialis L.] Bodesheim U, et al. **Pharmazie** 1997 May;52(5):386–91 (Eng. Abstr.) **(Ger)**

[Medicinal plants—concentrators of chromium. The role of chromium in alkaloid metabolism] Lovkova MIa, et al. **Izv Akad Nauk Ser Biol** 1996 Sep–Oct;(5):552–64 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Urinary excretion of N1-methyl-2-pyridone-5-carboxylic acid and the fate of remaining of trigonelline. Yuyama S, et al. **Adv Exp Med Biol** 1996;398:599-603

Pharmacokinetics of higenamine in rabbits. Lo CF, et al. **Biopharm Drug Dispos** 1996 Dec;17(9):791-803

Evidence for endogenous formation of tobacco-specific nitrosamines in rats treated with tobacco alkaloids and sodium nitrite. Carmella SG, et al. **Carcinogenesis** 1997 Mar; 18(3):587-92

An attempt to visualize baboon brain nicotinic receptors with N-[11C]ABT-418 and N-[11C]methyl-cytisine. Valette H, et al. **Nucl Med Commun** 1997 Feb;18(2):164-8

Comparison of nicotinic receptor binding and biotransformation of coniine in the rat and chick. Forsyth CS, et al. **Toxicol Lett** 1996 Dec 31;89(3):175-83

PHARMACOLOGY

Effect of endolymphatic hydrops on capsaicin-evoked increase in cochlear blood flow. Vass Z, et al. **Acta Otolaryngol (Stockh)** 1995 Nov;115(6):754-8

Steroidal glycoalkaloids: nature and consequences of bioactivity. Roddick JG. **Adv Exp Med Biol** 1996; 404:277-95 (131 ref.)

Naphthylisoquinoline alkaloids exhibit strong growth-inhibiting activities against Plasmodium falciparum and P. berghei in vitro--structure-activity relationships of dioncophylline C. François G, et al. **Ann Trop Med Parasitol** 1996 Apr;90(2):115-23

Effectiveness of yohimbine in the treatment of erectile disorder: four meta-analytic integrations. Carey MP, et al. **Arch Sex Behav** 1996 Aug;25(4):341-60

Tetrandrine inhibits signal-induced NF-kappa B activation in rat alveolar macrophages. Chen F, et al. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):99-102

Glycolytic enzyme binding in Otala lactea hepatopancreas: effect of taxol, colchicine and cytochalasin B and D on the in vivo enzyme distribution. Brooks SP, et al. **Biochem Mol Biol Int** 1997 Apr;41(4):841-9

Leukocyte function-associated antigen 1-dependent adhesion of rat hepatoma AH66F cells and inhibition by protein kinase C inhibitors. Nomura M, et al. **Biochem Pharmacol** 1997 May 9;53(9):1333-7

Cytotoxicity to macrophages of tetrandrine, an antisilicosis alkaloid, accompanied by an overproduction of prostaglandins [published erratum appears in Biochem Pharmacol 1997 Jun 15;53(12):1946] Pang L, et al. **Biochem Pharmacol** 1997 Mar 21;53(6):773-82

Specific interaction between tetrandrine and Quillaja saponins in promoting permeabilization of plasma membrane in human leukemic HL-60 cells. Leung YM, et al. **Biochim Biophys Acta** 1997 Apr 26;1325(2):318-28

Processing of nux vomica. VII. Antinociceptive effects of crude alkaloids from the processed and unprocessed seeds of Strychnos nux-vomica in mice. Cai B, et al. **Biol Pharm Bull** 1996 Jan;19(1):127-31

Potentiation by higenamine of the aconitine-induced positive chronotropic effect in isolated right atria of mice: the effects of cholera toxin, forskolin and pertussis toxin. Kimura I, et al. **Biol Pharm Bull** 1996 Aug;19(8):1032-7

Behavioral studies on alkaloids extracted from the leaves of Hunteria zeylanica [published erratum appears in Biol Pharm Bull 1996 Jun;19(6):909] Leewanich P, et al. **Biol Pharm Bull** 1996 Mar;19(3):394-9

Antinociceptive activities of 70% methanol extract of evodiae fructus (fruit of Evodia rutaecarpa var. bodinieri) and its alkaloidal components. Matsuda H, et al. **Biol Pharm Bull** 1997 Mar;20(3):243-8

Inhibitory effects of dehydrocorydaline isolated from Corydalis Tuber against type I-IV allergic models. Matsuda H, et al. **Biol Pharm Bull** 1997 Apr;20(4):431-4

Norreticuline and reticuline as possible new agents for hair growth acceleration. Nakaoji K, et al. **Biol Pharm Bull** 1997 May;20(5):586-8

Effects of biscoclaurine alkaloid cepharanthine on newborn rat skin epidermal and dermal cells. Ohkura K, et al. **Biol Pharm Bull** 1996 Apr;19(4):495-500

Heterogeneity of signal transduction mechanisms in human basophils and human skin mast cells. II. Effects of 7-O-methyl-UCN-01, NPC 15437 and bryostatin 1 and 2, four protein kinase C-modulatory agents, on mediator release. Noll T, et al. **Biol Signals** 1997 Jan-Feb;6(1):1-10

Screening of cell cycle inhibitors from microbial metabolites by a bioassay using a mouse cdc2 mutant cell line, tsFT210. Osada H, et al. **Bioorg Med Chem** 1997 Jan;5(1):193-203

Inhibition of neuronal activity in rat hippocampal slices by Aconitum alkaloids. Ameri A, et al. **Brain Res** 1996 Oct 28;738(1):154-7

Synergistic effects of tamoxifen and cepharanthine for circumventing the multidrug resistance. Hotta T, et al. **Cancer Lett** 1996 Oct 1;107(1):117-23

G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Akiyama T, et al. **Cancer Res** 1997 Apr 15;57(8):1495-501

7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Bunch RT, et al. **Cell Growth Differ** 1997 Jul; 8(7):779-88

Effects of tetrandrine on cytosolic free calcium in cultured rat myocardial cells. Li XT, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jan;17(1):55-8

Effects of tetrandrine and closely related bis-benzylisoquinoline derivatives on cytosolic Ca2+ in human leukaemic HL-60 cells: a structure-activity relationship study. Leung YM, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):653-9

Effects of veratridine on the action potentials and contractility of right and left ventricles from normo- and hypertensive rats. Nand V, et al. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):570-6

Tetrandrine as a calcium antagonist. Takemura H, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):751-3

Antihypertensive effects, determined by a telemetry method, of trichloromethiazide and 7-O-ethylfangchinoline, a derivative of tetrandrine, in spontaneously hypertensive rats. Kawashima K, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S300-1

Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. Kwan CY. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S297-9 (12 ref.)

Effects of spinal versus supraspinal administration of cyclic nucleotide-dependent protein kinase inhibitors on morphine tolerance in mice. Bernstein MA, et al. **Drug Alcohol Depend** 1997 Jan 10;44(1):41-6

Synthesis and bronchodilatory activity of four new derivatives of deoxyvasicine. Ojo B, et al. **Drug Des Discov** 1996 Mar;14(1):1-14

Action of Ukrain, a cytostatic and immunomodulating drug, on effects of irradiation. Boyko VN, et al. **Drugs Exp Clin Res** 1996;22(3-5):167-71

Synergic influence of Ukrain and protoporphyrin amino acid conjugates on human malignant cell lines. Brzosko WJ, et al. **Drugs Exp Clin Res** 1996;22(3-5):193-4

Estimation of direct influence of Ukrain preparation on influenza viruses and the bacteria E. coli and S. aureus. Ciebiada I, et al. **Drugs Exp Clin Res** 1996;22(3-5):219-23

Effect of six-month treatment with Ukrain on early osteoporosis induced by ovariectomy in rats. Part III. Preliminary studies of some hormone levels. Jagiełło-Wojtowicz E, et al. **Drugs Exp Clin Res** 1996; 22(3-5):181-4

Effect of six-month treatment with Ukrain on early osteoporosis induced by ovariectomy in rats. Part I: Preliminary studies of bone parameters. Jagiełło-Wojtowicz E, et al. **Drugs Exp Clin Res** 1996; 22(3-5):173-6

Effect of six-month treatment with Ukrain on early osteoporosis induced by ovariectomy in rats. Part II: Preliminary studies of peripheral blood parameters. Jagiełło-Wojtowicz E, et al. **Drugs Exp Clin Res** 1996; 22(3-5):177-80

Antinociceptive effect of ten day administration of Ukrain in mice and interaction of the treatment with morphine. Jagiełło-Wojtowicz E, et al. **Drugs Exp Clin Res** 1996; 22(3-5):201-3

Interaction between Ukrain and morphine in their ten-day treatment in mice in the writhing syndrome test. Jagiełło-Wojtowicz E, et al. **Drugs Exp Clin Res** 1996; 22(3-5):205-6

Mitogenic properties of Ukrain (NSC-6315170) on human peripheral blood monocytes: clinical implications. Jin YM, et al. **Drugs Exp Clin Res** 1996;22(3-5):99-101

Induction of bimodal programmed cell death in malignant cells by the derivative Ukrain (NSC-631570). Liepins A, et al. **Drugs Exp Clin Res** 1996;22(3-5):73-9

Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570). Liepins A, et al. **Drugs Exp Clin Res** 1996;22(3-5):103-13

Biological activity of some thiophosphamide derivatives of alkaloids with respect to influenza virus. Lisnyak OI, et al. **Drugs Exp Clin Res** 1996;22(3-5):225-8

Theoretical grounds and experimental confirmation of the antiviral effect of the preparation Ukrain. Lozjuk RM, et al. **Drugs Exp Clin Res** 1996;22(3-5):213-7

Influence of Ukrain on DNA, RNA and protein synthesis in malignant cells. Nowicky JW, et al. **Drugs Exp Clin Res** 1996;22(3-5):81-91

Influence of Ukrain on immunological blood parameters in vitro and in vivo. Nowicky JW, et al. **Drugs Exp Clin Res** 1996;22(3-5):163-5

Influence of Ukrain on human xenografts in vitro. Nowicky JW, et al. **Drugs Exp Clin Res** 1996;22(3-5):93-7

Inhibitory effect of thiophosphoric acid alkaloid derivatives from Chelidonium majus L. (Ukrain) on ovalbumin antigenicity and antiovalbumin IgE antibody response in mice. Wyczółkowska J, et al. **Drugs Exp Clin Res** 1996; 22(3-5):195-200

Influence of Ukrain on the redox processes of hepatocytes. Zhalilo LI, et al. **Drugs Exp Clin Res** 1996;22(3-5):189-91

Mechanism of inhibition of platelet aggregation by rutaecarpine, an alkaloid isolated from Evodia rutaecarpa. Sheu JR, et al. **Eur J Pharmacol** 1996 Dec 30; 318(2-3):469-75

Tetrandrine inhibits electrically induced [Ca2+]i transient in the isolated single rat cardiomyocyte. Wang HX, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):115-22

Ionic mechanisms of tetrandrine in cultured rat aortic smooth muscle cells. Wu SN, et al. **Eur J Pharmacol** 1997 May 30;327(2-3):233-8

7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53. Shao RG, et al. **Exp Cell Res** 1997 Aug 1; 234(2):388-97

Bacterial alkaloids mitigate seizure-induced hippocampal damage and spatial memory deficits. Smith-Swintosky VL, et al. **Exp Neurol** 1996 Oct;141(2):287-96

Positive interaction of bisbenzylisoquinoline alkaloid, cepharanthin, with vinca alkaloid agents against human tumors. Ono M, et al. **In Vivo** 1997 May-Jun;11(3):233-41

Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. Aogi K, et al. **Int J Cancer** 1997 Jul 17;72(2):295-300

Study on the anti-inflammatory action of Berberis vulgaris root extract, alkaloid fractions and pure alkaloids. Ivanovska N, et al. **Int J Immunopharmacol** 1996 Oct; 18(10):553-61

Studies of the cellular mechanisms underlying the vasorelaxant effects of rutaecarpine, a bioactive component extracted from an herbal drug. Chiou WF, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):490-8

Mechanisms of vasorelaxant effect of dehydroevodiamine: a bioactive isoquinazolinocarboline alkaloid of plant origin. Chiou WF, et al. **J Cardiovasc Pharmacol** 1996 Jun; 27(6):845-53

Effect of Ukrain preparation on immune response in mice affected by influenza virus. Ciebiada I, et al. **J Chemother** 1995 Nov;7 Suppl 4:101-4

Sanguinarine and chelerythrine as inhibitors of aromatic amino acid decarboxylase. Keller J, et al. **J Enzyme Inhib** 1996;10(4):231-237

Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. Soulimani R, et al. **J Ethnopharmacol** 1997 Jun;57(1):11-20

Pharmacological investigation of alkaloids from leaves of Mitragyna inermis (Rubiaceae). Toure H, et al. **J Ethnopharmacol** 1996 Oct;54(1):59-62

Nudicauline and elatine as potent norditerpenoid ligands at rat neuronal alpha-bungarotoxin binding sites: importance of the 2-(methylsuccinimido)benzoyl moiety for neuronal nicotinic acetylcholine receptor binding. Hardick DJ, et al. **J Med Chem** 1996 Nov 22;39(24):4860-6

Inhibitory effect of dehydroevodiamine and evodiamine on nitric oxide production in cultured murine macrophages. Chiou WF, et al. **J Nat Prod** 1997 Jul;60(7):708-11

In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta. Cimanga K, et al. **J Nat Prod** 1997 Jul;60(7):688-91

Lycaconitine revisited: partial synthesis and neuronal nicotinic acetylcholine receptor affinities. Jacyno JM, et al. **J Nat Prod** 1996 Jul;59(7):707-9

Perhydrogenation of tabersonine, ans Aspidiosperma indole alkaloid. Lewin G, et al. **J Nat Prod** 1997 Apr;60(4):419-20

Concentration-dependent stimulation and inhibition of growth cone behavior and neurite elongation by protein kinase inhibitors KT5926 and K-252a. Oberstar JV, et al. **J Neurobiol** 1997 Aug;33(2):161-71

Tetrandrine inhibits breakdown of blood-aqueous barrier induced by endotoxin and interleukin-1 alpha in rats. Xiao JG, et al. **J Ocul Pharmacol Ther** 1996 Fall;12(3):323-9

Inhibitory effects of tetrandrine on intracellular free Ca2+ increase induced by glutamate, serotonin and histamine in dissociated retina cells. Xuan B, et al. **J Ocul Pharmacol Ther** 1996 Fall;12(3):331-6

Inhibition of high K+ and norepinephrine-induced free intracellular calcium by tetrandrine in dissociated rabbit retina cells. Xuan B, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):151-8

Modification of Ca2+ metabolism in the rabbit aorta as a mechanism of spasmolytic action of warifteine, a bisbenzylisoquinoline alkaloid isolated from the leaves of Cissampelos sympodialis Eichl. (Menispermaceae). De Freitas MR, et al. **J Pharm Pharmacol** 1996 Mar;48(3):332-6

Portal hypotensive effects of tetrandrine and verapamil in portal hypertensive rats. Liu TB, et al. **J Pharm Pharmacol** 1997 Jan;49(1):85-8

Effects of tetrandrine on spontaneous and evoked release of acetylcholine at the mouse neuromuscular junction. Wiegand H, et al. **J Pharmacol Exp Ther** 1996 Nov; 279(2):891-901

Effects of tetrandrine on cardiac noradrenaline release evoked by electrical stimulation. Feng Y, et al. **J Tongji Med Univ** 1996;16(2):103-5

Inhibition by protein kinase C inhibitor of expression of leukocyte function-associated antigen-1 molecules in rat hepatoma AH66F cells. Nomura M, et al. **Jpn J Cancer Res** 1997 Mar;88(3):267-72

In vitro inhibition of proliferation of HL-60 cells by tetrandrine and coriolus versicolor peptide derived from Chinese medicinal herbs. Dong Y, et al. **Life Sci** 1997; 60(8):PL135-40

Interaction of ebeinone, an alkaloid from Fritillaria imperialis, at two muscarinic acetylcholine receptor subtypes. Gilani AH, et al. **Life Sci** 1997;60(8):535-44

Tetrandrine, a calcium antagonist of Chinese herbal origin, interacts with vascular muscle alpha 1-adrenoceptor. Kwan CY, et al. **Life Sci** 1996;59(23):PL 359-64

Diterpenoid and steroidal alkaloids. Atta-ur-Rahman, et al. **Nat Prod Rep** 1997 Apr;14(2):191-203 (53 ref.)

beta-Phenylethylamines and the isoquinoline alkaloids. Bentley KW. **Nat Prod Rep** 1997 Aug;14(4):387-411 (462 ref.)

Electrophysiological actions of the plant alkaloid 6-benzoylheteratisine in rat hippocampal slices. Ameri A. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Apr; 355(4):538-44

Effects of the putative P-type calcium channel blocker, R,R-(-)-daurisoline on neurotransmitter release. Waldmeier PC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec; 352(6):670-8

Effects of Psychotria colorata alkaloids in brain opioid system. Amador TA, et al. **Neurochem Res** 1996 Jan; 21(1):97-102

Tetrandrine blocks voltage-dependent calcium entry and inhibits the bradykinin-induced elevation of intracellular calcium in NG108-15 cells. Bickmeyer U, et al. **Neurotoxicology** 1996 Summer;17(2):335-41

Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells. Hotta T, et al. **Oncology** 1997 Mar-Apr;54(2):153-7

Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines. Shimizu E, et al. **Oncology** 1996 Nov-Dec;53(6):494-504

Pharmacological activities of Chelidonium majus L. (Papaveraceae). Colombo ML, et al. **Pharmacol Res** 1996 Feb;33(2):127-34 (63 ref.)

Tetrandrine inhibits lipid peroxidation but lacks reactivity towards superoxide anion and hydrogen peroxide. Hui SC, et al. **Pharmacol Toxicol** 1996 Mar;78(3):200-1

Influence of sanguinarine on the GABA synthesizing enzyme glutamate decarboxylase in vitro. Netopilova M, et al. **Pharmazie** 1996 Aug;51(8):589-91

Bicuculline-induced epileptiform activity in rat hippocampal slices: suppression by Aconitum alkaloids. Ameri A, et al. **Planta Med** 1997 Jun;63(3):228-32

Scavenging effect of tetrandrine of active oxygen radicals. Cao ZF. **Planta Med** 1996 Oct;62(5):413-4

Isoquinoline alkaloids from Argemone mexicana reduce morphine withdrawal in guinea pig isolated ileum. Capasso A, et al. **Planta Med** 1997 Aug;63(4):326-8

New aporphine alkaloids and cytotoxic constituents of Hernandia nymphaeifolia. Chen IS, et al. **Planta Med** 1997 Apr;63(2):154-7

Activity of extracts and alkaloids of thai Alstonia species against human lung cancer cell lines. Keawpradub N, et al. **Planta Med** 1997 Apr;63(2):97-101

Inhibitory effects of bisbenzylisoquinoline alkaloids on induction of proinflammatory cytokines, interleukin-1 and tumor necrosis factor-alpha. Onai N, et al. **Planta Med** 1995 Dec;61(6):497-501

Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa. Park CH, et al. **Planta Med** 1996 Oct;62(5):405-9

Benzophenanthridine alkaloids of Chelidonium majus; I. Inhibition of 5- and 12-lipoxygenase by a non-redox mechanism. Vavrečková C, et al. **Planta Med** 1996 Oct; 62(5):397-401

Benzophenanthridine alkaloids of Chelidonium majus; II. Potent inhibitory action against the growth of human keratinocytes. Vavrečková C, et al. **Planta Med** 1996 Dec; 62(6):491-4

Endothelium-dependent higenamine-induced aortic relaxation in isolated rat aorta. Wong KK, et al. **Planta Med** 1997 Apr;63(2):130-2

Inhibitory effects of tetrandrine and hernandezine on Ca2+ mobilization in rat glioma C6 cells. Imoto K, et al. **Res Commun Mol Pathol Pharmacol** 1997 Feb;95(2):129-46

[Inhibitory effect of tetrandrine on collagen synthesis of experimental hepatic fibrosis in rats] He Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Mar;21(3):177-9, 192 (Eng. Abstr.) **(Chi)**

[Effect of tetrandrine on intraacinar pulmonary arterial structural remodelling and pulmonary hypertension] Zhang S, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1996 Mar; 27(1):59-62 (Eng. Abstr.) **(Chi)**

[Protective effect of tetrandrine on neuronal injury in cultured cortical neurons of rats] Che JT, et al. **Yao Hsueh Hsueh Pao** 1996;31(3):161-5 (Eng. Abstr.) **(Chi)**

[Progress in the studies on medicinal plants of the genus Zanthoxylum Linn] Sun XW, et al. **Yao Hsueh Hsueh Pao** 1996;31(3):231-40 (67 ref.) **(Chi)**

[Recent results on the pharmacodynamics of Strychnos malgaches alkaloids] Rasoanaivo P, et al. **Sante** 1996 Jul-Aug;6(4):249-53 (23 ref.) (Eng. Abstr.) **(Fre)**

[The effect of synthetic polycation of the quarternary ammonium salts of polymetacryoil lupinin on the ionic permeability of erythrocyte membrane] Makhsudova GT, et al. **Biofizika** 1997 Jan-Feb;42(1):169-73 (Eng. Abstr.) **(Rus)**

[Sanguinarine and ellipticine cytotoxic alkaloids isolated from well-known antitumor plants. Intracellular targets of their action] Faddeeva MD, et al. **Tsitologiia** 1997; 39(2-3):181-208 (156 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Effectiveness of yohimbine in the treatment of erectile disorder: four meta-analytic integrations. Carey MP, et al. **Arch Sex Behav** 1996 Aug;25(4):341-60

Efficacy of a dentifrice and oral rinse containing sanguinaria extract in conjunction with initial periodontal therapy. Cullinan MP, et al. **Aust Dent J** 1997 Feb;42(1):47-51

A protein kinase C inhibitor NA-382 prolongs the life span of AH66F-bearing rats as well as inhibiting leukocyte function-associated antigen-1 (LFA-1)-dependent adhesion of the cells. Nomura M, et al. **Biol Pharm Bull** 1996 Dec;19(12):1611-3

Influence of Ukrain on breast cancer. Brzosko WJ, et al. **Drugs Exp Clin Res** 1996;22(3-5):127-33

Does the Ukrain preparation protect mice against lethal doses of bacteria? Ciebiada I, et al. **Drugs Exp Clin Res** 1996; 22(3-5):207-11

Influence of Ukrain on patients with surgically treated breast cancer. Part III. The immune system. Fomin KA, et al. **Drugs Exp Clin Res** 1996;22(3-5):143-5

Ukrain monotherapy in malignant melanoma (case report). Hamler F, et al. **Drugs Exp Clin Res** 1996;22(3-5):235-7

Ukrain therapy of recurrent breast cancer with lung metastases (case report). Kadan P, et al. **Drugs Exp Clin Res** 1996;22(3-5):243-5

Ukrain in the treatment of urethral recurrent carcinoma (case report). Kadan P, et al. **Drugs Exp Clin Res** 1996; 22(3-5):271-3

Ukrain treatment of rhabdomyosarcoma (case report). Kotsay B, et al. **Drugs Exp Clin Res** 1996;22(3-5):239-41

Ukrain treatment in carcinoma of the cervix (case report). Kroiss T, et al. **Drugs Exp Clin Res** 1996;22(3-5):255-7

Amino acids and their derivatives in blood plasma of patients with breast cancer treated with Ukrain. Part V. Nefyodov LI, et al. **Drugs Exp Clin Res** 1996;22(3-5):155-7

Amino acids and their derivatives in tumour tissue from patients with breast cancer treated with Ukrain. Part VI. Nefyodov LI, et al. **Drugs Exp Clin Res** 1996; 22(3-5):159-61

Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report). Sakalo VS, et al. **Drugs Exp Clin Res** 1996;22(3-5):263-5

Biophysiological effects of Ukrain therapy in a patient with breast cancer (case report). Schramm E, et al. **Drugs Exp Clin Res** 1996;22(3-5):247-54

Ukrain with chemotherapy in malignant melanoma (case report). Stabuc B, et al. **Drugs Exp Clin Res** 1996; 22(3-5):231-3

Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report). Steinacker J, et al. **Drugs Exp Clin Res** 1996; 22(3-5):275-7

Ukrain therapy of a recurrent astrocytoma of the optic nerve (case report). Steinacker J, et al. **Drugs Exp Clin Res** 1996; 22(3-5):279-81

Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. Susak YM, et al. **Drugs Exp Clin Res** 1996;22(3-5):115-22

Influence of Ukrain on patients with surgically treated breast cancer (introductory remarks). Uglyanica KN, et al. **Drugs Exp Clin Res** 1996;22(3-5):123-5

Influence of Ukrain on patients with surgically treated breast cancer. Part I. Clinical and laboratory parameters. Uglyanica KN, et al. **Drugs Exp Clin Res** 1996; 22(3-5):135-8

Influence of Ukrain on patients with surgically treated breast cancer. Part II. Hormonal profile. Uglyanica KN, et al. **Drugs Exp Clin Res** 1996;22(3-5):139-41

Influence of Ukrain on patients with surgically treated breast cancer. Part IV. Electromicroscopic and cytochemical evaluation. Uglyanica KN, et al. **Drugs Exp Clin Res** 1996; 22(3-5):147-53

Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma. Voltchek IV, et al. **Drugs Exp Clin Res** 1996;22(3-5):283-6

Ukrain treatment in carcinoma of the oesophagus (case report). Vyas JJ, et al. **Drugs Exp Clin Res** 1996; 22(3-5):267-9

Haemodynamic effects of chronic tetrandrine treatment in portal hypertensive rats. Huang YT, et al. **J Gastroenterol Hepatol** 1997 Aug;12(8):585-9

Exploration of P-type Ca2+ channels as drug targets for the treatment of epilepsy or ischemic stroke. Lingenhöhl K, et al. **Neuropharmacology** 1997 Jan;36(1):107-13

TOXICITY

A 90-day feeding study of the alkaloids of Lupinus angustifolius in the rat. Robbins MC, et al. **Food Chem Toxicol** 1996 Aug;34(8):679-86

Effect of alkaloids in cigarette smoke on human granulosa cell progesterone synthesis and cell viability. Gocze PM, et al. **Gynecol Endocrinol** 1996 Aug;10(4):223-8

Effects of sanguinarium, chlorhexidine and tetracycline on neutrophil viability and functions in vitro. Agarwal S, et al. **J Periodontal Res** 1997 Apr;32(3):335-44

Trigonelline, a naturally occurring constituent of green coffee beans behind the mutagenic activity of roasted coffee? Wu X, et al. **Mutat Res** 1997 Jul 14;391(3):171-7

Physicochemical and metabolic basis for the differing neurotoxicity of the pyrrolizidine alkaloids, trichodesmine and monocrotaline. Huxtable RJ, et al. **Neurochem Res** 1996 Feb;21(2):141-6

Cytotoxicity of sanguinarine chloride to cultured human cells from oral tissue. Babich H, et al. **Pharmacol Toxicol** 1996 Jun;78(6):397-403

Acute toxicity of higenamine in mice. Lo CF, et al. **Planta Med** 1997 Feb;63(1):95-6

Isolation and toxicity of Cylindrospermopsis raciborskii from an ornamental lake. Hawkins PR, et al. **Toxicon** 1997 Mar; 35(3):341-6

URINE

Determination of Aconitum alkaloids in blood and urine samples. I. High-performance liquid chromatographic separation, solid-phase extraction and mass spectrometric confirmation. Ohta H, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):351-6

ALKALOSIS

[Liddle syndrome] Tamura H, et al. **Nippon Rinsho** 1996 Mar; 54(3):807-11 (12 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Blood lactate and ammonia in short-term anaerobic work following induced alkalosis. Ibanez J, et al. **J Sports Med Phys Fitness** 1995 Sep;35(3):187-93

Relation between blood pH and ionized calcium during acute metabolic alteration of the acid-base balance in vivo. Gaiter AM, et al. **Scand J Clin Lab Invest** 1997 Jul;57(4):317-23

CHEMICALLY INDUCED

Hypocalcemic tetany and metabolic alkalosis in a dialysis patient: an unusual event. Kaye M, et al. **Am J Kidney Dis** 1997 Sep;30(3):440-4

Metabolic alkalosis and myoclonus from antacid ingestion. Okada K, et al. **Intern Med** 1996 Jun;35(6):515-6

COMPLICATIONS

Compensatory hypoventilation in severe metabolic alkalosis [letter] Perrone J, et al. **Acad Emerg Med** 1996 Oct; 3(10):981-2

Chronic metabolic alkalosis, sucrose diet and dentine formation in young rats. Bäckman T, et al. **Arch Oral Biol** 1997 Apr;42(4):299-304

[Heart failure, arterial hypertension, and hypokalemic alkalosis] Rivero M, et al. **Rev Clin Esp** 1996 Aug; 196(8):565-6 **(Spa)**

DIAGNOSIS

Hypokalemic metabolic alkalosis with hypomagnesuric hypermagnesemia and severe hypocalciuria: a new syndrome? Mehrotra R, et al. **Am J Kidney Dis** 1997 Jan; 29(1):106-14 (27 ref.)

DRUG THERAPY

[Efficacy of acetazolamide treatment of patients with hypercapnia and superimposed metabolic alkalosis] Prieto de Paula JM, et al. **Rev Clin Esp** 1997 Apr;197(4):237-40 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Metabolic alkalosis [letter; comment] D'Eufemia P, et al. **Acta Paediatr** 1996 Dec;85(12):1518. Comment on: Acta Paediatr 1995 Jan;84(1):103-5.

Severe metabolic alkalosis corrected by hemodialysis [letter] Leblanc M, et al. **Clin Nephrol** 1997 Jul;48(1):65

Alkalinization is troublesome in advanced cancer patients with dyspnea [letter; comment] Mercadante S. **J Pain Symptom Manage** 1997 Jun;13(6):316-8. Comment on: J Pain Symptom Manage 1996 Jul;12(1):11-7.

Acute metabolic alkalosis in cystic fibrosis: prospective study and review of the literature. Mauri S, et al. **Miner Electrolyte Metab** 1997;23(1):33-7

Infant metabolic alkalosis and soy-based formula--United States. 1979 [classical article] **MMWR Morb Mortal Wkly Rep** 1996 Nov 15;45(45):985-8

Metabolic alkalosis and chronic renal failure in a bulimic patient [letter] Inui A, et al. **Nephron** 1997;76(3):362

[Hypochloremic metabolic alkalosis. A case report] Bianco F, et al. **G Chir** 1996 Jun-Jul;17(6-7):339-41 (Eng. Abstr.) **(Ita)**

[Hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria; Bartter's syndrome in Gitelman's variant--case report] Bień B, et al. **Pol Arch Med Wewn** 1995 Nov;94(5):442-6 (Eng. Abstr.) **(Pol)**

GENETICS

Novel molecular variants of the Na-Cl cotransporter gene are responsible for Gitelman syndrome. Mastroianni N, et al. **Am J Hum Genet** 1996 Nov;59(5):1019-26

"The molecular basis of inherited hypokalemic alkalosis: Bartter's and Gitelman's syndromes" [editorial] Hebert SC, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):F957-9

The molecular basis of inherited hypokalemic alkalosis: Bartter's and Gitelman's syndromes. Simon DB, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):F961-6 (32 ref.)

METABOLISM

Divergent effects of extracellular and intracellular alkalosis on Ca2+ entry pathways in vascular endothelial cells. Wakabayashi I, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):567-73

Heat shock protein synthesis is affected by intracellular pH: inhibition by monensin-induced alkalosis in C6 rat glioma cells. Neuhaus-Steinmetz U, et al. **Brain Res** 1996 Jun 10; 724(1):16-24

Effects of sodium lactate on ventilation and acid-base balance

in healthy humans. Tappy L, et al. **Clin Physiol** 1996 Jul; 16(4):393–401

Metabolic alkalosis induced by pre–exercise ingestion of NaHCO3 does not modulate the slow component of VO2 kinetics in humans. Zołądź JA, et al.
J Physiol Pharmacol 1997 Jun;48(2):211–23

Regulation of AE1 anion exchanger and H(+)–ATPase in rat cortex by acute metabolic acidosis and alkalosis. Sabolić I, et al. **Kidney Int** 1997 Jan;51(1):125–37

[Case of Liddle syndrome with prominent hypokalemia] Takeda M, et al. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):136–7 **(Jpn)**

PATHOLOGY

Liddle's syndrome: a 14–year follow–up of the youngest diagnosed case. Vania A, et al. **Pediatr Nephrol** 1997 Feb; 11(1):7–11

PHYSIOPATHOLOGY

Relative role of alkalosis and sodium ions in reversal of class I antiarrhythmic drug–induced sodium channel blockade by sodium bicarbonate. Bou–Abboud E, et al.
Circulation 1996 Oct 15;94(8):1954–61

The effects of induced alkalosis on the metabolic response to prolonged exercise in humans. Galloway SD, et al.
Eur J Appl Physiol 1996;74(4):384–9

[Metabolic alkalosis on the surface but metabolic acidosis in depth] Halperin ML, et al. **Nephrologie** 1997;18(1):11–6 (17 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

[Ventilatory management during anesthesia in the patient with congenital cardiopathy undergoing non–cardiac surgery (letter; comment)] Reinoso–Barbero F.
Rev Esp Anestesiol Reanim 1996 Jun–Jul;43(6):222. Comment on: Rev Esp Anestesiol Reanim 1995 Oct;42(8):336–40. **(Spa)**

THERAPY

Severe metabolic alkalosis corrected by hemodialysis [letter] Leblanc M, et al. **Clin Nephrol** 1997 Jul;48(1):65

URINE

Effect of metabolic alkalosis and metabolic acidosis on urinary kallikrein excretion of anaesthetized rats: evidence for a role of blood pH as regulator of renal kallikrein secretion. Marin–Grez M, et al. **Pflugers Arch** 1996 Jun; 432(2):202–6

VETERINARY

Metabolic alkalosis in coliform mastitis. Ohtsuka H, et al.
J Vet Med Sci 1997 Jun;59(6):471–2

The effects of hypertonic saline in healthy and diseased animals. Cambier C, et al. **Vet Res Commun** 1997 Jul; 21(5):303–16 (52 ref.)

ALKALOSIS, RESPIRATORY

CHEMICALLY INDUCED

[Postoperative respiratory alkalosis as a complication of neuroendoscopy] Souto–Ferro JM, et al.
Rev Esp Anestesiol Reanim 1997 Feb;44(2):83–5 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Propranolol blocks the hypophosphaturia of acute respiratory alkalosis in human subjects. Tucker RR, et al.
J Lab Clin Med 1996 Oct;128(4):423–8

PHYSIOPATHOLOGY

The effects of bupivacaine and ropivacaine on baroreflex sensitivity with or without respiratory acidosis and alkalosis in rats. Watanabe Y, et al. **Anesth Analg** 1997 Feb; 84(2):398–404

Combined effects of hypocapnia and nicardipine on airway resistance: a pilot study. Combes P, et al.
Eur J Clin Pharmacol 1997;51(5):385–8

URINE

Propranolol blocks the hypophosphaturia of acute respiratory alkalosis in human subjects. Tucker RR, et al.
J Lab Clin Med 1996 Oct;128(4):423–8

ALKANES

The influence of cholesterol on phospholipid membrane curvature and bending elasticity. Chen Z, et al.
Biophys J 1997 Jul;73(1):267–76

On the origins of the hydrophobic effect: observations from simulations of n–dodecane in model solvents. Wallqvist A, et al. **Biophys J** 1996 Aug;71(2):600–8

ANALYSIS

A study of the efficiency of polybutadiene–coated zirconia as a reversed–phase chromatographic support. Li J, et al.
Anal Chem 1997 Jun 1;69(11):2193–201

Lipid biomarkers for bacterial ecosystems: studies of cultured organisms, hydrothermal environments and ancient sediments. Summons RE, et al. **Ciba Found Symp** 1996; 202:174–93; discussion 193–4 (33 ref.)

Genetics of a difference in cuticular hydrocarbons between Drosophila pseudoobscura and D. persimilis. Noor MA, et al. **Genet Res** 1996 Oct;68(2):117–23

CHEMISTRY

Using self–assembled monolayers to understand the interactions of man–made surfaces with proteins and cells. Mrksich M, et al. **Annu Rev Biophys Biomol Struct** 1996; 25:55–78 (87 ref.)

Lipid–helix interactions in membrane receptors. Zloh M, et al. **Biochem Soc Trans** 1996 May;24(2):305S

Molecular association of normal alkanoic acids with their thallium(I) salts: a new homologous series of fatty acid metal soaps. Fernández–García M, et al. **J Lipid Res** 1997 Feb;38(2):361–72

METABOLISM

Anaerobic degradation of polycyclic aromatic hydrocarbons and alkanes in petroleum–contaminated marine harbor sediments. Coates JD, et al. **Appl Environ Microbiol** 1997 Sep;63(9):3589–93

Rhamnolipid (biosurfactant) effects on cell aggregation and biodegradation of residual hexadecane under saturated flow conditions. Herman DC, et al. **Appl Environ Microbiol** 1997 Sep;63(9):3622–7

Sequence–selective binding to DNA of bis(amidinophenoxy)alkanes related to propamidine and pentamidine. Bailly C, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):23–31

Dimerization of a His117Gly azurin mutant by external addition of 1,omega–di(imidazol–1–yl)alkanes. van Pouderoyen G, et al. **Biochemistry** 1996 Oct 8; 35(40):13205–11

Polycyclic aromatic hydrocarbons and n–alkanes in Osilinus attratus from the coast of Tenerife (Canary Islands). Peña E, et al. **Bull Environ Contam Toxicol** 1996 Nov; 57(5):803–10

Uptake and utilization of n–octacosane and n–nonacosane by Arthrobacter nicotianae KCC B35. Radwan SS, et al.
J Appl Bacteriol 1996 Apr;80(4):370–4

Identification and characterization of xcpR encoding a subunit of the general secretory pathway necessary for dodecane degradation in Acinetobacter calcoaceticus ADP1. Parche S, et al. **J Bacteriol** 1997 Jul;179(14):4631–4

A novel type of pyridine nucleotide–disulfide oxidoreductase is essential for NAD+– and NADPH–dependent degradation of epoxyalkanes by Xanthobacter strain Py2. Swaving J, et al. **J Bacteriol** 1996 Nov;178(22):6644–6

PHARMACOKINETICS

Activation and inactivation of carcinogenic dihaloalkanes and other compounds by glutathione S–transferase 5–5 in Salmonella typhimurium tester strain NM5004. Shimada T, et al. **Chem Res Toxicol** 1996 Jan–Feb;9(1):333–40

Uptake and decay of volatile organic compounds at environmental concentrations: application of a four–compartment model to a chamber study of five human subjects. Wallace LA, et al.
J Expo Anal Environ Epidemiol 1997 Apr–Jun;7(2):141–63

PHARMACOLOGY

Cell and soft tissue interactions with methyl– and hydroxyl–terminated alkane thiols on gold surfaces. Lindblad M, et al. **Biomaterials** 1997 Aug;18(15):1059–68

Discrimination between subtypes of apamin–sensitive Ca(2+)–activated K+ channels by gallamine and a novel bis–quaternary quinolinium cyclophane, UCL 1530. Dunn PM, et al. **Br J Pharmacol** 1996 Jan;117(1):35–42

Effects of some saturated n–alkanes on the survival of Escherichia coli resting cells in sea water. Attrassi B, et al. **Cytobios** 1996;87(351):207–16

POISONING

Rhabdomyolysis and suicidal hydrocarbon inhalation [letter] Betrosian A, et al. **Ann Emerg Med** 1997 Feb;29(2):301–2

TOXICITY

Beyond TPH: health–based evaluation of petroleum hydrocarbon exposures. Hutcheson MS, et al.
Regul Toxicol Pharmacol 1996 Aug;24(1 Pt 1):85–101 (90 ref.)

ALKANESULFONATES

CHEMISTRY

Subchronic, developmental, and genetic toxicology studies with the ethane sulfonate metabolite of alachlor. Heydens WF, et al. **Fundam Appl Toxicol** 1996 Oct;33(2):173–81

Study of protein binding to a silica support with a polymeric cation–exchange coating. Ratnayake CK, et al.
J Chromatogr A 1996 Aug 30;743(1):15–23

METABOLISM

Assimilation of sulfur from alkyl– and arylsulfonates by Clostridium spp. Denger K, et al. **Arch Microbiol** 1997 Feb–Mar;167(2–3):177–81

Desulfonation of aliphatic sulfonates by Pseudomonas aeruginosa PAO. Kertesz MA. **FEMS Microbiol Lett** 1996 Apr 1;137(2–3):221–5

PHARMACOLOGY

Biocompatibility of sulphonated polyurethane surfaces. Keogh JR, et al. **Biomaterials** 1996 Oct;17(20):1987–94

ALKANESULFONIC ACIDS

CHEMISTRY

Sulfur and hydrogen isotope anomalies in meteorite sulfonic acids. Cooper GW, et al. **Science** 1997 Aug 22; 277(5329):1072–4

METABOLISM

Animal tissue–polypyrrole hybrid biomaterials: shrinkage temperature evaluation. Khor E, et al. **Biomaterials** 1996 Oct;17(19):1877–9

PHARMACOLOGY

Effect of 2–bromoethanesulfonic acid and Peptostreptococcus productus ATCC 35244 addition on stimulation of reductive acetogenesis in the ruminal ecosystem by selective inhibition of methanogenesis. Nollet L, et al. **Appl Environ Microbiol** 1997 Jan;63(1):194–200

TOXICITY

[Chronic toxic effects of surface–active substances varying in chemical structure] Szuliński S, et al.
Rocz Panstw Zakl Hig 1996;47(2):159–65 (Eng. Abstr.) **(Pol)**

[Anion–produced surface active agents, derivatives of alkylbenzyl sulfonic acid: toxicity and hazards] Sidorin GI, et al. **Med Tr Prom Ekol** 1996;(11):42–5 **(Rus)**

ALKAPTONURIA

COMPLICATIONS

Alkaptonuria with ochronotic nephropathy and multiple joint replacement for ochronotic arthropathy [letter] Jagose JT, et al. **N Z Med J** 1997 Jun 27;110(1046):235–6

[Alkaptonuria, prostatic calculi, and ectopic ureter] Concepción Masip T, et al. **Actas Urol Esp** 1997 Feb; 21(2):167–70 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Homogentisic acid interference in the measurement of urinary protein using benzethonium chloride. Sykes E, et al.
Ann Clin Biochem 1996 Jan;33 (Pt 1):86–8

ENZYMOLOGY

Cloning of the homogentisate 1,2–dioxygenase gene, the key enzyme of alkaptonuria in mouse. Schmidt SR, et al.
Mamm Genome 1997 Mar;8(3):168–71

GENETICS

Molecular defects in alkaptonuria. Gehrig A, et al.
Cytogenet Cell Genet 1997;76(1–2):14–6

The human homogentisate 1,2–dioxygenase (HGO) gene. Granadino B, et al. **Genomics** 1997 Jul 15;43(2):115–22

The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article] Garrod AE.
Mol Med 1996 May;2(3):274–82

HISTORY

Inborn errors of metabolism: Garrod's legacy. Bearn AG.
Mol Med 1996 May;2(3):271–3 (12 ref.)

The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article] Garrod AE.
Mol Med 1996 May;2(3):274–82

Alkaptonuria: from humans to moulds and back. Scazzocchio C. **Trends Genet** 1997 Apr;13(4):125–7

METABOLISM

[Disorders of organic acid metabolism] Tsuda M.
Ryoikibetsu Shokogun Shirizu 1996;(15):81–4 (11 ref.) **(Jpn)**

ALKENES

ADVERSE EFFECTS

Contact allergy to polyvinylpyrrolidone/hexadecene copolymer previously reported [letter] De Groot AC.
Am J Contact Dermat 1996 Dec;7(4):260

Studies on the toxic effects of crambe meal and two of its constituents, 1–cyano–2–hydroxy–3–butene (CHB) and epi–progoitrin, in broiler chick diets. Kloss P, et al.
Br Poult Sci 1996 Dec;37(5):971–86

CHEMICAL SYNTHESIS

Synthesis and antimicrobial activity of electron rich olefin derived cyclic ureas. Cetinkaya B, et al.
Arzneimittelforschung 1996 Dec;46(12):1154–8

ALKENES

CHEMISTRY

Modelling of additive diffusion in polyolefins. Limm W, et al. **Food Addit Contam** 1996 Nov-Dec;13(8):949-67

METABOLISM

Stable transfection of LLC-PK1 cells with human microsomal glutathione S-transferase gene increases haloalkene glutathione S-conjugate formation and cytotoxicity. Otieno MA, et al. **Biochem Biophys Res Commun** 1997 May 19;234(2):481-4

Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen. Pathak DN, et al. **Carcinogenesis** 1996 Sep;17(9):1785-90

Cytochrome P450-catalyzed hydroxylation of taxa-4(5),11(12)-diene to taxa-4(20),11(12)-dien-5alpha-ol: the first oxygenation step in taxol biosynthesis. Hefner J, et al. **Chem Biol** 1996 Jun;3(6):479-89

Friedel-Crafts alkylation of benzene and toluene with olefinic C6 hydrocarbons and esters. Black KD, et al. **Chem Phys Lipids** 1996 Jan 25;79(1):79-86

Metabolism and toxicity of 2-methylpropene (isobutene)--a review. Cornet M, et al. **Crit Rev Toxicol** 1997 May; 27(3):223-32 (50 ref.)

Purification and characterization of alpha,beta-ketoalkene double bond reductases from bovine eyes. Takeda Y, et al. **Curr Eye Res** 1997 Apr;16(4):327-32

Genetic analysis of Drosophila virilis sex pheromone: genetic mapping of the locus producing Z-(11)-pentacosene. Doi M, et al. **Genet Res** 1996 Aug;68(1):17-21

Genetics of a pheromonal difference affecting sexual isolation between Drosophila mauritiana and D. sechellia. Coyne JA, et al. **Genetics** 1997 Apr;145(4):1015-30

Oxidation of aliphatic olefins by toluene dioxygenase: enzyme rates and product identification. Lange CC, et al. **J Bacteriol** 1997 Jun;179(12):3858-65

Metabolic fate of 4-hydroxynonenal in hepatocytes: 1,4-dihydroxynonene is not the main product. Siems WG, et al. **J Lipid Res** 1997 Mar;38(3):612-22

TOXICITY

Stable transfection of LLC-PK1 cells with human microsomal glutathione S-transferase gene increases haloalkene glutathione S-conjugate formation and cytotoxicity. Otieno MA, et al. **Biochem Biophys Res Commun** 1997 May 19;234(2):481-4

Metabolism and toxicity of 2-methylpropene (isobutene)--a review. Cornet M, et al. **Crit Rev Toxicol** 1997 May; 27(3):223-32 (50 ref.)

Beyond TPH: health-based evaluation of petroleum hydrocarbon exposures. Hutcheson MS, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):85-101 (90 ref.)

7-ALKOXYCOUMARIN O-DEALKYLASE

BIOSYNTHESIS

Hierarchical cluster analysis of environmental pollutants through P450 induction in cultured hepatic cells. Dubois M, et al. **Ecotoxicol Environ Saf** 1996 Aug;34(3):205-15

DRUG EFFECTS

Ethoxycoumarin O-deethylation (ECOD) activity in rat liver slices exposed to beta-naphthoflavone (BNF) in vitro. Glockner R, et al. **Exp Toxicol Pathol** 1995 Sep; 47(4):319-24

METABOLISM

Cytochrome P450 monooxygenase activity in Haemonchus contortus (Nematoda). Kotze AC. **Int J Parasitol** 1997 Jan; 27(1):33-40

Effect of imidazole derivatives on cytochrome P-450 enzyme activities in a reconstructed human epidermis. Cotovio J, et al. **Skin Pharmacol** 1996;9(4):242-9

ALKYL GLYCERYL ETHERS see **GLYCERYL ETHERS**

ALKYL SULFONATES see **ALKANESULFONATES**

ALKYLATING AGENTS

Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin [letter] Storb R, et al. **Blood** 1997 May 15;89(10):3890-1

Induction of hprt gene mutations in splenic T-lymphocytes from the rat exposed in vivo to DNA methylating agents is correlated with formation of O6-methylguanine in bone marrow and not in the spleen. Jansen JG, et al. **Carcinogenesis** 1996 Oct;17(10):2183-91

ADMINISTRATION & DOSAGE

Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Smith DR, et al. **Ann Neurol** 1997 Sep;42(3):313-8

Pulse intravenous cyclophosphamide for treatment of autoimmune blistering disease. Is there an advantage over oral routes? [editorial;comment] Werth VP. **Arch Dermatol** 1997 Feb;133(2):229-30. Comment on: Arch Dermatol 1997 Feb;133(2):245.

Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation. Maschan AA, et al. **Bone Marrow Transplant** 1997 Feb;19(4):385-7

Diethylnitrosamine exposure-responses for DNA damage, centrilobular cytotoxicity, cell proliferation and carcinogenesis in rat liver exhibit some non-linearities. Williams GM, et al. **Carcinogenesis** 1996 Oct;17(10):2253-8

Adaptive and synergistic effects of a low-dose ENU pretreatment on the frequency of chromosomal aberrations induced by a challenge dose of ENU in human peripheral blood lymphocytes in vitro. Nikolova T, et al. **Mutat Res** 1996 Oct 25;357(1-2):131-41

ADVERSE EFFECTS

Prevention and treatment of hemorrhagic cystitis. West NJ. **Pharmacotherapy** 1997 Jul-Aug;17(4):696-706 (79 ref.)

ANALYSIS

N-alkylvaline levels in globin as a new type of biomarker in risk assessment of alkylating agents. Lewalter J. **Int Arch Occup Environ Health** 1996;68(6):519-30

Gas chromatographic/mass spectrometric analysis of methyl methanesulphonate and ethyl methanesulphonate in the bismesylate salt of DPI 201-106, a positive inotropic agent for the treatment of heart failure. Ramjit HG, et al. **J Mass Spectrom** 1996 Aug;31(8):867-72

CHEMISTRY

Quantum molecular modeling of the interaction between guanine and alkylating agents--1--sulfur mustard. Broch H, et al. **J Biomol Struct Dyn** 1996 Jun;13(6):903-14

Quantum molecular modeling of the interaction between guanine and alkylating agents--2--nitrogen mustard. Hamza A, et al. **J Biomol Struct Dyn** 1996 Jun;13(6):915-24

Reaction of human hemoglobin toward the alkylating agent S-(2-chloroethyl)glutathione. Erve JC, et al. **J Toxicol Environ Health** 1996 Oct 11;49(2):127-43

[Study of the interaction of polyreactive antibodies with nucleic acids using alkylating oligonucleotide derivatives] Pautova LV, et al. **Mol Biol (Mosk)** 1996 Jul-Aug; 30(4):941-50 **(Rus)**

PHARMACOKINETICS

Biological fate of sulphur mustard: identification of valine and histidine adducts in haemoglobin from casualties of sulphur mustard poisoning. Black RM, et al. **Xenobiotica** 1997 May;27(5):499-512

PHARMACOLOGY

Glutathione depletion in the yeast Saccharomyces cerevisiae. Fortuniak A, et al. **Biochem Mol Biol Int** 1996 Apr; 38(5):901-10

Conformational change in human DNA repair enzyme O6-methylguanine-DNA methyltransferase upon alkylation of its active site by SN1 (indirect-acting) and SN2 (direct-acting) alkylating agents: breaking a "salt-link". Oh HK, et al. **Biochemistry** 1996 Sep 24;35(38):12259-66

Effect of folate deficiency on mutations at the hprt locus in Chinese hamster ovary cells exposed to monofunctional alkylating agents. Branda RF, et al. **Cancer Res** 1997 Jul 1;57(13):2586-8

Specificity of DNA alkylation by 1-(2-chloroethyl)-3-alkyl-3-acyltriazenes depends on the structure of the acyl group: kinetic and product studies. Smith MB, et al. **Chem Res Toxicol** 1996 Mar;9(2):466-75

Abnormal cutaneous nerve outgrowth: a secondary effect of methyl triazene teratology in developing mouse limb buds. Milaire J, et al. **Eur J Morphol** 1996 Nov;34(4):301-10

Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells. Letourneau S, et al. **Hum Gene Ther** 1996 May 1;7(7):831-40

The in vivo and in vitro effects of an alkylating agent, mechlorethamine, on IL-6 production in mice and the role of macrophages. Bryniarski K, et al. **Immunopharmacology** 1996 Sep;34(2-3):73-8

Amplification of the DNA repair gene O6-methylguanine-DNA methyltransferase associated with resistance to alkylating drugs in a mammalian cell line. Tano K, et al. **J Biol Chem** 1997 May 16; 272(20):13250-4

In vitro response to interleukin-1 beta and streptozotocin in pancreatic islets isolated from male and female nonobese diabetic mice. Strandell E, et al. **J Endocrinol** 1997 Apr; 153(1):81-6

Quantitative changes in neuron and glial cells of neocortex following prenatal exposure to methylazoxymethanol. Ciaroni S, et al. **J Hirnforsch** 1996;37(4):537-46

Short exposure to methylazoxymethanol causes a long-term inhibition of axonal outgrowth from cultured embryonic rat hippocampal neurons. Hoffman JR, et al. **J Neurosci Res** 1996 Nov 1;46(3):349-59

The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat. Angley MT, et al. **J Pharm Pharmacol** 1996 Apr;48(4):386-9

Cross-sensitivity of X-ray-hypersensitive cells derived from LEC strain rats to DNA-damaging agents. Okui T, et al. **J Vet Med Sci** 1996 Nov;58(11):1067-71

Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard. Poon B, et al. **J Virol** 1997 May; 71(5):3961-71

Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function. Kuo ML, et al. **Mol Carcinog** 1997 Apr;18(4):221-31

The level of intracellular glutathione is a key regulator for the induction of stress-activated signal transduction pathways including Jun N-terminal protein kinases and p38 kinase by alkylating agents. Wilhelm D, et al. **Mol Cell Biol** 1997 Aug;17(8):4792-800

Effects of oxidation and reduction on the binding of transcription factors to cis-regulatory elements located in the FGF-4 gene. Lickteig K, et al. **Mol Reprod Dev** 1996 Jun;44(2):146-52

Mismatch repair provokes chromosome aberrations in hamster cells treated with methylating agents or 6-thioguanine, but not with ethylating agents. Armstrong MJ, et al. **Mutat Res** 1997 Feb 3;373(2):167-78

The mus206 gene of Drosophila melanogaster is required in the excision repair of alkylation-induced DNA lesions. Huang W, et al. **Mutat Res** 1997 Aug;384(2):81-8

Alkylation of [3H]8-OH-DPAT binding sites in rat cerebral cortex and hippocampus. Nénonéné EK, et al. **Neurochem Res** 1996 Feb;21(2):167-76

Reorganisation of the urothelial luminal plasma membrane in the cyclophosphamide treated rats. Romih R, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R241-2

THERAPEUTIC USE

Interstitial pneumonitis probably induced by cyclophosphamide in nephrosis. Harigaya H, et al. **Acta Paediatr Jpn** 1997 Jun;39(3):364-7

Reversal of erythema multiforme major with cyclophosphamide and prednisone. Eastham JH, et al. **Ann Pharmacother** 1996 Jun;30(6):606-7

Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Najean Y, et al. **Blood** 1997 Apr 1;89(7):2319-27

The therapeutic effect of a combination of cofpropamine, a caffeine derivative, and cyclophosphamide on the development of adjuvant arthritis of rats and collagen arthritis of mice. Kröger H, et al. **Gen Pharmacol** 1996 Oct;27(7):1215-8

Low-dose mitomycin C trabeculectomy in patients with advanced glaucoma. Costa VP, et al. **J Glaucoma** 1996 Jun; 5(3):193-9

Can intravenous cyclophosphamide be used for steroid-dependent nephrotic syndrome? [letter] Bircan Z, et al. **Pediatr Nephrol** 1997 Feb;11(1):127-8

HLA-DR7 predicts the response to alkylating agents in steroid-sensitive nephrotic syndrome. Konrad M, et al. **Pediatr Nephrol** 1997 Feb;11(1):16-9

TOXICITY

Effects of cyclophosphamide and ceftriaxone on gastrointestinal colonization of mice by Candida albicans. Samonis G, et al. **Antimicrob Agents Chemother** 1996 Sep; 40(9):2221-3

Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Harker LA, et al. **Blood** 1997 Jan 1;89(1):155-65

Hepatotoxic effects of SH-reagents in human and rat hepatocyte cultures and in situ perfused rat livers. Boot JH. **Cell Struct Funct** 1996 Aug;21(4):221-9

Developmental toxicity of dimethyl sulfate by inhalation in the rat. Alvarez L, et al. **Drug Chem Toxicol** 1997 Feb-May; 20(1-2):99-114

Significance of cell type specific formation and elimination of DNA-adducts in respiratory tissues of hamster and rat induced by alkylating chemical carcinogens. Seiler F, et al. **Exp Toxicol Pathol** 1996 Nov;48(6):544-7

Methylazoxymethanol acetate-induced apoptosis in the external granule cell layer of the developing cerebellum of the rat is associated with strong c-Jun expression and formation of high molecular weight c-Jun complexes. Ferrer I, et al. **J Neuropathol Exp Neurol** 1997 Jan;56(1):1-9

5-Hydroxytryptamine1B and alpha 2 adrenaline receptors in the brain of rats prenatally treated with methylazoxymethanol. Watanabe M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):69-73

Alterations in DNA and cell membranes in an initiation process of carcinogenesis by N-nitrosourea. Yano K, et al. **Nucleic Acids Symp Ser** 1995;(34):239-40

Influence of donor age on the cytotoxicity and mutagenicity of ethylnitrosourea in cultured human T-lymphocytes. Mei N, et al. **Sangyo Ika Daigaku Zasshi** 1997 Jun 1;19(2):133-45

Testicular development and fertility of mice treated prenatally with N-nitroso-N-ethylurea at various gestational stages. Nagao T, et al.
Teratog Carcinog Mutagen 1996;16(3):183-98
Embryotoxicity induced by alkylating agents: 10. Analysis of the combined teratogenic effects of methylnitrosourea and ethylmethanesulfonate in mice. Platzek T, et al.
Teratog Carcinog Mutagen 1995;15(4):201-14

ALKYLATING AGENTS, ANTINEOPLASTIC see **ANTINEOPLASTIC AGENTS, ALKYLATING**

ALKYNES

ADMINISTRATION & DOSAGE

A new metabolite of propargylglycine, gamma-glutamylpropargylcylglycine, in liver of D,L-propargylglycine-administered rats. Ohta J, et al.
Biochim Biophys Acta 1997 Mar 15;1334(2-3):240-6

BLOOD

Evaluation of a benchtop ion trap gas chromatographic-tandem mass spectrometric instrument for the analysis of a model drug, tebufelone, in plasma using a stable-isotope internal standard. Wehmeyer KR, et al.
J Chromatogr B Biomed Appl 1996 Feb 9;676(1):53-9

CHEMISTRY

Chemical and quantum mechanical studies of the free radical C-C bond formation in the lipoxygenase-catalyzed dimerisation of octodeca-9,12-diynoic acid. Nieuwenhuizen WF, et al. **Free Radic Biol Med** 1997; 22(6):1101-8
Bioactive polyacetylenes from Bidens pilosa [letter] Alvarez L, et al. **Planta Med** 1996 Aug;62(4):355-7

METABOLISM

Chemical and quantum mechanical studies of the free radical C-C bond formation in the lipoxygenase-catalyzed dimerisation of octodeca-9,12-diynoic acid. Nieuwenhuizen WF, et al. **Free Radic Biol Med** 1997; 22(6):1101-8

PHARMACOKINETICS

Pharmacokinetic behaviour and cardiovascular effects of intravenously administered hypoxoside and rooperol. Coetzee JF, et al. **Arzneimittelforschung** 1996 Oct; 46(10):997-1000

PHARMACOLOGY

Pharmacokinetic behaviour and cardiovascular effects of intravenously administered hypoxoside and rooperol. Coetzee JF, et al. **Arzneimittelforschung** 1996 Oct; 46(10):997-1000
Mechanism-based inhibition of mouse P4502b-10 by selected arylalkynes. Beebe LE, et al. **Biochem Pharmacol** 1996 Nov 22;52(10):1507-13
Characterization of the effects of tebufelone on hepatic cytochromes P450 in the beagle dog. Smith BJ, et al.
Drug Metab Dispos 1996 May;24(5):523-8
Sensitivity to radiation treatment and changes in metallothionein synthesis in a transplanted murine tumor. Shibuya K, et al. **Radiat Res** 1997 Sep;148(3):235-9

ALL, ADULT see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

ALL, CHILDHOOD see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

ALL-TERRAIN VEHICLES see **OFF-ROAD MOTOR VEHICLES**

ALLANTOIN

ADMINISTRATION & DOSAGE

The effectiveness of Allerpet/c in reducing the cat allergen Fel d 1 [see comments] Perzanowski MS, et al.
J Allergy Clin Immunol 1997 Sep;100(3):428-30. Comment in: J Allergy Clin Immunol 1997 Sep;100(3):290-2.
Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. duBouchet L, et al. **Sex Transm Dis** 1997 Mar;24(3):156-60

ANALOGS & DERIVATIVES

Absence of gastrointestinal absorption or urinary excretion of aluminium from an allantoinate complex contained in two antacid formulations in patients with normal renal function. Guillard O, et al.
Eur J Clin Chem Clin Biochem 1996 Aug;34(8):609-12

ANALYSIS

Effect of diet on milk allantoin and its relationship with urinary allantoin in dairy cows. Gonda HL, et al.
J Dairy Sci 1997 Feb;80(2):364-73

BLOOD

New evidence for the involvement of oxygen radicals in triggering neonatal chronic lung disease. Ogihara T, et al.
Pediatr Res 1996 Jan;39(1):117-9

CHEMISTRY

Unusual abundance of arginine and ornithine in porcine allantoic fluid. Wu G, et al. **Biol Reprod** 1996 Jun; 54(6):1261-5
PCB concentrations of eggs and chorioallantoic membranes of loggerhead sea turtles (Caretta caretta) from the Cape Romain National Wildlife Refuge. Cobb GP, et al.
Chemosphere 1997 Feb;34(3):539-49

METABOLISM

Oxidation of urate in human skeletal muscle during exercise. Hellsten Y, et al. **Free Radic Biol Med** 1997;22(1-2):169-74

THERAPEUTIC USE

Comparative effects of calcipotriol ointment (50 micrograms/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis. Pinheiro N. **Br J Clin Pract** 1997 Jan-Feb;51(1):16-9

URINE

Effect of diet on milk allantoin and its relationship with urinary allantoin in dairy cows. Gonda HL, et al.
J Dairy Sci 1997 Feb;80(2):364-73

ALLANTOIS

BLOOD SUPPLY

Microvascular growth in the chicken chorio-allantoic membrane. König MF, et al. **Adv Exp Med Biol** 1997; 411:353-8
Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. Oikawa T, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):93-6
The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Ribatti D, et al.
Int J Dev Biol 1996 Dec;40(6):1189-97 (76 ref.)
Pyogenic granuloma stimulates angiogenesis in the chick embryo chorioallantoic membrane. Ribatti D, et al.
Int J Microcirc Clin Exp 1996 Mar-Apr;16(2):82-8
Microvascular permselectivity in the chick chorioallantoic membrane during endothelial cell senescence. Rizzo V, et al. **Int J Microcirc Clin Exp** 1997 Mar-Apr;17(2):75-9
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Anand-Apte B, et al.
Invest Ophthalmol Vis Sci 1997 Apr;38(5):817-23
Measuring fractal dimension and complexity—an alternative approach with an application. Sandau K, et al.
J Microsc 1997 May;186 (Pt 2):164-76
Degranulation of mast cells in the chick chorioallantoic membrane does not increase macromolecular extravasation during normal angiogenesis. Rizzo V, et al.
Microcirculation 1996 Dec;3(4):387-93
Quantitation of angiogenesis in the chick chorioallantoic membrane model using fractal analysis. Kirchner LM, et al. **Microvasc Res** 1996 Jan;51(1):2-14
Implementation of intussusceptive microvascular growth in the chicken chorioallantoic membrane (CAM): 1. pillar formation by folding of the capillary wall. Patan S, et al. **Microvasc Res** 1996 Jan;51(1):80-98
Implementation of intussusceptive microvascular growth in the chicken chorioallantoic membrane (CAM). Patan S, et al. **Microvasc Res** 1997 Jan;53(1):33-52
Capillary sprouts restrict macromolecular extravasation during normal angiogenesis in the chick chorioallantoic membrane. Rizzo V, et al. **Microvasc Res** 1996 Jul; 52(1):47-57
Quantitative study of intussusceptive capillary growth in the chorioallantoic membrane (CAM) of the chicken embryo. Schlatter P, et al. **Microvasc Res** 1997 Jul;54(1):65-73
The chorioallantoic artery blood flow of the chick embryo from stage 34 to 43. van Golde J, et al. **Pediatr Res** 1996 Dec;40(6):867-71

CYTOLOGY

Ovine amniotic and allantoic epithelia across gestation. Shandley L, et al. **Anat Rec** 1997 Aug;248(4):542-53
Developmental potency of the murine allantois. Downs KM, et al. **Development** 1997 Jul;124(14):2769-80

DRUG EFFECTS

IRAG working group 2. CAM-based assays. Interagency Regulatory Alternatives Group. Spielmann H, et al.
Food Chem Toxicol 1997 Jan;35(1):39-66
The use of the chorio-allantoic membrane of the chick embryo as test for anti-inflammatory activity. Beckers M, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S29-30
Basic fibroblast growth factor-induced angiogenesis in the chick embryo chorioallantoic membrane: an electron microscopy study. Ribatti D, et al. **Microvasc Res** 1997 Mar;53(2):187-90
Developing allantois is a primary site of 2'-deoxycoformycin toxicity. Airhart MJ, et al. **Teratology** 1996 Jun; 53(6):361-73

ENZYMOLOGY

Studies into aromatase activity associated with fetal allantochorionic and maternal endometrial tissues of equine placenta. Identification of metabolites by gas chromatography mass spectrometry. Marshall DE, et al.
J Steroid Biochem Mol Biol 1996 Nov;59(3-4):281-96

METABOLISM

Changes in M-CSF-like activity during chicken embryonic development. Shao X, et al. **Reprod Fertil Dev** 1996; 8(1):103-9

PATHOLOGY

The chick embryo chorioallantoic membrane as an in vivo wound healing model. Ribatti D, et al.
Pathol Res Pract 1996 Oct;192(10):1068-76

PHYSIOLOGY

The chick embryo chorioallantoic membrane as an in vivo wound healing model. Ribatti D, et al.
Pathol Res Pract 1996 Oct;192(10):1068-76

ULTRASONOGRAPHY

Unusual fate of vesicoallantoic cyst with non-visualization of fetal urinary bladder in a case of patent urachus. Yoo SJ, et al. **Ultrasound Obstet Gynecol** 1997 Jun;9(6):422-4

ULTRASTRUCTURE

Observations on the chorioallantoic placenta of the Indian flying fox, Pteropus giganteus giganteus. Karim KB, et al.
Anat Anz 1996 Dec;178(6):523-30

VIROLOGY

Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. Ito T, et al.
J Virol 1997 Apr;71(4):3357-62
[Effect of components of virus-containing allantoic fluid on the stability of influenza virus during storage] Poryvaev VD, et al. **Vopr Virusol** 1996 May-Jun;41(3):126-9 (Eng. Abstr.) **(Rus)**

ALLELES

SfaNI polymorphism distinguishes the alleles of the glycophorin A locus that determine the MN blood group. Leos SH, et al. **Acta Haematol** 1997;98(1):51-3
Frequency of CYP2D6 allelic variants in multiple sclerosis. Agúndez JA, et al. **Acta Neurol Scand** 1995 Dec;92(6):464-7
Apolipoprotein E allele frequencies in patients with late-onset sporadic Alzheimer's dementia in Hungary. Kálmán J, et al. **Acta Neurol Scand** 1997 Jan;95(1):56-9
The frequency of apolipoprotein E4 allele is not increased in patients with probable vascular dementia. Pirttilä T, et al. **Acta Neurol Scand** 1996 May;93(5):352-4
Tuberous sclerosis-like lesions in epileptogenic human neocortex lack allelic loss at the TSC1 and TSC2 regions. Wolf HK, et al. **Acta Neuropathol (Berl)** 1997 Jan;93(1):93-6
Schizophrenia and neurotrophin-3 alleles. Jönsson E, et al.
Acta Psychiatr Scand 1997 May;95(5):414-9
Responsiveness to the major pollen allergen of Parietaria officinalis is associated with defined HLA-DRB1* alleles in Italian and Spanish allergic patients. Ruffilli A, et al.
Adv Exp Med Biol 1996;409:75-9
Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. Khoo SH, et al. **AIDS** 1997 Mar 15;11(4):423-8
Allele frequency of ADH2 and ALDH2 among Brazilians of different ethnic groups. Santos BR, et al. **Alcohol** 1997 May-Jun;14(3):205-7
A study on ADH2 and ALDH2 genotyping by PCR-RFLP and SSCP analyses with description of allele and genotype frequencies in Japanese, Finn and Lapp populations. Suzuki K, et al. **Alcohol Alcohol** 1994;29 Suppl 1:21-7
Alcohol dehydrogenase polymorphisms in Native Americans: identification of the ADH2*3 allele. Wall TL, et al.
Alcohol Alcohol 1997 Mar-Apr;32(2):129-32
Tyrosine hydroxylase and dopamine D4 receptor allelic distribution in Scandinavian chronic alcoholics. Geijer T, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):35-9
Lack of allelic association of dopamine D1 and D2 (TaqIA) receptor gene polymorphisms with reduced dopaminergic sensitivity to alcoholism. Heinz A, et al.
Alcohol Clin Exp Res 1996 Sep;20(6):1109-13
DRD2 haplotypes containing the TaqI A1 allele: implications for alcoholism research. Kidd KK, et al.
Alcohol Clin Exp Res 1996 Jun;20(4):697-705
Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Grönberg H, et al.
Am J Epidemiol 1997 Oct 1;146(7):552-7
Polymerase chain reaction-based approaches for detection of allelic loss in the p53 tumor suppressor gene in colon neoplasms. Yamaguchi K, et al. **Am J Gastroenterol** 1997 Feb;92(2):307-12
The apolipoprotein E epsilon 4 allele is associated with increased behavioral disturbance in Alzheimer's disease [letter] Murphy GM Jr, et al. **Am J Geriatr Psychiatry** 1997 Winter;5(1):88-9
Short alleles revealed by PCR demonstrate no heterozygote

deficiency at minisatellite loci D1S7, D7S21, and D12S11. Alonso S, et al. **Am J Hum Genet** 1997 Feb;60(2):417–25

Nonreplication of linkage disequilibrium between the dopamine D4 receptor locus and Tourette syndrome [letter; comment] Hebebrand J, et al. **Am J Hum Genet** 1997 Jul; 61(1):238–9. Comment on: Am J Hum Genet 1996 Sep;59(3):644–52.

Reduced frequency of extracolonic cancers in hereditary nonpolyposis colorectal cancer families with monoallelic hMLH1 expression. Jäger AC, et al. **Am J Hum Genet** 1997 Jul;61(1):129–38

Power studies for the transmission/disequilibrium tests with multiple alleles. Kaplan NL, et al. **Am J Hum Genet** 1997 Mar;60(3):691–702

The seventh form of autosomal recessive limb–girdle muscular dystrophy is mapped to 17q11–12. Moreira ES, et al. **Am J Hum Genet** 1997 Jul;61(1):151–9

Fc epsilon R1–beta polymorphism and total serum IgE levels in endemically parasitized Australian aborigines. Palmer LJ, et al. **Am J Hum Genet** 1997 Jul;61(1):182–8

Using discordant sib pairs to map loci for qualitative traits with high sibling recurrence risk. Rogus JJ, et al. **Am J Hum Genet** 1996 Dec;59(6):1376–81

Analysis of genetic linkage and somatic loss of heterozygosity in affected pairs of first–degree relatives. Rohde K, et al. **Am J Hum Genet** 1997 Aug;61(2):418–22 (13 ref.)

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences [see comments] Sachse C, et al. **Am J Hum Genet** 1997 Feb; 60(2):284–95. Comment in: Am J Hum Genet 1997 Feb;60(2):265–71.

Transmission/disequilibrium tests for multiallelic loci [letter] Sham P. **Am J Hum Genet** 1997 Sep;61(3):774–8

Estimating the age of alleles by use of intraallelic variability. Slatkin M, et al. **Am J Hum Genet** 1997 Feb;60(2):447–58

Allelic disequilibrium and allele frequency distribution as a function of social and demographic history. Thompson EA, et al. **Am J Hum Genet** 1997 Jan;60(1):197–204

Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Willing MC, et al. **Am J Hum Genet** 1996 Oct; 59(4):799–809

Gaucher disease: functional expression of the normal glucocerebrosidase and Gaucher T1366G and G1604A alleles in Baculovirus–transfected Spodoptera frugiperda cells. Choy FY, et al. **Am J Med Genet** 1996 Oct 28; 65(3):184–9

Preferential loss of the paternal alleles in the 18q– syndrome. Cody JD, et al. **Am J Med Genet** 1997 Mar 31;69(3):280–6

Segregation analysis of microcephaly. Cohen T, et al. **Am J Med Genet** 1996 Oct 28;65(3):226–34

No association between schizophrenia and the serotonin receptor 5HTR2a in an Italian population. Verga M, et al. **Am J Med Genet** 1997 Feb 21;74(1):21–5

No evidence for an allelic association between schizophrenia and markers D22S278 and D22S283. Williams NM, et al. **Am J Med Genet** 1997 Feb 21;74(1):37–9

Allelic loss detected on chromosomes 8, 10, and 17 by fluorescence in situ hybridization using single–copy P1 probes on isolated nuclei from paraffin–embedded prostate tumors. Deubler DA, et al. **Am J Pathol** 1997 Mar; 150(3):841–50

Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel–Lindau disease patients. Lubensky IA, et al. **Am J Pathol** 1996 Dec;149(6):2089–94

HLA class II alleles in Ainu living in Hidaka District, Hokkaido, northern Japan. Bannai M, et al. **Am J Phys Anthropol** 1996 Sep;101(1):1–9

Apolipoprotein E epsilon 4 allele and pupillary response to tropicamide. Higuchi S, et al. **Am J Psychiatry** 1997 May; 154(5):694–6

Lack of evidence for allelic association between personality traits and the dopamine D4 receptor gene polymorphisms. Jönsson EG, et al. **Am J Psychiatry** 1997 May;154(5):697–9

Maternal HLA class II alleles predispose to pregnancy losses in Danish women with recurrent spontaneous abortions and their female relatives. Christiansen OB, et al. **Am J Reprod Immunol** 1996 Mar;35(3):239–44

Analyses of HLA–DQ alleles in recurrent spontaneous abortion (RSA) couples. Wagenknecht DR, et al. **Am J Reprod Immunol** 1997 Jan;37(1):1–6

Peptide nucleic acid–mediated polymerase chain reaction clamping allows allelic allocation of CYP1A1 mutations. Mrozikiewicz PM, et al. **Anal Biochem** 1997 Aug 1; 250(2):256–7

Identification of a heterozygote for the silent and Kalow alleles of cholinesterase using a polymerase chain reaction technique. Campbell RA, et al. **Ann Clin Biochem** 1996 Nov;33 (Pt 6):568–70

Genetic predictors of common disease: apolipoprotein E genotype as a paradigm. Jarvik GP. **Ann Epidemiol** 1997 Jul;7(5):357–62 (39 ref.)

D1S80 locus variability in South American Indians. Hutz MH, et al. **Ann Hum Biol** 1997 May–Jun;24(3):249–55

Apolipoprotein E genotype epsilon 4/epsilon 2 in the STANISLAS Cohort Study--dominance of the epsilon 2 allele? Bohnet K, et al. **Ann Hum Genet** 1996 Nov;60 (Pt 6):509–16

Randomization tests of disease–marker associations. Morris AP, et al. **Ann Hum Genet** 1997 Jan;61 (Pt 1):49–60

Genetic heterogeneity in Wilson disease: lessons from rare alleles [editorial; comment] Pyeritz RE. **Ann Intern Med** 1997 Jul 1;127(1):70–2. Comment on: Ann Intern Med 1997 Jul 1;127(1):21–6.

Cerebral amyloid angiopathy and apolipoprotein E: bad news for the good allele? [editorial; comment] Greenberg SM, et al. **Ann Neurol** 1997 Jun;41(6):701–2. Comment on: Ann Neurol 1997 Jun;41(6):716–21.

High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy [see comments] Nicoll JA, et al. **Ann Neurol** 1997 Jun; 41(6):716–21. Comment in: Ann Neurol 1997 Jun;41(6):701–2.

Apolipoprotein E epsilon2 does not increase risk of early–onset sporadic Alzheimer's disease. Scott WK, et al. **Ann Neurol** 1997 Sep;42(3):376–8

Extensive DNA deletion associated with severe disease alleles on spinal muscular atrophy homologues. Wang CH, et al. **Ann Neurol** 1997 Jul;42(1):41–9

alpha 1–Antichymotrypsin as a risk modifier for late–onset Alzheimer's disease in Japanese apolipoprotein E epsilon 4 allele carriers. Yoshiiwa A, et al. **Ann Neurol** 1997 Jul; 42(1):115–7

Influence of the HLA–DR beta shared epitope on susceptibility to and clinical expression of rheumatoid arthritis in Chilean patients. González A, et al. **Ann Rheum Dis** 1997 Mar;56(3):191–3

Sequencing and analysis of four new Enterobacter ampD Alleles. Ehrhardt AF, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1953–6

D2 dopamine receptor A1 allele in Alzheimer disease and aging. Small GW, et al. **Arch Neurol** 1997 Mar;54(3):281–5

Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arnett FC, et al. **Arthritis Rheum** 1996 Sep;39(9):1507–18

Phenotyping for CYP 11D6 alleles [letter] Synnott IH. **Aust N Z J Psychiatry** 1997 Jun;31(3):431

Three allelic forms of the human endogenous retrovirus, ERV3, and their frequencies in multiple sclerosis patients and healthy individuals. Rasmussen HB, et al. **Autoimmunity** 1996;23(2):111–7

No association between general cognitive ability and the A1 allele of the D2 dopamine receptor gene. Petrill SA, et al. **Behav Genet** 1997 Jan;27(1):29–31

Vitamin D receptor alleles b, a, and T: risk factors for sporadic primary hyperparathyroidism (HPT) but not HPT of uremia or MEN 1. Carling T, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):329–32

Identification of a novel allele at the human NAT1 acetyltransferase locus. Doll MA, et al. **Biochem Biophys Res Commun** 1997 Apr 28;233(3):584–91

No association between Parkinson's disease and low–activity alleles of catechol O–methyltransferase. Hoda F, et al. **Biochem Biophys Res Commun** 1996 Nov 21;228(3):780–4

Alleles of the spontaneously hypertensive rat decrease blood pressure at loci on chromosomes 4 and 13. Kovács P, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):586–9

Molecular analysis of the O alleles at the blood group ABO locus in populations of different ethnic origin reveals novel crossing–over events and point mutations. Olsson ML, et al. **Biochem Biophys Res Commun** 1997 May 29; 234(3):779–82

Vitamin D receptor: no evidence for allele–specific mRNA stability in cells which are heterozygous for the Taq I restriction enzyme polymorphism. Verbeek W, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):77–80

Characterization of the N314D allele of human galactose–1–phosphate uridylyltransferase using a yeast expression system. Fridovich–Keil JL, et al. **Biochem Mol Med** 1995 Dec;56(2):121–30

Allelotype analysis in mouse hepatocellular carcinomas; frequent homozygous deletion of mouse homolog of p16/CDKN2 gene on chromosome 4 in culture. Miyasaka K, et al. **Biol Pharm Bull** 1996 May;19(5):683–91

Association study of NlaIII and MspI genetic polymorphisms of catechol–O–methyltransferase gene and susceptibility to schizophrenia. Chen CH, et al. **Biol Psychiatry** 1997 May 1;41(9):985–7

Lower frequency of apolipoprotein E4 allele in an "elderly" Down's syndrome population. Cosgrave M, et al. **Biol Psychiatry** 1996 Oct 15;40(8):811–3

Apolipoprotein E–epsilon 4 allele frequency in late–onset depression [letter; comment] Heidrich A, et al. **Biol Psychiatry** 1997 Apr 15;41(8):912–3. Comment on: Biol Psychiatry 1996 Jul 1;40(1):69–71.

Association of the D2 dopamine receptor A1 allele with alcoholism: medical severity of alcoholism and type of controls. Lawford BR, et al. **Biol Psychiatry** 1997 Feb 15; 41(4):386–93

Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium. Sander T, et al. **Biol Psychiatry** 1997 Feb 1;41(3):299–304

Improved PCR amplification of multiple specific alleles (PAMSA) using internally mismatched primers. Okimoto R, et al. **Biotechniques** 1996 Jul;21(1):20–2, 24, 26

Differentiating allele combinations of a transgene using multiple primer PCR. Pekhletski R, et al. **Biotechniques** 1996 Jun;20(6):956–8, 960

The A20210 allele of the prothrombin gene is not frequently associated with the factor V Arg 506 to Gln mutation in thrombophilic families [letter] Alhenc–Gelas M, et al. **Blood** 1997 Aug 15;90(4):1711

Modulation of clinical expression and band 3 deficiency in hereditary spherocytosis. Alloisio N, et al. **Blood** 1997 Jul 1;90(1):414–20

Human plasminogen activator inhibitor–1 (PAI–1) deficiency: characterization of a large kindred with a null mutation in the PAI–1 gene. Fay WP, et al. **Blood** 1997 Jul 1;90(1):204–8

Alternative splicing of a novel glycophorin allele GPHe(GL) generates two protein isoforms in the human erythrocyte membrane. Huang CH, et al. **Blood** 1997 Jul 1;90(1):391–7

Allelotype analysis in the evolution of chronic myelocytic leukemia. Mori N, et al. **Blood** 1997 Sep 1;90(5):2010–4

Molecular genetic analysis of variant phenotypes of the ABO blood group system. Ogasawara K, et al. **Blood** 1996 Oct 1;88(7):2732–7

Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs. Jepson A, et al. **BMJ** 1997 Jul 12; 315(7100):96–7

Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S–transferase (GSTM1 and GSTT1) and cytochrome P–450 (CYP1A1) loci. Esteller M, et al. **Br J Cancer** 1997;75(9):1385–8

Fractional allele loss data indicate distinct genetic populations in the development of non–small–cell lung cancer. Field JK, et al. **Br J Cancer** 1996 Dec;74(12):1968–74

Allelic imbalance on chromosome 5q predicts long–term survival in neuroblastoma. Meltzer SJ, et al. **Br J Cancer** 1996 Dec;74(12):1855–61

Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ. Munn KE, et al. **Br J Cancer** 1996 Nov;74(10):1578–85

Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas. Papp J, et al. **Br J Cancer** 1996 Nov;74(10):1592–7

Allele loss occurs frequently at hMLH1, but rarely at hMSH2, in sporadic colorectal cancers with microsatellite instability. Tomlinson IP, et al. **Br J Cancer** 1996 Nov; 74(10):1514–7

Allelic loss at chromosome 13q12–q13 is associated with poor prognosis in familial and sporadic breast cancer. van den Berg J, et al. **Br J Cancer** 1996 Nov;74(10):1615–9

No evidence for association between CNTF null mutant allele and schizophrenia [letter] Arinami T, et al. **Br J Psychiatry** 1996 Aug;169(2):253

Abeta1–40 but not Abeta1–42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Ishii K, et al. **Brain Res** 1997 Feb 14; 748(1–2):250–2

Chromosomal localization of the neurological mouse mutations tottering (tg), Purkinje cell degeneration (pcd), and nervous (nr). Campbell DB, et al. **Brain Res Mol Brain Res** 1996 Apr;37(1–2):79–84

Smoking, gender, and survival association with allele loss for the LOH11B lung cancer region on chromosome 11. Schreiber G, et al. **Cancer Epidemiol Biomarkers Prev** 1997 May;6(5):315–9

The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Buller RE, et al. **Cancer Gene Ther** 1997 Jul–Aug;4(4):239–45

Frequent allelic losses of 9p21 markers and low incidence of mutations at p16(CDKN2) gene in non–Hodgkin lymphomas of B–cell lineage. Fernández–Piqueras J, et al. **Cancer Genet Cytogenet** 1997 Oct 1;98(1):63–8

Allele loss in colorectal cancer at the Cowden disease/juvenile polyposis locus on 10q. Frayling IM, et al. **Cancer Genet Cytogenet** 1997 Aug;97(1):64–9

Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma. Godfrey TE, et al. **Cancer Genet Cytogenet** 1997 Oct 1; 98(1):36–42

Allelic imbalance at chromosome 1q21 in Wilms tumor. Law MH, et al. **Cancer Genet Cytogenet** 1997 Aug;97(1):54–9

Relaxation of imprinting of the insulin–like growth factor II gene in colorectal cancer. Kinouchi Y, et al. **Cancer Lett** 1996 Oct 1;107(1):105–8

Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Barrett MT, et al. **Cancer Res** 1996 Oct 1;56(19):4351–3

Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high–resolution allelotype. Boige V, et al. **Cancer Res** 1997 May 15;57(10):1986–90

Internal sequence variations in the Ha–ras variable number tandem repeat rare and common alleles identified by minisatellite variant repeat polymerase chain reaction. Conway K, et al. **Cancer Res** 1996 Oct 15;56(20):4773–7

Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cunningham JM, et al. **Cancer Res** 1996 Oct 1;56(19):4475–82

Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Fujii H, et al. **Cancer Res** 1996 Nov 15;56(22):5260–5

Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Hammoud ZT, et al. **Cancer Res** 1996 Oct 1;56(19):4499–502

BAT–26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Hoang JM, et al. **Cancer Res** 1997 Jan 15;57(2):300–3

Selective expression of one c–myc allele in two human

myeloma cell lines. Kuehl WM, et al. **Cancer Res** 1996 Oct 1;56(19):4370–3
Allelic deletions on chromosome 11q13 in multiple tumors from individual MEN1 patients. Lubensky IA, et al. **Cancer Res** 1996 Nov 15;56(22):5272–8
Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Mutter GL, et al. **Cancer Res** 1996 Oct 1; 56(19):4483–6
HLA–DRB1*0101 and *0405 as protective alleles in Japanese patients with renal cell carcinoma. Ozdemir E, et al. **Cancer Res** 1997 Feb 15;57(4):742–6
Quantitation of early clonal expansion of two mutant 61st codon c-Ha–ras alleles in DMBA/TPA treated mouse skin by nested PCR/RFLP. Finch JS, et al. **Carcinogenesis** 1996 Dec;17(12):2551–7
Interferon–alpha and p53 alleles involved in nasopharyngeal carcinoma. Golovleva I, et al. **Carcinogenesis** 1997 Apr; 18(4):645–7
Absence of mutations in the transforming growth factor–beta type II receptor in sporadic lung cancers with microsatellite instability and rare H–ras1 alleles. Takenoshita S, et al. **Carcinogenesis** 1997 Jul;18(7):1427–9
Constitutive expression of glutamic acid decarboxylase (GAD) by striatal cell lines immortalized using the tsA58 allele of the SV40 large T antigen. Giordano M, et al. **Cell Transplant** 1996 Sep–Oct;5(5):563–75
NKB1: a killer cell inhibitory receptor for class I HLA–B allotypes. D'Andrea A, et al. **Chem Immunol** 1996; 64:104–15 (44 ref.)
Compound heterozygosity for a structural apolipoprotein A–I variant, apo A–I(L141R)Pisa, and an apolipoprotein A–I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Miccoli R, et al. **Circulation** 1996 Oct 1;94(7):1622–8
Association of angiotensin–converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Montgomery HE, et al. **Circulation** 1997 Aug 5;96(3):741–7
Investigation of the loss of heterozygosity and familial segregation by PCR in retinoblastoma. Yazici H, et al. **Clin Biochem** 1996 Dec;29(6):595–8
Evidence of a strong, positive association between atopy and the HLA class II alleles DR4 and DR7. Aron Y, et al. **Clin Exp Allergy** 1996 Jul;26(7):821–8
Simultaneous detection of genetic and immunological markers in non–small cell lung cancer: prediction of metastatic potential of tumor. Zborovskaya I, et al. **Clin Exp Metastasis** 1996 Nov;14(6):490–500
Different allelic patterns at chromosome 11q13 in paired aldosterone–producing tumours and blood DNA. Gordon R, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul; 23(6–7):594–6
Alpha 1–antitrypsin deficiency alleles and blood pressure in an Australian population. Huggard PR, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul;23(6–7):600–1
HSP70–1 promoter region alleles and susceptibility to rheumatoid arthritis. Quadri SA, et al. **Clin Exp Rheumatol** 1996 Mar–Apr;14(2):183–5
Genetic mapping using fluorescent quantification of allele frequencies in pooled DNA loaded by solid support. Graff C, et al. **Clin Genet** 1997 Mar;51(3):145–52
Frequencies of five genetic polymorphisms in coronarographed patients and effects on lipid levels in a supposedly healthy population. Régis–Bailly A, et al. **Clin Genet** 1996 Nov;50(5):339–47
Apolipoprotein E e4 allele in the normal elderly: neuropsychologic and brain MRI correlates. Schmidt H, et al. **Clin Genet** 1996 Nov;50(5):293–9
Late juvenile metachromatic leukodystrophy (MLD) in three patients with a similar clinical course and identical mutation on one allele. Tylki–Szymanska A, et al. **Clin Genet** 1996 Nov;50(5):287–92
Allelic fusion of DNA topoisomerase II alpha and retinoic acid receptor alpha genes in adriamycin–resistant p388 murine leukemia revealed by fluorescence in situ hybridization. Squire JA, et al. **Cytogenet Cell Genet** 1996; 75(2–3):164–6
Cancer proneness of linear porokeratosis may be explained by allelic loss. Happle R. **Dermatology** 1997;195(1):20–5 (73 ref.)
Allelic imbalance and microsatellite instability in resected Duke's D colorectal cancer. Kochhar R, et al. **Diagn Mol Pathol** 1997 Apr;6(2):78–84
Analysis of the allele–specific PCR method for the detection of neoplastic disease. Rhodes CH, et al. **Diagn Mol Pathol** 1997 Feb;6(1):49–57
Length and sequence variation in D7S22 (g3) alleles studied by high resolution length measurements and nucleotide sequencing. Andreassen R, et al. **Electrophoresis** 1997 May; 18(5):675–81
Evaluation of the ALF DNA sequencer for high–speed sizing of short tandem repeat alleles. Decorte R, et al. **Electrophoresis** 1996 Oct;17(10):1542–9
Data–adaptive algorithms for calling alleles in repeat polymorphisms. Stoughton R, et al. **Electrophoresis** 1997 Jan;18(1):1–5
Mof4–1 is an allele of the UPF1/IFS2 gene which affects both mRNA turnover and –1 ribosomal frameshifting efficiency. Cui Y, et al. **EMBO J** 1996 Oct 15; 15(20):5726–36
A search for association between schizophrenia and dopamine–related alleles. Jönsson E, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(6):297–304
Threonine allele in codon 54 of the fatty acid binding protein 2 gene does not modify the fatty acid composition of serum lipids in obese subjects. Vidgren HM, et al. **Eur J Clin Invest** 1997 May;27(5):405–8
Molecular heterogeneity of beta–thalassaemia in a Spanish population from the area centre of Spain [letter] Villegas A, et al. **Eur J Haematol** 1996 Nov;57(5):389–91
Discrimination of human HLA–DRB1 alleles by PCR–SSCP (single–strand conformation polymorphism) method. Bannai M, et al. **Eur J Immunogenet** 1994 Feb;21(1):1–9
Tumour necrosis factor microsatellite alleles in an Italian population. Ciusani E, et al. **Eur J Immunogenet** 1997 Feb; 24(1):9–13
Determination of DRB alleles using PCR amplification and allele–specific primers. Lepage V, et al. **Eur J Immunogenet** 1994 Feb;21(1):45–58
DPB1 locus PCR–RFLP typing of the fourth Asia–Oceania Histocompatibility Workshop cell panel reveals a novel DPB1 allele. Naughton MJ, et al. **Eur J Immunogenet** 1994 Oct;21(5):351–64
A novel human complement component C7 phenotype detected in South Africa and proposed designation of the allele as C7*10. Orren A, et al. **Eur J Immunogenet** 1994 Jun;21(3):181–7
HLA–DR2 haplotypic diversity in populations of South–East Asia, northern China, Melanesia and Australian aborigines using PCR–RFLP for DRB1, DRB5, DQA1 and DQB1. A novel DRB1 allele: DRB1*16022. Trejaut J, et al. **Eur J Immunogenet** 1996 Dec;23(6):437–49
Frequency of HLA–DPB1 alleles in a Spanish population: their contribution to rheumatoid arthritis susceptibility. Yélamos J, et al. **Eur J Immunogenet** 1994 Apr;21(2):91–8
Distribution of HLA–A*28 alleles in a Spanish population. Yélamos J, et al. **Eur J Immunogenet** 1994 Apr;21(2):99–103
Differential expression of insulin–dependent diabetes mellitus–associated HLA–DQA1 alleles in vivo. Maffei A, et al. **Eur J Immunol** 1997 Jun;27(6):1549–56
The peptide binding motif of the disease associated HLA–DQ (alpha 1* 0501, beta 1* 0201) molecule. Vartdal F, et al. **Eur J Immunol** 1996 Nov;26(11):2764–72
Plasmodium falciparum: allelic variation in the merozoite surface protein 1 gene in wild isolates from southern Vietnam. Kaneko O, et al. **Exp Parasitol** 1997 May; 86(1):45–57
Allelic variation of the streptokinase gene in beta–hemolytic streptococci group C and G isolates of human origin. Tewodros W, et al. **FEMS Immunol Med Microbiol** 1996 Jan;13(1):29–34
Positive selection of allelic exchange mutants in Mycobacterium bovis BCG. Pelicic V, et al. **FEMS Microbiol Lett** 1996 Nov 1;144(2–3):161–6
HLA–DQA1 subtyping data in the Swiss population. Gehrig C, et al. **Forensic Sci Int** 1996 Nov 11;83(1):27–30
Distribution of HLA DQ A1 alleles and genotypes in two Spanish populations (Aragon and Asturias). Martínez–Jarreta B, et al. **Forensic Sci Int** 1996 Aug 15; 81(2–3):185–90
A genetic study of the short tandem repeat systems VWA and TH01 in an Austrian population. Neuhuber F, et al. **Forensic Sci Int** 1997 Jun 23;87(3):211–7
Infrared fluorescent detection of D1S80 alleles. Roy R. **Forensic Sci Int** 1997 May 23;87(1):63–71
Prognostic value of chromosome 1p allelic loss in colon cancer. Ogunbiyi OA, et al. **Gastroenterology** 1997 Sep; 113(3):761–6
Allelic basis for HLA–encoded susceptibility to type 1 autoimmune hepatitis. Strettell MD, et al. **Gastroenterology** 1997 Jun;112(6):2028–35
Tissue–specific expression of the K–ras allele from the A/J parent in (A/J x TSG–p53) F1 mice. Matzinger SA, et al. **Gene** 1997 Apr 1;188(2):261–9
PI locus (alpha–1–antitrypsin) allelic frequencies in an Andean Venezuelan population. Fonseca–Pérez T, et al. **Gene Geogr** 1996 Aug;10(2):65–74
Type distribution and allele frequencies of three serum proteins in the Asiago Plateau population (northern Italy). Ponzano E, et al. **Gene Geogr** 1996 Aug;10(2):147–50
Allele frequency distributions at seven DNA hypervariable loci in a population sample from Calabria (southern Italy). Rose G, et al. **Gene Geogr** 1996 Aug;10(2):135–45
Random and imprinted monoallelic expression. Watanabe D, et al. **Genes Cells** 1996 Sep;1(9):795–802 (78 ref.)
Correlations of allelic imbalance of chromosome 14 with adverse prognostic parameters in 148 renal cell carcinomas. Béroud C, et al. **Genes Chromosomes Cancer** 1996 Dec; 17(4):215–24
Detection of frequent allelic loss of 6q23–q25.2 in microdissected human breast cancer tissues. Fujii H, et al. **Genes Chromosomes Cancer** 1996 May;16(1):35–9
Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer. Komiya A, et al. **Genes Chromosomes Cancer** 1996 Dec; 17(4):245–53
Peculiar allelotype associated with susceptibility to neuroblastoma. Perri P, et al. **Genes Chromosomes Cancer** 1996 Sep;17(1):60–3
Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Tung WS, et al. **Genes Chromosomes Cancer** 1997 May;19(1):43–51
heartless encodes a fibroblast growth factor receptor (DFR1/DFGF–R2) involved in the directional migration of early mesodermal cells in the Drosophila embryo. Gisselbrecht S, et al. **Genes Dev** 1996 Dec 1;10(23):3003–17
HLA allele selection for designing peptide vaccines. Gulukota K, et al. **Genet Anal** 1996 Sep;13(3):81–6
Interactions between the regulatory regions of two Adh alleles. Freidman R, et al. **Genetica** 1996 Jan;97(1):1–14
Molecular structure of rare but geographically widespread sn–glycerol–3–phosphate dehydrogenase 'ultra–fast' electrophoretic alleles in Drosophila melanogaster. Wilanowski TM, et al. **Genetics** 1996 Mar;97(2):165–72
Opposite orientations of an inverted duplication and allelic variation at the mouse agouti locus. Chen Y, et al. **Genetics** 1996 Sep;144(1):265–77
Description and power analysis of two tests for detecting recent population bottlenecks from allele frequency data. Cornuet JM, et al. **Genetics** 1996 Dec;144(4):2001–14
Beaded of Goldschmidt, an antimorphic allele of Serrate, encodes a protein lacking transmembrane and intracellular domains. Hukriede NA, et al. **Genetics** 1997 Feb; 145(2):359–74
Genetic interactions between naturally occurring alleles at quantitative trait loci and mutant alleles at candidate loci affecting bristle number in Drosophila melanogaster. Long AD, et al. **Genetics** 1996 Dec;144(4):1497–510
Transmission genetics of allorecognition in Hydractinia symbiolongicarpus (Cnidaria:Hydrozoa). Mokady O, et al. **Genetics** 1996 Jun;143(2):823–7
Deletion formation between the two Salmonella typhimurium flagellin genes encoded on the mini F plasmid: Escherichia coli ssb alleles enhance deletion rates and change hot–spot preference for deletion endpoints. Mukaihara T, et al. **Genetics** 1997 Mar;145(3):563–72
A likelihood approach to populations samples of microsatellite alleles. Nielsen R. **Genetics** 1997 Jun; 146(2):711–6
The spread of an advantageous allele across a barrier: the effects of random drift and selection against heterozygotes. Piálek J, et al. **Genetics** 1997 Feb;145(2):493–504
Measuring and testing genetic differentiation with ordered versus unordered alleles. Pons O, et al. **Genetics** 1996 Nov; 144(3):1237–45
An allelic series of blue fluorescent trp1 mutants of Arabidopsis thaliana. Rose AB, et al. **Genetics** 1997 Jan; 145(1):197–205
Compensatory aspects of allele diversity at immunoglobulin loci: gene correlations in rabbit populations devoid of light chain diversity (Oryctolagus cuniculus L.; Kerguelen Islands). Van der Loo W, et al. **Genetics** 1996 Nov; 144(3):1181–94
Homoplasy for size at microsatellite loci in humans and chimpanzees. Garza JC, et al. **Genome Res** 1996 Mar; 6(3):211–7
Methods for precise sizing, automated binning of alleles, and reduction of error rates in large–scale genotyping using fluorescently labeled dinucleotide markers. FUSION (Finland–U.S. Investigation of NIDDM Genetics) Study Group. Ghosh S, et al. **Genome Res** 1997 Feb;7(2):165–78
An accurate method for comparing transcript levels of two alleles or highly homologous genes: application to fibrillin transcripts in Marfan patients' fibroblasts. Karttunen L, et al. **Genome Res** 1996 May;6(5):392–403
Physical analysis of the region deleted in the tw18 allele of the mouse tcl–4 complementation group. Barclay J, et al. **Genomics** 1996 Aug 15;36(1):39–46
RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. Ladero JM, et al. **Gut** 1996 Aug;39(2):330–3
Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers. Sakamoto T, et al. **Gynecol Oncol** 1996 Nov;63(2):173–9
Historical and anthropological correlates of beta S haplotypes and alpha– and beta–thalassemia alleles in the Arabian Peninsula. Adekile AD. **Hemoglobin** 1997 May; 21(3):281–96 (84 ref.)
Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Czaja AJ, et al. **Hepatology** 1997 Feb;25(2):317–23
The frequency of hemochromatosis–associated alleles is increased in British patients with sporadic porphyria cutanea tarda. Roberts AG, et al. **Hepatology** 1997 Jan; 25(1):159–61
Strains of Drosophila melanogaster differ in alcohol tolerance. Bokor K, et al. **Hereditas** 1997;126(2):103–13
Investigation of specimen mislabelling in paraffin–embedded tissue using a rapid, allele–specific, PCR–based HLA class II typing method. Bateman AC, et al. **Histopathology** 1996 Feb;28(2):169–74
Discriminating between allelic and interlocus differences among human immunoglobulin VH4 sequences by analyzing single spermatozoa. Cui X, et al. **Hum Genet** 1997 Jul;100(1):96–100
DNA multiallelic systems reveal gene/longevity associations not detected by diallelic systems. The APOB locus. De Benedictis G, et al. **Hum Genet** 1997 Mar;99(3):312–8
Quantification of the paternal allele bias for new germline mutations in the retinoblastoma gene. Dryja TP, et al. **Hum Genet** 1997 Sep;100(3–4):446–9
Association between the PI*M3 allele of alpha 1–antitrypsin and Alzheimer's disease? A preliminary report. Kowalska A, et al. **Hum Genet** 1996 Dec;98(6):744–6

ALLELES

Putative association of a mutant ROM1 allele with retinitis pigmentosa. Martínez-Mir A, et al. **Hum Genet** 1997 Jun; 99(6):827–30

Effect of p53 alleles on placental weight. Birgander R, et al. **Hum Hered** 1996 Sep–Oct;46(5):290–7

Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. Ebstein RP, et al. **Hum Hered** 1997 Jan–Feb;47(1):6–16

Allele frequencies for 20 microsatellites in a worldwide population survey. Pérez-Lezaun A, et al. **Hum Hered** 1997 Jul–Aug;47(4):189–96

Faster linkage analysis computations for pedigrees with loops or unused alleles. Schäffer AA. **Hum Hered** 1996 Jul–Aug; 46(4):226–35

A test of allelic independence based on distributions of allele size differences at microsatellite loci. Stivers DN, et al. **Hum Hered** 1997 Mar–Apr;47(2):66–75

HLA-B40, B18, B27, and B37 allele discrimination using group-specific amplification and SSCP method. Bannai M, et al. **Hum Immunol** 1996 Apr;46(2):107–13

Discrimination of HLA-B27 alleles by group-specific amplification followed by solid-phase sequencing. Blaszcyk R, et al. **Hum Immunol** 1996 Feb;45(2):117–23

Allele-specific variation in the degeneracy of major histocompatibility complex (MHC) restriction. Carmichael P, et al. **Hum Immunol** 1997 Apr 15;54(1):21–9

Mitogens, superantigens, and nominal antigens elicit distinctive patterns of TCRB CDR3 diversity. Currier JR, et al. **Hum Immunol** 1996 Jun–Jul;48(1–2):39–51

Association of responsiveness to the major pollen allergen of Parietaria officinalis with HLA-DRB1* alleles: a multicenter study. D'Amato M, et al. **Hum Immunol** 1996 Apr;46(2):100–6

A novel DR beta 1*03 allele identified by polymerase chain reaction–restriction fragment length polymorphism. Fenske B, et al. **Hum Immunol** 1996 Mar;46(1):55–7

Sequence of a new HLA-DR4 allele with an unusual residue at position 88 that does not seem to affect T-cell allo recognition. Gebuhrer L, et al. **Hum Immunol** 1996 Nov; 51(1):60–2

Description of a new HLA-E (E*01031) allele and its frequency in the Spanish population. Gomez-Casado E, et al. **Hum Immunol** 1997 Apr 15;54(1):69–73

T-cell receptor BV6S1 null alleles and HLA-DR1 haplotypes in polyarticular outcome juvenile rheumatoid arthritis. Grom AA, et al. **Hum Immunol** 1996 Feb; 45(2):152–6

An association in non-insulin-dependent diabetes mellitus subjects between susceptibility to retinopathy and tumor necrosis factor polymorphism. Hawrami K, et al. **Hum Immunol** 1996 Mar;46(1):49–54

Distribution of HLA class II alleles and haplotypes in insulin-dependent Moroccan diabetics. Izaabel H, et al. **Hum Immunol** 1996 Sep 1;49(2):137–43

Three HLA-DMB variants in Korean patients with autoimmune diseases. Kim TG, et al. **Hum Immunol** 1996 Mar;46(1):58–60

Two newly discovered alleles of major histocompatibility complex-encoded LMP7 in Korean populations. Kim TG, et al. **Hum Immunol** 1996 Mar;46(1):61–4

Transporter associated with antigen-processing-1 (TAP1) alleles in Gorilla gorilla: diversification of the locus postspeciation. Laud PR, et al. **Hum Immunol** 1996 Oct; 50(2):91–102

Allelic variants of human TCR BV17S1 defined by restriction fragment length polymorphism, single strand conformation polymorphism, and amplification refractory mutation system analyses. Li Y, et al. **Hum Immunol** 1996 Sep 1; 49(2):85–95

Novel HLA-B35 subtypes: putative gene conversion events with donor sequences from alleles common in native Americans (HLA-B*4002 or B*4801). Marcos CY, et al. **Hum Immunol** 1997 Apr 1;53(2):148–55

Allele typing of HLA-A10 group by nested-PCR–low ionic strength single stranded conformation polymorphism and a novel A26 allele (A26KY, A*2605). Maruya E, et al. **Hum Immunol** 1996 Oct;50(2):140–7

The role of HLA-DR–DR and HLA-DR–DP interactions in genetic susceptibility to rheumatoid arthritis. Perdriger A, et al. **Hum Immunol** 1996 Mar;46(1):42–8

Polymorphism of HLA-DRB, -DQA1, and -DQB1 in rheumatoid arthritis in Asian Indians: association with DRB1*0405 and DRB1*1001. Taneja V, et al. **Hum Immunol** 1996 Mar;46(1):35–41

Description of a novel HLA-B35 (B*3514) allele found in a Mexican family of Nahua Aztec descent. Vargas-Alarcon G, et al. **Hum Immunol** 1996 Feb;45(2):148–51

Interaction between certain major histocompatibility complex class II and T-cell receptor V beta alleles promotes the antibody production to extractable nuclear antigen-related peptides. Youinou P, et al. **Hum Immunol** 1997 Jan;52(1):12–21

Contribution of DNA sequence and CAG size to mutation frequencies of intermediate alleles for Huntington disease: evidence from single sperm analyses. Chong SS, et al. **Hum Mol Genet** 1997 Feb;6(2):301–9

Trinucleotide repeats in the human genome: size distributions for all possible triplets and detection of expanded disease alleles in a group of Huntington disease individuals by the repeat expansion detection method. Hofferbert S, et al. **Hum Mol Genet** 1997 Jan;6(1):77–83

Genetic mapping of the human homologue (T) of mouse T(Brachyury) and a search for allele association between human T and spina bifida. Morrison K, et al. **Hum Mol Genet** 1996 May;5(5):669–74

Expression of mutated glucocerebrosidase alleles in human cells. Pasmanik-Chor M, et al. **Hum Mol Genet** 1997 Jun; 6(6):887–95

CTG trinucleotide repeat lengths in myotonic dystrophy alleles of patients with senile cataracts [letter] Aves SJ, et al. **Hum Mutat** 1997;9(1):95–6

Complex cystic fibrosis allele R334W-R1158X results in reduced levels of correctly processed mRNA in a pancreatic sufficient patient. Duarte A, et al. **Hum Mutat** 1996;8(2):134–9

Two mutations in the same low-density lipoprotein receptor allele act in synergy to reduce receptor function in heterozygous familial hypercholesterolemia. Jensen HK, et al. **Hum Mutat** 1997;9(5):437–44

Allele-specific measurement of low-density lipoprotein receptor transcript levels. Jensen LG, et al. **Hum Mutat** 1996;8(2):126–33

Angiotensin-converting enzyme and angiotensinogen gene polymorphisms, plasma levels, cardiac dimensions. A twin study. Busjahn A, et al. **Hypertension** 1997 Jan;29(1 Pt 2):165–70

B cell development under the condition of allelic inclusion. Sonoda E, et al. **Immunity** 1997 Mar;6(3):225–33

Primate Mhc-E and -G alleles. Arnaiz-Villena A, et al. **Immunogenetics** 1997;46(4):251–66 (24 ref.)

Two newly identified HLA-DRB1 alleles: DRB1*1322 and DRB1*1327. Duran KJ, et al. **Immunogenetics** 1997; 46(5):442–3

On naming H2 haplotypes: functional significance of MHC class Ib alleles. Fischer Lindahl K. **Immunogenetics** 1997; 46(1):53–62 (139 ref.)

Allelic and interlocus comparison of the PERB11 multigene family in the MHC. Gaudieri S, et al. **Immunogenetics** 1997; 45(3):209–16

Identification of new mamu-DRB alleles using DGGE and direct sequencing. Knapp LA, et al. **Immunogenetics** 1997; 45(3):171–9

Identification of a new HLA-A allele (A*2502) by PCR-SSP. Krausa P, et al. **Immunogenetics** 1996;45(1):84–5

5' regulatory nucleotide sequence of an HLA-A*0101null allele. Lardy NM, et al. **Immunogenetics** 1997;46(2):152–5

The Igh-1 sequence of the non-obese diabetic (NOD) mouse assigns it to the IgG2c isotype. Martin RM, et al. **Immunogenetics** 1997;46(2):167–8

Differential expression of HLA-DQA1 alleles associated with promoter polymorphism. Morzycka-Wroblewska E, et al. **Immunogenetics** 1997;45(3):163–70

HLA-DRB1*1608: a new HLA-DRB1*16 allele with a short DRB1*03 sequence. Reviron D, et al. **Immunogenetics** 1997;46(5):444–5

Diversity associated with the second expressed HLA-DRB locus in the human population. Robbins F, et al. **Immunogenetics** 1997;46(2):104–10

Allele-specific expression of the mouse B-cell surface protein CD72 on T cells. Robinson WH, et al. **Immunogenetics** 1997;45(3):195–200

A new HLA-G allele (HLA-G*0105N) and its distribution in the Spanish population. Suárez MB, et al. **Immunogenetics** 1997;45(6):464–5

Identification of a new HLA-DPB1*6501 allele in a Caucasian individual. Versluis LF, et al. **Immunogenetics** 1996;44(6):483–4

Large-scale comparative mapping of the MHC class I region of predominant haplotypes in Japanese. Watanabe Y, et al. **Immunogenetics** 1997;46(2):135–41

A new TNFA promoter allele identified in South American Blacks. Zimmerman PA, et al. **Immunogenetics** 1996; 44(6):485–6

Characteristics and prevalence within serogroup O4 of a J96-like clonal group of uropathogenic Escherichia coli O4:H5 containing the class I and class III alleles of papG. Johnson JR, et al. **Infect Immun** 1997 Jun;65(6):2153–9

Allelic variation of the polyubiquitin gene in the tobacco hawkmoth, Manduca sexta, and its regulation by heat shock and programmed cell death. Myer A, et al. **Insect Biochem Mol Biol** 1996 Dec;26(10):1037–46

Multiple alleles encoding a virus-like particle protein in the ichneumonid endoparasitoid Venturia canescens. Hellers M, et al. **Insect Mol Biol** 1996 Nov;5(4):239–49

Use of eluted peptide sequence data to identify the binding characteristics of peptides to the insulin-dependent diabetes susceptibility allele HLA-DQ8 (DQ 3.2). Godkin A, et al. **Int Immunol** 1997 Jun;9(6):905–11

The NK2.1 receptor is encoded by Ly-49C and its expression is regulated by MHC class I alleles. Gosselin P, et al. **Int Immunol** 1997 Apr;9(4):533–40

APC gene mutations and allelic losses in sporadic ampullary tumours: evidence of genetic difference from tumours associated with familial adenomatous polyposis. Achille A, et al. **Int J Cancer** 1996 Nov 4;68(3):305–12

An allelotype of papillary thyroid cancer. Califano JA, et al. **Int J Cancer** 1996 Dec 20;69(6):442–4

Allele-specific PCR analysis of p53 codon 249 AGT transversion in liver tissues from patients with viral hepatitis. Kirby GM, et al. **Int J Cancer** 1996 Sep 27; 68(1):21–5

Infrequent allelic imbalance at the major susceptibility HPC1 locus in sporadic prostate tumours [letter] Latil A, et al. **Int J Cancer** 1997 Jun 11;71(6):1118

Rare alleles at different VNTR loci among lung-cancer patients with microsatellite instability in tumours. Lindstedt BA, et al. **Int J Cancer** 1997 Feb 7;70(4):412–5

Mutation analysis and loss of heterozygosity of PEDF in central nervous system primitive neuroectodermal tumors. Slavc I, et al. **Int J Cancer** 1997 Jul 17;72(2):277–82

Allelotype profiles of local recurrences and distant metastases from colorectal-cancer patients. Thorstensen L, et al. **Int J Cancer** 1996 Dec 20;69(6):452–6

Polymorphism analysis of the VNTR locus D17S5 in central Spain. Arroyo E, et al. **Int J Legal Med** 1996;109(2):98–9

Sequence analysis and allelic designation of the two short tandem repeat loci D18S51 and D8S1179. Barber MD, et al. **Int J Legal Med** 1996;109(2):62–5

Allele frequency distributions of 13 PCR-based systems in a population from North-East Spain. Crespillo M, et al. **Int J Legal Med** 1997;110(4):223–5

Hungarian population data on six STR loci--HUMVWFA31, HUMTH01, HUMCSF1PO, HUMFES/FPS, HUMTPOX, and HUMHPRTB--derived using multiplex PCR amplification and manual typing. Füredi S, et al. **Int J Legal Med** 1996;109(2):100–1

Population study of the STRs HUMCD4 and HUMF13A1 in Catalonia (Northeast Spain). Gené M, et al. **Int J Legal Med** 1997;110(1):44–5

A new method of STR interpretation using inferential logic--development of a criminal intelligence database. Gill P, et al. **Int J Legal Med** 1996;109(1):14–22

Population data for the STR systems HumTH01, HumVWA and FES/FPS in a population sample from lower Franconia. Günther S, et al. **Int J Legal Med** 1996; 109(2):102–3

Failed PCR amplifications of MBP-STR alleles due to polymorphism in the primer annealing region. Gusmão L, et al. **Int J Legal Med** 1996;108(6):313–5

Analysis of the short tandem repeat systems HumVWA and HumF13B in a population sample from northern Thailand. Horst B, et al. **Int J Legal Med** 1997;110(4):235–7

HLA-DQA1 in autochthonous Basques: description of a genocline for the DQA1*0201 allele in Europe. Iriondo M, et al. **Int J Legal Med** 1996;109(4):181–5

D1S80 (pMCT118) allele frequencies in a Malay population sample from Malaysia. Koh CL, et al. **Int J Legal Med** 1997;110(1):39–40

A highly variable STR at the D12S391 locus. Lareu MV, et al. **Int J Legal Med** 1996;109(3):134–8

ACTBP2 gene frequency distribution and sequencing of the allelic ladder and variants in the Japanese and Chinese populations. Liu C, et al. **Int J Legal Med** 1997; 110(4):208–12

Allele frequencies of nine STR systems in the Flemish population and application in parentage testing. Mertens G, et al. **Int J Legal Med** 1997;110(4):177–80

Genotyping of the ABO blood group system: analysis of nucleotide position 802 by PCR-RFLP and the distribution of ABO genotypes in a German population. Nishimukai H, et al. **Int J Legal Med** 1996;109(2):90–3

Population studies of three AMPFLPs systems in a north Polish population. Pawlowski R, et al. **Int J Legal Med** 1996;109(3):155–6

Italian population data on the loci LDLR, GYPA, HBGG, D7S8 and GC. Tagliabracci A, et al. **Int J Legal Med** 1996; 109(3):161–2

Beta 3-adrenergic-receptor allele distributions in children, adolescents and young adults with obesity, underweight or anorexia nervosa. Hinney A, et al. **Int J Obes Relat Metab Disord** 1997 Mar;21(3):224–30

Analysis of immunodominant piroplasm surface antigen alleles in mixed populations of Theileria sergenti and T. buffeli. Kubota S, et al. **Int J Parasitol** 1996 Jul;26(7):741–7

Correlation of allelic loss of the P53 gene and tumor grade, stage, and malignant progression in bladder cancer. Tsutsumi M, et al. **Int J Urol** 1997 Jan;4(1):74–8

Beta-thalassemia (beta 90 GAG-->TAG): genetic diagnosis by allele-specific polymerase chain reaction and estimation of mutant mRNA expression by reverse transcription polymerase chain reaction. Ekawa K, et al. **Intern Med** 1996 Jun;35(6):463–7

Expanded size span and multiple alleles exhibited by Ethiopian Jews analyzed with APC gene-linked DNA markers [letter] [see comments] Amikam D, et al. **Isr J Med Sci** 1997 Jan;33(1):78–9. Comment in: Isr J Med Sci 1997 Jan;33(1):63–5.

Effect of total allelic relationship on accuracy of evaluation and response to selection. Nejati-Javaremi A, et al. **J Anim Sci** 1997 Jul;75(7):1738–45

asmB, a suppressor locus for assembly-defective OmpF mutants of Escherichia coli, is allelic to envA (lpxC). Kloser AW, et al. **J Bacteriol** 1996 Sep;178(17):5138–43

The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas. Heckman C, et al. **J Biol Chem** 1997 Aug 1;272(31):19609–14

Reading-frame restoration by transcriptional slippage at long stretches of adenine residues in mammalian cells. Linton MF, et al. **J Biol Chem** 1997 May 30;272(22):14127–32

Expression studies of delta-globin gene alleles associated with reduced hemoglobin A2 levels in Greek Cypriots. Trifillis P, et al. **J Biol Chem** 1996 Oct 25;271(43):26931–8

Alternative splicing in COL1A1 mRNA leads to a partial null allele and two In-frame forms with structural defects in non-lethal osteogenesis imperfecta. Wang Q, et al. **J Biol Chem** 1996 Nov 8;271(45):28617–23

Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. White AL, et al. **J Biol Chem** 1997 Feb 21;272(8):5048–55

Defective folding of mutant p16(INK4) proteins encoded by tumor–derived alleles. Zhang B, et al. **J Biol Chem** 1996 Nov 15;271(46):28734–7

Influence of the vitamin D receptor gene alleles on bone mineral density in postmenopausal and osteoporotic women. Vandevyver C, et al. **J Bone Miner Res** 1997 Feb; 12(2):241–7

Inherited susceptibility and acquired allelic imbalance in rat mammary carcinogenesis. Gould MN, et al. **J Cell Biochem Suppl** 1996;25:37–40 (11 ref.)

Functional analysis of human RPS14 null alleles. Martin–Nieto J, et al. **J Cell Sci** 1997 Apr;110 (Pt 8):955–63

Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. Bates AS, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):818–24

Lack of an association between alleles of interleukin–1 alpha and interleukin–1 receptor antagonist genes and Graves' disease in a North American Caucasian population. Cuddihy RM, et al. **J Clin Endocrinol Metab** 1996 Dec; 81(12):4476–8

Evidence for numerous omp1 alleles of porcine Chlamydia trachomatis and novel chlamydial species obtained by PCR. Kaltenböck B, et al. **J Clin Microbiol** 1997 Jul; 35(7):1835–41

Bovine lymphocyte antigen class II alleles as risk factors for high somatic cell counts in milk of lactating dairy cows. Dietz AB, et al. **J Dairy Sci** 1997 Feb;80(2):406–12

Antigen–driven C–C chemokine–mediated HIV–1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild–type CCR–5 allele. Furci L, et al. **J Exp Med** 1997 Aug 4;186(3):455–60

The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains. Machold RP, et al. **J Exp Med** 1997 Jan 20;185(2):363–6

Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. Mandelboim O, et al. **J Exp Med** 1996 Sep 1; 184(3):913–22

Defining microsatellite alleles by genotyping global indigenous human populations and non–human primates. Jin L, et al. **J Forensic Sci** 1997 May;42(3):496–9

The distribution of the vWF alleles and genotypes in the Palestinian population. Khatib H, et al. **J Forensic Sci** 1997 May;42(3):504–5

PCR analysis of Lewis–negative gene mutations and the distribution of Lewis alleles in a Japanese population. Liu Y, et al. **J Forensic Sci** 1996 Nov;41(6):1018–21

Infrared fluorescent detection of PCR amplified gender identifying alleles. Roy R, et al. **J Forensic Sci** 1997 May; 42(3):452–60

Italian population allele and genotype frequencies for the AmpliType PM and the HLA–DQ–alpha loci. Spinella A, et al. **J Forensic Sci** 1997 May;42(3):514–8

Interpreting DNA mixtures. Weir BS, et al. **J Forensic Sci** 1997 Mar;42(2):213–22 (11 ref.)

Three major alleles of rotavirus NSP4 proteins identified by sequence analysis. Horie Y, et al. **J Gen Virol** 1997 Sep; 78 (Pt 9):2341–6

Microphthalmia cloudy–eye (mi(ce)): a new murine allele. Zimring DC, et al. **J Hered** 1996 Jul–Aug;87(4):334–8

Age– and gender–dependent association of the angiotensin–converting enzyme gene with essential hypertension in a Chinese population. Chiang FT, et al. **J Hum Hypertens** 1996 Dec;10(12):823–6

Insertion/deletion polymorphism of the angiotensin–converting enzyme gene and loss of the insertion allele in aldosterone–producing adenoma. Tunny TJ, et al. **J Hum Hypertens** 1996 Dec;10(12):827–30

Ambiguities in angiotensin–converting enzyme allele genotyping: a comparison of three methods [letter] Wierzbicki AS, et al. **J Hum Hypertens** 1997 Jul;11(7):467–8

Alleles of highly homologous rat T cell receptor beta–chain variable segments 8.2 and 8.4: strain–specific expression, reactivity to superantigens, and binding of the mAb R78. Asmuss A, et al. **J Immunol** 1996 Nov 15;157(10):4436–41

Multiple HLA–A alleles can present an immunodominant peptide of the human melanoma antigen Melan–A/MART–1 to a peptide–specific HLA–A*0201+ cytotoxic T cell line. Fleischhauer K, et al. **J Immunol** 1996 Jul 15;157(2):787–97

Natural inactivation of a common HLA allele (A*2402) has occurred on at least three separate occasions. Magor KE, et al. **J Immunol** 1997 Jun 1;158(11):5242–50

Allelic variation in the mouse Tap–1 and Tap–2 transporter genes. Marusina K, et al. **J Immunol** 1997 Jun 1; 158(11):5251–6

Species–dependent post–translational modification and position 2 allelism: effects on streptococcal superantigen SSA structure and V beta specificity. Stevens KR, et al. **J Immunol** 1996 Sep 15;157(6):2479–87

Cloning of minimally divergent allelic forms of the natural killer (NK) receptor Ly–49C, differentially controlled by host genes in the MHC and NK gene complexes. Sundbäck J, et al. **J Immunol** 1996 Nov 1;157(9):3936–42

Mutation prevalence among 47 unrelated Japanese patients with Gaucher disease: identification of four novel mutations. Ida H, et al. **J Inherit Metab Dis** 1997 Mar; 20(1):67–73

HLA–DR5 and DQB1*03 class II alleles are associated with cutaneous T–cell lymphoma. Jackow CM, et al. **J Invest Dermatol** 1996 Sep;107(3):373–6

Allele frequency and its forensic application of STR Y27 in Korean males. Lee SD, et al. **J Korean Med Sci** 1996 Oct;11(5):386–9

Allelic variation in the gene encoding the cholesteryl ester transfer protein is associated with variation in the plasma concentrations of cholesteryl ester transfer protein. McPherson R, et al. **J Lipid Res** 1996 Aug;37(8):1743–8

Characterisation of CAH alleles with non–radioactive DNA single strand conformation polymorphism analysis of the CYP21 gene. Bobba A, et al. **J Med Genet** 1997 Mar; 34(3):223–8

CFTR mutations and IVS8–5T variant in newborns with hypertrypsinaemia and normal sweat test. Castellani C, et al. **J Med Genet** 1997 Apr;34(4):297–301

Neonatal screening for hereditary fructose intolerance: frequency of the most common mutant aldolase B allele (A149P) in the British population. James CL, et al. **J Med Genet** 1996 Oct;33(10):837–41

On the genetics of hypodontia and microdontia: synergism or allelism of major genes in a family with six affected members. Lyngstadaas SP, et al. **J Med Genet** 1996 Feb; 33(2):137–42

Non–Mendelian transmission at the Machado–Joseph disease locus in normal females: preferential transmission of alleles with smaller CAG repeats. Rubinsztein DC, et al. **J Med Genet** 1997 Mar;34(3):234–6

Double mutant fibrillin–1 (FBN1) allele in a patient with neonatal Marfan syndrome. Wang M, et al. **J Med Genet** 1996 Sep;33(9):760–3

Novel alleles of the Escherichia coli dnaA gene. Sutton MD, et al. **J Mol Biol** 1997 Sep 5;271(5):693–703

Microsatellite allelic homoplasy due to variable flanking sequences. Grimaldi MC, et al. **J Mol Evol** 1997 Mar; 44(3):336–40

Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. Yarbrough WG, et al. **J Natl Cancer Inst** 1996 Oct 16;88(20):1489–91

Preferential recognition of synthetic peptides from HTLV–I gp21 envelope protein by HLA–DRB1 alleles associated with HAM/TSP (HTLV–I–associated myelopathy/tropical spastic paraparesis). Yamano Y, et al. **J Neuroimmunol** 1997 Jun;76(1–2):50–60

The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. Gasser T, et al. **J Neurol Neurosurg Psychiatry** 1996 Nov; 61(5):518–20

The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. Landén M, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):352–6

Frequency of the apolipoprotein E epsilon 4 allele in a case–control study of early onset Parkinson's disease. Whitehead AS, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):347–51

Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. Chen KS, et al. **J Neurosci** 1997 Oct 1;17(19):7288–96

Dietary fat and sex modify heterozygote effects of the rat fatty (fa) allele. Maher MA, et al. **J Nutr** 1996 Oct; 126(10):2487–93

Differences in the incidence of the CYP2C19 polymorphism affecting the S–mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. Xiao ZS, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):604–9

Population genetic studies of HLA–G: allele frequencies and linkage disequilibrium with HLA–A1 [published erratum appears in J Reprod Immunol 1997 Apr;33(1):89–90] Ober C, et al. **J Reprod Immunol** 1996 Dec;32(2):111–23

Increased frequency of HLA–DR4 allele in women with unexplained recurrent spontaneous abortions, detected by the method of PCR–SSP. Sasaki T, et al. **J Reprod Immunol** 1997 Feb;32(3):273–9

Position 26 of the first domain of the HLA–DQB1 allele in post–silicone implant scleroderma. Morse JH, et al. **J Rheumatol** 1995 Oct;22(10):1872–5

Complement activation by heparin–protamine complexes during cardiopulmonary bypass: effect of C4A null allele. Shastri KA, et al. **J Thorac Cardiovasc Surg** 1997 Sep; 114(3):482–8

A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation. Alexander L, et al. **J Virol** 1997 Aug; 71(8):6094–9

High frequency of defective nef alleles in a long–term survivor with nonprogressive human immunodeficiency virus type 1 infection. Mariani R, et al. **J Virol** 1996 Nov; 70(11):7752–64

Mutational analysis of the p53 and K–ras genes and allelotype study of the Rb–1 gene for investigating the pathogenesis of combined hapatocellular–cholangiocellular carcinomas. Imai Y, et al. **Jpn J Cancer Res** 1996 Oct;87(10):1056–62

Allelic loss of chromosome 16q in endometrial cancer: correlation with poor prognosis of patients and less differentiated histology. Kihana T, et al. **Jpn J Cancer Res** 1996 Nov;87(11):1184–90

Long Y–associated (GATA)n alleles were observed in a few ethnic groups in Asia. Lin SJ, et al. **Jpn J Hum Genet** 1996 Jun;41(2):243–6

Evidence that two phenotypically distinct mouse PKD mutations, bpk and jcpk, are allelic. Guay–Woodford LM, et al. **Kidney Int** 1996 Oct;50(4):1158–65

Interleukin–1 receptor antagonist allele: is it a genetic link between Henoch–Schönlein nephritis and IgA nephropathy? Liu ZH, et al. **Kidney Int** 1997 Jun; 51(6):1938–42

Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose–binding lectin. Garred P, et al. **Lancet** 1997 Jan 25;349(9047):236–40

Mannose–binding lectin alleles in a prospectively recruited UK population. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood [letter] Mead R, et al. **Lancet** 1997 Jun 7;349(9066):1669–70

Allele imbalance at tumour suppressor loci during the indolent phase of follicle centre cell lymphoma. Randerson J, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):113–7, follow. 186, color plate X

Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls. Shaw GL, et al. **Lung Cancer** 1997 May;17(1):61–8

A high–resolution genetic map around waltzer on mouse chromosome 10 and identification of a new allele of waltzer. Bryda EC, et al. **Mamm Genome** 1997 Jan;8(1):1–4

A new allele of the lurcher gene, lurcherJ. De Jager PL, et al. **Mamm Genome** 1997 Sep;8(9):647–50

Rat S–adenosylmethionine decarboxylase gene family: intronic genes are alleles. Heljasvaara R, et al. **Mamm Genome** 1996 Oct;7(10):776–9

Elevated frequency of the C2 allele of the ETS–1 oncogene in elderly subjects. Crossen PE, et al. **Mech Ageing Dev** 1996 Jul 5;88(1–2):61–5

The insertion allele at the angiotensin I–converting enzyme gene locus is associated with insulin resistance. Chiu KC, et al. **Metabolism** 1997 Apr;46(4):395–9

CYP2D6 multiallelism. Daly AK, et al. **Methods Enzymol** 1996;272:199–210

Identification of allelic variants of the human CYP1A1 gene. Kawajiri K, et al. **Methods Enzymol** 1996;272:226–32

Molecular population genetic analysis of a Streptococcus pyogenes bacteriophage–encoded hyaluronidase gene: recombination contributes to allelic variation. Marciel AM, et al. **Microb Pathog** 1997 Apr;22(4):209–17

Pleiotropic nuclear defects associated with a conditional allele of the novel nucleoporin Rat9p/Nup85p. Goldstein AL, et al. **Mol Biol Cell** 1996 Jun;7(6):917–34

Allelic diversity in alligator microsatellite loci is negatively correlated with GC content of flanking sequences and evolutionary conservation of PCR amplifiability [letter] Glenn TC, et al. **Mol Biol Evol** 1996 Oct;13(8):1151–4

Internal eliminated sequences interrupting the Oxytricha 81 locus: allelic divergence, conservation, conversions, and possible transposon origins. Seegmiller A, et al. **Mol Biol Evol** 1996 Dec;13(10):1351–62

Allelotypic and cytogenetic characterization of chemically induced mouse mammary tumors: high frequency of chromosome 4 loss of heterozygosity at advanced stages of progression. Aldaz CM, et al. **Mol Carcinog** 1996 Nov; 17(3):126–33

Allelic imbalance in mammary carcinomas induced by either 7,12–dimethylbenz[a]anthracene or ionizing radiation in rats carrying genes conferring differential susceptibilities to mammary carcinogenesis. Haag JD, et al. **Mol Carcinog** 1996 Nov;17(3):134–43

Consistent allelic loss on mouse chromosome 7 distal to tyrosinase in 4–nitroquinoline–1–oxide–induced oral cavity tumors with loss of heterozygosity at Ha–ras–1. Yuan B, et al. **Mol Carcinog** 1997 May;19(1):8–16

Illegitimate recombination leading to allelic loss and unbalanced translocation in p53–mutated human lymphoblastoid cells. Honma M, et al. **Mol Cell Biol** 1997 Aug;17(8):4774–81

A novel mutant allele of Schizosaccharomyces pombe rad26 defective in monitoring S–phase progression to prevent premature mitosis. Uchiyama M, et al. **Mol Cell Biol** 1997 Jun;17(6):3103–15

The grpD55 locus of Escherichia coli appears to be an allele of dnaB. Bull HJ, et al. **Mol Gen Genet** 1996 Oct 28; 252(6):755–60

Increasing the denaturation temperature during the first cycles of amplification reduces allele dropout from single cells for preimplantation genetic diagnosis. Ray PF, et al. **Mol Hum Reprod** 1996 Mar;2(3):213–8

Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Hu Y, et al. **Mol Pharmacol** 1997 Mar;51(3):370–6

Comparison of avrD alleles from Pseudomonas syringae pv. glycinea. Keith LW, et al. **Mol Plant Microbe Interact** 1997 Apr;10(3):416–22

The mdx–amplification–resistant mutation system assay, a simple and rapid polymerase chain reaction–based detection of the mdx allele. Amalfitano A, et al. **Muscle Nerve** 1996 Dec;19(12):1549–53

Apolipoprotein E allele frequencies in sporadic inclusion body myositis. Love S, et al. **Muscle Nerve** 1996 Dec; 19(12):1605–7

Allelic origin of the abnormal prion protein isoform in familial prion diseases. Chen SG, et al. **Nat Med** 1997 Sep;

3(9):1009–15
Neutrality or selection? [letter] Hedrick P. **Nature** 1997 May 8;387(6629):138
Microbial genetics. The tinkerer's evolving tool-box [news; comment] Moxon ER, et al. **Nature** 1997 Jun 12; 387(6634):659, 661–2. Comment on: Nature 1997 Jun 12;387(6634):700–2. Comment on: Nature 1997 Jun 12;387(6634):703–5.
Role of mutator alleles in adaptive evolution [see comments] Taddei F, et al. **Nature** 1997 Jun 12;387(6634):700–2. Comment in: Nature 1997 Jun 12;387(6634):659, 661–2.
Preliminary evidence for a role of apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk. Olmer M, et al. **Nephrol Dial Transplant** 1997 Apr; 12(4):691–3
Identification of a unique apolipoprotein E allele in Microcebus murinus; ApoE brain distribution and co-localization with beta-amyloid and tau proteins. Calenda A, et al. **Neurobiol Dis** 1995 Jun;2(3):169–76
Differential expression of normal and mutant Huntington's disease gene alleles. Persichetti F, et al. **Neurobiol Dis** 1996; 3(3):183–90
Chromosome 22q allelic losses at microsatellite loci in human astrocytic tumors. Muhammad AK, et al.
Neurol Med Chir (Tokyo) 1997 Aug;37(8):606–10; discussion 611
Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. Anouti A, et al. **Neurology** 1996 Apr; 46(4):1156–7
Homozygosity for an allele carrying intermediate CAG repeats in the dentatorubral-pallidoluysian atrophy (DRPLA) gene results in spastic paraplegia. Kurohara K, et al. **Neurology** 1997 Apr;48(4):1087–90
No association between the alpha 1-antichymotrypsin A allele and Alzheimer's disease. Murphy GM Jr, et al.
Neurology 1997 May;48(5):1313–6
Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease. Payami H, et al. **Neurology** 1997 Aug;49(2):512–8
Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Peroutka SJ, et al. **Neurology** 1997 Jul;49(1):201–6
Apolipoprotein E epsilon 4 allele and hippocampal volume in twins with normal cognition. Plassman BL, et al.
Neurology 1997 Apr;48(4):985–9
Machado-Joseph disease: cerebellar ataxia and autonomic dysfunction in a patient with the shortest known expanded allele (56 CAG repeat units) of the MJD1 gene. Takiyama Y, et al. **Neurology** 1997 Aug;49(2):604–6
Allelic variability in D21S11, but not in APP or APOE, is associated with cognitive decline in Down syndrome. Farrer MJ, et al. **Neuroreport** 1997 May 6;8(7):1645–9
The deletion allele of the angiotensin I converting enzyme gene as a genetic susceptibility factor for cognitive impairment. Amouyel P, et al. **Neurosci Lett** 1996 Oct 18; 217(2–3):203–5
Apolipoprotein E e4 allele frequency in patients with multiple system atrophy. Cairns NJ, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):161–4
High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Kunugi H, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):202–4
Analysis of the APOE alleles impact in Down's syndrome. Lambert JC, et al. **Neurosci Lett** 1996 Dec 6;220(1):57–60
Rate of cognitive decline in Alzheimer's disease is not affected by the alpha-1-antichymotrypsin A allele or the CYP2D6 B mutant. Murphy GM Jr, et al.
Neurosci Lett 1996 Oct 18;217(2–3):200–2
The allele frequency distribution at VNTR locus D17S5 (YNZ22) in a Japanese population sample. Harashima N, et al. **Nippon Hoigaku Zasshi** 1996 Aug;50(4):237–40
Allele distribution of a VNTR polymorphism at D4S43 locus in the Japanese population. Katsuyama Y, et al.
Nippon Hoigaku Zasshi 1996 Feb;50(1):6–9
Sequence variation found in the flanking region of a trimeric short tandem repeat at the PLA2 locus: its considerable effect on estimating alleles. Kurosaki K, et al.
Nippon Hoigaku Zasshi 1996 Feb;50(1):1–5
Complementary strand analysis: a new approach for allelic separation in complex polyallelic genetic systems. Arguello R, et al. **Nucleic Acids Res** 1997 Jun 1;25(11):2236–8
Molecular haplotyping of genetic markers 10 kb apart by allele-specific long-range PCR. Michalatos-Beloin S, et al. **Nucleic Acids Res** 1996 Dec 1;24(23):4841–3
Single-well genotyping of diallelic sequence variations by a two-color ELISA-based oligonucleotide ligation assay. Tobe VO, et al. **Nucleic Acids Res** 1996 Oct 1; 24(19):3728–32
Allelic loss determination in chronic lymphocytic leukemia by immunomagnetic bead sorting and microsatellite marker analysis. Gartenhaus RB. **Oncogene** 1997 Jan 23;14(3):375–8
Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus. Kerr J, et al. **Oncogene** 1996 Oct 17;13(8):1815–8
Comprehensive allelotyping of human hepatocellular carcinoma. Nagai H, et al. **Oncogene** 1997 Jun 19; 14(24):2927–33
Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Pershouse MA, et al.
Oncogene 1997 Jan 23;14(3):369–73
Characterization of the imprinted IPW gene: allelic expression in normal and tumorigenic human tissues. Rachmilewitz J, et al. **Oncogene** 1996 Oct 17;13(8):1687–92
Allelotyping of all chromosomal arms in invasive cervical cancer. Rader JS, et al. **Oncogene** 1996 Dec 19; 13(12):2737–41
Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Steenbergen RD, et al.
Oncogene 1996 Sep 19;13(6):1249–57
Class I and class II major histocompatibility complex alleles are associated with faecal egg counts following natural, predominantly Ostertagia circumcincta infection. Buitkamp J, et al. **Parasitol Res** 1996;82(8):693–6
Population genetics and the detection of immunogenic and drug-resistant loci in Plasmodium. Hastings IM.
Parasitology 1996 Feb;112 (Pt 2):155–64
Development of a sensitive PCR to detect allele loss in a model hematopoietic neoplasm. Fairman J, et al.
PCR Methods Appl 1994 Aug;4(1):6–12
Determining relative microsatellite allele frequencies in pooled DNA samples. Khatib H, et al.
PCR Methods Appl 1994 Aug;4(1):13–8
Differential allelic expression of lactoproteins: a model to study transcriptional regulation. Dovč P, et al.
Pflugers Arch 1996;431(6 Suppl 2):R203–4
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Chang TK, et al. **Pharmacogenetics** 1997 Jun;7(3):211–21
The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Crespi CL, et al. **Pharmacogenetics** 1997 Jun;7(3):203–10
Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Daly AK, et al.
Pharmacogenetics 1996 Aug;6(4):319–28
Nomenclature for human CYP2D6 alleles. Daly AK, et al.
Pharmacogenetics 1996 Jun;6(3):193–201
Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Marez D, et al. **Pharmacogenetics** 1997 Jun;7(3):193–202
CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping.
Mrozikiewicz PM, et al. **Pharmacogenetics** 1997 Aug; 7(4):303–7
Allele frequency of CYP2C19 in a Portuguese population. Ruas JL, et al. **Pharmacogenetics** 1997 Aug;7(4):333–5
Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Schulz WA, et al. **Pharmacogenetics** 1997 Jun;7(3):235–9
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Sullivan-Klose TH, et al.
Pharmacogenetics 1996 Aug;6(4):341–9
Insertion mutagenesis and study of transposable elements using a new unstable virescent seedling allele for isolation of haploid petunia lines. Renckens S, et al. **Plant J** 1996 Sep;10(3):533–44
A copia-like retrotransposon Tgmr closely linked to the Rps1-k allele that confers race-specific resistance of soybean to Phytophthora sojae. Bhattacharyya MK, et al.
Plant Mol Biol 1997 May;34(2):255–64
Characterization of the molecular defect in a null allele of the opaque-2 locus of maize. Hoschek G, et al.
Plant Mol Biol 1996 Dec;32(6):1159–61
Screening for imprinted genes by allelic message display: identification of a paternally expressed gene impact on mouse chromosome 18. Hagiwara Y, et al.
Proc Natl Acad Sci U S A 1997 Aug 19;94(17):9249–54
Mendel's dwarfing gene: cDNAs from the Le alleles and function of the expressed proteins. Martin DN, et al.
Proc Natl Acad Sci U S A 1997 Aug 5;94(16):8907–11
Mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4. Radany EH, et al.
Proc Natl Acad Sci U S A 1997 Aug 5;94(16):8664–9
Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Sreevatsan S, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9869–74
Human argininosuccinate lyase: a structural basis for intragenic complementation. Turner MA, et al.
Proc Natl Acad Sci U S A 1997 Aug 19;94(17):9063–8
Microsatellite instability in childhood rhabdomyosarcoma is locus specific and correlates with fractional allelic loss. Visser M, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20; 93(17):9172–6
Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Kawana Y, et al. **Prostate** 1997 Aug 1;32(3):205–13
Hypermethylated SUPERMAN epigenetic alleles in arabidopsis. Jacobsen SE, et al. **Science** 1997 Aug 22; 277(5329):1100–3
Analysis of HLA-DRB1 alleles using PCR-RFLP and PCR-MPH. Thalang ON, et al.
Southeast Asian J Trop Med Public Health 1996 Mar; 27(1):169–71
Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Gardemann A, et al. **Thromb Haemost** 1997 Jun; 77(6):1120–6
A hemi-nested, allele specific, whole blood PCR assay for the detection of the factor V Leiden mutation. Sinclair GD, et al. **Thromb Haemost** 1997 Jun;77(6):1154–5
A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Grubic N, et al.
Thromb Res 1996 Dec 15;84(6):431–43
Three new HLA-B alleles found in Mexican-Americans. Adams EJ, et al. **Tissue Antigens** 1995 Nov;46(5):414–16
HLA-DPA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) and distribution of DPA1 alleles in Caucasian, African and Oriental populations. Aldener-Cannavá A, et al. **Tissue Antigens** 1996 Sep;48(3):153–60
High polymorphism of Mhc-E locus in non-human primates: alleles with identical exon 2 and 3 are found in two different species. Alvarez M, et al. **Tissue Antigens** 1997 Feb; 49(2):160–7
Identification of a novel HLA-B allele (B*4202) in a Saudi Arabian family with Behçet's disease. Ando H, et al.
Tissue Antigens 1997 May;49(5):526–8
On the sequence of A*3101. Arnett KL, et al.
Tissue Antigens 1996 May;47(5):428–30
HLA-A *2607: sequence of a novel A*26 subtype predicted by DNA typing which shares the MA2.1 epitope with A*02, B*57 and B*58. Arnett KL, et al.
Tissue Antigens 1996 May;47(5):422–5
Identification of a new HLA-DR3 allele: DRB1*0305. Asu UM, et al. **Tissue Antigens** 1995 Nov;46(5):405–7
Identification by polymerase chain reaction and hybridization with sequence-specific oligoprobes and complete exon-2 cDNA sequencing of a new DRB1 (DRB1*1131) allele. Balas A, et al. **Tissue Antigens** 1997 Jul;50(1):96–8
Five HLA-B22 group alleles in Japanese. Bannai M, et al.
Tissue Antigens 1997 Apr;49(4):376–82
HLA-B*5603: sequence of a novel hybrid allele comprising B*56 and B*4601 segments. Barnardo MC, et al.
Tissue Antigens 1997 May;49(5):496–8
HLA-A* 1104: a new allele found in a Laotian family. Bettinotti MP, et al. **Tissue Antigens** 1996 Dec;48(6):717–9
High resolution HLA-C typing by PCR-SSP: identification of allelic frequencies and linkage disequilibria in 604 unrelated random UK Caucasoids and a comparison with serology [corrected and republished in Tissue Antigens 1997 Jul;50(1):100–11] Bunce M, et al. **Tissue Antigens** 1996 Dec;48(6):680–91
High resolution HLA-C typing by PCR-SSP: identification of allelic frequencies and linkage disequilibria in 604 unrelated random UK Caucasoids and a comparison with serology [corrected and republished article originally printed in Tissue Antigens 1996 Dec;48(6):680–91] Bunce M, et al. **Tissue Antigens** 1997 Jul;50(1):100–11
HLA haplotypes and class II molecular alleles in Sardinian and Italian patients with pemphigus vulgaris. Carcassi C, et al. **Tissue Antigens** 1996 Dec;48(6):662–7
Molecular analysis of HLA-B35 alleles and their relationship to HLA-B15 alleles. Cereb N, et al. **Tissue Antigens** 1997 Apr;49(4):389–96
Cw*1701, a new HLA-C allelic lineage with an unusual transmembrane domain. Cereb N, et al. **Tissue Antigens** 1997 Mar;49(3 Pt 1):252–5
The presence of HLA-A*2403 and HLA-B*1512 on the same haplotype in a Thai family. Chandanayingyong D, et al. **Tissue Antigens** 1996 May;47(5):426–7
The HLA system in the population of Mongolia. Chimge NO, et al. **Tissue Antigens** 1997 May;49(5):477–83
New DRB1*1120 allele; another example of the transition between the DR11 and DR13 families of alleles. Cizman BB, et al. **Tissue Antigens** 1996 Jul;48(1):52–4
A novel HLA-B allele, HLA-B*1803. Curran MD, et al.
Tissue Antigens 1996 Dec;48(6):708–10
A new HLA-B51 allele, B*5107 in RCE55 detected and characterized by PCR-SSOP, cloning and nucleotide sequence determination. Curran MD, et al.
Tissue Antigens 1996 Sep;48(3):228–30
Characterization of a new DRB4 allele (DRB4*0104). De Canck I, et al. **Tissue Antigens** 1996 Sep;48(3):213–6
MHC class II alleles and haplotypes in patients with pemphigus vulgaris from India. Delgado JC, et al.
Tissue Antigens 1996 Dec;48(6):668–72
A novel HLA DRB1 allele (DRB1*0309). Dufossé F, et al.
Tissue Antigens 1997 May;49(5):523–5
HLA-DR 52- and 51-associated DRB1 alleles in Kenya, east Africa. Dunand VA, et al. **Tissue Antigens** 1997 Apr; 49(4):397–402
HLA-B typing by allele separation followed by direct sequencing. Eberle M, et al. **Tissue Antigens** 1997 Apr; 49(4):365–75
Description of a modified sequencing strategy and the molecular characterization of HLA-B*8201. Ellexson M, et al. **Tissue Antigens** 1996 May;47(5):438–41
Identification of four new DR52-associated DRB1 alleles: DRB1*1424, *1425, *1323 and *1324. Ellis JM, et al.
Tissue Antigens 1997 Jul;50(1):42–6
Sequence-specific priming and exonuclease-released fluorescence detection of HLA-DQB1 alleles. Faas SJ, et al. **Tissue Antigens** 1996 Aug;48(2):97–112
Nucleotide sequence analysis of an HLA-B47 variant

(HLA-B*4702). Fischer GF, et al. **Tissue Antigens** 1997 May;49(5):540-2

Association of the TNFa2 microsatellite allele with the presence of colorectal cancer. Gallagher G, et al. **Tissue Antigens** 1997 Jul;50(1):47-51

Complete allele typing of DR2-DRB1 by a combination of PCR-RFLF and PCR-SSP. Granja CB, et al. **Tissue Antigens** 1996 Jan;47(1):80-4

Sequence of a new HLA-B7 variant, B*0707, that differs from the common B*0702 allele by one single residue in the peptide binding groove. Grundschober C, et al. **Tissue Antigens** 1997 May;49(5):508-11

Identification and nucleotide sequence of two novel DRB3 alleles, DRB3*0102 and DRB3*010133. Guttridge MG, et al. **Tissue Antigens** 1997 Jun;49(6):665-7

TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus. Hajeer AH, et al. **Tissue Antigens** 1997 Mar;49(3 Pt 1):222-7

A novel HLA-B27 allele (B*2711) encoding an antigen reacting with both B27- and B40-specific antisera. Hasegawa T, et al. **Tissue Antigens** 1997 Jun;49(6):649-52

Identification of new DRB1*01 (DRB1*01022), DRB1*14 (DRB1*1428) and DRB3* (DRB3*0206) alleles. Hashemi-Tavoularis S, et al. **Tissue Antigens** 1997 Jul; 50(1):89-93

Novel HLA-B alleles, B*8201, B*3515 and B*5106, add to the complexity of serologic identification of HLA types. Hurley CK, et al. **Tissue Antigens** 1996 Mar;47(3):179-87

Allelic variations in the TAP2 and LMP2 genes in Behçet's disease. Ishihara M, et al. **Tissue Antigens** 1996 Mar; 47(3):249-52

Analysis of allelic variation of the TAP2 gene in sarcoidosis. Ishihara M, et al. **Tissue Antigens** 1997 Feb;49(2):107-10

Two new DR2 alleles: DRB1*1607 identified in an Ashkenazi Jewish family and DRB1*15022 found in a single Caucasian donor. Israel S, et al. **Tissue Antigens** 1997 Feb;49(2):173-5

African-American HLA class II allele and haplotype diversity [corrected and republished article originally printed in Tissue Antigens 1996 Dec;48(6):636-44] Just JJ, et al. **Tissue Antigens** 1997 May;49(5):547-55

African-American HLA class II allele and haplotype diversity [corrected and republished in Tissue Antigens 1997 May;49(5):547-55] Just JJ, et al. **Tissue Antigens** 1996 Dec;48(6):636-44

Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma. Kageshita T, et al. **Tissue Antigens** 1997 May;49(5):466-70

Sequence of a new HLA-A allele (A*0218) encoding a serological variant, HLA-A2K, observed in Japanese. Kashiwase K, et al. **Tissue Antigens** 1996 Oct;48(4 Pt 1):329-30

A novel HLA-DRB1*11 allele (DRB1*1127). Knipper AJ, et al. **Tissue Antigens** 1997 Apr;49(4):414-6

A comprehensive PCR-SSP typing system for identification of HLA-A locus alleles. Krausa P, et al. **Tissue Antigens** 1996 Mar;47(3):237-44

Full-length cDNA nucleotide sequence of the HLA-B*4202 allele. Lardy NM, et al. **Tissue Antigens** 1997 Jul;50(1):83-4

The novel HLA-DRB1*0807 allele is present in a Carib Amerindian population: the Yucpa. Layrisse Z, et al. **Tissue Antigens** 1997 Apr;49(4):427-8

Serologic ambiguity and allelic frequency of the HLA-B40 family in the Korean population. Lee KW, et al. **Tissue Antigens** 1997 Apr;49(4):383-8

Suggested lineage of the rare DRB1*1417 allele from DRB1*1301--general implications for matched unrelated bone marrow donor searching. Lester S, et al. **Tissue Antigens** 1995 Nov;46(5):426-7

HLA-A*3004: a new A30 allele identified in an Australian Caucasoid population. Lienert K, et al. **Tissue Antigens** 1995 Nov;46(5):394-7

HLA-C typing of eleven Papua New Guineans: identification of an HLA-Cw4/Cw2 hybrid allele. Little AM, et al. **Tissue Antigens** 1996 Aug;48(2):113-7

HLA class II alleles and autoantibodies in Bulgarians with systemic lupus erythematosus. Marintchev LM, et al. **Tissue Antigens** 1995 Nov;46(5):422-5

Description of two new HLA-DRB alleles (DRB1*0310 and DRB3*01012) found in a Spanish infant. Martínez-Quiles N, et al. **Tissue Antigens** 1997 Jun;49(6):658-61

DPA1*0105, a novel DPA1 variant in a negroid population. May J, et al. **Tissue Antigens** 1996 Nov;48(5):593-4

Characterization of a new DQB1 allele (DQB1*0610) which differs from DQB1*0602 at the highly polymorphic 57-codon. Mersch G, et al. **Tissue Antigens** 1996 Sep; 48(3):217-20

DPB1*TF, a novel HLA class II DPB1 allele (DPB1*6701) identified in a Turkish family. Meyer CG, et al. **Tissue Antigens** 1996 Sep;48(3):231-2

A Bw6-associated B44 allele (B*4409) identified by SSOP and corresponding serological results. Middleton D, et al. **Tissue Antigens** 1997 Jun;49(6):655-7

Identification of a DRB1*0405 variant (DRB1*04052) using the PCR-RFLP method. Moribe T, et al. **Tissue Antigens** 1996 May;47(5):450-3

A novel DPA1 allele (DPA1*0203) composed of known epitopes. Muntau B, et al. **Tissue Antigens** 1997 Jun; 49(6):668-9

A new allelic variant of HLA-DRB1*1101 (DRB1*11013) segregating in a Sardinian family. Murru MR, et al. **Tissue Antigens** 1996 Nov;48(5):604-6

Analysis on allelic variation of the HLA-DMB gene in Japanese by PCR-RFLP as well as direct DNA sequencing and identification of a new DMB allele, DMB*0105. Naruse TK, et al. **Tissue Antigens** 1996 Jun;47(6):530-7

HLA-DRB4 genotyping by PCR-RFLP: diversity in the associations between HLA-DRB4 and DRB1 alleles. Naruse TK, et al. **Tissue Antigens** 1997 Feb;49(2):152-9

Allele walking: a new and highly accurate approach to HLA-DRB1 typing. Application to DRB1*04 alleles. Nieto A, et al. **Tissue Antigens** 1997 Feb;49(2):141-51

Six new DPB1 alleles identified in a study of 1,302 unrelated bone marrow donor-recipient pairs. Noreen H, et al. **Tissue Antigens** 1997 May;49(5):512-6

DQB1*0202 and the new DQB1*0203 allele: a fourth pair of DQB1 alleles differing only at codon 57. Olerup O, et al. **Tissue Antigens** 1997 Mar;49(3 Pt 1):271-3

Trinucleotide repeat polymorphism within exon 5 of the MICA gene (MHC class I chain-related gene A): allele frequency data in the nine population groups Japanese, Northern Han, Hui, Uygur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian. Ota M, et al. **Tissue Antigens** 1997 May;49(5):448-54

A new DRB1 allele (DRB1*1125) sharing DR11 and DR8 sequence motifs. Perrier P, et al. **Tissue Antigens** 1997 Jan; 49(1):84-7

Allele assignment for HLA-A, -B, and -C genes to the Tenth International Histocompatibility Workshop cell lines. Prasad VK, et al. **Tissue Antigens** 1996 Jun;47(6):538-46

Novel alleles HLA-B*7802 and B*51022: evidence for convergency in the HLA-B5 family. Prilliman K, et al. **Tissue Antigens** 1996 Jan;47(1):49-57

HLA-class II alleles and C4 null genes in Greeks with systemic lupus erythematosus. Reveille JD, et al. **Tissue Antigens** 1995 Nov;46(5):417-21

Identification of a new allele, DRB1*1204, during routine PCR-SSOP typing of National Marrow Donor Program volunteers. Rodriguez SG, et al. **Tissue Antigens** 1996 Sep; 48(3):221-3

A new HLA-DQB1*0306 allele sharing motifs from DQB1*03032 and DQB1*04 sequences. Saito S, et al. **Tissue Antigens** 1996 Nov;48(5):580-5

Characterization of two novel Mamu-DQA1 alleles of rhesus monkeys. Sauermann U, et al. **Tissue Antigens** 1995 Nov; 46(5):408-10

A novel DRB1*13 allele (DRB1*1327) on a DR17, DQ2 haplotype with a DRB1*0301 sequence motif in the 2nd hyperpolymorphic region. Schaffer M, et al. **Tissue Antigens** 1997 Feb;49(2):186-8

Nucleotide sequence of the corrected DQB1*06011 allele. Schranz P, et al. **Tissue Antigens** 1996 Aug;48(2):139-40

Genomic organization and allelic polymorphism of the human killer cell inhibitory receptor gene KIR103. Selvakumar A, et al. **Tissue Antigens** 1997 Jun;49(6):564-73

Two new DPB1 alleles identified in a study of the genetics of susceptibility to pauciarticular juvenile rheumatoid arthritis. Steiner LL, et al. **Tissue Antigens** 1997 Mar;49(3 Pt 1):262-6

Nucleotide sequence of HLA-B*5505, which expresses a unique HLA class I polymorphism. Szmania S, et al. **Tissue Antigens** 1997 May;49(5):537-9

A new silent mutation at codon 35 in exon 2 yielding DRB1*04012 allele. Thonnard J, et al. **Tissue Antigens** 1997 Mar;49(3 Pt 1):274-6

Results of Expedicion Humana. II. Analysis of HLA class II alleles in three African American populations from Colombia using the PCR/SSOP: identification of a novel DQB1*02 (*0203) allele. Trachtenberg EA, et al. **Tissue Antigens** 1996 Sep;48(3):192-8

A novel DRB1 allele (DRB1*0815) defined in an Australian Aborigine. Trejaut J, et al. **Tissue Antigens** 1997 May; 49(5):529-31

HLA class I genotyping by cDNA sequence of a Vietnamese family expressing a weak B46 antigen. Tzeng CM, et al. **Tissue Antigens** 1997 May;49(5):519-22

A new DRB1*15 allele (DRB1*1506) identified by sequence-based typing. van den Berg-Loonen E, et al. **Tissue Antigens** 1997 Feb;49(2):189-91

A novel HLA-B35 (B*3517) allele found in a Mexican of Otomi descent. Vargas-Alarcon G, et al. **Tissue Antigens** 1996 Jun;47(6):547-50

Six newly identified HLA-DRB alleles: DRB1*1121, *1419, *1420, *1421, DRB3*0203 and DRB5*0103. Verduyn W, et al. **Tissue Antigens** 1996 Aug;48(2):80-6

Correction of the DPB*02011 allele and assignment of DRB3*0202 to the cell line WT49. Versluis LF, et al. **Tissue Antigens** 1997 Jun;49(6):670-2

Complete coding regions of two novel HLA-B alleles detected by phototyping (PCR-SSP) in the British caucasoid population: B*5108 and B*5002. Vilches C, et al. **Tissue Antigens** 1997 Jul;50(1):38-41

The novel HLA-Cw*1802 allele is associated with B*5703 in the Bubi population from Equatorial Guinea. Vilches C, et al. **Tissue Antigens** 1997 Jun;49(6):644-8

Complete coding region of the new HLA-DQB1*0612 allele, obtained by RT-PCR. Vilches C, et al. **Tissue Antigens** 1996 Nov;48(5):589-92

Molecular cloning of two new HLA-C alleles: Cw*1801 and Cw*0706. Vilches C, et al. **Tissue Antigens** 1996 Dec; 48(6):698-702

Identification of a new HLA-DRB1*13 allele (DRB1*1326) with a short DRB1*16 sequence. Voorter CE, et al. **Tissue Antigens** 1997 Jan;49(1):88-91

Identification of a new DRB4 allele (DRB4*0105) by sequence-based typing. Voorter CE, et al. **Tissue Antigens** 1997 Jun;49(6):662-4

A novel allele, Cw*1702 with serological Cw2 specificity. Wang H, et al. **Tissue Antigens** 1997 Feb;49(2):183-5

Identification of HLA-C alleles using PCR-single-strand-conformation polymorphism and direct sequencing. Wang H, et al. **Tissue Antigens** 1997 Feb; 49(2):134-40

DNA typing of Cw*14 alleles in Japanese and the corrected sequence of Cw*1402. Wang H, et al. **Tissue Antigens** 1996 May;47(5):442-6

A novel recombinant HLA-B*39 allele (B*3910) in a South African Zulu. Wells RS, et al. **Tissue Antigens** 1996 Nov; 48(5):595-7

Identification of a new HLA-B*55 allele, HLA-B*5503. Williams F, et al. **Tissue Antigens** 1996 Nov;48(5):598-9

Identification of a new HLA-B allele, HLA-B*0708. Williams F, et al. **Tissue Antigens** 1997 Jun;49(6):653-4

Strategy for distinguishing a new DQB1 allele (DQB1*0611) from the closely related DQB1*0602 allele via sequence specific PCR or direct DNA sequencing. Williams TM, et al. **Tissue Antigens** 1996 Sep;48(3):143-7

Complete cDNA sequence of B*4406, an HLA-B allele containing sequences of B*5101 and B*4402. Zhao W, et al. **Tissue Antigens** 1996 May;47(5):431-4

Full cDNA of a novel HLA-B39 subtype, B*39061. Zhao W, et al. **Tissue Antigens** 1996 May;47(5):435-7

Rapid detection of the cisAB allele consisting of a chimera of normal A and B alleles by PCR-RFLPs. Fukumori Y, et al. **Transfus Med** 1996 Dec;6(4):337-44

Paramutation and related allelic interactions [see comments] Hollick JB, et al. **Trends Genet** 1997 Aug;13(8):302-8 (53 ref.). Comment in: Trends Genet 1997 Aug;13(8):293-5.

Recognition of contiguous allele-specific peptide elements in the rubella virus E1 envelope protein. Nepom GT, et al. **Vaccine** 1997 Apr-May;15(6-7):648-52

Identification of potential CTL epitopes of bovine RSV using allele-specific peptide motifs from bovine MHC class I molecules. Gaddum RM, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):211-9 (50 ref.)

A second nonsecretor allele of the blood group alpha(1,2)fucosyl-transferase gene (FUT2). Henry S, et al. **Vox Sang** 1996;70(1):21-5

Evidence for a new type of O allele at the ABO locus, due to a combination of the A2 nucleotide deletion and the Ael nucleotide insertion. Olsson ML, et al. **Vox Sang** 1996; 71(2):113-7

Review of allelic loss and gain in prostate cancer. Bova GS, et al. **World J Urol** 1996;14(5):338-46 (78 ref.)

Characterization of the Saccharomyces cerevisiae cdc42-1ts allele and new temperature-conditional-lethal cdc42 alleles. Miller PJ, et al. **Yeast** 1997 May;13(6):561-72

[Towards an allotype of second generation colon cancer] Buecher B, et al. **Gastroenterol Clin Biol** 1995 Dec; 19(12):1004-10 (Eng. Abstr.) **(Fre)**

[Analysis of gene effects on performance characteristics] Geldermann H. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):378-83 (16 ref.) (Eng. Abstr.) **(Ger)**

[Allele losses in squamous cell carcinomas of the larynx] Bockmühl U, et al. **Laryngorhinootologie** 1996 Jan; 75(1):48-62 (Eng. Abstr.) **(Ger)**

[Absence of an association of the D allele of the ACE gene with arterial pressure in mild-moderate essential arterial hypertension] Celentano A, et al. **Cardiologia** 1996 Oct; 41(10):995-1000 (Eng. Abstr.) **(Ita)**

[An alpha-1-antitrypsin deficiency allele PI*Siiyama found in a disputed paternity case] Umetsu K, et al. **Nippon Hoigaku Zasshi** 1996 Feb;50(1):37-40 (Eng. Abstr.) **(Jpn)**

[Structural polymorphism of ACTBP2 STR region] Yoshii T, et al. **Nippon Hoigaku Zasshi** 1997 Feb;51(1):18-25 (Eng. Abstr.) **(Jpn)**

[HLA class II alleles and leprosy (Hansen's disease) classified by WHO-MDT criteria] Joko S, et al. **Nippon Rai Gakkai Zasshi** 1996 Jul;65(2):121-7 (Eng. Abstr.) **(Jpn)**

[Direct determination of ABO and cisAB blood group genotypes using polymerase chain reaction amplification of specific alleles (PASA)--method] Hosoi E. **Rinsho Byori** 1996 Aug;44(8):783-90 (Eng. Abstr.) **(Jpn)**

[Molecular analysis of certain derivatives of mutants with the unstable white-starka allele] Aslanukov AR, et al. **Genetika** 1997 May;33(5):583-90 (Eng. Abstr.) **(Rus)**

[Genetic analysis of the lawc(p1) mutation in combination with different alleles of AS-C genes in Drosophila] Simonova OB, et al. **Genetika** 1996 Jul;32(7):949-55 (Eng. Abstr.) **(Rus)**

[Analysis of allelic polymorphism of two tetranucleotide tandem repeats in two urban populations in Russia] Chistiakov DA, et al. **Mol Biol (Mosk)** 1996 Nov-Dec; 30(6):1274-83 **(Rus)**

[The dynamics of the allele variants of biochemical markers in generations of cattle in the exclusion zone of the Chernobyl Atomic Electric Power Station] Glazko VI, et al. **Tsitol Genet** 1996 Jul-Aug;30(4):49-55 (Eng. Abstr.) **(Rus)**

[A population genetics study of the allelic polymorphism in the hypervariable region of the apolipoprotein B gene in the population of different regions of Ukraine] Kravchenko SA, et al. **Tsitol Genet** 1996 Sep-Oct;30(5):35-41 (Eng. Abstr.) **(Rus)**

ALLELES

[Huntington's disease: a mutation from an intermediate paternal allele expansion (letter)] Morlán L, et al. **Neurologia** 1997 Jun-Jul;12(6):266-7 **(Spa)**

ALLELISM TEST see **GENETIC COMPLEMENTATION TEST**

ALLERGEN BRONCHIAL PROVOCATION TESTS see **BRONCHIAL PROVOCATION TESTS**

ALLERGEN IMMUNOTHERAPY see **DESENSITIZATION, IMMUNOLOGIC**

ALLERGENS

see related
BITES AND STINGS
DUST
FEATHERS
FUNGI

The Allergen Bank: a source of extra contact allergens for the dermatologist in practice. Andersen KE, et al. **Acta Derm Venereol** 1996 Mar;76(2):136-40

Pseudoallergen-free diet in the treatment of chronic urticaria [letter; comment] Haustein UF. **Acta Derm Venereol** 1996 Nov;76(6):498-9. Comment on: Acta Derm Venereol 1995 Nov;75(6):484-7.

Maternal allergen stimulation suppressed respiratory allergy in offspring: with special reference to allergy related cells in the tonsil. Matsui K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:87-9

Hypersensitivity to carrot associated with specific IgE to grass and tree pollens. Gómez M, et al. **Allergy** 1996 Jun; 51(6):425-9

Environmental control of dust mite allergens. Johnson TA Jr. **Am Fam Physician** 1996 Oct;54(5):1651-4, 1657

Excited skin syndrome. Duarte I, et al. **Am J Contact Dermat** 1996 Mar;7(1):24-34

Clinical sequelae associated with squaric acid dibutylester topical sensitization. Foley S, et al. **Am J Contact Dermat** 1996 Jun;7(2):104-8

A 6-year experience with compositae mix. Hausen BM. **Am J Contact Dermat** 1996 Jun;7(2):94-9

Patch testing to cosmetics and topical drugs. Stewart LA. **Am J Contact Dermat** 1996 Mar;7(1):53-5

Sesquiterpene lactone allergy. Warshaw EM, et al. **Am J Contact Dermat** 1996 Mar;7(1):1-23 (97 ref.)

Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. Nimmagadda SR, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):87-93

Treatment of cat allergy with T-cell reactive peptides. Norman PS, et al. **Am J Respir Crit Care Med** 1996 Dec; 154(6 Pt 1):1623-8

Nitrogen dioxide exposure enhances asthmatic reaction to inhaled allergen in subjects with asthma. Strand V, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):881-7

Effects of mold proteases on the biological activity of allergenic pollen extracts. Rosenbaum MR, et al. **Am J Vet Res** 1996 Oct;57(10):1447-52

Acoustic rhinometry in the study of the acute nasal allergic response. Lane AP, et al. **Ann Otol Rhinol Laryngol** 1996 Oct;105(10):811-8

House dust mite allergens (Der p I and Der p V) within domestic environments of atopic and control children. Li CS, et al. **Arch Environ Health** 1997 May-Jun;52(3):208-12

Dynamics of soluble adhesion molecule levels in patients with pollinosis. Kato M, et al. **Arch Otolaryngol Head Neck Surg** 1996 Dec; 122(12):1398-400

Effects of local and systemic budesonide on allergen-induced airway reactions in the pig. Fornhem C, et al. **Br J Pharmacol** 1996 Jun;118(4):989-97

Specific immunoglobulins to soybean hull allergens in soybean asthma. Codina RM, et al. **Chest** 1997 Jan; 111(1):75-80

Tolerance to the protective effect of salmeterol on allergen challenge. Giannini D, et al. **Chest** 1996 Dec;110(6):1452-7

Predictive testing in contact dermatitis. Allergic contact dermatitis. Andersen KL, et al. **Clin Dermatol** 1997 Jul-Aug;15(4):645-54 (81 ref.)

Contact allergens--what's new? Metals. Burrows DD. **Clin Dermatol** 1997 Jul-Aug;15(4):505-9 (42 ref.)

Contact allergens--what's new? Cosmetic dermatitis. De Groot AC. **Clin Dermatol** 1997 Jul-Aug;15(4):485-91 (79 ref.)

Pigmented contact dermatitis. Ebihara T, et al. **Clin Dermatol** 1997 Jul-Aug;15(4):593-9 (20 ref.)

Contact allergens--what's new? Preservatives. Gruvberger B, et al. **Clin Dermatol** 1997 Jul-Aug;15(4):493-7 (41 ref.)

Photopatch testing. Isaksson M, et al. **Clin Dermatol** 1997 Jul-Aug;15(4):615-8 (39 ref.)

Contact allergens--what's new? Corticosteroids. Isaksson M, et al. **Clin Dermatol** 1997 Jul-Aug;15(4):527-31 (59 ref.)

Plastics/acrylics: material safety data sheets need to be improved. Kanerva L, et al. **Clin Dermatol** 1997 Jul-Aug; 15(4):533-46 (67 ref.)

Phytodermatitis. Lovell CR. **Clin Dermatol** 1997 Jul-Aug; 15(4):607-13 (75 ref.)

Contact allergens--what's new? Fragrances. Nethercott JR, et al. **Clin Dermatol** 1997 Jul-Aug;15(4):499-504 (45 ref.)

Occupational dermatitis--what's new? Metalworking industry. Rycroft RJ. **Clin Dermatol** 1997 Jul-Aug; 15(4):565-6

Ingested food in systemic allergic contact dermatitis. Veien NK. **Clin Dermatol** 1997 Jul-Aug;15(4):547-55 (128 ref.)

Dinitrohalobenzenes: evaluation of relative skin sensitization potential using the local lymph node assay. Basketter DA, et al. **Contact Dermatitis** 1997 Feb;36(2):97-100

Contact allergenic activity of Tween 80 before and after air exposure. Bergh M, et al. **Contact Dermatitis** 1997 Jul; 37(1):9-18

Pseudo flautist's lip: allergic contact cheilitis from geraniol. Chang YC, et al. **Contact Dermatitis** 1997 Jul;37(1):39

Contact sensitization to preservatives in children. Conti A, et al. **Contact Dermatitis** 1997 Jul;37(1):35-6

Sensitization to pepper (Capsicum annuum) in a latex-allergic patient. Gallo R, et al. **Contact Dermatitis** 1997 Jul; 37(1):36-7

Occupational contact dermatitis from anethole in food handlers. García-Bravo B, et al. **Contact Dermatitis** 1997 Jul;37(1):38

Concomitant contact dermatitis due to textile dyes and to colour film developers can be explained by the formation of the same hapten. Hansson C, et al. **Contact Dermatitis** 1997 Jul;37(1):27-31

Maintenance of hand eczema by oral pantothenic acid in a patient sensitized to dexpanthenol. Hemmer W, et al. **Contact Dermatitis** 1997 Jul;37(1):51

Contact dermatitis in a chimney sweep. Jenkinson HA. **Contact Dermatitis** 1997 Jul;37(1):35

Occupational allergic contact dermatitis caused by acrylic tri-cure glass ionomer. Kanerva L, et al. **Contact Dermatitis** 1997 Jul;37(1):49-50

Simultaneous contact sensitivity due to lidocaine and crotamiton. Kawada A, et al. **Contact Dermatitis** 1997 Jul; 37(1):45

Allergic contact dermatitis from grasses. Koh D, et al. **Contact Dermatitis** 1997 Jul;37(1):32-4

Crescendo reactions to sodium lauryl sulfate and retinoic acid in irritant patch tests. Löffler H, et al. **Contact Dermatitis** 1997 Jul;37(1):47-8

Pigmented contact dermatitis due to Naphthol AS in a pillowcase. Osawa J, et al. **Contact Dermatitis** 1997 Jul; 37(1):37-8

Relapse of colophony dermatitis from lottery tickets. Pereira F, et al. **Contact Dermatitis** 1997 Jul;37(1):43

Patch testing with lower concentrations of chromate and nickel. Rudzki E, et al. **Contact Dermatitis** 1997 Jul;37(1):46

Contact dermatitis in psoriasis due to propolis. Silvani S, et al. **Contact Dermatitis** 1997 Jul;37(1):48-9

A dermatitis flare after patch testing with Dermatophagoides pteronyssinus in an atopic patient. Stinco G, et al. **Contact Dermatitis** 1997 Jul;37(1):52

Allergic contact dermatitis from oleyl alcohol in lipstick cross-reacting with ricinoleic acid in castor oil and lanolin. Tan BB, et al. **Contact Dermatitis** 1997 Jul;37(1):41-2

Reactivity to nicotine patches wrongly blamed on contact allergy. von Bahr B, et al. **Contact Dermatitis** 1997 Jul; 37(1):44-5

Contact sensitivity to 1-(4-(2-chloroethyl)phenyl)-2-chloroethanol in a polymer chemist. Wakelinj SH, et al. **Contact Dermatitis** 1997 Jul; 37(1):39-40

Food allergens. Bush RK, et al. **Crit Rev Food Sci Nutr** 1996; 36 Suppl:S119-63 (349 ref.)

Why are some proteins allergenic? Implications for biotechnology. Lehrer SB, et al. **Crit Rev Food Sci Nutr** 1996 Jul;36(6):553-64 (66 ref.)

Principles and characteristics of food allergens. Taylor SL, et al. **Crit Rev Food Sci Nutr** 1996;36 Suppl:S91-118 (179 ref.)

Environmental control: an idea whose time has come [editorial; comment] Becker AB, et al. **Eur Respir J** 1997 Jun;10(6):1203-4. Comment on: Eur Respir J 1997 Jun;10(6):1217-23.

Effect of a bed covering system in children with asthma and house dust mite hypersensitivity. Frederick JM, et al. **Eur Respir J** 1997 Feb;10(2):361-6

Increased number of activated lymphocytes in human lung following swine dust inhalation. Müller-Suur C, et al. **Eur Respir J** 1997 Feb;10(2):376-80

Allergic and nonallergic interactions between house dust mite allergens and airway mucosa. Roche N, et al. **Eur Respir J** 1997 Mar;10(3):719-26 (83 ref.)

Allergen reduction measures in houses of allergic asthmatic patients: effects of air-cleaners and allergen-impermeable mattress covers [see comments] van der Heide S, et al. **Eur Respir J** 1997 Jun;10(6):1217-23. Comment in: Eur Respir J 1997 Jun;10(6):1203-4.

Inhalation of swine dust induces cytokine release in the upper and lower airways. Wang Z, et al. **Eur Respir J** 1997 Feb; 10(2):381-7

Molecular cloning and immunological characterisation of Cyn d 7, a novel calcium-binding allergen from Bermuda grass pollen. Suphioglu C, et al. **FEBS Lett** 1997 Feb 3; 402(2-3):167-72

Increase of asthma and allergic rhinitis prevalence in young Italian men. Ciprandi G, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):278-83

Allergic contact dermatitis: clinical features and profile of sensitizing allergens in Riyadh, Saudi Arabia. al-Sheikh OA, et al. **Int J Dermatol** 1996 Jul;35(7):493-7

The use of standardized allergen extracts. American Academy of Allergy, Asthma and Immunology (AAAAI). **J Allergy Clin Immunol** 1997 May;99(5):583-6

Sensitization to inhaled allergens as a risk factor for asthma and allergic diseases in Chinese population. Leung R, et al. **J Allergy Clin Immunol** 1997 May;99(5):594-9

Utility of a standard allergen series alone in the evaluation of allergic contact dermatitis: a retrospective study of 732 patients. Cohen DE, et al. **J Am Acad Dermatol** 1997 Jun; 36(6 Pt 1):914-8

Role of animal danders as inhalant allergens in bronchial asthma in India. Gupta S, et al. **J Asthma** 1996;33(5):339-48

A novel acidic allergen, Hev b 5, in latex. Purification, cloning and characterization. Akasawa A, et al. **J Biol Chem** 1996 Oct 11;271(41):25389-93

Identification, cloning, and sequence of a major allergen (Hev b 5) from natural rubber latex (Hevea brasiliensis). Slater JE, et al. **J Biol Chem** 1996 Oct 11;271(41):25394-9

Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. Schwarze J, et al. **J Clin Invest** 1997 Jul 1; 100(1):226-33

Evaluation of German cockroach (Orthoptera:Blattellidae) allergen and seasonal variation in low-income housing. Mollet JA, et al. **J Med Entomol** 1997 May;34(3):307-11

Skin-prick test sensitivity to olive pollen [letter] [corrected and republished in Med J Aust 1996 Oct 21;165(8):460] Azmi MH, et al. **Med J Aust** 1996 Sep 16;165(6):352

Allergy and asthma in central Australia [letter] Weiner JM, et al. **Med J Aust** 1996 Nov 4;165(9):526

Allergen source materials and quality control of allergenic extracts. Esch RE. **Methods** 1997 Sep;13(1):2-13

Prevention of asthma as a public health priority [editorial] Peat JK, et al. **Monaldi Arch Chest Dis** 1995 Dec; 50(6):423-6

Olfactory threshold after nasal allergen challenge. Hinriksdóttir I, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 Jan-Feb; 59(1):36-8

Respiratory syncytial virus infection: its role in aeroallergen sensitization during the first two years of life. Forster J, et al. **Pediatr Allergy Immunol** 1996 May;7(2):55-60

Allergic rhinitis. Recognizing signs, symptoms, and triggering allergens. Ferguson BJ. **Postgrad Med** 1997 May; 101(5):110-6 (9 ref.)

Subclass profile of allergen-specific IgG antibodies in atopic dogs. Day MJ, et al. **Res Vet Sci** 1996 Sep;61(2):136-42

Allergen avoidance measures. British Thoracic Society. Durham SR. **Respir Med** 1996 Sep;90(8):441-5

Specific IgE against milk allergens in children with insulin dependent diabetes mellitus. Boznański A, et al. **Rocz Akad Med Bialymst** 1995;40(3):494-8

[Food allergens] Bonneau JC. **Allerg Immunol (Paris)** 1997 May;29(5):137-8, 141-3 (17 ref.) (Eng. Abstr.) **(Fre)**

[So go allergens! (editorial)] Mougeolle JM. **Ann Dermatol Venereol** 1996;123(8):438-42 (4 ref.) **(Fre)**

[Allergenicity and specific protein profiles of mange mites Chorioptes bovis, Psoroptes ovis (Acari: Psoroptidae), Saroptes suis and Notoedres cati (Acari: Sarcoptidae) using SDS-PAGE and immunoblotting] Beck W, et al. **Berl Munch Tierarztl Wochenschr** 1997 Apr;110(4):128-33 (Eng. Abstr.) **(Ger)**

[Encasing evaluation: studies of dust retention and water permeability] Kainka E, et al. **Pneumologie** 1997 Jan; 51(1):2-9 (Eng. Abstr.) **(Ger)**

[Identification and characterization of allergens of Chironomus flaviplumus adults (Chironomidae, Diptera) in mice] Ree HI, et al. **Korean J Parasitol** 1996 Mar; 34(1):35-47 (Eng. Abstr.) **(Kor)**

[Study of allergenic factors in the environment (review)] Sidorenko GI, et al. **Gig Sanit** 1997 May-Jun;(3):49-52 (27 ref.) **(Rus)**

[Sensitization to industrial chemical allergens in bronchial asthma in children in environmental pollution] Dueva LA, et al. **Med Tr Prom Ekol** 1997;(2):41-5 (Eng. Abstr.) **(Rus)**

[Fatal and severe food hypersensitivity. Peanut and soya underestimated allergens] Foucard T, et al. **Lakartidningen** 1997 Jul 23;94(30-31):2635-8 (Eng. Abstr.) **(Swe)**

ADMINISTRATION & DOSAGE

Clinical efficacy and safety of local nasal immunotherapy. Andri L, et al. **Allergy** 1997;52(33 Suppl):36-9 (38 ref.)

Allergen-induced changes in airway responsiveness are related to baseline airway responsiveness. de Bruin-Weller MS, et al. **Allergy** 1996 Jun;51(6):401-6

A prospective safety-monitoring study of immunotherapy in mite-allergy patients with mass-units-standardized extract. González de la Cuesta C, et al. **Allergy** 1997 May; 52(5):580-3

An electrical impedance technique for assessment of wheals. Nyrén M, et al. **Allergy** 1996 Dec;51(12):923-6

An approach to the understanding of the nasal early-phase reaction induced by nasal allergen challenge. Wang D, et al. **Allergy** 1997 Feb;52(2):162-7

Effect of local allergen priming on early, late, delayed-phase, and epicutaneous skin reactions. Weller FR, et al. **Allergy** 1996 Dec;51(12):883-6

New routes and formulations for allergen-specific immunotherapy. Wheeler AW, et al. **Allergy** 1997 Jun; 52(6):602-12 (72 ref.)

Oral allergy syndrome to apple after a lover's kiss. Wüthrich

B. **Allergy** 1997 Feb;52(2):235–6

The immediate and late allergic response to segmental bronchopulmonary provocation in asthma. Jarjour NN, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1515–21

Elastase contributes to antigen–induced mucociliary dysfunction in ovine airways. O'Riordan TG, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1522–8

Topical squaric acid dibutylester therapy for alopecia areata: a double–sided patient–controlled study. Chua SH, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):842–7

Sustained eosinophil cationic protein release into tears after a single high–dose conjunctival allergen challenge [see comments] Montan PG, et al. **Clin Exp Allergy** 1996 Oct; 26(10):1125–30. Comment in: Clin Exp Allergy 1996 Oct;26(10):1105–7.

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study [see comments] Quirino T, et al. **Clin Exp Allergy** 1996 Nov; 26(11):1253–61. Comment in: Clin Exp Allergy 1996 Nov;26(11):1228–31.

Photopatch test reactivity: effect of photoallergen concentration and UVA dosaging. Hasan T, et al. **Contact Dermatitis** 1996 Jun;34(6):383–6

Elicitation thresholds for thiuram mix using petrolatum and ethanol/sweat as vehicles. Knudsen BB, et al. **Contact Dermatitis** 1996 Jun;34(6):410–3

Enzyme–potentiated desensitization: a major breakthrough [editorial] Pulec JL. **Ear Nose Throat J** 1996 Oct;75(10):640

Phenotypic analysis of lymphocyte subpopulations in lymph nodes draining the ear following exposure to contact allergens and irritants. Sikorski EE, et al. **Fundam Appl Toxicol** 1996 Nov;34(1):25–35

Effect of maturation on allergen–induced airflow obstruction and airway plasma exudation in sensitized guinea pigs. Arakawa H, et al. **Int Arch Allergy Immunol** 1997 Feb; 112(2):196–202

Therapeutic efficacy of allergen–monomethoxypolyethylene glycol conjugates in the treatment of allergen–induced asthmatic responses in guinea pigs. I–ijima H, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):323–5

Inhibition of allergen–induced histamine release from human basophils by cyclosporine A and FK–506. Sperr WR, et al. **Int Arch Allergy Immunol** 1997 Sep;114(1):68–73

Interaction of ozone and allergen challenges on bronchial responsiveness and inflammation in sensitised guinea pigs. Sun J, et al. **Int Arch Allergy Immunol** 1997 Feb; 112(2):191–5

IL–4 production by allergen–stimulated primary cultures: identification of basophils as the major IL–4–producing cell type. Kasaian MT, et al. **Int Immunol** 1996 Aug; 8(8):1287–97

Allergen bronchoprovocation of patients with mild allergic asthma after ozone exposure. Ball BA, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):563–72

Treatment with hot, humid air reduces the nasal response to allergen challenge. Desrosiers M, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):77–86

Evaluation of single–dose inhaled corticosteroid activity with an allergen challenge model. Kidney JC, et al. **J Allergy Clin Immunol** 1997 Jul;100(1):65–70

Determinants of airway responses to cat allergen: comparison of environmental challenge to quantitative nasal and bronchial allergen challenge. Sicherer SH, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):798–805

The mouse IgE test for the identification of potential chemical respiratory allergens: considerations of stability and controls. Hilton J, et al. **J Appl Toxicol** 1996 Mar–Apr; 16(2):165–70

Combined diesel exhaust particulate and ragweed allergen challenge markedly enhances human in vivo nasal ragweed–specific IgE and skews cytokine production to a T helper cell 2–type pattern. Diaz–Sanchez D, et al. **J Immunol** 1997 Mar 1;158(5):2406–13

Interaction of ozone exposure with airway hyperresponsiveness and inflammation induced by trimellitic anhydride in sensitized guinea pigs. Sun J, et al. **J Toxicol Environ Health** 1997 May;51(1):77–87

Allergies to wheat, yeast and royal jelly: a connection between ingestion and inhalation? Baldo BA. **Monogr Allergy** 1996;32:84–91 (12 ref.)

Impact of allergen exposure on bronchial hyperresponsiveness. Dreborg S. **Pediatr Allergy Immunol** 1996;7(9 Suppl):14–7 (27 ref.)

Exposure to indoor inhalant allergens. Lau S. **Pediatr Allergy Immunol** 1996;7(9 Suppl):108–10 (14 ref.)

Substance P enhances antigen–evoked mediator release from human nasal mucosa. Baumgarten CR, et al. **Peptides** 1996; 17(1):25–30

Association of apoptosis of neutrophils and eosinophils and their ingestion by macrophages with resolution of the allergen–induced cutaneous late–phase response in atopic human subjects. Ying S, et al. **Proc Assoc Am Physicians** 1997 Jan;109(1):42–50

Relationship between serum heat–stable neutrophil chemotactic activity during early airway reaction to allergen and the pattern of airway response (early versus late reactions) in asthmatic subjects. Dente FL, et al. **Respiration** 1997;64(4):285–90

Rush immunotherapy with house dust extract in patients with mild extrinsic asthma. Hirokawa Y, et al. **Tohoku J Exp Med** 1996 Apr;178(4):371–80

[How great is the value of oral hyposensitization in skin test assessed allergy in comparison with parenteral treatment?] Luger T. **Internist (Berl)** 1996 May;37(5):519–20 **(Ger)**

[Evaluation of the efficacy of immunotherapy with allergovit and catalet in patients with hay fever—multidrug evaluations] Hofman T, et al. **Pneumonol Alergol Pol** 1997; 65(1–2):65–70 (Eng. Abstr.) **(Pol)**

[Results of immunotherapy with Allergovit preparation of the Allergopharma Company in patients with hypersensitivity to pollen] Hofman T, et al. **Pol Merkuriusz Lek** 1996 Jul;1(1):41–2 (Eng. Abstr.) **(Pol)**

[Treatment of allergy by oral hyposensitization] Iorde V, et al. **Klin Med (Mosk)** 1996;74(4):27–9 **(Rus)**

ADVERSE EFFECTS

Nasal provocation test in the diagnostics of hairdressers' occupational rhinitis. Hytönen M, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;529:133–6

Respiratory allergy to parietaria pollen in 348 subjects. Masullo M, et al. **Allergol Immunopathol (Madr)** 1996 Jan–Feb;24(1):3–6

Sensitization to neumoallergens influence in mothers of asthmatic children. Sánchez Palacios A, et al. **Allergol Immunopathol (Madr)** 1996 Jan–Feb;24(1):7–12

Neoallergens in heated pecan nut: products of Maillard–type degradation? Berrens L. **Allergy** 1996 Apr;51(4):277–8

Allergen–irritant interaction and the role of corticosteroids. Davies RJ, et al. **Allergy** 1997;52(38 Suppl):59–65 (30 ref.)

Occupational allergy in saffron workers. Feo F, et al. **Allergy** 1997 Jun;52(6):633–41

The degree of natural allergen exposure modifies eosinophil activity markers in the circulation of patients with mild asthma. Fernvik E, et al. **Allergy** 1996 Oct;51(10):697–705

Identification of a masked allergen, alpha–lactalbumin, in baby–food cereal flour guaranteed free of cow's milk protein. Frémont S, et al. **Allergy** 1996 Oct;51(10):749–54

Anaphylactic reaction caused by neoallergens in heated pecan nut. Malanin K, et al. **Allergy** 1995 Dec;50(12):988–91

Indoor mite allergens in patients with respiratory allergy living in Porto, Portugal. Plácido JL, et al. **Allergy** 1996 Sep;51(9):633–9

The presence of latex can induce false–positive skin tests in subjects tested with penicillin determinants. Terrados S, et al. **Allergy** 1997 Feb;52(2):200–4

Natural rubber latex allergy. Turjanmaa K, et al. **Allergy** 1996 Sep;51(9):593–602 (96 ref.)

An approach to the understanding of the nasal early–phase reaction induced by nasal allergen challenge. Wang D, et al. **Allergy** 1997 Feb;52(2):162–7

Rapid expression of the CD69 antigen on T cells and natural killer cells upon antigenic stimulation of peripheral blood mononuclear cell suspensions. Werfel T, et al. **Allergy** 1997 Apr;52(4):465–9

Is the increase in asthma prevalence linked to increase in allergen load? Woolcock AJ, et al. **Allergy** 1995 Dec; 50(12):935–40 (64 ref.)

Pollen counts in the television media. Giberson JE, et al. **Allergy Asthma Proc** 1997 Jan–Feb;18(1):19–21

Safe use of natural rubber latex [editorial] Sussman GL, et al. **Allergy Asthma Proc** 1996 Mar–Apr;17(2):101–2

Contact dermatitis in the textile industry: a review of 72 patients. Soni BP, et al. **Am J Contact Dermat** 1996 Dec; 7(4):226–30 (21 ref.)

Latex allergy. Senst BL, et al. **Am J Health Syst Pharm** 1997 May 1;54(9):1071–5 (20 ref.)

Seasonal variations in house dust mite influence the circadian peak expiratory flow amplitude. Meijer GG, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):881–4

Kinetics of the development and recovery of the lung from IgE–mediated inflammation: dissociation of pulmonary eosinophilia, lung injury, and eosinophil–active cytokines. Shaver JR, et al. **Am J Respir Crit Care Med** 1997 Feb; 155(2):442–8

Bilateral increases in histamine after unilateral nasal allergen challenge. Wagenmann M, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):426–31

Inhibitory effects of BAY x 7195, a CYS leukotriene 1 receptor antagonist, on allergen–induced asthmatic responses. Boulet LP, et al. **Ann Allergy Asthma Immunol** 1997 Aug;79(2):155–61

EMLA cream for pain reduction in diagnostic allergy skin testing: effects on wheal and flare responses. Sicherer SH, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):64–8

Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen–induced rhinitis. Weido AJ, et al. **Ann Allergy Asthma Immunol** 1996 Nov;77(5):407–15

Respiratory function and immunologic status in workers processing dried fruits and teas. Zuskin E, et al. **Ann Allergy Asthma Immunol** 1996 Nov;77(5):417–22

Airborne fungus allergen in association with residential characteristics in atopic and control children in a subtropical region. Li CS, et al. **Arch Environ Health** 1997 Jan–Feb;52(1):72–9

Allergen avoidance in the primary prevention of atopy. Tariq SM. **Br J Clin Pract** 1996 Mar;50(2):99–102 (47 ref.)

The atopy patch test: an increased rate of reactivity in patients who have an air–exposed pattern of atopic eczema. Darsow U, et al. **Br J Dermatol** 1996 Aug;135(2):182–6

Allergen avoidance. Custovic A, et al. **Br J Hosp Med** 1996 Oct 16–Nov 5;56(8):409–12 (26 ref.)

Diversity of allergens causing occupational asthma among cereal workers as demonstrated by exposure procedures [see comments] Alvarez MJ, et al. **Clin Exp Allergy** 1996 Feb;26(2):147–53. Comment in: Clin Exp Allergy 1996 Feb;26(2):128–31.

Heating inactivates the enzymatic activity and partially inactivates the allergenic activity of Asp o 2. Baur X, et al. **Clin Exp Allergy** 1996 Feb;26(2):232–4

Human late asthmatic reactions. Bentley AM, et al. **Clin Exp Allergy** 1997 May;27 Suppl 1:71–86 (159 ref.)

Comparative degree and type of sensitization to common indoor and outdoor allergens in subjects with allergic rhinitis and/or asthma. Boulet LP, et al. **Clin Exp Allergy** 1997 Jan;27(1):52–9

Allergen–induced CD30 expression on T cells of atopic asthmatics. Leonard C, et al. **Clin Exp Allergy** 1997 Jul; 27(7):780–6

Oilseed rape sensitivity [editorial] McSharry C. **Clin Exp Allergy** 1997 Feb;27(2):125–7

Major Dermatophagoides mite allergen, Der 1, in soft toys. Nagakura T, et al. **Clin Exp Allergy** 1996 May;26(5):585–9

House dust mite allergy in Southern Africa—historical perspective and current status. Potter PC, et al. **Clin Exp Allergy** 1996 Feb;26(2):132–7 (26 ref.)

Pollen allergy in South Africa. Potter PC, et al. **Clin Exp Allergy** 1996 Dec;26(12):1347–54 (28 ref.)

Cereal–induced occupational asthma [editorial; comment] Sandiford CP. **Clin Exp Allergy** 1996 Feb;26(2):128–31. Comment on: Clin Exp Allergy 1996 Feb;26(2):147–53. Comment on: Clin Exp Allergy 1996 Feb;26(2):154–63.

Sibship size and self–reported inhalant allergy among adult women. ALSPAC Study Team. Strachan DP, et al. **Clin Exp Allergy** 1997 Feb;27(2):151–5

Asthma and anaphylaxis induced by royal jelly. Thien FC, et al. **Clin Exp Allergy** 1996 Feb;26(2):216–22

Thunderstorm–related asthma—the epidemic of 24/25 June 1994. Venables KM, et al. **Clin Exp Allergy** 1997 Jul; 27(7):725–36

A combined approach to reduce mite allergen in the bedroom. Weeks J, et al. **Clin Exp Allergy** 1995 Dec; 25(12):1179–83

Oxygen radical production by blood eosinophils is reduced during birch pollen season in allergic patients. Woschnagg C, et al. **Clin Exp Allergy** 1996 Sep;26(9):1064–72

Occupational allergic contact dermatitis caused by Euxyl K 400. Aalto–Korte K, et al. **Contact Dermatitis** 1996 Sep; 35(3):193–4

Contact allergy to aeroallergens in children with atopic dermatitis: comparison with allergic contact dermatitis. Cabon N, et al. **Contact Dermatitis** 1996 Jul;35(1):27–32

Threshold for occluded formaldehyde patch test in formaldehyde–sensitive patients. Relationship to repeated open application test with a product containing formaldehyde releaser. Flyvholm MA, et al. **Contact Dermatitis** 1997 Jan;36(1):26–33

Side–effects during treatment with SADBE. Frattasio A, et al. **Contact Dermatitis** 1997 Feb;36(2):118–9

The effect of topically applied corticosteroid on irritant and allergic patch test reactions. Green C. **Contact Dermatitis** 1996 Dec;35(6):331–3

Delayed and immediate allergy caused by methylhexahydrophthalic anhydride. Kanerva L, et al. **Contact Dermatitis** 1997 Jan;36(1):34–8

Airborne eczema due to mould allergy. Kanny G, et al. **Contact Dermatitis** 1996 Dec;35(6):378

Patch tests in children: a review of 14 years experience. Katsarou A, et al. **Contact Dermatitis** 1996 Jan;34(1):70–1 (9 ref.)

Contact allergy to diethylthiourea in a wet suit. Kerre S, et al. **Contact Dermatitis** 1996 Sep;35(3):176–8

Reactions to formaldehyde and formaldehyde releasers in a standard series. Kränke B, et al. **Contact Dermatitis** 1996 Sep;35(3):192–3

A proposed relevance scoring system for positive allergic patch test reactions: practical implications and limitations. Lachapelle JM. **Contact Dermatitis** 1997 Jan;36(1):39–43

The major allergen of Dendropanax trifidus Makino. Oka K, et al. **Contact Dermatitis** 1997 May;36(5):252–5

Corticosteroid allergy: report of 3 unusually acute cases. Rodríguez–Serna M, et al. **Contact Dermatitis** 1996 Dec; 35(6):361–2

Footwear contact dermatitis in children. Roul S, et al. **Contact Dermatitis** 1996 Dec;35(6):334–6

Contact dermatitis in children. Rudzki E, et al. **Contact Dermatitis** 1996 Jan;34(1):66–7

Day 4 is better than day 3 for a single patch test reading. Todd DJ, et al. **Contact Dermatitis** 1996 Jun;34(6):402–4

Sorbitan mono–oleate: a potential allergen in paste bandages. Wakelin SH, et al. **Contact Dermatitis** 1996 Dec;35(6):377

Patch testing with beryllium alloy samples in guinea pigs. Zissu D, et al. **Contact Dermatitis** 1996 Mar;34(3):196–200

Allergy caused by acrylics: past, present and prevention. Kanerva L, et al. **Curr Probl Dermatol** 1996;25:86–96 (30 ref.)

Glove powder—a risk factor for the development of latex allergy? Brehler R, et al. **Eur J Surg Suppl** 1997;(579):23–5

Type I allergies to latex and the aeroallergenic problem. Heese A, et al. **Eur J Surg Suppl** 1997;(579):19–22 (14 ref.)

Early and late allergic reaction in the nose assessed by whole body plethysmography. de Bruin–Weller MS, et al. **Eur Respir J** 1996 Aug;9(8):1701–6

Effect of the 21–aminosteroid U–74006F on antigen–induced bronchoconstriction and bronchoalveolar eosinophilia in

allergic sheep. Fujimoto K, et al. **Eur Respir J** 1996 Oct; 9(10):2044–9

Prevalence and intensity of rhinoconjunctivitis in subjects with occupational asthma. Malo JL, et al. **Eur Respir J** 1997 Jul;10(7):1513–5

Allergic alveolitis following exposure to epoxy polyester powder paint containing low amounts (<1%) of acid anhydrides. Piirilä P, et al. **Eur Respir J** 1997 Apr; 10(4):948–51

Asthmatic bronchial hyperresponsiveness varies with ambient levels of summertime air pollution. Taggart SC, et al. **Eur Respir J** 1996 Jun;9(6):1146–54

The local lymph node assay: status of validation. Chamberlain M, et al. **Food Chem Toxicol** 1996 Oct;34(10):999–1002 (20 ref.)

Evaluating clinical case report data for SAR modeling of allergic contact dermatitis. Gealy R, et al. **Hum Exp Toxicol** 1996 Jun;15(6):489–93

Experimental asthma developed by room air contamination with cockroach allergen. Kang BC, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):299–306

The 'traveling salesman problem': a new approach for identification of differences among pollen allergens. Kosman E, et al. **Int Arch Allergy Immunol** 1997 Apr; 112(4):371–7

Oleaceae pollinosis: a review. Liccardi G, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):210–7 (67 ref.)

Evaluation of cutaneous reactivity to recently marketed dermatologic products. Shelanski MV, et al. **Int J Dermatol** 1996 Feb;35(2):137–40

Asthma caused by Dermestidae (black carpet beetle): a new allergen in house dust. Cuesta-Herranz J, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):147–9

Exposure to indoor allergens in early infancy and sensitization. Munir AK, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):177–81

False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens. van der Veen MJ, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1028–34

Indoor allergen exposure is a risk factor for sensitization during the first three years of life. Wahn U, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):763–9

Methyldibromoglutaronitrile (Euxyl K 400): an important "new" allergen in cosmetics. De Groot AC, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):743–7 (35 ref.)

The role of allergy in the pathogenesis of atopic dermatitis [letter; comment] Langeveld-Wildschut A, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):280–1. Comment on: J Am Acad Dermatol 1995 Dec;33(6):1008–18.

Intradermal reactivity to various insect and arachnid allergens among dogs from the southeastern United States. Willis EL, et al. **J Am Vet Med Assoc** 1996 Oct 15; 209(8):1431–4

Annual and diurnal incidence of Cladosporium conidia in the atmosphere of Córdoba, Spain. Mediavilla Molina A, et al. **J Investig Allergol Clin Immunol** 1997 May-Jun; 7(3):179–82

Mite sensitivity and exposure in the city of Santa Fe, Argentina. Neffen HE, et al. **J Investig Allergol Clin Immunol** 1996 Sep-Oct;6(5):278–82

Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. Ragusa FV, et al. **J Investig Allergol Clin Immunol** 1997 May-Jun;7(3):151–4

Total serum IgE in trimellitic anhydride-induced asthma. Backman KS, et al. **J Occup Environ Med** 1996 Apr; 38(4):347–51

A discussion of the environmental influences on asthma and the role of Environmental Health Officers in combating it. Griffiths SD. **J R Soc Health** 1996 Aug;116(4):223–9

Abnormal modulation of cholinergic neurotransmission by endogenous nitric oxide in the bronchus of rats with hyperresponsiveness induced by allergen challenge. Misawa M, et al. **Jpn J Pharmacol** 1997 Feb;73(2):125–32

Quantitative cytology of nasal secretions and scrapings in Japanese cedar pollinosis patients. Takeuchi K, et al. **Laryngoscope** 1996 Nov;106(11):1419–23

Skinprick-test sensitivity to olive pollen [letter] Bateman PP. **Med J Aust** 1997 Mar 3;166(5):279–80

Allergen-induced airways inflammation in asthma. Robinson DS. **Monaldi Arch Chest Dis** 1996 Dec;51(6):469–74 (81 ref.)

Asthma and indoor exposure to allergens [editorial; comment] Platts-Mills TA, et al. **N Engl J Med** 1997 May 8; 336(19):1382–4. Comment on: N Engl J Med 1997 May 8;336(19):1356–63.

The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma [see comments] Rosenstreich DL, et al. **N Engl J Med** 1997 May 8;336(19):1356–63. Comment in: N Engl J Med 1997 May 8;336(19):1382–4.

Retrospective survey of a link between cat and dog antigens and allergic conjuctivitis. Fujishima H, et al. **Ophthalmologica** 1996;210(2):115–8

House dust mite exposure in asthmatic and healthy children: the difference is carpeting. Meijer GG, et al. **Pediatr Allergy Immunol** 1995 Nov;6(4):187–91

Prenatal contact with inhalant allergens. Van Duren-Schmidt K, et al. **Pediatr Res** 1997 Jan;41(1):128–31

Bronchial and alveolar allergen-induced anaphylaxis and the stimulation of bronchial mucociliary clearance in ragweed-sensitized dogs. Yeates DB, et al. **Proc Assoc Am Physicians** 1997 Jul;109(4):440–52

Multiple chemical sensitivity: state of the art symposium. The role of chemical allergens. Bernstein DI. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 2):S28–31 (18 ref.)

Death due to asthma at workplace in a diphenylmethane diisocyanate-sensitized subject. Carino M, et al. **Respiration** 1997;64(1):111–3 (16 ref.)

Lymphocyte activation markers in peripheral blood before and after natural exposure to allergen in asthmatic patients. Majori M, et al. **Respiration** 1997;64(1):45–9

Climate and aeroallergen levels in asthma: a 12 month prospective study. Epton MJ, et al. **Thorax** 1997 Jun; 52(6):528–34

Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma [see comments] Evans DJ, et al. **Thorax** 1996 Dec;51(12):1178–84. Comment in: Thorax 1996 Dec;51(12):1171–3.

Effect of allergen challenge on airway responsiveness to histamine and sodium metabisulphite in mild asthma. Evans DJ, et al. **Thorax** 1996 Dec;51(12):1185–91

Cooking and freezing may not protect against allergenic reactions to ingested Anisakis simplex antigens in humans. Audicana L, et al. **Vet Rec** 1997 Mar 1;140(9):235

[Questions about transgenic foods--importance and/or dangers-- importance of research on unexpected cross-reactions] Sabbah A. **Allerg Immunol (Paris)** 1996 Oct;28(8):288–9 (0 ref.) **(Fre)**

[Portable emergency kits prescribed for patients allergic to hymenoptera venoms] Wessel F. **Allerg Immunol (Paris)** 1996 Oct;28(8):282–7 (Eng. Abstr.) **(Fre)**

[Different threshold concentrations for sensitization by cattle hair allergen Bos d 2 in atopic and non-atopic farmers] Hinze S, et al. **Pneumologie** 1996 Feb;50(2):177–81 (Eng. Abstr.) **(Ger)**

[Allergy to synanthropic ticks] Mokronosova MA, et al. **Klin Med (Mosk)** 1997;75(1):19–21 (39 ref.) **(Rus)**

[Soy-seed asthma epidemics in small cities (letter)] García-Ortega P, et al. **Med Clin (Barc)** 1997 May 3; 108(17):677 **(Spa)**

[Eosinophilic gastroenteritis caused by bee pollen sensitization] Puente S, et al. **Med Clin (Barc)** 1997 May 10;108(18):698–700 (Eng. Abstr.) **(Spa)**

[Pollution and indoor allergens in respiratory allergy (editorial)] Peréz-Martín J. **Rev Alerg Mex** 1993 Sep-Oct; 40(5):107–9 **(Spa)**

[Hypersensitivity to common allergens in the central region of Coahuila] Ramos Morín CJ, et al. **Rev Alerg Mex** 1993 Nov-Dec;40(6):150–4 (22 ref.) (Eng. Abstr.) **(Spa)**

[Exposure to pollutants and allergens in the asthmatic child compared with the healthy child] Sarrazola Sanjuan DM, et al. **Rev Alerg Mex** 1997 Jan-Feb;44(1):13–6 (Eng. Abstr.) **(Spa)**

ANALYSIS

Allergenic proteins in different brands of latex and synthetic medical examination gloves. Hoeyveld EM, et al. **Acta Clin Belg** 1997;52(2):99–105

Protein and allergen content of various natural latex articles. Baur X, et al. **Allergy** 1997 Jun;52(6):661–4

Dust-mite-allergen concentrations in asthmatics' bedrooms in the Quad Cities (Illinois, USA) after the Mississippi River floods of 1993. Curtis L, et al. **Allergy** 1997 Jun;52(6):642–9

House-dust mite allergen Der p 1: amount or concentration? Doull IJ, et al. **Allergy** 1997 Feb;52(2):220–3

Further characterization of IgE-binding antigens in horse dander, with particular emphasis on glycoprotein allergens. Johnsen, et al. **Allergy** 1996 Sep;51(9):608–13

Measurement of mite allergen in the environment. Kuehr J. **Allergy** 1997 Apr;52(4):380–2 (22 ref.)

Indoor mite allergens in patients with respiratory allergy living in Porto, Portugal. Plácido JL, et al. **Allergy** 1996 Sep;51(9):633–9

Latex allergy diagnosis: in vivo and in vitro standardization of a natural rubber latex extract. Turjanmaa K, et al. **Allergy** 1997 Jan;52(1):41–50

Analytic aspects of the standardization of allergenic extracts. van Ree R. **Allergy** 1997 Aug;52(8):795–805 (167 ref.)

Cockroach allergen in house dust. van Wijnen JH, et al. **Allergy** 1997 Apr;52(4):460–4

Distribution of Dermatophagoides spp., D. farinae and D. pteronyssinus, antigen in homes of patients with asthma in eastern Massachusetts. Hannaway PJ, et al. **Allergy Asthma Proc** 1997 May-Jun;18(3):177–80

Aerodynamic properties of the major dog allergen Can f 1: distribution in homes, concentration, and particle size of allergen in the air. Custovic A, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):94–8

Evaluation of four bioaerosol samplers in the outdoor environment. Cage BR, et al. **Ann Allergy Asthma Immunol** 1996 Nov;77(5):401–6

A comparison of pollen recovery by three models of the Rotorod sampler. Frenz DA, et al. **Ann Allergy Asthma Immunol** 1997 Sep;79(3):256–8

House dust mite allergen in pillows [see comments] Kemp TJ, et al. **BMJ** 1996 Oct 12;313(7062):916. Comment in: BMJ 1997 Feb 15;314(7079):518.

Domestic allergens in public places. II: Dog (Can f1) and cockroach (Bla g 2) allergens in dust and mite, cat, dog and cockroach allergens in the air in public buildings [see comments] Custovic A, et al. **Clin Exp Allergy** 1996 Nov; 26(11):1246–52. Comment in: Clin Exp Allergy 1996 Nov;26(11):1225–7.

Fel d I levels in cat anal glands. De Andrade AD, et al. **Clin Exp Allergy** 1996 Feb;26(2):178–80

Reduction in humidity as a method of controlling mites and mite allergens: the use of mechanical ventilation in British domestic dwellings. Fletcher AM, et al. **Clin Exp Allergy** 1996 Sep;26(9):1051–6

The characterization of allergens [editorial] Frankland AW. **Clin Exp Allergy** 1996 Aug;26(8):865–7

A clinical evaluation in children of the Pharmacia ImmunoCAP system for inhalant allergens. Gleeson M, et al. **Clin Exp Allergy** 1996 Jun;26(6):697–702

Reduction of exposure to laboratory animal allergens in the workplace. Gordon S, et al. **Clin Exp Allergy** 1997 Jul; 27(7):744–51

Analysis of the allergenic composition of rat dust. Gordon S, et al. **Clin Exp Allergy** 1996 May;26(5):533–41

Oilseed rape pollen is a potentially relevant allergen. Hemmer W, et al. **Clin Exp Allergy** 1997 Feb;27(2):156–61

The importance of domestic allergens in a tropical environment [editorial; comment] Leung R, et al. **Clin Exp Allergy** 1997 Aug;27(8):856–9. Comment on: Clin Exp Allergy 1997 Aug;27(8):876–85.

Detection of snow-crab antigens by air sampling of a snow-crab production plant. Malo JL, et al. **Clin Exp Allergy** 1997 Jan;27(1):75–8

Variability and repeatability of house dust mite allergen measurement: implications for study design and interpretation. Marks GB, et al. **Clin Exp Allergy** 1995 Dec; 25(12):1190–7

Latex allergy: allergen identification in Hevea braziliensis fractions by immunoblotting. Muguerza J, et al. **Clin Exp Allergy** 1996 Oct;26(10):1177–81

Major Dermatophagoides mite allergen, Der 1, in soft toys. Nagakura T, et al. **Clin Exp Allergy** 1996 May;26(5):585–9

Determination of the stability of diluted allergen extracts using a concentration step prior to EAST inhibition. Niemeijer NR, et al. **Clin Exp Allergy** 1996 Aug;26(8):953–6

Stability of cereal allergens. Varjonen E, et al. **Clin Exp Allergy** 1996 Apr;26(4):436–43

Design of an optimally-diagnostic skin test solution for diagnosis of sensitivity to timothy grass (Phleum pratense) pollen. Wheeler AW, et al. **Clin Exp Allergy** 1996 Aug; 26(8):897–902

Prevalence and distribution of indoor allergens in Singapore [see comments] Zhang L, et al. **Clin Exp Allergy** 1997 Aug; 27(8):876–85. Comment in: Clin Exp Allergy 1997 Aug;27(8):856–9.

Natural ingredients based cosmetics. Content of selected fragrance sensitizers. Rastogi SC, et al. **Contact Dermatitis** 1996 Jun;34(6):423–6

Secondary prevention: detection of the allergen. Karlberg AT, et al. **Curr Probl Dermatol** 1996;25:145–53 (18 ref.)

Comparison of natural and recombinant isoforms of grass pollen allergens. Petersen A, et al. **Electrophoresis** 1997 May;18(5):819–25

Identification and characterization of wheat grain albumin/globulin allergens. Weiss W, et al. **Electrophoresis** 1997 May;18(5):826–33

Latex allergens in tire dust and airborne particles. Miguel AG, et al. **Environ Health Perspect** 1996 Nov; 104(11):1180–6

Immunocytochemical localization of allergenic proteins in Parietaria judaica L. (Urticaceae) pollen grains. Casas C, et al. **Eur J Cell Biol** 1996 Jun;70(2):179–88

Airborne particles from latex gloves in the hospital environment. Newsom SW, et al. **Eur J Surg Suppl** 1997; (579):31–3

The local lymph node assay: a viable alternative to currently accepted skin sensitization tests. Basketter DA, et al. **Food Chem Toxicol** 1996 Oct;34(10):985–97 (70 ref.)

Characterization of Ara h 1 by two-dimensional electrophoresis immunoblot and recombinant techniques: new digestion experiments with peanuts imitating the gastrointestinal tract. Becker WM. **Int Arch Allergy Immunol** 1997 May-Jul;113(1-3):118–21

Cow hair allergen (Bos d 2) content in house dust: correlation with sensitization in farmers with cow hair asthma. Hinze S, et al. **Int Arch Allergy Immunol** 1997 Mar;112(3):231–7

Clothing is a carrier of cat allergens. D'Amato G, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):577–8

Dust and airborne exposure to allergens derived from cockroach (Blattella germanica) in low-cost public housing in Strasbourg (France). de Blay F, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):107–12

Airborne levels of alpha-amylase allergens in bakeries. Houba R, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):286–92

Quantification of the major brown shrimp allergen Pen a 1 (tropomyosin) by a monoclonal antibody-based sandwich ELISA. Jeoung BJ, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):229–34

Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. Laffer S, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):652–8

Identification of the allergenic components of kiwi fruit and evaluation of their cross-reactivity with timothy and birch pollens. Pastorello EA, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):601–10

The role of mattress bases in the mite infestation of dwellings. Pauli G, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):261–3

Cross-reactivity of skin and serum specific IgE responses and allergen analysis for three mosquito species with worldwide distribution. Peng Z, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):192–8

Carrot-induced asthma: immunodetection of allergens. Quirce S, et al. **J Allergy Clin Immunol** 1997 May; 99(5):718–9

Cockroach allergen (Bla g 1) in school dust. Sarpong SB, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):486–92

House dust mite allergen levels in public places in New Zealand. Wickens K, et al. **J Allergy Clin Immunol** 1997 May;99(5):587–93

Size-exclusion liquid chromatography and capillary electrophoresis of pollen allergens. Pacáková V, et al. **J Chromatogr B Biomed Appl** 1996 May 31;681(1):47–53

The protein content of dental rubber dams. Martin KM, et al. **J Dent** 1997 May-Jul;25(3–4):347–50

Sequential determinations of Dermatophagoides spp. allergens in a tropical city. Fernández-Caldas E, et al. **J Investig Allergol Clin Immunol** 1996 Mar–Apr;6(2):98–102

Partial characterization of the silk allergens in mulberry silk extract. Zaoming W, et al. **J Investig Allergol Clin Immunol** 1996 Jul–Aug;6(4):237–41

Spetial and temporal distribution of house dust mite (Astigmata:Pyroglyphidae) allergens Der p 1 and Der f 1 in Barbadian homes. Barnes KC, et al. **J Med Entomol** 1997 Mar;34(2):212–8

Environmental allergen analyses. Hamilton RG, et al. **Methods** 1997 Sep;13(1):53–60

Allergenicity of foods derived from transgenic plants. Astwood JD, et al. **Monogr Allergy** 1996;32:105–20

Identification of allergens in apple, pear, celery, carrot and potato: cross-reactivity with pollen allergens. Ebner C, et al. **Monogr Allergy** 1996;32:73–7 (21 ref.)

Chemical composition and structure of food constituents: defining allergenic potential. Miller K, et al. **Monogr Allergy** 1996;32:100–4

Optimization, standardization and control of food allergens. Niemeijer NR, et al. **Monogr Allergy** 1996;32:50–6 (20 ref.)

Cross-reacting allergens in clinical syndromes. Pastorello EA, et al. **Monogr Allergy** 1996;32:57–62 (22 ref.)

Specific IgG antibodies as markers of adverse reactions to food. Contra! Wüthrich B. **Monogr Allergy** 1996;32:226–7 (10 ref.)

House dust mite and cat allergen levels in domestic dwellings in Christchurch. Martin IR, et al. **N Z Med J** 1997 Jun 27;110(1046):229–31

Application of an electrophoretic methodology for the identification of low molecular weight proteins in foods. Dean TP, et al. **Pediatr Allergy Immunol** 1996 Nov; 7(4):171–5

House dust mite exposure in asthmatic and healthy children: the difference is carpeting. Meijer GG, et al. **Pediatr Allergy Immunol** 1995 Nov;6(4):187–91

Childhood asthma and exposure to indoor allergens: low mite levels are associated with sensitivity. Warner AM, et al. **Pediatr Allergy Immunol** 1996 May;7(2):61–7

Plant allergens: a chemical perspective. Rowan MG. **Semin Dermatol** 1996 Jun;15(2):103–12 (19 ref.)

[Association between air pollen concentrations and seasonal allergies: synthesis of epidemiological studies published between 1978 and 1995] Quénel P, et al. **Rev Epidemiol Sante Publique** 1997 Jun;45(3):224–36 (41 ref.) (Eng. Abstr.) **(Fre)**

[Room air allergens: clinical significance, detection and prevention] Müsken H. **Pneumologie** 1996 Feb;50(2):168–76 (119 ref.) **(Ger)**

[Major feline antigen—Fel d I clinical aspects] Zielonka TM. **Pneumonol Alergol Pol** 1996;64(7–8):505–14 (38 ref.) **(Pol)**

BIOSYNTHESIS

Production of a recombinant protein from Alternaria containing the reported N-terminal of the Alt a1 allergen. Barnes CS, et al. **Adv Exp Med Biol** 1996;409:197–203

Identification, cloning, and sequence of a major allergen (Hev b 5) from natural rubber latex (Hevea brasiliensis). Slater JE, et al. **J Biol Chem** 1996 Oct 11;271(41):25394–9

High-level expression and purification of the major birch pollen allergen, Bet v 1. Hoffmann-Sommergruber K, et al. **Protein Expr Purif** 1997 Feb;9(1):33–9

Characterization of purified recombinant Bet v 1 with authentic N-terminus, cloned in fusion with maltose-binding protein. Spangfort MD, et al. **Protein Expr Purif** 1996 Nov;8(3):365–73

BLOOD

Depletion of circulating allergen-specific TH2 T lymphocytes after allergen exposure in asthma. Crimi E, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):788–97

Dichotomy of blood- and skin-derived IL-4-producing allergen-specific T cells and restricted V beta repertoire in nickel-mediated contact dermatitis. Werfel T, et al. **J Immunol** 1997 Mar 1;158(5):2500–5

CHEMISTRY

The effect of sucrose on the quality of ryegrass (Lolium perenne) pollen extracts. Cadot P, et al. **Allergy** 1995 Dec; 50(12):941–51

Molecular analysis of allergenic proteins in bovine dander. Rautiainen J, et al. **Allergy** 1996 Jun;51(6):378–82

Heating inactivates the enzymatic activity and partially inactivates the allergenic activity of Asp o 2. Baur X, et al. **Clin Exp Allergy** 1996 Feb;26(2):232–4

Allergenic and antigenic determinants of latex allergen Hev b 1: peptide mapping of epitopes recognized by human, murine and rabbit antibodies. Chen Z, et al. **Clin Exp Allergy** 1996 Apr;26(4):406–15

Characterization of a dominant antigenic determinant of Par o I encoded by recombinant DNA. D'Abusco AS, et al. **Clin Exp Allergy** 1996 Feb;26(2):223–31

Review: the biochemistry of common aeroallergens. C. A. Stewart and P. J. Thompson, September 1996; 26:1020–44 [letter; comment] Gordon S, et al. **Clin Exp Allergy** 1997 Jun;27(6):714–5. Comment on: Clin Exp Allergy 1996 Sep;26(9):1020–44.

Major grass pollen allergen Lol p 1 binds to diesel exhaust particles: implications for asthma and air pollution. Knox RB, et al. **Clin Exp Allergy** 1997 Mar;27(3):246–51

Detection, isolation and complete amino acid sequence of an aeroallergenic protein from rapeseed flour. Monsalve RI, et al. **Clin Exp Allergy** 1997 Jul;27(7):833–41

The biochemistry of common aeroallergens [see comments] Stewart GA, et al. **Clin Exp Allergy** 1996 Sep;26(9):1020–44 (151 ref.). Comment in: Clin Exp Allergy 1997 Jun;27(6):714–5.

Influence of culture period on the allergenic composition of Pityrosporum orbiculare extracts. Zargari A, et al. **Clin Exp Allergy** 1995 Dec;25(12):1235–45

QSAR predictive of contact allergy: scope and limitations. Hostýnek JJ, et al. **Curr Probl Dermatol** 1996;25:18–27 (34 ref.)

The complete cDNA sequence and expression of the first major allergenic protein of Malassezia furfur, Mal f 1. Schmidt M, et al. **Eur J Biochem** 1997 May 15;246(1):181–5

Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation. Thompson CD, et al. **Exp Eye Res** 1997 May;64(5):767–73

Primary structure and allergenic activity of trypsin inhibitors from the seeds of buckwheat (Fagopyrum esculentum Moench). Park SS, et al. **FEBS Lett** 1997 Jan 2;400(1):103–7

Cloning and expression pattern of Hor v 9, the group 9 pollen isoallergen from barley. Astwood JD, et al. **Gene** 1996 Dec 5;182(1–2):53–62

Chromosomal location of three wheat sequences with homology to pollen allergen encoding, DNA replication regulating, and DNA (cytosine-5)-methyltransferase genes in wheat and rye. Korzun V, et al. **Genome** 1996 Dec; 39(6):1213–5

Immunological and structural similarities among allergens: prerequisite for a specific and component-based therapy of allergy. Valenta R, et al. **Immunol Cell Biol** 1996 Apr; 74(2):187–94 (58 ref.)

X-ray crystal structures of birch pollen profilin and Phl p 2. Fedorov AA, et al. **Int Arch Allergy Immunol** 1997 May-Jul;113(1–3):109–13

Three-dimensional structure and epitopes of Bet v 1. Spangfort MD, et al. **Int Arch Allergy Immunol** 1997 May-Jul;113(1–3):243–5

Mercurialis annua: characterization of main allergens and cross-reactivity with other species. Vallverdú A, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):356–64

Zygophyllum fabago L: a new source of allergenic pollen. Belchí-Hernández J, et al. J **Allergy Clin Immunol** 1997 Apr;99(4):493–6

Characterization of Dac g 4, a major basic allergen from Dactylis glomerata pollen. Leduc-Brodard V, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1065–72

Absence of modification of endogenous soy allergens [letter; comment] Moneret-Vautrin DA, et al. **J Allergy Clin Immunol** 1996 Oct;98(4):854–5. Comment on: J Allergy Clin Immunol 1995 Dec;96(6 Pt 1):1008–10.

Characterization of the allergens of the house dust mite Euroglyphus maynei. Morgan MS, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):222–8

BDA20, a major bovine dander allergen characterized at the sequence level, is Bos d 2. Rautiainen J, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):251–2

Mapping of IgE-binding epitopes on the recombinant major group I allergen of velvet grass pollen, rHol l 1. Schramm G, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):781–7

A novel acidic allergen, Hev b 5, in latex. Purification, cloning and characterization. Akasawa A, et al. **J Biol Chem** 1996 Oct 11;271(41):25389–93

Crystallization and preliminary diffraction data of a major pollen allergen. Crystal growth separates a low molecular weight form with elevated biological activity. Bufe A, et al. **J Biol Chem** 1996 Nov 1;271(44):27193–6

The carbohydrate moiety of the bermuda grass antigen BG60. New oligosaccharides of plant origin. Ohsuga H, et al. **J Biol Chem** 1996 Oct 25;271(43):26653–8

Size-exclusion liquid chromatography and capillary electrophoresis of pollen allergens. Pacáková V, et al. **J Chromatogr B Biomed Appl** 1996 May 31;681(1):47–53

Major histocompatibility complex-independent recognition of a distinctive pollen antigen, most likely a carbohydrate, by human CD8+ alpha/beta T cells. Corinti S, et al. **J Exp Med** 1997 Sep 15;186(6):899–908

Sequencing and immunochemical characterization of the American cockroach per a 3 (Cr-PI) isoallergenic variants. Wu CH, et al. **Mol Immunol** 1997 Jan;34(1):1–8

Chemical composition and structure of food constituents: defining allergenic potential. Miller K, et al. **Monogr Allergy** 1996;32:100–4

Characterization of Mal d 1, the 18-kD major apple allergen, at the molecular level. Vieths S, et al. **Monogr Allergy** 1996; 32:63–72 (28 ref.)

X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Gajhede M, et al. **Nat Struct Biol** 1996 Dec; 3(12):1040–5

Structural characteristics of the Ascaris allergen, ABA-1. McGibbon AM, et al. **Parasite** 1995 Mar;2(1):41–8

Group I allergens of grass pollen as cell wall-loosening agents. Cosgrove DJ, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6559–64

Crystallization and preliminary X-ray investigation at 2.0 A resolution of Bet v 1, a birch pollen protein causing IgE-mediated allergy. Spangfort MD, et al. **Proteins** 1996 Nov;26(3):358–60

[Molecular biological analysis of house dust mite allergens] Okudaira H, et al. **Nippon Rinsho** 1996 Feb;54(2):466–71 (10 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

The characterization of allergens [editorial] Frankland AW. **Clin Exp Allergy** 1996 Aug;26(8):865–7

Dynamic patterns of allergic patch test reactions to 10 European standard allergens. An analysis of data recorded by the Information Network of Departments of Dermatology (IVDK). Brasch J, et al. **Contact Dermatitis** 1996 Jul;35(1):17–22

Interlaboratory evaluation of a human patch test for the identification of skin irritation potential/hazard. Griffiths HA, et al. **Food Chem Toxicol** 1997 Feb;35(2):255–60

Classification of chemical allergens according to cytokine secretion profiles of murine lymph node cells. Dearman RJ, et al. **J Appl Toxicol** 1997 Jan-Feb;17(1):53–62

DIAGNOSTIC USE

Diagnostic and therapeutic use of recombinant allergens. Kraft D. **Adv Exp Med Biol** 1996;409:471–4 (10 ref.)

Nasal response to allergen challenge in patients with immediate asthmatic reaction. Palczynski C, et al. **Allergol Immunopathol (Madr)** 1996 Jul-Aug;24(4):163–8

Recombinant mite allergens. New technologies for the management of patients with asthma. Chapman MD, et al. **Allergy** 1997 Apr;52(4):374–9 (34 ref.)

Efficacy of mequitazine in comparison with placebo assessed by ocular challenge with allergen in allergic conjunctivitis. Persi L, et al. **Allergy** 1997 Apr;52(4):451–4

Late phase response during nasal challenge: effect of astemizole on leukotriene B4 levels. Kumar NS, et al. **Allergy Asthma Proc** 1996 Mar-Apr;17(2):93–9

Effect of systemic corticoid and antihistamine alone or in combination on elements of the response to a two dose nasal allergen challenge. Brooks CD, et al. **Am J Rhinol** 1997 Mar-Apr;11(2):117–22

Evaluation of patch testing in patients with chronic vulvar symptoms. Brenan JA, et al. **Australas J Dermatol** 1996 Feb;37(1):40–3

Allergic contact dermatitis to plants: an analysis of 68 patients tested at the Skin and Cancer Foundation. Cook DK, et al. **Australas J Dermatol** 1997 Aug;38(3):129–31

Gramineae pollen as trigger factors of atopic eczema: evaluation of diagnostic measures using the atopy patch test. Darsow U, et al. **Br J Dermatol** 1997 Aug;137(2):201–7

Patch testing with a combination of unrelated allergens: a new strategy. McLelland J, et al. **Br J Dermatol** 1996 Oct; 135(4):566–71

Increased specificity of diagnostic tests with recombinant major bee venom allergen phospholipase A2. Müller U, et al. **Clin Exp Allergy** 1997 Aug;27(8):915–20

Design of an optimally-diagnostic skin test solution for diagnosis of sensitivity to timothy grass (Phleum pratense) pollen. Wheeler AW, et al. **Clin Exp Allergy** 1996 Aug; 26(8):897–902

An interlaboratory evaluation of the Buehler test for the identification and classification of skin sensitizers. Basketter DA, et al. **Contact Dermatitis** 1996 Sep;35(3):146–51

The value and limitations of rechallenge in the guinea pig maximization test. Frankild S, et al. **Contact Dermatitis** 1996 Sep;35(3):135–40 (45 ref.)

What is new in clinical research in contact dermatitis. Cohen DE, et al. **Dermatol Clin** 1997 Jan;15(1):137–48 (53 ref.)

Colonoscopic allergen provocation (COLAP): a new diagnostic approach for gastrointestinal food allergy. Bischoff SC, et al. **Gut** 1997 Jun;40(6):745–53

Skin test reactivity to recombinant Aspergillus fumigatus allergen I/a in patients with cystic fibrosis. Nikolaizik WH, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):403–8

Improving the safety of conjunctival provocation tests [letter; comment] Anderson DF, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):1000. Comment on: J Allergy Clin Immunol 1990 Dec;86(6 Pt 1):869–76. Comment on: J Allergy Clin Immunol 1993 Jul;92(1 Pt 1):49–55. Comment on: J Allergy Clin Immunol 1995 Feb;95(2):612–21.

Long-term oral corticosteroid therapy does not alter the results of immediate-type allergy skin prick tests. Des Roches A, et al. **J Allergy Clin Immunol** 1996 Sep; 98(3):522–7

Natural rubber latex skin testing reagents: safety and diagnostic accuracy of nonammoniated latex, ammoniated latex, and latex rubber glove extracts. Hamilton RG, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):872–83

Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen. Hammann C, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1045–50

A simple method to evaluate basophil tryptase after allergen challenge in vitro. Monasterolo G, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):575–6

Aeroallergen patch testing for patients presenting to contact dermatitis clinics. Whitmore SE, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):700–4

Bronchial and bronchoalveolar inflammation in single early and dual responders after allergen inhalation challenge. Silvestri M, et al. **Lung** 1997;175(4):277–85

Nasal responsiveness to allergen and histamine in patients with perennial rhinitis with and without a late phase response. de Graaf-in't Veld C, et al. **Thorax** 1997 Feb; 52(2):143–8

[Skin prick tests with allergens in general practice] Olsen OF. **Ugeskr Laeger** 1996 Nov 18;158(47):6771–4 (Eng. Abstr.) **(Dan)**

[Contribution of flow cytometry to allergologic diagnosis] Sabbah A, et al. **Allerg Immunol (Paris)** 1997 Jan; 29(1):15–21 (Eng. Abstr.) **(Fre)**

[Recombinant allergens and their potential in allergologic diagnosis] Crameri R, et al. **Pneumologie** 1996 Jun; 50(6):387–93 (84 ref.) **(Ger)**

[Bronchial inhalation challenge with antigens] Tohda Y, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:58–61 (5 ref.) **(Jpn)**

[Nasal eosinophilia after specific provocation in patients with perennial allergic rhinitis] Gamboa Vargas YG, et al. **Rev Alerg Mex** 1996 Jul–Aug;43(4):96–9 (Eng. Abstr.) **(Spa)**

[Nasal provocation tests: dose-response relationship during D. pteronyssinus challenge] Olivé Pérez A, et al. **Rev Alerg Mex** 1996 May–Jun;43(3):52–5 (Eng. Abstr.) **(Spa)**

[Comparison of extracts of cockroaches, house dust and Dermatophagoides with intradermal tests in allergy patients] Rodríguez Medina R, et al. **Rev Alerg Mex** 1996 Nov–Dec;43(6):139–42 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Gauvreau GM, et al. **Am J Respir Crit Care Med** 1996 Nov;154(5):1267–71

The effect of inhaled thiorphan on allergen-induced airway responses in asthmatic subjects. Diamant Z, et al. **Clin Exp Allergy** 1996 May;26(5):525–32

Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity [published erratum appears in J Allergy Clin Immunol 1997 Jul;100(1):146] Ciprandi G, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1088–96

GENETICS

Molecular characterization of Alternaria alternata and Cladosporium herbarum allergens. Achatz G, et al. **Adv Exp Med Biol** 1996;409:157–61

PJuFo: a phagemid for display of cDNA libraries on phage surface suitable for selective isolation of clones expressing allergens. Crameri R, et al. **Adv Exp Med Biol** 1996; 409:103–10 (59 ref.)

Isolation of a cDNA clone encoding a putative Alternaria alternata Alt a I subunit. De Vouge MW, et al. **Adv Exp Med Biol** 1996;409:205–12

Recombinant DNA technology in allergology: cloning and expression of plant profilins. Asturias JA, et al. **Allergol Immunopathol (Madr)** 1997 May–Jun;25(3):127–34

Influence of the route of allergen administration and genetic background on the murine allergic pulmonary response. Zhang Y, et al. **Am J Respir Crit Care Med** 1997 Feb; 155(2):661–9

Species-specific sequence in the repeat 3 region of the gene encoding a putative Loa loa allergen: a diagnostic tool for occult loiasis. Toure FS, et al. **Am J Trop Med Hyg** 1997 Jan;56(1):57–60

Sequence polymorphism and structural analysis of timothy grass pollen profilin allergen (Phl p 11). Asturias JA, et al. **Biochim Biophys Acta** 1997 Jun 26;1352(3):253–7

Isolation, cDNA cloning and expression of Lig v 1, the major allergen from privet pollen. Batanero E, et al. **Clin Exp Allergy** 1996 Dec;26(12):1401–10

Cloning and sequencing of the group 6 allergen of Dermatophagoides pteronyssinus. Bennett BJ, et al. **Clin Exp Allergy** 1996 Oct;26(10):1150–4

Sequence polymorphisms of the Der p 3 house dust mite allergen. Smith WA, et al. **Clin Exp Allergy** 1996 May; 26(5):571–9

cDNA cloning, sequence analysis and allergological characterization of Par j 2.0101, a new major allergen of the Parietaria judaica pollen. Duro G, et al. **FEBS Lett** 1996 Dec 16;399(3):295–8

Cloning and IgE binding of a recombinant allergen from the mite Blomia tropicalis, homologous with fatty acid-binding proteins. Caraballo L, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):341–7

Isolation and characterization of two cDNA clones coding for isoforms of the Parietaria judaica major allergen Par j 1.0101. Duro G, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):348–55

Functional effects of polymorphisms of house dust mite allergens. Thomas WR, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):96–8

Host genetic and adjuvant factors influence epitope specificity to a major recombinant grass allergen. Yang M, et al. **Int Arch Allergy Immunol** 1996 Oct;111(2):173–81

Genomic organization and polymorphisms of the major house dust mite allergen Der f2. Yuuki T, et al. **Int Arch Allergy Immunol** 1997 Jan;112(1):44–8

Inhibition of specific IgE response in vivo by allergen-gene transfer. Hsu CH, et al. **Int Immunol** 1996 Sep;8(9):1405–11

Cloning and expression of complementary DNA coding for an allergen with common antibody-binding specificities with three allergens of the house dust mite Blomia tropicalis. Caraballo L, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):573–9

Nucleotide sequence analysis of a complementary DNA coding for a Blomia tropicalis allergen. Puerta L, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):932–7

cDNA cloning and sequencing reveal the major horse allergen Equ c1 to be a glycoprotein member of the lipocalin superfamily. Gregoire C, et al. **J Biol Chem** 1996 Dec 20;271(51):32951–9

Cloning, sequencing and immunological characterization of Dac g 3, a major allergen from Dactylis glomerata pollen. Guérin-Marchand C, et al. **Mol Immunol** 1996 Jun; 33(9):797–806

Allergenicity of foods derived from transgenic plants. Astwood JD, et al. **Monogr Allergy** 1996;32:105–20

Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy [see comments] Takai T, et al. **Nat Biotechnol** 1997 Aug;15(8):754–8. Comment in: Nat Biotechnol 1997 Aug;15(8):718–9.

A pollen allergen-encoding gene is expressed in wheat ovaries. Balzer HJ, et al. **Plant Mol Biol** 1996 Nov; 32(3):435–45

Cloning of two distinct cDNAs encoding parvalbumin, the major allergen of Atlantic salmon (Salmo salar). Lindstrøm CD, et al. **Scand J Immunol** 1996 Oct;44(4):335–44

HISTORY

Historical background of aeropalynology in the Canary Islands. García Cobaleda I, et al. **Allergol Immunopathol (Madr)** 1996 Nov–Dec;24(6):269–84

IMMUNOLOGY

Humoral responses to bovine dust in dairy farmers with allergic rhinitis. Rautiainen M, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;529:169–72

Characterization of group 1 allergens from eleven grass species. Aasmul-Olsen S, et al. **Adv Exp Med Biol** 1996; 409:261–5

Use of recombinant group 5 allergens to investigate IgE-mediated sensitization to Blomia tropicalis and Dermatophagoides pteronyssinus. Arruda LK, et al. **Adv Exp Med Biol** 1996;409:173–6

Molecular characterization of Hor v 9. Conservation of a T-cell epitope among group IX pollen allergens and human VCAM and CD2. Astwood JD, et al. **Adv Exp Med Biol** 1996;409:269–77

Allergen dose dependent cytokine production regulates specific IgE and IgG antibody production. Blaser K. **Adv Exp Med Biol** 1996;409:295–303 (16 ref.)

Biological and immunological importance of Bet v 1 isoforms. Breitenbach M, et al. **Adv Exp Med Biol** 1996;409:117–26

Diversity of human T cell receptor sequences of T cell clones with specificity for Bet v 1 peptide/MHC II complexes. Breiteneder H, et al. **Adv Exp Med Biol** 1996;409:365–74

The function of allergens may determine allergenicity. Bufe A, et al. **Adv Exp Med Biol** 1996;409:399–402 (18 ref.)

HLA-DR3 is associated with the IgE immune responsiveness to a recombinant allergen from Blomia tropicalis (BT). Caraballo L, et al. **Adv Exp Med Biol** 1996;409:81–3

Structural and antigenic studies of cockroach allergens and their relevance to asthma. Chapman MD, et al. **Adv Exp Med Biol** 1996;409:95–101 (29 ref.)

Automated serology with recombinant allergens. A feasibility study. Crameri R, et al. **Adv Exp Med Biol** 1996;409:111–6

Modulation of IgE-binding properties of tree pollen allergens by site-directed mutagenesis. Ferreira F, et al. **Adv Exp Med Biol** 1996;409:127–35

Expression of the house dust mite allergen Der p2 and mutants in the baker's yeast Saccharomyces cerevisiae. Hakkaart GA, et al. **Adv Exp Med Biol** 1996;409:395–8 (5 ref.)

A major allergen involved in IgE mediated cockroach hypersensitivity is a 90 kD protein with multiple IgE binding domains. Helm RM, et al. **Adv Exp Med Biol** 1996; 409:267–8

Isolation and cloning of Bet v 1-homologous food allergens from celeriac (Api g1) and apple (Mal d1). Hoffmann-Sommergruber K, et al. **Adv Exp Med Biol** 1996; 409:219–24

Glutathione S-transferase induces murine dermatitis that resembles human allergic dermatitis. Hsu CH, et al. **Adv Exp Med Biol** 1996;409:33–7

Peptide mediated regulation of allergen specific immune responses. Lamb JR, et al. **Adv Exp Med Biol** 1996; 409:451–6

Characterization of allergenic determinants on the C-terminal region of the r-Lol p 1. Lamontagne P, et al. **Adv Exp Med Biol** 1996;409:425–9

Epitope structure of recombinant isoallergens of Bet v 1. Larsen JN, et al. **Adv Exp Med Biol** 1996;409:243–9

IgE and monoclonal antibody reactivities to the major shrimp allergen Pen a 1 (tropomyosin) and vertebrate tropomyosins. Reese G, et al. **Adv Exp Med Biol** 1996; 409:225–30

Responsiveness to the major pollen allergen of Parietaria officinalis is associated with defined HLA-DRB1* alleles in Italian and Spanish allergic patients. Ruffilli A, et al. **Adv Exp Med Biol** 1996;409:75–9

T cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense). Crossreactivity with group I allergens of different grasses. Schenk S, et al. **Adv Exp Med Biol** 1996;409:141–6

Molecular cloning and immunological characterization of the group 7 allergens of house dust mites. Shen HD, et al. **Adv Exp Med Biol** 1996;409:241–2

Lol pII allergen. Production and characterization of the recombinant protein and human antibody fragments. Sidoli A, et al. **Adv Exp Med Biol** 1996;409:255–60

Characterisation of recombinant isoforms of birch pollen allergen Bet v 1. Spangfort MD, et al. **Adv Exp Med Biol** 1996;409:251–4

Peanut hypersensitivity. IgE binding characteristics of a recombinant Ara h I protein. Stanley JS, et al. **Adv Exp Med Biol** 1996;409:213–6 (13 ref.)

Recombinant expression and epitope mapping of grass pollen allergens. Suphioglu C, et al. **Adv Exp Med Biol** 1996; 409:147–55

Production and characterization of profilin monoclonal antibodies. Arilla MC, et al. **Allergol Immunopathol (Madr)** 1997 May–Jun;25(3):145–51

Allergens from Brazil nut: immunochemical characterization. Bartolomé B, et al. **Allergol Immunopathol (Madr)** 1997 May–Jun;25(3):135–44

Sensitization to Olea europaea: geographical differences and discrepancies. Casanovas M, et al. **Allergol Immunopathol (Madr)** 1997 Jul–Aug;25(4):159–66

Fungal allergens from important allergenic fungi imperfecti. Cruz A, et al. **Allergol Immunopathol (Madr)** 1997 May–Jun;25(3):153–8 (25 ref.)

House dust mites and Der p I in Tenerife (Canary Islands, Spain): the relative importance of other non Dermatophagoides spp mites. Garcia Robaina JC, et al. **Allergol Immunopathol (Madr)** 1996 Jul–Aug;24(4):135–8

Evaluation of exposure to mite allergens; flotation, ELISA and Acarex comparative study. Kalpakhoğlu AF, et al. **Allergol Immunopathol (Madr)** 1996 Nov–Dec;24(6):248–53

Importance of tropomyosin in the allergy to household arthropods. Cross-reactivity with other invertebrate extracts. Martínez A, et al. **Allergol Immunopathol (Madr)** 1997 May–Jun;25(3):118–26

Monitoring of specific IgG4 antibodies in respiratory allergy due to the pollen of Parietaria judaica. Evidence for a protective role. Panzani RC, et al. **Allergol Immunopathol (Madr)** 1996 Nov–Dec;24(6):263–8

Allergenicity of acid protease secreted by Candida albicans. Akiyama K, et al. **Allergy** 1996 Dec;51(12):887–92

Clinical efficacy and safety of local nasal immunotherapy. Andri L, et al. **Allergy** 1997;52(33 Suppl):36–9 (38 ref.)

Blood markers of early and late airway responses to allergen in asthmatic subjects. Relationship with functional findings. Bancalari L, et al. **Allergy** 1997 Jan;52(1):32–40

Characterization of soybean allergens causing sensitization of occupationally exposed bakers. Baur X, et al. **Allergy** 1996 May;51(5):326–30

Binding affinities of allergens from pollen, mites, and house dust for specific IgG subclass antibodies. Boluda L, et al. **Allergy** 1996 Oct;51(10):706–11

Specific immunotherapy (SIT) in children. Cantani AD, et al. **Allergy** 1996 May;51(5):365–6 (16 ref.)

Immunogenicity and antigenicity of a partially hydrolyzed cow's milk infant formula. Chirico G, et al. **Allergy** 1997 Jan;52(1):82–8

Identification of casein as the major allergenic and antigenic protein of cow's milk. Docena GH, et al. **Allergy** 1996 Jun; 51(6):412–6

Bronchial allergen challenge methodological studies. Frølund L. **Allergy** 1996;51(29 Suppl):1–41 (135 ref.)

Allergic cross-reactions between cat and pig serum albumin. Study at the protein and DNA levels. Hilger C, et al. **Allergy** 1997 Feb;52(2):179–87

Further characterization of IgE-binding antigens in horse dander, with particular emphasis on glycoprotein allergens. Johnsen, et al. **Allergy** 1996 Sep;51(9):608–13

Sesame seed and sesame seed oil contain masked allergens of growing importance. Kanny G, et al. **Allergy** 1996 Dec; 51(12):952–7 (23 ref.)

A preceding airway reaction to one allergen may lead to priming of the airway responses to another allergen. Koh YY, et al. **Allergy** 1997 Mar;52(3):284–92

IgE antibodies against midge and moth found in Japanese asthmatic subjects and comparison of allergenicity between these insects. Komase Y, et al. **Allergy** 1997 Jan;52(1):75–81

Comparisons of IgE, IgG, and IgG4 responsiveness to Dermatophagoides farinae in children by immunoblotting. Noguchi E, et al. **Allergy** 1996 Dec;51(12):907–13

Receiver-operating characteristic (ROC) curves: a fundamental tool for improving the clinical usefulness of in vitro IgE tests. Plebani M, et al. **Allergy** 1996 Jun;

51(6):407–11
Group 5 determination in Pooideae grass pollen extracts by monoclonal antibody-based ELISA. Correlation with biologic activity. Ramírez J, et al. **Allergy** 1997 Aug; 52(8):806–13
Evaluation of recombinant allergens Bet v 1 and Bet v 2 (profilin) by Pharmacia CAP system in patients with pollen-related allergy to birch and apple. Rossi RE, et al. **Allergy** 1996 Dec;51(12):940–5
Specific nasal provocation test with powder allergen. Salzano FA. **Allergy** 1997;52(33 Suppl):32–5
Allergy to cockroaches in patients with asthma and rhinitis in an urban area (Madrid). Sastre J, et al. **Allergy** 1996 Aug;51(8):582–6
Clinical cross-reactivity between amoxicillin and cephadroxil in patients allergic to amoxicillin and with good tolerance of penicillin. Sastre J, et al. **Allergy** 1996 Jun;51(6):383–86
Asthma after consumption of snails in house-dust-mite-allergic patients: a case of IgE cross-reactivity. van Ree R, et al. **Allergy** 1996 Jun; 51(6):387–93
Mite-specific IgE cannot be used as a surrogate for mite exposure--where is the evidence? [letter; comment] Vervloet D, et al. **Allergy** 1995 Dec;50(12):1000. Comment on: Allergy 1995 Jun;50(6):532.
Allergenic properties of kiwi-fruit extract: cross-reactivity between kiwi-fruit and birch-pollen allergens. Voitenko V, et al. **Allergy** 1997 Feb;52(2):136–43
Effect of local allergen priming on early, late, delayed-phase, and epicutaneous skin reactions. Weller FR, et al. **Allergy** 1996 Dec;51(12):883–6
Analysis of cross-reactive allergens from American and German cockroaches by human IgE. Wu CH, et al. **Allergy** 1997 Apr;52(4):411–6
Characterization of latex allergens and correlation of serum IgE/IgG antibody ratio with clinical symptoms. Chen HD, et al. **Allergy Asthma Proc** 1996 May-Jun;17(3):143–8
Review of trimellitic anhydride (TMA) induced respiratory response. Grammer LC, et al. **Allergy Asthma Proc** 1997 Jul-Aug;18(4):235–7 (14 ref.)
Month of birth and sensitization to dust mites in New England. Saryan JA, et al. **Allergy Asthma Proc** 1996 Mar-Apr;17(2):65–9
Myofibroblast involvement in the allergen-induced late response in mild atopic asthma. Gizycki MJ, et al. **Am J Respir Cell Mol Biol** 1997 Jun;16(6):664–73
Allergen-specific IgE and IL-5 are essential for the development of airway hyperresponsiveness. Hamelmann E, et al. **Am J Respir Cell Mol Biol** 1997 Jun;16(6):674–82
Sensitization to Blomia tropicalis in patients with asthma and identification of allergen Blo t 5. Arruda LK, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):343–50
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response [see comments] Boulet LP, et al. **Am J Respir Crit Care Med** 1997 Jun; 155(6):1835–40. Comment in: Am J Respir Crit Care Med 1997 Jun;155(6):1825–7.
The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects [see comments] Fahy JV, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):1828–34. Comment in: Am J Respir Crit Care Med 1997 Jun;155(6):1825–7.
Specific IgE-dependent sensitization, atopy, and bronchial hyperresponsiveness in apprentices starting exposure to protein-derived agents. Gautrin D, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):1841–7
Alternaria as a major allergen for asthma in children raised in a desert environment. Halonen M, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1356–61
How important is IgE-mediated reaction in childhood asthma? [letter; comment] Kondo S, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):769–70. Comment on: Am J Respir Crit Care Med 1995 May;151(5):1388–92.
Sensitization to cat allergen is associated with asthma in older men and predicts new-onset airway hyperresponsiveness. The Normative Aging Study. Litonjua AA, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):23–7
Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Roquet A, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):1856–63
Allergen challenge of passively sensitized human bronchi alters M2 and beta2 receptor function. Song P, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1230–4
Peculiarities of egg allergy in children with bird protein sensitization. Bausela BA, et al. **Ann Allergy Asthma Immunol** 1997 Feb;78(2):213–6
Aeroallergen-specific IgE changes in individuals with rapid human immunodeficiency virus disease progression. Goetz DW, et al. **Ann Allergy Asthma Immunol** 1997 Mar; 78(3):301–6
Codfish allergy in adults: IgE cross-reactivity among fish species. Hansen TK, et al. **Ann Allergy Asthma Immunol** 1997 Feb;78(2):187–94
Predominant tree aeroallergens of the Washington, DC area: a six year survey (1989–1994). Kosisky SE, et al. **Ann Allergy Asthma Immunol** 1997 Apr;78(4):381–92
Cross-allergenicity of the house dust mites Euroglyphus maynei and Blomia tropicalis. Morgan MS, et al. **Ann Allergy Asthma Immunol** 1996 Nov;77(5):386–92
Performance characteristics of a new automated enzyme immunoassay for the measurement of allergen-specific IgE. Summary of the probability outcomes comparing results of allergen skin testing to results obtained with the HYTEC system and CAP system. Nolte H, et al. **Ann Allergy Asthma Immunol** 1997 Jul;79(1):27–34
Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. Stanley JS, et al. **Arch Biochem Biophys** 1997 Jun 15;342(2):244–53
Specific stabilization of the 4F7 molecule on dendritic cells by contact allergens. Jonuleit H, et al. **Arch Dermatol Res** 1996 Nov;288(12):745–52
Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollination. Ito Y, et al. **Auris Nasus Larynx** 1997 Apr;24(2):163–70
Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Mori A, et al. **Blood** 1997 Apr 15; 89(8):2891–900
The disturbance of epidermal barrier function in atopy patch test reactions in atopic eczema. Gfesser M, et al. **Br J Dermatol** 1996 Oct;135(4):560–5
The role of oak pollen in hay fever consultations in general practice and the factors influencing patients' decisions to consult. Ross AM, et al. **Br J Gen Pract** 1996 Aug; 46(409):451–5
Deficiency of nitric oxide in allergen-induced airway hyperreactivity to contractile agonists after the early asthmatic reaction: an ex vivo study. de Boer J, et al. **Br J Pharmacol** 1996 Nov;119(6):1109–16
Inducible nitric oxide synthase after sensitization and allergen challenge of Brown Norway rat lung. Liu SF, et al. **Br J Pharmacol** 1997 Aug;121(7):1241–6
Selectivity of IgE responses, mast cell sensitization, and cytokine expression in the immune response of Brown Norway rats to chemical allergens. Vento KL, et al. **Cell Immunol** 1996 Sep 15;172(2):246–53
Determination of the food specific IgE antibodies: comparison of MAST-CLA and CAP systems. Tang RB, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Mar; 57(3):219–23
Allergen recognition in the origin of asthma. Holt PG, et al. **Ciba Found Symp** 1997;206:35–49; discussion 49–55, 106–10 (53 ref.)
The role of domestic allergens. Platts-Mills TA, et al. **Ciba Found Symp** 1997;206:173–85; discussion 185–9 (52 ref.)
The conjunctival late-phase reaction and allergen provocation in the eye [editorial; comment] Anderson DF. **Clin Exp Allergy** 1996 Oct;26(10):1105–7. Comment on: Clin Exp Allergy 1996 Oct;26(10):1125–30.
Major allergens in soybean and clinical significance of IgG4 antibodies investigated by IgE- and IgG4-immunoblotting with sera from soybean-sensitive patients. Awazuhara H, et al. **Clin Exp Allergy** 1997 Mar;27(3):325–32
IgE cross-reactivity between birch pollen, mugwort pollen and celery is due to at least three distinct cross-reacting allergens: immunoblot investigation of the birch-mugwort-celery syndrome. Bauer L, et al. **Clin Exp Allergy** 1996 Oct;26(10):1161–70
Latex allergy can induce clinical reactions to specific foods. Beezhold DH, et al. **Clin Exp Allergy** 1996 Apr; 26(4):416–22
A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. Bentley AM, et al. **Clin Exp Allergy** 1996 Aug;26(8):909–17
Cutting the cord: is birth already too late for primary prevention of allergy? [editorial; comment] Brown MA, et al. **Clin Exp Allergy** 1997 Jan;27(1):4–6. Comment on: Clin Exp Allergy 1997 Jan;27(1):28–35.
Comparison between two automated systems to determine specific IgE: CAP and ELItest. Brunnée T, et al. **Clin Exp Allergy** 1996 Dec;26(12):1420–7
Immunohistological analysis of 'negative' patch test sites in atopic dermatitis. Buckley C, et al. **Clin Exp Allergy** 1996 Sep;26(9):1057–63
Analysis of sequence polymorphism of a major mite allergen, Der p 2. Chua KY, et al. **Clin Exp Allergy** 1996 Jul; 26(7):829–37
Feather mites are potentially an important source of allergens for pigeon and budgerigar keepers. Colloff MJ, et al. **Clin Exp Allergy** 1997 Jan;27(1):60–7
Automated specific IgE assay with recombinant allergens: evaluation of the recombinant Aspergillus fumigatus allergen I in the Pharmacia Cap System. Crameri R, et al. **Clin Exp Allergy** 1996 Dec;26(12):1411–9
Allergen content in dust from homes and schools in northern Norway in relation to sensitization and allergy symptoms in schoolchildren. Dotterud LK, et al. **Clin Exp Allergy** 1997 Mar;27(3):252–61
Purification and IgE binding capacity of Der s 3, a major allergen from Dermatophagoides siboney. Ferrándiz R, et al. **Clin Exp Allergy** 1997 Jun;27(6):700–4
Rye flour allergens associated with baker's asthma. Correlation between in vivo and in vitro activities and comparison with their wheat and barley homologues. García-Casado G, et al. **Clin Exp Allergy** 1996 Apr; 26(4):428–35
Allergy to furred animals [editorial; comment] Gordon S. **Clin Exp Allergy** 1997 May;27(5):479–81. Comment on: Clin Exp Allergy 1997 May;27(5):501–9.
Lack of evidence of a significant association between HLA-DR, DQ and DP genotypes and atopy in families with HDM allergy. Holloway JW, et al. **Clin Exp Allergy** 1996 Oct;26(10):1142–9
American cockroach Cr-PI allergen induces lymphocyte proliferation and cytokine production in atopic patients. Jeng KC, et al. **Clin Exp Allergy** 1996 Mar;26(3):349–56
Skin test and crossreactivity studies with Euroglyphus maynei and Dermatophagoides pteronyssinus. Kemp SF, et al. **Clin Exp Allergy** 1997 Aug;27(8):893–7
Overview on denominated allergens. Liebers V, et al. **Clin Exp Allergy** 1996 May;26(5):494–516 (287 ref.)
Increased prevalence of sensitization against aeroallergens in adults in West compared with East Germany. Nicolai T, et al. **Clin Exp Allergy** 1997 Aug;27(8):886–92
Fine structural specificity differences of trimethoprim allergenic determinants. Pham NH, et al. **Clin Exp Allergy** 1996 Oct;26(10):1155–60
The importance of the pecan tree pollen in allergic manifestations. Rachmiel M, et al. **Clin Exp Allergy** 1996 Mar;26(3):323–9
On the potential significance of the enzymatic activity of mite allergens to immunogenicity. Clues to structure and function revealed by molecular characterization. Robinson C, et al. **Clin Exp Allergy** 1997 Jan;27(1):10–21 (58 ref.)
IgE response to fur animal allergens and domestic animal allergens in fur farmers and fur garment workers [see comments] Savolainen J, et al. **Clin Exp Allergy** 1997 May; 27(5):501–9. Comment in: Clin Exp Allergy 1997 May;27(5):479–81.
Allergenic components in three different species of Penicillium: crossreactivity among major allergens. Shen HD, et al. **Clin Exp Allergy** 1996 Apr;26(4):444–51
Characterization of the 33-kilodalton major allergen of Penicillium citrinum by using MoAbs and N-terminal amino acid sequencing. Shen HD, et al. **Clin Exp Allergy** 1997 Jan;27(1):79–86
Molecular cloning and expression of a Penicillium citrinum allergen with sequence homology and antigenic crossreactivity to a hsp 70 human heat shock protein. Shen HD, et al. **Clin Exp Allergy** 1997 Jun;27(6):682–90
Characterization of the allergen Der f 7 from house dust mite extracts by species-specific and crossreactive monoclonal antibodies. Shen HD, et al. **Clin Exp Allergy** 1997 Jul;27(7):824–32
Crossreactivity and T-cell epitope specificity of Bet v 1-specific T cells suggest the involvement of multiple isoallergens in sensitization to birch pollen. Sparholt SH, et al. **Clin Exp Allergy** 1997 Aug;27(8):932–41
Characterization of allergens from deer: cross-reactivity with allergens from cow dander. Spitzauer S, et al. **Clin Exp Allergy** 1997 Feb;27(2):196–200
The most common phenotypes of sensitization to inhalant allergens in childhood. Storm van's Gravesande K, et al. **Clin Exp Allergy** 1997 Jun;27(6):646–52
Prenatal allergen contact with milk proteins [see comments] Szépfalusi Z, et al. **Clin Exp Allergy** 1997 Jan;27(1):28–35 . Comment in: Clin Exp Allergy 1997 Jan;27(1):4–6.
Seasonal differences in airway hyperresponsiveness in asthmatic patients: relationship with allergen exposure and sensitization to house dust mites. van der Heide S, et al. **Clin Exp Allergy** 1997 Jun;27(6):627–33
Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Van Ree R, et al. **Clin Exp Allergy** 1997 Jan;27(1):68–74
Der p I concentrations in mattress surface and floor dust collected from infants' bedrooms. van Strien RT, et al. **Clin Exp Allergy** 1995 Dec;25(12):1184–9
Immune reactivity of cow-asthmatic dairy farmers to the major allergen of cow (BDA20) and to other cow-derived proteins. The use of purified BDA20 increases the performance of diagnostic tests in respiratory cow allergy. Virtanen T, et al. **Clin Exp Allergy** 1996 Feb;26(2):188–96
Sensitization and enhanced allergen responsiveness. Wardlaw AJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:56–9 (0 ref.)
Cell surface expression of two major yeast allergens in the Pityrosporum genus. Zargari A, et al. **Clin Exp Allergy** 1997 May;27(5):584–92
The sweat of patients with atopic dermatitis contains specific IgE antibodies to inhalant allergens. Jung K, et al. **Clin Exp Dermatol** 1996 Sep;21(5):347–50
Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Bauer L, et al. **Clin Exp Immunol** 1997 Mar; 107(3):536–41
IgE epitope analysis of the hevein preprotein; a major latex allergen. Beezhold DH, et al. **Clin Exp Immunol** 1997 Apr; 108(1):114–21
Human T cell responses to recombinant mite antigens of Dermatophagoides farinae. Fujii S, et al. **Clin Exp Immunol** 1997 May;108(2):284–8
Comparative study of the complement-activating and specific IgE-binding properties of ragweed pollen allergen. Hidvégi T, et al. **Clin Exp Immunol** 1997 Apr;108(1):122–7
Aeroallergen contact dermatitis. Taïeb A, et al. **Clin Rev Allergy Immunol** 1996 Summer;14(2):209–23 (64 ref.)
The murine local lymph node assay: search for an alternative,

more adequate, vehicle than acetone/olive oil (4:1). Montelius J, et al. **Contact Dermatitis** 1996 Jun;34(6):428–30

Allergenic foods. Hefle SL, et al.
Crit Rev Food Sci Nutr 1996;36 Suppl:S69–89 (264 ref.)

Assessment of the allergenic potential of foods derived from genetically engineered crop plants. Metcalfe DD, et al.
Crit Rev Food Sci Nutr 1996;36 Suppl:S165–86 (118 ref.)

In vitro sensitization of human T cells with hapten–treated Langerhans cells: a screening test for the identification of contact allergens. Krasteva M, et al.
Curr Probl Dermatol 1996;25:28–36

Sensitizations to allergens of the European standard series at the Department of Dermatology in Zurich 1990–1994. Bangha E, et al. **Dermatology** 1996;193(1):17–21

Mapping and mutational analysis of the IgE–binding epitopes on Ara h 1, a legume vicilin protein and a major allergen in peanut hypersensitivity. Burks AW, et al.
Eur J Biochem 1997 Apr 15;245(2):334–9

Investigation of different recombinant isoforms of grass group–V allergens (timothy grass pollen) isolated by low–stringency cDNA hybridization—antibody binding capacity and allergenic activity. Gehlhar K, et al.
Eur J Biochem 1997 Jul 1;247(1):217–23

The intensity of T cell receptor engagement determines the cytokine pattern of human allergen–specific T helper cells. Carballido JM, et al. **Eur J Immunol** 1997 Feb;27(2):515–21

Bronchial and skin reactivity in asthmatic patients with and without atopic dermatitis. Brinkman L, et al.
Eur Respir J 1997 May;10(5):1033–40

Repeated allergen exposure enhances excitatory nonadrenergic noncholinergic nerve–mediated bronchoconstriction in sensitized guinea–pigs. Kageyama N, et al. **Eur Respir J** 1996 Jul;9(7):1439–44

Priming of circulating human eosinophils following late response to allergen challenge [letter; comment] Koenderman L. **Eur Respir J** 1997 Jan;10(1):251–2. Comment on: Eur Respir J 1996 Apr;9(4):703–8.

Airway endothelin levels in asthma: influence of endobronchial allergen challenge and maintenance corticosteroid therapy. Redington AE, et al.
Eur Respir J 1997 May;10(5):1026–32

Higher asthma occurrence in an urban than a suburban area: role of house dust mite skin allergy. Wieringa MH, et al.
Eur Respir J 1997 Jul;10(7):1460–6

Association of responsiveness to the major pollen allergen of Parietaria officinalis with HLA–DRB1* alleles: a multicenter study. D'Amato M, et al. **Hum Immunol** 1996 Apr;46(2):100–6

Germline TCR–A restriction of immunoglobulin E responses to allergen. Moffatt MF, et al. **Immunogenetics** 1997; 46(3):226–30

Immunologic responses following respiratory sensitization to house dust mite allergens in mice. O'Brien R, et al.
Immunol Cell Biol 1996 Apr;74(2):174–9 (23 ref.)

Allergen induced cytokine profiles in type I allergic individuals before and after immunotherapy. Söderlund A, et al. **Immunol Lett** 1997 Jun 1;57(1–3):177–81

T–cell responses to allergens: epitope–specificity and clinical relevance. van Neerven RJ, et al. **Immunol Today** 1996 Nov;17(11):526–32 (77 ref.)

Vaccination with a multi–epitopic recombinant allergen induces specific immune deviation via T–cell anergy. Cao Y, et al. **Immunology** 1997 Jan;90(1):46–51

Contribution of CD4+ and CD8+ T lymphocyte subsets to the cytokine secretion patterns induced in mice during sensitization to contact and respiratory chemical allergens. Dearman RJ, et al. **Immunology** 1996 Dec;89(4):502–10

Epitope specificity of IgE antibodies to a major allergen (Cry j 1) of Japanese cedar pollen in sera of humans and monkeys with pollinosis. Sakaguchi M, et al. **Immunology** 1997 Jun; 91(2):161–6

IL–13 production by allergen–stimulated T cells is increased in allergic disease and associated with IL–5 but not IFN–gamma expression. Till S, et al. **Immunology** 1997 May;91(1):53–7

Dissociation of histamine releasing activity and T –cell reactivity of allergen conjugated with synthetic polymer. Gushchin IS, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S67–8

Grass immunotherapy induces inhibition of allergen–specific human peripheral blood mononuclear cell proliferation. Baskar S, et al. **Int Arch Allergy Immunol** 1997 Feb; 112(2):184–90

Haptenic side chains as posttranslational IgE–binding determinants among pollen protein allergens. Berrens L, et al. **Int Arch Allergy Immunol** 1997 May–Jul; 113(1–3):236–7

Early immune responses to allergens. Björkstén B.
Int Arch Allergy Immunol 1997 May–Jul;113(1–3):80–2

Immunological and biological properties of recombinant Lol p 1. Boutin Y, et al. **Int Arch Allergy Immunol** 1997 Mar; 112(3):218–25

Enolases are highly conserved fungal allergens. Breitenbach M, et al. **Int Arch Allergy Immunol** 1997 May–Jul; 113(1–3):114–7

Defined epitopes: in vivo and in vitro studies using recombinant allergens. Chapman MD, et al.
Int Arch Allergy Immunol 1997 May–Jul;113(1–3):102–4

Allergen–specific conjunctival challenge in asthma. An additional diagnostic tool to define sensitization. Ciprandi G, et al. **Int Arch Allergy Immunol** 1997 Mar;112(3):247–50

Different profiles in specific IgE to rBet v 1 and rBet v 2 in patients allergic to birch pollen from six countries. Elfman L, et al. **Int Arch Allergy Immunol** 1997 May–Jul; 113(1–3):249–51

Analysis of individual cross–reacting allergens between Dermatophagoides siboney and other mites by immunoblot inhibition. Ferrándiz R, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):238–9

Isoforms of atopic allergens with reduced allergenicity but conserved T cell antigenicity: possible use for specific immunotherapy. Ferreira F, et al.
Int Arch Allergy Immunol 1997 May–Jul;113(1–3):125–7

Responses of monkeys with pollinosis to two major allergens of Japanese cedar pollen. Hashimoto M, et al.
Int Arch Allergy Immunol 1997 Jan;112(1):88–92

Factors influencing immediate responses to intradermal allergen administration in patients with respiratory allergy. Hong CS, et al. **Int Arch Allergy Immunol** 1997 May–Jul; 113(1–3):360–2

Mite–induced allergic airway inflammation in guinea pigs. Hsiue TR, et al. **Int Arch Allergy Immunol** 1997 Mar; 112(3):295–302

Allergic sensitization to native and heated celery root in pollen–sensitive patients investigated by skin test and IgE binding. Jankiewicz A, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):268–78

A sensitive ELISA to detect IgG subclass antibodies to Bet v 1 in infants. Jenmalm MC. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):252–4

The 'traveling salesman problem': a new approach for identification of differences among pollen allergens. Kosman E, et al. **Int Arch Allergy Immunol** 1997 Apr; 112(4):371–7

Bip 1, a monoclonal antibody with specificity for the major birch pollen allergen Bet v 1, modulates IgE binding to the allergen. Laffer S, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):260–1

Potential therapeutic efficacy of allergen–monomethoxypolyethylene glycol conjugates for in vivo inactivation of sensitized mast cells responsible for common allergies and asthma. Lang GM, et al.
Int Arch Allergy Immunol 1997 May–Jul;113(1–3):58–60

Recombinant proteins in newly developed foods: identification of allergenic activity. Lehrer SB, et al.
Int Arch Allergy Immunol 1997 May–Jul;113(1–3):122–4

Flow–cytometric analysis of T–cell receptor expression in peripheral blood lymphocytes. Liebers V, et al.
Int Arch Allergy Immunol 1997 Feb;112(2):133–9

Biological activity of recombinant Der p 2, Der p 5 and Der p 7 allergens of the house–dust mite Dermatophagoides pteronyssinus. Lynch NR, et al.
Int Arch Allergy Immunol 1997 Sep;114(1):59–67

Dermatophagoides farinae–1–derived peptides and HLA molecules recognized by T cells from atopic individuals. Matsuoka T, et al. **Int Arch Allergy Immunol** 1997 Apr; 112(4):365–70

Cloning, production, characterization and IgE cross–reactivity of different manganese superoxide dismutases in individuals sensitized to Aspergillus fumigatus. Mayer C, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):213–5

Integrated clinical experience with tolerogenic peptides. Nicodemus C, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):326–8

Clinical and immunologic effects of component peptides in Allervax Cat. Norman PS, et al.
Int Arch Allergy Immunol 1997 May–Jul;113(1–3):224–6

Peripheral blood T lymphocytes and basophils, freshly isolated from house–dust–mite–sensitive patients, produce interleukin–4 in response to allergen–specific stimulation. Ochi H, et al. **Int Arch Allergy Immunol** 1996 Nov; 111(3):253–61

Effects of phosphatidylinositol–3–kinase inhibitors on degranulation and gene induction in allergically triggered mouse mast cells. Pendl GG, et al.
Int Arch Allergy Immunol 1997 Apr;112(4):392–9

Immunological cross–reactivity of the major allergen from perennial ryegrass (Lolium perenne), Lol p I, and the cysteine proteinase, bromelain. Pike RN, et al.
Int Arch Allergy Immunol 1997 Apr;112(4):412–4

Allergen sensitization and perennial asthma. Platts–Mills TA, et al. **Int Arch Allergy Immunol** 1997 May–Jul; 113(1–3):83–6 (33 ref.)

Developing patterns of T cell memory to environmental allergens in the first two years of life. Prescott SL, et al.
Int Arch Allergy Immunol 1997 May–Jul;113(1–3):75–9

Early sensitization to farming–related antigens among young farmers: analysis of risk factors. Prior C, et al.
Int Arch Allergy Immunol 1996 Oct;111(2):182–7

Characterization of recombinant shrimp allergen Pen a 1 (tropomyosin). Reese G, et al.
Int Arch Allergy Immunol 1997 May–Jul;113(1–3):240–2

The 'atopy patch test' in evaluating the role of aeroallergens in atopic eczema. Ring J, et al.
Int Arch Allergy Immunol 1997 May–Jul;113(1–3):379–83

Cross–reacting allergens in tree pollen and pollen–related food allergy: implications for diagnosis of specific IgE. Scheiner O, et al. **Int Arch Allergy Immunol** 1997 May–Jul; 113(1–3):105–8

Mouse/human chimeric antibodies directed to two nonoverlapping epitopes of the house dust mite allergen, Der p 2. Schuurman J, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):262–3

Antigenic and molecular structure of the mite allergen Der p 2. Smith AM, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):99–101

Expression in Escherichia coli of human IgE antibody fragments with specificity for major timothy grass pollen allergens using the combinatorial library approach. Steinberger P, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):258–9

Total and birch pollen–specific human IgE in mice with severe combined immunodeficiency transplanted with human peripheral blood lymphocytes: donor dependence, seasonal variation and in vivo half–life. Steinsvik TE, et al. **Int Arch Allergy Immunol** 1997 Feb;112(2):175–83

IgE–mediated allergen presentation via Fc epsilon RI on antigen–presenting cells. Stingl G, et al.
Int Arch Allergy Immunol 1997 May–Jul;113(1–3):24–9 (46 ref.)

Mercurialis annua: characterization of main allergens and cross–reactivity with other species. Vallverdú A, et al.
Int Arch Allergy Immunol 1997 Apr;112(4):356–64

Division of the major birch pollen allergen, Bet v 1, into two non–anaphylactic fragments. Vrtala S, et al.
Int Arch Allergy Immunol 1997 May–Jul;113(1–3):246–8

Host genetic and adjuvant factors influence epitope specificity to a major recombinant grass allergen. Yang M, et al. **Int Arch Allergy Immunol** 1996 Oct;111(2):173–81

Dermatophagoides–farinae–induced pulmonary eosinophilic inflammation in mice. Yu CK, et al.
Int Arch Allergy Immunol 1997 Jan;112(1):73–82

Prediction of murine MHC class I epitopes in a major house dust mite allergen and induction of T1–type CD8+ T cell responses. Harris SJ, et al. **Int Immunol** 1997 Feb; 9(2):273–80

Quaternary structure of a carrier protein influences antigenicity and immunogenicity of an inserted T cell determinant. Janssen R, et al. **Int Immunol** 1996 Jun; 8(6):829–36

Induction of T cell responses to the invariant chain derived peptide CLIP in mice immunized with the group 1 allergen of house dust mite. Kristensen NM, et al. **Int Immunol** 1996 Jul;8(7):1091–8

Inhibition by lecithin–bound iodine (LBI) of inducible allergen–specific T lymphocytes' responses in allergic diseases. Kawano Y, et al. **Int J Immunopharmacol** 1996 Apr;18(4):241–9

Clinical effects of nedocromil sodium on allergen–related mechanisms. Bleecker ER, et al.
J Allergy Clin Immunol 1996 Nov;98(5 Pt 2):S118–23; discussion S140–2 (34 ref.)

Depletion of circulating allergen–specific TH2 T lymphocytes after allergen exposure in asthma. Crimi E, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):788–97

Clonal diversity of IL–4 and IL–13 expression in human allergen–specific T lymphocytes. Essayan DM, et al.
J Allergy Clin Immunol 1996 Dec;98(6 Pt 1):1035–44

Analysis of rat serum allergens. Gordon S, et al.
J Allergy Clin Immunol 1997 May;99(5):716–7

Identification of a 60 kd cross–reactive allergen in pollen and plant–derived food. Heiss S, et al.
J Allergy Clin Immunol 1996 Nov;98(5 Pt 1):938–47

Mapping of an allergenically important determinant of grass group I allergens. Hiller KM, et al.
J Allergy Clin Immunol 1997 Sep;100(3):335–40

Biologic allergen assay for in vivo test allergens with an in vitro model of the murine type I reaction. Hoffmann A, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):227–32

Late response to allergen is associated with increased concentrations of tumor necrosis factor–alpha and IL–5 in induced sputum. Keatings VM, et al.
J Allergy Clin Immunol 1997 May;99(5):693–8

Hornet venom allergen antigen 5, Dol m 5: its T–cell epitopes in mice and its antigenic cross–reactivity with a mammalian testis protein. King TP, et al. **J Allergy Clin Immunol** 1997 May;99(5):630–9

Rush immunotherapy results in allergen–specific alterations in lymphocyte function and interferon–gamma production in CD4+ T cells. Lack G, et al.
J Allergy Clin Immunol 1997 Apr;99(4):530–8

IgE reactivity against a cross–reactive allergen in crustacea and mollusca: evidence for tropomyosin as the common allergen. Leung PS, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):954–61

Is cross–reactivity a real or an imaginary concept? [letter] Mohapatra SS. **J Allergy Clin Immunol** 1997 May;99(5):724

Exposure to indoor allergens in early infancy and sensitization. Munir AK, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):177–81

Sensitization to hen's egg at the age of twelve months is predictive for allergic sensitization to common indoor and outdoor allergens at the age of three years. Nickel R, et al. **J Allergy Clin Immunol** 1997 May;99(5):613–7

Induction of allergen–specific IL–2 responsiveness of lymphocytes after respiratory syncytial virus infection and prediction of onset of recurrent wheezing and bronchial asthma. Noma T, et al. **J Allergy Clin Immunol** 1996 Oct; 98(4):816–26

Identification of the allergenic components of kiwi fruit and evaluation of their cross–reactivity with timothy and birch pollens. Pastorello EA, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):601–10

Production of a mouse/human chimeric IgE monoclonal antibody to the house dust mite allergen Der p 2 and its use for the absolute quantification of allergen–specific IgE.

Schuurman J, et al. **J Allergy Clin Immunol** 1997 Apr; 99(4):545–50

Absence of cross–reactivity of IgE antibodies from subjects allergic to Hevea brasiliensis latex with a new source of natural rubber latex from guayule (Parthenium argentatum). Siler DJ, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):895–902

Major cat and dog allergens share IgE epitopes. Spitzauer S, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):100–6

Allergenicity of gourmet nut oils processed by different methods. Teuber SS, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):502–7

Allergenic activity of heated and ovomucoid–depleted egg white. Urisu A, et al. **J Allergy Clin Immunol** 1997 Aug; 100(2):171–6

Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2. Vrtala S, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):913–21

Changes in eosinophil and leukocyte infiltration and expression of IL–6 and IL–7 messenger RNA in mite allergen patch test reactions in atopic dermatitis. Yamada N, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S201–6

The 14.6 kd rubber elongation factor (Hev b 1) and 24 kd (Hev b 3) rubber particle proteins are recognized by IgE from patients with spina bifida and latex allergy. Yeang HY, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):628–39

Ragweed sensitization alters pulmonary vascular responses to bronchoprovocation in beagle dogs. Theodorou A, et al. **J Appl Physiol** 1997 Sep;83(3):912–7

Induction of IgE antibody responses by glutathione S–transferase from the German cockroach (Blattella germanica). Arruda LK, et al. **J Biol Chem** 1997 Aug 15; 272(33):20907–12

Molecular and structural analysis of a continuous birch profilin epitope defined by a monoclonal antibody. Wiedemann P, et al. **J Biol Chem** 1996 Nov 22; 271(47):29915–21

Beta 2–microglobulin–dependent T cells are dispensable for allergen–induced T helper 2 responses. Zhang Y, et al. **J Exp Med** 1996 Oct 1;184(4):1507–12

Allergenic properties of ovomucoid in man. Cooke SK, et al. **J Immunol** 1997 Aug 15;159(4):2026–32

Lack of IL–12 signaling in human allergen–specific Th2 cells. Hilkens CM, et al. **J Immunol** 1996 Nov 15;157(10):4316–21

Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha– and Fc epsilon RI gamma–chains and can use this receptor for IgE–mediated allergen presentation. Maurer D, et al. **J Immunol** 1996 Jul 15;157(2):607–16

Inhibition of primary and recall allergen–specific T helper cell type 2–mediated responses by a T helper cell type 1 stimulus. Scott DE, et al. **J Immunol** 1997 Jul 1; 159(1):107–16

Epidermal cells enhance interleukin 4 and immunoglobulin E production after stimulation with protein allergen. Bellinghausen I, et al. **J Invest Dermatol** 1996 Oct; 107(4):582–8

Induction of low zone tolerance to contact allergens in mice does not require functional Langerhans cells. Steinbrink K, et al. **J Invest Dermatol** 1996 Aug;107(2):243–7

Retention of long–lived, allergen–specific T cells in atopic dermatitis skin –letter– van Reijsen FC, et al. **J Invest Dermatol** 1997 Apr;108(4):530

Allergen specificity of skin–infiltrating T cells is not restricted to a type–2 cytokine pattern in chronic skin lesions of atopic dermatitis. Werfel T, et al. **J Invest Dermatol** 1996 Dec;107(6):871–6

A three–year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. Cantani A, et al. **J Investig Allergol Clin Immunol** 1997 Mar–Apr;7(2):90–7

Skin prick tests with standardized extracts of inhalant allergens in 7099 adult patients with asthma or rhinitis: cross–sensitizations and relationships to age, sex, month of birth and year of testing. Eriksson NE, et al. **J Investig Allergol Clin Immunol** 1996 Jan–Feb;6(1):36–46

Sequential determinations of Dermatophagoides spp. allergens in a tropical city. Fernández–Caldas E, et al. **J Investig Allergol Clin Immunol** 1996 Mar–Apr;6(2):98–102

Why are nasal and bronchial symptoms mostly perennial in patients with monosensitization to Olea europaea pollen allergens? Liccardi G, et al. **J Investig Allergol Clin Immunol** 1996 Nov–Dec;6(6):371–7

Patch test response to house dust mites is positive in children with atopic dermatitis and in their parents. Meglio P, et al. **J Investig Allergol Clin Immunol** 1996 May–Jun; 6(3):190–5 (33 ref.)

Renaturation of blotted allergens increases the sensitivity of specific IgE detection. Muro MD, et al. **J Investig Allergol Clin Immunol** 1996 May–Jun;6(3):166–71 (36 ref.)

Alternative routes for allergen–specific immunotherapy. Passalacqua G, et al. **J Investig Allergol Clin Immunol** 1996 Mar–Apr;6(2):81–7 (69 ref.)

The mechanism of specific inhibition of stimulated chemiluminescence of polymorphonuclear blood leukocytes in allergic processes. Pytsky VI, et al. **J Investig Allergol Clin Immunol** 1996 Sep–Oct;6(5):320–3

Phenomenon of specific inhibition of luminol–dependent chemiluminescence of polymorphonuclear leukocytes under the influence of allergen. Pytsky VI, et al. **J Investig Allergol Clin Immunol** 1996 Jul–Aug;6(4):256–60

Allergen–specific low–dose immunotherapy in perennial allergic rhinitis: a double–blind placebo–controlled crossover study. Radcliffe MJ, et al. **J Investig Allergol Clin Immunol** 1996 Jul–Aug;6(4):242–7

Effect of allergen specific immunotherapy (IT) on natural killer cell activity (NK), IgE, IFN–gamma levels and clinical response in patients with allergic rhinitis and asthma. Sin B, et al. **J Investig Allergol Clin Immunol** 1996 Nov–Dec;6(6):341–7

Specific IgE to castor bean (Ricinus communis) pollen in the sera of clinically sensitive patients to seeds. Singh A, et al. **J Investig Allergol Clin Immunol** 1997 May–Jun; 7(3):169–74

Specific immunotherapy in pollinosis: II. Forecasting changes in certain cytoimmunological indicators after four years of immunotherapy in pollinosis. Zieliński AE. **J Investig Allergol Clin Immunol** 1996 Nov–Dec; 6(6):364–70

Isocyanate–induced occupational asthma: challenge and immunologic studies. Park HS, et al. **J Korean Med Sci** 1996 Aug;11(4):314–8

Identification of the major T–cell antigens present in the Brucella melitensis B115 protein preparation, Brucellergene OCB. Denoel PA, et al. **J Med Microbiol** 1997 Sep; 46(9):801–6

beta–Lactam drug allergens: fine structural recognition patterns of cephalosporin–reactive IgE antibodies. Pham NH, et al. **J Mol Recognit** 1996 Jul–Aug;9(4):287–96

Experimental autoimmune encephalomyelitis: antigen–induced inhibition of biochemical and immunohistological alterations. Bucher AE, et al. **J Neurosci Res** 1996 Nov 1;46(3):367–74

Reduction of the allergenicity of soybean by treatment with proteases. Yamanishi R, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Dec;42(6):581–7

Environmental chemicals and experimental allergic conjunctivitis. Miyata M, et al. **J Toxicol Sci** 1996 Feb; 21(1):57–9

Allergy to peanut [letter; comment] Dawe RS, et al. **Lancet** 1996 Nov 30;348(9040):1522–3. Comment on: Lancet 1996 Sep 14;348(9029):759–60.

Complement inactivation by allergenic plant pollen extracts. Berrens L, et al. **Life Sci** 1997;60(17):1497–503

Skinprick test sensitivity to olive pollen [letter] [corrected and republished article originally printed in Med J Aust 1996 Sep 16;165(6):352] Azmi MH, et al. **Med J Aust** 1996 Oct 21;165(8):460

Diagnostic allergy laboratory external proficiency testing in Europe. Fifield R. **Methods** 1997 Sep;13(1):33–42

Sequence comparisons of the CDR3 hyper–variable loops of human T cell receptors specific for three major T cell epitopes of the birch pollen allergen Bet v 1. Breiteneder H, et al. **Mol Immunol** 1996 Sep;33(13):1039–48

Expression, purification and immunochemical characterization of recombinant bovine beta–lactoglobulin, a major cow milk allergen. Chatel JM, et al. **Mol Immunol** 1996 Oct;33(14):1113–8

Extraordinary stability of IgE–binding Parietaria pollen allergens in relation to chemically bound flavonoids. González Romano ML, et al. **Mol Immunol** 1996 Dec; 33(17–18):1287–93

The affinity of allergen specific IgE and the competition between IgE and IgG for the allergen in Amb a V sensitive individuals. Kim KE, et al. **Mol Immunol** 1996 Jul; 33(10):873–80

Human recombinant antibody fragments specific for a rye–grass pollen allergen: characterization and potential applications. Lalla C de, et al. **Mol Immunol** 1996 Sep; 33(13):1049–58

Determination of the N– and C–terminal sequences required to bind human IgE of the major house dust mite allergen Der f 2 and epitope mapping for monoclonal antibodies. Takai T, et al. **Mol Immunol** 1997 Feb;34(3):255–61

Some limitations in the use of specific IgE in the diagnosis of food hypersensitivity. Bindslev–Jensen C, et al. **Monogr Allergy** 1996;32:216–20 (6 ref.)

Identification of allergens in apple, pear, celery, carrot and potato: cross–reactivity with pollen allergens. Ebner C, et al. **Monogr Allergy** 1996;32:73–7 (21 ref.)

Specific IgG antibodies as markers of adverse reactions to foods. Marinkovich V. **Monogr Allergy** 1996;32:221–5 (7 ref.)

Optimization, standardization and control of food allergens. Niemeijer NR, et al. **Monogr Allergy** 1996;32:50–6 (20 ref.)

Cross–reacting allergens in clinical syndromes. Pastorello EA, et al. **Monogr Allergy** 1996;32:57–62 (22 ref.)

Specific IgG antibodies as markers of adverse reactions to food. Contra! Wüthrich B. **Monogr Allergy** 1996;32:226–7 (10 ref.)

Immunotherapy for asthma [letter; comment] Bousquet J, et al. **N Engl J Med** 1997 Jun 26;336(26):1912; discussion 1913 . Comment on: N Engl J Med 1997 Jan 30;336(5):324–31.

Dusting off recombinant allergens [news; comment] Marshall GD Jr, et al. **Nat Biotechnol** 1997 Aug;15(8):718–9. Comment on: Nat Biotechnol 1997 Aug;15(8):754–8.

Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis. Bonini S, et al. **Ophthalmology** 1997 May; 104(5):849–53

Isolation of type 1 and type 2 cloned mite allergen–specific T cells from an asthmatic child. Chiang BL, et al. **Pediatr Allergy Immunol** 1996 Nov;7(4):193–8

Characterization of ovomucoid–specific T–cell lines and clones from egg–allergic subjects. Eigenmann PA, et al. **Pediatr Allergy Immunol** 1996 Feb;7(1):12–21

Month of birth, atopic disease, and sensitization to common aeroallergens in Greece. Karachaliou FH, et al. **Pediatr Allergy Immunol** 1995 Nov;6(4):216–9

Mite allergy, clinical atopy, and restriction by HLA class II immune response genes. Stephan V, et al. **Pediatr Allergy Immunol** 1996 Feb;7(1):28–34

Differences in the effect of allergen avoidance on bronchial hyperresponsiveness as measured by methacholine, adenosine 5'–monophosphate, and exercise in asthmatic children. Benckhuijsen J, et al. **Pediatr Pulmonol** 1996 Sep; 22(3):147–53

Allergen–induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma [see comments] Mehlhop PD, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1344–9. Comment in: Proc Natl Acad Sci U S A 1997 Mar 18;94(6):2101–2.

Asthmatic reactions after nasal allergen provocation. Baur X. **Respiration** 1996;63(2):84–7

Determination of sensitivity of inhalant allergens in patients with allergic rhinitis in West Athens. Kontothanasi G, et al. **Rhinology** 1995 Dec;33(4):234–5

Cloning of two distinct cDNAs encoding parvalbumin, the major allergen of Atlantic salmon (Salmo salar). Lindstrøm CD, et al. **Scand J Immunol** 1996 Oct;44(4):335–44

Lack of correlation between membrane CD30 expression and cytokine secretion pattern in allergen–primed naive cord blood T–cell lines and clones. Spinozzi F, et al. **Scand J Immunol** 1997 Apr;45(4):417–22

Airway response of asthmatic subjects to inhaled allergen after exposure to pollutants. Rusznak C, et al. **Thorax** 1996 Nov;51(11):1105–8

Japanese cedar pollinosis and HLA–DP5. Hori T, et al. **Tissue Antigens** 1996 Jun;47(6):485–91

HLA class II antigens DR4 and DQ8 are associated with allergy to hevein, a major allergen of Hevea latex. Rihs HP, et al. **Tissue Antigens** 1997 Jan;49(1):92–5

Selective modulation of T cell memory markers CD62L and CD44 on murine draining lymph node cells following allergen and irritant treatment. Gerberick GF, et al. **Toxicol Appl Pharmacol** 1997 Sep;146(1):1–10

Immunochemical studies of stinging insect venom allergens. King TP. **Toxicon** 1996 Nov–Dec;34(11–12):1455–8 (23 ref.)

[Does the pork/cat syndrome constitute a predisposition to heparin allergy?] Drouet M, et al. **Allerg Immunol (Paris)** 1997 Feb;29(2):43–5 (Eng. Abstr.) **(Fre)**

[Evaluation of the reproducibility of the MAST technique for pneumoallergens and food allergens. Biological study] Sainte–Laudy J, et al. **Allerg Immunol (Paris)** 1996 Dec; 28(10):340–2 (Eng. Abstr.) **(Fre)**

[Pathogenetic significance of IgE–binding epitopes allergens (published erratum appears in Pneumologie 1996 Dec;50(12):938)] Bufe A, et al. **Pneumologie** 1996 Sep; 50(9):625–31 (55 ref.) **(Ger)**

[Incidence of cutaneous sensitization to environmental allergens in obstructive sleep apnea syndrome] Duchna HW, et al. **Pneumologie** 1997 Aug;51 Suppl 3:763–6 (Eng. Abstr.) **(Ger)**

[Important cross–reactive allergens] Helbling A. **Schweiz Med Wochenschr** 1997 Mar 8;127(10):382–9 (56 ref.) (Eng. Abstr.) **(Ger)**

[Cross–reacting allergens—panallergens] Ebner C. **Wien Med Wochenschr** 1996;146(15):404–5 (12 ref.) (Eng. Abstr.) **(Ger)**

[Measurement of proliferation of allergen–stimulated peripheral blood lymphocytes by flow cytometry] Kimura M, et al. **Arerugi** 1996 Oct;45(10):1119–26 (Eng. Abstr.) **(Jpn)**

[Enhanced lymphocyte proliferative response to house dust mite in the older but not in the younger asthmatic children] Kimura M, et al. **Arerugi** 1997 Apr;46(4):384–90 (Eng. Abstr.) **(Jpn)**

[Analysis of T cell epitopes on birch pollen allergen] Mizumoto K, et al. **Hokkaido Igaku Zasshi** 1997 Jan; 72(1):59–67 (Eng. Abstr.) **(Jpn)**

[Role of fungi in pathogenesis of adulthood bronchial asthma] Akiyama K. **Jpn J Antibiot** 1997 Jan;50(1):71–4; discussion 75–6 **(Jpn)**

[The effect of initial treatment by FP aqueous nasal spray in patients with Japanese cedar pollinosis] Nakabayashi S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Sep; 99(9):1162–71 (Eng. Abstr.) **(Jpn)**

[Pulmonary infiltration with eosinophilia due to rabbit–fur antigen: diagnosis by allergen inhalation test] Hommura F, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Apr; 35(4):455–60 (Eng. Abstr.) **(Jpn)**

[Molecular immunology of Japanese cedar pollen allergens: analysis of T cell epitopes] Hashiguchi S, et al. **Nippon Rinsho** 1996 Aug;54(8):2233–42 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Environmental allergens and allergic diseases] Akiyama K. **Rinsho Byori** 1997 Jan;45(1):13–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Studies of allergen specific IgE antibodies with atopic dermatitis—evaluation of house dust 6 (house dust Japan) specific IgE antibody] Takamura T, et al. **Rinsho Byori**

1996 Feb;44(2):163–8 (Eng. Abstr.) **(Jpn)**

[A novel diagnostic method for allergy "LUCICA HRT"] Yamakoshi M, et al. **Rinsho Byori** 1997 Feb;45(2):163–73 (Eng. Abstr.) **(Jpn)**

[Major feline allergen—Fel d I immunologic–biochemical aspects] Zielonka TM. **Pneumonol Alergol Pol** 1996; 64(7–8):497–504 (38 ref.) **(Pol)**

[Luminescent analysis of peripheral blood lymphocytes in subjects engaged in production hazardous in reference to allergens] Iusupova LB, et al. **Klin Lab Diagn** 1993 May–Jun;(3):39–44 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Clinical evaluation of histamine release test: a novel method for identifying allergens from the whole blood of allergic patients. Mamiya S, et al.
Acta Otolaryngol Suppl (Stockh) 1996;525:93–7

Quality parameters for the production of mite extracts. Eraso E, et al. **Allergol Immunopathol (Madr)** 1997 May–Jun; 25(3):113–7

Latex allergen elimination in natural latex sap and latex gloves by treatment with alkaline potassium hydroxide solution. Baur X, et al. **Allergy** 1997 Mar;52(3):306–11

Food allergy to pumpkinseed—characterization of allergens. Fritsch R, et al. **Allergy** 1997 Mar;52(3):335–7

Improvement of fruit allergenic extracts for immunoblotting experiments. Martínez A, et al. **Allergy** 1997 Feb; 52(2):155–61

Airborne fungus allergen in association with residential characteristics in atopic and control children in a subtropical region. Li CS, et al. **Arch Environ Health** 1997 Jan–Feb;52(1):72–9

Isolation, cDNA cloning and expression of Lig v 1, the major allergen from privet pollen. Batanero E, et al.
Clin Exp Allergy 1996 Dec;26(12):1401–10

Purification and characterization of a soybean hull allergen responsible for the Barcelona asthma outbreaks. II. Purification and sequencing of the Gly m 2 allergen. Codina R, et al. **Clin Exp Allergy** 1997 Apr;27(4):424–30

Overview on denominated allergens. Liebers V, et al.
Clin Exp Allergy 1996 May;26(5):494–516 (287 ref.)

The major allergen of Dendropanax trifidus Makino. Oka K, et al. **Contact Dermatitis** 1997 May;36(5):252–5

Purification, amino acid sequence and immunological characterization of Ole e 6, a cysteine–enriched allergen from olive tree pollen. Batanero E, et al. **FEBS Lett** 1997 Jun 30;410(2–3):293–6

Isolation and characterization of two cDNA clones coding for isoforms of the Parietaria judaica major allergen Par j 1.0101. Duro G, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):348–55

Purification of a major allergen, Asp f 2 binding to IgE in allergic bronchopulmonary aspergillosis, from culture filtrate of Aspergillus fumigatus. Banerjee B, et al.
J Allergy Clin Immunol 1997 Jun;99(6 Pt 1):821–7

Cross–reactivity between Cupressus arizonica and Cupressus sempervirens pollen extracts. Barletta B, et al.
J Allergy Clin Immunol 1996 Oct;98(4):797–804

Cloning and expression of complementary DNA coding for an allergen with common antibody–binding specificities with three allergens of the house dust mite Blomia tropicalis. Caraballo L, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):573–9

Identification of unique peanut and soy allergens in sera adsorbed with cross–reacting antibodies. Eigenmann PA, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):969–78

Identification of a novel hydroxyproline–rich glycoprotein as the major allergen in Parthenium pollen. Gupta N, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):903–12

The isolation and characterization of a novel collagenolytic serine protease allergen (Der p 9) from the dust mite Dermatophagoides pteronyssinus. King C, et al.
J Allergy Clin Immunol 1996 Oct;98(4):739–47

Yellow jacket venom allergens, hyaluronidase and phospholipase: sequence similarity and antigenic cross–reactivity with their hornet and wasp homologs and possible implications for clinical allergy. King TP, et al.
J Allergy Clin Immunol 1996 Sep;98(3):588–600

Characterization of Dac g 4, a major basic allergen from Dactylis glomerata pollen. Leduc–Brodard V, et al.
J Allergy Clin Immunol 1996 Dec;98(6 Pt 1):1065–72

Identification of the first major allergen of a squid (Todarodes pacificus). Miyazawa H, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):948–53

Cloning, sequencing and immunological characterization of Dac g 3, a major allergen from Dactylis glomerata pollen. Guérin–Marchand C, et al. **Mol Immunol** 1996 Jun; 33(9):797–806

Reinvestigation of the major peanut allergen Ara h 1 on molecular level. Buschmann L, et al. **Monogr Allergy** 1996; 32:92–8

[Optimization of a method of production of allergen extracts from ambrosia pollen] Gordienko AI, et al.
Ukr Biokhim Zh 1996 Jan–Feb;68(1):81–4 (Eng. Abstr.) **(Rus)**

[The isolation and characteristics of a chemically modified allergen (allergoid) from Dermatophagoides pteronyssinus mites] Petrunov B, et al.
Zh Mikrobiol Epidemiol Immunobiol 1996 Nov–Dec; (6):53–6 (Eng. Abstr.) **(Rus)**

METABOLISM

Pharmacokinetics of allergens after local administration. Falagiani P, et al. **Allergy** 1997;52(33 Suppl):17–21 (17 ref.)

RANTES in human allergen–induced rhinitis: cellular source and relation to tissue eosinophilia. Rajakulasingam K, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):696–703

Heterogeneous proteolytic specificity and activity of the house dust mite proteinase allergen Der p I. Hewitt CR, et al. **Clin Exp Allergy** 1997 Feb;27(2):201–7

Cell surface expression of two major yeast allergens in the Pityrosporum genus. Zargari A, et al. **Clin Exp Allergy** 1997 May;27(5):584–92

Interaction of human lung surfactant proteins A and D with mite (Dermatophagoides pteronyssinus) allergens. Wang JY, et al. **Clin Exp Immunol** 1996 Nov;106(2):367–73

Role of complex asparagine–linked glycans in the allergenicity of plant glycoproteins. Garcia–Casado G, et al. **Glycobiology** 1996 Jun;6(4):471–7

Innate defect? Bronchial epithelial cells of atopic patients with asthma lack the ability to activate allergens. Kimber I. **Hum Exp Toxicol** 1996 May;15(5):455

Allergen binding to specific IgE in the nasal mucosa of allergic patients. KleinJan A, et al.
J Allergy Clin Immunol 1997 Apr;99(4):515–21

Molecular characterization of Bip 1, a monoclonal antibody that modulates IgE binding to birch pollen allergen, Bet v 1. Laffer S, et al. **J Immunol** 1996 Dec 1;157(11):4953–62

Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. Visco V, et al.
J Immunol 1996 Jul 15;157(2):956–62

PHARMACOLOGY

Dual effects of allergen–mPEG conjugates. Induction of immunological suppression and inactivation of sensitized mast cells. Sehon AH, et al. **Adv Exp Med Biol** 1996; 409:177–84 (17 ref.)

Recombinant allergens. Steps on the way to diagnosis and therapy of type I allergy. Valenta R, et al.
Adv Exp Med Biol 1996;409:185–96 (31 ref.)

IgE–mediated basophil releasability is influenced by intrinsic factors and by IgE on the cell surface. Mita H, et al.
Allergy 1995 Dec;50(12):952–8

Allergen–induced cytokine production in atopic disease and its relationship to disease severity. Leonard C, et al.
Am J Respir Cell Mol Biol 1997 Sep;17(3):368–75

Mast cell numbers are increased in the smooth muscle of human sensitized isolated bronchi. Ammit AJ, et al.
Am J Respir Crit Care Med 1997 Mar;155(3):1123–9

Codfish allergy in adults: IgE cross–reactivity among fish species. Hansen TK, et al.
Ann Allergy Asthma Immunol 1997 Feb;78(2):187–94

Interaction between air pollutants and aeroallergens. Emberlin J. **Clin Exp Allergy** 1995 Nov;25 Suppl 3:33–9 (0 ref.)

Granulocyte function in the airways of allergen–challenged pigs: effects of inhaled and systemic budesonide. Fornhem C, et al. **Clin Exp Allergy** 1996 Dec;26(12):1436–48

Eosinophil locomotion and the release of IL–3 and IL–5 by allergen–stimulated mononuclear cells are effectively downregulated in vitro by budesonide. Lantero S, et al.
Clin Exp Allergy 1996 Jun;26(6):656–64

Insect venom immunotherapy induces interleukin–10 production and a Th2–to–Th1 shift, and changes surface marker expression in venom–allergic subjects.
Bellinghausen I, et al. **Eur J Immunol** 1997 May; 27(5):1131–9

Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of sensitization with antigen–specific IgE. Machado DC, et al. **Eur J Immunol** 1996 Dec; 26(12):2972–80

Allergen–induced release of GM–CSF and IL–8 in vitro by nasal polyp tissue from atopic subjects prolongs eosinophil survival. Park HS, et al. **Eur Respir J** 1997 Jul; 10(7):1476–82

Characterization of allergoids from ovalbumin in vitro and in vivo. Salgado J, et al. **Immunobiology** 1996;196(4):375–86

Effect of T–440, a novel type IV phosphodiesterase inhibitor, on allergen–induced immediate and late asthmatic reaction and leukocyte infiltration into the airways of guinea pigs. Kaminuma O, et al. **Int Arch Allergy Immunol** 1997 Apr; 112(4):406–11

Evidence that allergen–induced contraction of guinea pig bronchi is mediated in part by the release of tachykinins. Kohrogi H, et al. **Int Arch Allergy Immunol** 1997 Mar; 112(3):303–8

Neurotropin inhibits accumulation of eosinophils induced by allergen through the suppression of sensitized T–cells. Yoshii H, et al. **Int J Immunopharmacol** 1995 Nov; 17(11):879–86

Evaluation of single–dose inhaled corticosteroid activity with an allergen challenge model. Kidney JC, et al.
J Allergy Clin Immunol 1997 Jul;100(1):65–70

Attenuation of allergen–evoked nasal responses by local pretreatment with exogenous neuropeptide Y in atopic patients. Lacroix JS, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):611–6

Enhanced expression of high–affinity IgE receptor (Fc epsilon RI) alpha chain in human allergen–induced rhinitis with co–localization to mast cells, macrophages, eosinophils, and dendritic cells. Rajakulasingam K, et al.
J Allergy Clin Immunol 1997 Jul;100(1):78–86

Protective effect of inhaled lysine acetylsalicylate on allergen–induced early and late asthmatic reactions. Sestini P, et al. **J Allergy Clin Immunol** 1997 Jul;100(1):71–7

IL–5 secretion by allergen–stimulated CD4+ T cells in primary culture: relationship to expression of allergic disease. Till S, et al. **J Allergy Clin Immunol** 1997 Apr; 99(4):563–9

IgE and mast cell response on intestinal allergen exposure: a murine model to study the onset of food allergy. van Halteren AG, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):94–9

Failure of aged rats to accumulate eosinophils in allergic inflammation of the airway. Yagi T, et al.
J Allergy Clin Immunol 1997 Jan;99(1 Pt 1):38–47

Effects of neonatal immunization and repeated allergen exposure on airway responsiveness in the rabbit. Minshall E, et al. **J Appl Physiol** 1996 Jun;80(6):2108–19

Selective stimulation of cutaneous interleukin 6 expression by skin allergens. Holliday MR, et al. **J Appl Toxicol** 1996 Jan–Feb;16(1):65–70

Aeroallergen–induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL–4 and allergen–specific immunoglobulins. Hogan SP, et al. **J Clin Invest** 1997 Mar 15;99(6):1329–39

Altered T cell ligands derived from a major house dust mite allergen enhance IFN–gamma but not IL–4 production by human CD4+ T cells. Tsitoura DC, et al. **J Immunol** 1996 Sep 1;157(5):2160–5

Phenomenon of specific inhibition of luminol–dependent chemiluminescence of polymorphonuclear leukocytes under the influence of allergen. Pytsky VI, et al.
J Investig Allergol Clin Immunol 1996 Jul–Aug;6(4):256–60

Effects of contact allergens on human Langerhans cells in skin organ culture: migration, modulation of cell surface molecules, and early expression of interleukin–1 beta protein. Rambukkana A, et al. **Lab Invest** 1996 Feb; 74(2):422–36

Canine leucocyte histamine release: response to antigen and to anti–IgE. Jackson HA, et al.
Vet Immunol Immunopathol 1996 Oct;53(3–4):195–206

PHYSIOLOGY

Profilin: an update [letter] Baatout S.
Eur J Clin Chem Clin Biochem 1996 Jul;34(7):575–7

Allergen–induced recruitment of Fc epsilon RI+ eosinophils in human atopic skin. Barata LT, et al. **Eur J Immunol** 1997 May;27(5):1236–41

IL–4 as a key factor influencing the development of allergen–specific Th2–like cells in atopic individuals. Ricci M, et al. **J Investig Allergol Clin Immunol** 1997 May–Jun; 7(3):144–50 (63 ref.)

THERAPEUTIC USE

Clinical use of recombinant allergens and epitopes. Bousquet J, et al. **Adv Exp Med Biol** 1996;409:463–9 (48 ref.)

Diagnostic and therapeutic use of recombinant allergens. Kraft D. **Adv Exp Med Biol** 1996;409:471–4 (10 ref.)

Production of recombinant allergens and their application for immunotherapy. Okumura Y. **Adv Exp Med Biol** 1996; 409:163–71 (6 ref.)

Modulation of anti–allergen immune responses by allergen–antibody complexes. Saint–Remy JM.
Adv Exp Med Biol 1996;409:417–24 (24 ref.)

Advantages and disadvantages of recombinant allergens and peptides for specific immunotherapy. Schou C.
Adv Exp Med Biol 1996;409:137–40 (13 ref.)

Recombinant allergens for immunotherapy. Thomas WR.
Adv Exp Med Biol 1996;409:85–93 (78 ref.)

The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children. Caramia G, et al. **Allerg Immunol (Paris)** 1996 Nov;28(9):308–10

A double–blind, placebo–controlled study of preventive immunotherapy with E.P.D., in the treatment of seasonal allergic disease. Di Stanislao C, et al.
Allerg Immunol (Paris) 1997 Feb;29(2):39–42

Double–blind placebo controlled specific immunotherapy with mixed Cupressaceae taxodiaceae pollens in respiratory allergy to Cupressus sempervirens. Ariano R, et al.
Allergol Immunopathol (Madr) 1997 Jan–Feb;25(1):23–9

Rush sublingual immunotherapy in Parietaria allergic patients [published erratum appears in Allergol Immunopathol (Madr) 1996 Nov–Dec;24(6):262] D'Ambrosio FP, et al.
Allergol Immunopathol (Madr) 1996 Jul–Aug;24(4):146–51

The early effect of specific immunotherapy on lymphocyte response to PHA and allergens in atopic patients with allergic rhinitis. Kinikli G, et al.
Allergol Immunopathol (Madr) 1996 Mar–Apr;24(2):65–9

Specific immunotherapy in asthma: reflexions of an "old" allergist. The need for more clinical works. Panzani RC.
Allergol Immunopathol (Madr) 1997 Jan–Feb;25(1):52–7 (18 ref.)

Preseasonal specific immunotherapy with modified Phleum pratense allergenic extracts: tolerability and effects. Ricca V, et al. **Allergol Immunopathol (Madr)** 1997 Jul–Aug; 25(4):167–75

Preseasonal specific immunotherapy with modified phleum pratense allergenic extracts: tolerability and effects. Vittorio R, et al. **Allergol Immunopathol (Madr)** 1996 Nov–Dec;24(6):255–62

Specific immunotherapy (SIT) in children. Cantani AD, et al. **Allergy** 1996 May;51(5):365–6 (16 ref.)
Recombinant mite allergens. New technologies for the management of patients with asthma. Chapman MD, et al. **Allergy** 1997 Apr;52(4):374–9 (34 ref.)
Effects of immunotherapy on symptoms, PEFR, spirometry, and airway responsiveness in patients with allergic asthma to house–dust mites (D. pteronyssinus) on inhaled steroid therapy. Costa JC, et al. **Allergy** 1996 Apr;51(4):238–44
Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose–titration study. Olaguibel JM, et al. **Allergy** 1997 Feb; 52(2):168–78
Immunotherapy with an alum–adsorbed Parietaria–pollen allergoid: a 2–year, double–blind, placebo–controlled study. Tari MG, et al. **Allergy** 1997 Jan;52(1):65–74
New routes and formulations for allergen–specific immunotherapy. Wheeler AW, et al. **Allergy** 1997 Jun; 52(6):602–12 (72 ref.)
House dust mite immunotherapy results in a decrease in Der p 2–specific IFN–gamma and IL–4 expression by circulating T lymphocytes. O'Brien RM, et al. **Clin Exp Allergy** 1997 Jan;27(1):46–51
Clinical efficacy of specific immunotherapy to cat dander: a double–blind placebo–controlled trial. Varney VA, et al. **Clin Exp Allergy** 1997 Aug;27(8):860–7
Treatment of alopecia areata with squaric acid dibutylester. Micali G, et al. **Int J Dermatol** 1996 Jan;35(1):52–6
Practice parameters for allergen immunotherapy. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1001–11
Risk management in allergen immunotherapy. Greineder DK. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S330–4 (24 ref.)
Short–term immunotherapy: a prospective, randomized, double–blind, placebo–controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen–induced allergic rhinitis. Zenner HP, et al. **J Allergy Clin Immunol** 1997 Jul;100(1):23–9
Epitope–specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL–2 and IL–15 in vitro. Akdis CA, et al. **J Clin Invest** 1996 Oct 1; 98(7):1676–83
Localized periorbital edema as a clinical manifestation of sulfite sensitivity. Park HS, et al. **J Korean Med Sci** 1996 Aug;11(4):356–7
Dusting off recombinant allergens [news; comment] Marshall GD Jr, et al. **Nat Biotechnol** 1997 Aug;15(8):718–9. Comment on: Nat Biotechnol 1997 Aug;15(8):754–8.
Rush immunotherapy with house dust extract in patients with mild extrinsic asthma. Hirokawa Y, et al. **Tohoku J Exp Med** 1996 Apr;178(4):371–80

TOXICITY

Characterization of soybean allergens causing sensitization of occupationally exposed bakers. Baur X, et al. **Allergy** 1996 May;51(5):326–30
Increased immune and inflammatory responses to dust mite antigen in rats exposed to 5 ppm NO2. Gilmour MI, et al. **Fundam Appl Toxicol** 1996 May;31(1):65–70
Workshop overview. Identification of respiratory allergens. Kimber I, et al. **Fundam Appl Toxicol** 1996 Sep;33(1):1–10
Early and late phase bronchoconstrictions in conscious sensitized guinea–pigs after macro– and microshock inhalation of allergen and associated airway accumulation of leukocytes. Lewis CA, et al. **Int J Immunopharmacol** 1996 Jun–Jul;18(6–7):415–22
Evaluation of the sensitizing potential of eugenol and isoeugenol in mice and guinea pigs. Hilton I, et al. **J Appl Toxicol** 1996 Sep–Oct;16(5):459–64
Application of sensitive mouse lymph node assay for detection of contact sensitization capacity of dyes. Ikarashi Y, et al. **J Appl Toxicol** 1996 Jul–Aug;16(4):349–54
Local lymph node activation and IgE responses in brown Norway and Wistar rats after dermal application of sensitizing and non–sensitizing chemicals. Arts JH, et al. **Toxicology** 1997 Feb 28;117(2–3):229–34
Assessment of the sensitization potential of five metal salts in the murine local lymph node assay. Mandervelt C, et al. **Toxicology** 1997 Jun 6;120(1):65–73

URINE

Exposure of laboratory animal workers to airborne rat and mouse urinary allergens. Hollander A, et al. **Clin Exp Allergy** 1997 Jun;27(6):617–26

ALLERGIC ALVEOLITIS, EXTRINSIC see **ALVEOLITIS, EXTRINSIC ALLERGIC**

ALLERGIC ANGIITIS see **CHURG–STRAUSS SYNDROME**

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS see **ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY**

ALLERGIC CONJUNCTIVITIS see **CONJUNCTIVITIS, ALLERGIC**

ALLERGIC CONTACT DERMATITIS see **DERMATITIS, ALLERGIC CONTACT**

ALLERGIC CUTANEOUS ANGIITIS see **VASCULITIS, ALLERGIC CUTANEOUS**

ALLERGIC CUTANEOUS VASCULITIS see **VASCULITIS, ALLERGIC CUTANEOUS**

ALLERGIC GRANULOMATOUS ANGIITIS see **CHURG–STRAUSS SYNDROME**

ALLERGIC PURPURA see **PURPURA, SCHOENLEIN–HENOCH**

ALLERGY see **HYPERSENSITIVITY**

ALLERGY (SPECIALTY) see **ALLERGY AND IMMUNOLOGY**

ALLERGY AND IMMUNOLOGY

The annual meeting of the European Academy of Allergology and Clinical Immunology. EAACI '96. Budapest, Hungary, June 2–5, 1996. Abstracts. **Allergy** 1996;51(31 Suppl):1–208
XIX Nordic Congress on Allergology. Helsinki, Finland, August 10–13, 1996. Abstracts. **Allergy** 1996;51(32 Suppl):1–106
Information technology and media in allergy. The Computing Group of the Audiovisual Subcommittee of the European Academy of Allergology and Clinical Immunology. **Allergy** 1996 Sep;51(9):603–7 (23 ref.)
The annual meeting of the European Academy of Allergology and Clinical Immunology (EAACI) '97. Rhodes, Hellas, June 1–5, 1997. Abstracts. **Allergy** 1997; 52(37 Suppl):10–253
Referral pattern to the allergist for hay fever in a health–care system with open access to specialists. Francillon C, et al. **Allergy** 1995 Dec;50(12):959–63
Transpacific allergy and immunology: research abstracts. **Allergy Asthma Proc** 1996 May–Jun;17(3):115–35
The role of outcome studies in allergy and clinical immunology. Blaiss MS. **Allergy Asthma Proc** 1996 Nov–Dec;17(6):355–8 (15 ref.)
Care of asthma: allergy clinic versus emergency room. Moore CM, et al. **Ann Allergy Asthma Immunol** 1997 Apr; 78(4):373–80
Specialty differences in the management of asthma. A cross–sectional assessment of allergists' patients and generalists' patients in a large HMO. Vollmer WM, et al. **Arch Intern Med** 1997 Jun 9;157(11):1201–8
Rheumatology and immunology in Bergen—from basic science to clinical application. Haga HJ, et al. **Br J Rheumatol** 1996 Nov;35(11):1159–60
Secrecy in research: cooperation and costimulation in immunology [editorial] Rosenberg SA. **Curr Opin Immunol** 1996 Oct;8(5):611–2
Why I think the chicken should survive in immunology and developmental biology. Simonsen M. **Curr Top Microbiol Immunol** 1996;212:1–6 (6 ref.)
The 7th Congress of the International Society of Developmental and Comparative Immunology. Williamsburg, Virginia, July 21–25, 1997. Abstracts. **Dev Comp Immunol** 1997 Mar–Apr;21(2):77–252
Current recommendations for the management of bladder cancer. Drug therapy. Witjes JA. **Drugs** 1997 Mar; 53(3):404–14 (67 ref.)
IUPAC–IUBMB Joint Commission on Biochemical Nomenclature (JCBN) and Nomenclature Committee of IUBMB (NC–IUBMB). Newsletter 1996. Liébecq C. **Eur J Biochem** 1997 Jul 15;247(2):733–9
Tolerance: a case of self/not–self discrimination maintained by clonal deletion? Lafferty KJ, et al. **Hum Immunol** 1997 Feb;52(2):119–26 (45 ref.)
27th annual meeting of the Deutsche Gesellschaft für Immunologie. Hamberg, September 26–28, 1996. Abstracts. **Immunobiology** 1996;196(1–3):1–320
Invited contributions from the 13th European Immunology Meeting. Amsterdam, The Netherlands, 22–25 June 1997. **Immunol Lett** 1997 Jun 1;57(1–3):1–223
13th European Immunology Meeting. Amsterdam, The Netherlands, 22–25 June 1997. Abstracts. **Immunol Lett** 1997 May;56(1–3):1–525
Joint Congress of the British Society for Immunology and the Biochemical Society. Harrogate, United Kingdom, 10–13 December 1996. Abstracts. **Immunology** 1996 Nov; 89 Suppl 1:1–101
Allergy—A Disease of Modern Society. Proceedings of the 21st Symposium of the Collegium Internationale Allergolgicum. Salzburg, Austria, September 6–11, 1996. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):1–392
American Academy of Allergy, Asthma and Immunology, the American Association of Immunologists, Clinical Immunology Society joint meeting. San Francisco, California, February 21–26, 1997. Abstracts. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 2):S1–738
Veterinarian honored with Nobel Prize in medicine [news] Meehan SK. **J Am Vet Med Assoc** 1996 Nov 15; 209(10):1671, 1673
VII Congress of the Italian Neuroimmunology Group. Annunziata P, et al. **J Neuroimmunol** 1997 May; 75(1–2):210–1
Polly Matzinger: immunology's dangerous thinker [news] Larkin M. **Lancet** 1997 Jul 5;350(9070):38
Creating knowledge relevant for public health applications in immunology and aging. Dean K. **Mech Ageing Dev** 1997 Mar;94(1–3):251–62 (64 ref.)
Cytokine research as one of the exciting fields in immunology [editorial] Benjamin D. **Methods** 1997 Jan;11(1):81–2
Immunology resources on the World Wide Web. Skipper J, et al. **Mol Med Today** 1996 Aug;2(8):320–3
Diverse opportunities for immunologists. Horton B, et al. **Nature** 1997 Feb 13;385(6617):657–60
Nobel goes to T–cell pioneers whose work 'changed face of immunology' [news] Masood E, et al. **Nature** 1996 Oct 10;383(6600):465
Proceedings of the joint meeting of the European Society of Pediatric Allergy and Clinical Immunology (ESPACI) and the Paediatric Assembly of the European Respiratory Society (ERS). Odense, Denmark, May 22–25, 1996. **Pediatr Allergy Immunol** 1996;7(9 Suppl):1–122
Synopsis book. Best articles relevant to pediatric allergy and immunology. 1995–1996. **Pediatrics** 1997 Aug;100(2 Pt 2):279–321
Immune responses: diversity of initiation and functional outcome. Proceedings of the 1996 European Network of Immunology Institutes (ENII) conference. Les Embiez, France, May 15–19, 1996. **Res Immunol** 1996 Sep; 147(7):457–79
The XXIVth National Immunology Conference. Bucharest, 25 September 1995. Abstracts. **Roum Arch Microbiol Immunol** 1995 Jul–Sep;54(3):141–234
Anniversary scientific session. Bucharest, September 17–19, 1996. Abstracts. **Roum Arch Microbiol Immunol** 1996 Jan–Mar;55(1):5–86
The XXVth National Immunology Conference. Bucharest, 9–11 September 1996. Abstracts. **Roum Arch Microbiol Immunol** 1996 Apr–Jun;55(2):147–71
The 1996 Nobel prizes in science. Unveiling an antiviral defense. Rennie J, et al. **Sci Am** 1997 Jan;276(1):16, 18
Nobel prizes. Unraveling immune–cell mysteries [news] Gura T. **Science** 1996 Oct 18;274(5286):345
Mathematical and computational challenges in population biology and ecosystems science. Levin SA, et al. **Science** 1997 Jan 17;275(5298):334–43 (108 ref.)
Papers presented at the 4th Summer School in Immunotoxicology. Aix–les–Bains, France, 18–20 October 1995. **Toxicology** 1997 Apr 11;119(1):1–101
Cumulative indexes–volumes 26–50, 1990–1996. **Vet Immunol Immunopathol** 1996 Apr;50(3–4):185–359
Proceedings of the 4th International Veterinary Immunology Symposium. Davis, California, July 1995. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):1–387
[National meeting of the French Society of Clinical Allergy and Immunology. Angers, France, May 8–11, 1996. Abstracts] **Allerg Immunol (Paris)** 1996 May;28(5):150–74 **(Fre)**
[Nobel Prize for medicine 1996] Hengartner H. **Dtsch Med Wochenschr** 1996 Dec 20;121(51–52):1616–8 **(Ger)**
[9th spring meeting of the Japanese Society of Allergology. Chiba, Japan. May 1–3, 1997. Abstracts] **Arerugi** 1997 Mar; 46(2–3):65–346 **(Jpn)**
[8th spring meeting of the Japanese Society of Allergology. Yokohama, Japan. April 25–27, 1996. Abstracts] **Arerugi** 1996 Mar;45(2–3):83–362 **(Jpn)**
[46th general meeting of the Japanese Society of Allergology, Tochigi, Japan. October 30–November 1, 1996. Abstracts] **Arerugi** 1996 Sep;45(8–9):680–1074 **(Jpn)**
[The 25th annual meeting of the Japanese Society of Clinical Immunology. Tokyo. Japan. September 17–19, 1997. Abstracts] **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Aug; 20(4):207–415 **(Jpn)**
[Resolution of the main board of the Polish Society of Allergology] Płusa T. **Pneumonol Alergol Pol** 1997; 65(1–2):129–33 **(Pol)**
[Anniversary scientific session of the Cantacuzino Institute and the Pasteur Institute. Bucharest, 17–19 September 1996. Abstracts] **Bacteriol Virusol Parazitol Epidemiol** 1996 Jul–Dec;41(3–4):161–94 **(Rum)**
[Problems of noninvasive diagnosis in a clinical laboratory: materials and methods] Men'shikov VV, et al. **Klin Lab Diagn** 1996 Jul–Aug;(4):33–8 **(Rus)**
[The allergist in the education of asthma concepts for the non–specialist (editorial)] Pérez Martín J. **Rev Alerg Mex** 1996 May–Jun;43(3):50–1 **(Spa)**

ECONOMICS

Legal issues in allergy and clinical immunology. Gibofsky A. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S334–8 (34 ref.)
Economic and political implications of immunology and aging on tomorrow's society. Butler RN. **Mech Ageing Dev** 1997 Feb;93(1–3):7–13

EDUCATION

Medical students' views on the teaching of immunology [letter] Bansal AS. **Acad Med** 1997 Aug;72(8):662
Clinical neuroimmunology. Xu X, et al. **Adv Neuroimmunol** 1996;6(3):249–57
European Academy of Allergology and Clinical Immunology (EAACI) guidelines for continuing medical education.

Essentials for accreditation, standards for commercial support, and system of credits. Buscaglia S, et al. **Allergy** 1997 May;52(5):490–503

Who knows how to use a metered dose inhaler? [letter; comment] Lee–Chiong TL Jr. **Ann Allergy Asthma Immunol** 1997 May;78(5):525. Comment on: Ann Allergy Asthma Immunol 1996 Feb;76(2):145–8.

The allergist as an educator: an evolving relationship between specialty and primary care clinicians [editorial] Squillace SP, et al. **Ann Allergy Asthma Immunol** 1996 Nov; 77(5):341–4 (16 ref.)

On hubris and humility [editorial] Metzger H. **Curr Opin Immunol** 1996 Dec;8(6):763–5

Allergy and immunology core curriculum outline 1996. Core Curriculum Subcommittee of the Training Program Directors. American Academy of Allergy, Asthma and Immunology. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1012–5

On the semantics of immune recognition. Medzhitov R, et al. **Res Immunol** 1996 May;147(4):208–14 (31 ref.)

Workshop: veterinary immunology teaching. Brunner CJ. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):385–7

HISTORY

Sheer luck made me an immunologist. Koshland ME. **Annu Rev Immunol** 1996;14:viii–xv

Paul Ehrlich: pathfinder in cell biology. 1. Chronicle of his life and accomplishments in immunology, cancer research, and chemotherapy. Kasten FH. **Biotech Histochem** 1996 Jan;71(1):2–37

Paul Ehrlich: the founding of pediatric immunology. Silverstein AM. **Cell Immunol** 1996 Nov 25;174(1):1–6

Allergic Lung Disease. Proceedings of a symposium dedicated to Jack Pepys. London, United Kingdom, 22 May 1996. **Clin Exp Allergy** 1997 May;27 Suppl 1:vii, 1–86

The life and work of Jack Pepys. Kay AB. **Clin Exp Allergy** 1997 May;27 Suppl 1:1–3

The discovery of immunologic tolerance. Brent L. **Hum Immunol** 1997 Feb;52(2):75–81

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG [published erratum appears in Immunol Res 1997;16(2):215] Junghans RP. **Immunol Res** 1997 Feb; 16(1):29–57 (108 ref.)

The development of otolaryngic allergy in the United States. Mabry RL, et al. **Laryngoscope** 1997 Feb;107(2):158–60

Economic and political implications of immunology and aging on tomorrow's society. Butler RN. **Mech Ageing Dev** 1997 Feb;93(1–3):7–13

Immunology and the elderly: an historical perspective for future international action. Weksler ME. **Mech Ageing Dev** 1997 Feb;93(1–3):1–6

A hundred years of vaccination: the legacy of Louis Pasteur. Plotkin SA. **Pediatr Infect Dis J** 1996 May;15(5):391–4

Darwinism and antibody diversity: a historical perspective. Podolsky SH, et al. **Res Immunol** 1996 May;147(4):199–202 (23 ref.)

Eva Klein: the Ruggero Ceppellini lecturer, 1997. Gergely J. **Tissue Antigens** 1997 May;49(5):544–5

[Historical outline of immune system study] Gołąb B. **Arch Hist Med (Warsz)** 1972;35(4):443–7 **(Pol)**

[Obituary notice. Professor Stefan Slopek (1914–1995). Participating member of PAN] Mordarski M. **Med Dosw Mikrobiol** 1995;47(3–4):117–8 **(Pol)**

[Immunology in its century. Miguel F. Jiménez Conference, 1996] Kretschmer RR. **Gac Med Mex** 1996 Nov–Dec; 132(6):599–609 **(Spa)**

[The golden age of Dr. Carlos Canseco González: the man, the doctor, and the Rotarian (editorial)] González Díaz SN, et al. **Rev Alerg Mex** 1996;43 Spec No:2–5 **(Spa)**

INSTRUMENTATION

Immunology and the confocal microscope. Ojcius DM, et al. **Res Immunol** 1996 Mar–Apr;147(3):175–88 (40 ref.)

LEGISLATION & JURISPRUDENCE

Legal issues in allergy and clinical immunology. Gibofsky A. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S334–8 (34 ref.)

MANPOWER

Training Program Directors Committee position statement on Health Care Reform. American Academy of Allergy, Asthma and Immunology. **J Allergy Clin Immunol** 1996 Oct;98(4):719–20

METHODS see IMMUNOLOGIC TECHNIQUES

STANDARDS

Asthma care [letter; comment] Yawn BP. **N J Med** 1996 Sep;93(9):10. Comment on: N J Med 1996 Mar;93(3):168–70.

TRENDS

How do lymphocytes know where to go: current concepts and enigmas of lymphocyte homing. Salmi M, et al. **Adv Immunol** 1997;64:139–218 (568 ref.)

Seeking a common language for artificial organists, transplantologists, and immunologists [editorial] Nosé Y. **Artif Organs** 1996 Oct;20(10):1061

An evaluation of immunology in Brazil (1981–1993). Rumjanek VM, et al. **Braz J Med Biol Res** 1996 Aug; 29(8):923–31

Recent Progress in the research and development of immunoprotected cell therapy. Lysaght MJ. **Cell Transplant** 1996 Sep–Oct;5(5 Suppl 1):S3–4 (8 ref.)

The Erwin Neter Memorial Lecture: looking to the future of medical laboratory immunology, a personal view. Normansell DE. **Clin Diagn Lab Immunol** 1996 Jul; 3(4):369–70

The Th2 cell in asthma: initial expectations yet to be realised. Krug N, et al. **Clin Exp Allergy** 1997 Feb;27(2):142–50 (82 ref.)

On hubris and humility [editorial] Metzger H. **Curr Opin Immunol** 1996 Dec;8(6):763–5

Immunologic renaissance in the 21st century. Cruse JM, et al. **Immunol Res** 1997 Feb;16(1):1–2

HLA–C revisited. Ten years of change. Falk CS, et al. **Immunol Res** 1997;16(2):203–14 (77 ref.)

Murine natural killer cell differentiation: past, present, and future. Moore TA, et al. **Immunol Res** 1996;15(2):151–62 (94 ref.)

European Immunologists meet in Amsterdam. Clevers H, et al. **Immunol Today** 1997 Jun;18(6):257

New perspectives on recombinant human antibodies. de Kruif J, et al. **Immunol Today** 1996 Oct;17(10):453–5 (13 ref.)

Immunology in emerging nations. Robertson SA, et al. **Immunol Today** 1996 Oct;17(10):445

Role of the allergist/immunologist as a subspecialist. Committee on the Role of the Allergist/Immunologist as a Subspecialist. **J Allergy Clin Immunol** 1997 Sep; 100(3):288–9

Reduction of the central nervous system adverse effects associated with antihistamines in the management of allergic disorders: strategies and progress. Gengo FM. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S319–25 (31 ref.)

Allergy care in the next millennium: guidelines for the specialty. Kaliner M. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):729–34

Changing concepts of allergic disease: the attempt to keep up with real changes in lifestyles. Platts–Mills TA, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 3):S297–306 (75 ref.)

New directions in food allergy research. Plaut M. **J Allergy Clin Immunol** 1997 Jul;100(1):7–10

Highlights of the Thomas G. Wegmann Memorial Symposium on Reproductive Immunology, Banff, Canada: 10–12 September 1996. Head JR. **J Reprod Immunol** 1997 Feb;32(3):193–200

Immunology update: topics in basic and clinically applied reproductive immunology. Hunt JS. **J Reprod Immunol** 1996 May;30(2–3):187–9

Reproductive immunology update: the 52nd annual meeting of the American Society of Reproductive Medicine. Kauma SW. **J Reprod Immunol** 1997 Feb;32(3):265–8

BSI workshop on cytokines in reproduction. Searle R. **J Reprod Immunol** 1996 May;30(2–3):191–3

Immunology update: symposium on antiphospholipid antibodies. Silver RM. **J Reprod Immunol** 1997 Feb; 32(3):269–72

Food allergy: problems, fiction and hard facts. de Weck AL. **Monogr Allergy** 1996;32:1–8 (22 ref.)

Impact of the discovery of membrane inhibitors of complement. Atkinson JP. **Res Immunol** 1996 Feb; 147(2):95–100 (58 ref.)

The evolutionary origins of immunoglobulins and T-cell receptors: possibilities and probabilities. Langman RE. **Res Immunol** 1996 May;147(4):214–7 (2 ref.)

HLA: what's in a name? A commentary on HLA nomenclature development over the years. Bodmer WF. **Tissue Antigens** 1997 Mar;49(3 Pt 2):293–6 (5 ref.)

Mutant and transgenic mice in immunotoxicology: an introduction. Løvik M. **Toxicology** 1997 Apr 11; 119(1):65–76 (64 ref.)

Current trends in drug–induced autoimmunity. Uetrecht JP. **Toxicology** 1997 Apr 11;119(1):37–43 (41 ref.)

The immunology of domestic animals: its present and future. Charley B. **Vet Immunol Immunopathol** 1996 Nov; 54(1–4):3–6

[Immunomorphology––yesterday, today and tomorrow] Trufakin Va, et al. **Vestn Ross Akad Med Nauk** 1996; (6):38–42 (48 ref.) (Eng. Abstr.) **(Rus)**

[The ideas of Louis Pasteur and the development of infectology and immunology] Vorob'ev AA. **Vestn Ross Akad Med Nauk** 1996;(6):6–11 **(Rus)**

ALLERTON VIRUS see **HERPESVIRUS 2, BOVINE**

ALLESCHERIA see **PSEUDALLESCHERIA**

ALLETHRIN

Bioefficacy of mosquito mat, coil and dispenser formulations containing allethrin group of synthetic pyrethroids against mosquito vectors. Amalraj DD, et al. **J Commun Dis** 1996 Jun;28(2):85–93

STANDARDS

Biological activity of permethrin, phenothrin/allerthrin and D–phenothrin on Periplaneta americana and Blattella germanica cockroaches. Lukwa N, et al. **East Afr Med J** 1997 Apr;74(4):252–4

ALLIED HEALTH OCCUPATIONS

Undervalued resources: the professions allied to medicine. Robinson PR. **Br J Hosp Med** 1997 Feb 19–Mar 4; 57(4):167–8

Mapping the literature of allied health: project overview. Schloman BF. **Bull Med Libr Assoc** 1997 Jul;85(3):271–7

Index of graduate theses and projects in allied health. **J Allied Health** 1995 Fall;24(4):283–357

Internet resources for allied health professionals. Hedl JJ Jr. **J Allied Health** 1996 Spring;25(2):179–88

EDUCATION

Potential patterns––conceptual and practical issues in interdisciplinary education. Huff F, et al. **J Allied Health** 1995 Fall;24(4):359–65

Ethics education: curricular considerations for the allied health disciplines. Layman E. **J Allied Health** 1996 Spring; 25(2):149–60 (65 ref.)

A case for unique allied health student enrollment control within a selective university setting. Shaw RC, et al. **J Allied Health** 1996 Spring;25(2):161–70

The 1996 National Pilot Data Collection Project of the Association of Schools of Allied Health Professions. Wingate L. **J Allied Health** 1997 Winter;26(1):45–6

Predictors of students' success in the Medical Service Apprentice course. Porter RD, et al. **Mil Med** 1997 Jul; 162(7):495–500

The facilitated lecture. Cross DS, et al. **Radiol Technol** 1997 Mar–Apr;68(4):339–42

MANPOWER see ALLIED HEALTH PERSONNEL

ALLIED HEALTH PERSONNEL

Undervalued resources: the professions allied to medicine. Robinson PR. **Br J Hosp Med** 1997 Feb 19–Mar 4; 57(4):167–8

Assessing and addressing the library needs of health care personnel in a large regional hospital. Crabtree AB, et al. **Bull Med Libr Assoc** 1997 Apr;85(2):167–75

Regarding Brasil, et al.'s adverse effects in leprosy's WHO/MDT and paramedic's role in leprosy control program [letter; comment] Cunha M da G, et al. **Int J Lepr Other Mycobact Dis** 1997 Jun;65(2):257–9. Comment on: Int J Lepr Other Mycobact Dis 1996 Jun;64(2):97–104.

Paramedic care: the case for minimum intervention [letter] Evans S. **J Accid Emerg Med** 1997 Jan;14(1):60

Effectiveness of ambulance paramedics versus ambulance technicians in managing out of hospital cardiac arrest. Nguyen–Van–Tam JS, et al. **J Accid Emerg Med** 1997 May; 14(3):142–8

Efficiency and effectiveness to shape our future. Barr JT. **J Allied Health** 1997 Winter;26(1):3–5

Internet resources for allied health professionals. Hedl JJ Jr. **J Allied Health** 1996 Spring;25(2):179–88

The evolving health care system: the role of the Health Resources and Services Administration. Sumaya CV. **J Allied Health** 1997 Winter;26(1):17–9

Implementation of the Patient Self–Determination Act (PSDA) in nursing homes in New York City [see comments] Mezey M, et al. **J Am Geriatr Soc** 1997 Jan; 45(1):43–9. Comment in: J Am Geriatr Soc 1997 Jan;45(1):114–6.

Postexposure prophylaxis after an occupational exposure to HIV. Porche DJ. **J Assoc Nurses AIDS Care** 1997 Jan–Feb; 8(1):83–7

Do fireservice paramedics (EMT–P) seek follow–up medical information about patients brought to a level I trauma center? [letter] Chapman JJ. **J Emerg Med** 1997 Jan–Feb; 15(1):107

The South Carolina Geriatric Rural Initiative Project: the paraprofessional geriatric technician in care coordination. Hornung CA, et al. **J S C Med Assoc** 1997 Jul;93(7):248–54

Knowledge, attitude and practice survey of acquired immune deficiency syndrome (AIDS) among paramedicals in a tertiary care hospital in Pakistan. Siddiqi S, et al. **JPMA J Pak Med Assoc** 1995 Aug;45(8):200–2

Tuberculosis skin test conversion among health care workers at a military medical center. Ball R, et al. **Mil Med** 1997 May;162(5):338–43

Improving combat casualty care and field medicine: focus on the military medic. De Lorenzo RA. **Mil Med** 1997 Apr;162(4):268–72

Intravenous line diameter: is bigger really better? [see comments] Leibovici D, et al. **Mil Med** 1997 Mar; 162(3):183–5. Comment in: Mil Med 1997 Jun;162(6):ii–iii.

Working with AIDS patients [letter] Gauch RR. **N J Med** 1997 Mar;94(3):8

Are MIBI/tetrofosmin heart studies a potential radiation hazard to technologists? Clarke EA, et al. **Nucl Med Commun** 1997 Jun;18(6):574–7

Making use of portable defibrillators. Ezelle PA. **Occup Health Saf** 1997 Feb;66(2):53–5, 61

Role of allied health professionals in policy making and legislative actions. Sumaya CV. **P R Health Sci J** 1997 Mar;16(1):55–6

Pentamidine aerosols and environmental contamination: health-care workers at risk. Ros JJ, et al. **Pharm World Sci** 1996 Aug;18(4):148-52

Predictors of weight increases over 7 years in fire fighters and paramedics. Gerace TA, et al. **Prev Med** 1996 Sep-Oct; 25(5):593-600

Paraprofessional delivery of a theory based HIV prevention counseling intervention for women. Cabral RJ, et al. **Public Health Rep** 1996;111 Suppl 1:75-82

A patient writes: listen, care, empathize [editorial] Greathouse GF. **Radiol Technol** 1997 Mar-Apr;68(4):360

Chemical substance use among R.T.s in Georgia. Lam RW, et al. **Radiol Technol** 1996 Jul-Aug;67(6):501-12

[Testing a medically-staffed ambulance in Aarhus. A pilot study] Hansen TM, et al. **Ugeskr Laeger** 1996 Sep 23; 158(39):5438-42 (Eng. Abstr.) **(Dan)**

EDUCATION

CBS program promotes strong interdisciplinary foundation [letter] Belch R, et al. **Acad Med** 1997 May;72(5):319-20

Prerequisites for academic occupational therapy assistant programs. Gitlow L. **Am J Occup Ther** 1997 May; 51(5):385-7

Program and curriculum characteristics of allied health master's degree programs that prepare health professionals for educational roles. **J Allied Health** 1996 Fall; 25(4):389-402

Allied health faculty attitudes toward rural clinical practice. Boonyawiroj EB, et al. **J Allied Health** 1996 Summer; 25(3):263-74

The role of national skill standards in the design of core curriculum in allied health. DaVanzo JE. **J Allied Health** 1997 Spring;26(2):71-6 (18 ref.)

Moving toward a core curriculum in Schools of the Allied Health Professions: knowledge and skills considered important by department chairs in four disciplines. Elder OC Jr, et al. **J Allied Health** 1997 Spring;26(2):51-6

Innovative teaching methods to enhance training in managed care issues. Hallowell B. **J Allied Health** 1997 Winter; 26(1):31-4

Changes in student perceptions of interdisciplinary practice in the rural setting. Hayward KS, et al. **J Allied Health** 1996 Fall;25(4):315-27

Mergers and re-engineering--possible implications for allied health students (the Minnesota Story). Karni KR. **J Allied Health** 1997 Winter;26(1):35-40

Medical training in the army from first aid to advanced trauma life support. The development of an integrated package [letter] Gale RG. **J R Army Med Corps** 1994 Jun; 140(2):99-100

The Royal Naval Reserve Medical Service Medical Support Assistant revisited. Brockie B. **J R Nav Med Serv** 1996 Summer;82(2):117-8

Integrating a theoretical framework with street outreach services: issues for successful training. Cheney R, et al. **Public Health Rep** 1996;111 Suppl 1:83-8

Intubation with laryngoscope versus transillumination performed by paramedic students on manikins and cadavers. Wik L, et al. **Resuscitation** 1997 Jan;33(3):215-8

Where have all the doctors gone--and does it matter? Snadden D. **Scott Med J** 1996 Aug;41(4):105-7

Problem-based learning for tuberculosis and leprosy supervisors. Alabi GA, et al. **World Health Forum** 1996; 17(4):411-4

LEGISLATION & JURISPRUDENCE

$3 Million suit exposes 'de-skilling' [news] **Am J Nurs** 1996 Nov;96(11):70

Who shoulders the risk? Liability and allied health providers. McBride D. **Iowa Med** 1996 May-Jun;86(5):201-2

Liability and allied health professionals. Whose risk is it anyway? Midwest Medical Insurance Company, Risk Management Committee. **Minn Med** 1996 Sep;79(9):29-31

[Prohibition of competition for practice assistants in promotion. Verdict of the Federal Court on June 13, 1996] Rieger HJ. **Dtsch Med Wochenschr** 1997 May 9; 122(19):627-30 **(Ger)**

PSYCHOLOGY

Perception of sickle cell haemoglobinopathy among 'would-be' counsellors. Omotade OO. **Afr J Med Med Sci** 1995 Dec;24(4):315-20

From "bugging-out" to "chilling-out": manipulating emotion and evoking reason in a forensic psychiatric hospital. Gaffin D. **Cult Med Psychiatry** 1996 Jun;20(2):199-228

Posttraumatic stress disorder, ego defense mechanisms, and empathy among urban paramedics. Grevin F. **Psychol Rep** 1996 Oct;79(2):483-95

Paramedics organizational culture and their care for relatives of cardiac arrest victims. Steen E, et al. **Resuscitation** 1997 Feb;34(1):57-63

Social support and network conflict in firefighters and paramedics. Beaton RD, et al. **West J Nurs Res** 1997 Jun; 19(3):297-313

STANDARDS

Health hazards in nursing and health care: an overview. Rogers B. **Am J Infect Control** 1997 Jun;25(3):248-61 (154 ref.)

Paramedic skills. Two tier system of advanced life support and basic life support ambulances is needed [letter; comment] Carley S, et al. **BMJ** 1997 Feb 8;314(7078):445 . Comment on: BMJ 1996 Oct 26;313(7064):1052-3.

Paramedic skills. Data collected on paramedic care need national standardisation [letter; comment] Goodacre S, et al. **BMJ** 1997 Feb 8;314(7078):444-5. Comment on: BMJ 1996 Oct 26;313(7064):1052-3.

The role of national skill standards in the design of core curriculum in allied health. DaVanzo JE. **J Allied Health** 1997 Spring;26(2):71-6 (18 ref.)

Multi-competencies: a challenge for the allied health professions. Blasini-Caceres L, et al. **P R Health Sci J** 1997 Mar;16(1):67-75

STATISTICS & NUMERICAL DATA

The lay death investigator: in search of a common ground. Haglund WD, et al. **Am J Forensic Med Pathol** 1997 Mar; 18(1):21-5

Prevalence of childhood sexual abuse among Malaysian paramedical students. Singh HS, et al. **Child Abuse Negl** 1996 Jun;20(6):487-92

The underrepresentation of Hispanic women in the health professions. Zambrana RE. **J Am Med Womens Assoc** 1996 Aug-Oct;51(4):147-52 (13 ref.)

SUPPLY & DISTRIBUTION

Allied health workforce shortages: the systemic barriers to response. Jones WJ, et al. **J Allied Health** 1996 Summer; 25(3):219-32

Labor force planning issues for allied health in Australia. Smith CS, et al. **J Allied Health** 1995 Fall;24(4):249-65

The 1996 National Pilot Data Collection Project of the Association of Schools of Allied Health Professions. Wingate L. **J Allied Health** 1997 Winter;26(1):45-6

Are we promoting too many allied health professionals instead of physicians? Gibson DM, et al. **N J Med** 1996 Dec;93(12):57-9

TRENDS

Cardiovascular and interventional technologists: their growing role in the interventional suite [letter] Burke TH, et al. **J Vasc Interv Radiol** 1997 Jul-Aug;8(4):720

Tasks performed by certified ophthalmic medical personnel [letter; comment] Servodidio CA. **Ophthalmology** 1997 Jan; 104(1):4. Comment on: Ophthalmology 1995 Dec;102(12):1973-86.

Analysis of tasks performed by certified ophthalmic medical personnel [see comments] Woodworth KE Jr, et al. **Ophthalmology** 1995 Dec;102(12):1973-86. Comment in: Ophthalmology 1997 Jan;104(1):4.

Past, present and future of allied health professions in Florida. Cuadrado RR. **P R Health Sci J** 1997 Mar;16(1):79-80

UTILIZATION

Hidden impact of paramedic interventions. Powar M, et al. **J Accid Emerg Med** 1996 Nov;13(6):383-5

ALLIGATORS AND CROCODILES

Concurrent gout and suspected hypovitaminosis A in crocodile hatchlings. Ariel E, et al. **Aust Vet J** 1997 Apr; 75(4):247-9

Isolation of Dermatophilus sp from skin lesions in farmed saltwater crocodiles (Crocodylus porosus). Buenviaje GN, et al. **Aust Vet J** 1997 May;75(5):365-7

Providencia rettgeri meningitis in hatchling saltwater crocodiles (Crocodylus porosus). Ladds PW, et al. **Aust Vet J** 1996 Nov;74(5):397-8

Interdigital subcutaneous emphysema ("bubble foot") in Crocodylus porosus hatchlings. Turton JA, et al. **Aust Vet J** 1996 Nov;74(5):395-7

Mercury distribution in American alligators (Alligator mississippiensis) in Florida. Heaton-Jones TG, et al. **J Zoo Wildl Med** 1997 Mar;28(1):62-70

ANATOMY & HISTOLOGY

Morphometric comparison of the motor trigeminal neurons. Setoyama S, et al. **Okajimas Folia Anat Jpn** 1997 Mar; 73(6):301-12

BLOOD

Relationship of blood corticosterone, immunoglobulin and haematological values in young crocodiles (Crocodylus porosus) to water temperature, clutch of origin and body weight. Turton JA, et al. **Aust Vet J** 1997 Feb;75(2):114-9

A hemoglobin-based blood substitute: transplanting a novel allosteric effect of crocodile Hb. Komiyama N, et al. **Biol Chem** 1996 Sep;377(9):543-8 (26 ref.)

Examination of reptilian erythrocytes as models of the progenitor of mammalian red blood cells. Mauro NA, et al. **Comp Biochem Physiol A Physiol** 1997 Apr;116(4):323-7

Caiman crocodilus yacare plasma kininogen detection. Araujo MS, et al. **Immunopharmacology** 1996 May; 32(1-3):82-4

EMBRYOLOGY

Yolk steroids decline during sexual differentiation in the alligator. Conley AJ, et al. **Gen Comp Endocrinol** 1997 Aug; 107(2):191-200

GENETICS

Allelic diversity in alligator microsatellite loci is negatively correlated with GC content of flanking sequences and evolutionary conservation of PCR amplifiability [letter] Glenn TC, et al. **Mol Biol Evol** 1996 Oct;13(8):1151-4

METABOLISM

Tissue mercury concentrations in alligators (Alligator mississippiensis) from the Florida Everglades and the Savannah River Site, South Carolina. Yanochko GM, et al. **Arch Environ Contam Toxicol** 1997 Apr;32(3):323-8

Identification and characterization of estrogen and progesterone receptors from the oviduct of the American alligator (Alligator mississippiensis). Vonier PM, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):308-12

CCK-A- and CCK-B-like receptors in the gallbladder and stomach of the alligator (Alligator mississippiensis). Oliver AS, et al. **Gen Comp Endocrinol** 1997 Jan;105(1):91-101

Caiman crocodilus yacare plasma kininogen detection. Araujo MS, et al. **Immunopharmacology** 1996 May; 32(1-3):82-4

The isolation of parvalbumin isoforms from the tail muscle of the American alligator (Alligator mississipiensis). Laney EL, et al. **J Inorg Biochem** 1997 Apr;66(1):67-76

MICROBIOLOGY

Mycoplasma crocodyli sp. nov., a new species from crocodiles. Kirchhoff H, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):742-6

PHYSIOLOGY

Intraocular pressure variation associated with body length in young American alligators (Alligator mississippiensis). Whittaker CJ, et al. **Am J Vet Res** 1995 Oct;56(10):1380-3

Assessment of transmyocardial perfusion in alligator hearts [see comments] Kohmoto T, et al. **Circulation** 1997 Mar 18;95(6):1585-91. Comment in: Circulation 1997 Mar 18;95(6):1357-9.

Alterations in steroidogenesis in alligators (Alligator mississippiensis) exposed naturally and experimentally to environmental contaminants. Crain DA, et al. **Environ Health Perspect** 1997 May;105(5):528-33

Interaction of environmental chemicals with the estrogen and progesterone receptors from the oviduct of the American alligator. Vonier PM, et al. **Environ Health Perspect** 1996 Dec;104(12):1318-22

A preliminary investigation of the effects of vasoactive intestinal peptide on secretion from the lingual salt glands of Crocodylus porosus. Franklin CE, et al. **Gen Comp Endocrinol** 1996 Apr;102(1):74-8

Plasma insulin-like growth factor-I concentration during the reproductive cycle of the American alligator (Alligator mississippiensis). Guillette LJ Jr, et al. **Gen Comp Endocrinol** 1996 Oct;104(1):116-22

Effects of long-term corticosterone implants on growth and immune function in juvenile alligators, Alligator mississippiensis. Morici LA, et al. **J Exp Zool** 1997 Oct 1;279(2):156-62

ALLIUM

Effect of onion extract on immune response in rabbits. Chisty MM, et al. **Bangladesh Med Res Counc Bull** 1996 Aug; 22(2):81-5

Oxides, onions, and other matters gastrointestinal--1996--a perspective. Kapadia CR. **J Clin Gastroenterol** 1997 Apr; 24(3):133-9 (50 ref.)

New furostanol glycosides, chinenoside IV and V, from Allium chinense. Peng J, et al. **Planta Med** 1996 Oct; 62(5):465-8

CHEMISTRY

Recent results in the organosulfur and organoselenium chemistry of genus Allium and Brassica plants. Relevance for cancer prevention. Block E. **Adv Exp Med Biol** 1996; 401:155-69 (75 ref.)

19 new steroidal saponins from Allium plants: isolation, structural elucidation and effect on blood coagulability. Peng JP, et al. **Adv Exp Med Biol** 1996;404:511-26

Allium vegetables and the potential for chemoprevention of cancer. Wargovich MJ, et al. **Adv Exp Med Biol** 1996; 401:171-7 (34 ref.)

Allium vegetables: their role in the prevention of cancer. Wargovich MJ, et al. **Biochem Soc Trans** 1996 Aug; 24(3):811-4 (30 ref.)

Therapeutic values of onion (Allium cepa L.) and garlic (Allium sativum L.). Augusti KT. **Indian J Exp Biol** 1996 Jul;34(7):634-40 (77 ref.)

DRUG EFFECTS

Mitotic effects of the aqueous leaf extract of Cymbopogon citratus in Allium cepa root tips. Williams GO, et al. **Cytobios** 1996;87(350):161-8

ENZYMOLOGY

Fructan of the inulin neoseries is synthesized in transgenic chicory plants (Cichorium intybus L.) harbouring onion (Allium cepa L.) fructan:fructan 6G-fructosyltransferase. Vijn I, et al. **Plant J** 1997 Mar;11(3):387-98

ALLIUM

GENETICS

The Ty1-copia group retrotransposons of Allium cepa are distributed throughout the chromosomes but are enriched in the terminal heterochromatin. Pearce SR, et al. **Chromosome Res** 1996 Aug;4(5):357–64

How do Alliaceae stabilize their chromosome ends in the absence of TTTAGGG sequences? Pich U, et al. **Chromosome Res** 1996 Apr;4(3):207–13

Competence for nuclear replication and the NOR-chromosomes of Allium cepa L. Panzera F, et al. **Eur J Cell Biol** 1997 Jan;72(1):9–12

Persistence of cadmium-induced adaptive response to genotoxicity of maleic hydrazide and methyl mercuric chloride in root meristem cells of Allium cepa L.: differential inhibition by cycloheximide and buthionine sulfoximine. Panda KK, et al. **Mutat Res** 1997 Mar 17; 389(2–3):129–39

Allium cepa anaphase-telophase root tip chromosome aberration assay on N-methyl-N-nitrosourea, maleic hydrazide, sodium azide, and ethyl methanesulfonate. Rank J, et al. **Mutat Res** 1997 Apr 24;390(1–2):121–7

[On the effect of Chinese lacquer upon the cell division of root tip of Allium cepa] Xing H, et al. **I Chuan Hsueh Pao** 1997;24(1):50–3 (Eng. Abstr.) **(Chi)**

METABOLISM

Monoclonal antibody raised against human mitotic cyclin B1, identifies cyclin B-like mitotic proteins in synchronized onion (Allium cepa L.) root meristem. Chaudhuri SK, et al. **Cell Biol Int** 1997 Mar;21(3):159–66

An evaluation of garlic and onion as antithrombotic agents. Bordia T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Mar; 54(3):183–6

Antiplatelet activity in onion (Allium cepa) is sulfur dependent. Goldman IL, et al. **Thromb Haemost** 1996 Sep; 76(3):450–2

PHYSIOLOGY

Isolation and characterization of lectins and lectin-alliinase complexes from bulbs of garlic (Allium sativum) and ramsons (Allium ursinum). Smeets K, et al. **Glycoconj J** 1997 Apr;14(3):331–43

Nuclear degeneration in epidermal cells of drying onion bulb leaf bases. Bhattacharya PK, et al. **Mech Ageing Dev** 1996 Jul 5;88(1–2):83–94

RADIATION EFFECTS

A fast comet assay variant for solid tissue cells. The assessment of DNA damage in higher plants. Navarrete MH, et al. **Mutat Res** 1997 Mar 17;389(2–3):271–7

ALLIUM SATIVUM see **GARLIC**

ALLNORTOXIFERINE see **ALCURONIUM**

ALLOANTIBODIES see **ISOANTIBODIES**

ALLOANTIGENS see **ISOANTIGENS**

ALLOCEBUS see **CHEIROGALEIDAE**

ALLOGRAFT see **TRANSPLANTATION, HOMOLOGOUS**

ALLOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

ALLOLEVIVIRUS

CHEMISTRY

The crystal structure of bacteriophage Q beta at 3.5 A resolution. Golmohammadi R, et al. **Structure** 1996 May 15;4(5):543–54

ENZYMOLOGY

Recognition of bacteriophage Qbeta plus strand RNA as a template by Qbeta replicase: role of RNA interactions mediated by ribosomal proteins S1 and host factor. Miranda G, et al. **J Mol Biol** 1997 Apr 18;267(5):1089–103

GENETICS

Translational activation in coliphage Qbeta: on a polycistronic messenger RNA, repression of one gene can activate translation of another. Priano C, et al. **J Mol Biol** 1997 Aug 22;271(3):299–310

MS2 coat protein mutants which bind Qbeta RNA. Spingola M, et al. **Nucleic Acids Res** 1997 Jul 15;25(14):2808–15

PHYSIOLOGY

Replication of coliphage Q beta as affected by host cell number, nutrition, competition from insusceptible cells and non-FRNA coliphages. Woody MA, et al. **J Appl Microbiol** 1997 Apr;82(4):431–40

RADIATION EFFECTS

Photo-induced inactivation of viruses: adsorption of methylene blue, thionine, and thiopyronine on Qbeta bacteriophage. Jockusch S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7446–51

ALLOMYCES see **MASTIGOMYCOTINA**

ALLOPURINOL

ADMINISTRATION & DOSAGE

Double-blind, placebo-controlled, cross-over trial of allopurinol as add-on therapy in childhood refractory epilepsy. Coppola G, et al. **Brain Dev** 1996 Jan-Feb; 18(1):50–2

Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Martinez S, et al. **Clin Infect Dis** 1997 Feb; 24(2):165–9

Computer-supported analysis (MegaBlot) of allopurinol-induced changes in the autoantibody repertoires of rats suffering from experimental lens-induced uveitis. Grus FH, et al. **Electrophoresis** 1997 Mar-Apr; 18(3–4):516–9

Difference of the plasma concentration and urinary excretion of allopurinol, oxypurinol, and purine bases between dietary intake and fasting. Yamamoto T, et al. **Int J Clin Pharmacol Ther** 1996 Apr;34(4):157–62

[A study of serum oxipurinol concentration and renal function in patients administered allopurinol] Saji M. **Nippon Jinzo Gakkai Shi** 1996 Dec;38(12):640–50 (Eng. Abstr.) **(Jpn)**

[How to select and use urate lowering agents for hyperuricemia] Yamanaka H. **Nippon Rinsho** 1996 Dec; 54(12):3261–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Azathioprine and allopurinol: the price of an avoidable drug interaction. Kennedy DT, et al. **Ann Pharmacother** 1996 Sep;30(9):951–4

Cystitis associated with allopurinol. Bramble FJ, et al. **Br J Urol** 1997 May;79(5):817

Perforating foot ulceration with allopurinol therapy. Bouloc A, et al. **Clin Exp Dermatol** 1996 Sep;21(5):351–2

Acute renal failure with chronic lymphocytic leukaemia. Martinez-Vea A, et al. **Postgrad Med J** 1996 Dec; 72(854):763–5

Cerebral vasculitis following allopurinol treatment. Rothwell PM, et al. **Postgrad Med J** 1996 Feb;72(844):119–20

Hypothyroidism on Colchimax revealed by restless legs syndrome [letter] Bon E, et al. **Rev Rhum Engl Ed** 1996 Apr;63(4):304

Allopurinol hypersensitivity syndrome. Carpenter C. **Tenn Med** 1997 Apr;90(4):151–2

[Xanthine urinary calculus in a patient with Lesch-Nyhan syndrome. Apropos of a case] Volpe P, et al. **Prog Urol** 1997 Feb;7(1):74–7 (Eng. Abstr.) **(Fre)**

[Granuloma annulare disseminatum as a rare side effect of allopurinol (letter; comment)] Brechtel B, et al. **Hautarzt** 1996 Feb;47(2):143. Comment on: Hautarzt 1995 May;46(5):343–5. **(Ger)**

[Allopurinol induced pancytopenia in a patient with myeloproliferative disorder] Shinagawa A, et al. **Rinsho Ketsueki** 1997 Jan;38(1):64–71 (Eng. Abstr.) **(Jpn)**

[Fixed drug eruption caused by allopurinol (letter)] Gimbel Moral LF, et al. **Med Clin (Barc)** 1996 Jan 27;106(3):119 **(Spa)**

ANALOGS & DERIVATIVES

Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Delpy E, et al. **Br J Pharmacol** 1996 Oct;119(3):471–8

Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization. Delpy E, et al. **Br J Pharmacol** 1996 Jul; 118(6):1377–84

[Acute hepatitis caused by tisopurine. A case (letter)] Viguier J, et al. **Gastroenterol Clin Biol** 1997;21(4):342 **(Fre)**

ANALYSIS

Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Allen LV Jr, et al. **Am J Health Syst Pharm** 1996 Aug 15;53(16):1944–9

METABOLISM

Difference of the plasma concentration and urinary excretion of allopurinol, oxypurinol, and purine bases between dietary intake and fasting. Yamamoto T, et al. **Int J Clin Pharmacol Ther** 1996 Apr;34(4):157–62

Microencapsulation of allopurinol by solvent evaporation and controlled release investigation of drugs. Arabi H, et al. **J Microencapsul** 1996 Sep-Oct;13(5):527–35

PHARMACOKINETICS

Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles. Bartges JW, et al. **Am J Vet Res** 1997 May;58(5):504–10

Influence of two diets on pharmacokinetic parameters of allopurinol and oxypurinol in healthy beagles. Bartges JW, et al. **Am J Vet Res** 1997 May;58(5):511–5

Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol. Walter-Sack I, et al. **J Rheumatol** 1996 Mar; 23(3):498–501

Pharmacokinetics of allopurinol in Dalmatian dogs. Ling GV, et al. **J Vet Pharmacol Ther** 1997 Apr;20(2):134–8

PHARMACOLOGY

Prophylactic action of allopurinol against chemotherapy-induced stomatitis--inhibition of superoxide dismutase and proteases. Nakamura K, et al. **Anticancer Drugs** 1996 May;7(3):235–9

The effects of allopurinol on the ultrastructure of ischaemic and reperfused large intestine of sheep. Ahmadinejad M, et al. **Aust Vet J** 1996 Aug;74(2):135–9

Free radical scavengers suppress the accumulation of platinum in the cerebral cortex. Minami T, et al. **Biol Trace Elem Res** 1996 Oct-Nov;55(1–2):1–7

Effect of allopurinol on lipid peroxidation induced in corporeal tissue by veno-occlusive priapism in a rat model. Evliyaoglu Y, et al. **Br J Urol** 1997 Sep;80(3):476–9

Kinetics of high-energy phosphates in allopurinol-pretreated ischaemic and post-ischaemic skeletal muscle: an in vivo magnetic resonance spectroscopy study. Gürke L, et al. **Eur Surg Res** 1997;29(2):101–6

Leishmania infantum promastigotes: flow cytometry as a possible tool for assessing the effects of drugs on cellular functions. Azas N, et al. **Exp Parasitol** 1997 Sep;87(1):1–7

Antioxidant activity of allopurinol on copper-catalysed human lipoprotein oxidation. Lapenna D, et al. **FEBS Lett** 1997 Jun 9;409(2):265–8

Allopurinol, an inhibitor of xanthine oxidase, reduces uric acid levels and modifies the signs associated with copper deficiency in rats fed fructose. Fields M, et al. **Free Radic Biol Med** 1996;20(4):595–600

Allopurinol: discrimination of antioxidant from enzyme inhibitory activities. Klein AS, et al. **Free Radic Biol Med** 1996;21(5):713–7

Peroxidative damage in sickle-cell erythrocyte ghosts: protective effect of allopurinol. Sertac A, et al. **Gen Pharmacol** 1997 Mar;28(3):427–8

Immunomodulating activity of allopurinol in experimental lens-induced uveitis. Grus FH, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Feb;235(2):118–23

Failure of allopurinol to improve left ventricular stroke work after cardiopulmonary bypass surgery. Coetzee A, et al. **J Cardiothorac Vasc Anesth** 1996 Aug;10(5):627–33

Control of oxygen cytotoxicity with allopurinol and superoxide dismutase: a canine model of global myocardial ischemia-reperfusion injury. Qayumi AK, et al. **J Invest Surg** 1997 Jan-Apr;10(1–2):63–8

The protective effect of allopurinol on cholestatic liver injury induced by bile duct ligation. Mun KC, et al. **J Korean Med Sci** 1996 Jun;11(3):239–43

The effect of allopurinol pretreatment on intestinal hypoperfusion encountered after correction of intestinal volvulus. Akgür FM, et al. **J Pediatr Surg** 1996 Sep; 31(9):1205–7

Allopurinol improves scavenging ability of the liver after ischemia/reperfusion injury. Karwinski W, et al. **Liver** 1997 Jun;17(3):139–43

Purine metabolism and inhibition of xanthine oxidase in severely hypoxic neonates going onto extracorporeal membrane oxygenation. Marro PJ, et al. **Pediatr Res** 1997 Apr;41(4 Pt 1):513–20

Allopurinol reduces bacterial translocation, intestinal mucosal lipid peroxidation, and neutrophil-derived myeloperoxidase activity in chronic portal hypertensive and common bile duct-ligated growing rats. Schimpl G, et al. **Pediatr Res** 1996 Sep;40(3):422–8

Further investigation of allopurinol effects on MPTP-induced oxidative stress in the striatum and brain stem of the rat. Desole MS, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):377–83

Effects of EGF and allopurinol on prostaglandin and lipid peroxide levels in mucosa of stomach in restraint cold stress. Aricioğlu A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Apr; 54(4):285–8

Effect of allopurinol on the formation of reactive oxygen species during intense exercise in the horse. Mills PC, et al. **Res Vet Sci** 1997 Jan-Feb;62(1):11–6

Administration of oral allopurinol as a means of preventing ischemia and reperfusion damage to the intestine. Argibay P, et al. **Transplant Proc** 1996 Oct;28(5):2640–1

L-Arginine and allopurinol protect against cyclosporine nephrotoxicity. Assis SM, et al. **Transplantation** 1997 Apr 27;63(8):1070–3

THERAPEUTIC USE

Allopurinol therapy in post-kala-azar dermal leishmaniasis [letter] Ramesh V. **Acta Derm Venereol** 1996 Jul; 76(4):328–9

Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Velez I, et al. **Ann Intern Med** 1997 Feb 1;126(3):232–6

Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Brechtel B, et al. **Br J Dermatol** 1996 Aug;135(2):307–9

Antioxidants in the treatment of severe pre-eclampsia: an explanatory randomised controlled trial. Gülmezoğlu AM,

et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):689–96

Effects of allopurinol, ibuprofen and cyclosporin A on local microcirculatory disturbance due to burn injuries. Cetinkale O, et al. **Burns** 1997 Feb;23(1):43–9

Mannitol, but not allopurinol, modulates changes in cerebral blood flow, intracranial pressure, and brain water content during pneumococcal meningitis in the rat. Lorenzl S, et al. **Crit Care Med** 1996 Nov;24(11):1874–80

Allopurinol treatment results in elevated prostate-specific antigen levels in prostatic fluid and serum of patients with non-bacterial prostatitis. Persson BE, et al. **Eur Urol** 1996; 29(1):111–4

Evaluating treatment for visceral leishmaniosis [letter; comment] Vercammen F. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1379. Comment on: J Am Vet Med Assoc 1996 Aug 1;209(3):615–7.

Fluconazole plus allopurinol in treatment of visceral leishmaniasis [letter] Torrús D, et al. **J Antimicrob Chemother** 1996 May;37(5):1042–3

Allopurinol in the treatment of zoonotic cutaneous leishmaniasis. Ghanem BM, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):619–28

Chagas' disease reactivation after heart transplantation: efficacy of allopurinol treatment. Almeida DR, et al. **J Heart Lung Transplant** 1996 Oct;15(10):988–92

The role of allopurinol in preventing oxygen free radical injury to skeletal muscle and endothelial cells after ischemia–reperfusion. Ferrari RP, et al. **J Reconstr Microsurg** 1996 Oct;12(7):447–50

Re: Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double-blind controlled study [letter; comment] Nickel JC, et al. **J Urol** 1997 Feb;157(2):628–9 . Comment on: J Urol 1996 Mar;155(3):961–4.

Cochlear protection from carbon monoxide exposure by free radical blockers in the guinea pig. Fechter LD, et al. **Toxicol Appl Pharmacol** 1997 Jan;142(1):47–55

A case of autochthonous canine leishmaniasis in The Netherlands. Díaz-Espiñeira MM, et al. **Vet Q** 1997 Jun; 19(2):69–71

Antibody kinetics during allopurinol treatment in canine leishmaniasis. Vercammen F, et al. **Vet Rec** 1996 Sep 14; 139(11):264

[Leishmaniasis in dogs in Germany: epidemiological case analysis and alternatives to conventional causal therapy] Gothe R, et al. **Tierarztl Prax** 1997 Jan;25(1):68–73 (Eng. Abstr.) **(Ger)**

[Chronic tophaceous gout] Toker R, et al. **Harefuah** 1997 Jun 1;132(11):759–61, 823 (Eng. Abstr.) **(Heb)**

[Evaluation of treatment of uric acid urolithiasis and prevention of stone formation in children] Gadomska-Prokop K, et al. **Pediatr Pol** 1996 Aug; 71(8):685–7 (Eng. Abstr.) **(Pol)**

ALLOSTERIC REGULATION

Protein dynamics and conformational transitions in allosteric proteins. Jardetzky O. **Prog Biophys Mol Biol** 1996; 65(3):171–219 (220 ref.)

Structures of a hemoglobin-based blood substitute: insights into the function of allosteric proteins. Kroeger KS, et al. **Structure** 1997 Feb 15;5(2):227–37 (57 ref.)

ALLOSTERIC SITE

A kinetic mechanism for nicotinic acetylcholine receptors based on multiple allosteric transitions. Edelstein SJ, et al. **Biol Cybern** 1996 Nov;75(5):361–79

Detection of changes in pairwise interactions during allosteric transitions: coupling between local and global conformational changes in GroEL. Aharoni A, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1698–702

ALLOTYPES, IMMUNOGLOBULIN see **IMMUNOGLOBULIN ALLOTYPES**

ALLOTYPES, IMMUNOGLOBULIN GM see **IMMUNOGLOBULIN GM ALLOTYPES**

ALLOTYPIC ANTIBODIES see **IMMUNOGLOBULIN ALLOTYPES**

ALLOWING TO DIE see **EUTHANASIA, PASSIVE**

ALLOXAN

Renal natriuretic effects of atrial natriuretic peptide in dogs with alloxan-induced acute pulmonary edema. Levy M, et al. **Clin Invest Med** 1996 Dec;19(6):435–43

ANTAGONISTS & INHIBITORS

The pyridoindole antioxidant stobadine prevents alloxan-induced lipid peroxidation by inhibiting its propagation. Stefek M, et al. **Pharmacol Toxicol** 1996 Feb; 78(2):77–81

METABOLISM

Glutathione dependent reduction of alloxan to dialuric acid catalyzed by thioltransferase (glutaredoxin): a possible role for thioltransferase in alloxan toxicity. Washburn MP, et al. **Free Radic Biol Med** 1997;23(4):563–70

PHARMACOLOGY

Microsphere distribution in the pancreas of anesthetized rats. Alloxan stimulates the blood flow to all islets whereas glucose only affects the blood perfusion of a subgroup of islets. Jansson L. **Int J Pancreatol** 1996 Aug;20(1):69–74

Striatal dopaminergic D1 and D2 receptors after intracerebroventricular application of alloxan and streptozocin in rat. Salkovic M, et al. **J Neural Transm Gen Sect** 1995;100(2):137–45

Activation of a novel non-selective cation channel by alloxan and H2O2 in the rat insulin-secreting cell line CRI-G1. Herson PS, et al. **J Physiol (Lond)** 1997 May 15;501 (Pt 1):59–66

Alloxan stimulation and subsequent inhibition of insulin release from in situ perfused rat pancreas. Kliber A, et al. **J Physiol Pharmacol** 1996 Jun;47(2):321–8

The pyridoindole antioxidant stobadine prevents alloxan-induced lipid peroxidation by inhibiting its propagation. Stefek M, et al. **Pharmacol Toxicol** 1996 Feb; 78(2):77–81

[Oxyferriscorbone: anti-ulcer effect and its possible mechanisms] Rasulov MM, et al. **Biull Eksp Biol Med** 1994 May;117(5):490–3 **(Rus)**

TOXICITY

Glutathione dependent reduction of alloxan to dialuric acid catalyzed by thioltransferase (glutaredoxin): a possible role for thioltransferase in alloxan toxicity. Washburn MP, et al. **Free Radic Biol Med** 1997;23(4):563–70

ALLOXAN DIABETES see **DIABETES MELLITUS, EXPERIMENTAL**

ALLOXANTHINE see **OXYPURINOL**

ALLOYS

Self-expanding metal stents in malignant esophageal obstruction: a comparison between two stent types [see comments] Schmassmann A, et al. **Am J Gastroenterol** 1997 Mar;92(3):400–6. Comment in: Am J Gastroenterol 1997 Mar;92(3):373–6.

Effect of different surface finishing and of hydroxyapatite coatings on passive and corrosion current of Ti6Al4V alloy in simulated physiological solution. Cabrini M, et al. **Biomaterials** 1997 Jun;18(11):783–7

In-vitro corrosion and wear of titanium alloys in the biological environment. Khan MA, et al. **Biomaterials** 1996 Nov;17(22):2117–26

Histomorphometric analysis of the response of rat tibiae to shape memory alloy (nitinol). Takeshita F, et al. **Biomaterials** 1997 Jan;18(1):21–5

Review of shape memory alloys medical applications in Russia. Brailovski V, et al. **Biomed Mater Eng** 1996; 6(4):291–8 (25 ref.)

Studies and applications of NiTi shape memory alloys in the medical field in China. Dai K, et al. **Biomed Mater Eng** 1996;6(4):233–40 (40 ref.)

The utility of superelasticity in medicine. Duerig TW, et al. **Biomed Mater Eng** 1996;6(4):255–66 (4 ref.)

On the nature of the biocompatibility and on medical applications of NiTi shape memory and superelastic alloys. Shabalovskaya SA. **Biomed Mater Eng** 1996;6(4):267–89 (39 ref.)

Application of a NiTi staple in the metatarsal osteotomy. Tang RG, et al. **Biomed Mater Eng** 1996;6(4):307–12

Corrosion resistance improvement of NiTi osteosynthesis staples by plasma polymerized tetrafluoroethylene coating. Villermaux F, et al. **Biomed Mater Eng** 1996;6(4):241–54

Treatment of a malignant esophageal fistula with a Gore-Tex-covered flexible nitinol stent. Kishi K, et al. **Cardiovasc Intervent Radiol** 1997 Jan–Feb;20(1):63–6

Temporary arterial stenting: comparison to permanent stenting and conventional balloon injury in a rabbit carotid artery model. Rechavia E, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):85–92

Subacute thrombosis and vascular injury resulting from slotted-tube nitinol and stainless steel stents in a rabbit carotid artery model [published erratum appears in Circulation 1996 Nov 15;94(10):2668] Sheth S, et al. **Circulation** 1996 Oct 1;94(7):1733–40

Acute and chronic effects of self-expanding nitinol stents in porcine coronary arteries. Hong MK, et al. **Coron Artery Dis** 1997 Jan;8(1):45–8

Nitinol self-expanding stents: when severe twisting occurs, self-expansion may ensue after a waiting period. Chung JP, et al. **Endoscopy** 1997 Mar;29(3):211–3

The first 15 months of transluminal abdominal aortic aneurysm management: a single centre experience. Kretschmer G, et al. **Eur J Vasc Endovasc Surg** 1997 Jul; 14(1):24–32

Self-expanding stents in transjugular intrahepatic portosystemic shunt: experience with nitinol Strecker stents. Rossi P, et al. **Eur Radiol** 1996;6(5):741–7

Technical feasibility and performance studies of a 0.009-inch nitinol microguidewire for potential neuroendovascular applications. Putman CM, et al. **Invest Radiol** 1997 Apr; 32(4):241–7

Gallium alloy [letter; comment] Mahler DB. **J Am Dent Assoc** 1996 Dec;127(12):1700, 1702. Comment on: J Am Dent Assoc 1996 Aug;127(8):1195–200.

Biocompatibility testing of NiTi screws using immunohistochemistry on sections containing metallic implants. Berger-Gorbet M, et al. **J Biomed Mater Res** 1996 Oct;32(2):243–8

Relationship between microstructure and ductility of investment cast ASTM F-75 implant alloy. Gómez M, et al. **J Biomed Mater Res** 1997 Feb;34(2):157–63

Different effects of phagocytosable particles during bone formation versus remodeling. Goodman S, et al. **J Biomed Mater Res** 1996 Fall;33(3):153–8

Bone bonding behavior of titanium and its alloys when coated with titanium oxide (TiO2) and titanium silicate (Ti5Si3). Kitsugi T, et al. **J Biomed Mater Res** 1996 Oct;32(2):149–56

Fretting corrosion resistance and fretting corrosion product cytocompatibility of ferritic stainless steel. Xulin S, et al. **J Biomed Mater Res** 1997 Jan;34(1):9–14

Clinical experience with a new nitinol self-expanding stent in peripheral arteries. Henry M, et al. **J Endovasc Surg** 1996 Nov;3(4):369–79

A shape memory airway stent for tracheobronchomalacia in children: an experimental and clinical study. Tsugawa C, et al. **J Pediatr Surg** 1997 Jan;32(1):50–3

Distal retraction and inversion of the Simon nitinol filter during surgical venous procedures: report of two cases. Cooper SG, et al. **J Vasc Interv Radiol** 1997 May–Jun; 8(3):433–5

Percutaneous treatment of peripheral aneurysms with the Cragg EndoPro System. Rousseau H, et al. **J Vasc Interv Radiol** 1996 Jan–Feb;7(1):35–9

Effect of counterface material on the characteristics of retrieved uncemented cobalt-chromium and titanium alloy total hip replacements. Brummitt K, et al. **Proc Inst Mech Eng [H]** 1996;210(3):191–5

Treatment of abdominal aortic aneurysms with transfemoral placement of stent-grafts: complications and secondary radiologic intervention. Dorffner R, et al. **Radiology** 1997 Jul;204(1):79–86

[Presentation of a new self-expanding vascular spiral stent] Rilinger N, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Dec;165(6):578–81 (Eng. Abstr.) **(Ger)**

[Initial clinical experiences with endovascular stent-grafts for treatment of infrarenal abdominal aortic aneurysm] Spillner G, et al. **Zentralbl Chir** 1996;121(9):727–33 (Eng. Abstr.) **(Ger)**

[Endovascular treatment of abdominal aorta aneurysms using the Stentor device. Preliminary experience] Jausseran JM, et al. **Minerva Cardioangiol** 1996 Nov;44(11):563–79 (Eng. Abstr.) **(Ita)**

[Self-expanding nitinol stents for treatment of tracheobronchial and esophageal stenosis caused by lung cancer] Muro K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec; 44(12):2205–11 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Patch testing with beryllium alloy samples in guinea pigs. Zissu D, et al. **Contact Dermatitis** 1996 Mar;34(3):196–200

Tandem expandable stent technique for a fractured nitinol stent [letter] Trowers EA, et al. **Gastrointest Endosc** 1997 Feb;45(2):217–8

[Influence of industrial factors on health status of workers engaged in obtaining and processing non-ferrous alloys] Ozhiganova VN, et al. **Med Tr Prom Ekol** 1996;(7):4–9 (Eng. Abstr.) **(Rus)**

ANALYSIS

Characterization of in vivo wear debris from ceramic-ceramic total hip arthroplasties. Lerouge S, et al. **J Biomed Mater Res** 1996 Dec;32(4):627–33

CHEMISTRY

Wear of a titanium-alloy shoulder prosthetic head. Simon JP, et al. **Acta Orthop Belg** 1997 Jun;63(2):126–7

Stability of trypsin immobilized on inorganic orthopedic biomaterials. Holt LJ, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1996 Nov; 24(6):613–20

Surface characterization of C/Ti-6Al-4V coating treated with ion beam. Demri B, et al. **Biomaterials** 1997 Feb; 18(4):305–10

Influence of the surface structure of titanium materials on the adhesion of fibroblasts. Eisenbarth E, et al. **Biomaterials** 1996 Jul;17(14):1399–403

Corrosion resistance tests on NiTi shape memory alloy. Rondelli G. **Biomaterials** 1996 Oct;17(20):2003–8

Effect of hydroxyapatite thickness on metal ion release from Ti6Al4V substrates. Sousa SR, et al. **Biomaterials** 1996 Feb; 17(4):397–404

Thermomechanical analysis of shape memory devices. Trochu F, et al. **Biomed Mater Eng** 1996;6(6):389–403

Electrochemical and histomorphometric evaluation of the TiNiCu shape memory alloy. Wen X, et al. **Biomed Mater Eng** 1997;7(1):1–11

Application of hydrogen absorbing alloys to medical and rehabilitation equipment. Wakisaka Y, et al. **IEEE Trans Rehabil Eng** 1997 Jun;5(2):148–57

Assessment of wrought ASTM F1058 cobalt alloy properties for permanent surgical implants. Clerc CO, et al. **J Biomed Mater Res** 1997 Fall;38(3):229–34

Comparative study of the corrosion behavior of MA-956

ALLOYS

and conventional metallic biomaterials. Escudero ML, et al. **J Biomed Mater Res** 1996 Jul;31(3):313–7

In vivo wear of Ti6A14V femoral heads: a retrieval study. McGovern TE, et al. **J Biomed Mater Res** 1996 Nov; 32(3):447–57

Fracture toughness of CoCr alloy–PMMA cement interface. Mann KA, et al. **J Biomed Mater Res** 1997 Fall;38(3):211–9

Effects of Ca and H2O2 added to RPMI on the fretting corrosion of Ti6Al4V. Montague A, et al. **J Biomed Mater Res** 1996 Dec;32(4):519–26

Effect of compressive straining on corrosion resistance of a shape memory Ni–Ti alloy in Ringer's solution. Montero–Ocampo C, et al. **J Biomed Mater Res** 1996 Dec; 32(4):583–91

Dental gallium alloy composites studied by SEM and TEM. Gunnaes AE, et al. **J Microsc** 1997 Feb;185 (Pt 2):188–98

NiTi shape memory alloys treated by plasma–polymerized tetrafluoroethylene. A physicochemical and electrochemical characterization. Yahia LH, et al. **Med Prog Technol** 1996–97;21(4):187–93

[Use of shape memory alloy in cardiac surgery] Matsumoto H, et al. **Rinsho Kyobu Geka** 1988 Feb;8(1):81–4 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

In vitro human monocyte response to wear particles of titanium alloy containing vanadium or niobium. Rogers SD, et al. **J Bone Joint Surg Br** 1997 Mar;79(2):311–5

STANDARDS

Wear–resistant, hemocompatible Ti–Nb–Zr and Zr–Nb alloys to improve blood pump design and performance. Davidson JA, et al. **Artif Organs** 1996 Jun;20(6):513–22 (57 ref.)

THERAPEUTIC USE

Self–expandable nitinol coil stent for management of colonic obstruction due to a malignant anastomotic stricture. Bashir RM, et al. **Gastrointest Endosc** 1996 Oct;44(4):497–501 (44 ref.)

Memory metal stents for palliation of malignant obstruction of the oesophagus and cardia. Sterling MJ, et al. **Gastrointest Endosc** 1996 Oct;44(4):513–5

TOXICITY

Cobalt–chromium–molybdenum but not titanium–6aluminium–4vanadium alloy discs inhibit human T cell activation in vitro. Faleiro C, et al. **Biometals** 1996 Oct;9(4):321–6

ALLYL COMPOUNDS

3–Chloro–2–methylpropene. **IARC Monogr Eval Carcinog Risks Hum** 1995;63:325–33 (27 ref.)

Efficient chemical conversion of louisianin A to C and D, the inhibitor of angiogenesis. Sunazuka T, et al. **Jpn J Antibiot** 1997 Mar;50(3):274–5

CHEMICAL SYNTHESIS

Efficient, convergent syntheses of oligosaccharide allyl glycosides corresponding to the Streptococcus group A cell–wall polysaccharide. Auzanneau FI, et al. **Carbohydr Res** 1996 Sep 23;291:21–41

Improvement of enantioselective syntheses and chiral high resolution gas chromatographic analyses of (+)–2–allyl–2–carboethoxy–cyclopentanol. Fraga CA, et al. **Chirality** 1997;9(4):321–4

Application of the allyloxycarbonyl protecting group for the indole of Trp in solid–phase peptide synthesis. Vorherr T, et al. **Int J Pept Protein Res** 1996 Dec;48(6):553–8

Efficient chemical conversion of louisianin A to C and D, the inhibitor of angiogenesis. Sunazuka T, et al. **Jpn J Antibiot** 1997 Mar;50(3):274–5

METABOLISM

Sulfotransferase–mediated activation of some benzylic and allylic alcohols. Surh YJ. **Adv Exp Med Biol** 1996; 387:339–45 (31 ref.)

The mechanism of oxidation of allylic alcohols to alpha,beta–unsaturated ketones by cytochrome P450. Bellucci G, et al. **Chem Res Toxicol** 1996 Jul–Aug; 9(5):871–4

Biotransformation of allyl chloride in the rat. Influence of inducers on the urinary metabolic profile. de Rooij BM, et al. **Drug Metab Dispos** 1996 Jul;24(7):765–72

PHARMACOKINETICS

Dermal absorption of cis–1,3–dichloropropene vapour: human experimental exposure. Kežić S, et al. **Hum Exp Toxicol** 1996 May;15(5):396–9

PHARMACOLOGY

Glutathione S–transferases of female A/J mouse lung and their induction by anticarcinogenic organosulfides from garlic. Hu X, et al. **Arch Biochem Biophys** 1997 Apr 15; 340(2):279–86

L–Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse. Thiffault C, et al. **Brain Res Mol Brain Res** 1997 Mar;44(2):238–44

Hydroxyl and peroxyl radical trapping by the monoamine oxidase–B inhibitors deprenyl and MDL 72,974A: implications for protection of biological substrates. Thomas CE, et al. **Free Radic Biol Med** 1997;22(4):733–7

Protective effect of diallyl sulfone against acetaminophen–induced hepatotoxicity in mice. Lin MC, et al. **J Biochem Toxicol** 1996;11(1):11–20

Isoprenyl phenyl ethers from liverworts of the genus Trichocolea: cytotoxic activity, structural corrections, and synthesis. Perry NB, et al. **J Nat Prod** 1996 Aug; 59(8):729–33

In vitro efficacy of a compound derived from garlic against Pneumocystis carinii [letter] Abdullah TH. **J Natl Med Assoc** 1996 Nov;88(11):694, 704

Modulation of rat hepatic cytochrome P–450 activity by garlic organosulfur compounds. Reicks MM, et al. **Nutr Cancer** 1996;25(3):241–8

Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans. Shen J, et al. **Planta Med** 1996 Oct;62(5):415–8

Mössbauer and electron paramagnetic resonance studies of chloroperoxidase following mechanism–based inactivation with allylbenzene. Debrunner PG, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):12791–8

TOXICITY

Subchronic toxicity of ingested 1,3–dichloropropene in rats and mice. Haut KT, et al. **Fundam Appl Toxicol** 1996 Aug; 32(2):224–32

[Testicular toxicity of allyl chloride] Zhao M. **Fukuoka Igaku Zasshi** 1997 Mar;88(3):49–55 (Eng. Abstr.) **(Jpn)**

ALLYLAMINE

ANALOGS & DERIVATIVES

Comparative efficacy of naftifine, oxiconazole, and terbinafine in short–term treatment of tinea pedis. Ablon G, et al. **Int J Dermatol** 1996 Aug;35(8):591–3

Absorption, distribution and excretion of GT31–104, a novel bile acid sequestrant, in rats and dogs after acute and subchronic administration. Rosenbaum DP, et al. **J Pharm Sci** 1997 May;86(5):591–5

Effect of haloallylamines on polyamine oxidase activity and spermine levels in Ascaris suum. Müller S, et al. **Parasitol Res** 1996;82(6):571–3

Effect of naftifine on neutrophil adhesion. Choi TS, et al. **Skin Pharmacol** 1996;9(3):190–6

[Reflections on pain treatment (letter)] Moi H. **Tidsskr Nor Laegeforen** 1997 Apr 20;117(10):1511 **(Nor)**

PHARMACOLOGY

Differential processing of osteopontin characterizes the proliferative vascular smooth muscle cell phenotype induced by allylamine. Parrish AR, et al. **J Cell Biochem** 1997 May;65(2):267–75

ALLYLESTRENOL

PHARMACOLOGY

Benzpyrene treatment decreases the sexual activity of adult rats, what is reversed in neonatally allylestrenol treated animals. Karabélyos C, et al. **Acta Physiol Hung** 1996; 84(2):131–7

Effects of steroid 5alpha–reductase inhibitor ONO–9302 and anti–androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats. Yasuda N, et al. **Jpn J Pharmacol** 1997 Jul;74(3):243–52

THERAPEUTIC USE

Transition zone ratio and prostate–specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti–androgen therapy. Kurita Y, et al. **Br J Urol** 1997 Jul;80(1):78–83

ALLYLISOPROPYLACETAMIDE

PHARMACOLOGY

cDNA–expressed human cytochrome P450 isozymes. Inactivation by porphyrinogenic xenobiotics. McNamee JP, et al. **Drug Metab Dispos** 1997 Apr;25(4):437–41

ALMANACS

HISTORY

Dr. Ames defines his profession. McCarter D. **Trans Stud Coll Physicians Phila** 1995 Dec;17:115–31

ALMITRINE

ADVERSE EFFECTS

Reversible hepatic cytolysis during almitrine bismesylate treatment for posttraumatic ARDS [letter] Sicsic JC, et al. **Intensive Care Med** 1996 Feb;22(2):173–4

ANALOGS & DERIVATIVES

An almitrine analog acts as hypoxia in isolated rat lungs. Robineau P, et al. **Respir Physiol** 1996 Sep;105(3):225–33

Neuronal and muscular inclusions in rats with hindlimb dysfunction after treating with difluorobenzhydrylpiperadine. Yamanaka Y, et al. **Toxicol Pathol** 1997 Mar–Apr;25(2):150–7

METABOLISM

Neuronal and muscular inclusions in rats with hindlimb dysfunction after treating with difluorobenzhydrylpiperadine. Yamanaka Y, et al. **Toxicol Pathol** 1997 Mar–Apr;25(2):150–7

PHARMACOLOGY

Action potentials in right and left ventricles from chronic hypoxic rats: effect of almitrine. Kreher P, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1856–63

Cardiorespiratory and renal responses to arterial chemoreceptor stimulation by hypoxia or almitrine in men. Brauer H, et al. **Clin Exp Pharmacol Physiol** 1996 Dec; 23(12):1021–7

Effect of arterial chemoreceptor stimulation with almitrine bismesylate on plasma renin activity, aldosterone, ACTH and cortisol in anaesthetized, artificially ventilated cats. Honig A, et al. **Clin Exp Pharmacol Physiol** 1996 Feb; 23(2):106–10

Effect of almitrine on ventilation and on diaphragm and geniohyoid muscle activity in the rat. O'Halloran KD, et al. **Clin Sci (Colch)** 1996 Sep;91(3):337–45

Almitrine and doxapram decrease fatigue and increase subsequent recovery in isolated rat diaphragm. McGuire M, et al. **J Appl Physiol** 1997 Jul;83(1):52–8

Differential effects of ventilatory stimulation by sex hormones and almitrine on hypoxic erythrocytosis. Favier R, et al. **Pflugers Arch** 1997 May;434(1):97–103

THERAPEUTIC USE

Effects of almitrine bismesylate in a microswine model of hypoxemic hypothermia. Gentile BJ, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):824–8

Additive beneficial effects of the prone position, nitric oxide, and almitrine bismesylate on gas exchange and oxygen transport in acute respiratory distress syndrome. Jolliet P, et al. **Crit Care Med** 1997 May;25(5):786–94

TOXICITY

Neuronal and muscular inclusions in rats with hindlimb dysfunction after treating with difluorobenzhydrylpiperadine. Yamanaka Y, et al. **Toxicol Pathol** 1997 Mar–Apr;25(2):150–7

ALMITRINE BISMESYLATE see **ALMITRINE**

ALMSHOUSES

HISTORY

The hospital department of the AlMS House of Charleston. King SL. **J S C Med Assoc** 1996 Dec;92(12):503–6

ALOE

Phase III double–blind evaluation of an aloe vera gel as a prophylactic agent for radiation–induced skin toxicity. Williams MS, et al. **Int J Radiat Oncol Biol Phys** 1996 Sep 1;36(2):345–9

Antiinflammatory activity of extracts from Aloe vera gel. Vázquez B, et al. **J Ethnopharmacol** 1996 Dec;55(1):69–75

CHEMISTRY

Inhibition of benzo[a]pyrene–DNA adduct formation by Aloe barbadensis Miller. Kim HS, et al. **Carcinogenesis** 1997 Apr;18(4):771–6

Activation of a mouse macrophage cell line by acemannan: the major carbohydrate fraction from Aloe vera gel. Zhang L, et al. **Immunopharmacology** 1996 Nov;35(2):119–28

Isolation and characterization of the glycoprotein fraction with a proliferation–promoting activity on human and hamster cells in vitro from Aloe vera gel. Yagi A, et al. **Planta Med** 1997 Feb;63(1):18–21

ENZYMOLOGY

Isozymes of superoxide dismutase from Aloe vera. Sabeh F, et al. **Enzyme Protein** 1996;49(4):212–21

Isolation of a cDNA for a phosphoenolpyruvate carboxylase from a monocot CAM–plant, Aloe arborescens: structure and its gene expression. Honda H, et al. **Plant Cell Physiol** 1996 Sep;37(6):881–8

ALOE EMODIN see **EMODIN**

ALOPECIA

Cerebello–trigeminal–dermal dysplasia (Gómez–López–Hernández syndrome): description of three new cases and review. Muñoz R MV, et al. **Am J Med Genet** 1997 Oct 3;72(1):34–9 (8 ref.)

GAPO syndrome in Türkiye [letter; comment] Sayli BS, et

al. **Am J Med Genet** 1996 Oct 28;65(3):252–3. Comment on: Am J Med Genet 1995 Jul 31;58(1):87–90.
GAPO syndrome: first Egyptian case with ultrastructural changes in the gingiva. Meguid NA, et al. **Clin Genet** 1997 Aug;52(2):110–5
Clinical updates in hair. Sawaya ME. **Dermatol Clin** 1997 Jan;15(1):37–43 (42 ref.)
Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. Whiting DA.
J Am Acad Dermatol 1996 Dec;35(6):899–906
Androgenetic alopecia. Battling a losing proposition. Rubin MB. **Postgrad Med** 1997 Aug;102(2):129–31, 136 (5 ref.)
GAPO syndrome (Radiographic clues to early diagnosis). Baxova A, et al. **Radiol Med (Torino)** 1997 Mar; 93(3):289–91

BLOOD

Cytokines in alopecia areata: contrasting cytokine profiles in localized form and extensive form (alopecia universalis). Teraki Y, et al. **Acta Derm Venereol** 1996 Nov;76(6):421–3

CHEMICALLY INDUCED

Hair loss in children on long-acting gonadotropin-releasing hormone agonist triptorelin treatment [letter] Kauschansky A, et al. **Acta Derm Venereol** 1997 Jul;77(4):333
Diffuse alopecia associated with omeprazole [letter] Borum ML, et al. **Am J Gastroenterol** 1997 Sep;92(9):1576
Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. Maurer M, et al.
Am J Pathol 1997 Apr;150(4):1433–41
Alopecia and mood stabilizer therapy. McKinney PA, et al. **Ann Clin Psychiatry** 1996 Sep;8(3):183–5 (12 ref.)
Tamoxifen-induced female androgenetic alopecia in a patient with breast cancer [letter] Ayoub JP, et al.
Ann Intern Med 1997 May 1;126(9):745–6
Alopecia and breast disease. Gateley CA, et al. **BMJ** 1997 Feb 15;314(7079):481
Alopecia universalis and cyclosporin A [letter] Parodi A, et al. **Br J Dermatol** 1996 Oct;135(4):657
Abdominal pain, leg weakness, and alopecia in a teenage boy. Fred HL, et al. **Hosp Pract (Off Ed)** 1997 Apr 15; 32(4):69–70
Two cases of hair loss after sertraline use [letter] Bourgeois JA. **J Clin Psychopharmacol** 1996 Feb;16(1):91–2
Vitamin D3 and chemotherapy-induced alopecia [editorial] Jimenez JJ, et al. **Nutrition** 1996 Jun;12(6):448–9
[Alopecia secondary to tenoxicam. An undescribed adverse effect? (letter)] Aroca García MD, et al. **Aten Primaria** 1997 Jul–Aug;20(3):157 **(Spa)**

CLASSIFICATION

Heritable factors distinguish two types of alopecia areata. Price VH, et al. **Dermatol Clin** 1996 Oct;14(4):679–89 (37 ref.)
Quantitating hair loss in women: a critical approach. Guarrera M, et al. **Dermatology** 1997;194(1):12–6

COMPLICATIONS

Alopecia syphilitica in a prepubertal girl [letter] Taniguchi S, et al. **Acta Derm Venereol** 1997 May;77(3):243–4
Baldness and other correlates of sex hormones in relation to testicular cancer. Petridou E, et al. **Int J Cancer** 1997 Jun 11;71(6):982–5
Polymyositis, alopecia universalis, and primary sclerosing cholangitis in a patient with Crohn's disease. Seibold F, et al. **J Clin Gastroenterol** 1996 Sep;23(2):121–4
Multiple basaloid cell hamartoma with alopecia and autoimmune disease (systemic lupus erythematosus). Akasaka T, et al. **J Dermatol** 1996 Nov;23(11):821–4 (12 ref.)

CONGENITAL

Congenital Alopecia and nail dystrophy associated with severe functional T-cell immunodeficiency in two sibs. Pignata C, et al. **Am J Med Genet** 1996 Oct 16;65(2):167–70
Congenital triangular alopecia. Armstrong DK, et al.
Pediatr Dermatol 1996 Sep–Oct;13(5):394–6

DIAGNOSIS

Loose anagen syndrome and loose anagen hair. Li VW, et al. **Dermatol Clin** 1996 Oct;14(4):745–51 (28 ref.)
A simplified approach to the diagnosis of alopecia. Rietschel RL. **Dermatol Clin** 1996 Oct;14(4):691–5 (6 ref.)
Chronic telogen effluvium. Whiting DA. **Dermatol Clin** 1996 Oct;14(4):723–31
Sarcoidosis presenting as a scarring alopecia: report of a rare cutaneous manifestation of systemic sarcoidosis. Takahashi H, et al. **Dermatology** 1996;193(2):144–6
Alopecia: histologic diagnosis by transverse sections. Templeton SF, et al. **Semin Diagn Pathol** 1996 Feb; 13(1):2–18 (33 ref.)
[Tufted hair folliculitis] Trüeb RM, et al. **Hautarzt** 1997 Apr; 48(4):266–9 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Diffuse hypertrichosis during treatment with 5% topical minoxidil. Peluso AM, et al. **Br J Dermatol** 1997 Jan; 136(1):118–20
Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Paus R, et al. **Cancer Res** 1996 Oct 1;56(19):4438–43
Successful treatment with topical PUVA of nodular cutaneous plasmacytosis associated with alopecia of the scalp. Kaneda M, et al. **Clin Exp Dermatol** 1996 Sep; 21(5):360–4
Effects of ozonized autohaemotherapy on human hair cycle. Riva Sanseverino E, et al. **Panminerva Med** 1995 Sep; 37(3):129–32
[Chlormadinone acetate alone as therapy (letter)] Zaun H. **Hautarzt** 1996 Jan;47(1):66 **(Ger)**
[Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia?] Spinucci G, et al. **Clin Ter** 1996 Jun;147(6):305–15 (41 ref.) (Eng. Abstr.) **(Ita)**

ENZYMOLOGY

Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. Sawaya ME, et al.
J Invest Dermatol 1997 Sep;109(3):296–300

EPIDEMIOLOGY

Re: "Baldness and ischemic heart disease in a national sample of men" [letter; comment] Sheikh K. **Am J Epidemiol** 1997 Apr 1;145(7):670–1. Comment on: Am J Epidemiol 1996 Apr 1;143(7):651–7.

ETIOLOGY

Telogen alopecia from UV rays [letter] Camacho F, et al. **Arch Dermatol** 1996 Nov;132(11):1398–9
Cicatricial alopecia and keratosis pilaris. Keratosis follicularis spinulosa decalvans. Romine KA, et al. **Arch Dermatol** 1997 Mar;133(3):381, 384
Growth retardation, alopecia, pseudoanodontia, and optic atrophy (GAPO syndrome) with congenital glaucoma. Mullaney PB, et al. **Arch Ophthalmol** 1997 Jul;115(7):940–1
Premature grey hair and hair loss among smokers: a new opportunity for health education? Mosley JG, et al.
BMJ 1996 Dec 21–28;313(7072):1616
Alopecia in liver transplant recipients [letter; comment] Sale GE. **Br J Dermatol** 1997 Apr;136(4):635. Comment on: Br J Dermatol 1995 Oct;133(4):663–4.
Linear scleroderma with orbital involvement: follow up and magnetic resonance imaging [letter] [corrected and republished in Br J Ophthalmol 1997 Jan;81(1):90–3] Ramboer K, et al. **Br J Ophthalmol** 1996 Oct;80(10):930–2
Alopecia of the unburned scalp. Chow IJ, et al. **Burns** 1996 May;22(3):250–1
Occipital alopecia after cardiac surgery [letter] Calla S, et al. **Can J Anaesth** 1996 Nov;43(11):1180–1
How far should we investigate diffuse alopecia in women? [letter] Dupont C. **Clin Exp Dermatol** 1996 Jul;21(4):320
Cicatricial alopecia. Headington JT. **Dermatol Clin** 1996 Oct; 14(4):773–82 (7 ref.)
Relationship between follicular nerve supply and alopecia. Hordinsky MK, et al. **Dermatol Clin** 1996 Oct;14(4):651–60 (25 ref.)
Androgen metabolism as it affects hair growth in androgenetic alopecia. Kaufman KD. **Dermatol Clin** 1996 Oct;14(4):697–711 (67 ref.)
The pathogenesis of alopecia areata. McDonagh AJ, et al. **Dermatol Clin** 1996 Oct;14(4):661–70 (126 ref.)
Mouse models for the study of human hair loss. Sundberg JP, et al. **Dermatol Clin** 1996 Oct;14(4):619–32 (92 ref.)
Anagen hairs may fail to replace telogen hairs in early androgenic female alopecia. Guarrera M, et al.
Dermatology 1996;192(1):28–31
Cutaneous fibrous dysplasia: an incomplete form of the McCune-Albright syndrome. Schwartz RA, et al.
Dermatology 1996;192(3):258–61 (16 ref.)
Lymphocyte-mediated alopecia in C57BL/6 mice following successful immunotherapy for melanoma. Becker JC, et al. **J Invest Dermatol** 1996 Oct;107(4):627–32
Hair loss after routine immunizations. Wise RP, et al.
JAMA 1997 Oct 8;278(14):1176–8
Alopecia. Wyndham M. **Practitioner** 1996 Dec;240(1569):704
[Different methods of evaluation—object assessment of hair loss and alopecia] Bouhanna P.
Schweiz Rundsch Med Prax 1997 Jun 4;86(23):1000–3 (9 ref.) **(Fre)**
[Current treatment of androgenetic male and female alopecia (with the exception of hormone treatment)] Bouhanna P. **Schweiz Rundsch Med Prax** 1997 Jun 4;86(23):996–9 (12 ref.) (Eng. Abstr.) **(Fre)**
[Cycle of hair growth and evaluation of alopecia] Piérard-Franchimont C, et al.
Schweiz Rundsch Med Prax 1997 Jun 4;86(23):979–81 (6 ref.) (Eng. Abstr.) **(Fre)**
[Cicatricial alopecias: diagnosis and therapy] Trüeb RM.
Schweiz Rundsch Med Prax 1997 Jun 4;86(23):987–92 (16 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Genetic control of cytokines. Cytokine gene polymorphisms in alopecia areata. Cork MJ, et al. **Dermatol Clin** 1996 Oct; 14(4):671–8 (71 ref.)
Heritable factors distinguish two types of alopecia areata. Price VH, et al. **Dermatol Clin** 1996 Oct;14(4):679–89 (37 ref.)
Pseudopelade: an inherited alopecia. Sahl WJ.
Int J Dermatol 1996 Oct;35(10):715–9
Lanceolate hair (lah): a recessive mouse mutation with alopecia and abnormal hair. Montagutelli X, et al.
J Invest Dermatol 1996 Jul;107(1):20–5
Vesicle formation and follicular root sheath separation in mice homozygous for deleterious alleles at the balding (bal) locus. Montagutelli X, et al. **J Invest Dermatol** 1997 Sep; 109(3):324–8

IMMUNOLOGY

Alopecia universalis with remission during pregnancy and prednisolone therapy. Asanuma N, et al. **Am J Med Sci** 1997 Jan;313(1):67–9
Alopecia areata but not androgenetic alopecia is characterized by a restricted and oligoclonal T-cell receptor-repertoire among infiltrating lymphocytes. Dressel D, et al. **J Cutan Pathol** 1997 Mar;24(3):164–8

METABOLISM

Increased scalp skin and serum 5 alpha-reductase reduced androgens in a man relevant to the acquired progressive kinky hair disorder and developing androgenetic alopecia. Boudou P, et al. **Arch Dermatol** 1997 Sep;133(9):1129–33 (44 ref.)
Glutathione, glutathione S-transferase and reactive oxygen species of human scalp sebaceous glands in male pattern baldness. Giralt M, et al. **J Invest Dermatol** 1996 Aug; 107(2):154–8

PATHOLOGY

Pachyonychia congenita-associated alopecia. A microscopic analysis using transverse section technique. Templeton SF, et al. **Am J Dermatopathol** 1997 Apr;19(2):180–4
Scarring folliculitis in the ectrodactyly-ectodermal dysplasia-clefting syndrome. Histologic, scanning electron-microscopic and biophysical studies of hair. Trüeb RM, et al. **Dermatology** 1997;194(2):191–4
Mucinous lupus alopecia associated with papulonodular mucinosis as a new manifestation of lupus erythematosus [letter] Lee WS, et al. **Int J Dermatol** 1996 Jan;35(1):72–3
Pseudopelade: an inherited alopecia. Sahl WJ.
Int J Dermatol 1996 Oct;35(10):715–9
Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris. Kossard S, et al.
J Am Acad Dermatol 1997 Jan;36(1):59–66
A case of dermatopathia pigmentosa reticularis. Bu TS, et al. **J Dermatol** 1997 Apr;24(4):266–9
Pincer nails and alopecia as markers of gastrointestinal malignancy. Jemec GB, et al. **J Dermatol** 1997 Jul; 24(7):479–81
Alopecia: histologic diagnosis by transverse sections. Templeton SF, et al. **Semin Diagn Pathol** 1996 Feb; 13(1):2–18 (33 ref.)
[Postmenopausal frontal fibrosing alopecia] Feldmann R, et al. **Hautarzt** 1996 Jul;47(7):533–6 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Regrowth of alopecia areata simulating the pattern of androgenetic alopecia [letter] Muñoz MA, et al.
Arch Dermatol 1997 Jan;133(1):114–5
Photographic documentation of hair growth in androgenetic alopecia. Canfield D. **Dermatol Clin** 1996 Oct;14(4):713–21 (6 ref.)
Trichodynia [letter] Rebora A, et al. **Dermatology** 1996; 192(3):292–3
Inhibition of hair growth by testosterone in the presence of dermal papilla cells from the frontal bald scalp of the postpubertal stumptailed macaque. Obana N, et al.
Endocrinology 1997 Jan;138(1):356–61

PREVENTION & CONTROL

Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. Maurer M, et al.
Am J Pathol 1997 Apr;150(4):1433–41
Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Lemenager M, et al.
Eur J Cancer 1997 Feb;33(2):297–300
Vitamin D3 and chemotherapy-induced alopecia [editorial] Jimenez JJ, et al. **Nutrition** 1996 Jun;12(6):448–9
Scalp cooling in the prevention of alopecia in patients receiving depilating chemotherapy. Ron IG, et al.
Support Care Cancer 1997 Mar;5(2):136–8

PSYCHOLOGY

Changes in self-concept and body image during alopecia induced cancer chemotherapy. Münstedt K, et al.
Support Care Cancer 1997 Mar;5(2):139–43

SURGERY

The role of facial proportion in hair restoration surgery. Stough DB, et al. **Ann Plast Surg** 1997 Feb;38(2):129–36
What's new in hair replacement surgery. Unger WP.
Dermatol Clin 1996 Oct;14(4):783–802 (43 ref.)
The aesthetics of follicular transplantation [see comments] Bernstein RM, et al. **Dermatol Surg** 1997 Sep;23(9):785–99

. Comment in: Dermatol Surg 1997 Sep;23(9):801–5.
A comparison of the scalp kinetics in scalp–lifting with and without an intact occipital neurovascular bundle. Brandy DA. **Dermatol Surg** 1997 Sep;23(9):819–27
Experience with a make–it–yourself scalp extender with hooks. Bridenstine JB. **Dermatol Surg** 1997 Jun; 23(6):469–73
Anchor scalp reduction. Seery GE. **Dermatol Surg** 1996 Dec; 22(12):1009–13
On: follicular transplantation by Bernstein and Rassman [editorial; comment] Unger WP. **Dermatol Surg** 1997 Sep; 23(9):801–5. Comment on: Dermatol Surg 1997 Sep;23(9):785–99.
Concepts in scalp and forehead reconstruction. TerKonda RP, et al. **Otolaryngol Clin North Am** 1997 Aug; 30(4):519–39 (23 ref.)
Minigraft preparation in surgical hair replacement. Fan J, et al. **Scand J Plast Reconstr Surg Hand Surg** 1997 Mar; 31(1):83–6
[Full–load expansion techniques and preliminary clinical application] Hu H, et al.
Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih 1995 May;11(3):167–70 (Eng. Abstr.) **(Chi)**

THERAPY

Comparative effects of exposure to different light sources (He–Ne laser, InGaAl diode laser, a specific type of noncoherent LED) on skin blood flow for the head. Pöntinen PJ, et al. **Acupunct Electrother Res** 1996 Apr–Jun; 21(2):105–18
Intravenous gammaglobulin therapy of Satoyoshi syndrome. Arita J, et al. **Brain Dev** 1996 Sep–Oct;18(5):409–11
Treatment of alopecia areata. Fiedler VC, et al.
Dermatol Clin 1996 Oct;14(4):733–7 (46 ref.)
Topical immunotherapy in alopecia areata. What, how, and why? Hoffmann R, et al. **Dermatol Clin** 1996 Oct; 14(4):739–44 (23 ref.)
Growth factors and cytokines in hair follicle development and cycling: recent insights from animal models and the potentials for clinical therapy. Danilenko DM, et al.
Mol Med Today 1996 Nov;2(11):460–7 (40 ref.)

VETERINARY

Investigation of the reproductive and growth hormone status of dogs affected by idiopathic recurrent flank alopecia. Curtis CF, et al. **J Small Anim Pract** 1996 Sep;37(9):417–22
What is your diagnosis? Alopecia. Dunn K.
J Small Anim Pract 1997 May;38(5):186, 208
Apoptosis of hair follicle cells during doxorubicin–induced alopecia in rats. Cece R, et al. **Lab Invest** 1996 Oct; 75(4):601–9

ALOPECIA, ANDROGENETIC see **ALOPECIA**

ALOPECIA AREATA

Alopecia areata. Schwartz RA, et al. **Cutis** 1997 May; 59(5):238–41 (71 ref.)

BLOOD

Cytokines in alopecia areata: contrasting cytokine profiles in localized form and extensive form (alopecia universalis). Teraki Y, et al. **Acta Derm Venereol** 1996 Nov;76(6):421–3

COMPLICATIONS

Acquired eyelash trichomegaly and alopecia areata in a human immunodeficiency virus–infected patient. Grossman MC, et al. **Dermatology** 1996;193(1):52–3 (23 ref.)
Colocalization of alopecia areata and lichen planus [letter] Dhar S, et al. **Pediatr Dermatol** 1996 May–Jun;13(3):258–9

CONGENITAL

Congenital alopecia areata. de Viragh PA, et al.
Dermatology 1997;195(1):96–8

DIAGNOSIS

Eosinophils in fibrous tracts and near hair bulbs: a helpful diagnostic feature of alopecia areata. Elston DM, et al.
J Am Acad Dermatol 1997 Jul;37(1):101–6

DRUG THERAPY

Topical squaric acid dibutylester therapy for alopecia areata: a double–sided patient–controlled study. Chua SH, et al.
Ann Acad Med Singapore 1996 Nov;25(6):842–7
Prognostic factors for clinical response of alopecia areata to topical immunotherapy with squaric acid dibutylester [letter] Iijima S, et al. **Arch Dermatol** 1997 Apr; 133(4):539–40
IFN–gamma–induced HLA–DR but not ICAM–1 expression on cultured dermal papilla cells is downregulated by TNF–alpha. König A, et al. **Arch Dermatol Res** 1997 Jul; 289(8):466–70
Photo–induced toxic epidermal necrolysis caused by clobazam. Redondo P, et al. **Br J Dermatol** 1996 Dec; 135(6):999–1002
Side–effects during treatment with SADBE. Frattasio A, et al. **Contact Dermatitis** 1997 Feb;36(2):118–9
Pulse steroid therapy for children's severe alopecia areata? Kiesch N, et al. **Dermatology** 1997;194(4):395–7
Minimal benefit from photochemotherapy for alopecia areata. Alabdulkareem AS, et al. **Int J Dermatol** 1996 Dec; 35(12):890–1
Topical tretinoin as an adjunctive therapy with intralesional triamcinolone acetonide for alopecia areata. Clinical experience in northern Saudi Arabia [letter] Kubeyinje EP, et al. **Int J Dermatol** 1997 Apr;36(4):320
Treatment of alopecia areata with squaric acid dibutylester. Micali G, et al. **Int J Dermatol** 1996 Jan;35(1):52–6
Pulsed administration of corticosteroids in the treatment of alopecia areata. Sharma VK. **Int J Dermatol** 1996 Feb; 35(2):133–6
Systemic cyclosporine and low–dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. Shapiro J, et al.
J Am Acad Dermatol 1997 Jan;36(1):114–7
New treatments for alopecia areata. Lebwohl M. **Lancet** 1997 Jan 25;349(9047):222–3

EPIDEMIOLOGY

Profile of alopecia areata in Northern India. Sharma VK, et al. **Int J Dermatol** 1996 Jan;35(1):22–7
A clinical study of childhood alopecia areata in Chandigarh, India. Sharma VK, et al. **Pediatr Dermatol** 1996 Sep–Oct; 13(5):372–7

ETIOLOGY

Alopecia areata in a renal transplant recipient on cyclosporin [letter] Dyall–Smith D. **Australas J Dermatol** 1996 Nov; 37(4):226–7
Alopecia areata in a patient with Turner's syndrome [letter] Lee WS, et al. **Br J Dermatol** 1996 Dec;135(6):1013
Alopecia areata heralding cytomegalovirus reactivation in AIDS [letter] Piras MA, et al. **J Infect** 1997 Mar; 34(2):159–60
Myasthenia gravis and alopecia areata. Kubota A, et al.
Neurology 1997 Mar;48(3):774–5
[Testing the significance of psychic factors in the etiology of alopecia areata. II. Examination of personality by means of Eysenck's Personality Inventory (MPI) adapted by Choynowski] Wyględowska–Kania M, et al. **Przegl Lek** 1995;52(11):562–4 (Eng. Abstr.) **(Pol)**
[Psychic factors in case histories of patients with alopecia areata—preliminary report] Wyględowska–Kania M, et al.
Psychiatr Pol 1996 Jul–Aug;30(4):669–76 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Hair follicle structures targeted by antibodies in patients with alopecia areata. Tobin DJ, et al. **Arch Dermatol** 1997 Jan; 133(1):57–61
Lesional alopecia areata T lymphocytes downregulate epithelial cell proliferation. Thein C, et al.
Arch Dermatol Res 1997 Jun;289(7):384–8
Effects of interleukins, colony–stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin–1 and tumour necrosis factor–alpha in alopecia areata. Philpott MP, et al.
Br J Dermatol 1996 Dec;135(6):942–8
Serological screening for coeliac disease in vitiligo and alopecia areata [letter] Volta U, et al. **Br J Dermatol** 1997 May;136(5):801–2
A flowcytometric study of CD4+ & CD19+ cell lymphopenia in patients with alopecia areata. Sharma VK, et al. **Indian J Med Res** 1996 Nov;104:296–8
Alopecia areata but not androgenetic alopecia is characterized by a restricted and oligoclonal T–cell receptor–repertoire among infiltrating lymphocytes. Dressel D, et al. **J Cutan Pathol** 1997 Mar;24(3):164–8
Detection of antibodies to human melanoma cells in vitiligo and alopecia areata by Western blot analysis. Hann SK, et al. **J Dermatol** 1996 Feb;23(2):100–3
Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata–like hair loss. Tobin DJ, et al.
J Invest Dermatol 1997 Sep;109(3):329–33

PATHOLOGY

Sisaipho: a new form of presentation of alopecia areata [letter] Muñoz MA, et al. **Arch Dermatol** 1996 Oct;132(10):1255–6
Ultrastructural abnormalities in the dermal papillae of both lesional and clinically normal follicles from alopecia areata scalps. Nutbrown M, et al. **Br J Dermatol** 1996 Aug; 135(2):204–10
Trichotillomania in connection with alopecia areata. Trüeb RM, et al. **Cutis** 1996 Jul;58(1):67–70 (10 ref.)
Alopecia areata: immunohistochemistry and ultrastructure of infiltrate and identification of adhesion molecule receptors. Ghersetich I, et al. **Int J Dermatol** 1996 Jan;35(1):28–33
Morphological analysis of hair follicles in alopecia areata. Tobin SJ. **Microsc Res Tech** 1997 Aug 15;38(4):443–51

PHYSIOPATHOLOGY

Possible involvement of neuropeptidergic sensory nerves in alopecia areata. Rossi R, et al. **Neuroreport** 1997 Mar 24; 8(5):1135–8
[Contact thermometry of lesions in alopecia areata] Mijailović B, et al. **Vojnosanit Pregl** 1997 Jan–Feb; 54(1):31–3 (Eng. Abstr.) **(Scr)**

PSYCHOLOGY

Stress and alopecia areata: a psychodermatologic study. Gupta MA, et al. **Acta Derm Venereol** 1997 Jul;77(4):296–8
Children with alopecia areata: psychiatric symptomatology and life events. Liakopoulou M, et al.
J Am Acad Child Adolesc Psychiatry 1997 May; 36(5):678–84
Psychiatric diagnoses in children with alopecia areata. Reeve EA, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Nov; 35(11):1518–22

THERAPY

In vivo depletion of CD8+ T cells restores hair growth in the DEBR model for alopecia areata. McElwee KJ, et al.
Br J Dermatol 1996 Aug;135(2):211–7
Alopecia areata in children: treatment with diphencyprone. Schuttelaar ML, et al. **Br J Dermatol** 1996 Oct;135(4):581–5

VIROLOGY

No correlation between cytomegalovirus and alopecia areata [letter] Tosti A, et al. **J Invest Dermatol** 1996 Sep;107(3):443

ALOPECIA, MALE PATTERN see **ALOPECIA**

ALOPECIA MUCINOSA see **MUCINOSIS, FOLLICULAR**

ALOUATTA

ANATOMY & HISTOLOGY

Atelines, apes and wrist joints. Youlatos D.
Folia Primatol (Basel) 1996;67(4):193–8

GENETICS

Genetic diversity in black howler monkeys (Alouatta pigra) from Belize. James RA, et al. **Am J Phys Anthropol** 1997 Mar;102(3):329–36
Chromosome painting defines genomic rearrangements between red howler monkey subspecies. Consigliere S, et al. **Chromosome Res** 1996 Jun;4(4):264–70
Meiotic behavior of the X1X2Y1Y2 quadrivalent of the primate Alouatta caraya. Rahn MI, et al.
Chromosome Res 1996 Aug;4(5):350–6

IMMUNOLOGY

Antibody immunoglobulin G (IgG) response to Alouattamyia baeri (Diptera:Cuterebridae) parasitism of howler monkeys, Alouatta palliata, in Panama. Baron RW, et al.
J Med Entomol 1996 Nov;33(6):946–51

PSYCHOLOGY

Conspecific aggression and predation: costs for a solitary mantled howler monkey. Cuarón AD.
Folia Primatol (Basel) 1997;68(2):100–5

ALPACAS see **CAMELIDS, NEW WORLD**

ALPERS SYNDROME see **CEREBRAL SCLEROSIS, DIFFUSE**

ALPHA 1–ACID GLYCOPROTEIN see **OROSOMUCOID**

ALPHA 1–ACID SEROMUCOID see **OROSOMUCOID**

ALPHA–ACTININ see **ACTININ**

ALPHA 2–ACUTE PHASE GLOBULINS see **ALPHA–MACROGLOBULINS**

ALPHA–ADRENERGIC BLOCKING AGENTS see **ADRENERGIC ALPHA–ANTAGONISTS**

ALPHA–ADRENERGIC RECEPTOR AGONISTS see **ADRENERGIC ALPHA–AGONISTS**

ALPHA–ADRENERGIC RECEPTOR BLOCKADERS see **ADRENERGIC ALPHA–ANTAGONISTS**

ALPHA–ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA**

ALPHA–1 ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA–1**

ALPHA–2 ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA–2**

ALPHA,ALPHA–DIPYRIDYL see **2,2'–DIPYRIDYL**

ALPHA–AMINOADIPIC ACID see **2–AMINOADIPIC ACID**

ALPHA–AMINO–3–HYDROXY–5–METHYL–4–ISOXAZOLEPROPIONIC ACID

see related
RECEPTORS, AMPA

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID

ANALOGS & DERIVATIVES

Heteroaryl analogues of AMPA. Synthesis and quantitative structure-activity relationships. Bang-Andersen B, et al. **J Med Chem** 1997 Aug 29;40(18):2831-42

ANTAGONISTS & INHIBITORS

Thiocyanate ions inhibit AMPA-activated currents in recombinant non-NMDA receptors expressed in Xenopus laevis oocytes: the role of the GluR2 subunit. Eugène D, et al. **Eur J Neurosci** 1996 Sep;8(9):1983-93

Pharmacology of AMPA antagonists and their role in neuroprotection. Gill R, et al. **Int Rev Neurobiol** 1997; 40:197-232 (186 ref.)

AMPA antagonists differ from NMDA antagonists in their effects on operant DRL and delayed matching to position tasks. Stephens DN, et al. **Psychopharmacology (Berl)** 1996 Aug;126(3):249-59

CHEMICAL SYNTHESIS

Heteroaryl analogues of AMPA. Synthesis and quantitative structure-activity relationships. Bang-Andersen B, et al. **J Med Chem** 1997 Aug 29;40(18):2831-42

METABOLISM

Altered distribution of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subunit GluR2(4) and the N-methyl-D-aspartate receptor subunit NMDAR1 in the hippocampus of patients with temporal lobe epilepsy. Blümcke I, et al. **Acta Neuropathol (Berl)** 1996 Dec;92(6):576-87

Stable expression of homomeric AMPA-selective glutamate receptors in BHK cells. Andersen PH, et al. **Eur J Pharmacol** 1996 Sep 5;311(1):95-100

Effects of thiocyanate and AMPA receptor ligands on (S)-5-fluorowillardiine, (S)-AMPA and (R,S)-AMPA binding. Hawkinson JE, et al. **Eur J Pharmacol** 1997 Jun 25;329(2-3):213-21

Localization of AMPA-selective glutamate receptors in the auditory brainstem of the barn owl. Levin MD, et al. **J Comp Neurol** 1997 Feb 10;378(2):239-53

Ca(2+)-permeable AMPA/kainate and NMDA channels: high rate of Ca2+ influx underlies potent induction of injury. Lu YM, et al. **J Neurosci** 1996 Sep 1;16(17):5457-65

Ultraviolet radiation, thiol reagents, and solubilization enhance AMPA receptor binding affinity via a common mechanism. Hall RA, et al. **Neurochem Res** 1996 Aug; 21(8):963-8

PHARMACOLOGY

Desensitization of AMPA receptors and AMPA-NMDA receptor interaction: an in vivo cyclic GMP microdialysis study in rat cerebellum. Fedele E, et al. **Br J Pharmacol** 1996 Mar;117(6):1133-8

Muscarinic reduction of GABAergic synaptic potentials results in disinhibition of the AMPA/kainate-mediated EPSP in auditory cortex. Aramakis VB, et al. **Brain Res** 1997 May 30;758(1-2):107-17

The glycine site of the NMDA receptor contributes to neurokinin1 receptor agonist facilitation of NMDA receptor agonist-evoked activity in rat dorsal horn neurons. Heppenstall PA, et al. **Brain Res** 1997 Jan 9;744(2):235-45

Characterization of NMDA- and AMPA-induced enhancement of AP-1 DNA binding activity in rat cerebellar granule cells. Hou YN, et al. **Brain Res** 1997 Apr 18;754(1-2):79-87

Changes in the sensitivity of frontal cortical neurones to acetylcholine after unilateral lesion of the nucleus basalis with alpha-amino-3-OH-4-isoxozole propionic acid (AMPA): effects of basal forebrain transplants into neocortex. Abdulla FA, et al. **Brain Res Bull** 1997; 42(3):169-86

Behavioural specificity of neocortical grafts of fetal basal forebrain tissue after unilateral lesion of the nucleus basalis with alpha-amino-3-OH-4-isoxozole propionic acid (AMPA). Abdulla FA, et al. **Brain Res Bull** 1997; 42(6):407-14

The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-EPSP, and GABA-IPSP in the rat hippocampus. Ko GY, et al. **Brain Res Bull** 1997;42(4):297-302

Arginine-481 mutation abolishes ligand-binding of the AMPA-selective glutamate receptor channel alpha1-subunit. Kawamoto S, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1-2):339-44

Pharmacological characterization of AMPA-induced biting behaviour in mice. Brambilla A, et al. **Eur J Pharmacol** 1996 Jun 3;305(1-3):115-7

Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain. McCoy L, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):41-5

Nonsteroidal antiinflammatory drug modulation of behavioral responses to intrathecal N-methyl-D-aspartate, but not to substance P and amino-methyl-isoxazole-propionic acid in the rat. Björkman R, et al. **J Clin Pharmacol** 1996 Dec;36(12 Suppl):20S-26S

Cyclothiazide unmasks an AMPA-evoked release of arachidonic acid from cultured striatal neurones. Williams RJ, et al. **J Neurochem** 1996 Oct;67(4):1551-8

Immunocytochemical characterization of AMPA-selective glutamate receptor subunits: laminar and compartmental distribution in macaque striate cortex. Carder RK. **J Neurosci** 1997 May 1;17(9):3352-63

AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal dentate gyrus of patients with Alzheimer disease. Evidence for hippocampal plasticity. Armstrong DM, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):59-64

Kainic acid, AMPA, and dihydrokainic acid effect on uptake and efflux of D-[3H] aspartic acid in cerebellar slices. Bouazzaoui M, et al. **Neurochem Res** 1996 Dec; 21(12):1527-33

Stereoselective effects-of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies. Lodge D, et al. **Neuropharmacology** 1996;35(12):1681-8

Fast increases of AMPA receptor sensitivity following tetanus-induced potentiation in the CA1 region of the rat hippocampus. Fedorov NB, et al. **Neuroreport** 1997 Jan 20;8(2):411-4

Localisation and properties of AMPA-insensitive kainate sites: receptor autoradiography and gene expression in rat brain. Lunn ML, et al. **Neurosci Lett** 1996 Feb 2; 204(1-2):121-4

New developments in the molecular pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors. Fletcher EJ, et al. **Pharmacol Ther** 1996;70(1):65-89 (251 ref.)

Context-specific cross-sensitization between systemic cocaine and intra-accumbens AMPA infusion in the rat. Bell K, et al. **Psychopharmacology (Berl)** 1996 Oct; 127(4):377-83

Effects of AMPA and D1 receptor activation on striatal and nigral GABA efflux. Byrnes EM, et al. **Synapse** 1997 Jul; 26(3):254-68

Long-lasting decreases of AMPA responses following postsynaptic activity in single hippocampal neurons. Vickery RM, et al. **Synapse** 1997 Jan;25(1):103-6

TOXICITY

Dissociable effects of AMPA-induced lesions of the vertical limb diagonal band of Broca on performance of the 5-choice serial reaction time task and on acquisition of a conditional visual discrimination. Muir JL, et al. **Behav Brain Res** 1996 Dec;82(1):31-44

AMPA neurotoxicity in cultured cerebellar granule neurons: mode of cell death. Cebers G, et al. **Brain Res Bull** 1997; 43(4):393-403

GYKI 53665, a 2,3-benzodiazepine, non-competitively protects cultured neurones against AMPA toxicity. Kovács AD, et al. **Eur J Pharmacol** 1997 Jul 16;331(1):93-6

(S)-5-fluorowillardiine-mediated neurotoxicity in cultured murine cortical neurones occurs via AMPA and kainate receptors. Larm JA, et al. **Eur J Pharmacol** 1996 Oct 24; 314(1-2):249-54

Protection against non-NMDA receptor-mediated excitotoxicity by GYKI 52466 in mature telencephalic cultures of the rat. Kovács AD, et al. **Neurobiology (Bp)** 1996;4(1-2):59-72

Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats. Zhou S, et al. **Neuroreport** 1996 Mar 22;7(4):895-900

ALPHA-AMINOTOLUENE see **BENZYLAMINES**

ALPHA-AMYLASE

Production, purification and characterization of an extracellular alpha-amylase enzyme isolated from Aspergillus flavus. Abou-Zeid AM. **Microbios** 1997; 89(358):55-66

ADVERSE EFFECTS

Occupational allergic contact urticaria from fungal but not bacterial alpha-amylase. Kanerva L, et al. **Contact Dermatitis** 1997 Jun;36(6):306-7

Hypersensitivity reactions and specific antibodies in workers exposed to industrial enzymes at a biotechnology plant. Biagini RE, et al. **J Appl Toxicol** 1996 Mar-Apr; 16(2):139-45

[Respiratory symptoms and occupational sensitization in a group of trainee bakers: results of a 6-month follow up] De Zotti R, et al. **Med Lav** 1997 Mar-Apr;88(2):155-65 (Eng. Abstr.) **(Ita)**

ANALYSIS

High levels of alpha-amylase in seminal fluid may represent a simple artifact in the collection process [letter] Hochmeister MN, et al. **J Forensic Sci** 1997 May; 42(3):535-6

Kinetic determination of amylase on microtiter plates: an improved substrate [letter] Laine J, et al. **Pancreas** 1996 Aug;13(2):217

ANTAGONISTS & INHIBITORS

Extraction, purification and some partial characterization of alpha-amylase inhibitors from wheat Iapar 28-Igapó. Kondo NK, et al. **Arch Latinoam Nutr** 1995 Dec; 45(4):310-6

alpha-Amylase inhibitors from wheat: amino acid sequences and patterns of inhibition of insect and human alpha-amylases. Feng GH, et al. **Insect Biochem Mol Biol** 1996 May;26(5):419-26

Wheat alpha-amylase inhibitor: a second route of allergic sensitization. James JM, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):239-44

Complete sequence, subunit structure, and complexes with pancreatic alpha-amylase of an alpha-amylase inhibitor from Phaseolus vulgaris white kidney beans. Kasahara K, et al. **J Biochem (Tokyo)** 1996 Jul;120(1):177-83

Structural characterization of an alpha-amylase inhibitor from a wild common bean (Phaseolus vulgaris): insight into the common structural features of leguminous alpha-amylase inhibitors. Nakaguchi T, et al. **J Biochem (Tokyo)** 1997 Feb;121(2):350-4

An assessment of nonspecific adsorption to Eudragit S-100 during affinity precipitation. Kumar A, et al. **Mol Biotechnol** 1996 Aug;6(1):1-6

Characterization of a barley gene coding for an alpha-amylase inhibitor subunit (CMd protein) and analysis of its promoter in transgenic tobacco plants and in maize kernels by microprojectile bombardment. Grosset J, et al. **Plant Mol Biol** 1997 May;34(2):331-8

[Degradation of Maillard reaction products by amylolytic enzymes. 3. Inhibition of glucoamylase, alpha-amylase and alpha-glucosidase by heat treated alpha-glucans and melanoidins] Schumacher D, et al. **Z Lebensm Unters Forsch** 1996 Oct;203(4):391-4 (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Salivary alpha-amylase as a measure of endogenous adrenergic activity. Chatterton RT Jr, et al. **Clin Physiol** 1996 Jul;16(4):433-48

Thermostable alpha-amylase production using Bacillus licheniformis NRRL B14368. Bose K, et al. **Indian J Exp Biol** 1996 Dec;34(12):1279-82

Significance of HPr in catabolite repression of alpha-amylase. Voskuil MI, et al. **J Bacteriol** 1996 Dec;178(23):7014-5

Secretion of mouse alpha-amylase from Kluyveromyces lactis. Tokunaga M, et al. **Yeast** 1997 Jun 30;13(8):699-706

BLOOD

Determination of total and pancreatic alpha-amylase in human serum with 2-chloro-4-nitrophenyl-alpha-D-maltotrioside as substrate. Gella FJ, et al. **Clin Chim Acta** 1997 Mar 18; 259(1-2):147-60

Origin of serum alpha-amylase isoenzymes from healthy adult rats. Tomasik A, et al. **Mater Med Pol** 1995 Apr-Jun; 27(2):57-61

CHEMISTRY

Modification of alpha-amylase functions by protein engineering. Terashima M, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:65-9

Purification and characterization of the extracellular alpha-amylase from Clostridium acetobutylicum ATCC 824. Paquet V, et al. **Appl Environ Microbiol** 1991 Jan; 57(1):212-8

Structure of the Aspergillus oryzae alpha-amylase complexed with the inhibitor acarbose at 2.0 A resolution. Brzozowski AM, et al. **Biochemistry** 1997 Sep 9;36(36):10837-45

alpha-Amylase and salivary albumin adsorption onto titanium, enamel and dentin: an in vivo study. Kohavi D, et al. **Biomaterials** 1997 Jul;18(13):903-6

Monte Carlo simulation of multiple attack mechanism of alpha-amylase. Nakatani H. **Biopolymers** 1996 Nov; 39(5):665-9

The alpha-amylase from the yellow meal worm: complete primary structure, crystallization and preliminary X-ray analysis. Strobl S, et al. **FEBS Lett** 1997 Jun 2;409(1):109-14

Structural and functional aspects of chloride binding to Alteromonas haloplanctis alpha-amylase. Feller G, et al. **J Biol Chem** 1996 Sep 27;271(39):23836-41

Crystal structure of thermostable alpha-amylase from Bacillus licheniformis refined at 1.7 A resolution. Hwang KY, et al. **Mol Cells** 1997 Apr 30;7(2):251-8

Physicochemical and serological characterization of rice alpha-amylase isoforms and identification of their corresponding genes. Mitsui T, et al. **Plant Physiol** 1996 Apr;110(4):1395-404

Hyperthermostable mutants of Bacillus licheniformis alpha-amylase: thermodynamic studies and structural interpretation. Declerck N, et al. **Protein Eng** 1997 May; 10(5):541-9

Hyperthermostable mutants of Bacillus licheniformis alpha-amylase: multiple amino acid replacements and molecular modelling. Declerck N, et al. **Protein Eng** 1995 Oct;8(10):1029-37

Crystallization and preliminary X-ray diffraction studies of alpha-amylase from the antarctic psychrophile Alteromonas haloplanctis A23. Aghajari N, et al. **Protein Sci** 1996 Oct;5(10):2128-9

Invariant glycines and prolines flanking in loops the strand beta 2 of various (alpha/beta)8-barrel enzymes: a hidden homology? Janeček S. **Protein Sci** 1996 Jun;5(6):1136-43

ALPHA-AMYLASE

Substrate mimicry in the active center of a mammalian alpha-amylase: structural analysis of an enzyme-inhibitor complex. Bompard-Gilles C, et al. **Structure** 1996 Dec 15; 4(12):1441-52

DIAGNOSTIC USE

Enzymatic measurement of sweat sodium and chloride [letter; comment] Taylor RP, et al. **Ann Clin Biochem** 1997 Mar; 34 (Pt 2):211. Comment on: Ann Clin Biochem 1996 Sep;33 (Pt 5):459-61.

GENETICS

Amy as a reporter gene for promoter activity in Nocardia lactamdurans: comparison of promoters of the cephamycin cluster. Chary VK, et al. **Appl Environ Microbiol** 1997 Aug; 63(8):2977-82

Cloning, sequencing, and expression of the gene encoding extracellular alpha-amylase from Pyrococcus furiosus and biochemical characterization of the recombinant enzyme. Dong G, et al. **Appl Environ Microbiol** 1997 Sep; 63(9):3569-76

Location of the alpha-amylase gene in rumen Streptococcus bovis strains distinguished by unstable amylase activity. Mareková M, et al. **Folia Microbiol (Praha)** 1995; 40(2):181-4

A novel cloning system for direct screening using a suicidal strategy. Barros EV, et al. **Gene** 1996 Nov 14;179(2):287-9

Cloning and expression of a chicken alpha-amylase gene. Benkel BF, et al. **Gene** 1997 Jun 19;192(2):261-70

Molecular cloning of bruchid (Zabrotes subfasciatus) alpha-amylase cDNA and interactions of the expressed enzyme with bean amylase inhibitors. Grossi de Sa MF, et al. **Insect Biochem Mol Biol** 1997 Apr;27(4):271-81

Properties and gene structure of the Thermotoga maritima alpha-amylase AmyA, a putative lipoprotein of a hyperthermophilic bacterium. Liebl W, et al. **J Bacteriol** 1997 Feb;179(3):941-8

Cloning, sequencing, characterization, and expression of an extracellular alpha-amylase from the hyperthermophilic archaeon Pyrococcus furiosus in Escherichia coli and Bacillus subtilis. Jorgensen S, et al. **J Biol Chem** 1997 Jun 27;272(26):16335-42

Expression, secretion, and processing of rice alpha-amylase in the yeast Yarrowia lipolytica. Park CS, et al. **J Biol Chem** 1997 Mar 14;272(11):6876-81

Carbohydrate starvation stimulates differential expression of rice alpha-amylase genes that is modulated through complicated transcriptional and posttranscriptional processes. Sheu JJ, et al. **J Biol Chem** 1996 Oct 25; 271(43):26998-7004

Domain evolution in the alpha-amylase family. Janecek S, et al. **J Mol Evol** 1997 Sep;45(3):322-31

Molecular evolution of the Amy multigenes in the subgenus Sophophora of Drosophila. Inomata N, et al. **Mol Biol Evol** 1997 Sep;14(9):942-50

Molecular evolution of the 5'-flanking regions of the duplicated Amy genes in Drosophila melanogaster species subgroup. Okuyama E, et al. **Mol Biol Evol** 1996 Apr; 13(4):574-83

An Aspergillus nidulans nuclear protein, AnCP, involved in enhancement of Taka-amylase A gene expression, binds to the CCAAT-containing taaG2, amdS, and gatA promoters. Kato M, et al. **Mol Gen Genet** 1997 Mar 26; 254(2):119-26

Amylase on Pecten maximus (Mollusca, bivalves): protein and cDNA characterization; quantification of the expression in the digestive gland. Le Moine S, et al. **Mol Mar Biol Biotechnol** 1997 Sep;6(3):228-37

Contacts between Bacillus subtilis catabolite regulatory protein CcpA and amyO target site. Kim JH, et al. **Nucleic Acids Res** 1997 Sep 1;25(17):3490-6

Hyperthermostable mutants of Bacillus licheniformis alpha-amylase: multiple amino acid replacements and molecular modelling. Declerck N, et al. **Protein Eng** 1995 Oct;8(10):1029-37

Cloning, mapping and characterization of a genomic copy of the Lipomyces kononenkoae alpha-amylase-encoding gene (LKA1). Steyn AJ, et al. **Yeast** 1996 Aug; 12(10):925-37

[Cloning the Saccharomycopsis fibuligera alpha-amylase gene and its expression in Saccharomyces cerevisiae] Baeva LF, et al. **Prikl Biokhim Mikrobiol** 1996 May-Jun; 32(3):311-4 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Clinical responses to ingested fungal alpha-amylase and hemicellulase in persons sensitized to Aspergillus fumigatus? Cullinan P, et al. **Allergy** 1997 Mar;52(3):346-9

ISOLATION & PURIFICATION

Separation of alpha-amylase by reversed micellar extraction. Effect of solvent type and cosolvent concentration on the transfer process. Chang QL, et al. **Appl Biochem Biotechnol** 1997 Feb-Mar;62(2-3):119-29

Raw-starch-digesting and thermostable alpha-amylase from the yeast Cryptococcus sp. S-2: purification, characterization, cloning and sequencing. Iefuji H, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):989-96

Production and certification of an enzyme reference material for pancreatic alpha-amylase (CRM 476). Gubern G, et al. **Clin Chim Acta** 1996 Jul 30;251(2):145-62

Purification of thermamylase in multicompartment electrolyzers with isoelectric membranes: the problem of protein solubility. Esteve-Romero JS, et al. **Electrophoresis** 1996 Jul;17(7):1242-7

The alpha-amylase from the yellow meal worm: complete primary structure, crystallization and preliminary X-ray analysis. Strobl S, et al. **FEBS Lett** 1997 Jun 2;409(1):109-14

Amylase on Pecten maximus (Mollusca, bivalves): protein and cDNA characterization; quantification of the expression in the digestive gland. Le Moine S, et al. **Mol Mar Biol Biotechnol** 1997 Sep;6(3):228-37

METABOLISM

Enzymic activity of whole cells entrapped in reversed micelles. Studies on alpha-amylase and invertase in the entrapped yeast cells. Gajjar L, et al. **Appl Biochem Biotechnol** 1997 May;66(2):159-72

Monte Carlo simulation of multiple attack mechanism of alpha-amylase. Nakatani H. **Biopolymers** 1996 Nov; 39(5):665-9

Action pattern of porcine pancreatic alpha-amylase on three different series of beta-maltooligosaccharide glycosides. Kandra L, et al. **Carbohydr Res** 1997 Mar 5;298(3):237-42

Thermostability of purified human pancreatic alpha-amylase is increased by the combination of Ca2+ and human serum albumin. Tessier AJ, et al. **Clin Chim Acta** 1996 Aug 15; 252(1):11-20

The mechanism of porcine pancreatic alpha-amylase. Kinetic evidence for two additional carbohydrate-binding sites. Alkazaz M, et al. **Eur J Biochem** 1996 Nov 1;241(3):787-96

Electron microscopic investigation of the diffusion of Bacillus licheniformis alpha-amylase into corn starch granules. Helbert W, et al. **Int J Biol Macromol** 1996 Oct;19(3):165-9

Improved activity and modulated action pattern obtained by random mutagenesis at the fourth beta-alpha loop involved in substrate binding to the catalytic (beta/alpha)8-barrel domain of barley alpha-amylase 1. Matsui I, et al. **J Biol Chem** 1997 Sep 5;272(36):22456-63

Domain evolution in the alpha-amylase family. Janecek S, et al. **J Mol Evol** 1997 Sep;45(3):322-31

The activity of alpha-amylase and its salivary isoenzymes in serum and urine of patients with neoplastic diseases of female reproductive organs. Zakrzewska I, et al. **Rocz Akad Med Bialymst** 1996;41(2):492-8

[Diagnostic value of studying salivary enzymes in leukemia patients] Volchkova VM, et al. **Vopr Med Khim** 1996 Jan-Mar;42(1):46-53 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Biomechanical and morphological studies on the periodontal ligament of the rat molar after treatment with alpha-amylase in vitro. Watanabe Y, et al. **Connect Tissue Res** 1997;36(1):35-49

Content of starch and sugars and in vitro digestion of starch by alpha-amylase in five minor millets. Krishnakumari S, et al. **Plant Foods Hum Nutr** 1995 Dec;48(4):327-33

SECRETION

Secretion of Bacillus alpha-amylase from yeast directed by glucoamylase I signal sequence of Saccharomyces diastaticus. Kang DO, et al. **Biochem Mol Biol Int** 1996 May;39(1):181-90

Morphobiochemical studies on alpha-amylase secretion by pancreatic follicles of guinea pigs after the application of exogenous histamine. Kmieć BL, et al. **Folia Histochem Cytobiol** 1997;35(2):113-4

Kidney bean and soybean lectins cause enzyme secretion by pancreatic acini in vitro. Grant G, et al. **Life Sci** 1997; 60(18):1589-95

Enhancement of protein secretion in Saccharomyces cerevisiae by overproduction of Sso protein, a late-acting component of the secretory machinery. Ruohonen L, et al. **Yeast** 1997 Mar 30;13(4):337-51

ALPHA 1-ANTICHYMOTRYPSIN

ANALYSIS

Two-dimensional gel electrophoresis detects prostate-specific antigen-alpha1-antichymotrypsin complex in serum but not in prostatic fluid. Qian Y, et al. **Clin Chem** 1997 Feb;43(2):352-9

[Expression of proteinase inhibitors in the human trabecular meshwork] Fukuchi T, et al. **Nippon Ganka Gakkai Zasshi** 1997 Mar;101(3):265-71 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Coordinate expression of group II phospholipase A2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells. Vadas P, et al. **Clin Exp Immunol** 1997 Apr;108(1):175-80

Expression of alpha-1-antichymotrypsin in prostate carcinoma. Cho NH, et al. **J Korean Med Sci** 1997 Jun; 12(3):228-33

Interleukin-1 beta and tumor necrosis factor-alpha induce expression of alpha 1-antichymotrypsin in human astrocytoma cells by activation of nuclear factor-kappa B. Lieb K, et al. **J Neurochem** 1996 Nov;67(5):2039-44

Synthesis and secretion of active alpha 1-antichymotrypsin by murine primary astrocytes. Kanemaru K, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):767-71

BLOOD

Serological alpha 1-antichymotrypsin in patients with probable senile dementia of Alzheimer type: a short-term longitudinal study. Licastro F, et al. **Alzheimer Dis Assoc Disord** 1996 Winter;10(4):192-6

Effect of improved vitamin A status on response to iron supplementation in Pakistani infants [see comments] Northrop-Clewes CA, et al. **Am J Clin Nutr** 1996 Nov; 64(5):694-9. Comment in: Am J Clin Nutr 1996 Nov;64(5):789-90.

alpha 1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E epsilon 4 allele carriers. Yoshiiwa A, et al. **Ann Neurol** 1997 Jul; 42(1):115-7

Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease. España F, et al. **Eur Urol** 1996;30(4):512-8

Free/total prostate-specific antigen ratio—hope and controversies. Ravery V, et al. **Eur Urol** 1997;31(4):385-8 (19 ref.)

CHEMISTRY

Intrinsic specificity of the reactive site loop of alpha1-antitrypsin, alpha1-antichymotrypsin, antithrombin III, and protease nexin I. Djie MZ, et al. **J Biol Chem** 1997 Jun 27;272(26):16268-73

Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building. Villoutreix BO, et al. **Protein Sci** 1996 May; 5(5):836-51

DEFICIENCY

Serine protease inhibitors in patients with chronic viral hepatitis. Elzouki AN, et al. **J Hepatol** 1997 Jul;27(1):42-8

GENETICS

No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. Fallin D, et al. **Am J Med Genet** 1997 Apr 18; 74(2):192-4

Analysis of alpha-1 antichymotrypsin, presenilin-1, angiotensin-converting enzyme, and methylenetetrahydrofolate reductase loci as candidates for dementia. Tysoe C, et al. **Am J Med Genet** 1997 Apr 18; 74(2):207-12

Polygenic determinants of Alzheimer's disease: modulation of the risk by alpha-1-antichymotrypsin. DeKosky ST, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:27-34

No association between alpha 1-antichymotrypsin and familial Alzheimer's disease. Haines JL, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:35-41

Apolipoprotein E and alpha1-antichymotrypsin polymorphism in Alzheimer's disease. Nacmias B, et al. **Ann Neurol** 1996 Oct;40(4):678-80

Genetic association between susceptibility to Parkinson's disease and alpha1-antichymotrypsin polymorphism. Yamamoto M, et al. **Brain Res** 1997 Jun 6;759(1):153-5

Gender-specific nonrandom association between the alpha 1-antichymotrypsin and apolipoprotein E polymorphisms in the general population and its implication for the risk of Alzheimer's disease. Kamboh MI, et al. **Genet Epidemiol** 1997;14(2):169-80

Re: Genetic effect of alpha 1-antichymotrypsin on the risk of Alzheimer disease [letter; comment] Kamboh MI, et al. **Genomics** 1997 Mar 1;40(2):382-5. Comment on: Genomics 1996 Apr 1;33(1):53-6.

Microsatellite polymorphism of the alpha 1-antichymotrypsin gene locus associated with sporadic Alzheimer's disease. Morgan K, et al. **Hum Genet** 1997 Jan;99(1):27-31

Absence of the A1252G mutation in alpha 1-antichymotrypsin in a North American population suffering from dementia. Gilfix BM, et al. **J Cereb Blood Flow Metab** 1997 Feb;17(2):233-5

Alpha 1-antichymotrypsin gene polymorphism and risk for Alzheimer's disease. Muramatsu T, et al. **J Neural Transm** 1996;103(10):1205-10

No effect of the alpha1-antichymotrypsin A allele in Alzheimer's disease. Didierjean O, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):103-5

Lack of association between alpha 1-antichymotrypsin polymorphism, Alzheimer's disease, and allele epsilon 4 of apolipoprotein E. Müller U, et al. **Neurology** 1996 Dec; 47(6):1575-7

No association between the alpha 1-antichymotrypsin A allele and Alzheimer's disease. Murphy GM Jr, et al. **Neurology** 1997 May;48(5):1313-6

Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and alpha1-antichymotrypsin type A allele in Alzheimer's disease. Higuchi M, et al. **Neuroreport** 1997 Aug 18; 8(12):2639-43

Polymorphism in AACT gene may lower age of onset of Alzheimer's disease. Talbot C, et al. **Neuroreport** 1996 Jan 31;7(2):534-6

No association between alpha1-antichymotrypsin

polymorphism, apolipoprotein E and patients with late-onset Alzheimer's disease. Helisalmi S, et al. **Neurosci Lett** 1997 Aug 1;231(1):56–8

Rate of cognitive decline in Alzheimer's disease is not affected by the alpha-1-antichymotrypsin A allele or the CYP2D6 B mutant. Murphy GM Jr, et al. **Neurosci Lett** 1996 Oct 18;217(2–3):200–2

Analysis of apolipoprotein E, alpha1-antichymotrypsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man. Nacmias B, et al. **Neurosci Lett** 1997 Jul 4;229(3):177–80

Alpha1 antichymotrypsin signal peptide polymorphism in sporadic Creutzfeldt-Jakob disease. Salvatore M, et al. **Neurosci Lett** 1997 May 16;227(2):140–2

METABOLISM

Degradation of nuclear matrix and DNA cleavage in apoptotic thymocytes. Weaver VM, et al. **J Cell Sci** 1996 Jan;109 (Pt 1):45–56

Addition of purified prostate specific antigen to serum from female subjects: studies on the relative inhibition by alpha 2-macroglobulin and alpha 1-antichymotrypsin. Chen Z, et al. **J Urol** 1996 Oct;156(4):1357–63

Synthesis and secretion of active alpha 1-antichymotrypsin by murine primary astrocytes. Kanemaru K, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):767–71

PHARMACOLOGY

Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. Ma J, et al. **Neurobiol Aging** 1996 Sep–Oct; 17(5):773–80

Alpha 1-antichymotrypsin interaction with A beta (1–42) does not inhibit fibril formation but attenuates the peptide toxicity. Aksenov MY, et al. **Neurosci Lett** 1996 Oct 18; 217(2–3):117–20

alpha-1-antichymotrypsin interaction with A beta (1–40) inhibits fibril formation but does not affect the peptide toxicity. Aksenova MV, et al. **Neurosci Lett** 1996 Jun 14; 211(1):45–8

Interaction of subtilisins with serpins. Komiyama T, et al. **Protein Sci** 1996 May;5(5):874–82

PHYSIOLOGY

Alpha 1-antichymotrypsin. Kalsheker NA. **Int J Biochem Cell Biol** 1996 Sep;28(9):961–4 (10 ref.)

Multiple functions of alpha 1-antitrypsin and alpha 1-antichymotrypsin. 2. Role of serpins and their target enzymes in controlling neutrophil chemotaxis. Luisetti M. **Monaldi Arch Chest Dis** 1997 Feb;52(1):48–9

Multiple functions of alpha 1-antitrypsin and alpha 1-antichymotrypsin. 1. Role of lung epithelial cells in the proteinase-proteinase inhibitor balance. Luisetti M. **Monaldi Arch Chest Dis** 1996 Oct;51(5):424–5

Multiple functions of alpha 1-antitrypsin and alpha 1-antichymotrypsin. 3. Regulation of extracellular surfactant metabolism and amyloid fibril formation. Luisetti M. **Monaldi Arch Chest Dis** 1997 Jun;52(3):285–6

ALPHA 1-ANTITRYPSIN

Alpha-1-proteinase inhibitor prolongs small intestinal graft preservation and survival. Yang R, et al. **J Pediatr Surg** 1996 Aug;31(8):1052–5

ADMINISTRATION & DOSAGE

Opportunities for the use of aerosolized alpha 1-antitrypsin for the treatment of cystic fibrosis. Allen ED. **Chest** 1996 Dec;110(6 Suppl):256S–260S (61 ref.)

ANALYSIS

Doppler sonography evaluation of superior mesenteric artery flow to assess Crohn's disease activity: correlation with clinical evaluation, Crohn's disease activity index, and alpha 1-antitrypsin clearance in feces. van Oostayen JA, et al. **AJR Am J Roentgenol** 1997 Feb;168(2):429–33

Heterozygous alpha 1-antitrypsin phenotypes in patients with end stage liver disease. Eigenbrodt ML, et al. **Am J Gastroenterol** 1997 Apr;92(4):602–7

Salivary levels of alpha 2-macroglobulin, alpha 1-antitrypsin, C-reactive protein, cathepsin G and elastase in humans with or without destructive periodontal disease. Pederson ED, et al. **Arch Oral Biol** 1995 Dec;40(12):1151–5

Microheterogeneity of alpha 1-antitrypsin in relation to the concentration of its complex with immunoglobulin A in the sera of patients with rheumatoid arthritis [see comments] Hrycaj P, et al. **Clin Exp Rheumatol** 1996 Mar–Apr;14(2):119–23. Comment in: Clin Exp Rheumatol 1997 Jan–Feb;15(1):117–8.

Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case-control study. Dansinger ML, et al. **Clin Infect Dis** 1996 Jun;22(6):932–7

Serum alpha-1-antitrypsin in ischemia and rheumatic heart diseases. Somayajulu GL, et al. **Indian J Pathol Microbiol** 1996 Oct;39(4):271–5

Serum alpha 1-antitrypsin concentration in dogs with panniculitis. Hughes D, et al. **J Am Vet Med Assoc** 1996 Nov 1;209(9):1582–4

Adjunctive controlled topical application of tetracycline HCl in the treatment of localized persistent or recurrent periodontitis. Effects on clinical parameters and elastase-alpha1-proteinase inhibitor in gingival crevicular fluid. Flemmig TF, et al. **J Clin Periodontol** 1996 Oct; 23(10):914–21

Measurement of faecal alpha 1-antitrypsin: methodologies and clinical application. Choudhary S, et al. **J Gastroenterol Hepatol** 1996 Apr;11(4):311–8

Fecal alpha 1-antitrypsin in newborn infants. Keller KM, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):271–5

Active and alpha-1 proteinase inhibitor complexed leukocyte elastase levels in crevicular fluid from patients with periodontal diseases. Meyer J, et al. **J Periodontol** 1997 Mar;68(3):256–61

Genetic markers and duodenal ulcer. Shahid A, et al. **JPMA J Pak Med Assoc** 1997 May;47(5):135–7

Serum alpha 1 antitrypsin and pulmonary emphysema. Shahid A, et al. **JPMA J Pak Med Assoc** 1996 May;46(5):102–4

Elevated levels of complement components C5 and C9 and decreased antitrypsin activity in the serum of patients with X-linked vacuolated myopathy. Louboutin JP, et al. **Muscle Nerve** 1996 Sep;19(9):1144–7

Capillary plasma neutrophil elastase alpha-1-proteinase inhibitor as infection parameter in neonates. Jensen JG, et al. **Scand J Clin Lab Invest** 1996 Feb;56(1):37–40

[Expression of proteinase inhibitors in the human trabecular meshwork] Fukuchi T, et al. **Nippon Ganka Gakkai Zasshi** 1997 Mar;101(3):265–71 (Eng. Abstr.) **(Jpn)**

[Alpha 1-antitrypsin clearance] Nagayama R, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:120–2 (9 ref.) **(Jpn)**

[Investigations of alpha-1-antitrypsin level in blood serum of patients with melanoma of the choroid] Matysik A, et al. **Klin Oczna** 1995 Sep–Oct;97(9–10):273–5 (Eng. Abstr.) **(Pol)**

[The prognostic significance of the level of the blood antiproteinase potential in peritonitis] Zhebelenko GI, et al. **Vestn Khir Im I I Grek** 1995;154(4–6):29–30 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Comparison of IgA-alpha 1-antitrypsin levels in rheumatoid and reactive arthritis. Scott LJ, et al. **Biochem Soc Trans** 1997 May;25(2):370S

Human colon carcinoma cells synthesize and secrete alpha 1-proteinase inhibitor. Keppler D, et al. **Biol Chem Hoppe Seyler** 1996 May;377(5):301–11

Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor. Luisetti M, et al. **Chest** 1996 Dec;110(6 Suppl):278S–283S (41 ref.)

Biosynthesis of alpha1-proteinase inhibitor by human lung-derived epithelial cells. Cichy J, et al. **J Biol Chem** 1997 Mar 28;272(13):8250–5

Oncostatin M, but not interleukin-6 or leukemia inhibitory factor, stimulates expression of alpha1-proteinase inhibitor in A549 human alveolar epithelial cells. Sallenave JM, et al. **J Interferon Cytokine Res** 1997 Jun;17(6):337–46

[Synthesis, cloning, and expression in Escherichia coli cells of human alpha1-antitrypsin cDNA] Tikunova NV, et al. **Mol Gen Mikrobiol Virusol** 1996 Jul–Sep;(3):36–40 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Computer modelling of human alpha 1-antitrypsin reactive site loop behaviour under mild conditions. Koloczek H, et al. **Acta Biochim Pol** 1996;43(3):467–74

The glycosylation of human recombinant alpha-1-antitrypsin expressed in transgenic mice. Kemp PA, et al. **Biochem Soc Trans** 1996 Aug;24(3):339S

The P6-P2 region of serpins is critical for proteinase inhibition and complex stability. Chaillan-Huntington CE, et al. **Biochemistry** 1997 Aug 5;36(31):9562–70

Effect of glycosylation on the stability of alpha1-antitrypsin toward urea denaturation and thermal deactivation. Kwon KS, et al. **Biochim Biophys Acta** 1997 Jun 6;1335(3):265–72

Inhibition of human serine proteases by SPAAT, the C-terminal 44-residue peptide from alpha1-antitrypsin. Niemann MA, et al. **Biochim Biophys Acta** 1997 Jun 20; 1340(1):123–30

Alpha 1-antitrypsin deficiency. A conformational disease. Carrell RW, et al. **Chest** 1996 Dec;110(6 Suppl):243S–247S (31 ref.)

Microheterogeneity of alpha 1-antitrypsin in relation to the concentration of its complex with immunoglobulin A in the sera of patients with rheumatoid arthritis [see comments] Hrycaj P, et al. **Clin Exp Rheumatol** 1996 Mar–Apr;14(2):119–23. Comment in: Clin Exp Rheumatol 1997 Jan–Feb;15(1):117–8.

TaqI polymorphism in the 3' flanking region of the PI gene among Kuwaiti Arabs and Russians. Samilchuk E, et al. **Dis Markers** 1997 Apr;13(2):87–92

Commercial plasma alpha1-antitrypsin (Prolastin) contains a conformationally inactive, latent component. Lomas DA, et al. **Eur Respir J** 1997 Mar;10(3):672–5

Prevention of peroxynitrite-dependent tyrosine nitration and inactivation of alpha1-antiproteinase by antibiotics. Whiteman M, et al. **Free Radic Res** 1997 Jan;26(1):49–56

Intrinsic specificity of the reactive site loop of alpha1-antitrypsin, alpha1-antichymotrypsin, antithrombin III, and protease nexin I. Djie MZ, et al. **J Biol Chem** 1997 Jun 27;272(26):16268–73

Folding and stability of the Z and S(iiyama) genetic variants of human alpha1-antitrypsin. Kang HA, et al. **J Biol Chem** 1997 Jan 3;272(1):510–6

Fluorescence-detected polymerization kinetics of human alpha 1-antitrypsin. Koloczek H, et al. **J Protein Chem** 1996 Jul;15(5):447–54

Immunoglobulin A—alpha-1-antitrypsin complex in rheumatic diseases. Łącki JK, et al. **Mater Med Pol** 1996 Oct-Dec;28(4):138–40 (21 ref.)

Structural explanation for the deficiency of S alpha 1-antitrypsin [letter] Elliott PR, et al. **Nat Struct Biol** 1996 Nov;3(11):910–1

Major proteinase movement upon stable serpin-proteinase complex formation. Stratikos E, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21;94(2):453–8

Serpin alpha 1proteinase inhibitor probed by intrinsic tryptophan fluorescence spectroscopy. Koloczek H, et al. **Protein Sci** 1996 Nov;5(11):2226–35

The native strains in the hydrophobic core and flexible reactive loop of a serine protease inhibitor: crystal structure of an uncleaved alpha1-antitrypsin at 2.7 A. Ryu SE, et al. **Structure** 1996 Oct 15;4(10):1181–92

Quantification of circulating activated protein C in human plasma by immunoassays—enzyme levels are proportional to total protein C levels. Espana F, et al. **Thromb Haemost** 1996 Jan;75(1):56–61

DEFICIENCY

Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition. Sveger T, et al. **Acta Paediatr** 1997 Jan;86(1):37–40

Primary prevention in a high-risk group: smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD). Thelin T, et al. **Acta Paediatr** 1996 Oct; 85(10):1207–12

Relationship between loss in parenchymal elastic recoil pressure and maximal airway narrowing in subjects with alpha1-antitrypsin deficiency. Cheung D, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):135–40

Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypsin deficiency. Eden E, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):68–74

Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group. Turino GM, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1718–25

The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. Vogelmeier C, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):536–41

Molecular basis, clinical consequences and diagnosis of alpha-1 antitrypsin deficiency. Norman MR, et al. **Ann Clin Biochem** 1997 May;34 (Pt 3):230–46 (96 ref.)

Alpha-1-antitrypsin deficiency: biochemistry and clinical manifestations. Perlmutter DH. **Ann Med** 1996 Oct; 28(5):385–94 (70 ref.)

Simultaneous single-lung transplantation and lung volume reduction. Todd TR, et al. **Ann Thorac Surg** 1997 May; 63(5):1468–70

Alpha 1-antitrypsin deficiency in a child with X-linked lymphoproliferative disease. Skoda-Smith S, et al. **Arch Pathol Lab Med** 1997 Sep;121(9):996–9

Alpha1-antitrypsin deficiency, arthritis, and pancreatitis: comment on the dermatologic vignette by Shbeeb et al [letter] Rubinstein HM. **Arthritis Rheum** 1997 Sep; 40(9):1732

Antiproteinase deficiency, emphysema and replacement therapy. Burdon JG, et al. **Aust N Z J Med** 1996 Dec; 26(6):769–71 (28 ref.)

Alpha 1-antitrypsin deficiency. A conformational disease. Carrell RW, et al. **Chest** 1996 Dec;110(6 Suppl):243S–247S (31 ref.)

A 30-year perspective on alpha 1-antitrypsin deficiency. Eriksson S. **Chest** 1996 Dec;110(6 Suppl):237S–242S (29 ref.)

Pathogenesis of hereditary emphysema and replacement therapy for alpha 1-antitrypsin deficiency. Insight into the more common forms of emphysema. Gadek JE, et al. **Chest** 1996 Dec;110(6 Suppl):248S–250S

Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor. Luisetti M, et al. **Chest** 1996 Dec;110(6 Suppl):278S–283S (41 ref.)

Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. McElvaney NG, et al. **Chest** 1997 Feb; 111(2):394–403

Pathogenesis and pathology of liver disease associated with alpha 1-antitrypsin deficiency. Massi G. **Chest** 1996 Dec; 110(6 Suppl):251S–255S (51 ref.)

Quality control of spirometry testing in the registry for patients with severe alpha1-antitrypsin deficiency. alpha1-Antitrypsin Deficiency Registry Study Group. Stoller JK, et al. **Chest** 1997 Apr;111(4):899–909

Clinical features and natural history of severe alpha 1-antitrypsin deficiency. Roger S. Mitchell Lecture. Stoller JK. **Chest** 1997 Jun;111(6 Suppl):123S–128S (30 ref.)

Lung transplantation for alpha 1-antitrypsin deficiency emphysema. Trulock EP. **Chest** 1996 Dec;110(6 Suppl):284S–294S (37 ref.)

ALPHA 1-ANTITRYPSIN

Rapid screening for alpha1-antitrypsin Z and S mutations. Lam CW, et al. **Clin Chem** 1997 Feb;43(2):403-4

Alpha 1-antitrypsin deficiency alleles and blood pressure in an Australian population. Huggard PR, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):600-1

Rapid and simple diagnosis of the two common alpha 1-proteinase inhibitor deficiency alleles Pi*Z and Pi*S by DNA analysis. Braun A, et al. **Eur J Clin Chem Clin Biochem** 1996 Sep;34(9):761-4

Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Elzouki AN, et al. **Eur J Gastroenterol Hepatol** 1996 Oct;8(10):989-94

Lack of association between porphyria cutanea tarda and alpha 1-antitrypsin deficiency. Fargion S, et al. **Eur J Gastroenterol Hepatol** 1996 Apr;8(4):387-91

Pulmonary function in children with homozygous alpha1-protease inhibitor deficiency. Wiebicke W, et al. **Eur J Pediatr** 1996 Jul;155(7):603-7

Yeast mutants deficient in ER-associated degradation of the Z variant of alpha-1-protease inhibitor. McCracken AA, et al. **Genetics** 1996 Dec;144(4):1355-62

No association between genetic hemochromatosis and alpha1-antitrypsin deficiency. Fargion S, et al. **Hepatology** 1996 Nov;24(5):1161-4

Molecular pathogenesis of liver disease in alpha1-antitrypsin deficiency. Teckman JH, et al. **Hepatology** 1996 Dec; 24(6):1504-16 (142 ref.)

Polymerase chain reaction-mediated site-directed mutagenesis detection of Z and S alpha-1-antitrypsin alleles in family members. Hammerberg G, et al. **J Clin Lab Anal** 1996;10(6):384-8

Review: alpha 1-antitrypsin deficiency associated liver disease. Qu D, et al. **J Gastroenterol Hepatol** 1997 May; 12(5):404-16 (99 ref.)

Serine protease inhibitors in patients with chronic viral hepatitis. Elzouki AN, et al. **J Hepatol** 1997 Jul;27(1):42-8

Severe alpha1-antitrypsin deficiency (PiZ homozygosity) with membranoproliferative glomerulonephritis and nephrotic syndrome, reversible after orthotopic liver transplantation. Elzouki AN, et al. **J Hepatol** 1997 Jun; 26(6):1403-7

Case records of the Department of Medicine University of Mississippi Medical Center. Chronic active hepatitis with cirrhosis of liver secondary to alpha-1 antitrypsin deficiency [clinical conference] Daly EF 3rd, et al. **J Miss State Med Assoc** 1997 May;38(5):161-7

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-1997. A 68-year-old woman with hepatic encephalopathy [clinical conference] **N Engl J Med** 1997 Mar 27;336(13):939-47

ANCA-positive vasculitis and alpha 1-antitrypsin deficiency: could free ANCA antigens released by neutrophils mediate vasculitic lesions? [editorial] Esnault VL. **Nephrol Dial Transplant** 1997 Feb;12(2):249-51

Reversible renal failure and SZ alpha 1-antitrypsin phenotype. Association with liver disease and ethanol abuse. Nunes JP, et al. **Nephrol Dial Transplant** 1995 Dec; 10(12):2340-2

Alpha 1-antitrypsin deficiency and asthma. The continuing search for the relationship. Pina JS, et al. **Postgrad Med** 1997 Apr;101(4):153-6, 159-62, 167-8 (19 ref.)

Wegener's granulomatosis in a patient with severe PiZZ alpha 1-antitrypsin deficiency [letter] Elzouki AN, et al. **QJM** 1996 Nov;89(11):877

New insights into the structural basis of alpha 1-antitrypsin deficiency. Lomas DA. **QJM** 1996 Nov;89(11):807-12 (47 ref.)

Systemic necrotizing vasculitides in severe alpha1-antitrypsin deficiency. Mazodier P, et al. **QJM** 1996 Aug;89(8):599-611

Body mass index and mortality in patients with severe alpha 1-antitrypsin deficiency. Seersholm N. **Respir Med** 1997 Feb;91(2):77-82

The effect of inhaled glucocorticosteroids in emphysema due to alpha1-antitrypsin deficiency. Wilcke JT, et al. **Respir Med** 1997 May;91(5):275-9

Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency--three-year follow-up. Schwaiblmair M, et al. **Respiration** 1997; 64(1):10-5

alpha 1-antitrypsin deficiency and idiopathic pulmonary fibrosis in a family. Kim H, et al. **South Med J** 1996 Oct; 89(10):1008-10

Heterozygous alpha 1-antitrypsin deficiency (PiSZ) in an adolescent with asthma. Nuckton TJ, et al. **South Med J** 1996 Oct;89(10):1011-3 (21 ref.)

PI SZ phenotype in chronic obstructive pulmonary disease. Alvarez-Granda L, et al. **Thorax** 1997 Jul;52(7):659-61

Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ). Piitulainen E, et al. **Thorax** 1997 Mar;52(3):244-8

alpha 1-antitrypsin deficiency-associated panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation. O'Riordan K, et al. **Transplantation** 1997 Feb 15;63(3):480-2

[Severe alpha 1-antitrypsin deficiency diagnosed at 73 years of age (letter)] Galezowski N, et al. **Presse Med** 1996 Sep 7;25(25):1166 **(Fre)**

[Is heterozygote alpha 1-antitrypsin deficiency a risk factor in the etiology of aortic aneurysm?] Hernandez-Richter T, et al. **Chirurg** 1997 May;68(5):513-6 (Eng. Abstr.) **(Ger)**

[Gene therapy of hereditary respiratory tract diseases] Yoshimura K. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):645-50 (38 ref.) **(Jpn)**

[An alpha-1-antitrypsin deficiency allele PI*Siiyama found in a disputed paternity case] Umetsu K, et al. **Nippon Hoigaku Zasshi** 1996 Feb;50(1):37-40 (Eng. Abstr.) **(Jpn)**

[Long-term follow-up and autopsy of a Japanese patient who had emphysema associated with alpha 1-antitrypsin deficiency] Nakamura H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Sep; 34(9):1040-3 (Eng. Abstr.) **(Jpn)**

[Alpha 1-antitrypsin deficiency in Japan] Seyama K, et al. **Nippon Rinsho** 1996 Feb;54(2):533-8 (6 ref.) (Eng. Abstr.) **(Jpn)**

[A case of premature emphysema with hereditary alpha-1-antiproteinase deficiency] Szmidt M, et al. **Pneumonol Alergol Pol** 1996;64(11-12):785-91 (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Influence of methanol and its metabolites on the activity of alpha1-antitrypsin. Skrzydlewska E, et al. **Alcohol** 1997 May-Jun;14(3):295-9

Protection against peroxynitrite-dependent tyrosine nitration and alpha 1-antiproteinase inactivation by ascorbic acid. A comparison with other biological antioxidants. Whiteman M, et al. **Free Radic Res** 1996 Sep;25(3):275-83

Oncostatin M, but not interleukin-6 or leukemia inhibitory factor, stimulates expression of alpha1-proteinase inhibitor in A549 human alveolar epithelial cells. Sallenave JM, et al. **J Interferon Cytokine Res** 1997 Jun;17(6):337-46

GENETICS

Evidence for the presence of different alpha-1-proteinase inhibitor genes products in mouse plasma. Dubin A, et al. **Acta Biochim Pol** 1996;43(3):475-9

alpha1-antitrypsin gene mutation hot spot associated with the formation of a retained and degraded null variant. Brantly M, et al. **Am J Respir Cell Mol Biol** 1997 Mar; 16(3):225-31

Porcine alpha-1-antitrypsin (PI): cDNA sequence, polymorphism and assignment to chromosome 7q2.4- > q2.6. Archibald AL, et al. **Anim Genet** 1996 Apr;27(2):85-9

Long-term expression of the human alpha1-antitrypsin gene in mice employing anionic and cationic liposome vector. Aliño SF. **Biochem Pharmacol** 1997 Jul 1;54(1):9-13 (35 ref.)

Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Le M, et al. **Blood** 1997 Feb 15;89(4):1254-9

Rapid screening for alpha1-antitrypsin Z and S mutations. Lam CW, et al. **Clin Chem** 1997 Feb;43(2):403-4

Alpha 1-antitrypsin deficiency alleles and blood pressure in an Australian population. Huggard PR, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):600-1

TaqI polymorphism in the 3' flanking region of the PI gene among Kuwaiti Arabs and Russians. Samilchuk E, et al. **Dis Markers** 1997 Apr;13(2):87-92

PI locus (alpha-1-antitrypsin) allelic frequencies in an Andean Venezuelan population. Fonseca-Pérez T, et al. **Gene Geogr** 1996 Aug;10(2):65-74

Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Kuzmin AI, et al. **Gene Ther** 1997 Apr;4(4):309-16

Molecular pathogenesis of liver disease in alpha1-antitrypsin deficiency. Teckman JH, et al. **Hepatology** 1996 Dec; 24(6):1504-16 (142 ref.)

Evidence for the systemic delivery of a transgene product from salivary glands. Kagami H, et al. **Hum Gene Ther** 1996 Nov 10;7(17):2177-84

Association between the PI*M3 allele of alpha 1-antitrypsin and Alzheimer's disease? A preliminary report. Kowalska A, et al. **Hum Genet** 1996 Dec;98(6):744-6

Analysis of the allelic diversity of a (CA)n repeat polymorphism among alpha 1-antitrypsin gene products from northern Portugal. Rocha J, et al. **Hum Genet** 1997 Feb;99(2):194-8

A case of systemic nodular panniculitis associated with M1 (Val213) Z phenotype of alpha 1-protease inhibitor. Gaillard MC, et al. **Int J Dermatol** 1997 Apr;36(4):278-80

Cathepsin G, acid phosphatase, and alpha 1-proteinase inhibitor messenger RNA levels in keratoconus corneas. Whitelock RB, et al. **Invest Ophthalmol Vis Sci** 1997 Feb; 38(2):529-34

Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. Wadsworth SC, et al. **J Virol** 1997 Jul;71(7):5189-96

Expression of the alpha 1-proteinase inhibitor gene family during evolution of the genus Mus. Goodwin RL, et al. **Mol Biol Evol** 1997 Apr;14(4):420-7

Isolation and characterization of human hepatoma cells with targeted insertions of a gpt selectable marker in the alpha 1-antitrypsin locus. Porter MB, et al. **Somat Cell Mol Genet** 1996 Jul;22(4):311-27

A human SP-C promoter fragment targets alpha 1-proteinase inhibitor gene expression to lung alveolar type II cells in transgenic mice. Degryse E, et al. **Transgenic Res** 1996 Mar; 5(2):139-43

[An alpha-1-antitrypsin deficiency allele PI*Siiyama found in a disputed paternity case] Umetsu K, et al. **Nippon Hoigaku Zasshi** 1996 Feb;50(1):37-40 (Eng. Abstr.) **(Jpn)**

[Alpha 1-antitrypsin deficiency in Japan] Seyama K, et al. **Nippon Rinsho** 1996 Feb;54(2):533-8 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Study of the frequency of different phenotypes of alpha-1-antitrypsin in a population of Barcelona] Vidal R, et al. **Med Clin (Barc)** 1996 Jul 6;107(6):211-4 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Immunological discrimination of diverse forms of human alpha 1-proteinase inhibitor. Wawrzos I, et al. **Acta Biochim Pol** 1996;43(3):481-7

Prospective study of the clinical value of determining circulating IgA-alpha 1-antitrypsin complex using a prototype ELISA kit in patients with rheumatoid arthritis. Iwana K, et al. **Ann Rheum Dis** 1996 Nov;55(11):848-51

Recognition of complement factor H by a monoclonal antibody used for "specifically" measuring IgA-alpha 1 antitrypsin complexes [letter; comment] Mattey DL, et al. **Clin Exp Rheumatol** 1997 Jan-Feb;15(1):117-8. Comment on: Clin Exp Rheumatol 1996 Mar-Apr;14(2):119-23.

METABOLISM

Hepatocytic globules in end-stage hepatic disease: relationship to alpha1-antitrypsin phenotype. Iezzoni JC, et al. **Am J Clin Pathol** 1997 Jun;107(6):692-7

Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. Tremblay GM, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):1092-8

Complexed plasma elastase as an in vivo marker for leukocyte activation in antineutrophil cytoplasmic antibody-associated vasculitis. Haubitz M, et al. **Arthritis Rheum** 1997 Sep;40(9):1680-4

Retinol and retinaldehyde specifically increase alpha1-proteinase inhibitor in the human cornea. Bosković G, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):751-6

Analysis of the endoplasmic reticular Ca2+ requirement for alpha1-antitrypsin processing and transport competence. Cooper GR, et al. **Biochem J** 1997 Aug 1;325 (Pt 3):601-8

The glycosylation of human recombinant alpha-1-antitrypsin expressed in transgenic mice. Kemp PA, et al. **Biochem Soc Trans** 1996 Aug;24(3):339S

Complexes between proteinase 3, alpha 1-antitrypsin and proteinase 3 anti-neutrophil cytoplasm autoantibodies: a comparison between alpha 1-antitrypsin PiZ allele carriers and non-carriers with Wegener's granulomatosis. Baslund B, et al. **Eur J Clin Invest** 1996 Sep;26(9):786-92

Rapid development of hepatic alpha1-antitrypsin globules after liver transplantation for chronic hepatitis C. Combs C, et al. **Gastroenterology** 1997 Apr;112(4):1372-5

Do synovial fluid acute phase proteins from patients with rheumatoid arthritis originate from serum? Havenaar EC, et al. **Glycoconj J** 1997 Jun;14(4):457-65

Association of respiratory symptoms with serum protease inhibitors and albumin levels in Japanese children. Shima M, et al. **Int J Epidemiol** 1996 Dec;25(6):1213-9

Intracellular association between UDP-glucose:glycoprotein glucosyltransferase and an incompletely folded variant of alpha1-antitrypsin. Choudhury P, et al. **J Biol Chem** 1997 May 16;272(20):13446-51

Intracellular disposal of incompletely folded human alpha1-antitrypsin involves release from calnexin and post-translational trimming of asparagine-linked oligosaccharides. Liu Y, et al. **J Biol Chem** 1997 Mar 21; 272(12):7946-51

Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. Qu D, et al. **J Biol Chem** 1996 Sep 13;271(37):22791-5

Postmortem diagnosis of diabetic metabolic derangement: elevated alpha 1-antitrypsin and haptoglobin glycosylation levels as an index of antemortem hyperglycemia. Ritz S, et al. **J Forensic Sci** 1996 Jan;41(1):94-100

Sequential study of serum glycoprotein fucosylation in acute hepatitis. Seta N, et al. **J Hepatol** 1997 Feb;26(2):265-71

Activity of alpha 1-antitrypsin and cigarette smoking in subarachnoid haemorrhage from ruptured aneurysm. Gaetani P, et al. **J Neurol Sci** 1996 Sep 15;141(1-2):33-8

alpha 1-Proteinase inhibitor in gingival crevicular fluid of humans with adult periodontitis: serpinolytic inhibition by doxycycline. Lee HM, et al. **J Periodontal Res** 1997 Jan; 32(1 Pt 1):9-19

Plasma levels of granulocyte elastase-alpha-proteinase inhibitor complex in patients with rheumatoid arthritis: measurements with a system free from rheumatoid factor interference [letter] Fujimori J, et al. **J Rheumatol** 1996 Mar;23(3):571

Kinetic characterisation of alpha-1-antitrypsin F as an inhibitor of human neutrophil elastase. Cook L, et al. **Pathology** 1996 Aug;28(3):242-7

Alpha-1-antitrypsin kinetics [letter] Jones G. **Pathology** 1997 Aug;29(3):331-3

Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation. Winklhofer-Roob BM, et al. **Pediatr Res** 1996 Jul;

40(1):130-4
[Gastric protein loss and alcoholic cirrhosis. Study by measurement of gastric clearance of alpha 1-antitrypsin] Becheur H, et al. **Gastroenterol Clin Biol** 1996; 20(8-9):669-73 (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. Vogelmeier C, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):536-41
Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Barker AF, et al. **Chest** 1997 Sep;112(3):607-13

PHARMACOLOGY

Divergent effects of alpha 1-antitrypsin on the regulation of iron metabolism in human erythroleukaemic (K562) and myelomonocytic (THP-1) cells. Weiss G, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):897-902
Effects of serpin binding on the target proteinase: global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site. Kaslik G, et al. **Biochemistry** 1997 May 6;36(18):5455-64
Proprotein-processing endoprotease furin controls growth of pancreatic beta-cells. Kayo T, et al. **Diabetes** 1997 Aug; 48(8):1296-304
Plasminogen modulation of IL-1-stimulated degradation in bovine and human articular cartilage explants. The role of the endogenous inhibitors: PAI-1, alpha 2-antiplasmin, alpha 1-PI, alpha 2-macroglobulin and TIMP. Oleksyszyn J, et al. **Inflamm Res** 1996 Sep;45(9):464-72
Inhibitory mechanism of serpins. Mobility of the C-terminal region of the reactive-site loop. Hopkins PC, et al. **J Biol Chem** 1997 Feb 14;272(7):3905-9
Alpha 1-antitrypsin blocks the release of transforming growth factor-alpha from MCF-7 human breast cancer cells. Yavelow J, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):745-52
Elastase inhibitory capacity of purified canine alpha-1-antitrypsin. Vatne M, et al. **J Comp Pathol** 1996 Apr;114(3):211-9
Anticryptosporidial potential of alpha-1-antitrypsin. Forney JR, et al. **J Eukaryot Microbiol** 1996 Sep-Oct;43(5):63S
alpha1-Antitrypsin inhibits the lethal response to TNF in mice. Libert C, et al. **J Immunol** 1996 Dec 1;157(11):5126-9
Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice. Van Molle W, et al. **J Immunol** 1997 Oct 1;159(7):3555-64
Antagonistic effect of human alpha-1-antitrypsin on excystation of Cryptosporidium parvum oocysts. Forney JR, et al. **J Parasitol** 1997 Aug;83(4):771-4
Interaction of subtilisins with serpins. Komiyama T, et al. **Protein Sci** 1996 May;5(5):874-82
Low density lipoprotein catabolism is enhanced by the cleaved form of alpha-1-antitrypsin. Janciauskiene S, et al. **Scand J Clin Lab Invest** 1997 Jul;57(4):325-35

PHYSIOLOGY

Multiple functions of alpha 1-antitrypsin and alpha 1-antichymotrypsin. 1. Role of lung epithelial cells in the proteinase-proteinase inhibitor balance. Luisetti M. **Monaldi Arch Chest Dis** 1996 Oct;51(5):424-5
Multiple functions of alpha 1-antitrypsin and alpha 1-antichymotrypsin. 2. Role of serpins and their target enzymes in controlling neutrophil chemotaxis. Luisetti M. **Monaldi Arch Chest Dis** 1997 Feb;52(1):48-9
Multiple functions of alpha 1-antitrypsin and alpha 1-antichymotrypsin. 3. Regulation of extracellular surfactant metabolism and amyloid fibril formation. Luisetti M. **Monaldi Arch Chest Dis** 1997 Jun;52(3):285-6
Function of a rare variant of alpha-1-antitrypsin, phenotype P(i) EFranklin S, a poor inhibitor of human neutrophil elastase. Cook L, et al. **Res Exp Med (Berl)** 1997; 196(6):355-62
Immunochemical and functional properties of biliary alpha-1-antitrypsin. Janciauskiene S, et al. **Scand J Clin Lab Invest** 1996 Nov;56(7):597-608
[Plasma elastase alpha 1-proteinase inhibitor complex in children with bronchitis] Polańska B, et al. **Pediatr Pol** 1996 Sep;71(9):765-9 (Eng. Abstr.) **(Pol)**

SECRETION

Activated neutrophils secrete stored alpha 1-antitrypsin. Pääkkö P, et al. **Am J Respir Crit Care Med** 1996 Dec; 154(6 Pt 1):1829-33

SUPPLY & DISTRIBUTION

Alpha 1-proteinase inhibitor (human) shortage [letter] Horowitz ID. **Chest** 1996 Dec;110(6):1624-5

THERAPEUTIC USE

Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor. Luisetti M, et al. **Chest** 1996 Dec;110(6 Suppl):278S-283S (41 ref.)
Evidence for the systemic delivery of a transgene product from salivary glands. Kagami H, et al. **Hum Gene Ther** 1996 Nov 10;7(17):2177-84
Intravenous alpha-1-antitrypsin replacement therapy: case report after one year of treatment. Ward AC, et al. **Ir J Med Sci** 1997 Jan-Mar;166(1):7-9 (10 ref.)
Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency--three-year follow-up. Schwaiblmair M, et al. **Respiration** 1997; 64(1):10-5
Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation. Bingle L, et al. **Thorax** 1996 Dec;51(12):1273-4 (13 ref.)
alpha 1-antitrypsin deficiency-associated panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation. O'Riordan K, et al. **Transplantation** 1997 Feb 15;63(3):480-2

URINE

Long-term stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain-immunoreactivity, orosomucoid and alpha 1-antitrypsin in urine stored at -20 degrees C. Tencer J, et al. **Scand J Urol Nephrol** 1997 Feb; 31(1):67-71

ALPHA-BLOCKERS, ADRENERGIC see **ADRENERGIC ALPHA-ANTAGONISTS**

ALPHA-CARBOXYLASE see **PYRUVATE DECARBOXYLASE**

ALPHA-CELL TUMOR see **GLUCAGONOMA**

ALPHA-CHAIN DISEASE see **IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE**

ALPHA-CHLORHYDRIN see **ALPHA-CHLOROHYDRIN**

ALPHA-CHLOROHYDRIN

ANALOGS & DERIVATIVES

Low-dose diethyldithiocarbamate attenuates the hepatotoxicity of 1,3-dichloro-2-propanol and selectively inhibits CYP2E1 activity in the rat. Stott I, et al. **Hum Exp Toxicol** 1997 May;16(5):262-6
Involvement of cytochrome P4502E1 in the toxicity of dichloropropanol to rat hepatocyte cultures. Hammond AH, et al. **Toxicology** 1997 Mar 28;118(2-3):171-9

PHARMACOLOGY

Synchronous assessment of sperm motility and fertilizing ability in the hamster following treatment with alpha-chlorohydrin. Slott VL, et al. **J Androl** 1995 Nov-Dec;16(6):523-35

ALPHA-1,24-CORTICOTROPIN see **COSYNTROPIN**

ALPHA-DIFLUOROMETHYLORNITHINE see **EFLORNITHINE**

5 ALPHA-DIHYDROTESTOSTERONE see **STANOLONE**

ALPHA-ENDORPHIN

CHEMISTRY

Characterization of unstable intermediates and oxidized products formed during cyanogen bromide cleavage of peptides and proteins by electrospray mass spectrometry. Zhang X, et al. **Anal Chem** 1996 Oct 1;68(19):3422-30

ALPHA-ENDOTHELIAL GROWTH FACTOR see **ENDOTHELIAL GROWTH FACTORS**

ALPHA-FETOPROTEINS

The phylogeny of alpha-fetoprotein in vertebrates: survey of biochemical and physiological data. Mizejewski GJ. **Crit Rev Eukaryot Gene Expr** 1995;5(3-4):281-316 (284 ref.)
Receptor-mediated transfer of pSV2CAT DNA to mouse liver cells using asialofetuin-labeled liposomes. Hara T, et al. **Gene Ther** 1995 Dec;2(10):784-8

ANALYSIS

Lectin affinity electrophoresis of alpha-fetoprotein detected by immunoenzymatic and chemiluminescent amplification followed by direct scanning. Ogata M, et al. **Acta Med Okayama** 1996 Jun;50(3):119-24
Regional variations in neural tube defects and alfa-fetoprotein screening in Denmark 1983-88. Jacobsen P. **Acta Obstet Gynecol Scand** 1996 Aug;75(7):620-3
Human hepatocyte growth factor in alcoholic liver disease: a comparison with change in alpha-fetoprotein. Department of Veterans Affairs Cooperative Study Group 275. Mendenhall CL, et al. **Alcohol Clin Exp Res** 1996 Dec; 20(9):1625-30
Benefits of maternal serum alpha-fetoprotein testing [letter] Dyson RD. **Am Fam Physician** 1996 Nov 1;54(6):1890, 1893
Increasing serum levels of alpha-fetoprotein in a patient with relapsing gallbladder carcinoma. Cocquyt V, et al. **Am J Clin Oncol** 1996 Oct;19(5):465-8
Markedly elevated serum alpha fetoprotein is an indicator of extrauterine pregnancy [letter] Kaur M, et al. **Am J Med Genet** 1997 Mar 3;69(1):112-3
Diagnostic dilemma with elevated level of alpha-fetoprotein in an undiagnosed twin pregnancy with a small discordant holoacardius acephalus. Entezami M, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):466-8
Maternal serum screening for Down syndrome in the United States: a 1995 survey. Palomaki GE, et al. **Am J Obstet Gynecol** 1997 May;176(5):1046-51
Hepatoid adenocarcinoma of the lung: report of a case of an unusual alpha-fetoprotein-producing lung tumor. Arnould L, et al. **Am J Surg Pathol** 1997 Sep;21(9):1113-8
Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery. Lemoine A, et al. **Ann Surg** 1997 Jul;226(1):43-50
Detection of alpha-fetoprotein and hepatitis-B surface antigen in blood spotted on filter paper: use as a screen for hepatocellular carcinoma in Alaska Natives. Parkinson AJ, et al. **Arctic Med Res** 1996 Jul;55(3):123-8
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer. de Wit R, et al. **Br J Cancer** 1997;75(3):432-5
Detection of alphafetoprotein-expressing cells in the blood of patients with hepatoma and hepatitis. Jiang SY, et al. **Br J Cancer** 1997;75(6):928-33
Germ cell tumors express a specific alpha-fetoprotein variant detectable by isoelectric focusing. Johnson PJ, et al. **Cancer** 1995 Apr 1;75(7):1663-8
Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Shimada M, et al. **Cancer** 1996 Nov 15;78(10):2094-100
Medians for second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol; differences between races or ethnic groups. Benn PA, et al. **Clin Chem** 1997 Feb;43(2):333-7
Alpha-foetoprotein heterogeneity: what is its value in managing patients with germ cell tumours? de Takats PG, et al. **Clin Oncol (R Coll Radiol)** 1996;8(5):323-6
The significance of placental pathology in pregnancies with unexplained abnormal concentrations of MSAFP or MShCG. Morssink LP, et al. **Early Hum Dev** 1996 Dec 30;47 Suppl:S63-5
Separation of 1-aminopyrene-3,6,8-trisulfonate-labeled asparagine-linked fetuin glycans by capillary gel electrophoresis. Guttman A, et al. **Electrophoresis** 1996 Feb;17(2):412-7
Fingerprinting of glycans as their 2-aminoacridone derivatives by capillary electrophoresis and laser-induced fluorescence. Harland GB, et al. **Electrophoresis** 1996 Feb; 17(2):406-11
Affinity electrophoretic determination of oligosaccharide specificity of Butea monosperma agglutinin. Wongkham S, et al. **Electrophoresis** 1996 Jan;17(1):98-103
Quantitative nephelometric assay for determining alpha-foetoprotein evaluated. Bernard DR, et al. **Eur J Clin Chem Clin Biochem** 1996 Oct;34(10):847-52
Diagnosis of premature rupture of the membranes in preterm patients, using an improved AFP kit: comparison with ROM-check and/or nitrazine test. Kishida T, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Nov;69(2):77-82
Effect of Hispanic ethnicity on interpretation of maternal serum screening. Byrne JL, et al. **Fetal Diagn Ther** 1997 Mar-Apr;12(2):102-6
Abnormal biochemical serum screening versus 2nd-trimester ultrasound-detected minor anomalies as predictors of aneuploidy in low-risk patients. Drugan A, et al. **Fetal Diagn Ther** 1996 Sep-Oct;11(5):301-5
Doppler velocimetry of the umbilical artery as a predictor of pregnancy outcome in pregnancies characterized by elevated maternal serum alpha-fetoprotein and normal amniotic fluid alpha-fetoprotein. Jaffa A, et al. **Fetal Diagn Ther** 1997 Mar-Apr;12(2):85-8
Maternal serum triple analyte screening and adverse pregnancy outcome. Milunsky A, et al. **Fetal Diagn Ther** 1996 Jul-Aug;11(4):249-53
Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Yamashita F, et al. **Gastroenterology** 1996 Oct; 111(4):996-1001
Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Funaki NO, et al. **Hepatology** 1997 Mar;25(3):564-8
Feto-maternal bleeding following coelocentesis. Makrydimas G, et al. **Hum Reprod** 1997 Apr;12(4):845-6
Spontaneous drastic reduction of alpha-fetoprotein in hepatocellular carcinoma. Phadke AY, et al. **Indian J Gastroenterol** 1996 Jul;15(3):111
Interpretation of serum alpha-feto protein in an infant with hepatomegaly. Kapoor G, et al. **Indian Pediatr** 1996 Jan; 33(1):65-9
ACOG educational bulletin. Maternal serum screening. Number 228, September 1996 (replaces no. 154, April 1991). Committee on Educational Bulletins of the American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Dec;55(3):299-308 (34 ref.)
Maternal serum alpha-fetoprotein in placental abruption associated with preterm labor. Bartha JL, et al. **Int J Gynaecol Obstet** 1997 Mar;56(3):231-6

ALPHA-FETOPROTEINS

Expectations and fears of women regarding two methods of prenatal screening. Esen UI, et al. **Int J Gynaecol Obstet** 1997 May;57(2):193–4

Sacrococcygeal teratoma associated with a normal alpha-fetoprotein concentration. Hung TH, et al. **Int J Gynaecol Obstet** 1997 Sep;58(3):321–2

Alpha feto-protein and albumin in ascitic fluid in hepatocellular carcinoma patients. Sadek A, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):455–64

Double cancer of the stomach, one AFP-producing tumor. Hyodo T, et al. **J Gastroenterol** 1996 Dec;31(6):851–4

High polyunsaturated fatty acid, thromboxane A2, and alpha-fetoprotein concentrations at the human feto-maternal interface. Benassayag C, et al. **J Lipid Res** 1997 Feb;38(2):276–86

Maternal thyroid function does not alter maternal serum alpha-fetoprotein interpretation. Hallak M, et al. **J Matern Fetal Med** 1997 Mar-Apr;6(2):115–7

Maternal serum human chorionic gonadotropin as a marker for the delivery of low-birth-weight infants in women with unexplained elevations in maternal serum alpha-fetoprotein. Hurley TJ, et al. **J Matern Fetal Med** 1996 Nov-Dec;5(6):340–4

Sertoli Leydig cell tumor with malignant heterologous elements and raised alpha-fetoprotein: a case report. Singh ZN, et al. **J Obstet Gynaecol Res** 1996 Dec;22(6):595–8

Comparison of an improved AFP kit with the intra-amniotic PSP dye-injection method in equivocal cases of preterm premature rupture of the fetal membranes. Yamada H, et al. **J Obstet Gynaecol Res** 1997 Jun;23(3):307–11

The importance of genetic counseling before amniocentesis. Cohn GM, et al. **J Perinatol** 1996 Sep-Oct;16(5):352–7; quiz 358–9

Predicting pregnancy outcome from the degree of maternal serum alpha-fetoprotein elevation. Cusick W, et al. **J Reprod Med** 1996 May;41(5):327–32

Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. Shirabe K, et al. **J Surg Oncol** 1997 Feb; 64(2):143–6

Amniotic fluid alpha-fetoprotein determination at the time of genetic amniocentesis: has it outlived its usefulness? Shields LE, et al. **J Ultrasound Med** 1996 Nov;15(11):735–9

Tumor markers in hydrocele fluids of patients with benign and malignant scrotal diseases. Dorfinger K, et al. **J Urol** 1997 Sep;158(3 Pt 1):851–5

Alpha-fetoprotein derived synthetic peptides: assay of an estrogen-modifying regulatory segment. Mizejewski GJ, et al. **Mol Cell Endocrinol** 1996 Apr 19;118(1–2):15–23

Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies. Frishman GN, et al. **Obstet Gynecol** 1997 Jul;90(1):98–101

Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an Asian population. Hsieh TT, et al. **Obstet Gynecol** 1997 Jun;89(6):937–40

Cost-effectiveness of strategies used in the evaluation of pregnancies complicated by elevated maternal serum alpha-fetoprotein levels [letter; comment] Lenke R. **Obstet Gynecol** 1997 Aug;90(2):317–8. Comment on: Obstet Gynecol 1997 May;89(5 Pt 1):660–5.

Race-ethnicity-specific variation in multiple-marker biochemical screening: alpha-fetoprotein, hCG, and estriol. O'Brien JE, et al. **Obstet Gynecol** 1997 Mar;89(3):355–8

The association between hypertensive disorders of pregnancy and abnormal second-trimester maternal serum levels of hCG and alpha-fetoprotein [letter] Roque H. **Obstet Gynecol** 1997 Sep;90(3):480–1

The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Waller DK, et al. **Obstet Gynecol** 1996 Nov;88(5):816–22

A teratoid Wilms' tumor with raised serum alpha-fetoprotein level. Ashworth MT, et al. **Pediatr Pathol Lab Med** 1996 Sep-Oct;16(5):853–9

Ethnic origin and maternal serum markers of Down syndrome in Israel [letter] Barkai G, et al. **Prenat Diagn** 1996 Sep;16(9):870–2

Maternal serum marker levels in two pregnancies affected with Smith-Lemli-Opitz syndrome [letter] Canick JA, et al. **Prenat Diagn** 1997 Feb;17(2):187–9

First-trimester biochemical screening for Down syndrome with the use of PAPP-A, AFP, and beta-hCG. Casals E, et al. **Prenat Diagn** 1996 May;16(5):405–10

Elevated maternal serum and amniotic fluid alpha-fetoprotein levels in the Denys-Drash syndrome. Devriendt K, et al. **Prenat Diagn** 1996 May;16(5):455–7

Alpha-fetoprotein and AChE in early amniocentesis [letter] Eiben B, et al. **Prenat Diagn** 1996 Jan;16(1):87–8

Maternal serum screening and trisomy 16 confined to the placenta. Groli C, et al. **Prenat Diagn** 1996 Aug;16(8):685–9

Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction [see comments] Groutz A, et al. **Prenat Diagn** 1996 Aug; 16(8):723–7. Comment in: Prenat Diagn 1997 May;17(5):488–90.

Concordant anencephaly in monoamniotic twins and an analysis of maternal serum markers. Hansen LM, et al. **Prenat Diagn** 1997 May;17(5):471–3

Uterine malformation: a cause of elevated maternal serum alpha-fetoprotein concentrations. Heinonen S, et al. **Prenat Diagn** 1996 Jul;16(7):635–9

Comparison of Down's syndrome screening strategies in Asians combining serum free beta-hCG and alpha-fetoprotein with maternal age. Hsu JJ, et al. **Prenat Diagn** 1997 Aug;17(8):707–16

Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high-risk pregnancies. Jauniaux E, et al. **Prenat Diagn** 1996 Dec;16(12):1129–35

Free beta hCG screening of hydropic and non-hydropic Turner syndrome pregnancies. Laundon CH, et al. **Prenat Diagn** 1996 Sep;16(9):853–6

Placental mosaicism is associated with unexplained second-trimester elevation of MShCG levels, but not with elevation of MSAFP levels. Morssink LP, et al. **Prenat Diagn** 1996 Sep;16(9):845–51

The HELLP syndrome: its association with unexplained elevation of MSAFP and MShCG in the second trimester. Morssink LP, et al. **Prenat Diagn** 1997 Jul;17(7):601–6

Maternal serum screening for fetal Down syndrome in IVF pregnancies. Ribbert LS, et al. **Prenat Diagn** 1996 Jan; 16(1):35–8

Sonographic and maternal serum screening abnormalities in fetuses affected by spinal muscular atrophy. Rijhsinghani A, et al. **Prenat Diagn** 1997 Feb;17(2):166–9

Results of 12 years' combined maternal serum alpha-fetoprotein screening and ultrasound fetal monitoring for prenatal detection of fetal malformations in Havana City, Cuba. Rodríguez L, et al. **Prenat Diagn** 1997 Apr;17(4):301–4

The detection of non-immune hydrops through second-trimester maternal serum screening. Saller DN Jr, et al. **Prenat Diagn** 1996 May;16(5):431–5

The association of early-onset fetal growth restriction, elevated maternal serum alpha-fetoprotein, and the development of severe pre-eclampsia. Shipp TD, et al. **Prenat Diagn** 1997 Apr;17(4):305–9

Biochemical markers of trisomy 21 in amniotic fluid. Spencer K, et al. **Prenat Diagn** 1997 Jan;17(1):31–7

Between-pregnancy biological variability of maternal serum alpha-fetoprotein and free beta hCG: implications for Down syndrome screening in subsequent pregnancies. Spencer K. **Prenat Diagn** 1997 Jan;17(1):39–45

Urinary transforming growth factor-beta 1 in relation to serum alpha-fetoprotein in hepatocellular carcinoma. Tsai JF, et al. **Scand J Gastroenterol** 1997 Mar;32(3):254–60

High serum alpha-fetoprotein concentration associated with pseudoinfarction of a cirrhotic liver: report of a case. Matsushita K, et al. **Surg Today** 1996;26(10):818–21

Serum alpha-fetoprotein concentrations in urban and rural Southern African blacks with hepatocellular carcinoma. Kew MC, et al. **Trop Gastroenterol** 1995 Oct-Dec; 16(4):11–5

[Evaluation of the combined assay of alpha-feto protein and gamma-glutamyl transpeptidase isoenzyme II in the diagnosis of primary hepatic carcinoma] Ding S, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):690–2 (Eng. Abstr.) **(Chi)**

[Prenatal studies of trisomy 21: triple test more efficient than age criterion (letter; comment)] Drenthe-Schonk A. **Ned Tijdschr Geneeskd** 1996 Dec 7;140(49):2477. Comment on: Ned Tijdschr Geneeskd 1996 Oct 12;140(41):2032–5. **(Dut)**

[Prenatal serum screening of aneuploidy and of neural tube defects in the second trimester of pregnancy among the population of Luxembourg. Evaluation of risk by the triple test (AFP+THCG+UE3)] Thix J. **Bull Soc Sci Med Grand Duche Luxemb** 1997;134(1):25–9 (Eng. Abstr.) **(Fre)**

[Increase of serum alpha-fetoprotein in a patient with acinar cell carcinoma of the pancreas (letter)] Balian A, et al. **Gastroenterol Clin Biol** 1997;21(3):231–2 **(Fre)**

[Importance of AFPplus-screening in daily practice. Evaluation of 2641 analyses] Longoni S, et al. **Schweiz Rundsch Med Prax** 1997 Apr 30;86(18):741–7 (Eng. Abstr.) **(Ger)**

[Ca-19-9, carcinoembryonic antigen, and alpha-fetoprotein in the serum of nononcological patients and their clinical significance] Skvortsov SV, et al. **Biull Eksp Biol Med** 1997 May;123(5):566–9 **(Rus)**

[Analytical characteristics of commercial IRMA-AFP kit for determination of human alpha-fetoprotein] Andreev AV, et al. **Klin Lab Diagn** 1993 May-Jun;(3):54–8 (Eng. Abstr.) **(Rus)**

[The level of embryonic antigens in the blood serum and cerebrospinal fluid of neuro-oncological patients] Rudenko VA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Jul-Sep;(3):32–5 (Eng. Abstr.) **(Rus)**

[Tumor markers in medullary thyroid carcinoma. Biochemical and immunohistochemical study (letter)] López-Guzmán A, et al. **An Med Interna** 1996 Jul; 13(7):358–9 **(Spa)**

[Unexplained increase in maternal plasma in alpha-fetoproteins in the second trimester of pregnancy: perinatal results] Cox M U, et al. **Rev Chil Obstet Ginecol** 1995;60(3):174–80 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Kanai F, et al. **Cancer Res** 1997 Feb 1;57(3):461–5

RXR-mediated regulation of the alpha-fetoprotein gene through an upstream element. Li C, et al. **DNA Cell Biol** 1996 Nov;15(11):955–63

Negative regulation of the alpha-foetoprotein gene in fibroblasts: identification and characterization of cis and trans elements. Henriette MF, et al. **Folia Biol (Praha)** 1997; 43(1):5–13

Expression of alpha-fetoprotein and stem cell factor/c-kit system in bile duct ligated young rats. Omori M, et al. **Hepatology** 1997 May;25(5):1115–22

The expression of fetuin in the development and maturation of the hemopoietic and immune systems. Dziegielewska K, et al. **Histochem Cell Biol** 1996 Sep;106(3):319–30

Non-alpha-fetoprotein-producing anaplastic hepatoblastoma cell line [letter] Tsunoda Y, et al. **In Vitro Cell Dev Biol Anim** 1996 Apr;32(4):194–6

Hepatoid adenocarcinoma of the endometrium associated with alpha-fetoprotein production. Hoshida Y, et al. **Int J Gynecol Pathol** 1996 Jul;15(3):266–9

Alpha-fetoprotein-producing adenocarcinoma of the lung. Yoshino I, et al. **Lung Cancer** 1996 Aug;15(1):125–30 (16 ref.)

Malignant müllerian mixed tumor of the uterus with a prominent alpha-fetoprotein-producing component of yolk sac tumor. Shokeir MO, et al. **Mod Pathol** 1996 Jun; 9(6):647–51 (22 ref.)

Alpha-fetoprotein-producing renal cell carcinoma with increased activity of N-acetylglucosaminyl-transferase III. Aoyagi Y, et al. **Nephron** 1996;74(2):409–14

A teratoid Wilms' tumor with raised serum alpha-fetoprotein level. Ashworth MT, et al. **Pediatr Pathol Lab Med** 1996 Sep-Oct;16(5):853–9

Alpha-fetoprotein-producing carcinoma of the colon: report of a case. Kurihara K, et al. **Surg Today** 1997;27(5):453–6

[Effective transcatheter arterial embolization for hepatic metastasis in a case of AFP producing gastric cancer] Kobayashi T, et al. **Gan To Kagaku Ryoho** 1996 Oct; 23(12):1705–8 (Eng. Abstr.) **(Jpn)**

[A case of alpha-fetoprotein-producing pancreatic carcinoma—review of 41 cases reported in Japan] Shimizu E, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Dec; 93(12):921–6 (20 ref.) **(Jpn)**

CHEMISTRY

'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Johnson PJ, et al. **Br J Cancer** 1997;75(2):236–40

Comparison of carbohydrate structures of serum alpha-fetoprotein by sequential glycosidase digestion and lectin affinity electrophoresis. Shimizu K, et al. **Clin Chim Acta** 1996 Oct 15;254(1):23–40

Structural determination of the O-linked sialyl oligosaccharides liberated from fetuin with endo-alpha-N-acetylgalactosaminidase-S by HPLC analysis and 600-MHz 1H-NMR spectroscopy. Ishii-Karakasa I, et al. **Eur J Biochem** 1997 Jul 15; 247(2):709–15

Ligand-free form of human alpha-fetoprotein: evidence for the molten globule state. Uversky VN, et al. **FEBS Lett** 1997 Jun 30;410(2–3):280–4

[Stabilization of the alpha-fetoprotein structure with sucrose] Kirkitadze MD, et al. **Bioorg Khim** 1996 Jun;22(6):408–14 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Contrast enhancement in experimental radiation-induced liver injury: comparison of hepatocellular and reticuloendothelial particulate contrast agents. Stiskal M, et al. **J Magn Reson Imaging** 1996 Mar-Apr;6(2):286–90

GENETICS

Sequence requirements for alpha-fetoprotein gene expression during liver regeneration. Lin Y, et al. **Cell Growth Differ** 1995 Dec;6(12):1549–58

Regulation and activities of alpha-fetoprotein. Chen H, et al. **Crit Rev Eukaryot Gene Expr** 1997;7(1–2):11–41 (364 ref.)

RXR-mediated regulation of the alpha-fetoprotein gene through an upstream element. Li C, et al. **DNA Cell Biol** 1996 Nov;15(11):955–63

Chicken ovalbumin upstream promoter-transcription factor, hepatocyte nuclear factor 3, and CCAAT/enhancer binding protein control the far-upstream enhancer of the rat alpha-fetoprotein gene. Thomassin H, et al. **DNA Cell Biol** 1996 Dec;15(12):1063–74

Restriction of tumoricidal gene therapy to selected hepatocellular carcinoma cells. Gagandeep S, et al. **Hepatology** 1996 Nov;24(5):1317–9

Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Xu GW, et al. **Hepatology** 1996 Nov;24(5):1264–8

Sequence requirements for Afr-2 regulation of alpha-fetoprotein gene expression during liver regeneration. Jin DK, et al. **Somat Cell Mol Genet** 1996 May;22(3):211–26

[Expression of a hybrid protein between human gamma-interferon and alpha-fetoprotein in E. coli cells] Tat'kov SI, et al. **Mol Biol (Mosk)** 1996 Nov-Dec; 30(6):1299–306 **(Rus)**

IMMUNOLOGY

Detection of hepatocellular carcinoma with a new alpha-fetoprotein antibody imaging kit. Dresel S, et al. **J Clin Oncol** 1997 Jul;15(7):2683–90

[Antigen showing alternative to alpha-fetoprotein expression in rat hepatomas] Eraĭzer TL, et al. **Biull Eksp Biol Med** 1996 Nov;122(11):536–40 **(Rus)**

ISOLATION & PURIFICATION

Purification and characterization of human and mouse recombinant alpha-fetoproteins expressed in Escherichia coli. Boismenu R, et al. **Protein Expr Purif** 1997 Jun; 10(1):10–26

METABOLISM

Binding of mouse sperm to beta-galactose residues on egg zona pellucida and asialofetuin-coupled beads. Mori E, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):95–9

Isolation and characterization of AFP-binding proteins from tumor and fetal human tissues. Kanevsky VYu, et al. **Biochem Mol Biol Int** 1997 May;41(6):1143–51

Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. Tsai JF, et al. **Br J Cancer** 1997;75(10):1460–6

Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters. Berry E, et al. **Br J Obstet Gynaecol** 1997 Jul;104(7):811–7

Maternal serum alpha-fetoprotein in fetal neural tube and abdominal wall defects at 10 to 14 weeks of gestation. Sebire NJ, et al. **Br J Obstet Gynaecol** 1997 Jul; 104(7):849–51

Developmental changes in expression of the ATBF1 transcription factor gene. Watanabe M, et al. **Brain Res Mol Brain Res** 1996 Dec;42(2):344–9

Vimentin and alpha-fetoprotein expression in breast cancer smears: relationship with various prognostic factors. Athanassiadou P, et al. **Cancer Detect Prev** 1997; 21(3):207–12

Immature teratoma producing alpha-fetoprotein without components of yolk sac tumor in the pineal region. Yamashita N, et al. **Childs Nerv Syst** 1997 Apr;13(4):225–8

Maternal serum screening for fetal Down syndrome: clinical aspects. Saller DN Jr, et al. **Clin Obstet Gynecol** 1996 Dec; 39(4):783–92 (11 ref.)

Maternal serum screening for fetal Down syndrome: the detection of other pathologies. Saller DN Jr, et al. **Clin Obstet Gynecol** 1996 Dec;39(4):793–800 (12 ref.)

Regulation and activities of alpha-fetoprotein. Chen H, et al. **Crit Rev Eukaryot Gene Expr** 1997;7(1–2):11–41 (364 ref.)

Neural tube defects/alpha-fetoprotein/Down's syndrome screening. Aitken DA, et al. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):113–20 (62 ref.)

Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Ohnishi T, et al. **Eur J Biochem** 1997 Feb 1;243(3):753–61

Multiple marker screening in multifetal gestations: failure to predict adverse pregnancy outcomes. Drugan A, et al. **Fetal Diagn Ther** 1996 Jan–Feb;11(1):16–9

Increased amniotic fluid alpha-fetoprotein in patients with fetal nuchal edema. Drugan A, et al. **Fetal Diagn Ther** 1996 Jan–Feb;11(1):6–8

Comparative cross-linking activities of lactose-specific plant and animal lectins and a natural lactose-binding immunoglobulin G fraction from human serum with asialofetuin. Gupta D, et al. **Glycobiology** 1996 Dec; 6(8):843–9

alpha-Fetoprotein-producing (hepatoid) carcinoma of the fallopian tube. Aoyama T, et al. **Gynecol Oncol** 1996 Nov; 63(2):261–6

Hepatocellular carcinoma as a rare cause of an excessive increase in alpha-fetoprotein during pregnancy. Entezami M, et al. **Gynecol Oncol** 1996 Sep;62(3):405–7

The low positive rate of serum alpha-fetoprotein levels in hepatitis C virus antibody-positive patients with hepatocellular carcinoma. Furui J, et al. **Hepatogastroenterology** 1995 Sep–Oct;42(5):445–9

Early recurrence after surgery of hepatocellular carcinoma. Ikeda Y, et al. **Hepatogastroenterology** 1995 Sep–Oct; 42(5):469–72

Limited proteolysis of human alpha2-HS glycoprotein/fetuin. Evidence that a chymotryptic activity can release the connecting peptide. Nawratil P, et al. **J Biol Chem** 1996 Dec 6;271(49):31735–41

Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group. Van Tornout JM, et al. **J Clin Oncol** 1997 Mar;15(3):1190–7

Alpha-fetoprotein, carcinoembryonic antigen, and carbohydrate antigen 19-9-producing gallbladder cancer. Ono T, et al. **J Gastroenterol** 1996 Oct;31(5):742–6 (14 ref.)

Sequential study of serum glycoprotein fucosylation in acute hepatitis. Seta N, et al. **J Hepatol** 1997 Feb;26(2):265–71

Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Wang SS, et al. **J Hepatol** 1996 Aug;25(2):166–71

Correlation between serum level of, and tissue positivity for, alpha-fetoprotein in hepatocellular carcinoma. Ogawa A, et al. **J Med** 1996;27(1–2):33–40

The role of subfractionation of alpha-fetoprotein in the treatment of pediatric surgical patients. Tsuchida Y, et al. **J Pediatr Surg** 1997 Mar;32(3):514–7

Prevalence of elevated anticardiolipin antibodies in pregnant women with unexplained elevations of alpha-fetoprotein. Yetman DL, et al. **J Reprod Immunol** 1997 Apr;33(1):71–81

The association between hypertensive disorders of pregnancy and abnormal second-trimester maternal serum levels of hCG and alpha-fetoprotein. Morssink LP, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):666–70

Cost-effectiveness of strategies used in the evaluation of pregnancies complicated by elevated maternal serum alpha-fetoprotein levels [see comments] Nadel AS, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):660–5. Comment in: Obstet Gynecol 1997 Aug;90(2):317–8.

A proposal of additional immunohistochemical markers for hepatoid carcinomas of the foregut [letter; comment] Caruso RA, et al. **Pathology** 1996 Aug;28(3):288. Comment on: Pathology 1995 Jul;27(3):277–9.

Re: Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction [letter; comment] Shulman LP, et al. **Prenat Diagn** 1997 May;17(5):488–90. Comment on: Prenat Diagn 1996 Aug;16(8):723–7.

Maternal serum markers for Down's syndrome pregnancies. Chew S, et al. **Singapore Med J** 1995 Aug;36(4):417–23 (85 ref.)

Resection of liver metastasis from alpha-fetoprotein-producing early gastric cancer: report of a case. Tsurumachi T, et al. **Surg Today** 1997;27(6):563–6 (11 ref.)

Elevated alpha-fetoprotein secondary to Hodgkin's lymphoma. Hurley LJ, et al. **Urology** 1996 Dec;48(6):936–8

[The triple test scenario for Styria. With data of the Styria Abnormalities Register] Häusler MC, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(3):169–77 (Eng. Abstr.) **(Ger)**

[Comparison between age-dependent (Wald alpha program) and age-independent (Ulm index) analysis program for prenatal detection of Down's syndrome with serum markers] Zwahr C, et al. **Z Geburtshilfe Neonatol** 1996 Sep–Oct;200(5):181–5 (Eng. Abstr.) **(Ger)**

[Double primary lung cancers producing alpha-fetoprotein] Bessho T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2216–20 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Dependence of the concentration of maternal serum markers on the haptoglobin gene] Chivilev IV, et al. **Genetika** 1997 Mar;33(3):399–404 (Eng. Abstr.) **(Rus)**

[Alpha-fetoprotein: biochemical properties, function, and clinico-diagnostic significance] Shevtsova AI. **Ukr Biokhim Zh** 1995 Nov–Dec;67(6):11–21 (92 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Covalent grafting of fibronectin and asialofetuin at surface of poly(ethylene terephthalate) track-etched membranes improves adhesion but not differentiation of rat hepatocytes. Jaumotte-Thelen S, et al. **J Biomed Mater Res** 1996 Dec;32(4):569–82

Induction of apoptosis in human hepatoma cells by alpha-fetoprotein. Semenkova LN, et al. **Tumour Biol** 1997; 18(5):261–73

Alpha-fetoprotein as a TNF resistance factor for the human hepatocarcinoma cell line HepG2. Semenkova LN, et al. **Tumour Biol** 1997;18(1):30–40

PHYSIOLOGY

Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Ohnishi T, et al. **Eur J Biochem** 1997 Feb 1;243(3):753–61

Fetuin protects the fetus from TNF [letter] Wang H, et al. **Lancet** 1997 Sep 20;350(9081):861–2

alpha-fetoprotein as a biologic response modifier: relevance to domain and subdomain structure. Mizejewski GJ. **Proc Soc Exp Biol Med** 1997 Sep;215(4):333–62 (256 ref.)

Alpha-fetoprotein as a TNF resistance factor for the human hepatocarcinoma cell line HepG2. Semenkova LN, et al. **Tumour Biol** 1997;18(1):30–40

SECRETION

[Immunosuppressive substances induced by liver grafting] Kobayashi E. **Tanpakushitsu Kakusan Koso** 1997 Jul; 42(9):1420–6 (40 ref.) **(Jpn)**

ALPHA-GALACTOSIDASE

ANTAGONISTS & INHIBITORS

Biological activities of the nortropane alkaloid, calystegine B2, and analogs: structure-function relationships. Goldmann A, et al. **J Nat Prod** 1996 Dec;59(12):1137–42

BIOSYNTHESIS

Glucoamylase gene fusions alleviate limitations for protein production in Aspergillus awamori at the transcriptional and (post) translational levels. Gouka RJ, et al. **Appl Environ Microbiol** 1997 Feb;63(2):488–97

Comparison of cell wall proteins of Saccharomyces cerevisiae as anchors for cell surface expression of heterologous proteins. Van der Vaart JM, et al. **Appl Environ Microbiol** 1997 Feb;63(2):615–20

The entire genomic sequence and cDNA expression of mouse alpha-galactosidase A. Gotlib RW, et al. **Biochem Mol Med** 1996 Apr;57(2):139–48

Three alpha-galactosidase genes of Trichoderma reesei cloned by expression in yeast. Margolles-Clark E, et al. **Eur J Biochem** 1996 Aug 15;240(1):104–11

Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Medin JA, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23; 93(15):7917–22

CHEMISTRY

Role of methionine in the active site of alpha-galactosidase from Trichoderma reesei. Kachurin AM, et al. **Biochem J** 1995 Jun 15;308 (Pt 3):955–64

Cloning, expression and characterization of a blood group B active recombinant alpha-D-galactosidase from soybean (Glycine max). Davis MO, et al. **Biochem Mol Biol Int** 1996 Jun;39(3):471–85

DEFICIENCY

alpha-Galactosidase A deficient mice: a model of Fabry disease. Ohshima T, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2540–4

Galactosialidosis in two siblings [published erratum appears in Turk J Pediatr 1996 Apr–Jun;38(2):287] Yuce A, et al. **Turk J Pediatr** 1996 Jan–Mar;38(1):85–9

GENETICS

Missense mutation in exon 2 of alpha-galactosidase A in a patient with Fabry disease. Ishida S, et al. **Arch Dermatol Res** 1997 Apr;289(5):303–5

Cloning, sequence, and expression of a blood group B active recombinant alpha-D-galactosidase from pinto bean (Phaseolus vulgaris). Davis MO, et al. **Biochem Mol Biol Int** 1997 Jul;42(3):453–67

The entire genomic sequence and cDNA expression of mouse alpha-galactosidase A. Gotlib RW, et al. **Biochem Mol Med** 1996 Apr;57(2):139–48

Coexistence of gene mutations causing Fabry disease and Duchenne muscular dystrophy in a Japanese boy. Takenaka T, et al. **Clin Genet** 1996 May;49(5):255–60

Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy. Sawada K, et al. **Clin Nephrol** 1996 May;45(5):289–94

Fabry disease: fourteen alpha-galactosidase A mutations in unrelated families from the United Kingdom and other European countries. Davies JP, et al. **Eur J Hum Genet** 1996;4(4):219–24

Gene transfer and expression of human alpha-galactosidase from mouse muscle in vitro and in vivo. Novo FJ, et al. **Gene Ther** 1997 May;4(5):488–92

Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry disease. Germain D, et al. **Hum Genet** 1996 Dec;98(6):719–26

A sensitive mutation screening strategy for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene. Blanch LC, et al. **Hum Mutat** 1996;8(1):38–43

A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted. Miyamura N, et al. **J Clin Invest** 1996 Oct 15;98(8):1809–17

Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. Redonnet-Vernhet I, et al. **J Med Genet** 1996 Aug; 33(8):682–8

Two novel mutations in the alpha-galactosidase gene in Japanese classical hemizygotes with Fabry disease. Okumiya T, et al. **Jpn J Hum Genet** 1996 Sep;41(3):313–21

Superfamily of alpha-galactosidase MEL genes of the Saccharomyces sensu stricto species complex. Naumova ES, et al. **Mol Gen Genet** 1996 Nov 27;253(1–2):111–7

Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Eng CM, et al. **Mol Med** 1997 Mar; 3(3):174–82

[alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)] Okumiya T, et al. **Rinsho Byori** 1997 Feb;45(2):127–35 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Superfamily of alpha-galactosidase MEL genes from Saccharomyces cerevisiae] Naumov GI, et al. **Dokl Akad Nauk** 1997 Mar;353(3):426–9 **(Rus)**

ISOLATION & PURIFICATION

Purification and characterization of extremely thermostable beta-mannanase, beta-mannosidase, and alpha-galactosidase from the hyperthermophilic

eubacterium Thermotoga neapolitana 5068. Duffaud GD, et al. **Appl Environ Microbiol** 1997 Jan;63(1):169–77

METABOLISM

Characterization of coffea canephora alpha-D-galactosidase blood group B activity. Phillips R, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1996 Sep; 24(5):489–502

Trp-16 is essential for the activity of alpha-galactosidase and alpha-N-acetylgalactosaminidase. Zhu A, et al. **Biochim Biophys Acta** 1996 Sep 13;1297(1):99–104

Only sphingolipid activator protein B (SAP-B or saposin B) stimulates the degradation of globotriaosylceramide by recombinant human lysosomal alpha-galactosidase in a detergent-free liposomal system. Kase R, et al. **FEBS Lett** 1996 Sep 9;393(1):74–6

ALPHA-GLOBIN see **GLOBIN**

ALPHA-GLOBULINS

Alpha 2 mu, alpha 2u, or alpha 2u [letter; comment] Witschi H. **Environ Health Perspect** 1997 Apr;105(4):362–3. Comment on: Environ Health Perspect 1996 Dec;104(12):1264–7.

ANALYSIS

Quantitation of alpha(2)-microglobulin after administration of structurally divergent chemical compounds. Hildebrand H, et al. **Arch Toxicol** 1997;71(6):351–9

Inter-alpha-trypsin inhibitor and its related proteins in Syrian hamster urine and plasma. Yamamoto T, et al. **J Biochem (Tokyo)** 1996 Jul;120(1):145–52

BIOSYNTHESIS

PPAR alpha mediates peroxisome proliferator-induced transcriptional repression of nonperoxisomal gene expression in mouse. Motojima K, et al. **Biochem Biophys Res Commun** 1997 Jan 3;230(1):155–8

CHEMISTRY

Female protein, amyloidosis, and hormonal carcinogenesis in Turkish hamster: differences from Syrian hamster. Coe JE, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R934–41

Purification and characterization of pig inter-alpha-inhibitor and its constitutive heavy chains. Carrette O, et al. **Biochim Biophys Acta** 1997 Mar 7;1338(1):21–30

Adsorption of alpha-1-microglobulin from biological fluids onto polymer surfaces. Santin M, et al. **Biomaterials** 1997 Jun;18(11):823–7

An investigation of the binding site of alpha 2u-globulin using isotopically labeled ligands and inverse nuclear magnetic resonance techniques. Huwe JK, et al. **Chem Res Toxicol** 1996 Jan-Feb;9(1):215–22

Prothrombin, albumin and immunoglobulin A form covalent complexes with alpha1-microglobulin in human plasma. Berggård T, et al. **Eur J Biochem** 1997 May 1;245(3):676–83

Changes in luminal fluid protein composition in the rat cauda epididymidis following partial sympathetic denervation. Ricker DD, et al. **J Androl** 1996 Mar-Apr;17(2):117–26

Mutations which introduce free cysteine residues in the Gla-domain of vitamin K dependent proteins result in the formation of complexes with alpha 1-microglobulin. Wojcik EG, et al. **Thromb Haemost** 1996 Jan;75(1):70–5

GENETICS

ITI (inter-alpha trypsin inhibitor) phenotyping by immunogold staining. Kimura Y, et al. **Gene Geogr** 1995 Dec;9(3):191–6

Comparative assignments of the genes of the inter-alpha-inhibitor family in human and mouse: ITIH4 is close to ITIH1 and ITIH3, on HSA 3 and MMU 14. Jean L, et al. **Genomics** 1997 Apr 1;41(1):139–40

Molecular cloning and sequencing of cDNAs encoding three heavy-chain precursors of the inter-alpha-trypsin inhibitor in Syrian hamster: implications for the evolution of the inter-alpha-trypsin inhibitor heavy chain family. Nakatani T, et al. **J Biochem (Tokyo)** 1997 Jul;122(1):71–82

Sequence requirements for secondary glucocorticoid inducibility of rat alpha 2u globulin genes. Schwartz DA, et al. **Mol Cell Endocrinol** 1996 Jul 1;120(2):153–9

Characterization of a novel rice bZIP protein which binds to the alpha-globulin promoter. Nakase M, et al. **Plant Mol Biol** 1997 Feb;33(3):513–22

METABOLISM

Hepatic alpha 2 mu-globulin: a potential metabolic role in the rat proximal tubule. Borkan SC, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F527–38

Female protein, amyloidosis, and hormonal carcinogenesis in Turkish hamster: differences from Syrian hamster. Coe JE, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R934–41

Inter-alpha-trypsin inhibitor is concentrated in the pericellular environment of mouse granulosa cells through hyaluronan-binding. Hirashima Y, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 May;73(1):79–84

Expression of a lipocalin in Pichia pastoris: secretion, purification and binding activity of a recombinant mouse major urinary protein. Ferrari E, et al. **FEBS Lett** 1997 Jan 13;401(1):73–7

In vitro uptake of methyl tert-butyl ether in male rat kidney: use of a two-compartment model to describe protein interactions. Poet TS, et al. **Toxicol Appl Pharmacol** 1997 Aug;145(2):340–8

Cumulus expansion initiates physical and developmental autonomy of the oocyte. Larsen WJ, et al. **Zygote** 1996 Nov;4(4):335–41

PHARMACOLOGY

Effect of continual light deprivation and alpha-2u-globulin replacement therapy on serum concentration of gonadotropins and testicular activity in rats. Ghosh PK, et al. **Andrologia** 1996 Nov-Dec;28(6):309–13

PHYSIOLOGY

1,3,5-Trinitrobenzene-induced alpha-2u-globulin nephropathy. Kim S, et al. **Toxicol Pathol** 1997 Mar-Apr; 25(2):195–201

TOXICITY

Alpha 2 mu-globulin nephropathy in white ravens [letter] [see comments] Ashby J. **Environ Health Perspect** 1996 Dec;104(12):1264–7. Comment in: Environ Health Perspect 1997 Apr;105(4):362–3.

URINE

Measurement of albumin and low molecular weight proteins in the urine of newborn infants using a cotton wool ball collection method. Fell JM, et al. **Acta Paediatr** 1997 May; 86(5):518–22

Increase of bikunin and alpha1-microglobulin concentrations in urine of rats during pregnancy is due to decreased tubular reabsorption. Blom AM, et al. **Biochim Biophys Acta** 1997 Aug 22;1361(2):198–202

Changes in the ratio of urinary alpha 1-microglobulin to ulinastatin levels in patients with psychiatric diseases. Inagaki T, et al. **Biol Psychiatry** 1996 Oct 15;40(8):800–3

An investigation of the binding site of alpha 2u-globulin using isotopically labeled ligands and inverse nuclear magnetic resonance techniques. Huwe JK, et al. **Chem Res Toxicol** 1996 Jan-Feb;9(1):215–22

Comparison of urinary excretion of albumin, alpha 1-microglobulin and retinol-binding protein in diabetic patients [published erratum appears in Diabetes Metab 1997 Feb;23(1):118] Galanti LM, et al. **Diabetes Metab** 1996 Oct; 22(5):324–30

Evaluation of antibiotic-induced nephrotoxicity in preterm neonates by determining urinary alpha 1-microglobulin. Fanos V, et al. **Pediatr Nephrol** 1996 Oct;10(5):645–7

Changes in the ratio of urinary alpha 1-microglobulin to ulinastatin levels in patients with Alzheimer-type dementia and vascular dementia. Inagaki T, et al. **Psychiatry Clin Neurosci** 1995 Dec;49(5–6):287–90

Nullification of a positive correlation between urinary levels of alpha 1-microglobulin and ulinastatin by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Shikimi T, et al. **Psychoneuroendocrinology** 1997 May; 22(4):269–75

Serum levels of IgG antibodies against Tamm-Horsfall protein and urinary excretion of NAG and alpha-1-microglobulin as possible markers for tubular damage in patients with a continent ileal reservoir for urinary diversion. Campanello M, et al. **Scand J Urol Nephrol** 1997 Jun;31(3):237–43

Long-term stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain-immunoreactivity, orosomucoid and alpha 1-antitrypsin in urine stored at -20 degrees C. Tencer J, et al. **Scand J Urol Nephrol** 1997 Feb; 31(1):67–71

[Renal function in children with reflux nephropathy followed up more than 10 years after disappearance of vesicoureteral reflux: usefulness of alpha 1-microglobulin as a marker to predict the prognosis of these children] Ota S, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Nov;87(11):1236–42 (Eng. Abstr.) **(Jpn)**

[The significance of diagnosing microalbuminuria and microglobulinuria in diabetes mellitus and arterial hypertension] Kasprowicz B, et al. **Przegl Lek** 1997; 54(3):180–4 (70 ref.) (Eng. Abstr.) **(Pol)**

1,4-ALPHA-GLUCAN BRANCHING ENZYME

ANALYSIS

[Nine cases of debrancher deficiency (glycogen storage disease type III) presenting muscle weakness—study on clinicobiochemical analysis] Fukuda T, et al. **Rinsho Shinkeigaku** 1996 Apr;36(4):540–3 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

The multiple forms of starch-branching enzyme I in Solanum tuberosum. Khoshnoodi J, et al. **Eur J Biochem** 1996 Nov 15;242(1):148–55

DEFICIENCY

A new variant of type IV glycogenosis with primary cardiac manifestation and complete branching enzyme deficiency. In vivo detection by heart muscle biopsy. Nase S, et al. **Eur Heart J** 1995 Nov;16(11):1698–704

GENETICS

A complex arrangement of genes at a starch branching enzyme I locus in the D-genome donor of wheat. Rahman S, et al. **Genome** 1997 Aug;40(4):465–74

Independent genetic control of maize starch-branching enzymes IIa and IIb. Isolation and characterization of a Sbe2a cDNA. Gao M, et al. **Plant Physiol** 1997 May; 114(1):69–78

Differential expression and properties of starch branching enzyme isoforms in developing wheat endosperm. Morell MK, et al. **Plant Physiol** 1997 Jan;113(1):201–8

METABOLISM

Comparing the properties of Escherichia coli branching enzyme and maize branching enzyme. Guan H, et al. **Arch Biochem Biophys** 1997 Jun 1;342(1):92–8

Structure of the cyclic glucan produced from amylopectin by Bacillus stearothermophilus branching enzyme. Takata H, et al. **Carbohydr Res** 1996 Dec 13;295:91–101

Differential action of branching enzymes according to its source. Lerner LR, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Jul;42(5):599–608

[The problem of existing errors in reproducing the Petrov method of isolating amylose isomerase—a branching enzyme] Kochkina VM, et al. **Mol Biol (Mosk)** 1996 Mar-Apr;30(2):478–80 **(Rus)**

[Errors in reproducing experimental studies of the muscle branched enzyme, amylose isomerase] Petrova AN. **Mol Biol (Mosk)** 1996 Mar-Apr;30(2):475–7 **(Rus)**

ALPHA 2-GLUCOPROTEINS see **ALPHA-MACROGLOBULINS**

1,4-ALPHA-GLUCOSIDASE, EXO see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

ALPHA-GLUCOSIDASES

ANALYSIS

Apyrase and alpha-glucosidase in the salivary glands of Aedes albopictus. Marinotti O, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Apr; 113(4):675–9

ANTAGONISTS & INHIBITORS

Acarbose: an alpha-glucosidase inhibitor. Martin AE, et al. **Am J Health Syst Pharm** 1996 Oct 1;53(19):2277–90; quiz 2336–7 (111 ref.)

Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Ahr HJ, et al. **Arzneimittelforschung** 1997 Jun;47(6):734–45

In vitro study of the effect of miglitol on carbohydrate digestion and intestinal metabolism in normal and non-insulin-dependent diabetic rats. Tormo MA, et al. **Can J Physiol Pharmacol** 1996 Nov;74(11):1196–203

An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Hara T, et al. **Diabetes Care** 1996 Jun;19(6):642–7

Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients? Johnson AB, et al. **Diabetes Care** 1996 Jun;19(6):559–63

Rapid improvement of serum 1,5-anhydroglucitol concentrations after administration of alpha-glucosidase inhibitor [letter] Yoshioka K, et al. **Diabetes Care** 1997 Mar; 20(3):462

Effect of an alpha-glucosidase inhibitor on glomerular basement membrane anionic sites in streptozotocin induced mildly diabetic rats. Sato H, et al. **Diabetes Res Clin Pract** 1997 Aug;37(2):91–9

Inhibition of glucose absorption in the rat jejunum: a novel action of alpha-D-glucosidase inhibitors. Hirsh AJ, et al. **Gastroenterology** 1997 Jul;113(1):205–11

Homonojirimycin and N-methyl-homonojirimycin inhibit N-linked oligosaccharide processing. Zeng Y, et al. **Glycobiology** 1997 Mar;7(2):297–304

Evaluation of differential disaccharide excretion in urine for non-invasive investigation of altered intestinal disaccharidase activity caused by alpha-glucosidase inhibition, primary hypolactasia, and coeliac disease. Bjarnason I, et al. **Gut** 1996 Sep;39(3):374–81

Postprandial serum lipids and tissue lipoprotein lipase are acutely altered in rats by the alpha-glucosidase inhibitor acarbose. Picard F, et al. **Horm Metab Res** 1996 Aug; 28(8):377–80

The effect of a very low dose of tolbutamide combined with an alpha-glucosidase inhibitor in non-insulin-dependent diabetes mellitus. Okada S, et al. **J Int Med Res** 1996 Sep-Oct;24(5):433–7

The effect of an alpha-glucosidase inhibitor and insulin on glucose metabolism and lipid profiles in non-insulin-dependent diabetes mellitus. Okada S, et al. **J Int Med Res** 1996 Sep-Oct;24(5):438–47

Can alpha-glucosidase inhibitors reduce the insulin dosage administered to patients with non-insulin-dependent diabetes mellitus? Okada S, et al. **J Int Med Res** 1995

Nov-Dec;23(6):487-91
Effect of alpha-glucosidase inhibitor in combination with sulphonylurea compounds on lipid profile in patients with non-insulin-dependent diabetes mellitus. Okada S, et al. **J Int Med Res** 1995 Nov-Dec;23(6):492-6
Insulin secretion levels necessary for efficacy of an alpha-glucosidase inhibitor on glucose metabolism in patients with non-insulin-dependent diabetes mellitus. Okada S, et al. **J Int Med Res** 1995 Nov-Dec;23(6):497-501
Can alpha-glucosidase inhibitors reduce the dosage of sulphonylurea compounds needed by patients with non-insulin-dependent diabetes mellitus? Okada S, et al. **J Int Med Res** 1995 Nov-Dec;23(6):502-7
Efficacy of acarbose as monotherapy in NIDDM patients. Deerochanawong C, et al. **J Med Assoc Thai** 1996 Feb; 79(2):69-75
Synthesis of alpha-glucosidase I inhibitors showing antiviral (HIV-1) and immunosuppressive activity. van den Broek LA, et al. **J Pharm Pharmacol** 1996 Feb;48(2):172-8
Novel alpha-glucosidase inhibitors identified using multiple cyclic peptide combinatorial libraries. Eichler J, et al. **Mol Divers** 1996 Aug;1(4):233-40
A review of the safety and efficacy of acarbose in diabetes mellitus. Yee HS, et al. **Pharmacotherapy** 1996 Sep-Oct; 16(5):792-805 (80 ref.)
New treatments for patients with type 2 diabetes mellitus. Wolffenbuttel BH, et al. **Postgrad Med J** 1996 Nov; 72(853):657-62 (44 ref.)
Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Khan KN, et al. **Toxicol Pathol** 1996 Sep-Oct;24(5):531-8
Castanospermine, an oligosaccharide processing inhibitor, reduces membrane expression of adhesion molecules and prolongs heart allograft survival in rats. Grochowicz PM, et al. **Transpl Immunol** 1996 Dec;4(4):275-85
[Degradation of Maillard reaction products by amylolytic enzymes. 3. Inhibition of glucoamylase, alpha-amylase and alpha-glucosidase by heat treated alpha-glucans and melanoidins] Schumacher D, et al. **Z Lebensm Unters Forsch** 1996 Oct;203(4):391-4 (Eng. Abstr.) **(Ger)**
[Occurrence of ileus after voglibose treatment in an elderly diabetic patient with gait disturbance caused by cerebral hemorrhage] Hayaishi R, et al. **Nippon Ronen Igakkai Zasshi** 1996 Aug;33(8):607-12 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Expression of a cDNA encoding the glucose trimming enzyme glucosidase II in CHO cells and molecular characterization of the enzyme deficiency in a mutant mouse lymphoma cell line. Flura T, et al. **Glycobiology** 1997 Jul;7(5):617-24

CHEMISTRY

Purification and characterization of the cell-wall-associated and extracellular alpha-glucosidases from Saccharomycopsis fibuligera. Reiser V, et al. **Biochem J** 1995 Jun 15;308 (Pt 3):753-60
Structure-function relationships in glucosidase I: amino acids involved in binding the substrate to the enzyme. Romaniouk A, et al. **Glycobiology** 1997 Apr;7(3):399-404
Identification of the CD45-associated 116-kDa and 80-kDa proteins as the alpha- and beta-subunits of alpha-glucosidase II. Arendt CW, et al. **J Biol Chem** 1997 May 16;272(20):13117-25
Endoplasmic reticulum glucosidase II is composed of a catalytic subunit, conserved from yeast to mammals, and a tightly bound noncatalytic HDEL-containing subunit. Trombetta ES, et al. **J Biol Chem** 1996 Nov 1; 271(44):27509-16
Crystal structure of a maltotetraose-forming exo-amylase from Pseudomonas stutzeri. Morishita Y, et al. **J Mol Biol** 1997 Apr 4;267(3):661-72

DEFICIENCY

Homozygous deletion of exon 18 leads to degradation of the lysosomal alpha-glucosidase precursor and to the infantile form of glycogen storage disease type II. Ausems MG, et al. **Clin Genet** 1996 Jun;49(6):325-8
Expression of a cDNA encoding the glucose trimming enzyme glucosidase II in CHO cells and molecular characterization of the enzyme deficiency in a mutant mouse lymphoma cell line. Flura T, et al. **Glycobiology** 1997 Jul;7(5):617-24

DRUG EFFECTS

Oral insulinlike growth factor-I stimulates intestinal enzyme maturation in newborn rats. Ma L, et al. **Life Sci** 1997; 61(1):51-8

GENETICS

Deletion analysis of promoter elements of the Aspergillus oryzae agdA gene encoding alpha-glucosidase. Minetoki T, et al. **Curr Genet** 1996 Nov;30(5):432-8
6-phospho-alpha-D-glucosidase from Fusobacterium mortiferum: cloning, expression, and assignment to family 4 of the glycosylhydrolases. Bouma CL, et al. **J Bacteriol** 1997 Jul;179(13):4129-37
Change in the expression of hypopharyngeal-gland proteins of the worker honeybees (Apis mellifera L.) with age and/or role. Kubo T, et al. **J Biochem (Tokyo)** 1996 Feb; 119(2):291-5
A mutation in a highly conserved region in brush-border sucrase-isomaltase and lysosomal alpha-glucosidase results in Golgi retention. Moolenaar CE, et al. **J Cell Sci** 1997 Mar;110 (Pt 5):557-67
Molecular cloning of a gene encoding acid alpha-glucosidase from Tetrahymena pyriformis. Alam MS, et al. **J Eukaryot Microbiol** 1996 Jul-Aug;43(4):295-303
A novel acid alpha-glucosidase mutation identified in a Pakistani family with glycogen storage disease type II. Kroos MA, et al. **J Inherit Metab Dis** 1997 Aug;20(4):556-8
Molecular cloning and characterization of a cDNA encoding alpha-glucosidase from spinach. Sugimoto M, et al. **Plant Mol Biol** 1997 Mar;33(4):765-8
Tandemly repeated 147 bp elements cause structural and functional variation in divergent MAL promoters of Saccharomyces cerevisiae. Bell PJ, et al. **Yeast** 1997 Sep 30;13(12):1135-44

METABOLISM

N1-alkyl-D-gluconamidines: are they 'perfect' mimics of the first transition state of glucosidase action? Legler G, et al. **Carbohydr Res** 1996 Oct 4;292:103-15
Synthesis of alpha-D-Glcp-(1-->2)-alpha-D-Glcp-(1-->3)-alpha-D-Glcp-O-(CH2)8 COOCH3 for use in the assay of alpha-glucosidase I activity [published erratum appears in Carbohydr Res 1997 Mar 5;298(3):243] Scaman CH, et al. **Carbohydr Res** 1996 Dec 24;296:203-13
Carbohydrate digestion in sandflies: alpha-glucosidase activity in the midgut of Phlebotomus langeroni. Dillon RJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Jan;116(1):35-40
Bacillus thermoamyloliquefaciens KP1071 alpha-glucosidase II is a thermostable M(r) 540,000 homohexameric alpha-glucosidase with both exo-alpha-1,4-glucosidase and oligo-1,6-glucosidase activities. Suzuki Y, et al. **Eur J Biochem** 1997 Apr 1;245(1):129-36
Endoplasmic reticulum retention mediated by the transmembrane domain of type II membrane proteins Sec12p and glucosidase 1. Tang BL, et al. **Eur J Cell Biol** 1997 Jun;73(2):98-104
Regulation of maltose utilization in Saccharomyces cerevisiae by genes of the RAS/protein kinase A pathway. Wanke V, et al. **FEBS Lett** 1997 Feb 3;402(2-3):251-5
Structure-function relationships in glucosidase I: amino acids involved in binding the substrate to the enzyme. Romaniouk A, et al. **Glycobiology** 1997 Apr;7(3):399-404
alpha-Glucosidase activity in the rat epididymis under different physiological conditions. Kalla NR, et al. **Int J Androl** 1997 Apr;20(2):92-5
Contribution of a neopullulanase, a pullulanase, and an alpha-glucosidase to growth of Bacteroides thetaiotaomicron on starch. D'Elia JN, et al. **J Bacteriol** 1996 Dec;178(24):7173-9
Altering substrate specificity of Bacillus sp. SAM1606 alpha-glucosidase by comparative site-specific mutagenesis. Inohara-Ochiai M, et al. **J Biol Chem** 1997 Jan 17;272(3):1601-7
Synthesis of a novel vitamin E derivative, 2-(alpha-D-glucopyranosyl) methyl-2,5,7,8-tetramethylchroman-6-ol, by alpha-glucosidase-catalyzed transglycosylation. Murase H, et al. **Lipids** 1997 Jan;32(1):73-8
Recombinant HIV envelope expressed in an alpha-glucosidase I-deficient CHO cell line and its parental cell line in the presence of 1-deoxynojirimycin is functional. Fenouillet E, et al. **Virology** 1997 Apr 28; 231(1):89-95
[Synthesis of beta-maltosides, derivatives of p-nitrophenol, 2-chloro-4-nitrophenol, and 4-methylumbelliferone, and their use as substrates for determining alpha-glucosidase activity] Voznyĭ IaV, et al. **Vopr Med Khim** 1996 Oct-Dec; 42(4):348-54 (Eng. Abstr.) **(Rus)**

URINE

alpha-Glucosidase and N-acetylglucosamine-6-sulphatase are the major mannose-6-phosphate glycoproteins in human urine. Sleat DE, et al. **Biochem J** 1997 May 15;324 (Pt 1):33-9
[Urinary enzymes in insulin-dependent diabetes mellitus] Platonova LV, et al. **Vopr Med Khim** 1996 Jan-Mar; 42(1):70-6 (Eng. Abstr.) **(Rus)**

ALPHA-HELICAL CONFORMATION, PROTEIN see **PROTEIN STRUCTURE, SECONDARY**

ALPHA-HEPARIN see **HEPARIN**

17 ALPHA-HYDROXYPROGESTERONE see **17-HYDROXYPROGESTERONE**

20 ALPHA-HYDROXYPROGESTERONE see **DIHYDROPROGESTERONE**

17 ALPHA-HYDROXYPROGESTERONE ALDOLASE

ANALYSIS

Characterization of the adrenal cytochrome P450C17 in the hamster, a small animal model for the study of adrenal dehydroepiandrosterone biosynthesis. Cloutier M, et al. **DNA Cell Biol** 1997 Mar;16(3):357-68
Developmentally regulated expression and activity of 17alpha-hydroxylase/C-17,20-lyase cytochrome P450 in rat liver. Vianello S, et al. **Endocrinology** 1997 Aug; 138(8):3166-74
Immunolocalization and biochemical determination of cytochrome P450C17 in adrenals of hamsters treated with ACTH. Brière N, et al. **J Histochem Cytochem** 1997 Oct; 45(10):1409-16
Kinetic analysis of duodenal and testicular cytochrome P450c17 in the rat. Dalla Valle L, et al. **J Steroid Biochem Mol Biol** 1996 Aug;58(5-6):577-84
Intraovarian immunolocalization of steroidogenic enzymes in a Hokkaido brown bear, Ursus arctos yesoensis during the mating season. Araki H, et al. **J Vet Med Sci** 1996 Aug;58(8):787-90

ANTAGONISTS & INHIBITORS

Inhibition of steroid C17(20) lyase with C-17-heteroaryl steroids. Burkhart JP, et al. **Bioorg Med Chem** 1996 Sep; 4(9):1411-20
20-amino and 20,21-aziridinyl pregnene steroids: development of potent inhibitors of 17 alpha-hydroxylase/C17,20-lyase (P450 17). Njar VC, et al. **Bioorg Med Chem** 1996 Sep;4(9):1447-53
Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Klus GT, et al. **Cancer Res** 1996 Nov 1;56(21):4956-64
Synthesis and evaluation of pregnane derivatives as inhibitors of human testicular 17 alpha-hydroxylase/C17,20-lyase. Li JS, et al. **J Med Chem** 1996 Oct 11;39(21):4335-9
Synthesis of novel 21-trifluoropregnane steroids: inhibitors of 17 alpha-hydroxylase/17,20-lyase (17 alpha-lyase). Njar VC, et al. **Steroids** 1997 Jun;62(6):468-73

BIOSYNTHESIS

Differential transcription of steroidogenic enzymes in the equine primary corpus luteum during diestrus and early pregnancy. Albrecht BA, et al. **Biol Reprod** 1997 Apr; 56(4):821-9
Expression of 17 alpha-hydroxylase and aromatase in the syndrome of androgen resistance: a case report. Doldi N, et al. **Gynecol Endocrinol** 1996 Aug;10(4):281-4
Repression of cAMP-induced expression of the mouse P450 17 alpha-hydroxylase/C17-20 lyase gene (Cyp17) by androgens. Burgos-Trinidad M, et al. **Mol Endocrinol** 1997 Jan;11(1):87-96

BLOOD

Lack of an ovarian function influence on the increased adrenal androgen secretion present in women with functional ovarian hyperandrogenism. Escobar-Morreale HF, et al. **Fertil Steril** 1997 Apr;67(4):654-62

CHEMISTRY

Homology modelling of the enzyme P450 17 alpha-hydroxylase/17,20-lyase--a target for prostate cancer chemotherapy--from the crystal structure of P450BM-3. Burke DF, et al. **Anticancer Drug Des** 1997 Mar;12(2):113-23
The regulation of 17,20 lyase activity. Miller WL, et al. **Steroids** 1997 Jan;62(1):133-42 (77 ref.)

DEFICIENCY

A new variant of the cytochrome P450c17 (CYP17) gene mutation in three patients with 17 alpha-hydroxylase deficiency. Monno S, et al. **Ann Hum Genet** 1997 May;61 (Pt 3):275-9
Ovarian hyperstimulation syndrome with low oestradiol in non-classical 17 alpha-hydroxylase, 17,20-lyase deficiency: what is the role of oestrogens? Meirow D, et al. **Hum Reprod** 1996 Oct;11(10):2119-21
A 5'-splice site mutation in the cytochrome P450 steroid 17alpha-hydroxylase gene in 17alpha-hydroxylase deficiency. Yamaguchi H, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1934-8
17 Alpha-hydroxylase deficiency. Biglieri EG. **J Endocrinol Invest** 1995 Jul-Aug;18(7):540-4 (13 ref.)
17 alpha-Hydroxylase deficiency; a rare cause of chronic hypertension. Spronk PE, et al. **Neth J Med** 1996 Nov; 49(5):205-8
The regulation of 17,20 lyase activity. Miller WL, et al. **Steroids** 1997 Jan;62(1):133-42 (77 ref.)

GENETICS

A new variant of the cytochrome P450c17 (CYP17) gene mutation in three patients with 17 alpha-hydroxylase deficiency. Monno S, et al. **Ann Hum Genet** 1997 May;61 (Pt 3):275-9
cAMP-dependent transactivation involving the

homeodomain protein Pbx1. Ogo A, et al. **Arch Biochem Biophys** 1997 Feb 15;338(2):193–200

Regulation by gonadotropins of the messenger ribonucleic acid for P450 side-chain cleavage, P450(17) alpha-hydroxylase/C17,20-lyase, and 3 beta-hydroxysteroid dehydrogenase in cultured pig Leydig cells. Clark AM, et al. **Biol Reprod** 1996 Aug;55(2):347–54

The 17 alpha-hydroxylase/17,20 lyase gene (CYP17) and polycystic ovary syndrome [comment] Franks S. **Clin Endocrinol (Oxf)** 1997 Feb;46(2):135–6. Comment on: Clin Endocrinol (Oxf) 1997 Feb;46(2):131–4.

Frequency of a polymorphism in the regulatory region of the 17 alpha-hydroxylase-17,20-lyase (CYP17) gene in hyperandrogenic states [see comments] Techatraisak K, et al. **Clin Endocrinol (Oxf)** 1997 Feb;46(2):131–4. Comment in: Clin Endocrinol (Oxf) 1997 Feb;46(2):135–6.

A polymorphism in intron 6 of the CYP17 gene. Crocitto LE, et al. **Clin Genet** 1997 Jul;52(1):68–9

A putative binding site for Sp1 is involved in transcriptional regulation of CYP17 gene expression in bovine ovary. Borroni R, et al. **Endocrinology** 1997 May;138(5):2011–20

Developmentally regulated expression and activity of 17alpha-hydroxylase/C-17,20-lyase cytochrome P450 in rat liver. Vianello S, et al. **Endocrinology** 1997 Aug; 138(8):3166–74

5' polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries [letter] Gharani N, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4174

Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17. Miura K, et al. **J Clin Endocrinol Metab** 1996 Oct; 81(10):3797–801 (36 ref.)

Transcription of the human genes for cytochrome P450scc and P450c17 is regulated differently in human adrenal NCI-H295 cells than in mouse adrenal Y1 cells. Rodriguez H, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):365–71

CYP17 gene analysis in hyperandrogenised women with and without exaggerated 17-hydroxyprogesterone response to ovarian stimulation. Liović M, et al. **J Endocrinol Invest** 1997 Apr;20(4):189–93

The orphan nuclear receptor steroidogenic factor-1 regulates the cyclic adenosine 3',5'-monophosphate-mediated transcriptional activation of rat cytochrome P450c17 (17 alpha-hydroxylase/c17-20 lyase). Zhang P, et al. **Mol Endocrinol** 1996 Feb;10(2):147–58

Regulation of androgen synthesis: the late steroidogenic pathway. Dufau ML, et al. **Steroids** 1997 Jan;62(1):128–32

Transcriptional regulation of the bovine CYP17 gene by cAMP. Lund J, et al. **Steroids** 1997 Jan;62(1):43–5

The testis and the adrenal are (transcriptionally) the same. Mellon SH, et al. **Steroids** 1997 Jan;62(1):46–52

METABOLISM

The function of recombinant cytochrome P450s in intact Escherichia coli cells: the 17 alpha-hydroxylation of progesterone and pregnenolone by P450c17. Shet MS, et al. **Arch Biochem Biophys** 1997 Mar 1;339(1):218–25

Hypersecretion of androgens by polycystic ovaries: the role of genetic factors in the regulation of cytochrome P450c17 alpha. Franks S, et al. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):193–203 (33 ref.)

Protein phosphorylation changes ligand-binding efficiency of cytochrome P450c17 (CYP17) and accelerates its proteolytic degradation: putative relevance for hormonal regulation of CYP17 activity. Löhr JB, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):403–8

Interaction of human CYP17 (P-450(17alpha), 17alpha-hydroxylase-17,20-lyase) with cytochrome b5: importance of the orientation of the hydrophobic domain of cytochrome b5. Lee-Robichaud P, et al. **Biochem J** 1997 Feb 1;321 (Pt 3):857–63

Modulation of the activity of human 17 alpha-hydroxylase-17,20-lyase (CYP17) by cytochrome b5: endocrinological and mechanistic implications. Lee-Robichaud P, et al. **Biochem J** 1995 Jun 15;308 (Pt 3):901–8

Temporal changes in inhibin, steroid hormones, and steroidogenic enzymes during induced follicular atresia in the hypophysectomized cyclic hamster. Otsuka M, et al. **Biol Reprod** 1997 Feb;56(2):423–9

Improvement of cytochrome P450c17 catalytic processivity as a novel mechanism to attenuate hormonal consequences of enzyme decay in the testes after a gonadotropin surge. Kühn-Velten WN. **Eur J Endocrinol** 1997 Apr; 136(4):438–43

Rapid down-regulation of testicular androgen biosynthesis at increased environmental temperature is due to cytochrome P450c17 (CYP17) thermolability in Leydig cells, but not in endoplasmic reticulum membranes. Kühn-Velten WN. **Exp Clin Endocrinol Diabetes** 1996; 104(3):243–9

Negatively charged anabaena flavodoxin residues (Asp144 and Glu145) are important for reconstitution of cytochrome P450 17alpha-hydroxylase activity. Jenkins CM, et al. **J Biol Chem** 1997 Sep 5;272(36):22509–13

Differential control of 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase expression in human adrenocortical H295R cells. Bird IM, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2171–8

Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. Moghetti P, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):881–6

Microbial transformations of steroids--X. Cytochromes P-450 11 alpha-hydroxylase and C17-C20 lyase and a 1-ene dehydrogenase transform steroids in Nectria haematococca. Ahmed F, et al. **J Steroid Biochem Mol Biol** 1996 Jun;58(3):337–49

Detection of aromatase cytochrome P450, 17 alpha-hydroxylase cytochrome P450 and NADPH:P450 reductase on the surface of cells in which they are expressed. Amarneh BA, et al. **Mol Cell Endocrinol** 1996 May 17;119(1):69–74

Regulation of androgen synthesis: the late steroidogenic pathway. Dufau ML, et al. **Steroids** 1997 Jan;62(1):128–32

Transcriptional regulation of the bovine CYP17 gene by cAMP. Lund J, et al. **Steroids** 1997 Jan;62(1):43–5

The testis and the adrenal are (transcriptionally) the same. Mellon SH, et al. **Steroids** 1997 Jan;62(1):46–52

The regulation of 17,20 lyase activity. Miller WL, et al. **Steroids** 1997 Jan;62(1):133–42 (77 ref.)

ALPHA IMMUNOGLOBULINS see **IMMUNOGLOBULINS, ALPHA-CHAIN**

ALPHA-INTERFERON see **INTERFERON-ALPHA**

ALPHA-KETOACID CARBOXYLASE see **PYRUVATE DECARBOXYLASE**

ALPHA-LINOLENIC ACID

[3-13C] gamma-linolenic acid: a new probe for 13C nuclear magnetic resonance studies of arachidonic acid synthesis in the suckling rat. Cunnane SC, et al. **Lipids** 1997 Feb; 32(2):211–7

ADMINISTRATION & DOSAGE

Linoleic and alpha-linolenic acids differently modify the effects of elaidic acid on polyunsaturated fatty acid metabolism and some immune indices in rats. Koga T, et al. **Br J Nutr** 1997 Apr;77(4):645–56

The relationships between dietary alpha-linolenic:linoleic acid and rat platelet eicosapentaenoic and arachidonic acids. Leece EA, et al. **Br J Nutr** 1996 Sep;76(3):447–52

Intake and sources of alpha-linolenic acid in Dutch elderly men. Voskuil DW, et al. **Eur J Clin Nutr** 1996 Dec; 50(12):784–7

Effects of dietary supplementation with alpha-linolenic acid on the phospholipid fatty acid composition and quality of spermatozoa in cockerel from 24 to 72 weeks of age. Kelso KA, et al. **J Reprod Fertil** 1997 May;110(1):53–9

Dietary linolenic acid-mediated increase in vascular prostacyclin formation. Rupp H, et al. **Mol Cell Biochem** 1996 Sep 6;162(1):59–64

Is docosahexaenoic acid necessary in infant formula? Evaluation of high linolenate diets in the neonatal rat. Woods J, et al. **Pediatr Res** 1996 Nov;40(5):687–94

ANALYSIS

Capillary supercritical fluid chromatography—atmospheric pressure chemical ionization mass spectrometry of gamma- and alpha-linolenic acid containing triacylglycerols in berry oils. Manninen P, et al. **Lipids** 1997 Aug;32(8):825–31

CHEMISTRY

2-Hydroxy-succinaldehyde, a lipid peroxidation product proving that polyunsaturated fatty acids are able to react with three molecules of oxygen. Mlakar A, et al. **Free Radic Res** 1997 Jan;26(1):57–62

DEFICIENCY

The Canadian Society for Nutritional Sciences 1995 Young Scientist Award Lecture. Recent studies on the synthesis, beta-oxidation, and deficiency of linoleate and alpha-linolenate: are essential fatty acids more aptly named indispensable or conditionally dispensable fatty acids? Cunnane SC. **Can J Physiol Pharmacol** 1996 Jun; 74(6):629–39 (78 ref.)

Synaptic vesicle ultrastructural changes in the rat hippocampus induced by a combination of alpha-linolenate deficiency and a learning task. Yoshida S, et al. **J Neurochem** 1997 Mar;68(3):1261–8

METABOLISM

Does an increase in dietary linoleic acid modify tissue concentrations of cervonic acid and consequently alter alpha-linolenic requirements? Minimal requirement of linoleic acid in adult rats. Bourre JM, et al. **Biochem Mol Biol Int** 1996 Jun;39(3):607–19

Mechanisms and kinetics of alpha-linolenic acid uptake in Caco-2 clone TC7. Tranchant T, et al. **Biochim Biophys Acta** 1997 Apr 1;1345(2):151–61

Identification of radical adducts formed in the reactions of unsaturated fatty acids with soybean lipoxygenase using continuous flow fast atom bombardment with tandem mass spectrometry. Iwahashi H, et al. **Free Radic Res** 1996 Sep; 25(3):255–74

Correlation of suppressed linoleic acid metabolism with the hypocholesterolemic action of eritadenine in rats. Sugiyama K, et al. **Lipids** 1997 Aug;32(8):859–66

The very low birth weight premature infant is capable of synthesizing arachidonic and docosahexaenoic acids from linoleic and linolenic acids. Carnielli VP, et al. **Pediatr Res** 1996 Jul;40(1):169–74

Age-related changes in essential fatty acid metabolism in cultured rat heart myocytes. Lorenzini A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Aug; 57(2):143–7

Cytotoxicity of food preservatives in cultured rat hepatocytes loaded with linolenic acid. Sugihara N, et al. **Toxicology** 1997 Jun 6;120(1):29–36

PHARMACOLOGY

Alpha-linolenic acid and marine long-chain n-3 fatty acids differ only slightly in their effects on hemostatic factors in healthy subjects. Freese R, et al. **Am J Clin Nutr** 1997 Sep;66(3):591–8

The effect of alpha-linolenic acid-rich emulsion on fatty acid metabolism and leukotriene generation of the colon in a rat model with inflammatory bowel disease. Inui K, et al. **Ann Nutr Metab** 1996;40(3):175–82

The nutritional effect of a-linolenic acid-rich emulsion with total parenteral nutrition in a rat model with inflammatory bowel disease. Inui K, et al. **Ann Nutr Metab** 1996; 40(4):227–33

Activity of hepatic fatty acid oxidation enzymes in rats fed alpha-linolenic acid. Kabir Y, et al. **Biochim Biophys Acta** 1996 Nov 22;1304(2):105–19

Reevaluation of the effect of a high alpha-linolenate and a high linoleate diet on antigen-induced antibody and anaphylactic responses in mice. Oh-hashi K, et al. **Biol Pharm Bull** 1997 Mar;20(3):217–23

A high linoleate and a high alpha-linolenate diet induced changes in learning behavior of rats. Effects of a shift in diets and reversal of training stimuli. Okaniwa Y, et al. **Biol Pharm Bull** 1996 Apr;19(4):536–40

Short-term depression and long-term enhancement of ACh-gated channel currents induced by linoleic and linolenic acid. Nishizaki T, et al. **Brain Res** 1997 Mar 21; 751(2):253–8

Synergistic suppression of azoxymethane-induced foci of colonic aberrant crypts by the combination of beta-carotene and perilla oil in rats. Komaki C, et al. **Carcinogenesis** 1996 Sep;17(9):1897–901

Effector molecules of the host defence mechanism against Mycobacterium avium complex: the evidence showing that reactive oxygen intermediates, reactive nitrogen intermediates, and free fatty acids each alone are not decisive in expression of macrophage antimicrobial activity against the parasites. Tomioka H, et al. **Clin Exp Immunol** 1997 Aug;109(2):248–54

O/w-emulsion of alpha-linolenic acid stabilized with hydrophobized polysaccharide. Its effect on the growth of human colon cancer cells. Fukui H, et al. **J Biomater Sci Polym Ed** 1996;7(10):829–38

Stimulation of the activities of hepatic fatty acid oxidation enzymes by dietary fat rich in alpha-linolenic acid in rats. Ide T, et al. **J Lipid Res** 1996 Mar;37(3):448–63

Perilla oil prevents the excessive growth of visceral adipose tissue in rats by down-regulating adipocyte differentiation. Okuno M, et al. **J Nutr** 1997 Sep;127(9):1752–7

Effect of dietary linoleic/alpha-linolenic acid ratio on growth and visual function of term infants [see comments] Jensen CL, et al. **J Pediatr** 1997 Aug;131(2):200–9. Comment in: J Pediatr 1997 Aug;131(2):173–5.

Comparative hypocholesterolemic effects of capybara (Hydrochoerus hydrochaeris dabbenei) oil, horse oil, and sardine oil in cholesterol-fed rats. Fukushima M, et al. **Lipids** 1997 Apr;32(4):391–5

Effect of dietary linoleic to linolenic acid ratio and vitamin E supplementation on vitamin E status of poults. Applegate TJ, et al. **Poult Sci** 1996 Jul;75(7):881–90

Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids. Do TQ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7534–9

Antithromboxane activity of dietary alpha-linolenic acid: a pilot study. Ferretti A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Jun; 54(6):451–5

Cytotoxic action of alpha-linolenic and eicosapentaenoic acids on myeloma cells in vitro. Sravan Kumar G, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Apr; 56(4):285–93

RADIATION EFFECTS

The effect of microwave heating on vitamins B1 and E, and linoleic and linolenic acids, and immunoglobulins in human milk. Ovesen L, et al. **Int J Food Sci Nutr** 1996 Sep; 47(5):427–36

THERAPEUTIC USE

Prophylactic treatment of migraine with gamma-linolenic and alpha-linolenic acids. Wagner W, et al. **Cephalalgia** 1997 Apr;17(2):127–30; discussion 102

Essential fatty acids: the effects of dietary supplementation among children with recurrent respiratory infections. Venuta A, et al. **J Int Med Res** 1996 Jul-Aug;24(4):325–30

Functional effects of increasing omega-3 fatty acid intake [editorial; comment] Carlson SE. **J Pediatr** 1997 Aug; 131(2):173-5. Comment on: J Pediatr 1997 Aug;131(2):200-9.

ALPHA-LIPOPROTEIN DEFICIENCY, FAMILIAL see **TANGIER DISEASE**

ALPHA-LIPOPROTEINS see **LIPOPROTEINS, HDL**

ALPHA-MACROFETOPROTEINS see **ALPHA-MACROGLOBULINS**

ALPHA-MACROGLOBULINS

Natural anti-proteases in rainbow trout, Oncorhynchus mykiss and brook charr, Salvelinus fontinalis and the in vitro neutralization of fish alpha 2-macroglobulin by the metalloprotease from the pathogenic haemoflagellate, Cryptobia salmositica. Zuo X, et al. **Parasitology** 1997 Apr; 114 (Pt 4):375-81

ANALYSIS

Plasma levels of prekallikrein, alpha-2-macroglobulin and C1-esterase inhibitor in patients with urticarial reaction to contrast media. Mikkonen R, et al. **Acta Radiol** 1997 May; 38(3):466-73

Plasma concentration of total and transformed alpha 2-macroglobulin in systemic sclerosis. Birkenmeier G, et al. **Arch Dermatol Res** 1996 Jun;288(7):405-7

Salivary levels of alpha 2-macroglobulin, alpha 1-antitrypsin, C-reactive protein, cathepsin G and elastase in humans with or without destructive periodontal disease. Pederson ED, et al. **Arch Oral Biol** 1995 Dec;40(12):1151-5

Identification and partial characterization of alpha 2-macroglobulin from the tuatara (Sphenodon punctatus). Brown MA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Apr; 113(4):731-6

Optimal conditions for collection of blood samples for assay of alpha 2-macroglobulin-trypsin complex-like substance (MTLS). Kato M, et al. **J Clin Lab Anal** 1996;10(5):239-42

Acute Chagas' disease: plasma levels of alpha-2-macroglobulin and C-reactive protein in children under 13 years in a high endemic area of Bolivia. Medrano NM, et al. **J Trop Pediatr** 1996 Apr;42(2):68-74

Evidence for tissue-associated alpha(2) macroglobulin in mouse skeletal muscle. Fumagalli L, et al. **Mol Chem Neuropathol** 1996 Apr;27(3):211-23

Glomerular deposition of alpha 2-macroglobulin in glomerular diseases. Yang AH, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):465-9

Plasminogen: an important hemostatic parameter in septic patients. Duboscq C, et al. **Thromb Haemost** 1997 Jun; 77(6):1090-5

[Expression of proteinase inhibitors in the human trabecular meshwork] Fukuchi T, et al. **Nippon Ganka Gakkai Zasshi** 1997 Mar;101(3):265-71 (Eng. Abstr.) **(Jpn)**

[Apolipoprotein E epsilon 4 allel frequencies, plasma alpha 2-macroglobulin and plasminogen activator inhibitor 1 levels in residents of a rural area in Gunma prefecture] Muramatsu S, et al. **Nippon Ronen Igakkai Zasshi** 1997 Mar; 34(3):196-201 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Comparison of Limulus alpha-macroglobulin with human alpha2-macroglobulin: thiol ester characterization, subunit organization, and conformational change. Bowen ME, et al. **Arch Biochem Biophys** 1997 Jan 15;337(2):191-201

The conformational state of human alpha 2-macroglobulin influences its dissociation into half-molecules by sodium thiocyanate. Shanbhag VP, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):35-41

Structural and functional analysis of the spontaneous re-formation of the thiol ester bond in human alpha 2-macroglobulin, rat alpha 1-inhibitor-3 and chemically modified derivatives. Grøn H, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):539-45

Identification of residues in alpha-macroglobulins involved in activation of the alpha 2-macroglobulin signaling receptor. Howard GC, et al. **Biochim Biophys Acta** 1996 Oct 17;1297(2):111-4

The contact zones in human alpha2-macroglobulin--functional domains important for the regulation of the trapping mechanism. Shanbhag VP, et al. **Eur J Biochem** 1997 Mar 15;244(3):694-9

The novel three-dimensional structure of native human alpha 2-macroglobulin and comparisons with the structure of the methylamine derivative. Kolodziej SJ, et al. **J Struct Biol** 1996 May-Jun;116(3):366-76

Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets. Hevessy Z, et al. **Thromb Haemost** 1996 Jan;75(1):161-7

DEFICIENCY

The influence of 6-AHA on the fibrin clot degradation initiated by streptokinase in normal and alpha 2-antiplasmin-deficient plasma. Andrianov SL, et al. **Ukr Biokhim Zh** 1996 Jul-Aug;68(4):26-7

[Studies on alpha 2 macroglobulin deficiency in association with cancer metastasis] Kanoh Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Feb;20(1):30-43 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

The conformational state of human alpha 2-macroglobulin influences its dissociation into half-molecules by sodium thiocyanate. Shanbhag VP, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):35-41

Effects of two weeks of topical budesonide treatment on microvascular exudative responsiveness in healthy human nasal airways. Greiff L, et al. **Eur Respir J** 1997 Apr; 10(4):841-5

GENETICS

Inhibition of intracellular proteolytic processing of soluble proproteins by an engineered alpha 2-macroglobulin containing a furin recognition sequence in the bait region. Van Rompaey L, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):507-14

Prolactin-induced activation and binding of stat proteins to the IL-6RE of the alpha 2-macroglobulin (alpha 2M) promoter: relation to the expression of alpha 2M in the rat ovary. Russell DL, et al. **Biol Reprod** 1996 Nov; 55(5):1029-38

Molecular cloning of Limulus alpha 2-macroglobulin. Iwaki D, et al. **Eur J Biochem** 1996 Dec 15;242(3):822-31

Cloning and sequencing of cDNAs encoding plasma alpha-macroglobulin and murinoglobulin from guinea pig: implications for molecular evolution of alpha-macroglobulin family. Iwasaki H, et al. **J Biochem (Tokyo)** 1996 Dec;120(6):1167-75

Prolactin induction of the alpha 2-Macroglobulin gene in rat ovarian granulosa cells: stat 5 activation and binding to the interleukin-6 response element. Dajee M, et al. **Mol Endocrinol** 1996 Feb;10(2):171-84

IMMUNOLOGY

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA. Nilsson O, et al. **Br J Cancer** 1997;75(6):789-97

Functional characterization of monoclonal antibody inhibitors of alpha 2-antiplasmin that accelerate fibrinolysis in different animal plasmas. Reed GL. **Hybridoma** 1997 Jun; 16(3):281-6

Actin filaments facilitate two steps of endocytosis. Durrbach A, et al. **J Cell Sci** 1996 Feb;109 (Pt 2):457-65

Immune function of alpha 2-macroglobulin in invertebrates. Armstrong PB, et al. **Prog Mol Subcell Biol** 1996;15:101-30 (193 ref.)

[Cytotoxic activity of complexes formed during an interaction between tumor necrosis factor-alpha and alpha2-macroglobulin] Bondarev IE, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):673-5 **(Rus)**

ISOLATION & PURIFICATION

A procedure for human pregnancy zone protein (and human alpha 2-macroglobulin) purification using hydrophobic interaction chromatography on phenyl-sepharose CL-4B column. Chiabrando G, et al. **Protein Expr Purif** 1997 Apr; 9(3):399-406

METABOLISM

Characterization of alpha 2-macroglobulin binding to human trabecular meshwork cells: presence of the alpha 2-macroglobulin signaling receptor. Howard GC, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):19-26

Modification of the erythrocyte surface in rats bearing Yoshida ascites sarcoma is brought about by a tumour variant of alpha2-macroglobulin. Sanjay A, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):379-84

Proteinases are isoform-specific regulators of the binding of transforming growth factor beta to alpha 2-macroglobulin. Webb DJ, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):551-5

Nickel is a specific antagonist for the catabolism of activated alpha 2-macroglobulin. Kancha RK, et al. **Biochim Biophys Acta** 1997 Mar 1;1355(3):231-40

Characterization of alpha 2-macroglobulin receptor low density lipoprotein receptor-related protein (alpha 2 MR/LRP) in White Carneau pigeon peritoneal macrophages: its role in lipoprotein metabolism. Seo T, et al. **Biochim Biophys Acta** 1997 Jan 21;1344(2):171-88

Clearance of the alpha 2 macroglobulin-trypsin complex and uptake of trypsin by perfused liver. Nagaoka MR, et al. **Braz J Med Biol Res** 1996 Jun;29(6):797-803

Binding of monofluorophosphate to alpha2-macroglobulin and C3. Rigalli A, et al. **Calcif Tissue Int** 1997 Jan; 60(1):86-9

Prostate-specific antigen concentrations in serum in acute illnesses. Honda SA, et al. **Clin Chem** 1996 Nov; 42(11):1785-8

Topical azelastine has a 12-hour duration of action as assessed by histamine challenge-induced exudation of alpha 2-macroglobulin into human nasal airways. Greiff L, et al. **Clin Exp Allergy** 1997 Apr;27(4):438-44

Interactions between ovine cathepsin L, cystatin C and alpha 2-macroglobulin. Potential role in the genital tract. Peloille S, et al. **Eur J Biochem** 1997 Feb 15;244(1):140-6

Coagulation and fibrinolysis activation markers in prostatic carcinoma patients. Geenen RW, et al. **Eur J Clin Chem Clin Biochem** 1997 Feb;35(2):69-72

The concentration of high molecular weight compounds in interstitial tissue fluid: a study in patients with post-reconstructive leg oedema. Haaverstad R, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):355-60

Free/total prostate-specific antigen ratio--hope and controversies. Ravery V, et al. **Eur Urol** 1997;31(4):385-8 (19 ref.)

Localisation of the major reactive lysine residue involved in the self-crosslinking of proteinase-activated Limulus alpha 2-macroglobulin. Dolmer K, et al. **FEBS Lett** 1996 Sep 9;393(1):37-40

Receptor-mediated endocytosis of alpha 2macroglobulin-protease complexes by fibroblasts in culture. Competitive inhibition by bacitracin. Van Leuven F, et al. **FEBS Lett** 1981 Nov 2;134(1):83-7

Chemical modification of alpha2-macroglobulin to generate derivatives that bind transforming growth factor-beta with increased affinity. Webb DJ, et al. **FEBS Lett** 1997 Jun 30;410(2-3):249-53

Alpha 2-macroglobulin: a binding protein for transforming growth factor-beta and various cytokines. Feige JJ, et al. **Horm Res** 1996;45(3-5):227-32 (36 ref.)

Follistatins and alpha 2-macroglobulin are soluble binding proteins for inhibin and activin. Mather JP. **Horm Res** 1996; 45(3-5):207-10 (29 ref.)

Insulin-like growth factor-I and alpha 2-macroglobulin in seminal plasma correlate with semen quality. Glander HJ, et al. **Hum Reprod** 1996 Nov;11(11):2454-60

Association of respiratory symptoms with serum protease inhibitors and albumin levels in Japanese children. Shima M, et al. **Int J Epidemiol** 1996 Dec;25(6):1213-9

Up-regulation of the alpha2-macroglobulin signaling receptor on rheumatoid synovial fibroblasts. Misra UK, et al. **J Biol Chem** 1997 Jan 3;272(1):497-502

Segments in the C-terminal folding domain of lipoprotein lipase important for binding to the low density lipoprotein receptor-related protein and to heparan sulfate proteoglycans. Nielsen MS, et al. **J Biol Chem** 1997 Feb 28;272(9):5821-7

Murine alpha-macroglobulins demonstrate divergent activities as neutralizers of transforming growth factor-beta and as inducers of nitric oxide synthesis. A possible mechanism for the endotoxin insensitivity of the alpha2-macroglobulin gene knock-out mouse. Webb DJ, et al. **J Biol Chem** 1996 Oct 4;271(40):24982-8

The binding of receptor-recognized alpha2-macroglobulin to the low density lipoprotein receptor-related protein and the alpha2M signaling receptor is decoupled by oxidation. Wu SM, et al. **J Biol Chem** 1997 Aug 15;272(33):20627-35

Ligand interaction of human alpha 2-macroglobulin-alpha 2-macroglobulin receptor studied by partitioning in aqueous two-phase systems. Birkenmeier G, et al. **J Chromatogr B Biomed Appl** 1996 May 17;680(1-2):97-103

Plasma alpha 2-macroglobulin-trypsin complexlike substance (MTLS) in pancreatic disease. Kato M, et al. **J Clin Lab Anal** 1996;10(6):399-402

Transforming growth factor-beta-induced collagen synthesis by human liver myofibroblasts is inhibited by alpha2-macroglobulin. Tiggelman AM, et al. **J Hepatol** 1997 Jun;26(6):1220-8

Studies on the interaction of IL-8 with human plasma alpha 2-macroglobulin: evidence for the presence of IL-8 complexed to alpha 2-macroglobulin in lung fluids of patients with adult respiratory distress syndrome. Kurdowska A, et al. **J Immunol** 1997 Feb 15;158(4):1930-40

alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein. Du Y, et al. **J Neurochem** 1997 Jul; 69(1):299-305

The potential role of alpha 2-macroglobulin in the control of cysteine proteinases (gingipains) from Porphyromonas gingivalis. Grøn H, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 1):61-8

Addition of purified prostate specific antigen to serum from female subjects: studies on the relative inhibition by alpha 2-macroglobulin and alpha 1-antichymotrypsin. Chen Z, et al. **J Urol** 1996 Oct;156(4):1357-63

Shot-gun phage display mapping of two streptococcal cell-surface proteins. Jacobsson K, et al. **Microbiol Res** 1997 Jul;152(2):121-8

Major secretory product of the mesometrial decidua in the rat, a variant of alpha-2-macroglobulin, binds insulin-like growth factor I via a protease-dependent mechanism. da Silva GC, et al. **Mol Reprod Dev** 1996 May;44(1):103-10

Immunocytochemical demonstration of alpha 2-M-R/LRP on Müller (glial) cells isolated from rabbit and human retina. Birkenmeier G, et al. **Neuroreport** 1996 Dec 20; 8(1):149-51

Gene transfer mediated by alpha2-macroglobulin. Schneider H, et al. **Nucleic Acids Res** 1996 Oct 1;24(19):3873-4

Alpha-2-macroglobulin binds to the surface of Trypanosoma cruzi. Coutinho CM, et al. **Parasitol Res** 1997;83(2):144-50

Serum alpha 2-macroglobulin levels in psoriatic patients treated with UVB and PUVA. Gasior-Chrzan B, et al. **Riv Eur Sci Med Farmacol** 1996 May-Jun;18(3):125-8

The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats. van der Kaaden ME, et al. **Thromb Haemost** 1997 Apr;77(4):710-7

Experimental haemorrhage and blood component transfusion in humans: no change in plasma concentration of

thrombin–antithrombin complex and plasmin–antiplasmin complex. Henriksson AE, et al. **Thromb Res** 1996 Jun 1; 82(5):409–15

Methyl tert–butyl ether causes alpha2u–globulin nephropathy and enhanced renal cell proliferation in male Fischer–344 rats. Prescott–Mathews JS, et al.
Toxicol Appl Pharmacol 1997 Apr;143(2):301–14

Further characterization of alpha 2–macroglobulin binding properties of Actinomyces pyogenes. Ding H, et al.
Zentralbl Veterinarmed [B] 1997 May;44(3):129–32

[Proteinase inhibitors as markers of stomach cancer] Beliaev MV, et al. **Vopr Onkol** 1996;42(4):30–1 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Effects of fibrin and alpha2–antiplasmin on plasminogen activation by staphylokinase. Okada K, et al.
Am J Hematol 1996 Nov;53(3):151–7

Alpha 2–macroglobulin protects some of the protein constituents of dialysis–associated amyloidosis from protease degradation. Gouin–Charnet A, et al.
Biochem Biophys Res Commun 1997 Feb 3;231(1):48–51

Structural and functional analysis of the spontaneous re–formation of the thiol ester bond in human alpha 2–macroglobulin, rat alpha 1–inhibitor–3 and chemically modified derivatives. Grøn H, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):539–45

Inhibition of intracellular proteolytic processing of soluble proproteins by an engineered alpha 2–macroglobulin containing a furin recognition sequence in the bait region. Van Rompaey L, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):507–14

Protection by alpha2–macroglobulin of tissue plasminogen activator against inhibition by plasminogen activator inhibitor–1. Ieko M, et al. **Br J Haematol** 1997 Apr; 97(1):214–8

Neurite–promoting effect of alpha 2–macroglobulin in rat cerebral cortex is mainly associated with alpha 2–macroglobulin receptor. Ishii M, et al. **Brain Res** 1996 Oct 21;737(1–2):269–74

alpha 2–macroglobulin stimulation of protein tyrosine phosphorylation in macrophages via the mannose receptor for Fc gamma receptor–mediated phagocytosis activation. Murai M, et al. **Immunology** 1996 Nov;89(3):436–41

Plasminogen modulation of IL–1–stimulated degradation in bovine and human articular cartilage explants. The role of the endogenous inhibitors: PAI–1, alpha 2–antiplasmin, alpha 1–PI, alpha 2–macroglobulin and TIMP. Oleksyszyn J, et al. **Inflamm Res** 1996 Sep;45(9):464–72

Transforming growth factor–beta–induced collagen synthesis by human liver myofibroblasts is inhibited by alpha2–macroglobulin. Tiggelman AM, et al. **J Hepatol** 1997 Jun;26(6):1220–8

Alteration of dopamine release by rat caudate putamen tissues superfused with alpha 2–macroglobulin. Hu YQ, et al.
J Neurosci Res 1996 Jan 1;43(1):71–7

Alpha 2–macroglobulin of rabbits inhibits the habutobin activity. Oka U, et al. **Toxicon** 1996 Aug;34(8):903–12

PHYSIOLOGY

Transformed alpha 2–macroglobulin as a low–affinity growth hormone–binding protein. Kratzsch J, et al.
Acta Paediatr Suppl 1996 Oct;417:108–10

The role of alpha 2–antiplasmin in the inhibition of clot lysis in newborns and adults. Ries M, et al. **Biol Neonate** 1996; 69(5):298–306

Immune function of alpha 2–macroglobulin in invertebrates. Armstrong PB, et al. **Prog Mol Subcell Biol** 1996;15:101–30 (193 ref.)

ULTRASTRUCTURE

Similar architectures of native and transformed human alpha2–macroglobulin suggest the transformation mechanism. Boisset N, et al. **J Biol Chem** 1996 Oct 18; 271(42):25762–9

ALPHA–METHYLDOPA see **METHYLDOPA**

ALPHA–MSH

ADMINISTRATION & DOSAGE

Behavioral effects of alpha–MSH and MCH after central administration in the female rat. Gonzalez MI, et al.
Peptides 1996;17(1):171–7

ANALOGS & DERIVATIVES

Enhanced binding and inertness to dehalogenation of alpha–melanotropic peptides labeled using N–succinimidyl 3–iodobenzoate. Garg PK, et al. **Bioconjug Chem** 1996 Mar–Apr;7(2):233–9

Skin pigmentation and pharmacokinetics of melanotan–I in humans. Ugwu SO, et al. **Biopharm Drug Dispos** 1997 Apr; 18(3):259–69

Different cardiovascular profiles of three melanocortins in conscious rats; evidence for antagonism between gamma 2–MSH and ACTH–(1–24). Van Bergen P, et al.
Br J Pharmacol 1997 Apr;120(8):1561–7

Binding and internalization of the melanocyte stimulating hormone receptor ligand [Nle4, D–Phe7] alpha–MSH in B16 melanoma cells. Wong W, et al.
Int J Biochem Cell Biol 1996 Nov;28(11):1223–32

Molecular basis for the interaction of [Nle4,D–Phe7]melanocyte stimulating hormone with the human melanocortin–1 receptor. Yang Yk, et al.
J Biol Chem 1997 Sep 12;272(37):23000–10

Determination of melanotan II in rabbit urine using solid–phase extraction sample preparation followed by reversed–phase high–performance liquid chromatography. Walters AE, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):99–103

Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. Haskell–Luevano C, et al. **J Med Chem** 1997 Jul 4; 40(14):2133–9

Controlled–release delivery system for the alpha–MSH analog melanotan–I using poloxamer 407. Bhardwaj R, et al. **J Pharm Sci** 1996 Sep;85(9):915–9

Systemic delivery of melanotan II through the ocular route in rabbits [letter] Pinsuwan S, et al. **J Pharm Sci** 1997 Mar; 86(3):396–7

Melanocortin probes for the melanoma MC1 receptor: synthesis, receptor binding and biological activity. Erskine–Grout ME, et al. **Melanoma Res** 1996 Apr; 6(2):89–94

Fluorine–18–labeled [Nle4,D–Phe7]–alpha–MSH, an alpha–melanocyte stimulating hormone analogue. Vaidyanathan G, et al. **Nucl Med Biol** 1997 Feb;24(2):171–8

Truncation studies of alpha–melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity. Haskell–Luevano C, et al. **Peptides** 1996; 17(6):995–1002

POMC–related products in the intermediate pituitary of the amphibian, Bufo marinus: differential subcellular processing in the Golgi and secretory granules. Steveson TC, et al.
Peptides 1996;17(3):425–34

The administration of an alpha–MSH analogue reduces the serum release of IL–1 alpha and TNF alpha induced by the injection of a sublethal dose of lipopolysaccharides in the BALB/c mouse. Gonindard C, et al.
Pigment Cell Res 1996 Jun;9(3):148–53

Human epidermal melanocyte and keratinocyte melanocortin receptors: visualization by melanotropic peptide conjugated microspheres (latex beads). Jiang J, et al.
Pigment Cell Res 1996 Oct;9(5):240–7

ANALYSIS

NF–kappa B transcription factor subunits in rat brain: colocalization of p65 and alpha–MSH. Joseph SA, et al.
Peptides 1996;17(4):655–64

ANTAGONISTS & INHIBITORS

Comparative biological activities of alpha–MSH antagonists in vertebrate pigment cells. Castrucci AM, et al.
Gen Comp Endocrinol 1997 Mar;105(3):410–6

Agouti signaling protein inhibits melanogenesis and the response of human melanocytes to alpha–melanotropin. Suzuki I, et al. **J Invest Dermatol** 1997 Jun;108(6):838–42

Melanin–concentrating hormone (MCH) antagonizes the effects of alpha–MSH and neuropeptide E–I on grooming and locomotor activities in the rat. Sanchez M, et al.
Peptides 1997;18(3):393–6

BIOSYNTHESIS

Differential action of secreto–inhibitors on proopiomelanocortin biosynthesis in the intermediate pituitary of Xenopus laevis. Dotman CH, et al.
Endocrinology 1996 Nov;137(11):4551–7

BLOOD

The neuropeptide alpha–MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Catania A, et al. **Peptides** 1996;17(4):675–9

CHEMICAL SYNTHESIS

Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. Haskell–Luevano C, et al. **J Med Chem** 1997 Jul 4; 40(14):2133–9

CHEMISTRY

Synthesis and characterization of rhenium–complexed alpha–melanotropin analogs. Giblin MF, et al.
Bioconjug Chem 1997 May–Jun;8(3):347–53

Molecular modelling of beta turns in a cyclic melanotropin. Chan NC, et al. **J Pharm Pharmacol** 1996 Feb;48(2):218–22

METABOLISM

Phenotypic characterization and functional correlation of alpha–MSH binding to pituitary cells. Zheng T, et al.
Am J Physiol 1997 Feb;272(2 Pt 1):E282–7

Salt–loading induces decreased POMC mRNA levels, increased alpha–MSH immunoreactivity, and sustained elevated fos expression in rat pituitary intermediate lobe melanotropes. Sharma P, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:295–9

ART (protein product of agouti–related transcript) as an antagonist of MC–3 and MC–4 receptors. Fong TM, et al. **Biochem Biophys Res Commun** 1997 Aug 28; 237(3):629–31

Glutamine235 and arginine272 in human melanocortin 5 receptor determines its low affinity to MSH. Frändberg PA, et al. **Biochem Biophys Res Commun** 1997 Jul 18; 236(2):489–92

Enhanced binding and inertness to dehalogenation of alpha–melanotropic peptides labeled using N–succinimidyl 3–iodobenzoate. Garg PK, et al. **Bioconjug Chem** 1996 Mar–Apr;7(2):233–9

Alterations in brain and plasma concentrations of alpha–melanocyte–stimulating hormone during habituation of prey–catching behavior in toads. Kim Y, et al.
Brain Behav Evol 1997;49(3):149–61

Immunoreactive alpha–melanotropin as an autocrine effector in human melanoma cells. Loir B, et al. **Eur J Biochem** 1997 Mar 15;244(3):923–30

Corticotropin–releasing hormone administration increases alpha–melanocyte–stimulating hormone levels in the inferior petrosal sinuses in a subset of patients with Cushing's disease. Colao A, et al. **Horm Res** 1996 Jul; 46(1):26–32

Evidence for the differential expression of the functional alpha–melanocyte–stimulating hormone receptor MC–1 on human monocytes. Bhardwaj R, et al. **J Immunol** 1997 Apr 1;158(7):3378–84

Receptor binding affinities and biological activities of linear and cyclic melanocortins in B16 murine melanoma cells expressing the native MC1 receptor. Sahm UG, et al.
J Pharm Pharmacol 1996 Feb;48(2):197–200

alpha–MSH receptor autoradiography on mouse and human melanoma tissue sections and biopsies. Bagutti C, et al.
J Recept Signal Transduct Res 1995 Jan–Mar; 15(1–4):427–42

Interactions of alpha–melanotropin and agouti on B16 melanoma cells: evidence for inverse agonism of agouti. Siegrist W, et al. **J Recept Signal Transduct Res** 1997 Jan–May;17(1–3):75–98

Melanocortin probes for the melanoma MC1 receptor: synthesis, receptor binding and biological activity. Erskine–Grout ME, et al. **Melanoma Res** 1996 Apr; 6(2):89–94

Endotoxin causes release of alpha–melanocyte–stimulating hormone in normal human subjects. Catania A, et al.
Neuroimmunomodulation 1995 Sep–Oct;2(5):258–62

Disulfiram causes sustained behavioral and biochemical effects in rats. Rahman MA, et al.
Pharmacol Biochem Behav 1997 Mar;56(3):409–15

Obesity sheds its secrets [news] Gura T. **Science** 1997 Feb 7;275(5301):751–3

PHARMACOLOGY

Effects of alpha–MSH and cholinergic agents on cGMP and IP3 levels in rat brain slices. Lezcano NE, et al.
Acta Physiol Pharmacol Ther Latinoam 1996;46(3):193–201

Agouti protein inhibits the cAMP response to alpha–MSH stimulation in the rat adrenal gland. Kapas S, et al.
Biochem Soc Trans 1997 Feb;25(1):115S

Resuscitating effect of melanocortin peptides after prolonged respiratory arrest. Guarini S, et al. **Br J Pharmacol** 1997 Aug;121(7):1454–60

Alpha–MSH stimulates neurite outgrowth of neonatal rat corticospinal neurons in vitro. Joosten EA, et al.
Brain Res 1996 Oct 14;736(1–2):91–8

Inhibition of peripheral interleukin–1 beta–induced hyperalgesia by the intracerebroventricular administration of diclofenac and alpha–melanocyte–stimulating hormone. Oka T, et al. **Brain Res** 1996 Oct 14;736(1–2):237–42

Melanocortin receptors mediate alpha–MSH–induced stimulation of neurite outgrowth in neuro 2A cells. Adan RA, et al. **Brain Res Mol Brain Res** 1996 Feb;36(1):37–44

Hyperstimulation of leukocytes by plasma from cardiopulmonary bypass patients is diminished by alpha–MSH pretreatment. Bilfinger TV, et al.
Int J Cardiol 1996 Apr 26;53 Suppl:S47–53

Alpha–melanocyte–stimulating hormone protects against renal injury after ischemia in mice and rats. Chiao H, et al. **J Clin Invest** 1997 Mar 15;99(6):1165–72

Evidence for an interaction between alpha–MSH and opioids in the regulation of gonadotropin secretion in man. Limone P, et al. **J Endocrinol Invest** 1997 Apr;20(4):207–10

Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce increased levels of IL–8 upon stimulation with alpha–melanocyte–stimulating hormone. Hartmeyer M, et al. **J Immunol** 1997 Aug 15;159(4):1930–7

Antipyretic role of endogenous melanocortins mediated by central melanocortin receptors during endotoxin–induced fever. Huang QH, et al. **J Neurosci** 1997 May 1; 17(9):3343–51

alpha–MSH modulates local and circulating tumor necrosis factor–alpha in experimental brain inflammation. Rajora N, et al. **J Neurosci** 1997 Mar 15;17(6):2181–6

Melanocortins and opiate addiction. Alvaro JD, et al.
Life Sci 1997;61(1):1–9 (73 ref.)

The protective effects of alpha–melanocyte stimulating hormone on canine brain stem ischemia. Huh SK, et al.
Neurosurgery 1997 Jan;40(1):132–9; discussion 139–40

Beneficial effects of the melanocortin alpha–melanocyte–stimulating hormone on clinical and neurophysiological recovery after experimental spinal cord injury. van de Meent H, et al. **Neurosurgery** 1997 Jan; 40(1):122–30; discussion 130–1

The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Catania A, et al. **Peptides** 1996;17(4):675-9

Effect of alpha-MSH upon cyclic AMP levels induced by the glutamatergic agonists NMDA, quisqualic acid, and kainic acid. de Barioglio SR, et al. **Peptides** 1996; 17(8):1303-6

alpha-Melanocyte-stimulating hormone (alpha-MSH) and melanin-concentrating hormone (MCH) modify monoaminergic levels in the preoptic area of the rat. Gonzalez MI, et al. **Peptides** 1997;18(3):387-92

alpha-MSH modulates experimental inflammatory bowel disease. Rajora N, et al. **Peptides** 1997;18(3):381-5

The amphibian melanization inhibiting factor (MIF) blocks the alpha-MSH effect on mouse malignant melanocytes. López-Contreras AM, et al. **Pigment Cell Res** 1996 Dec; 9(6):311-6

PHYSIOLOGY

Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Lipton JM, et al. **Immunol Today** 1997 Mar; 18(3):140-5 (39 ref.)

alpha-Melanocyte stimulating hormone downregulates differentiation-driven heat shock protein 70 expression in keratinocytes. Orel L, et al. **J Invest Dermatol** 1997 Apr; 108(4):401-5

The role of alpha-MSH, its agonists, and C-AMP in in vitro avian melanocytes. Bowers RR, et al. **Pigment Cell Res** 1997 Feb-Apr;10(1-2):41-5

SECRETION

Acid stress induces a D1-like dopamine receptor in pituitary MSH cells of Oreochromis mossambicus. Lamers AE, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R387-92

Effect of posterior pituitary denervation (PPD) on prolactin (PRL) and alpha-melanocyte-stimulating hormone (alpha-MSH) secretion of lactating rats. Vecsernyés M, et al. **Brain Res Bull** 1997;43(3):313-9

Neuroendocrine gamma-aminobutyric acid (GABA): functional differences in GABAA versus GABAB receptor inhibition of the melanotrope cell of Xenopus laevis. Buzzi M, et al. **Endocrinology** 1997 Jan;138(1):203-12

Dopaminergic regulation of adrenocorticotrophic hormone, alpha-melanocyte-stimulating hormone and cortisol secretion in the ovine fetus. Hagan DM, et al. **J Endocrinol** 1996 Dec;151(3):439-47

Pulsatile secretion of alpha-MSH and the differential effects of dexamethasone and haloperidol on the secretion of alpha-MSH and ACTH in dogs. Kooistra HS, et al. **J Endocrinol** 1997 Jan;152(1):113-21

ALPHA-NAPHTHYLAMINE see **1-NAPHTHYLAMINE**

ALPHA-NAPHTHYLISOTHIOCYANATE see **1-NAPHTHYLISOTHIOCYANATE**

ALPHA PARTICLES

Alpha particles initiate biological production of superoxide anions and hydrogen peroxide in human cells. Narayanan PK, et al. **Cancer Res** 1997 Sep 15;57(18):3963-71

Cytogenetic and molecular genetic analysis of tumorigenic human bronchial epithelial cells induced by radon alpha particles. Weaver DA, et al. **Carcinogenesis** 1997 Jun; 18(6):1251-7

Long-term effects of internally deposited alpha-particle emitting radionuclides. Epidemiological, pathological and molecular-biological studies of Danish Thorotrast-administered patients and their offspring. Andersson M. **Dan Med Bull** 1997 Apr;44(2):169-90 (140 ref.)

Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells. Larsen RH, et al. **Int J Radiat Biol** 1997 Jul;72(1):79-90

Genetic factors influencing alpha-particle-induced chromosomal instability. Watson GE, et al. **Int J Radiat Biol** 1997 May;71(5):497-503

The assessment of doses and effects from intakes of radioactive particles. Harrison JD, et al. **J Anat** 1996 Dec; 189 (Pt 3):521-30 (23 ref.)

Radiation risk estimation based on activity measurements of zirconium oxide implants. Porstendörfer J, et al. **J Biomed Mater Res** 1996 Dec;32(4):663-7

Radiation, chimpanzees, and the origin of AIDS. Reines BP. **Perspect Biol Med** 1996 Winter;39(2):187-92

Contribution from the inner shell of water vapour to dose profiles under proton and alpha particle irradiation. Olivera GH, et al. **Phys Med Biol** 1996 Sep;41(9):1633-47

Targeted therapy using alpha emitters. Vaidyanathan G, et al. **Phys Med Biol** 1996 Oct;41(10):1915-31 (76 ref.)

Mutagenic effects of a single and an exact number of alpha particles in mammalian cells [see comments] Hei TK, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3765-70 . Comment in: Proc Natl Acad Sci U S A 1997 Jun 10;94(12):5996-7.

What are the risks of low-level exposure to alpha radiation from radon? [see comments] Little JB. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5996-7 (21 ref.). Comment in: Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3765-70.

Biophysical analysis of the dose-dependent overdispersion and the restricted linear energy transfer dependence expressed in dicentric chromosome data from alpha-irradiated human lymphocytes. Greinert R, et al. **Radiat Environ Biophys** 1997 Jun;36(2):89-95

DNA complex lesions induced by protons and alpha-particles: track structure characteristics determining linear energy transfer and particle type dependence. Ottolenghi A, et al. **Radiat Environ Biophys** 1997 Jun; 36(2):97-103

Analysis of chromosome aberrations in human peripheral lymphocytes induced by in vitro alpha-particle irradiation. Schmid E, et al. **Radiat Environ Biophys** 1996 Aug; 35(3):179-84

Dose dependent of sister chromatid exchanges in humans lymphocytes induced by in vitro alpha-particle irradiation. Schmid E, et al. **Radiat Environ Biophys** 1996 Nov; 35(4):311-4

The survival of mouse spermatogonia exposed to alpha particles [letter; comment] Charlton DE. **Radiat Res** 1997 Feb;147(2):270-1. Comment on: Radiat Res 1994 Mar;137(3):352-60.

Alpha-particle-induced sister chromatid exchange in normal human lung fibroblasts: evidence for an extranuclear target. Deshpande A, et al. **Radiat Res** 1996 Mar;145(3):260-7

The severity of alpha-particle-induced DNA damage is revealed by exposure to cell-free extracts. Hodgkins PS, et al. **Radiat Res** 1996 Dec;146(6):660-7

Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo. Howell RW, et al. **Radiat Res** 1997 Mar; 147(3):342-8

Cumulative genetic damage in hematopoietic stem cells in a patient with a 40-year exposure to alpha particles emitted by thorium dioxide. Littlefield LG, et al. **Radiat Res** 1997 Aug;148(2):135-44

Relationships between cell survival and specific energy spectra for therapeutic alpha-particle emitters. Roeske JC, et al. **Radiat Res** 1996 Mar;145(3):268-73

Evaluation of internal alpha-particle radiation exposure and subsequent fertility among a cohort of women formerly employed in the radium dial industry. Schieve LA, et al. **Radiat Res** 1997 Feb;147(2):236-44

Variations in the concentration of plutonium, strontium-90 and total alpha-emitters in human teeth collected within the British Isles. O'Donnell RG, et al. **Sci Total Environ** 1997 Aug 18;201(3):235-43

Induction of single- and double-strand breaks in plasmid DNA by monoenergetic alpha-particles with energies below the Bragg-maximum. Scholz V, et al. **Z Naturforsch [C]** 1997 May-Jun;52(5-6):364-72

[Radiation protective effects of laser irradiation with wavelength 532 nm] Voskanian KSh, et al. **Radiats Biol Radioecol** 1996 Sep-Oct;36(5):731-3 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Extracellular factor(s) following exposure to alpha particles can cause sister chromatid exchanges in normal human cells. Lehnert BE, et al. **Cancer Res** 1997 Jun 1; 57(11):2164-71

p53 gene mutation analysis in tumors of patients exposed to alpha-particles. Hollstein M, et al. **Carcinogenesis** 1997 Mar;18(3):511-6

THERAPEUTIC USE

Alpha-particle-emitting radioisotopes coupled to antibody for acute myeloid leukaemia treatment [news] Featherstone C. **Mol Med Today** 1997 Jun;3(6):232-3

ALPHA 2-PLASMIN INHIBITOR see **ANTIPLASMIN**

ALPHA 1-PROTEASE INHIBITOR see **ALPHA 1-ANTITRYPSIN**

ALPHA 1-PROTEINASE INHIBITOR see **ALPHA 1-ANTITRYPSIN**

ALPHA RAYS see **ALPHA PARTICLES**

5-ALPHA-REDUCTASE, TESTOSTERONE see **TESTOSTERONE 5-ALPHA-REDUCTASE**

ALPHA RHYTHM

Is the alpha rhythm a control parameter for brain responses? Başar E, et al. **Biol Cybern** 1997 Jun;76(6):471-80

Abnormality of EEG alpha asymmetry in female adolescent suicide attempters. Graae F, et al. **Biol Psychiatry** 1996 Oct 15;40(8):706-13

Discrimination and study of rhythmical brain activities in the alpha band: a neuromagnetic frequency responsiveness test. Narici L, et al. **Brain Res** 1995 Dec 12;703(1-2):31-44

Relative alpha desynchronization and synchronization during speech perception. Krause CM, et al. **Brain Res Cogn Brain Res** 1997 Jun;5(4):295-9

The effect of pre-stimulus alpha activity on the auditory P300 paradigm: a prospective study. Price GW. **Brain Topogr** 1997 Spring;9(3):169-76

Developmental changes in the alpha response system. Yordanova JY, et al. **Electroencephalogr Clin Neurophysiol** 1996 Dec; 99(6):527-38

Event-related desynchronization (ERD) in the alpha frequency during development of implicit and explicit learning. Zhuang P, et al. **Electroencephalogr Clin Neurophysiol** 1997 Apr; 102(4):374-81

Influence of uvulopalatopharyngoplasty on alpha-EEG arousals in nonapnoeic snorers. Boudewyns A, et al. **Eur Respir J** 1997 Jan;10(1):129-32

Alpha sleep and information processing, perception of sleep, pain, and arousability in fibromyalgia. Perlis ML, et al. **Int J Neurosci** 1997 Feb;89(3-4):265-80

Developmentally advanced EEG alpha power in gifted male and female adolescents. Alexander JE, et al. **Int J Psychophysiol** 1996 Aug-Sep;23(1-2):25-31

Alpha EEG activity and subcortical pathology in HIV infection. Baldeweg T, et al. **Int J Psychophysiol** 1997 Jun; 26(1-3):431-42

Some aspects of alpha activity in relation to a new generalized model for the EEG. Barlow JS. **Int J Psychophysiol** 1997 Jun;26(1-3):341-52 (8 ref.)

Functional correlates of alphas panel discussion of the conference 'Alpha Processes in the Brain'. Başar E, et al. **Int J Psychophysiol** 1997 Jun;26(1-3):455-74

Alpha oscillations in brain functioning: an integrative theory. Başar E, et al. **Int J Psychophysiol** 1997 Jun;26(1-3):5-29 (120 ref.)

Visual and auditory evoked phase resetting of the alpha EEG. Brandt ME. **Int J Psychophysiol** 1997 Jun;26(1-3):285-98

Mathematical cognitive style and arithmetic sign comprehension: a study of EEG alpha and theta activity. Earle JB, et al. **Int J Psychophysiol** 1996 Jan;21(1):1-13

Is there a way from behavior to non-linear brain dynamics? On quantal periods in cognition and the place of alpha in brain resonances. Geissler HG. **Int J Psychophysiol** 1997 Jun;26(1-3):381-93 (31 ref.)

EEG-alpha rhythms and memory processes. Klimesch W. **Int J Psychophysiol** 1997 Jun;26(1-3):319-40 (35 ref.)

Event-related desynchronization (ERD) and the Dm effect: does alpha desynchronization during encoding predict later recall performance? Klimesch W, et al. **Int J Psychophysiol** 1996 Nov;24(1-2):47-60

Memory processes, brain oscillations and EEG synchronization. Klimesch W. **Int J Psychophysiol** 1996 Nov;24(1-2):61-100 (138 ref.)

Spatio-temporal dynamics of alpha brain electric fields, and cognitive modes. Lehmann D, et al. **Int J Psychophysiol** 1997 Jun;26(1-3):99-112 (51 ref.)

Alpha rhythms: noise, dynamics and models. Lopes da Silva FH, et al. **Int J Psychophysiol** 1997 Jun;26(1-3):237-49 (44 ref.)

EEG alpha dynamics as viewed from EEG dimension dynamics. Lutzenberger W. **Int J Psychophysiol** 1997 Jun; 26(1-3):273-83

Alpha rhythm parameters and short-term memory span. Maltseva IV, et al. **Int J Psychophysiol** 1997 Jun; 26(1-3):369-80

Driven and synchronized brain activities in the alpha band: a neuromagnetic test for frequency responsiveness. Narici L. **Int J Psychophysiol** 1997 Jun;26(1-3):137-48

Alpha rhythms as physiological and abnormal phenomena. Niedermeyer E. **Int J Psychophysiol** 1997 Jun; 26(1-3):31-49 (84 ref.)

Measurements by biphasic changes of the alpha band amplitude as indicators of arousal level. Ota T, et al. **Int J Psychophysiol** 1996 Nov;24(1-2):25-37

The possible meaning of the upper and lower alpha frequency ranges for cognitive and creative tasks. Petsche H, et al. **Int J Psychophysiol** 1997 Jun;26(1-3):77-97

Event-related synchronization (ERS) in the alpha band--an electrophysiological correlate of cortical idling: a review. Pfurtscheller G, et al. **Int J Psychophysiol** 1996 Nov; 24(1-2):39-46 (47 ref.)

Preliminary evidence that daily changes in frontal alpha asymmetry correlate with changes in affect in therapy sessions. Rosenfeld JP, et al. **Int J Psychophysiol** 1996 Aug-Sep;23(1-2):137-41

Rhythms in the alpha band in cats and their behavioural correlates. Rougeul-Buser A, et al. **Int J Psychophysiol** 1997 Jun;26(1-3):191-203 (39 ref.)

Normal and pathological changes in alpha rhythms. Samson-Dollfus D, et al. **Int J Psychophysiol** 1997 Jun; 26(1-3):395-409

A possible role of evoked alpha in primary sensory processing: common properties of cat intracranial recordings and human EEG and MEG. Schürmann M, et al. **Int J Psychophysiol** 1997 Jun;26(1-3):149-70

Intention as a component of the alpha-rhythm response to mental activity. Shaw JC. **Int J Psychophysiol** 1996 Nov; 24(1-2):7-23 (140 ref.)

Study of human occipital alpha rhythm: the alphon hypothesis and alpha suppression. Williamson SJ, et al. **Int J Psychophysiol** 1997 Jun;26(1-3):63-76 (35 ref.)

Alpha response system in children: changes with age. Yordanova J, et al. **Int J Psychophysiol** 1997 Jun; 26(1-3):411-30

Alpha-pattern coma in primary brainstem hemorrhage; clinical, electrophysiologic, and cerebral blood flow studies. Hayashi R, et al. **Intern Med** 1996 Nov;35(11):905-8

Alpha frequency, reaction time, and the speed of processing information. Klimesch W, et al. **J Clin Neurophysiol** 1996 Nov;13(6):511-8

ALPHA RHYTHM

Modulation of the parieto–occipital alpha rhythm during object detection. Vanni S, et al. **J Neurosci** 1997 Sep 15; 17(18):7141–7

The alpha rhythm in the electroencephalogram: a theory based on a neurophysiological model. Johannisson T, et al. **Med Hypotheses** 1996 Jun;46(6):557–61

On the existence of different alpha band rhythms in the hand area of man. Andrew C, et al. **Neurosci Lett** 1997 Jan 31; 222(2):103–6

Effects of smoking on EEG alpha asymmetry during production of random sequences of numbers. Hori T, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):827–34

Theta synchronization and alpha desynchronization in a memory task. Klimesch W, et al. **Psychophysiology** 1997 Mar;34(2):169–76

Negative symptoms and EEG alpha in schizophrenia: a replication. Merrin EL, et al. **Schizophr Res** 1996 May; 19(2–3):151–61

The alpha attenuation test: assessing excessive daytime sleepiness in narcolepsy–cataplexy. Alloway CE, et al. **Sleep** 1997 Apr;20(4):258–66

Power density in theta/alpha frequencies of the waking EEG progressively increases during sustained wakefulness. Cajochen C, et al. **Sleep** 1995 Dec;18(10):890–4

Language in dreaming and regional EEG alpha power. Hong CC, et al. **Sleep** 1996 Apr;19(3):232–5

[Rhythmic alpha/theta bursts in the electroencephalogram of early premature infants: (2). Correlation with background EEG activity] Kuremoto K, et al. **No To Hattatsu** 1997 May;29(3):244–8 (Eng. Abstr.) **(Jpn)**

[Rhythmic alpha/theta bursts in the electroencephalogram of early premature infants: (1). The features in normal early premature infants] Kuremoto K, et al. **No To Hattatsu** 1997 May;29(3):239–43 (Eng. Abstr.) **(Jpn)**

[Heterogeneity and age–related dynamics of the alpha–rhythm of the electroencephalogram] Farber DA, et al. **Fiziol Cheloveka** 1996 Sep–Oct;22(5):5–12 **(Rus)**

[Formation of electroencephalographic mu– and alpha–rhythms in children during the second to third years of life] Galkina NS, et al. **Fiziol Cheloveka** 1996 Sep–Oct; 22(5):30–6 **(Rus)**

[Dynamics of alpha–band frequency components in the electroencephalogram of 9–10–year–old children under conditions of relaxation] Gorev AS. **Fiziol Cheloveka** 1996 Sep–Oct;22(5):45–8 **(Rus)**

[Dependence of equivalent sources of different alpha–rhythm subbands on the status of the visual system in eight– to ten–year–old children] Tolstova VA, et al. **Fiziol Cheloveka** 1996 Sep–Oct;22(5):13–9 **(Rus)**

[The individual typological characteristics of the EEG correlates of human emotional reactions] Kalashnikova IG. **Fiziol Zh Im I M Sechenova** 1995 Oct;81(10):108–12 **(Rus)**

[The functional significance of alpha activity in the visual cortex for the recognition of images and movement] Shevelev IA. **Fiziol Zh Im I M Sechenova** 1996 Oct–Nov; 82(10–11):20–33 (Eng. Abstr.) **(Rus)**

[The resonance EEG reactions in rhythmical photostimulation and the changes in functional status] Fedotchev AI, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 May–Jun; 46(3):447–56 (Eng. Abstr.) **(Rus)**

[Differences in the the EEG frequency characteristics during the perception of positive–emotional, negative–emotional and neutral words] Il'iuchenok IR. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 May–Jun; 46(3):457–68 (Eng. Abstr.) **(Rus)**

[The relationship of visual illusions to the frequency and phase shift of rhythmic photostimulation synchronized with the EEG alpha wave] Kamenkovich VM, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 May–Jun; 47(3):461–8 (Eng. Abstr.) **(Rus)**

[A model of the structure of the dipole source of the alpha rhythm in the human visual cortex] Verkhliutov VM. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 May–Jun; 46(3):496–503 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Alpha brainwave training and perception of time passing: preliminary findings. Wacker MS. **Biofeedback Self Regul** 1996 Dec;21(4):303–9

[The dynamics of the dominant alpha–rhythm frequency in the perception and reproduction of time intervals] Shestova IA, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Mar–Apr;46(2):253–9 (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Segregation of the thalamic alpha rhythms from cortical alpha activity using the Savit–Green S–statistic and estimated correlation dimension. Pritchard WS, et al. **Int J Psychophysiol** 1997 Jun;26(1–3):263–71

Non–linear dynamics of alpha and theta rhythm: correlation dimensions and Lyapunov exponents from healthy subject's spontaneous EEG. Röschke J, et al. **Int J Psychophysiol** 1997 Jun;26(1–3):251–61

ALPHA–THALASSEMIA

Preimplantation diagnosis of alpha–thalassemia by blastomere aspiration and polymerase chain reaction: preliminary experience. Chang MY, et al. **J Formos Med Assoc** 1996 Mar;95(3):203–8

BLOOD

The unusual pathobiology of hemoglobin constant spring red blood cells. Schrier SL, et al. **Blood** 1997 Mar 1; 89(5):1762–9

Red blood cell phenotypes in the alpha + thalassaemias from early childhood to maturity. Williams TN, et al. **Br J Haematol** 1996 Nov;95(2):266–72

Pathobiology of thalassemic erythrocytes. Schrier SL. **Curr Opin Hematol** 1997 Mar;4(2):75–8 (20 ref.)

Increased serum levels of macrophage colony–stimulating factor (M–CSF) in alpha– and beta–thalassaemia syndromes: correlation with anaemia and monocyte activation. Wiener E, et al. **Eur J Haematol** 1996 Nov; 57(5):364–9

Elevated zinc protoporphyrin associated with thalassemia trait and hemoglobin E. Graham EA, et al. **J Pediatr** 1996 Jul;129(1):105–10

Prenatal diagnosis of haemoglobin Bart's disease by cordocentesis at 12–14 weeks' gestation. Lam YH, et al. **Prenat Diagn** 1997 Jun;17(6):501–4

Invasion and growth of Plasmodium falciparum is inhibited in fractionated thalassaemic erythrocytes. Senok AC, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):138–43

COMPLICATIONS

Limb defects and congenital anomalies of the genitalia in an infant with homozygous alpha–thalassemia. Abuelo DN, et al. **Am J Med Genet** 1997 Jan 20;68(2):158–61 (20 ref.)

Limb defects in homozygous alpha–thalassemia: report of three cases. Chitayat D, et al. **Am J Med Genet** 1997 Jan 20;68(2):162–7

Self–induced vomiting in X–linked alpha–thalassemia/mental retardation syndrome [letter] Kurosawa K, et al. **Am J Med Genet** 1996 Jun 14;63(3):505–6

Relation of haemolytic anaemia and erythrocyte–bound IgG in alpha– and beta–thalassaemic syndromes. Chinprasertsuk S, et al. **Eur J Haematol** 1997 Feb;58(2):86–91

High incidence of malaria in alpha–thalassaemic children [see comments] Williams TN, et al. **Nature** 1996 Oct 10; 383(6600):522–5. Comment in: Nature 1996 Oct 10;383(6600):480–1.

Second–trimester hydrops fetalis in pregnancies affected by homozygous alpha–thalassaemia–1. Lam YH, et al. **Prenat Diagn** 1997 Mar;17(3):267–9

Osteochondroma in a patient with juvenile ankylosing spondylitis associated with idiopathic thrombocytopenic purpura and alpha thalassemia. Tsai CY, et al. **Scand J Rheumatol** 1996;25(1):61–2

DIAGNOSIS

Prenatal diagnosis based on simultaneous DNA analysis for alpha– and beta–globin genes [letter] Oron–Karni V, et al. **Am J Hematol** 1996 Nov;53(3):203–4

Validation of an automated HPLC method for quantification of hemoglobin S. Fisher SI, et al. **Clin Chem** 1997 Sep; 43(9):1667–9

Alpha thalassemia and its impact on other clinical conditions. Bowie LJ, et al. **Clin Lab Med** 1997 Mar;17(1):97–108 (28 ref.)

A fast hemoglobin variant on newborn screening is associated with alpha–thalassemia trait. Miller ST, et al. **Clin Pediatr (Phila)** 1997 Feb;36(2):75–8

Is cellulose acetate electrophoresis a suitable technique for detection of Hb Bart's at birth? Desai S, et al. **Hum Hered** 1997 Jul–Aug;47(4):181–4

Screening for genetic diseases [editorial; comment] [see comments] Motulsky AG. **N Engl J Med** 1997 May 1; 336(18):1314–6. Comment on: N Engl J Med 1997 May 1;336(18):1298–301. Comment in: N Engl J Med 1997 Aug 28;337(9):639–40.

Misdiagnosis of homozygous alpha–thalassaemia 1 may occur if polymerase chain reaction alone is used in prenatal diagnosis. Ko TM, et al. **Prenat Diagn** 1997 Jun;17(6):505–9

EPIDEMIOLOGY

Milder clinical course of sickle cell disease in patients with alpha thalassemia in the Indian subcontinent [letter] Mukherjee MB, et al. **Blood** 1997 Jan 15;89(2):732

Prevalence and genotypes of alpha– and beta–thalassemia carriers in Hong Kong — implications for population screening [see comments] Lau YL, et al. **N Engl J Med** 1997 May 1;336(18):1298–301. Comment in: N Engl J Med 1997 May 1;336(18):1314–6.

ETHNOLOGY

Frequency of deletional alpha–thalassemia genotypes in a predominantly Asian–American population. Hofgärtner WT, et al. **Am J Clin Pathol** 1997 May;107(5):576–81

GENETICS

Frequency of deletional alpha–thalassemia genotypes in a predominantly Asian–American population. Hofgärtner WT, et al. **Am J Clin Pathol** 1997 May;107(5):576–81

Nondeletional alpha–thalassemia: first description of alpha Hph alpha and alpha Nco alpha mutations in a Spanish population [see comments] Ayala S, et al. **Am J Hematol** 1996 Jul;52(3):144–9. Comment in: Am J Hematol 1997 Apr;54(4):342–3.

Effect of alpha–thalassemia and beta–globin gene cluster haplotypes on the hematological and clinical features of sickle–cell anemia in Brazil. Figueiredo MS, et al. **Am J Hematol** 1996 Oct;53(2):72–6

Human alpha–thalassemia syndromes: detection of molecular defects. Kattamis AC, et al. **Am J Hematol** 1996 Oct; 53(2):81–91 (89 ref.)

Sickle cell disorder, beta–globin gene cluster haplotypes and alpha–thalassemia in neonates and adults from Guadeloupe. Kéclard L, et al. **Am J Hematol** 1997 May;55(1):24–7

Effect of alpha–thalassemia on sickle–cell anemia linked to the Arab–Indian haplotype in India. Mukherjee MB, et al. **Am J Hematol** 1997 Jun;55(2):104–9

Detection of alpha–thalassemia–2 (–3.7 kb) and its corresponding triplication (alpha)(alpha)(alpha) (anti–3.7 kb) by PCR: an improved technical change [letter] Smetanina NS, et al. **Am J Hematol** 1996 Nov;53(3):202–3

Nondeletional alpha–thalassemia in a Spanish population [letter; comment] Villegas A, et al. **Am J Hematol** 1997 Apr;54(4):342–3. Comment on: Am J Hematol 1996 Jul;52(3):144–9.

Limb defects in homozygous alpha–thalassemia: report of three cases. Chitayat D, et al. **Am J Med Genet** 1997 Jan 20;68(2):162–7

Presence of hemoglobinopathies in Sicily: a historic perspective. Schilirò G, et al. **Am J Med Genet** 1997 Mar 17;69(2):200–6

Mouse zeta– and alpha–globin genes: embryonic survival, alpha–thalassemia, and genetic background effects. Leder A, et al. **Blood** 1997 Aug 1;90(3):1275–82

First description of a frameshift mutation in the alpha1–globin gene associated with alpha–thalassaemia. Ayala S, et al. **Br J Haematol** 1997 Jul;98(1):47–50

Haemoglobin Lleida: a new alpha 2–globin variant (12 bp deletion) with mild thalassaemic phenotype. Ayala S, et al. **Br J Haematol** 1996 Sep;94(4):639–44

Hb Utrecht [alpha 2 129(H12)Leu––>Pro], a new unstable alpha 2–chain variant associated with a mild alpha–thalassaemic phenotype. Harteveld CL, et al. **Br J Haematol** 1996 Sep;94(3):483–5

An IVS1–116 (A–––>G) acceptor splice site mutation in the alpha 2 globin gene causing alpha + thalassaemia in two Dutch families. Harteveld CL, et al. **Br J Haematol** 1996 Dec;95(3):461–6

Alpha thalassemia and its impact on other clinical conditions. Bowie LJ, et al. **Clin Lab Med** 1997 Mar;17(1):97–108 (28 ref.)

Determination of the genomic structure of the XNP/ATRX gene encoding a potential zinc finger helicase. Villard L, et al. **Genomics** 1997 Jul 15;43(2):149–55

Detection of alpha–globin gene disorders by a simple PCR methodology [see comments] [published erratum appears in Haematologica 1996 Nov–Dec;81(6):XVI] Foglietta E, et al. **Haematologica** 1996 Sep–Oct;81(5):387–96. Comment in: Haematologica 1996 Sep–Oct;81(5):385–6.

Historical and anthropological correlates of beta S haplotypes and alpha– and beta–thalassemia alleles in the Arabian Peninsula. Adekile AD. **Hemoglobin** 1997 May; 21(3):281–96 (84 ref.)

Hb E and alpha–thalassemia; variability in the assembly of beta E chain containing tetramers. Huisman TH. **Hemoglobin** 1997 May;21(3):227–36

Hb Seal Rock [(alpha 2)142 term–––>Glu, codon 142 TAA–––>GAA]: an extended alpha chain variant associated with anemia, microcytosis, and alpha–thalassemia–2 (–3.7 Kb). Merritt D, et al. **Hemoglobin** 1997 Jul;21(4):331–44

Hb Sögn or alpha 2 beta 2 14(A11)Leu–––>Arg in combination with an alpha–thalassemia heterozygosity. Miller DR, et al. **Hemoglobin** 1996 May;20(2):131–4

Detection of the alpha–thalassemia–2 (3.7 kb) deletion in DNA extracted from 20–year–old blood smears. Okeagu JE, et al. **Hemoglobin** 1997 Jan;21(1):53–8

Hb Valletta [beta 87(F3)Thr–––>Pro] due to an A–––>C substitution at codon 87 in a Calabrian family with alpha–thalassemia. Qualtieri A, et al. **Hemoglobin** 1997 Jan; 21(1):97–103

Modulation of the phenotypic diversity of sickle cell anemia. Steinberg MH. **Hemoglobin** 1996 Feb;20(1):1–19 (88 ref.)

alpha–thalassemia caused by a 16 bp deletion in the 3' untranslated region of the alpha 2–globin gene including the first nucleotide of the poly A signal sequence. Tamary H, et al. **Hemoglobin** 1997 Mar;21(2):121–30

Molecular basis of alpha–thalassemia in Sicily. Fichera M, et al. **Hum Genet** 1997 Mar;99(3):381–6

The involvement of Alu repeats in recombination events at the alpha–globin gene cluster: characterization of two alphazero–thalassaemia deletion breakpoints. Harteveld KL, et al. **Hum Genet** 1997 Apr;99(4):528–34

alpha–Thalassemia in The Netherlands: a heterogeneous spectrum of both deletions and point mutations. Harteveld KL, et al. **Hum Genet** 1997 Sep;100(3–4):465–71

Alpha–thalassemia genes in Israel: deletional and nondeletional mutations in patients of various origins. Shalmon L, et al. **Hum Hered** 1996 Jan–Feb;46(1):15–9

Chromosomal stabilisation by a subtelomeric rearrangement involving two closely related Alu elements. Flint J, et al. **Hum Mol Genet** 1996 Aug;5(8):1163–9

ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism

underlying the ATR-X syndrome. Picketts DJ, et al. **Hum Mol Genet** 1996 Dec;5(12):1899-907

A Japanese patient with X-linked alpha-thalassemia/mental retardation syndrome: an additional case report. Kurosawa K, et al. **Jpn J Hum Genet** 1996 Sep;41(3):329-32

Malaria. Protective selective pressure [news; comment] Miller LH. **Nature** 1996 Oct 10;383(6600):480-1. Comment on: Nature 1996 Oct 10;383(6600):522-5.

The risk of alpha-thalassaemia in offspring of beta-thalassaemia carriers in Hong Kong. Lam YH, et al. **Prenat Diagn** 1997 Aug;17(8):733-6

[Association of alpha and beta thalassemia with alpha gene triplication in one family] Villegas A, et al. **Med Clin (Barc)** 1997 May 24;108(20):781-3 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Erythroblast- and erythrocyte-bound antibodies in alpha and beta thalassaemia syndromes. Wiener E, et al. **Transfus Med** 1991 Dec;1(4):229-38

METABOLISM

Binding of nitric oxide to thiols and hemes in hemoglobin H: implications for alpha-thalassemia and hypertension. Reddy PL, et al. **Clin Chem** 1997 Aug;43(8 Pt 1):1442-7

PATHOLOGY

Liver injury due to iron overload in thalassemia: histopathologic and ultrastructural studies. Thakerngpol K, et al. **Biometals** 1996 Apr;9(2):177-83

PHYSIOPATHOLOGY

Influence of alpha-thalassemia trait on spleen function in sickle cell anemia patients with high HbF. Adekile AD, et al. **Am J Hematol** 1996 Sep;53(1):1-5

PREVENTION & CONTROL

Frequency of alpha-thalassemia-1 of the Southeast Asian-type among pregnant women in northern Thailand determined by PCR technique. Kitsirisakul B, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):362-3

ULTRASONOGRAPHY

Early ultrasound prediction of pregnancies affected by homozygous alpha-thalassaemia-1. Lam YH, et al. **Prenat Diagn** 1997 Apr;17(4):327-32

ALPHA-TOXIN see **PHOSPHOLIPASE C**

ALPHA-TRANS-INDUCING FACTOR, HERPES SIMPLEX VIRUS 1 see **HERPES SIMPLEX VIRUS PROTEIN VMW65**

ALPHA-TRANSDUCIN see **TRANSDUCIN**

ALPHA-TRICHOSANTHIN see **TRICHOSANTHIN**

ALPHA-VINCULIN see **VINCULIN**

ALPHACETYLMETHADOL see **METHADYL ACETATE**

ALPHADIONE see **ALTHESIN**

ALPHAHERPESVIRINAE

New therapeutic approaches to the alphaherpesvirus infections. Cassady KA, et al. **J Antimicrob Chemother** 1997 Feb;39(2):119-28 (77 ref.)

Pathogenesis of ruminant herpesvirus infections. Engels M, et al. **Vet Microbiol** 1996 Nov;53(1-2):3-15 (53 ref.)

DRUG EFFECTS

Inhibition of three alphaherpesviruses (herpes simplex 1 and 2 and pseudorabies virus) by heparin, heparan and other sulfated polyelectrolytes [published erratum appears in Arch Med Res 1996 Summer;27(2):following 255] Ramos-Kuri M, et al. **Arch Med Res** 1996 Spring;27(1):43-8

ENZYMOLOGY

Sequence of the canine herpesvirus thymidine kinase gene: taxon-preferred amino acid residues in the alphaherpesviral thymidine kinases. Rémond M, et al. **Virus Res** 1995 Dec; 39(2-3):341-54

GENETICS

Characterization of the feline herpesvirus type 1 immediate early gene expression. Kawaguchi Y, et al. **J Vet Med Sci** 1996 Aug;58(8):715-21

Mutational analysis of the virion host shutoff gene (UL41) of herpes simplex virus (HSV): characterization of HSV type 1 (HSV-1)/HSV-2 chimeras. Everly DN Jr, et al. **J Virol** 1997 Oct;71(10):7157-66

Rapid differentiation of vaccine strains and field isolates of infectious laryngotracheitis virus by restriction fragment length polymorphism of PCR products. Chang PC, et al. **J Virol Methods** 1997 Jul;66(2):179-86

In vivo properties of a feline herpesvirus type 1 mutant carrying a lacZ insertion at the gI locus of the unique short segment. Willemse MJ, et al. **Vaccine** 1996 Jan;14(1):1-5

Identification and characterization of the bovine herpesvirus 5 US4 gene and gene products. Engelhardt T, et al. **Virology** 1996 Nov 1;225(1):126-35

Identification and characterization of the feline herpesvirus type 1 glycoprotein C gene. Maeda K, et al. **Virus Genes** 1997;14(2):105-9

IMMUNOLOGY

Adhesion of insect cells expressing the feline herpesvirus type 1 hemagglutinin (gD) to feline cell lines. Maeda K, et al. **J Vet Med Sci** 1997 Mar;59(3):217-9

METABOLISM

Characterization of the feline herpesvirus type 1 immediate early gene expression. Kawaguchi Y, et al. **J Vet Med Sci** 1996 Aug;58(8):715-21

ALPHASONE ACETOPHENIDE see **ALGESTONE ACETOPHENIDE**

ALPHAVIRUS

Glomerulonephritis secondary to Barmah Forest virus infection. Katz IA, et al. **Med J Aust** 1997 Jul 7;167(1):21-3

CHEMISTRY

Distribution of Mayaro virus RNA in polysomes during heat shock. Rosas SL, et al. **Virus Res** 1997 May;48(2):133-41

GENETICS

Genetic stability among temporally and geographically diverse isolates of Barmah Forest virus. Poidinger M, et al. **Am J Trop Med Hyg** 1997 Aug;57(2):230-4

Alphavirus expression vectors and their use as recombinant vaccines: a minireview. Tubulekas I, et al. **Gene** 1997 Apr 29;190(1):191-5 (32 ref.)

Alphavirus-based expression vectors: strategies and applications. Frolov I, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11371-7 (72 ref.)

Nucleotide sequence of the Barmah Forest virus genome. Lee E, et al. **Virology** 1997 Jan 20;227(2):509-14

Complete nucleotide sequence and full-length cDNA clone of S.A.AR86 a South African alphavirus related to Sindbis. Simpson DA, et al. **Virology** 1996 Aug 15;222(2):464-9

Molecular epidemiology and evolution of mosquito-borne flaviviruses and alphaviruses enzootic in Australia. Mackenzie JS, et al. **Virus Genes** 1995;11(2-3):225-37 (57 ref.)

[Recombination of alpha-viruses during mixed infection in cultured cells. Formation of hybrid forms of RNA of Venezuelan equine encephalomyelitis virus and Karelian fever virus in the region of genes for nucleocapsid and envelope proteins] Sokolova TM, et al. **Vopr Virusol** 1996 Nov-Dec;41(6):245-52 (Eng. Abstr.) **(Rus)**

[Comparative analysis of primary structure of nucleocapsid protein from Western equine encephalomyelitis virus and other alphaviruses] Uryvaev LV, et al. **Vopr Virusol** 1996 Nov-Dec;41(6):252-9 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Alphavirus hybrid virion vaccines. Shafferman A, et al. **Adv Exp Med Biol** 1996;397:41-7

ISOLATION & PURIFICATION

Emergence of Barmah Forest virus in Western Australia. Lindsay M, et al. **Emerg Infect Dis** 1995 Jan-Mar;1(1):22-6

Identification of mayaro virus nucleocapsid protein in nucleus of Aedes albopictus cells. Mitchell C, et al. **Virus Res** 1997 Jan;47(1):67-77

O'nyong-nyong (ONN) fever. **Wkly Epidemiol Rec** 1997 Mar 28;72(13):93 **(Eng, Fre)**

METABOLISM

[Localization of a group-specific, hemagglutinating epitope of alphavirus glycoprotein E2 using a phage peptide library] Kuz'micheva GA, et al. **Dokl Akad Nauk** 1997 Jan;352(1):113-6 **(Rus)**

PHYSIOLOGY

Alphavirus-based expression systems. Rice CM. **Adv Exp Med Biol** 1996;397:31-40 (38 ref.)

Alphavirus infection in mosquitoes at the Ross River reservoir, north Queensland, 1990-1993. Kay BH, et al. **J Am Mosq Control Assoc** 1996 Sep;12(3 Pt 1):421-8

Superinfection exclusion of alphaviruses in three mosquito cell lines persistently infected with Sindbis virus. Karpf AR, et al. **J Virol** 1997 Sep;71(9):7119-23

Identification of a protein binding site on the surface of the alphavirus nucleocapsid and its implication in virus assembly. Lee S, et al. **Structure** 1996 May 15;4(5):531-41

Distribution of Mayaro virus RNA in polysomes during heat shock. Rosas SL, et al. **Virus Res** 1997 May;48(2):133-41

ALPHAVIRUS INFECTIONS

Ross River virus and Barmah Forest virus infection. Commonly asked questions. Hills S. **Aust Fam Physician** 1996 Dec;25(12):1822-4

Ross River virus in a joint military exercise. Hueston L, et al. **Commun Dis Intell** 1997 Jul 10;21(14):193

Blood-brain barrier breakdown and increased intercellular adhesion molecule (ICAM-1/CD54) expression after Semliki Forest (A7) virus infection facilitates the development of experimental allergic encephalomyelitis. Erälinna JP, et al. **J Neuroimmunol** 1996 May; 66(1-2):103-14

Production and role of cytokines in the CNS of mice with acute viral encephalomyelitis. Mokhtarian F, et al. **J Neuroimmunol** 1996 May;66(1-2):11-22

COMPLICATIONS

Barmah Forest virus causing anaemia? [letter] Marshall CL, et al. **Aust N Z J Med** 1997 Jun;27(3):345-6

Ross River virus disease and rheumatoid arthritis [letter] Douglas WA. **Med J Aust** 1997 Aug 18;167(4):229-30

Glomerulonephritis secondary to Barmah Forest virus infection. Katz IA, et al. **Med J Aust** 1997 Jul 7;167(1):21-3

DRUG THERAPY

[Effect of the amide of 1-adamantanecarboxylic acid (AACA) and its combination with ribavirin on the course of experimental infection, caused by the sindbis virus in tissue culture and in mouse brain. Possible isolation of the virus mutant resistant to ribavirin and to a combination of the inhibitors] Andronova VL. **Antibiot Khimioter** 1997; 42(7):3-7 (Eng. Abstr.) **(Rus)**

[Effectiveness of the interferon inducers ridostin and camedon in prevention and treatment of experimental alpha- and flavivirus infections] Barinskii IF, et al. **Vopr Virusol** 1996 May-Jun;41(3):133-5 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Genetic stability among temporally and geographically diverse isolates of Barmah Forest virus. Poidinger M, et al. **Am J Trop Med Hyg** 1997 Aug;57(2):230-4

Ross River virus infection on the North Coast of New South Wales. Westley-Wise VJ, et al. **Aust N Z J Public Health** 1996 Feb;20(1):87-92

Communicable diseases surveillance. Ross River virus infection reports increasing. **Commun Dis Intell** 1997 Feb 6;21(3):34-9

Emergence of Barmah Forest virus in Western Australia. Lindsay M, et al. **Emerg Infect Dis** 1995 Jan-Mar;1(1):22-6

An outbreak of Ross River virus disease in Southwestern Australia. Lindsay M, et al. **Emerg Infect Dis** 1996 Apr-Jun; 2(2):117-20

Emergence of epidemic O'nyong-nyong fever in southwestern Uganda, after an absence of 35 years [letter] Rwaguma EB, et al. **Emerg Infect Dis** 1997 Jan-Mar;3(1):77

The changing epidemiology of Ross River virus disease in South Australia [letter; comment] Careless DJ. **Med J Aust** 1997 Mar 17;166(6):334. Comment on: Med J Aust 1996 Sep 16;165(6):313-7.

The Southern Oscillation Index and Ross river virus outbreaks [letter] Harley DO, et al. **Med J Aust** 1996 Nov 4;165(9):531-2

The changing epidemiology of Ross River virus disease in South Australia [letter; comment] Keary PJ, et al. **Med J Aust** 1997 Mar 17;166(6):333; discussion 334. Comment on: Med J Aust 1996 Sep 16;165(6):313-7.

Changing epidemiology of Ross River virus disease in South Australia [see comments] Selden SM, et al. **Med J Aust** 1996 Sep 16;165(6):313-7. Comment in: Med J Aust 1997 Mar 17;166(6):333; discussion 334. Comment in: Med J Aust 1997 Mar 17;166(6):334.

O'nyong-nyong (ONN) fever. **Wkly Epidemiol Rec** 1997 Mar 28;72(13):93 **(Eng, Fre)**

ETIOLOGY

The Southern Oscillation Index and Ross river virus outbreaks [letter] Harley DO, et al. **Med J Aust** 1996 Nov 4;165(9):531-2

IMMUNOLOGY

Alphavirus hybrid virion vaccines. Shafferman A, et al. **Adv Exp Med Biol** 1996;397:41-7

Regulation of brain-derived T cells during acute central nervous system inflammation. Irani DN, et al. **J Immunol** 1997 Mar 1;158(5):2318-26

METABOLISM

Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection. Morris MM, et al. **J Neuroimmunol** 1997 Apr; 74(1-2):185-97

PATHOLOGY

An eruption associated with alphavirus infection. Autio P, et al. **Br J Dermatol** 1996 Aug;135(2):320-3

Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection. Morris MM, et al. **J Neuroimmunol** 1997 Apr; 74(1-2):185-97

ALPHAVIRUS INFECTIONS

PHYSIOPATHOLOGY

Susceptibility to a neurotropic virus and its changing distribution in the developing brain is a function of CNS maturity. Oliver KR, et al. **J Neurovirol** 1997 Feb; 3(1):38–48

Long-term effects of Semliki Forest virus infection in the mouse central nervous system. Donnelly SM, et al. **Neuropathol Appl Neurobiol** 1997 Jun;23(3):235–41

Sindbis virus infection of neonatal mice results in a severe stress response. Trgovcich J, et al. **Virology** 1997 Jan 6; 227(1):234–8

PREVENTION & CONTROL

An ecological approach to public health intervention: Ross River virus in Australia. Weinstein P. **Environ Health Perspect** 1997 Apr;105(4):364–6

[Effectiveness of the interferon inducers ridostin and camedon in prevention and treatment of experimental alpha- and flavivirus infections] Barinskiĭ IF, et al. **Vopr Virusol** 1996 May-Jun;41(3):133–5 (Eng. Abstr.) **(Rus)**

VIROLOGY

bcl-2 acts early to restrict Semliki Forest virus replication and delays virus-induced programmed cell death. Scallan MF, et al. **J Virol** 1997 Feb;71(2):1583–90

Fatal Sindbis virus infection of neonatal mice in the absence of encephalitis. Trgovcich J, et al. **Virology** 1996 Oct 1; 224(1):73–83

Characterization of the infection of Aedes albopictus cell clones by Sindbis virus. Karpf AR, et al. **Virus Res** 1997 Jul;50(1):1–13

ALPORT'S SYNDROME see **NEPHRITIS, HEREDITARY**

ALPRAZOLAM

Alprazolam dependence prevented by substituting with the beta-carboline abecarnil. Pinna G, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2719–23

ADMINISTRATION & DOSAGE

Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics. Sheehan DV, et al. **Anxiety** 1996;2(1):40–6

Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients. Pols H, et al. **Biol Psychiatry** 1996 Nov 1;40(9):913–7

Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Hossain M, et al. **Pharm Res** 1997 Mar;14(3):309–15

[The efficiency of alprazolam for seasonal affective disorder (SAD, autumn/winter type)] Yamadera H, et al. **Nippon Ika Daigaku Zasshi** 1997 Feb;64(1):53–6 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Coma from the health food store: interaction between kava and alprazolam [letter] Almeida JC, et al. **Ann Intern Med** 1996 Dec 1;125(11):940–1

Alprazolam-induced hypomania. Reddy J, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):550–2

Allergy to tartrazine in alprazolam. Bhatia MS. **Indian J Med Sci** 1996 Aug;50(8):285–6

Two cases of alprazolam-induced hyperprolactinemia in patients with panic disorder. Shioiri T, et al. **Int Clin Psychopharmacol** 1996 Jun;11(2):149–52

Neuropathy associated with tricyclic antidepressants [letter] Benazzi F, et al. **Int J Geriatr Psychiatry** 1997 Aug; 12(8):868–9

Galactorrhoea induced by a pharmacodynamic interaction between citalopram, alprazolam and tramadol: a case report [letter] Bondolfi G, et al. **Therapie** 1997 Jan–Feb;52(1):76–7

ANALOGS & DERIVATIVES

Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values [see comments] Fraser AD, et al. **J Anal Toxicol** 1996 Jul-Aug; 20(4):217–23. Comment in: J Anal Toxicol 1997 Jan–Feb;21(1):76.

Determination of alprazolam and alpha-hydroxyalprazolam in human plasma by gas chromatography/negative-ion chemical ionization mass spectrometry. Höld KM, et al. **J Mass Spectrom** 1996 Sep;31(9):1033–8

ANALYSIS

Detection of alprazolam in hair by negative ion chemical ionization mass spectrometry. Höld KM, et al. **Forensic Sci Int** 1997 Jan 17;84(1–3):201–9

Enhanced detection of benzodiazepines by immunoassay [letter; comment] Bellet N. **J Anal Toxicol** 1997 Jan–Feb; 21(1):76. Comment on: J Anal Toxicol 1996 Jul-Aug;20(4):217–23.

BLOOD

High-performance liquid chromatography of alprazolam in postmortem blood using solid-phase extraction. Hall MA, et al. **J Anal Toxicol** 1995 Oct;19(6):511–3

Detection of alprazolam in three cases of methadone/benzodiazepine overdose. Rogers WO, et al. **J Forensic Sci** 1997 Jan;42(1):155–6

DIAGNOSTIC USE

New diagnostic tests for Cushing's syndrome: uses of naloxone, vasopressin and alprazolam. Jackson RV, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6–7):579–81

METABOLISM

Alprazolam hydroxylation by mouse liver microsomes in vitro: the effect of age and phenobarbital induction. Charpentier KP, et al. **Biopharm Drug Dispos** 1997 Mar; 18(2):139–49

PHARMACOKINETICS

Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. Otani K, et al. **Int Clin Psychopharmacol** 1997 May;12(3):153–7

Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship. Wright CE, et al. **J Clin Pharmacol** 1997 Apr;37(4):321–9

Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes. Cotreau-Bibbo MM, et al. **J Pharm Sci** 1996 Nov;85(11):1180–5

Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam. Otani K, et al. **Neuropsychopharmacology** 1997 Jan;16(1):8–14

[The relationship between single-oral dose kinetics of alprazolam and cytochrome P4503A and cytochrome P4502C19] Yasui N. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):109–12 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder. Klein E, et al. **Acta Psychiatr Scand** 1995 Dec;92(6):399–408

Antinociceptive interaction between alprazolam and opioids. Pick CG. **Brain Res Bull** 1997;42(3):239–43

Effect of alprazolam on opiate withdrawal: a combined behavioural and microdialysis study. Gray AM. **Eur J Pharmacol** 1996 Oct 10;313(1–2):73–7

Strain differences in mice antinociception: relationship between alprazolam and opioid receptor subtypes. Pick CG. **Eur Neuropsychopharmacol** 1996 Aug;6(3):201–5

Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Rush CR, et al. **Exp Clin Psychopharmacol** 1997 Feb;5(1):28–38

A novel tool to quantify physical activities: ambulatory accelerometry in psychopharmacology. Tulen JH, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):202–7

Tolerance to the anxiolytic effects of the triazolobenzodiazepines triazolam and alprazolam, as measured by the ingestion of a hypertonic sodium chloride solution in rats. Barbarito EJ, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1201–8

Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects. Bertz RJ, et al. **J Pharmacol Exp Ther** 1997 Jun; 281(3):1317–29

Differential reinforcement of low rate performance, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling: independent interaction of alprazolam and caffeine. Lau CE, et al. **J Pharmacol Exp Ther** 1997 Jun; 281(3):1013–29

Hypoglycemia-induced inhibition of LH and stimulation of ACTH secretion in the rhesus monkey is blocked by alprazolam. Van Vugt DA, et al. **Neuroendocrinology** 1997 May;65(5):344–52

Effects of alprazolam and bromazepam on visual search and verbal recognition memory in humans: a study with event-related brain potentials. Münte TF, et al. **Neuropsychobiology** 1996;34(1):49–56

Catecholaminergic, neuroendocrine and anxiety responses to acute psychological stress in healthy subjects: influence of alprazolam administration. Santagostino G, et al. **Neuropsychobiology** 1996;34(1):36–43

Assessment of the anxiolytic and amnesic effects of three benzodiazepines, diazepam, alprazolam and triazolam, by conflict and non-matching to sample tests in mice. Kuribara H, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Feb;17(1):1–6

Anticonflict effect of alpidem as compared with the benzodiazepine alprazolam in rats. Hascoët M, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):317–24

Alprazolam increases food intake in humans. Haney M, et al. **Psychopharmacology (Berl)** 1997 Aug;132(3):311–4

Alprazolam, caffeine and their interaction: relating DRL performance to pharmacokinetics. Lau CE, et al. **Psychopharmacology (Berl)** 1996 Jul;126(2):115–24

Effects of alprazolam and lorazepam on catecholaminergic and cardiovascular activity during supine rest, mental load and orthostatic challenge. van den Berg F, et al. **Psychopharmacology (Berl)** 1996 Nov;128(1):21–30

POISONING

Detection of alprazolam in three cases of methadone/benzodiazepine overdose. Rogers WO, et al. **J Forensic Sci** 1997 Jan;42(1):155–6

THERAPEUTIC USE

Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder. Klein E, et al. **Acta Psychiatr Scand** 1995 Dec;92(6):399–408

A naturalistic 6-year follow-up study of patients with panic disorder. Lepola U, et al. **Acta Psychiatr Scand** 1996 Mar; 93(3):181–3

Personality dimensions in panic disorder before and after effective treatment. Starcevic V, et al. **Anxiety** 1996; 2(2):95–8

Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Curtis GC, et al. **Biol Psychiatry** 1997 Jan 1;41(1):76–85

Alprazolam-reinforced medication use in outpatients with anxiety. Roache JD, et al. **Drug Alcohol Depend** 1997 May 2;45(3):143–55

Alprazolam in chronic tension type headache. Shukla R, et al. **J Assoc Physicians India** 1996 Sep;44(9):641–4

Alprazolam and suicidal ideation: a meta-analysis of controlled trials in the treatment of depression [see comments] Jonas JM, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):208–11. Comment in: J Clin Psychopharmacol 1997 Aug;17(4):328; discussion 329.

Reevaluation of "Alprazolam and suicidal ideation: a meta-analysis of controlled trials in the treatment of depression" [letter; comment] Yoo K, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):328; discussion 329 . Comment on: J Clin Psychopharmacol 1996 Jun;16(3):208–11.

Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect. Srisurapanont M, et al. **J Med Assoc Thai** 1997 Mar; 80(3):183–8

Hypothalamic-pituitary-adrenal axis activity in panic disorder: effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. Abelson JL, et al. **J Psychiatr Res** 1996 Mar-Apr;30(2):79–93

Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment. Kiliç C, et al. **Psychother Psychosom** 1997;66(4):175–8

[Alprazolam in the treatment of anxiety disorders and mixed anxiety and depressive disorders. Results of multicenter clinical trial] Kiejna A, et al. **Psychiatr Pol** 1996 Nov-Dec; 30(6):973–92 (Eng. Abstr.) **(Pol)**

URINE

Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values [see comments] Fraser AD, et al. **J Anal Toxicol** 1996 Jul-Aug; 20(4):217–23. Comment in: J Anal Toxicol 1997 Jan–Feb;21(1):76.

ALPRENOLOL

ANALOGS & DERIVATIVES

The effects of bromoacetylalprenololmenthane on the responses to isoprenaline of the left ventricle from normo-, prehyper- and hypertensive rats. Doggrell SA, et al. **J Auton Pharmacol** 1997 Jun;17(3):183–90

Relationship between desensitization and downregulation of beta-adrenoceptors in cardiac tissues after prolonged in vivo infusion of T-0509, a beta 1-adrenoceptor agonist. Sato Y, et al. **Jpn J Pharmacol** 1997 Apr;73(4):325–32

METABOLISM

Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine1A receptor. Kuipers W, et al. **Mol Pharmacol** 1997 May; 51(5):889–96

PHARMACOLOGY

Modulation of honey bee thermoregulation by adrenergic compounds. Belzunces LP, et al. **Neuroreport** 1996 Jul 8; 7(10):1601–4

(-)Alprenolol potentiates the disrupting effects of dizocilpine on sensorimotor function in the rat. Zhang J, et al. **Psychopharmacology (Berl)** 1997 Aug;132(3):281–8

ALPROSTADIL

cAMP-mediated vascular protection in an orthotopic rat lung transplant model. Insights into the mechanism of action of prostaglandin E1 to improve lung preservation. Naka Y, et al. **Circ Res** 1996 Oct;79(4):773–83

Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Belch JJ, et al. **Circulation** 1997 May 6; 95(9):2298–302

Prostaglandin fever in rats throughout the estrous cycle late pregnancy and post parturition. Martin SM, et al.

J Neuroendocrinol 1996 Feb;8(2):145–51

[The effect of epidural anesthesia with combined use of vasodilator on hemodynamics and stress hormone levels during hepatectomy] Arai M, et al. **Masui** 1997 Feb; 46(2):158–65 (Eng. Abstr.) **(Jpn)**

[Prostagrandin E1–induced hypotension well maintains cerebral circulation and carbon dioxide reactivity in non–neurosurgical patients under sevoflurane–anesthesia] Hotta K, et al. **Masui** 1997 Feb;46(2):193–8 (Eng. Abstr.) **(Jpn)**

[Cerebral blood volume, cerebral hemoglobin and cytochrome AA3 during hypotension induced by prostaglandin E1 or epidural anesthesia under general anesthesia] Shinohara M, et al. **Masui** 1996 Aug;45(8):961–6 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Reduction of canine infarct size by bolus intravenous administration of liposomal prostaglandin E1: comparison with control, placebo liposomes, and continuous intravenous infusion of prostaglandin E1. Feld S, et al. **Am Heart J** 1996 Oct;132(4):747–57

Comparison of stellate ganglion block with intravascular infusion of prostaglandin E1 on brachial artery blood flow in dogs. Okuda Y, et al. **Anesth Analg** 1997 Jun; 84(6):1329–32

Topical administration of prostaglandin E1 with iontophoresis for skin flap viability. Asai S, et al. **Ann Plast Surg** 1997 May;38(5):514–7

Intracavernosal drug–induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction. Soderdahl DW, et al. **Br J Urol** 1997 Jun; 79(6):952–7

Prostaglandin E1––bridge to cardiac transplantation. Technique, dosage, results. Pacher R, et al. **Eur Heart J** 1997 Feb;18(2):318–29

Progress in the prostaglandin E1–therapy of the intermittent claudication by means of bolus injections of LIPO–prostaglandin E1 (LIPO–PGE1). Scheffler P, et al. **Eur J Clin Pharmacol** 1996;51(3–4):235–9

Metabolism studies on transdermal prostaglandin E1 in human foreskin in vitro. Foldvari M, et al. **Eur J Drug Metab Pharmacokinet** 1997 Apr–Jun; 22(2):111–20

Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Walmrath D, et al. **Eur Respir J** 1997 May;10(5):1084–92

Lipo–PGE1, prostaglandin E1 incorporated in lipid microspheres, protects injury of the liver caused by warm ischemia reperfusion. Egashira T, et al. **Free Radic Biol Med** 1996;21(3):353–6

Chemolipiodolization and prostaglandin E1 administration with use of hepatic arterial infusion port for the treatment of hepatocellular carcinoma and liver cirrhosis. Kakizoe S, et al. **Hepatogastroenterology** 1996 Sep–Oct; 43(11):1377–82

Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction [see comments] Bechara A, et al. **J Urol** 1997 Jun;157(6):2132–4. Comment in: J Urol 1997 Jun;157(6):2139.

Diffuse veno–occlusive dysfunction: the underlying hemodynamic abnormality resulting in failure to respond to intracavernous pharmacotherapy [see comments] Martins FE, et al. **J Urol** 1996 Dec;156(6):1942–6. Comment in: J Urol 1996 Dec;156(6):1951.

Recovery of spontaneous erectile function after nerve–sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. Montorsi F, et al. **J Urol** 1997 Oct;158(4):1408–10

Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo–controlled double–blind trial. Diehm C, et al. **J Vasc Surg** 1997 Mar;25(3):537–44

Dose–effect relationships of prostaglandin E1 in severe endstage chronic heart failure. Stanek B, et al. **Jpn Heart J** 1997 Jan;38(1):53–65

Intraurethral alprostadil for impotence. **Med Lett Drugs Ther** 1997 Mar 28;39(997):32

Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group [see comments] Padma–Nathan H, et al. **N Engl J Med** 1997 Jan 2; 336(1):1–7. Comment in: ACP J Club 1997 Jul–Aug;127(1):7.

Effect of prostaglandin E1 infusion in severe chronic heart failure. Pacher R, et al. **Prostaglandins** 1997 Apr; 53(4):221–35

Long–term experience of self–injection therapy with prostaglandin E1 for erectile dysfunction. Lundberg L, et al. **Scand J Urol Nephrol** 1996 Oct;30(5):395–7

Special precautions to be observed while using alprostadil in patients with spinal cord injury [letter] Vaidyanathan S, et al. **Spinal Cord** 1997 Jun;35(6):402–3

Omental delivery of prostaglandin E1 effectively increases portal venous blood flow in 66%–hepatectomized rats. Aono T, et al. **Surg Today** 1997;27(5):473–6

Beneficial effects of administering intraportal prostaglandin E1 postoperatively to hepatectomy patients with massive intraoperative blood loss. Katsuramaki T, et al. **Surg Today** 1996;26(11):895–9

Platelet response during prostaglandin E1–therapy in patients with non–insulin–dependent diabetes mellitus. Kritz H, et al. **Thromb Res** 1997 Jul 15;87(2):257–61

Prophylactic administration of prostaglandin E1 in liver transplantation: results of a pilot trial. Giostra E, et al. **Transplant Proc** 1997 Aug;29(5):2381–4

Efficacy of intraportal infusion of prostaglandin E1 to improve the hepatic blood flow and graft viability in porcine liver transplantation. Kawachi S, et al. **Transplantation** 1997 Jul 27;64(2):205–9

A double–blind, placebo–controlled evaluation of the erectile response to transurethral alprostadil. Hellstrom WJ, et al. **Urology** 1996 Dec;48(6):851–6

Improvement in the quality of life after i.v. PGE1 therapy for intermittent claudication. Creutzig A, et al. **Vasa** 1997 May;26(2):122–7

Effects of adjuvant PGE1 therapy following profundaplasty in patients with severe limb ischaemia. Early and long–term results. Gruss JD. **Vasa** 1997 May;26(2):117–21

Acceptance of a pump–driven infusion therapy with prostaglandin E1 as a bridge to heart transplantation. Daneschvar H, et al. **Wien Klin Wochenschr** 1996; 108(16):510–4

[Dose adaptation during training of intracavernous self–injections of prostaglandin E1] Staerman F, et al. **Prog Urol** 1996 Aug–Sep;6(4):564–8 (Eng. Abstr.) **(Fre)**

[Prostaglandin E1 (PGE1) in diagnosis and long–term therapy of erectile dysfunction] Derouet H, et al. **Urologe A** 1996 Jan;35(1):62–7 (Eng. Abstr.) **(Ger)**

[Effect of prostaglandin E1 on extravascular lung water in patients with severe heart failure] Lenz K, et al. **Wien Klin Wochenschr** 1996;108(16):505–9 (Eng. Abstr.) **(Ger)**

[Some aspects of the use of prostaglandin E1 in cases of erectile dysfunction] Fekete F. **Orv Hetil** 1997 Jun 22; 138(25):1631–4 (Eng. Abstr.) **(Hun)**

[Clinical effect of intra–arterial carboplatin–combined chemotherapy for advanced uterine cervical cancer and increased tissue platinum levels with Lipo PGE1 administration before chemotherapy] Takeda S, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1697–703 (Eng. Abstr.) **(Jpn)**

[Prevention of postoperative liver dysfunction by intraoperative administration of PGE1 and dopamine] Arai T, et al. **Masui** 1996 Dec;45 Suppl:S79–85 **(Jpn)**

[The effect of low–dose prostaglandin E1 on intra– and post–operative renal function] Hayashida M, et al. **Masui** 1997 Apr;46(4):464–70 (Eng. Abstr.) **(Jpn)**

[The effect of low–rose prostaglandin E1 on circulation, respiration and body temperature during surgical anesthesia] Hayashida M, et al. **Masui** 1997 Mar; 46(3):363–72 (Eng. Abstr.) **(Jpn)**

[The effect of low–dose prostaglandin E1 on intra– and post–operative liver function] Hayashida M, et al. **Masui** 1997 May;46(5):618–27 (Eng. Abstr.) **(Jpn)**

[The effect of vasodilator on the occurrence of postoperative shivering and the fall of core temperature] Kabutan K, et al. **Masui** 1997 May;46(5):669–73 (Eng. Abstr.) **(Jpn)**

[Prostaglandin E1 at low–doses improved right ventricular ejection fraction in anesthetic management for CABG] Oohata H, et al. **Masui** 1996 Oct;45(10):1272–7 (Eng. Abstr.) **(Jpn)**

[Statistical analysis of recovery from sudden deafness among treatment groups] Kitamura K, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Nov;99(11):1676–83 (Eng. Abstr.) **(Jpn)**

[The intracavernous injection of Edex (prostaglandin E1) in the treatment of erectile impotence in persons in older age groups] Gorilovskiĭ LM. **Urol Nefrol (Mosk)** 1996 Nov–Dec;(6):31–3 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Bone and tissue changes following prostaglandin therapy in neonates. Kaufman MB, et al. **Ann Pharmacother** 1996 Mar; 30(3):269–74, 277 (29 ref.)

Combined effects of prolonged prostaglandin E1–induced hypotension and haemodilution on human hepatic function. Fukusaki M, et al. **Eur J Anaesthesiol** 1997 Mar; 14(2):157–63

Cortical hyperostosis simulating osteomyelitis after short–term prostaglandin E1 infusion. Kalloghlian AK, et al. **Eur J Pediatr** 1996 Mar;155(3):173–4

Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1. Buvat J, et al. **Int J Impot Res** 1996 Jun;8(2):41–6

Characteristics of pain following intracavernous injection of prostaglandin E1. Kim SC, et al. **J Korean Med Sci** 1997 Aug;12(4):327–31

Prostaglandin E1–induced hyperostosis: clinicopathologic correlations and possible pathogenetic mechanisms. Faye–Petersen OM, et al. **Pediatr Pathol Lab Med** 1996 May–Jun;16(3):489–507

Acute gastric outlet obstruction following the administration of prostaglandin: an additional case. Kobayashi N, et al. **Pediatr Radiol** 1997 Jan;27(1):57–9

Relation of gastric distention to prostaglandin therapy in neonates. Kriss VM, et al. **Radiology** 1997 Apr; 203(1):219–21

Myocardial infarction associated with intra–cavernosal administration of alprostadil in a patient with spinal cord injury and paraplegia [letter] Vaidyanathan S, et al. **Spinal Cord** 1996 Dec;34(12):754–5

[Falls in PaO2 owing to prostaglandin E1 infusion in an obese patient undergoing laparoscopic cholecystectomy––detection by intra–arterial blood gas monitoring] Koitabashi T, et al. **Masui** 1997 Feb; 46(2):258–61 (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

A randomized trial of 2 regimens for the administration of vaginal prostaglandins (gemeprost) for the induction of midtrimester abortion. Armatage RJ, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):296–9

Prolonged induction to delivery time in termination of pregnancy using 16, 16–dimethyl–PGE1–methyl ester (gemeprost) for fetuses with a neural tube defect or hydrocephalus. Nesbitt D, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):300–3

Termination of early human pregnancy with either 50 mg or 200 mg single oral dose of mifepristone (RU486) in combination with either 0.5 mg or 1.0 mg vaginal gemeprost. Prasad RN, et al. **Aust N Z J Obstet Gynaecol** 1996 Feb;36(1):20–3

The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study––final results. **Contraception** 1997 Jan;55(1):1–5

Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: a randomised comparative trial. Ho PC, et al. **Contraception** 1996 May;53(5):281–3

A randomised study of two doses of gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. Thong KJ, et al. **Contraception** 1996 Aug;54(2):97–100

Termination of second trimester pregnancy with gemeprost and misoprostol: a randomized double–blind placebo–controlled trial. Wong KS, et al. **Contraception** 1996 Jul;54(1):23–5

Prostaglandins increase proMMP–1 and proMMP–3 secretion by human ciliary smooth muscle cells. Lindsey JD, et al. **Curr Eye Res** 1996 Aug;15(8):869–75

Interindividual variation in the enzymatic 15–keto–reduction of 13,14–dihydro–15–keto–prostaglandin E1 in human liver and in human erythrocytes. Rady–Pentek P, et al. **Eur J Clin Pharmacol** 1997;52(2):147–53

The prostaglandin analogs, misoprostol and SC–46275, potently inhibit cytokine release from activated human monocytes. Widomski D, et al. **Immunopharmacol Immunotoxicol** 1997 May;19(2):165–74

The use of a synthetic prostaglandin E1 analog as a gastric protectant against aspirin–induced hemorrhage in the dog. Bowersox TS, et al. **J Am Anim Hosp Assoc** 1996 Sep–Oct; 32(5):401–7

Analysis of localization of adult T–cell leukemia–derived factor in the transient ischemic rat retina after treatment with OP–1206 alpha–CD, a prostaglandin E1 analogue. Yamamoto M, et al. **J Histochem Cytochem** 1997 Jan; 45(1):63–70

Effects of OP–1206 (prostaglandin E1) on nerve–conduction velocity in the dog cauda equina subjected to acute experimental compression. Konno S, et al. **J Spinal Disord** 1996 Apr;9(2):103–6

Functional analysis and chromosomal gene assignment of rat kidney prostaglandin EP3 receptor. Takeuchi K, et al. **Kidney Int Suppl** 1996 Jun;55:S183–6

Membrane depolarization by activation of prostaglandin E receptor EP3 subtype of putative serotonergic neurons in the dorsal raphe nucleus of the rat. Momiyama T, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Mar; 353(4):377–81

Anti–inflammatory effects of beraprost sodium, a stable analogue of PGI2, and its mechanisms. Ueno Y, et al. **Prostaglandins** 1997 Apr;53(4):279–89

[Current method for pregnancy termination with prostaglandins in the 2nd and 3rd trimester] Winkler M, et al. **Z Geburtshilfe Neonatol** 1997 Mar–Apr;201(2):39–43 **(Ger)**

[Stereochemistry of substituting the allyl hydroxyl group with fluorine atom in prostaglandins. Synthesis of 15–fluoro–11,15–dideoxyprostaglandins E1] Bezuglov VV, et al. **Bioorg Khim** 1996 Oct–Nov;22(10–11):814–22 (Eng. Abstr.) **(Rus)**

[Comparative study of misoprostol and nifedipine in the treatment of Raynaud's phenomenon secondary to systemic diseases. Hemodynamic assessment with Doppler duplex] Varela–Aguilar JM, et al. **Rev Clin Esp** 1997 Feb; 197(2):77–83 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

In vivo formation of prostaglandin E1 and prostaglandin E2 in atopic dermatitis. Leonhardt A, et al. **Br J Dermatol** 1997 Mar;136(3):337–40

CHEMISTRY

Association and release of prostaglandin E1 from liposomes. Davidson SM, et al. **Biochim Biophys Acta** 1997 Jul 5; 1327(1):97–106

DIAGNOSTIC USE

Natural erection induced by prostaglandin–E1 in the diagnosis and treatment of congenital penile anomalies. Perovic S, et al. **Br J Urol** 1997 Jan;79(1):43–6

ALPROSTADIL

[Usefulness of prostaglandin E1 in the diagnosis of corpora cavernosa fracture. Report of a case] Rodríguez de Ledesma Vega JM, et al. **Arch Esp Urol** 1997 Apr; 50(3):302–4 (Eng. Abstr.) **(Spa)**

METABOLISM

Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells. Schrör K, et al. **Agents Actions Suppl** 1997;48:63–91 (123 ref.)

Effects of hypoxia and hyperoxia on lung prostaglandin E1 metabolism. Pisarello JB, et al. **Am J Med Sci** 1997 Mar; 313(3):147–52

Analysis of effects of adrenaline and collagen on the activity of prostaglandin E1–stimulated human platelet adenylyl cyclase. Juška A. **Blood Coagul Fibrinolysis** 1996 Mar; 7(2):199–201

Morphine dependence in human neuroblastoma SH–SY5Y cells is associated with adaptive changes in both the quantity and functional interaction of PGE1 receptors and stimulatory G proteins. Ammer H, et al. **Brain Res** 1996 Jan 29;707(2):235–44

Metabolism studies on transdermal prostaglandin E1 in human foreskin in vitro. Foldvari M, et al. **Eur J Drug Metab Pharmacokinet** 1997 Apr–Jun; 22(2):111–20

PHARMACOKINETICS

Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short–term infusion of prostaglandin E1 in patients with erectile dysfunction. Cawello W, et al. **J Urol** 1997 Oct; 158(4):1403–7

PHARMACOLOGY

Improvement of arterial oxygenation by selective infusion of prostaglandin E1 to ventilated lung during one–lung ventilation [see comments] Chen TL, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):7–13. Comment in: Acta Anaesthesiol Scand 1996 Jan;40(1):2–4.

Protective effects of prostaglandin E1 on acute lung injury of caerulein–induced acute pancreatitis in rats. Yamanaka K, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):G23–30

Regulation of magnesium efflux from rat spleen lymphocytes. Wolf FI, et al. **Arch Biochem Biophys** 1997 Aug 15; 344(2):397–403

Inhibitory effect of prostaglandin E1 on intimal thickening following photochemically induced endothelial injury in the rat femoral artery. Umemura K, et al. **Atherosclerosis** 1997 Apr;130(1–2):11–6

Cytochrome P–450 and free radical generation in rat liver microsomes under the influence of prostaglandin E1. Buko VU, et al. **Biochem Mol Biol Int** 1996 Aug;39(6):1177–84

Platelet aggregation, sensitivity to prostaglandin E1 and thromboxane A2 release in recombinant hirudin– and heparin–anticoagulated blood. Viigimaa M, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):259–61

Promotion of the osteogenetic activity of recombinant human bone morphogenetic protein by prostaglandin E1. Ono I, et al. **Bone** 1996 Dec;19(6):581–8

Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers. Sobhani I, et al. **Br J Clin Pharmacol** 1996 Feb;41(2):109–14

Inhibition of purinergic transmission by prostaglandin E1 and E2 in the guinea–pig vas deferens: an electrophysiological study. Brock JA, et al. **Br J Pharmacol** 1996 Jun; 118(3):776–82

Role of potassium channels and nitric oxide in the effects of iloprost and prostaglandin E1 on hypoxic vasoconstriction in the isolated perfused lung of the rat. Dumas M, et al. **Br J Pharmacol** 1997 Feb;120(3):405–10

Prostaglandin E1 potentiation of the spontaneous phasic contraction of rat isolated portal vein by a cyclopiazonic acid–sensitive mechanism. Miwa T, et al. **Br J Pharmacol** 1997 Apr;120(8):1419–26

Effects of agents which elevate cyclic AMP on guinea–pig eosinophil homotypic aggregation. Teixeira MM, et al. **Br J Pharmacol** 1996 Aug;118(8):2099–106

Prostaglandin E1 attenuates the hypertensive response to tracheal extubation. Nishina K, et al. **Can J Anaesth** 1996 Jul;43(7):678–83

Prostaglandin E1 stimulates interleukin–6 secretion via protein kinase A in osteoblast–like cells. Watanabe–Tomita Y, et al. **Cell Signal** 1997 Jan;9(1):105–8

Quantification of actively transcribing RNA polymerase B molecules in human sperm chromatin and the effect of prostaglandin E1. Pironcheva GL, et al. **Cytobios** 1996; 88(352):7–10

The influence of prostaglandin E1 on in vitro transcription of sperm chromatin from healthy males. Pironcheva GL, et al. **Cytobios** 1996;88(353):79–82

Acute haemodilution and prostaglandin E1–induced hypotension: effects on the coagulation–fibrinolysis system. Fukusaki M, et al. **Eur J Anaesthesiol** 1997 Jul;14(4):443–9

Prostaglandin E1 decreases human arterial accumulation of radiolabeled apo B–containing lipoproteins in vivo. Kritz H, et al. **Eur J Clin Pharmacol** 1997;52(3):191–7

Effects of prostaglandins and cyclic AMP on cytokine production in rat leukocytes. Oh–ishi S, et al. **Eur J Pharmacol** 1996 Apr 11;300(3):255–9

Effects of beraprost sodium and prostaglandin E1 on skin blood flow in diabetic rats and normal dogs. Ueno Y, et al. **Gen Pharmacol** 1996 Mar;27(2):333–5

Effect of prostaglandin E1 on the rat inner ear microvascular thrombosis. Umemura K, et al. **Gen Pharmacol** 1997 Feb; 28(2):221–4

Prostaglandin E1, E2, and cholera toxin increase transcription of the brain creatine kinase gene in human U87 glioblastoma cells. Kuzhikandathil EV, et al. **Glia** 1995 Dec;15(4):471–9

Prostaglandin E1 (PGE1) reduces cardiac–derived TXA2 release in ischaemic arrest in isolated working rat heart. Feng J, et al. **Int J Cardiol** 1996 Aug;55(3):265–70

Prostaglandin E1 reduces the glomerular mRNA expression of monocyte–chemoattractant protein 1 in anti–thymocyte antibody–induced glomerular injury. Jocks T, et al. **J Am Soc Nephrol** 1996 Jun;7(6):897–905

PGE1, dexamethasone, U–74389G, or Bt2–cAMP as an additive to promote protection by UW solution in I/R injury. Chiang CH, et al. **J Appl Physiol** 1997 Aug; 83(2):583–90

Influence of pregnancy on the febrile response to ICV administration of PGE1 in rats studied in a thermocline. Eliason HL, et al. **J Appl Physiol** 1997 May;82(5):1453–8

Influence of pregnancy on the febrile response to intracerebroventricular administration of PGE1 in rats. Stobie–Hayes KM, et al. **J Appl Physiol** 1996 Sep; 81(3):1312–5

Role of protein kinase A in collagenase–1 gene regulation by prostaglandin E1: studies in a rabbit synoviocyte cell line, HIG–82. Suzuki K, et al. **J Bone Miner Res** 1997 Apr; 12(4):561–7

Effect of aging on arteriolar dilatation induced by prostaglandin E(1) incorporated in lipid microspheres. Hirose M, et al. **J Cardiovasc Pharmacol** 1996 May; 27(5):749–51

Does prostaglandin E1 infusion affect the left ventricular filling pattern of end–stage dilated cardiomyopathy? A combined hemodynamic–echo Doppler study. Marino P, et al. **J Cardiovasc Pharmacol** 1997 Feb;29(2):188–95

Catecholamine and renin–angiotensin response during controlled hypotension induced by prostaglandin E1 combined with hemodilution during isoflurane anesthesia. Fukusaki M, et al. **J Clin Anesth** 1997 Jun;9(4):321–7

Effects of vasodilators guanethidine, nicardipine, nitroglycerin, and prostaglandin E1 on primary afferent nociceptors in humans. Mashimo T, et al. **J Clin Pharmacol** 1997 Apr;37(4):330–5

Effects of prostaglandin E1 on cultured dermal fibroblasts from normal and hypertrophic scarred skin. Zhou LJ, et al. **J Dermatol Sci** 1997 Mar;14(3):217–24

Retrograde flush and cold storage for twenty–two to twenty–five hours lung preservation with and without prostaglandin E1. Chen CZ, et al. **J Heart Lung Transplant** 1997 Jun;16(6):658–66

Dietary gamma–linolenic acid enhances mouse macrophage–derived prostaglandin E1 which inhibits vascular smooth muscle cell proliferation. Fan YY, et al. **J Nutr** 1997 Sep;127(9):1765–71

Synergistic inhibition of human polymorphonuclear function by prostaglandin E1 and linsidomine. Gladis–Villanueva M, et al. **J Pharm Pharmacol** 1996 Jul;48(7):706–11

NG methyl–L–arginine increases the hyperthermic effects of prostaglandin E1. Monda M, et al. **J Physiol Paris** 1996; 90(2):79–83

Prostaglandin E1 resuscitates hepatic organic anion transport independent of its hemodynamic effect after warm ischemia. Shinohara H, et al. **J Surg Res** 1997 Feb 15; 68(1):56–62

Indocyanine green disappearance enhanced by prostaglandin E1 in patients with hepatic resection. Tsukada K, et al. **J Surg Res** 1996 Nov;66(1):64–8

A positive pharmacological erection test does not rule out arteriogenic erectile dysfunction [see comments] Cormio L, et al. **J Urol** 1996 Nov;156(5):1628–30. Comment in: J Urol 1996 Nov;156(5):1636.

Prostaglandin E1 inhibits collagen expression in anti–thymocyte antibody–induced glomerulonephritis: possible role of TGF beta. Schneider A, et al. **Kidney Int** 1996 Jul;50(1):190–9

The transcriptional repressor ICER and cAMP–induced programmed cell death. Ruchaud S, et al. **Oncogene** 1997 Aug 14;15(7):827–36

Evaluation of cyclic AMP accumulation in EBV–transformed human B–lymphocytes: effects of dopamine agonists, isoproterenol, prostaglandin E1, cholera toxin, forskolin, and phorbol 12–myristate–13 acetate. Natsukari N, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jan; 20(1):99–108

Prostaglandin E1 decreases circulating endothelial cells. Sinzinger H, et al. **Prostaglandins** 1996 Jan;51(1):61–8

PGE1 or PGE2 not LH regulates secretion of progesterone in vitro by the 88–90 day ovine corpus luteum of pregnancy. Weems YS, et al. **Prostaglandins** 1997 May; 53(5):337–53

Prostanoid modulation of glucose transport in isolated diabetic rat uterus. González ET, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Apr; 54(4):293–6

Okadaic acid enhances prostaglandin E1–induced alkaline phosphatase activity in osteoblast–like cells: regulation at a point downstream from protein kinase A. Ito Y, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Nov; 55(5):357–61

PGE1–induced arterial thromboresistance is a vascular property as identified by cross–perfusion technique. Sinzinger H, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Apr; 56(4):325–30

Use of prostaglandin E1 during preparation of platelet concentrates. Hawker RJ, et al. **Transfus Med** 1996 Sep; 6(3):249–54

Beneficial effects of prostaglandin E1 on hemodynamic changes during liver transplantation in pigs. Oishi M, et al. **Transpl Int** 1996;9 Suppl 1:S100–4

Intraportal infusion of prostaglandin E1 improves graft viability after orthotopic liver transplantation in pigs. Kawachi S, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):374–5

Effect of dopamine, norepinephrine, and prostaglandin–E1 on graft perfusion in small bowel transplantation in pigs. Majno PE, et al. **Transplant Proc** 1996 Oct;28(5):2549–50

Successful long–term xenoperfusion of the pig liver: continuous administration of prostaglandin E1 and insulin. Terajima H, et al. **Transplantation** 1997 Feb 27;63(4):507–12

[Effects of prostaglandin E1 on transient forebrain ischemia, especially in hippocampal CA 1 regions of the gerbil] Abe H, et al. **Masui** 1996 Oct;45(10):1216–22 (Eng. Abstr.) **(Jpn)**

[The effect of low–dose prostaglandin E1 on serum and urinary fluoride concentrations in patients anesthetized with sevoflurane] Hayashida M, et al. **Masui** 1997 Jun; 46(6):736–42 (Eng. Abstr.) **(Jpn)**

[The effect of prostaglandin E1 on body temperature, catecholamines and stress hormones during prolonged surgery] Okuda M, et al. **Masui** 1996 Jan;45(1):30–7 (Eng. Abstr.) **(Jpn)**

[Imbalance of blood flow induced by sympathetic block was corrected by prostaglandin E1] Okuda Y, et al. **Masui** 1996 Jan;45(1):27–9 (Eng. Abstr.) **(Jpn)**

[The effect of prostaglandin E1 on choleresis in the rat liver after relief of biliary obstruction] Ikeda T. **Nippon Shokakibyo Gakkai Zasshi** 1996 Nov;93(11):821–7 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Endogenous ADP prevents PGE1–induced tyrosine dephosphorylation of focal adhesion kinase in thrombin–activated platelets. Vostal JG, et al. **Biochim Biophys Acta** 1996 Nov 8;1314(1–2):1–12

STANDARDS

[The Alprostajil Reference Standard (Control 921) of the National Institute of Health Sciences] Kitajima A, et al. **Eisei Shikenjo Hokoku** 1994;(112):188–91 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Lipo–prostaglandin E1 therapy for livedo reticularis with ulceration [letter] Nonaka Y, et al. **Acta Derm Venereol** 1997 May;77(3):246–7

Antimitotic actions of vasodilatory prostaglandins––clinical aspects. Sinzinger H, et al. **Agents Actions Suppl** 1997; 48:92–106 (33 ref.)

A comparative study of the vasodilator effects of prostaglandin E1 in patients with pulmonary hypertension after mitral valve replacement and with adult respiratory distress syndrome. Kunimoto F, et al. **Anesth Analg** 1997 Sep;85(3):507–13

Hypothenar hammer syndrome successfully managed with intravenous prostaglandin E1 and heparin and with correction of the thrombogenic risk profile. A case report. Wieczorek I, et al. **Angiology** 1996 Nov;47(11):1111–6

Clinical effectiveness of an ointment containing prostaglandin E1 for the treatment of burn wounds. Gunji H, et al. **Burns** 1996 Aug;22(5):399–405

Randomized, double–blind, placebo–controlled study evaluating the efficacy and safety of AS–013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Belch JJ, et al. **Circulation** 1997 May 6; 95(9):2298–302

The use of alprostadil sterile powder in a home self–injection study of Asian men with erectile dysfunction. Wu CC, et al. **Clin Ther** 1996 Mar–Apr;18(2):256–64

Systemic lupus erythematosus with ischemic peripheral neuropathy and lupus anticoagulant: response to intravenous prostaglandin E1. Yoshikawa Y, et al. **Cutis** 1996 Dec;58(6):393–6 (8 ref.)

Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Walmrath D, et al. **Eur Respir J** 1997 May;10(5):1084–92

Alprostadil sterile powder formulation for intracavernous treatment of erectile dysfunction. Colli E, et al. **Eur Urol** 1996;29(1):59–62

Lipo–PGE1, prostaglandin E1 incorporated in lipid microspheres, protects injury of the liver caused by warm ischemia reperfusion. Egashira T, et al. **Free Radic Biol Med** 1996;21(3):353–6

Prostaglandins in liver transplantation: a $50,000 bonus [letter; comment] Henley KS, et al. **Gastroenterology** 1997 Feb;112(2):670–1. Comment on: Gastroenterology 1996 Sep;111(3):710–5. Comment on: Gastroenterology 1996 Sep;111(3):819–20.

Prostaglandin E1 administration following orthotopic liver

transplantation: a randomized prospective multicenter trial [see comments] Klein AS, et al. **Gastroenterology** 1996 Sep; 111(3):710–5. Comment in: Gastroenterology 1996 Sep;111(3):819–20. Comment in: Gastroenterology 1997 Feb;112(2):670–1.

Anxiety–induced failure in erectile response to intracorporeal prostaglandin–E1 in non–organic male impotence: a new diagnostic approach. Aversa A, et al. **Int J Androl** 1996 Oct;19(5):307–13

The effect of prostaglandin E1 on experimental colitis in the rat. Terzioğlu T, et al. **Int J Colorectal Dis** 1997;12(2):63–6

A dose–response study of alprostadil sterile powder (S.Po.) (Caverject) for the treatment of erectile dysfunction in Korean and Indonesian men. Choi HK, et al. **Int J Impot Res** 1997 Mar;9(1):47–51

Experience with intracavernous PGE–1 in the treatment of erectile dysfunction: dose considerations and efficacy. Ismail M, et al. **Int J Impot Res** 1997 Mar;9(1):39–42

Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction. Meinhardt W, et al. **Int J Impot Res** 1996 Mar;8(1):5–7

Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure. Purvis K, et al. **Int J Impot Res** 1996 Mar;8(1):9–16

Acute and long–term effects of prostaglandin E1 assessed by clinical and microcirculatory parameters in critical limb ischemia: a pilot study. Stricker H, et al. **Int J Microcirc Clin Exp** 1996 Mar–Apr;16(2):57–63

Effective hyperbaric oxygenation with prostaglandin E1 for radiation cystitis and colitis after pelvic radiotherapy. Miura M, et al. **Int Urol Nephrol** 1996;28(5):643–7

Prostaglandin E1 ameliorates decreased tracheal blood flow after esophagectomy and aggressive upper mediastinal lymphadenectomy for esophageal carcinoma. Hasegawa S, et al. **J Am Coll Surg** 1996 Oct;183(4):371–6

Influence of prostaglandin E1 on tissue ischemia during surgical repair of the abdominal aorta. Gabriel A, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):201–6

Hemodynamic and neurohumoral effects of long–term prostaglandin E1 infusions in outpatients with severe congestive heart failure. Hülsmann M, et al. **J Heart Lung Transplant** 1997 May;16(5):556–62

Prostaglandin E1 inhibits platelet decrease after massive blood transfusions during major surgery: influence on coagulation cascade? Locker GJ, et al. **J Trauma** 1997 Mar; 42(3):525–31

Quality of life effects of alprostadil therapy for erectile dysfunction. Willke RJ, et al. **J Urol** 1997 Jun;157(6):2124–8

Intraurethral alprostadil for impotence. **Med Lett Drugs Ther** 1997 Mar 28;39(997):32

Spontaneous laser doppler flux distribution in ischemic ulcers and the effect of prostanoids: a crossover study comparing the acute action of prostaglandin E1 and iloprost vs saline. Gschwandtner ME, et al. **Microvasc Res** 1996 Jan; 51(1):29–38

Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report. Tang SF, et al. **Paraplegia** 1995 Dec;33(12):731–3

Effect of prostaglandin E1 infusion in severe chronic heart failure. Pacher R, et al. **Prostaglandins** 1997 Apr; 53(4):221–35

Ischemia and reperfusion injury: prevention of pulmonary hypertension and leukosequestration following lower limb ischemia. Bengisun J, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Feb; 56(2):117–20

Prostaglandin E1 in heart failure: the Vienna experience [editorial] Pacher R, et al. **Wien Klin Wochenschr** 1996; 108(16):491–5 (59 ref.)

[Pharmacologically induced erection—therapeutic use] Kirkeby HJ. **Ugeskr Laeger** 1996 Dec 9;158(50):7260–2 **(Dan)**

[Alprostadil (PGE 1) and cyclosporin A in treatment of vasculitis in rheumatoid arthritis] Peichl P, et al. **Z Rheumatol** 1997 Mar–Apr;56(2):89–91 (Eng. Abstr.) **(Ger)**

[Did the arrival of prostanoids modify therapeutic indications in peripheral obstructive arteriopathies? Considerations based on our experience] Cardia G, et al. **G Chir** 1997 May; 18(5):297–300 (Eng. Abstr.) **(Ita)**

[Short– and long–term evaluation of treatment of critical ischemia of the lower lim with PGE1 (alprostadyl alpha–cyclodestrine)] Amitrano M, et al. **Minerva Cardioangiol** 1996 Jul–Aug;44(7–8):391–6 (Eng. Abstr.) **(Ita)**

[Epidemiology and treatment of long–term male impotence] Andriani E, et al. **Minerva Cardioangiol** 1996 May; 44(5):237–42 (Eng. Abstr.) **(Ita)**

[Effects of PGE1 (alprostadil alpha–cyclodestrin) in a case of probable paraneoplastic thrombocytopenic purpura] Pettine G, et al. **Minerva Cardioangiol** 1996 Dec; 44(12):669–73 (Eng. Abstr.) **(Ita)**

[31P magnetic resonance spectroscopy: a noninvasive method for studying skeletal muscle metabolism in patients with arteriosclerosis obliterans of the vessels of the lower extremities and for assessing the efficacy of vasoprostan therapy] Sinitsyn VE, et al. **Ter Arkh** 1996;68(12):69–72 **(Rus)**

[PGE1 program in erectile dysfunction: etiopathogenic and pharmacologic aspects] Ruiz Rubio JL, et al. **Actas Urol Esp** 1996 Jul–Aug;20(7):636–9 (Eng. Abstr.) **(Spa)**

ALTEPLASE

ADMINISTRATION & DOSAGE

TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. Barbagelata NA, et al. **Am Heart J** 1997 Mar;133(3):273–82

Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. Bär FW, et al. **Am J Cardiol** 1997 Mar 15;79(6):727–32

Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Bearman SI, et al. **Blood** 1997 Mar 1;89(5):1501–6

High–dose, continuous r–TPA infusion for treatment of VOD [letter] Graphakos S, et al. **Bone Marrow Transplant** 1996 Nov;18(5):1026–8

Prospective randomized trial of high–dose bolus versus low–dose tissue plasminogen activator infusion in the management of acute limb ischaemia. Thrombolysis Study Group. Braithwaite BD, et al. **Br J Surg** 1997 May; 84(5):646–50

Long–term benefit of one thrombolytic over another [letter] Grobman BJ. **Circulation** 1997 Sep 16;96(6):2093

Accelerated TPA for treatment of prosthetic valve thrombosis. DeNofrio D, et al. **Clin Cardiol** 1996 Aug; 19(8):665–8

ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction. Malcolm AD, et al. **Eur Heart J** 1996 Oct; 17(10):1522–31

From thrombolysis to thrombogenesis in clinical practice: coronary ruptured plaque angiography. Gavaliatsis IP. **Int J Cardiol** 1996 Jul 5;55(1):103–5

A prospective, randomized, double–blind multicenter trial of a single bolus injection of the novel modified t–PA E6010 in the treatment of acute myocardial infarction: comparison with native t–PA. E6010 Study Group. Kawai C, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1447–53

Recombinant lys–plasminogen given before, but not after, recombinant tissue–type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis. Chen LY, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):283–9

The preparation of tissue–type Plasminogen Activator (t–PA) containing liposomes: entrapment efficiency and ultracentrifugation damage. Heeremans JL, et al. **J Drug Target** 1995;3(4):301–10

Pulse–spray treatment of subclavian and jugular venous thrombi with recombinant tissue plasminogen activator. Chang R, et al. **J Vasc Interv Radiol** 1996 Nov–Dec; 7(6):845–51

A comparison of continuous infusion of alteplase with double–bolus administration for acute myocardial infarction. The Continuous Infusion versus Double–Bolus Administration of Alteplase (COBALT) Investigators. **N Engl J Med** 1997 Oct 16;337(16):1124–30

Equivalence trials [editorial; comment] Ware JH, et al. **N Engl J Med** 1997 Oct 16;337(16):1159–61. Comment on: N Engl J Med 1997 Oct 16;337(16):1118–23.

Acute inferior vena cava thrombosis in a patient with membranous nephropathy treated by rt–PA lysis. Jeremiah P, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):195–7

Intra–aneurysmal GDC embolization followed by intrathecal tPA administration for poor–grade basilar tip aneurysm. Ezura M, et al. **Surg Neurol** 1997 Feb;47(2):144–7; discussion 147–8 (20 ref.)

Comparison of the recombinant Escherichia coli–produced protease domain of tissue–type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis. Martin U, et al. **Thromb Haemost** 1996 Dec;76(6):1096–101

Procoagulant properties of intravenous staphylokinase versus tissue–type plasminogen activator. Okada K, et al. **Thromb Haemost** 1996 Dec;76(6):857–9

An experimental model of intracranial hemorrhage during thrombolytic therapy with t–PA. Paoni NF, et al. **Thromb Haemost** 1996 May;75(5):820–6

Comparative effects of staphylokinase and alteplase in rabbit bleeding time models. Vanderschueren S, et al. **Thromb Haemost** 1996 May;75(5):816–9

High and constant plasma levels of tissue plasminogen activator and PEG–hirudin can be achieved by subcutaneous delivery. Humphries J, et al. **Thromb Res** 1997 Jul 1;87(1):123–9

Local treatment of venous ulcers with tissue type plasminogen activator containing ointment. Zeegelaar JE, et al. **Vasa** 1997 May;26(2):81–4

[Local intra–arterial thrombolysis in acute ischemia of an extremity] Enevoldsen MT, et al. **Ugeskr Laeger** 1996 Sep 2;158(36):5011–4 (29 ref.) (Eng. Abstr.) **(Dan)**

[Local intra–arterial thrombolysis. Results in arterial thromboses and graft occlusions] Hansen AK, et al. **Ugeskr Laeger** 1997 Mar 24;159(13):1950–3 (Eng. Abstr.) **(Dan)**

[Treatment with tissue plasminogen activator (tPA) in risk patients with fibrin reactions after cataract operations] Heiligenhaus A, et al. **Ophthalmologe** 1996 Feb;93(1):49–53 (Eng. Abstr.) **(Ger)**

[Success and complications of rTPA treatment of the anterior eye segment (see comments)] Löffler KU, et al. **Ophthalmologe** 1997 Jan;94(1):50–2 (Eng. Abstr.). Comment in: Ophthalmologe 1997 Jun;94(6):446–7. **(Ger)**

[Intraocular rt–PA injection in fibrin formation after combined glaucoma and cataract operation] Steinkamp GW, et al. **Ophthalmologe** 1996 Oct;93(5):558–60 (Eng. Abstr.) **(Ger)**

[Regional hyperthermic fibrinolytic perfusion as ultima ratio in critical ischemia of the lower extremities] Mumme A, et al. **Zentralbl Chir** 1996;121(12):1069–75 (Eng. Abstr.) **(Ger)**

[Systemic venous thrombolysis with rt–PA in arterial embolism of the legs in the elderly] Marci M, et al. **Clin Ter** 1996 Jul–Aug;147(7–8):371–6 (Eng. Abstr.) **(Ita)**

[Intra–arterial thrombolysis in peripheral bypass and arterial occlusions. Results and predictive factors for thrombolysis] Sandbaek G, et al. **Tidsskr Nor Laegeforen** 1996 Oct 20; 116(25):3000–4 (Eng. Abstr.) **(Nor)**

[Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery] Oficjalska–Młyńczak J, et al. **Klin Oczna** 1996;98(6):423–5 (Eng. Abstr.) **(Pol)**

[Low doses of rtPA administered as a bolus in treatment of clinically acute massive pulmonary embolism] Tomkowski W, et al. **Pneumonol Alergol Pol** 1996;64 Suppl 2:161–5 (Eng. Abstr.) **(Pol)**

[Very low doses of tissue plasminogen activator in treatment of acute massive pulmonary embolism] Tomkowski W, et al. **Pneumonol Alergol Pol** 1996;64 Suppl 2:207–10 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Transcranial duplex monitoring discloses hemorrhagic complication following rt–PA thrombolysis. Kaps M, et al. **Acta Neurol Scand** 1996 Jan;93(1):61–3

Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Bovill EG, et al. **Am J Cardiol** 1997 Feb 15; 79(4):391–6

Intraventricular bleeding after the use of thrombolytics in a cocaine user [see comments] LoVecchio F, et al. **Am J Emerg Med** 1996 Nov;14(7):663–4. Comment in: Am J Emerg Med 1996 Nov;14(7):693–5.

Asymmetric angioneurotic edema associated with thrombolysis for acute stroke. Pancioli A, et al. **Ann Emerg Med** 1997 Aug;30(2):227–9

Simultaneous bilateral thalamic hemorrhages following the administration of intravenous tissue plasminogen activator. Dromerick AW, et al. **Arch Phys Med Rehabil** 1997 Jan; 78(1):92–4

Atheroembolic disease following administration of tissue plasminogen activator (TPA). Aggarwal K, et al. **Clin Cardiol** 1996 Nov;19(11):906–8

Unsuspected vasculitis and intracranial hemorrhage following thrombolysis. Srinivasan G, et al. **Clin Cardiol** 1997 Jan;20(1):84–6

Fibrinolytic treatment in suspected acute myocardial infarction—use and risks in clinical practice. Beermann B, et al. **Eur J Clin Pharmacol** 1997;52(3):179–82

Haemarthrosis following thrombolytic therapy for acute myocardial infarction. Finlayson J, et al. **Injury** 1997 Mar; 28(2):146–7

Complications from the use of thrombolytic agents in patients with cocaine associated chest pain. Hollander JE, et al. **J Emerg Med** 1996 Nov–Dec;14(6):731–6

Mental Dullness after thrombolytic therapy. Woo KS, et al. **Postgrad Med J** 1997 Jun;73(860):347–9

Management of spinal epidural hematoma after tissue plasminogen activator. A case report. Connolly ES Jr, et al. **Spine** 1996 Jul 15;21(14):1694–8 (29 ref.)

Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Larrue V, et al. **Stroke** 1997 May; 28(5):957–60

Ischemic cerebral infarction after rt–PA and heparin therapy for acute myocardial infarction. The TIMI–II pilot and randomized clinical trial combined experience. Sloan MA, et al. **Stroke** 1997 Jun;28(6):1107–14

Thromboembolism related to a Port–a–Cath device in a patient with cystic fibrosis. Yung B, et al. **Thorax** 1997 Jan;52(1):98–9

[Acute band–shaped keratopathy after intraocular fibrinolysis with recombinant tissue plasminogen activator (rt–PA)] Althaus C, et al. **Klin Monatsbl Augenheilkd** 1996 Nov; 209(5):318–21 (Eng. Abstr.) **(Ger)**

[Band–like keratopathy after treatment of postoperative fibrin reaction with tissue plasminogen activator] Wollensak G, et al. **Klin Monatsbl Augenheilkd** 1996 Jul;209(1):43–6 (Eng. Abstr.) **(Ger)**

[Intracerebral hemorrhage after systemic thrombolysis in patients with occlusion of the central retinal artery. Report of 2 cases] Barth H, et al. **Ophthalmologe** 1996 Dec; 93(6):739–44 (Eng. Abstr.) **(Ger)**

[Successes and complications of rTPA treatment of the anterior eye segment. Comment on the contribution by K.U. Löffler et al. (letter; comment)] Hesse L, et al. **Ophthalmologe** 1997 Jun;94(6):446–7. Comment on: Ophthalmologe 1997 Jan;94(1):50–2. **(Ger)**

[Bilateral acute retrobulbar space–occupying lesion within the scope of thrombolytic therapy in myocardial infarct—a case report] Vécsei PV, et al. **Z Kardiol** 1996 Oct; 85(10):798–803 (Eng. Abstr.) **(Ger)**

[Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)] Cannas S, et al. **G Ital Cardiol** 1997 Mar;27(3):278-80 (Eng. Abstr.) **(Ita)**

[Pulmonary hemorrhage and acute respiratory failure secondary to thrombolytic treatment with tissue plasminogen activator (rt-PA) in patients with acute myocardial infarction (letter)] Sandar Núñez D, et al. **Med Clin (Barc)** 1997 Mar 1;108(8):318 **(Spa)**

[Epidural spinal hematoma following thrombolytic therapy for an acute myocardial infarct] Zafra Sánchez J, et al. **Rev Esp Cardiol** 1997 Jun;50(6):448-50 (Eng. Abstr.) **(Spa)**

AGONISTS

Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Charlton PA, et al. **Thromb Haemost** 1996 May;75(5):808-15

ANALYSIS

Analysis of tissue plasminogen activator specificity using peptidyl fluorogenic substrates. Butenas S, et al. **Biochemistry** 1997 Feb 25;36(8):2123-31

Expression of tissue-type plasminogen activator, plasminogen activator inhibitor and von Willebrand factor in the supernatant of endothelial cell cultures in response to the seeding of adenocarcinoma cell line HRT-18. Morganti M, et al. **Biomed Pharmacother** 1996;50(8):373-5

A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Grebenschikov N, et al. **Int J Biol Markers** 1997 Jan-Mar;12(1):6-14

t-Plasminogen activator and von Willebrand factor in patients with unstable angina. Tousoulis D, et al. **Int J Cardiol** 1996 Apr 19;54(1):89-92

Comparison of ampholytes used for slab gel and capillary isoelectric focusing of recombinant tissue-type plasminogen activator glycoforms. Chen AB, et al. **J Chromatogr A** 1996 Sep 13;744(1-2):279-84

Examination of capillary zone electrophoresis, capillary isoelectric focusing and sodium dodecyl sulfate capillary electrophoresis for the analysis of recombinant tissue plasminogen activator. Thorne JM, et al. **J Chromatogr A** 1996 Sep 13;744(1-2):155-65

Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction. Wållberg-Jonsson S, et al. **J Rheumatol** 1996 Oct; 23(10):1704-9

Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta. Shireman PK, et al. **J Vasc Surg** 1997 Jan;25(1):157-64

Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Xu Y, et al. **Kidney Int** 1996 Dec; 50(6):2011-9

The plasminogen activation system in tumour invasion and metastasis. de Vries TJ, et al. **Pathol Res Pract** 1996 Jul; 192(7):718-33 (242 ref.)

Immunohistochemically identifiable tissue plasminogen activator in cavernous angioma: mechanism for re-hemorrhage and lesion growth. Frim DM, et al. **Pediatr Neurosurg** 1996 Sep;25(3):137-41; discussion 141-2

Localization of fibrinolytic activators and inhibitors in normal and atherosclerotic vessels. Falkenberg M, et al. **Thromb Haemost** 1996 Jun;75(6):933-8

Release of tissue plasminogen activator during reperfusion after different times of ischaemia in isolated, perfused rat hearts. Winnerkvist A, et al. **Thromb Res** 1996 Jun 15; 82(6):533-42

[Tissue plasminogen activator (t-PA) in aqueous humor of patients with cataract] Kotschy M, et al. **Klin Oczna** 1996 Mar;98(3):201-3 (Eng. Abstr.) **(Pol)**

[Post-mortem concentration of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1) in the vitreous body of the human eye] Przygońska J, et al. **Klin Oczna** 1996 Mar;98(3):205-8 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

Nitric oxide reverses aspirin antagonism of t-PA thrombolysis in a rabbit model of thromboembolic stroke. Bednar MM, et al. **Exp Neurol** 1997 Aug;146(2):513-7

The tissue-type plasminogen activator inhibitor ETIa from Erythrina variegata: structural basis for the inhibitory activity by cloning, expression, and mutagenesis of the cDNA encoding ETIa. Kouzuma Y, et al. **J Biochem (Tokyo)** 1997 Mar;121(3):456-63

Variants of tissue-type plasminogen activator that display extraordinary resistance to inhibition by the serpin plasminogen activator inhibitor type 1. Tachias K, et al. **J Biol Chem** 1997 Jun 6;272(23):14580-5

BIOSYNTHESIS

Effects of S-dC28 on vascular smooth muscle cell adhesion and plasminogen activator production. Wang W, et al. **Antisense Nucleic Acid Drug Dev** 1997 Apr;7(2):101-7

Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT). Rox JM, et al. **Arch Dermatol Res** 1996 Aug;288(9):554-8

Antifibrinolytic properties of the vascular wall. Dependence on the history of smooth muscle cell doublings in vitro and in vivo. Christ G, et al. **Arterioscler Thromb Vasc Biol** 1997 Apr;17(4):723-30

The expression of plasminogen activators and their inhibitors in cultured human retinal capillary endothelial cells. Redmill BS, et al. **Biochem Soc Trans** 1996 May;24(2):206S

Calcium spirulan as an inducer of tissue-type plasminogen activator in human fetal lung fibroblasts. Hayakawa Y, et al. **Biochim Biophys Acta** 1997 Mar 1;1355(3):241-7

Expression of avian urokinase and tissue-type plasminogen activator messenger ribonucleic acid during follicle development and atresia. Johnson AL, et al. **Biol Reprod** 1997 Mar;56(3):581-8

An autocrine/paracrine role of human decidual relaxin. I. Interstitial collagenase (matrix metalloproteinase-1) and tissue plasminogen activator. Qin X, et al. **Biol Reprod** 1997 Apr;56(4):800-11

Temporal expression of extracellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion. Tyagi SC, et al. **Can J Physiol Pharmacol** 1996 Aug;74(8):983-95

9,13-di-cis-Retinoic acid induces the production of tPA and activation of latent TGF-beta via RAR alpha in a human liver stellate cell line, LI90. Imai S, et al. **FEBS Lett** 1997 Jul 7;411(1):102-6

Clinical features and molecular analysis of a family with multiple colon tumours and reduced plasminogen activator activity. Tomlinson IP, et al. **Int J Colorectal Dis** 1997; 12(1):1-3

The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. Cuzner ML, et al. **J Neuropathol Exp Neurol** 1996 Dec;55(12):1194-204

Effect of tension-force on plasminogen activator activity from human periodontal ligament cells. Yamaguchi M, et al. **J Periodontal Res** 1997 Apr;32(3):308-14

Use of engineered ribozymes to catalyze chimeric gene assembly. Mikheeva S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7486-90

Production of tissue-type plasminogen activator (t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in mildly cirrhotic rat liver. Seki T, et al. **Thromb Haemost** 1996 May;75(5):801-7

BLOOD

Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors. Katz RJ, et al. **Am J Cardiol** 1996 Oct 15;78(8):876-80

Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients. Warshofsky MK, et al. **Am J Cardiol** 1997 Jul 15;80(2):145-9

ApoE genotype does not affect plasma tPA and PAI-1 antigen levels. Mermod JJ, et al. **Am J Med Genet** 1997 Apr 18;74(2):172-5

Evaluation of chromogenic substrate assays for fibrinolytic analytes in dogs. Lanevschi A, et al. **Am J Vet Res** 1996 Aug;57(8):1124-30

The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs. Dahl OE, et al. **Blood Coagul Fibrinolysis** 1995 Dec;6(8):709-17

Interference of an activity assay of tissue-type plasminogen activator in human plasma by endogenous factors. Mukherjee M, et al. **Blood Coagul Fibrinolysis** 1996 Jun; 7(4):491-6

The effects of chronic smoking on the fibrinolytic potential of plasma and platelets. Simpson AJ, et al. **Br J Haematol** 1997 Apr;97(1):208-13

Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population. Welty FK, et al. **Circulation** 1997 Feb 18; 95(4):825-30

Point-of-care fibrinolytic tests: the other side of blood coagulation. Oberhardt BJ, et al. **Clin Chem** 1997 Sep; 43(9):1697-702

Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Kopeikina LT, et al. **Clin Rheumatol** 1997 May;16(3):254-60

Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation [see comments] Kahn SR, et al. **CMAJ** 1997 Sep 15;157(6):685-9. Comment in: CMAJ 1997 Sep 15;157(6):695-7.

Transmyocardial fibrinolytic activity in patients with unstable angina pectoris. Daniel WC, et al. **Coron Artery Dis** 1996 Jan;7(1):45-9

Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction. Pedersen OD, et al. **Coron Artery Dis** 1997 May;8(5):283-91

Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease. Suefuji H, et al. **Coron Artery Dis** 1996 Feb;7(2):167-72

Proinsulin, intact insulin, and fibrinolytic variables and fibrinogen in healthy subjects. A population study. Eliasson M, et al. **Diabetes Care** 1997 Aug;20(8):1252-5

The search for markers of endothelial injury during open heart surgery [letter; comment] Valen G. **Eur J Cardiothorac Surg** 1996;10(4):297-8. Comment on: Eur J Cardiothorac Surg 1995;9(1):18-21.

Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait. Akanji AO, et al. **Eur J Clin Invest** 1997 May; 27(5):380-6

Tissue plasminogen activator and plasminogen activator inhibitor status in Budd-Chiari syndrome. Dayal S, et al. **Haemostasis** 1996 Sep-Oct;26(5):284-7

Regular leisure time physical activity predicts high activity of tissue plasminogen activator: The Northern Sweden MONICA Study. Eliasson M, et al. **Int J Epidemiol** 1996 Dec;25(6):1182-8

Insulin resistance syndrome and fibrinolytic activity: the northern Sweden MONICA study. Lindahl B, et al. **Int J Epidemiol** 1996 Apr;25(2):291-9

Coagulation inhibitors and fibrinolytic parameters in patients on peritoneal dialysis and haemodialysis. Alwakeel J, et al. **Int Urol Nephrol** 1996;28(2):255-61

Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden. Eliasson M, et al. **J Hypertens** 1997 Apr; 15(4):349-56

Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study in Stockholm (APSIS). A comparison with healthy controls. Held C, et al. **J Intern Med** 1997 Jan;241(1):59-69

Tissue plasminogen activator and plasminogen activator inhibitors of type 1 and type 2 in the plasma of parturient women. Uszyński M, et al. **J Perinat Med** 1996;24(4):339-45

Pulmonary blood flow regulates plasma tissue plasminogen activator concentrations in patients with congenital heart defects. Mishima A, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):742-7

Release of creatine kinase, troponin-T, and tissue plasminogen activator in arterial and coronary venous blood during coronary artery bypass surgery. Valen G, et al. **Scand J Clin Lab Invest** 1997 Feb;57(1):85-93

Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by tPA on the surface of leukocytic cells. Félez J, et al. **Thromb Haemost** 1996 Oct;76(4):577-84

Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Johansson JO, et al. **Thromb Haemost** 1996 Sep;76(3):422-8

Limiting systemic plasminogenolysis reduces the bleeding potential for tissue-type plasminogen activators but not for streptokinase. Thomas GR, et al. **Thromb Haemost** 1996 Jun;75(6):915-20

Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. CALC Group. Violl F, et al. **Thromb Haemost** 1996 Aug; 76(2):177-83

Plasma Lp(a) and t-PA-PAI-1 complex levels in coronary heart disease. Süer S, et al. **Thromb Res** 1996 Jul 1; 83(1):77-85

[Tissue plasminogen activator (T-PA) and tissue plasminogen activator inhibitor (PAI-1) in patients after head injury] Beuth W, et al. **Neurol Neurochir Pol** 1996 May-Jun; 30(3):427-34 (Eng. Abstr.) **(Pol)**

[The fibrinolytic system in patients with dilated myocardiopathy] Fernández P, et al. **Sangre (Barc)** 1996 Oct;41(5):351-5 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Endogenous tissue plasminogen activator in neonatal cerebrospinal fluid. Whitelaw A, et al. **Eur J Pediatr** 1996 Feb;155(2):117-9

CHEMICAL SYNTHESIS

Preparation of excipient-free recombinant human tissue-type plasminogen activator by lyophilization from ammonium bicarbonate solution: an investigation of the two-stage sublimation phenomenon [published erratum appears in J Pharm Sci 1997 Jul;86(7):880] Overcashier DE, et al. **J Pharm Sci** 1997 Apr;86(4):455-9

CHEMISTRY

Effective enzyme thrombolytic composition on the basis of wild-type and chemically modified plasminogen activators. Maksimenko AV, et al. **Ann N Y Acad Sci** 1996 Oct 12; 799:146-50

Integrin-specific tissue-type plasminogen activator engineered by introduction of the Arg-Gly-Asp sequence. Yamada T, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):306-11

Renaturation and purification of recombinant tissue-type plasminogen activator expressed in E. coli. Hua ZC. **Biochem Mol Biol Int** 1997 Apr;41(4):815-20

Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. Renatus M, et al. **EMBO J** 1997 Aug 15;16(16):4797-805

Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors. Renatus M, et al. **J Biol Chem** 1997 Aug 29; 272(35):21713-9

Converting tissue type plasminogen activator into a zymogen.

Important role of Lys156. Tachias K, et al. **J Biol Chem** 1997 Jan 3;272(1):28–31

Examination of capillary zone electrophoresis, capillary isoelectric focusing and sodium dodecyl sulfate capillary electrophoresis for the analysis of recombinant tissue plasminogen activator. Thorne JM, et al. **J Chromatogr A** 1996 Sep 13;744(1–2):155–65

A pig collagen peptide fraction. A unique material for maintaining biological activity during lyophilization and during storage in the liquid state. Gaffney PJ, et al. **J Pharm Pharmacol** 1996 Sep;48(9):896–8

Locating the unpaired cysteine of tissue–type plasminogen activator. Sehl LC, et al. **Protein Eng** 1996 Mar;9(3):283–90

Domain structure and interactions of plasminogen activators. Medved LV, et al. **Ukr Biokhim Zh** 1996 Jul–Aug; 68(4):39–40

DEFICIENCY

Chronic nicotine treatment enhances focal ischemic brain injury and depletes free pool of brain microvascular tissue plasminogen activator in rats. Wang L, et al. **J Cereb Blood Flow Metab** 1997 Feb;17(2):136–46

Plasminogen–dependent and –independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes. Lijnen HR, et al. **Thromb Haemost** 1997 Feb;77(2):362–7

DIAGNOSTIC USE

Scintigraphic visualization of pulmonary thrombi with 123I–YPACK–TNK–tPA. De Bruyn VH, et al. **Coron Artery Dis** 1995 Sep;6(9):715–21

Technetium–99m–modified recombinant tissue plasminogen activator to detect deep venous thrombosis. Butler SP, et al. **J Nucl Med** 1996 May;37(5):744–8

Detection of postoperative deep–venous thrombosis using technetium–99m–labeled tissue plasminogen activator. Butler SP, et al. **J Nucl Med** 1997 Feb;38(2):219–23

DRUG EFFECTS

The inhibitory effect of heparin for vascular smooth muscle cell proliferation or migration is not mediated by u–PA and t–PA. Herbert JM, et al. **Thromb Res** 1997 May 15; 86(4):317–24

Lead perturbs the regulation of spontaneous release of tissue plasminogen activator and plasminogen activator inhibitor–1 from vascular smooth muscle cells and fibroblasts in culture. Yamamoto C, et al. **Toxicology** 1997 Feb 28;117(2–3):153–61

GENETICS

Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. van der Bom JG, et al. **Circulation** 1997 Jun 17;95(12):2623–7

Changes in ovarian expression of tissue–type plasminogen activator and plasminogen activator inhibitor type–1 messenger ribonucleic acids during ovulation in rat. Shen X, et al. **Endocr J** 1997 Jun;44(3):341–8

Clinical features and molecular analysis of a family with multiple colon tumours and reduced plasminogen activator activity. Tomlinson IP, et al. **Int J Colorectal Dis** 1997; 12(1):1–3

Identification of a multihormone responsive enhancer far upstream from the human tissue–type plasminogen activator gene. Bulens F, et al. **J Biol Chem** 1997 Jan 3; 272(1):663–71

Bone resorption and response to calcium–regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor. Leloup G, et al. **J Bone Miner Res** 1996 Aug;11(8):1146–57

Expression of hepatocyte growth factor/scatter factor, its receptor, c–met, and tissue–type plasminogen activator during development of the murine olfactory system. Thewke DP, et al. **J Neurosci** 1996 Nov 1;16(21):6933–44

Expression of plasminogen activator and inhibitor, urokinase receptor and inhibin subunits in rhesus monkey testes. Zhang T, et al. **Mol Hum Reprod** 1997 Mar;3(3):223–31

Enhancement of mRNA expression of tissue–type plasminogen activator by L–threo–3,4–dihydroxyphenylserine in association with ocular dominance plasticity. Mataga N, et al. **Neurosci Lett** 1996 Nov 8;218(3):149–52

Cell–type specific DNA–protein interactions at the tissue–type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro. Arts J, et al. **Nucleic Acids Res** 1997 Jan 15;25(2):311–7

Construction, expression and characterization of tissue–type plasminogen activator mutants. Liu S, et al. **Sci China B** 1995 Nov;38(11):1341–8

Adenovirus–mediated transfer of tissue–type plasminogen activator gene to human endothelial cells. Sugawara Y, et al. **Surgery** 1997 Jul;122(1):91–100

Substitution of serine or threonine at position 473 of tissue–type plasminogen activator increases its stability in plasma. Alibhai M, et al. **Thromb Haemost** 1996 Jan; 75(1):107–12

[mRNA for tissue–type plasminogen activator in various human tissues and organs] Sarafanov AG, et al. **Mol Biol (Mosk)** 1996 Nov–Dec;30(6):1326–33 **(Rus)**

IMMUNOLOGY

Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA–DQ7. Morse JH, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):274–8

Epitopes on plasminogen activator inhibitor type–1 important for binding to tissue plasminogen activator. Björquist P, et al. **Biochim Biophys Acta** 1997 Aug 15;1341(1):87–98

Antibodies to fibrin–bound tissue–type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis. Salazar–Paramo M, et al. **Lupus** 1996 Aug;5(4):275–8

[Tissue plasminogen activator and inhibitor and the severity and extensiveness of vascular lesions in peripheral atherosclerosis of the legs] Rość D, et al. **Pol Merkuriusz Lek** 1996 Oct;1(4):235–7 (Eng. Abstr.) **(Pol)**

ISOLATION & PURIFICATION

Renaturation and purification of recombinant tissue–type plasminogen activator expressed in E. coli. Hua ZC. **Biochem Mol Biol Int** 1997 Apr;41(4):815–20

METABOLISM

Anesthesia and surgery influences regional net release and uptake rates of tissue–type plasminogen activator. An experimental study in the intact pig. Seeman–Lodding H, et al. **Acta Anaesthesiol Scand Suppl** 1997;110:151–3

The role of urokinase–type plasminogen activator and its inhibitor PAI–1 in gastric cancer. Herszényi L, et al. **Acta Physiol Hung** 1995;83(3):213–21

The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. Yamamoto K, et al. **Am J Pathol** 1997 Sep;151(3):725–34

Venous thrombolysis by tissue–type plasminogen activator in conjunction with the urokinase–fibrinogen covalent conjugate. Effects of potentiation and faster action in dogs. Maksimenko AV, et al. **Appl Biochem Biotechnol** 1996 Oct–Nov;61(1–2):123–8

Competition between plasminogen and procathepsin B as a probe to demonstrate the in vitro activation of procathepsin B by the tissue plasminogen activator. Dalet–Fumeron V, et al. **Arch Biochem Biophys** 1996 Nov 15;335(2):351–7

Denatured proteins as cofactors for plasminogen activation. Machovich R, et al. **Arch Biochem Biophys** 1997 Aug 15; 344(2):343–9

Isolation and characterization of tissue–type plasminogen activator– binding proteoglycans from human umbilical vein endothelial cells. Böhm T, et al. **Arterioscler Thromb Vasc Biol** 1996 May;16(5):665–72

Fibrinolytic activity is similar in physically active men with and without a history of myocardial infarction. Fernhall B, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun; 17(6):1106–13

Integrin–specific tissue–type plasminogen activator engineered by introduction of the Arg–Gly–Asp sequence. Yamada T, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):306–11

Role of tryptophan–63 of the kringle 2 domain of tissue–type plasminogen activator in its thermal stability, folding, and ligand binding properties. Chang Y, et al. **Biochemistry** 1997 Jun 24;36(25):7652–63

Enhancement of tissue–type plasminogen activator (t–PA) activity by purified t–PA receptor expressed in human endothelial cells. Fukao H, et al. **Biochim Biophys Acta** 1997 Mar 27;1356(1):111–20

Glycosylation properties of the Pichia pastoris–expressed recombinant kringle 2 domain of tissue–type plasminogen activator. Miele RG, et al. **Biotechnol Appl Biochem** 1997 Apr;25 (Pt 2):151–7

High–level secretion in Pichia pastoris and biochemical characterization of the recombinant kringle 2 domain of tissue–type plasminogen activator. Nilsen SL, et al. **Biotechnol Appl Biochem** 1997 Feb;25 (Pt 1):63–74

Adenovirus–mediated transfer of tissue–type plasminogen activator augments thrombolysis in tissue–type plasminogen activator–deficient and plasminogen activator inhibitor–1–overexpressing mice. Carmeliet P, et al. **Blood** 1997 Aug 15;90(4):1527–34

The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator. Williams S, et al. **Blood Coagul Fibrinolysis** 1995 Dec;6(8):718–25

Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a). Dudani AK, et al. **Br J Haematol** 1996 Oct; 95(1):168–78

Protection by alpha2–macroglobulin of tissue plasminogen activator against inhibition by plasminogen activator inhibitor–1. Ieko M, et al. **Br J Haematol** 1997 Apr; 97(1):214–8

Lack of correlation between blood fibrinolysis and the immediate or post–operative blood loss in transurethral resection of the prostate. Nielsen JD, et al. **Br J Urol** 1997 Jul;80(1):105–10

Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Häckel C, et al. **Cancer** 1997 Jan 1;79(1):53–8

Cyclic strain–induced monocyte chemotactic protein–1 gene expression in endothelial cells involves reactive oxygen species activation of activator protein 1. Wung BS, et al. **Circ Res** 1997 Jul;81(1):1–7

Effect of lipids on glomerular fibrinolysis in vitro. Fujii Y, et al. **Contrib Nephrol** 1997;120:140–5

Lysine 156 promotes the anomalous proenzyme activity of tPA: X–ray crystal structure of single–chain human tPA. Renatus M, et al. **EMBO J** 1997 Aug 15;16(16):4797–805

Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease. Caputo M, et al. **Eur Heart J** 1996 Sep;17(9):1329–36

Opposing effects of interleukin–1 and transforming growth factor–beta on the regulation of tissue–type plasminogen activator and plasminogen activator inhibitor type–1 expression by human mesangial cells. Wilson HM, et al. **Exp Nephrol** 1997 May–Jun;5(3):233–8

Myosin as cofactor and substrate in fibrinolysis. Machovich R, et al. **FEBS Lett** 1997 Apr 21;407(1):93–6

Fibrinolysis and the biliary tree. Scott–Coombes DM, et al. **Gut** 1997 Jan;40(1):92–4

Plasma kallikrein and tissue–type plasminogen activator compete for a common pathway into the liver. Nagaoka MR, et al. **Immunopharmacology** 1996 May;32(1–3):88–90

Degradation of human plasma and extracellular matrix fibronectin by tissue type plasminogen activator and urokinase. Marchina E, et al. **Int J Biochem Cell Biol** 1996 Oct;28(10):1141–50

Acceleration of plasminogen activation by tissue plasminogen activator on surface–bound histidine–proline–rich glycoprotein. Borza DB, et al. **J Biol Chem** 1997 Feb 28; 272(9):5718–26

Low density lipoprotein receptor–related protein modulates the expression of tissue–type plasminogen activator in human colon fibroblasts. Hardy MM, et al. **J Biol Chem** 1997 Mar 7;272(10):6812–7

Cell–surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell–associated plasminogen by tissue–type plasminogen activator. Hembrough TA, et al. **J Biol Chem** 1996 Oct 11;271(41):25684–91

A steady–state template model that describes the kinetics of fibrin–stimulated [Glu1]– and [Lys78]plasminogen activation by native tissue–type plasminogen activator and variants that lack either the finger or kringle–2 domain. Horrevoets AJ, et al. **J Biol Chem** 1997 Jan 24; 272(4):2183–91

Distinguishing the specificities of closely related proteases. Role of P3 in substrate and inhibitor discrimination between tissue–type plasminogen activator and urokinase. Ke SH, et al. **J Biol Chem** 1997 Jun 27;272(26):16603–9

Identification of a hydrophobic exosite on tissue type plasminogen activator that modulates specificity for plasminogen. Ke SH, et al. **J Biol Chem** 1997 Jan 17; 272(3):1811–6

Tissue plasminogen activator (t–PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t–PA. Parmer RJ, et al. **J Biol Chem** 1997 Jan 17;272(3):1976–82

Converting tissue–type plasminogen activator into a zymogen. Tachias K, et al. **J Biol Chem** 1996 Nov 15; 271(46):28749–52

Do tissue plasminogen activator–plasminogen activator inhibitor–1 complexes relate to the complications of insulin–dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study. Maser RE, et al. **J Diabetes Complications** 1997 Jul–Aug;11(4):243–9

Interaction of tissue plasminogen activator inhibitor with cell surface guanidinobenzoatase and urokinase plasminogen activator. Anees M. **J Enzyme Inhib** 1996;10(4):281–8

Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. Kitching AR, et al. **J Exp Med** 1997 Mar 3;185(5):963–8

Regulation of the fibrinolytic potential of cultured human umbilical vein endothelial cells: astragaloside IV downregulates plasminogen activator inhibitor–1 and upregulates tissue–type plasminogen activator expression. Zhang WJ, et al. **J Vasc Res** 1997 Jul–Aug;34(4):273–80

Preliminary studies on the role of plasminogen activator in seminal plasma of human and rhesus monkey. Liu K, et al. **Mol Hum Reprod** 1996 Feb;2(2):99–104

Domain–domain interactions in hybrids of tissue–type plasminogen activator and urokinase–type plasminogen activator. Bakker AH, et al. **Protein Eng** 1995 Dec; 8(12):1295–1302

Monoclonal antibodies against the human mannose receptor that inhibit the binding of tissue–type plasminogen activator. Barrett–Bergshoeff M, et al. **Thromb Haemost** 1997 Apr;77(4):718–24

Selective stimulation of tissue–type plasminogen activator (t–PA) in vivo by infusion of bradykinin. Brown NJ, et al. **Thromb Haemost** 1997 Mar;77(3):522–5

Kinetic parameters for plasminogen activation by tissue type plasminogen activator [letter] Machovich R. **Thromb Haemost** 1997 May;77(5):1041–2

The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue–type plasminogen activator. van Meijer M, et al. **Thromb Haemost** 1997 Mar;77(3):516–21

Studies of the t–PA–catalyzed Glu–plasminogen activation on different models of polymeric fibrin. Druzhyna NN, et al. **Thromb Res** 1997 Jul 1;87(1):131–9

Amyloid beta peptides stimulate tissue–type plasminogen activator but not recombinant prourokinase. Wnendt S, et

al. **Thromb Res** 1997 Feb 1;85(3):217–24

The plasminogen–plasmin fibrinolytic system accelerates degradation of alginate–poly–L–lysine–alginate microcapsules in vitro. Hsu BR, et al. **Transplant Proc** 1997 May;29(3):1877–80

Bovine erythrocyte haemolysates enhance plasminogen activation by tissue–type plasminogen activator. Yamada M, et al. **Vet Res Commun** 1997 Feb;21(2):75–84

[Expression of tissue–type plasminogen activator (t–PA) in smooth muscle cells of injured iliac arteries in rabbits] Ma X, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Jun; 25(3):145–8 (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

Antagonists of the mannose receptor and the LDL receptor–related protein dramatically delay the clearance of tissue plasminogen activator. Biessen EA, et al. **Circulation** 1997 Jan 7;95(1):46–52

Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI–1) complex: relationship to elevated TPA antigen in patients with high PAI–1 activity levels. Chandler WL, et al. **Circulation** 1997 Aug 5;96(3):761–8

Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue–type plasminogen activator. van Griensven JM, et al. **Clin Pharmacol Ther** 1996 Nov;60(5):504–11

Pharmacokinetics of human recombinant tissue–type plasminogen activator, administered intra–abdominally, in a rat peritonitis model. van Goor H, et al. **Eur Surg Res** 1996 Jul–Aug;28(4):287–94

PHARMACOLOGY

Lysis of surface–localized fibrin clots by adsorbed plasminogen in the presence of tissue plasminogen activator. Woodhouse KA, et al. **Biomaterials** 1996 Jan; 17(1):75–7

Interaction of reteplase with heparin. A comparison between reteplase and alteplase. Rijken DC, et al. **Blood Coagul Fibrinolysis** 1996 Jul;7(5):561–6

Alpha 2–antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism. Butte AN, et al. **Circulation** 1997 Apr 1;95(7):1886–91

A tissue plasminogen activator/P–selectin fusion protein is an effective thrombolytic agent. Fujise K, et al. **Circulation** 1997 Feb 4;95(3):715–22

Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys–plasminogen in nonhuman primates. Sundell IB, et al. **Circulation** 1997 Aug 5;96(3):941–8

Acute hypertension, but not thrombolysis, increases the incidence and severity of hemorrhagic transformation following experimental stroke in rabbits. Bowes MP, et al. **Exp Neurol** 1996 Sep;141(1):40–6

Reexamination of the extent of the activation of Lys78 plasminogen by tissue plasminogen activator in the presence of polymerized fibrin. Urano T, et al. **Haemostasis** 1996 Jul–Aug;26(4):220–7

Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro. Stringer KA, et al. **Inflammation** 1997 Feb;21(1):27–34

Improved perfusion with rt–PA and hirulog in a rabbit model of embolic stroke. Yenari MA, et al. **J Cereb Blood Flow Metab** 1997 Apr;17(4):401–11

Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasmin–independent, receptor–mediated mechanism. Welling TH, et al. **J Surg Res** 1996 Nov;66(1):36–42

Recombinant tissue plasminogen activator prevents intimal hyperplasia after balloon angioplasty in hypercholesterolemic rabbits. Kanamasa K, et al. **Jpn Circ J** 1996 Nov;60(11):889–94

The effect of oral antiplatelet agents on tissue plasminogen activator–mediated thrombolysis in a rabbit model of thromboembolic stroke. Bednar MM, et al. **Neurosurgery** 1996 Aug;39(2):352–9

Comparison of intrathecally administered urokinase, tissue–type plasminogen activator, and combination of urokinase and lysine–plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs. Kajimoto Y, et al. **Neurosurgery** 1997 Mar;40(3):572–7

Novel mechanism to enhance tPA–induced fibrinolysis: effect of limited proteolysis of PAI–1 by neutrophil elastase. Urano T, et al. **Pol J Pharmacol** 1996 Mar–Apr; 48(2):209–13

Perturbation of platelet adhesion to endothelial cells by plasminogen activation in vitro. Chen H, et al. **Thromb Haemost** 1997 Aug;78(2):934–8

Platelet adhesion following the administration of tissue–type plasminogen activator and its reversal by vitamin E in rats. Jen CJ, et al. **Thromb Haemost** 1996 Jan;75(1):101–6

In vitro effects of rt–PA on platelet function and clot strength. D'Amico EA, et al. **Thromb Res** 1997 Mar 15; 85(6):519–22

Impaired clot lysis by rt–PA catalyzed mini–plasminogen activation. Duboscq C, et al. **Thromb Res** 1997 Jun 15; 86(6):505–13

The effect of fibrinogen polymerization and crosslinking on exposure of fibrin–specific epitopes and t–PA mediated plasminogen activation. Mosesson MW, et al. **Ukr Biokhim Zh** 1996 Jul–Aug;68(4):37–8

[Behavior of postoperative adhesions after intraperitoneal administration of fibrinolytic drugs in a rat model] Stapel A, et al. **Langenbecks Arch Chir** 1997;382(1):33–6 (Eng. Abstr.) **(Ger)**

[The vasomotor effects of the enzymes of the fibrinolytic system in rats] Sergeev IIu, et al. **Fiziol Zh Im I M Sechenova** 1996 Oct–Nov;82(10–11):52–7 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Vascular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator–dependent mechanisms: evidence for a specific tissue–type plasminogen activator receptor on these cells. Ellis V, et al. **Blood** 1997 Sep 15;90(6):2312–22

Tissue plasminogen activator–biologic perspective for surgeons. Chang R, et al. **J Am Coll Surg** 1997 May; 184(5):529–39 (102 ref.)

Urokinase and tissue–type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet–derived growth factor–BB for vascular smooth muscle cells. Herbert JM, et al. **J Biol Chem** 1997 Sep 19;272(38):23585–91

Clinical implications of the involvement of tPA in neuronal cell death. Tsirka SE. **J Mol Med** 1997 May;75(5):341–7 (52 ref.)

Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke. Bednar MM, et al. **J Neurosurg** 1997 Jan;86(1):139–42

Neuronal cell death and tPA [letter] Tsirka SE, et al. **Nature** 1996 Nov 14;384(6605):123–4

Endothelial nitric oxide, prostacyclin (PGI2) and tissue plasminogen activator (t–PA): alliance or neutrality? Gryglewski RJ. **Pol J Pharmacol** 1995 Sep–Oct; 47(5):467–72 (22 ref.)

Endothelium in hemostasis and thrombosis. Lijnen HR, et al. **Prog Cardiovasc Dis** 1997 Jan–Feb;39(4):343–50 (54 ref.)

[Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes] Rość D, et al. **Pol Merkuriusz Lek** 1997 Jan;2(7):24–5 (Eng. Abstr.) **(Pol)**

SECRETION

Effect of 15–hydroperoxyeicosatetraenoic acid on the fibrinolytic factor release and the antithrombin binding of vascular endothelial cells. Soeda S, et al. **Biol Pharm Bull** 1997 Jan;20(1):15–9

Alterations in endothelial cell proteinase and inhibitor polarized secretion following treatment with interleukin–1, phorbol ester, and human melanoma cell conditioned medium. Cottam DW, et al. **J Cell Biochem** 1996 Jan; 60(1):148–60

Sympathoadrenal activation and muscarinic receptor stimulation induce acute release of tissue–type plasminogen activator but not von Willebrand factor across the human forearm. Jern C, et al. **Thromb Haemost** 1997 Aug; 78(2):887–91

THERAPEUTIC USE

Thrombolysis acute ischemic stroke. Fieschi C, et al. **Acta Neurochir Suppl (Wien)** 1996;66:76–80 (39 ref.)

Direct endovascular thrombolytic therapy for dural sinus thrombosis: infusion of alteplase. Kim SY, et al. **AJNR Am J Neuroradiol** 1997 Apr;18(4):639–45

Concomitant nitroglycerin and rTPA [letter; comment] Massel D. **Am Heart J** 1997 Jun;133(6):713–4. Comment on: Am Heart J 1995 Oct;130(4):692–7.

Randomized coronary patency trial of double–bolus recombinant staphylokinase versus front–loaded alteplase in acute myocardial infarction. Vanderschueren S, et al. **Am Heart J** 1997 Aug;134(2 Pt 1):213–9

Hyperacute stroke therapy with tissue plasminogen activator. Alberts MJ. **Am J Cardiol** 1997 Aug 28;80(4C):29D–34D; discussion 35D–39D (14 ref.)

Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. Gibson CM, et al. **Am J Cardiol** 1997 Jul 1;80(1):21–6

Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO–I Investigators. Global Utilization of Streptokinase and t–PA for Occluded Coronary Arteries. Labinaz M, et al. **Am J Cardiol** 1996 Dec 15;78(12):1338–44

Facilitating emergency use of alteplase for stroke [letter] Stump LS, et al. **Am J Health Syst Pharm** 1997 Jun 15; 54(12):1447–9

Successful treatment of acute myocardial infarction during pregnancy with tissue plasminogen activator. Schumacher B, et al. **Am J Obstet Gynecol** 1997 Mar;176(3):716–9

Thrombolysis in acute stroke. Hachinski V. **Arch Fam Med** 1997 Mar–Apr;6(2):104

Tissue–type plasminogen activator should not be used in acute ischemic stroke. Riggs JE. **Arch Fam Med** 1997 Mar–Apr;6(2):102–4

Thrombolysis for stroke. Brott T. **Arch Neurol** 1996 Dec; 53(12):1305–6

Thrombolysis in acute stroke. Hachinski V. **Arch Neurol** 1996 Dec;53(12):1308

Tissue–type plasminogen activator should not be used in acute ischemic stroke. Riggs JE. **Arch Neurol** 1996 Dec; 53(12):1306–8

TPA for sclerostomy occlusion [letter] Foo K, et al. **Aust N Z J Ophthalmol** 1996 Nov;24(4):391–2

Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt–PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. Agnelli G, et al. **Blood Coagul Fibrinolysis** 1997 Jun;8(4):216–22

Results of American and European studies of thrombolysis in acute stroke are not conflicting [letter; comment] Bruno A. **BMJ** 1997 Jan 4;314(7073):76. Comment on: BMJ 1996 Sep 14;313(7058):640–1.

Treatment of hepatic veno–occlusive disease with low–dose tissue plasminogen activator: impact on coagulation profile. Goldberg SL, et al. **Bone Marrow Transplant** 1996 Sep; 18(3):633–6

Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno–occlusive disease in pediatric bone marrow transplant patients. Leahey AM, et al. **Bone Marrow Transplant** 1996 Jun;17(6):1101–4

Management cost of acute limb ischaemia. Braithwaite BD, et al. **Br J Surg** 1996 Oct;83(10):1390–3

Efficacy of tissue plasminogen activator (t–PA) in subretinal hemorrhage removal. Claes C, et al. **Bull Soc Belge Ophtalmol** 1996;261:115–8

Recombinant tissue type plasminogen activator treatment of thrombosed mitral valve prosthesis during pregnancy. Fleyfel M, et al. **Can J Anaesth** 1997 Jul;44(7):735–8

Tissue plasminogen activator in a vertebral artery dissection. Gasecki AP, et al. **Can J Neurol Sci** 1997 May;24(2):151–4

Time to treatment with thrombolytic therapy: determinants and effect on short–term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries [see comments] Cox JL, et al. **Can Med Assoc J** 1997 Feb 15;156(4):497–505. Comment in: Can Med Assoc J 1997 Feb 15;156(4):509–11. Comment in: CMAJ 1997 Aug 1;157(3):250–1.

Thrombolysis after acute myocardial infarction: are Canadian physicians up to the challenge? [comment] Williams WL. **Can Med Assoc J** 1997 Feb 15;156(4):509–11. Comment on: Can Med Assoc J 1997 Feb 15;156(4):497–505.

Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome. Ho YL, et al. **Cardiology** 1996 Jul–Aug;87(4):354–7

Does plasma endothelin during thrombolysis depend on infarct size? A pilot study [letter] Di Pasquale P, et al. **Cardiovasc Drugs Ther** 1995 Dec;9(6):831–2

Coagulation alterations due to local fibrinolytic therapy with recombinant tissue–type plasminogen activator (rt–PA) in patients with peripheral arterial occlusive disease. Rauber K, et al. **Cardiovasc Intervent Radiol** 1997 May–Jun; 20(3):169–73

Massive pulmonary embolism: treatment with thrombus fragmentation and local fibrinolysis with recombinant human–tissue plasminogen activator. Stock KW, et al. **Cardiovasc Intervent Radiol** 1997 Sep–Oct;20(5):364–8

Outcome of different reperfusion strategies in patients with former contraindications to thrombolytic therapy: a comparison of primary angioplasty and tissue plasminogen activator. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators [see comments] Stone GW, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):333–9. Comment in: Cathet Cardiovasc Diagn 1996 Dec;39(4):340.

Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO–I) trial. An observational study. Berger PB, et al. **Circulation** 1997 Jul 1;96(1):122–7

One–year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO–I) trial. GUSTO–I Investigators [see comments] Califf RM, et al. **Circulation** 1996 Sep 15;94(6):1233–8. Comment in: Circulation 1996 Sep 15;94(6):1203–5. Comment in: ACP J Club 1997 Jan–Feb;126(1):3.

TNK–tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose–ranging trial. Cannon CP, et al. **Circulation** 1997 Jan 21;95(2):351–6

Combined accelerated tissue–plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo–controlled, dose–ranging trial. IMPACT–AMI Investigators [see comments] Ohman EM, et al. **Circulation** 1997 Feb 18;95(4):846–54. Comment in: Circulation 1997 Feb 18;95(4):793–5.

Hemoptysis and unilateral intra–alveolar hemorrhage complicating intravenous thrombolysis for myocardial infarction. Hammoudeh AJ, et al. **Clin Cardiol** 1996 Jul; 19(7):595–6

Local thrombolysis with recombinant tissue plasminogen activator for thrombosed vascular access in hemodialysis patients [letter] [see comments] Vlassopoulos D, et al. **Clin Nephrol** 1996 Jul;46(1):77–8. Comment in: Clin Nephrol 1997 Mar;47(3):208.

Case report: venous sinus thrombosis: the use of thrombolysis. Renowden SA, et al. **Clin Radiol** 1997 May;52(5):396–9

Enhancement of recombinant tissue–type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison

with heparin and hirudin in a rabbit thrombosis model. Kornowski R, et al. **Coron Artery Dis** 1996 Dec;7(12):903–9

Intracoronary recombinant tissue–type plasminogen activator (rt–PA). Tiefenbrunn AJ. **Coron Artery Dis** 1996 Sep; 7(9):637–40 (27 ref.)

Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans [see comments] Aiuto LT, et al. **Crit Care Med** 1997 Jun;25(6):1079–82. Comment in: Crit Care Med 1997 Jun;25(6):909.

Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans [editorial; comment] Horne MD 3rd. **Crit Care Med** 1997 Jun;25(6):909. Comment on: Crit Care Med 1997 Jun;25(6):1079–82.

Thrombolytic therapy in the elderly. Pharmacoeconomic considerations. Ramanathan K, et al. **Drugs Aging** 1996 Apr;8(4):237–44 (52 ref.)

Thrombolysis in acute pulmonary embolism: to whom, how much and how? [editorial; comment] Jezek V. **Eur Heart J** 1997 Jul;18(7):1045. Comment on: Eur Heart J 1997 Jul;18(7):1141–8.

Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction [see comments] Meneveau N, et al. **Eur Heart J** 1997 Jul;18(7):1141–8. Comment in: Eur Heart J 1997 Jul;18(7):1045.

The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Weaver WD. **Eur Heart J** 1996 Dec;17 Suppl F:9–15 (36 ref.)

Pulmonary thrombo–embolism in nephrotic syndrome treated with tissue plasminogen activator. Reid CJ, et al. **Eur J Pediatr** 1997 Aug;156(8):647–9

Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions. Schweizer J, et al. **Eur J Radiol** 1996 May; 22(2):129–32

Successful use of recombinant tissue plasminogen activator in the treatment of aortic thrombosis in a premature neonate. Torkington J, et al. **Eur J Vasc Endovasc Surg** 1997 May;13(5):515–6

Catheter–directed lysis of iliofemoral vein thrombosis with use of rt–PA. Verhaeghe R, et al. **Eur Radiol** 1997; 7(7):996–1001

Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. Stringer KA, et al. **Free Radic Biol Med** 1997;22(6):985–8

Impact of early accelerated dose tissue plasminogen activator on in–hospital patency of the infarcted vessel in patients with acute right ventricular infarction. Giannitsis E, et al. **Heart** 1997 Jun;77(6):512–6

Evaluation of mortality and morbidity during four years after late thrombolysis in acute myocardial infarct [letter] Liguori A, et al. **Heart** 1996 Sep;76(3):291

Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease. Pedersen OD, et al. **Heart** 1997 Feb;77(2):122–7

Acute thrombosis in a contralateral kidney after radical nephrectomy: successful treatment by thrombolytic therapy using a tissue–type plasminogen activator. Tsutsumi M, et al. **Int J Urol** 1996 Nov;3(6):508–10

Left atrial thrombus in a 10–month–old boy—successful thrombolysis with recombinant tissue–type plasminogen activator after open–heart surgery: review of the literature. Kehl HG, et al. **Intensive Care Med** 1996 Sep;22(9):968–71 (11 ref.)

Thrombolysis and Q wave versus non–Q wave first acute myocardial infarction: a GUSTO–I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. Barbagelata A, et al. **J Am Coll Cardiol** 1997 Mar 15;29(4):770–7

Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO–I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Crenshaw BS, et al. **J Am Coll Cardiol** 1997 Aug; 30(2):406–13

Aortic counterpulsation may improve late patency of the occluded coronary artery in patients with early failure of thrombolytic therapy. Kono T, et al. **J Am Coll Cardiol** 1996 Oct;28(4):876–81

Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO–I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Mak KH, et al. **J Am Coll Cardiol** 1997 Jul; 30(1):171–9

Analysis of the relative costs and effectiveness of primary angioplasty versus tissue–type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators. Stone GW, et al. **J Am Coll Cardiol** 1997 Apr;29(5):901–7

Multiplane transesophageal echocardiography to detect effectiveness of selective pulmonary recombinant tissue–type plasminogen activator thrombolysis in pulmonary embolism and patent foramen ovale. Colonna P, et al. **J Am Soc Echocardiogr** 1997 May;10(4):384–8

Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery. Wedrich A, et al. **J Cataract Refract Surg** 1997 Jul–Aug;23(6):873–7

Veno–occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt–PA) treatment. Lee JH, et al. **J Korean Med Sci** 1996 Apr;11(2):118–26

Emergency endovascular treatment of stroke. Connors JJ 3rd, et al. **J La State Med Soc** 1996 Nov;148(11):490–7 (10 ref.)

Recombinant tissue plasminogen activator to declot dialysis fistulas. Boobes Y, et al. **J Nephrol** 1997 Mar–Apr; 10(2):107–10

Use of recombinant tissue–type plasminogen activator to treat massive pulmonary embolism after cesarean section: a case report. Onoyama Y, et al. **J Obstet Gynaecol Res** 1996 Jun; 22(3):201–8

Successful systemic low–dose lysis of a caval thrombus by rt–PA in a neonate with congenital nephrotic syndrome. Kändler C, et al. **J Pediatr Hematol Oncol** 1997 Jul–Aug; 19(4):348–50

Comparative study of a mutant tissue–type plasminogen activator, YM866, with a tissue–type plasminogen activator in a canine model of femoral arterial thrombosis. Kawasaki T, et al. **J Pharm Pharmacol** 1996 Oct;48(10):1041–8

S–nitrosylated tissue–type plasminogen activator protects against myocardial ischemia/reperfusion injury in cats: role of the endothelium. Delyani JA, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1174–80

Local intravenous thrombolysis with recombinant tissue plasminogen activator for salvage of forearm replantation. Hashim HA, et al. **J Reconstr Microsurg** 1996 Nov; 12(8):543–6

Microvascular and thrombolytic revascularization of an arm in a 32–week–gestation neonate: case report and review of the literature. Theile RJ, et al. **J Reconstr Microsurg** 1996 Nov;12(8):539–42

Thrombolysis for acute ischemic stroke in the primary antiphospholipid syndrome. Julkunen H, et al. **J Rheumatol** 1997 Jan;24(1):181–3

Long–term follow–up of gender–specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO–I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Moen EK, et al. **J Womens Health** 1997 Jun; 6(3):285–93

Thrombolysis for stroke [letter; comment] Pincus MM. **JAMA** 1997 Jan 1;277(1):19–20. Comment on: JAMA 1996 Sep 25;276(12):961–6. Comment on: JAMA 1996 Sep 25;276(12):995–6.

Tissue–plasminogen activator for acute ischaemic stroke [letter; comment] Bruno A. **Lancet** 1997 Feb 15; 349(9050):503–4. Comment on: Lancet 1996 Dec 14;348(9042):1600–1.

TPA within 3 hours of acute ischaemic stroke? [see comments] Dorman P, et al. **Lancet** 1996 Dec 14; 348(9042):1600–1. Comment in: Lancet 1997 Feb 15;349(9050):503–4. Comment in: Lancet 1997 Feb 15;349(9050):504.

Tissue–plasminogen activator for acute ischaemic stroke [letter; comment] Ellis SJ. **Lancet** 1997 Feb 15; 349(9050):504. Comment on: Lancet 1996 Dec 14;348(9042):1600–1.

Ischaemic brain tissue salvaged from infarction with alteplase [letter] Heiss WD, et al. **Lancet** 1997 May 31; 349(9065):1599–600

Thrombolytic therapy in acute ischaemic stroke: the jury needs more evidence. Hankey GJ. **Med J Aust** 1997 Apr 21;166(8):419–22 (27 ref.)

Alteplase for thrombolysis in acute ischemic stroke. **Med Lett Drugs Ther** 1996 Nov 8;38(987):99–100

A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators [published erratum appears in N Engl J Med 1997 Jul 24;337(4):287] **N Engl J Med** 1997 Jun 5;336(23):1621–8

A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators [see comments] **N Engl J Med** 1997 Oct 16;337(16):1118–23. Comment in: N Engl J Med 1997 Oct 16;337(16):1159–61.

Thrombolytic therapy in acute ischemic stroke [letter; comment] Frankel MR. **N Engl J Med** 1997 Jan 2;336(1):65; discussion 66–7. Comment on: N Engl J Med 1996 Jul 18;335(3):145–50.

Primary coronary angioplasty versus thrombolysis [letter] Pasceri V. **N Engl J Med** 1997 Oct 16;337(16):1169–70

Primary coronary angioplasty versus thrombolysis [letter] Stone GW, et al. **N Engl J Med** 1997 Oct 16;337(16):1168–9; discussion 1170

Boehringer Mannheim's new clot buster [news] **Nat Biotechnol** 1997 Feb;15(2):114

New clot busters threaten Genentech's tPA [news] Davidson S. **Nat Biotechnol** 1997 May;15(5):405

Thrombolytic therapy with tissue plasminogen activator for prevention of vasospasm in experimental subarachnoid hemorrhage: its efficacy and problems. Asada M, et al. **Neurol Res** 1996 Aug;18(4):342–4

Evaluation of regional cerebral blood flow using single photon emission tomography for the selection of patients for local fibrinolytic therapy of acute cerebral embolism. Ezura M, et al. **Neurosurg Rev** 1996;19(4):231–6

Submacular hemorrhage removal. Lim JI, et al. **Ophthalmology** 1995 Sep;102(9):1393–9

Thrombus in right atrium in two infants successfully treated with tissue plasminogen activator. Martínez–Tallo E, et al. **Pediatr Emerg Care** 1997 Feb;13(1):37–9

Controlled trials comparing reteplase with alteplase and streptokinase in patients with acute myocardial infarction. Amsterdam EA. **Pharmacotherapy** 1996 Sep–Oct;16(5 Pt 2):137S–140S (9 ref.)

Validity of the GUSTO trial's main conclusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronaries. Eisenberg C. **Pharmacotherapy** 1997 Jul–Aug;17(4):850–2

Resolution of pulmonary embolism: effect of therapy and putative age of emboli. Palla A, et al. **Respiration** 1997; 64(1):50–3

The use of intravitreal tissue plasminogen activator in the treatment of experimental subretinal hemorrhage in the pig model. Boone DE, et al. **Retina** 1996;16(6):518–24

Left ventricular function after late thrombolysis with alteplase in myocardial infarction. Gil VM, et al. **Rev Port Cardiol** 1996 May;15(5):413–20, 366

TPA for acute ischemic stroke. Fischer J. **S D J Med** 1997 Feb;50(2):69–70

A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt–PA Stroke Study Group. **Stroke** 1997 Aug;28(8):1530–40

Effect of BQ–123 and tissue plasminogen activator on vasospasm after subarachnoid hemorrhage in monkeys. Kim CJ, et al. **Stroke** 1996 Sep;27(9):1629–33

Ventricular dilatation in experimental intraventricular hemorrhage in pigs. Characterization of cerebrospinal fluid dynamics and the effects of fibrinolytic treatment. Mayfrank L, et al. **Stroke** 1997 Jan;28(1):141–8

Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t–PA Stroke Trial. Tilley BC, et al. **Stroke** 1996 Nov;27(11):2136–42

Intravenous thrombolysis with recombinant staphylokinase versus tissue–type plasminogen activator in a rabbit embolic stroke model [see comments] Vanderschueren S, et al. **Stroke** 1997 Sep;28(9):1783–8. Comment in: Stroke 1997 Sep;28(9):1657–9.

In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis—study in healthy subjects and correlation with blood fibrinolytic parameters. Colucci M, et al. **Thromb Haemost** 1997 Apr;77(4):725–9

Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. Cugno M, et al. **Thromb Haemost** 1996 Aug;76(2):234–8

The Fab–fragment of a PAI–1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. van Giezen JJ, et al. **Thromb Haemost** 1997 May;77(5):964–9

Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Elman MJ. **Trans Am Ophthalmol Soc** 1996;94:471–504

Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Hägglund H, et al. **Transplantation** 1996 Oct 27;62(8):1076–80

[Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy] Zhao P, et al. **Chung Hua Yen Ko Tsa Chih** 1995 Jul;31(4):255–8 (Eng. Abstr.) **(Chi)**

[Rt–PA thrombolysis in the treatment of massive pulmonary embolism] Van Hover P, et al. **J Belge Radiol** 1996 Nov; 79(5):208–10 (Eng. Abstr.) **(Dut)**

[Ilio–femoral vein thrombosis treated with tissue plasminogen activator in a pregnant woman] Grand A, et al. **Ann Cardiol Angeiol (Paris)** 1996 Nov;45(9):517–22 (14 ref.) (Eng. Abstr.) **(Fre)**

[Thrombolytic therapy with rt–PA of recurrent thrombosis in tricuspid valve prosthesis during pregnancy] Di Roio C, et al. **Ann Fr Anesth Reanim** 1996;15(5):666–8 (Eng. Abstr.) **(Fre)**

[Spontaneous neonatal arterial thrombosis treated with tissue plasminogen activator] Daoud P, et al. **Arch Pediatr** 1997 Apr;4(4):343–6 (Eng. Abstr.) **(Fre)**

[Comparison of efficacy and tolerability of a thrombolytic treatment with rt–PA in acute massive pulmonary embolism in the elderly and patients under 75 years of age] Gisselbrecht M, et al. **Rev Med Interne** 1997 Jul;18(7):521–7 (Eng. Abstr.) **(Fre)**

[Portal vein thrombosis after occlusion of a transjugular intrahepatic portosystemic stent–shunt (TIPSS). Shunt dilatation with subsequent local and systemic thrombolysis] Gabler R, et al. **Dtsch Med Wochenschr** 1997 Feb 14; 122(7):188–92 (Eng. Abstr.) **(Ger)**

[Thrombolysis in stroke—results of the ECASS study (European Cooperative Acute Stroke Study)] **Nervenarzt** 1995 Aug;66(8 Suppl):1–8 **(Ger)**

[Tissue–type plasminogen activator. An enzyme with multiple uses in ophthalmology] Hesse L. **Ophthalmologe** 1997 May;94(5):366–71 (44 ref.) **(Ger)**

[Modified manual rt–PA pulse–spray lysis in occlusions of leg arteries and femoro–popliteal bypasses] Müller–Hülsbeck S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Dec;165(6):557–62 (Eng. Abstr.) **(Ger)**

[Thrombolysis following myocardial infarct. European

Secondary Prevention Study] Schilling J, et al. **Schweiz Rundsch Med Prax** 1996 Oct 15;85(42):1311–5 (Eng. Abstr.) **(Ger)**

[Bolus thrombolysis in pulmonary embolism. Review of experimental and clinical data] Zonzin P, et al. **Ann Ital Med Int** 1996 Apr–Jun;11(2):132–7 (35 ref.) (Eng. Abstr.) **(Ita)**

[Evaluation of the cost–effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective] Lorenzoni R, et al. **G Ital Cardiol** 1997 Jul;27(7):721–6 (Eng. Abstr.) **(Ita)**

[Massive pulmonary embolism during the third trimester of pregnancy: effectiveness of thrombolytic treatment with alteplase] Saviotti M, et al. **G Ital Cardiol** 1997 Jan; 27(1):72–5 (Eng. Abstr.) **(Ita)**

[Floating thromboembolism of the right atrium in pulmonary embolism. Effectiveness of treatment with rTPA] Stefanini MG, et al. **Minerva Cardioangiol** 1997 Jan–Feb;45(1–2):21–4 (Eng. Abstr.) **(Ita)**

[Thrombus in the right ventricle in an infant––a good result of thrombolytic therapy with recombinant tissue plasminogen activator] Aleszewicz–Baranowska J, et al. **Przegl Lek** 1997;54(3):201–3 (Eng. Abstr.) **(Pol)**

[Acute embolic stroke treated with rt–PA during elective coronary angiography] Ascer E, et al. **Arq Bras Cardiol** 1996 Sep;67(3):171–3 (Eng. Abstr.) **(Por)**

[Thrombolytic therapy in acute myocardial infarct––is it being used to the fullest?] Carôla B, et al. **Rev Port Cardiol** 1996 Dec;15(12):867–76, 863 (Eng. Abstr.) **(Por)**

[Mobile thrombus in the right atrium and pulmonary embolism: efficacy of thrombolytic treatment with alteplase (letter)] López–Haldón JE, et al. **Med Clin (Barc)** 1997 Feb 8;108(5):198 **(Spa)**

TOXICITY

Single and repeated intravenous toxicity studies of pamiteplase (genetical recombination) in rats and monkeys. Ishikawa A, et al. **J Toxicol Sci** 1997 May;22(2):117–33

ALTERNARIA

Chemistry and biological activity of AAL toxins. Winter CK, et al. **Adv Exp Med Biol** 1996;392:307–16 (42 ref.)

Onychomycosis and keratomycosis caused by Alternaria sp. A bipolar opportunistic infection in a wood–pulp worker on chronic steroid therapy. Arrese JE, et al. **Am J Dermatopathol** 1996 Dec;18(6):611–3

Cutaneous Alternaria alternata infection successfully treated with itraconazole. Del Palacio A, et al. **Clin Exp Dermatol** 1996 May;21(3):241–3

A case of Alternaria keratitis treated with fluconazole [letter] Koç AN, et al. **Eur J Clin Microbiol Infect Dis** 1997 Apr; 16(4):322–3

Mycotoxins in ingredients of animal feeding stuffs: I. Determination of Alternaria mycotoxins in oilseed rape meal and sunflower seed meal. Nawaz S, et al. **Food Addit Contam** 1997 Apr;14(3):249–62

Co–existence of cutaneous and presumptive pulmonary alternariosis. Lerner LH, et al. **Int J Dermatol** 1997 Apr; 36(4):285–8

Phaeohyphomycosis due to Alternaria spp. and Phaeosclera dematioides: a histopathological study. Pec J, et al. **Mycoses** 1996 May–Jun;39(5–6):217–21

Cutaneous phaeohyphomycosis due to Alternaria tenuissima. Romano C, et al. **Mycoses** 1996 May–Jun;39(5–6):211–5

CHEMISTRY

Synthesis, structure, and properties of MeSer1–tentoxin, a new cyclic tetrapeptide which interacts specifically with chloroplast F1 H(+)–ATPase differentiation of inhibitory and stimulating effects. Pinet E, et al. **Biochemistry** 1996 Oct 1;35(39):12804–11

Gas chromatography–mass spectrometry of Alternaria mycotoxins. Scott PM, et al. **J Chromatogr A** 1997 Mar 28;765(2):255–63

[Tentoxin: structure–activity relationship. Application to the study of its action on chloroplast ATP–synthase] André F, et al. **C R Seances Soc Biol Fil** 1997;191(3):401–32 (124 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular characterization of Alternaria alternata and Cladosporium herbarum allergens. Achatz G, et al. **Adv Exp Med Biol** 1996;409:157–61

Isolation of a cDNA clone encoding a putative Alternaria alternata Alt a I subunit. De Vouge MW, et al. **Adv Exp Med Biol** 1996;409:205–12

The Alternaria alternata melanin biosynthesis gene restores appressorial melanization and penetration of cellulose membranes in the melanin–deficient albino mutant of Colletotrichum lagenarium. Takano Y, et al. **Fungal Genet Biol** 1996 Feb;21(1):131–40

Circular DNA plasmid in the phytopathogenic fungus Alternaria alternata: its temperature–dependent curing and association with pathogenicity. Katsuya S, et al. **Genetics** 1997 May;146(1):111–20

Isolation and expression of a cDNA clone encoding an Alternaria alternata Alt a 1 subunit. De Vouge MW, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):385–95

The melanin biosynthesis genes of Alternaria alternata can restore pathogenicity of the melanin–deficient mutants of Magnaporthe grisea. Kawamura C, et al. **Mol Plant Microbe Interact** 1997 May;10(4):446–53

IMMUNOLOGY

Alternaria as a major allergen for asthma in children raised in a desert environment. Halonen M, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1356–61

In vitro synthesis of Alternaria allergens and their recognition by murine monoclonal and human IgE antibodies. Bush RK, et al. **Ann Allergy Asthma Immunol** 1997 Mar; 78(3):287–92

Sensitization to Alternaria and Cladosporium by the age of 4 years. Tariq SM, et al. **Clin Exp Allergy** 1996 Jul; 26(7):794–8

Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. Bernardis P, et al. **J Investig Allergol Clin Immunol** 1996 Jan–Feb;6(1):55–62

ISOLATION & PURIFICATION

Clinical review of nasal allergy due to fungus. Kim Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:105–7

Evaluation of four bioaerosol samplers in the outdoor environment. Cage BR, et al. **Ann Allergy Asthma Immunol** 1996 Nov;77(5):401–6

Cutaneous alternariosis: role of corticosteroid–induced cutaneous fragility. Machet L, et al. **Dermatology** 1996; 193(4):342–4 (17 ref.)

Evaluation of Alternaria and its mycotoxins during ensiling of sunflower seeds. Dacero AM, et al. **Nat Toxins** 1997; 5(1):20–3

[Allergic fungal sinusitis: is this rare disease an allergy or infection?] Berrettini S, et al. **Acta Otorhinolaryngol Ital** 1996 Oct;16(5):447–54 (Eng. Abstr.) **(Ita)**

METABOLISM

Production of a recombinant protein from Alternaria containing the reported N–terminal of the Alt a1 allergen. Barnes CS, et al. **Adv Exp Med Biol** 1996;409:197–203

Biosynthesis of fumonisin and aal derivatives by Alternaria and Fusarium in laboratory culture. Mirocha CJ, et al. **Adv Exp Med Biol** 1996;392:213–24

The presence and phytotoxicity of fumonisins and AAL–toxin in Alternaria alternata [published erratum appears in Toxicon 1996 Apr;34(4):503] Abbas HK, et al. **Toxicon** 1996 Jan;34(1):133–6

PATHOGENICITY

Alternaria mycotoxins in black rot lesion of tomato fruit: conditions and regulation of their production. Hasan HA. **Acta Microbiol Immunol Hung** 1996;43(2–3):125–33

Pathogen–induced systemic activation of a plant defensin gene in Arabidopsis follows a salicylic acid–independent pathway. Penninckx IA, et al. **Plant Cell** 1996 Dec; 8(12):2309–23

ALTERNATE BINAURAL LOUDNESS BALANCE TEST see **RECRUITMENT DETECTION (AUDIOLOGY)**

ALTERNATIVE COMPLEMENT PATHWAY see **COMPLEMENT PATHWAY, ALTERNATIVE**

ALTERNATIVE MEDICINE

Defining and describing complementary and alternative medicine. Panel on Definition and Description, CAM Research Methodology Conference, April 1995. **Altern Ther Health Med** 1997 Mar;3(2):49–57

A communication process: a new paradigm applied to high–dilution effects on the living body. Bastide M, et al. **Altern Ther Health Med** 1997 Jul;3(4):35–9

The healing power of pets: a look at animal–assisted therapy. Dossey L. **Altern Ther Health Med** 1997 Jul;3(4):8–16 (31 ref.)

Running scared: how we hide from who we are [see comments] Dossey L. **Altern Ther Health Med** 1997 Mar; 3(2):8–15 (50 ref.). Comment in: Altern Ther Health Med 1997 Jul;3(4):19. Comment in: Altern Ther Health Med 1997 Jul;3(4):19–20, 22. Comment in: Altern Ther Health Med 1997 Jul;3(4):22.

Our research approaches must meet the goal of improving patient care. Edwards RA. **Altern Ther Health Med** 1997 Jan;3(1):100, 99

Illustration of a method for selecting research grant applications. Frey FJ, et al. **Altern Ther Health Med** 1997 May;3(3):35–8

Joan Halifax, PhD. Being with death and dying [interview by Bonnie Horrigan] Halifax J. **Altern Ther Health Med** 1997 Jul;3(4):68–75

Stuart Hameroff, MD consciousness and microtubules in a quantum world [interview by Bonnie Horrigan] Hameroff S. **Altern Ther Health Med** 1997 May;3(3):70–9

Integrating complementary and alternative medicine into conventional medical practice. Hufford DJ. **Altern Ther Health Med** 1997 May;3(3):81–3

Authority, knowledge, and substituted judgment, Part II. Hufford DJ. **Altern Ther Health Med** 1997 Mar;3(2):86–9

Cultural diversity, folk medicine, and alternative medicine. Hufford DJ. **Altern Ther Health Med** 1997 Jul;3(4):78–80

Jim Jealous, DO. Healing and the natural world [interview by Bonnie Horrigan] Jealous J. **Altern Ther Health Med** 1997 Jan;3(1):68–76

Entrainment and the cranial rhythmic impulse. McPartland JM, et al. **Altern Ther Health Med** 1997 Jan;3(1):40–5 (80 ref.)

Comments on the nature of prayer research [letter; comment] Miners S. **Altern Ther Health Med** 1997 Jul;3(4):19–20, 22 . Comment on: Altern Ther Health Med 1997 Mar;3(2):8–15.

Humanizing medicine: the humanities program at Marin General Hospital. Moore NG. **Altern Ther Health Med** 1997 Jul;3(4):33–4

Psychiatry and alternative medicine: constructing a rationale for integration [news] Moore NG. **Altern Ther Health Med** 1997 Mar;3(2):24, 26–7, 114 passim

Griffin Hospital: tailoring its facility and services to the needs of its patients. Moore NG. **Altern Ther Health Med** 1997 Mar;3(2):29–31

King County natural medicine clinic: public funding for integrated medicine. Moore NG. **Altern Ther Health Med** 1997 May;3(3):32–3

Spirituality in medicine [news] Moore NG. **Altern Ther Health Med** 1996 Nov;2(6):24–6, 103–5

Stress–induced immunosuppression and therapeutic touch. Olson M, et al. **Altern Ther Health Med** 1997 Mar; 3(2):68–74

Alternative medicine: a worldview. Pell SC. **Altern Ther Health Med** 1996 Nov;2(6):95

Bruce Pomeranz, PHD. Acupuncture and the raison d'être for alternative medicine [interview by Bonnie Horrigan] Pomeranz B. **Altern Ther Health Med** 1996 Nov;2(6):85–91

A review of complementary medicine in Europe. Rees R. **Altern Ther Health Med** 1997 Jan;3(1):82–3, 90

Rachel Naomi Remen, MD kitchen table wisdom: a conversation that heals [interview by Bonnie Horrigan] Remen RN. **Altern Ther Health Med** 1997 Mar;3(2):76–84

The mystery of health: reclaiming medicine's soul. Riley DS. **Altern Ther Health Med** 1997 Mar;3(2):128, 127

Causal modeling and alternative medicine. Schuck JR, et al. **Altern Ther Health Med** 1997 Mar;3(2):40–7 (72 ref.)

Dynamical energy systems and modern physics: fostering the science and spirit of complementary and alternative medicine. Schwartz GE, et al. **Altern Ther Health Med** 1997 May;3(3):46–56 (53 ref.)

A scientific plan for the evaluation of alternative medicine in the treatment of HIV/AIDS. Standish LJ, et al. **Altern Ther Health Med** 1997 Mar;3(2):58–67

The power to do harm [letter; comment] Taylor S. **Altern Ther Health Med** 1997 Jul;3(4):19. Comment on: Altern Ther Health Med 1997 Mar;3(2):8–15.

Complementary medicine use in a dementia clinic population. Hogan DB, et al. **Alzheimer Dis Assoc Disord** 1996 Summer;10(2):63–7

Complementary therapeutic alternatives: what can we learn? [editorial] Ku Y, et al. **Alzheimer Dis Assoc Disord** 1996 Summer;10(2):61–2

Different viewpoints on alternative medicine [letter; comment] Brown P. **Am Fam Physician** 1997 May 1; 55(6):2080; discussion 2083–4. Comment on: Am Fam Physician 1996 Nov 15;54(7):2184. 2187. Comment on: Am Fam Physician 1996 Nov 15;54(7):2205–12, 2218–20.

Why alternative medicine? [editorial; comment] [see comments] Chung MK. **Am Fam Physician** 1996 Nov 15; 54(7):2184, 2187. Comment on: Am Fam Physician 1996 Nov 15;54(7):2205–12, 2218–20. Comment in: Am Fam Physician 1997 May 1;55(6):2080; discussion 2083–4.

Different viewpoints on alternative medicine [letter; comment] Davis EH. **Am Fam Physician** 1997 May 1; 55(6):2079; discussion 2083–4. Comment on: Am Fam Physician 1996 Nov 15;54(7):2205–12, 2218–20.

Alternative medicine and the family physician [see comments] Gordon JS. **Am Fam Physician** 1996 Nov 15; 54(7):2205–12, 2218–20 (37 ref.). Comment in: Am Fam Physician 1996 Nov 15;54(7):2184, 2187. Comment in: Am Fam Physician 1997 May 1;55(6):2079; discussion 2083–4. Comment in: Am Fam Physician 1997 May 1;55(6):2080; discussion 2083–4. Comment in: Am Fam Physician 1997 May 1;55(6):2080, 2082; discussion 2083–4. Comment in: Am Fam Physician 1997 May 1;55(6):2083; discussion 2083–4.

Different viewpoints on alternative medicine [letter; comment] Hanson DE. **Am Fam Physician** 1997 May 1; 55(6):2080, 2082; discussion 2083–4. Comment on: Am Fam Physician 1996 Nov 15;54(7):2205–12, 2218–20.

Different viewpoints on alternative medicine [letter; comment] Schiller RM, et al. **Am Fam Physician** 1997 May 1;55(6):2083; discussion 2083–4. Comment on: Am Fam Physician 1996 Nov 15;54(7):2205–12, 2218–20.

Advising patients who seek alternative medical therapies. Eisenberg DM. **Ann Intern Med** 1997 Jul 1;127(1):61–9

Alternative therapies for cutaneous disorders [editorial; comment] Eisenberg D. **Arch Dermatol** 1997 Mar; 133(3):379–80. Comment on: Arch Dermatol 1997 Mar;133(3):316–21.

Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma [see comments] Söllner W, et al. **Arch Dermatol** 1997 Mar;133(3):316–21. Comment in: Arch Dermatol 1997 Mar;133(3):379–80.

And now, alternative medicine... [editorial; comment] Spencer J, et al. **Arch Fam Med** 1997 Mar–Apr;6(2):155–6

. Comment on: Arch Fam Med 1997 Mar-Apr;6(2):149-54. Comment on: Arch Fam Med 1997 Mar-Apr;6(2):181-4.

The mind-body-spirit connection. Goldberg B. **ASHA** 1997 Summer;39(3):24-9, 31

Exploring alternative medicine on the Internet. Kuster JM. **ASHA** 1997 Summer;39(3):47

AMA cautions on alternative therapies [news] McDaniel CG. **BMJ** 1997 Jan 11;314(7074):94

Complementary medicine. Most private medical insurers will pay for certain forms of complementary medicine [letter; comment] Pal B. **BMJ** 1996 Oct 26;313(7064):1080. Comment on: BMJ 1996 Jul 20;313(7050):131-3.

European campaign backs complementary medicine [news] Watson R. **BMJ** 1996 Oct 26;313(7064):1035

Audiological and psychological characteristics of a group of tinnitus sufferers, prior to tinnitus management training. Dineen R, et al. **Br J Audiol** 1997 Feb;31(1):27-38

Iatrogenic Mycobacterium abscessus infection: histopathology of 71 patients. Rodríguez G, et al. **Br J Dermatol** 1997 Aug;137(2):214-8

Complementary medicine [letter; comment] Barnes J, et al. **Br J Gen Pract** 1997 May;47(418):329. Comment on: Br J Gen Pract 1997 Jan;47(414):47-9.

Complementary medicine--doing more good than harm? [editorial] [see comments] Ernst E. **Br J Gen Pract** 1996 Feb;46(403):60-1. Comment in: Br J Gen Pract 1996 Jul;46(408):440.

Referrals between GPs and complementary practitioners [letter] Ernst E, et al. **Br J Gen Pract** 1996 Aug;46(409):494

Alternative medicine: where's the evidence? [editorial] Beyerstein B. **Can J Public Health** 1997 May-Jun; 88(3):149-52 **(Eng, Fre)**

Physicians' attitudes toward patients' use of alternative cancer therapies. Bourgeault IL. **Can Med Assoc J** 1996 Dec 15;155(12):1679-85

Psychiatric perspective of persons with "environmental illness". Black DW. **Clin Rev Allergy Immunol** 1996 Fall; 14(3):337-55 (38 ref.)

Chinese herbal medicine in the treatment of asthma and allergies. But P, et al. **Clin Rev Allergy Immunol** 1996 Fall; 14(3):253-69 (40 ref.)

Controversial forms of treatment for asthma. Chanez P, et al. **Clin Rev Allergy Immunol** 1996 Fall;14(3):247-52 (26 ref.)

Alternative and complementary therapy for asthma. Gershwin ME, et al. **Clin Rev Allergy Immunol** 1996 Fall; 14(3):241-5 (0 ref.)

Complementary and alternative medicine and asthma. Hackman RM, et al. **Clin Rev Allergy Immunol** 1996 Fall; 14(3):321-36 (95 ref.)

International perspectives on controversial practices in allergic diseases: the South American experience. Malka S, et al. **Clin Rev Allergy Immunol** 1996 Fall;14(3):271-87 (58 ref.)

Unconventional therapy in asthma. Ziment I. **Clin Rev Allergy Immunol** 1996 Fall;14(3):289-320 (38 ref.)

Factors predisposing to the resort of complementary therapies in patients with fibromyalgia. Dimmock S, et al. **Clin Rheumatol** 1996 Sep;15(5):478-82

Alternatives to conventional hormone replacement therapy. Taylor M. **Compr Ther** 1997 Aug;23(8):514-32 (88 ref.)

Alternative psychotherapeutic practice among middle class Americans: I: Case studies and follow-up. Zatzick DF, et al. **Cult Med Psychiatry** 1997 Mar;21(1):53-88

Complementary medicine. Schimpff SC. **Curr Opin Oncol** 1997 Jul;9(4):327-31 (18 ref.)

Communicating with and treating cancer patients: how does the use of non-proven therapies and patients' feeling of mental distress influence the interaction between the patient and the hospital staff. Risberg T, et al. **Eur J Cancer** 1997 May;33(6):883-90

Why are cancer patients using non-proven complementary therapies? A cross-sectional multicentre study in Norway. Risberg T, et al. **Eur J Cancer** 1997 Apr;33(4):575-80

The attitude against immunisation within some branches of complementary medicine. Ernst E. **Eur J Pediatr** 1997 Jul; 156(7):513-5 (32 ref.)

Alternative health practices in ethnically diverse rural areas: a collaborative research project. Vest GW, et al. **Health Soc Work** 1997 May;22(2):95-100

Managed care ... alternative medicine [news] **Hosp Health Netw** 1996 Dec 20;70(24):10-1

Bringing mind-body medicine into the mainstream. Taylor E, et al. **Hosp Pract (Off Ed)** 1997 May 15;32(5):183-4, 193-6

Alternative medicine and enlightened physicians [letter; comment] Becker K. **Image J Nurs Sch** 1997 Spring;29(1):8. Comment on: Image J Nurs Sch 1996 Summer;28(2):95-9.

Complementary AIDS therapies: the good, the bad and the ugly [editorial] Ernst E. **Int J STD AIDS** 1997 May; 8(5):281-5 (35 ref.)

How should we research unconventional therapies? A panel report from the Conference on Complementary and Alternative Medicine Research Methodology, National Institutes of Health. Vickers A, et al. **Int J Technol Assess Health Care** 1997 Winter;13(1):111-21

Alternative medicine. Kligman E. **Iowa Med** 1997 Jul-Aug; 87(6):232-4 (0 ref.)

Blind faith? A cause of pre-operative eye infection. Blake J. **Ir Med J** 1996 Jan-Feb;89(1):27

Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents. Ostrow MJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jun 1;15(2):115-20

In praise of alternative medicine: views of a healthcare consumer and college health employee. Dinur E. **J Am Coll Health** 1997 Jan;45(4):183-6

Beyond anecdote: OAM investigates alternative therapies. Friebele E. **J Am Pharm Assoc (Wash)** 1997 May-Jun; NS37(3):287-90

Members oppose AVMA's guidelines for alternative and complementary veterinary medicine [letter] [see comments] Anderson BC. **J Am Vet Med Assoc** 1996 Nov 15; 209(10):1687. Comment in: J Am Vet Med Assoc 1997 Jan 15;210(2):168; discussion 169-70. Comment in: J Am Vet Med Assoc 1997 Jan 15;210(2):168-9; discussion 169-70. Comment in: J Am Vet Med Assoc 1997 Jan 15;210(2):169; discussion 169-70.

Wherefore complementary medicine? Wynn SG. **J Am Vet Med Assoc** 1996 Oct 1;209(7):1228-33 (46 ref.)

Complementary and alternative medicine and HIV/AIDS. Part I: Issues and context. MacIntyre RC, et al. **J Assoc Nurses AIDS Care** 1997 Jan-Feb;8(1):23-31 (54 ref.)

Complementary and alternative medicine and HIV/AIDS. Part II: Selected literature review. MacIntyre RC, et al. **J Assoc Nurses AIDS Care** 1997 Mar-Apr;8(2):25-38 (84 ref.)

Health beliefs and alternative medicine: a qualitative study of breast cancer patients. Brown PJ, et al. **J Cancer Educ** 1996 Winter;11(4):226-9

Complementary therapies resource list. Casey A. **J Cardiovasc Nurs** 1996 Apr;10(3):87-91

Complementary therapies [comment] Stuart EM. **J Cardiovasc Nurs** 1996 Apr;10(3):v-x. Comment on: J Cardiovasc Nurs 1996 Apr;10(3):1-3. Comment on: J Cardiovasc Nurs 1996 Apr;10(3):4-26. Comment on: J Cardiovasc Nurs 1996 Apr;10(3):27-49. Comment on: J Cardiovasc Nurs 1996 Apr;10(3):55-64. Comment on: J Cardiovasc Nurs 1996 Apr;10(3):65-77. Comment on: J Cardiovasc Nurs 1996 Apr;10(3):78-86.

The physician and unorthodox cancer therapies. The American Society of Clinical Oncology. **J Clin Oncol** 1997 Jan;15(1):401-6

Alternative medicine: more than chicken soup? [editorial] Barnett ML. **J Dent Res** 1996 Oct;75(10):1721-2

Alternative medicine [editorial] Jonas WB. **J Fam Pract** 1997 Jul;45(1):34-7

Women's use of complementary medicine. Combining mainstream medicine with alternative practices. Burg MA. **J Fla Med Assoc** 1996 Aug-Sep;83(7):482-8 (21 ref.)

Complementary medicine: from quackery to science? [editorial] Ernst E. **J Lab Clin Med** 1996 Mar;127(3):244-5

Against nonscientific treatments [editorial] Lerner IJ. **J Lab Clin Med** 1996 Mar;127(3):242-3

Complementary medicine: a different dimension [letter] Yeolekar ME. **J Lab Clin Med** 1997 Feb;129(2):266

Healthy aging: the body/mind/spirit connection. Schotanus WM. **J Med Assoc Ga** 1997 Apr;86(2):127-8

The ethics of complementary medicine [editorial] Ernst E. **J Med Ethics** 1996 Aug;22(4):197-8

Green tea, mistletoe, and more: Canadians test alternative cancer therapies [news] Holzman D. **J Natl Cancer Inst** 1997 May 21;89(10):683-4

Use of alternative therapies: estimates from the 1994 Robert Wood Johnson Foundation National Access to Care Survey. Paramore LC. **J Pain Symptom Manage** 1997 Feb; 13(2):83-9

Physician perspectives on unconventional cancer therapies. Gray RE, et al. **J Palliat Care** 1997 Summer;13(2):14-21

Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. Moser G, et al. **J Psychosom Res** 1996 May;40(5):503-9

Medicine: alternative, complementary or competitive? Some thoughts on other ways of doing things. Ngu Blackett K. **J R Coll Physicians Lond** 1997 Mar-Apr;31(2):155-7

Science versus quackery [letter; comment] Baldwin E. **J R Soc Med** 1996 Dec;89(12):727. Comment on: J R Soc Med 1996 Oct;89(10):543-7.

Science versus quackery [letter; comment] De Hoff JB. **J R Soc Med** 1997 Feb;90(2):119. Comment on: J R Soc Med 1996 Oct;89(10):543-7.

Do complementary practitioners have a better bedside manner than physicians? [letter] Ernst E, et al. **J R Soc Med** 1997 Feb;90(2):118-9

Complementary medicine in the medical curriculum [letter] Grange JM. **J R Soc Med** 1997 May;90(5):300

Quack cancer cures or scientific remedies? [letter; comment] Mackay-James M. **J R Soc Med** 1997 Jan;90(1):59. Comment on: J R Soc Med 1996 Oct;89(10):543-7.

Stress and cancer [letter] Rosch PJ. **J R Soc Med** 1997 Apr; 90(4):238

Nonphysician practitioner treatments and fibromyalgia syndrome. Fitzcharles MA, et al. **J Rheumatol** 1997 May; 24(5):937-40

Lessons from antineoplaston [editorial] [see comments] **Lancet** 1997 Mar 15;349(9054):741. Comment in: Lancet 1997 May 17;349(9063):1480. Comment in: Lancet 1997 May 17;349(9063):1481.

Lessons from antineoplaston [letter; comment] Baldwin of Bewdley. **Lancet** 1997 May 17;349(9063):1480. Comment on: Lancet 1997 Mar 15;349(9054):741.

Wheat and chaff in alternative medicine [letter] Bellavite P. **Lancet** 1997 May 31;349(9065):1629

Lessons from antineoplaston [letter; comment] Fahner JB. **Lancet** 1997 May 17;349(9063):1480. Comment on: Lancet 1997 Mar 15;349(9054):741.

Wheat and chaff in alternative medicine [letter] Fisher P. **Lancet** 1997 May 31;349(9065):1629

Lessons from antineoplaston [letter; comment] Silver H. **Lancet** 1997 May 17;349(9063):1480. Comment on: Lancet 1997 Mar 15;349(9054):741.

Lessons from antineoplaston [letter; comment] Tweddle S, et al. **Lancet** 1997 May 17;349(9063):1481. Comment on: Lancet 1997 Mar 15;349(9054):741.

Ear candles--efficacy and safety. Seely DR, et al. **Laryngoscope** 1996 Oct;106(10):1226-9

Alternative drug use for the climacteric in Finland. Mäntyranta T, et al. **Maturitas** 1997 May;27(1):5-11

Technology and alternative cancer therapies: an analysis of heterodoxy and constructivism. Hess DJ. **Med Anthropol Q** 1996 Dec;10(4):657-74 (62 ref.)

Making treatment decisions with HIV infection: a pilot study of patient preferences. Rosenfeld BD, et al. **Med Decis Making** 1997 Jul-Sep;17(3):307-14

Exploiting complementary therapeutic strategies for the treatment of type II diabetes and prevention of its complications. McCarty MF. **Med Hypotheses** 1997 Aug; 49(2):143-52

Patterns of alternative medicine use by cancer patients [see comments] Begbie SD, et al. **Med J Aust** 1996 Nov 18; 165(10):545-8. Comment in: Med J Aust 1996 Nov 18;165(10):536-7.

Alternative cancer treatments [editorial; comment] Lowenthal RM. **Med J Aust** 1996 Nov 18;165(10):536-7. Comment on: Med J Aust 1996 Nov 18;165(10):545-8.

Use of micronutrients and alternative drugs by children with acute lymphoblastic leukemia. Möttönen M, et al. **Med Pediatr Oncol** 1997 Mar;28(3):205-8

Hepatic and renal toxicity among patients ingesting sheep bile as an unconventional remedy for diabetes mellitus--Saudi Arabia, 1995. **MMWR Morb Mortal Wkly Rep** 1996 Nov 1;45(43):941-3

Integrative geriatrics. Combining traditional and alternative medicine. O'Brien ME. **N C Med J** 1996 Nov-Dec; 57(6):364-7

Consequences of cupping [letter; comment] Dearlove O, et al. **N Engl J Med** 1997 Apr 10;336(15):1109. Comment on: N Engl J Med 1996 Oct 24;335(17):1281.

Images in clinical medicine. Consequences of cupping [see comments] Manber H, et al. **N Engl J Med** 1996 Oct 24; 335(17):1281. Comment in: N Engl J Med 1997 Apr 10;336(15):1109.

Traveling down a different path: alternative medicine. Berlin B. **N J Med** 1997 Apr;94(4):35-7

That's an herb, Herb [editorial] Slobodien HD. **N J Med** 1996 Dec;93(12):17-8

Well done [letter; comment] Arnold M. **N Y State Dent J** 1997 May;63(5):10-1. Comment on: N Y State Dent J 1997 Mar;63(3):32-7.

Not fit to print [letter; comment] Cooper BC. **N Y State Dent J** 1997 May;63(5):10, 13-4. Comment on: N Y State Dent J 1997 Mar;63(3):32-7.

Where's the proof? [letter; comment] Friedman MS. **N Y State Dent J** 1997 May;63(5):10, 13-14. Comment on: N Y State Dent J 1997 Mar;63(3):32-7.

Editor should step down [letter; comment] Kull RS. **N Y State Dent J** 1997 May;63(5):12. Comment on: N Y State Dent J 1997 Mar;63(3):32-7.

Time warp [letter; comment] Levine SW. **N Y State Dent J** 1997 May;63(5):12, 13-4. Comment on: N Y State Dent J 1997 Mar;63(3):32-7.

Let me be the judge [letter; comment] Mark BM. **N Y State Dent J** 1997 May;63(5):11, 13-4. Comment on: N Y State Dent J 1997 Mar;63(3):32-7.

A circus atmosphere [letter; comment] Miller JS. **N Y State Dent J** 1997 May;63(5):11-2. Comment on: N Y State Dent J 1997 Mar;63(3):32-7.

Dentistry and alternative therapy [see comments] Schissel MJ, et al. **N Y State Dent J** 1997 Mar;63(3):32-7. Comment in: N Y State Dent J 1997 May;63(5):10, 13-4. Comment in: N Y State Dent J 1997 May;63(5):10-1. Comment in: N Y State Dent J 1997 May;63(5):11, 13-4. Comment in: N Y State Dent J 1997 May;63(5):11-2. Comment in: N Y State Dent J 1997 May;63(5):12. Comment in: N Y State Dent J 1997 May;63(5):12, 13-4.

Silly season [letter] Shaskan SE. **N Y State Dent J** 1997 Jun-Jul;63(6):10

Researching alternative medicine. Jonas WB. **Nat Med** 1997 Aug;3(8):824-7

'Integrated' medical care combines allopathic and alternative treatments [news] Das Dores Silva YJ. **Natl Med J India** 1997 May-Jun;10(3):146-7

Alternative therapy bias [letter] Ernst E, et al. **Nature** 1997 Feb 6;385(6616):480

The nurse practitioner and issues of alternative therapies [letter] Slagle MW. **Nurse Pract** 1996 Feb;21(2):16,18-9

Complementary therapies: an adjunct to traditional therapies [letter] Whitmore SM, et al. **Nurse Pract** 1996 Aug;21(8):10, 12-3

Unconventional therapy in Pennsylvania practices. Baldwin FD. **Pa Med** 1996 Nov;99(11):9-11

Alternative therapy for colds [letter] Turow V. **Pediatrics**

1997 Aug;100(2 Pt 1):274–5

Alternative therapeutic modalities. Alternative medicine. Kaul PN. **Prog Drug Res** 1996;47:251–77 (129 ref.)

Lessons from the windmill [editorial] Freeman JW. **S D J Med** 1997 Feb;50(2):51–2

Health care and consumer choice: medical and alternative therapies. Kelner M, et al. **Soc Sci Med** 1997 Jul; 45(2):203–12

The choice of alternative therapy for health care: testing some propositions [published erratum appears in Soc Sci Med 1996 Apr;42(7):III] McGregor KJ, et al. **Soc Sci Med** 1996 Nov;43(9):1317–27

Medical heresy—the view of a heretic. Stambolovic V. **Soc Sci Med** 1996 Sep;43(5):601–4

Contingent legitimacy: U.K. alternative practitioners and inter-sectoral acceptance. Tovey P. **Soc Sci Med** 1997 Oct; 45(7):1129–33

No alternative. Pearson RM. **Tenn Med** 1997 Feb;90(2):41

Chelation therapy for cardiovascular disease. Review and commentary [editorial] Lewin MR. **Tex Heart Inst J** 1997; 24(2):81–9 (66 ref.)

Radio-opaque punctate opacities on the chest radiograph following intravenous injection of a bismuth compound. Addrizzo-Harris DJ, et al. **Thorax** 1997 Mar;52(3):303–4

Complementary medicine and oncologists' attitudes: a survey in Italy. Crocetti E, et al. **Tumori** 1996 Nov–Dec; 82(6):539–42

Complementary medicine: patients first? [editorial; comment] Ernst E. **Wien Klin Wochenschr** 1996;108(20):631–3. Comment on: Wien Klin Wochenschr 1996;108(20):654–63.

Alternative medicines—do you know what your patients are using? Burke JD. **Wis Med J** 1997 Mar;96(3):19–20

Magnetic therapy is ineffective for the treatment of snoring and obstructive sleep apnea syndrome [see comments] Dexter D Jr. **Wis Med J** 1997 Mar;96(3):35–7. Comment in: Wis Med J 1997 Mar;96(3):10–1.

Alternative medicine and snoring [editorial; comment] Leo G. **Wis Med J** 1997 Mar;96(3):10–1. Comment on: Wis Med J 1997 Mar;96(3):35–7.

Alternative medicine—is it a new payment system or a weird remedy, or just another way to solve a medical problem? [editorial] Renner JH. **Wis Med J** 1997 Mar;96(3):8–9

An ancient heritage beckons pharmacists. Vance DA. **Wis Med J** 1997 Mar;96(3):32–4

[Iridodiagnosis in modern health care (letter)] Doležalová V. **Cesk Slov Oftalmol** 1996 Nov;52(6):407–8 **(Cze)**

[Components that divide (letter; comment)] Launsø L. **Ugeskr Laeger** 1996 Oct 21;158(43):6122–3. Comment on: Ugeskr Laeger 1996 Aug 5;158(32):4527–8. **(Dan)**

[Allergology and alternative medicine. The Specialists Commission of the Société Suisse d'Allergologie et d'Immunologie (SSAI)] **Schweiz Monatsschr Zahnmed** 1996;106(4):394–6, 412, 414–5 **(Fre, Ger)**

[No medicine without scientific evidence of effectiveness. Doubts regarding alternative medicine] Marx HH. **Fortschr Med** 1996 Oct 10;114(28):12–4; discussion 14 **(Ger)**

[Current therapy of idiopathic Parkinson disease. 2: Recent and alternative therapies] Müller T, et al. **Fortschr Med** 1997 May 10;115(13):37–41 (0 ref.) (Eng. Abstr.) **(Ger)**

[Bioresonance therapy in treatment of allergies. Every person has his own vibration pattern (interview by Beatrice Wagner)] Süss S. **Fortschr Med** 1997 Apr 20;115(11):16, 18 **(Ger)**

[Alternatives in therapy of arthroses] Weihmayr T. **Fortschr Med** 1997 Feb 20;115(5):37 **(Ger)**

[Complementary or alternative medicine] Kafman M, et al. **Harefuah** 1996 Jul;131(1–2):46–50 (33 ref.) **(Heb)**

[Propolis and poplar bud extract. Some thoughts on alternative medicine (editorial; comment)] Rák K. **Orv Hetil** 1996 Jun 23;137(25):1363–4. Comment on: Orv Hetil 1996 Jun 23;137(25):1365–70. **(Hun)**

[Alternative medicine. State of the art and perspectives] Guarini G. **Recenti Prog Med** 1997 Feb;88(2):61–4 **(Ita)**

[Norwegian physicians and alternative medicine. Knowledge, attitudes and experiences] Aasland OG, et al. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2464–8 (Eng. Abstr.) **(Nor)**

[Research in alternative medicine. What is documented, and what is documentation?] Borchgrevink CF. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2469–73 (34 ref.) (Eng. Abstr.) **(Nor)**

[Medical art and scientific medicine] Iversen JG. **Tidsskr Nor Laegeforen** 1997 Jan 20;117(2):253–4 **(Nor)**

[Searching for alternatives (editorial)] Nylenna M. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2431 **(Nor)**

[Position of the Principle Board of the Polish Allergy Society on unconventional methods of diagnosis and treatment] **Pol Merkuriusz Lek** 1996 Oct;1(4):291 **(Pol)**

[Bioresonance therapy. MORA therapy. BICOM (biocommunication)] **Pol Merkuriusz Lek** 1996 Oct; 1(4):294–8 (14 ref.) **(Pol)**

[Decision by the Principle Board of the Polish Allergy Society] Płusa T, et al. **Pol Merkuriusz Lek** 1996 Oct; 1(4):292–3 **(Pol)**

[Speech given at the reunion of the Federation of National Academies of Medicine of the European Community which took place the 19th day of April of 1996] Armijo Valenzuela M, et al. **An R Acad Nac Med (Madr)** 1996; 113(2):241–60 **(Spa)**

ECONOMICS

A review of reimbursement policies for alternative and complementary therapies [news] Moore NG. **Altern Ther Health Med** 1997 Jan;3(1):26–9, 91–2

Managed care and alternative medicine: who will manage what, and how? Rossman ML, et al. **Altern Ther Health Med** 1997 May;3(3):63–8

EU to support complementary medicine? [news] **Ann Oncol** 1997 Jan;8(1):3

Regulating complementary medicine. Only 0.08% of funding for research in NHS goes to complementary medicine [letter] Ernst E. **BMJ** 1996 Oct 5;313(7061):882

Complementary medicine [letter; comment] Pal B, et al. **J R Coll Physicians Lond** 1997 Jan–Feb;31(1):111–2. Comment on: J R Coll Physicians Lond 1996 Sep–Oct;30(5):406–9.

Using willingness to pay to value alternative models of antenatal care. Ryan M, et al. **Soc Sci Med** 1997 Feb; 44(3):371–80

[The dilemma of effectiveness and economic value of alternative medicine] Marx HH. **Gesundheitswesen** 1997 May;59(5):297–301 (Eng. Abstr.) **(Ger)**

EDUCATION

Metaphors in the teaching of holistic medicine. Leskowitz E. **Altern Ther Health Med** 1997 Jul;3(4):112, 111

A proposal for teaching critical thinking to students and practitioners of complementary medicine. Vickers A. **Altern Ther Health Med** 1997 May;3(3):57–62

Finding out about patients' alternative medicines. King RS. **Am J Health Syst Pharm** 1996 Oct 1;53(19):2270–1

Alternative therapies [letter; comment] Jewell CE. **Image J Nurs Sch** 1997;29(2):108. Comment on: Image J Nurs Sch 1996 Summer;28(2):95–9.

Complementary medicine in the medical curriculum [letter] Bullock K. **J R Soc Med** 1997 Apr;90(4):239

Complementary medicine in the medical curriculum [letter; comment] Goodman J. **J R Soc Med** 1997 Mar;90(3):178 . Comment on: J R Soc Med 1997 Jan;90(1):19–22.

Introducing complementary medicine into the medical curriculum [see comments] Rampes H, et al. **J R Soc Med** 1997 Jan;90(1):19–22. Comment in: J R Soc Med 1997 Mar;90(3):178.

Complementary medicine in the medical curriculum [letter] Rampes H, et al. **J R Soc Med** 1997 Jun;90(6):357

HISTORY

Foretelling the future. Arabic astrology and English medicine in the late twelfth century. French R. **Isis** 1996 Sep; 87(3):453–80

"Swapping grief": the role of the laity in alternative medical encounters. Clow B. **J Hist Med Allied Sci** 1997 Apr; 52(2):175–201

Aristophanes' Wealth: ancient alternative medicine and its modern survival. Koutouvidis N, et al. **J R Soc Med** 1996 Nov;89(11):651–3

Med Chi vs. the Thomsonians: a legislative vignette. Burri M. **Md Med J** 1996 Feb;45(2):127–8

Consequences of cupping [letter; comment] Kaptchuk TD. **N Engl J Med** 1997 Apr 10;336(15):1109. Comment on: N Engl J Med 1996 Oct 24;335(17):1281.

'Natural remedies,' medical care, and politics [editorial] Bollet AJ. **South Med J** 1997 Apr;90(4):457–9

[History of healing; animal magnetism] Vijselaar J. **Ned Tijdschr Geneeskd** 1997 Jan 18;141(3):157–61 (Eng. Abstr.) **(Dut)**

[Health regimen of Anonymus Luneburgensis in 1442. 2: Medical consultations—Anonymus Luneburgensis consultations] Keil G. **Fortschr Med** 1996 Dec 20; 114(35–36):505–8 (Eng. Abstr.) **(Ger)**

["Lingue di seripi", "serpents' tongues" and "glossopetrae". Highlights from the history of popular "cult" medicine in early modern times] Freller T. **Sudhoffs Arch Z Wissenschaftsgesch** 1997;81(1):62–83 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Adverse reactions to alternative medicine [editorial] Thompson CA. **Am J Health Syst Pharm** 1997 Aug 1; 54(15):1707

Complementary medicine. Norwegian Ministry of Health is discussing whether to authorise various treatments [letter; comment] Engehaugen K, et al. **BMJ** 1996 Oct 26; 313(7064):1080–1. Comment on: BMJ 1996 Jul 20;313(7050):131–3.

Regulating complementary medicine. Statutory regulation is essential [letter; comment] Phillips KD. **BMJ** 1996 Oct 5; 313(7061):882. Comment on: BMJ 1996 Jun 15;312(7045):1492–3.

Regulating complementary medicine. Researchers into complementary therapy do not have to "sacrifice their therapeutic integrity" [letter; comment] Vickers A. **BMJ** 1996 Oct 5;313(7061):881–2. Comment on: BMJ 1996 Jun 15;312(7045):1492–3.

Courts, licensing bodies turning their attention to alternative therapies. Capen K. **Can Med Assoc J** 1997 May 1; 156(9):1307–8

Herbal medicine at a crossroads [news] Taylor D. **Environ Health Perspect** 1996 Sep;104(9):924–8

[Healing practitioner—a German phenomenon. What are the rights and responsibilities of healing practitioners?] Ernst E. **Fortschr Med** 1997 Feb 10;115(4):38–41 (Eng. Abstr.) **(Ger)**

[The physician as alternative practitioner?—regrettably impossible] Sautter R. **Fortschr Med** 1997 Mar 30; 115(9):55–6 **(Ger)**

MANPOWER

A proposal for teaching critical thinking to students and practitioners of complementary medicine. Vickers A. **Altern Ther Health Med** 1997 May;3(3):57–62

Trends in the education and practice of alternative medicine clinicians. Cooper RA, et al. **Health Aff (Millwood)** 1996 Fall;15(3):226–38

METHODS

Unconventional therapies in asthma: an overview. Lewith GT, et al. **Allergy** 1996 Nov;51(11):761–9 (105 ref.)

Hypertrophic obstructive cardiomyopathy: alternative therapeutic options [letter] Cheng TO. **Clin Cardiol** 1997 Jul;20(7):667

Alternative psychotherapeutic practice among middle class Americans: II: Some conceptual and practical comparisons. Zatzick DF, et al. **Cult Med Psychiatry** 1997 Jun; 21(2):213–46

Alternative therapies for asthma. Ziment I. **Curr Opin Pulm Med** 1997 Jan;3(1):61–71 (93 ref.)

Treating TMJ [letter] Hartstein S. **Ear Nose Throat J** 1997 Jan;76(1):47

Coning candles—an alert for otolaryngologists? [letter; comment] Seely DR, et al. **Ear Nose Throat J** 1997 Jan; 76(1):47. Comment on: Ear Nose Throat J 1996 Sep;75(9):585, 588.

Alternative cures for workers' comp injuries. Overman S. **Occup Health Saf** 1996 Apr;65(4):48, 50–1

Unorthodox treatment practices in rheumatology [editorial] Kahn MF. **Rev Rhum Engl Ed** 1997 Feb;64(2):75–7 (73 ref.)

[Non-conventional gastroenterology] Rapoport SI. **Klin Med (Mosk)** 1997;75(5):14–7 (27 ref.) **(Rus)**

[The combined treatment of peptic ulcer with the differentiated use of nontraditional physiotherapeutic methods] Asauliuk IK, et al. **Lik Sprava** 1996 Oct–Dec; (10–12):119–22 (Eng. Abstr.) **(Rus)**

[The current methods in the nontraditional therapy of peptic ulcer (a review of the literature and the authors' own data)] Filippov IuA, et al. **Lik Sprava** 1996 Oct–Dec; (10–12):14–20 (28 ref.) **(Rus)**

ORGANIZATION & ADMINISTRATION

Systematic clinical auditing in complementary medicine: rationale, concept, and a pilot study. Melchart D, et al. **Altern Ther Health Med** 1997 Jan;3(1):33–9

The Columbia-Presbyterian Complementary Care Center: comprehensive care of the mind, body, and spirit. Moore NG. **Altern Ther Health Med** 1997 Jan;3(1):30–2

Complementary medicine in the United Kingdom. Rees R. **Altern Ther Health Med** 1997 May;3(3):84–6

Centers provide OAM with 'deliverables'. Villaire M. **Altern Ther Health Med** 1997 Jan;3(1):20–4

Growing popularity of complementary medicine leads to national organization for MDs. Gray C. **CMAJ** 1997 Jul 15;157(2):186–8

STANDARDS

Clinical practice guidelines in complementary and alternative medicine. An analysis of opportunities and obstacles. Practice and Policy Guidelines Panel, National Institutes of Health Office of Alternative Medicine [see comments] **Arch Fam Med** 1997 Mar–Apr;6(2):149–54 (70 ref.). Comment in: Arch Fam Med 1997 Mar–Apr;6(2):155–6.

A measure of success [see comments] Lewith GT. **Br J Gen Pract** 1997 Jan;47(414):47–9. Comment in: Br J Gen Pract 1997 May;47(418):329.

Complementary medicine: use and attitudes among GPs. White AR, et al. **Fam Pract** 1997 Aug;14(4):302–6

Autonomy and practice: the case of complementary practitioners in the UK. Tovey P. **Int J Qual Health Care** 1997 Feb;9(1):55–9

Members oppose AVMA's guidelines for alternative and complementary veterinary medicine [letter] [see comments] Roberts SJ. **J Am Vet Med Assoc** 1996 Nov 15; 209(10):1687–8. Comment in: J Am Vet Med Assoc 1997 Jan 15;210(2):168; discussion 169–70. Comment in: J Am Vet Med Assoc 1997 Jan 15;210(2):168–9; discussion 169–70. Comment in: J Am Vet Med Assoc 1997 Jan 15;210(2):169; discussion 169–70.

Complementary medicine—is there a reasonable basis for dialogue? [editorial; comment] [see comments] Brewin TB. **J R Coll Physicians Lond** 1996 Sep–Oct;30(5):406–9. Comment on: J R Coll Physicians Lond 1996 Sep–Oct;30(5):410–2. Comment in: J R Coll Physicians Lond 1997 Jan–Feb;31(1):111–2.

Complementary medicine—the case for dialogue [see comments] Ernst E, et al. **J R Coll Physicians Lond** 1996 Sep–Oct;30(5):410–2. Comment in: J R Coll Physicians Lond 1996 Sep–Oct;30(5):406–9. Comment in: J R Coll Physicians Lond 1997 Jan–Feb;31(1):406–9.

Olfactory remediation: current evidence and possible applications. Martin GN. **Soc Sci Med** 1996 Jul;43(1):63–70 (75 ref.)

STATISTICS & NUMERICAL DATA

The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population. Stadberg E, et al.
Acta Obstet Gynecol Scand 1997 May;76(5):442–8

Cross sectional study of use of alternative medicines in Chinese cancer patients. Liu JM, et al.
Jpn J Clin Oncol 1997 Feb;27(1):37–41

[Decision to use complementary medicine: fact oriented or irrational? (see comments)] Hentschel C, et al.
Dtsch Med Wochenschr 1996 Dec 13;121(50):1553–60 (Eng. Abstr.). Comment in: Dtsch Med Wochenschr 1997 Apr 25;122(17):563. **(Ger)**

[Use of alternative medicine among Norwegian hospitalized cancer patients] Risberg T, et al.
Tidsskr Nor Laegeforen 1997 Jun 30;117(17):2458–63 (Eng. Abstr.) **(Nor)**

TRENDS

CMA symposium on alternative medicine draws standing-room-only crowd. Sullivan P.
Can Med Assoc J 1996 Nov 1;155(9):1330

Towards quality in complementary health care: is the German "Heilpraktiker" a model for complementary practitioners? Ernst E. **Int J Qual Health Care** 1996 Apr; 8(2):187–90

Medical ethnobotany survey in Martinique. Longuefosse JL, et al. **J Ethnopharmacol** 1996 Sep;53(3):117–42

A spot of tea [editorial] McIntyre RV.
J Okla State Med Assoc 1996 Sep;89(9):311

Alternative medicine: an expanding health industry [editorial; comment] Shenfield GM, et al. **Med J Aust** 1997 May 19; 166(10):516–7. Comment on: Med J Aust 1997 May 19;166(10):538–41.

A perspective on complementary medicine. Davey W.
Med Leg J 1997;65 (Pt 2):65–85

Extending the boundaries of medicine [comment] Haggerty RJ. **Pediatr Rev** 1996 Aug;17(8):263. Comment on: Pediatr Rev 1996 Aug;17(8):279–83.

Separation or synthesis: a holistic approach to therapeutics [see comments] Kemper KJ. **Pediatr Rev** 1996 Aug; 17(8):279–83 (25 ref.). Comment in: Pediatr Rev 1996 Aug;17(8):263.

Herbal treatments find their way into mainstream America. Pittenger J. **Wis Med J** 1997 Mar;96(3):30–1

[Alternative treatment in psychiatric and psychotherapy facilities in Germany] Andritzky W. **Gesundheitswesen** 1996 Jan;58(1):21–30 (Eng. Abstr.) **(Ger)**

[Science entails responsibility. Opening address of the president of the 103rd Congress of the German Society of Internal Medicine, Wiesbaden, 6 April 1997] Köbberling J. **Med Klin** 1997 Apr 15;92(4):181–9 **(Ger)**

[Science priority, medical paternalism or participation in medical practice] Gibiński K. **Pol Merkuriusz Lek** 1996 Sep;1(3):213–5 (39 ref.) (Eng. Abstr.) **(Pol)**

UTILIZATION

Use of alternative health care by family practice patients [see comments] Elder NC, et al. **Arch Fam Med** 1997 Mar–Apr; 6(2):181–4. Comment in: Arch Fam Med 1997 Mar–Apr;6(2):155–6.

Chiropractic for children. Turow VD.
Arch Pediatr Adolesc Med 1997 May;151(5):527–8

Complementary medicine [letter; comment] Paterson C.
Br J Gen Pract 1996 Jul;46(408):440. Comment on: Br J Gen Pract 1996 Feb;46(403):60–1.

How different are users and non-users of alternative medicine? Blais R, et al. **Can J Public Health** 1997 May–Jun;88(3):159–62

Use of alternative health care practitioners by Canadians. Millar WJ. **Can J Public Health** 1997 May–Jun;88(3):154–8

Unconventional cancer therapies. Gentile A.
Chronic Dis Can 1997;18(2):93–4

Use of complementary therapies by individuals with 'arthritis'. Resch KL, et al. **Clin Rheumatol** 1997 Jun; 16(4):391–5

Alternative therapies commonly used within a population of patients with psoriasis. Fleischer AB Jr, et al. **Cutis** 1996 Sep;58(3):216–20

Complementary medicine: use and attitudes among GPs. White AR, et al. **Fam Pract** 1997 Aug;14(4):302–6

Safety issues in herbal medicine: implications for the health professions [see comments] Drew AK, et al.
Med J Aust 1997 May 19;166(10):538–41 (38 ref.). Comment in: Med J Aust 1997 May 19;166(10):516–7.

Alternative/complementary therapies. Freeman JW, et al.
S D J Med 1997 Feb;50(2):65–6

Nonconventional medicine in Israel: consultation patterns of the Israeli population and attitudes of primary care physicians. Bernstein JH, et al. **Soc Sci Med** 1997 May; 44(9):1341–8

Health perceptions and self-care response to illness among users of medical and alternative health services in St Andrew, Jamaica. Williams SK. **West Indian Med J** 1996 Sep;45(3):78–81

Natural-borne healers. Kennedy M. **Wis Med J** 1997 Mar; 96(3):21–7

[The decision for complementary medicine—fact-oriented or irrational? (letter; comment)] Marx HH.
Dtsch Med Wochenschr 1997 Apr 25;122(17):563. Comment on: Dtsch Med Wochenschr 1996 Dec 13;121(50):1553–60. **(Ger)**

[Academic medical versus unconventional cancer therapy: anthropological viewpoints of an endless history] Kappauf H, et al. **Geburtshilfe Frauenheilkd** 1996 Aug;56(8):M116–9 **(Ger)**

[ICD diagnoses in university polyclinic naturopathy consultation] Hentschel C, et al. **Versicherungsmedizin** 1996 Aug 1;48(4):129–33 (Eng. Abstr.) **(Ger)**

VETERINARY

Do alternative therapies (acupuncture, herbalism, homeopathy, etc) have a role in your practice?
Aust Vet J 1996 Oct;74(4):273–4

Do alternative (acupuncture, herbalism, homeopathy etc) have a role in your practice? Thompson F, et al.
Aust Vet J 1996 Dec;74(6):426–7

More thoughts on alternative and complementary veterinary medicine [letter; comment] Ferguson B.
J Am Vet Med Assoc 1997 Jan 15;210(2):168–9; discussion 169–70. Comment on: J Am Vet Med Assoc 1996 Nov 15;209(10):1687. Comment on: J Am Vet Med Assoc 1996 Nov 15;209(10):1687–8.

More thoughts on alternative and complementary veterinary medicine [letter; comment] Ortenburger AI.
J Am Vet Med Assoc 1997 Jan 15;210(2):169; discussion 169–70. Comment on: J Am Vet Med Assoc 1996 Nov 15;209(10):1687. Comment on: J Am Vet Med Assoc 1996 Nov 15;209(10):1687–8.

More thoughts on alternative and complementary veterinary medicine [letter; comment] Shor L.
J Am Vet Med Assoc 1997 Jan 15;210(2):168; discussion 169–70. Comment on: J Am Vet Med Assoc 1996 Nov 15;209(10):1687. Comment on: J Am Vet Med Assoc 1996 Nov 15;209(10):1687–8.

ALTERNATIVE SPLICING

Fas splicing variants and their effect on apoptosis. Ruberti G, et al. **Adv Exp Med Biol** 1996;406:125–34 (67 ref.)

Alteration of CD44 expression in HIV type 1-infected T cell lines. Giordanengo V, et al.
AIDS Res Hum Retroviruses 1996 Nov 20;12(17):1615–22

A rare branch-point mutation is associated with missplicing of fibrillin-2 in a large family with congenital contractural arachnodactyly. Maslen C, et al. **Am J Hum Genet** 1997 Jun;60(6):1389–98

Alternative splicing of the FMR1 gene in human fetal brain neurons. Huang T, et al. **Am J Med Genet** 1996 Aug 9; 64(2):252–5

Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts. Coito AJ, et al. **Am J Pathol** 1997 May;150(5):1757–72

Physiologically regulated alternative splicing patterns of fast troponin T RNA are conserved in mammals. Briggs MM, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C298–305

Molecular cloning of two rat GRK6 splice variants. Firsov D, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C953–61

Properties of three COOH-terminal splice variants of a human cardiac L-type Ca2+-channel alpha1-subunit. Klöckner U, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1372–81

Tissue specificity and alternative splicing of the Na+/Ca2+ exchanger isoforms NCX1, NCX2, and NCX3 in rat. Quednau BD, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1250–61

Insulin receptor mRNA splicing and altered metabolic control in aged and mildly insulin-deficient rats. Wiersma MM, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E607–15

Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Horiuchi T, et al. **Am J Respir Cell Mol Biol** 1997 Jul;17(1):70–7

Quantitation of estrogen receptor mRNA and its alternatively spliced mRNAs in breast tumor cells and tissues. Fasco MJ. **Anal Biochem** 1997 Feb 15;245(2):167–78

Differential signaling and immediate-early gene activation by four splice variants of the human pituitary adenylate cyclase-activating polypeptide receptor (hPACAP-R). Pisegna JR, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:54–64; discussion 64–6

Alternative splicing of CYP2D mRNA in human breast tissue. Huang Z, et al. **Arch Biochem Biophys** 1997 Jul 1; 343(1):101–8

Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Cao Y, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):493–8

Differential splicing of the GTP cyclohydrolase I RNA in dopa-responsive dystonia. Hirano M, et al.
Biochem Biophys Res Commun 1997 May 19;234(2):316–9

cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS protein (BMAL1) and identification of alternatively spliced variants with alternative translation initiation site usage. Ikeda M, et al.
Biochem Biophys Res Commun 1997 Apr 7;233(1):258–64

Expression in hematopoietic cells of GATA-1 transcripts from the alternative "testis" promoter during development and cell differentiation. Moroni E, et al.
Biochem Biophys Res Commun 1997 Feb 13;231(2):299–304

Subcellular localization and protein interaction of the human LIMK2 gene expressing alternative transcripts with tissue-specific regulation. Osada H, et al.
Biochem Biophys Res Commun 1996 Dec 13;229(2):582–9

Follitropin signal transduction: alternative splicing of the FSH receptor gene produces a dominant negative form of receptor which inhibits hormone action. Sairam MR, et al. **Biochem Biophys Res Commun** 1996 Sep 24; 226(3):717–22

Dog CREM transcription factors: cloning, tissue distribution, and identification of new isoforms. Uyttersprot N, et al.
Biochem Biophys Res Commun 1997 Aug 8;237(1):74–8

The unique cytoplasmic domain of the human integrin variant beta4E is produced by partial retention of intronic sequences. van Leusden MR, et al.
Biochem Biophys Res Commun 1997 Jun 27;235(3):826–30

A novel trans-spliced mRNA from Onchocerca volvulus encodes a functional S-adenosylmethionine decarboxylase. Da'Dara AA, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):519–30

Alternative splicing of ClC-6 (a member of the ClC chloride-channel family) transcripts generates three truncated isoforms one of which, ClC-6c, is kidney-specific. Eggermont J, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):269–76

Species-specific alternative splicing of the epidermal growth factor-like domain 1 of cartilage aggrecan. Fülöp C, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):935–40

Alternative splicing of the human IgA Fc receptor CD89 in neutrophils and eosinophils. Pleass RJ, et al.
Biochem J 1996 Sep 15;318 (Pt 3):771–7

Sequence elements surrounding the acceptor site suppress alternative splicing of the sarco/endoplasmic reticulum Ca2+-ATPase 2 gene transcript. Van Den Bosch L, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):885–91

Two forms of Wilson disease protein produced by alternative splicing are localized in distinct cellular compartments. Yang XL, et al. **Biochem J** 1997 Sep 15;326 (Pt 3):897–902

Identification of a splice site mutation in the cystathionine beta-synthase gene resulting in variable and novel splicing defects of pre-mRNA. Tsai MY, et al.
Biochem Mol Med 1997 Jun;61(1):9–15

The N-terminal alternately spliced regions of PDE4A cAMP-specific phosphodiesterases determine intracellular targeting and regulation of catalytic activity. Houslay MD.
Biochem Soc Trans 1996 Nov;24(4):980–6

Regulation of the expression of distinct human secreted IgE proteins produced by alternative RNA splicing. Saxon A, et al. **Biochem Soc Trans** 1997 May;25(2):383–7 (14 ref.)

The divergent 5' termini of the alpha human folate receptor (hFR) mRNAs originate from two tissue-specific promoters and alternative splicing: characterization of the alpha hFR gene structure. Elwood PC, et al.
Biochemistry 1997 Feb 11;36(6):1467–78

Alternative splicing determines the binding of platelet-derived growth factor (PDGF-AA) to glycosaminoglycans. Lustig F, et al. **Biochemistry** 1996 Sep 17;35(37):12077–85

Casein kinase I alpha and alpha L: alternative splicing-generated kinases exhibit different catalytic properties. Zhang J, et al. **Biochemistry** 1996 Dec 17; 35(50):16319–27

Amyloid precursor protein in guinea pigs—complete cDNA sequence and alternative splicing. Beck M, et al.
Biochim Biophys Acta 1997 Mar 20;1351(1–2):17–21

Organization of the murine reduced folate carrier gene and identification of variant splice forms. Brigle KE, et al.
Biochim Biophys Acta 1997 Aug 7;1353(2):191–8

Isolation of chicken alpha ENaC splice variants from a cochlear cDNA library. Killick R, et al.
Biochim Biophys Acta 1997 Jan 3;1350(1):33–7

Preferential expression of alternatively spliced transcript of type II procollagen in the rabbit notochordal remnant and developing fibrocartilages. Takaishi H, et al.
Biochim Biophys Acta 1997 Feb 28;1350(3):253–8

Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). Jasper JR, et al. **Br J Pharmacol** 1997 Sep;122(1):126–32

Human choline acetyltransferase mRNAs with different 5'-region produce a 69-kDa major translation product. Misawa H, et al. **Brain Res Mol Brain Res** 1997 Mar; 44(2):323–33

Comparison of tissue distribution of two novel serine/threonine kinase genes containing the LIM motif (LIMK-1 and LIMK-2) in the developing rat. Mori T, et al. **Brain Res Mol Brain Res** 1997 May;45(2):247–54

Expression of the prolactin gene in normal and neoplastic human breast tissues and human mammary cell lines: promoter usage and alternative mRNA splicing. Shaw-Bruha CM, et al. **Breast Cancer Res Treat** 1997 Jul; 44(3):243–53

Alternative splicing of the erythropoietin receptor gene correlates with erythroid differentiation in rat hematopoietic and leukemic cells. Fujita M, et al.
Cancer Lett 1997 Jan 15;112(1):47–55

Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Neufeld G, et al.
Cancer Metastasis Rev 1996 Jun;15(2):153–8 (48 ref.)

Characterization of functional messenger RNA splice variants of BRCA1 expressed in nonmalignant and tumor-derived breast cells. Lu M, et al. **Cancer Res** 1996 Oct 15;56(20):4578–81

Alternative splicing of the APC gene and its association with terminal differentiation. Santoro IM, et al. **Cancer Res** 1997

Feb 1;57(3):488–94

Cloning and characterization of p10, an alternatively spliced form of p15 cyclin-dependent kinase inhibitor. Tsubari M, et al. **Cancer Res** 1997 Jul 15;57(14):2966–73

Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Wolff B, et al. **Chem Biol** 1997 Feb;4(2):139–47

Alternative splicing of natriuretic peptide A and B receptor transcripts in the rat brain. Francoeur F, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S172–4

ELAV, a Drosophila neuron-specific protein, mediates the generation of an alternatively spliced neural protein isoform. Koushika SP, et al. **Curr Biol** 1996 Dec 1; 6(12):1634–41

Change in plasma membrane Ca2(+)-ATPase splice-variant expression in response to a rise in intracellular Ca2+. Zacharias DA, et al. **Curr Biol** 1996 Dec 1;6(12):1642–52

Hormonally regulated expression and alternative splicing of kit ligand may regulate kit-induced inhibition of meiosis in rat oocytes. Ismail RS, et al. **Dev Biol** 1997 Apr 15; 184(2):333–42

Two Otx proteins generated from multiple transcripts of a single gene in Strongylocentrotus purpuratus. Li X, et al. **Dev Biol** 1997 Jul 15;187(2):253–66

Cloning and characterization of the murine homolog of the sno proto-oncogene reveals a novel splice variant. Pelzer T, et al. **Dev Dyn** 1996 Feb;205(2):114–25

Identification of four trp1 gene variants murine pancreatic beta-cells. Sakura H, et al. **Diabetologia** 1997 May; 40(5):528–32

Molecular cloning of htra2-beta-1 and htra2-beta-2, two human homologs of tra-2 generated by alternative splicing. Beil B, et al. **DNA Cell Biol** 1997 Jun;16(6):679–90

DNase I primary transcript is alternatively spliced in both normal and apoptotic cells: no evidence of up-regulation in apoptosis. Liu QY, et al. **DNA Cell Biol** 1997 Aug; 16(8):911–8

Expression and alternative processing of a chicken gene encoding both growth hormone-releasing hormone and pituitary adenylate cyclase-activating polypeptide. McRory JE, et al. **DNA Cell Biol** 1997 Jan;16(1):95–102

The SR splicing factors ASF/SF2 and SC35 have antagonistic effects on intronic enhancer-dependent splicing of the beta-tropomyosin alternative exon 6A. Gallego ME, et al. **EMBO J** 1997 Apr 1;16(7):1772–84

Bovine activin receptor type IIB messenger ribonucleic acid displays alternative splicing involving a sequence homologous to Src-homology 3 domain binding sites. Ethier JF, et al. **Endocrinology** 1997 Jun;138(6):2425–34

Tissue-specific transcription start sites and alternative splicing of the parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor gene: a new PTH/PTHrP receptor splice variant that lacks the signal peptide. Joun H, et al. **Endocrinology** 1997 Apr;138(4):1742–9

The human gene for the regulatory subunit RI alpha of cyclic adenosine 3', 5'-monophosphate-dependent protein kinase: two distinct promoters provide differential regulation of alternately spliced messenger ribonucleic acids. Solberg R, et al. **Endocrinology** 1997 Jan;138(1):169–81

Coordinate expression of splice variants of the murine pregnancy-specific glycoprotein (PSG) gene family during placental development. Kromer B, et al. **Eur J Biochem** 1996 Dec 1;242(2):280–7

Seven novel additional small mutations and a new alternative splicing in the human dystrophin gene detected by heteroduplex analysis and restricted RT-PCR heteroduplex analysis of illegitimate transcripts. Barbieri AM, et al. **Eur J Hum Genet** 1996;4(3):183–7

Analysis of alternative splicing patterns in the cystic fibrosis transmembrane conductance regulator gene using mRNA derived from lymphoblastoid cells of cystic fibrosis patients. Bienvenu T, et al. **Eur J Hum Genet** 1996; 4(3):127–34

Distribution of HLA-G alternative mRNAs including soluble forms in normal lymphocytes and in lymphoid cell-derived leukemia. Amiot L, et al. **Eur J Immunogenet** 1996 Aug; 23(4):311–20

Expression and splicing of the fibronectin gene in healthy and diseased periodontal tissue. Parkar MH, et al. **Eur J Oral Sci** 1997 Jun;105(3):264–70

A splice variant of arrestin from human retina. Smith WC. **Exp Eye Res** 1996 Jun;62(6):585–92

Tissue-specific expression of splice variants of the mouse voltage-gated calcium channel alpha2/delta subunit. Angelotti T, et al. **FEBS Lett** 1996 Nov 18;397(2–3):331–7

Desensitization of the P2X(2) receptor controlled by alternative splicing. Brändle U, et al. **FEBS Lett** 1997 Mar 10;404(2–3):294–8

A truncated isoform of Ca2+/calmodulin-dependent protein kinase II expressed in human islets of Langerhans may result from trans-splicing. Breen MA, et al. **FEBS Lett** 1997 Jun 16;409(3):375–9

Attenuated function of a variant form of the helix-loop-helix protein, Id-3, generated by an alternative splicing mechanism. Deed RW, et al. **FEBS Lett** 1996 Sep 9; 393(1):113–6

Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. Diamant M, et al. **FEBS Lett** 1997 Jul 28;412(2):379–84

cDNA cloning reveals a tissue specific expression of alternatively spliced transcripts of the ryanodine receptor type 3 (RyR3) calcium release channel. Marziali G, et al. **FEBS Lett** 1996 Sep 23;394(1):76–82

Tissue-specific alternative splicing of mouse brain type ryanodine receptor/calcium release channel mRNA. Miyatake R, et al. **FEBS Lett** 1996 Oct 21;395(2–3):123–6

Alternatively spliced forms of the cGMP-gated channel in human keratinocytes. Oda Y, et al. **FEBS Lett** 1997 Sep 1;414(1):140–5

Differential splicing of the growth hormone-releasing hormone gene in rat placenta generates a novel pre-proGHRH mRNA that encodes a different C-terminal flanking peptide. Pérez-Riba M, et al. **FEBS Lett** 1997 Feb 3;402(2–3):273–6

Sequence analysis and distribution of two new human cathepsin L splice variants. Rescheleit DK, et al. **FEBS Lett** 1996 Oct 7;394(3):345–8

Human serotonin 5-HT7 receptor: cloning and pharmacological characterisation of two receptor variants. Stam NJ, et al. **FEBS Lett** 1997 Aug 25;413(3):489–94

Characterization of new human c-myc mRNA species produced by alternative splicing. Bodescot M, et al. **Gene** 1996 Sep 26;174(1):115–20

Variant chicken kidney AE1 anion exchanger transcripts are derived from a single promoter by alternative splicing. Cox KH, et al. **Gene** 1996 Sep 16;173(2):221–6

Expression of alternatively spliced PCTAIRE-1 mRNA in PC12 cells and neonatal rat brain. Gao CY, et al. **Gene** 1996 Oct 17;176(1–2):243–7

Alternative forms of the human thioredoxin mRNA: identification and characterization. Hariharan J, et al. **Gene** 1996 Sep 16;173(2):265–70

Identification of an alternatively spliced transcript of equine interleukin-1 beta. Kato H, et al. **Gene** 1996 Oct 24; 177(1–2):11–6

Alternative polyadenylation of the gene transcripts encoding a rat DNA polymerase beta. Konopiński R, et al. **Gene** 1996 Oct 17;176(1–2):191–5

Alternative splicing in lecithin:cholesterol acyltransferase mRNA: an evolutionary paradigm in humans and great apes. Miller M, et al. **Gene** 1997 May 6;190(2):309–13

Alternative RNA splicing of the MLL gene in normal and malignant cells. Nam DK, et al. **Gene** 1996 Oct 31; 178(1–2):169–75

Human gene encoding CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase): organization, nucleotide sequence and alternative splicing. Nata K, et al. **Gene** 1997 Feb 28; 186(2):285–92

Rat and chicken s-rex/NSP mRNA: nucleotide sequence of main transcripts and expression of splice variants in rat tissues. Ninkina NN, et al. **Gene** 1997 Jan 15;184(2):205–10

Identification of cis-acting elements involved in an alternative splicing of the amyloid precursor protein (APP) gene. Shibata A, et al. **Gene** 1996 Oct 10;175(1–2):203–8

Novel alternative splicing predicts a secreted extracellular isoform of the human receptor-like protein tyrosine phosphatase LAR. Tabiti K, et al. **Gene** 1996 Oct 10; 175(1–2):7–13

Organization, structure and alternate splicing of the murine RFC-1 gene encoding a folate transporter. Tolner B, et al. **Gene** 1997 Apr 11;189(1):1–7

Primary structure and developmental acidic to basic transition of 13 alternatively spliced mouse fast skeletal muscle troponin T isoforms. Wang J, et al. **Gene** 1997 Jul 1;193(1):105–14

Characterization of mouse fibronectin alternative mRNAs reveals an unusual isoform present transiently during liver development. Górski GK, et al. **Gene Expr** 1996; 6(3):139–49

Differential splicing of exon 5 of the Wilms tumour (WTI) gene. Renshaw J, et al. **Genes Chromosomes Cancer** 1997 Aug;19(4):256–66

Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. Xu CF, et al. **Genes Chromosomes Cancer** 1997 Feb;18(2):102–10

The characterization and localization of the mouse thymopoietin/lamina-associated polypeptide 2 gene and its alternatively spliced products. Berger R, et al. **Genome Res** 1996 May;6(5):361–70

Organization of the human protein 4.1 genomic locus: new insights into the tissue-specific alternative splicing of the pre-mRNA. Baklouti F, et al. **Genomics** 1997 Feb 1; 39(3):289–302

Avian and murine LR8B and human apolipoprotein E receptor 2: differentially spliced products from corresponding genes. Brandes C, et al. **Genomics** 1997 Jun 1;42(2):185–91

Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene. Fruman DA, et al. **Genomics** 1996 Oct 1;37(1):113–21

Complete primary structure of two splice variants of collagen XII, and assignment of alpha 1(XII) collagen (COL12A1), alpha 1(IX) collagen (COL9A1), and alpha 1(XIX) collagen (COL19A1) to human chromosome 6q12–q13. Gerecke DR, et al. **Genomics** 1997 Apr 15;41(2):236–42

Alternatively spliced exons encode the tissue-specific 5' termini of leukocyte pp52 and stromal cell S37 mRNA isoforms. Thompson AA, et al. **Genomics** 1996 Mar 15; 32(3):352–7

The human serotonin 5-HT2C receptor: complete cDNA, genomic structure, and alternatively spliced variant. Xie E, et al. **Genomics** 1996 Aug 1;35(3):551–61

The human E6-AP gene (UBE3A) encodes three potential protein isoforms generated by differential splicing. Yamamoto Y, et al. **Genomics** 1997 Apr 15;41(2):263–6

Multiple products in the protein truncation test due to alternative splicing in the adenomatous polyposis coli (APC) gene. Bala S, et al. **Hum Genet** 1996 Nov; 98(5):528–33

Alternative splicing of hMSH2 in normal human tissues. Mori Y, et al. **Hum Genet** 1997 May;99(5):590–5

Alternative splicing of dystrophin exon 4 in normal human muscle. Torelli S, et al. **Hum Genet** 1996 Apr;97(4):521–3

Identification of mutations in two major mRNA isoforms of the Chediak-Higashi syndrome gene in human and mouse. Barbosa MD, et al. **Hum Mol Genet** 1997 Jul; 6(7):1091–8

Increased proportion of exon 9 alternatively spliced CFTR transcripts in vas deferens compared with nasal epithelial cells. Teng H, et al. **Hum Mol Genet** 1997 Jan;6(1):85–90

Alternatively spliced Ly-49D and H transcripts are found in IL-2-activated NK cells. Silver ET, et al. **Immunogenetics** 1996;44(6):478–82

Cloning of novel kinectin splice variants with alternative C-termini: structure, distribution and evolution of mouse kinectin. Leung E, et al. **Immunol Cell Biol** 1996 Oct; 74(5):421–33

The novel variants of mb-1 and B29 transcripts generated by alternative mRNA splicing. Koyama M, et al. **Immunol Lett** 1995 Sep;47(3):151–6

Altered interleukin-2 receptor alpha-chain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism. Horiuchi S, et al. **Immunology** 1997 May; 91(1):28–34

Kinase-inactive splice variants of the activin type I receptor [letter] McKeehan K, et al. **In Vitro Cell Dev Biol Anim** 1996 Mar;32(3):131–4

Structure of the Bombyx sorbitol dehydrogenase gene: a possible alternative use of the promoter. Niimi T, et al. **Insect Mol Biol** 1996 Nov;5(4):269–80

Expression of Vpre-B3 (8HS-20) molecules by alternative RNA processing. Hagiwara S, et al. **Int Immunol** 1996 Aug; 8(8):1237–44

The gene for the human interleukin-11 receptor alpha chain locus is highly homologous to the murine gene and contains alternatively spliced first exons. Nandurkar HH, et al. **Int J Biochem Cell Biol** 1997 May;29(5):753–66

Soluble CD44 splice variants in metastasizing human breast cancer. Martin S, et al. **Int J Cancer** 1997 Aug 22; 74(4):443–5

Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae. Mighell AJ, et al. **Int J Cancer** 1997 Jul 17;72(2):236–40

Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Niedermeyer J, et al. **Int J Cancer** 1997 May 2;71(3):383–9

Alternative splicing of DNA polymerase beta mRNA is not tumor-specific. Nowak R, et al. **Int J Cancer** 1996 Oct 9;68(2):199–202

Developmental expression of splicing variants of fibroblast growth factor receptor 3 (FGFR3) in mouse. Wuechner C, et al. **Int J Dev Biol** 1996 Dec;40(6):1185–8

The tight junction protein ZO-2 contains three PDZ (PSD-95/Discs-Large/ZO-1) domains and an alternatively spliced region. Beatch M, et al. **J Biol Chem** 1996 Oct 18;271(42):25723–6

Overlapping expression and redundant activation of mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 ligands. Blunt AG, et al. **J Biol Chem** 1997 Feb 7;272(6):3733–8

Genomic organization of human and mouse genes for vascular endothelial growth factor C. Chilov D, et al. **J Biol Chem** 1997 Oct 3;272(40):25176–83

SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors. Colwill K, et al. **J Biol Chem** 1996 Oct 4;271(40):24569–75

Alternative splicing of human inducible nitric-oxide synthase mRNA. tissue-specific regulation and induction by cytokines. Eissa NT, et al. **J Biol Chem** 1996 Oct 25; 271(43):27184–7

Molecular characterization of a novel human endothelin receptor splice variant. Elshourbagy NA, et al. **J Biol Chem** 1996 Oct 11;271(41):25300–7

Murine laminin alpha3A and alpha3B isoform chains are generated by usage of two promoters and alternative splicing. Ferrigno O, et al. **J Biol Chem** 1997 Aug 15; 272(33):20502–7

Human GRB-IRbeta/GRB10. Splice variants of an insulin and growth factor receptor-binding protein with PH and SH2 domains. Frantz JD, et al. **J Biol Chem** 1997 Jan 31; 272(5):2659–67

Transfection analysis of expression of mRNA isoforms encoding the nuclear autoantigen La/SS-B. Grölz D, et al. **J Biol Chem** 1997 May 2;272(18):12076–82

The sequence of the alternatively spliced sixth exon of alpha-tropomyosin is critical for cooperative actin binding but not for interaction with troponin. Hammell RL, et al. **J Biol Chem** 1997 Sep 5;272(36):22409–16

Characterization of two alternately spliced forms of

phospholipase D1. Activation of the purified enzymes by phosphatidylinositol 4,5-bisphosphate, ADP-ribosylation factor, and Rho family monomeric GTP-binding proteins and protein kinase C-alpha. Hammond SM, et al. **J Biol Chem** 1997 Feb 7;272(6):3860-8

Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. Han P, et al. **J Biol Chem** 1997 Jun 27; 272(26):16152-7

Two splice variants of a tyrosine phosphatase differ in substrate specificity, DNA binding, and subcellular location. Kamatkar S, et al. **J Biol Chem** 1996 Oct 25; 271(43):26755-61

Exon/intron organization, chromosome localization, alternative splicing, and transcription units of the human apolipoprotein E receptor 2 gene. Kim DH, et al. **J Biol Chem** 1997 Mar 28;272(13):8498-504

Ovarian- and somatic-specific transcripts of the mosquito clathrin heavy chain gene generated by alternative 5'-exon splicing and polyadenylation. Kokoza VA, et al. **J Biol Chem** 1997 Jan 10;272(2):1164-70

NFI-B3, a novel transcriptional repressor of the nuclear factor I family, is generated by alternative RNA processing. Liu Y, et al. **J Biol Chem** 1997 Apr 18;272(16):10739-45

Functionally distinct double-stranded RNA-binding domains associated with alternative splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase. Liu Y, et al. **J Biol Chem** 1997 Feb 14;272(7):4419-28

The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family. Norris FA, et al. **J Biol Chem** 1997 Sep 19;272(38):23859-64

Alternative splicing of the sodium channel SCN8A predicts a truncated two-domain protein in fetal brain and non-neuronal cells. Plummer NW, et al. **J Biol Chem** 1997 Sep 19;272(38):24008-15

Tissue-specific alternative splicing generates two synaptojanin isoforms with differential membrane binding properties. Ramjaun AR, et al. **J Biol Chem** 1996 Oct 4; 271(40):24856-61

A cysteine-rich domain defined by a novel exon in a slo variant in rat adrenal chromaffin cells and PC12 cells. Saito M, et al. **J Biol Chem** 1997 May 2;272(18):11710-7

The mammalian homolog of suppressor-of-white-apricot regulates alternative mRNA splicing of CD45 exon 4 and fibronectin IIICS. Sarkissian M, et al. **J Biol Chem** 1996 Dec 6;271(49):31106-14

Cell shape-dependent regulation of protein 4.1 alternative pre-mRNA splicing in mammary epithelial cells. Schischmanoff PO, et al. **J Biol Chem** 1997 Apr 11; 272(15):10254-9

Selective regulation of agrin mRNA induction and alternative splicing in PC12 cells by Ras-dependent actions of nerve growth factor. Smith MA, et al. **J Biol Chem** 1997 Jun 20;272(25):15675-81

Identification and characterization of two alternative splice variants of human interleukin-2. Tsytsikov VN, et al. **J Biol Chem** 1996 Sep 20;271(38):23055-60

Alternative splicing in COL1A1 mRNA leads to a partial null allele and two In-frame forms with structural defects in non-lethal osteogenesis imperfecta. Wang Q, et al. **J Biol Chem** 1996 Nov 8;271(45):28617-23

Comparison of binding and block produced by alternatively spliced Kvbeta1 subunits. Wang Z, et al. **J Biol Chem** 1996 Nov 8;271(45):28311-7

The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. Yan C, et al. **J Biol Chem** 1996 Oct 11;271(41):25699-706

Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain. Yao KM, et al. **J Biol Chem** 1997 Aug 8;272(32):19827-36

Alternative splicing of the unique "PLUS" domain of chicken PG-M/versican is developmentally regulated. Zako M, et al. **J Biol Chem** 1997 Apr 4;272(14):9325-31

An alternative gonadotropin-releasing hormone (GnRH) RNA splicing product found in cultured GnRH neurons and mouse hypothalamus. Zhen S, et al. **J Biol Chem** 1997 May 9;272(19):12620-5

The Pax-5 gene is alternatively spliced during B-cell development. Zwollo P, et al. **J Biol Chem** 1997 Apr 11; 272(15):10160-8

Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. Endo N, et al. **J Bone Miner Res** 1996 Apr;11(4):535-43

Alternative splicing and cycling kinetics of myosin change during hypertrophy of human smooth muscle cells. Morano I, et al. **J Cell Biochem** 1997 Feb;64(2):171-81

Expression and distribution of two alternatively spliced transcripts from the chicken alpha 2 (VI) collagen gene. Wälchli C, et al. **J Cell Biochem** 1996 Nov 1;63(2):207-20

Small, membrane-bound, alternatively spliced forms of ankyrin 1 associated with the sarcoplasmic reticulum of mammalian skeletal muscle. Zhou D, et al. **J Cell Biol** 1997 Feb 10;136(3):621-31

Nuclear accumulation of the E2F heterodimer regulated by subunit composition and alternative splicing of a nuclear localization signal. de la Luna S, et al. **J Cell Sci** 1996 Oct;109 (Pt 10):2443-52

Alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of women. Agarwal VR, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):70-4

Tumor-specific expression of alternatively spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenomas. Chaidarun SS, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1058-65

Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. Utsumi T, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2344-9

Detection of CD44 splice variants in formalin-fixed, paraffin-embedded specimens of human skin cancer. Dietrich A, et al. **J Cutan Pathol** 1997 Jan;24(1):37-42

Cloning, DNA sequence, and alternative splicing of opossum amelogenin mRNAs. Hu CC, et al. **J Dent Res** 1996 Oct; 75(10):1728-34

Cloning, cDNA sequence, and alternative splicing of porcine amelogenin mRNAs. Hu CC, et al. **J Dent Res** 1996 Oct; 75(10):1735-41

Alternate splicing of mouse fusin/CXC chemokine receptor-4: stromal cell-derived factor-1alpha is a ligand for both CXC chemokine receptor-4 isoforms. Heesen M, et al. **J Immunol** 1997 Apr 15;158(8):3561-4

A novel A-->G mutation in intron I of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency. Brand K, et al. **J Lipid Res** 1996 Jun; 37(6):1213-23

Expression of human myometrial G alpha s messenger ribonucleic acid transcript during pregnancy and labour: involvement of alternative splicing pathways. Europe-Finner GN, et al. **J Mol Endocrinol** 1997 Feb; 18(1):15-25

An alternative splice variant of the mouse TRH receptor mRNA is the major form expressed in the mouse pituitary gland. Jones KE, et al. **J Mol Endocrinol** 1996 Apr; 16(2):197-204

A novel rat tyrosine hydroxylase mRNA species generated by alternative splicing. Lanièce P, et al. **J Neurochem** 1996 May;66(5):1819-25

Two alternatively spliced forms of the cGMP-gated channel alpha-subunit from cone photoreceptor are expressed in the chick pineal organ. Bönigk W, et al. **J Neurosci** 1996 Dec 1;16(23):7458-68

Alternative splicing of exon 12 of the COL2A1 gene interrupts the triple helix of type-II collagen in the Kniest form of spondyloepiphyseal dysplasia. Chen L, et al. **J Orthop Res** 1996 Sep;14(5):712-21

Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. Zhang QX, et al. **J Steroid Biochem Mol Biol** 1996 Nov;59(3-4):251-60

Inhibition of human T-cell leukemia virus type 2 Rex function by truncated forms of Rex encoded in alternatively spliced mRNAs. Ciminale V, et al. **J Virol** 1997 Apr; 71(4):2810-8

Mutational analysis of ICP0R, a transrepressor protein created by alternative splicing of the ICP0 gene of herpes simplex virus type 1. Spatz SJ, et al. **J Virol** 1996 Nov; 70(11):7360-70

Multiple forms of messenger ribonucleic acid encoding glycodelin in male genital tract. Koistinen H, et al. **Lab Invest** 1997 May;76(5):683-90

Differential expression of alternatively spliced pX mRNAs in HTLV-I-infected cell lines. Cereseto A, et al. **Leukemia** 1997 Jun;11(6):866-70

Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells. Fujita M, et al. **Leukemia** 1997 Apr;11 Suppl 3:444-5

An acute myeloid leukemia gene, AML1, regulates transcriptional activation and hemopoietic myeloid cell differentiation antagonistically by two alternative spliced forms. Tanaka T, et al. **Leukemia** 1997 Apr;11 Suppl 3:299-302

Alternative splice variants of cytokines: making a list. Atamas SP. **Life Sci** 1997;61(12):1105-12 (53 ref.)

Extensive alternate exon usage at the 5' end of the sheep tropoelastin gene. Mauch JC, et al. **Matrix Biol** 1995 Oct; 14(8):635-41

Transcription regulation and alternative splicing of an early zygotic gene encoding two structurally distinct zinc finger proteins in Xenopus laevis. Bellefroid E, et al. **Mech Dev** 1997 Apr;63(1):99-108

Alternative splicing of the rabbit beta-globin pre-mRNA in vivo after transient transfection of myoblast and myotube cells. Pironcheva GL, et al. **Microbios** 1997;89(358):31-8

Regulated use of an alternative spliced leader exon in the plant parasitic nematode Meloidogyne javanica. Koltai H, et al. **Mol Biochem Parasitol** 1997 May;86(1):107-10

Altered levels of the Drosophila HRB87F/hrp36 hnRNP protein have limited effects on alternative splicing in vivo. Zu K, et al. **Mol Biol Cell** 1996 Jul;7(7):1059-73

The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Almog N, et al. **Mol Cell Biol** 1997 Feb;17(2):713-22

Conserved intron elements repress splicing of a neuron-specific c-src exon in vitro. Chan RC, et al. **Mol Cell Biol** 1997 May;17(5):2970

A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype [published erratum appears in Mol Cell Biol 1997 Jan;17(1):528] Collesi C, et al. **Mol Cell Biol** 1996 Oct; 16(10):5518-26

Multiple interdependent sequence elements control splicing of a fibroblast growth factor receptor 2 alternative exon. Del Gatto F, et al. **Mol Cell Biol** 1997 Sep;17(9):5106-16

HRS/SRp40-mediated inclusion of the fibronectin EIIIB exon, a possible cause of increased EIIIB expression in proliferating liver. Du K, et al. **Mol Cell Biol** 1997 Jul; 17(7):4096-104

restless, an active Ac-like transposon from the fungus Tolypocladium inflatum: structure, expression, and alternative RNA splicing. Kempken F, et al. **Mol Cell Biol** 1996 Nov;16(11):6563-72

Editing of glutamate receptor B subunit ion channel RNAs by four alternatively spliced DRADA2 double-stranded RNA adenosine deaminases. Lai F, et al. **Mol Cell Biol** 1997 May;17(5):2413-24

An alternative splicing event which occurs in mouse pachytene spermatocytes generates a form of DNA ligase III with distinct biochemical properties that may function in meiotic recombination. Mackey ZB, et al. **Mol Cell Biol** 1997 Feb;17(2):989-98

Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Thakur S, et al. **Mol Cell Biol** 1997 Jan;17(1):444-52

An alternative splicing event in the Pax-3 paired domain identifies the linker region as a key determinant of paired domain DNA-binding activity. Vogan KJ, et al. **Mol Cell Biol** 1996 Dec;16(12):6677-86

Functional properties of p54, a novel SR protein active in constitutive and alternative splicing. Zhang WJ, et al. **Mol Cell Biol** 1996 Oct;16(10):5400-8

Cloning of Caenorhabditis U2AF65: an alternatively spliced RNA containing a novel exon. Zorio DA, et al. **Mol Cell Biol** 1997 Feb;17(2):946-53

Calcitonin mRNA is produced in liver by two different splicing pathways. Bracq S, et al. **Mol Cell Endocrinol** 1997 Apr 4;128(1-2):111-5

Expression of human relaxin genes: characterization of a novel alternatively-spliced human relaxin mRNA species. Gunnersen JM, et al. **Mol Cell Endocrinol** 1996 Apr 19; 118(1-2):85-94

Expression of follicle-stimulating hormone-receptor mRNA alternate transcripts in bovine granulosa cells during luteinization in vivo and in vitro. Rajapaksha WR, et al. **Mol Cell Endocrinol** 1996 Jun 18;120(1):25-30

Mutation detection in exons 1-14 of the adenomatous polyposis coli gene: identification of an alternatively spliced transcript. Hamzehloei T, et al. **Mol Cell Probes** 1996 Oct; 10(5):379-85

An alternatively spliced polycistronic mRNA encoding cyclic adenosine 3',5'-monophosphate (cAMP)-responsive transcription factor CREB (cAMP response element-binding protein) in human testis extinguishes expression of an internally translated inhibitor CREB isoform. Girardet C, et al. **Mol Endocrinol** 1996 Jul; 10(7):879-891

Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Grosse R, et al. **Mol Endocrinol** 1997 Aug; 11(9):1305-18

Cloning, characterization, and steroid-dependent posttranscriptional processing of RUSH-1 alpha and beta, two uteroglobin promoter-binding proteins. Hayward-Lester A, et al. **Mol Endocrinol** 1996 Nov; 10(11):1335-49

Expression of alternatively spliced isoforms of the parathyroid hormone (PTH)/PTH-related peptide receptor messenger RNA in human kidney and bone cells. Jobert AS, et al. **Mol Endocrinol** 1996 Sep;10(9):1066-76

A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Ross RJ, et al. **Mol Endocrinol** 1997 Mar;11(3):265-73

The modular nodulins Nvf-28/32 of broad bean (Vicia faba L.): alternative exon combinations account for different modular structures. Küster H, et al. **Mol Gen Genet** 1996 Oct 28;252(6):648-57

Multiple transcripts of the murine immunoglobulin epsilon membrane locus are generated by alternative splicing and differential usage of two polyadenylation sites. Anand S, et al. **Mol Immunol** 1997 Feb;34(2):175-83

Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing. Canton H, et al. **Mol Pharmacol** 1996 Oct;50(4):799-807

Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Strassburg CP, et al. **Mol Pharmacol** 1997 Aug;52(2):212-20

Heat-shock inducible polyubiquitin gene Ubi undergoes alternative initiation and alternative splicing in mature chicken testes. Mezquita J, et al. **Mol Reprod Dev** 1997 Apr;46(4):471-5

Transcription of c-mos protooncogene in the pig involves both tissue-specific promoters and alternative polyadenylation sites. Newman B, et al. **Mol Reprod Dev** 1996 Jul;44(3):275-88

Structural analysis of the mouse prosaposin (SGP-1) gene reveals the presence of an exon that is alternatively spliced in transcribed mRNAs. Zhao Q, et al. **Mol Reprod Dev** 1997 Sep;48(1):1-8

A glucose-6-phosphate dehydrogenase (G6PD) splice site consensus sequence mutation associated with G6PD enzyme deficiency. Sanders S, et al. **Mutat Res** 1997 Mar 4;374(1):79-87

Human metabotropic glutamate receptor 1: mRNA distribution, chromosome localization and functional expression of two splice variants. Stephan D, et al. **Neuropharmacology** 1996;35(12):1649–60

Splice variants of glutamate receptor subunits 2 and 3 in striatal projection neurons. Tallaksen-Greene SJ, et al. **Neuroscience** 1996 Dec;75(4):1057–64

Expression and alternative splicing of Pit-1 messenger ribonucleic acid in pituitary adenomas. Hamada K, et al. **Neurosurgery** 1996 Feb;38(2):362–6

Heterogeneity of circulating growth hormone. Baumann G, et al. **Nucl Med Biol** 1994 Apr;21(3):369–79 (36 ref.)

A short CIC-2 mRNA transcript is produced by exon skipping. Chu S, et al. **Nucleic Acids Res** 1996 Sep 1; 24(17):3453–7

Alternative poly(A) site selection in complex transcription units: means to an end? Edwalds-Gilbert G, et al. **Nucleic Acids Res** 1997 Jul 1;25(13):2547–61 (287 ref.)

Recent evolutionary acquisition of alternative pre-mRNA splicing and 3' processing regulations induced by intronic B2 SINE insertion. Michel D, et al. **Nucleic Acids Res** 1997 Aug 15;25(16):3228–34

DNA binding specificity of proteins derived from alternatively spliced mouse p53 mRNAs. Miner Z, et al. **Nucleic Acids Res** 1997 Apr 1;25(7):1319–26

Cyclin ET, a new splice variant of human cyclin E with a unique expression pattern during cell cycle progression and differentiation. Mumberg D, et al. **Nucleic Acids Res** 1997 Jun 1;25(11):2098–105

Nuclear and mitochondrial uracil-DNA glycosylases are generated by alternative splicing and transcription from different positions in the UNG gene. Nilsen H, et al. **Nucleic Acids Res** 1997 Feb 15;25(4):750–5

Proto-oncogene Sno expression, alternative isoforms and immediate early serum response. Pearson-White S, et al. **Nucleic Acids Res** 1997 Jul 15;25(14):2930–7

Conceptual translation of timeless reveals alternative initiating methionines in Drosophila. Rosato E, et al. **Nucleic Acids Res** 1997 Feb 1;25(3):455–8

Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control? Baldin V, et al. **Oncogene** 1997 May 22;14(20):2485–95

Analysis of possible WT1 RNA processing in primary Wilms tumors. Gunning KB, et al. **Oncogene** 1996 Sep 19; 13(6):1179–85

The expression of RET and its multiple splice forms in developing human kidney. Ivanchuk SM, et al. **Oncogene** 1997 Apr 17;14(15):1811–8

RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2. Lorenzo MJ, et al. **Oncogene** 1997 Feb 20;14(7):763–71

The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma. Luan X, et al. **Oncogene** 1997 Jul 3;15(1):79–86

Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Pim D, et al. **Oncogene** 1997 Jul 17; 15(3):257–64

Frequent association of alternative splicing of NER, a nuclear hormone receptor gene in cancer tissues. Saito H, et al. **Oncogene** 1997 Feb 6;14(5):617–21

Murine Wnt10a and Wnt10b: cloning and expression in developing limbs, face and skin of embryos and in adults. Wang J, et al. **Oncogene** 1996 Oct 3;13(7):1537–44

Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Wilson CA, et al. **Oncogene** 1997 Jan 9;14(1):1–16

RT-PCR investigation of fibronectin mRNA isoforms in malignant, normal and reactive oral mucosa. Mighell AJ, et al. **Oral Oncol** 1997 May;33(3):155–62

Retrotransposon insertion into the maize waxy gene results in tissue-specific RNA processing. Marillonnet S, et al. **Plant Cell** 1997 Jun;9(6):967–78

Possible involvement of differential splicing in regulation of the activity of Arabidopsis ANP1 that is related to mitogen-activated protein kinase kinase kinases (MAPKKKs). Nishihama R, et al. **Plant J** 1997 Jul; 12(1):39–48

Expression and RNA splicing of the maize glutathione S-transferase Bronze2 gene is regulated by cadmium and other stresses. Marrs KA, et al. **Plant Physiol** 1997 Jan; 113(1):93–102

Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Bloom TJ, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):14188–92

Alternatively spliced mRNAs predicted to yield frame-shift proteins and stable intron 1 RNAs of the herpes simplex virus 1 regulatory gene alpha 0 accumulate in the cytoplasm of infected cells. Carter KL, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12535–40

Alternative splicing of the human diacylglycerol kinase zeta gene in muscle. Ding L, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5519–24

Neuronal nitric oxide synthase alternatively spliced forms: prominent functional localizations in the brain. Eliasson MJ, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1; 94(7):3396–401

In vivo analysis of the functional domains of the Drosophila splicing regulator RBP1. Heinrichs V, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):115–20

Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy. Le Fur N, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):5332–7

Selective constraints on the activation domain of transcription factor Pit-1. Majumdar S, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10256–61

LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Screaton GR, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4615–9

Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. Siebert PD, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2198–203

Alternative splicing of exon 3 of the human growth hormone receptor is the result of an unusual genetic polymorphism. Stallings-Mann ML, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12394–9

CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. Yamanaka R, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6462–7

A highly stable duplex structure sequesters the 5' splice site region of hnRNP A1 alternative exon 7B. Blanchette M, et al. **RNA** 1997 Apr;3(4):405–19

Mutation of PTB binding sites causes misregulation of alternative 3' splice site selection in vivo. Pérez I, et al. **RNA** 1997 Jul;3(7):764–78

Characterization of Neurospora mitochondrial group I introns reveals different CYT-18 dependent and independent splicing strategies and an alternative 3' splice site for an intron ORF. Wallweber GJ, et al. **RNA** 1997 Feb;3(2):114–31

Differential expression of CD44 splice variants in malignant and benign pleural effusions. Tojo N, et al. **Tohoku J Exp Med** 1996 Aug;179(4):273–9

Role of tissue specific alternative pre-mRNA splicing in the differentiation of the erythrocyte membrane. Benz EJ Jr, et al. **Trans Am Clin Climatol Assoc** 1996;108:78–95 (43 ref.)

Distinct fibronectin splicing variants: potential targets for therapeutic immunomodulation in organ allograft recipients. Coito AJ, et al. **Transplant Proc** 1997 Feb-Mar; 29(1-2):1060–1

Directing alternative splicing: cast and scenarios. Chabot B. **Trends Genet** 1996 Nov;12(11):472–8 (63 ref.)

Characterization of the protein product encoded by a splicing variant of the Marek's disease virus Eco-Q gene (Meq). Peng Q, et al. **Virology** 1996 Dec 1;226(1):77–82

Alternative expression of a chitosanase gene produces two different proteins in cells infected with Chlorella virus CVK2. Yamada T, et al. **Virology** 1997 Apr 14;230(2):361–8

[Messenger RNA expression of alternatively spliced CS-1 fibronectin isoforms in Rheumatoid arthritis (RA) synovium] Müller-Ladner U, et al. **Verh Dtsch Ges Pathol** 1996;80:329 **(Ger)**

[Higher expression levels of alternatively spliced pX mRNA in human T lymphotropic virus type I (HTLV-I) asymptomatic carriers positive for antibodies to p40tax protein] Hirata M. **Fukuoka Igaku Zasshi** 1996 Jan; 87(1):23–34 (Eng. Abstr.) **(Jpn)**

[Short 5'-terminal sequence of pre-mRNA tryptophanyl-tRNA-synthetase inhibits splicing of alternative exons] Turpaev KT, et al. **Dokl Akad Nauk** 1996 Aug;349(5):698–700 **(Rus)**

[Alternative splicing of 5'-terminal exons of the human tryptophanyl-tRNA synthetase gene] Sokolova IV, et al. **Mol Biol (Mosk)** 1996 Mar-Apr;30(2):319–29 **(Rus)**

DRUG EFFECTS

Serum deprivation alters the expression and the splicing at exons 7, 8 and 15 of the beta-amyloid precursor protein in the C6 glioma cell line. Sudoh S, et al. **Brain Res Mol Brain Res** 1996 Jul;39(1-2):12–22

Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells. Condon TP, et al. **J Biol Chem** 1996 Nov 29;271(48):30398–403

GENETICS

The regulation of splice-site selection, and its role in human disease. Cooper TA, et al. **Am J Hum Genet** 1997 Aug; 61(2):259–66 (74 ref.)

Function of a pseudoknot in the suppression of an alternative splicing event in a group I intron. Jaeger L, et al. **Biochimie** 1996;78(6):466–73

Alternative splicing of the NMDAR1 subunit affects modulation by calcium. Koltchine VV, et al. **Brain Res Mol Brain Res** 1996 Jul;39(1-2):99–108

A novel splice variant of the cell adhesion molecule BIG-2 is expressed in the olfactory and vomeronasal neuroepithelia. Mimmack ML, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1-2):345–50

Cloning and characterization of Kir3.1 (GIRK1) C-terminal alternative splice variants. Nelson CS, et al. **Brain Res Mol Brain Res** 1997 Jun;46(1-2):185–96

Fibronectin mRNA alternative splicing is temporally and spatially regulated during chondrogenesis in vivo and in vitro. Gehris AL, et al. **Dev Dyn** 1996 Jun;206(2):219–30

Alternative splicing of mouse alpha1(XIII) collagen RNAs results in at least 17 different transcripts, predicting alpha1(XIII) collagen chains with length varying between 651 and 710 amino acid residues. Peltonen S, et al. **DNA Cell Biol** 1997 Feb;16(2):227–34

The splicing factor SRp20 modifies splicing of its own mRNA and ASF/SF2 antagonizes this regulation. Jumaa H, et al. **EMBO J** 1997 Aug 15;16(16):5077–85

Smooth muscle alternative splicing induced in fibroblasts by heterologous expression of a regulatory gene. Roberts GC, et al. **EMBO J** 1996 Nov 15;15(22):6301–10

Differential expression of syntrophins and analysis of alternatively spliced dystrophin transcripts in the mouse brain. Górecki DC, et al. **Eur J Neurosci** 1997 May; 9(5):965–76

Alternate splice-site utilization in the gene for the catalytic subunit of the DNA-activated protein kinase, DNA-PKcs. Connelly MA, et al. **Gene** 1996 Oct 10;175(1-2):271–3

Use of an alternate splice donor site in the human GAP gene is responsible for synthesis of the p100 isoform. Liao L, et al. **Gene** 1997 Jan 3;184(1):39–43

Alternative splicing of IgA Fc receptor (CD89) transcripts. Reterink TJ, et al. **Gene** 1996 Oct 10;175(1-2):279–80

Isolation and promoter mapping of the gene encoding murine co-stimulatory factor B7-1. Zhang H, et al. **Gene** 1996 Dec 12;183(1-2):1–6

The alternative splicing factor PSI regulates P-element third intron splicing in vivo. Adams MD, et al. **Genes Dev** 1997 Jan 1;11(1):129–38

Alternative promoters of gene MAGE4a. De Plaen E, et al. **Genomics** 1997 Mar 1;40(2):305–13

Base substitution at different alternative splice donor sites of the tyrosinase gene in murine albinism. Le Fur N, et al. **Genomics** 1996 Oct 15;37(2):245–8

Characterization of the mouse gene for the alpha 1 chain of type XVIII collagen (Col18a1) reveals that the three variant N-terminal polypeptide forms are transcribed from two widely separated promoters. Rehn M, et al. **Genomics** 1996 Mar 15;32(3):436–46

Alternative splicing of repetitive units is responsible for the polydispersities of integumentary mucin B.1 (FIM-B.1) from Xenopus laevis. Joba W, et al. **Glycoconj J** 1996 Oct; 13(5):735–40

Alternate promoters and alternate splicing of human tenascin-X, a gene with 5' and 3' ends buried in other genes. Speek M, et al. **Hum Mol Genet** 1996 Nov;5(11):1749–58

Regulation of expression of the human MTH1 gene encoding 8-oxo-dGTPase. Alternative splicing of transcription products. Oda H, et al. **J Biol Chem** 1997 Jul 11; 272(28):17843–50

Alternative splicing of the Brn-3a and Brn-3b transcription factor RNAs is regulated in neuronal cells. Liu YZ, et al. **J Mol Neurosci** 1996 Spring;7(1):77–85

The thyroperoxidase doublet is not produced by alternative splicing. Cetani F, et al. **Mol Cell Endocrinol** 1995 Dec 29;115(2):125–32

Imprint switching on human chromosome 15 may involve alternative transcripts of the SNRPN gene [see comments] Dittrich B, et al. **Nat Genet** 1996 Oct;14(2):163–70. Comment in: Nat Genet 1996 Oct;14(2):119–21.

APP gene family: unique age-associated changes in splicing of Alzheimer's betaA4-amyloid protein precursor. Sandbrink R, et al. **Neurobiol Dis** 1994 Nov;1(1-2):13–24

Structure and alternative splicing of the presenilin-2 gene. Prihar G, et al. **Neuroreport** 1996 Jul 8;7(10):1680–4

A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Reiter JL, et al. **Nucleic Acids Res** 1996 Oct 15;24(20):4050–6

Structural and functional conservation of the Drosophila doublesex splicing enhancer repeat elements. Hertel KJ, et al. **RNA** 1996 Oct;2(10):969–81

IMMUNOLOGY

Molecular pathology of the X-linked hyper-immunoglobulin M syndrome: detection of wild-type transcripts in a patient with a complex splicing defect of the CD40 ligand. Ameratunga R, et al. **Clin Diagn Lab Immunol** 1996 Nov; 3(6):722–6

Complex CD44 splicing combinations in synovial fibroblasts from arthritic joints. Croft DR, et al. **Eur J Immunol** 1997 Jul;27(7):1680–4

Cloning of the mucosal addressin MAdCAM-1 from human brain: identification of novel alternatively spliced transcripts. Leung E, et al. **Immunol Cell Biol** 1996 Dec; 74(6):490–6

Plasma membrane Ca2+ pump in rat brain. Patterns of alternative splices seen by isoform-specific antibodies. Filoteo AG, et al. **J Biol Chem** 1997 Sep 19;272(38):23741–7

Analysis of the genes encoding the mast cell function-associated antigen and its alternatively spliced transcripts. Bocek P Jr, et al. **J Immunol** 1997 Apr 1; 158(7):3235–43

The role of the B7-1a molecule, an alternatively spliced form of murine B7-1 (CD80), on T cell activation. Inobe M, et al. **J Immunol** 1996 Jul 15;157(2):582–8

T cell development in mice expressing splice variants of the protein tyrosine phosphatase CD45. Kozieradzki I, et al. **J Immunol** 1997 Apr 1;158(7):3130–9

Identification of a novel, spliced variant of CREB that is preferentially expressed in the thymus. Yang L, et al. **J Immunol** 1997 Mar 15;158(6):2522–5

PHYSIOLOGY

Induction of alternative splicing of HLA-B27 by bacterial invasion. Huang F, et al. **Arthritis Rheum** 1997 Apr; 40(4):694-703

Activation of a cryptic splice-site in intron 24 leads to the formation of apolipoprotein B-27.6. Nemeth-Slany A, et al. **Atherosclerosis** 1997 Sep;133(2):163-70

The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation. Takagaki Y, et al. **Cell** 1996 Nov 29; 87(5):941-52

Differential expression of the regularly spliced wild-type p53 and its COOH-terminal alternatively spliced form during epidermal differentiation. Rehberger PA, et al. **Cell Growth Differ** 1997 Aug;8(8):851-60

Alternative transcript of the chick alpha 2(I) collagen gene is transiently expressed during endochondral bone formation and during development of the central nervous system. Nah HD, et al. **Dev Dyn** 1996 Jun;206(2):146-58

Expression of alternatively spliced and canonical basic fibroblast growth factor mRNAs in the early embryo and developing heart. Zhu X, et al. **Dev Dyn** 1996 Jun; 206(2):139-45

Novel exploitation of a nuclear function by influenza virus: the cellular SF2/ASF splicing factor controls the amount of the essential viral M2 ion channel protein in infected cells. Shih SR, et al. **EMBO J** 1996 Oct 1;15(19):5415-27

Alternative splicing of CREB and CREM mRNAs in an immortalized germ cell line. Sanborn BM, et al. **J Androl** 1997 Jan-Feb;18(1):62-70

Different steady state subcellular distributions of the three splice variants of lysosome-associated membrane protein LAMP-2 are determined largely by the COOH-terminal amino acid residue. Gough NR, et al. **J Cell Biol** 1997 Jun 2;137(5):1161-9

Two independent domains of hDlg are sufficient for subcellular targeting: the PDZ1-2 conformational unit and an alternatively spliced domain. Lue RA, et al. **J Cell Biol** 1996 Nov;135(4):1125-37

Tissue-specific alternative splicing of Shaker potassium channel transcripts results from distinct modes of regulating 3' splice choice. Iverson LE, et al. **J Neurobiol** 1997 May; 32(5):457-68

Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization. Heidmann DE, et al. **J Neurochem** 1997 Apr;68(4):1372-81

Novel isoforms of rat brain fructose 6-phosphate 2-kinase/fructose 2,6-bisphosphatase are generated by tissue-specific alternative splicing. Watanabe F, et al. **J Neurochem** 1997 Jul;69(1):1-9

Myelin/oligodendrocyte glycoprotein is alternatively spliced in humans but not mice. Ballenthin PA, et al. **J Neurosci Res** 1996 Oct 15;46(2):271-81

Identification of three new JC virus proteins generated by alternative splicing of the early viral mRNA. Trowbridge PW, et al. **J Neurovirol** 1995 Jun;1(2):195-206

In vivo regulation of alternative pre-mRNA splicing by the Clk1 protein kinase. Duncan PI, et al. **Mol Cell Biol** 1997 Oct;17(10):5996-6001

ALTERNATIVES TO ANIMAL TESTING see **ANIMAL TESTING ALTERNATIVES**

ALTHESIN

[Total intravenous anesthesia (TIVA) with alphaxolon/alphadolon (Saffan) for permanent restraint of two cats with severe dyspnea] Tacke S. **Tierarztl Prax** 1996 Oct;24(5):484-8 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Actions of the anaesthetic Saffan on rat sympathetic preganglionic neurones in vitro. Nolan MF, et al. **Br J Pharmacol** 1997 May;121(2):324-30

Effect of thiopental, saffan, and propofol anesthesia on cardiovascular parameters and bronchial smooth muscle in the rhesus monkey. Foster A, et al. **Lab Anim Sci** 1996 Jun;46(3):327-34

ALTITUDE

see related
MOUNTAINEERING

Maximal muscle activation is not limited by pulmonary ventilation in chronic hypoxia. Savard GK, et al. **Acta Physiol Scand** 1996 Jun;157(2):187-90

Changes in systemic vascular resistance during exposure to moderate altitude [letter; comment] Malagon I. **Am J Obstet Gynecol** 1996 Aug;175(2):505-6. Comment on: Am J Obstet Gynecol 1995 Apr;172(4 Pt 1):1170-8; discussion 1178-80.

Simultaneous 31P MRS of the soleus and gastrocnemius in Sherpas during graded calf muscle exercise. Allen PS, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R999-1007

Activator calcium and myocardial contractility in fetal sheep exposed to long-term high-altitude hypoxia. Browne VA, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1196-204

High altitude-induced changes in alpha1-adrenergic receptors and Ins(1,4,5)P3 responses in cerebral arteries. Ueno N, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R669-74

Ins(1,4,5)P3 receptors in cerebral arteries: changes with development and high-altitude hypoxia. Zhou L, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1954-9

The effect of high altitude and other risk factors on birthweight: independent or interactive effects? Jensen GM, et al. **Am J Public Health** 1997 Jun;87(6):1003-7

New aspects of altitude training. Rusko HR. **Am J Sports Med** 1996;24(6 Suppl):S48-52 (29 ref.)

Effect of altitude on body composition during mountaineering expeditions: interrelationships with changes in dietary habits. Zamboni M, et al. **Ann Nutr Metab** 1996; 40(6):315-24

The distribution of common intestinal nematodes along an altitudinal transect in KwaZulu-Natal, South Africa. Appleton CC, et al. **Ann Trop Med Parasitol** 1996 Apr; 90(2):181-8

The effect of 610 m altitude on rowing ergometer performance. Wood RJ, et al. **Aust J Sci Med Sport** 1995 Dec;27(4):98-102

Relation of sympathetic activation to ventilation in man at 4300 m altitude. Asano K, et al. **Aviat Space Environ Med** 1997 Feb;68(2):104-10

Clothing insulation in a hypobaric environment. Chang SK, et al. **Aviat Space Environ Med** 1996 Sep;67(9):827-34

Predictors of barotrauma events in a Navy altitude chamber. Davenport NA. **Aviat Space Environ Med** 1997 Jan; 68(1):61-5

Ventilatory capacities at sea level and high altitude. Forte VA Jr, et al. **Aviat Space Environ Med** 1997 Jun; 68(6):488-93

Acute ventilatory response to simulated altitude, normobaric hypoxia, and hypobaria. Loeppky JA, et al. **Aviat Space Environ Med** 1996 Nov;67(11):1019-22

Left ventricular gas emboli in six cases of altitude-induced decompression sickness. Pilmanis AA, et al. **Aviat Space Environ Med** 1996 Nov;67(11):1092-6

Aviation spatial orientation in relationship to head position, altitude interpretation, and control. Smith DR, et al. **Aviat Space Environ Med** 1997 Jun;68(6):472-8

Relationship between age and susceptibility to altitude decompression sickness. Sulaiman ZM, et al. **Aviat Space Environ Med** 1997 Aug;68(8):695-8

Survival at high altitudes: wheel-well passengers. Veronneau SJ, et al. **Aviat Space Environ Med** 1996 Aug;67(8):784-6 (6 ref.)

Physiological training in Jordan. al-Wedyan IA, et al. **Aviat Space Environ Med** 1996 Sep;67(9):882-4

Fire hazard in oxygen-enriched atmospheres at low barometric pressures. West JB. **Aviat Space Environ Med** 1997 Feb;68(2):159-62 (6 ref.)

Recovery from infectious mononucleosis after altitude training in an elite middle distance runner. Bailey DM, et al. **Br J Sports Med** 1997 Jun;31(2):153-4

Physiological implications of altitude training for endurance performance at sea level: a review. Bailey DM, et al. **Br J Sports Med** 1997 Sep;31(3):183-90 (111 ref.)

Extreme altitude transient aphasia [see comments] Garrido E, et al. **Br J Sports Med** 1996 Dec;30(4):364. Comment in: Br J Sports Med 1996 Dec;30(4):275-6.

Moderate altitude has no effect on choice reaction time in international rugby players. O'Carroll RE, et al. **Br J Sports Med** 1997 Jun;31(2):151-2

Duodenal ulcer and Helicobacter pylori infection at high altitude: experience from southern Saudi Arabia. Ahmed ME, et al. **Can J Gastroenterol** 1997 May-Jun;11(4):313-6

High-altitude pulmonary edema. Mechanisms and management. Sartori C, et al. **Cardiologia** 1997 Jun; 42(6):559-67 (92 ref.)

Acute and persistent effects of a 46-kilometer wilderness trail run at altitude: cardiovascular autonomic modulation and baroreflexes. Bernardi L, et al. **Cardiovasc Res** 1997 May; 34(2):273-80

Urinary leukotriene E4 levels in high-altitude pulmonary edema. A possible role for inflammation. Kaminsky DA, et al. **Chest** 1996 Oct;110(4):939-45

Urinary leukotriene E4 levels increase upon exposure to hypobaric hypoxia. Roach JM, et al. **Chest** 1996 Oct; 110(4):946-51

Effect of high-altitude exposure in the elderly: the Tenth Mountain Division study. Levine BD, et al. **Circulation** 1997 Aug 19;96(4):1224-32

Cough frequency and cough-receptor sensitivity are increased in man at altitude. Barry PW, et al. **Clin Sci (Colch)** 1997 Aug;93(2):181-6

Hypoxia, hypocapnia and spirometry at altitude. Pollard AJ, et al. **Clin Sci (Colch)** 1997 Jun;92(6):593-8

Oxygen sensors in the organism: examples of regulation under altitude hypoxia in mammals. Richalet JP. **Comp Biochem Physiol A Physiol** 1997 Sep;118(1):9-14 (16 ref.)

Influence of simulated altitude on the performance of five blood glucose meters. Gautier JF, et al. **Diabetes Care** 1996 Dec;19(12):1430-3

Acute effects of exercise at low altitude (350 meters below sea level) on hormones of the anterior pituitary & cortisol in athletes. Bashir N, et al. **Endocr Res** 1996 Aug; 22(3):289-98

Exercise at low altitude (Jordan Valley) causes changes in serum levels of ACTH, insulin, cortisol and lactate. el-Migdadi F, et al. **Endocr Res** 1996 Nov;22(4):763-7

Thermal status of wet-suited divers using closed circuit O2 apparatus in sea water of 17-18.5 degrees C. Arieli R, et al. **Eur J Appl Physiol** 1997;76(1):69-74

Accuracy of pulse oximetry during intense exercise under severe hypoxic conditions. Benoit H, et al. **Eur J Appl Physiol** 1997;76(3):260-3

Training-induced increases in sea level VO2max and endurance are not enhanced by acute hypobaric exposure. Emonson DL, et al. **Eur J Appl Physiol** 1997;76(1):8-12

Reduced performance of male and female athletes at 580 m altitude. Gore CJ, et al. **Eur J Appl Physiol** 1997; 75(2):136-43

Lactate during exercise at high altitude. Kayser B. **Eur J Appl Physiol** 1996;74(3):195-205 (51 ref.)

Diurnal variations of serum erythropoietin at sea level and altitude. Klausen T, et al. **Eur J Appl Physiol** 1996; 72(4):297-302

Effects of long-term acclimatization in lowlanders migrating to high altitude: comparison with high altitude residents. Niu W, et al. **Eur J Appl Physiol** 1995;71(6):543-8

Effects of high altitude acclimatization on heart rate variability in resting humans. Perini R, et al. **Eur J Appl Physiol** 1996;73(6):521-8

Pre-adaptation, adaptation and de-adaptation to high altitude in humans: cardio-ventilatory and haematological changes. Savourey G, et al. **Eur J Appl Physiol** 1996;73(6):529-35

General and local cold responses in humans after 2 weeks at high altitude. Savourey G, et al. **Eur J Appl Physiol** 1997;75(1):28-33

Volume changes in the forearm and lower limbs during 2 h of acute hypobaric hypoxia in nonacclimatized subjects. Schirlo C, et al. **Eur J Appl Physiol** 1997;75(2):124-31

Hypoxic ventilatory response during rest and exercise after a Himalayan expedition. Steinacker JM, et al. **Eur J Appl Physiol** 1996;73(3-4):202-9

Effects of physical training in a hypobaric chamber on the physical performance of competitive triathletes. Vallier JM, et al. **Eur J Appl Physiol** 1996;73(5):471-8

The effect of endurance exercise at moderate altitude on serum lipid peroxidation and antioxidative functions in humans. Vasankari TJ, et al. **Eur J Appl Physiol** 1997; 75(5):396-9

Capillary filtration coefficient and urinary albumin leak at altitude. Lewis DM, et al. **Eur J Clin Invest** 1997 Jan; 27(1):64-8

Effects of high-altitude chronic hypoxia on platelet alpha 2-receptors in man. Zaccaria M, et al. **Eur J Clin Invest** 1997 Apr;27(4):316-21

Weekly iron supplementation is as effective as 5 day per week iron supplementation in Bolivian school children living at high altitude. Berger J, et al. **Eur J Clin Nutr** 1997 Jun; 51(6):381-6

Calcium antagonist treatment and cardiovascular responses to a cold pressor test at high altitude. Hankø E, et al. **Eur J Clin Pharmacol** 1996;51(3-4):265-7

Nasal mucociliary transport is impaired at altitude. Barry PW, et al. **Eur Respir J** 1997 Jan;10(1):35-7

Gas exchange at extreme altitude: results from the British 40th Anniversary Everest Expedition [see comments] Peacock AJ, et al. **Eur Respir J** 1997 Jul;10(7):1439-44. Comment in: Eur Respir J 1997 Jul;10(7):1431-2.

Pulmonary gas exchange on Mount Everest [editorial; comment] West JB. **Eur Respir J** 1997 Jul;10(7):1431-2. Comment on: Eur Respir J 1997 Jul;10(7):1439-44.

Bilateral buried optic nerve drusen presenting with central retinal artery occlusion at high altitude [letter] Newsom RS, et al. **Eye** 1995;9 (Pt 6):806-8

High altitude training increases reactive carbonyl derivatives but not lipid peroxidation in skeletal muscle of rats. Radak Z, et al. **Free Radic Biol Med** 1997;22(6):1109-14

Glycophorin A somatic cell mutation frequencies in residents of Tibet at high altitudes. Jensen RH, et al. **Health Phys** 1997 Oct;73(4):663-7

Thyroid response to exercise at low altitude (Jordan valley) is confined to changes in triiodothyronine (T3) [letter] el-Migdadi F, et al. **Horm Metab Res** 1997 Apr;29(4):196

Quantitative genetic analysis of arterial oxygen saturation in Tibetan highlanders. Beall CM, et al. **Hum Biol** 1997 Oct; 69(5):597-604

Body mass index and age at menarche in Peruvian children living at high altitude and at sea level. Gonzales GF, et al. **Hum Biol** 1996 Apr;68(2):265-75

Evidence for a genetic basis to the enhanced total lung capacity of Andean highlanders. Greksa LP. **Hum Biol** 1996 Feb;68(1):119-29

Visual scene properties relevant for simulating low-altitude flight: a multidimensional scaling approach. Kleiss JA. **Hum Factors** 1995 Dec;37(4):711-34

Potential impact of altitude on lung function. Wolf C, et al. **Int Arch Occup Environ Health** 1997;69(2):106-8

Metabolic responses during initial days of altitude acclimatization in the eastern Himalayas. Basu CK, et al. **Int J Biometeorol** 1996 Sep;39(3):133-8

Thermal resistance parameters of the air environment at various altitudes. Kandjov IM. **Int J Biometeorol** 1997 Apr; 40(2):91-4

Influence of vanadium on acclimatization of humans to high altitude. Rawal SB, et al. **Int J Biometeorol** 1997 Apr; 40(2):95-8

Comparison of muscle force, muscle endurance, and electromyogram activity during an expedition at high altitude. Terasawa K, et al. **Int J Biometeorol** 1996 Sep; 39(3):111-5

High altitude and spontaneous preterm birth. Ali KZ, et al.

Int J Gynaecol Obstet 1996 Jul;54(1):11–5
Hormone profile during the menstrual cycle at high altitude. Escudero F, et al. **Int J Gynaecol Obstet** 1996 Oct; 55(1):49–58
Full-term birth weight and placental morphology at high and low altitude. Khalid ME, et al.
Int J Gynaecol Obstet 1997 Jun;57(3):259–65
Branched-chain amino acid supplementation during repeated prolonged skiing exercises at altitude. Bigard AX, et al. **Int J Sport Nutr** 1996 Sep;6(3):295–306
After-effects of a high altitude expedition on blood. Böning D, et al. **Int J Sports Med** 1997 Apr;18(3):179–85
Transient right but not left ventricular dysfunction after strenuous exercise at high altitude. Dávila-Román VG, et al. **J Am Coll Cardiol** 1997 Aug;30(2):468–73
Effect of altitude and socioeconomic status on VO2max and anaerobic power in prepubertal Bolivian girls. Blonc S, et al. **J Appl Physiol** 1996 Jun;80(6):2002–8
Exercise performance of Tibetan and Han adolescents at altitudes of 3,417 and 4,300 m. Chen QH, et al.
J Appl Physiol 1997 Aug;83(2):661–7
Muscle tissue adaptations of high-altitude natives to training in chronic hypoxia or acute normoxia. Desplanches D, et al. **J Appl Physiol** 1996 Nov;81(5):1946–51
Pulmonary hemodynamic response to exercise in subjects with prior high-altitude pulmonary edema. Eldridge MW, et al. **J Appl Physiol** 1996 Aug;81(2):911–21
Hormonal and metabolic adjustments during exercise in hypoxia or normoxia in highland natives. Favier R, et al. **J Appl Physiol** 1996 Feb;80(2):632–7
Water turnover and body composition during long-term exposure to high altitude (4,900–7,600 m). Fusch C, et al. **J Appl Physiol** 1996 Apr;80(4):1118–25
Increased arterial desaturation in trained cyclists during maximal exercise at 580 m altitude. Gore CJ, et al.
J Appl Physiol 1996 Jun;80(6):2204–10
Peak blood lactate and blood lactate vs. workload during acclimatization to 5,050 m and in deacclimatization. Grassi B, et al. **J Appl Physiol** 1996 Feb;80(2):685–92
Shift working in the Chilean Andes (> 3,600 m) and its influence on erythropoietin and the low-pressure system. Gunga HC, et al. **J Appl Physiol** 1996 Aug;81(2):846–52
Augmented hypoxic cerebral vasodilation in men during 5 days at 3,810 m altitude. Jensen JB, et al.
J Appl Physiol 1996 Apr;80(4):1214–8
Muscle ultrastructure and biochemistry of lowland Tibetans. Kayser B, et al. **J Appl Physiol** 1996 Jul;81(1):419–25
Lactate and epinephrine during exercise in altitude natives. Kayser B, et al. **J Appl Physiol** 1996 Dec;81(6):2488–94
Evidence against an increase in capillary permeability in subjects exposed to high altitude. Kleger GR, et al.
J Appl Physiol 1996 Nov;81(5):1917–23
Hypoxia- and normoxia-induced reversibility of autonomic control in Andean guinea pig heart. León-Velarde F, et al. **J Appl Physiol** 1996 Nov;81(5):2229–34
Alveolar Pco2 and Po2 of high-altitude natives living at sea level. León-Velarde F, et al. **J Appl Physiol** 1996 Oct; 81(4):1615–9
"Living high-training low": effect of moderate-altitude acclimatization with low-altitude training on performance. Levine BD, et al. **J Appl Physiol** 1997 Jul;83(1):102–12
Exercise-induced VA/Q inequality in subjects with prior high-altitude pulmonary edema. Podolsky A, et al.
J Appl Physiol 1996 Aug;81(2):922–32
Energy expenditure and requirement while climbing above 6,000 m. Pulfrey SM, et al. **J Appl Physiol** 1996 Sep; 81(3):1306–11
Acute mountain sickness: increased severity during simulated altitude compared with normobaric hypoxia. Roach RC, et al. **J Appl Physiol** 1996 Nov;81(5):1908–10
Recovery processes after repeated supramaximal exercise at the altitude of 4,350 m. Robach P, et al.
J Appl Physiol 1997 Jun;82(6):1897–904
Acclimatization to 4,300-m altitude decreases reliance on fat as a substrate. Roberts AC, et al. **J Appl Physiol** 1996 Oct; 81(4):1762–71
Altitude and beta-blockade augment glucose utilization during submaximal exercise. Roberts AC, et al.
J Appl Physiol 1996 Feb;80(2):605–15
Altitude acclimatization and blood volume: effects of exogenous erythrocyte volume expansion. Sawka MN, et al. **J Appl Physiol** 1996 Aug;81(2):636–42
Effect of high-altitude hypoxia on feeding responses and hedonic matrix in rats. Singh SB, et al. **J Appl Physiol** 1996 Apr;80(4):1133–7
Prediction of barometric pressures at high altitude with the use of model atmospheres. West JB. **J Appl Physiol** 1996 Oct;81(4):1850–4
Water balance and acute mountain sickness before and after arrival at high altitude of 4,350 m. Westerterp KR, et al.
J Appl Physiol 1996 Jun;80(6):1968–72
Effects of acute exposure to simulated altitude on heart rate variability during exercise. Yamamoto Y, et al.
J Appl Physiol 1996 Sep;81(3):1223–9
Effects of erythrocyte infusion on VO2max at high altitude. Young AJ, et al. **J Appl Physiol** 1996 Jul;81(1):252–9
FEF25-75 as a marker of airway obstruction in asthmatic children during reduced mite exposure at high altitude. Valletta EA, et al. **J Asthma** 1997;34(2):127–31
Pharmacokinetics of meperidine in healthy volunteers after short- and long-term exposure to high altitude. Ritschel WA, et al. **J Clin Pharmacol** 1996 Jul;36(7):610–6
Bronchoarterial ratio on thin section CT: comparison between high altitude and sea level. Kim JS, et al.
J Comput Assist Tomogr 1997 Mar–Apr;21(2):306–11
Ostertagia nianqingtanggulaensis Kúng & Li, 1965 (Nematoda: Trichostrongyloidea) from sheep and goats at high altitudes in Nepal. Joshi BR, et al. **J Helminthol** 1997 Mar;71(1):21–7
Race specific altitude effects on blood pressure. Hasler E, et al. **J Hum Hypertens** 1997 Jul;11(7):435–8
High-altitude pulmonary hypertension: effects of captopril on pulmonary and systemic arterial pressures. Niazova ZA, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S141–2
Reduction of I(Ca,L) and I(to1) density in hypertrophied right ventricular cells by simulated high altitude in adult rats. Chouabe C, et al. **J Mol Cell Cardiol** 1997 Jan; 29(1):193–206
Respiratory mechanics during exhaustive submaximal exercise at high altitude in healthy humans. Cibella F, et al. **J Physiol (Lond)** 1996 Aug 1;494 (Pt 3):881–90
Hyperopic shift induced by high altitude after radial keratotomy. Creel DJ, et al. **J Refract Surg** 1997 Jul–Aug; 13(4):398–400
The effects of moderate altitude on circulating thyroid hormones and thyrotropin in training athletes. Koistinen P, et al. **J Sports Med Phys Fitness** 1996 Jun;36(2):108–11
Hematologic and body fluid changes during simulated high altitude exposure in naproxen-treated rats. Biswas HM, et al. **Jpn J Physiol** 1996 Feb;46(1):67–73
Cardiorespiratory response to exercise in elite Sherpa climbers transferred to sea level. Garrido E, et al.
Med Sci Sports Exerc 1997 Jul;29(7):937–42
Skeletal muscle adaptations to training under normobaric hypoxic versus normoxic conditions. Melissa L, et al.
Med Sci Sports Exerc 1997 Feb;29(2):238–43
A new method for monitoring hydration at high altitude by bioimpedance analysis. Piccoli A, et al.
Med Sci Sports Exerc 1996 Dec;28(12):1517–22
Visual system effects of exercise on Mauna Kea at 2,200 and 4,200 meters altitude. Schmeisser ET, et al. **Mil Med** 1997 Mar;162(3):186–9
Definition and prevalence of anemia in Bolivian women of childbearing age living at high altitudes: the effect of iron-folate supplementation. Berger J, et al. **Nutr Rev** 1997 Jun;55(6):247–56
LASIK at 16,000 feet [letter; comment] Davidorf JM.
Ophthalmology 1997 Apr;104(4):565–6. Comment on: Ophthalmology 1996 Aug;103(8):1188–95.
Unilateral agenesis of the pulmonary artery and high-altitude pulmonary edema (HAPE) at moderate altitude. Sebbane M, et al. **Pediatr Pulmonol** 1997 Aug;24(2):111–4
Effects of prolonged exposure to and physical training in hypobaric conditions on skeletal muscle morphology and metabolic enzymes in rats. Perhonen M, et al.
Pflugers Arch 1996 May;432(1):50–8
The influence of habitat and altitude on oxygen uptake in sub-Antarctic weevils. Chown SL, et al. **Physiol Zool** 1997 Jan–Feb;70(1):116–24
Does hypercapillarization influence the branching pattern of terminal villi in the human placenta at high altitude? Ali KZ, et al. **Placenta** 1996 Nov;17(8):677–82
Term ovine placental vasculature: comparison of sea level and high altitude conditions by corrosion cast and histomorphometry. Krebs C, et al. **Placenta** 1997 Jan; 18(1):43–51
Effects of altitude above sea level on the cooking time and nutritional value of common beans. Bressani R, et al.
Plant Foods Hum Nutr 1996 Jan;49(1):53–61
Key factors in success of altitude training for swimming. Miyashita M. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S76–8 (10 ref.)
Exercise and the environment: focus on altitude. Saltin B. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S1–10 (33 ref.)
Dynamics of periodic breathing and arousal during sleep at extreme altitude. Khoo MC, et al. **Respir Physiol** 1996 Jan; 103(1):33–43
Fiber capillarization in flight muscle of pigeons native and flying at altitude. Mathieu-Costello O, et al.
Respir Physiol 1996 Feb;103(2):187–94
Haldane and indifferent gases: O2 secretion or CO excretion? Torrance RW. **Respir Physiol** 1996 Nov;106(2):109–13
Smaller alveolar-arterial O2 gradients in Tibetan than Han residents of Lhasa (3658 m). Zhuang J, et al.
Respir Physiol 1996 Jan;103(1):75–82
Reference limits for routine haematological measurements in 7–14-year-old children living at an intermediate altitude (1869 m, Erzurum, Turkey). Akdağ R, et al.
Scand J Clin Lab Invest 1996 Apr;56(2):103–9
Physical activity at altitude in pregnancy. Huch R.
Semin Perinatol 1996 Aug;20(4):303–14 (59 ref.)
Altitude training for improvements in sea level performance. Is the scientific evidence of benefit? Wolski LA, et al.
Sports Med 1996 Oct;22(4):251–63
Effect of altitude on children with asthma [letter; comment] Polosa R. **Thorax** 1997 May;52(5):494. Comment on: Thorax 1996 Jun;51(6):582–4.
Altitude and the risk of bites from mosquitoes infected with malaria and filariasis among the Mianmin people of Papua New Guinea. Attenborough RD, et al.
Trans R Soc Trop Med Hyg 1997 Jan–Feb;91(1):8–10
Relationship of the time course of venous gas bubbles to altitude decompression illness. Conkin J, et al.
Undersea Hyperb Med 1996 Sep;23(3):141–9
Testing of hypotheses about altitude decompression sickness by statistical analyses. Van Liew HD, et al.
Undersea Hyperb Med 1996 Dec;23(4):225–33
Differences in the biological stress responses of two cattle breeds to walking up to mountain pastures in the Pyrenees. García-Belenguer S, et al. **Vet Res** 1996;27(4–5):515–26
Age at menarche amongst school girls in a high altitude Nigerian town. Ekele BA, et al. **West Afr J Med** 1996 Jul–Sep;15(3):170–2
High-altitude pulmonary edema at a ski resort. Hultgren HN, et al. **West J Med** 1996 Mar;164(3):222–7
[High-altitude pulmonary edema in Japan] Kobayashi T.
Nippon Kyobu Shikkan Gakkai Zasshi 1995 Dec;33 Suppl:1–6 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Periodic breathing at high altitude relation to acclimatization and acute mountain sickness] Sugie T.
Nippon Kyobu Shikkan Gakkai Zasshi 1995 Dec; 33(12):1355–60 (Eng. Abstr.) **(Jpn)**
[Quality of sleep and periodic breathing during sleep in healthy persons at a height of 3200 meters] Koziej M, et al. **Pneumonol Alergol Pol** 1996;64(9–10):651–7 (Eng. Abstr.) **(Pol)**
[Effect of altitude on blood oxygenation during sleep in patients with bronchial asthma] Mańkowski M, et al.
Pneumonol Alergol Pol 1996;64(9–10):658–63 (Eng. Abstr.) **(Pol)**
[Role of hypoxia in the development of epileptiform seizures] Agadzhanian NA, et al. **Aviakosm Ekolog Med** 1996; 30(4):40–4 (Eng. Abstr.) **(Rus)**
[The intensity of respiration in pea and corn seedlings under high-altitude hypoxia] Astafurova TP, et al.
Aviakosm Ekolog Med 1996;30(3):35–9 (Eng. Abstr.) **(Rus)**
[Effects of high altitude on changes in blood coagulation in rats during prolonged administration of noradrenaline] Zakharov GA, et al. **Aviakosm Ekolog Med** 1996;30(2):33–7 (Eng. Abstr.) **(Rus)**
[Ultrastructure of the kidney in acute massive hemorrhage at moderate and high altitudes] Zufarov KA, et al.
Aviakosm Ekolog Med 1997;31(3):48 **(Rus)**
[Morphological changes in dogs liver during altitude adaptation] Orlova EV, et al. **Biull Eksp Biol Med** 1997 Jun;123(6):714–7 **(Rus)**
[Decompression regimens for diving descents to a depth of 60 meters under medium-altitude conditions] Lastochkin GI, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):137–9 **(Rus)**
[Bioclimatic evaluation of mountainous territories] Shanazarov AS, et al. **Fiziol Cheloveka** 1997 Jan–Feb; 23(1):15–9 **(Rus)**
[Changes in cardiovascular function of ischemic heart disease patients on the course of rehabilitation at low-mountain health resort after surgical revascularization of myocardium] Amiiants VI, et al. **Klin Med (Mosk)** 1997; 75(2):26–8 (Eng. Abstr.) **(Rus)**
[Evaluation intensity and hardness of work in conditions of high altitude migration] Chernook TB, et al.
Med Tr Prom Ekol 1997;(4):26–9 **(Rus)**
[Structural changes in the liver of dogs under physical training at high altitude] Orlova EV, et al. **Morfologiia** 1997;111(2):83–7 (Eng. Abstr.) **(Rus)**
[Stress-induced hemodynamic changes in shepherds during migration and winter stay in the mountains] Bekbolotova AK, et al. **Patol Fiziol Eksp Ter** 1997 Jul–Sep;(3):15–8 **(Rus)**
[Effect of adaptation to medium altitude (1600 m) on the stability of parameters of lipid metabolism of the myocardium during stress] Kostiuchenko LS.
Patol Fiziol Eksp Ter 1996 Apr–Jun;(2):18–20 (Eng. Abstr.) **(Rus)**
[The characteristics of the adaptation to the hypoxic conditions at a low-altitude health resort in IHD patients after an aortocoronary bypass] Amiiants VIu. **Ter Arkh** 1996;68(9):52–4 (Eng. Abstr.) **(Rus)**
[The effect of rehabilitation by stages at a low-altitude health resort on the late results of the surgical treatment of ischemic heart disease] Amiiants VIu, et al. **Ter Arkh** 1997; 69(1):58–9 (Eng. Abstr.) **(Rus)**
[A genetic epidemiological study of arterial hypertension in an isolated mountain area of Dagestan] Guseinov GG, et al. **Ter Arkh** 1996;68(12):64–6 (Eng. Abstr.) **(Rus)**
[History of solving medical problems of safety provisions of altitude flights] Dvornikov MV, et al.
Vestn Ross Akad Med Nauk 1996;(7):15–9 (Eng. Abstr.) **(Rus)**
[Pharmacological correction of lipid peroxidation during hypoxia and possibility to enhance human resistance to high altitude by using preparations of the metabolic type of action] Nagornev SN, et al.
Vestn Ross Akad Med Nauk 1996;(7):53–60 (Eng. Abstr.) **(Rus)**
[Changes in lymphocyte cytochemical markers in radiation-exposed patients under mountain conditions] Taradii NN, et al. **Vestn Ross Akad Med Nauk** 1997;(5):33–7 (Eng. Abstr.) **(Rus)**
[The dynamic clinical manifestations of ischemic heart disease during the rehabilitation at a low-altitude health resort of patients who have undergone surgical myocardial revascularization] Amiiants VIu, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1996 Nov–Dec;(6):7–9 (Eng. Abstr.) **(Rus)**
[The effect of geophysical and meteorological factors on the

course of chronic obstructive lung diseases at a low-mountain altitude] Povazhnaia EL, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 May-Jun; (3):18-21 (Eng. Abstr.) **(Rus)**

[Heat transfer, convection and altitudinal gradient] Bozinovic F, et al. **Arch Biol Med Exp (Santiago)** 1987;20(1):85-8 (Eng. Abstr.) **(Spa)**

[Iron metabolism during pregnancy at high altitudes] Reynafarje Hurtado C. **Arch Biol Med Exp (Santiago)** 1987; 20(1):31-7 (Eng. Abstr.) **(Spa)**

[Hematologic values and altitudinal distribution of Chilean amphibians] Ruiz G, et al. **Arch Biol Med Exp (Santiago)** 1987;20(1):79-84 (Eng. Abstr.) **(Spa)**

[Isoniazid acetylation, its relation to genetic and environmental altitude factors] Taboada Lopez G, et al. **Arch Biol Med Exp (Santiago)** 1987;20(1):13-9 (Eng. Abstr.) **(Spa)**

[Determination of the content of common protein in biological samples using chemical stabilizers] Iarmol'chuk HM. **Ukr Biokhim Zh** 1996 Sep-Oct;68(5):103-5 (Eng. Abstr.) **(Ukr)**

ALTITUDE SICKNESS

[Acute high altitude sickness--medical experiences from Mount Everest during the spring season 1996] Rostrup M. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1110-7 (Eng. Abstr.) **(Nor)**

[Diseases in mountain expeditions (letter; comment)] Bellmunt Molins J. **Med Clin (Barc)** 1997 Jun 14; 109(3):116-7. Comment on: Med Clin (Barc) 1996 Sep 7;107(7):270-4. **(Spa)**

BLOOD

Changes in plasma electrolytes during acclimatization at high altitude. Khan DA, et al. **JPMA J Pak Med Assoc** 1996 Jun;46(6):128-31

[The significance of changes in plasma renin angiotensin aldosterone system and atrial natriuretic factor in patients with high altitude myocardial hypoxidosis] Li Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Dec;34(12):812-5 (Eng. Abstr.) **(Chi)**

[Immuno-physiological and hematological aspects of flight certification examination] Goranchuk VV, et al. **Aviakosm Ekolog Med** 1996;30(1):54-7 (12 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

High-altitude retinopathy. Lang GE, et al. **Am J Ophthalmol** 1997 Mar;123(3):418-20

Involvement of nitric oxide and N-methyl-D-aspartate in acute hypoxic altitude convulsion in mice. Chen CH, et al. **Aviat Space Environ Med** 1997 Apr;68(4):296-9

Effect of high-altitude exposure in the elderly: the Tenth Mountain Division study. Levine BD, et al. **Circulation** 1997 Aug 19;96(4):1224-32

Endothelin-1 and interleukin-8 in high altitude pulmonary oedema. Droma Y, et al. **Eur Respir J** 1996 Sep;9(9):1947-9

Full-term birth weight and placental morphology at high and low altitude. Khalid ME, et al. **Int J Gynaecol Obstet** 1997 Jun;57(3):259-65

Hypercoagulable state in a hypobaric, hypoxic environment causes non-bacterial thrombotic endocarditis in rats. Nakanishi K, et al. **J Pathol** 1997 Mar;181(3):338-46

Everest nails [letter] Hutchison SJ, et al. **N Engl J Med** 1997 Jan 16;336(3):229

High altitude-induced albuminuria in normal man is enhanced by infusion of low-dose dopamine. Hansen JM, et al. **Scand J Clin Lab Invest** 1996 Jul;56(4):367-72

[Acute altitude pulmonary edema] Savoy J, et al. **Rev Med Suisse Romande** 1997 Jun;117(6):471-4 (22 ref.) **(Fre)**

DIAGNOSIS

Acute mountain sickness -- experience on the roof of Africa expedition and military implications. Roberts MJ. **J R Army Med Corps** 1994 Feb;140(1):49-51

Acute mountain sickness [letter; comment] Murdoch DR. **J R Soc Med** 1996 Dec;89(12):728. Comment on: J R Soc Med 1996 Jun;89(6):359-60.

DIET THERAPY

Acute mountain sickness is not altered by a high carbohydrate diet nor associated with elevated circulating cytokines. Swenson ER, et al. **Aviat Space Environ Med** 1997 Jun;68(6):499-503

DRUG THERAPY

Effects of almitrine bismesylate in a microswine model of hypoxemic hypothermia. Gentile BJ, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):824-8

The role of drugs in high altitude disorders. Aslam M, et al. **JPMA J Pak Med Assoc** 1996 Apr;46(4):90-2 (11 ref.)

[Impairment of antiviral cellular resistance and possibilities of its correction during acute altitude hypoxia] Sinopal'nikov DO, et al. **Aviakosm Ekolog Med** 1997; 31(2):28-32 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

[Adaptation of the circulatory system to medium- and high-altitude hypoxia in heterozygous and homozygous adolescent twins] Zaslavskaia RM, et al. **Fiziol Cheloveka** 1997 Jan-Feb;23(1):29-32 **(Rus)**

ETIOLOGY

The role of menopause in the development of chronic mountain sickness. León-Velarde F, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R90-4

Association between raised body temperature and acute mountain sickness: cross sectional study. Maggiorini M, et al. **BMJ** 1997 Aug 16;315(7105):403-4

Acute hypoxic pulmonary vascular response does not accompany plasma endothelin-1 elevation in subjects susceptible to high altitude pulmonary edema. Droma Y, et al. **Intern Med** 1996 Apr;35(4):257-60

Inflammatory processes may predispose children to high-altitude pulmonary edema. Durmowicz AG, et al. **J Pediatr** 1997 May;130(5):838-40

HISTORY

T.H. Ravenhill and his contributions to mountain sickness. West JB. **J Appl Physiol** 1996 Mar;80(3):715-24

Historical perspectives regarding our understanding of physical performance during hypoxia. Buskirk ER. **Res Q Exerc Sport** 1996 Sep;67(3 Suppl):S73-5

IMMUNOLOGY

Cytokines in bronchoalveolar lavage fluid in patients with high altitude pulmonary oedema at moderate altitude in Japan. Kubo K, et al. **Thorax** 1996 Jul;51(7):739-42

[Immuno-physiological and hematological aspects of flight certification examination] Goranchuk VV, et al. **Aviakosm Ekolog Med** 1996;30(1):54-7 (12 ref.) (Eng. Abstr.) **(Rus)**

[Impairment of antiviral cellular resistance and possibilities of its correction during acute altitude hypoxia] Sinopal'nikov DO, et al. **Aviakosm Ekolog Med** 1997; 31(2):28-32 (Eng. Abstr.) **(Rus)**

METABOLISM

Renal function of substance P in rats chronically exposed to hypoxia. Chen CF, et al. **Aviat Space Environ Med** 1997 Aug;68(8):705-9

PHYSIOPATHOLOGY

Acid-base balance and O2 transport at high altitude. Samaja M, et al. **Acta Physiol Scand** 1997 Mar;159(3):249-56

Nocturnal periodic breathing and the development of acute high altitude illness. Eichenberger U, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1748-54

Respiratory changes during initial days of acclimatization to increasing altitudes. Basu CK, et al. **Aviat Space Environ Med** 1996 Jan;67(1):40-5

Effects of altitude hypoxia on middle latency auditory evoked potentials in humans. Bouchet P, et al. **Aviat Space Environ Med** 1997 Aug;68(8):699-704

The initial signs and symptoms of altitude decompression sickness. Ryles MT, et al. **Aviat Space Environ Med** 1996 Oct;67(10):983-9 (25 ref.)

Survival at high altitudes: wheel-well passengers. Veronneau SJ, et al. **Aviat Space Environ Med** 1996 Aug;67(8):784-6 (6 ref.)

Comparisons of altitude tolerance and hypoxia symptoms between nonsmokers and habitual smokers. Yoneda I, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):807-11

The sensation of respiration in men experiencing high-altitude chronic hypoxia. Noël-Jorand MC, et al. **Biol Psychol** 1996 Mar 8;43(1):1-12

High-altitude pulmonary edema. Mechanisms and management. Sartori C, et al. **Cardiologia** 1997 Jun; 42(6):559-67 (92 ref.)

Low pulmonary diffusing capacity in subjects with acute mountain sickness. Ge RL, et al. **Chest** 1997 Jan; 111(1):58-64

Pain perception under chronic high-altitude hypoxia. Noël-Jorand MC, et al. **Eur J Neurosci** 1996 Oct; 8(10):2075-9

High altitude pulmonary edema: hemodynamic aspects. Hultgren HN. **Int J Sports Med** 1997 Jan;18(1):20-5 (59 ref.)

Exaggerated pulmonary hypertension with monocrotaline in rats susceptible to chronic mountain sickness. Colice GL, et al. **J Appl Physiol** 1997 Jul;83(1):25-31

Pathophysiological effects of hemodilution in chronic mountain sickness in rats. Du HK, et al. **J Appl Physiol** 1996 Feb;80(2):574-82

Pulmonary hemodynamic response to exercise in subjects with prior high-altitude pulmonary edema. Eldridge MW, et al. **J Appl Physiol** 1996 Aug;81(2):911-21

Exercise-induced VA/Q inequality in subjects with prior high-altitude pulmonary edema. Podolsky A, et al. **J Appl Physiol** 1996 Aug;81(2):922-32

Acute mountain sickness: increased severity during simulated altitude compared with normobaric hypoxia. Roach RC, et al. **J Appl Physiol** 1996 Nov;81(5):1908-10

Breathing and brain blood flow during sleep in patients with chronic mountain sickness. Sun S, et al. **J Appl Physiol** 1996 Aug;81(2):611-8

Pulmonary, vascular responses in rats exposed to chronic hypobaric hypoxia at two different altitude levels. Nakanishi K, et al. **Pathol Res Pract** 1996 Oct; 192(10):1057-67

Ventilation during simulated altitude, normobaric hypoxia and normoxic hypobaria. Loeppky JA, et al. **Respir Physiol** 1997 Mar;107(3):231-9

Respiratory training, hypoxic ventilatory response and acute mountain sickness. Markov G, et al. **Respir Physiol** 1996 Sep;105(3):179-86

[A preliminary report on changes in micro-circulation of conjunctiva in patients with high altitude pulmonary edema] Guo L, et al. **Chung Hua Yen Ko Tsa Chih** 1995 Jul;31(4):285-7 (Eng. Abstr.) **(Chi)**

[Altitude sickness] Bielenberg J. **Med Monatsschr Pharm** 1996 Aug;19(8):232-4 (7 ref.) **(Ger)**

[Sleep and respiration at an altitude of 6,400 m (Aconcagua, Argentina] Netzer N, et al. **Pneumologie** 1997 Aug;51 Suppl 3:729-35 (Eng. Abstr.) **(Ger)**

[Periodic breathing at high altitude relation to acclimatization and acute mountain sickness] Sugie T. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec; 33(12):1355-60 (Eng. Abstr.) **(Jpn)**

[Character of the changes in bioelectrical activity of the brain in persons performing operator work under conditions of high-altitude hypoxia] Dzhunusova GS, et al. **Fiziol Cheloveka** 1997 Jul-Aug;23(4):52-7 **(Rus)**

[The effect of experimental and high-altitude hypoxia on the bioelectrical processes of different brain structures and intercentral relations] Soroko SI, et al. **Fiziol Cheloveka** 1997 May-Jun;23(3):11-9 (44 ref.) **(Rus)**

PREVENTION & CONTROL

The effect of positive pressure breathing for altitude protection on intraocular pressure. Ryles MT, et al. **Aviat Space Environ Med** 1996 Dec;67(12):1179-84

High-altitude medicine. Zafren K, et al. **Emerg Med Clin North Am** 1997 Feb;15(1):191-222 (201 ref.)

RADIONUCLIDE IMAGING

Alterations of myocardial sympathetic innervation in response to hypoxia. Scherrer-Crosbie M, et al. **J Nucl Med** 1997 Jun;38(6):954-7

THERAPY

Acute mountain sickness -- experience on the roof of Africa expedition and military implications. Roberts MJ. **J R Army Med Corps** 1994 Feb;140(1):49-51

[Emergency respirator therapy in intermediate altitude with the Ambu Matic] Röggla M, et al. **Acta Med Austriaca** 1996;23(5):168-9 (Eng. Abstr.) **(Ger)**

[Therapeutic limit values of acute, arterial hypoxia] Zander R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):372-4 **(Ger)**

URINE

Urinary leukotriene E4 levels increase upon exposure to hypobaric hypoxia. Roach JM, et al. **Chest** 1996 Oct; 110(4):946-51

Capillary filtration coefficient and urinary albumin leak at altitude. Lewis DM, et al. **Eur J Clin Invest** 1997 Jan; 27(1):64-8

ALTRETAMINE

ADMINISTRATION & DOSAGE

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. Rustin GJ, et al. **J Clin Oncol** 1997 Jan;15(1):172-6

THERAPEUTIC USE

N-(Hydroxymethyl) melamines. Coley HM. **Gen Pharmacol** 1997 Feb;28(2):177-82 (31 ref.)

Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Manetta A, et al. **Gynecol Oncol** 1997 Jul;66(1):20-6 (39 ref.)

ALTRUISM

Altruism under fire [letter; comment] David TJ. **Arch Dis Child** 1997 May;76(5):479. Comment on: Arch Dis Child 1996 Nov;75(5):366.

Cooperation among unrelated individuals: reciprocal altruism, by-product mutualism and group selection in fishes. Dugatkin LA, et al. **Biosystems** 1996;37(1-2):19-30

Parents' reactions to children's negative emotions: relations to children's social competence and comforting behavior. Eisenberg N, et al. **Child Dev** 1996 Oct;67(5):2227-47

Ethical and policy issues in altruistic living and cadaveric organ donation. Spital A. **Clin Transplant** 1997 Apr; 11(2):77-87 (93 ref.)

A research note about military-civilian humanitarianism: more questions than answers. Weiss TG. **Disasters** 1997 Jun;21(2):95-117 (116 ref.)

Altruism: a framework for caring and providing care.

ALTRUISM

Gormley KJ. **Int J Nurs Stud** 1996 Dec;33(6):581–8

Where are the heroes of bioethics? [see comments] Freedman B. **J Clin Ethics** 1996 Winter;7(4):297–9. Comment in: J Clin Ethics 1996 Winter;7(4):291–6. Comment in: J Clin Ethics 1996 Winter;7(4):301–5. Comment in: J Clin Ethics 1996 Winter;7(4):307–9.

Everyday heroes in ethics: Part I [comment] Howe EG. **J Clin Ethics** 1996 Winter;7(4):291–6. Comment on: J Clin Ethics 1996 Winter;7(4):297–9.

Procuring gametes for research and therapy: the argument for unisex altruism—a response to Donald Evans [comment] [see comments] Dickenson DL. **J Med Ethics** 1997 Apr;23(2):93–5. Comment on: J Med Ethics 1995 Oct;21(5):261–4. Comment in: J Med Ethics 1997 Apr;23(2):67–8.

The gift of blood in Europe: an ethical defence of EC directive 89/381 [see comments] Keown J. **J Med Ethics** 1997 Apr;23(2):96–100. Comment in: J Med Ethics 1997 Apr;23(2):67–8.

Willingness to sacrifice in close relationships. Van Lange PA, et al. **J Pers Soc Psychol** 1997 Jun;72(6):1373–95

A change of mind [editorial] [see comments] Black D. **J R Coll Physicians Lond** 1997 Mar–Apr;31(2):122. Comment in: J R Coll Physicians Lond 1997 Mar–Apr;31(2):123–4.

The effects of cognitive and affective perspective taking on empathic concern and altruistic helping. Oswald PA. **J Soc Psychol** 1996 Oct;136(5):613–23

Humanitarianism under the gun. Sharp VL, et al. **JAMA** 1997 Jul 9;278(2):160

Altruism—a flawed morality? [letter] Foley JM. **Pharos** 1997 Spring;60(2):45–6

Altruism—a flawed morality? [letter] [see comments] Lanard MS. **Pharos** 1997 Winter;60(1):39. Comment in: Pharos 1996 Fall;59(4):14–7.

Altruism—a flawed morality? [letter] Ziegler DK. **Pharos** 1997 Winter;60(1):39

Altruism toward deviant persons in cities, suburbs, and small towns. Bridges FS. **Psychol Rep** 1996 Aug;79(1):313–4

Effects of sex of caller, implied sexual orientation of caller, and urgency on altruistic response using the wrong number technique. Gore KY, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):927–30

Altruistic preferences for life-saving public programs: do baseline risks matter? Van Houtven GL. **Risk Anal** 1997 Feb;17(1):85–92

Finding an appropriate ethic in a world of moral acquaintances. Loewy EH. **Theor Med** 1997 Mar–Jun; 18(1–2):79–97

Asking for altruism when death occurs: who asks for organ donation and why? Siminoff LA, et al. **Transplant Proc** 1996 Dec;28(6):3632–8

Who pays for failed organ procurement and what is the cost of altruism? Grossman MD, et al. **Transplantation** 1996 Dec 27;62(12):1828–31

[Training of health personnel in the framework of humanitarian action. Choosing an assessment model] Marchand C, et al. **Sante** 1996 Sep–Oct;6(5):279–83 (Eng. Abstr.) **(Fre)**

[Living organ donation for an unknown person—pure altruism? Little change in discussion of the transplantation law] Krautkrämer H. **Fortschr Med** 1996 Sep 30;114(27):14, 16 **(Ger)**

[International humanitarian aid in the control of tuberculosis in Voronezh Province] Mottskus B, et al. **Probl Sotsialnoi Gig Istor Med** 1996 Nov–Dec;(6):49–51 (Eng. Abstr.) **(Rus)**

[The human, humanistic, humanist and humanitarian in medicine] Lifshitz A. **Gac Med Mex** 1997 May–Jun; 133(3):237–43 (Eng. Abstr.) **(Spa)**

ALU REPETITIVE SEQUENCE see **REPETITIVE SEQUENCES, NUCLEIC ACID**

ALUM COMPOUNDS

Effect of alum on methamphetamine screening tests [letter] Kaufman MS, et al. **Clin Chem** 1996 Oct;42(10):1720–1

CHEMISTRY

Studies on aluminium leaching from cookware in tea and coffee and estimation of aluminium content in toothpaste, baking powder and paan masala. Rajwanshi P, et al. **Sci Total Environ** 1997 Jan 30;193(3):243–9

METABOLISM

Immunotherapy with an alum–adsorbed Parietaria–pollen allergoid: a 2–year, double–blind, placebo–controlled study. Tari MG, et al. **Allergy** 1997 Jan;52(1):65–74

PHARMACOKINETICS

Renal excretion of aluminium in the rat: effect of citrate infusion. Lote CJ, et al. **Hum Exp Toxicol** 1995 Dec; 14(12):945–8

PHARMACOLOGY

Inhibitors of the polymerase chain reaction in Papanicolaou stain. Removal with a simple destaining procedure. Chen JT, et al. **Acta Cytol** 1996 Sep–Oct;40(5):873–7

Effect of alum on free–living and copepod–associated Vibrio cholerae O1 and O139. Chowdhury MA, et al. **Appl Environ Microbiol** 1997 Aug;63(8):3323–6

Immunogenicity of HIV–1LAI gp160 and env peptides in squirrel monkey Saimiri sciureus using alumine and experimental adjuvants. Perraut R, et al. **Clin Exp Immunol** 1996 Dec;106(3):434–41

Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects. Barrios C, et al. **Eur J Immunol** 1996 Nov; 26(11):2666–70

The promotion of iron–induced generation of reactive oxygen species in nerve tissue by aluminum. Bondy SC, et al. **Mol Chem Neuropathol** 1996 Feb;27(2):185–94

The effects of adjuvants on CTL induction by V3:Ty–virus–like particles (V3–VLPs) in mice. Harris SJ, et al. **Vaccine** 1996 Jul;14(10):971–6

Mechanisms of adjuvancy: I—Metal oxides as adjuvants. Naim JO, et al. **Vaccine** 1997 Aug;15(11):1183–93

THERAPEUTIC USE

Effect of supervised use of an alum mouthrinse on dental caries incidence in caries–susceptible children: a pilot study. Kleber CJ, et al. **ASDC J Dent Child** 1996 Nov–Dec; 63(6):393–402

Comparative three–year caries protection from an aluminum–containing and a fluoride–containing toothpaste. Heidmann J, et al. **Caries Res** 1997;31(2):85–90

TOXICITY

Cytogenetic, developmental, and biochemical effects of aluminum, iron, and their mixture in sea urchins and mussels. Pagano G, et al. **Arch Environ Contam Toxicol** 1996 Nov;31(4):466–74

A1 toxicity in yeast. A role for Mg? MacDiarmid CW, et al. **Plant Physiol** 1996 Nov;112(3):1101–9

Evaluation of the toxicity of alum (aluminum sulfate) in young broiler chickens. Huff WE, et al. **Poult Sci** 1996 Nov;75(11):1359–65

[A 13–week toxicity study of simultaneous administration of cochineal and aluminum potassium sulfate in rats] Kawasaki Y, et al. **Eisei Shikenjo Hokoku** 1994;(112):48–56 (Eng. Abstr.) **(Jpn)**

ALUMINA see **ALUMINUM OXIDE**

ALUMINUM

Aluminum polymeric implants: in vitro–in vivo evaluations. Pathak YV, et al. **J Biomater Appl** 1996 Jul;11(1):62–75

Analytical methodology in quantitative digital subtraction radiography: analyses of the aluminum reference wedge. Allen KM, et al. **J Periodontol** 1996 Dec;67(12):1317–21

Excited triplet state photophysics of the sulphonated aluminium phathalocyanines bound to human serum albumin. Foley MS, et al. **J Photochem Photobiol B** 1997 Mar;38(1):10–7

Added aluminum shielding to attenuate back scatter electrons from intra–oral lead shields. Weidlich GA, et al. **Med Dosim** 1996 Fall;21(3):165–7

Metals suitable for fluorine gas target bodies: first use of aluminum for the production of [18F]F2. Bishop A, et al. **Nucl Med Biol** 1996 Apr;23(3):181–8

Hexachlorobenzene and octachlorostyrene in plasma of aluminium foundry workers using hexachloroethane for degassing. Seldén AI, et al. **Occup Environ Med** 1997 Aug; 54(8):613–8

Are aluminium potroom workers at increased risk of neurological disorders? Sim M, et al. **Occup Environ Med** 1997 Apr;54(4):229–35

Composition and distribution of polycyclic aromatic hydrocarbon contamination in surficial marine sediments from Kitimat Harbor, Canada. Simpson CD, et al. **Sci Total Environ** 1996 Mar 29;181(3):265–78

ADMINISTRATION & DOSAGE

Metabolic responses of postmenopausal women to supplemental dietary boron and aluminum during usual and low magnesium intake: boron, calcium, and magnesium absorption and retention and blood mineral concentrations. Hunt CD, et al. **Am J Clin Nutr** 1997 Mar;65(3):803–13

Aluminum potentiates P(i) transport stimulation induced by fluoride in osteoblast–like cells. Imai T, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):E694–701

Aluminum potentiates the effect of fluoride on tyrosine phosphorylation and osteoblast replication in vitro and bone mass in vivo. Caverzasio J, et al. **J Bone Miner Res** 1996 Jan;11(1):46–55

Effect of small variations of aluminum intake on calcium metabolism in young rats. Boudey M, et al. **J Pediatr Gastroenterol Nutr** 1997 Feb;24(2):124–7

ADVERSE EFFECTS

Adverse effects of aluminium–chelating compounds for clinical use. Domingo JL. **Adverse Drug React Toxicol Rev** 1996 Aug;15(3):145–65 (159 ref.)

Aluminium in antacids and cooking pots and the risk of hip fractures in elderly people. Cumming RG, et al. **Age Ageing** 1994 Nov;23(6):468–72

Clinical images: aluminum–modified renal osteopathy. Buttgereit F, et al. **Arthritis Rheum** 1997 Sep;40(9):1724

Cytocompatibility of Ti–6Al–4V and Ti–5Al–2.5Fe alloys according to three surface treatments, using human fibroblasts and osteoblasts. Bordji K, et al. **Biomaterials** 1996 May;17(9):929–40

A case–control study of Alzheimer's disease and aluminium occupation. Salib E, et al. **Br J Psychiatry** 1996 Feb; 168(2):244–9

Evaluation of cutaneous hypersensitivity to aluminum by routine patch testing with A1C1(3). Hemmer W, et al. **Contact Dermatitis** 1996 Mar;34(3):217–8

Aluminium and Alzheimer's disease: review of possible pathogenic mechanisms. Armstrong RA, et al. **Dementia** 1996 Jan–Feb;7(1):1–9 (107 ref.)

Silica and aluminum in drinking water and cognitive impairment in the elderly. Jacqmin–Gadda H, et al. **Epidemiology** 1996 May;7(3):281–5

Aluminum concentrations in drinking water and risk of Alzheimer's disease. Martyn CN, et al. **Epidemiology** 1997 May;8(3):281–6

A follow–up study of five cases of aluminosis. Sjögren B, et al. **Int Arch Occup Environ Health** 1996;68(3):161–4

Cutaneous granulomas caused by an aluminum–zirconium complex: an ingredient of antiperspirants. Montemarano AD, et al. **J Am Acad Dermatol** 1997 Sep;37(3 Pt 1):496–8

Aluminium and injection site reactions. Culora GA, et al. **J Clin Pathol** 1996 Oct;49(10):844–7

Further thoughts on the aluminum–Alzheimer's disease link [comment] Forbes WF, et al. **J Epidemiol Community Health** 1996 Aug;50(4):401–3. Comment on: J Epidemiol Community Health 1995 Jun;49(3):253–8. Comment on: J Epidemiol Community Health 1995 Jun;49(3):323–4.

Increased variability in bronchial responsiveness in aluminum potroom workers with work–related asthma–like symptoms. Soyseth V, et al. **J Occup Environ Med** 1996 Jan;38(1):66–9

Increased neutrophil chemotactic activity is noted in alminum–induced occupational asthma. Park HS, et al. **Korean J Intern Med** 1996 Jan;11(1):69–73

Aluminum neurotoxicity in preterm infants receiving intravenous–feeding solutions. Bishop NJ, et al. **N Engl J Med** 1997 May 29;336(22):1557–61

Aluminum toxicity in preterm infants [letter] Driscoll WR, et al. **N Engl J Med** 1997 Oct 9;337(15):1090–1

Is aluminum toxicity responsible for uremic pruritus in chronic hemodialysis patients? Friga V, et al. **Nephron** 1997; 75(1):48–53

Investigation of a cluster of pituitary adenomas in workers in the aluminum industry. Cullen MR, et al. **Occup Environ Med** 1996 Nov;53(11):782–6

[Toxic aluminum encephalopathy. Predominant involvement of the limbic system on MRI] Lévêque C, et al. **J Neuroradiol** 1996 Dec;23(3):168–72 (Eng. Abstr.) **(Fre)**

[Evaluation of bone mineral density in the distal radius of former workers employed at the Aluminum Works] Czerwiński E, et al. **Przegl Lek** 1997;54(4):269–71 (Eng. Abstr.) **(Pol)**

ANALYSIS

Inorganic particles in the lungs of five aluminum smelter workers with pleuro–pulmonary cancer. Dufresne A, et al. **Am Ind Hyg Assoc J** 1996 Apr;57(4):370–5

Sampling and analytical quality control of the determination of aluminium in soybean leaves. Dong D, et al. **Analyst** 1997 May;122(5):421–4

French external quality assessment schemes for lead in blood and aluminum in plasma and dialysis water. Guillard O, et al. **Ann Ist Super Sanita** 1996;32(2):241–5

Age–dependent aluminum accumulation in the human aorta and cerebral artery. Minami T, et al. **Biol Trace Elem Res** 1996 Oct–Nov;55(1–2):199–205

Preparation of an intra–laboratory reference material—determination of the aluminum content of a pooled 5% albumin (human) solution by ETAAS, MFS and ICP–AES. Progar JJ, et al. **Biologicals** 1996 Jun; 24(2):87–93

Aluminum content of various canned and bottled beverages. Aikoh H, et al. **Bull Environ Contam Toxicol** 1996 Jan; 56(1):1–7

Aluminum concentrations in selected foods prepared in aluminum cookware, and its implications for human health. Fimreite N, et al. **Bull Environ Contam Toxicol** 1997 Jan; 58(1):1–7

Correlation of drug–related aluminum intake and dialysis treatment with deposition of argyrophilic aluminum–containing inclusions in CNS and in organ systems of patients with dialysis–associated encephalopathy. Reusche E, et al. **Clin Neuropathol** 1996 Nov–Dec;15(6):342–7

A laser microprobe mass analysis of brain aluminum and iron in dementia pugilistica: comparison with Alzheimer's disease. Bouras C, et al. **Eur Neurol** 1997;38(1):53–8

Aluminium levels in Italian diets and in selected foods from aluminium utensils. Gramiccioni L, et al. **Food Addit Contam** 1996 Oct;13(7):767–74

Aluminum ions in analysis of released fluoride from glass ionomers. Nakajima H, et al. **J Dent** 1997 Mar;25(2):137–44

Evaluation of flow injection sample to standard addition method for the inductively coupled plasma mass spectrometric determination of aluminium in biological tissues. Coedo AG, et al. **J Mass Spectrom** 1996 Apr;

31(4):427–32

Effect of small variations of aluminum intake on calcium metabolism in young rats. Boudey M, et al. **J Pediatr Gastroenterol Nutr** 1997 Feb;24(2):124–7

Aluminum in enteral nutrition formulas and parenteral solutions. Baydar T, et al. **J Toxicol Clin Toxicol** 1997; 35(3):277–81

Determination of aluminium in samples from bone and liver of elderly Norwegians. Hongve D, et al. **J Trace Elem Med Biol** 1996 Apr;10(1):6–11

Staining of bone aluminium: comparison between aluminon and solochrome azurine and their correlation with bone aluminium content. Fernández-Martín JL, et al. **Nephrol Dial Transplant** 1996;11 Suppl 3:80–5

Alzheimer's disease and aluminum [letter; comment] Levallois P. **Neurology** 1997 Apr;48(4):1141–2. Comment on: Neurology 1996 Feb;46(2):401–5.

Effect of aluminium hydroxide administration on normal mice: tissue distribution and ultrastructural localization of aluminium in liver. Fiejka M, et al. **Pharmacol Toxicol** 1996 Mar;78(3):123–8

Monte Carlo design study of a moderated 252Cf source for in vivo neutron activation analysis of aluminium. Lewis DG, et al. **Phys Med Biol** 1997 Apr;42(4):625–36

A comparison of the techniques of secondary ion mass spectrometry and resonance ionization mass spectrometry for the analysis of potentially toxic element accumulation in neural tissue. Jones OR, et al. **Rapid Commun Mass Spectrom** 1997;11(2):179–83

Studies on aluminium leaching from cookware in tea and coffee and estimation of aluminium content in toothpaste, baking powder and paan masala. Rajwanshi P, et al. **Sci Total Environ** 1997 Jan 30;193(3):243–9

Possible aluminum content of canned drinks. Abercrombie DE, et al. **Toxicol Ind Health** 1997 Sep–Oct;13(5):649–54

[Aluminum contents in dried and cooked sea vegetables] Matsushima F, et al. **Nippon Eiseigaku Zasshi** 1997 Jan; 51(4):763–9 (Eng. Abstr.) **(Jpn)**

[Determination of the amount of aluminum migration from kitchen utensils into milk] Skibniewska KA, et al. **Rocz Panstw Zakl Hig** 1996;47(2):239–45 (Eng. Abstr.) **(Pol)**

BLOOD

Quantitative studies of aluminium binding species in human uremic serum by fast protein liquid chromatography coupled with electrothermal atomic absorption spectrometry. Soldado Cabezuelo AB, et al. **Analyst** 1997 Jun;122(6):573–7

Aluminum in Saudi children. al-Saleh I, et al. **Biometals** 1996 Oct;9(4):385–92

Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients [letter] Klemm A, et al. **Clin Nephrol** 1997 Feb; 47(2):133–4

Identification of aluminium fractions in serum using the techniques of high performance liquid chromatography, ultrafiltration and Zeeman atomic absorption spectrometry. Röllin HB, et al. **Eur J Clin Chem Clin Biochem** 1997 Mar; 35(3):215–22

Biological levels of aluminium after use of aluminium-containing bone cement in post-otoneurosurgery. Guillard O, et al. **J Trace Elem Med Biol** 1997 Apr;11(1):53–6

Analysis of aluminium in serum and urine for the biomonitoring of occupational exposure. Valkonen S, et al. **Sci Total Environ** 1997 Jun 20;199(1–2):103–10

CEREBROSPINAL FLUID

Aluminium speciation in cerebrospinal fluid of acutely aluminium-intoxicated dialysis patients before and after desferrioxamine treatment; a step in the understanding of the element's neurotoxicity. Van Landeghem GF, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1692–8

CHEMISTRY

An aluminum heat sink and radiator for electrophoresis capillaries. Rapp TL, et al. **Anal Chem** 1996 Dec 15; 68(24):4446–50

Aluminum-succinate complex equilibria and their potential implications for aluminum metabolism. Alliey N, et al. **Ann Clin Lab Sci** 1996 Mar–Apr;26(2):122–32

Aluminum chelation by 3-hydroxypyridin-4-ones in the rat demonstrated by microdialysis. Yokel RA. **Biol Trace Elem Res** 1996 Summer;53(1–3):193–203

Behaviour and ecotoxicology of aluminium in soil and water--review of the scientific literature. Klöppel H, et al. **Chemosphere** 1997 Jul;35(1–2):353–63 (33 ref.)

Comparative study of the corrosion behavior of MA-956 and conventional metallic biomaterials. Escudero ML, et al. **J Biomed Mater Res** 1996 Jul;31(3):313–7

Fluorimetric determination of chloroxine using manual and flow-injection methods. Pérez-Ruiz T, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1505–11

Preservation of native conformation during aluminium-induced aggregation of tau protein. Madhav TR, et al. **Neuroreport** 1996 Apr 10;7(5):1072–6

Two-dimensional magic-angle spinning isotropic reconstruction sequences for quadrupolar nuclei. Massiot D, et al. **Solid State Nucl Magn Reson** 1996 Feb;6(1):73–83

11B[27Al] and 27Al[11B] double resonance experiments on a glassy sodium aluminoborate. van Wüllen L, et al. **Solid State Nucl Magn Reson** 1996 Jun;6(3):203–12

[Evaluation of the liberation of aluminum and magnesium ions from preparations made up of antacid] Pawlaczyk J, et al. **Acta Pol Pharm** 1992;49(1–2):11–5 (Eng. Abstr.) **(Pol)**

[Determination of polycyclic aromatic hydrocarbons in the working environment during aluminum production] Brzeźnicki S, et al. **Med Pr** 1996;47(1):1–8 (Eng. Abstr.) **(Pol)**

METABOLISM

Content of brain aluminum is not elevated in Alzheimer disease. Bjertness E, et al. **Alzheimer Dis Assoc Disord** 1996 Fall;10(3):171–4

Mechanisms of aluminum absorption in rats. Whitehead MW, et al. **Am J Clin Nutr** 1997 May;65(5):1446–52

Biodistribution of trace elements in normal, aluminum-overloaded and cadmium-overloaded mice. An application of the radioactive multitracer technique. Amano R, et al. **Ann Clin Lab Sci** 1996 Nov-Dec; 26(6):531–41

ADP-fluoroaluminate complexes are formed cooperatively at two catalytic sites of wild-type and mutant alpha3beta3gamma subcomplexes of the F1-ATPase from the thermophilic Bacillus PS3. Dou C, et al. **Biochemistry** 1997 Mar 25;36(12):3719–27

Developmental patterns of aluminum and five essential mineral elements in the central nervous system of the fetal and infant guinea pig. Golub MS, et al. **Biol Trace Elem Res** 1996 Dec;55(3):241–51

Histomorphological reaction of bone to different concentrations of phagocytosable particles of high-density polyethylene and Ti-6Al-4V alloy in vivo. Goodman SB, et al. **Biomaterials** 1996 Oct;17(20):1943–7

Uptake of 26-Al and 67-Ga into brain and other tissues of normal and hypotransferrinaemic mice. Radunović A, et al. **Biometals** 1997 Jul;10(3):185–91

Accumulation and effect of cadmium in the wood-rotting basidiomycete Daedalea quercina. Gabriel J, et al. **Bull Environ Contam Toxicol** 1996 Sep;57(3):383–90

Effects of silicon, citrate and the fasting state on the intestinal absorption of aluminium in rats. Drüeke TB, et al. **Clin Sci (Colch)** 1997 Jan;92(1):63–7

Competition of iron and aluminum for transferrin: the molecular basis for aluminum deposition in iron-overloaded dialysis patients? Van Landeghem GF, et al. **Exp Nephrol** 1997 May-Jun;5(3):239–45

Aluminum interaction with plasma membrane lipids and enzyme metal binding sites and its potential role in Al cytotoxicity. Jones DL, et al. **FEBS Lett** 1997 Jan 2; 400(1):51–7

Bullous dermatosis of end-stage renal disease: a possible association between abnormal porphyrin metabolism and aluminium [see comments] Gafter U, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1787–91. Comment in: Nephrol Dial Transplant 1997 May;12(5):1083.

Bullous dermatosis of end-stage renal disease and aluminium [letter; comment] Tercedor J, et al. **Nephrol Dial Transplant** 1997 May;12(5):1083. Comment on: Nephrol Dial Transplant 1996 Sep;11(9):1787–91.

Aluminium accumulation in some tissues of rats with compromised kidney function induced by cadmium-metallothionein. Liu J, et al. **Pharmacol Toxicol** 1996 May;78(5):289–95

[Unilateral mixed-dust pneumoconiosis with aluminum deposition associated with interstitial pneumonia] Sunami K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Feb; 35(2):189–95 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Adverse effects of aluminium-chelating compounds for clinical use. Domingo JL. **Adverse Drug React Toxicol Rev** 1996 Aug;15(3):145–65 (159 ref.)

Aluminum-succinate complex equilibria and their potential implications for aluminum metabolism. Alliey N, et al. **Ann Clin Lab Sci** 1996 Mar-Apr;26(2):122–32

Gastrointestinal absorption of aluminum is increased in Down's syndrome. Moore PB, et al. **Biol Psychiatry** 1997 Feb 15;41(4):488–92

Correlation of drug-related aluminum intake and dialysis treatment with deposition of argyrophilic aluminum-containing inclusions in CNS and in organ systems of patients with dialysis-associated encephalopathy. Reusche E, et al. **Clin Neuropathol** 1996 Nov-Dec;15(6):342–7

Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. Schönholzer KW, et al. **Clin Sci (Colch)** 1997 Apr;92(4):379–83

Aluminum detoxication mechanism in Pseudomonas fluorescens is dependent on iron. Appanna VD, et al. **FEMS Microbiol Lett** 1996 Oct 1;143(2–3):223–8

P-Cresol, a uremic compound, enhances the uptake of aluminum in hepatocytes. Abreo K, et al. **J Am Soc Nephrol** 1997 Jun;8(6):935–42

Hepatic and cerebrospinal fluid accumulation of aluminium and bismuth in volunteers taking short course anti-ulcer therapy. Gane E, et al. **J Gastroenterol Hepatol** 1996 Oct; 11(10):911–5

Aluminium-containing agents may be toxic in predialysis chronic renal insufficiency patients. Lin JL, et al. **J Intern Med** 1996 Oct;240(4):243–8

Effect of iron status on the intestinal absorption of aluminum: a reappraisal. Ittel TH, et al. **Kidney Int** 1996 Dec; 50(6):1879–88

Ultrasensitive analysis of the intestinal absorption and compartmentalization of aluminium in uraemic rats: a 26Al tracer study employing accelerator mass spectrometry. Ittel TH, et al. **Nephrol Dial Transplant** 1997 Jul;12(7):1369–75

Calcium carbonate can enhance aluminium absorption from aluminium hydroxide in patients with impaired renal function [letter] Lin JL, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1891–3

Aluminum-sensitive degradation of amyloid beta-protein 1–40 by murine and human intracellular enzymes [published erratum appears in Neurotoxicol Teratol 1997 Jan-Feb;19(1):73] Banks WA, et al. **Neurotoxicol Teratol** 1996 Nov-Dec;18(6):671–7

Aluminum (26AI) metabolism in rats. Zafar TA, et al. **Proc Soc Exp Biol Med** 1997 Oct;216(1):81–5

Enhancement of aluminum digestive absorption by fluoride in rats. Allain P, et al. **Res Commun Mol Pathol Pharmacol** 1996 Feb;91(2):225–31

Aluminum citrate is transported from brain into blood via the monocarboxylic acid transporter located at the blood-brain barrier. Ackley DC, et al. **Toxicology** 1997 Jun 27;120(2):89–97

The effect of age on aluminum retention in rats. Gómez M, et al. **Toxicology** 1997 Jan 15;116(1–3):1–8

PHARMACOLOGY

Ca(2+)- and Al(3+)-induced conformational transitions of amyloid fragment H-Ile-Ile-Gly-Leu-Met-NH2. Laczkó I, et al. **Arch Biochem Biophys** 1996 Nov 15;335(2):381–7

Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. Paik SR, et al. **Arch Biochem Biophys** 1997 Aug 15; 344(2):325–34

Myelin is a preferential target of aluminum-mediated oxidative damage. Verstraeten SV, et al. **Arch Biochem Biophys** 1997 Aug 15;344(2):289–94

Voltage-dependent effect of Al3+ on channel activities in hippocampal neurons. Kanazirska M, et al. **Biochem Biophys Res Commun** 1997 Mar 6;232(1):84–7

Fluoroaluminate induces pertussis toxin-sensitive protein phosphorylation: differences in MC3T3-E1 osteoblastic and NIH3T3 fibroblastic cells. Susa M, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):680–4

Aluminum alters iron and manganese uptake and regulation of surface transferrin receptors in primary rat oligodendrocyte cultures. Golub MS, et al. **Brain Res** 1996 May 6;719(1–2):72–7

Slow dendritic transport of dissociated mouse hippocampal neurons exposed to aluminum. Wakayama I, et al. **Brain Res** 1997 Feb 14;748(1–2):237–40

Inhibition of TEA-induced LTP by aluminum. Platt B, et al. **Exp Neurol** 1996 Oct;141(2):240–7

Effect of acid or aluminum on growth and adrenal function in young chickens. Capdevielle MC, et al. **Gen Comp Endocrinol** 1996 Jul;103(1):54–9

Plasma and tissue thyroxine and triiodothyronine contents in sublethally stressed, aluminum-exposed brown trout (Salmo trutta). Waring CP, et al. **Gen Comp Endocrinol** 1997 Apr;106(1):120–6

Fluoroaluminate induces rapid release of endothelin-1 in the isolated perfused arterial and venous vessels of the rat mesentery. Cirino G, et al. **Gen Pharmacol** 1997 Mar; 28(3):459–62

Interaction of aluminum with paired helical filament tau is involved in neurofibrillary pathology of Alzheimer's disease. Shin RW. **Gerontology** 1997;43 Suppl 1:16–23 (60 ref.)

Sequestration of centrally administered insulin by the brain: effects of starvation, aluminum, and TNF-alpha. Cashion MF, et al. **Horm Behav** 1996 Sep;30(3):280–6

Effect of aluminum ion on Fe(2+)-induced lipid peroxidation in phospholipid liposomes under acidic conditions. Ohyashiki T, et al. **J Biochem (Tokyo)** 1996 Nov;120(5):895–900

Inhibition of the GDP/GTP exchange reaction of ras p21 by aluminum ion. Landino LM, et al. **J Inorg Biochem** 1997 May 1;66(2):99–102

Effect of aluminium on expression and processing of amyloid precursor protein. Neill D, et al. **J Neurosci Res** 1996 Nov 15;46(4):395–403

Aluminum effect on lipid peroxidation and on the activities of superoxide dismutase and catalase in the cerebral hemisphere and liver of young chicks. Swain C, et al. **J Trace Elem Med Biol** 1997 Jun;11(2):77–82

Effects of the application of aluminium, strontium and magnesium solutions to the leaf surface of maize, and determinations of these elements by ICP-AES. Csikkel-Szolnoki A, et al. **Magnes Res** 1996 Dec; 9(4):263–72

Depressed erythroid progenitor cell activity in aluminum-overloaded mice. Garbossa G, et al. **Miner Electrolyte Metab** 1996;22(4):214–8

Regional alterations in calcium homeostasis in the primate brain following chronic aluminium exposure. Sarin S, et al. **Mol Cell Biochem** 1997 Mar;168(1–2):95–100

ALUMINUM

Effects of aluminium on the mineral metabolism of rats in relation to age. Sánchez DJ, et al. **Pharmacol Toxicol** 1997 Jan;80(1):11–7

Effect of aluminum on superoxide dismutase, catalase and lipid peroxidation of rat liver. Chainy GB, et al. **Res Commun Mol Pathol Pharmacol** 1996 Nov;94(2):217–20

Effect of aluminum on regional brain antioxidant defense status in Wistar rats. Julka D, et al. **Res Exp Med (Berl)** 1996;196(3):187–94

POISONING

Comparative study of chronic aluminum-induced neurofilamentous aggregates with intracytoplasmic inclusions of amyotrophic lateral sclerosis. Wakayama I, et al. **Acta Neuropathol (Berl)** 1996 Dec;92(6):545–54

The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine. Yokel RA, et al. **Drug Metab Dispos** 1996 Jan;24(1):105–11

Influence of aluminium overload on the course of post-transplant parathyroid function. Garay G, et al. **Nephrol Dial Transplant** 1996;11 Suppl 3:65–8

Aluminium speciation in cerebrospinal fluid of acutely aluminium-intoxicated dialysis patients before and after desferrioxamine treatment; a step in the understanding of the element's neurotoxicity. Van Landeghem GF, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1692–8

Tau in aluminum-induced neurofibrillary tangles. Singer SM, et al. **Neurotoxicology** 1997;18(1):63–76

Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients. Janssen MJ, et al. **Pharm World Sci** 1996 Oct;18(5):187–91

[The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis] Wang G, et al. **Chung Hua Nei Ko Tsa Chih** 1996 Jan; 35(1):36–40 (Eng. Abstr.) **(Chi)**

[Aluminum toxicity in patients with chronic renal failure] Wanic-Kossowska M, et al. **Przegl Lek** 1995;52(12):603–5 (32 ref.) **(Pol)**

TOXICITY

Effects of dietary aluminum on chicks Gallus gallus domesticus with different dietary intake of calcium and phosphorus. Nybø S. **Arch Environ Contam Toxicol** 1996 Aug;31(2):177–83

Oral aluminum administration and oxidative injury. Katyal R, et al. **Biol Trace Elem Res** 1997 May;57(2):125–30

Zinc status does not affect aluminum deposition in tissues of rats. McNall AD, et al. **Biol Trace Elem Res** 1996 Summer;53(1–3):7–18

Aluminum speciation and morphological differentiation in murine neuroblastoma cells. Zatta P, et al. **Biol Trace Elem Res** 1996 Jan;51(1):77–85

Ti-6Al-4V ion solution inhibition of osteogenic cell phenotype as a function of differentiation timecourse in vitro. Thompson GJ, et al. **Biomaterials** 1996 Oct; 17(20):1949–54

Aluminium-induced bone disease in uremic rats: effect of deferoxamine. Jablonski G, et al. **Biosci Rep** 1996 Feb; 16(1):49–63

Intraneuronal aluminum potentiates iron-induced oxidative stress in cultured rat hippocampal neurons. Xie CX, et al. **Brain Res** 1996 Dec 16;743(1–2):271–7

Aluminum toxicity and nutrient utilization in the mycorrhizal fungus Hebeloma mesophacus. Kong F, et al. **Bull Environ Contam Toxicol** 1997 Jul;59(1):125–31

Behaviour and ecotoxicology of aluminium in soil and water—review of the scientific literature. Klöppel H, et al. **Chemosphere** 1997 Jul;35(1–2):353–63 (33 ref.)

Toxicity of acid-sulfate soil leachate and aluminum to embryos of the Sydney Rock oyster. Wilson SP, et al. **Ecotoxicol Environ Saf** 1997 Jun;37(1):30–6

Aluminum detoxication mechanism in Pseudomonas fluorescens is dependent on iron. Appanna VD, et al. **FEMS Microbiol Lett** 1996 Oct 1;143(2–3):223–8

Effect of prenatal aluminium lactate exposure on conditioned taste aversion and passive avoidance task in the rat. Gonda Z, et al. **J Appl Toxicol** 1996 Nov-Dec;16(6):529–32

Involvement of altered cytoskeletal protein phosphorylation in aluminum-induced CNS dysfunction. Julka D, et al. **J Biochem Toxicol** 1996;11(5):227–33

Aluminum (III) induces alterations on the physical state of the erythrocytic membrane: an ESR evaluation. Zatta P, et al. **J Inorg Biochem** 1997 Feb 1;65(2):109–14

Oral aluminum administration during pregnancy and lactation produces gastric and renal lesions in rat mothers and delay in CNS development of their pups. Poulos BK, et al. **Mol Chem Neuropathol** 1996 Sep;29(1):15–26

Aluminum-sensitive mutants of Saccharomyces cerevisiae. Schott EJ, et al. **Mol Gen Genet** 1997 Mar 18;254(1):63–72

Aluminium toxicity: its relationship with bone and iron metabolism. Cannata Andía JB. **Nephrol Dial Transplant** 1996;11 Suppl 3:69–73 (75 ref.)

Diagnosis and treatment of aluminium bone disease. D'Haese PC, et al. **Nephrol Dial Transplant** 1996;11 Suppl 3:74–9 (17 ref.)

Calcium carbonate can enhance aluminium absorption from aluminium hydroxide in patients with impaired renal function [letter] Lin JL, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1891–3

Effect of long-term low-dose aluminum-containing agents on hemoglobin synthesis in patients with chronic renal insufficiency. Lin JL, et al. **Nephron** 1996;74(1):33–8

Aluminum-sensitive degradation of amyloid beta-protein 1–40 by murine and human intracellular enzymes [published erratum appears in Neurotoxicol Teratol 1997 Jan-Feb;19(1):73] Banks WA, et al. **Neurotoxicol Teratol** 1996 Nov-Dec;18(6):671–7

Aluminum-induced neuropathology: transient changes in microtubule-associated proteins. Muma NA, et al. **Neurotoxicol Teratol** 1996 Nov-Dec;18(6):679–90

Neuronal gene expression in aluminum-induced neurofibrillary pathology: an in situ hybridization study. Chambers CB, et al. **Neurotoxicology** 1997;18(1):77–88

Neurotoxicity induced by prenatal aluminum exposure in rats. Gonda Z, et al. **Neurotoxicology** 1996 Summer;17(2):459–69

Chronic effect of aluminium ingestion on bone in calcium-deficient rats. Konishi Y, et al. **Pharmacol Toxicol** 1996 Jun;78(6):429–34

cDNA clones encoding 1,3-beta-glucanase and a fimbrin-like cytoskeletal protein are induced by Al toxicity in wheat roots. Cruz-Ortega R, et al. **Plant Physiol** 1997 Aug;114(4):1453–60

Arabidopsis mutants with increased sensitivity to aluminum. Larsen PB, et al. **Plant Physiol** 1996 Mar;110(3):743–51

Aluminum tolerance in transgenic plants by alteration of citrate synthesis. de la Fuente JM, et al. **Science** 1997 Jun 6;276(5318):1566–8

Hepatic clearance and retention of aluminium: studies in the isolated perfused rat liver. Wilhelm M, et al. **Toxicol Lett** 1996 Dec 31;89(3):257–63

[Experimental and clinical aspects of the neurotoxic action of aluminum] Nowak P, et al. **Postepy Hig Med Dosw** 1996; 50(6):621–33 (85 ref.) (Eng. Abstr.) **(Pol)**

[Aluminum: its current toxicological and hygienic aspects (a review of the literature)] Prokopov VA, et al. **Lik Sprava** 1996 Oct-Dec;(10–12):56–62 (41 ref.) **(Rus)**

URINE

Renal excretion of aluminium in the rat: effect of citrate infusion. Lote CJ, et al. **Hum Exp Toxicol** 1995 Dec; 14(12):945–8

ALUMINUM COMPOUNDS

ADVERSE EFFECTS

Routine patch testing with AlCl3 [letter] Veien NK. **Contact Dermatitis** 1996 Aug;35(2):126

Aluminium-containing agents may be toxic in predialysis chronic renal insufficiency patients. Lin JL, et al. **J Intern Med** 1996 Oct;240(4):243–8

CHEMICAL SYNTHESIS

A solid-state NMR study of the molecular sieve VPI-5 synthesized in the presence of a CTABr surfactant. Blasco T, et al. **Solid State Nucl Magn Reson** 1997 May;8(3):185–94

CHEMISTRY

Structure of ADP x AlF4(-)-stabilized nitrogenase complex and its implications for signal transduction. Schindelin H, et al. **Nature** 1997 May 22;387(6631):370–6

DIAGNOSTIC USE

Evaluation of cutaneous hypersensitivity to aluminum by routine patch testing with A1C1(3). Hemmer W, et al. **Contact Dermatitis** 1996 Mar;34(3):217–8

METABOLISM

Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity. Yokel RA, et al. **Drug Metab Dispos** 1997 Feb;25(2):182–90

Aluminum fluoride associates with the small guanine nucleotide binding proteins. Ahmadian MR, et al. **FEBS Lett** 1997 May 26;408(3):315–8

PHARMACOKINETICS

Chronic aluminum treatment results in aluminum deposits and affects Ml muscarinic receptors in rat brain. Harkány T, et al. **Neurobiology (Bp)** 1996;4(1–2):35–43

In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Flarend RE, et al. **Vaccine** 1997 Aug-Sep;15(12–13):1314–8

PHARMACOLOGY

Dual role for AlF4(-)-sensitive G proteins in the function of T84 epithelial cells: transport and barrier effects. Ries J, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C794–803

Aluminium activation of "immediate early" gene expression in Swiss 3T3 fibroblasts. Bates J, et al. **Biochem Soc Trans** 1996 Aug;24(3):499S

Aluminium-induced changes in amyloid precursor protein mRNA expression. Sinclair MA, et al. **Biochem Soc Trans** 1996 Aug;24(3):500S

Relationship between specific binding of 125I-omega-conotoxin GVIA and GTP binding protein: effects of the GTP analogues, mastoparan and A1F4-. Ichida S, et al. **Biochim Biophys Acta** 1997 Apr 26; 1325(2):215–25

Characterisation of the role of calcium in AlF4-induced long-term potentiation in area CA1 of rat hippocampus. Breakwell NA, et al. **Biosci Rep** 1997 Apr;17(2):209–18

Fluctuation analysis of nonselective cation currents induced by AlF complex in guinea-pig chromaffin cells. Inoue M, et al. **Brain Res** 1996 Nov 11;739(1–2):350–5

ADP indirectly supports activation of non-selective cation channels by AlF complex in guinea-pig chromaffin cells. Inoue M, et al. **Brain Res** 1996 Jan 29;707(2):298–302

Secretagogue-induced apocrine secretion in the Harderian gland of the rat. Gesase AP, et al. **Cell Tissue Res** 1996 Sep;285(3):501–7

A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. Maya MT, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct-Dec; 20(4):275–9

Activation of G-proteins with AlF-4 induces LFA-1-mediated adhesion of T-cell hybridoma cells to ICAM-1 by signal pathways that differ from phorbol ester- and manganese-induced adhesion. Driessens MH, et al. **Exp Cell Res** 1997 Mar 15;231(2):242–50

Bidirectional regulation of neuronal potassium currents by the G-protein activator aluminum fluoride as a function of intracellular calcium concentration. Matzel LD, et al. **Neuroscience** 1996 Oct;74(4):1175–85

POISONING

Free radical scavengers & lipid peroxidation in acute aluminium phosphide poisoning. Chugh SN, et al. **Indian J Med Res** 1996 Aug;104:190–3

Need for antidote for aluminium phosphide poisoning [letter] Yadav J. **Indian J Physiol Pharmacol** 1997 Apr;41(2):189

Serial blood phosphine levels in acute aluminium phosphide poisoning [see comments] Chugh SN, et al. **J Assoc Physicians India** 1996 Mar;44(3):184–5. Comment in: J Assoc Physicians India 1996 Nov;44(11):841–2.

Combined toxicity due to alcohol and aluminium phosphide [letter] Gupta MS, et al. **J Assoc Physicians India** 1995 Jan;43(1):74

Acute myocardial injury in aluminium phosphide poisoning. Gupta MS, et al. **J Assoc Physicians India** 1995 Jan;43(1):58

Serial blood phosphine levels in aluminium phosphide [ALP] poisoning [letter; comment] Singh S. **J Assoc Physicians India** 1996 Nov;44(11):841–2. Comment on: J Assoc Physicians India 1996 Mar;44(3):184–5.

Histopathological changes in aluminium phosphide poisoning. Arora B, et al. **J Indian Med Assoc** 1995 Oct; 93(10):380–1

Intravascular haemolysis after aluminium phosphide ingestion. Sood AK, et al. **J R Soc Med** 1997 Jan;90(1):47–8

Aluminum phosphide ingestion—a clinico-pathologic study. Singh S, et al. **J Toxicol Clin Toxicol** 1996;34(6):703–6

[Poisoning with aluminum phospholipide used as a poison against moles] Andersen TS, et al. **Ugeskr Laeger** 1996 Sep 16;158(38):5308–9 (Eng. Abstr.) **(Dan)**

THERAPEUTIC USE

Topical aluminum chloride for social phobia-related hyperhidrosis [letter] Bohn P, et al. **Am J Psychiatry** 1996 Oct;153(10):1368

Effects of Fuller's Earth and activated charcoal on oral absorption of paraquat in rabbits. Idid SZ, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):679–81

Using mineral trioxide aggregate as a pulp-capping material. Ford TR, et al. **J Am Dent Assoc** 1996 Oct;127(10):1491–4

Repair of furcal perforations with mineral trioxide aggregate: two case reports. Arens DE, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jul;82(1):84–8

Pure silicate fragment in a recurrent stone former of calcium oxalate. Ichiyanagi O, et al. **Urol Int** 1997;58(3):192–6

TOXICITY

Effects of aluminum chloride on normal and uremic adult male rats. Tissue distribution, brain choline acetyltransferase activity, and some biological variables. Cherroret G, et al. **Biol Trace Elem Res** 1996 Jul; 54(1):43–53

Effects of aluminum chloride on the kinetics of rat cortex synaptosomal ATP diphosphohydrolase (EC 3.6.1.5). Schetinger MR, et al. **Biol Trace Elem Res** 1995 Dec; 50(3):209–19

Effect of aluminum on hematopoiesis after intraperitoneal exposure in rats. Chmielnicka J, et al. **Ecotoxicol Environ Saf** 1996 Apr;33(3):201–6

Effect of prenatal aluminium lactate exposure on conditioned taste aversion and passive avoidance task in the rat. Gonda Z, et al. **J Appl Toxicol** 1996 Nov-Dec;16(6):529–32

Chronic aluminum treatment results in aluminum deposits and affects Ml muscarinic receptors in rat brain. Harkány T, et al. **Neurobiology (Bp)** 1996;4(1–2):35–43

(-) deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures. Munirathinam S, et al. **Neurodegeneration** 1996 Jun;5(2):161–7

The effect of social learning on a conditioned avoidance response of rats treated prenatally with aluminum lactate. Gonda Z, et al. **Neurotoxicol Teratol** 1997 Jan-Feb; 19(1):59–63

Enhanced ex vivo cosedimentation of high molecular weight neurofilament protein (NFH) with microtubules following

in vivo aluminum chloride exposure: inhibition of dephosphorylation-dependent dissociation. Cunningham K, et al. **Neurotoxicology** 1997;18(2):355–62

Effects of aluminum exposure on behavioral parameters in the rat. Struys-Ponsar C, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):643–8

Arabidopsis mutants with increased sensitivity to aluminum. Larsen PB, et al. **Plant Physiol** 1996 Mar;110(3):743–51

ALUMINUM L-GLUTAMATE see **GLUTAMATES**

ALUMINUM HYDROXIDE

Role of the electrostatic attractive force in the adsorption of proteins by aluminum hydroxide adjuvant. Chang MF, et al. **PDA J Pharm Sci Technol** 1997 Jan-Feb;51(1):25–9

[Determination of formulation quantities for three kinds of antacid using triangle coordinates] Sofue M, et al. **Yakugaku Zasshi** 1997 Mar;117(3):185–92 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats. al Gohary OM, et al. **Boll Chim Farm** 1996 Jul-Aug; 135(7):421–8

Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. Jankovic D, et al. **J Immunol** 1997 Sep 1;159(5):2409–17

Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide. Corvaïa N, et al. **J Infect Dis** 1997 Sep;176(3):560–9

CHEMISTRY

Absence of gastrointestinal absorption or urinary excretion of aluminium from an allantoinate complex contained in two antacid formulations in patients with normal renal function. Guillard O, et al. **Eur J Clin Chem Clin Biochem** 1996 Aug;34(8):609–12

A kinetic study of phosphate adsorption by boehmite. Tang WP, et al. **J Pharm Sci** 1997 Feb;86(2):230–5

PHARMACOKINETICS

The kinetics of initial gastrointestinal absorption of an aluminium-containing antacid (Tisacid) in patients with various stages of chronic renal insufficiency [letter] Sárszegi Z, et al. **Nephrol Dial Transplant** 1997 Feb; 12(2):372–3

Effect of aluminium hydroxide administration on normal mice: tissue distribution and ultrastructural localization of aluminium in liver. Fiejka M, et al. **Pharmacol Toxicol** 1996 Mar;78(3):123–8

In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Flarend RE, et al. **Vaccine** 1997 Aug-Sep;15(12-13):1314–8

PHARMACOLOGY

Interaction of an aluminum-magnesium containing antacid and gastric mucus: possible contribution to the cytoprotective function of antacids. Grübel P, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):139–45

Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. Wong SL, et al. **Biopharm Drug Dispos** 1997 Aug;18(6):533–41

In vitro evaluation of magaldrate antacid efficacy in the presence of some drugs and its effect on their dissolution rates: Part I. al Gohary OM. **Boll Chim Farm** 1996 Dec; 135(11):621–37

Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Bullingham R, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):513–6

Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Mück W, et al. **Int J Clin Pharmacol Ther** 1997 Jun;35(6):261–4

Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. Teng R, et al. **J Antimicrob Chemother** 1997 Jun;39 Suppl B:93–7

Interaction of meloxicam with cimetidine, Maalox, or aspirin. Busch U, et al. **J Clin Pharmacol** 1996 Jan;36(1):79–84

A non-denaturing enzyme linked immunosorbent assay with protein preadsorbed onto aluminum hydroxide. Houen G, et al. **J Immunol Methods** 1997 Jan 15;200(1-2):99–105

Liposomal subunit vaccines: effects of lipid A and aluminum hydroxide on immunogenicity. Richards RL, et al. **J Pharm Sci** 1996 Dec;85(12):1286–9

Effect of antacid magaldrate oral suspension on in-vitro and in-vivo availability of indomethacin in dogs. al-Gohary OM, et al. **Pharm Acta Helv** 1997 Apr;72(2):81–6

Effect of aluminium hydroxide administration on normal mice: tissue distribution and ultrastructural localization of aluminium in liver. Fiejka M, et al. **Pharmacol Toxicol** 1996 Mar;78(3):123–8

Mechanisms of adjuvancy: I--Metal oxides as adjuvants. Naim JO, et al. **Vaccine** 1997 Aug;15(11):1183–93

THERAPEUTIC USE

Efficacy of aluminum hydroxide-adjuvanted Escherichia coli bacterin in turkey poults. Trampel DW, et al. **Avian Dis** 1997 Apr-Jun;41(2):263–8

Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats. al Gohary OM, et al. **Boll Chim Farm** 1996 Jul-Aug; 135(7):421–8

TOXICITY

Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Goto N, et al. **Vaccine** 1997 Aug-Sep; 15(12-13):1364–71

ALUMINUM HYDROXIDE GEL see **ALUMINUM HYDROXIDE**

ALUMINUM OXIDE

Histological and biochemical evaluation of osteogenic response in porous hydroxyapatite coated alumina ceramics. Takaoka T, et al. **Biomaterials** 1996 Aug; 17(15):1499–505

Determination of apomorphine in human plasma by alumina extraction and high-performance liquid chromatography with electrochemical detection. Bolner A, et al. **Forensic Sci Int** 1997 Sep 19;89(1-2):81–91

Bone tissue response to commercially pure titanium implants blasted with fine and coarse particles of aluminum oxide. Wennerberg A, et al. **Int J Oral Maxillofac Implants** 1996 Jan-Feb;11(1):38–45

Wear of retrieved cemented polyethylene acetabula with alumina femoral heads. Bragdon CR, et al. **J Arthroplasty** 1997 Feb;12(2):119–25

Biocompatibility of alumina ceramic and polyethylene as materials for pivot bearings of a centrifugal blood pump. Takami Y, et al. **J Biomed Mater Res** 1997 Sep 5; 36(3):381–6

Copy-milled aluminous core ceramic crowns: a clinical report. Rinke S, et al. **J Prosthet Dent** 1996 Oct;76(4):343–6

[Wear behavior of coupled aluminum oxide ceramics-carbon fiber bond as hip acetabulum inlay in a simulated trial] Scheller G, et al. **Biomed Tech (Berl)** 1996 Dec; 41(12):338–40 (Eng. Abstr.) **(Ger)**

[Long-term outcome of managing medial femoral neck fractures with ceramic head endoprostheses] Degreif J, et al. **Unfallchirurg** 1996 Oct;99(10):744–9 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Peptomer aluminum oxide nanoparticle conjugates as systemic and mucosal vaccine candidates: synthesis and characterization of a conjugate derived from the C4 domain of HIV-1MN gp120. Frey A, et al. **Bioconjug Chem** 1997 May-Jun;8(3):424–33

ADVERSE EFFECTS

Absence of skin sensitivity to oxides of aluminium, silicon, titanium or zirconium in patients with Crohn's disease [see comments] Lee JC, et al. **Gut** 1996 Aug;39(2):231–3. Comment in: Gut 1996 Aug;39(2):340–1.

ANALYSIS

Mineralogical analysis of the respiratory tract in aluminium oxide-exposed workers. Voisin C, et al. **Eur Respir J** 1996 Sep;9(9):1874–9

Characterization of in vivo wear debris from ceramic-ceramic total hip arthroplasties. Lerouge S, et al. **J Biomed Mater Res** 1996 Dec;32(4):627–33

CHEMISTRY

Experimental study of turned and grit-blasted screw-shaped implants with special emphasis on effects of blasting material and surface topography. Wennerberg A, et al. **Biomaterials** 1996 Jan;17(1):15–22

Determination of hydrophobicity parameters of antibiotics by reversed-phase chromatography. The effect of support. Cserháti T, et al. **Biomed Chromatogr** 1996 May-Jun; 10(3):117–21

Characterization of the resistance of pyrolytic carbon to abrasive wear. Vitale E, et al. **Int J Artif Organs** 1995 Dec; 18(12):777–85

A kinetic study of phosphate adsorption by boehmite. Tang WP, et al. **J Pharm Sci** 1997 Feb;86(2):230–5

Effect of different cooling rates on fracture toughness and microhardness of a glazed alumina reinforced porcelain. Baharav H, et al. **J Prosthet Dent** 1996 Jul;76(1):19–22

Lased and sandblasted denture base surface preparations affecting resilient liner bonding. Jacobsen NL, et al. **J Prosthet Dent** 1997 Aug;78(2):153–8

1H MAS and 1H[23Na] double resonance NMR studies on the modification of surface hydroxyl groups of gamma-alumina by sodium. Deng F, et al. **Solid State Nucl Magn Reson** 1997 Feb;7(4):281–90

A time resolved 27Al NMR study of the cooling process of liquid alumina from 2450 degrees C to crystallisation. Florian P, et al. **Solid State Nucl Magn Reson** 1995 Dec; 5(3):233–8

PHARMACOKINETICS

Benzo[a]pyrene coated ferric oxide and aluminum oxide particles: uptake, metabolism and DNA binding in hamster pulmonary alveolar macrophages and tracheal epithelial cells in vitro [published erratum appears in Carcinogenesis 1997 May;18(5):1123] Cheu J, et al. **Carcinogenesis** 1997 Jan;18(1):167–75

PHARMACOLOGY

Prostaglandin release from rat femurs after implantation of hydroxylapatite and aluminium oxide ceramics. Wittenberg JM, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Dec;53(6):413–7

Mechanisms of adjuvancy: I--Metal oxides as adjuvants. Naim JO, et al. **Vaccine** 1997 Aug;15(11):1183–93

ALUMINUM SILICATES

The emergence of the non-cellular phase of life on the fine-grained clayish particles of the early Earth's regolith. Nussinov MD, et al. **Biosystems** 1997;42(2-3):111–8 (40 ref.)

Reversible, site-specific immobilization of polyarginine-tagged fusion proteins on mica surfaces. Nock S, et al. **FEBS Lett** 1997 Sep 8;414(2):233–8

Interaction of nonionic polymers at a clay interface. Grandjean J, et al. **Magn Reson Imaging** 1996;14(7-8):983–4

AFM analysis of DNA-protamine complexes bound to mica. Allen MJ, et al. **Nucleic Acids Res** 1997 Jun 1;25(11):2221–6

[Augmentation of the temporal fossa with Ionos bone cement] Schick B, et al. **HNO** 1996 Aug;44(8):467–70 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Toxic aluminum encephalopathy. Predominant involvement of the limbic system on MRI] Lévêque C, et al. **J Neuroradiol** 1996 Dec;23(3):168–72 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Evaluation of a resin-reinforced glass ionomer cement for use as an orthodontic bonding agent. Komori A, et al. **Angle Orthod** 1997;67(3):189–95

Molluscicide acute and sub-chronic toxicity to the three non-target organisms Hexagenia limbata, Ceriodaphnia dubia, and Pimephelas promelas, and neutralization of that toxicity by bentonite clay. Bargar TA, et al. **Bull Environ Contam Toxicol** 1997 Feb;58(2):275–82

Microcracks in dental porcelain and their behavior during multiple firing. Mackert JR Jr, et al. **J Dent Res** 1996 Jul; 75(7):1484–90

Relationship between infrared spectra and isomorphous substitution in smectites: a computer simulation study. Chatterjee A, et al. **J Mol Graph** 1996 Oct;14(5):302–5, 285–6

Bonding of a mica-based castable ceramic material with a tri-n-butylborane-initiated adhesive resin. Morikawa T, et al. **J Oral Rehabil** 1996 Jul;23(7):450–5

Prospects for the direct electron crystallographic determination of zeolite structures. Dorset DL, et al. **Microsc Res Tech** 1997 Feb 1;36(3):212–23

PHARMACOLOGY

Hydrated sodium calcium aluminosilicate (HSCAS), acidic HSCAS, and activated charcoal reduce urinary excretion of aflatoxin M1 in turkey poults. Lack of effect by activated charcoal on aflatoxicosis. Edrington TS, et al. **Toxicol Lett** 1996 Dec 16;89(2):115–22

[Importance of the specific surface area in the study of the biological effects of dusts*of industrial use] Governa M, et al. **G Ital Med Lav** 1995 Jan-Nov;17(1-6):105–9 (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

[An antibacterial sorptive preparation for preparing the large intestine for a surgical intervention] Rudichenko VM, et al. **Klin Khir** 1995;(3):28–9 **(Ukr)**

TOXICITY

Effects of ionomer cement on guinea pig cochleas. Kobayashi T, et al. **Ear Nose Throat J** 1997 Apr;76(4):223–6, 228, 230

ALUMINUM SUCROSE SULFATE see **SUCRALFATE**

ALVEOLALGIA see **DRY SOCKET**

ALVEOLAR ABSCESS, APICAL see **PERIAPICAL ABSCESS**

ALVEOLAR BONE LOSS

CLASSIFICATION

Assessment of the trabecular pattern before endosseous implant treatment: diagnostic outcome of periapical radiography in the mandible. Lindh C, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Sep;82(3):335–43

COMPLICATIONS

Height of mandibular basal bone in dentate and edentulous

subjects. Xie Q, et al. **Acta Odontol Scand** 1996 Dec; 54(6):379–83

Fractures of the atrophic, edentulous maxilla during Le Fort I osteotomy. Li KK, et al. **Int J Oral Maxillofac Surg** 1996 Dec;25(6):430–2

A study on factors associated with pathologic tooth migration. Martinez-Canut P, et al. **J Clin Periodontol** 1997 Jul;24(7):492–7

The effect of chronic periodontal disease on human jaw muscles: a pilot study using computed tomography. Gilbert AD, et al. **J Oral Rehabil** 1997 Apr;24(4):259–64

DIAGNOSIS

How an implant caliper can aid in planning dental implant restoration. Davis WM. **J Am Dent Assoc** 1996 Sep; 127(9):1377

A device for measuring bone thickness in relation to dental implants. Jisander S. **J Oral Maxillofac Surg** 1996 Oct; 54(10):1254–5

Damping characteristics of teeth with periodontal breakdown: correlation of mobility meter values with bone and attachment loss. Demirel K, et al. **J Periodontol** 1997 Feb;68(2):166–71

DRUG THERAPY

Recombinant human bone morphogenetic protein-2 promotes wound healing in rat periodontal fenestration defects. King GN, et al. **J Dent Res** 1997 Aug;76(8):1460–70

ETIOLOGY

Alveolar bone loss of maxillary anterior teeth in adult orthodontic patients. Nelson PA, et al.
Am J Orthod Dentofacial Orthop 1997 Mar;111(3):328–34

Correlation between mucosal inflammation and marginal bone loss around hydroxyapatite-coated implants: a 3-year cross-sectional study. Teixeira ER, et al.
Int J Oral Maxillofac Implants 1997 Jan–Feb;12(1):74–81

Combining reconstructive and regenerative therapies. White C Jr, et al. **J Am Dent Assoc** 1997 May;128(5):625–9

Treatment of 3rd molar-induced periodontal defects with guided tissue regeneration. Oxford GE, et al.
J Clin Periodontol 1997 Jul;24(7):464–9

Radicular cysts are involved in the recruitment of osteoclast precursors. Zecchi-Orlandini S, et al.
J Oral Pathol Med 1996 Jul;25(6):325–30

Cephalometric evaluation of maxillary complete, mandibular fixed-removable partial prosthesis: a 5-year longitudinal study. Uçtaşli S, et al. **J Oral Rehabil** 1997 Feb;24(2):164–9

Periodontal findings in Cohen syndrome with chronic neutropenia. Alaluusua S, et al. **J Periodontol** 1997 May; 68(5):473–8

Experimental peri-implant tissue breakdown around hydroxyapatite-coated implants. Hanisch O, et al.
J Periodontol 1997 Jan;68(1):59–66

The association between estrogen status and alveolar bone density changes in postmenopausal women with a history of periodontitis. Payne JB, et al. **J Periodontol** 1997 Jan; 68(1):24–31

Experimentally induced periodontitis in beagle dogs causes rapid increases in osteoclastic resorption of alveolar bone. Shibutani T, et al. **J Periodontol** 1997 Apr;68(4):385–91

Diagnosis of an advanced endodontic/periodontic lesion: report of a case. Chang KM, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jul;84(1):79–81

IMMUNOLOGY

Expression of inflammatory cytokine genes in vivo by human alveolar bone-derived polymorphonuclear leukocytes isolated from chronically inflamed sites of bone resorption. Takeichi O, et al. **Calcif Tissue Int** 1996 Apr;58(4):244–8

Effects of T cell adoptive transfer into nude mice on alveolar bone resorption induced by endotoxin. Ukai T, et al.
J Periodontal Res 1996 Aug;31(6):414–22

Papillon–Lefèvre syndrome. Analysis of neutrophil chemotaxis. Firatli E, et al. **J Periodontol** 1996 Jun; 67(6):617–20

METABOLISM

The reversal line may be a key modulator of osteoblast function: observations from an alveolar bone wound-healing model. Romano PR, et al.
J Periodontal Res 1997 Jan;32(1 Pt 2):143–7

Relationship of sulphated glycosaminoglycans in human gingival crevicular fluid with active periodontal disease. Waddington RJ, et al. **J Periodontal Res** 1996 Apr; 31(3):168–70

MICROBIOLOGY

Microbial findings of deep peri-implant bone defects. Augthun M, et al. **Int J Oral Maxillofac Implants** 1997 Jan–Feb;12(1):106–12

Alveolar bone loss in rats infected with a strain of Prevotella intermedia and Fusobacterium nucleatum isolated from a child with prepubertal periodontitis. Yoshida-Minami I, et al. **J Periodontol** 1997 Jan;68(1):12–7

PATHOLOGY

Can the location of tooth agenesis and the location of initial bone loss seen in juvenile periodontitis be explained by neural developmental fields in the jaws? Kjaer I.
Acta Odontol Scand 1997 Jan;55(1):70–2

Ehlers-Danlos syndrome (type VIII). Apaydin A.
J Nihon Univ Sch Dent 1995 Dec;37(4):214–7

Relationship between size of denture foundation area and resorption of alveolar ridge in the edentulous mandible. Suenaga K, et al. **J Oral Rehabil** 1997 Apr;24(4):315–9

Is periodontal breakdown a fractal process? Simulations using the Weierstrass-Mandelbrot function. Landini G.
J Periodontal Res 1997 Apr;32(3):300–7

Periodontal findings in Cohen syndrome with chronic neutropenia. Alaluusua S, et al. **J Periodontol** 1997 May; 68(5):473–8

Healing of intrabony defects and its relationship to root canal therapy. A histologic and histometric study in dogs. Lima LA, et al. **J Periodontol** 1997 Mar;68(3):240–8

PHYSIOPATHOLOGY

Stress analysis of a cantilevered fixed partial denture with normal and reduced bone support. Yang HS, et al.
J Prosthet Dent 1996 Oct;76(4):424–30

PREVENTION & CONTROL

Using 45S5 bioglass cones as endosseous ridge maintenance implants to prevent alveolar ridge resorption: a 5-year evaluation. Stanley HR, et al.
Int J Oral Maxillofac Implants 1997 Jan–Feb;12(1):95–105

Minimum periodontal bone loss in dentally-aware adults. A 10-year prospective study. Eliasson S, et al.
J Clin Periodontol 1997 Jan;24(1):34–8

Enantiospecific inhibition of ligature-induced periodontitis in beagles with topical (S)-ketoprofen. Paquette DW, et al. **J Clin Periodontol** 1997 Aug;24(8):521–8

Bone level changes in patients with transmandibular implants. Kwakman JM, et al. **J Oral Maxillofac Surg** 1997 Jan; 55(1):15–8; discussion 18–9

A bone regenerative approach to alveolar ridge maintenance following tooth extraction. Report of 10 cases. Lekovic V, et al. **J Periodontol** 1997 Jun;68(6):563–70

Reconstruction of alveolar bone defects after extraction of mandibular third molars: a pilot study. Dodson TB.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Sep;82(3):241–7

RADIOGRAPHY

The predictive value of radiographic diagnosis of implant instability. Gröndahl K, et al.
Int J Oral Maxillofac Implants 1997 Jan–Feb;12(1):59–64

A comparison of radiographic bone height and probing attachment level measurements adjacent to porous-coated dental implants in humans. Levy D, et al.
Int J Oral Maxillofac Implants 1997 Jul–Aug;12(4):541–6

Marginal bone level buccal to mandibular molars in digital radiographs from charge-coupled device and storage phosphor systems. An in vitro study. Borg E, et al.
J Clin Periodontol 1997 May;24(5):306–12

Selection of the most accurate method of conventional radiography for the assessment of periodontal osseous destruction. Pepelassi EA, et al. **J Clin Periodontol** 1997 Aug;24(8):557–67

Testing the consistency of measurements of the distance between the cemento-enamel junction and the alveolar bone crest on bitewing radiographs. Schuller AA, et al.
J Clin Periodontol 1996 Nov;23(11):977–81

The relationship of bone loss observed on panoramic radiographs with clinical periodontal screening. Walsh TF, et al. **J Clin Periodontol** 1997 Mar;24(3):153–7

Digital image ratio: a new radiographic method for quantifying changes in alveolar bone. Part 1: Theory and methodology. Jean A, et al. **J Periodontal Res** 1996 Apr; 31(3):161–7

Efficacy of quantitative digital subtraction radiography using radiographs exposed in a multicenter trial. Jeffcoat MK, et al. **J Periodontal Res** 1996 Apr;31(3):157–60

Analytical methodology in quantitative digital subtraction radiography: analyses of the aluminum reference wedge. Allen KM, et al. **J Periodontol** 1996 Dec;67(12):1317–21

Radiographic measurement of alveolar bone loss in the living rat. Reymond F, et al. **J Periodontol** 1997 Feb;68(2):141–4

Quantitative analysis of periodontal defects in a skull model by subtraction radiography using a digital imaging device. Young SJ, et al. **J Periodontol** 1996 Aug;67(8):763–9

Diagnostic accuracy of direct digital dental radiography for the detection of periapical bone lesions: overall comparison between conventional and direct digital radiography. Kullendorff B, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Sep;82(3):344–50

Diagnostic accuracy of direct digital dental radiography for the detection of periapical bone lesions. II. Effects on diagnostic accuracy after application of image processing. Kullendorff B, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Nov;82(5):585–9

Assessment of the trabecular pattern before endosseous implant treatment: diagnostic outcome of periapical radiography in the mandible. Lindh C, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Sep;82(3):335–43

[A cross-sectional radiographic study of proximal alveolar bone loss in molars with adult periodontitis] Lin IC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Dec; 12(12):716–27 (Eng. Abstr.) **(Chi)**

SURGERY

Clinical and histological results in alveolar ridge enlargement using coralline calcium carbonate. Piattelli A, et al.
Biomaterials 1997 Apr;18(8):623–7

Transmandibular implant versus intramobile cylinder implants: a randomized, prospective clinical trial [published erratum appears in Int J Oral Maxillofac Surg 1997 Apr;26(2):157] Kwakman JM, et al.
Int J Oral Maxillofac Surg 1996 Dec;25(6):433–8

Horseshoe Le Fort I osteotomy in combination with endosteal implants--a median-term follow-up study. Watzinger F, et al. **Int J Oral Maxillofac Surg** 1996 Dec; 25(6):424–9

Guided tissue repair of complete buccal dehiscences associated with periapical defects: a clinical retrospective study. Pompa DG. **J Am Dent Assoc** 1997 Jul;128(7):989–97

Guided tissue regeneration using a collagen membrane in chronic adult and rapidly progressive periodontitis patients in the treatment of 3-wall intrabony defects. Benqué E, et al. **J Clin Periodontol** 1997 Aug;24(8):544–9

Combined collagen membrane and hydroxyapatite/collagen chondroitin-sulfate spacer placement in the treatment of 2-wall intrabony defects in chronic adult and rapidly progressive periodontitis patients. Benqué E, et al.
J Clin Periodontol 1997 Aug;24(8):550–6

Periodontal regeneration of intrabony defects with resorbable and non-resorbable membranes: 30-month results. Christgau M, et al. **J Clin Periodontol** 1997 Jan;24(1):17–27

Bacterial colonization of barrier material and periodontal regeneration. De Sanctis M, et al. **J Clin Periodontol** 1996 Nov;23(11):1039–46

Guided tissue regeneration with non-resorbable and biodegradable barriers: 6 months results. Eickholz P, et al. **J Clin Periodontol** 1997 Feb;24(2):92–101

Human histologic evaluation of HTR polymer and freeze-dried bone allograft. A case report. Froum SJ.
J Clin Periodontol 1996 Jul;23(7):615–20

Bone density changes after 1 year in periodontal lesions treated surgically with or without ePTFE membrane placement. Iversen B, et al. **J Clin Periodontol** 1996 Jun; 23(6):512–6

Periodontal healing following reconstructive surgery: effect of guided tissue regeneration. Nygaard-Ostby P, et al.
J Clin Periodontol 1996 Dec;23(12):1073–9

Treatment of 3rd molar-induced periodontal defects with guided tissue regeneration. Oxford GE, et al.
J Clin Periodontol 1997 Jul;24(7):464–9

Factors affecting the healing response of intrabony defects following guided tissue regeneration and access flap surgery. Tonetti MS, et al. **J Clin Periodontol** 1996 Jun; 23(6):548–56

Particulate bioglass as a grafting material in the treatment of periodontal intrabony defects. Zamet JS, et al.
J Clin Periodontol 1997 Jun;24(6):410–8

Treatment of interproximal angular defects by guided tissue regeneration: 1 year follow-up. Mora F, et al.
J Oral Rehabil 1996 Sep;23(9):599–606

A prospective multi-center study evaluating periodontal regeneration for Class II furcation invasions and intrabony defects after treatment with a bioabsorbable barrier membrane: 1-year results. Becker W, et al.
J Periodontol 1996 Jul;67(7):641–9

Evaluation of bioabsorbable elastin-fibrin matrix as a barrier in surgical periodontal treatment. Da Costa-Noble R, et al. **J Periodontol** 1996 Sep;67(9):927–34

Bacterial colonization of bioabsorbable barrier material and periodontal regeneration. De Sanctis M, et al.
J Periodontol 1996 Nov;67(11):1193–200

Guided tissue regeneration therapy of 203 consecutively treated intrabony defects using a bioabsorbable matrix barrier. Clinical and radiographic findings. Falk H, et al.
J Periodontol 1997 Jun;68(6):571–81

A clinical evaluation of guided tissue regeneration with a bioabsorbable matrix membrane combined with an allograft bone graft. A series of case reports. Harris RJ.
J Periodontol 1997 Jun;68(6):598–607

Guided periodontal tissue regeneration in interproximal intrabony defects following treatment with a synthetic bioabsorbable barrier. Hürzeler MB, et al. **J Periodontol** 1997 May;68(5):489–97

Guided periodontal tissue regeneration in Class II furcation defects following treatment with a synthetic bioabsorbable barrier. Hürzeler MB, et al. **J Periodontol** 1997 May; 68(5):498–505

Periodontal repair in intrabony defects treated with a calcium carbonate implant and guided tissue regeneration. Kim CK, et al. **J Periodontol** 1996 Dec;67(12):1301–6

Osseous repair of a lateral periodontal cyst. Lehrhaupt NB, et al. **J Periodontol** 1997 Jun;68(6):608–11

A clinical evaluation of demineralized freeze-dried bone allograft in combination with tetracycline in the treatment of periodontal osseous defects. Masters LB, et al.
J Periodontol 1996 Aug;67(8):770–81

Influence of smoking on long-term clinical results of intrabony defects treated with regenerative therapy. Rosen PS, et al. **J Periodontol** 1996 Nov;67(11):1159–63

Comparison between 2 surgical techniques for the treatment of early-onset periodontitis. Sirirat M, et al.

J Periodontol 1996 Jun;67(6):603–7
Assessment of guided tissue regeneration procedures in intrabony defects with bioabsorbable and non–resorbable barriers. Weltman R, et al. **J Periodontol** 1997 Jun; 68(6):582–90

ALVEOLAR ECHINOCOCCIS, HEPATIC see **ECHINOCOCCOSIS, HEPATIC**

ALVEOLAR LAVAGE FLUID see **BRONCHOALVEOLAR LAVAGE FLUID**

ALVEOLAR MACROPHAGES see **MACROPHAGES, ALVEOLAR**

ALVEOLAR NERVE, INFERIOR see **MANDIBULAR NERVE**

ALVEOLAR NERVE, SUPERIOR see **MAXILLARY NERVE**

ALVEOLAR PROCESS

see related
ALVEOLECTOMY
ALVEOLOPLASTY
DENTAL ARCH

ABNORMALITIES

Application of thiamine in preventing malformations, specifically cleft alveolus and palate, during the intrauterine development of rats. Bienengräber V, et al.
Cleft Palate Craniofac J 1997 Jul;34(4):318–24
Radiographic assessment of secondary autogenous alveolar bone grafting in cleft lip and palate patients. Kindelan JD, et al. **Cleft Palate Craniofac J** 1997 May;34(3):195–8
Three–dimensional comparison between the palatal forms in infants with complete unilateral cleft lip, alveolus, and palate (UCLP) with and without Hotz's plate. Mishima K, et al. **Cleft Palate Craniofac J** 1996 Jan;33(1):77–83
Comparison of 2–D calculations from periapical and occlusal radiographs versus 3–D calculations from CAT scans in determining bone support for cleft–adjacent teeth following early alveolar bone grafts. Rosenstein SW, et al.
Cleft Palate Craniofac J 1997 May;34(3):199–205
Use of an osseointegrated implant for dental rehabilitation after cleft repair by periosteoplasty: a case report. Takahashi T, et al. **Cleft Palate Craniofac J** 1997 May; 34(3):268–71
Secondary alveolar bone grafting—five–year periodontal and radiographic evaluation in 100 consecutive cases. Tan AE, et al. **Cleft Palate Craniofac J** 1996 Nov;33(6):513–8
Pain following iliac crest bone grafting of alveolar clefts. Dawson KH, et al. **J Craniomaxillofac Surg** 1996 Jun; 24(3):151–4
Endosseous implants for prosthetic rehabilitation in bone grafted alveolar clefts. Ronchi P, et al.
J Craniomaxillofac Surg 1995 Dec;23(6):382–6
Prospective evaluation of morbidity associated with iliac crest harvest for alveolar cleft grafting. Rudman RA.
J Oral Maxillofac Surg 1997 Mar;55(3):219–23; discussion 223–4
Tension–releasing suture in the repair of alveolar cleft defects. Steinberg B. **J Oral Maxillofac Surg** 1997 Feb; 55(2):197–8
Use of endosseous implants for dental reconstruction of patients with grafted alveolar clefts. Takahashi T, et al. **J Oral Maxillofac Surg** 1997 Jun;55(6):576–83; discussion 584
[Correction of alveolar cleft by bone graft in the patients with cleft lip and palate] Ma L, et al.
Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih 1996 Mar;12(2):107–9 (Eng. Abstr.) **(Chi)**

ANATOMY & HISTOLOGY

Proximal alveolar bone level after orthodontic treatment with magnets, superelastic coils and straight–wire appliances. Bondemark L, et al. **Angle Orthod** 1997;67(1):7–14
Alveolar bone height of primary and first permanent molars in healthy seven– to nine–year–old children. Needleman HL, et al. **ASDC J Dent Child** 1997 May–Jun;64(3):188–96, 165
Histomorphometric study of age–related changes in remodelling activity of human desmodontal bone. Jäger A. **J Anat** 1996 Oct;189 (Pt 2):257–64
Alveolar bone patterns in sickle cell anemia and non–sickle cell anemia adolescent Nigerians: a comparative study. Arowojolu MO, et al. **J Periodontol** 1997 Mar;68(3):225–8

BLOOD SUPPLY

Large arteriovenous high–flow mandibular, malformation with exsanguinating dental socket haemorrhage: a case report. Fathi M, et al. **J Craniomaxillofac Surg** 1997 Aug; 25(4):228–31

CHEMISTRY

Dual X–ray absorptiometry for alveolar bone: precision of peri–implant mineral measurements ex vivo. Denissen H, et al. **J Periodontal Res** 1996 May;31(4):265–70

CYTOLOGY

Histological evaluation of the biocompatibility of a glass–ionomer cement in rat alveolus. Brentegani LG, et al. **Biomaterials** 1997 Jan;18(2):137–40

DRUG EFFECTS

Immediate implantation of glass–ionomer cement granules increases osteogenesis during rat alveolar wound healing. Brentegani LG, et al. **J Nihon Univ Sch Dent** 1996 Dec; 38(3–4):141–5
Comparative effects of platelet–derived growth factor–BB and insulin–like growth factor–I, individually and in combination, on periodontal regeneration in Macaca fascicularis. Giannobile WV, et al. **J Periodontal Res** 1996 Jul;31(5):301–12
Minocycline–induced intraoral pharmacogenic pigmentation: case reports and review of the literature. Westbury LW, et al. **J Periodontol** 1997 Jan;68(1):84–91 (78 ref.)

EMBRYOLOGY

Location of alveolar clefts relative to the incisive fissure. Lisson JA, et al. **Cleft Palate Craniofac J** 1997 Jul; 34(4):292–6

ENZYMOLOGY

Distributional changes of osteoclasts and pre–osteoclastic cells in periodontal tissues during experimental tooth movement as revealed by quantitative immunohistochemistry of H(+)–ATPase. Yokoya K, et al. **J Dent Res** 1997 Jan;76(1):580–7

GROWTH & DEVELOPMENT

Development, maturation, and aging of the alveolar bone. New insights. Zernik JH, et al. **Dent Clin North Am** 1997 Jan;41(1):1–15 (41 ref.)

INNERVATION

Can the location of tooth agenesis and the location of initial bone loss seen in juvenile periodontitis be explained by neural developmental fields in the jaws? Kjaer I.
Acta Odontol Scand 1997 Jan;55(1):70–2
Electrophysiologic evidence showing the existence of sensory receptors within the alveolar bone in anesthetized cats. Héraud J, et al. **Int J Oral Maxillofac Implants** 1996 Nov–Dec;11(6):800–5

METABOLISM

Markers of bone and cementum formation accumulate in tissues regenerated in periodontal defects treated with expanded polytetrafluoroethylene membranes. Amar S, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):148–58

MICROBIOLOGY

Abscess formation around a hydroxyapatite–coated implant placed into the extraction socket with autogenous bone graft. A histological study using light microscopy, image processing, and confocal laser scanning microscopy. Takeshita F, et al. **J Periodontol** 1997 Mar;68(3):299–305

PATHOLOGY

A method of measuring the apical base. Sergl HG, et al. **Eur J Orthod** 1996 Oct;18(5):479–83
Immediate implantation of pure titanium implants into extraction sockets of Macaca fascicularis. Part II: Histologic observations. Barzilay I, et al.
Int J Oral Maxillofac Implants 1996 Jul–Aug;11(4):489–97
Soft tissue and marginal bone conditions at osseointegrated implants that have exposed threads: a 5–year retrospective study. Lekholm U, et al.
Int J Oral Maxillofac Implants 1996 Sep–Oct;11(5):599–604
Guided bone regeneration using resorbable and nonresorbable membranes: a comparative histologic study in humans. Simion M, et al.
Int J Oral Maxillofac Implants 1996 Nov–Dec;11(6):735–42
A clinical and histologic examination in humans of the osseous response to implanted natural bone mineral. Skoglund A, et al. **Int J Oral Maxillofac Implants** 1997 Mar–Apr;12(2):194–9
Skeletal and dento–alveolar stability of Le Fort I intrusion osteotomies and bimaxillary osteotomies in anterior open bite deformities. A retrospective three–centre study. Hoppenreijs TJ, et al. **Int J Oral Maxillofac Surg** 1997 Jun;26(3):161–75
Histological findings in the alveolar sockets and tooth roots after experimental mandibular fractures in dogs. Freitag V, et al. **J Craniomaxillofac Surg** 1997 Aug;25(4):203–11
Skeletal and dentoalveolar changes after extraction of the second molars in the upper jaw. Stellzig A, et al.
J Orofac Orthop 1996 Oct;57(5):288–97 **(Eng, Ger)**
Clinical and histologic observations of sites implanted with intraoral autologous bone grafts or allografts. 15 human case reports. Becker W, et al. **J Periodontol** 1996 Oct; 67(10):1025–33
Histologic evaluation of human extraction sockets treated with demineralized freeze–dried bone allograft (DFDBA) and cell occlusive membrane. Brugnami F, et al.
J Periodontol 1996 Aug;67(8):821–5
Spontaneous bony exposure: a report of 4 cases of idiopathic exposure and sequestration of alveolar bone. Sonnier KE, et al. **J Periodontol** 1997 Aug;68(8):758–62
Judson C. Hickey Scientific Writing Award Winner. Fabrication of a guide for nonradiographic evaluation of bone contour. Pesun IJ. **J Prosthet Dent** 1997 Jun; 77(6):621–3
Atypical cartilage in reactive osteocartilagenous metaplasia of the traumatized edentulous mandibular ridge. Daley TD, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jan;83(1):26–9
[Periodontal tissue status in shortening of the interalveolar distance] Rulikov VR, et al. **Stomatologiia (Mosk)** 1997; 76(2):40–2 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Alveolar bone turnover and tooth movement in male rats after removal of orthodontic appliances. King GJ, et al.
Am J Orthod Dentofacial Orthop 1997 Mar;111(3):266–75
Clinical and histological results in alveolar ridge enlargement using coralline calcium carbonate. Piattelli A, et al.
Biomaterials 1997 Apr;18(8):623–7
Bone tissue reactions to demineralized freeze–dried bone in conjunction with e–PTFE barrier membranes in man. Donath K, et al. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 1)):96–101
Success and failure rates of osseointegrated implants in function in regenerated bone for 6 to 51 months: a preliminary report. Fugazzotto PA.
Int J Oral Maxillofac Implants 1997 Jan–Feb;12(1):17–24
Histologic and histometric evaluation of rat alveolar wound healing around polyurethane resin implants. Carvalho TL, et al. **Int J Oral Maxillofac Surg** 1997 Apr;26(2):149–52
Immediate implantation of glass–ionomer cement granules increases osteogenesis during rat alveolar wound healing. Brentegani LG, et al. **J Nihon Univ Sch Dent** 1996 Dec; 38(3–4):141–5
The reversal line may be a key modulator of osteoblast function: observations from an alveolar bone wound–healing model. Romano PR, et al.
J Periodontal Res 1997 Jan;32(1 Pt 2):143–7

PHYSIOPATHOLOGY

Comparison of the effects of passive posterior bite–blocks with different construction bites on the craniofacial and dentoalveolar structures. Iscan HN, et al.
Am J Orthod Dentofacial Orthop 1997 Aug;112(2):171–8
Effect of ovariectomy on the local residual ridge remodeling. Jahangiri L, et al. **J Prosthet Dent** 1997 Apr;77(4):435–43

RADIOGRAPHY

Comparison of 2–D calculations from periapical and occlusal radiographs versus 3–D calculations from CAT scans in determining bone support for cleft–adjacent teeth following early alveolar bone grafts. Rosenstein SW, et al.
Cleft Palate Craniofac J 1997 May;34(3):199–205
A 1–year radiographic evaluation of marginal bone around dental implants. Jung YC, et al.
Int J Oral Maxillofac Implants 1996 Nov–Dec;11(6):811–8
Bone density changes after 1 year in periodontal lesions treated surgically with or without ePTFE membrane placement. Iversen B, et al. **J Clin Periodontol** 1996 Jun; 23(6):512–6
Height of the residual ridge and radiographic appearance of bony structure in the jaws of clinically edentulous elderly people. Soikkonen K, et al. **J Oral Rehabil** 1996 Jul;23(7):470–5
Digital image ratio: a new radiographic method for quantifying changes in alveolar bone. Part II: Clinical application. Jean A, et al. **J Periodontal Res** 1996 Nov; 31(8):533–9
Analytical methodology in quantitative digital subtraction radiography: analyses of the aluminum reference wedge. Allen KM, et al. **J Periodontol** 1996 Dec;67(12):1317–21
The effect of image variations on fractal dimension calculations. Shrout MK, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jul;84(1):96–100
Fractal dimension in radiographic analysis of alveolar process bone. Southard TE, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Nov;82(5):569–76
Studies on the use of digital radiography for the assessment of periapical bone lesions. Kullendorff B.
Swed Dent J Suppl 1996;118:1–40
[Indications for dental–CT. Case reports] Schom C, et al.
Aktuelle Radiol 1996 Nov;6(6):317–24 (Eng. Abstr.) **(Ger)**

SURGERY

Iliac apophyseal cartilage augmentation of the deficient piriform rim and maxilla in alveolar cleft grafting. Kokkinos PP, et al. **Am J Orthod Dentofacial Orthop** 1997 Aug; 112(2):145–53
Secondary alveolar bone grafting—five–year periodontal and radiographic evaluation in 100 consecutive cases. Tan AE, et al. **Cleft Palate Craniofac J** 1996 Nov;33(6):513–8
Donor site morbidity of the anterior iliac crest following cancellous bone harvest. Beirne JC, et al.
Int J Oral Maxillofac Surg 1996 Aug;25(4):268–71

ALVEOLAR PROCESS

Guided tissue repair of complete buccal dehiscences associated with periapical defects: a clinical retrospective study. Pompa DG. **J Am Dent Assoc** 1997 Jul;128(7):989–97

Capnography and ventilatory assessment during ambulatory dentoalveolar surgery. Bennett J, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):921–5;discussion 925–6

Tension-releasing suture in the repair of alveolar cleft defects. Steinberg B. **J Oral Maxillofac Surg** 1997 Feb; 55(2):197–8

Biologic responses of the pulp to single-tooth dento-osseous osteotomy. Yoshida S, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Aug;82(2):152–60

Use of a soft denture liner as a protective dressing for alveolar bone grafting [letter] Cheng CA, et al. **Plast Reconstr Surg** 1997 Jul;100(1):275–6

[Mandibular ridge augmentation with hydroxylapatite and its extension] Huang H, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1996 Jan;31(1):34–7 (Eng. Abstr.) **(Chi)**

[The use of a Kolapol preparation for eliminating perforation of the floor of the maxillary sinus and defects in the maxillary alveolar process] Romanov IA, et al. **Stomatologiia (Mosk)** 1996;75(5):48–50 (Eng. Abstr.) **(Rus)**

ALVEOLAR RESORPTION see **ALVEOLAR BONE LOSS**

ALVEOLAR RIDGE AUGMENTATION

Titanium implants and onlay bone graft to the atrophic edentulous maxilla: a 3-year longitudinal study. Astrand P, et al. **Int J Oral Maxillofac Surg** 1996 Feb;25(1):25–9

Simultaneous placement of endosteal implants and mandibular onlay grafting for treatment of the atrophic mandible. A preliminary report. McGrath CJ, et al. **Int J Oral Maxillofac Surg** 1996 Jun;25(3):184–8

Vestibuloplasty with a split thickness skin graft in a patient with Ehlers-Danlos syndrome. Borris TJ, et al. **J Oral Maxillofac Surg** 1997 Apr;55(4):419–23

[Mandibular ridge augmentation with hydroxylapatite and its extension] Huang H, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1996 Jan;31(1):34–7 (Eng. Abstr.) **(Chi)**

ADVERSE EFFECTS

Bilateral mandibular radiopacities with mucosal masses [clinical conference] Will MJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Dec;82(6):607–9

METHODS

Initiation of alveolar ridge augmentation in the rat mandible by subperiosteal implantation of octacalcium phosphate. Kamakura S, et al. **Arch Oral Biol** 1996 Nov;41(11):1029–38

Maxillary augmentation with a microvascularly anastomosed fibula: a preliminary report. Bähr W. **Int J Oral Maxillofac Implants** 1996 Nov–Dec;11(6):719–27

Ridge widening for the thin maxilla: a clinical report. Duncan JM, et al. **Int J Oral Maxillofac Implants** 1997 Mar–Apr; 12(2):224–7

Alveolar reconstruction with splitting osteotomy and microfixation of implants. Engelke WG, et al. **Int J Oral Maxillofac Implants** 1997 May–Jun;12(3):310–8

Vertical ridge augmentation using polylactic membranes in conjunction with immediate implants in periodontally compromised extraction sites: an experimental study in dogs. Schliephake H, et al. **Int J Oral Maxillofac Implants** 1997 May–Jun;12(3):325–34

A clinical and histologic examination in humans of the osseous response to implanted natural bone mineral. Skoglund A, et al. **Int J Oral Maxillofac Implants** 1997 Mar–Apr;12(2):194–9

Six-year clinical and histologic study of sinus-lift grafts. Wheeler SL, et al. **Int J Oral Maxillofac Implants** 1996 Jan–Feb;11(1):26–34

Autogenous onlay bone grafts fixed with screw implants for the treatment of severely resorbed maxillae. Radiographic evaluation of preoperative bone dimensions, postoperative bone loss, and changes in soft-tissue profile. Nyström E, et al. **Int J Oral Maxillofac Surg** 1996 Oct;25(5):351–9

Mandibular bone graft in the anterior maxilla for single-tooth implants. Presentation of surgical method. Widmark G, et al. **Int J Oral Maxillofac Surg** 1997 Apr;26(2):106–9

Guided bone regeneration to facilitate implant and prosthodontic therapy: three case reports. Jones T, et al. **J Can Dent Assoc** 1996 Oct;62(10):799–803

Sinus inlay bone augmentation: comparison of implant positioning after one- or two-staged procedures. Blomqvist JE, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):804–10

Radiographic evaluation of mandibular augmentation with prefabricated hydroxylapatite/fibrin glue implants. Meijer HJ, et al. **J Oral Maxillofac Surg** 1997 Feb;55(2):138–44; discussion 144–5

Continuing the use hydroylapatite for ridge augmentation [letter] Mercier P. **J Oral Maxillofac Surg** 1997 Jul; 55(7):788

Augmentation of localized defects of the anterior maxillary ridge with autogenous bone before insertion of implants. Raghoebar GM, et al. **J Oral Maxillofac Surg** 1996 Oct; 54(10):1180–5; discussion 1185–6

Avoiding ridge resorption when using hydroxylapatite for augmentation [letter] Schaffer AB. **J Oral Maxillofac Surg** 1997 Sep;55(9):1036–7

Clinical and histologic observations of sites implanted with intraoral autologous bone grafts or allografts. 15 human case reports. Becker W, et al. **J Periodontol** 1996 Oct; 67(10):1025–33

The thickness of masticatory mucosa in the human hard palate and tuberosity as potential donor sites for ridge augmentation procedures. Studer SP, et al. **J Periodontol** 1997 Feb;68(2):145–51

Expression of extracellular matrix macromolecules around demineralized freeze-dried bone allografts. Xiao Y, et al. **J Periodontol** 1996 Nov;67(11):1233–44

[Lateral alveolar ridge augmentation in implantology. A report on the GBR-Master's Course in Waldenburg of 22 September 1995 (news)] Metzler C. **Schweiz Monatsschr Zahnmed** 1996;106(3):280 **(Ger)**

[Augmentation of the maxillary sinus by Le Fort osteotomy in endosseous implantology. A clinical case report] Pappalardo S, et al. **Minerva Stomatol** 1997 Apr;46(4):201–5 (Eng. Abstr.) **(Ita)**

ALVEOLECTOMY

The effect of tramadol on dento-alveolar surgical pain. Collins M, et al. **Br J Oral Maxillofac Surg** 1997 Feb; 35(1):54–8

Prospective evaluation of morbidity associated with iliac crest harvest for alveolar cleft grafting. Rudman RA. **J Oral Maxillofac Surg** 1997 Mar;55(3):219–23; discussion 223–4

ALVEOLITIS, EXTRINSIC ALLERGIC

Extrinsic allergic alveolitis and eosinophilic lung disease. Screaton NJ, et al. **Br J Hosp Med** 1996 Jul 10–Aug 20; 56(2–3):90–3 (14 ref.)

Update on hypersensitivity pneumonitis. Craig TJ, et al. **Compr Ther** 1996 Sep;22(9):559–64 (24 ref.)

[Present status and future prospect of study on hypersensitivity pneumonitis in Japan] Ando M. **Jpn J Antibiot** 1997 Jan;50(1):77–83; discussion 83–84 **(Jpn)**

CHEMICALLY INDUCED

Chemical pneumonitis following household exposure to hydrofluoric acid. Bennion JR, et al. **Am J Ind Med** 1997 Apr;31(4):474–8

Hypersensitivity pneumonitis-like reaction and occupational asthma associated with 1,3-bis(isocyanatomethyl) cyclohexane pre-polymer. Simpson C, et al. **Am J Ind Med** 1996 Jul;30(1):48–55

Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Salaffi F, et al. **Clin Rheumatol** 1997 May;16(3):296–304 (53 ref.)

Perindopril-associated pneumonitis. Benard A, et al. **Eur Respir J** 1996 Jun;9(6):1314–6 (10 ref.)

Allergic alveolitis following exposure to epoxy polyester powder paint containing low amounts (<1%) of acid anhydrides. Piirilä P, et al. **Eur Respir J** 1997 Apr; 10(4):948–51

Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature. Sviri S, et al. **J Clin Gastroenterol** 1997 Jan;24(1):34–6

[A study of clinical significance of leukocyte migration inhibition test in drug-induced hypersensitivity pneumonitis] Uno K, et al. **Arerugi** 1995 Dec;44(12):1401–9 (Eng. Abstr.) **(Jpn)**

[Pneumonitis due to Hangeshashin-to] Oketani N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Sep;34(9):983–8 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

A case of acute eosinophilic pneumonia. Evidence for hypersensitivity-like pulmonary reaction. Iwami T, et al. **Chest** 1996 Dec;110(6):1618–21

Hypersensitivity pneumonitis in a patient with hypogammaglobulinemia. Schkade PA, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):710–2

[Subacute extrinsic allergic alveolitis with lesion edema] Farnoux C, et al. **Arch Pediatr** 1996 Oct;3(10):988–92 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Pulmonary illness associated with exposure to Mycobacterium-avium complex in hot tub water. Hypersensitivity pneumonitis or infection? [see comments] Embil J, et al. **Chest** 1997 Mar;111(3):813–6. Comment in: Chest 1997 Mar;111(3):534–6.

The diagnosis of hypersensitivity pneumonitis [editorial; comment] Schuyler M, et al. **Chest** 1997 Mar;111(3):534–6 . Comment on: Chest 1997 Mar;111(3):813–6.

Hypersensitivity pneumonitis. Daroowalla F, et al. **Compr Ther** 1997 Apr;23(4):244–8 (4 ref.)

Bias toward use of T-cell receptor variable regions in the lung: research tool or clinically useful technique? [editorial; comment] Semenzato G. **Eur Respir J** 1997 Apr;10(4):767–9 (33 ref.). Comment on: Eur Respir J 1997 Apr;10(4):772–9.

Allergic alveolitis in a school environment. Thörn A, et al. **Scand J Work Environ Health** 1996 Aug;22(4):311–4

[A boy highly suspected of hypersensitivity pneumonitis characterized by generalized mucosal lesions] Wada Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Oct; 19(5):524–36 (Eng. Abstr.) **(Jpn)**

[Hypersensitivity pneumonitis monitored with serum KL-6, a marker of interstitial pneumonia] Kobayashi J, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul;34(7):837–42 (Eng. Abstr.) **(Jpn)**

[Occupation exogenous allergic alveolitis] Khomenko AG, et al. **Probl Tuberk** 1996;(6):72–5 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

High prevalence of mollusc shell hypersensitivity pneumonitis in nacre factory workers. Orriols R, et al. **Eur Respir J** 1997 Apr;10(4):780–6

ETIOLOGY

Hypersensitivity pneumonitis induced by exposure to the legume algarroba. Franco-Vicario R, et al. **Allergy** 1997 Apr;52(4):478–9

Cheese workers' lung. Marcer G, et al. **Allergy** 1996 Dec; 51(12):959–60

Feather wreath lung: chasing a dead bird. Meyer FJ, et al. **Eur Respir J** 1996 Jun;9(6):1323–4 (6 ref.)

Hypersensitivity pneumonitis induced by spores of Pholiota nameko. Inage M, et al. **Intern Med** 1996 Apr;35(4):301–4

Hypersensitivity pneumonitis in workers exposed to esparto grass (Stipa tenacissima) fibers. Hinojosa M, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):985–91

Decreased pulmonary perfusion in hypersensitivity pneumonitis caused by Shiitake mushroom spores. Murakami M, et al. **J Intern Med** 1997 Jan;241(1):85–8

[Allergic alveolitis caused by exposure to molds in relation with damp housing] Kerätär R, et al. **Duodecim** 1995; 111(11):1033–8 **(Fin)**

[Summer-type hypersensitivity pneumonitis] Ando M. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1595–9 (15 ref.) **(Jpn)**

[Contaminated esparto fibers: the cause of extrinsic allergic alveolitis (letter) (see comments)] Fraj Lázaro J, et al. **Arch Bronconeumol** 1997 May;33(5):258–9. Comment in: Arch Bronconeumol 1996 Oct;32(8):377–8. **(Spa)**

[Hypersensitivity pneumonitis: new entities (editorial) (see comments)] Morell F, et al. **Arch Bronconeumol** 1996 Oct; 32(8):377–8. Comment in: Arch Bronconeumol 1997 May;33(5):258–9. **(Spa)**

[Extrinsic allergic alveolitis in male plaster worker (letter] Prieto de Paula JM, et al. **Arch Bronconeumol** 1997 Jan; 33(1):56 **(Spa)**

GENETICS

[Summer-type hypersensitivity pneumonitis in a family] Kawayama T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34(12):1401–5 (Eng. Abstr.) **(Jpn)**

HISTORY

Extrinsic allergic alveolitis (hypersensitivity pneumonitis): past, present and future. Salvaggio JE. **Clin Exp Allergy** 1997 May;27 Suppl 1:18–25 (54 ref.)

IMMUNOLOGY

Selection of T lymphocytes bearing limited TCR-Vbeta regions in the lung of hypersensitivity pneumonitis and sarcoidosis. Trentin L, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):587–96

Lung and blood T-cell receptor repertoire in extrinsic allergic alveolitis [see comments] Wahlström J, et al. **Eur Respir J** 1997 Apr;10(4):772–9. Comment in: Eur Respir J 1997 Apr;10(4):767–71.

Interstitial pneumonitis induced in guinea pigs by the antigens of Rhizopus nigricans. Alonso A, et al. **J Investig Allergol Clin Immunol** 1997 Mar–Apr;7(2):103–9

Is the different T helper cell activity in sarcoidosis and extrinsic allergic alveolitis also reflected by the cellular bronchoalveolar lavage fluid profile? Drent M, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1997 Mar;14(1):31–8

[Summer-type hypersensitivity pneumonitis in a patient with a positive skin test (15 minutes) for Trichosporon mucoides and a high serum IgE level] Nakajima M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Oct; 34(10):1168–73 (20 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Metalworking fluid-associated hypersensitivity pneumonitis: a workshop summary. Kreiss K, et al. **Am J Ind Med** 1997 Oct;32(4):423–32

Assignment and serotyping of Trichosporon species: the causative agents of summer-type hypersensitivity pneumonitis. Nishiura Y, et al. **J Med Vet Mycol** 1997 Jan–Feb;35(1):45–52

Partial sequences of large subunit ribosomal DNA of a new yeast species, Trichosporon domesticum and related species. Sugita T, et al. **Microbiol Immunol** 1997;41(7):571–3

PATHOLOGY

Experimental extrinsic allergic alveolitis and pulmonary

angiitis induced by intratracheal or intravenous challenge with Corynebacterium parvum in sensitized rats. Yi ES, et al. **Am J Pathol** 1996 Oct;149(4):1303–12

PHYSIOPATHOLOGY

Decreased pulmonary perfusion in hypersensitivity pneumonitis caused by Shiitake mushroom spores. Murakami M, et al. **J Intern Med** 1997 Jan;241(1):85–8

C–C chemokine–induced eosinophil chemotaxis during allergic airway inflammation. Lukacs NW, et al. **J Leukoc Biol** 1996 Nov;60(5):573–8

[Bradykinin level in bronchoalveolar lavage fluid in patients with extrinsic allergic alveolitis] Ziora D, et al. **Pol Arch Med Wewn** 1996 Jul;96(1):39–44 (Eng. Abstr.) **(Pol)**

[Pulmonary elastic pressure as an indicator of lung tissue morpho–functional restructure] Nefedov VB, et al. **Probl Tuberk** 1997;(3):34–6 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Small airways disease: expiratory computed tomography comes of age. Desai SR, et al. **Clin Radiol** 1997 May; 52(5):332–7 (6 ref.)

Air–trapping in extrinsic allergic alveolitis on computed tomography. Small JH, et al. **Clin Radiol** 1996 Oct; 51(10):684–8

ALVEOLITIS, FIBROSING see **PULMONARY FIBROSIS**

ALVEOLOCAPILLARY MEMBRANE see **BLOOD–AIR BARRIER**

ALVEOLOPLASTY

see related
DENTURE, COMPLETE, IMMEDIATE

The use of gingivoperiosteoplasty in CUCLP [letter] Berkowitz S. **Cleft Palate Craniofac J** 1997 Jul;34(4):363–4

Pain following iliac crest bone grafting of alveolar clefts. Dawson KH, et al. **J Craniomaxillofac Surg** 1996 Jun; 24(3):151–4

Endosseous implants for prosthetic rehabilitation in bone grafted alveolar clefts. Ronchi P, et al. **J Craniomaxillofac Surg** 1995 Dec;23(6):382–6

[Secondary early osteoplasty of the maxillary alveolar process in the combined treatment of patients with bilateral congenital clefts of the upper lip and palate] Davydov BN, et al. **Stomatologiia (Mosk)** 1996;75(3):49–52 (Eng. Abstr.) **(Rus)**

METHODS

Radiographic assessment of secondary autogenous alveolar bone grafting in cleft lip and palate patients. Kindelan JD, et al. **Cleft Palate Craniofac J** 1997 May;34(3):195–8

Use of an osseointegrated implant for dental rehabilitation after cleft repair by periosteoplasty: a case report. Takahashi T, et al. **Cleft Palate Craniofac J** 1997 May; 34(3):268–71

Secondary alveolar bone grafting––five–year periodontal and radiographic evaluation in 100 consecutive cases. Tan AE, et al. **Cleft Palate Craniofac J** 1996 Nov;33(6):513–8

Gingivoperiosteoplasty and midfacial growth. Wood RJ, et al. **Cleft Palate Craniofac J** 1997 Jan;34(1):17–20

Alveolar reconstruction with splitting osteotomy and microfixation of implants. Engelke WG, et al. **Int J Oral Maxillofac Implants** 1997 May–Jun;12(3):310–8

Tension–releasing suture in the repair of alveolar cleft defects. Steinberg B. **J Oral Maxillofac Surg** 1997 Feb; 55(2):197–8

Use of endosseous implants for dental reconstruction of patients with grafted alveolar clefts. Takahashi T, et al. **J Oral Maxillofac Surg** 1997 Jun;55(6):576–83; discussion 584

Histologic evaluation of human extraction sockets treated with demineralized freeze–dried bone allograft (DFDBA) and cell occlusive membrane. Brugnami F, et al. **J Periodontol** 1996 Aug;67(8):821–5

Long–term assessment of early alveolar bone grafts using three–dimensional computer–assisted tomography: a pilot study. Dado DV, et al. **Plast Reconstr Surg** 1997 Jun; 99(7):1840–5

ALZHEIMER BETA–PROTEIN see **AMYLOID BETA–PROTEIN**

ALZHEIMER'S DISEASE

see related
AMYLOID BETA–PROTEIN
AMYLOID BETA–PROTEIN PRECURSOR
APHASIA, PRIMARY PROGRESSIVE
NEUROFIBRILLARY TANGLES
NEUROFILAMENT PROTEINS
TAU PROTEINS

Procedural memory stimulation in Alzheimer's disease: impact of a training programme. Zanetti O, et al. **Acta Neurol Scand** 1997 Mar;95(3):152–7

Attentional problems and older drivers. Ball K. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:42–7 (33 ref.)

Knowledge about Alzheimer disease among primary care physicians, psychologists, nurses, and social workers. Barrett JJ, et al. **Alzheimer Dis Assoc Disord** 1997 Jun; 11(2):99–106

Motor vehicle crashes and drivers with DAT. Carr DB. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:38–41

Literature update. Agnosia in Alzheimer disease. Gura C. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):180

The ethics of end–of–life care. Gura C. **Alzheimer Dis Assoc Disord** 1996 Spring;10(1):57–8

Meeting report: the Fifth International Conference on Alzheimer's Disease and Related Disorders. Kalaria RN, et al. **Alzheimer Dis Assoc Disord** 1997 Jun;11(2):113–9

Disclosure of financial interest: a new policy for Alzheimer disease and associated disorders [editorial] Whitehouse PJ, et al. **Alzheimer Dis Assoc Disord** 1996 Spring;10(1):1–2

Alzheimer's disease in women. Filley CM. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):1–7

Concentration–dependent inhibitory effects of apolipoprotein E on Alzheimer's beta–amyloid fibril formation in vitro. Naiki H, et al. **Biochemistry** 1997 May 20;36(20):6243–50

Dementia: an intimate death. Garner J. **Br J Med Psychol** 1997 Jun;70 (Pt 2):177–84 (37 ref.)

Acquisition and long–term retention of a fine motor skill in Alzheimer's disease. Dick MB, et al. **Brain Cogn** 1995 Dec; 29(3):294–306

Inhibitory control during sentence comprehension in individuals with dementia of the Alzheimer type. Faust ME, et al. **Brain Lang** 1997 Apr;57(2):225–53

Alzheimer's disease. Pendlebury WW, et al. **Clin Symp** 1996; 48(3):2–32 (13 ref.)

Alzheimer's disease for the primary care physician. Gambert SR. **Compr Ther** 1997 Mar;23(3):174–8 (10 ref.)

George Bush did it right with parachute jump [editorial] Butler RN. **Geriatrics** 1997 May;52(5):14–5

Living with Alzheimer's: understanding the family's and patient's perspective. Moore I. **Geriatrics** 1997 Sep;52 Suppl 2:S33–6

Findings from a statewide program of respite care: a comparison of service users, stoppers, and nonusers. Cox C. **Gerontologist** 1997 Aug;37(4):511–7

Strategies for increasing participation of ethnic minorities in Alzheimer's Disease Diagnostic Centers: a multifaceted approach in California. Hart VR, et al. **Gerontologist** 1996 Apr;36(2):259–62

A cross–cultural validation of coping strategies and their associations with caregiving distress. Shaw WS, et al. **Gerontologist** 1997 Aug;37(4):490–504

Accumulation of aluminium and silicon in lipofuscin granules. Tokutake S, et al. **Gerontology** 1995;41 Suppl 2:131–44

Ethical dilemmas in discharge planning for patients with Alzheimer's disease. Cummings SM, et al. **Health Soc Work** 1997 May;22(2):101–8 (39 ref.)

Alzheimer's Disease International [editorial] Graham N, et al. **Int J Geriatr Psychiatry** 1997 Jul;12(7):691–2

Alzheimer's disease in Poland [editorial] Szczepanowska B. **Int J Geriatr Psychiatry** 1997 Jul;12(7):693–4

What depressive symptoms are reported in Alzheimer's patients? Weiner MF, et al. **Int J Geriatr Psychiatry** 1997 Jun;12(6):648–52

Alzheimer's disease: new horizons in diagnosis and treatment. Rankin L. **Iowa Med** 1997 May–Jun;87(5):199–201

Eligibility of Alzheimer's disease clinic patients for clinical trials. Schneider LS, et al. **J Am Geriatr Soc** 1997 Aug; 45(8):923–8

Why Alzheimer's disease is a women's health issue. McCann JJ, et al. **J Am Med Womens Assoc** 1997 Summer; 52(3):132–7

Clinical Developments in Alzheimer's Disease. Tucson, Arizona, February 14–17, 1996. Proceedings of a symposium. **J Clin Psychiatry** 1996;57 Suppl 14:3–44

Selective attention in a reaching task: effect of normal aging and Alzheimer's disease. Simone PM, et al. **J Exp Psychol Hum Percept Perform** 1997 Jun; 23(3):595–608

Update on Alzheimer's disease. Moore NC. **J Med Assoc Ga** 1997 Apr;86(2):81–2 (13 ref.)

Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. Malloy PF, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):189–97 (73 ref.)

An intervention to delay nursing home placement [letter; comment] Butler RN. **JAMA** 1997 Apr 2;277(13):1035. Comment on: JAMA 1996 Dec 4;276(21):1725–31. Comment on: JAMA 1996 Dec 4;276(21):1756–7.

A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial [see comments] Mittelman MS, et al. **JAMA** 1996 Dec 4;276(21):1725–31. Comment in: JAMA 1996 Dec 4;276(21):1756–7. Comment in: JAMA 1997 Apr 2;277(13):1035. Comment in: ACP J Club 1997 May–Jun;126(3):67.

Alzheimer disease research comes of age. The pace accelerates [editorial] Morrison–Bogorad M, et al. **JAMA** 1997 Mar 12;277(10):837–40

European research on Alzheimer's disease [letter; comment] Winblad B, et al. **Lancet** 1997 Jul 5;350(9070):73–4. Comment on: Lancet 1997 May 24;349(9064):1546–9.

The biology of Alzheimer's disease. Edelberg HK, et al. **Mech Ageing Dev** 1996 Oct 25;91(2):95–114 (81 ref.)

Alzheimer disease. Outreach to the African American community. Ford A. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):121–4

Serpents on the road to dementia and death. Accumulating evidence from several studies points to the normal function of presenilin 1 and suggests how the mutant protein contributes to deposition of amyloid plaques in Alzheimer's disease [news; comment] Beyreuther K, et al. **Nat Med** 1997 Jul;3(7):723–5. Comment on: Nat Med 1997 Jul;3(7):756–60.

The 5th International Conference on Alzheimer's Disease and Related Disorders. Osaka, Japan, July 24–29, 1996. Abstracts. **Neurobiol Aging** 1996;17(4 Suppl):S1–213

Overview: clinical sites, case material, and special studies. Heyman A, et al. **Neurology** 1997 Sep;49(3 Suppl 3):S2–6

Psychogeriatric clinical, electro–encephalographic and autopsy findings. Müller HF, et al. **Neuropsychobiology** 1997;35(2):95–101

Neurotoxicity of apolipoprotein E thrombin cleavage fragments: implications for Alzheimer's disease [letter] Gurwitz D. **Neuroreport** 1997 Mar 3;8(4):1067–8

Nutrition and Alzheimer's disease. Folstein M. **Nutr Rev** 1997 Jan;55(1 Pt 1):23–5 (37 ref.)

Alzheimer's disease. Gilman S. **Perspect Biol Med** 1997 Winter;40(2):230–45 (53 ref.)

Disaggregation of Alzheimer beta–amyloid by site–directed mAb. Solomon B, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):4109–12

Caregivers' appraisals of efficacy in coping with dementia. Gignac MA, et al. **Psychol Aging** 1996 Jun;11(2):214–25

Response biases as a confound to expressed burden among spousal caregivers of suspected dementia patients. O'Rourke N, et al. **Psychol Aging** 1996 Jun;11(2):377–80

Psychosocial modulation of cytokine–induced natural killer cell activity in older adults. Esterling BA, et al. **Psychosom Med** 1996 May–Jun;58(3):264–72

Effects of formal supports on stress outcomes in family caregivers of Alzheimer's patients. Winslow BW. **Res Nurs Health** 1997 Feb;20(1):27–37

New 'Alzheimer's mouse' produced [news; comment] Marx J. **Science** 1996 Oct 11;274(5285):177–8. Comment on: Science 1996 Oct 4;274(5284):99–102.

Caregiving and social support in two illness groups. Monahan DJ, et al. **Soc Work** 1997 May;42(3):278–87

[Progresses in neurology in China, 1996] Wang X. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):891–2 (0 ref.) **(Chi)**

[Alzheimer's disease] Salmon E, et al. **Rev Med Liege** 1997 Apr;52(4):258–61 (24 ref.) **(Fre)**

[Alzheimer dementia. Main goal: improve quality of life for patients and family] **Dtsch Med Wochenschr** 1997 Apr 25; 122(17 Suppl):1–4 **(Ger)**

[Experimental techniques for developing new drugs acting on dementia (10)––Alzheimer's disease animal model induced by beta–amyloid protein] Nitta A, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):85–90 (Eng. Abstr.) **(Jpn)**

[Dementia––causes, diagnosis, treatment, and care] Morimatsu M. **Nippon Ronen Igakkai Zasshi** 1997 Feb; 34(2):93–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Alzheimer's disease––the molecular biological mechanism and the therapeutic drug design] Nabeshima T, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):132–4 (0 ref.) **(Jpn)**

[Clinical feature of dementia of the Alzheimer type] Sasaki H. **Rinsho Byori** 1996 Mar;44(3):207–12 (13 ref.) (Eng. Abstr.) **(Jpn)**

[New approach for the studies on Alzheimer's disease: a beta 1–42 and acetylcholine] Hoshi M. **Seikagaku** 1997 Mar; 69(3):181–7 (19 ref.) **(Jpn)**

[Manifestation of the symptoms in demented patients after the Great Hanshin Earthquake in Japan] Maeda K, et al. **Seishin Shinkeigaku Zasshi** 1996;98(5):320–8 (Eng. Abstr.) **(Jpn)**

BLOOD

Erythrocytic calpain–calpastatin system in Alzheimer's disease. Soldati L, et al. **Aging (Milano)** 1996 Apr;8(2):106–8

Serological alpha 1–antichymotrypsin in patients with probable senile dementia of Alzheimer type: a short–term longitudinal study. Licastro F, et al. **Alzheimer Dis Assoc Disord** 1996 Winter;10(4):192–6

GH response to GH–releasing hormone (GHRH) in Alzheimer and vascular dementia. Relation with somatostatin cerebrospinal levels. Gómez IM, et al. **Ann Endocrinol (Paris)** 1996;57(2):107–10

alpha 1–Antichymotrypsin as a risk modifier for late–onset Alzheimer's disease in Japanese apolipoprotein E epsilon 4 allele carriers. Yoshiiwa A, et al. **Ann Neurol** 1997 Jul; 42(1):115–7

Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Di Luca M, et al. **Arch Neurol** 1996 Nov;53(11):1162–6

Altered amyloid protein processing in platelets of patients with Alzheimer disease. Rosenberg RN, et al. **Arch Neurol** 1997 Feb;54(2):139–44

A twin study of late–onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. Steffens DC, et al. **Biol Psychiatry** 1997 Apr 15;41(8):851–6

Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. Asthana S, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):276–82

Serum amyloid P component level in Alzheimer's disease. Nishiyama E, et al. **Dementia** 1996 Sep–Oct;7(5):256–9

ALZHEIMER'S DISEASE

Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) in Alzheimer's disease and in cerebrovascular dementia. Yanase T, et al. **Endocr J** 1996 Feb;43(1):119-23

Cerebrospinal fluid and plasma disposition of yohimbine and 11-hydroxy-yohimbine in young and older healthy subjects, and Alzheimer's disease patients. Le Corre PA, et al. **Eur J Clin Pharmacol** 1997;52(2):135-8

Platelet and lymphocyte benzodiazepine binding in patients with Alzheimer's disease. Bongioanni P, et al. **Exp Neurol** 1997 Aug;146(2):560-6

Physiology and function of platelets from patients with Alzheimer's disease. Rao GH, et al. **Indian J Physiol Pharmacol** 1996 Jan;40(1):5-14

Increase in mean cell volume--a possible peripheral marker for Alzheimer's disease? [letter] Prasher VP. **Int J Geriatr Psychiatry** 1997 Jan;12(1):130-1

Conditions altering plasma concentrations of urea cycle and other amino acids in elderly human subjects. Prior RL, et al. **J Am Coll Nutr** 1996 Jun;15(3):237-47

Holotranscobalamin II levels in plasma are related to dementia in older people [letter] Johnston CS, et al. **J Am Geriatr Soc** 1997 Jun;45(6):779-80

Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? Joosten E, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar; 52(2):M76-9

Membrane modifications of red blood cells in Alzheimer's disease. Sabolovic D, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):B217-20

T-cell tumour necrosis factor-alpha receptor binding in demented patients. Bongioanni P, et al. **J Neurol** 1997 Jul; 244(7):418-25

The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. Landén M, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):352-6

Apolipoprotein E polymorphism and late onset Alzheimer's disease in Argentina [letter] Morelli L, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):426-7

Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia. Alonso DF, et al. **J Neurol Sci** 1996 Jul; 139(1):83-8

The antioxidant enzymatic blood profile in Alzheimer's and vascular diseases. Their association and a possible assay to differentiate demented subjects and controls. Famulari AL, et al. **J Neurol Sci** 1996 Sep 15;141(1-2):69-78

Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. Tamaoka A, et al. **J Neurol Sci** 1996 Sep 15;141(1-2):65-8

Menopause and the brain. van Duijn CM. **J Psychosom Obstet Gynaecol** 1997 Jun;18(2):121-5 (31 ref.)

Blood transferrin and ferritin in Alzheimer's disease. Fischer P, et al. **Life Sci** 1997;60(25):2273-8

Oxidative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimer's disease. Thome J, et al. **Life Sci** 1997; 60(1):13-9

Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Alvarez XA, et al. **Mol Chem Neuropathol** 1996 Oct-Dec; 29(2-3):237-52

Erythrocyte aging characteristics in elderly individuals with beginning dementia. Bosman GJ, et al. **Neurobiol Aging** 1997 May-Jun;18(3):291-5

Activated Alzheimer disease platelets retain more beta amyloid precursor protein. Davies TA, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):147-53

Moderate and advanced Alzheimer's patients exhibit platelet activation differences. Davies TA, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):155-62

Free intracellular calcium in peripheral cells in Alzheimer's disease. Eckert A, et al. **Neurobiol Aging** 1997 May-Jun; 18(3):281-4

Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Hartmann A, et al. **Neurobiol Aging** 1997 May-Jun;18(3):285-9

Monoamine oxidase molecular activity in platelets of parkinsonian and demented patients. Bongioanni P, et al. **Neurodegeneration** 1996 Dec;5(4):351-7

ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Blacker D, et al. **Neurology** 1997 Jan; 48(1):139-47

The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Kosaka T, et al. **Neurology** 1997 Mar; 48(3):741-5

Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Taddei K, et al. **Neurosci Lett** 1997 Feb 14;223(1):29-32

Autoantibody reactivity in serum of patients with Alzheimer's disease and other age-related dementias. Schott K, et al. **Psychiatry Res** 1996 Jan 31;59(3):251-4

[The role of apolipoproteins E genotyping in the differential diagnosis of dementia] Slooter AJ, et al. **Ned Tijdschr Geneeskd** 1996 Oct 19;140(42):2073-6 **(Dut)**

[The direct and reverse processes of cholesterol and triglyceride transport in patients with Alzheimer's disease] Voloshina NP. **Lik Sprava** 1997 Jan-Feb;(1):65-8 (Eng. Abstr.) **(Rus)**

[Apo E: blood lipids, ischemic cardiopathy and Alzheimer's disease] Lahoz C, et al. **Med Clin (Barc)** 1997 May 31; 109(1):31-6 (82 ref.) **(Spa)**

CEREBROSPINAL FLUID

Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia. Minthon L, et al. **Alzheimer Dis Assoc Disord** 1996 Winter;10(4):197-203

Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. Almkvist O, et al. **Arch Neurol** 1997 May;54(5):641-4

Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions. Skoog I, et al. **Arch Neurol** 1997 Mar;54(3):267-72

Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type. Strittmatter M, et al. **Biol Psychiatry** 1997 Jun 1;41(11):1124-30

Cerebrospinal fluid and plasma gamma-aminobutyric acid in Alzheimer's disease. Weiner MF, et al. **Biol Psychiatry** 1996 Nov 1;40(9):933-4

Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia. Minthon L, et al. **Dement Geriatr Cogn Disord** 1997 Jul-Aug; 8(4):232-9

Neurochemical differences in the CSF between Binswanger's and Alzheimer's disease. Strittmatter M, et al. **Dement Geriatr Cogn Disord** 1997 Jan-Feb;8(1):34-42

Tau proteins in cerebrospinal fluid from patients with Alzheimer's disease: a longitudinal study [letter] Isoe K, et al. **Dementia** 1996 May-Jun;7(3):175-6

Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. Landén M, et al. **Dementia** 1996 Sep-Oct;7(5):273-8

Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Wallin A, et al. **Dementia** 1996 Sep-Oct;7(5):267-72

Cerebrospinal fluid and plasma disposition of yohimbine and 11-hydroxy-yohimbine in young and older healthy subjects, and Alzheimer's disease patients. Le Corre PA, et al. **Eur J Clin Pharmacol** 1997;52(2):135-8

Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. Tohgi H, et al. **J Neural Transm** 1996;103(10):1211-20

Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: impact on non Alzheimer's dementia? Rösler N, et al. **J Neural Transm Suppl** 1996;47:259-66

The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. Johnson GV, et al. **J Neurochem** 1997 Jan;68(1):430-3

Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. Rosengren LE, et al. **J Neurochem** 1996 Nov;67(5):2013-8

Effect of cerebrospinal fluid from normal and Alzheimer's patients with different apolipoprotein E phenotypes on in vitro aggregation of amyloid beta-protein. Chauhan A, et al. **J Neurol Sci** 1996 Sep 15;141(1-2):54-8

Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. Merched A, et al. **J Neurol Sci** 1997 Jan;145(1):33-9

Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. Tamaoka A, et al. **J Neurol Sci** 1997 May 1;148(1):41-5

Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase [letter] Riemenschneider M, et al. **Lancet** 1997 Sep 13; 350(9080):784

Microglial cerebrospinal fluid antibodies. Significance for Alzheimer disease. McRae A, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):89-95

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Galasko D, et al. **Neurology** 1997 Mar;48(3):632-5

Low cerebrospinal fluid concentrations of peptide histidine valine and somatostatin-28 in Alzheimer's disease: altered processing of prepro-vasoactive intestinal peptide and prepro-somatostatin. Yasuda M, et al. **Neuropeptides** 1995 Dec;29(6):325-30

Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Blomberg M, et al. **Neurosci Lett** 1996 Aug 23;214(2-3):163-6

Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. Hahne S, et al. **Neurosci Lett** 1997 Mar 14;224(2):99-102

Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Hampel H, et al. **Neurosci Lett** 1997 Jun 13;228(3):143-6

Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Lefranc D, et al. **Neurosci Lett** 1996 Jul 12;212(2):91-4

CHEMICALLY INDUCED

A case-control study of Alzheimer's disease and aluminium occupation. Salib E, et al. **Br J Psychiatry** 1996 Feb; 168(2):244-9

Aluminum concentrations in drinking water and risk of Alzheimer's disease. Martyn CN, et al. **Epidemiology** 1997 May;8(3):281-6

Further thoughts on the aluminum-Alzheimer's disease link [comment] Forbes WF, et al. **J Epidemiol Community Health** 1996 Aug;50(4):401-3. Comment on: J Epidemiol Community Health 1995 Jun;49(3):253-8. Comment on: J Epidemiol Community Health 1995 Jun;49(3):323-4.

Long-term antipsychotic medication of schizophrenics does not promote the development of Alzheimer's disease brain pathology. Niizato K, et al. **J Neurol Sci** 1996 Jun; 138(1-2):165-7

CLASSIFICATION

Classification of dementia and Alzheimer's disease. Morris JC. **Acta Neurol Scand Suppl** 1996;165:41-50 (77 ref.)

A comparison of semantic memory in vascular dementia and dementia of Alzheimer's type. Bentham PW, et al. **Int J Geriatr Psychiatry** 1997 May;12(5):575-80

COMPLICATIONS

Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases. Claus JJ, et al. **Acta Neurol Scand** 1996 May;93(5):346-51

Is celiac disease associated with Alzheimer's disease? Frisoni GB, et al. **Acta Neurol Scand** 1997 Mar;95(3):147-51

Patterns of neuropsychological impairment in mild dementia: a comparison between Alzheimer's disease and multi-infarct dementia. Padovani A, et al. **Acta Neurol Scand** 1995 Dec;92(6):433-42

Use of electroencephalography to detect Alzheimer's disease in Down's syndrome. Visser FE, et al. **Acta Neurol Scand** 1996 Aug;94(2):97-103

Zolpidem for dementia-related insomnia and nighttime wandering. Shelton PS, et al. **Ann Pharmacother** 1997 Mar; 31(3):319-22

Alzheimer disease and nonfluent progressive aphasia. Greene JD, et al. **Arch Neurol** 1996 Oct;53(10):1072-8 (51 ref.)

Extrapyramidal signs in patients with probable Alzheimer disease. Lopez OL, et al. **Arch Neurol** 1997 Aug; 54(8):969-75

The role of magnetic resonance imaging in the diagnosis of Alzheimer disease in adults with Down syndrome. Prasher VP, et al. **Arch Neurol** 1996 Dec;53(12):1310-3

Weight loss in people with Alzheimer's disease: a prospective population based analysis. Cronin-Stubbs D, et al. **BMJ** 1997 Jan 18;314(7075):178-9

Inferior parietal perfusion, lateralization, and neuropsychological dysfunction in Alzheimer's disease. Keilp JG, et al. **Brain Cogn** 1996 Dec;32(3):365-83

Issues in the assessment of cognitive function in dementia. Milberg W. **Brain Cogn** 1996 Jul;31(2):114-32 (42 ref.)

Predicting rate of cognitive decline in probable Alzheimer's disease. Rasmusson DX, et al. **Brain Cogn** 1996 Jul; 31(2):133-47

Longitudinal analysis of clock drawing in Alzheimer's disease patients. Rouleau I, et al. **Brain Cogn** 1996 Jun;31(1):17-34

Tip-of-the-tongue states and lexical access in dementia. Astell AJ, et al. **Brain Lang** 1996 Aug;54(2):196-215

Phrase repetition in Alzheimer's disease: effect of meaning and length. Bayles KA, et al. **Brain Lang** 1996 Aug; 54(2):246-61

Comparative study of oral and written picture description in patients with Alzheimer's disease. Croisile B, et al. **Brain Lang** 1996 Apr;53(1):1-19

The production of specific and generic associates of living and nonliving, high- and low-familiarity stimuli in Alzheimer's disease. Gainotti G, et al. **Brain Lang** 1996 Aug;54(2):262-74

Anomaly judgments of subject-predicate relations in Alzheimer's disease. Grossman M, et al. **Brain Lang** 1996 Aug;54(2):216-32

Agraphia in Alzheimer's disease: an independent lexical impairment. Lambert J, et al. **Brain Lang** 1996 May; 53(2):222-33

Lexical priming by pictures and words in normal aging and in dementia of the Alzheimer's type. Margolin DI, et al. **Brain Lang** 1996 Aug;54(2):275-301

Classification deficits in Alzheimer's disease with special reference to living and nonliving things. Montanes P, et al. **Brain Lang** 1996 Aug;54(2):335-58

Sentence context influences the interpretation of word meaning by Alzheimer patients. Nebes RD, et al. **Brain Lang** 1996 Aug;54(2):233-45

On the nature of naming errors in aging and dementia: a study of semantic relatedness. Nicholas M, et al. **Brain Lang** 1996 Aug;54(2):184-95

Influence of disorders of visual perception in word-to-picture matching tasks in patients with Alzheimer's disease. Silveri MC, et al. **Brain Lang** 1996 Aug;54(2):326-34

Deterioration of spontaneous speech in AD patients during a 1-year follow-up: homogeneity of profiles and factors associated with progression. Romero B, et al. **Dementia** 1996 Jan-Feb;7(1):35-40

Differential susceptibility to neurofibrillary pathology among

patients with Down syndrome. Wegiel J, et al. **Dementia** 1996 May-Jun;7(3):135-41

Applied behavior analysis for behavior problems in Alzheimer's disease. Bakke BL. **Geriatrics** 1997 Sep;52 Suppl 2:S40-3

Behavioral complications and their treatment in Alzheimer's disease. Devanand DP. **Geriatrics** 1997 Sep;52 Suppl 2:S37-9

Retiring the pacemaker. Reitemeier PJ, et al. **Hastings Cent Rep** 1997 Jan-Feb;27(1):24; discussion 24-6

Roadblocks encountered in recruiting patients for a study of sleep disruption in Alzheimer's disease. Dowling GA, et al. **Image J Nurs Sch** 1997 Spring;29(1):59-64

Prevalence and correlates of aggressive behaviours occurring in patients with Alzheimer's disease. Eastley R, et al. **Int J Geriatr Psychiatry** 1997 Apr;12(4):484-7

Brief correspondence: impaired perceptually-based implicit memory in Alzheimer's disease. Jelicic M. **Int J Neurosci** 1996 Oct;87(1-2):103-6

Neuropsychological subgroups of dementia of the Alzheimer's type. Williams RN, et al. **Int J Neurosci** 1996 Oct;87(1-2):79-90

Non-insulin-dependent diabetes mellitus and Alzheimer's disease [letter; comment] Landi F, et al. **J Am Geriatr Soc** 1997 May;45(5):654-5. Comment on: J Am Geriatr Soc 1996 Aug;44(8):897-904.

Lesch-Nyan syndrome in an Alzheimer's disease patient: a case report [letter] Shua-Haim JR, et al. **J Am Geriatr Soc** 1997 Aug;45(8):1034

Optometric management of patients with Alzheimer's disease. Baker DR, et al. **J Am Optom Assoc** 1997 Aug;68(8):483-94 (59 ref.)

The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. Lalowski M, et al. **J Biol Chem** 1996 Dec 27; 271(52):33623-31

The treatment of depressed demented patients. Alexopoulos GS. **J Clin Psychiatry** 1996;57 Suppl 14:14-20 (70 ref.)

Ideational and semantic contributions to narrative production in adults with dementia of the Alzheimer's type . Ehrlich JS, et al. **J Commun Disord** 1997 Mar-Apr;30(2):79-98; quiz 98-9

Lexical decisions in patients with Alzheimer's disease: some notes on automatic versus controlled processing. Snyder LS, et al. **J Commun Disord** 1996 Sep-Oct;29(5):389-98; quiz 398-9

Memory and emotion processing in cortical and subcortical dementia. Baker JG. **J Gen Psychol** 1996 Jul;123(3):185-91

Patterns of motor impairement in normal aging, mild cognitive decline, and early Alzheimer's disease. Kluger A, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Jan; 52(1):P28-39

Behavioral treatment of depression in dementia patients: a controlled clinical trial. Teri L, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Jul;52(4):P159-66

Dementia in older people with intellectual disability: symptoms of physical and mental illness, and levels of adaptive behaviour. Moss S, et al. **J Intellect Disabil Res** 1997 Feb;41 (Pt 1):60-9

The epidemiology of Alzheimer disease in intellectual disability: results and recommendations from an international conference. Zigman W, et al. **J Intellect Disabil Res** 1997 Feb;41 (Pt 1):76-80

New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. Braak H, et al. **J Neural Transm Suppl** 1996;48:1-6 (24 ref.)

Inhibition of beta-amyloid formation by haloperidol: a possible mechanism for reduced frequency of Alzheimer's disease pathology in schizophrenia. Higaki J, et al. **J Neurochem** 1997 Jan;68(1):333-6

Medial temporal structures relate to memory impairment in Alzheimer's disease: an MRI volumetric study. Mori E, et al. **J Neurol Neurosurg Psychiatry** 1997 Aug;63(2):214-21

The effects of additional pathology on the cognitive deficit in Alzheimer disease. Nagy Z, et al. **J Neuropathol Exp Neurol** 1997 Feb;56(2):165-70

Conversational repair by individuals with dementia of the Alzheimer's type. Orange JB, et al. **J Speech Hear Res** 1996 Aug;39(4):881-95

Brain infarction and the clinical expression of Alzheimer disease [letter; comment] Mirra SS, et al. **JAMA** 1997 Jul 9;278(2):113; discussion 114. Comment on: JAMA 1997 Mar 12;277(10):813-7.

Brain infarction and the clinical expression of Alzheimer disease [letter; comment] Roman GC. **JAMA** 1997 Jul 9; 278(2):113-4. Comment on: JAMA 1997 Mar 12;277(10):813-7.

Brain infarction and the clinical expression of Alzheimer disease. The Nun Study [see comments] Snowdon DA, et al. **JAMA** 1997 Mar 12;277(10):813-7. Comment in: JAMA 1997 Jul 9;278(2):113; discussion 114. Comment in: JAMA 1997 Jul 9;278(2):113-4.

EEG spectral abnormalities and psychosis as predictors of cognitive and functional decline in probable Alzheimer's disease. Lopez OL, et al. **Neurology** 1997 Jun;48(6):1521-5

An association between head circumference and Alzheimer's disease in a population-based study of aging and dementia. Schofield PW, et al. **Neurology** 1997 Jul;49(1):30-7

Education and cognitive function in Alzheimer's disease. Filley CM, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Jan; 10(1):48-51

Effect of multiple presentations of words on event-related potential and reaction time repetition effects in Alzheimer's patients and young and older controls. Kazmerski VA, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Jan; 10(1):32-47

Response programming in dementia of the Alzheimer type: a kinematic analysis. Bellgrove MA, et al. **Neuropsychologia** 1997 Mar;35(3):229-40

Random number generation in dementia of the Alzheimer type: a test of frontal executive functions. Brugger P, et al. **Neuropsychologia** 1996 Feb;34(2):97-103

Automatic semantic priming of nouns and verbs in patients with Alzheimer's disease. Bushell CM, et al. **Neuropsychologia** 1997 Aug;35(8):1059-67

Autobiographical memory and executive function in early dementia of Alzheimer type. Greene JD, et al. **Neuropsychologia** 1995 Dec;33(12):1647-70

Advances in pharmacotherapy for decline of memory and cognition in patients with Alzheimer's disease. Kumar V, et al. **Psychiatr Serv** 1996 Mar;47(3):249-53 (28 ref.)

Olfactory evoked potentials in Parkinson's disease, Alzheimer's disease and anosmic patients [published erratum appears in Psychiatry Clin Neurosci 1996 Aug;50(4):234] Sakuma K, et al. **Psychiatry Clin Neurosci** 1996 Feb;50(1):35-40

Methodological control of semantic priming in Alzheimer's disease. Shenaut GK, et al. **Psychol Aging** 1996 Sep; 11(3):443-8

A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Taragano FE, et al. **Psychosomatics** 1997 May-Jun;38(3):246-52

[A critical review of available tools for evaluating memory enhancers in Alzheimer's disease] Poitrenaud J, et al. **Rev Med Interne** 1997;18(1):59-71 (59 ref.) (Eng. Abstr.) **(Fre)**

[Vision in Alzheimer's disease] Ceccaldi M. **Rev Neurol (Paris)** 1996 Jun-Jul;152(6-7):441-6 (57 ref.) (Eng. Abstr.) **(Fre)**

[Neuro-cognitive models of spelling and Alzheimer disease: mutual clarification] Eustache F, et al. **Rev Neurol (Paris)** 1996 Nov;152(11):658-68 (60 ref.) (Eng. Abstr.) **(Fre)**

[Parkinsonism in Alzheimer's disease] Odawara T, et al. **Nippon Rinsho** 1997 Jan;55(1):149-52 (18 ref.) (Eng. Abstr.) **(Jpn)**

[A preliminary study of low dosage zuclopenthixol depot in Alzheimer's disease] Robles A, et al. **Rev Neurol** 1996 Mar;24(127):273-5 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Three-dimensional "BURST" functional magnetic resonance imaging: initial clinical applications. Mattay VS, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S379-83

Pupil response to tropicamide in Alzheimer's disease and other neurodegenerative disorders. Gómez-Tortosa E, et al. **Acta Neurol Scand** 1996 Aug;94(2):104-9

Use of electroencephalography to detect Alzheimer's disease in Down's syndrome. Visser FE, et al. **Acta Neurol Scand** 1996 Aug;94(2):97-103

Biological markers and diagnostic investigations in Alzheimer's disease. Wahlund LO. **Acta Neurol Scand Suppl** 1996;165:85-91 (32 ref.)

Magnetic resonance imaging and computed tomography in Alzheimer's disease. Wahlund LO. **Acta Neurol Scand Suppl** 1996;168:50-3 (47 ref.)

The effect of white matter low attenuation on cognitive performance in dementia of the Alzheimer type. Amar K, et al. **Age Ageing** 1996 Nov;25(6):443-8

Gait disturbance in Alzheimer's disease: a clinical study. O'Keeffe ST, et al. **Age Ageing** 1996 Jul;25(4):313-6

Does it make sense to speak of senile dementia? [letter] Pérez Trullen JM, et al. **Age Ageing** 1997 Mar;26(2):163

Hippocampal atrophy as detected by width of the temporal horn is greater in Alzheimer dementia than in nondementing cognitive impairment [letter] Frisoni GB, et al. **AJNR Am J Neuroradiol** 1997 Jun-Jul;18(6):1192-3; discussion 1193-5

Tissue segmentation of the brain in Alzheimer disease. Tanabe JL, et al. **AJNR Am J Neuroradiol** 1997 Jan; 18(1):115-23

Cultural issues in the clinical diagnosis of Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Amaducci L, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:19-21

Diagnostic criteria for dementia in clinical trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Antuono P, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:22-5

Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group. Bodick N, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:50-3

Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease. Clark CM, et al. **Alzheimer Dis Assoc Disord** 1996 Spring; 10(1):31-9

The P1 component of the middle latency auditory potential may differentiate a brainstem subgroup of Alzheimer disease. Green JB, et al. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):153-7

Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Rasmusson DX, et al. **Alzheimer Dis Assoc Disord** 1996 Winter;10(4):180-8

The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photon-emission computed tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population. Scheltens P, et al. **Alzheimer Dis Assoc Disord** 1997 Jun; 11(2):63-70

Measures of psychiatric symptoms in Alzheimer patients: a review. Weiner MF, et al. **Alzheimer Dis Assoc Disord** 1996 Spring;10(1):20-30 (62 ref.)

Guidelines for early identification of Alzheimer Disease [editorial] Whitehouse PJ, et al. **Alzheimer Dis Assoc Disord** 1997 Jun;11(2):61-2

Early identification of Alzheimer's disease and related dementias. Early Identification of Alzheimer's Disease and Related Dementias Panel. **Am Fam Physician** 1997 Mar; 55(4):1303-14

Quantitative anatomic measures and comorbid medical illness in late-life major depression. Kumar A, et al. **Am J Geriatr Psychiatry** 1997 Winter;5(1):15-25

Can the sensitivity of the Alzheimer's Disease Assessment Scale be increased? Mattes JA. **Am J Geriatr Psychiatry** 1997 Summer;5(3):258-60

Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. Alexander GE, et al. **Am J Psychiatry** 1997 Feb;154(2):165-72

Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. Davidson M, et al. **Am J Psychiatry** 1996 Oct;153(10):1274-9

Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Elrod R, et al. **Am J Psychiatry** 1997 Jan;154(1):25-30

Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Levy ML, et al. **Am J Psychiatry** 1996 Nov; 153(11):1438-43

Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease. Mori E, et al. **Am J Psychiatry** 1997 Jan;154(1):18-24

No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. Murphy GM Jr, et al. **Am J Psychiatry** 1997 May;154(5):603-8

Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease: clinical implications. Pietrini P, et al. **Am J Psychiatry** 1996 Oct;153(10):1261-8

Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases [see comments] Weiner MF, et al. **Am J Psychiatry** 1996 Oct; 153(10):1269-73. Comment in: Am J Psychiatry 1997 Sep;154(9):1322-3. Comment in: Am J Psychiatry 1997 Sep;154(9):1323.

Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Small GW, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:70-8

The use of apolipoprotein E genotyping as a diagnostic test in suspected Alzheimer's disease. van Gool WA. **Ann N Y Acad Sci** 1996 Dec 16;802:79-91

Prediction for unimpaired subjects is different from diagnosis of demented patients [letter; comment] Roses AD, et al. **Ann Neurol** 1997 Mar;41(3):414-6. Comment on: Ann Neurol 1996 Jul;40(1):55-66.

The course of psychopathologic features in mild to moderate Alzheimer disease. Devanand DP, et al. **Arch Gen Psychiatry** 1997 Mar;54(3):257-63

Response of the pupil to tropicamide is not a reliable test for Alzheimer disease. FitzSimon JS, et al. **Arch Neurol** 1997 Feb;54(2):155-9

Pupil dilation to tropicamide is not specific for Alzheimer disease. Growdon JH, et al. **Arch Neurol** 1997 Jul; 54(7):841-4

Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Kattapong VJ, et al. **Arch Neurol** 1996 Jul;53(7):678-80

The validity of the family history method for identifying Alzheimer disease. Li G, et al. **Arch Neurol** 1997 May; 54(5):634-40

A very long goodbye. The ravages of Alzheimer's disease. Goldberg B. **ASHA** 1996 Fall;38(4):24-6, 28-9, 31

Slow-wave activity in the spectral analysis of the electroencephalogram and volumes of hippocampus in subgroups of Alzheimer's disease patients. Helkala EL, et al. **Behav Neurosci** 1996 Dec;110(6):1235-43

The predictive value of hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer's disease. Swanwick GR, et al. **Biol Psychiatry** 1996 Jun 1;39(11):976-8

Telling the diagnosis to patients with Alzheimer's disease. Relatives should act as proxy for patient [letter; comment] [see comments] Barnes RC. **BMJ** 1997 Feb 1; 314(7077):375-6. Comment on: BMJ 1996 Aug 31;313(7056):529-30. Comment in: BMJ 1997 Feb 1;314(7077):321-2.

Telling the diagnosis to patients with Alzheimer's disease. Geriatricians' and psychiatrists' practice differs [letter; comment] [see comments] Rice K, et al. **BMJ** 1997 Feb 1;314(7077):376. Comment on: BMJ 1996 Aug 31;313(7056):529-30. Comment in: BMJ 1997 Feb 1;314(7077):321-2.

ALZHEIMER'S DISEASE

Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia (MOUSEPAD). Allen NH, et al. **Br J Psychiatry** 1996 Sep;169(3):293–307

Head circumference as a measure of cognitive reserve. Association with severity of impairment in Alzheimer's disease. Graves AB, et al. **Br J Psychiatry** 1996 Jul; 169(1):86–92

White matter lesions in depression and Alzheimer's disease [letter; comment] O'Brien JT, et al. **Br J Psychiatry** 1996 Nov;169(5):671. Comment on: Br J Psychiatry 1996 Jul;169(1):114.

Use of structural imaging to study the progression of Alzheimer's disease. Smith AD, et al. **Br Med Bull** 1996 Jul;52(3):575–86 (35 ref.)

Acquisition and long-term retention of a fine motor skill in Alzheimer's disease. Dick MB, et al. **Brain Cogn** 1995 Dec; 29(3):294–306

Differences between Alzheimer's disease and vascular dementia on information processing measures. Mendez MF, et al. **Brain Cogn** 1997 Jul;34(2):301–10

The dementias: nosological and clinical factors related to diagnosis. Stuss DT, et al. **Brain Cogn** 1996 Jul;31(2):99–113 (100 ref.)

Analysis of conversational topic shifts: a multiple case study. Garcia LJ, et al. **Brain Lang** 1997 Jun 1;58(1):92–114

Verb comprehension deficits in probable Alzheimer's disease. Grossman M, et al. **Brain Lang** 1996 Jun;53(3):369–89

Naming and knowing in dementia of Alzheimer's type. Hodges JR, et al. **Brain Lang** 1996 Aug;54(2):302–25

Early identification of Alzheimer's disease and related dementias. Agency for Health Care Policy and Research. **Clin Pract Guidel Quick Ref Guide Clin** 1996 Nov;(19):1–28

Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. White KE, et al. **Compr Psychiatry** 1996 May–Jun;37(3):188–95

Memory disorders in Alzheimer's disease and the organization of human memory. Desgranges B, et al. **Cortex** 1996 Sep;32(3):387–412

Access to information about famous individuals in Alzheimer's disease. Dopkins S, et al. **Cortex** 1997 Jun; 33(2):333–9

Dementia with Lewy bodies. Kosaka K, et al. **Curr Opin Neurol** 1996 Aug;9(4):271–5 (43 ref.)

Spectrum of memory dysfunction in degenerative disease. Perry RJ, et al. **Curr Opin Neurol** 1996 Aug;9(4):281–5 (60 ref.)

Reduction of regional cerebral blood flow and cognitive impairment in patients with Alzheimer's disease: evaluation of an observer-independent analytic approach. Hirsch C, et al. **Dement Geriatr Cogn Disord** 1997 Mar–Apr; 8(2):98–104

Diagnosing Alzheimer's disease in community-dwelling elderly: a comparison of EEG and MRI. Strijers RL, et al. **Dement Geriatr Cogn Disord** 1997 May–Jun;8(3):198–202

Quantitative EEG and statistical mapping of wakefulness and REM sleep in the evaluation of mild to moderate Alzheimer's disease. Hassainia F, et al. **Eur Neurol** 1997; 37(4):219–24

Atypical white matter changes in Alzheimer's disease. Leker RR, et al. **Eur Neurol** 1997;37(4):254–5

Comparisons between SPECT and quantitative EEG measures of cortical impairment in mild to moderate Alzheimer's disease. Montplaisir J, et al. **Eur Neurol** 1996; 36(4):197–200

Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging. Scheltens P, et al. **Eur Neurol** 1997;37(2):95–9

Comparison of the memory performances of young and old subjects with those of Alzheimer's disease patients: support for a discontinuity between natural and pathological aging. Caltagirone C. **Funct Neurol** 1997 May–Aug;12(3–4):213

Behavioral disorders in dementia. Marini G, et al. **Funct Neurol** 1997 May–Aug;12(3–4):207–10 (15 ref.)

Ethical issues in genetic testing for Alzheimer's disease. Kahn J. **Geriatrics** 1997 Sep;52 Suppl 2:S30–2

Alzheimer's disease: a review of clinical assessment and management issues. Morris JC. **Geriatrics** 1997 Sep;52 Suppl 2:S22–5 (8 ref.)

Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Arai H, et al. **Gerontology** 1997;43 Suppl 1:2–10 (35 ref.)

Continuum of care ... stereotypes about addled old folks should be retired [news] **Hosp Health Netw** 1996 Nov 5; 70(21):22–3

Variables which distinguish patients fulfilling clinical criteria for dementia with Lewy bodies from those with Alzheimer's disease. Graham C, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):314–8

Can frontotemporal dementia and Alzheimer's disease be differentiated using a brief battery of tests? Gregory CA, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):375–83

A comparison of the clock drawing test and the Pfeiffer Short Portable Mental Status Questionnaire in a geropsychiatry clinic. Gruber NP, et al. **Int J Geriatr Psychiatry** 1997 May; 12(5):526–32

Proton magnetic resonance spectroscopy in dementia of Alzheimer type. Heun R, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):349–58

Reliability of the Modified Ordinal Scales of Psychological Development: a cognitive assessment battery for severe dementia. Auer SR, et al. **Int Psychogeriatr** 1996 Summer; 8(2):225–31

The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) Rating Scale. Auer SR, et al. **Int Psychogeriatr** 1996 Summer;8(2):247–66

The Hierarchic Dementia Scale: usage. Bickel H. **Int Psychogeriatr** 1996 Summer;8(2):213–24

Falling, hoarding and hiding, eating disturbances, and sexual disinhibition. Brännström B. **Int Psychogeriatr** 1996;8 Suppl 3:419–22

Depression in persons with dementia. Brodaty H, et al. **Int Psychogeriatr** 1996 Winter;8(4):609–22

Direct observation of behavioral disturbances of dementia and their environmental context. Burgio L. **Int Psychogeriatr** 1996;8 Suppl 3:343–6

Misidentifications. Burns A. **Int Psychogeriatr** 1996;8 Suppl 3:393–7; discussion 423–4

Diagnostic classification of neuropsychiatric signs and symptoms in patients with dementia. Caine ED. **Int Psychogeriatr** 1996;8 Suppl 3:273–9; discussion 289–91 (12 ref.)

Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Cohen-Mansfield J. **Int Psychogeriatr** 1996;8 Suppl 3:309–15; discussion 351–4 (45 ref.)

Assessment of agitation. Cohen-Mansfield J. **Int Psychogeriatr** 1996 Summer;8(2):233–45 (26 ref.)

The Hierarchic Dementia Scale: conceptualization. Cole MG, et al. **Int Psychogeriatr** 1996 Summer;8(2):205–12 (32 ref.)

Theories behind existing scales for rating behavior in dementia. Cummings JL. **Int Psychogeriatr** 1996;8 Suppl 3:293–300 (34 ref.)

1995 IPA/Bayer Research Awards in Psychogeriatrics. Bihemispheric language disorders in early-stage dementia of the Alzheimer type: evidence from a novel metalinguistic task. De Vreese LP, et al. **Int Psychogeriatr** 1996 Spring; 8(1):63–81

Vascular dementia and Alzheimer's disease: should we be studying both within the same study? Eriksson S. **Int Psychogeriatr** 1996;8 Suppl 3:443–5; discussion 447–8

Patterns of neuropsychological functioning among patients with multi-infarct and Alzheimer's dementia: a comparative analysis. Erker GJ, et al. **Int Psychogeriatr** 1995 Fall;7(3):393–406

Dementia Behavior Disturbance Scale. Gauthier S, et al. **Int Psychogeriatr** 1996;8 Suppl 3:325–7

Emotional lability, intrusiveness, and catastrophic reactions. Haupt M. **Int Psychogeriatr** 1996;8 Suppl 3:409–14

Implicit memory performance of patients with Alzheimer's disease: a brief review. Jelicic M, et al. **Int Psychogeriatr** 1995 Fall;7(3):385–92 (36 ref.)

Environmental and social aspects of behavioral disturbances in dementia. Lawlor BA. **Int Psychogeriatr** 1996;8 Suppl 3:259–61

Use of the clock drawing task in the diagnosis of mild and very mild Alzheimer's disease. Lee H, et al. **Int Psychogeriatr** 1996 Fall;8(3):469–76

Differentiating behavioral disturbances of dementia from symptoms of delirium. Luxenberg JS. **Int Psychogeriatr** 1996;8 Suppl 3:425–7; discussion 447–8

The Mini-Mental State Examination in Alzheimer's disease and multi-infarct dementia. Magni E, et al. **Int Psychogeriatr** 1996 Spring;8(1):127–34

Utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia. Mohr E, et al. **Int Psychogeriatr** 1996 Fall;8(3):397–411

The Alzheimer's Disease Assessment Scale. Mohs RC. **Int Psychogeriatr** 1996 Summer;8(2):195–203 (21 ref.)

Dysfunctional Behavior Rating Instrument. Molloy DW, et al. **Int Psychogeriatr** 1996;8 Suppl 3:333–41; discussion 351–4

Agitation, wandering, pacing, restlessness, and repetitive mannerisms. Neistein S, et al. **Int Psychogeriatr** 1996;8 Suppl 3:399–402 (13 ref.)

Behavioral disturbances of dementia: practical and conceptual issues. Rabins PV. **Int Psychogeriatr** 1996;8 Suppl 3:281–3; discussion 289–91

Depression, anxiety, and sleep disturbances. Reifler BV. **Int Psychogeriatr** 1996;8 Suppl 3:415–8; discussion 423–4

Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Reisberg B, et al. **Int Psychogeriatr** 1996;8 Suppl 3:301–8; discussion 351–4 (14 ref.)

Behavioral disturbances of dementia in ambulatory care settings. Ritchie K. **Int Psychogeriatr** 1996;8 Suppl 3:439–42

Behavioral disturbances of dementia in the nursing home. Rovner BW. **Int Psychogeriatr** 1996;8 Suppl 3:435–7

Family and physicians' views of surrogate decision-making: the roles and how to choose. Silberfeld M, et al. **Int Psychogeriatr** 1996 Winter;8(4):589–96

Neuroimaging and the origin of psychiatric symptoms in dementia. Sultzer DL. **Int Psychogeriatr** 1996;8 Suppl 3:239–43; discussion 269–72 (11 ref.)

Dementia Mood Assessment Scale. Sunderland T, et al. **Int Psychogeriatr** 1996;8 Suppl 3:329–31

Utility of ischemic scores in the differential diagnosis of Alzheimer's disease and ischemic vascular dementia. Swanwick GR, et al. **Int Psychogeriatr** 1996 Fall; 8(3):413–24

Caretaker Obstreperous Behavior Rating Scale. Swearer JM, et al. **Int Psychogeriatr** 1996;8 Suppl 3:321–4

CERAD behavior rating scale for dementia. Tariot PN. **Int Psychogeriatr** 1996;8 Suppl 3:317–20; discussion 351–4

Behavioral manifestations of dementia: a research agenda. Tariot PN. **Int Psychogeriatr** 1996;8 Suppl 1:31–8 (11 ref.)

Delusions. Trabucchi M, et al. **Int Psychogeriatr** 1996;8 Suppl 3:383–5; discussion 423–4

Disinhibition, apathy, indifference, fatigability, complaining, and negativism. Webster J, et al. **Int Psychogeriatr** 1996; 8 Suppl 3:403–8 (27 ref.)

Hallucinations. Whitehouse PJ, et al. **Int Psychogeriatr** 1996; 8 Suppl 3:387–92

Behavioral disturbances of dementia and caregiver issues. Zarit SH. **Int Psychogeriatr** 1996;8 Suppl 3:263–8; discussion 269–72

Behavioral disturbances of dementia in DSM-IV and ICD-10: fact or fiction? Zaudig M. **Int Psychogeriatr** 1996; 8 Suppl 3:285–8 (10 ref.)

HM-PAO (CERETEC) SPECT brain scanning in the diagnosis of Alzheimer's disease. Bergman H, et al. **J Am Geriatr Soc** 1997 Jan;45(1):15–20

Cognitive markers preceding Alzheimer's dementia in the healthy oldest old. Howieson DB, et al. **J Am Geriatr Soc** 1997 May;45(5):584–9

APOE4 genotyping [letter] Kandel R. **J Am Geriatr Soc** 1997 Sep;45(9):1154–6

Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease. Small GW. **J Clin Psychiatry** 1996;57 Suppl 14:9–13 (41 ref.)

Naming in dementia secondary to Parkinson's, Huntington's, and Alzheimer's diseases. Frank EM, et al. **J Commun Disord** 1996 May–Jun;29(3):183–97

Accurate registration of serial 3D MR brain images and its application to visualizing change in neurodegenerative disorders. Freeborough PA, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):1012–22

Utility of developmental reflexes in the differential diagnosis and prognosis of incontinence in Alzheimer's disease. Franssen EH, et al. **J Geriatr Psychiatry Neurol** 1997 Jan; 10(1):22–8

Disruptive behavior and actigraphic measures in home-dwelling patients with Alzheimer's disease: preliminary report. Friedman L, et al. **J Geriatr Psychiatry Neurol** 1997 Apr;10(2):58–62

Behavioral phenomenology in Alzheimer's disease, frontotemporal dementia, and late-life depression: a retrospective analysis. Swartz JR, et al. **J Geriatr Psychiatry Neurol** 1997 Apr;10(2):67–74

Lewy bodies and progressive dementia: a critical review and meta-analysis. Cercy SP, et al. **J Int Neuropsychol Soc** 1997 Mar;3(2):179–94

Computerized neuropsychological tests in the early detection of dementia: prospective findings. Fowler KS, et al. **J Int Neuropsychol Soc** 1997 Mar;3(2):139–46

Diagnosis of dementia in individuals with intellectual disability. Aylward EH, et al. **J Intellect Disabil Res** 1997 Apr;41 (Pt 2):152–64

Normal ageing in adults with Down's syndrome: a longitudinal study. Devenny DA, et al. **J Intellect Disabil Res** 1996 Jun;40 (Pt 3):208–21

Preparing for presymptomatic DNA testing for early onset Alzheimer's disease/cerebral haemorrhage and hereditary Pick disease. Tibben A, et al. **J Med Genet** 1997 Jan; 34(1):63–72

Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence. Jelic V, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):59–65

Altered pupillary size and darkness and light reflexes in Alzheimer's disease. Prettyman R, et al. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):665–8

Neuropsychological, psychiatric, and cerebral perfusion correlates of leukoaraiosis in Alzheimer's disease. Starkstein SE, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul; 63(1):66–73

Neuropsychological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia. Starkstein SE, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):381–7

The relation of cerebral magnetic resonance signal hyperintensities to Alzheimer's disease. Fazekas F, et al. **J Neurol Sci** 1996 Oct;142(1–2):121–5

Working memory and on-line sentence comprehension in patients with Alzheimer's disease. Waters GS, et al. **J Psycholinguist Res** 1997 Jul;26(4):377–400

The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. Post SG, et al. **JAMA** 1997 Mar 12;277(10):832–6 (75 ref.)

Alzheimer disease experts advise a 'wait for the data' response to new diagnostic test [news] Stephenson J. **JAMA** 1997 Mar 19;277(11):870

Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase [letter] Riemenschneider M, et al. **Lancet** 1997 Sep 13; 350(9080):784

Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease [letter] Sáez-Valero J, et al. **Lancet** 1997 Sep 27;350(9082):929

Impact on management of new diagnostic tests in Alzheimer's disease [letter] van Gool WA, et al. **Lancet** 1996 Oct 5; 348(9032):961

Tropicamide eyedrops cannot be used for reliable diagnosis

of Alzheimer's disease [see comments] Graff-Radford NR, et al. **Mayo Clin Proc** 1997 Jun;72(6):495–504. Comment in: Mayo Clin Proc 1997 Jun;72(6):581–2.

The eyes don't have it in Alzheimer's disease [editorial; comment] Newman NJ. **Mayo Clin Proc** 1997 Jun; 72(6):581–2. Comment on: Mayo Clin Proc 1997 Jun;72(6):495–504.

Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Parnetti L, et al. **Mech Ageing Dev** 1997 Jul;97(1):9–14

DNA repair 'test' for Alzheimer's disease? [news] Stewart A. **Mol Med Today** 1997 Jul;3(7):278

Effects of sequential neuropsychological testing of an elderly community-based sample. Frank R, et al. **Neuroepidemiology** 1996;15(5):257–68

Is vascular dementia really Alzheimer's disease or mixed dementia? Gorelick PB, et al. **Neuroepidemiology** 1996; 15(6):286–90 (27 ref.)

Standardization of the diagnosis of dementia in the Canadian Study of Health and Aging. Graham JE, et al. **Neuroepidemiology** 1996;15(5):246–56

A presenilin-1 mutation in a Japanese family with Alzheimer's disease and distinctive abnormalities on cranial MRI. Aoki M, et al. **Neurology** 1997 Apr;48(4):1118–20

Differential diagnosis of Alzheimer's disease. Geldmacher DS, et al. **Neurology** 1997 May;48(5 Suppl 6):S2–9 (65 ref.)

Midline cerebral morphometry distinguishes frontotemporal dementia and Alzheimer's disease. Kaufer DI, et al. **Neurology** 1997 Apr;48(4):978–85

Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects? Litvan I, et al. **Neurology** 1996 Nov;47(5):1324–6

The apolipoprotein E epsilon 4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Lopez OL, et al. **Neurology** 1997 Sep; 49(3):794–7

Preclinical AD [letter; comment] [see comments] Perez Trullen JM, et al. **Neurology** 1996 Apr;46(4):1195. Comment on: Neurology 1995 May;45(5):957–62. Comment in: Neurology 1997 Feb;48(2):549–50.

Neuropsychological assessment of Alzheimer's disease. Welsh-Bohmer KA, et al. **Neurology** 1997 Sep;49(3 Suppl 3):S11–3

The role of the electroencephalogram in the diagnosis of dementia of the Alzheimer type: an attempt at technology assessment. Jonkman EJ. **Neurophysiol Clin** 1997 Jun; 27(3):211–9 (103 ref.)

Atrophy of the hippocampus, parietal cortex, and insula in Alzheimer's disease: a volumetric magnetic resonance imaging study. Foundas AL, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr; 10(2):81–9

Breakdown of cross-modal function in dementia. Freedman M, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr;10(2):102–6

Anosognosia and procedural learning in Alzheimer's disease. Starkstein SE, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr; 10(2):96–101

Cognitive predictors of incident Alzheimer's disease: a prospective longitudinal study. Small BJ, et al. **Neuropsychology** 1997 Jul;11(3):413–20

Multiplex fluorescence-based primer extension method for quantitative mutation analysis of mitochondrial DNA and its diagnostic application for Alzheimer's disease. Fahy E, et al. **Nucleic Acids Res** 1997 Aug 1;25(15):3102–9

Pathological diagnosis of Alzheimer-type dementia for old-old and oldest-old patients. Mizutani T. **Pathol Int** 1996 Nov;46(11):842–54

Characteristics of postural control and locomotion of patients with vascular and Alzheimer-type dementias. Okuzumi H, et al. **Percept Mot Skills** 1997 Feb;84(1):16–8

Pupil dilation response to tropicamide: a biological test for Alzheimer's disease? Kurz A, et al. **Pharmacopsychiatry** 1997 Jan;30(1):12–5

Is it Alzheimer's disease? Gambert SR. **Postgrad Med** 1997 Jun;101(6):42–3, 48–9, 52–4 passim

After the diagnosis. Ham RJ. **Postgrad Med** 1997 Jun; 101(6):57–8, 60–4, 66 passim

Neuropsychological testing and assessment scales for dementia of the Alzheimer's type. Morgan CD, et al. **Psychiatr Clin North Am** 1997 Mar;20(1):25–43 (69 ref.)

Current advances in Alzheimer's disease. A medical model paradigm for psychiatric education. Rubin EH. **Psychiatr Clin North Am** 1997 Mar;20(1):77–89 (34 ref.)

Changes in the ratio of urinary alpha 1-microglobulin to ulinastatin levels in patients with Alzheimer-type dementia and vascular dementia. Inagaki T, et al. **Psychiatry Clin Neurosci** 1995 Dec;49(5–6):287–90

Regional atrophy of the corpus callosum in subjects with Alzheimer's disease and multi-infarct dementia. Lyoo IK, et al. **Psychiatry Res** 1997 May 16;74(2):63–72

Learning and retention in preclinical and early Alzheimer's disease. Grober E, et al. **Psychol Aging** 1997 Mar; 12(1):183–8

Qualitative magnetic resonance imaging findings in geriatric depression. Possible link between later-onset depression and Alzheimer's disease? Greenwald BS, et al. **Psychol Med** 1997 Mar;27(2):421–31

Performance on the delayed word recall test (DWR) fails to differentiate clearly between depression and Alzheimer's disease in the elderly. O'Carroll RE, et al. **Psychol Med** 1997 Jul;27(4):967–71

Hippocampal transverse relaxation times in patients with Alzheimer disease. Campeau NG, et al. **Radiology** 1997 Oct; 205(1):197–201

Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Ernst T, et al. **Radiology** 1997 Jun;203(3):829–36

Screening for Alzheimer's disease [editorial] Krause A, et al. **S Afr Med J** 1997 Feb;87(2):128–30

Diagnosis of Alzheimer's disease in a community hospital-based brain bank program. Pearl GS. **South Med J** 1997 Jul;90(7):720–2

Biological markers for the clinical diagnosis of Alzheimer's disease. Arai H. **Tohoku J Exp Med** 1996 Jun;179(2):65–79 (81 ref.)

The mydriatic effect of tropicamide and its diagnostic use in Alzheimer's disease. Reitner A, et al. **Vision Res** 1997 Jan;37(1):165–8

[Current diagnostic tests for Alzheimer's disease in clinical practice] van Gool WA, et al. **Ned Tijdschr Geneeskd** 1996 Oct 19;140(42):2071–3 **(Dut)**

[From Alzheimer's disease to dementia of the Alzheimer's type] Cambier J. **Bull Acad Natl Med** 1996 Oct; 180(7):1669–72 **(Fre)**

["The living image sign" in a patient with Alzheimer's disease] Demers P, et al. **J Psychiatry Neurosci** 1996 May; 21(3):198–201 **(Fre)**

[Can age-dependent cognitive functions be measured? P300 potentials—concept of brain aging—early diagnosis of dementia processes] Kügler C. **Fortschr Med** 1996 Oct 10; 114(28):357–60 (Eng. Abstr.) **(Ger)**

[Dementias—diagnosis, differential diagnosis and therapy] Rösler N, et al. **Fortschr Med** 1996 Oct 10;114(28):351–6 (24 ref.) (Eng. Abstr.) **(Ger)**

[Cranial magnetic resonance tomography—value in diagnosis of dementia. Important additional information for differential diagnosis] Welter F, et al. **Fortschr Med** 1996 Nov 30;114(33):451–5 (Eng. Abstr.) **(Ger)**

[Therapy of dementia] **Nervenarzt** 1994 Feb;65(2 Suppl):1–12 **(Ger)**

[Alzheimer dementia and normal aging. Clinical, neuroradiologic, neurophysiologic and molecular biology follow-up data] Förstl H, et al. **Nervenarzt** 1996 Sep; 67(9):730–8 (40 ref.) (Eng. Abstr.) **(Ger)**

[Structural magnetic resonance tomography in diagnosis and research of Alzheimer type dementia] Hampel H, et al. **Nervenarzt** 1997 May;68(5):365–78 (108 ref.) (Eng. Abstr.) **(Ger)**

[Early and differential diagnosis of 1,000 patients examined in a memory clinic] Heuft G, et al. **Nervenarzt** 1997 Mar; 68(3):259–69 (Eng. Abstr.) **(Ger)**

[Degree of disability of demented patients as judged by relatives and experts (disability insurance)] Zerfass R, et al. **Psychiatr Prax** 1997 Mar;24(2):84–7 (Eng. Abstr.) **(Ger)**

[Patient assessment in suspected dementia] Nehen HG. **Ther Umsch** 1997 Jun;54(6):309–13 (Eng. Abstr.) **(Ger)**

[Clinical and instrumental diagnosis of Alzheimer's and multi-infarct dementia] Fornarelli D, et al. **Radiol Med (Torino)** 1996 Jul–Aug;92(1–2):22–7 (Eng. Abstr.) **(Ita)**

[Recent progress in the management of Alzheimer disease] Nakamura S. **Nippon Naika Gakkai Zasshi** 1996 Sep 10; 85(9):1569–73 (12 ref.) **(Jpn)**

[1H-MRSI of Alzheimer's disease] Ide M, et al. **Nippon Rinsho** 1997 Jul;55(7):1768–73 (Eng. Abstr.) **(Jpn)**

[Tau protein in cerebrospinal fluid—a potential marker of Alzheimer's disease] Arai H, et al. **Nippon Ronen Igakkai Zasshi** 1996 Sep;33(9):669–75 (Eng. Abstr.) **(Jpn)**

[A 76-year-old man with loss of vision and dementia (clinical conference)] Miyashita N, et al. **No To Shinkei** 1997 Aug; 49(8):773–82 (Eng. Abstr.) **(Jpn)**

[Differences of neuroimaging between early-onset and late-onset Alzheimer-type dementia] Hanyu H, et al. **Rinsho Shinkeigaku** 1995 Oct;35(10):1104–9 (Eng. Abstr.) **(Jpn)**

[Extrapyramidal signs in Alzheimer's disease] Pfeffer-Baczuk A, et al. **Neurol Neurochir Pol** 1996 May–Jun;30(3):389–98 (Eng. Abstr.) **(Pol)**

[Standardization of the Alzheimer's Disease Assessment Scale in a Spanish population] Pascual LF, et al. **Neurologia** 1997 Jun–Jul;12(6):238–44 (Eng. Abstr.) **(Spa)**

[Shortened version of the Barcelona test (III): criterion validity with the ADAS-Cog] Peña-Casanova J, et al. **Neurologia** 1997 Mar;12(3):117–9 (Eng. Abstr.) **(Spa)**

[Adaptation and normalization of the Alzheimer's disease Assessment Scale for Spain (NORMACODEM) (II)] Peña-Casanova J, et al. **Neurologia** 1997 Feb;12(2):69–77 (Eng. Abstr.) **(Spa)**

[Normalization of cognitive and functional assessment instruments for dementia (NORMACODEM) (I): objectives, content and population] Peña-Casanova J, et al. **Neurologia** 1997 Feb;12(2):61–8 (98 ref.) (Eng. Abstr.) **(Spa)**

[Clinico-pathological correlation in the main types of dementia] Estupiñán B, et al. **Rev Neurol** 1997 Apr; 25(140):547–9 (Eng. Abstr.) **(Spa)**

[Experience with pupil tropicamide test in Alzheimer's disease] Robles A, et al. **Rev Neurol** 1996 Jan;24(125):65–8 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies. Gracon SI. **Acta Neurol Scand Suppl** 1996;165:114–22

Use of tacrine hydrochloride (Cognex) in private practice. Howell GJ. **Acta Neurol Scand Suppl** 1996;165:123–7

Functional studies of new drugs for the treatment of Alzheimer's disease. Nordberg A. **Acta Neurol Scand Suppl** 1996;165:137–44 (43 ref.)

Pharmacological treatment of cognitive dysfunction in dementia disorders. Nordberg A. **Acta Neurol Scand Suppl** 1996;168:87–92 (67 ref.)

Treatment of Alzheimer's disease: future directions. Wilcock GK, et al. **Acta Neurol Scand Suppl** 1996;165:128–36 (85 ref.)

The presence of leuko-araiosis in patients with Alzheimer's disease predicts poor tolerance to tacrine, but does not discriminate responders from non-responders. Amar K, et al. **Age Ageing** 1997 Jan;26(1):25–9

Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Becker RE, et al. **Alzheimer Dis Assoc Disord** 1996 Fall; 10(3):124–31

Issues in accelerating the pace of development for neuroprotective agents. Davis KL. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:36–7

Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Feldman H, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:61–4

Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Ferris SH, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:34–8

Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Gauthier S, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:6–7

Information technology and the International Working Group on Harmonization of Dementia Drug Guidelines. Harvey RJ, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:29–32

Clinical trials of treatment for noncognitive symptoms of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Homma A, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:54–5

A treatment and withdrawal trial of besipirdine in Alzheimer disease. Huff FJ, et al. **Alzheimer Dis Assoc Disord** 1996 Summer;10(2):93–102

length of clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Levy R. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:33

Ethical issues in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Post SG, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:26–8

Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Reisberg B, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:8–18

Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study. Sano M, et al. **Alzheimer Dis Assoc Disord** 1996 Fall;10(3):132–40

Quality-of-life assessment in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Whitehouse PJ, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:56–60

The International Working Group on Harmonization of Dementia Drug Guidelines: past, present, and future. Whitehouse PJ. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:2–5

Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Winblad B, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:39–45

An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. Pollock BG, et al. **Am J Geriatr Psychiatry** 1997 Winter; 5(1):70–8

Study suggests antioxidants slow decline in Alzheimer's disease [news] **Am J Health Syst Pharm** 1997 Jul 1; 54(13):1478, 1481

Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Satlin A, et al. **Am J Psychiatry** 1997 Oct;154(10):1459–61

Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Birkmayer JG. **Ann Clin Lab Sci** 1996 Jan–Feb;26(1):1–9

Apolipoprotein E genotype and gender influence response to tacrine therapy. Farlow MR, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:101–10

Current developments in neurology, Part II: Advances in

the pharmacotherapy of Alzheimer disease, Parkinson's disease, and stroke. Gidal BE, et al. **Ann Pharmacother** 1996 Dec;30(12):1446–51 (53 ref.)

Efficacy and safety of BMY 21,502 in Alzheimer disease. Shrotriya RC, et al. **Ann Pharmacother** 1996 Dec; 30(12):1376–80

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Bodick NC, et al. **Arch Neurol** 1997 Apr;54(4):465–73

Dementia improvement with cytotoxic chemotherapy. A case of Alzheimer disease and multiple myeloma. Keimowitz RM. **Arch Neurol** 1997 Apr;54(4):485–8

Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. Raskind MA, et al. **Arch Neurol** 1997 Jul;54(7):836–40

A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Toide K, et al. **Behav Brain Res** 1997 Feb;83(1–2):147–51

Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Yamada K, et al. **Behav Brain Res** 1997 Feb;83(1–2):117–22 (32 ref.)

Advertisements for donepezil (Aricept) in the BMJ. Advertisement suggests an unrealistic improvement in mental status [letter] Gray S. **BMJ** 1997 May 24; 314(7093):1555

Drug treatments for Alzheimer's disease [editorial] Kelly CA, et al. **BMJ** 1997 Mar 8;314(7082):693–4

Advertisements for donepezil (Aricept) in the BMJ. Local committee has declined to approve NHS hospital prescription of donepezil [letter] Wagner N. **BMJ** 1997 May 24;314(7093):1555–6

A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. Rockwood K, et al. **Can J Neurol Sci** 1997 May;24(2):140–5

Cognition–enhancing drugs in dementia: a guide to the near future. van Reekum R, et al. **Can J Psychiatry** 1997 Jun; 42 Suppl 1:35S–50S (190 ref.)

Potent inhibition of interleukin–6 expression in a human astrocytoma cell line by tenidap. Lieb K, et al. **Cell Tissue Res** 1997 May;288(2):251–7

A comparative QSAR analysis of acetylcholinesterase inhibitors currently studied for the treatment of Alzheimer's disease. Recanatini M, et al. **Chem Biol Interact** 1997 Aug 1;105(3):199–228

Development of neurotrophic factor therapy for Alzheimer's disease. Hefti F, et al. **Ciba Found Symp** 1996;196:54–63; discussion 63–9 (36 ref.)

Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates. Mohr E, et al. **Clin Neuropharmacol** 1997 Aug;20(4):338–45

Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. Asthana S, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):276–82

Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group. Canal N, et al. **Clin Pharmacol Ther** 1996 Aug;60(2):218–28

Drugs used in Alzheimer's disease and neuroplasticity. Allain H, et al. **Clin Ther** 1997 Jan–Feb;19(1):4–15; discussion 2–3 (74 ref.)

Cost–effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Aronson SM. **Clin Ther** 1997 Jan–Feb;19(1):139–47; discussion 126–7

Donepezil (Aricept) therapy for Alzheimer's disease. Geldmacher DS. **Compr Ther** 1997 Jul;23(7):492–3

Strategies to alter the progression of Alzheimer's disease. Siman R, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):601–7 (49 ref.)

Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients. Augustinsson LE, et al. **Dement Geriatr Cogn Disord** 1997 Jan–Feb;8(1):26–33

Nicergoline: parallel evolution of clinical trial methodology and drug development in dementias. Crook TH. **Dement Geriatr Cogn Disord** 1997;8 Suppl 1:22–6

A 12–month, randomized, placebo–controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III–R. The European Propentofylline Study Group. Marcusson J, et al. **Dement Geriatr Cogn Disord** 1997 Sep–Oct;8(5):320–8

Altered neurotransmission and signal transduction: targets for nicergoline treatment. Winblad B. **Dement Geriatr Cogn Disord** 1997;8 Suppl 1:2–5

A pilot study of prednisone in Alzheimer's disease. Aisen PS, et al. **Dementia** 1996 Jul–Aug;7(4):201–6

An enriched–population, double–blind, placebo–controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970–6 Study Group. Foster NL, et al. **Dementia** 1996 Sep–Oct;7(5):260–6

Steady–state pharmacokinetics of tacrine in long–term treatment of Alzheimer patients. Johansson M, et al. **Dementia** 1996 Mar–Apr;7(2):111–7

The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double–Blind, Placebo–Controlled Trial. The Donepezil Study Group. Rogers SL, et al. **Dementia** 1996 Nov–Dec;7(6):293–303

The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease. Snaedal J, et al. **Dementia** 1996 Jan–Feb;7(1):47–52

A risk–benefit assessment of tacrine in the treatment of Alzheimer's disease. Samuels SC, et al. **Drug Saf** 1997 Jan; 16(1):66–77 (55 ref.)

Cognitive enhancement therapy for Alzheimer's disease. The way forward. Parnetti L, et al. **Drugs** 1997 May; 53(5):752–68 (107 ref.)

Donepezil. Bryson HM, et al. **Drugs Aging** 1997 Mar; 10(3):234–9; discussion 240–1 (26 ref.)

Do nonsteroidal anti–inflammatory drugs have a protective effect against dementia? Van Muiswinkel FL, et al. **Drugs Aging** 1996 Jul;9(1):1–7

Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art. Fariello RG. **Funct Neurol** 1997 May–Aug;12(3–4):221–5 (20 ref.)

Pharmaceutical treatment of cognitive disorders in Alzheimer's disease. Senin U, et al. **Funct Neurol** 1997 May–Aug;12(3–4):211–2

Alzheimer's disease: a review of clinical assessment and management issues. Morris JC. **Geriatrics** 1997 Sep;52 Suppl 2:S22–5 (8 ref.)

Effects of central muscarinic–1 receptor stimulation on blood pressure regulation. Medina A, et al. **Hypertension** 1997 Mar;29(3):828–34

Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. Lawlor BA, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):319–22

Essential fatty acids preparation (SR–3) improves Alzheimer's patients quality of life. Yehuda S, et al. **Int J Neurosci** 1996 Nov;87(3–4):141–9

Outcome methodologies for pharmacologic trials in mild, moderate, and severe Alzheimer's disease. Proceedings of a meeting. New York, New York, July 26, 1994. **Int Psychogeriatr** 1996 Summer;8(2):155–344

Behavioral symptoms in dementia: community–based research. Auer SR, et al. **Int Psychogeriatr** 1996;8 Suppl 3:363–6; discussion 381–2

Nursing home research from industry's perspective. Brecher M. **Int Psychogeriatr** 1996;8 Suppl 3:367–70

Antipsychotic treatment in outpatients with dementia. Devanand DP. **Int Psychogeriatr** 1996;8 Suppl 3:355–61; discussion 381–2

Differentiating behavioral disturbances of dementia from drug side effects. Eastham JH, et al. **Int Psychogeriatr** 1996; 8 Suppl 3:429–34; discussion 447–8 (57 ref.)

Nursing home research from investigators' perspective. Finkel SI, et al. **Int Psychogeriatr** 1996;8 Suppl 3:371–3; discussion 381–2

Long–term treatment of elderly individuals with emotional disturbances: an open study with citalopram. Ragneskog H, et al. **Int Psychogeriatr** 1996 Winter;8(4):659–68

Overview of methodologic issues for pharmacologic trials in mild, moderate, and severe Alzheimer's disease. Reisberg B, et al. **Int Psychogeriatr** 1996 Summer;8(2):159–93 (85 ref.)

Clinical global impressions in Alzheimer's clinical trials. Schneider LS, et al. **Int Psychogeriatr** 1996 Summer; 8(2):277–88; discussion 288–90 (17 ref.)

Meta–analysis of controlled pharmacologic trials. Schneider LS. **Int Psychogeriatr** 1996;8 Suppl 3:375–9; discussion 381–2

Thiamin status and cognitive impairment in the elderly [editorial; comment] [see comments] Kanofsky JD. **J Am Coll Nutr** 1996 Jun;15(3):197–8. Comment on: J Am Coll Nutr 1996 Jun;15(3):206–22. Comment in: J Am Coll Nutr 1997 Feb;16(1):96–8.

Bridging study of S12024 in 53 in–patients with Alzheimer's disease [letter] Allain H, et al. **J Am Geriatr Soc** 1997 Jan; 45(1):125–6

Efficacy and tolerability of tacrine in nursing home residents with Alzheimer's dementia [letter] Woo JK, et al. **J Am Geriatr Soc** 1996 Nov;44(11):1411–2

Alzheimer's disease: an overview for the pharmacist. McGuffey EC. **J Am Pharm Assoc (Wash)** 1997 May–Jun; NS37(3):347–52 (28 ref.)

The use of survival analysis techniques in evaluating the effect of long–term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease. Smith F, et al. **J Biopharm Stat** 1996 Nov; 6(4):395–409

Mixed–model analysis of incomplete longitudinal data from a high–dose trial of tacrine (Cognex) in Alzheimer's patients. Smith F. **J Biopharm Stat** 1996 Mar;6(1):59–67

Analysis of repeated measurements with dropouts among Alzheimer's disease patients using summary measures and meta–analysis. Talwalker S. **J Biopharm Stat** 1996 Mar; 6(1):49–58

The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in Alzheimer's disease patients. Talwalker S. **J Biopharm Stat** 1996 Nov;6(4):443–56

New therapeutic approaches to Alzheimer's disease. Schneider LS. **J Clin Psychiatry** 1996;57 Suppl 14:30–6 (51 ref.)

Cognitive effects of flumazenil in patients with Alzheimer's disease. Ott BR, et al. **J Clin Psychopharmacol** 1996 Oct; 16(5):400–2

Gabapentin for behavioral agitation in Alzheimer's disease [letter] Regan WM, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):59–60

Selegiline and vitamin E in Alzheimer's disease. Adelman A. **J Fam Pract** 1997 Aug;45(2):98–100

Velnacrine for the treatment of Alzheimer's disease: a double–blind, placebo–controlled trial. The Mentane Study Group. Zemlan FP. **J Neural Transm** 1996; 103(8–9):1105–16

Influence of vitamin B12 on brain methionine adenosyltransferase activity in senile dementia of the Alzheimer's type. Gomes–Trolin C, et al. **J Neural Transm Gen Sect** 1996;103(7):861–72

Clinical findings with nimodipine in dementia: test of the calcium hypothesis. Fritze J, et al. **J Neural Transm Suppl** 1995;46:439–53 (87 ref.)

Protection against developmental retardation in apolipoprotein E–deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. Gozes I, et al. **J Neurobiol** 1997 Sep;33(3):329–42

Dementia and subnormal levels of vitamin B12: effects of replacement therapy on dementia. Teunisse S, et al. **J Neurol** 1996 Jul;243(7):522–9

Anticoagulant therapy for Alzheimer's disease [letter; comment] Walsh AC. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):361–2. Comment on: J Neuropsychiatry Clin Neurosci 1996 Spring;8(2):202–5.

From the Food and Drug Administration. Nightingale SL. **JAMA** 1997 Jan 1;277(1):10

Evaluating estrogen for Alzheimer disease poses ethical and logistical challenges [news] Skolnick AA. **JAMA** 1997 Jun 18;277(23):1831–3

Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy [news] Skolnick AA. **JAMA** 1997 Mar 12;277(10):776

From molecular structure to Alzheimer therapy. Giacobini E. **Jpn J Pharmacol** 1997 Jul;74(3):225–41 (87 ref.)

Long–term tacrine treatment in Alzheimer's disease [letter; comment] Farré M, et al. **Lancet** 1996 Oct 26; 348(9035):1181–2. Comment on: Lancet 1996 Jul 27;348(9022):275–6.

From mechanisms to drugs in Alzheimer's disease [news] Fricker J. **Lancet** 1997 Feb 15;349(9050):480

Issues in drug treatment for Alzheimer's disease [letter] Kellett JM. **Lancet** 1997 Sep 20;350(9081):887

Guidelines on drug treatments for Alzheimer's disease. Lovestone S, et al. **Lancet** 1997 Jul 26;350(9073):232–3

Issues in drug treatment for Alzheimer's disease [letter] Mackay AV. **Lancet** 1997 Sep 20;350(9081):887

Issues in drug treatment for Alzheimer's disease [letter] McShane R, et al. **Lancet** 1997 Sep 20;350(9081):886–7

APOE genotyping and response to drug treatment in Alzheimer's disease [letter] Richard F, et al. **Lancet** 1997 Feb 22;349(9051):539

Muscarinic agonists in Alzheimer's disease. Growdon JH. **Life Sci** 1997;60(13–14):993–8

Donepezil (Aricept) for Alzheimer's disease. **Med Lett Drugs Ther** 1997 Jun 6;39(1002):53–4

Pharmacoepidemiology of tacrine in Alzheimer's disease. Begaud B, et al. **Methods Find Exp Clin Pharmacol** 1996; 18 Suppl B:77–8

Alzheimer's disease: new pharmacological perspectives. Palacios JM. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:67–8

Methodological aspects in assessing antidementia drugs. Rascol O, et al. **Methods Find Exp Clin Pharmacol** 1996; 18 Suppl B:69–70

GDNF, a multispecific neurotrophic factor with potential therapeutic applications in neurodegenerative disorders [news] Arenas E. **Mol Psychiatry** 1996 Jul;1(3):179–82

Treatment of Alzheimer's disease -- searching for a breakthrough, settling for less [editorial; comment] Drachman DA, et al. **N Engl J Med** 1997 Apr 24; 336(17):1245–7. Comment on: N Engl J Med 1997 Apr 24;336(17):1216–22.

Alpha–tocopherol and Alzheimer's disease [letter; comment] Kilander L, et al. **N Engl J Med** 1997 Aug 21;337(8):572–3 . Comment on: N Engl J Med 1997 Apr 24;336(17):1216–22.

Alpha–tocopherol and Alzheimer's disease [letter; comment] Pincus MM. **N Engl J Med** 1997 Aug 21;337(8):572; discussion 573. Comment on: N Engl J Med 1997 Apr 24;336(17):1216–22.

A controlled trial of selegiline, alpha–tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study [see comments] Sano M, et al. **N Engl J Med** 1997 Apr 24;336(17):1216–22. Comment in: N Engl J Med 1997 Apr 24;336(17):1245–7. Comment in: N Engl J Med 1997 Aug 21;337(8):572; discussion 573. Comment in: N Engl J Med 1997 Aug 21;337(8):572–3.

Hope on the horizon for Alzheimer's patients. Berlin B. **N J Med** 1997 Jul;94(7):25–7

Rapid drug screening for Alzheimer's [news] Döbeli H. **Nat Biotechnol** 1997 Mar;15(3):223–4

Amyloid hypothesis of Alzheimer's rides high—for now [news] Schehr RS. **Nat Biotechnol** 1997 Jan;15(1):19–20

Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Breitner JC. **Neurobiol Aging** 1996 Sep–Oct;17(5):789–94 (93 ref.)

Inflammatory mechanisms and anti–inflammatory therapy in Alzheimer's disease [editorial] O'Banion MK, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):669–71 (38 ref.)

Metal cations defibrillize the amyloid beta–protein fibrils. Chauhan VP, et al. **Neurochem Res** 1997 Jul;22(7):805–9

The bridging concept: optimizing dose for phase II/III in Alzheimer's disease. Cutler NR, et al. **Neurodegeneration** 1996 Dec;5(4):511–4 (16 ref.)

Pyramidal neurone modulation: a therapeutic target for Alzheimer's disease. Francis PT. **Neurodegeneration** 1996 Dec;5(4):461–5 (31 ref.)

Current approaches to the treatment of Alzheimer's disease.

Wilcock GK. **Neurodegeneration** 1996 Dec;5(4):505–9 (24 ref.)

The search for disease-modifying treatment for Alzheimer's disease. Aisen PS, et al. **Neurology** 1997 May;48(5 Suppl 6):S35–41 (89 ref.)

The role of estrogen in the treatment of Alzheimer's disease. Birge SJ. **Neurology** 1997 May;48(5 Suppl 7):S36–41 (55 ref.)

Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Borson S, et al. **Neurology** 1997 May;48(5 Suppl 6):S17–24 (71 ref.)

NSAIDs and cognition in Alzheimer's disease [letter] Doraiswamy PM, et al. **Neurology** 1996 Apr;46(4):1194

Physostigmine and Alzheimer's disease [letter; comment] Gold M. **Neurology** 1997 Aug;49(2):642–3. Comment on: Neurology 1996 Dec;47(6):1389–95.

A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Thal LJ, et al. **Neurology** 1996 Sep;47(3):705–11

Tacrine and nursing home placement [letter] Thal LJ, et al. **Neurology** 1997 Sep;49(3):897–9

A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group [see comments] Thal LJ, et al. **Neurology** 1996 Dec; 47(6):1389–95. Comment in: Neurology 1997 Aug;49(2):642–3.

Therapeutic efficacy of vincamine in dementia. Fischhof PK, et al. **Neuropsychobiology** 1996;34(1):29–35

A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Weyer G, et al. **Neuropsychobiology** 1997;36(2):73–82

Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine positron emission tomography study. Parks RW, et al. **Neuropsychol Rev** 1996 Jun; 6(2):61–79 (79 ref.)

Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease. Raffaele KC, et al. **Neuropsychopharmacology** 1996 Aug;15(2):163–70

Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease. Riekkinen P Jr, et al. **Neuroreport** 1997 May 27;8(8):1845–9

Treating Alzheimer's disease.Pharmacologic options now and in the near future. Tariot PN, et al. **Postgrad Med** 1997 Jun;101(6):73–6, 81, 84 passim

New trends in cholinergic therapy for Alzheimer disease: nicotinic agonists or cholinesterase inhibitors? Giacobini E. **Prog Brain Res** 1996;109:311–23 (72 ref.)

Cholinomimetic treatment of Alzheimer's disease. Thal LJ. **Prog Brain Res** 1996;109:299–309 (86 ref.)

Inositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trial. Barak Y, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 May; 20(4):729–35

Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Henderson VW, et al. **Psychoneuroendocrinology** 1996 May;21(4):421–30

Lines of therapeutics research in Alzheimer's disease. Shvaloff A, et al. **Psychopharmacol Bull** 1996;32(3):343–52 (100 ref.)

The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease. van Dyck CH, et al. **Psychopharmacology (Berl)** 1997 Aug; 132(3):217–26

Cholinergic delirium and neurotoxicity associated with tacrine for Alzheimer's dementia. Trzepacz PT, et al. **Psychosomatics** 1996 May–Jun;37(3):299–301

Estrogen stakes claim to cognition [news] Wickelgren I. **Science** 1997 May 2;276(5313):675–8

Alzheimer's disease. Hier DB. **Surg Neurol** 1997 Jan; 47(1):84–5 (10 ref.)

Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease? Liberini P, et al. **Trends Pharmacol Sci** 1996 Apr; 17(4):155–60 (56 ref.)

[Alzheimer's disease: etiopathogenic mechanisms and development of new drugs] Wülfert E. **J Pharm Belg** 1997 Mar–Apr;52(2):97–8 **(Fre)**

[Pharma-clinics. Drug of the month. Tacrine (Cognex)] Scheen AJ. **Rev Med Liege** 1996 May;51(5):379–81 **(Fre)**

[Study methods of drugs in Alzheimer disease] Dubois B, et al. **Therapie** 1996 Jul–Aug;51(4):444–8 (Eng. Abstr.) **(Fre)**

[Pharmacotherapy of Alzheimer dementia: therapy of cognitive symptoms--new results of clinical studies] Heidrich A, et al. **Fortschr Neurol Psychiatr** 1997 Mar; 65(3):108–21 (180 ref.) (Eng. Abstr.) **(Ger)**

[Value of acetylcholine in the management of Alzheimer disease] **Nervenarzt** 1993 Dec;64(12 Suppl):1–8 **(Ger)**

[Therapy approaches in cerebral cognitive deficits--neuropsychiatric aspects] Reisecker F. **Wien Med Wochenschr** 1996;146(21–22):546–8 (Eng. Abstr.) **(Ger)**

[Effectiveness of brief infusions with Ginkgo biloba Special Extract EGb 761 in dementia of the vascular and Alzheimer type] Haase J, et al. **Z Gerontol Geriatr** 1996 Jul–Aug; 29(4):302–9 (Eng. Abstr.) **(Ger)**

[Case report of sodium valproate treatment of aggression associated with Alzheimer's disease] Takahashi M, et al. **No To Shinkei** 1996 Aug;48(8):757–60 (Eng. Abstr.) **(Jpn)**

[Should Alzheimer disease be treated with tacrine? Review of the literature (see comments)] Arsland D, et al. **Tidsskr Nor Laegeforen** 1996 Sep 30;116(23):2791–4 (34 ref.) (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1997 Feb 20;117(5):726. **(Nor)**

[Tacrine and "profitability" (letter; comment)] Nygaard HA. **Tidsskr Nor Laegeforen** 1997 Feb 20;117(5):726. Comment on: Tidsskr Nor Laegeforen 1996 Sep 30;116(23):2791–4. **(Nor)**

[Tacrine in Alzheimer's disease] López de Munain A. **Rev Neurol** 1997 Jul;25 Suppl 1:S70–2 (23 ref.) **(Spa)**

[Pharmacotherapeutical perspectives in Alzheimer's disease] Martínez-Lage JM. **Rev Neurol** 1997 Jul;25 Suppl 1:S63–9 (16 ref.) **(Spa)**

[Alzheimer disease and related conditions. Increased knowledge. New preparations are on the way] Basun H, et al. **Lakartidningen** 1996 Dec 11;93(50):4617–9 **(Swe)**

ECONOMICS

Cognitive function and the costs of Alzheimer disease. An exploratory study [see comments] Ernst RL, et al. **Arch Neurol** 1997 Jun;54(6):687–93. Comment in: Arch Neurol 1997 Jun;54(6):683.

Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Aronson SM. **Clin Ther** 1997 Jan–Feb;19(1):139–47; discussion 126–7

The economic impact of the tacrine in the treatment of Alzheimer's disease. Henke CJ, et al. **Clin Ther** 1997 Mar–Apr;19(2):330–45

"The Alzheimerization of aging": a response [letter; comment] Gilman S, et al. **Gerontologist** 1996 Feb;36(1):9–10. Comment on: Gerontologist 1995 Aug;35(4):526–32.

The economic burden of Alzheimer's disease in Israel. Rothstein Z, et al. **Isr J Med Sci** 1996 Nov;32(11):1120–3

Costs: measuring the economic burden of Alzheimer's disease care. **J Nurs Adm** 1997 Jan;27(1):4

ENZYMOLOGY

Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. Mimori Y, et al. **Behav Brain Res** 1997 Feb; 83(1–2):25–30

Reduction of plasma glutamyl aminopeptidase activity in sporadic Alzheimer's disease. Kuda T, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):526–30

Impaired G-protein-stimulated adenylyl cyclase activity in Alzheimer's disease brain is not accompanied by reduced cyclic-AMP-dependent protein kinase A activity. Bonkale WL, et al. **Brain Res** 1996 Oct 21;737(1–2):155–61

Quantitative cytochemistry of cytochrome oxidase and cellular morphometry of the human inferior colliculus in control and Alzheimer's patients. Gonzalez-Lima F, et al. **Brain Res** 1997 Mar 28;752(1–2):117–26

Transglutaminase activity is increased in Alzheimer's disease brain. Johnson GV, et al. **Brain Res** 1997 Mar 21; 751(2):323–9

Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology. Shiurba RA, et al. **Brain Res** 1996 Oct 21;737(1–2):119–32

Neuronal nitric oxide synthase (nNOS) mRNA expression and NADPH-diaphorase staining in the frontal cortex, visual cortex and hippocampus of control and Alzheimer's disease brains. Norris PJ, et al. **Brain Res Mol Brain Res** 1996 Sep 5;41(1–2):36–49

Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. Mantle D, et al. **Clin Chim Acta** 1996 May 30; 249(1–2):129–39

Tissue kallikrein-like immunoreactive material decorates neuritic plaques of Alzheimer patients. Bernstein HG. **Clin Neuropathol** 1997 Mar–Apr;16(2):69–71

The expression of creatine kinase isoenzymes in neocortex of patients with neurodegenerative disorders: Alzheimer's and Pick's disease. Aksenov MY, et al. **Exp Neurol** 1997 Aug;146(2):458–65

Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Tocco G, et al. **Exp Neurol** 1997 Apr;144(2):339–49

Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type--place of the extracellular glutathione peroxidase. Ceballos-Picot I, et al. **Free Radic Biol Med** 1996;20(4):579–87

Platelet monoamine oxidase molecular activity in demented patients. Bongioanni P, et al. **Ital J Neurol Sci** 1997 Jun; 18(3):151–6

Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. Imahori K, et al. **J Biochem (Tokyo)** 1997 Feb;121(2):179–88 (63 ref.)

Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. Little SP, et al. **J Biol Chem** 1997 Oct 3;272(40):25135–42

Cysteine proteinases are responsible for characteristic transketolase alterations in Alzheimer fibroblasts. Paoletti F, et al. **J Cell Physiol** 1997 Jul;172(1):63–8

Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. Vodovotz Y, et al. **J Exp Med** 1996 Oct 1;184(4):1425–33

Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease. Appelt DM, et al. **J Histochem Cytochem** 1996 Dec;44(12):1421–7

Matrix metalloproteinases in dog brains exhibiting Alzheimer-like characteristics. Lim GP, et al. **J Neurochem** 1997 Apr;68(4):1606–11

The antioxidant enzymatic blood profile in Alzheimer's and vascular diseases. Their association and a possible assay to differentiate demented subjects and controls. Famulari AL, et al. **J Neurol Sci** 1996 Sep 15;141(1–2):69–78

Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes. Ladner CJ, et al. **J Neuropathol Exp Neurol** 1996 Aug;55(8):924–31

Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. Pei JJ, et al. **J Neuropathol Exp Neurol** 1997 Jan;56(1):70–8

Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Iyo M, et al. **Lancet** 1997 Jun 21;349(9068):1805–9

The significance of the activity of CSF cholinesterases in dementias. Shen ZX. **Med Hypotheses** 1996 Nov; 47(5):363–76 (104 ref.)

Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. Baum L, et al. **Mol Chem Neuropathol** 1996 Oct–Dec;29(2–3):253–61

Aberrant expression of the constitutive endothelial nitric oxide synthase gene in Alzheimer disease. de la Monte SM, et al. **Mol Chem Neuropathol** 1997 Jan–Feb;30(1–2):139–59

Cortical cathepsin D activity and immunolocalization in Alzheimer disease, critical coronary artery disease, and aging. Haas U, et al. **Mol Chem Neuropathol** 1996 Sep; 29(1):1–14

Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease. Chang JW, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):801–8

Glycogen synthase kinase 3 alpha and 3 beta do not colocalize with neurofibrillary tangles. Harr SD, et al. **Neurobiol Aging** 1996 May–Jun;17(3):343–8

Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. Stephenson DT, et al. **Neurobiol Dis** 1996 Feb;3(1):51–63

Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Greenfield S. **Neurochem Int** 1996 May–Jun;28(5–6):485–90 (38 ref.)

Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Layer PG. **Neurochem Int** 1996 May–Jun;28(5–6):491–5 (28 ref.)

Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Small DH, et al. **Neurochem Int** 1996 May–Jun; 28(5–6):453–83 (399 ref.)

Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from patients with Alzheimer's disease. Molina JA, et al. **Neurology** 1997 Mar;48(3):636–8

Differential regulation of adenylyl cyclase in fibroblasts from sporadic and familial Alzheimer's disease cases with PS1 and APP mutations. Vestling M, et al. **Neuroreport** 1997 May 27;8(8):2031–5

Reduced immunoreactivity of adenylyl cyclase in dementia of the Alzheimer type. Yamamoto M, et al. **Neuroreport** 1996 Nov 25;7(18):2965–70

Decreased beta-adrenoceptor-stimulated adenylyl cyclase activity in lymphocytes from Alzheimer's disease patients. Garlind A, et al. **Neurosci Lett** 1997 Apr 18;226(1):37–40

Alteration of acylphosphatase levels in familial Alzheimer's disease fibroblasts with presenilin gene mutations. Liguri G, et al. **Neurosci Lett** 1996 Jun 7;210(3):153–6

Human brain beta-secretase contains heparan sulfate glycoconjugates. Matsumoto A, et al. **Neurosci Lett** 1996 Jun 21;211(2):105–8

[Relevance of metabolism of membrane phospholipids for Alzheimer dementia] Gattaz WF, et al. **Fortschr Neurol Psychiatr** 1996 Jan;64(1):8–12 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Apolipoprotein E allele frequencies in patients with late-onset sporadic Alzheimer's dementia in Hungary. Kálmán J, et al. **Acta Neurol Scand** 1997 Jan;95(1):56–9

Epidemiology of Alzheimer's disease and current possibilities for prevention. Fratiglioni L. **Acta Neurol Scand Suppl** 1996;165:33–40 (68 ref.)

Translation of clinical and neuropsychological instruments into French: the CERAD experience. Demers P, et al. **Age Ageing** 1994 Nov;23(6):449–51

Demographic and clinical features of Alzheimer disease in black Americans: preliminary observations on an outpatient sample in Atlanta, Georgia. Auchus AP. **Alzheimer Dis Assoc Disord** 1997 Mar;11(1):38–46

Methods of screening for dementia: a meta-analysis of studies comparing an informant questionnaire with a brief cognitive test. Jorm AF. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):158–62

Evidence for apolipoprotein E epsilon 4 association in early-onset Alzheimer's patients with late-onset relatives. Pérez-Tur J, et al. **Am J Med Genet** 1995 Dec 18; 60(6):550–3

Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Visser FE, et al. **Am J Ment Retard** 1997 Jan; 101(4):400–12

Low rate of Alzheimer's disease in Nigeria [letter; comment]

Mattes JA. **Am J Psychiatry** 1996 Dec;153(12):1654–5. Comment on: Am J Psychiatry 1995 Oct;152(10):1485–92.

Confirmation of an association between family history of affective disorder and the depressive syndrome in Alzheimer's disease. Strauss ME, et al. **Am J Psychiatry** 1996 Oct;153(10):1340–2

Risk of Alzheimer's disease among elderly patients with anemia: population–based investigations in Olmsted County, Minnesota. Beard CM, et al. **Ann Epidemiol** 1997 Apr;7(3):219–24

Age at onset and pattern of neuropsychological impairment in mild early–stage Alzheimer disease. A study of a community–based population. Reid W, et al. **Arch Neurol** 1996 Oct;53(10):1056–61

Mutational screening of APP gene in patients with early–onset Alzheimer disease utilizing mismatched PCR–RFLP. Nishiwaki Y, et al. **Clin Genet** 1996 Mar; 49(3):119–23

Diabetes mellitus and Álzheimer's disease [letter] Lithner F. **Diabetologia** 1996 Oct;39(10):1242

The PREMAP Study: prevalence and risk factors of dementia and clinically diagnosed Alzheimer's disease in Provence, France. Prevalence of Alzheimer's Disease in Provence. Obadia Y, et al. **Eur J Epidemiol** 1997 Apr; 13(3):247–53

Epidemiology of Alzheimer's disease. Hendrie HC. **Geriatrics** 1997 Sep;52 Suppl 2:S4–8

Aging and Alzheimer's disease: lessons from the Nun Study. Snowdon DA. **Gerontologist** 1997 Apr;37(2):150–6

A study of aggression among referrals to a community–based psychiatry of old age service. Gibbons P, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):384–8

Some contributions to the epidemiology of dementia and depression. Henderson AS, et al. **Int J Geriatr Psychiatry** 1997 Feb;12(2):145–54 (70 ref.)

A case–control study of smoking and Alzheimer's disease. Hillier V, et al. **Int J Geriatr Psychiatry** 1997 Mar; 12(3):295–300

Orthostatic hypotension and low blood pressure in organic dementia: a study of prevalence and related clinical characteristics. Passant U, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):395–403

Prevalence of dementia in a rural setting: A report from India [editorial] Rajkumar S, et al. **Int J Geriatr Psychiatry** 1997 Jul;12(7):702–7

An empirical test of telephone screening to identify potential dementia cases. Gatz M, et al. **Int Psychogeriatr** 1995 Fall; 7(3):429–38

A population–based study on the incidence of dementia disorders between 85 and 88 years of age [see comments] Aevarsson O, et al. **J Am Geriatr Soc** 1996 Dec; 44(12):1455–60. Comment in: J Am Geriatr Soc 1996 Dec;44(12):1482–3.

The epidemiology of dementia and Alzheimer's disease: an evolving field [editorial; comment] Evans DA. **J Am Geriatr Soc** 1996 Dec;44(12):1482–3. Comment on: J Am Geriatr Soc 1996 Dec;44(12):1455–60.

Apolipoprotein E genotype: utility in clinical practice in Alzheimer's disease [editorial; comment] Roses AD, et al. **J Am Geriatr Soc** 1996 Dec;44(12):1479–81. Comment on: J Am Geriatr Soc 1996 Dec;44(12):1469–71.

Referral bias in Alzheimer's disease [letter; comment] Barnhart RL, et al. **J Clin Epidemiol** 1997 Mar;50(3):365–6 . Comment on: J Clin Epidemiol 1996 Jan;49(1):79–83.

Use of surrogate respondents in studies of stroke and dementia. Weiss A, et al. **J Clin Epidemiol** 1996 Oct; 49(10):1187–94

Mini–Mental State Examination item scores as predictors of Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Small BJ, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):M299–304

The epidemiology of Alzheimer disease in intellectual disability: results and recommendations from an international conference. Zigman W, et al. **J Intellect Disabil Res** 1997 Feb;41 (Pt 1):76–80

Inhibition of beta–amyloid formation by haloperidol: a possible mechanism for reduced frequency of Alzheimer's disease pathology in schizophrenia. Higaki J, et al. **J Neurochem** 1997 Jan;68(1):333–6

Alzheimer's disease after remote head injury: an incidence study. Schofield PW, et al. **J Neurol Neurosurg Psychiatry** 1997 Feb;62(2):119–24

Alzheimer's disease then and now. Can we really explain the disparity in prevalence? Lewis JM. **N C Med J** 1996 May–Jun;57(3):158–9; discussion 159–60

Histamine H2 blocking drugs and the risk for Alzheimer's disease: the Rotterdam Study. Launer LJ, et al. **Neurobiol Aging** 1997 Mar–Apr;18(2):257–9

ApoE–4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Blacker D, et al. **Neurology** 1997 Jan; 48(1):139–47

Background and purpose of the Consortium to Establish a Registry for Alzheimer's Disease. Buckholtz N. **Neurology** 1997 Sep;49(3 Suppl 3):S1

Design and implementation of a longitudinal multicenter database. Edland SD, et al. **Neurology** 1997 Sep;49(3 Suppl 3):S17–9

Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Fratiglioni L, et al. Neurology 1997 Jan; 48(1):132–8

Gender and AD [letter; comment] Heun R, et al. **Neurology** 1996 Nov;47(5):1357–8. Comment on: Neurology 1996 Jan;46(1):126–9.

Alzheimer's disease and aluminum [letter; comment] Levallois P. **Neurology** 1997 Apr;48(4):1141–2. Comment on: Neurology 1996 Feb;46(2):401–5.

Arthritis and anti–inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies [see comments] McGeer PL, et al. **Neurology** 1996 Aug;47(2):425–32. Comment in: Neurology 1997 May;48(5):1473–4.

An association between head circumference and Alzheimer's disease in a population–based study of aging and dementia. Schofield PW, et al. **Neurology** 1997 Jul;49(1):30–7

Linking estrogen to Alzheimer's disease: an informatics approach. Smalheiser NR, et al. **Neurology** 1996 Sep; 47(3):809–10

Age, neurofibrillary changes, A beta–amyloid and the onset of Alzheimer's disease. Braak H, et al. **Neurosci Lett** 1996 May 31;210(2):87–90

[Risk factors of Alzheimer's disease. Epidemiologic approach] Alpérovitch A, et al. **Bull Acad Natl Med** 1996 Oct;180(7):1673–80; discussion 1680–5 (12 ref.) (Eng. Abstr.) **(Fre)**

[Role of Alzheimer's type dementia among dementias of the elderly] Petit H, et al. **Bull Acad Natl Med** 1996 Oct; 180(7):1715–25; discussion 1725–9 (Eng. Abstr.) **(Fre)**

[Social aspects of dementia] Haidinger G. **Wien Med Wochenschr** 1996;146(21–22):538–41 (Eng. Abstr.) **(Ger)**

[Genetic neuroepidemiology] Coria F, et al. **Neurologia** 1995 Dec;10 Suppl 1:50–5 (34 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Behavioral and psychological signs and symptoms of dementia: implications for research and treatment. Cross–cultural perspectives: India. Chandra V. **Int Psychogeriatr** 1996;8 Suppl 3:479–81; discussion 491–2

Cross–cultural perspectives: Caribbean, Native American, and Yoruba. Hendrie HC, et al. **Int Psychogeriatr** 1996;8 Suppl 3:483–6

Behavioral and psychological signs and symptoms of dementia: implications for research and treatment. Cross–cultural perspectives. Argentina. Mangone CA. **Int Psychogeriatr** 1996;8 Suppl 3:473–8; discussion 491–2

Cross–cultural perspectives: agitation in demented patients in the United States. Mintzer JE, et al. **Int Psychogeriatr** 1996;8 Suppl 3:487–90; discussion 491–2

ETIOLOGY

Occupational risk factors for Alzheimer disease: a case–control study. Gun RT, et al. **Alzheimer Dis Assoc Disord** 1997 Mar;11(1):21–7

Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. O'Meara ES, et al. **Am J Epidemiol** 1997 Sep 1;146(5):373–84

A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype. Payami H, et al. **Am J Hum Genet** 1997 Apr;60(4):948–56

Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Wilson DM, et al. **Am J Pathol** 1997 Jun;150(6):2181–95

Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1–40). Relevance to Alzheimer's disease. Aleshkov S, et al. **Biochemistry** 1997 Aug 26;36(34):10571–80

Blood pressure and dementia in the elderly: epidemiologic perspectives. Guo Z, et al. **Biomed Pharmacother** 1997; 51(2):68–73 (50 ref.)

Amyloid beta protein and Alzheimer disease. Square D. **Can Med Assoc J** 1997 Apr 1;156(7):1040–2

beta–Amyloid–associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Butterfield DA. **Chem Res Toxicol** 1997 May;10(5):495–506 (113 ref.)

Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal. Sayre LM, et al. **Chem Res Toxicol** 1997 May;10(5):518–26 (141 ref.)

Metabolism of amyloid proteins. Benson MD, et al. **Ciba Found Symp** 1996;199:104–13; discussion 113–8

Alzheimer's disease: genesis of amyloid. Beyreuther K, et al. **Ciba Found Symp** 1996;199:119–27; discussion 127–31

Apolipoprotein E and amyloidogenesis. Frangione B, et al. **Ciba Found Symp** 1996;199:132–41; discussion 141–5

Aluminium and Alzheimer's disease: review of possible pathogenic mechanisms. Armstrong RA, et al. **Dementia** 1996 Jan–Feb;7(1):1–9 (107 ref.)

Human apolipoprotein E: the Alzheimer's disease connection. Weisgraber KH, et al. **FASEB J** 1996 Nov;10(13):1485–94 (58 ref.)

Neuroautoimmunity: pathogenic implications for Alzheimer's disease. Singh VK. **Gerontology** 1997;43(1–2):79–94 (82 ref.)

Deleterious network: a testable pathogenetic concept of Alzheimer's disease. Ying W. **Gerontology** 1997; 43(4):242–53

Elevated blood pressure and Alzheimer's disease [editorial] Skoog I. **Hosp Pract (Off Ed)** 1997 Apr 15;32(4):13–4, 16, 21

Head injury and the risk of Alzheimer's disease: a case control study. Salib E, et al. **Int J Geriatr Psychiatry** 1997 Mar; 12(3):363–8

An etiological role of amyloidogenic carboxyl–terminal fragments of the beta–amyloid precursor protein in Alzheimer's disease. Suh YH. **J Neurochem** 1997 May; 68(5):1781–91 (121 ref.)

The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis [letter; comment] Larner AJ. **J Neuropathol Exp Neurol** 1997 Feb;56(2):214–5. Comment on: J Neuropathol Exp Neurol 1996 Oct;55(10):1023–5.

The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis [letter; comment] Rosenblum WI. **J Neuropathol Exp Neurol** 1997 Feb;56(2):213. Comment on: J Neuropathol Exp Neurol 1996 Oct;55(10):1023–5.

The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis [letter; comment] Smith MA, et al. **J Neuropathol Exp Neurol** 1997 Feb;56(2):217. Comment on: J Neuropathol Exp Neurol 1996 Oct;55(10):1023–5.

The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis [letter; comment] Swaab DF, et al. **J Neuropathol Exp Neurol** 1997 Feb;56(2):216. Comment on: J Neuropathol Exp Neurol 1996 Oct;55(10):1023–5.

Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study [see comments] Hofman A, et al. **Lancet** 1997 Jan 18; 349(9046):151–4. Comment in: Lancet 1997 Apr 19;349(9059):1174.

Herpes simplex virus and risk of Alzheimer's disease [letter; comment] Itabashi S, et al. **Lancet** 1997 Apr 12; 349(9058):1102. Comment on: Lancet 1997 Jan 25;349(9047):241–4.

Arteriosclerosis, apolipoprotein E, and Alzheimer's disease [letter; comment] Kalaria RN. **Lancet** 1997 Apr 19; 349(9059):1174. Comment on: Lancet 1997 Jan 18;349(9046):151–4.

Herpes simplex virus and risk of Alzheimer's disease [letter; comment] Latchman DS. **Lancet** 1997 Apr 12; 349(9058):1101; discussion 1101–2. Comment on: Lancet 1997 Jan 25;349(9047):241–4.

Alzheimer's disease risk factors as related to cerebral blood flow. Crawford JG. **Med Hypotheses** 1996 Apr; 46(4):367–77 (163 ref.)

Interleukin–1 beta: a common cause of Alzheimer's disease and diabetes mellitus. Holden RJ, et al. **Med Hypotheses** 1995 Dec;45(6):559–71 (108 ref.)

Alzheimer's disease, Kuf's disease, tellurium and selenium. Larner AJ. **Med Hypotheses** 1996 Aug;47(2):73–5

The possible role of peroxynitrite in Alzheimer's disease: a simple hypothesis that could be tested more thoroughly. Van Dyke K. **Med Hypotheses** 1997 May;48(5):375–80 (49 ref.)

Evidence that the precursor protein of non–A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random–coil. Kim J. **Mol Cells** 1997 Feb 28;7(1):78–83

Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Smith MA, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):41–8 (41 ref.)

Progress in understanding the pathogenesis of Alzheimer's disease [news; comment] Davis KL. **Mol Psychiatry** 1996 Mar;1(1):11–2. Comment on: Mol Psychiatry 1996 Mar;1(1):27–40.

Amyloid hypothesis of Alzheimer's rides high—for now [news] Schehr RS. **Nat Biotechnol** 1997 Jan;15(1):19–20

Alzheimer's disease. Tangle disentanglement [news; comment] Beyreuther K, et al. **Nature** 1996 Oct 10; 383(6600):476–7. Comment on: Nature 1996 Oct 10;383(6600):550–3.

The role of the Maillard reaction in other pathologies: Alzheimer's disease. Colaco CA, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:7–12 (51 ref.)

Sequence of deposition of heterogeneous amyloid beta–peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Lemere CA, et al. **Neurobiol Dis** 1996 Feb;3(1):16–32

Alzheimer's disease and history of blood transfusion by apolipoprotein–E genotype. O'Meara ES, et al. **Neuroepidemiology** 1997;16(2):86–93

Preclinical AD [letter; comment] Roberts HJ. **Neurology** 1997 Feb;48(2):549–50. Comment on: Neurology 1995 May;45(5):957–62. Comment on: Neurology 1996 Apr;46(4):1195.

EMFs and Alzheimer's disease [letter] Schulte PA, et al. **Neurology** 1997 Jul;49(1):312–3

Elevated risk of Alzheimer's disease among workers with likely electromagnetic field exposure. Sobel E, et al. **Neurology** 1996 Dec;47(6):1477–81

Electromagnetic field exposure may cause increased production of amyloid beta and eventually lead to Alzheimer's disease. Sobel E, et al. **Neurology** 1996 Dec; 47(6):1594–600

Genesis of Alzheimer's disease. Whitehouse PJ. **Neurology** 1997 May;48(5 Suppl 7):S2–7 (58 ref.)

The Alzheimer family of diseases: many etiologies, one pathogenesis? [comment] Hardy J. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2095–7 (21 ref.). Comment on: Proc Natl Acad Sci U S A 1997 Mar 4;94(5):2025–30.

Dissecting how presinilins function—and malfunction [news] Marx J. **Science** 1996 Dec 13;274(5294):1838–40

[Conclusions of the meeting on the theme of Alzheimer's disease] Serratrice G. **Bull Acad Natl Med** 1996 Oct; 180(7):1747–51 **(Fre)**

[Alzheimer's disease: etiopathogenic mechanisms and development of new drugs] Wülfert E. **J Pharm Belg** 1997 Mar–Apr;52(2):97–8 **(Fre)**

[Risk factors in Alzheimer's dementia] Aksari P, et al. **Fortschr Neurol Psychiatr** 1996 Nov;64(11):425–32 (94 ref.) (Eng. Abstr.) **(Ger)**

[LRP (alpha 2–macroglobulin receptor) and Alzheimer lesions] Akiyama H, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug;41(10):1470–5 (11 ref.) **(Jpn)**

[Apolipoprotein E and its receptors in Alzheimer's disease] Ikeda K. **Tanpakushitsu Kakusan Koso** 1996 Aug; 41(10):1465–9 (29 ref.) **(Jpn)**

[Molecular genetics of apolipoprotein E and its receptors, implications for genetic risk factors of Alzheimer's disease] Okuizumi K, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug; 41(10):1460–4 (20 ref.) **(Jpn)**

[APP, the causal gene for Alzheimer's disease] Tamaoka A, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug;41(10):1453–9 (35 ref.) **(Jpn)**

GENETICS

Presenilin–1 polymorphism in patients with Alzheimer's disease, vascular dementia and alcohol–associated dementia in Japanese population. Isoe K, et al. **Acta Neurol Scand** 1996 Nov;94(5):326–8

Apolipoprotein E allele frequencies in patients with late–onset sporadic Alzheimer's dementia in Hungary. Kálmán J, et al. **Acta Neurol Scand** 1997 Jan;95(1):56–9

Diagnosis of Alzheimer's disease: defining genetic profiles (genotype vs phenotype). Cacabelos R. **Acta Neurol Scand Suppl** 1996;165:72–84 (104 ref.)

Molecular genetics of Alzheimer's disease. Hardy J. **Acta Neurol Scand Suppl** 1996;165:13–7 (52 ref.)

Genetics of Alzheimer's disease. Lannfelt L. **Acta Neurol Scand Suppl** 1996;168:25–7 (33 ref.)

Issues in genetic testing for susceptibility to alcoholism: lessons from Alzheimer's disease and Huntington's disease. Quaid KA, et al. **Alcohol Clin Exp Res** 1996 Nov; 20(8):1430–7 (72 ref.)

Studies in a large family with late–onset Alzheimer disease (LOAD). Martin ES, et al. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):163–70

Familial Alzheimer disease: first report from India. Satishchandra P, et al. **Alzheimer Dis Assoc Disord** 1997 Jun;11(2):107–9

The use of genetic information in large–scale clinical trials: applications to Alzheimer research. Schork NJ, et al. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:22–6

The apolipoprotein E epsilon 4 allele is associated with increased behavioral disturbance in Alzheimer's disease [letter] Murphy GM Jr, et al. **Am J Geriatr Psychiatry** 1997 Winter;5(1):88–9

Molecular basis of Alzheimer's disease. Gooch MD, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1545–57; quiz 1603–4 (122 ref.)

Apolipoprotein E and Alzheimer disease: genotype–specific risks by age and sex. Bickeböller H, et al. **Am J Hum Genet** 1997 Feb;60(2):439–46

No association between the intronic presenilin–1 polymorphism and Alzheimer's disease in clinic and population–based samples. Cai X, et al. **Am J Med Genet** 1997 Apr 18;74(2):202–3

No interaction between the APOE and the alpha–1–antichymotrypsin genes on risk for Alzheimer's disease. Fallin D, et al. **Am J Med Genet** 1997 Apr 18; 74(2):192–4

S182 and STM2 gene missense mutations in sporadic Alzheimer disease [letter] Higuchi S, et al. **Am J Med Genet** 1996 Jul 26;67(4):429

Allelic association but only weak evidence for linkage to the apolipoprotein E locus in late–onset Swedish Alzheimer families. Liu L, et al. **Am J Med Genet** 1996 May 31; 67(3):306–11

Allele doses of apolipoprotein E type epsilon 4 in sporadic late–onset Alzheimer's disease. Lucotte G, et al. **Am J Med Genet** 1995 Dec 18;60(6):566–9

The use of apolipoprotein E genotype for preclinical detection of risk's group for Alzheimer's disease [letter] Oliveira JR, et al. **Am J Med Genet** 1997 Apr 18;74(2):216–7

Evidence for apolipoprotein E epsilon 4 association in early–onset Alzheimer's patients with late–onset relatives. Pérez–Tur J, et al. **Am J Med Genet** 1995 Dec 18; 60(6):550–3

Immunohistochemical detection of 4–hydroxy–2–nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Montine KS, et al. **Am J Pathol** 1997 Feb;150(2):437–43

Clinical genetics, IV. Alzheimer's disease: from gene to pathology. Jay G. **Am J Psychiatry** 1997 Oct;154(10):1359

No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. Murphy GM Jr, et al. **Am J Psychiatry** 1997 May;154(5):603–8

Images in neuroscience. Alzheimer's disease: from genes to pathogenesis. Selkoe DJ. **Am J Psychiatry** 1997 Sep; 154(9):1198

New insights into the genetics of Alzheimer's disease. Hardy J. **Ann Med** 1996 Jun;28(3):255–8 (38 ref.)

Apolipoprotein E genotyping in Alzheimer's disease. Chicago, Illinois, October 21–22, 1995. Proceedings. **Ann N Y Acad Sci** 1996 Dec 16;802:1–224

Polygenic determinants of Alzheimer's disease: modulation of the risk by alpha–1–antichymotrypsin. DeKosky ST, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:27–34

Just caring: the moral and economic costs of APOE genotyping for Alzheimer's disease. Fleck LM. **Ann N Y Acad Sci** 1996 Dec 16;802:128–38

No association between alpha 1–antichymotrypsin and familial Alzheimer's disease. Haines JL, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:35–41

Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. Hyman BT, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:1–5

Medicolegal, employment, and insurance issues in APOE genotyping and Alzheimer's disease. Kapp MB. **Ann N Y Acad Sci** 1996 Dec 16;802:139–48

A pilot experience in genetic counseling for Alzheimer's disease. Findings relevant to the potential use of APOE genotyping in cognitively impaired individuals. Karlinsky H, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:120–7

NIA/AIzA Conference on apolipoprotein E genotyping in Alzheimer's disease. Bibliography. Kwon YJ, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:177–224

Familial and population–based studies of apolipoprotein E and Alzheimer's disease. Mullan M, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:16–26

Predictive value of APOE genotyping in incipient Alzheimer's disease. Petersen RC, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:58–69

On not jumping the gun: ethical aspects of APOE gene testing for Alzheimer's disease. Post SG. **Ann N Y Acad Sci** 1996 Dec 16;802:111–9

The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease. Relkin NR, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:149–76

Apolipoprotein E and Alzheimer's disease. A rapidly expanding field with medical and epidemiological consequences. Roses AD. **Ann N Y Acad Sci** 1996 Dec 16;802:50–7

The effect of apolipoprotein E genotype on biochemical markers of Alzheimer's disease. Schenk D, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:92–100

Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer's disease. Tang MX, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:6–15

Wide range in age of onset for chromosome 1––related familial Alzheimer's disease. Bird TD, et al. **Ann Neurol** 1996 Dec;40(6):932–6

Early–onset Alzheimer's disease with a presenilin–1 mutation at the site corresponding to the Volga German presenilin–2 mutation. Crook R, et al. **Ann Neurol** 1997 Jul;42(1):124–8

Clinical correlates of apolipoprotein E in Alzheimer's disease [letter] Frisoni GB, et al. **Ann Neurol** 1996 Oct;40(4):688–9

A novel presenilin–1 mutation: increased beta–amyloid and neurofibrillary changes. Gómez–Isla T, et al. **Ann Neurol** 1997 Jun;41(6):809–13

The clinical phenotype of two missense mutations in the presenilin I gene in Japanese patients. Ikeda M, et al. **Ann Neurol** 1996 Dec;40(6):912–7

Presenilin–1 protein expression in familial and sporadic Alzheimer's disease. Levey AI, et al. **Ann Neurol** 1997 Jun; 41(6):742–53

Genetic factors in Alzheimer's disease: a review of recent advances. Levy–Lahad E, et al. **Ann Neurol** 1996 Dec; 40(6):829–40 (146 ref.)

Amyloid (Abeta) deposition in chromosome 1–linked Alzheimer's disease: the Volga German families. Mann DM, et al. **Ann Neurol** 1997 Jan;41(1):52–7

Apolipoprotein E and alpha1–antichymotrypsin polymorphism in Alzheimer's disease. Nacmias B, et al. **Ann Neurol** 1996 Oct;40(4):678–80

Apolipoprotein E epsilon2 does not increase risk of early–onset sporadic Alzheimer's disease. Scott WK, et al. **Ann Neurol** 1997 Sep;42(3):376–8

The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Stern Y, et al. **Ann Neurol** 1997 May;41(5):615–20

Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer's Disease. Welsh–Bohmer KA, et al. **Ann Neurol** 1997 Sep;42(3):319–25

alpha 1–Antichymotrypsin as a risk modifier for late–onset Alzheimer's disease in Japanese apolipoprotein E epsilon 4 allele carriers. Yoshiiwa A, et al. **Ann Neurol** 1997 Jul; 42(1):115–7

Apolipoprotein E and Alzheimer's disease. Strittmatter WJ, et al. **Annu Rev Neurosci** 1996;19:53–77 (90 ref.)

The role of heredity in late–onset Alzheimer disease and vascular dementia. A twin study. Bergem AL, et al. **Arch Gen Psychiatry** 1997 Mar;54(3):264–70

Cerebrospinal fluid levels of alpha–secretase–cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. Almkvist O, et al. **Arch Neurol** 1997 May;54(5):641–4

No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Corder EH, et al. **Arch Neurol** 1997 Mar; 54(3):273–7

Apolipoprotein E genotype and the rate of decline in probable Alzheimer disease [letter; comment] Corder EH, et al. **Arch Neurol** 1996 Nov;53(11):1094–5. Comment on: Arch Neurol 1996 Apr;53(4):345–50.

Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease [see comments] Dal Forno G, et al. **Arch Neurol** 1996 Apr;53(4):345–50. Comment in: Arch Neurol 1996 Nov;53(11):1094–5.

The validity of the family history method for identifying Alzheimer disease. Li G, et al. **Arch Neurol** 1997 May; 54(5):634–40

Genetic factors for the development of Alzheimer disease in the Cherokee Indian. Rosenberg RN, et al. **Arch Neurol** 1996 Oct;53(10):997–1000

D2 dopamine receptor A1 allele in Alzheimer disease and aging. Small GW, et al. **Arch Neurol** 1997 Mar;54(3):281–5

Apolipoprotein E genotyping in Alzheimer's disease in an Australian sample. Yang JG, et al. **Aust N Z J Med** 1996 Oct;26(5):658–61

Familial Alzheimer's disease–linked mutations at Val717 of amyloid precursor protein are specific for the increased secretion of A beta 42(43). Maruyama K, et al. **Biochem Biophys Res Commun** 1996 Oct 23;227(3):730–5

Alzheimer's disease–associated presenilins 1 and 2: accelerated amyloid fibril formation of mutant 410 Cys––>Tyr and 141 Asn––>Ile peptides. Maury CP, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):249–52

Sequence–specific interactions of minor groove binders with the 154 base pair HindIII–RsaI restriction fragment of cDNA of the human Tau 40 protein involved in pathology of Alzheimer's disease. Kittler L, et al. **Biochem Mol Biol Int** 1997 Jan;41(1):143–52

No association between apolipoprotein E genotype and late–onset depression in Alzheimer's disease. Cantillon M, et al. **Biol Psychiatry** 1997 Jan 15;41(2):246–8

The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles. Tsuang D, et al. **Biol Psychiatry** 1997 Jan 15;41(2):191–5

Alzheimer's disease in twins. Räihä I, et al. **Biomed Pharmacother** 1997;51(3):101–4 (32 ref.)

Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Fox NC, et al. **Brain** 1997 Mar;120 (Pt 3):491–501

Inherited neurodegenerative diseases and transgenic models. Price DL, et al. **Brain Pathol** 1996 Oct;6(4):467–80 (220 ref.)

Gene expression of ND4, a subunit of complex I of oxidative phosphorylation in mitochondria, is decreased in temporal cortex of brains of Alzheimer's disease patients. Fukuyama R, et al. **Brain Res** 1996 Mar 25;713(1–2):290–3

Abeta1–40 but not Abeta1–42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Ishii K, et al. **Brain Res** 1997 Feb 14; 748(1–2):250–2

Decreased expression of nuclear and mitochondrial DNA–encoded genes of oxidative phosphorylation in association neocortex in Alzheimer disease. Chandrasekaran K, et al. **Brain Res Mol Brain Res** 1997 Feb;44(1):99–104

Quantification of APP and APLP2 mRNA in APOE genotyped Alzheimer's disease brains. Johnston JA, et al. **Brain Res Mol Brain Res** 1996 Dec 31;43(1–2):85–95

Apolipoprotein E genotyping in patients with neurodegenerative diseases. Ballering LA, et al. **Clin Biochem** 1997 Jul;30(5):405–11

Familial Alzheimer's disease co–segregates with a Met146Ile substitution in presenilin–1. Jørgensen P, et al. **Clin Genet** 1996 Nov;50(5):281–6

Mutational screening of APP gene in patients with early–onset Alzheimer disease utilizing mismatched PCR–RFLP. Nishiwaki Y, et al. **Clin Genet** 1996 Mar; 49(3):119–23

The underlying molecular mechanism of apolipoprotein E polymorphism: relationships to lipid disorders, cardiovascular disease, and Alzheimer's disease. Contois JH, et al. **Clin Lab Med** 1996 Mar;16(1):105–23 (109 ref.)

The role of presenilin 1 in the genetics of Alzheimer's disease. Clark RF, et al. **Cold Spring Harb Symp Quant Biol** 1996; 61:551–8

Cell biology of the beta–amyloid precursor protein and the genetics of Alzheimer's disease. Selkoe DJ. **Cold Spring Harb Symp Quant Biol** 1996;61:587–96 (100 ref.)

Two homologous genes causing early–onset familial Alzheimer's disease. Sr George–Hyslop PH, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:559–64

Protein: protein interactions in Alzheimer's disease and the CAG triplet repeat diseases. Strittmatter WJ, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:597–605 (73 ref.)

Evolution of senescence: Alzheimer's disease and evolution. Charlesworth B. **Curr Biol** 1996 Jan 1;6(1):20–2 (14 ref.)

Strategies to alter the progression of Alzheimer's disease. Siman R, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):601–7 (49 ref.)

The Alzheimer diseases. Roses AD. **Curr Opin Neurobiol** 1996 Oct;6(5):644–50 (48 ref.)

Neurotoxicity of beta–amyloid and prion peptides. Forloni G. **Curr Opin Neurol** 1996 Dec;9(6):492–500 (111 ref.)

Presenile because of presenilin: the presenilin genes and early onset Alzheimer's disease. Haass C. **Curr Opin Neurol** 1996 Aug;9(4):254–9 (39 ref.)

ALZHEIMER'S DISEASE

Apolipoprotein E in neurology. Roses AD. **Curr Opin Neurol** 1996 Aug;9(4):265–70 (63 ref.)

Apolipoprotein-E genotyping in Alzheimer's disease and frontotemporal dementia. Gustafson L, et al. **Dement Geriatr Cogn Disord** 1997 Jul–Aug;8(4):240–3

Screening for mutation of the presenilin 2 gene in Alzheimer's disease [letter] Isoe K, et al. **Dement Geriatr Cogn Disord** 1997 Jan–Feb;8(1):60

The gain of apolipoprotein E genotyping to separate patients with Alzheimer's disease from normal individuals: relevance to community studies. Frisoni GB, et al. **Dementia** 1996 Nov–Dec;7(6):336–42

Apolipoprotein E and Alzheimer's disease: strength of association is related to age at onset. Murman DL, et al. **Dementia** 1996 Sep–Oct;7(5):251–5

G protein betagamma complex-mediated apoptosis by familial Alzheimer's disease mutant of APP. Giambarella U, et al. **EMBO J** 1997 Aug 15;16(16):4897–907

Association of the epsilon 4 allele of apolipoprotein E with poor performance on a dementia screen in African Americans. Hui SL, et al. **Ethn Dis** 1996 Autumn; 6(3–4):266–71

Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease. Boissiere F, et al. **Exp Neurol** 1997 May;145(1):245–52

Presenilin-1 polymorphism in Alzheimer's disease and vascular dementia. Matsushita S, et al. **Exp Neurol** 1997 Aug;146(2):567–9

Possible mechanism for resistance to Alzheimer's disease (AD) in mice suggests a new approach to generate a mouse model for sporadic AD and may explain familial resistance to AD in man. Volloch V. **Exp Neurol** 1997 Mar; 144(1):214–8 (39 ref.)

Gene expression of Alzheimer-associated presenilin-2 in the frontal cortex of Alzheimer and aged control brain. Deng G, et al. **FEBS Lett** 1996 Sep 23;394(1):17–20

Potential CRE suppression by familial Alzheimer's mutants of APP independent of adenylyl cyclase regulation. Giambarella U, et al. **FEBS Lett** 1997 Jul 21;412(1):97–101

A beta-amyloid peptide variant related with familial Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis is poorly eliminated by cathepsin D. Hamazaki H. **FEBS Lett** 1996 Nov 18;397(2–3):313–5

Quantification of presenilin-1 mRNA in Alzheimer's disease brains. Johnston JA, et al. **FEBS Lett** 1996 Oct 7; 394(3):279–84

Alzheimer's disease: phenotypes and genotypes. Sorbi S, et al. **Funct Neurol** 1997 May–Aug;12(3–4):147–51 (13 ref.)

No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Fallin D, et al. **Genet Epidemiol** 1997;14(3):299–305

Gender-specific nonrandom association between the alpha 1-antichymotrypsin and apolipoprotein E polymorphisms in the general population and its implication for the risk of Alzheimer's disease. Kamboh MI, et al. **Genet Epidemiol** 1997;14(2):169–80

Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease. Li G, et al. **Genet Epidemiol** 1996; 13(3):285–98

No association or linkage between an intronic polymorphism of presenilin-1 and sporadic or late-onset familial Alzheimer disease. Scott WK, et al. **Genet Epidemiol** 1997; 14(3):307–15

Re: Genetic effect of alpha 1-antichymotrypsin on the risk of Alzheimer disease [letter; comment] Kamboh MI, et al. **Genomics** 1997 Mar 1;40(2):382–5. Comment on: Genomics 1996 Apr 1;33(1):53–6.

Genomic structure and expression of STM2, the chromosome 1 familial Alzheimer disease gene. Levy-Lahad E, et al. **Genomics** 1996 Jun 1;34(2):198–204

Analysis of the 5' sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease. Rogaev EI, et al. **Genomics** 1997 Mar 15;40(3):415–24

Molecular genetics of Alzheimer's disease. Goate AM. **Geriatrics** 1997 Sep;52 Suppl 2:S9–12 (11 ref.)

Genetic association study between senile dementia of Alzheimer's type and APOE/C1/C2 gene cluster. Kamino K, et al. **Gerontology** 1996;42 Suppl 1:12–9

Helping Alzheimer's research [letter] **Hosp Pract (Off Ed)** 1996 Oct 15;31(10):40, 42

The genetics of aging. Martin GM. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):47–50, 55–6, 59–61 passim (8 ref.)

Alzheimer's disease: the genetics of risk. Roses AD. **Hosp Pract (Off Ed)** 1997 Jul 15;32(7):51–5, 58–63, 67–9 (9 ref.)

Exits from the maze of apoptosis? Kass GE. **Hum Exp Toxicol** 1996 Aug;15(8):694–5

Microsatellite polymorphism in the human heme oxygenase-1 gene promoter and its application in association studies with Alzheimer and Parkinson disease. Kimpara T, et al. **Hum Genet** 1997 Jul;100(1):145–7

Association between the PI*M3 allele of alpha 1-antitrypsin and Alzheimer's disease? A preliminary report. Kowalska A, et al. **Hum Genet** 1996 Dec;98(6):744–6

Microsatellite polymorphism of the alpha 1-antichymotrypsin gene locus associated with sporadic Alzheimer's disease. Morgan K, et al. **Hum Genet** 1997 Jan;99(1):27–31

A novel mutation of presenilin 1 in familial Alzheimer's disease in Israel detected by denaturing gradient gel electrophoresis. Reznik-Wolf H, et al. **Hum Genet** 1996 Dec;98(6):700–2

Distribution of apolipoprotein E gene polymorphisms in Japanese patients with Alzheimer's disease and in Japanese centenarians. Yamagata Z, et al. **Hum Hered** 1997 Jan–Feb; 47(1):22–6

The presenilins and Alzheimer's disease. Hutton M, et al. **Hum Mol Genet** 1997;6(10):1639–46 (70 ref.)

Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Sherrington R, et al. **Hum Mol Genet** 1996 Jul;5(7):985–8

Apolipoprotein E and the cost of Alzheimer's disease [letter] Frisoni GB, et al. **Int J Geriatr Psychiatry** 1997 May; 12(5):588–9

Apolipoprotein E genotypes and serum lipid levels in Alzheimer's disease and multi-infarct dementia. Wieringa GE, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):359–62

Self-reports of memory problems in relatives of patients with probable Alzheimer's disease. McPherson S, et al. **Int Psychogeriatr** 1995 Fall;7(3):367–76

Mutational and susceptibility genetics are different clinical paradigms [editorial] Roses AD. **Int Psychogeriatr** 1997 Mar;9(1):7–10 (11 ref.)

Apolipoprotein E genotype: utility in clinical practice in Alzheimer's disease [see comments] Hyman BT. **J Am Geriatr Soc** 1996 Dec;44(12):1469–71. Comment in: J Am Geriatr Soc 1996 Dec;44(12):1479–81.

APOE4 testing for Alzheimer's disease [letter] Karlawish JH, et al. **J Am Geriatr Soc** 1997 Sep;45(9):1153–4

Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions [see comments] Plassman BL, et al. **J Am Geriatr Soc** 1996 Oct;44(10):1242–50 (150 ref.). Comment in: J Am Geriatr Soc 1996 Oct;44(10):1261–2.

Neuronal expression of beta-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid beta and cytoplasmic domains. McPhie DL, et al. **J Biol Chem** 1997 Oct 3;272(40):24743–6

Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence. Reaume AG, et al. **J Biol Chem** 1996 Sep 20;271(38):23380–8

Requirement of the familial Alzheimer's disease gene PS2 for apoptosis. Opposing effect of ALG-3. Vito P, et al. **J Biol Chem** 1996 Dec 6;271(49):31025–8

Interaction of the phosphotyrosine interaction/phosphotyrosine binding-related domains of Fe65 with wild-type and mutant Alzheimer's beta-amyloid precursor proteins. Zambrano N, et al. **J Biol Chem** 1997 Mar 7;272(10):6399–405

Apolipoprotein E in Alzheimer's disease risk and case detection: a case-control study. Kukull WA, et al. **J Clin Epidemiol** 1996 Oct;49(10):1143–8

Neurobiology of Alzheimer's disease. Peskind ER. **J Clin Psychiatry** 1996;57 Suppl 14:5–8 (53 ref.)

Genetics of Alzheimer's disease. Tsuang MT, et al. **J Formos Med Assoc** 1996 Oct;95(10):733–40 (69 ref.)

Interfamilial and intrafamilial phenotypic heterogeneity in familial Alzheimer's disease. Lopez-Alberola RF, et al. **J Geriatr Psychiatry Neurol** 1997 Jan;10(1):1–6

Heritability for Alzheimer's disease: the study of dementia in Swedish twins. Gatz M, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar;52(2):M117–25

Apolipoprotein E genotype does not affect age at onset in patients with chromosome 14 encoded Alzheimer's disease [letter] **J Med Genet** 1996 Feb;33(2):174–5

No founder effect in three novel Alzheimer's disease families with APP 717 Val-->Ile mutation. Clerget-darpoux. French Alzheimer's Disease Study Group. Campion D, et al. **J Med Genet** 1996 Aug;33(8):661–4

Alzheimer's disease, blood lipids, and heart disease: what are the interrelationships? [comment] Luft FC. **J Mol Med** 1997 Feb;75(2):73–4. Comment on: J Mol Med 1997 Feb;75(2):130–8.

Alpha 1-antichymotrypsin gene polymorphism and risk for Alzheimer's disease. Muramatsu T, et al. **J Neural Transm** 1996;103(10):1205–10

Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias. Morris CM, et al. **J Neural Transm Suppl** 1996;47:205–18

Defective neurite extension is caused by a mutation in amyloid beta/A4 (A beta) protein precursor found in familial Alzheimer's disease. Li HL, et al. **J Neurobiol** 1997 May;32(5):469–80

Identification of heparin-binding domains in the amyloid precursor protein of Alzheimer's disease by deletion mutagenesis and peptide mapping. Clarris HJ, et al. **J Neurochem** 1997 Mar;68(3):1164–72

Molecular evolution of tau protein: implications for Alzheimer's disease. Nelson PT, et al. **J Neurochem** 1996 Oct;67(4):1622–32

Expression of Bcl-2 in adult human brain regions with special reference to neurodegenerative disorders. Vyas S, et al. **J Neurochem** 1997 Jul;69(1):223–31

Apolipoprotein E genotype and concomitant clinical features in early-onset Alzheimer's disease. Bronzova J, et al. **J Neurol** 1996 Jun;243(6):465–8

Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups. Kurz A, et al. **J Neurol** 1996 Jun;243(6):452–6

Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease [letter] Ballard C, et al. **J Neurol Neurosurg Psychiatry** 1997 Aug; 63(2):273–4

No effect of the alpha1-antichymotrypsin A allele in Alzheimer's disease. Didierjean O, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):103–5

Clinical rationale of genetic testing in dementia [editorial] Frisoni GB, et al. **J Neurol Neurosurg Psychiatry** 1997 Mar; 62(3):217–21

Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. Holmes C, et al. **J Neurol Neurosurg Psychiatry** 1996 Dec;61(6):580–3

Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence. Jelic V, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):59–65

Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val-->Ile) mutation cases: a morphometric investigation. Fukutani Y, et al. **J Neurol Sci** 1997 Aug;149(2):177–84

DNA damage distribution in the human brain as shown by in situ end labeling; area-specific differences in aging and Alzheimer disease in the absence of apoptotic morphology. Lucassen PJ, et al. **J Neuropathol Exp Neurol** 1997 Aug; 56(8):887–900

Depression, delusions, and hallucinations in Alzheimer's disease: no relationship to apolipoprotein E genotype. Lyketsos CG, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter;9(1):64–7

Apo-E genotype and verbal deficits in Alzheimer's disease. Rasmusson DX, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):335–7

DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. Anderson AJ, et al. **J Neurosci** 1996 Mar 1;16(5):1710–9

Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons [see comments] Evans DA, et al. **JAMA** 1997 Mar 12; 277(10):822–4. Comment in: ACP J Club 1997 Sep-Oct;127(2):49.

Exploring the etiology of Alzheimer disease using molecular genetics. Lendon CL, et al. **JAMA** 1997 Mar 12; 277(10):825–31 (130 ref.)

Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. Lopera F, et al. **JAMA** 1997 Mar 12;277(10):793–9

Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12 [see comments] Pericak-Vance MA, et al. **JAMA** 1997 Oct 15; 278(15):1237–41. Comment in: JAMA 1997 Oct 15;278(15):1282–3.

The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. Post SG, et al. **JAMA** 1997 Mar 12;277(10):832–6 (75 ref.)

Molecular neurogenetics: the genome is settling the issue [editorial; comment] Rosenberg RN. **JAMA** 1997 Oct 15; 278(15):1282–3. Comment on: JAMA 1997 Oct 15;278(15):1237–41. Comment on: JAMA 1997 Oct 15;278(15):1256–61.

Researchers find evidence of a new gene for late-onset Alzheimer disease [news] Stephenson J. **JAMA** 1997 Mar 12;277(10):775

Genetic testing for Alzheimer disease [letter] Tracy KB. **JAMA** 1997 Sep 24;278(12):978–9

APOE epsilon 4 allele in Alzheimer's and non-Alzheimer's dementias [letter; comment] Itabashi S, et al. **Lancet** 1996 Oct 5;348(9032):960–1. Comment on: Lancet 1996 Jul 13;348(9020):90–3.

Alzheimer's disease and apolipoprotein E epsilon 4 allele in older drivers who died in automobile accidents [letter] Johansson K, et al. **Lancet** 1997 Apr 19;349(9059):1143–4

Presenilin polymorphisms in Alzheimer's disease [letter] Korovaitseva GI, et al. **Lancet** 1997 Sep 27;350(9082):959

Allen Roses:"enfant terrible" of Alzheimer's research [news] Larkin M. **Lancet** 1997 May 3;349(9061):1302

Characteristics of Alzheimer's disease patients with and without ApoE4 allele [letter] Ritchie K, et al. **Lancet** 1996 Oct 5;348(9032):960

Presenilin polymorphisms in Alzheimer's disease [letter] Singleton AB, et al. **Lancet** 1997 Sep 27;350(9082):958–9

Telomere shortening, ageing, and chromosome damage. Kormann-Bortolotto MH, et al. **Mech Ageing Dev** 1996 Jul 31;89(1):45–9

APOE-related frequency of cognitive and noncognitive symptoms in dementia. Cacabelos R, et al. **Methods Find Exp Clin Pharmacol** 1996 Dec;18(10):693–706

Neurotropic viruses and Alzheimer disease. Interaction of herpes simplex type 1 virus and apolipoprotein E in the etiology of the disease. Lin WR, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):135–41

Unraveling the molecular pathway of Alzheimer's disease: research about presenilins gathers momentum. Sandbrink R, et al. **Mol Psychiatry** 1996 Dec;1(6):438–44 (54 ref.)

Genes contributing to Alzheimer's disease [see comments] Sandbrink R, et al. **Mol Psychiatry** 1996 Mar;1(1):27–40 (129 ref.). Comment in: Mol Psychiatry 1996 Mar;1(1):11–2.

Dog from hell chases Alzheimer's [news] Brower V.

Nat Biotechnol 1997 Apr;15(4):311

alpha–Synuclein––a link between Parkinson and Alzheimer diseases? [news] Heintz N, et al. **Nat Genet** 1997 Aug; 16(4):325–7

Mutant presenilins of Alzheimer's disease increase production of 42–residue amyloid beta–protein in both transfected cells and transgenic mice [see comments] Citron M, et al. **Nat Med** 1997 Jan;3(1):67–72. Comment in: Nat Med 1997 Jan;3(1):28–9.

Presenilins, amyloid–beta and Alzheimer's disease [news; comment] Lamb BT. **Nat Med** 1997 Jan;3(1):28–9. Comment on: Nat Med 1997 Jan;3(1):67–72.

The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Lemere CA, et al. **Nat Med** 1996 Oct; 2(10):1146–50

Formation of stable complexes between two Alzheimer's disease gene products: presenilin–2 and beta–amyloid precursor protein. Weidemann A, et al. **Nat Med** 1997 Mar; 3(3):328–32

Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains. Pirttilä T, et al. **Neurobiol Aging** 1997 Jan–Feb;18(1):121–7

APP gene family: unique age–associated changes in splicing of Alzheimer's betaA4–amyloid protein precursor. Sandbrink R, et al. **Neurobiol Dis** 1994 Nov;1(1–2):13–24

The gene defects responsible for familial Alzheimer's disease. Tanzi RE, et al. **Neurobiol Dis** 1996;3(3):159–68 (80 ref.)

Topographic associations between DNA fragmentation and Alzheimer's disease neuropathology in the hippocampus. Sugaya K, et al. **Neurochem Int** 1997 Aug;31(2):275–81

Alteration in brain presenilin 1 mRNA expression in early onset familial Alzheimer's disease. Barton AJ, et al. **Neurodegeneration** 1996 Sep;5(3):213–8

A further presenilin 1 mutation in the exon 8 cluster in familial Alzheimer's disease. Perez–Tur J, et al. **Neurodegeneration** 1996 Sep;5(3):207–12

Clinical features of sporadic and familial Alzheimer's disease. Rossor MN, et al. **Neurodegeneration** 1996 Dec;5(4):393–7 (40 ref.)

A presenilin–1 mutation in a Japanese family with Alzheimer's disease and distinctive abnormalities on cranial MRI. Aoki M, et al. **Neurology** 1997 Apr;48(4):1118–20

The 5–repeat allele in the very–low–density lipoprotein receptor gene polymorphism is not increased in sporadic Alzheimer's disease in Japanese. Arinami T, et al. **Neurology** 1996 Nov;47(5):1349–50

ApoE epsilon 4 allele and cognitive decline in patients with Alzheimer's disease [see comments] Asada T, et al. **Neurology** 1996 Aug;47(2):603. Comment in: Neurology 1996 Aug;47(2):317–20.

Chromosome 17 and hereditary dementia: linkage studies in three non–Alzheimer families and kindreds with late–onset FAD. Bird TD, et al. **Neurology** 1997 Apr;48(4):949–54

Alzheimer's disease: clinical implications of the apolipoprotein E genotype. Farlow MR. **Neurology** 1997 May;48(5 Suppl 6):S30–4 (46 ref.)

Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease [see comments] Growdon JH, et al. **Neurology** 1996 Aug;47(2):444–8. Comment in: Neurology 1996 Aug;47(2):317–20.

Genetic association of the low–density lipoprotein receptor–related protein gene (LRP), an apolipoprotein E receptor, with late–onset Alzheimer's disease. Kang DE, et al. **Neurology** 1997 Jul;49(1):56–61

The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid–beta protein ending at A beta42(43). Kosaka T, et al. **Neurology** 1997 Mar; 48(3):741–5

Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease [see comments] Kurz A, et al. **Neurology** 1996 Aug; 47(2):440–3. Comment in: Neurology 1996 Aug;47(2):317–20.

The apolipoprotein E epsilon 4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Lopez OL, et al. **Neurology** 1997 Sep; 49(3):794–7

Lack of overlap in genetic risks for Alzheimer's disease and Parkinson's disease. Mickel SF, et al. **Neurology** 1997 Apr; 48(4):942–9

Lack of association between alpha 1–antichymotrypsin polymorphism, Alzheimer's disease, and allele epsilon 4 of apolipoprotein E. Müller U, et al. **Neurology** 1996 Dec; 47(6):1575–7

No association between the alpha 1–antichymotrypsin A allele and Alzheimer's disease. Murphy GM Jr, et al. **Neurology** 1997 May;48(5):1313–6

The impact of apolipoprotein E4 on cause of death in Alzheimer's disease. Olichney JM, et al. **Neurology** 1997 Jul;49(1):76–81

Evidence for association of HLA–A2 allele with onset age of Alzheimer's disease. Payami H, et al. **Neurology** 1997 Aug;49(2):512–8

Apolipoprotein E and cognitive decline in Alzheimer's disease [editorial; comment] Plassman BL, et al. **Neurology** 1996 Aug;47(2):317–20. Comment on: Neurology 1996 Aug;47(2):440–3. Comment on: Neurology 1996 Aug;47(2):444–8. Comment on: Neurology 1996 Aug;47(2):603.

Familial Alzheimer's disease–linked presenilin 1 variants elevate Abeta1–42/1–40 ratio in vitro and in vivo. Borchelt DR, et al. **Neuron** 1996 Nov;17(5):1005–13

Presenilins: genes for life and death. Haass C. **Neuron** 1997 May;18(5):687–90 (26 ref.)

Pupil dilatation assay by tropicamide is modulated by apolipoprotein E epsilon 4 allele dosage in Alzheimer's disease. Arai H, et al. **Neuroreport** 1996 Mar 22;7(4):918–20

A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29 years. Campion D, et al. **Neuroreport** 1996 Jul 8;7(10):1582–4

HLA–DR antigens associated with major genetic risk for late–onset Alzheimer's disease. Curran M, et al. **Neuroreport** 1997 Apr 14;8(6):1467–9

Alzheimer's PS–1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta–peptide. Guo Q, et al. **Neuroreport** 1996 Dec 20; 8(1):379–83

Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and alpha1–antichymotrypsin type A allele in Alzheimer's disease. Higuchi M, et al. **Neuroreport** 1997 Aug 18; 8(12):2639–43

Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease. Hutton M, et al. **Neuroreport** 1996 Feb 29;7(3):801–5

Association between a PS–1 intronic polymorphism and late onset Alzheimer's disease. Kehoe P, et al. **Neuroreport** 1996 Sep 2;7(13):2155–8

Two novel (M233T and R278T) presenilin–1 mutations in early–onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin–1 mutations with a novel phenotype. Kwok JB, et al. **Neuroreport** 1997 Apr 14;8(6):1537–42

Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimer's disease. Li T, et al. **Neuroreport** 1997 Feb 10; 8(3):683–6

The intracellular fate of apolipoprotein E is tau dependent and apoe allele–specific. Lovestone S, et al. **Neuroreport** 1996 Apr 10;7(5):1005–8

A presenilin 1 mutation in an early onset Alzheimer's family: no association with presenilin 2. Poduslo SE, et al. **Neuroreport** 1996 Aug 12;7(12):2018–20

Presenilins and early–onset familial Alzheimer's disease. Rohan de Silva HA, et al. **Neuroreport** 1997 May 27; 8(8):i–xii (145 ref.)

Polymorphism in AACT gene may lower age of onset of Alzheimer's disease. Talbot C, et al. **Neuroreport** 1996 Jan 31;7(2):534–6

Differential regulation of adenylyl cyclase in fibroblasts from sporadic and familial Alzheimer's disease cases with PS1 and APP mutations. Vestling M, et al. **Neuroreport** 1997 May 27;8(8):2031–5

Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow–up. Blomberg M, et al. **Neurosci Lett** 1996 Aug 23;214(2–3):163–6

Association of the apolipoprotein A–IV codon 360 mutation in patients with Alzheimer's disease. Császár A, et al. **Neurosci Lett** 1997 Jul 25;230(3):151–4

The genotype 2/2 of the presenilin–1 polymorphism is decreased in Spanish early–onset Alzheimer's disease. Ezquerra M, et al. **Neurosci Lett** 1997 May 23;227(3):201–4

Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer's disease. Fukutani Y, et al. **Neurosci Lett** 1996 Aug 16;214(1):33–6

Further evidence for an association between a mutation in the APP gene and Lewy body formation. Halliday G, et al. **Neurosci Lett** 1997 May 9;227(1):49–52

Interleukin–6 is not altered in cerebrospinal fluid of first–degree relatives and patients with Alzheimer's disease. Hampel H, et al. **Neurosci Lett** 1997 Jun 13;228(3):143–6

Screening for amyloid beta precursor protein codon 665, 670/671 and 717 mutations in Finnish patients with Alzheimer's disease. Helisalmi S, et al. **Neurosci Lett** 1996 Feb 16;205(1):68–70

No association between alpha1–antichymotrypsin polymorphism, apolipoprotein E and patients with late–onset Alzheimer's disease. Helisalmi S, et al. **Neurosci Lett** 1997 Aug 1;231(1):56–8

Mutation analysis of chromosome 19 calmodulin (CALM3) gene in Alzheimer's disease patients. Ibarreta D, et al. **Neurosci Lett** 1997 Jul 4;229(3):157–60

Tau phosphorylation in cells transfected with wild–type or an Alzheimer's disease mutant Presenilin 1. Irving NG, et al. **Neurosci Lett** 1997 Jan 31;222(2):71–4

Increased A beta 42(43)–plaque deposition in early–onset familial Alzheimer's disease brains with the deletion of exon 9 and the missense point mutation (H163R) in the PS–1 gene. Ishii K, et al. **Neurosci Lett** 1997 May 30;228(1):17–20

Three different mutations of presenilin 1 gene in early–onset Alzheimer's disease families. Kamino K, et al. **Neurosci Lett** 1996 Apr 26;208(3):195–8

Embryonic genes expressed in Alzheimer's disease brains. Kondo T, et al. **Neurosci Lett** 1996 May 17;209(3):157–60

A polymorphism in the presenilin 1 gene does not modify risk for Alzheimer's disease in a cohort with sporadic early onset. Lendon CL, et al. **Neurosci Lett** 1997 Jun 13; 228(3):212–4

Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Lendon CL, et al. **Neurosci Lett** 1997 Feb 7;222(3):187–90

Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Mann DM, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):81–4

An intronic polymorphism in the presenilin–1 gene does not influence the amount or molecular form of the amyloid beta protein deposited in Alzheimer's disease. Mann DM, et al. **Neurosci Lett** 1997 Jan 24;222(1):57–60

Different effects of Alzheimer–associated mutations of presenilin 1 on its processing. Murayama O, et al. **Neurosci Lett** 1997 Jun 20;229(1):61–4

Rate of cognitive decline in Alzheimer's disease is not affected by the alpha–1–antichymotrypsin A allele or the CYP2D6 B mutant. Murphy GM Jr, et al. **Neurosci Lett** 1996 Oct 18;217(2–3):200–2

T/G polymorphism at intron 9 of presenilin 1 gene is associated with, but not responsible for sporadic late–onset Alzheimer's disease in Japanese population. Nishiwaki Y, et al. **Neurosci Lett** 1997 May 16;227(2):123–6

Transthyretin gene in Alzheimer's disease patients. Palha JA, et al. **Neurosci Lett** 1996 Feb 9;204(3):212–4

Apolipoprotein–E genotype in normal aging, age–associated memory impairment, Alzheimer's disease and vascular dementia patients. Palumbo B, et al. **Neurosci Lett** 1997 Aug 1;231(1):59–61

Presenilin–1 gene intronic polymorphism in sporadic and familial Alzheimer's disease. Sorbi S, et al. **Neurosci Lett** 1997 Jan 31;222(2):132–4

Assignment of Alzheimer's presenilin–2 (PS–2) gene to 1q42.1 by fluorescence in situ hybridization. Takano T, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):205–7

Assignment of Alzheimer's presenilin–1 (PS–1) gene to 14q24.3 by fluorescence in situ hybridization. Takano T, et al. **Neurosci Lett** 1996 Aug 16;214(1):69–71

Sequence analysis of presenilin–1 gene mutation in Japanese Alzheimer's disease patients. Tanahashi H, et al. **Neurosci Lett** 1996 Nov 1;218(2):139–41

Presenilin–1 intron 8 polymorphism is not associated with autopsy–confirmed late–onset Alzheimer's disease. Tysoe C, et al. **Neurosci Lett** 1997 Jan 24;222(1):68–9

A novel missense mutation in the presenilin–1 gene in a familial Alzheimer's disease pedigree with abundant amyloid angiopathy. Yasuda M, et al. **Neurosci Lett** 1997 Aug 22;232(1):29–32

Mutation of potential N–linked glycosylation sites in the Alzheimer's disease amyloid precursor protein (APP). Yazaki M, et al. **Neurosci Lett** 1996 Dec 27;221(1):57–60

Presenilin 1 mRNA expression in hippocampi of sporadic Alzheimer's disease patients. Nishiyama K, et al. **Neurosci Res** 1996 Sep;26(1):75–8

Biomarkers in Alzheimer's disease? [editorial] Mattila KM, et al. **Pathol Biol (Paris)** 1996 Oct;44(8):685–8 (40 ref.)

Glutathione S–transferase theta genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer's patients. Becquemont L, et al. **Pharmacogenetics** 1997 Jun;7(3):251–3

Expression and analysis of presenilin 1 in a human neuronal system: localization in cell bodies and dendrites. Cook DG, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9223–8

Mutations in mitochondrial cytochrome c oxidase genes segregate with late–onset Alzheimer disease. Davis RE, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4526–31

The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue [see comments] Tomita T, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):2025–30. Comment in: Proc Natl Acad Sci U S A 1997 Mar 18;94(6):2095–7.

The genetics of dementia in late life. Plassman BL, et al. **Psychiatr Clin North Am** 1997 Mar;20(1):59–76 (150 ref.)

No association between c–fos gene polymorphisms and sporadic Alzheimer's disease. Dai XY, et al. **Psychiatry Clin Neurosci** 1996 Dec;50(6):331–3

Subject and informant variables affecting family history diagnoses of depression and dementia. Heun R, et al. **Psychiatry Res** 1997 Aug 8;71(3):175–80

Pathogenesis of Alzheimer's disease: current status on apolipoprotein E4 gene research. Das HK, et al. **Rev Neurosci** 1996 Oct–Dec;7(4):277–83 (25 ref.)

A mitochondrial Alzheimer's gene? [news] Barinaga M. **Science** 1997 May 2;276(5313):682

Alzheimer's maverick moves to industry [news] Marshall E. **Science** 1997 Jun 27;276(5321):1962

Alzheimer's disease: genotypes, phenotypes, and treatments. Selkoe DJ. **Science** 1997 Jan 31;275(5300):630–1 (17 ref.)

Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Wolozin B, et al. **Science** 1996 Dec 6;274(5293):1710–3

Genetics of Alzheimer's disease: just how is molecular biology going to help grandma? [editorial] Chen CP. **Singapore Med J** 1997 Mar;38(3):100–1 (10 ref.)

Alzheimer transgenic mouse models come of age. Duff K. **Trends Neurosci** 1997 Jul;20(7):279–80 (11 ref.)

Amyloid, the presenilins and Alzheimer's disease. Hardy J. **Trends Neurosci** 1997 Apr;20(4):154–9 (53 ref.)

Mother's legacy: mitochondrial DNA mutations and Alzheimer's disease. Mattson MP. **Trends Neurosci** 1997 Sep;20(9):373–5 (28 ref.)

Mixed signals in Alzheimer's disease. Neve RL. **Trends Neurosci** 1996 Sep;19(9):371–2

Presenilin mutations in Alzheimer's disease: molecular models suggest a potential functional locus [published erratum

appears in Trends Pharmacol Sci 1996 Dec;17(12):465] Murgolo NJ, et al. **Trends Pharmacol Sci** 1996 Nov; 17(11):389–93 (22 ref.)

[Alzheimer's disease precipitating mutations in presenile genes result in increased production of amyloid peptide A beta(42)] Jensen PH, et al. **Ugeskr Laeger** 1997 May 12; 159(20):3025–6 **(Dan)**

[Apolipoprotein E genotypes in patients investigated for dementia] Johannsen P, et al. **Ugeskr Laeger** 1997 Sep 15; 159(38):5658–61 (Eng. Abstr.) **(Dan)**

[Alzheimer's disease and genes] Jørgensen AL, et al. **Ugeskr Laeger** 1997 Sep 15;159(38):5648–52 (40 ref.) (Eng. Abstr.) **(Dan)**

[Genetics of Alzheimer's disease] Hannequin D, et al. **Rev Med Interne** 1996;17(7):545–50 (76 ref.) (Eng. Abstr.) **(Fre)**

[Genetics of dominant autosomal forms of Alzheimer disease: 3 genes and one phenotype. Groupe de Recherche Francais sur la Maladie d'Alzheimer (editorial)] Brice A, et al. **Rev Neurol (Paris)** 1996 Dec;152(12):725–6 **(Fre)**

[Alzheimer disease: involvement of the complement system in cell death. Gene expression of C1q and C3 in the frontal cortex of patients with Alzheimer disease and control probands] Fischer B, et al. **Fortschr Med** 1996 May 10; 114(13):161–3 (Eng. Abstr.) **(Ger)**

[Recent advances in Alzheimer's disease research—amyloid precursor protein trafficking, processing, and mutations in Alzheimer's disease linked genes] Fukatsu R, et al. **Hokkaido Igaku Zasshi** 1997 Jan;72(1):3–11 (44 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular genetic approach to geriatric diseases] Kumahara Y. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):489–94 (20 ref.) **(Jpn)**

[Presenilin–1 (S182) causative gene of early–onset familial Alzheimer's disease] Ikeda M. **Tanpakushitsu Kakusan Koso** 1996 Aug;41(10):1441–7 (28 ref.) **(Jpn)**

[STM–2, a candidate gene for the familiar Alzheimer's disease on chromosome 1] Oshima J, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug;41(10):1448–52 (28 ref.) **(Jpn)**

[Molecular biology of Alzheimer's disease: a light at the end of the tunnel?] Almeida OP. **Rev Assoc Med Bras** 1997 Jan–Mar;43(1):77–81 (68 ref.) **(Por)**

[Genetic neuroepidemiology] Coria F, et al. **Neurologia** 1995 Dec;10 Suppl 1:50–5 (34 ref.) (Eng. Abstr.) **(Spa)**

[Apolipoprotein E and Alzheimer's disease (editorial)] Lahoz C, et al. **Rev Clin Esp** 1997 Feb;197(2):73–4 **(Spa)**

[Molecular basis of dementias] Poza JJ, et al. **Rev Neurol** 1996 Mar;24(127):329–34 **(Spa)**

[Genetic predisposition to Alzheimer's disease] Staufenbiel M, et al. **Rev Neurol** 1997 Aug;25(144):1285–8 (34 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

Geriatrics photo quiz. Alzheimer's disease or 'syndrome'. Shua-Haim JR, et al. **Geriatrics** 1997 Feb;52(2):16, 70

Alzheimer's disease in senile dementia: loss of neurones in the basal forebrain. Whitehouse, P., Price, D., Struble, R., Clarke, A., Coyle, J. and Delong, M. Science (1982), 215, 1237–1239 [classical article] Burns A, et al. **Int J Geriatr Psychiatry** 1997 Jan;12(1):7–10

Auguste D and Alzheimer's disease [letter; comment] Hamann C. **Lancet** 1997 Jul 26;350(9073):297–8. Comment on: Lancet 1997 May 24;349(9064):1546–9.

Auguste D and Alzheimer's disease [see comments] Maurer K, et al. **Lancet** 1997 May 24;349(9064):1546–9. Comment in: Lancet 1997 Jul 5;350(9070):73–4. Comment in: Lancet 1997 Jul 26;350(9073):297–8. Comment in: Lancet 1997 Jul 26;350(9073):298.

Florence Nightingale's memory loss. Bourkes J. **N Z Med J** 1997 Mar 28;110(1040):98–9

Alzheimer's disease: from acetylcholine to beta–amyloid. A tribute to the work of Professor David M. Bowen. Palmer AM, et al. **Neurodegeneration** 1996 Dec;5(4):379–80

Alzheimer's original patient [letter; comment] Amaducci L. **Science** 1996 Oct 18;274(5286):328. Comment on: Science 1996 Jul 5;273(5271):28.

[The 1906 neurological meeting in Tübingen and the first Alzheimer's disease case. A critical study] Pérez–Trullén JM, et al. **Rev Neurol** 1996 Oct;24(134):1283–9 **(Spa)**

IMMUNOLOGY

Inconstant apolipoprotein E (ApoE)–like immunoreactivity in amyloid beta protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease. Uchihara T, et al. **Acta Neuropathol (Berl)** 1996 Aug;92(2):180–5

Widespread immunoreactivity of presenilin in neurons of normal and Alzheimer's disease brains: double–labeling immunohistochemical study. Uchihara T, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):325–30

Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase–3 beta and cyclin–dependent kinase 5, a component of TPK II. Yamaguchi H, et al. **Acta Neuropathol (Berl)** 1996 Sep;92(3):232–41

Antibodies to presenilin proteins detect neurofibrillary tangles in Alzheimer's disease. Murphy GM Jr, et al. **Am J Pathol** 1996 Dec;149(6):1839–46

Interleukin–8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer's disease. Xia M, et al. **Am J Pathol** 1997 Apr;150(4):1267–74

T–cell interferon gamma binding in patients with dementia of the Alzheimer type. Bongioanni P, et al. **Arch Neurol** 1997 Apr;54(4):457–62

The immune response in the Alzheimer's disease brain. Banati RB. **Biochem Soc Trans** 1997 May;25(2):683–5 (13 ref.)

Acute phase reactants in Alzheimer's disease. Lawlor BA, et al. **Biol Psychiatry** 1996 Jun 15;39(12):1051–2

Differences in dexamethasone–sensitivity between lymphocytes from patients with Alzheimer's disease and patients with multi–infarct dementia. Nijhuis EWP, et al. **Brain Behav Immun** 1996 Jun;10(2):115–25

The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. McGeer PL, et al. **Brain Res Brain Res Rev** 1995 Sep;21(2):195–218 (308 ref.)

AD2, a phosphorylation–dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. Buée–Scherrer V, et al. **Brain Res Mol Brain Res** 1996 Jul;39(1–2):79–88

Excitatory pattern of gamma–interferon on natural killer cell activity in senile dementia of the Alzheimer type. Solerte SB, et al. **Dement Geriatr Cogn Disord** 1997 Sep–Oct; 8(5):308–13

Enhanced cytotoxic response of natural killer cells to interleukin–2 in Alzheimer's disease. Solerte SB, et al. **Dementia** 1996 Nov–Dec;7(6):343–8

Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. Aisen PS. **Gerontology** 1997; 43(1–2):143–9 (63 ref.)

Neuroautoimmunity: pathogenic implications for Alzheimer's disease. Singh VK. **Gerontology** 1997;43(1–2):79–94 (82 ref.)

Humoral and cell–mediated immune responses following lesions of the nucleus basalis magnocellularis in the rat. Popović M, et al. **Int J Neurosci** 1997 Feb;89(3–4):165–76

Association between Alzheimer's disease and bound autochthonous IgM on T cells. Kell SH, et al. **J Am Geriatr Soc** 1996 Nov;44(11):1362–5

The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. Carmel G, et al. **J Biol Chem** 1996 Dec 20;271(51):32789–95

Expression of CD43 in human microglia and its downregulation in Alzheimer's disease. Matsuo A, et al. **J Neuroimmunol** 1996 Dec;71(1–2):81–6

Interactions of the Alzheimer beta amyloid fragment (25–35) with peripheral blood dendritic cells. Schmitt TL, et al. **Mech Ageing Dev** 1997 Mar;94(1–3):223–32

Increased incidence of anti–beta–amyloid autoantibodies secreted by Epstein–Barr virus transformed B cell lines from patients with Alzheimer's disease. Xu S, et al. **Mech Ageing Dev** 1997 Mar;94(1–3):213–22

Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau. Farías G, et al. **Mol Cell Biochem** 1997 Mar;168(1–2):59–66

Microglial cerebrospinal fluid antibodies. Significance for Alzheimer disease. McRae A, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):89–95

Immune–activation model in Alzheimer disease. Singh VK. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):105–11 (26 ref.)

Inflammatory mechanisms in Alzheimer disease: the role of beta–amyloid/glial interactions. Pachter JS. **Mol Psychiatry** 1997 Mar;2(2):91–5 (58 ref.)

Molecular aspects of inflammatory and immune responses in Alzheimer's disease. Kalaria RN, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):687–93 (76 ref.)

Immunocytochemical detection of anti–hippocampal antibodies in Alzheimer's disease and normal cerebrospinal fluid. Loeffler DA, et al. **Neurochem Res** 1997 Feb; 22(2):209–14

Evidence for association of HLA–A2 allele with onset age of Alzheimer's disease. Payami H, et al. **Neurology** 1997 Aug;49(2):512–8

Identification of monocyte chemoattractant protein–1 in senile plaques and reactive microglia of Alzheimer's disease. Ishizuka K, et al. **Psychiatry Clin Neurosci** 1997 Jun;51(3):135–8

Autoantibody reactivity in serum of patients with Alzheimer's disease and other age–related dementias. Schott K, et al. **Psychiatry Res** 1996 Jan 31;59(3):251–4

[Expression of decay–accelerating factor on CD8–positive lymphocytes as an index of aging and of host defense function] Fuchino Y, et al. **Nippon Ronen Igakkai Zasshi** 1996 Aug;33(8):580–5 (Eng. Abstr.) **(Jpn)**

METABOLISM

The neurochemistry of Alzheimer's disease. Engelborghs S, et al. **Acta Neurol Belg** 1997 Jun;97(2):67–84 (226 ref.)

Neurotransmitters, signal transduction and second–messengers in Alzheimer's disease. Cowburn RF, et al. **Acta Neurol Scand Suppl** 1996;165:25–32 (63 ref.)

Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease. Hoyer S. **Acta Neurol Scand Suppl** 1996;165:18–24 (90 ref.)

Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. Nagy Z, et al. **Acta Neuropathol (Berl)** 1997 Mar;93(3):294–300

Differential pattern of beta–amyloid, amyloid precursor protein and apolipoprotein E expression in cortical senile plaques. Thal DR, et al. **Acta Neuropathol (Berl)** 1997 Sep; 94(3):255–65

Expression of interleukin–1 receptor antagonist protein in post–mortem human brain tissues of Alzheimer's disease and control cases. Yasuhara O, et al. **Acta Neuropathol (Berl)** 1997 Apr;93(4):414–20

Content of brain aluminum is not elevated in Alzheimer disease. Bjertness E, et al. **Alzheimer Dis Assoc Disord** 1996 Fall;10(3):171–4

Reductions in membrane proteins and lipids in basal ganglia of classic Alzheimer disease patients. Gottfries CG, et al. **Alzheimer Dis Assoc Disord** 1996 Summer;10(2):77–81

APOE–epsilon 4 in patients with Alzheimer disease and vascular dementia. Treves TA, et al. **Alzheimer Dis Assoc Disord** 1996 Winter;10(4):189–91

Expression and distribution of amyloid precursor protein–like protein–2 in Alzheimer's disease and in normal brain. Crain BJ, et al. **Am J Pathol** 1996 Oct;149(4):1087–95

Presenilin–1–immunoreactive neurons are preserved in late–onset Alzheimer's disease. Giannakopoulos P, et al. **Am J Pathol** 1997 Feb;150(2):429–36

Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. McShea A, et al. **Am J Pathol** 1997 Jun;150(6):1933–9

Immunohistochemical detection of 4–hydroxy–2–nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Montine KS, et al. **Am J Pathol** 1997 Feb;150(2):437–43

Charge–based binding of complement component C1q to the Alzheimer amyloid beta–peptide. Webster S, et al. **Am J Pathol** 1997 May;150(5):1531–6

Presenilin–1 is associated with Alzheimer's disease amyloid. Wisniewski T, et al. **Am J Pathol** 1997 Aug;151(2):601–10

Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Pietrini P, et al. **Am J Psychiatry** 1997 Aug;154(8):1063–9

Brain proton magnetic resonance spectroscopy (1H–MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Satlin A, et al. **Am J Psychiatry** 1997 Oct;154(10):1459–61

Laboratory examinations correlated with severity of dementia. Oishi M, et al. **Ann Clin Lab Sci** 1996 Jul–Aug; 26(4):340–5

Alterations of peptide metabolism and neuropeptidase activity in senile dementia of the Alzheimer's type. Waters SM, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:30–9

A novel presenilin–1 mutation: increased beta–amyloid and neurofibrillary changes. Gómez–Isla T, et al. **Ann Neurol** 1997 Jun;41(6):809–13

Presenilin–1 protein expression in familial and sporadic Alzheimer's disease. Levey AI, et al. **Ann Neurol** 1997 Jun; 41(6):742–53

Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Minoshima S, et al. **Ann Neurol** 1997 Jul;42(1):85–94

Stopped–flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer beta (1–40) amyloid fibrils. LeVine H 3rd. **Arch Biochem Biophys** 1997 Jun 15;342(2):306–16

Aluminum–induced structural alterations of the precursor of the non–A beta component of Alzheimer's disease amyloid. Paik SR, et al. **Arch Biochem Biophys** 1997 Aug 15; 344(2):325–34

No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Corder EH, et al. **Arch Neurol** 1997 Mar; 54(3):273–7

Proton magnetic resonance spectroscopy of vascular– and Alzheimer–type dementia. Kattapong VJ, et al. **Arch Neurol** 1996 Jul;53(7):678–80

The participation of interleukin–6, a stress–inducible cytokine, in the pathogenesis of Alzheimer's disease. Hüll M, et al. **Behav Brain Res** 1996 Jun;78(1):37–41

Altered G–protein coupling of a frontal cortical low affinity [3H]8–hydroxy–N,N–dipropyl–2–aminotetralin serotonergic binding site in Alzheimer's disease. Weinstein D, et al. **Behav Brain Res** 1996;73(1–2):325–9

Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Horie K, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):327–32

Changes of p53 in the brains of patients with Alzheimer's disease. Kitamura Y, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):418–21

Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. Shimohama S, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):239–42

Alzheimer's disease amyloid beta peptide 25–35 inhibits lipid peroxidation as a result of its membrane interactions. Walter MF, et al. **Biochem Biophys Res Commun** 1997 Apr 28; 233(3):760–4

Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites. Hoffmann R, et al. **Biochemistry** 1997 Jul 1;36(26):8114–24

Phosphorylation of Alzheimer beta–amyloid precursor–like proteins. Suzuki T, et al. **Biochemistry** 1997 Apr 15; 36(15):4643–9

NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Weinreb PH, et al. **Biochemistry** 1996 Oct 29;35(43):13709–15

Seeding of A beta fibril formation is inhibited by all three

isotypes of apolipoprotein E. Wood SJ, et al. **Biochemistry** 1996 Sep 24;35(38):12623–8

Somatostatin–positive neurons in the different parts of the brain in normal aging and Alzheimer's disease. Li WP, et al. **Biol Signals** 1996 Nov–Dec;5(6):343–8

Impaired peripheral zinc metabolism in patients with senile dementia of probable Alzheimer's type as shown by low plasma concentrations of thymulin. Licastro F, et al. **Biol Trace Elem Res** 1996 Jan;51(1):55–62

Amyloid precursor protein, copper and Alzheimer's disease. Multhaup G. **Biomed Pharmacother** 1997;51(3):105–11 (72 ref.)

The choline–leakage hypothesis for the loss of acetylcholine in Alzheimer's disease. Ehrenstein G, et al. **Biophys J** 1997 Sep;73(3):1276–80

Modulation of fibrin assembly and polymerization by the beta–amyloid of Alzheimer's disease. Merkle DL, et al. **Blood Coagul Fibrinolysis** 1996 Sep;7(6):650–8

A confocal microscopic analysis of galaninergic hyperinnervation of cholinergic basal forebrain neurons in Alzheimer's disease. Bowser R, et al. **Brain Pathol** 1997 Apr;7(2):723–30

Brain amyloid—a physicochemical perspective. Maggio JE, et al. **Brain Pathol** 1996 Apr;6(2):147–62 (99 ref.)

C-reactive protein–like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. Duong T, et al. **Brain Res** 1997 Feb 21;749(1):152–6

Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor. Frey WH 2nd, et al. **Brain Res** 1996 Apr 1; 714(1–2):87–94

Inhibition of protein phosphatase–2B (calcineurin) activity towards Alzheimer abnormally phosphorylated tau by neuroleptics. Gong CX, et al. **Brain Res** 1996 Nov 25; 741(1–2):95–102

Active site–directed antibodies identify calpain II as an early–appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Grynspan F, et al. **Brain Res** 1997 Jul 25;763(2):145–58

Reduction of telencephalin immunoreactivity in the brain of patients with Alzheimer's disease. Hino H, et al. **Brain Res** 1997 Apr 11;753(2):353–7

Immunohistochemical localization of tissue factor pathway inhibitor–1 (TFPI–1), a Kunitz proteinase inhibitor, in Alzheimer's disease. Hollister RD, et al. **Brain Res** 1996 Jul 22;728(1):13–9

Abeta1–40 but not Abeta1–42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Ishii K, et al. **Brain Res** 1997 Feb 14; 748(1–2):250–2

The synaptic protein NACP is abnormally expressed during the progression of Alzheimer's disease. Iwai A, et al. **Brain Res** 1996 May 13;720(1–2):230–4

Increased collagen content of cerebral microvessels in Alzheimer's disease. Kalaria RN, et al. **Brain Res** 1995 Dec 24;705(1–2):349–52

Interaction of Alzheimer beta–amyloid peptide with the human monocytic cell line THP–1 results in a protein kinase C–dependent secretion of tumor necrosis factor–alpha. Klegeris A, et al. **Brain Res** 1997 Jan 30; 747(1):114–21

Protein kinase C activity and protein levels in Alzheimer's disease. Lanius RA, et al. **Brain Res** 1997 Aug 1; 764(1–2):75–80

Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus. MacGibbon GA, et al. **Brain Res** 1997 Mar 7;750(1–2):223–34

Elevated connexin43 immunoreactivity at sites of amyloid plaques in Alzheimer's disease. Nagy JI, et al. **Brain Res** 1996 Apr 22;717(1–2):173–8

Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls. Pirttilä T, et al. **Brain Res** 1996 May 25;722(1–2):71–7

Effects of freezing storage time on the density of muscarinic receptors in the human postmortem brain: an autoradiographic study in control and Alzheimer's disease brain tissues. Rodriguez–Puertas R, et al. **Brain Res** 1996 Jul 22;728(1):65–71

Changes of neurocalcin, a calcium–binding protein, in the brain of patients with Alzheimer's disease. Shimohama S, et al. **Brain Res** 1996 Apr 15;716(1–2):233–6

Brain beta–spectrin is a component of senile plaques in Alzheimer's disease. Sihag RK, et al. **Brain Res** 1996 Dec 16;743(1–2):249–57

Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease. Smith MA, et al. **Brain Res** 1996 Apr 22;717(1–2):99–108

Alzheimer's disease amyloid precursor protein on the surface of cortical neurons in primary culture co–localizes with adhesion patch components. Storey E, et al. **Brain Res** 1996 Oct 7;735(2):217–31

Expression of presenilin–1 and –2 mRNAs in rat and Alzheimer's disease brains. Takami K, et al. **Brain Res** 1997 Feb 14;748(1–2):122–30

Enhancement of immunoreactivity for NF–kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Terai K, et al. **Brain Res** 1996 Sep 30;735(1):159–68

Heme from Alzheimer's brain inhibits muscarinic receptor binding via thiyl radical generation. Venters HD Jr, et al. **Brain Res** 1997 Aug 1;764(1–2):93–100

Expression of activating transcription factor–2 (ATF–2), one of the cyclic AMP response element (CRE) binding proteins, in Alzheimer disease and non–neurological brain tissues. Yamada T, et al. **Brain Res** 1997 Feb 28; 749(2):329–34

Zinc and Alzheimer's disease: is there a direct link? Cuajungco MP, et al. **Brain Res Brain Res Rev** 1997 Apr; 23(3):219–36 (249 ref.)

Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Mattson MP, et al. **Brain Res Brain Res Rev** 1997 Feb; 23(1–2):47–61 (119 ref.)

Advanced glycation endproducts in ageing and Alzheimer's disease. Münch G, et al. **Brain Res Brain Res Rev** 1997 Feb;23(1–2):134–43 (78 ref.)

Identification of microtubule–associated protein tau isoforms in Alzheimer's paired helical filaments. McLaughlin L, et al. **Brain Res Bull** 1997;43(5):501–8

Gap–43 message levels in anterior cerebellum in Alzheimer's disease. Cheetham JE, et al. **Brain Res Mol Brain Res** 1996 Feb;36(1):145–51

Trk receptor alterations in Alzheimer's disease. Connor B, et al. **Brain Res Mol Brain Res** 1996 Nov;42(1):1–17

Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Fahnestock M, et al. **Brain Res Mol Brain Res** 1996 Nov;42(1):175–8

Quantification of APP and APLP2 mRNA in APOE genotyped Alzheimer's disease brains. Johnston JA, et al. **Brain Res Mol Brain Res** 1996 Dec 31;43(1–2):85–95

Isoform–specific binding of human apolipoprotein E to the non–amyloid beta component of Alzheimer's disease amyloid. Olesen OF, et al. **Brain Res Mol Brain Res** 1997 Feb;44(1):105–12

Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase–2A, –2B and –1. Wang JZ, et al. **Brain Res Mol Brain Res** 1996 Jun;38(2):200–8

Implications of aging– and degeneration–related changes in anion exchange proteins for the maintenance of neuronal homeostasis. Bosman GJ, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 Nov;42(7):905–18

Posttranslational modifications of brain and erythrocyte band 3 during aging and disease [published erratum appears in Cell Mol Biol (Noisy–le–grand) 1997 May;43(3):469] Kay MM, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 Nov; 42(7):919–44

Nuclear microscope analysis in Alzheimer's and Parkinson's disease: A review. Watt F. **Cell Mol Biol (Noisy–le–grand)** 1996 Feb;42(1):17–26 (34 ref.)

beta–Amyloid–associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Butterfield DA. **Chem Res Toxicol** 1997 May;10(5):495–506 (113 ref.)

Nitric oxide and derived species as toxic agents in stroke, AIDS dementia, and chronic neurodegenerative disorders. Hensley K, et al. **Chem Res Toxicol** 1997 May;10(5):527–32 (64 ref.)

Disruption of brain cell ion homeostasis in Alzheimer's disease by oxy radicals, and signaling pathways that protect therefrom. Mattson MP, et al. **Chem Res Toxicol** 1997 May; 10(5):507–17 (85 ref.)

Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal. Sayre LM, et al. **Chem Res Toxicol** 1997 May;10(5):518–26 (141 ref.)

Beta–amyloid protein and Alzheimer's disease. Bao X. **Chin Med J (Engl)** 1996 Jan;109(1):41–3 (0 ref.)

Beta–amyloid precursor protein and early–onset Alzheimer's disease. Hendriks L, et al. **Ciba Found Symp** 1996; 199:170–80

Interaction of transthyretin with amyloid beta–protein: binding and inhibition of amyloid formation. Schwarzman AL, et al. **Ciba Found Symp** 1996;199:146–60; discussion 160–4

Molecular dissection of the neurofibrillary lesions of Alzheimer's disease. Goedert M, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:565–73 (57 ref.)

Cell biology of the beta–amyloid precursor protein and the genetics of Alzheimer's disease. Selkoe DJ. **Cold Spring Harb Symp Quant Biol** 1996;61:587–96 (100 ref.)

Protein: protein interactions in Alzheimer's disease and the CAG triplet repeat diseases. Strittmatter WJ, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:597–605 (73 ref.)

Neuronal sorting and processing of amyloid precursor protein: implications for Alzheimer's disease. Tienari PJ, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:575–85 (67 ref.)

Trk neurotrophin receptors in cholinergic neurons of patients with Alzheimer's disease. Boissière F, et al. **Dement Geriatr Cogn Disord** 1997 Jan–Feb;8(1):1–8

Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Nordberg A, et al. **Dement Geriatr Cogn Disord** 1997 Mar–Apr;8(2):78–84

Subpial amyloid plaques in the cerebellum in a case of Alzheimer's disease. Takamatsu J, et al. **Dement Geriatr Cogn Disord** 1997 May–Jun;8(3):157–62

Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patterns. Blesa R, et al. **Dementia** 1996 Sep–Oct;7(5):239–45 (51 ref.)

Sequential changes of tau–site–specific phosphorylation during development of paired helical filaments. Kimura T, et al. **Dementia** 1996 Jul–Aug;7(4):177–81

Apolipoprotein E genotype does not promote the clinical progression of manifest Alzheimer's disease [letter] Sarochan M, et al. **Dementia** 1996 Mar–Apr;7(2):120

Cortical NMDA receptor properties and membrane fluidity are altered in Alzheimer's disease. Scheuer K, et al. **Dementia** 1996 Jul–Aug;7(4):210–4

Low apolipoprotein E4 allelic frequency in Alzheimer's disease and functional psychiatric disorders [letter] Thilmann P, et al. **Dementia** 1996 Mar–Apr;7(2):118–9

Normal glutamate metabolism in Alzheimer's disease fibroblasts deficient in alpha–ketoglutarate dehydrogenase complex activity. Cooper AL, et al. **Dev Neurosci** 1996; 18(5–6):499–504

Regional correlations between the EEG and oxygen metabolism in dementia of Alzheimer's type. Buchan RJ, et al. **Electroencephalogr Clin Neurophysiol** 1997 Sep; 103(3):409–17

Neurochemical parameters in senile dementia of the Alzheimer type. A longitudinal study in four cases [letter] Strittmatter M, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(2):110–11

A possible role for cathepsins D, E, and B in the processing of beta–amyloid precursor protein in Alzheimer's disease. Mackay EA, et al. **Eur J Biochem** 1997 Mar 1;244(2):414–25

Characterization of the interactions of Alzheimer beta–amyloid peptides with phospholipid membranes. McLaurin J, et al. **Eur J Biochem** 1997 Apr 15; 245(2):355–63

Neuropeptides and Alzheimer's disease. Gottfries CG, et al. **Eur Neuropsychopharmacol** 1995 Dec;5(4):491–500 (113 ref.)

Factors determining the size frequency distribution of beta–amyloid (A beta) deposits in Alzheimer's disease. Armstrong RA, et al. **Exp Neurol** 1997 Jun;145(2 Pt 1):574–9

Evidence for physiological down–regulation of brain oxidative phosphorylation in Alzheimer's disease. Chandrasekaran K, et al. **Exp Neurol** 1996 Nov;142(1):80–8 (103 ref.)

Aging, metabolism, and Alzheimer disease: review and hypotheses. Finch CE, et al. **Exp Neurol** 1997 Jan; 143(1):82–102 (218 ref.)

Reduction in p140–TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Mufson EJ, et al. **Exp Neurol** 1997 Jul;146(1):91–103

Presenilin–1 immunoreactivity is localized intracellularly in Alzheimer's disease brain, but not detected in amyloid plaques. Weber LL, et al. **Exp Neurol** 1997 Jan;143(1):37–44

RNA stimulates aggregation of microtubule–associated protein tau into Alzheimer–like paired helical filaments. Kampers T, et al. **FEBS Lett** 1996 Dec 16;399(3):344–9

Immunohistochemical analysis of presenilin–1 expression in the mouse brain. Moussaoui S, et al. **FEBS Lett** 1996 Apr 1;383(3):219–22

Lithium inhibits Alzheimer's disease–like tau protein phosphorylation in neurons. Muñoz–Montaño JR, et al. **FEBS Lett** 1997 Jul 14;411(2–3):183–8

Heterogeneity of water–soluble amyloid beta–peptide in Alzheimer's disease and Down's syndrome brains. Russo C, et al. **FEBS Lett** 1997 Jun 16;409(3):411–6

Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. Sergeant N, et al. **FEBS Lett** 1997 Aug 4;412(3):578–82

X–ray diffraction and far–UV CD studies of filaments formed by a leucine–rich repeat peptide: structural similarity to the amyloid fibrils of prions and Alzheimer's disease beta–protein. Symmons MF, et al. **FEBS Lett** 1997 Jul 28; 412(2):397–403

Alzheimer's presenilin 1 gene expression in platelets and megakaryocytes. Identification of a novel splice variant. Vidal R, et al. **FEBS Lett** 1996 Sep 9;393(1):19–23

Increased susceptibility of Alzheimer's disease temporal cortex to oxygen free radical–mediated processes. McIntosh LJ, et al. **Free Radic Biol Med** 1997;23(2):183–90

Oxidative stress hypothesis in Alzheimer's disease. Markesbery WR. **Free Radic Biol Med** 1997;23(1):134–47 (155 ref.)

Determination of malonaldehyde in Alzheimer's disease: a comparative study of high–performance liquid chromatography and thiobarbituric acid test. Bermejo P, et al. **Gerontology** 1997;43(4):218–22

Involvement of neuronal anion exchange proteins in cell death in Alzheimer's disease. Bosman GJ, et al. **Gerontology** 1997;43(1–2):67–78

Brain and erythrocyte anion transporter protein, band 3, as a marker for Alzheimer's disease: structural changes detected by electron microscopy, phosphorylation, and antibodies. Kay MM, et al. **Gerontology** 1997;43(1–2):44–66

Glial cells in Alzheimer's disease: preferential effect of APOE risk on scattered microglia. Saitoh T, et al. **Gerontology** 1997;43(1–2):109–18

Phosphorylation events mediated by protein kinase C alpha and epsilon participate in regulation of tau steady–state levels and generation of certain "Alzheimer–like" phospho–epitopes. Boyce JJ, et al. **Int J Dev Neurosci** 1997 Jun;15(3):295–307

Snake coiled fibres in rat soleus muscle in chloroquine induced myopathy share immunohistochemical characteristics with amyloid depositions in Alzheimer's disease brain tissue. Tsuzuki K, et al. **Int J Exp Pathol**

1997 Feb;78(1):1–8

Nutritional status of patients with Alzheimer's disease: a 1–year study. Spindler AA, et al. **J Am Diet Assoc** 1996 Oct;96(10):1013–8

No evidence for a higher resting metabolic rate in noninstitutionalized Alzheimer's disease patients. Donaldson KE, et al. **J Am Geriatr Soc** 1996 Oct; 44(10):1232–4

Deletion of an endosomal/lysosomal targeting signal promotes the secretion of Alzheimer's disease amyloid precursor protein (APP). Ono Y, et al. **J Biochem (Tokyo)** 1997 Mar;121(3):585–90

Abeta(1–40) prevents heparanase–catalyzed degradation of heparan sulfate glycosaminoglycans and proteoglycans in vitro. A role for heparan sulfate proteoglycan turnover in Alzheimer's disease. Bame KJ, et al. **J Biol Chem** 1997 Jul 4;272(27):17005–11

Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease–associated presenilins. De Strooper B, et al. **J Biol Chem** 1997 Feb 7;272(6):3590–8

Nontoxic amyloid beta peptide 1–42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer's disease. Hoshi M, et al. **J Biol Chem** 1997 Jan 24;272(4):2038–41

Alzheimer amyloid protein precursor is localized in nerve terminal preparations to Rab5–containing vesicular organelles distinct from those implicated in the synaptic vesicle pathway. Ikin AF, et al. **J Biol Chem** 1996 Dec 13;271(50):31783–6

Membrane disruption by Alzheimer beta–amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. McLaurin J, et al. **J Biol Chem** 1996 Oct 25;271(43):26482–9

Fusogenic properties of the C–terminal domain of the Alzheimer beta–amyloid peptide. Pillot T, et al. **J Biol Chem** 1996 Nov 15;271(46):28757–65

Generation of Alzheimer amyloid beta peptide through nonspecific proteolysis. Tjernberg LO, et al. **J Biol Chem** 1997 Jan 17;272(3):1870–5

Secreted glypican binds to the amyloid precursor protein of Alzheimer's disease (APP) and inhibits APP–induced neurite outgrowth. Williamson TG, et al. **J Biol Chem** 1996 Dec 6;271(49):31215–21

Interaction between Alzheimer's disease beta A4 precursor protein (APP) and the extracellular matrix: evidence for the participation of heparan sulfate proteoglycans. Cáceres J, et al. **J Cell Biochem** 1997 May;65(2):145–58

Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. LaFerla FM, et al. **J Clin Invest** 1997 Jul 15;100(2):310–20

Regional metabolic alterations in Alzheimer's disease: an in vitro 1H NMR study of the hippocampus and cerebellum. Mohanakrishnan P, et al. **J Gerontol A Biol Sci Med Sci** 1997 Mar;52(2):B111–7

Neuronal expression of STM2 mRNA in human brain is reduced in Alzheimer's disease. McMillan PJ, et al. **J Histochem Cytochem** 1996 Nov;44(11):1215–22

Phospholipid metabolism in Alzheimer's disease and in a human cholinergic cell. Kanfer JN, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):361–3 (7 ref.)

Cholecystokinin peptides and receptor binding in Alzheimer's disease. Löfberg C, et al. **J Neural Transm Gen Sect** 1996; 103(7):851–60

Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? Blum–Degen D, et al. **J Neural Transm Suppl** 1995;46:139–47

The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. Gsell W, et al. **J Neural Transm Suppl** 1996;47:73–101

Models of Alzheimer's disease: cellular and molecular aspects. Hoyer S. **J Neural Transm Suppl** 1997;49:11–21 (85 ref.)

Corticotropin–releasing factor (CRF), CRF–binding protein (CRF–BP), and CRF/CRF–BP complex in Alzheimer's disease and control postmortem human brain. Behan DP, et al. **J Neurochem** 1997 May;68(5):2053–60

Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. Butterfield DA, et al. **J Neurochem** 1997 Jun;68(6):2451–7

Identification of heparin–binding domains in the amyloid precursor protein of Alzheimer's disease by deletion mutagenesis and peptide mapping. Clarris HJ, et al. **J Neurochem** 1997 Mar;68(3):1164–72

Aggregation of beta–amyloid peptide is promoted by membrane phospholipid metabolites elevated in Alzheimer's disease brain. Klunk WE, et al. **J Neurochem** 1997 Jul;69(1):266–72

Alzheimer's disease neurofibrillary tangles contain mitosis–specific phosphoepitopes. Kondratick CM, et al. **J Neurochem** 1996 Dec;67(6):2405–16

The state of phosphorylation of normal adult brain tau, fetal tau, and tau from Alzheimer paired helical filaments at amino acid residue Ser262. Liu WK, et al. **J Neurochem** 1996 Mar;66(3):1131–9

An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. Lyras L, et al. **J Neurochem** 1997 May;68(5):2061–9

Heat shock induces rapid dephosphorylation of tau in both female and male rats followed by hyperphosphorylation only in female rats: implications for Alzheimer's disease. Papasozomenos SC. **J Neurochem** 1996 Mar;66(3):1140–9

1251–galanin binding sites in Alzheimer's disease: increases in hippocampal subfields and a decrease in the caudate nucleus. Rodriguez–Puertas R, et al. **J Neurochem** 1997 Mar;68(3):1106–13

4–Hydroxynonenal–derived advanced lipid peroxidation end products are increased in Alzheimer's disease. Sayre LM, et al. **J Neurochem** 1997 May;68(5):2092–7

Two–dimensional characterization of paired helical filament–tau from Alzheimer's disease: demonstration of an additional 74–kDa component and age–related biochemical modifications. Sergeant N, et al. **J Neurochem** 1997 Aug;69(2):834–44

Unchanged amounts of vasopressin mRNA in the supraoptic and paraventricular nucleus during aging and in Alzheimer's disease. Lucassen PJ, et al. **J Neuroendocrinol** 1997 Apr;9(4):297–305

Anti–brain spectrin immunoreactivity in Alzheimer's disease: degradation of spectrin in an animal model of cholinergic degeneration. Fernández–Shaw C, et al. **J Neuroimmunol** 1997 Jul;77(1):91–8

Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer's disease as shown by MRI and PET. Yamaguchi S, et al. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):596–600

Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. Deibel MA, et al. **J Neurol Sci** 1996 Nov; 143(1–2):137–42

Modulation of neuronal thread protein expression with neuritic sprouting: relevance to Alzheimer's disease. de la Monte SM, et al. **J Neurol Sci** 1996 Jun;138(1–2):26–35

Altered energy metabolism in Alzheimer's disease. Ogawa M, et al. **J Neurol Sci** 1996 Jul;139(1):78–82

The mean A beta load in the hippocampus correlates with duration and severity of dementia in subgroups of Alzheimer disease. Bartoo GT, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):531–40

Profiles of neuronal thread protein expression in Alzheimer's disease. De La Monte SM, et al. **J Neuropathol Exp Neurol** 1996 Oct;55(10):1038–50

Amyloid beta–protein (A beta) accumulation in the leptomeninges during aging and in Alzheimer disease. Hamano T, et al. **J Neuropathol Exp Neurol** 1997 Aug; 56(8):922–32

Neuronal expression and intracellular localization of presenilins in normal and Alzheimer disease brains. Huynh DP, et al. **J Neuropathol Exp Neurol** 1997 Sep; 56(9):1009–17

The loss of GluR2(3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brains. Ikonomovic MD, et al. **J Neuropathol Exp Neurol** 1997 Sep;56(9):1018–27

Characterization of the precursor protein of the non–A beta component of senile plaques (NACP) in the human central nervous system. Irizarry MC, et al. **J Neuropathol Exp Neurol** 1996 Aug;55(8):889–95

Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. Li S, et al. **J Neuropathol Exp Neurol** 1997 Aug;56(8):901–11

Association of vascular amyloid beta and cells of the mononuclear phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer disease. Maat–Schieman ML, et al. **J Neuropathol Exp Neurol** 1997 Mar;56(3):273–84

Astrocyte–apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: a regional immunohistochemical study. Shao Y, et al. **J Neuropathol Exp Neurol** 1997 Apr;56(4):376–81

Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl–2 expression, and brain pathology. Su JH, et al. **J Neuropathol Exp Neurol** 1997 Jan;56(1):86–93

Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. Sze CI, et al. **J Neuropathol Exp Neurol** 1997 Aug;56(8):933–44

Gender differences in cortical glucose metabolism in Alzheimer's disease and normal aging. Siegel BV Jr, et al. **J Neuropsychiatry Clin Neurosci** 1996 Spring;8(2):211–4

Neuronal localization of presenilin–1 and association with amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Busciglio J, et al. **J Neurosci** 1997 Jul 1; 17(13):5101–7

Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta–amyloidogenesis. Cataldo AM, et al. **J Neurosci** 1997 Aug 15;17(16):6142–51

Specific domains of beta–amyloid from Alzheimer plaque elicit neuron killing in human microglia. Giulian D, et al. **J Neurosci** 1996 Oct 1;16(19):6021–37

Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta–amyloid precursor protein and Alzheimer's disease. Masliah E, et al. **J Neurosci** 1996 Sep 15;16(18):5795–811

Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. Pappolla MA, et al. **J Neurosci** 1997 Mar 1;17(5):1683–90

Amyloid beta peptide of Alzheimer's disease downregulates Bcl–2 and upregulates bax expression in human neurons. Paradis E, et al. **J Neurosci** 1996 Dec 1;16(23):7533–9

Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients. Russo–Neustadt A, et al. **J Neurosci** 1997 Jul 15; 17(14):5573–80

Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. Sheehan JP, et al. **J Neurosci** 1997 Jun 15;17(12):4612–22

Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. Vincent I, et al. **J Neurosci** 1997 May 15;17(10):3588–98

Scavenging of Alzheimer's amyloid beta–protein by microglia in culture. Ard MD, et al. **J Neurosci Res** 1996 Jan 15;43(2):190–202

Bcl–xl–specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states. Drache B, et al. **J Neurosci Res** 1997 Jan 1;47(1):98–108

Microtubule assembly competence analysis of freshly–biopsied human tau, dephosphorylated tau, and Alzheimer tau. Garver TD, et al. **J Neurosci Res** 1996 Apr 1;44(1):12–20

Disappearance of actin–binding protein, drebrin, from hippocampal synapses in Alzheimer's disease. Harigaya Y, et al. **J Neurosci Res** 1996 Jan 1;43(1):87–92

Alzheimer's beta–amyloid precursor protein is expressed on the surface of immediately ex vivo brain cells: a flow cytometric study. Jung SS, et al. **J Neurosci Res** 1996 Nov 1;46(3):336–48

Association of human, rat, and rabbit apolipoprotein E with beta–amyloid. LaDu MJ, et al. **J Neurosci Res** 1997 Jul 1;49(1):9–18

Monoclonal antibody PHF–9 recognizes phosphorylated serine 404 of tau protein and labels paired helical filaments. Zemlan FP, et al. **J Neurosci Res** 1996 Oct 1;46(1):90–7

Decreased medial temporal oxygen metabolism in Alzheimer's disease shown by PET. Ishii K, et al. **J Nucl Med** 1996 Jul;37(7):1159–65

Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. Ishii K, et al. **J Nucl Med** 1997 Jun; 38(6):925–8

Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease. Chargé SB, et al. **J Pathol** 1996 Aug;179(4):443–7

A synthetic substrate assay for the gamma–secretase of the beta–A4 amyloid of Alzheimer's disease. Evin G, et al. **J Pept Sci** 1995 Mar–Apr;1(2):132–9

Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease. Lou G, et al. **J Psychiatry Neurosci** 1996 Nov;21(5):334–9

Brain mercury in neurodegenerative disorders. Fung YK, et al. **J Toxicol Clin Toxicol** 1997;35(1):49–54

Assessment of protein kinase C mRNA levels in Alzheimer's disease brains. Chachin M, et al. **Jpn J Pharmacol** 1996 Jun;71(2):175–7

First–order kinetic model of Alzheimer's beta–amyloid fibril extension in vitro. Naiki H, et al. **Lab Invest** 1996 Feb; 74(2):374–83

Pinning the suspect to the crime in Alzheimer's [news] Finkel E. **Lancet** 1996 Nov 30;348(9040):1506

Dehydroepiandrosterone (DHEA) increases production and release of Alzheimer's amyloid precursor protein. Danenboerg HD, et al. **Life Sci** 1996;59(19):1651–7

Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti–amyloidogenic role of the blood–brain barrier. Zlokovic BV. **Life Sci** 1996; 59(18):1483–97 (83 ref.)

Alzheimer's disease and Down syndrome: leukocyte membrane fluidity alterations. Scott RB, et al. **Mech Ageing Dev** 1994 Jul;75(1):1–10

The possible role of peroxynitrite in Alzheimer's disease: a simple hypothesis that could be tested more thoroughly. Van Dyke K. **Med Hypotheses** 1997 May;48(5):375–80 (49 ref.)

Inhibition of brain tubulin–guanosine 5'–triphosphate interactions by mercury: similarity to observations in Alzheimer's diseased brain. Pendergrass JC, et al. **Met Ions Biol Syst** 1997;34:461–78 (35 ref.)

An experimental model to study the cytotoxic effects induced by beta–amyloid, histamine, LPS and serum from Alzheimer patients on cultured rat endothelial cells. Maneiro E, et al. **Methods Find Exp Clin Pharmacol** 1997 Jan–Feb;19(1):5–12

Muscarinic receptors in Alzheimer's disease. Pavía J, et al. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:71–5

Potentiation of GSK–3–catalyzed Alzheimer–like phosphorylation of human tau by cdk5. Sengupta A, et al. **Mol Cell Biochem** 1997 Feb;167(1–2):99–105

The possible place of cathepsins and cystatins in the puzzle of Alzheimer disease: a review. Bernstein HG, et al. **Mol Chem Neuropathol** 1996 Apr;27(3):225–47 (138 ref.)

Neurotrophin receptors and selective loss of cholinergic neurons in Alzheimer disease. Boissière F, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):219–23 (17 ref.)

Retinoic acid synthesis in normal and Alzheimer diseased brain and human neural cells. Connor MJ, et al. **Mol Chem Neuropathol** 1997 Apr;30(3):239–52

Hippocampal damage and cytoskeletal disruption resulting from impaired energy metabolism. Implications for Alzheimer disease. Geddes JW, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):65–74

Laminins in the adult and aged brain. Jucker M, et al.

Mol Chem Neuropathol 1996 May-Aug;28(1-3):209-18 (44 ref.)

Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Smith MA, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):41-8 (41 ref.)

Trypsin interaction with the senile plaques of Alzheimer disease is mediated by beta-protein precursor. Smith MA, et al. **Mol Chem Neuropathol** 1996 Feb;27(2):145-54

The cytoplasmic domain of Alzheimer's amyloid precursor protein is phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and cultured cells. Oishi M, et al. **Mol Med** 1997 Feb;3(2):111-23

The Alzheimer's disease-associated presenilins are differentially phosphorylated proteins located predominantly within the endoplasmic reticulum. Walter J, et al. **Mol Med** 1996 Nov;2(6):673-91

Mechanism of Alzheimer neurofibrillary degeneration and the formation of tangles [news] Iqbal K, et al. **Mol Psychiatry** 1997 May;2(3):178-80

Unraveling the molecular pathway of Alzheimer's disease: research about presenilins gathers momentum. Sandbrink R, et al. **Mol Psychiatry** 1996 Dec;1(6):438-44 (54 ref.)

Reductionist science and Alzheimer's disease: redoubling our effort in redox chemistry [news] Wolozia B. **Mol Psychiatry** 1996 Nov;1(5):352-5

Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Cook DG, et al. **Nat Med** 1997 Sep;3(9):1021-3

Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Hartmann T, et al. **Nat Med** 1997 Sep;3(9):1016-20

Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Kennard ML, et al. **Nat Med** 1996 Nov;2(11):1230-5

Hyperaccumulation of FAD-linked presenilin 1 variants in vivo [see comments] Lee MK, et al. **Nat Med** 1997 Jul; 3(7):756-60. Comment in: Nat Med 1997 Jul;3(7):723-5.

Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Velazquez P, et al. **Nat Med** 1997 Jan;3(1):77-9

Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Barger SW, et al. **Nature** 1997 Aug 28;388(6645):878-81

Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans [see comments] Goedert M, et al. **Nature** 1996 Oct 10;383(6600):550-3. Comment in: Nature 1996 Oct 10;383(6600):476-7.

Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein [see comments] Nalbantoglu J, et al. **Nature** 1997 May 29; 387(6632):500-5. Comment in: Nature 1997 May 29;387(6632):457-8.

The role of the Maillard reaction in other pathologies: Alzheimer's disease. Colaco CA, et al. **Nephrol Dial Transplant** 1996;11 Suppl 5:7-12 (51 ref.)

Beta AP deposition and head trauma. Adle-Biassette H, et al. **Neurobiol Aging** 1996 May-Jun;17(3):415-9

Relationship between multifunctional protein "clusterin" and Alzheimer disease. Choi-Miura NH, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):717-22 (76 ref.)

Evolutionary perspectives on amyloid and inflammatory features of Alzheimer disease. Finch CE, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):809-15 (131 ref.)

Calcium responses in human fibroblasts: a diagnostic molecular profile for Alzheimer's disease. Hirashima N, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):549-55

Neurofibrillary tangle-associated alteration of stathmin in Alzheimer's disease. Jin LW, et al. **Neurobiol Aging** 1996 May-Jun;17(3):331-41

Molecular aspects of inflammatory and immune responses in Alzheimer's disease. Kalaria RN, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):687-93 (76 ref.)

Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Klunk WE, et al. **Neurobiol Aging** 1996 May-Jun;17(3):349-57

Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. Ma J, et al. **Neurobiol Aging** 1996 Sep-Oct; 17(5):773-80

Free Ca2+ levels and expression of biochemical markers in Alzheimer's fibroblasts [letter] Paoletti F, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):261-2

Expression of CAP37, a novel inflammatory mediator, in Alzheimer's disease. Pereira HA, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):753-9

Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains. Pirttilä T, et al. **Neurobiol Aging** 1997 Jan-Feb;18(1):121-7

Human brain S100 beta and S100 beta mRNA expression increases with age: pathogenic implications for Alzheimer's disease. Sheng JG, et al. **Neurobiol Aging** 1996 May-Jun; 17(3):359-63

APOE alleles in Alzheimer's disease and vascular dementia in a population aged 85+. Sulkava R, et al. **Neurobiol Aging** 1996 May-Jun;17(3):373-6

Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Tamaoka A, et al. **Neurobiol Aging** 1996 May-Jun; 17(3):405-14

APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Trieb K, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):541-7

Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue. Podlisny MB, et al. **Neurobiol Dis** 1997;3(4):325-37

Apolipoprotein E uptake and low-density lipoprotein receptor-related protein expression by the NTera2/D1 cell line: a cell culture model of relevance for late-onset Alzheimer's disease. Williams KR, et al. **Neurobiol Dis** 1997;4(1):58-67

Heparin promotes beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Leveugle B, et al. **Neurochem Int** 1997 Jun;30(6):543-8

Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. Farooqui AA, et al. **Neurochem Res** 1997 Apr;22(4):523-7 (48 ref.)

Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. McDermott JR, et al. **Neurochem Res** 1997 Jan; 22(1):49-56

Alteration in brain presenilin 1 mRNA expression in early onset familial Alzheimer's disease. Barton AJ, et al. **Neurodegeneration** 1996 Sep;5(3):213-8

Acetylcholine receptor targets on cortical pyramidal neurones as targets for Alzheimer's therapy. Chessell JP. **Neurodegeneration** 1996 Dec;5(4):453-9

Neurotransmitter receptor/G-protein mediated signal transduction in Alzheimer's disease brain. Cowburn RF, et al. **Neurodegeneration** 1996 Dec;5(4):483-8 (37 ref.)

Amyloid precursor protein mRNAs in Alzheimer's disease. Harrison PJ, et al. **Neurodegeneration** 1996 Dec;5(4):409-15 (51 ref.)

Decreased inositol (1,4,5)-trisphosphate receptor levels in Alzheimer's disease cerebral cortex: selectivity of changes and possible correlation to pathological severity. Haug LS, et al. **Neurodegeneration** 1996 Jun;5(2):169-76

From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Nitsch RM. **Neurodegeneration** 1996 Dec;5(4):477-82 (44 ref.)

Neurochemical studies of Alzheimer's disease. Palmer AM. **Neurodegeneration** 1996 Dec;5(4):381-91 (80 ref.)

Characterization of appican, the chondroitin sulfate proteoglycan form of the Alzheimer amyloid precursor protein. Pangalos MN, et al. **Neurodegeneration** 1996 Dec; 5(4):445-51 (57 ref.)

Glial cell derived neurotrophic factors and Alzheimer's disease. Patel AJ, et al. **Neurodegeneration** 1996 Dec; 5(4):489-96 (43 ref.)

Neurochemical correlates of dementia. Procter AW. **Neurodegeneration** 1996 Dec;5(4):403-7 (39 ref.)

Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease. Rapoport SI, et al. **Neurodegeneration** 1996 Dec; 5(4):473-6 (27 ref.)

Energy metabolism, oxidative stress and neuronal degeneration in Alzheimer's disease. Sims NR. **Neurodegeneration** 1996 Dec;5(4):435-40 (49 ref.)

Daily energy expenditure in free-living non-institutionalized Alzheimer's patients: a doubly labeled water study. Poehlman ET, et al. **Neurology** 1997 Apr;48(4):997-1002

Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Tedeschi G, et al. **Neurology** 1996 Sep;47(3):696-704

Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Paresce DM, et al. **Neuron** 1996 Sep;17(3):553-65

Amyloid deposition is associated with c-Jun expression in Alzheimer's disease and amyloid angiopathy. Ferrer I, et al. **Neuropathol Appl Neurobiol** 1996 Dec;22(6):521-6

Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression. Sheng JG, et al. **Neuropathol Appl Neurobiol** 1996 Aug;22(4):334-41

Ubiquitin and Alzheimer's amyloid beta precursor protein colocalize to endosomes-lysosomes in cultured human cells. Ali-Khan Z, et al. **Neuroreport** 1996 Dec 20; 8(1):385-9

Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. Arendt T, et al. **Neuroreport** 1996 Nov 25;7(18):3047-9

Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain. Bao F, et al. **Neuroreport** 1996 Jul 29;7(11):1733-9

Induction of a specific tau Alzheimer epitope in SY-5Y neuroblastoma cells. Caillet-Boudin ML, et al. **Neuroreport** 1996 Dec 20;8(1):307-10

A beta 42 is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury. Gentleman SM, et al. **Neuroreport** 1997 Apr 14; 8(6):1519-22

Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. Guo Q, et al. **Neuroreport** 1996 Dec 20; 8(1):379-83

Processing of presenilin 1 in brains of patients with Alzheimer's disease and controls. Hendriks L, et al. **Neuroreport** 1997 May 6;8(7):1717-21

Abundance of the longer A beta 42 in neocortical and cerebrovascular amyloid beta deposits in Swedish familial Alzheimer's disease and Down's syndrome. Kalaria RN, et al. **Neuroreport** 1996 May 31;7(8):1377-81

Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease. Mufson EJ, et al. **Neuroreport** 1996 Dec 20;8(1):25-9

Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Narisawa-Saito M, et al. **Neuroreport** 1996 Nov 25;7(18):2925-8

Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Oka A, et al. **Neuroreport** 1997 Mar 24;8(5):1161-4

Presenilins and early-onset familial Alzheimer's disease. Rohan de Silva HA, et al. **Neuroreport** 1997 May 27; 8(8):i-xii (145 ref.)

Alzheimer's beta-amyloid peptide is conformationally modified by apolipoprotein E in vitro. Soto C, et al. **Neuroreport** 1996 Feb 29;7(3):721-5

Up-regulation of Bcl-2 is associated with neuronal DNA damage in Alzheimer's disease. Su JH, et al. **Neuroreport** 1996 Jan 31;7(2):437-40

Is amyloid beta-protein glycated in Alzheimer's disease? Tabaton M, et al. **Neuroreport** 1997 Mar 3;8(4):907-9

HB-GAM is a cytokine present in Alzheimer's and Down's syndrome lesions. Wisniewski T, et al. **Neuroreport** 1996 Jan 31;7(2):667-71

The amino-terminally truncated forms of amyloid beta-protein in brain macrophages in the ischemic lesions of Alzheimer's disease patients. Akiyama H, et al. **Neurosci Lett** 1996 Nov 22;219(2):115-8

beta-Amyloid (A beta) deposition in the medial temporal lobe of patients with dementia with Lewy bodies. Armstrong RA, et al. **Neurosci Lett** 1997 May 23; 227(3):193-6

Relationships between beta-amyloid (A beta) deposits and blood vessels in patients with sporadic and familial Alzheimer's disease. Armstrong RA, et al. **Neurosci Lett** 1996 Apr 5;207(3):171-4

Choline acetyltransferase mRNA expression in the striatal neurons of patients with Alzheimer's disease. Boissière F, et al. **Neurosci Lett** 1997 Apr 11;225(3):169-72

Expression of catalytic trkB gene in the striatum and the basal forebrain of patients with Alzheimer's disease: an in situ hybridization study. Boissière F, et al. **Neurosci Lett** 1997 Jan 17;221(2-3):141-4

Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease. Braak H, et al. **Neurosci Lett** 1996 May 31;210(2):87-90

Lack of effect of Presenilin 1, betaAPP and their Alzheimer's disease-related mutated forms on Xenopus oocytes membrane currents. Dauch P, et al. **Neurosci Lett** 1997 Jan 17;221(2-3):85-8

The effect of tetraethylammonium on intracellular calcium concentration in Alzheimer's disease fibroblasts with APP, S182 and E5-1 missense mutations. Failli P, et al. **Neurosci Lett** 1996 Apr 26;208(3):216-8

Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. Fergusson J, et al. **Neurosci Lett** 1996 Nov 29;219(3):167-70

Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Golombowski S, et al. **Neurosci Lett** 1997 Apr 11;225(3):213-5

Screening for amyloid beta precursor protein codon 665, 670/671 and 717 mutations in Finnish patients with Alzheimer's disease. Helisalmi S, et al. **Neurosci Lett** 1996 Feb 16;205(1):68-70

Apolipoprotein E polymorphism in patients with different neurodegenerative disorders. Helisalmi S, et al. **Neurosci Lett** 1996 Feb 16;205(1):61-4

Microtubule-associated protein tau in human fibroblasts with the Swedish Alzheimer mutation. Ingelson M, et al. **Neurosci Lett** 1996 Dec 6;220(1):9-12

Increased A beta 42(43)-plaque deposition in early-onset familial Alzheimer's disease brains with the deletion of exon 9 and the missense point mutation (H163R) in the PS-1 gene. Ishii K, et al. **Neurosci Lett** 1997 May 30;228(1):17-20

Embryonic genes expressed in Alzheimer's disease brains. Kondo T, et al. **Neurosci Lett** 1996 May 17;209(3):157-60

Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease. Li YM, et al. **Neurosci Lett** 1997 May 2;226(3):155-8

Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Liang JS, et al. **Neurosci Lett** 1997 Apr 4;225(2):73-6

Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Lindh M, et al. **Neurosci Lett** 1997 Jun 27;229(2):85-8

Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Mann DM, et al. **Neurosci Lett** 1997 Jan 17;221(2-3):81-4

Abnormal distribution of neurofilament L in neurons with Alzheimer's disease. Nakamura Y, et al. **Neurosci Lett** 1997 Apr 11;225(3):201-4

No association between very low density lipoprotein receptor (VLDL-R) and Alzheimer disease in American Caucasians. Pritchard ML, et al. **Neurosci Lett** 1996 May 10;

209(2):105–8
Cerebrospinal protein tau is elevated in early Alzheimer's disease. Riemenschneider M, et al. **Neurosci Lett** 1996 Jul 19;212(3):209–11
Neuritic plaques in the Lewy body variant of Alzheimer disease lack paired helical filaments. Samuel W, et al. **Neurosci Lett** 1997 Feb 21;223(2):73–6
Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease. Schneider C, et al. **Neurosci Lett** 1997 Feb 7;222(3):183–6
Evidence against increased glycoxidation in patients with Alzheimer's disease. Seidl R, et al. **Neurosci Lett** 1997 Aug 22;232(1):49–52
G protein subunit levels in fibroblasts from familial Alzheimer's disease patients: lower levels of high molecular weight Gs alpha isoform in patients with decreased beta-adrenergic receptor stimulated cAMP formation. Shanahan C, et al. **Neurosci Lett** 1997 Aug 22;232(1):33–6
Early contribution of oxidative glycation in Alzheimer disease [letter; comment] Smith MA, et al. **Neurosci Lett** 1996 Oct 18;217(2–3):210–1. Comment on: Neurosci Lett 1996 Apr 12;208(1):53–6.
Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Svensson AL, et al. **Neurosci Lett** 1997 Aug 22;232(1):37–40
Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Takedo A, et al. **Neurosci Lett** 1996 Dec 27;221(1):17–20
Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Wavrant-DeVrièze F, et al. **Neurosci Lett** 1997 May 9; 227(1):68–70
Pancreastatin-like immunoreactivity in globular dystrophic neurites of senile plaques in brains of patients with Alzheimer's disease. Yasuhara O, et al. **Neurosci Lett** 1996 Apr 26;208(3):167–70
Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Salehi A, et al. **Neuroscience** 1996 Nov;75(2):373–87
Decreased expression of N-methyl-D-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain. Ulas J, et al. **Neuroscience** 1997 Aug;79(4):973–82
Mercury vapor inhalation inhibits binding of GTP to tubulin in rat brain: similarity to a molecular lesion in Alzheimer diseased brain. Pendergrass JC, et al. **Neurotoxicology** 1997; 18(2):315–24
Oxidative stress in Parkinson's disease and other neurodegenerative disorders. Jenner P. **Pathol Biol (Paris)** 1996 Jan;44(1):57–64 (51 ref.)
Apolipoprotein E and Alzheimer's disease: a review of recent studies. Higgins GA, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):675–85 (118 ref.)
Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Alonso AD, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7; 94(1):298–303
Specific transcellular binding between membrane proteins crucial to Alzheimer disease. Dewji NN, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12575–80
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Johnson-Wood K, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1550–5
Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Kaltschmidt B, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2642–7
In situ hybridization analysis of presenilin 1 mRNA in Alzheimer disease and in lesioned rat brain. Page K, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):14020–4
The heat shock-induced hyperphosphorylation of tau is estrogen-independent and prevented by androgens: implications for Alzheimer disease. Papasozomenos SC. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6612–7
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Smith MA, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9866–8
Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Spillantini MG, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):4113–8
Proteolytic processing of the Alzheimer disease-associated presenilin-1 generates an in vivo substrate for protein kinase C. Walter J, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):5349–54
Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. Xia W, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8208–13
Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides. Forloni G, et al. **Prog Neurobiol** 1996 Jul;49(4):287–315 (273 ref.)
Alterations in apolipoprotein E expression during aging and neurodegeneration. Masliah E, et al. **Prog Neurobiol** 1996 Dec;50(5–6):493–503 (80 ref.)
Is the binding of beta-amyloid protein to antichymotrypsin in Alzheimer plaques mediated by a beta-strand insertion? Lukacs CM, et al. **Proteins** 1996 Aug;25(4):420–4
Protein folding, nucleation phenomena and delayed neurodegeneration in Alzheimer's disease. Fox N, et al. **Rev Neurosci** 1996 Jan–Mar;7(1):21–8 (61 ref.)
The significance of glucose turnover in the brain in the pathogenetic mechanisms of Alzheimer's disease. Meier-Ruge W, et al. **Rev Neurosci** 1996 Jan–Mar;7(1):1–19 (207 ref.)
Alterations of the blood–brain barrier and glial cells in white matter lesions in cerebrovascular and Alzheimer's disease patients [letter; comment] Leys D, et al. **Stroke** 1997 Apr; 28(4):874–6. Comment on: Stroke 1996 Nov;27(11):2069–74.
Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. Rodríguez-Puertas R, et al. **Synapse** 1997 Aug;26(4):341–50
Dopamine D2-like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline. Seeman P, et al. **Synapse** 1997 Feb; 25(2):137–46
Ionic effects of the Alzheimer's disease beta-amyloid precursor protein and its metabolic fragments. Fraser SP, et al. **Trends Neurosci** 1997 Feb;20(2):67–72 (91 ref.)
Apolipoprotein E, memory and Alzheimer's disease. Soininen HS, et al. **Trends Neurosci** 1996 Jun;19(6):224–8
Protein conformation and disease. Nandi PK. **Vet Res** 1996; 27(4–5):373–82 (61 ref.)
[Glucose metabolism and Alzheimer's dementia] Itagaki T, et al. **Nippon Ronen Igakkai Zasshi** 1996 Aug;33(8):569–72 (Eng. Abstr.) **(Jpn)**
[Alzheimer's disease and apolipoprotein E] Yamaguchi H. **No To Shinkei** 1996 Nov;48(11):981–90 (74 ref.) **(Jpn)**
[Thrombin deposition in brains of patients with Alzheimer's disease--activation of the coagulation system in the central nervous system] Akiyama H. **Rinsho Byori** 1997 Feb;Suppl 104:117–23 (31 ref.) **(Jpn)**
[Physiology and pathology of the lipid transport in the brain] Chiba H. **Rinsho Byori** 1996 Mar;44(3):231–6 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Biological characteristics of amyloid precursor protein and Alzheimer's disease] Fukatsu R, et al. **Rinsho Byori** 1996 Mar;44(3):213–24 (56 ref.) (Eng. Abstr.) **(Jpn)**
[Diffusional anisotropy in the cerebral white matter in Alzheimer-type dementia] Hanyu H, et al. **Rinsho Shinkeigaku** 1996 Jul;36(7):909–11 (Eng. Abstr.) **(Jpn)**
[Spatial resolution of proteolytic reactions in brain ischemia and Alzheimer's disease] Saido TC. **Seikagaku** 1996 Sep; 68(9):1507–22 (73 ref.) **(Jpn)**
[Neuroimmunology of Alzheimer's disease] Novák M. **Bratisl Lek Listy** 1997 Jun;98(6):303–14 (178 ref.) (Eng. Abstr.) **(Slo)**
[Not all cerebrovascular accidents are equal (editorial; comment)] Martinez López de Letona J. **An Med Interna** 1996 Jun;13(6):259–60. Comment on: An Med Interna 1996 Jun;13(6):261–4. **(Spa)**
[Molecular mechanisms in Alzheimer's disease] Coria F, et al. **Rev Neurol** 1997 Jul;25 Suppl 1:S50–4 (50 ref.) **(Spa)**

MICROBIOLOGY

Propionibacterium acnes in the cortex of patients with Alzheimer's disease [letter] [see comments] Kornhuber HH. **Eur Arch Psychiatry Clin Neurosci** 1996;246(2):108–9. Comment in: Eur Arch Psychiatry Clin Neurosci 1996;246(4):224–6.

MORTALITY

Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Moritz DJ, et al. **Arch Neurol** 1997 Jul;54(7):878–85
Somatic pathology in elderly demented patients. Annoni G, et al. **Funct Neurol** 1997 May–Aug;12(3–4):205–6
Mortality and temporal course of probable Alzheimer's disease: a 5-year prospective study. Reisberg B, et al. **Int Psychogeriatr** 1996 Summer;8(2):291–311
The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease. Smith F, et al. **J Biopharm Stat** 1996 Nov; 6(4):395–409
Risk of mortality and institutionalization in demented patients with delusions. Magni E, et al. **J Geriatr Psychiatry Neurol** 1996 Jul;9(3):123–6
Predicting time to nursing home care and death in individuals with Alzheimer disease [see comments] Stern Y, et al. **JAMA** 1997 Mar 12;277(10):806–12. Comment in: JAMA 1997 Jun 25;277(24):1933–4. Comment in: ACP J Club 1997 Sep–Oct;127(2):43.
Survival in early onset dementia: effects of urbanization and socio-economic deprivation. Thomas BM, et al. **Neuroepidemiology** 1997;16(3):134–40
Predictors of mortality in patients diagnosed with probable Alzheimer's disease. Bowen JD, et al. **Neurology** 1996 Aug; 47(2):433–9
Increased risk of mortality in Alzheimer's disease patients with higher education? A replication study. Geerlings MI, et al. **Neurology** 1997 Sep;49(3):798–802
The impact of apolipoprotein E4 on cause of death in Alzheimer's disease. Olichney JM, et al. **Neurology** 1997 Jul;49(1):76–81
Tacrine and nursing home placement [letter] Thal LJ, et al. **Neurology** 1997 Sep;49(3):897–9

NURSING

The Bedford Alzheimer Nursing Severity scale for the severely demented: validation study. Bellelli G, et al. **Alzheimer Dis Assoc Disord** 1997 Jun;11(2):71–7
Computer networks: new tools for nursing practice [editorial] Brennan PF. **Appl Nurs Res** 1996 Nov;9(4):159–60
Application of an attribution-affect-action model of caregiving behavior. Fopma-Loy J, et al. **Arch Psychiatr Nurs** 1997 Aug;11(4):210–7
Case management styles for people with AD: do the differences make a difference? Arnsberger P. **Geriatrics** 1997 Sep;52 Suppl 2:S44–7
Patients, caregivers, and managing care. Baxter E. **Geriatrics** 1997 Sep;52 Suppl 2:S48–9
Racial, ethnic, and cultural differences in dementia caregiving: review and analysis. Connell CM, et al. **Gerontologist** 1997 Jun;37(3):355–64
Burden and well-being: the same coin or related currency. Stuckey JC, et al. **Gerontologist** 1996 Oct;36(5):686–93
Caregiver training for people with Alzheimer's based on a stress threshold model. Gerdner LA, et al. **Image J Nurs Sch** 1996 Fall;28(3):241–6
Interventions for caregivers of patients with Alzheimer's disease: a review and analysis of content, process, and outcomes. Bourgeois MS, et al. **Int J Aging Hum Dev** 1996; 43(1):35–92 (117 ref.)
Strain among caregivers: comparing the experiences of African American and Hispanic caregivers of Alzheimer's relatives. Cox C, et al. **Int J Aging Hum Dev** 1996; 43(2):93–105
Perspective of a clinical trials research nurse. Cooler CY. **Int Psychogeriatr** 1996;8 Suppl 3:465–8; discussion 469–72
Perspective of an institution-based research nurse. Norberg A. **Int Psychogeriatr** 1996;8 Suppl 3:459–63; discussion 469–73 (30 ref.)
Research project to aid caregivers of people with Alzheimer's disease [news] **J Adv Nurs** 1996 Jul;24(1):3
A word from WIPRO. Alzheimer's disease caregiver cooperative project. Miesbauer K, et al. **Wis Med J** 1996 Oct;95(10):721–3

PATHOLOGY

Altered beta-APP metabolism after head injury and its relationship to the aetiology of Alzheimer's disease. Graham DI, et al. **Acta Neurochir Suppl (Wien)** 1996; 66:96–102 (53 ref.)
The neurochemistry of Alzheimer's disease. Blennow K, et al. **Acta Neurol Scand Suppl** 1996;168:77–86 (129 ref.)
Evolution of the neuropathology of Alzheimer's disease. Braak H, et al. **Acta Neurol Scand Suppl** 1996;165:3–12 (53 ref.)
Frontal lobe degeneration of non-Alzheimer type. Structural characteristics, diagnostic criteria and relation to other frontotemporal dementias. Brun A, et al. **Acta Neurol Scand Suppl** 1996;168:28–30 (37 ref.)
Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease? Beach TG, et al. **Acta Neuropathol (Berl)** 1997 Feb;93(2):146–53
Alzheimer's disease: transiently developing dendritic changes in pyramidal cells of sector CA1 of the Ammon's horn. Braak E, et al. **Acta Neuropathol (Berl)** 1997 Apr; 93(4):323–5
Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Braak H, et al. **Acta Neuropathol (Berl)** 1996 Aug;92(2):197–201
Dissociation of Alzheimer type pathology in a disconnected piece of cortex. Duyckaerts C, et al. **Acta Neuropathol (Berl)** 1997 May;93(5):501–7
Coexistence of paired helical filaments and polyglucosan bodies in the same neuron in an autopsy case of Alzheimer's disease. Inoue M, et al. **Acta Neuropathol (Berl)** 1996 Nov; 92(5):511–4
Rattan bamboo blind (Japanese sudare)-like profiles of neurofibrillary tangles in Alzheimer's disease. Inoue M, et al. **Acta Neuropathol (Berl)** 1996;91(4):448–50
Eosinophilic bodies in the cerebral cortex of Alzheimer's disease cases. Inoue M, et al. **Acta Neuropathol (Berl)** 1996 Dec;92(6):555–61
Scanning electron microscopical study of the neurofibrillary tangles of Alzheimer's disease. Itoh Y, et al. **Acta Neuropathol (Berl)** 1997 Jul;94(1):78–86
Distribution of amyloid deposits in the cerebral white matter of the Alzheimer's disease brain: relationship to blood vessels. Iwamoto N, et al. **Acta Neuropathol (Berl)** 1997 Apr;93(4):334–40
Alzheimer-type pathology in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Kaido M, et al. **Acta Neuropathol (Berl)** 1996 Sep;92(3):312–8
No correlation between nigral degeneration and striatal plaques in Alzheimer's disease. Love S, et al. **Acta Neuropathol (Berl)** 1996;91(4):432–6
A quantitative comparison of plaque types in Alzheimer's disease and senile dementia of the Lewy body type. McKenzie JE, et al. **Acta Neuropathol (Berl)** 1996; 91(5):526–9

Atypical amyloid (A beta) deposition in the cerebellum in Alzheimer's disease: an immunohistochemical study using end-specific A beta monoclonal antibodies. Mann DM, et al. **Acta Neuropathol (Berl)** 1996;91(6):647–53

Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Mena R, et al. **Acta Neuropathol (Berl)** 1996;91(6):633–41

Cell cycle markers in the hippocampus in Alzheimer's disease. Nagy Z, et al. **Acta Neuropathol (Berl)** 1997 Jul; 94(1):6–15

Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease. Praprotnik D, et al. **Acta Neuropathol (Berl)** 1996;91(3):226–35

Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Schmidt ML, et al. **Acta Neuropathol (Berl)** 1996; 91(5):475–81

Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Sheng JG, et al. **Acta Neuropathol (Berl)** 1997 Jul;94(1):1–5

Comparison of the neurofibrillary pathology in Alzheimer's disease and familial presenile dementia with tangles. Spillantini MG, et al. **Acta Neuropathol (Berl)** 1996 Jul; 92(1):42–8

Widespread immunoreactivity of presenilin in neurons of normal and Alzheimer's disease brains: double-labeling immunohistochemical study. Uchihara T, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):325–30

Differential expression of intercellular adhesion molecule-1 (ICAM-1) in the A beta-containing lesions in brains of patients with dementia of the Alzheimer type. Verbeek MM, et al. **Acta Neuropathol (Berl)** 1996;91(6):608–15

Neurofibrillary tangles in the dentate granule cells of patients with Alzheimer's disease, Lewy body disease and progressive supranuclear palsy. Wakabayashi K, et al. **Acta Neuropathol (Berl)** 1997 Jan;93(1):7–12

Retinal nerve fiber layer abnormalities in Alzheimer's disease. Hedges TR 3rd, et al. **Acta Ophthalmol Scand** 1996 Jun; 74(3):271–5

Innervation in human taste buds and its decrease in Alzheimer's disease patients. Yamagishi M, et al. **Acta Otolaryngol (Stockh)** 1995 Sep;115(5):678–84

Abnormalities of the endosomal–lysosomal system in Alzheimer's disease: relationship to disease pathogenesis. Cataldo AM, et al. **Adv Exp Med Biol** 1996;389:271–80 (44 ref.)

Apoptosis in neurodegenerative diseases. Nishimoto I, et al. **Adv Pharmacol** 1997;41:337–68 (267 ref.)

Spatial pattern analysis of beta-amyloid (A beta) deposits in Alzheimerdisease by linear regression. Armstrong RA, et al. **Alzheimer Dis Assoc Disord** 1996 Spring;10(1):40–5

Positron emission tomography metabolic data corrected for cortical atrophy using magnetic resonance imaging. Labbé C, et al. **Alzheimer Dis Assoc Disord** 1996 Fall;10(3):141–70

Presenilin-1-immunoreactive neurons are preserved in late-onset Alzheimer's disease. Giannakopoulos P, et al. **Am J Pathol** 1997 Feb;150(2):429–36

Antibodies to presenilin proteins detect neurofibrillary tangles in Alzheimer's disease. Murphy GM Jr, et al. **Am J Pathol** 1996 Dec;149(6):1839–46

Monoclonal antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains. Schmidt ML, et al. **Am J Pathol** 1997 Jul;151(1):69–80

Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Baldessarini RJ, et al. **Am J Psychiatry** 1997 Jun;154(6):861–3

Clinical genetics, IV. Alzheimer's disease: from gene to pathology. Jay G. **Am J Psychiatry** 1997 Oct;154(10):1359

Images in neuroscience. Alzheimer's disease: from genes to pathogenesis. Selkoe DJ. **Am J Psychiatry** 1997 Sep; 154(9):1198

Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer's type. Bertoni-Freddari C, et al. **Anal Quant Cytol Histol** 1996 Jun;18(3):209–13

Automated identification and quantitative morphometry of the senile plaques of Alzheimer's disease. Hibbard LS, et al. **Anal Quant Cytol Histol** 1997 Apr;19(2):123–38

Neuropeptides and Alzheimer's disease pathology. Bissette G. **Ann N Y Acad Sci** 1997 Apr 24;814:17–29 (72 ref.)

Pathological tau proteins in postencephalitic parkinsonism: comparison with Alzheimer's disease and other neurodegenerative disorders. Buée-Scherrer V, et al. **Ann Neurol** 1997 Sep;42(3):356–9

Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques. Ginsberg SD, et al. **Ann Neurol** 1997 Feb;41(2):200–9

Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Gómez-Isla T, et al. **Ann Neurol** 1997 Jan;41(1):17–24

Neuronal activity and early neurofibrillary tangles in Alzheimer's disease. Hatanpää K, et al. **Ann Neurol** 1996 Sep;40(3):411–20

Pathological correlates of extrapyramidal signs in Alzheimer's disease. Liu Y, et al. **Ann Neurol** 1997 Mar; 41(3):368–74

The pathology of Alzheimer's disease: numbers count [editorial] Terry RD. **Ann Neurol** 1997 Jan;41(1):7

Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Harper JD, et al. **Annu Rev Biochem** 1997;66:385–407 (97 ref.)

Posterior cortical atrophy: neuropathological correlations [letter; comment] Ala TA, et al. **Arch Neurol** 1996 Oct; 53(10):958. Comment on: Arch Neurol 1988 Jul;45(7):789–93. Comment on: Arch Neurol 1994 Mar;51(3):269–74.

Selective cortical and hippocampal volume correlates of Mattis Dementia Rating Scale in Alzheimer disease. Fama R, et al. **Arch Neurol** 1997 Jun;54(6):719–28

The role of magnetic resonance imaging in the diagnosis of Alzheimer disease in adults with Down syndrome. Prasher VP, et al. **Arch Neurol** 1996 Dec;53(12):1310–3

The cellular mechanism underlying neuronal degeneration in glaucoma: parallels with Alzheimer's disease. Vickers JC. **Aust N Z J Ophthalmol** 1997 May;25(2):105–9 (47 ref.)

Patterns of synaptic and nerve cell pathology in Alzheimer's disease. Lassmann H. **Behav Brain Res** 1996 Jun;78(1):9–14 (61 ref.)

Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Kuo YM, et al. **Biochem Biophys Res Commun** 1997 Aug 8;237(1):188–91

Self-assembly of the brain MAP-2 microtubule-binding region into polymeric structures resembling Alzheimer filaments. Zhang EY, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):176–81

Lewy body variant of Alzheimer's disease (AD) identified by postmortem ubiquitin staining in a previously reported case of AD associated with REM sleep behavior disorder [letter] Schenck CH, et al. **Biol Psychiatry** 1997 Sep 15; 42(6):527–8

A case of REM sleep behavior disorder with autopsy-confirmed Alzheimer's disease: postmortem brain stem histochemical analyses. Schenck CH, et al. **Biol Psychiatry** 1996 Sep 1;40(5):422–5

Somatostatin-positive neurons in the different parts of the brain in normal aging and Alzheimer's disease. Li WP, et al. **Biol Signals** 1996 Nov-Dec;5(6):343–8

In situ characterization of beta-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy. Choo LP, et al. **Biophys J** 1996 Oct; 71(4):1672–9

Pathogenesis of white matter lesions in Alzheimer's disease and depression [letter; comment] [see comments] Rao R. **Br J Psychiatry** 1996 Jul;169(1):114. Comment on: Br J Psychiatry 1996 Apr;168(4):477–85. Comment in: Br J Psychiatry 1996 Nov;169(5):671.

Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Fox NC, et al. **Brain** 1997 Mar;120 (Pt 3):491–501

Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Fox NC, et al. **Brain** 1996 Dec; 119 (Pt 6):2001–7

The significance of cortical pathology in progressive supranuclear palsy. Clinico-pathological data in 10 cases. Verny M, et al. **Brain** 1996 Aug;119 (Pt 4):1123–36

A confocal microscopic analysis of galaninergic hyperinnervation of cholinergic basal forebrain neurons in Alzheimer's disease. Bowser R, et al. **Brain Pathol** 1997 Apr;7(2):723–30

Mechanisms of neuronal death in Alzheimer's disease. Cotman CW, et al. **Brain Pathol** 1996 Oct;6(4):493–506 (83 ref.)

Pathological aging in Africans: a benign form of cerebral amyloidosis vs. pre-clinical Alzheimer's disease? [editorial; comment] Dickson DW. **Brain Pathol** 1996 Apr;6(2):107–8 . Comment on: Brain Pathol 1996 Apr;6(2):101–7.

Cerebral amyloid beta protein deposits and other Alzheimer lesions in non-demented elderly east Africans [see comments] Ogeng'o JA, et al. **Brain Pathol** 1996 Apr; 6(2):101–7. Comment in: Brain Pathol 1996 Apr;6(2):107–8.

Brain parenchymal and microvascular amyloid in Alzheimer's disease. Vinters HV, et al. **Brain Pathol** 1996 Apr;6(2):179–95 (169 ref.)

Quantitative cytochemistry of cytochrome oxidase and cellular morphometry of the human inferior colliculus in control and Alzheimer's patients. Gonzalez-Lima F, et al. **Brain Res** 1997 Mar 28;752(1-2):117–26

Immunoreactivity of presenilin-1 in human, rat and mouse brain. Kim KS, et al. **Brain Res** 1997 May 16;757(1):159–63

Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex. Nielson KA, et al. **Brain Res** 1996 Nov 25;741(1-2):284–93

Distribution of apolipoprotein E in senile plaques in brains with Alzheimer's disease: investigation with the confocal laser scan microscope. Nishiyama E, et al. **Brain Res** 1997 Mar 7;750(1-2):20–4

Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Su JH, et al. **Brain Res** 1996 Nov 11;739(1-2):79–87

The autonomic-related cortex: pathology in Alzheimer's disease. Chu CC, et al. **Cereb Cortex** 1997 Jan-Feb; 7(1):86–95

Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Geula C, et al. **Cereb Cortex** 1996 Mar-Apr;6(2):165–77

Neuroimaging for differentiating vascular from Alzheimer's dementias. Meyer JS, et al. **Cerebrovasc Brain Metab Rev** 1996 Spring;8(1):1–10 (51 ref.)

Neocortical temporal lobe sclerosis masquerading as Alzheimer dementia: does herpes virus encephalopathy protect against Alzheimer's disease? Ball MJ, et al. **Clin Neuropathol** 1997 Jan-Feb;16(1):1–12

Tissue kallikrein-like immunoreactive material decorates neuritic plaques of Alzheimer patients. Bernstein HG. **Clin Neuropathol** 1997 Mar-Apr;16(2):69–71

Molecular dissection of the neurofibrillary lesions of Alzheimer's disease. Goedert M, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:565–73 (57 ref.)

Staging of Alzheimer-type pathology: an interrater-intrarater study. Nagy Z, et al. **Dement Geriatr Cogn Disord** 1997 Jul-Aug;8(4):248–51

Vascular variant of Alzheimer's disease characterized by severe plaque-like beta protein angiopathy. Yamada M, et al. **Dement Geriatr Cogn Disord** 1997 May-Jun;8(3):163–8

The use of multivariate methods in the identification of subtypes of Alzheimer's disease: a comparison of principal components and cluster analysis. Armstrong RA, et al. **Dementia** 1996 Jul-Aug;7(4):215–20

The spatial pattern of discrete beta-amyloid deposits in Alzheimer's disease reflects synaptic disconnection. Armstrong RA. **Dementia** 1996 Mar-Apr;7(2):86–90

Frontal lobe degeneration and Alzheimer's disease: a controlled study on clinical findings, volumetric brain changes and quantitative electroencephalography data. Förstl H, et al. **Dementia** 1996 Jan-Feb;7(1):27–34

Usefulness of simple measures of temporal lobe atrophy in probable Alzheimer's disease. Frisoni GB, et al. **Dementia** 1996 Jan-Feb;7(1):15–22

Atrophy of hippocampus in patients with Alzheimer's disease and other diseases with memory impairment. Horn R, et al. **Dementia** 1996 Jul-Aug;7(4):182–6

Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. Liu X, et al. **Dementia** 1996 May-Jun;7(3):128–34

Specificity of temporal amygdala atrophy in Alzheimer's disease: quantitative assessment with magnetic resonance imaging. Maunoury C, et al. **Dementia** 1996 Jan-Feb; 7(1):10–14

Clustering of pathological features in Alzheimer's disease: clinical and neuroanatomical aspects. Nagy Z, et al. **Dementia** 1996 May-Jun;7(3):121–7

Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria. Nagy Z, et al. **Dementia** 1996 Mar-Apr; 7(2):76–81

Quantitative assessment of synaptic density in the outer molecular layer of the hippocampal dentate gyrus in Alzheimer's disease. Scheff SW, et al. **Dementia** 1996 Jul-Aug;7(4):226–32

Critical comments on "Propionibacterium acnes in the cortex of patients with Alzheimer's disease" by H.H.Kornhuber (Eur Arch Psychiatry Clin Neurosci, 1996, 246:108–109) [letter; comment] Bauer J, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(4):224–6. Comment on: Eur Arch Psychiatry Clin Neurosci 1996;246(2):108–9.

A laser microprobe mass analysis of brain aluminum and iron in dementia pugilistica: comparison with Alzheimer's disease. Bouras C, et al. **Eur Neurol** 1997;38(1):53–8

Morphology and neurochemical characteristics of the vulnerable neurons in brain aging and Alzheimer's disease. Hof PR. **Eur Neurol** 1997;37(2):71–81 (90 ref.)

Regenerative failure: a potential mechanism for neuritic dystrophy in Alzheimer's disease. DeWitt DA, et al. **Exp Neurol** 1996 Nov;142(1):103–10

Amyloid load and neural elements in Alzheimer's disease and nondemented individuals with high amyloid plaque density. Mochizuki A, et al. **Exp Neurol** 1996 Nov;142(1):89–102

The cellular basis for the relative resistance of parvalbumin and calretinin immunoreactive neocortical neurons to the pathology of Alzheimer's disease. Sampson VL, et al. **Exp Neurol** 1997 May;145(1):295–302

Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques. Wallace MN, et al. **Exp Neurol** 1997 Apr;144(2):266–72

A promising rat model of Alzheimer's disease-like neuropathology. Pluta R, et al. **Folia Morphol (Warsz)** 1996; 55(4):417–9

The cholinergic system in Alzheimer's disease and dementia with Lewy bodies: from animal models to neuropathological data. Liberini P. **Funct Neurol** 1997 May-Aug;12(3-4):153–7 (18 ref.)

New insights into the neuropathology and cell biology of Alzheimer's disease. Weldon DT, et al. **Geriatrics** 1997 Sep; 52 Suppl 2:S13–6 (12 ref.)

Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. de la Torre JC. **Gerontology** 1997;43(1-2):26–43 (154 ref.)

Microglial in neurodegenerative disorders: emphasis on Alzheimer's disease. McRae A, et al. **Gerontology** 1997; 43(1-2):95–108 (100 ref.)

Interaction of aluminum with paired helical filament tau is involved in neurofibrillary pathology of Alzheimer's disease. Shin RW. **Gerontology** 1997;43 Suppl 1:16–23 (60 ref.)

Systemic overexpression of a C-terminal fragment of human amyloid beta-protein precursor causes accumulation of

Alzheimer beta-amyloid fibrils in pancreas of transgenic mice. Shoji M, et al. **Gerontology** 1996;42 Suppl 1:48–56

The neuropathological changes associated with normal brain aging. Hof PR, et al. **Histol Histopathol** 1996 Oct; 11(4):1075–88 (70 ref.)

The presenilin genes: a new gene family involved in Alzheimer disease pathology. Cruts M, et al. **Hum Mol Genet** 1996;5 Spec No:1449–55 (55 ref.)

Histopathological & immunohistochemical evaluation of ageing changes in normal human brain. Yasha TC, et al. **Indian J Med Res** 1997 Mar;105:141–50

Neuropathology of psychotic symptoms in Alzheimer's disease. Bondareff W. **Int Psychogeriatr** 1996;8 Suppl 3:233–7; discussion 269–72 (8 ref.)

Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. Gottfries CG, et al. **Int Psychogeriatr** 1996 Fall;8(3):365–72

Clinicopathologic and neurochemical correlates of major depression and psychosis in primary dementia. Zubenko GS. **Int Psychogeriatr** 1996;8 Suppl 3:219–23; discussion 269–72

Nicotinic system and Alzheimer's disease [letter; comment] Gambassi G, et al. **J Am Geriatr Soc** 1997 May;45(5):655–6 . Comment on: J Am Geriatr Soc 1996 Aug;44(8):905–9.

Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. LaFerla FM, et al. **J Clin Invest** 1997 Jul 15;100(2):310–20

Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. Simić G, et al. **J Comp Neurol** 1997 Mar 24;379(4):482–94

Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia. Larson EB, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov;51(6):M313–8

Alzheimer's disease severely affects areas of the claustrum connected with the entorhinal cortex. Morys J, et al. **J Hirnforsch** 1996;37(2):173–80

Three-dimensional reconstruction of senile plaques in Alzheimer's disease. Rickert CH, et al. **J Microsc** 1997 Jun; 186 (Pt 3):263–9

Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits [see comments] Streit WJ, et al. **J Mol Med** 1997 Feb;75(2):130–8. Comment in: J Mol Med 1997 Feb;75(2):73–4.

Terminal dUTP nick end labeling (TUNEL) positive cells in the different regions of the brain in normal aging and Alzheimer patients. Li WP, et al. **J Mol Neurosci** 1997 Apr;8(2):75–82

Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. Blennow K, et al. **J Neural Transm Gen Sect** 1996;103(5):603–18

MR-imaging of non-Alzheimer's dementia. Aichner F, et al. **J Neural Transm Suppl** 1996;47:143–53 (16 ref.)

Mechanisms of cell death in Alzheimer's disease. Bancher C, et al. **J Neural Transm Suppl** 1997;50:141–52

Clinical features of frontal lobe dementia in comparison to Alzheimer's disease. Gregory CA, et al. **J Neural Transm Suppl** 1996;47:103–23 (67 ref.)

The relationship of Alzheimer-type pathology to dementia in Parkinson's disease. Jendroska K. **J Neural Transm Suppl** 1997;49:23–31 (66 ref.)

Animal model and in vitro studies of anti neurofilament antibodies mediated neurodegeneration in Alzheimer's disease. Oron L, et al. **J Neural Transm Suppl** 1997;49:77–84 (13 ref.)

Monoclonal antibodies against the human metalloprotease EC 3.4.24.15 label neurofibrillary tangles in Alzheimer's disease brain. Conn KJ, et al. **J Neurochem** 1996 May;66(5):2011–8

Magnetic stimulation in Alzheimer's disease. de Carvalho M, et al. **J Neurol** 1997 May;244(5):304–7

Medial temporal lobe atrophy in memory disorders. Pasquier F, et al. **J Neurol** 1997 Mar;244(3):175–81

White matter magnetic resonance imaging hyperintensity in Alzheimer's disease: correlations with corpus callosum atrophy. Vermersch P, et al. **J Neurol** 1996 Mar; 243(3):231–4

Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. Ala TA, et al. **J Neurol Neurosurg Psychiatry** 1997 Jan;62(1):16–21

Medial temporal structures relate to memory impairment in Alzheimer's disease: an MRI volumetric study. Mori E, et al. **J Neurol Neurosurg Psychiatry** 1997 Aug;63(2):214–21

Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val-->Ile) mutation cases: a morphometric investigation. Fukutani Y, et al. **J Neurol Sci** 1997 Aug;149(2):177–84

Alzheimer's disease, Lewy body disease and aging: a comparative study of the perforant pathway. Lippa CF, et al. **J Neurol Sci** 1997 Apr 15;147(2):161–6

Alzheimer-type of pathological changes in Chinese. Ng H, et al. **J Neurol Sci** 1997 Jan;145(1):97–103 (45 ref.)

Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. Sparks DL, et al. **J Neurol Sci** 1996 Jun;138(1-2):97–104

Counting plaques and tangles in Alzheimer's disease: concordance of technicians and pathologists. van Belle G, et al. **J Neurol Sci** 1997 Feb 12;145(2):141–6

Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. Bobinski M, et al. **J Neuropathol Exp Neurol** 1997 Apr;56(4):414–20

The pathogenesis of senile plaques. Dickson DW. **J Neuropathol Exp Neurol** 1997 Apr;56(4):321–39 (166 ref.)

Microglial cell activation in aging and Alzheimer disease: partial linkage with neurofibrillary tangle burden in the hippocampus. DiPatre PL, et al. **J Neuropathol Exp Neurol** 1997 Feb;56(2):143–9

Distinct patterns of neuronal loss and Alzheimer's disease lesion distribution in elderly individuals older than 90 years. Giannakopoulos P, et al. **J Neuropathol Exp Neurol** 1996 Dec;55(12):1210–20

The loss of GluR2(3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brains. Ikonomovic MD, et al. **J Neuropathol Exp Neurol** 1997 Sep;56(9):1018–27

Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes. Ladner CJ, et al. **J Neuropathol Exp Neurol** 1996 Aug;55(8):924–31

DNA damage distribution in the human brain as shown by in situ end labeling; area-specific differences in aging and Alzheimer disease in the absence of apoptotic morphology. Lucassen PJ, et al. **J Neuropathol Exp Neurol** 1997 Aug; 56(8):887–900

Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. Lue LF, et al. **J Neuropathol Exp Neurol** 1996 Oct;55(10):1083–8

Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. Samuel W, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):499–508

Astrocyte-apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: a regional immunohistochemical study. Shao Y, et al. **J Neuropathol Exp Neurol** 1997 Apr;56(4):376–81

Glial-neuronal interactions in Alzheimer disease: progressive association of IL-1alpha+ microglia and S100beta+ astrocytes with neurofibrillary tangle stages. Sheng JG, et al. **J Neuropathol Exp Neurol** 1997 Mar;56(3):285–90

In situ labeling of dying cortical neurons in normal aging and in Alzheimer's disease: correlations with senile plaques and disease progression. Troncoso JC, et al. **J Neuropathol Exp Neurol** 1996 Nov;55(11):1134–42

Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer disease. Verbeek MM, et al. **J Neuropathol Exp Neurol** 1997 Jul;56(7):751–61 (88 ref.)

Psychiatric correlates of MR deep white matter lesions in probable Alzheimer's disease. Lopez OL, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):246–50

Ventromedial temporal lobe anatomy, with comments on Alzheimer's disease and temporal injury. Van Hoesen GW. **J Neuropsychiatry Clin Neurosci** 1997 Summer;9(3):331–41 (55 ref.)

DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. Anderson AJ, et al. **J Neurosci** 1996 Mar 1;16(5):1710–9

Neuronal localization of presenilin-1 and association with amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Busciglio J, et al. **J Neurosci** 1997 Jul 1; 17(13):5101–7

Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. Giulian D, et al. **J Neurosci** 1996 Oct 1;16(19):6021–37

Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. Masliah E, et al. **J Neurosci** 1996 Sep 15;16(18):5795–811

Widespread peroxynitrite-mediated damage in Alzheimer's disease. Smith MA, et al. **J Neurosci** 1997 Apr 15; 17(8):2653–7

The mechanism of Bodian's silver staining: effect of copper ion on silver impregnation. Kondo H, et al. **J Neurosci Methods** 1996 Oct;68(2):275–80

Predicting progression of Alzheimer disease [letter; comment] Rabins PV. **JAMA** 1997 Jun 25;277(24):1933–4 . Comment on: JAMA 1997 Mar 12;277(10):806–12.

Brain infarction and the clinical expression of Alzheimer disease. The Nun Study [see comments] Snowdon DA, et al. **JAMA** 1997 Mar 12;277(10):813–7. Comment in: JAMA 1997 Jul 9;278(2):113; discussion 114. Comment in: JAMA 1997 Jul 9;278(2):113–4.

Hirano bodies and Alzheimer's disease. Mitake S, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Jan; 13(1):10–8 (63 ref.)

Hair abnormalities in Alzheimer's disease [letter] de Berker D, et al. **Lancet** 1997 Jul 5;350(9070):34

Neurobiology of Alzheimer's disease. Lamour Y, et al. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:63–4

Modeling neuronal degeneration in the rodent hippocampus: an approach for studying degenerative neuropathology in dementia. Miguel-Hidalgo JJ, et al. **Methods Find Exp Clin Pharmacol** 1997 Mar;19(2):133–42 (63 ref.)

Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. Baum L, et al. **Mol Chem Neuropathol** 1996 Oct-Dec;29(2-3):253–61

Neurotrophin receptors and selective loss of cholinergic neurons in Alzheimer disease. Boissière F, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):219–23 (17 ref.)

Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease? Davidsson P, et al. **Mol Chem Neuropathol** 1996 Feb;27(2):195–210

Hippocampal damage and cytoskeletal disruption resulting from impaired energy metabolism. Implications for Alzheimer disease. Geddes JW, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):65–74

Ultrastructural localization of butyrylcholinesterase in senile plaques in the brains of aged and Alzheimer disease patients. Gómez-Ramos P, et al. **Mol Chem Neuropathol** 1997 Apr;30(3):161–73

Neurodegeneration in Alzheimer disease. Is apoptosis involved? Kusiak JW, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):153–62 (41 ref.)

Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mecocci P, et al. **Mol Chem Neuropathol** 1997 May;31(1):53–64

Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments [news] Inestrosa NC, et al. **Mol Psychiatry** 1996 Nov;1(5):359–61

Glia-derived cytokines and the biogenesis of amyloid plaques in Alzheimer's disease. Patel AJ, et al. **Mol Psychiatry** 1997 Mar;2(2):130–2 (20 ref.)

Amyloid beta-peptide and the dementia of Parkinson's disease. Jendroska K, et al. **Mov Disord** 1996 Nov; 11(6):647–53

Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Blanks JC, et al. **Neurobiol Aging** 1996 May-Jun;17(3):377–84

Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Blanks JC, et al. **Neurobiol Aging** 1996 May-Jun;17(3):385–95

Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Breitner JC. **Neurobiol Aging** 1996 Sep-Oct;17(5):789–94 (93 ref.)

Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches. Chen S, et al. **Neurobiol Aging** 1996 Sep-Oct; 17(5):781–7

Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Convit A, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):131–8

Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. De Leon MJ, et al. **Neurobiol Aging** 1997 Jan-Feb;18(1):1–11

Glycation and microglial reaction in lesions of Alzheimer's disease. Dickson DW, et al. **Neurobiol Aging** 1996 Sep-Oct; 17(5):733–43

Topography of brain atrophy during normal aging and Alzheimer's disease. Double KL, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):513–21

Modeling the relation between neurofibrillary tangles and intellectual status. Duyckaerts C, et al. **Neurobiol Aging** 1997 May-Jun;18(3):267–73

The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Eikelenboom P, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):673–80 (99 ref.)

Evolutionary perspectives on amyloid and inflammatory features of Alzheimer disease. Finch CE, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):809–15 (131 ref.)

Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options. Hüll M, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):795–800

MR T2 relaxometry in Alzheimer's disease and age-associated memory impairment. Laakso MP, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):535–40

Characterization of glial cultures from rapid autopsies of Alzheimer's and control patients. Lue LF, et al. **Neurobiol Aging** 1996 May-Jun;17(3):421–9

Inflammatory mechanisms and anti-inflammatory therapy in Alzheimer's disease [editorial] O'Banion MK, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):669–71 (38 ref.)

Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Pasinetti GM. **Neurobiol Aging** 1996 Sep-Oct;17(5):707–16 (157 ref.)

Inflammation and Alzheimer's disease pathogenesis. Rogers J, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):681–6 (100 ref.)

In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Sheng JG, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):761–6

Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Troncoso JC, et al. **Neurobiol Aging** 1996 May-Jun;17(3):365–71

TG-1: a marker for neuronal nuclei in Alzheimer's disease. Vincent I, et al. **Neurobiol Dis** 1994 Dec;1(3):145–57

Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology [editorial; comment] Zlokovic B. **Neurobiol Dis** 1997; 4(1):23–6 (19 ref.). Comment on: Neurobiol Dis 1997 ;4(1):27–34.

Neuropathologic changes in the olfactory bulb in Alzheimer's disease. Kovács I, et al. **Neurobiology (Bp)** 1996; 4(1-2):123–6

Topographic associations between DNA fragmentation and Alzheimer's disease neuropathology in the hippocampus.

Sugaya K, et al. **Neurochem Int** 1997 Aug;31(2):275–81

Improved selectivity and sensitivity in the visualization of neurofibrillary tangles, plaques and neuropil threads. Cullen KM, et al. **Neurodegeneration** 1996 Jun;5(2):177–87

Structural correlates of cognition in dementia: quantification and assessment of synapse change. DeKosky ST, et al. **Neurodegeneration** 1996 Dec;5(4):417–21 (32 ref.)

Cellular aspects of the inflammatory response in Alzheimer's disease. Kalaria RN, et al. **Neurodegeneration** 1996 Dec; 5(4):497–503 (47 ref.)

Quantification of Alzheimer-type neurofibrillary lesions by automated image analysis. McKenzie JE, et al. **Neurodegeneration** 1996 Sep;5(3):251–8

Comparative investigation of neurofibrillary damage in the temporal lobe in Alzheimer's disease, Down's syndrome and dementia pugilistica. McKenzie JE, et al. **Neurodegeneration** 1996 Sep;5(3):259–64

Pyramidal nerve cell loss in Alzheimer's disease. Mann DM. **Neurodegeneration** 1996 Dec;5(4):423–7 (58 ref.)

From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Nitsch RM. **Neurodegeneration** 1996 Dec;5(4):477–82 (44 ref.)

Cortical connections and the pathology of Alzheimer's disease. Pearson RC. **Neurodegeneration** 1996 Dec; 5(4):429–34 (24 ref.)

Energy metabolism, oxidative stress and neuronal degeneration in Alzheimer's disease. Sims NR. **Neurodegeneration** 1996 Dec;5(4):435–40 (49 ref.)

Decreased senile plaque density in Alzheimer neocortex adjacent to an omental transposition. Relkin NR, et al. **Neurol Res** 1996 Aug;18(4):291–4; discussion 295–6

Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Hansen LA, et al. **Neurology** 1997 Jan; 48(1):126–32

Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Jack CR Jr, et al. **Neurology** 1997 Sep;49(3):786–94

AD neuropathology [letter; comment] Jellinger KA, et al. **Neurology** 1996 Apr;46(4):1186–7. Comment on: Neurology 1995 Mar;45(3 Pt 1):461–6.

Apolipoprotein E–epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Lippa CF, et al. **Neurology** 1997 Feb;48(2):515–9

Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Mega MS, et al. **Neurology** 1996 Dec;47(6):1403–9

Neuropathologic assessment of Alzheimer's disease. Mirra SS, et al. **Neurology** 1997 Sep;49(3 Suppl 3):S14–6

Noninvasive perfusion MRI in Alzheimer's disease: a preliminary report. Sandson TA, et al. **Neurology** 1996 Nov;47(5):1339–42

Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Tedeschi G, et al. **Neurology** 1996 Sep;47(3):696–704

The Fifth International Conference on Alzheimer's Disease and Related Disorders, Osaka, Japan, 24–29 July 1996. Nicoll JA. **Neuropathol Appl Neurobiol** 1996 Oct; 22(5):463–4

Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression. Sheng JG, et al. **Neuropathol Appl Neurobiol** 1996 Aug;22(4):334–41

Review. David Oppenheimer Memorial Lecture 1995: Some neuropathological aspects of Alzheimer's disease and its relevance to other disciplines. Wisniewski HM, et al. **Neuropathol Appl Neurobiol** 1996 Feb;22(1):3–11 (61 ref.)

Perivascular astrocytes within Alzheimer's disease plaques. Cullen KM. **Neuroreport** 1997 May 27;8(8):1961–6

Physical damage to rat cortical axons mimics early Alzheimer's neuronal pathology. King CE, et al. **Neuroreport** 1997 May 6;8(7):1663–5

Up-regulation of Bcl-2 is associated with neuronal DNA damage in Alzheimer's disease. Su JH, et al. **Neuroreport** 1996 Jan 31;7(2):437–40

Dementia with Lewy bodies: clustering of Lewy bodies in human patients. Armstrong RA, et al. **Neurosci Lett** 1997 Mar 7;224(1):41–4

Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. Cairns NJ, et al. **Neurosci Lett** 1997 Jul 11;230(1):49–52

Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer's disease. Fukutani Y, et al. **Neurosci Lett** 1996 Aug 16;214(1):33–6

Hippocampal atrophy secondary to entorhinal cortical degeneration in Alzheimer-type dementia. Mizutani T, et al. **Neurosci Lett** 1997 Jan 31;222(2):119–22

Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Rezaie P, et al. **Neurosci Lett** 1996 Jul 12;212(2):111–4

Neuritic plaques in the Lewy body variant of Alzheimer disease lack paired helical filaments. Samuel W, et al. **Neurosci Lett** 1997 Feb 21;223(2):73–6

Evidence against increased glycoxidation in patients with Alzheimer's disease. Seidl R, et al. **Neurosci Lett** 1997 Aug 22;232(1):49–52

Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer's diseased brain. Brady DR, et al. **Neuroscience** 1997 Oct;80(4):1113–25

Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease. Cullen KM, et al. **Neuroscience** 1997 Jun;78(3):641–52

A cellular mechanism for the neuronal changes underlying Alzheimer's disease. Vickers JC. **Neuroscience** 1997 Jun; 78(3):629–39 (123 ref.)

Aggregation and disaggregation of senile plaques in Alzheimer disease. Cruz L, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7612–6

Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Kaltschmidt B, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2642–7

Selective inhibition of Alzheimer disease–like tau aggregation by phenothiazines. Wischik CM, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):11213–8

The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. Mesulam MM. **Prog Brain Res** 1996; 109:285–97 (105 ref.)

Conventional MRI volumetric measures of parietal and insular cortex in Alzheimer's disease. Foundas AL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Oct; 20(7):1131–44

Magnetic resonance imaging of Alzheimer's disease. Xanthakos S, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 May; 20(4):597–626 (90 ref.)

Immunohistochemical examination of phosphorylated tau in granulovacuolar degeneration granules. Ikegami K, et al. **Psychiatry Clin Neurosci** 1996 Jun;50(3):137–40

Quantitative MRI volume changes in late onset schizophrenia and Alzheimer's disease compared to normal controls. Barta PE, et al. **Psychiatry Res** 1997 Feb 7;68(2–3):65–75

Quantitative magnetic resonance imaging and neuropsychological functions in dementia of the Alzheimer type. Pantel J, et al. **Psychol Med** 1997 Jan;27(1):221–9

New lesion found in diseased brains [news] Roush W. **Science** 1997 Jul 4;277(5322):31–2

Alterations of the blood–brain barrier and glial cells in white matter lesions in cerebrovascular and Alzheimer's disease patients [letter; comment] Leys D, et al. **Stroke** 1997 Apr; 28(4):874–6. Comment on: Stroke 1996 Nov;27(11):2069–74.

Alterations of the blood–brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer's disease patients [see comments] Tomimoto H, et al. **Stroke** 1996 Nov;27(11):2069–74. Comment in: Stroke 1997 Apr;28(4):874–6.

[Is the topography of Alzheimer's disease lesions a clue to their pathogenesis?] Duyckaerts C, et al. **Bull Acad Natl Med** 1996 Oct;180(7):1703–14 (Eng. Abstr.) **(Fre)**

[Alzheimer's disease lesions: from morphology to cell biology] Hauw JJ, et al. **Bull Acad Natl Med** 1996 Oct; 180(7):1687–700; discussion 1700–1 (41 ref.) (Eng. Abstr.) **(Fre)**

[Posterior cortical atrophy--a new dementia syndrome or a form of Alzheimer's disease?] Pantel J, et al. **Fortschr Neurol Psychiatr** 1996 Dec;64(12):492–508 (91 ref.) (Eng. Abstr.) **(Ger)**

[Histopathologic studies in dementia--comparison with clinical findings] Zachhuber C, et al. **Z Gerontol Geriatr** 1997 Jan-Feb;30(1):29–33 (Eng. Abstr.) **(Ger)**

[Clinico-pathological evaluation of leukoaraisosis in Alzheimer's disease] Ishijima M, et al. **Nippon Ronen Igakkai Zasshi** 1996 Oct;33(10):744–53 (Eng. Abstr.) **(Jpn)**

[Neuropathological study on progression of the limbic degeneration in senile dementia of Alzheimer type] Kasahara M, et al. **No To Shinkei** 1997 Jan;49(1):51–8 (Eng. Abstr.) **(Jpn)**

[Characterization of glial fibrillary tangles in progressive supranuclear palsy and Alzheimer's disease] Nishimura M. **No To Shinkei** 1996 Oct;48(10):895–903 (32 ref.) **(Jpn)**

[An autopsy case of amyotrophic lateral sclerosis with concomitant Alzheimer's and incidental Lewy body diseases] Su M, et al. **No To Shinkei** 1996 Oct;48(10):931–6 (Eng. Abstr.) **(Jpn)**

[A comparative study on histopathological findings between Alzheimer's disease and senile dementia of Alzheimer type] Nakamura N. **Rinsho Byori** 1996 Mar;44(3):225–30 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Relationship between SPECT and pathological alterations in Alzheimer's disease--a study of a case with left-hemisphere dominant lesions] Nakano N, et al. **Seishin Shinkeigaku Zasshi** 1996;98(7):441–59 (Eng. Abstr.) **(Jpn)**

[Alzheimer-type dementia and related disorders: their neuropathological aspects] Ikeda K. **Tanpakushitsu Kakusan Koso** 1996 Aug;41(10):1476–82 (18 ref.) **(Jpn)**

[The quantitative characteristics of the changes in the synaptic contacts in the hippocampus in Alzheimer's disease] Kiktenko AI, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(5):95–6 **(Rus)**

PHYSIOPATHOLOGY

Quantified-EEG in normal aging and dementias. d'Onofrio F, et al. **Acta Neurol Scand** 1996 May;93(5):336–45

Category fluency is also predominantly affected in Swiss Alzheimer's disease patients. Monsch AU, et al. **Acta Neurol Scand** 1997 Feb;95(2):81–4

Cerebrospinal fluid nitrate levels in patients with Alzheimer's disease. Navarro JA, et al. **Acta Neurol Scand** 1996 Dec; 94(6):411–4

Patterns of neuropsychological impairment in mild dementia: a comparison between Alzheimer's disease and multi-infarct dementia. Padovani A, et al. **Acta Neurol Scand** 1995 Dec;92(6):433–42

Utilizing compensatory task conditions for episodic memory in Alzheimer's disease. Bäckman L. **Acta Neurol Scand Suppl** 1996;165:109–13 (40 ref.)

Clinical subgroups of the Alzheimer syndrome. Wallin A, et al. **Acta Neurol Scand Suppl** 1996;165:51–7 (39 ref.)

Regressive changes of astroglia in white matter lesions in cerebrovascular disease and Alzheimer's disease patients. Tomimoto H, et al. **Acta Neuropathol (Berl)** 1997 Aug; 94(2):146–52

Unexpected dental behavior in five Alzheimer patients. Differences between cognitive and functional capacity, graphic performance, and dental behavior. Nordenram G, et al. **Acta Odontol Scand** 1995 Dec;53(6):381–8

The pupillary response to tropicamide in Alzheimer's disease. Fridh M, et al. **Acta Ophthalmol Scand** 1996 Jun;74(3):276–9

Demographic and clinical features of Alzheimer disease in black Americans: preliminary observations on an outpatient sample in Atlanta, Georgia. Auchus AP. **Alzheimer Dis Assoc Disord** 1997 Mar;11(1):38–46

Sexual behavioral changes in Alzheimer disease. Derouesné C, et al. **Alzheimer Dis Assoc Disord** 1996 Summer; 10(2):86–92

The role of selective attention in driving and dementia of the Alzheimer type. Duchek JM, et al. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:48–56 (32 ref.)

Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Ellis RJ, et al. **Alzheimer Dis Assoc Disord** 1996 Summer;10(2):103–14 (76 ref.)

Outcome variables in presymptomatic individuals at higher risk of developing Alzheimer disease. Gauthier S, et al. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:19–21

Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease. Gonzalez RG, et al. **Alzheimer Dis Assoc Disord** 1996 Spring;10(1):46–52

Blood–cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: indication for disease subsets. Hampel H, et al. **Alzheimer Dis Assoc Disord** 1997 Jun;11(2):78–87

Alzheimer-like visual deficits in Down syndrome. Rocco FJ, et al. **Alzheimer Dis Assoc Disord** 1997 Jun;11(2):88–98

Cross-sectional analysis of Alzheimer disease effects on oral discourse in a picture description task. Tomoeda CK, et al. **Alzheimer Dis Assoc Disord** 1996 Winter;10(4):204–15

Neuropeptides and Alzheimer's disease pathology. Bissette G. **Ann N Y Acad Sci** 1997 Apr 24;814:17–29 (72 ref.)

Neuronal activity and early neurofibrillary tangles in Alzheimer's disease. Hatanpää K, et al. **Ann Neurol** 1996 Sep;40(3):411–20

In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Kuhl DE, et al. **Ann Neurol** 1996 Sep;40(3):399–410

Cerebral blood flow correlates of apathy in Alzheimer disease. Craig AH, et al. **Arch Neurol** 1996 Nov; 53(11):1116–20

Response of the pupil to tropicamide is not a reliable test for Alzheimer disease. FitzSimon JS, et al. **Arch Neurol** 1997 Feb;54(2):155–9

Reliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type. Hunt LA, et al. **Arch Neurol** 1997 Jun;54(6):707–12

Olfactory dysfunction for pyridine and dementia progression in Alzheimer disease. Nordin S, et al. **Arch Neurol** 1997 Aug;54(8):993–8

Simulated car crashes and crash predictors in drivers with Alzheimer disease. Rizzo M, et al. **Arch Neurol** 1997 May; 54(5):545–51

Modeling the influence of extrapyramidal signs on the progression of Alzheimer disease. Stern Y, et al. **Arch Neurol** 1996 Nov;53(11):1121–6

Disturbed synaptic plasticity and the psychobiology of Alzheimer's disease [editorial] Bauer J. **Behav Brain Res** 1996 Jun;78(1):1–2

Synaptic dysfunction in Alzheimer's disease: clinical assessment using quantitative EEG. Cook IA, et al. **Behav Brain Res** 1996 Jun;78(1):15–23 (42 ref.)

Is brain plasticity preserved during aging and in Alzheimer's disease? Mirmiran M, et al. **Behav Brain Res** 1996 Jun; 78(1):43–8 (77 ref.)

Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Robbins TW, et al. **Behav Brain Res** 1997 Feb; 83(1–2):15–23 (34 ref.)

Slow-wave activity in the spectral analysis of the electroencephalogram and volumes of hippocampus in subgroups of Alzheimer's disease patients. Helkala EL, et al. **Behav Neurosci** 1996 Dec;110(6):1235–43

Analysis of galanin and the galanin antagonist M40 on delayed non-matching-to-position performance in rats lesioned with the cholinergic immunotoxin 192 IgG-saporin. McDonald MP, et al. **Behav Neurosci** 1997

Jun;111(3):552–63
In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes. Frederick BB, et al. **Biol Psychiatry** 1997 Jul 15; 42(2):147–50
Increased mydriatic response to tropicamide is a sign of cholinergic hypersensitivity but not specific to late-onset sporadic type of Alzheimer's dementia. Kálmán J, et al. **Biol Psychiatry** 1997 Apr 15;41(8):909–11
Hypothalamic-pituitary-adrenocortical axis responses to physostigmine: effects of Alzheimer's disease and gender. Peskind ER, et al. **Biol Psychiatry** 1996 Jul 1;40(1):61–8
The predictive value of hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer's disease. Swanwick GR, et al. **Biol Psychiatry** 1996 Jun 1;39(11):976–8
Circadian rest-activity rhythm disturbances in Alzheimer's disease. van Someren EJ, et al. **Biol Psychiatry** 1996 Aug 15;40(4):259–70
Electroencephalographic abnormalities in patients with presenile dementia of the Alzheimer type: quantitative analysis at rest and during photic stimulation. Wada Y, et al. **Biol Psychiatry** 1997 Jan 15;41(2):217–25
Pupillary response to topical tropicamide as a marker for Alzheimer's disease. Treloar AJ, et al. **Br J Clin Pharmacol** 1996 Mar;41(3):256–7
Longitudinal cognitive, electroencephalographic and morphological brain changes in ageing and Alzheimer's disease. Forstl H, et al. **Br J Psychiatry** 1996 Mar; 168(3):280–6
Clinical and magnetic resonance imaging correlates of hypothalamic-pituitary-adrenal axis function in depression and Alzheimer's disease. O'Brien JT, et al. **Br J Psychiatry** 1996 Jun;168(6):679–87
Spatial- and object-based attentional deficits in Alzheimer's disease. Relationship to HMPAO-SPECT measures of parietal perfusion. Buck BH, et al. **Brain** 1997 Jul;120 (Pt 7):1229–44
Focal cortical atrophy syndromes. Black SE. **Brain Cogn** 1996 Jul;31(2):188–229 (207 ref.)
Clinical and neuropathological findings in Lewy body dementias. Galasko D, et al. **Brain Cogn** 1996 Jul; 31(2):166–75
Comparison between oral and written spelling in Alzheimer's disease. Croisile B, et al. **Brain Lang** 1996 Sep;54(3):361–87
Double dissociation of semantic categories in Alzheimer's disease. Gonnerman LM, et al. **Brain Lang** 1997 Apr; 57(2):254–79
Introduction. The investigation of lexical semantic representation in Alzheimer's disease. Henderson VW. **Brain Lang** 1996 Aug;54(2):179–83 (13 ref.)
Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Loeffler DA, et al. **Brain Res** 1996 Nov 4;738(2):265–74
Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Maurice T, et al. **Brain Res** 1996 Jan 15;706(2):181–93
Aggregates of a beta-amyloid peptide are required to induce calcium currents in neuron-like human teratocarcinoma cells: relation to Alzheimer's disease. Sanderson KL, et al. **Brain Res** 1997 Jan 2;744(1):7–14
Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Uchida K, et al. **Brain Res** 1996 Apr 22;717(1–2):154–9
Olfactory functions in Parkinson's disease and Alzheimer's disease. Lehrner JP, et al. **Chem Senses** 1997 Feb; 22(1):105–10
Postprandial hypotension in Alzheimer's disease. Idiaquez J, et al. **Clin Auton Res** 1997 Jun;7(3):119–20
Visual evoked responses in Alzheimer's disease: a review. Moore NC. **Clin Electroencephalogr** 1997 Jul;28(3):137–42 (48 ref.)
Written numeral transcoding in patients with Alzheimer's disease. Kessler J, et al. **Cortex** 1996 Dec;32(4):755–61
Transgenic models of neurodegenerative diseases. Lee MK, et al. **Curr Opin Neurobiol** 1996 Oct;6(5):651–60 (115 ref.)
Oxidative stress and mitochondrial dysfunction in neurodegeneration. Schapira AH. **Curr Opin Neurol** 1996 Aug;9(4):260–4 (49 ref.)
Tone duration discrimination in demented, memory-impaired, and healthy elderly. Hellström A, et al. **Dement Geriatr Cogn Disord** 1997 Jan–Feb;8(1):49–54
Reduction of regional cerebral blood flow and cognitive impairment in patients with Alzheimer's disease: evaluation of an observer-independent analytic approach. Hirsch C, et al. **Dement Geriatr Cogn Disord** 1997 Mar–Apr; 8(2):98–104
Weight, blood pressure, osmolarity, and glucose levels across various stages of Alzheimer's disease and vascular dementia. Hogan DB, et al. **Dement Geriatr Cogn Disord** 1997 May–Jun;8(3):147–51
The cerebellum in Alzheimer's disease. Larner AJ. **Dement Geriatr Cogn Disord** 1997 Jul–Aug;8(4):203–9 (80 ref.)
Age vs. aging in the pathogenesis of senile dementia of the Alzheimer type: electrophysiological evidence. Politoff AL, et al. **Dement Geriatr Cogn Disord** 1997 Jan–Feb; 8(1):18–25
Relations between symptomatology and brain function in dementias: double-blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline. Saletu B, et al. **Dement Geriatr Cogn Disord** 1997;8 Suppl 1:12–21
Functional imaging of the frontal lobes in organic dementia. Regional cerebral blood flow findings in normals, in patients with frontotemporal dementia and in patients with Alzheimer's disease, performing a word fluency test. Warkentin S, et al. **Dement Geriatr Cogn Disord** 1997 Mar–Apr;8(2):105–9
Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patterns. Blesa R, et al. **Dementia** 1996 Sep–Oct;7(5):239–45 (51 ref.)
Quantitative electroencephalography power and coherence in Alzheimer's disease and mild cognitive impairment. Jelic V, et al. **Dementia** 1996 Nov–Dec;7(6):314–23
Pattern visual evoked potential mapping in Alzheimer's disease: correlations with visuospatial impairment. Martinelli V, et al. **Dementia** 1996 Mar–Apr;7(2):63–8
Comparative study of aprosody in Alzheimer's disease and in multi-infarct dementia. Pérez Trullen JM, et al. **Dementia** 1996 Mar–Apr;7(2):59–62
Cognition-related EEG abnormalities in nondemented Down syndrome subjects. Politoff AL, et al. **Dementia** 1996 Mar–Apr;7(2):69–75
Discrimination of Alzheimer's disease and normal aging by EEG data. Besthorn C, et al. **Electroencephalogr Clin Neurophysiol** 1997 Aug; 103(2):241–8
Regional correlations between the EEG and oxygen metabolism in dementia of Alzheimer's type. Buchan RJ, et al. **Electroencephalogr Clin Neurophysiol** 1997 Sep; 103(3):409–17
N400 evidence of abnormal responses to speech in Alzheimer's disease. Ford JM, et al. **Electroencephalogr Clin Neurophysiol** 1996 Sep; 99(3):235–46
Event-related brain potentials during semantic categorization in normal aging and senile dementia of the Alzheimer's type. Iragui V, et al. **Electroencephalogr Clin Neurophysiol** 1996 Sep; 100(5):392–406
Intrusions in Alzheimer's disease in immediate and delayed memory as a function of presentation modality. Manning SK, et al. **Exp Aging Res** 1996 Oct–Dec;22(4):343–61
Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease. Chandrasekaran K, et al. **Exp Neurol** 1996 Nov;142(1):80–8 (103 ref.)
Regenerative failure: a potential mechanism for neuritic dystrophy in Alzheimer's disease. DeWitt DA, et al. **Exp Neurol** 1996 Nov;142(1):103–10
Increase of cerebral blood flow in rats after human b-amyloid peptide infusion. Pluta R, et al. **Folia Morphol (Warsz)** 1996; 55(4):420–1
An ultrastructural and molecular perspective of the pathological hallmarks of Alzheimer's disease. Sobow T. **Folia Neuropathol** 1996;34(1):55–62 (74 ref.)
Pattern of tau-1 and ubiquitin immunoreactivity in the white matter of temporal lobe in senile and with Alzheimer's disease brains. Taraszewska A, et al. **Folia Neuropathol** 1996;34(1):49–54
Manipulation of the cholinergic system. Geroldi C, et al. **Funct Neurol** 1997 May–Aug;12(3–4):187–91 (23 ref.)
The role of astroglial cell-derived nitric oxide and prostanoids in neurodegenerative disorders. Mollace V, et al. **Funct Neurol** 1997 May–Aug;12(3–4):199–203 (24 ref.)
Neuropeptides and senile dementia: focus on galanin. Valenti G, et al. **Funct Neurol** 1997 May–Aug;12(3–4):181–6
Brain reserve and the clinical expression of Alzheimer's disease. Mortimer JA. **Geriatrics** 1997 Sep;52 Suppl 2:S50–3
Alzheimer's disease research: a game of connect the dots. Adams C. **Gerontology** 1997;43(1–2):8–19 (56 ref.)
Alzheimer's, ageing and amyloid: an absurd allegory? Fowler CJ, et al. **Gerontology** 1997;43(1–2):132–42 (97 ref.)
Relationship between falls and stride length variability in senile dementia of the Alzheimer type. Nakamura T, et al. **Gerontology** 1996;42(2):108–13
Low blood pressure in Down's syndrome, A link with Alzheimer's disease? Morrison RA, et al. **Hypertension** 1996 Oct;28(4):569–75
Brain samples from Alzheimer's patients have elevated levels of loosely bound iron. Kala SV, et al. **Int J Neurosci** 1996 Sep;86(3–4):263–9
Behavioral and adaptive status in an experimental model of Alzheimer's disease in rats. Popović M, et al. **Int J Neurosci** 1996 Sep;86(3–4):281–99
Measuring functional competence in older persons with Alzheimer's disease. Doble SE, et al. **Int Psychogeriatr** 1997 Mar;9(1):25–38
Neurochemistry and neurotransmitters. Gottfries CG. **Int Psychogeriatr** 1996;8 Suppl 3:225–31
Circadian rhythm-related behavioral disturbances and structural hypothalamic changes in Alzheimer's disease. Hoogendijk WJ, et al. **Int Psychogeriatr** 1996;8 Suppl 3:245–52; discussion 269–72
Alzheimer's disease and driving: prediction and assessment of driving performance. Fox GK, et al. **J Am Geriatr Soc** 1997 Aug;45(8):949–53
A longitudinal analysis of weight change in Alzheimer's disease [letter] White H, et al. **J Am Geriatr Soc** 1997 Apr; 45(4):531–2
The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. Castaño EM, et al. **J Biol Chem** 1996 Dec 13; 271(50):32185–91
The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in Alzheimer's disease patients. Talwalker S. **J Biopharm Stat** 1996 Nov;6(4):443–56
Hemispheric asymmetry in Alzheimer's disease is apparent in motor functioning. Massman PJ, et al. **J Clin Exp Neuropsychol** 1996 Feb;18(1):110–21
Memory and emotion processing in cortical and subcortical dementia. Baker JG. **J Gen Psychol** 1996 Jul;123(3):185–91
Neurobiology of disruptive nocturnal behavior [letter; comment] Friedman EH. **J Geriatr Psychiatry Neurol** 1996 Apr;9(2):102. Comment on: J Geriatr Psychiatry Neurol 1995 Apr;8(2):107–10.
Neurodegeneration, sleep, and cerebral energy metabolism: a testable hypothesis. Mamelak M. **J Geriatr Psychiatry Neurol** 1997 Jan;10(1):29–32 (42 ref.)
Reliability of physical performance measures in nursing home residents with Alzheimer's disease. Tappen RM, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):M52–5
From prion diseases to Alzheimer's disease. Hsiao KK. **J Neural Transm Suppl** 1997;49:135–44 (43 ref.)
Animal model and in vitro studies of anti neurofilament antibodies mediated neurodegeneration in Alzheimer's disease. Oron L, et al. **J Neural Transm Suppl** 1997;49:77–84 (13 ref.)
Possible role of the cholinergic system and disease models. Weinstock M. **J Neural Transm Suppl** 1997;49:93–102 (46 ref.)
Magnetic stimulation in Alzheimer's disease. de Carvalho M, et al. **J Neurol** 1997 May;244(5):304–7
Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. Gnanalingham KK, et al. **J Neurol Neurosurg Psychiatry** 1997 Mar;62(3):243–52
Constraints on the cerebral basis for semantic processing from neuroimaging studies of Alzheimer's disease. Grossman M, et al. **J Neurol Neurosurg Psychiatry** 1997 Aug;63(2):152–8
Progressive biparietal atrophy: an atypical presentation of Alzheimer's disease. Ross SJ, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):388–95
Opiate receptor avidity and cerebral blood flow in Alzheimer's disease. Cohen RM, et al. **J Neurol Sci** 1997 May 29;148(2):171–80
Evaluation of the motor cortex by magnetic stimulation in patients with Alzheimer disease. Perretti A, et al. **J Neurol Sci** 1996 Jan;135(1):31–7
Microglial cell activation in aging and Alzheimer disease: partial linkage with neurofibrillary tangle burden in the hippocampus. DiPatre PL, et al. **J Neuropathol Exp Neurol** 1997 Feb;56(2):143–9
The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis [see comments] Terry RD. **J Neuropathol Exp Neurol** 1996 Oct;55(10):1023–5 (25 ref.) . Comment in: J Neuropathol Exp Neurol 1997 Feb;56(2):213. Comment in: J Neuropathol Exp Neurol 1997 Feb;56(2):214–5. Comment in: J Neuropathol Exp Neurol 1997 Feb;56(2):216. Comment in: J Neuropathol Exp Neurol 1997 Feb;56(2);217.
Correlations between SPECT regional cerebral blood flow and psychometric testing in patients with Alzheimer's disease. Sabbagh MN, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter;9(1):68–74
Alzheimer's disease: a dissection of its etiology. Jay G. **J Neurovirol** 1997 May;3 Suppl 1:S41–2
Changes in cerebral blood flow and oxygen metabolism related to magnetic resonance imaging white matter hyperintensities in Alzheimer's disease. Yamaji S, et al. **J Nucl Med** 1997 Sep;38(9):1471–4
The PHA-induced calcium signal in lymphocytes is altered after blockade of K(+)-channels in Alzheimer's disease. Bondy B, et al. **J Psychiatr Res** 1996 May–Jun;30(3):217–27
Apolipoprotein E in the brain and its role in Alzheimer's disease. Poirier J. **J Psychiatry Neurosci** 1996 Mar; 21(2):128–34
Effects of age and Alzheimer's disease on recognition of gated spoken words. Marshall NB, et al. **J Speech Hear Res** 1996 Aug;39(4):724–33
Predicting time to nursing home care and death in individuals with Alzheimer disease [see comments] Stern Y, et al. **JAMA** 1997 Mar 12;277(10):806–12. Comment in: JAMA 1997 Jun 25;277(24):1933–4. Comment in: ACP J Club 1997 Sep–Oct;127(2):43.
Role of amyloid precursor protein in the mechanisms of neurodegeneration in Alzheimer's disease. Masliah E. **Lab Invest** 1997 Sep;77(3):197–209 (164 ref.)
Auguste D and Alzheimer's disease [letter; comment] Gurwitz D. **Lancet** 1997 Jul 26;350(9073):298. Comment on: Lancet 1997 May 24;349(9064):1546–9.
Galanin receptors: involvement in feeding, pain, depression and Alzheimer's disease. Kask K, et al. **Life Sci** 1997; 60(18):1523–33 (110 ref.)
A computational model of the progression of Alzheimer's disease. Hasselmo ME. **MD Comput** 1997 May–Jun; 14(3):181–91
Alzheimer's disease risk factors as related to cerebral blood flow. Crawford JG. **Med Hypotheses** 1996 Apr; 46(4):367–77 (163 ref.)
Loss of intraventricular fluid melatonin can explain the neuropathology of Alzheimer's disease. Maurizi CP. **Med Hypotheses** 1997 Aug;49(2):153–8
A new hypothesis of neurodegenerative diseases: the deleterious network hypothesis. Ying W.

Med Hypotheses 1996 Oct;47(4):307–13

Inflammation and Alzheimer disease. Aisen PS. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):83–8 (37 ref.)

AMPA–selective glutamate receptor subtype immunoreactivity in the hippocampal dentate gyrus of patients with Alzheimer disease. Evidence for hippocampal plasticity. Armstrong DM, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):59–64

The heat shock/oxidative stress connection. Relevance to Alzheimer disease. Pappolla MA, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):21–34 (57 ref.)

Neurodegenerative mechanisms in Alzheimer disease. A role for oxidative damage in amyloid beta protein precursor–mediated cell death. Sopher BL, et al. **Mol Chem Neuropathol** 1996 Oct–Dec;29(2–3):153–68

Amyloid beta–peptide and oxidative cellular injury in Alzheimer's disease. Mark RJ, et al. **Mol Neurobiol** 1996 Jun;12(3):211–24 (91 ref.)

Does Alzheimer's disease start early in life? Ohm TG. **Mol Psychiatry** 1997 Jan;2(1):21–5

Alzheimer's disease. Short precursor shortens memory [news; comment] Mattson MP, et al. **Nature** 1997 May 29; 387(6632):457–8. Comment on: Nature 1997 May 29;387(6632):500–5.

Neuronal–based synaptic compensation: a computational study in Alzheimer's disease. Horn D, et al. **Neural Comput** 1996 Aug 15;8(6):1227–43

Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain. Jope RS, et al. **Neurobiol Aging** 1997 Jan–Feb;18(1):111–20

MR T2 relaxometry in Alzheimer's disease and age–associated memory impairment. Laakso MP, et al. **Neurobiol Aging** 1996 Jul–Aug;17(4):535–40

Spectral analysis of EEG in Alzheimer's disease: relation to apolipoprotein E polymorphism. Lehtovirta M, et al. **Neurobiol Aging** 1996 Jul–Aug;17(4):523–6

Different manifestations of circadian rhythms in senile dementia of Alzheimer's type and multi–infarct dementia. Mishima K, et al. **Neurobiol Aging** 1997 Jan–Feb; 18(1):105–9

Eyeblink classical conditioning in Alzheimer's disease and cerebrovascular dementia. Woodruff–Pak DS, et al. **Neurobiol Aging** 1996 Jul–Aug;17(4):505–12

Alzheimer's disease and eyeblink conditioning: 750 ms trace vs. 400 ms delay paradigm. Woodruff–Pak DS, et al. **Neurobiol Aging** 1996 May–Jun;17(3):397–404

Can blood–brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology [editorial; comment] Zlokovic B. **Neurobiol Dis** 1997; 4(1):23–6 (19 ref.). Comment on: Neurobiol Dis 1997 ;4(1):27–34.

The role of serum amyloid P (SAP) component in Alzheimer's disease. Urbányi Z. **Neurobiology (Bp)** 1996; 4(3):283–4

Cortical connections and the pathology of Alzheimer's disease. Pearson RC. **Neurodegeneration** 1996 Dec; 5(4):429–34 (24 ref.)

Clinical features of sporadic and familial Alzheimer's disease. Rossor MN, et al. **Neurodegeneration** 1996 Dec;5(4):393–7 (40 ref.)

Talking while walking: the effect of a dual task in aging and Alzheimer's disease. Camicioli R, et al. **Neurology** 1997 Apr;48(4):955–8

Clinical assessment of Alzheimer's disease. Morris JC. **Neurology** 1997 Sep;49(3 Suppl 3):S7–10

Subchronic intraventricular infusion of quinolinic acid produces working memory impairment—a model of progressive excitotoxicity. Misztal M, et al. **Neuropharmacology** 1996 Apr;35(4):449–58

Scalp topographic mapping of middle–latency somatosensory evoked potentials in normal aging and dementia. Ferri R, et al. **Neurophysiol Clin** 1996;26(5):311–9

Alexia and agraphia in posterior cortical atrophy. Ardila A, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Jan; 10(1):52–9

Orienting of visual attention in Alzheimer's disease: its implication in favor of the interhemispheric balance. Caffarra P, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr; 10(2):90–5

Response programming in dementia of the Alzheimer type: a kinematic analysis. Bellgrove MA, et al. **Neuropsychologia** 1997 Mar;35(3):229–40

Random number generation in dementia of the Alzheimer type: a test of frontal executive functions. Brugger P, et al. **Neuropsychologia** 1996 Feb;34(2):97–103

The deterioration of semantic networks in patients with Alzheimer's disease: a cross–sectional study. Chan AS, et al. **Neuropsychologia** 1997 Mar;35(3):241–8

Electrophysiological insights into the nature of the semantic deficit in Alzheimer's disease. Schwartz TJ, et al. **Neuropsychologia** 1996 Aug;34(8):827–41

Differentiating the roles of the hippocampal complex and the neocortex in long–term memory storage: evidence from the study of semantic dementia and Alzheimer's disease. Graham KS, et al. **Neuropsychology** 1997 Jan;11(1):77–89

Controlling the focus of spatial attention during visual search: effects of advanced aging and Alzheimer disease. Greenwood PM, et al. **Neuropsychology** 1997 Jan; 11(1):3–12

Loss of high–frequency brain electrical response to thiopental administration in Alzheimer's–type dementia. Holschneider DP, et al. **Neuropsychopharmacology** 1997 Apr;16(4):269–75

Alzheimer's disease affects parallel processing between the auditory cortices. Pekkonen E, et al. **Neuroreport** 1996 May 31;7(8):1365–8

Altered mitochondrial membrane fluidity in AD brain. Mecocci P, et al. **Neurosci Lett** 1996 Mar 29;207(2):129–32

Cerebrospinal protein tau is elevated in early Alzheimer's disease. Riemenschneider M, et al. **Neurosci Lett** 1996 Jul 19;212(3):209–11

A sex difference in neurodegeneration of the human hypothalamus. Schultz C, et al. **Neurosci Lett** 1996 Jul 12; 212(2):103–6

Visual field defects in Alzheimer's disease patients may reflect differential pathology in the primary visual cortex. Armstrong RA. **Optom Vis Sci** 1996 Nov;73(11):677–82

Acetylcholine, aging, and Alzheimer's disease. Muir JL. **Pharmacol Biochem Behav** 1997 Apr;56(4):687–96 (124 ref.)

Cognitive and neurobiologic markers of early Alzheimer disease. Albert MS. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13547–51 (62 ref.)

Amyloid–beta peptide–receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage–colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Du Yan S, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):5296–301

The systems–level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. Mesulam MM. **Prog Brain Res** 1996; 109:285–97 (105 ref.)

Alterations of the blood–brain barrier and glial cells in white–matter lesions in cerebrovascular and Alzheimer's disease patients [see comments] Tomimoto H, et al. **Stroke** 1996 Nov;27(11):2069–74. Comment in: Stroke 1997 Apr;28(4):874–6.

Apolipoprotein E, memory and Alzheimer's disease. Soininen HS, et al. **Trends Neurosci** 1996 Jun;19(6):224–8

[New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced glycation end products (AGEs)] Thome J, et al. **Nervenarzt** 1996 Nov;67(11):924–9 (36 ref.) (Eng. Abstr.) **(Ger)**

[Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities] Klivényi P, et al. **Orv Hetil** 1997 Feb 9; 138(6):331–5 (43 ref.) (Eng. Abstr.) **(Hun)**

[Benzodiazepine receptor and cerebral blood flow in early Alzheimer's disease—SPECT study using 123I–iomazenil and 123I–IMP] Kitamura S, et al. **Kaku Igaku** 1996 Jan; 33(1):49–56 (Eng. Abstr.) **(Jpn)**

[A quantitative study of regional cerebral blood flow in patients with dementia of Alzheimer type using single photon emission computed tomography—clinical application of the IMP autoradiographic method (IMP ARG method)] Koshi Y, et al. **Kaku Igaku** 1996 Sep; 33(9):991–8 (Eng. Abstr.) **(Jpn)**

[Regional cerebral blood flow measurements using 99mTc–ECD SPECT in patients with Alzheimer's disease (ad) in the early stage] Nakano S, et al. **Kaku Igaku** 1996 Nov;33(11):1197–206 (Eng. Abstr.) **(Jpn)**

[Hypersensitivity in the pupil dilation response to a cholinergic antagonist in patients with Alzheimer's disease and Down's syndrome] Kono K, et al. **Nippon Ronen Igakkai Zasshi** 1996 Nov;33(11):829–34 (Eng. Abstr.) **(Jpn)**

[Variability in gait among patients with Alzheimer–type dementia] Nakamura T. **Nippon Ronen Igakkai Zasshi** 1996 Nov;33(11):816–9 (Eng. Abstr.) **(Jpn)**

[Topographic analysis of resting EEG and photic driving responses in patients with presenile Alzheimer's disease] Nanbu Y, et al. **Rinsho Byori** 1997 Mar;45(3):277–81 (Eng. Abstr.) **(Jpn)**

[Pupil abnormality in central nervous diseases] Ishikawa S. **Rinsho Shinkeigaku** 1996 Dec;36(12):1352–3 **(Jpn)**

[Extrapyramidal signs in Alzheimer's disease] Pfeffer–Baczuk A, et al. **Neurol Neurochir Pol** 1996 May–Jun;30(3):389–98 (Eng. Abstr.) **(Pol)**

[Interaction of the nervous and immune systems during normal aging and in dementias of the Alzheimer's type] Fokin VF, et al. **Fiziol Cheloveka** 1996 Nov–Dec;22(6):55–9 **(Rus)**

[Interhemispheric asymmetry and neuroimmune modulation in normal aging and Alzheimer's–type dementias] Fokin VF, et al. **Fiziol Cheloveka** 1997 May–Jun;23(3):20–4 **(Rus)**

[Memory loss in dementia, old drama and new hypothesis (editorial)] Muchnik S. **Medicina (B Aires)** 1996;56(3):316–8 **(Spa)**

[Implicit memory in Alzheimer's disease] Cacho Gutiérrez J. **Neurologia** 1996 Nov;11(9):341–3 (30 ref.) **(Spa)**

[Cerebral mapping in patients with dementia of Alzheimer's type] Almárcegui C, et al. **Rev Neurol** 1997 Mar; 25(139):448–51 (Eng. Abstr.) **(Spa)**

[Clinico–pathological correlation in the main types of dementia] Estupiñán B, et al. **Rev Neurol** 1997 Apr; 25(140):547–9 (Eng. Abstr.) **(Spa)**

[Pathological background in Alzheimer's disease] García JH. **Rev Neurol** 1997 Jan;25(137):94–6 (6 ref.) **(Spa)**

[Interaction between neuropsychological deficit in execution/ performance and ability to carry out daily activities in Alzheimer type dementia] Perea MV, et al. **Rev Neurol** 1997 Apr;25(140):513–8 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Epidemiology of Alzheimer's disease and current possibilities for prevention. Fratiglioni L. **Acta Neurol Scand Suppl** 1996;165:33–40 (68 ref.)

Statistical issues in prevention and therapeutic trials of Alzheimer disease. Brookmeyer R, et al. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:27–30

Is a randomized trial of antioxidants in the primary prevention of Alzheimer disease warranted? Evans DA, et al. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:45–9

Alzheimer disease and cataract: common threads [letter] Harding JJ. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):123

Potential prevention of Alzheimer disease and dementia. Kuller LH. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:13–6

Prevention of Alzheimer disease: a perspective based on successes in the prevention of other chronic diseases. Larson EB, et al. **Alzheimer Dis Assoc Disord** 1996 Fall; 10 Suppl 1:9–12

Observations and suggestions on antidementia drug development. Leber P. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:31–5

Development of a national prospective study of Alzheimer disease. Mayeux R. **Alzheimer Dis Assoc Disord** 1996 Fall; 10 Suppl 1:38–44

Fisher symposium: strategies for the prevention of Alzheimer disease—overview of research planning meeting III. Radebaugh TS, et al. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:1–5

Approaches to the prevention of Alzheimer disease. Scherr PA. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:17–8

Potential prevention strategies for Alzheimer disease. Thal LJ. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:6–8

Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Thal LJ, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 3:46–9

Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Gozes I, et al. **Ann N Y Acad Sci** 1997 Apr 24;814:161–6 (33 ref.)

Estrogen replacement therapy and risk of Alzheimer disease. Paganini–Hill A, et al. **Arch Intern Med** 1996 Oct 28; 156(19):2213–7

Disruption of brain cell ion homeostasis in Alzheimer's disease by oxy radicals, and signaling pathways that protect therefrom. Mattson MP, et al. **Chem Res Toxicol** 1997 May; 10(5):507–17 (85 ref.)

The gain of apolipoprotein E genotyping to separate patients with Alzheimer's disease from normal individuals: relevance to community studies. Frisoni GB, et al. **Dementia** 1996 Nov–Dec;7(6):336–42

Association of the epsilon 4 allele of apolipoprotein E with poor performance on a dementia screen in African Americans. Hui SL, et al. **Ethn Dis** 1996 Autumn; 6(3–4):266–71

The Clock Drawing Test for dementia of the Alzheimer's type: A comparison of three scoring methods in a memory disorders clinic. Brodaty H, et al. **Int J Geriatr Psychiatry** 1997 Jun;12(6):619–27

Alzheimer's Disease International [editorial] Graham N. **Int Psychogeriatr** 1997 Mar;9(1):5–6

Oestrogen and Alzheimer's disease [letter; comment] Barrett–Connor E, et al. **Lancet** 1996 Oct 12; 348(9033):1028; discussion 1029. Comment on: Lancet 1996 Aug 17;348(9025):429–32.

Oestrogen and Alzheimer's disease [letter; comment] Eaker ED. **Lancet** 1996 Oct 12;348(9033):1028; discussion 1029–30 . Comment on: Lancet 1996 Aug 17;348(9025):429–32.

Oestrogen and Alzheimer's disease [letter; comment] Gambassi G, et al. **Lancet** 1996 Oct 12;348(9033):1029; discussion 1029–30. Comment on: Lancet 1996 Aug 17;348(9025):429–32.

Oestrogen and Alzheimer's disease [letter; comment] Kellet JM. **Lancet** 1996 Oct 12;348(9033):1027–8; discussion 1029–30. Comment on: Lancet 1996 Aug 17;348(9025):429–32.

Smoking and oestrogen–replacement therapy as protective factors for Alzheimer's disease [letter] [see comments] Lerner A, et al. **Lancet** 1997 Feb 8;349(9049):403–4. Comment in: Lancet 1997 Jul 26;350(9073):295.

Oestrogen and Alzheimer's disease [letter; comment] O'Brien C, et al. **Lancet** 1996 Oct 12;348(9033):1028–9; discussion 1029–30. Comment on: Lancet 1996 Aug 17;348(9025):429–32.

Smoking and Alzheimer's disease [letter; comment] Peto R. **Lancet** 1997 Jul 26;350(9073):295. Comment on: Lancet 1997 Feb 8;349(9049):403–4.

Steroid therapy in AD [letter; comment] Gambassi G, et al. **Neurology** 1997 May;48(5):1473–4. Comment on: Neurology 1996 Aug;47(2):425–32.

The epidemiology of estrogen replacement therapy and Alzheimer's disease. Henderson VW. **Neurology** 1997 May; 48(5 Suppl 7):S27–35 (142 ref.)

A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Kawas C, et al. **Neurology** 1997 Jun;48(6):1517–21

Risk of Alzheimer's disease and duration of NSAID use [see comments] Stewart WF, et al. **Neurology** 1997 Mar; 48(3):626–32. Comment in: ACP J Club 1997 Sep–Oct;127(2):46–7.

Does estrogen replacement therapy protect against

Alzheimer's disease? Paganini-Hill A. **Osteoporos Int** 1997; 7 Suppl 1:S12-7 (61 ref.)
[Neuroprotective therapy of Alzheimer's disease?] Mielke R. **Dtsch Med Wochenschr** 1996 Nov 29;121(48):1515 **(Ger)**
[Does estrogen replacement prevent Alzheimer's disease? (news)] Reiss J. **Fortschr Med** 1997 Feb 20;115(5):6 **(Ger)**

PSYCHOLOGY

Neuropsychological features of early Alzheimer's disease: preclinical and clinical stages. Almkvist O. **Acta Neurol Scand Suppl** 1996;165:63-71 (98 ref.)
Dental management of Alzheimer patients. A predictive test of dental cooperation in individualized treatment planning. Nordenram G, et al. **Acta Odontol Scand** 1997 Jun; 55(3):148-54
The development of a care-giving burden scale. Gerritsen JC, et al. **Age Ageing** 1994 Nov;23(6):483-91
Educational level and neuropsychological heterogeneity in dementia of the Alzheimer type. Caramelli P, et al. **Alzheimer Dis Assoc Disord** 1997 Mar;11(1):9-15
Safe mobility for people with Alzheimer disease: a commentary. Eberhard JW. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:76-7
Strategies for driving cessation in Alzheimer Disease. Friedland RP. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:73-5 (8 ref.)
An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Galasko D, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 2:S33-9
Environmental cueing may effect performance on a road test for drivers with dementia of the Alzheimer type. Hunt LA, et al. **Alzheimer Dis Assoc Disord** 1997 Jun;11 Suppl 1:13-6
Delusions of theft in dementia of the Alzheimer type: a preliminary report. Hwang JP, et al. **Alzheimer Dis Assoc Disord** 1997 Jun;11(2):110-2
Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study. Koss E, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 2:S45-50
Delirium in Alzheimer disease. Lerner AJ, et al. **Alzheimer Dis Assoc Disord** 1997 Mar;11(1):16-20
Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. The Alzheimer's Disease Cooperative Study. Mackell JA, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 2:S65-9
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Mohs RC, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 2:S13-21
Awareness of variability in awareness [editorial; comment] Neundorfer MM. **Alzheimer Dis Assoc Disord** 1997 Sep; 11(3):121-2. Comment on: Alzheimer Dis Assoc Disord 1997 Sep;11(3):125-31.
Impaired awareness of deficits in Alzheimer disease. Ott BR, et al. **Alzheimer Dis Assoc Disord** 1996 Summer;10(2):68-76
A longitudinal study of behavioral pathology across five levels of dementia severity in Alzheimer's disease: the CERAD Behavior Rating Scale for Dementia. The Alzheimer's Disease Cooperative Study. Patterson MB, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 2:S40-4
Driving with Alzheimer disease: the anatomy of a crash. Reinach SJ, et al. **Alzheimer Dis Assoc Disord** 1997 Jun; 11 Suppl 1:21-7
The Spanish Instrument Protocol: design and implementation of a study to evaluate treatment efficacy Instruments for Spanish-speaking patients with Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Sano M, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 2:S57-64
Is decreased use of analgesics in Alzheimer disease due to a change in the affective component of pain? Scherder EJ, et al. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):171-4
The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Schmitt FA, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 2:S51-6
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Schneider LS, et al. **Alzheimer Dis Assoc Disord** 1997;11 Suppl 2:S22-32
The role of attention in a spatial memory task in Alzheimer disease patients. Simone PM, et al. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):140-52
Physical aggression and associated factors in probable Alzheimer disease. Tsai SJ, et al. **Alzheimer Dis Assoc Disord** 1996 Summer;10(2):82-5
Unawareness of cognitive deficit in Alzheimer disease and related dementias [see comments] Wagner MT, et al. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):125-31. Comment in: Alzheimer Dis Assoc Disord 1997 Sep;11(3):121-2.
Durable power of attorney and informed consent with Alzheimer's disease patients: a clinical study. Dukoff R, et al. **Am J Psychiatry** 1997 Aug;154(8):1070-5
Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease. Tolbert SR, et al. **Ann Pharmacother** 1996 Oct;30(10):1122-9 (90 ref.)
Comparative evolution of Alzheimer disease, vascular dementia, and mixed dementia. Bowler JV, et al. **Arch Neurol** 1997 Jun;54(6):697-703
Cognitive function and the costs of Alzheimer disease. An exploratory study [see comments] Ernst RL, et al. **Arch Neurol** 1997 Jun;54(6):687-93. Comment in: Arch Neurol 1997 Jun;54(6):683.
Selective cortical and hippocampal volume correlates of Mattis Dementia Rating Scale in Alzheimer disease. Fama R, et al. **Arch Neurol** 1997 Jun;54(6):719-28
Classification and staging of dementia of the Alzheimer type: a comparison between neural networks and linear discriminant analysis. French BM, et al. **Arch Neurol** 1997 Aug;54(8):1001-9
Reliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type. Hunt LA, et al. **Arch Neurol** 1997 Jun;54(6):707-12
Alzheimer disease and frontotemporal dementias. Behavioral distinctions [see comments] Levy ML, et al. **Arch Neurol** 1996 Jul;53(7):687-90. Comment in: Arch Neurol 1997 Apr;54(4):350.
Extrapyramidal signs in patients with probable Alzheimer disease. Lopez OL, et al. **Arch Neurol** 1997 Aug; 54(8):969-75
Neuropsychological assessment of severely demeted elderly: the severe cognitive impairment profile. Peavy GM, et al. **Arch Neurol** 1996 Apr;53(4):367-72
Age at onset and pattern of neuropsychological impairment in mild early-stage Alzheimer disease. A study of a community-based population. Reid W, et al. **Arch Neurol** 1996 Oct;53(10):1056-61
Simulated car crashes and crash predictors in drivers with Alzheimer disease. Rizzo M, et al. **Arch Neurol** 1997 May; 54(5):545-51
Alzheimer disease and frontotemporal dementia [letter; comment] Rozzini L, et al. **Arch Neurol** 1997 Apr;54(4):350 . Comment on: Arch Neurol 1996 Jul;53(7):687-90.
Premorbid personality and behavioral symptoms in Alzheimer disease. Some cautions. Strauss ME, et al. **Arch Neurol** 1997 Mar;54(3):257-9
Mismatch negativity during attend and ignore conditions in Alzheimer's disease. Kazmerski VA, et al. **Biol Psychiatry** 1997 Sep 1;42(5):382-402
A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. Steffens DC, et al. **Biol Psychiatry** 1997 Apr 15;41(8):851-6
Telling patients they have Alzheimer's disease [editorial; comment] [published erratum appears in BMJ 1997 Apr 12;314(7087):1063] Meyers BS. **BMJ** 1997 Feb 1; 314(7077):321-2. Comment on: BMJ 1997 Feb 1;314(7077):375-6. Comment on: BMJ 1997 Feb 1;314(7077):376.
A one-year follow-up study of depression in dementia sufferers. Ballard CG, et al. **Br J Psychiatry** 1996 Mar; 168(3):287-91
Encoding-retrieval interactions in mild Alzheimer's disease: the role of access to categorical information. Lipinska B, et al. **Brain Cogn** 1997 Jul;34(2):274-86
Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex. Nielson KA, et al. **Brain Res** 1996 Nov 25;741(1-2):284-93
Psychotic symptoms in psychiatric inpatients with dementia of the Alzheimer and vascular types. Hwang JP, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jul;58(1):35-9
Knowledge of concept meanings in Alzheimer's disease. Laatu S, et al. **Cortex** 1997 Mar;33(1):27-45
Generation effect in short-term verbal and visuospatial memory: comparisons between dementia of Alzheimer type and dementia of frontal lobe type. Souliez L, et al. **Cortex** 1996 Jun;32(2):347-56
Distinguishing between patients with depression or very mild Alzheimer's disease using the Delayed-Word-Recall test. Coen RF, et al. **Dement Geriatr Cogn Disord** 1997 Jul-Aug; 8(4):244-7
The disturbances of object vision and spatial vision in Alzheimer's disease. Fujimori M, et al. **Dement Geriatr Cogn Disord** 1997 Jul-Aug;8(4):228-31
Effect of repetition and inspection times on picture recall in patients with dementia of Alzheimer type. Heun R, et al. **Dement Geriatr Cogn Disord** 1997 May-Jun;8(3):152-6
Procedural memory in patients with mild Alzheimer's disease. Hirono N, et al. **Dement Geriatr Cogn Disord** 1997 Jul-Aug;8(4):210-6
Effect of normal aging and of Alzheimer's disease on, episodic memory. Le Moal S, et al. **Dement Geriatr Cogn Disord** 1997 Sep-Oct;8(5):281-7
Alzheimer's Disease Assessment Scale: the validation of the scale in Greece in elderly demented patients and normal subjects. Tsolaki M, et al. **Dement Geriatr Cogn Disord** 1997 Sep-Oct;8(5):273-80
Letter and category fluency in Alzheimer's disease: a prognostic indicator of progression? Coen RF, et al. **Dementia** 1996 Sep-Oct;7(5):246-50
Quantitative electroencephalography power and coherence in Alzheimer's disease and mild cognitive impairment. Jelic V, et al. **Dementia** 1996 Nov-Dec;7(6):314-23
Clustering of pathological features in Alzheimer's disease: clinical and neuroanatomical aspects. Nagy Z, et al. **Dementia** 1996 May-Jun;7(3):121-7
Family caregiving: the positive impact on adolescent relationships. Beach DL. **Gerontologist** 1997 Apr; 37(2):233-8
Modifying repetitive verbalizations of community-dwelling patients with AD. Bourgeois MS, et al. **Gerontologist** 1997 Feb;37(1):30-9
Anticipatory dementia: a link between memory appraisals and concerns about developing Alzheimer's disease. Cutler SJ, et al. **Gerontologist** 1996 Oct;36(5):657-64
Differential predictors of strain and gain among husbands caring for wives with dementia. Kramer BJ. **Gerontologist** 1997 Apr;37(2):239-49
The Pleasant Events Schedule-AD: psychometric properties and relationship to depression and cognition in Alzheimer's disease patients. Logsdon RG, et al. **Gerontologist** 1997 Feb; 37(1):40-5
Awareness of deficit in Alzheimer's disease: relation to caregiver burden. Seltzer B, et al. **Gerontologist** 1997 Feb; 37(1):20-4
The right to bow out: yet another dilemma. Laster L. **Hosp Pract (Off Ed)** 1997 Apr 15;32(4):193-4
Caregiver training for people with Alzheimer's based on a stress threshold model. Gerdner LA, et al. **Image J Nurs Sch** 1996 Fall;28(3):241-6
Cognitive developmental approach to dementia. Matteson MA, et al. **Image J Nurs Sch** 1996 Fall;28(3):233-40 (98 ref.)
Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. Coen RF, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):331-6
Identification of body parts in Alzheimer's disease: evidence for a body schema hypothesis. Mozaz MJ, et al. **Int J Neurosci** 1997 Feb;89(3-4):207-16
Effect of physostigmine and verapamil on active avoidance in an experimental model of Alzheimer's disease. Popović M, et al. **Int J Neurosci** 1997 Jun;90(1-2):87-97
Facial expressions of patients with dementia: a comparison of two methods of interpretation. Asplund K, et al. **Int Psychogeriatr** 1995 Winter;7(4):527-34
Measuring functional competence in older persons with Alzheimer's disease. Doble SE, et al. **Int Psychogeriatr** 1997 Mar;9(1):25-38
Monolingual and bilingual communication between patients with dementia diseases and their caregivers. Ekman SL. **Int Psychogeriatr** 1996;8 Suppl 1:127-32
Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Finkel SI, et al. **Int Psychogeriatr** 1996;8 Suppl 3:497-500 (0 ref.)
How do we prevent families from "closing the door" when caring for patients with Alzheimer's disease? Grafström M. **Int Psychogeriatr** 1996;8 Suppl 1:137-9
Perspectives of a family caregiver. Kenowsky S. **Int Psychogeriatr** 1996;8 Suppl 3:449-53
Future research directions. Khachaturian Z. **Int Psychogeriatr** 1996;8 Suppl 3:493-5
Self-psychology: its application to understanding patients with Alzheimer's disease. Lazarus LW, et al. **Int Psychogeriatr** 1996;8 Suppl 3:253-8
Deterioration of functional capacities in Alzheimer's disease after a 1-year period. Loewenstein DA, et al. **Int Psychogeriatr** 1995 Winter;7(4):495-503
Emotional expression during mid- to late-stage dementia. Magai C, et al. **Int Psychogeriatr** 1996 Fall;8(3):383-95
Assessment of quality of life: preservation of the self. Ronch JL. **Int Psychogeriatr** 1996 Summer;8(2):267-75 (35 ref.)
Assessing behavioral symptoms of dementia of the Alzheimer type: categorical and quantitative approaches. Zaudig M. **Int Psychogeriatr** 1996;8 Suppl 2:183-200 (48 ref.)
Psychopathology in dementia. Becker D, et al. **Isr J Psychiatry Relat Sci** 1997;34(2):98-107 (41 ref.)
Quality of life in patients with Alzheimer's disease as reported by patient proxies [see comments] Albert SM, et al. **J Am Geriatr Soc** 1996 Nov;44(11):1342-7. Comment in: J Am Geriatr Soc 1996 Nov;44(11):1400-2.
Psychotic symptoms and physically aggressive behavior in Alzheimer's disease. Gilley DW, et al. **J Am Geriatr Soc** 1997 Sep;45(9):1074-9
Advance planning for dementia caregivers. McCurry SM, et al. **J Am Geriatr Soc** 1997 Sep;45(9):1102-3
Cognitive models that predict physician judgments of capacity to consent in mild Alzheimer's disease. Marson DC, et al. **J Am Geriatr Soc** 1997 Apr;45(4):458-64
Consistency of physician judgments of capacity to consent in mild Alzheimer's disease. Marson DC, et al. **J Am Geriatr Soc** 1997 Apr;45(4):453-7
A survey of grief and bereavement in nursing homes: the importance of hospice grief and bereavement for the end-stage Alzheimer's disease patient and family [see comments] Murphy K, et al. **J Am Geriatr Soc** 1997 Sep; 45(9):1104-7. Comment in: J Am Geriatr Soc 1997 Sep;45(9):1147-9.
Physician-assisted suicide in Alzheimer's disease. Post SG. **J Am Geriatr Soc** 1997 May;45(5):647-51
Letter and category fluency in community-dwelling Canadian seniors: a comparison of normal participants to those with dementia of the Alzheimer or vascular type. Crossley M, et al. **J Clin Exp Neuropsychol** 1997 Feb; 19(1):52-62
Semantic memory impairment in Alzheimer's disease. Daum I, et al. **J Clin Exp Neuropsychol** 1996 Oct;18(5):648-65
Performance of elderly White and African American community residents on the abbreviated CERAD Boston Naming Test. Fillenbaum GG, et al. **J Clin Exp Neuropsychol** 1997 Apr;19(2):204-10
Neuropsychological subgroups of patients with Alzheimer's disease. Fisher NJ, et al. **J Clin Exp Neuropsychol** 1996

Jun;18(3):349–70
Comparison of temporal order memory in early and middle stage Alzheimer's disease. Johnson DL, et al. **J Clin Exp Neuropsychol** 1997 Feb;19(1):83–100
Picture naming deficits in vascular dementia and Alzheimer's disease. Laine M, et al. **J Clin Exp Neuropsychol** 1997 Feb; 19(1):126–40
Utility of a Wisconsin Card Sorting Test short form in persons with Alzheimer's and Parkinson's disease. Paolo AM, et al. **J Clin Exp Neuropsychol** 1996 Dec;18(6):892–7
Automatic semantic facilitation in Alzheimer's disease. Silveri MC, et al. **J Clin Exp Neuropsychol** 1996 Jun;18(3):371–82
Longitudinal examination of American National Adult Reading Test (AMNART) performance in dementia of the Alzheimer type (DAT): validation and correction based on degree of cognitive decline. Taylor KI, et al. **J Clin Exp Neuropsychol** 1996 Dec;18(6):883–91
Monitoring frequency of occurrence without awareness: evidence from patients with Alzheimer's disease. Wiggs CL, et al. **J Clin Exp Neuropsychol** 1997 Apr;19(2):235–44
Appraisal, coping, and social support as mediators of well-being in black and white family caregivers of patients with Alzheimer's disease. Haley WE, et al. **J Consult Clin Psychol** 1996 Feb;64(1):121–9
Stroop performance in healthy younger and older adults and in individuals with dementia of the Alzheimer's type. Spieler DH, et al. **J Exp Psychol Hum Percept Perform** 1996 Apr;22(2):461–79
Clinical evaluation of global change in Alzheimer's disease: identifying consensus. Olin JT, et al. **J Geriatr Psychiatry Neurol** 1996 Oct;9(4):176–80
A multinomial modeling analysis of memory deficits in Alzheimer's disease and vascular dementia. Batchelder WH, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Sep; 52(5):P206–15
Metalinguistic judgments in normal aging and Alzheimer's disease. Kemper S. **J Gerontol B Psychol Sci Soc Sci** 1997 May;52(3):P147–55
Concordance between direct observation and staff rating of behavior in nursing home residents with Alzheimer's disease. McCann JJ, et al. **J Gerontol B Psychol Sci Soc Sci** 1997 Mar;52(2):P63–72
Covert versus overt self-recognition in late stage Alzheimer's disease. Bologna SM, et al. **J Int Neuropsychol Soc** 1997 Mar;3(2):195–8
Emotion processing in Alzheimer's disease. Cadieux NL, et al. **J Int Neuropsychol Soc** 1997 Sep;3(5):411–9
A population-based analysis of qualitative features of the neuropsychological test performance of individuals with dementia of the Alzheimer type: implications for individuals with questionable dementia. Cahn DA, et al. **J Int Neuropsychol Soc** 1997 Jul;3(4):387–93
Neuropsychological asymmetry in Alzheimer's disease: verbal versus visuoconstructional deficits across stages of dementia. Strite D, et al. **J Int Neuropsychol Soc** 1997 Sep; 3(5):420–7
Cognitive effects of scopolamine in dementia. Rabey JM, et al. **J Neural Transm Gen Sect** 1996;103(7):873–81
Clinical features of frontal lobe dementia in comparison to Alzheimer's disease. Gregory CA, et al. **J Neural Transm Suppl** 1996;47:103–23 (67 ref.)
Neuropsychology of memory and SPECT in the diagnosis and staging of dementia of Alzheimer type. Greene JD, et al. **J Neurol** 1996 Feb;243(2):175–90
Two domains of anosognosia in Alzheimer's disease. Starkstein SE, et al. **J Neurol Neurosurg Psychiatry** 1996 Nov;61(5):485–90
Neuropsychological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia. Starkstein SE, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):381–7
The mean A beta load in the hippocampus correlates with duration and severity of dementia in subgroups of Alzheimer disease. Bartoo GT, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):531–40
Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. Samuel W, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):499–508
Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. Sze CI, et al. **J Neuropathol Exp Neurol** 1997 Aug;56(8):933–44
Methylphenidate treatment of negative symptoms in patients with dementia. Galynker I, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):231–9 (76 ref.)
Depression, delusions, and hallucinations in Alzheimer's disease: no relationship to apolipoprotein E genotype. Lyketsos CG, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter;9(1):64–7
A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. Petracca G, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer; 8(3):270–5
Apo-E genotype and verbal deficits in Alzheimer's disease. Rasmusson DX, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):335–7
Correlations between SPECT regional cerebral blood flow and psychometric testing in patients with Alzheimer's disease. Sabbagh MN, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter;9(1):68–74
The impact of dementia on the sufferer and available treatment interventions: an overview. Midence K, et al. **J Psychol** 1996 Nov;130(6):589–602 (70 ref.)
Not gone and not forgotten: a spouse's experience of late-stage Alzheimer's disease. Bonnel WB. **J Psychosoc Nurs Ment Health Serv** 1996 Aug;34(8):23–7
Geriatric ethics: responsibilities and conspiracies. Ainslie N, et al. **Kans Med** 1996 Summer–Fall;97(2):24–5
Modeling the relation between neurofibrillary tangles and intellectual status. Duyckaerts C, et al. **Neurobiol Aging** 1997 May–Jun;18(3):267–73
Olfactory identification in elderly schizophrenia and Alzheimer's disease. Moberg PJ, et al. **Neurobiol Aging** 1997 Mar–Apr;18(2):163–7
Structural correlates of cognition in dementia: quantification and assessment of synapse change. DeKosky ST, et al. **Neurodegeneration** 1996 Dec;5(4):417–21 (32 ref.)
Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Borson S, et al. **Neurology** 1997 May;48(5 Suppl 6):S17–24 (71 ref.)
Talking while walking: the effect of a dual task in aging and Alzheimer's disease. Camicioli R, et al. **Neurology** 1997 Apr;48(4):955–8
The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease. Clark CM, et al. **Neurology** 1997 Jul;49(1):70–5
Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Cummings JL, et al. **Neurology** 1996 Oct;47(4):876–83 (101 ref.)
The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Doraiswamy PM, et al. **Neurology** 1997 Jun;48(6):1511–7
NSAIDs and cognition in Alzheimer's disease [letter] Doraiswamy PM, et al. **Neurology** 1996 Apr;46(4):1194
Alzheimer's disease: clinical implications of the apolipoprotein E genotype. Farlow MR. **Neurology** 1997 May;48(5 Suppl 6):S30–4 (46 ref.)
Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Klatka LA, et al. **Neurology** 1996 Nov;47(5):1148–52
EEG spectral abnormalities and psychosis as predictors of cognitive and functional decline in probable Alzheimer's disease. Lopez OL, et al. **Neurology** 1997 Jun;48(6):1521–5
Frontotemporal dementia versus Alzheimer's disease: differential cognitive features. Mendez MF, et al. **Neurology** 1996 Nov;47(5):1189–94
Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Morris JC, et al. **Neurology** 1997 Jun; 48(6):1508–10
Comparison of African-American and white persons with Alzheimer's disease on language measures. Ripich DN, et al. **Neurology** 1997 Mar;48(3):781–3
Prosody impairment and associated affective and behavioral disturbances in Alzheimer's disease. Roberts VJ, et al. **Neurology** 1996 Dec;47(6):1482–8
Examination of the working memory components in normal aging and in dementia of the Alzheimer type. Belleville S, et al. **Neuropsychologia** 1996 Mar;34(3):195–207
The influence of semantic encoding on recognition memory in Alzheimer's disease. Dalla Barba G, et al. **Neuropsychologia** 1996 Dec;34(12):1181–6
Stem-completion priming in Alzheimer's disease: the importance of target word articulation. Downes JJ, et al. **Neuropsychologia** 1996 Jan;34(1):63–75
Word-stem completion priming for perceptually and conceptually encoded words in patients with Alzheimer's disease [published erratum appears in Neuropsychologia 1997 May;35(5):745] Fleischman DA, et al. **Neuropsychologia** 1997 Jan;35(1):25–35
Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Greene JD, et al. **Neuropsychologia** 1996 Jun;34(6):537–51
Dysgraphia in mild dementia of Alzheimer's type. Hughes JC, et al. **Neuropsychologia** 1997 Apr;35(4):533–45
Perceptual priming in Alzheimer's and Parkinson's diseases. Koivisto M, et al. **Neuropsychologia** 1996 May;34(5):449–57
Inhibition of return and visuospatial attention in healthy older adults and individuals with dementia of the Alzheimer type. Faust ME, et al. **Neuropsychology** 1997 Jan;11(1):13–29
Effects of relatedness and number of distractors on attribute judgments in Alzheimer's disease. Johnson MK, et al. **Neuropsychology** 1997 Jul;11(3):392–9
Generation effects and source memory in healthy older adults and in adults with dementia of the Alzheimer type. Multhaup KS, et al. **Neuropsychology** 1997 Jul;11(3):382–91
Patients with Alzheimer's disease who cannot perform some motor skills show normal learning of other motor skills. Willingham DB, et al. **Neuropsychology** 1997 Apr; 11(2):261–71
Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease. Raffaele KC, et al. **Neuropsychopharmacology** 1996 Aug;15(2):163–70
Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease. Riekkinen P Jr, et al. **Neuroreport** 1997 May 27;8(8):1845–9
Rate of cognitive decline in Alzheimer's disease is not affected by the alpha-1-antichymotrypsin A allele or the CYP2D6 B mutant. Murphy GM Jr, et al. **Neurosci Lett** 1996 Oct 18;217(2–3):200–2
Dementia and response to pain in the elderly. Porter FL, et al. **Pain** 1996 Dec;68(2–3):413–21
Preservation of temporal skills in Alzheimer's disease. Levy B, et al. **Percept Mot Skills** 1997 Aug;85(1):83–96
Depth perception in Alzheimer's disease. Mendez MF, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 1):987–95
Cognitive and neurobiologic markers of early Alzheimer disease. Albert MS. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13547–51 (62 ref.)
Memory systems analyses of mnemonic disorders in aging and age-related diseases. Gabrieli JD. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13534–40 (57 ref.)
Episodic remembering in a population-based sample of nonagenarians: does major depression exacerbate the memory deficits seen in Alzheimer's disease? Bäckman L, et al. **Psychol Aging** 1996 Dec;11(4):649–57
Sentence comprehension in Alzheimer's disease: effects of grammatical complexity, speech rate, and repetition. Small JA, et al. **Psychol Aging** 1997 Mar;12(1):3–11
Quantitative magnetic resonance imaging and neuropsychological functions in dementia of the Alzheimer type. Pantel J, et al. **Psychol Med** 1997 Jan;27(1):221–9
Correlation among three psychological scales used in research of caregivers for patients with Alzheimer's disease. Fritz CL, et al. **Psychol Rep** 1997 Feb;80(1):67–80
Companion animals and the psychological health of Alzheimer patients' caregivers. Fritz CL, et al. **Psychol Rep** 1996 Apr;78(2):467–81
Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Henderson VW, et al. **Psychoneuroendocrinology** 1996 May;21(4):421–30
Memory, language, and praxis in Alzheimer's disease: norms for outpatient clinical trial populations. Doraiswamy PM, et al. **Psychopharmacol Bull** 1997;33(1):123–8
Plasma catecholamine and lymphocyte beta 2-adrenergic receptor alterations in elderly Alzheimer caregivers under stress. Mills PJ, et al. **Psychosom Med** 1997 May–Jun; 59(3):251–6
Insulin and glucose: relationships with hassles, anger, and hostility in nondiabetic older adults. Vitaliano PP, et al. **Psychosom Med** 1996 Sep–Oct;58(5):489–99
Validation of a cognitive test for delirium in medical ICU patients. Hart RP, et al. **Psychosomatics** 1996 Nov–Dec; 37(6):533–46
Measuring memory in a mouse model of Alzheimer's disease [letter; comment] Routtenberg A. **Science** 1997 Aug 8; 277(5327):839–41. Comment on: Science 1996 Oct 4;274(5284):99–102.
[Alzheimer disease: courage for diagnosis, courage for therapy] Kurz A. **Fortschr Med** 1997 May 10;115(13):50–2 **(Ger)**
[Alzheimer dementia. Purpose of primary importance: improving the quality of life for patient and family. American Medical Association] **Fortschr Neurol Psychiatr** 1997 Apr;65(4 Suppl Alzhei):1–4 **(Ger)**
[Self and informant perception of clinical manifestations of Alzheimer dementia: results of a structured interview (CAMDEX)] Förstl H, et al. **Fortschr Neurol Psychiatr** 1996 Jun;64(6):228–33 (Eng. Abstr.) **(Ger)**
["I never feel free"—women care for the demented husband, father or mother] Adler C, et al. **Gesundheitswesen** 1996 Sep;58 Suppl 2:125–31 (Eng. Abstr.) **(Ger)**
[The German Alzheimer Family Groups. An assessment of current status] Wormstall H, et al. **Nervenarzt** 1996 Sep; 67(9):751–6 (Eng. Abstr.) **(Ger)**
[Changes in the structure of an Alzheimer family group] Wormstall H, et al. **Psychiatr Prax** 1997 May;24(3):117–9 (Eng. Abstr.) **(Ger)**
[Effects of psychopathological components of the onset of Alzheimer's disease] Mauri MC, et al. **Minerva Psichiatr** 1995 Dec;36(4):203–7 (Eng. Abstr.) **(Ita)**
[Case report of sodium valproate treatment of aggression associated with Alzheimer's disease] Takahashi M, et al. **No To Shinkei** 1996 Aug;48(8):757–60 (Eng. Abstr.) **(Jpn)**
[Care of aged, demented patients during large-scale disasters— experience during Hanshin Earthquake] Maeda K, et al. **Seishin Shinkeigaku Zasshi** 1996;98(10):760–5; discussion 777–81 **(Jpn)**
[The disturbance of reversible operation in space in the early stage of Alzheimer's disease] Utsumi K, et al. **Seishin Shinkeigaku Zasshi** 1997;99(5):304–20 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Regional HmPAO SPECT and CT measurements in the diagnosis of Alzheimer's disease. Mattman A, et al. **Can J Neurol Sci** 1997 Feb;24(1):22–8
Regional cerebral blood volume measured by dynamic susceptibility contrast MR imaging in Alzheimer's disease: a principal components analysis. Maas LC, et al. **J Magn Reson Imaging** 1997 Jan–Feb;7(1):215–9
Neuroimaging and early Alzheimer's disease [letter; comment] Smith AD, et al. **Lancet** 1996 Sep 21; 348(9030):829–30. Comment on: Lancet 1996 Jul 13;348(9020):94–7.

ALZHEIMER'S DISEASE

RADIONUCLIDE IMAGING

Postural and gait disturbance correlated with decreased frontal cerebral blood flow in Alzheimer disease. Nakamura T, et al. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):132–9

Regional HmPAO SPECT and CT measurements in the diagnosis of Alzheimer's disease. Mattman A, et al. **Can J Neurol Sci** 1997 Feb;24(1):22–8

Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography. Claus JJ, et al. **Eur J Nucl Med** 1997 Jun;24(6):602–8

Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Donnemiller E, et al. **Eur J Nucl Med** 1997 Mar;24(3):320–5

Demonstration of decreased posterior cingulate perfusion in mild Alzheimer's disease by means of H215O positron emission tomography. Ishii K, et al. **Eur J Nucl Med** 1997 Jun;24(6):670–3

Reduced cortical distribution volume of iodine-123 iomazenil in Alzheimer's disease as a measure of loss of synapses. Soricelli A, et al. **Eur J Nucl Med** 1996 Oct;23(10):1323–8

Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Walker Z, et al. **Eur J Nucl Med** 1997 Jun;24(6):609–14

The ratio of mesial to neocortical temporal lobe blood flow as a predictor of dementia. Cohen RM, et al. **J Am Geriatr Soc** 1997 Mar;45(3):329–33

Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer's disease from other dementias. Masterman DL, et al. **J Geriatr Psychiatry Neurol** 1997 Jan;10(1):15–21 (50 ref.)

Functional imaging techniques in the diagnosis of non-Alzheimer dementias. Brooks DJ. **J Neural Transm Suppl** 1996;47:155–67 (63 ref.)

Constraints on the cerebral basis for semantic processing from neuroimaging studies of Alzheimer's disease. Grossman M, et al. **J Neurol Neurosurg Psychiatry** 1997 Aug;63(2):152–8

The study of neurological disorders using positron emission tomography and single photon emission computed tomography. Newberg AB, et al. **J Neurol Sci** 1996 Feb; 135(2):91–108 (263 ref.)

Use of positron emission tomography in diagnosing Alzheimer's disease [news] **J Neurosci Nurs** 1996 Aug; 28(4):275

Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. Bartenstein P, et al. **J Nucl Med** 1997 Jul;38(7):1095–101

Comparison of iodine-123-iomazenil SPECT and technetium-99m-HMPAO-SPECT in Alzheimer's disease. Fukuchi K, et al. **J Nucl Med** 1997 Mar;38(3):467–70

Decreased medial temporal oxygen metabolism in Alzheimer's disease shown by PET. Ishii K, et al. **J Nucl Med** 1996 Jul;37(7):1159–65

MRI-guided SPECT measurements of medial temporal lobe blood flow in Alzheimer's disease. Julin P, et al. **J Nucl Med** 1997 Jun;38(6):914–9

Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer's type. Pickut BA, et al. **J Nucl Med** 1997 Jun;38(6):929–34

Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. Vander Borght T, et al. **J Nucl Med** 1997 May; 38(5):797–802

Comparison of technetium-99m-HMPAO and technetium-99m-ECD cerebral SPECT images in Alzheimer's disease. van Dyck CH, et al. **J Nucl Med** 1996 Nov;37(11):1749–55

Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: a SPECT blood flow study. Brown DR, et al. **J Psychiatr Res** 1996 Mar-Apr;30(2):109–26

SPECT in AD [letter; comment] Claus JJ, et al. **Neurology** 1997 Apr;48(4):1139–40. Comment on: Neurology 1996 Jan;46(1):278–85.

Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Meltzer CC, et al. **Neurology** 1996 Aug;47(2):454–61

Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM. Pizzolato G, et al. **Neurology** 1996 Oct;47(4):1065–8

Longitudinal study of cerebral blood flow in Alzheimer's disease using single photon emission tomography. Sachdev P, et al. **Psychiatry Res** 1997 Feb 7;68(2-3):133–41

[Semiquantitative 99mTc-HMPAO SPECT in dementia of the Alzheimer type: influence of the selection of reconstruction filter and reference region] Elser H, et al. **Nuklearmedizin** 1996 Dec;35(6):243–50 (Eng. Abstr.) **(Ger)**

[A quantitative study of regional cerebral blood flow in patients with dementia of Alzheimer type using single photon emission computed tomography—clinical application of the IMP autoradiographic method (IMP ARG method)] Koshi Y, et al. **Kaku Igaku** 1996 Sep; 33(9):991–8 (Eng. Abstr.) **(Jpn)**

[Regional cerebral blood flow measurements using 99mTc-ECD SPECT in patients with Alzheimer's disease (ad) in the early stage] Nakano S, et al. **Kaku Igaku** 1996 Nov;33(11):1197–206 (Eng. Abstr.) **(Jpn)**

[Relationship between SPECT and pathological alterations in Alzheimer's disease—a study of a case with left-hemisphere dominant lesions] Nakano N, et al. **Seishin Shinkeigaku Zasshi** 1996;98(7):441–59 (Eng. Abstr.) **(Jpn)**

REHABILITATION

Non pharmacological treatment in Alzheimer's disease. Bianchetti A, et al. **Funct Neurol** 1997 May-Aug; 12(3-4):215–7

Medium-term outcomes of Alzheimer patients in special care units. Bono G, et al. **Funct Neurol** 1997 May-Aug; 12(3-4):219–20

Improvement of picture recall by repetition in patients with dementia of Alzheimer type. Heun R, et al. **Int J Geriatr Psychiatry** 1997 Jan;12(1):85–92

Psychiatric symptoms in patients with dementia treated in a psychogeriatric day hospital. Johansson A, et al. **Int Psychogeriatr** 1996 Winter;8(4):645–58

Minimizing excess disability: a common strategy for chronic disease management [editorial; comment] Larson EB. **J Geriatr Psychiatry Neurol** 1997 Apr;10(2):49–50. Comment on: J Geriatr Psychiatry Neurol 1997 Jan;10(1):33–8.

Symptomatic treatment of elderly patients with early Alzheimer's disease at a memory clinic [see comments] Walstra GJ, et al. **J Geriatr Psychiatry Neurol** 1997 Jan; 10(1):33–8. Comment in: J Geriatr Psychiatry Neurol 1997 Apr;10(2):49–50.

Interactive computer-based cognitive training in patients with Alzheimer's disease. Hofmann M, et al. **J Psychiatr Res** 1996 Nov-Dec;30(6):493–501

[Can "cerebral training" prevent or at least modify age-related memory loss?] Stoppe G. **Internist (Berl)** 1996 Mar; 37(3):317–8 **(Ger)**

[Nursing care aspects for relatives from the viewpoint of a self-help group] Pammer E. **Wien Med Wochenschr** 1996; 146(21-22):569–73 (Eng. Abstr.) **(Ger)**

[Cerebral cognitive deficits today (editorial)] Rameis H. **Wien Med Wochenschr** 1996;146(21-22):537 **(Ger)**

SURGERY

Omental transposition for Alzheimer's disease. Goldsmith HS. **Neurol Res** 1996 Apr;18(2):103–8

THERAPY

Future prospects for Alzheimer's disease therapy: ethical and policy issues for the international community. Whitehouse PJ. **Acta Neurol Scand Suppl** 1996;165:145–9

Statistical issues in prevention and therapeutic trials of Alzheimer disease. Brookmeyer R, et al. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:27–30

Phototherapy for patients with Alzheimer disease with disturbed sleep patterns: results of a community-based pilot study. Colenda CC, et al. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):175–8

A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study. Ferris SH, et al. **Alzheimer Dis Assoc Disord** 1997; 11 Suppl 2:S1–12

Conference report: the Fourth International Nice/Springfield Symposium on Advances in Alzheimer Therapy. Giacobini E, et al. **Alzheimer Dis Assoc Disord** 1997 Mar;11(1):57–9

Ethical aspects of medical decision-making in demented patients: a report from the Netherlands [see comments] Hertogh CM, et al. **Alzheimer Dis Assoc Disord** 1996 Spring;10(1):11–9 (44 ref.). Comment in: Alzheimer Dis Assoc Disord 1996 Spring;10(1):3–4.

Effect of fever-management strategy on the progression of dementia of the Alzheimer type [see comments] Hurley AC, et al. **Alzheimer Dis Assoc Disord** 1996 Spring; 10(1):5–10. Comment in: Alzheimer Dis Assoc Disord 1996 Spring;10(1):3–4.

Complementary therapeutic alternatives: what can we learn? [editorial] Ku Y, et al. **Alzheimer Dis Assoc Disord** 1996 Summer;10(2):61–2

Dementia care at the end of life: empirical research and international collaboration [comment] Whitehouse PJ, et al. **Alzheimer Dis Assoc Disord** 1996 Spring;10(1):3–4. Comment on: Alzheimer Dis Assoc Disord 1996 Spring;10(1):5–10. Comment on: Alzheimer Dis Assoc Disord 1996 Spring;10(1):11–9.

Progress in Alzheimer's disease. Pause and perspective [editorial] Cohen GD. **Am J Geriatr Psychiatry** 1997 Summer;5(3):185–7

Practice guidelines cover management of Alzheimer's disease [news] **Am J Health Syst Pharm** 1997 Jul 1;54(13):1481, 1485

Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association. **Am J Psychiatry** 1997 May;154(5 Suppl):1–39

Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. Kaplitt M, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:42–9

Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients. Van Someren EJ, et al. **Biol Psychiatry** 1997 May 1;41(9):955–63

Row over force feeding of patients with Alzheimer's disease [news] Sheldon T. **BMJ** 1997 Aug 9;315(7104):327

Single case evaluation of the effects of aromatherapy and massage on disturbed behaviour in severe dementia. Brooker DJ, et al. **Br J Clin Psychol** 1997 May;36 (Pt 2):287–96

Ex vivo gene therapy for Alzheimer's disease and spinal cord injury. Blesch A, et al. **Clin Neurosci** 1995–96;3(5):268–74 (51 ref.)

Biological therapies for Alzheimer's disease: focus on trophic factors. Koliatsos VE. **Crit Rev Neurobiol** 1996; 10(2):205–38 (160 ref.)

Behavioral approaches to the treatment of Alzheimer's disease: research strategies. Proceedings of a conference. **Int Psychogeriatr** 1996;8 Suppl 1:5–144

A dynamic long-term care system for the demented elderly. Annerstedt L, et al. **Int Psychogeriatr** 1996 Winter; 8(4):561–74

Challenges in management of Alzheimer's disease behavioral symptoms. Baldwin BA. **Int Psychogeriatr** 1996;8 Suppl 1:117–9

Interventions, outcomes, and efficacy in Alzheimer's disease behavioral research. Beck C. **Int Psychogeriatr** 1996;8 Suppl 1:63–6

Evaluation of interventions in Alzheimer's disease. Beck C. **Int Psychogeriatr** 1996;8 Suppl 1:17–20

Impediments to research progress in development of behavioral approaches to treatment and care of persons with Alzheimer's disease. Berg L. **Int Psychogeriatr** 1996; 8 Suppl 1:113–4

Supporting functional behavior in Alzheimer's disease. Borell L. **Int Psychogeriatr** 1996;8 Suppl 1:123–5

Interventions for family caregivers of patients with Alzheimer's disease in community-based settings: items for consideration. Buckwalter K. **Int Psychogeriatr** 1996;8 Suppl 1:121–2

Interventions for the behavioral complications of Alzheimer's disease: behavioral approaches. Burgio L. **Int Psychogeriatr** 1996;8 Suppl 1:45–52 (35 ref.)

New ways to approach manifestations of Alzheimer's disease and to reduce caregiver burden. Cohen-Mansfield J. **Int Psychogeriatr** 1996;8 Suppl 1:91–4

Neuropsychiatric assessment and intervention in Alzheimer's disease. Cummings JL. **Int Psychogeriatr** 1996;8 Suppl 1:25–30 (15 ref.)

Barriers to behavioral research on dementia. Cummings JL. **Int Psychogeriatr** 1996;8 Suppl 1:21–3

Behavioral intervention strategies for sleep-activity disruption. Dowling GA. **Int Psychogeriatr** 1996;8 Suppl 1:77–86 (34 ref.)

Behavioral treatment of Alzheimer's disease. Ferris SH, et al. **Int Psychogeriatr** 1996;8 Suppl 1:87–90 (3 ref.)

Using technology in behavioral approaches to Alzheimer's disease. Holmes D, et al. **Int Psychogeriatr** 1996;8 Suppl 1:67–71

Supporting everyday activities in dementia. Josephsson S. **Int Psychogeriatr** 1996;8 Suppl 1:141–4

Behavioral problems and interventions in Alzheimer's disease: research needs. Lawton MP. **Int Psychogeriatr** 1996;8 Suppl 1:95–8

Relationship between patient characteristics and the effectiveness of nonpharmacologic approaches to prevent or treat behavioral symptoms. Maslow K. **Int Psychogeriatr** 1996;8 Suppl 1:73–6

Next steps for social and behavioral research related to Alzheimer's disease. Montgomery RJ. **Int Psychogeriatr** 1996;8 Suppl 1:103–7

Measuring outcomes in Alzheimer's disease. Montgomery RJ. **Int Psychogeriatr** 1996;8 Suppl 1:13–6 (13 ref.)

Behavioral approaches to the treatment of Alzheimer's disease: research strategies. Radebaugh TS, et al. **Int Psychogeriatr** 1996;8 Suppl 1:7–12

A research agenda for disruptive behaviors in Alzheimer's disease: a combined biomedical and behavioral approach. Raskind M. **Int Psychogeriatr** 1996;8 Suppl 1:53–8 (29 ref.)

Behavioral approaches to treatment of Alzheimer's disease. Reifler BV. **Int Psychogeriatr** 1996;8 Suppl 1:99–102

Behavioral intervention approaches to the treatment and management of Alzheimer's disease: a research agenda. Reisberg B. **Int Psychogeriatr** 1996;8 Suppl 1:38–44

Methodological issues in the management of behavioral disturbances in dementia. Swearer JM. **Int Psychogeriatr** 1996;8 Suppl 1:59–62

Selecting outcome measures for clinical trials of behavioral disturbances of dementia. Teri L. **Int Psychogeriatr** 1996; 8 Suppl 3:347–9; discussion 351–4

Barriers to behavioral studies in Alzheimer's disease. Wells TJ. **Int Psychogeriatr** 1996;8 Suppl 1:115–6

Relationship of behavioral disturbances in demented patients to institutional care. Winblad B. **Int Psychogeriatr** 1996;8 Suppl 1:133–5

Interventions for family management of patients with Alzheimer's disease. Wykle ML. **Int Psychogeriatr** 1996;8 Suppl 1:109–11

Hospice care for dementia patients [editorial; comment] Volicer L. **J Am Geriatr Soc** 1997 Sep;45(9):1147–9. Comment on: J Am Geriatr Soc 1997 Sep;45(9):1054–9. Comment on: J Am Geriatr Soc 1997 Sep;45(9):1104–7.

Developing treatment guidelines for Alzheimer's disease and other dementias. Rabins PV. **J Clin Psychiatry** 1996;57 Suppl 14:37–8 (11 ref.)

Practice guidelines for the clinical assessment and care

management of Alzheimer's disease and other dementias among adults with intellectual disability. AAMR-IASSID Workgroup on Practice Guidelines for Care Management of Alzheimer's Disease among Adults with Intellectual Disability. Janicki MP, et al. **J Intellect Disabil Res** 1996 Aug;40 (Pt 4):374–82

Ethical concerns in the use of palliative drug treatment for Alzheimer's Disease [see comments] Filley CM, et al. **J Neuropsychiatry Clin Neurosci** 1996 Spring;8(2):202–5. Comment in: J Neuropsychiatry Clin Neurosci 1996 Summer;8(3):361–2.

Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders. Mahoney MJ, et al. **J Pharm Sci** 1996 Dec;85(12):1276–81 (46 ref.)

Acetylcholine receptor targets on cortical pyramidal neurones as targets for Alzheimer's therapy. Chessell JP. **Neurodegeneration** 1996 Dec;5(4):453–9

Participation in clinical trials and long-term outcomes in Alzheimer's disease. Albert SM, et al. **Neurology** 1997 Jul; 49(1):38–43

The family caregiver's role in Alzheimer's disease. Haley WE. **Neurology** 1997 May;48(5 Suppl 6):S25–9 (63 ref.)

Predictors of time to institutionalization of patients with Alzheimer's disease: the CERAD experience, part XVII. Heyman A, et al. **Neurology** 1997 May;48(5):1304–9

Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Levey AI. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13541–6 (64 ref.)

Alzheimer's: treating a family disease. Kennedy M. **Wis Med J** 1996 Oct;95(10):690–4 (0 ref.)

[Peripheral nerve stimulation in Alzheimer's disease] Scherder E, et al. **Tijdschr Gerontol Geriatr** 1997 Apr; 28(2):59–68 (Eng. Abstr.) **(Dut)**

[Alzheimer's disease. A medical and social challenge] Forette F. **Bull Acad Natl Med** 1996 Oct;180(7):1731–45; discussion 1745–6 (61 ref.) (Eng. Abstr.) **(Fre)**

[Bad experiences with ambulatory nursing service (interview by Dr. rer. nat. Anita Schweiger)] Lamby E. **Fortschr Med** 1996 Oct 10;114(28):24–5, 8 **(Ger)**

[Possibilities for psychotherapy treatment of Alzheimer disease patients in the early stage of the disease] Bauer J. **Nervenarzt** 1997 May;68(5):421–4 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Senile dementia of Alzheimer type and multi-infarct dementia investigated by transcranial Doppler sonography. Sattel H, et al. **Dementia** 1996 Jan–Feb;7(1):41–6

URINE

Acid-stable serine proteinase inhibitors in the urine of Alzheimer disease subjects. Sparro G, et al. **Dis Markers** 1996 Aug;13(1):31–41

VIROLOGY

Neurotropic viruses and Alzheimer's disease: a search for varicella zoster virus DNA by the polymerase chain reaction. Lin WR, et al. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):586–9

Herpes simplex virus type 1 in brain and risk of Alzheimer's disease [see comments] Itzhaki RF, et al. **Lancet** 1997 Jan 25;349(9047):241–4. Comment in: Lancet 1997 Apr 12;349(9058):1101; discussion 1101–2. Comment in: Lancet 1997 Apr 12;349(9058):1102.

Neurotropic viruses and Alzheimer disease. Interaction of herpes simplex type 1 virus and apolipoprotein E in the etiology of the disease. Lin WR, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):135–41

Herpes simplex virus and Alzheimer's disease [news] Jack DB. **Mol Med Today** 1996 Jul;2(7):270

AMANITA

[Treatment of poisoning with Amanita phalloides—facts and controversies] Kołaciński Z. **Pol Tyg Lek** 1996 Jun; 51(23–26):350–4, 356 (40 ref.) **(Pol)**

CHEMISTRY

Polysaccharides in fungi. XXXVII. Immunomodulating activities of carboxymethylated derivatives of linear (1-->3)-alpha-D-glucans extracted from the fruiting bodies of Agrocybe cylindracea and Amanita muscaria. Yoshida I, et al. **Biol Pharm Bull** 1996 Jan;19(1):114–21

Analysis of amatoxins alpha-amanitin and beta-amanitin in toadstool extracts and body fluids by capillary zone electrophoresis with photodiode array detection. Brüggemann O, et al. **J Chromatogr A** 1996 Sep 13; 744(1–2):167–76

AMANITINS

ADMINISTRATION & DOSAGE

Hemoperfusion with alpha-amanitin: an in vitro study. Mydlík M, et al. **Int J Artif Organs** 1997 Feb;20(2):105–7

ANALYSIS

Analysis of amatoxins alpha-amanitin and beta-amanitin in toadstool extracts and body fluids by capillary zone electrophoresis with photodiode array detection. Brüggemann O, et al. **J Chromatogr A** 1996 Sep 13; 744(1–2):167–76

CHEMISTRY

Elucidation of the structure of constrained bicyclopeptides in solution by two-dimensional cross-relaxation spectroscopy: amatoxin analogues. Isernia C, et al. **J Pept Sci** 1996 Jan–Feb;2(1):3–13

METABOLISM

Transcriptional competition and homeosis in Drosophila. Burke LP, et al. **Biochem Genet** 1996 Feb;34(1–2):45–59

PHARMACOLOGY

Thogoto and Dhori virus replication is blocked by inhibitors of cellular polymerase II activity but does not cause shutoff of host cell protein synthesis. Siebler J, et al. **Arch Virol** 1996;141(8):1587–94

Transcription in the early diverging eukaryote Trichomonas vaginalis: an unusual RNA polymerase II and alpha-amanitin-resistant transcription of protein-coding genes. Quon DVK, et al. **J Mol Evol** 1996 Sep;43(3):253–62

In vitro transcription of human T-cell leukemia virus type 1 is RNA polymerase II dependent. Lenzmeier BA, et al. **J Virol** 1997 Mar;71(3):2577–80

Effect of amino acids and alpha-amanitin on the development of rabbit embryos in modified protein-free KSOM with HEPES. Liu Z, et al. **Mol Reprod Dev** 1996 Oct; 45(2):157–62

Effects of amino acids and alpha-amanitin on bovine embryo development in a simple protein-free medium. Liu Z, et al. **Mol Reprod Dev** 1997 Mar;46(3):278–85

TOXICITY

New aspects of amanitin and phalloidin poisoning. Faulstich H, et al. **Adv Exp Med Biol** 1996;391:309–14 (11 ref.)

Tumor necrosis factor-induced apoptosis during the poisoning of mice with hepatotoxins. Leist M, et al. **Gastroenterology** 1997 Mar;112(3):923–34

URINE

Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) in toxicological analysis. Studies on the detection of clobenzorex and its metabolites within a systematic toxicological analysis procedure by GC-MS and by immunoassay and studies on the detection of alpha- and beta-amanitin in urine by atmospheric pressure ionization electrospray LC-MS. Maurer HH, et al. **J Chromatogr B Biomed Appl** 1997 Feb 7;689(1):81–9

AMANTADINE

ADMINISTRATION & DOSAGE

Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Plioplys AV, et al. **Neuropsychobiology** 1997; 35(1):16–23

ADVERSE EFFECTS

Anticholinergic syndrome with severe rhabdomyolysis—an unusual feature of amantadine toxicity [letter] Yang CC, et al. **Intensive Care Med** 1997 Mar;23(3):355–6

Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: evidence from a double-blind crossover study [letter] Silver H, et al. **J Clin Psychopharmacol** 1996 Dec;16(6):463–4

Triphasic waves in serotonin syndrome [letter] Dike GL. **J Neurol Neurosurg Psychiatry** 1997 Feb;62(2):200

ANALOGS & DERIVATIVES

Effect of adamantylamide dipeptide on reinfection resistance after primary infection eradication in experimental Schistosomiasis mansoni. Botros S, et al. **Arzneimittelforschung** 1996 Jan;46(1):74–8

Bromontan, a new doping agent [letter] Burnat P, et al. **Lancet** 1997 Sep 27;350(9082):963–4

DIAGNOSTIC USE

Medicated chronic schizophrenic patients do not demonstrate left turning asymmetry. Levine J, et al. **Neuropsychobiology** 1997;36(1):22–4

PHARMACOKINETICS

Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse [see comments] Rees WA, et al. **Equine Vet J** 1997 Mar; 29(2):104–10. Comment in: Equine Vet J 1997 Mar;29(2):89–91.

Intravenous application of amantadine and antiparkinsonian efficacy in Parkinsonian patients. Müller T, et al. **J Neural Transm Suppl** 1995;46:407–13

PHARMACOLOGY

Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Kakkar R, et al. **Brain Res** 1997 Feb 28;749(2):290–4

Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Takahashi T, et al. **Brain Res Bull** 1996;41(6):363–7

Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse [see comments] Rees WA, et al. **Equine Vet J** 1997 Mar; 29(2):104–10. Comment in: Equine Vet J 1997 Mar;29(2):89–91.

Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Parsons CG, et al. **Eur J Neurosci** 1996 Mar;8(3):446–54

Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. Quack G, et al. **J Neural Transm Suppl** 1995;46:97–105

Trapping channel block of NMDA-activated responses by amantadine and memantine. Blanpied TA, et al. **J Neurophysiol** 1997 Jan;77(1):309–23

Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. Matsubayashi H, et al. **J Pharmacol Exp Ther** 1997 May;281(2):834–44

Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies. Danysz W, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):455–68 (151 ref.)

THERAPEUTIC USE

Use of amantadine for chronic fatigue syndrome [letter] Bowman MA, et al. **Arch Intern Med** 1997 Jun 9; 157(11):1264–5

Can we treat respiratory failure in Friedreich ataxia? Botez MI, et al. **Arch Neurol** 1997 Aug;54(8):1030–3

Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses. Lee MG, et al. **Arch Virol** 1996;141(10):1979–89

Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia. Yamada K, et al. **Biol Psychiatry** 1997 May 15; 41(10):1062–4

The combined use of amantadine and l-dopa/carbidopa in the treatment of chronic brain injury. Kraus MF, et al. **Brain Inj** 1997 Jun;11(6):455–60

Amantadine susceptibility in influenza A virus isolates: determination methods and lack of resistance in a Canadian sample, 1991–94. Prud'homme IT, et al. **Clin Diagn Virol** 1997 May;8(1):41–51

Treatment of chronic hepatitis C with amantadine. Smith JP. **Dig Dis Sci** 1997 Aug;42(8):1681–7

Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Kampman K, et al. **Drug Alcohol Depend** 1996 May;41(1):25–33

Amantadine in man and horse—can we learn from each other? [editorial; comment] Oxford JS. **Equine Vet J** 1997 Mar;29(2):89–91. Comment on: Equine Vet J 1997 Mar;29(2):104–10.

Use of antivirals in influenza in the elderly: prophylaxis and therapy. Nicholson KG. **Gerontology** 1996;42(5):280–9 (55 ref.)

Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus. D'Agostini C, et al. **Int J Immunopharmacol** 1996 Feb;18(2):95–102

Alternative medications for ADHD [letter; comment] Masters KJ. **J Am Acad Child Adolesc Psychiatry** 1997 Mar; 36(3):301–2. Comment on: J Am Acad Child Adolesc Psychiatry 1996 Apr;35(4):409–32. Comment on: J Am Acad Child Adolesc Psychiatry 1996 Aug;35(8):978–87.

Sequential outbreak of influenza A and B in a nursing home: efficacy of vaccine and amantadine. Libow LS, et al. **J Am Geriatr Soc** 1996 Oct;44(10):1153–7

Influenza, influenza vaccine, and amantadine/rimantadine. Zimmerman RK, et al. **J Fam Pract** 1997 Aug;45(2):107–22; quiz 123–4 (44 ref.)

Twenty-five years of amantadine therapy in Parkinson's disease. Danielczyk W. **J Neural Transm Suppl** 1995; 46:399–405 (34 ref.)

Amantadine in Parkinson's disease: pro and contra. Greulich W, et al. **J Neural Transm Suppl** 1995;46:415–21 (27 ref.)

Amantadine in advanced Parkinson's disease: good use of an old drug [letter] Adler CH, et al. **J Neurol** 1997 May; 244(5):336–7

Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study [letter] Colosimo C, et al. **J Neurol** 1996 May;243(5):422–5

Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine. Northoff G, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):404–6

Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. Kraus MF, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):222–30

Intermittent amantadine for fluoxetine-induced anorgasmia. Balon R. **J Sex Marital Ther** 1996 Winter;22(4):290–2

Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression [letter] [see comments] Bode L, et al. **Lancet** 1997 Jan 18; 349(9046):178–9. Comment in: Lancet 1997 Mar 29;349(9056):958.

Depression, Borna disease, and amantadine [letter; comment] Lieb K, et al. **Lancet** 1997 Mar 29;349(9056):958. Comment on: Lancet 1997 Jan 18;349(9046):178–9.

Prevention and control of influenza: recommendations of the

AMANTADINE

Advisory Committee on Immunization Practices (ACIP). **MMWR Morb Mortal Wkly Rep** 1997 Apr 25; 46(RR-9):1-25

Treatment of postherpetic neuralgia [letter; comment] Rösler A, et al. **N Engl J Med** 1996 Dec 5;335(23):1769; discussion 1769. Comment on: N Engl J Med 1996 Jul 4;335(1):32-42.

Fatigue in MS [letter; comment] Dulli D, et al. **Neurology** 1996 Nov;47(5):1351. Comment on: Neurology 1995 Nov;45(11):1956-61.

Fatigue in MS [letter; comment] Poser CM. **Neurology** 1996 Nov;47(5):1351. Comment on: Neurology 1995 Nov;45(11):1956-61.

Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. König P, et al. **Neuropsychobiology** 1996; 33(2):80-4

Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. Baptista T, et al. **Pharmacopsychiatry** 1997 Mar;30(2):43-54

[Initial treatment of Parkinson's disease] Kulisevsky J, et al. **Rev Neurol** 1997 Aug;25 Suppl 2:S163-9 (42 ref.) (Eng. Abstr.) **(Spa)**

AMAPARI VIRUS see **TACARIBE COMPLEX VIRUSES**

AMARANTH

CHEMISTRY

Microbiological, nutritional and sensory aspects of stored amaranth biscuits and amaranth crackers. Hozová B, et al. **Nahrung** 1997 Jun;41(3):155-8

METABOLISM

Betaine-aldehyde dehydrogenase from amaranth leaves efficiently catalyzes the NAD-dependent oxidation of dimethylsulfoniopropionaldehyde to dimethylsulfoniopropionate. Vojtechová M, et al. **Arch Biochem Biophys** 1997 Jan 1;337(1):81-8

AMAUROSIS see **BLINDNESS**

AMAUROTIC FAMILIAL IDIOCY see **LIPOIDOSIS**

AMBATHIZON see **THIOACETAZONE**

AMBER

Really ancient DNA. Lights turning red on amber [news] Sykes B. **Nature** 1997 Apr 24;386(6627):764-5

AMBIDEXTERITY see **LATERALITY**

AMBLYOPIA

Strabismus & amblyopia in children: the role of primary care. Brooks SE. **Compr Ther** 1997 Jan;23(1):60-6

Amblyopia & strabismus. Sala NA. **Pa Med** 1996 Mar;99 Suppl:63-6

COMPLICATIONS

Anisometropia and amblyopia--chicken or egg? [editorial; comment] Fielder AR, et al. **Br J Ophthalmol** 1996 Oct; 80(10):857-8. Comment on: Br J Ophthalmol 1996 Oct;80(10):860-3.

Posterior polymorphous dystrophy associated with astigmatism and amblyopia in children. DeRespinis PA, et al. **J Refract Surg** 1996 Sep-Oct;12(6):709-14

The association of strabismus, amblyopia, and refractive errors in spasmus nutans. Young TL, et al. **Ophthalmology** 1997 Jan;104(1):112-7

CONGENITAL

[Photoscreening for early detection of amblyogenic eye changes] Schworm HD, et al. **Klin Monatsbl Augenheilkd** 1997 Mar;210(3):158-64 (Eng. Abstr.) **(Ger)**

[Amblyopia, refractive errors and strabismus in congenital ptosis] Stärk N, et al. **Ophthalmologe** 1996 Aug;93(4):345-50 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Screening of amblyopic children and long-term follow-up. Latvala ML, et al. **Acta Ophthalmol Scand** 1996 Oct; 74(5):488-92

Juvenile pilocytic astrocytoma masquerading as amblyopia. Roh S, et al. **Am J Ophthalmol** 1997 May;123(5):692-4

Evaluation of photoscreener instruments in a childhood population. 1. Otago photoscreener and Dortmans videophotorefractor. Cooper CD, et al. **Aust N Z J Ophthalmol** 1996 Nov;24(4):347-55

Preschool vision screening: outcome of children referred to the hospital eye service. Newman DK, et al. **Br J Ophthalmol** 1996 Dec;80(12):1077-82

Screening for amblyopia: a comparison of paediatric letter tests. Simmers AJ, et al. **Br J Ophthalmol** 1997 Jun; 81(6):465-9

Preschool vision screening: a prospective comparative evaluation. Bray LC, et al. **Eye** 1996;10 (Pt 6):714-8

Visual field testing [letter; comment] Sherman J. **J Am Optom Assoc** 1996 May;67(5):255-6. Comment on: J Am Optom Assoc 1995 Nov;66(11):664-5.

Off-axis photorefractive eye screening in children. Morgan KS, et al. **J Cataract Refract Surg** 1997 Apr;23(3):423-8

Methodology for a randomised controlled trial of preschool vision screening. A new approach with the 'ALSPAC' project. Williams C, et al. **Ophthalmic Epidemiol** 1996 Jun; 3(2):63-76

A comparison of tests to determine acuity deficits in children with amblyopia. Geer I, et al. **Ophthalmic Physiol Opt** 1996 Sep;16(5):367-74

Preschool vision screening: rationale, methodology and outcome. Simons K. **Surv Ophthalmol** 1996 Jul-Aug; 41(1):3-30 (366 ref.)

[The application of the pattern visual-evoked potential in the diagnosis and treatment of amblyopia] Shao C, et al. **Yen Ko Hsueh Pao** 1995 Jun;11(2):108-10 (Eng. Abstr.) **(Chi)**

[Measuring depth perception in stereoamblyopia by using a suprathreshold stimulus] Gockeln R. **Klin Monatsbl Augenheilkd** 1997 Feb;210(2):86-92 (Eng. Abstr.) **(Ger)**

[Visual evoked potentials in patients with refraction amblyopia in the presence of high myopia] Shpak AA. **Vestn Oftalmol** 1996 Sep-Oct;112(5):19-21 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Hydroxocobalamin versus cyanocobalamin [letter] Freeman AG. **J R Soc Med** 1996 Nov;89(11):659

ENZYMOLOGY

Pattern of ocular dominance columns and cytochrome oxidase activity in a macaque monkey with naturally occurring anisometropic amblyopia. Horton JC, et al. **Vis Neurosci** 1997 Jul-Aug;14(4):681-9

EPIDEMIOLOGY

[Can we identify risk groups for the development of amblyopia and strabismus?] Sjöstrand J, et al. **Klin Monatsbl Augenheilkd** 1996 Jan;208(1):23-6 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Binocular function and amblyopia after early surgery in infantile eosotropia. O'Keefe M, et al. **Acta Ophthalmol Scand** 1996 Oct;74(5):461-2

Natural history of infantile anisometropia [see comments] Abrahamsson M, et al. **Br J Ophthalmol** 1996 Oct; 80(10):860-3. Comment in: Br J Ophthalmol 1996 Oct;80(10)857-8.

The neural basis of suppression and amblyopia in strabismus. Sengpiel F, et al. **Eye** 1996;10 (Pt 2):250-8 (80 ref.)

Amblyopia resulting from shield ulcers and plaques of the cornea in vernal keratoconjunctivitis. Cameron JA, et al. **J Pediatr Ophthalmol Strabismus** 1997 Jul-Aug;34(4):261-2

HISTORY

Babe Ruth: with vision like that, how could he hit the ball? Voisin A, et al. **Optom Vis Sci** 1997 Mar;74(3):144-6

METABOLISM

Cat-301 immunoreactivity in the lateral geniculate nucleus and visual cortex of the strabismic amblyopic cat. Yin ZQ, et al. **Aust N Z J Ophthalmol** 1997 May;25 Suppl 1:S107-9

Distribution and localization of NMDA receptor subunit 1 in the visual cortex of strabismic and anisometropic amblyopic cats. Yin ZQ, et al. **Neuroreport** 1996 Nov 25; 7(18):2997-3003

PATHOLOGY

Pattern of ocular dominance columns in human striate cortex in strabismic amblyopia. Horton JC, et al. **Vis Neurosci** 1996 Jul-Aug;13(4):787-95

PHYSIOPATHOLOGY

Amblyopia: a developmental disorder of the central visual pathways. Kiorpes L, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:39-48

The prognostic value of visual evoked response latency in the treatment of amblyopia caused by strabismus. Iliakis E, et al. **Doc Ophthalmol** 1996-97;92(3):223-8

Monocular contribution to the peak time of the binocular pattern visual evoked potential. McKerral M, et al. **Doc Ophthalmol** 1995-96;91(2):181-93

Interocular interaction assessed by VEPs to pattern-onset, -reversal, and -offset in normally sighted and amblyopic subjects. Shawkat FS, et al. **Electroencephalogr Clin Neurophysiol** 1997 Jan;104(1):74-81

Evaluation of amblyopic scotoma by electrophysiological examinations and computerized perimetry. Fioretto M, et al. **Eur J Ophthalmol** 1996 Apr-Jun;6(2):201-7

Psychophysics of suppression. Harrad R. **Eye** 1996;10 (Pt 2):270-3 (28 ref.)

Colour contrast thresholds are normal in functional amblyopia. Mangelschots E, et al. **Eye** 1996;10 (Pt 4):479-84

Neuronal basis of amblyopia: a review. Grigg J, et al. **Indian J Ophthalmol** 1996 Jun;44(2):69-76 (40 ref.)

Improvement in Vernier acuity in adults with amblyopia. Practice makes better. Levi DM, et al. **Invest Ophthalmol Vis Sci** 1997 Jul;38(8):1493-510 (58 ref.)

Vernier acuity in amblyopic and nonamblyopic children. Cox JF, et al. **J Pediatr Ophthalmol Strabismus** 1996 Jan-Feb; 33(1):39-46

Unifying concepts in mechanism of amblyopia. Tong LM. **Med Hypotheses** 1997 Feb;48(2):97-102 (31 ref.)

Reduced activity in the extrastriate visual cortex of individuals with strabismic amblyopia. Imamura K, et al. **Neurosci Lett** 1997 Apr 11;225(3):173-6

Effect of exposure duration on spatial uncertainty in normal and amblyopic eyes. Demanins R, et al. **Vision Res** 1996 Apr;36(8):1189-93

Positional loss in strabismic amblyopia: inter-relationship of alignment threshold, bias, spatial scale and eccentricity. Demanins R, et al. **Vision Res** 1996 Sep;36(17):2771-94

A reduced motion aftereffect in strabismic amblyopia. Hess RF, et al. **Vision Res** 1997 May;37(10):1303-11

Abnormal long-range spatial interactions in amblyopia. Polat U, et al. **Vision Res** 1997 Mar;37(6):737-44

Contrast detection and orientation discrimination thresholds associated with meridional amblyopia. St John R. **Vision Res** 1997 Jun;37(11):1451-7

[The visual evoked potentials of non-amblyopic eyes in children with amblyopia] Li S, et al. **Chung Hua Yen Ko Tsa Chih** 1995 Nov;31(6):422-5 (Eng. Abstr.) **(Chi)**

[Improvement in the vision of an eye with amblyopia after losing the other normal eye] Kontkanen M, et al. **Duodecim** 1995;111(10):926-8 **(Fin)**

PREVENTION & CONTROL

Preschool vision screening [letter] Catford GV. **Br J Ophthalmol** 1997 May;81(5):421

Prevention of amblyopia and the concept of cure. Sjöstrand J, et al. **Eur J Ophthalmol** 1997 Apr-Jun;7(2):121-9 (83 ref.)

Two infant vision screening programmes: prediction and prevention of strabismus and amblyopia from photo- and videorefractive screening. Atkinson J, et al. **Eye** 1996;10 (Pt 2):189-98

Tackling amblyopia in human infants. Vital-Durand F, et al. **Eye** 1996;10 (Pt 2):239-44

Visual acuity in preschool children: the Chapel Hill-Durham Day-Care Vision Study. Merritt JC, et al. **J Natl Med Assoc** 1996 Nov;88(11):709-12

[Quality of vision screening in childhood] Hohmann A, et al. **Klin Monatsbl Augenheilkd** 1997 Jul;211(1):41-7 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Is amblyopia an impediment to binocular function? Hess RF. **Eye** 1996;10 (Pt 2):245-9 (25 ref.)

SURGERY

[Optical sector iridectomy: an alternative to perforating keratoplasty in Peters' anomaly] Jünemann A, et al. **Klin Monatsbl Augenheilkd** 1996 Aug-Sep;209(2-3):117-24 (Eng. Abstr.) **(Ger)**

THERAPY

Waiting times for and attendance at paediatric ophthalmology outpatient appointments. Bowman RJ, et al. **BMJ** 1996 Nov 16;313(7067):1244

Atropine penalisation versus occlusion as the primary treatment for amblyopia. Foley-Nolan A, et al. **Br J Ophthalmol** 1997 Jan;81(1):54-7

The prognostic value of visual evoked response latency in the treatment of amblyopia caused by strabismus. Iliakis E, et al. **Doc Ophthalmol** 1996-97;92(3):223-8

Results of occlusion therapy in anisomyopic amblyopia with myelinated nerve fibers. Käsmann B, et al. **Ger J Ophthalmol** 1996 Jul;5(4):241-5

Treatment for amblyopia: results using occlusive contact lens. Eustis HS, et al. **J Pediatr Ophthalmol Strabismus** 1996 Nov-Dec;33(6):319-22

Treating amblyopia [letter] Goldstein JH. **J Pediatr Ophthalmol Strabismus** 1997 Jul-Aug; 34(4):209-10

Future directions in the treatment of amblyopia [see comments] Campos EC. **Lancet** 1997 Apr 26; 349(9060):1190. Comment in: Lancet 1997 Jun 28;349(9069):1917-8.

Future directions in treatment of amblyopia [letter; comment] Moseley MJ, et al. **Lancet** 1997 Jun 28;349(9069):1917-8. Comment on: Lancet 1997 Apr 26;349(9060):1190.

[The possibility for using the phenomenon of polarized light interference in treating amblyopia] Abramov VG, et al. **Vestn Oftalmol** 1996 Apr-Jun;112(2):29-31 (Eng. Abstr.) **(Rus)**

[Method of treatment of amblyopia with dynamic color stimuli emerging in polarized light interference] Kashchenko TP, et al. **Vestn Oftalmol** 1997 Jan-Feb; 113(1):31-3 (Eng. Abstr.) **(Rus)**

AMBLYSTOMA see **AMBYSTOMA**

AMBROXOL

ADMINISTRATION & DOSAGE

[Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis] Michnar M, et al. **Pneumonol Alergol Pol** 1996; 64 Suppl 1:90–6 (Eng. Abstr.) **(Pol)**

[Inhalation and peroral mucolytic therapy in mucoviscidosis in children] Uglitskikh AK, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Sep–Oct;(5):15–8 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

[Non–pigmented fixed drug–induced erythema] García Puga JM, et al. **An Esp Pediatr** 1996 Dec;45(6):642–4 **(Spa)**

ANALOGS & DERIVATIVES

Effects of a short course of treatment with acebrophylline on the mucus rheological characteristics and respiratory function parameters in patients suffering from chronic obstructive pulmonary disease. Agliati G. **J Int Med Res** 1996 May–Jun;24(3):302–10

ANALYSIS

Determination of bromhexine and ambroxol in pharmaceutical dosage forms, urine and blood serum. Pérez–Ruiz T, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):199–205

PHARMACOLOGY

Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol. Pfeifer S, et al. **Eur J Med Res** 1997 Mar 24;2(3):129–32

Ambroxol improves the broncho–spasmolytic activity of clenbuterol in the guinea–pig. Pairet M, et al. **J Pharm Pharmacol** 1997 Feb;49(2):184–6

The antioxidative activity of the mucoregulatory agents: ambroxol, bromhexine and N–acetyl–L–cysteine. A pulse radiolysis study. Felix K, et al. **Life Sci** 1996;59(14):1141–7

Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro. Gillissen A, et al. **Lung** 1997;175(4):235–42

Oxidant scavenger function of ambroxol in vitro: a comparison with N–acetylcysteine. Gillissen A, et al. **Res Exp Med (Berl)** 1997;196(6):389–98

[Glucocorticosteroids and ambroxol inhibit secretion of inflammatory cytokines in tracheobronchial epithelial cells: Possible role of the NF–kappa B transcription factor] Betz R. **Pneumologie** 1997 May;51(5):491–2 **(Ger)**

[Surfactants of the airways. Critical review and personal research] Mira E, et al. **Acta Otorhinolaryngol Ital** 1997 Feb;17(1 Suppl 56):3–16 (77 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Antenatal ambroxol treatment does not prevent the respiratory distress syndrome in premature infants. Dani C, et al. **Eur J Pediatr** 1997 May;156(5):392–3

Effect of paraquat intoxication and ambroxol treatment on hydrogen peroxide production and lipid peroxidation in selected organs of rat. Piotrowski WJ, et al. **J Appl Toxicol** 1996 Nov–Dec;16(6):501–7

[COPD—a neglected disease entity] **Fortschr Med Suppl** 1997;179:1–12 **(Ger)**

AMBULANCES

A multisite survey of factors contributing to medically unnecessary ambulance transports. Billittier AJ, et al. **Acad Emerg Med** 1996 Nov;3(11):1046–52

Early defibrillation by first responding ambulance personnel [editorial] Bossaert LL. **Acta Clin Belg** 1997;52(2):69–71

Guidelines for pediatric equipment and supplies for basic and advanced life support ambulances. Committee on Ambulance Equipment and Supplies, National Emergency Medical Services for Children Resource Alliance [see comments] **Ann Emerg Med** 1996 Dec;28(6):699–701. Comment in: Ann Emerg Med 1996 Dec;28(6):704–5.

Lights and siren in pediatric 911 ambulance transports: are they being misused? Lacher ME, et al. **Ann Emerg Med** 1997 Feb;29(2):223–7

Measurement of radiofrequency electromagnetic fields in and around ambulances. Boivin WS, et al. **Biomed Instrum Technol** 1997 Mar–Apr;31(2):145–54

Ambulance use, misuse, and unmet needs in a developing emergency medical services system. Chen JC, et al. **Eur J Emerg Med** 1996 Jun;3(2):73–8

Patients with psychiatric emergencies transported by an ambulance in an urban region. Spooren D, et al. **Eur J Emerg Med** 1996 Mar;3(1):14

Effectiveness of ambulance paramedics versus ambulance technicians in managing out of hospital cardiac arrest. Nguyen–Van–Tam JS, et al. **J Accid Emerg Med** 1997 May; 14(3):142–8

Prioritisation of ambulance response [letter] Williams L, et al. **J Accid Emerg Med** 1996 May;13(3):231

MAST 96. Chang AK, et al. **J Emerg Med** 1996 Jul–Aug; 14(4):419–24

Prehospital use of activated charcoal: a pilot study. Crockett R, et al. **J Emerg Med** 1996 May–Jun;14(3):335–8

A brief history of MUSC student outpatient obstetrics department (OPD) and ambulance service at Roper Hospital, 1950–1952. Hunter WH. **J S C Med Assoc** 1996 Aug;92(8):355–60

Trauma patients: an analysis of rural ambulance trip reports. Morrisey MA, et al. **J Trauma** 1996 Oct;41(4):741–6

The Hungarian (Budapest) neonatal interfacility transport system: insight into program development and results. Woodward GA, et al. **Pediatr Emerg Care** 1997 Aug; 13(4):290–3

On an ambulance stretcher suspension concerned with the reduction of patient's blood pressure variation. Sagawa K, et al. **Proc Inst Mech Eng [H]** 1997;211(2):199–208

[119 emergency medical transport of the elderly] Chi CH, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Dec; 12(12):699–706 (Eng. Abstr.) **(Chi)**

[Testing a medically–staffed ambulance in Aarhus. A pilot study] Hansen TM, et al. **Ugeskr Laeger** 1996 Sep 23; 158(39):5438–42 (Eng. Abstr.) **(Dan)**

[Relevance of the 112–emergency calls among the clientele of the emergency department of the Herlev hospital admitting office] Holm O, et al. **Ugeskr Laeger** 1997 Mar 17;159(12):1749–51 (Eng. Abstr.) **(Dan)**

[Prehospital emergency treatment in the county of Northern Jutland 1993] Pedersen G, et al. **Ugeskr Laeger** 1997 Jun 2;159(23):3586–91 (Eng. Abstr.) **(Dan)**

[Unnecessary ambulance transportations? Medical necessity or a community service? (editorial)] Stephensen N. **Ugeskr Laeger** 1997 Mar 17;159(12):1734 **(Dan)**

[Blue lights and syrens in emergency services (see comments)] Grøgaard PF. **Tidsskr Nor Laegeforen** 1997 Mar 10; 117(7):986. Comment in: Tidsskr Nor Laegeforen 1997 May 20;117(13):1950–1. **(Nor)**

[Blue lights and sirens in emergency services (letter; comment)] Holmboe J, et al. **Tidsskr Nor Laegeforen** 1997 May 20;117(13):1950–1. Comment on: Tidsskr Nor Laegeforen 1997 Mar 10;117(7):986. **(Nor)**

[Ambulance care = quality? (letter) (see comments)] Friberg R. **Lakartidningen** 1997 Jan 8;94(1–2):20. Comment in: Lakartidningen 1997 Feb 5;94(6):412. **(Swe)**

[Concentrate on available paramedics (letter; comment)] Gårdelöf B. **Lakartidningen** 1997 Mar 12;94(11):939. Comment on: Lakartidningen 1997 Feb 5;94(6):412. **(Swe)**

[Care during the initial phase of suspected myocardial infarct. Lack of knowledge results in deficient treatment] Herlitz J. **Lakartidningen** 1997 Jul 9;94(28–29):2536–8 **(Swe)**

[More effective resuscitation in a special ambulance. Increased survival after cardiac arrest in Gothenburg] Herlitz J, et al. **Lakartidningen** 1996 Nov 27;93(48):4453–6, 4459 **(Swe)**

[Ambulance services are not to be jeopardized by labor unions (letter; comment) (see comments)] Karlsson K. **Lakartidningen** 1997 Feb 5;94(6):412. Comment on: Lakartidningen 1997 Jan 8;94(1–2):20. Comment in: Lakartidningen 1997 Mar 12;94(11):939. **(Swe)**

[Dfferent priorities in ambulance transportation. High competence is necessary for everybody] Karlsten R, et al. **Lakartidningen** 1997 May 14;94(20):1920–1 **(Swe)**

[Ambulance services in Paris: firemen and physicians cooperate in a military emergency service organization] Nordstrand H. **Lakartidningen** 1997 Feb 5;94(6):396–7 **(Swe)**

HISTORY

Civilian ambulances and lifesaving societies: the European experience, 1870–1914. Hutchinson JF. **Clio Med** 1997; 41:158–78

[Surgical drainage with rubber tubes and Baron Larrey's mobile ambulances introduced by Dr. Ignacio Gama] Quijano–Pitman F. **Gac Med Mex** 1997 May–Jun; 133(3):249 **(Spa)**

STANDARDS

Helicopter transport of injured children: system effectiveness and triage criteria. Moront ML, et al. **J Pediatr Surg** 1996 Aug;31(8):1183–6; discussion 1187–8

Guidelines for pediatric equipment and supplies for basic and advanced life support ambulances. Committee on Ambulance Equipment and Supplies, National EMSC Resource Alliance. **Pediatr Emerg Care** 1996 Dec; 12(6):452–3

STATISTICS & NUMERICAL DATA

Patient–specific predictors of ambulance use. Rucker DW, et al. **Ann Emerg Med** 1997 Apr;29(4):484–91

Regional variation of nonrural pediatric ambulance transport rates: an ecological study. Maio RF, et al. **Pediatr Emerg Care** 1996 Aug;12(4):277–82

AMBULANCES, AIR see **AIR AMBULANCES**

AMBULATION, EARLY see **EARLY AMBULATION**

AMBULATORY BLOOD PRESSURE MONITORING see **BLOOD PRESSURE MONITORING, AMBULATORY**

AMBULATORY CARE

Treatment of out–of–hospital supraventricular tachycardia: adenosine vs verapamil [see comments] Brady WJ Jr, et al. **Acad Emerg Med** 1996 Jun;3(6):574–85. Comment in: Acad Emerg Med 1996 Jun;3(6):564–6.

To treat or not to treat (out–of–hospital) paroxysmal supraventricular tachycardia, that is the question [editorial; comment] Gausche M. **Acad Emerg Med** 1996 Jun; 3(6):564–6. Comment on: Acad Emerg Med 1996 Jun;3(6):574–85.

The effect of an ambulatory internal medicine rotation on students' career choices. Bauer RL, et al. **Acad Med** 1997 Feb;72(2):147–9

Defining and evaluating quality for ambulatory care educational programs [see comments] Bowen JL, et al. **Acad Med** 1997 Jun;72(6):506–10. Comment in: Acad Med 1997 Jun;72(6):505.

Community–based psychiatry clerkship in an ambulatory care setting [letter] Christensen RC. **Acad Med** 1997 Jul; 72(7):565

Ambulatory teaching "lite": less clinic time, more educationally fulfilling [see comments] DaRosa DA, et al. **Acad Med** 1997 May;72(5):358–61. Comment in: Acad Med 1997 May;72(5):357.

Strategies for efficient and effective teaching in the ambulatory care setting. Ferenchick G, et al. **Acad Med** 1997 Apr;72(4):277–80

Ideas for medical education [comment] Irby DM, et al. **Acad Med** 1997 May;72(5):357. Comment on: Acad Med 1997 May;72(5):358–61.

Residents' perceptions of inpatient and outpatient rotation characteristics. Miller MD. **Acad Med** 1997 May;72(5):404

Costs of preceptors' time spent teaching during a third–year family medicine outpatient rotation. Ricer RE, et al. **Acad Med** 1997 Jun;72(6):547–51

Protecting time for teaching in the ambulatory care setting. Skeff KM, et al. **Acad Med** 1997 Aug;72(8):694–7; discussion 693

The roles of experience and reflection in ambulatory care education. Smith CS, et al. **Acad Med** 1997 Jan;72(1):32–5

Time for medical education reform [letter] Weinberg MA, et al. **Acad Med** 1996 Dec;71(12):1279–80

A break–even analysis of optimum faculty assignment for ambulatory primary care training. Xakellis GC, et al. **Acad Med** 1996 Dec;71(12):1337–43

Problems in outpatients with laryngeal hyperplastic lesions. Goldman NC. **Acta Otolaryngol Suppl (Stockh)** 1997; 527:70–3

The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Finney JW, et al. **Addiction** 1996 Dec;91(12):1773–96; discussion 1803–20 (72 ref.)

Nephrology pharmacy practice in the outpatient dialysis setting. Pahre S. **Adv Ren Replace Ther** 1997 Apr; 4(2):179–81

Reduction mammaplasty: a safe and effective outpatient procedure. Short KK, et al. **Aesthetic Plast Surg** 1996 Nov–Dec;20(6):513–8

Screening for anxiety and depression in elderly medical outpatients. Neal RM, et al. **Age Ageing** 1994 Nov; 23(6):461–4

The natural history of outpatient alcohol and drug abuse treatment in a private healthcare setting. Pettinati HM, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):847–52

Intermittent inotropic therapy in an outpatient setting: a cost–effective therapeutic modality in patients with refractory heart failure. Marius–Nunez AL, et al. **Am Heart J** 1996 Oct;132(4):805–8

The effect of cisapride in patients with reflux esophagitis: an ambulatory esophageal manometry/pH–metry study. Paterson WG, et al. **Am J Gastroenterol** 1997 Feb; 92(2):226–30

Yield of laboratory tests for case–finding in the ambulatory general medical examination [letter; comment] Gambino R, et al. **Am J Med** 1997 May;102(5):504; discussion 504–6 . Comment on: Am J Med 1996 Aug;101(2):142–52.

Yield of laboratory tests for case–finding in the ambulatory general medical examination [letter; comment] Hortin GL, et al. **Am J Med** 1997 May;102(5):503–4; discussion 504–6 . Comment on: Am J Med 1996 Aug;101(2):142–52.

Introducing ambulatory care during the medicine clerkship: impact on evaluation and attitudes. Davidson RA, et al. **Am J Med Sci** 1996 Nov;312(5):206–13

Three student manuals for obstetric and gynecologic outpatient care. Chez RA. **Am J Obstet Gynecol** 1997 May; 176(5):1112–5

Minilaparotomy: a laparoscopic viewpoint [letter; comment] Pelosi MA 3rd, et al. **Am J Obstet Gynecol** 1996 Dec; 175(6):1676. Comment on: Am J Obstet Gynecol 1995 Dec;173(6):1727–9; discussion 1729–30.

Management of the symptomatic placenta previa: a randomized, controlled trial of inpatient versus outpatient expectant management. Wing DA, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):806–11

Two–year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Marder SR, et al. **Am J Psychiatry** 1996 Dec;153(12):1585–92

D–dimer testing for suspected pulmonary embolism in outpatients. Perrier A, et al. **Am J Respir Crit Care Med** 1997 Aug;156(2 Pt 1):492–6

The utility of preoperative laboratory testing in general surgery patients for outpatient procedures. Wattsman TA, et al. **Am Surg** 1997 Jan;63(1):81–90

Asthma self care efficacy and morbidity in polyclinic

outpatients. Lee KA, et al. **Ann Acad Med Singapore** 1995 Nov;24(6):846–50

Outpatient management of HIV–related pneumonia [letter; comment] Becker SL. **Ann Intern Med** 1996 Dec 1; 125(11):938–9. Comment on: Ann Intern Med 1996 Feb 15;124(4):451–3.

Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force. Ansell JE, et al. **Ann Pharmacother** 1997 May;31(5):604–15 (60 ref.)

Treatment of depression with outpatient electroconvulsive therapy. Irvin SM. **AORN J** 1997 Mar;65(3):573–8, 581–2 (44 ref.)

The National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Rationale and methods [see comments] Crits–Christoph P, et al. **Arch Gen Psychiatry** 1997 Aug; 54(8):721–6. Comment in: Arch Gen Psychiatry 1997 Aug;54(8):691–4.

Prediction of compliance with outpatient referral in patients with schizophrenia and psychoactive substance use disorders [see comments] Miner CR, et al. **Arch Gen Psychiatry** 1997 Aug;54(8):706–12. Comment in: Arch Gen Psychiatry 1997 Aug;54(8):691–4.

Outpatient treatment of bleb infection. Chen PP, et al. **Arch Ophthalmol** 1997 Sep;115(9):1124–8

Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clinical significance. Brigden M, et al. **Arch Pathol Lab Med** 1997 Sep;121(9):963–7

Intravenous sedation for outpatient treatment of child dental patients: an exploratory study. Veerkamp JS, et al. **ASDC J Dent Child** 1997 Jan–Feb;64(1):48–54 (45 ref.)

Outpatient hysteroscopy—problems. Bellingham FR. **Aust N Z J Obstet Gynaecol** 1997 May;37(2):202–5

Community leg ulcer clinics. Early vascular assessment should be carried out [letter; comment] Ghauri S, et al. **BMJ** 1996 Oct 12;313(7062):943. Comment on: BMJ 1996 Jun 29;312(7047):1648–51.

Commentary: interesting idea, but case not proved. Pringle M. **BMJ** 1997 Feb 1;314(7077):348

Community leg ulcer clinics. Data were missing from paper [letter; comment] Sheehan–Dare R. **BMJ** 1996 Oct 12; 313(7062):942–3. Comment on: BMJ 1996 Jun 29;312(7047):1648–51.

Antidepressant–treated patients in ambulatory care long–term use of non–psychotropic and psychotropic drugs. Bingefors K, et al. **Br J Psychiatry** 1996 Mar;168(3):292–8

Hysterosalpingo–contrast sonography (HyCoSy) using Echovist–200 in the outpatient investigation of infertility patients. Ayida G, et al. **Br J Radiol** 1996 Oct;69(826):910–3

Single–visit venous ulcer assessment clinic: the first year. Scriven JM, et al. **Br J Surg** 1997 Mar;84(3):334–6

A prospective audit of the use of a prostate clinic. Cutinha PE, et al. **Br J Urol** 1996 Nov;78(5):733–6

Improved reliability of uroflowmetry investigations: results of a portable home–based uroflowmetry study. De La Rosette JJ, et al. **Br J Urol** 1996 Sep;78(3):385–90

Ambulatory urodynamics [letter; comment] Klevmark B. **Br J Urol** 1997 Mar;79(3):490. Comment on: Br J Urol 1996 Mar;77(3):333–8.

Ambulatory urodynamic monitoring [letter; comment] Rosario DJ, et al. **Br J Urol** 1996 Dec;78(6):965–6. Comment on: Br J Urol 1996 Mar;77(3):333–8.

Rebuttal to 'surviving without "McMedicine"' [letter] Borkenhagen R. **Can Fam Physician** 1997 Apr;43:613, 615

Walk–in clinics. Medical heresy or pragmatic reality? [editorial] Borkenhagen RH. **Can Fam Physician** 1996 Oct; 42:1879–83, 1888–93 **(Eng, Fre)**

Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment–induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation [published erratum appears in Circulation 1997 Aug 5;96(3):1065] Mancia G, et al. **Circulation** 1997 Mar 18;95(6):1464–70

Day–case adenoidectomy—is it safe? Ahmed K, et al. **Clin Otolaryngol** 1993 Oct;18(5):406–9

Implementation of multiple outpatient formularies: undesirable effects. Stein CM, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):1–7 (32 ref.)

A quality assurance review of the patient referral process and user satisfaction of outpatient general anaesthesia services for dental treatment. Podesta JR, et al. **Community Dent Health** 1996 Dec;13(4):228–31

A strategy for precepting medical students in ambulatory settings. Kernan WN, et al. **Conn Med** 1996 Apr;60(4):203–9

Ambulatory phlebectomy of the foot. Review of 75 patients. Olivencia JA. **Dermatol Surg** 1997 Apr;23(4):279–80

Out–patient treatment of atopic dermatitis with crude coal tar. van der Valk PG, et al. **Dermatology** 1996;193(1):41–4

Fine–needle biopsy of pediatric lesions: a three–year study in an outpatient biopsy clinic. Eisenhut CC, et al. **Diagn Cytopathol** 1996 Feb;14(1):43–50

Medical residents' colorectal cancer screening may be dependent on ambulatory care education. Borum ML. **Dig Dis Sci** 1997 Jun;42(6):1176–8

Inpatient vs. outpatient bowel preparation for elective colorectal surgery. Lee EC, et al. **Dis Colon Rectum** 1996 Apr;39(4):369–73

Comparative review of the adverse effects of sedatives used in children undergoing outpatient procedures. D'Agostino J, et al. **Drug Saf** 1996 Mar;14(3):146–57 (134 ref.)

Partial or full–time hospitalization: patients' preference. Schene AH, et al. **Epidemiol Psichiatr Soc** 1997 Jan–Apr; 6(1 Suppl):145–54

EMLA cream for renal extracorporeal shock wave lithotripsy in ambulatory patients. Bárcena M, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):373–6

A prospective analysis of 949 long–term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. Nightingale CE, et al. **Eur J Cancer** 1997 Mar;33(3):398–403

Out–of–hospital experience in patients with implantable mechanical circulatory support: present and future trends. Fey O, et al. **Eur J Cardiothorac Surg** 1997 Apr;11 Suppl:S51–3

Staged discharge out of hospital of the Novacor left ventricular assist system (LVAS) recipients. Viganó M, et al. **Eur J Cardiothorac Surg** 1997 Apr;11 Suppl:S45–50

Full polysomnography versus home sleep study: searching for the optimal procedure [editorial; comment] Teschler H, et al. **Eur Respir J** 1997 Aug;10(8):1699–700. Comment on: Eur Respir J 1997 Aug;10(8):1720–4.

Why do patients default from follow up at a genitourinary clinic? [letter; comment] Thompson C, et al. **Genitourin Med** 1996 Oct;72(5):386–7. Comment on: Genitourin Med 1995 Dec;71(6):393–5.

Engaging and retaining women in outpatient alcohol and other drug treatment: the effect of referral intensity. Loneck B, et al. **Health Soc Work** 1997 Feb;22(1):38–46

Staging of abdominal cancer by local anesthesia outpatient laparoscopy. Sand J, et al. **Hepatogastroenterology** 1996 Nov–Dec;43(12):1685–8

Knee arthroscopy in the office. Michalska M. **Hosp Pract (Off Ed)** 1997 Mar 15;32(3):179–82, 184, 190

Ambulatory chrono–chemotherapy by portable pumps: feasibility and compliance. Nursing aspects. Mohnen L, et al. **In Vivo** 1995 Nov–Dec;9(6):565–71

Evidence for high prevalence & rapid transmission of HIV among individuals attending STD clinics in Pune, India. Mehendale SM, et al. **Indian J Med Res** 1996 Dec; 104:327–35

Ambulatory follow–up of aortic dissection: comparison between computed tomography and biplane transesophageal echocardiography [see comments] Maffei S, et al. **Int J Card Imaging** 1996 Jun;12(2):105–11. Comment in: Int J Card Imaging 1996 Jun;12(2):137–8.

Outpatient cardiac catheterisation. Skinner JS, et al. **Int J Cardiol** 1996 Mar;53(3):209–19 (34 ref.)

Preventive and promotive medicine in ambulatory clinical practice: a prospective simulated patient study [see comments] Wong YY, et al. **Int J Qual Health Care** 1995 Dec;7(4):333–41. Comment in: Int J Qual Health Care 1995 Dec;7(4):323–4.

Users' views of a drop–in project for the homeless. Bhugra D, et al. **Int J Soc Psychiatry** 1997 Summer;43(2):95–103

State–of–the–art flexible hysteroscopy for office gynecologic evaluation. Bradley LD, et al. **J Am Assoc Gynecol Laparosc** 1995 May;2(3):263–7

Vaginoscopic approach to outpatient hysteroscopy. Paschopoulos M, et al. **J Am Assoc Gynecol Laparosc** 1997 Aug;4(4):465–7

Outpatient coronary stent implantation. Kiemeneij F, et al. **J Am Coll Cardiol** 1997 Feb;29(2):323–7

Adverse drug events in high risk older outpatients. Hanlon JT, et al. **J Am Geriatr Soc** 1997 Aug;45(8):945–8

A meta–analysis of 16 randomized controlled trials to evaluate computer–based clinical reminder systems for preventive care in the ambulatory setting [see comments] Shea S, et al. **J Am Med Inform Assoc** 1996 Nov–Dec; 3(6):399–409. Comment in: ACP J Club 1997 May–Jun;126(3):80.

Psychometric properties and diagnostic utility of the Beck Anxiety Inventory and the State–Trait Anxiety Inventory with older adult psychiatric outpatients. Kabacoff RI, et al. **J Anxiety Disord** 1997 Jan–Feb;11(1):33–47

The accelerated intake: a method for increasing initial attendance to outpatient cocaine treatment. Festinger DS, et al. **J Appl Behav Anal** 1996 Fall;29(3):387–9

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. Bertheault–Cvitkovic F, et al. **J Clin Oncol** 1996 Nov; 14(11):2950–8

Outpatient high–dose chemotherapy with autologous stem–cell rescue for hematologic and nonhematologic malignancies. Meisenberg BR, et al. **J Clin Oncol** 1997 Jan; 15(1):11–7

Relationship between the prescriber's instructions and compliance with antibiotherapy in outpatients treated for an acute infectious disease. Favre O, et al. **J Clin Pharmacol** 1997 Mar;37(3):175–8

Iron overload among a psychiatric outpatient population. Feifel D, et al. **J Clin Psychiatry** 1997 Feb;58(2):74–8

A double–blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. Kiev A, et al. **J Clin Psychiatry** 1997 Apr;58(4):146–52

Evaluation and monitoring of symptom severity and change in depressed outpatients. Senra C. **J Clin Psychol** 1996 May; 52(3):317–24

Effectiveness of an outpatient intervention targeting suicidal young adults: preliminary results. Rudd MD, et al. **J Consult Clin Psychol** 1996 Feb;64(1):179–90

Outpatient treatment of spontaneous pneumothorax in a community hospital using a Heimlich flutter valve: a case series. Campisi P, et al. **J Emerg Med** 1997 Jan–Feb; 15(1):115–9

A prediction rule for community–acquired pneumonia. Stevermer JJ, et al. **J Fam Pract** 1997 Apr;44(4):338–9

Meeting walk–in patients' expectations for testing. Effects on satisfaction. Froehlich GW, et al. **J Gen Intern Med** 1996 Aug;11(8):470–4

Patient satisfaction in the ambulatory setting. Influence of data collection methods and sociodemographic factors. Harpole LH, et al. **J Gen Intern Med** 1996 Jul;11(7):431–4

Assessing functional status: correlation between performance on tasks conducted in a clinic setting and performance on the same task conducted at home. The Salisbury Eye Evaluation Project Team. West SK, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jul;52(4):M209–17

Hemodynamic and neurohumoral effects of long–term prostaglandin E1 infusions in outpatients with severe congestive heart failure. Hülsmann M, et al. **J Heart Lung Transplant** 1997 May;16(5):556–62

Difference between office and ambulatory blood pressure and response to antihypertensive treatment. Parati G, et al. **J Hypertens** 1996 Jun;14(6):791–7

Application of ambulatory infusion devices in infusional cancer chemotherapy: a model for nursing management. Moore C, et al. **J Infus Chemother** 1996 Fall;6(4):181–5 (9 ref.)

Awareness of illness in schizophrenia and outpatient treatment adherence. Cuffel BJ, et al. **J Nerv Ment Dis** 1996 Nov;184(11):653–9

Cynicism, hostility, and suicidal ideation in depressed outpatients. Nierenberg AA, et al. **J Nerv Ment Dis** 1996 Oct;184(10):607–10

Defense style in depressed and anxious psychiatric outpatients: an explorative study. Spinhoven P, et al. **J Nerv Ment Dis** 1997 Feb;185(2):87–94

Outpatient surgical treatment of cervical radiculopathy. Tomaras CR, et al. **J Neurosurg** 1997 Jul;87(1):41–3

Avoiding solid waste contamination problems from iodine–131 patients [news] Marcus CS, et al. **J Nucl Med** 1997 Sep;38(9):26N

An Angelman syndrome clinic: report on 24 patients. Leitner RP, et al. **J Paediatr Child Health** 1996 Apr;32(2):94–8

The febrile child with sickle cell disease: a pediatrician's quandary [editorial; comment] Platt OS. **J Pediatr** 1997 May;130(5):693–4. Comment on: J Pediatr 1997 May;130(5):814–6.

Outpatient liver biopsy in children: a medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. Fox VL, et al. **J Pediatr Gastroenterol Nutr** 1996 Oct;23(3):213–6 (20 ref.)

A brief history of MUSC student outpatient obstetrics department (OPD) and ambulance service at Roper Hospital, 1950–1952. Hunter WH. **J S C Med Assoc** 1996 Aug;92(8):355–60

Improvement in exercise tolerance and spirometric values in stable chronic obstructive pulmonary disease patients after an individualized outpatient rehabilitation programme. Alfaro V, et al. **J Sports Med Phys Fitness** 1996 Sep; 36(3):195–203

An initial evaluation of the psychosocial dimensions of the American Society of Addiction Medicine criteria for inpatient versus intensive outpatient substance abuse rehabilitation. McKay JR, et al. **J Stud Alcohol** 1997 May; 58(3):239–52

Impact of HIV risk and infection on delivery of psychosocial treatment services in outpatient programs. Sorensen JL, et al. **J Subst Abuse Treat** 1996 Sep–Oct;13(5):387–95; discussion 439 (80 ref.)

The impact of outpatient drug services on abstinence among pregnant and parenting women. Zlotnick C, et al. **J Subst Abuse Treat** 1996 May–Jun;13(3):195–202

Regarding "Healing of venous ulcers in an ambulatory care program: the roles of chronic venous insufficiency and patient compliance" [letter; comment] Scriven JM, et al. **J Vasc Surg** 1996 Nov;24(5):905. Comment on: J Vasc Surg 1995 Nov;22(5):629–36.

Direct observation of community–based ambulatory encounters involving medical students. Frank SH, et al. **JAMA** 1997 Sep 3;278(9):712–6

Treatment of gunshot wounds [letter; comment] Baker MS. **Mil Med** 1997 Jul;162(7):ii. Comment on: Mil Med 1997 Apr;162(4):266–7.

Outpatient antibiotic treatment of uncomplicated gunshot wounds: ramifications for military use [see comments] Brouker ME. **Mil Med** 1997 Apr;162(4):266–7 (6 ref.). Comment in: Mil Med 1997 Jul;162(7):ii.

Redesigning graduate medical education—location and content [letter; comment] Feinberg DM. **N Engl J Med** 1996 Nov 7;335(19):1459. Comment on: N Engl J Med 1996 Aug 15;335(7):507–9.

Redesigning graduate medical education—location and content [letter; comment] Joseph C, et al. **N Engl J Med** 1996 Nov 7;335(19):1459–60. Comment on: N Engl J Med 1996 Aug 15;335(7):507–9.

Redesigning graduate medical education—location and content [letter; comment] Robinson JW, et al. **N Engl J Med** 1996 Nov 7;335(19):1460. Comment on: N Engl J Med 1996 Aug 15;335(7):507–9.

Successful treatment on an out–patient basis of a patient with Down's syndrome and disseminated testicular seminoma. Sleijfer S, et al. **Neth J Med** 1996 Mar;48(3):89–91

Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Beydoun A, et al. **Neurology** 1997 Sep;49(3):746–52

What happens when effective outpatient civil commitment is terminated? Munetz MR, et al. **New Dir Ment Health Serv** 1997 Fall;(75):49–59

Outpatient chemotherapy: telephone triage for symptom management. Anastasia PJ, et al. **Oncol Nurs Forum** 1997 Jan-Feb;24(1 Suppl):13–22 (42 ref.)

New approach allows high-dose chemotherapy to be given entirely on an outpatient basis [news] **Oncology (Huntingt)** 1996 Feb;10(2):221–2

Pain in ambulatory AIDS patients. I: Pain characteristics and medical correlates. Breitbart W, et al. **Pain** 1996 Dec; 68(2–3):315–21

Does invasive medical treatment confound the assessment of out-patient cognitive-behavioral therapy for chronic non-malignant pain? Millard RW, et al. **Pain** 1996 Jan; 64(1):206–7

Pain in ambulatory AIDS patients. II: Impact of pain on psychological functioning and quality of life. Rosenfeld B, et al. **Pain** 1996 Dec;68(2–3):323–8

Inpatient vs. outpatient pain management: results of a randomised controlled trial. Williams AC, et al. **Pain** 1996 Jul;66(1):13–22

Continuation of antibiotic therapy for serious bacterial infections outside of the hospital. Gutierrez K. **Pediatr Ann** 1996 Nov;25(11):639–45

The management of common infections in ambulatory children. Mason WH. **Pediatr Ann** 1996 Nov;25(11):620–9 (56 ref.)

Use of racemic epinephrine, dexamethasone, and mist in the outpatient management of croup. Kunkel NC, et al. **Pediatr Emerg Care** 1996 Jun;12(3):156–9

Day care renal biopsy. White RH, et al. **Pediatr Nephrol** 1996 Aug;10(4):408–11

Outpatient management practices associated with reduced risk of pediatric asthma hospitalization and emergency department visits. Lieu TA, et al. **Pediatrics** 1997 Sep;100(3 Pt 1):334–41

Prescribing practice with cognition enhancers in outpatient care: are there differences regarding type of dementia?—Results of a representative survey in lower Saxony, Germany. Stoppe G, et al. **Pharmacopsychiatry** 1996 Jul;29(4):150–5

Pharmacists' ability to influence outcomes of hypertension therapy. Erickson SR, et al. **Pharmacotherapy** 1997 Jan-Feb;17(1):140–7

Clinician information activities in diverse ambulatory care practices. Tang PC, et al. **Proc AMIA Annu Fall Symp** 1996;:12–6

Neuroleptic dosage in psychiatric outpatients [letter] [see comments] Lin KM, et al. **Psychiatr Serv** 1996 May; 47(5):536. Comment in: Psychiatr Serv 1997 Jan;48(1):105.

Psychiatric characteristics of consecutively evaluated outpatient renal transplant candidates and comparisons with consultation-liaison inpatients. RundelL JR, et al. **Psychosomatics** 1997 May-Jun;38(3):269–76

Outpatient treatment of iatrogenic pneumothorax after needle biopsy. Brown KT, et al. **Radiology** 1997 Oct;205(1):249–52

Epilepsy in a children's hospital: an out-patient survey. Hughes AP, et al. **Seizure** 1995 Dec;4(4):279–85

Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Thompson JA, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S44–8

Early intervention for human immunodeficiency virus in Baltimore Sexually Transmitted Diseases Clinics. Impact on gonorrhea incidence in patients infected with HIV. Golden MR, et al. **Sex Transm Dis** 1996 Sep–Oct; 23(5):370–7

Sleep disturbances in the demented elderly: treatment in ambulatory care. Stoppe G, et al. **Sleep** 1995 Dec; 18(10):844–8

Effect of drug user treatment on psychosocial change: a comparison of in-treatment and out-of-treatment cocaine users. Bell DC, et al. **Subst Use Misuse** 1996 Jul; 31(9):1083–100

The effect of an orientation-to-treatment group on the retention of alcoholics in outpatient treatment. Verinis JS. **Subst Use Misuse** 1996 Aug;31(10):1423–31

Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients. Escalante CP, et al. **Support Care Cancer** 1996 Sep;4(5):358–63 (18 ref.)

New ways to teach general internal medicine--the role of ambulatory subspecialty rotations. Hellmann DB, et al. **Trans Am Clin Climatol Assoc** 1996;108:259–67; discussion 267–70

Outpatient inflatable penile prosthesis insertion. Garber BB. **Urology** 1997 Apr;49(4):600–3

Partner violence: a systematic approach to identification and intervention in outpatient health care. Ambuel B, et al. **Wis Med J** 1996 May;95(5):292–7

[Five parameters of ambulatory treatment in psychiatry in the North-American context] Deumié L. **Ann Med Psychol (Paris)** 1996 Jun;154(4):254–7; discussion 258 **(Fre)**

[Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program] Tourani JM, et al. **Bull Cancer** 1997 Apr;84(4):351–6 (Eng. Abstr.) **(Fre)**

[Evaluating quality of life of depressed patients in ambulatory care treatment] Dazord A, et al. **Encephale** 1996 Jul–Aug; 22(4):247–54 (Eng. Abstr.) **(Fre)**

[Percutaneous hepatic puncture biopsy in ambulatory care. 231 patients] Bourgaux JF, et al. **Presse Med** 1997 Mar 1;26(6):262–4 (Eng. Abstr.) **(Fre)**

[Should ambulatory nutritional recovery centers in Niamey (Niger) be closed? Analysis of the situation, proposals and evaluation of an intervention] Barennes H. **Sante** 1996 Jul-Aug;6(4):220–8 (Eng. Abstr.) **(Fre)**

[Ambulatory management of moderately and severely malnourished children in the rural health district of Kapolowe in Shaba (Zaire)] Tellier V, et al. **Sante** 1996 Jul-Aug;6(4):213–9 (Eng. Abstr.) **(Fre)**

[In recent studies patients with deep venous thrombosis (popliteal vein, femoral vein) were treated on an ambulatory basis with low molecular weight heparin (without immobilization!)] Wagner T. **Internist (Berl)** 1996 Sep;37(9):943 **(Ger)**

[Cancer therapy facing radical change: ambulatory care or partial hospitalization, whenever possible?] **Med Klin** 1996 May;91(5 Suppl):1–4 **(Ger)**

[Epilepsy and personality disorder—a now 9-year inpatient-ambulatory treatment continuity] Schlicht F. **Psychiatr Prax** 1997 Jan;24(1):37–8 (Eng. Abstr.) **(Ger)**

[Possibilities for greater flexibility in a cardiologic rehabilitation clinic by supplementary ambulatory/partial inpatient therapeutic services] Karoff M, et al. **Rehabilitation (Stuttg)** 1996 Nov;35(4):205–10 (Eng. Abstr.) **(Ger)**

[Asylum seekers and refugees in ambulatory health care: communication between physician and patient] Blöchliger C, et al. **Schweiz Rundsch Med Prax** 1997 May 7; 86(19):800–10 (Eng. Abstr.) **(Ger)**

[Current antibiotics for clinical practice] Zimmerli W. **Schweiz Rundsch Med Prax** 1996 Oct 1;85(40):1240–4 (20 ref.) (Eng. Abstr.) **(Ger)**

[Ambulatory intensive therapy in the bulbar form of amyotrophic lateral sclerosis] Kirisits H, et al. **Wien Med Wochenschr** 1996;146(9–10):202–3 (Eng. Abstr.) **(Ger)**

[Ambulatory medical treatment of drug dependent patients] Gölz J. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):271–8 (5 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities and limits of drug substitution treatment in ambulatory practice] Siegel I. **Z Arztl Fortbild (Jena)** 1996 Jun;90(4):307–13 (11 ref.) (Eng. Abstr.) **(Ger)**

[Ambulatory geriatric rehabilitation—concepts, chances and responsibilities of participating physicians] Stamm T, et al. **Z Arztl Fortbild (Jena)** 1995 Dec;89(8):847–57 (Eng. Abstr.) **(Ger)**

[Comparative analysis of diagnoses by the referring family physician and the hospital admission committee in ambulatory patients at an internal medicine department (see comments)] Hajnal F, et al. **Orv Hetil** 1997 May 25; 138(21):1341–5 (Eng. Abstr.). Comment in: Orv Hetil 1997 Aug 10;138(32):2042–3. **(Hun)**

[Psychopathological and clinical features among the ambulatory population of obese patients] Ricca V, et al. **Minerva Psichiatr** 1996 Jun;37(2):53–8 (Eng. Abstr.) **(Ita)**

[A patient under the influence of alcohol under acute care in the emergency department] Frańczuk B, et al. **Folia Med Cracov** 1996;37(3–4):35–9 (Eng. Abstr.) **(Pol)**

[Level of depression in outpatients with low back pain syndromes] Jodzio K, et al. **Psychiatr Pol** 1995 Nov–Dec; 29(6):809–18 (Eng. Abstr.) **(Pol)**

[Coronary angiography in the outpatient with angina pectoris] Gomes RS. **Acta Med Port** 1997 Apr;10(4):263–6 (Eng. Abstr.) **(Por)**

[The treatment of bursitis of the olecranon at a polyclinic] Tomashuk IP. **Klin Khir** 1994;(12):60–1 **(Rus)**

[The results of combined acupuncture and laser therapy of outpatients with duodenal ulcer] Burtsev VI, et al. **Klin Med (Mosk)** 1997;75(2):34–6 (Eng. Abstr.) **(Rus)**

[The results of an expert evaluation of continuity in the rehabilitation of the patients from hospitals and outpatient institutions] Logvinenko IA, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):186–8 **(Rus)**

[Current opportunities for the improvement of diagnostic processes in cardiovascular diseases during preadmission period] Bart BYa, et al. **Probl Sotsialnoi Gig Istor Med** 1995 May-Jun;(3):18–9 **(Rus)**

[The use of the cephalosporin antibiotic Zinnat under polyclinic conditions in treating patients with bronchopulmonary infections] Bart BIa, et al. **Ter Arkh** 1996;68(12):36–9 (Eng. Abstr.) **(Rus)**

[The current status of the diagnosis of lung cancer under the conditions of the long-term dispensary care of a population group] Denisov LE, et al. **Ter Arkh** 1997; 69(4):51–4 (Eng. Abstr.) **(Rus)**

[The therapeutic and prophylactic use of Olicard-Retard under outpatient polyclinical conditions in stenocardia patients] Mikhallusova MP, et al. **Ter Arkh** 1997;69(1):17–20 (Eng. Abstr.) **(Rus)**

[Enhancement in the efficacy of dispensary care for adolescents with gastroduodenal pathology] Vakhrushev IaM, et al. **Ter Arkh** 1996;68(2):21–2 (Eng. Abstr.) **(Rus)**

[Problems in the outpatient diagnosis of cancerous diseases] Savvin IuN, et al. **Voen Med Zh** 1996 Nov;317(11):14–7 **(Rus)**

[The anniversary scientific and practical conference of physicians of the 2nd Central Polyclinic of the Ministry of Defense of the Russian Federation] Serebrianskii IuE. **Voen Med Zh** 1996 Oct;317(10):74–6 **(Rus)**

[The structure of the diagnosis of neuromuscular diseases (the examination chart of outpatients for computer analysis)] Dunaevskaia GN. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(2):39–43 (Eng. Abstr.) **(Rus)**

[The home treatment of deep venous thromboses with low-molecular-weight heparin] Grau Segura E, et al. **Rev Clin Esp** 1997 Jun;197(6):398–401 (Eng. Abstr.) **(Spa)**

[Is a transitory ischemic accident diagnosed during inpatient or outpatient care?] Alvarez-Sabín J. **Rev Neurol** 1997 Jul; 25(143):1104–9 (45 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

How well do ambulatory care groups predict expenditures on mental health and substance abuse patients? Ettner SL, et al. **Adm Policy Ment Health** 1997 Mar;24(4):339–57

Capitation adjustment for pediatric populations [letter; comment] Starfield B, et al. **Pediatrics** 1997 Apr;99(4):651 . Comment on: Pediatrics 1996 Jul;98(1):10–7.

ECONOMICS

Adverse events and cost savings three years after implementation of guidelines for outpatient contrast-agent use. Grant KL, et al. **Am J Health Syst Pharm** 1997 Jun 15;54(12):1395–401

The cost/benefits of outpatient-based pulmonary rehabilitation. Reina-Rosenbaum R, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3):240–4

Human resources ... health care professionals who work in ambulatory and home health care are getting paid more [news] **Hosp Health Netw** 1996 Dec 20;70(24):13

The effect of first-contact care on ambulatory health care expenditures. Becker LA. **J Fam Pract** 1996 Nov; 43(5):435–6

What is the cost of ambulatory education? Adams M, et al. **J Gen Intern Med** 1997 Apr;12 Suppl 2:S104–10 (27 ref.)

Cost-benefit and cost-effectiveness analyses of behavioral marital therapy as an addition to outpatient alcoholism treatment. O'Farrell TJ, et al. **J Subst Abuse** 1996; 8(2):145–66

Safety and cost effectiveness of pediatric percutaneous renal biopsy. Chesney DS, et al. **Pediatr Nephrol** 1996 Aug; 10(4):493–5

Salary survey of ambulatory care clinical pharmacists. Anastasio GD, et al. **Pharmacotherapy** 1997 May-Jun; 17(3):565–8

Shorter stays, higher per diem charges found in partial hospital, ambulatory behavioral programs [news] **Psychiatr Serv** 1997 Feb;48(2):258–9

Reduced substance-abuse-related health care costs among voluntary participants in Alcoholics Anonymous. Humphreys K, et al. **Psychiatr Serv** 1996 Jul;47(7):709–13

Effect of conversion from a fee-for-service plan to a capitation reimbursement system on a circumscribed outpatient radiology practice of 20,000 persons. Kangarloo H, et al. **Radiology** 1996 Oct;201(1):79–84

[Prescribing practice for beta blockers at patient discharge to ambulatory care. A health care economic evaluation in a cardiology patient sample with special reference to drug budgeting] Weltermann B, et al. **Gesundheitswesen** 1997 Apr;59(4):258–61 (Eng. Abstr.) **(Ger)**

[Cost savings with preoperative ambulatory diagnosis in elective gastrointestinal operations (letter)] Eisold H. **Leber Magen Darm** 1996 Nov;26(6):326–7 **(Ger)**

[Direct costs of ambulatory treatment of diabetes mellitus. Comparison of observed costs with estimated costs of adherence to the treatment standard] von Ferber L, et al. **Med Klin** 1996 Dec 15;91(12):802–8 (Eng. Abstr.) **(Ger)**

[Cost-effectiveness studies of ambulatory educational programs for children with asthma and their families] Scholtz W, et al. **Pneumologie** 1996 Aug;50(8):538–43 (Eng. Abstr.) **(Ger)**

[Cost of outpatient care] Shipova VM. **Probl Sotsialnoi Gig Istor Med** 1997 Jul–Aug;(4):29–31 (Eng. Abstr.) **(Rus)**

HISTORY

[Polyclinical therapy—an essential part of the study of internal diseases (on the centenary of the Department of Outpatient Care of Internal Diseases) (editorial)] Galkin VA. **Ter Arkh** 1997;69(1):5–8 **(Rus)**

LEGISLATION & JURISPRUDENCE

Outpatient treatment of mentally disordered offenders in Austria. Knecht G, et al. **Int J Law Psychiatry** 1996 Winter; 19(1):87–91

Forensic psychiatric aftercare following hospital order treatment. Muller-Isberner JR. **Int J Law Psychiatry** 1996 Winter;19(1):81–6

Outpatient treatment of forensic patients in Germany: current structure and future developments. Nedopil N, et al. **Int J Law Psychiatry** 1996 Winter;19(1):75–9

Interpreting the effectiveness of involuntary outpatient

commitment: a conceptual model. Swanson JW, et al. **J Am Acad Psychiatry Law** 1997;25(1):5–16

Treatment outcomes for severely mentally ill patients on conditional discharge to community-based treatment. O'Keefe C, et al. **J Nerv Ment Dis** 1997 Jun;185(6):409–11

[Changes in the spectrum of the health services contract and effects on general practice, hospitals and clinics—from the viewpoint of the established surgeon] Bauch J. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:676–7 (Eng. Abstr.) **(Ger)**

MANPOWER

Defining primary care. Empirical analysis of the National Ambulatory Medical Care Survey. Franks P, et al. **Med Care** 1997 Jul;35(7):655–68

METHODS

A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Pereira S, et al. **Acta Psychiatr Scand** 1997 Jun;95(6):464–8

Remifentanil compared with alfentanil for ambulatory surgery using total intravenous anesthesia. The Remifentanil/Alfentanil Outpatient TIVA Group. Philip BK, et al. **Anesth Analg** 1997 Mar;84(3):515–21

Addition of epinephrine to intrathecal bupivacaine and sufentanil for ambulatory labor analgesia. Campbell DC, et al. **Anesthesiology** 1997 Mar;86(3):525–31

Epidural catheter insertion and satisfactory analgesia—the mobile versus the immobile patient [letter; comment] Moore DC. **Anesthesiology** 1997 Mar;86(3):747–9. Comment on: Anesthesiology 1996 Jun;84(6):1524–5.

Outpatient angioplasty: 4-year experience in one practice. Payne SP, et al. **Ann R Coll Surg Engl** 1997 Sep;79(5):331–4

Ambulatory extradural analgesia in labour and mode of delivery [letter] Jenkins JG. **Br J Anaesth** 1997 Jun; 78(6):776–7

Withdrawal strategies for outpatients. Alcohol, benzodiazepine, barbiturate, and opiate addictions. Mezciems PE. **Can Fam Physician** 1996 Sep;42:1745–52 (27 ref.)

The electronic medication event monitor. Lessons for pharmacotherapy. Urquhart J. **Clin Pharmacokinet** 1997 May;32(5):345–56 (79 ref.)

Screening for patients at risk of diabetic foot ulceration in a general diabetic outpatient clinic. Klenerman L, et al. **Diabet Med** 1996 Jun;13(6):561–3

Frequent outpatient follow-up improves severe hypoglycaemia and moderate hyperglycaemia in insulin-dependent diabetic patients [letter] Haardt MJ, et al. **Diabetes Metab** 1997 Feb;23(1):84–6

Pain relief during and following outpatient curettage and hysterosalpingography: a double blind study to compare the efficacy and safety of tramadol versus naproxen. Cobra Research Group. Peters AA, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 May;66(1):51–6

A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Bourin M, et al. **Fundam Clin Pharmacol** 1997;11(2):127–32

Infection control in ambulatory care. Nafziger DA, et al. **Infect Dis Clin North Am** 1997 Jun;11(2):279–96 (81 ref.)

Intensive outpatient treatment: methods and outcomes [editorial] Gottheil E. **J Addict Dis** 1997;16(2):xv–xix

"Intensive" outpatient substance abuse treatment: comparisons with "traditional" outpatient treatment. McLellan AT, et al. **J Addict Dis** 1997;16(2):57–84

Evolution of intensive outpatient treatment (IOP) as a "legitimate" treatment modality [editorial] Washton AM. **J Addict Dis** 1997;16(2):xxi–xxvii

Outpatient intravenous antibiotic therapy. Conlon CP. **J Antimicrob Chemother** 1996 Oct;38(4):557–9

Outpatient management of lipid disorders. La Forge R, et al. **J Cardiovasc Nurs** 1996 Oct;11(1):39–53

Relative role of ambulatory and residential rehabilitation. Cobelli F, et al. **J Cardiovasc Risk** 1996 Apr;3(2):172–5 (20 ref.)

Options for venous access in ambulatory care: issues in selection and management. Herbst SL. **J Infus Chemother** 1996 Fall;6(4):186–94 (36 ref.)

Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study. Hammack JE, et al. **J Pain Symptom Manage** 1996 Oct;12(4):234–40

Computer-supported analysis of continuous ambulatory manometric recordings in the human small bowel. Andrioli A, et al. **Med Biol Eng Comput** 1996 Sep;34(5):336–43

Ambulatory long-term jejunal manometry in diabetic patients with cardiac autonomic neuropathy. Hackelsberger N, et al. **Neurogastroenterol Motil** 1997 Jun;9(2):77–83

Outpatient burn management. Mertens DM, et al. **Nurs Clin North Am** 1997 Jun;32(2):343–64 (40 ref.)

A comparison of pain report and adequacy of analgesic therapy in ambulatory AIDS patients with and without a history of substance abuse. Breitbart W, et al. **Pain** 1997 Aug;72(1–2):235–43

The undertreatment of pain in ambulatory AIDS patients. Breitbart W, et al. **Pain** 1996 May-Jun;65(2–3):243–9

Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. Hirsh J, et al. **Thromb Haemost** 1997 Jul; 78(1):689–92 (33 ref.)

[Self-controlled analgesia and ambulatory palliative care (letter)] Bouffet E, et al. **Arch Pediatr** 1996 Jun;3(6):611–2 **(Fre)**

[Ambulatory therapy of multiple myeloma with vincristine, adriamycin and dexamethasone] Egerer G, et al. **Dtsch Med Wochenschr** 1997 Apr 25;122(17):531–5 (Eng. Abstr.) **(Ger)**

[Automated information system for management of an outpatient hospital] Ruden' VV. **Probl Sotsialnoi Gig Istor Med** 1997 Jul–Aug;(4):40–2 (Eng. Abstr.) **(Rus)**

[The treatment of patients with intestinal infections at a polyclinic] Mashilov VP, et al. **Ter Arkh** 1996;68(11):30–2 (Eng. Abstr.) **(Rus)**

ORGANIZATION & ADMINISTRATION

Graduate medical education for the twenty-first century: a team approach to patient care. Bussing RC, et al. **Acad Med** 1996 Oct;71(10 Suppl):S77–9

Restructuring VA ambulatory care and medical education: the PACE model of primary care. Cope DW, et al. **Acad Med** 1996 Jul;71(7):761–71

A model to structure student learning in ambulatory care settings. Kurth RJ, et al. **Acad Med** 1997 Jul;72(7):601–6

Evaluation of the VA's Pilot Program in Institutional Reorganization toward Primary and Ambulatory Care: Part I, Changes in process and outcomes of care. Rubenstein LV, et al. **Acad Med** 1996 Jul;71(7):772–83

A conversation between two cardiologists [letter] Nash DT. **Am J Cardiol** 1996 Oct 1;78(7):859

Practical aspects of out-of-hospital transfusion. Fridey JL. **Am J Clin Pathol** 1997 Apr;107(4 Suppl 1):S64–71 (23 ref.)

Planning for an ambulatory care service. Rosum RW. **Am J Health Syst Pharm** 1997 Jul 15;54(14):1584, 1587

Pharmaceutical services in a capitated geriatric care program. Sorrento TA, et al. **Am J Health Syst Pharm** 1996 Dec 1;53(23):2848–52

Resources allocation to OPD services at public and private dispensaries in Iringa District, Tanzania. Conestà N, et al. **Ann Ig** 1997 Mar–Apr;9(2):169–76

Ambulatory paediatrics—making a difference. Meates M. **Arch Dis Child** 1997 May;76(5):468–73; discussion 473–6

Long-term follow-up in outpatient clinics. 2: The view from the specialist clinic. Burkey Y, et al. **Fam Pract** 1997 Feb; 14(1):29–33

Pushing the envelope: VA's mail-service operation. Posey LM. **J Am Pharm Assoc (Wash)** 1997 May-Jun; NS37(3):291–5

Outpatient care for elderly HMO patients. Hale W. **J Fam Pract** 1997 Sep;45(3):200

HealthSouth's integrated service model: a case study. Fonner E Jr. **J Health Care Finance** 1996 Fall;23(1):12–6

Administrative and technical support of ambulatory infusional cancer chemotherapy (ICC). Moore C, et al. **J Infus Chemother** 1996 Fall;6(4):161–3 (6 ref.)

Ambulatory infusional cancer chemotherapy: nursing role in patient management. The Cancer Center of Boston. Moore C, et al. **J Infus Chemother** 1996 Fall;6(4):164–70 (22 ref.)

Linking customer judgments with process measures to improve access to ambulatory care. Anctil B, et al. **Jt Comm J Qual Improv** 1996 May;22(5):345–57

Conditional release: court-ordered outpatient treatment for insanity acquittees. Stafford KP, et al. **New Dir Ment Health Serv** 1997 Fall;(75):61–72 (11 ref.)

Oncology nurses fill roles as nurse coordinator/case manager. Starcher S. **Oncol Nurs Forum** 1997 Jun;24(5):801

The role of a secondary pediatric ambulatory care service within the community. Shanon A, et al. **Pediatr Emerg Care** 1997 Feb;13(1):50–3

Early intervention for human immunodeficiency virus in Baltimore Sexually Transmitted Diseases Clinics. Impact on gonorrhea incidence in patients infected with HIV. Golden MR, et al. **Sex Transm Dis** 1996 Sep-Oct; 23(5):370–7

Out-of-hospital transfusion. Evans CS. **Transfusion** 1997 Jul; 37(7):756–67 (55 ref.)

[The prevalence of digestive organ diseases and the organization of specialized care] Khoziainov IuA. **Probl Sotsialnoi Gig Istor Med** 1997 Mar–Apr;(2):9–11 (Eng. Abstr.) **(Rus)**

[Organization of in- and outpatient treatment of new cases of destructive pulmonary tuberculosis] Ursov IG, et al. **Probl Tuberk** 1997;(4):4–5 (6 ref.) (Eng. Abstr.) **(Rus)**

[The day hospital in the polyclinic—an efficient form of delivery of medical care to the population (editorial)] Bart BIa, et al. **Ter Arkh** 1997;69(1):9–11 **(Rus)**

[The work experience of the Department of Outpatient Therapy of the Saratov State Medical University] Orlova GG. **Ter Arkh** 1997;69(1):80–1 **(Rus)**

[Experience in supplying the family members of servicemen with drugs in outpatient treatment] Zemskov NE. **Voen Med Zh** 1996 Sep;317(9):51–3 **(Rus)**

[Planning and assessment of ambulatory care in for drug addiction (published erratum appears in Med Clin (Barc) 1996 Oct 5;107(11):413)] Manzanera R, et al. **Med Clin (Barc)** 1996 Jun 22;107(4):135–42 **(Spa)**

PSYCHOLOGY

Implications of cognitive research for ambulatory care education. Gruppen LD. **Acad Med** 1997 Feb;72(2):117–20

Prognostic significance of the white coat effect. Verdecchia P, et al. **Hypertension** 1997 Jun;29(6):1218–24

[Ambulatory management during the transformation process—a survey of physicians in new German districts] Heim N, et al. **Gesundheitswesen** 1997 Jan;59(1):29–35 (Eng. Abstr.) **(Ger)**

[Subjective criteria of schizophrenic patients in selecting a physician in ambulatory care] Haasen C, et al. **Psychiatr Prax** 1997 Mar;24(2):74–6 (Eng. Abstr.) **(Ger)**

STANDARDS

Improving ambulatory management of asthmatic patients [letter; comment] Ruffin DM, et al. **Am J Med** 1997 Aug; 103(2):168–70. Comment on: Am J Med 1996 Apr;100(4):381–2.

Diagnostic accuracy of outpatient hysteroscopy [letter; comment] Habiba MA. **Am J Obstet Gynecol** 1997 Jun; 176(6):1399–400. Comment on: Am J Obstet Gynecol 1996 Jun;174(6):1678–82.

Inappropriate medication prescribing for the elderly by office-based physicians. Aparasu RR, et al. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):823–9

Reliability of a modified medication appropriateness index in ambulatory older persons [see comments] Fitzgerald LS, et al. **Ann Pharmacother** 1997 May;31(5):543–8. Comment in: Ann Pharmacother 1997 May;31(5):643–4.

Ethics in the outpatient setting: new challenges and opportunities. Young EW. **Camb Q Healthc Ethics** 1997 Summer;6(3):293–8

Outpatient versus inpatient care of children newly diagnosed with IDDM. Charron-Prochownik D, et al. **Diabetes Care** 1997 Apr;20(4):657–60 (18 ref.)

Setting up waiting-time targets to satisfy patients: an application of mathematical programming. Huang XM, et al. **IMA J Math Appl Med Biol** 1995 Sep-Dec; 12(3–4):235–47

ACOG criteria set. Ambulatory care sensitive indicator: ectopic pregnancy, ruptured. Number 21, December 1996. Committee on Quality Assessment. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 May;57(2):229–30

ACOG criteria set. Ambulatory care criteria set: hypoestrogenism. Number 22, April 1997. Committee on Quality Assessment. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 May; 57(2):231–2

Ambulatory care criteria set: intervention for domestic violence. Number 20, November 1996. Committee on Quality Assessment. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 Apr;57(1):93–4

What is important in psychiatric outpatient care? Quality of care from the patient's perspective. Bjoerkman T, et al. **Int J Qual Health Care** 1995 Dec;7(4):355–62

Validity review of performance measures. Lawthers AG. **Int J Qual Health Care** 1996 Jun;8(3):299–306

Quality assessment: is the focus on providers or on patients? Scholle SH, et al. **Int J Qual Health Care** 1996 Jun; 8(3):231–41

Efficacy of outpatient intensive treatment for drug abuse. Campbell J, et al. **J Addict Dis** 1997;16(2):15–25

Randomized comparison of intensive outpatient vs. individual therapy for cocaine abusers. Weinstein SP, et al. **J Addict Dis** 1997;16(2):41–56

Ambulatory care training standards for continuity of care in osteopathic family medicine. Winters FD, et al. **J Am Osteopath Assoc** 1996 Apr;96(4):235–42

Factors affecting diabetes treatment and patient education among Latinos: results of a preliminary study in Chicago. Lipton R, et al. **J Med Syst** 1996 Oct;20(5):267–76

Conceptualizing services research on outpatient commitment. Draine J. **J Ment Health Adm** 1997 Summer;24(3):306–15

Improving patient follow-up through implementation of an ambulatory care quality improvement program. Granneman S, et al. **J Nurs Care Qual** 1997 Feb;11(3):62–7

More is better: counseling participation and the effectiveness of outpatient drug treatment. Fiorentine R, et al. **J Subst Abuse Treat** 1996 Jul–Aug;13(4):341–8

Auditing the use of radiological investigations in a day centre [letter] Royle D, et al. **Palliat Med** 1997 May;11(3):255–6

Patients' requests and satisfaction with services in an outpatient psychiatric setting [see comments] Perreault M, et al. **Psychiatr Serv** 1996 Mar;47(3):287–92. Comment in: Psychiatr Serv 1996 Oct;47(10):1128–9.

An instrument to evaluate the process of psychiatric care in ambulatory settings. Popkin MK, et al. **Psychiatr Serv** 1997 Apr;48(4):524–7

A model for evaluating intensive outpatient behavioral health care programs. Raskin R, et al. **Psychiatr Serv** 1996 Nov; 47(11):1227–32

[Quality and the profit situation in ambulatory radiotherapy (see comments)] Schulz U, et al. **Strahlenther Onkol** 1996 Mar;172(3):121–7; discussion 154 (Eng. Abstr.). Comment in: Strahlenther Onkol 1996 Mar;172(3):117. **(Ger)**

[An evaluation of the possibilities for a paraclinical study in outpatient pneumophthisiology care and proposals for its improvement] Didilescu C, et al. **Pneumoftiziologia** 1996 Jul–Dec;45(3–4):131–8 (Eng. Abstr.) **(Rum)**

[Ways to improve outpatient polyclinic care for servicemen] Serebriankii IuE. **Voen Med Zh** 1997 Mar;318(3):13–20 **(Rus)**

[Experience in improving outpatient polyclinic care] Sharaevskiĭ GIu, et al. **Voen Med Zh** 1997 May;318(5):11–3 **(Rus)**

STATISTICS & NUMERICAL DATA

Emergency department utilization by the elderly: analysis of the National Hospital Ambulatory Medical Care Survey [see comments] Wofford JL, et al. **Acad Emerg Med** 1996 Jul;3(7):694–9. Comment in: Acad Emerg Med 1996 Jul;3(7):658–9.

The prevalence of depression in geriatric medical outpatients. McCrea D, et al. **Age Ageing** 1994 Nov;23(6):465–7

Comparative mortality of people with mental retardation in institutions and the community [see comments] Strauss D, et al. **Am J Ment Retard** 1996 Jul;101(1):26–40. Comment in: Am J Ment Retard 1997 Jan;101(4):424–9.

Missed appointments and Medicaid managed care. Majeroni BA, et al. **Arch Fam Med** 1996 Oct;5(9):507–11

Waiting times for and attendance at paediatric ophthalmology outpatient appointments. Bowman RJ, et al. **BMJ** 1996 Nov 16;313(7067):1244

The two-year follow-up of a randomized comparison of in-patient multidisciplinary team care and routine out-patient care for active rheumatoid arthritis. Vliet Vlieland TP, et al. **Br J Rheumatol** 1997 Jan;36(1):82–5

Ambulatory medical care for non-Hispanic whites, African-Americans, and Mexican-Americans with NIDDM in the U.S. Cowie CC, et al. **Diabetes Care** 1997 Feb;20(2):142–7

Pretreatment dropouts: characteristics and outcomes. Gottheil E, et al. **J Addict Dis** 1997;16(2):1–14

Chronic neuroleptic exposure in bipolar outpatients [published erratum appears in J Clin Psychiatry 1997 Jun;58(6):275] Sernyak MJ, et al. **J Clin Psychiatry** 1997 May;58(5):193–5

A survey of outpatient visits in a United States Army forward unit during Operation Desert Shield. Wasserman GM, et al. **Mil Med** 1997 Jun;162(6):374–9

Continuity of pediatric ambulatory care in a universally insured population. Mustard CA, et al. **Pediatrics** 1996 Dec; 98(6 Pt 1):1028–34

A national survey of hospital -and community-based approaches to pretrial mental health evaluations. Grisso T, et al. **Psychiatr Serv** 1996 Jun;47(6):642–4

The urgency of visits to hospital emergency departments: data from the National Hospital Ambulatory Medical Care Survey (NHAMCS), 1992 [see comments] Schappert SM. **Stat Bull Metrop Insur Co** 1995 Oct-Dec;76(4):10–9. Comment in: Stat Bull Metrop Insur Co 1995 Oct-Dec;76(4):20.

Ambulatory care visits of physician offices, hospital outpatient departments, and emergency departments: United States, 1995. Schappert SM.
Vital Health Stat 13 1997 Jun;(129):1–38

[Recurrence of pulmonary tuberculosis: in- and outpatient data] Rudoĭ NM, et al. **Probl Tuberk** 1997;(4):6–7 (Eng. Abstr.) **(Rus)**

[Comparative study of ambulatory care activities: the visit and the care event] Sala Barbany J, et al.
Aten Primaria 1996 Feb 15;17(2):114–22 (Eng. Abstr.) **(Spa)**

TRENDS

Evolution of intensive outpatient treatment (IOP) as a "legitimate" treatment modality [editorial] Washton AM. **J Addict Dis** 1997;16(2):xxi–xxvii

[Integration of new psychosocial facilities into the health care system: considerations on a social ecological evaluation concept exemplified by ambulatory crisis care] Leferink K, et al. **Psychiatr Prax** 1996 Nov;23(6):270–4 (Eng. Abstr.) **(Ger)**

[Linkage between ambulatory and inpatient rehabilitation in the Euregio Model] Zilvold G, et al.
Rehabilitation (Stuttg) 1996 Nov;35(4):201–4 (Eng. Abstr.) **(Ger)**

[The basic trends in improving the dispensary care for servicemen subjected to irradiation as a result of radiation accidents] Nikiforov AM, et al. **Voen Med Zh** 1996 Jun; 317(6):37–42 **(Rus)**

UTILIZATION

HIV risk behavior, street outreach, and condom use in eight high-risk populations. Anderson JE, et al.
AIDS Educ Prev 1996 Jun;8(3):191–204

Outpatient mental health care in nonhospital settings: distribution of patients across provider groups. Olfson M, et al. **Am J Psychiatry** 1996 Oct;153(10):1353–6

The ambulatory workload of office-based neurologists: implications of the National Ambulatory Medical Care Survey. Menken M. **Arch Neurol** 1996 Apr;53(4):379–81

Rheumatology out-patient workload increases inexorably. Kirwan JR. **Br J Rheumatol** 1997 Apr;36(4):481–6

Effects of psychiatric consultation on medical consumption in medical outpatients with low back pain. Koopmans GT, et al. **Gen Hosp Psychiatry** 1996 May;18(3):145–54

Outpatient geriatric evaluation and management: is there an investment effect? Toseland RW, et al. **Gerontologist** 1997 Jun;37(3):324–32

Determinants of ambulatory mental health services use for school-age children and adolescents. Cunningham PJ, et al. **Health Serv Res** 1996 Oct;31(4):409–27

The influence of distance on ambulatory care use, death, and readmission following a myocardial infarction. Piette JD, et al. **Health Serv Res** 1996 Dec;31(5):573–91

Frequency of 'obesity' in medical records and utilization of out-patient health care by 'obese' subjects in Germany. An analysis of health insurance data. Hauner H, et al.
Int J Obes Relat Metab Disord 1996 Sep;20(9):820–4

Utilization of outpatient care for psoriasis. Stern RS.
J Am Acad Dermatol 1996 Oct;35(4):543–5

A randomized trial of group outpatient visits for chronically ill older HMO members: the Cooperative Health Care Clinic [see comments] Beck A, et al. **J Am Geriatr Soc** 1997 May;45(5):543–9. Comment in: J Am Geriatr Soc 1997 May;45(5):643–4.

The impact of aging and chronic disease on use of hospital and outpatient services in a large HMO: 1971–1991 [see comments] Haan MN, et al. **J Am Geriatr Soc** 1997 Jun; 45(6):667–74. Comment in: J Am Geriatr Soc 1997 Jun;45(6):768–9.

Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. Metlay JP, et al.
J Gen Intern Med 1997 Jul;12(7):423–30

Access to ambulatory care for adolescents: the role of a usual source of care. Bartman BA, et al.
J Health Care Poor Underserved 1997 May;8(2):214–26

The influence of SCUD missile attacks on the utilization of ambulatory services in a family practice. Nakar S, et al.
Med Confl Surviv 1996 Apr-Jun;12(2):149–53

Ambulatory mental health treatment under universal coverage: policy insights from Israel. Feinson MC, et al.
Milbank Q 1997;75(2):235–60

Differences in the use of psychiatric outpatient services between the United States and Ontario [see comments] Kessler RC, et al. **N Engl J Med** 1997 Feb 20;336(8):551–7 . Comment in: N Engl J Med 1997 Feb 20;336(8):578–9. Comment in: N Engl J Med 1997 Jul 17;337(3):204; discussion 205. Comment in: N Engl J Med 1997 Jul 17;337(3):204–5. Comment in: N Engl J Med 1997 Jul 17;337(3):205.

Improving outpatient psychiatric care [editorial; comment] Michels R. **N Engl J Med** 1997 Feb 20;336(8):578–9. Comment on: N Engl J Med 1997 Feb 20;336(8):551–7.

General practitioners use of hospital and community based paediatric out-patient services in Nottingham. Blair M, et al. **Public Health** 1997 Mar;111(2):97–100

Determinants of the use of ambulant social care by the elderly. Crets S. **Soc Sci Med** 1996 Dec;43(12):1709–20

[Patterns of service utilization of mental health outpatients] Lerner Y, et al. **Harefuah** 1996 Oct;131(7–8):236–41, 295 (Eng. Abstr.) **(Heb)**

AMBULATORY CARE FACILITIES

Learning in the social context of ambulatory care clinics. Bowen JL, et al. **Acad Med** 1997 Mar;72(3):187–90

Trends in HIV seroprevalence in men who have sex with men: New York City Department of Health sexually transmitted disease clinics, 1988–1993. Torian LV, et al. **AIDS** 1996 Feb;10(2):187–92

Outpatient management of Stevens-Johnson syndrome: a report of four cases and management strategy. Noskin GA, et al. **Allergy Asthma Proc** 1997 Jan-Feb;18(1):29–32

Are patients who undergo open-access endoscopy more anxious about their procedures than patients referred from the GI clinic? [see comments] Mahajan RJ, et al.
Am J Gastroenterol 1996 Dec;91(12):2505–8. Comment in: Am J Gastroenterol 1997 Aug;92(8):1403–4.

Selective screening versus presumptive treatment criteria for identification of women with chlamydial infection in public clinics: New Jersey. Finelli L, et al.
Am J Obstet Gynecol 1996 May;174(5):1527–33

Breast and cervical cancer screening in an inner-city medical walk-in clinic: taking advantage of an often missed opportunity. Doyle JP, et al. **Am J Prev Med** 1996 Sep-Oct; 12(5):345–50

A follow-up study of first trimester induced abortions at hospitals and family planning clinics in Sichuan province, China. Luo L, et al. **Contraception** 1996 May;53(5):267–73

Project for the development of an ambulatory and semi-ambulatory community center for the third age. Tataru N. **Dement Geriatr Cogn Disord** 1997 Mar-Apr; 8(2):128–31

Tension headache in a primary health care setting. Sebit MB. **East Afr Med J** 1996 Jul;73(7):463–4

Evaluation of general practitioner referrals to a specialist breast clinic according to the UK national guidelines. Cochrane RA, et al. **Eur J Surg Oncol** 1997 Jun; 23(3):198–201

Increasing the availability of vasectomy in public-sector clinics. Haws JM, et al. **Fam Plann Perspect** 1997 Jul-Aug; 29(4):185–6, 190

Efficacy of selection criteria for ovarian reserve screening using the clomiphene citrate challenge test in a tertiary fertility center population [see comments] Hofmann GE, et al. **Fertil Steril** 1996 Jul;66(1):49–53. Comment in: Fertil Steril 1996 Dec;66(6):1044–5.

Sharing prescribing of continuous aciclovir treatment: effects of a new policy and general practitioner responses [letter] Vonau B, et al. **Genitourin Med** 1997 Jun;73(3):225–6

Cervical cytology and colposcopy in clinics for sexually transmitted diseases--when are they appropriate? [editorial] Wilson JD. **Genitourin Med** 1996 Dec;72(6):396–7

Prevalence and clinical features of chronic daily headache in a headache clinic. Srikiatkhachorn A, et al.
Headache 1997 May;37(5):277–80

Team spirit [interview by Terese Hudson] Webb K.
Hosp Health Netw 1996 Dec 5;70(23):26–7

Guide to donor insemination and IVF clinics. A patient's guide or a government league table? Jacobs HS, et al.
Hum Reprod 1996 Sep;11(9):1835–6

Pattern of uveitis in a referral uveitis clinic in India [published erratum appears in Indian J Ophthalmol 1995 Dec;43(4):176] Das D, et al. **Indian J Ophthalmol** 1995 Sep; 43(3):117–21

Patient profile, referral sources, and consultant utilization in a primary care sports medicine clinic. Butcher JD, et al.
J Fam Pract 1996 Dec;43(6):556–60

Hypertension control in multi-ethnic primary care clinics. Pavlik VN, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S19–23

The hidden savings of an on-site corporate medical center. Pachman JS, et al. **J Occup Environ Med** 1996 Oct; 38(10):1047–8

Partnership for a nurse practitioner-directed student health primary care center. Hale JF, et al. **J Prof Nurs** 1996 Nov-Dec;12(6):365–72

Managing heart failure in a specialist clinic. Houghton AR, et al. **J R Coll Physicians Lond** 1997 May-Jun;31(3):276–9

The hospital and the clinic. Tosteson DC. **Med Educ** 1995; 29 Suppl 1:109

Providing a primary care open access clinic for osteoporosis. Fordham JN. **Osteoporos Int** 1996;6 Suppl 2:26–7

Establishing an osteoporosis service. Woolf AD.
Osteoporos Int 1996;6 Suppl 2:9–10

Sexual mixing patterns of patients attending sexually transmitted diseases clinics. Garnett GP, et al.
Sex Transm Dis 1996 May-Jun;23(3):248–57

Trends in the acquisition of sexually transmitted diseases among HIV-positive patients at STD clinics, Miami 1988–1992. Osewe PL, et al. **Sex Transm Dis** 1996 May-Jun;23(3):230–3

Usefulness of human immunodeficiency virus post-test counseling by telephone for low-risk clients of an urban sexually transmitted diseases clinic. Schluter WW, et al.
Sex Transm Dis 1996 May-Jun;23(3):190–7

[Outpatient sports clinic, first impressions (letter; comment)] Jansen FA. **Ned Tijdschr Geneeskd** 1996 Sep 28; 140(39):1967–8. Comment on: Ned Tijdschr Geneeskd 1996 Jul 27;140(30):1548–51. **(Dut)**

[Administrative or economic regulation of ambulatory surgery units?] Bazin G. **Cah Anesthesiol** 1996;44(3):249–51 **(Fre)**

[Therapy of the patient with chronic renal failure. A study from general practice of an ambulatory dialysis center] Urban B. **Fortschr Med** 1996 Oct 20;114(29):380 **(Ger)**

[Clinical and therapeutic experience during two years at the "Consultation Center for the study of menopausal and postmenopausal problems established at the USL 19 in East Bologna] Masi P, et al. **Minerva Ginecol** 1996 May; 48(5):205–9 (Eng. Abstr.) **(Ita)**

[Supporting roles of health centers in community health practice by municipalities] Yasuda N, et al.
Nippon Koshu Eisei Zasshi 1996 Nov;43(11):997–1002 (Eng. Abstr.) **(Jpn)**

[The antibiotic resistance of Staphylococcus aureus strains isolated in units with an elevated nosocomial risk and in outpatient facilities in 1995] Grigore L, et al.
Bacteriol Virusol Parazitol Epidemiol 1997 Jan-Jun; 42(1–2):51–4 (Eng. Abstr.) **(Rum)**

[An analysis of the diagnoses and prescription for chronic patients at a health center] Ausejo Segura M, et al.
Aten Primaria 1997 Jan;19(1):35–40 (Eng. Abstr.) **(Spa)**

ECONOMICS

Clinics had greatest growth in prescription drug sales in 1995, says IMS [news] **Am J Health Syst Pharm** 1996 Jul 15; 53(14):1661

Impact of capitation on free-standing dialysis facilities: can you survive? McMurray SD, et al. **Am J Kidney Dis** 1997 Oct;30(4):542–8

[Computerized medical records in primary health care: mostly a losing business] Olsen A. **Lakartidningen** 1997 Mar 19;94(12):1044–5 **(Swe)**

HISTORY

[A centennial of the ORL clinic of the I.M. Sechenov Moscow Medical Academy] Ovchinnikov IuM.
Vestn Otorinolaringol 1996 May-Jun;(3):3–11 **(Rus)**

ORGANIZATION & ADMINISTRATION

Establishing a peritoneal dialysis program in a nursing home. Jorden L. **Adv Ren Replace Ther** 1996 Jul;3(3):266–8

The Union Health Center: a working model of clinical care linked to preventive occupational health services. Herbert R, et al. **Am J Ind Med** 1997 Mar;31(3):263–73

A lipid clinic associated with a research laboratory working on dyslipoproteinemias and atherosclerosis. Davignon J. **Can J Cardiol** 1996 Oct;12(10):885–90

Pattern of neuro-ophthalmic disorders in a tertiary eye care centre in Addis Ababa. Bayu S, et al. **Ethiop Med J** 1997 Jan;35(1):43–51

Services for female prostitutes in genitourinary medicine clinics in the UK [letter] Donegan C, et al.
Genitourin Med 1996 Dec;72(6):450–1

Market changes and physicians [letter; comment] Clough JD. **Health Aff (Millwood)** 1996 Fall;15(3):282–3. Comment on: Health Aff (Millwood) 1996 Summer;15(2):170–84.

AMBULATORY CARE FACILITIES

Introducing technology into the public STD clinic. Conlon RT. **Health Educ Behav** 1997 Feb;24(1):12–9

Brand central [interview by Chris Serb] Scrushy R. **Hosp Health Netw** 1997 May 20;71(10):30

Nursing care models increase care quality while reducing costs. Leenerts MH, et al. **J Assoc Nurses AIDS Care** 1996 Jul–Aug;7(4):37–49

Establishing outreach health services for homeless persons: an emerging role for nurse managers. Testani–Dufour L, et al. **J Community Health Nurs** 1996;13(4):221–35

Clinic services for persons with AIDS. Experience in a high–prevalence state [see comments] Markson LE, et al. **J Gen Intern Med** 1997 Mar;12(3):141–9. Comment in: J Gen Intern Med 1997 Mar;12(3):195–7.

Nurse practice centers in academia: an emerging subsystem. Boettcher JH. **J Nurs Educ** 1996 Feb;35(2):63–8

Failure of patients to attend a medical outpatient clinic [letter; comment] Bateson MC. **J R Coll Physicians Lond** 1997 May–Jun;31(3):340. Comment on: J R Coll Physicians Lond 1997 Jan–Feb;31(1):70–3.

Failure of patients to attend a medical outpatient clinic [letter; comment] Burns–Cox CJ. **J R Coll Physicians Lond** 1997 May–Jun;31(3):340. Comment on: J R Coll Physicians Lond 1997 Jan–Feb;31(1):70–3.

Failure of patients to attend a medical outpatient clinic [see comments] Simmons AV, et al. **J R Coll Physicians Lond** 1997 Jan–Feb;31(1):70–3. Comment in: J R Coll Physicians Lond 1997 May–Jun;31(3):340.

Uncertainty considerations in group decisions: staffing and ratesetting in a health promotion center. Hatcher ME. **J Soc Health Syst** 1997;5(3):31–42

Nurse–managed corporate employee wellness centers. Lugo NR. **Nurse Pract** 1997 Apr;22(4):104–8, 112–3

Impact of a computerized patient tracking system in a pediatric clinic. Borowitz SM. **Proc AMIA Annu Fall Symp** 1996;:508–11

Panel one: marketing strategies and informing the patient/consumer. A fertility center describes its shared–risk program. Levy MJ. **Womens Health Issues** 1997 May–Jun;7(3):172–6; discussion 186–7

Accountability, representation, and advertising. Sher G, et al. **Womens Health Issues** 1997 May–Jun;7(3):153–61

[Organization and operation of special menopause clinics] Sándor TK, et al. **Orv Hetil** 1996 Feb 4;137(5):243–9 (Eng. Abstr.) **(Hun)**

[Archiving and reporting data in an ambulatory angiologic service] Cordopatri F, et al. **Minerva Cardioangiol** 1997 Apr;45(4):139–45 (Eng. Abstr.) **(Ita)**

[Organization of an out–patient surgical aid and ways of it's improvement] Mikheev NM, et al. **Khirurgiia (Mosk)** 1997; (5):59–62 (Eng. Abstr.) **(Rus)**

[The problems in the information support for the activities of an outpatient polyclinic institution in the system of obligatory medical insurance] Togunov IA. **Probl Sotsialnoi Gig Istor Med** 1996 Sep–Oct;(5):26–30 **(Rus)**

[The continuity of the work of the hospital and the polyclinic] Kartashov VT, et al. **Voen Med Zh** 1997 Feb;318(2):8–12, 79 (Eng. Abstr.) **(Rus)**

[Reorganized primary health care in the region of Ume]. Mostly nurses among the heads of ambulatory care centers] Fällman H. **Lakartidningen** 1996 Oct 23;93(43):3756–7 **(Swe)**

STANDARDS

Comparison of patient satisfaction with ambulatory visits in competing health care delivery settings in Geneva, Switzerland. Perneger TV, et al. **J Epidemiol Community Health** 1996 Aug;50(4):463–8

An audit of the organization of adult epilepsy services in the UK: a comparative review of epilepsy and general neurology clinics. Wallace HK, et al. **Seizure** 1997 Jun; 6(3):185–91

Accountability, representation, and advertising. Sher G, et al. **Womens Health Issues** 1997 May–Jun;7(3):153–61

[Measurement of efficiency and quality of work in hospitals and ambulatory facilities] Martinov–Cvejin M, et al. **Med Pregl** 1996;49(11–12):465–8 (Eng. Abstr.) **(Scr)**

[Quality assurance of asthma care within primary health care in the E–county. Fewer symptoms and emergency visits with a local care program] Dahlberg U, et al. **Lakartidningen** 1997 Sep 10;94(37):3135–9 **(Swe)**

[How good or bad are the analyses performed at health care centers? (letter)] Fager PJ. **Lakartidningen** 1996 Oct 2; 93(40):3448 **(Swe)**

[A quality assurance instrument at ambulatory health centers. A scale for identification of depression among the elderly] Gottfries CG, et al. **Lakartidningen** 1997 Mar 19; 94(12):1099–102 **(Swe)**

[A tool–box in health care centers stimulates quality development of health care] Lindström K, et al. **Lakartidningen** 1997 Sep 3;94(36):3041–2 **(Swe)**

[Study from the County Council shows: private practices are more efficient than public ones] Orn P. **Lakartidningen** 1996 Nov 27;93(48):4364–5 **(Swe)**

STATISTICS & NUMERICAL DATA

Profile of a liver transplant follow–up clinic in a nontransplant Canadian urban centre. Bazylewski R, et al. **Can J Gastroenterol** 1997 Apr;11(3):235–8

An audit of waiting times in the diabetic outpatient clinic: role of patients' punctuality and level of medical staffing. Perros P, et al. **Diabet Med** 1996 Jul;13(7):669–73

Who goes to sexually transmitted diseases clinics? Results from a national population survey (Genitourin Med 1996; 72:197–202) [letter; comment] Scoular A, et al. **Genitourin Med** 1997 Apr;73(2):148–9. Comment on: Genitourin Med 1996 Jun;72(3):197–202.

Provision of diagnostic services for genital chlamydial infection in genitourinary medicine clinics: England and Wales 1996 [letter] Simms I, et al. **Genitourin Med** 1997 Apr;73(2):147–8

Applying the sisterhood method for estimating maternal mortality to a health facility–based sample: a comparison with results from a household–based sample. Danel I, et al. **Int J Epidemiol** 1996 Oct;25(5):1017–22

Evaluating health outcomes in a clinic environment. Burnhill MS. **Int J Fertil Womens Med** 1997 Mar–Apr;42(2):85–93

[Medical consultation about Pakistani immigrants. The pattern of consultations and diagnosis at a health center in Oslo] Steihaug S, et al. **Tidsskr Nor Laegeforen** 1997 Jun 30;117(17):2440–3 (Eng. Abstr.) **(Nor)**

[Number of consultations in an outpatient clinic practice] Togunov I. **Probl Sotsialnoi Gig Istor Med** 1996 Mar–Apr; (2):49–51 (Eng. Abstr.) **(Rus)**

TRENDS

A decade of the Massachusetts General Hospital Neuroendocrine Clinical Center. Biller BM, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1668–74

UTILIZATION

A primary health care service for Glasgow street sex workers—6 years experience of the 'drop–in centre', 1989–1994. Carr S, et al. **AIDS Care** 1996 Aug;8(4):489–97

Patterns of health–care utilization and morbidity in a rural community near Lahore, Pakistan. Suleman M. **Ann Trop Med Parasitol** 1996 Feb;90(1):79–85

Utilization of services for otitis media by children enrolled in Medicaid. Byrns PJ, et al. **Arch Pediatr Adolesc Med** 1997 Apr;151(4):407–13

Sports injury clinics. Knill–Jones R. **Br J Sports Med** 1997 Jun;31(2):95–6

Severity of disturbance among Asian American outpatients. Durvasula R, et al. **Cult Divers Ment Health** 1996; 2(1):43–51

Long–term follow–up in outpatient clinics. 1: The view from general practice. Reeve H, et al. **Fam Pract** 1997 Feb; 14(1):24–8

The proportion of medical consultations motivated by skin diseases in the health centers of Bamako (Republic of Mali). Mahé A, et al. **Int J Dermatol** 1997 Mar;36(3):185–6

Characteristics of self referred patients attending minor injury units. Dolan B, et al. **J Accid Emerg Med** 1997 Jul; 14(4):212–4

Do patients use minor injury units appropriately? Dale J, et al. **J Public Health Med** 1996 Jun;18(2):152–6

Sexually transmitted diseases in patients attending a Baltimore tuberculosis clinic. Assessment of use of multiple categoric services. Peek M, et al. **Sex Transm Dis** 1997 Jan;24(1):8–10

[Increase in the search for treatment by crack users in 2 outpatient clinics at the city of Sao Paulo from 1990 to 1993] Ferri CP, et al. **Rev Assoc Med Bras** 1997 Jan–Mar; 43(1):25–8 (Eng. Abstr.) **(Por)**

AMBULATORY CARE FACILITIES, HOSPITAL see **OUTPATIENT CLINICS, HOSPITAL**

AMBULATORY CARE INFORMATION SYSTEMS

Going paperless. A well–informed investment. Appleby C. **Hosp Health Netw** 1997 Sep 5;71(17):82

Validity review of performance measures. Lawthers AG. **Int J Qual Health Care** 1996 Jun;8(3):299–306

Database management on a personal computer. Redwine DB, et al. **J Am Assoc Gynecol Laparosc** 1996 Nov;4(1):95–101

A randomized controlled trial of a computer–based physician workstation in an outpatient setting: implementation barriers to outcome evaluation [see comments] Rotman BL, et al. **J Am Med Inform Assoc** 1996 Sep–Oct;3(5):340–8. Comment in: J Am Med Inform Assoc 1996 Sep–Oct;3(5):358–9.

Testing informatics innovations: the value of negative trials [editorial; comment] Tierney WM, et al. **J Am Med Inform Assoc** 1996 Sep–Oct;3(5):358–9. Comment on: J Am Med Inform Assoc 1996 Sep–Oct;3(5):340–8.

A computerised implementation of a minimum set of health indicators. Blignaut PJ, et al. **Methods Inf Med** 1997 Feb; 36(2):122–6

Restructuring routinely collected patient data: ORCA applied to andrology. Pierik FH, et al. **Methods Inf Med** 1997 Aug;36(3):184–90

Tobacco–use prevention and cessation. For infants, children, adolescents, and adults. Institute for Clinical Systems Integration. **Postgrad Med** 1997 Mar;101(3):292–300, 302

A decision–supported outpatient practice system. Barrows RC Jr, et al. **Proc AMIA Annu Fall Symp** 1996;:792–6

Impact of a computerized patient tracking system in a pediatric clinic. Borowitz SM. **Proc AMIA Annu Fall Symp** 1996;:508–11

Mapping clinical scenarios to functional requirements: a tool for evaluating clinical information systems. Einbinder LH, et al. **Proc AMIA Annu Fall Symp** 1996;:747–51

Supporting the "clinic without walls" with an event–directed messaging system integrated into an electronic medical record. Rappaport SH. **Proc AMIA Annu Fall Symp** 1996; :648–52

Clinician information activities in diverse ambulatory care practices. Tang PC, et al. **Proc AMIA Annu Fall Symp** 1996;:12–6

[Archiving and reporting data in an ambulatory angiologic service] Cordopatri F, et al. **Minerva Cardioangiol** 1997 Apr;45(4):139–45 (Eng. Abstr.) **(Ita)**

ECONOMICS

Medical informatics and the quality of professional life. Powsner SM. **Psychiatr Serv** 1997 Jan;48(1):27–8

ORGANIZATION & ADMINISTRATION

[The problems in the information support for the activities of an outpatient polyclinic institution in the system of obligatory medical insurance] Togunov IA. **Probl Sotsialnoi Gig Istor Med** 1996 Sep–Oct;(5):26–30 **(Rus)**

TRENDS

Cyberspaced. Appleby C. **Hosp Health Netw** 1997 Mar 5; 71(5):30–2

AMBULATORY ELECTROCARDIOGRAPHY see **ELECTROCARDIOGRAPHY, AMBULATORY**

AMBULATORY MONITORING see **MONITORING, AMBULATORY**

AMBULATORY SURGERY

see related
SURGICENTERS

Safe use of muscle relaxants in day care. van den Broek L. **Acta Anaesthesiol Belg** 1997;48(1):23–7

Is minilaparotomy an alternative to laparoscopy for the ambulatory management of ovarian cysts [letter; comment] Canis M, et al. **Am J Obstet Gynecol** 1996 Aug; 175(2):509–10. Comment on: Am J Obstet Gynecol 1995 Dec;173(6):1727–9; discussion 1729–30.

Mivacurium in daycase surgical patients. Cade L, et al. **Anaesth Intensive Care** 1997 Apr;25(2):133–7

Day surgery survey [letter; comment] Hutchinson BR. **Anaesth Intensive Care** 1996 Oct;24(5):624. Comment on: Anaesth Intensive Care 1996 Feb;24(1):74–8.

A comparison of the efficacy of ketorolac and indomethacin for postoperative analgesia following laparoscopic surgery in day patients. Murrell GC, et al. **Anaesth Intensive Care** 1996 Apr;24(2):237–40

Acupuncture and postoperative vomiting in day–stay paediatric patients. Schwager KL, et al. **Anaesth Intensive Care** 1996 Dec;24(6):674–7

Laparoscopic cholecystectomy as a day surgery procedure. Singleton RJ, et al. **Anaesth Intensive Care** 1996 Apr; 24(2):231–6

A randomized double–blinded comparison of metoclopramide, ondansetron and cyclizine in day–case laparoscopy. Watts SA. **Anaesth Intensive Care** 1996 Oct; 24(5):546–51

Analgesia after day case laparoscopic sterilisation. A comparison of tramadol with paracetamol/dextropropoxyphene and paracetamol/codeine combinations. Crighton IM, et al. **Anaesthesia** 1997 Jul;52(7):649–52

Pre–operative oral administration of morphine in day–case gynaecological laparoscopy. Rasanayagam R, et al. **Anaesthesia** 1996 Dec;51(12):1179–81

Feasibility of day case laparoscopic cholecystectomy in unselected patients. Tuckey JP, et al. **Anaesthesia** 1996 Oct; 51(10):965–8

Use of alfentanil and propofol for outpatient monitored anesthesia care: determining the optimal dosing regimen. Avramov MN, et al. **Anesth Analg** 1997 Sep;85(3):566–72

Spinal bupivacaine in ambulatory surgery: the effect of saline dilution. Ben–David B, et al. **Anesth Analg** 1996 Oct; 83(4):716–20

Small–dose hypobaric lidocaine–fentanyl spinal anesthesia for short duration outpatient laparoscopy. II. Optimal fentanyl dose. Chilvers CR, et al. **Anesth Analg** 1997 Jan;84(1):65–70

Postoperative pain in ambulatory surgery. Chung F, et al. **Anesth Analg** 1997 Oct;85(4):808–16

A randomized multicenter study of remifentanil compared with alfentanil, isoflurane, or propofol in anesthetized pediatric patients undergoing elective strabismus surgery. Davis PJ, et al. **Anesth Analg** 1997 May;84(5):982–9

A comparison of light wand and suspension laryngoscopic intubation techniques in outpatients. Friedman PG, et al. **Anesth Analg** 1997 Sep;85(3):578–82

Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery. Graczyk SG, et al. **Anesth Analg** 1997 Feb;84(2):325–30

Use of the laryngeal mask airway as an alternative to the tracheal tube during ambulatory anesthesia. Joshi GP, et

al. **Anesth Analg** 1997 Sep;85(3):573–7

The incidence of latex sensitivity in ambulatory surgical patients: a correlation of historical factors with positive serum immunoglobin E levels. Lebenbom–Mansour MH, et al. **Anesth Analg** 1997 Jul;85(1):44–9

Caudal anesthesia and urinary retention in ambulatory surgery [letter] Pappas AL, et al. **Anesth Analg** 1997 Sep; 85(3):706

Midazolam premedication increases sedation but does not prolong discharge times after brief outpatient general anesthesia for laparoscopic tubal sterilization. Richardson MG, et al. **Anesth Analg** 1997 Aug;85(2):301–5

Small–dose propofol by continuous infusion does not prevent postoperative vomiting in females undergoing outpatient laparoscopy. Scuderi PE, et al. **Anesth Analg** 1997 Jan; 84(1):71–5

Recovery after propofol with and without intraoperative fentanyl in patients undergoing ambulatory gynecologic laparoscopy. Sukhani R, et al. **Anesth Analg** 1996 Nov; 83(5):975–81

The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery. Sun R, et al. **Anesth Analg** 1997 Feb;84(2):331–6

Eltanolone as an alternative to propofol for ambulatory anesthesia. Tang J, et al. **Anesth Analg** 1997 Oct;85(4):801–7

Small–dose hypobaric lidocaine–fentanyl spinal anesthesia for short duration outpatient laparoscopy. I. A randomized comparison with conventional dose hyperbaric lidocaine. Vaghadia H, et al. **Anesth Analg** 1997 Jan;84(1):59–64

Comparison of emergence and recovery characteristics of sevoflurane, desflurane, and halothane in pediatric ambulatory patients. Welborn LG, et al. **Anesth Analg** 1996 Nov;83(5):917–20

A comparison of oral ketorolac and hydrocodone–acetaminophen for analgesia after ambulatory surgery: arthroscopy versus laparoscopic tubal ligation. White PF, et al. **Anesth Analg** 1997 Jul;85(1):37–43

Dose–response characteristics of spinal bupivacaine in volunteers. Clinical implications for ambulatory anesthesia. Liu SS, et al. **Anesthesiology** 1996 Oct;85(4):729–36

Challenges in ambulatory surgery: discharge criteria. Boey WK. **Ann Acad Med Singapore** 1995 Nov;24(6):906–9 (13 ref.)

Outpatient reduction mammaplasty: a review of 338 consecutive cases. Buenaventura S, et al. **Ann Plast Surg** 1996 Feb;36(2):162–6

Mycobacterium smegmatis infection in a healthy woman following a facelift: case report and review of the literature. Pennekamp A, et al. **Ann Plast Surg** 1997 Jul;39(1):80–3 (12 ref.)

Demand on primary health care after day surgery. Kong KL, et al. **Ann R Coll Surg Engl** 1997 Jul;79(4):291–5

Provision of a day case abscess service. Loftus IM, et al. **Ann R Coll Surg Engl** 1997 Jul;79(4):289–90

Day–stay tonsillectomy: is hospital stay reduced at the expense of increased community care? Mitchell RB, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5):440–3

Ambulatory surgical management of breast carcinoma using a paravertebral block [letter; comment] Dalton EP. **Ann Surg** 1997 Mar;225(3):341. Comment on: Ann Surg 1995 Jul;222(1):19–26.

Preoperative patient teaching in ambulatory surgery settings. Brumfield VC, et al. **AORN J** 1996 Dec;64(6):941–6, 948, 951–2

Preadmission testing [letter; comment] Walker L. **AORN J** 1997 Jun;65(6):1038. Comment on: AORN J 1996 Nov;64(5):776–80.

Outpatient parotidectomy at the Fallon Clinic. The first 2 years. Bentkover SH, et al. **Arch Otolaryngol Head Neck Surg** 1996 Oct; 122(10):1049–53

Outpatient parotidectomy [letter] Cheng D. **Arch Otolaryngol Head Neck Surg** 1997 Sep;123(9):1021

Ambulatory parathyroidectomy for primary hyperparathyroidism. Irvin GL 3rd, et al. **Arch Surg** 1996 Oct;131(10):1074–8

Local anesthesia in outpatient knee arthroscopy: a comparison of efficacy and cost. Lintner S, et al. **Arthroscopy** 1996 Aug;12(4):482–8

The use of large loop excision of the transformation zone (LLETZ) in an outpatient setting. Powell B. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):338–46

Day surgery in ophthalmology [letter; comment] Smith R. **Aust N Z J Ophthalmol** 1997 Feb;25(1):89. Comment on: Aust N Z J Ophthalmol 1996 Aug;24(3):166–7.

"Drive by" mastectomies to be banned [news] Josefson D. **BMJ** 1997 Jan 11;314(7074):92

Comparison of propofol and a propofol–methohexitone mixture for induction of day–case anaesthesia. Thompson N, et al. **Br J Anaesth** 1996 Aug;77(2):213–6

Inhalation induction with sevoflurane: a double–blind comparison with propofol. Thwaites A, et al. **Br J Anaesth** 1997 Apr;78(4):356–61

Day surgery and community health services work load: a descriptive study. Fletcher J, et al. **Br J Gen Pract** 1996 Nov;46(412):681–2

The day unit as a teaching environment. Jarrett PE. **Br J Hosp Med** 1996 Sep 18–Oct 1;56(6):279–81

Anaesthesia for day–case surgery [letter; comment] Susay SR. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):50. Comment on: Br J Hosp Med 1995 Sep 6–19;54(5):202–6.

First day follow up for routine phacoemulsification? [letter] Talks SJ, et al. **Br J Ophthalmol** 1997 May;81(5):421–2

The use of pH adjusted lignocaine in controlling operative pain in the day surgery unit: a prospective, randomised trial. Fitton AR, et al. **Br J Plast Surg** 1996 Sep;49(6):404–8

Exclusion from day surgery: a 1–year clinical audit. Clark SK, et al. **Br J Surg** 1996 Oct;83(10):1384–5

Outpatient laparoscopic cholecystectomy. Mjåland O, et al. **Br J Surg** 1997 Jul;84(7):958–61

Surgical outpatients: challenges and responses. Waghorn A, et al. **Br J Surg** 1997 Mar;84(3):300–7 (114 ref.)

Out–patient surgery for the correction of penile curvature. Hsu GL, et al. **Br J Urol** 1997 Jan;79(1):36–9

Music increases satisfaction in elderly outpatients undergoing cataract surgery. Cruise CJ, et al. **Can J Anaesth** 1997 Jan; 44(1):43–8

A comparison of three regional anaesthesia techniques for outpatient knee arthroscopy. Goranson BD, et al. **Can J Anaesth** 1997 Apr;44(4):371–6

Inpatient today––outpatient tomorrow? [editorial; comment] Girotti MJ. **Can J Surg** 1997 Aug;40(4):247–8. Comment on: Can J Surg 1997 Aug;40(4):284–8.

Symposium on ambulatory surgery: principles, practice, pitfalls [see comments] MacFarlane JK. **Can J Surg** 1997 Aug;40(4):259–63. Comment in: Can J Surg 1997 Aug;40(4):246.

Continuing transition in surgical care [editorial; comment] Milne CA. **Can J Surg** 1997 Aug;40(4):246. Comment on: Can J Surg 1997 Aug;40(4):259–63.

Establishing outpatient cholecystectomy as a hospital routine [see comments] Voitk AJ. **Can J Surg** 1997 Aug;40(4):284–8 . Comment in: Can J Surg 1997 Aug;40(4):247–8.

Establishment and cost analysis of an office surgical suite. Way JC, et al. **Can J Surg** 1996 Oct;39(5):379–83

The feasibility of day case surgery for dilatation and curettage procedures in Sri Lanka [letter] Gunawardana RH, et al. **Ceylon Med J** 1996 Dec;41(4):166

Assessment of sequelae at home following adenotonsillectomy. A basis for day–case management? Benson–Mitchell R, et al. **Clin Otolaryngol** 1993 Aug; 18(4):282–4

Suitability of children for ENT day case procedures. Drake–Lee A, et al. **Clin Otolaryngol** 1997 Jun;22(3):215–8

Day–case tonsillectomy––is it appropriate? Pringle MB, et al. **Clin Otolaryngol** 1996 Dec;21(6):504–11

Outpatient laparoscopic interval female sterilization. Intaraprasert S, et al. **Contraception** 1997 May;55(5):283–6 (17 ref.)

"At least a nurse anesthetist" may not be enough! [letter] Field LM. **Dermatol Surg** 1997 Sep;23(9):847–8

Ambulatory phlebectomy [letter; comment] Gross DJ. **Dermatol Surg** 1996 Oct;22(10):893–4. Comment on: Dermatol Surg 1996 Jan;22(1):53–5.

Ambulatory phlebectomy of the foot. Review of 75 patients. Olivencia JA. **Dermatol Surg** 1997 Apr;23(4):279–80

Hook–needle puncture. A new technique of local anesthesia for anorectal surgery. Sobrado CW, et al. **Dis Colon Rectum** 1996 Nov;39(11):1330–1

Powered nasal polypectomy in the office setting. Krouse JH, et al. **Ear Nose Throat J** 1996 Sep;75(9):608–10

Nitrous oxide inhalation as an adjunct to intravenous induction of general anaesthesia with propofol for day surgery. Johnson GW, et al. **Eur J Anaesthesiol** 1997 May; 14(3):295–9

Ambulatory mediastinal biopsy for hematologic malignancies. Venuta F, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):218–21

Day surgery: the impact on general practice–based primary care [editorial] Stott N. **Fam Pract** 1995 Dec;12(4):392–3

Office laparoscopy under local anesthesia for gamete intrafallopian transfer: technique and tolerance. Milki AA, et al. **Fertil Steril** 1997 Jul;68(1):128–32

How effective is patient–controlled analgesia? A randomized comparison of two protocols for pain relief during oocyte recovery. Bhattacharya S, et al. **Hum Reprod** 1997 Jul; 12(7):1440–2

Office hysteroscopic tubal occlusion with siloxane intratubal devices (the Ovabloc method). van der Leij G, et al. **Int J Gynaecol Obstet** 1996 Jun;53(3):253–60

The risk of postoperative haemorrhage in tonsillectomy as an outpatient procedure in children. Rakover Y, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jul 18;41(1):29–36

Surgery of varicose veins on ambulatory basis. Early and late results. Dimakakos P, et al. **Int Surg** 1995 Jul–Sep; 80(3):267–70

Patients' perspectives and experiences of day case surgery. Otte DI. **J Adv Nurs** 1996 Jun;23(6):1228–37

Twenty–two years of office and outpatient laparoscopy: current techniques and why I chose them. Penfield AJ. **J Am Assoc Gynecol Laparosc** 1995 May;2(3):365–8

Sterilization by open laparoscopy in a private office. Schnepper FW. **J Am Assoc Gynecol Laparosc** 1997 Aug; 4(4):469–72

Laparoscopic cholecystectomy as an outpatient procedure. Lam D, et al. **J Am Coll Surg** 1997 Aug;185(2):152–5

Postoperative infection in a double–occupancy operating room. A prospective study of two thousand four hundred and fifty–eight procedures on the extremities. Kleinert JM, et al. **J Bone Joint Surg Am** 1997 Apr;79(4):503–13

Day–case cataract surgery in rural Spain. Ramón Villada J, et al. **J Cataract Refract Surg** 1997 May;23(4):581–2

Preoperative preparation in children: a cross–sectional study. Kain ZN, et al. **J Clin Anesth** 1996 Sep;8(6):508–14

Ondansetron prevents postoperative emesis in male outpatients. S3A–379 Study Group. Kovac AL, et al. **J Clin Anesth** 1996 Dec;8(8):644–51

Outpatient bone marrow harvesting [letter; comment] Maurer W, et al. **J Clin Anesth** 1997 Jun;9(4):345. Comment on: J Clin Anesth 1996 Nov;8(7):551–6.

Prolonged surgery increases the likelihood of admission of scheduled ambulatory surgery patients. Mingus ML, et al. **J Clin Anesth** 1997 Sep;9(6):446–50

Epidural hematoma in an ambulatory surgical patient. Porterfield WR, et al. **J Clin Anesth** 1997 Feb;9(1):74–7

Outpatient general anesthesia: a comparison of a combination of midazolam plus propofol and propofol alone. Reinhart DJ, et al. **J Clin Anesth** 1997 Mar;9(2):130–7

Autologous bone marrow harvesting in outpatients [see comments] Thorne AC, et al. **J Clin Anesth** 1996 Nov; 8(7):551–6. Comment in: J Clin Anesth 1997 Jun;9(4):345.

Preoperative anesthetic concerns of men and women in the ambulatory surgical setting [letter] Zvara DA, et al. **J Clin Anesth** 1997 Feb;9(1):88–9

Day care surgery for advanced Dupuytren's contracture. Ebskov LB, et al. **J Hand Surg [Br]** 1997 Apr;22(2):191–2

Lord's procedure: a curative outpatient operation for primary hydrocele. Singh DR, et al. **J Indian Med Assoc** 1996 Apr; 94(4):141–2

Fat graft myringoplasty in children––a safe and successful day–stay procedure. Mitchell RB, et al. **J Laryngol Otol** 1997 Feb;111(2):106–8

Day–case adenoidectomy: how popular and safe in a rural environment? Siddiqui N, et al. **J Laryngol Otol** 1997 May; 111(5):444–6

Capnography and ventilatory assessment during ambulatory dentoalveolar surgery. Bennett J, et al. **J Oral Maxillofac Surg** 1997 Sep;55(9):921–5;discussion 925–6

Same–day versus staged anterior–posterior spinal surgery in a neuromuscular scoliosis population: the evaluation of medical complications. Ferguson RL, et al. **J Pediatr Orthop** 1996 May–Jun;16(3):293–303

Outpatient minilaparotomy ovarian cystectomy for benign teratomas in teenagers. Silva PD, et al. **J Pediatr Surg** 1996 Oct;31(10):1383–6

Experience of day–case ENT surgery in a military hospital. Bricknell MC, et al. **J R Army Med Corps** 1994 Feb; 140(1):18–21

Day case cataract surgery without a dedicated unit. Jain S, et al. **J R Coll Surg Edinb** 1996 Oct;41(5):336–8

Day–case surgery in children under 2 years of age: experience in a district general hospital and survey of parental satisfaction. Stiff G, et al. **J R Coll Surg Edinb** 1996 Dec; 41(6):408–11

The holmium YAG laser in office based arthroscopy of the knee: comparison with standard interventional instruments in patients with arthritis. Wei N, et al. **J Rheumatol** 1997 Sep;24(9):1806–8

Day surgery for cervical microdiscectomy: is it safe and effective? Silvers HR, et al. **J Spinal Disord** 1996 Aug; 9(4):287–93

Extraction of Kuntscher (femoral) implant under local anaesthesia: an appraisal of patients tolerance and merits. Onwuanyi ON, et al. **JPMA J Pak Med Assoc** 1997 Jun; 47(6):153–5

An optimal choice: home intravenous hydration after tonsillectomy. Blakeslee DB, et al. **Laryngoscope** 1997 Oct; 107(10):1332–5

Teaching and learning in day surgery units: a UK survey. Seabrook MA, et al. **Med Educ** 1997 Mar;31(2):105–8

Day ophthalmic surgery: aspects of perioperative care [letter; comment] Siebert S. **Med J Aust** 1997 May 5;166(9):511–2 . Comment on: Med J Aust 1996 Oct 7;165(7):379–81.

Office repair of retinal detachment using a Lincoff Temporary balloon buckle [see comments] Green SN, et al. **Ophthalmology** 1996 Nov;103(11):1804–10. Comment in: Ophthalmology 1997 Jul;104(7):1059–61.

Office carpal tunnel release with wrist block and wrist tourniquet [see comments] Derkash RS, et al. **Orthopedics** 1996 Jul;19(7):589–90. Comment in: Orthopedics 1996 Oct;19(10):845.

Outpatient uvuloplasty [letter] Ylikoski J. **Otolaryngol Head Neck Surg** 1996 Oct;115(4):373

Oral midazolam premedication for paediatric day case patients. Cray SH, et al. **Paediatr Anaesth** 1996;6(4):265–70

Intranasal ketamine preinduction of paediatric outpatients. Diaz JH. **Paediatr Anaesth** 1997;7(4):273–8

An audit of paediatric day care surgery in a district general hospital. Jolliffe DM. **Paediatr Anaesth** 1997;7(4):317–23

Pain and activity disturbance after paediatric day case adenoidectomy. Kokki H, et al. **Paediatr Anaesth** 1997; 7(3):227–31

Comparison of wound infiltration with ketorolac versus intravenous regional anesthesia with ketorolac for postoperative analgesia following ambulatory hand surgery. Reuben SS, et al. **Reg Anesth** 1996 Nov–Dec; 21(6):565–8

Definitive breast cancer surgery as an outpatient: a rational basis for the transition. Hoehn JL. **Semin Surg Oncol** 1996 Jan–Feb;12(1):53–8 (14 ref.)

Is outpatient laparoscopic cholecystectomy wise? [letter; comment] Hargreaves R. **Surg Endosc** 1996 Sep;10(9):950–1 . Comment on: Surg Endosc 1995 Dec;9(12):1263–8.

Same day surgery for radical retropubic prostatectomy: is it an attainable goal? [letter; comment] Koch MO, et al.

Urology 1996 Oct;48(4):660–1. Comment on: Urology 1996 Jan;47(1):23–8.

Scope and problems of day-care surgery in a plastic surgical unit. Jiburum BC, et al. **West Afr J Med** 1996 Oct–Dec; 15(4):237–9

Selecting paediatric surgical patients for day care surgery--a ten year experience (1980–1989) in the UNTH, Enugu, Nigeria. Nwako FA, et al. **West Afr J Med** 1996 Jul–Sep; 15(3):149–54

[Ambulatory cataract surgery] Diblík P, et al. **Cesk Slov Oftalmol** 1996 Nov;52 Suppl:17–9 (Eng. Abstr.) **(Cze)**

[The physician can recommend a procedure. But only God knows whether the patient can tolerate it] Jacobsen JB, et al. **Ugeskr Laeger** 1997 Feb 17;159(8):1118–9 **(Dan)**

[Effective preoperative studies in outpatient anesthesiology (letter; comment)] De Maeseneer J, et al. **Ned Tijdschr Geneeskd** 1996 Oct 19;140(42):2102–3. Comment on: Ned Tijdschr Geneeskd 1996 Aug 24;140(34):1723–6. **(Dut)**

[Experiences with outpatient laparoscopic cholecystectomy] Keulemans YC, et al. **Ned Tijdschr Geneeskd** 1997 Apr 5;141(14):686–9 (Eng. Abstr.) **(Dut)**

[Ambulatory anal surgery: a feasibility study] Martel E, et al. **Ann Chir** 1996;50(8):589–92 (Eng. Abstr.) **(Fre)**

[Administrative or economic regulation of ambulatory surgery units?] Bazin G. **Cah Anesthesiol** 1996;44(3):249–51 **(Fre)**

[Volatile agents in ambulatory anesthesia] Clergue F. **Rev Med Suisse Romande** 1997 May;117(5):383–8 (16 ref.) **(Fre)**

[Local and regional anesthesia for ambulatory surgery] Ecoffey C, et al. **Rev Med Suisse Romande** 1997 May; 117(5):379–82 (25 ref.) **(Fre)**

[Specificity of the anesthetic consultation for ambulatory surgery] Forster A, et al. **Rev Med Suisse Romande** 1997 May;117(5):371–3 (1 ref.) **(Fre)**

[Intravenous anesthetic agents in ambulatory anesthesia] Servin F. **Rev Med Suisse Romande** 1997 May;117(5):375–7 (15 ref.) **(Fre)**

[Spinal anesthesia for ambulatory arthroscopy. The view of the patients: results and patient's viewpoint] Fritz KW, et al. **Anaesthesist** 1997 May;46(5):430–3 (Eng. Abstr.) **(Ger)**

[Spinal anesthesia for ambulatory interventions--contra] Bachmann-Mennenga B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Nov; 31(9):573–4 **(Ger)**

[Spinal anesthesia for ambulatory interventions--pro] Hempel V. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Nov; 31(9):575–6 **(Ger)**

[Specialist graduate education in accordance with the recommendations of DGAI and OGARI. Preoperative anesthesiologic patient visit, outpatient anesthesia. Risk assessment, patient preparation and planing perioperative procedures] Madler C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Dec; 31(10):633–53 **(Ge.)**

[Spinal anesthesia for ambulatory interventions: pro and contra (letter)] Van Damme E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Apr; 32(4):263 **(Ger)**

[Ambulatory surgery--preoperative and postoperative care] **Chirurg** 1994 May;65(5 Suppl):1–12 **(Ger)**

[Malpractice risks in ambulatory surgery. Measures for decreasing and preventing the risk] Bergmann KO, et al. **Chirurg** 1996 Oct;67(10):suppl 246–50 **(Ger)**

[Hygiene plans for ambulatory surgery practices] Felsing HH, et al. **Chirurg** 1997 Jul;68(7):197–201 **(Ger)**

[Surgical therapy of advanced hemorrhoidal disease--is an ambulatory surgery intervention possible?] Gawenda M, et al. **Chirurg** 1996 Sep;67(9):940–3 (Eng. Abstr.) **(Ger)**

[Topic for discussion. Ambulatory appendectomy by the established surgeon] Hierholzer E. **Chirurg** 1997 Mar; 68(3):suppl 76–9 **(Ger)**

[Ambulatory laparoscopic cholecystectomy] Schweins M, et al. **Chirurg** 1997 Jun;68(6):613–7 (Eng. Abstr.) **(Ger)**

[Ambulatory removal of nasal polyps using laser methods?] Vollrath M. **Dtsch Med Wochenschr** 1997 Mar 14; 122(11):347 **(Ger)**

[Patient education before ambulatory surgery] Rehborn M. **Geburtshilfe Frauenheilkd** 1996 Jul;56(7):M100–1 **(Ger)**

[Ambulatory surgery from the viewpoint of hand surgery] Fischer K. **Handchir Mikrochir Plast Chir** 1997 May; 29(3):164–5 (Eng. Abstr.) **(Ger)**

[Perioperative follow-up of physiologic and cognitive functions after oral premedication with midazolam 3.75 mg in women for retrobulbar anesthesia] Weindler J, et al. **Ophthalmologe** 1996 Feb;93(1):59–67 (Eng. Abstr.) **(Ger)**

[Ambulatory surgery--pre- and postoperative care] **Orthopade** 1994 Jun;23(3 Suppl):1–12 **(Ger)**

[Laparoscopy in the day clinic—a prospective multicenter study for evaluating complications] Hennefründ J, et al. **Zentralbl Gynakol** 1996;118(2):113–6 (Eng. Abstr.) **(Ger)**

[Ambulatory phlebectomy. Literature review and personal experience] Alonzo U, et al. **Minerva Cardioangiol** 1997 Apr;45(4):121–9 (Eng. Abstr.) **(Ita)**

[Spinal anesthesia in ambulatory surgery?] Flaatten H. **Tidsskr Nor Laegeforen** 1997 Apr 10;117(9):1265–6 **(Nor)**

[Ambulatory surgery and patients' experiences] Forsdahl BA. **Tidsskr Nor Laegeforen** 1997 Apr 10;117(9):1308–10 (Eng. Abstr.) **(Nor)**

[Spinal anesthesia in ambulatory surgery. Extent, routines and patient satisfaction] Wisborg T, et al. **Tidsskr Nor Laegeforen** 1997 Apr 10;117(9):1267–9 (Eng. Abstr.) **(Nor)**

[Readaptation after total intravenous anesthesia in one-day surgery] Buravtsev VA, et al. **Anesteziol Reanimatol** 1997 Jan–Feb;(1):67–9 (Eng. Abstr.) **(Rus)**

[Organization of an out-patient surgical aid and ways of it's improvement] Mikheev NM, et al. **Khirurgiia (Mosk)** 1997; (5):59–62 (Eng. Abstr.) **(Rus)**

[Diprivan (propofol) in the anesthesiological support of outpatient dental interventions] Gritsuk SF, et al. **Stomatologiia (Mosk)** 1997;76(1):63–4 **(Rus)**

[Reconstructive-restorative operations on the hand in the polyclinic] Apanasenko BG, et al. **Vestn Khir Im I I Grek** 1995;154(4–6):108–10 **(Rus)**

[One day surgery--personal experience] Labaš P, et al. **Rozhl Chir** 1997 May;76(5):262–4 (Eng. Abstr.) **(Slo)**

[Satisfaction of parents of children undergoing outpatient surgery] Marco Macián A, et al. **Clr Pediatr** 1996 Apr; 9(2):73–7 (Eng. Abstr.) **(Spa)**

[Electrosurgical excision of the transformation zone carried out as ambulatory procedure, in patients with abnormal cervical cytology] Montalvo TS, et al. **Ginecol Obstet Mex** 1996 Jan;64:36–9 (Eng. Abstr.) **(Spa)**

[Estimation of potential impact of ambulatory surgery in Catalonia] Espinàs JA, et al. **Med Clin (Barc)** 1997 Jun 14;109(3):81–4 (Eng. Abstr.) **(Spa)**

[Major ambulatory surgery and short-stay surgery. Expectations, current reality and possibilities (editorial)] Sierra Gil E. **Med Clin (Barc)** 1997 Jun 14;109(3):92–4 **(Spa)**

[Fluoroscopy-controlled percutaneous gastrostomy in ambulatory care. Our experience] Górriz E, et al. **Nutr Hosp** 1996 May–Jun;11(3):195–9 (Eng. Abstr.) **(Spa)**

[Use of ondansetron for prevention of postoperative nausea and vomiting in major ambulatory surgery (letter; comment)] García del Valle S, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):300–1. Comment on: Rev Esp Anestesiol Reanim 1996 Apr;43(4):138–41. **(Spa)**

ADVERSE EFFECTS

Outpatient adenotonsillectomy. Is it safe in children younger than 3 years? Mitchell RB, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jul;123(7):681–3

Postoperative syncope after office surgery [letter] Fletman H. **Dermatol Surg** 1997 May;23(5):403

Safety of direct laryngoscopy as an outpatient procedure. Armstrong M, et al. **Laryngoscope** 1997 Aug;107(8):1060–5

Patient safety in accredited office surgical facilities. Morello DC, et al. **Plast Reconstr Surg** 1997 May;99(6):1496–500

[Thromboembolic complications after ambulatory herniotomy] Riber C, et al. **Ugeskr Laeger** 1997 May 26; 159(22):3401–2 (Eng. Abstr.) **(Dan)**

CONTRAINDICATIONS

Day case tonsillectomy in adults: how many are suitable? [published erratum appears in J R Coll Surg Edinb 1997 Feb;42(1):63] Moralee SJ, et al. **J R Coll Surg Edinb** 1996 Oct;41(5):331–2

ECONOMICS

Care pathway reduces hospitalizations and cost for hemodialysis vascular access surgery. Becker BN, et al. **Am J Kidney Dis** 1997 Oct;30(4):525–31

"Same-day" thyroid surgery: an analysis of safety, cost savings, and outcome. McHenry CR. **Am Surg** 1997 Jul; 63(7):586–9; discussion 589–90

Knee arthroscopy: a cost analysis of general and local anesthesia. Trieshmann HW Jr. **Arthroscopy** 1996 Feb; 12(1):60–3

Low-cost office laparoscopic sterilization. Love BR, et al. **J Am Assoc Gynecol Laparosc** 1994 Aug;1(4 Pt 1):379–82

Cancellation of pediatric outpatient surgery: economic and emotional implications for patients and their families. Tait AR, et al. **J Clin Anesth** 1997 May;9(3):213–9

Economic outcomes analysis from an ambulatory surgical center. Marcinko DE, et al. **J Foot Ankle Surg** 1996 Nov–Dec;35(6):544–9

Same-day admissions and other cost-saving strategies for elective aortoiliac surgery. Calligaro KD, et al. **J Vasc Surg** 1997 Jan;25(1):141–4

Ambulatory surgery. An evolution. DeFazio-Quinn DM. **Nurs Clin North Am** 1997 Jun;32(2):377–86

[Substitution possibilities in ambulatory surgery] Brenner G. **Chirurg** 1997 Jan;68(1):Suppl 10–5 **(Ger)**

[Thoughts on the current status of ambulatory surgery and the new financing concept] Felsing HH, et al. **Chirurg** 1997 May;68(5):Suppl 134–6 **(Ger)**

[What reimbursement can ambulatory surgery physicians expect?] Hohmann UH. **Chirurg** 1997 Jun;68(6):Suppl 171–4 **(Ger)**

[Ambulatory surgery clinic in a public general hospital. Organization and results] Scheidegger A, et al. **Swiss Surg** 1996;2(4):171–5 (Eng. Abstr.) **(Ger)**

[Cost analysis of inguinal hernia surgery in ambulatory and inpatient management] van den Oever R, et al. **Zentralbl Chir** 1996;121(10):836–40 (Eng. Abstr.) **(Ger)**

[Evaluation of costs in surgery of inguinal hernia. Day surgery and one day surgery versus ordinary admission] Saviano MS, et al. **Ann Ital Chir** 1996 Sep–Oct;67(5):615–9 (Eng. Abstr.) **(Ita)**

[Outpatient treatment of bladder cancer--lower cost and satisfied patients] Hedelin H, et al. **Nord Med** 1997 Feb; 112(2):48–51 (Eng. Abstr.) **(Swe)**

METHODS

Outpatient thyroidectomy. Samson PS, et al. **Am J Surg** 1997 Jun;173(6):499–503

Daycase transurethral incision of the prostate using the holmium: YAG laser: initial experience. Cornford PA, et al. **Br J Urol** 1997 Mar;79(3):383–4

Out-patient arthroscopy. Pellacci F, et al. **Chir Organi Mov** 1996 Apr–Jun;81(2):165–72 (22 ref.) **(Eng, Ita)**

Ambulatory narrow excision for thin melanoma (< or = 2 mm): results of a prospective study. Bono A, et al. **Eur J Cancer** 1997 Jul;33(8):1330–2

Digital fracture polypectomy for juvenile rectal polyps is safe [letter] Madan U, et al. **Indian Pediatr** 1996 May; 33(5):431

An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. Ulmsten U, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(2):81–5; discussion 85–6

Distal hypospadias repair with meatal-based flaps on an outpatient basis. Sariyüce O, et al. **Int Urol Nephrol** 1997; 29(2):241–4

Morbidity and mortality with outpatient anesthesia: the experience of a residency training program. Hunter MJ, et al. **J Oral Maxillofac Surg** 1997 Jul;55(7):684–7; discussion 687–8

Office probing for congenital nasolacrimal duct obstruction: a study of parental satisfaction. Goldblum TA, et al. **J Pediatr Ophthalmol Strabismus** 1996 Jul–Aug;33(4):244–7

Outpatient loop electrosurgical excision procedure for cervical intraepithelial neoplasia. Can it replace cold knife conization? Eduardo AM, et al. **J Reprod Med** 1996 Oct; 41(10):729–32

Surgical office procedures. Cunningham SJ. **Pediatr Ann** 1996 Dec;25(12):699–704 (4 ref.)

[Ambulatory surgery in developing countries] Yangni-Angaté A. **West Afr J Med** 1996 Jul–Sep; 15(3):155–7 **(Fre)**

[Ambulatory surgery in clinical practice: limits and possibilities] Giovanoli P, et al. **Schweiz Rundsch Med Prax** 1996 Sep 10;85(37):1146–8 (Eng. Abstr.) **(Ger)**

[Lichtenstein's technic in the repair of inguinal hernias] Donnola G, et al. **Minerva Chir** 1997 May;52(5):571–6 (Eng. Abstr.) **(Ita)**

[Combined outpatient surgical-cryotherapeutic treatment of anal fissures. Our experience] Maturanza M, et al. **Minerva Chir** 1997 Apr;52(4):393–5 (Eng. Abstr.) **(Ita)**

[Choice of optimal anesthesia in outpatient treatment of varicose veins] Larin SI, et al. **Khirurgiia (Mosk)** 1997; (6):51–5 **(Rus)**

[Ambulatory surgery for inguinal hernia. Patients' experiences with simplified routines] Gunnarsson U, et al. **Lakartidningen** 1997 Apr 2;94(14):1292–4, 1296 **(Swe)**

[Tonsillectomy in adults is performed as day surgery. Risk assessment and experiences from Uppsala] Jonsson L, et al. **Lakartidningen** 1997 Apr 2;94(14):1284–6 **(Swe)**

NURSING

Pediatric dental rehabilitation procedures in the OR. Haskins DR. **AORN J** 1996 Oct;64(4):573–9 (23 ref.)

A patient classification system for ambulatory surgery centers. Kusler-Jensen JA. **AORN J** 1996 Aug;64(2):273–7

The ambulatory surgical nurse. Evolution, competency, and vision. Brockway PM. **Nurs Clin North Am** 1997 Jun; 32(2):387–94 (14 ref.)

Patient teaching in ambulatory surgery. Lancaster KA. **Nurs Clin North Am** 1997 Jun;32(2):417–27 (18 ref.)

Ambulatory surgery. Care of the special needs patient. Litwack K. **Nurs Clin North Am** 1997 Jun;32(2):457–68 (10 ref.)

Ambulatory surgery. Preoperative assessment and health history interview. Williams GD. **Nurs Clin North Am** 1997 Jun;32(2):395–416 (22 ref.)

PSYCHOLOGY

Audit of patient acceptance of nasal surgery as a day case procedure. Tierney PA, et al. **Br J Clin Pract** 1996 Oct–Nov;50(7):357–9

Patients' perceptions of pre-operative preparation for day surgery. Mitchell M. **J Adv Nurs** 1997 Aug;26(2):356–63

Cancellation of pediatric outpatient surgery: economic and emotional implications for patients and their families. Tait AR, et al. **J Clin Anesth** 1997 May;9(3):213–9

Care of the pediatric patient in ambulatory surgery. Lancaster KA. **Nurs Clin North Am** 1997 Jun;32(2):441–55 (19 ref.)

An evaluation of preoperative anxiety in a population of parents of infants and children undergoing ambulatory surgery. Litman RS, et al. **Paediatr Anaesth** 1996;6(6):443–7

Day-case laparoscopy in a Ghanaian teaching hospital: the patient's perspective. Nkyekyer K. **Trop Doct** 1996 Oct; 26(4):147–50

STANDARDS

"Same-day" thyroid surgery: an analysis of safety, cost savings, and outcome. McHenry CR. **Am Surg** 1997 Jul; 63(7):586–9; discussion 589–90

Same-day admission thyroidectomy programme: quality assurance study. Matthews TW, et al. **J Otolaryngol** 1996 Oct;25(5):290–5

Same day surgery: results of a patient satisfaction survey. de Jesus G, et al. **J Qual Clin Pract** 1996 Sep;16(3):165–73

Legal issues in ambulatory surgery. Ireland D. **Nurs Clin North Am** 1997 Jun;32(2):469–76

Quality improvement in the ambulatory surgical setting. New SW, et al. **Nurs Clin North Am** 1997 Jun;32(2):477–88

[Accreditation of the surgical service in the ambulatory component as a factor in raising the quality of its activities] Vinnik LF, et al. **Vestn Khir Im I I Grek** 1997;156(2):122–5 **(Rus)**

[Effectiveness of dermatologic minor surgery in the office of the family physician and patient satisfaction in relation with ambulatory surgery] Arribas Blanco JM, et al. **Med Clin (Barc)** 1996 Dec 7;107(20):772–5 (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

What happens after discharge? Return hospital visits after ambulatory surgery. Twersky R, et al. **Anesth Analg** 1997 Feb;84(2):319–24

Day-case transfer of inpatients for diagnostic and therapeutic endoscopic retrograde cholangiopancreatography. Kyriakides C, et al. **Br J Surg** 1997 Sep;84(9):1260–3

Outpatient orthognathic surgery: review of 205 cases. Lupori JP, et al. **J Oral Maxillofac Surg** 1997 Jun;55(6):558–63

National Survey of Ambulatory Surgery: 1994. Hall MJ, et al. **Stat Bull Metrop Insur Co** 1997 Jul–Sep;78(3):18–27

Day surgery at Korle Bu Teaching Hospital: a six year review. Archampong EQ, et al. **West Afr J Med** 1996 Jul–Sep;15(3):143–8

[Day hospital surgery. Our experience] Garetto F, et al. **Minerva Chir** 1996 Jun;51(6):439–42 (Eng. Abstr.) **(Ita)**

TRENDS

Ambulatory surgery. An evolution. DeFazio-Quinn DM. **Nurs Clin North Am** 1997 Jun;32(2):377–86

[Ambulatory anesthesia: towards what future? (editorial)] Ravussin P, et al. **Rev Med Suisse Romande** 1997 May; 117(5):369–70 (7 ref.) **(Fre)**

[BSG accepts point value decline in ambulatory surgery for 1993 and 1994. Decisions of the Federal Social Court 7 February 1996—6 RKa 61/94 and 42/95] Andreas M, et al. **Chirurg** 1996 Oct;67(10):suppl 243–5 **(Ger)**

[Ambulatory surgery—what is feasible, what is sensible? Legal aspects] Bock RW. **Chirurg** 1996 Aug;67(8):Suppl 183–6 **(Ger)**

[Ambulatory surgery, quo vadis] Werding G. **Chirurg** 1996 Oct;67(10):suppl 242–3 **(Ger)**

UTILIZATION

Maxillofacial surgery and the role of the extended day case. Bryant CJ, et al. **Br Dent J** 1997 Feb 22;182(4):134–8

Minimal access therapy: scope, evaluation and future direction. Cushcieri A. **Health Bull (Edinb)** 1996 Nov; 54(6):514–21

AMBYSTOMA

EMBRYOLOGY

Morphogenesis of the axolotl pronephric duct: a model system for the study of cell migration in vivo. Drawbridge J, et al. **Int J Dev Biol** 1996 Aug;40(4):709–13

How to observe surface contraction waves on axolotl embryos. Gordon R, et al. **Int J Dev Biol** 1996 Aug; 40(4):913–4

Urodele (e.g., axolotl) embryos in the undergraduate laboratory class: an essay describing a multifaceted learning experience. Malacinski GM, et al. **Int J Dev Biol** 1996 Aug; 40(4):901–5

Surface contraction and expansion waves correlated with differentiation in axolotl embryos. II. In contrast to urodeles, the anuran Xenopus laevis does not show furrowing surface contraction waves. Nieuwkoop PD, et al. **Int J Dev Biol** 1996 Aug;40(4):661–4

Lens induction in axolotls: comparison with inductive signaling mechanisms in Xenopus laevis. Servetnick MD, et al. **Int J Dev Biol** 1996 Aug;40(4):755–61 (36 ref.)

A method for the isolation and culture of embryonic cardiomyocytes from Mexican axolotl. Zajdel RW, et al. **Int J Dev Biol** 1996 Aug;40(4):907–8

PG-M/versican-like proteoglycans are components of large disulfide-stabilized complexes in the axolotl embryo. Stigson M, et al. **J Biol Chem** 1997 Feb 7;272(6):3246–53

Hypochord, an enigmatic embryonic structure: study of the axolotl embryo. Löfberg J, et al. **J Morphol** 1997 Apr; 232(1):57–66

Improved preservation of the subepidermal extracellular matrix in axolotl embryos using electron microscopical techniques based on cryoimmobilization. Epperlein HH, et al. **J Struct Biol** 1997 Feb;118(1):43–61

GENETICS

Structure and diversity of the heavy chain VDJ junctions in the developing Mexican axolotl. Golub R, et al. **Immunogenetics** 1997;46(5):402–9

GROWTH & DEVELOPMENT

The effects of used motor oil, silt, and the water mold Saprolegnia parasitica on the growth and survival of mole salamanders (genus Ambystoma). Lefcort H, et al. **Arch Environ Contam Toxicol** 1997 May;32(4):383–8

Differential expression of C-protein isoforms in the developing heart of normal and cardiac lethal mutant axolotls (Ambystoma mexicanum). Ward SM, et al. **Dev Dyn** 1996 Feb;205(2):93–103

Interactions of androgens and estradiol on sex accessory ducts of larval tiger salamanders, Ambystoma tigrinum. Norris DO, et al. **Gen Comp Endocrinol** 1997 Jun; 106(3):348–55

METABOLISM

Differential expression of a novel isoform of alpha-tropomyosin in cardiac and skeletal muscle of the Mexican axolotl (Ambystoma mexicanum). Luque EA, et al. **Gene** 1997 Feb 7;185(2):175–80

The renal electrogenic Na+:HCO-3 cotransporter. Boron VF, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):263–8 (24 ref.)

Role of cytoplasmic calcium concentration in the bleaching adaptation of salamander cone photoreceptors. Matthews HR, et al. **J Physiol (Lond)** 1996 Jan 15;490 (Pt 2):293–303

Histochemistry and role of nitric oxide synthase in the amphibian (Ambystoma tigrinum) inner ear. Flores A, et al. **Neurosci Lett** 1996 Feb 23;205(2):131–4

PHYSIOLOGY

Expression of integrins during axolotl limb regeneration. Tsonis PA, et al. **Dev Growth Differ** 1997 Feb;39(1):9–14

Interrenal function in larval Ambystoma tigrinum. IV. Acid-base balance and the renin-angiotensin system. Eskandari S, et al. **Gen Comp Endocrinol** 1997 Jan; 105(1):18–30

Courtship behavior and plasma levels of androgens and corticosterone in male marbled salamanders, Ambystoma opacum (ambystomatidae). Houck LD, et al. **Gen Comp Endocrinol** 1996 Nov;104(2):243–52

Axolotls in the second grade. Coppedge V. **Int J Dev Biol** 1996 Aug;40(4):895–6

What insights into vertebrate pigmentation has the axolotl model system provided? Frost-Mason SK, et al. **Int J Dev Biol** 1996 Aug;40(4):685–93 (44 ref.)

Molecular mechanisms in the control of limb regeneration: the role of homeobox genes. Gardiner DM, et al. **Int J Dev Biol** 1996 Aug;40(4):797–805 (76 ref.)

What mechanisms control neoteny and regulate induced metamorphosis in urodeles? Rosenkilde P, et al. **Int J Dev Biol** 1996 Aug;40(4):665–73 (55 ref.)

Equivalence of background and bleaching desensitization in isolated rod photoreceptors of the larval tiger salamander. Jones GJ, et al. **J Gen Physiol** 1996 Oct;108(4):333–40

Persistent activation of transducin by bleached rhodopsin in salamander rods. Matthews HR, et al. **J Gen Physiol** 1996 Dec;108(6):557–63

Insights into pigmentary phenomena provided by grafting and chimera formation in the axolotl. Houillon C, et al. **Pigment Cell Res** 1996 Dec;9(6):281–8

A glutamate-elicited chloride current with transporter-like properties in rod photoreceptors of the tiger salamander. Grant GB, et al. **Vis Neurosci** 1996 Jan–Feb;13(1):135–44

Synaptic inputs mediating bipolar cell responses in the tiger salamander retina. Maple BR, et al. **Vision Res** 1996 Dec; 36(24):4015–23

AMBYSTOMA MEXICANUM

EMBRYOLOGY

Neural crest potential for tooth development in a urodele amphibian: developmental and evolutionary significance. Graveson AC, et al. **Dev Biol** 1997 Aug 1;188(1):34–42

Expression pattern of an axolotl floor plate-specific fork head gene reflects early developmental differences between frogs and salamanders. Whiteley M, et al. **Dev Genet** 1997; 20(2):145–51

Pattern formation in the urodele mechanoreceptive lateral line: what features can be exploited for the study of development and evolution? Smith SC. **Int J Dev Biol** 1996 Aug;40(4):727–33 (41 ref.)

GENETICS

Isolation of Mhc class I cDNAs from the axolotl Ambystoma mexicanum. Sammut B, et al. **Immunogenetics** 1997; 45(5):285–94

IMMUNOLOGY

Activation by mitogens and superantigens of axolotl lymphocytes: functional characterization and ontogenic study. Salvadori F, et al. **Immunology** 1996 Aug; 88(4):586–92

Abbreviated junctional sequences impoverish antibody diversity in urodele amphibians. Patel HM, et al. **J Immunol** 1997 Oct 1;159(7):3391–9

METABOLISM

Influence of insulin-like growth factors and insulin on the [35S]sulfate uptake by cartilage of the axolotl (Ambystoma mexicanum). Schneider A, et al. **Gen Comp Endocrinol** 1996 Oct;104(1):92–102

PHYSIOLOGY

Synaptic body movements in the sensory cells of lateral line organs in the urodele amphibian Ambystoma mexicanum. Flock A, et al. **Hear Res** 1997 Feb;104(1–2):177–82

AMCHA see **TRANEXAMIC ACID**

AMDINOCILLIN

PHARMACOLOGY

Rapid flow cytometric assessment of mecillinam and ampicillin bacterial susceptibility. Walberg M, et al. **J Antimicrob Chemother** 1996 Jun;37(6):1063–75

AMDINOCILLIN PIVOXIL

ADVERSE EFFECTS

Pivalic acid-induced carnitine deficiency and physical exercise in humans. Abrahamsson K, et al. **Metabolism** 1996 Dec;45(12):1501–7

THERAPEUTIC USE

[Antibiotic treatment of acute gastroenteritis] Segura Porta F, et al. **Rev Clin Esp** 1997 Apr;197(4):241–4 (Eng. Abstr.) **(Spa)**

AMEBA see **AMOEBA**

AMEBIASIS

see related
AMEBICIDES

Proceedings of the XIII Seminar on Amebiasis. Mexico City, Mexico, January 29–31, 1997. **Arch Med Res** 1997;28 Spec No:1–329

Kidney and liver transplants from a donor infected with Naegleria fowleri. Kramer MH, et al. **J Clin Microbiol** 1997 Apr;35(4):1032–3

Non-acanthamoeba amoebic keratitis [letter] Hay J, et al. **J Infect** 1997 Jan;34(1):89–91

Amoebiasis of the female genital tract: a case report. Nopdonrattakoon L. **J Obstet Gynaecol Res** 1996 Jun; 22(3):235–8

[Protozoal pericarditis] Seto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):508–10 (8 ref.) **(Jpn)**

COMPLICATIONS

Acanthamoeba endophthalmitis in acquired immunodeficiency syndrome. Heffler KF, et al. **Am J Ophthalmol** 1996 Oct;122(4):584–6

Hartmannella vermiformis isolated from the cerebrospinal fluid of a young male patient with meningoencephalitis and bronchopneumonia. Centeno M, et al. **Arch Med Res** 1996 Winter;27(4):579–86

Coexistent Acanthamoeba keratitis and herpetic keratitis. Mathers WD, et al. **Arch Ophthalmol** 1997 Jun;115(6):714–8

Invasive amoebiasis in two patients with AIDS and cytomegalovirus colitis. Fätkenheuer G, et al. **J Clin Microbiol** 1997 Aug;35(8):2168–9

Cutaneous lesions due to Acanthamoeba sp in a patient with AIDS. Deluol AM, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):130S–131S

Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in amoebic liver abscess. Abbas Z, et al. **J Infect** 1997 Jan;34(1):79–81

CONGENITAL

The possibility of congenital infection with Acanthamoeba culbertsoni. Awadalla HN, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):601–8

DIAGNOSIS

Granulomatous amebic encephalitis caused by leptomyxid amebae in an HIV-infected patient. Zagardo MT, et al. **AJNR Am J Neuroradiol** 1997 May;18(5):903–8

Electron microscopy in AIDS-related infectious diseases. I. Acanthamoebiasis. Hashimoto K, et al. **J Dermatol** 1996 Nov;23(11):773–7 (11 ref.)

Granulomatous amebic encephalitis caused by acanthamoeba. Sell JJ, et al. **Neuroradiology** 1997 Jun;39(6):434–6

[Cases of primary amebic meningoencephalitis in Kherson Province] Andriushchenko IuA, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):164–5 **(Rus)**

DRUG THERAPY

Additive effect of diloxanide furoate and metronidazole (Entamizole) in experimental mouse caecal amoebiasis. Bhopale KK, et al. **Indian J Exp Biol** 1995 Jan;33(1):73–4

Chronic amebiasis—treat couples [letter] Malshe PC. **J Assoc Physicians India** 1995 Jan;43(1):74

AMEBIASIS

Efficacy of a combined diloxanide furoate–metronidazole preparation in the treatment of amoebiasis and giardiasis. Qureshi H, et al. **J Int Med Res** 1997 May–Jun;25(3):167–70

Generic prescription and anti-amoebic drugs [letter] Gupta RK. **Natl Med J India** 1997 May–Jun;10(3):152

EPIDEMIOLOGY

Giardiasis and amebiasis in southern Iran [letter] Mirdehghan MM. **Indian Pediatr** 1996 May;33(5):431–2

Prevalence of intestinal parasitic infection among children in two villages in Lao PDR. Kobayashi J, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):562–5

[Amebiasis and amebic liver abscess in Mexico: a present–day public health problem] Escandón Romero C, et al. **Rev Gastroenterol Mex** 1996 Oct–Dec;61(4):378–86 (18 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

WHO/PAHO/UNESCO report. A consultation with experts on amoebiasis. Mexico City, Mexico 28–29 January, 1997. **Epidemiol Bull** 1997 Mar;18(1):13–4

IMMUNOLOGY

Clinical significance of immunoglobulin alterations in amoebiasis [letter] Sharma V, et al. **Indian J Pathol Microbiol** 1996 Jul;39(3):251

Free living amoebae as opportunistic parasites in immunocompromised hosts. el–Fakahany AF, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):515–27

Amebicidal activity of wild animal serum. John DT, et al. **J Parasitol** 1997 Aug;83(4):757–9

PARASITOLOGY

Primary amebic meningoencephalitis in a patient with AIDS: unusual protozoological findings. Clavel A, et al. **Clin Infect Dis** 1996 Dec;23(6):1314–5

Dependence of growth, metabolic expression, and pathogenicity of Naegleria fowleri on exogenous porphyrins. Bradley SG, et al. **J Parasitol** 1996 Oct; 82(5):763–8

Fatal granulomatous amoebic encephalitis caused by Balamuthia mandrillaris. Reed RP, et al. **Med J Aust** 1997 Jul 21;167(2):82–4 (10 ref.)

Primary amoebic meningoencephalitis with Naegleria fowleri: clinical review. Barnett ND, et al. **Pediatr Neurol** 1996 Oct;15(3):230–4 (22 ref.)

PATHOLOGY

Granulomatous amebic encephalitis due to Balamuthia mandrillaris (Leptomyxiidae): report of four cases from Mexico. Riestra–Castaneda JM, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):603–7

Free–living, amphizoic and opportunistic amebas. Martinez AJ, et al. **Brain Pathol** 1997 Jan;7(1):583–98 (100 ref.)

Acanthamoeba infection. Wortman PD. **Int J Dermatol** 1996 Jan;35(1):48–51 (31 ref.)

Animal model Balamuthia mandrillaris CNS infection: contrast and comparison in immunodeficient and immunocompetent mice: a murine model of "granulomatous" amebic encephalitis. Janitschke K, et al. **J Neuropathol Exp Neurol** 1996 Jul;55(7):815–21

Primary amebic meningoencephalitis due to Naegleria fowleri in a South American tapir. Lozano–Alarcón F, et al. **Vet Pathol** 1997 May;34(3):239–43

Fatal infections with Balamuthia mandrillaris (a free–living amoeba) in gorillas and other Old World primates. Rideout BA, et al. **Vet Pathol** 1997 Jan;34(1):15–22

PREVENTION & CONTROL

Progress in an oral vaccine for amebiasis. Expression of the serine rich Entamoeba histolytica protein (SREHP) in the avirulent vaccine strain Salmonella typhi TY2 chi 4297 (delta cya delta crp delta asd): safety and immunogenicity in mice. Zhang T, et al. **Arch Med Res** 1997;28 Spec No:269–71

Safe water practices can lower risk of contracting primary amoebic meningoencephalitis. Dingley D. **Tex Med** 1996 Oct;92(10):28–9

SURGERY

Ileal amoebiasis. Singh B, et al. **J R Coll Surg Edinb** 1997 Jun;42(3):200–2

THERAPY

[Clinical course and treatment of amebiasis] Tanimoto Weki M. **Rev Gastroenterol Mex** 1995 Oct–Dec;60(4 Suppl 1):S19–20 **(Spa)**

TRANSMISSION

Primary amoebic meningoencephalitis after swimming in the Rio Grande. DeNapoli TS, et al. **Tex Med** 1996 Oct; 92(10):59–63

VETERINARY

Amoebic meningoencephalitis caused by Balamuthia mandrillaris in an orang utan. Canfield PJ, et al. **Aust Vet J** 1997 Feb;75(2):97–100

Amebiasis in a dog with gastric ulcers and adenocarcinoma. Steele KE, et al. **J Vet Diagn Invest** 1997 Jan;9(1):91–3

Primary amebic meningoencephalitis due to Naegleria fowleri in a South American tapir. Lozano–Alarcón F, et al. **Vet Pathol** 1997 May;34(3):239–43

Fatal infections with Balamuthia mandrillaris (a free–living amoeba) in gorillas and other Old World primates. Rideout BA, et al. **Vet Pathol** 1997 Jan;34(1):15–22

AMEBIASIS, HEPATIC see **LIVER ABSCESS, AMEBIC**

AMEBIASIS, INTESTINAL see **DYSENTERY, AMEBIC**

AMEBIC DYSENTERY see **DYSENTERY, AMEBIC**

AMEBICIDES

ADMINISTRATION & DOSAGE

Development and characterization of a mini capsular extrusion system for enteric delivery of metronidazole bearing liposomes. Singh R, et al. **J Drug Target** 1997; 4(5):265–70

ANALYSIS

Fluorimetric determination of chloroxine using manual and flow–injection methods. Pérez–Ruiz T, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1505–11

ECONOMICS

Generic prescription and anti-amoebic drugs [letter] Gupta RK. **Natl Med J India** 1997 May–Jun;10(3):152

PHARMACOLOGY

Physiology and molecular biology of multidrug resistance in Entamoeba histolytica. Gómez MD, et al. **Arch Med Res** 1996 Autumn;27(3):421–5 (24 ref.)

Putative amplification of the EhPgp genes in Entamoeba histolytica emetine–resistant mutants. López C, et al. **Arch Med Res** 1997;28 Spec No:66–8

Energy production in Entamoeba histolytica: new perspectives in rational drug design. Saavedra–Lira E, et al. **Arch Med Res** 1996 Autumn;27(3):257–64 (62 ref.)

A morphodynamic live study of the interaction of metronidazole with E. histolytica trophozoites using acridine orange. Silva Gómez A, et al. **Arch Med Res** 1997; 28 Spec No:302–3

In vitro amoebicidal activity of propamidine and pentamidine isethionate against Acanthamoeba species and toxicity to corneal tissues. Alizadeh H, et al. **Cornea** 1997 Jan; 16(1):94–100

Effects of polyhexamethylene biguanide and chlorhexidine on four species of Acanthamoeba in vitro. Tirado–Angel J, et al. **Curr Eye Res** 1996 Feb;15(2):225–8

Inhibition of complete development of Cryptosporidium parvum in Caco–2 cells [letter] Egraz–Bernard M, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):897–900

Overexpression of P–glycoprotein gene 1 by transfected Entamoeba histolytica confers emetine–resistance. Ghosh SK, et al. **Mol Biochem Parasitol** 1996 Nov 25;82(2):257–60

Stable coexpression of a drug–resistance gene and a heterologous gene in an ancient parasitic protozoan Giardia lamblia. Yu DC, et al. **Mol Biochem Parasitol** 1996 Dec 2;83(1):81–91

In vitro drug susceptibility of Acanthamoeba castellani to chloroquine, ivermectin and fungizon. Rain AN, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):319–24

THERAPEUTIC USE

In vitro susceptibility of Entamoeba histolytica to fluoroquinolones, nitrofurans and other antiamebic agents. Cedillo–Rivera R, et al. **Arch Med Res** 1997;28 Spec No:295–7

Determination of the antiamebic effect of a metronidazole/gossypol blend. Cruz–Vega DE, et al. **Arch Med Res** 1997;28 Spec No:300–1

Gossypol anti–amebic effect in vivo. González–Garza MT, et al. **Arch Med Res** 1997;28 Spec No:298–9

Comparative trial of four antibiotic combinations for perforated appendicitis in children. Ciftci AO, et al. **Eur J Surg** 1997 Aug;163(8):591–6

Correlation of biological activity (therapeutic and toxic) with solvochromic properties of metronidazole, emetine hydrochloride and diloxanide furoate. Sengupta M, et al. **Indian J Biochem Biophys** 1995 Oct;32(5):302–7

Additive effect of diloxanide furoate and metronidazole (Entamizole) in experimental mouse caecal amoebiasis. Bhopale KK, et al. **Indian J Exp Biol** 1995 Jan;33(1):73–4

Is there a rationale for fixed–dose antibiotic–antiamebic drug combinations in diarrhea? [letter] Nanivadekar S, et al. **Indian J Gastroenterol** 1997 Apr;16(2):76–7

A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Ozgoztasi O, et al. **Int J Dermatol** 1997 Jan; 36(1):61–3

Efficacy of a combined diloxanide furoate–metronidazole preparation in the treatment of amoebiasis and giardiasis. Qureshi H, et al. **J Int Med Res** 1997 May–Jun;25(3):167–70

Evaluation of paromomycin sulphate topical ointment as effective therapeutic agent in cutaneous leishmaniasis. Sahibzada NJ, et al. **JPMA J Pak Med Assoc** 1996 Mar; 46(3):53–5

TOXICITY

Cytotoxicity of polyamines to Amoeba proteus: role of polyamine oxidase. Schenkel E, et al. **Cell Biol Toxicol** 1996 Feb;12(1):1–9

AMEBOMA see **AMEBIASIS**

AMEIURUS see **ICTALURIDAE**

AMELIA see **ECTROMELIA**

AMELOBLASTOMA

Ameloblastoma: the Zimbabwean experience over 10 years. Chidzonga MM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jul;82(1):38–41

Ameloblastoma of the maxilla: a series of three cases. Kieserman SP, et al. **Otolaryngol Head Neck Surg** 1997 Mar;116(3):395–8

CLASSIFICATION

Odontogenic classification of craniopharyngiomas: a clinicopathological study of 54 cases. Paulus W, et al. **Histopathology** 1997 Feb;30(2):172–6

Some current concepts on the pathology of ameloblastomas. Gardner DG. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Dec;82(6):660–9 (34 ref.)

GENETICS

Monosomy 22 and del(10)(p12) in an ameloblastoma previously diagnosed as an adenoid cystic carcinoma of the salivary gland. Barril N, et al. **Cancer Genet Cytogenet** 1996 Oct 1;91(1):74–6

IMMUNOLOGY

Characterization of novel monoclonal antibodies raised against formalin–fixed, paraffin–embedded human ameloblastoma. Kumamoto H, et al. **J Oral Pathol Med** 1996 Oct;25(9):484–90

Granular cell ameloblastoma. An immunocytochemical study. Dina R, et al. **Pathol Res Pract** 1996 Jun;192(6):541–6

METABOLISM

Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) in 23 cases of ameloblastoma. Funaoka K, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):328–32

PATHOLOGY

Fine needle aspiration cytology of ameloblastoma. A report of 10 cases. Günhan O. **Acta Cytol** 1996 Sep–Oct; 40(5):967–9

Ameloblastoma. Cytologic findings and literature review. Mathew S, et al. **Acta Cytol** 1997 Jul–Aug;41(4):955–60 (15 ref.)

Malignant ameloblastoma. Witterick IJ, et al. **Am J Otolaryngol** 1996 Mar–Apr;17(2):122–6

Pathological case of the month. Adamantinoma. Iravani S, et al. **Arch Pediatr Adolesc Med** 1997 Apr;151(4):427–8

Atypical ameloblastoma: report of 3 cases and a review of the literature. Ameerally P, et al. **Br J Oral Maxillofac Surg** 1996 Jun;34(3):235–9 (35 ref.)

Peripheral ameloblastoma: report of a case with malignant aspect. Califano L, et al. **Br J Oral Maxillofac Surg** 1996 Jun;34(3):240–2

Ameloblastoma in a female Wistar rat. Ernst H, et al. **Exp Toxicol Pathol** 1995 Nov;47(5):335–40

Distribution of extracellular matrix components in adamantinoma of long bones suggests fibrous–to–epithelial transformation. Hazelbag HM, et al. **Hum Pathol** 1997 Feb; 28(2):183–8

Intraosseous carcinoma arising from mandibular ameloblastoma with progressive invasion and pulmonary metastasis. Ueta E, et al. **Int J Oral Maxillofac Surg** 1996 Oct;25(5):370–2

An anatomical classification of maxillary ameloblastoma as an aid to surgical treatment. Jackson IT, et al. **J Craniomaxillofac Surg** 1996 Aug;24(4):230–6

Clear cell ameloblastoma or odontogenic carcinoma. A case report. Marí A, et al. **J Craniomaxillofac Surg** 1995 Dec; 23(6):387–90 (18 ref.)

Adamantinoma of tibia with predominant features of fibrous dysplasia--a case report. Kim JY, et al. **J Korean Med Sci** 1996 Oct;11(5):444–8

Peripheral ameloblastoma. Niccoli–Filho W, et al. **J Nihon Univ Sch Dent** 1997 Mar;39(1):34–7

Desmoplastic ameloblastoma: correlative histopathology, radiology and CT–MR imaging. Thompson IO, et al. **J Oral Pathol Med** 1996 Aug;25(7):405–10

Granular cell ameloblastoma versus central odontogenic granular cell tumor [letter; comment] Slater L. **Oral Oncol** 1997 Mar;33(2):145. Comment on: Eur J Cancer B Oral Oncol 1996 May;32B(3):210–2.

Clear–cell ameloblastoma (clear–cell odontogenic carcinoma): report of a case. de Aguiar MC, et al.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Jan;81(1):79–83

Some current concepts on the pathology of ameloblastomas. Gardner DG.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Dec;82(6):660–9 (34 ref.)

Mass in the infratemporal fossa [clinical conference] Todd R, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Aug;84(2):116–8

Midfacial degloving for the management of nasal, sinus, and skull-base neoplasms. Maniglia AJ, et al.
Otolaryngol Clin North Am 1995 Dec;28(6):1127–43

Melanocytes in malignant ameloblastoma. Takeda Y.
Pathol Int 1996 Oct;46(10):777–81

Granular cell ameloblastoma. An immunocytochemical study. Dina R, et al. **Pathol Res Pract** 1996 Jun;192(6):541–6

[Desmoplastic ameloblastoma. Report of a case] Lo Muzio L, et al. **Minerva Stomatol** 1996 Jun;45(6):285–8 (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Giant ameloblastoma: radiologic diagnosis and treatment. Dunn JL, et al. **Radiographics** 1997 Mar–Apr;17(2):531–6

[Clinical and radiographic analysis of 56 cases of mural ameloblastoma] Wu Y, et al.
Chung Hua Kou Chiang Hsueh Tsa Chih 1995 Sep; 30(5):263–5, 319 (Eng. Abstr.) **(Chi)**

RADIONUCLIDE IMAGING

The use of positron emission tomography in the evaluation of orofacial malignancy and disease. Hemingway R, et al. **Br Dent J** 1996 Oct 5;181(7):250–3

RADIOTHERAPY

Malignant fibrous histiocytoma after radiation for ameloblastoma of the maxilla. Li KK, et al.
J Oral Maxillofac Surg 1997 Jan;55(1):85–8 (19 ref.)

SECONDARY

Ameloblastoma of the mandible metastasizing to the orbit with malignant transformation. A histopathological and immunohistochemical study. Hayashi N, et al.
Virchows Arch 1997 Jun;430(6):501–7

SURGERY

Malignant ameloblastoma. Witterick IJ, et al.
Am J Otolaryngol 1996 Mar–Apr;17(2):122–6

Clinical features and management of ameloblastoma of the mandible in children and adolescents. Olaitan AA, et al. **Br J Oral Maxillofac Surg** 1996 Jun;34(3):248–51

The combined costal cartilage and rectus abdominis myocutaneous free flap [letter] Yano K, et al.
Br J Plast Surg 1996 Sep;49(6):423–4

An anatomical classification of maxillary ameloblastoma as an aid to surgical treatment. Jackson IT, et al.
J Craniomaxillofac Surg 1996 Aug;24(4):230–6

Unicystic ameloblastoma of the mandible: a long-term follow-up. Olaitan AA, et al. **J Oral Maxillofac Surg** 1997 Apr;55(4):345–8; discussion 349–50

Midfacial degloving for the management of nasal, sinus, and skull-base neoplasms. Maniglia AJ, et al.
Otolaryngol Clin North Am 1995 Dec;28(6):1127–43

[Benign odontogenic cysts and tumors of the jaws (apropos of 38 cases)] Janah A, et al.
Rev Laryngol Otol Rhinol (Bord) 1997;118(2):95–8 (Eng. Abstr.) **(Fre)**

[One-step replacement of the fragmentary mandibular defects during the removal of suppurating benign formations] Semkin VA, et al. **Stomatologiia (Mosk)** 1996;Spec No:76–7 **(Rus)**

ULTRASTRUCTURE

Nucleolar organizer regions (AgNORs) in odontogenic cysts and ameloblastomas. Coleman HG, et al.
J Oral Pathol Med 1996 Sep;25(8):436–40

Morphometric study of nucleolar organiser regions in ameloblastoma and basal cell carcinoma. Rosa LE, et al. **Oral Oncol** 1997 May;33(3):209–14

VETERINARY

Ameloblastoma with prominent ossification in the mandible of a dog. Sakai H, et al. **J Vet Med Sci** 1996 Nov; 58(11):1113–5

VIROLOGY

Latent infection with Epstein-Barr virus in odontogenic disorders: comparison among ameloblastoma, dentigerous cyst and odontogenic keratocyst. Fujita S, et al.
Pathol Int 1997 Jul;47(7):449–53

AMELOBLASTS

CYTOLOGY

Structure and function of secretory ameloblasts in enamel formation. Sasaki T, et al. **Ciba Found Symp** 1997;205:32–46; discussion 46–50 (41 ref.)

Tooth morphogenesis and the differentiation of ameloblasts. Thesleff I, et al. **Ciba Found Symp** 1997;205:3–12; discussion 12–7 (39 ref.)

DRUG EFFECTS

Morphometry and autoradiography of altered rat enamel protein processing due to chronic exposure to fluoride. Zhou R, et al. **Arch Oral Biol** 1996 Aug–Sep;41(8–9):739–47

ENZYMOLOGY

The immunohistochemical localization of signal-transduction pathway components Jak1, Jak2, Jak3, Tyk2 and STAT-1 during early enamel and dentine formation in rat molars. Tanase S, et al. **Arch Oral Biol** 1996 Oct;41(10):925–40

IMMUNOLOGY

Phagocytotic processing of apoptotic bodies of transitional ameloblasts by MHC Class II-expressing macrophages in rat incisor. Nishikawa S, et al. **J Histochem Cytochem** 1996 Dec;44(12):1459–67

METABOLISM

Expression of cytokeratin 14 in ameloblast-lineage cells of the developing tooth of rat, both in vivo and in vitro. Tabata MJ, et al. **Arch Oral Biol** 1996 Nov;41(11):1019–27

The murine amelogenin promoter: developmentally regulated expression in transgenic animals. Snead ML, et al.
Connect Tissue Res 1996;35(1–4):41–7

Amelin: an enamel-related protein, transcribed in the cells of epithelial root sheath. Fong CD, et al.
J Bone Miner Res 1996 Jul;11(7):892–8

Production of amelogenin by enamel epithelium of Hertwig's root sheath. Hamamoto Y, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Jun;81(6):703–9

PHYSIOLOGY

Structure and function of secretory ameloblasts in enamel formation. Sasaki T, et al. **Ciba Found Symp** 1997;205:32–46; discussion 46–50 (41 ref.)

A novel gene expressed in rat ameloblasts codes for proteins with cell binding domains. Cerný R, et al.
J Bone Miner Res 1996 Jul;11(7):883–91

Apoptosis (programmed cell death) of transitional ameloblasts and MHC class II expression in rat incisors. Nishikawa S, et al. **Kaibogaku Zasshi** 1996 Dec; 71(6):597–603 (22 ref.)

AMELOGENESIS

The immunohistochemical localization of stat-2, -3, -4 and -5 during early enamel and dentine formation in rat molars. Tanase S, et al. **Arch Oral Biol** 1996 Dec;41(12):1149–60

Disturbances of the secretory stage of amelogenesis in fluorosed deer teeth: a scanning electron-microscopic study. Kierdorf H, et al. **Cell Tissue Res** 1997 Jul; 289(1):125–35

Dental Enamel. Proceedings of a Symposium. London, 23–25 April 1996. **Ciba Found Symp** 1997;205:1–284

GENETICS

Molecular strategies of tooth enamel formation are highly conserved during vertebrate evolution. Slavkin HC, et al. **Ciba Found Symp** 1997;205:73–80; discussion 81–4

Nuclear DNA fragmentation during postnatal tooth development of mouse and hamster and during dentin repair in the rat. Bronckers AL, et al. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 1)):102–11

PHYSIOLOGY

The immunohistochemical localization of signal-transduction pathway components Jak1, Jak2, Jak3, Tyk2 and STAT-1 during early enamel and dentine formation in rat molars. Tanase S, et al. **Arch Oral Biol** 1996 Oct;41(10):925–40

Amelogenin proteins of developing dental enamel. Fincham AG, et al. **Ciba Found Symp** 1997;205:118–30; discussion 130–4 (47 ref.)

Structure and function of secretory ameloblasts in enamel formation. Sasaki T, et al. **Ciba Found Symp** 1997;205:32–46; discussion 46–50 (41 ref.)

Two types of intraoral distribution of fluorotic enamel. van Palenstein Helderman WH, et al.
Community Dent Oral Epidemiol 1997 Jun;25(3):251–5

AMELOGENESIS IMPERFECTA

CLASSIFICATION

Molecular biology of hereditary enamel defects. Aldred MJ, et al. **Ciba Found Symp** 1997;205:200–5; discussion 205–9 (29 ref.)

Inherited enamel defects. Bäckman B. **Ciba Found Symp** 1997; 205:175–82; discussion 183–6 (37 ref.)

GENETICS

An amelogenin gene defect associated with human X-linked amelogenesis imperfecta. Collier PM, et al.
Arch Oral Biol 1997 Mar;42(3):235–42

Genetic heterogeneity of autosomal dominant amelogenesis imperfecta demonstrated by its exclusion from the AIH2 region on human chromosome 4Q. Kärrman C, et al.
Arch Oral Biol 1996 Aug–Sep;41(8–9):893–900

Molecular biology of hereditary enamel defects. Aldred MJ, et al. **Ciba Found Symp** 1997;205:200–5; discussion 205–9 (29 ref.)

Inherited enamel defects. Bäckman B. **Ciba Found Symp** 1997; 205:175–82; discussion 183–6 (37 ref.)

Tuftelin: enamel mineralization and amelogenesis imperfecta. Deutsch D, et al. **Ciba Found Symp** 1997;205:135–47; discussion 147–155 (51 ref.)

Mapping of the locus for autosomal dominant amelogenesis imperfecta (AIH2) to a 4-Mb YAC contig on chromosome 4q11–q21. Kärrman C, et al. **Genomics** 1997 Jan 15; 39(2):164–70

Ameloblastin gene (AMBN) maps within the critical region for autosomal dominant amelogenesis imperfecta at chromosome 4q21. MacDougall M, et al. **Genomics** 1997 Apr 1;41(1):115–8

DNA diagnosis of X-linked amelogenesis imperfecta (AIH1). Lench NJ, et al. **J Oral Pathol Med** 1997 Mar;26(3):135–7

[Kohlschütter syndrome—an example of a rare progressive neuroectodermal disease. Case report and review of the literature] Wygold T, et al. **Klin Padiatr** 1996 Sep–Oct; 208(5):271–5 (4 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

The enamel proteins in human amelogenesis imperfecta. Wright JT, et al. **Arch Oral Biol** 1997 Feb;42(2):149–59

The protein composition of normal and developmentally defective enamel. Wright JT, et al. **Ciba Found Symp** 1997; 205:85–99; discussion 99–106

PATHOLOGY

Amelogenesis imperfecta with enamel opacities and taurodontism: an alternative diagnosis for 'idiopathic dental fluorosis'. Winter GB. **Br Dent J** 1996 Sep 7;181(5):167–72

REHABILITATION

Rehabilitation of young patients with amelogenesis imperfecta: a report of two cases. Bouvier D, et al.
ASDC J Dent Child 1996 Nov–Dec;63(6):443–7

AMENORRHEA

The use of lactational amenorrhea as a fertility regulating method. Rivera R. **Adv Contracept** 1996 Sep;12(3):179–85 (10 ref.)

Effects of age at introduction of complementary foods to breast-fed infants on duration of lactational amenorrhea in Honduran women. Dewey KG, et al.
Am J Clin Nutr 1997 May;65(5):1403–9

Clinical syndromes of primary amenorrhea. Batrinos ML, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:235–40 (08 ref.)

Lactation, nutrition, and postpartum amenorrhea in lowland Papua New Guinea. Tracer DP. **Hum Biol** 1996 Apr; 68(2):277–92

Contraceptive use during lactational amenorrhea.
Hight-Laukaran V, et al. **Int J Gynaecol Obstet** 1996 Aug; 54(2):101–8

Lactational amenorrhea method for family planning. Kennedy KI, et al. **Int J Gynaecol Obstet** 1996 Jul; 54(1):55–7

Consensus statement. Lactational amenorrhea method for family planning. **J Nurse Midwifery** 1996 Sep–Oct; 41(5):405–6 (00 ref.)

American College of Sports Medicine position stand. The Female Athlete Triad. Otis CL, et al.
Med Sci Sports Exerc 1997 May;29(5):i–ix

An assessment of the nine-month lactational amenorrhea method (MAMA-9) in Rwanda. Cooney KA, et al.
Stud Fam Plann 1996 May–Jun;27(3):102–71

BLOOD

Variations of free and total tryptophan serum levels after GN-RH administration in patients with amenhorrea. Preliminary results. Carretti N, et al.
Adv Exp Med Biol 1996;398:433–7

Resumption of menses in anorexia nervosa. New research findings and their clinical implications [editorial; comment] Silber TJ. **Arch Pediatr Adolesc Med** 1997 Jan;151(1):14–5 . Comment on: Arch Pediatr Adolesc Med 1997 Jan;151(1):16–21.

Women with functional hypothalamic amenorrhea but not other forms of anovulation display amplified cortisol concentrations. Berga SL, et al. **Fertil Steril** 1997 Jun; 67(6):1024–30

Plasma concentrations of beta-endorphin in trained eumenorrheic and amenorrheic women. Harber VJ, et al. **Fertil Steril** 1997 Apr;67(4):648–53

Circulating nitric oxide levels in galactorrheic, hyperprolactinemic, amenorrheic women. Shaarawy M, et al. **Fertil Steril** 1997 Sep;68(3):454–9

Post-suckling prolactin:oestradiol ratio—a potential index to predict the duration of lactational amenorrhoea in women. Campino C, et al. **Hum Reprod** 1997 Jul;12(7):1421–6

Hypoleptinemia in women athletes: absence of a diurnal rhythm with amenorrhea. Laughlin GA, et al.
J Clin Endocrinol Metab 1997 Jan;82(1):318–21

Endothelin plasma levels in primary amenorrheic adolescents before and after estrogen treatment. Creatsas GC, et al.

J Soc Gynecol Investig 1996 Nov–Dec;3(6):350–3

Low leptin levels predict amenorrhea in underweight and eating disordered females [see comments] Köpp W, et al. **Mol Psychiatry** 1997 Jul;2(4):335–40. Comment in: Mol Psychiatry 1997 Jul;2(4):267–9.

CHEMICALLY INDUCED

Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Del Mastro L, et al. **Breast Cancer Res Treat** 1997 Apr;43(2):183–90 (43 ref.)

Spontaneous recovery of chemotherapy-induced primary ovarian failure: implications for management. Nasir J, et al. **Clin Endocrinol (Oxf)** 1997 Feb;46(2):217–9

COMPLICATIONS

Refractory ulcerative lupus vulgaris associated with CD4 lymphocytopenia, inversion of chromosome 14, primary amenorrhoea and mental retardation. Ozarmagan G, et al. **Acta Derm Venereol** 1997 Jul;77(4):309–10

Resumption of menses in anorexia nervosa [letter; comment] Needles CF. **Arch Pediatr Adolesc Med** 1997 Jun; 151(6):634–5. Comment on: Arch Pediatr Adolesc Med 1997 Jan;151(1);16–21.

Recommendations for exogenous estrogen to prevent glucocorticoid-induced osteoporosis in premenopausal women with oligo- or amenorrhea: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis [letter; comment] Buyon JP, et al. **Arthritis Rheum** 1997 Aug;40(8):1548–9. Comment on: Arthritis Rheum 1996 Nov;39(11):1791–801.

Displaced stress fracture of the femoral neck in an active amenorrhoeic adolescent. Haddad FS, et al. **Br J Sports Med** 1997 Mar;31(1):70–2

Ovarian Sertoli-Leydig cell tumor in an amenorrheic hirsute patient. Tsai CC, et al. **Chang Keng I Hsueh** 1996 Jun; 19(2):191–5

The female athlete triad. Grooms AM. **J Fla Med Assoc** 1996 Aug–Sep;83(7):479–81 (20 ref.)

DIAGNOSIS

Long-term administration of pulsatile gonadotropin-releasing hormone for exploration of pituitary functionality in amenorrheic patients. Graña M, et al. **Gynecol Endocrinol** 1997 Apr;11(2):91–9

Mayer-Rokitansky-Kuster-Hauser syndrome diagnosed by magnetic resonance imaging in a 15-year-old girl. Russ PD, et al. **J Pediatr Adolesc Gynecol** 1997 May;10(2):89–92

Primary amenorrhea: evaluation with MR imaging. Reinhold C, et al. **Radiology** 1997 May;203(2):383–90

DRUG THERAPY

Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Hergenroeder AC, et al. **Am J Obstet Gynecol** 1997 May; 176(5):1017–25

A practical guide to the diagnosis and management of amenorrhoea. Crosignani PG, et al. **Drugs** 1996 Nov; 52(5):671–81 (59 ref.)

Changes in the erythrocyte antioxidant enzyme system during transdermal estradiol therapy for secondary amenorrhea. Massafra C, et al. **Gynecol Endocrinol** 1996 Jun;10(3):155–8

Factors associated with withdrawal bleeding after administration of oral dydrogesterone or medroxyprogesterone acetate in women with secondary amenorrhea. Battino S, et al. **Gynecol Obstet Invest** 1996; 42(2):113–6

A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea. Taylor AE, et al. **J Clin Endocrinol Metab** 1996 Oct; 81(10):3615–21

ENZYMOLOGY

Effects of estradiol and medroxyprogesterone-acetate treatment on erythrocyte antioxidant enzyme activities and malondialdehyde plasma levels in amenorrhoic women. Massafra C, et al. **J Clin Endocrinol Metab** 1997 Jan; 82(1):173–5

EPIDEMIOLOGY

Dies endogeneity matter? A comparison of empirical analyses with and without control for endogeneity [see comments] Zohoori N. **Ann Epidemiol** 1997 May;7(4):258–66. Comment in: Ann Epidemiol 1997 May;7(4):249–50.

Investigation on breastfeeding and lactational amenorrhoeic women in mountainous areas of Pengxian County, Southwest China. Cui N, et al. **J Obstet Gynaecol** 1995 Aug;21(4):373–80

Amenorrhea in ballet dancers in the Netherlands. Fogelholm M, et al. **Med Sci Sports Exerc** 1996 May;28(5):545–50

Prevalence of menstrual dysfunction in Norwegian long-distance runners participating in the Oslo Marathon games. Tomten SE. **Scand J Med Sci Sports** 1996 Jun; 6(3):164–71

[Risk analysis of menstrual disorders in young women from urban population] Skierska E, et al. **Przegl Epidemiol** 1996; 50(4):467–74 (Eng. Abstr.) **(Pol)**

ETHNOLOGY

Maternal education, breastfeeding behaviours and lactational amenorrhoea: studies among two ethnic communities in Ile Ife, Nigeria. Davies-Adetugbo AA, et al. **Nutr Health** 1996;11(2):115–26

ETIOLOGY

Effect of skim milk supplementation of the maternal diet on lactational amenorrhea, maternal prolactin, and lactational behavior [see comments] Tennekoon KH, et al. **Am J Clin Nutr** 1996 Sep;64(3):283–90. Comment in: Am J Clin Nutr 1996 Sep;64(3):377–8.

Bone mineral metabolism in diet-induced amenorrhea. Bruni V, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:250–62

Clinical syndromes of secondary amenorrhea. Mavroudis K. **Ann N Y Acad Sci** 1997 Jun 17;816:241–9 (17 ref.)

Sports-related problems in reproductive function. Orley J. **Ann N Y Acad Sci** 1997 Jun 17;816:285–94 (15 ref.)

Amenorrhea in beta-homozygous thalassemia major. Tolis G, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:274–9 (40 ref.)

Athletic amenorrhea. Wolf AS, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:295–304 (36 ref.)

Prolactinomas. Katznelson L, et al. **Cancer Treat Res** 1997; 89:41–55 (40 ref.)

Galactorrhoea and amenorrhoea due to an intradural neurinoma originating from a thoracic intercostal nerve radicle. Katsuren E, et al. **Clin Endocrinol (Oxf)** 1997 May; 46(5):631–6

Hypogonadotrophic hypogonadism and primary amenorrhoea associated with increased melatonin secretion from a cystic pineal lesion. Walker AB, et al. **Clin Endocrinol (Oxf)** 1996 Sep;45(3):353–6

Ovarian resistance to luteinizing hormone: a novel cause of amenorrhea and infertility. Arnhold IJ, et al. **Fertil Steril** 1997 Feb;67(2):394–7

A case of Pendred's syndrome presenting with amenorrhea. Mushayandebvu TI, et al. **Gynecol Obstet Invest** 1996; 42(4):277–8

Nutritional aspects of amenorrhea in the female athlete triad. Benson JE, et al. **Int J Sport Nutr** 1996 Jun;6(2):134–45 (71 ref.)

Role of energy balance in athletic menstrual dysfunction. Dueck CA, et al. **Int J Sport Nutr** 1996 Jun;6(2):165–90 (85 ref.)

The association between secondary amenorrhea and common eating disordered weight control practices in an adolescent population. Selzer R, et al. **J Adolesc Health** 1996 Jul; 19(1):56–61

Resumption of menstruation after amenorrhea in women treated by endometrial ablation and myometrial resection. Seeras RC, et al. **J Am Assoc Gynecol Laparosc** 1997 May; 4(3):305–9

Normogonadotropic primary amenorrhea in a growth hormone-deficient woman with ectopic posterior pituitary: gonadotropin pulsatility and follicle-stimulating hormone bioactivity. Crottaz B, et al. **J Endocrinol Invest** 1996 Jan; 19(1):48–53

Vaginal inversion and uterus acollis with primary amenorrhoea. Pratibha D, et al. **J Indian Med Assoc** 1995 Oct;93(10):401

Primary amenorrhoea out of craniopharyngioma. Sanyal C, et al. **J Indian Med Assoc** 1997 Jan;95(1):21–2

Secondary amenorrhea due to hydrocephalus treated with endoscopic ventriculocisternostomy. Case report. Lowry DW, et al. **J Neurosurg** 1996 Dec;85(6):1148–52 (37 ref.)

Mayer-Rokitansky-Kuster-Hauser syndrome diagnosed by magnetic resonance imaging in a 15-year-old girl. Russ PD, et al. **J Pediatr Adolesc Gynecol** 1997 May;10(2):89–92

Bilateral absence of the ovaries and distal fallopian tubes. A case report. Gold MA, et al. **J Reprod Med** 1997 Jun; 42(6):375–7

Amenorrhoea. Baird DT. **Lancet** 1997 Jul 26;350(9073):275–9 (30 ref.)

Secondary amenorrhea leading to osteoporosis: incidence and prevention. McGee C. **Nurse Pract** 1997 May;22(5):38, 41–5, 48 passim (40 ref.)

[Hypergonadotropic secondary amenorrhea: clinical analysis of 126 cases] Lin J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 May;31(5):278–82 (Eng. Abstr.) **(Chi)**

[Tuberculosis as an unusual cause of oligoamenorrhea and infertility] Goddijn M, et al. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):105–7 (Eng. Abstr.) **(Dut)**

[Primary amenorrhea revealing congenital hydrocephalus] Thibaud D, et al. **Arch Pediatr** 1996 Nov;3(11):1099–101 (Eng. Abstr.) **(Fre)**

[The female athletes' triad: eating disorders, amenorrhea, osteoporosis] Resch M. **Orv Hetil** 1997 Jun 1; 138(22):1393–7 (Eng. Abstr.) **(Hun)**

[Cervical agenesis with secondary endometriosis. Surgical treatment of a case] Salas-Ceniceros S, et al. **Ginecol Obstet Mex** 1996 Oct;64:477–81 (Eng. Abstr.) **(Spa)**

GENETICS

Luteinizing hormone resistance syndromes. Tsigos C, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:263–73

An inactivating mutation of the luteinizing hormone receptor causes amenorrhea in a 46,XX female. Toledo SP, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):3850–4

Results of cytogenetic investigation in adolescent patients with primary or secondary amenorrhea. Temoçin K, et al. **J Pediatr Adolesc Gynecol** 1997 May;10(2):86–8

Fluorescent in-situ hybridization and sequence-tagged sites for delineation of an X;Y translocation in a patient with secondary amenorrhoea. Delon B, et al. **Mol Hum Reprod** 1997 May;3(5):439–43

Isolated deficiency of follicle-stimulating hormone re-revisited [letter] Matthews C, et al. **N Engl J Med** 1997 Aug 28;337(9):642

[Study on the relationship between clinical phenotypes and X chromosome abnormalities] Shintaku Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Apr;48(4):281–4 **(Jpn)**

METABOLISM

Effects of thyrotropin-releasing hormone and metoclopramide on PRL secretion in normally cycling and amenorrheic alcoholic women. Vescovi PP, et al. **Drug Alcohol Depend** 1997 Apr 14;45(1–2):115–9

Nutritional and endocrine-metabolic aberrations in amenorrheic athletes. Laughlin GA, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4301–9

PHYSIOPATHOLOGY

Does maternal supplementation shorten the duration of lactational amenorrhea? [editorial; comment] Dewey KG. **Am J Clin Nutr** 1996 Sep;64(3):377–8. Comment on: Am J Clin Nutr 1996 Sep;64(3):283–90.

Effect of skim milk supplementation of the maternal diet on lactational amenorrhea, maternal prolactin, and lactational behavior [see comments] Tennekoon KH, et al. **Am J Clin Nutr** 1996 Sep;64(3):283–90. Comment in: Am J Clin Nutr 1996 Sep;64(3):377–8.

Stress and ovarian function. Berga SL. **Am J Sports Med** 1996;24(6 Suppl):S36–7

Bone mineral metabolism in diet-induced amenorrhea. Bruni V, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:250–62

Sports-related problems in reproductive function. Orley J. **Ann N Y Acad Sci** 1997 Jun 17;816:285–94 (15 ref.)

Luteinizing hormone resistance syndromes. Tsigos C, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:263–73

Athletic amenorrhea. Wolf AS, et al. **Ann N Y Acad Sci** 1997 Jun 17;816:295–304 (36 ref.)

Exercise-associated amenorrhea, low bone density, and estrogen replacement therapy. Cumming DC. **Arch Intern Med** 1996 Oct 28;156(19):2193–5

Resumption of menses in anorexia nervosa [see comments] Golden NH, et al. **Arch Pediatr Adolesc Med** 1997 Jan; 151(1):16–21. Comment in: Arch Pediatr Adolesc Med 1997 Jan;151(1):14–5. Comment in: Arch Pediatr Adolesc Med 1997 Jun;151(6):634–5.

Effectiveness of lactational amenorrhoea in prevention of pregnancy in Manila, the Philippines: non-comparative prospective trail [see comments] Ramos R, et al. **BMJ** 1996 Oct 12;313(7062):909–12. Comment in: BMJ 1996 Oct 12;313(7062):893–4.

Lactational amenorrhoea method for family planning [editorial; comment] Van Look PF. **BMJ** 1996 Oct 12; 313(7062):893–4. Comment on: BMJ 1996 Oct 12;313(7062):909–12.

Corticotrophin and vasopressin responses to metoclopramide in patients with hypothalamic amenorrhoea. Seki K, et al. **Clin Endocrinol (Oxf)** 1997 Feb;46(2):203–7

Bone density in amenorrheic athletes and in anorexia nervosa [letter; comment] Mehler PS. **JAMA** 1996 Nov 6; 276(17):1384–5. Comment on: JAMA 1996 Jul 17;276(3):238–40.

Leptin in anorexia nervosa and amenorrhea [editorial; comment] Licinio J. **Mol Psychiatry** 1997 Jul;2(4):267–9 (23 ref.). Comment on: Mol Psychiatry 1997 Jul;2(4):330–4. Comment on: Mol Psychiatry 1997 Jul;2(4):335–40.

Ovulation induction in the nonestrogenized patient. Hurst BS. **Semin Reprod Endocrinol** 1996 Nov;14(4):299–308 (71 ref.)

[Decreased bone mineral density in premenopausal women with amenorrhea] Kinoshita T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Sep;48(9):793–8 (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Secondary amenorrhea leading to osteoporosis: incidence and prevention. McGee C. **Nurse Pract** 1997 May;22(5):38, 41–5, 48 passim (40 ref.)

PSYCHOLOGY

Body image in secondary amenorrhea. Orlandi E, et al. **J Psychosom Obstet Gynaecol** 1997 Mar;18(1):45–52

Discrepancies between genital responses and subjective sexual function during testosterone substitution in women with hypothalamic amenorrhea. Tutten A, et al. **Psychosom Med** 1996 May–Jun;58(3):234–41

SURGERY

The value of two stage laser treatment for severe Asherman's syndrome. Chapman R, et al. **Br J Obstet Gynaecol** 1996 Dec;103(12):1256–8

THERAPY

Delayed puberty in girls and primary amenorrhea. Thomas MA, et al. **Curr Ther Endocrinol Metab** 1997;6:223–6 (7 ref.)

Anorexia, bulimia, and exercise-induced amenorrhea: medical approach. Warren MP. **Curr Ther Endocrinol Metab** 1997;6:13–7 (9 ref.)

Amenorrhoea. Baird DT. **Lancet** 1997 Jul 26;350(9073):275–9 (30 ref.)

Ovulation induction in the nonestrogenized patient. Hurst BS. **Semin Reprod Endocrinol** 1996 Nov;14(4):299–308 (71 ref.)

ULTRASONOGRAPHY

Color Doppler analysis in oligo- and amenorrheic women with polycystic ovary syndrome. Battaglia C, et al. **Gynecol Endocrinol** 1997 Apr;11(2):105–10

AMERICAN CANCER SOCIETY

American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. Byers T, et al. **CA Cancer J Clin** 1997 May–Jun; 47(3):154–60

The American Cancer Society's prostate cancer position [editorial] Eyre HJ. **CA Cancer J Clin** 1997 Sep–Oct; 47(5):259–60

American Cancer Society guidelines for the early detection of breast cancer: update 1997. Leitch AM, et al. **CA Cancer J Clin** 1997 May–Jun;47(3):150–3

The American Cancer Society's National Prostate Cancer Detection Project. Littrup PJ. **Can J Oncol** 1994 Nov;4 Suppl 1:65–9

The American Cancer Society and Mission 2000. Eyre HJ. **Cancer** 1997 Feb 1;79(3 Suppl):658–60

National Cancer Act 1971–1996. National Cancer Institute/American Cancer Society relationship—June 1996. Eyre HJ. **Cancer** 1996 Dec 15;78(12):2609–10

American Cancer Society restructures research and professional training programs [news] **Oncology (Huntingt)** 1996 Feb;10(2):259

HISTORY

The 25th anniversary of the National Cancer Act of 1971. Letton AH. **Cancer** 1996 Dec 15;78(12):2597–8

AMERICAN DENTAL ASSOCIATION

Developing the American Dental Association concept model for the standard computer-based oral health record. Diehl M. **J Am Coll Dent** 1995 Winter;62(4):30–2

JADA readers favor a practical approach. **J Am Dent Assoc** 1997 Jul;128(7):1014–6

ADA supports vital tooth bleaching—but look for the seal. Burrell KH. **J Am Dent Assoc** 1997 Apr;128 Suppl:3S–5S

A banner year for organized dentistry. Rainwater G. **J Am Dent Assoc** 1996 Dec;127(12):1717–9

Meeting the challenges of changing times. Zapp JS. **J Am Dent Assoc** 1996 Dec;127(12):1725–7

Perspectives from the profession. Ten Pas WS. **J Dent Educ** 1996 Nov;60(11):883–5

ADA takes stand on at-home bleaching products [news] **N Y State Dent J** 1997 May;63(5):41

ADA statement on FDA toothpaste warning labels [news] **N Y State Dent J** 1997 Aug–Sep;63(7):50

American Dental Association statement on backflow prevention and the dental office [news] **N Y State Dent J** 1996 Nov;62(9):74–5

ORGANIZATION & ADMINISTRATION

American Dental Association Division of Legal Affairs. **J Am Coll Dent** 1997 Summer;64(2):33–4

Strength in numbers. Warford JH. **J Am Dent Assoc** 1996 Dec;127(12):1729–32

AMERICAN HEART ASSOCIATION

Fish consumption, fish oil, lipids, and coronary heart disease. Stone NJ. **Am J Clin Nutr** 1997 Apr;65(4):1083–6 (41 ref.)

Developing and revising the American Heart Association guidelines for advanced cardiac life support. Kirby AK, et al. **J Cardiovasc Nurs** 1996 Jul;10(4):15–23

The American Heart Association and emergency cardiac care training in Louisiana—past, present, and future. Sea C. **J La State Med Soc** 1997 May;149(5):168–71

The American Heart Association. Focus on public advocacy issues. Snyder DW. **J La State Med Soc** 1997 May; 149(5):161–3

[Trends—ACE inhibition improves coronary dysfunction. Symposium within the scope of the American Heart Association Congress, Anaheim, November 1995] Müller-Lissner S. **Internist (Berl)** 1996 Mar;37(3):328–9 **(Ger)**

ORGANIZATION & ADMINISTRATION

Update on American Heart Association education and information initiatives. O'Neal TB, et al. **J La State Med Soc** 1997 May;149(5):172–4

Cardiovascular research support by the American Heart Association in Louisiana. Sheridan FM, et al. **J La State Med Soc** 1997 May;149(5):164–7

AMERICAN HOSPITAL ASSOCIATION

The new portfolio of American Heart Association National Research Awards: initial experience [news] Barry WH. **Circulation** 1997 Aug 19;96(4):1068–9

ORGANIZATION & ADMINISTRATION

Mergers/acquisitions ... American Academy of Healthcare Attorneys with the National Health Lawyers Association [news] **Hosp Health Netw** 1997 Aug 5;71(15):19

Tough as he needs to be. Bilchik GS. **Hosp Health Netw** 1997 Aug 20;71(16):28–30, 32

AMERICAN MEDICAL ASSOCIATION

Tobacco control and the American Medical Association. Houston TP. **Alaska Med** 1996 Jan–Mar;38(1):49–50

The scope of the data available in the AMA's Physician Masterfile [letter; comment] Kenward K. **Am J Public Health** 1996 Oct;86(10):1481–2. Comment on: Am J Public Health 1995 Oct;85(10):1402–7.

American Medical Association endorses consumer products [news] Charatan FB. **BMJ** 1997 Aug 23;315(7106):445

Institute for Medical Ethics faces up to flood of dilemmas [news] Emanuel L. **BMJ** 1997 Jun 28;314(7098):1853

American Medical Association backs amended abortion bill [news] Macready N. **BMJ** 1997 May 31;314(7094):1572

Except in emergencies: AMA ethics and physician autonomy. Clark CC. **Camb Q Healthc Ethics** 1996 Summer;5(3):440–3

Gastroenterology, research, and the American Gastroenterological Association: today's investigation, tomorrow's practice. Podolsky DK. **Gastroenterology** 1996 Dec;111(6):1753–7

"Miracle and wonder": the AMA embraces quality measurement [see comments] Millenson ML. **Health Aff (Millwood)** 1997 May–Jun;16(3):183–94. Comment in: Health Aff (Millwood) 1997 May–Jun;16(3):195–7.

Restoring the ethical balance in health care [see comments] Seward PJ. **Health Aff (Millwood)** 1997 May–Jun; 16(3):195–7. Comment in: Health Aff (Millwood) 1997 May–Jun;16(3):183–93.

Tobacco control and the AMA: health, policy and politics. Houston TP. **Indiana Med** 1996 Mar–Apr;89(2):129–31

Getting serious about tobacco control. Role for organized medicine. A message from the American Medical Association. Houston TP. **J Fla Med Assoc** 1996 Feb; 83(2):96–7

Heart and vision. Palmisano DJ. **J La State Med Soc** 1996 Aug;148(8):350–2

Uniting our forces. Fine P. **J Med Assoc Ga** 1996 Nov; 85(4):216–7

AMA goes on the World Wide Web [news] Keoun B. **J Natl Cancer Inst** 1996 Nov 20;88(22):1611

Report 59 of the AMA Board of Trustees (A–96). Physician-assisted suicide. Reference Committee on Amendments to Constitution and Bylaws. **J Okla State Med Assoc** 1996 Aug;89(8):281–93

Use and misuse of the AMA guides in assessing impairment. Gaw DW, et al. **J Tenn Med Assoc** 1996 Mar;89(3):77–8

Index to Volume 276. June – December 1996. **JAMA** 1996 Dec 25;276(24):1996–2053

'Doing what is best for patients': a sesquicentennial rededication [news] Goldsmith MF. **JAMA** 1997 Apr 23–30;277(16):1265–8

Selling out [editorial] **Lancet** 1997 Aug 23;350(9077):529

Significant gains won in Congress [news] **Md Med J** 1996 Nov;45(11):904

Physician biographical information and reference library now available on AMA web site [news] **Md Med J** 1996 Nov; 45(11):904–5

Check your biography on the new AMA database. All active, licensed physicians are included. **Mich Med** 1996 Oct; 95(10):13

IMGs set goals for AMA section. Ward RD. **Mich Med** 1997 Jun;96(6):28–9

AMA Study of the Federation. Phillips R. **Mo Med** 1996 Apr;93(4):164–5

The high price of product endorsement [editorial]] Kassirer JP, et al. **N Engl J Med** 1997 Sep 4;337(10):700

Physician—heal thyself [letter] Bush ST. **Pa Med** 1996 Nov; 99(11):4, 6

Membership of the Association of American Physicians. May 1996. **Proc Assoc Am Physicians** 1996 May;108(3):239–84

Membership of the Association of American Physicians. **Proc Assoc Am Physicians** 1997 May;109(3):302–49

Furor over company deal roils AMA [news] Kaiser J. **Science** 1997 Oct 3;278(5335):26

Physician-assisted suicide. Above all else do no harm. Bahan I. **Tenn Med** 1997 Feb;90(2):45–6

Overhauling the federation of medicine. Sewell T. **Tenn Med** 1996 Sep;89(9):319–21

ECONOMICS

All physicians should pay dues! Norland C. **Mo Med** 1996 Oct;93(10):639–41

HISTORY

Preserving individualism in the organizational society: "Cooperation" and American medical practice, 1900–1920. Madison DL. **Bull Hist Med** 1996 Fall;70(3):442–83

ORGANIZATION & ADMINISTRATION

A new Federation [editorial] Hall J. **Iowa Med** 1996 May–Jun;86(5):183

AMERICAN NURSES' ASSOCIATION

Strengthening nursing through partnerships. Malone B. **Am J Nurs** 1996 Nov;96(11):80

ANA leaders launch sequel to 'Nursing's Agenda'. Marullo G. **Am J Nurs** 1997 Sep;97(9):63–5

Quality and staffing issues dominate the ANA agenda. Peterson C, et al. **Am J Nurs** 1997 Feb;97(2):53–4

ANA document helps school nurses deal with HIV/AIDS [news] **MCN Am J Matern Child Nurs** 1997 Mar–Apr; 22(2):107

HISTORY

The ANA's Economic Security Program: the first 20 years. Grando VT. **Nurs Res** 1997 Mar–Apr;46(2):111–5

Evolution of the American Nurses Association's position on health insurance for the aged: 1933–1965. Woods CQ. **Nurs Res** 1996 Sep–Oct;45(5):304–10

AMERICAN SPEECH-LANGUAGE-HEARING ASSOCIATION

Your association, past, present, and ...future perfect? Butler K. **ASHA** 1996 Spring;38(2):7

GADabouts! Goldberg B. **ASHA** 1996 Spring;38(2):24–31

Tailoring to fit. Altering our approach to multicultural populations. Goldberg B. **ASHA** 1997 Spring;39(2):22–8

Internet. More commands to remember. Kuster JM. **ASHA** 1996 Spring;38(2):51

The perils of free speech. Carefully craft your compliments! Malone R. **ASHA** 1996 Spring;38(2):56

Breaking the silence. Welcoming lesbian, gay and bisexual colleagues and consumers. Peppard RC, et al. **ASHA** 1996 Fall;38(4):32–5

(Un)civilized speech. Should ASHA care? [editorial] Werven G. **ASHA** 1996 Spring;38(2):8;54

ORGANIZATION & ADMINISTRATION

How should we redesign our body? Golper LA, et al. **ASHA** 1997 Spring;39(2):10–1

AMERICIUM

Chelation therapy by DFO–HOPO and 3,4,3–LIHOPO for injected Pu–238 and Am–241 in the rat: effect of dosage, time and mode of chelate administration. Volf V, et al. **Int J Radiat Biol** 1996 Dec;70(6):765–72

Microdosimetric evaluation of relative biological effectiveness for 103Pd, 125I, 241Am, and 192Ir brachytherapy sources. Wuu CS, et al. **Int J Radiat Oncol Biol Phys** 1996 Oct 1;36(3):689–97

ADMINISTRATION & DOSAGE

[The effect of multiple combined external exposure to gamma radiation and the administration of 241Am on the body of the rat] Romanova IB. **Radiats Biol Radioecol** 1997 Mar–Apr;37(2):202–6 (Eng. Abstr.) **(Rus)**

[Effects of pectins with different levels of esterification and food additive Medetopect on colon microflora in rats after lead poisoning and lesions by radioactive isotopes] Ivanov AA, et al. **Vopr Pitan** 1997;(2):15–8 (Eng. Abstr.) **(Rus)**

ANALYSIS

Environmental and human monitoring of Americium–241 utilizing extraction chromatography and alpha-spectrometry. Goldstein SJ, et al. **Anal Chem** 1997 Mar 1;69(5):809–12

Computer model generated density correction factors for gamma spectroscopy counting. Darman JJ, et al. **Health Phys** 1997 Feb;72(2):313–7

Data quality objectives for surface-soil cleanup operation using in situ gamma spectrometry for concentration measurements. Fong SH, et al. **Health Phys** 1997 Feb; 72(2):286–95

Issues in establishing an aerosol radiological baseline for the waste isolation pilot plant near Carlsbad, New Mexico. Rodgers JC, et al. **Health Phys** 1997 Feb;72(2):300–8

[Cesium–137 and Americium–141 levels in foodstuffs] Riolfatti M, et al. **Ann Ig** 1997 Jan–Feb;9(1):49–57 **(Ita)**

METABOLISM

Identification of 137Cs-and 241Am-binding sites in the oyster Crassostrea gigas. Milcent MC, et al. **Biochem Mol Biol Int** 1996 May;39(1):137–48

PHARMACOKINETICS

Chest wall thickness measurements: the alternative approach extended for 241Am. Kramer GH, et al. **Health Phys** 1997

AMERICIUM

Feb;72(2):309–12

URINE

Method for actinides and Sr–90 determination in urine samples. Alvarez A, et al. **Appl Radiat Isot** 1996 Sep–Oct; 47(9–10):869–73

AMERINDS, CENTRAL AMERICAN see **INDIANS, CENTRAL AMERICAN**

AMERINDS, NORTH AMERICAN see **INDIANS, NORTH AMERICAN**

AMERINDS, SOUTH AMERICAN see **INDIANS, SOUTH AMERICAN**

AMETAZOLE see **BETAZOLE**

AMETHOCAINE see **TETRACAINE**

AMETHOPTERIN see **METHOTREXATE**

AMETROPIA see **REFRACTIVE ERRORS**

AMFEPRAMON see **DIETHYLPROPION**

AMIDASES see **AMIDOHYDROLASES**

AMIDAZINE see **ETHIONAMIDE**

AMIDES

Synthesis and application of novel nucleoside phosphonates and phosphoramidites modified at the base moiety. Seela F, et al. **Acta Biochim Pol** 1996;43(1):45–52

Postoperative epidural ropivacaine [letter] Knuth S, et al. **Anaesth Intensive Care** 1997 Aug;25(4):435

Comparison of 0.5% ropivacaine and 0.5% bupivacaine in lumbar epidural anaesthesia for lower limb orthopaedic surgery. McGlade DP, et al. **Anaesth Intensive Care** 1997 Jun;25(3):262–6

Ropivacaine 0.75% for extradural anaesthesia in elective caesarean section: an open clinical and pharmacokinetic study in mother and neonate. Morton CP, et al. **Br J Anaesth** 1997 Jul;79(1):3–8

Preliminary risk–benefit analysis of ropivacaine in labour and following surgery. Cederholm I. **Drug Saf** 1997 Jun; 16(6):391–402 (60 ref.)

Ropivacaine—a new local anesthetic. **Med Lett Drugs Ther** 1997 Aug 15;39(1007):80

Hydration effects on the duplex stability of phosphoramidate DNA–RNA oligomers. Barsky D, et al. **Nucleic Acids Res** 1997 Feb 15;25(4):830–5

[Ropivacaine for spinal anesthesia. A dose-finding study] Wahedi W, et al. **Anaesthesist** 1996 Aug;45(8):737–44 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Epidural ropivacaine 0.2% infusion for postoperative pain relief [letter] Watts DW. **Anaesth Intensive Care** 1997 Apr; 25(2):200–1

Continuous epidural ropivacaine 0.2% for analgesia after lower abdominal surgery. Etches RC, et al. **Anesth Analg** 1997 Apr;84(4):784–90

Continuous extradural infusion of ropivacaine 2 mg ml–1 for pain relief during labour. Benhamou D, et al. **Br J Anaesth** 1997 Jun;78(6):748–50

Double-blind comparison of epidural ropivacaine 0.25% and bupivacaine 0.25%, for the relief of childbirth pain. Muir HA, et al. **Can J Anaesth** 1997 Jun;44(6):599–604

Preoperative local infiltration with ropivacaine for postoperative pain relief after inguinal hernia repair. A randomised controlled trial. Johansson B, et al. **Eur J Surg** 1997 May;163(5):371–8

ADVERSE EFFECTS

Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Knudsen K, et al. **Br J Anaesth** 1997 May;78(5):507–14

ANALYSIS

Effect of aging on the amide group of bone matrix, measured by FTIR spectrophotometry, in adult subjects deceased as a result of violent death. Very JM, et al. **Calcif Tissue Int** 1997 Mar;60(3):271–5

Analysis of heparin-like pharmaceuticals by capillary zone electrophoresis and isotachophoresis. Mala Z, et al. **Electrophoresis** 1996 Jan;17(1):125–9

Validation of a capillary electrophoresis method for the enantiomeric purity testing of ropivacaine, a new local anaesthetic compound. Sänger-van de Griend CE, et al. **J Pharm Biomed Anal** 1996 Jan;14(3):295–304

A chiral capillary electrophoresis method for ropivacaine hydrochloride in pharmaceutical formulations: validation and comparison with chiral liquid chromatography. Sänger-van de Griend CE, et al. **J Pharm Biomed Anal** 1997 May;15(8):1051–61

BLOOD

Direct injection of large volumes of plasma in a column-switching system for the analysis of local anaesthetics. I. Optimization of semi-permeable surface precolumns in the system and characterization of some interference peaks. Yu Z, et al. **J Chromatogr A** 1996 Feb 19;725(1):137–47

Direct injection of large volumes of plasma in a column-switching system for the analysis of local anaesthetics. II. Determination of bupivacaine in human plasma with an alkyldiol silica precolumn. Yu Z, et al. **J Chromatogr A** 1996 Feb 19;725(1):149–55

CHEMICAL SYNTHESIS

Synthesis of some 2-arylpropionic acid amides as prodrugs. Akgün H, et al. **Arzneimittelforschung** 1996 Sep;46(9):891–4

Synthesis and evaluation of antitumor activity of arylamides and cyclohexylamides of isomeric 3-chloro-4-(2-chloroethylthio)butanoic- and 4-chloro-3-(2-chloroethylthio)butanoic acids. Vektarienė A, et al. **Arzneimittelforschung** 1997 Feb;47(2):217–22

Synthesis of indole-N-propionitrile, N-propionic acid and N-propionamide derivatives of potential biological activity. El-Desokey SI, et al. **Boll Chim Farm** 1996 Jan; 135(1):24–30

Synthesis of glycolipids containing disaccharides and two longer alkyl chains and their applications as enzyme modifiers. Zhang Z, et al. **Carbohydr Res** 1996 Oct 4; 292:47–59

Synthesis and nematocidal activity of aralkyl- and aralkenylamides related to piperamide on second-stage larvae of Toxocara canis. Kiuchi F, et al. **Chem Pharm Bull (Tokyo)** 1997 Apr;45(4):685–96

Benzoxazines. II. Synthesis, conformational analysis, and structure—activity relationships of 3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide derivatives as potent and long-acting serotonin-3 (5-HT3) receptor antagonists. Kuroita T, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2051–60

Meso-2,3-dimercaptosuccinic acid mono-N-alkylamides: syntheses and biological activity as novel in vivo cadmium mobilizing agents. Singh PK, et al. **Chem Res Toxicol** 1996 Sep;9(6):965–9

Synthesis of amides with anti-inflammatory and analgesic activities. Pau A, et al. **Farmaco** 1997 Feb;52(2):93–8

Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity. Devadas B, et al. **J Med Chem** 1997 Aug 1;40(16):2609–25

N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists. Elworthy TR, et al. **J Med Chem** 1997 Aug 15;40(17):2674–87

(1 alpha, 2 beta, 3 beta, 4 alpha)-1,2-bis[N-propyl-N-(4-phenoxybenzyl) amino]carbonyl]cyclobutane-3,4-dicarboxylic acid (A-87049): a novel potent squalene synthase inhibitor. Fung AK, et al. **J Med Chem** 1997 Jul 4;40(14):2123–5

Alkyl-substituted amino acid amides and analogous di- and triamines: new non-peptide G protein activators. Leschke C, et al. **J Med Chem** 1997 Sep 12;40(19):3130–9

Synthesis of some 2,6-bis(alkylthio)-4-pyridine carboxamides and carboxthioamides and their antimycobacterial and antialgal activity. Miletín M, et al. **Pharmazie** 1997 Jul; 52(7):558–60

In vitro alkylating of alpha, beta-unsaturated amidoesters, diethyl pyridylmethylphosphonates and their cis-Pt(II)complexes. Najman-Bronzewska L, et al. **Pharmazie** 1997 Mar;52(3):198–202

CHEMISTRY

DNA minor groove cleaving agents: synthesis, binding and strand cleaving properties of anthraquinone-oligopyrrolecarboxamide hybrids. Helissey P, et al. **Anticancer Drug Des** 1996 Oct;11(7):527–51

Amide backbone and water-related H/D isotope effects on the dynamics of a protein folding reaction. Parker MJ, et al. **Biochemistry** 1997 May 13;36(19):5786–94

Alkylsyringamides, new inducers of Agrobacterium tumefaciens virulence genes. Dyé F, et al. **Biochimie** 1997; 79(1):3–6

Siderophore activity of chemically synthesized dihydroxybenzoyl derivatives of spermidines and cystamide. Reissbrodt R, et al. **Biometals** 1997 Apr; 10(2):95–103

Synthesis of 2"-oxidized derivatives of 5-deoxy-5-epi-5-fluoro-dibekacin and -arbekacin, and study on structure-chemical shift relationships of urethane(or amide)-type NH protons in synthetic intermediates. Kobayashi Y, et al. **Carbohydr Res** 1997 Mar 13;298(4):261–77

Synthesis of novel succinamide derivatives having the 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one skeleton as potent and selective M2 muscarinic receptor antagonists. I. Watanabe T, et al. **Chem Pharm Bull (Tokyo)** 1997 Jun;45(6):996–1007

Sequence-selective intercalation of antitumour bis-naphthalimides into DNA. Evidence for an approach via the major groove. Bailly C, et al. **Eur J Biochem** 1996 Aug 15;240(1):195–208

New ligands binding to the human leukocyte antigen class II molecule DRB1*0101 based on the activity pattern of an undecapeptide library. Fleckenstein B, et al. **Eur J Biochem** 1996 Aug 15;240(1):71–7

Comparison of the amide proton exchange behavior of the rapidly formed folding intermediate and the native state of an antibody scFv fragment. Freund C, et al. **FEBS Lett** 1997 Apr 21;407(1):42–6

Several polyhydroxymonoamide renin inhibitors assume similar conformations in the unbound and renin-bound states. Laplante SR, et al. **Int J Pept Protein Res** 1996 Nov; 48(5):401–10

EI-1511-3, -5 and EI-1625-2, novel interleukin-1 beta converting enzyme inhibitors produced by Streptomyces sp. E-1511 and E-1625. II. Structure determination. Uosaki Y, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1079–84

Studies on the desamidation of bovine collagen. Radhika M, et al. **J Biomed Mater Res** 1997 Jun 15;35(4):497–503

Molecular dynamics simulations of peptides from BPTI: a closer look at amide-aromatic interactions. van der Spoel D, et al. **J Biomol NMR** 1996 Oct;8(3):229–38

Selectivity of alkylamide bonded-phases with respect to organic acids under reversed-phase conditions. Czajkowska T, et al. **J Chromatogr A** 1997 Feb 21; 762(1-2):147–58

Measurement of amide 15N-1H one-bond couplings in proteins using accordion heteronuclear-shift-correlation experiments. Tolman JR, et al. **J Magn Reson B** 1996 Sep; 112(3):269–74

A quantitative J-correlation experiment for the accurate measurement of one-bond amide 15N-1H couplings in proteins. Tolman JR, et al. **J Magn Reson B** 1996 Sep; 112(3):245–52

Effect of alkyl substitution at the amide nitrogen on amide bond cleavage: electrospray ionization/surface-induced dissociation fragmentation of substance P and two alkylated analogs. Nair H, et al. **J Mass Spectrom** 1996 Oct; 31(10):1141–8

Probing the non-covalent structure of proteins by amide hydrogen exchange and mass spectrometry. Smith DL, et al. **J Mass Spectrom** 1997 Feb;32(2):135–46

Novel indole-2-carboxamide and cycloalkeno[1,2-b]indole derivatives. Structure-activity relationships for high inhibition of human LDL peroxidation. Kuehm-Caubere C, et al. **J Med Chem** 1997 Apr 11;40(8):1201–10

Conformationally constrained [p-(omega-aminoalkyl)phenacetyl]-L-seryl-L-lysyl dipeptide amides as potent peptidomimetic inhibitors of Candida albicans and human myristoyl-CoA:protein N-myristoyl transferase. Nagarajan SR, et al. **J Med Chem** 1997 May 9;40(10):1422–38

N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region. Ohnmacht CJ, et al. **J Med Chem** 1996 Nov 8;39(23):4592–601

Amide hydrogen exchange and internal dynamics in the chemotactic protein CheY from Escherichia coli. Lacroix E, et al. **J Mol Biol** 1997 Aug 22;271(3):472–87

Antioxidative activity of barley hordein and its loss by deamidation. Chiue H, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Feb;43(1):145–54

Thermodynamic analysis of the effect of selective monodeamidation at asparagine 67 in ribonuclease A. Catanzano F, et al. **Protein Sci** 1997 Aug;6(8):1682–93

Strategy to design peptide inhibitors: structure of a complex of proteinase K with a designed octapeptide inhibitor N-Ac-Pro-Ala-Pro-Phe-DAla-Ala-Ala-Ala-NH2 at 2.5 A resolution. Saxena AK, et al. **Protein Sci** 1996 Dec; 5(12):2453–8

Thermal-induced unfolding domains in aldolase identified by amide hydrogen exchange and mass spectrometry. Zhang Z, et al. **Protein Sci** 1996 Jul;5(7):1282–9

ISOLATION & PURIFICATION

Enantiomeric resolution by HPLC of axial chiral amides using amylose tris[(S)-1-phenylethylcarbamate]. Cass QB, et al. **Chirality** 1997;9(2):109–12

EI-1511-3, -5 and EI-1625-2, novel interleukin-1 beta converting enzyme inhibitors produced by Streptomyces sp. E-1511 and E-1625. I. Taxonomy of producing strain, fermentation and isolation. Tanaka T, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1073–8

Bioactive amides from Glycosmis species. Greger H, et al. **J Nat Prod** 1996 Dec;59(12):1163–8

Cytotoxic amides from the octocoral Telesto riisei. Liyanage GK, et al. **J Nat Prod** 1996 Feb;59(2):148–51

Epopromycins, novel cell wall synthesis inhibitors of plant protoplast produced by Streptomyces sp. NK04000. Tsuchiya K, et al. **Jpn J Antibiot** 1997 Mar;50(3):261–3

Xylaramide, a new antifungal compound, and other secondary metabolites from Xylaria longipes. Schneider G, et al. **Z Naturforsch [C]** 1996 Nov-Dec;51(11-12):802–6

METABOLISM

Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Ekström G, et al. **Drug Metab Dispos** 1996 Sep;24(9):955–61

Metabolism and excretion of ropivacaine in humans. Halldin MM, et al. **Drug Metab Dispos** 1996 Sep;24(9):962–8

Dioxygenation of N-linoleoyl amides by soybean lipoxygenase-1. van der Stelt M, et al. **FEBS Lett** 1997

Jul 14;411(2-3):287-90

Amide metabolism: a putative ABC transporter in Rhodococcus sp. R312. Chebrou H, et al. **Gene** 1996 Dec 5;182(1-2):215-8

Pyruvate-extended amino acid derivatives as highly potent inhibitors of carboxyl-terminal peptide amidation. Mounier CE, et al. **J Biol Chem** 1997 Feb 21;272(8):5016-23

Towards the automatic design of synthetically accessible protein ligands: peptides, amides and peptidomimetics. Böhm HJ. **J Comput Aided Mol Des** 1996 Aug;10(4):265-72

Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. Sheskin T, et al. **J Med Chem** 1997 Feb 28;40(5):659-67

Permeability and reflection coefficients of urea and small amides in the human red cell. Toon MR, et al. **J Membr Biol** 1996 Sep;153(2):137-46

Reduction in the amide hydrogen exchange rates of an anti-lysozyme Fv fragment due to formation of the Fv-lysozyme complex. Williams DC Jr, et al. **J Mol Biol** 1997 Aug 1;270(5):751-62

Neuropeptide amidation in Drosophila: separate genes encode the two enzymes catalyzing amidation. Kolhekar AS, et al. **J Neurosci** 1997 Feb 15;17(4):1363-76

Epidermal aminopeptidase activity and metabolism as observed in an organized HaCaT cell sheet model. Steinsträsser I, et al. **J Pharm Sci** 1997 Mar;86(3):378-83

Involvement of vulnibactin and exocellular protease in utilization of transferrin- and lactoferrin-bound iron by Vibrio vulnificus. Okujo N, et al. **Microbiol Immunol** 1996; 40(8):595-8

Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Cravatt BF, et al. **Nature** 1996 Nov 7;384(6604):83-7

RNase H-independent antisense activity of oligonucleotide N3 '-> P5 ' phosphoramidates. Heidenreich O, et al. **Nucleic Acids Res** 1997 Feb 15;25(4):776-80

PHARMACOKINETICS

Ropivacaine gel in active distal ulcerative colitis and proctitis -- a pharmacokinetic and exploratory clinical study. Arlander E, et al. **Aliment Pharmacol Ther** 1996 Feb; 10(1):73-81

Comparative pharmacokinetics of ropivacaine and bupivacaine in nonpregnant and pregnant ewes. Santos AC, et al. **Anesth Analg** 1997 Jul;85(1):87-93

Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Barel S, et al. **Clin Pharmacol Ther** 1997 Apr;61(4):442-9

Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. Blotnik S, et al. **Drug Metab Dispos** 1996 May;24(5):560-4

Metabolism and excretion of ropivacaine in humans. Halldin MM, et al. **Drug Metab Dispos** 1996 Sep;24(9):962-8

Pharmacokinetics and safety of single oral doses of VX-366 (isobutyramide) in healthy volunteers. Brettman LR, et al. **J Clin Pharmacol** 1996 Jul;36(7):617-22

Intraindividual and interindividual variability in the disposition of the local anesthetic ropivacaine in healthy subjects. Emanuelsson BM, et al. **Ther Drug Monit** 1997 Apr;19(2):126-31

PHARMACOLOGY

The effects of topical and intravenous ropivacaine on canine pial microcirculation. Ishiyama T, et al. **Anesth Analg** 1997 Jul;85(1):75-81

The effects of bupivacaine and ropivacaine on baroreflex sensitivity with or without respiratory acidosis and alkalosis in rats. Watanabe Y, et al. **Anesth Analg** 1997 Feb; 84(2):398-404

Direct effects of ropivacaine and bupivacaine on spinal pial vessels in canine. Assessment with closed spinal window technique. Iida H, et al. **Anesthesiology** 1997 Jul;87(1):75-81

Effects of ropivacaine on a potassium channel (hKv1.5) cloned from human ventricle. Valenzuela C, et al. **Anesthesiology** 1997 Mar;86(3):718-28

Research on heterocyclic compounds. XXXVIII. Synthesis and pharmacological activity of imidazo[1,2-b]pyridazine-2-carboxylic derivatives. Luraschi E, et al. **Farmaco** 1997 Apr;52(4):213-7

Bcl-2 antagonizes apoptotic cell death induced by two new ceramide analogues. Wieder T, et al. **FEBS Lett** 1997 Jul 14;411(2-3):260-4

EI-1511-3, -5 and EI-1625-2, novel interleukin-1 beta converting enzyme inhibitors produced by Streptomyces sp. E-1511 and E-1625. III. Biochemical properties of EI-1511-3, -5 and EI-1625-2. Tanaka T, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1085-90

Neuroprotective properties of the benzodiazepine receptor, partial agonist PNU-101017 in the gerbil forebrain ischemia model. Hall ED, et al. **J Cereb Blood Flow Metab** 1997 Aug;17(8):875-83

Amide cross-linking: an alternative to glutaraldehyde fixation. Girardot JM, et al. **J Heart Valve Dis** 1996 Sep; 5(5):518-25

Modulation of ATP-sensitive and large-conductance Ca++-activated K+ channels by Zeneca ZD6169 in guinea pig bladder smooth muscle cells. Hu S, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):38-45

Non-steroidal L-245,976 acts as a classical antiandrogen in vitro. Toney JH, et al. **J Steroid Biochem Mol Biol** 1997 Jan;60(1-2):131-6

An outer-membrane porin inducible by short-chain amides and urea in the methylotrophic bacterium Methylophilus methylotrophus. Mills J, et al. **Microbiology** 1997 Jul;143 (Pt 7):2373-9

Comparative effects of intravesical versus extravesical administration of ZD6169 and cromakalim on the response of the in vitro rat whole bladder to field stimulation. Chun A, et al. **Pharmacology** 1996 Jun;52(6):347-52

Zeneca ZD6169 activates ATP-sensitive K+ channels in the urinary bladder of the guinea pig. Heppner TJ, et al. **Pharmacology** 1996 Sep;53(3):170-9

Antinociceptive and motor-blocking efficacy of ropivacaine and bupivacaine after epidural administration in the dog. Feldman HS, et al. **Reg Anesth** 1996 Jul-Aug;21(4):318-26

The effect of continuous lumbar epidural infusion of ropivacaine (0.1%, 0.2%, and 0.3%) and 0.25% bupivacaine on sensory and motor block in volunteers: a double-blind study. Zaric D, et al. **Reg Anesth** 1996 Jan-Feb;21(1):14-25

POISONING

Hepatotoxicity of N, N-dimethylformamide (DMF) in acute poisoning with the veterinary euthanasia drug T-61. Buylaert W, et al. **Hum Exp Toxicol** 1996 Aug;15(8):607-11

THERAPEUTIC USE

Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. An Z, et al. **Clin Exp Metastasis** 1997 Mar;15(2):184-95

Ropivacaine. A review of its pharmacology and therapeutic use in regional anaesthesia. Markham A, et al. **Drugs** 1996 Sep;52(3):429-49 (90 ref.)

TOXICITY

Cytotoxic amides from the octocoral Telesto riisei. Liyanage GK, et al. **J Nat Prod** 1996 Feb;59(2):148-51

Analysis of structure-toxicity relationships for a series of amide herbicides using statistical methods and neural network. Zakarya D, et al. **SAR QSAR Environ Res** 1996; 5(4):269-79

AMIDINES

Persistent neuronal labeling by retrograde fluorescent tracers: a comparison between Fast Blue, Fluoro-Gold and various dextran conjugates. Novikova L, et al. **J Neurosci Methods** 1997 Jun 6;74(1):9-15

ADMINISTRATION & DOSAGE

Estimates of the convergence of association projections from area 17 to rostral area 18 in the cat depend on injection site size. Price DJ, et al. **Neurosci Lett** 1996 Jan 19; 203(2):93-6

ANALYSIS

Column-switching high-performance liquid chromatography combined with ionspray tandem mass spectrometry for the simultaneous determination of the platelet inhibitor Ro 44-3888 and its pro-drug and precursor metabolite in plasma. Zell M, et al. **J Mass Spectrom** 1997 Jan;32(1):23-32

BLOOD

Automated quantitative determination of a new polyamine biosynthesis inhibitor (CGP 48 664) and a potential metabolite in human and animal plasma by high-performance liquid chromatography. Degen PH, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):339-45

CHEMICAL SYNTHESIS

Synthesis and assessment of formamidines as new histamine H2-receptor antagonists. Anglada L, et al. **Arzneimittelforschung** 1997 Apr;47(4A):431-4

Synthesis and antimicrobial activity of N-(1,2-benzisothiazol-3-yl)amidines. Vicini P, et al. **Farmaco** 1997 Jan;52(1):21-4

CHEMISTRY

Synthesis and biochemical activity of novel amidine derivatives as m1 muscarinic receptor agonists. Ojo B, et al. **Bioorg Med Chem** 1996 Oct;4(10):1605-15

Novel histamine H3 receptor antagonists: synthesis and evaluation of formamidine and S-methylisothiourea derivatives. Goto T, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb;45(2):305-11

METABOLISM

Initiation of LDL oxidation by copper ions or AAPH yields different kinetic parameters which are correlated [letter] Leonhardt W, et al. **Clin Chim Acta** 1997 Mar 18; 259(1-2):195-7

A novel assay for drug-DNA binding mode, affinity, and exclusion number: scanning force microscopy. Coury JE, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12283-6

PHARMACOLOGY

Inhibitory effect of estrogens on the oxidative hemolysis induced by 2-amidinopropane hydrochloride, a free radical generator. Vibert-Li JL, et al. **Acta Med Okayama** 1996 Jun;50(3):125-30

Inhibition of polyamine synthesis influences contractility of intestinal smooth muscle in culture. Swärd K, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C77-84

F1F0-ATPase, early target of the radical initiator 2,2'-azobis-(2-amidinopropane) dihydrochloride in rat liver mitochondria in vitro. Beauseigneur F, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):571-6

CGP 48664, a potent and specific S-adenosylmethionine decarboxylase inhibitor: effects on regulation and stability of the enzyme. Svensson F, et al. **Biochem J** 1997 Feb 15; 322 (Pt 1):297-302

4-Amidinoindan-1-one 2'-amidinohydrazone (CGP 48664A) exerts in vitro growth inhibitory effects that are not only related to S-adenosylmethionine decarboxylase (SAMdc) inhibition. Dorhout B, et al. **Biochim Biophys Acta** 1997 Apr 17;1335(1-2):144-52

Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Thomsen LL, et al. **Cancer Res** 1997 Aug 1; 57(15):3300-4

Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Xing RH, et al. **Cancer Res** 1997 Aug 15;57(16):3585-93

Synthesis and antiparasitic activities of amidinic azolated derivatives. Danan A, et al. **Farmaco** 1997 Apr;52(4):227-9

1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. Garvey EP, et al. **J Biol Chem** 1997 Feb 21;272(8):4959-63

ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. Zhang ZG, et al. **J Cereb Blood Flow Metab** 1996 Jul;16(4):599-604

Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein. Halvorsen B, et al. **J Lipid Res** 1996 Jul;37(7):1591-600

The effect of methyl linoleate hydroperoxides and radical initiator 2,2'-azobis (2-amidinopropane) dihydrochloride on antibody production by mouse spleen cells. Oarada M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Jun;43(3):377-85

THERAPEUTIC USE

Observations with an S-adenosylmethionine decarboxylase inhibitor in rats with prostatic adenocarcinoma. Seiler N, et al. **Arzneimittelforschung** 1996 Mar;46(3):311-5

AMIDINOTRANSFERASES

Recombinant expression and isolation of human L-arginine:glycine amidinotransferase and identification of its active-site cysteine residue. Humm A, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):771-6

CHEMISTRY

Structure and reaction mechanism of L-arginine:glycine amidinotransferase. Humm A, et al. **Biol Chem** 1997 Mar-Apr;378(3-4):193-7 (43 ref.)

Crystal structure and mechanism of human L-arginine:glycine amidinotransferase: a mitochondrial enzyme involved in creatine biosynthesis. Humm A, et al. **EMBO J** 1997 Jun;16(12):3373-85

Substrate binding and catalysis by L-arginine:glycine amidinotransferase--a mutagenesis and crystallographic study. Fritsche E, et al. **Eur J Biochem** 1997 Jul 15; 247(2):483-90

METABOLISM

Structure and reaction mechanism of L-arginine:glycine amidinotransferase. Humm A, et al. **Biol Chem** 1997 Mar-Apr;378(3-4):193-7 (43 ref.)

Substrate binding and catalysis by L-arginine:glycine amidinotransferase--a mutagenesis and crystallographic study. Fritsche E, et al. **Eur J Biochem** 1997 Jul 15; 247(2):483-90

AMIDO BLACK

Application of a combination of neutral red and amido black staining for rapid, reliable cytotoxicity testing of biomaterials. Ciapetti G, et al. **Biomaterials** 1996 Jul; 17(13):1259-64

Is 570 nm the wavelength of choice for scanning protein agarose electrophoresis plates stained with amidoschwarz? [letter] Izquierdo JM, et al. **Eur J Clin Chem Clin Biochem** 1997 May;35(5):397

CHEMISTRY

Sensitivity and applications of the nondenaturing staining of proteins on polyvinylidene difluoride membranes with Amido black 10B in water followed by destaining in water. Gentile F, et al. **Anal Biochem** 1997 Feb 15;245(2):260-2

A simple assay for quantification of protein in tissue sections, cell cultures, and cell homogenates, and of protein immobilized on solid surfaces. Dieckmann-Schuppert A, et al. **Cell Tissue Res** 1997 Apr;288(1):119-26

AMIDOHYDROLASES

The hog intestinal mucosa acylase I: subcellular localization, isolation, kinetic studies and biological function. Giardina T, et al. **Biochimie** 1997 May;79(5):265–73

ANALYSIS

[14C]ceramide synthesis by sphingolipid ceramide N-deacylase: new assay for ceramidase activity detection. Mitsutake S, et al. **Anal Biochem** 1997 Apr 5;247(1):52–7

Visualisation of hippuricase activity on native polyacrylamide gels. McCleave MJ, et al. **Biochem Soc Trans** 1997 Feb; 25(1):143S

In situ assay of acid sphingomyelinase and ceramidase based on LDL-mediated lysosomal targeting of ceramide-labeled sphingomyelin. Levade T, et al. **J Lipid Res** 1996 Dec; 37(12):2525–38

Determination of biotinidase activity with biotinyl-6-aminoquinoline as substrate. Hayakawa K, et al. **Methods Enzymol** 1997;279:435–42 (24 ref.)

Preparation of bifluorescent-labeled glycopeptides for glycoamidase assay. Lee KB, et al. **Methods Enzymol** 1997; 278:512–9

ANTAGONISTS & INHIBITORS

Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. De Petrocellis L, et al. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):82–8

Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Deutsch DG, et al. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):217–21

Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Deutsch DG, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):255–60

Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Watanabe K, et al. **Biol Pharm Bull** 1996 Aug;19(8):1109–11

Acephate insecticide toxicity: safety conferred by inhibition of the bioactivating carboxyamidase by the metabolite methamidophos. Mahajna M, et al. **Chem Res Toxicol** 1997 Jan;10(1):64–9

Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one. Beltramo M, et al. **FEBS Lett** 1997 Feb 24;403(3):263–7

Inhibitors of anandamide breakdown. Deutsch DG, et al. **NIDA Res Monogr** 1997;173:65–84 (39 ref.)

Antibacterial agents that inhibit lipid A biosynthesis [see comments] Onishi HR, et al. **Science** 1996 Nov 8; 274(5289):980–2. Comment in: Science 1996 Nov 8;274(5289):939–40.

Lipid A: target for antibacterial drugs [comment] Vaara M. **Science** 1996 Nov 8;274(5289):939–40 (12 ref.). Comment on: Science 1996 Nov 8;274(5289):980–2.

BIOSYNTHESIS

Induction of creatininase activity in chronic renal failure: timing of creatinine degradation and effect of antibiotics. Dunn SR, et al. **Am J Kidney Dis** 1997 Jan;29(1):72–7

Characterization of a salicylic acid–insensitive mutant (sai1) of Arabidopsis thaliana, identified in a selective screen utilizing the SA-inducible expression of the tms2 gene. Shah J, et al. **Mol Plant Microbe Interact** 1997 Jan; 10(1):69–78

Overproduction of D-aminoacylase from Alcaligenes xylosoxydans subsp. xylosoxydans A-6 in Escherichia coli and its purification. Wakayama M, et al. **Protein Expr Purif** 1996 Jun;7(4):395–9

BLOOD

Biotin reagents for antibody pretargeting. Synthesis, radioiodination, and in vitro evaluation of water soluble, biotinidase resistant biotin derivatives. Wilbur DS, et al. **Bioconjug Chem** 1997 Jul–Aug;8(4):572–84

Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics [letter; comment] [see comments] Fujiwara Y, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):260–2. Comment on: J Natl Cancer Inst 1995 Apr 19;87(8):573–80. Comment in: J Natl Cancer Inst 1997 Jul 2;89(13):968–70.

Determination of serum biotinidase activity with radioiodinated biotinylamide analogs. Livaniou E, et al. **Methods Enzymol** 1997;279:442–51 (13 ref.)

CHEMISTRY

Cloning and overexpression of thermostable D-hydantoinase from thermophile in E. coli and its application to the synthesis of optically active D-amino acids. Lee DC, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:401–5

Ion binding induces closed conformation in Pseudomonas 7A glutaminase-asparaginase (PGA): crystal structure of the PGA-SO4(2-)-NH4+ complex at 1.7 A resolution. Jakob CG, et al. **Biochemistry** 1997 Jan 28;36(4):923–31

Study of the amidase signature group. Chebrou H, et al. **Biochim Biophys Acta** 1996 Dec 5;1298(2):285–93

Alkaline unfolding and salt-induced folding of aminoacylase at high pH. Huang MQ, et al. **Enzyme Protein** 1994–95; 48(4):229–37

Molecular characterisation of formamidase from Methylophilus methylotrophus. Wyborn NR, et al. **Eur J Biochem** 1996 Sep 1;240(2):314–22

Comparison of inactivation and conformational changes of aminoacylase during denaturation in lithium dodecylsulphate solutions. He B, et al. **Int J Biol Macromol** 1997 Feb;20(1):53–62

Domain structure of rat 10-formyltetrahydrofolate dehydrogenase. Resolution of the amino-terminal domain as 10-formyltetrahydrofolate hydrolase. Krupenko SA, et al. **J Biol Chem** 1997 Apr 11;272(15):10273–8

Inactivation and conformational changes of aminoacylase in trifluoroethanol solutions. Zhang YX, et al. **J Protein Chem** 1996 Oct;15(7):631–7

Molecular characterization of human and mouse fatty acid amide hydrolases. Giang DK, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2238–42

An evolutionary treasure: unification of a broad set of amidohydrolases related to urease. Holm L, et al. **Proteins** 1997 May;28(1):72–82

DEFICIENCY

Mutation (Q456H) is the most common cause of profound biotinidase deficiency in children ascertained by newborn screening in the United States. Norrgard KJ, et al. **Biochem Mol Med** 1997 Jun;61(1):22–7

Profound biotinidase deficiency caused by a point mutation that creates a downstream cryptic 3' splice acceptor site within an exon of the human biotinidase gene. Pomponio RJ, et al. **Hum Mol Genet** 1997 May;6(5):739–45

Deletion/insertion mutation that causes biotinidase deficiency may result from the formation of a quasipalindromic structure. Pomponio RJ, et al. **Hum Mol Genet** 1996 Oct; 5(10):1657–61

Dihydropyrimidinase deficiency, a progressive neurological disorder? Putman CW, et al. **Neuropediatrics** 1997 Apr; 28(2):106–10

GENETICS

Identification, cloning, and expression of the Escherichia coli pyrazinamidase and nicotinamidase gene, pncA. Frothingham R, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1426–31

Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Sreevatsan S, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):636–40

Two amino acid amidohydrolase genes encoding L-stereospecific carbamoylase and aminoacylase are organized in a common operon in Bacillus stearothermophilus. Batisse N, et al. **Appl Environ Microbiol** 1997 Feb;63(2):763–6

Mutation (Q456H) is the most common cause of profound biotinidase deficiency in children ascertained by newborn screening in the United States. Norrgard KJ, et al. **Biochem Mol Med** 1997 Jun;61(1):22–7

Localization of an open reading frame with homology to human aspartoacylase upstream from psbA in the prokaryote Prochlorococcus marinus CCMP 1375. Hess WR. **DNA Seq** 1997;7(5):301–6

Transcription antitermination regulation of the Pseudomonas aeruginosa amidase operon. Wilson SA, et al. **EMBO J** 1996 Nov 1;15(21):5907–16

A novel amidohydrolase gene from Bacillus subtilis cloning: DNA-sequence analysis and map position of amhX. Kempf B, et al. **FEMS Microbiol Lett** 1996 Aug 1;141(2-3):129–37

Amide metabolism: a putative ABC transporter in Rhodococcus sp. R312. Chebrou H, et al. **Gene** 1996 Dec 5;182(1-2):215–8

A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Hamajima N, et al. **Gene** 1996 Nov 21; 180(1-2):157–63

Genomic organization of the human heparan sulfate-N-deacetylase/N-sulfotransferase gene: exclusion from a causative role in the pathogenesis of Treacher Collins syndrome. Gladwin AJ, et al. **Genomics** 1996 Mar 15;32(3):471–3

Arg538 to Cys mutation in a CpG dinucleotide of the human biotinidase gene is the second most common cause of profound biotinidase deficiency in symptomatic children. Pomponio RJ, et al. **Hum Genet** 1997 Apr;99(4):506–12

Profound biotinidase deficiency caused by a point mutation that creates a downstream cryptic 3' splice acceptor site within an exon of the human biotinidase gene. Pomponio RJ, et al. **Hum Mol Genet** 1997 May;6(5):739–45

Cloning, expression, and purification of UDP-3-O-acyl-GlcNAc deacetylase from Pseudomonas aeruginosa: a metalloamidase of the lipid A biosynthesis pathway. Hyland SA, et al. **J Bacteriol** 1997 Mar; 179(6):2029–37

asmB, a suppressor locus for assembly-defective OmpF mutants of Escherichia coli, is allelic to envA (lpxC). Kloser AW, et al. **J Bacteriol** 1996 Sep;178(17):5138–43

A germination-specific spore cortex-lytic enzyme from Bacillus cereus spores: cloning and sequencing of the gene and molecular characterization of the enzyme. Moriyama R, et al. **J Bacteriol** 1996 Sep;178(17):5330–2

A gene (sleB) encoding a spore cortex-lytic enzyme from Bacillus subtilis and response of the enzyme to L-alanine-mediated germination. Moriyama R, et al. **J Bacteriol** 1996 Oct;178(20):6059–63

Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. Chen L, et al. **J Biol Chem** 1997 Sep 5; 272(36):22966–73

Two sporulation-specific chitin deacetylase-encoding genes are required for the ascospore wall rigidity of Saccharomyces cerevisiae. Christodoulidou A, et al. **J Biol Chem** 1996 Dec 6;271(49):31420–5

Expression cloning of PIG-L, a candidate N-acetylglucosaminyl-phosphatidylinositol deacetylase. Nakamura N, et al. **J Biol Chem** 1997 Jun 20; 272(25):15834–40

Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. Scorpio A, et al. **J Clin Microbiol** 1997 Jan;35(1):106–10

An outer-membrane porin inducible by short-chain amides and urea in the methylotrophic bacterium Methylophilus methylotrophus. Mills J, et al. **Microbiology** 1997 Jul;143 (Pt 7):2373–9

Regulation of the inducible acetamidase gene of Mycobacterium smegmatis. Parish T, et al. **Microbiology** 1997 Jul;143 (Pt 7):2267–76

Primary structure, sequence analysis, and expression of the thermostable D-hydantoinase from Bacillus stearothermophilus SD1. Kim GJ, et al. **Mol Gen Genet** 1997 Jun;255(2):152–6

Assembly of an active enzyme by the linkage of two protein modules. Nixon AE, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1069–73

The common nodABC genes of Rhizobium meliloti are host-range determinants. Roche P, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15305–10

An evolutionary treasure: unification of a broad set of amidohydrolases related to urease. Holm L, et al. **Proteins** 1997 May;28(1):72–82

Cloning and expression of two chitin deacetylase genes of Saccharomyces cerevisiae. Mishra C, et al. **Yeast** 1997 Mar 30;13(4):327–36

ISOLATION & PURIFICATION

Purification and characterization of thermostable D-hydantoinase from thermophilic Bacillus stearothermophilus SD-1. Lee SG, et al. **Appl Biochem Biotechnol** 1997 Feb-Mar;62(2-3):251–66

Purification and characterization of the D-hydantoinase from Bacillus circulans. Lukša V, et al. **Appl Biochem Biotechnol** 1997 Feb-Mar;62(2-3):219–31

N-acetylglucosamine-6-phosphate deacetylase from Escherichia coli: purification and molecular and kinetic characterization. Souza JM, et al. **Arch Biochem Biophys** 1997 Apr 15;340(2):338–46

A thermostable D-hydantoinase isolated from a mesophilic Bacillus sp.AR9. Sharma R, et al. **Biochem Biophys Res Commun** 1997 May 19;234(2):485–8

Purification and characterization of rhesus monkey liver amido hydrolases and their roles in the metabolic polymorphism for E6123, a platelet-activating factor receptor antagonist. Kusano K, et al. **Drug Metab Dispos** 1996 Nov;24(11):1186–91

Imidase, a dihydropyrimidinase-like enzyme involved in the metabolism of cyclic imides. Ogawa J, et al. **Eur J Biochem** 1997 Jan 15;243(1-2):322–7

Purification and properties of brain lipoamidase. Oizumi J, et al. **Methods Enzymol** 1997;279:202–10 (23 ref.)

Formyltetrahydrofolate hydrolase from Escherichia coli. Zalkin H. **Methods Enzymol** 1997;281:214–8

Overproduction of D-aminoacylase from Alcaligenes xylosoxydans subsp. xylosoxydans A-6 in Escherichia coli and its purification. Wakayama M, et al. **Protein Expr Purif** 1996 Jun;7(4):395–9

METABOLISM

[14C]ceramide synthesis by sphingolipid ceramide N-deacylase: new assay for ceramidase activity detection. Mitsutake S, et al. **Anal Biochem** 1997 Apr 5;247(1):52–7

Changes in sperm-bound amidase activity suggest subtle damage to ram sperm acrosomes by freezing/thawing, not detected by light microscopy. de las Heras MA, et al. **Anim Reprod Sci** 1996 Dec 2;45(1-2):81–9

Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase. Kurahashi Y, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):512–5

A thermostable D-hydantoinase isolated from a mesophilic Bacillus sp.AR9. Sharma R, et al. **Biochem Biophys Res Commun** 1997 May 19;234(2):485–8

Localization of human heparan glucosaminyl N-deacetylase/N-sulphotransferase to the trans-Golgi network. Humphries DE, et al. **Biochem J** 1997 Jul 15;325 (Pt 2):351–7

Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Katayama K, et al. **Biochim Biophys Acta** 1997 Aug 16;1347(2-3):212–8

Thermal resistance of pantetheine hydrolase. Pitari G, et al. **Biochim Biophys Acta** 1996 Nov 14;1298(1):31–6

Thermostable aminoacylase from Bacillus stearothermophilus: significance of the metal center for catalysis and protein stability. Weiss HM, et al. **Biol Chem Hoppe Seyler** 1995 Nov;376(11):643–9

N-acetylglucosamine kinase and N-acetylglucosamine 6-phosphate deacetylase in normal human erythrocytes and Plasmodium falciparum. Weidanz JA, et al.

Br J Haematol 1996 Dec;95(4):645–53
Biotinidase and its roles in biotin metabolism. Hymes J, et al. **Clin Chim Acta** 1996 Nov 15;255(1):1–11 (64 ref.)
Partial purification and characterization of a jasmonic acid conjugate cleaving amidohydrolase from the fungus Botryodiplodia theobromae. Hertel SC, et al. **FEBS Lett** 1997 Apr 21;407(1):105–10
The N-end rule pathway of protein degradation. Varshavsky A. **Genes Cells** 1997 Jan;2(1):13–28 (75 ref.)
Comparison of inactivation and conformational changes of aminoacylase during denaturation in lithium dodecylsulphate solutions. He B, et al. **Int J Biol Macromol** 1997 Feb;20(1):53–62
Kinetics of inhibition of aminoacylase activity by dithiothreitol or 2-mercaptoethanol. Yang Y, et al. **Int J Pept Protein Res** 1996 Dec;48(6):532–8
Cloning, expression, and purification of UDP-3-O-acyl-GlcNAc deacetylase from Pseudomonas aeruginosa: a metalloamidase of the lipid A biosynthesis pathway. Hyland SA, et al. **J Bacteriol** 1997 Mar; 179(6):2029–37
A mouse amidase specific for N-terminal asparagine. The gene, the enzyme, and their function in the N-end rule pathway. Grigoryev S, et al. **J Biol Chem** 1996 Nov 8; 271(45):28521–32
Bimodal regulation of ceramidase by interleukin-1beta. Implications for the regulation of cytochrome p450 2C11. Nikolova-Karakashian M, et al. **J Biol Chem** 1997 Jul 25; 272(30):18718–24
Regulation of UDP-3-O-[R-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase in Escherichia coli. The second enzymatic step of lipid a biosynthesis. Sorensen PG, et al. **J Biol Chem** 1996 Oct 18;271(42):25898–905
Transacylase-mediated alkylacyl-GPC synthesis and its hydrolysis by phospholipase D occur in separate cell compartments in the human neutrophil. Ribbes G, et al. **J Cell Biochem** 1996 Jul;62(1):56–68
High-performance liquid chromatographic determination of lipoamidase (lipoyl-X hydrolase) activity with a novel substrate, lipoyl-6-aminoquinoline. Yoshikawa K, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1–2):41–7
Abnormal expression of sphingomyelin acylase in atopic dermatitis: an etiologic factor for ceramide deficiency? Murata Y, et al. **J Invest Dermatol** 1996 Jun;106(6):1242–9
Crystallographic and fluorescence studies of ligand binding to N-carbamoylsarcosine amidohydrolase from Arthrobacter sp. Zajc A, et al. **J Mol Biol** 1996 Oct 25; 263(2):269–83
Inactivation and conformational changes of aminoacylase in trifluoroethanol solutions. Zhang YX, et al. **J Protein Chem** 1996 Oct;15(7):631–7
Biotinidase in serum and tissues. Hymes J, et al. **Methods Enzymol** 1997;279:422–34 (54 ref.)
Formyltetrahydrofolate hydrolase from Escherichia coli. Zalkin H. **Methods Enzymol** 1997;281:214–8
Metabolism of AF1 (KNEFIRF-NH2) in the nematode, Ascaris suum, by aminopeptidase, endopeptidase and deamidase enzymes. Sajid M, et al. **Mol Biochem Parasitol** 1996 Jan;75(2):159–68
Primary structure, sequence analysis, and expression of the thermostable D-hydantoinase from Bacillus stearothermophilus SD1. Kim GJ, et al. **Mol Gen Genet** 1997 Jun;255(2):152–6
The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. Paria BC, et al. **Mol Reprod Dev** 1996 Oct;45(2):183–92
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Cravatt BF, et al. **Nature** 1996 Nov 7;384(6604):83–7
Molecular characterization of human and mouse fatty acid amide hydrolases. Giang DK, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2238–42
Site-specific de-N-glycosylation of diglycosylated ovalbumin in hen oviduct by endogenous peptide: N-glycanase as a quality control system for newly synthesized proteins. Suzuki T, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6244–9

URINE

Urinary biotinidase and alanine excretion in patients with insulin-dependent diabetes mellitus. Terentyeva EA, et al. **Eur J Clin Chem Clin Biochem** 1997 Jan;35(1):21–4

AMIDOLACETATE see **METHADYL ACETATE**

AMIDONE see **METHADONE**

AMIDOPHENAZON see **AMINOPYRINE**

AMIDOPHOSPHORIBOSYLTRANSFERASE

[Amidophosphoribosyltransferase] Iwahana H, et al. **Nippon Rinsho** 1996 Dec;54(12):3202–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Mechanisms of inhibition of amido phosphoribosyltransferase from mouse L1210 leukemia cells. Schoettle SL, et al. **Biochemistry** 1997 May 27;36(21):6377–83

GENETICS

Role of NRF-1 in bidirectional transcription of the human GPAT-AIRC purine biosynthesis locus. Chen S, et al. **Nucleic Acids Res** 1997 May 1;25(9):1809–16

METABOLISM

Mechanism of the synergistic end-product regulation of Bacillus subtilis glutamine phosphoribosylpyrophosphate amidotransferase by nucleotides. Chen S, et al. **Biochemistry** 1997 Sep 2;36(35):10718–26
Coupled formation of an amidotransferase interdomain ammonia channel and a phosphoribosyltransferase active site. Krahn JM, et al. **Biochemistry** 1997 Sep 16; 36(37):11061–8

PHYSIOLOGY

Amidophosphoribosyltransferase limits the rate of cell growth-linked de novo purine biosynthesis in the presence of constant capacity of salvage purine biosynthesis. Yamaoka T, et al. **J Biol Chem** 1997 Jul 11; 272(28):17719–25

AMIDOTREZOATE see **DIATRIZOATE**

AMIFOSTINE

ADMINISTRATION & DOSAGE

Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Ramnath N, et al. **Am J Clin Oncol** 1997 Aug;20(4):368–72
Amifostine (Ethyol): dosing, administration and patient management guidelines. Bukowski RM. **Eur J Cancer** 1996; 32A Suppl 4:S46–9 (11 ref.)
Radioprotectors as late preventive agents against carbon tetrachloride induced liver necrosis: protection by 2-(3-aminopropylamino) ethylphosphorothioic acid (WR2721). Valles EG, et al. **Exp Mol Pathol** 1995 Oct; 63(2):101–9
Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. Tannehill SP, et al. **J Clin Oncol** 1997 Aug;15(8):2850–7
Advances in supportive therapy. Facchini T. **Zentralbl Gynakol** 1996;118(10):589–90
[Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy] Wrembel-Wargocka J, et al. **Przegl Lek** 1996;53(11):820–5 (15 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma. Korst AE, et al. **J Chromatogr B Biomed Appl** 1997 May 23; 693(1):167–74

CHEMISTRY

Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Savoye C, et al. **Int J Radiat Biol** 1997 Feb;71(2):193–202

PHARMACOKINETICS

Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. Korst AE, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):162–6
Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. van der Vijgh WJ, et al. **Eur J Cancer** 1996;32A Suppl 4:S26–30 (21 ref.)

PHARMACOLOGY

Amifostine for protection from antineoplastic drug toxicity. Foster-Nora JA, et al. **Am J Health Syst Pharm** 1997 Apr 1;54(7):787–800 (101 ref.)
Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. Dunn TA, et al. **Anticancer Drugs** 1996 Sep;7(7):795–9
Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Fichtner I, et al. **Anticancer Drugs** 1997 Feb;8(2):174–81
Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro. Fulda S, et al. **Anticancer Drugs** 1997 Jan;8(1):34–41
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. Korst AE, et al. **Br J Cancer** 1997;75(10):1439–46
Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro. Dorr RT, et al. **Eur J Cancer** 1996;32A Suppl 4:S21–5
The potential role of amifostine (Ethyol) in haematological malignancies. Gorin NC. **Eur J Cancer** 1996;32A Suppl 4:S31–9 (22 ref.)
The modulatory effect of aminothiols on the clastogenic activity of X-rays assayed by the vivo mouse micronucleus test. Mazur L. **Folia Biol (Krakow)** 1996;44(1–2):55–9
Anticlastogenic effect of S-2-(3-aminopropylamino) ethylphosphorothioic acid against X-rays in mice. Mazur L. **Physiol Res** 1996;45(1):59–63
[Binding of epirubicin to human plasma protein and erythrocytes: interaction with the cytoprotective amifostine] Pernkopf I, et al. **Pharmazie** 1996 Nov; 51(11):897–901 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin. Borsi JD, et al. **Anticancer Drugs** 1996 Jan;7(1):121–6
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Budd GT, et al. **Cancer** 1997 Sep 15;80(6):1134–40
Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma. Avilés A, et al. **Eur J Cancer** 1997 Jul;33(8):1323–5
Clinical effects of amifostine (Ethyol) in patients treated with carboplatin. Budd GT, et al. **Eur J Cancer** 1996;32A Suppl 4:S43–5 (8 ref.)
The need for cytoprotection. Bukowski RM. **Eur J Cancer** 1996;32A Suppl 4:S2–4 (27 ref.)
Current approaches in cytoprotection: the role of amifostine (Ethyol) in altering and ameliorating toxicities in cancer therapy. Bukowski RM. **Eur J Cancer** 1996;32A Suppl 4:S1
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Capizzi RL. **Eur J Cancer** 1996;32A Suppl 4:S5–16 (88 ref.)
Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol). Schuchter LM. **Eur J Cancer** 1996;32A Suppl 4:S40–2 (19 ref.)
[Amifostine: current and future applications in cytoprotection] Lenoble M. **Bull Cancer** 1996 Sep; 83(9):773–87 (48 ref.) (Eng. Abstr.) **(Fre)**
[The cytoprotective agent amifostine (WR-2721): current clinical use and trends in its development] Dragojević-Simić V, et al. **Vojnosanit Pregl** 1996 Jul–Aug; 53(4):305–10 (54 ref.) **(Scr)**

AMIKACIN

ADMINISTRATION & DOSAGE

Absorbable, delayed-release antibiotic beads reduce surgical wound infection. Galandiuk S, et al. **Am Surg** 1997 Sep; 63(9):831–5
Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient [see comments] Botha FJ, et al. **Intensive Care Med** 1996 May;22(5):443–6. Comment in: Intensive Care Med 1997 Feb;23(2):236–7.
Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model. Petersen EA, et al. **J Antimicrob Chemother** 1996 Nov; 38(5):819–28
Outpatient antimicrobial protocol for febrile neutropenia: a nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents. Sahu S, et al. **Pediatr Hematol Oncol** 1997 May-Jun;14(3):205–11
Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Charnas R, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):346–53
Liposomal amikacin for treatment of M. avium infections in clinically relevant experimental settings. Ehlers S, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):218–31

ADVERSE EFFECTS

Unusual hypokalaemia. Selvais PL, et al. **Acta Clin Belg** 1996; 51(5):357–9
Macula toxicity after intravitreal amikacin. Seawright AA, et al. **Aust N Z J Ophthalmol** 1996 May;24(2):143–6

ANTAGONISTS & INHIBITORS

Attenuation of aminoglycoside ototoxicity by glutathione. Nishida I, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Mar-Apr;58(2):68–73

BLOOD

Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin.lesassays@ukneqasaa.win-uk.net. White LO, et al. **J Antimicrob Chemother** 1997 Mar;39(3):355–61
Determination of amikacin in human plasma by high-performance capillary electrophoresis with fluorescence detection. Oguri S, et al. **J Chromatogr B Biomed Appl** 1996 Nov 15;686(2):205–10

CHEMISTRY

Stability and antimicrobial activity of gentamicin sulfate, tobramycin sulfate and amikacin sulfate in polypropylene

syringes for use in once-daily aminoglycoside therapy. Mitrzyk B, et al. **Am J Health Syst Pharm** 1996 Dec 1; 53(23):2855-9

PHARMACOKINETICS

Aminoglycoside levels in the rabbit vitreous cavity after intravenous administration [see comments] el-Massry A, et al. **Am J Ophthalmol** 1996 Nov;122(5):684-9. Comment in: Am J Ophthalmol 1996 Nov;122(5):724-6.

Population pharmacokinetics of amikacin in critically ill patients. Bressolle F, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1682-9

Influence of experimental rat model of multiple organ dysfunction on cefepime and amikacin pharmacokinetics. Mimoz O, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):819-21

Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Lugo G, et al. **Crit Care Med** 1997 May;25(5):806-11

Population pharmacokinetics of amikacin in geriatric patients studied with the NPEM-2 algorithm. Debord J, et al. **Int J Clin Pharmacol Ther** 1997 Jan;35(1):24-7

Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient [see comments] Botha FJ, et al. **Intensive Care Med** 1996 May;22(5):443-6. Comment in: Intensive Care Med 1997 Feb;23(2):236-7.

Volume distribution of amikacin [letter; comment] Sleigh JW. **Intensive Care Med** 1997 Feb;23(2):236-7. Comment on: Intensive Care Med 1996 May;22(5):443-6.

Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients. Canis F, et al. **J Antimicrob Chemother** 1997 Mar;39(3):431-3

Pharmacokinetics of amikacin in intensive care unit patients. Fernández de Gatta MM, et al. **J Clin Pharm Ther** 1996 Dec;21(6):417-21

The pharmacokinetics of a single intramuscular dose of amikacin in red-tailed hawks (Buteo jamaicensis). Bloomfield RB, et al. **J Zoo Wildl Med** 1997 Mar; 28(1):55-61

Disposition of single-dose intravenously administered amikacin in emus (Dromaius novaehollandiae). Helmick KE, et al. **J Zoo Wildl Med** 1997 Mar;28(1):49-54

Amikacin pharmacokinetics and the effects of ambient temperature on the dosage regimen in ball pythons (Python regius). Johnson JH, et al. **J Zoo Wildl Med** 1997 Mar; 28(1):80-8

Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Lugo G, et al. **Ther Drug Monit** 1997 Jun;19(3):271-6

[Clinical, pharmacokinetic and therapeutic study of amikacin with single daily dose and in combination in neutropenic children with fever] Bertrand Y, et al. **Arch Pediatr** 1996 Sep;3(9):854-60 (Eng. Abstr.) **(Fre)**

[In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model] Elkhaïli H, et al. **Pathol Biol (Paris)** 1997 May; 45(5):347-56 (Eng. Abstr.) **(Fre)**

[Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology] Pivot-Dumarest C, et al. **Pathol Biol (Paris)** 1996 Apr; 44(4):299-305 (Eng. Abstr.) **(Fre)**

[Individual variability of pharmacokinetic parameters of amikacin in the elderly: retrospective studies] Vincent S, et al. **Pathol Biol (Paris)** 1996 Sep;44(7):667-74 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies. Bajaksouzian S, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1073-6

Resistance to amikacin and isepamicin in rabbits with experimental endocarditis of an aac(6')-Ib-bearing strain of Klebsiella pneumoniae susceptible in vitro. Caulin E, et al. **Antimicrob Agents Chemother** 1996 Dec; 40(12):2848-53

Characterization of the 6'-N-aminoglycoside acetyltransferase gene aac(6')-II associated with a sulI-type integron. Hannecart-Pokorni E, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):314-8

Comparison of the effects of amikacin and kanamycins A and B on dimyristoylphosphatidylglycerol bilayers. An infrared spectroscopic investigation. Carrier D, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):401-8

Age-related differences in the glomerular and renal tubular effects of amikacin in the rat. Meléndez E, et al. **Biol Neonate** 1996;70(4):229-34

Outer membrane proteins and elastase of Pseudomonas aeruginosa after the postantibiotic effect induced by amikacin. Hoštacká A, et al. **Chemotherapy** 1997 Mar-Apr; 43(2):118-22

Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices. Biedenbach DJ, et al. **Diagn Microbiol Infect Dis** 1997 Jan-Feb;27(1-2):1-5

In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. Milatovic D, et al. **Eur J Clin Microbiol Infect Dis** 1996 Aug;15(8):688-93

In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Tessier F, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb;16(2):159-62

In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa. Giamarellos-Bourboulis EJ, et al. **J Antimicrob Chemother** 1996 Aug;38(2):287-91

Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo. Mimoz O, et al. **J Antimicrob Chemother** 1997 Mar;39(3):363-9

Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages. Pellegrin I, et al. **J Antimicrob Chemother** 1996 Mar;37(3):501-10

A new anti-infective collagen dressing containing antibiotics. Grzybowski J, et al. **J Biomed Mater Res** 1997 Aug; 36(2):163-6

In vivo bacterial regrowth-inhibition effect of cefbuperazone and amikacin in puerperal uterine cavity. Izumi K, et al. **J Chemother** 1995 Nov;7 Suppl 4:173-6

Recognition of a Nocardia transvalensis complex by resistance to aminoglycosides, including amikacin, and PCR-restriction fragment length polymorphism analysis. Wilson RW, et al. **J Clin Microbiol** 1997 Sep;35(9):2235-42

Vancomycin and amikacin in cell cultures for virus isolation. Lo JY, et al. **Pathology** 1996 Nov;28(4):366-9

Selection of subpopulations resistnat to amikacin and netilmicin of gentamicin-resistant clinical strains of Staphylococcus aureus and Staphylococcus epidermidis. Torres García M, et al. **Zentralbl Bakteriol** 1996 Jun; 284(1):58-66

[In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model] Elkhaïli H, et al. **Pathol Biol (Paris)** 1997 May; 45(5):347-56 (Eng. Abstr.) **(Fre)**

["Killing" of pseudomonas aeruginosa isolated from patients with critical post-operative complications. Effect of various antibiotics] Delogu G, et al. **Ann Ital Chir** 1997 Mar-Apr;68(2):219-24 (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Disseminated tuberculosis treated with amikacin in a patient with acute myelocytic leukemia. Engervall P, et al. **Acta Oncol** 1997;36(4):444-6

In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model. Bugnon D, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1164-9

Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. Lounis N, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1168-9

Amikacin may be drug of choice in Nocardia keratitis [letter] Denk PO, et al. **Br J Ophthalmol** 1996 Oct;80(10):928-9

Comparison of the bactericidal action of amikacin, netilmicin and tobramycin in free and liposomal formulation against Pseudomonas aeruginosa. Omri A, et al. **Chemotherapy** 1996 May-Jun;42(3):170-6

Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Cordonnier C, et al. **Clin Infect Dis** 1997 Jan;24(1):41-51

Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Lugo G, et al. **Crit Care Med** 1997 May;25(5):806-11

Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Vic P, et al. **Eur J Pediatr** 1996 Nov;155(11):948-53

Aminoglycoside prescription, therapeutic monitoring and nephrotoxicity at a university hospital in Saudi Arabia. Eltahawy AT, et al. **J Chemother** 1996 Aug;8(4):278-83

Amikacin as first-choice aminoglycoside in a medical intensive care unit: a one-year bacteriological surveillance study. Peetermans WE, et al. **J Chemother** 1996 Feb; 8(1):17-24

Antimicrobial effects of amikacin therapy on experimentally induced Salmonella typhimurium infection in fowls. Itoh N, et al. **J Vet Med Sci** 1996 May;58(5):425-9

Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever. Engervall P, et al. **Scand J Infect Dis** 1996;28(3):297-303

[Clinical, pharmacokinetic and therapeutic study of amikacin with single daily dose and in combination in neutropenic children with fever] Bertrand Y, et al. **Arch Pediatr** 1996 Sep;3(9):854-60 (Eng. Abstr.) **(Fre)**

[Effects of hyperbaric oxygenation in skin and pulmonary infections caused by Pseudomonas aeruginosa] Marmo M, et al. **Minerva Anestesiol** 1996 Sep;62(9):281-7 (Eng. Abstr.) **(Ita)**

[Antioxidants and immunomodulating action of antibiotics and antibiotic-treated erythrocytes in staphylococcal infections] Prokopenko LG, et al. **Antibiot Khimioter** 1997; 42(3):15-9 (Eng. Abstr.) **(Rus)**

TOXICITY

Does the organ of Corti attempt to differentiate new hair cells after antibiotic intoxication in rat pups? Lenoir M, et al. **Int J Dev Neurosci** 1997 Jul;15(4-5):487-95

The spontaneous appearance of hair cell-like cells in the mammalian cochlea following aminoglycoside ototoxicity. Romand R, et al. **Neuroreport** 1996 Dec 20;8(1):133-7

AMILORIDE

ADMINISTRATION & DOSAGE

[Amiloride inhalation] Lindemann H. **Pneumologie** 1996 Dec; 50 Suppl 3:841-4 **(Ger)**

ADVERSE EFFECTS

Biochemical changes during moduretic treatment of hypertension in African patients. Ahaneku JE, et al. **Kobe J Med Sci** 1995 Aug;41(4):83-93

ANALOGS & DERIVATIVES

Intracellular pH regulation in cultured human pleural mesothelial cells. Liaw YS, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):597-602

Reduced infarct size in the rabbit heart in vivo by ethylisopropyl-amiloride. A role for Na+/H+ exchange. Bugge E, et al. **Basic Res Cardiol** 1996 May-Jun; 91(3):203-9

The amiloride-sensitive Na+/H+ exchange antiporter and control of intracellular pH in hippocampal brain slices. Lin CW, et al. **Brain Res** 1996 Aug 26;731(1-2):108-13

Short-term inhibition of the Na-H exchanger limits acidosis and reduces ischemic injury in the rat heart. Schaefer S, et al. **Cardiovasc Res** 1997 May;34(2):329-36

Reversal of doxorubicin resistance by the amiloride analogue EIPA in multidrug resistant human colon carcinoma cells. Pannocchia A, et al. **Cell Biochem Funct** 1996 Mar; 14(1):11-8

Is calcium a mediator of infarct size reduction with preconditioning in canine myocardium? Przyklenk K, et al. **Circulation** 1997 Aug 19;96(4):1305-12

Protective effect of the sodium/hydrogen exchange inhibitors during global low-flow ischemia. Khandoudi N, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):540-6

Effect of methylisobutyl amiloride on [Na+]i, reperfusion arrhythmias, and function in ischemic rat hearts. Tani M, et al. **J Cardiovasc Pharmacol** 1996 Jun;27(6):794-801

Vibrio alginolyticus mutants resistant to phenamil, a specific inhibitor of the sodium-driven flagellar motor. Kojima S, et al. **J Mol Biol** 1997 Jan 24;265(3):310-8

Modulation of the electrophysiological effects of ischemia reperfusion by methylisobutyl amiloride. Ruiz Petrich E, et al. **J Mol Cell Cardiol** 1996 May;28(5):1129-41

Egg activation induced by osmotic pressure change and the effects of amiloride on the cryopreservation of mouse oocytes [see comments] Inagaki N, et al. **Mol Hum Reprod** 1996 Nov;2(11):835-43. Comment in: Mol Hum Reprod 1997 May;3(5):457.

Regulation of D2 dopamine receptors by amiloride and amiloride analogs. Hoare SR, et al. **Mol Pharmacol** 1996 Nov;50(5):1295-308

Inhibitors of intracellular pH regulation induce cisplatin resistance in EMT6 mouse mammary tumor cells. Laurencot CM, et al. **Oncol Res** 1995;7(7-8):363-9

Role of Na(+)-H+ exchange on reperfusion related myocardial injury and arrhythmias in an open-chest swine model. Fukuta M, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):2027-33

Cystic fibrosis and non-cystic-fibrosis human nasal epithelium show analogous Na+ absorption and reversible block by phenamil. Blank U, et al. **Pflugers Arch** 1997 May; 434(1):19-24

Inhibition by 5-N-(4-chlorobenzyl)-2',4'-dimethylbenzamil of Na+/Ca2+ exchange and L-type Ca2+ channels in isolated cardiomyocytes. Sharikabad MN, et al. **Pharmacol Toxicol** 1997 Feb;80(2):57-61

ANALYSIS

Statistical optimization of a reversed-phase liquid chromatographic method for the determination of amiloride and methyclothiazide in tablets. Zivanovic LJ, et al. **J Pharm Biomed Anal** 1996 Jun;14(8-10):1245-50

ANTAGONISTS & INHIBITORS

Inhibition by xipamide of amiloride-induced acidification in cultured rat cardiocytes. Taouil K, et al. **Eur J Pharmacol** 1997 Apr 18;324(2-3):289-94

BLOOD

Determination and pharmacokinetics of a furosemide-amiloride drug combination. Jankowski A, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):383-91

CHEMISTRY

Identification of an amiloride binding domain within the alpha-subunit of the epithelial Na+ channel. Ismailov II, et al. **J Biol Chem** 1997 Aug 22;272(34):21075-83

METABOLISM

Random mutagenesis reveals a novel site involved in inhibitor interaction within the fourth transmembrane segment of the Na+/H+ exchanger-1. Counillon L, et al. **Biochemistry** 1997 Mar 11;36(10):2951-9

Structure and regulation of the amiloride-sensitive epithelial sodium channel. Barbry P, et al. **Ion Channels** 1996;4:115-67 (255 ref.)

Regulation and amiloride-binding site of epithelial Na+ channels. Kunzelmann K. **Kidney Blood Press Res** 1997; 20(3):151-3

Low-amiloride-affinity Na+ channel in the epithelial cells isolated from the endolymphatic sac of guinea-pigs. Mori N, et al. **Pflugers Arch** 1996 Nov-Dec;433(1-2):58-64

PHARMACOKINETICS

Pharmacokinetic studies of amiloride and its analogs using reversed-phase high-performance liquid chromatography. Lee C, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11; 685(1):151-7

Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis. Jones KM, et al. **Pharmacotherapy** 1997 Mar-Apr; 17(2):263-70

PHARMACOLOGY

Stretch modulates amiloride sensitivity and cation selectivity of sodium channels in human B lymphocytes. Achard JM, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C224-34

Inhibition of amiloride-sensitive Na+ channel by isothiouronium derivatives. Avigdor A, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1457-62

The amiloride-sensitive epithelial Na+ channel: binding sites and channel densities. Blazer-Yost BL, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C761-9 (87 ref.)

Liddle's disease: abnormal regulation of amiloride-sensitive Na+ channels by beta-subunit mutation. Bubien JK, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C208-13

Whole cell and unitary amiloride-sensitive sodium currents in M-1 mouse cortical collecting duct cells. Chalfant ML, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):C998-1010

Heterologous expression of rat NHE4: a highly amiloride-resistant Na+/H+ exchanger isoform. Chambrey R, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):C90-8

Cell-specific expression of amiloride-sensitive, Na(+)-conducting ion channels in the kidney. Ciampolillo F, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1303-15

Mechanisms of amiloride stimulation of Mg2+ uptake in immortalized mouse distal convoluted tubule cells. Dai LJ, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):F249-56

Regulation of amiloride-sensitive Na+ channels by endothelin-1 in distal nephron cells. Gallego MS, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F451-60

Effects of NO synthase inhibitors, arginine-deficient diet, and amiloride in pregnant rats. Greenberg SS, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1031-45

cAMP stimulates CFTR-like Cl- channels and inhibits amiloride-sensitive Na+ channels in mouse CCD cells. Letz B, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C657-66

Luminal adenosine receptors regulate amiloride-sensitive Na+ channels in A6 distal nephron cells. Ma H, et al. **Am J Physiol** 1996 May;270(5 Pt 2):F798-805

Amiloride inhibits cytokine production in epithelium infected with respiratory syncytial virus. Mastronarde JG, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):L201-7

Biophysical and molecular properties of amiloride-inhibitable Na+ channels in alveolar epithelial cells. Matalon S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):L1-22 (152 ref.)

Immortalized human bladder cell line exhibits amiloride-sensitive sodium absorption. Perrone RD, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):F148-53

Localization of amiloride-sensitive sodium channels in A6 cells by atomic force microscopy. Smith PR, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1295-8

Amiloride-sensitive Na+ channels in human nasal epithelium are different from classical epithelial Na+ channels. Rückes C, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):488-91

Inhibition of melibiose transporter by amiloride in Escherichia coli. Young-Mog K, et al. **Biochem Biophys Res Commun** 1997 Apr 7;233(1):147-9

Point mutations in alpha bENaC regulate channel gating, ion selectivity, and sensitivity to amiloride. Fuller CM, et al. **Biophys J** 1997 Apr;72(4):1622-32

Temperature and amiloride alter taste nerve responses to Na+, K+, and NH+4 salts in rats. Lundy RF Jr, et al. **Brain Res** 1997 Jan 9;744(2):309-17

Active 22Na+ transport by the intact lung during early postnatal life. O'Brodovich HM, et al. **Can J Physiol Pharmacol** 1997 May;75(5):431-5

Inhibition by amiloride of experimental carcinogenesis induced by azaserine in rat pancreas. Tatsuta M, et al. **Cancer Lett** 1996 Aug 23;106(1):23-8

Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Jankun J, et al. **Cancer Res** 1997 Feb 15;57(4):559-63

Effects of Na(+)-H+ exchange blocker amiloride on left ventricular remodeling after anterior myocardial infarction in rats. Hasegawa S, et al. **Cardiovasc Drugs Ther** 1995 Dec;9(6):823-6

Amiloride effects on taste quality: comparison of single and multiple response category procedures. Ossebaard CA, et al. **Chem Senses** 1997 Jun;22(3):267-75

Anterior tongue stimulation with amiloride suppresses NaCl saltiness, but not citric acid sourness in humans. Tennissen AM, et al. **Chem Senses** 1996 Apr;21(2):113-20

Amiloride-sensitive Na+/H+ exchange in erythrocytes of patients with NIDDM: a prospective study. Koren W, et al. **Diabetologia** 1997 Mar;40(3):302-6

Effects of amiloride on the neurally mediated contraction of rat mesenteric artery. Shimamura K, et al. **Eur J Pharmacol** 1997 Feb 5;320(1):37-42

The effect of bile acid on the activation of amiloride-sensitive sodium channels in frog skin. Lima MS, et al. **Exp Physiol** 1996 Sep;81(5):755-66

Molecular biology of the amiloride-sensitive epithelial Na+ channel. Lingueglia E, et al. **Exp Physiol** 1996 May; 81(3):483-92 (30 ref.)

An amiloride-sensitive, volume-dependent Na+ transport across the lamprey (Lampetra fluviatilis) erythrocyte membrane. Gusev GP, et al. **Gen Physiol Biophys** 1996 Apr;15(2):129-43

Kinetic interconversion of rat and bovine homologs of the alpha subunit of an amiloride-sensitive Na+ channel by C-terminal truncation of the bovine subunit. Fuller CM, et al. **J Biol Chem** 1996 Oct 25;271(43):26602-8

Distribution and characterization of functional amiloride-sensitive sodium channels in rat tongue. Doolin RE, et al. **J Gen Physiol** 1996 Apr;107(4):545-54

Identification of amino acid residues in the alpha, beta, and gamma subunits of the epithelial sodium channel (ENaC) involved in amiloride block and ion permeation. Schild L, et al. **J Gen Physiol** 1997 Jan;109(1):15-26

Associated proteins and renal epithelial Na+ channel function. Ismailov II, et al. **J Membr Biol** 1996 Jan; 149(2):123-32

Amplification of EPSPs by low Ni(2+)- and amiloride-sensitive Ca2+ channels in apical dendrites of rat CA1 pyramidal neurons. Gillessen T, et al. **J Neurophysiol** 1997 Mar;77(3):1639-43

Salt taste responses of mouse chorda tympani neurons: evidence for existence of two different amiloride-sensitive receptor components for NaCl with different temperature dependencies. Ninomiya Y. **J Neurophysiol** 1996 Nov; 76(5):3550-4

Responses of gustatory cells in the nucleus of the solitary tract of the hamster after NaCl or amiloride adaptation. Smith DV, et al. **J Neurophysiol** 1996 Jul;76(1):47-58

Amiloride disrupts NaCl versus KCl discrimination performance: implications for salt taste coding in rats. Spector AC, et al. **J Neurosci** 1996 Dec 15;16(24):8115-22

Regulation of intracellular pH in salamander retinal rods. Saarikoski J, et al. **J Physiol (Lond)** 1997 Jan 1;498 (Pt 1):61-72

Hyposmolality-induced enhancement of ADH action on amiloride-sensitive Isc in renal epithelial A6 cells. Niisato N, et al. **Jpn J Physiol** 1997 Feb;47(1):131-7

Diversity and regulation of amiloride-sensitive Na+ channels. Benos DJ, et al. **Kidney Int** 1996 Jun;49(6):1632-7 (35 ref.)

Regulation of D2 dopamine receptors by amiloride and amiloride analogs. Hoare SR, et al. **Mol Pharmacol** 1996 Nov;50(5):1295-308

The ENaC channel as the primary determinant of two human diseases: Liddle syndrome and pseudohypoaldosteronism. Schild L. **Nephrologie** 1996;17(7):395-400 (27 ref.)

The amiloride inhibitable Na+ conductance of rat colonic crypt cells is suppressed by forskolin. Ecke D, et al. **Pflugers Arch** 1996 Apr;431(6):984-6

cAMP-activation of amiloride-sensitive Na+ channels from guinea-pig colon expressed in Xenopus oocytes. Liebold KM, et al. **Pflugers Arch** 1996 Apr;431(6):913-22

Partial recovery of in vivo function by improved incubation conditions of isolated renal proximal tubule. I. Change of amiloride-inhibitable K+ conductance. Müller-Berger S, et al. **Pflugers Arch** 1997 Aug;434(4):373-82

Amiloride-inhibitable Na+ conductance in rat proximal tubule. Willmann JK, et al. **Pflugers Arch** 1997 Jun; 434(2):173-8

Amiloride inhibits taste nerve responses to NaCl and KCl in Sprague-Dawley and Fischer 344 rats. Minear MM, et al. **Physiol Behav** 1996 Aug;60(2):507-16

Amiloride suppresses the sourness of NaCl and LiCl. Ossebaard CA, et al. **Physiol Behav** 1996 Nov;60(5):1317-22

Effects of lung expansion on lung liquid production in vitro by lungs from fetal guinea-pigs. I. Basic studies and the effects of amiloride and propranolol. Nelson PG, et al. **Reprod Fertil Dev** 1996;8(3):335-46

Nitric oxide-induced hyperpermeability of human intestinal epithelial monolayers is augmented by inhibition of the amiloride-sensitive Na(+)-H+ antiport: potential role of peroxynitrous acid. Unno N, et al. **Surgery** 1997 Aug; 122(2):485-91; discussion 491-2

[The amiloride sensitive sodium channel] Barbry P, et al. **Nephrologie** 1996;17(7):389-93 (26 ref.) (Eng. Abstr.) **(Fre)**

[Effect of amiloride on the early and late stage of postischemic recovery in isolated perfused rat hearts--possible involvement of Na+/H+ and Na+/Ca2+ exchange] Yoshizumi M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep;44(9):1735-41 (Eng. Abstr.) **(Jpn)**

[Inhibition of angiogenesis in the cornea with amiloride] Ignjatović Z, et al. **Srp Arh Celok Lek** 1996 May-Jun; 124(5-6):120-3 (Eng. Abstr.) **(Scc)**

THERAPEUTIC USE

Comparative study of inhaled amiloride and inhaled furosemide in exercise-induced asthma. Larramendi CH, et al. **Allergol Immunopathol (Madr)** 1997 Mar-Apr; 25(2):85-90

Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. Bénétos A, et al. **J Hum Hypertens** 1996 Feb;10(2):77-82

Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride. Witko-Sarsat V, et al. **J Immunol** 1996 Sep 15;157(6):2728-35

Blood pressure and blood glucose levels during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients. Ahaneku JE. **Kobe J Med Sci** 1996 Feb;42(1):19-29

Modification of nasal membrane potential difference with inhaled amiloride and loperamide in the cystic fibrosis (CF) mouse. Ghosal S, et al. **Thorax** 1996 Dec;51(12):1229-32

[Potassium-sparing diuretics (spironolactone, triamterene, amylorid)] Haris A, et al. **Orv Hetil** 1996 Sep 1; 137(35):1907-14 (72 ref.) (Eng. Abstr.) **(Hun)**

TOXICITY

The binding site on cochlear stereocilia for antisera raised against renal Na+ channels is blocked by amiloride and dihydrostreptomycin. Furness DN, et al. **Hear Res** 1996 Apr;93(1-2):136-46

The effect of amiloride and sodium chloride on rat renal and hepatic 11 beta-hydroxysteroid dehydrogenase activities. Niepel T, et al. **Pharmacol Toxicol** 1997 Mar; 80(3):127-31

URINE

Direct determination of amiloride in urine using isopotential fluorimetry. Murillo Pulgarín JA, et al. **Analyst** 1997 Mar; 122(3):247-52

AMINACRINE

ADMINISTRATION & DOSAGE

Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. duBouchet L, et al. **Sex Transm Dis** 1997 Mar;24(3):156-60

PHARMACOLOGY

Influence of drug binding on DNA flexibility: a normal mode analysis. Ha Duong T, et al. **J Biomol Struct Dyn** 1997 Jun;14(6):691-701

THERAPEUTIC USE

Could an aminoacridine interfere with the cellular mechanisms involved in the process of human immunodeficiency virus infection? Sotelo J. **Med Hypotheses** 1996 Jul;47(1):43-7

TOXICITY

Reproductive toxicology. 9-Aminoacridine hydrochloride. **Environ Health Perspect** 1997 Feb;105 Suppl 1:269-70

AMINE OXIDASE (COPPER-CONTAINING)

Ultrastructural localization of histamine in human basophils and mast cells; changes associated with anaphylactic degranulation and recovery demonstrated with a diamine oxidase-gold probe. Dvorak AM. **Allergy** 1997;52(34 Suppl):14-24 (30 ref.)

ANALYSIS

Comparative study of three vaginal markers of the premature rupture of membranes. Insulin like growth factor binding protein 1 diamine-oxidase pH. Gaucherand P, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):536-40

ANTAGONISTS & INHIBITORS

Inhibition of copper amine oxidase by haloamines: a killer product mechanism. Medda R, et al. **Biochemistry** 1997 Mar 4;36(9):2595-602

Aminoguanidine--effects on endoneurial vasoactive nitric oxide and on motor nerve conduction velocity in control and streptozotocin-diabetic rats. Dewhurst M, et al. **Br J Pharmacol** 1997 Feb;120(4):593-8

Inhibition of diamine oxidase promotes uptake of putrescine from rat small intestine. Nilsson BO, et al. **Inflamm Res** 1996 Oct;45(10):513-8

BIOSYNTHESIS

The fungus Gibberella fujikuroi produces copper/topaquinone-containing amine oxidase when induced by N-butylamine. Frébort I, et al.

Biochem Mol Biol Int 1997 Jan;41(1):11-23

BLOOD

Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Boomsma F, et al. **Cardiovasc Res** 1997 Feb;33(2):387-91

Histaminase activity in patients with vernal keratoconjunctivitis. Abelson MB, et al. **Ophthalmology** 1995 Dec;102(12):1958-63

Diamine oxidase plasma activity and jejunal mucosa integrity in children with protracted diarrhoea. Toporowska-Kowalska E, et al. **Rocz Akad Med Bialymst** 1995;40(3):499-503

[Gastrinemia and heparin stimulated secretion of diamine oxidase on the course of diabetic autonomic neuropathy] Loba J, et al. **Pol Merkuriusz Lek** 1997 Jan;2(7):10-3 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Inhibition of copper amine oxidase by haloamines: a killer product mechanism. Medda R, et al. **Biochemistry** 1997 Mar 4;36(9):2595-602

Catalytic mechanism of the quinoenzyme amine oxidase from Escherichia coli: exploring the reductive half-reaction. Wilmot CM, et al. **Biochemistry** 1997 Feb 18;36(7):1608-20

Lactoferrin: similarity to diamine oxidase and purification by aminohexyl affinity chromatography. Houen G, et al. **Eur J Biochem** 1996 Oct 1;241(1):303-8

Probing structure-activity relationship in diamine oxidase--reactivities of lysine and arginine residues. Shah MA, et al. **Int J Biol Macromol** 1996 Feb;18(1-2):77-81

Diamine oxidase-gold enzyme-affinity ultrastructural demonstration that human gut mucosal mast cells secrete histamine by piecemeal degranulation in vivo. Dvorak AM, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):812-20

Role of conserved Asn-Tyr-Asp-Tyr sequence in bacterial copper/2,4, 5-trihydroxyphenylalanyl quinone-containing histamine oxidase. Choi YH, et al. **J Biol Chem** 1996 Sep 13;271(37):22598-603

DIAGNOSTIC USE

A cell-based immunobiosensor with engineered molecular recognition--Part II: Enzyme amplification systems. Page DL, et al. **Biosens Bioelectron** 1997;12(6):457-66

GENETICS

Cloning and sequencing of a copper-containing, topa quinone-containing monoamine oxidase from human placenta. Zhang X, et al. **Gene** 1996 Nov 14;179(2):279-86

ISOLATION & PURIFICATION

The isolation and purification of diamine oxidase of pea seedlings and pig liver. Güvenilir YA, et al. **Appl Biochem Biotechnol** 1996 Mar;56(3):235-41

Mechanistic studies of topa quinone biogenesis in phenylethylamine oxidase. Ruggiero CE, et al. **Biochemistry** 1997 Feb 25;36(8):1953-9

Purification and characterization of diamine oxidase from porcine kidney and intestine. Schwelberger HG, et al. **Biochim Biophys Acta** 1997 Jun 20;1340(1):152-64

METABOLISM

Substrate specificity of lentil seedling amine oxidase. Medda R, et al. **Biochem Mol Biol Int** 1996 Oct;40(3):629-37

Dopaquinone hydroxylation through topaquinone cofactor in copper amine oxidases: a simplified chemical model. Rinaldi AC, et al. **Biochem Mol Biol Int** 1996 Sep; 40(1):189-97

Catalytic mechanism of the quinoenzyme amine oxidase from Escherichia coli: exploring the reductive half-reaction. Wilmot CM, et al. **Biochemistry** 1997 Feb 18;36(7):1608-20

Colorectal carcinoma: some reflections on bile flow through the terminal ileum [letter; comment] Stoneham M. **Br J Cancer** 1997;76(1):136-7. Comment on: Br J Cancer 1996 Jul;74(1):145-51.

Tear histamine and histaminase during the early (EPR) and late (LPR) phases of the allergic reaction and the effects of lodoxamide. Leonardi AA, et al. **Eur J Ophthalmol** 1996 Apr-Jun;6(2):106-12

The histaminase activity of rat white adipocytes. Raimondi L, et al. **Inflamm Res** 1997 Apr;46(4):125-31

Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. Lyles GA. **Int J Biochem Cell Biol** 1996 Mar;28(3):259-74 (113 ref.)

Probing structure-activity relationship in diamine oxidase--reactivities of lysine and arginine residues. Shah MA, et al. **Int J Biol Macromol** 1996 Feb;18(1-2):77-81

Effect of metal on 2,4,5-trihydroxyphenylalanine (topa) quinone biogenesis in the Hansenula polymorpha copper amine oxidase. Cai D, et al. **J Biol Chem** 1997 Aug 1; 272(31):19277-81

New quinocofactors in eukaryotes. Klinman JP. **J Biol Chem** 1996 Nov 1;271(44):27189-92 (39 ref.)

Some histamine-related compounds interacting with the benzylamine-oxidizing activity of rat white adipocytes. Raimondi L, et al. **J Pharm Pharmacol** 1997 May; 49(5):542-50

AMINE OXIDASE (FLAVIN-CONTAINING) see **MONOAMINE OXIDASE**

AMINE OXIDOREDUCTASES

ANALYSIS

Folate and 10-formyltetrahydrofolate dehydrogenase in human and rat retina: relation to methanol toxicity. Martinasevic MK, et al. **Toxicol Appl Pharmacol** 1996 Dec; 141(2):373-81

ANTAGONISTS & INHIBITORS

Effects of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on the growth of tumorigenic cell lines in culture. Shi XP, et al. **Biochim Biophys Acta** 1997 Jan 10;1310(1):119-26

Evidence of semicarbazide-sensitive amine oxidase activity in guinea pig tissues. Puliti M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Oct; 115(2):159-65

Comparison of kinetic properties between plant and fungal amine oxidases. Luhová L, et al. **J Enzyme Inhib** 1996; 10(4):251-262

Effect of haloallylamines on polyamine oxidase activity and spermine levels in Ascaris suum. Müller S, et al. **Parasitol Res** 1996;82(6):571-3

BIOSYNTHESIS

Medium-reductant directed expression of methyl coenzyme M reductase isoenzymes in Methanobacterium thermoautotrophicum (strain deltaH). Pennings JL, et al. **FEBS Lett** 1997 Jun 30;410(2-3):235-7

Differential induction of polyamine oxidase activity in liver and heart of iron-overloaded rats. Tipnis UR, et al. **J Toxicol Environ Health** 1997 Jun 27;51(3):235-44

BLOOD

Consideration of the optimum pH for the analysis of serum p-phenylenediamine oxidase activity in thoroughbred horses. Okumura M, et al. **J Vet Med Sci** 1997 Feb; 59(2):137-9

CHEMISTRY

Transient kinetics of polyamine oxidase from Zea mays L. Bellelli A, et al. **Arch Biochem Biophys** 1997 Jul 1; 343(1):146-8

Reactions of the oxidized organic cofactor in copper-depleted bovine serum amine oxidase. Agostinelli E, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):497-501

Identification of molybdopterins in molybdenum- and selenium-containing enzymes. Gladyshev VN, et al. **Biofactors** 1995-96;5(2):93-7

Expression, purification, and properties of the aldehyde dehydrogenase homologous carboxyl-terminal domain of rat 10-formyltetrahydrofolate dehydrogenase. Krupenko SA, et al. **J Biol Chem** 1997 Apr 11;272(15):10266-72

Domain structure of rat 10-formyltetrahydrofolate dehydrogenase. Resolution of the amino-terminal domain as 10-formyltetrahydrofolate hydrolase. Krupenko SA, et al. **J Biol Chem** 1997 Apr 11;272(15):10273-8

Crystal structure of a eukaryotic (pea seedling) copper-containing amine oxidase at 2.2 A resolution. Kumar V, et al. **Structure** 1996 Aug 15;4(8):943-55

DEFICIENCY

MR and proton MR spectroscopy of the brain in hyperhomocysteinemia caused by methylenetetrahydrofolate reductase deficiency. Engelbrecht V, et al. **AJNR Am J Neuroradiol** 1997 Mar; 18(3):536-9

Severe and mild mutations in cis for the methylenetetrahydrofolate reductase (MTHFR) gene, and description of five novel mutations in MTHFR. Goyette P, et al. **Am J Hum Genet** 1996 Dec;59(6):1268-75

Molecular genetics of methylenetetrahydrofolate reductase deficiency. Rozen R. **J Inherit Metab Dis** 1996;19(5):589-94 (21 ref.)

[An adult case of homocystinuria probably due to methylenetetrahydrofolate-reductase deficiency--treatment with folic acid and the course of coagulation-fibrinolysis parameters] Hamano H, et al. **Rinsho Shinkeigaku** 1996 Feb;36(2):330-5 (Eng. Abstr.) **(Jpn)**

GENETICS

The (Ala-Val) mutation of methylenetetrahydrofolate reductase as a genetic risk factor for vascular disease in non-insulin-dependent diabetic patients [letter] Brulhart MC, et al. **Am J Hum Genet** 1997 Jan;60(1):228-9

Methylenetetrahydrofolate reductase thermolabile variant and human longevity [letter] Faure-Delanef L, et al. **Am J Hum Genet** 1997 Apr;60(4):999-1001

Severe and mild mutations in cis for the methylenetetrahydrofolate reductase (MTHFR) gene, and description of five novel mutations in MTHFR. Goyette P, et al. **Am J Hum Genet** 1996 Dec;59(6):1268-75

Differences in methylenetetrahydrofolate reductase genotype frequencies, between Whites and Blacks [letter; comment] Stevenson RE, et al. **Am J Hum Genet** 1997 Jan; 60(1):229-30. Comment on: Am J Hum Genet 1996 Jan;58(1):17-20.

Analysis of alpha-1 antichymotrypsin, presenilin-1, angiotensin-converting enzyme, and methylenetetrahydrofolate reductase loci as candidates for dementia. Tysoe C, et al. **Am J Med Genet** 1997 Apr 18; 74(2):207-12

The Agaricus bisporus pruA gene encodes a cytosolic delta 1-pyrroline-5-carboxylate dehydrogenase which is expressed in fruit bodies but not in gill tissue. Schaap PJ, et al. **Appl Environ Microbiol** 1997 Jan;63(1):57-62

Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Christensen B, et al. **Arterioscler Thromb Vasc Biol** 1997 Mar;17(3):569-73

The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Malinow MR, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun; 17(6):1157-62

Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Bostom AG, et al. **Atherosclerosis** 1996 Jun; 123(1-2):193-202

A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Brugada R, et al. **Atherosclerosis** 1997 Jan 3;128(1):107-12

Analysis of the apo E/apo C-I, angiotensin converting enzyme and methylenetetrahydrofolate reductase genes as candidates affecting human longevity. Galinsky D, et al. **Atherosclerosis** 1997 Mar 21;129(2):177-83

The 677C-->T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Verhoef P, et al. **Atherosclerosis** 1997 Jul 11; 132(1):105-13

The VITA project: C677T mutation in the methylene-tetrahydrofolate reductase gene and risk of venous thromboembolism. Tosetto A, et al. **Br J Haematol** 1997 Jun;97(4):804-6

A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Chen J. et al. **Cancer Res** 1996 Nov 1;56(21):4862-4

Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Ma J, et al. **Cancer Res** 1997 Mar 15;57(6):1098-102

Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Deloughery TG, et al. **Circulation** 1996 Dec 15;94(12):3074-8

Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Gallagher PM, et al. **Circulation** 1996 Nov 1;94(9):2154-8

Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Ma J, et al. **Circulation** 1996 Nov 15; 94(10):2410-6

Methylenetetrahydrofolate reductase mutation and coronary artery disease [letter; comment] Narang R, et al. **Circulation** 1996 Nov 1;94(9):2322-3. Comment on: Circulation 1996 Jan 1;93(1):7-9.

Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. Schmitz C, et al. **Circulation** 1996 Oct 15;94(8):1812-4

Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Schwartz SM, et al. **Circulation** 1997 Jul 15;96(2):412-7

Methylenetetrahydrofolate reductase gene and coronary artery disease. van Bockxmeer FM, et al. **Circulation** 1997 Jan 7;95(1):21-3

C677T mutation of methylenetetrahydrofolate reductase gene determined in blood or plasma by multiple-injection capillary electrophoresis and laser-induced fluorescence detection. Ulvik A, et al. **Clin Chem** 1997 Feb;43(2):267-72

Are common mutations of cystathionine beta-synthase involved in the aetiology of neural tube defects? Ramsbottom D, et al. **Clin Genet** 1997 Jan;51(1):39-42

Overexpression of the coenzyme-F420-dependent N5,N10-methylenetetrahydromethanopterin dehydrogenase gene from the hyperthermophilic Methanopyrus kandleri. Klein AR, et al. **Eur J Biochem** 1997 Apr 15;245(2):386-91

Ozone stress modulates amine oxidase and lipoxygenase expression in lentil (Lens culinaris) seedlings. Maccarrone M, et al. **FEBS Lett** 1997 May 19;408(2):241-4

Human retina-specific amine oxidase (RAO): cDNA cloning, tissue expression, and chromosomal mapping. Imamura Y, et al. **Genomics** 1997 Mar 1;40(2):277-83

The gene coding for human deoxyhypusine synthase (DHPS) maps to chromosome 19p13.11-p13.12. Jones T, et al. **Genomics** 1996 Aug 1;35(3):635-7

Assignment of the human gene encoding the delta 1-pyrroline-5-carboxylate synthetase (P5CS) to 10q24.3 by in situ hybridization. Liu G, et al. **Genomics** 1996 Oct 1;37(1):145-6

Membrane amine oxidase cloning and identification as a major protein in the adipocyte plasma membrane. Morris NJ, et al. **J Biol Chem** 1997 Apr 4;272(14):9388-92

Determinants and vitamin responsiveness of intermediate

hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study. Guttormsen AB, et al. **J Clin Invest** 1996 Nov 1;98(9):2174–83

Molecular genetics of methylenetetrahydrofolate reductase deficiency. Rozen R. **J Inherit Metab Dis** 1996;19(5):589–94 (21 ref.)

Methylenetetrahydrofolate reductase polymorphism and pre–eclampsia. Sohda S, et al. **J Med Genet** 1997 Jun; 34(6):525–6

A common mutation in methylenetetrahydrofolate reductase gene among the Japanese population. Nishio H, et al. **Jpn J Hum Genet** 1996 Jun;41(2):247–51

V677 mutation of methylenetetrahydrofolate reductases and cardiovascular disease in Canadian Inuit [letter] Hegele RA, et al. **Lancet** 1997 Apr 26;349(9060):1221–2

Methylenetetrahydrofolate reductase mutation and neural tube defects [letter] Kirke PN, et al. **Lancet** 1996 Oct 12; 348(9033):1037–8

Genetic risk factor for unexplained recurrent early pregnancy loss [letter] Nelen WL, et al. **Lancet** 1997 Sep 20; 350(9081):861

Defective homocysteine metabolism as a risk factor for diabetic retinopathy [letter] Neugebauer S, et al. **Lancet** 1997 Feb 15;349(9050):473–4

Moderate hyperhomocysteinaemia and retinopathy in insulin–dependent diabetes [letter] Vaccaro O, et al. **Lancet** 1997 Apr 12;349(9058):1102–3

MTHFR 677C–>T mutation, folate intake, neural–tube defect, and risk of cardiovascular disease. Wilcken DE. **Lancet** 1997 Aug 30;350(9078):603–4

The methylenetetrahydrofolate reductase (Mthfr) gene maps to distal mouse chromosome 4. Frosst P, et al. **Mamm Genome** 1996 Nov;7(11):864–5

Expression of the mau gene cluster of Paracoccus denitrificans is controlled by MauR and a second transcription regulator. Delorme C, et al. **Microbiology** 1997 Mar;143 (Pt 3):793–801

Organization of methylamine utilization genes (mau) in 'Methylobacillus flagellatum ' KT and analysis of mau mutants. Gak ER, et al. **Microbiology** 1997 Jun;143 (Pt 6):1827–35

2–phenylethylamine catabolism by Escherichia coli K–12: gene organization and expression. Hanlon SP, et al. **Microbiology** 1997 Feb;143 (Pt 2):513–8

Reciprocal regulation of delta 1–pyrroline–5–carboxylate synthetase and proline dehydrogenase genes controls proline levels during and after osmotic stress in plants. Peng Z, et al. **Mol Gen Genet** 1996 Dec 13;253(3):334–41

Characterization of the gene for delta1–pyrroline–5–carboxylate synthetase and correlation between the expression of the gene and salt tolerance in Oryza sativa L. Igarashi Y, et al. **Plant Mol Biol** 1997 Mar; 33(5):857–65

Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. Adams M, et al. **QJM** 1996 Jun;89(6):437–44

Is the common 677C–>T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta–analysis. van der Put NM, et al. **QJM** 1997 Feb;90(2):111–5

A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Markus HS, et al. **Stroke** 1997 Sep; 28(9):1739–43

The mutation Ala677–>Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Arruda VR, et al. **Thromb Haemost** 1997 May;77(5):818–21

Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Rozen R. **Thromb Haemost** 1997 Jul;78(1):523–6 (32 ref.)

High frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in Northern Italy [letter] Sacchi E, et al. **Thromb Haemost** 1997 Aug;78(2):963–4

Identification of a putative methylenetetrahydrofolate reductase by sequence analysis of a 6.8 kb DNA fragment of yeast chromosome VII. Tizon B, et al. **Yeast** 1996 Sep; 12(10B Suppl):1047–51

[Gene Polymorphism of 5, 10–methylenetetrahydrofolate reductase as a coronary risk factor] Morita H, et al. **J Cardiol** 1997 Jun;29(6):309–15 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Biochemical and immunological characterization of deoxyhypusine synthase purified from the yeast Saccharomyces carlsbergensis. Abid MR, et al. **J Biochem (Tokyo)** 1997 Apr;121(4):769–78

Purification of folate–dependent enzymes from rabbit liver. Schirch V. **Methods Enzymol** 1997;281:146–61

[Amine oxidase from the bacterial strain Methanosarcina barkeri 27] Dianova MM, et al. **Zh Evol Biokhim Fiziol** 1996 May–Jun;32(3):241–7 (Eng. Abstr.) **(Rus)**

METABOLISM

Cysteamine oxidation by lentil seedling amine oxidase. Medda R, et al. **Biochem Mol Biol Int** 1997 Feb;41(2):395–405

Characterization of a cyclic compound formed after spermine oxidation by lentil amine oxidase. Padiglia A, et al. **Biochem Mol Biol Int** 1997 Feb;41(2):407–13

Why methanopterin? Comparative bioenergetics of the reactions catalyzed by methylene tetrahydrofolate reductase and methylene tetrahydromethanopterin reductase. Maden BE. **Biochem Soc Trans** 1996 Aug; 24(3):466S

Mechanism–based inactivation of a yeast methylamine oxidase mutant: implications for the functional role of the consensus sequence surrounding topaquinone. Cai D, et al. **Biochemistry** 1997 Sep 23;36(38):11472–8

Properties of tetrahydropteroylpentaglutamate bound to 10–formyltetrahydrofolate dehydrogenase. Kim DW, et al. **Biochemistry** 1996 Dec 10;35(49):15772–83

Topaquinone–dependent amine oxidases: identification of reaction intermediates by Raman spectroscopy. Nakamura N, et al. **Biochemistry** 1997 Sep 23;36(38):11479–86

Aging and polyamine acetylation in rat kidney. Ferioli ME, et al. **Biochim Biophys Acta** 1996 Oct 7;1317(1):15–8

Evidence of semicarbazide–sensitive amine oxidase activity in guinea pig tissues. Puliti M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Oct; 115(2):159–65

On the amine oxidases of Klebsiella aerogenes strain W70. Cooper RA. **FEMS Microbiol Lett** 1997 Jan 1;146(1):85–9

Enzyme–substrate intermediate formation at lysine 329 of human deoxyhypusine synthase. Wolff EC, et al. **J Biol Chem** 1997 Jun 20;272(25):15865–71

Comparison of kinetic properties between plant and fungal amine oxidases. Luhová L, et al. **J Enzyme Inhib** 1996; 10(4):251–262

Covalent binding of acetaminophen to N–10–formyltetrahydrofolate dehydrogenase in mice. Pumford NR, et al. **J Pharmacol Exp Ther** 1997 Jan; 280(1):501–5

Use of 10–formyl–5,8–dideazafolate as substrate for rat 10–formyltetrahydrofolate dehydrogenase. Cook RJ. **Methods Enzymol** 1997;281:129–34

Amine–oxidizing quinoproteins. Hartmann C, et al. **Methods Enzymol** 1997;280:98–150

Distribution of amine oxidases and amine dehydrogenases in bacteria grown on primary amines and characterization of the amine oxidase from Klebsiella oxytoca. Hacisalihoglu A, et al. **Microbiology** 1997 Feb;143 (Pt 2):505–12

Methionine and serine formation in control and mutant human cultured fibroblasts: evidence for methyl trapping and characterization of remethylation defects. Fowler B, et al. **Pediatr Res** 1997 Jan;41(1):145–51

Onchocerca volvulus: immunohistochemical and immunoelectron microscopical distribution of a polyamine oxidizing enzyme. Gutiérrez–Peña EJ, et al. **Trop Med Int Health** 1997 May;2(5):472–81

PHYSIOLOGY

Cytotoxicity of polyamines to Amoeba proteus: role of polyamine oxidase. Schenkel E, et al. **Cell Biol Toxicol** 1996 Feb;12(1):1–9

Biochemical and immunological characterization of deoxyhypusine synthase purified from the yeast Saccharomyces carlsbergensis. Abid MR, et al. **J Biochem (Tokyo)** 1997 Apr;121(4):769–78

AMINES

Exposure assessment of heterocyclic amines (HCAs) in epidemiologic studies. Sinha R, et al. **Mutat Res** 1997 May 12;376(1–2):195–202

Overview of carcinogenic heterocyclic amines. Sugimura T. **Mutat Res** 1997 May 12;376(1–2):211–9 (62 ref.)

History, present and future, of heterocyclic amines, cooked food mutagens. Sugimura T. **Princess Takamatsu Symp** 1995;23:214–31 (88 ref.)

ADVERSE EFFECTS

Molecular epidemiology of bladder cancer. Vineis P, et al. **Ann Ist Super Sanita** 1996;32(1):21–7 (39 ref.)

Interplay between heterocyclic amines in cooked meat and metabolic phenotype in the etiology of colon cancer. Vineis P, et al. **Cancer Causes Control** 1996 Jul;7(4):479–86 (53 ref.)

Mutagenic heterocyclic aromatic amines (HAAs) in 'processed food flavour' samples. Stavric B, et al. **Food Chem Toxicol** 1997 Feb;35(2):185–97

Bladder cancer incidence in arylamine workers. Ouellet–Hellstrom R, et al. **J Occup Environ Med** 1996 Dec;38(12):1239–47

ANALYSIS

The quantification of protein amino groups by the trinitrobenzenesulfonic acid method: a reexamination. Cayot P, et al. **Anal Biochem** 1997 Jul 1;249(2):184–200

2–Methyl–3–oxo–4–phenyl–2,3–dihydrofuran–2–yl acetate: a fluorogenic reagent for detection and analysis of primary amines. Chen P, et al. **Anal Chem** 1997 Jul 15; 69(14):2806–11

4–(5',6'–Dimethoxybenzothiazolyl)benzoyl fluoride and 2–(5',6'–dimethoxybenzothiazolyl)benzenesulfonyl chloride as sensitive fluorescence derivatization reagents for amines in high–performance liquid chromatography. Hara S, et al. **Analyst** 1997 May;122(5):475–9

Determination of complex mixtures of airborne isocyanates and amines. Part 3. Methylenediphenyl diisocyanate, methylenediphenylamino isocyanate and methylenediphenyldiamine and structural analogues after thermal degradation of polyurethane. Tinnerberg H, et al. **Analyst** 1997 Mar;122(3):275–8

Micro–bore LC of nonapeptides and some primary amine drugs on a polymer column applying postcolumn fluorescamine labelling. Baeyens WR, et al. **Biomed Chromatogr** 1997 Mar–Apr;11(2):111–2

Heterocyclic amines: occurrence and prevention in cooked food. Robbana–Barnat S, et al. **Environ Health Perspect** 1996 Mar;104(3):280–8

Determination of heterocyclic amines in flame–grilled fish patty by capillary electrophoresis. Wu J, et al. **Food Addit Contam** 1996 Oct;13(7):851–61

Effects of marinating on heterocyclic amine carcinogen formation in grilled chicken. Salmon CP, et al. **Food Chem Toxicol** 1997 May;35(5):433–41

Polar and non–polar heterocyclic amines in cooked fish and meat products and their corresponding pan residues. Skog K, et al. **Food Chem Toxicol** 1997 Jun;35(6):555–65

Heterocyclic aromatic amine content in pre–processed meat cuts produced in Canada. Stavric B, et al. **Food Chem Toxicol** 1997 Feb;35(2):199–206

Ion chromatography of amylamine and tert.–butylamine in pharmaceuticals. Jagota NK, et al. **J Chromatogr A** 1996 Jul 19;739(1–2):343–9

Methods for the determination of mutagenic heterocyclic amines and their applications in environmental analysis. Kataoka H. **J Chromatogr A** 1997 Jul 11;774(1–2):121–42 (159 ref.)

Analysis of foods for heterocyclic aromatic amine carcinogens by solid–phase extraction and high–performance liquid chromatography. Knize MG, et al. **J Chromatogr A** 1997 Feb 28;763(1–2):179–85

Determination of heterocyclic aromatic amines by micellar electrokinetic chromatography with amperometric detection. Olsson JC, et al. **J Chromatogr A** 1997 Mar 28; 765(2):329–35

Liquid chromatography–atmospheric–pressure chemical ionization mass spectrometry as a routine method for the analysis of mutagenic amines in beef extracts. Pais P, et al. **J Chromatogr A** 1997 Aug 22;778(1–2):207–18

Chiral separation of primary amino compounds using a non–chiral crown ether with beta–cyclodextrin by capillary electrophoresis. Huang WX, et al. **J Chromatogr B Biomed Appl** 1997 Jul 18;695(1):157–62

Micellar electrokinetic capillary chromatography with laser–induced fluorimetric detection of amines in beer. Preston LM, et al. **J Chromatogr B Biomed Appl** 1997 Jul 18;695(1):175–80

Rapid gas chromatographic profiling and screening of biologically active amines. Kim KR, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1309–18

Determination of heterocyclic aromatic amines in food products: automation of the sample preparation method prior to HPLC and HPLC–MS quantification. Fay LB, et al. **Mutat Res** 1997 May 12;376(1–2):29–35

Chemical and swelling evaluations of amino group crosslinking in gelatin and modified gelatin matrices. Ofner CM 3rd, et al. **Pharm Res** 1996 Dec;13(12):1821–7

Quantitative determination of heterocyclic amines in food products. Gross GA, et al. **Princess Takamatsu Symp** 1995; 23:20–9 (23 ref.)

Mutagenic activity and heterocyclic amine content of the human diet. Knize MG, et al. **Princess Takamatsu Symp** 1995;23:30–8 (37 ref.)

Identification of new mutagenic heterocyclic amines and quantification of known heterocyclic amines. Wakabayashi K, et al. **Princess Takamatsu Symp** 1995;23:39–49 (31 ref.)

CHEMICAL SYNTHESIS

Synthesis of cis– and trans– 2–arylmethylcycloalkylamines: potential dopaminergic agents. Anchisi C, et al. **Farmaco** 1997 Jan;52(1):55–9

Alkyl–substituted amino acid amides and analogous di– and triamines: new non–peptide G protein activators. Leschke C, et al. **J Med Chem** 1997 Sep 12;40(19):3130–9

Effect of N,N–dimethylalkylamine N–oxides on the activity of purified sarcoplasmic reticulum (Ca–Mg)ATPase. Andriamainty F, et al. **Pharmazie** 1997 Mar;52(3):240–2

Stereoselective syntheses and CNS activity of novel tricyclic amines. Wünsch B, et al. **Pharmazie** 1997 Feb;52(2):87–91

CHEMISTRY

Heterocyclic N–acetoxyarylamines, models for the putative ultimate carcinogens of aromatic amines: 2–acetoxyamino–5–phenylpyridine and 2–acetoxyaminopyridine. Ojala WH, et al. **Acta Crystallogr C** 1997 May 15;53 (Pt 5):634–7

Size–selective derivatizations with polymer immobilized reagents. Szulc M, et al. **Biomed Chromatogr** 1997 Jul–Aug; 11(4):207–23

Substituted amines synergistic with tobramycin against Burkholderia cepacia in vitro. Cohn RC, et al. **Chemotherapy** 1997 Mar–Apr;43(2):100–7

Modification of amino groups in Candida utilis uricase with naphthoquinone disulfonic acid in relation to the enzymic activity. Yoshida K, et al. **FEBS Lett** 1981 Nov 2; 134(1):50–2

Effect of amine activators on the properties of chemical cured dental composites. Mathew L, et al. **J Biomater Appl** 1997 Jan;11(3):349–59

Application of tertiary amines with reduced toxicity to the

curing process of acrylic bone cements. Vazquez B, et al. **J Biomed Mater Res** 1997 Jan;34(1):129–36

Selective DNA binding of (N–alkylamine)–substituted naphthalene imides and diimides to G+C–rich DNA. Liu ZR, et al. **J Biomol Struct Dyn** 1996 Dec;14(3):331–9

Nonlinear partial least squares modeling of phenyl alkylamines with the monoamine oxidase inhibitory activities. Hasegawa K, et al. **J Chem Inf Comput Sci** 1996 Sep–Oct;36(5):1025–9

Hydrolytically stable amino–silica glass coating material for manipulation of the electroosmotic flow in capillary electrophoresis. Guo Y, et al. **J Chromatogr A** 1996 Sep 13;744(1–2):17–29

Liquid chromatography–electrospray mass spectrometry with in–source fragmentation for the identification and quantification of fourteen mutagenic amines in beef extracts. Pais P, et al. **J Chromatogr A** 1997 Jul 18; 775(1–2):125–36

Simultaneous solid–phase extraction and gas chromatographic–mass spectrometric determination of hemoglobin adducts from tobacco–specific nitrosamines and aromatic amines. Kutzer C, et al. **J Chromatogr Sci** 1997 Jan;35(1):1–6

Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. Delong R, et al. **J Pharm Sci** 1997 Jun;86(6):762–4

Encoded combinatorial chemistry: binary coding using chemically robust secondary amine tags. Ni ZJ, et al. **Methods Enzymol** 1996;267:261–72

Review of mutagenicity of monocyclic aromatic amines: quantitative structure–activity relationships. Chung KT, et al. **Mutat Res** 1997 Aug;387(1):1–16 (75 ref.)

Quantitative structure–activity (QSAR) relationships of mutagenic aromatic and heterocyclic amines. Hatch FT, et al. **Mutat Res** 1997 May 12;376(1–2):87–96

Complex formation of heterocyclic amines with porphyrins: its use in detection and prevention. Hayatsu H. **Princess Takamatsu Symp** 1995;23:172–80 (14 ref.)

Organic synthesis in experimental impact shocks. McKay CP, et al. **Science** 1997 Apr 18;276(5311):390–2

Catalytic hydroxyl/amine dyads within serine proteases. Paetzel M, et al. **Trends Biochem Sci** 1997 Jan;22(1):28–31 (33 ref.)

ISOLATION & PURIFICATION

Electroosmotic control of chiral separation in capillary zone electrophoresis. Hong S, et al. **Electrophoresis** 1995 Nov; 16(11):2132–6

Enantioselective gas chromatographic assay of 2–alkylamines using N–(trifluoroacetyl)prolyl derivatives and a chiral capillary column. Durden DA, et al. **J Chromatogr B Biomed Appl** 1997 Feb 7;689(1):165–73

Primary tetradecenyl amines from the ant Monomorium floricola. Jones TH, et al. **J Nat Prod** 1996 Aug;59(8):801–2

METABOLISM

Effects of chaihu–guizhi–ganjiang–tang on the levels of monoamines and their related substances, and acetylcholine in discrete brain regions of mice. Itoh T, et al. **Am J Chin Med** 1996;24(1):53–64

IMP reamination to AMP in rat skeletal muscle fiber types. Tullson PC, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):C1067–74

Heterocyclic amines, cytochrome P4501A2, and N–acetyltransferase: issues involved in incorporating putative genetic susceptibility markers into epidemiological studies. Sinha R, et al. **Ann Epidemiol** 1997 Jul;7(5):350–6

Characterization of rabbit UDP–glucuronosyltransferase UGT1A7: tertiary amine glucuronidation is catalyzed by UGT1A7 and UGT1A4. Bruck M, et al. **Arch Biochem Biophys** 1997 Aug 15;344(2):357–64

Initiation of radicals in biochemical systems: ferritin–hydroperoxides–aromatic amines. Metelitza DI, et al. **Biochemistry (Mosc)** 1997 Apr;62(4):391–400

Interactions of procarcinogenic heterocyclic amines and indolocarbazoles with the dioxin receptor. Kleman M, et al. **Biol Chem** 1996 Nov;377(11):741–62 (270 ref.)

Functional properties of the uptake of amines in immortalised peptidergic neurones (transport–P). Al–Damluji S, et al. **Br J Pharmacol** 1996 Jan;117(1):111–8

Visual detection of transport–P in peptidergic neurones. al–Damluji S, et al. **Br J Pharmacol** 1997 Mar;120(5):876–82

Induction by low Na+ or Cl– of cocaine sensitive carrier–mediated efflux of amines from cells transfected with the cloned human catecholamine transporters. Pifl C, et al. **Br J Pharmacol** 1997 May;121(2):205–12

Dorsal lesions of the prefrontal cortex: effects on alcohol consumption and subcortical monoaminergic systems. Deckel AW, et al. **Brain Res** 1996 Jun 3;723(1–2):70–6

Effects of morphine treatment and withdrawal on striatal and limbic monoaminergic activity and ascorbic acid oxidation in the rat. Desole MS, et al. **Brain Res** 1996 Jun 3;723(1–2):154–61

Metabolic activation of aromatic amines by human pancreas. Anderson KE, et al. **Carcinogenesis** 1997 May; 18(5):1085–92

Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. Hammons GJ, et al. **Carcinogenesis** 1997 Apr;18(4):851–4

N–oxygenation of primary amines and hydroxylamines and retroreduction of hydroxylamines by adult human liver microsomes and adult human flavin–containing monooxygenase 3. Lin J, et al. **Chem Res Toxicol** 1996 Oct–Nov;9(7):1183–93

Measurement and validation of kinetic parameter values for prediction of biodegradation rates in sewage treatment. Blok J, et al. **Ecotoxicol Environ Saf** 1996 Apr;33(3):217–27

Trimethylamine and the amine 'wiff' test not related in bacterial vaginosis [letter] Jones BM. **Int J STD AIDS** 1996 Mar–Apr;7(2):147–8

Synaptic and nonsynaptic monoaminergic neuron systems in the lamprey spinal cord. Schotland JL, et al. **J Comp Neurol** 1996 Aug 19;372(2):229–44

Comparison of kinetic properties between plant and fungal amine oxidases. Luhová L, et al. **J Enzyme Inhib** 1996; 10(4):251–262

Dot–blot analysis of the degree of covalent modification of proteins and antibodies at amino groups. Morçöl T, et al. **J Immunol Methods** 1997 Apr 11;203(1):45–53

The role of monoamine metabolism in oxidative glutamate toxicity. Maher P, et al. **J Neurosci** 1996 Oct 15; 16(20):6394–401

Distribution of amine oxidases and amine dehydrogenases in bacteria grown on primary amines and characterization of the amine oxidase from Klebsiella oxytoca. Hacisalihoglu A, et al. **Microbiology** 1997 Feb;143 (Pt 2):505–12

Evidence for a role of a perferryl–oxygen complex, FeO3+, in the N–oxygenation of amines by cytochrome P450 enzymes. Guengerich FP, et al. **Mol Pharmacol** 1997 Jan; 51(1):147–51

Naturally occurring diallyl disulfide inhibits the formation of carcinogenic heterocyclic aromatic amines in boiled pork juice. Tsai SJ, et al. **Mutagenesis** 1996 May;11(3):235–40

Role of acetyltransferases in the metabolism and carcinogenicity of aromatic amines. King CM, et al. **Mutat Res** 1997 May 12;376(1–2):123–8 (23 ref.)

DNA adducts of heterocyclic amines: formation, removal and inhibition by dietary components. Schut HA, et al. **Mutat Res** 1997 May 12;376(1–2):185–94

Metabolism of food–derived heterocyclic amines in nonhuman primates. Snyderwine EG, et al. **Mutat Res** 1997 May 12;376(1–2):203–10

NAT2*12A (803A—>G) codes for rapid arylamine n–acetylation in humans. Cascorbi I, et al. **Pharmacogenetics** 1996 Jun;6(3):257–9

Effects of chronic episodic hypoxia on monoamine metabolism and motor activity. Li R, et al. **Physiol Behav** 1996 Oct;60(4):1071–6

Mechanisms of cytochrome P450 1A2–mediated formation of N–hydroxy arylamines and heterocyclic amines and their reaction with guanyl residues. Guengerich FP, et al. **Princess Takamatsu Symp** 1995;23:78–84 (32 ref.)

Function and localization of cytochromes P450 involved in the metabolic activation of food–derived heterocyclic amines. McKinnon RA, et al. **Princess Takamatsu Symp** 1995;23:145–53

Superoxide radical generation from heterocyclic amines. Maeda H, et al. **Princess Takamatsu Symp** 1995;23:103–12 (27 ref.)

Activation and effects of the food–derived heterocyclic amines in extrahepatic tissues. Overvik E, et al. **Princess Takamatsu Symp** 1995;23:123–33 (50 ref.)

Possible relationship between tissue distribution of DNA adducts and genotoxicity of food–derived heterocyclic amines. Thorgeirsson SS, et al. **Princess Takamatsu Symp** 1995;23:85–92

Activation and detoxication of carcinogenic arylamines by sulfation. Yamazoe Y, et al. **Princess Takamatsu Symp** 1995; 23:154–62 (47 ref.)

Recognition of novel artifacts produced during the microsomal incubation of secondary alicyclic amines in the presence of cyanide. Gorrod JW, et al. **Xenobiotica** 1997 Apr;27(4):389–99

[Effect of hydrocortisone on levels of amines in thymus] Sergeeva VE, et al. **Biull Eksp Biol Med** 1997 Jun; 123(6):677–9 **(Rus)**

PHARMACOKINETICS

Primary aromatic amines: their N–oxidative bioactivation. Hlavica P, et al. **Hum Exp Toxicol** 1997 Aug;16(8):441–8 (81 ref.)

The effect of acetylation and deacetylation on the disposition of dapsone and monoacetyl dapsone hydroxylamines in human erythrocytes in–vitro. Coleman MD, et al. **J Pharm Pharmacol** 1996 Apr;48(4):401–6

The role of iminium–enamine species in the toxication and detoxication of cyclic tertiary amines. Sayre LM, et al. **NIDA Res Monogr** 1997;173:106–27 (35 ref.)

PHARMACOLOGY

Antimicrobial effects of oligoamines. Rehse K, et al. **Arch Pharm (Weinheim)** 1996 Mar;329(3):155–60

Effects of amphiphilic compounds on metabolic and biological activities of Salmonella typhimurium. Majtánová L, et al. **Arzneimittelforschung** 1996 Jan;46(1):64–7

Inhibition of copper amine oxidase by haloamines: a killer product mechanism. Medda R, et al. **Biochemistry** 1997 Mar 4;36(9):2595–602

Oxidation–dependent inactivation of aryl sulfotransferase IV by primary N–hydroxy arylamines during in vitro assays. King RS, et al. **Carcinogenesis** 1997 Apr;18(4):843–9

Substituted amines synergistic with tobramycin against Burkholderia cepacia in vitro. Cohn RC, et al. **Chemotherapy** 1997 Mar–Apr;43(2):100–7

Synthesis and microbiological evaluations of (N–heteroaryl) arylmethanamines and their Schiff bases. Fioravanti R, et al. **Farmaco** 1996 Oct;51(10):643–52

Sphingosine, oleylamine and stearylamine inhibit both CD11a/CD18–dependent and –independent homotypic aggregation: demonstration by cytofluorimetry. Aussel C, et al. **Immunol Lett** 1995 Sep;47(3):175–80

Dietary heterocyclic amines as potential human carcinogens: experimental data from nonhuman primates. Thorgeirsson UP, et al. **In Vivo** 1996 Mar–Apr;10(2):145–52

Effect of dietary phenolic amines on testicular function and luteinizing hormone secretion in male angora goats. Vera–Avila HR, et al. **J Anim Sci** 1997 Jun;75(6):1612–20

Nonlinear partial least squares modeling of phenyl alkylamines with the monoamine oxidase inhibitory activities. Hasegawa K, et al. **J Chem Inf Comput Sci** 1996 Sep–Oct;36(5):1025–9

Mutagenicity of nitro– and amino–substituted carbazoles in Salmonella typhimurium. III. Methylated derivatives of 9H–carbazole. André V, et al. **Mutat Res** 1997 Mar 17; 389(2–3):247–60

Review of mutagenicity of monocyclic aromatic amines: quantitative structure–activity relationships. Chung KT, et al. **Mutat Res** 1997 Aug;387(1):1–16 (75 ref.)

Effect of alkalinization of cytosolic pH by amines on intracellular Ca2+ activity in HT29 cells. Benning N, et al. **Pflugers Arch** 1996 May;432(1):126–33

Induction of cytochrome P4501A isozymes by heterocyclic amines and other food–derived compounds. Kleman MI, et al. **Princess Takamatsu Symp** 1995;23:163–71 (37 ref.)

[Irreversible specific inhibition of E. coli inorganic pyrophosphatase with amines] Burobin AV, et al. **Bioorg Khim** 1997 Feb;23(2):104–9 (Eng. Abstr.) **(Rus)**

[Preparation and pharmacologic characteristics of aryloxyaminopropanol derivatives with an assumed cardiovascular effect] Mlynárová R, et al. **Ceska Slov Farm** 1996 Sep;45(5):260–4 (Eng. Abstr.) **(Slo)**

THERAPEUTIC USE

Plaque bacteria counts and vitality during chlorhexidine, meridol and listerine mouthrinses. Netuschil L, et al. **Eur J Oral Sci** 1995 Dec;103(6):355–61

The effectiveness of an amine fluoride/stannous fluoride dentifrice on the gingival health of teenagers: results after six months. Sgan–Cohen HD, et al. **Int Dent J** 1996 Aug; 46(4):340–5

Comparative study of plaque and gingivitis prevention by AmF/SnF2 and NaF. A clinical and microbiological 9–month study. Mengel R, et al. **J Clin Periodontol** 1996 Apr;23(4):372–8

Researchers seek new weapon against the flu [news] Service RF. **Science** 1997 Feb 7;275(5301):756–7

TOXICITY

Biomonitoring workers exposed to arylamines: application to hazard assessment. Sepai O, et al. **Adv Exp Med Biol** 1996;387:451–5

Human exposure to carcinogenic heterocyclic amines and their mutational fingerprints in experimental animals. Nagao M, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:497–501 (31 ref.)

Enhancement of hepatocarcinogenesis by combined administration of food–derived heterocyclic amines at low doses in the rat. Hasegawa R, et al. **Food Chem Toxicol** 1996 Nov–Dec;34(11–12):1097–101

Analysis of synergism in hepatocarcinogenesis based on preneoplastic foci induction by 10 heterocyclic amines in the rat. Hasegawa R, et al. **Jpn J Cancer Res** 1996 Nov; 87(11):1125–33

Inhibition of the genotoxic effects of heterocyclic amines in human derived hepatoma cells by dietary bioantimutagens. Sanyal R, et al. **Mutagenesis** 1997 Jul;12(4):297–303

Health risks of heterocyclic amines. Felton JS, et al. **Mutat Res** 1997 May 12;376(1–2):37–41 (25 ref.)

Genetic changes induced by heterocyclic amines. Nagao M, et al. **Mutat Res** 1997 May 12;376(1–2):161–7 (43 ref.)

The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Windmill KF, et al. **Mutat Res** 1997 May 12; 376(1–2):153–60 (44 ref.)

Effect of some organic ammonium salts and amine oxides in the SOS chromotest. Majtán V, et al. **Pharmazie** 1996 Oct;51(10):753–5

Heterocyclic amine mutagenicity/carcinogenicity: influence of repair, metabolism, and structure. Felton JS, et al. **Princess Takamatsu Symp** 1995;23:50–8 (25 ref.)

Enhancement of rat liver cell foci development by combined treatment with heterocyclic amines at low doses. Ito N, et al. **Princess Takamatsu Symp** 1995;23:251–9

Activation and effects of the food–derived heterocyclic amines in extrahepatic tissues. Overvik E, et al. **Princess Takamatsu Symp** 1995;23:123–33 (50 ref.)

Dietary modulation of the carcinogenicity of the heterocyclic amines. Weisburger JH, et al. **Princess Takamatsu Symp** 1995;23:240–50

Diaminonaphthalenes and related aminocompounds: mutagenicity, CYP1A induction and interaction with the

Ah receptor. Cheung YL, et al. **Toxicology** 1997 Mar 28; 118(2-3):115-27

[Relationships "structure--methemoglobin-forming activity" in the series of aromatic amines] Kharchevnikova NV, et al. **Gig Sanit** 1997 May-Jun;(3):41-4 **(Rus)**

AMINES, BIOGENIC see **BIOGENIC AMINES**

AMINES, SYMPATHOMIMETIC see **SYMPATHOMIMETICS**

AMINO ACID ACTIVATING ENZYMES see **AMINO ACYL T RNA SYNTHETASES**

AMINO ACID ACTIVATION

see related

AMINO ACYL T RNA SYNTHETASES

A method for preparation of amino acid thiohydantoins from free amino acids activated by acetyl chloride for development of protein C-terminal sequencing. Mo B, et al. **Anal Biochem** 1997 Jul 1;249(2):207-11

AMINO ACID CHLOROMETHYL KETONES

Use of thrombin inhibitors ex vivo allows critical care clinical chemistry and hematology testing on common specimens. Lyon AW, et al. **Clin Biochem** 1997 Mar;30(2):121-7

ANALYSIS

Narrow-bore liquid chromatography-tandem mass spectrometry with simultaneous radioactivity monitoring for partially characterizing the biliary metabolites of an arginine fluoroalkyl ketone analog of D-MePhe-Pro-Arg, a potent thrombin inhibitor. Heath TG, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):281-9

CHEMISTRY

Identification of the reactive histidine of cucumisin, a plant serine protease: modification with peptidyl chloromethyl ketone derivative of peptide substrate. Yonezawa H, et al. **J Biochem (Tokyo)** 1995 Nov;118(5):917-20

DIAGNOSTIC USE

Scintigraphic visualization of pulmonary thrombi with 123I-YPACK-TNK-tPA. De Bruyn VH, et al. **Coron Artery Dis** 1995 Sep;6(9):715-21

PHARMACOLOGY

ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis. Rouquet N, et al. **Curr Biol** 1996 Sep 1;6(9):1192-5

Effect of anti-apoptotic genes and peptide inhibitors on cytoplasmic acidification during apoptosis. Pardhasaradhi BV, et al. **FEBS Lett** 1997 Jul 7;411(1):67-70

Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1(CD95)-mediated apoptosis in renal-cell-cancer cells. Tomita Y, et al. **Int J Cancer** 1996 Sep 27;68(1):132-5

Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor [published erratum appears in J Biol Chem 1997 Jun 27;272(26):16708] Sorensen BB, et al. **J Biol Chem** 1997 May 2;272(18):11863-8

Genetic and metabolic status of NGF-deprived sympathetic neurons saved by an inhibitor of ICE family proteases. Deshmukh M, et al. **J Cell Biol** 1996 Dec;135(5):1341-54

Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. Rodriguez I, et al. **J Exp Med** 1996 Nov 1;184(5):2067-72

The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. Chinnaiyan AM, et al. **Nat Med** 1997 Mar; 3(3):333-7

Baculovirus p35 and Z-VAD-fmk inhibit thapsigargin-induced apoptosis of breast cancer cells. Qi XM, et al. **Oncogene** 1997 Sep 4;15(10):1207-12

Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood-various anticoagulants are not equal. Golański J, et al. **Thromb Res** 1996 Aug 1;83(3):199-216

THERAPEUTIC USE

ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha. Künstle G, et al. **Immunol Lett** 1997 Jan;55(1):5-10

AMINO ACID DECARBOXYLASES, AROMATIC see **AROMATIC AMINO ACID DECARBOXYLASES**

AMINO ACID ISOMERASES

ANALYSIS

Leaderless polypeptides efficiently extracted from whole cells by osmotic shock. Thorstenson YR, et al. **J Bacteriol** 1997 Sep;179(17):5333-9

Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. Billich A, et al. **J Exp Med** 1997 Mar 3;185(5):975-80

ANTAGONISTS & INHIBITORS

Carboxymethylation of MutS-cysteine-15 specifically inactivates adenosylcobalamin-dependent glutamate mutase. Examination of the role of this residue in coenzyme-binding and catalysis. Holloway DE, et al. **J Biol Chem** 1996 Nov 15;271(46):29121-5

A Cyclosporin A-sensitive small molecular weight cyclophilin of filarial parasites. Ma D, et al. **Mol Biochem Parasitol** 1996 Aug;79(2):235-41

Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Franke EK, et al. **Virology** 1996 Aug 1;222(1):279-82

BIOSYNTHESIS

Cyclophilins are induced by hypoxia and heat stress in myogenic cells. Andreeva L, et al. **Biochem Biophys Res Commun** 1997 Aug 8;237(1):6-9

Regulation of the glutamate racemase of Escherichia coli investigated by site-directed mutagenesis. Doublet P, et al. **Microb Drug Resist** 1996 Spring;2(1):43-9

Characterization of a Schistosoma mansoni cDNA encoding a B-like cyclophilin and its expression in Escherichia coli. Klinkert MQ, et al. **Mol Biochem Parasitol** 1995 Dec; 75(1):99-111

Trigger factor is induced upon cold shock and enhances viability of Escherichia coli at low temperatures. Kandror O, et al. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):4978-81

CHEMISTRY

Adenosylcobalamin-dependent glutamate mutase: properties of a fusion protein in which the cobalamin-binding subunit is linked to the catalytic subunit. Holloway DE, et al. **Biochem J** 1996 Dec 15;320 (Pt 3):825-30

How enzymes control the reactivity of adenosylcobalamin: effect on coenzyme binding and catalysis of mutations in the conserved histidine-aspartate pair of glutamate mutase. Chen HP, et al. **Biochemistry** 1997 Jun 24;36(25):7884-9

Modulation of cyclosporin A/cyclophilin interactions by drug vehicles. Janowski B, et al. **Bioorg Med Chem** 1997 Jan;5(1):179-86

Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Ranganathan R, et al. **Cell** 1997 Jun 13; 89(6):875-86

Structural basis for the activation of phenylalanine in the non-ribosomal biosynthesis of gramicidin S. Conti E, et al. **EMBO J** 1997 Jul 16;16(14):4174-83

An internal FK506-binding domain is the catalytic core of the prolyl isomerase activity associated with the Bacillus subtilis trigger factor. Göthel SF, et al. **Eur J Biochem** 1997 Feb 15;244(1):59-65

A nuclear RNA-binding cyclophilin in human T cells. Mi H, et al. **FEBS Lett** 1996 Dec 2;398(2-3):201-5

Crystal structure of cytoplasmic Escherichia coli peptidyl-prolyl isomerase: evidence for decreased mobility of loops upon complexation. Edwards KJ, et al. **J Mol Biol** 1997 Aug 15;271(2):258-65

Multiple cycles of global unfolding of GroEL-bound cyclophilin A evidenced by NMR. Nieba-Axmann SE, et al. **J Mol Biol** 1997 Sep 5;271(5):803-18

The NMR solution conformation of unligated human cyclophilin A. Ottiger M, et al. **J Mol Biol** 1997 Sep 12; 272(1):64-81

Modular structure of the trigger factor required for high activity in protein folding. Zarnt T, et al. **J Mol Biol** 1997 Sep 5;271(5):827-37

The modular organization of multifunctional peptide synthetases. Vater J, et al. **J Protein Chem** 1997 Jul; 16(5):557-64

Fault lines in the HIV core? [editorial] **Nat Struct Biol** 1997 Feb;4(2):85-6

Chaperone activity and structure of monomeric polypeptide binding domains of GroEL [see comments] Zahn R, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15024-9. Comment in: Proc Natl Acad Sci U S A 1997 Jan 7;94(1):7-8.

Cyclophilin A complexed with a fragment of HIV-1 gag protein: insights into HIV-1 infectious activity. Zhao Y, et al. **Structure** 1997 Jan 15;5(1):139-46

CLASSIFICATION

ScCypB is a novel second cytosolic cyclophilin from Streptomyces chrysomallus which is phylogenetically distant from ScCypA. Pahl A, et al. **Microbiology** 1997 Jan;143 (Pt 1):117-26

DRUG EFFECTS

Correlations between Mycoplasma pneumoniae sensitivity to cyclosporin A and cyclophilin-mediated regulation of mycoplasma cytadherence. Reddy SP, et al. **Microb Pathog** 1996 Mar;20(3):155-69

GENETICS

Adenosylcobalamin-dependent glutamate mutase: properties of a fusion protein in which the cobalamin-binding subunit is linked to the catalytic subunit. Holloway DE, et al. **Biochem J** 1996 Dec 15;320 (Pt 3):825-30

cDNA cloning of rat mitochondrial cyclophilin. Woodfield KY, et al. **Biochim Biophys Acta** 1997 Mar 20; 1351(1-2):27-30

Contrasting effects of electroconvulsive shock on mRNAs encoding the high affinity kainate receptor subunits (KA1 and KA2) and cyclophilin in the rat. Porter RH, et al. **Brain Res** 1996 Feb 26;710(1-2):97-102

Cyclophilin 40 (PPID) gene map position 4q31.3. Ratajczak T, et al. **Chromosome Res** 1997 Apr;5(2):151

Assignment of cyclophilin A (PPIA) to human chromosome band 7p13by in situ hybridization. Braaten D, et al. **Cytogenet Cell Genet** 1996;74(4):262

Cloning, expression and chromosomal mapping of a novel cyclophilin-related gene (PPIL1) from human fetal brain. Ozaki K, et al. **Cytogenet Cell Genet** 1996;72(2-3):242-5

Isolation of a cDNA encoding the chicken homologue of the human calcium-modulating cyclophilin ligand. Bram RJ. **Gene** 1996 Oct 3;174(2):307-9

The structure and complete nucleotide sequence of the human cyclophilin 40 (PPID) gene. Yokoi H, et al. **Genomics** 1996 Aug 1;35(3):448-55

Regulation of the glutamate racemase of Escherichia coli investigated by site-directed mutagenesis. Doublet P, et al. **Microb Drug Resist** 1996 Spring;2(1):43-9

ScCypB is a novel second cytosolic cyclophilin from Streptomyces chrysomallus which is phylogenetically distant from ScCypA. Pahl A, et al. **Microbiology** 1997 Jan;143 (Pt 1):117-26

Purification of two Bacillus subtilis proteins which cross-react with antibodies directed against eukaryotic protein kinase C, the His HPr kinase and trigger factor. Zouari N, et al. **Microbiology** 1997 Apr;143 (Pt 4):1151-61

Sequence conservation of schistosome cyclophilins. Klinkert MQ, et al. **Mol Biochem Parasitol** 1996 Oct 30;81(2):239-42

A stage regulated cyclophilin gene from Theileria annulata. Swan DG, et al. **Mol Biochem Parasitol** 1996 Oct 18; 81(1):111-4

A cyclophilin-like peptidyl-prolyl cis/trans isomerase from Legionella pneumophila--characterization, molecular cloning and overexpression. Schmidt B, et al. **Mol Microbiol** 1996 Sep;21(6):1147-60

Amino acid sequence of peptidyl-prolyl isomerase a of Fusarium sporotrichioides. Chow LP, et al. **Nat Toxins** 1996;4(4):149-55

A novel plant peptidyl-prolyl-cis-trans-isomerase (PPIase): cDNA cloning, structural analysis, enzymatic activity and expression. Blecher O, et al. **Plant Mol Biol** 1996 Nov; 32(3):493-504

Identification of two CyP-40-like cyclophilins in Saccharomyces cerevisiae, one of which is required for normal growth. Duina AA, et al. **Yeast** 1996 Aug; 12(10):943-52

ISOLATION & PURIFICATION

RS cyclophilins: identification of an NK-TR1-related cyclophilin. Nestel FP, et al. **Gene** 1996 Nov 21; 180(1-2):151-5

Identification and characterization of Schistosoma mansoni p17.7, a cyclophilin. Kiang D, et al. **Mol Biochem Parasitol** 1996 Feb-Mar;76(1-2):73-82

METABOLISM

Catalysis of the refolding of urea denatured creatine kinase by peptidyl-prolyl cis-trans isomerase. Yang HP, et al. **Biochim Biophys Acta** 1997 Apr 4;1338(2):147-50

Characterization of cyclophilin 40: highly conserved protein that directly associates with Hsp90. Yokoi H, et al. **Biol Pharm Bull** 1996 Apr;19(4):506-11

Cyclophilin A is present in rat germ cells and is associated with spermatocyte apoptosis. Reproductive Toxicology Group. Wine RN, et al. **Biol Reprod** 1997 Feb;56(2):439-46

Conformational polymorphism in peptidic and nonpeptidic drug molecules. Taylor P, et al. **Biopolymers** 1996; 40(5):585-92

Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Ranganathan R, et al. **Cell** 1997 Jun 13; 89(6):875-86

Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. Belshaw PJ, et al. **Chem Biol** 1996 Sep; 3(9):731-8

A large-scale processing of kinetic data files with derivation of the inhibitory constant Ki: an application to proline isomerases. Galat A. **Comput Chem** 1996 Jun;20(2):279-81

The chaperonin cycle cannot substitute for prolyl isomerase activity, but GroEL alone promotes productive folding of a cyclophilin-sensitive substrate to a cyclophilin-resistant form. von Ahsen O, et al. **EMBO J** 1997 Aug 1; 16(15):4568-78

Cellular catabolism in apoptosis: DNA degradation and endonuclease activation. Montague JW, et al. **Experientia** 1996 Oct 31;52(10-11):957-62 (59 ref.)

HIV protease substrate conformation: modulation by cyclophilin A. McCornack MA, et al. **FEBS Lett** 1997 Sep 1;414(1):84-8

Cyclophilin active site mutants have native prolyl isomerase activity with a protein substrate. Scholz C, et al.

FEBS Lett 1997 Sep 1;414(1):69–73

Extended binding sites of cyclophilin as revealed by the interaction with HIV–1 Gag polyprotein derived oligopeptides. Schutkowski M, et al. **FEBS Lett** 1996 Oct 7;394(3):289–94

Comparative mutational analysis of peptidyl prolyl cis/trans isomerases: active sites of Escherichia coli trigger factor and human FKBP12. Tradler T, et al. **FEBS Lett** 1997 Apr 28;407(2):184–90

SurA, a periplasmic protein with peptidyl–prolyl isomerase activity, participates in the assembly of outer membrane porins. Rouvière PE, et al. **Genes Dev** 1996 Dec 15; 10(24):3170–82

Immunophilins, ligands, and the control of signal transduction. Schreiber SL, et al. **Harvey Lect** 1995–96; 91:99–114 (89 ref.)

Luciferase assembly after transport into mammalian microsomes involves molecular chaperones and peptidyl–prolyl cis/trans–isomerases. Brunke M, et al. **J Biol Chem** 1996 Sep 20;271(38):23487–94

FKBP–12 recognition is dispensable for signal generation by type I transforming growth factor–beta receptors. Charng MJ, et al. **J Biol Chem** 1996 Sep 20;271(38):22941–4

The amino–terminal 118 amino acids of Escherichia coli trigger factor constitute a domain that is necessary and sufficient for binding to ribosomes. Hesterkamp T, et al. **J Biol Chem** 1997 Aug 29;272(35):21865–71

The Escherichia coli SlyD is a metal ion–regulated peptidyl–prolyl cis/trans–isomerase. Hottenrott S, et al. **J Biol Chem** 1997 Jun 20;272(25):15697–701

Trigger factor associates with GroEL in vivo and promotes its binding to certain polypeptides. Kandror O, et al. **J Biol Chem** 1997 Jan 17;272(3):1730–4

Native recombinant cyclophilins A, B, and C degrade DNA independently of peptidylprolyl cis–trans–isomerase activity. Potential roles of cyclophilins in apoptosis. Montague JW, et al. **J Biol Chem** 1997 Mar 7; 272(10):6677–84

Cyclic ADP–ribose binds to FK506–binding protein 12.6 to release Ca2+ from islet microsomes. Noguchi N, et al. **J Biol Chem** 1997 Feb 7;272(6):3133–6

Casein kinase II catalyzes tyrosine phosphorylation of the yeast nucleolar immunophilin Fpr3. Wilson LK, et al. **J Biol Chem** 1997 May 16;272(20):12961–7

Neuronal localization of the cyclophilin A protein in the adult rat brain. Göldner FM, et al. **J Comp Neurol** 1996 Aug 19;372(2):283–93

The rate of isomerisation of peptidyl–proline bonds as a probe for interactions in the physiological denatured state of chymotrypsin inhibitor 2. Tan YJ, et al. **J Mol Biol** 1997 Jun 20;269(4):611–22

Molecular recognition in the HIV–1 capsid/cyclophilin A complex. Yoo S, et al. **J Mol Biol** 1997 Jun 27;269(5):780–95

The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein. Braaten D, et al. **J Virol** 1997 Mar; 71(3):2107–13

Active–site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions. Dorfman T, et al. **J Virol** 1997 Sep;71(9):7110–3

Cyclophilin–related protein RanBP2 acts as chaperone for red/green opsin. Ferreira PA, et al. **Nature** 1996 Oct 17; 383(6601):637–40

A novel plant peptidyl–prolyl–cis–trans–isomerase (PPIase): cDNA cloning, structural analysis, enzymatic activity and expression. Blecher O, et al. **Plant Mol Biol** 1996 Nov; 32(3):493–504

Interconversion of red opsin isoforms by the cyclophilin–related chaperone protein Ran–binding protein 2. Ferreira PA, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1556–61

Peptidyl prolyl cis–trans isomerase activity of cyclophilin A in functional homo–oligomeric receptor expression. Helekar SA, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):5432–7

FK506–binding protein mutational analysis: defining the active–site residue contributions to catalysis and the stability of ligand complexes. DeCenzo MT, et al. **Protein Eng** 1996 Feb;9(2):173–80

Comparison of cyclophilin binding assay and radioimmunoassay in monitoring of blood cyclosporine. Huupponen R, et al. **Ther Drug Monit** 1997 Aug; 19(4):446–9

PHARMACOLOGY

Cyclosporine A–resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. Braaten D, et al. **J Virol** 1996 Aug;70(8):5170–6

PHYSIOLOGY

Functional analysis of the yeast 40 kDa cyclophilin Cyp40 and its role for viability and steroid receptor regulation. Warth R, et al. **Biol Chem** 1997 May;378(5):381–91

Absconding with the chaperone: essential cyclophilin–Gag interaction in HIV–1 virions. Luban J. **Cell** 1996 Dec 27; 87(7):1157–9

Cooperation of enzymatic and chaperone functions of trigger factor in the catalysis of protein folding. Scholz C, et al. **EMBO J** 1997 Jan 2;16(1):54–8

Inhibition of cyclophilin function in HIV–I infection by cyclosporin A. Huss R. **Immunol Today** 1996 Jun; 17(6):259–60

The modular organization of multifunctional peptide synthetases. Vater J, et al. **J Protein Chem** 1997 Jul; 16(5):557–64

Cyclophilin A–induced alterations of human immunodeficiency virus type 1 CA protein in vitro. Agresta BE, et al. **J Virol** 1997 Sep;71(9):6921–7

Host–cell cyclophilin is important for the intracellular replication of Leishmania major. Hoerauf A, et al. **Mol Microbiol** 1997 Apr;24(2):421–9

A cyclophilin function in Hsp90–dependent signal transduction [see comments] Duina AA, et al. **Science** 1996 Dec 6;274(5293):1713–5. Comment in: Science 1996 Dec 6;274(5293):1613–4.

Molecular chaperone machines: chaperone activities of the cyclophilin Cyp–40 and the steroid aporeceptor–associated protein p23 [see comments] Freeman BC, et al. **Science** 1996 Dec 6;274(5293):1718–20. Comment in: Science 1996 Dec 6;274(5293):1613–4.

ULTRASTRUCTURE

Crystal structure of human cyclophilin A bound to the amino–terminal domain of HIV–1 capsid. Gamble TR, et al. **Cell** 1996 Dec 27;87(7):1285–94

AMINO ACID METABOLISM, INBORN ERRORS

Maternal non–phenylketonuric mild hyperphenylalaninemia. Levy HL, et al. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S20–5

Untreated non–phenylketonuric–hyperphenylalaninaemia: intellectual and neurological outcome. Weglage J, et al. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S26–8

Richner–Hanhart syndrome: importance of early diagnosis and early intervention. Tallab TM. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 2):857–9

BLOOD

Clinical and biochemical heterogeneity in females of a large pedigree with ornithine transcarbamylase deficiency due to the R141Q mutation [published erratum appears in Am J Med Genet 1997 Jul 11;71(1):125] Ahrens MJ, et al. **Am J Med Genet** 1996 Dec 18;66(3):311–5

Pancreatic secretory trypsin inhibitor as a diagnostic marker for adult–onset type II citrullinemia. Kobayashi K, et al. **Hepatology** 1997 May;25(5):1160–5

Determination of the 8–methyl ether of xanthurenic acid in human serum by high–performance liquid chromatography with fluorescence detection. Imai J, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1–2):204–7

Magnetic resonance imaging and spectroscopy of the brain in propionic acidemia: clinical and biochemical considerations. Bergman AJ, et al. **Pediatr Res** 1996 Sep; 40(3):404–9 (30 ref.)

[Hyperhomocyst(e)inemia––an independent risk factor of stroke] Lalouschek W, et al. **Fortschr Neurol Psychiatr** 1996 Jul;64(7):271–7 (61 ref.) (Eng. Abstr.) **(Ger)**

[Late onset type I tyrosinemia] Kljuber V, et al. **Orv Hetil** 1997 Jul 13;138(28):1805–8 (Eng. Abstr.) **(Hun)**

COMPLICATIONS

Parathyroid hormone resistance and B cell lymphopenia in propionic acidemia. Griffin TA, et al. **Acta Paediatr** 1996 Jul;85(7):875–8

Prolidase deficiency and systemic lupus erythematosus. Shrinath M, et al. **Arch Dis Child** 1997 May;76(5):441–4

Congenital glaucoma associated with an arginase deficit: a case report. Saccà SC, et al. **Eur J Ophthalmol** 1996 Oct–Dec;6(4):421–6

Homocysteine, oxidative stress, and vascular disease [see comments] Welch GN, et al. **Hosp Pract (Off Ed)** 1997 Jun 15;32(6):81–2, 85, 88–92 (13 ref.). Comment in: Hosp Pract (Off Ed) 1997 Aug 15;32(8):44.

Case report: recurrent hyperammonaemic encephalopathy due to citrullinaemia in a 52 year old man. Chow WC, et al. **J Gastroenterol Hepatol** 1996 Jul;11(7):621–5

Immune complex disease consistent with systemic lupus erythematosus in a patient with lysinuric protein intolerance. Parsons H, et al. **J Inherit Metab Dis** 1996; 19(5):627–34

Pregnancy and argininosuccinic aciduria. Worthington S, et al. **J Inherit Metab Dis** 1996;19(5):621–3

Primary treatment of propionic acidemia complicated by acute thiamine deficiency. Matern D, et al. **J Pediatr** 1996 Nov;129(5):758–60

Nephropathy of tyrosinemia and its long–term outlook. Paradis K, et al. **J Pediatr Gastroenterol Nutr** 1997 Jan; 24(1):113–4

DIAGNOSIS

MR and proton MR spectroscopy of the brain in hyperhomocysteinemia caused by methylenetetrahydrofolate reductase deficiency. Engelbrecht V, et al. **AJNR Am J Neuroradiol** 1997 Mar; 18(3):536–9

Variability of the methionine loading test: no effect of a low protein diet. den Heijer M, et al. **Ann Clin Biochem** 1996 Nov;33 (Pt 6):551–4

The human plasmalemmal carnitine transporter defect is expressed in cultured lymphoblasts: a new non–invasive method for diagnosis [letter] Tein I, et al. **Clin Chim Acta** 1996 Aug 30;252(2):201–4

Diagnosis and management of tyrosinemia type I. Holme E, et al. **Curr Opin Pediatr** 1995 Dec;7(6):726–32 (45 ref.)

Adult–onset type II citrullinemia: clinical pictures before and after liver transplantation. Kawata A, et al. **Intern Med** 1997 Jun;36(6):408–12

In vivo nitrogen metabolism in ornithine transcarbamylase deficiency. Yudkoff M, et al. **J Clin Invest** 1996 Nov 1; 98(9):2167–73

Amino acid and DNA analyses in a family with ornithine transcarbamylase deficiency. Hou JW, et al. **J Formos Med Assoc** 1996 Feb;95(2):144–7

Issues for consideration in dihydropteridine reductase (DHPR) deficiency: a variant form of hyperphenylalaninaemia. Pogson D. **J Intellect Disabil Res** 1997 Jun;41 (Pt 3):208–14

Hyperargininemia presenting as persistent neonatal jaundice and hepatic cirrhosis. Braga AC, et al. **J Pediatr Gastroenterol Nutr** 1997 Feb;24(2):218–21

Special imaging casebook. Hereditary tyrosinemia, acute type I. Herman TE, et al. **J Perinatol** 1997 Jan–Feb;17(1):87–90

CT and MRI in a girl with late–onset ornithine transcarbamylase deficiency: case report. Bajaj SK, et al. **Neuroradiology** 1996 Nov;38(8):796–9

Imaging features of type 1 hereditary tyrosinemia: a review of 30 patients. Dubois J, et al. **Pediatr Radiol** 1996 Dec; 26(12):845–51

Amniotic fluid odd–chain fatty acids are increased in propionic acidaemia. Coker M, et al. **Prenat Diagn** 1996 Oct;16(10):941–4

Use of amniotic fluid amino acids in prenatal testing for argininosuccinic aciduria and citrullinaemia. Mandell R, et al. **Prenat Diagn** 1996 May;16(5):419–24

Gestational age–related reference values for amniotic fluid amino acids: a useful tool for prenatal diagnosis of aminoacidopathies. Rabier D, et al. **Prenat Diagn** 1996 Jul; 16(7):623–8

Pediatric case of the day. Hepatorenal tyrosinemia (tyrosinemia type I). Gallant JM, et al. **Radiographics** 1996 Sep;16(5):1221–4

Lysinuric protein intolerance presenting as coma in a middle–aged man. Gare M, et al. **West J Med** 1996 Oct; 165(4):231–3

[Lysinuric dibasic protein intolerance: characteristic aspects of bone marrow involvement] Doireau V, et al. **Arch Pediatr** 1996 Sep;3(9):877–80 (Eng. Abstr.) **(Fre)**

DIET THERAPY

Amino acid composition of food products used in the treatment of patients with disorders of the amino acid and protein metabolism. Bremer HJ, et al. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S108–14

Clinical outcome and long–term management of 17 patients with propionic acidaemia. van der Meer SB, et al. **Eur J Pediatr** 1996 Mar;155(3):205–10

DRUG THERAPY

Is infantile alternating hemiplegia mediated by glutamate toxicity and can it be treated with memantine? [letter] Korinthenberg R. **Neuropediatrics** 1996 Oct;27(5):277–8

Effect of carnitine administration on glycine metabolism in patients with isovaleric acidemia: significance of acetylcarnitine determination to estimate the proper carnitine dose. Itoh T, et al. **Tohoku J Exp Med** 1996 Jun; 179(2):101–9

ENZYMOLOGY

Tyrosine and its catabolites: from disease to cancer. Tanguay RM, et al. **Acta Biochim Pol** 1996;43(1):209–16 (33 ref.)

Prenatal monitoring in a family at high risk for ornithine transcarbamylase (OTC) deficiency: a new mutation of an A–to–C transversion in position +4 of intron 1 of the OTC gene that is likely to abolish enzyme activity. Hoshide R, et al. **Am J Med Genet** 1996 Aug 23;64(3):459–64

Mild form of beta–ketothiolase deficiency (mitochondrial acetoacetyl–CoA thiolase deficiency) in two Japanese siblings: identification of detectable residual activity and cross–reactive material in EB–transformed lymphocytes. Fukao T, et al. **Clin Genet** 1996 Oct;50(4):263–6

beta–Ketothiolase (2–methylacetoacetyl–coenzyme A thiolase) deficiency: identification of two patients in Israel. Gibson KM, et al. **J Inherit Metab Dis** 1996;19(5):698–9

EPIDEMIOLOGY

Vomiting, ataxia, and altered mental status in an adolescent: late–onset ornithine transcarbamylase deficiency. Myers JH, et al. **Am J Emerg Med** 1996 Oct;14(6):553–7

GENETICS

Glutaric aciduria type I in the Arab and Jewish communities in Israel. Anikster Y, et al. **Am J Hum Genet** 1996 Nov; 59(5):1012–8

Gene structure and mutations of glutaryl–coenzyme A dehydrogenase: impaired association of enzyme subunits that is due to an A421V substitution causes glutaric acidemia type I in the Amish. Biery BJ, et al. **Am J Hum Genet** 1996 Nov;59(5):1006–11

Lysinuric protein intolerance (LPI) gene maps to the long arm of chromosome 14. Lauteala T, et al. **Am J Hum Genet** 1997 Jun;60(6):1479–86

Clinical and biochemical heterogeneity in females of a large pedigree with ornithine transcarbamylase deficiency due to the R141Q mutation [published erratum appears in Am J Med Genet 1997 Jul 11;71(1):125] Ahrens MJ, et al. **Am J Med Genet** 1996 Dec 18;66(3):311–5

Prevalence of familial mild hyperhomocysteinemia. Franken DG, et al. **Atherosclerosis** 1996 Aug 23;125(1):71–80

Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. Kang SS, et al. **Atherosclerosis** 1996 Jan 26;119(2):135–8 (21 ref.)

A YAC contig spanning the blepharophimosis–ptosis–epicanthus inversus syndrome and propionic acidemia loci. Piemontese MR, et al. **Eur J Hum Genet** 1997 May–Jun;5(3):171–4

Sudden infant death and lysinuric protein intolerance [letter; comment] de Klerk JB, et al. **Eur J Pediatr** 1996 Mar; 155(3):256–7. Comment on: Eur J Pediatr 1995 May;154(5):421–2.

The influence of mutations of enzyme activity and phenylalanine tolerance in phenylalanine hydroxylase deficiency. Güttler F, et al. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S6–10 (27 ref.)

The mouse mutation sarcosinemia (sar) maps to chromosome 2 in a region homologous to human 9q33–q34. Brunialti AL, et al. **Genomics** 1996 Aug 15;36(1):182–4

Molecular cloning, tissue distribution, and chromosomal localization of human cationic amino acid transporter 2 (HCAT2). Hoshide R, et al. **Genomics** 1996 Dec 1; 38(2):174–8

Human cationic amino acid transporter gene hCAT-2 is assigned to 8p22 but is not the causative gene in lysinuric protein intolerance. Lauteala T, et al. **Hum Genet** 1997 Jul; 100(1):80–3

Missense mutations in the human glutathione synthetase gene result in severe metabolic acidosis, 5-oxoprolinuria, hemolytic anemia and neurological dysfunction. Dahl N, et al. **Hum Mol Genet** 1997 Jul;6(7):1147–52

Mutations and DNA diagnoses of classical citrullinemia. Kakinoki H, et al. **Hum Mutat** 1997;9(3):250–9

Identification of mutations causing 6-pyruvoyl-tetrahydropterin synthase deficiency in four Italian families. Oppliger T, et al. **Hum Mutat** 1997; 10(1):25–35

Ornithine transcarbamylase deficiency: ten new mutations and high proportion of de novo mutations in heterozygous females. Oppliger Leibundgut E, et al. **Hum Mutat** 1997; 9(5):409–11

Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview. St-Louis M, et al. **Hum Mutat** 1997;9(4):291–9 (44 ref.)

Three prevalent mutations in a patient with phenylalanine hydroxylase deficiency: implications for diagnosis and genetic counselling. Guldberg P, et al. **J Med Genet** 1996 Feb;33(2):161–4

Phenotypic variability in male patients carrying the mutant ornithine transcarbamylase (OTC) allele, Arg40His, ranging from a child with an unfavourable prognosis to an asymptomatic older adult. Matsuda I, et al. **J Med Genet** 1996 Aug;33(8):645–8

Hydroxyprolinemia: comparison of a patient and her unaffected twin sister. Kim SZ, et al. **J Pediatr** 1997 Mar; 130(3):437–41

Mutations in the glutathione synthetase gene cause 5-oxoprolinuria. Shi ZZ, et al. **Nat Genet** 1996 Nov; 14(3):361–5

Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency [see comments] Hoffmann GF, et al. **Neuropediatrics** 1996 Jun; 27(3):115–23. Comment in: Neuropediatrics 1996 Dec;27(6):335–6.

Prognostic clues and outcome of early treatment of nonketotic hyperglycinemia. Boneh A, et al. **Pediatr Neurol** 1996 Sep;15(2):137–41

Frequency of the IVS12 + 5G-->A splice mutation of the fumarylacetoacetate hydrolase gene in carriers of hereditary tyrosinaemia in the French Canadian population of Saguenay-Lac-St-Jean. Poudrier J, et al. **Prenat Diagn** 1996 Jan;16(1):59–64

Guanidinoacetate methyltransferase deficiency: a newly recognized inborn error of creatine biosynthesis. Stöckler S, et al. **Wien Klin Wochenschr** 1997 Feb 14;109(3):86–8

METABOLISM

Stable isotope studies in propionic and methylmalonic acidaemia. Leonard JV. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S67–9 (19 ref.)

Abnormal glutathione conjugation in patients with tyrosinaemia type I. Mulders TM, et al. **J Inherit Metab Dis** 1997 Aug;20(4):473–85

Pregnancy and argininosuccinic aciduria. Worthington S, et al. **J Inherit Metab Dis** 1996;19(5):621–3

Non-kinetic hyperglycinaemia: prolonged survival in a patient with a mild variant. Wraith JE. **J Inherit Metab Dis** 1996;19(5):695–6

Guanidino compounds in guanidinoacetate methyltransferase deficiency, a new inborn error of creatine synthesis. Stöckler S, et al. **Metabolism** 1997 Oct;46(10):1189–93

Effect of carnitine administration on glycine metabolism in patients with isovaleric acidemia: significance of acetylcarnitine determination to estimate the proper carnitine dose. Itoh T, et al. **Tohoku J Exp Med** 1996 Jun; 179(2):101–9

PATHOLOGY

Lysinuric protein intolerance with thymic hypoplasia. Hasanoğlu A, et al. **J Inherit Metab Dis** 1996;19(3):372–3

Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH)-syndrome. Ultrastructural changes of mitochondria in cultured dermal fibroblasts of three patients. Haust MD, et al. **Pathol Res Pract** 1996 Mar;192(3):271–80

Ciliated cultured dermal fibroblasts in a patient with hyperornithinemia, hyperammonemia and homocitrullinuria (HHH) syndrome. Haust MD. **Pathol Res Pract** 1995 Oct;191(10):1062–5

Richner-Hanhart's syndrome: new ultrastructural observations on skin lesions of two cases. el-Shoura SM, et al. **Ultrastruct Pathol** 1997 Jan–Feb;21(1):51–6

PHYSIOPATHOLOGY

Tyrosinemia: the Quebec experience. Paradis K. **Clin Invest Med** 1996 Oct;19(5):311–6 (26 ref.)

Renal tubular dysfunction in multiple acyl-CoA dehydrogenase deficiency. Morris AA, et al. **J Inherit Metab Dis** 1997 Aug;20(4):604–5

Clinical heterogeneity and prognosis in combined methylmalonic aciduria and homocystinuria (cblC). Rosenblatt DS, et al. **J Inherit Metab Dis** 1997 Aug; 20(4):528–38

SURGERY

Adult-onset type II citrullinemia: clinical pictures before and after liver transplantation. Kawata A, et al. **Intern Med** 1997 Jun;36(6):408–12

Auxiliary liver transplantation for metabolic diseases. Rela M, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):444–5

[Living related liver transplantation for patients with ornithine transcarbamylase deficiency] Tazuke M, et al. **Masui** 1997 Jun;46(6):783–7 (Eng. Abstr.) **(Jpn)**

THERAPY

Tyrosinemia: the Quebec experience. Paradis K. **Clin Invest Med** 1996 Oct;19(5):311–6 (26 ref.)

Diagnosis and management of tyrosinemia type I. Holme E, et al. **Curr Opin Pediatr** 1995 Dec;7(6):726–32 (45 ref.)

The sparse fur mouse as a model for gene therapy in ornithine carbamoyltransferase deficiency. Batshaw ML, et al. **Gene Ther** 1995 Dec;2(10):743–9

Hepatocyte transplantation: "Only the strong survive." Bezerra JA, et al. **Hepatology** 1996 Nov;24(5):1321–3

Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter. Kiwaki K, et al. **Hum Gene Ther** 1996 May 1;7(7):821–30

Primary treatment of propionic acidemia complicated by acute thiamine deficiency. Matern D, et al. **J Pediatr** 1996 Nov;129(5):758–60

URINE

750 MHz 1H NMR spectroscopy characterisation of the complex metabolic pattern of urine from patients with inborn errors of metabolism: 2-hydroxyglutaric aciduria and maple syrup urine disease. Holmes E, et al. **J Pharm Biomed Anal** 1997 Jul;15(11):1647–59

AMINO ACID NAPHTHYLAMIDASES

ANTAGONISTS & INHIBITORS

Cholesterol and steroids action on aminopeptidases. Martinez JM, et al. **Biochem Soc Trans** 1997 Feb;25(1):113S

BIOSYNTHESIS

Formation of a dipeptidyl arylamidase by Bacteroides splanchnicus NCTC 10825 with specificities towards glycylprolyl-x and valylalanine-x substrates. Macfarlane S, et al. **J Med Microbiol** 1997 Jul;46(7):547–55

BLOOD

L-cystine-di-beta-naphthylamidase activity in plasma of the snake Bothrops jararaca after chronic challenges of water balance. Silveira PF, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Jul;114(3):185–92

METABOLISM

Subcellular distribution of soluble and membrane-bound Arg-beta-naphthylamide hydrolyzing activities in the developing and aged rat brain. Arechaga G, et al. **Cell Mol Biol Res** 1995;41(5):369–75

AMINO ACID NEUROTRANSMITTERS

see related
RECEPTORS, AMINO ACID

ANALYSIS

Immunocytochemical detection of amino acid neurotransmitters in paraformaldehyde-fixed tissues. Pow DV. **Methods Mol Biol** 1997;72:103–23

Microbore liquid chromatography analysis of amino acid transmitters. Smolders I, et al. **Methods Mol Biol** 1997; 72:197–204

BIOSYNTHESIS

The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Kapetanovic IM, et al. **Epilepsy Res** 1995 Nov;22(3):167–73

Pre- and postnatal expression of amino acid neurotransmitters, calcium binding proteins, and nitric oxide synthase in the developing superior colliculus. Mize RR, et al. **Prog Brain Res** 1996;108:313–32 (85 ref.)

CEREBROSPINAL FLUID

Reference values of neuroactive amino acids in the cerebrospinal fluid by high-performance liquid chromatography with electrochemical and fluorescence detection. Rizzo V, et al. **J Chromatogr A** 1996 Apr 5; 729(1–2):181–8

METABOLISM

Endurance training effects on neurotransmitter release in rat striatum: an in vivo microdialysis study. Meeusen R, et al. **Acta Physiol Scand** 1997 Apr;159(4):335–41

Amino acid neurotransmitter receptor/chloride channels of mammalian sperm and the acrosome reaction. Meizel S. **Biol Reprod** 1997 Mar;56(3):569–74 (86 ref.)

Neurochemical mechanisms in soman-induced seizures. Shih TM, et al. **J Appl Toxicol** 1997 Jul–Aug;17(4):255–64

Evidence of taurine depletion and accumulation of cysteinesulfinic acid in chronic dialysis patients. Suliman ME, et al. **Kidney Int** 1996 Nov;50(5):1713–7

Monitoring amino acid neurotransmitter release in the brain by in vivo microdialysis. Zuiderwijk M, et al. **Methods Mol Biol** 1997;72:239–50

Free radicals and the ischemia-evoked extracellular accumulation of amino acids in rat cerebral cortex. O'Regan MH, et al. **Neurochem Res** 1997 Mar;22(3):273–80

Effect of diabetes on levels and uptake of putative amino acid neurotransmitters in rat retina and retinal pigment epithelium. Vilchis C, et al. **Neurochem Res** 1996 Oct; 21(10):1167–71

Aspartate, glutamate, glutamine, glycine and gamma-aminobutyric acid in human bioptic neocortical areas: comparison to autoptic tissue. Knörle R, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):169–72

The neurotransmitter candidature of sulphur-containing excitatory amino acids in the mammalian central nervous system. Thompson GA, et al. **Pharmacol Ther** 1996; 72(1):25–36 (109 ref.)

[Abnormal neurotransmission in the epileptic brain] Morimoto K, et al. **Rinsho Shinkeigaku** 1996 Dec; 36(12):1326–7 **(Jpn)**

[Balance of neuromediatory amino acids and impairment of integral brain activity caused by local ischemia of frontal lobe in rats: effects of piracetam and glycine] Raevskiĭ KS, et al. **Biull Eksp Biol Med** 1997 Apr;123(4):370–3 **(Rus)**

PHYSIOLOGY

Respiratory rhythm generation and synaptic inhibition of expiratory neurons in pre-Bötzinger complex: differential roles of glycinergic and GABAergic neural transmission. Shao XM, et al. **J Neurophysiol** 1997 Apr;77(4):1853–60

Amino acid-mediated regulation of spontaneous synaptic activity patterns in the rat basolateral amygdala. Smith BN, et al. **J Neurophysiol** 1996 Sep;76(3):1958–67

Modulation of excitatory synaptic transmission in locus coeruleus by multiple presynaptic metabotropic glutamate receptors. Dubé GR, et al. **Neuroscience** 1997 Sep; 80(2):511–21

THERAPEUTIC USE

The effect of central amino acid neurotransmitters on the antihypertensive response to angiotensin blockade in spontaneous hypertension. Yamada K, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1624–30

D-AMINO-ACID OXIDASE

ANALYSIS

D-amino-acid oxidase is not present in the mouse liver. Konno R, et al. **Biochim Biophys Acta** 1997 Apr 17; 1335(1–2):173–81

CHEMISTRY

Identification of a reactive cysteine in the flavin-binding domain of Rhodotorula gracilis D-amino acid oxidase. Pollegioni L, et al. **Arch Biochem Biophys** 1997 Jul 1; 343(1):1–5

Active site plasticity in D-amino acid oxidase: a crystallographic analysis. Todone F, et al. **Biochemistry** 1997 May 13;36(19):5853–60

Kinetics and thermodynamics studies on the interaction of

D-AMINO-ACID OXIDASE

D-amino acid oxidase and sodium n-dodecyl sulphate in the presence and absence of flavin adenine dinucleotide. Shareghi B, et al. **Int J Biol Macromol** 1996 Jul;19(1):9–13

Three-dimensional structure of porcine kidney D-amino acid oxidase at 3.0 A resolution. Mizutani H, et al. **J Biochem (Tokyo)** 1996 Jul;120(1):14–7

Chemical modification of histidyl residues in D-amino acid oxidase from Rhodotorula gracilis. Ramón F, et al. **J Biochem (Tokyo)** 1995 Nov;118(5):911–6

Crystallization of expressed porcine kidney D-amino acid oxidase and preliminary X-ray crystallographic characterization. Setoyama C, et al. **J Biochem (Tokyo)** 1996 Jun;119(6):1114–7

Crystal structure of D-amino acid oxidase: a case of active site mirror-image convergent evolution with flavocytochrome b2. Mattevi A, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7496–501

GENETICS

Lrp is a direct repressor of the dad operon in Escherichia coli. Mathew E, et al. **J Bacteriol** 1996 Dec;178(24):7234–40

Glycerol-assisted restorative adjustment of flavoenzyme conformation perturbed by site-directed mutagenesis. Raibekas AA, et al. **J Biol Chem** 1997 Aug 29; 272(35):22248–52

METABOLISM

Active site plasticity in D-amino acid oxidase: a crystallographic analysis. Todone F, et al. **Biochemistry** 1997 May 13;36(19):5853–60

Limited proteolysis and X-ray crystallography reveal the origin of substrate specificity and of the rate-limiting product release during oxidation of D-amino acids catalyzed by mammalian D-amino acid oxidase. Vanoni MA, et al. **Biochemistry** 1997 May 13;36(19):5624–32

Stability of D-amino acid oxidase: denaturation by guanidine hydrochloride and urea. Shareghi B, et al. **Indian J Biochem Biophys** 1996 Oct;33(5):357–62

On the mechanism of D-amino acid oxidase. Structure/linear free energy correlations and deuterium kinetic isotope effects using substituted phenylglycines. Pollegioni L, et al. **J Biol Chem** 1997 Feb 21;272(8):4924–34

Hepatic and renal D-amino acid oxidase activities in the growing rat after ten days of protein undernutrition and refeeding. Carreira S, et al. **Reprod Nutr Dev** 1996; 36(1):73–82

AMINO ACID OXIDOREDUCTASES

ANALYSIS

Light and electron microscopic localization of D-aspartate oxidase in peroxisomes of bovine kidney and liver: an immunocytochemical study. Zaar K. **J Histochem Cytochem** 1996 Sep;44(9):1013–9

ANTAGONISTS & INHIBITORS

Inactivation of 1-aminocyclopropane-1-carboxylate oxidase involves oxidative modifications. Barlow JN, et al. **Biochemistry** 1997 Mar 25;36(12):3563–9

L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. Moynihan K, et al. **Cancer Chemother Pharmacol** 1997;39(3):179–86

Inhibition by 1-aminocyclobutane-1-carboxylate of the activity of 1-aminocyclopropane-1-carboxylate oxidase obtained from senescing petals of carnation (Dianthus caryophyllus L.) flowers. Kosugi Y, et al. **Plant Cell Physiol** 1997 Mar;38(3):312–8

BIOSYNTHESIS

Heterologous expression and site-directed mutagenesis of the 1-aminocyclopropane-1-carboxylate oxidase from kiwi fruit. Lay VJ, et al. **Eur J Biochem** 1996 Dec 1; 242(2):228–34

Effect of pollination on accumulation of ACC synthase and ACC oxidase transcripts, ethylene production and flower petal abscission in geranium (Pelargonium x hortorum L.H. Bailey). Clark DG, et al. **Plant Mol Biol** 1997 Aug; 34(6):855–65

CHEMICAL SYNTHESIS

Construction of a new leucine dehydrogenase with preferred specificity for NADP+ by site-directed mutagenesis of the strictly NAD+-specific enzyme. Galkin A, et al. **Protein Eng** 1997 Jun;10(6):687–90

CHEMISTRY

Three-dimensional structure of meso-diaminopimelic acid dehydrogenase from Corynebacterium glutamicum. Scapin G, et al. **Biochemistry** 1996 Oct 22;35(42):13540–51

Heterologous expression and site-directed mutagenesis of the 1-aminocyclopropane-1-carboxylate oxidase from kiwi fruit. Lay VJ, et al. **Eur J Biochem** 1996 Dec 1; 242(2):228–34

Primary structures of fungal fructosyl amino acid oxidases and their application to the measurement of glycated proteins. Yoshida N, et al. **Eur J Biochem** 1996 Dec 15; 242(3):499–505

Identification of lysine 74 in the pyruvate binding site of alanine dehydrogenase from Bacillus subtilis. Chemical modification with 2,4,6-trinitrobenzenesulfonic acid, n-succinimidyl 3-(2-pyridyldithio)propionate, and 5'-(p-(fluorosulfonyl)benzoyl)adenosine. Delforge D, et al. **J Biol Chem** 1997 Jan 24;272(4):2276–84

Analysis of the quaternary structure, substrate specificity, and catalytic mechanism of valine dehydrogenase. Turnbull AP, et al. **J Biol Chem** 1997 Oct 3;272(40):25105–11

Glycerol-induced development of catalytically active conformation of Crotalus adamanteus L-amino acid oxidase in vitro. Raibekas AA, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7546–51

GENETICS

cDNA cloning and expression of the flavoprotein D-aspartate oxidase from bovine kidney cortex. Simonic T, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):729–35

Characterization and expression analysis of a banana gene encoding 1-aminocyclopropane-1-carboxylate oxidase. Huang PL, et al. **Biochem Mol Biol Int** 1997 Apr; 41(5):941–50

Primary structures of fungal fructosyl amino acid oxidases and their application to the measurement of glycated proteins. Yoshida N, et al. **Eur J Biochem** 1996 Dec 15; 242(3):499–505

Cloning, sequencing, overexpression in Escherichia coli, and inactivation of the valine dehydrogenase gene in the polyether antibiotic producer Streptomyces cinnamonensis. Leiser A, et al. **Gene** 1996 Oct 24;177(1–2):217–22

Cloning, and molecular characterization of the GCV1 gene encoding the glycine cleavage T-protein from Saccharomyces cerevisiae. McNeil JB, et al. **Gene** 1997 Feb 20;186(1):13–20

Structural and functional characterization of the human brain D-aspartate oxidase. Setoyama C, et al. **J Biochem (Tokyo)** 1997 Apr;121(4):798–803

Molecular cloning and expression of amadoriase isoenzyme (fructosyl amine:oxygen oxidoreductase, EC 1.5.3) from Aspergillus fumigatus. Takahashi M, et al. **J Biol Chem** 1997 May 9;272(19):12505–7

A Neurospora crassa mutant altered in the regulation of L-amino acid oxidase. Calderón J, et al. **Microbiology** 1997 Jun;143 (Pt 6):1969–74

A 12 kb nucleotide sequence containing the alanine dehydrogenase gene at 279 degrees on the Bacillus subtilis chromosome. Oudega B, et al. **Microbiology** 1997 May;143 (Pt 5):1489–91

Characterization of a hexamer motif and b element of the nopaline synthase (nos) promoter. Kim Y, et al. **Mol Cells** 1997 Feb 28;7(1):84–9

Identification of transposon-like elements in non-coding regions of tomato ACC oxidase genes. Blume B, et al. **Mol Gen Genet** 1997 Apr 16;254(3):297–303

Interactions between distinct types of DNA binding proteins enhance binding to ocs element promoter sequences. Zhang B, et al. **Plant Cell** 1995 Dec;7(12):2241–52

Differential and wound-inducible expression of 1-aminocylopropane-1-carboxylate oxidase genes in sunflower seedlings. Liu JH, et al. **Plant Mol Biol** 1997 Aug;34(6):923–33

Construction of a new leucine dehydrogenase with preferred specificity for NADP+ by site-directed mutagenesis of the strictly NAD+-specific enzyme. Galkin A, et al. **Protein Eng** 1997 Jun;10(6):687–90

Expression, purification, and crystallization of meso-diaminopimelate dehydrogenase from Corynebacterium glutamicum. Reddy SG, et al. **Proteins** 1996 Aug;25(4):514–6

ISOLATION & PURIFICATION

Microbial D-amino acid oxidases (EC .4.3.3). Fischer L, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:683–8

A study of combined filtration and adsorption on nylon-based dye-affinity membranes: separation of recombinant L-alanine dehydrogenase from crude fermentation broth. Weissenborn M, et al. **Biotechnol Appl Biochem** 1997 Apr; 25 (Pt 2):159–68

Tauropine dehydrogenase from the sandworm Arabella iricolor (Polychaeta: Errantia): purification and characterization. Kanno N, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Aug; 114(4):409–16

Purification and characterization of a membrane-bound deglycating enzyme (1-deoxyfructosyl alkyl amino acid oxidase, EC 1.5.3) from a Pseudomonas sp. soil strain. Saxena AK, et al. **J Biol Chem** 1996 Dec 20;271(51):32803–9

Isolation, purification, and characterization of amadoriase isoenzymes (fructosyl amine-oxygen oxidoreductase EC 1.5.3) from Aspergillus sp. Takahashi M, et al. **J Biol Chem** 1997 Feb 7;272(6):3437–43

Apoxin I, a novel apoptosis-inducing factor with L-amino acid oxidase activity purified from Western diamondback rattlesnake venom. Torii S, et al. **J Biol Chem** 1997 Apr 4;272(14):9539–42

Biospecific affinity chromatographic purification of octopine dehydrogenase from molluscs. Mulcahy P, et al. **Protein Expr Purif** 1997 Feb;9(1):109–14

METABOLISM

Studies on non-haem ferrous-dependent oxygenases and oxidases. Barlow JN, et al. **Biochem Soc Trans** 1997 Feb; 25(1):86–90 (30 ref.)

Glutamate 94 of [2Fe-2S]-ferredoxins is important for efficient electron transfer in the 1:1 complex formed with ferredoxin-glutamate synthase (GltS) from Synechocystis sp. PCC 6803. Schmitz S, et al. **Biochim Biophys Acta** 1996 Nov 12;1277(1–2):135–40

L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. Moynihan K, et al. **Cancer Chemother Pharmacol** 1997;39(3):179–86

Distribution of D-aspartate oxidase and free D-glutamate and D-aspartate in chicken and pigeon tissues. Kera Y, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Sep;115(1):121–6

Enzymes that regulate ethylene levels--1-aminocyclopropane-1-carboxylic acid (ACC) deaminase, ACC synthase and ACC oxidase. Penrose DM, et al. **Indian J Exp Biol** 1997 Jan;35(1):1–17

Structural and functional characterization of the human brain D-aspartate oxidase. Setoyama C, et al. **J Biochem (Tokyo)** 1997 Apr;121(4):798–803

A novel bifunctional fusion enzyme catalyzing ethylene synthesis via 1-aminocyclopropane1-carboxylic acid. Li N, et al. **J Biol Chem** 1996 Oct 18;271(42):25738–41

Apoxin I, a novel apoptosis-inducing factor with L-amino acid oxidase activity purified from Western diamondback rattlesnake venom. Torii S, et al. **J Biol Chem** 1997 Apr 4;272(14):9539–42

Analysis of the quaternary structure, substrate specificity, and catalytic mechanism of valine dehydrogenase. Turnbull AP, et al. **J Biol Chem** 1997 Oct 3;272(40):25105–11

Postcolumn co-immobilized leucine dehydrogenase-NADH oxidase reactor for the determination of branched-chain amino acids by high-performance liquid chromatography with chemiluminescence detection. Kiba N, et al. **J Chromatogr A** 1996 Feb 16;724(1–2):355–7

13C nuclear magnetic resonance detection of interactions of serine hydroxymethyltransferase with C1-tetrahydrofolate synthase and glycine decarboxylase complex activities in Arabidopsis. Prabhu V, et al. **Plant Physiol** 1996 Sep; 112(1):207–16

PHARMACOLOGY

[Effect of L-lysine-alpha-oxidase on the synthesis of cell proteins, targets of autoimmune pathology in HIV infection] Berezov TT, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):36–8 **(Rus)**

AMINO ACID RECEPTORS see **RECEPTORS, AMINO ACID**

AMINO ACID SEQUENCE

Discovery of a new type of proteinase inhibitor family whose members have an anchoring sequence. Hirose S, et al. **Adv Exp Med Biol** 1996;389:43–9 (24 ref.)

Mining genomes with MS. Yates JR 3rd, et al. **Anal Chem** 1996 Sep 1;68(17):534A–540A (35 ref.)

Bridging the protein sequence-structure gap by structure predictions. Rost B, et al. **Annu Rev Biophys Biomol Struct** 1996;25:113–36 (99 ref.)

Small peptide libraries: combinatorial split-mix synthesis followed by combinatorial amino acid analysis of selected variants. Weinberger H, et al. **Arch Pharm (Weinheim)** 1997 Apr;330(4):109–11

A non-local gap-penalty for profile alignment. Taylor WR. **Bull Math Biol** 1996 Jan;58(1):1–18

Development of an expert system for amino acid sequence identification. Hu L, et al. **Comput Appl Biosci** 1996 Aug; 12(4):311–8

Computational method to predict mitochondrially imported proteins and their targeting sequences. Claros MG, et al. **Eur J Biochem** 1996 Nov 1;241(3):779–86

Conservation of amino acids in multiple alignments: aspartic acid has unexpected conservation. Fiser A, et al. **FEBS Lett** 1996 Nov 18;397(2–3):225–9

Inverse sequence similarity in proteins and its relation to the three-dimensional fold. Preissner R, et al. **FEBS Lett** 1997 Sep 8;414(2):425–9

The neuronal nitric oxide synthase PDZ motif binds to -G(D,E)XV* carboxyterminal sequences. Schepens J, et al. **FEBS Lett** 1997 Jun 2;409(1):53–6

Amino acid residues required for binding of vascular cell adhesion molecule-1 to integrin alpha 4 beta 7. Kilger G, et al. **Int Immunol** 1997 Feb;9(2):219–26

The megaprior heuristic for discovering protein sequence patterns. Bailey TL, et al. **Ismb** 1996;4:15–24 (12 ref.)

His-X-X-X-His motif in S100 protein, calprotectin: relation to microbiostatic activity [letter] Clohessy PA, et al. **J Leukoc Biol** 1996 Nov;60(5):674

Significant improvement in accuracy of multiple protein sequence alignments by iterative refinement as assessed by reference to structural alignments. Gotoh O. **J Mol Biol** 1996 Dec 13;264(4):823–38

Multiple sequence threading: an analysis of alignment quality and stability. Taylor WR. **J Mol Biol** 1997 Jun 27; 269(5):902–43

Converting amino acid alignment scores into measures of evolutionary time: a simulation study of various relationships. Feng DF, et al. **J Mol Evol** 1997 Apr; 44(4):361–70

Molecular evolutionary analysis of the thiamine-diphosphate-dependent enzyme, transketolase. Schenk G, et al. **J Mol Evol** 1997 May;44(5):552–72

Accuracies of ancestral amino acid sequences inferred by the parsimony, likelihood, and distance methods. Zhang J, et al. **J Mol Evol** 1997;44 Suppl 1:S139–46
Analysis and organization of protein sequence data: a retrospective spanning four decades. Barker WC, et al. **J Protein Chem** 1997 Jul;16(5):459–62
Determination of the primary structure of homologous proteins by sequence analysis of peptide mixtures. Caporale C, et al. **J Protein Chem** 1996 May;15(4):405–12
Computational sequence analysis of the tissue inhibitor of metalloproteinase family. Douglas DA, et al. **J Protein Chem** 1997 May;16(4):237–55 (88 ref.)
Double coupling Edman chemistry for high-sensitivity automated protein sequencing. Ireland ID, et al. **J Protein Chem** 1997 Jul;16(5):491–3
Peptide sequencing by mass spectrometry for homology searches and cloning of genes. Shevchenko A, et al. **J Protein Chem** 1997 Jul;16(5):481–90
Prediction of protein secondary structure from amino acid sequence. Yang JT. **J Protein Chem** 1996 Feb;15(2):185–91
Evolution of the self-reproducing system to the biosynthesis of the membrane: an approach from the amino acid sequence similarity in proteins. Fukuchi S, et al. **J Theor Biol** 1996 Sep 21;182(2):117–36
Computer analysis of cloned sequences. Caron PR. **Methods Mol Biol** 1997;69:247–60
Amino acid sequencing of neuropeptides. Li KW, et al. **Methods Mol Biol** 1997;73:17–25
Sequence-selective nonmacrocyclic two-armed receptors for peptides. Nestler HP. **Mol Divers** 1996 Oct;2(1–2):35–40 (18 ref.)
The PROSITE database, its status in 1997. Bairoch A, et al. **Nucleic Acids Res** 1997 Jan 1;25(1):217–21
The SWISS-PROT protein sequence data bank and its supplement TrEMBL. Bairoch A, et al. **Nucleic Acids Res** 1997 Jan 1;25(1):31–6
The Protein Information Resource (PIR) and the PIR-International Protein Sequence Database. George DG, et al. **Nucleic Acids Res** 1997 Jan 1;25(1):24–8
MIPS: a database for protein sequences, homology data and yeast genome information. Mewes HW, et al. **Nucleic Acids Res** 1997 Jan 1;25(1):28–30
Yeast Protein database (YPD): a database for the complete proteome of Saccharomyces cerevisiae. Payne WE, et al. **Nucleic Acids Res** 1997 Jan 1;25(1):57–62
Compilation and analysis of intein sequences. Perler FB, et al. **Nucleic Acids Res** 1997 Mar 15;25(6):1087–93
Systematic isolation of peptide signal molecules regulating development in hydra: LWamide and PW families. Takahashi T, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1241–6
The N-end rule: functions, mysteries, uses. Varshavsky A. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12142–9 (79 ref.)
Incorporation of non-local interactions in protein secondary structure prediction from the amino acid sequence. Frishman D, et al. **Protein Eng** 1996 Feb;9(2):133–42
A databank (3D-ali) collecting related protein sequences and structures. Pascarella S, et al. **Protein Eng** 1996 Mar; 9(3):249–51
An analysis of structural instances of low complexity sequence segments. Saqi M. **Protein Eng** 1995 Nov; 8(11):1069–73
Protein sequence-structure compatibility criteria in terms of statistical hypothesis testing. Sunyaev S, et al. **Protein Eng** 1997 Jun;10(6):635–46
Searching for common sequence patterns among distantly related proteins. Suyama M, et al. **Protein Eng** 1995 Nov; 8(11):1075–80
Protein fold recognition using sequence-derived predictions. Fischer D, et al. **Protein Sci** 1996 May;5(5):947–55
Three-dimensional structures and contexts associated with recurrent amino acid sequence patterns. Han KF, et al. **Protein Sci** 1997 Jul;6(7):1587–90
Construction and analysis of a profile library characterizing groups of structurally known proteins. Ogiwara A, et al. **Protein Sci** 1996 Oct;5(10):1991–9
First steps in peptide science. Schwyzer R. **Protein Sci** 1996 Nov;5(11):2358–63
Coupling backbone flexibility and amino acid sequence selection in protein design. Su A, et al. **Protein Sci** 1997 Aug;6(8):1701–7
Accessing the Kabat antibody sequence database by computer. Martin AC. **Proteins** 1996 May;25(1):130–3
Pfam: a comprehensive database of protein domain families based on seed alignments. Sonnhammer EL, et al. **Proteins** 1997 Jul;28(3):405–20
Sequence patents [letter; comment] Cullen SE. **Science** 1997 Mar 28;275(5308):1861–2. Comment on: Science 1997 Feb 7;275(5301):777–80.
Primary sequence of the envelope glycoprotein of a dengue type 2 virus isolated from patient with dengue hemorrhagic fever and encephalopathy. Sistayanarain A, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):221–7
The UBA domain: a sequence motif present in multiple enzyme classes of the ubiquitination pathway. Hofmann K, et al. **Trends Biochem Sci** 1996 May;21(5):172–3
[Analysis of protein primary structures by mass spectrometry] Takao T. **Seikagaku** 1996 Jan;68(1):1–13 (64 ref.) **(Jpn)**
[A novel version of PROF—PAT 1.0 data bank of protein families: technology of formation nad rapid search programs] Bachinskiĭ AG, et al. **Mol Biol (Mosk)** 1996 Nov–Dec;30(6):1409–19 **(Rus)**
[Statistical analysis of correspondence between the primary and tertiary protein structure] Siuniaev ShR, et al. **Mol Biol (Mosk)** 1996 Sep–Oct;30(5):1115–23 **(Rus)**

GENETICS

Mutations within the propeptide, the primary cleavage site or the catalytic site, or deletion of C-terminal sequences, prevents secretion of proPC2 from transfected COS-7 cells. Taylor NA, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):367–73
Subtyping of Neisseria meningitidis strains isolated in Quebec, Canada: correlation between deduced amino acid sequences and serosubtyping techniques. Arhin FF, et al. **Can J Microbiol** 1997 Mar;43(3):234–8
Effectiveness of correlation analysis in identifying protein residues undergoing correlated evolution. Pollock DD, et al. **Protein Eng** 1997 Jun;10(6):647–57
Prediction of the stability of protein mutants based on structural environment-dependent amino acid substitution and propensity tables. Topham CM, et al. **Protein Eng** 1997 Jan;10(1):7–21

IMMUNOLOGY

Conservation of minor histocompatibility antigens between human and non-human primates. den Haan JM, et al. **Eur J Immunol** 1996 Nov;26(11):2680–5
Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. Maeurer MJ, et al. **Eur J Immunol** 1996 Nov;26(11):2613–23
Met-11 of HLA class II DP alpha 1 first domain associated with onchocerciasis. Meyer CG, et al. **Exp Clin Immunogenet** 1996;13(1):12–9
Role of non-anchor residues of Db-restricted peptides in class I binding and TCR triggering. Sigal LJ, et al. **Mol Immunol** 1996 Dec;33(17–18):1323–33

PHYSIOLOGY

Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein. Mori T, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):218–22
The carboxyl terminus of mouse delta-opioid receptor is not required for agonist-dependent activation. Zhu X, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):513–6
Protein phosphatases are pest containing proteins. Gomes AV, et al. **Biochem Mol Biol Int** 1997 Jan;41(1):65–73
Regulation of class I-restricted epitope processing by local or distal flanking sequence. Yellen-Shaw AJ, et al. **J Immunol** 1997 Feb 15;158(4):1727–33
Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Nielsen H, et al. **Protein Eng** 1997 Jan;10(1):1–6

AMINO ACID-SPECIFIC TRANSFER RNA see **RNA, TRANSFER, AMINO ACID-SPECIFIC**

AMINO ACID-SPECIFIC TRNA see **RNA, TRANSFER, AMINO ACID-SPECIFIC**

AMINO ACIDS

see related
RECEPTORS, AMINO ACID

Proton equilibria in the minor groove of DNA. Hanlon S, et al. **Biophys J** 1997 Jan;72(1):291–300
Acoustic absorption due to proton transfer in solutions of proteins, peptides and amino acids at neutral pH. Holmes AK, et al. **J Acoust Soc Am** 1996 Sep;100(3):1865–77
Internal packing conditions and fluctuations of amino acid residues in globular proteins. Bhaskaran R, et al. **J Biomol Struct Dyn** 1996 Feb;13(4):627–39
1-Aminocyclobutanecarboxylic acid derivatives as novel structural elements in bioactive peptides: application to tuftsin analogs. Gershonov E, et al. **J Med Chem** 1996 Nov 22;39(24):4833–43
Synthesis and activity of 6-substituted purine linker amino acid immunostimulants. Zacharie B, et al. **J Med Chem** 1997 Aug 29;40(18):2883–94
Human amino acid requirements. Millward DJ. **J Nutr** 1997 Sep;127(9):1842–6 (48 ref.)
Genetic code synonym quotas and amino acid complexity: cutting the cost of proteins? Dufton MJ. **J Theor Biol** 1997 Jul 21;187(2):165–73
Role of hydrophobic amino acid clusters in the transactivation activity of the human glucocorticoid receptor. Almlöf T, et al. **Mol Cell Biol** 1997 Feb; 17(2):934–45
Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system. Tomiyoshi K, et al. **Nucl Med Commun** 1997 Feb;18(2):169–75
Amino acids, protein, and body weight [comment] Bray GA. **Obes Res** 1997 Jul;5(4):373–6. Comment on: Obes Res 1997 Jul;5(4):377–80. Comment on: Obes Res 1997 Jul;5(4):381–4.
Polyglucose and amino acids: preliminary results. Faller B, et al. **Perit Dial Int** 1997;17 Suppl 2:S63–7
Modification of an amino acid solution for peritoneal dialysis to reduce risk of acidemia. Jones M, et al. **Perit Dial Int** 1997 Jan–Feb;17(1):66–71
Further animal and human experience with a 0.6% amino acid/1.4% glycerol peritoneal dialysis solution. Van Biesen W, et al. **Perit Dial Int** 1997;17 Suppl 2:S56–62
The alpha and omega of G-protein coupled receptors: a novel method for classification. Part 1. Moereels H, et al. **Receptors Channels** 1996;4(1):19–30
Clinical nutrition—its critical future and new strategies. Fürst P. **S Afr Med J** 1996 Apr;86(4 Suppl):463–72

ADMINISTRATION & DOSAGE

Use of a four parameter logistic equation and parameter sharing to evaluate animal responses to graded levels of nitrogen or amino acids. Gahl MJ, et al. **Adv Food Nutr Res** 1996;40:157–67 (20 ref.)
Nutritional effects of amino acid dialysate (Nutrineal) in CAPD patients. Misra M, et al. **Adv Perit Dial** 1996; 12:311–4
Hepatic protein synthesis in the sheep: effect of intake as monitored by use of stable-isotope-labelled glycine, leucine and phenylalanine. Connell A, et al. **Br J Nutr** 1997 Feb; 77(2):255–71
Comparison of growth performance and nutrient retention of weaner pigs given diets based on casein, free amino acids or conventional proteins. Officer DI, et al. **Br J Nutr** 1997 May;77(5):731–44
Infrequent Ki-ras and an absence of p53 mutations in hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Tsujiuchi T, et al. **Cancer Lett** 1996 Nov 12;108(1):137–41
Six-month overnight administration of intraperitoneal amino acids does not improve lean mass. Maurer O, et al. **Clin Nephrol** 1996 May;45(5):303–9
Recommendations for protein and amino acid intake in phenylketonuric patients. Cockburn F, et al. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S125–9
Utilisation of amino acid mixtures in adolescents with phenylketonuria. Mönch E, et al. **Eur J Pediatr** 1996 Jul; 155 Suppl 1:S115–20
Recommendations for protein and amino acid intake in phenylketonuria patients. Przyrembel H. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S130–1
Inhibitory effects of N,N'-diphenyl-p-phenylenediamine on the early stage of the enhanced hepatocarcinogenesis caused by coadministration of ethionine and a choline-deficient L-amino acid-defined diet in rats. Kobayashi E, et al. **Exp Toxicol Pathol** 1996 Jun; 48(4):275–82
Efficacy of amino acid infusion for improving protein metabolism after surgery: a prospective randomized study in patients undergoing subtotal gastrectomy. Mimura Y, et al. **J Am Coll Surg** 1997 Aug;185(2):163–71
Comparison of subcutaneous and intravenous administration of a solution of amino acids in older patients. Ferry M, et al. **J Am Geriatr Soc** 1997 Jul;45(7):857–60
Production and composition of milk from Jersey cows administered bovine somatotropin and fed ruminally protected amino acids. Bremmer DR, et al. **J Dairy Sci** 1997 Jul;80(7):1374–80
Zinc oxide and amino acids as sources of dietary zinc for calves: effects on uptake and immunity. Kincaid RL, et al. **J Dairy Sci** 1997 Jul;80(7):1381–8
Responses in milk constituents to intravascular administration of two mixtures of amino acids to dairy cows. Metcalf JA, et al. **J Dairy Sci** 1996 Aug;79(8):1425–9
Adequacy of amino acids in diets fed to lactating dairy cows. Wu Z, et al. **J Dairy Sci** 1997 Aug;80(8):1713–21
Impaired renal haemodynamic response to amino acid infusion in essential hypertension during angiotensin converting enzyme inhibitor treatment. Tietze IN, et al. **J Hypertens** 1997 May;15(5):551–60
Increased telomerase activity in hyperplastic nodules and hepatocellular carcinomas induced by a choline-deficient L-amino acid-defined diet in rats. Tsujiuchi T, et al. **Jpn J Cancer Res** 1996 Nov;87(11):1111–5
Effect of amino acid administration on uremic muscle metabolism: a 31P-spectroscopy study. De Bisschop E, et al. **Kidney Int** 1997 Apr;51(4):1182–7
Correlation between glomerular morphology and renal haemodynamic response to amino-acid administration in patients with IgA nephropathy. Pluvio C, et al. **Nephrol Dial Transplant** 1996 Dec;11(12):2421–5
Effects of caloric intake on anticancer therapy in rats with valine-depleted amino acid imbalance. Komatsu H, et al. **Nutr Cancer** 1997;28(1):107–12
Modulation of thermogenic response to parenteral amino acid infusion in surgical stress. Tsujinaka T, et al. **Nutrition** 1996 Jan;12(1):36–9
Use of amino acid peritoneal dialysate for one year in a child on CCPD. Brem AS, et al. **Perit Dial Int** 1996 Nov–Dec; 16(6):634–6
Sources of amino acids for protein synthesis during early organogenesis in the rat. 4. Mechanisms before envelopment of the embryo by the yolk sac. Beckman DA, et al. **Placenta** 1996 Nov;17(8):635–41
Sources of amino acids for protein synthesis during early organogenesis in the rat. 3. Methionine incorporation. Lloyd JB, et al. **Placenta** 1996 Nov;17(8):629–34
Amino acid supply and metabolism by the ruminant mammary gland. Bequette BJ, et al. **Proc Nutr Soc** 1997 Jul;56(2):593–605 (45 ref.)

Nutritional control of amino acid supply to the mammary gland during lactation in the pig. Trottier NL. **Proc Nutr Soc** 1997 Jul;56(2):581–91 (39 ref.)

[The effect of dialysis solutions containing amino acids on the nutritional status of patients treated with continuous ambulatory peritoneal dialysis] Opatrná S, et al. **Cas Lek Cesk** 1997 Jun 26;136(13):409–12 (Eng. Abstr.) **(Cze)**

[Plasma amino acid concentrations and isoleucine–phenylalanine quotient in patients with acute myocardial infarct during amino acid infusion] Bodmann KF, et al. **Med Klin** 1997 Jul 15;92(7):376–80 (Eng. Abstr.) **(Ger)**

[Cerebrolysin in treatment of painful diabetic neuropathy] Biesenbach G, et al. **Wien Med Wochenschr** 1997; 147(3):63–6 (Eng. Abstr.) **(Ger)**

[Hemodilution therapy with neuron metabolism specific therapy in ischemic stroke--encouraging results of a comparative study] Koppi S, et al. **Wien Med Wochenschr** 1996;146(3):41–8 (Eng. Abstr.) **(Ger)**

[Experience with using high doses of cerebrolysin in vascular dementia] Iakhno NN, et al. **Ter Arkh** 1996;68(10):65–9 (Eng. Abstr.) **(Rus)**

[The effect of intravenous amino acids in total parenteral nutrition on the healing of experimental colonic anastomoses in the rat] Vázquez Prado A, et al. **Nutr Hosp** 1997 Mar–Apr;12(2):73–9 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

The choleretic effect of nonsteroidal anti–inflammatory drugs in total parenteral nutrition–associated cholestasis. Nussinovitch M, et al. **Isr J Med Sci** 1996 Dec; 32(12):1262–4

Effect of prednisolone on amino acid–induced changes in renal haemodynamics and tubular function. Ivarsen P, et al. **Scand J Clin Lab Invest** 1996 Aug;56(5):449–59

ANALYSIS

The neurochemistry of Alzheimer's disease. Engelborghs S, et al. **Acta Neurol Belg** 1997 Jun;97(2):67–84 (226 ref.)

Amino acid profile and nitric oxide pathway in patients on continuous ambulatory peritoneal dialysis: L–arginine depletion in acute peritonitis. Suh H, et al. **Am J Kidney Dis** 1997 May;29(5):712–9

Levels of amino acids and related compounds in bronchoalveolar lavage fluids of asthmatic patients. Hofford JM, et al. **Am J Respir Crit Care Med** 1997 Feb; 155(2):432–5

Vitreous body glutamate concentration in dogs with glaucoma. Brooks DE, et al. **Am J Vet Res** 1997 Aug; 58(8):864–7

Amino acid analysis by reverse–phase high–performance liquid chromatography: improved derivatization and detection conditions with 9–fluorenylmethyl chloroformate. Bank RA, et al. **Anal Biochem** 1996 Sep 5;240(2):167–76

Increasing the sensitivity of 6–aminoquinolyl–N–hydroxysuccinimidyl carbamate amino acid analysis: a simple solution. Crimmins DL, et al. **Anal Biochem** 1997 Jan 15;244(2):407–10

Correction for amino acid loss during acid hydrolysis of a purified protein. Darragh AJ, et al. **Anal Biochem** 1996 May 1;236(2):199–207

Detection of modified amino acids in lantibiotic peptide mutacin II by chemical derivation and electrospray ionization–mass spectroscopic analysis. Novák J, et al. **Anal Biochem** 1996 May 1;236(2):358–60

Quantitative determination of amino acid levels in neutral and glucosamine–containing carbohydrate polymers. Palace GP, et al. **Anal Biochem** 1997 Jan 15;244(2):393–403

Proton: a major factor for the racemization and the dehydration at the cyclization/cleavage stage in the Edman sequencing method. Matsunaga H, et al. **Anal Chem** 1996 Sep 1;68(17):2850–6

High–performance liquid chromatographic determination of some amino acids after derivatization with 2–hydroxy–1–naphthaldehyde. el–Brashy AM, et al. **Analyst** 1997 Feb;122(2):147–50

Colocalization of amino acid signal molecules in neurons and endocrine cells. Davanger S. **Anat Embryol (Berl)** 1996 Jul; 194(1):1–12 (192 ref.)

Decision support techniques for the interpretation of quantitative amino acid data. Briddon A. **Ann Clin Biochem** 1996 May;33 (Pt 3):227–33 (26 ref.)

N–terminal binding domain of Galpha subunits: involvement of amino acids 11–14 of Galphao in membrane attachment. Busconi L, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):239–44

Regulation of N–linked core glycosylation: use of a site–directed mutagenesis approach to identify Asn–Xaa–Ser/Thr sequons that are poor oligosaccharide acceptors. Kasturi L, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):415–9

Identification of amino acid residues responsible for differences in substrate specificity and inhibitor sensitivity between two human liver dihydrodiol dehydrogenase isoenzymes by site–directed mutagenesis. Matsuura K, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):61–4

Identification of critical amino acid residues of Saccharomyces cerevisiae carbamoyl–phosphate synthetase: definition of the ATP site involved in carboxy–phosphate formation. Zheng W, et al. **Biochim Biophys Acta** 1997 Aug 15;1341(1):35–48

Separation of chiral amino acids by micellular electrokinetic chromatography with derivatized cyclodextrins. DeSilva K, et al. **Biomed Chromatogr** 1997 Jul–Aug;11(4):230–5

Analytical chemistry and biochemistry of D–amino acids. Imai K, et al. **Biomed Chromatogr** 1996 Nov–Dec; 10(6):303–12 (157 ref.)

Selective and sensitive determination of protein and non–protein amino acids by capillary gas chromatography with nitrogen–phosphorus selective detection. Kataoka H. **Biomed Chromatogr** 1997 May–Jun;11(3):154–9

High–performance liquid chromatography of alpha–amino acids and aztreonam on reversed phase columns with aqueous Cu2+ as eluent. Khedr A. **Biomed Chromatogr** 1996 Jul–Aug;10(4):167–71

Identification in the rat neurotensin receptor of amino–acid residues critical for the binding of neurotensin. Botto JM, et al. **Brain Res Mol Brain Res** 1997 Jun;46(1–2):311–7

Copper(II) complexes of N2–alkyl–(S)–amino acid amides as chiral selectors for dynamically coated chiral stationary phases in RP–HPLC. Galaverna G, et al. **Chirality** 1996; 8(2):189–96

Amino acid determination in biological fluids by automated ion–exchange chromatography: performance of Hitachi L–8500A. Le Boucher J, et al. **Clin Chem** 1997 Aug;43(8 Pt 1):1421–8

Buffalo (Bos buffali L.) chymosin purification and properties. Abdel Malak CA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):57–62

Detection of different metabolites in the rabbit lens by high resolution 1H NMR spectroscopy. Midelfart A, et al. **Curr Eye Res** 1996 Dec;15(12):1175–81

Amino acid analysis of proteins separated by two–dimensional electrophoresis in maize: isoform detection and function identification. Touzet P, et al. **Electrophoresis** 1996 Aug;17(8):1393–401

To determine the effects of ultraviolet light, natural light and ionizing radiation on pyridinium cross–links in bone and urine using high–performance liquid chromatography. Colwell A, et al. **Eur J Clin Invest** 1996 Dec;26(12):1107–14

Amino acid composition of food products used in the treatment of patients with disorders of the amino acid and protein metabolism. Bremer HJ, et al. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S108–14

Hippocampal and cerebellar extracellular amino acids during pilocarpine–induced seizures in freely moving rats. Smolders I, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):21–9

Deficiency of total collagen content and of deoxypyridinoline in intracranial aneurysm walls. Gaetani P, et al. **FEBS Lett** 1997 Mar 10;404(2–3):303–6

Comparison of 5–hydroxy–2–amino valeric acid with carbonyl group content as a marker of oxidized protein in human and mouse liver tissues. Ayala A, et al. **Free Radic Biol Med** 1996;21(4):551–8

Mitogens, superantigens, and nominal antigens elicit distinctive patterns of TCRB CDR3 diversity. Currier JR, et al. **Hum Immunol** 1996 Jun–Jul;48(1–2):39–51

Amino acid and fatty acid compositions of Adenopus breviflorus benth seed. Oshodi AA. **Int J Food Sci Nutr** 1996 Jul;47(4):295–8

Alterations in plasma free tryptophan and large neutral amino acids do not affect perceived exertion and prolactin during 90 min of treadmill exercise. Struder HK, et al. **Int J Sports Med** 1996 Feb;17(2):73–9

Evaluation of the 15N–isotope dilution technique for determining the recovery of endogenous protein in ileal digesta of pigs: effect of the pattern of blood sampling, precursor pools, and isotope dilution technique. Lien KA, et al. **J Anim Sci** 1997 Jan;75(1):159–69

The amino acid composition of protein feedstuffs before and after ruminal incubation and after subsequent passage through the intestines of dairy cows. O'Mara FP, et al. **J Anim Sci** 1997 Jul;75(7):1941–9

Use of amino acid profiles of preterm and term human milks in evaluating scoring patterns for routine protein quality assessment of infant formulas. Sarwar G, et al. **J AOAC Int** 1996 Mar–Apr;79(2):498–502

Mutational analysis of 39 residues of vaccinia DNA topoisomerase identifies Lys–220, Arg–223, and Asn–228 as important for covalent catalysis. Cheng C, et al. **J Biol Chem** 1997 Mar 28;272(13):8263–9

Functional consequences of truncating amino acid side chains located at a calmodulin–peptide interface. Chin D, et al. **J Biol Chem** 1997 Feb 28;272(9):5510–3

A new spatial representation of amino acid residues in globular proteins. Prabhakaran M. **J Biomol Struct Dyn** 1997 Apr;14(5):561–6

Semipreparative isolation of collagen types I, II, III and V by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and electroelution. Açil Y, et al. **J Chromatogr A** 1997 Jan 17;758(2):313–8

Gas chromatographic amino acid profiling of wine samples for pattern recognition. Kim KR, et al. **J Chromatogr A** 1996 Jan 26;722(1–2):303–9

Investigation on enantiomeric separations of fluorenylmethoxycarbonyl amino acids and peptides by high–performance liquid chromatography using native cyclodextrins as chiral stationary phases. Tang Y, et al. **J Chromatogr A** 1996 Sep 6;743(2):261–71

Determination of amino acids in the foods by reversed–phase high–performance liquid chromatography with a new precolumn derivative, butylthiocarbamyl amino acid, compared to the conventional phenylthiocarbamyl derivatives and ion–exchange chromatography. Woo KL, et al. **J Chromatogr A** 1996 Jul 26;740(1):31–40

Separation and determination of amino acids, creatinine, bioactive amines and nucleic acid bases by dual–mode gradient ion–pair chromatography. Yokoyama Y, et al. **J Chromatogr A** 1996 Jul 19;739(1–2):333–42

Reversed–phase high–performance liquid chromatography coupled with second–order derivative spectroscopy for the quantitation of aromatic amino acids in peptides: application to hemorphins. Zhao Q, et al. **J Chromatogr A** 1996 Feb 2;723(1):35–41

Chiral separation of primary amino compounds using a non–chiral crown ether with beta–cyclodextrin by capillary electrophoresis. Huang WX, et al. **J Chromatogr B Biomed Appl** 1997 Jul 18;695(1):157–62

Evaluation of D–amino acid levels in rat by gas chromatography–selected ion monitoring mass spectrometry: no evidence for subacute toxicity of orally fed D–proline and D–aspartic acid. Schieber A, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):1–12

Isolation and quantitation of isotopically labeled amino acids from biological samples. van Eijk HM, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):287–96

Characterization of glutathione conjugates of pyrrolylated amino acids and peptides by liquid chromatography–mass spectrometry and tandem mass spectrometry with electrospray ionization. Zhu M, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):187–96

Ruminal degradation, amino acid composition, and intestinal digestibility of the residual components of five protein supplements. Maiga HA, et al. **J Dairy Sci** 1996 Sep; 79(9):1647–53

Some considerations regarding the use of amino acid racemization in human dentine as an indicator of age at death. Carolan VA, et al. **J Forensic Sci** 1997 Jan;42(1):10–6

Estimation of age from teeth by amino acid racemization: influence of fixative. Ohtani S, et al. **J Forensic Sci** 1997 Jan;42(1):137–9

Chemical modification of bovine tissues by dye–mediated photooxidation. McIlroy BK, et al. **J Heart Valve Dis** 1997 Jul;6(4):416–23

Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. Medesan C, et al. **J Immunol** 1997 Mar 1;158(5):2211–7

Nucleotide composition bias affects amino acid content in proteins coded by animal mitochondria. Foster PG, et al. **J Mol Evol** 1997 Mar;44(3):282–8

Amino acid composition, immunoreactivity, sequence analysis, and function of bovine hippocampal metallothionein isoforms. Ebadi M, et al. **J Neurochem** 1996 May;66(5):2121–7

Amino acid signatures in the primate retina [published erratum appears in J Neurosci 1997 Jan 1;17(1):500–3] Kalloniatis M, et al. **J Neurosci** 1996 Nov 1;16(21):6807–29

Analysis of the phosphoamino acid content of phosphoproteins. de Witte PA, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1063–7

Determination of amino acids in biological fluids by capillary gas chromatography with nitrogen–phosphorus selective detection. Kataoka H, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1271–9

Thermospray liquid chromatography/mass spectrometry study of diastereomeric isoindole derivatives of amino acids and amino acid amides. van Leuken RG, et al. **J Pharm Biomed Anal** 1995 Nov;13(12):1459–64

High–sensitivity detection of 4–(3–pyridinylmethylaminocarboxypropyl) phenylthiohydantoins by capillary liquid chromatography–microelectrospray ion trap mass spectrometry. Ducret A, et al. **J Protein Chem** 1997 Jul; 16(5):323–8

Taxonomy of nuclear receptors and SERPINS by multivariate analysis of amino–acid composition. Ojasoo T, et al. **J Steroid Biochem Mol Biol** 1996 May;58(2):167–81

Finger printing of Mycobacterium tuberculosis in patients with intracranial tuberculomas by using in vivo, ex vivo, and in vitro magnetic resonance spectroscopy. Gupta RK, et al. **Magn Reson Med** 1996 Dec;36(6):829–33

Analysis of sites of protein phosphorylation. Aitken A, et al. **Methods Mol Biol** 1997;64:293–306

Identifying the carboxy terminal amino acid of a protein. Akiyama TH, et al. **Methods Mol Biol** 1997;64:235–42

Automated methods for C–terminal protein sequencing. Bailey JM, et al. **Methods Mol Biol** 1997;64:259–69

Enzymatic and chemical methods for manual C–terminal peptide sequencing. Casagranda F, et al. **Methods Mol Biol** 1997;64:243–57

Hydrolysis of samples for amino acid analysis. Davidson I. **Methods Mol Biol** 1997;64:119–29

Protein sequencer maintenance and troubleshooting. Dunbar B. **Methods Mol Biol** 1997;64:217–33

Amino acid analysis. Precolumn derivatization methods. Irvine GB. **Methods Mol Biol** 1997;64:131–8

Postcolumn amino acid analysis. Smith AJ. **Methods Mol Biol** 1997;64:139–46

The dansyl method for identifying N–terminal amino acids. Walker JM. **Methods Mol Biol** 1997;64:189–95

Conservation of key amino acids among the cysteine proteinases of multiple malarial species. Rosenthal PJ.

Mol Biochem Parasitol 1996 Jan;75(2):255–60

Extracellular glial fibrillary acidic protein and amino acids in brain regions of patients with subarachnoid hemorrhage—correlation with level of consciousness and site of bleeding. Runnerstam M, et al. **Neurol Res** 1997 Aug;19(4):361–8

Identification of the amino acid subsets accounting for the ligand binding specificity of a glutamate receptor [published erratum appears in Neuron 1997 Jan;18(1):177] Paas Y, et al. **Neuron** 1996 Nov;17(5):979–90

A parenteral nutrition regimen with ornithine substituted for arginine alters the amino acid, but not polyamine, content of the ward colon tumor. Grossie VB Jr, et al. **Nutr Cancer** 1997;27(1):102–6

Effect of arginine administration on plasma and brain levels of arginine and various related amino compounds in the rat. Buchmann I, et al. **Pharmacology** 1996 Sep;53(3):133–42

Jack bean (Canavalia ensiformis): nutrition related aspects and needed nutrition research. Akpapunam MA, et al. **Plant Foods Hum Nutr** 1997;50(2):93–9

Fertilizer effects on yield, mineral and amino acid composition, dietary fibre content and nutritive value of leeks. Eppendorfer WH, et al. **Plant Foods Hum Nutr** 1996 Feb;49(2):163–74

Amino acid composition and chemical evaluation of protein quality of cereals as affected by insect infestation. Jood S, et al. **Plant Foods Hum Nutr** 1995 Sep;48(2):159–67

Amino acid composition, available lysine content and in vitro protein digestibility of selected tropical crop seeds. Petzke KJ, et al. **Plant Foods Hum Nutr** 1997;50(2):151–62

Protein and amino acid quality of meat and bone meal. Parsons CM, et al. **Poult Sci** 1997 Feb;76(2):361–8

Artificial neural network prediction of amino acid levels in feed ingredients. Roush WB, et al. **Poult Sci** 1997 May; 76(5):721–7

Order of amino acid limitation in meat and bone meal. Wang X, et al. **Poult Sci** 1997 Jan;76(1):54–8

Amino acid substitutions preserve protein folding by conserving steric and hydrophobicity properties. Ladunga I, et al. **Protein Eng** 1997 Mar;10(3):187–96

Quantitative analysis of pyridinium crosslinks of collagen in the synovial fluid of patients with rheumatoid arthritis using high-performance liquid chromatography. Müller A, et al. **Rheumatol Int** 1996;16(1):23–8

Standardization of marker assays—pyridinoline/deoxypyridinoline. Kent GN. **Scand J Clin Lab Invest Suppl** 1997;227:73–9 (29 ref.)

Amino acid sequence of two neurotoxins from the venom of the Egyptian black snake (Walterinnesia aegyptia). Samejima Y, et al. **Toxicon** 1997 Feb;35(2):151–7

Amino acids in storage solution predict primary nonfunction in fatty liver grafts. Frankenberg MV, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1331–2

Analysis of free amino acids in green coffee beans. II. Changes of the amino acid content in arabica coffees in connection with post-harvest model treatment. Arnold U, et al. **Z Lebensm Unters Forsch** 1996 Oct;203(4):379–84

[A comparative study on amino acids of guang horn, buffalo horn and cattle horn] Fan G, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Mar;21(3):139–41, 189 (Eng. Abstr.) **(Chi)**

[Etiology of the cribra orbitalia: effect of amino acid profile in bone collagen and the iron content of bone minerals] Grupe G. **Z Morphol Anthropol** 1995 Dec;81(1):125–37 (Eng. Abstr.) **(Ger)**

[Determination by HPLC of amino acids in amniotic fluid] Gambaro V, et al. **Boll Chim Farm** 1997 Apr;136(4):372–6 **(Ita)**

[High performance liquid chromatography in the analysis of amino acids contents of the stomach and duodenum] Pokrasen NM, et al. **Klin Lab Diagn** 1997 Apr;(4):18–21 (Eng. Abstr.) **(Rus)**

[The determination of phosphoethanolamine and other amino components in the lipopolysaccharides of gram-negative bacteria by ion-exchange chromatography] Veremeĭchenko SN. **Mikrobiol Z** 1996 Mar–Apr;58(2):70–5 (Eng. Abstr.) **(Rus)**

[The amino acid composition of the antigenic structures of the human heart conduction system] Bobrov VA, et al. **Ukr Biokhim Zh** 1996 Mar–Apr;68(2):48–50 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Insulin-mimetic agents vanadate and pervanadate stimulate glucose but inhibit amino acid uptake. Tsiani E, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):C156–62

L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. Moynihan K, et al. **Cancer Chemother Pharmacol** 1997;39(3):179–86

Effect of prednisolone on amino acid-induced changes in renal haemodynamics and tubular function. Ivarsen P, et al. **Scand J Clin Lab Invest** 1996 Aug;56(5):449–59

BIOSYNTHESIS

Cloning and overexpression of thermostable D-hydantoinase from thermophile in E. coli and its application to the synthesis of optically active D-amino acids. Lee DC, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:401–5

Production of plant non-protein amino acids by recombinant enzymes of sequential biosynthetic reactions in bacteria. Saito K, et al. **Biol Pharm Bull** 1997 Jan;20(1):47–53

Microbial amino acid synthesis and utilization in rats: the role of coprophagy. Torrallardona D, et al. **Br J Nutr** 1996 Nov;76(5):701–9

Helicobacter pylori utilises urea for amino acid synthesis. Williams CL, et al. **FEMS Immunol Med Microbiol** 1996 Jan;13(1):87–94

Cross-pathway and pathway-specific control of amino acid biosynthesis in Magnaporthe grisea. Shen WC, et al. **Fungal Genet Biol** 1996 Feb;21(1):40–9

Production of free amino acids by some earthworm-borne microorganisms. Joy EK, et al. **Hindustan Antibiot Bull** 1995 Feb–Nov;37(1–4):16–24

Ribose biosynthesis and evidence for an alternative first step in the common aromatic amino acid pathway in Methanococcus maripaludis. Tumbula DL, et al. **J Bacteriol** 1997 Oct;179(19):6010–3

Genetic tools for selective labeling of proteins with alpha-15N-amino acids. Waugh DS. **J Biomol NMR** 1996 Sep;8(2):184–92

Gas chromatography/combustion/isotope ratio mass spectrometric comparison of N-acetyl- and N-pivaloyl amino acid esters to measure 15N isotopic abundances in physiological samples: a pilot study on amino acid synthesis in the upper gastro-intestinal tract of minipigs. Metges CC, et al. **J Mass Spectrom** 1996 Apr;31(4):367–76

Energy from redox disproportionation of sugar carbon drives biotic and abiotic synthesis. Weber AL. **J Mol Evol** 1997 Apr;44(4):354–60

Biological role of the general control of amino acid biosynthesis in Saccharomyces cerevisiae. Niederberger P, et al. **Mol Cell Biol** 1981 Jul;1(7):584–93

Determination of de novo synthesized amino acids in cellular proteins revisited by 13C NMR spectroscopy. Flögel U, et al. **NMR Biomed** 1997 Apr;10(2):50–8

BLOOD

Taurine supplementation prevents hyperaminoacidemia in growing term infants fed high-protein cow's milk formula. Räihä NC, et al. **Acta Paediatr** 1996 Dec;85(12):1403–7

Age dependence of large neutral amino acid levels in plasma. Focus on Tryptophan. Demling J, et al. **Adv Exp Med Biol** 1996;398:579–82

Taurine administration raises plasma taurine levels and affects certain plasma amino acids and related compounds in rats. Korang K, et al. **Adv Exp Med Biol** 1996;403:51–3

Predicting value of tryptophan/large neutral amino acids ratio on selective serotonin reuptake inhibitors. Lucini V, et al. **Adv Exp Med Biol** 1996;398:559

Delirium after cardiac surgery. The possible role of tryptophan in relation to the other neutral aminoacids. van der Mast RC, et al. **Adv Exp Med Biol** 1996;398:93–6

Responses of circulating urea cycle and branched-chain amino acids to feeding in adult and aged Fischer-344 rats. Hartman WJ, et al. **Aging (Milano)** 1997 Jun;9(3):198–206

A prospective randomized study of glutamine-enriched parenteral compared with enteral feeding in postoperative patients. Fish J, et al. **Am J Clin Nutr** 1997 Apr; 65(4):977–83

A double-blind, prospective, randomized study of glutamine-enriched compared with standard peptide-based feeding in critically ill patients [see comments] Jensen GL, et al. **Am J Clin Nutr** 1996 Oct;64(4):615–21. Comment in: Am J Clin Nutr 1996 Oct;64(4):645–7.

Preexercise meal composition alters plasma large neutral amino acid responses during exercise and recovery. Paul GL, et al. **Am J Clin Nutr** 1996 Nov;64(5):778–86

Glutamine supplementation in catabolic illness [editorial; comment] Ziegler TR. **Am J Clin Nutr** 1996 Oct; 64(4):645–7. Comment on: Am J Clin Nutr 1996 Oct;64(4):615–21.

Maternal concentrations and fetal-maternal concentration differences of plasma amino acids in normal and intrauterine growth-restricted pregnancies. Cetin I, et al. **Am J Obstet Gynecol** 1996 May;174(5):1575–83

Insulin and hyperaminoacidemia regulate by a different mechanism leucine turnover and oxidation in obesity. Luzi L, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):E273–81

Effect of amino acid and glucose administration during postexercise recovery on protein kinetics in dogs. Okamura K, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E1023–30

Effects of amino acids on synthesis and degradation of skeletal muscle proteins in humans. Svanberg E, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):E718–24

Insulin-stimulated amino acid utilization during glucose and amino acid clamps decreases with development. Wray-Cahen D, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):E305–14

Measurement of 15N/14N isotopic composition in individual plasma free amino acids of human adults at natural abundance by gas chromatography-combustion isotope ratio mass spectrometry. Metges CC, et al. **Anal Biochem** 1997 Apr 5;247(1):158–64

High-performance liquid chromatographic determination of pyridinium crosslinks in serum, urine and dialysate of patients in chronic renal failure. Ibrahim S, et al. **Ann Clin Biochem** 1996 Jan;33 (Pt 1):31–5

Serum pyridinoline crosslinks as markers of tumour-induced bone resorption. Nemoto R, et al. **Br J Urol** 1997 Aug; 80(2):274–80

Pyridinium crosslinks in the monitoring of patients with bone metastases from carcinoma of the breast. Walne AJ, et al. **Clin Oncol (R Coll Radiol)** 1997;9(1):30–4

Enteral administration of ornithine alpha-ketoglutarate or arginine alpha-ketoglutarate: a comparative study of their effects on glutamine pools in burn-injured rats. Le Boucher J, et al. **Crit Care Med** 1997 Feb;25(2):293–8

Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Perseghin G, et al. **Diabetes** 1997 Jun;46(6):1001–9

Diagnostic value of serum lactate dehydrogenase isoenzyme and amino acid patterns in several schistosomal and non-schistosomal disorders as compared to other biochemical parameters. Ahmed SA, et al. **Dis Markers** 1996 Aug;13(1):19–29

Amino acids and their derivatives in blood plasma of patients with breast cancer treated with Ukrain. Part V. Nefyodov LI, et al. **Drugs Exp Clin Res** 1996;22(3–5):155–7

Effect of corn peptide on alcohol metabolism and plasma free amino acid concentrations in healthy men. Yamaguchi M, et al. **Eur J Clin Nutr** 1996 Oct;50(10):682–8

Effects of oral contraceptives on plasma neutral amino acids and cholesterol during a menstrual cycle. Moller SE, et al. **Eur J Clin Pharmacol** 1996;50(3):179–84

Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression. Fekkes D, et al. **Eur Neuropsychopharmacol** 1997 Aug; 7(3):235–9

Free deoxypyridinoline in urine and serum—results in children and adolescents. Rauch F, et al. **Exp Clin Endocrinol Diabetes** 1996;104(5):396–9

Effects of insulin-like growth factor I (IGF-I) on the porto-arterial concentration differences of amino acids and glucose: a comparison between oral and intraperitoneal administration in the newborn piglet. Fhölenhog K, et al. **Horm Metab Res** 1996 Nov;28(11):582–7

Predictive value of tryptophan/large neutral amino acids ratio to antidepressant response. Lucini V, et al. **J Affect Disord** 1996 Jan 22;36(3–4):129–33

Conditions altering plasma concentrations of urea cycle and other amino acids in elderly human subjects. Prior RL, et al. **J Am Coll Nutr** 1996 Jun;15(3):237–47

The effect of abomasal infusion of casein and recombinant somatotropin hormone injection on nitrogen balance and amino acid fluxes in portal-drained viscera and net hepatic and total splanchnic blood in Holstein steers. Bruckental I, et al. **J Anim Sci** 1997 Apr;75(4):1119–29

Evaluation of the 15N-isotope dilution technique for determining the recovery of endogenous protein in ileal digesta of pigs: effect of the pattern of blood sampling, precursor pools, and isotope dilution technique. Lien KA, et al. **J Anim Sci** 1997 Jan;75(1):159–69

Plasma amino acid uptake by the mammary gland of the lactating sow. Trottier NL, et al. **J Anim Sci** 1997 May; 75(5):1266–78

Comparison of the metabolic disturbances caused by end-to-side and side-to-side portacaval shunts. Hawkins PA, et al. **J Appl Physiol** 1996 Mar;80(3):885–91

Changes in brain and plasma amino acids of mice intoxicated with methyl isocyanate. Gupta M, et al. **J Appl Toxicol** 1996 Nov–Dec;16(6):469–73

The renal clearance of free and conjugated pyridinium cross-links of collagen. Colwell A, et al. **J Bone Miner Res** 1996 Dec;11(12):1976–80

Evaluation of systematic errors due to deproteinization, calibration and storage of plasma for amino acid assay by ion-exchange chromatography. de Jonge LH, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23;677(1):61–8

State-of-the-art of high-performance liquid chromatographic analysis of amino acids in physiological samples. Fekkes D. **J Chromatogr B Biomed Appl** 1996 Jun 28;682(1):3–22 (43 ref.)

Determination of amino acids in human serum by capillary gas chromatography. Matsumura S, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):375–80

Determination of pyridinium crosslinks in serum an optimization of sample preparation. Spaček P, et al. **J Chromatogr B Biomed Appl** 1997 Feb 21;689(2):404–8

Whole blood analysis of gluconeogenic amino acids for estimation of de novo gluconeogenesis using pre-column o-phthalaldehyde derivatization and high-performance liquid chromatography. Venkatakrishnan A, et al. **J Chromatogr B Biomed Appl** 1996 Feb 9;676(1):1–6

Amino acid and DNA analyses in a family with ornithine transcarbamylase deficiency. Hou JW, et al. **J Formos Med Assoc** 1996 Feb;95(2):144–7

A profile of amino acid and catecholamine levels during endotoxin-induced acute lung injury in sheep: searching for potential markers of the acute respiratory distress syndrome. Hofford JM, et al. **J Lab Clin Med** 1996 Dec; 128(6):545–51

Decreased plasma ratio of tryptophan to competing large neutral amino acids in human immunodeficiency virus type 1 infected subjects: possible implications for development of neuro-psychiatric disorders. Eriksson T, et al. **J Neural Transm** 1996;103(1–2):157–64

Acute-phase protein synthesis in rats is influenced by alterations in plasma and muscle free amino acid pools related to lower plasma volume following trauma. Sevaljević LM, et al. **J Nutr** 1996 Dec;126(12):3136–42 (39 ref.)

Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. Mak RH. **J Pediatr** 1996 Jul;129(1):97–104

Effects of amitriptyline on rat plasma and brain content of

monoamine precursors and other large neutral amino acids. Eriksson T, et al. **J Pharm Pharmacol** 1995 Dec; 47(12A):1007–14

Leucine supplementation and serum amino acids, testosterone, cortisol and growth hormone in male power athletes during training. Mero A, et al. **J Sports Med Phys Fitness** 1997 Jun;37(2):137–45

Arterial–jugular vein free amino acid levels in patients with head injuries: important role of glutamine in cerebral nitrogen metabolism. Petersen SR, et al. **J Trauma** 1996 Oct;41(4):687–94; discussion 694–5

Serum and urinary amino acid levels in sickle cell disease. VanderJagt DJ, et al. **J Trop Pediatr** 1997 Aug;43(4):220–5

Plasma amino acid concentrations in term–born infants fed a whey predominant or a whey hydrolysate formula. Hauser B, et al. **JPEN J Parenter Enteral Nutr** 1997 Jan–Feb;21(1):27–30

Cerebrospinal and plasma amino acid concentrations after administration of i.v. glycyl–glutamine and glycyl–tyrosine containing amino acid solutions in humans. Himmelseher S, et al. **JPEN J Parenter Enteral Nutr** 1996 Jul–Aug; 20(4):281–6

Amino acid profiles and muscle protein composition in rats with a reduced renal mass in the fed state. Cupisti A, et al. **Nephron** 1996;74(1):183–8

Hypermetabolism and increased peripheral release of amino acids after subarachnoidal hemorrhage and its operative treatment. Suojaranta–Ylinen R, et al. **Nutrition** 1996 May; 12(5):327–33

Brain serotonin content: physiological regulation by plasma neutral amino acids. 1971 [classical article] [see comments] Fernstrom JD, et al. **Obes Res** 1997 Jul;5(4):377–80. Comment in: Obes Res 1997 Jul;5(4):373–6.

Relationship between serum amino acid concentration and fluctuations in appetite. 1956 [classical article] [see comments] Mellinkoff SM, et al. **Obes Res** 1997 Jul; 5(4):381–4. Comment in: Obes Res 1997 Jul;5(4):373–6.

Increased plasma concentrations of the 5–HT precursor amino acid tryptophan and other large neutral amino acids in violent criminals. Eriksson T, et al. **Psychol Med** 1997 Mar;27(2):477–81

Comparison of growth, serum prealbumin, transferrin, IgG and amino acids of term infants fed breast mild or formula. Kurugöl Z, et al. **Turk J Pediatr** 1997 Apr–Jun; 39(2):195–202

[Determination of serum free amino acids and ammonia in pregnant women with severe pregnancy induced hypertension] Li J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Aug;31(8):468–70 (Eng. Abstr.) **(Chi)**

[Serum and urinary pyridinium cross–links in patients with predialysis chronic renal failure] Kagebayashi Y, et al. **Nippon Jinzo Gakkai Shi** 1996 Jun;38(6):248–53 (Eng. Abstr.) **(Jpn)**

[Homocysteine and methylmalonic acid. New tests—for what benefit?] Berentsen S, et al. **Tidsskr Nor Laegeforen** 1996 Sep 20;116(22):2677–9 (Eng. Abstr.) **(Nor)**

[Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients] Navarro–Quesada FJ, et al. **Rev Neurol** 1997 Jul; 25(143):1037–44 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Cerebrospinal fluid amino acid levels in newborn infants with intracranial hemorrhage. Yurdakök M, et al. **Acta Paediatr Jpn** 1995 Dec;37(6):694–6

The effect of alpha–trinositol (D–myo–inositol 1,2,6–trisphosphate) on formalin–evoked spinal amino acid and prostaglandin E2 levels. Malmberg AB, et al. **Brain Res** 1997 Jan 30;747(1):160–4

Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease. Jiménez–Jiménez FJ, et al. **J Neurol Sci** 1996 Sep 15;141(1–2):39–44

Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. Molina JA, et al. **J Neurol Sci** 1997 Sep 10;150(2):123–7

Cerebrospinal and plasma amino acid concentrations after administration of i.v. glycyl–glutamine and glycyl–tyrosine containing amino acid solutions in humans. Himmelseher S, et al. **JPEN J Parenter Enteral Nutr** 1996 Jul–Aug; 20(4):281–6

Levels of free gamma–aminobutyric acid and other neuroactive amino acids in cerebrospinal fluid of patients with neurological disorders] Doroshenko Ye M, et al. **Ukr Biokhim Zh** 1996 Sep–Oct;68(5):89–94

CHEMICAL SYNTHESIS

Synthesis of an amino acid analogue to incorporate p–aminobenzyl–EDTA in peptides. Song AI, et al. **Bioconjug Chem** 1997 Mar–Apr;8(2):249–52

Synthesis of novel (N–farnesyl) amino acids and their incorporation into peptides. Byk G, et al. **Int J Pept Protein Res** 1996 May;47(5):333–9

Synthesis of lipidic amino acid and dipeptide inhibitors of human platelet phospholipase A2. Kokotos G, et al. **Int J Pept Protein Res** 1996 Aug;48(2):160–6

The use of N–urethane–protected N–carboxyanhydrides (UNCAs) in amino acid and peptide synthesis. Fehrentz JA, et al. **J Pept Sci** 1995 Mar–Apr;1(2):124–31

Proteinogenic amino acids labelled with 15N and/or 13C for application in peptide synthesis: a short review with a comprehensive list of published derivatives. Ragnarsson U. **J Pept Sci** 1995 May–Jun;1(3):149–56 (50 ref.)

Biological active acridine derivatives. Part 3: acridinylamino acids and their esters; synthesis and cytostatic activity. Lyakhov SA, et al. **Pharmazie** 1997 Jul;52(7):560–1

[Lipoamino acids and lipopeptides as potential 5– and 12–lipoxygenase inhibitors] Presenz P. **Pharmazie** 1997 Feb; 52(2):164–5 **(Ger)**

CHEMISTRY

Covariability of V3 loop amino acids. Bickel PJ, et al. **AIDS Res Hum Retroviruses** 1996 Oct 10;12(15):1401–11

Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Veltri M, et al. **Am J Health Syst Pharm** 1996 Nov 1;53(21):2611–3

Measurement of 15N/14N isotopic composition in individual plasma free amino acids of human adults at natural abundance by gas chromatography–combustion isotope ratio mass spectrometry. Metges CC, et al. **Anal Biochem** 1997 Apr 5;247(1):158–64

A method for preparation of amino acid thiohydantoins from free amino acids activated by acetyl chloride for development of protein C–terminal sequencing. Mo B, et al. **Anal Biochem** 1997 Jul 1;249(2):207–11

Accurate determination of 13C enrichments in nonprotonated carbon atoms of isotopically enriched amino acids by 1H nuclear magnetic resonance. Wendisch VF, et al. **Anal Biochem** 1997 Feb 15;245(2):196–202

Retention behavior of amino acids and peptides on protoporphyrin–silica stationary phases with varying metal ion centers. Xiao J, et al. **Anal Chem** 1996 Sep 1; 68(17):2818–25

D–amino acids in animal peptides. Kreil G. **Annu Rev Biochem** 1997;66:337–45 (53 ref.)

Molecular modeling of the interaction of anthracenyl–amino acid topoisomerase inhibitors with the DNA sequence d(CGTACG). Cummings J, et al. **Anticancer Drugs** 1996 Aug;7(6):636–41

Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation. McGuigan C, et al. **Antiviral Res** 1997 Aug;35(3):195–204

Pattern and spacing of basic amino acids in heparin binding sites. Fromm JR, et al. **Arch Biochem Biophys** 1997 Jul 1;343(1):92–100

Synthesis and mass spectrometric identification of the major amino acid adducts formed between sulphur mustard and haemoglobin in human blood. Noort D, et al. **Arch Toxicol** 1997;71(3):171–8

Protein engineering of venom toxins by synthetic approach and NMR dynamic simulation: status of basic amino acid residues in waglerin I. Hsiao YM, et al. **Biochem Biophys Res Commun** 1996 Oct 3;227(1):59–63

A receptor binding site on intrinsic factor is located between amino acids 25–44 and interacts with other parts of the protein. Wen J, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):348–51

Butachlor impact on protein, free amino acid and glutamine contents, and on activity levels of aminotransferases, glutamate dehydrogenase and glutamine synthetase in the fresh water snail, Pila globosa (Swainson). Rajyalakshmi T, et al. **Biochem Mol Biol Int** 1996 Aug;39(5):949–60

Evaluation of functionally important amino acids in L–aspartate ammonia–lyase from Escherichia coli. Jayasekera MM, et al. **Biochemistry** 1997 Jul 29; 36(30):9145–50

Structure–based thermodynamic scale of alpha–helix propensities in amino acids. Luque I, et al. **Biochemistry** 1996 Oct 22;35(42):13681–8

Conformations and orientations of aromatic amino acid residues of tachyplesin I in phospholipid membranes. Oishi O, et al. **Biochemistry** 1997 Apr 8;36(14):4352–9

Influence of conserved amino acids on the structure and environment of the heme of cytochrome c2. A resonance Raman study. Othman S, et al. **Biochemistry** 1997 May 6; 36(18):5499–508

Noncoded amino acid replacement probes of the aspartate aminotransferase mechanism. Park Y, et al. **Biochemistry** 1997 Aug 26;36(34):10517–25

Random mutagenesis of the poly(ADP–ribose) polymerase catalytic domain reveals amino acids involved in polymer branching. Rolli V, et al. **Biochemistry** 1997 Oct 7; 36(40):12147–54

A comprehensive survey of the acid–stable fluorescent cross–links formed by ribose with basic amino acids, and partial characterization of a novel Maillard cross–link. Graham L. **Biochim Biophys Acta** 1996 Sep 13;1297(1):9–16

Mechanism of action of weak electromagnetic field on ionic currents in aqueous solutions of amino acids. Novikov VV, et al. **Bioelectromagnetics** 1997;18(1):25–7

Characterization of imidazopyrroloquinoline compounds synthesized from coenzyme PQQ and various amino acids. Urakami T, et al. **Biofactors** 1995–96;5(2):75–81

Chalcogen–analogs of amino acids. Their use in X–ray crystallographic and folding studies of peptides and proteins. Besse D, et al. **Biol Chem** 1997 Mar–Apr; 378(3–4):211–8 (40 ref.)

Phosphoamino acids in proteasome subunits. Wehren A, et al. **Biol Chem** 1996 Jul–Aug;377(7–8):497–503

Hydrolytic cleavage of pyroglutamyl–peptide bond. II. Effects of amino acid residue neighboring the pGlu moiety. Saito S, et al. **Biol Pharm Bull** 1996 May;19(5):768–70

Analytical chemistry and biochemistry of D–amino acids. Imai K, et al. **Biomed Chromatogr** 1996 Nov–Dec; 10(6):303–12 (157 ref.)

Boron trifluoride–etherate (Lewis acid) as an efficient acid at cyclization/cleavage reaction of D/L–amino acids affording the retention of their original configuration in the Edman sequencing method of peptides. Matsunaga H, et al. **Biomed Chromatogr** 1996 Mar–Apr;10(2):95–6

Use of BOP–Cl in the presence of Boc–amino monothioacids for the thioacylation of imino acid residues. Le HT, et al. **Bioorg Med Chem** 1996 Dec;4(12):2201–9

Omega amino acids in peptide design: incorporation into helices. Banerjee A, et al. **Biopolymers** 1996 Dec; 39(6):769–77

Strategies for in vitro and in vivo translation with non–natural amino acids. Ibba M. **Biotechnol Genet Eng Rev** 1996;13:197–216 (116 ref.)

Synthesis and tryptic hydrolysis of p–guanidinophenyl esters derived from amino acids and peptides. Sekizaki H, et al. **Chem Pharm Bull (Tokyo)** 1996 Aug;44(8):1577–9

Reactions of 3,4–estrone quinone with mimics of amino acid side chains. Abul–Hajj YJ, et al. **Chem Res Toxicol** 1996 Mar;9(2):434–8

Reaction of trifluoroacetaldehyde with amino acids, nucleotides, lipid nucleophiles, and their analogs. Yin H, et al. **Chem Res Toxicol** 1996 Jan–Feb;9(1):140–6

Thermodynamic roles of solubility in taste responses of amino acids. Yamanaka T. **Chem Senses** 1996 Aug;21(4):405–9

The determination of pyridinium crosslinks in urine and serum as a possible marker of cartilage degradation in rheumatoid arthritis. Hein G, et al. **Clin Rheumatol** 1997 Mar;16(2):167–72

Changes in protein content and free amino acid composition in metal–contaminated gypsy moth larvae (Lymantria dispar L., Lymantriidae, Lepidoptera). Ortel J. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Nov;112(3):291–8

Comparative mutagenesis of nuclear localization signals reveals the importance of neutral and acidic amino acids. Makkerh JPS, et al. **Curr Biol** 1996 Aug 1;6(8):1025–7

Determination of association constants of dansyl–amino acids and beta–cyclodextrin in N–methylformamide by capillary electrophoresis. Valkó IE, et al. **Electrophoresis** 1997 Jun; 18(6):919–23

Discrimination ability of pyridinoline crosslinks related markers for bone resorption in postmenopause and osteoporosis. Takahashi M, et al. **Endocr Res** 1997 Feb–May;23(1–2):105–17

A synthetic peptide corresponding to amino acid residues 34 to 37 of human follicle–stimulating hormone beta–subunit accelerates the onset of puberty in male and female mice. Grasso P, et al. **Endocrinology** 1997 Oct; 138(10):4215–9

Identification of amino acids of endonuclease VII essential for binding and cleavage of cruciform DNA. Golz S, et al. **Eur J Biochem** 1997 May 1;245(3):573–80

Amino acids of the alpha1B–adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes. Cavalli A, et al. **FEBS Lett** 1996 Dec 9;399(1–2):9–13

Acetylcholine receptor subunit homomer formation requires compatibility between amino acid residues of the M1 and M2 transmembrane segments. Vicente–Agulló F, et al. **FEBS Lett** 1996 Dec 9;399(1–2):83–6

Chirality differences in amino acid retention and release from acid–extractable pool of cultured mammalian cells. Wheatley DN, et al. **Int J Biochem Cell Biol** 1996 Dec; 28(12):1349–64

Hydrophobic distribution and spatial arrangement of amino acid residues in membrane proteins. Gromiha MM, et al. **Int J Pept Protein Res** 1996 Nov;48(5):452–60

Prediction of conformational states of amino acids using a Ramachandran plot. Kolaskar AS, et al. **Int J Pept Protein Res** 1996 Jan–Feb;47(1–2):110–6

An effective organic solvent system for the dissolution of amino acids. Mitin YV. **Int J Pept Protein Res** 1996 Oct; 48(4):374–6

Conformation–activity correlations for chemotactic tripeptide analogs incorporating dialkyl residues with linear and cyclic alkyl sidechains at position 2. Prasad S, et al. **Int J Pept Protein Res** 1996 Oct;48(4):312–8

Motifs and conformational analysis of amino acid residues adjoining beta–turns in proteins. Ramakrishnan C, et al. **Int J Pept Protein Res** 1996 Nov;48(5):420–8

Phosphoryl transfer reaction regulated by amino acid side chains: a model for phosphoproteins. Zhao YF, et al. **Int J Pept Protein Res** 1996 Apr;47(4):276–81

Binding of L–branched–chain amino acids causes a conformational change in BkdR. Madhusudhan KT, et al. **J Bacteriol** 1997 Jan;179(1):276–9

Effect of salt concentration on the pKa of acidic residues in lysozyme. Abe Y, et al. **J Biochem (Tokyo)** 1995 Nov; 118(5):946–52

Deletion of amino acid residues 18–75 inactivates the plasma membrane Ca2+ pump. Grimaldi ME, et al. **J Biol Chem** 1996 Oct 25;271(43):26995–7

Molecular site specificity of pyridinoline and pyrrole cross–links in type I collagen of human bone. Hanson DA, et al. **J Biol Chem** 1996 Oct 25;271(43):26508–16

Alanine exchanges of polar amino acids in the transmembrane domains of a platelet–activating factor receptor generate both constitutively active and inactive mutants. Ishii I, et

al. **J Biol Chem** 1997 Mar 21;272(12):7846–54
Strains of Synechocystis sp. PCC 6803 with altered PsaC. II. EPR and optical spectroscopic properties of FA and FB in aspartate, serine, and alanine replacements of cysteines 14 and 51. Jung YS, et al. **J Biol Chem** 1997 Mar 21;272(12):8040–9
Role of hydrophobic amino acids at beta85 and beta88 in stabilizing F helix conformation of hemoglobin S. Reddy LR, et al. **J Biol Chem** 1996 Oct 4;271(40):24564–8
A key amino acid responsible for substrate selectivity of monoamine oxidase A and B. Tsugeno Y, et al. **J Biol Chem** 1997 May 30;272(22):14033–6
Phase labeling of C–H and C–C spin–system topologies: application in constant–time PFG–CBCA(CO)NH experiments for discriminating amino acid spin–system types. Rios CB, et al. **J Biomol NMR** 1996 Oct;8(3):345–50
Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross–links. Randall AG, et al. **J Bone Miner Res** 1996 Aug;11(8):1176–84
Basic amino acid residue cluster within nuclear targeting sequence motif is essential for cytoplasmic plectin–vimentin network junctions. Nikolic B, et al. **J Cell Biol** 1996 Sep; 134(6):1455–67
Electrochemical activity of 6–aminoquinolyl urea derivatives of amino acids and peptides. Application to high–performance liquid chromatography with electrochemical detection. Li GD, et al. **J Chromatogr A** 1996 Feb 16;724(1–2):147–57
Use of sodium perchlorate at low pH for peptide separations by reversed–phase liquid chromatography. Influence of perchlorate ion on apparent hydrophilicity of positively charged amino acid side–chains. Sereda TJ, et al. **J Chromatogr A** 1997 Jul 25;776(1):153–65
Investigation on enantiomeric separations of fluorenylmethoxycarbonyl amino acids and peptides by high–performance liquid chromatography using native cyclodextrins as chiral stationary phases. Tang Y, et al. **J Chromatogr A** 1996 Sep 6;743(2):261–71
Organometallic anticancer agents. 2. Aqueous chemistry and interaction of niobocene dichloride with nucleic acid constituents and amino acids. Harding MM, et al. **J Med Chem** 1996 Dec 6;39(25):5012–6
Disallowed Ramachandran conformations of amino acid residues in protein structures. Gunasekaran K, et al. **J Mol Biol** 1996 Nov 22;264(1):191–8
Small–molecule–substrate interactions with a self–aminoacylating ribozyme. Illangasekare M, et al. **J Mol Biol** 1997 May 9;268(3):631–9
Novel knowledge–based mean force potential at atomic level. Melo F, et al. **J Mol Biol** 1997 Mar 21;267(1):207–22
Determination of atomic desolvation energies from the structures of crystallized proteins. Zhang C, et al. **J Mol Biol** 1997 Apr 4;267(3):707–26
Adaptive amino acid replacements accompanied by domain fusion in reverse transcriptase. Shirai T, et al. **J Mol Evol** 1997;44 Suppl 1:S155–62
Salicylaldehyde–metal–amino acid ternary complex: a new tool for immobilized metal affinity chromatography. Leibler D, et al. **J Mol Recognit** 1996 Sep–Dec; 9(5–6):375–82
Preparation and properties of N alpha–Bpoc–amino acid pentafluorophenyl esters. Carey RI, et al. **J Pept Res** 1997 Jun;49(6):570–81
New renin inhibitors containing novel analogues of statine. Jones DM, et al. **J Pept Res** 1997 Aug;50(2):109–21
Use of Fmoc–N–(2–hydroxy–4–methoxybenzyl)amino acids in peptide synthesis. Zeng W, et al. **J Pept Res** 1997 Mar; 49(3):273–9
Conformational characterization of the 1–aminocyclobutane–1–carboxylic acid residue in model peptides. Gatos M, et al. **J Pept Sci** 1997 Mar–Apr; 3(2):110–22
Preferred conformation of peptides rich in Ac8c, a medium–ring alicyclic C (alpha,alpha)–disubstituted glycine. Moretto V, et al. **J Pept Sci** 1996 Jan–Feb; 2(1):14–27
Synthesis and screening of an indexed motif–library containing non–proteinogenic amino acids. Ostergaard S, et al. **J Pept Sci** 1997 Mar–Apr;3(2):123–32
A modified McLafferty rearrangement in the electron impact mass spectra of dansylated amino–acid methyl esters. Oprean R, et al. **J Pharm Biomed Anal** 1996 Jun; 14(8–10):1031–5
Classification of the environment of protein residues. Deerfield DW 2nd, et al. **J Protein Chem** 1997 Jul; 16(5):441–7
Prediction of membrane protein topology utilizing multiple sequence alignments. Persson B, et al. **J Protein Chem** 1997 Jul;16(5):453–7
Four stereochemical types of protein amino acids: synchronic determination with chemical characteristics, atom and nucleon number [letter] Rakočević M, et al. **J Theor Biol** 1996 Dec 7;183(3):345–9
A new approach to clustering the amino acids. Stanfel LE. **J Theor Biol** 1996 Nov 21;183(2):195–205
Preparation of low molecular weight model conjugates for ADP–ribose linkages to protein. Cervantes–Laurean D, et al. **Methods Enzymol** 1997;280:275–87
Chemical modification of proteins for sequence analysis. Carne AF, et al. **Methods Mol Biol** 1997;64:271–84
Identification of PTH–amino acids by high–performance liquid chromatography. Grant GA, et al. **Methods Mol Biol** 1997;64:197–215
High–performance liquid chromatography on–line derivative spectroscopy for the characterization of peptides with aromatic amino acid residues. Turck CW. **Methods Mol Biol** 1997;64:109–17
Letter codes, structures, masses, and derivatives of amino acids. Turner JP, et al. **Methods Mol Biol** 1997;64:329–56
Phosphorus–based combinatorial libraries: use of amino acid derivatives as synthons. Fathi R, et al. **Mol Divers** 1997 Mar;2(3):125–34
Tolerance of different proteins for amino acid diversity. Suzuki M, et al. **Mol Divers** 1996 Oct;2(1–2):111–8
Dose–response relations for unnatural amino acids at the agonist binding site of the nicotinic acetylcholine receptor: tests with novel side chains and with several agonists. Kearney PC, et al. **Mol Pharmacol** 1996 Nov;50(5):1401–12
Residue–based control of helix shape in beta–peptide oligomers. Appella DH, et al. **Nature** 1997 May 22; 387(6631):381–4
Origins of life. A left–handed solar system? [news; comment] Chyba CF. **Nature** 1997 Sep 18;389(6648):234–5. Comment on: Nature 1997 Sep 18;389(6648):265–8.
Isotopic evidence for extraterrestrial non–racemic amino acids in the Murchison meteorite [see comments] Engel MH, et al. **Nature** 1997 Sep 18;389(6648):265–8. Comment in: Nature 1997 Sep 18;389(6648):234–5.
Betas are brought into the fold [news] Iverson BL. **Nature** 1997 Jan 9;385(6612):113, 115
Direct interaction between amino– and carboxyl–terminal domains of cyclic nucleotide–gated channels. Gordon SE, et al. **Neuron** 1997 Aug;19(2):431–41
Rapid selection of aminoacyl–tRNAs based on biotinylation of alpha–NH2 group of charged amino acids. Pütz J, et al. **Nucleic Acids Res** 1997 May 1;25(9):1862–3
Synthesis and properties of oligo–omega–amino acids derivatives containing nucleosides. Wada T, et al. **Nucleic Acids Symp Ser** 1995;(34):189–90
Racemization of lens crystalline constituents in UV–induced cataract evaluated by chiral GC/MS spectroscopy. Jung WT, et al. **Ophthalmic Res** 1996;28 Suppl 2:26–31
The beta–sheets of proteins, the biosynthetic relationships between amino acids, and the origin of the genetic code. Di Giulio M. **Orig Life Evol Biosph** 1996 Dec;26(6):589–609
Synthesis of N alpha–protected aminoacyl 7–amino–4–methyl–coumarin amide by phosphorous oxychloride and preparation of specific fluorogenic substrates for papain. Alves LC, et al. **Pept Res** 1996 Mar–Apr;9(2):92–6
Novel N omega–xanthenyl–protecting groups for asparagine and glutamine, and applications to N alpha–9–fluorenylmethyloxycarbonyl (Fmoc) solid–phase peptide synthesis. Han Y, et al. **Pept Res** 1996 Jul–Aug; 9(4):166–73
Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV–1 GP41 sequence. Jiang S, et al. **Pept Res** 1995 Nov–Dec;8(6):345–8
D–amino acid substitution of residues 32 to 46 of the glycoprotein hormone common alpha–subunit: development of a synthetic glycoprotein hormone antagonist. Leng N, et al. **Pept Res** 1996 Jul–Aug; 9(4):188–94
Peptide destabilization by two adjacent D–amino acids in single–stranded amphipathic alpha–helices. Rothemund S, et al. **Pept Res** 1996 Mar–Apr;9(2):79–87
Large–pore polydimethylacrylamide resin for solid–phase peptide synthesis: applications in Fmoc chemistry. Sparrow JT, et al. **Pept Res** 1996 Nov–Dec;9(6):297–304
Mass spectrometric sequencing of synthetic peptides containing alpha, alpha–dialkylated amino acid residues by MALDI post–source decay analysis. Wenschuh H, et al. **Pept Res** 1996 May–Jun;9(3):122–6
Solid–phase synthesis of hydroxyethylamine angiotensin analogues. Chambers SL, et al. **Peptides** 1997;18(4):505–12
Endoproteolysis at tetrabasic amino acid sites in procalcitonin gene–related peptide by pituitary cell lines. Rosenblatt MI, et al. **Peptides** 1997;18(4):567–76
Correlation of physiochemical parameters to the hydrophobic contribution constants of amino acid residues in small peptides. Palekar D, et al. **Pharm Res** 1996 Aug; 13(8):1191–5
Synthesis and in vitro investigations of nalidixic acid amides of amino acid esters as prodrugs. Aboul–Fadl T, et al. **Pharmazie** 1996 Jan;51(1):30–3
Direct evidence for modified solvent structure within the hydration shell of a hydrophobic amino acid. Pertsemlidis A, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1; 93(20):10769–74
Conformation and design of peptides with alpha,beta–dehydro–amino acid residues. Singh TP, et al. **Prog Biophys Mol Biol** 1996;66(2):141–65 (96 ref.)
Pyridoxamine–amino acid chimeras in semisynthetic aminotransferase mimics. Roy RS, et al. **Protein Eng** 1997 Jun;10(6):691–8
Analysis of amino acid indices and mutation matrices for sequence comparison and structure prediction of proteins. Tomii K, et al. **Protein Eng** 1996 Jan;9(1):27–36
Prediction of the stability of protein mutants based on structural environment–dependent amino acid substitution and propensity tables. Topham CM, et al. **Protein Eng** 1997 Jan;10(1):7–21
Extracting hydrophobicity parameters from solute partition and protein mutation/unfolding experiments. Vajda S, et al. **Protein Eng** 1995 Nov;8(11):1081–92
Hydrophobicity regained. Karplus PA. **Protein Sci** 1997 Jun; 6(6):1302–7
Structure–based subsite specificity mapping of human cathepsin D using statine–based inhibitors. Majer P, et al. **Protein Sci** 1997 Jul;6(7):1458–66
Optimization of the electrostatic interactions between ionized groups and peptide dipoles in proteins. Spassov VZ, et al. **Protein Sci** 1997 Jun;6(6):1190–6
Comparison of straight chain and cyclic unnatural amino acids embedded in the core of staphylococcal nuclease. Wynn R, et al. **Protein Sci** 1997 Aug;6(8):1621–6
Prediction of secondary structural content of proteins from their amino acid composition alone. I. New analytic vector decomposition methods. Eisenhaber F, et al. **Proteins** 1996 Jun;25(2):157–68
Prediction of secondary structural content of proteins from their amino acid composition alone. II. The paradox with secondary structural class. Eisenhaber F, et al. **Proteins** 1996 Jun;25(2):169–79
Interresidue interactions in protein classes. Gugolya Z, et al. **Proteins** 1997 Mar;27(3):360–6
Mutation matrices and physical–chemical properties: correlations and implications. Koshi JM, et al. **Proteins** 1997 Mar;27(3):336–44
Ion pair formation of phosphorylated amino acids and lysine and arginine side chains: a theoretical study. Mavri J, et al. **Proteins** 1996 Apr;24(4):495–501
Constructing amino acid residue substitution classes maximally indicative of local protein structure. Thompson MJ, et al. **Proteins** 1996 May;25(1):28–37
Predicting solvent accessibility: higher accuracy using Bayesian statistics and optimized residue substitution classes. Thompson MJ, et al. **Proteins** 1996 May;25(1):38–47
Meteoritics. Extraterrestrial handedness? [comment] Bada JL. **Science** 1997 Feb 14;275(5302):942–3. Comment on: Science 1997 Feb 14;275(5302):951–5.
Enantiomeric excesses in meteoritic amino acids [see comments] Cronin JR, et al. **Science** 1997 Feb 14; 275(5302):951–5. Comment in: Science 1997 Feb 14;275(5302):942–3.
Amino acid alchemy transmutes sheets to coils [news] Service RF. **Science** 1997 Jul 11;277(5323):179
Hydrogen bonding effects on amine rotation rates in crystalline amino acids. Gu Z, et al. **Solid State Nucl Magn Reson** 1996 Dec;7(3):161–72
Steroids 54. Amino acylamidosteroids. Vincze I, et al. **Steroids** 1996 Dec;61(12):697–702
Fibrin polymerisation. Evidence for a secondary polymerisation site on the carboxy terminal end of the AA chain using a human fibrin specific murine monoclonal antibody. Gaffney PJ, et al. **Ukr Biokhim Zh** 1996 Jul–Aug; 68(4):43–4
Oral immunization with a model protein entrapped in microspheres prepared from derivatized alpha–amino acids. Haas S, et al. **Vaccine** 1996 Jun;14(8):785–91
[Distribution of amino acid residue conformation in three–dimensional protein structures. Analysis of the non–glycine residues in "positive" conformations] Basharov MA. **Biofizika** 1997 May–Jun;42(3):753–64 (25 ref.) (Eng. Abstr.) **(Rus)**
[Enthalpy of interaction of amino acids and peptides with 6–azauracil in water] Lapshev PV, et al. **Biofizika** 1996 Nov–Dec;41(6):1157–62 (Eng. Abstr.) **(Rus)**
[Condensation of amino acids in aqueous solutions after exposure to weak electromagnetic fields] Novikov VV, et al. **Biofizika** 1996 Nov–Dec;41(6):1163–7 (Eng. Abstr.) **(Rus)**
[The chemiluminescence and fluorescence of aromatic amino acids in the presence of iodine] Kornev VM, et al. **Klin Lab Diagn** 1996 Nov–Dec;(6):30–1 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Reappraisal of indispensable amino acids. Design of parenteral synthetic dipeptides: synthesis and characterization. Fürst P, et al. **Ann Nutr Metab** 1997; 41(1):1–9 (47 ref.)
[Amino acids and nomenclature (letter; comment)] Szecsi PB. **Ugeskr Laeger** 1997 Jun 2;159(23):3619. Comment on: Ugeskr Laeger 1997 Mar 10;159(11):1593–6. **(Dan)**

DEFICIENCY

Identification and partial characterization of a novel membrane glycoprotein induced by amino acid deprivation in renal epithelial cells. Burston J, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):551–5
Induction of the stress protein Grp75 by amino acid deprivation in CHO cells does not involve an increase in Grp75 mRNA levels. Heal RD, et al. **Biochim Biophys Acta** 1997 Jun 5;1357(1):31–40
Temporal–spatial pattern of c–fos expression in the rat brain in response to indispensable amino acid deficiency. I. The initial recognition phase. Wang Y, et al. **Brain Res Mol Brain Res** 1996 Aug;40(1):27–34
Efficacy of supplemental 1 alpha–hydroxycholecalciferol and microbial phytase for young pigs fed phosphorus– or amino acid–deficient corn–soybean meal diets. Biehl RR, et al.

J Anim Sci 1996 Dec;74(12):2960–6

The cbpA chaperone gene function compensates for dnaJ in lambda plasmid replication during amino acid starvation of Escherichia coli. Węgrzyn A, et al. **J Bacteriol** 1996 Oct;178(19):5847–9

Small changes in essential amino acid concentrations alter diet selection in amino acid–deficient rats. Hrupka BJ, et al. **J Nutr** 1997 May;127(5):777–84

DRUG EFFECTS

The effect of MK–801 on extracellular neuroactive amino acids in hippocampus after closed head injury followed by hypoxia in rats. Katoh H, et al. **Brain Res** 1997 May 30;758(1–2):153–62

Changes in brain and plasma amino acids of mice intoxicated with methyl isocyanate. Gupta M, et al. **J Appl Toxicol** 1996 Nov–Dec;16(6):469–73

GENETICS

Amino acid variants in the human leptin receptor: lack of association to juvenile onset obesity. Echwald SM, et al. **Biochem Biophys Res Commun** 1997 Apr 7;233(1):248–52

Random mutagenesis of the poly(ADP–ribose) polymerase catalytic domain reveals amino acids involved in polymer branching. Rolli V, et al. **Biochemistry** 1997 Oct 7; 36(40):12147–54

Two naturally occurring amino acid substitutions of the 5–HT2A receptor: similar prevalence in patients with seasonal affective disorder and controls. Ozaki N, et al. **Biol Psychiatry** 1996 Dec 15;40(12):1267–72

The hypercube structure of the genetic code explains conservative and non–conservative aminoacid substitutions in vivo and in vitro. Jiménez–Montaño MA, et al. **Biosystems** 1996;39(2):117–25

Strategies for in vitro and in vivo translation with non–natural amino acids. Ibba M. **Biotechnol Genet Eng Rev** 1996;13:197–216 (116 ref.)

Molecular basis of the D variant phenotypes DNU and DII allows localization of critical amino acids required for expression of Rh D epitopes epD3, 4 and 9 to the sixth external domain of the Rh D protein. Avent ND, et al. **Br J Haematol** 1997 May;97(2):366–71

Development of improved tRNAs for in vitro biosynthesis of proteins containing unnatural amino acids. Cload ST, et al. **Chem Biol** 1996 Dec;3(12):1033–8

Ehlers–Danlos syndrome type IV caused by Gly400Glu, Gly595Cys and Gly1003Asp substitutions in collagen III: clinical features, biochemical screening, and molecular confirmation. Mackay K, et al. **Clin Genet** 1996 Jun; 49(6):286–95

A prevalent amino acid polymorphism at codon 98 in the hepatocyte nuclear factor–1alpha gene is associated with reduced serum C–peptide and insulin responses to an oral glucose challenge. Urhammer SA, et al. **Diabetes** 1997 May; 46(5):912–6

Analysis of amino–acid and nucleotide variants in the spinocerebellar ataxia type 1 (SCA1) gene in schizophrenic patients. Pujana MA, et al. **Hum Genet** 1997 Jun;99(6):772–5

A single residue polymorphism at DR beta 37 affects recognition of peptides by T cells. Chen YZ, et al. **Hum Immunol** 1997 Apr 15;54(1):30–9

Comparative studies of the phage T2 and T4 DNA (N6–adenine)methyltransferases: amino acid changes that affect catalytic activity. Kossykh VG, et al. **J Bacteriol** 1997 May;179(10):3239–43

Single amino acid substitutions in the glycoprotein B carboxy terminus influence the fusion from without property of herpes simplex virus type 1. Lingen M, et al. **J Gen Virol** 1995 Jul;76 (Pt 7):1843–9

Basic amino acids at the C–terminus of the third intracellular loop are required for the activation of phospholipase C by cholecystokinin–B receptors. Wang HL. **J Neurochem** 1997 Apr;68(4):1728–35

Recent advances in the biochemical and molecular biological basis of cystinuria. Gitomer WL, et al. **J Urol** 1996 Dec; 156(6):1907–12 (33 ref.)

Evolution of eutherian cytochrome c oxidase subunit II: heterogeneous rates of protein evolution and altered interaction with cytochrome c. Adkins RM, et al. **Mol Biol Evol** 1996 Dec;13(10):1393–404

Modeling residue usage in aligned protein sequences via maximum likelihood. Bruno WJ. **Mol Biol Evol** 1996 Dec; 13(10):1368–74

The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme [letter] Curnow KM, et al. **Nat Struct Biol** 1997 Jan;4(1):32–5

Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A–Raf and Raf–1. Bosch E, et al. **Oncogene** 1997 Aug 28;15(9):1021–33

Prediction of the stability of protein mutants based on structural environment–dependent amino acid substitution and propensity tables. Topham CM, et al. **Protein Eng** 1997 Jan;10(1):7–21

IMMUNOLOGY

HLA class II DR–DQ amino acids and insulin–dependent diabetes mellitus: application of the haplotype method. Valdes AM, et al. **Am J Hum Genet** 1997 Mar;60(3):717–28

Selective antibody reactivity with peptides from human endogenous retroviruses and nonviral poly(amino acids) in patients with systemic lupus erythematosus. Bengtsson A, et al. **Arthritis Rheum** 1996 Oct;39(10):1654–63

Different roles of D–amino acids in immune phenomena. Sela M, et al. **FASEB J** 1997 May;11(6):449–56 (79 ref.)

Characterization of the HLA–restrictive elements of a rubella virus–specific cytotoxic T cell clone: influence of HLA–DR4 beta chain residue 74 polymorphism on antigenic peptide–T cell interaction. Ou D, et al. **Int Immunol** 1996 Oct;8(10):1577–86

Contribution of heavy chain junctional amino acid diversity to antibody affinity among p–azophenylarsonate–specific antibodies. Parhami–Seren B, et al. **J Immunol** 1996 Sep 1;157(5):2066–72

Molecular mapping of the 8.12 SLE–associated idiotype specificity at the single amino acid level. Irigoyen M, et al. **Mol Immunol** 1996 Nov;33(16):1255–65

ISOLATION & PURIFICATION

Separation of 18 6–aminoquinolyl–carbamyl–amino acids by ion–pair chromatography. Shindo N, et al. **Anal Biochem** 1997 Jun 15;249(1):79–82

Evaluation of temperature effects on selectivity in RPLC separations using polybutadiene–coated zirconia. Li J, et al. **Anal Chem** 1997 Jun 1;69(11):2202–6

A comparative study of HPLC and TLC separation of amino acids using Cu(II) ion. Bhushan R, et al. **Biomed Chromatogr** 1996 Jan–Feb;10(1):37–9

Kinetic resolution of amino acid esters catalyzed by lipases. Houng JY, et al. **Chirality** 1996;8(6):418–22

Standardization of pyridinium crosslinks, pyridinoline and deoxypyridinoline, for use as biochemical markers of collagen degradation. Robins SP, et al. **Clin Chem** 1996 Oct;42(10):1621–6

Electrokinetic chromatography in suppressed electroosmotic flow environment: use of a charged cyclodextrin for the separation of enantiomers and geometric isomers. Janini GM, et al. **Electrophoresis** 1996 Oct;17(10):1575–83

Comparison of alkylglycoside surfactants in enantioseparation by capillary electrophoresis. Mechref Y, et al. **Electrophoresis** 1997 Jun;18(6):912–8

Chiral o–phthaldialdehyde reagents for fluorogenic on–column labeling of D– and L–amino acids in micellar electrokinetic chromatography. Tivesten A, et al. **Electrophoresis** 1997 Jun;18(6):970–7

Vancomycin as a chiral selector in capillary electrophoresis: an appraisal of advantages and limitations. Vespalec R, et al. **Electrophoresis** 1996 Jul;17(7):1214–21

Enantioseparation of amino acids and dipeptides using vancomycin as chiral selector in capillary electrophoresis. Wan H, et al. **Electrophoresis** 1996 Dec;17(12):1938–44

Optical resolution of phenylthiohydantoin–amino acids by capillary electrophoresis and identification of the phenylthiohydantoin–D–amino acid residue of [D–Ala2]–methionine enkephalin. Kurosu Y, et al. **J Chromatogr A** 1996 Nov 1;752(1–2):279–86

Computerized optimization of the high–performance liquid chromatographic enantioseparation of a mixture of 4–dinitrophenyl amino acids on a quinine carbamate–type chiral stationary phase using DRYLAB. Lämmerhofer M, et al. **J Chromatogr B Biomed Appl** 1997 Feb 7; 689(1):123–35

Rapid method for the isolation of hydroxylysylpyridinoline and lysylpyridinoline from concentrated bone hydrolysates by liquid chromatographic techniques. Lamprecht G. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):297–304

Capillary electrochromatographic separation of amino acid enantiomers using on–column prepared molecularly imprinted polymer. Lin JM, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1351–8

Trace analysis in chiral separation of selected amino enantiomers. Pronce T, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1175–84

METABOLISM

Cell adhesion mechanisms: modeling using derivatized beads and sea urchin cell systems. Roque RL, et al. **Acta Histochem** 1996 Nov;98(4):441–51

Lactic acid and amino acid fluctuations measured using microdialysis reflect physiological derangements in head injury. Goodman JC, et al. **Acta Neurochir Suppl (Wien)** 1996;67:37–9

Evaluation of the digestibility of nutrients in pigs by ileal cannulation technique. Szelényi–Galátai M, et al. **Acta Vet Hung** 1996;44(4):411–32

Effect of the pyrrolizidine alkaloid monocrotaline on taurine and sulfur amino acid metabolism in the rat liver. Yan CC, et al. **Adv Exp Med Biol** 1996;403:135–45

Epinephrine does not impair utilization of exogenous amino acids in humans. Schiefermeier M, et al. **Am J Clin Nutr** 1997 Jun;65(6):1765–73

An abundant supply of amino acids enhances the metabolic effect of exercise on muscle protein. Biolo G, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E122–9

Effects of dietary protein restriction on regional amino acid metabolism in insulin–dependent diabetes mellitus. Brodsky IG, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):E148–57

Hypertonic activation and recovery of system A amino acid transport in renal MDCK cells. Chen JG, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):F419–24

Osmotic regulation of amino acids and system A transport in Madin–Darby canine kidney cells. Horio M, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C804–9

Molecular and functional characterization of intestinal Na(+)–dependent neutral amino acid transporter B0. Kekuda R, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):G1463–72

Rat adipose tissue amino acid metabolism in vivo as assessed by microdialysis and arteriovenous techniques. Kowalski TJ, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E613–22

Effects of circulating IGF–I on glucose and amino acid kinetics in the ovine fetus. Liechty EA, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E177–85

MK–801 reduces uptake and stimulates efflux of excitatory amino acids via membrane depolarization. Longuemare MC, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1398–404

Effect of low–protein diet–induced intrauterine growth retardation on rat placental amino acid transport. Malandro MS, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C295–303

Swelling–activated efflux of taurine and other organic osmolytes in endothelial cells. Manolopoulos VG, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C214–22

Volume regulation in NIH/3T3 cells not expressing P–glycoprotein. II. Chloride and amino acid fluxes. Morán J, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):C1804–9

Na+ –independent transport of bipolar and cationic amino acids across the luminal membrane of the small intestine. Munck BG, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1060–8

Compartmentation of amino acids in the rat kidney. Silbernagl S, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):F154–63

Changes in myocardial concentration of glutamate and aspartate during coronary artery surgery. Suleiman MS, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1063–9

Protein degradation and synthesis measured with multiple amino acid tracers in vivo. Tessari P, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):E733–41

Gut proteolysis contributes essential amino acids during exercise. Williams BD, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):E85–90

Octreotide diminishes luminal nutrient transport activity, which is reversed by epidermal growth factor. Seydel AS, et al. **Am J Surg** 1996 Sep;172(3):267–71

Reappraisal of indispensable amino acids. Design of parenteral synthetic dipeptides: synthesis and characterization. Fürst P, et al. **Ann Nutr Metab** 1997; 41(1):1–9 (47 ref.)

An rRNA approach for assessing the role of obligate amino acid–fermenting bacteria in ruminal amino acid deamination. Krause DO, et al. **Appl Environ Microbiol** 1996 Mar;62(3):815–21

An aminotransferase from Lactococcus lactis initiates conversion of amino acids to cheese flavor compounds. Yvon M, et al. **Appl Environ Microbiol** 1997 Feb; 63(2):414–9

Association of HSP60–like proteins with the L–system amino acid transporter. Woodlock TJ, et al. **Arch Biochem Biophys** 1997 Feb 1;338(1):50–6

Effects of dehulling, cooking and storage conditions on protein quality and digestibility of soybeans. Cabral LC, et al. **Arch Latinoam Nutr** 1995 Mar;45(1):41–5

Retention and utilization of amino acids in piglets fed ad libitum or restrictively diets supplemented with organic acids. Walz OP, et al. **Arch Tierernahr** 1997;50(3):227–38

Glutamine and other amino acid losses during continuous venovenous hemodiafiltration. Novák I, et al. **Artif Organs** 1997 May;21(5):359–63

The role of substrates in the regulation of protein metabolism. Tessari P, et al. **Baillieres Clin Endocrinol Metab** 1996 Oct; 10(4):511–32 (125 ref.)

Cleavage of amino acid residue(s) from the N–terminal region of alpha A– and alpha B–crystallins in human crystalline lens during aging. Kamei A, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):373–8

Expression of the surface antigen 4F2hc affects system–L–like neutral–amino–acid–transport activity in mammalian cells. Bröer S, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):535–41

Haemolytic activity of stonustoxin from stonefish (Synanceja horrida) venom: pore formation and the role of cationic amino acid residues. Chen D, et al. **Biochem J** 1997 Aug 1;325 (Pt 3):685–91

An amino acid channel activated by hypotonically induced swelling of Leishmania major promastigotes. Vieira LL, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):691–7

Ontogeny of neurotransmitter amino acids in human fetal brains. Das SK, et al. **Biochem Mol Biol Int** 1997 Jun; 42(1):193–202

Amino acid metabolism in the kidneys of genetic and nutritionally obese rats. Herrero MC, et al. **Biochem Mol Biol Int** 1997 Jun;42(2):261–9

Role of PM–ATPase, amino acid transport and free amino acid pool in the salt stress of, Candida membranefaciens [corrected and republished article originally printed in Biochem Mol Biol Int 1996 Mar;38(3): 635–43] Khaware RK, et al. **Biochem Mol Biol Int** 1996 May;39(2):421–9

Effects of vanadate and insulin on the activities of selected enzymes of amino acid metabolism in alloxan diabetic rat kidney. Salimuddin, et al. **Biochem Mol Biol Int** 1996 Nov; 40(4):853–60

The use of Langendorff perfused guinea–pig heart to study the efflux of amino acids from heart cells. Carter JM, et al. **Biochem Soc Trans** 1996 Aug;24(3):482S

Modulation of transport systems for neutral and anionic amino acids in mesenchymal cells. Dall'Asta V, et al. **Biochem Soc Trans** 1996 Aug;24(3):864–9 (43 ref.)

Mammalian amino acid transporters and their regulation: introduction. McGivan JD. **Biochem Soc Trans** 1996 Aug; 24(3):837–8 (3 ref.)

Regulation of cationic amino acid transporter (CAT) gene expression. MacLeod CL. **Biochem Soc Trans** 1996 Aug; 24(3):846–52 (46 ref.)

Rat placental amino acid transport after protein–deprivation–induced intrauterine growth retardation. Malandro MS, et al. **Biochem Soc Trans** 1996 Aug;24(3):839–43

Mammary tissue protein synthesis is regulated by cell volume. Millar ID, et al. **Biochem Soc Trans** 1996 May;24(2):335S

Induction of high affinity glutamate transport activity by amino acid deprivation is dependent on cellular glutamate concentrations in renal epithelial cells does not involve an increase in the amount of transporter protein. Nicholson B, et al. **Biochem Soc Trans** 1996 Aug;24(3):481S

Role of the b(o,+)–like amino acid–transport system in the renal reabsorption of cystine and dibasic amino acids. Palacín M, et al. **Biochem Soc Trans** 1996 Aug;24(3):856–63 (53 ref.)

Amino acid transport in heart and skeletal muscle and the functional consequences. Rennie MJ, et al. **Biochem Soc Trans** 1996 Aug;24(3):869–73 (35 ref.)

Definition of amino acids sufficient for plasma membrane association of CD45 and CD45–associated protein. Cahir McFarland ED, et al. **Biochemistry** 1997 Jun 10; 36(23):7169–75

Limited proteolysis and X–ray crystallography reveal the origin of substrate specificity and of the rate–limiting product release during oxidation of D–amino acids catalyzed by mammalian D–amino acid oxidase. Vanoni MA, et al. **Biochemistry** 1997 May 13;36(19):5624–32

Synthesis and structure–activity relationships of some pesticides with an alpha–amino acid function. Chollet JF, et al. **Biochim Biophys Acta** 1997 Aug 29;1336(2):331–41

Regional distribution and postnatal changes of D–amino acids in rat brain. Hamase K, et al. **Biochim Biophys Acta** 1997 Mar 15;1334(2–3):214–22

Volume regulation and the efflux of amino acids from cells in incubated slices of rat cerebral cortex. I. Characteristics of transport mechanisms. Law RO. **Biochim Biophys Acta** 1996 Nov 8;1314(1–2):34–42

Volume regulation and the efflux of amino acids from cells in incubated slices of rat cerebral cortex. II. Dependence on Ca2+ ions. Law RO. **Biochim Biophys Acta** 1996 Nov 8;1314(1–2):43–8

Evidence for increased hydroxylation of pyrrolidone amino acid residues in the cuticle of mature Onchocerca volvulus. Sakwe AM, et al. **Biochim Biophys Acta** 1997 May 24; 1360(3):196–202

Amino acid concentrations in hypothalamic and caudate nuclei during microwave–induced thermal stress: analysis by microdialysis. Mason PA, et al. **Bioelectromagnetics** 1997;18(3):277–83

Effects of osmotic stress on metabolism, shape, and amino acid content of Leishmania. Blum JJ. **Biol Cell** 1996; 87(1–2):9–16 (63 ref.)

In vitro 1H–magnetic resonance spectroscopy of postmortem brains with schizophrenia. Omori M, et al. **Biol Psychiatry** 1997 Sep 1;42(5):359–66

Synergistic effect of alanine and glycine on bovine embryos cultured in a chemically defined medium and amino acid uptake by vitro–produced bovine morulae and blastocysts. Lee ES, et al. **Biol Reprod** 1996 Dec;55(6):1383–9

Study of free iron and pyridinoline in hypertrophic scars and normal skin. Wan KC, et al. **Br J Biomed Sci** 1996 Sep; 53(3):196–203

Microbial amino acid synthesis and utilization in rats: incorporation of 15N from 15NH4Cl into lysine in the tissues of germ–free and conventional rats. Torrallardona D, et al. **Br J Nutr** 1996 Nov;76(5):689–700

Vitamin C and copper interactions in guinea–pigs and a study of collagen cross–links. Tsuchiya H, et al. **Br J Nutr** 1997 Feb;77(2):315–25

Digestion of feed amino acids in the rumen and small intestine of dairy cows measured with nylon–bag techniques. van Straalen WM, et al. **Br J Nutr** 1997 Jan;77(1):83–97

Conversion of [15N]ammonia into urea and amino acids in humans and the effect of nutritional status. Weijs PJ, et al. **Br J Nutr** 1996 Oct;76(4):491–9

The effect of condensed tannins from heated and unheated cottonseed on the ileal digestibility of amino acids for the growing rat and pig. Yu F, et al. **Br J Nutr** 1996 Sep; 76(3):359–71

Comparison of the autoradiographic binding distribution of [3H]–gabapentin with excitatory amino acid receptor and amino acid uptake site distributions in rat brain. Thurlow RJ, et al. **Br J Pharmacol** 1996 Jun;118(3):457–65

Influence of caecectomy and dietary protein concentration on apparent excreta amino acid digestibility in adult cockerels. Angkanaporn K, et al. **Br Poult Sci** 1997 Jul; 38(3):270–6

Maximum nutritional response to poor–quality protein and amino acid utilisation. Boorman KN, et al. **Br Poult Sci** 1996 Mar;37(1):145–56

A comparative study between mature ostriches (Struthio camelus) and adult cockerels with regard to the true and apparent digestibilities of amino acids. Cilliers SC, et al. **Br Poult Sci** 1997 Jul;38(3):311–3

Ileal amino acid digestibility assay for the growing meat chicken—effect of the imposition of a fasting period and the nature of the test diet. Kadim IT, et al. **Br Poult Sci** 1997 Jul;38(3):285–90

Development of an ileal amino acid digestibility assay for the growing chicken—effects of time after feeding and site of sampling. Kadim IT, et al. **Br Poult Sci** 1997 Mar; 38(1):89–95

Regional excitatory and inhibitory amino acid concentrations in pentylenetetrazol kindling and kindled rat brain. Sejima H, et al. **Brain Dev** 1997 Apr;19(3):171–5

Effect of intrahippocampal dexamethasone on the levels of amino acid transmitters and neuronal excitability. Abrahám I, et al. **Brain Res** 1996 Sep 9;733(1):56–63

Differences in striatal extracellular amino acid concentrations between Wistar and Fischer 344 rats after middle cerebral artery occlusion. Herz RC, et al. **Brain Res** 1996 Apr 9; 715(1–2):163–71

The disruption of spatial cognition and changes in brain amino acid, monoamine and acetylcholine in rats with transient cerebral ischemia. Iwasaki K, et al. **Brain Res** 1996 Feb 19;709(2):163–72

Effects of mild hypothermia on cerebral blood flow–independent changes in cortical extracellular levels of amino acids following contusion trauma in the rat. Koizumi H, et al. **Brain Res** 1997 Feb 7;747(2):304–12

Inhibition by anion channel blockers of ischemia–evoked release of excitotoxic and other amino acids from rat cerebral cortex. Phillis JW, et al. **Brain Res** 1997 May 30; 758(1–2):9–16

Co–variation of free amino acids in brain interstitial fluid during pentylenetetrazole–induced convulsive status epilepticus. Sechi G, et al. **Brain Res** 1997 Aug 1; 764(1–2):230–6

Decreased basal and acute insulin–stimulated effect on the uptake of glucose and amino acid in vitro by thyroid glands from streptozotocin–diabetic rats. Machado VL, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1549–55

Use of Tn5–gusA5 to investigate environmental and nutritional effects on gene expression in the coronatine biosynthetic gene cluster of Pseudomonas syringae pv. glycinea. Palmer DA, et al. **Can J Microbiol** 1997 Jun; 43(6):517–25

Characterization of amino acid and glutathione adducts of cis–2–butene–1,4–dial, a reactive metabolite of furan. Chen LJ, et al. **Chem Res Toxicol** 1997 Aug;10(8):866–74

Effect of a protein–rich meal on urinary and salivary free amino acid concentrations in human subjects. Brand HS, et al. **Clin Chim Acta** 1997 Aug 8;264(1):37–47

Children on continuous ambulatorial peritoneal dialysis: muscle and plasma proteins, amino acids and nutritional status. Canepa A, et al. **Clin Nephrol** 1996 Aug;46(2):125–31

Effect of amino acid based dialysate on peritoneal blood flow and permeability in stable CAPD patients: a potential role for nitric oxide? Douma CE, et al. **Clin Nephrol** 1996 May; 45(5):295–302

Microdialysis of human breast tissue during the menstrual cycle. Dabrosin C, et al. **Clin Sci (Colch)** 1997 May; 92(5):493–6

Impact of ethanol stress on components of the allantoic fluid of the chicken embryo. ten Busch M, et al. **Comp Biochem Physiol A Physiol** 1997 Feb;116(2):125–9

Regulation of substances in allantoic and amniotic fluid of the chicken embryo. ten Busch M, et al. **Comp Biochem Physiol A Physiol** 1997 Feb;116(2):131–6

Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity. Mousa SA, et al. **Coron Artery Dis** 1996 Oct; 7(10):767–74

Family of neutral and acidic amino acid transporters: molecular biology, physiology and medical implications. Kanai Y. **Curr Opin Cell Biol** 1997 Aug;9(4):565–72 (62 ref.)

Elevation of amino acids in the interstitial space of the rat brain following infusion of large neutral amino and keto acids by microdialysis: leucine infusion. Huang Y, et al. **Dev Neurosci** 1996;18(5–6):415–9

Elevation of amino acids in the interstitial space of the rat brain following infusion of large neutral amino and keto acids by microdialysis: alpha–ketoisocaproate infusion. Zielke HR, et al. **Dev Neurosci** 1996;18(5–6):420–5

Glucose and amino acid turnover in untreated gestational diabetes. Zimmer DM, et al. **Diabetes Care** 1996 Jun; 19(6):591–6

Amino acids and their derivatives in tumour tissue from patients with breast cancer treated with Ukrain. Part VI. Nefyodov LI, et al. **Drugs Exp Clin Res** 1996; 22(3–5):159–61

Comparison of seizure related amino acid release in human epileptic hippocampus versus a chronic, kainate rat model of hippocampal epilepsy. Wilson CL, et al. **Epilepsy Res** 1996 Dec;26(1):245–54

Efflux of compatible solutes in Corynebacterium glutamicum mediated by osmoregulated channel activity. Ruffert S, et al. **Eur J Biochem** 1997 Jul 15;247(2):572–80

Tumour growth and fetal uptake of amino acids in the pregnant rat. Carbó N, et al. **Eur J Cancer** 1996 Jul; 32A(8):1413–9

Pyridinium cross–links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy—a pilot study of the German Myeloma Treatment Group (GMTG). Peest D, et al. **Eur J Cancer** 1996 Nov;32A(12):2053–7

Moderate hyperthyroidism reduces liver amino nitrogen conversion, muscle nitrogen contents and overall nitrogen balance in rats. Grofte T, et al. **Eur J Clin Invest** 1997 Jan;27(1):85–92

Role of glycation in human lens protein structure change. Ramalho JS, et al. **Eur J Ophthalmol** 1996 Apr–Jun; 6(2):155–61

Stable isotopes in biosciences, their measurement and models for amino acid metabolism. Bier DM. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S2–8 (31 ref.)

Integration of amino acid and carbon intermediary metabolism: studies with uniformly labeled tracers and mass isotopomer analysis. Reeds PJ, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S50–8

Effects of uptake carrier blockers SK & F 89976–A and L–trans–PDC on in vivo release of amino acids in rat hippocampus. Zuiderwijk M, et al. **Eur J Pharmacol** 1996 Jul 4;307(3):275–82

Effect of 21–aminosteroid on extracellular energy–related metabolites and amino acids after compression injury of rat spinal cord. Farooque M, et al. **Exp Brain Res** 1997 Jan;113(1):1–4

The release of amino acids from ischemic retina [letter] Muller A, et al. **Exp Eye Res** 1997 Feb;64(2):291–3

Changes in the intracellular free amino acid pool in human saphenous vein tissue culture. Suleiman MS, et al. **Exp Physiol** 1996 May;81(3):435–46

Partial purification and characterization of a jasmonic acid conjugate cleaving amidohydrolase from the fungus Botryodiplodia theobromae. Hertel SC, et al. **FEBS Lett** 1997 Apr 21;407(1):105–10

Aromatic amino acid methyl ester analogs form quinonoidal species with Dopa decarboxylase. Moore PS, et al. **FEBS Lett** 1997 Jul 21;412(1):245–8

Import of branched–chain amino acids in Saccharomyces cerevisiae. Didion T, et al. **Folia Microbiol (Praha)** 1996; 41(1):87

Effect of amino acid peroxides on the erythrocyte. Soszynski M, et al. **Free Radic Biol Med** 1996;20(1):45–51

Horseradish peroxidase–catalyzed conjugation of eugenol with basic amino acids. Medeiros MH, et al. **Free Radic Res** 1996 Jul;25(1):5–12

Allelic basis for HLA–encoded susceptibility to type 1 autoimmune hepatitis. Strettell MD, et al. **Gastroenterology** 1997 Jun;112(6):2028–35

Ascorbic acid and amino acid values in the aqueous humor of a patient with Lowe's syndrome. Hayasaka S, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Apr;235(4):217–21

The incorporation and turnover of radiolabelled amino acids in developing stereocilia of the chick cochlea. Pickles JO, et al. **Hear Res** 1996 Nov 1;101(1–2):45–54

Protection of B lymphocyte hybridoma against starvation–induced apoptosis: survival–signal role of some amino acids. Franěk F, et al. **Immunol Lett** 1996 Sep; 52(2–3):139–44

The effect of amino acid composition of serum–free medium on DNA synthesis in primary hepatocyte cultures in the presence of epidermal growth factor. Li Y, et al. **In Vitro Cell Dev Biol Anim** 1995 Dec;31(11):867–70

Lack of functional correlation between gamma–glutamyl transpeptidase and amino acid transport in the lactating mouse mammary gland. Kansal R, et al. **Indian J Exp Biol** 1996 Mar;34(3):267–9

Chirality differences in amino acid retention and release from acid–extractable pool of cultured mammalian cells. Wheatley DN, et al. **Int J Biochem Cell Biol** 1996 Dec; 28(12):1349–64

Investigations into mechanisms of amino acid supply to the rat embryo using whole–embryo culture. Beckman DA, et al. **Int J Dev Biol** 1997 Apr;41(2):315–8 (23 ref.)

Dietary goitrogen–induced changes in the transport of 2–deoxy–D–glucose and amino acids across the rat blood–brain barrier. Bala TS, et al. **Int J Dev Neurosci** 1996 Aug;14(5):575–83

Growth of yeasts in milk and associated changes to milk composition. Roostita R, et al. **Int J Food Microbiol** 1996 Aug;31(1–3):205–19

Amino acid losses and nitrogen balance during slow diurnal hemodialysis in critically ill patients with renal failure. Kihara M, et al. **Intensive Care Med** 1997 Jan;23(1):110–3

The effect of abomasal infusion of casein and recombinant somatotropin hormone injection on nitrogen balance and amino acid fluxes in portal–drained viscera and net hepatic and total splanchnic blood in Holstein steers. Bruckental I, et al. **J Anim Sci** 1997 Apr;75(4):1119–29

Effect of dietary neutral detergent fiber on ileal digestibility and portal flux of nitrogen and amino acids and on nitrogen utilization in growing pigs. Lenis NP, et al. **J Anim Sci** 1996 Nov;74(11):2687–99

Effect of beta–glucanase supplementation to hulless barley– or wheat–soybean meal diets on the digestibilities of energy, protein, beta–glucans, and amino acids in young pigs. Li S, et al. **J Anim Sci** 1996 Jul;74(7):1649–56

Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. Smith EA, et al. **J Appl Bacteriol** 1996 Sep;81(3):288–302

Mutations that render the promoter of the histidine operon of Salmonella typhimurium insensitive to nutrient–rich

medium repression and amino acid downshift. Da Costa XJ, et al. **J Bacteriol** 1997 Aug;179(16):5211–7

Amino acid transport in taxonomically diverse cyanobacteria and identification of two genes encoding elements of a neutral amino acid permease putatively involved in recapture of leaked hydrophobic amino acids. Montesinos ML, et al. **J Bacteriol** 1997 Feb;179(3):853–62

Enhanced excretion of intermediates of aromatic amino acid catabolism during chlorophenol degradation due to nutrient limitation in the yeast Candida maltosa. Hammer E, et al. **J Basic Microbiol** 1996;36(4):239–43

Role of basic amino acids in the cleavage of synthetic peptide substrates by mitochondrial processing peptidase. Song MC, et al. **J Biochem (Tokyo)** 1996 Dec;120(6):1163–6

An intracellular trafficking defect in type I cystinuria rBAT mutants M467T and M467K. Chillarón J, et al. **J Biol Chem** 1997 Apr 4;272(14):9543–9

Involvement of protein kinase Cepsilon in the stimulation of anionic amino acid transport in cultured human fibroblasts. Franchi-Gazzola R, et al. **J Biol Chem** 1996 Oct 18;271(42):26124–30

Monoclonal antibodies against Nalpha-(5'-phosphopyridoxyl)-L-lysine. Screening and spectrum of pyridoxal 5'-phosphate-dependent activities toward amino acids. Gramatikova SI, et al. **J Biol Chem** 1997 Apr 11;272(15):9779–84

Cloning and characterization of a brain-specific cationic amino acid transporter. Hosokawa H, et al. **J Biol Chem** 1997 Mar 28;272(13):8717–22

Adaptive regulation of the cationic amino acid transporter-1 (Cat-1) in Fao cells. Hyatt SL, et al. **J Biol Chem** 1997 Aug 8;272(32):19951–7

Three amino acid substitutions selectively disrupt the activation but not the repression function of the glucocorticoid receptor N terminus. Iñiguez-Lluhí JA, et al. **J Biol Chem** 1997 Feb 14;272(7):4149–56

Amino acid residues responsible for galactose recognition in yeast Gal2 transporter. Kasahara M, et al. **J Biol Chem** 1997 Jul 4;272(27):16721–4

Regulation of type I collagen mRNA by amino acid deprivation in human lung fibroblasts. Krupsky M, et al. **J Biol Chem** 1997 May 23;272(21):13864–8

A novel bifunctional fusion enzyme catalyzing ethylene synthesis via 1-aminocyclopropane1-carboxylic acid. Li N, et al. **J Biol Chem** 1996 Oct 18;271(42):25738–41

Dynamic compartmentation of vacuolar amino acids in Penicillium cyclopium. Cytosolic adenylates act as a control signal for efflux into the cytosol. Roos W, et al. **J Biol Chem** 1997 Jun 20;272(25):15849–55

An engineered Tetrahymena tRNAGln for in vivo incorporation of unnatural amino acids into proteins by nonsense suppression. Saks ME, et al. **J Biol Chem** 1996 Sep 20;271(38):23169–75

The potential roles of the conserved amino acids in human liver mitochondrial aldehyde dehydrogenase. Sheikh S, et al. **J Biol Chem** 1997 Jul 25;272(30):18817–22

Amino acid and adenine cross-pathway regulation act through the same 5'-TGACTC-3' motif in the yeast HIS7 promoter. Springer C, et al. **J Biol Chem** 1996 Nov 22; 271(47):29637–43

The active sites of fructose 6-phosphate,2-kinase: fructose-2, 6-bisphosphatase from rat testis. Roles of Asp-128, Thr-52, Thr-130, Asn-73, and Tyr-197. Uyeda K, et al. **J Biol Chem** 1997 Mar 21;272(12):7867–72

Processing of the rne transcript by an RNase E-independent amino acid-dependent mechanism. Woo WM, et al. **J Biol Chem** 1997 Jun 13;272(24):15516–20

Effect of the amino acid attached to Escherichia coli initiator tRNA on its affinity for the initiation factor IF2 and on the IF2 dependence of its binding to the ribosome. Wu XQ, et al. **J Biol Chem** 1997 Jan 17;272(3):1891–5

Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. Anderson MM, et al. **J Clin Invest** 1997 Feb 1;99(3):424–32

Localisation of amino acid neurotransmitters during postnatal development of the rat retina. Fletcher EL, et al. **J Comp Neurol** 1997 Apr 21;380(4):449–71

15N enrichments of casein and plasma protein amino acids in cows ingesting 15N-labelled ammonium sulphate. Casseron F, et al. **J Dairy Res** 1997 Aug;64(3):367–76

Effect of type of protein supplementation on duodenal amino acid flow and absorption in lactating dairy cows. Mabjeesh SJ, et al. **J Dairy Sci** 1996 Oct;79(10):1792–1801

Lasalocid effects on ruminal degradation of protein and postruminal supply of amino acids in Holstein steers. Wessels RH, et al. **J Dairy Sci** 1996 Oct;79(10):1802–08

Osmotic homeostasis in Dictyostelium discoideum: excretion of amino acids and ingested solutes. Steck TL, et al. **J Eukaryot Microbiol** 1997 Sep–Oct;44(5):503–10

Molecular characteristics of mammalian and insect amino acid transporters: implications for amino acid homeostasis. Castagna M, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):269–86 (200 ref.)

Hepatic amino acid and protein metabolism in non-anorectic, moderately cachectic tumor-bearing rats. de Blaauw I, et al. **J Hepatol** 1997 Feb;26(2):396–408

Pyridinoline collagen cross-links in patients with chronic viral hepatitis and cirrhosis. Hayasaka A, et al. **J Hepatol** 1996 Jun;24(6):692–8

Biotinylation of proteins via amino groups can induce binding to U937 cells, HL-60 cells, monocytes and granulocytes. Storm D, et al. **J Immunol Methods** 1996 Nov 29; 199(1):87–99

Identification of single amino acid residues of human IL-6 involved in receptor binding and signal initiation. Ehlers M, et al. **J Interferon Cytokine Res** 1996 Aug;16(8):569–76

Amino acid utilisation and deamination of glutamine and asparagine by Helicobacter pylori. Stark RM, et al. **J Med Microbiol** 1997 Sep;46(9):793–800

Volume-regulatory amino acid release from the protozoan parasite Crithidia luciliae. Bursell JD, et al. **J Membr Biol** 1996 Nov;154(2):131–41

Linkage between postabsorptive amino acid release and glutamate uptake in skeletal muscle tissue of healthy young subjects, cancer patients, and the elderly. Holm E, et al. **J Mol Med** 1997 Jun;75(6):454–61

Change in the concentrations of amino acids in CSF and serum of patients with essential tremor. Málly J, et al. **J Neural Transm Gen Sect** 1996;103(5):555–60

Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative Cerebrolysin. Hutter-Paier B, et al. **J Neural Transm Suppl** 1996;47:267–73

Glutathione content as an indicator for the presence of metabolic pathways of amino acids in astroglial cultures. Dringen R, et al. **J Neurochem** 1996 Oct;67(4):1375–82

Effects of methylprednisolone on extracellular lactic acidosis and amino acids after severe compression injury of rat spinal cord. Farooque M, et al. **J Neurochem** 1996 Mar; 66(3):1125–30

Glutamate uptake impairment and neuronal damage in young and aged rats in vivo. Massieu L, et al. **J Neurochem** 1997 Sep;69(3):1151–60

Metabolic precursors and compartmentation of cerebral GABA in vigabatrin-treated rats. Preece NE, et al. **J Neurochem** 1996 Oct;67(4):1718–25

Portacaval anastomosis results in altered neuron--astrocytic metabolic trafficking of amino acids: evidence from 13C-NMR studies. Sonnewald U, et al. **J Neurochem** 1996 Oct;67(4):1711–7

In vivo evidence for the link between L- and D-serine metabolism in rat cerebral cortex. Takahashi K, et al. **J Neurochem** 1997 Sep;69(3):1286–90

Effects of ketone bodies on astrocyte amino acid metabolism. Yudkoff M, et al. **J Neurochem** 1997 Aug;69(2):682–92

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Moghaddam B, et al. **J Neurosci** 1997 Apr 15;17(8):2921–7

Effects of moderate hypothermia on extracellular lactic acid and amino acids after severe compression injury of rat spinal cord. Farooque M, et al. **J Neurotrauma** 1997 Jan; 14(1):63–9

Changes of extracellular levels of amino acids after graded compression trauma to the spinal cord: an experimental study in the rat using microdialysis. Farooque M, et al. **J Neurotrauma** 1996 Sep;13(9):537–48

The use of 15N-labeled dietary proteins for determining true ileal amino acid digestibilities is limited by their rapid recycling in the endogenous secretions of pigs. Leterme P, et al. **J Nutr** 1996 Sep;126(9):2188–98

The protein digestibility-corrected amino acid score method overestimates quality of proteins containing antinutritional factors and of poorly digestible proteins supplemented with limiting amino acids in rats. Sarwar G. **J Nutr** 1997 May; 127(5):758–64

Effect of epidermal growth factor on placental amino acid transport and regulation of epidermal growth factor receptor expression of hepatocyte in rat. Masuyama H, et al. **J Perinat Med** 1996;24(3):213–20

Effects of amitriptyline on rat plasma and brain content of monoamine precursors and other large neutral amino acids. Eriksson T, et al. **J Pharm Pharmacol** 1995 Dec; 47(12A):1007–14

Influence of pH on skin permeation of amino acids. Hatanaka T, et al. **J Pharm Pharmacol** 1996 Jul;48(7):675–9

Epidermal aminopeptidase activity and metabolism as observed in an organized HaCaT cell sheet model. Steinsträsser I, et al. **J Pharm Sci** 1997 Mar;86(3):378–83

Human growth hormone induces system B transport in short bowel syndrome. Iannoli P, et al. **J Surg Res** 1997 Apr; 69(1):150–8

Model of milk protein synthesis. A mechanistic model of milk protein synthesis in the lactating bovine mammary gland. Maas JA, et al. **J Theor Biol** 1997 Aug 7;187(3):363–78

Effect of ferrous ion on amino acid metabolism in mildiomycin production by Streptoverticillium rimofaciens. Kishimoto K, et al. **Jpn J Antibiot** 1997 Mar;50(3):206–11

Effects of recombinant human growth hormone on plasma and dialysate amino acid profiles in CAPD patients. Ikizler TA, et al. **Kidney Int** 1996 Jul;50(1):229–34

Dual action of colchicine on hypertonic activation of system A amino acid transport in vascular smooth muscle cells. Chen JG, et al. **Life Sci** 1997;61(1):29–37

Hepatic protein synthesis and serum aminoacid levels during liver regeneration in young and old malnourished rats. Carrillo MC, et al. **Mech Ageing Dev** 1996 Oct 4;91(1):55–64

Effect of endurance training on ammonia and amino acid metabolism in humans. Graham TE, et al. **Med Sci Sports Exerc** 1997 May;29(5):646–53 (57 ref.)

Neuroactive amino acids in hepatic encephalopathy. Butterworth RF. **Metab Brain Dis** 1996 Jun;11(2):165–73

Effects of simulated upper gastrointestinal hemorrhage on ammonia and related amino acids in blood and brain of chronic portacaval-shunted rats. Olde Damink SW, et al. **Metab Brain Dis** 1997 Jun;12(2):121–35

Growth hormone modulates amino acid oxidation in the surgical patient: leucine kinetics during the fasted and fed state using moderate nitrogenous and caloric diet and recombinant human growth hormone. Carli F, et al. **Metabolism** 1997 Jan;46(1):23–8

Amino acid handling in uremic rats: citrulline, a reliable marker of renal insufficiency and proximal tubular dysfunction. Levillain O, et al. **Metabolism** 1997 Jun; 46(6):611–8

Affinity selection-amplification from randomized ribooligonucleotide pools. Ciesiolka J, et al. **Methods Enzymol** 1996;267:315–35

Amounts of free amino acids during early sporulation in Saccharomyces cerevisiae. Ota A. **Microbios** 1996; 86(347):117–20

Generation of hemoglobin peptides in the acidic digestive vacuole of Plasmodium falciparum implicates peptide transport in amino acid production. Kolakovich KA, et al. **Mol Biochem Parasitol** 1997 Aug;87(2):123–35

Amino acid uptake and intracellular accumulation in Leishmania major promastigotes are largely determined by an H(+)-pump generated membrane potential. Vieira LL, et al. **Mol Biochem Parasitol** 1995 Dec;75(1):15–23

Effects of valproate on amino acid and monoamine concentrations in striatum of audiogenic seizure-prone Balb/c mice. Vriend JP, et al. **Mol Chem Neuropathol** 1996 Apr;27(3):307–24

Expression of the Bacillus subtilis gabP gene is regulated independently in response to nitrogen and amino acid availability. Ferson AE, et al. **Mol Microbiol** 1996 Nov; 22(4):693–701

Dose-response relations for unnatural amino acids at the agonist binding site of the nicotinic acetylcholine receptor: tests with novel side chains and with several agonists. Kearney PC, et al. **Mol Pharmacol** 1996 Nov;50(5):1401–12

A putative amino acid transporter is specifically expressed in haustoria of the rust fungus Uromyces fabae. Hahn M, et al. **Mol Plant Microbe Interact** 1997 May;10(4):438–45

A microdialysis study of glycinamide, glycine and other amino acid neurotransmitters in rat frontal cortex and hippocampus after the administration of milacemide, a glycine pro-drug. Doheny MH, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jul; 354(2):157–63

alpha-Ketoglutarate application in hemodialysis patients improves amino acid metabolism. Riedel E, et al. **Nephron** 1996;74(2):261–5

In vivo amino acid release from the striatum of aging rats: adenosine modulation. Corsi C, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):243–50

Amino acid distribution in immature rat brain. Banay-Schwartz M, et al. **Neurobiology (Bp)** 1996; 4(4):393–403

Specificity of cysteine sulfinate decarboxylase (CSD) for sulfur-containing amino-acids. Do KQ, et al. **Neurochem Int** 1996 Apr;28(4):363–71

Inhibition of sodium-dependent uptake processes in purified rat brain synaptosomes by Lophozozymus pictor toxin and palytoxin. Lau CO, et al. **Neurochem Int** 1996 Apr; 28(4):385–90

Gamma-glutamyl peptides and related amino acids in rat hippocampus in vitro: effect of depolarization and gamma-glutamyl transpeptidase inhibition. Li X, et al. **Neurochem Int** 1996 Aug;29(2):121–8

Changes in extracellular amino acid neurotransmitters and purines during and following ischemias of different durations in the rat cerebral cortex. Phillis JW, et al. **Neurochem Int** 1996 Aug;29(2):115–20

Regional and developmental variations in metabolite concentration in the rat brain and eye: a study using 1H NMR spectroscopy and high performance liquid chromatography. Florian CL, et al. **Neurochem Res** 1996 Sep;21(9):1065–74

Amino acid neurotransmission: dynamics of vesicular uptake. Fykse EM, et al. **Neurochem Res** 1996 Sep;21(9):1053–60 (68 ref.)

Effect of nicotine on the level of extracellular amino acids in the hippocampus of rat. Toth E. **Neurochem Res** 1996 Aug;21(8):903–7

Free radical scavenging activity of the Japanese herbal medicine toki-shakuyaku-san (TJ-23) and its effect on superoxide dismutase activity, lipid peroxides, glutamate, and monoamine metabolites in aged rat brain. Ueda Y, et al. **Neurochem Res** 1996 Aug;21(8):909–14

Evidence to suggest that gonadotropin-releasing hormone inhibits its own secretion by affecting hypothalamic amino acid neurotransmitter release. Feleder C, et al. **Neuroendocrinology** 1996 Oct;64(4):298–304

Acetaldehyde-induced changes in monoamine and amino acid extracellular microdialysate content of the nucleus accumbens. Ward RJ, et al. **Neuropharmacology** 1997 Feb; 36(2):225–32

Examining serotonin function: a modified technique for rapid tryptophan depletion. Krahn LE, et al. **Neuropsychopharmacology** 1996 Oct;15(4):325–8

Interleukin-6 affects scopolamine-induced amnesia, but not brain amino acid levels in mice. Bianchi M, et al. **Neuroreport** 1997 May 6;8(7):1775-8

Slow wave sleep is accompanied by release of certain amino acids in the thalamus of cats. Kékesi KA, et al. **Neuroreport** 1997 Mar 24;8(5):1183-6

Nitric oxide enhances amino acid release from immature chick embryo retina. Ientile R, et al. **Neurosci Lett** 1996 Nov 22;219(2):79-82

Different preferences in the utilization of amino acids for glutathione synthesis in cultured neurons and astroglial cells derived from rat brain. Kranich O, et al. **Neurosci Lett** 1996 Nov 29;219(3):211-4

The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Derlon JM, et al. **Neurosurgery** 1997 Feb;40(2):276-87; discussion 287-8

Synthesis and evaluation of radioiodinated 6-iodo-L-DOPA as a cerebral L-amino acid transport marker. Kawai K, et al. **Nucl Med Biol** 1996 Apr;23(3):251-5

Feasibility of labeled alpha-acetamido-aminoisobutyric acid as new tracer compound for kinetic labeling of neutral amino acid transport: preparation of alpha-(N-[1-11C]acetyl)- and alpha-(N-[1-14C]acetyl)-aminoisobutyric acid. Prenant C, et al. **Nucl Med Biol** 1996 Apr;23(3):359-63

RNA base-amino acid interaction strengths derived from structures and sequences. Lustig B, et al. **Nucleic Acids Res** 1997 Jul 1;25(13):2562-5

Effect of nitrous oxide and propofol on amino acid metabolism in neoplasic patients. Crespo ML, et al. **Nutr Cancer** 1997;27(1):80-3

Influence of ingesting a solution of branched-chain amino acids on plasma and muscle concentrations of amino acids during prolonged submaximal exercise [see comments] Blomstrand E, et al. **Nutrition** 1996 Jul-Aug;12(7-8):485-90 . Comment in: Nutrition 1996 Jul-Sep;12(7-8):553-4.

Metabolic analysis of the rabbit cornea by proton nuclear magnetic resonance spectroscopy. Midelfart A, et al. **Ophthalmic Res** 1996;28(5):319-29

Characterization of time course of spinal amino acids, citrulline and PGE2 release after carrageenan/kaolin-induced knee joint inflammation: a chronic microdialysis study. Yang LC, et al. **Pain** 1996 Oct; 67(2-3):345-54

Diagnostic value of the amino acid consumption test in pancreatic diseases. Gullo L, et al. **Pancreas** 1996 Jan; 12(1):64-7

Effect of fetal growth restriction on system A amino acid transporter activity in the maternal facing plasma membrane of rat syncytiotrophoblast. Glazier JD, et al. **Pediatr Res** 1996 Aug;40(2):325-9

Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity. Kågedahl M, et al. **Pharm Res** 1997 Feb; 14(2):176-80

Neurotoxicology and amino acid intake during development: the case of threonine. Castagne V, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):653-62 (138 ref.)

Effect of repeated stress on a number of plasma amino acids and related compounds in young and old rats. Milakofsky L, et al. **Physiol Behav** 1996 Sep;60(3):969-71

Superfused microcarrier cultures of choriocarcinoma cells: a dynamic model for studying transport of glucose and amino acids. Eaton BM, et al. **Placenta** 1996 May; 17(4):209-15

Changes in targeting efficiencies of proteins to plant microbodies caused by amino acid substitutions in the carboxy-terminal tripeptide. Hayashi M, et al. **Plant Cell Physiol** 1997 Jun;38(6):759-68

Comparison of two methods for determining in vitro intestinal absorption of nutrients using rats fed different diets. Singh J, et al. **Plant Foods Hum Nutr** 1996 Apr; 49(3):235-40

Additivity of apparent and true ileal amino acid digestibilities in soybean meal, sunflower meal, and meat and bone meal for broilers. Angkanaporn K, et al. **Poult Sci** 1996 Sep; 75(9):1098-103

Microbial phytase improves amino acid utilization in young chicks fed diets based on soybean meal but not diets based on peanut meal. Biehl RR, et al. **Poult Sci** 1997 Feb; 76(2):355-60

Effect of microbial phytase on nitrogen and amino acid digestibility and nitrogen retention of turkey poults fed corn-soybean meal diets. Yi Z, et al. **Poult Sci** 1996 Aug; 75(8):979-90

Amino acid supply and metabolism by the ruminant mammary gland. Bequette BJ, et al. **Proc Nutr Soc** 1997 Jul;56(2):593-605 (45 ref.)

Modelling post-absorptive protein and amino acid metabolism in the ruminant. Hanigan MD, et al. **Proc Nutr Soc** 1997 Jul;56(2):631-43 (49 ref.)

Mammary-tissue amino acid transport systems. Shennan DB, et al. **Proc Nutr Soc** 1997 Mar;56(1A):177-91 (64 ref.)

Thermoanaerobacter brockii alcohol dehydrogenase: characterization of the active site metal and its ligand amino acids. Bogin O, et al. **Protein Sci** 1997 Feb;6(2):450-8

Role of aromatic amino acids in carbohydrate binding of plant lectins: laser photo chemically induced dynamic nuclear polarization study of hevein domain-containing lectins. Siebert HC, et al. **Proteins** 1997 Jun;28(2):268-84

Consumption of amino acids by bovine preimplantation embryos. Partridge RJ, et al. **Reprod Fertil Dev** 1996; 8(6):945-50

Mechanisms of amino acid supply to the rat conceptus in normal and abnormal development. Beckman DA. **Reprod Toxicol** 1997 Jul-Aug;11(4):595-9

Changes in the release of amino acid neurotransmitters in the brains of calves and sheep after head-only electrical stunning and throat cutting. Cook CJ, et al. **Res Vet Sci** 1996 May;60(3):255-61

Hepatic amino acid transport. Moseley RH. **Semin Liver Dis** 1996 May;16(2):137-45 (121 ref.)

Functional characteristics of the hypermetabolic isolated perfused liver. Dahn MS, et al. **Shock** 1996 Jul;6(1):52-6

Influence of glutamine-supplemented parenteral nutrition on intestinal amino acid metabolism in rats after small bowel resection. Chen K, et al. **Surg Today** 1996;26(8):618-23

[Charge selectivity of peritoneal transport in CAPD patients under stable states and during peritonitis] Nakao T, et al. **Nippon Jinzo Gakkai Shi** 1996 Nov;38(11):502-6 (Eng. Abstr.) **(Jpn)**

[Na+ -dependent amino acid transporters: their structure and function] Kanai Y. **Nippon Rinsho** 1996 Mar; 54(3):368-45 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Biochemical basis of enteral nutrition] Freitas O, et al. **Arch Latinoam Nutr** 1995 Jun;45(2):84-9 (67 ref.) (Eng. Abstr.) **(Por)**

[Characteristics of amino acid metabolism in patients with severe sepsis and septic shock] Leiderman IN, et al. **Anesteziol Reanimatol** 1997 Jan-Feb;(1):45-8 (Eng. Abstr.) **(Rus)**

[Pool of free amino acids in mycelium and culture fluid of Streptomyces galbus (F) subsp. achromogenes 695, a strain producing actinomycin complex and its variants] Iocheva LD, et al. **Antibiot Khimioter** 1996 Mar;41(3):9-14 (Eng. Abstr.) **(Rus)**

[Effect of mexidol on the level of monoamine mediators and amino acids in rat brain structures] Miroshnichenko II, et al. **Biull Eksp Biol Med** 1996 Feb;121(2):170-3 **(Rus)**

[The interaction of organophosphorus amino acid analogs with cytochrome P-450 2B4] Shumiantseva VV, et al. **Izv Akad Nauk Ser Biol** 1996 Nov-Dec;(6):749-53 (Eng. Abstr.) **(Rus)**

[Taurine induces an imbalance in the pool of neuroactive amino acids and biogenic amines in regions of the brain] Nefedov LI, et al. **Ukr Biokhim Zh** 1996 Jan-Feb; 68(1):21-6 (Eng. Abstr.) **(Rus)**

[Amino acid pattern variation in animals after the administration of hypocaloric peripheral parenteral nutrition] de la Hoz Riesco ML, et al. **Nutr Hosp** 1996 May-Jun;11(3):178-84 (Eng. Abstr.) **(Spa)**

[Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients] Navarro-Quesada FJ, et al. **Rev Neurol** 1997 Jul; 25(143):1037-44 (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Maintaining muscle protein anabolism after a metabolic stress: role of dextrose vs. amino acid availability. Borel MJ, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E36-44

Glucose and amino acid absorption in house sparrow intestine and its dietary modulation. Caviedes-Vidal E, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R561-8

Effects of cold preservation and rewarming on rat liver cell volume regulation and concentrative amino acid uptake. Serrar H, et al. **Gastroenterology** 1997 Apr;112(4):1344-53

Plasma amino acid uptake by the mammary gland of the lactating sow. Trottier NL, et al. **J Anim Sci** 1997 May; 75(5):1266-78

Developmental study of ultrastructural and biochemical changes in isolated chick brain microvessels. Nico B, et al. **Microvasc Res** 1997 Jan;53(1):79-91

PHARMACOLOGY

PO2-dependent glomerular ultrafiltration of middle-weight protein is modified by protective amino acids. Gronow G, et al. **Adv Exp Med Biol** 1997;411:267-74

Delayed tumor onset in transgenic mice fed an amino acid-based diet supplemented with red wine solids. Clifford AJ, et al. **Am J Clin Nutr** 1996 Nov;64(5):748-56

Osmotic agents and buffers in peritoneal dialysis solution: monocyte cytokine release and in vitro cytotoxicity. Plum J, et al. **Am J Kidney Dis** 1997 Sep;30(3):413-22

Role of renal nerves and endogenous dopamine in amino acid-induced glomerular hyperfiltration. Mühlbauer B, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):F144-9

Effect of amino acid and glucose administration during postexercise recovery on protein kinetics in dogs. Okamura K, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):E1023-30

Amino acids suppress proteolysis independent of insulin throughout the neonatal period. Poindexter BB, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E592-9

Acute administration of a tryptophan-free amino acid mixture decreases 5-HT release in rat hippocampus in vivo. Stancampiano R, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R991-4

Effect of cysteine, N-acetyl-L-cysteine and glutathione on cytotoxic activity of antioxidants. Satoh K, et al. **Anticancer Res** 1997 May-Jun;17(3C):2175-9

Dose-dependent behavioural effects of two protein-free peptide derivatives on the passive avoidance reaction of rats. Hutter-Paier B, et al. **Arzneimittelforschung** 1996 Mar; 46(3):242-6

Effects of two protein-free peptide derivatives on passive avoidance behaviour of 24-month-old rats. Hutter-Paier B, et al. **Arzneimittelforschung** 1996 Mar;46(3):237-41

A biologically active form of chromium may activate a membrane phosphotyrosine phosphatase (PTP). Davis CM, et al. **Biochemistry** 1996 Oct 1;35(39):12963-9

Effect of some amino acids on the rectal irritation caused by sodium caprate in conscious rats. Kinouchi Y, et al. **Biol Pharm Bull** 1996 Mar;19(3):375-8

Gonadotropins, serum, and amino acids alter nuclear maturation, cumulus expansion, and oocyte morphology in hamster cumulus-oocyte complexes in vitro [published erratum appears in Biol Reprod 1997 Jul;57(1):214] Kito S, et al. **Biol Reprod** 1997 May;56(5):1281-9

Development of ovine embryos in synthetic oviductal fluid containing amino acids at oviductal fluid concentrations. Walker SK, et al. **Biol Reprod** 1996 Sep;55(3):703-8

Inactivation of monoamine oxidase B by benzyl 1-(aminomethyl) cyclopropane-1-carboxylate. Silverman RB, et al. **Bioorg Med Chem** 1997 Feb;5(2):297-304

Effect of heterogeneity of hydrophobic moieties on surface activity of lichenysin A, a lipopeptide biosurfactant from Bacillus licheniformis BAS50. Yakimov MM, et al. **Biotechnol Appl Biochem** 1996 Feb;23 (Pt 1):13-8

Effect of amino acid infusion on body temperature during anaesthesia [letter; comment] Donmez A, et al. **Br J Anaesth** 1997 Mar;78(3):338-9. Comment on: Br J Anaesth 1996 Feb;76(2):227-34.

Contribution of chorda tympani and glossopharyngeal nerves to taste preferences of rat for amino acids and NaCl. Tabuchi E, et al. **Brain Res** 1996 Nov 11;739(1-2):139-55

Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Glinsky GV, et al. **Cancer Res** 1996 Dec 1;56(23):5319-24

Enhancement of attention processing by Kantroll in healthy humans: a pilot study. DeFrance JF, et al. **Clin Electroencephalogr** 1997 Apr;28(2):68-75

Renal functional reserve in pigs: renal haemodynamics, renal tubular function and salt and water homeostatic hormones during amino acid and dopamine stimulation. Poulsen EU, et al. **Clin Physiol** 1997 Jan;17(1):57-69

Renal effects of amino acids and dopamine in renal transplant recipients treated with or without cyclosporin A. Hansen JM, et al. **Clin Sci (Colch)** 1996 Oct;91(4):489-96

Augmented thermic effect of amino acids under general anaesthesia occurs predominantly in extra-splanchnic tissues. Selldén E, et al. **Clin Sci (Colch)** 1996 Oct; 91(4):431-9

Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity. Mousa SA, et al. **Coron Artery Dis** 1996 Oct; 7(10):767-74

Comparative analysis of brain protection by N-methyl-D-aspartate receptor antagonists after transient focal ischemia in cats. Miyabe M, et al. **Crit Care Med** 1997 Jun;25(6):1037-43

A varicella vaccine stable at 5 degrees C. Fanget B, et al. **Dev Biol Stand** 1996;87:167-71

Growth hormone release induced by an amino acid mixture from primary cultured anterior pituitary cells of goats. Ohata Y, et al. **Domest Anim Endocrinol** 1997 Mar; 14(2):99-107

Inhibition of metoprolol metabolism by amino acids in perfused rat livers. Insights into the food effect? Wang BO, et al. **Drug Metab Dispos** 1997 Mar;25(3):287-95

Synergic influence of Ukrain and protoporphyrin amino acid conjugates on human malignant cell lines. Brzosko WJ, et al. **Drugs Exp Clin Res** 1996;22(3-5):193-4

Acute or prolonged exposure to 1-aminocyclopropanecarboxylic acid protects spinal neurons against NMDA toxicity. Lin Y, et al. **Eur J Pharmacol** 1996 Dec 30;318(2-3):491-6

Actions of D-amino acid-substituted analogues of des-Asp-angiotensin I on the central pressor action of angiotensin III. Radhakrishnan R, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):337-9

Physiological effects and brain protection by hypothermia and cerebrolysin after moderate forebrain ischemia in rats. Schwab M, et al. **Exp Toxicol Pathol** 1997 Feb; 49(1-2):105-16

Morphofunctional effects of moderate forebrain ischemia combined with short-term hypoxia in rats--protective effects of Cerebrolysin. Schwab M, et al. **Exp Toxicol Pathol** 1997 Feb;49(1-2):29-37

Alleviation of the '2-cell block' and development to the blastocyst of CF1 mouse embryos: role of amino acids, EDTA and physical parameters. Gardner DK, et al. **Hum Reprod** 1996 Dec;11(12):2703-12

Polyvinyl alcohol and amino acids as substitutes for bovine serum albumin in culture media for mouse preimplantation embryos. Biggers JD, et al. **Hum Reprod Update** 1997 Mar-Apr;3(2):125-35

Amino acid requirements for the growth and enterotoxin production by Staphylococcus aureus in chemically defined media. Onoue Y, et al. **Int J Food Microbiol** 1997 Apr 29;36(1):77-82

Effects of protein source and amino acid supplementation on plasma cholesterol in guinea pigs. Atwal AS, et al. **Int J Vitam Nutr Res** 1997;67(3):192-5

AMINO ACIDS

Free amino acid supplementation to steers: effects on ruminal fermentation and performance. Campbell CG, et al. **J Anim Sci** 1997 Apr;75(4):1167–78

The effect of postruminal amino acid flow on muscle cell proliferation and protein turnover. Reecy JM, et al. **J Anim Sci** 1996 Sep;74(9):2158–69

Effectiveness of a zinc amino acid chelate and zinc sulfate in restoring serum and soft tissue zinc concentrations when fed to zinc-depleted pigs. Swinkels JW, et al. **J Anim Sci** 1996 Oct;74(10):2420–30

The effect of reducing excess dietary amino acids on growing-finishing pig performance: an elevation of the ideal protein concept. Tuitoek K, et al. **J Anim Sci** 1997 Jun;75(6):1575–83

Nonessential amino acids and glutamine decrease the time of the first three cleavage divisions and increase compaction of mouse zygotes in vitro. Lane M, et al. **J Assist Reprod Genet** 1997 Aug;14(7):398–403

CodY is required for nutritional repression of Bacillus subtilis genetic competence. Serror P, et al. **J Bacteriol** 1996 Oct; 178(20):5910–5

The effect of individual amino acids on ApoB100 and Lp(a) secretion by HepG2 cells. Cianflone K, et al. **J Biol Chem** 1996 Nov 15;271(46):29136–45

Effect of intravenous amino acid infusion on leucine oxidation across the mammary gland of the lactating goat. Bequette BJ, et al. **J Dairy Sci** 1996 Dec;79(12):2217–24

Mechanisms of amino acid–induced insulin secretion from the glucose-responsive BRIN-BD11 pancreatic B-cell line. McClenaghan NH, et al. **J Endocrinol** 1996 Dec; 151(3):349–57

Luminal peptide YY-releasing factors in the isolated vascularly perfused rat colon. Plaisancié P, et al. **J Endocrinol** 1996 Dec;151(3):421–9

Inhibition of octapeptide N-myristoylation by acyl amino acids and acyl alkanolamines. Tabuchi M, et al. **J Enzyme Inhib** 1997 Apr;12(1):27–36

Effects of intravenous infusion of amino acids on cholecystokinin release and gallbladder contraction in humans. Shirohara H, et al. **J Gastroenterol** 1996 Aug; 31(4):572–7

Increased hepatic urea synthesis in patients with active inflammatory bowel disease. Lundsgaard C, et al. **J Hepatol** 1996 May;24(5):587–93

Chronic administration of a partial agonist at strychnine-insensitive glycine receptors: a novel experimental approach to the treatment of ischemias. Fossom LH, et al. **J Neural Transm Suppl** 1997;49:235–44 (38 ref.)

The long-term effect of NGF, b-FGF and Cerebrolysin on the spatial memory after fimbria-fornix lesion in rats. Francis-Turner L, et al. **J Neural Transm Suppl** 1996;47:277

The influence of Cerebrolysin and E021 on spatial navigation of young rats. Gschanes A, et al. **J Neural Transm Suppl** 1996;47:278

Cerebrolysin protects neurons from ischemia-induced loss of microtubule--associated protein 2. Hutter-Paier B, et al. **J Neural Transm Suppl** 1996;47:276

Effects of Cerebrolysin on cytoskeletal proteins after focal ischemia in rats. Schwab M, et al. **J Neural Transm Suppl** 1996;47:279

The short-term influence of b-FGF, NGF and Cerebrolysin on the memory impaired after fimbria-fornix lesion. Valoušková V, et al. **J Neural Transm Suppl** 1996;47:280

Brain tissue hydrolysate, Cerebrolysin, acts on presynaptic adenosine receptors in the rat hippocampus. Wojtowicz JM, et al. **J Neural Transm Suppl** 1996;47:281

Electrophysiological responses of single olfactory bulb neurons to amino acids in the channel catfish, Ictalurus punctatus. Kang J, et al. **J Neurophysiol** 1995 Oct; 74(4):1421–34

Electrophysiological responses of single olfactory bulb neurons to binary mixtures of amino acids in the channel catfish, Ictalurus punctatus. Kang J, et al. **J Neurophysiol** 1995 Oct;74(4):1435–43

In vivo responses of single olfactory receptor neurons of channel catfish to binary mixtures of amino acids. Kang J, et al. **J Neurophysiol** 1997 Jan;77(1):1–8

Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides? [editorial; comment] [see comments] Behr TM, et al. **J Nucl Med** 1996 May; 37(5):834–6. Comment on: J Nucl Med 1996 May;37(5):829–33. Comment in: J Nucl Med 1997 May;38(5):829.

Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion [see comments] Behr TM, et al. **J Nucl Med** 1996 May;37(5):829–33. Comment in: J Nucl Med 1996 May;37(5):834–6. Comment in: J Nucl Med 1996 May;37(5):837–8.

Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates [editorial; comment] [see comments] DeNardo SJ, et al. **J Nucl Med** 1996 May; 37(5):837–8. Comment on: J Nucl Med 1996 MaY;37(5):829–33. Comment in: J Nucl Med 1997 May;38(5):829.

Dietary protein and amino acid levels alter threonine dehydrogenase activity in hepatic mitochondria of Gallus domesticus. Davis AJ, et al. **J Nutr** 1997 May;127(5):738–44

The efflux of lysine from the basolateral membrane of human cultured intestinal cells (Caco-2) occurs by different mechanisms depending on the extracellular availability of amino acids. Ferruzza S, et al. **J Nutr** 1997 Jun; 127(6):1183–90

Long-term consumption of an amino acid diet reduces the pancreatic enzyme secretion response to a trypsin inhibitor in rats. Miura Y, et al. **J Nutr** 1997 Jul;127(7):1377–81

The protein digestibility-corrected amino acid score method overestimates quality of proteins containing antinutritional factors and of poorly digestible proteins supplemented with limiting amino acids in rats. Sarwar G. **J Nutr** 1997 May; 127(5):758–64

Minimal haemolysis in blood co-infused with amino acid and dextrose solutions in vitro. Jankov RP, et al. **J Paediatr Child Health** 1997 Jun;33(3):250–2

Facilitating effect of amino acids on fructose and sorbitol absorption in children. Hoekstra JH, et al. **J Pediatr Gastroenterol Nutr** 1996 Aug;23(2):118–24

Effect of amino acids on the stability properties of nitrofurantoin suspensions. Flocculation and redispersion compared with interaction energy curves. Gallardo V, et al. **J Pharm Pharmacol** 1996 May;48(5):450–5

In vitro evaluation of a series of N-dodecanoyl-L-amino acid methyl esters as dermal penetration enhancers. Fincher TK, et al. **J Pharm Sci** 1996 Sep;85(9):920–3

Mechanisms for stimulation of rat anterior pituitary cells by arginine and other amino acids. Villalobos C, et al. **J Physiol (Lond)** 1997 Jul 15;502 (Pt 2):421–31

Differential regulation of mouse embryo development and viability by amino acids. Lane M, et al. **J Reprod Fertil** 1997 Jan;109(1):153–64

Insulin and amino acid infusion after cardiac operations: effects on systemic and renal perfusion. Jeppsson A, et al. **J Thorac Cardiovasc Surg** 1997 Mar;113(3):594–602

Cytoprotection of kidney epithelial cells by compounds that target amino acid gated chloride channels. Venkatachalam MA, et al. **Kidney Int** 1996 Feb;49(2):449–60

Nitric oxide synthase inhibitors: amino acids. Griffith OW, et al. **Methods Enzymol** 1996;268:375–92

Influence of ovine oviducal amino acid concentrations and an ovine oestrus-associated glycoprotein on development and viability of bovine embryos. Hill JL, et al. **Mol Reprod Dev** 1997 Jun;47(2):164–9

Effect of amino acids and alpha-amanitin on the development of rabbit embryos in modified protein-free KSOM with HEPES. Liu Z, et al. **Mol Reprod Dev** 1996 Oct; 45(2):157–62

Effects of amino acids and alpha-amanitin on bovine embryo development in a simple protein-free medium. Liu Z, et al. **Mol Reprod Dev** 1997 Mar;46(3):278–85

Amino acids excess increase SCEs in human lymphocytes. Xing W, et al. **Mutat Res** 1996 Nov 11;372(1):75–8

Selective modulation of non-protein sulfhydryl levels in Ehrlich ascites tumor bearing mice. Włodek LB, et al. **Neoplasma** 1996;43(4):259–63

Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Przegaliński E, et al. **Neuropharmacology** 1997 Jan;36(1):31–7

Biphenyl-derivatives of 2-amino-7-phosphonoheptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonist--I. Pharmacological characterization in vitro. Urwyler S, et al. **Neuropharmacology** 1996 Jun;35(6):643–54

Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. Urwyler S, et al. **Neuropharmacology** 1996 Jun;35(6):655–69

1-Aminocyclopropane-carboxylic acid reduces NMDA-induced hippocampal neurodegeneration in vivo. Zapata A, et al. **Neuroreport** 1996 Jan 31;7(2):397–400

Brain-derived peptides increase the expression of a blood-brain barrier GLUT1 glucose transporter reporter gene. Boado RJ. **Neurosci Lett** 1996 Dec 6;220(1):53–6

Correlation between amino acid induced changes in energy expenditure and protein metabolism in humans. Giordano M, et al. **Nutrition** 1997 Apr;13(4):309–12

Learned olfactory discrimination of amino acids and their binary mixtures in bullhead catfish (Ameiurus nebulosus). Valentinčič T, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R313–4

Potentiation of GABAA receptor in cultured mouse hippocampal cells by brain-derived peptide mixture cerebrolysin. Zemková H, et al. **Physiol Res** 1995; 44(3):151–5

Inhibition by 1-aminocyclobutane-1-carboxylate of the activity of 1-aminocyclopropane-1-carboxylate oxidase obtained from senescing petals of carnation (Dianthus caryophyllus L.) flowers. Kosugi Y, et al. **Plant Cell Physiol** 1997 Mar;38(3):312–8

Isolation and characterization of mutants of Arabidopsis thaliana with increased resistance to growth inhibition by indoleacetic acid-amino acid conjugates. Campanella JJ, et al. **Plant Physiol** 1996 Oct;112(2):735–45

Effects of amino acids on development in vitro of cleavage-stage bovine embryos into blastocysts. Pinyopummintr T, et al. **Reprod Fertil Dev** 1996;8(5):835–41

Regional differences in the effect of mucosal glucose and amino acids on ion transport in normal and cholera toxin-stimulated porcine small intestine. Grøndahl ML, et al. **Scand J Gastroenterol** 1997 May;32(5):478–84

Effect of energy substrates on the preservation outcome of hepatocytes and sinusoidal endothelial cells in an experimental hypoxia/reoxygenation model. Zeilinger K, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):403–5

[The influence of intrathecal NMDA receptor antagonist on the isoflurane MAC and on the motor function] Yamazaki M. **Masui** 1996 Jan;45(1):70–6 (Eng. Abstr.) **(Jpn)**

[The mechanisms of the inhibition of gastric acid secretion induced by intraduodenal amino acids in rats] Ikeda M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan; 94(1):12–20 (Eng. Abstr.) **(Jpn)**

[Differences in immune response, phagocytosis and detoxifying properties due to effect of peptide and amino acid preparations] Belokrylov GA, et al. **Biull Eksp Biol Med** 1996 May;121(5):509–12 **(Rus)**

[Ambiguous effect of large and small doses of amino acid preparations on the immune response and phagocytosis in mice] Belokrylov GA, et al. **Biull Eksp Biol Med** 1994 May;117(5):500–1 **(Rus)**

PHYSIOLOGY

Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Hutson RG, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1691–9

IGF-I stimulation of muscle protein synthesis in the awake rat: permissive role of insulin and amino acids. Jacob R, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):E60–6

Volume regulation in rat brain glial cells: lack of a substantial contribution of free amino acids. Mountian I, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1319–25

Molecular cloning of a bovine renal G-protein coupled receptor gene (bRGR): regulation of bRGR mRNA levels by amino acid availability. Ferrer-Martínez A, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):107–12

Evaluation of functionally important amino acids in L-aspartate ammonia-lyase from Escherichia coli. Jayasekera MM, et al. **Biochemistry** 1997 Jul 29; 36(30):9145–50

Mechanisms of myocardial protection by amino acids: facts and hypotheses. Pisarenko OI. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):627–33 (88 ref.)

Different roles of D-amino acids in immune phenomena. Sela M, et al. **FASEB J** 1997 May;11(6):449–56 (79 ref.)

Replication and amplification of lambda plasmids in Escherichia coli during amino acid starvation and limitation. Wróbel B, et al. **FEMS Microbiol Lett** 1997 Aug 1;153(1):151–7

A single point mutation of hamster aminoacyl-tRNA synthetase causes apoptosis by deprivation of cognate amino acid residue. Fukushima K, et al. **Genes Cells** 1996 Dec;1(12):1087–99

Allogeneic recognition of HLA-DRB1*0406 by T cells with HLA-DRB1*0403: role of amino acid residue 37 on the beta sheet in T cell recognition. Kaneko T, et al. **Immunobiology** 1996 Aug;195(3):261–70

Amino acid residues required for binding of vascular cell adhesion molecule-1 to integrin alpha 4 beta 7. Kilger G, et al. **Int Immunol** 1997 Feb;9(2):219–26

Modulation of amino acid-gated ion channels by protein phosphorylation. Moss SJ, et al. **Int Rev Neurobiol** 1996; 39:1–52 (183 ref.)

Amino acid and energy interrelationships in growing beef steers: I. The effect of level of feed intake on ruminal characteristics and intestinal amino acid flows. Ludden PA, et al. **J Anim Sci** 1997 Sep;75(9):2550–60

Electrogenic L-histidine transport in neutral and basic amino acid transporter (NBAT)-expressing Xenopus laevis oocytes. Evidence for two functionally distinct transport mechanisms induced by NBAT expression. Ahmed A, et al. **J Biol Chem** 1997 Jan 3;272(1):125–30

Amino acid neurotransmission and initiation of puberty: evidence from nonketotic hyperglycinemia in a female infant and gonadotropin-releasing hormone secretion by rat hypothalamic explants. Bourguignon JP, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1899–903

Identification of amino acid residues in the alpha, beta, and gamma subunits of the epithelial sodium channel (ENaC) involved in amiloride block and ion permeation. Schild L, et al. **J Gen Physiol** 1997 Jan;109(1):15–26

The 25 amino acid residues at the carboxy terminus of the herpes simplex virus type 1 UL26.5 protein are required for the formation of the capsid shell around the scaffold. Kennard J, et al. **J Gen Virol** 1995 Jul;76 (Pt 7):1611–21

Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. Medesan C, et al. **J Immunol** 1997 Mar 1;158(5):2211–7

Second messengers, trafficking-related proteins, and amino acid residues that contribute to the functional regulation of the rat brain GABA transporter GAT1. Quick MW, et al. **J Neurosci** 1997 May 1;17(9):2967–79

Some amino acids are indispensable for growth (Osborne and Mendel, 1914–1916). Carpenter KJ. **J Nutr** 1997 May;127(5 Suppl):1031S–1032S

Charged amino acids near the pore entrance influence ion-conduction of a human L-type cardiac calcium channel. Bahinski A, et al. **Mol Cell Biochem** 1997 Jan; 166(1-2):125–34

Extensive mutagenesis of a transcriptional activation domain identifies single hydrophobic and acidic amino acids important for activation in vivo. Sainz MB, et al. **Mol Cell Biol** 1997 Jan;17(1):115–22

The GABAergic control of gonadotropin-releasing hormone secretion in male rats during sexual maturation involves effects on hypothalamic excitatory and inhibitory amino acid systems. Feleder C, et al. **Neuroendocrinology** 1996

Oct;64(4):305-12

Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1. Bosch E, et al. **Oncogene** 1997 Aug 28;15(9):1021-33

Amino acid residues which distinguish the mitogenic potentials of two FGF receptors. Wang JK, et al. **Oncogene** 1997 Apr 17;14(15):1767-78

Regulation of pancreatic beta-cell electrical activity and insulin release by physiological amino acid concentrations. Bolea S, et al. **Pflugers Arch** 1997 Apr;433(6):699-704

Neuropeptides, amines and amino acids in an elementary insect ganglion: functional and chemical anatomy of the unfused abdominal ganglion. Nässel DR. **Prog Neurobiol** 1996 Mar-Apr;48(4-5):325-420 (360 ref.)

Involvement of biogenic amines and amino acids in the central regulation of cardiovascular homeostasis. Singewald N, et al. **Trends Pharmacol Sci** 1996 Oct; 17(10):356-63 (50 ref.)

RADIATION EFFECTS

[Condensation of amino acids in aqueous solutions after exposure to weak electromagnetic fields] Novikov VV, et al. **Biofizika** 1996 Nov-Dec;41(6):1163-7 (Eng. Abstr.) **(Rus)**

SECRETION

Amino acid secretion of the hen's oviduct during the egg formation cycle. Barna J, et al. **Acta Vet Hung** 1996; 44(2):233-41

Release of amino acids from fatty livers during organ harvest for transplantation. von Frankenberg M, et al. **Ann Clin Lab Sci** 1997 Jul-Aug;27(4):287-92

Release of amino acids and related compounds from the adrenal equivalent and caudal vein of the eel in vitro. Milakofsky L, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Nov;112(3):275-83

Inhibition of tyrosine phosphorylation attenuates amino acid neurotransmitter release from the ischemic/reperfused rat cerebral cortex. Phillis JW, et al. **Neurosci Lett** 1996 Apr 5;207(3):151-4

STANDARDS

Evaluation of National Research Council amino acid recommendations for large white turkeys. Waldroup PW, et al. **Poult Sci** 1997 May;76(5):711-20

THERAPEUTIC USE

Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria [see comments] van Spronsen FJ, et al. **Am J Clin Nutr** 1996 Dec;64(6):916-21. Comment in: Am J Clin Nutr 1996 Dec;64(6):974-5.

The addition of aminoacids and phosphate to hemodiafiltration solutions in newborns with hyperammonemic coma. Fründ S, et al. **Clin Nephrol** 1996 Jul;46(1):64-6

Three coins in a nutrition fountain. Koretz RL. **Gastroenterology** 1997 Jan;112(1):307-9

Treatment products and approaches for phenylketonuria: improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials. Prince AP, et al. **J Inherit Metab Dis** 1997 Aug;20(4):486-98

Acid-induced gastric damage in rats is aggravated by starvation and prevented by several nutrients. Hung CR, et al. **J Nutr** 1997 Apr;127(4):630-6

Amino acid-based peritoneal dialysis solutions. Faller B. **Kidney Int Suppl** 1996 Nov;56:S81-5 (39 ref.)

In vivo and in vitro effects of amino-acid-based and bicarbonate-buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations. Plum J, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1652-60

Amine precursor amino acid therapy: from neurochemical basis to clinical aspects. Nakajima T. **Neurochem Res** 1996 Feb;21(2):251-8 (52 ref.)

A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Tandan R, et al. **Neurology** 1996 Nov;47(5):1220-6

Parallel antioxidant and antiexcitotoxic therapy improves outcome after incomplete global cerebral ischemia in dogs. Davis S, et al. **Stroke** 1997 Jan;28(1):198-204; discussion 204-5

TOXICITY

Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid. Brulez HF, et al. **Nephron** 1996; 74(1):26-32

Neurotoxicology and amino acid intake during development: the case of threonine. Castagne V, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):653-62 (138 ref.)

Effect of glycine on antidepressant- and anxiolytic-like action of 1-aminocyclopropanecarboxylic acid (ACPC) in rats. Chojnacka-Wójcik E, et al. **Pol J Pharmacol** 1996 Nov-Dec;48(6):627-9

URINE

Rapid decrease of urinary pyridinoline excretion in growth hormone deficient children following discontinuation of growth hormone therapy. Kuno T, et al. **Acta Paediatr Jpn** 1997 Feb;39(1):18-20

Validation of a high-performance liquid chromatographic assay for lysylpyridinoline in urine: a potential biomarker of bone resorption. Casserly UM, et al. **Anal Biochem** 1996 Nov 15;242(2):255-60

Detection of an asymptomatic primary hyperthyroidism by increased urinary deoxypyridinoline excretion [letter] Datta HK, et al. **Ann Clin Biochem** 1996 Jul;33 (Pt 4):357-9

Biological variation in urinary excretion of pyridinium crosslinks: recommendations for the optimum specimen. Panteghini M, et al. **Ann Clin Biochem** 1996 Jan;33 (Pt 1):36-42

Pyridinium crosslinks of collagen as a marker of bone resorption rates in children and adolescents: normal values and clinical application. Marowska J, et al. **Bone** 1996 Dec; 19(6):669-77

Short-term effects of dietary sodium intake on bone metabolism in postmenopausal women measured using urinary deoxypyridinoline excretion. Lietz G, et al. **Br J Nutr** 1997 Jul;78(1):73-82

Neridronate preferentially suppresses the urinary excretion of peptide-bound deoxypyridinoline in postmenopausal women. Tobias JH, et al. **Calcif Tissue Int** 1996 Nov; 59(5):407-9

Comparison of analytical performance and biological variability of three bone resorption assays. Ju HS, et al. **Clin Chem** 1997 Sep;43(9):1570-6

Measurements of deoxypyridinoline and hydroxyproline in 24-h, first morning, and second morning urine samples. Leino A, et al. **Clin Chem** 1996 Dec;42(12):2037-9

Serum concentration of the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen and urinary concentration of deoxypyridinoline as markers of bone metastases in human prostate carcinoma [letter] Yoshida K, et al. **Clin Chim Acta** 1996 Oct 15;254(1):93-5

Phosphaturia, glycosuria and aminoaciduria associated with idiopathic acquired sideroblastic anemia. Hanson B, et al. **Clin Nephrol** 1995 Dec;44(6):382-8

Urinary pyridinium cross-link excretion is increased in critically ill surgical patients. Shapses SA, et al. **Crit Care Med** 1997 Jan;25(1):85-90

Analysis of urinary pyridinoline and deoxypyridinoline in patients undergoing long-term anticonvulsant drug therapy. Ohishi T, et al. **Eur Neurol** 1996;36(5):300-2

Free deoxypyridinoline in urine and serum--results in children and adolescents. Rauch F, et al. **Exp Clin Endocrinol Diabetes** 1996;104(5):396-9

Conditions altering plasma concentrations of urea cycle and other amino acids in elderly human subjects. Prior RL, et al. **J Am Coll Nutr** 1996 Jun;15(3):237-47

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. Garnero P, et al. **J Bone Miner Res** 1996 Oct;11(10):1531-8

Automated method for the measurement of amino acids in urine by high-performance liquid chromatography. Carducci C, et al. **J Chromatogr A** 1996 Apr 5; 729(1-2):173-80

Different responses of free and peptide-bound cross-links to vitamin D and calcium supplementation in elderly women with vitamin D insufficiency. Kamel S, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3717-21

Urinary excretion of the collagen cross-link pyridinoline increases during liver fibrogenesis. Grenard P, et al. **J Hepatol** 1997 Jun;26(6):1356-62

Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma. Papatheofanis FJ. **J Nucl Med** 1997 Aug;38(8):1175-9

Evaluation of urinary pyridinoline in healthy adults and patients with rheumatoid arthritis by an improved high-performance liquid chromatographic assay. Otsuka M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Oct; 42(5):485-90

Serum and urinary amino acid levels in sickle cell disease. VanderJagt DJ, et al. **J Trop Pediatr** 1997 Aug;43(4):220-5

Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. Takeuchi S, et al. **J Urol** 1996 Nov;156(5):1691-5

Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study. Samma S, et al. **Jpn J Clin Oncol** 1997 Feb;27(1):26-30

Urinary immunoreactive deoxypyridinoline in children and adolescents: variations with age, sex and growth velocity. Rauch F, et al. **Scand J Clin Lab Invest** 1996 Dec; 56(8):715-9

Biochemical markers in menopausal women. Griesmacher A, et al. **Scand J Clin Lab Invest Suppl** 1997;227:64-72

[Urinary excretion of free and total deoxypyridinoline during secondary hyperparathyroidism in the elderly. Comparison of chromatographic (HPLC) and immunoenzymatic (Pyrilinks-D) methods] Meddah B, et al. **Ann Biol Clin (Paris)** 1996;54(10-11):353-8 (Eng. Abstr.) **(Fre)**

[Deoxypyridinoline and other biochemical markers of bone resorption in distinct pathologies] Rivero Marcotegui A, et al. **Rev Clin Esp** 1997 Jun;197(6):389-92 (Eng. Abstr.) **(Spa)**

AMINO ACIDS, BRANCHED-CHAIN

ADMINISTRATION & DOSAGE

Acrodermatitis enteropathica-like eruption during treatment of maple syrup urine disease: report of one case. Tain YL, et al. **Acta Paediatr Sin** 1996 Sep-Oct;37(5):357-60

Branched-chain amino acid supplementation during repeated prolonged skiing exercises at altitude. Bigard AX, et al. **Int J Sport Nutr** 1996 Sep;6(3):295-306

Influence of ingesting a solution of branched-chain amino acids on plasma and muscle concentrations of amino acids during prolonged submaximal exercise [see comments] Blomstrand E, et al. **Nutrition** 1996 Jul-Aug;12(7-8):485-90 . Comment in: Nutrition 1996 Jul-Sep;12(7-8):553-4.

The effect of branched-chain amino acid-enriched parenteral nutrition on gut permeability. McCauley R, et al. **Nutrition** 1996 Mar;12(3):176-9

ADVERSE EFFECTS

Gastric emptying in humans: influence of different regimens of parenteral nutrition. Swails WS, et al. **JPEN J Parenter Enteral Nutr** 1996 May-Jun;20(3):240-2

BLOOD

Effect of valine on 5-HT neurotransmission and mood. Cowen PJ, et al. **Adv Exp Med Biol** 1996;398:67-71

Responses of circulating urea cycle and branched-chain amino acids to feeding in adult and aged Fischer-344 rats. Hartman WJ, et al. **Aging (Milano)** 1997 Jun;9(3):198-206

Aromatic and branched-chain amino acid levels in alcoholics. Saito T, et al. **Alcohol Alcohol** 1994;29 Suppl 1:133-5

Spectrophometric assay for measuring branched-chain amino acid concentrations: application for measuring the sensitivity of protein metabolism to insulin. Beckett PR, et al. **Anal Biochem** 1996 Aug 15;240(1):48-53

Effect of carnitine on decrease of branched chain amino acids and glutamine in serum of septic rats. Hayashi N, et al. **Biol Pharm Bull** 1996 Jan;19(1):157-9

Changes in the albumin binding of tryptophan during postoperative recovery: a possible link with central fatigue? Yamamoto T, et al. **Brain Res Bull** 1997;43(1):43-6

Effect of exercise intensity on free tryptophan to branched-chain amino acids ratio and plasma prolactin during endurance exercise. Strüder HK, et al. **Can J Appl Physiol** 1997 Jun;22(3):280-91

Responses of plasma glutamine, free tryptophan and branched-chain amino acids to prolonged exercise after a regime designed to reduce muscle glycogen. Zanker CL, et al. **Eur J Appl Physiol** 1997;75(6):543-8

Changes in plasma tryptophan/branched chain amino acid ratio in responses to training volume variation. Tanaka H, et al. **Int J Sports Med** 1997 May;18(4):270-5

Effect of ruminally degraded protein on protein available at the intestine assessed using blood amino acid concentrations. Dhiman TR, et al. **J Anim Sci** 1997 Jun; 75(6):1674-80

Postcolumn co-immobilized leucine dehydrogenase-NADH oxidase reactor for the determination of branched-chain amino acids by high-performance liquid chromatography with chemiluminescence detection. Kiba N, et al. **J Chromatogr A** 1996 Feb 16;724(1-2):355-7

Immediately elevated postoperative serum branched-chain amino acids following effective GI decompression and enteral feeding. Nassif AC, et al. **Nutrition** 1996 Mar; 12(3):159-63

[A comparison of plasma amino acid concentrations between appropriate and small for gestational age fetuses] Su L, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb;31(2):93-6 (Eng. Abstr.) **(Chi)**

ISOLATION & PURIFICATION

Removal of branched-chain amino acids and alpha-ketoisocaproate by haemofiltration and haemodiafiltration. Gouyon JB, et al. **J Inherit Metab Dis** 1996;19(5):610-20

METABOLISM

The increased skeletal muscle protein turnover of the streptozotocin diabetic rat is associated with high concentrations of branched-chain amino acids. Rodríguez T, et al. **Biochem Mol Med** 1997 Jun;61(1):87-94

STP1, a gene involved in pre-tRNA processing in yeast, is important for amino-acid uptake and transcription of the permease gene BAP2. Jorgensen MU, et al. **Curr Genet** 1997 Mar;31(3):241-7

Metabolism of branched-chain amino acids in maple syrup urine disease. Schadewaldt P, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S62-6 (17 ref.)

Brain metabolism of branched-chain amino acids. Yudkoff M. **Glia** 1997 Sep;21(1):92-8 (54 ref.)

Enteral branched-chain amino acids increase the specific activity of jejunal glutaminase and reduce jejunal atrophy. McCauley RD, et al. **J Gastroenterol Hepatol** 1997 Jun; 12(6):429-33

Hyperammonemia-induced depletion of glutamate and branched-chain amino acids in muscle and plasma. Leweling H, et al. **J Hepatol** 1996 Nov;25(5):756-62

Cellular distribution of branched-chain amino acid aminotransferase isoenzymes among rat brain glial cells in

AMINO ACIDS, BRANCHED-CHAIN

culture. Bixel MG, et al. **J Histochem Cytochem** 1997 May; 45(5):685–94

Neuronal metabolism of branched-chain amino acids: flux through the aminotransferase pathway in synaptosomes. Yudkoff M, et al. **J Neurochem** 1996 May;66(5):2136–45

PHARMACOLOGY

Influence of ingesting a solution of branched-chain amino acids on perceived exertion during exercise. Blomstrand E, et al. **Acta Physiol Scand** 1997 Jan;159(1):41–9

Prolonged submaximal eccentric exercise is associated with increased levels of plasma IL-6. Rohde T, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E85–91

Effect of a 6-week endurance training programme and branched-chain amino acid supplementation on histomorphometric characteristics of aged human muscle. Freyssenet D, et al. **Arch Physiol Biochem** 1996; 104(2):157–62

Mobilization of visceral adipose tissue related to the improvement in insulin sensitivity in response to physical training in NIDDM. Effects of branched-chain amino acid supplements. Mourier A, et al. **Diabetes Care** 1997 Mar; 20(3):385–91

Regulation of glutamate dehydrogenase by branched-chain amino acids in skeletal muscle from rats and chicks. Zhou X, et al. **Int J Biochem Cell Biol** 1996 Jul;28(7):787–93

Combined effects of caloric restriction and branched-chain amino acid supplementation on body composition and exercise performance in elite wrestlers. Mourier A, et al. **Int J Sports Med** 1997 Jan;18(1):47–55

Stimulation of muscle ammonia production during exercise following branched-chain amino acid supplementation in humans. MacLean DA, et al. **J Physiol (Lond)** 1996 Jun 15;493 (Pt 3):909–22

Branched chain amino acids improve body composition and nitrogen balance in a rat model of extra hepatic biliary atresia. Sokal EM, et al. **Pediatr Res** 1996 Jul;40(1):66–71

The antinociceptive effects of branched-chain amino acids: evidence for their ability to potentiate morphine analgesia. Manner T, et al. **Pharmacol Biochem Behav** 1996 Feb; 53(2):449–54

Effect of dietary supplementation with branched-chain amino acids on spontaneous motor activity and muscle function in beta,beta'-iminodipropionitrile-treated rats: a model for motorneuropathy. Kitahara Y, et al. **Physiol Behav** 1997 Sep;62(3):453–62

THERAPEUTIC USE

Parenteral administration of different amounts of branch-chain amino acids in septic patients: clinical and metabolic aspects. García-de-Lorenzo A, et al. **Crit Care Med** 1997 Mar;25(3):418–24

Nutrient-induced thermogenesis and protein-sparing effect by rapid infusion of a branched chain-enriched amino acid solution to cirrhotic patients. Watanabe A, et al. **J Med** 1996;27(3–4):176–82

Alanylglutamine-enriched total parenteral nutrition improves protein metabolism more than branched chain amino acid-enriched total parenteral nutrition in protracted peritonitis [see comments] Naka S, et al. **J Trauma** 1997 Feb;42(2):183–90. Comment in: J Trauma 1997 Feb;42(2):343–4.

How should we evaluate the efficacy of nutrition support? [editorial; comment] Souba WW. **J Trauma** 1997 Feb; 42(2):343–4. Comment on: J Trauma 1997 Feb;42(2):183–90.

AMINO ACIDS, DIAMINO

BIOSYNTHESIS

Characterization of genes for the biosynthesis of the compatible solute ectoine from Marinococcus halophilus and osmoregulated expression in Escherichia coli. Louis P, et al. **Microbiology** 1997 Apr;143 (Pt 4):1141–9

CHEMISTRY

Studies on the neuroexcitotoxin beta-N-oxalo-L-alpha,beta-diaminopropionic acid and its isomer alpha-N-oxalo-L-alpha,beta-diaminopropionic acid from the root of Panax species. Long YC, et al. **Int J Pept Protein Res** 1996 Jan-Feb;47(1–2):42–6

Cis-Dichloro(diaminosuccinate diethyl ester)palladium (II) as Pd(II)/Pt(II) model compound for DNA-binding and antitumor properties: solution equilibria of their aqua-, hydroxo-, and/or chloro-species. González S, et al. **J Inorg Biochem** 1996 Mar;61(4):261–72

METABOLISM

Differential role of homologous positively charged amino acid residues for ligand binding in retinoic acid receptor alpha compared with retinoic acid receptor beta. Scafonas A, et al. **J Biol Chem** 1997 Apr 25;272(17):11244–9

PHARMACOLOGY

Inhibition of tyrosine aminotransferase by beta-N-oxalyl-L-alpha,beta-diaminopropionic acid, the Lathyrus sativus neurotoxin. Shasi Vardhan K, et al. **J Neurochem** 1997 Jun;68(6):2477–84

Plant-derived amino acids increase hippocampal BDNF, NGF, c-fos and hsp70 mRNAs. Andersson H, et al. **Neuroreport** 1997 May 27;8(8):1813–7

AMINO ACIDS, DIBASIC see **AMINO ACIDS, DIAMINO**

AMINO ACIDS, DICARBOXYLIC

CHEMISTRY

Fourier transform infrared study on the primary donor P798 of Heliobacterium modesticaldum: cysteine S-H coupled to P798 and molecular interactions of carbonyl groups. Noguchi T, et al. **Biochemistry** 1997 Oct 7;36(40):12329–36

METABOLISM

Interaction between anionic amino acids and the mammary tissue (Na(+)-glutamate) cotransporter. Millar ID, et al. **Biochem Soc Trans** 1996 May;24(2):333S

PHARMACOLOGY

Pharmacological characterization of [3H]MK-801 binding in the rat spinal cord. Souverbie F, et al. **Eur J Pharmacol** 1996 Jul 4;307(3):347–53

Effects of the selective metabotropic glutamate receptor agonist, L-CCG-I, on acquisition of a Morris task by rats. Van der Staay FJ, et al. **Eur J Pharmacol** 1995 Dec 27; 294(1):361–5

mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro. Huang LQ, et al. **Neuroreport** 1997 Feb 10;8(3):687–93

URINE

Glutamate transporter EAAC-1-deficient mice develop dicarboxylic aminoaciduria and behavioral abnormalities but no neurodegeneration. Peghini P, et al. **EMBO J** 1997 Jul 1;16(13):3822–32

AMINO ACIDS, ESSENTIAL

Glutamine: an essential amino acid for the gut. van der Hulst RR, et al. **Nutrition** 1996 Nov-Dec;12(11–12 Suppl):S78–81 (22 ref.)

ADMINISTRATION & DOSAGE

Comparison of the protein quality of dietetically treated phenylketonuria patients with the recommendations of the WHO Expert Consultation. Krauch G, et al. **Eur J Pediatr** 1996 Jul;155 Suppl 1:S153–7

Calcium and phosphate solubility curves for parenteral nutrient solutions containing Vaminolact. Mo-Suwan L, et al. **J Med Assoc Thai** 1997 Aug;80(8):516–20

Homoarginine influences voluntary feed intake, tissue basic amino acid concentrations and arginase activity in chickens. Angkanaporn K, et al. **J Nutr** 1997 Jun;127(6):1128–36

[The intake of proteins and essential amino acids in top-competing women athletes] Nuviala Mateo RJ, et al. **Nutr Hosp** 1997 Mar-Apr;12(2):85–91 (Eng. Abstr.) **(Spa)**

ANALYSIS

Small changes in essential amino acid concentrations alter diet selection in amino acid-deficient rats. Hrupka BJ, et al. **J Nutr** 1997 May;127(5):777–84

BIOSYNTHESIS

Biosynthesis of 'essential' amino acids by scleractinian corals. Fitzgerald LM, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):213–21

BLOOD

[A comparison of plasma amino acid concentrations between appropriate and small for gestational age fetuses] Su L, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb;31(2):93–6 (Eng. Abstr.) **(Chi)**

GENETICS

Identification of essential amino acids in the Streptococcus mutans glucosyltransferases. Tsumori H, et al. **J Bacteriol** 1997 Jun;179(11):3391–6

METABOLISM

The search for the uremic toxin: the case for metabolic acidosis [see comments] Bailey JL, et al. **Wien Klin Wochenschr** 1997 Jan 17;109(1):7–12 (50 ref.). Comment in: Wien Klin Wochenschr 1997 Jan 17;109(1):1–2.

PHARMACOLOGY

Small changes in essential amino acid concentrations alter diet selection in amino acid-deficient rats. Hrupka BJ, et al. **J Nutr** 1997 May;127(5):777–84

Response of rainbow trout (Oncorhynchus mykiss) to supplements of individual essential amino acids in a semipurified diet, including an estimate of the maintenance requirement for essential amino acids. Rodehutscord M, et al. **J Nutr** 1997 Jun;127(6):1166–75

Optimizing the pattern of essential amino acids as the sole source of dietary nitrogen supports near-maximal growth in kittens. Taylor TP, et al. **J Nutr** 1996 Sep;126(9):2243–52

PHYSIOLOGY

[L-tryptophan. An essential amino acid for structural and functional metabolism] Loew D. **Fortschr Med** 1997 Jan 30;115(3):40–2 (Eng. Abstr.) **(Ger)**

TOXICITY

Lack of involvement of glutamate-induced excitotoxicity in MPP+ toxicity in striatal dopaminergic terminals: possible involvement of ascorbate. Matarredona ER, et al. **Br J Pharmacol** 1997 Jul;121(5):1038–44

AMINO ACIDS, EXCITATORY see **EXCITATORY AMINO ACIDS**

AMINO ACIDS, EXCITATORY, AGENTS see **EXCITATORY AMINO ACID AGENTS**

AMINO ACIDS, EXCITATORY, AGONISTS see **EXCITATORY AMINO ACID AGONISTS**

AMINO ACIDS, EXCITATORY, ANTAGONISTS see **EXCITATORY AMINO ACID ANTAGONISTS**

AMINO ACIDS, SECONDARY see **IMINO ACIDS**

AMINO ACIDS, SULFUR

[Glutathione levels in human colon cancer cell line M7609 following culture in a low sulfur amino acid medium and its sensitivity to various anticancer drugs] Saito T, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):823–7 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Dietary sulphur amino acid adequacy influences glutathione synthesis and glutathione-dependent enzymes during the inflammatory response to endotoxin and tumour necrosis factor-alpha in rats. Hunter EA, et al. **Clin Sci (Colch)** 1997 Mar;92(3):297–305

Sulfur amino acid requirement and cystine replacement value of broiler chicks during the period three to six weeks posthatching. Baker DH, et al. **Poult Sci** 1996 Jun; 75(6):737–42

ANALYSIS

Correction for amino acid loss during acid hydrolysis of a purified protein. Darragh AJ, et al. **Anal Biochem** 1996 May 1;236(2):199–207

Hair sulfur amino acid analysis. Zahn H, et al. **EXS** 1997; 78:239–58 (47 ref.)

Detection of cystathionine ketimine and lanthionine ketimine in human brain. Fontana M, et al. **Neurochem Res** 1997 Jul;22(7):821–4

Gestational age-related reference values for amniotic fluid amino acids: a useful tool for prenatal diagnosis of aminoacidopathies. Rabier D, et al. **Prenat Diagn** 1996 Jul; 16(7):623–8

BLOOD

Content of sulfur amino acids and vitamin B6 and related enzyme activities in rats with chronic renal failure fed a high methionine diet. Asagi K, et al. **Nephron** 1996; 74(1):175–82

CHEMISTRY

Detection, number, and sequence location of sulfur-containing amino acids and disulfide bridges in peptides by ultrahigh-resolution MALDI FTICR mass spectrometry. Solouki T, et al. **Anal Chem** 1997 Mar 15; 69(6):1163–8

METABOLISM

Effect of the pyrrolizidine alkaloid monocrotaline on taurine and sulfur amino acid metabolism in the rat liver. Yan CC, et al. **Adv Exp Med Biol** 1996;403:135–45

Studies on the biosynthesis of ovothiol A. Identification of 4-mercaptohistidine as an intermediate. Steenkamp DJ, et al. **Eur J Biochem** 1996 Dec 15;242(3):557–66

Low de novo glutathione synthesis from circulating sulfur amino acids in the lens epithelium. Mackic JB, et al. **Exp Eye Res** 1997 Apr;64(4):615–26

Parasite sulphur amino acid metabolism. Walker J, et al. **Int J Parasitol** 1997 Aug;27(8):883–97 (90 ref.)

Sulfur amino acid utilization by growing steers. Campbell CG, et al. **J Anim Sci** 1997 Jan;75(1):230–8

Solubilization of [35S]lanthionine ketimine binding sites from bovine brain. Fontana M, et al. **Neurochem Int** 1996 Feb; 28(2):169–73

Digestible sulfur amino acid requirement of starting turkeys. Boling SD, et al. **Poult Sci** 1997 Jun;76(6):873–7

PHARMACOLOGY

Sulphur-containing amino acids modulate noradrenaline release from hippocampal slices. Selema G, et al. **J Neurochem** 1997 Apr;68(4):1534–41

Antioxidant properties of the decarboxylated dimer of

aminoethylcysteine ketimine. Pecci L, et al. **Physiol Chem Phys Med NMR** 1995;27(3):223–9

TOXICITY

[Cytotoxicity of excitatory sulfur amino acids in primary cultured rat cerebral neurons] Abeta S. **Rinsho Shinkeigaku** 1995 Oct;35(10):1092–7 (Eng. Abstr.) **(Jpn)**

URINE

Aminoethylcysteine ketimine decarboxylated dimer detected in normal human urine by gas–liquid chromatography, selected–ion monitoring and mass spectrometry. Matarese RM, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30; 683(2):269–72

AMINO ACYL T RNA SYNTHETASES

CHEMISTRY

Aminoacyl thioester chemistry of class II aminoacyl–tRNA synthetases. Jakubowski H. **Biochemistry** 1997 Sep 16; 36(37):11077–85

Mutational analysis of a leucine heptad repeat motif in a class I aminoacyl–tRNA synthetase. Ohannesian DW, et al. **Biochemistry** 1996 Nov 12;35(45):14405–12

Chemical modification and site–directed mutagenesis of the single cysteine in motif 3 of class II Escherichia coli prolyl–tRNA synthetase. Stehlin C, et al. **Biochemistry** 1997 Mar 11;36(10):2932–8

The crystal structures of T. thermophilus lysyl–tRNA synthetase complexed with E. coli tRNA(Lys) and a T. thermophilus tRNA(Lys) transcript: anticodon recognition and conformational changes upon binding of a lysyl–adenylate analogue. Cusack S, et al. **EMBO J** 1996 Nov 15;15(22):6321–34

Interaction between human tRNA synthetases involves repeated sequence elements. Rho SB, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10128–33

When protein engineering confronts the tRNA world. Schimmel P, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10007–9 (24 ref.)

Aminoacyl–tRNA synthetases in biology and disease: new evidence for structural and functional diversity in an ancient family of enzymes. Francklyn C, et al. **RNA** 1997 Sep;3(9):954–60 (67 ref.)

The crystal structure of phenylalanyl–tRNA synthetase from thermus thermophilus complexed with cognate tRNAPhe. Goldgur Y, et al. **Structure** 1997 Jan 15;5(1):59–68

Structural and functional considerations of the aminoacylation reaction. Arnez JG, et al. **Trends Biochem Sci** 1997 Jun;22(6):211–6 (45 ref.)

GENETICS

Aminoacyl–tRNA synthetase gene regulation in Bacillus subtilis. Condon C, et al. **Biochimie** 1996;78(6):381–9 (54 ref.)

Evolution of the aminoacyl–tRNA synthetase family and the organization of the Drosophila glutamyl–prolyl–tRNA synthetase gene. Intron/exon structure of the gene, control of expression of the two mRNAs, selective advantage of the multienzyme complex. Cerini C, et al. **Eur J Biochem** 1997 Feb 15;244(1):176–85

Mitochondrial asparaginyl–tRNA synthetase is encoded by the yeast nuclear gene YCR24c [published erratum appears in Eur J Biochem 1997 Apr 15;245(2):520] Landrieu I, et al. **Eur J Biochem** 1997 Jan 15;243(1–2):268–73

The p18 component of the multisynthetase complex shares a protein motif with the beta and gamma subunits of eukaryotic elongation factor 1. Quevillon S, et al. **FEBS Lett** 1996 Oct 14;395(1):63–7

Glutaminyl–tRNA synthetase: from genetics to molecular recognition. Ibba M, et al. **Genes Cells** 1996 May;1(5):421–7 (36 ref.)

The Staphylococcus aureus ileS gene, encoding isoleucyl–tRNA synthetase, is a member of the T–box family. Grundy FJ, et al. **J Bacteriol** 1997 Jun; 179(11):3767–72

Genetic analysis of functional connectivity between substrate recognition domains of Escherichia coli glutaminyl–tRNA synthetase. Kitabatake M, et al. **Mol Gen Genet** 1996 Oct 28;252(6):717–22

Dominant negative inhibition by fragments of a monomeric enzyme. Michaels JE, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14452–5

IMMUNOLOGY

Interstitial lung disease with autoantibodies against aminoacyl–tRNA synthetases in the absence of clinically apparent myositis. Friedman AW, et al. **Semin Arthritis Rheum** 1996 Aug;26(1):459–67

ISOLATION & PURIFICATION

Analysis of aminoacylation of human mitochondrial tRNAs. Enriquez JA, et al. **Methods Enzymol** 1996;264:183–96

METABOLISM

Chemical modification and site–directed mutagenesis of the single cysteine in motif 3 of class II Escherichia coli prolyl–tRNA synthetase. Stehlin C, et al. **Biochemistry** 1997 Mar 11;36(10):2932–8

A strategy of tRNA recognition that includes determinants of RNA structure. Hamann CS, et al. **Bioorg Med Chem** 1997 Jun;5(6):1011–9

Rescuing an essential enzyme–RNA complex with a non–essential appended domain. Whelihan EF, et al. **EMBO J** 1997 May 15;16(10):2968–74

Differences in the magnesium dependences of the class I and class II aminoacyl–tRNA synthetases from Escherichia coli. Airas RK. **Eur J Biochem** 1996 Aug 15;240(1):223–31

Glutaminyl–tRNA synthetase: from genetics to molecular recognition. Ibba M, et al. **Genes Cells** 1996 May;1(5):421–7 (36 ref.)

Further study on association of 5SrRNA–L5 protein complex and methionyl–tRNA to methionyl–tRNA synthetase in the macromolecular aminoacyl–tRNA synthetase complex. Ogata K, et al. **J Biochem (Tokyo)** 1996 Nov;120(5):869–80

Leishmania tarentolae contains distinct cytosolic and mitochondrial glutaminyl–tRNA synthetase activities. Nabholz CE, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):7903–8

Interaction between human tRNA synthetases involves repeated sequence elements. Rho SB, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10128–33

Four primordial modes of tRNA–synthetase recognition, determined by the (G,C) operational code. Rodin SN, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):5183–8

Structural and functional considerations of the aminoacylation reaction. Arnez JG, et al. **Trends Biochem Sci** 1997 Jun;22(6):211–6 (45 ref.)

PHYSIOLOGY

Aminoacyl–tRNA synthetases in biology and disease: new evidence for structural and functional diversity in an ancient family of enzymes. Francklyn C, et al. **RNA** 1997 Sep;3(9):954–60 (67 ref.)

[Structure and function of aminoacyl–tRNA synthetases] Siatecka M, et al. **Postepy Biochem** 1995;41(4):266–75 (61 ref.) **(Pol)**

RADIATION EFFECTS

Effect of continuous–wave and amplitude–modulated 2.45 GHz microwave radiation on the liver and brain aminoacyl–transfer RNA synthetases of in utero exposed mice. Kubinyi G, et al. **Bioelectromagnetics** 1996; 17(6):497–503

AMINO ACYL TRNA see **RNA, TRANSFER, AMINO ACYL**

AMINO ALCOHOLS

ANALYSIS

Chiral separation of primary amino compounds using a non–chiral crown ether with beta–cyclodextrin by capillary electrophoresis. Huang WX, et al. **J Chromatogr B Biomed Appl** 1997 Jul 18;695(1):157–62

CHEMICAL SYNTHESIS

[Synthetic 2–amino alcohol derivatives as chiral auxiliaries] Ishizuka T. **Yakugaku Zasshi** 1997 Jun;117(6):339–52 (35 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Adsorption/desorption of amine fluorides to hydroxyapatite. Sefton J, et al. **Biomaterials** 1996 Jan;17(1):37–46

PHARMACOLOGY

Inhibition of octapeptide N–myristoylation by acyl amino acids and acyl alkanolamines. Tabuchi M, et al. **J Enzyme Inhib** 1997 Apr;12(1):27–36

BRS1, a C30 bis–amino, bis–hydroxy polyunsaturated lipid from an Australian calcareous sponge that inhibits protein kinase C. Willis RH, et al. **Toxicon** 1997 Jul;35(7):1125–9

TOXICITY

Environmental assessment of the alkanolamines. Davis JW, et al. **Rev Environ Contam Toxicol** 1997;149:87–137 (94 ref.)

AMINO SUGARS

ADMINISTRATION & DOSAGE

Ribavirin conjugated with lactosaminated poly–L–lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis. Di Stefano G, et al. **Biochem Pharmacol** 1997 Aug 1;54(3):357–63

ANALYSIS

Structural differences and the presence of unsubstituted amino groups in heparan sulphates from different tissues and species. Toida T, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):499–506

Expression and characterization of a lactosaminoglycan–carrying glycoprotein of Zajdela hepatoma cell surface––structural analysis of the carbohydrate moiety. Goulut–Chassaing C, et al. **Eur J Biochem** 1997 Aug 1;247(3):1091–101

[The determination of phosphoethanolamine and other amino components in the lipopolysaccharides of gram–negative bacteria by ion–exchange chromatography] Veremeichenko SN. **Mikrobiol Z** 1996 Mar–Apr;58(2):70–5 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

In vitro biosynthesis of a decasaccharide prototype of multiply branched polylactosaminoglycan backbones. Leppanen A, et al. **Biochemistry** 1997 Jun 10;36(23):7026–36

Chemoenzymatic synthesis and lectin binding properties of dendritic N–acetyllactosamine. Zanini D, et al. **Bioconjug Chem** 1997 Mar–Apr;8(2):187–92

Complete synthesis of 3'–sialyl–N–acetyllactosamine by regioselective transglycosylation. Vetere A, et al. **FEBS Lett** 1996 Dec 16;399(3):203–6

CHEMICAL SYNTHESIS

Chemoenzymatic synthesis and lectin binding properties of dendritic N–acetyllactosamine. Zanini D, et al. **Bioconjug Chem** 1997 Mar–Apr;8(2):187–92

Glycosyl azides as building blocks in convergent syntheses of oligomeric lactosamine and Lewis(x) saccharides. Bröder W, et al. **Bioorg Med Chem** 1997 Jan;5(1):1–19

Stereocontrolled syntheses of O–glycans of core class 2 with a linear tetrameric lactosamine chain and with three lactosamine branches. Wang ZG, et al. **Carbohydr Res** 1996 Dec 13;295:25–39

CHEMISTRY

N–Tetrachlorophthaloyl (TCP) for ready protection/deprotection of amino sugar glycosides. Debenham JS, et al. **Bioorg Med Chem** 1996 Nov; 4(11):1909–18

Isolation and characterization of an amino sugar–rich glycopeptide from the surface layer glycoprotein of Thermoanaerobacterium thermosaccharolyticum E207–71. Altman E, et al. **Carbohydr Res** 1996 Dec 13;295:245–53

Structural studies of the O–antigenic polysaccharide of the lipopolysaccharide from Acinetobacter (DNA group 11) strain 94 containing 3–amino–3,6–dideoxy–D–galactose substituted by the previously unknown amide–linked L–2–acetoxypropionic acid or L–2–hydroxypropionic acid. Haseley SR, et al. **Eur J Biochem** 1997 Aug 1;247(3):815–9

Elongation of N–acetyllactosamine repeats in diantennary oligosaccharides. Hummel M, et al. **Eur J Biochem** 1997 Apr 15;245(2):428–33

Synthesis of a new nanomolar saccharide inhibitor of lymphocyte adhesion: different polylactosamine backbones present multiple sialyl Lewis x determinants to L–selectin in high–affinity mode. Renkonen O, et al. **Glycobiology** 1997 Jun;7(4):453–61

Expression of human H–type alpha1,2–fucosyltransferase encoding for blood group H(O) antigen in Chinese hamster ovary cells. Evidence for preferential fucosylation and truncation of polylactosamine sequences. Prieto PA, et al. **J Biol Chem** 1997 Jan 24;272(4):2089–97

Potentiometric and spectroscopic study of copper (II) ion binding by 1,6–anhydro–derivatives of aminosugars. Jezowska–Bojczuk M, et al. **J Inorg Biochem** 1996 Feb 15;61(3):213–9

METABOLISM

Origin of carbohydrate recognition specificity of human lysozyme revealed by affinity labeling. Muraki M, et al. **Biochemistry** 1996 Oct 22;35(42):13562–7

Characterization of lactoferrin–binding proteins of human macrophage membrane: multiple species of lactoferrin–binding proteins with polylactosamine–binding ability. Eda S, et al. **Biol Pharm Bull** 1997 Feb;20(2):127–33

Formylcolchicine bound to lactosaminated serum albumin is a more active antifibrotic agent than free colchicine. Palmerini CA, et al. **Clin Chim Acta** 1996 Oct 29; 254(2):149–57

The beta 1,6–GlcNAc transferase activity present in hog gastric mucosal microsomes catalyses site–specific branch formation on a long polylactosamine backbone. Helin J, et al. **FEBS Lett** 1997 Aug 4;412(3):637–42

Specification of receptor–binding phenotypes of influenza virus isolates from different hosts using synthetic sialylglycopolymers: non–egg–adapted human H1 and H3 influenza A and influenza B viruses share a common high binding affinity for 6'–sialyl(N–acetyllactosamine). Gambaryan AS, et al. **Virology** 1997 Jun 9;232(2):345–50

PHARMACOLOGY

B–1 cell (CD5+B220+) outgrowth in murine schistosomiasis is genetically restricted and is largely due to activation by polylactosamine sugars. Velupillai P, et al. **J Immunol** 1997 Jan 1;158(1):338–44

AMINOACETIC ACID see **GLYCINE**

AMINOACIDURIA, RENAL

COMPLICATIONS

L–2–Hydroxyglutaric aciduria: clinical, biochemical and magnetic resonance imaging in six Portuguese pediatric patients. Barbot C, et al. **Brain Dev** 1997 Jun;19(4):268–73

AMINOACIDURIA, RENAL

DIAGNOSIS

2-Hydroxyglutaric aciduria: a case report on an infant with the D-isomeric form with review of the literature. Geerts Y, et al. **J Neurol Sci** 1996 Nov;143(1-2):166-9 (20 ref.)

Use of amniotic fluid amino acids in prenatal testing for argininosuccinic aciduria and citrullinaemia. Mandell R, et al. **Prenat Diagn** 1996 May;16(5):419-24

METABOLISM

[Renal tubule transport defect of amino acids] Takita H. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):637-40 (7 ref.) **(Jpn)**

9-AMINOACRIDINE see **AMINACRINE**

AMINOACRIDINES

ANALYSIS

Fingerprinting of glycans as their 2-aminoacridone derivatives by capillary electrophoresis and laser-induced fluorescence. Harland GB, et al. **Electrophoresis** 1996 Feb; 17(2):406-11

Analysis of the imidazoacridinone C1311 by high-performance liquid chromatography. Calabrese CR, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7; 690(1-2):275-81

CHEMISTRY

A coordinated high-performance liquid chromatographic, capillary electrophoretic, and mass spectrometric approach for the analysis of oligosaccharide mixtures derivatized with 2-aminoacridone. Okafo G, et al. **Anal Chem** 1996 Dec 15;68(24):4424-30

Highly selective acridine and ethidium staining of bacterial DNA and RNA. Bruno JG, et al. **Biotech Histochem** 1996 May;71(3):130-6

Nucleic acid specificity of an acridine derivative permits its use for flow cytometric analysis of the cell cycle. Jayat-Vignoles C, et al. **Cytometry** 1997 Feb 1;27(2):153-60

Photochemical and photophysical studies of 3-amino-6-iodoacridine and the inactivation of lambda phage. Chen T, et al. **Photochem Photobiol** 1996 Oct; 64(4):622-31

METABOLISM

32P-post-labelling analysis of nucleobases involved in the formation of DNA adducts by antitumor 1-nitroacridines. Bartoszek A, et al. **Chem Biol Interact** 1997 Feb 28; 103(2):131-9

PHARMACOLOGY

Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation. Lamb J, et al. **Br J Cancer** 1996 Nov;74(9):1359-68

32P-post-labelling analysis of nucleobases involved in the formation of DNA adducts by artitumor 1-nitroacridines. Bartoszek A, et al. **Chem Biol Interact** 1997 Feb 28; 103(2):131-9

THERAPEUTIC USE

Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Burger AM, et al. **Br J Cancer** 1996 Nov;74(9):1369-74

2-AMINOADIPIC ACID

ANALOGS & DERIVATIVES

In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68. Mihara M, et al. **Immunopharmacology** 1996 Oct;35(1):41-6

A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice. Mihara M, et al. **Int Arch Allergy Immunol** 1997 Aug;113(4):454-9

Preventive effect of a novel antifolate, MX-68, in murine systemic lupus erythematosus (SLE). Mihara M, et al. **Int J Immunopharmacol** 1997 Feb;19(2):67-74

METABOLISM

Characterization of L-alpha-aminoadipic acid transport in cultured rat astrocytes. Tsai MJ, et al. **Brain Res** 1996 Nov 25;741(1-2):166-73

PHARMACOLOGY

Development of the neonatal rabbit retina in organ culture. 1. Comparison with histogenesis in vivo, and the effect of a gliotoxin (alpha-aminoadipic acid). Germer A, et al. **Anat Embryol (Berl)** 1997 Jul;196(1):67-79

L-alpha-aminoadipate reduces glutamate release from brain tissue exposed to combined oxygen and glucose deprivation. Haugstad TS, et al. **J Cereb Blood Flow Metab** 1997 May;17(5):567-70

Inhibition of the high-affinity uptake of D-[3H]aspartate in rate by L-alpha-aminoadipate and arachidonic acid. Lundy DF, et al. **J Neurol Sci** 1996 Aug;139 Suppl:1-9

L-alpha-aminoadipate inhibits kynurenate synthesis in rat brain hippocampus and tissue culture. Chang YF, et al. **Neurochem Res** 1997 Jul;22(7):825-9

Induction of glutamine synthetase by L-alpha-aminoadipate in developmental stages of cultured astrocytes. Koyama Y, et al. **Neurosci Lett** 1997 Feb 14;223(1):65-8

The effects of D-alpha-aminoadipic acid on long-term potentiation in the hippocampus of the rat in vitro. Hicks TP, et al. **Neurosci Res** 1996 Jan;24(2):139-50

AMINOANTIPYRINE see **AMPYRONE**

AMINOBENZENESULFONIC ACIDS see **SULFANILIC ACIDS**

4-AMINOBENZOIC ACID

ADMINISTRATION & DOSAGE

The ursodeoxycholic acid-p-aminobenzoic acid deconjugation test, a new tool for the diagnosis of bacterial overgrowth syndrome. Kiss ZF, et al. **Eur J Gastroenterol Hepatol** 1997 Jul;9(7):679-82

ADVERSE EFFECTS

Milia as unusual sequelae to allergic contact dermatitis. Ibbotson SH, et al. **Contact Dermatitis** 1996 Jul;35(1):49-50

ANALOGS & DERIVATIVES

Proteinase inhibitors and pemphigus vulgaris. An in vitro and in vivo study. Dobrev H, et al. **Arch Dermatol Res** 1996 Oct;288(11):648-55

Topical pharyngeal anesthesia improves tolerance of upper gastrointestinal endoscopy: a randomized double-blind study. Campo R, et al. **Endoscopy** 1995 Nov;27(9):659-64

Increased defaecation caused by 5-HT4 receptor activation in the mouse. Banner SE, et al. **Eur J Pharmacol** 1996 Jul 18;308(2):181-6

Determination of ester-type local anesthetic drugs (procaine, tetracaine, and T-caine) in human serum by wide-bore capillary gas chromatography with nitrogen-phosphorus detection. Terada M, et al. **J Anal Toxicol** 1996 Sep; 20(5):318-22

High-performance liquid chromatographic assay for common sunscreening agents in cosmetic products, bovine serum albumin solution and human plasma. Jiang R, et al. **J Chromatogr B Biomed Appl** 1996 Jun 28;682(1):137-45

Identification and assay of folate catabolites in human urine. McPartlin J, et al. **Methods Enzymol** 1997;281:70-7

Determination of the exocrine pancreatic function with the NBT-PABA test using a novel dual isotope technique and gas chromatography-mass spectrometry. Larsen B, et al. **Scand J Clin Lab Invest** 1997 Apr;57(2):159-65

p-Aminobenzoic acid, but not its metabolite p-acetamidobenzoic acid, inhibits thrombin induced thromboxane formation in human platelets in a non NSAID like manner. Barbieri B, et al. **Thromb Res** 1997 Apr 15; 86(2):127-40

[Absorption test of protein] Nakamura T. **Nippon Rinsho** 1997 Apr;55 Suppl 2:109-10 (3 ref.) **(Jpn)**

[PFD test (bentiromide test, BT-PABA test)] Oyama H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:202-5 (6 ref.) **(Jpn)**

ANALYSIS

Simple spectrofluorometric determination of p-aminobenzoic and p-aminosalicylic acids in biological fluids by use of terbium-sensitized luminescence. Lianidou ES, et al. **Clin Chem** 1996 Oct;42(10):1659-65

Detection and determination of the hydrazo and azo photoproducts of 4-aminobenzoic acid by high-performance liquid chromatography. Langford SA, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1615-23

BLOOD

Determination of p-aminobenzoic acid and its metabolites in rabbit plasma by high-performance liquid chromatography with fluorescence detection. Song DJ, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23;677(1):69-75

DIAGNOSTIC USE

[The ursodeoxycholic acid-p-aminobenzoic acid test in the diagnosis of small bowel bacterial overgrowth syndrome] Kiss Z, et al. **Orv Hetil** 1997 May 18;138(20):1255-8 (Eng. Abstr.) **(Hun)**

METABOLISM

Aminobenzoic acid compounds as HOCl traps for activated neutrophils. She ZW, et al. **Free Radic Biol Med** 1997; 22(6):989-98

In vitro human skin barrier modulation by fatty acids: skin permeation and thermal analysis studies. Tanojo H, et al. **Pharm Res** 1997 Jan;14(1):42-9

Evidence for arylamine N-acetyltransferase activity in the bacterium Helicobacter pylori. Chung JG, et al. **Toxicol Lett** 1997 Mar 14;91(1):63-71

PHARMACOLOGY

UVA-potentiated damage to calf thymus DNA by Fenton reaction system and protection by para-aminobenzoic acid. Shih MK, et al. **Photochem Photobiol** 1996 Mar; 63(3):286-91

p-Aminobenzoic acid, but not its metabolite p-acetamidobenzoic acid, inhibits thrombin induced thromboxane formation in human platelets in a non NSAID like manner. Barbieri B, et al. **Thromb Res** 1997 Apr 15; 86(2):127-40

[Para=aminobenzoic acid as a stimulator of angiogenesis] Akberova SI, et al. **Biull Eksp Biol Med** 1996 Nov; 122(11):499-501 **(Rus)**

THERAPEUTIC USE

Linear atrophoderma of Moulin: treatment with Potaba. Artola Igarza JL, et al. **Dermatology** 1996;193(4):345-7 (7 ref.)

[Comparative evaluation of the anti-arrhythmia effect of KLN-93, dicaine, and lidocaine during neurogenic atrial fibrillation] Leonidov NB, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):77-80 **(Rus)**

[Para-aminobenzoic acid in therapy of experimental keratitis caused by herpes simplex virus in rabbits: the therapeutic effect and decrease of infectious titer] Akberova SI, et al. **Vestn Oftalmol** 1996 Sep-Oct;112(4):23-6 (Eng. Abstr.) **(Rus)**

URINE

The ursodeoxycholic acid-p-aminobenzoic acid deconjugation test, a new tool for the diagnosis of bacterial overgrowth syndrome. Kiss ZF, et al. **Eur J Gastroenterol Hepatol** 1997 Jul;9(7):679-82

P-AMINOBENZOIC ACID see **4-AMINOBENZOIC ACID**

AMINOBENZOIC ACIDS

CHEMICAL SYNTHESIS

Combinatorial synthesis of small-molecule libraries using 3-amino-5-hydroxybenzoic acid. Dankwardt SM, et al. **Mol Divers** 1996 Feb;1(2):113-20

CHEMISTRY

Combinatorial synthesis of small-molecule libraries using 3-amino-5-hydroxybenzoic acid. Dankwardt SM, et al. **Mol Divers** 1996 Feb;1(2):113-20

METABOLISM

[3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. Bonhaus DW, et al. **Neuropharmacology** 1997 Apr-May;36(4-5):671-9

PHARMACOKINETICS

Correlation between percutaneous rates of p-aminobenzoates and their molecular structure parameters. Fu XC, et al. **Pharmazie** 1997 Aug;52(8):646-7

PHARMACOLOGY

Quinoxaline chemistry. Part 7. 2-[aminobenzoates]- and 2-[aminobenzoylglutamate]-quinoxalines as classical antifolate agents. Synthesis and evaluation of in vitro anticancer, anti-HIV and antifungal activity. Loriga M, et al. **Farmaco** 1997 Mar;52(3):157-66

The effects of systemic procaine, lidocaine and dimethocaine on nociception in mice. Rigon AR, et al. **Gen Pharmacol** 1996 Jun;27(4):647-50

Differential class III antiarrhythmic effects of ambasilide and dofetilide at different extracellular potassium and pacing frequencies. Gjini V, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):314-20

Stimulant activities of dimethocaine in mice: reinforcing and anxiogenic effects. Rigon AR, et al. **Psychopharmacology (Berl)** 1996 Oct;127(4):323-7

O-AMINOBENZOIC ACIDS see **ANTHRANILIC ACIDS**

AMINOBIPHENYL COMPOUNDS

ANALYSIS

Immunohistochemical analysis of 4-aminobiphenyl-DNA adducts in oral mucosal cells of smokers and nonsmokers. Romano G, et al. **Anticancer Res** 1997 Jul-Aug; 17(4A):2827-30

Immunoperoxidase quantitation of 4-aminobiphenyl- and polycyclic aromatic hydrocarbon-DNA adducts in exfoliated oral and urothelial cells of smokers and nonsmokers. Hsu TM, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Mar;6(3):193-9

Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Landi MT, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Sep;5(9):693-8

METABOLISM

Co-oxidative metabolism of 4-aminobiphenyl by lipoxygenase from soybean and human term placenta. Datta K, et al. **Drug Metab Dispos** 1997 Feb;25(2):196-205

Plant-activation of the bicyclic aromatic amines benzidine and 4-aminobiphenyl. Ju YH, et al.

Environ Mol Mutagen 1997;29(1):81–90

Immunochemical, 32P-postlabeling, and GC/MS detection of 4-aminobiphenyl-DNA adducts in human peripheral lung in relation to metabolic activation pathways involving pulmonary N-oxidation, conjugation, and peroxidation. Culp SJ, et al. **Mutat Res** 1997 Aug 1;378(1–2):97–112

Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens. Fretland AJ, et al. **Toxicol Appl Pharmacol** 1997 Feb;142(2):360–6

PHARMACOLOGY

Decrease of prostaglandin E2 and 5-bromo-2'-deoxyuridine labeling but not prostate tumor development by indomethacin treatment of rats given 3,2'-dimethyl-4-aminobiphenyl and testosterone propionate. Kawabe M, et al. **Jpn J Cancer Res** 1997 Apr; 88(4):350–5

TOXICITY

Plant-activation of the bicyclic aromatic amines benzidine and 4-aminobiphenyl. Ju YH, et al. **Environ Mol Mutagen** 1997;29(1):81–90

Establishment and characterization of three androgen-independent, metastatic carcinoma cell lines from 3,2'-dimethyl-4-aminobiphenyl-induced prostatic tumors in F344 rats. Nakanishi H, et al. **Jpn J Cancer Res** 1996 Dec;87(12):1218–26

3,2'-Dimethyl-4-aminobiphenyl-DNA adduct formation in tumor target and nontarget organs of rapid and slow acetylator Syrian hamsters cogenic at the NAT2 locus. Feng Y, et al. **Toxicol Appl Pharmacol** 1996 Oct; 140(2):315–21

Chronic, topical administration of 4-aminobiphenyl induces tissue-specific DNA adducts in mice. Underwood PM, et al. **Toxicol Appl Pharmacol** 1997 Jun;144(2):325–31

AMINOBUTYRATE AMINOTRANSFERASE

ANTAGONISTS & INHIBITORS

EEG changes induced by vigabatrin monotherapy in focal epilepsy. Marciani MG, et al. **Acta Neurol Scand** 1997 Feb; 95(2):115–20

Effects of chronic oral treatment with GABA-transaminase inhibitors on the GABA system in brain, liver, kidney, and plasma of the rat. Qume M, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1355–63

Mechanism-based inactivation of gamma-aminobutyric acid aminotransferase by 3-amino-4-fluorobutanoic acid. Silverman RB, et al. **Bioorg Med Chem** 1996 Sep; 4(9):1521–35

Severe persistent visual field constriction associated with vigabatrin [see comments] Eke T, et al. **BMJ** 1997 Jan 18; 314(7075):180–1. Comment in: BMJ 1997 Jun 7;314(7095):1693. Comment in: BMJ 1997 Jun 7;314(7095):1693–4. Comment in: BMJ 1997 Jun 7;314(7095):1694. Comment in: BMJ 1997 Jun 7;314(7095):1694–5.

Low-dose vigabatrin (gamma-vinyl GABA)-induced damage in the immature rat brain. Sidhu RS, et al. **Exp Neurol** 1997 Apr;144(2):400–5

Vigabatrin in partial seizures in children. Nabbout RC, et al. **J Child Neurol** 1997 Apr;12(3):172–7

Inhibition of gamma-aminobutyric acid aminotransferase from rat brain mitochondria by chloride and acetate. Kraus P, et al. **J Enzyme Inhib** 1996;10(2):125–33

Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA). Matern D, et al. **J Inherit Metab Dis** 1996;19(3):313–8

Interactions between dopamine and GABA in the control of ambulatory activity. Agmo A, et al. **J Neural Transm** 1996;103(8–9):925–34

Metabolic precursors and compartmentation of cerebral GABA in vigabatrin-treated rats. Preece NE, et al. **J Neurochem** 1996 Oct;67(4):1718–25

The rate of turnover of cortical GABA from [1-13C]glucose is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA). Manor D, et al. **Neurochem Res** 1996 Sep;21(9):1031–41

The neuroprotective effects of gamma-vinyl GABA in transient global ischemia: a morphological study with early and delayed evaluations. Shuaib A, et al. **Neurosci Lett** 1996 Feb 2;204(1–2):1–4

CEREBROSPINAL FLUID

Levels of glutamic acid decarboxylase (GAD), gamma amino butyric acid transaminase (GABA-T), glutamic acid dehydrogenase (GLDH) and proteins in cerebrospinal fluid of certain neurological disorders. Far SR, et al. **Indian J Med Sci** 1996 Apr;50(4):99–102

GENETICS

Recombinant brain 4-aminobutyrate aminotransferases overexpression, purification, and identification of Lys-330 at the active site. Kim YT, et al. **Biochim Biophys Acta** 1997 Feb 8;1337(2):248–56

IMMUNOLOGY

Human brain GABA transaminase is immunologically distinct from those of other mammalian brains. Choi EY, et al. **Neurochem Int** 1996 May-Jun;28(5–6):597–600

ISOLATION & PURIFICATION

Recombinant brain 4-aminobutyrate aminotransferases overexpression, purification, and identification of Lys-330 at the active site. Kim YT, et al. **Biochim Biophys Acta** 1997 Feb 8;1337(2):248–56

METABOLISM

Ontogeny of GABA pathway in human fetal brains. Das SK, et al. **Biochem Biophys Res Commun** 1996 Nov 12; 228(2):544–8

Neurochemical actions of vigabatrin and tiagabine alone and in combination in mouse cortex. Leach JP, et al. **Gen Pharmacol** 1997 May;28(5):715–9

PHYSIOLOGY

Basic aspects of GABA-transmission in alcoholism, with particular reference to GABA-transaminase. Sherif FM, et al. **Eur Neuropsychopharmacol** 1997 Feb;7(1):1–7 (61 ref.)

4-AMINOBUTYRIC ACID see **GABA**

AMINOBUTYRIC ACIDS

see related

RECEPTORS, GABA-A

Structural versatility of peptides from C alpha, alpha-disubstituted glycines: crystal-state conformational analysis of peptides from C alpha-methylhomophenylalanine, (alpha Me) Hph. Doi M, et al. **Int J Pept Protein Res** 1996 Jun;47(6):491–7

ANALYSIS

Leucobacter komagatae gen. nov., sp. nov., a new aerobic gram-positive, nonsporulating rod with 2,4-diaminobutyric acid in the cell wall. Takeuchi M, et al. **Int J Syst Bacteriol** 1996 Oct;46(4):967–71

CHEMICAL SYNTHESIS

N-acyl-(alpha, gamma diaminobutyric acid)n hydrazide as an efficient gene transfer vector in mammalian cells in culture. Legendre JY, et al. **Pharm Res** 1997 May; 14(5):619–24

CHEMISTRY

Structure-activity studies of L-canaline-mediated inhibition of porcine alanine aminotransferase. Worthen DR, et al. **Chem Res Toxicol** 1996 Dec;9(8):1293–7

Human ornithine aminotransferase complexed with L-canaline and gabaculine: structural basis for substrate recognition. Shah SA, et al. **Structure** 1997 Aug 15; 5(8):1067–75

DIAGNOSTIC USE

Feasibility of labeled alpha-acetamido-aminoisobutyric acid as new tracer compound for kinetic labeling of neutral amino acid transport: preparation of alpha-(N-[1-11C]acetyl)- and alpha-(N-[1-14C]acetyl)-aminoisobutyric acid. Prenant C, et al. **Nucl Med Biol** 1996 Apr;23(3):359–63

METABOLISM

Stereospecific production of the herbicide phosphinothricin (glufosinate): purification of aspartate transaminase from Bacillus stearothermophilus, cloning of the corresponding gene, aspC, and application in a coupled transaminase process. Bartsch K, et al. **Appl Environ Microbiol** 1996 Oct; 62(10):3794–9

PHARMACOKINETICS

Phenylglycines can evoke quisqualate-primed depolarizations in rat cingulate cortex: an effect associated with [3H]DL-AP4 uptake. Sheardown MJ, et al. **Eur J Neurosci** 1996 Dec;8(12):2599–604

Pharmacokinetics of intravenous and oral prethcamide in horses. Sams RA, et al. **J Pharm Biomed Anal** 1997 Feb; 15(5):639–51

Activity-dependent transport of GABA analogues into specific cell types demonstrated at high resolution using a novel immunocytochemical strategy. Pow DV, et al. **Neuroscience** 1996 Aug;73(4):1129–43

PHARMACOLOGY

L-AP4 (L-(+)-2-amino-4-phosphonobutyric acid) induced impairment of spatial learning in the rat is antagonized by MAP4 ((S)-2-amino-2-methyl-4-phosphonobutanoic acid). Hölscher C, et al. **Behav Brain Res** 1996 Nov; 81(1–2):69–79

Actions of the anticonvulsant agent 2-amino-4-phosphonobutyrate on the release of [3H]D-aspartate from rat forebrain slices. Sundaralingam J, et al. **Biochem Soc Trans** 1996 May;24(2):294S

Mechanism-based inactivation of gamma-aminobutyric acid aminotransferase by 3-amino-4-fluorobutanoic acid. Silverman RB, et al. **Bioorg Med Chem** 1996 Sep; 4(9):1521–35

Structure-activity studies of L-canaline-mediated inhibition of porcine alanine aminotransferase. Worthen DR, et al. **Chem Res Toxicol** 1996 Dec;9(8):1293–7

Decrease in [Ca2+]c but not in cAMP Mediates L-AP4 inhibition of glutamate release: PKC-mediated suppression of this inhibitory pathway. Herrero I, et al. **Eur J Neurosci** 1996 Apr;8(4):700–9

Pharmacology of the skate electroretinogram indicates independent ON and OFF bipolar cell pathways. Chappell RL, et al. **J Gen Physiol** 1996 Apr;107(4):535–44

Changes in eye growth produced by drugs which affect retinal ON or OFF responses to light. Crewther DP, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):193–208

L-canaline: a potent antimetabolite and anti-cancer agent from leguminous plants. Rosenthal GA. **Life Sci** 1997; 60(19):1635–41 (40 ref.)

Potent antagonists at the L-AP4- and (1S,3S)-ACPD-sensitive presynaptic metabotropic glutamate receptors in the neonatal rat spinal cord. Jane DE, et al. **Neuropharmacology** 1996;35(8):1029–35

Antagonism of the presumed presynaptic action of L-AP4 on GABAergic transmission in the ventrobasal thalamus by the novel mGluR antagonist MPPG. Salt TE, et al. **Neuropharmacology** 1996 Feb;35(2):239–41

Two phenylglycine derivatives antagonize responses to L-AP4 in ON bipolar cells of the amphibian retina. Thoreson WB, et al. **Neuropharmacology** 1997 Jan; 36(1):13–20

Inhibition of AMPA receptor-stimulated 57Co2+ influx by D- and L-2-amino-4-phosphonobutanoic acid (D- and L-AP4) and L-serine-O-phosphate (L-SOP) in cultured cerebellar granule cells. Toms NJ, et al. **Neuropharmacology** 1997 Mar;36(3):335–43

The metabotropic glutamate agonist 2-amino-4-phosphonobutyric acid (APB) does not activate currents in postnatal retinal ganglion cells. Liets LC, et al. **Neuroreport** 1996 Nov 25;7(18):2873–7

L-AP4 inhibits high voltage-activated Ca2+ currents in pyramidal cortical neurones. Stefani A, et al. **Neuroreport** 1996 Jan 31;7(2):421–4

L-AP4 inhibition of depolarization-evoked cGMP formation in rat cerebellum. Cartmell J, et al. **Neurosci Lett** 1997 Jun 13;228(3):191–4

Apoptosis induced by glufosinate ammonium in the neuroepithelium of developing mouse embryos in culture. Watanabe T. **Neurosci Lett** 1997 Jan 24;222(1):17–20

Nitric oxide, 2-amino-4-phosphonobutyric acid and light/dark adaptation modulate short-wavelength-sensitive synaptic transmission to retinal horizontal cells. Furukawa T, et al. **Neurosci Res** 1997 Jan;27(1):65–74

Psychotropic activity of N-methyl-2-amino-4-phosphonobutyric acid (N-methyl AP4). Zalewska A, et al. **Pol J Pharmacol** 1996 Jul-Aug; 48(4):415–23

POISONING

Hemodialysis and hemoperfusion in the successful treatment of a poisoning with a herbicide containing glufosinate ammonium and a surfactant [letter] Shinohara M, et al. **Clin Nephrol** 1997 Jul;48(1):61

THERAPEUTIC USE

Anti-epileptogenic and anticonvulsant activity of L-2-amino-4-phosphonobutyrate, a presynaptic glutamate receptor agonist. Abdul-Ghani AS, et al. **Brain Res** 1997 May 2;755(2):202–12

TOXICITY

Developmental and dysmorphogenic effects of glufosinate ammonium on mouse embryos in culture. Watanabe T, et al. **Teratog Carcinog Mutagen** 1996;16(6):287–99

Cardiovascular effects of a herbicide containing glufosinate and a surfactant: in vitro and in vivo analyses in rats. Koyama K, et al. **Toxicol Appl Pharmacol** 1997 Aug; 145(2):409–14

6-AMINOCAPROIC ACID

ADMINISTRATION & DOSAGE

Topical aminocaproic acid in the treatment of traumatic hyphema [see comments] Crouch ER Jr, et al. **Arch Ophthalmol** 1997 Sep;115(9):1106–12. Comment in: Arch Ophthalmol 1997 Sep;115(9):1189–90.

The treatment of traumatic hyphema with topical epsilon-aminocaproic acid [editorial; comment] Goldberg MF. **Arch Ophthalmol** 1997 Sep;115(9):1189–90. Comment on: Arch Ophthalmol 1997 Sep;115(9):1106–12.

The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations [letter] Landymore RW, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):798–800

ADVERSE EFFECTS

Rhabdomyolysis induced by epsilon-aminocaproic acid. Seymour BD, et al. **Ann Pharmacother** 1997 Jan;31(1):56–8

6-AMINOCAPROIC ACID

Intravascular thrombosis after exsanguination in a patient treated with epsilon-aminocaproic acid. Haddy SM, et al. **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):510-2

ANALOGS & DERIVATIVES

Zinc uptake in five sectors of the rat gastrointestinal tract: kinetic study in the whole colon. Gisbert-González SL, et al. **Pharm Res** 1996 Aug;13(8):1154-61

Antifibrinolytic activity of epsilon-aminocaproyl derivatives of amino acids. Midura-Nowaczek K, et al. **Pharmazie** 1996 Oct;51(10):775-7

[A multicenter clinical trial. Zinc acexamate versus famotidine in the treatment of acute duodenal ulcer. Study Group of Zinc acexamate (new UP doses)] García-Plaza A, et al. **Rev Esp Enferm Dig** 1996 Nov;88(11):757-62 (Eng. Abstr.) **(Spa)**

BLOOD

epsilon-Aminocaproic acid plasma levels during cardiopulmonary bypass. Bennett-Guerrero E, et al. **Anesth Analg** 1997 Aug;85(2):248-51

PHARMACOLOGY

Differing effects of aprotinin and epsilon-aminocaproic acid on cytokine-induced inducible nitric oxide synthase expression. Hill GE, et al. **Ann Thorac Surg** 1997 Jan; 63(1):74-7

Study of post-natal effect of chemopreventive agents on ethylnitrosourea-induced transplacental carcinogenesis in rats. III. Inhibitory action of indomethacin, voltaren, theophylline and epsilon-aminocaproic acid. Alexandrov VA, et al. **Carcinogenesis** 1996 Sep;17(9):1935-9

[The effect of epsilon-aminocaproic acid and prednisolone on the activation of the complement system due to x-ray contrast agents in rats in vitro] Napolov IuK. **Eksp Klin Farmakol** 1997 Mar-Apr;60(2):62-4 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Aminocaproic acid used to control upper gastrointestinal bleeding in radiation gastritis. Grover N, et al. **Dig Dis Sci** 1997 May;42(5):982-4

Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy [see comments] Leipzig TJ, et al. **J Neurosurg** 1997 Feb; 86(2):220-5. Comment in: J Neurosurg 1997 Sep;87(3):486-7.

Antifibrinolytic therapy [letter; comment] Schisano G, et al. **J Neurosurg** 1997 Sep;87(3):486-7. Comment on: J Neurosurg 1997 Feb;86(2):220-5.

Use of epsilon-aminocaproic acid to reduce bleeding [letter; comment] Lemmer JH Jr. **J Thorac Cardiovasc Surg** 1997 Jun;113(6):1125-7. Comment on: J Thorac Cardiovasc Surg 1996 Oct;112(4):1098-107.

Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid [see comments] Vander Salm TJ, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):1098-107. Comment in: J Thorac Cardiovasc Surg 1997 Jun;113(6):1125-7.

Long-term treatment of C1 inhibitor deficiency with epsilon-aminocaproic acid in two patients. Van Dellen RG. **Mayo Clin Proc** 1996 Dec;71(12):1175-8

Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Teboul BK, et al. **Ophthalmology** 1995 Nov;102(11):1646-53

Hemophilia and EACA [letter] Radivoyevitch MA. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Aug;82(2):118

The effect of low-dose epsilon-aminocaproic acid on patients following coronary artery bypass surgery. Montesano RM, et al. **Perfusion** 1996 Jan;11(1):53-6

[Favorable effects of epsilon-aminocaproic acid on the children with nephrotic syndrome and Schonlein-Henoch syndrome treated with corticosteroids] Prandota J, et al. **Pol Merkuriusz Lek** 1996 Oct;1(4):241-5 (Eng. Abstr.) **(Pol)**

AMINOCAPROIC ACIDS

CHEMICAL SYNTHESIS

Synthesis and activity of N alpha-(epsilon-aminocaproyl)-alanines and N epsilon-(epsilon-aminocaproyl)-caproic acid. Midura-Nowaczek K, et al. **Acta Pol Pharm** 1995 Nov-Dec;52(6):505-7

CHEMISTRY

[Synthesis and properties of antifibrinolytic dipeptides containing E-aminocaproic acid] Midura-Nowaczek K, et al. **Acta Pol Pharm** 1992;49(1-2):89-92 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Synthesis and activity of N alpha-(epsilon-aminocaproyl)-alanines and N epsilon-(epsilon-aminocaproyl)-caproic acid. Midura-Nowaczek K, et al. **Acta Pol Pharm** 1995 Nov-Dec;52(6):505-7

AMINOCAPROIC LACTAM see **CAPROLACTAM**

1-AMINOCYCLOPENTANECARBOXYLIC ACID see **CYCLOLEUCINE**

AMINOETHANOLS see **ETHANOLAMINES**

2-AMINOETHYLISOTHIURONIUM BROMIDE see **AET**

AMINOETHYLPHOSPHONIC ACID

ANALOGS & DERIVATIVES

2-aminoethylphosphonic acid: biodistribution of a naturally occurring phosphonate after labelling with technetium-99m. Castronovo FP, et al. **Nucl Med Commun** 1996 Oct;17(10):902-6

CHEMISTRY

Structure of the O-specific polysaccharide of Hafnia alvei PCM 1222 containing 2-aminoethyl phosphate. Toukach FV, et al. **Carbohydr Res** 1996 Dec 13;295:117-26

PHARMACOKINETICS

2-aminoethylphosphonic acid: biodistribution of a naturally occurring phosphonate after labelling with technetium-99m. Castronovo FP, et al. **Nucl Med Commun** 1996 Oct;17(10):902-6

2-AMINOETHYLPHOSPHONIC ACID see **AMINOETHYLPHOSPHONIC ACID**

AMINOFORM see **METHENAMINE**

AMINOGLUTETHIMIDE

ADMINISTRATION & DOSAGE

Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. Figg WD, et al. **Acta Oncol** 1996; 35(6):763-5

CHEMICAL SYNTHESIS

Synthesis and biological evaluation of 3-(prop-2-enyl)- and 3-(prop-2-ynyl)pyrrolidine-2,5-dione derivatives as potential aromatase inhibitors. Barrell KJ, et al. **J Pharm Pharmacol** 1996 Feb;48(2):154-9

PHARMACOLOGY

Effects of corticosteroid synthesis inhibitors on the sensitization of reward by food restriction. Abrahamsen GC, et al. **Brain Res** 1996 Jul 8;726(1-2):39-48

THERAPEUTIC USE

Second-line endocrine treatment of advanced breast cancer--a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide. Hultborn R, et al. **Acta Oncol** 1996;35 Suppl 5:75

Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: a case report. Chouinard G, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Aug; 20(6):1067-79

AMINOGLYCOSIDE ANTIBIOTICS see **ANTIBIOTICS, AMINOGLYCOSIDE**

AMINOGLYCOSIDES

ADMINISTRATION & DOSAGE

Successful medical treatment of multiple Serratia marcescens brain abscesses in a neonate [letter] Kimpen JL, et al. **Eur J Pediatr** 1996 Oct;155(10):916

Combination intravenous ceftazidime and aminoglycosides in the treatment of pseudomonal scleritis. Hehm CJ, et al. **Ophthalmology** 1997 May;104(5):838-43 (30 ref.)

ADVERSE EFFECTS

Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. Hamasaki K, et al. **Biochemistry** 1997 Oct 7;36(40):12323-8

Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation. Usami S, et al. **Laryngoscope** 1997 Apr;107(4):483-90

Aminoglycoside nephrotoxicity. Swan SK. **Semin Nephrol** 1997 Jan;17(1):27-33 (83 ref.)

CHEMISTRY

Structure-based discovery of ligands targeted to the RNA double helix. Chen Q, et al. **Biochemistry** 1997 Sep 23; 36(38):11402-7

METABOLISM

Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. Hamasaki K, et al. **Biochemistry** 1997 Oct 7;36(40):12323-8

Characterization of gentamicin 2'-N-acetyltransferase from Providencia stuartii: its use of peptidoglycan metabolites for acetylation of both aminoglycosides and peptidoglycan. Payie KG, et al. **J Bacteriol** 1997 Jul;179(13):4106-14

RNA sequence determinants for aminoglycoside binding to an A-site rRNA model oligonucleotide. Recht MI, et al. **J Mol Biol** 1996 Oct 4;262(4):421-36

PHARMACOKINETICS

General versus subpopulation values in Bayesian prediction of aminoglycoside pharmacokinetics in hematology-oncology patients. Radomski KM, et al. **Am J Health Syst Pharm** 1997 Mar 1;54(5):541-4

PHARMACOLOGY

The alteration of ultrastructure and immunoreactivity of human embryonic organ of Corti tissue culture after exposure to aminoglycoside (neomycin) ototoxicity. Mu MY, et al. **Acta Otolaryngol (Stockh)** 1996 Nov; 116(6):799-804

Cellular mechanism of aminoglycoside tolerance in long-term gentamicin treatment. Sundin DP, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1309-18

pH modulation of aminoglycoside resistance in Staphylococcus epidermidis harbouring 6'-N-aminoglycoside acetyltransferase. Culebras E, et al. **J Antimicrob Chemother** 1996 May;37(5):881-9

The effect of rifampicin on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Xiong YQ, et al. **J Antimicrob Chemother** 1996 May;37(5):993-8

Characterization of a Staphylococcus aureus transposon, Tn5405, located within Tn5404 and carrying the aminoglycoside resistance genes, aphA-3 and aadE. Derbise A, et al. **Plasmid** 1996 May;35(3):174-88

6-AMINOHEXANOIC ACID see **6-AMINOCAPROIC ACID**

4-AMINOHIPPURIC ACID see **P-AMINOHIPPURIC ACID**

P-AMINOHIPPURIC ACID

ANALYSIS

A new method of measuring renal function in conscious rats without the use of radioisotopes. Gabel RA, et al. **J Pharmacol Toxicol Methods** 1996 Dec;36(4):189-97

Urinary 1-naphthol excretion in the assessment of exposure to creosote in an impregnation facility. Heikkilä PR, et al. **Scand J Work Environ Health** 1997 Jun;23(3):199-205

CHEMISTRY

Mobilization of PAH and PCB from contaminated soil using a digestive tract model. Hack A, et al. **Toxicol Lett** 1996 Nov;88(1-3):199-210

METABOLISM

Indirect coupling of urate and p-aminohippurate transport to sodium in human brush-border membrane vesicles. Roch-Ramel F, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):F61-8

Effect of renal ischemia on organic anion and cation transport in rabbit proximal tubule. Kim YK, et al. **Kidney Blood Press Res** 1996;19(6):332-9

Luminal transport step of para-aminohippurate (PAH): transport from PAH-loaded proximal tubular cells into the tubular lumen of the rat kidney in vivo. Ullrich KJ, et al. **Pflugers Arch** 1997 Apr;433(6):735-43

PHARMACOKINETICS

Effect of alpha-KG in lumen on PAH transport by isolated perfused rabbit renal proximal tubules. Dantzler WH, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F521-6

Regulation of p-aminohippurate transport by protein kinase C in OK kidney epithelial cells. Takano M, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F469-75

Effects of extracorporeal shock wave lithotripsy to one kidney on bilateral glomerular filtration rate and PAH clearance in minipigs. Willis LR, et al. **J Urol** 1996 Oct; 156(4):1502-6

Tubular PAH transport capacity in human kidney tissue and in renal cell carcinoma: correlation with various clinical and morphological parameters of the tumor. Fleck C, et al. **Urol Res** 1997;25(3):167-71

PHARMACOLOGY

Effect of para-aminohippurate on the efflux of valproic acid from the central nervous system of the rabbit. Adkison KD, et al. **Epilepsy Res** 1996 Mar;23(2):95-104

TOXICITY

Induction effects of polychlorinated biphenyls, polycyclic aromatic hydrocarbons and other widespread aromatic environmental pollutants on microsomal monooxygenase activities in chick embryo liver. Machala M, et al. **Arch Toxicol** 1996;70(6):362-7

The carcinogenic potency of carbon particles with and

without PAH after repeated intratracheal administration in the rat. Dasenbrock C, et al. **Toxicol Lett** 1996 Nov; 88(1-3):15-21

URINE

Determination of urinary metabolites of polycyclic aromatic hydrocarbons (PAH) for the risk assessment of PAH-exposed workers. Grimmer G, et al. **Int Arch Occup Environ Health** 1997;69(4):231-9

AMINOHIPPURIC ACIDS

ADMINISTRATION & DOSAGE

Assessment of the accuracy of quantitative urine collection in mink (Mustela vison) using osmotic pumps for continuous release of p-amino-hippuric acid and inulin. Wamberg S, et al. **Lab Anim** 1996 Jul;30(3):267-72

AMINOHYDROLASES

ANALYSIS

Activity of 5-formyl tetrahydrofolate cyclodehydrase and 5,10-methenyl tetrahydrofolate cyclohydrolase in primary brain tumors in children. Tzortzatou-Stathopoulou F, et al. **Pediatr Hematol Oncol** 1996 Nov-Dec;13(6):511-9

CHEMISTRY

Crystallization of the bifunctional methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase domain of the human trifunctional enzyme. Allaire M, et al. **Proteins** 1996 Dec;26(4):479-80

Purification, crystallization, and preliminary x-ray studies of a bifunctional 5,10-methenyl/methylene-tetrahydrofolate cyclohydrolase/dehydrogenase from Escherichia coli. Cheung E, et al. **Proteins** 1997 Feb;27(2):322-4

GENETICS

Site-directed mutagenesis of a highly conserved aspartate in the putative 10-formyl-tetrahydrofolate binding site of yeast C1-tetrahydrofolate synthase. Kirksey TJ, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):251-9

Acetylpolyamine amidohydrolase from Mycoplana ramosa: gene cloning and characterization of the metal-substituted enzyme. Sakurada K, et al. **J Bacteriol** 1996 Oct; 178(19):5781-6

Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily. Leipe DD, et al. **Nucleic Acids Res** 1997 Sep 15;25(18):3693-7

Transcriptional regulation of the Rhodococcus rhodochrous J1 nitA gene encoding a nitrilase. Komeda H, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10572-7

ISOLATION & PURIFICATION

Purification of folate-dependent enzymes from rabbit liver. Schirch V. **Methods Enzymol** 1997;281:146-61

METABOLISM

Site-directed mutagenesis of a highly conserved aspartate in the putative 10-formyl-tetrahydrofolate binding site of yeast C1-tetrahydrofolate synthase. Kirksey TJ, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):251-9

Mitochondrial NAD-dependent methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase. MacKenzie RE. **Methods Enzymol** 1997;281:171-7

13C nuclear magnetic resonance detection of interactions of serine hydroxymethyltransferase with C1-tetrahydrofolate synthase and glycine decarboxylase complex activities in Arabidopsis. Prabhu V, et al. **Plant Physiol** 1996 Sep; 112(1):207-16

AMINOIMIDAZOLE CARBOXAMIDE

ANALOGS & DERIVATIVES

Substrate cycling between 5-amino-4-imidazolecarboxamide riboside and its monophosphate in isolated rat hepatocytes. Vincent MF, et al. **Biochem Pharmacol** 1996 Oct 11; 52(7):999-1006

Hypoglycaemic effect of AICAriboside in mice. Vincent MF, et al. **Diabetologia** 1996 Oct;39(10):1148-55

Cardioprotection with a novel adenosine regulating agent mediated by intravascular adenosine. Kurz MA, et al. **Eur J Pharmacol** 1997 Mar 19;322(2-3):211-20

Potentiation of excitatory amino acid-evoked adenosine release from rat cortex by inhibitors of adenosine kinase and adenosine deaminase and by acadesine. White TD. **Eur J Pharmacol** 1996 May 6;303(1-2):27-38

Occurrence and biosynthesis of 5-aminoimidazole-4-carboxamide ribonucleotide and N-(beta-D-ribofuranosyl)formamide 5'-phosphate in Methanobacterium thermoautotrophicum delta(H). White RH. **J Bacteriol** 1997 Jan;179(2):563-6

Spectrophotometric determination of the cardioprotective drug GP531 in human plasma. Grettenberger HM, et al. **J Biochem Biophys Methods** 1996 Oct 15;33(1):25-30

A sensitive assay for the aminoimidazole-containing drug GP531 in plasma using liquid chromatography with amperometric electrochemical detection: a new class of electroactive compounds. Chen LS, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1535-8

Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Mangano DT. **JAMA** 1997 Jan 22-29;277(4):325-32

Genetic evidence for 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) as a negative effector of cytochrome terminal oxidase cbb3 production in Rhizobium etli. Soberón M, et al. **Mol Gen Genet** 1997 May;254(6):665-73

The synthesis and stability of oligodeoxyribonucleotides containing the deoxyadenosine mimic 1-(2'-deoxy-beta-D-ribofuranosyl)imidazole-4-carboxamide. Johnson WT, et al. **Nucleic Acids Res** 1997 Feb 1;25(3):559-67

AMINOISOBUTYRIC ACIDS

ANALYSIS

Aib-containing analogues of the insect kinin neuropeptide family demonstrate resistance to an insect angiotensin-converting enzyme and potent diuretic activity. Nachman RJ, et al. **Peptides** 1997;18(1):53-7

CHEMICAL SYNTHESIS

Synthesis of [11C-methyl]-alpha-aminoisobutyric acid (AIB). Schmall B, et al. **Nucl Med Biol** 1996 Apr; 23(3):263-6

CHEMISTRY

Helical preferences of alanine, glycine, and aminoisobutyric homopeptides. Alemán C, et al. **Proteins** 1997 May; 28(1):83-93

DIAGNOSTIC USE

System A amino acid transport in cultured human tumor cells: implications for tumor imaging with PET. Bading JR, et al. **Nucl Med Biol** 1996 Aug;23(6):779-86

IMMUNOLOGY

Improved detection of human antibodies to a Plasmodium antigen using a peptide modified with Aib residues. Bossus M, et al. **J Pept Sci** 1997 Jan-Feb;3(1):47-53

METABOLISM

Selective inhibition of oxalate-stimulated Ca2+ transport by cyclopiazonic acid and thapsigargin in smooth muscle microsomes. Darby PJ, et al. **Can J Physiol Pharmacol** 1996 Feb;74(2):182-92

Interactions between angiotensin II and adenosine 3':5'-cyclic monophosphate in the regulation of amino acid transport by vascular smooth muscle cells. McCumbee WD, et al. **Can J Physiol Pharmacol** 1996 Feb;74(2):173-81

Insulin signaling and its regulation of system A amino acid uptake in cultured rat vascular smooth muscle cells. Obata T, et al. **Circ Res** 1996 Dec;79(6):1167-76

rBAT is an amino acid exchanger with variable stoichiometry. Coady MJ, et al. **J Membr Biol** 1996 Jan; 149(1):1-8

Intracellular monosaccharide and amino acid concentrations and activities and the mechanisms of insulin action. Horowitz SB, et al. **Mol Cell Biol** 1981 Sep;1(9):769-84

PHARMACOKINETICS

Phenobarbital transiently stimulates uptake of 2-aminoisobutyric acid in hepatocytes. Leibold E, et al. **Arch Toxicol** 1996;70(6):368-72

Uptake and release of 2-aminoisobutyrate by Leishmania donovani: culture-age dependent effects of osmolality and of protein kinase inhibitors. Blum JJ. **Biol Cell** 1996; 87(1-2):75-82

Changes in transport of [14C] alpha-aminoisobutyric acid across the blood-brain barrier during pentylenetetrazol-induced status epilepticus in the immature rat. Padou V, et al. **Epilepsy Res** 1995 Nov; 22(3):175-83

Blood-endothelial cell and blood-brain transport of L-proline, alpha-aminoisobutyric acid, and L-alanine. Benrabh H, et al. **Neurochem Res** 1996 Oct;21(10):1227-35

PHARMACOLOGY

Induction of a glucose-dependent insulin secretory response by the nonmetabolizable amino acid alpha-aminoisobutyric acid. McClenaghan N, et al. **Pancreas** 1997 Jan;14(1):65-70

AMINOLEVULINATE HYDRO-LYASE see **AMINOLEVULINIC ACID DEHYDRATASE**

AMINOLEVULINIC ACID

ADMINISTRATION & DOSAGE

Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Jeffes EW, et al. **Arch Dermatol** 1997 Jun;133(6):727-32

Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism. Fritsch C, et al. **Arch Dermatol Res** 1996 Aug;288(9):517-21

Porphyrins preferentially accumulate in a melanoma following intravenous injection of 5-aminolevulinic acid. Fritsch C, et al. **Biol Chem** 1997 Jan;378(1):51-7

Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. Datta SN, et al. **Br J Cancer** 1997;76(3):312-7

Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. Rhodes LE, et al. **J Invest Dermatol** 1997 Jan; 108(1):87-91

Inhalation of 5-aminolevulinic acid: a new technique for fluorescence detection of early stage lung cancer. Baumgartner R, et al. **J Photochem Photobiol B** 1996 Nov; 36(2):169-74

In vivo fluorescence kinetics of porphyrins following intravesical instillation of 5-aminolaevulinic acid in normal and tumour-bearing rat bladders. Heil P, et al. **J Photochem Photobiol B** 1997 Apr;38(2-3):158-63

Effect of 5-aminolevulinic acid dose and estrogen on protoporphyrin IX concentrations in the rat uterus. Roy BN, et al. **J Soc Gynecol Investig** 1997 Jan-Feb;4(1):40-6

5-Aminolevulinic acid (ALA)-induced protoporphyrin IX fluorescence and photodynamic effects in the rat bladder: an in vivo study comparing oral and intravesical ALA administration. Chang SC, et al. **Lasers Surg Med** 1997; 20(3):254-64

Laser-induced fluorescence studies of normal and malignant tumour tissue of rat following intravenous injection of delta-amino levulinic acid. Johansson J, et al. **Lasers Surg Med** 1997;20(3):272-9

Accumulation of porphyrins in plasma and tissues of dogs after delta-aminolevulinic acid administration: implications for photodynamic therapy. Egger NG, et al. **Pharmacology** 1996 Jun;52(6):362-70

ADVERSE EFFECTS

Køebner reaction induced by photodynamic therapy using delta-aminolevulinic acid. A case report. Stender IM, et al. **Acta Derm Venereol** 1996 Sep;76(5):392-3

Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. Wolf P, et al. **Dermatology** 1997;194(1):53-4

Side effects and photosensitization of human tissues after aminolevulinic acid. Webber J, et al. **J Surg Res** 1997 Feb 15;68(1):31-7

ANALYSIS

Determination of 5-aminolevulinic acid in blood plasma, tissues and cell cultures by high-performance liquid chromatography with electrochemical detection. Costa CA, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1; 695(2):245-50

BLOOD

Aminolevulinic acid dehydratase genotype mediates plasma levels of the neurotoxin, 5-aminolevulinic acid, in lead-exposed workers. Sithisarankul P, et al. **Am J Ind Med** 1997 Jul;32(1):15-20

Correlation between plasma 5-aminolevulinic acid concentrations and indicators of oxidative stress in lead-exposed workers. Costa CA, et al. **Clin Chem** 1997 Jul;43(7):1196-202

Lead exposure in indoor firing ranges: environmental impact and health risk to the range users. Abudhaise BA, et al. **Int J Occup Med Environ Health** 1996;9(4):323-9

Fluorometric HPLC determination of delta-aminolevulinic acid (ALA) in the plasma and urine of lead workers: biological indicators of lead exposure. Oishi H, et al. **J Anal Toxicol** 1996 Mar-Apr;20(2):106-10

CHEMISTRY

Chemical instability of 5-aminolevulinic acid used in the fluorescence diagnosis of bladder tumours. Novo M, et al. **J Photochem Photobiol B** 1996 Jul;34(2-3):143-8

DIAGNOSTIC USE

Fluorescence imaging and spectroscopy of 5-aminolevulinic acid induced protoporphyrin IX for the detection of neoplastic lesions in the oral cavity. Leunig A, et al. **Am J Surg** 1996 Dec;172(6):674-7

In vivo fluorescence detection of ovarian cancer in the NuTu-19 epithelial ovarian cancer animal model using 5-aminolevulinic acid (ALA). Major AL, et al. **Gynecol Oncol** 1997 Jul;66(1):122-32

Chemical instability of 5-aminolevulinic acid used in the fluorescence diagnosis of bladder tumours. Novo M, et al. **J Photochem Photobiol B** 1996 Jul;34(2-3):143-8

Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Jichlinski P, et al. **Lasers Surg Med** 1997;20(4):402-8

[Experimental validation of laser light-induced fluorescence diagnosis (LIFD) of dysplasias and early carcinomas of the colon] Gahlen J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:141-4

AMINOLEVULINIC ACID

(Eng. Abstr.) (Ger)
[Photodynamic diagnosis of neoplasms of the mouth cavity after local administration of 5-aminolevulinic acid] Leunig A, et al. **Laryngorhinootologie** 1996 Aug;75(8):459–64 (Eng. Abstr.) (Ger)

METABOLISM

Selective photosensitizer localization in the human endometrium after intrauterine application of 5-aminolevulinic acid. Fehr MK, et al. **Am J Obstet Gynecol** 1996 Nov;175(5):1253–9

5-Aminolevulinate production by Escherichia coli containing the Rhodobacter sphaeroides hemA gene. van der Werf MJ, et al. **Appl Environ Microbiol** 1996 Oct;62(10):3560–6

Stimulation of tetrapyrrole synthesis in mammalian epithelial cells in culture by exposure to aminolaevulinic acid. Washbrook R, et al. **Br J Cancer** 1997;75(3):381–7

Oxidative stress in acute intermittent porphyria and lead poisoning may be triggered by 5-aminolevulinic acid. Bechara EJ. **Braz J Med Biol Res** 1996 Jul;29(7):841–51 (78 ref.)

Comparison between males and females with respect to the porphyrin metabolic disorders found in workers occupationally exposed to lead. Oishi H, et al. **Int Arch Occup Environ Health** 1996;68(5):298–304

Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients. Guolo M, et al. **Int J Biochem Cell Biol** 1996 Mar;28(3):311–7

Photobleaching of protoporphyrin IX in cells incubated with 5-aminolevulinic acid. Moan J, et al. **Int J Cancer** 1997 Jan 6;70(1):90–7

Identification of the lrp gene in Bradyrhizobium japonicum and its role in regulation of delta-aminolevulinic acid uptake. King ND, et al. **J Bacteriol** 1997 Mar; 179(5):1828–31

Role of the hemA gene product and delta-aminolevulinic acid in regulation of Escherichia coli heme synthesis. Verderber E, et al. **J Bacteriol** 1997 Jul;179(14):4583–90

Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. Peng Q, et al. **J Photochem Photobiol B** 1996 Jun;34(1):95–6

Time-dependent intracellular accumulation of delta-aminolevulinic acid, induction of porphyrin synthesis and subsequent phototoxicity. Gibson SL, et al. **Photochem Photobiol** 1997 Mar;65(3):416–21

PHARMACOKINETICS

delta-Aminolevulinic acid uptake is mediated by the gamma-aminobutyric acid-specific permease UGA4. Bermúdez Moretti M, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Jun;42(4):519–23

Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. Rhodes LE, et al. **J Invest Dermatol** 1997 Jan; 108(1):87–91

Pharmacokinetics of 5-aminolevulinic-acid-induced porphyrins in tumour-bearing mice. Sroka R, et al. **J Photochem Photobiol B** 1996 Jun;34(1):13–9

On-line fluorescence of human tissues after oral administration of 5-aminolevulinic acid. Webber J, et al. **J Photochem Photobiol B** 1997 Apr;38(2–3):209–14

Detection of early stages of carcinogenesis in adenomas of murine lung by 5-aminolevulinic acid-induced protoporphyrin IX fluorescence. Campbell DL, et al. **Photochem Photobiol** 1996 Oct;64(4):676–82

Subcellular localization of Photofrin and aminolevulinic acid and photodynamic cross-resistance in vitro in radiation-induced fibrosarcoma cells sensitive or resistant to photofrin-mediated photodynamic therapy. Wilson BC, et al. **Photochem Photobiol** 1997 Jan;65(1):166–76

PHARMACOLOGY

delta-Aminolevulinic acid-induced synaptosomal Ca2+ uptake and mitochondrial permeabilization. Penatti CA, et al. **Arch Biochem Biophys** 1996 Nov 1;335(1):53–60

Influence of a haematoporphyrin derivative on the protoporphyrin IX synthesis and photodynamic effect after 5-aminolaevulinic acid sensitization in human colon carcinoma cells. Messmann H, et al. **Br J Cancer** 1997; 76(7):878–83

Photodynamic therapy using intravenous delta-aminolaevulinic acid-induced protoporphyrin IX sensitisation in experimental hepatic tumours in rats. Svanberg K, et al. **Br J Cancer** 1996 Nov;74(10):1526–33

Comparison of delta-aminolaevulinic acid and its methyl ester as an inducer of porphyrin synthesis in cultured cells. Washbrook R, et al. **Br J Cancer** 1997;75(10):1417–20

Factors affecting aminolaevulinic acid-induced generation of protoporphyrin IX. Wyld L, et al. **Br J Cancer** 1997; 76(6):705–12

The pH dependency of protoporphyrin IX formation in cells incubated with 5-aminolevulinic acid. Bech O, et al. **Cancer Lett** 1997 Feb 26;113(1–2):25–9

Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues. Heyerdahl H, et al. **Cancer Lett** 1997 Jan 30; 112(2):225–31

Oxidative tissue response promoted by 5-aminolevulinic acid promptly induces the increase of plasma antioxidant capacity. Demasi M, et al. **Free Radic Res** 1997 Mar; 26(3):235–43

Control of the availability of exogenous 5-aminolevulinic acid in Escherichia coli. Nakayashiki T, et al. **Genes Genet Syst** 1996 Aug;71(4):237–41

Regeneration processes in rabbit endometrium: a photodynamic therapy model. Wyss P, et al. **Hum Reprod** 1996 Sep;11(9):1992–7

Release of aldehydic products from glutamate or deoxyuridine by delta-aminolevulinic acid in presence of copper ions. Singh V, et al. **Indian J Exp Biol** 1996 Mar; 34(3):208–10

Photobleaching during and re-appearance after photodynamic therapy of topical ALA-induced fluorescence in UVB-treated mouse skin. Van der Veen N, et al. **Int J Cancer** 1997 Jul 3;72(1):110–8

The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. Stringer MR, et al. **J Invest Dermatol** 1996 Jul;107(1):76–81

The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study. Chang SC, et al. **J Photochem Photobiol B** 1997 Apr; 38(2–3):114–22

H-dependent formation of 5-aminolaevulinic acid-induced protoporphyrin IX in fibrosarcoma cells. Fuchs C, et al. **J Photochem Photobiol B** 1997 Aug;40(1):49–54

The importance of fluorescence distribution and kinetics of ALA-induced PpIX in the bladder in photodynamic therapy. Grönlund-Pakkanen S, et al. **J Photochem Photobiol B** 1997 Apr;38(2–3):269–73

In-vitro investigation of ALA-induced protoporphyrin IX. Krammer B, et al. **J Photochem Photobiol B** 1996 Nov; 36(2):121–6

Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid. Webber J, et al. **J Photochem Photobiol B** 1997 Jan;37(1–2):151–3

Ex vivo application of delta-aminolevulinic acid induces high and specific porphyrin levels in human skin tumors: possible basis for selective photodynamic therapy. Fritsch C, et al. **Photochem Photobiol** 1997 Jul;66(1):114–8

5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Peng Q, et al. **Photochem Photobiol** 1997 Feb;65(2):235–51 (234 ref.)

The effect of L-cysteine and N-acetylcysteine on porphyrin/heme biosynthetic pathway in cells treated with 5-aminolevulinic acid and exposed to radiation. He D, et al. **Photodermatol Photoimmunol Photomed** 1996 Oct; 12(5):194–9

Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX. Chang SC, et al. **Prostate** 1997 Jul 1;32(2):89–98

The effect of brief illumination on intracellular free calcium concentration in cells with 5-aminolevulinic acid-induced protoporphyrin IX synthesis. Gederaas OA, et al. **Scand J Clin Lab Invest** 1996 Nov;56(7):583–9

Protoporphyrin-IX distribution and photodynamic effect in rat oesophagus after aminolaevulinic acid administration. Mäkinen K, et al. **Scand J Gastroenterol** 1997 Jul; 32(7):633–7

Pro-oxidant effects of delta-aminolevulinic acid (delta-ALA) on Chinese hamster ovary (CHO) cells. Neal R, et al. **Toxicol Lett** 1997 May 16;91(3):169–78

[Endogenous porphyrins for photodynamic therapy of cataracts in vitro] Joussen AM, et al. **Ophthalmologe** 1997 Jun;94(6):428–35 (Eng. Abstr.) (Ger)

THERAPEUTIC USE

Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp. Wennberg AM, et al. **Arch Dermatol Res** 1996 Sep; 288(10):561–4

In vitro studies on the potential use of 5-aminolaevulinic acid-mediated photodynamic therapy for gynaecological tumours. Rossi FM, et al. **Br J Cancer** 1996 Sep;74(6):881–7

Large patches of Bowen's disease treated by topical aminolaevulinic acid photodynamic therapy. Stables GI, et al. **Br J Dermatol** 1997 Jun;136(6):957–60

Photodynamic therapy with 5-aminolevulinic acid in the treatment of actinic cheilitis. Stender IM, et al. **Br J Dermatol** 1996 Sep;135(3):454–6

Photodynamic therapy of bladder cancer cell lines. Datta SN, et al. **Br J Urol** 1997 Sep;80(3):421–6

Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Fan KF, et al. **Cancer** 1996 Oct 1;78(7):1374–83

5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Peng Q, et al. **Cancer** 1997 Jun 15;79(12):2282–308 (225 ref.)

Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Gaullier JM, et al. **Cancer Res** 1997 Apr 15;57(8):1481–6

Treatment of recalcitrant verrucae by photodynamic therapy with topical application of delta-aminolaevulinic acid [letter] Stender IM, et al. **Clin Exp Dermatol** 1996 Sep; 21(5):390

Photodynamic treatment of skin malignancies with aminolevulinic acid. Emphasis on anatomical observations and in vitro erythema visual assessment [editorial; comment] Salasche SJ. **Dermatol Surg** 1997 Mar;23(3):161 . Comment on: Dermatol Surg 1996 Nov;22(11):929–34.

Photodynamic treatment of skin malignancies with aminolevulinic acid. Emphasis on anatomical observations and in vivo erythema visual assessment [see comments] Tosca AD, et al. **Dermatol Surg** 1996 Nov;22(11):929–34 . Comment in: Dermatol Surg 1997 Mar;23(3):161.

Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Szeimies RM, et al. **Dermatology** 1996;192(3):246–51

Eradication of high-grade dysplasia using 5-ALA and acid suppression: a (photo)dynamic duo. Heller SJ, et al. **Gastroenterology** 1997 Jun;112(6):2156–8

Enhancement of photodynamic therapy in gastric cancer cells by removal of iron. Tan WC, et al. **Gut** 1997 Jul;41(1):14–8

Effects of the inhibitors of energy metabolism, lonidamine and levamisole, on 5-aminolevulinic-acid-induced photochemotherapy. Shevchuk I, et al. **Int J Cancer** 1996 Sep 17;67(6):791–9

Photosensitization of experimental hepatocellular carcinoma with protoporphyrin synthesized from administered delta-aminolevulinic acid: studies with cultured cells and implanted tumors. Egger NG, et al. **J Hepatol** 1997 Apr; 26(4):913–20

Photodynamic therapy with 5-aminolaevulinic acid-induced porphyrins of an amelanotic melanoma in vivo. Abels C, et al. **J Photochem Photobiol B** 1997 Aug;40(1):76–83

Electromotive diffusion (EMD) and photodynamic therapy with delta-aminolaevulinic acid (delta-ALA) for superficial bladder cancer. Stenzl A, et al. **J Photochem Photobiol B** 1996 Nov;36(2):233–6

Intraoperative phototherapy: a comparative study of intravenous and topical photofrin II and aminolevulinic acid. Davis RK, et al. **Otolaryngol Head Neck Surg** 1997 Feb;116(2):223–7

Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Kloek J, et al. **Photochem Photobiol** 1996 Dec; 64(6):994–1000

Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells. Bachor R, et al. **Urol Res** 1996;24(5):285–9

TOXICITY

Uroporphyria induced by 5-aminolaevulinic acid alone in Ahrd SWR mice. Constantin D, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1407–13

Intrauterine 5-aminolevulinic acid induces selective endometrial fluorescence in the rhesus and cynomolgus monkey. Yang JZ, et al. **J Soc Gynecol Investig** 1996 May-Jun;3(3):152–7

URINE

Alcohol-induced changes in urinary aminolevulinic acid and porphyrins: unrelated to liver disease. Schoenfeld N, et al. **Alcohol** 1996 Jan-Feb;13(1):59–63 (18 ref.)

Fluorometric HPLC determination of delta-aminolevulinic acid (ALA) in the plasma and urine of lead workers: biological indicators of lead exposure. Oishi H, et al. **J Anal Toxicol** 1996 Mar-Apr;20(2):106–10

Possible oral lead intake via contaminated facial skin. Karita K, et al. **Sci Total Environ** 1997 Jun 20;199(1–2):125–31

Lead exposure among Malaysian school children using delta-aminolevulinic acid as an indicator. Ming LO, et al. **Sci Total Environ** 1997 Jan 30;193(3):207–13

AMINOLEVULINIC ACID DEHYDRATASE

ANTAGONISTS & INHIBITORS

Inhibitory effect of selenium on enzymes involved in heme biosynthetic pathway in chick embryos. Padmaja K, et al. **J Enzyme Inhib** 1996 Aug;11(1):1–11

BLOOD

Effect of subclinical lead intoxication on laryngeal cancer. Kandiloris DC, et al. **Br J Clin Pract** 1997 Mar;51(2):69–70

Zinc aminolevulinic acid dehydratase reactivation index as a tool for diagnosis of lead exposure. Polo CF, et al. **Ecotoxicol Environ Saf** 1995 Dec;32(3):267–72

Reduced aminolevulinate dehydrase activity in rats with functional renal failure induced by cyclosporin A. Fontanellas A, et al. **Exp Nephrol** 1997 Jul-Aug;5(4):323–9

Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients. Guolo M, et al. **Int J Biochem Cell Biol** 1996 Mar;28(3):311–7

Determination of 5-aminolaevulinic acid dehydratase activity in erythrocytes and porphobilinogen in urine by micellar electrokinetic capillary chromatography. Luo JL, et al. **J Chromatogr A** 1996 Jan 26;722(1–2):353–7

delta-Aminolevulinic acid dehydratase genotype modifies four hour urinary lead excretion after oral administration of dimercaptosuccinic acid. Schwartz BS, et al. **Occup Environ Med** 1997 Apr;54(4):241–6

Delta-aminolevulinic acid dehydratase and zinc protoporphyrin in very low lead-exposed pets: a community study. Ambrogi C, et al. **Vet Hum Toxicol** 1996 Oct;38(5):336–9

CHEMISTRY

Comparative studies on the 5-aminolaevulinic acid dehydratases from Pisum sativum, Escherichia coli and

Saccharomyces cerevisiae. Senior NM, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):401–12
Structural studies on 5-aminolaevulinic acid dehydratase from Saccharomyces cerevisiae (yeast). Senior NM, et al. **Biochem Soc Trans** 1997 Feb;25(1):78S
Folding and unfolding of delta-aminolevulinic acid dehydratase and porphobilinogen deaminase induced by uro- and protoporphyrin. Afonso SG, et al. **Int J Biochem Cell Biol** 1997 Mar;29(3):493–503
Crystallization of 5-aminolaevulinic acid dehydratase from Escherichia coli and Saccharomyces cerevisiae and preliminary X-ray characterization of the crystals. Erskine PT, et al. **Protein Sci** 1997 Aug;6(8):1774–6

DRUG EFFECTS

Effect of beryllium on delta-aminolevulinic acid dehydratase and porphobilinogen deaminase in pregnant mice. Sakaguchi S, et al. **Pharmacol Toxicol** 1996 Oct;79(4):214–6

GENETICS

Aminolevulinic acid dehydratase genotype mediates plasma levels of the neurotoxin, 5-aminolevulinic acid, in lead-exposed workers. Sithisarankul P, et al. **Am J Ind Med** 1997 Jul;32(1):15–20
Delta-aminolevulinic acid dehydratase polymorphism: influence on lead levels and kidney function in humans. Bergdahl IA, et al. **Arch Environ Health** 1997 Mar–Apr; 52(2):91–6
Associations of subtypes of hemoglobin with delta-aminolevulinic acid dehydratase genotype and dimercaptosuccinic acid–chelatable lead levels. Schwartz BS, et al. **Arch Environ Health** 1997 Mar–Apr;52(2):97–103
Transcriptional regulation of delta-aminolevulinic acid dehydratase synthesis by oxygen in Bradyrhizobium japonicum and evidence for developmental control of the hemB gene. Chauhan S, et al. **J Bacteriol** 1997 Jun; 179(11):3706–10
Metals control activity and expression of the heme biosynthesis enzyme delta-aminolevulinic acid dehydratase in Bradyrhizobium japonicum. Chauhan S, et al. **J Bacteriol** 1997 Sep;179(17):5516–20
delta-Aminolevulinic acid dehydratase genotype modifies four hour urinary lead excretion after oral administration of dimercaptosuccinic acid. Schwartz BS, et al. **Occup Environ Med** 1997 Apr;54(4):241–6

METABOLISM

Comparative studies on the 5-aminolaevulinic acid dehydratases from Pisum sativum, Escherichia coli and Saccharomyces cerevisiae. Senior NM, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):401–12
Characterization of a recombinant pea 5-aminolevulinic acid dehydratase and comparative inhibition studies with the Escherichia coli dehydratase. Cheung KM, et al. **Biochemistry** 1997 Feb 4;36(5):1148–56
Reduced aminolevulinic dehydrase activity with increased blood porphyrins in experimental chronic renal failure. Fontanellas A, et al. **Exp Nephrol** 1997 Jan–Feb;5(1):95–9
Heme biosynthesis by the malarial parasite. Import of delta-aminolevulinate dehydrase from the host red cell. Bonday ZQ, et al. **J Biol Chem** 1997 Aug 29; 272(35):21839–46
Effect of mercuric chloride intoxication and dimercaprol treatment on delta-aminolevulinate dehydratase from brain, liver and kidney of adult mice. Emanuelli T, et al. **Pharmacol Toxicol** 1996 Sep;79(3):136–43

AMINOLEVULINIC ACID SYNTHETASE

ANALYSIS

Heme metabolism in promastigotes of Leishmania donovani. Srivastava P, et al. **Mol Cell Biochem** 1997 Jun; 171(1–2):65–8

ANTAGONISTS & INHIBITORS

Cimetidine in the treatment of acute intermittent porphyria. Rogers PD. **Ann Pharmacother** 1997 Mar;31(3):365–7 (14 ref.)

BIOSYNTHESIS

Evidence that protein kinase C is involved in delta-aminolevulinate synthase expression in rat hepatocytes. Varone CL, et al. **Arch Biochem Biophys** 1997 May 15;341(2):259–66
Glucose inhibits phenobarbital-induced delta-aminolevulinate synthase expression in normal but not in diabetic rat hepatocytes. Varone CL, et al. **Biochem Cell Biol** 1996;74(2):271–81
Hepatic 5-aminolevulinic acid synthase mRNA stability is modulated by inhibitors of heme biosynthesis and by metalloporphyrins. Cable EE, et al. **Eur J Biochem** 1996 Aug 15;240(1):112–7
Expression and purification of mammalian 5-aminolevulinate synthase. Dailey HA, et al. **Methods Enzymol** 1997; 281:336–40
Protein tyrosine phosphatase-dependent activation of beta-globin and delta-aminolevulinic acid synthase genes in the camptothecin-induced IW32 erythroleukemia cell differentiation. Wang MC, et al. **Mol Pharmacol** 1997 Apr; 51(4):558–66
Yeast 5-aminolevulinate synthase provides additional chlorophyll precursor in transgenic tobacco. Zavgorodnyaya A, et al. **Plant J** 1997 Jul;12(1):169–78

CHEMISTRY

Mutations at a glycine loop in aminolevulinate synthase affect pyridoxal phosphate cofactor binding and catalysis. Gong J, et al. **Biochemistry** 1996 Nov 12;35(45):14109–17

GENETICS

5-Aminolevulinate production by Escherichia coli containing the Rhodobacter sphaeroides hemA gene. van der Werf MJ, et al. **Appl Environ Microbiol** 1996 Oct;62(10):3560–6
Pyridoxine refractory X-linked sideroblastic anemia caused by a point mutation in the erythroid 5-aminolevulinate synthase gene. Furuyama K, et al. **Blood** 1997 Jul 15; 90(2):822–30
Translational control of erythroid delta-aminolevulinate synthase in immature human erythroid cells by heme. Smith SJ, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Feb; 43(1):103–14
Identification of an arginine452 to histidine substitution in the erythroid 5-aminolaevulinate synthetase gene in a large pedigree with X-linked hereditary sideroblastic anaemia. Edgar AJ, et al. **Eur J Haematol** 1997 Jan;58(1):1–4
5-Aminolevulinate synthase expression and hemoglobin synthesis in a human myelogenous leukemia cell line. Nagai T, et al. **J Biochem (Tokyo)** 1997 Mar;121(3):487–95
Regulation of the aminolevulinate synthase gene in the Syrian hamster Harderian gland: changes during development and circadian rhythm and role of some hormones. Rodriguez C, et al. **Microsc Res Tech** 1996 May 1;34(1):65–70 (50 ref.)
Characterization of the delta-aminolevulinate synthase gene homologue in P. falciparum [corrected and republished in Mol Biochem Parasitol 1996 Jul;79(1):135–40] Wilson CM, et al. **Mol Biochem Parasitol** 1996 Jan;75(2):271–6
Characterization of the delta-aminolevulinate synthase gene homologue in P. falciparum [corrected and republished article originally printed in Mol Biochem Parasitol 1996 Jan;75(2):271–6] Wilson CM, et al. **Mol Biochem Parasitol** 1996 Jul;79(1):135–40
Evolutionary consideration on 5-aminolevulinate synthase in nature. Oh-hama T. **Orig Life Evol Biosph** 1997 Aug; 27(4):405–12 (62 ref.)
Mechanisms for posttranscriptional regulation by iron-responsive elements and iron regulatory proteins. Muckenthaler M, et al. **Prog Mol Subcell Biol** 1997; 18:93–115 (100 ref.)
Isolation and characterization of the KlHEM1 gene in Kluyveromyces lactis. González-Domínguez M, et al. **Yeast** 1997 Aug;13(10):961–71

ISOLATION & PURIFICATION

Expression and purification of mammalian 5-aminolevulinate synthase. Dailey HA, et al. **Methods Enzymol** 1997; 281:336–40

METABOLISM

Novel regulation of delta-aminolevulinate synthase in the rat harderian gland. Nagai M, et al. **Biochem Pharmacol** 1997 Mar 7;53(5):643–50
Effect of chronic anesthesia on the drug-metabolizing enzyme system and heme pathway regulation. Buzaleh AM, et al. **Gen Pharmacol** 1997 Apr;28(4):577–82
Inhibitory effect of selenium on enzymes involved in heme biosynthetic pathway in chick embryos. Padmaja K, et al. **J Enzyme Inhib** 1996 Aug;11(1):1–11
Continuous coupled assay for 5-aminolevulinate synthase. Shoolingin-Jordan PM, et al. **Methods Enzymol** 1997; 281:309–16
Regulation of the aminolevulinate synthase gene in the Syrian hamster Harderian gland: changes during development and circadian rhythm and role of some hormones. Rodriguez C, et al. **Microsc Res Tech** 1996 May 1;34(1):65–70 (50 ref.)
The role of iron supply in the regulation of 5-aminolevulinate synthase mRNA levels in murine erythroleukemia cells. Fuchs O, et al. **Neoplasma** 1996;43(1):31–6
Evolutionary consideration on 5-aminolevulinate synthase in nature. Oh-hama T. **Orig Life Evol Biosph** 1997 Aug; 27(4):405–12 (62 ref.)

1-AMINONAPHTHALENE see **1-NAPHTHYLAMINE**

2-AMINONAPHTHALENE see **2-NAPHTHYLAMINE**

6-AMINONICOTINAMIDE

Genome scan for teratogen-induced clefting susceptibility loci in the mouse: evidence of both allelic and locus heterogeneity distinguishing cleft lip and cleft palate. Diehl SR, et al. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):5231–6

PHARMACOLOGY

Quantitation of metabolic and radiobiological effects of 6-aminonicotinamide in RIF-1 tumor cells in vitro. Street JC, et al. **Cancer Res** 1997 Sep 15;57(18):3956–62
Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies. Koutcher JA, et al. **Magn Reson Med** 1996 Dec; 36(6):887–92
Effect of 6-aminonicotinamide on metabolism of astrocytes and C6-glioma cells. Haghighat N, et al. **Metab Brain Dis** 1996 Mar;12(1):29–45
In vivo detection by 31P NMR of pentose phosphate pathway block secondary to biochemical modulation. Mahmood U, et al. **NMR Biomed** 1996 May;9(3):114–20

TOXICITY

Cytotoxicity and mutagenicity of 6-aminonicotinamide in Chinese hamster ovary cells. Sanz F, et al. **Teratog Carcinog Mutagen** 1996;16(1):19–25

AMINOOXYACETATE see **AMINOOXYACETIC ACID**

AMINOOXYACETIC ACID

ADMINISTRATION & DOSAGE

[The effect of aminooxyacetic acid on the antidote activity of diazepam after exposure to GABA-lytics] Golovko AI, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):441–3 **(Rus)**

PHARMACOLOGY

Hyperexcitability of entorhinal cortex and hippocampus after application of aminooxyacetic acid (AOAA) to layer III of the rat medial entorhinal cortex in vitro. Scharfman HE. **J Neurophysiol** 1996 Nov;76(5):2986–3001
Effects of metabolic inhibitors on mouse preimplantation embryo development and the energy metabolism of isolated inner cell masses. Hewitson LC, et al. **Mol Reprod Dev** 1996 Mar;43(3):323–30
Effectors of D-[3H]aspartate release from rat cerebellum. Svarna R, et al. **Neurochem Res** 1996 May;21(5):603–8

AMINOPEPTIDASE N see **ANTIGENS, CD13**

AMINOPEPTIDASES

ANALYSIS

An automatic continuous-flow aminopeptidase detector and its applications. Hui KS, et al. **Anal Biochem** 1996 Nov 15;242(2):271–3
Formate dehydrogenase-coupled spectrophotometric assay of peptide deformylase. Lazennec C, et al. **Anal Biochem** 1997 Jan 1;244(1):180–2
Analysis of sodium dodecyl sulfate-stable cell wall aminopeptidases in strains of viridans streptococci. Linder LE, et al. **FEMS Microbiol Lett** 1996 Sep 15;143(1):19–23
Electrophoretic variations of peptidase E (PEPE) in characterizing clones and isolates of Plasmodium falciparum from different geographical areas. Ang HH, et al. **Folia Parasitol (Praha)** 1997;44(2):128–30
[Aminopeptidases in cells of non-Hodgkin's lymphoma of varying degrees of malignancy and in lymphogranulomatosis] Bukaeva IA, et al. **Arkh Patol** 1997 Jul–Aug;59(4):31–8 (Eng. Abstr.) **(Rus)**
[Utility of pyrrolidonyl-arylamidase detection for typing Enterobacteriaceae and non-fermenting Gram-negative bacteria] Nicola F, et al. **Rev Argent Microbiol** 1995 Oct–Dec;27(4):204–9 (Eng. Abstr.) **(Spa)**

ANTAGONISTS & INHIBITORS

Effect of bestatin, an aminopeptidase inhibitor, on alcohol intake in alcohol-preferring P rats. Szczepanska R, et al. **Alcohol Clin Exp Res** 1996 May;20(3):561–5
Cryptosporidium parvum metalloaminopeptidase inhibitors prevent in vitro excystation. Okhuysen PC, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2781–4
Cholesterol and steroids action on aminopeptidases. Martinez JM, et al. **Biochem Soc Trans** 1997 Feb;25(1):113S
Inhibition of tumor cell invasion and matrix degradation by aminopeptidase inhibitors. Fujii H, et al. **Biol Pharm Bull** 1996 Jan;19(1):6–10
3-Amino-2-hydroxy-propionaldehyde and 3-amino-1-hydroxy-propan-2-one derivatives: new classes of aminopeptidase inhibitors. Tarnus C, et al. **Bioorg Med Chem** 1996 Aug;4(8):1287–97
Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Griffith EC, et al. **Chem Biol** 1997 Jun;4(6):461–71
Characterization of the decline in alcohol consumption by aminopeptidase inhibition. Szczepanska R, et al. **Drug Alcohol Depend** 1996 Dec 11;43(3):133–41
An aminopeptidase inhibitor, bestatin, enhances gonadotrophin-stimulated ovulation in mice. Nakamura K, et al. **Hum Reprod** 1996 Sep;11(9):1952–7
Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation. Erşahin C, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):96–101
Peptidase inhibitor-induced antidiuresis mediated through angiotensin and opioid receptors in the rat hypothalamus. Tsushima H, et al. **Jpn J Pharmacol** 1996 May;71(1):61–71
Potentiation of the pro-inflammatory effects of bradykinin by inhibition of angiotensin-converting enzyme and

aminopeptidase P in rat paws. Damas J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):670–6

Inhibition of aminopeptidase A activity causes an acute albuminuria in mice: an angiotensin II–mediated effect? Mentzel S, et al. **Nephrol Dial Transplant** 1996 Nov; 11(11):2163–9

Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Zini S, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11968–73

BLOOD

Reduction of plasma glutamyl aminopeptidase activity in sporadic Alzheimer's disease. Kuda T, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):526–30

CHEMISTRY

Spectroscopically distinct cobalt(II) sites in heterodimetallic forms of the aminopeptidase from Aeromonas proteolytica: characterization of substrate binding. Bennett B, et al. **Biochemistry** 1997 Aug 12;36(32):9837–46

Proteolytic fragmentation reveals the oligomeric and domain structure of porcine aminopeptidase A. Hesp JR, et al. **Biochemistry** 1997 Mar 11;36(10):3000–7

Disulfide bonds and free SH–group in pig kidney aminopeptidase P. Mann K. **Biol Chem** 1996 Dec; 377(12):857–8

Crystallization and preliminary X–ray diffraction analysis of proline iminopeptidase from Xanthomonas campestris pv. citri. Medrano FJ, et al. **FEBS Lett** 1997 Jan 2;400(1):91–3

Streptomyces griseus aminopeptidase: X–ray crystallographic structure at 1.75 A resolution. Greenblatt HM, et al. **J Mol Biol** 1997 Feb 7;265(5):620–36

Structure–function relationships within the peptide deformylase family. Evidence for a conserved architecture of the active site involving three conserved motifs and a metal ion. Meinnel T, et al. **J Mol Biol** 1997 Apr 4; 267(3):749–61

A new subclass of the zinc metalloproteases superfamily revealed by the solution structure of peptide deformylase. Meinnel T, et al. **J Mol Biol** 1996 Sep 27;262(3):375–86

GENETICS

Prolyl aminopeptidase gene from Flavobacterium meningosepticum: cloning, purification of the expressed enzyme, and analysis of its sequence. Kitazono A, et al. **Arch Biochem Biophys** 1996 Dec 1;336(1):35–41

Molecular cloning and expression in COS–1 cells of pig kidney aminopeptidase P. Hyde RJ, et al. **Biochem J** 1996 Oct 1;319 (Pt 1):197–201

Isolation and characterization of the gene encoding an aminopeptidase involved in the selective toxicity of ascamycin toward Xanthomonas campestris pv. citri. Sudo T, et al. **Biochem J** 1996 Oct 1;319 (Pt 1):99–102

Cloning and functional expression of pig kidney aminopeptidase P. Hyde RJ, et al. **Biochem Soc Trans** 1996 Aug;24(3):470S

Cloning and characterization of a microsomal aminopeptidase from the intestine of the nematode Haemonchus contortus. Smith TS, et al. **Biochim Biophys Acta** 1997 Apr 4; 1338(2):295–306

cDNA cloning and expression of chicken aminopeptidase H, possessing endopeptidase as well as aminopeptidase activity. Adachi H, et al. **Eur J Biochem** 1997 Apr 15; 245(2):283–8

Tricorn protease (TRI) interacting factor 1 from Thermoplasma acidophilum is a proline iminopeptidase. Tamura T, et al. **FEBS Lett** 1996 Nov 25;398(1):101–5

Increased production of peptide deformylase eliminates retention of formylmethionine in bovine somatotropin overproduced in Escherichia coli. Warren WC, et al. **Gene** 1996 Oct 3;174(2):235–8

The mouse BP–1 gene: structure, chromosomal localization, and regulation of expression by type I interferons and interleukin–7. Wang J, et al. **Genomics** 1996 Apr 15; 33(2):167–76

Regulation of the Salmonella typhimurium pepT gene by cyclic AMP receptor protein (CRP) and FNR acting at a hybrid CRP–FNR site. Lombardo MJ, et al. **J Bacteriol** 1997 Mar;179(6):1909–17

Molecular cloning and expression of rat liver aminopeptidase B. Fukasawa KM, et al. **J Biol Chem** 1996 Nov 29; 271(48):30731–5

A survey of polypeptide deformylase function throughout the eubacterial lineage. Mazel D, et al. **J Mol Biol** 1997 Mar 14;266(5):939–49

Cloning of the human puromycin–sensitive aminopeptidase and evidence for expression in neurons. Tobler AR, et al. **J Neurochem** 1997 Mar;68(3):889–97

Expression and retinoid modulation of N–arginine dibasic convertase and an aminopeptidase–B in human neuroblastoma cell lines. Draoui M, et al. **J Neurooncol** 1997 Jan;31(1–2):99–106

Proline iminopeptidase gene from Xanthomonas campestris pv. citri. Alonso J, et al. **Microbiology** 1996 Oct;142 (Pt 10):2951–7

Lactobacillus delbrueckii subsp. lactis DSM7290 pepG gene encodes a novel cysteine aminopeptidase. Klein JR, et al. **Microbiology** 1997 Feb;143 (Pt 2):527–37

An operon from Lactobacillus helveticus composed of a proline iminopeptidase gene (pepI) and two genes coding for putative members of the ABC transporter family of proteins. Varmanen P, et al. **Microbiology** 1996 Dec;142 (Pt 12):3459–68

Methionine aminopeptidase–1: the MAP of the mitochondrion? [letter] Keeling PJ, et al. **Trends Biochem Sci** 1996 Aug;21(8):285–6

IMMUNOLOGY

Aminopeptidase A antiserum inhibits intracerebroventricular angiotensin II–induced dipsogenic and pressor responses. Song L, et al. **Brain Res** 1997 Jan 2;744(1):1–6

ISOLATION & PURIFICATION

Basic aminopeptidase from rabbit kidney: purification and partial characterization. Oliveira SM, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1437–9

Purification of aminopeptidase from Australian classified barley flour. Doi H, et al. **Int J Biochem Cell Biol** 1997 Feb;29(2):345–52

Purification and characterization of aminopeptidase P from Lactococcus lactis subsp. cremoris. Mc Donnell M, et al. **J Dairy Res** 1997 Aug;64(3):399–407

Purification and characterization of aminopeptidase M from muscle and mucosa of the pig intestine. Terashima H, et al. **J Gastroenterol** 1995 Dec;30(6):696–704

A new, broad–substrate–specificity aminopeptidase from the dairy organism Lactobacillus helveticus SBT 2171. Sasaki M, et al. **Microbiology** 1996 Apr;142 (Pt 4):799–808

Metabolism of enkephalins in head membranes of the leech Theromyzon tessulatum by peptidases: isolation of an enkephalin–degrading aminopeptidase. Laurent V, et al. **Regul Pept** 1996 Sep 9;65(2):123–31

METABOLISM

Insulin stimulates cell surface aminopeptidase activity toward vasopressin in adipocytes. Herbst JJ, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E600–6

The development of two fluorimetric assays for the determination of pyroglutamyl aminopeptidase type–II activity. Gallagher SP, et al. **Anal Biochem** 1997 Jul 15; 250(1):1–9

Continuous spectrophotometric assay of peptide deformylase. Wei Y, et al. **Anal Biochem** 1997 Jul 15;250(1):29–34

A novel mammalian high–molecular–weight aminopeptidase. Erbeznik H, et al. **Arch Biochem Biophys** 1997 Aug 1; 344(1):228–34

Evidence that the human homologue of a rat initiation factor–2 associated protein (p67) is a methionine aminopeptidase. Li X, et al. **Biochem Biophys Res Commun** 1996 Oct 3;227(1):152–9

A new type of major aminopeptidase in bovine brain. Yanagisawa J, et al. **Biochem Mol Med** 1996 Dec; 59(2):161–8

The possible role of aminopeptidases from starter culture Lactococcus lactis subspecies cremoris AM2 in cheese making. McDonnell M, et al. **Biochem Soc Trans** 1997 Feb; 25(1):119S

Mechanistic studies on the aminopeptidase from Aeromonas proteolytica: a two–metal ion mechanism for peptide hydrolysis. Chen G, et al. **Biochemistry** 1997 Apr 8; 36(14):4278–86

Transfer of aminopeptidase activity from prostasomes to sperm. Arienti G, et al. **Biochim Biophys Acta** 1997 Aug 29;1336(2):269–74

The main neutral aminopeptidase activity of human lymphoid tumour cell lines does not originate from the aminopeptidase N–(APN; CD13) gene. Wex T, et al. **Biochim Biophys Acta** 1997 Feb 4;1355(2):147–54

Subcellular analysis of Tyr–aminopeptidase activities in the developing rat cerebellum. de Gandarias JM, et al. **Brain Res Dev Brain Res** 1997 Mar 17;99(1):66–71

Modulation of the pituitary and basomedial hypothalamic lysyl–aminopeptidase activities be beta–estradiol and/or an aqueous extract of Physalis alkekengi fruits. Vessal M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Oct; 115(2):267–71

Aminopeptidase–like protease released from oocytes affects oocyte surfaces and suppresses the acrosome reaction in establishment of polyspermy block in oocytes of the mussel Mytilus edulis. Togo T, et al. **Dev Biol** 1997 Feb 15; 182(2):219–27

Regulation of the adenohypophyseal thyrotropin–releasing hormone–degrading ectoenzyme by estradiol. Schomburg L, et al. **Endocrinology** 1997 Sep;138(9):3587–93

Insulin regulation and selective segregation with glucose transporter–4 of the membrane aminopeptidase vp165 in rat skeletal muscle cells. Sumitani S, et al. **Endocrinology** 1997 Mar;138(3):1029–34

Vp165 and GLUT4 share similar vesicle pools along their trafficking pathways in rat adipose cells. Malide D, et al. **FEBS Lett** 1997 Jun 16;409(3):461–8

Tricorn protease (TRI) interacting factor 1 from Thermoplasma acidophilum is a proline iminopeptidase. Tamura T, et al. **FEBS Lett** 1996 Nov 25;398(1):101–5

Increased production of peptide deformylase eliminates retention of formylmethionine in bovine somatotropin overproduced in Escherichia coli. Warren WC, et al. **Gene** 1996 Oct 3;174(2):235–8

Aminopeptidase P is disposed on human endothelial cells. Ryan JW, et al. **Immunopharmacology** 1996 May; 32(1–3):149–52

Trypsin and aminopeptidase gene expression is affected by age and food composition in Anopheles gambiae. Lemos FJ, et al. **Insect Biochem Mol Biol** 1996 Jul;26(7):651–8

Developmental changes of Tyr–aminopeptidase activity in different subcellular fractions of the subcortical region of the rat brain. Varona A, et al. **Int J Dev Biol** 1996;Suppl 1:165S–166S

Mouse glomerular epithelial cells in culture with features of podocytes in vivo express aminopeptidase A and angiotensinogen but not other components of the renin–angiotensin system. Mentzel S, et al. **J Am Soc Nephrol** 1997 May;8(5):706–19

Transport of a large oligomeric protein by the cytoplasm to vacuole protein targeting pathway. Kim J, et al. **J Cell Biol** 1997 May 5;137(3):609–18

Aminopeptidase I is targeted to the vacuole by a nonclassical vesicular mechanism. Scott SV, et al. **J Cell Biol** 1997 Jul 14;138(1):37–44

Purification and characterization of aminopeptidase M from muscle and mucosa of the pig intestine. Terashima H, et al. **J Gastroenterol** 1995 Dec;30(6):696–704

Localization of aminopeptidase activity in freshly excised human skin: direct visualization by confocal laser scanning microscopy. Boderke P, et al. **J Invest Dermatol** 1997 Jan; 108(1):83–6

Folding of the presequence of yeast pAPI into an amphipathic helix determines transport of the protein from the cytosol to the vacuole. Martinez E, et al. **J Mol Biol** 1997 Apr 18;267(5):1124–38

Nociceptin/orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15. Montiel JL, et al. **J Neurochem** 1997 Jan;68(1):354–61

Cloning of the human puromycin–sensitive aminopeptidase and evidence for expression in neurons. Tobler AR, et al. **J Neurochem** 1997 Mar;68(3):889–97

Aminopeptidase a is a constituent of activated pericytes in angiogenesis. Schlingemann RO, et al. **J Pathol** 1996 Aug; 179(4):436–42

Epidermal aminopeptidase activity and metabolism as observed in an organized HaCaT cell sheet model. Steinsträsser I, et al. **J Pharm Sci** 1997 Mar;86(3):378–83

Interspecies aminopeptidase–N chimeras reveal species–specific receptor recognition by canine coronavirus, feline infectious peritonitis virus, and transmissible gastroenteritis virus. Benbacer L, et al. **J Virol** 1997 Jan;71(1):734–7

A new, broad–substrate–specificity aminopeptidase from the dairy organism Lactobacillus helveticus SBT 2171. Sasaki M, et al. **Microbiology** 1996 Apr;142 (Pt 4):799–808

Metabolism of AF1 (KNEFIRF–NH2) in the nematode, Ascaris suum, by aminopeptidase, endopeptidase and deamidase enzymes. Sajid M, et al. **Mol Biochem Parasitol** 1996 Jan;75(2):159–68

Accessory proteins impose site selectivity during ColE1 dimer resolution. Guhathakurta A, et al. **Mol Microbiol** 1996 May;20(3):613–20

Aminopeptidase A: distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats. Zini S, et al. **Neuroscience** 1997 Jun;78(4):1187–93

The in vivo metabolism of cholecystokinin (CCK–8) is essentially ensured by aminopeptidase A. Migaud M, et al. **Peptides** 1996;17(4):601–7

Aminopeptidase B from the rat testis is a bifunctional enzyme structurally related to leukotriene–A4 hydrolase. Cadel S, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):2963–8

Cytoplasm–to–vacuole targeting and autophagy employ the same machinery to deliver proteins to the yeast vacuole. Scott SV, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29; 93(22):12304–8

The anti–angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP–2. Sin N, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6099–103

Age–related changes in the soluble and the membrane–bound Tyr–aminopeptidase activities in several areas of the male and female rat brain. de Gandarias JM, et al. **Reprod Fertil Dev** 1996;8(3):465–9

Peripherally active analgesia of aminopeptidase–resistant sugar–coupled leucine enkephalin. Mizuma T, et al. **Res Commun Mol Pathol Pharmacol** 1997 Jan;95(1):83–91

Developmental changes of soluble and membrane–bound aspartate aminopeptidase activities in rat brain. Arechaga G, et al. **Rev Esp Fisiol** 1996 Sep;52(3):149–54

Influence of constant light and darkness on arginyl aminopeptidase activity. Sánchez B, et al. **Rev Esp Fisiol** 1997 Jun;53(2):249–50

[Function of proline–rich regions in proteins and proline specific peptidases] Maruyama S. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):857–64 (56 ref.) **(Jpn)**

PHARMACOLOGY

Microinfusion of aminopeptidase M into the paraventricular nucleus of the hypothalamus in normotensive and hypertensive rats. Batt CM, et al. **Brain Res Bull** 1996; 39(4):235–40

The amino terminus of insulin–responsive aminopeptidase causes Glut4 translocation in 3T3–L1 adipocytes. Waters SB, et al. **J Biol Chem** 1997 Sep 12;272(37):23323–7

PHYSIOLOGY

Requirement for surface aminopeptidase activities during development of CD8+ fetal thymocytes. Appasamy PM, et al. **Cell Immunol** 1997 Apr 10;177(1):1–8

Cell surface peptidases in human endometrium. Imai K, et al. **Mol Hum Reprod** 1996 Jun;2(6):425–31 (123 ref.)

[Age-related changes in the cytolytic activity of aspartyl aminopeptidase in the cerebral cortex of the rat] Iribar MC, et al. **Rev Neurol** 1997 Jan;25(137):37–9 (Eng. Abstr.) **(Spa)**

AMINOPHENAZONE see **AMINOPYRINE**

AMINOPHENOLS

CHEMISTRY

2-aminophenol 1,6-dioxygenase: a novel aromatic ring cleavage enzyme purified from Pseudomonas pseudoalcaligenes JS45. Lendenmann U, et al. **J Bacteriol** 1996 Nov;178(21):6227–32

PHARMACOLOGY

Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Yoshimatsu K, et al. **Cancer Res** 1997 Aug 1;57(15):3208–13

Development of new anticancer drugs in Japan—tubulin-interacting agents. Tsukagoshi S. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:94–9 (5 ref.)

TOXICITY

The role of free radicals in p-aminophenol-induced nephrotoxicity: does reduced glutathione have a protective effect? Kanbak G, et al. **Clin Chim Acta** 1996 Aug 15; 252(1):61–71

Lack of correlation between para-aminophenol toxicity in vivo and in vitro in female Sprague-Dawley rats. Shao R, et al. **Fundam Appl Toxicol** 1996 Jun;31(2):268–78

Induction of chromosomal aberrations by 2,4-dichloro-6-aminophenol in cultured V79 cells. Heng ZC, et al. **Teratog Carcinog Mutagen** 1996;16(2):81–7

URINE

Quantitative colorimetric determination of urinary p-aminophenol with an automated analyzer. Van Bocxlaer JF, et al. **Clin Chem** 1997 Apr;43(4):627–34

2-AMINO-5-PHOSPHONOPENTANOIC ACID see **2-AMINO-5-PHOSPHONOVALERATE**

2-AMINO-5-PHOSPHONOVALERATE

ANALOGS & DERIVATIVES

Neuroprotective effect of D-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid in the gerbil model of transient global cerebral ischemia. Okada M, et al. **Arzneimittelforschung** 1997 Jun;47(6):700–2

Effect of D-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid on focal cerebral ischemia in cat. Okada M, et al. **Arzneimittelforschung** 1997 Jun;47(6):703–5

Effect of D-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid on ischemic brain damage induced by four-vessel occlusion in rats. Okada M, et al. **Arzneimittelforschung** 1997 Feb; 47(2):115–9

Early NMDA receptor blockade impairs defensive behavior and increases cell proliferation in the dentate gyrus of developing rats. Gould E, et al. **Behav Neurosci** 1997 Feb; 111(1):49–56

Selective block of N-methyl-D-aspartic acid (NMDA)-evoked whole-cell currents in mouse cultured spinal neurones by CGP 40116. D'Hooge R, et al. **Br J Pharmacol** 1997 Jan;120(2):211–4

Regionally different N-methyl-D-aspartate receptors distinguished by ligand binding and quantitative autoradiography of [3H]-CGP 39653 in rat brain. Mugnaini M, et al. **Br J Pharmacol** 1996 Nov;119(5):819–28

Lack of development of tolerance to anticonvulsant effects of two excitatory amino acid antagonists, CGP [corrected] 37849 and CGP 39551 in genetically epilepsy-prone rats [published erratum appears in Brain Res 1997 Mar 7;750(1–2):329] De Sarro G, et al. **Brain Res** 1996 Sep 23; 734(1–2):91–7

Chronic pre-explant blockade of the NMDA receptor affects survival of cerebellar granule cells explanted in vitro. Ciani E, et al. **Brain Res Dev Brain Res** 1997 Mar 17;99(1):112–7

Competitive NMDA receptor antagonist, CGP 40116, substitutes for the discriminative stimulus effects of ethanol. Bienkowski P, et al. **Eur J Pharmacol** 1996 Oct 31; 314(3):277–80

Ca2+ channel blockade and the antielectroshock activity of NMDA receptor antagonists, CGP 40116 and CGP 43487, in mice. Gasior M, et al. **Eur J Pharmacol** 1996 Sep 19;312(1):27–33

The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. Jessa M, et al. **Eur Neuropsychopharmacol** 1996 Mar; 6(1):55–61

Extracts from rhizomes of Cyperus articulatus (Cyperaceae) displace [3H]CGP39653 and [3H]glycine binding from cortical membranes and selectively inhibit NMDA receptor-mediated neurotransmission. Bum EN, et al. **J Ethnopharmacol** 1996 Nov;54(2–3):103–11

CGP 39653 binding in the chick CNS after NMDA receptor antagonist treatment. White BH, et al. **J Neural Transm** 1996;103(11):1247–53

Competitive and non-competitive NMDA receptor antagonists induce c-Fos expression in the rat anterior, cingulate cortex. Wędzony K, et al. **J Physiol Pharmacol** 1996 Sep;47(3):525–33

Effects of N-methyl-D-aspartate-receptor blockade on high-potassium-induced neuronal death and glutamate release. Fujikawa DG. **Neurosci Lett** 1997 Apr 18; 226(1):25–8

Reduction of excitotoxicity-induced brain damage by the competitive NMDA antagonist CGP 40116: a longitudinal study using diffusion-weighted imaging. Laurent D, et al. **Neurosci Lett** 1996 Aug 9;213(3):209–12

Excitatory amino acid antagonists and pentylenetetrazol-induced seizures during ontogenesis. IV. Effects of CGP 39551. Velisek L, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):493–8

Discriminative stimulus effects of the NMDA receptor antagonists MK-801 and CGP 37849 in rats. Zajaczkowski W, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):163–8

Locomotor activity and motor disturbances induced by the competitive NMDA receptor antagonist CGP 37849. Kolasiewicz W, et al. **Pol J Pharmacol** 1996 Sep–Oct; 48(5):467–79

Rapid down-regulation of beta-adrenergic receptors evoked by combined forced swimming test and CGP 37849—a competitive antagonist of NMDA receptors. Wędzony K, et al. **Pol J Pharmacol** 1995 Nov–Dec;47(6):537–40

The memory-facilitating effects of the competitive NMDA-receptor antagonist CGP 37849 are steroid-sensitive, whereas its memory-impairing effects are not. Mondadori C, et al. **Psychopharmacology (Berl)** 1996 Apr;124(4):380–3

PHARMACOLOGY

Role of spinal NMDA and AMPA receptors in episodic hypertension in conscious spinal rats. Maiorov DN, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1266–74

Role of AMPA/kainate receptors in transmission of the sympathetic baroreflex in rat CVLM. Miyawaki T, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R800–12

Double dissociation of hippocampal and dorsal-striatal memory systems by posttraining intracerebral injections of 2-amino-5-phosphonopentanoic acid. Packard MG, et al. **Behav Neurosci** 1997 Jun;111(3):543–51

Long-term potentiation in the in vitro perirhinal cortex displays associative properties. Bilkey DK. **Brain Res** 1996 Sep 16;733(2):297–300

NMDA receptor antagonist blocks the bradycardic but not the pressor response to L-glutamate microinjected into the nucleus tractus solitarius (NTS) of unanesthetized rats. Colombari E, et al. **Brain Res** 1997 Feb 28;749(2):209–13

Intrastriatal AP5 differentially affects behaviors induced by local infusions of D1 vs. D2 dopamine agonists. McPherson RJ, et al. **Brain Res** 1996 Nov 11;739(1–2):19–25

Administration of DL-2-amino-5-phosphonovaleric acid (AP5) induces transient inhibition of reminder-activated memory retrieval in day-old chicks. Summers MJ, et al. **Brain Res Cogn Brain Res** 1997 Jun;5(4):311–21

Evidence for functional differences between entopeduncular nucleus and substantia nigra: effects of APV (DL-2-amino-5-phosphonovaleric acid) microinfusion on reaction time performance in the rat. Baunez C, et al. **Eur J Neurosci** 1996 Sep;8(9):1972–82

Chronic NMDA receptor antagonism during retinotopic map formation depresses CaM kinase II differentiation in rat superior colliculus. Scheetz AJ, et al. **Eur J Neurosci** 1996 Jul;8(7):1322–8

Intraseptal infusion of selective and competitive glutamate receptor agonist NMDA and antagonist D-2-amino-5-phosphonopentanoic acid spectral implications for the physostigmine-induced hippocampal theta rhythm in urethane-anesthetized rats. Puma C, et al. **Exp Brain Res** 1996 Jun;109(3):384–92

The effects of an intrathecal NMDA antagonist (AP5) on the behavioral changes induced by colorectal inflammation with turpentine in rats. Ide Y, et al. **Life Sci** 1997; 60(16):1359–63

Blockade of NMDA receptors in the anterior forebrain impairs sensory acquisition in the zebra finch (Poephila guttata). Basham ME, et al. **Neurobiol Learn Mem** 1996 Nov;66(3):295–304

Influence of the N-methyl-D-aspartate receptor antagonist DL-2-amino-5-phosphonovaleric acid on auditory filial imprinting in the domestic chick. Bock J, et al. **Neurobiol Learn Mem** 1996 Mar;65(2):177–88

NMDA receptor-dependent and -independent long-term depression in the CA1 region of the adult rat hippocampus in vitro. Kemp N, et al. **Neuropharmacology** 1997 Mar; 36(3):397–9

Biphenyl-derivatives of 2-amino-7-phosphonoheptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonist—I. Pharmacological characterization in vitro. Urwyler S, et al. **Neuropharmacology** 1996 Jun;35(6):643–54

Reduced NMDA receptor sensitivity may underlie the resistance of subpopulations of PVN neurons to excitotoxicity. Bains JS, et al. **Neuroreport** 1997 Jul 7; 8(9–10):2101–5

Effect of chronic administration of NMDA antagonists on synaptic development. Brooks WJ, et al. **Synapse** 1997 Jun; 26(2):104–13

Turning behavior induced by injections of glutamate receptor antagonists into the substantia nigra of the rat. Murer G, et al. **Synapse** 1996 Oct;24(2):147–55

2-AMINO-5-PHOSPHONOVALERIC ACID see **2-AMINO-5-PHOSPHONOVALERATE**

AMINOPHYLLINE

ADMINISTRATION & DOSAGE

Theophylline concentration following equal doses of intravenous aminophylline and oral theophylline in preterm infants. al-Omran A, et al. **Am J Perinatol** 1997 Mar; 14(3):147–9

Improvement of exercise-induced ischaemia and myocardial perfusion after aminophylline. Roig E, et al. **Coron Artery Dis** 1996 Jan;7(1):69–73

Effect of oral aminophylline in patients with angina and normal coronary arteriograms (cardiac syndrome X). Elliott PM, et al. **Heart** 1997 Jun;77(6):523–6

Aminophylline reduces cardiac ischemic pain during percutaneous transluminal coronary angioplasty. Hashino T, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1725–31

Aminophylline dosing in the treatment of apnea of prematurity — a commentary [comment] Gagnon AJ. **Pharmacotherapy** 1996 Mar–Apr;16(2):317–9. Comment on: Pharmacotherapy 1995 Mar–Apr;15(2):246–50.

Effects of high-dose ipratropium bromide and oral aminophylline on spirometry and exercise tolerance in COPD. Shivaram U, et al. **Respir Med** 1997 Jul; 91(6):327–34

[Bronchodilating effect of inhalation of aerosolized aminophylline in asthmatic patients] Kokubu H. **Arerugi** 1995 Dec;44(12):1379–86 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Comment: aminophylline-containing cream [letter] Simon PA. **Ann Pharmacother** 1996 Nov;30(11):1341–2

Intravenous aminophylline increases the degree of saturation of urine with calcium phosphate and struvite. Siwińska A, et al. **Int Urol Nephrol** 1997;29(2):141–6

ANALOGS & DERIVATIVES

Properties controlling the diffusion and release of water-soluble solutes from poly(ethylene oxide) hydrogels: 3. Device geometry. McNeill ME, et al. **J Biomater Sci Polym Ed** 1996;7(11):937–51

Properties controlling the diffusion and release of water-soluble solutes from poly(ethylene oxide) hydrogels. 4. Extended constant rate release from partly-coated spheres. McNeill ME, et al. **J Biomater Sci Polym Ed** 1996; 7(11):953–63

ANALYSIS

Aminophylline stability in total parenteral nutrition admixtures. Ciszewska-Jędrasik M, et al. **Acta Pol Pharm** 1995 Nov–Dec;52(6):487–90

CONTRAINDICATIONS

Asthma guidelines [letter; comment] Emerton D. **Thorax** 1997 Jul;52(7):665; discussion 665–6. Comment on: Thorax 1997 Feb;52 Suppl 1:S2–8, S11–5, S20–1.

PHARMACOKINETICS

Selected pharmacokinetics of theophylline ethylenediamine in pre-term and term goat kids. Lidl GM, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):69–72

The pharmacologic effects of recombinant, human colony-stimulating factors and their modulation by theophylline. Petros WP, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):742–8

PHARMACOLOGY

The effect of aminophylline on pharmacological stress with intravenous adenosine. Nahser PJ Jr, et al. **Am J Card Imaging** 1996 Jul;10(3):149–53

The different effect of salbutamol and aminophylline on platelet activating factor-induced plasma exudation into guinea pig tracheal wall and lumen. Liu CY, et al. **Chang Keng I Hsueh** 1996 Sep;19(3):211–6

Postexposure treatment with aminophylline protects against phosgene-induced acute lung injury. Sciuto AM, et al. **Exp Lung Res** 1997 Jul–Aug;23(4):317–32

Dual effect of aminophylline on the ventilatory response to hypoxia in the rat. Maskrey M, et al. **J Basic Clin Physiol Pharmacol** 1994 Jul–Dec;5(3–4):227–38

Influence of aminophylline and strychnine on the protective activity of excitatory amino acid antagonists against maximal electroshock-induced convulsions in mice. Tutka P, et al. **J Neural Transm** 1996;103(3):307–14

In vitro and in vivo anti-leukemic efficacy of cyclic AMP modulating agents against human leukemic B-cell

AMINOPHYLLINE

precursors. Myers DE, et al. **Leuk Lymphoma** 1996 Jul; 22(3–4):259–64

A pilot pharmacokinetic–pharmacodynamic study of benzodiazepine antagonism by flumazenil and aminophylline. Bonfiglio MF, et al. **Pharmacotherapy** 1996 Nov–Dec;16(6):1166–72

The pharmacologic effects of recombinant, human colony-stimulating factors and their modulation by theophylline. Petros WP, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):742–8

Inhibition of antigen–induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats. Howell RE, et al. **Pulm Pharmacol** 1995 Apr–Jun;8(2–3):83–9

THERAPEUTIC USE

Effects of theophylline on renal function in premature infants. Mazkereth R, et al. **Am J Perinatol** 1997 Jan;14(1):45–9

Aminophylline as an adjunct to standard advanced cardiac life support in prolonged cardiac arrest. Burton JH, et al. **Ann Emerg Med** 1997 Aug;30(2):154–8

Aminophylline for cellulite removal. Dickinson BI, et al. **Ann Pharmacother** 1996 Mar;30(3):292–3

Dibutyryl cAMP prevents increased vascular permeability caused by air embolism in isolated rat lungs. Hsu K, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):802–6

Significance of the therapeutic range of serum theophylline concentration in the treatment of an attack of bronchial asthma. Nakahara Y, et al. **Biol Pharm Bull** 1996 May; 19(5):710–5

The effect of intravenous aminophylline on essential tremor. Buss DC, et al. **Br J Clin Pharmacol** 1997 Jan;43(1):119–21

Aminophylline is effective on acute exacerbations of asthma in adults—objective improvements in peak flow, spirogram, arterial blood gas measurements and lung sounds. Ohta K, et al. **Clin Exp Allergy** 1996 Mar;26 Suppl 2:32–7

Adenosine receptor antagonism in refractory asystolic cardiac arrest: results of a human pilot study. Mader TJ, et al. **Resuscitation** 1997 Aug;35(1):3–7

[Controlled clinical study of doxophylline versus aminophylline in the treatment of acute cardiorespiratory insufficiency syndromes] Checchini M, et al. **Minerva Cardioangiol** 1997 Apr;45(4):185–90 (Eng. Abstr.) **(Ita)**

TOXICITY

[Effect of beta 2–adrenergic agonists on neurotoxic action of aminophyllines] Lupina T, et al. **Pneumonol Alergol Pol** 1996;64 Suppl 1:70–7 (Eng. Abstr.) **(Pol)**

[The influence of selected antibiotics on the central action of aminophyllines—experimental studies] Szmygin K. **Pneumonol Alergol Pol** 1996;64 Suppl 1:63–9 (Eng. Abstr.) **(Pol)**

AMINOPROPANOLS see **PROPANOLAMINES**

3–AMINOPROPIONIC ACID see **BETA–ALANINE**

AMINOPROPIONITRILE

see related
LATHYRISM

ADVERSE EFFECTS

Effects of vitamin B6 on beta–aminoproprionitrile–induced palatal cleft formation in the rat. Jacobsson C, et al. **Cleft Palate Craniofac J** 1997 Mar;34(2):95–100

PHARMACOLOGY

In vitro measurement of orthodontic tooth movement in rats given beta–aminopropionitrile or hydrocortisone using a time–lapse videotape recorder. Yamane A, et al. **Eur J Orthod** 1997 Feb;19(1):21–8

Formation of lamellar bone on the surface of woven bone is not prevented by BAPN. Moskalewski S, et al. **Folia Histochem Cytobiol** 1996;34(2):79–83

Changes in alveolar capillary formation in growing rat lung by repeated injections of a lathyrogen. Ogata M, et al. **Growth Dev Aging** 1996 Autumn–Winter;60(3–4):153–62

THERAPEUTIC USE

Inhibition of wound contraction with locally injected lathyrogenic drugs. Joseph HL, et al. **Am J Surg** 1997 Sep; 174(3):347–50

Treatment of superficial digital flexor tendonitis [letter] Dyson S. **Vet Rec** 1996 Jul 13;139(2):48

3–AMINOPROPYLENE see **ALLYLAMINE**

AMINOPROPYLTRANSFERASE see **SPERMIDINE SYNTHASE**

AMINOPTERIN

ANALOGS & DERIVATIVES

A phase II trial of edatrexate in previously treated squamous cell cervical cancer: a Gynecologic Oncology Group study. Broun ER, et al. **Am J Clin Oncol** 1997 Feb;20(1):78–80

A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Dreicer R, et al. **Am J Clin Oncol** 1997 Jun; 20(3):251–3

Phase II trial of edatrexate in patients with metastatic colorectal cancer. Clamon GH, et al. **Invest New Drugs** 1996;13(4):359–61

Posttranscriptionally mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue–resistant variants of the L1210 cell. Evidence for an altered cognate mRNA in the variants affecting the rate of de novo synthesis of the enzyme. Roy K, et al. **J Biol Chem** 1997 Mar 14;272(11):6903–8

Dipyridamole mediated enhanced antiproliferative activity of 10–ethyl–10–deazaaminopterin (10–EDAM) against human lung cancer cell lines. Dearing MP, et al. **J Cell Biochem Suppl** 1996;24:165–72

Novel high–performance liquid chromatographic assay using fluorescence detection for the quantitation of plasma gamma–methylene–10–deazaaminopterin and its major metabolite, 7–hydroxy–gamma–methylene–10–deazaaminopterin, in patients with solid cancers in a phase I trial. Su H, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1;695(2):401–8

Analogues of methotrexate in rheumatoid arthritis. 2. Effects of 5–deazaaminopterin, 5,10–dideazaaminopterin, and analogues on type II collagen–induced arthritis in mice. Piper JR, et al. **J Med Chem** 1997 Jan 31;40(3):377–84

Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Chatterjee DJ, et al. **Pharm Res** 1997 Aug;14(8):1058–65

PHARMACOLOGY

A heritable folate–sensitive fragile site on chromosome 2p 11.2 (FRA2L). Schuffenhauer S, et al. **Chromosome Res** 1996 Apr;4(3):252–4

THERAPEUTIC USE

Clinical trials renew interest in old drug for children with leukemia [news] **Oncology (Huntingt)** 1996 May;10(5):665–6

2–AMINOPURINE

2–Aminopurine labelled RNA bulge loops. Synthesis and thermodynamics. Zagórowska I, et al. **Biochimie** 1996; 78(2):123–30

ANALOGS & DERIVATIVES

Famciclovir in AIDS–related acute retinal necrosis [letter; comment] Klein JL, et al. **AIDS** 1996 Sep;10(11):1300–1. Comment on: AIDS 1996 Jan;10(1):55–60.

Famciclovir: a new systemic antiviral agent for herpesvirus infections. Stott GA. **Am Fam Physician** 1997 May 15; 55(7):2501–4

Confusion and bradykinesia associated with famciclovir therapy for herpes zoster [letter] Gales BJ, et al. **Am J Health Syst Pharm** 1996 Jun 15;53(12):1454, 1456

Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. Huse DM, et al. **Am J Health Syst Pharm** 1997 May 15;54(10):1180–4

Famciclovir for the treatment of acute retinal necrosis (ARN) syndrome. Figueroa MS, et al. **Am J Ophthalmol** 1997 Feb; 123(2):255–7

Famciclovir for treatment of herpesvirus infections. Luber AD, et al. **Ann Pharmacother** 1996 Sep;30(9):978–85 (42 ref.)

Famciclovir: review of clinical efficacy and safety. Cirelli R, et al. **Antiviral Res** 1996 Mar;29(2–3):141–51 (54 ref.)

Biotransformation and pharmacokinetics of prodrug 9–(beta–D–1,3–dioxolan–4–yl)–2–aminopurine and its antiviral metabolite 9–(beta–D–1,3–dioxolan–4–yl)guanine in mice. Manouilov KK, et al. **Antiviral Res** 1997 Aug; 35(3):187–93

Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79–E cells. I. Purine nucleoside analogues. Thust R, et al. **Antiviral Res** 1996 Jun;31(1–2):105–13

Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double–blind, placebo–controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Mertz GJ, et al. **Arch Intern Med** 1997 Feb 10;157(3):343–9

The clinical pharmacokinetics of famciclovir. Gill KS, et al. **Clin Pharmacokinet** 1996 Jul;31(1):1–8 (25 ref.)

In vitro oxidation of famciclovir and 6–deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Rashidi MR, et al. **Drug Metab Dispos** 1997 Jul; 25(7):805–13

Treatment of herpes simplex & varicella zoster infection [editorial] Barrg C, et al. **Ir Med J** 1996 Jul–Aug; 89(4):132–4 (8 ref.)

Pharmacology of new antiherpes agents: famciclovir and valacyclovir. Stein GE. **J Am Pharm Assoc (Wash)** 1997 Mar–Apr;NS37(2):157–63 (39 ref.)

Unusual contribution of 2–aminoadenine to the thermostability of DNA. Sági J, et al. **J Biomol Struct Dyn** 1996 Jun;13(6):1035–41

Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes. Diaz–Mitoma F, et al. **J Clin Microbiol** 1996 Mar; 34(3):657–63

Oral famciclovir for recurrent genital herpes. Brown D. **J Fam Pract** 1996 Oct;43(4):341–2

Treatment of hepatitis B–related polyarteritis nodosa with famciclovir and interferon alfa–2b. Kruger M, et al. **J Hepatol** 1997 Apr;26(4):935–9

A double blind, placebo–controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. Main J, et al. **J Viral Hepat** 1996 Jul;3(4):211–5

Famciclovir for genital herpes [letter; comment] Goldman BD. **JAMA** 1997 Jan 15;277(3):210–1. Comment on: JAMA 1996 Jul 3;276(1):44–9.

Footprinting of echinomycin and actinomycin D on DNA molecules asymmetrically substituted with inosine and/or 2,6–diaminopurine. Jennewein S, et al. **Nucleic Acids Res** 1997 Apr 15;25(8):1502–10

Effects of diaminopurine and inosine substitutions on A–tract induced DNA curvature. Importance of the 3'–A–tract junction. Mollegaard NE, et al. **Nucleic Acids Res** 1997 Sep 1;25(17):3497–502

The pharmacological profile of famciclovir. Crumpacker C. **Semin Dermatol** 1996 Jun;15(2 Suppl 1):14–26 (44 ref.)

Genital herpes simplex virus and its treatment: focus on famciclovir. Sacks SL. **Semin Dermatol** 1996 Jun;15(2 Suppl 1):32–6 (43 ref.)

Efficacy of famciclovir in the treatment of herpes zoster. Tyring SK. **Semin Dermatol** 1996 Jun;15(2 Suppl 1):27–31 (23 ref.)

Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation. Haller GW, et al. **Transpl Int** 1996;9 Suppl 1:S210–2

Conversion of recurrent delta–positive hepatitis B infection to seronegativity with famciclovir after liver transplantation. Klein M, et al. **Transplantation** 1997 Jul 15;64(1):162–3

[Famciclovir plus interferon in the treatment of a patient with chronic hepatitis B and severe liver failure] Piqueras B, et al. **Rev Esp Enferm Dig** 1997 Mar;89(3):217–21 (Eng. Abstr.) **(Spa)**

ANALYSIS

Spectroscopic and calorimetric characterizations of DNA duplexes containing 2–aminopurine. Law SM, et al. **Biochemistry** 1996 Sep 24;35(38):12329–37

CHEMISTRY

Using 2–aminopurine fluorescence and mutational analysis to demonstrate an active role of bacteriophage T4 DNA polymerase in strand separation required for 3' —> 5'–exonuclease activity. Marquez LA, et al. **J Biol Chem** 1996 Nov 15;271(46):28903–11

PHARMACOLOGY

2–Aminopurine induces spindle cell morphology in MM14 myoblasts in the absence of differentiation signals. Palmer DK, et al. **Exp Cell Res** 1997 Feb 1;230(2):262–74

2–Aminopurine unravels a role for pRB in the regulation of gene expression by transforming growth factor beta. Giannini G, et al. **J Biol Chem** 1997 Feb 21;272(8):5313–9

4–AMINOPYRIDINE

Developmental features of 4–aminopyridine induced epileptogenesis. Psarropoulou C, et al. **Brain Res Dev Brain Res** 1996 Jun 14;94(1):52–9

ADMINISTRATION & DOSAGE

Quantitative assessment of sustained–release 4–aminopyridine for symptomatic treatment of multiple sclerosis. Schwid SR, et al. **Neurology** 1997 Apr;48(4):817–21

ADVERSE EFFECTS

Protection by NMDA receptor antagonists against seizures induced by intracerebral administration of 4–aminopyridine. Morales–Villagrán A, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):87–93

ANALOGS & DERIVATIVES

3,4–Diaminopyridine masks the inhibition of noradrenaline release from chick sympathetic neurons via presynaptic alpha 2–adrenoceptors: insights into the role of N– and L–type calcium channels. Doležal V, et al. **Brain Res** 1996 May 20;721(1–2):101–10

Properties of 3,4–diaminopyridine–evoked dopamine and acetylcholine release in rabbit caudate nucleus slices: involvement of facilitatory adenosine A2 receptors or nitric oxide? Ries V, et al. **Brain Res** 1996 Dec 16;743(1–2):303–14

Effects of DAP on diaphragm force and fatigue, including fatigue due to neurotransmission failure. Van Lunteren E, et al. **J Appl Physiol** 1996 Nov;81(5):2214–20

Effect of 4–aminopyridine and 3,4–diaminopyridine on guinea–pig isolated ileum. Velasco A, et al. **J Auton Pharmacol** 1997 Feb;17(1):53–7

3,4–diaminopyridine in childhood myasthenia: double–blind, placebo–controlled trial. Anlar B, et al. **J Child Neurol** 1996 Nov;11(6):458–61

A double–blind placebo–controlled study of 3,4–diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit. Aisen ML, et al. **J Neurol Sci** 1996 Jun;138(1–2):93–6

Pyridine derivatives stimulate phosphatidylcholine secretion in primary cultures of rat type II pneumocytes. Kai H, et al. **J Pharm Pharmacol** 1996 Jan;48(1):53–6

Stimulated single–fiber electromyography in Lambert–Eaton myasthenic syndrome before and after 3,4–diaminopyridine. Sadeh M, et al. **Muscle Nerve** 1997 Jun;20(6):735–9

Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double–blind, placebo–controlled, crossover trial. Bever CT Jr, et al. **Neurology** 1996 Dec;47(6):1457–62

Acute ventilatory failure in Lambert–Eaton myasthenic syndrome and its response to 3,4–diaminopyridine. Smith AG, et al. **Neurology** 1996 Apr;46(4):1143–5 (15 ref.)

3,4–Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert–Eaton myasthenic syndrome. Molgó J, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R295–6 (25 ref.)

[Catabolism of phosphoinositides after treatment with opioid agonist phenaridin and its antagonist in brain synaptosomes of albion rats in vitro] Vartanian GS, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):405–6 **(Rus)**

ANALYSIS

Optimization of the determination of 4–aminopyridine in human serum and urine by column liquid chromatography. Gupta RN, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23;677(1):183–9

PHARMACOKINETICS

A method for determining 4–aminopyridine in plasma: pharmacokinetics in anaesthetized guinea pigs after intravenous administration. Capacio BR, et al. **Biomed Chromatogr** 1996 May–Jun;10(3):111–6

PHARMACOLOGY

Induction of human myeloblastic ML–1 cell G1 arrest by suppression of K+ channel activity. Xu B, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):C2037–44

Sodium effects on 4–aminopyridine–sensitive transient outward current in canine ventricular cells. Zygmunt AC, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H1–11

Regulation of 4–aminopyridine–sensitive, delayed rectifier K+ channels in vascular smooth muscle by phosphorylation. Cole WC, et al. **Biochem Cell Biol** 1996; 74(4):439–47 (52 ref.)

Extracellular action potentials of skeletal muscle fibre affected by 4–aminopyridine: a model study. Slavcheva G, et al. **Biol Cybern** 1996 Mar;74(3):235–41

The effects of anticonvulsants on 4–aminopyridine–induced bursting: in vitro studies on rat peripheral nerve and dorsal roots. Lees G. **Br J Pharmacol** 1996 Feb;117(3):573–579

The inhibitory effects of iberiotoxin and 4–aminopyridine on the relaxation induced by beta 1– and beta 2–adrenoceptor activation in rat aortic rings. Satake N, et al. **Br J Pharmacol** 1996 Oct;119(3):505–10

Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury. Fehlings MG, et al. **Brain Res** 1996 Oct 14; 736(1–2):135–45

4–aminopyridine and l–cis–diltiazem block the cGMP–activated K+ channels closed by light in the molluscan extra–ocular photoreceptors. Gotow T, et al. **Brain Res** 1997 Jan 16;745(1–2):303–8

pH–dependent actions of 4–aminopyridine on atrial repolarization: effects on the transient outward current. Qi A, et al. **Can J Physiol Pharmacol** 1996 Mar;74(3):305–12

The positive inotropic effect of alpha 1A–adrenoceptor stimulation is inhibited by 4–aminopyridine. Williamson AP, et al. **Eur J Pharmacol** 1996 May 23;304(1–3):73–80

Extracellular K+ accumulations and synchronous GABA–mediated potentials evoked by 4–aminopyridine in the adult rat hippocampus. Morris ME, et al. **Exp Brain Res** 1996 Apr;109(1):71–82

Effect of 4–aminopyridine and 3,4–diaminopyridine on guinea–pig isolated ileum. Velasco A, et al. **J Auton Pharmacol** 1997 Feb;17(1):53–7

Oxygen–induced constriction of rabbit ductus arteriosus occurs via inhibition of a 4–aminopyridine–, voltage–sensitive potassium channel [see comments] Tristani–Firouzi M, et al. **J Clin Invest** 1996 Nov 1; 98(9):1959–65. Comment in: J Clin Invest 1996 Nov 1;98(9):1945–6.

Micromolar 4–aminopyridine enhances invasion of a vertebrate neurosecretory terminal arborization: optical recording of action potential propagation using an ultrafast photodiode–MOSFET camera and a photodiode array. Obaid AL, et al. **J Gen Physiol** 1996 Mar;107(3):353–68

Differential effects of 4–aminopyridine, serotonin, and phorbol esters on facilitation of sensorimotor connections in Aplysia. Sugita S, et al. **J Neurophysiol** 1997 Jan; 77(1):177–85

Enhanced fast synaptic transmission and a delayed depolarization induced by transient potassium current blockade in rat hippocampal slice as studied by optical recording. Barish ME, et al. **J Neurosci** 1996 Sep 15; 16(18):5672–87

Effects of 4–aminopyridine on muscle and motor unit force in canine motor neuron disease. Pinter MJ, et al. **J Neurosci** 1997 Jun 1;17(11):4500–7

4–Aminopyridine causes apoptosis and blocks an outward rectifier K+ channel in malignant astrocytoma cell lines. Chin LS, et al. **J Neurosci Res** 1997 Apr 15;48(2):122–7

Effects of 4–aminopyridine on motor evoked potentials in patients with spinal cord injury. Qiao J, et al. **J Neurotrauma** 1997 Mar;14(3):135–49

The potassium channel blockers 4–aminopyridine and tetraethylammonium increase the spontaneous basal release of [3H]5–hydroxytryptamine in rat hippocampal slices. Schechter LE. **J Pharmacol Exp Ther** 1997 Jul; 282(1):262–70

Reverse use dependence of Kv4.2 blockade by 4–aminopyridine. Tseng GN, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):865–76

Extracellular free potassium and calcium during synchronous activity induced by 4–aminopyridine in the juvenile rat hippocampus. Avoli M, et al. **J Physiol (Lond)** 1996 Jun 15;493 (Pt 3):707–17

Slow gating charge immobilization in the human potassium channel Kv1.5 and its prevention by 4–aminopyridine. Fedida D, et al. **J Physiol (Lond)** 1996 Jul 15;494 (Pt 2):377–87

4–aminopyridine activates potassium currents by activation of a muscarinic receptor in feline atrial myocytes. Navarro–Polanco RA, et al. **J Physiol (Lond)** 1997 Feb 1;498 (Pt 3):663–78

Mechanism of inhibition of delayed rectifier K+ current by 4–aminopyridine in rabbit coronary myocytes. Remillard CV, et al. **J Physiol (Lond)** 1996 Mar 1;491 (Pt 2):383–400

Nivalin P–induced changes in muscle fiber membrane processes. Radicheva N, et al. **Methods Find Exp Clin Pharmacol** 1996 Jun;18(5):301–8

Suppression by GABAB receptors of 4–aminopyridine–induced hyperactivity in guinea–pig dentate neurons. Bijak M, et al. **Neurosci Lett** 1996 Feb 16;205(1):49–52

Developmental changes of the ultrarapid delayed rectifier K+ current in rat ventricular myocytes. Guo W, et al. **Pflugers Arch** 1997 Feb;433(4):442–5

The effects of taxol, methylprednisolone, and 4–aminopyridine in compressive spinal cord injury: a qualitative experimental study. Perez–Espejo MA, et al. **Surg Neurol** 1996 Oct;46(4):350–7

4–Aminopyridine antagonizes saxitoxin–and tetrodotoxin–induced cardiorespiratory depression. Chang FC, et al. **Toxicon** 1996 Jun;34(6):671–90

[The effect of 4–aminopyridine on indirectly evoked contractions of the diaphragm in rats in situ] Ivković–Lanier B, et al. **Vojnosanit Pregl** 1996 Mar–Apr; 53(2):121–3 (Eng. Abstr.) **(Scr)**

THERAPEUTIC USE

4–Aminopyridine improves pulmonary function in quadriplegic humans with longstanding spinal cord injury. Segal JL, et al. **Pharmacotherapy** 1997 May–Jun; 17(3):415–23

Effects of 4–aminopyridine on saxitoxin intoxication. Chen HM, et al. **Toxicol Appl Pharmacol** 1996 Nov;141(1):44–8

TOXICITY

4–Aminopyridine effects on summating potentials in the guinea pig. van Emst MG, et al. **Hear Res** 1996 Dec 1; 102(1–2):70–80

Pyridine derivatives stimulate phosphatidylcholine secretion in primary cultures of rat type II pneumocytes. Kai H, et al. **J Pharm Pharmacol** 1996 Jan;48(1):53–6

AMINOPYRIDINES

ADMINISTRATION & DOSAGE

[Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double–blind study] Wörz R, et al. **Fortschr Med** 1996 Dec 20;114(35–36):500–4 (Eng. Abstr.) **(Ger)**

ANALYSIS

Simultaneous determination of tenoxicam and 2–aminopyridine using derivative spectrophotometry and high–performance liquid chromatography. el Walily AF, et al. **J Pharm Biomed Anal** 1997 Aug;15(12):1923–8

CHEMISTRY

Heterocyclic N–acetoxyarylamines, models for the putative ultimate carcinogens of aromatic amines: 2–acetoxyamino–5–phenylpyridine and 2–acetoxyaminopyridine. Ojala WH, et al. **Acta Crystallogr C** 1997 May 15;53 (Pt 5):634–7

Analysis of pyridylaminated O–linked sugar chains by two–dimensional sugar mapping. Kuraya N, et al. **Anal Biochem** 1996 Jan 15;233(2):205–11

High–sensitivity detection and postsource decay of 2–aminopyridine–derivatized oligosaccharides with matrix–assisted laser desorption/ionization mass spectrometry. Okamoto M, et al. **Anal Chem** 1997 Aug 1; 69(15):2919–26

Chiral recognition by the copper(II) complex of 6–deoxy–6–N–(2–methylaminopyridine)–beta–cyclodextrin. Bonomo RP, et al. **Chirality** 1997;9(4):341–9

DIAGNOSTIC USE

In vivo SPECT imaging of 5–HT1A receptors with [123I]p–MPPI in nonhuman primates. Kung HF, et al. **Synapse** 1996 Nov;24(3):273–81

METABOLISM

Ion exchange HPLC microanalysis of chondroitin sulfate: quantitative derivatization of chondroitin lyase digestion products with 2–aminopyridine. Plaas AH, et al. **Glycobiology** 1996 Dec;6(8):823–9

New 5–HT1A receptor antagonist: [3H]p–MPPF. Kung HF, et al. **Synapse** 1996 Aug;23(4):344–6

P–[18F]–MPPF: a potential radioligand for PET studies of 5–HT1A receptors in humans. Shiue CY, et al. **Synapse** 1997 Feb;25(2):147–54

PHARMACOKINETICS

5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: II. Pharmacokinetics and demonstration of clinical safety. Khandwala A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):231–8

PHARMACOLOGY

Effect of SB–205384 on the decay of GABA–activated chloride currents in granule cells cultured from rat cerebellum. Meadows HJ, et al. **Br J Pharmacol** 1997 Aug; 121(7):1334–8

Flupirtine reduces functional deficits and neuronal damage after global ischemia in rats. Block F, et al. **Brain Res** 1997 Apr 18;754(1–2):279–84

Flupirtine increases the levels of glutathione and Bc1–2 in hNT (human Ntera/D1) neurons: mode of action of the drug–mediated anti–apoptotic effect. Perovic S, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):157–64

Substituted 4–aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D4 receptor. Schlachter SK, et al. **Eur J Pharmacol** 1997 Mar 19;322(2–3):283–6

Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Schmidt WJ, et al. **Eur J Pharmacol** 1997 May 26;327(1):1–9

Induction of apoptosis in cultured human retinal pigment epithelial cells is counteracted by flupirtine. Osborne NN, et al. **Invest Ophthalmol Vis Sci** 1997 Jun;38(7):1390–400

Cholinesterase inhibition by derivatives of 2–amino–4,6–dimethylpyridine. Debord J, et al. **J Enzyme Inhib** 1997 Apr;12(1):13–26

Protection of flupirtine on beta–amyloid–induced apoptosis in neuronal cells in vitro: prevention of amyloid–induced glutathione depletion. Müller WE, et al. **J Neurochem** 1997 Jun;68(6):2371–7

Nitric oxide synthase inhibitor facilitates aminopyridine induced neocortical seizure. Boda B, et al. **Neurobiology (Bp)** 1996;4(1–2):103–4

SB 242084, a selective and brain penetrant 5–HT2C receptor antagonist. Kennett GA, et al. **Neuropharmacology** 1997 Apr–May;36(4–5):609–20

The 5–HT1A receptor antagonist p–MPPI blocks responses mediated by postsynaptic and presynaptic 5–HT1A receptors. Allen AR, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):301–7

Neurotoxicity in rat cortical cells caused by N–methyl–D–aspartate (NMDA) and gp120 of HIV–1: induction and pharmacological intervention. Müller WE, et al. **Prog Mol Subcell Biol** 1996;16:44–57

Anxiolytic–like profile of p–MPPI, a novel 5HT1A receptor antagonist, in the murine elevated plus–maze. Cao BJ, et al. **Psychopharmacology (Berl)** 1997 Feb;129(4):365–71

[Clinical pilot study of the myogenic effects of flupirtine in comparison to tetrazepam and placebo] Lobisch M, et al. **Arzneimittelforschung** 1996 Mar;46(3):293–8 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Antiparkinsonian effect of flupirtine in monoamine–depleted rats. Schwarz M, et al. **J Neural Transm Gen Sect** 1996; 103(5):581–90

5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: I. Clinical demonstration of acceleration of healing and resolution of pain. Khandwala A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):222–30

5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: II. Pharmacokinetics and demonstration of clinical safety. Khandwala A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):231–8

[Mechanism of action of a new anti–inflammatory analgesic drug in some eye disorders] Manusia M. **Minerva Oftalmol** 1967 Jul–Aug;9(4):137–9 (Eng. Abstr.) **(Ita)**

TOXICITY

Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. Smith CP, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):710–20

AMINOPYRINE

ADVERSE EFFECTS

Reactive metabolites and agranulocytosis. Uetrecht JP. **Eur J Haematol Suppl** 1996;60:83–8 (38 ref.)

[33-year-old patient with postpartum myocardial infarct] Rosenkranz S, et al. **Internist (Berl)** 1997 Jun;38(6):602–5 **(Ger)**

ANALOGS & DERIVATIVES

High-performance liquid chromatographic analysis of dipyrone metabolites to study their formation in human liver microsomes. Geisslinger G, et al. **Pharm Res** 1996 Aug;13(8):1272–5

METABOLISM

Redox mediation in the peroxidase-catalyzed oxidation of aminopyrine: possible implications for drug–drug interactions. Goodwin DC, et al. **Chem Res Toxicol** 1996 Mar;9(2):476–83

Oxidation of aminopyrine by the hydroperoxidase activity of lipoxygenase: a new proposed mechanism of N-demethylation. Pérez-Gilabert M, et al. **Free Radic Biol Med** 1997;23(4):548–55

Microsomal and peroxisomal fatty acid oxidation in bile duct ligated rats: a comparative study between liver and kidney. Orellana M, et al. **Gen Pharmacol** 1997 Apr;28(4):525–9

PHARMACOLOGY

Antipyrine and aminopyrine induce acetaldehyde accumulation from ethanol in isolated hepatocytes. Efthivoulou MA, et al. **Alcohol Clin Exp Res** 1997 Apr; 21(2):267–74

AMINOPYRINE N-DEMETHYLASE

METABOLISM

In vivo and in vitro effect of sulfamethazine on hepatic mixed function oxidases in rats. Kodam KM, et al. **Vet Hum Toxicol** 1997 Jun;39(3):141–6

AMINOQUINOLINES

Increasing the sensitivity of 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate amino acid analysis: a simple solution. Crimmins DL, et al. **Anal Biochem** 1997 Jan 15;244(2):407–10

High-resolution reversed-phase high-performance liquid chromatography analysis of polyamines and their monoacetyl conjugates by fluorescence detection after derivatization with N-hydroxysuccinimidyl 6-quinolinyl carbamate. Weiss T, et al. **Anal Biochem** 1997 May 1; 247(2):294–304

ADMINISTRATION & DOSAGE

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Savage P, et al. **Br J Cancer** 1996 Nov;74(9):1482–6

BLOOD

Simultaneous determination of a novel anticancer drug, TAS-103, and its N-demethylated metabolite in monkey plasma by high-performance liquid chromatography using solid-phase extraction. Azuma R, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):179–85

CHEMICAL SYNTHESIS

Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites. Heier RF, et al. **J Med Chem** 1997 Feb 28;40(5):639–46

Synthesis, structural analysis and pharmacological effects of N2-substituted 3,4-dihydrobenzo[h]quinolin-2-amines. Wendelin W, et al. **Pharmazie** 1996 Nov;51(11):816–22

CHEMISTRY

Alpha and beta phases of 4-aminoquinoline-2-carboxylic acid monohydrate. Burd CJ, et al. **Acta Crystallogr C** 1997 May 15;53 (Pt 5):602–5

Separation of 18 6-aminoquinolyl-carbamyl-amino acids by ion-pair chromatography. Shindo N, et al. **Anal Biochem** 1997 Jun 15;249(1):79–82

Cytotoxic quinolines (part 2). Azolylalkylamino and-thio quinolines. Abel MD, et al. **Drug Des Discov** 1996 Mar; 14(1):31–42

H2O2-driven reduction of the Fe3+-quin2 chelate and the subsequent formation of oxidizing species. Sandström BE, et al. **Free Radic Biol Med** 1997;23(5):744–53

Design and synthesis of a beta-strand inducer. Application to ICAM-1/LFA-1 mediated cellular adhesion. Michne WF, et al. **Int J Pept Protein Res** 1996 Jan-Feb;47(1-2):2–8

Electrochemical activity of 6-aminoquinolyl urea derivatives of amino acids and peptides. Application to high-performance liquid chromatography with electrochemical detection. Li GD, et al. **J Chromatogr A** 1996 Feb 16;724(1-2):147–57

Polyamine analysis using N-hydroxysuccinimidyl-6-aminoquinoyl carbamate for pre-column derivatization. Merali S, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26;675(2):321–6

Chemometric methodologies in a quantitative structure-activity relationship study: the antibacterial activity of 6-aminoquinolones. Cecchetti V, et al. **J Med Chem** 1997 May 23;40(11):1698–706

Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues. O'Neill PM, et al. **J Med Chem** 1997 Feb 14;40(4):437–48

METABOLISM

Characterization of simian malarial parasite (Plasmodium knowlesi)-induced putrescine transport in rhesus monkey erythrocytes. A novel putrescine conjugate arrests in vitro growth of simian malarial parasite (Plasmodium knowlesi) and cures multidrug resistant murine malaria (Plasmodium yoelii) infection in vivo. Singh S, et al. **J Biol Chem** 1997 May 23;272(21):13506–11

High-performance liquid chromatographic determination of lipoamidase (lipoyl-X hydrolase) activity with a novel substrate, lipoyl-6-aminoquinoline. Yoshikawa K, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1-2):41–7

PHARMACOLOGY

Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro. De D, et al. **Am J Trop Med Hyg** 1996 Dec;55(6):579–83

Potential use of WR6026 as prophylaxis against transfusion-transmitted American trypanosomiasis. Chiari E, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):613–5

4-aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum. Ridley RG, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1846–54

Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males [see comments] Colao A, et al. **Eur J Endocrinol** 1996 Nov;135(5):548–52. Comment in: Eur J Endocrinol 1997 Jun;136(6):630.

Pharmacology of U-91356A, an agonist for the dopamine D2 receptor subtype. Piercey MF, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):29–38

Tricyclic heteroaromatic systems. 3-substituted 1,2,3,5,6,7-hexahydro-2,5,6-trioxopyrazino[1,2,3-de]-quinoxalines as novel antagonists at the glycine-NMDA site. Varano F, et al. **Farmaco** 1997 Mar;52(3):179–82

Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production. Fujisawa H, et al. **J Interferon Cytokine Res** 1996 Jul; 16(7):555–9

Chemometric methodologies in a quantitative structure-activity relationship study: the antibacterial activity of 6-aminoquinolones. Cecchetti V, et al. **J Med Chem** 1997 May 23;40(11):1698–706

PET measurement of dopamine D2 receptor-mediated changes in striatopallidal function. Black KJ, et al. **J Neurosci** 1997 May 1;17(9):3168–77

Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia. Kojima J, et al. **Methods Find Exp Clin Pharmacol** 1997 May;19(4):245–51

4-Aminoquinoline resistance of Plasmodium falciparum: insights from the study of amodiaquine uptake. Bray PG, et al. **Mol Pharmacol** 1996 Dec;50(6):1551–8

Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. Goulet M, et al. **Neuroscience** 1997 Jul;79(2):497–507

[Inhibition of RAS-transformation by SCH51344] Kumar CC. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1503–11 (35 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Obaldia N 3rd, et al. **Am J Trop Med Hyg** 1997 May;56(5):508–10

Evidence that certain 8-aminoquinolines are potentially effective drugs against Chagas disease. Kinnamon KE, et al. **Ann Trop Med Parasitol** 1997 Mar;91(2):147–52

Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Morange I, et al. **Eur J Endocrinol** 1996 Oct;135(4):413–20

Effect of different dopaminergic agents in the treatment of acromegaly. Colao A, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):518–23

Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy [letter; comment] Colao A, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2756. Comment on: J Clin Endocrinol Metab 1997 Aug;82(8):2755–6.

Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy [letter; comment] [see comments] Delgrange E, et al. **J Clin Endocrinol Metab** 1997 Aug; 82(8):2755–6. Comment on: J Clin Endocrinol Metab 1997 Mar;82(3):876–83. Comment in: J Clin Endocrinol Metab 1997 Aug;82(8):2756.

In vivo and In vitro interferon induction in chickens by S-28828, an imidazoquinolinamine immunoenhancer. Karaca K, et al. **J Interferon Cytokine Res** 1996 Apr;16(4):327–32

An exploration of the structure-activity relationships of 4-aminoquinolines: novel antimalarials with activity in-vivo. Ismail FM, et al. **J Pharm Pharmacol** 1996 Aug; 48(8):841–50

Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning. Deshpande SS, et al. **Toxicon** 1997 Mar;35(3):433–45

[Quinagolide and macroprolactinomas a progress?] Jaquet P. **Ann Endocrinol (Paris)** 1997;58(2):83–5 (35 ref.) **(Fre)**

[Treatment of macroprolactinomas with quinagolide (Norprolac)] Tabarin A, et al. **Ann Endocrinol (Paris)** 1997; 58(2):87–94 (30 ref.) (Eng. Abstr.) **(Fre)**

[An evaluation of the results of the long-term treatment of rheumatoid arthritis patients with gold salts, aminoquinoline preparations and nonsteroidal anti-inflammatory preparations] Ivanova MM, et al. **Ter Arkh** 1997;69(5):27–32 **(Rus)**

AMINOREX

ADVERSE EFFECTS

The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Frank H, et al. **Chest** 1997 Sep;112(3):714–21

Appetite-suppressant drugs and primary pulmonary hypertension [letter; comment] Fishman AP. **N Engl J Med** 1997 Feb 13;336(7):511; discussion 512-3. Comment on: N Engl J Med 1996 Aug 29;335(9):609–16.

PHARMACOLOGY

Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Weir EK, et al. **Circulation** 1996 Nov 1;94(9):2216–20

TOXICITY

The effects of aminorex and related compounds on brain monoamines and metabolites in CBA mice. Zheng Y, et al. **J Pharm Pharmacol** 1997 Jan;49(1):89–96

4-AMINOSALICYLIC ACID see **P-AMINOSALICYLIC ACID**

P-AMINOSALICYLIC ACID

ADMINISTRATION & DOSAGE

Four-drug initial therapy for TB is standard treatment. Brennan PJ, et al. **Pa Med** 1996 Jan;99(1):18–9

ANALYSIS

Simple spectrofluorometric determination of p-aminobenzoic and p-aminosalicylic acids in biological fluids by use of terbium-sensitized luminescence. Lianidou ES, et al. **Clin Chem** 1996 Oct;42(10):1659–65

METABOLISM

The effect of surfactants on the rate of decarboxylation of p-aminosalicylic acid in acidic aqueous solutions. Plamondon JE, et al. **J Pharm Sci** 1997 Feb;86(2):205–8

PHARMACOKINETICS

Determination of diffusion coefficients of sodium p-aminosalicylate in sheep nasal mucosae and dialysis membranes by Fourier transform infrared horizontal attenuated total reflectance spectroscopy. Nardviriyakul N, et al. **J Pharm Sci** 1997 Jan;86(1):19–25

PHARMACOLOGY

The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cells. Schmidt C, et al. **Curr Med Res Opin** 1996;13(7):417–25

THERAPEUTIC USE

Controlled trial of 4-ASA in ulcerative colitis. Beeken W, et al. **Dig Dis Sci** 1997 Feb;42(2):354–8

AMINOSALICYLIC ACIDS

ADMINISTRATION & DOSAGE

Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis. Lucidarme D, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):335–40

Innovations in topical therapy. Richter F, et al. **Baillieres Clin Gastroenterol** 1997 Mar;11(1):97–109 (82 ref.)

Topical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis [letter] Rymes N, et al. **Bone Marrow Transplant** 1996 Aug;18(2):484

The topical treatment of distal ulcerative colitis. Ardizzone S, et al. **Eur J Gastroenterol Hepatol** 1996 Jun;8(6):599–602 (14 ref.)

Immune thrombocytopenia and ulcerative colitis: response to nonoperative therapy. McCaulley ME. **J Clin Gastroenterol** 1996 Oct;23(3):242–3

5-Aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis.

Odes HS. **J Clin Gastroenterol** 1997 Jun;24(4):287–8

Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. Takaya T, et al. **J Drug Target** 1997;4(5):271–6

ADVERSE EFFECTS

Adverse events in patients treated with 5-aminosalicyclic acid: 1993–1994 pharmacovigilance report for Pentasa in France. Marteau P, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):949–56 (83 ref.)

5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Walker AM, et al. **Am J Gastroenterol** 1997 May;92(5):816–20

Interstitial pneumonitis due to mesalamine [letter] Pascual-Lledó JF, et al. **Ann Pharmacother** 1997 Apr; 31(4):499

Mesalamine-induced lung disease [letter] Lázaro MT, et al. **Arch Intern Med** 1997 Feb 24;157(4):462

Hypersensitivity to 5-ASA suppositories. Borum ML, et al. **Dig Dis Sci** 1997 May;42(5):1076–8 (44 ref.)

5-Aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease. Hämling J, et al. **Digestion** 1997;58(3):304–7

Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Schreiber S, et al. **Gut** 1997 Jun;40(6):761–6

Nephrotic syndrome from 5-ASA for ulcerative colitis? Complicated by carcinoma of the colon and sclerosing cholangitis. Fornaciari G, et al. **J Clin Gastroenterol** 1997 Jan;24(1):37–9

Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature. Sviri S, et al. **J Clin Gastroenterol** 1997 Jan;24(1):34–6

Cholestasis associated with mesalazine therapy in a patient with Crohn's disease. Stoschus B, et al. **J Hepatol** 1997 Feb;26(2):425–8

Mesalazine-associated interstitial nephritis [letter; comment] Mani V. **Nephrol Dial Transplant** 1997 Mar;12(3):622–3. Comment on: Nephrol Dial Transplant 1996 Apr;11(4):614–21.

Minimal-change nephropathy induced by 5-aminosalicylic acid [letter] Zorzets Z, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):1187–8

Olsalazine-induced lupus syndrome. Gunnarsson I, et al. **Scand J Rheumatol** 1997;26(1):65–6

[Hypersensitivity to 5-aminosalicylic acid. Value of desensitization by oral route] Lachaux A, et al. **Arch Pediatr** 1997 Feb;4(2):144–6 (Eng. Abstr.) **(Fre)**

[Side effects of 5-aminosalicylic acid] Marteau P, et al. **Gastroenterol Clin Biol** 1997;21(5):377–86 (118 ref.) **(Fre)**

[Pneumonitis caused by mesalazine] Pascual Lledó F, et al. **Arch Bronconeumol** 1997 Jun;33(6):309–11 (Eng. Abstr.) **(Spa)**

ANALYSIS

Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine [letter] Tzivras M, et al. **Eur J Gastroenterol Hepatol** 1997 Jul;9(7):729–30

Simultaneous determination of 5-aminosalicylic acid, acetyl-5-aminosalicylic acid and 2,5-dihydroxybenzoic acid in endoscopic intestinal biopsy samples in humans by high-performance liquid chromatography with electrochemical detection. Palumbo G, et al. **J Pharm Biomed Anal** 1995 Dec;14(1–2):175–80

DIAGNOSTIC USE

Basic studies on 5-(7-hydroxy-3-O-phosphonocholyl)aminosalicylic acid for the evaluation of microbial overgrowth. Konishi T, et al. **Biol Pharm Bull** 1997 Apr;20(4):370–5

HISTORY

[The 50th anniversary of para-amino-salicylic acid—a historical retrospect. Again and important agent in tuberculosis] Berglund E. **Lakartidningen** 1997 Jun 4; 94(23):2205–6, 2209 **(Swe)**

METABOLISM

5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Stretch GL, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):941–7

Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. Karamanolis DG, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1083–8

PHARMACOKINETICS

Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Gionchetti P, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):601–5

Distribution of mesalazine enemas in active and quiescent ulcerative colitis. van Bodegraven AA, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):327–32

PHARMACOLOGY

The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cells. Schmidt C, et al. **Curr Med Res Opin** 1996;13(7):417–25

Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine [letter] Tzivras M, et al. **Eur J Gastroenterol Hepatol** 1997 Jul;9(7):729–30

The anti-oxidant properties of 5-aminosalicylic acid. Pearson DC, et al. **Free Radic Biol Med** 1996;21(3):367–73

Cytokine gene transcription of human colonic intraepithelial lymphocytes costimulated with epithelial cells bearing HLA-DR and its inhibition by 5-aminosalicylic acid. Chen D, et al. **J Clin Immunol** 1996 Jul;16(4):237–41

THERAPEUTIC USE

5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Stretch GL, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):941–7

Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome. Tebano MT, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):659–63

Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Thomson AB, et al. **Aliment Pharmacol Ther** 1995 Dec; 9(6):673–83

Cytokines and mechanisms of action of glucocorticoids and aminosalicylates in the treatment of ulcerative colitis and Crohn's disease. Zimmerman MJ, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:93–8; discussion 99 (56 ref.)

Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. d'Albasio G, et al. **Am J Gastroenterol** 1997 Jul;92(7):1143–7

The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease. Bonapace CR, et al. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):907–13 (32 ref.)

Successful treatment of epidermolysis bullosa acquisita with mesalazine [letter] Robinowitz BN, et al. **Br J Dermatol** 1997 Jul;137(1):154–5

Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. Karamanolis DG, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1083–8

Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Mulder CJ, et al. **Eur J Gastroenterol Hepatol** 1996 Jun;8(6):549–53

A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Hawkey CJ, et al. **Gastroenterology** 1997 Mar;112(3):718–24

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Sutherland LR, et al. **Gastroenterology** 1997 Apr;112(4):1069–77

Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution? Sahmoud T, et al. **Gut** 1997 Feb;40(2):284–5

Regarding Martenson et al., IJROBP 35:299–303; 1996 [letter] Michalowski AS. **Int J Radiat Oncol Biol Phys** 1996 Dec 1;36(5):1285–6

Is it possible to prevent recurrent Crohn's disease with medical or surgical interventions? Mcleod RS. **Neth J Med** 1996 Feb;48(2):68–70 (15 ref.)

A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Resbeut M, et al. **Radiother Oncol** 1997 Jul; 44(1):59–63

Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease. Brynskov J, et al. **Scand J Gastroenterol Suppl** 1996; 216:175–80 (48 ref.)

[Pharmacological studies of BX661A. 5-[4-(2-carboxyethylcarbamoyl)-phenylazo]-salicylic acid disodium salt dihydrate (1). Therapeutic effects on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) model in rats] Kimura I, et al. **Nippon Yakurigaku Zasshi** 1997 Feb;109(2):85–94 (Eng. Abstr.) **(Jpn)**

[The treatment of inflammatory intestinal diseases with preparations of 5-aminosalicylic acid] Frol'kis AV. **Ter Arkh** 1996;68(2):75–7 (49 ref.) **(Rus)**

[Pharmacological bases of therapy with 5-ASA] Beltrán B, et al. **Gastroenterol Hepatol** 1997 Jun–Jul;20(6):322–34 (107 ref.) **(Spa)**

AMINOSIDINE see **PAROMOMYCIN**

AMINOTRANSFERASES

BIOSYNTHESIS

Molecular characterisation of kynurenine pathway enzymes. 3-Hydroxyanthranilic-acid dioxygenase and kynurenine aminotransferase. Cesura AM, et al. **Adv Exp Med Biol** 1996;398:477–83

Cloning of rat and human kynurenine aminotransferase. Mosca M, et al. **Adv Exp Med Biol** 1996;398:449–54

Induction of L-lysine epsilon-aminotransferase by L-lysine in Streptomyces clavuligerus, producer of cephalosporins [published erratum appears in FEMS Microbiol Lett 1997 Jan 15;146(2):319] Rius N, et al. **FEMS Microbiol Lett** 1996 Nov 1;144(2–3):207–11

Kynurenic acid and kynurenine aminotransferase in heart. Baran H, et al. **Pediatr Res** 1997 Mar;41(3):404–10

Molecular cloning, characterization and expression of cDNA encoding phosphoserine aminotransferase involved in phosphorylated pathway of serine biosynthesis from spinach. Saito K, et al. **Plant Mol Biol** 1997 Jan; 33(2):359–66

BLOOD

Elevated aminotransferase activity as an indication of muscular dystrophy: case reports and review of the literature. Zamora S, et al. **Can J Gastroenterol** 1996 Oct; 10(6):389–93 (30 ref.)

Pyridoxal-5' -phosphate stimulation of aminotransferase activities in serum of hemodialysis patients and renal-transplant recipients [letter] Jung K. **Clin Nephrol** 1996 Jun;45(6):416–7

Celiac disease presenting with marked aminotransferase elevation. A patient report and review of the literature. Mahajan L, et al. **Clin Pediatr (Phila)** 1996 Dec; 35(12):653–5 (12 ref.)

Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. Farrow AC, et al. **J Clin Oncol** 1997 Apr;15(4):1560–6

Prevalence and clinical and histological manifestation of hepatitis G/GBV-C infections in patients with elevated aminotransferases of unknown etiology. Sarrazin C, et al. **J Hepatol** 1997 Aug;27(2):276–83

Are elevated aminotransferases and decreased bilirubin additional characteristics of the metabolic syndrome? Torgerson JS, et al. **Obes Res** 1997 Mar;5(2):105–14

[Appearance of hepatitis C virus replication and increase of aminotransferase activity after corticoid treatment of presumed autoimmune hepatitis. 2 cases] Béchade D, et al. **Gastroenterol Clin Biol** 1996;20(8–9):696–9 (Eng. Abstr.) **(Fre)**

[Persistent increase of serum activity of aminotransferases disclosing muscular diseases in children and adolescents (letter)] Michaud L, et al. **Gastroenterol Clin Biol** 1997; 21(2):159–60 **(Fre)**

[Chronic idiopathic hypertransaminasemia] Zancan L, et al. **Minerva Pediatr** 1996 May;48(5):209–16 (Eng. Abstr.) **(Ita)**

[A statistical epidemiological study of a possible correlation between serum transaminase levels and viral hepatic pathology markers and lichen planus orale] Serpico R, et al. **Minerva Stomatol** 1997 Mar;46(3):97–102 (Eng. Abstr.) **(Ita)**

[Asymptomatic hypertransaminasemia] Balli F, et al. **Pediatr Med Chir** 1996 Jul–Aug;18(4):363–4 (Eng. Abstr.) **(Ita)**

[Significant increase in transaminases in a patient with acute calculous cholecystitis (letter; comment)] Perello Roso A, et al. **An Med Interna** 1997 Feb;14(2):104. Comment on: An Med Interna 1994 Aug;11(8):414–5. **(Spa)**

[Isolated hypertransaminemia as a form of presentation of celiac disease in adults (letter)] Garrido C, et al. **Gastroenterol Hepatol** 1996 Nov;19(9):489–90 **(Spa)**

[Changes in liver function tests during intensive prolonged exercise (letter)] Gutiérrez Stampa MA, et al. **Med Clin (Barc)** 1996 Sep 28;107(10):396 **(Spa)**

CHEMICAL SYNTHESIS

Pyridoxamine-amino acid chimeras in semisynthetic aminotransferase mimics. Roy RS, et al. **Protein Eng** 1997 Jun;10(6):691–8

CHEMISTRY

Molecular characterisation of kynurenine pathway enzymes. 3-Hydroxyanthranilic-acid dioxygenase and kynurenine aminotransferase. Cesura AM, et al. **Adv Exp Med Biol** 1996;398:477–83

Cloning of rat and human kynurenine aminotransferase. Mosca M, et al. **Adv Exp Med Biol** 1996;398:449–54

Context dependency of the PTS1 motif in human alanine: glyoxylate aminotransferase 1. Oatey PB, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:652–3

Cloning and characterization of the tyrB gene from Salmonella typhimurium. Nakai Y, et al. **Biochim Biophys Acta** 1996 Sep 11;1308(3):189–92

Three-dimensional structure of Escherichia coli branched-chain amino acid aminotransferase at 2.5 A resolution. Okada K, et al. **J Biochem (Tokyo)** 1997 Apr; 121(4):637–41

Paracoccus denitrificans aromatic amino acid aminotransferase: a model enzyme for the study of dual substrate recognition mechanism. Oue S, et al. **J Biochem (Tokyo)** 1997 Jan;121(1):161–71

Pyridoxamine-amino acid chimeras in semisynthetic aminotransferase mimics. Roy RS, et al. **Protein Eng** 1997 Jun;10(6):691–8

Crystallization and preliminary X-ray analysis of phosphoserine aminotransferase from Bacillus circulans subsp. alkalophilus. Moser M, et al. **Protein Sci** 1996 Jul; 5(7):1426–8

AMINOTRANSFERASES

DRUG EFFECTS

In vitro stabilization and in vivo solubilization of foreign proteins by the beta subunit of a chaperonin from the hyperthermophilic archaeon Pyrococcus sp. strain KOD1. Yan Z, et al. **Appl Environ Microbiol** 1997 Feb;63(2):785–9

GENETICS

A vertical (pseudodominant) pattern of inheritance in the autosomal recessive disease primary hyperoxaluria type 1: lack of relationship between genotype, enzymic phenotype, and disease severity. Hoppe B, et al. **Am J Kidney Dis** 1997 Jan;29(1):36–44 (27 ref.)

Cloning and expression of a rat kidney cytosolic glutamine transaminase K that has strong sequence homology to kynurenine pyruvate aminotransferase. Abraham DG, et al. **Arch Biochem Biophys** 1996 Nov 15;335(2):311–20

Identification of stsC, the gene encoding the L-glutamine:scyllo-inosose aminotransferase from streptomycin-producing Streptomycetes. Ahlert J, et al. **Arch Microbiol** 1997 Aug;168(2):102–13

Cloning of the rat and human mitochondrial branched chain aminotransferases (BCATm). Bledsoe RK, et al. **Biochim Biophys Acta** 1997 Apr 25;1339(1):9–13

Cloning and characterization of the tyrB gene from Salmonella typhimurium. Nakai Y, et al. **Biochim Biophys Acta** 1996 Sep 11;1308(3):189–92

Nucleotide sequence of the Bacillus licheniformis ATCC 10716 dat gene and comparison of the predicted amino acid sequence with those of other bacterial species. Taylor PP, et al. **Biochim Biophys Acta** 1997 Jan 3;1350(1):38–40

Cloning and expression of the gene for serine-glyoxylate aminotransferase from an obligate methylotroph Hyphomicrobium methylovorum GM2. Hagishita T, et al. **Eur J Biochem** 1996 Oct 1;241(1):1–5

Role of the Escherichia coli O157:H7 O side chain in adherence and analysis of an rfb locus. Bilge SS, et al. **Infect Immun** 1996 Nov;64(11):4795–801

Identification and analysis of a gene encoding L-2,4-diaminobutyrate:2-ketoglutarate 4-aminotransferase involved in the 1,3-diaminopropane production pathway in Acinetobacter baumannii. Ikai H, et al. **J Bacteriol** 1997 Aug;179(16):5118–25

Maximization of transcription of the serC (pdxF)-aroA multifunctional operon by antagonistic effects of the cyclic AMP (cAMP) receptor protein-cAMP complex and Lrp global regulators of Escherichia coli K-12. Man TK, et al. **J Bacteriol** 1997 Jun;179(11):3458–69

Molecular, genetic, and biochemical characterization of the serC gene of Methanosarcina barkeri Fusaro. Metcalf WW, et al. **J Bacteriol** 1996 Oct;178(19):5797–802

Mitochondrial and cytosolic branched-chain amino acid transaminases from yeast, homologs of the myc oncogene-regulated Eca39 protein. Kispal G, et al. **J Biol Chem** 1996 Oct 4;271(40):24458–64

Nitrogen metabolism in actinorhizal nodules of Alnus glutinosa: expression of glutamine synthetase and acetylornithine transaminase. Guan C, et al. **Plant Mol Biol** 1996 Dec;32(6):1177–84

ISOLATION & PURIFICATION

Purification and properties of aromatic amino acid aminotransferases from Azospirillum brasilense UAP 14 strain. Soto-Urzua L, et al. **Can J Microbiol** 1996 Mar; 42(3):294–8

METABOLISM

Kynurenine aminotransferase in hypercholesterolemic rats. Bertazzo A, et al. **Adv Exp Med Biol** 1996;398:465–9

Kynurenine aminotransferases in the rat. Localization and characterization. Okuno E, et al. **Adv Exp Med Biol** 1996; 398:455–64

Enzymes of central nitrogen metabolism from hyperthermophiles: characterization, thermostability, and genetics. Diruggiero J, et al. **Adv Protein Chem** 1996; 48:311–39 (100 ref.)

Separate effects of the coffee diterpenes cafestol and kahweol on serum lipids and liver aminotransferases. Urgert R, et al. **Am J Clin Nutr** 1997 Feb;65(2):519–24

An aminotransferase from Lactococcus lactis initiates conversion of amino acids to cheese flavor compounds. Yvon M, et al. **Appl Environ Microbiol** 1997 Feb; 63(2):414–9

Molecular cloning and expression of cDNAs for rat and human kidney cysteine conjugate beta-lyase. Goldfarb P, et al. **Biochem Soc Trans** 1996 May;24(2):330S

Identification and analysis of a gene encoding L-2,4-diaminobutyrate:2-ketoglutarate 4-aminotransferase involved in the 1,3-diaminopropane production pathway in Acinetobacter baumannii. Ikai H, et al. **J Bacteriol** 1997 Aug;179(16):5118–25

Pyridoxal 5'-phosphate binding of a recombinant rat serine: pyruvate/alanine:glyoxylate aminotransferase. Ishikawa K, et al. **J Biochem (Tokyo)** 1996 May;119(5):970–8

Three-dimensional structure of Escherichia coli branched-chain amino acid aminotransferase at 2.5 A resolution. Okada K, et al. **J Biochem (Tokyo)** 1997 Apr; 121(4):637–41

Paracoccus denitrificans aromatic amino acid aminotransferase: a model enzyme for the study of dual substrate recognition mechanism. Oue S, et al. **J Biochem (Tokyo)** 1997 Jan;121(1):161–71

Cellular distribution of branched-chain amino acid aminotransferase isoenzymes among rat brain glial cells in culture. Bixel MG, et al. **J Histochem Cytochem** 1997 May; 45(5):685–94

Neuronal metabolism of branched-chain amino acids: flux through the aminotransferase pathway in synaptosomes. Yudkoff M, et al. **J Neurochem** 1996 May;66(5):2136–45

Strategies for the prenatal diagnosis of primary hyperoxaluria type 1. Danpure CJ, et al. **Prenat Diagn** 1996 Jul; 16(7):587–98 (36 ref.)

The ubiquitous cofactor NADH protects against substrate-induced inhibition of a pyridoxal enzyme. Jones WM, et al. **Protein Sci** 1996 Dec;5(12):2545–51

PHYSIOLOGY

Energy-dependent degradation of a mutant serine: pyruvate/alanin: glyoxylate aminotransferase in a primary hyperoxaluria type 1 case. Suzuki T, et al. **Adv Exp Med Biol** 1996;389:137–40 (12 ref.)

AMINOTRIAZOLE see **AMITROLE**

AMINOXAFEN see **AMINOREX**

AMIODARONE

Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro. Leeder RG, et al. **J Biochem Toxicol** 1996;11(3):147–60

[Class III antiarrhythmic drugs] Aiba T, et al. **Nippon Rinsho** 1996 Aug;54(8):2125–31 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Amiodarone and the lung] Mendonça C, et al. **Rev Port Cardiol** 1996 Oct;15(10):745–51 (48 ref.) (Eng. Abstr.) **(Por)**

ADMINISTRATION & DOSAGE

The rational use of intravenous amiodarone in the perioperative period. Balser JR. **Anesthesiology** 1997 Apr; 86(4):974–87 (83 ref.)

Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: efficacy and safety. Lee KL, et al. **Clin Cardiol** 1997 Apr; 20(4):372–7

Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy. James PR, et al. **Heart** 1997 Jun;77(6):583–4

Low-dose amiodarone in severe chronic heart failure. Biswas A, et al. **Indian Heart J** 1996 Jul-Aug;48(4):361–4

Intravenous amiodarone. Kowey PR, et al. **J Am Coll Cardiol** 1997 May;29(6):1190–8 (110 ref.)

Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. Ayers GM, et al. **J Cardiovasc Electrophysiol** 1996 Aug;7(8):713–21

Low-dose amiodarone-related complications after cardiac operations. Dimopoulou I, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):31–7

Effects of long-term oral administration of amiodarone on the ventricular repolarization of rabbit hearts. Iwata H, et al. **Jpn Circ J** 1996 Sep;60(9):662–72

Amiodarone in a newborn with ventricular tachycardia and an intracardiac tumor: adjusting the dose according to an individualized dosing regimen. Bouillon T, et al. **Pediatr Cardiol** 1996 Mar-Apr;17(2):112–4

The effect of low-dose amiodarone in prevention of paroxysmal atrial fibrillation. Zdrenghea D, et al. **Rom J Intern Med** 1996 Jul-Dec;34(3-4):199–204

[Successful treatment of fetal supraventricular tachycardia with a combination of digoxin and amiodarone] Hajdú J, et al. **Orv Hetil** 1996 Oct 6;137(40):2209–11 (Eng. Abstr.) **(Hun)**

[The effect of intravenously given amiodarone on maintenance of ventricular signal averaged electrocardiogram in patients with ischemic heart disease] Banasiak W, et al. **Przegl Lek** 1996;53(6):463–7 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Enlargement of extraocular muscles during treatment with amiodarone. Sundelin K, et al. **Acta Ophthalmol Scand** 1997 Jun;75(3):333–4

Lithium treatment in amiodarone-induced thyrotoxicosis. Dickstein G, et al. **Am J Med** 1997 May;102(5):454–8

Amiodarone-induced thyrotoxicosis. Tavackoli S, et al. **Am J Med Sci** 1997 Aug;314(2):97–100 (29 ref.)

Regional anesthesia for thyroidectomy in two patients with amiodarone-induced hyperthyroidism. Klein SM, et al. **Anesth Analg** 1997 Jul;85(1):222–4

Preoperative therapy with amiodarone and the incidence of acute organ dysfunction after cardiac surgery. Rady MY, et al. **Anesth Analg** 1997 Sep;85(3):489–97

Amiodarone and thyroid function [letter] Biddle JR. **Ann Intern Med** 1997 Oct 15;127(8 (Pt 1)):653

Amiodarone and thyroid function [letter] Isidro ML, et al. **Ann Intern Med** 1997 Oct 15;127(8 (Pt 1)):653

Amiodarone pulmonary toxicity. Amiodarone should be used with caution in patients in intensive care [letter; comment] Donaldson L, et al. **BMJ** 1997 Jun 21;314(7097):1832. Comment on: BMJ 1997 Mar 1;314(7081):619–20.

Amiodarone pulmonary toxicity [editorial] [see comments] Jessurun GA, et al. **BMJ** 1997 Mar 1;314(7081):619–20. Comment in: BMJ 1997 Jun 21;314(7097):1831–2. Comment in: BMJ 1997 Jun 21;314(7097):1832.

Amiodarone pulmonary toxicity. Authors did not emphasise typical radiological and histological features sufficiently [letter; comment] Leonard A, et al. **BMJ** 1997 Jun 21; 314(7097):1831–2. Comment on: BMJ 1997 Mar 1;314(7081):619–20.

Amiodarone and dysthyroid eye disease [letter] Banerjee S, et al. **Br J Ophthalmol** 1996 Sep;80(9):851–2

Gallium-67 lung imaging and pulmonary clearance of 99mTc-DTPA aerosol in patients with amiodarone pneumonitis. Terra-Filho M, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1467–71

Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade. Skanes AC, et al. **Can J Cardiol** 1997 Apr;13(4):383–6 (36 ref.)

Sudden hypothyroidism and amiodarone-lithium combination: an interaction. Ahmad S. **Cardiovasc Drugs Ther** 1995 Dec;9(6):827–8

Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis. Goldstein I, et al. **Chest** 1997 May;111(5):1446–7

Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. Winters SL, et al. **Chest** 1997 May; 111(5):1454–7 (6 ref.)

Bronchiolitis obliterans organizing pneumonia during low-dose amiodarone therapy. Jessurun GA, et al. **Clin Cardiol** 1997 Mar;20(3):300–2

Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation. Kounis NG, et al. **Clin Cardiol** 1996 Jul;19(7):592–4

Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone-induced thyroiditis. Samaras K, et al. **Clin Endocrinol (Oxf)** 1996 Sep;45(3):365–8

Towards an animal model of amiodarone-induced thyroid dysfunction [comment] Wiersinga WM. **Eur J Endocrinol** 1997 Jul;137(1):15–7. Comment on: Eur J Endocrinol 1997 Jul;137(1):89–98.

Amiodarone-induced epididymitis. Report of 2 cases. Hamoud K, et al. **Eur Urol** 1996;29(4):497–8

Torsade de pointes occurring early during oral amiodarone treatment [letter] Faggiano P, et al. **Int J Cardiol** 1996 Jul 26;55(2):205–8

Akinesia and amiodarone therapy [letter] Malaterre HR, et al. **Int J Cardiol** 1997 Mar;59(1):107–8

Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). Singh SN, et al. **J Am Coll Cardiol** 1997 Aug;30(2):514–7

Adverse effects of amiodarone at low dose: plus ça change [editorial; comment] Sopher SM, et al. **J Am Coll Cardiol** 1997 Sep;30(3):799–801. Comment on: J Am Coll Cardiol 1997 Sep;30(3):791–8.

Adverse effects of low dose amiodarone: a meta-analysis [see comments] Vorperian VR, et al. **J Am Coll Cardiol** 1997 Sep;30(3):791–8. Comment in: J Am Coll Cardiol 1997 Sep;30(3):799–801.

Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. Bartalena L, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2930–3

Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia. Iervasi G, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):275–80

Iodine accumulation in the liver during long-term treatment with amiodarone. Beuers U, et al. **J Hepatol** 1997 Feb; 26(2):439

Amiodarone-induced dysthyroidism. Pitfalls and management. Leenhardt L. **J Med Liban** 1995;43(3):148–9 (14 ref.)

Low-dose amiodarone-related complications after cardiac operations. Dimopoulou I, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):31–7

A case of amiodarone-induced thyrotoxicosis successfully treated with prednisolone. Hayashi K, et al. **Jpn Circ J** 1997 Apr;61(4):361–6

Amiodarone after myocardial infarction: EMIAT and CAMIAT trials [letter; comment] Incalzi RA, et al. **Lancet** 1997 Jun 14;349(9067):1768; discussion 1769–70. Comment on: Lancet 1997 Mar 8;349(9053):667–74.

Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: clinical, radiological and histological pattern. Conte SC, et al. **Monaldi Arch Chest Dis** 1997 Feb; 52(1):24–6

Amiodarone induced hyperthyroidism: a case series and brief review of literature. Harjai KJ, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 1):1548–54 (26 ref.)

Relationship of amiodarone to postoperative complications of transthoracic implantation of automatic implantable cardioverter defibrillators. Calkins H, et al. **Panminerva Med** 1996 Jun;38(2):89–97

Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Bogazzi F, et al. **Thyroid** 1997 Aug;7(4):541–5

[Amiodarone neuropathy of the optic nerve from the viewpoint of the neuro-ophthalmologist] Jirásková N, et

al. **Cesk Slov Oftalmol** 1996 Oct;52(5):308–18 (Eng. Abstr.) **(Cze)**

[Amiodarone–induced thyrotoxicosis cured by thyroidectomy] Le Cosquer P, et al. **Ann Fr Anesth Reanim** 1996;15(7):1092–4 (Eng. Abstr.) **(Fre)**

[Amiodarone–induced hypothyroidism followed by hyperthyroidism. Apropos of 2 new cases] Wilhelm JM, et al. **Ann Med Interne (Paris)** 1996;147(5):369–72 (20 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of amiodarone–induced hyperthyroidism by carbimazole with maintenance of amiodarone] Talard P, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89(10):1301–3 (Eng. Abstr.) **(Fre)**

[Non–thyroidal side effects of amiodarone] Creplet J. **Rev Med Brux** 1996 Sep;17(4):198–202 (15 ref.) (Eng. Abstr.) **(Fre)**

[Early pulmonary changes caused by amiodarone] Leipner N, et al. **Aktuelle Radiol** 1996 Sep;6(5):235–8 (Eng. Abstr.) **(Ger)**

[Amiodarone pigmentation] Ammann R, et al. **Hautarzt** 1996 Dec;47(12):930–1 (Eng. Abstr.) **(Ger)**

[Increased liver density in computed tomography as a result of anti–arrhythmia therapy with amiodarone] Heuck A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):14–7 (Eng. Abstr.) **(Ger)**

[Amiodarone–induced pulmonary fibrosis (letter; comment)] Füzesi K, et al. **Orv Hetil** 1997 Jan 5;138(1):43. Comment on: Orv Hetil 1996 Aug 11;137(32):1759–62. **(Hun)**

[Amiodarone–induced pulmonary fibrosis (see comments)] Lengyel C, et al. **Orv Hetil** 1996 Aug 11;137(32):1759–62 (Eng. Abstr.). Comment in: Orv Hetil 1997 Jan 5;138(1):43. **(Hun)**

[Amiodarone and the thyroid] Martino E, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):173–8 **(Ita)**

[Thoracic radiography and high resolution computerized tomography in the diagnosis of pulmonary disorders caused by amiodarone] Polverosi R, et al. **Radiol Med (Torino)** 1996 Jul–Aug;92(1–2):58–62 (Eng. Abstr.) **(Ita)**

[Amiodarone and the lung] Mendonça C, et al. **Rev Port Cardiol** 1996 Oct;15(10):745–51 (48 ref.) (Eng. Abstr.) **(Por)**

[Subtotal thyroidectomy. A treatment to keep in mind in amiodarone–induced thyrotoxicosis] López Mínguez JR, et al. **Rev Esp Cardiol** 1996 Jun;49(6):474–6 (Eng. Abstr.) **(Spa)**

ANALOGS & DERIVATIVES

Relation between amiodarone and desethylamiodarone plasma concentrations and ventricular defibrillation energy requirements. Daoud EG, et al. **Am J Cardiol** 1997 Jan 1;79(1):97–100

Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer–assisted radio telemetry. Kharidia J, et al. **Biopharm Drug Dispos** 1996 Mar;17(2):93–106

Microassay of amiodarone and desethylamiodarone in serum by capillary electrophoresis with head–column field–amplified sample stacking. Zhang CX, et al. **Clin Chem** 1996 Nov;42(11):1805–11

ANALYSIS

Unusual interference from primary collection tube in a high–performance liquid chromatography assay of amiodarone. Murthy VV. **J Clin Lab Anal** 1997;11(4):232–4

BLOOD

Relation between amiodarone and desethylamiodarone plasma concentrations and ventricular defibrillation energy requirements. Daoud EG, et al. **Am J Cardiol** 1997 Jan 1;79(1):97–100

Microassay of amiodarone and desethylamiodarone in serum by capillary electrophoresis with head–column field–amplified sample stacking. Zhang CX, et al. **Clin Chem** 1996 Nov;42(11):1805–11

CHEMISTRY

Stability of amiodarone in an oral suspension stored under refrigeration and at room temperature. Nahata MC. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):851–2

METABOLISM

Awareness of potential drug interactions may aid avoidance [letter] DeVane CL, et al. **Ther Drug Monit** 1997 Jun; 19(3):366–7

PHARMACOKINETICS

Intestinal absorption kinetics of amiodarone in rat small intestine. Martín–Algarra RV, et al. **Biopharm Drug Dispos** 1997 Aug;18(6):523–32

Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. Korth–Bradley JM, et al. **J Clin Pharmacol** 1996 Aug;36(8):715–9

Disposition of intravenous amiodarone in subjects with normal and impaired renal function. Ujhelyi MR, et al. **J Clin Pharmacol** 1996 Feb;36(2):122–30

Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function [published erratum appears in J Clin Pharmacol 1997 Jan;37(1):73–5] Vadiei K, et al. **J Clin Pharmacol** 1996 Aug;36(8):720–7

Population pharmacokinetics of intravenous amiodarone and comparison with two–stage pharmacokinetic analysis. Vadiei K, et al. **J Clin Pharmacol** 1997 Jul;37(7):610–7

Redistribution of amiodarone in heart transplant recipients treated with the drug before operation. Nanas JN, et al. **J Heart Lung Transplant** 1997 Apr;16(4):387–9

PHARMACOLOGY

Effects of amiodarone on thyroid function. Harjai KJ, et al. **Ann Intern Med** 1997 Jan 1;126(1):63–73 (109 ref.)

Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Chow MS. **Ann Pharmacother** 1996 Jun; 30(6):637–43 (38 ref.)

Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Varró A, et al. **Br J Pharmacol** 1996 Mar;117(6):1181–6

Cellular electropharmacology of amiodarone. Kodama I, et al. **Cardiovasc Res** 1997 Jul;35(1):13–29 (188 ref.)

Amiodarone inhibits production of tumor necrosis factor–alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. Matsumori A, et al. **Circulation** 1997 Sep 2;96(5):1386–9

More on amiodarone and torsade de pointes [letter; comment] Ostermaier R, et al. **Circulation** 1996 Nov 1;94(9):2316–8 . Comment on: Circulation 1995 Dec 1;92(11):3255–63. Comment on: Circulation 1995 Dec 1;92(11):3264–72.

Amiodarone affects membrane water permeability properties of human erythrocytes and rat mitochondria. Federico A, et al. **Eur J Pharmacol** 1996 May 23;304(1–3):237–41

Clinical electrophysiologic effects of a single high oral dose of amiodarone. Deharo JC, et al. **Fundam Clin Pharmacol** 1997;11(3):275–80

Triiodothyronine and amiodarone effects on beta 3–adrenoceptor density and lipolytic response to the beta 3–adrenergic agonist BRL 37344 in rat white adipocytes. Germack R, et al. **Fundam Clin Pharmacol** 1996; 10(3):289–97

Cardiomyocytes in culture––a model to study the cellular actions of amiodarone. Kessler–Icekson G, et al. **Isr J Med Sci** 1996 Dec;32(12):1212–6

Interaction between amiodarone and lidocaine. Ha HR, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):533–9

Amiodarone–induced lymphocyte toxicity and mitochondrial function. Yasuda SU, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):94–100

Modifications in the evolution of the dominant frequency in ventricular fibrillation induced by amiodarone, diltiazem, and flecainide. An experimental study. Chorro FJ, et al. **J Electrocardiol** 1996 Oct;29(4):319–26

Tri–iodothyronine prevents the amiodarone–induced decrease in the expression of the liver low–density lipoprotein receptor gene. Hudig F, et al. **J Endocrinol** 1997 Mar;152(3):413–21

Mechanisms of amiodarone–induced inhibition of Ca2+ current in isolated neonatal rabbit ventricular myocytes. Chen F, et al. **J Investig Med** 1996 Dec;44(9):583–9

Evidences of antagonism between amiodarone and triiodothyronine on the K+ channel activities of cultured rat cardiomyocytes. Guo W, et al. **J Mol Cell Cardiol** 1997 Feb;29(2):617–27

Inhibitory effect of amiodarone on the muscarinic acetylcholine receptor–operated potassium current in guinea pig atrial cells. Watanabe Y, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):617–24

Propranolol–like action of amiodarone. An electronmicroscopic study in rats under cold stress. Lopes AC, et al. **J Submicrosc Cytol Pathol** 1997 Apr;29(2):253–6

Effect of amiodarone on cytokine release and on enzyme activities of mouse alveolar macrophages, bone marrow macrophages, and blood monocytes. Futamura Y. **J Toxicol Sci** 1996 May;21(2):125–34

Acute and chronic effects of amiodarone on mammalian ventricular cells. Kodama I, et al. **Jpn Heart J** 1996 Sep; 37(5):719–30 (25 ref.)

How to measure AV nodal refractoriness in the presence of verapamil, amiodarone, digoxin, and diltiazem. Stark G, et al. **Pacing Clin Electrophysiol** 1996 Feb;19(2):157–64

[Amiodarone and thyroid: pharmacologic and toxic effects] Unger J. **Rev Med Brux** 1996 Sep;17(4):203–5 (24 ref.) (Eng. Abstr.) **(Fre)**

[Class III antiarrhythmic drugs] Aiba T, et al. **Nippon Rinsho** 1996 Aug;54(8):2125–31 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Correction with cordaron of changes in beta–glucosidase activity induced by toxic effect of strophanthin K and simulated heart decompensation] Galenko–Iaroshevskii PA, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):645–7 **(Rus)**

[Correction with cordarone of changes in cathepsin D induced by simulated circulatory insufficiency and toxic effect of strophanthin] Galenko–Iarpsjevskii' PA, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):407–9 **(Rus)**

THERAPEUTIC USE

Effects of amiodarone on the circadian pattern of sudden cardiac death (Department of Veterans Affairs Congestive Heart Failure–Survival Trial of Antiarrhythmic Therapy). Behrens S, et al. **Am J Cardiol** 1997 Jul 1;80(1):45–8

Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single–center study [see comments] Giorgberidze I, et al. **Am J Cardiol** 1997 Sep 11;80(5B):3F–9F. Comment in: Am J Cardiol 1997 Sep 11;80(5B):1F–2F.

Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). Roy D, et al. **Am J Cardiol** 1997 Aug 15;80(4):464–8

Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Tieleman RG, et al. **Am J Cardiol** 1997 Jan 1;79(1):53–7

Amiodarone: a late comer. Futterman LG, et al. **Am J Crit Care** 1997 May;6(3):233–9 (23 ref.)

The role of intravenous amiodarone in the management of cardiac arrhythmias. Desai AD, et al. **Ann Intern Med** 1997 Aug 15;127(4):294–303 (71 ref.)

Cost–effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death [see comments] Owens DK, et al. **Ann Intern Med** 1997 Jan 1;126(1):1–12. Comment in: ACP J Club 1997 May–Jun;126(3):61.

Beta–blockers for ventricular arrhythmias: have we underestimated their value? Campbell TJ. **Aust N Z J Med** 1996 Oct;26(5):689–96 (59 ref.)

Effects of hypothyroidism on the vulnerability to ventricular fibrillation in dogs: a comparative study with amiodarone. Liu P, et al. **Cardiovasc Drugs Ther** 1996 Jul;10(3):369–78

Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA–GEMA Investigators. Doval HC, et al. **Circulation** 1996 Dec 15;94(12):3198–203

Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF–STAT Investigators. Massie BM, et al. **Circulation** 1996 Jun 15;93(12):2128–34

Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias. Cybulski J, et al. **Clin Cardiol** 1996 Jul; 19(7):563–6

Effect of amiodarone on QT dispersion in the 12–lead standard electrocardiogram and its significance for subsequent arrhythmic events. Grimm W, et al. **Clin Cardiol** 1997 Feb;20(2):107–10

Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct–current cardioversion. Opolski G, et al. **Clin Cardiol** 1997 Apr;20(4):337–40

Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Singh BN. **Clin Cardiol** 1997 Jul;20(7):608–18 (33 ref.)

Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias. Fogoros RN. **Control Clin Trials** 1996 Jun;17(3 Suppl):37S–46S (18 ref.)

Lack of effect of amiodarone on survival after extensive infarction. Polish Amiodarone Trial. Budaj A, et al. **Coron Artery Dis** 1996 Apr;7(4):315–9

Survival analysis and clinical medicine. An observational comparison of the implantable cardioverter defibrillator, amiodarone treatment, and heart transplantation. Ector H, et al. **Eur Heart J** 1996 Sep;17(9):1444–7

Normalization of peripheral thyroid hormone metabolism induced by successful chronic amiodarone treatment in patients with ventricular arrhythmias. Iervasi G, et al. **Eur J Clin Invest** 1996 May;26(5):382–90

Subchronic pulmonary inflammation and fibrosis induced by silica in rats are attenuated by amiodarone. Blake TL, et al. **Exp Lung Res** 1996 Jan–Feb;22(1):113–31

Amiodarone in high–risk post–infarction patients, Lessons from EMIAT and CAMIAT. European Myocardial Infarct Amiodarone Trial and Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Gambhir DS. **Indian Heart J** 1996 Jul–Aug;48(4):339–41 (14 ref.)

Influence of amiodarone on QT dispersion in patients with life–threatening ventricular arrhythmias and clinical outcome. Meierhenrich R, et al. **Int J Cardiol** 1997 Aug 8;60(3):289–94

Intravenous amiodarone in treatment of recent–onset atrial fibrillation [letter; comment] Lip GY. **J Am Coll Cardiol** 1996 Oct;28(4):1080–2. Comment on: J Am Coll Cardiol 1996 Apr;27(5):1079–82.

Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA–GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina–Grupo de Estudios Multicéntricos en Argentina. Nul DR, et al. **J Am Coll Cardiol** 1997 May;29(6):1199–205

Long–term prevention of atrial fibrillation after coronary artery bypass surgery: comparison of quinidine, verapamil, and amiodarone in maintaining sinus rhythm. Yilmaz AT, et al. **J Card Surg** 1996 Jan–Feb;11(1):61–4

The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. Larbuisson R, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):229–34

Sustained ventricular tachycardia in cardiac hemochromatosis treated with amiodarone. Yalçinkaya S, et al. **J Electrocardiol** 1997 Apr;30(2):147–9

Randomised trial of outcome after myocardial infarction in

patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators [published erratum appears in Lancet 1997 Jun 14;349(9067):1776] [see comments] Cairns JA, et al. **Lancet** 1997 Mar 8;349(9053):675–82. Comment in: Lancet 1997 Mar 8;349(9053):662–3. Comment in: Lancet 1997 Jun 14;349(9067):1767. Comment in: ACP J Club 1997 Sep–Oct;127(2):30–1.

Randomised trial of effect of amiodarone on mortality in patients with left–ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators [published errata appear in Lancet 1997 Apr 19;349(9059):1180 and 1997 Jun 14;349(9067):1776] [see comments] Julian DG, et al. **Lancet** 1997 Mar 8;349(9053):667–74. Comment in: Lancet 1997 Mar 8;349(9053):662–3. Comment in: Lancet 1997 Jun 14;349(9067):1767. Comment in: Lancet 1997 Jun 14;349(9067):1768; discussion 1769–70. Comment in: Lancet 1997 Jun 14;349(9067):1768–9; discussion 1769–70. Comment in: ACP J Club 1997 Sep–Oct;127(2):31.

Amiodarone after myocardial infarction: EMIAT and CAMIAT trials [letter; comment] Norris RM. **Lancet** 1997 Jun 14;349(9067):1767. Comment on: Lancet 1997 Mar 8;349(9053):662–3. Comment on: Lancet 1997 Mar 8;349(9053):667–74. Comment on: Lancet 1997 Mar 8;349(9053):675–82.

Amiodarone after myocardial infarction: EMIAT and CAMIAT trials [letter; comment] Pinski SL. **Lancet** 1997 Jun 14;349(9067):1768–9; discussion 1769–70. Comment on: Lancet 1997 Mar 8;349(9053):667–74.

201Tl scintigraphy does not allow visualization of the thyroid in euthyroid and hyperthyroid patients treated with amiodarone. van de Wiele C, et al. **Nucl Med Commun** 1997 Jun;18(6):513–6

Amiodarone as treatment for atrial tachycardias after surgery. Villain E. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2130–2

Class III antiarrhythmic agents: the next wave. Bauman JL. **Pharmacotherapy** 1997 Mar–Apr;17(2 Pt 2):76S–83S; discussion 89S–91S (28 ref.)

Acute management of ventricular arrhythmias: role of antiarrhythmic agents. Singh BN. **Pharmacotherapy** 1997 Mar–Apr;17(2 Pt 2):56S–64S; discussion 89S–91S (32 ref.)

Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT–CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. Pinto JV Jr, et al. **Prog Cardiovasc Dis** 1997 Jul–Aug;40(1):85–93 (34 ref.)

Short– and intermediate–term efficacy of amiodarone in infants and children with cardiac arrhythmia. Celiker A, et al. **Turk J Pediatr** 1997 Apr–Jun;39(2):219–25

[Predictive factors of induction of ventricular arrhythmia under amiodarone] Bourret N, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89(10):1277–81 (Eng. Abstr.) **(Fre)**

[Amiodarone in arrhythmia] **Internist (Berl)** 1996 Nov;37(11 Suppl):1–4 **(Ger)**

[Arrhythmia as risk factor] **Internist (Berl)** 1997 Feb;38(2 Suppl Risikofakt):1–8 **(Ger)**

[Modern therapy of tachycardiac heart arrhythmias] **Internist (Berl)** 1995 Sep;36(9 Suppl Moderne):1–8 **(Ger)**

[Anti–arrhythmia therapy after myocardial infarct: preliminary results of EMIAT and CAMIAT studies] Kuck KH. **Z Kardiol** 1996;85 Suppl 6:107–13 (11 ref.) (Eng. Abstr.) **(Ger)**

[Prediction of long–term efficacy of amiodarone for refractory ventricular tachycardia: clinical significance of electrophysiologic study and Holter monitoring] Tsuchiya M, et al. **J Cardiol** 1996 Nov;28(5):267–76 (Eng. Abstr.) **(Jpn)**

[Implantable automatic defibrillator after MADIT and EMIAT (editorial) Farré J. **Rev Esp Cardiol** 1996 Oct; 49(10):709–13 **(Spa)**

[Plasma concentrations and amiodarone/desethylamiodarone relations in patients subjected to chronic treatment] Ortiz M, et al. **Rev Med Chil** 1996 Jan;124(1):77–82 (Eng. Abstr.) **(Spa)**

TOXICITY

Chronic amiodarone ingestion induces pulmonary toxicity in rats. Carvalho CR, et al. **Braz J Med Biol Res** 1996 Jun;29(6):779–91

Mechanisms in the pathogenesis of amiodarone–induced pulmonary toxicity. Massey TE, et al. **Can J Physiol Pharmacol** 1995 Dec;73(12):1675–85 (142 ref.)

Cytotoxicity of amiodarone in cultured human endothelial cells. Baudin B, et al. **Cardiovasc Drugs Ther** 1996 Nov; 10(5):557–60

Amiodarone induces a different pattern of ultrastructural change in the thyroid to iodine excess alone in both the BB/W rat and the Wistar rat [see comments] Pitsiavas V, et al. **Eur J Endocrinol** 1997 Jul;137(1):89–98. Comment in: Eur J Endocrinol 1997 Jul;137(1):15–7.

Toxicity of amiodarone on mouse pulmonary endothelial cells cultured with or without alveolar macrophages. Futamura Y. **J Toxicol Sci** 1996 Nov;21(4):253–67

Amiodarone induces two different types of disorders in mouse alveolar macrophages. Futamura Y. **Jpn J Pharmacol** 1997 May;74(1):21–8

AMITHIOZONE see THIOACETAZONE

AMITRIPTYLINE

ADMINISTRATION & DOSAGE

Oestradiol treatment helped a depressed postmenopausal woman to stop her psychotropic medication: a case report. Korhonen S, et al. **Acta Psychiatr Scand** 1996 Dec; 94(6):480–1

A double–blind, randomized, fixed–dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Taragano FE, et al. **Psychosomatics** 1997 May–Jun;38(3):246–52

[Transcranial magnetic stimulation in depressed patients: a new antidepressive therapeutic principle? Presentation of a pilot trial] Koppi S, et al. **Wien Med Wochenschr** 1996; 146(3):49–54 (Eng. Abstr.) **(Ger)**

[Ultrastructural changes in various regions of rat brain after administration of amitriptyline] Bardakhch'ian EA, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):457–61 **(Rus)**

ADVERSE EFFECTS

Modified oral anticoagulant potency in an amitriptyline–treated patient? Hampel H, et al. **Acta Haematol** 1996;96(3):178–80

Photosensitivity and thrombocytopenia due to amitriptyline [letter] Taniguchi S, et al. **Am J Hematol** 1996 Sep; 53(1):49–50

Comment: Serotonin syndrome associated with combined sertraline–amitriptyline treatment [letter; comment] Alderman CP, et al. **Ann Pharmacother** 1996 Dec; 30(12):1499–500. Comment on: Ann Pharmacother 1996 May;30(5):527–33.

Double–blind comparative study of the antidepressant, unwanted and cardiac effects of minaprine and amitriptyline. Edwards JG, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):491–8

A case of serotonin syndrome induced by concomitant treatment with low–dose trazodone and amitriptyline and lithium. Nisijima K, et al. **Int Clin Psychopharmacol** 1996 Dec;11(4):289–90

Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients. Sommers DK, et al. **Int Clin Psychopharmacol** 1997 May;12(3):141–5

Combined pharmacotherapy or polypharmacy? Levy F, et al. **J Paediatr Child Health** 1996 Jun;32(3):265–6

Fatality associated with combined fluoxetine–amitriptyline therapy [letter] Preskorn SH, et al. **JAMA** 1997 Jun 4; 277(21):1682

Unstable anticoagulation in the course of amitriptyline treatment. Hampel H, et al. **Pharmacopsychiatry** 1996 Jan; 29(1):33–7

[Severe bradyarrythmia induced by tricyclic antidepressants in an elderly patient] Lebre AT, et al. **Rev Assoc Med Bras** 1995 Jul–Aug;41(4):271–3 (Eng. Abstr.) **(Por)**

ANALOGS & DERIVATIVES

Formation of mammalian metabolites of cyclobenzaprine by the fungus, Cunninghamella elegans. Zhang D, et al. **Chem Biol Interact** 1996 Oct 21;102(2):79–92

Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Wang RW, et al. **Drug Metab Dispos** 1996 Jul;24(7):786–91

Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Kobayashi H, et al. **Eur J Pharmacol** 1996 Sep 5;311(1):29–35

Response to "Neuroleptic malignant–like syndrome due to cyclobenzaprine?" [letter] Fink M. **J Clin Psychopharmacol** 1996 Feb;16(1):97–9

[The use of the amitriptyline analog amizol in depressions] Avedisova AS. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(4):55–8 **(Rus)**

ANALYSIS

Quantitative analysis of amitriptyline and nortriptyline in human plasma and liver microsomal preparations by high–performance liquid chromatography. Ghahramani P, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25; 685(2):307–13

Voltammetric determination of imipramine hydrochloride and amitriptyline hydrochloride using a polymer–modified carbon paste electrode. Biryol I, et al. **J Pharm Biomed Anal** 1996 Dec;15(3):371–81

BLOOD

A fluconazole/amitriptyline drug interaction in three male adults. Newberry DL, et al. **Clin Infect Dis** 1997 Feb; 24(2):270–1

Simultaneous determination of amitriptyline, nortriptyline and four hydroxylated metabolites in serum by capillary gas–liquid chromatography with nitrogen–phosphorus–selective detection. Ulrich S, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):81–9

Detection of tricyclic antidepressants in whole blood by headspace solid–phase microextraction and capillary gas chromatography. Lee XP, et al. **J Chromatogr Sci** 1997 Jul;35(7):302–8

Low serum levels of tricyclic antidepressants in amitriptyline– and doxepin–treated inpatients with depressive syndromes are associated with nonresponse. Rao ML, et al. **Pharmacopsychiatry** 1996 May;29(3):97–102

Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state. Shimoda K, et al. **Psychiatry Clin Neurosci** 1997 Feb; 51(1):35–41

Influence of heparin on the assay of amitriptyline, clomipramine, and their metabolites. Levering SC, et al. **Ther Drug Monit** 1996 Jun;18(3):304–5

CHEMISTRY

Polyelectrolyte/amphiphile interaction studied by surface tension measurements. Persson B, et al. **Int J Biol Macromol** 1996 Dec;19(4):263–9

METABOLISM

Comparison of amitriptyline metabolism in hepatocytes from streptozocin–induced diabetic rats and from non–diabetic rats. Coudoré F, et al. **Cell Biol Toxicol** 1997 Feb; 13(2):131–7

Hockey stick or boomerang. Dickins M, et al. **Hum Exp Toxicol** 1996 Dec;15(12):980–1

Quantitative analysis of amitriptyline and nortriptyline in human plasma and liver microsomal preparations by high–performance liquid chromatography. Ghahramani P, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25; 685(2):307–13

Regioselectivity and substrate concentration–dependency of involvement of the CYP2D subfamily in oxidative metabolism of amitriptyline and nortriptyline in rat liver microsomes. Masubuchi Y, et al. **J Pharm Pharmacol** 1996 Sep;48(9):925–9

Metabolism of amitriptyline with CYP2D6 expressed in a human cell line. Coutts RT, et al. **Xenobiotica** 1997 Jan; 27(1):33–47

PHARMACOKINETICS

Cytochromes P450 mediating the N–demethylation of amitriptyline. Ghahramani P, et al. **Br J Clin Pharmacol** 1997 Feb;43(2):137–44

Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N–demethylation. Schmider J, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):593–604

Biphasic kinetics of quaternary ammonium glucuronide formation from amitriptyline and diphenhydramine in human liver microsomes. Breyer–Pfaff U, et al. **Drug Metab Dispos** 1997 Mar;25(3):340–5

Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after one and six half–life repeated administrations to rats. Coudore F, et al. **Gen Pharmacol** 1996 Mar;27(2):215–9

Pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites in streptozocin–induced diabetic rats. Coudoré F, et al. **Gen Pharmacol** 1996 Jul;27(5):803–7

Possible markers for postmortem drug redistribution. Langford AM, et al. **J Forensic Sci** 1997 Jan;42(1):88–92

PHARMACOLOGY

A physiologic assessment of intrathecal amitriptyline in sheep. Cerda SE, et al. **Anesthesiology** 1997 May; 86(5):1094–103

Alfentanil, but not amitriptyline, reduces pain, hyperalgesia, and allodynia from intradermal injection of capsaicin in humans. Eisenach JC, et al. **Anesthesiology** 1997 Jun; 86(6):1279–87

The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance. Kerr JS, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):239–41

Chronic amitriptyline exposure reduces 5–HT3 receptor–mediated cyclic GMP formation in NG 108–15 cells. Shimizu M, et al. **Brain Res** 1996 Nov 25; 741(1–2):89–94

Migraine prophylactic drugs: proof of efficacy, utilization and cost. Ramadan NM, et al. **Cephalalgia** 1997 Apr; 17(2):73–80

Regulation of extracellular concentrations of norepinephrine in hypothalamus of the conscious rat: effect of amitriptyline. Engleman EA, et al. **Chin J Physiol** 1996; 39(1):9–13

Blockade of clomipramine and amitriptyline analgesia by an antisense oligonucleotide to mKv1.1, a mouse Shaker–like K+ channel. Galeotti N, et al. **Eur J Pharmacol** 1997 Jul 2;330(1):15–25

Amitriptyline inhibits the G protein and K+ channel in the cloned thyroid cell line. Yoshida A, et al. **Eur J Pharmacol** 1996 Sep 19;312(1):115–9

The effect of chronic administration of amitriptyline on the effects of subsequent electroconvulsive treatment on responsiveness of alpha 1–and beta–adrenoceptors in the rat cortical slices. Vetulani J, et al. **J Neural Transm** 1996; 103(3):363–76

Effects of amitriptyline on rat plasma and brain content of monoamine precursors and other large neutral amino acids. Eriksson T, et al. **J Pharm Pharmacol** 1995 Dec; 47(12A):1007–14

Dimeric tubulin-stimulated adenylyl cyclase activity is augmented after long-term amitriptyline treatment. **Kamada H, et al. Life Sci** 1997;60(1):57–66

The opposite effects of amitriptyline on noradrenaline- and methoxamine-evoked venoconstriction in man. Abdelmawla AH, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jun; 354(1):25–9

Comparative electrophysiological effects of the antidepressants fluvoxamine and amitriptyline in the canine heart after myocardial infarction. Ikeda Y, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jun; 354(1):30–7

Inhibitory effect of amitriptyline on contraction of the rat isolated trachea. Huang Y, et al. **Pharmacology** 1997 Jun; 54(6):312–8

Bulbectomy-induced loss of raphe neurons is counteracted by antidepressant treatment. Nesterova IV, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):127–40

Reflexes of the cutaneous microcirculation in amitriptyline and in fluoxetine treated patients. Mück-Weymann M, et al. **Psychopharmacology (Berl)** 1996 Apr;124(3):241–4

[Effects of amitriptyline on the contractile function of the myocardium. Dobutrex in the role of a positive inotropic agent] Meledin VIu, et al. **Anesteziol Reanimatol** 1997 Jan-Feb;(1):76–9 (Eng. Abstr.) **(Rus)**

POISONING

Magnesium sulphate in the treatment of ventricular fibrillation in amitriptyline poisoning [letter] Knudsen K, et al. **Eur Heart J** 1997 May;18(5):881–2

Death attributed to the toxic interaction of triazolam, amitriptyline and other psychotropic drugs. Kudo K, et al. **Forensic Sci Int** 1997 Apr 18;86(1–2):35–41

Hyperthermia complicating tricyclic antidepressant overdose [see comments] Hantson P, et al. **Intensive Care Med** 1996 May;22(5):453–5. Comment in: Intensive Care Med 1997 Apr;23(4):480–1.

Site to site variability of postmortem drug concentrations in liver and lung. Pounder DJ, et al. **J Forensic Sci** 1996 Nov;41(6):927–32

[Laboratory diagnosis of acute amitriptyline poisoning in children] Kuznetsova NI. **Klin Lab Diagn** 1996 May-Jun; (3):22–4 **(Rus)**

THERAPEUTIC USE

Paroxetine and amitriptyline in the treatment of depression in general practice. Christiansen PE, et al. **Acta Psychiatr Scand** 1996 Mar;93(3):158–63

A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Høyberg OJ, et al. **Acta Psychiatr Scand** 1996 Mar;93(3):184–90

Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Stahl S, et al. **Acta Psychiatr Scand Suppl** 1997;391:22–30

Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Nicolodi M, et al. **Adv Exp Med Biol** 1996; 398:373–9

Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication? Reynolds CF 3rd, et al. **Am J Psychiatry** 1997 Jul;154(7):958–62

Treatment outcome in recurrent major depression: a post hoc comparison of elderly ("young old") and midlife patients. Reynolds CF 3rd, et al. **Am J Psychiatry** 1996 Oct; 153(10):1288–92

A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Goldenberg D, et al. **Arthritis Rheum** 1996 Nov;39(11):1852–9

Amitriptyline and dexamethasone combined treatment in drug-induced headache. Bonuccelli U, et al. **Cephalalgia** 1996 May;16(3):198–200

Amitriptyline, a combined serotonin and noradrenaline re-uptake inhibitor, reduces exteroceptive suppression of temporal muscle activity in patients with chronic tension-type headache. Bendtsen L, et al. **Electroencephalogr Clin Neurophysiol** 1996 Oct; 101(5):418–22

Clinical response and plasma concentrations of amitriptyline and its metabolite-nortriptyline in depressive patients. Miljković B, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jul-Sep;21(3):251–5

Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Kasper S, et al. **Eur Neuropsychopharmacol** 1997 May;7(2):115–24

Peripheral neuropathy in scleroderma successfully treated with amitriptyline [letter] Bondavalli P, et al. **Int J Dermatol** 1997 Mar;36(3):234–5

Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. Greil W, et al. **J Affect Disord** 1996 Oct 14;40(3):179–90

Right hemisphere abnormalities in major depression: quantitative electroencephalographic findings before and after treatment. Kwon JS, et al. **J Affect Disord** 1996 Oct 14;40(3):169–73

A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. Kye CH, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Sep; 35(9):1139–44

Fluoxetine and amitriptyline in the treatment of fibromyalgia. Johnson SP. **J Fam Pract** 1997 Feb;44(2):128–30

Spinal manipulation vs. amitriptyline for the treatment of chronic tension headache: a randomized clinical trial [letter; comment] Hobson WH, et al. **J Manipulative Physiol Ther** 1996 May;19(4):278–9. Comment on: J Manipulative Physiol Ther 1995 Mar-Apr;18(3):148–54.

The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. Bowsher D. **J Pain Symptom Manage** 1997 Jun;13(6):327–31

Recognition of rapid-eye-movement sleep from single-channel EEG data by artificial neural networks: a study in depressive patients with and without amitriptyline treatment. Grözinger M, et al. **Neuropsychobiology** 1996; 33(3):155–9

Can the effects of antidepressants be observed in the first two weeks of treatment? [letter] Katz MM, et al. **Neuropsychopharmacology** 1997 Aug;17(2):110–5

Comments on Pilowskey et al. Spanswick C, et al. **Pain** 1996 Jan;64(1):205–6

Amitriptyline versus vasopressin in the treatment of nocturnal enuresis [letter; comment] Robson WL, et al. **Pediatr Nephrol** 1996 Jun;10(3):396–7. Comment on: Pediatr Nephrol 1995 Aug;9(4):438–40.

Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse. Rao ML, et al. **Pharmacopsychiatry** 1996 May;29(3):97–102

Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state. Shimoda K, et al. **Psychiatry Clin Neurosci** 1997 Feb; 51(1):35–41

A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Taragano FE, et al. **Psychosomatics** 1997 May-Jun;38(3):246–52

[Exploratory study of amitriptyline resistance in depressed patients: results of WHO French collaborating center on depressions resistant to treatments] Loas G, et al. **Ann Med Psychol (Paris)** 1996 Jun;154(3):202–3 (Eng. Abstr.) **(Fre)**

[Pharmacological treatment of delusional depression] Amore M, et al. **Minerva Psichiatr** 1996 Mar;37(1):29–33 (28 ref.) (Eng. Abstr.) **(Ita)**

[The comparative efficacy of Aurorix and amitriptyline in treating depressions] Iakovlev VA. **Voen Med Zh** 1997 Apr; 318(4):37–8 **(Rus)**

TOXICITY

Epinephrine and sodium bicarbonate independently and additively increase survival in experimental amitriptyline poisoning. Knudsen K, et al. **Crit Care Med** 1997 Apr; 25(4):669–74

AMITROLE

ADMINISTRATION & DOSAGE

[The use of the amitriptyline analog amizol in depressions] Avedisova AS. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(4):55–8 **(Rus)**

PHARMACOLOGY

Effect of 3-aminotriazole on hyperthermia-mediated cardioprotection in rabbits. Kingma JG Jr, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):H1165–71

Hydrogen peroxide-induced impairment of reactivity in rat isolated aorta: potentiation by 3-amino-1,2,4-triazole. Mian KB, et al. **Br J Pharmacol** 1997 Jun;121(4):813–9

[The effect of catalase inhibitor 3-amino-1,2,4-triazole on coupled oxidative phosphorylation and the state of adenyl system in liver mitochondria of albino rats] Manoĭlov SE, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):638–40 **(Rus)**

AMLODIPINE

ADMINISTRATION & DOSAGE

Sex- and age-related antihypertensive effects of amlodipine [letter; comment] Spratt KA. **Am J Cardiol** 1997 Mar 15; 79(6):843–4. Comment on: Am J Cardiol 1996 Apr 1;77(9):713–22.

A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD. Sajkov D, et al. **Chest** 1997 Jun;111(6):1622–30

ADVERSE EFFECTS

Amlodipine-induced acute intermittent porphyria exacerbation [letter] Kepple A, et al. **Ann Pharmacother** 1997 Feb;31(2):253

Hypertension medication and periodontosis [letter] Bowell GR. **Aust Dent J** 1997 Apr;42(2):140

Generalised pruritus associated with amlodipine. Orme S, et al. **BMJ** 1997 Aug 23;315(7106):463

Calcium antagonist-induced photo-exposed telangiectasia [letter] Basarab T, et al. **Br J Dermatol** 1997 Jun; 136(6):974–5

Prevalence of amlodipine-related gingival hyperplasia. Jorgensen MG. **J Periodontol** 1997 Jul;68(7):676–8

[Gingival hyperplasia associated with amlodipine] Infante Cossio P, et al. **An Med Interna** 1997 Feb;14(2):83–5 (Eng. Abstr.) **(Spa)**

ANALYSIS

Automated gas chromatographic assay for amlodipine in plasma and gingival crevicular fluid. Monkman SC, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):360–4

Use of 1H-NMR spectroscopy to determine the enantioselective mechanism of neutral and anionic cyclodextrins in capillary electrophoresis. Owens PK, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1603–19

BLOOD

Amlodipine—does the effect-time profile directly reflect the concentration-time profile throughout a 24-hour period? Meredith PA, et al. **Clin Cardiol** 1994 Sep;17(9 Suppl Iii):III7–11

Clinical evaluation of serum amlodipine level in patients with angina pectoris. Watanabe K, et al. **Gen Pharmacol** 1996 Mar;27(2):205–9

Automated gas chromatographic assay for amlodipine in plasma and gingival crevicular fluid. Monkman SC, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):360–4

Quantitative determination of amlodipine in serum by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. Yasuda T, et al. **J Mass Spectrom** 1996 Aug;31(8):879–84

Coupled-column chromatography on a Chiral-AGP phase for determination of amlodipine enantiomers in human plasma: an HPLC assay with electrochemical detection. Josefsson M, et al. **J Pharm Biomed Anal** 1996 Nov; 15(2):267–77

CHEMISTRY

Method development in liquid chromatography with a charged cyclodextrin additive for chiral resolution of rac-amlodipine utilising a central composite design. Owens PK, et al. **Chirality** 1996;8(7):466–76

ISOLATION & PURIFICATION

Method development in liquid chromatography with a charged cyclodextrin additive for chiral resolution of rac-amlodipine utilising a central composite design. Owens PK, et al. **Chirality** 1996;8(7):466–76

Semi-preparative chromatographic purification of the enantiomers S-(-)-amlodipine and R-(+)-amlodipine. Luksa J, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6; 693(2):367–75

METABOLISM

Slow dissociation of long-acting Ca2+ antagonist amlodipine from 3H-PN200-110 binding sites in membranes of rat hearts and brains. Sugiyama K, et al. **Biol Pharm Bull** 1996 Feb;19(2):195–8

PHARMACOKINETICS

Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration. Laine K, et al. **Br J Clin Pharmacol** 1997 Jan;43(1):29–33

Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. van Zwieten PA. **Clin Cardiol** 1994 Sep;17(9 Suppl Iii):III3–6 (35 ref.)

Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Josefsson M, et al. **Eur J Clin Pharmacol** 1996;51(2):189–93

PHARMACOLOGY

Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Furukawa T, et al. **Br J Pharmacol** 1997 Jul;121(6):1136–40

Effect of amlodipine on renin secretion and renin gene expression in rats. Schricker K, et al. **Br J Pharmacol** 1996 Oct;119(4):744–50

Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Timour Q, et al. **Cardiovasc Drugs Ther** 1996 Sep; 10(4):447–54

Amlodipine—does the effect-time profile directly reflect the concentration-time profile throughout a 24-hour period? Meredith PA, et al. **Clin Cardiol** 1994 Sep;17(9 Suppl Iii):III7–11

Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. van Zwieten PA. **Clin Cardiol** 1994 Sep;17(9 Suppl Iii):III3–6 (35 ref.)

Amlodipine and benazepriIat differently affect the responses to endothelin-1 and bradykinin in porcine ciliary arteries: effects of a low and high dose combination. Lang MG, et al. **Curr Eye Res** 1997 Mar;16(3):208–13

Amlodipine, a Ca2+ channel antagonist, modifies cerebral blood flow autoregulation in hypertensive rats. Cai H, et al. **Eur J Pharmacol** 1996 Oct 10;313(1–2):103–6

Venodilator effects of pranidipine, a 1,4-dihydropyridine Ca2+ channel antagonist, in rats: comparison with

nifedipine and amlodipine. Hirano T, et al. **Eur J Pharmacol** 1997 Apr 18;324(2–3):201–4

Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Iwatsubo H, et al. **Hypertension** 1997 Jan;29(1 Pt 2):286–90

Effects of the dihydropyridine calcium channel blocker amlodipine on ventricular and atrial protein synthesis in an aortic constriction model of hypertension and, following chronic treatment, in the left ventricle of SHR rats. Patel VB, et al. **Int J Cardiol** 1997 Feb;58(3):241–55

Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. Chen L, et al. **J Am Coll Cardiol** 1997 Aug; 30(2):569–75

Decreased blood viscosity and serum levels of erythropoietin after anti-hypertensive treatment with amlodipine or metoprolol: results of a cross-over study. Linde T, et al. **J Hum Hypertens** 1996 Mar;10(3):199–205

Amlodipine prevents and reverses the elevation in [Ca2+]i and the impaired phagocytosis of PMNL of diabetic rats [see comments] Seyrek N, et al. **Nephrol Dial Transplant** 1997 Feb;12(2):265–72. Comment in: Nephrol Dial Transplant 1997 Feb;12(2):248–9.

A calcium-channel blocker, amlodipine, attenuates insulin antinatriuresis but does not modulate insulin-mediated attenuation of cardiovascular reactivity in healthy man. Stenvinkel P, et al. **Nephrol Dial Transplant** 1997 Aug; 12(8):1600–7

[Effect of the calcium antagonist amlodipine on non-vascular smooth muscle exemplified by the uterus] Lechner W, et al. **Wien Med Wochenschr** 1996;146(17):466–8 (Eng. Abstr.) **(Ger)**

POISONING

Amlodipine overdose [see comments] Stanek EJ, et al. **Ann Pharmacother** 1997 Jul-Aug;31(7–8):853–6. Comment in: Ann Pharmacother 1997 Jul-Aug;31(7–8):924–5.

THERAPEUTIC USE

Effect of amlodipine on norepinephrine kinetics and baroreflex function in patients with congestive heart failure. Goldsmith SR. **Am Heart J** 1997 Jul;134(1):13–9

Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists. Davies GJ, et al. **Am J Cardiol** 1997 Aug 21;80(4B):34C–39C

Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists. Massie BM, et al. **Am J Cardiol** 1997 Aug 21;80(4B):27C–33C

Short-term antihypertensive medication does not exacerbate sleep-disordered breathing in newly diagnosed hypertensive patients. Bartel PR, et al. **Am J Hypertens** 1997 Jun;10(6):640–5

Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure. Kario K, et al. **Am J Hypertens** 1997 Mar;10(3):261–8

Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension. Lacourcière Y, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 1):1154–9

Drug treatment of hypertension in acute intermittent porphyria: doxazosin and amlodipine [letter] Gorchein A. **Br J Clin Pharmacol** 1997 Mar;43(3):339–40

Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Leenen FH, et al. **Br J Clin Pharmacol** 1996 Feb;41(2):83–8

Possible prevention by amlodipine of ventricular fibrillation related to brief ischemia episodes. Timour Q, et al. **Can J Physiol Pharmacol** 1996 Dec;74(12):1308–14

Acute hemodynamic effects of amlodipine 15 days after a myocardial infarction in normotensive patients treated with atenolol. Rocha P, et al. **Cardiovasc Drugs Ther** 1997 Apr; 11(2):139–47

Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. Wang WZ, et al. **Circulation** 1997 Jan 7; 95(1):245–51

Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient Compliance. Detry JM. **Clin Cardiol** 1994 Sep;17(9 Suppl Iii):III12–6

A double-blind evaluation of amlodipine in patients with chronic, stable angina: sustained efficacy and lack of "withdrawal phenomenon" upon abrupt discontinuation. Mehta JL, et al. **Clin Cardiol** 1994 Sep;17(9 Suppl Iii):III17–22

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Corea L, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):341–6

Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Kuschnir E, et al. **Clin Ther** 1996 Nov-Dec;18(6):1213–24

Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Oparil S, et al. **Clin Ther** 1996 Jul-Aug; 18(4):608–25

Treatment effects on the total ischaemic burden and prognostic implications. Deanfield J. **Eur Heart J** 1996 Dec;17 Suppl G:64–8 (30 ref.)

Effects of nimodipine, felodipine and amlodipine on electroconvulsive shock-induced amnesia in the rat. Zupan G, et al. **Eur J Pharmacol** 1996 Aug 29;310(2–3):103–6

Treatment of systemic hypertension in cats with amlodipine besylate. Henik RA, et al. **J Am Anim Hosp Assoc** 1997 May-Jun;33(3):226–34

Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. Mohler ER 3rd, et al. **J Am Coll Cardiol** 1997 Jul;30(1):35–41

Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. Pesavento TE, et al. **J Am Soc Nephrol** 1996 Jun;7(6):831–5

Evaluation of amlodipine in mild to moderate hypertension--a clinical report. Yajnik VH, et al. **J Assoc Physicians India** 1995 Jan;43(1):34–5

Fixed combination of benazepril and low-dose amlodipine in the treatment of mild to moderate essential hypertension: evaluation by 24-hour noninvasive ambulatory blood pressure monitoring. Fogari R, et al. **J Cardiovasc Pharmacol** 1997 Aug;30(2):176–81

Felodipine and amlodipine in stable angina pectoris: results of a randomized double-blind crossover trial. Koenig W, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):520–4

Physical performance is preserved after regression of left ventricular hypertrophy. Lacourcière Y, et al. **J Cardiovasc Pharmacol** 1997 Sep;30(3):383–91

Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomized double-blind study. Lau CP, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):328–31

Hemodynamic and 24-h blood pressure profile of amlodipine monotherapy. Ibrahim MM, et al. **J Hum Hypertens** 1996 Jul;10(7):489–94

A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group. Viskoper RJ, et al. **J Hum Hypertens** 1997 Jun;11(6):387–93

Blood pressure and blood glucose levels during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients. Ahaneku JE. **Kobe J Med Sci** 1996 Feb;42(1):19–29

Amlodipine in chronic heart failure [letter; comment] Allan JJ. **N Engl J Med** 1997 Apr 3;336(14):1023–4; discussion 1024. Comment on: N Engl J Med 1996 Oct 10;335(15):1107–14.

Amlodipine in chronic heart failure [letter; comment] Bobbio M. **N Engl J Med** 1997 Apr 3;336(14):1023; discussion 1024 . Comment on: N Engl J Med 1996 Oct 10;335(15):1107–14.

Amlodipine in chronic heart failure [letter; comment] Poole-Wilson PA. **N Engl J Med** 1997 Apr 3;336(14):1023; discussion 1024. Comment on: N Engl J Med 1996 Oct 10;335(15):1107–14.

Amlodipine inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Takahashi T, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jan; 91(1):17–32

[The first clinical experience in Italy with angiotensin II receptor antagonists: results of a multicenter study on the efficacy and tolerance in arterial hypertension] Trimarco B. **Cardiologia** 1995 Dec;40(12 Suppl 1):193–5 **(Ita)**

[Transcutaneous oximetry in smokers with moderate hypertension and peripheral arterial disease treated with amlodipine and defibrotide, also with total smoking cessation] Cicco G, et al. **Minerva Cardioangiol** 1995 Oct; 43(10):423–8 (Eng. Abstr.) **(Ita)**

-Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension- Kokot F, et al. **Pol Arch Med Wewn** 1995 Oct;94(4):342–8 (Eng. Abstr.) **(Pol)**

[The role of calcium inhibitors in the treatment of arterial hypertension] Hrnčiar J, et al. **Vnitr Lek** 1997 Feb; 43(2):74–80 (Eng. Abstr.) **(Slo)**

[Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients] Oliván J, et al. **An Med Interna** 1996 Nov;13(11):531–6 (Eng. Abstr.) **(Spa)**

AMMOIDIN see **METHOXSALEN**

AMMONIA

Effect of sodium bisulfate on ammonia concentration, fly population, and manure pH in a horse barn. Sweeney CR, et al. **Am J Vet Res** 1996 Dec;57(12):1795–8

A simplified silver diammine method for the staining of nucleic acids in polyacrylamide gels. Vari F, et al. **Electrophoresis** 1996 Jan;17(1):20–5

ADMINISTRATION & DOSAGE

Mucosal irritation, adaptive cytoprotection, and adaptation to topical ammonia in the rat stomach. Brzozowski T, et al. **Scand J Gastroenterol** 1996 Sep;31(9):837–46

ADVERSE EFFECTS

Chronic lung disease secondary to ammonia inhalation injury: a report on three cases. de la Hoz RE, et al. **Am J Ind Med** 1996 Feb;29(2):209–14

Astrocytic-ammonia interactions in hepatic encephalopathy. Norenberg MD. **Semin Liver Dis** 1996 Aug;16(3):245–53 (165 ref.)

Association of interleukin-6 in the cerebrospinal fluid during crisis of calf with ammoniated feed syndrome. Nakajima Y, et al. **Vet Immunol Immunopathol** 1997 Jun;57(1–2):79–85

ANALYSIS

Retrograded (RS3) but not uncooked (RS2) resistant starch lowers fecal ammonia concentrations in healthy men [letter; comment] Heijnen ML, et al. **Am J Clin Nutr** 1997 Jan; 65(1):167–9. Comment on: Am J Clin Nutr 1996 May;63(5):766–72.

Detection and analysis of the growth characteristics of Proteus vulgaris with a bulk acoustic wave ammonia sensor. Tan H, et al. **Analyst** 1997 Feb;122(2):179–84

Ammonia in ruminal and abomasal contents of cows with abomasal displacement. Geishauser T, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Nov;103(11):465–8

Colorimetric determination of blood and brain ammonia in vitro by a modified method. Jayakumar AR, et al. **Indian J Biochem Biophys** 1996 Jun;33(3):231–3

Lactate and ammonia concentration in blood and sweat during incremental cycle ergometer exercise. Ament W, et al. **Int J Sports Med** 1997 Jan;18(1):35–9

Method for the determination of 15NH3 enrichment in biological samples by gas chromatography/electron impact ionization mass spectrometry. Nieto R, et al. **J Mass Spectrom** 1996 Mar;31(3):289–94

Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. Davies S, et al. **Kidney Int** 1997 Jul;52(1):223–8

[Investigations on the concentration and emission of ammonia and nitrous oxide in various deep litter keeping systems for fattening pigs and in slatted floor keeping] Hoy S, et al. **Berl Munch Tierarztl Wochenschr** 1997 Mar;110(3):90–5 (Eng. Abstr.) **(Ger)**

[Analysis of lactate, ammonia and urea in skin excretions] Khramov VA. **Klin Lab Diagn** 1996 May-Jun;(3):15–7 (Eng. Abstr.) **(Rus)**

[Detection of minimal ammonia concentrations using the aerosol method] Korableva AA, et al. **Med Tr Prom Ekol** 1996;(10):31–4 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Inhibition of glutamine synthetase reduces ammonia-induced astrocyte swelling in rat. Willard-Mack CL, et al. **Neuroscience** 1996 Mar;71(2):589–99

BLOOD

Helicobacter pylori, hyperammonemia, and hepatic encephalopathy: is there a correlation? [letter] Rinaldi V, et al. **Am J Gastroenterol** 1997 Apr;92(4):723–4

Prenatal monitoring in a family at high risk for ornithine transcarbamylase (OTC) deficiency: a new mutation of an A-to-C transversion in position +4 of intron 1 of the OTC gene that is likely to abolish enzyme activity. Hoshide R, et al. **Am J Med Genet** 1996 Aug 23;64(3):459–64

Carnitine for valproic acid-induced hyperammonemia [letter] Raby WN. **Am J Psychiatry** 1997 Aug;154(8):1168–9

The contribution of various organs to ammonia formation. Factors determining the arterial concentration [letter; comment] Agroyannis B, et al. **Ann Clin Biochem** 1997 Mar; 34 (Pt 2):210–1. Comment on: Ann Clin Biochem 1996 Jan;33 (Pt 1):23–30.

The contribution of various organs to ammonia formation: a review of factors determining the arterial ammonia concentration [see comments] Huizenga JR, et al. **Ann Clin Biochem** 1996 Jan;33 (Pt 1):23–30 (63 ref.). Comment in: Ann Clin Biochem 1997 Mar;34 (Pt 2):210–1.

Hepatic glutamine synthetase deficiency in fatal hyperammonemia after lung transplantation. Tuchman M, et al. **Ann Intern Med** 1997 Sep 15;127(6):446–9

Gender differences in blood ammonia response during exercise. Derave W, et al. **Arch Physiol Biochem** 1997 Apr; 105(2):203–9

Effects of acute cardioselective and non-selective beta-adrenergic blockade on plasma ammonia levels in exercising dogs. Matthys D, et al. **Arch Physiol Biochem** 1996;104(1):14–9

Microencapsulated genetically engineered E. coli DH5 cells for plasma urea and ammonia removal based on: 1. Column bioreactor and 2. Oral administration in uremic rats. Prakash S, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1996 May; 24(3):201–18

Determinants of ammonia clearance by hemodialysis. Cordoba J, et al. **Artif Organs** 1996 Jul;20(7):800–3

Serum analytes in the Tammar wallaby, Macropus eugenii. Deane EM, et al. **Aust Vet J** 1997 Feb;75(2):141–2

Expression, purification and kinetic characterization of wild-type human ornithine transcarbamylase and a recurrent mutant that produces 'late onset' hyperammonaemia. Morizono H, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):625–31

Idiopathic hyperammonemia: a frequently lethal

complication of bone marrow transplantation. Davies SM, et al. **Bone Marrow Transplant** 1996 Jun;17(6):1119–25

High–dose 5–fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy [letter] Yeh KH, et al. **Br J Cancer** 1997; 75(3):464–5

Modulation of ligand binding to components of the GABAA receptor complex by ammonia: implications for the pathogenesis of hyperammonemic syndromes. Ha JH, et al. **Brain Res** 1996 May 13;720(1–2):35–44

Acute liver failure and hyperammonemia increase peripheral–type benzodiazepine receptor binding and pregnenolone synthesis in mouse brain. Itzhak Y, et al. **Brain Res** 1995 Dec 24;705(1–2):345–8

Arterial ammonia with Blood Ammonia Checker II and with indophenol reaction to assess presence of hepatic encephalopathy. Huizenga JR, et al. **Clin Chim Acta** 1996 Aug 15;252(1):73–82

The addition of aminoacids and phosphate to hemodiafiltration solutions in newborns with hyperammonemic coma. Fründ S, et al. **Clin Nephrol** 1996 Jul;46(1):64–6

Fatal clinical course of ornithine transcarbamylase deficiency in an adult heterozygous female patient. Heringlake S, et al. **Digestion** 1997;58(1):83–6

Ammonia and encephalopathy in the horse [editorial; comment] Mair TS. **Equine Vet J** 1997 Jan;29(1):1–2. Comment on: Equine Vet J 1997 Jan;29(1):70–4.

Hyperammonaemia associated with encephalopathy and abdominal pain without evidence of liver disease in four mature horses [see comments] Peek SF, et al. **Equine Vet J** 1997 Jan;29(1):70–4. Comment in: Equine Vet J 1997 Jan;29(1):1–2.

Quantitation of metabolic compartmentation in hyperammonemic brain by natural abundance 13C–NMR detection of 13C–15N coupling patterns and isotopic shifts. Lapidot A, et al. **Eur J Biochem** 1997 Feb 1;243(3):597–604

Fatal hyperammonemia following orthotopic lung transplantation [see comments] Lichtenstein GR, et al. **Gastroenterology** 1997 Jan;112(1):236–40. Comment in: Gastroenterology 1997 Jun;112(6):2162.

Effects of Helicobacter pylori eradication therapy on hyperammonaemia in patients with liver cirrhosis [see comments] Miyaji H, et al. **Gut** 1997 Jun;40(6):726–30. Comment in: Gut 1997 Jun;40(6):805–6.

Helicobacter pylori, ammonia and the brain [comment] Taylor–Robinson SD, et al. **Gut** 1997 Jun;40(6):805–6. Comment on: Gut 1997 Jun;40(6):726–30.

Focal glycogenosis of the liver in disorders of ureagenesis: its occurrence and diagnostic significance. Badizadegan K, et al. **Hepatology** 1997 Aug;26(2):365–73

A novel two–nucleotide deletion in the ornithine transcarbamylase gene causing fatal hyperammonia in early pregnancy. Schimanski U, et al. **Hepatology** 1996 Dec; 24(6):1413–5

Partial duplication [dup. TCAC (178)] and novel point mutations (T125M, G188R, A209V, and H302L) of the ornithine transcarbamylase gene in congenital hyperammonemia. Gilbert–Dussardier B, et al. **Hum Mutat** 1996;8(1):74–6

A 3–base pair in–frame deletion in exon 8 (delGlu272/273) of the ornithine transcarbamylase gene in late–onset hyperammonemic coma. Ségues B, et al. **Hum Mutat** 1996; 8(4):373–4

Lactate and ammonia concentration in blood and sweat during incremental cycle ergometer exercise. Ament W, et al. **Int J Sports Med** 1997 Jan;18(1):35–9

Comparison of the metabolic disturbances caused by end–to–side and side–to–side portacaval shunts. Hawkins PA, et al. **J Appl Physiol** 1996 Mar;80(3):885–91

Methionine sulfoximine, a glutamine synthetase inhibitor, attenuates increased extracellular potassium activity during acute hyperammonemia. Sugimoto H, et al. **J Cereb Blood Flow Metab** 1997 Jan;17(1):44–9

Amino acid and DNA analyses in a family with ornithine transcarbamylase deficiency. Hou JW, et al. **J Formos Med Assoc** 1996 Feb;95(2):144–7

Case report: recurrent hyperammonaemic encephalopathy due to citrullinaemia in a 52 year old man. Chow WC, et al. **J Gastroenterol Hepatol** 1996 Jul;11(7):621–5

Hyperammonemia–induced depletion of glutamate and branched–chain amino acids in muscle and plasma. Leweling H, et al. **J Hepatol** 1996 Nov;25(5):756–62

L–ornithine vs. L–ornithine–L–aspartate as a treatment for hyperammonemia–induced encephalopathy in rats. Vogels BA, et al. **J Hepatol** 1997 Jan;26(1):174–82

The effects of ammonia and portal–systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia–induced encephalopathy. Vogels BA, et al. **J Hepatol** 1997 Feb; 26(2):387–95

Two models of acute hepatic failure with extensive hepatic necrosis and blood ammonia elevation in small animals. Watanabe A, et al. **J Med** 1997;28(1–2):45–8

Phenotypic variability in male patients carrying the mutant ornithine transcarbamylase (OTC) allele, Arg40His, ranging from a child with an unfavourable prognosis to an asymptomatic older adult. Matsuda I, et al. **J Med Genet** 1996 Aug;33(8):645–8

Glial alkalinization detected in vivo by 1H–15N heteronuclear multiple–quantum coherence–transfer NMR in severely hyperammonemic rat. Kanamori K, et al. **J Neurochem** 1997 Mar;68(3):1209–20

Portacaval shunting and hyperammonemia stimulate the uptake of L–[3H] arginine but not of L–[3H]nitroarginine into rat brain synaptosomes. Rao VL, et al. **J Neurochem** 1997 Jan;68(1):337–43

Relation of taurine transport and brain edema in rats with simple hyperammonemia or liver failure. Hilgier W, et al. **J Neurosci Res** 1996 Jul 1;45(1):69–74

Effective hemodialysis and hemofiltration driven by an extracorporeal membrane oxygenation pump in infants with hyperammonemia. Summar M, et al. **J Pediatr** 1996 Mar; 128(3):379–82

A syndrome of congenital hyperinsulinism and hyperammonemia. Weinzimer SA, et al. **J Pediatr** 1997 Apr;130(4):661–4

Blood lactate and ammonia in short–term anaerobic work following induced alkalosis. Ibanez J, et al. **J Sports Med Phys Fitness** 1995 Sep;35(3):187–93

Effects of hyperammonemia on brain protein kinase C substrates. Grau E, et al. **Metab Brain Dis** 1996 Sep; 11(3):205–16 (48 ref.)

Effects of acute hyperammonemia in vivo on oxidative metabolism in nonsynaptic rat brain mitochondria. Kosenko E, et al. **Metab Brain Dis** 1996 Mar;12(1):69–82

Biochemical evaluation of a patient with a familial form of leucine–sensitive hypoglycemia and concomitant hyperammonemia. Zammarchi E, et al. **Metabolism** 1996 Aug;45(8):957–60

Human blood lactate and ammonia levels after supramaximal uphill and downhill running. Itoh H, et al. **Nagoya J Med Sci** 1996 Dec;59(3–4):135–42

Progressive decrease of cerebral cytochrome C oxidase activity in sparse–fur mice: role of acetyl–L–carnitine in restoring the ammonia–induced cerebral energy depletion. Rao KV, et al. **Neurosci Lett** 1997 Mar 14;224(2):83–6

Hyperornithinemia–hyperammonemia–homocitrullinuria (HHH)–syndrome. Ultrastructural changes of mitochondria in cultured dermal fibroblasts of three patients. Haust MD, et al. **Pathol Res Pract** 1996 Mar;192(3):271–80

Ciliated cultured dermal fibroblasts in a patient with hyperornithinemia, hyperammonemia and homocitrullinuria (HHH) syndrome. Haust MD. **Pathol Res Pract** 1995 Oct;191(10):1062–5

Diet– and valproate–induced transient hyperammonemia: effect of L–carnitine. Gidal BE, et al. **Pediatr Neurol** 1997 May;16(4):301–5

Tyrosine uptake and regional brain monoamine metabolites in a rat model resembling congenital hyperammonemia. Colombo JP, et al. **Pediatr Res** 1996 Jun;39(6):1036–40

Behavioral and electroencephalographic studies of beagles with an Eck's fistula: suitability as a model of hepatic encephalopathy. Watanabe M, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):367–75

Intravenous arginine dramatically improved hyperammonemia in a patient with late–onset ornithine transcarbamylase deficiency. Kodama H, et al. **Tohoku J Exp Med** 1996 Sep;180(1):83–6

[Determination of serum free amino acids and ammonia in pregnant women with severe pregnancy induced hypertension] Li J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Aug;31(8):468–70 (Eng. Abstr.) **(Chi)**

[Blood chemical analysis. A. Effects of sample collection and subsequent processing on the test results—determination of blood ammonia level by direct deproteinization colorimetry] Doi M, et al. **Rinsho Byori** 1996 Nov;Suppl 103:156–61 **(Jpn)**

[Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients] Navarro–Quesada FJ, et al. **Rev Neurol** 1997 Jul; 25(143):1037–44 (Eng. Abstr.) **(Spa)**

CHEMICAL SYNTHESIS

Production of [13N]ammonia applicable to low energy accelerators. Dence CS, et al. **Nucl Med Biol** 1994 Oct; 21(7):987–96

CHEMISTRY

Supercritical fluid extraction of 11C–labeled metabolites in tissue using supercritical ammonia. Jacobson GB, et al. **Anal Chem** 1997 Feb 1;69(3):275–80

Avoidance of sulfur loss during ammonia treatment of oligonucleotide phosphorothioates. Reese CB, et al. **Nucleic Acids Res** 1997 Jul 15;25(14):2943–4

A 2H NMR spin–lattice relaxation study of –NH+3 group dynamics in polycrystalline L–alanine. Williams MA, et al. **Solid State Nucl Magn Reson** 1996 Feb;6(1):47–53

DIAGNOSTIC USE

Quantitative evaluation of myocardial blood flow with [13N]ammonia. Hutchins GD. **Cardiology** 1997 Jan–Feb; 88(1):106–15 (50 ref.)

Estimation of myocardial blood flow for longitudinal studies with 13N–labeled ammonia and positron emission tomography. DeGrado TR, et al. **J Nucl Cardiol** 1996 Nov–Dec;3(6 Pt 1):494–507

Three–dimensional correction for spillover and recovery of myocardial PET images. Nuyts H, et al. **J Nucl Med** 1996 May;37(5):767–74

Generator–produced copper–62–PTSM as a myocardial PET perfusion tracer compared with nitrogen–13–ammonia. Tadamura E, et al. **J Nucl Med** 1996 May;37(5):729–35

Coronary flow and flow reserve by PET simplified for clinical applications using rubidium–82 or nitrogen–13–ammonia. Yoshida K, et al. **J Nucl Med** 1996 Oct;37(10):1701–12

METABOLISM

Na(+)–K+(NH4+)–2Cl– cotransport in medullary thick ascending limb: control by PKA, PKC, and 20–HETE. Amlal H, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C455–63

Carbonic anhydrase facilitates CO2 and NH3 transport across the sarcolemma of trout white muscle. Henry RP, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1754–61

Ammonia movement and distribution after exercise across white muscle cell membranes in rainbow trout. Wang Y, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R738–50

Regulation of ammonia assimilation in an obligate methylotroph Methylobacillus flagellatum under steady–state and transient growth conditions. Baev MV, et al. **Antonie Van Leeuwenhoek** 1997 May;71(4):353–61

Enzymology of the oxidation of ammonia to nitrite by bacteria. Hooper AB, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1–2):59–67 (83 ref.)

Cell density–regulated recovery of starved biofilm populations of ammonia–oxidizing bacteria. Batchelor SE, et al. **Appl Environ Microbiol** 1997 Jun;63(6):2281–6

Analysis of ammonia–oxidizing bacteria of the beta subdivision of the class Proteobacteria in coastal sand dunes by denaturing gradient gel electrophoresis and sequencing of PCR–amplified 16S ribosomal DNA fragments. Kowalchuk GA, et al. **Appl Environ Microbiol** 1997 Apr; 63(4):1489–97

Biochemical and mutational analysis of a gingipain–like peptidase activity from Prevotella ruminicola B(1)4 and its role in ammonia production by ruminal bacteria. Madeira HM, et al. **Appl Environ Microbiol** 1997 Feb; 63(2):670–5

Molecular diversity of soil and marine 16S rRNA gene sequences related to beta–subgroup ammonia–oxidizing bacteria. Stephen JR, et al. **Appl Environ Microbiol** 1996 Nov;62(11):4147–54

Ammonia–excreting mutants of Klebsiella pneumoniae with a pleiotropic defect in nitrogen metabolism. Kuczius T, et al. **Arch Microbiol** 1996 Dec;166(6):388–93

Anaerobic ammonia oxidation with nitrogen dioxide by Nitrosomonas eutropha. Schmidt I, et al. **Arch Microbiol** 1997 Feb–Mar;167(2–3):106–11

Chronic sodium benzoate therapy in children with inborn errors of urea synthesis: effect on carnitine metabolism and ammonia nitrogen removal. Feoli–Fonseca JC, et al. **Biochem Mol Med** 1996 Feb;57(1):31–6

Coupled formation of an amidotransferase interdomain ammonia channel and a phosphoribosyltransferase active site. Krahn JM, et al. **Biochemistry** 1997 Sep 16; 36(37):11061–8

Permeation of ammonia across bilayer lipid membranes studied by ammonium ion selective microelectrodes. Antonenko YN, et al. **Biophys J** 1997 May;72(5):2187–95

Conversion of [15N]ammonia into urea and amino acids in humans and the effect of nutritional status. Weijs PJ, et al. **Br J Nutr** 1996 Oct;76(4):491–9

Examination of 7–ethoxycoumarin deethylation and ammonia removal activities in 31 hepatocyte cell lines. Enosawa S, et al. **Cell Transplant** 1996 Sep–Oct;5(5 Suppl 1):S39–40

Participation of NH4+ in total ammonia absorption across the rumen epithelium of sheep (Ovis aries). Bödeker D, et al. **Comp Biochem Physiol A Physiol** 1996 Aug; 114(4):305–10

Ammonia transport by the urinary bladder of Bufo marinus. Melton LB, et al. **Comp Biochem Physiol A Physiol** 1996 Oct;115(2):153–8

Nitrate reduction to ammonia by enteric bacteria: redundancy, or a strategy for survival during oxygen starvation? Cole J. **FEMS Microbiol Lett** 1996 Feb 1; 136(1):1–11 (49 ref.)

The glial glutamate transporter in hyperammonemia and hepatic encephalopathy: relation to energy metabolism and glutamatergic neurotransmission. Norenberg MD, et al. **Glia** 1997 Sep;21(1):124–33

Ammonia and GABA–ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Basile AS, et al. **Hepatology** 1997 Jun;25(6):1303–5 (43 ref.)

Glutamine, myo–inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia–induced brain edema. Cordoba J, et al. **Hepatology** 1996 Oct;24(4):919–23

Effect of ammonia starvation on hydroxylamine oxidoreductase activity of Nitrosomonas europaea. Nejidat A, et al. **J Biochem (Tokyo)** 1997 May;121(5):957–60

Mitochondrial ammonia metabolism and the proton–neutral theory of hepatic ammonia detoxication. Campbell JW. **J Exp Zool** 1997 Aug 1;278(5):308–21 (121 ref.)

High acid secretion may protect the gastric mucosa from injury caused by ammonia produced by Helicobacter pylori in duodenal ulcer patients. Shibata T, et al. **J Gastroenterol Hepatol** 1996 Jul;11(7):674–80

Evidence for a commensal, symbiotic relationship between Gardnerella vaginalis and Prevotella bivia involving ammonia: potential significance for bacterial vaginosis. Pybus V, et al. **J Infect Dis** 1997 Feb;175(2):406–13

Effects of tumor necrosis factor–alpha and interleukin–6 on

fluid-phase permeability and ammonia diffusion in CNS-derived endothelial cells. Duchini A, et al. **J Investig Med** 1996 Oct;44(8):474–82

Severity of hyperammonemic encephalopathy correlates with brain ammonia level and saturation of glutamine synthetase in vivo. Kanamori K, et al. **J Neurochem** 1996 Oct; 67(4):1584–94

Effects of photoreceptor metabolism on interstitial and glial cell pH in bee retina: evidence of a role for NH4+. Coles JA, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):305–18

Stimulation of muscle ammonia production during exercise following branched-chain amino acid supplementation in humans. MacLean DA, et al. **J Physiol (Lond)** 1996 Jun 15;493 (Pt 3):909–22

Hormonal mediators of ammoniagenesis: mechanism of action of PGF2 alpha and the implications for other hormones [editorial] Tannen RL, et al. **Kidney Int** 1996 Jul; 50(1):15–25 (121 ref.)

FISH mapping of three ammonia metabolism genes (Glul, Cps1, Glud1) in rat, and the chromosomal localization of GLUL in human and Cps1 in mouse. Helou K, et al. **Mamm Genome** 1997 May;8(5):362–4

Effect of endurance training on ammonia and amino acid metabolism in humans. Graham TE, et al. **Med Sci Sports Exerc** 1997 May;29(5):646–53 (57 ref.)

Effects of simulated upper gastrointestinal hemorrhage on ammonia and related amino acids in blood and brain of chronic portacaval-shunted rats. Olde Damink SW, et al. **Metab Brain Dis** 1997 Jun;12(2):121–35

Measurement of the expiratory ammonia concentration and its clinical significance. Wakabayashi H, et al. **Metab Brain Dis** 1997 Jun;12(2):161–9

Ammonium transport and the role of the Na,K-ATPase. Wall SM. **Miner Electrolyte Metab** 1996;22(5–6):311–7 (43 ref.)

Treatment of hepatic encephalopathy. Riordan SM, et al. **N Engl J Med** 1997 Aug 14;337(7):473–9 (73 ref.)

Ammonia and glutamine metabolism during liver insufficiency: the role of kidney and brain in interorgan nitrogen exchange. Dejong CH, et al. **Scand J Gastroenterol Suppl** 1996;218:61–77 (134 ref.)

Excretion of ammonia by Lucilia cuprina larvae suppresses immunity in sheep. Guerrini VH. **Vet Immunol Immunopathol** 1997 May;56(3–4):311–7

[Efficacy of various therapeutic measures in metabolic hyperammonemia] Pérez Rodríguez MJ, et al. **An Esp Pediatr** 1997 May;46(5):460–3 (Eng. Abstr.) **(Spa)**

[Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients] Navarro-Quesada FJ, et al. **Rev Neurol** 1997 Jul; 25(143):1037–44 (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Ammonia uptake in inactive muscles during exercise in humans. Bangsbo J, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):E101–6

PHARMACOLOGY

Ammonia effect on calcium-activated chloride secretion in T84 intestinal epithelial monolayers. Mayol JM, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C634–42

Effects of ammonia and nitrate concentration on hematologic and serum biochemical profiles of hybrid striped bass (Morone chrysops x Morone saxatilis). Hrubec TC, et al. **Am J Vet Res** 1997 Feb;58(2):131–5

The influence of ammonia, biogenic amines and gamma-aminobutyric acid on grass silage intake in sheep. Van Os M, et al. **Br J Nutr** 1996 Sep;76(3):347–58

Modulation of ligand binding to components of the GABAA receptor complex by ammonia: implications for the pathogenesis of hyperammonemic syndromes. Ha JH, et al. **Brain Res** 1996 May 13;720(1–2):35–44

NH3- and CO2-induced suppression of taste nerve responses in clawed toads and eels. Yoshii K, et al. **Brain Res** 1997 May 23;757(2):202–8

Ammonia inhibits proliferation and cell cycle progression at S-phase in human gastric cells. Matsui T, et al. **Dig Dis Sci** 1997 Jul;42(7):1394–9

Effects of intragastric ammonia on collagen metabolism of gastric ulcer base in rats. Endo H, et al. **Digestion** 1996 Nov-Dec;57(6):411–9

Gastric mucosal damage and adaptive protection by ammonia and ammonium ion in rats. Konturek SJ, et al. **Digestion** 1996 Nov-Dec;57(6):433–45

Helicobacter pylori-human polymorphonuclear leucocyte interaction in the presence of ammonia. Mayo K, et al. **Eur J Gastroenterol Hepatol** 1997 May;9(5):457–61

Effects of ruminally degradable nitrogen intake and in vitro addition of ammonia and propionate on the metabolic fate of L-[1-14C]alanine and L-[15N]alanine in isolated sheep hepatocytes. Mutsvangwa T, et al. **J Anim Sci** 1997 Apr; 75(4):1149–59

Ammonia-induced taurine release from cultured rabbit Müller cells is an osmoresistant process mediated by intracellular accumulation of cyclic AMP. Faff L, et al. **J Neurosci Res** 1996 Oct 15;46(2):231–8

Augmented chemiluminescence response of bronchoalveolar lavage cells in calves receiving repeated daily sprayings of ammonia mist into the nasal cavities. Murata H. **J Vet Med Sci** 1997 Feb;59(2):141–2

Two modes of stimulation by ammonia of taurine release from cultured rabbit Müller cells. Faff L, et al. **Neurochem Int** 1997 Aug;31(2):301–5

Effects of ammonia on L-glutamate uptake in cultured astrocytes. Bender AS, et al. **Neurochem Res** 1996 May; 21(5):567–73

Effectors of D-[3H]aspartate release from rat cerebellum. Svarna R, et al. **Neurochem Res** 1996 May;21(5):603–8

Ammonia stimulates glutamine uptake to the cerebral non-synaptic mitochondria of the rat. Dolińska M, et al. **Neurosci Lett** 1996 Jul 26;213(1):45–8

Airway protective reflexes elicited by laryngeal ammonia: role of C-fiber afferents. Naida AM, et al. **Respir Physiol** 1996 Jan;103(1):11–7

Mucosal irritation, adaptive cytoprotection, and adaptation to topical ammonia in the rat stomach. Brzozowski T, et al. **Scand J Gastroenterol** 1996 Sep;31(9):837–46

POISONING

Acute ammonia inhalation [letter] Darchy B, et al. **Intensive Care Med** 1997 May;23(5):597–8

Ketamine reduces lethality on the acute ammonia intoxication in mice. Boscán PL, et al. **Invest Clin** 1996 Jun;37(2):129–35

Ammonia gassing deaths--a report on two cases. Chao TC, et al. **Singapore Med J** 1996 Apr;37(2):147–9 (11 ref.)

[Changes in the blood morphofunctional characteristics of cyprinid fishes in ammonia poisoning] Hrubinko VV, et al. **Fiziol Zh** 1996;42(1–2):40–6 (Eng. Abstr.) **(Ukr)**

TOXICITY

Toxicity of nitrogenous compounds to juveniles of flatfish Paralichthys orbignyanus. Bianchini A, et al. **Bull Environ Contam Toxicol** 1996 Mar;56(3):453–9

Effect of ammonia on survival and adenylate energy charge in the shrimp Palaemonetes varians. Marazza D, et al. **Ecotoxicol Environ Saf** 1996 Jul;34(2):103–8

Synergistic role of gaseous ammonia in etiology of Pasteurella multocida-induced atrophic rhinitis in swine. Hamilton TD, et al. **J Clin Microbiol** 1996 Sep;34(9):2185–90

Severity of hyperammonemic encephalopathy correlates with brain ammonia level and saturation of glutamine synthetase in vivo. Kanamori K, et al. **J Neurochem** 1996 Oct; 67(4):1584–94

Carnitine and choline derivatives containing a trimethylamine group prevent ammonia toxicity in mice and glutamate toxicity in primary cultures of neurons. Miñana MD, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):194–9

Response of rat cerebral somatostatinergic system to a high ammonia diet. Boyano-Adánez MC, et al. **Neurochem Int** 1996 Nov;29(5):469–76

NMDA receptor antagonists prevent acute ammonia toxicity in mice. Hermenegildo C, et al. **Neurochem Res** 1996 Oct; 21(10):1237–44

Adjuvant effect of respiratory irritation on pulmonary allergic sensitization: time and site dependency. Siegel PD, et al. **Toxicol Appl Pharmacol** 1997 Jun;144(2):356–62

Ammonia pipeline rupture: risk assessment to cattle. Morgan SE. **Vet Hum Toxicol** 1997 Jun;39(3):159–61

A morphometric and functional study of the toxicity of atmospheric ammonia in the extrathoracic airways in pigs. Urbain B, et al. **Vet Res Commun** 1996;20(4):381–99

URINE

Urinary excretion of endogenous nitrogen metabolites in adult domestic cats using a protein-free diet and the regression technique. Hendriks WH, et al. **J Nutr** 1997 Apr; 127(4):623–9

AMMONIA-LYASES

METABOLISM

Maize phenylalanine ammonia-lyase has tyrosine ammonia-lyase activity. Rösler J, et al. **Plant Physiol** 1997 Jan;113(1):175–9

ULTRASTRUCTURE

Monofunctional domains of formiminotransferase-cyclodeaminase retain similar conformational stabilities outside the bifunctional octamer. Murley LL, et al. **Biochim Biophys Acta** 1997 Apr 4; 1338(2):223–32

AMMONIUM CHLORIDE

Neonatal chorda tympani transection alters adult preference for ammonium chloride in the rat. Sollars SI, et al. **Behav Neurosci** 1996 Jun;110(3):551–8

ADMINISTRATION & DOSAGE

Axial distribution of band 3-positive intercalated cells in the collecting duct of control and ammonium chloride-loaded rabbits. Verlander JW, et al. **Kidney Int Suppl** 1996 Dec; 57:S137–47

ADVERSE EFFECTS

[Prescription of ammonium chloride: anecdotic but catastrophic (letter)] Le Roy F, et al. **Presse Med** 1997 Mar 29;26(10):465 **(Fre)**

DIAGNOSTIC USE

Adenovirus-mediated in vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge. Ye X, et al. **Pediatr Res** 1997 Apr; 41(4 Pt 1):527–34

METABOLISM

Microbial amino acid synthesis and utilization in rats: incorporation of 15N from 15NH4Cl into lysine in the tissues of germ-free and conventional rats. Torrallardona D, et al. **Br J Nutr** 1996 Nov;76(5):689–700

Seromuscular colocystoplasty lined with urothelium protects dogs from acidosis during ammonium chloride loading. Denes ED, et al. **J Urol** 1997 Sep;158(3 Pt 2):1075–80

PHARMACOLOGY

Simultaneous measurements of cytosolic calcium ion and pH in cultured superior cervical ganglion cells of rat. Yoshizaki K, et al. **Adv Exp Med Biol** 1996;410:221–6

NH4Cl activates AE2 anion exchanger in Xenopus oocytes at acidic pHi. Humphreys BD, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1232–40

Ammonium inhibition of Ca(2+)-dependent inwardly rectifying K+ currents in HeLa cells. Díaz M, et al. **Biochim Biophys Acta** 1996 Oct 23;1284(2):119–21

Effect of ammonia on motor function in adult rats. Jayakumar AR, et al. **Brain Res Bull** 1997;43(3):275–8

Stimulation of cortical actin polymerization in the sea urchin egg cortex by NH4Cl, procaine and urethane: elevation of cytoplasmic pH is not the common mechanism of action. Begg DA, et al. **Cell Motil Cytoskeleton** 1996;35(3):210–24

Aging effects on the organic base transporter and stereoselective renal clearance. Ujhelyi MR, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):117–28

Gastric mucosal damage and adaptive protection by ammonia and ammonium ion in rats. Konturek SJ, et al. **Digestion** 1996 Nov-Dec;57(6):433–45

NH4Cl-induced contraction of porcine coronary artery involves activation of dihydropyridine-sensitive Ca2+ entry. Wakabayashi I, et al. **Eur J Pharmacol** 1996 Mar 28;299(1-3):139–47

Mechanism of the potentiating effect of NH4Cl on vasoconstriction in rat aorta. Tanaka H, et al. **Gen Pharmacol** 1996 Apr;27(3):535–8

Effects of propionate and ammonium on contractions produced by sodium removal in human internal mammary artery and saphenous vein. Miyahara K, et al. **Jpn J Physiol** 1996 Jun;46(3):243–8

The effect of ammonium chloride on hepatic and renal metabolism in the rat. Lardner AL, et al. **Kidney Blood Press Res** 1997;20(1):57–61

TOXICITY

Role of lysosomal cathepsin activities in cell hypertrophy induced by NH4Cl in cultured renal proximal tubule cells. Ling H, et al. **J Am Soc Nephrol** 1996 Jan;7(1):73–80

[Morphological effects of ammonia on cultured fetal rat neurons] Zhu J, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Jun;25(3):139–41 (Eng. Abstr.) **(Chi)**

AMMONIUM COMPOUNDS

see related
PYRIDINIUM COMPOUNDS
QUINOLINIUM COMPOUNDS

Unique immunomodulating properties of dimethyl dioctadecyl ammonium bromide (DDA) in experimental viral vaccines. Katz D, et al. **Adv Exp Med Biol** 1996; 397:115–25 (22 ref.)

16-BAC/SDS-PAGE: a two-dimensional gel electrophoresis system suitable for the separation of integral membrane proteins. Hartinger J, et al. **Anal Biochem** 1996 Aug 15;240(1):126–33

Separation of alpha-amylase by reversed micellar extraction. Effect of solvent type and cosolvent concentration on the transfer process. Chang QL, et al. **Appl Biochem Biotechnol** 1997 Feb-Mar;62(2-3):119–29

Osmium ammine: review of current applications to visualize DNA in electron microscopy. Biggiogera M, et al. **Biol Cell** 1996;87(3):121–32 (38 ref.)

Osmium ammine-B and electron spectroscopic imaging of ribonucleoproteins: correlation of stain and phosphorus. Olins AL, et al. **Biol Cell** 1996;87(3):143–7

The osmium ammine-SO2 staining method for studying the in situ configuration of viral genomes in ultrathin sections of DNA virus infected cells. Puvion-Dutilleul F, et al. **Biol Cell** 1996;87(3):133–41 (33 ref.)

Evaluation of DNA sequencing ambiguities using tetramethylammonium chloride hybridization conditions. Connors TD, et al. **Biotechniques** 1997 Jun;22(6):1088–90

Labeling of RNA transcripts of eukaryotic cells in culture with BrUTP using a liposome transfection reagent (DOTAP). Haukenes G, et al. **Biotechniques** 1997 Feb; 22(2):308–12

Germ warfare. Medlin J. **Environ Health Perspect** 1997 Mar; 105(3):290–2

Plasmid DNA molecules complexed with cationic liposomes are protected from degradation by nucleases and shearing by aerosolisation. Crook K, et al. **Gene Ther** 1996 Sep;

3(9):834–9
Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV–CFTR–DOTAP. McLachlan G, et al. **Gene Ther** 1996 Dec;3(12):1113–23
Efficacy of vancomycin/tri–iododecyclemethyl ammonium chloride–coated ventriculostomy catheters in reducing infection. Hamilton AJ, et al. **Neurosurgery** 1997 May; 40(5):1043–9
Bimodal effect of amphiphilic biocide concentrations on fluidity of lipid membranes. Podolak M, et al. **Z Naturforsch [C]** 1996 Nov–Dec;51(11–12):853–8

ADMINISTRATION & DOSAGE

Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme). Takle GB, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):177–85
Factors controlling the efficiency of cationic lipid–mediated transfection in vivo via intravenous administration. Liu F, et al. **Gene Ther** 1997 Jun;4(6):517–23
The effectiveness of Allerpet/c in reducing the cat allergen Fel d 1 [see comments] Perzanowski MS, et al. **J Allergy Clin Immunol** 1997 Sep;100(3):428–30. Comment in: J Allergy Clin Immunol 1997 Sep;100(3):290–2.
Liposomal targeting of bcl–2 antisense oligonucleotides with enhanced stability into human myeloma cell lines. Ollikainen H, et al. **Leuk Lymphoma** 1996 Dec; 24(1–2):165–74
Effects exerted by otilonium bromide administration on precipitated opioid withdrawal syndrome in rats. Pinelli A, et al. **Toxicology** 1997 Sep 26;122(1–2):23–37

ADVERSE EFFECTS

Occupational allergic contact dermatitis from 2,3–epoxypropyl trimethyl ammonium chloride (EPTMAC) and Kathon LX in a starch modification factory. Estlander T, et al. **Contact Dermatitis** 1997 Apr; 36(4):191–4
Urticaria and contact urticaria due to basic blue 99 in a hair dye. Jagtman BA. **Contact Dermatitis** 1996 Jul;35(1):52
Contact dermatitis due to ammonium bisulfite in a bleaching cream. Pambor M. **Contact Dermatitis** 1996 Jul;35(1):48–9
[Interactions with cold remedies and weight reducing drugs (letter)] Iwata J, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1786 **(Jpn)**

ANALYSIS

Anti–aflatoxin mutagenic factors in corn. Weng CY, et al. **Food Addit Contam** 1997 Apr;14(3):269–79
Ion chromatographic study of sodium, potassium and ammonium in human body fluids with bulk acoustic wave detection. Yu BS, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):43–9
Observations of emission bands in comet Hale–Bopp [letter; comment] Rauer H, et al. **Science** 1997 Sep 5; 277(5331):1526–7. Comment on: Science 1997 Mar 28;275(5308):1909–12.

BLOOD

Hyperammonemia after heart–lung transplantation [letter; comment] Yoshida EM, et al. **Gastroenterology** 1997 Jun; 112(6):2162. Comment on: Gastroenterology 1997 Jan;112(1):236–40.
Hyperammonemia inhibits platelet aggregation in rats. Shinya H, et al. **Thromb Res** 1996 Jan 15;81(2):195–201

CHEMICAL SYNTHESIS

Synthesis and antimicrobial activity of new quaternary ammonium chlorides. Brycki B, et al. **Arch Pharm (Weinheim)** 1996 Jun;329(6):279–82
Syntheses of pure tetramethylammonium peroxynitrite. Bohle DS, et al. **Methods Enzymol** 1996;269:302–11 (13 ref.)
Synthesis and local anaesthetic activities of N,N–diethyl–3–allyloxy–2–(2–alkoxyphenylcarbamoyloxy) –propylammonium chlorides. Csöllei J. **Pharmazie** 1997 Aug;52(8):639–40
A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Wheeler CJ, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11454–9

CHEMISTRY

Selective modification of alkylammonium ion specificity in trimethylamine dehydrogenase by the rational engineering of cation–pi bonding. Basran J, et al. **Biochemistry** 1997 Feb 25;36(8):1989–98
Synthetic cationic amphiphile for liposome–mediated DNA transfection with less cytotoxicity. Kato T, et al. **Biol Pharm Bull** 1996 Jun;19(6):860–3
Muscarinic thioligands with cyclopentane nucleus. Piergentili A, et al. **Bioorg Med Chem** 1996 Dec;4(12):2193–9
Selective carriers of norepinephrine and ammonium ions: ionophoric properties and molecular modelling studies of diester crown compounds containing a 1,3–bis(1H–pyrazol–1–yl)propane unit. Rodríguez–Franco MI, et al. **Bioorg Med Chem** 1997 Feb;5(2):363–71
Differential scanning calorimetric studies on the effect of ammonium and tetraalkylammonium halides on the stability of lysozyme. Jain S, et al. **Biophys Chem** 1996 Mar 7; 59(1–2):171–7
Fluoridation of hydroxyapatite powder by ammonium hexafluorosilicate. Murata H, et al. **Caries Res** 1996; 30(6):465–70
The use of cationic liposomes DC–CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors. Szala S, et al. **Gene Ther** 1996 Nov;3(11):1026–31
Ammonium containing buffers should be avoided during enzymatic release of glycans from glycoproteins when followed by reducing terminal derivatization [letter] Küster B, et al. **Glycobiology** 1997 Mar;7(2):vii–ix
Endolymph volume changes during osmotic dehydration measured by two marker techniques. Salt AN, et al. **Hear Res** 1995 Oct;90(1–2):12–23
Efficiency of different lipofection agents in Drosophila S–2 cells [letter] Søndergaard L. **In Vitro Cell Dev Biol Anim** 1996 Jul–Aug;32(7):386–7
Conformational transition of insulin induced by n–alkyltrimethylammonium bromides in aqueous solution. Pombo C, et al. **Int J Biol Macromol** 1996 Feb; 18(1–2):55–60
Chromatographic behaviour in reversed–phase high–performance liquid chromatography with micellar and submicellar mobile phases: effects of the organic modifier. Fischer J, et al. **J Chromatogr B Biomed Appl** 1996 May 31;681(1):3–19
Protein partitioning in weakly charged polymer–surfactant aqueous two–phase systems. Sivars U, et al. **J Chromatogr B Biomed Appl** 1996 May 17;680(1–2):43–53
Isolating RNA from clinical samples with Catrimox–14 and lithium chloride. Macfarlane DE, et al. **J Clin Lab Anal** 1997;11(3):132–9
DNA transfer in a Biomphalaria glabrata embryonic cell line by DOTAP lipofection. Lardans V, et al. **Parasitol Res** 1996;82(6):574–6
Allosteric effects of phenyltrimethylammonium and propidium on acetylcholinesterase active site. Stalc A, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R277–8
Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Zelphati O, et al. **Pharm Res** 1996 Sep;13(9):1367–72
Micellization and other associations of amphiphilic antimicrobial quaternary ammonium salts in aqueous solutions. Kopecky F. **Pharmazie** 1996 Mar;51(3):135–44 (121 ref.)
Anisotropy of the proton T1 and the low–field relaxation in NH4 ClO4 below 20K. Birczyn'ski A, et al. **Solid State Nucl Magn Reson** 1996 Nov;7(2):105–19
Spin–lattice relaxation in ammonium compounds with a complex molecular dynamics. Lalowicz ZT, et al. **Solid State Nucl Magn Reson** 1997 Apr;8(2):89–107
35Cl NOR and 19F NMR relaxation studies of CClF2 group dynamics in N(CH3)4H(ClF2CCOO)2. Zdanowska–Frączek M, et al. **Solid State Nucl Magn Reson** 1996 Apr;6(2):141–6
[Competitive binding of tetrabutylammonium and cetylpyridinium cations on C18 surfaces] Szász G, et al. **Acta Pharm Hung** 1996 May;66(3):101–4 (Eng. Abstr.) **(Hun)**
[Spectrophotometric study of DNA complexes with dodecyltrimethylammonium bromide] Khutsishvili IG, et al. **Biofizika** 1997 Mar–Apr;42(2):363–6 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

[New development of cellulose–ferric ammonium citrate solution as a contrast–enhancement agent for magnetic resonance imaging of esophageal diseases] Ogawa Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1994 Oct 25; 54(12):1178–80 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Immunization with meningococcal class 1 outer membrane protein produced in Bacillus subtilis and reconstituted in the presence of Zwittergent or Triton X–100. Idänpään–Heikkilä I, et al. **Vaccine** 1996 Jun;14(9):886–91

METABOLISM

NH+4 augments net acid secretion by a ouabain–sensitive mechanism in isolated perfused inner medullary collecting ducts. Wall SM. **Am J Physiol** 1996 Mar;270(3 Pt 2):F432–9
Effects of reactive oxygen and nitrogen species induced by ammonium dinitramide decomposition in aqueous solutions of deoxyribose nucleic acid. Steel–Goodwin L, et al. **Ann Clin Lab Sci** 1997 May–Jun;27(3):236–45
Cation–pi bonding and amino–aromatic interactions in the biomolecular recognition of substituted ammonium ligands. Scrutton NS, et al. **Biochem J** 1996 Oct 1;319 (Pt 1):1–8 (60 ref.)
K+/NH4+ antiporter: a unique ammonium carrying transporter in the kidney inner medulla. Amlal H, et al. **Biochim Biophys Acta** 1997 Jan 31;1323(2):319–33
15N–NMR study of ammonium assimilation in Agaricus bisporus. Baars JJ, et al. **Biochim Biophys Acta** 1997 Jan 10;1310(1):74–80
Participation of NH4+ in total ammonia absorption across the rumen epithelium of sheep (Ovis aries). Bödeker D, et al. **Comp Biochem Physiol A Physiol** 1996 Aug; 114(4):305–10
Biphasic kinetics of quaternary ammonium glucuronide formation from amitriptyline and diphenhydramine in human liver microsomes. Breyer–Pfaff U, et al. **Drug Metab Dispos** 1997 Mar;25(3):340–5
Effect of methionine sulfoximine on nitrogen metabolism and externally supplied ammonium assimilation in kidney bean. Sadunishvili T, et al. **Ecotoxicol Environ Saf** 1996 Jun; 34(1):70–5
The basolateral organic cation transport system of rabbit kidney proximal tubules. Influence of anorganic anions. Hohage H, et al. **J Pharmacol Exp Ther** 1996 Dec; 279(3):1086–91
Ammonium transport and the role of the Na,K–ATPase. Wall SM. **Miner Electrolyte Metab** 1996;22(5–6):311–7 (43 ref.)
A family of ammonium transporters in Saccharomyces cerevisiae. Marini AM, et al. **Mol Cell Biol** 1997 Aug; 17(8):4282–93
The remarkable complexity of hydroxylamine oxidoreductase [news; comment] Prince RC, et al. **Nat Struct Biol** 1997 Apr;4(4):247–50. Comment on: Nat Struct Biol 1997 Apr;4(4):276–87.
Renal ammoniagenesis and tubulointerstitial injury in hypertension [letter] Agroyannis B, et al. **Nephrol Dial Transplant** 1995 Dec;10(12):2372–3
An efficient DDAB–mediated transfection of Drosophila S2 cells. Han K. **Nucleic Acids Res** 1996 Nov 1;24(21):4362–3
NH4+ conductance in Xenopus laevis oocytes. I. Basic observations. Burckhardt BC, et al. **Pflugers Arch** 1997 Jul; 434(3):306–12
Aluminum citrate is transported from brain into blood via the monocarboxylic acid transporter located at the blood–brain barrier. Ackley DC, et al. **Toxicology** 1997 Jun 27;120(2):89–97
[The hyperbaric oxygen therapy of disordered ammonia detoxication in the operated liver] Savilov PN. **Anesteziol Reanimatol** 1996 Sep–Oct;(5):64–7 (Eng. Abstr.) **(Rus)**
[Biosynthesis of nactinic compounds by population variants of macrotetrolide–producing streptomycetes] Sverdlova AN, et al. **Antibiot Khimioter** 1996 Jun;41(6):3–9 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Evolution of anisotropic diffusion in the developing rat corpus callosum. Vorisek I, et al. **J Neurophysiol** 1997 Aug; 78(2):912–9
Inhibition of the sodium/hydrogen antiport by ammonium ion. Stampfer DS, et al. **J Urol** 1997 Jan;157(1):362–5

PHARMACOLOGY

Effects of clofilium, a K channel blocker, on electrogenic K secretion and afferent discharge at the frog semicircular canal. A preliminary report. Rossi ML, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):277–9
Submicellar complexes may initiate the fungicidal effects of cationic amphiphilic compounds on Candida albicans. Ahlström B, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):544–50
Effects of amphiphilic compounds on metabolic and biological activities of Salmonella typhimurium. Majtánová L, et al. **Arzneimittelforschung** 1996 Jan;46(1):64–7
Inhibition of restriction endonucleases by DNA sequence–reading ligands. Kittler L, et al. **Biochem Mol Biol Int** 1996 Oct;40(2):263–72
Comparative fungicidal activity of a new quaternary ammonium salt, N–alkyl–N–2–hydroxyethyl–N,N–dimethylammonium butyl phosphate and commonly used disinfectants. Ohta S, et al. **Biol Pharm Bull** 1996 Feb;19(2):308–10
Muscarinic thioligands with cyclopentane nucleus. Piergentili A, et al. **Bioorg Med Chem** 1996 Dec;4(12):2193–9
Block of the cGMP–gated cation channel of catfish rod and cone photoreceptors by organic cations. Stotz SC, et al. **Biophys J** 1996 Dec;71(6):3136–47
Otilonium: a potent blocker of neuronal nicotinic ACh receptors in bovine chromaffin cells. Gandía L, et al. **Br J Pharmacol** 1996 Feb;117(3):463–470
The effect of clofilium, a K–channel blocker, on the electrogenic K secretion and the sensory discharge at the frog semicircular canal. Rossi ML, et al. **Brain Res** 1996 May 20;721(1–2):174–80
Protein stabilisation using additives based on multiple electrostatic interactions. Gibson TD. **Dev Biol Stand** 1996; 87:207–17
The clinical pharmacology of single doses of otilonium bromide in healthy volunteers. Sutton JA, et al. **Eur J Clin Pharmacol** 1997;52(5):365–9
Blocking effects of otilonium on Ca2+ channels and secretion in rat chromaffin cells. Gandía L, et al. **Eur J Pharmacol** 1996 Mar 7;298(2):199–205
Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241. Suessbrich H, et al. **FEBS Lett** 1997 Sep 8;414(2):435–8
Immunomodulatory effect of some amphiphilic detergents on the human promyelocytic HL–60 cells. Kačáni L, et al. **Folia Biol (Praha)** 1996;42(1–2):11–6
Antimicrobial efficacy of quaternary bisammonium salts and the effect of their sub–MICs on Pseudomonas aeruginosa virulence factors. Hoštacká A, et al. **Folia Microbiol (Praha)** 1995;40(3):283–7
Subinhibitory concentrations of organic ammonium salts: the effect on biological properties of Salmonella typhimurium. Majtánová L, et al. **Folia Microbiol (Praha)** 1995;

40(2):153–8
DL-leucine transport in a Saccharomyces cerevisiae mutant resistant to quaternary ammonium salts. Obłąk E, et al. **Folia Microbiol (Praha)** 1996;41(1):116–8
Concentration-dependent inhibitory and stimulating effects of amphiphilic ammonium salts upon photosynthetic activity of spinach chloroplasts. Seršeň F, et al. **Gen Physiol Biophys** 1996 Feb;15(1):27–36
Induction of age pigment accumulation in the brain cells of young male rats through iron-injection into the cerebrospinal fluid. Zs.-Nagy I, et al. **Gerontology** 1995;41 Suppl 2:145–58
Susceptibility of antibiotic-susceptible and antibiotic-resistant hospital bacteria to disinfectants. Rutala WA, et al. **Infect Control Hosp Epidemiol** 1997 Jun; 18(6):417–21
Mechanism of denaturation of bovine serum albumin by dodecyl trimethylammonium bromide. Moosavi-Movahedi AA, et al. **Int J Biochem Cell Biol** 1996 Sep;28(9):991–8
Antibacterial efficacy of new commercially manufactured disinfectant substances against Salmonella typhimurium. Majtán V, et al. **J Basic Microbiol** 1997;37(1):41–4
Early afterdepolarizations produced by d,l-sotalol and clofilium. Patterson E, et al. **J Cardiovasc Electrophysiol** 1997 Jun;8(6):667–78
Changes in atrioventricular conduction properties with refractory-period modulation. Hewett KW, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):824–32
Selectivity of class-III antiarrhythmic action of clofilium in guinea pig ventricular myocytes. Li Q, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):401–10
Reduction of wall adsorption in capillary zone electrophoresis of a basic single-chain antibody fragment by a cationic polymeric buffer additive. Morand M, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):192–6
Facilitation of epinephrine-induced afterdepolarizations by class III antiarrhythmic drugs. Patterson E, et al. **J Electrocardiol** 1997 Jul;30(3):217–24
Clofilium-induced block of delayed rectifier type K+ current in atrial tumor cells (AT-1 cells). Bhattacharyya ML, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):301–7
Effects of ammonium ions on the depolarization-induced and direct activation of the contractile apparatus in mechanically skinned fast-twitch skeletal muscle fibres of the rat. Stephenson GM, et al. **J Muscle Res Cell Motil** 1996 Dec;17(6):611–6
Chorda tympani responses under lingual voltage clamp: implications for NH4 salt taste transduction. Kloub MA, et al. **J Neurophysiol** 1997 Mar;77(3):1393–406
Bitter taste transduction of denatonium in the mudpuppy Necturus maculosus. Ogura T, et al. **J Neurosci** 1997 May 15;17(10):3580–7
Voltage-dependent interaction of open-channel blocking molecules with gating of NMDA receptors in rat cortical neurons. Antonov SM, et al. **J Physiol (Lond)** 1996 Jun 1;493 (Pt 2):425–45
Effects of quaternary ammonium compounds with 0.1% sodium hydroxide on swine vesicular disease virus. Shirai J, et al. **J Vet Med Sci** 1997 May;59(5):323–8
Screening for novel drug effects with a microphysiometer: a potent effect of clofilium unrelated to potassium channel blockade. Rabinowitz JD, et al. **Life Sci** 1997; 61(7):PL87–94
Short chain fatty acid and glucose metabolism in isolated pig colonocytes: modulation by NH4+. Darcy-Vrillon B, et al. **Mol Cell Biochem** 1996 Mar 23;156(2):145–51
Ammonium repression of the nitrite-nitrate (nasAB) assimilatory operon of Azotobacter vinelandii is enhanced in mutants expressing the nifO gene at high levels. Gutierrez JC, et al. **Mol Gen Genet** 1997 Jun;255(2):172–9
A C-terminal di-leucine motif and nearby sequences are required for NH4(+)-induced inactivation and degradation of the general amino acid permease, Gap1p, of Saccharomyces cerevisiae. Hein C, et al. **Mol Microbiol** 1997 May;24(3):607–16
Iron overload increases hepatic development of Plasmodium yoelii in mice. Goma J, et al. **Parasitology** 1996 Feb;112 (Pt 2):165–8
Effect of beta-cyclodextrin on antimicrobial and photosynthesis inhibiting activity of the cationic surfactant N,N'-bis[4-(4-tert.butylphenoxy)butyl-dimethyl]-1,6-hexanediammonium dibromide. Král'ová K, et al. **Pharmazie** 1996 Aug;51(8):606–8
Effect of organic ammonium salts on metabolic processes in Pseudomonas aeruginosa. Majtán V, et al. **Pharmazie** 1996 Jan;51(1):54–6
The photodynamic effect of Victoria blue BO on peripheral blood mononuclear and leukemic cells. Fiedorowicz M, et al. **Photochem Photobiol** 1997 May;65(5):855–61
Subtractive hybridization between cDNAs from untreated and AMO-1618-treated cultures of Gibberella fujikuroi. Jennings JC, et al. **Plant Cell Physiol** 1996 Sep;37(6):847–54
Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse. Javitt DC, et al. **Psychopharmacology (Berl)** 1997 Jan;129(1):96–8
Endothelial cell apoptosis is accelerated by inorganic iron and heat via an oxygen radical dependent mechanism. Jacob AK, et al. **Surgery** 1997 Aug;122(2):243–53; discussion 254
Effects exerted by otilonium bromide administration on precipitated opioid withdrawal syndrome in rats. Pinelli A, et al. **Toxicology** 1997 Sep 26;122(1-2):23–37
Cationic lipid-mediated transfer of the hIL-10 gene prolongs survival of allogeneic hepatocytes in Nagase analbuminemic rats. Fabrega AJ, et al. **Transplantation** 1996 Dec 27;62(12):1866–71
Resistance of Escherichia coli growing as biofilms to disinfectants. Ntsama-Essomba C, et al. **Vet Res** 1997 Jul-Aug;28(4):353–63
[The effect of affinity on the type of action of ammonium compounds on skeletal muscle cholinoreceptors] Danilov AF, et al. **Eksp Klin Farmakol** 1996 Nov-Dec;59(6):10–2 (Eng. Abstr.) **(Rus)**
[The synergistic action of quaternary ammonium derivatives and inhibitors of nitrate reduction in respect to Pseudomonas aeruginosa] Vievskil AN. **Mikrobiol Z** 1994 Jul-Sep;56(4):16–20 (Eng. Abstr.) **(Rus)**
[Role of putrescine and potassium transport in the adaptation of Escherichia coli to ammonium starvation] Tkachenko AG, et al. **Mikrobiologiia** 1996 Nov-Dec;65(6):740–4 (Eng. Abstr.) **(Rus)**
[The antimicrobial activity and cytotoxicity of anti-infective preparations in a human cell-culture model] Afinogenov GE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep-Oct;(5):3–7 (Eng. Abstr.) **(Rus)**

POISONING

Hepatotoxicity of N, N-dimethylformamide (DMF) in acute poisoning with the veterinary euthanasia drug T-61. Buylaert W, et al. **Hum Exp Toxicol** 1996 Aug;15(8):607–11

THERAPEUTIC USE

Intravenous clofilium for conversion of atrial fibrillation. Borzak S, et al. **Am J Cardiol** 1997 Jan 1;79(1):94–7
Urinary urge incontinence: randomised crossover trials of penthienate versus placebo and propantheline. Coombes GM, et al. **Med J Aust** 1996 Nov 4;165(9):473–6
[Clinical observation of treatment of tooth hypersensitiveness with silver ammonia fluoride and potassium nitrate solution] Liu Y, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Nov; 30(6):352–4 (Eng. Abstr.) **(Chi)**
[Immobilized proteases and their activators as immunocorrective agents] Khmelevskaia IG, et al. **Antibiot Khimioter** 1997;42(3):11–4 (Eng. Abstr.) **(Rus)**
[Ethonium in the treatment of patients with gastric and duodenal peptic ulcers] Babak OIa, et al. **Lik Sprava** 1996 Mar-Apr;(3-4):123–5 (Eng. Abstr.) **(Rus)**
[Ligenten treatment of sinusitis] Poliakova TS, et al. **Vestn Otorinolaringol** 1997;(2):38–40 (Eng. Abstr.) **(Rus)**

TOXICITY

Molluscicide acute and sub-chronic toxicity to the three non-target organisms Hexagenia limbata, Ceriodaphnia dubia, and Pimephelas promelas, and neutralization of that toxicity by bentonite clay. Bargar TA, et al. **Bull Environ Contam Toxicol** 1997 Feb;58(2):275–82
Quaternary ammonium compound toxicity in broiler chickens. Hutchison TW, et al. **Can Vet J** 1996 Aug; 37(8):482
Effect of some organic ammonium salts and amine oxides in the SOS chromotest. Majtán V, et al. **Pharmazie** 1996 Oct;51(10):753–5
Reproductive toxicity screen of ammonium dinitramide administered in the drinking water of Sprague-Dawley rats. Kinkead ER, et al. **Toxicol Ind Health** 1995 Jul-Aug; 11(4):437–48

AMMONIUM SULFATE

CHEMISTRY

Crystal structure of Escherichia coli inorganic pyrophosphatase complexed with SO4(2-). Ligand-induced molecular asymmetry. Avaeva S, et al. **FEBS Lett** 1997 Jun 30;410(2-3):502–8

PHARMACOLOGY

Induction of ammonia monooxygenase and hydroxylamine oxidoreductase mRNAs by ammonium in Nitrosomonas europaea. Sayavedra-Soto LA, et al. **Mol Microbiol** 1996 May;20(3):541–8
The influence of ammonium persulfate on guinea pig tracheal muscle tone: release of nitric oxide. Mensing T, et al. **Pharmacol Toxicol** 1996 May;78(5):336–40

AMMON'S HORN see **HIPPOCAMPUS**

AMMOTHERAPY

METHODS

[Stimulation for sebum excretion of PCDDs, PCDFs and coplanar PCBs on bathing ceramic sand bath] Iida T, et al. **Fukuoka Igaku Zasshi** 1997 May;88(5):186–92 (Eng. Abstr.) **(Jpn)**

AMNESIA

Hypnotic amnesia and learning: a dissociation interpretation. Kinnunen T, et al. **Am J Clin Hypn** 1996 Apr;38(4):247–53
Transient global amnesia: alarming but benign condition. Mahmoud S, et al. **Br J Hosp Med** 1996 Jul 10-Aug 20; 56(2-3):113
Transient global amnesia: disease or syndrome? Moccia F, et al. **Ital J Neurol Sci** 1996 Jun;17(3):211–4

CHEMICALLY INDUCED

Effects of benzodiazepines, sleep and sleep deprivation on vigilance and memory. Coenen AM, et al. **Acta Neurol Belg** 1997 Jun;97(2):123–9
Potential morphine sparing effect of midazolam [letter; comment] Verheecke G. **Anaesthesia** 1997 Apr;52(4):389. Comment on: Anaesthesia 1996 Sep;51(9):808–11.
Hypothesis: inhaled anesthetics produce immobility and amnesia by different mechanisms at different sites. Eger EI 2nd, et al. **Anesth Analg** 1997 Apr;84(4):915–8
NMDA antagonists potentiate scopolamine-induced amnesic effect. Li HB, et al. **Behav Brain Res** 1997 Feb; 83(1-2):225–8
Reversion of beta 25-35-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists. Maurice T, et al. **Brain Res** 1996 Aug 26;731(1-2):249–53
Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy. Stip E. **Can J Psychiatry** 1996 Oct;41(8 Suppl 2):S27–34 (67 ref.)
Amnestic syndrome induced by zoplclone [letter] Fava GA. **Eur J Clin Pharmacol** 1996;50(6):509
In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat. Delobette S, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):1–4
U-50488H, a selective kappa-opioid receptor agonist, improves carbon monoxide-induced delayed amnesia in mice. Hiramatsu M, et al. **Eur J Pharmacol** 1996 Nov 14; 315(2):119–25
Visual hallucinations and amnesia associated with the use of zolpidem [letter] van Puijenbroek EP, et al. **Int J Clin Pharmacol Ther** 1996 Jul;34(7):318
Doxycycline-induced lithium toxicity [letter] Miller SC. **J Clin Psychopharmacol** 1997 Feb;17(1):54–5
A pure amnestic syndrome after MDMA ("ecstasy") ingestion [letter] Spatt J, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):418–9
Antibody to day-old chick brain glycoprotein produces amnesia in adult rats. Alexinsky T, et al. **Neurobiol Learn Mem** 1997 Jan;67(1):14–20
Chicks injected with antisera to either S-100 alpha or S-100 beta protein develop amnesia for a passive avoidance task. O'Dowd BS, et al. **Neurobiol Learn Mem** 1997 May; 67(3):197–206
Interleukin-6 affects scopolamine-induced amnesia, but not brain amino acid levels in mice. Bianchi M, et al. **Neuroreport** 1997 May 6;8(7):1775–8
Antisense oligodeoxynucleotides to c-fos are amnestic for passive avoidance in the chick. Mileusnic R, et al. **Neuroreport** 1996 May 17;7(7):1269–72
Neurokinin A and senktide attenuate scopolamine-induced impairment of spontaneous alternation performance in mice. Ukai M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):97–101
Tolerance develops to the spatial learning deficit produced by diazepam in rats. McNamara RK, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):383–9
Amnesia possibly associated with zolpidem administration. Canaday BR. **Pharmacotherapy** 1996 Jul-Aug;16(4):687–9
Atenolol induced memory impairment: a case report. Ramanathan M. **Singapore Med J** 1996 Apr;37(2):218–9
[Toxicity of carbon monoxide on the central nervous system: special reference to amnesia] Nabeshima T. **J Toxicol Sci** 1996 May;21(2):App 59–74 (75 ref.) **(Jpn)**

CLASSIFICATION

[Clinical types of memory disorders and their diagnosis] Yamadori A. **Rinsho Shinkeigaku** 1996 Dec;36(12):1358–9 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Cognitive procedural learning in amnesia. Schmidtke K, et al. **Brain Cogn** 1996 Dec;32(3):441–67
Posttraumatic stress disorder in patients with traumatic brain injury and amnesia for the event? Warden DL, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter;9(1):18–22
Transient global amnesia and dural arteriovenous fistula of the anterior cranial fossa. Takahashi Y, et al. **Kurume Med J** 1996;43(3):223–9
Failure to recall [letter; comment] Hawley RJ, et al. **Neurology** 1997 Jan;48(1):292–3. Comment on: Neurology 1996 Apr;46(4):1036–9.

DIAGNOSIS

Episodic memory deficit in elderly adults with suspected delusional disorder. Herlitz A, et al. **Acta Psychiatr Scand** 1996 May;93(5):355–61
Sodium amobarbital memory tests: what do they predict? Dade LA, et al. **Brain Cogn** 1997 Mar;33(2):189–209
Amnesia following infarction in the right retrosplenial region. Yasuda Y, et al. **Clin Neurol Neurosurg** 1997 May; 99(2):102–5
Autonomic and recognition indices of memory in amnesic and healthy control subjects. Diamond BJ, et al. **Cortex** 1996 Sep;32(3):439–59

The relationship between retrograde and anterograde amnesia in patients with typical global amnesia. Mayes AR, et al. **Cortex** 1997 Jun;33(2):197–217

Spectrum of memory dysfunction in degenerative disease. Perry RJ, et al. **Curr Opin Neurol** 1996 Aug;9(4):281–5 (60 ref.)

Detecting simulated amnesia for autobiographical and recently learned information using the P300 event-related potential. Ellwanger J, et al. **Int J Psychophysiol** 1996 Aug–Sep;23(1–2):9–23

Recurrent coital amnesia [letter] Lane RJ. **J Neurol Neurosurg Psychiatry** 1997 Aug;63(2):260

Memory deficits in schizophrenia: inadequate assimilation or true amnesia? Findings from the Wechsler Memory Scale--revised. Hawkins KA, et al. **J Psychiatry Neurosci** 1997 May;22(3):169–79 (24 ref.)

The performance of amnesic subjects on tests of delayed matching-to-sample and delayed matching-to-position. Holdstock JS, et al. **Neuropsychologia** 1995 Dec; 33(12):1583–96

[Cerebral cognitive deficits in the aged. Diagnostic and therapeutic standards: organization of strategies for problem detection and solution] Stoppe G, et al. **Z Arztl Fortbild (Jena)** 1996 Aug;90(5):449–53 (Eng. Abstr.) **(Ger)**

[Clinical types of memory disorders and their diagnosis] Yamadori A. **Rinsho Shinkeigaku** 1996 Dec;36(12):1358–9 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Effects of nefiracetam on amnesia animal models with neuronal dysfunctions. Hiramatsu M, et al. **Behav Brain Res** 1997 Feb;83(1–2):107–15

Peripherally administered GM–CSF interferes with scopolamine-induced amnesia in mice: involvement of interleukin-1. Bianchi M, et al. **Brain Res** 1996 Aug 12; 729(2):285–8

Herbal pharmacotherapy for the attenuation of electroconvulsive shock-induced anterograde and retrograde amnestic deficits. Faruqi S, et al. **Convuls Ther** 1995 Dec;11(4):241–7

U–50488H, a selective kappa-opioid receptor agonist, improves carbon monoxide-induced delayed amnesia in mice. Hiramatsu M, et al. **Eur J Pharmacol** 1996 Nov 14; 315(2):119–25

Piracetam and fipexide prevent PTZ-kindling-provoked amnesia in rats. Genkova-Papazova MG, et al. **Eur Neuropsychopharmacol** 1996 Nov;6(4):285–90

Physostigmine reversal of scopolamine-induced hypofrontality. Prohovnik I, et al. **J Cereb Blood Flow Metab** 1997 Feb;17(2):220–8

Effect of long-term administration of berberine on scopolamine-induced amnesia in rats. Peng WH, et al. **Jpn J Pharmacol** 1997 Jul;74(3):261–6

Effects of verapamil on electroconvulsive shock- and clonidine-induced amnesia. Bojanova E, et al. **Methods Find Exp Clin Pharmacol** 1997 Mar;19(2):93–7

Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia. Kojima J, et al. **Methods Find Exp Clin Pharmacol** 1997 May;19(4):245–51

Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa. Park CH, et al. **Planta Med** 1996 Oct;62(5):405–9

Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands. Maurice T, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):69–102 (224 ref.)

[Effect of aceclidine on amnesia induced by scopolamine and electroshock in rats] Mashkovskiĭ MD, et al. **Biull Eksp Biol Med** 1997 Mar;123(3):296–8 **(Rus)**

EPIDEMIOLOGY

Incidence of transient global amnesia in the Belluno province, Italy: 1985 through 1995. Results of a community-based study. Lauria G, et al. **Acta Neurol Scand** 1997 May; 95(5):303–10

ETIOLOGY

Transient global amnesia after cerebral angiography. A case report. Meder JF, et al. **Acta Radiol** 1997 Mar;38(2):273–4

Amnesia in acute herpetic and nonherpetic encephalitis. Hokkanen L, et al. **Arch Neurol** 1996 Oct;53(10):972–8

Severe anterograde amnesia with onset in childhood as a result of anoxic encephalopathy. Broman M, et al. **Brain** 1997 Mar;120 (Pt 3):417–33

Sodium amobarbital memory tests: what do they predict? Dade LA, et al. **Brain Cogn** 1997 Mar;33(2):189–209

Transient global amnesia and migraine in young people. Tosi L, et al. **Clin Neurol Neurosurg** 1997 Feb;99(1):63–5

Human memory: the hippocampus is the key. Parkin AJ. **Curr Biol** 1996 Dec 1;6(12):1583–5 (7 ref.)

Diencephalic temporal order amnesia. Shuren JE, et al. **J Neurol Neurosurg Psychiatry** 1997 Feb;62(2):163–8

Rotated drawing: a mini mental state examination performance with strong lateralising significance [letter] Turnbull OH, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):419–20

Three cases of enduring memory impairment after bilateral damage limited to the hippocampal formation. Rempel-Clower NL, et al. **J Neurosci** 1996 Aug 15; 16(16):5233–55

Value of recording duration of post-traumatic amnesia. Greenwood R. **Lancet** 1997 Apr 12;349(9058):1041–2

The relationships between temporal lobe and diencephalic structures implicated in anterograde amnesia. Aggleton JP, et al. **Memory** 1997 Jan–Mar;5(1–2):49–71 (92 ref.)

A positive approach to viewing processing deficit theories of amnesia. Cermak LS. **Memory** 1997 Jan–Mar; 5(1–2):89–98

Concluding comments: common themes, disagreements, and future directions. Downes JJ, et al. **Memory** 1997 Jan–Mar; 5(1–2):301–11

Comments on Mayes and Downes: "What do theories of the functional deficit(s) underlying amnesia have to explain?". Kopelman MD. **Memory** 1997 Jan–Mar;5(1–2):105–14

Theories of organic amnesia [editorial] Mayes A, et al. **Memory** 1997 Jan–Mar;5(1–2):1–2

What do theories of the functional deficit(s) underlying amnesia have to explain? Mayes AR, et al. **Memory** 1997 Jan–Mar;5(1–2):3–36 (87 ref.)

Predicting syndromes of amnesia from a composite holographic associative recall/recognition model (CHARM). Metcalfe J. **Memory** 1997 Jan–Mar; 5(1–2):233–53

Consolidating dispersed neocortical memories: the missing link in amnesia. Paller KA. **Memory** 1997 Jan–Mar; 5(1–2):73–88

How should a database on human amnesia evolve? Comments on Mayes and Downes "What do theories of the functional deficit(s) underlying amnesia have to explain?" Parkin AJ, et al. **Memory** 1997 Jan–Mar;5(1–2):99–104

Pure amnesia caused by bilateral temporal lobe astrocytoma--case report. Umemura A, et al. **Neurol Med Chir (Tokyo)** 1997 Jul;37(7):556–9

Pure transient amnesia during nonconvulsive status epilepticus [letter; comment] Dasheiff RM. **Neurology** 1997 Jun;48(6):1736; discussion 1736–7. Comment on: Neurology 1996 Apr;46(4):1036–9.

Failure to recall [letter; comment] Dasheiff RM. **Neurology** 1997 Jan;48(1):292; discussion 293. Comment on: Neurology 1996 Apr;46(4):1036–9.

Pure transient amnesia during nonconvulsive status epilepticus [letter; comment] Hawley RJ, et al. **Neurology** 1997 Jun;48(6):1736; discussion 1736–7. Comment on: Neurology 1996 Apr;46(4):1036–9.

Amnesia following damage to the mammillary bodies. Tanaka Y, et al. **Neurology** 1997 Jan;48(1):160–5

Failure to recall (but not to remember): pure transient amnesia during nonconvulsive status epilepticus [see comments] Vuilleumier P, et al. **Neurology** 1996 Apr; 46(4):1036–9. Comment in: Neurology 1997 Jan;48(1):292; discussion 293. Comment in: Neurology 1997 Jan;48(1):292–3. Comment in: Neurology 1997 Jun;48(6):1736; discussion 1736–7.

Rates of forgetting in organic amnesia following temporal lobe, diencephalic, or frontal lobe lesions. Kopelman MD, et al. **Neuropsychology** 1997 Jul;11(3):343–56

Duration of transient amnesia correlates with cognitive outcome in acute encephalitis. Hokkanen L, et al. **Neuroreport** 1997 Aug 18;8(12):2721–5

Transient global amnesia of epileptic origin accompanied by fever. Meo R, et al. **Seizure** 1995 Dec;4(4):311–7

Transient global amnesia in a young woman on prolonged treatment with oral contraceptive drugs [letter] Orefice G, et al. **Thromb Haemost** 1996 Jun;75(6):980

[Memory disorders] Heuser I. **Internist (Berl)** 1996 Nov; 37(11):1189–202 (0 ref.) **(Ger)**

[Early and differential diagnosis of 1,000 patients examined in a memory clinic] Heuft G, et al. **Nervenarzt** 1997 Mar; 68(3):259–69 (Eng. Abstr.) **(Ger)**

[Memory disorder] Bärschneider M. **Wien Med Wochenschr** 1996;146(17):482 (Eng. Abstr.) **(Ger)**

[Prolonged antegrade amnesia due to left anterior thalamic infarct, and SPECT findings] Tsuboi Y, et al. **No To Shinkei** 1997 Jan;49(1):77–80 (Eng. Abstr.) **(Jpn)**

[Transient prosopagnosia and lasting topographical disorientation after the total removal of a right occipital arteriovenous malformation] Suzuki K, et al. **Rinsho Shinkeigaku** 1996 Sep;36(9):1114–7 (Eng. Abstr.) **(Jpn)**

[Transient global amnesia during subarachnoid anesthesia (letter)] Domingo I, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):74–5 **(Spa)**

METABOLISM

Molecular basis of the activity of the dopamine synapse in the mechanisms of learning and amnesia. Podgornaya EK, et al. **Neurosci Behav Physiol** 1997 Mar–Apr;27(2):131–6

NURSING

The problem of arriving at a phenomenological description of memory loss. Moyle W, et al. **J Adv Nurs** 1997 Jul; 26(1):120–5 (31 ref.)

PATHOLOGY

Isolated amnesia with slow onset and stable course, without ensuing dementia: MRI and PET data and a six-year neuropsychological follow-up. Miceli G, et al. **Dementia** 1996 Mar–Apr;7(2):104–10

PHYSIOPATHOLOGY

Dissociable properties of memory systems: differences in the flexibility of declarative and nondeclarative knowledge. Reber PJ, et al. **Behav Neurosci** 1996 Oct;110(5):861–71

Impaired recognition memory in patients with lesions limited to the hippocampal formation. Reed JM, et al. **Behav Neurosci** 1997 Aug;111(4):667–75

Alterations of peak distribution of auditory ERPs during transient global amnesia: a case report. Saito M, et al. **Biol Psychiatry** 1997 Jan 15;41(2):237–40

Memory and executive functions in amnesic and non-amnesic patients with aneurysms of the anterior communicating artery. Diamond BJ, et al. **Brain** 1997 Jun;120 (Pt 6):1015–25

The 'petites Madeleines' phenomenon in two amnesic patients. Sudden recovery of forgotten memories [letter; comment] Kapur N. **Brain** 1996 Aug;119 (Pt 4):1401–4. Comment on: Brain 1995 Feb;118 (Pt 1):167–83.

The mechanisms of spontaneous and provoked confabulations. Schnider A, et al. **Brain** 1996 Aug;119 (Pt 4):1365–75

Disorientation in amnesia. A confusion of memory traces. Schnider A, et al. **Brain** 1996 Oct;119 (Pt 5):1627–32

Confabulation, memory deficits, and frontal dysfunction. Johnson MK, et al. **Brain Cogn** 1997 Jul;34(2):189–206

Long-term perceptual priming in transient global amnesia. Kapur N, et al. **Brain Cogn** 1996 Jun;31(1):63–74

Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Maurice T, et al. **Brain Res** 1996 Jan 15;706(2):181–93

Transient global amnesia and thalamic hemorrhage. Chen WH, et al. **Clin Neurol Neurosurg** 1996 Nov;98(4):309–11

Evidence for a specific information processing deficit in monkeys with lesions of the septo-hippocampal system. Ridley RM, et al. **Cortex** 1997 Mar;33(1):167–76

Memory consolidation, retrograde amnesia and the hippocampal complex. Nadel L, et al. **Curr Opin Neurobiol** 1997 Apr;7(2):217–27 (88 ref.)

Brain/behaviour dissociation on old/new distinction in a patient with amnesic syndrome. Lalouschek W, et al. **Electroencephalogr Clin Neurophysiol** 1997 May; 104(3):222–7

Semantic amnesia without dementia: documentation of a case. Rusconi ML, et al. **Ital J Neurol Sci** 1997 Jun;18(3):167–71

Failure of prospective memory after acquired brain damage: preliminary investigation and suggestions for future directions. Cockburn J. **J Clin Exp Neuropsychol** 1996 Apr; 18(2):304–9

Item priming and skill learning in amnesia. Rich JB, et al. **J Clin Exp Neuropsychol** 1996 Feb;18(1):148–58

Reversible hyperperfusion of the right medial temporal lobe in transient global amnesia [letter] Jung HH, et al. **J Neurol Neurosurg Psychiatry** 1996 Dec;61(6):654–5

Measurement of post-traumatic amnesia: how reliable is it? King NS, et al. **J Neurol Neurosurg Psychiatry** 1997 Jan; 62(1):38–42

P300 abnormalities in patients with selective impairment of recent memory. Honda M, et al. **J Neurol Sci** 1996 Jul; 139(1):95–105

H. M.'s medial temporal lobe lesion: findings from magnetic resonance imaging. Corkin S, et al. **J Neurosci** 1997 May 15;17(10):3964–79

Implicit memory: what must theories of amnesia explain? Curran T, et al. **Memory** 1997 Jan–Mar;5(1–2):37–47

Extending models of hippocampal function in animal conditioning to human amnesia. Gluck MA, et al. **Memory** 1997 Jan–Mar;5(1–2):179–212

Implicit and explicit memory in amnesia: some explanations and predictions by the TraceLink model. Murre JM. **Memory** 1997 Jan–Mar;5(1–2):213–32

New approaches to the study of amnesic patients: what can a neurofunctional philosophy and neural network methods offer? Pickering AD. **Memory** 1997 Jan–Mar; 5(1–2):255–300

Systems of memory in the human brain. Willingham DB. **Neuron** 1997 Jan;18(1):5–8 (19 ref.)

The role of the hippocampus in recognition memory. Baxendale SA. **Neuropsychologia** 1997 May;35(5):591–8

Bilateral temporal lobe pathology with sparing of medial temporal lobe structures: lesion profile and pattern of memory disorder. Kapur N, et al. **Neuropsychologia** 1994 Jan;32(1):23–38

Anterograde but not retrograde memory loss following combined mammillary body and medial thalamic lesions. Kapur N, et al. **Neuropsychologia** 1996 Jan;34(1):1–8

Strategic retrieval and the frontal lobes: evidence from confabulation and amnesia. Moscovitch M, et al. **Neuropsychologia** 1997 Jul;35(7):1017–34

Impairment of memory following discrete thalamic infarction. Parkin AJ, et al. **Neuropsychologia** 1994 Jan; 32(1):39–51

Preserved verb generation priming in global amnesia. Seger CA, et al. **Neuropsychologia** 1997 Aug;35(8):1069–74

Fragments of memory. Weiskrantz L. **Neuropsychologia** 1997 Jul;35(7):1051–7

Intact and impaired conceptual memory processes in amnesia. Keane MM, et al. **Neuropsychology** 1997 Jan;11(1):59–69

Persistent global amnesia following right thalamic stroke: an 11-year longitudinal study. Sala SD, et al. **Neuropsychology** 1997 Jan;11(1):90–103

Effects of Gastrodia elata and its active constituents on scopolamine-induced amnesia in rats. Wu CR, et al.

AMNESIA

Planta Med 1996 Aug;62(4):317–21

Illusory memories: a cognitive neuroscience analysis. Schacter DL. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13527–33 (85 ref.)

Structure and function of declarative and nondeclarative memory systems. Squire LR, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13515–22 (66 ref.)

PREVENTION & CONTROL

Bicuculline administered into the amygdala after training blocks benzodiazepine–induced amnesia. Dickinson–Anson H, et al. **Brain Res** 1997 Mar 28;752(1–2):197–202

Systemic administration of dynorphin A–(1–13) markedly improves cycloheximide–induced amnesia in mice. Ukai M, et al. **Eur J Pharmacol** 1996 Oct 10;313(1–2):11–5

Effects of nimodipine, felodipine and amlodipine on electroconvulsive shock–induced amnesia in the rat. Zupan G, et al. **Eur J Pharmacol** 1996 Aug 29;310(2–3):103–6

Effects of dynorphin A (1–13) on carbon monoxide–induced delayed amnesia in mice. Hiramatsu M, et al. **Pharmacol Biochem Behav** 1997 Jan;56(1):73–9

PSYCHOLOGY

Transient global amnesia: memory and metamemory. Neri M, et al. **Aging (Milano)** 1995 Dec;7(6):423–9

Emotional arousal and phobia in transient global amnesia. Inzitari D, et al. **Arch Neurol** 1997 Jul;54(7):866–73

Use of a comprehensive program of external cueing to chance procedural memory in a patient with dense amnesia. Brain Injury, 10(1): 17–25 [letter; comment] Giles GM, et al. **Brain Inj** 1997 Jun;11(6):466–8. Comment on: Brain Inj 1996 Jan;10(1):17–25.

Is cognitive psychopathology plausible? Illustrations from memory research. Danion JM, et al. **Can J Psychiatry** 1996 Sep;41(7 Suppl 1):S5–13 (70 ref.)

False attribution of suggestibility to explain recovered memory of childhood sexual abuse following extended amnesia. Leavitt F. **Child Abuse Negl** 1997 Mar; 21(3):265–72

Remembering and knowing the past: a case study of isolated retrograde amnesia. Dalla Barba G, et al. **Cortex** 1997 Mar; 33(1):143–54

Transient procedural amnesia. Stracciari A, et al. **Ital J Neurol Sci** 1997 Feb;18(1):35–6

Prospective evaluation of verbal memory performance after cardiopulmonary bypass surgery. Vingerhoets G, et al. **J Clin Exp Neuropsychol** 1996 Apr;18(2):187–96

Spatial location memory in amnesia: binding item and location information under incidental and intentional encoding conditions. Chalfonte BL, et al. **Memory** 1996 Nov;4(6):591–614

Failure to recall (but not to remember): pure transient amnesia during nonconvulsive status epilepticus [see comments] Vuilleumier P, et al. **Neurology** 1996 Apr; 46(4):1036–9. Comment in: Neurology 1997 Jan;48(1):292; discussion 293. Comment in: Neurology 1997 Jan;48(1):292–3. Comment in: Neurology 1997 Jun;48(6):1736; discussion 1736–7.

Amnesia and recognition memory: a re–analysis of psychometric data. Aggleton JP, et al. **Neuropsychologia** 1996 Jan;34(1):51–62

When implicit learning fails: amnesia and the problem of error elimination. Baddeley A, et al. **Neuropsychologia** 1994 Jan; 32(1):53–68

A case of simulated, psychogenic or focal pure retrograde amnesia: did an entire life become unconscious? Barbarotto R, et al. **Neuropsychologia** 1996 Jun;34(6):575–85

Asperger's syndrome and memory: similarity to autism but not amnesia. Bowler DM, et al. **Neuropsychologia** 1997 Jan; 35(1):65–70

Recency effect in anterograde amnesia: evidence for distinct memory stores underlying enhanced retrieval of terminal items in immediate and delayed recall paradigms. Carlesimo GA, et al. **Neuropsychologia** 1996 Mar;34(3):177–84

Perceptual and conceptual components in implicit and explicit stem completion. Carlesimo GA, et al. **Neuropsychologia** 1996 Aug;34(8):785–92

Unconscious influences on amnesics' word–stem completion. Cermak LS, et al. **Neuropsychologia** 1997 May;35(5):605–10

Priming arithmetic facts in amnesic patients. Delazer M, et al. **Neuropsychologia** 1997 May;35(5):623–34

Retrograde amnesia: a study of its relation to anterograde amnesia and semantic memory deficits. Schmidtke K, et al. **Neuropsychologia** 1997 Apr;35(4):505–18

Errorless learning of novel associations in amnesia. Squires EJ, et al. **Neuropsychologia** 1997 Aug;35(8):1103–11

Emotional perception and memory in amnesia. Hamann SB, et al. **Neuropsychology** 1997 Jan;11(1):104–13

Illusory memories in amnesic patients: conceptual and perceptual false recognition. Schacter DL, et al. **Neuropsychology** 1997 Jul;11(3):331–42

Does induced recovery from amnesia represent a disinhibition effect? Harrod SB, et al. **Physiol Behav** 1996 Nov; 60(5):1375–8

Illusory memories: a cognitive neuroscience analysis. Schacter DL. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13527–33 (85 ref.)

Recovery of high speed memory scanning after transient global amnesia: a case report. Okura M, et al. **Psychiatry Clin Neurosci** 1996 Dec;50(6):317–21

Short–term memory impairment and arithmetical ability. Butterworth B, et al. **Q J Exp Psychol A** 1996 Feb; 49(1):251–62

[Memory complaints and anxiety. Apropos of 40 patients attending a specialized memory consultation] Thomas–Antérion C, et al. **Encephale** 1997 Jan–Feb; 23(1):42–7 (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Brain SPECT imaging in a patient with epilepsy and memory dysfunction. Terada T, et al. **Clin Nucl Med** 1997 May; 22(5):337

Reversible hyperperfusion of the right medial temporal lobe in transient global amnesia [letter] Jung HH, et al. **J Neurol Neurosurg Psychiatry** 1996 Dec;61(6):654–5

[Cerebral blood flow study using SPECT in patients with memory disorders] Valiente E, et al. **Rev Neurol** 1997 Mar; 25(139):460–4 (Eng. Abstr.) **(Spa)**

REHABILITATION

Everyday memory following traumatic brain injury. Kinsella G, et al. **Brain Inj** 1996 Jul;10(7):499–507

Symptomatic treatment of elderly patients with early Alzheimer's disease at a memory clinic [see comments] Walstra GJ, et al. **J Geriatr Psychiatry Neurol** 1997 Jan; 10(1):33–8. Comment in: J Geriatr Psychiatry Neurol 1997 Apr;10(2):49–50.

[Can "cerebral training" prevent or at least modify age–related memory loss?] Stoppe G. **Internist (Berl)** 1996 Mar; 37(3):317–8 **(Ger)**

THERAPY

My experience of analysis with Fairbairn and Winnicott. (How complete a result does psychoanalytic therapy achieve?) 1975 [classical article] Guntrip H. **Int J Psychoanal** 1996 Aug;77 (Pt 4):739–54

The case of Harry Guntrip. Padel J. **Int J Psychoanal** 1996 Aug;77 (Pt 4):755–61

A study and meta–analysis of lay attributions of cures for overcoming specific psychological problems. Furnham A, et al. **J Genet Psychol** 1997 Sep;158(3):315–31

AMNESIA, RETROGRADE

DIAGNOSIS

Does midazolam cause retrograde amnesia, and can flumazenil reverse that amnesia? Koht A, et al. **Anesth Analg** 1997 Jul;85(1):211–2

The relationship between retrograde and anterograde amnesia in patients with typical global amnesia. Mayes AR, et al. **Cortex** 1997 Jun;33(2):197–217

Impaired episodic memory retrieval in a case of probable psychogenic amnesia. Markowitsch HJ, et al. **Psychiatry Res** 1997 May 16;74(2):119–26

[Individualization of retrograde amnesias. On the basis of autobiographical and semantic forms] Barraquer–Bordas LL. **Rev Neurol** 1997 Jul;25(143):1134 **(Spa)**

DRUG THERAPY

Herbal pharmacotherapy for the attenuation of electroconvulsive shock–induced anterograde and retrograde amnestic deficits. Faruqi S, et al. **Convuls Ther** 1995 Dec;11(4):241–7

ETIOLOGY

Is memory loss without anatomical damage tantamount to a psychogenic deficit? The case of pure retrograde amnesia. Di Renzi E, et al. **Neuropsychologia** 1997 Jun;35(6):781–94

[Autobiographical memory loss following herpes encephalitis] Mimura M, et al. **No To Shinkei** 1997 Aug; 49(8):759–64 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Intact perceptual memory in the absence of conscious memory. Hamann SB, et al. **Behav Neurosci** 1997 Aug; 111(4):850–4

Retrieval of old memories: the temporofrontal hypothesis. Kroll NE, et al. **Brain** 1997 Aug;120 (Pt 8):1377–99

TraceLink: a model of amnesia and consolidation of memory. Murre JM. **Hippocampus** 1996;6(6):675–84

How can be best explain retrograde amnesia in human memory disorder? Kapur N. **Memory** 1997 Jan–Mar; 5(1–2):115–29

Anterograde but not retrograde memory loss following combined mammillary body and medial thalamic lesions. Kapur N, et al. **Neuropsychologia** 1996 Jan;34(1):1–8

Remote memory in patients with acute brain injuries. Leplow B, et al. **Neuropsychologia** 1997 Jun;35(6):881–92

Severe amnesia: an usual late complication after temporal lobectomy. Oxbury S, et al. **Neuropsychologia** 1997 Jul; 35(7):975–88

Studies of retrograde memory: a long–term view. Warrington EK. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13523–6

PSYCHOLOGY

Retrograde amnesia in rats with dorsomedial thalamic damage. Peinado–Manzano MA, et al. **Behav Brain Res** 1996 Oct;80(1–2):177–84

Involvement of entorhinal cortex or parietal cortex in long–term spatial discrimination memory in rats: retrograde amnesia. Cho YH, et al. **Behav Neurosci** 1996 Jun; 110(3):436–42

Autobiographical memory in multiple sclerosis. Paul RH, et al. **J Int Neuropsychol Soc** 1997 May;3(3):246–51

A case of simulated, psychogenic or focal pure retrograde amnesia: did an entire life become unconscious? Barbarotto R, et al. **Neuropsychologia** 1996 Jun;34(6):575–85

Retrograde amnesia: a study of its relation to anterograde amnesia and semantic memory deficits. Schmidtke K, et al. **Neuropsychologia** 1997 Apr;35(4):505–18

Studies of retrograde memory: a long–term view. Warrington EK. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13523–6

AMNIOCENTESIS

see related
CHORIONIC VILLI SAMPLING

Chromosomal mosaicism in prenatal diagnosis: a problem still unsolved. Kerber S, et al. **Acta Univ Carol [Med] (Praha)** 1992;38(1–4):75–82

Prenatal diagnosis of a fetus with two balanced de novo chromosome rearrangements. Cotter PD, et al. **Am J Med Genet** 1996 Dec 11;66(2):197–9 (12 ref.)

Prenatally diagnosed de novo apparently balanced complex chromosome rearrangements: two new cases and review of the literature. Ruiz C, et al. **Am J Med Genet** 1996 Aug 23;64(3):478–84 (37 ref.)

Twin–to–twin transfusion syndrome: aggressive therapeutic amniocentesis. Dennis LG, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):342–7; discussion 347–9

Abnormal triple–test result plus normal ultrasonographic results equal amniocentesis? [letter; comment] Ginsberg N, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1081–2 . Comment on: Am J Obstet Gynecol 1995 Oct;173(4):1106–10.

Anti–D administration in early pregnancy––time for a new protocol [letter; comment] Carmody F. **Aust N Z J Obstet Gynaecol** 1996 May;36(2):227–8. Comment on: Aust N Z J Obstet Gynaecol 1995 Nov;35(4):385–7.

False negative cytogenetic results following amniocentesis. Fraser S, et al. **Aust N Z J Obstet Gynaecol** 1996 May; 36(2):149–51

Rhesus D genotyping in amniotic fluid. Müller TH, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:1–6

Bladder visualisation as a prognostic sign in oligohydramnios–polyhydramnios sequence in twin pregnancies treated using therapeutic amniocentesis. Kilby MD, et al. **Br J Obstet Gynaecol** 1997 Aug;104(8):939–42

Amniocentesis. The experience in a district hospital. Ogueh O, et al. **Clin Exp Obstet Gynecol** 1996;23(3):133–5

A case of mosaic trisomy 2 diagnosed at amniocentesis in an abnormal fetus and confirmed in multiple fetal tissues. Robinson J, et al. **Clin Genet** 1997 Jun;51(6):417–20

Complete resolution of CMV–associated acute hydramnios by single large volume reduction amniocentesis and maternal indomethacin. A case report. Bondagji N, et al. **Fetal Diagn Ther** 1996 Sep–Oct;11(5):345–7

Women's informed choice of prenatal diagnosis: early ultrasound examination–routine ultrasound examination–age–independent amniocentesis. Crang–Svalenius E, et al. **Fetal Diagn Ther** 1996 Jan–Feb; 11(1):20–5

The early amniocentesis study: a randomized clinical trial of early amniocentesis versus midtrimester amniocentesis. Johnson JM, et al. **Fetal Diagn Ther** 1996 Mar–Apr; 11(2):85–93

Comparison of chorion villus sampling and early amniocentesis for karyotyping in 1,492 singleton pregnancies. Nicolaides KH, et al. **Fetal Diagn Ther** 1996 Jan–Feb;11(1):9–15

Serial amniocenteses in the management of twin–twin transfusion syndrome: when is it valuable? Trespidi L, et al. **Fetal Diagn Ther** 1997 Jan–Feb;12(1):15–20

Effects of therapeutic amniocentesis on uterine and umbilical artery velocimetry in cases of severe symptomatic polyhydramnios. Guzman ER, et al. **J Matern Fetal Med** 1996 Nov–Dec;5(6):299–304

The importance of genetic counseling before amniocentesis. Cohn GM, et al. **J Perinatol** 1996 Sep–Oct;16(5):352–7; quiz 358–9

Amniotic fluid alpha–fetoprotein determination at the time of genetic amniocentesis: has it outlived its usefulness? Shields LE, et al. **J Ultrasound Med** 1996 Nov;15(11):735–9

Chorionic villus sampling and early amniocentesis for prenatal diagnosis [letter; comment] Greenough A, et al. **Lancet** 1997 May 10;349(9062):1395–6; discussion 1396–7. Comment on: Lancet 1997 Mar 8;349(9053):711–4.

Chorionic villus sampling and early amniocentesis for prenatal diagnosis [letter; comment] Johnson P. **Lancet** 1997 May 10;349(9062):1396; discussion 1396–7. Comment on: Lancet 1997 Mar 8;349(9053):711–4.

Chorionic villus sampling and amniocentesis for prenatal diagnosis [see comments] Stranc LC, et al. **Lancet** 1997 Mar 8;349(9053):711–4 (50 ref.). Comment in: Lancet 1997 May 10;349(9062):1395–6; discussion 1396–7. Comment in: Lancet 1997 May 10;349(9062):1396; discussion 1396–7.

Placental echolucencies: does their presence influence outcome following genetic amniocentesis? Carter SM, et al. **Mil Med** 1996 Apr;161(4):243–5

Use of low-frequency electrical impedance measurements to determine phospholipid content in amniotic fluid. De Luca F, et al. **Phys Med Biol** 1996 Sep;41(9):1863–9

A prospective comparative study on transabdominal chorionic villus sampling and amniocentesis performed at 10–13 week's gestation. Cederholm M, et al. **Prenat Diagn** 1997 Apr;17(4):311–7

Serum screening in complete triploidy 69,XXX [letter] Dormeier A, et al. **Prenat Diagn** 1996 Jun;16(6):578

Alpha-fetoprotein and AChE in early amniocentesis [letter] Eiben B, et al. **Prenat Diagn** 1996 Jan;16(1):87–8

Effect of pre-amniocentesis uterine manipulation on amniocyte concentration and culture duration: a randomized, clinical trial [letter] Fischer RL, et al. **Prenat Diagn** 1996 Jul;16(7):673–4

Prenatal diagnosis of succinyl-coenzyme A:3-ketoacid coenzyme A transferase deficiency. Fukao T, et al. **Prenat Diagn** 1996 May;16(5):471–4

Prenatal diagnosis by enzyme analysis in 15 pregnancies at risk for the Lesch-Nyhan syndrome. Graham GW, et al. **Prenat Diagn** 1996 Jul;16(7):647–51

Is genetic amniocentesis warranted when isolated choroid plexus cysts are found? Gray DL, et al. **Prenat Diagn** 1996 Nov;16(11):983–90

Incidence and significance of chromosome mosaicism involving an autosomal structural abnormality diagnosed prenatally through amniocentesis: a collaborative study. Hsu LY, et al. **Prenat Diagn** 1996 Jan;16(1):1–28

Fetal death after exposure to methylene blue dye during mid-trimester amniocentesis in twin pregnancy. Kidd SA, et al. **Prenat Diagn** 1996 Jan;16(1):39–47

Prenatal identification of a heterozygous status in two fetuses at risk for glucose-galactose malabsorption. Martín MG, et al. **Prenat Diagn** 1996 May;16(5):458–62

Cytogenetic and molecular genetic characterization of trisomy 20 mosaicism in fetal blood and tissues. Micale MA, et al. **Prenat Diagn** 1996 Oct;16(10):893–7

Trisomy 12/monosomy X/normal female mosaicism: prenatal detection and confirmation in a liveborn. Spiro R, et al. **Prenat Diagn** 1996 Aug;16(8):734–40

Trisomy 16 mosaicism in amniotic fluid cell cultures. Tantravahi U, et al. **Prenat Diagn** 1996 Aug;16(8):749–54

Prenatal diagnosis of a tetraploid fetus. Teyssier M, et al. **Prenat Diagn** 1997 May;17(5):474–8 (21 ref.)

Misinterpretation of trisomy 18 as a pseudomosaicism at third-trimester amniocentesis of a child with a mosaic 46,XY/47,XY, +3/48,XXY, +18 karyotype. van Ravenswaaij-Arts CM, et al. **Prenat Diagn** 1997 Apr; 17(4):375–9

Risk and benefit analysis of offering karyotyping for an isolated choroid plexus cyst [letter; comment] Donnenfeld AE. **Ultrasound Obstet Gynecol** 1997 Jan;9(1):67–8. Comment on: Ultrasound Obstet Gynecol 1996 Oct;8(4):223–4.

[In vitro transformation of amniotic cells to muscle cells--background and outlook] Streubel B, et al. **Wien Med Wochenschr** 1996;146(9–10):216–7 (Eng. Abstr.) **(Ger)**

[Cytogenic characterization of chromosome markers detected at amniocentesis: implications for karyotype-phenotype correlations] Valerio D, et al. **Minerva Ginecol** 1996 Sep; 48(9):365–9 (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Elevated amniotic fluid interleukin-6 levels at genetic amniocentesis predict subsequent pregnancy loss. Wenstrom KD, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):830–3

Midtrimester genetic amniocentesis of a twin gestation complicated by immediate severe fetal bradycardia with subsequent associated fetal anomalies. Sherer DM, et al. **Am J Perinatol** 1996 Aug;13(6):347–50

Ocular perforation in utero. Gobert A, et al. **Bull Soc Belge Ophtalmol** 1995;259:77–80

Severe malformation of one foot from amniocentesis needle injury. Holmes LB. **Clin Dysmorphol** 1997 Jul;6(3):273–9; discussion 279–80

Invasive antenatal procedures and requirement for neonatal intensive care unit admission. Greenough A, et al. **Eur J Pediatr** 1997 Jul;156(7):550–2

Constriction of an extremity after amnioreduction in a TRAP-like sequence. von Eckardstein S, et al. **Fetal Diagn Ther** 1997 Jan-Feb;12(1):50–3

Evaluation of auditory system in preschool children whose mothers had mid-second trimester amniocentesis. Annapoorna V, et al. **J Perinat Med** 1996;24(3):207–12

Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. Sundberg K, et al. **Lancet** 1997 Sep 6;350(9079):697–703

Pregnancy outcome following amniocentesis at 11–14 versus 16–19 weeks' gestation [letter; comment] Wilson RD, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):638–9. Comment on: Obstet Gynecol 1996 Jul;88(1):114–8.

Early and midtrimester genetic amniocenteses. Safety and outcomes. Reece EA. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):71–81 (44 ref.)

Perinatal lung function and invasive antenatal procedures. Yüksel B, et al. **Thorax** 1997 Feb;52(2):181–4

ECONOMICS

Cost-effectiveness of strategies used in the evaluation of pregnancies complicated by elevated maternal serum alpha-fetoprotein levels [see comments] Nadel AS, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):660–5. Comment in: Obstet Gynecol 1997 Aug;90(2):317–8.

Economic evaluation of prenatal diagnosis: a methodological review. Shackley P. **Prenat Diagn** 1996 May;16(5):389–95 (29 ref.)

METHODS

Current status of amniotic fluid tests of fetal maturity. Field NT, et al. **Clin Obstet Gynecol** 1997 Jun;40(2):366–86 (51 ref.)

Clinical assessment of amniotic fluid. Moore TR. **Clin Obstet Gynecol** 1997 Jun;40(2):303–13 (52 ref.)

The early amniocentesis study: a randomized clinical trial of early amniocentesis and midtrimester amniocentesis. II. Evaluation of procedure details and neonatal congenital anomalies. Wilson RD, et al. **Fetal Diagn Ther** 1997 Mar-Apr;12(2):97–101

Early and midtrimester genetic amniocenteses. Safety and outcomes. Reece EA. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):71–81 (44 ref.)

Turner's syndrome 45,X found by coelocentesis [letter] Crüger DG, et al. **Prenat Diagn** 1997 Jun;17(6):588–9

A false-positive diagnosis of Turner syndrome by amniocentesis [letter; comment] Fejgin MD, et al. **Prenat Diagn** 1997 Jan;17(1):88–9. Comment on: Prenat Diagn 1996 May;16(5):463–6.

Prenatal diagnosis of Sanfilippo A syndrome: experience in 35 pregnancies at risk and the use of a new fluorogenic substrate for the heparin sulphamidase assay. Kleijer WJ, et al. **Prenat Diagn** 1996 Sep;16(9):829–35

An additional report of prenatal detection of mosaic isochromosome 20q at amniocentesis [letter] Storto P, et al. **Prenat Diagn** 1997 Jan;17(1):89–90

Early filtration amniocentesis for further investigation of mosaicism diagnosed by chorionic villus sampling. Sundberg K, et al. **Prenat Diagn** 1996 Dec;16(12):1121–7

[Value and limits of transabdominal cytogenetic amniocenteses during the first trimester of pregnancy] Irion O, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(5):500–4 (17 ref.) (Eng. Abstr.) **(Fre)**

[Detection of the presence of ethyl alcohol in amniotic fluid drawn by trans-abdominal echo-guided amniocentesis] Del Borrello E, et al. **Boll Chim Farm** 1997 Apr;136(4):391–3 **(Ita)**

[Karyotyping of fetal cells in the prenatal diagnosis in Costa Rica] Castro Volio I, et al. **Rev Biol Trop** 1995 Apr-Dec; 43(1-3):31–7 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Responding to parental concerns after a prenatal diagnosis of trisomy 21. Stein MT, et al. **J Dev Behav Pediatr** 1997 Feb;18(1):42–6

STANDARDS

Cost-effectiveness of strategies used in the evaluation of pregnancies complicated by elevated maternal serum alpha-fetoprotein levels [see comments] Nadel AS, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):660–5. Comment in: Obstet Gynecol 1997 Aug;90(2):317–8.

A false-positive diagnosis of Turner syndrome by amniocentesis [see comments] Griffiths MJ, et al. **Prenat Diagn** 1996 May;16(5):463–6. Comment in: Prenat Diagn 1997 Jan;17(1):88–9.

STATISTICS & NUMERICAL DATA

Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis. Kuppermann M, et al. **Med Decis Making** 1997 Jan-Mar;17(1):42–55

A cohort study of pregnancy outcome after amniocentesis in twin pregnancy. Kidd SA, et al. **Paediatr Perinat Epidemiol** 1997 Apr;11(2):200–13

VETERINARY

Use of transabdominal ultrasound-guided amniocentesis for detection of equid herpesvirus 1-induced fetal infection in utero. Smith KC, et al. **Am J Vet Res** 1997 Sep; 58(9):997–1002

AMNION

A prospective randomized trial of two solutions for intrapartum amnioinfusion: effects on fetal electrolytes, osmolality, and acid-base status. Pressman EK, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):945–9

Chlorhexidine versus sterile water vaginal wash during labor to prevent peripartum infection. Sweeten KM, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):426–30

Transabdominal amnioinfusion in oligohydramnios at term before induction of labor with intact membranes: a randomized clinical trial. Vergani P, et al. **Am J Obstet Gynecol** 1996 Aug;175(2):465–70

Amnioinfusion for the prevention of meconium aspiration during labour. Rogers MS, et al. **Aust N Z J Obstet Gynaecol** 1996 Nov;36(4):407–10

Clinical role of amnio-infusion. Ouzounian JG, et al. **Baillieres Clin Obstet Gynaecol** 1996 Jun;10(2):259–72 (56 ref.)

Therapeutic interventions for oligohydramnios: amnioinfusion and maternal hydration. Kilpatrick SJ. **Clin Obstet Gynecol** 1997 Jun;40(2):328–36 (39 ref.)

Serial transabdominal amnioinfusion in the management of gastroschisis with severe oligohydramnios. Dommergues M, et al. **J Pediatr Surg** 1996 Sep;31(9):1297–9

Surfactant administration to the human fetus in utero: a new approach to prevention of neonatal respiratory distress syndrome (RDS). Cosmi EV, et al. **J Perinat Med** 1996; 24(2):191–3

Method of obtaining and preparation of fresh human amniotic membrane for clinical use. Ganatra MA, et al. **JPMA J Pak Med Assoc** 1996 Jun;46(6):126–8

Amnioinfusion for meconium staining: does it help? Folsom MS. **MCN Am J Matern Child Nurs** 1997 Mar-Apr; 22(2):74–9

The effect of amnioinfusion on the duration of labor. Strong TH Jr. **Obstet Gynecol** 1997 Jun;89(6):1044–6

Monoamniotic twins delivered liveborn with a forked umbilical cord. Fraser RB, et al. **Pediatr Pathol Lab Med** 1997 Jul-Aug;17(4):639–44 (9 ref.)

[Amnioinfusion: indications and results] Luton D, et al. **Presse Med** 1996 Dec 7;25(38):1881–4 (30 ref.) (Eng. Abstr.) **(Fre)**

[Caudal appendix in sequential defects of amniotic rupture. A case report] Bustamante-Sarabia J, et al. **Ginecol Obstet Mex** 1997 Mar;65:114–7 (Eng. Abstr.) **(Spa)**

ABNORMALITIES

The effect of amniotic sheet orientation on subsequent maternal and fetal complications. Lazebnik N, et al. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):267–71

BLOOD SUPPLY

Measurement of blood flow by the 133Xe clearance technique to grafts of amnion used in vestibuloplasty. Güler R, et al. **Br J Oral Maxillofac Surg** 1997 Aug;35(4):280–3

CHEMISTRY

Tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 expression in human amnion mesenchymal and epithelial cells. Rowe TF, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):915–21

Nuclear microanalysis of the effect of magnesium and taurine on the ionic distribution in the human amniotic membrane. Bara M, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Feb; 42(1):27–38

Analogs of cord red blood cell membrane components displayed on placenta, amnion and amniotic cells in culture. Lunghi M, et al. **Eur J Histochem** 1996;40(2):129–36

Effects of buffering intracellular free calcium on neutrophil migration through three-dimensional matrices. Mandeville JT, et al. **J Cell Physiol** 1997 May;171(2):168–78

Inflammatory cytokine mRNA in human gestational tissues: implications for term and preterm labor. Dudley DJ, et al. **J Soc Gynecol Investig** 1996 Nov-Dec;3(6):328–35

CYTOLOGY

Ovine amniotic and allantoic epithelia across gestation. Shandley L, et al. **Anat Rec** 1997 Aug;248(4):542–53

Treatment of patients with Niemann-Pick type is using repeated amniotic epithelial cells implantation: correction of aggregation and coagulation abnormalities [see comments] Cerneca F, et al. **Clin Pediatr (Phila)** 1997 Mar; 36(3):141–6. Comment in: Clin Pediatr (Phila) 1997 Mar;36(3):147–8.

A very sticky riddle [letter; comment] D'Hooghe TM, et al. **Fertil Steril** 1997 Jan;67(1):182–3; discussion 183, 185–6 . Comment on: Fertil Steril 1996 Jan;65(1):76–80.

Repair kinetics of amnion cells after microsurgical injury. Quintero RA, et al. **Fetal Diagn Ther** 1996 Sep-Oct; 11(5):348–56

Hypotonic stress increases cyclooxygenase-2 expression and prostaglandin release from amnion-derived WISH cells. Lundgren DW, et al. **J Biol Chem** 1997 Aug 8; 272(32):20118–24

A program of cell death and extracellular matrix degradation is activated in the amnion before the onset of labor [see comments] Lei H, et al. **J Clin Invest** 1996 Nov 1; 98(9):1971–8. Comment in: J Clin Invest 1996 Nov 1;98(9):1971–8.

Life and death at labor [editorial; comment] Streuli CH, et al. **J Clin Invest** 1996 Nov 1;98(9):1947–8. Comment on: J Clin Invest 1996 Nov 1;98(9):1971–8.

An electron microscope study of the interaction between Trichomonas vaginalis and epithelial cells of the human amnion membrane. Mirhaghani A, et al. **Parasitol Res** 1996; 82(1):43–7

The low proliferation rates of human amniotic cells are neither associated to deregulated proto-oncogenes' expression nor to the effect of IFN alpha 2. Oliveira JG, et al. **Placenta** 1997 Mar-Apr;18(2-3):163–8

DRUG EFFECTS

Stimulation of prostaglandin E2 synthesis by interleukin-1beta is amplified by interferons but inhibited by interleukin-4 in human amnion-derived WISH cells. Harding L, et al. **Biochim Biophys Acta** 1997 Jan 10; 1310(1):48–52

AMNION

Eicosanoid production by placental and amnion tissues from control and non-insulin-dependent diabetic rats. Influence of oxytocin in the incubating medium. Jawerbaum A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jun; 56(6):425-9

EMBRYOLOGY

Formation of reticulated endoderm, Reichert's membrane, and amniogenesis in blastocysts of captive-bred, short-tailed fruit bats, Carollia perspicillata. Badwaik NK, et al. **Anat Rec** 1997 Jan;247(1):85-101

Unusual aspects of inner cell mass formation, endoderm differentiation, Reichert's membrane development, and amniogenesis in the lesser bulldog bat, Noctilio albiventris. Rasweiler JJ 4th, et al. **Anat Rec** 1996 Oct;246(2):293-304

ENZYMOLOGY

Regulation of prostaglandin endoperoxide H2 synthase in term human gestational tissues. Zakar T, et al. **Acta Physiol Hung** 1996;84(2):109-18

Changes in activity of cytosolic phospholipase A2 in human amnion at parturition. Skannal DG, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):179-84

Evaluation of two markers of cell maturation and proliferation in cultured amniotic cells of trisomic 18 fetuses at the 15th week of gestation. Vergnes H, et al. **Early Hum Dev** 1997 Jul 24;49(1):1-5

Lysyl oxidase (ras recision gene) expression in human amnion: ontogeny and cellular localization. Casey ML, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):167-72

Expression of prostaglandin G/H synthase-1 and -2 in ovine amnion and placenta following glucocorticoid-induced labour onset. McLaren WJ, et al. **J Endocrinol** 1996 Oct; 151(1):125-35

Prostaglandin H synthase-2 in human gestational tissues: regulation in amnion. Trautman MS, et al. **Placenta** 1996 May;17(4):239-45

The expression of cyclooxygenase-2 (COX-2) in amnion and decidua following spontaneous labor. Fuentes A, et al. **Prostaglandins** 1996 Oct;52(4):261-7

IMMUNOLOGY

In vitro cytokine and prostaglandin production by amnion cells in the presence of bacteria. Reisenberger K, et al. **Am J Obstet Gynecol** 1997 May;176(5):981-4

Focal adhesion kinase pp125FAK is associated with both intercellular junctions and matrix adhesion sites in vivo. Tani T, et al. **Histochem Cell Biol** 1996 Jan;105(1):17-25

Characterization of human amniotic epithelial cells transformed with origin-defective SV40 T-antigen gene. Tohyama J, et al. **Tohoku J Exp Med** 1997 May; 182(1):75-82

INJURIES

Limb and other postcranial skeletal defects induced by amniotic sac puncture in the mouse. Chang HH, et al. **J Anat** 1996 Aug;189 (Pt 1):37-49

METABOLISM

Interleukin-10 inhibition of interleukin-6 in human amniochorionic membrane: transcriptional regulation. Fortunato SJ, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1057-65

Amnion epithelial cells, in contrast to trophoblast cells, express all classical HLA class I molecules together with HLA-G. Hammer A, et al. **Am J Reprod Immunol** 1997 Feb;37(2):161-71

Rapid and transient induction of cyclo-oxygenase 2 by epidermal growth factor in human amnion-derived WISH cells. Perkins DJ, et al. **Biochem J** 1997 Feb 1;321 (Pt 3):677-81

Interstitial collagen synthesis and processing in human amnion: a property of the mesenchymal cells. Casey ML, et al. **Biol Reprod** 1996 Dec;55(6):1253-60

Amniotic membrane collagen content and type distribution in women with preterm premature rupture of the membranes in pregnancy. Hampson V, et al. **Br J Obstet Gynaecol** 1997 Sep;104(9):1087-91

NPY and VIP neuropeptides endogenous factors in the induction of preterm delivery labour. Rolfini G, et al. **Clin Exp Obstet Gynecol** 1996;23(4):233-5

Glucocorticoids stimulate prostaglandin H synthase type-2 (PGHS-2) in the fibroblast cells in human amnion cultures. Economopoulos P, et al. **Mol Cell Endocrinol** 1996 Mar 25;117(2):141-7

Constitutive and induced cytokine production by human placenta and amniotic membrane at term. Paradowska E, et al. **Placenta** 1997 Jul-Aug;18(5-6):441-6

The biochemical role of platelet-activating factor in reproduction. Frenkel RA, et al. **Prog Lipid Res** 1996; 35(2):155-68 (101 ref.)

Cyclosporin A inhibits prostaglandin E2 production by fetal amnion cells in response to various stimuli. Edwin SS, et al. **Prostaglandins** 1996 Jul;52(1):51-61

Eicosanoid production by placental and amnion tissues from control and non-insulin-dependent diabetic rats. Influence of oxytocin in the incubating medium. Jawerbaum A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jun; 56(6):425-9

Characterization of human amniotic epithelial cells transformed with origin-defective SV40 T-antigen gene. Tohyama J, et al. **Tohoku J Exp Med** 1997 May; 182(1):75-82

CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line. Fendrick JL, et al. **Tumour Biol** 1997;18(5):278-89

MICROBIOLOGY

Interleukin-6 concentrations in cervical secretions identify microbial invasion of the amniotic cavity in patients with preterm labor and intact membranes. Rizzo G, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):812-7

Chlamydia trachomatis infection in prelabour amniorrhexis. Vile Y, et al. **Br J Obstet Gynaecol** 1997 Sep;104(9):1091-3

Chorioamnionitis caused by gram-negative bacteria as an etiologic factor in preterm birth. Sherman DJ, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jun;16(6):417-23

Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection. Gomez R, et al. **Infect Dis Clin North Am** 1997 Mar; 11(1):135-76 (220 ref.)

The activity of azithromycin on the infectivity of Chlamydia trachomatis in human amniotic cells. Patton DL, et al. **J Antimicrob Chemother** 1995 Dec;36(6):951-9

In vitro permeation of human chorioamniotic membranes by Campylobacter jejuni. Diker KS, et al. **Zentralbl Bakteriol** 1997 Apr;285(4):518-24

PARASITOLOGY

An electron microscope study of the interaction between Trichomonas vaginalis and epithelial cells of the human amnion membrane. Mirhaghani A, et al. **Parasitol Res** 1996; 82(1):43-7

PATHOLOGY

A case control study of chorioamniotic infection and histological chorioamnionitis in stillbirth. Folgosa E, et al. **APMIS** 1997 Apr;105(4):329-36

Histologic features of chorioamnion membrane rupture: development of methodology. Bendon RW, et al. **Pediatr Pathol Lab Med** 1997 Jan-Feb;17(1):27-42

[Surviving mono-amniotic twins. Case report and review of the literature] Golaszewski T, et al. **Z Geburtshilfe Neonatol** 1997 Mar-Apr;201(2):62-4 (11 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Influence of gestational age on the time from spontaneous rupture of the chorioamniotic membranes to the onset of labor. Savitz DA, et al. **Am J Perinatol** 1997 Mar; 14(3):129-33

Differentiation potential of rat amnion. Knezevic V. **J Anat** 1996 Aug;189 (Pt 1):1-7

Neonatal herpes simplex virus infection after cesarean section with intact amniotic membranes. Peng J, et al. **J Perinatol** 1996 Sep-Oct;16(5):397-9 (17 ref.)

Population profile of brain asymmetry in rats after intra-amniotic administration of vasopressin. Klement'ev BI, et al. **Neurosci Behav Physiol** 1997 May-Jun;27(3):283-7

[Characteristics of the stimulatory adrenergic reaction of isolated chick embryo amnion] Boĭko OV, et al. **Dokl Akad Nauk** 1997 Mar;353(3):411-4 **(Rus)**

[Possible involvement of histamine in humoral regulation of the spontaneous contractile activity of the chick embryo amnion] Khodorova AB, et al. **Dokl Akad Nauk** 1997 Jul; 355(2):282-4 **(Rus)**

SURGERY

Are obstetric interventions such as cervical ripening, induction of labor, amnioinfusion, or amniotomy associated with umbilical cord prolapse? Roberts WE, et al. **Am J Obstet Gynecol** 1997 Jun;176(6):1181-3; discussion 1183-5

Early amniotomy increases the frequency of fetal heart rate abnormalities. Amniotomy Study Group. Goffinet F, et al. **Br J Obstet Gynaecol** 1997 May;104(5):548-53

Amniotomy in labour? No, thanks! [editorial; comment] Grant JM. **Br J Obstet Gynaecol** 1997 Mar;104(3):vii-iii. Comment on: Br J Obstet Gynaecol 1997 Mar;104(3):340-6.

Randomised trial comparing a policy of early with selective amniotomy in uncomplicated labour at term [see comments] Johnson N, et al. **Br J Obstet Gynaecol** 1997 Mar; 104(3):340-6. Comment in: Br J Obstet Gynaecol 1997 Mar;104(3):vii-viii.

Induction of labour: a randomised clinical trial of amniotomy versus amniotomy with oxytocin infusion [letter; comment] Turner M, et al. **Br J Obstet Gynaecol** 1996 Oct; 103(10):1050. Comment on: Br J Obstet Gynaecol 1996 Apr;103(4):306-12.

Internalization of pleuroamniotic shunt causing neonatal demise. Blanch G, et al. **Fetal Diagn Ther** 1996 Jan-Feb; 11(1):32-6 (17 ref.)

Correction of hemodynamic abnormalities by vesicoamniotic shunting in familial congenital megacystis. Tomlinson MW, et al. **Fetal Diagn Ther** 1996 Jan-Feb;11(1):46-9

Clinical trial comparing artificial rupture of membranes plus oral PGE2 tablets versus artificial rupture of membranes plus intravenous oxytocin for induction of labour in primigravid patients at term. Nassief SA, et al. **Ulster Med J** 1996 Nov;65(2):145-8

[Prenatal use of a vesico-amniotic shunt in obstructive uropathy] Cermák A, et al. **Rozhl Chir** 1997 Jan;76(1):6-8 (Eng. Abstr.) **(Cze)**

TRANSPLANTATION

Amniotic membrane transplantation for persistent epithelial defects with ulceration. Lee SH, et al. **Am J Ophthalmol** 1997 Mar;123(3):303-12

Measurement of blood flow by the 133Xe clearance technique to grafts of amnion used in vestibuloplasty. Güler R, et al. **Br J Oral Maxillofac Surg** 1997 Aug;35(4):280-3

Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Prabhasawat P, et al. **Ophthalmology** 1997 Jun; 104(6):974-85

ULTRASONOGRAPHY

First-trimester detection of amniotic sac in relation to miscarriage. Ikegawa A. **J Obstet Gynaecol Res** 1997 Jun; 23(3):283-8

Intra-amniotic debris identified at ultrasound scanning: a feature of congenital ichthyosis. Montague I, et al. **Ultrasound Obstet Gynecol** 1997 May;9(5):350-1

[Measuring amniochorionic membrane thickness with high frequency ultrasound] Frigo P, et al. **Ultraschall Med** 1996 Aug;17(4):167-70 (Eng. Abstr.) **(Ger)**

VIROLOGY

Effect of exogenous tumor necrosis factor alpha, interleukin 6 and interferons on vesicular stomatitis virus replication in human placenta and amniotic membrane organ cultures. Paradowska E, et al. **Arch Immunol Ther Exp (Warsz)** 1996; 44(1):57-62

AMNIONITIS see **CHORIOAMNIONITIS**

AMNIOTIC BAND SYNDROME

[Caudal appendix in sequential defects of amniotic rupture. A case report] Bustamante-Sarabia J, et al. **Ginecol Obstet Mex** 1997 Mar;65:114-7 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

First report of distal obstructive uropathy and prune-belly syndrome in an infant with amniotic band syndrome. Chen CP, et al. **Am J Perinatol** 1997 Jan;14(1):31-3

Amniotic bands and the EEC syndrome. Guion-Almeida ML, et al. **Birth Defects Orig Artic Ser** 1996;30(1):171-7

Limb ring constriction. Mutsuddi M, et al. **J Indian Med Assoc** 1996 Feb;94(2):82

Craniofacial damage from amniotic band syndrome subsequent to pathologic chorioamniotic separation at 10 weeks' gestation. Finberg HJ, et al. **J Ultrasound Med** 1996 Sep;15(9):665-8

DIAGNOSIS

Chorioamniotic membrane separation: a potentially lethal finding. Graf JL, et al. **Fetal Diagn Ther** 1997 Mar-Apr; 12(2):81-4

PATHOLOGY

Amniotic band syndrome: report of two autopsy cases. Huang CC, et al. **Chang Keng I Hsueh** 1995 Dec;18(4):371-7

Craniofacial manifestations of the amniotic band syndrome. Bagatin M, et al. **Otolaryngol Head Neck Surg** 1997 Apr; 116(4):525-8 (15 ref.)

Prenatal diagnosis of vasa previa presenting as amniotic band. 'A not so innocent amniotic band'. Clerici G, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):61-3

SURGERY

[The surgical treatment of amniotic strangulation of the extremities] Mikusev IE. **Vestn Khir Im I I Grek** 1996; 155(2):94-5 **(Rus)**

ULTRASONOGRAPHY

Amniotic sheets: ultrasonography and pathologic correlation. Nelson LH, et al. **J Ultrasound Med** 1996 Jul;15(7):543-5

A case of fetal decapitation. Shipp TD, et al. **J Ultrasound Med** 1996 Jul;15(7):535-7

Prenatal diagnosis of amniotic band syndrome in a methadone user: review of the literature and a case report. Daly CA, et al. **Ultrasound Obstet Gynecol** 1996 Aug;8(2):123-5 (12 ref.)

AMNIOTIC BANDS see **AMNIOTIC BAND SYNDROME**

AMNIOTIC FLUID

see related
EMBOLISM, AMNIOTIC FLUID
OLIGOHYDRAMNIOS
POLYHYDRAMNIOS

Comparison between the single deepest pocket and amniotic fluid index in predicting fetal distress in small-for-gestational age fetuses. Miyamura T, et al. **Acta Obstet Gynecol Scand** 1997 Feb;76(2):123-7

Attractiveness of amniotic fluid odor: evidence of prenatal olfactory learning? Varendi H, et al. **Acta Paediatr** 1996 Oct;85(10):1223–7

Amniotic fluid embolism (it can present without respiratory manifestations). Case report. Gad N. **Clin Exp Obstet Gynecol** 1996;23(4):248–51

Fetal redistribution of blood flow and amniotic fluid volume in growth-retarded fetuses. Yoshimura S, et al. **Early Hum Dev** 1997 Feb 20;47(3):297–304

Prophylactic intrapartum amnioinfusion: a controlled retrospective study of 135 cases. De Meeus JB, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Apr;72(2):141–8

Amniotic fluid gram stain and leukocyte count in the prediction of intrauterine infection in preterm prelabour amniorrhexis. Carroll SG, et al. **Fetal Diagn Ther** 1996 Jan–Feb;11(1):1–5

Effect of amniotic fluid on cationic lipid mediated transfection and retroviral infection. Douar AM, et al. **Gene Ther** 1996 Sep;3(9):789–96

Intraamniotic interleukin-1 accelerates surfactant protein synthesis in fetal rabbits and improves lung stability after premature birth. Bry K, et al. **J Clin Invest** 1997 Jun 15; 99(12):2992–9

Role of amniotic fluid in newborn acceptance and bonding in canines. Abitbol ML, et al. **J Matern Fetal Med** 1997 Jan–Feb;6(1):49–52

Meconium does not guarantee fetal lung maturity. Lauria MR, et al. **J Matern Fetal Med** 1997 May–Jun;6(3):180–3

Intrapartum amniotic fluid index. A poor diagnostic test for adverse perinatal outcome. Chauhan SP, et al. **J Reprod Med** 1996 Nov;41(11):860–6

Interleukin-1 beta intra-amniotic infusion induces tumor necrosis factor-alpha, prostaglandin production, and preterm contractions in pregnant rhesus monkeys. Baggia S, et al. **J Soc Gynecol Investig** 1996 May–Jun;3(3):121–6

The effect of amniotic fluid suctioning during caesarean section on intestinal motility [letter] Özel A. **S Afr Med J** 1997 Feb;87(2 Suppl):231–2

Reproducibility of the amniotic fluid index: its effect on clinical practice. Chang TC, et al. **Ultrasound Obstet Gynecol** 1995 Dec;6(6):416–20

[Green amniotic fluid as initial symptom of high intestinal obstruction in infants] Swarte RM, et al. **Ned Tijdschr Geneeskd** 1997 Jan 25;141(4):202–4 (Eng. Abstr.) **(Dut)**

[Amniotic fluid embolism: review] Guasch E, et al. **Rev Esp Anestesiol Reanim** 1996 May;43(5):180–4 (59 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Gastrin levels in mothers and neonates at delivery in various perinatal conditions. Morán C, et al. **Acta Obstet Gynecol Scand** 1996 Aug;75(7):608–11

Ethanol resistive microbubble test: a modification of the stable microbubble test used to predict respiratory distress syndrome. Cho K, et al. **Acta Paediatr Jpn** 1996 Aug; 38(4):322–7

Diagnostic dilemma with elevated level of alpha-fetoprotein in an undiagnosed twin pregnancy with a small discordant holoacardius acephalus. Entezami M, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):466–8

Angiogenin: a marker for preterm delivery in midtrimester amniotic fluid [letter] Farina A, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):483–4

Amniotic fluid tumor necrosis factor-alpha and the risk of respiratory distress syndrome among preterm infants. Hitti J, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):50–6

Angiogenin: a marker for preterm delivery in midtrimester amniotic fluid. Spong CY, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):415–8

Association between second-trimester bacterial invasion of amniotic fluid and spectrophotometry at 450 nm [letter; comment] Sziller I, et al. **Am J Obstet Gynecol** 1996 Oct; 175(4 Pt 1):1082–3. Comment on: Am J Obstet Gynecol 1996 Mar;174(3):839–42.

Elevated amniotic fluid interleukin-6 levels at genetic amniocentesis predict subsequent pregnancy loss. Wenstrom KD, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):830–3

Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Yoon BH, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):19–26

Interpretation of the TDx-FLM fluorescence polarization assay in pregnancies complicated by diabetes mellitus. Del Valle GO, et al. **Am J Perinatol** 1997 May;14(5):241–4

Elevation of amniotic fluid interleukin-4 concentrations in women with preterm labor and chorioamnionitis. Dudley DJ, et al. **Am J Perinatol** 1996 Oct;13(7):443–7

Amniotic fluid endothelin-1 levels are increased in pregnancy-induced hypertension and intrauterine growth retardation. Di Iorio R, et al. **Am J Reprod Immunol** 1996 Nov;36(5):260–3

A microcentrifugation assay of phospholipid in lung surfactant from amniotic fluid. Almog R, et al. **Anal Biochem** 1996 Nov 1;242(1):147–50

The ability of the Haemonetics 4 Cell Saver System to remove tissue factor from blood contaminated with amniotic fluid. Bernstein HH, et al. **Anesth Analg** 1997 Oct; 85(4):831–3

Maternal plasma and amniotic fluid dehydroepiandrosterone-sulfate concentrations in preterm labor and delivery. Mazor M, et al. **Arch Gynecol Obstet** 1996;259(1):7–12

Characterization of a new calcium-binding protein abundant in amniotic fluid, CAAF2, which is produced by fetal epidermal keratinocytes during embryogenesis. Hitomi J, et al. **Biochem Biophys Res Commun** 1996 Nov 21; 228(3):757–63

Effect of IL-1 in amniotic fluid on the fetal keratinocyte. Kamada M, et al. **Biochem Mol Biol Int** 1996 May; 39(1):13–20

The role of macrophage migration inhibitory factor in pregnancy and development of murine embryos. Suzuki H, et al. **Biochem Mol Biol Int** 1996 Feb;38(2):409–16

Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Melegos DN, et al. **Clin Biochem** 1996 Dec;29(6):555–62

Low molecular mass proteins and urinary enzymes in amniotic fluid of healthy pregnant women at progressive stages of gestation. Mussap M, et al. **Clin Biochem** 1996 Feb;29(1):51–6

Analytical and clinical evaluation of refractive index-matched anomalous diffraction (RIMAD) for assessment of fetal lung maturation. Rohlfs EM, et al. **Clin Chem** 1996 Nov;42(11):1861–8

Amniotic fluid for screening of lysosomal storage diseases presenting in utero (mainly as non-immune hydrops fetalis). Piraud M, et al. **Clin Chim Acta** 1996 Apr 30;248(2):143–55

Current status of amniotic fluid tests of fetal maturity. Field NT, et al. **Clin Obstet Gynecol** 1997 Jun;40(2):366–86 (51 ref.)

Clinical assessment of amniotic fluid. Moore TR. **Clin Obstet Gynecol** 1997 Jun;40(2):303–13 (52 ref.)

Comparative concentrations of growth hormone-binding protein in maternal circulation, fetal circulation, and amniotic fluid. Harada I, et al. **Endocr J** 1997 Feb; 44(1):111–6

Detection of novel molecules recognized by anti-placental lactogen antibody in rat amniotic fluid. Imai A, et al. **Endocr J** 1997 Apr;44(2):265–74

Analogs of cord red blood cell membrane components displayed on placenta, amnion and amniotic cells in culture. Lunghi M, et al. **Eur J Histochem** 1996;40(2):129–36

Diagnosis of premature rupture of the membranes in preterm patients, using an improved AFP kit: comparison with ROM-check and/or nitrazine test. Kishida T, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Nov;69(2):77–82

Evaluation of human fetal urine as a source of amniotic fluid phospholipids. Bar-Oz B, et al. **Fetal Diagn Ther** 1996 Jul–Aug;11(4):271–4

Doppler velocimetry of the umbilical artery as a predictor of pregnancy outcome in pregnancies characterized by elevated maternal serum alpha-fetoprotein and normal amniotic fluid alpha-fetoprotein. Jaffa A, et al. **Fetal Diagn Ther** 1997 Mar–Apr;12(2):85–8

Thrombin-antithrombin III complexes and antithrombin III in amniotic fluid. Uszyński M, et al. **Gynecol Obstet Invest** 1997;43(1):29–33

Inhibin in extra-embryonic coelomic and amniotic fluids and maternal serum in early pregnancy. Riley SC, et al. **Hum Reprod** 1996 Dec;11(12):2772–6

Presence of Vicia graminea lectin- and Vicia unijuga lectin-binding (Vgu) glycoprotein in human amniotic fluid and some of its chemical and serological properties. Ohyama K, et al. **Int J Biochem Cell Biol** 1997 Mar; 29(3):455–64

Prediction of fetal lung maturity from near-infrared spectra of amniotic fluid. Liu KZ, et al. **Int J Gynaecol Obstet** 1997 May;57(2):161–8

Detection of cocaine and its metabolites in amniotic fluid and umbilical cord tissue. Winecker RE, et al. **J Anal Toxicol** 1997 Mar–Apr;21(2):97–104

Analysis of dipalmitoyl phosphatidylcholine in amniotic fluid by high-performance liquid chromatography. Alvarez JG, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7; 690(1–2):338–42

Dimeric inhibins in amniotic fluid, maternal serum, and fetal serum in human pregnancy. Wallace EM, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):218–22

High levels of fetal membrane activin beta A and activin receptor IIB mRNAs and augmented concentration of amniotic fluid activin A in women in term or preterm labor. Petraglia F, et al. **J Endocrinol** 1997 Jul;154(1):95–101

Amniotic fluid inhibin-A in chromosomally normal and Down's syndrome pregnancies. Wallace EM, et al. **J Endocrinol** 1997 Jan;152(1):109–12

Rapid antibody test for prenatal diagnosis of fragile X syndrome on amniotic fluid cells: a new appraisal. Willemsen R, et al. **J Med Genet** 1997 Mar;34(3):250–1

Comparison of an improved AFP kit with the intra-amniotic PSP dye-injection method in equivocal cases of preterm premature rupture of the fetal membranes. Yamada H, et al. **J Obstet Gynaecol Res** 1997 Jun;23(3):307–11

A comparison of the shake test, optical density, L/S ratio (planimetric and stechiometric) and PG for the assessment of fetal lung maturity. Anceschi MM, et al. **J Perinat Med** 1996;24(4):355–62

Measurement of surface tension in biological fluids by a pulsating capillary technique. Boda D, et al. **J Perinat Med** 1997;25(2):146–52

Indication and results of insulin therapy for gestational diabetes mellitus. Hopp H, et al. **J Perinat Med** 1996; 24(5):521–30

Lamellar body count in amniotic fluid as a rapid screening test for fetal lung maturity. Lee IS, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 1):176–80

Elevated concentrations of prorenin and renin in amniotic fluid of women with chorioamnionitis. Mitchell MD, et al. **J Perinatol** 1997 Mar–Apr;17(2):116–8

Mouse fetal antigen 1 (mFA1), the circulating gene product of mdlk, pref-1 and SCP-1: isolation, characterization and biology. Bachmann E, et al. **J Reprod Fertil** 1996 Jul; 107(2):279–85

Promotion of proliferation of murine hematopoietic stem cells by growth factors in murine amniotic fluid. Heidari Z, et al. **J Reprod Immunol** 1996 Aug;31(1–2):51–64

Lung maturity tests. Relation to source, clarity, gestational age and neonatal outcome. Lauria MR, et al. **J Reprod Med** 1996 Sep;41(9):685–91

Amniotic fluid alpha-fetoprotein determination at the time of genetic amniocentesis: has it outlived its usefulness? Shields LE, et al. **J Ultrasound Med** 1996 Nov;15(11):735–9

Isolation of human surfactant protein A from amniotic fluid. Cheong KB, et al. **Malays J Pathol** 1995 Dec;17(2):97–101

Characterization of the growth factor activity of amniotic fluid on cells from hematopoietic and lymphoid organs of different life stages. Heidari Z, et al. **Microbiol Immunol** 1996;40(8):583–9

Performance of the dipalmitoyl phosphatidylcholine test in predicting respiratory distress syndrome in contaminated samples of amniotic fluid [see comments] Cohen B, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):719–22. Comment in: Obstet Gynecol 1997 Aug;90(2):319–20.

Performance of the dipalmitoyl phosphatidylcholine test in predicting respiratory distress syndrome in contaminated samples of amniotic fluid [letter; comment] Lenke R. **Obstet Gynecol** 1997 Aug;90(2):319–20. Comment on: Obstet Gynecol 1997 May;89(5 Pt 1):719–22.

Use of low-frequency electrical impedance measurements to determine phospholipid content in amniotic fluid. De Luca F, et al. **Phys Med Biol** 1996 Sep;41(9):1863–9

Amniotic fluid odd-chain fatty acids are increased in propionic acidaemia. Coker M, et al. **Prenat Diagn** 1996 Oct;16(10):941–4

Elevated maternal serum and amniotic fluid alpha-fetoprotein levels in the Denys-Drash syndrome. Devriendt K, et al. **Prenat Diagn** 1996 May;16(5):455–7

Use of amniotic fluid amino acids in prenatal testing for argininosuccinic aciduria and citrullinaemia. Mandell R, et al. **Prenat Diagn** 1996 May;16(5):419–24

Gestational age-related reference values for amniotic fluid amino acids: a useful tool for prenatal diagnosis of aminoacidopathies. Rabier D, et al. **Prenat Diagn** 1996 Jul; 16(7):623–8

Biochemical markers of trisomy 21 in amniotic fluid. Spencer K, et al. **Prenat Diagn** 1997 Jan;17(1):31–7

Amniotic fluid and maternal serum levels of CA125 in pregnancies affected by Down syndrome: a re-evaluation of the role of CA125 in Down syndrome screening. Spencer K, et al. **Prenat Diagn** 1997 Aug;17(8):701–6

The relationship between second-trimester amniotic fluid insulin and glucose levels and subsequent gestational diabetes. Star J, et al. **Prenat Diagn** 1997 Feb;17(2):149–54

Increase in prostaglandin bioavailability precedes the onset of human parturition [published erratum appears in Prostaglandins Leukot Essent Fatty Acids 1996 Dec;55(6):458] Romero R, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Mar; 54(3):187–91

Monoclonal antibody against an amniotic protein carrying ABH blood group epitopes and its forensic application. Nagae M, et al. **Tohoku J Exp Med** 1995 Dec;177(4):353–64

Amniotic fluid polarization of fluorescence and lecithin/sphingomyelin ratio decision criteria assessed. Bernstein LH, et al. **Yale J Biol Med** 1995 May–Aug; 68(3–4):101–17

[Prevention of congenital toxoplasmosis with spiramycin; value and limits of levels in amniotic fluid (letter)] Bourget P, et al. **Therapie** 1996 Nov–Dec;51(6):685–7 **(Fre)**

[Fetal ultrasound biometry and amniotic fluid insulin concentration in pregnant diabetic patients] Hüttner U, et al. **Gynakol Geburtshilfliche Rundsch** 1997;37(1):21–4 (Eng. Abstr.) **(Ger)**

[Relaxin in amniotic fluid and serum of pregnant patients] Wiest E, et al. **Z Geburtshilfe Neonatol** 1997 Jan–Feb; 201(1):21–5 (Eng. Abstr.) **(Ger)**

[Detection of the presence of ethyl alcohol in amniotic fluid drawn by trans-abdominal echo-guided amniocentesis] Del Borrello E, et al. **Boll Chim Farm** 1997 Apr;136(4):391–3 **(Ita)**

[Determination by HPLC of amino acids in amniotic fluid] Gambaro V, et al. **Boll Chim Farm** 1997 Apr;136(4):372–6 **(Ita)**

[Collagen degradation products in amniotic fluid] Gogiel T, et al. **Ginekol Pol** 1996 Sep;67(9):425–31 (Eng. Abstr.) **(Pol)**

[Evaluation of fetal condition in pregnancy complicated by hypertension—biochemical assessment of amniotic fluid. I. Protein and lipid components and kidney maturation] Smolarczyk R, et al. **Ginekol Pol** 1996 Dec;67(12):593–7 (Eng. Abstr.) **(Pol)**

[Evaluation of the intrauterine fetus in hypertension—biochemical assessment of amniotic fluid. IV. Ions] Smolarczyk R, et al. **Ginekol Pol** 1997 Jan; 68(1):1–5 (Eng. Abstr.) **(Pol)**

AMNIOTIC FLUID

[A comparative study of the sodium, potassium, urea, creatinine, and uric acid concentrations in the human amniotic fluid between weeks 15–20 and 38–42] Bauk FA, et al. **Rev Assoc Med Bras** 1996 Jan–Mar;42(1):7–10 (Eng. Abstr.) **(Por)**

[Peptide-like substances in sheep amniotic fluid which regulate proliferation of BP-A31 cells] Blahovec J, et al. **Vet Med (Praha)** 1997 Jul;42(7):185–9 (Eng. Abstr.) **(Slo)**

[Quantification of lamellar bodies in amniotic fluid: a method for the evaluation of fetal pulmonary maturity] Carrillo J, et al. **Ginecol Obstet Mex** 1997 May;65:202–6 (Eng. Abstr.) **(Spa)**

CYTOLOGY

Fetal origin of amniotic fluid polymorphonuclear leukocytes. Sampson JE, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):77–81

Premature rupture of the amniotic membranes diagnosed by placental bed biopsy. Craven CM, et al. **Arch Pathol Lab Med** 1997 Feb;121(2):167–8

Open neural tube defects: immunocytochemical demonstration of neuroepithelial cells in amniotic fluid. Greenebaum E, et al. **Diagn Cytopathol** 1997 Feb; 16(2):143–4

Evidence for active acetylcholine metabolism in human amniotic epithelial cells: applicable to intracerebral allografting for neurologic disease. Sakuragawa N, et al. **Neurosci Lett** 1997 Aug 22;232(1):53–6

Serum C-reactive protein, white blood cell count, and amniotic fluid white blood cell count in women with preterm premature rupture of membranes. Yoon BH, et al. **Obstet Gynecol** 1996 Dec;88(6):1034–40

Prenatal detection of chromosome aneuploidies by fluorescence in situ hybridization: experience with 2000 uncultured amniotic fluid samples in a prospective preclinical trial. Bryndorf T, et al. **Prenat Diagn** 1997 Apr; 17(4):333–41

Quantitative evaluation of fluorescence in situ hybridization (FISH) signals in uncultured coelomic cells. Crüger DG, et al. **Prenat Diagn** 1997 Jul;17(7):635–42

Effect of pre-amniocentesis uterine manipulation on amniocyte concentration and culture duration: a randomized, clinical trial [letter] Fischer RL, et al. **Prenat Diagn** 1996 Jul;16(7):673–4

Rare trisomy mosaicism diagnosed in amniocytes, involving an autosome other than chromosomes 13, 18, 20, and 21: karyotype/phenotype correlations. Hsu LY, et al. **Prenat Diagn** 1997 Mar;17(3):201–42

ALDP expression in fetal cells and its application in prenatal diagnosis of X-linked adrenoleukodystrophy. Ruiz M, et al. **Prenat Diagn** 1997 Jul;17(7):651–6

Trisomy 16 mosaicism in amniotic fluid cell cultures. Tantravahi U, et al. **Prenat Diagn** 1996 Aug;16(8):749–54

Maternal cell contamination in uncultured amniotic fluid. Winsor EJ, et al. **Prenat Diagn** 1996 Jan;16(1):49–54

Amniotic fluid leukocytes and leukocyte esterase activity in parturients delivered by caesarean section. Keski-Nisula L, et al. **Scand J Infect Dis** 1997;29(3):291–6

[In vitro transformation of amniotic cells to muscle cells—background and outlook] Streubel B, et al. **Wien Med Wochenschr** 1996;146(9–10):216–7 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Medical amnioreduction with sulindac to reduce cord complications in monoamniotic twins. Peek MJ, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):334–6

ENZYMOLOGY

Faint and positive amniotic fluid acetylcholinesterase with a normal sonogram. Brown CL, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1000–3

A comparison of rapid amniotic fluid markers in the prediction of microbial invasion of the uterine cavity and preterm delivery. Garry D, et al. **Am J Obstet Gynecol** 1996 Nov;175(5):1336–41

A pilot study identifying type V collagenolytic activity in human amniotic fluid. Polzin WJ, et al. **Am J Perinatol** 1997 Feb;14(2):103–6

Detection of superoxide dismutase isozymes in normal and X-irradiated chick amniotic fluid by using isoelectric focussing. Sarala P, et al. **Indian J Exp Biol** 1996 Sep; 34(9):901–4

Assay of gamma-glutamyl transpeptidase activity in amniotic fluid offers a possible prenatal diagnosis of biliary atresia in the rat model. Hosoda Y, et al. **Prenat Diagn** 1997 Jan; 17(1):9–12

Amniotic fluid leukocytes and leukocyte esterase activity in parturients delivered by caesarean section. Keski-Nisula L, et al. **Scand J Infect Dis** 1997;29(3):291–6

[Cathepsin D activity in amniotic fluid and serum during labor and puerperium in normal cases and those complicated by EPH-gestosis] Michalak S, et al. **Ginekol Pol** 1997 Jan;68(1):17–21 (Eng. Abstr.) **(Pol)**

[Evaluation of fetal condition in pregnancy complicated by hypertension—biochemical assessment of amniotic fluid. II. Enzymes] Smolarczyk R, et al. **Ginekol Pol** 1996 Dec; 67(12):598–602 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Midtrimester amniotic fluid tumor necrosis factor-alpha does not predict small-for-gestational-age infants. Spong CY, et al. **Am J Reprod Immunol** 1997 Mar;37(3):236–9

Cytokines of the human reproductive tract. Srivastava MD, et al. **Am J Reprod Immunol** 1996 Sep;36(3):157–66

Detection of novel molecules recognized by anti-placental lactogen antibody in rat amniotic fluid. Imai A, et al. **Endocr J** 1997 Apr;44(2):265–74

Amniotic fluid antibacterial activity and nutritional parameters in term Mozambican and Swedish pregnant women. Axemo P, et al. **Gynecol Obstet Invest** 1996; 42(1):24–7

Amniotic fluid interleukin-10 (IL-10) concentrations during pregnancy and with labor. Dudley DJ, et al. **J Reprod Immunol** 1997 Jun;33(2):147–56

Tumor necrosis factor-beta in human pregnancy and labor. Laham N, et al. **J Reprod Immunol** 1997 Apr;33(1):53–69

METABOLISM

Paralysis of the preterm rabbit fetus inhibits the pulmonary uptake of intraamniotic iron dextran. Galan HL, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):42–9

Need for placental and experimental pathologic examination to determine pathogenetic influences of chronically present intraamniotic meconium [letter; comment] Hyde S, et al. **Am J Obstet Gynecol** 1996 May;174(5):1669–70. Comment on: Am J Obstet Gynecol 1995 Oct;173(4):1075–8.

Detect of adrenomedullin, a hypotensive peptide, in amniotic fluid and fetal membranes. Macri CJ, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):906–11

Serial amniotic fluid index in severe preeclampsia: a poor predictor of adverse outcome. Schucker JL, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1018–23

Elevated amniotic fluid interleukin-6 levels during the early second trimester are associated with greater risk of subsequent preterm delivery. Ghidini A, et al. **Am J Reprod Immunol** 1997 Mar;37(3):227–31

Cleft beak induced by hydrocortisone in the chick is prevented by increased cell division after experimental reduction of amniotic fluid. Peterka M, et al. **Anat Embryol (Berl)** 1997 Apr;195(4):387–91

Six alternative methods to the lecithin/sphingomyelin ratio in amniotic fluid for assessing fetal lung maturity. Dilena BA, et al. **Ann Clin Biochem** 1997 Jan;34 (Pt 1):106–8

Effect of hypoxia on amniotic fluid erythropoietin levels in fetal rats. Kakuya F, et al. **Biol Neonate** 1997;72(2):118–24

Source of inhibin in ovine fetal plasma and amniotic fluid during late gestation: half-life of fetal inhibin. Miller S, et al. **Biol Reprod** 1997 Aug;57(2):347–53

Daily changes in plasma and amniotic fluid prolactin during the last third of pregnancy in the baboon. Nguyen T, et al. **Biol Reprod** 1997 Mar;56(3):597–601

Polymorphonuclear elastase and interleukin-6 in amniotic fluid in preterm labor [letter] Rivero-Marcotegui A, et al. **Clin Chem** 1997 May;43(5):857–9

Regulation of substances in allantoic and amniotic fluid of the chicken embryo. ten Busch M, et al. **Comp Biochem Physiol A Physiol** 1997 Feb;116(2):131–6

Levels of amniotic fluid insulin and profiles of maternal blood glucose in pregnant women with diabetes type-I. Kainer F, et al. **Early Hum Dev** 1997 Sep 19;49(2):97–105

Ultrasound growth parameters in relation to levels of amniotic fluid insulin in women with diabetes type-I. Kainer F, et al. **Early Hum Dev** 1997 Sep 19;49(2):113–21

Fetal pharyngeal distention—is it a normal component of fetal swallowing? Petrikovsky B, et al. **Early Hum Dev** 1996 Sep 20;46(1-2):77–81

Kinetics of the degradation of NG-nitro-L-arginine and its methyl ester in human umbilical vein blood and amniotic fluid. Klein BH, et al. **Eur J Clin Chem Clin Biochem** 1996 Oct;34(10):805–10

Increased amniotic fluid alpha-fetoprotein in patients with fetal nuchal edema. Drugan A, et al. **Fetal Diagn Ther** 1996 Jan–Feb;11(1):6–8

Raised level of amniotic endothelin in pregnancies with fetal aneuploidy. Vesce F, et al. **Fetal Diagn Ther** 1996 Mar–Apr; 11(2):94–8

In vivo transfer of gene and oligodeoxynucleotides into skin of fetal rats by incubation in amniotic fluid. Hayashi SI, et al. **Gene Ther** 1996 Oct;3(10):878–85

Amniotic fluid interleukins in Swedish and Mozambican pregnant women. Axemo P, et al. **Gynecol Obstet Invest** 1996;41(2):113–7

Amniotic fluid endothelin-1 levels in patients with gestational diabetes mellitus. Di Iorio R, et al. **Horm Metab Res** 1996 Jan;28(1):39–40

A novel calcium-binding protein in amniotic fluid, CAAF1: its molecular cloning and tissue distribution. Hitomi J, et al. **J Cell Sci** 1996 Apr;109 (Pt 4):805–15

Changes in amniotic fluid immunoreactive corticotropin-releasing factor (CRF) and CRF-binding protein levels in pregnant women at term and during labor. Florio P, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):835–8

Levels of pulmonary surfactant protein A in fetal lung and amniotic fluid from protein-malnourished pregnant rats. Kohri T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Jun; 42(3):209–18

Correlation between cytokine levels of amniotic fluid and histological chorioamnionitis in preterm delivery. Negishi H, et al. **J Perinat Med** 1996;24(6):633–9

Interleukin-6, interferon-gamma, interleukin-8, and granulocyte-macrophage colony stimulating factor levels in human amniotic fluid at term. Oláh KS, et al. **J Reprod Immunol** 1996 Nov;32(1):89–98

Time course of ethylene thiourea in maternal plasma, amniotic fluid and embryos in rats following single oral dosing. Iwase T, et al. **J Vet Med Sci** 1996 Dec; 58(12):1235–6

Insulin-like growth factor binding protein concentration and post-translational modification in embryological fluid. Miell JP, et al. **Mol Hum Reprod** 1997 Apr;3(4):343–9

Granulocyte-macrophage colony-stimulating factor in amniotic fluid and in airway specimens of newborn infants. Bry K, et al. **Pediatr Res** 1997 Jan;41(1):105–9

5-Hydroxyeicosatetraenoic acid and human parturition. Edwin SS, et al. **Prostaglandins** 1996 Jun;51(6):403–12

Significant decrease in parathyroid hormone-related protein concentrations in amniotic fluid with labour at term but not preterm. Mitchell MD, et al. **Reprod Fertil Dev** 1996; 8(2):231–4

Changes in M-CSF-like activity during chicken embryonic development. Shao X, et al. **Reprod Fertil Dev** 1996; 8(1):103–9

TCDD endrin and lindane induced increases in lipid metabolites in maternal sera and amniotic fluids of pregnant C57BL/6J and DBA/2J mice. Hassoun EA, et al. **Res Commun Mol Pathol Pharmacol** 1996 Nov;94(2):157–69

[Glucose tolerance in pregnancy and amniotic fluid insulin in labor] Schäfer U, et al. **Geburtshilfe Frauenheilkd** 1996 Aug;56(8):414–7 (Eng. Abstr.) **(Ger)**

[Evaluation of fetal condition in pregnancy complicated by hypertension—biochemical assessment of amniotic fluid. III. Acid-base balance] Smolarczyk R, et al. **Ginekol Pol** 1996 Dec;67(12):603–6 (Eng. Abstr.) **(Pol)**

MICROBIOLOGY

Intraamniotic infection in patients with preterm labor and twin pregnancies. Mazor M, et al. **Acta Obstet Gynecol Scand** 1996 Aug;75(7):624–7

Application of a new perchloric acid treatment method to measure endotoxin in both amniotic fluid and cord blood by an endotoxin-specific chromogenic Limulus test in intra-amniotic infection. Suda H, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):444–8

Does intraamniotic infection in the early phase of the second trimester really exist? [letter; comment] Fernandez H, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1077–8. Comment on: Am J Obstet Gynecol 1990 Oct;163(4 Pt 1):1261–3.

Bacterial vaginosis and intraamniotic infection. Newton ER, et al. **Am J Obstet Gynecol** 1997 Mar;176(3):672–7

Characterization and control of intraamniotic infection in an urban teaching hospital [see comments] Soper DE, et al. **Am J Obstet Gynecol** 1996 Aug;175(2):304–9; discussion 309–10. Comment in: Am J Obstet Gynecol 1997 Feb;176(2):493–4.

Association between second-trimester bacterial invasion of amniotic fluid and spectrophotometry at 450 nm [letter; comment] Sziller I, et al. **Am J Obstet Gynecol** 1996 Oct; 175(4 Pt 1):1082–3. Comment on: Am J Obstet Gynecol 1996 Mar;174(3):839–42.

Amniotic fluid U. urealyticum colonization: significance for maternal peripartal infections at term. Keski-Nisula L, et al. **Am J Perinatol** 1997 Mar;14(3):151–6

The contribution of pathological examination of the placenta in the investigation of the causes of foetal mortality. Agapitos E, et al. **Arch Anat Cytol Pathol** 1996;44(1):5–11

Broad-spectrum bacterial rDNA polymerase chain reaction assay for detecting amniotic fluid infection among women in premature labor. Hitti J, et al. **Clin Infect Dis** 1997 Jun; 24(6):1228–32

Intra-amniotic Chlamydia trachomatis infection. Djukić S, et al. **Gynecol Obstet Invest** 1996;42(2):109–12

Cesarean delivery. Microbial colonization in amniotic fluid. Keski-Nisula L, et al. **J Reprod Med** 1997 Feb;42(2):91–8

[Microbiologic cervix and amniotic fluid studies in early 2nd trimester: prognostic value for subsequent course of pregnancy?] Winkler M, et al. **Z Geburtshilfe Neonatol** 1996 Nov–Dec;200(6):213–7 (Eng. Abstr.) **(Ger)**

PARASITOLOGY

Interlaboratory comparison of polymerase chain reaction for the detection of Toxoplasma gondii DNA added to samples of amniotic fluid. Guy EC, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):836–9

The effect of sample storage on polymerase chain reaction-based detection of Toxoplasma gondii in amniotic fluids. Joss AW, et al. **J Med Microbiol** 1997 Jan;46(1):92–6

PHYSIOLOGY

Predicting poor neonatal outcome: a comparative study of noninvasive antenatal testing methods. Dubinsky T, et al. **AJR Am J Roentgenol** 1997 Mar;168(3):827–31

Effects of prolonged hypoxemia on fetal renal function and amniotic fluid volume in sheep. Cock ML, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):320–6

Mathematic modeling of human amniotic fluid dynamics. Mann SE, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):937–44

Amniotic fluid index predicts the relief of variable

decelerations after amnioinfusion bolus. Spong CY, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1066–7

Increase in ambient temperature may explain decrease in amniotic fluid index. Sciscione AC, et al. **Am J Perinatol** 1997 May;14(5):249–51

Residual amniotic fluid volume in preterm rupture of membranes: association with fetal presentation and incidence of clinical and histologic evidence of infection. Sherer DM, et al. **Am J Perinatol** 1997 Mar;14(3):125–8

Renal and amniotic fluid responses to umbilicoplacental embolization for 20 days in fetal sheep. Cock ML, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1094–102

Clearance of intra-amniotic lung surfactant: uptake and utilization by the fetal rabbit lung. Hallman M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):L55–63

Physiology of amniotic fluid volume regulation. Brace RA. **Clin Obstet Gynecol** 1997 Jun;40(2):280–9 (20 ref.)

Fetal swallowing: relation to amniotic fluid regulation. Ross MG, et al. **Clin Obstet Gynecol** 1997 Jun;40(2):352–65 (56 ref.)

Effect of amniotic fluid in corneal sensitivity and nerve regeneration after excimer laser ablation. Lee HS, et al. **Cornea** 1996 Sep;15(5):517–24

Esophageal ligation: effects on the development of fetal organic systems. Karnak I, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):328–33

Amniotic fluid index in South Indian pregnancies [letter] Mathai M, et al. **Int J Gynaecol Obstet** 1996 Mar; 52(3):287–8

Ovine fetal adaptations to chronically reduced urine flow: preservation of amniotic fluid volume. Mann SE, et al. **J Appl Physiol** 1996 Dec;81(6):2588–94

Amniotic fluid volume in spurious labour. Biswas A, et al. **J Obstet Gynaecol Res** 1997 Feb;23(1):63–7

Effect of the environment on fetal skin wound healing. Sancho MA, et al. **J Pediatr Surg** 1997 May;32(5):663–6

Maternal intravenous hydration and amniotic fluid index in patients with preterm ruptured membranes. Chelmow D, et al. **J Soc Gynecol Investig** 1996 May–Jun;3(3):127–30

The missing link in rhesus monkey amniotic fluid volume regulation: intramembranous absorption. Gilbert WM, et al. **Obstet Gynecol** 1997 Mar;89(3):462–5

Human amniotic fluid motogenic activity for fetal alveolar type II cells by way of hepatocyte growth factor. Itakura A, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):729–33

The analgesia-enhancing component of ingested amniotic fluid does not affect nicotine-induced antinociception in naltrexone-treated rats. Robinson-Vanderwerf TM, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):147–51

Use of low-frequency electrical impedance measurements to determine phospholipid content in amniotic fluid. De Luca F, et al. **Phys Med Biol** 1996 Sep;41(9):1863–9

Confirmation of fetal aneuploidy with primed in situ hybridization on amniotic fluid during selective fetal reduction [letter] Phillips OP, et al. **Prenat Diagn** 1997 Jun; 17(6):586–8

[Amniotic fluid—an important factor in fetal development (a review of the literature)] Khaidar A, et al. **Akush Ginekol (Sofiia)** 1996;35(4):28–30 (11 ref.) **(Bul)**

[Effect of amniotic fluid on cell differentiation in neural tissue culture in pathologic embryo development (anencephaly)] Bobryshev IuV, et al. **Biull Eksp Biol Med** 1996 Jul; 122(7):87–90 **(Rus)**

[Adrenomodulating effects of human blood, cerebrospinal fluid, urine, saliva, and amniotic fluid] Tsirkin VI, et al. **Dokl Akad Nauk** 1997 Jan;352(1):124–6 **(Rus)**

ULTRASONOGRAPHY

Ultrasonographic assessment of amniotic fluid does not reflect actual amniotic fluid volume. Chauhan SP, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):291–6; discussion 296–7

Amniotic fluid index estimation of amniotic fluid volume must be validated [letter; comment] Magann EF, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):757–8. Comment on: Am J Obstet Gynecol 1996 Mar;174(3):1003–7.

A randomised comparison between amniotic fluid index and maximum pool depth in the monitoring of post-term pregnancy. Alfirevic Z, et al. **Br J Obstet Gynaecol** 1997 Feb;104(2):207–11

Intrapartum amniotic fluid index and two-diameter pocket are poor predictors of adverse neonatal outcome. Chauhan SP, et al. **J Perinatol** 1997 May–Jun;17(3):221–4

Sonographic measurement of amniotic fluid volume in the first trimester of pregnancy. Weissman A, et al. **J Ultrasound Med** 1996 Nov;15(11):771–4

Amniotic fluid distribution in predicting perinatal outcome in patients with ruptured membranes. Myles TD, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):723–8

The effects of hemodialysis on total intrauterine volume. Brost BC, et al. **Ultrasound Obstet Gynecol** 1996 Jul; 8(1):34–6

Amniotic fluid index in twin gestation. Gerson A, et al. **Ultrasound Obstet Gynecol** 1997 Aug;10(2):98–102

Standards for the quantification of serial changes in the amniotic fluid index. Owen P, et al. **Ultrasound Obstet Gynecol** 1996 Dec;8(6):403–7

[Ultrasonographic density of amniotic fluid and its correlation with fetal pulmonary maturity] Romero-Gutiérrez G, et al. **Ginecol Obstet Mex** 1996 Jul;64:289–92 (Eng. Abstr.) **(Spa)**

VIROLOGY

Prenatal diagnosis of fetal cytomegalovirus infection in seropositive pregnant women. Kyriazopoulou V, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Nov;69(2):91–5

AMNIOTIC MEMBRANE DRESSINGS see BIOLOGICAL DRESSINGS

AMOBARBITAL

Semantic, phonological, and perceptual changes following left and right intracarotid injection (Wada) with a low amytal dosage. Fedio P, et al. **Brain Cogn** 1997 Feb; 33(1):98–117

Memory performance on the intracarotid amobarbital procedure as a predicator of seizure focus. Roman DD, et al. **Epilepsy Res** 1996 Nov;25(3):243–8

ADMINISTRATION & DOSAGE

Localization of language cortices by functional MR imaging compared with intracarotid amobarbital hemispheric sedation. Bahn MM, et al. **AJR Am J Roentgenol** 1997 Aug; 169(2):575–9

A reconsideration of bilateral language representation based on the intracarotid amobarbital procedure. Risse GL, et al. **Brain Cogn** 1997 Feb;33(1):118–32

Carotid angiography in conjunction with amytal testing of epilepsy patients. Silfvenius H, et al. **Brain Cogn** 1997 Feb; 33(1):33–49 (56 ref.)

Endovascular electroencephalography: the technique and its application during carotid amytal assessment. Boniface SJ, et al. **J Neurol Neurosurg Psychiatry** 1997 Feb;62(2):193–5

ADVERSE EFFECTS

Amobarbital memory testing: some personal reflections. Milner B. **Brain Cogn** 1997 Feb;33(1):14–7

Safety of amobarbital [letter; comment] McCall WV. **J Clin Psychiatry** 1997 Apr;58(4):175. Comment on: J Clin Psychiatry 1996 Mar;57(3):111–3.

ANALOGS & DERIVATIVES

HPLC analysis for amobarbital N-glycosides in urine. Nandi V, et al. **J Pharm Biomed Anal** 1997 May;15(8):1187–95

DIAGNOSTIC USE

Sequential injections of amobarbital sodium and lidocaine for provocative neurologic testing in the external carotid circulation. Deveikis JP. **AJNR Am J Neuroradiol** 1996 Jun–Jul;17(6):1143–7

Absence of neglect for mental representations during the intracarotid amobarbital procedure. Manoach DS, et al. **Arch Neurol** 1996 Apr;53(4):333–6

Cerebral hemispheric lateralization in cardiac autonomic control. Yoon BW, et al. **Arch Neurol** 1997 Jun;54(6):741–4

Sodium amobarbital memory tests: what do they predict? Dade LA, et al. **Brain Cogn** 1997 Mar;33(2):189–209

An exploratory comparison of three methods of memory assessment with the intracarotid amobarbital procedure. Dodrill CB, et al. **Brain Cogn** 1997 Mar;33(2):210–23

A reconsideration of bilateral language representation based on the intracarotid amobarbital procedure. Risse GL, et al. **Brain Cogn** 1997 Feb;33(1):118–32

Effect of focus lateralization on memory assessment during the intracarotid amobarbital procedure. Rouleau I, et al. **Brain Cogn** 1997 Mar;33(2):224–41

Carotid angiography in conjunction with amytal testing of epilepsy patients. Silfvenius H, et al. **Brain Cogn** 1997 Feb; 33(1):33–49 (56 ref.)

Reading errors following right hemisphere injection of sodium amobarbital. Schwartz TH, et al. **Brain Lang** 1997 Jun 1;58(1):70–91

Intracartotid amobarbital procedure memory performance and age at first risk for seizures distinguish between lateral neocortical and mesial temporal lobe epilepsy. Hamberger MJ, et al. **Epilepsia** 1996 Nov;37(11):1088–92

Effect of Wada memory stimulus type in discriminating lateralized temporal lobe impairment. Loring DW, et al. **Epilepsia** 1997 Feb;38(2):219–24

Wada memory and timing of stimulus presentation. Loring DW, et al. **Epilepsy Res** 1997 Mar;26(3):461–4

Safety of amobarbital [letter; comment] McCall WV. **J Clin Psychiatry** 1997 Apr;58(4):175. Comment on: J Clin Psychiatry 1996 Mar;57(3):111–3.

Individual patient prediction of seizure lateralization in temporal lobe epilepsy: a comparison between neuropsychological memory measures and the Intracarotid Amobarbital Procedure. Kneebone AC, et al. **J Int Neuropsychol Soc** 1997 Mar;3(2):159–68

Lateralization of memory for music: evidence from the intracarotid sodium amobarbital procedure. Plenger PM, et al. **Neuropsychologia** 1996 Oct;34(10):1015–8

Superselective intra-arterial amytal (Wada test) in temporal lobe epilepsy: basics for neuroradiological investigations. Brassel F, et al. **Neuroradiology** 1996 Jul;38(5):417–21

A proposed modification of the Wada test for presurgical assessment in temporal lobe epilepsy. Weissenborn K, et al. **Neuroradiology** 1996 Jul;38(5):422–9

Memory for objects presented early after intracarotid sodium amytal: a sensitive clinical neuropsychological indicator of temporal lobe pathology. Carpenter K, et al. **Seizure** 1996 Jun;5(2):103–8

[Super selective amytal test for functional evaluation of the brain—a less invasive functional test] Kinoshita Y, et al. **No To Shinkei** 1996 Dec;48(12):1121–5 (Eng. Abstr.) **(Jpn)**

HISTORY

The intracarotid amobarbital procedure: an historical perspective. Snyder PJ, et al. **Brain Cogn** 1997 Feb; 33(1):18–32

PHARMACOKINETICS

HPLC analysis for amobarbital N-glycosides in urine. Nandi V, et al. **J Pharm Biomed Anal** 1997 May;15(8):1187–95

PHARMACOLOGY

Clinical and research contributions of the intracarotid amobarbital procedure to neuropsychology. Jones-Gotman M, et al. **Brain Cogn** 1997 Feb;33(1):1–6 (20 ref.)

Assessment of the functional effect of the intracarotid sodium amobarbital procedure using co-registered MRI/HMPAO-SPECT and SEEG. McMackin D, et al. **Brain Cogn** 1997 Feb;33(1):50–70

Level of consciousness and memory during the intracarotid sodium amobarbital procedure. Meador KJ, et al. **Brain Cogn** 1997 Mar;33(2):178–88

Amobarbital memory testing: some personal reflections. Milner B. **Brain Cogn** 1997 Feb;33(1):14–7

Effects of hemisphere speech dominance and seizure focus on patterns of behavioral response errors for three types of stimuli. Rausch R, et al. **Brain Cogn** 1997 Mar; 33(2):161–77

Serial recovery of language during the intracarotid amobarbital procedure. Ravdin LD, et al. **Brain Cogn** 1997 Mar;33(2):151–60

Clinical experimental observations of carotid artery injections of sodium amytal. Wada JA. **Brain Cogn** 1997 Feb; 33(1):11–3

The anterior and posterior selective temporal lobe amobarbital tests: angiographic, clinical, electroencephalographic, PET, SPECT findings, and memory performance. Wieser HG, et al. **Brain Cogn** 1997 Feb;33(1):71–97

The mechanisms of the ocular autonomic dysfunction during the intracarotid amytal suppression test. DeToledo JC, et al. **Epilepsy Res** 1997 Jan;26(2):309–13

Episodic memory dysfunction during sodium amytal testing of epileptic patients in relation to posterior cerebral artery perfusion. Morton N, et al. **J Clin Exp Neuropsychol** 1996 Feb;18(1):24–37

Cardiac pump function of the isolated rat heart at two modes of energy deprivation and effect of adrenergic stimulation. Kapelko VI, et al. **Mol Cell Biochem** 1996 Oct–Nov; 163–164:131–6

Effect of intravenous sodium amytal on cutaneous limb temperatures and sympathetic skin responses in normal subjects and pain patients with and without Complex Regional Pain Syndromes (type I and II). I. Mailis A, et al. **Pain** 1997 Mar;70(1):59–68

THERAPEUTIC USE

Effect of intravenous sodium amytal on cutaneous sensory abnormalities, spontaneous pain and algometric pain pressure thresholds in neuropathic pain patients: a placebo-controlled study. II. Mailis A, et al. **Pain** 1997 Mar;70(1):69–81

AMODIAQUINE

ANALOGS & DERIVATIVES

Manipulation of the N-alkyl substituent in amodiaquine to overcome the verapamil-sensitive chloroquine resistance component. Hawley SR, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2345–9

Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. Naisbitt DJ, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):884–93

BLOOD

Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. Naisbitt DJ, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):884–93

METABOLISM

Amodiaquine accumulation in Plasmodium falciparum as a possible explanation for its superior antimalarial activity over chloroquine. Hawley SR, et al. **Mol Biochem Parasitol** 1996 Sep;80(1):15–25

4-Aminoquinoline resistance of Plasmodium falciparum: insights from the study of amodiaquine uptake. Bray PG, et al. **Mol Pharmacol** 1996 Dec;50(6):1551–8

PHARMACOKINETICS

[Pharmacokinetics of rectal absorption of amodiaquine in rabbits] Blum Z, et al. **Acta Pharm Hung** 1997 Jan;67(1):3–8 (Eng. Abstr.) **(Hun)**

AMODIAQUINE

PHARMACOLOGY

Manipulation of the N-alkyl substituent in amodiaquine to overcome the verapamil-sensitive chloroquine resistance component. Hawley SR, et al.
Antimicrob Agents Chemother 1996 Oct;40(10):2345-9

Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Duraisingh MT, et al. **Parasitology** 1997 Mar; 114 (Pt 3):205-11

THERAPEUTIC USE

Amodiaquine [letter; comment] Bloland PB, et al. **Lancet** 1996 Dec 14;348(9042):1659-60. Comment on: Lancet 1996 Nov 2;348(9036):1196-201.

Systematic review of amodiaquine treatment in uncomplicated malaria [see comments] Olliaro P, et al. **Lancet** 1996 Nov 2;348(9036):1196-201 (15 ref.). Comment in: Lancet 1996 Nov 2;348(9036):1184-5. Comment in: Lancet 1996 Dec 14;348(9042):1659-60.

Can amodiaquine be resurrected? [comment] White NJ. **Lancet** 1996 Nov 2;348(9036):1184-5. Comment on: Lancet 1996 Nov 2;348(9036):1196-201.

AMOEBA

see related
AMEBICIDES

CLASSIFICATION

Free-living, amphizoic and opportunistic amebas. Martinez AJ, et al. **Brain Pathol** 1997 Jan;7(1):583-98 (100 ref.)

CYTOLOGY

A Ca(2+)-dependent early functional heterogeneity in amoebae of Dictyostelium discoideum, revealed by flow cytometry. Azhar M, et al. **Exp Cell Res** 1996 Sep 15; 227(2):344-51

[The cell biology of amebas and ameba-flagellates--parasites of man and animals] Sopina VA. **Tsitologiia** 1997; 39(4-5):361-86 (126 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Cytotoxicity of polyamines to Amoeba proteus: role of polyamine oxidase. Schenkel E, et al. **Cell Biol Toxicol** 1996 Feb;12(1):1-9

ENZYMOLOGY

Cytotoxicity of polyamines to Amoeba proteus: role of polyamine oxidase. Schenkel E, et al. **Cell Biol Toxicol** 1996 Feb;12(1):1-9

Evidence for symbiont-induced alteration of a host's gene expression: irreversible loss of SAM synthetase from Amoeba proteus. Choi JY, et al. **J Eukaryot Microbiol** 1997 Sep-Oct;44(5):412-9

GENETICS

The miniaturized nuclear genome of eukaryotic endosymbiont contains genes that overlap, genes that are cotranscribed, and the smallest known spliceosomal introns. Gilson PR, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23; 93(15):7737-42

Substitution rate calibration of small subunit ribosomal RNA identifies chlorarachniophyte endosymbionts as remnants of green algae. Van de Peer Y, et al.
Proc Natl Acad Sci U S A 1996 Jul 23;93(15):7732-6

GROWTH & DEVELOPMENT

[Patterns in the growth and functioning of single-cell organisms under conditions of altered gravitational force] Tairbekov MG, et al. **Izv Akad Nauk Ser Biol** 1997 May-Jun;(3):266-73 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Quantification and isotype analysis of the serum anti-amebic antibody response produced after mucosal and systemic immunization in male and female mice. Moreno-Fierros L, et al. **Folia Biol (Praha)** 1996;42(3):99-103

ISOLATION & PURIFICATION

Granulomatous amebic encephalitis due to Balamuthia mandrillaris (Leptomyxiidae): report of four cases from Mexico. Riestra-Castaneda JM, et al.
Am J Trop Med Hyg 1997 Jun;56(6):603-7

Free living amoebae as opportunistic parasites in immunocompromised hosts. el-Fakahany AF, et al.
J Egypt Soc Parasitol 1997 Aug;27(2):515-27

METABOLISM

Unusual distribution of gamma-tubulin in the giant fresh water amoeba Reticulomyxa filosa. Kube-Granderath E, et al. **Eur J Cell Biol** 1997 Apr;72(4):287-96

MICROBIOLOGY

Interaction of Mycobacterium avium with environmental amoebae enhances virulence. Cirillo JD, et al.
Infect Immun 1997 Sep;65(9):3759-67

PHYSIOLOGY

Intracellular pressure is a motive force for cell motion in Amoeba proteus. Yanai M, et al.
Cell Motil Cytoskeleton 1996;33(1):22-9

AMOEBIASIS see **AMEBIASIS**

AMOSITE ASBESTOS see **ASBESTOS, AMOSITE**

AMOXICILLIN

ADMINISTRATION & DOSAGE

A study on prophylactic antibiotics in cesarean sections--is it worthwhile? Yip SK, et al.
Acta Obstet Gynecol Scand 1997 Jul;76(6):547-9

Enhanced eradication of Helicobacter pylori by pre- versus post-prandial amoxycillin suspension with omeprazole: implications for antibiotic delivery. Atherton JC, et al.
Aliment Pharmacol Ther 1996 Aug;10(4):631-5

Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. Labenz J, et al.
Aliment Pharmacol Ther 1997 Feb;11(1):95-100

Antimicrobial liquid formulations: a blind taste comparison of three brands of penicillin VK and three brands of amoxicillin. Chan DS, et al. **Ann Pharmacother** 1996 Feb; 30(2):130-2

Comparative study of once-weekly azithromycin and once-daily amoxicillin treatments in prevention of recurrent acute otitis media in children. Marchisio P, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2732-6

Omeprazole plus amoxicillin versus triple therapy eradicates Helicobacter pylori in the Chinese with peptic ulcer disease. Wang K, et al.
Chung Hua I Hsueh Tsa Chih (Taipei) 1996 Mar; 57(3):184-90

Tonsillar diffusion kinetics of amoxycillin after oral administration of 1 g to adults. Chomarat M, et al.
Eur J Drug Metab Pharmacokinet 1997 Apr-Jun; 22(2):141-4

Eradication of Helicobacter pylori in peptic ulcer disease with amoxycillin, 2.0 g, and omeprazole, 80 or 120 mg: a prospective randomized trial. Fleischmann R, et al.
Eur J Gastroenterol Hepatol 1997 Jun;9(6):593-8

Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Yamada M, et al.
Eur J Pediatr 1997 Mar;156(3):182-5

Efficacy of twice-daily dosing of amoxycillin/clavulanate in acute otitis media in children. Behre U, et al.
Infection 1997 May-Jun;25(3):163-6

One-week therapy for Helicobacter pylori. A randomized trial of two treatment regimens. Scheiman JM, et al.
J Clin Gastroenterol 1996 Oct;23(3):170-3

6-day amoxicillin vs 10-day penicillin V for GABHS. Bramson R. **J Fam Pract** 1997 Mar;44(3):241-2

Sustained-release microcapsules of nitrofurantoin and amoxicillin; preparation, in-vitro release rate, kinetic and micromeritic studies. Ertan G, et al. **J Microencapsul** 1997 May-Jun;14(3):379-88

Triple therapy in duodenal ulcer healing--a follow up study. Qureshi H, et al. **JPMA J Pak Med Assoc** 1996 Sep; 46(9):194-5

Six-day amoxicillin vs. ten-day penicillin V therapy for group A streptococcal tonsillopharyngitis. Cohen R, et al.
Pediatr Infect Dis J 1996 Aug;15(8):678-82

Continuous twice daily or once daily amoxicillin prophylaxis compared with placebo for children with recurrent acute otitis media. Roark R, et al. **Pediatr Infect Dis J** 1997 Apr; 16(4):376-81

Five day and ten day triple therapy (amoxicillin, furazolidone and metronidazole) in the treatment of duodenal ulcer. Zaterka S, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Sep-Oct;51(5):162-5

Galenic formulations and Helicobacter pylori eradication [letter; comment] Boixeda D, et al.
Scand J Gastroenterol 1996 Jul;31(7):736. Comment on: Scand J Gastroenterol 1996 Jan;31(1):49-53.

[Triple ranitidine therapy in Helicobacter pylori infection. Recommendation for effective, safe and cost effective combination for Helicobacter pylori eradication] Miederer S. **Fortschr Med** 1996 Nov 30;114(33):460-2 (Eng. Abstr.) **(Ger)**

[Helicobacter pylori eradication therapy with bismuth citrate/amoxycillin combination therapy] Stanescu A, et al. **Leber Magen Darm** 1996 Jan;26(1):32-6 (Eng. Abstr.) **(Ger)**

[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment] Tokushima H, et al. **Nippon Jinzo Gakkai Shi** 1996 Aug;38(8):349-55 (Eng. Abstr.) **(Jpn)**

[A case of gastric MALT lymphoma regressed endoscopically and pathologically after eradication of Helicobacter pylori] Seko A, et al.
Nippon Shokakibyo Gakkai Zasshi 1997 Jan;94(1):21-6 **(Jpn)**

[One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer] Gisbert JP, et al. **Med Clin (Barc)** 1997 Apr 12;108(14):524-9 (Eng. Abstr.) **(Spa)**

[The efficacy of using a short course of 6-day duration (OCA-6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin (letter)] Rodrigo Sáez L, et al. **Rev Esp Enferm Dig** 1997 Feb; 89(2):146-7 **(Spa)**

[Eradication of Helicobacter pylori in patients with recurrent abdominal pain using a triple drug treatment] Ramírez Mayans J, et al. **Rev Gastroenterol Mex** 1996 Oct-Dec; 61(4):310-3 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes. Barbaud AM, et al. **Arch Dermatol** 1997 Apr;133(4):481-6

Acute liver injury associated with amoxicillin-clavulanic acid [letter; comment] Fletcher AP, et al. **Arch Intern Med** 1997 Feb 10;157(3):358. Comment on: Arch Intern Med 1996 Jun 24;156(12):1327-32.

Delayed allergic reactions to amoxycillin and clindamycin. García R, et al. **Contact Dermatitis** 1996 Aug;35(2):116-7

Bullous pemphigoid-like lesions induced by amoxicillin. Miralles J, et al. **Int J Dermatol** 1997 Jan;36(1):42-7

Intrahepatic cholestasis without hepatitis induced by amoxycillin/clavulanic acid. Pedro-Botet J, et al.
J Clin Gastroenterol 1996 Sep;23(2):137-8

Adverse hepatic events associated with drug therapy [letter] Hewitt J, et al. **Med J Aust** 1996 Sep 16;165(6):347, 350

Amoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses. Bandrowsky T, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Dec;82(6):610-2

Prospective study of toxigenic Clostridium difficile in children given amoxicillin/clavulanate for otitis media. Mitchell DK, et al. **Pediatr Infect Dis J** 1996 Jun; 15(6):514-9

Acute renal failure associated with amoxicillin and ibuprofen in an 11-year-old boy [letter] Primack WA, et al.
Pediatr Nephrol 1997 Feb;11(1):125-6

[Unusual clinical form of amoxicillin allergy] Drouet M, et al. **Allerg Immunol (Paris)** 1996 Nov;28(9):311-2 **(Fre)**

[Lyell syndrome after amoxicillin administration in a 2 year old child] Surbled M, et al. **Ann Fr Anesth Reanim** 1996; 15(7):1095-8 (Eng. Abstr.) **(Fre)**

[Hepatitis caused by the amoxicillin-clavulanic acid combination. An example of drug-induced biliary hepatotoxicity] Bralet MP, et al. **Ann Pathol** 1996 Dec; 16(6):425-9 (Eng. Abstr.) **(Fre)**

[Toxic megacolon after Helicobacter pylori eradication therapy] Schweigart U, et al. **Internist (Berl)** 1997 Apr; 38(4):352-4 **(Ger)**

[Changes in the blood picture with combination carbamazepine, perazine and antibiotic treatment] Volkmann GS, et al. **Psychiatr Prax** 1996 Nov;23(6):304-5 **(Ger)**

[Generalized acute exanthematous pustulosis: two case reports] Gibert Agulló A, et al. **An Esp Pediatr** 1997 Mar; 46(3):285-7 **(Spa)**

[Cholestatic hepatitis caused by amoxycillin-clavulanic acid. Report of a new case] Bustamante Balén M, et al.
Gastroenterol Hepatol 1997 Apr;20(4):187-9 (14 ref.) (Eng. Abstr.) **(Spa)**

[Hepatotoxicity caused by amoxicillin, clavulanic acid or both? (letter) (see comments)] Caballero Plasencia AM, et al. **Gastroenterol Hepatol** 1997 Jan;20(1):45-6. Comment in: Gastroenterol Hepatol 1997 Jun-Jul;20(6):337-8. **(Spa)**

[Hepatotoxicity caused by amoxicillin-clavulanic acid (letter; comment)] Reñe JM, et al. **Gastroenterol Hepatol** 1997 Jun-Jul;20(6):337-8. Comment on: Gastroenterol Hepatol 1997 Jan;20(1):45-6. **(Spa)**

ANALYSIS

Ampicillin and amoxicillin residue detection in milk, using microbial receptor assay (Charm II) and liquid chromatography methods, after extra-label administration of the drugs to lactating cows. Anderson KL, et al.
Am J Vet Res 1996 Jan;57(1):73-8

Determination of amoxicillin in catfish and salmon tissues by liquid chromatography with precolumn formaldehyde derivatization. Ang CYW, et al. **J AOAC Int** 1996 Mar-Apr;79(2):389-96

Sensitive assay for measuring amoxicillin in human plasma and middle ear fluid using solid-phase extraction and reversed-phase high-performance liquid chromatography. Yuan Z, et al. **J Chromatogr B Biomed Appl** 1995 Dec 1;674(1):93-9

Investigation of a new amoxicillin sodium impurity unstable in solution. Valvo L, et al. **J Pharm Biomed Anal** 1997 Jan;15(4):487-93

BLOOD

Improved high-performance liquid chromatographic determination of amoxicillin in human plasma by means of column switching. Muth P, et al. **J Chromatogr A** 1996 Apr 5;729(1-2):259-66

Sensitive assay for measuring amoxicillin in human plasma and middle ear fluid using solid-phase extraction and reversed-phase high-performance liquid chromatography. Yuan Z, et al. **J Chromatogr B Biomed Appl** 1995 Dec 1;674(1):93-9

Analysis of amoxycillin in bustard plasma by high-performance liquid chromatography after administration of a long-acting formulation. Bailey TA, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):313-5

IMMUNOLOGY

Drug allergy to the beta-lactam antibiotics clavulanic acid and amoxicillin. Cahen YD, et al. **Allergy** 1997 Jan; 52(1):117-8

Clinical cross-reactivity between amoxicillin and cephadroxil in patients allergic to amoxicillin and with good tolerance of penicillin. Sastre J, et al. **Allergy** 1996 Jun;51(6):383-86

Anaphylaxis to penicillins after non-therapeutic exposure: an immunological investigation. Blanca M, et al. **Clin Exp Allergy** 1996 Mar;26(3):335-40

ISOLATION & PURIFICATION

Determination of penicillins in animal tissues at trace residue concentrations: II. Determination of amoxicillin and ampicillin in liver and muscle using cation exchange and porous graphitic carbon solid phase extraction and high-performance liquid chromatography. Rose MD, et al. **Food Addit Contam** 1997 Feb-Mar;14(2):127-33

METABOLISM

High-performance liquid chromatographic analysis of amoxicillin in human and chinchilla plasma, middle ear fluid and whole blood. Yuan Z, et al. **J Chromatogr B Biomed Appl** 1997 May 9;692(2):361-6

PHARMACOKINETICS

Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects. Pommerien W, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):295-301

Pharmacokinetics of amoxicillin/clavulanic acid combination and of both drugs alone after intravenous administration to goats. Escudero E, et al. **Br Vet J** 1996 Sep;152(5):551-9

Study of the pharmacokinetic interaction between ethinylestradiol and amoxicillin in rabbits. Fernández N, et al. **Contraception** 1997 Jan;55(1):47-52

Tonsillar diffusion kinetics of amoxycillin after oral administration of 1 g to adults. Chomarat M, et al. **Eur J Drug Metab Pharmacokinet** 1997 Apr-Jun; 22(2):141-4

Pharmacokinetics of a new oral formulation of amoxicillin. Prevot MH, et al. **Eur J Drug Metab Pharmacokinet** 1997 Jan-Mar;22(1):47-52

Effect of Khat chewing on the bioavailability of ampicillin and amoxycillin. Attef OA, et al. **J Antimicrob Chemother** 1997 Apr;39(4):523-5

Modeling of drug release from erodible tablets. Katzhendler I, et al. **J Pharm Sci** 1997 Jan;86(1):110-5

Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Seikel K, et al. **Pediatr Infect Dis J** 1997 Jul;16(7):710-1

Gastrointestinal transit of amoxicillin modified-release tablets and a placebo tablet including pharmacokinetic assessments of amoxicillin [see comments] Gottfries J, et al. **Scand J Gastroenterol** 1996 Jan;31(1):49-53. Comment in: Scand J Gastroenterol 1996 Jul;31(7):736.

PHARMACOLOGY

Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects. Pommerien W, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):295-301

Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumococcal strains: a phase I study. Aguilar L, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1389-91

In vitro assessment of the effect of clavulanic acid at concentrations achieved in human serum on the bactericidal activity of amoxicillin at physiological concentrations against Staphylococcus aureus: implications for dosage regimens. Aguilar L, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1403-5

Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: in vitro pharmacodynamic simulation. Balcabao IP, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2904-6

In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. Meyer JM, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1607-8

Is bactericidal activity of amoxicillin against Helicobacter pylori concentration dependent? [letter; comment] Midolo PD, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1327-8. Comment on: Antimicrob Agents Chemother 1995 Aug;39(8):1859-61.

Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate. Thorburn CE, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2796-801

Evaluation of Haemophilus influenzae isolates with elevated MICs to amoxicillin/clavulanic acid. Jacobs MR, et al. **Diagn Microbiol Infect Dis** 1997 Jul;28(3):105-12

Potentiation of human polymorphonuclear leukocyte phagocytosis and intracellular bactericidal activity by amoxycillin/clavulanic acid. Cuffini AM, et al. **Drugs Exp Clin Res** 1996;22(1):9-15

In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori. Alarcón T, et al. **Eur J Clin Microbiol Infect Dis** 1996 Dec;15(12):937-40

Bactericidal effect of sparfloxacin alone and in combination with amoxicillin against Streptococcus pneumoniae as determined by kill-kinetic studies. Barakett V, et al. **Infection** 1996 Jan-Feb;24(1):22-5

Potential effects of amoxycillin/clavulanic acid and ticarcillin/clavulanic acid on human granulocyte activity: a comparative study. Cuffini AM, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1013-22

Effects of omeprazole and amoxycillin on the human oral and gastrointestinal microflora in patients with Helicobacter pylori infection. Stark CA, et al. **J Antimicrob Chemother** 1996 Dec;38(6):927-39

Activity of amoxicillin, metronidazole, bismuth salicylate and six aminoglycosides against Helicobacter pylori. Brenciaglia MI, et al. **J Chemother** 1996 Feb;8(1):52-4

Correlation of in vitro susceptibility results for amoxicillin-clavulanate and ampicillin-sulbactam tested against Escherichia coli. O'Shaughnessy EM, et al. **J Clin Microbiol** 1997 Jul;35(7):1902-3

Amoxicillin for the treatment of Helicobacter pylori infection. Hirschl AM, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:44-7

Correlation between in vitro and in vivo activity of amoxicillin against Streptococcus pneumoniae in a murine pneumonia model. Moine P, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):310-5

The antibacterial activity of amoxycillin/clavulanic acid against Staphylococcus aureus ingested by human granulocytes. Cuffini AM, et al. **Microbios** 1996; 87(350):31-8

Choice of an oral beta-lactam antibiotic for infections due to penicillin-resistant Streptococcus pneumoniae. Goldstein FW. **Scand J Infect Dis** 1997;29(3):255-7

[Neisseria meningitidis with limited sensitivity to ampicillin-amoxicillin combination (letter)] Boize P, et al. **Arch Pediatr** 1997 Jan;4(1):97-8 **(Fre)**

[Resistance to amoxicillin and amoxicillin-clavulanic acid combination of 231 clinical strains of Escherichia coli, isolated in 1992 at the Cochin Hospital] Bémer-Melchior P, et al. **Pathol Biol (Paris)** 1995 Nov;43(9):760-5 (Eng. Abstr.) **(Fre)**

[Amoxicillin and Streptococcus pneumoniae] Soriano F, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):267 **(Spa)**

[Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid] Villar HE, et al. **Enferm Infecc Microbiol Clin** 1996 May;14(5):308-10 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. Bell GD, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):637-44

Successful low-dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole-resistant Helicobacter pylori. Breuer T, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):523-7

Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. Cammarota G, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):997-1000

Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients. Kato M, et al. **Aliment Pharmacol Ther** 1996 Oct; 10(5):821-7

Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. Labenz J, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):515-22

Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Laine L, et al. **Aliment Pharmacol Ther** 1996 Dec; 10(6):1029-33

Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. Lim AG, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):537-40

High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection. Malaty H, et al. **Aliment Pharmacol Ther** 1996 Dec; 10(6):1001-4

Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. Pommerien W, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):303-8

Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Segura AM, et al. **Aliment Pharmacol Ther** 1997 Jun;11(3):529-32

One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. Yousfi MM, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):617-21

Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Barlan IB, et al. **Ann Allergy Asthma Immunol** 1997 Jun;78(6):598-601

Therapeutic aspects of typhoidal salmonellosis in childhood: the Karachi experience. Bhutta ZA. **Ann Trop Paediatr** 1996 Dec;16(4):299-306

Development of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime, and meropenem. Ponte C, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2698-702

Efficacy of ebrotidine and ranitidine combined with amoxicillin and metronidazole in the eradication of Helicobacter pylori in patients with duodenal ulcer. Popiela T, et al. **Arzneimittelforschung** 1997 Apr;47(4A):573-7

Omeprazole, amoxicillin and bismuth for peptic ulcer healing and Helicobacter pylori eradication. Treiber G, et al. **Arzneimittelforschung** 1997 Jan;47(1):47-50

Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. Axon AT, et al. **BMJ** 1997 Feb 22; 314(7080):565-8

Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections. MacFarlane JT, et al. **Br J Gen Pract** 1996 Jun; 46(407):357-60

Comparison of ceftibuten versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Aubier MA. **Chemotherapy** 1997 Jul-Aug;43(4):297-302

Prophylaxis with amoxicillin or sulfisoxazole for otitis media: effect on the recovery of penicillin-resistant bacteria from children. Brook I, et al. **Clin Infect Dis** 1996 Jan;22(1):143-5

Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group. Calver AD, et al. **Clin Infect Dis** 1997 Apr;24(4):570-4

Comparative evaluation of cefixime versus amoxicillin-clavulanate following ceftriaxone therapy of pneumonia. Amir J, et al. **Clin Pediatr (Phila)** 1996 Dec; 35(12):629-33

Clinical application of gastric histology to monitor treatment of dual therapy in H. pylori eradication. Yang HB, et al. **Dig Dis Sci** 1997 Sep;42(9):1835-40

Cefdinir versus amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children. Adler M, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):214-9

Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study [see comments] Bayerdörffer E, et al. **Eur J Gastroenterol Hepatol** 1996 Apr;8(4):343-9. Comment in: Eur J Gastroenterol Hepatol 1996 Apr;8(4):333-4.

Clarithromycin or amoxycillin plus high-dose ranitidine in the treatment of Helicobacter pylori-positive functional dyspepsia. Schütze K, et al. **Eur J Gastroenterol Hepatol** 1996 Jan;8(1):41-6

Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Sackmann M, et al. **Gastroenterology** 1997 Oct;113(4):1087-90

A randomised study on the impact of peroral amoxicillin in women with prelabour rupture of membranes preterm. Almeida L, et al. **Gynecol Obstet Invest** 1996;41(2):82-4

Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. Soriano F, et al. **J Antimicrob Chemother** 1996 Aug;38(2):227-36

Prophylactic administration of amoxicillin and clavulanic acid in pregnant women with premature rupture of the membranes. Tampakoudis P, et al. **J Chemother** 1996 Aug; 8(4):290-4

Is amoxicillin beneficial in acute maxillary sinusitis? Zamorski M. **J Fam Pract** 1997 Jul;45(1):22-3

Significant increase in eradication rates of Helicobacter pylori infection with two consecutive dual therapies (omeprazole and amoxycillin or omeprazole and clarithromycin). A randomized study in 450 Spanish patients. Moreno JA, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:48-52

Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection. Hazell SL, et al. **J Gastroenterol Hepatol** 1997 Feb;12(2):93-9

Is amoxicillin-cotrimoxazole the most appropriate antibiotic regimen for listeria meningoencephalitis? Review of 22 cases and the literature. Merle-Melet M, et al. **J Infect** 1996 Sep;33(2):79-85

Antibiotic treatment in acute bacterial sinusitis [letter; comment] Philpot CR. **Lancet** 1997 May 17;349(9063):1476; discussion 1476-7. Comment on: Lancet 1997 Mar 8;349(9053):683-7.

Primary-care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis [see comments] van Buchem FL, et al. **Lancet** 1997 Mar 8; 349(9053):683-7. Comment in: Lancet 1997 May 17;349(9063):1476; discussion 1476-7.

A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. Rolfs RT, et al. **N Engl J Med** 1997 Jul 31;337(5):307-14

Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis [letter] Tucci A, et al. **N Engl J Med** 1997 Mar 27;336(13):957-8

Efficacy of antimicrobial prophylaxis for recurrent middle

AMOXICILLIN

ear effusion. Mandel EM, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1074–82

Efficacy of ceftibuten compared with amoxicillin for otitis media with effusion in infants and children. Mandel EM, et al. **Pediatr Infect Dis J** 1996 May;15(5):409–14

Prospective study of toxigenic Clostridium difficile in children given amoxicillin/clavulanate for otitis media. Mitchell DK, et al. **Pediatr Infect Dis J** 1996 Jun; 15(6):514–9

Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics. Solcia E, et al. **Scand J Gastroenterol Suppl** 1996;215:105–10

6–day amoxicillin versus 10–day penicillin V for group A beta–haemolytic streptococcal acute tonsillitis in adults: a French multicentre, open–label, randomized study. The French Study Group Clamorange. Peyramond D, et al. **Scand J Infect Dis** 1996;28(5):497–501

Cefuroxime compared to amoxicillin–clavulanic acid in the treatment of community–acquired pneumonia [see comments] Oh HM, et al. **Singapore Med J** 1996 Jun; 37(3):255–7. Comment in: Singapore Med J 1997 Mar;38(3):139.

Development of duodenal ulcer concomitant with successful Helicobacter pylori eradication. Pohle T, et al. **Z Gastroenterol** 1997 Jul;35(7):563–5

[Clarithromycin versus amoxicillin–clavulanic acid in the treatment of acute maxillary sinusitis in adults] Géhanno P, et al. **Pathol Biol (Paris)** 1996 Apr;44(4):293–7 (Eng. Abstr.) **(Fre)**

[Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer] Kayser S, et al. **Schweiz Med Wochenschr** 1997 Apr 26;127(17):722–7 (Eng. Abstr.) **(Ger)**

[Helicobacter pylori: pretherapeutic resistance status in Germany (Ruhr area)] Tillenburg B, et al. **Z Gastroenterol** 1997 Mar;35(3):165–9 (Eng. Abstr.) **(Ger)**

[Effect of treatment with lansoprazole and amoxicillin in combination on healing process of duodenal ulcer] Maruyama M. **Nippon Ika Daigaku Zasshi** 1996 Oct; 63(5):349–55 (Eng. Abstr.) **(Jpn)**

[The treatment of children with Helicobarter pylory by triple therapy can be shortened without the risk of losing it eradicating efficacy. Letter] Cilleruelo ML, et al. **An Esp Pediatr** 1996 Nov;45(5):550 **(Spa)**

[Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients] Gisbert JP, et al. **Rev Clin Esp** 1996 Sep;196(9):588–93 (Eng. Abstr.) **(Spa)**

AMP see ADENOSINE MONOPHOSPHATE

AMP AMINASE see AMP DEAMINASE

AMP DEAMINASE

BIOSYNTHESIS

Protective effect of adenylate deaminase (from Penicillium lanoso–viride) against acute infections in mice. Nikolajeva V, et al. **Immunopharmacology** 1996 Nov;35(2):163–9

CHEMISTRY

Association of purified skeletal–muscle AMP deaminase with a histidine–proline–rich–glycoprotein–like molecule. Ranieri–Raggi M, et al. **Biochem J** 1997 Sep 15;326 (Pt 3):641–8

AMP–deaminases from chicken and rabbit muscle: partial primary sequences of homologous 17–kDa CNBr fragments: autorecognition by rabbit anti–[chicken AMPD] Chilson OP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Mar; 116(3):371–7

[Modification of the histidine in rat skeletal muscle deaminase by diethylpyrocarbonate] Mardanian SS, et al. **Biokhimiia** 1996 Oct;61(10):1751–7 (Eng. Abstr.) **(Rus)**

DEFICIENCY

Myoadenylate deaminase deficiency myopathy in pregnancy. Bellver J, et al. **Arch Gynecol Obstet** 1997;259(3):157–9

Tension myalgia versus myoadenylate deaminase deficiency: a case report. Marin R, et al. **Arch Phys Med Rehabil** 1997 Jan;78(1):95–7

Beneficial effect of a treatment with xylitol in a patient with myoadenylate deaminase deficiency [letter] Bruyland M, et al. **Clin Neuropharmacol** 1994 Oct;17(5):492–3

Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency. Gross M. **J Inherit Metab Dis** 1997 Jun;20(2):186–92 (30 ref.)

GENETICS

Cloning and expression of cDNA encoding heart–type isoform of AMP deaminase. Wang X, et al. **Gene** 1997 Apr 1;188(2):285–90

Subunit composition of AMPD varies in response to changes in AMPD1 and AMPD3 gene expression in skeletal muscle. Fortuin FD, et al. **Proc Assoc Am Physicians** 1996 Jul; 108(4):329–33

IMMUNOLOGY

AMP–deaminases from chicken and rabbit muscle: partial primary sequences of homologous 17–kDa CNBr fragments: autorecognition by rabbit anti–[chicken AMPD] Chilson OP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Mar; 116(3):371–7

METABOLISM

Creatine analogue beta–guanidinopropionic acid alters skeletal muscle AMP deaminase activity. Tullson PC, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C76–85

Regulation of rat AMP deaminase 3 (isoform C) by development and skeletal muscle fibre type. Mahnke–Zizelman DK, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):521–9

Adenosine–5'–phosphate deaminase. A novel herbicide target. Dancer JE, et al. **Plant Physiol** 1997 May; 114(1):119–29

Activation of AMP deaminase in human erythrocytes by calcium ions. Engström I, et al. **Scand J Clin Lab Invest** 1996 Jul;56(4):345–50

Inosine monophosphate accumulation in energy–deficient human skeletal muscle with reference to substrate availability, fibre types and AMP deaminase activity. Norman B. **Scand J Clin Lab Invest** 1995 Dec;55(8):733–41

[Solubilization of the AMP deaminase in the muscles of the teleost fish Scorpaena] Smirnova IuD, et al. **Ukr Biokhim Zh** 1996 Mar–Apr;68(2):63–8 (Eng. Abstr.) **(Ukr)**

THERAPEUTIC USE

Protective effect of adenylate deaminase (from Penicillium lanoso–viride) against acute infections in mice. Nikolajeva V, et al. **Immunopharmacology** 1996 Nov;35(2):163–9

5'–AMP NUCLEOTIDASE see 5'–NUCLEOTIDASE

AMP PHOSPHATASE see 5'–NUCLEOTIDASE

AMP PYROPHOSPHORYLASE see ADENINE PHOSPHORIBOSYLTRANSFERASE

AMPA see ALPHA–AMINO–3–HYDROXY–5–METHYL–4–ISOXAZOLEPROPIONIC ACID

AMPA RECEPTORS see RECEPTORS, AMPA

AMPHETAMINE

Choosing a cut–off on the Severity of Dependence Scale (SDS) for amphetamine users. Topp L, et al. **Addiction** 1997 Jul;92(7):839–45

D2 dopamine receptor gene TaqI A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant–preferring polysubstance abusers. Persico AM, et al. **Biol Psychiatry** 1996 Oct 15;40(8):776–84

Intracerebral haemorrhage in a young adult: consider amphetamine abuse. El–Omar MM, et al. **Br J Clin Pract** 1996 Mar;50(2):115–6

A cluster of fentanyl–related deaths among drug addicts in Sweden. Kronstrand R, et al. **Forensic Sci Int** 1997 Aug 22;88(3):185–93

[Drug abuse in 1997 in Poland (editorial)] Chruściel TL. **Przegl Lek** 1997;54(6):379–83 **(Pol)**

ADMINISTRATION & DOSAGE

Haloperidol and MK–801 block increases in striatal calmodulin resulting from repeated amphetamine treatment. Gnegy ME, et al. **Brain Res** 1996 Sep 23; 734(1–2):35–42

Central noradrenergic & dopaminergic modulation of brewer's yeast–induced inflammation & nociception in rats. Hore SK, et al. **Indian J Med Res** 1997 Feb;105:93–7

Food and amphetamine self–administration by baboons: effects of alternatives. Foltin RW. **J Exp Anal Behav** 1997 Jul;68(1):47–66

Selegiline for the delivery of small doses of amphetamine [letter] Schaller JL, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):301–2

Extracellular dopamine and amphetamine after systemic amphetamine administration: comparison to the behavioral response. Kuczenski R, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):591–6

Repeated binge exposures to amphetamine and methamphetamine: behavioral and neurochemical characterization. Segal DS, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):561–73

Individual differences in sugar consumption following systemic or intraaccumbens administration of low doses of amphetamine in nondeprived rats. Sills TL, et al. **Pharmacol Biochem Behav** 1996 Aug;54(4):665–70

Amphetamine self–administration by humans: modulation by contingencies associated with task performance. Comer SD, et al. **Psychopharmacology (Berl)** 1996 Sep;127(1):39–46

["The amphetamine treatment helped my child". Is it time to reevaluate Swedish practice in hyperactivity syndrome?] **Lakartidningen** 1996 Nov 20;93(47):4307–8 **(Swe)**

ADVERSE EFFECTS

Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Hall W, et al. **Addiction** 1996 Jan;91(1):81–7

Amphetamine–related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Hando J, et al. **Drug Alcohol Depend** 1997 Jun 6;46(1–2):105–13

Are metabolites of l–deprenyl (selegiline) useful or harmful? Indications from preclinical research. Yasar S, et al. **J Neural Transm Suppl** 1996;48:61–73 (50 ref.)

Striatal acetylcholine release correlates with behavioral sensitization in rats withdrawn from chronic amphetamine. Bickerdike MJ, et al. **J Pharmacol Exp Ther** 1997 Aug; 282(2):818–26

Regional differences in the effects of amphetamine withdrawal on dopamine dynamics in the striatum [letter] Lee TH, et al. **Neuropsychopharmacology** 1997 Apr; 16(4):311–4

ANALOGS & DERIVATIVES see AMPHETAMINES

ANALYSIS

Determination of stimulants in a single human hair sample by high–performance liquid chromatographic method with chemiluminescence detection. Takayama N, et al. **Biomed Chromatogr** 1997 Jan–Feb;11(1):25–8

Central composite design in the chiral analysis of amphetamines by capillary electrophoresis. Varesio E, et al. **Electrophoresis** 1997 Jun;18(6):931–7

Determination of amphetamine and methylenedioxy–amphetamine–derivatives in hair. Röhrich J, et al. **Forensic Sci Int** 1997 Jan 17;84(1–3):179–88

Hair concentrations and self–reported abuse history of 20 amphetamine and ecstasy users. Rothe M, et al. **Forensic Sci Int** 1997 Sep 19;89(1–2):111–28

Simple extractive derivatization of methamphetamine and its metabolites in biological materials with Extrelut columns for their GC–MS determination. Hara K, et al. **J Anal Toxicol** 1997 Jan–Feb;21(1):54–8

Hair analysis for drugs of abuse. XVI. Disposition of fenethylline and its metabolite into hair and discrimination between fenethylline use and amphetamine use by hair analysis. Kikura R, et al. **J Anal Toxicol** 1997 Jul–Aug; 21(4):291–6

Evaluation of internal standards for the analysis of amphetamine and methamphetamine. Valtier S, et al. **J Anal Toxicol** 1995 Oct;19(6):375–80

[Digestive amines of bacterial origin and behavior disorders. Apropos of a case] Gabastou JM, et al. **Pathol Biol (Paris)** 1996 Apr;44(4):275–81 (Eng. Abstr.) **(Fre)**

ANTAGONISTS & INHIBITORS

Reversal of amphetamine–induced behaviours by MDL 100,907, a selective 5–HT2A antagonist. Moser PC, et al. **Behav Brain Res** 1996;73(1–2):163–7

R(+)–8–OH–DPAT, a 5–HT1A receptor agonist, inhibits amphetamine–induced serotonin and dopamine release in rat medial prefrontal cortex. Kuroki T, et al. **Brain Res** 1996 Dec 16;743(1–2):357–61

Mifepristone prevents the expression of long–term behavioural sensitization to amphetamine. De Vries TJ, et al. **Eur J Pharmacol** 1996 Jun 27;307(2):R3–4

Ibogaine interferes with the establishment of amphetamine place preference learning. Moroz I, et al. **Exp Clin Psychopharmacol** 1997 May;5(2):119–22

Actinomycin D blocks the reducing effect of dexamethasone on amphetamine and cocaine hypermotility in mice. Capasso A, et al. **Gen Pharmacol** 1996 Jun;27(4):707–12

The effects of D– and L–fenfluramine (and their interactions with D–amphetamine) on psychomotor function and mood. Feeney S, et al. **Int Clin Psychopharmacol** 1996 Jun; 11(2):89–99

GABAergic drugs inhibit amphetamine–induced distractibility in the rat. Agmo A, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):119–26

5–HT3 receptor antagonist MDL 72222 dose–dependently attenuates cocaine– and amphetamine–induced elevations of extracellular dopamine in the nucleus accumbens and the dorsal striatum. Kankaanpää A, et al. **Pharmacol Toxicol** 1996 May;78(5):317–21

Nitric oxide synthase inhibitor L–NAME prevents amphetamine–induced prodynorphin gene expression in the rat. Przewlocka B, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Oct; 20(7):1229–37

BLOOD

Simultaneous gas chromatographic determination of methamphetamine, amphetamine and their p–hydroxylated metabolites in plasma and urine. Cheung S, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):77–87

CHEMISTRY

Quantitative determination of amphetamine and alpha–phenylethylamine enantiomers in judicial samples using capillary gas chromatography. Van Boxlaer JF, et al. **J Anal Toxicol** 1997 Jan–Feb;21(1):5–11

ISOLATION & PURIFICATION

Direct chiral resolution of phenylalkylamines using a crown ether chiral stationary phase. Aboul-Enein HY, et al. **Biomed Chromatogr** 1997 Jan-Feb;11(1):7-10

Detection and quantitation of amphetamine and methamphetamine: electron impact and chemical ionization with ammonia—comparative investigation on Shimadzu QP 5000 GC-MS system. Dallakian P, et al. **J Anal Toxicol** 1996 Jul-Aug;20(4):255-61

METABOLISM

Extracellular dopamine and amphetamine after systemic amphetamine administration: comparison to the behavioral response. Kuczenski R, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):591-6

PHARMACOKINETICS

Urine screening for drugs and trazodone [letter] [see comments] Craig RJ. **Br J Psychiatry** 1996 Nov; 169(5):669-70. Comment in: Br J Psychiatry 1997 Mar;170:290.

Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. Mascher HJ, et al. **Int J Clin Pharmacol Ther** 1997 Jan; 35(1):9-13

Major role of the CYP2C isozymes in deamination of amphetamine and benzphetamine: evidence for the quinidine-specific inhibition of the reactions catalysed by rabbit enzyme. Shiiyama S, et al. **Xenobiotica** 1997 Apr; 27(4):379-87

PHARMACOLOGY

From laboratory to clinic: noradrenergic enhancement of physical therapy for stroke or trauma patients. Feeney DM. **Adv Neurol** 1997;73:383-94 (49 ref.)

Amphetamine and fenfluramine suppress ethanol intake in ethanol-dependent rats. Yu YL, et al. **Alcohol** 1997 Jan-Feb;14(1):45-8

Differential effects of prenatal exposure to cocaine and amphetamine on growth parameters and morphometry of the prefrontal cortex in the rat. Tavares MA, et al. **Ann N Y Acad Sci** 1996 Oct 31;801:256-73

Effects of amphetamine, morphine and dizocilpine (MK-801) on spontaneous alternation in the 8-arm radial maze. Hölter SM, et al. **Behav Brain Res** 1996 Nov;81(1-2):53-9

Ibotenic acid lesions of prefrontal cortex do not prevent expression of behavioral sensitization to amphetamine. Li Y, et al. **Behav Brain Res** 1997 Mar;84(1-2):285-9

Ethological and 6-[18F]fluoro-L-DOPA-PET profiles of long-term vulnerability to chronic amphetamine. Melega WP, et al. **Behav Brain Res** 1997 Mar;84(1-2):259-68

Differential involvement of the shell and core subterritories of the nucleus accumbens in latent inhibition and amphetamine-induced activity. Weiner I, et al. **Behav Brain Res** 1996 Nov;81(1-2):123-33

Sensitization to the psychomotor stimulant effects of amphetamine: modulation by associative learning. Anagnostaras SG, et al. **Behav Neurosci** 1996 Dec; 110(6):1397-414

Repeated isolation in the neonatal rat produces alterations in behavior and ventral striatal dopamine release in the juvenile after amphetamine challenge. Kehoe P, et al. **Behav Neurosci** 1996 Dec;110(6):1435-44

Inhibition by amphetamine of testosterone secretion through a mechanism involving an increase of cyclic AMP production in rat testes. Tsai SC, et al. **Br J Pharmacol** 1996 Jun;118(4):984-8

Amphetamine induces Fos-like immunoreactivity in the striatum of primates. Asin KE, et al. **Brain Res** 1996 May 6;719(1-2):138-42

Signalled versus unsignalled intravenous amphetamine: large differences in the acute psychomotor response and sensitization. Crombag HS, et al. **Brain Res** 1996 May 25; 722(1-2):227-31

Amphetamine-induced changes in nigrostriatal terminal excitability are modified following repeated amphetamine pretreatment. Garcia-Munoz M, et al. **Brain Res** 1996 May 13;720(1-2):131-8

The role of the frontal cortex in the mouse in behavioral sensitization to amphetamine. Karler R, et al. **Brain Res** 1997 May 23;757(2):228-35

A novel nicotinic-cholinergic role in behavioral sensitization to amphetamine-induced stereotypy in mice. Karler R, et al. **Brain Res** 1996 Jul 1;725(2):192-8

Enhanced CREB phosphorylation and changes in c-Fos and FRA expression in striatum accompany amphetamine sensitization. f Turgeon SM, et al. **Brain Res** 1997 Feb 21; 749(1):120-6

Effects of selective adenosine A1 and A2a agonists on amphetamine-induced locomotion and c-Fos in striatum and nucleus accumbens. Turgeon SM, et al. **Brain Res** 1996 Jan 22;707(1):75-80

Amphetamine-induced Fos expression in globus pallidus is altered by frontal cortex injury. Vargo JM, et al. **Brain Res** 1996 Apr 15;716(1-2):207-12

Intrastriatal injection of a muscarinic receptor agonist and antagonist regulates striatal neuropeptide mRNA expression in normal and amphetamine-treated rats. Wang JQ, et al. **Brain Res** 1997 Feb 14;748(1-2):62-70

Low-dose amphetamine elevates movement-related firing of rat striatal neurons. West MO, et al. **Brain Res** 1997 Jan 16;745(1-2):331-5

Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Miller DW, et al. **Brain Res Bull** 1996;40(1):57-62

Effect of pertussis toxin injected into the ventral tegmental area on amphetamine-induced Fos protein in the nucleus accumbens. Narayanan S, et al. **Brain Res Bull** 1997; 43(4):435-9

Amphetamine-induced preprodynorphin mRNA expression and kappa-opioid receptor binding in basal ganglia of adult rats after prenatal exposure to diazepam. Inderbitzin S, et al. **Brain Res Dev Brain Res** 1997 Jan 2;98(1):114-24

Hippocampal glucocorticoid receptor mRNA is up-regulated by acute and down-regulated by chronic amphetamine treatment. Shilling PD, et al. **Brain Res Mol Brain Res** 1996 May;38(1):156-60

Knockout mice and dirty drugs. Drug addiction. Uhl GR, et al. **Curr Biol** 1996 Aug 1;6(8):935-6 (15 ref.)

Effects of some phenylethylamines in rhesus monkeys trained to discriminate (+)-amphetamine from saline. Woolverton WL, et al. **Drug Alcohol Depend** 1997 Mar 14;44(2-3):79-85

Effects of amphetamine on human nasal mucosa. Wang HW, et al. **Eur Arch Otorhinolaryngol** 1996;253(8):498-500

Phenotype of striatal cells expressing c-Fos following amphetamine treatment of rats with intrastriatal dopaminergic grafts. Abrous DN, et al. **Eur J Neurosci** 1996 Dec;8(12):2521-9

Reduction of dopamine release and synthesis by repeated amphetamine treatment: role in behavioral sensitization. Imperato A, et al. **Eur J Pharmacol** 1996 Dec 19; 317(2-3):231-7

1S,3R-ACPD has cataleptogenic effects and reverses MK-801-, and less pronounced, D,L-amphetamine-induced locomotion. Kronthaler UO, et al. **Eur J Pharmacol** 1996 Dec 5;316(2-3):129-36

Conditional control by midazolam and amphetamine in a rapid appetitive discrimination procedure. Maes JH, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):5-11

Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia. Neisewander JL, et al. **Eur J Pharmacol** 1996 Jun 3;305(1-3):13-21

Dopaminergic basis for the facilitation of brain stimulation reward by the NMDA receptor antagonist, MK-801. Olds ME. **Eur J Pharmacol** 1996 Jun 13;306(1-3):23-32

Individual differences in sugar consumption predict amphetamine-induced dopamine overflow in nucleus accumbens. Sills TL, et al. **Eur J Pharmacol** 1996 May 15;303(3):177-81

Foetal nigral cell suspension grafts influence dopamine release in the non-grafted side in the 6-hydroxydopamine rat model of Parkinson's disease: in vivo voltammetric data. Earl CD, et al. **Exp Brain Res** 1996 Apr;109(1):179-84

The effect of repeated amphetamine and cocaine administration on adrenal, gonadal and thyroid hormone levels in the rat plasma. Budziszewska B, et al. **Exp Clin Endocrinol Diabetes** 1996;104(4):334-8

Characterization of the sympathetic nerve responses to amphetamine: role of central alpha 2-adrenergic receptors. Liu W, et al. **J Cardiovasc Pharmacol** 1996 Nov; 28(5):712-22

Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. Carson RE, et al. **J Cereb Blood Flow Metab** 1997 Apr;17(4):437-47

Intranasal administration of the dopaminergic agonists L-DOPA, amphetamine, and cocaine increases dopamine activity in the neostriatum: a microdialysis study in the rat. De Souza Silva MA, et al. **J Neurochem** 1997 Jan; 68(1):233-9

Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. Kuczenski R, et al. **J Neurochem** 1997 May; 68(5):2032-7

Differential effects of delta- and mu-opioid receptor antagonists on the amphetamine-induced increase in extracellular dopamine in striatum and nucleus accumbens. Schad CA, et al. **J Neurochem** 1996 Dec;67(6):2292-9

Enhanced amphetamine sensitivity and increased expression of dopamine D2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex. Flores G, et al. **J Neurosci** 1996 Nov 15;16(22):7366-75

Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. Konradi C, et al. **J Neurosci** 1996 Jul 1;16(13):4231-9

An escalating dose/multiple high-dose binge pattern of amphetamine administration results in differential changes in the extracellular dopamine response profiles in caudate-putamen and nucleus accumbens. Kuczenski R, et al. **J Neurosci** 1997 Jun 1;17(11):4441-7

Repeated cocaine modifies the mechanism by which amphetamine releases dopamine. Pierce RC, et al. **J Neurosci** 1997 May 1;17(9):3254-61

Amphetamine and task-specific practice augment recovery of vibrissae-evoked forelimb placing after unilateral sensorimotor cortical injury in the rat. Schmanke T, et al. **J Neurotrauma** 1997 Jul;14(7):459-68

Enduring enhancement of amphetamine sensitization by drug-associated environmental stimuli. Badiani A, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):787-94

Mu opioid agonists potentiate amphetamine- and cocaine-induced rotational behavior in the rat. Kimmel HL, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):734-46

Enhancement of amphetamine- and cocaine-induced locomotor activity after chronic ethanol administration. Manley SJ, et al. **J Pharmacol Exp Ther** 1997 Jun; 281(3):1330-9

Increased responsiveness of ventral tegmental area dopamine neurons to glutamate after repeated administration of cocaine or amphetamine is transient and selectively involves AMPA receptors. Zhang XF, et al. **J Pharmacol Exp Ther** 1997 May;281(2):699-706

Context-dependent cross-sensitization between cocaine and amphetamine. Bonate PL, et al. **Life Sci** 1997;60(1):PL1-7

Functional echoplanar brain imaging correlates of amphetamine administration to normal subjects and subjects with the narcoleptic syndrome. Howard RJ, et al. **Magn Reson Imaging** 1996;14(9):1013-6

Peripheral post-training administration of 4-OH amphetamine enhances retention of a reduction in reward magnitude. Salinas JA, et al. **Neurobiol Learn Mem** 1996 Mar;65(2):192-5

Quantification of dopamine D1 and D2 receptor mRNA levels associated with the development of behavioral sensitization in amphetamine treated rats. Richtand NM, et al. **Neurochem Int** 1997 Jul;31(1):131-7

Quantitative trait loci contributing to phencyclidine-induced and amphetamine-induced locomotor behavior in inbred mice [published erratum appears in Neuropsychopharmacology 1996 Dec;15(6):609] Alexander RC, et al. **Neuropsychopharmacology** 1996 Nov; 15(5):484-90

Sensitization of the locomotor response to psychostimulants after repeated opiate exposure: role of the nucleus accumbens. Cunningham ST, et al. **Neuropsychopharmacology** 1997 Feb;16(2):147-55

Medullary pathways of cardiovascular responses to 5-HT2 and 5-HT3 receptor stimulation in the rat nucleus tractus solitarius. Sévoz C, et al. **Neuroreport** 1996 Aug 12; 7(12):1965-9

Amphetamine-induced sensitization and release of dopamine in slices from the ventral tegmental area of rats is enhanced following administration of cholera toxin into the ventral tegmental area. Byrnes JJ, et al. **Neurosci Lett** 1997 Feb 14;223(1):45-8

Amphetamine releases dopamine from synaptic vesicles by dual mechanisms. Floor E, et al. **Neurosci Lett** 1996 Aug 30;215(1):53-6

Intrastriatal injection of the metabotropic glutamate receptor antagonist MCPG attenuates acute amphetamine-stimulated neuropeptide mRNA expression in rat striatum. Wang JQ, et al. **Neurosci Lett** 1996 Oct 25;218(1):13-6

Differential effects of ventral striatal lesions on the conditioned place preference induced by morphine or amphetamine. Olmstead MC, et al. **Neuroscience** 1996 Apr; 71(3):701-8

Cocaine and amphetamine elicit differential effects in rats with a unilateral injection of dopamine transporter antisense oligodeoxynucleotides. Silvia CP, et al. **Neuroscience** 1997 Feb;76(3):737-47

Muscarinic receptors regulate striatal neuropeptide gene expression in normal and amphetamine-treated rats. Wang JQ, et al. **Neuroscience** 1996 Nov;75(1):43-56

The role of the striatum in the mouse in behavioral sensitization to amphetamine. Bedingfield JB, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):305-10

D1 and D2 dopamine and opiate receptors are involved in the restraint stress-induced sensitization to the psychostimulant effects of amphetamine. Díaz-Otañez CS, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):9-14

Intake of dietary sucrose or fat reduces amphetamine drinking in rats. Kanarek RB, et al. **Pharmacol Biochem Behav** 1996 Aug;54(4):719-23

Individual differences in sugar consumption following systemic or intraaccumbens administration of low doses of amphetamine in nondeprived rats. Sills TL, et al. **Pharmacol Biochem Behav** 1996 Aug;54(4):665-70

Female rats that rapidly acquire a d-amphetamine discrimination generalize more to d-amphetamine. Tomie A, et al. **Pharmacol Biochem Behav** 1996 Aug;54(4):699-703

Clobenzorex: evidence for amphetamine-like behavioral actions. Young R, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):311-6

Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats. Tuomainen P, et al. **Pharmacol Toxicol** 1996 Jun;78(6):392-6

Differences in some behavioural effects of deprenyl and amphetamine enantiomers in rats. Timár J, et al. **Physiol Behav** 1996 Aug;60(2):581-7

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Breier A, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2569-74

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Laruelle M, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9235-40

Potential brain neuronal targets for amphetamine-,

methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Lin JS, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):14128-33

VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Takahashi N, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9938-43

Dexfenfluramine lacks amphetamine-like abuse potential. Locke KW, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1996 Aug; 20(6):1019-35

Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex. Pehek EA, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1997 May; 21(4):671-82

Actions of methoxylated amphetamine hallucinogens on serotonergic neurons of the brain. Penington NJ.
Prog Neuropsychopharmacol Biol Psychiatry 1996 Aug; 20(6):951-65

Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system? Arnt J.
Psychopharmacology (Berl) 1996 Mar;124(1-2):117-25

Effects of naltrexone on amphetamine-induced locomotion and rearing: acute and repeated injections. Balcells-Olivero M, et al. **Psychopharmacology (Berl)** 1997 Jun;131(3):230-8

Comparative behavioral sensitization to stereotypy by direct and indirect dopamine agonists in CF-1 mice. Bedingfield JB, et al. **Psychopharmacology (Berl)** 1996 Apr; 124(3):219-25

Time-dependent exacerbation of amphetamine-induced taste aversions following exposure to footshock. Bowers WJ, et al. **Psychopharmacology (Berl)** 1996 May;125(1):43-9

Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Brauer LH, et al. **Psychopharmacology (Berl)** 1997 Mar;130(1):2-13 (112 ref.)

The effect of systemic d-amphetamine on motor versus motivational processes in the rat. Brown VJ, et al.
Psychopharmacology (Berl) 1996 Nov;128(2):171-80

Dose-dependent aversive and rewarding effects of amphetamine as revealed by a new place conditioning apparatus. Cabib S, et al. **Psychopharmacology (Berl)** 1996 May;125(1):92-6

Impairments produced by amphetamine and stress on memory storage are reduced following a chronic stressful experience. Cabib S, et al. **Psychopharmacology (Berl)** 1997 Jan;129(2):161-7

Rebound responding following a single dose of drug using an amphetamine-vehicle-haloperidol drug discrimination. Caul WF, et al. **Psychopharmacology (Berl)** 1996 Dec; 128(3):274-9

Individual differences in dopamine release but not rotational behavior correlate with extracellular amphetamine levels in caudate putamen in unlesioned rats. Clausing P, et al.
Psychopharmacology (Berl) 1996 Oct;127(3):187-94

Ontogeny of dopamine agonist-induced sensitization: role of NMDA receptors. Duke MA, et al.
Psychopharmacology (Berl) 1997 Jan;129(2):153-60

The role of mesolimbic and nigrostriatal dopamine in latent inhibition as measured with the conditioned taste aversion paradigm. Ellenbroek BA, et al.
Psychopharmacology (Berl) 1997 Jan;129(2):112-20

Injection of 5-HT into the nucleus accumbens reduces the effects of d-amphetamine on responding for conditioned reward. Fletcher PJ. **Psychopharmacology (Berl)** 1996 Jul; 126(1):62-9

Repeated d-amphetamine enhances stimulated mesoamygdaloid dopamine transmission. Harmer CJ, et al.
Psychopharmacology (Berl) 1997 Aug;132(3):247-54

Enhanced acquisition of discriminative approach following intra-amygdala d-amphetamine. Hitchcott PK, et al.
Psychopharmacology (Berl) 1997 Aug;132(3):237-46

Amygdala and hippocampus control dissociable aspects of drug-associated conditioned rewards. Hitchcott PK, et al.
Psychopharmacology (Berl) 1997 May;131(2):187-95

Symmetrical effects of amphetamine and alpha-flupenthixol on conditioned punishment and conditioned reinforcement: contrasts with midazolam. Killcross AS, et al.
Psychopharmacology (Berl) 1997 Jan;129(2):141-52

Retarded acquisition and reduced expression of conditioned locomotor activity in adult rats following repeated early maternal separation: effects of prefeeding, d-amphetamine, dopamine antagonists and clonidine. Matthews K, et al.
Psychopharmacology (Berl) 1996 Jul;126(1):75-84

Interaction of expectancy and the pharmacological effects of d-amphetamine: subjective effects and self-administration. Mitchell SH, et al.
Psychopharmacology (Berl) 1996 Jun;125(4):371-8

Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells. Stockton ME, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1-2):50-6

Effects of nicotine and amphetamine on latent inhibition in human subjects. Thornton JC, et al.
Psychopharmacology (Berl) 1996 Sep;127(2):164-73

Evidence for dissociable mechanisms of amphetamine- and stress-induced behavioral sensitization: effects of MK-801 and haloperidol pretreatment. Tolliver BK, et al.
Psychopharmacology (Berl) 1996 Aug;126(3):191-8

Morphine-induced long-term sensitization to the locomotor effects of morphine and amphetamine depends on the temporal pattern of the pretreatment regimen. Vanderschuren LJ, et al. **Psychopharmacology (Berl)** 1997 May;131(2):115-22

Effect of sensitization of stereotypy on the acquisition and retention of tolerance to amphetamine hypophagia. Wolgin DL, et al. **Psychopharmacology (Berl)** 1996 Aug; 126(3):219-25

Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Shelton J, et al. **Sleep** 1995 Dec;18(10):817-26

Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptosomes. Iwata S, et al.
Synapse 1997 Jul;26(3):281-91

Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Laruelle M, et al. **Synapse** 1997 Jan;25(1):1-14

Amphetamine-induced c-fos mRNA expression is altered in rats with neonatal ventral hippocampal damage. Lillrank SM, et al. **Synapse** 1996 Aug;23(4):292-301

Repeated amphetamine administration alters the expression of mRNA for AMPA receptor subunits in rat nucleus accumbens and prefrontal cortex. Lu W, et al. **Synapse** 1997 Jul;26(3):269-80

Cocaine and amphetamine preferentially stimulate glutamate release in the limbic system: studies on the involvement of dopamine. Reid MS, et al. **Synapse** 1997 Oct;27(2):95-105

Amphetamine-induced release of dendritic dopamine in substantia nigra pars reticulata: D1-mediated behavioral and electrophysiological effects. Timmerman W, et al.
Synapse 1996 Aug;23(4):280-91

[Influence of melatonin and amphetamine on formation of time-dependent conditional reflex in rats] Arushanian EB, et al. **Eksp Klin Farmakol** 1997 May-Jun;60(3):9-11 (Eng. Abstr.) **(Rus)**

[The influence of calcium channel blockers on the effects of haloperidol and phenamine in mice and rats] Kozlovskii VL, et al. **Eksp Klin Farmakol** 1996 May-Jun;59(3):12-5 (Eng. Abstr.) **(Rus)**

[The effect on rat behavior of phenamine contained in a cannula chronically implanted in the neostriatum] Iakimovskii AF, et al.
Zh Vyssh Nerv Deiat Im I P Pavlova 1996 Mar-Apr; 46(2):335-41 (Eng. Abstr.) **(Rus)**

[A comparison of the effects of dopamine agonists on self-stimulation of the hypothalamus with destruction of the mesolimbic brain structures in rats raised under conditions of social isolation] Panchenko GN, et al.
Zh Vyssh Nerv Deiat Im I P Pavlova 1996 Sep-Oct; 46(5):937-43 (Eng. Abstr.) **(Rus)**

POISONING

Self-mutilation and severe self-injurious behavior associated with amphetamine psychosis. Kratofil PH, et al.
Gen Hosp Psychiatry 1996 Mar;18(2):117-20

THERAPEUTIC USE

Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Gillberg C, et al. **Arch Gen Psychiatry** 1997 Sep; 54(9):857-64

Lack of delayed effects of amphetamine, methoxamine, and prazosin (adrenergic drugs) on behavioral outcome after lateral fluid percussion brain injury in the rat. Dose JM, et al. **J Neurotrauma** 1997 May;14(5):327-37

Amphetamine and negative symptoms of schizophrenia. Sanfilipo M, et al. **Psychopharmacology (Berl)** 1996 Jan; 123(2):211-4

[Practical experiences in the therapy of postweaning edema disease in piglets] Papp I, et al.
Berl Munch Tierarztl Wochenschr 1996 Oct;109(10):385-7 (Eng. Abstr.) **(Ger)**

TOXICITY

Effects of prenatal exposure to amphetamine in the medial prefrontal cortex of the rat. Tavares MA, et al.
Int J Dev Neurosci 1996 Aug;14(5):585-96

The neurotoxic effects of continuous cocaine and amphetamine in Habenula: implications for the substrates of psychosis. Ellison G, et al. **NIDA Res Monogr** 1996; 163:117-45 (72 ref.)

6-[18F]fluoro-L-DOPA-PET studies show partial reversibility of long-term effects of chronic amphetamine in monkeys. Melega WP, et al. **Synapse** 1996 Jan;22(1):63-9

URINE

Rapid determination of amphetamine stereoisomer ratios in urine by gas chromatography-mass spectroscopy. Tetlow VA, et al. **Ann Clin Biochem** 1996 Jan;33 (Pt 1):50-4

Buflomedil interference with the monoclonal EMIT d.a.u. amphetamine/methamphetamine immunoassay. Papa P, et al. **Eur J Clin Chem Clin Biochem** 1997 May;35(5):369-70

Detection of amphetamine following administration of fenproporex. Cody JT, et al. **J Anal Toxicol** 1996 Oct; 20(6):425-31

Detection and quantitation of amphetamine and methamphetamine: electron impact and chemical ionization with ammonia--comparative investigation on Shimadzu QP 5000 GC-MS system. Dallakian P, et al.
J Anal Toxicol 1996 Jul-Aug;20(4):255-61

Solid-phase extraction in amphetamine and methamphetamine analysis of urine. Lee MR, et al.
J Anal Toxicol 1997 Jul-Aug;21(4):278-82

Reagent lot-to-lot variability in sensitivity for amphetamine with the Syva Emit II Monoclonal Amphetamine/Methamphetamine assay [letter] Singh J.
J Anal Toxicol 1997 Mar-Apr;21(2):174-5

Amphetamine and methamphetamine determination in urine by reversed-phase high-performance liquid chromatography with simultaneous sample clean-up and derivatization with 1,2-naphthoquinone 4-sulphonate on solid-phase cartridges. Campins-Falcó P, et al.
J Chromatogr B Biomed Appl 1996 Dec 6;687(1):239-46

Simultaneous gas chromatographic determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine. Cheung S, et al.
J Chromatogr B Biomed Appl 1997 Mar 7;690(1-2):77-87

Direct high-performance liquid chromatographic and high-performance liquid chromatographic-thermospray-mass spectrometric determination of enantiomers of methamphetamine and its main metabolites amphetamine and p-hydroxymethamphetamine in human urine. Katagi M, et al. **J Chromatogr B Biomed Appl** 1996 Feb 9;676(1):35-43

Determination of amphetamine in human urine by dansyl derivatization and high-performance liquid chromatography with fluorescence detection. Wang TK, et al. **J Chromatogr B Biomed Appl** 1996 Nov 15; 686(2):285-90

D-AMPHETAMINE see **DEXTROAMPHETAMINE**

L-AMPHETAMINE see **AMPHETAMINE**

AMPHETAMINES

see related
APPETITE DEPRESSANTS
CENTRAL NERVOUS SYSTEM STIMULANTS

Validation of the amphetamine dependence syndrome and the SAmDQ. Topp L, et al. **Addiction** 1997 Feb; 92(2):151-62

When hypertension is resistant...we think it over! [letter] Mazza A, et al. **Am J Hypertens** 1997 May;10(5 Pt 1):578

ABC of mental health. Addiction and dependence--I: Illicit drugs. Gerada C, et al. **BMJ** 1997 Aug 2;315(7103):297-300 (0 ref.)

Sensitivity and specificity to amphetamine of a French version of the 49-item form of the addiction research center inventory. Warot D, et al. **Drug Alcohol Depend** 1997 May 2;45(3):177-83

Amphetamine derivative related deaths. Lora-Tamayo C, et al. **Forensic Sci Int** 1997 Feb 28;85(2):149-57

Drug-abusing homeless clients in California's substance abuse treatment system. Wenzel SL, et al.
J Psychoactive Drugs 1996 Apr-Jun;28(2):147-59

Hepatitis A outbreak amongst intravenous amphetamine abusers in Finland. Leino T, et al. **Scand J Infect Dis** 1997; 29(3):213-6

ADMINISTRATION & DOSAGE

Prescribing amphetamines to drug misusers: data from the 1995 national survey of community pharmacies in England and Wales. Strang J, et al. **Addiction** 1997 Jul;92(7):833-8

Similarities in the pharmacology of spontaneous and DOI-induced head-shakes suggest 5HT2A receptors are active under physiological conditions. Dursun SM, et al.
Psychopharmacology (Berl) 1996 Nov;128(2):198-205

ADVERSE EFFECTS

Acute dissection of the aorta with amphetamine misuse. Dihmis WC, et al. **BMJ** 1997 Jun 7;314(7095):1665

Adverse effects of stimulant drugs in a community sample of drug users. Williamson S, et al.
Drug Alcohol Depend 1997 Mar 14;44(2-3):87-94

Severe weight loss induced by Adderall in a child with ADHD [letter] Kalikow KT, et al.
J Child Adolesc Psychopharmacol 1996 Spring;6(1):81-2

ANALYSIS

Interlaboratory comparison of quantitative determination of amphetamine and related compounds in hair samples. Kintz P, et al. **Forensic Sci Int** 1997 Jan 17;84(1-3):151-6

Analysis of "Ecstasy" by capillary electrophoresis. Frost M, et al. **Int J Legal Med** 1996;109(2):53-7

Determination of phenylisothiocyanate derivatives of amphetamine and its analogues in biological fluids by HPLC-APCI-MS or DAD. Bogusz MJ, et al.
J Anal Toxicol 1997 Jan-Feb;21(1):59-69

One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites. Iwersen S, et al.
J Anal Toxicol 1996 Sep;20(5):301-4 (21 ref.)

Detecting comorbid substance misuse among people with schizophrenia in the community: a study comparing the results of questionnaires with analysis of hair and urine. McPhillips MA, et al. **Schizophr Res** 1997 May 24; 25(2):141-8

Identification and quantification of amphetamine and

analogues by capillary zone electrophoresis. Esseiva P, et al. **Sci Justice** 1997 Apr-Jun;37(2):113-9

ANTAGONISTS & INHIBITORS

Effect of haloperidol on the behavioral stimulation by N-cyanomethylmethamphetamine, a main product of smoking methamphetamine mixed with tobacco. Kuribara H, et al. **Eur J Pharmacol** 1996 Jun 3;305(1-3):1-6

Ritanserin attenuates the in vitro effects of the 5-HT2 receptor agonist DOI on skeletal muscles from malignant hyperthermia-susceptible patients. Wappler F, et al. **J Clin Anesth** 1997 Jun;9(4):306-11

Effect of interferon-alpha on DOI-induced wet-dog shakes in rats. Kugaya A, et al. **J Neural Transm** 1996; 103(8-9):947-55

DIAGNOSTIC USE

Cerebral perfusion changes in traumatic diffuse brain injury; IMP SPECT studies. Ito H, et al. **Ann Nucl Med** 1997 May;11(2):167-72

I-123 iofetamine single-photon computed emission tomography in rapid cycling bipolar disorder: a clinical study. Gyulai L, et al. **Biol Psychiatry** 1997 Jan 15; 41(2):152-61

Correlation of functional independence measure (FIM) and SPECT Iofetamine (I-123) as a predictor of functional return in stroke. Rupright J, et al. **Brain Inj** 1997 Jan; 11(1):49-57

Diffuse visualization of bone marrow with I-123 IMP in a malignant melanoma. Kanegae K, et al. **Clin Nucl Med** 1996 Sep;21(9):734-6

I-123 iodoamphetamine scintigraphic detection of bone metastases from malignant melanoma. Otsuka N, et al. **Clin Nucl Med** 1996 Nov;21(11):847-50

Reduction in cortical IMP-SPET tracer uptake with recent cigarette consumption in a young group of healthy males. San Diego HIV Neurobehavioral Research Center. Rourke SB, et al. **Eur J Nucl Med** 1997 Apr;24(4):422-7

Regional cerebral blood flow measurement with iodine-123-IMP autoradiography: normal values, reproducibility and sensitivity to hypoperfusion. Hatazawa J, et al. **J Nucl Med** 1997 Jul;38(7):1102-8

Quantification of cerebral blood flow and partition coefficient using iodine-123-iodoamphetamine. Odano I, et al. **J Nucl Med** 1997 Aug;38(8):1248-53

A comparative study of simple methods to measure regional cerebral blood flow using iodine-123-IMP SPECT. Ohkubo M, et al. **J Nucl Med** 1997 Apr;38(4):597-601

Acetazolamide challenge and technetium-99m-ECD versus iodine-123-IMP SPECT in chronic occlusive cerebrovascular disease. Ohnishi T, et al. **J Nucl Med** 1997 Sep;38(9):1463-7

Quantitative 123I IMP and 99mTc HMPAO imaging in the dog following cocaine administration. Susskind H, et al. **Nucl Med Biol** 1996 Apr;23(3):343-52

[Benzodiazepine receptor and cerebral blood flow in early Alzheimer's disease--SPECT study using 123I-iomazenil and 123I-IMP] Kitamura S, et al. **Kaku Igaku** 1996 Jan; 33(1):49-56 (Eng. Abstr.) **(Jpn)**

[A quantitative study of regional cerebral blood flow in patients with dementia of Alzheimer type using single photon emission computed tomography--clinical application of the IMP autoradiographic method (IMP ARG method)] Koshi Y, et al. **Kaku Igaku** 1996 Sep; 33(9):991-8 (Eng. Abstr.) **(Jpn)**

[Evaluation of 123I-iomazenil SPECT in patients with ischemic cerebrovascular disease: comparative study with 123I-IMP SPECT] Moriwaki H, et al. **Kaku Igaku** 1996 Jun;33(6):587-97 (Eng. Abstr.) **(Jpn)**

[A functional diagnostic method by measuring of distribution volume of 123I-IMP with SPECT] Odano I, et al. **Kaku Igaku** 1996 Jun;33(6):579-86 (Eng. Abstr.) **(Jpn)**

[A comparative study of the quality of SPECT images obtained by 123I-IMP, 99mTc-HMPAO and 99mTc-ECD] Odano I, et al. **Kaku Igaku** 1997 Mar; 34(3):189-94 (Eng. Abstr.) **(Jpn)**

[The quantitative regional cerebral blood flow measurement with autoradiography method using 123I-IMP SPECT: evaluation of arterialized venous blood sampling as a substitute for arterial blood sampling] Ohnishi T, et al. **Kaku Igaku** 1996 Oct;33(10):1105-9 (Eng. Abstr.) **(Jpn)**

[Reproducibility of regional cerebral blood flow measurement at rest with autoradiography method using 123I-IMP and SPECT] Saito K, et al. **Kaku Igaku** 1997 May;34(5):343-8 (Eng. Abstr.) **(Jpn)**

[Diagnostic value of high N-isopropyl-p-[123I] iodoamphetamine (IMP) uptake in brain tumors] Fukahori T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jan; 56(1):53-9 (Eng. Abstr.) **(Jpn)**

[Analysis of Parkinson's disease and related syndromes using 123I-IMP-SPECT with the ARG method] Kageyama H, et al. **Nippon Rinsho** 1997 Jan;55(1):238-42 (Eng. Abstr.) **(Jpn)**

[A quantitative study of regional cerebral blood flow in childhood using 123I-IMP-SPECT: with emphasis on age-related changes] Kobayashi A, et al. **No To Hattatsu** 1996 Nov;28(6):501-7 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Determination of amphetamine and related compounds in urine using on-line derivatization in octadecyl silica columns with 9-fluorenylmethyl chloroformate and liquid chromatography. Herráez-Hernández R, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1-2):69-78

METABOLISM

Binding cells of 125I-iodoamphetamine in rat liver. Hijioka T, et al. **Ann Nucl Med** 1997 Feb;11(1):27-32

Hair analysis for drugs of abuse. XIII. Effect of structural factors on incorporation of drugs into hair: the incorporation rates of amphetamine analogs. Nakahara Y, et al. **Arch Toxicol** 1996;70(12):841-9

Abuse of smoking methamphetamine mixed with tobacco. V. Plasma metabolites of N-cyanomethylmethamphetamine, a pyrolysis product formed by smoking methamphetamine in tobacco, and the species difference between mouse and rat. Sekine H, et al. **Biol Pharm Bull** 1996 Jun;19(6):845-51

Hair analysis for drugs of abuse. XVI. Disposition of fenethylline and its metabolite into hair and discrimination between fenethylline use and amphetamine use by hair analysis. Kikura R, et al. **J Anal Toxicol** 1997 Jul-Aug; 21(4):291-6

Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat. Owens MJ, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1040-9

Deamination of amphetamines by cytochromes P450: studies on substrate specificity and regioselectivity with microsomes and purified CYP2C subfamily isozymes. Yamada H, et al. **J Toxicol Sci** 1997 Feb;22(1):65-73

PHARMACOKINETICS

Hair analysis for drug abuse. XV. Disposition of 3, 4-methylenedioxymethamphetamine (MDMA) and its related compounds into rat hair and application to hair analysis for MDMA abuse. Kikura R, et al. **Forensic Sci Int** 1997 Jan 17;84(1-3):165-77

Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. Mascher HJ, et al. **Int J Clin Pharmacol Ther** 1997 Jan; 35(1):9-13

Quantitative 123I IMP and 99mTc HMPAO imaging in the dog following cocaine administration. Susskind H, et al. **Nucl Med Biol** 1996 Apr;23(3):343-52

[High uptake of N-isopropyl-p-[123I]-iodoamphetamine (123I-IMP) demonstrated by dynamic SPECT in some cases of glioma] Sugou N, et al. **Kaku Igaku** 1996 Jul; 33(7):695-704 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Non-aminergic effects of amphetamine on the NMDA receptor in primary cultured cortical cells. Yamamoto H, et al. **Ann N Y Acad Sci** 1996 Oct 31;801:327-39

Interactions of amphetamine analogs with human liver CYP2D6. Wu D, et al. **Biochem Pharmacol** 1997 Jun 1; 53(11):1605-12

Amphetamine induction of c-fos in the nucleus accumbens is not inhibited by glutamate antagonists. Dalia A, et al. **Brain Res** 1995 Oct 2;694(1-2):299-307

Effects of 8-OH-DPAT, a 5-HT1A receptor agonist, and DOI, a 5-HT2A/2C agonist, on monosynaptic transmission in spinalized rats. Hasegawa Y, et al. **Brain Res** 1996 Oct 28;738(1):158-61

DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Sipes TE, et al. **Brain Res** 1997 Jun 27;761(1):97-104

Role of serotonin receptor subtypes in the development of amygdaloid kindling in rats. Wada Y, et al. **Brain Res** 1997 Feb 7;747(2):338-42

Suppression of neocortical high-voltage spindles by nicotinic acetylcholine and 5-HT2 receptor stimulation. Jäkälä P, et al. **Eur J Pharmacol** 1996 Mar 28;299(1-3):47-60

Drug states as modulators of conditioned immobility in a latent discrimination procedure. Maes JH, et al. **Eur J Pharmacol** 1996 Aug 8;309(2):131-40

Antagonism by the 5-HT2A/C receptor agonist DOI of raclopride-induced catalepsy in the rat. Wadenberg ML, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):247-51

Effect of the selective 5-HT receptor agonists 8-OHDPAT and DOI on behavior and brain biogenic amines of rats. Gaggi R, et al. **Gen Pharmacol** 1997 Apr;28(4):583-7

Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). Waitzinger J, et al. **Int J Clin Pharmacol Ther** 1996 Oct; 34(10):427-32

Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. Heinonen EH, et al. **J Clin Pharmacol** 1997 Jul; 37(7):602-9

Effects of D-amphetamine on response acquisition with immediate and delayed reinforcement. LeSage MG, et al. **J Exp Anal Behav** 1996 Nov;66(3):349-67

L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. Mytilineou C, et al. **J Neurochem** 1997 Jan;68(1):434-6

5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. Vaidya VA, et al. **J Neurosci** 1997 Apr 15; 17(8):2785-95

Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA). Li Q, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1261-7

LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. Marek GJ, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1373-82

Repeated administration of meta-chlorophenylpiperazine or 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane produces tolerance to its stimulatory effect on adrenocorticotropin hormone but not prolactin or corticosterone secretion in rats. Mazzola-Pomietto P, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):782-9

Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. Willins DL, et al. **J Pharmacol Exp Ther** 1997 Aug; 282(2):699-706

Chronic cocaine exposure potentiates prolactin and head shake responses to 5-HT2 receptor stimulation in rats. Baumann MH, et al. **Neuropharmacology** 1996 Mar; 35(3):295-301

Protective actions of the 5-HT2A/2C receptor agonist, DOI, on 5-HT1A receptor-mediated inhibition of lordosis behavior. Maswood S, et al. **Neuropharmacology** 1996 Apr; 35(4):497-501

Chronic electroconvulsive shock enhances 5-HT2 receptor-mediated head shakes but not brain C-fos induction. Moorman JM, et al. **Neuropharmacology** 1996 Mar;35(3):303-13

The role of excitatory amino acids in the actions of abused drugs. **NIDA Res Monogr** 1994;140:65-8

Ritanserin blocks DOI-altered embryonic motility and posthatch learning in the developing chicken. Bollweg G, et al. **Pharmacol Biochem Behav** 1996 Nov;55(3):397-403

Differential effects of activation of lumbar and thoracic 5-HT2A/2C receptors on nociception in rats. Kjørsvik A, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):523-7

Behavioral effects of N-cyanomethylmethamphetamine, a product derived from smoking methamphetamine with tobacco, in mice and rats. Sekine H, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):167-72

Clobenzorex: evidence for amphetamine-like behavioral actions. Young R, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):311-6

Characteristics of behavioural stimulant effect of N-cyanomethylmethamphetamine, a main product of smoking methamphetamine mixed with tobacco: evaluation by ambulatory activity in mice. Kuribara H, et al. **Pharmacol Toxicol** 1996 Jun;78(6):374-80

Differential ontogenesis of three DOI-induced behaviors in mice. Darmani NA, et al. **Physiol Behav** 1996 Dec; 60(6):1495-500

Circadian rhythm in the responsiveness of central 5-HT2A receptor to DOI in rats. Nagayama H, et al. **Psychopharmacology (Berl)** 1996 Sep;127(2):113-6

THERAPEUTIC USE

[Effect of Aponeuron in the treatment of children with hyperkinetic syndrome] Paclt I, et al. **Ceska Slov Psychiatr** 1996 May;92 Suppl 1:41-57 (Eng. Abstr.) **(Cze)**

TOXICITY

d-Amphetamine-induced hepatotoxicity: possible contribution of catecholamines and hyperthermia to the effect studied in isolated rat hepatocytes. Carvalho F, et al. **Arch Toxicol** 1997;71(7):429-36

Neurotoxicity of amphetamines and their metabolites. Gibb JW, et al. **NIDA Res Monogr** 1997;173:128-45 (27 ref.)

Developmental toxicity of 4-substituted amphetamines in mice. Buttar HS, et al. **Reprod Toxicol** 1996 Jul-Aug; 10(4):301-10

URINE

Comparison of polyclonal and monoclonal assays for routine screening of urines for amphetamines. Moore FM, et al. **Ann Clin Biochem** 1996 Jan;33 (Pt 1):78-81

A simple HPLC method for the separation of amphetamine isomers in urine and its application in differentiating between 'street' amphetamine and prescribed D-amphetamine. Palfrey S, et al. **Ann Clin Biochem** 1996 Jul;33 (Pt 4):344-6

Urine screening for drugs [letter; comment] Browne R, et al. **Br J Psychiatry** 1997 Mar;170:290. Comment on: Br J Psychiatry 1996 Nov;169(5):669-70.

False-negative results with Emit amphetamine confirmation kit [letter] Morland H, et al. **Clin Chem** 1996 Oct; 42(10):1726-7

False-positive results for urine amphetamine and opiate immunoassays in a patient intoxicated with perazine [letter] Schmolke M, et al. **Clin Chem** 1996 Oct;42(10):1725-6

Detection of amphetamine following administration of fenproporex. Cody JT, et al. **J Anal Toxicol** 1996 Oct; 20(6):425-31

Time-lapse changes of d- and l-enantiomers of racemic

AMPHETAMINES

(dl)-ethylamphetamine in human urine. Nagai T, et al. **J Anal Toxicol** 1997 Mar-Apr;21(2):112-5

Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) in toxicological analysis. Studies on the detection of clobenzorex and its metabolites within a systematic toxicological analysis procedure by GC-MS and by immunoassay and studies on the detection of alpha- and beta-amanitin in urine by atmospheric pressure ionization electrospray LC-MS. Maurer HH, et al. **J Chromatogr B Biomed Appl** 1997 Feb 7;689(1):81-9

Liquid chromatographic analysis of amphetamine and related compounds in urine using solid-phase extraction and 3,5-dinitrobenzoyl chloride for derivatization. Herráez-Hernández R, et al. **J Chromatogr Sci** 1997 Apr; 35(4):169-75

A convenient derivatization method for the determination of amphetamine and related drugs in urine. Jonsson J, et al. **J Forensic Sci** 1996 Jan;41(1):148-51

AMPHIBIA

Developmental responses of amphibians to solar and artificial UVB sources: a comparative study. Hays JB, et al. **Photochem Photobiol** 1996 Sep;64(3):449-56

Infectious and parasitic disease of captive reptiles and amphibians, with special emphasis on husbandry practices which prevent or promote diseases. Ippen R, et al. **Rev Sci Tech** 1996 Mar;15(1):43-54 (1 ref.)

ANATOMY & HISTOLOGY

Scanning electron microscopic study of amphibians otoconia. Kido T, et al. **Auris Nasus Larynx** 1997 Apr;24(2):125-30

Distribution of vasotocin- and mesotocin-like immunoreactivities in the brain of typhlonectes compressicauda (Amphibia, gymnophiona): further assessment of primitive and derived traits of amphibian neuropeptidergic systems. González A, et al. **Cell Tissue Res** 1997 Feb;287(2):305-14

Motor nuclei of nerves innervating the tongue and hypoglossal musculature in a caecilian (amphibia:gymnophiona), as revealed by HRP transport. Schmidt A, et al. **J Comp Neurol** 1996 Jul 1;370(3):342-9

Sexual dimorphism and species differences in the neurophysiology and morphology of the acoustic communication system of two neotropical hylids. McClelland BE, et al. **J Comp Physiol [A]** 1997 May; 180(5):451-62

Neuroepithelial bodies and solitary neuroendocrine cells in the lungs of amphibia. Goniakowska-Witalińska L. **Microsc Res Tech** 1997 Apr 1;37(1):13-30 (71 ref.)

BLOOD

The phylogenetic odyssey of the erythrocyte. IV. The amphibians. Glomski CA, et al. **Histol Histopathol** 1997 Jan;12(1):147-70 (156 ref.)

CLASSIFICATION

Morphologists learn to live with molecular upstarts [news] [see comments] Balter M. **Science** 1997 May 16; 276(5315):1032-4. Comment in: Science 1997 Jun 13;276(5319):1629.

EMBRYOLOGY

Neural induction and antero-posterior patterning in the amphibian embryo: past, present and future. Gould SE, et al. **Cell Mol Life Sci** 1997 Apr;53(4):319-38 (136 ref.)

Short historical survey of pattern formation in the endo-mesoderm and the neural anlage in the vertebrates: the role of vertical and planar inductive actions. Nieuwkoop PD. **Cell Mol Life Sci** 1997 Apr;53(4):305-18 (133 ref.)

Neural induction in amphibians. Grunz H. **Curr Top Dev Biol** 1997;35:191-228 (237 ref.)

Factors responsible for the establishment of the body plan in the amphibian embryo. Grunz H. **Int J Dev Biol** 1996 Feb;40(1):279-89 (121 ref.)

The long road to chemical and molecular embryology. What amphibians can teach us on differentiation. An interview with Professor Heinz Tiedemann [interview by Horst Grunz] Tiedemann H. **Int J Dev Biol** 1996 Feb;40(1):113-22

Differentiation processes in the amphibian brain with special emphasis on heterochronies. Schmidt A, et al. **Int Rev Cytol** 1996;169:83-150 (247 ref.)

GENETICS

Thyroid hormone receptor genes of neotenic amphibians. Safi R, et al. **J Mol Evol** 1997 Jun;44(6):595-604

'Living fossil' fish is dethroned [news] Roush W. **Science** 1997 Sep 5;277(5331):1436

[Chromosome aberrations in different tissues of the murine rodents and amphibians from radionuclide-contaminated regions of Belarus] Eliseeva KG, et al. **Tsitol Genet** 1996 Jul-Aug;30(4):20-5 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Holtfreter revisited: unsolved problems in amphibian morphogenesis. Keller R. **Dev Dyn** 1996 Mar;205(3):257-64 (16 ref.)

METABOLISM

Environmental effects of heavy spillage from a destroyed pesticide store near Hargeisa (Somaliland) assessed during the dry season, using reptiles and amphibians as bioindicators. Lambert MR. **Arch Environ Contam Toxicol** 1997 Jan;32(1):80-93

Urea and amphibian water economy. Jørgensen CB. **Comp Biochem Physiol A Physiol** 1997 Jun;117(2):161-70 (87 ref.)

Purification and structural characterization of insulin from the lesser siren, Siren intermedia (Amphibia: Caudata). Conlon JM, et al. **Gen Comp Endocrinol** 1997 Jun; 106(3):295-300

Thyroid hormone receptors in perennibranchiate amphibians. Safi R, et al. **Int J Dev Biol** 1997 Jun;41(3):533-5

PHYSIOLOGY

200 years of amphibian water economy: from Robert Townson to the present. Jørgensen CB. **Biol Rev Camb Philos Soc** 1997 May;72(2):153-237 (390 ref.)

Estivation in South American amphibians and reptiles. Abe AS. **Braz J Med Biol Res** 1995 Nov-Dec;28(11-12):1241-7 (38 ref.)

Biphasic intestinal development in amphibians: embryogenesis and remodeling during metamorphosis. Shi YB, et al. **Curr Top Dev Biol** 1996;32:205-35 (117 ref.)

Basal ganglia organization in amphibians: catecholaminergic innervation of the striatum and the nucleus accumbens. Marín O, et al. **J Comp Neurol** 1997 Feb 3;378(1):50-69

Distribution of gonadotropin-releasing hormone immunoreactivity in the brain of Ichthyophis beddomei (Amphibia: Gymnophiona). Pinelli C, et al. **J Comp Neurol** 1997 Jul 28;384(2):283-92

Sexual dimorphism and species differences in the neurophysiology and morphology of the acoustic communication system of two neotropical hylids. McClelland BE, et al. **J Comp Physiol [A]** 1997 May; 180(5):451-62

Hypometabolic homeostasis in overwintering aquatic amphibians. Boutilier RG, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):387-400 (122 ref.)

[New data on the characteristics of sleep and the organization of the wakefulness-sleep cycle in cold-blooded vertebrates] Karmanova IG. **Zh Evol Biokhim Fiziol** 1996 Jul-Aug; 32(4):511-35 (10 ref.) **(Rus)**

AMPHIBIAN VENOMS

ANALYSIS

Absence of tetrodotoxins in a captive-raised riparian frog, Atelopus varius. Daly JW, et al. **Toxicon** 1997 May; 35(5):705-9

POISONING

Treatment of toad venom poisoning with digoxin-specific Fab fragments [see comments] Brubacher JR, et al. **Chest** 1996 Nov;110(5):1282-8. Comment in: Chest 1996 Nov;110(5):1139-41.

AMPHIBOLE ASBESTOS see **ASBESTOS, AMPHIBOLE**

AMPHISTOMIDAE see **PARAMPHISTOMATIDAE**

AMPHIUMA see **URODELA**

AMPHOLINES see **AMPHOLYTE MIXTURES**

AMPHOLYTE MIXTURES

CHEMISTRY

Comparison of ampholytes used for slab gel and capillary isoelectric focusing of recombinant tissue-type plasminogen activator glycoforms. Chen AB, et al. **J Chromatogr A** 1996 Sep 13;744(1-2):279-84

METABOLISM

Effect of hyperglycemia on the polyol pathway in rat kidney during the perinatal period. Freund N, et al. **Eur J Biochem** 1996 Nov 15;242(1):86-9

AMPHOTERICIN B

Amphotericin B is incompatible with lipid emulsions [letter] Ericsson O, et al. **Ann Pharmacother** 1996 Mar;30(3):298

Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Mehta J. **Leuk Res** 1997 Mar;21(3):183-8 (33 ref.)

[Amphotericin B deoxycholate (Fungizone): old drug, new versions] Chavanet P. **Rev Med Interne** 1997;18(2):153-65 (145 ref.) (Eng. Abstr.) **(Fre)**

[Amphotericin B--lipid complex] **Enferm Infecc Microbiol Clin** 1997 Jan;15(1):53 **(Spa)**

ADMINISTRATION & DOSAGE

Orally administered amphotericin B in the treatment of oral candidiasis in HIV-infected patients caused by azole-resistant Candida albicans [letter] Nguyen MT, et al. **AIDS** 1996 Dec;10(14):1745-7

Amphotericin B in fat emulsion [editorial; comment] Kintzel PE. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2701. Comment on: Am J Health Syst Pharm 1996 Nov 15;53(22):2724-7.

Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Sundar S, et al. **Ann Intern Med** 1997 Jul 15; 127(2):133-7

Nutritional impact of lipid-associated amphotericin B formulations [letter] Sacks GS, et al. **Ann Pharmacother** 1997 Jan;31(1):121-2

Aerosolized amphotericin B in prophylaxis of pulmonary aspergillosis. Tsourounis C, et al. **Ann Pharmacother** 1996 Oct;30(10):1175-6

Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Gangneux JP, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1214-8

Controlled pilot study of rapid amphotericin B infusions. Dele Davies H, et al. **Arch Dis Child** 1997 Feb;76(2):165-6

Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Mehta J, et al. **Bone Marrow Transplant** 1997 Jul;20(1):39-43

Liposomal amphotericin (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency. Pasic S, et al. **Bone Marrow Transplant** 1997 Jun;19(12):1229-32

Successful program to prevent aspergillus infections in children undergoing marrow transplantation: use of nasal amphotericin. Trigg ME, et al. **Bone Marrow Transplant** 1997 Jan;19(1):43-7

A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Okuno SH, et al. **Cancer** 1997 Jun 1;79(11):2193-9

Hypothermia following the intravenous administration of amphotericin B. Barlows TG 3rd, et al. **Clin Infect Dis** 1996 Nov;23(5):1187-8

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Davidson RN, et al. **Clin Infect Dis** 1996 Jun;22(6):938-43

Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Gonzalez CE, et al. **Clin Infect Dis** 1997 Feb;24(2):192-6 (37 ref.)

Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Wasan KM, et al. **Clin Infect Dis** 1996 Nov;23(5):1126-38 (111 ref.)

Carrier effects on biological activity of amphotericin B. Brajtburg J, et al. **Clin Microbiol Rev** 1996 Oct;9(4):512-31 (202 ref.)

Administration of amphotericin B in lipid emulsion [letter; comment] Devlin J, et al. **Crit Care Med** 1997 May; 25(5):892; discussion 893-4. Comment on: Crit Care Med 1996 Aug;24(8):1311-5.

Administration of amphotericin B in lipid emulsion [letter; comment] O'Neil MG, et al. **Crit Care Med** 1997 May; 25(5):892-3; discussion 893-4. Comment on: Crit Care Med 1996 Aug;24(8):1311-5.

Comparison of the leishmanicidal activity of fungizone, liposomal AmB and amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Ramos H, et al. **Drugs Exp Clin Res** 1995;21(6):211-6

Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Evdoridou J, et al. **Infection** 1997 Mar-Apr;25(2):112-6 (29 ref.)

Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis. Roth C, et al. **Infection** 1996 Sep-Oct;24(5):354-60

In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits. Chavanet P, et al. **J Antimicrob Chemother** 1997 Mar;39(3):427-30

The value of a single amphotericin B bladder washout in candiduria. Fong IW. **J Antimicrob Chemother** 1995 Dec; 36(6):1067-71

The use of amphotericin B lipid complex [letter] Franklin IM, et al. **J Antimicrob Chemother** 1997 Feb;39(2):288-90

Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. Joly V, et al. **J Antimicrob Chemother** 1996 Jul;38(1):117-26

The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. Shadkhan Y, et al. **J Antimicrob Chemother** 1997 May;39(5):655-8

Treatment of visceral leishmaniasis with a 10 day course of L-ampB-LRC (Bombay), a liposomal amphotericin B. Bodhe PV, et al. **J Assoc Physicians India** 1996 Mar; 44(3):222

Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. Legrand P, et al. **J Drug Target** 1997;4(5):311-9

Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and flucytosine in the treatment of cryptococcal meningitis in AIDS. Chotmongkol V, et al. **J Med Assoc Thai** 1997 Jul;80(7):416-25

Local application of antimycotics in mucormycosis cerebri: a case report. Mohsenipour I, et al.

J Neurol Neurosurg Psychiatry 1996 Nov;61(5):521–2

Treatment of visceral leishmaniasis in children with liposomal amphotericin B. di Martino L, et al. **J Pediatr** 1997 Aug; 131(2):271–7

Disposition of aerosolized liposomal amphotericin B. Lambros MP, et al. **J Pharm Sci** 1997 Sep;86(9):1066–9

Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation. Krüger W, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):491–9

Use of intralipid as a vehicle for amphotericin B in the treatment of cryptococcal meningitis in a renal transplant recipient [letter] Nicol AJ, et al. **Nephron** 1996;73(2):312–3

FDA clears new treatment for invasive aspergillosis. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):107

Candida peritonitis treated with liposomal amphotericin B [letter] Ng SY, et al. **Postgrad Med J** 1996 Oct; 72(852):636–7

Fatal outcome of disseminated candidosis after allogeneic bone marrow transplantation under treatment with liposomal and conventional amphotericin-B. A report of 4 cases with determination of the Mic values. Krüger W, et al. **Scand J Infect Dis** 1996;28(3):313–6

Liposomal formulations of cytotoxic drugs. Janknegt R. **Support Care Cancer** 1996 Jul;4(4):298–304 (31 ref.)

A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Alak A, et al. **Ther Drug Monit** 1996 Oct; 18(5):604–9

Successful treatment of visceral leishmaniasis with high-dose amphotericin B diluted in fat emulsion: a case report. Herbrecht R, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):322–3

Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients. Merhav H, et al. **Transplant Proc** 1997 Sep;29(6):2670–4

Amphotericin B: new life for an old drug. Hartsel S, et al. **Trends Pharmacol Sci** 1996 Dec;17(12):445–9 (51 ref.)

Empirical liposomal amphotericin-B therapy in a neutropenic patient: breakthrough of disseminated Blastoschizomyces capitatus infection. Plum G, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):361–6

[Amphotericin B deoxycholate (Fungizone): old drug, new versions] Chavanet P. **Rev Med Interne** 1996;17 Suppl 3:349s–353s (86 ref.) **(Fre)**

[Drug treatment of invasive aspergillosis of the paranasal sinuses] Streppel M, et al. **Laryngorhinootologie** 1997 Jan; 76(1):19–22 (Eng. Abstr.) **(Ger)**

[Amphotericin B. Lipid complex versus liposomes. Which, why, when? (editorial)] Pahissa A. **Enferm Infecc Microbiol Clin** 1997 Jan;15(1):1–3 **(Spa)**

ADVERSE EFFECTS

Acute renal failure with amphotericin B in lipid emulsion [letter] Gales MA, et al. **Ann Pharmacother** 1996 Sep; 30(9):1036

Amphotericin B-associated hypertension. Le Y, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):765–7

Anaphylactic reaction to liposomal amphotericin B in children [letter] Torre I, et al. **Ann Pharmacother** 1996 Sep; 30(9):1036–7

Efficacy of nefopam for the prevention and treatment of amphotericin B-induced shivering. Rosa G, et al. **Arch Intern Med** 1997 Jul 28;157(14):1589–92

Safety of amphotericin B colloidal dispersion. Herbrecht R. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):74–80

Hypomagnesaemia-associated tetany due to intravenous administration of amphotericin B [letter] Narita M, et al. **Eur J Pediatr** 1997 May;156(5):421–2

Safety and efficacy of Intralipid emulsions of amphotericin B [letter] Herbrecht R, et al. **J Antimicrob Chemother** 1997 Jul;40(1):137–9 (9 ref.)

Urinary adenosine excretion in patients receiving amphotericin B. Carlson MA, et al. **Surgery** 1997 Feb; 121(2):190–3

[Amphotericin B–intralipid 20% combination. In vivo evaluation of its tolerability (letter)] Débat Zoguéreh D, et al. **Ann Med Interne (Paris)** 1997;148(1):100–2 **(Fre)**

[Thrombopenia induced by amphotericin B in an extremely premature infant with congenital candidiasis (letter)] Baud O, et al. **Arch Pediatr** 1996 Aug;3(8):831–2 **(Fre)**

[Cyanotic Raynaud phenomenon as a side effect of Amphotericin B] Zernikow B, et al. **Klin Padiatr** 1996 Mar–Apr;208(2):53–5 (Eng. Abstr.) **(Ger)**

ANALOGS & DERIVATIVES

Stereostructure of amphotericin A. Sowiński P, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1232–5

Treatment of experimental systemic mycoses with BRL 49594A. Najvar LK, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1005–1011

Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry. Pleskoff O, et al. **J Virol** 1996 Nov;70(11):8247–51

Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Mehta J. **Leuk Res** 1997 Mar;21(3):183–8 (33 ref.)

Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Adjou KT, et al. **Res Virol** 1996 Jul–Aug;147(4):213–8

In vitro determination of antiviral activity of MS8209, a new amphotericin B derivative, against primary isolates of HIV1. Magierowska-Jung M, et al. **Res Virol** 1996 Sep–Oct;147(5):313–8

[Synthesis and biological activity of hydrophosphoryl derivatives of amphotericin B] Belakhov VV, et al. **Antibiot Khimioter** 1996;41(7–8):4–8 (Eng. Abstr.) **(Rus)**

ANALYSIS

Amphotericin B enzyme-linked immunosorbent assay. Cleary JD, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):637–41

New high-performance liquid chromatographic method for amphotericin B analysis using an internal standard. Lambros MP, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):135–40

BLOOD

Amphotericin B enzyme-linked immunoassay for clinical use: comparison with bioassay and HPLC. Cleary JD, et al. **Ann Pharmacother** 1997 Jan;31(1):39–44

Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Bhamra R, et al. **Antimicrob Agents Chemother** 1997 May;41(5):886–92

Determination of amphotericin B in human serum by liquid chromatography. Lopez-Galera R, et al. **J Chromatogr B Biomed Appl** 1995 Dec 15;674(2):298–300

Rapid determination of amphotericin B in serum and urine by third-order derivative spectrophotometry. Botsoglou NA, et al. **J Pharm Sci** 1996 Apr;85(4):402–6

A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Alak A, et al. **Ther Drug Monit** 1996 Oct; 18(5):604–9

CHEMISTRY

Precipitation of amphotericin B from i.v. fat emulsion [letter] Heide PE. **Am J Health Syst Pharm** 1997 Jun 15; 54(12):1449

Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion [see comments] Lopez RM, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2724–7. Comment in: Am J Health Syst Pharm 1996 Nov 15;53(22):2701.

Comment: compatibility of amphotericin B with lipid emulsions [letter] Montoro JB, et al. **Ann Pharmacother** 1996 Dec;30(12):1501

Amphotericin B protects cis-parinaric acid against peroxyl radical-induced oxidation: amphotericin B as an antioxidant. Osaka K, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):743–7

Ion coordination in the amphotericin B channel. Khutorsky V. **Biophys J** 1996 Dec;71(6):2984–95

The effect of aggregation state of amphotericin-B on its interactions with cholesterol- or ergosterol-containing phosphatidylcholine monolayers. Barwicz J, et al. **Chem Phys Lipids** 1997 Feb 28;85(2):145–55

Amphotericin B intralipid formulation: stability and particle size. Ranchère JY, et al. **J Antimicrob Chemother** 1996 Jun; 37(6):1165–9

Lipid complexes of amphotericin B: the competitive picture [editorial] Richardson MD. **J Med Microbiol** 1997 Mar; 46(3):185–7 (10 ref.)

Conformational analysis of amphotericin B molecule. Silberstein AYa, et al. **Membr Cell Biol** 1997;10(5):553–63

Evidence for the formation of amphotericin B–phospholipid complexes in Langmuir monolayers. Lance MR, et al. **Pharm Res** 1996 Jul;13(7):1008–14

CONTRAINDICATIONS

Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet. Zaman MM, et al. **Clin Infect Dis** 1996 Feb; 22(2):378

ECONOMICS

Comment: expense of amphotericin B product [letter; comment] Andersen JM. **Ann Pharmacother** 1996 Nov; 30(11):1342. Comment on: Ann Pharmacother 1996 Apr;30(4):409–12.

METABOLISM

The formation of amphotericin B ion channels in lipid bilayers. Fujii G, et al. **Biochemistry** 1997 Apr 22; 36(16):4959–68

PHARMACOKINETICS

Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Ayestarán A, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):609–12

Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Bhamra R, et al. **Antimicrob Agents Chemother** 1997 May;41(5):886–92

Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Heinemann V, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1275–80

Serum pharmacology of amphotericin B applied in lipid emulsions. Heinemann V, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):728–32

Carrier effects on biological activity of amphotericin B. Brajtburg J, et al. **Clin Microbiol Rev** 1996 Oct;9(4):512–31 (202 ref.)

Biopharmaceutical aspects of lipid formulations of amphotericin B. Storm G, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):64–73 (63 ref.)

Diversity of lipid-based polyene formulations and their behavior in biological systems. Wasan KM, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):81–92 (87 ref.)

Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. Legrand P, et al. **J Antimicrob Chemother** 1996 Mar; 37(3):519–33

Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. Hutchaleelaha A, et al. **J Pharm Pharmacol** 1997 Feb; 49(2):178–83

Disposition of aerosolized liposomal amphotericin B. Lambros MP, et al. **J Pharm Sci** 1997 Sep;86(9):1066–9

PHARMACOLOGY

Cryptococcosis. Aberg JA, et al. **Adv Pharmacol** 1997; 37:215–51 (117 ref.)

Influence of amphotericin B on the sodium pump of porcine lens epithelium. Delamere NA, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):C465–73

Antagonistic effect of amphotericin B on carboplatin antitumor activity in human osteosarcoma xenografts. Crnalic S, et al. **Anticancer Drugs** 1996 Jun;7(4):489–92

Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Franzot SP, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):331–6

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Klepser ME, et al. **Antimicrob Agents Chemother** 1997 Jun; 41(6):1392–5

Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Mozaffarian N, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1825–9

In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Oakley KL, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1124–6

Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Paul M, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1731–4

Evaluation of a flow cytofluorometric method for rapid determination of amphotericin B susceptibility of yeast isolates. Peyron F, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1537–40

Effects of incubation temperature, inoculum size, and time of reading on broth microdilution susceptibility test results for amphotericin B fgainst Fusarium. Pujol I, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):808–11

Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Sanati H, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1345–8

Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide. Tohyama M, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1919–23

In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Uzun O, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1156–7

In vitro interaction between amphotericin B and azoles in Candida albicans. Vazquez JA, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2511–6

In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp. Wardle HM, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2229–31

Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis. Wasan KM, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1806–10

Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice. Okutomi T, et al. **Br J Cancer** 1997;75(11):1613–6

Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells. Poulain L, et al. **Cancer Chemother Pharmacol** 1997;40(5):385–90

Strain variation and antifungal susceptibility among bloodstream isolates of Candida species from 21 different medical institutions. Pfaller MA, et al. **Clin Infect Dis** 1995 Dec;21(6):1507–9

Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Sterling TR, et al. **Clin Infect Dis** 1996 Jul;23(1):187–8

Assessment of amphotericin B susceptibility in Leishmania infantum promastigotes by flow cytometric membrane potential assay. Azas N, et al. **Cytometry** 1997 Jun 1; 28(2):165–9

In vitro susceptibility of 115 isolates of Candida to amphotericin B, fluconazole and itraconazole. Mallié M, et al. **Drugs Exp Clin Res** 1996;22(6):301–7

Comparison of the leishmanicidal activity of fungizone, liposomal AmB and amphotericin B incorporated into egg lecithin–bile salt mixed micelles. Ramos H, et al. **Drugs Exp Clin Res** 1995;21(6):211–6

Effects of cisplatin and amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. Bergström P, et al. **Eur J Cancer** 1997 Jan; 33(1):153–9

Leishmania infantum promastigotes: flow cytometry as a possible tool for assessing the effects of drugs on cellular functions. Azas N, et al. **Exp Parasitol** 1997 Sep;87(1):1–7

Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. Kelly SL, et al. **FEBS Lett** 1997 Jan 2;400(1):80–2

Amphotericin B prophylaxis against invasive fungal infections in neutropenic patients: a single center experience from 1980 to 1995. De Laurenzi A, et al. **Infection** 1996 Sep–Oct;24(5):361–6

No increase in cyclosporin neurotoxicity in transplant recipients treated with liposomal amphotericin B [letter] Ringdén O, et al. **Infection** 1996 May–Jun;24(3):269

Amphotericin B resistance testing of Candida spp.: a comparison of methods. Law D, et al. **J Antimicrob Chemother** 1997 Jul;40(1):109–12

Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. Oliva G, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1013–9

Safety and efficacy of Intralipid emulsions of amphotericin B. Sievers TM, et al. **J Antimicrob Chemother** 1996 Sep; 38(3):333–47

In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system. Tabosa Do Egito ES, et al. **J Antimicrob Chemother** 1996 Sep;38(3):485–97

Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans. van Etten EW, et al. **J Antimicrob Chemother** 1995 Dec;36(6):961–74

The in-vitro activity of an antifungal antibiotic benanomicin A in comparison with amphotericin B. Watanabe M, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1073–7

Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar blue tests. Jahn B, et al. **J Clin Microbiol** 1996 Aug;34(8):2039–41

Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B. Lozano-Chiu M, et al. **J Clin Microbiol** 1997 Jan; 35(1):270–2

Rapid flow cytometric susceptibility testing of Candida albicans. Ramani R, et al. **J Clin Microbiol** 1997 Sep; 35(9):2320–4

Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test [letter; comment] Rodríguez-Tudela JL, et al. **J Clin Microbiol** 1997 Jan;35(1):336–7. Comment on: J Clin Microbiol 1996 Apr;34(4):842–7.

Identification of an amphotericin B resistant strain of Candida albicans using a rapid 3H-glucose incorporation microassay. Sweeney JF, et al. **J Infect** 1996 Nov; 33(3):221–6

Role of macrophages in the candidacidal activity of liposomal amphotericin B. Mehta RT, et al. **J Infect Dis** 1997 Jan; 175(1):214–7

Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. Joseph-Horne T, et al. **J Med Vet Mycol** 1996 Jun–Jul; 34(3):223–5

In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. Nelson PW, et al. **J Med Vet Mycol** 1997 Jul–Aug;35(4):285–7

Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. Wasan KM. **J Pharmacol Toxicol Methods** 1996 Sep; 36(1):1–11 (68 ref.)

Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients [letter] Kelly SL, et al. **Lancet** 1996 Nov 30;348(9040):1523–4

In vitro amphotericin B effects on growth, viability and dimorphism of Paracoccidioides brasiliensis: reversal of the treatment. Jesuino RS, et al. **Microbiol Immunol** 1997; 41(2):93–9

A disc plate assay for characterization of the effect of interaction between polyenes and azoles on growth of Candida albicans CA12. Cao B, et al. **Microbios** 1996; 87(352):161–7

Effect of amphotericin B on the lipids of yeast cells of Sporothrix schenckii. Hamdan JS, et al. **Mycopathologia** 1996–97;136(3):125–31

Evaluation of the in vitro activity of seven selected antimicrobial agents to be used for the isolation of human intestinal spirochaetes. Calderaro A, et al. **New Microbiol** 1997 Jan;20(1):35–45

Characterization of whole-cell currents in mucosal and connective tissue rat mast cells using amphotericin-B-perforated patches and temperature control. Hill PB, et al. **Pflugers Arch** 1996 Oct; 432(6):986–94

Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans. Shen J, et al. **Planta Med** 1996 Oct;62(5):415–8

Postantifungal effect and effects of low concentrations of amphotericin B and fluconazole on previously treated Candida albicans. Mínguez F, et al. **Scand J Infect Dis** 1996; 28(5):503–6

In vitro drug susceptibility of Acanthamoeba castellani to chloroquine, ivermectin and fungizon. Rain AN, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):319–24

Probing the dynamics of prion diseases with amphotericin B. Adjou KT, et al. **Trends Microbiol** 1997 Jan;5(1):27–31 (31 ref.)

[Determination of in vitro synergy when amphotericin B is combined with various antimicrobial agents against yeasts by using a colorimetric microdilution checkerboard] Yamane N, et al. **Rinsho Byori** 1997 Jul;45(7):689–95 (Eng. Abstr.) **(Jpn)**

[Effect of cyclosporin A and amphotericin B on protoplasts of Tolypocladium inflatum] Sazukin IuO, et al. **Antibiot Khimioter** 1997;42(3):3–5 (Eng. Abstr.) **(Rus)**

[Amphotericin B: properties, chemical structure, screening of derivatives] Shenin IuD, et al. **Antibiot Khimioter** 1997; 42(4):34–46 (102 ref.) **(Rus)**

THERAPEUTIC USE

Mucormycosis in diabetes. Hopkins MA, et al. **Am J Crit Care** 1997 Sep;6(5):363–7

Criteria for use of amphotericin B lipid complex injections in adults and children. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2751–2

Renal tolerance with the use of intralipid-amphotericin B in low-birth-weight neonates. Friedlich PS, et al. **Am J Perinatol** 1997 Aug;14(7):377–83

Migration of Leishmania donovani amastigotes in the cerebrospinal fluid. Prasad LS, et al. **Am J Trop Med Hyg** 1996 Dec;55(6):652–4

Fluconazole and amphotericin B for cryptococcal meningitis. Clark AB, et al. **Ann Pharmacother** 1996 Dec; 30(12):1408–10

Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections? Nagata MP, et al. **Ann Pharmacother** 1996 Jul–Aug; 30(7–8):811–8 (58 ref.)

Comparison of fluconazole and amphotericin B in prophylaxis of experimental Candida endocarditis caused by non-C. albicans strains. Bayer AS, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):494–6

Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits. Chemlal K, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):263–6

Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Cicogna CE, et al. **Antimicrob Agents Chemother** 1997 Feb; 41(2):259–61

Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Nolte FS, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):196–9

Effects of pentoxifylline or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: evidence of neuroexcitatory pathogenic mechanisms. Ostrosky-Zeichner L, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1194–7

Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Yardley V, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):752–6

Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis. Kretschmar M, et al. **Arzneimittelforschung** 1996 Jul; 46(7):711–5

Prophylactic and empirical antifungal treatment in cancer complicated by neutropenia. Combining different antifungal strategies in same systematic review is inappropriate [letter] Kibbler CC, et al. **BMJ** 1997 Aug 23;315(7106):488–9

Resolution of invasive central nervous system aspergillosis in a transplant recipient. Khoury H, et al. **Bone Marrow Transplant** 1997 Jul;20(2):179–80

Autologous bone marrow transplantation is feasible in patients with a prior history of invasive pulmonary aspergillosis. Michailov G, et al. **Bone Marrow Transplant** 1996 Apr;17(4):569–72

Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Wingard JR. **Bone Marrow Transplant** 1997 Feb;19(4):343–7

Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Lake DE, et al. **Chemotherapy** 1996 Jul–Aug;42(4):308–14

Chemotherapy of parasitic diseases. Current status and new directions. Liu Y. **Chin Med J (Engl)** 1996 Aug; 109(8):579–82 (28 ref.)

The role of azole antifungal agents for systemic antifungal therapy. Lee YP, et al. **Cleve Clin J Med** 1997 Feb; 64(2):99–106 (67 ref.)

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Anaissie EJ, et al. **Clin Infect Dis** 1996 Nov;23(5):964–72 (31 ref.)

Failure of systemic empirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer. Blumberg EA, et al. **Clin Infect Dis** 1996 Mar; 22(3):462–6

Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients [see comments] Jacobs LG, et al. **Clin Infect Dis** 1996 Jan;22(1):30–5. Comment in: Clin Infect Dis 1996 Aug;23(2):416.

Oral azoles versus bladder irrigation with amphotericin B for the treatment of fungal urinary tract infections [letter; comment] [see comments] Johnson JR. **Clin Infect Dis** 1996 Aug;23(2):416. Comment on: Clin Infect Dis 1996 Jan;22(1):30–5. Comment in: Clin Infect Dis 1997 Jun;24(6):1284–5.

Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Joly V, et al. **Clin Infect Dis** 1996 Sep;23(3):556–62

Resistance to fluconazole and amphotericin B in a patient with AIDS who was being treated for candidal esophagitis. Le TP, et al. **Clin Infect Dis** 1996 Sep;23(3):649–50

Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS [see comments] Sharkey PK, et al. **Clin Infect Dis** 1996 Feb;22(2):315–21. Comment in: Clin Infect Dis 1996 Feb;22(2):329–30.

Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. White MH, et al. **Clin Infect Dis** 1997 Apr;24(4):635–42

Ultra-long amphotericin B therapy for hepatosplenic candidiasis complicating acute promyelocytic leukaemia [letter] Lai ST, et al. **Clin Lab Haematol** 1996 Mar; 18(1):62–3

Musculoskeletal coccidioidomycosis. A review of 25 cases. Kushwaha VP, et al. **Clin Orthop** 1996 Nov;(332):190–9

Entomophthoramycosis: therapeutic success by using amphotericin B and terbinafine. Foss NT, et al. **Dermatology** 1996;193(3):258–60

Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Viscoli C, et al. **Eur J Cancer** 1996 May;32A(5):814–20

Nonsurgical cure of isolated cerebral mucormycosis in an intravenous drug user. Blázquez R, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jul;15(7):598–9

Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Erjavec Z, et al. **Eur J Clin Microbiol Infect Dis** 1997 May;16(5):364–8

Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Phillips P, et al. **Eur J Clin Microbiol Infect Dis** 1997 May;16(5):337–45

Combined treatment with amphotericin-B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation. Catalano L, et al. **Haematologica** 1997 Jan–Feb;82(1):71–2

Amphotericin B in visceral leishmaniasis [letter; comment] Jha BB. **Indian Pediatr** 1996 Nov;33(11):971. Comment on: Indian Pediatr 1996 Jun;33(6):499–501.

Amphotericin B in resistant visceral leishmaniasis [see comments] Sahay AS, et al. **Indian Pediatr** 1996 Jun; 33(6):499–501. Comment in: Indian Pediatr 1996 Nov;33(11):971.

A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Abele-Horn M, et al. **Infection** 1996 Nov–Dec;24(6):426–32

Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Evdoridou J, et al. **Infection** 1997 Mar–Apr;25(2):112–6 (29 ref.)

Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis. Roth C, et al. **Infection** 1996 Sep–Oct;24(5):354–60

Liposomal amphotericin B and recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in the treatment of paediatric AIDS-related cryptococcosis. Manfredi R, et al. **Int J STD AIDS** 1997 Jun;8(6):406–8

Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination (SOD). Abele-Horn M, et al. **Intensive Care Med** 1997 Feb; 23(2):187–95

Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Nolla-Salas J, et al. **Intensive Care Med** 1997 Jan; 23(1):23–30

Changes in the natural history of invasive pulmonary aspergillosis in neutropenic leukemic patients. Ruchlemer

R, et al. **Isr J Med Sci** 1996 Nov;32(11):1089–92

Ocular blastomycosis in dogs: 73 cases, 108 eyes (1985–1993). Bloom JD, et al. **J Am Vet Med Assoc** 1996 Oct 1; 209(7):1271–4

Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs. Krawiec DR, et al. **J Am Vet Med Assoc** 1996 Dec 15;209(12):2073–5

Safety and efficacy of Intralipid emulsions of amphotericin B [letter] Herbrecht R, et al. **J Antimicrob Chemother** 1997 Jul;40(1):137–9 (9 ref.)

Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. Leenders AC, et al. **J Antimicrob Chemother** 1996 Aug;38(2):215–25

The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole. Ohtsuka K, et al. **J Antimicrob Chemother** 1997 Jan; 39(1):71–7

Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients [letter] Petit N, et al. **J Antimicrob Chemother** 1996 Jul; 38(1):154–7

Safety and efficacy of Intralipid emulsions of amphotericin B. Sievers TM, et al. **J Antimicrob Chemother** 1996 Sep; 38(3):333–47

Breakthrough fungemia due to Hansenula anomala in a leukemia patient successfully treated with amphotericin B [letter] Kunovà A, et al. **J Chemother** 1996 Feb;8(1):85–6

Histoplasmosis—a ten year follow-up. Johnston AW, et al. **J Infect** 1996 Sep;33(2):111–3

Reversal of encephalopathy during treatment with amphotericin-B. Antonini G, et al. **J Neurol Sci** 1996 Dec; 144(1–2):212–3

Treatment of coccidioidal spinal infection: experience in 16 cases. Herron LD, et al. **J Spinal Disord** 1997 Jun; 10(3):215–22 (11 ref.)

Selective intestinal decontamination in multiple trauma patients: prospective, controlled trial. Lingnau W, et al. **J Trauma** 1997 Apr;42(4):687–94

Pneumonia during remission induction chemotherapy in patients with AML or MDS. Wilhelm M, et al. **Leukemia** 1996 Dec;10(12):1870–3

Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Andström EE, et al. **Mycoses** 1996 May–Jun;39(5–6):185–93

Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients. Böhme A, et al. **Mycoses** 1996 Nov–Dec;39(11–12):419–26

Tracheobronchial aspergillosis in a patient with AIDS treated with aerosolized amphotericin B combined with itraconazole. Dal Conte I, et al. **Mycoses** 1996 Sep–Oct; 39(9–10):371–4

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. van der Horst CM, et al. **N Engl J Med** 1997 Jul 3;337(1):15–21

Use of intralipid as a vehicle for amphotericin B in the treatment of cryptococcal meningitis in a renal transplant recipient [letter] Nicol AJ, et al. **Nephron** 1996;73(2):312–3

Intraconal amphotericin B for the treatment of rhino-orbital mucormycosis. Luna JD, et al. **Ophthalmic Surg Lasers** 1996 Aug;27(8):706–8

Successful therapy of Candida albicans arthritis with a sequential intravenous amphotericin B and oral fluconazole regimen. Barson WJ, et al. **Pediatr Infect Dis J** 1996 Dec; 15(12):1119–22 (42 ref.)

Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Driessen M, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1107–12

Successful combination of amphotericin therapy and surgical resection for fungal necrotizing pneumoniae in a child receiving chemotherapy for leukemia. Suc A, et al. **Pediatr Pulmonol** 1997 May;23(5):386–8

Nosocomial cerebral aspergillosis: a report of 3 cases. Darras-Joly C, et al. **Scand J Infect Dis** 1996;28(3):317–9 (28 ref.)

Fatal outcome of disseminated candidosis after allogeneic bone marrow transplantation under treatment with liposomal and conventional amphotericin-B. A report of 4 cases with determination of the Mic values. Krüger W, et al. **Scand J Infect Dis** 1996;28(3):313–6

Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis. Castagnola E, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):317–8

Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Gangneux JP, et al. **Trans R Soc Trop Med Hyg** 1996 Sep–Oct;90(5):574–7

Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. Nonata R, et al. **Trans R Soc Trop Med Hyg** 1997 Jan–Feb;91(1):77

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Thakur CP, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):319–22

Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Reichenspurner H, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):627–8

Mucormycosis. Adjunctive therapy with hydrogen peroxide. Blaine DA, et al. **Va Med Q** 1996 Winter;123(1):30–2

[Palliative percutaneous treatment under ultrasonographic control of inoperable pulmonary aspergilloma: Galenic analysis (letter)] Meges B, et al. **Rev Mal Respir** 1996 Dec; 13(6):614–5 **(Fre)**

[Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B] Sampaio RN, et al. **Rev Soc Bras Med Trop** 1997 Mar–Apr; 30(2):125–8 (Eng. Abstr.) **(Por)**

[Otorhinolaryngological manifestations of mucormycosis. Study of 6 cases] Duque Fisher CS, et al. **Acta Otorrinolaringol Esp** 1996 Jul–Aug;47(4):291–4 (Eng. Abstr.) **(Spa)**

[Comments on the treatment of rhinocerebral mucormycosis] Pardal Refoyo JL, et al. **Acta Otorrinolaringol Esp** 1997 Mar;48(2):175–6 (Eng. Abstr.) **(Spa)**

[Liposomal amphotericin B in the treatment of systemic fungal infection in the neonate. The results of one case] Baquero Artigao F, et al. **An Esp Pediatr** 1996 Aug; 45(2):209–12 **(Spa)**

[Resolution of a disseminated infection by Fusarium solani in a patient with acute promyelocytic leukemia and granulocytopenia secondary to chemotherapy by the combined use of G-CSF and liposomal amphotericin B (letter)] Sancho JM, et al. **Med Clin (Barc)** 1997 Jun 21; 109(4):156–7 **(Spa)**

[Oral amphotericin B inefficacy in the treatment of fluconazole++ resistant oropharyngeal candidiasis in HIV-positive patients (letter)] Laguna F, et al. **Rev Clin Esp** 1996 Dec;196(12):878–9 **(Spa)**

TOXICITY

Nephrotoxicity of amphotericin B administered to dogs in a fat emulsion versus five percent dextrose solution. Randall SR, et al. **Am J Vet Res** 1996 Jul;57(7):1054–8

Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B. Walev I, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1116–20

Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Wasan KM, et al. **Clin Infect Dis** 1997 Jan; 24(1):78–80

Effect of amphotericin B associated with a lipid emulsion on the oxidative burst of human polymorphonuclear leukocytes. Marzzullo L, et al. **Gen Pharmacol** 1997 Feb; 28(2):203–7

Protection from amphotericin B-induced lipid peroxidation in rats by fructose-1,6-diphosphate. Rao MR, et al. **Res Commun Mol Pathol Pharmacol** 1997 Feb;95(2):217–20

Amphotericin B: new life for an old drug. Hartsel S, et al. **Trends Pharmacol Sci** 1996 Dec;17(12):445–9 (51 ref.)

URINE

Rapid determination of amphotericin B in serum and urine by third-order derivative spectrophotometry. Botsoglou NA, et al. **J Pharm Sci** 1996 Apr;85(4):402–6

AMPICILLIN

ADMINISTRATION & DOSAGE

The effect of timing of single-dose transplacental ampicillin-sulbactam therapy for prevention of neonatal group B streptococcal colonization and bacteremia in a rabbit model. McDuffie RS Jr, et al. **Am J Obstet Gynecol** 1996 Aug;175(2):406–10

Spinal epidural abscess associated with epidural anesthesia: gadolinium-enhanced magnetic resonance imaging and its usefulness in diagnosis and treatment. Higuchi T, et al. **Intern Med** 1996 Nov;35(11):902–4

Sustained release of antibiotic from a fibrin-gelatin-antibiotic mixture. Park MS, et al. **Laryngoscope** 1997 Oct; 107(10):1378–81

Improvement of some pharmaceutical properties of drugs by cyclodextrin complexation. Part 6: Ampicillin. Ammar HO, et al. **Pharmazie** 1996 Aug;51(8):568–70

[Enhancement of treatment efficacy in experimental plague by the sequential administration of antibiotics] Makarovskaia LN, et al. **Antibiot Khimioter** 1996; 41(11):25–7 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Acute upper extremity ischemia during concomitant use of ergotamine tartrate and ampicillin. Fukui S, et al. **Ann Vasc Surg** 1997 Jul;11(4):420–4

Does treatment of bloody diarrhea due to Shigella dysenteriae type 1 with ampicillin precipitate hemolytic uremic syndrome? Bin Saeed AA, et al. **Emerg Infect Dis** 1995 Oct–Dec;1(4):134–7

Corneal graft after drug-induced toxic epidermal necrolysis (Lyell's disease). Rodrigues-Ares MT, et al. **Int Ophthalmol** 1997;21(1):39–41

Evaluation of hypersensitivity to microencapsulated ampicillin in guinea pigs. Barsoum IS, et al. **J Antimicrob Chemother** 1997 Jan;39(1):63–9

[Neisseria meningitidis strains with decreased susceptibility to penicillin and ampicillin] Quiles Durá JL, et al. **An Esp Pediatr** 1997 Apr;46(4):325–7 (Eng. Abstr.) **(Spa)**

ANALOGS & DERIVATIVES

Oral bioavailability and in vitro stability of pivampicillin, bacampicillin, talampicillin, and ampicillin in horses. Ensink JM, et al. **Am J Vet Res** 1996 Jul;57(7):1021–4

Modified fluorimetric assay for estimating ampicilloate concentrations and its use for detecting beta-lactamase and penicillin acylase activity in bacteria. Baker WL. **Analyst** 1997 May;122(5):447–53

Susceptibility of Pseudomonas aeruginosa of various pyocin types to the newly synthesized ampicillin derivative, N-(6,7-difluoroquinolonyl)ampicillin. Chen CH, et al. **J Antimicrob Chemother** 1997 Mar;39(3):325–30

ANALYSIS

Ampicillin and amoxicillin residue detection in milk, using microbial receptor assay (Charm II) and liquid chromatography methods, after extra-label administration of the drugs to lactating cows. Anderson KL, et al. **Am J Vet Res** 1996 Jan;57(1):73–8

Rapid determination of ampicillin in bovine milk by liquid chromatography with fluorescence detection. Ang CY, et al. **J AOAC Int** 1997 Jan–Feb;80(1):25–30

Rapid method for the determination of ampicillin residues in animal muscle tissues by high-performance liquid chromatography with fluorescence detection. Luo W, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):401–7

Determination of ampicillin residues in milk by ion-pair reversed phase high performance liquid chromatography after precolumn derivatization. Verdon E, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1201–7

Interlaboratory study of the analysis of ampicillin by liquid chromatography. Zhu Y, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1151–6

Modeling drug residue uptake by eggs: yolks contain ampicillin residues even after drug withdrawal and nondetectability in the plasma. Donoghue DJ, et al. **Poult Sci** 1997 Mar;76(3):458–62

BLOOD

Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Gavaldà J, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):173–8

CHEMISTRY

Liposome-encapsulated ampicillin: physicochemical and antibacterial properties. Schumacher I, et al. **J Pharm Sci** 1997 May;86(5):635–41

ECONOMICS

Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. McKinnon PS, et al. **Clin Infect Dis** 1997 Jan;24(1):57–63

IMMUNOLOGY

Anaphylaxis to penicillins after non-therapeutic exposure: an immunological investigation. Blanca M, et al. **Clin Exp Allergy** 1996 Mar;26(3):335–40

METABOLISM

Modification of penicillin-binding protein 5 associated with high-level ampicillin resistance in Enterococcus faecium. Ligozzi M, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):354–7

Distribution of penicillins into subcutaneous tissue chambers in ponies. Ensink JM, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):439–44

PHARMACOKINETICS

Oral bioavailability and in vitro stability of pivampicillin, bacampicillin, talampicillin, and ampicillin in horses. Ensink JM, et al. **Am J Vet Res** 1996 Jul;57(7):1021–4

Distribution of systemically administered ampicillin, benzylpenicillin, and flucloxacillin in excisional wounds in diabetic and normal rats and effects of local topical vasodilator treatment. Cross SE, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1703–10

Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Gavaldà J, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):173–8

Pharmacokinetic evaluation of liposomal encapsulated ampicillin in male and female rats. Pardue RL, et al. **Biopharm Drug Dispos** 1997 May;18(4):279–92

Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers. Champoux N, et al. **Br J Clin Pharmacol** 1996 Sep;42(3):325–31

Disposition of ampicillin sodium in horses, ponies and donkeys after intravenous administration. Horspool LJ, et al. **Equine Vet J Suppl** 1992 Feb;(11):59–61

Penetration of ampicillin and sulbactam into human epididymis and testis. Klotz T, et al. **Infection** 1996 Sep–Oct;24(5):372–4

Effect of Khat chewing on the bioavailability of ampicillin and amoxycillin. Attef OA, et al. **J Antimicrob Chemother** 1997 Apr;39(4):523–5

Mechanism of absorption enhancement in humans after rectal

administration of ampicillin in suppositories containing sodium caprate. Lindmark T, et al. **Pharm Res** 1997 Jul; 14(7):930–5
Single-dose pharmacokinetics of ampicillin/sulbactam (2:1) combination after intravenous administration to sheep and goats. Carceles CM, et al. **Res Vet Sci** 1996 Sep;61(2):143–6
Bioavailability of pivampicillin and ampicillin trihydrate administered as an oral paste in horses. Ensink JM, et al. **Vet Q** 1996;18 Suppl 2:S117–20
Some pharmacokinetic parameters of ampicillin/sulbactam combination after intravenous and intramuscular administration to goats. Espuny A, et al. **Vet Q** 1996 Dec; 18(4):136–40

PHARMACOLOGY

Treatment of experimental endocarditis due to ampicillin-susceptible or ampicillin-resistant Salmonella enteritidis. Fernández Guerrero ML, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1589–93
Ampicillin susceptibilities of vaginal and placental isolates of group B streptococcus and Escherichia coli obtained between 1992 and 1994. Meyn LA, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1173–4
Enhancement of in vitro renaturation of recombinant human pro-urokinase by ampicillin. Hua ZC, et al. **Biochem Mol Biol Int** 1996 Aug;39(6):1093–7
Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Lipsky BA, et al. **Clin Infect Dis** 1997 Apr;24(4):643–8
Resistance patterns of Streptococcus pneumoniae and Haemophilus influenzae isolates recovered in Egypt from children with pneumonia. The Antimicrobial Resistance Surveillance Study Group. Ostroff SM, et al. **Clin Infect Dis** 1996 Nov;23(5):1069–74
Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Hachem CY, et al. **Diagn Microbiol Infect Dis** 1996 Jan; 24(1):37–41
Assessment of the synergistic interactions of levofloxacin and ampicillin against Enterococcus faecium by the checkerboard agar dilution and time-kill methods. Smith CE, et al. **Diagn Microbiol Infect Dis** 1997 Mar;27(3):85–92
Evaluation of the resistance induction in enteric flora in children caused by oral ampicillin plus sulbactam. Soylu A, et al. **J Antimicrob Chemother** 1997 Jun;39(6):833–5
Rapid flow cytometric assessment of mecillinam and ampicillin bacterial susceptibility. Walberg M, et al. **J Antimicrob Chemother** 1996 Jun;37(6):1063–75
Plasmid characterization and pulsed-field electrophoretic analysis demonstrate that ampicillin-resistant strains of Salmonella enteritidis phage type 6a are derived from Salm. enteritidis phage type 4. Ridley AM, et al. **J Appl Bacteriol** 1996 Dec;81(6):613–8
Pril-ampicillin-dextrin-ethanol agar for the isolation and quantification of Aeromonas spp. from polluted environmental waters. Imziln B, et al. **J Appl Microbiol** 1997 May;82(5):557–66
Bioluminescence measurements of the antilisterial activity of nisin: comparison with ampicillin and streptomycin. Ukuku DO, et al. **J Biolumin Chemilumin** 1996 May-Jun; 11(3):169–73
The influence of cefuroxime and ampicillin on uterus contractility. Kouvelas D, et al. **J Chemother** 1995 Nov; 7 Suppl 4:99–100
Correlation of in vitro susceptibility results for amoxicillin-clavulanate and ampicillin-sulbactam tested against Escherichia coli. O'Shaughnessy EM, et al. **J Clin Microbiol** 1997 Jul;35(7):1902–3
Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks. Zerva L, et al. **J Clin Microbiol** 1996 Aug; 34(8):1970–4
Effect of time and temperature on inactivation of aminoglycosides by ampicillin at neonatal dosages. Daly JS, et al. **J Perinatol** 1997 Jan-Feb;17(1):42–5
Liposome-encapsulated ampicillin: physicochemical and antibacterial properties. Schumacher I, et al. **J Pharm Sci** 1997 May;86(5):635–41
Minimal inhibitory concentrations of sulbactam/ampicillin against drug sensitive and drug resistant isolates of Mycobacterium tuberculosis. Paramasivan CN, et al. **Microbios** 1997;89(360–361):135–41
In vitro susceptibility patterns of nonserotypable Haemophilus influenzae from patients with chronic bronchitis. Butt HL, et al. **Pathology** 1997 Feb;29(1):72–5
Meningitis caused by Neisseria meningitidis C relatively resistant to penicillin and ampicillin [letter] Pisano A, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):643
Improvement of some pharmaceutical properties of drugs by cyclodextrin complexation. Part 6: Ampicillin. Ammar HO, et al. **Pharmazie** 1996 Aug;51(8):568–70
[Neisseria meningitidis with limited sensitivity to ampicillin-amoxicillin combination (letter)] Boize P, et al. **Arch Pediatr** 1997 Jan;4(1):97–8 **(Fre)**
[Enterobacteriaceae isolated in eastern Romania: the evolution of ampicillin sensitivity in the 1970–1995 period] Poiata A, et al. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan-Jun;42(1-2):21–6 (Eng. Abstr.) **(Rum)**
[Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid] Villar HE, et al. **Enferm Infecc Microbiol Clin** 1996 May;14(5):308–10 (Eng. Abstr.) **(Spa)**
[Streptococcus pyogenes: in vitro susceptibility to several antimicrobials in two date periods] Giglio MS, et al. **Rev Med Chil** 1996 Jun;124(6):715–9 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Ampicillin for neonatal group B streptococcal prophylaxis: how rapidly can bactericidal concentrations be achieved? Bloom SL, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):974–6
Group B Streptococcus and preterm premature rupture of membranes: a randomized, double-blind clinical trial of antepartum ampicillin. Grable IA, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1036–42
PCR-based detection of bacterial DNA after antimicrobial treatment is indicative of persistent, viable bacteria in the chinchilla model of otitis media. Post JC, et al. **Am J Otolaryngol** 1996 Mar-Apr;17(2):106–11
Outcome of leptospirosis in children. Marotto PC, et al. **Am J Trop Med Hyg** 1997 Mar;56(3):307–10
Ampicillin-metronidazole treatment in idiopathic preterm labour: a randomised controlled multicentre trial. Svare J, et al. **Br J Obstet Gynaecol** 1997 Aug;104(8):892–7
Comparison of efficacy of sulbactam: ampicillin to ampicillin and saline for treatment of experimentally induced Escherichia coli diarrhea in neonatal calves. Lofstedt J, et al. **Can J Vet Res** 1996 Jul;60(3):210–5
Community-acquired pneumonia: need for a cost-effective approach to treatment [letter] Prabhudesai PP, et al. **Chest** 1997 Sep;112(3):861–2
Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. McKinnon PS, et al. **Clin Infect Dis** 1997 Jan;24(1):57–63
Does treatment of bloody diarrhea due to Shigella dysenteriae type 1 with ampicillin precipitate hemolytic uremic syndrome? Bin Saeed AA, et al. **Emerg Infect Dis** 1995 Oct-Dec;1(4):134–7
Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Falagas ME, et al. **Eur J Clin Microbiol Infect Dis** 1996 Dec; 15(12):913–21
Ampicillin/sulbactam versus cefotetan for the prevention of infection following cesarean delivery in high-risk patients: a randomized double-blind trial. Bracero LA. **Gynecol Obstet Invest** 1997;44(1):21–5
Impact of intrapartum intravenous ampicillin on pregnancy outcome in women with preterm labor: a randomised, placebo-controlled study. Nadisauskiene R, et al. **Gynecol Obstet Invest** 1996;41(2):85–8
Ampicillin in the treatment of preterm labor: a randomised, placebo-controlled study. Nadisauskiene R, et al. **Gynecol Obstet Invest** 1996;41(2):89–92
Leprosy resistant to multi-drug-therapy (MDT) successfully treated with ampicillin-sulbactam combination--(a case report). Mehta VR. **Indian J Med Sci** 1996 Nov; 50(11):305–7
Effectiveness of ampicillin and combination of penicillin and chloramphenicol in the treatment of pneumonias: randomized controlled trial. Deivanayagam N, et al. **Indian Pediatr** 1996 Oct;33(10):813–6
Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections. Akova M, et al. **J Chemother** 1996 Aug;8(4):284–9
Ampicillin/sulbactam vs. clindamycin/gentamicin in the treatment of postpartum endometritis. Gall S, et al. **J Reprod Med** 1996 Aug;41(8):575–80
Evaluation of antibiotics for the elimination of the tonsillar carrier state of Streptococcus suis in pigs. Amass SF, et al. **J Vet Diagn Invest** 1996 Jan;8(1):64–7
Clinical efficacy of ampicillin, pivampicillin and procaine penicillin G in a soft tissue infection model in ponies. Ensink JM, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):445–53
A hospital outbreak of high-level beta-lactam-resistant Enterobacter spp.: association more with ampicillin and cephalosporin therapy than with nosocomial transmission. Walder M, et al. **Scand J Infect Dis** 1996;28(3):293–6
A survey of horses with acute diarrhoea: diagnosis, assessment of the prognosis, and comparison of two antibiotic therapies. van Duijkeren E, et al. **Vet Q** 1996 Dec;18(4):153–6
[High percentage of antibiotic resistance in Shigella infections in children in Curaçao] Wolfs TF, et al. **Ned Tijdschr Geneeskd** 1996 Dec 14;140(50):2510–3 (Eng. Abstr.) **(Dut)**
[Effectiveness of medical treatment of endocarditis due to Candida in premature newborns] García Cantó E, et al. **An Esp Pediatr** 1997 Mar;46(3):277–9 **(Spa)**
[Comparison of the therapeutic efficacy of the piperacillin/tazobactame combination vs. ampicillin and gentamycin in in the management of post-cesarean endometritis] Figueroa-Damian R, et al. **Ginecol Obstet Mex** 1996 May;64:214–8 (Eng. Abstr.) **(Spa)**

AMPICILLIN PIVALOYL ESTER see **PIVAMPICILLIN**

AMPICILLIN RESISTANCE

Antimicrobial resistance in fecal flora: longitudinal community-based surveillance of children from urban Mexico. Calva JJ, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1699–702
Treatment of experimental endocarditis due to ampicillin-susceptible or ampicillin-resistant Salmonella enteritidis. Fernández Guerrero ML, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1589–93
Ampicillin susceptibilities of vaginal and placental isolates of group B streptococcus and Escherichia coli obtained between 1992 and 1994. Meyn LA, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1173–4
Present status of drug resistance in cases of enteric fever in Rajasthan. Maheshwari VD, et al. **J Assoc Physicians India** 1996 Sep;44(9):618–9
Revised approach for identification and detection of ampicillin and vancomycin resistance in Enterococcus species by using MicroScan panels. Iwen PC, et al. **J Clin Microbiol** 1996 Jul;34(7):1779–83
Correlation of in vitro susceptibility results for amoxicillin-clavulanate and ampicillin-sulbactam tested against Escherichia coli. O'Shaughnessy EM, et al. **J Clin Microbiol** 1997 Jul;35(7):1902–3
Minimal inhibitory concentrations of sulbactam/ampicillin against drug sensitive and drug resistant isolates of Mycobacterium tuberculosis. Paramasivan CN, et al. **Microbios** 1997;89(360–361):135–41
[Amoxicillin and Streptococcus pneumoniae] Soriano F, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):267 **(Spa)**
[Ampicillin esters are environment friendly (letter; comment)] Cronberg S. **Lakartidningen** 1997 May 14;94(20):1867–8. Comment on: Lakartidningen 1997 Mar 19;94(12):1061–4, 1067–8. **(Swe)**

GENETICS

Method for joining DNA fragments using positive selection. Gubin AN. **Biotechniques** 1996 Sep;21(3):412–4
Vectors encoding alternative antibiotic resistance for use in the yeast two-hybrid system. Watson MA, et al. **Biotechniques** 1996 Aug;21(2):255–9
Molecular epidemiology of antibiotic resistance of Salmonella enteritidis during a 7-year period in Greece. Tassios PT, et al. **J Clin Microbiol** 1997 Jun;35(6):1316–21
Dimerization of plasmid DNA accelerates selection for antibiotic resistance. Mazin AV, et al. **Mol Microbiol** 1996 Apr;20(1):101–8
The real threat from antibiotics [letter; comment] [see comments] Salyers A. **Nature** 1996 Nov 28;384(6607):304 . Comment on: Nature 1996 Oct 17;383(6601):559. Comment in: Nature 1997 Jan 23;385(6614):290.

PHYSIOLOGY

Characterization of clinical isolates of beta-lactamase-negative, highly ampicillin-resistant Enterococcus faecalis. Cercenado E, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2420–2

AMPLIFIERS

A targeting-and-extracting technique to enhance hearing in the presence of competing speech. Liu C, et al. **J Acoust Soc Am** 1997 May;101(5 Pt 1):2877–91
Assistive devices for the elderly. Kaplan H. **J Am Acad Audiol** 1996 Jun;7(3):203–11
The methodology and scope of human microneurography. Gandevia SC, et al. **J Neurosci Methods** 1997 Jun 27; 74(2):123–36 (87 ref.)
Microphone sensitivity as a source of variation in nasalance scores. Zajac DJ, et al. **J Speech Hear Res** 1996 Dec; 39(6):1228–31
Optimizing MRI signal-to-noise ratio for quadrature unmatched RF coils: two preamplifiers are better than one. Sorgenfrei BL, et al. **Magn Reson Med** 1996 Jul; 36(1):104–10
Biopotential amplifier for simultaneous operation with biomagnetic instruments. Virtanen J, et al. **Med Biol Eng Comput** 1997 Jul;35(4):402–8
Ambulatory polysomnography using a new programmable amplifier system with on-line digitization of data: technical and clinical findings. Drewes AM, et al. **Sleep** 1996 May; 19(4):347–54

ADVERSE EFFECTS

Epidemiological evaluation of hearing damage related to strongly amplified music (personal cassette players, discotheques, rock concerts)--high-definition audiometric survey on 1364 subjects. Meyer-Bisch C. **Audiology** 1996 May-Jun;35(3):121–42

AMPROLIUM

ANALYSIS

High performance liquid chromatographic assay of amprolium and ethopabate in chicken feed using solid-phase extraction. Tan HS, et al. **J Pharm Biomed Anal** 1996 Nov;15(2):259–65

BLOOD

Rapid and sensitive determination of amprolium in chicken plasma by high-performance liquid chromatography with

post-column reaction. Hamamoto K, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):489–92

AMPULLA OF VATER see **VATER'S AMPULLA**

AMPUTATION

Palliative major amputation and quality of life in cancer patients. Merimsky O, et al. **Acta Oncol** 1997;36(2):151–7

Reconstruction of the heel pad in ankle disarticulation with a free muscle transfer. Pinzur MS, et al. **Am J Orthop** 1997 Jul;26(7):491–3

Limb loss after lower extremity bypass. Reifsnyder T, et al. **Am J Surg** 1997 Aug;174(2):149–51

Concomitant orthopedic and vascular injuries as predictors for limb loss in blunt lower extremity trauma. Moniz MP, et al. **Am Surg** 1997 Jan;63(1):24–8

Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Taber SW, et al. **Ann Surg Oncol** 1997 Jul–Aug;4(5):440–5 (30 ref.)

Forequarter amputation with fasciocutaneous deltoid flap reconstruction for malignant tumors of the upper extremity. Volpe CM, et al. **Ann Surg Oncol** 1997 Jun;4(4):298–302

Bullous drug eruption treated with amputation. A challenging case of vancomycin-induced linear IgA disease. Bitman LM, et al. **Arch Dermatol** 1996 Nov;132(11):1289–90

Lower extremity amputation secondary to heparin-associated thrombocytopenia with thrombosis. Diamant DS. **Arch Phys Med Rehabil** 1996 Oct;77(10):1090–2

Transtibial prosthesis for a patient with Kaposi's sarcoma lesions on the residual limb. Ethans KD, et al. **Arch Phys Med Rehabil** 1997 Jan;78(1):106–8

Arterial injury in the lower limb from blunt trauma. Faris IB, et al. **Aust N Z J Surg** 1997 Jan;67(1):25–30

'Trash foot' following operations involving the abdominal aorta. Kuhan G, et al. **Aust N Z J Surg** 1997 Jan;67(1):21–4 (14 ref.)

Skin from the amputated limb should not be wasted [letter] Taylor PR. **Br J Surg** 1996 Nov;83(11):1653–4

Lower limb amputation and grade of surgeon. White SA, et al. **Br J Surg** 1997 Apr;84(4):509–11

Reorganizational and perceptional changes after amputation. Knecht S, et al. **Brain** 1996 Aug;119 (Pt 4):1213–9

Four limb amputations due to electrical burn caused by TV antenna contact with overhead electric cables. Celiköz B, et al. **Burns** 1997 Feb;23(1):81–4 (17 ref.)

Stride analysis after proximal tibial replacement. Zohman GL, et al. **Clin Orthop** 1997 Jun;(339):180–4

Squamous cell carcinoma arising in osteomyelitis and chronic wounds. Treatment with Mohs micrographic surgery vs amputation. Kirsner RS, et al. **Dermatol Surg** 1996 Dec; 22(12):1015–8

Report of the Diabetic Foot and Amputation Group. Edmonds M, et al. **Diabet Med** 1996 Sep;13(9 Suppl 4):S27–42 (76 ref.)

Diabetes and nontraumatic lower extremity amputations. Incidence, risk factors, and prevention--a 12-year follow-up study in Nauru. Humphrey AR, et al. **Diabetes Care** 1996 Jul;19(7):710–4

A foot risk classification system to predict diabetic amputation in Pima Indians. Mayfield JA, et al. **Diabetes Care** 1996 Jul;19(7):704–9

Therapeutic footwear can reduce plantar pressures in patients with diabetes and transmetatarsal amputation. Mueller MJ, et al. **Diabetes Care** 1997 Apr;20(4):637–41

Determination of amputation level in ischemic limbs. Reappraisal of the measurement of TcPo2. Wütschert R, et al. **Diabetes Care** 1997 Aug;20(8):1315–8

The concept of knee salvage: why does a failed femorocrural/pedal arterial bypass not affect the amputation level? Panayiotopoulos YP, et al. **Eur J Vasc Endovasc Surg** 1997 May;13(5):477–85

Foot function in diabetic patients after partial amputation. Garbalosa JC, et al. **Foot Ankle Int** 1996 Jan;17(1):43–8

Control of the residual tibia in transtibial amputation. Pinzur MS, et al. **Foot Ankle Int** 1996 Sep;17(9):538–40

Benchmark analysis on diabetics at high risk for lower extremity amputation. Pinzur MS, et al. **Foot Ankle Int** 1996 Nov;17(11):695–700

State of the art--treatment of peripheral occlusive arterial disease (POAD) with drugs vs. vascular reconstruction or amputation. Haustein KO. **Int J Clin Pharmacol Ther** 1997 Jul;35(7):266–74 (101 ref.)

Should chemical sympathectomy precede below knee amputation? Lantsberg L, et al. **Int Surg** 1996 Jan–Mar; 81(1):85–7

Digital occurrence of nodular malignant melanoma. Knedgen JF, et al. **J Am Podiatr Med Assoc** 1997 Apr;87(4):178–82

After amputation. Rehabilitation of the diabetic amputee. Van Ross ER. **J Am Podiatr Med Assoc** 1997 Jul;87(7):332–5

Antibody-induced arterial thromboembolism resulting in amputation after total knee arthroplasty. Markovich GD, et al. **J Arthroplasty** 1997 Apr;12(3):350–2

Energy expenditure during walking by children who have proximal femoral focal deficiency. Fowler E, et al. **J Bone Joint Surg Am** 1996 Dec;78(12):1857–62

Continuous postoperative infusion of a regional anesthetic after an amputation of the lower extremity. A randomized clinical trial. Pinzur MS, et al. **J Bone Joint Surg Am** 1996 Oct;78(10):1501–5

Management of fibular hemimelia: amputation or limb lengthening. Naudie D, et al. **J Bone Joint Surg Br** 1997 Jan;79(1):58–65

The impact of gender on amputation. Armstrong DG, et al. **J Foot Ankle Surg** 1997 Jan–Feb;36(1):66–9; discussion 81

Effectiveness of diabetic insoles to reduce foot pressures. Ashry HR, et al. **J Foot Ankle Surg** 1997 Jul–Aug; 36(4):268–71; discussion 328–9

The natural history of great toe amputations. Murdoch DP, et al. **J Foot Ankle Surg** 1997 May–Jun;36(3):204–8; discussion 256

Replantation-revascularization and primary amputation in major hand injuries. Resources spent on treatment and the indirect costs of sick leave in Sweden. Holmberg J, et al. **J Hand Surg [Br]** 1996 Oct;21(5):576–80

Outcomes associated with diabetes-related amputations in The Netherlands and in the state of California, USA. Van Houtum WH, et al. **J Intern Med** 1996 Oct;240(4):227–31

Increased phantom limb pain as an initial symptom of spinal-neoplasia [published erratum appears in J Pain Symptom Manage 1997 Sep;14(3):135] Chang VT, et al. **J Pain Symptom Manage** 1997 Jun;13(6):362–4 (18 ref.)

Neonatal gangrene of the extremities. Letts M, et al. **J Pediatr Orthop** 1997 May–Jun;17(3):397–401

Amputation and prostheses in Khartoum. Mohamed IA, et al. **J R Coll Surg Edinb** 1997 Aug;42(4):248–51

Prognostic factors in carcinoma of the penis: multivariate analysis of 145 patients treated with amputation and lymphadenectomy. Lopes A, et al. **J Urol** 1996 Nov; 156(5):1637–42

Anesthesia type does not influence early graft patency or limb salvage rates of lower extremity arterial bypass. Pierce ET, et al. **J Vasc Surg** 1997 Feb;25(2):226–32; discussion 232–3

Chopping of hands [letter] Hussain SS. **Lancet** 1997 Jun 7; 349(9066):1704

Amputation for premature peripheral atherosclerosis: do young patients do better? [comment] [see comments] Skinner JA, et al. **Lancet** 1996 Nov 23;348(9039):1396. Comment on: Lancet 1996 Nov 23;348(9039):1417–9. Comment in: Lancet 1997 Feb 1;349(9048):362.

Decision making and results in subtotal and total lower leg amputations: reconstruction versus amputation. Hierner R, et al. **Microsurgery** 1995;16(12):830–9

Aggressive surgical treatment of digital papillary adenocarcinoma. Singla AK, et al. **Plast Reconstr Surg** 1997 Jun;99(7):2058–60

A young female patient with reflex sympathetic dystrophy of the upper limb in whom amputation became inevitable. Geertzen JH, et al. **Prosthet Orthot Int** 1997 Aug; 21(2):159–61

Painful neuromata following upper limb amputation. Geraghty TJ, et al. **Prosthet Orthot Int** 1996 Dec; 20(3):176–81

Local anesthetic infusion through nerve sheath catheters for analgesia following upper extremity amputation. Clinical report. Enneking FK, et al. **Reg Anesth** 1997 Jul–Aug; 22(4):351–6

Results of minor foot amputations in diabetic mellitus. Wong YS, et al. **Singapore Med J** 1996 Dec;37(6):604–6

Surgical morbidity and the risk of amputation due to infected puncture wounds in diabetic versus nondiabetic adults. Armstrong DG, et al. **South Med J** 1997 Apr;90(4):384–9

Oxygen costs using a reciprocating gait orthosis in a paraplegic (T9) patient with a bilateral below-knee amputation: case report. Smith WE, et al. **Spinal Cord** 1997 Feb;35(2):121–3

Toe amputation in the diabetic patient. Kerstein MD, et al. **Surgery** 1997 Sep;122(3):546–7

The burden of diabetes in Wisconsin: diabetes-related amputations, 1994. Ford EJ, et al. **Wis Med J** 1996 Sep; 95(9):643–4

[Rheology and occlusive arterial disease of the legs] Dupuy-Fons C, et al. **J Mal Vasc** 1996;21(3):165–70 (Eng. Abstr.) **(Fre)**

[Vascular reconstruction and/or amputation in severely handicapped patients] Schwilden ED. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:866–9 (Eng. Abstr.) **(Ger)**

[Loss of extremities caused by heparin-induced thrombocytopenia] Wenzl ME, et al. **Unfallchirurg** 1996 Aug;99(8):607–11 (Eng. Abstr.) **(Ger)**

[Surgical amputation and prosthetic management in congenital fibrosarcoma of the lower extremity] Zembsch A, et al. **Z Orthop Ihre Grenzgeb** 1996 Nov–Dec; 134(6):517–9 (Eng. Abstr.) **(Ger)**

[Anaerobic gas gangrene after the amputation of an extremity] Izmailov GA, et al. **Vestn Khir Im I I Grek** 1996;155(5):77–9 (Eng. Abstr.) **(Rus)**

[Bacteremia by Porphyromonas asaccharolytica (letter)] Melón O, et al. **Enferm Infecc Microbiol Clin** 1997 Feb; 15(2):121 **(Spa)**

ADVERSE EFFECTS

Prevention of painful neuromas by epineural ligatures, flaps and grafts. Yüksel F, et al. **Br J Plast Surg** 1997 Apr; 50(3):182–5

Phantom eye: features and prevalence. The predisposing role of headache. Nicolodi M, et al. **Cephalalgia** 1997 Jun; 17(4):501–4

The primary care physician's role in evaluating the pediatric amputee. O'Neal ML, et al. **Compr Ther** 1997 Aug; 23(8):546–53 (20 ref.)

Improved wound healing in transtibial amputees receiving supplementary nutrition. Eneroth M, et al. **Int Orthop** 1997; 21(2):104–8

Amputation level assessment using lightguide spectrophotometry. Harrison DK, et al. **Prosthet Orthot Int** 1995 Dec;19(3):139–47

ECONOMICS

Surgical treatment for chronic critical leg ischaemia: a 5 year follow-up of socioeconomic outcome. Luther M. **Eur J Vasc Endovasc Surg** 1997 May;13(5):452–9

The cost-effectiveness of limb salvage for bone tumours. Grimer RJ, et al. **J Bone Joint Surg Br** 1997 Jul; 79(4):558–61

HISTORY

The Journal 150 and 100 years ago. April 1846 and 1896. Colon GA. **J La State Med Soc** 1996 Apr;148(4):146–8

METHODS

Minor amputations on the feet after revascularization for gangrene. A consecutive series of 95 limbs. Albrektsen SB, et al. **Acta Orthop Scand** 1997 Jun;68(3):291–3

Role of Gritti-Stokes amputation in peripheral vascular disease. Yusuf SW, et al. **Ann R Coll Surg Engl** 1997 Mar; 79(2):102–4

Transthoracic forequarter amputation and left pneumonectomy. Fianchini A, et al. **Ann Thorac Surg** 1996 Dec;62(6):1841–3

Transcutaneous partial oxygen pressure changes following skew flap and Burgess-type below-knee amputations. Johnson WC, et al. **Arch Surg** 1997 Mar;132(3):261–3

Prevention of painful neuromas by epineural ligatures, flaps and grafts. Yüksel F, et al. **Br J Plast Surg** 1997 Apr; 50(3):182–5

Major ablative procedures in orthopaedic surgery. Soucacos PN, et al. **Bull Hosp Jt Dis** 1996;55(1):46–52

Current concepts: amputation surgery in peripheral vascular disease. Pinzur MS. **Instr Course Lect** 1997;46:501–9 (24 ref.)

Amputation versus limb salvage. Tornetta P 3rd, et al. **Instr Course Lect** 1997;46:511–8

Modified Boyd amputation. Kornah B. **J Bone Joint Surg Br** 1996 Jan;78(1):149–50

Pulp neurovascular island flap for finger amputation. Lanzetta M, et al. **J Hand Surg [Am]** 1996 Sep;21(5):918–21

Total middle ray amputation. Lyall H, et al. **J Hand Surg [Br]** 1996 Oct;21(5):675–80

Analysis of a vertical compliance prosthetic foot. Miller LA, et al. **J Rehabil Res Dev** 1997 Jan;34(1):52–7

Stair ambulation in persons with transtibial amputation: an analysis of the Seattle LightFoot. Powers CM, et al. **J Rehabil Res Dev** 1997 Jan;34(1):9–18

Interface pressures and shear stresses at thirteen socket sites on two persons with transtibial amputation. Sanders JE, et al. **J Rehabil Res Dev** 1997 Jan;34(1):19–43

Uterine problems discovered after presumed hysterectomy: the Manchester operation revisited. Hopkins MP, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):846–8

Amputations of the foot and ankle: review of techniques and results. Choudhury SN, et al. **Orthopedics** 1997 May; 20(5):446–57; quiz 458–9 (70 ref.)

Rotationplasty. Kotz R. **Semin Surg Oncol** 1997 Jan–Feb; 13(1):34–40

MORTALITY

Mortality following lower extremity amputation in minorities with diabetes mellitus. Lavery LA, et al. **Diabetes Res Clin Pract** 1997 Jul;37(1):41–7

Relative mortality in lower limb amputees with diabetes mellitus. Ebskov LB. **Prosthet Orthot Int** 1996 Dec; 20(3):147–52

PSYCHOLOGY

Psychological status of diabetic people with or without lower limb disability. Carrington AL, et al. **Diabetes Res Clin Pract** 1996 Apr;32(1–2):19–25

Preoperative psychological evaluation and intervention in prospective amputees [letter] Zarif A, et al. **Plast Reconstr Surg** 1997 Aug;100(2):546

REHABILITATION

Effect of prosthetic mass on swing phase work during above-knee amputee ambulation. Gitter A, et al. **Am J Phys Med Rehabil** 1997 Mar–Apr;76(2):114–21

Predicting prosthetic rehabilitation outcome in lower limb amputee patients with the functional independence measure. Leung EC, et al. **Arch Phys Med Rehabil** 1996 Jun;77(6):605–8

Therapeutic footwear: enhanced function in people with diabetes and transmetatarsal amputation. Mueller MJ, et al. **Arch Phys Med Rehabil** 1997 Sep;78(9):952–6

Daily functioning of the lower extremity amputee: an overview of the literature. Pernot HF, et al. **Clin Rehabil** 1997 May;11(2):93–106 (71 ref.)

Relationships between measures of function, strength and walking speed in patients with diabetes and transmetatarsal amputation. Salsich GB, et al. **Clin Rehabil** 1997 Feb; 11(1):60–7

AMPUTATION

Predicting the use of prostheses by vascular amputees. Campbell WB, et al. **Eur J Vasc Endovasc Surg** 1996 Oct; 12(3):342–5

The effect of cognitive status on outcomes following rehabilitation. Resnick B, et al. **Fam Med** 1997 Jun; 29(6):400–5

Rehabilitation of lower limb traumatic amputees: the Sandy Gall Afghanistan Appeal's experience. Hettiaratchy SP, et al. **Injury** 1996 Sep;27(7):499–501

Rehabilitation of the older lower limb amputee: a brief review. Cutson TM, et al. **J Am Geriatr Soc** 1996 Nov; 44(11):1388–93 (60 ref.)

Stability of walking frames. Deathe AB, et al. **J Rehabil Res Dev** 1996 Feb;33(1):30–5

Obesity and metabolic disorders in adults with lower limb amputation. Kurdibaylo SF. **J Rehabil Res Dev** 1996 Oct; 33(4):387–94

Functional limitations in patients with diabetes and transmetatarsal amputations. Mueller MJ, et al. **Phys Ther** 1997 Sep;77(9):937–43

Pre and post-amputation mobility of trans-tibial amputees: correlation to medical problems, age and mortality. Johnson VJ, et al. **Prosthet Orthot Int** 1995 Dec; 19(3):159–64

The status of lower-limb amputation in Bangladesh: a 6-year review. Aftabuddin M, et al. **Surg Today** 1997;27(2):130–4

[Restoration of grip function in both hands after frostbite of all fingers and toes. A case report] Hofmann AK, et al. **Handchir Mikrochir Plast Chir** 1997 Jan;29(1):50–4 (Eng. Abstr.) **(Ger)**

[Special case report: Gangrene of all 4 extremities caused by disseminated intravascular coagulation in pneumococcal sepsis] Greitemann B, et al. **Z Orthop Ihre Grenzgeb** 1996 Nov–Dec;134(6):511–6 (Eng. Abstr.) **(Ger)**

[Swimming as a means of enhancing the adaptive potentials of the disabled after amputation of the lower extremities] Kurdyballo SF, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Jan–Feb;(1):25–8 (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

Survey of above knee (A/K) prostheses currently used in the Chugoku-Shikoku district of Japan. Nakano M, et al. **Acta Med Okayama** 1997 Feb;51(1):45–50

Popliteal artery trauma. Systemic anticoagulation and intraoperative thrombolysis improves limb salvage. Melton SM, et al. **Ann Surg** 1997 May;225(5):518–27; discussion 527–9

Risk factors predicting lower extremity amputations in patients with NIDDM. Lehto S, et al. **Diabetes Care** 1996 Jun;19(6):607–12

Incidence of lower limb amputations and diabetes. Trautner C, et al. **Diabetes Care** 1996 Sep;19(9):1006–9

Regional variation in the incidence of diabetes-related amputations in The Netherlands. van Houtum WH, et al. **Diabetes Res Clin Pract** 1996 Mar;31(1–3):125–32

Major lower limb amputation in diabetic patients: development during 1982 to 1993. Ebskov B, et al. **Diabetologia** 1996 Dec;39(12):1607–10

Cumulative risk of bypass, amputation or death following percutaneous transluminal angioplasty. Gutteridge W, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):134–9

Falling incidence of amputations for peripheral occlusive arterial disease in Western Australia between 1980 and 1992. Mattes E, et al. **Eur J Vasc Endovasc Surg** 1997 Jan; 13(1):14–22

Amputation and reamputation of the diabetic foot. Armstrong DG, et al. **J Am Podiatr Med Assoc** 1997 Jun;87(6):255–9

The acutely infected diabetic foot is not adequately evaluated in an inpatient setting. Edelson GW, et al. **J Am Podiatr Med Assoc** 1997 Jun;87(6):260–5

Lower extremity amputations of US elderly population on the rise. Renzi RM. **J Am Podiatr Med Assoc** 1996 Apr; 86(4):176–9

The impact of diabetes-related lower-extremity amputations in The Netherlands. van Houtum WH, et al. **J Diabetes Complications** 1996 Nov–Dec;10(6):325–30

Impact of arterial surgery and balloon angioplasty on amputation: a population-based study of 1155 procedures between 1973 and 1992. Hallett JW Jr, et al. **J Vasc Surg** 1997 Jan;25(1):29–38

Regarding "Impact of arterial surgery and balloon angioplasty on amputation: a population-based study of 1155 procedures between 1973 and 1992" [letter] Robicsek F. **J Vasc Surg** 1997 Aug;26(2):353

Lower limb amputees in Southern Finland. Alaranta H, et al. **Prosthet Orthot Int** 1995 Dec;19(3):155–8

Statistical analysis of amputations and trends in Korea. Kim YC, et al. **Prosthet Orthot Int** 1996 Aug;20(2):88–95

[2-year results of leg amputation in Hungary based on a nationwide data base] Kullmann L, et al. **Orv Hetil** 1997 Sep 14;138(37):2327–32 (Eng. Abstr.) **(Hun)**

[Limb amputations carried out in hospitals of the national health service in the years from 1990 to 1993] Sequeira FM, et al. **Acta Med Port** 1996 Jul–Sep;9(7–9):207–10 (Eng. Abstr.) **(Por)**

[Amputation of the lower extremities for non-traumatic causes in Slovakia in 1995] Petrašovič N, et al. **Rozhl Chir** 1996 Oct;75(10):504–8 (Eng. Abstr.) **(Slo)**

TRENDS

Statistical analysis of amputations and trends in Korea. Kim YC, et al. **Prosthet Orthot Int** 1996 Aug;20(2):88–95

UTILIZATION

Seasonal variations in lower extremity amputation. Armstrong DG, et al. **J Foot Ankle Surg** 1997 Mar–Apr; 36(2):146–50

VETERINARY

The absence of neuromas in beaks of adult hens after conservative trimming at hatch [published erratum appears in Aust Vet J 1996 Aug;74(2):161] Lunam CA, et al. **Aust Vet J** 1996 Jul;74(1):46–9

Cosmetic tail docking of dogs [see comments] Wansbrough RK. **Aust Vet J** 1996 Jul;74(1):59–63 (11 ref.). Comment in: Aust Vet J 1996 Dec;74(6):476–7.

An ethicist's commentary on the case of the bull mastiff with osteosarcoma. Barton F. **Can Vet J** 1997 Sep;38(9):536–7

Amputation and dexniguldipine as treatment for canine appendicular osteosarcoma. Hahn KA, et al. **J Cancer Res Clin Oncol** 1997;123(1):34–8

Canine osteosarcoma: amputation and chemotherapy. Berg J. **Vet Clin North Am Small Anim Pract** 1996 Jan; 26(1):111–21 (29 ref.)

Canine osteosarcoma: amputation and chemoimmunotherapy. MacEwen EG, et al. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):123–33 (50 ref.)

Limb-sparing surgery versus amputation for dogs with bone tumors. Straw RC, et al. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):135–43 (28 ref.)

[Follow-up studies of resections of claws in cattle] Grisiger M, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Nov; 103(11):454–7 (Eng. Abstr.) **(Ger)**

AMPUTATION, INTRAUTERINE see **AMNIOTIC BAND SYNDROME**

AMPUTATION STUMPS

see related
PHANTOM LIMB

Oral ketamine therapy in the treatment of postamputation stump pain [see comments] Nikolajsen L, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):427–9. Comment in: Acta Anaesthesiol Scand 1997 Mar;41(3):329–31.

Femur lengthening with a vascularized tibia bone flap. Fealy MJ, et al. **Ann Plast Surg** 1996 Aug;37(2):140–6

Phantom pain and sensation among British veteran amputees. Wartan SW, et al. **Br J Anaesth** 1997 Jun;78(6):652–9

The quadrifoliate flap: a combination of scapular, parascapular, latissimus dorsi and scapula bone flaps. Bakhach J, et al. **Br J Plast Surg** 1996 Oct;49(7):477–81

Amputation stump neuroma: ultrasound features. Provost N, et al. **J Clin Ultrasound** 1997 Feb;25(2):85–9

Endoscopic revision of an infected Syme amputation. Case report and review of the literature. Prymka M, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(2):125–8

The relationship of phantom limb pain to other phantom limb phenomena in upper extremity amputees. Montoya P, et al. **Pain** 1997 Aug;72(1–2):87–93

Factors affecting healing of below knee amputation. Low CK, et al. **Singapore Med J** 1996 Aug;37(4):392–3

[Reconstruction of the shape of the shoulder after scapulothoracic amputation] Gounot N, et al. **Ann Chir Plast Esthet** 1996 Jun;41(3):295–8 (Eng. Abstr.) **(Fre)**

[Dermatoses in leg amputees] Wlotzke U, et al. **Hautarzt** 1996 Jul;47(7):493–501 (44 ref.) (Eng. Abstr.) **(Ger)**

[The blood rheological properties in patients with amputation stumps and concomitant ischemic heart disease] Kaznacheev LN, et al. **Ter Arkh** 1997;69(5):69–71 (Eng. Abstr.) **(Rus)**

BLOOD SUPPLY

Fasciocutaneous blood supply in below-knee amputation. Humzah MD, et al. **J Bone Joint Surg Br** 1997 May; 79(3):441–3 (21 ref.)

INNERVATION

Autonomous stump movements in brain death. Lang CJ, et al. **Eur Neurol** 1997;37(4):249

Abnormal access of axial vibrotactile input to deafferented somatosensory cortex in human upper limb amputees. Kew JJ, et al. **J Neurophysiol** 1997 May;77(5):2753–64

PATHOLOGY

Stump length as related to atrophy and strength of the thigh muscles in trans-tibial amputees. Isakov E, et al. **Prosthet Orthot Int** 1996 Aug;20(2):96–100

PHYSIOPATHOLOGY

Wound healing and tissue repair of the surgical amputation of limbs [editorial] Burgess EM. **J Rehabil Res Dev** 1997 Jan;34(1):vii–ix

Interface pressures and shear stresses at thirteen socket sites on two persons with transtibial amputation. Sanders JE, et al. **J Rehabil Res Dev** 1997 Jan;34(1):19–43

Painful neuromata following upper limb amputation. Geraghty TJ, et al. **Prosthet Orthot Int** 1996 Dec; 20(3):176–81

Stump length as related to atrophy and strength of the thigh muscles in trans-tibial amputees. Isakov E, et al. **Prosthet Orthot Int** 1996 Aug;20(2):96–100

The use of Methenamine as an antiperspirant for amputees. Susak Z, et al. **Prosthet Orthot Int** 1996 Dec;20(3):172–5

[Prosthesis edge nodule and verrucous hyperplasia in leg amputees] Wlotzke U, et al. **Z Orthop Ihre Grenzgeb** 1997 May–Jun;135(3):233–5 (Eng. Abstr.) **(Ger)**

[Changes in the somatosensory evoked potentials in patients with amputated limbs with and without phantom pain syndrome] Reshetniak VK, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):4–7 (Eng. Abstr.) **(Rus)**

SURGERY

Results of humeral stump angulation osteotomy. Neusel E, et al. **Arch Orthop Trauma Surg** 1997;116(5):263–5

ULTRASONOGRAPHY

3-D imaging of residual limbs using ultrasound. He P, et al. **J Rehabil Res Dev** 1997 Jul;34(3):269–78

AMPUTATION, TRAUMATIC

see related
REPLANTATION

Cutaneous pulse oximetry in the preoperative assessment of devascularized digits [letter] Isenberg JS, et al. **Ann Plast Surg** 1996 Jun;36(6):659–61

Foreign-body sensation following 3M coupler use in the hand. Kind GM, et al. **Ann Plast Surg** 1996 Oct; 37(4):418–21

Salvage of a below-the-knee amputation with a fillet of foot free flap: a 15-year follow-up. Shaw WW, et al. **Ann Plast Surg** 1996 Oct;37(4):433–8

Pediatric amputation injuries: etiology, cost, and outcome. Trautwein LC, et al. **J Trauma** 1996 Nov;41(5):831–8

Reorganization of human cortical motor output maps following traumatic forearm amputation. Pascual-Leone A, et al. **Neuroreport** 1996 Sep 2;7(13):2068–70

Amputation of the penis during traditional circumcision. Ameh EA, et al. **Trop Doct** 1997 Apr;27(2):117

[Report of a case of traumatic avulsion of the penile skin with amputation of the glans] Martina G, et al. **Arch Esp Urol** 1996 Nov;49(9):981–3 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Prevention of painful neuromas by epineural ligatures, flaps and grafts. Yüksel F, et al. **Br J Plast Surg** 1997 Apr; 50(3):182–5

The primary care physician's role in evaluating the pediatric amputee. O'Neal ML, et al. **Compr Ther** 1997 Aug; 23(8):546–53 (20 ref.)

DIAGNOSIS

Using the Internet for rapid exchange of photographs and X-ray images to evaluate potential extremity replantation candidates. Buntic RF, et al. **J Trauma** 1997 Aug; 43(2):342–4

EPIDEMIOLOGY

Train injuries in children. Blazar PE, et al. **J Orthop Trauma** 1997 Feb–Mar;11(2):126–9

ETIOLOGY

Extremity lawn-mower injuries in children: report by the Research Committee of the Pediatric Orthopaedic Society of North America. Loder RT, et al. **J Pediatr Orthop** 1997 May–Jun;17(3):360–9

Ring avulsion injuries in a field environment. Varela CD. **Mil Med** 1996 May;161(5):308–10 (9 ref.)

PATHOLOGY

Complete transection of the trunk of passengers in car accidents. Nadjem H, et al. **Am J Forensic Med Pathol** 1996 Jun;17(2):167–71

PSYCHOLOGY

Emotional disturbances in trauma patients during the rehabilitation phase: studies of posttraumatic stress disorder and alexithymia. Fukunishi I, et al. **Gen Hosp Psychiatry** 1996 Mar;18(2):121–7

REHABILITATION

Mobility of persons after traumatic lower limb amputation. Burger H, et al. **Disabil Rehabil** 1997 Jul;19(7):272–7

Metacarpal lengthening after traumatic amputation of the thumb. Finsen V, et al. **J Bone Joint Surg Br** 1996 Jan; 78(1):133–6

Free vascularized transfer of the metatarsophalangeal and proximal interphalangeal joints of the second toe for reconstruction of the metacarpophalangeal joints of the thumb and index finger using a single vascular pedicle. Tsai TM, et al. **Plast Reconstr Surg** 1996 Nov;98(6):1080–6

Metacarpal hand: classification and guidelines for microsurgical reconstruction with toe transfers. Wei FC, et al. **Plast Reconstr Surg** 1997 Jan;99(1):122–8

[Reconstruction of the shape of the shoulder after scapulothoracic amputation] Gounot N, et al. **Ann Chir Plast Esthet** 1996 Jun;41(3):295–8 (Eng. Abstr.) **(Fre)**

SURGERY

The radial Chinese flap at the expense of the palmar radiocarpal arch. A case report. Gutierrez de la Cámara A, et al. **Ann Chir Main Memb Super** 1997;16(2):111–7

Homodigital neurovascular island flaps with "direct flow" vascularization. Adani R, et al. **Ann Plast Surg** 1997 Jan; 38(1):36–40

Anatomy, physiology, and functional restoration of the thumb. Emerson ET, et al. **Ann Plast Surg** 1996 Feb; 36(2):180–91 (58 ref.)

Distraction lengthening following growth cessation due to thumb replantation in a child. Hallock GG. **Ann Plast Surg** 1996 Dec;37(6):624–8

Above-elbow arm replantation during pregnancy. Haws MJ, et al. **Ann Plast Surg** 1996 Jan;36(1):93–6

Salvage of fingertip amputated at nail level: new surgical principles and treatments. Hirase Y. **Ann Plast Surg** 1997 Feb;38(2):151–7

Rodeo thumb: an unusual etiology of avulsion amputation of the thumb. Isenberg JS. **Ann Plast Surg** 1996 Aug; 37(2):187–90

Replantation of ring avulsion of index, long, and ring fingers. Tseng OF, et al. **Ann Plast Surg** 1996 Jun;36(6):625–8

Nasal amputation due to human bite: microsurgical replantation. Hussain G, et al. **Aust N Z J Surg** 1997 Jun; 67(6):382–4

Temporary ectopic implantation for salvage of amputated digits [letter; comment] Cooper TM. **Br J Plast Surg** 1997 Feb;50(2):144. Comment on: Br J Plast Surg 1996 Apr;49(3):174–7.

Replantation of part of an ear as an open fan composite graft. Lin SC, et al. **Br J Plast Surg** 1997 Feb;50(2):135–8

Finger replantation in a 12-month-old child: a long-term follow-up. Nagase T, et al. **Br J Plast Surg** 1996 Dec; 49(8):555–8

Fingertip reconstruction with a dorsal island homodigital flap. Shibu MM, et al. **Br J Plast Surg** 1997 Feb;50(2):121–4

Thumb reconstruction. Brunelli GA, et al. **Bull Hosp Jt Dis** 1996;54(4):245–8 (21 ref.)

Advances in digital replantation. Merle M, et al. **Clin Plast Surg** 1997 Jan;24(1):87–105 (27 ref.)

Replantation of four severed limbs in one patient. Pei GX, et al. **Injury** 1997 Jan;28(1):73–6

Thumb reconstruction by micro-vascular techniques. Foucher G, et al. **Int Angiol** 1995 Sep;14(3):313–8

One-stage immediate reconstruction of partial auricular amputation by dog bite. Giraldo-Ansio F, et al. **Int J Oral Maxillofac Surg** 1997 Aug;26(4):260–2

Transfer of a severely damaged digit to reconstruct an amputated thumb. Foucher G, et al. **J Bone Joint Surg Am** 1996 Dec;78(12):1889–96

Use of an osteocutaneous plantar free flap for salvage of a below-the-knee amputation in a child. A case report. Waters PM, et al. **J Bone Joint Surg Am** 1997 Jul; 79(7):1073–5

Transplantation of second and third toes to the hand [letter; comment] Tsai TM. **J Hand Surg [Am]** 1996 May;21(3):532 . Comment on: J Hand Surg [Am] 1995 May;20(3 Pt 2):S34–45.

Replantation and revascularization at the transmetacarpal level: long-term functional results. Weinzweig N, et al. **J Hand Surg [Am]** 1996 Sep;21(5):877–83

Contralateral transplantation of a finger for restoration of thumb function. Brüser P, et al. **J Hand Surg [Br]** 1997 Jun;22(3):336–40

Very distal finger amputations: replantation or "reposition-flap" repair? Dubert T, et al. **J Hand Surg [Br]** 1997 Jun;22(3):353–8

The dorsal middle phalangeal finger flap. Mid-term results of 43 cases. Leupin P, et al. **J Hand Surg [Br]** 1997 Jun; 22(3):362–71

Composite graft replacement of digital tips. 2. A study in children. Moiemen NS, et al. **J Hand Surg [Br]** 1997 Jun; 22(3):346–52

Cross leg flap in a bilateral traumatic amputee. Thomas SJ, et al. **J Orthop Trauma** 1996;10(7):510–3

Cross-over replantation after bilateral traumatic lower-leg amputation: a case report with a six-year follow-up. Betz AM, et al. **J Reconstr Microsurg** 1996 May;12(4):247–55

Replantation and revascularization of the digits in a community microsurgical practice. Pomerance J, et al. **J Reconstr Microsurg** 1997 Apr;13(3):163–70

Two-stage toe-to-thumb reconstruction in pollicized second metacarpal and useless fingers. Sastre N, et al. **J Reconstr Microsurg** 1996 Oct;12(7):431–7

Re: Circumcision: successful glanular reconstruction and survival following traumatic amputation [letter; comment] Van Howe RS. **J Urol** 1997 Aug;158(2):550 (16 ref.). Comment on: J Urol 1996 Aug;156(2 Pt 2):842–4.

Avulsive amputations of the thumb: comparison of replantation techniques. Cao X, et al. **Microsurgery** 1996; 17(1):17–20

Replantation of a completely detached degloved thumb. Chen L, et al. **Microsurgery** 1996;17(1):48–50

One hundred sixty-seven thumb replantations and revascularisations: early microvascular results. Janezic TF, et al. **Microsurgery** 1996;17(5):259–63

Functional results of 46 thumb replantations and revascularisations. Janezic TF, et al. **Microsurgery** 1996; 17(5):264–7

Latissimus dorsi musculocutaneous free flap transplantation to salvage below-elbow amputation in an emergency operation: a case report. Naito T, et al. **Microsurgery** 1996; 17(3):155–7

Eight years experience in crush and avulsion type finger amputation. Ozerkan F, et al. **Microsurgery** 1995; 16(11):739–42

Chopart amputations [letter; comment] Keagy RD. **Orthopedics** 1997 May;20(5):388. Comment on: Orthopedics 1996 Aug;19(8):689–91.

Lawn mower injury resulting in Chopart amputation in a young child [see comments] Rougraff BT, et al. **Orthopedics** 1996 Aug;19(8):689–91. Comment in: Orthopedics 1997 May;20(5):388.

Total traumatic amputation of the lower face and upper half of the neck. Bite U, et al. **Plast Reconstr Surg** 1997 Feb; 99(2):527–33

The free forearm fillet flap in traumatic arm amputation [letter; comment] Cavadas PC. **Plast Reconstr Surg** 1996 Nov;98(6):1119–20. Comment on: Plast Reconstr Surg 1994 Sep;94(3):507–12. Comment on: Plast Reconstr Surg 1995 Aug;96(2):488–91.

Cheng's method for reconstruction of a functionally sensitive penis. Cheng KX, et al. **Plast Reconstr Surg** 1997 Jan; 99(1):87–91; discussion 92

Total ear replantation. Kind GM, et al. **Plast Reconstr Surg** 1997 Jun;99(7):1858–67 (21 ref.)

Ear replantation without microsurgery. Pribaz JJ, et al. **Plast Reconstr Surg** 1997 Jun;99(7):1868–72

Toe-to-hand transfer for traumatic digital amputations in children and adolescents. Wei FC, et al. **Plast Reconstr Surg** 1997 Sep;100(3):605–9

Substantial volar defects of the fingers treated with free thenar flaps. Kamei K, et al. **Scand J Plast Reconstr Surg Hand Surg** 1997 Mar; 31(1):87–90

Microsurgical replantation of the amputated penis and scrotum in a 29-year-old man. Darewicz J, et al. **Urol Int** 1996;57(3):197–8

Use of a subcutaneous tunnel following replantation of an amputated penis. Harris DD, et al. **Urology** 1996 Oct; 48(4):628–30

[Hueston's flap in distal digital amputations. Apropos of 43 cases] Dallassera M, et al. **Ann Chir Plast Esthet** 1996 Jun; 41(3):235–9 (Eng. Abstr.) **(Fre)**

[Cover plasties of distal finger amputations. Focus on techniques and indications] Foucher G, et al. **Ann Chir Plast Esthet** 1996 Jun;41(3):227–34 (Eng. Abstr.) **(Fre)**

[Primary thumb replacement-plasty—44 years later (letter)] Ritzmann W. **Chirurg** 1996 Aug;67(8):865 **(Ger)**

[Comment on the contribution: 202 toe transplants to the hand (letter; comment)] Graf P, et al. **Handchir Mikrochir Plast Chir** 1996 Jan;28(1):53–4. Comment on: Handchir Mikrochir Plast Chir 1995 Mar;27(2):105–10. **(Ger)**

[Case report on management of grade 4 infected open comminuted tarsus fracture by tibio-Chopart arthrodesis] Klauss R, et al. **Zentralbl Chir** 1996;121(11):1000–4 (Eng. Abstr.) **(Ger)**

[Fibrinolytic treatment of postoperative ischemia of the hand caused by thrombotic obstruction of the interdigital artery: a case] Salvatori FM, et al. **Radiol Med (Torino)** 1996 Sep; 92(3):328–31 **(Ita)**

[Replantation of amputated limb and digit] Tamai S. **Nippon Seikeigeka Gakkai Zasshi** 1996 Jul;70(7):380–90 (8 ref.) **(Jpn)**

[Restorative operations on the radial nerve in a wound to the upper extremity] Iunusov MIu, et al. **Klin Khir** 1996; (7):22–4 **(Rus)**

[Hand reconstruction and prosthesis] Borovikov AM, et al. **Vestn Khir Im I I Grek** 1996;155(3):40–4 (Eng. Abstr.) **(Rus)**

[Current problems in the reconstructive surgery of the locomotor apparatus in children] Kupatadze DD, et al. **Vestn Khir Im I I Grek** 1997;156(2):94–6 (Eng. Abstr.) **(Rus)**

[The scope of the emergency care in tearing of the floor of the auricle] Kruchinskii GV. **Vestn Otorinolaringol** 1997; (1):61 **(Rus)**

[Report of a case of traumatic avulsion of the penile skin with amputation of the glans] Martina G, et al. **Arch Esp Urol** 1996 Nov;49(9):981–3 (Eng. Abstr.) **(Spa)**

THERAPY

Penile replantation using the leech Hirudo medicinalis. Pantuck AJ, et al. **Urology** 1996 Dec;48(6):953–6

AMPUTEES

Estimating urea volume in amputees on peritoneal dialysis by modified anthropometric formulas. Tzamaloukas AH, et al. **Adv Perit Dial** 1996;12:143–6

Functional outcome of quadruple amputees with end-stage renal disease. Garrison SJ, et al. **Am J Phys Med Rehabil** 1997 May-Jun;76(3):226–30

Physiological comparison of walking among bilateral above-knee amputee and able-bodied subjects, and a model to account for the differences in metabolic cost. Hoffman MD, et al. **Arch Phys Med Rehabil** 1997 Apr;78(4):385–92

Joint kinetics in unilateral below-knee amputee patients during running. Sanderson DJ, et al. **Arch Phys Med Rehabil** 1996 Dec;77(12):1279–85

Phantom limbs in people with congenital limb deficiency or amputation in early childhood. Melzack R, et al. **Brain** 1997 Sep;120 (Pt 9):1603–20

Energy transfer mechanisms as a compensatory strategy in below knee amputee runners. Czerniecki JM, et al. **J Biomech** 1996 Jun;29(6):717–22

The performance of the ICEROSS prostheses amongst transtibial amputees with a special reference to the workplace—a preliminary study. Icelandic Roll on Silicone Socket. Dasgupta AK, et al. **Occup Med (Oxf)** 1997 May; 47(4):228–36

Creatinine clearance in amputees on CPD: body surface area calculations [letter; comment] Tzamaloukas AH, et al. **Perit Dial Int** 1996 Jul-Aug;16(4):426. Comment on: Perit Dial Int 1994;14(4):356–61.

Stump-socket interface pressure as an aid to socket design in prostheses for trans-femoral amputees—a preliminary study. Lee VS, et al. **Proc Inst Mech Eng [H]** 1997; 211(2):167–80

The efficacy of the one-leg cycling test for determining the anaerobic threshold (AT) of lower limb amputees. Chin T, et al. **Prosthet Orthot Int** 1997 Aug;21(2):141–6

The use of Methenamine as an antiperspirant for amputees. Susak Z, et al. **Prosthet Orthot Int** 1996 Dec;20(3):172–5

Double-limb support and step-length asymmetry in below-knee amputees. Isakov E, et al. **Scand J Rehabil Med** 1997 Jun;29(2):75–9

[Asymmetry of posture and truncal musculature following unilateral arm amputation—a clinical, electromyographic, posture analytical and photogrammetric study] Greitemann B, et al. **Z Orthop Ihre Grenzgeb** 1996 Nov-Dec; 134(6):498–510 (39 ref.) (Eng. Abstr.) **(Ger)**

[High density lipoproteins composition in leg amputees] Kaznacheev LN, et al. **Klin Med (Mosk)** 1997;75(3):35–8 **(Rus)**

[The characteristics of the blood lipid transport system in the disabled with lost lower extremities] Kaznacheev LN, et al. **Ter Arkh** 1997;69(1):62–5 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Functional status in children with limb deficiency: development and initial validation of an outcome measure. Pruitt SD, et al. **Arch Phys Med Rehabil** 1996 Dec; 77(12):1233–8

Upper limb traumatic amputees. Review of prosthetic use. Gaine WJ, et al. **J Hand Surg [Br]** 1997 Feb;22(1):73–6

Outcome of fitting an ICEROSS prosthesis: views of trans-tibial amputees. Datta D, et al. **Prosthet Orthot Int** 1996 Aug;20(2):111–5

REHABILITATION

Functional status in children with limb deficiency: development and initial validation of an outcome measure. Pruitt SD, et al. **Arch Phys Med Rehabil** 1996 Dec; 77(12):1233–8

Mechanical work adaptations of above-knee amputee ambulation. Seroussi RE, et al. **Arch Phys Med Rehabil** 1996 Nov;77(11):1209–14

Interface mechanics in lower-limb external prosthetics: a review of finite element models. Zachariah SG, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):288–302 (35 ref.)

Rehabilitation of the older lower limb amputee: a brief review. Cutson TM, et al. **J Am Geriatr Soc** 1996 Nov; 44(11):1388–93 (60 ref.)

Rehabilitation of the older amputee [letter] Wainapel SF. **J Am Geriatr Soc** 1997 Aug;45(8):1033

A successful rehabilitation service for older amputees at Waikato Hospital. Weatherall M. **N Z Med J** 1997 Aug 8;110(1049):289–90

The life style of young persons after lower limb amputation caused by injury. Burger H, et al. **Prosthet Orthot Int** 1997 Apr;21(1):35–9

Outcome of fitting an ICEROSS prosthesis: views of trans-tibial amputees. Datta D, et al. **Prosthet Orthot Int** 1996 Aug;20(2):111–5

Use of an instrumented treadmill for real-time gait symmetry evaluation and feedback in normal and trans-tibial amputee subjects. Dingwell JB, et al. **Prosthet Orthot Int** 1996 Aug; 20(2):101–10

The effects of prosthesis mass on metabolic cost of ambulation in non-vascular trans-tibial amputees. Gailey RS, et al. **Prosthet Orthot Int** 1997 Apr;21(1):9–16

Functional outcome of lower-limb amputees: a prospective descriptive study in a general hospital. Greive AC, et al. **Prosthet Orthot Int** 1996 Aug;20(2):79–87

Stump length as related to atrophy and strength of the thigh muscles in trans-tibial amputees. Isakov E, et al. **Prosthet Orthot Int** 1996 Aug;20(2):96–100

Influence of speed on gait parameters and on symmetry in trans-tibial amputees. Isakov E, et al. **Prosthet Orthot Int** 1996 Dec;20(3):153–8

ICEROSS—a consensus view: a questionnaire survey of the use of ICEROSS in the United Kingdom. McCurdie I, et

AMPUTEES

al. **Prosthet Orthot Int** 1997 Aug;21(2):124–8

Energy storage and release of prosthetic feet. Part 1: Biomechanical analysis related to user benefits. Postema K, et al. **Prosthet Orthot Int** 1997 Apr;21(1):17–27

Energy storage and release of prosthetic feet. Part 2: Subjective ratings of 2 energy storing and 2 conventional feet, user choice of foot and deciding factor. Postema K, et al. **Prosthet Orthot Int** 1997 Apr;21(1):28–34

Clinical rehabilitation of the amputee: a retrospective study. Rommers GM, et al. **Prosthet Orthot Int** 1996 Aug; 20(2):72–8

A comparison of energy expenditure by a high level trans-femoral amputee using the Intelligent Prosthesis and conventionally damped prosthetic limbs. Taylor MB, et al. **Prosthet Orthot Int** 1996 Aug;20(2):116–21

Analysis of torso movement of trans-femoral amputees during level walking. Tazawa E. **Prosthet Orthot Int** 1997 Aug;21(2):129–40

[Swimming as a means of enhancing the adaptive potentials of the disabled after amputation of the lower extremities] Kurdybaĭlo SF, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1997 Jan–Feb;(1):25–8 (Eng. Abstr.) **(Rus)**

STATISTICS & NUMERICAL DATA

The population of users of upper limb prostheses attending the Oxford Limb Fitting Service. Kyberd PJ, et al.
Prosthet Orthot Int 1997 Aug;21(2):85–91

Epidemiology of lower limb amputees in the north of The Netherlands: aetiology, discharge destination and prosthetic use. Rommers GM, et al. **Prosthet Orthot Int** 1997 Aug;21(2):92–9

Congenital limb anomalies and amputees Tayside, Scotland 1965–1994. Stewart CP, et al. **Prosthet Orthot Int** 1995 Dec;19(3):148–54 (14 ref.)

AMPYRONE

METABOLISM

High-performance liquid chromatographic analysis of dipyrone metabolites to study their formation in human liver microsomes. Geisslinger G, et al. **Pharm Res** 1996 Aug;13(8):1272–5

AMRINONE

ADMINISTRATION & DOSAGE

Intraarterial injection of amrinone for vasospasm induced by subarachnoid hemorrhage. Yoshida K, et al.
AJNR Am J Neuroradiol 1997 Mar;18(3):492–6

[Effects of amrinone on oxygen demand-supply relationship after cardiopulmonary bypass in patient undergoing coronary bypass surgery] Sha K, et al. **Masui** 1997 May; 46(5):635–9 (Eng. Abstr.) **(Jpn)**

[Hemodynamic effects of amrinone, phosphodiesterase inhibitor, early after coronary artery bypass grafting] Shibata T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Nov;44(11):2027–31 (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

Hemodynamic effects of N-acetylamrinone in a porcine model of group B streptococcal sepsis. Allen EM, et al. **Drug Metab Dispos** 1996 Sep;24(9):1028–31

DIAGNOSTIC USE

Amrinone stimulation test: ability to predict improvement in left ventricular ejection fraction after coronary bypass surgery in patients with poor baseline left ventricular function. Perez-Baliño NA, et al. **J Am Coll Cardiol** 1996 Nov 15;28(6):1488–92

PHARMACOLOGY

Amrinone reverses bupivacaine-induced regional myocardial dysfunction. Fujita Y. **Acta Anaesthesiol Scand** 1996 Jan; 40(1):47–52

Growth factor expression and effects of amrinone in monocrotaline-induced pulmonary hypertension in rats. Burch GH, et al. **Biochem Mol Med** 1996 Aug;58(2):204–10

Human platelet Ca2+ mobilization, glycoprotein IIb/IIIa activation, and experimental coronary thrombosis in vivo in dogs are all inhibited by the inotropic agent amrinone. Sill JC, et al. **Circulation** 1997 Sep 2;96(5):1647–53

Inotropes inhibit endothelial cell surface adhesion molecules induced by interleukin-1beta. Fortenberry JD, et al.
Crit Care Med 1997 Feb;25(2):303–8

Hemodynamic effects of N-acetylamrinone in a porcine model of group B streptococcal sepsis. Allen EM, et al. **Drug Metab Dispos** 1996 Sep;24(9):1028–31

The effects of amrinone and glucagon on verapamil-induced myocardial depression in a rat isolated heart model. Tuncok Y, et al. **Gen Pharmacol** 1997 May;28(5):773–6

The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. Ohte N, et al.
J Pharmacol Exp Ther 1997 Jul;282(1):23–31

The vasorelaxant effects of amrinone on neonatal rabbit thoracic aortic strips. Hassan S, et al. **Kobe J Med Sci** 1996 Feb;42(1):73–91

[Effect of amrinone and vagotomy on airway constriction in dogs: analysis by respiratory system impedance method] Miyazawa N. **Masui** 1997 Jan;46(1):31–41 (Eng. Abstr.) **(Jpn)**

[Hemodynamic effects of amrinone combined with dopamine in patients undergoing living renal transplantation] Okuno Y, et al. **Masui** 1997 Jan;46(1):87–94 (Eng. Abstr.) **(Jpn)**

[Amrinone (50 micrograms.kg-1.min-1) does not impair regional myocardial tissue metabolism during the 40%-decrease of left anterior descending coronary flow] Tateyama T, et al. **Masui** 1996 Feb;45(2):148–52 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Amrinone as an antidote in experimental verapamil overdose. Koury SI, et al. **Acad Emerg Med** 1996 Aug;3(8):762–7

Amrinone and verapamil overdose study design [letter] Manoach SM, et al. **Acad Emerg Med** 1997 Aug;4(8):839–40

Amrinone improves lung compliance in patients receiving mechanical ventilation for cardiogenic pulmonary edema. Takeda S, et al. **Acta Anaesthesiol Scand** 1997 May; 41(5):624–8

Amrinone versus dobutamine in cardiac surgical patients with severe pulmonary hypertension after cardiopulmonary bypass: a prospective, randomized double-blinded trial. Jenkins IR, et al. **Anaesth Intensive Care** 1997 Jun; 25(3):245–9

A comparison of the hemodynamic effects of amrinone and sodium nitroprusside in infants after cardiac surgery. Bailey JM, et al. **Anesth Analg** 1997 Feb;84(2):294–8

Comparative effects of dobutamine and amrinone on coronary blood flow in patients with idiopathic dilated cardiomyopathy [see comments] Takeuchi M, et al.
Cathet Cardiovasc Diagn 1997 Jun;41(2):157–63. Comment in: Cathet Cardiovasc Diagn 1997 Jun;41(2):164–5.

The effects of amrinone and glucagon on verapamil-induced cardiovascular toxicity in anaesthetized rats. Tuncok Y, et al. **Int J Exp Pathol** 1996 Oct;77(5):207–12

Effect of amrinone on murine viral myocarditis. Seta Y, et al. **Res Commun Mol Pathol Pharmacol** 1997 Jan; 95(1):57–66

Amrinone and theophylline differentially regulate cytokine and nitric oxide production in endotoxemic mice. Németh ZH, et al. **Shock** 1997 May;7(5):371–5

M-AMSA see **AMSACRINE**

AMSACRINE

ADMINISTRATION & DOSAGE

Polymeric controlled-release amsacrine chemotherapy in an experimental glioma model. Wahlberg LU, et al.
Acta Neurochir (Wien) 1996;138(11):1323–9; discussion 1329–30

ANALOGS & DERIVATIVES

Molecular origins of selectivity in the interaction of amsacrine-4-carboxamide with GC-rich sequences in DNA. Bailly C, et al. **Anticancer Drug Des** 1996 Dec; 11(8):611–24

A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine. Baguley BC, et al. **Eur J Cancer** 1997 Feb;33(2):272–9

Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines. Gamage SA, et al. **J Med Chem** 1997 Aug 1;40(16):2634–42

CHEMISTRY

Copper-dependent oxidative and topoisomerase II-mediated DNA cleavage by a netropsin/4'-(9-acridinylamino)methanesulfon-m-anisidide combilexin. Henichart JP, et al.
Mol Pharmacol 1997 Mar;51(3):448–61

METABOLISM

Interaction of DNA-threading peptide-amsacrine conjugates with DNA and chromatin. Bourdouxhe-Housiaux C, et al. **Anticancer Drug Des** 1996 Oct;11(7):509–25

Intracellular molecular interactions of antitumor drug amsacrine (m-AMSA) as revealed by surface-enhanced Raman spectroscopy. Chourpa I, et al. **FEBS Lett** 1996 Nov 11;397(1):61–4

PHARMACOLOGY

Aniline mustard analogues of the DNA-intercalating agent amsacrine: DNA interaction and biological activity. Fan JY, et al. **Anticancer Drug Des** 1997 Apr;12(3):181–203

Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta. Marsh KL, et al. **Biochem Pharmacol** 1996 Dec 13; 52(11):1675–85

Induction of apoptotic cell death by DNA topoisomerase II inhibitors. Negri C, et al. **Biochimie** 1995;77(11):893–9

A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine. Baguley BC, et al. **Eur J Cancer** 1997 Feb;33(2):272–9

Bacteriophage T4 mutants hypersensitive to an antitumor agent that induces topoisomerase-DNA cleavage complexes. Woodworth DL, et al. **Genetics** 1996 Jul; 143(3):1081–90

Role of recombinational repair in sensitivity to an antitumour agent that inhibits bacteriophage T4 type II DNA topoisomerase. Neece SH, et al. **Mol Microbiol** 1996 Jun; 20(6):1145–54

Lack of effects of ciprofloxacin and the topoisomerase II inhibitors, m-AMSA and nalidixic acid, on DNA repair in cultured rat liver cells. Rosen JE, et al.
Toxicol Appl Pharmacol 1996 Oct;140(2):254–63

TOXICITY

Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats. Graziano MJ, et al.
Fundam Appl Toxicol 1996 Jul;32(1):53–65

Subchronic intravenous toxicity of the antineoplastic drug, amsacrine, in male Wistar rats. Pegg DG, et al.
Fundam Appl Toxicol 1996 Jul;32(1):45–52

Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Nitiss JL, et al. **Mol Pharmacol** 1996 Nov;50(5):1095–102

[Examination of the toxicity of the liposomal form of amsacrine and retinoic acid] Tarasiuk A.
Acta Pol Pharm 1992;49(1–2):17–20 (Eng. Abstr.) **(Pol)**

AMYGDALA see **AMYGDALOID BODY**

AMYGDALIN

METABOLISM

Two-step hydrolysis of amygdalin in molds [letter] Brimer L, et al. **Riv Biol** 1996;89(3):493–6

POISONING

Accidental choke-cherry poisoning: early symptoms and neurological sequelae of an unusual case of cyanide intoxication. Pentore R, et al. **Ital J Neurol Sci** 1996 Jun; 17(3):233–5

AMYGDALOID BODY

ANATOMY & HISTOLOGY

Amygdalo-hypothalamic projections in the lizard Podarcis hispanica: a combined anterograde and retrograde tracing study. Lanuza E, et al. **J Comp Neurol** 1997 Aug 11; 384(4):537–55

Intrinsic connections of the rat amygdaloid complex: projections originating in the accessory basal nucleus. Savander V, et al. **J Comp Neurol** 1996 Oct 14; 374(2):291–313

Cortical, thalamic, and amygdaloid projections of rat temporal cortex. Shi CJ, et al. **J Comp Neurol** 1997 Jun 2;382(2):153–75

GABAergic neurons in rat nuclei of solitary tracts receive inhibitory-type synapses from amygdaloid efferents lacking detectable GABA-immunoreactivity. Pickel VM, et al.
J Neurosci Res 1996 Jun 1;44(5):446–58

Projections of the amygdaloid body and dopaminergic mesencephalic formations in the entopeduncular nucleus of the cat brain. Gorbachevskaya AI.
Neurosci Behav Physiol 1997 Mar-Apr;27(2):194–7

Topographic projections from the periamygdaloid cortex to select subregions of the lateral nucleus of the amygdala in the rat. Savander V, et al. **Neurosci Lett** 1996 Jun 28; 211(3):167–70

Cortico-cortical and cortico-amygdaloid projections of the rat occipital cortex: a Phaseolus vulgaris leucoagglutinin study. Mcdonald AJ, et al. **Neuroscience** 1996 Mar; 71(1):37–54

Projections of the medial and lateral prefrontal cortices to the amygdala: a Phaseolus vulgaris leucoagglutinin study in the rat. Mcdonald AJ, et al. **Neuroscience** 1996 Mar; 71(1):55–75

Lateral nucleus of the rat amygdala is reciprocally connected with basal and accessory basal nuclei: a light and electron microscopic study. Savander V, et al. **Neuroscience** 1997 Apr;77(3):767–81

Interamygdaloid projections of the basal and accessory basal nuclei of the rat amygdaloid complex. Savander V, et al. **Neuroscience** 1997 Feb;76(3):725–35

BLOOD SUPPLY

Comparative study of arterial vascularization of the amygdaloid body in man and sheep. Goetzen B, et al.
Folia Neuropathol 1996;34(3):143–8

CHEMISTRY

N-methyl-D-aspartate receptors in the basolateral amygdala are required for both acquisition and expression of conditional fear in rats. Maren S, et al. **Behav Neurosci** 1996 Dec;110(6):1365–74

Calcium binding proteins in the development of central nucleus of amygdaloid body--a morphometric and immunohistochemical study. Sidorowicz M, et al.
Folia Morphol (Warsz) 1996;55(4):437–9

Neurotensin receptors in the human amygdaloid complex. Topographical and quantitative autoradiographic study. Lantos TA, et al. **J Chem Neuroanat** 1996 Sep;11(3):209–17

Glutamate and aspartate immunoreactive neurons of the rat basolateral amygdala: colocalization of excitatory amino acids and projections to the limbic circuit. Mcdonald AJ. **J Comp Neurol** 1996 Feb 12;365(3):367–79

Distribution of pituitary adenylate cyclase activating polypeptide (PACAP) immunoreactivity in the hypothalamus and extended amygdala of the rat. Piggins HD, et al. **J Comp Neurol** 1996 Dec 9;376(2):278–94

Distribution of oxytocin– and vasopressin–binding sites in the rat extended amygdala: a histoautoradiographic study. Veinante P, et al. **J Comp Neurol** 1997 Jul 7;383(3):305–25

Neurochemical compartments in the human forebrain: evidence for a high density of secretoneurin–like immunoreactivity in the extended amygdala. Kaufmann WA, et al. **Synapse** 1997 Jun;26(2):114–30

CYTOLOGY

Projections from the lateral part of the central amygdalar nucleus to the postulated fear conditioning circuit. Petrovich GD, et al. **Brain Res** 1997 Jul 25;763(2):247–54

Convergence of ventrolateral medulla and aortic baroreceptor inputs onto amygdala neurons. Roder S, et al. **Brain Res** 1995 Dec 24;705(1–2):71–8

Limbic system–associated membrane protein (LAMP) in primate amygdala and hippocampus. Côté PY, et al. **Hippocampus** 1996;6(5):483–94

Evidence of gamma–aminobutyric acidergic control over the catecholaminergic projection from the medulla oblongata to the central nucleus of the amygdala. Jia HG, et al. **J Comp Neurol** 1997 May 12;381(3):262–81

Collateral projections of single neurons in the posterior thalamic region to both the temporal cortex and the amygdala: a fluorescent retrograde double–labeling study in the rat. Namura S, et al. **J Comp Neurol** 1997 Jul 21; 384(1):59–70

Organization of projections from the basomedial nucleus of the amygdala: a PHAL study in the rat. Petrovich GD, et al. **J Comp Neurol** 1996 Oct 21;374(3):387–420

Transneuronal labeling of a nociceptive pathway, the spino–(trigemino–)parabrachio–amygdaloid, in the rat. Jasmin L, et al. **J Neurosci** 1997 May 15;17(10):3751–65

Cellular organization of lateral hypothalamic efferents to the central amygdaloid nucleus of the rat. Touzani K, et al. **Neuroreport** 1996 Jan 31;7(2):517–20

Cholinergic responses of morphologically and electrophysiologically characterized neurons of the basolateral complex in rat amygdala slices. Yajeya J, et al. **Neuroscience** 1997 Jun;78(3):731–43

[The projections of the ventral field of the tegmentum mesencephali, substantia nigra and amygdaloid nuclei to different segments of the putamen in the dog] Gorbachevskaia AI. **Morfologiia** 1996;110(4):42–7 (Eng. Abstr.) **(Rus)**

[Projections of the amygdaloid body and dopaminergic mesencephalic formations to the entopeduncular nucleus of the cat brain] Gorbachevskaia AI. **Morfologiia** 1996; 109(3):19–21 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

6–OHDA bilateral lesions to the central amygdala do not affect vasopressin improvement of recall in rats. Winnicka MM. **Acta Neurobiol Exp (Warsz)** 1996;56(4):943–8

Ethanol inhibits single–unit responses in the nucleus accumbens evoked by stimulation of the basolateral nucleus of the amygdala. Criado JR, et al. **Alcohol Clin Exp Res** 1997 Apr;21(2):368–74

Intra–amygdala muscimol decreases operant ethanol self–administration in dependent rats. Roberts AJ, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1289–98

Inhibitory avoidance impairments induced by intra–amygdala propranolol are reversed by glutamate but not glucose. Lennartz RC, et al. **Behav Neurosci** 1996 Oct;110(5):1033–9

Functional inactivation of the lateral and basal nuclei of the amygdala by muscimol infusion prevents fear conditioning to an explicit conditioned stimulus and to contextual stimuli. Muller J, et al. **Behav Neurosci** 1997 Aug; 111(4):683–91

Effects of excitotoxic lesions of the central amygdaloid nucleus on the potentiation of reward–related stimuli by intra–accumbens amphetamine. Robledo P, et al. **Behav Neurosci** 1996 Oct;110(5):981–90

Modulation of the pressor response elicited by carbachol and electrical stimulation of the amygdala by muscarinic antagonists in conscious rats. Aslan N, et al. **Br J Pharmacol** 1997 May;121(1):35–40

Inhibition of synaptic transmission and epileptiform activity in central neurones by fluspirilene. Wang SJ, et al. **Br J Pharmacol** 1997 Mar;120(6):1114–8

The anti–epileptic effect of 3–aminopropylarsonate on electrically–kindled and N–methyl–D–aspartate–kindled amygdala. Abdul–Ghani AS, et al. **Brain Res** 1996 Dec 2;742(1–2):305–12

Bicuculline administered into the amygdala after training blocks benzodiazepine–induced amnesia. Dickinson–Anson H, et al. **Brain Res** 1997 Mar 28;752(1–2):197–202

Liposome–entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db–cAMP/EDTA in rats. Mori N, et al. **Brain Res** 1995 Dec 12;703(1–2):184–90

Microinjection of thyrotropin–releasing hormone analogue into the central nucleus of the amygdala stimulates gastric contractility in rats. Morrow NS, et al. **Brain Res** 1996 Sep 30;735(1):141–8

The effects of N–methyl–D–aspartate (NMDA) and its competitive antagonist, 3–(2–carboxypiperazine–4–yl)propyl–1–phosphonic acid (CPP), injected into caudate–putamen on kindled amygdaloid seizures in rats. Osonoe M, et al. **Brain Res** 1996 Jul 29;728(2):242–6

Ibotenic acid lesions of the amygdala basolateral complex or central nucleus differentially effect the response to reductions in reward. Salinas JA, et al. **Brain Res** 1996 Dec 2;742(1–2):283–93

Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Shirayama Y, et al. **Brain Res** 1996 Nov 11; 739(1–2):70–8

Chronic and intra–amygdala administrations of the ACTH(4–9) analog ORG 2766 modulate behavioral changes after manipulation of NMDA–receptor activity. van Rijzingen IM, et al. **Brain Res** 1996 Apr 22; 717(1–2):200–3

Distribution and time course of appearance of "dark" neurons and EEG activity after amygdaloid kainate lesion. Hajnal A, et al. **Brain Res Bull** 1997;43(2):235–43

Effects of dietary preference and galanin administration in the paraventricular or amygdaloid nucleus on diet self–selection. Smith BK, et al. **Brain Res Bull** 1996; 39(3):149–54

Neonatal androgen manipulation differentially affects the development of monoamine systems in rat cerebral cortex, amygdala and hypothalamus. Siddiqui A, et al. **Brain Res Dev Brain Res** 1997 Feb 20;98(2):247–52

Gonadal steroids target AMPA glutamate receptor–containing neurons in the rat hypothalamus, septum and amygdala: a morphological and biochemical study. Diano S, et al. **Endocrinology** 1997 Feb;138(2):778–89

Anticonvulsant effects by combined treatment with a glycineB receptor antagonist and a polyamine site antagonist in amygdala–kindled rats. Ebert U, et al. **Eur J Pharmacol** 1997 Mar 19;322(2–3):179–84

6–OHDA lesions to the central amygdala abolish angiotensins facilitation of object recognition in rats. Winnicka MM, et al. **Gen Pharmacol** 1997 Aug;29(2):239–43

Study of neurons and glial cells of basolateral amygdala in male and female rats neonatally treated with estrogen. Dmitar D, et al. **Int J Neurosci** 1995 Dec;83(3–4):145–51

Infusions of lidocaine into the amygdala, but not the preoptic area, block pseudopregnancy in the rat. Coopersmith C, et al. **J Neuroendocrinol** 1996 Apr;8(4):259–66

Laterality in the histological effects of injections of amyloid–beta 25–35 into the amygdala of young Fischer rats. Sigurdsson EM, et al. **J Neuropathol Exp Neurol** 1997 Jun;56(6):714–25

Metabotropic glutamate receptor agonist–induced hyperpolarizations in rat basolateral amygdala neurons: receptor characterization and ion channels. Holmes KH, et al. **J Neurophysiol** 1996 Nov;76(5):3059–69

Quisqualate–preferring metabotropic glutamate receptor activates Na(+)–Ca2+ exchange in rat basolateral amygdala neurones. Keele NB, et al. **J Physiol (Lond)** 1997 Feb 15;499 (Pt 1):87–104

Bicuculline administration into basolateral amygdala facilitates trace conditioning of odor aversion in the rat. Ferry B, et al. **Neurobiol Learn Mem** 1997 Jan;67(1):80–3

The effects of intra–amygdala infusion of the AMPA receptor antagonist CNQX on retention performance following aversive training. Meses MH, et al. **Neurobiol Learn Mem** 1996 Nov;66(3):324–40

Different brain areas are involved in memory expression at different times from training. Quillfeldt JA, et al. **Neurobiol Learn Mem** 1996 Sep;66(2):97–101

Glucocorticoid receptor agonist and antagonist administration into the basolateral but not central amygdala modulates memory storage. Roozendaal B, et al. **Neurobiol Learn Mem** 1997 Mar;67(2):176–9

Posttraining intraamygdala infusions of oxotremorine and propranolol modulate storage of memory for reductions in reward magnitude. Salinas JA, et al. **Neurobiol Learn Mem** 1997 Jul;68(1):51–9

Effects of anxiety and memory of systemic and intra–amygdala injection of 5–HT3 receptor antagonist BRL 46470A. Gargiulo PA, et al. **Neuropsychobiology** 1996;33(4):189–95

Tiagabine exerts an anti–epileptogenic effect in amygdala kindling epileptogenesis in the rat. Dalby NO, et al. **Neurosci Lett** 1997 Jun 27;229(2):135–7

Effects of N–methyl–D–aspartate–receptor blockade on high–potassium–induced neuronal death and glutamate release. Fujikawa DG. **Neurosci Lett** 1997 Apr 18; 226(1):25–8

Arginine vasopressin release by acetylcholine or norepinephrine: region–specific and cytokine–specific regulation [published erratum appears in Neuroscience 1996 Jul;73(2):623] Raber J, et al. **Neuroscience** 1996 Apr; 71(3):747–59

Mediation of the discriminative stimulus properties of cocaine by mesocorticolimbic dopamine systems. Callahan PM, et al. **Pharmacol Biochem Behav** 1997 Jul;57(3):601–7 (54 ref.)

Repeated d–amphetamine enhances stimulated mesoamygdaloid dopamine transmission. Harmer CJ, et al. **Psychopharmacology (Berl)** 1997 Aug;132(3):247–54

Enhanced acquisition of discriminative approach following intra–amygdala d–amphetamine. Hitchcott PK, et al. **Psychopharmacology (Berl)** 1997 Aug;132(3):237–46

Amygdala and hippocampus control dissociable aspects of drug–associated conditioned rewards. Hitchcott PK, et al. **Psychopharmacology (Berl)** 1997 May;131(2):187–95

Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaine–seeking behaviour under a second–order schedule of reinforcement. Whitelaw RB, et al. **Psychopharmacology (Berl)** 1996 Oct;127(3):213–24

GABAA and GABAB receptors differentially regulate synaptic transmission in the auditory thalamo–amygdala pathway: an in vivo microiontophoretic study and a model. Li XF, et al. **Synapse** 1996 Oct;24(2):115–24

Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons. Wang SJ, et al. **Synapse** 1996 Nov;24(3):248–55

ENZYMOLOGY

Acetylcholinesterase activity as a marker of maturation of the basolateral complex of the amygdaloid body in the rat. Berdel B, et al. **Int J Dev Neurosci** 1996 Aug;14(5):543–9

Input from central nucleus of the amygdala efferents to pericoerulear dendrites, some of which contain tyrosine hydroxylase immunoreactivity. Van Bockstaele EJ, et al. **J Neurosci Res** 1996 Aug 1;45(3):289–302

Rat gustatory memory requires protein kinase C activity in the amygdala and cortical gustatory area. Yasoshima Y, et al. **Neuroreport** 1997 Apr 14;8(6):1363–7

GROWTH & DEVELOPMENT

Acetylcholinesterase activity as a marker of maturation of the basolateral complex of the amygdaloid body in the rat. Berdel B, et al. **Int J Dev Neurosci** 1996 Aug;14(5):543–9

INJURIES

Lesions of the ventral striatum mimic the effect of olfactory bulbectomy to prevent short photoperiod–induced testicular regression in golden hamsters. Gomez DM, et al. **Brain Res** 1996 Jun 3;723(1–2):148–53

[The comparative effect of melatonin and diazepam on shifts in the anxiety–phobia status of rats evoked by damage to the amygdala] Arushanian EB, et al. **Eksp Klin Farmakol** 1997 Jan–Feb;60(1):7–9 (Eng. Abstr.) **(Rus)**

METABOLISM

Plasticity in the maternal circuit: effects of maternal experience on Fos–Lir in hypothalamic, limbic, and cortical structures in the postpartum rat. Fleming AS, et al. **Behav Neurosci** 1996 Jun;110(3):567–82

Levels of serum steroids, aromatase activity, and estrogen receptors in preoptic area, hypothalamus, and amygdala of B6D2F1 male house mice that differ in the display of copulatory behavior after castration. Sinchak K, et al. **Behav Neurosci** 1996 Jun;110(3):593–602

Stress persistently increases NMDA receptor–mediated binding of [3H]PDBu (a marker for protein kinase C) in the amygdala, and re–exposure to the stressful context reactivates the increase. Shors TJ, et al. **Brain Res** 1997 Mar 7;750(1–2):293–300

Inhibitory avoidance learning alters the amygdala calcium/calmodulin–dependent protein kinase II activity in rats. Tan SE, et al. **Brain Res** 1997 Feb 14; 748(1–2):227–33

Dimorphic expression of calbindin–D28K in the medial basal hypothalamus from perinatal male and female rats. Lephart ED. **Brain Res Dev Brain Res** 1996 Oct 23;96(1–2):281–4

Altered expression of group I metabotropic glutamate receptors in the hippocampus of amygdala–kindled rats. Akbar MT, et al. **Brain Res Mol Brain Res** 1996 Dec 31; 43(1–2):105–16

Identification of projections from the central nucleus of the amygdala to the paraventricular nucleus of the hypothalamus which are immunoreactive for corticotrophin–releasing hormone in the rat. Marcilhac A, et al. **Exp Physiol** 1997 Mar;82(2):273–81

Calbindin–D28k immunoreactivity in the rat amygdala. McDonald AJ. **J Comp Neurol** 1997 Jun 30;383(2):231–44

Calretinin–immunoreactive cells and fibers in the human amygdaloid complex. Sorvari H, et al. **J Comp Neurol** 1996 May 27;369(2):188–208

Central amygdala Fos expression during hypotensive or febrile, nonhypotensive endotoxemia in conscious rats. Tkacs NC, et al. **J Comp Neurol** 1997 Mar 24; 379(4):592–602

Localisation of ionotropic glutamate receptor subunits, and gamma–aminobutyric acid (GABA) in the monkey amygdala—a double immunolabelling and electron microscopic study. He Y, et al. **J Hirnforsch** 1996; 37(4):479–503

Brainstem hemisection decreases corticotropin–releasing hormone mRNA in the paraventricular nucleus but not in the central amygdaloid nucleus. Pacak K, et al. **J Neuroendocrinol** 1996 Jul;8(7):543–51

Modulation of high voltage–activated calcium channels by somatostatin in acutely isolated rat amygdaloid neurons. Viana F, et al. **J Neurosci** 1996 Oct 1;16(19):6000–11

The effects of a 5–HT1A receptor agonist and antagonist on the 5–hydroxytryptamine release in the central nucleus of the amygdala: a microdialysis study with flesinoxan and

WAY 100635. Bosker F, et al.
Naunyn Schmiedebergs Arch Pharmacol 1997 Mar; 355(3):347–53

Norepinephrine release in the amygdala in response to footshock stimulation. Galvez R, et al.
Neurobiol Learn Mem 1996 Nov;66(3):253–7

Interferon–alpha and transforming growth factor–beta 1 regulate corticotropin–releasing factor release from the amygdala: comparison with the hypothalamic response. Raber J, et al. **Neurochem Int** 1997 Apr–May; 30(4–5):455–63

Feeding–related dopamine in the amygdala of freely moving rats. Hajnal A, et al. **Neuroreport** 1997 Aug 18; 8(12):2817–20

Inhibition of N–type calcium currents by lamotrigine in rat amygdalar neurones. Wang SJ, et al. **Neuroreport** 1996 Nov 25;7(18):3037–40

Thyroid hormone metabolism in the rat brain in an animal model of 'behavioral dependence' on ethanol. Baumgartner A, et al. **Neurosci Lett** 1997 May 9;227(1):25–8

Picrotoxin induces both hypertension and dopamine release in the rat amygdala. Chu TF, et al. **Neurosci Lett** 1996 Nov 8;218(3):169–72

Sex differences in benzodiazepine binding in the frontal cortex and amygdala of the rat 24 hours after restraint stress. Farabollini F, et al. **Neurosci Lett** 1996 Nov 8; 218(3):177–80

Localization of AMPA glutamate receptor subunits in subpopulations of non–pyramidal neurons in the rat basolateral amygdala. McDonald AJ. **Neurosci Lett** 1996 Apr 26;208(3):175–8

Zinc transport in the rat olfactory system. Takeda A, et al. **Neurosci Lett** 1997 Mar 28;225(1):69–71

Developmental expression of calretinin in the medial basal hypothalamus and amygdala from male and female rats. Lephart ED, et al. **Neurosci Res** 1997 Jul;28(3):269–73

In vivo elevation of extracellular potassium in the rat amygdala increases extracellular glutamate and aspartate and damages neurons. Fujikawa DG, et al.
Neuroscience 1996 Oct;74(3):695–706

Immunohistochemical localization of the beta 2 and beta 3 subunits of the GABAA receptor in the basolateral amygdala of the rat and monkey. McDonald AJ, et al.
Neuroscience 1996 Nov;75(2):407–19

Attack priming in female Syrian golden hamsters is associated with a c–fos–coupled process within the corticomedial amygdala. Potegal M, et al. **Neuroscience** 1996 Dec; 75(3):869–80

Muscarinic acetylcholine receptor immunoreactivity in the amygdala—II. Fear–induced plasticity. Roozendaal B, et al. **Neuroscience** 1997 Jan;76(1):75–83

Calbindin–D28K–immunoreactive cells and fibres in the human amygdaloid complex. Sorvari H, et al.
Neuroscience 1996 Nov;75(2):421–43

Muscarinic acetylcholine receptor immunoreactivity in the amygdala—I. Cellular distribution correlated with fear–induced behavior. van der Zee EA, et al.
Neuroscience 1997 Jan;76(1):63–73

Opposite changes in the expression of enkephalin in the amygdala and hypothalamus after lesions of the bed nucleus of the stria terminalis in the rat. Vankova M, et al.
Neuroscience 1996 Sep;74(1):219–35

Kainate microinjection into the dorsal raphe nucleus induces 5–HT release in the amygdala and periaqueductal gray. Viana MB, et al. **Pharmacol Biochem Behav** 1997 Sep; 58(1):167–72

Activation of corticotropin–releasing factor in the limbic system during cannabinoid withdrawal [see comments] Rodriguez de Fonseca F, et al. **Science** 1997 Jun 27; 276(5321):2050–4. Comment in: Science 1997 Jun 27;276(5321):1967–8. Comment in: Science 1997 Aug 8;277(5327):749; discussion 750–2.

PATHOLOGY

Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Schmidt ML, et al. **Acta Neuropathol (Berl)** 1996; 91(5):475–81

Neuronal loss and gliosis of the amygdaloid nucleus in temporal lobe epilepsy. A quantitative analysis of 70 surgical specimens. Wolf HK, et al.
Acta Neuropathol (Berl) 1997 Jun;93(6):606–10

Reversible signal abnormalities in the hippocampus and neocortex after prolonged seizures. Chan S, et al.
AJNR Am J Neuroradiol 1996 Oct;17(9):1725–31

Hyperinsulinemia in rats with obesity–inducing amygdaloid lesions. King BM, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1156–9

Increased mRNA for corticotrophin releasing hormone in the amygdala of fawn–hooded rats: a potential animal model of anxiety. Altemus M, et al. **Anxiety** 1994–95; 1(6):251–7

Specificity of temporal amygdala atrophy in Alzheimer's disease: quantitative assessment with magnetic resonance imaging. Maunoury C, et al. **Dementia** 1996 Jan–Feb; 7(1):10–14

Vigabatrin and carbamazepine have different efficacies in the prevention of status epilepticus induced neuronal damage in the hippocampus and amygdala. Pitkänen A, et al.
Epilepsy Res 1996 May;24(1):29–45

Decrease in somatostatin–immunoreactive neurons in the rat amygdaloid complex in a kindling model of temporal lobe epilepsy. Tuunanen J, et al. **Epilepsy Res** 1997 Jan; 26(2):315–27

Status epilepticus causes selective regional damage and loss of GABAergic neurons in the rat amygdaloid complex. Tuunanen J, et al. **Eur J Neurosci** 1996 Dec;8(12):2711–25

Medial temporal lobe heterotopia as a cause of increased hippocampal and amygdaloid MRI volumes. Watson C, et al. **J Neuroimaging** 1996 Oct;6(4):231–4

A volumetric MRI study of Gilles de la Tourette's syndrome. Moriarty J, et al. **Neurology** 1997 Aug;49(2):410–5

The amygdala and intractable temporal lobe epilepsy: a quantitative magnetic resonance imaging study. Van Paesschen W, et al. **Neurology** 1996 Oct;47(4):1021–31

Reliability and validity of MRI measurement of the amygdala and hippocampus in children with fragile X syndrome. Kates WR, et al. **Psychiatry Res** 1997 Aug 8;75(1):31–48

PHYSIOLOGY

6–OHDA bilateral lesions to the central amygdala do not affect vasopressin improvement of recall in rats. Winnicka MM. **Acta Neurobiol Exp (Warsz)** 1996;56(4):943–8

Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Davis M, et al.
Ann N Y Acad Sci 1997 Jun 21;821:305–31 (76 ref.)

The effects of electrical stimulation of the medial preoptic area and the medial amygdala on maternal responsiveness in female rats. Morgan HD, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:602–5

Amygdaloid control of alerting and behavioral arousal in rats: involvement of serotonergic mechanisms. Sanford LD, et al. **Arch Ital Biol** 1995 Dec;134(1):81–99

Ipsilateral connections between the gustatory cortex, amygdala and parabrachial nucleus are necessary for acquisition and retrieval of conditioned taste aversion in rats. Bielavska E, et al. **Behav Brain Res** 1996 Nov; 81(1–2):25–31

Unilateral amygdala inactivation after training attenuates memory for reduced reward. Coleman–Mesches K, et al.
Behav Brain Res 1996 May;77(1–2):175–80

Opposite effects on two different measures of retention following unilateral inactivation of the amygdala. Coleman–Mesches K, et al. **Behav Brain Res** 1997 Jun; 86(1):17–23

The amygdala modulates memory for changes in reward magnitude: involvement of the amygdaloid GABAergic system. Salinas JA, et al. **Behav Brain Res** 1996 Oct; 80(1–2):87–98

The effects of the medial and cortical amygdala lesions on post–stress analgesia in rats. Werka T. **Behav Brain Res** 1997 Jun;86(1):59–65

Lack of a temporal gradient of retrograde amnesia following NMDA–induced lesions of the basolateral amygdala assessed with the fear–potentiated startle paradigm. Lee Y, et al. **Behav Neurosci** 1996 Aug;110(4):836–9

Retrograde abolition of conditional fear after excitotoxic lesions in the basolateral amygdala of rats: absence of a temporal gradient. Maren S, et al. **Behav Neurosci** 1996 Aug;110(4):718–26

Role of the hippocampus plus subjacent cortex but not amygdala in visuomotor conditional learning in rhesus monkeys. Murray EA, et al. **Behav Neurosci** 1996 Dec; 110(6):1261–70

Basolateral amygdala lesions block glucocorticoid–induced modulation of memory for spatial learning. Roozendaal B, et al. **Behav Neurosci** 1996 Oct;110(5):1074–83

Characterisation of N–methyl–D–aspartate (NMDA)–induced kindling. Croucher MJ, et al.
Biochem Soc Trans 1996 May;24(2):295S

Changes in emotional behavior produced by long–term amygdala kindling in rats. Kalynchuk LE, et al.
Biol Psychiatry 1997 Feb 15;41(4):438–51

Evidence for membrane remodeling in ipsilateral thalamus and amygdala following left amygdala–kindled seizures in awake rats. Arai T, et al. **Brain Res** 1996 Dec 16; 743(1–2):131–40

Amygdala input to medial prefrontal cortex (mPFC) in the rat: a light and electron microscope study. Bacon SJ, et al. **Brain Res** 1996 May 13;720(1–2):211–9

Role of the central amygdala in social communication in Syrian hamsters (Mesocricetus auratus). Bamshad M, et al.
Brain Res 1997 Jan 2;744(1):15–22

Amygdala lesions block the effect of cocaine on memory in mice. Cestari V, et al. **Brain Res** 1996 Mar 25; 713(1–2):286–9

Amygdala kindling does not change emotional responding as measured by the acoustic startle response in the rat. Ebert U, et al. **Brain Res** 1996 Sep 16;733(2):193–202

5–HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus–maze. Gonzalez LE, et al.
Brain Res 1996 Sep 2;732(1–2):145–53

The role of amygdala and hypothalamus in GABAA antagonist bicuculline–induced cardiovascular responses in conscious rats. Gören Z, et al. **Brain Res** 1996 May 25; 722(1–2):118–24

Medial amygdaloid suppression of predatory attack behavior in the cat: I Role of a substance P pathway from the medial amygdala to the medial hypothalamus. Han Y, et al.
Brain Res 1996 Apr 15;716(1–2):59–71

Medial amygdaloid suppression of predatory attack behavior in the cat: II. Role of a GABAergic pathway from the medial to the lateral hypothalamus. Han Y, et al.
Brain Res 1996 Apr 15;716(1–2):72–83

Dentate gyrus field potentials evoked by stimulation of the basolateral amygdaloid nucleus in anesthetized rats. Ikegaya Y, et al. **Brain Res** 1996 Apr 29;718(1–2):53–60

Kindling induces a lasting, regionally selective increase of kynurenic acid in the nucleus accumbens. Löscher W, et al. **Brain Res** 1996 Jul 1;725(2):252–6

Kindling antagonism: interactions of the amygdala with the piriform, perirhinal, and insular cortices. Mohapel P, et al. **Brain Res** 1996 Sep 16;733(2):211–8

Neonatal ablations of the amygdala and inferior temporal cortex alter the vocal response to social separation in rhesus macaques. Newman JD, et al. **Brain Res** 1997 May 30; 758(1–2):180–6

Opioid antagonists in the periaqueductal gray inhibit morphine and beta–endorphin analgesia elicited from the amygdala of rats. Pavlovic ZW, et al. **Brain Res** 1996 Nov 25;741(1–2):13–26

Effect of intraperitoneal and intrahippocampal (CA1) 2–chloroadenosine in amygdaloid kindled rats.
Pourgholami MH, et al. **Brain Res** 1997 Mar 21; 751(2):259–64

The memory–modulatory effects of glucocorticoids depend on an intact stria terminalis. Roozendaal B, et al.
Brain Res 1996 Feb 19;709(2):243–50

Excitatory amino acid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Sajdyk TJ, et al. **Brain Res** 1997 Aug 1;764(1–2):262–4

Forebrain contribution to the induction of a brainstem correlate of conditioned taste aversion: I. The amygdala. Schafe GE, et al. **Brain Res** 1996 Nov 25;741(1–2):109–16

Amygdala–kindled seizures increase the expression of corticotropin–releasing factor (CRF) and CRF–binding protein in GABAergic interneurons of the dentate hilus. Smith MA, et al. **Brain Res** 1997 Jan 16;745(1–2):248–56

Role of serotonin receptor subtypes in the development of amygdaloid kindling in rats. Wada Y, et al. **Brain Res** 1997 Feb 7;747(2):338–42

Effect of glucocorticoids on the adrenocortical axis responses to electrical stimulation of the amygdala and the ventral noradrenergic bundle. Weidenfeld J, et al. **Brain Res** 1997 Apr 18;754(1–2):187–94

The effect of satiety on responses of gustatory neurons in the amygdala of alert cynomolgus macaques. Yan J, et al.
Brain Res 1996 Nov 18;740(1–2):193–200

Circuitry and functional aspects of the insular lobe in primates including humans. Augustine JR.
Brain Res Brain Res Rev 1996 Oct;22(3):229–44 (81 ref.)

Memory for the changing cost of a reward is mediated by the sublenticular extended amygdala. Brown VJ, et al.
Brain Res Bull 1996;39(3):163–70

Norepinephrine depletion in the amygdala inhibits CRF–41, ACTH, and corticosterone responses following photic simulation. Feldman S, et al. **Brain Res Bull** 1996;41(2):83–6

Developmental profile of messenger RNA for the corticotropin–releasing hormone receptor in the rat limbic system. Avishai–Eliner S, et al.
Brain Res Dev Brain Res 1996 Feb 26;91(2):159–63

Stimulus generalization of fear responses: effects of auditory cortex lesions in a computational model and in rats. Armony JL, et al. **Cereb Cortex** 1997 Mar;7(2):157–65

Formation and retrieval of inhibitory avoidance memory: differential roles of glutamate receptors in the amygdala and medial prefrontal cortex. Liang KC, et al.
Chin J Physiol 1996;39(3):155–66

Forebrain pathways and their behavioural interactions with neuroendocrine and cardiovascular function in the rat. Bohus B, et al. **Clin Exp Pharmacol Physiol** 1996 Feb; 23(2):177–82

Emotional memory: what does the amygdala do? Phelps EA, et al. **Curr Biol** 1997 May 1;7(5):R311–4 (25 ref.)

The amygdala and emotion. Gallagher M, et al.
Curr Opin Neurobiol 1996 Apr;6(2):221–7 (40 ref.)

Induction of burst–suppression and activation of epileptiform activity after methohexital and selective amygdalo–hippocampectomy. Wennberg R, et al.
Electroencephalogr Clin Neurophysiol 1997 May; 102(5):443–51

Bradycardia induced from stimulation of the left versus right central nucleus of the amygdala. Healy B, et al.
Epilepsy Res 1997 Sep;28(2):101–4

Effects of chronic morphine pretreatment on amygdaloid kindling development, postictal seizure and suppression and benzodiazepine receptor binding in rats. Rocha L, et al.
Epilepsy Res 1996 Apr;23(3):225–33

Topiramate: a potent anticonvulsant in the amygdala–kindled rat. Wauquier A, et al. **Epilepsy Res** 1996 Jun;24(2):73–7

Effects of acute treatment and long–term treatment with MK–801 against amygdaloid kindled seizures in rats. Yoshida M, et al. **Epilepsy Res** 1997 Mar;26(3):407–13

Non–NMDA receptor antagonists and the development of amygdala kindling. Meldrum BS, et al.
Epilepsy Res Suppl 1996;12:283–91

The basomedial and basolateral amygdaloid nuclei contribute to the induction of long–term potentiation in the dentate gyrus in vivo. Ikegaya Y, et al. **Eur J Neurosci** 1996 Sep; 8(9):1833–9

Sequential role of hippocampus and amygdala, entorhinal cortex and parietal cortex in formation and retrieval of memory for inhibitory avoidance in rats. Izquierdo I, et al. **Eur J Neurosci** 1997 Apr;9(4):786–93

Basolateral amygdala lesions block the memory-enhancing effect of glucocorticoid administration in the dorsal hippocampus of rats. Roozendaal B, et al. **Eur J Neurosci** 1997 Jan;9(1):76–83

The protective effect of 2-chloroadenosine against the development of amygdala kindling and on amygdala-kindled seizures. Abdul-Ghani AS, et al. **Eur J Pharmacol** 1997 May 12;326(1):7–14

Differential role of nitric oxide in long-term potentiation in the medial and lateral amygdala. Abe K, et al. **Eur J Pharmacol** 1996 Feb 15;297(1–2):43–6

Interrelationships between tyrosine hydroxylase-immunoreactive dopaminergic afferents and somatostatinergic neurons in the rat central amygdaloid nucleus. Asan E. **Histochem Cell Biol** 1997 Jan;107(1):65–79

Relationship between rhythmic discharge patterns of neurons in the central nucleus of the amygdala, blood pressure fluctuations and cortical activity. Schulz G, et al. **J Auton Nerv Syst** 1996 Mar 7;57(3):158–62

Organization of connections between the amygdaloid complex and the perirhinal and parahippocampal cortices in macaque monkeys. Stefanacci L, et al. **J Comp Neurol** 1996 Nov 25;375(4):552–82

Postnatal development of amygdaloid projections to the prefrontal cortex in the rat studied with retrograde and anterograde tracers. Verwer RW, et al. **J Comp Neurol** 1996 Dec 2;376(1):75–96

Amygdala kindling modifies extracellular opioid peptide content in rat hippocampus measured by microdialysis. Rocha LL, et al. **J Neurochem** 1997 Feb;68(2):616–24

Projection neurons of the lateral amygdaloid nucleus are virtually silent throughout the sleep—waking cycle. Gaudreau H, et al. **J Neurophysiol** 1996 Mar;75(3):1301–5

Loss of mGluR-mediated hyperpolarizations and increase in mGluR depolarizations in basolateral amygdala neurons in kindling-induced epilepsy. Holmes KH, et al. **J Neurophysiol** 1996 Oct;76(4):2808–12

Similar inhibitory processes dominate the responses of cat lateral amygdaloid projection neurons to their various afferents. Lang EJ, et al. **J Neurophysiol** 1997 Jan; 77(1):341–52

Synaptic and synaptically activated intrinsic conductances underlie inhibitory potentials in cat lateral amygdaloid projection neurons in vivo. Lang EJ, et al. **J Neurophysiol** 1997 Jan;77(1):353–63

Amino acid-mediated regulation of spontaneous synaptic activity patterns in the rat basolateral amygdala. Smith BN, et al. **J Neurophysiol** 1996 Sep;76(3):1958–67

Dihydropyridine- and neurotoxin-sensitive and -insensitive calcium currents in acutely dissociated neurons of the rat central amygdala. Yu B, et al. **J Neurophysiol** 1997 Feb; 77(2):690–701

Neurobiology of fear responses: the role of the amygdala. Davis M. **J Neuropsychiatry Clin Neurosci** 1997 Summer; 9(3):382–402 (305 ref.)

Organization of corticostriatal and corticoamygdalar projections arising from the anterior inferotemporal area TE of the macaque monkey: a Phaseolus vulgaris leucoagglutinin study. Cheng K, et al. **J Neurosci** 1997 Oct 15;17(20):7902–25

Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat. Frankland PW, et al. **J Neurosci** 1997 Mar 1;17(5):1838–47

The role of an amygdalo-nigrostriatal pathway in associative learning. Han JS, et al. **J Neurosci** 1997 May 15; 17(10):3913–9

Neurotoxic lesions of basolateral, but not central, amygdala interfere with Pavlovian second-order conditioning and reinforcer devaluation effects. Hatfield T, et al. **J Neurosci** 1996 Aug 15;16(16):5256–65

Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. Lee Y, et al. **J Neurosci** 1997 Aug 15;17(16):6434–46

Excitotoxic lesions of the amygdala fail to produce impairment in visual learning for auditory secondary reinforcement but interfere with reinforcer devaluation effects in rhesus monkeys. Málková L, et al. **J Neurosci** 1997 Aug 1;17(15):6011–20

Epileptogenesis in vivo enhances the sensitivity of inhibitory presynaptic metabotropic glutamate receptors in basolateral amygdala neurons in vitro. Neugebauer V, et al. **J Neurosci** 1997 Feb 1;17(3):983–95

Interaction of the hypothalamic paraventricular nucleus and central nucleus of the amygdala in naloxone blockade of neuropeptide Y-induced feeding revealed by c-fos expression. Pomonis JD, et al. **J Neurosci** 1997 Jul 1; 17(13):5175–82

Amygdalar lesions block discriminative avoidance learning and cingulothalamic training-induced neuronal plasticity in rabbits. Poremba A, et al. **J Neurosci** 1997 Jul 1; 17(13):5237–44

Basal amygdaloid complex afferents to the rat nucleus accumbens are compartmentally organized. Wright CI, et al. **J Neurosci** 1996 Mar 1;16(5):1877–93

Effect of electrical stimulation of the central amygdaloid nucleus on the nociceptive neuron of the cortex (SI) in the cat. Kawarada K, et al. **Jpn J Physiol** 1996 Dec; 46(6):485–90

Synaptic transmission and plasticity in the amygdala. An emerging physiology of fear conditioning circuits. Maren S. **Mol Neurobiol** 1996 Aug;13(1):1–22 (140 ref.)

REM sleep and amygdala [news] Maquet P, et al. **Mol Psychiatry** 1997 May;2(3):195–6

Second-order fear conditioning prevented by blocking NMDA receptors in amygdala. Gewirtz JC, et al. **Nature** 1997 Jul 31;388(6641):471–4

Different types of fear-conditioned behaviour mediated by separate nuclei within amygdala. Killcross S, et al. **Nature** 1997 Jul 24;388(6640):377–80

A differential neural response in the human amygdala to fearful and happy facial expressions. Morris JS, et al. **Nature** 1996 Oct 31;383(6603):812–5

Feeding and acetylcholine in the amygdala: microdialysis in freely moving rats. Hajnal A, et al. **Neurobiology (Bp)** 1996; 4(1–2):109–10

Response and habituation of the human amygdala during visual processing of facial expression. Breiter HC, et al. **Neuron** 1996 Nov;17(5):875–87

Single neuron activity in human hippocampus and amygdala during recognition of faces and objects. Fried I, et al. **Neuron** 1997 May;18(5):753–65

The amygdala and fear conditioning: has the nut been cracked? Maren S, et al. **Neuron** 1996 Feb;16(2):237–40 (25 ref.)

Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Duxon MS, et al. **Neuropharmacology** 1997 Apr-May; 36(4–5):601–8

Facial expression processing after amygdalotomy. Young AW, et al. **Neuropsychologia** 1996 Jan;34(1):31–9

Prolonged enhancement of REM sleep produced by carbachol microinjection into the amygdala. Calvo JM, et al. **Neuroreport** 1996 Jan 31;7(2):577–80

Involvement of amygdalar alpha adrenoceptors in hypothalamo-pituitary-adrenocortical responses. Feldman S, et al. **Neuroreport** 1996 Nov 25;7(18):3055–7

Human amygdala activation detected with echo-planar functional magnetic resonance imaging. Irwin W, et al. **Neuroreport** 1996 Jul 29;7(11):1765–9

The effect of electrolytic lesioning of the midbrain prior to amygdala kindling in rats. Chiba S, et al. **Neurosci Lett** 1997 May 16;227(2):83–6

The role of the basolateral nucleus of the amygdala in the pathway between the amygdala and the midbrain periaqueductal gray in the rat. Da Costa Gomez TM, et al. **Neurosci Lett** 1996 Aug 16;214(1):5–8

Parvalbumin-immunoreactive neurons make inhibitory synapses on pyramidal cells in the human amygdala: a light and electron microscopic study. Sorvari H, et al. **Neurosci Lett** 1996 Oct 18;217(2-3):93–6

Anticonvulsant action of metabotropic glutamate receptor agonists in kindled amygdala of rats. Suzuki K, et al. **Neurosci Lett** 1996 Feb 2;204(1–2):41–4

Blockade of isoproterenol-induced synaptic potentiation by tetra-9-aminoacridine in the rat amygdala. Wang SJ, et al. **Neurosci Lett** 1996 Aug 23;214(2-3):87–90

Gustatory and visceral inputs to the amygdala of the rat: conditioned taste aversion and induction of c-fos-like immunoreactivity. Yamamoto T, et al. **Neurosci Lett** 1997 Apr 25;226(2):127–30

Centrally acting histamine H1 antagonists promote the development of amygdala kindling in rats. Yokoyama H, et al. **Neurosci Lett** 1996 Oct 18;217(2-3):194–6

Recurrent inhibition in amygdalo-cortical projection neurons of the rat via collaterals of fast-conducting axons. Matsuda Y, et al. **Neurosci Res** 1996 Aug;25(4):385–9

Amygdala kindling alters N-methyl-D-aspartate receptor subunit messenger RNA expression in the rat supraoptic nucleus. Al-Ghoul WM, et al. **Neuroscience** 1997 Apr; 77(4):985–92

Amygdala kindling in the rat: anxiogenic-like consequences. Helfer V, et al. **Neuroscience** 1996 Aug;73(4):971–8

Lateral nucleus of the rat amygdala is reciprocally connected with basal and accessory basal nuclei: a light and electron microscopic study. Savander V, et al. **Neuroscience** 1997 Apr;77(3):767–81

The basolateral amygdala regulates sensorimotor gating of acoustic startle in the rat. Wan FJ, et al. **Neuroscience** 1997 Feb;76(3):715–24

Integration of chemosensory and hormonal cues is essential for sexual behaviour in the male Syrian hamster: role of the medial amygdaloid nucleus. Wood RI, et al. **Neuroscience** 1997 Jun;78(4):1027–35

Patterns of overlap and segregation between insular cortical, intermediodorsal thalamic and basal amygdaloid afferents in the nucleus accumbens of the rat. Wright CI, et al. **Neuroscience** 1996 Jul;73(2):359–73

Cholinergic responses of morphologically and electrophysiologically characterized neurons of the basolateral complex in rat amygdala slices. Yajeya J, et al. **Neuroscience** 1997 Jun;78(3):731–43

Spatial and visual discrimination learning in CD1 mice: partial analogy between the effect of lesions to the hippocampus and the amygdala. Ammassari-Teule M, et al. **Physiol Behav** 1996 Jul;60(1):265–71

Posterodorsal amygdaloid lesions in rats: long-term effects on body weight. King BM, et al. **Physiol Behav** 1996 Dec; 60(6):1569–71

Roles of the basolateral amygdala and hippocampus in social recognition in rats. Maaswinkel H, et al. **Physiol Behav** 1996 Jul;60(1):55–63

Effects of small amygdala lesions on fear, but not aggression, in the rat. Oakes ME, et al. **Physiol Behav** 1997 Jan; 61(1):45–55

Lesions of the amygdala do not affect the enhancement of the acoustic startle response by background noise. Schanbacher A, et al. **Physiol Behav** 1996 Nov;60(5):1341–6

Amygdala activity at encoding correlated with long-term, free recall of emotional information. Cahill L, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8016–21

Involvement of the amygdala in memory storage: interaction with other brain systems. McGaugh JL, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13508–14 (110 ref.)

Emotion, olfaction, and the human amygdala: amygdala activation during aversive olfactory stimulation. Zald DH, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):4119–24

The neurobiology of memory for emotional events: adrenergic activation and the amygdala. Cahill L, et al. **Proc West Pharmacol Soc** 1996;39:81–4 (24 ref.)

The neurobiology of the central nucleus of the amygdala in relation to neuroendocrine and autonomic outflow. Bohus B, et al. **Prog Brain Res** 1996;107:447–60 (91 ref.)

Brain region-specific and time-dependent decreases of G alpha i2 in amygdala-kindled rats. Cutz JC, et al. **Synapse** 1996 Mar;22(3):226–31

Effects of electrical stimulation of the central nucleus of the amygdala on the in vivo electrophysiological activity of rat nigral dopaminergic neurons. Rouillard C, et al. **Synapse** 1995 Dec;21(4):348–56

[The neuronal organization of the amygdala-visceral reflex arch] Baklavadzhian OG, et al. **Usp Fiziol Nauk** 1996 Jul-Sep;27(3):51–77 (193 ref.) (Eng. Abstr.) **(Rus)**

[A comparative evaluation of the effect of removal of the epiphysis and damage to the amygdala on the behavioral reactions of rats] Arushanian EB, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jul-Aug; 46(4):762–8 (Eng. Abstr.) **(Rus)**

[The similarity and difference between dogs assessed by the indices of the summary electrical activity of the frontal cortex, hippocampus, amygdala and hypothalamus] Chilingarian LI, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Nov-Dec; 46(6):1018–31 (Eng. Abstr.) **(Rus)**

[Interneuronal relationships in the basolateral amygdala of cats trained for choice in the quality of food reinforcement] Merzhanova GKh, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 May-Jun; 47(3):500–6 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Dissociations among the anxiolytic effects of septal, hippocampal, and amygdaloid lesions. Treit D, et al. **Behav Neurosci** 1997 Jun;111(3):653–8

Startle reflex and emotion modulation impairment after a right amygdala lesion. Angrilli A, et al. **Brain** 1996 Dec; 119 (Pt 6):1991–2000

The interpretation of sentence ambiguity in patients with unilateral focal brain surgery. Zaidel DW, et al. **Brain Lang** 1995 Dec;51(3):458–68

Interspike intervals during interictal periods in human temporal lobe epilepsy. Colder BW, et al. **Brain Res** 1996 May 6;719(1–2):96–103

Characterization of epileptiform field potentials recorded in the in vitro perirhinal cortex of amygdala-kindled epileptogenesis. Matsumoto Y, et al. **Brain Res** 1996 Nov 25;741(1–2):44–51

The amygdala: corticotropin-releasing factor, steroids, and stress. Gray TS, et al. **Crit Rev Neurobiol** 1996;10(2):155–68 (109 ref.)

Involvement of the claustrum in the convulsive evolution of temporal limbic seizure in feline amygdaloid kindling. Wada JA, et al. **Electroencephalogr Clin Neurophysiol** 1997 Aug;103(2):249–56

Amygdala-hippocampus relationships in temporal lobe seizures: a phase-coherence study. Gotman J, et al. **Epilepsy Res** 1996 Sep;25(1):51–7

Effects of single and repeated administration of sulthiame on amygdaloid kindled seizures in rats. Song HK, et al. **Epilepsy Res** 1997 May;27(2):81–7

The effects of focal N-methyl-D-aspartate pretreatment on the parameters of amygdaloid electrical kindling. Croucher MJ, et al. **Eur J Pharmacol** 1997 Jan 29;319(2-3):207–13

Amygdala-kindled convulsions in suspended rats. Chen L, et al. **Exp Neurol** 1996 Oct;141(2):347–9

Antecedent tone presentation differentially alters the rate of amygdala kindling: continued exposure is not required for this region-specific effect. Kline AE, et al. **Exp Neurol** 1997 Jan;143(1):124–31

Regulation of the adrenocorticotrophin response to stress by the central nucleus of the amygdala in rats depends upon the nature of the stressor. Marcilhac A, et al. **Exp Physiol** 1996 Nov;81(6):1035–8

Cognitive and psychiatric impairment in herpes simplex virus encephalitis suggest involvement of the amygdalo-frontal pathways. Caparros-Lefebvre D, et al. **J Neurol** 1996 Mar; 243(3):248–56

A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Post RM, et al. **Mol Neurobiol** 1996 Aug; 13(1):33–60 (132 ref.)

Impaired auditory recognition of fear and anger following bilateral amygdala lesions. Scott SK, et al. **Nature** 1997 Jan 16;385(6613):254–7

Insular cortex and amygdala lesions induced after aversive

AMYGDALOID BODY

training impair retention: effects of degree of training. Bermúdez-Rattoni F, et al. **Neurobiol Learn Mem** 1997 Jan; 67(1):57–63

Selective facilitation of kindled seizures from the amygdala after hippocampal lesions induced by perforant path stimulation. Mazarati AM, et al. **Neurosci Lett** 1997 Mar 21;224(3):165–8

Enhanced population responses in the basolateral amygdala of kainate-treated, epileptic rats in vitro. Smith BN, et al. **Neurosci Lett** 1997 Jan 24;222(1):1–4

The amygdala is critical for seizure propagation from brainstem to forebrain. Hirsch E, et al. **Neuroscience** 1997 Apr;77(4):975–84

Acoustic startle-evoked potentials in the rat amygdala: effect of kindling. Ebert U, et al. **Physiol Behav** 1997 Sep; 62(3):557–62

SURGERY

Low grade glioma in intractable epilepsy: lesionectomy versus epilepsy surgery. Lombardi D, et al. **Acta Neurochir Suppl (Wien)** 1997;68:70–4

Mesial atrophy and outcome after amygdalohippocampectomy or temporal lobe removal. Arruda F, et al. **Ann Neurol** 1996 Sep;40(3):446–50

Double dissociations of memory and executive functions in working memory tasks following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Owen AM, et al. **Brain** 1996 Oct;119 (Pt 5):1597–615

The interpretation of sentence ambiguity in patients with unilateral focal brain surgery. Zaidel DW, et al. **Brain Lang** 1995 Dec;51(3):458–68

Unilateral amygdalatomy and hemispherectomy [letter; comment] Balasubramaniam V. **Childs Nerv Syst** 1997 Mar; 13(3):121. Comment on: Childs Nerv Syst 1996 Jul;12(7):376–84.

A reliable system of ventricular coordinates for the cartography and stereotaxy of the amygdala (and anterior hippocampus) in macaques. Percheron G. **J Neurosci Methods** 1997 Jul 18;75(1):5–14

Subtemporal transparahippocampal amygdalohippocampectomy for surgical treatment of mesial temporal lobe epilepsy. Technical note [see comments] Park TS, et al. **J Neurosurg** 1996 Dec; 85(6):1172–6. Comment in: J Neurosurg 1997 Jun;86(6):1072.

Amygdalohippocampectomy [letter; comment] Rapport RL. **J Neurosurg** 1997 Jun;86(6):1072. Comment on: J Neurosurg 1996 Dec;85(6):1172–6.

TRANSPLANTATION

Effects of combined ventral forebrain grafts to neocortex and amygdala on behavior of rats with damage to the nucleus basalis magnocellularis. Shoham S, et al. **Brain Res Bull** 1997;43(4):381–92

ULTRASTRUCTURE

Pericapillary and distant axon terminals in the nuclei of the cat amygdala: a morphometric study. Lukaszyk I, et al. **Anat Embryol (Berl)** 1996 Mar;193(3):297–302

Ultrastructural features of tyrosine-hydroxylase-immunoreactive afferents and their targets in the rat amygdala. Asan E. **Cell Tissue Res** 1997 Jun;288(3):449–69

Projections of the ventral tegmentum area, formations of the substantia nigra and nuclei of the amygdaloid body on different segments of the caudate nucleus and the accumbens nucleus in dogs. Gorbachevskaya AI. **Neurosci Behav Physiol** 1996 May-Jun;26(3):213–9

NMDA and AMPA receptors in the lateral nucleus of the amygdala are postsynaptic to auditory thalamic afferents. Farb CR, et al. **Synapse** 1997 Oct;27(2):106–21

AMYGDALOSIDE see **AMYGDALIN**

AMYL NITRITE

ADVERSE EFFECTS

[Amyl nitrite: drugs and intoxicants] Jacobsen P. **Ugeskr Laeger** 1996 Sep 30;158(40):5645–6 **(Dan)**

ANALOGS & DERIVATIVES

Synthesis of peroxynitrite in a two-phase system using isoamyl nitrite and hydrogen peroxide. Uppu RM, et al. **Anal Biochem** 1996 May 1;236(2):242–9

Vascular and hemodynamic differences between organic nitrates and nitrites. Bauer JA, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):326–31

METABOLISM

Subunit specificity and organ distribution of glutathione transferase-catalysed S-nitrosoglutathione formation from alkyl nitrites in the rat. Akerboom TP, et al. **Biochem Pharmacol** 1997 Jan 10;53(1):117–20

POISONING

Methaemoglobinaemia presenting with status epilepticus. Malhotra R, et al. **J Accid Emerg Med** 1996 Nov; 13(6):427–30

THERAPEUTIC USE

Treatment of cyanide poisoning in an industrial setting. Wurzburg H. **Vet Hum Toxicol** 1996 Feb;38(1):44–7

AMYLASES

ADVERSE EFFECTS

Diversity of allergens causing occupational asthma among cereal workers as demonstrated by exposure procedures [see comments] Alvarez MJ, et al. **Clin Exp Allergy** 1996 Feb;26(2):147–53. Comment in: Clin Exp Allergy 1996 Feb;26(2):128–31.

Heating inactivates the enzymatic activity and partially inactivates the allergenic activity of Asp o 2. Baur X, et al. **Clin Exp Allergy** 1996 Feb;26(2):232–4

Allergy to flour and fungal amylase in bakery workers. Smith TA, et al. **Occup Med (Oxf)** 1997 Jan;47(1):21–4

ANALYSIS

Immunohistochemical and quantitative changes in salivary EGF, amylase and haptocorrin following radiotherapy for oral cancer. Christensen ME, et al. **Acta Otolaryngol (Stockh)** 1996 Jan;116(1):137–43

Gastric tonometry and drain amylase analysis in the detection of cervical oesophagogastric leakage. Machens A, et al. **Br J Surg** 1996 Nov;83(11):1614–5

Amylase concentration of drainage fluid after total gastrectomy. Sano T, et al. **Br J Surg** 1997 Sep;84(9):1310–2

Identification of serum and urine proteins responsible for enhanced pigment production by group B streptococci as amylases. Rosa-Fraile M, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):594–6

Airborne levels of alpha-amylase allergens in bakeries. Houba R, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):286–92

Amylase in bronchial washings as an aid to early diagnosis of bronchogenic carcinoma. Rao S. **J Assoc Physicians India** 1995 Jun;43(6):400

Chromatographic methods for amylases. Brena BM, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):217–37 (123 ref.)

Hydrolases acting on glycosidic bonds: chromatographic and electrophoretic separations. Moriyama T, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):201–16 (199 ref.)

Studies on local strains of amylolytic Lactobacillus from Nigerian fermented foods. Olasupo NA, et al. **Nahrung** 1996 Feb;40(1):45–6

A comparison of two methods to measure amylase, lipase, trypsin, and chymotrypsin activity and the effect of freezing and thawing on enzyme activities in pancreatic juice. Gabert VM, et al. **Pancreas** 1997 Aug;15(2):183–90

Calibration of the Ektachem Amylase method using human reference materials and the Phadebas Blue Starch method as an interim reference method. Mogensen PK, et al. **Scand J Clin Lab Invest** 1996 Oct;56(6):505–9

[A case of abdominal bronchogenic cyst which had interesting ultrasonographic finding, and contained fluid with an increase in amylase] Hase N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):594–8 (19 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Character of a wheat amylase inhibitor preparation and effects on fasting human pancreaticobiliary secretions and hormones. Choudhury A, et al. **Gastroenterology** 1996 Nov; 111(5):1313–20

BIOSYNTHESIS

Elevated amylase is related to the development of respiratory failure in organophosphate poisoning. Matsumiya N, et al. **Hum Exp Toxicol** 1996 Mar;15(3):250–3

Production of extracellular proteases and amylases by some acidophilic and alkalophilic bacteria. Sharma A, et al. **Indian J Exp Biol** 1996 Mar;34(3):232–4

[A case of ectopic amylase-producing lung cancer] Nakao M, et al. **Kyobu Geka** 1996 Dec;49(13):1069–73 (Eng. Abstr.) **(Jpn)**

[Diffuse bronchiolo-alveolar cell carcinoma that produced both amylase and CA19-9] Nonogaki T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Apr; 35(4):426–31 (Eng. Abstr.) **(Jpn)**

BLOOD

Unusual association of macroamylasemia and hyperlipasemia: report of two cases. Gullo L, et al. **Am J Gastroenterol** 1996 Nov;91(11):2441–2

Serum amylase and lipase in the evaluation of acute abdominal pain. Chase CW, et al. **Am Surg** 1996 Dec; 62(12):1028–33

Hyperamylasaemia in asymptomatic HIV patients. Foo Y, et al. **Ann Clin Biochem** 1997 May;34 (Pt 3):259–62

Elevated serum amylase levels after seizures [letter] Graham WR, et al. **Ann Intern Med** 1997 Jan 1;126(1):89

Serum amylase level on admission in the diagnosis of blunt injury to the pancreas: its significance and limitations. Takishima T, et al. **Ann Surg** 1997 Jul;226(1):70–6

Pancreatitis may occur with a normal amylase concentration in hypertriglyceridaemia [letter; comment] Sharma P, et al. **BMJ** 1996 Nov 16;313(7067):1265. Comment on: BMJ 1996 Aug 10;313(7053):333–7.

Is hyperamylasemia related to dyslipidemia? [letter; comment] Cavallini G, et al. **Gastroenterology** 1997 Mar; 112(3):1058–9. Comment on: Gastroenterology 1996 Jun;110(6):1905–8.

Chronic nonpathological hyperamylasemia of pancreatic origin [see comments] Gullo L. **Gastroenterology** 1996 Jun; 110(6):1905–8. Comment in: Gastroenterology 1997 Mar;112(3):1057. Comment in: Gastroenterology 1997 Mar;112(3):1058–9.

Asymptomatic chronic hyperamylasemia of unknown origin: an infrequent entity? [letter; comment] Martínez J, et al. **Gastroenterology** 1997 Mar;112(3):1057. Comment on: Gastroenterology 1996 Jun;110(6):1905–8.

Familial hyperamylasaemia. Cuckow PM, et al. **Gut** 1997 May;40(5):689–90

Elevated amylase is related to the development of respiratory failure in organophosphate poisoning. Matsumiya N, et al. **Hum Exp Toxicol** 1996 Mar;15(3):250–3

Hyperamylasemia after cardiac surgery in infants and children. Tikanoja T, et al. **Intensive Care Med** 1996 Sep; 22(9):959–63

Serum procarboxypeptidase B, amylase and lipase in chronic renal failure. Chen CC, et al. **J Gastroenterol Hepatol** 1996 May;11(5):496–9

Acute pancreatitis-induced enzyme release and necrosis are attenuated by IL-1 antagonism through an indirect mechanism. Fink G, et al. **J Surg Res** 1997 Jan;67(1):94–7

Increased serum pancreatic enzymes in uremia: relation with treatment modality and pancreatic involvement. Masoero G, et al. **Pancreas** 1996 Nov;13(4):350–5

Effect of antioxidants on postoperative hyperamylasemia in coronary bypass surgery. Paajanen H, et al. **Pancreas** 1996 Oct;13(3):236–40

Long-term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. Testoni PA, et al. **Pancreas** 1996 Jul; 13(1):61–5

Epstein-Barr virus-associated malignant lymphoma with macroamylasemia and monoclonal gammopathy in a patient with Wiskott-Aldrich syndrome. Yoshida K, et al. **Pediatr Hematol Oncol** 1997 Jan-Feb;14(1):85–9

Hyperamylasemia due to macroamylasemia in adult gluten enteropathy. Bonetti G, et al. **Scand J Clin Lab Invest** 1997 May;57(3):271–3

Marked hyperlipasemia after radiotherapy in a patient with prostate cancer [letter] Thanigaraj S, et al. **South Med J** 1996 Nov;89(11):1127–8

Co-monitoring serum anodal trypsinogen, serum amylase, and serum creatinine accurately differentiates rejection from other causes of allograft dysfunction after simultaneous pancreas-kidney transplantation. Lieberman JM, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):676–7

[Octreotide in the prevention of hyperamylasemia following ERCP (a controlled multicenter study)] Döbrönte Z, et al. **Orv Hetil** 1996 Oct 20;137(42):2309–12 (Eng. Abstr.) **(Hun)**

[Simultaneous presence of macroamylase and macrolipase in a patient] Yamashiro A, et al. **Rinsho Byori** 1997 Apr; 45(4):391–4 (Eng. Abstr.) **(Jpn)**

[Exocrine pancreatic function and gastric mucosa and duodenal mucosa in patients with chronic kidney failure] Sosnowski S, et al. **Pol Merkuriusz Lek** 1996 Sep;1(3):182–4 (Eng. Abstr.) **(Pol)**

[Hyperamylasemia after cardiac surgery in children] Torre Rodríguez I, et al. **An Esp Pediatr** 1997 Feb;46(2):156–60 (Eng. Abstr.) **(Spa)**

[Laboratory diagnosis of acute pancreatitis. Amylase analysis is still the leading one, but a "urinary strip" is on its way to be marketed] Andrén-Sandberg A, et al. **Lakartidningen** 1997 Jun 25;94(26–27):2451–3 (17 ref.) **(Swe)**

CHEMISTRY

Specificity of amylases and cyclodextrin-glucanotransferase in reactions with 2-deoxy-maltooligosaccharides. Evers B, et al. **Carbohydr Res** 1997 May 12;300(2):153–9

Heating inactivates the enzymatic activity and partially inactivates the allergenic activity of Asp o 2. Baur X, et al. **Clin Exp Allergy** 1996 Feb;26(2):232–4

Single crystals of V amylose complexed with glycerol. Hulleman SH, et al. **Int J Biol Macromol** 1996 Feb; 18(1–2):115–22

Biochemical characterization and mass spectrometric disulfide bond mapping of periplasmic alpha-amylase MalS of Escherichia coli. Spiess C, et al. **J Biol Chem** 1997 Aug 29;272(35):22125–33

DRUG EFFECTS

Hyperamylasemia in response to ritodrine or ephedrine administered to pregnant women. Takahashi T, et al. **J Am Coll Surg** 1997 Jan;184(1):31–6

GENETICS

Regulation of salivary-gland-specific gene expression. Ann DK, et al. **Crit Rev Oral Biol Med** 1997;8(3):244–52 (62 ref.)

Construction and characterization of new corynebacterial plasmids carrying the alpha-amylase gene. Ugorčáková J, et al. **Folia Microbiol (Praha)** 1996;41(1):10–4

Distribution and evolution of introns in Drosophila amylase

genes. Da Lage JL, et al. **J Mol Evol** 1996 Oct;43(4):334–47
Effect of thyroxine on pancreatic digestive enzymes and ornithine decarboxylase gene expression in neonatal rats. Lin CH, et al. **J Pediatr Gastroenterol Nutr** 1997 Jan; 24(1):18–24
Overexpression, purification, and characterization of recombinant barley alpha-amylases 1 and 2 secreted by the methylotrophic yeast Pichia pastoris. Juge N, et al. **Protein Expr Purif** 1996 Sep;8(2):204–14
[Localization and polymorphism of amylase genes in Drosophila of the virilis group] Mitrofanov VG, et al. **Dokl Akad Nauk** 1996 May;348(3):422–3 **(Rus)**

IMMUNOLOGY

Characterization of a monoclonal antibody that specifically inhibits pullulanase activity of Bacillus circulans amylase-pullulanase enzyme. Kim CH, et al. **Appl Biochem Biotechnol** 1997 Feb–Mar;62(2–3):191–200
Airborne levels of alpha-amylase allergens in bakeries. Houba R, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):286–92

ISOLATION & PURIFICATION

Chromatographic methods for amylases. Brena BM, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):217–37 (123 ref.)
Human salivary mucin MG1 selectively forms heterotypic complexes with amylase, proline-rich proteins, statherin, and histatins. Iontcheva I, et al. **J Dent Res** 1997 Mar; 76(3):734–43

METABOLISM

Targeting of signal sequenceless proteins for export in Escherichia coli with altered protein translocase. Prinz WA, et al. **EMBO J** 1996 Oct 1;15(19):5209–17
RBI, a one-domain alpha-amylase/trypsin inhibitor with completely independent binding sites. Maskos K, et al. **FEBS Lett** 1996 Nov 11;397(1):11–6
Construction and characterization of new corynebacterial plasmids carrying the alpha-amylase gene. Ugorčáková J, et al. **Folia Microbiol (Praha)** 1996;41(1):10–4
Changes of amylase levels in the acute experimental pancreatitis treated with Fibrolan. Madej B, et al. **Folia Morphol (Warsz)** 1996;55(4):388–9
Munkoyo beverage, a traditional Zambian fermented maize gruel using Rhynchosia root as amylase source. Zulu RM, et al. **Int J Food Microbiol** 1997 Mar 3;34(3):249–58
Studies on an amylolytic strain of Saccharomyces cerevisiae isolated from yam tuber. Olasupo NA, et al. **J Basic Microbiol** 1996;36(4):283–8
Passive sorting in maturing granules of AtT-20 cells: the entry and exit of salivary amylase and proline-rich protein. Castle AM, et al. **J Cell Biol** 1997 Jul 14;138(1):45–54
Biochemical assessment of pancreatic disease in human immunodeficiency virus infected men. Hancock MR, et al. **J Clin Pathol** 1997 Aug;50(8):674–6
Effects of saturated fatty acids on amylase release from exocrine pancreatic segments of sheep, rats, hamsters, field voles and mice. Ohbo M, et al. **J Comp Physiol [B]** 1996; 166(5):305–9
Supplementation of methionine to a low soybean protein diet strikingly increases pancreatic amylase activity in rats. Hara H, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Feb;43(1):161–6
Digestive enzymes in human milk: stability at suboptimal storage temperatures. Hamosh M, et al. **J Pediatr Gastroenterol Nutr** 1997 Jan;24(1):38–43
Absorption of nutrients from an energy-dense diet liquefied with amylase from germinated wheat in infants with acute diarrhea. Rahman MM, et al. **J Pediatr Gastroenterol Nutr** 1997 Feb;24(2):119–23
Dietary management of acute diarrhoea in children: effect of fermented and amylase-digested weaning foods on intestinal permeability. Willumsen JF, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):235–41
Acute penoscrotal edema due to acute necrotizing pancreatitis. Choong KK. **J Ultrasound Med** 1996 Mar; 15(3):247–8
Clearance ratios of amylase isoenzymes and IgG subclasses: do they reflect glomerular charge selectivity? Buis B, et al. **Nephron** 1997;75(4):444–50
An immunohistochemical analysis of anti-amylase antibody reactivity in acinic cell adenocarcinoma. Childers EL, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jun;81(6):691–4
Correlative morphometric and biochemical study on pancreatic amylase in normal and streptozotocin-diabetic rats. Aughsteen AA, et al. **Pancreas** 1996 Oct;13(3):295–303
Enzyme changes in zymogen granules and in pancreatic secretion throughout long-term CCK treatment. de Dios I, et al. **Peptides** 1997;18(1):101–10
Postoperative hyperamylasaemia in cardiac surgery. Paajanen H, et al. **Scand Cardiovasc J** 1997;31(3):137–40
[Changes in activity of alpha amylase and its salivary isoenzyme in serum and urine after surgical treatment of ovarian neoplasms] Zakrzewska I, et al. **Ginekol Pol** 1996 Oct;67(10):504–9 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Stunting syndrome in broilers: effect of age and exogenous amylase and protease on performance, development of the digestive tract, digestive enzyme activity, and apparent digestibility. Shapiro F, et al. **Poult Sci** 1995 Dec; 74(12):2019–28

PHYSIOLOGY

Stunting syndrome in broilers: effect of age and exogenous amylase and protease on performance, development of the digestive tract, digestive enzyme activity, and apparent digestibility. Shapiro F, et al. **Poult Sci** 1995 Dec; 74(12):2019–28

RADIATION EFFECTS

Immunohistochemical and quantitative changes in salivary EGF, amylase and haptocorrin following radiotherapy for oral cancer. Christensen ME, et al. **Acta Otolaryngol (Stockh)** 1996 Jan;116(1):137–43

SECRETION

MgATP acts before Ca2+ to prime amylase secretion from permeabilized rat pancreatic acini. Padfield PJ, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G655–60
Cholecystokinin peptides stimulate pancreatic secretion by multiple signal transduction pathways. Yoshida H, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):G735–47
Induction of amylase release from rat parotid acinar cells by cooling in vitro. Takuma T, et al. **Arch Oral Biol** 1996 Jun;41(6):547–51
Inhibitory action of sphingosine or ceramide on amylase secretion from isolated rat pancreatic acini. Shinkai M, et al. **Biochem Biophys Res Commun** 1997 Jun 9; 235(1):197–200
Effects of K+ channel blockers and K+ ionophore on isoprenaline-induced secretion of amylase from rat parotid acini. Murayama T, et al. **Eur J Pharmacol** 1997 Mar 12; 322(1):21–5
Inhibition of expression of PKC-alpha by antisense mRNA is associated with diminished cell growth and inhibition of amylase secretion by AR4-2J cells. Zhang X, et al. **Exp Cell Res** 1997 May 25;233(1):225–31
The effect of cyclosporine A and trifluoperazine on amylase secretion from rat parotid glands in vitro. Samini M, et al. **Fundam Clin Pharmacol** 1995;9(6):540–4
Histamine does not potentiate cyclic AMP-mediated amylase secretion in the guinea-pig pancreatic acinar cells. Camello C, et al. **Gen Pharmacol** 1997 Aug;29(2):211–5
Evidence that an N-terminal S-layer protein fragment triggers the release of a cell-associated high-molecular-weight amylase in Bacillus stearothermophilus ATCC 12980. Egelseer EM, et al. **J Bacteriol** 1996 Oct;178(19):5602–9
Heterotrimeric G-protein Gq/11 localized on pancreatic zymogen granules is involved in calcium-regulated amylase secretion. Ohnishi H, et al. **J Biol Chem** 1997 Jun 20; 272(25):16056–61
Long-term consumption of an amino acid diet reduces the pancreatic enzyme secretion response to a trypsin inhibitor in rats. Miura Y, et al. **J Nutr** 1997 Jul;127(7):1377–81
Effects of structural modulation on biological activity of bombesin analogues with (E)-alkene bond. Fujimoto K, et al. **Life Sci** 1997;60(1):29–34
Effect of morphine on secretion of amylase from isolated parotid acini. Miwa Y, et al. **Life Sci** 1996;59(21):1809–19
Endogenous arachidonic acid release and pancreatic amylase secretion. Hou W, et al. **Pancreas** 1997 Apr;14(3):301–8
Ethanol inhibits CCK-induced enzyme secretion by affecting calcium-pump activity in isolated rat pancreatic acini. Tachibana I, et al. **Pancreas** 1996 Oct;13(3):316–23
Effect of substance P and receptor antagonists on secretion of lingual lipase and amylase from rat von Ebner's gland. Field RB, et al. **Peptides** 1997;18(2):277–85
Amylin mobilizes [Ca2+]i and stimulates the release of pancreatic digestive enzymes from rat acinar AR42J cells: evidence for an exclusive receptor system of amylin. Huang Y, et al. **Peptides** 1996;17(3):497–502

THERAPEUTIC USE

[Immobilized proteases and their activators as immunocorrective agents] Khmelevskaia IG, et al. **Antibiot Khimioter** 1997;42(3):11–4 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Crystal structures of a mutant maltotetraose-forming exo-amylase cocrystallized with maltopentaose. Yoshioka Y, et al. **J Mol Biol** 1997 Aug 29;271(4):619–28

AMYLOBARBITONE see **AMOBARBITAL**

AMYLOGLUCOSIDASE see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

AMYLOID

see related
AMYLOID NEUROPATHIES

Chronic infusion of islet amyloid polypeptide causes anorexia in rats. Arnelo U, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1654–9
The nature and origin of amyloid fibrils. Proceedings of a symposium. Oeiras, Portugal, 23–25 October 1995. **Ciba Found Symp** 1996;199:1–253
USAN council. List No.392. New names. Amlintide. **Clin Pharmacol Ther** 1997 Apr;61(4):500
USAN Council. List No.392. New names. Pramlintide. **Clin Pharmacol Ther** 1997 Apr;61(4):501
Amyloid colitis mimicking collagenous colitis. Groisman GM, et al. **Histopathology** 1997 Aug;31(2):201–2
[Amylin] Blanchet C, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:327–34 (46 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Protection by amylin of gastric erosions induced by indomethacin or ethanol in rats. Guidobono F, et al. **Br J Pharmacol** 1997 Feb;120(4):581–6
Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. Colburn WA, et al. **J Clin Pharmacol** 1996 Jan;36(1):13–24

ANALYSIS

Fine needle aspiration cytology of amyloid goiter. A report of four cases. Nijhawan VS, et al. **Acta Cytol** 1997 May–Jun;41(3):830–4
Immunohistochemical characterization of amyloid fibril precursors in renal tissue. Wągrowska-Danilewicz M, et al. **Acta Histochem** 1996 Jul;98(3):301–8
Characterization of spherical amyloid protein from a prolactin-producing pituitary adenoma. Hinton DR, et al. **Acta Neuropathol (Berl)** 1997 Jan;93(1):43–9
Introduction to the Amyloid Symposium. Vinters HV, et al. **Brain Pathol** 1996 Apr;6(2):109
Brain parenchymal and microvascular amyloid in Alzheimer's disease. Vinters HV, et al. **Brain Pathol** 1996 Apr;6(2):179–95 (169 ref.)
The origin of amyloid in cerebral vessels of aged dogs. Wegiel J, et al. **Brain Res** 1995 Dec 24;705(1–2):225–34
Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Withers GS, et al. **Brain Res Dev Brain Res** 1997 Mar 17; 99(1):87–94
Histomorphological patterns of renal amyloidosis: a correlation between histology and chemical type of amyloidosis. Looi LM, et al. **Hum Pathol** 1997 Jul; 28(7):847–9
Reply to M. Yamada's letter to the editor: an amyloid protein in familial cerebral amyloid angiopathy (British type) [letter; comment] Plant GT. **J Neurol Sci** 1996 Jun; 138(1–2):168. Comment on: J Neurol Sci 1996 Feb;135(2):181.
Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease. Chargé SB, et al. **J Pathol** 1996 Aug;179(4):443–7
Monomeric and dimeric beta 2-microglobulin may be extracted from amyloid deposits in vitro. García-García M, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1192–8
Late onset type I familial amyloidotic polyneuropathy: presentation of three autopsy cases in comparison with 19 autopsy cases of the ordinary type. Takahashi K, et al. **Pathol Int** 1997 Jun;47(6):353–9
Localized amyloid in the menisci of the knee joint. Rumpelt HJ, et al. **Pathol Res Pract** 1996 Jun;192(6):547–51
Massive amyloid deposition in pancreatic vipoma: a case report. Crowley PF, et al. **Pathology** 1996 Nov;28(4):377–9
Charcot knee arthropathy with articular amyloid deposition in familial amyloidotic polyneuropathy. Shiraishi M, et al. **Scand J Rheumatol** 1997;26(1):61–4
Visceral organ involvement and extracellular matrix changes in beta 2-microglobulin amyloidosis--a comparative study with systemic AA and AL amyloidosis. Ohashi K, et al. **Virchows Arch** 1997 Jun;430(6):479–87

ANTAGONISTS & INHIBITORS

Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Tomiyama T, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):859–65
Effect of (8-32) salmon calcitonin, an amylin antagonist, on insulin, glucagon and somatostatin release: study in the perfused pancreas of the rat. Silvestre RA, et al. **Br J Pharmacol** 1996 Jan;117(2):347–50
Different influence of CGRP (8-37), an amylin and CGRP antagonist, on the anorectic effects of cholecystokinin and bombesin in diabetic and normal rats. Lutz TA, et al. **Peptides** 1997;18(5):643–9

BIOSYNTHESIS

NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. Hashimoto M, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):611–6
The synaptic protein NACP is abnormally expressed during the progression of Alzheimer's disease. Iwai A, et al. **Brain Res** 1996 May 13;720(1–2):230–4
Metabolism of amyloid proteins. Benson MD, et al. **Ciba Found Symp** 1996;199:104–13; discussion 113–8
FAP mutations destabilize transthyretin facilitating conformational changes required for amyloid formation. Colon W, et al. **Ciba Found Symp** 1996;199:228–38; discussion 239–42
Proteoglycans and amyloid fibrillogenesis. Kisilevsky R, et al. **Ciba Found Symp** 1996;199:58–67; discussion 68–72,

90–103
Modulating conformational factors in transthyretin amyloid. Saraiva MJ, et al. **Ciba Found Symp** 1996;199:47–52; discussion 52–7
Altered immunoreactivity of islet amyloid polypeptide (IAPP) may reflect major modifications of the IAPP molecule in amyloidogenesis. Ma Z, et al. **Diabetologia** 1997 Jul;40(7):793–801
Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats [published erratum appears in Diabetologia 1996 Aug;39(8):1004] Mulder H, et al. **Diabetologia** 1996 Jun;39(6):649–57
Expression of islet amyloid polypeptide in fetal and adult porcine and human pancreatic islet cells [corrected and republished with original paging, article originally printed in Endocrinology 1996 Dec;137(12):5319–25] Lukinius A, et al. **Endocrinology** 1997 Apr;138(4):5319–25
Transgenic overproduction of islet amyloid polypeptide (amylin) is not sufficient for islet amyloid formation. Verchere CB, et al. **Horm Metab Res** 1997 Jun;29(6):311–6 (33 ref.)
Identification of cis- and trans-active factors regulating human islet amyloid polypeptide gene expression in pancreatic beta-cells. Carty MD, et al. **J Biol Chem** 1997 May 2;272(18):11986–93
An etiological role of amyloidogenic carboxyl-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. Suh YH. **J Neurochem** 1997 May; 68(5):1781–91 (121 ref.)
Induction of insulin and islet amyloid polypeptide production in pancreatic islet glucagonoma cells by insulin promoter factor 1. Serup P, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9015–20
De novo amyloid synthesis in ocular tissue in familial amyloidotic polyneuropathy after liver transplantation [letter] Ando Y, et al. **Transplantation** 1996 Oct 15; 62(7):1037–8

BLOOD

The effect of different glucose endovenous administrations on amylin and insulin blood concentration in healthy subjects. Testa I, et al. **Boll Soc Ital Biol Sper** 1996 Mar–Apr;72(3–4):103–8
Effect of insulin treatment on circulating islet amyloid polypeptide in patients with NIDDM. Lindström T, et al. **Diabet Med** 1997 Jun;14(6):472–6
Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Kautzky-Willer A, et al. **Diabetes** 1997 Apr;46(4):607–14
The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM. Mooradian AD, et al. **Diabetes Care** 1996 Aug;19(8):883–4
Pancreatic cancer in rats and hamsters does not induce IAPP-related hyperglycaemia. Oosterwijk C, et al. **Int J Cancer** 1997 Aug 7;72(4):637–41
Hyperamylinemia is associated with hyperinsulinemia in the glucose-tolerant, insulin-resistant offspring of two Mexican-American non-insulin-dependent diabetic parents. Gulli G, et al. **Metabolism** 1997 Oct;46(10):1157–61
The use of chromogranin, synaptophysin and islet amyloid polypeptide as markers for neuroendocrine tumours. Stridsberg M. **Ups J Med Sci** 1995;100(3):169–99 (186 ref.)

CHEMISTRY

Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques? Dickson DW. **Am J Pathol** 1997 Jul;151(1):7–11 (33 ref.)
Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. Paik SR, et al. **Arch Biochem Biophys** 1997 Aug 15; 344(2):325–34
Involvement of an SAF-like transcription factor in the activation of serum amyloid A gene in monocyte/macrophage cells by lipopolysaccharide. Ray BK, et al. **Biochemistry** 1997 Apr 15;36(15):4662–8
NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Weinreb PH, et al. **Biochemistry** 1996 Oct 29;35(43):13709–15
Elevated connexin43 immunoreactivity at sites of amyloid plaques in Alzheimer's disease. Nagy JI, et al. **Brain Res** 1996 Apr 22;717(1–2):173–8
Kinetics and mechanism of amyloid formation by the prion protein H1 peptide as determined by time-dependent ESR. Lundberg KM, et al. **Chem Biol** 1997 May;4(5):345–55
Islet pathology of non-insulin-dependent diabetes mellitus (NIDDM). Westermark P. **Diabet Med** 1996 Sep;13(9 Suppl 6):S46–8 (23 ref.)
Altered immunoreactivity of islet amyloid polypeptide (IAPP) may reflect major modifications of the IAPP molecule in amyloidogenesis. Ma Z, et al. **Diabetologia** 1997 Jul;40(7):793–801
The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid beta-peptide as modeled with N-terminal decapeptide fragments. Szendrei GI, et al. **Int J Pept Protein Res** 1996 Apr;47(4):289–96
Polymorphic fibrillar assembly of human amylin. Goldsbury CS, et al. **J Struct Biol** 1997 Jun;119(1):17–27
Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis. Niwa T, et al. **Kidney Int** 1996 Oct; 50(4):1303–9
Evidence that the precursor protein of non-A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil. Kim J. **Mol Cells** 1997 Feb 28;7(1):78–83
Direct conversion of an oligopeptide from a beta-sheet to an alpha-helix: a model for amyloid formation. Zhang S, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):23–8
Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous beta-sheet helix. Blake C, et al. **Structure** 1996 Aug 15;4(8):989–98
Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Kelly JW. **Structure** 1997 May 15;5(5):595–600 (73 ref.)
[Transmissible cerebral amyloidoses or prion diseases: is the structure of the infectious agent really understood?] Liberski PP, et al. **Postepy Biochem** 1996;42(4):320–30 (129 ref.) **(Pol)**

DEFICIENCY

Microheterogeneity of serum glycoproteins and their liver precursors in patients with carbohydrate-deficient glycoprotein syndrome type I: apparent deficiencies in clusterin and serum amyloid P [see comments] Henry H, et al. **J Lab Clin Med** 1997 Apr;129(4):412–21. Comment in: J Lab Clin Med 1997 Apr;129(4):394–5.

GENETICS

Glucose regulation of islet amyloid polypeptide gene expression in rat pancreatic islets. Gasa R, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E543–9
Islet amyloid polypeptide and insulin gene expression are regulated in parallel by glucose in vivo in rats. Mulder H, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):E1008–14
Involvement of the homeodomain-containing transcription factor PDX-1 in islet amyloid polypeptide gene transcription. Watada H, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):746–51
Transcription of the amylin gene in newborn dogs. Feng BC, et al. **Biochem Mol Med** 1997 Aug;61(2):192–7
Peripheral nerve amyloidosis. Reilly MM, et al. **Brain Pathol** 1996 Apr;6(2):163–77 (118 ref.)
Modulating conformational factors in transthyretin amyloid. Saraiva MJ, et al. **Ciba Found Symp** 1996;199:47–52; discussion 52–7
Biologically active human islet amyloid polypeptide/amylin in transgenic mice. van Hulst KL, et al. **Eur J Endocrinol** 1997 Jan;136(1):107–13
In vitro expression analysis shows that the secretory form of gelsolin is the sole source of amyloid in gelsolin-related amyloidosis. Kangas H, et al. **Hum Mol Genet** 1996 Sep; 5(9):1237–43
Investigation of the effects of antisense oligodeoxynucleotides to islet amyloid polypeptide mRNA on insulin release, content and expression. Kulkarni RN, et al. **J Endocrinol** 1996 Dec;151(3):341–8
Cloning of mouse islet amyloid polypeptide gene and characterization of its promoter. Ekawa K, et al. **J Mol Endocrinol** 1997 Aug;19(1):79–86
Activation of amylin gene transcription by LIM domain homeobox gene isl-1. Wang M, et al. **Mol Endocrinol** 1996 Mar;10(3):243–51
Signals related to glucose metabolism regulate islet amyloid polypeptide (IAPP) gene expression in human pancreatic islets. Gasa R, et al. **Regul Pept** 1997 Jan 29;68(2):99–104
The amino acid sequence of the glycosylated amyloid immunoglobulin light chain protein AL MS. Omtvedt LA, et al. **Scand J Immunol** 1997 May;45(5):551–6
[Familial amyloidotic polyneuropathy with a transthyretin variant (Val30-->Leu)] Shimizu H, et al. **No To Shinkei** 1996 Feb;48(2):175–8 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques? Dickson DW. **Am J Pathol** 1997 Jul;151(1):7–11 (33 ref.)
Further characterization of a monoclonal antibody recognizing apolipoprotein E peptides in amyloid deposits. Yamada T, et al. **Ann Clin Lab Sci** 1997 Jul–Aug; 27(4):276–81
Primary localized amyloidosis of the eyelid: two cases of immunoglobulin light chain-derived proteins, subtype lambda V respectively lambda VI. Olsen KE, et al. **Clin Exp Immunol** 1996 Nov;106(2):362–6 (27 ref.)
Development and characterization of monoclonal antibodies specific for amylin. Phelps JL, et al. **Hybridoma** 1996 Oct; 15(5):379–86

ISOLATION & PURIFICATION

Islet amyloid and islet amyloid polypeptide in cynomolgus macaques (Macaca fascicularis): an animal model of human non-insulin-dependent diabetes mellitus. O'Brien TD, et al. **Vet Pathol** 1996 Sep;33(5):479–85

METABOLISM

Multiple sclerosis and amyloid deposits in the white matter of the brain. Nennesmo I, et al. **Acta Neuropathol (Berl)** 1997 Feb;93(2):205–9 (36 ref.)
Distribution of amyloid bodies in the aged human vestibulocochlear nerve. Fujii M, et al. **Acta Otolaryngol (Stockh)** 1996 Jul;116(4):566–71
The role of proteolytic enzymes in the deposition of amyloid proteins. Sato A, et al. **Adv Enzyme Regul** 1996;36:307–24
Metabolism of normal and Met30 transthyretin. Hanes D, et al. **Adv Food Nutr Res** 1996;40:149–55
Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Kohno K, et al. **Am J Pathol** 1997 Apr;150(4):1497–508
Prolactin-derived amyloid in the aging pituitary gland. Westermark P, et al. **Am J Pathol** 1997 Jan;150(1):67–73
Female protein, amyloidosis, and hormonal carcinogenesis in Turkish hamster: differences from Syrian hamster. Coe JE, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R934–41
Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin. Wookey PJ, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):F289–94
Lymphadenopathy due to amyloid deposition in non-Hodgkin's lymphoma. Simmonds PD, et al. **Ann Oncol** 1997 Mar;8(3):267–70
Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Harper JD, et al. **Annu Rev Biochem** 1997;66:385–407 (97 ref.)
Focal tenosynovial amyloid deposition as a rare cause of median nerve compression at the wrist. Subramaniam P, et al. **Aust N Z J Surg** 1997 Feb–Mar;67(2–3):138–9
Oxidative stress is found in amyloid deposits in systemic amyloidosis. Ando Y, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):497–502
Alpha 2-macroglobulin protects some of the protein constituents of dialysis-associated amyloidosis from protease degradation. Gouin-Charnet A, et al. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):48–51
B cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. Janciauskiene S, et al. **Biochem Biophys Res Commun** 1997 Jul 30; 236(3):580–5
Alzheimer's disease-associated presenilins 1 and 2: accelerated amyloid fibril formation of mutant 410 Cys-->Tyr and 141 Asn-->Ile peptides. Maury CP, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):249–52
Accumulation of pro-apolipoprotein A-II in mouse senile amyloid fibrils. Higuchi K, et al. **Biochem J** 1997 Aug 1; 325 (Pt 3):653–9
Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Jensen PH, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):539–46
Characterization of two highly amyloidogenic mutants of transthyretin. Goldsteins G, et al. **Biochemistry** 1997 May 6;36(18):5346–52
Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. Naiki H, et al. **Biochemistry** 1997 May 20;36(20):6243–50
Calcium-dependent and -independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: enhanced binding at slightly acid pH. Danielsen B, et al. **Biochim Biophys Acta** 1997 Apr 25;1339(1):73–8
Islet amyloid polypeptide and calcitonin gene-related peptide expression are down-regulated in dorsal root ganglia upon sciatic nerve transection. Mulder H, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1–2):322–30
Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy. Pepys MB, et al. **Ciba Found Symp** 1996;199:73–81; discussion 81–9
Ageing and amyloid fibrillogenesis: lessons from apolipoprotein AI, transthyretin and islet amyloid polypeptide. Westermark P, et al. **Ciba Found Symp** 1996; 199:205–18; discussion 218–22
Prion protein amyloid: separation of scrapie infectivity from PrP polymers. Wille H, et al. **Ciba Found Symp** 1996; 199:181–99; discussion 199–201
Nonsecretory immunoglobulin-derived amyloidosis of the heart: diagnosis by immunohistochemistry of the endomyocardium. Chau EM, et al. **Clin Cardiol** 1997 May; 20(5):494–6
Amyloid deposits of immunohistochemically different classes in the ligamentum flavum in biopsies from patients with herniated discs or lumbar spinal stenosis. Gies U, et al. **Clin Neuropathol** 1996 Jan–Feb;15(1):54–9
Islet pathology of non-insulin-dependent diabetes mellitus (NIDDM). Westermark P. **Diabet Med** 1996 Sep;13(9 Suppl 6):S46–8 (23 ref.)
Islet amyloid polypeptide/amylin contents in pancreas change with increasing age in genetically obese and diabetic mice. Takada K, et al. **Diabetes Res Clin Pract** 1996 Aug; 33(3):153–8
Expression of islet amyloid polypeptide in fetal and adult porcine and human pancreatic islet cells [corrected and republished in Endocrinology 1997 Apr;138(4):5319–25] Lukinius A, et al. **Endocrinology** 1996 Dec;137(12):5319–25
Islet amyloid polypeptide (amylin) does not seem to be directly involved in the development of gestational diabetes mellitus. Grigorakis SI, et al. **Gynecol Obstet Invest** 1997; 44(1):6–10
The classification of amyloid deposits in clinicopathological practice. Röcken C, et al. **Histopathology** 1996 Oct; 29(4):325–35

Amyloid goiter: radiological study in a case presenting hypothyroidism. Ishimura E, et al. **Horm Metab Res** 1996 Jan;28(1):27–31

Snake coiled fibres in rat soleus muscle in chloroquine induced myopathy share immunohistochemical characteristics with amyloid depositions in Alzheimer's disease brain tissue. Tsuzuki K, et al. **Int J Exp Pathol** 1997 Feb;78(1):1–8

Renal transplantation relieves the symptoms but does not reverse beta 2–microglobulin amyloidosis. Mourad G, et al. **J Am Soc Nephrol** 1996 May;7(5):798–804

Acceleration of amyloid fibril formation by specific binding of Abeta–(1–40) peptide to ganglioside–containing membrane vesicles. Choo–Smith LP, et al. **J Biol Chem** 1997 Sep 12;272(37):22987–90

Detection of amyloid deposition in various regions of the feline pancreas by different staining techniques. Lutz TA, et al. **J Comp Pathol** 1997 Feb;116(2):157–70

Differential effect of insulin treatment on islet amyloid polypeptide (amylin) and insulin gene expression in streptozotocin–induced diabetes in rats. Mulder H, et al. **J Endocrinol** 1997 Mar;152(3):495–501

Characterization of the precursor protein of the non–A beta component of senile plaques (NACP) in the human central nervous system. Irizarry MC, et al. **J Neuropathol Exp Neurol** 1996 Aug;55(8):889–95

Neuronal localization of presenilin–1 and association with amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Busciglio J, et al. **J Neurosci** 1997 Jul 1; 17(13):5101–7

Long term effect of renal transplantation on dialysis–related amyloid deposits and symptomatology. Tan SY, et al. **Kidney Int** 1996 Jul;50(1):282–9

Expression of human islet amyloid polypeptide/amylin impairs insulin secretion in mouse pancreatic beta cells. Tokuyama T, et al. **Metabolism** 1997 Sep;46(9):1044–51

Three–dimensional cultures of keratinocytes and an application to in vitro–amyloid production of cutaneous amyloidosis. Horiguchi Y, et al. **Microsc Res Tech** 1997 Aug 15;38(4):387–93

Multiple functions of alpha 1–antitrypsin and alpha 1–antichymotrypsin. 3. Regulation of extracellular surfactant metabolism and amyloid fibril formation. Luisetti M. **Monaldi Arch Chest Dis** 1997 Jun;52(3):285–6

Amyloid deposition in the synovium and ligament in idiopathic carpal tunnel syndrome. Nakamichi KI, et al. **Muscle Nerve** 1996 Oct;19(10):1349–51

Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Botto M, et al. **Nat Med** 1997 Aug;3(8):855–9

Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis [see comments] Booth DR, et al. **Nature** 1997 Feb 27;385(6619):787–93. Comment in: Nature 1997 Feb 27;385(6619):773, 775.

Amyloid fibrils. Mutations make enzyme polymerize [news; comment] Perutz MF. **Nature** 1997 Feb 27;385(6619):773, 775. Comment on: Nature 1997 Feb 27;385(6619):787–93.

Immunotactoid glomerulopathy with extrarenal deposits in the bone, and chronic cholestatic liver disease. Wallner M, et al. **Nephrol Dial Transplant** 1996 Aug;11(8):1619–24

Evolutionary perspectives on amyloid and inflammatory features of Alzheimer disease. Finch CE, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):809–15 (131 ref.)

From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Nitsch RM. **Neurodegeneration** 1996 Dec;5(4):477–82 (44 ref.)

Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease. Li YM, et al. **Neurosci Lett** 1997 May 2;226(3):155–8

Increased storage and secretion of islet amyloid polypeptide relative to insulin in the spontaneously diabetic GK rat. Leckström A, et al. **Pancreas** 1996 Oct;13(3):259–67

Comparison of amyloid deposition in two lines of transgenic mouse that model familial amyloidotic polyneuropathy, type I. Takaoka Y, et al. **Transgenic Res** 1997 Jul;6(4):261–9

Ultrastructural evidence for colocalization of kappa light chain– and beta 2–microglobulin–derived amyloids using double labelling immunogold electron microscopy. Takahashi M, et al. **Virchows Arch** 1996 Dec;429(6):383–8

[Histopathological study of valvular deposits of amyloid protein in cardiac amyloidosis] Hisaki R, et al. **J Cardiol** 1996;27 Suppl 2:31–7; discussion 38 (Eng. Abstr.) **(Jpn)**

[Plasma cell leukemia with amyloid deposition and osteogenetic change at the site of an extramedullary plasmacytoma] Kurosu T, et al. **Rinsho Ketsueki** 1997 Jan; 38(1):58–63 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro–amylin, human) after intravenous bolus and infusion doses in patients with insulin–dependent diabetes. Colburn WA, et al. **J Clin Pharmacol** 1996 Jan;36(1):13–24

PHARMACOLOGY

Amylin, calcitonin gene–related peptide, and adrenomedullin: effects on thiazide receptor and calcium. Blakely P, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):F410–5

Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney. Harris PJ, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):F13–21

Different pharmacological characteristics in L6 and C2C12 muscle cells and intact rat skeletal muscle for amylin, CGRP and calcitonin. Pittner RA, et al. **Br J Pharmacol** 1996 Mar;117(5):847–52

Multiple receptors for calcitonin gene–related peptide and amylin on guinea–pig ileum and vas deferens. Tomlinson AE, et al. **Br J Pharmacol** 1996 Mar;117(6):1362–8

Human amylin mimics amyloid beta protein–induced reactive gliosis and inhibition of cellular redox activity in cultured astrocytes. Abe K, et al. **Brain Res** 1997 Jul 11; 762(1–2):285–8

Amylin and the gastrointestinal tract. Macdonald IA. **Diabet Med** 1997 Jun;14 Suppl 2:S24–8 (21 ref.)

Effects of amylin and the amylin agonist pramlintide on glucose metabolism. Schmitz O, et al. **Diabet Med** 1997 Jun;14 Suppl 2:S19–23 (29 ref.)

Rat amylin mediates a pressor response in the anaesthetised rat: implications for the association between hypertension and diabetes mellitus. Haynes JM, et al. **Diabetologia** 1997 Mar;40(3):256–61

Amylin, amyloid and age–related disease. Cooper GJ, et al. **Drugs Aging** 1996 Sep;9(3):202–12 (133 ref.)

Chronic low dose islet amyloid polypeptide infusion reduces food intake, but does not influence glucose metabolism, in unrestrained conscious rats: studies using a novel aortic catheterization technique. Arnelo U, et al. **Endocrinology** 1997 Oct;138(10):4081–5

Lack of effect of calcitonin gene–related peptide and amylin on major markers of glucose metabolism in hepatocytes. Pittner RA. **Eur J Pharmacol** 1997 May 1;325(2–3):189–97

Comparison of the in vitro and in vivo pharmacology of adrenomedullin, calcitonin gene–related peptide and amylin in rats. Vine W, et al. **Eur J Pharmacol** 1996 Oct 24; 314(1–2):115–21

Acute effects of the human amylin analog AC137 on basal and insulin–stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin–dependent diabetes mellitus. Nyholm B, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1083–9

Dose–response for glucagonostatic effect of amylin in rats. Gedulin BR, et al. **Metabolism** 1997 Jan;46(1):67–70

A beta deposition inhibitor screen using synthetic amyloid. Esler WP, et al. **Nat Biotechnol** 1997 Mar;15(3):258–63

Behavioral effects of amylin injected intracerebroventricularly in the rat. Clementi G, et al. **Peptides** 1996;17(4):589–91

Amylin mobilizes [Ca2+]i and stimulates the release of pancreatic digestive enzymes from rat acinar AR42J cells: evidence for an exclusive receptor system of amylin. Huang Y, et al. **Peptides** 1996;17(3):497–502

The histaminergic, but not the serotoninergic, system mediates amylin's anorectic effect. Lutz TA, et al. **Peptides** 1996;17(8):1317–22

Effects of amylin on human osteoblast–like cells. Villa I, et al. **Peptides** 1997;18(4):537–40

Amylin and food intake in mice: effects on motivation to eat and mechanism of action. Morley JE, et al. **Pharmacol Biochem Behav** 1997 Jan;56(1):123–9

The effects of amylin on motivated behavior in rats. Kovács AM, et al. **Physiol Behav** 1996 Jul;60(1):183–6

Influence of glucose concentration on the inhibitory effect of amylin on insulin secretion. Study in the perfused rat pancreas. Silvestre RA, et al. **Regul Pept** 1997 Jan 15; 68(1):31–5

Effects of acute and chronic infusion of islet amyloid polypeptide on food intake in rats. Arnelo U, et al. **Scand J Gastroenterol** 1996 Jan;31(1):83–9

PHYSIOLOGY

Islet amyloid polypeptide: actions and role in the pathogenesis of diabetes. Clark A, et al. **Biochem Soc Trans** 1996 May;24(2):594–9 (48 ref.)

Amyloid precursor protein, A beta and amyloid–associated proteins involved in chloroquine retinopathy in rats—immunopathological studies. Yoshida T, et al. **Brain Res** 1997 Aug 1;764(1–2):283–8

Amylin, calcitonin gene–related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Wimalawansa SJ. **Crit Rev Neurobiol** 1997;11(2–3):167–239 (606 ref.)

Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide. Kolterman OG. **Diabet Med** 1997 Jun;14 Suppl 2:S35–8 (20 ref.)

Amylin: history and overview. Ludvik B, et al. **Diabet Med** 1997 Jun;14 Suppl 2:S9–13 (36 ref.)

Modulation of gastric emptying as a therapeutic approach to glycaemic control. Moyses C, et al. **Diabet Med** 1996 Sep;13(9 Suppl 5):S34–8 (19 ref.)

Role of amylin in nutrient intake – animal studies. Young A. **Diabet Med** 1997 Jun;14 Suppl 2:S14–8 (51 ref.)

Amylin, amyloid and age–related disease. Cooper GJ, et al. **Drugs Aging** 1996 Sep;9(3):202–12 (133 ref.)

Biologically active human islet amyloid polypeptide/amylin in transgenic mice. van Hulst KL, et al. **Eur J Endocrinol** 1997 Jan;136(1):107–13

The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis [letter; comment] Larner AJ. **J Neuropathol Exp Neurol** 1997 Feb;56(2):214–5. Comment on: J Neuropathol Exp Neurol 1996 Oct;55(10):1023–5.

The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis [letter; comment] Rosenblum WI. **J Neuropathol Exp Neurol** 1997 Feb;56(2):213. Comment on: J Neuropathol Exp Neurol 1996 Oct;55(10):1023–5.

The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis [letter; comment] Smith MA, et al. **J Neuropathol Exp Neurol** 1997 Feb;56(2):217. Comment on: J Neuropathol Exp Neurol 1996 Oct;55(10):1023–5.

The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis [letter; comment] Swaab DF, et al. **J Neuropathol Exp Neurol** 1997 Feb;56(2):216. Comment on: J Neuropathol Exp Neurol 1996 Oct;55(10):1023–5.

Sleep and sleep regulation in normal and prion protein–deficient mice. Tobler I, et al. **J Neurosci** 1997 Mar 1;17(5):1869–79

Amylin—its role in the kidney [editorial] Cooper ME, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):8–10 (17 ref.)

The histaminergic, but not the serotoninergic, system mediates amylin's anorectic effect. Lutz TA, et al. **Peptides** 1996;17(8):1317–22

[Amylin/IAPP (islet amyloid polypeptide)—physiology and clinical significance] Ludvik B. **Wien Klin Wochenschr** 1997 Jun 6;109(11):379–83 (41 ref.) (Eng. Abstr.) **(Ger)**

[Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome] Hrnčiar J. **Vnitr Lek** 1996 Aug;42(8):557–60 (21 ref.) (Eng. Abstr.) **(Slo)**

SECRETION

Amylin release during oral glucose tolerance test. Thomaseth K, et al. **Diabet Med** 1997 Jun;14 Suppl 2:S29–34

Dissociated secretion of islet amyloid polypeptide and insulin in serum–free culture media conditioned by human pancreatic adenocarcinoma cell lines. Wang F, et al. **Int J Pancreatol** 1997 Apr;21(2):157–64

Age–related changes in amylin secretion. Edwards BJ, et al. **Mech Ageing Dev** 1996 Jan 5;86(1):39–51

Islet amyloid polypeptide (IAPP) secretion from pancreatic islets isolated from non–obese diabetic (NOD) mice. Karlsson E, et al. **Regul Pept** 1996 May 7;63(1):39–45

THERAPEUTIC USE

Modulation of gastric emptying as a therapeutic approach to glycaemic control. Moyses C, et al. **Diabet Med** 1996 Sep;13(9 Suppl 5):S34–8 (19 ref.)

Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C–peptide concentrations in patients with type 2 diabetes. Thompson RG, et al. **Diabet Med** 1997 Jul;14(7):547–55

Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Thompson RG, et al. **Diabetes** 1997 Apr; 46(4):632–6

Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Kong MF, et al. **Diabetologia** 1997 Jan;40(1):82–8

TOXICITY

Serpins inhibit the toxicity of amyloid peptides. Schubert D. **Eur J Neurosci** 1997 Apr;9(4):770–7

Insulin–like growth factor I protects and rescues hippocampal neurons against beta–amyloid– and human amylin–induced toxicity. Doré S, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4772–7

ULTRASTRUCTURE

B cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. Janciauskiene S, et al. **Biochem Biophys Res Commun** 1997 Jul 30; 236(3):580–5

A molecular model of the amyloid fibril. Blake CC, et al. **Ciba Found Symp** 1996;199:6–15; discussion 15–21, 40–6

Acceleration of amyloid fibril formation by specific binding of Abeta–(1–40) peptide to ganglioside–containing membrane vesicles. Choo–Smith LP, et al. **J Biol Chem** 1997 Sep 12;272(37):22987–90

Ultrastructural immunolabelling of amyloid fibrils in acquired and hereditary amyloid neuropathies. Adams D, et al. **J Neurol** 1996 Jan;243(1):63–7

Amyloid deposits in labial salivary glands identified by electron microscopy. Delgado WA, et al. **J Oral Pathol Med** 1997 Jan;26(1):51–2

Polymorphic fibrillar assembly of human amylin. Goldsbury CS, et al. **J Struct Biol** 1997 Jun;119(1):17–27

Prion–inducing domain 2–114 of yeast Sup35 protein transforms in vitro into amyloid–like filaments. King CY, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6618–22

URINE

[Organ–specific nodular pulmonary amyloidosis of the A lambda type in Sjogren syndrome] Schneider F, et al. **Z Arztl Fortbild (Jena)** 1997 Jan;90(8):719–23 (Eng. Abstr.) **(Ger)**

AMYLOID A PROTEIN see **AMYLOID PROTEIN AA**

AMYLOID A4 PROTEIN PRECURSOR see **AMYLOID BETA–PROTEIN PRECURSOR**

AMYLOID ANGIOPATHY, CEREBRAL see **CEREBRAL AMYLOID ANGIOPATHY**

AMYLOID BETA-PROTEIN

see related
CEREBRAL AMYLOID ANGIOPATHY

[Experimental techniques for developing new drugs acting on dementia (10)—Alzheimer's disease animal model induced by beta-amyloid protein] Nitta A, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):85–90 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

In vivo vascular damage, leukocyte activation and inflammatory response induced by beta-amyloid. Thomas T, et al. **J Submicrosc Cytol Pathol** 1997 Jul;29(3):293–304

[The effect of the administration of beta-amyloid peptide fragment (25–35) on behavior in rats] Stepanichev MIu, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1997 May–Jun; 47(3):597–600 **(Rus)**

ANALOGS & DERIVATIVES

Neuropathology of synthetic beta-amyloid peptide analogs in vivo. Chen SY, et al. **Brain Res** 1996 Apr 9; 715(1–2):44–50

ANALYSIS

Quantitative analysis of tau protein-immunoreactive accumulations and beta amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus. Giannakopoulos P, et al. **Acta Neuropathol (Berl)** 1997 Aug; 94(2):131–9

Distinct distribution of apolipoprotein E and beta-amyloid immunoreactivity in the hippocampus of Parkinson dementia complex of Guam. Schwab C, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):378–85

Spatial pattern analysis of beta-amyloid (A beta) deposits in Alzheimerdisease by linear regression. Armstrong RA, et al. **Alzheimer Dis Assoc Disord** 1996 Spring;10(1):40–5

Pathological aging in Africans: a benign form of cerebral amyloidosis vs. pre-clinical Alzheimer's disease? [editorial; comment] Dickson DW. **Brain Pathol** 1996 Apr;6(2):107–8 . Comment on: Brain Pathol 1996 Apr;6(2):101–7.

Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): II--A review of histopathological aspects. Maat-Schieman ML, et al. **Brain Pathol** 1996 Apr; 6(2):115–20 (54 ref.)

Cerebral amyloid beta protein deposits and other Alzheimer lesions in non-demented elderly east Africans [see comments] Ogeng'o JA, et al. **Brain Pathol** 1996 Apr; 6(2):101–7. Comment in: Brain Pathol 1996 Apr;6(2):107–8.

Brain parenchymal and microvascular amyloid in Alzheimer's disease. Vinters HV, et al. **Brain Pathol** 1996 Apr;6(2):179–95 (169 ref.)

Brain beta-spectrin is a component of senile plaques in Alzheimer's disease. Sihag RK, et al. **Brain Res** 1996 Dec 16;743(1–2):249–57

Subpopulation of dogs with severe brain parenchymal beta amyloidosis distinguished with cluster analysis. Węgiel J, et al. **Brain Res** 1996 Jul 22;728(1):20–6

Improved electrophoretic separation and immunoblotting of beta-amyloid (A beta) peptides 1–40, 1–42, and 1–43. Wiltfang J, et al. **Electrophoresis** 1997 Mar–Apr; 18(3–4):527–32

Factors determining the size frequency distribution of beta-amyloid (A beta) deposits in Alzheimer's disease. Armstrong RA, et al. **Exp Neurol** 1997 Jun;145(2 Pt 1):574–9

Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques. Wallace MN, et al. **Exp Neurol** 1997 Apr;144(2):266–72

The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1–42 in Alzheimer's disease. Castaño EM, et al. **J Biol Chem** 1996 Dec 13; 271(50):32185–91

Three-dimensional reconstruction of senile plaques in Alzheimer's disease. Rickert CH, et al. **J Microsc** 1997 Jun; 186 (Pt 3):263–9

Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. Webster S, et al. **J Neurochem** 1997 Jul;69(1):388–98

Distribution of beta-amyloid precursor and B-cell lymphoma protooncogene proteins in the rat retina after optic nerve transection or vascular lesion. Chen ST, et al. **J Neuropathol Exp Neurol** 1996 Oct;55(10):1073–82

Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. Lue LF, et al. **J Neuropathol Exp Neurol** 1996 Oct;55(10):1083–8

Amyloid beta-peptide and the dementia of Parkinson's disease. Jendroska K, et al. **Mov Disord** 1996 Nov; 11(6):647–53

Identification of a unique apolipoprotein E allele in Microcebus murinus; ApoE brain distribution and co-localization with beta-amyloid and tau proteins. Calenda A, et al. **Neurobiol Dis** 1995 Jun;2(3):169–76

Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid beta protein (A beta) only in the form of A beta 42(43). Mann DM, et al. **Neurodegeneration** 1996 Jun;5(2):115–20

A beta 42 is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury. Gentleman SM, et al. **Neuroreport** 1997 Apr 14; 8(6):1519–22

Distribution of beta-amyloid in the canine brain. Hou Y, et al. **Neuroreport** 1997 Mar 3;8(4):1009–12

Abundance of the longer A beta 42 in neocortical and cerebrovascular amyloid beta deposits in Swedish familial Alzheimer's disease and Down's syndrome. Kalaria RN, et al. **Neuroreport** 1996 May 31;7(8):1377–81

beta-Amyloid (A beta) deposition in the medial temporal lobe of patients with dementia with Lewy bodies. Armstrong RA, et al. **Neurosci Lett** 1997 May 23; 227(3):193–6

Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease. Braak H, et al. **Neurosci Lett** 1996 May 31;210(2):87–90

Amyloid beta protein and transthyretin, sequestrating protein colocalize in normal human kidney. Tsuzuki K, et al. **Neurosci Lett** 1997 Feb 7;222(3):163–6

A novel missense mutation in the presenilin-1 gene in a familial Alzheimer's disease pedigree with abundant amyloid angiopathy. Yasuda M, et al. **Neurosci Lett** 1997 Aug 22;232(1):29–32

ANTAGONISTS & INHIBITORS

Influence of cell culture conditions on the protective effect of antioxidants against beta-amyloid toxicity: studies with lazaroids. Lucca E, et al. **Brain Res** 1997 Aug 1; 764(1–2):293–8

A strategy for designing inhibitors of beta-amyloid toxicity. Ghanta J, et al. **J Biol Chem** 1996 Nov 22;271(47):29525–8

Inhibition of beta-amyloid formation by haloperidol: a possible mechanism for reduced frequency of Alzheimer's disease pathology in schizophrenia. Higaki J, et al. **J Neurochem** 1997 Jan;68(1):333–6

A beta deposition inhibitor screen using synthetic amyloid. Esler WP, et al. **Nat Biotechnol** 1997 Mar;15(3):258–63

Inhibition of amyloid beta-protein production in neural cells by the serine protease inhibitor AEBSF. Citron M, et al. **Neuron** 1996 Jul;17(1):171–9

Alpha 1-antichymotrypsin interaction with A beta (1–42) does not inhibit fibril formation but attenuates the peptide toxicity. Aksenov MY, et al. **Neurosci Lett** 1996 Oct 18; 217(2–3):117–20

BIOSYNTHESIS

Differential pattern of beta-amyloid, amyloid precursor protein and apolipoprotein E expression in cortical senile plaques. Thal DR, et al. **Acta Neuropathol (Berl)** 1997 Sep; 94(3):255–65

A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Reyes AE, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):652–5

Specific inhibitor for prolyl endopeptidase suppresses the generation of amyloid beta protein in NG108–15 cells. Shinoda M, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):641–5

Amyloid alpha peptide formation in cell-free preparations. Regulation by protein kinase C, calmodulin, and calcineurin. Desdouits F, et al. **J Biol Chem** 1996 Oct 4; 271(40):24670–4

Neuronal expression of beta-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid beta and cytoplasmic domains. McPhie DL, et al. **J Biol Chem** 1997 Oct 3;272(40):24743–6

Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D. Saftig P, et al. **J Biol Chem** 1996 Nov 1;271(44):27241–4

Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. Xia W, et al. **J Biol Chem** 1997 Mar 21;272(12):7977–82

Phorbol esters affect multiple steps in beta-amyloid precursor protein trafficking and amyloid beta-protein production. Koo EH. **Mol Med** 1997 Mar;3(3):204–11

Alzheimer's A beta(1–42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Cook DG, et al. **Nat Med** 1997 Sep;3(9):1021–3

Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Hartmann T, et al. **Nat Med** 1997 Sep;3(9):1016–20

Patterns of abnormal protein expression in target formations and unstructured cores. De Bleecker JL, et al. **Neuromuscul Disord** 1996 Oct;6(5):339–49

Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Citron M, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13170–5

Stimulation of amyloid precursor protein synthesis by adrenergic receptors coupled to cAMP formation. Lee RKK, et al. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):5422–6

Intracellular and secreted Alzheimer beta-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. Tienari PJ, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):4125–30

BLOOD

Altered amyloid protein processing in platelets of patients with Alzheimer disease. Rosenberg RN, et al. **Arch Neurol** 1997 Feb;54(2):139–44

Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. Biere AL, et al. **J Biol Chem** 1996 Dec 20;271(51):32916–22

Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. Tamaoka A, et al. **J Neurol Sci** 1996 Sep 15;141(1–2):65–8

Activated Alzheimer disease platelets retain more beta amyloid precursor protein. Davies TA, et al. **Neurobiol Aging** 1997 Mar–Apr;18(2):147–53

The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Kosaka T, et al. **Neurology** 1997 Mar; 48(3):741–5

Evidence of blood-brain barrier permeability/leakage for circulating human Alzheimer's beta-amyloid-(1–42)-peptide. Pluta R, et al. **Neuroreport** 1996 May 17;7(7):1261–5

[Beta amyloid in blood and cerebrospinal fluid is associated with high density lipoproteins] Kudinova NV, et al. **Vopr Med Khim** 1996 Jul-Sep;42(3):253–62 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

The recognition of haemoglobin by antibodies raised for the immunoassay of beta-amyloid. Cutler P, et al. **FEBS Lett** 1997 Jul 28;412(2):341–5

Selective aggregation of endogenous beta-amyloid peptide and soluble amyloid precursor protein in cerebrospinal fluid by zinc. Brown AM, et al. **J Neurochem** 1997 Sep; 69(3):1204–12

Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. Tamaoka A, et al. **J Neurol Sci** 1997 May 1;148(1):41–5

[Beta amyloid in blood and cerebrospinal fluid is associated with high density lipoproteins] Kudinova NV, et al. **Vopr Med Khim** 1996 Jul-Sep;42(3):253–62 (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Crudes of synthesis of neuropeptide Y and beta-amyloid peptide examined by liquid chromatography/electrospray tandem mass spectrometry. Rovatti L, et al. **Rapid Commun Mass Spectrom** 1997;11(11):1223–9

[Solid phase synthesis of beta amyloid (1–42)] Sidorova MV, et al. **Bioorg Khim** 1997 Jan;23(1):46–55 (Eng. Abstr.) **(Rus)**

CHEMISTRY

The beta-amyloid peptide, peptide self-assembly, and the emergence of biological activities. A new principle in peptide function and the induction of neuropathology. Cotman CW. **Ann N Y Acad Sci** 1997 Apr 24;814:1–16 (55 ref.)

Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Kuo YM, et al. **Biochem Biophys Res Commun** 1997 Aug 8;237(1):188–91

Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Soto C, et al. **Biochem Biophys Res Commun** 1996 Sep 24;226(3):672–80

Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence. Esler WP, et al. **Biochemistry** 1996 Nov 5;35(44):13914–21

Three-dimensional structures of the amyloid beta peptide (25–35) in membrane-mimicking environment. Kohno T, et al. **Biochemistry** 1996 Dec 17;35(50):16094–104

Nicotine inhibits amyloid formation by the beta-peptide. Salomon AR, et al. **Biochemistry** 1996 Oct 22; 35(42):13568–78

Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Wood SJ, et al. **Biochemistry** 1996 Sep 24;35(38):12623–8

Brain amyloid—a physicochemical perspective. Maggio JE, et al. **Brain Pathol** 1996 Apr;6(2):147–62 (99 ref.)

Characterization of amyloid beta protein species in cerebral amyloid angiopathy of a squirrel monkey by immunocytochemistry and enzyme-linked immunosorbent assay. Sawamura N, et al. **Brain Res** 1997 Aug 1; 764(1–2):225–9

Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides. Ashburn TT, et al. **Chem Biol** 1996 May;3(5):351–8

Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Harper JD, et al. **Chem Biol** 1997 Feb;4(2):119–25

Refined fibril structures: the hydrophobic core in Alzheimer's amyloid beta-protein and prion as revealed by X-ray diffraction. Inouye H, et al. **Ciba Found Symp** 1996; 199:22–35; discussion 35–9

Simultaneous assessment of conformation and aggregation of beta-amyloid peptide using electrospray ionization mass spectrometry. Chen XG, et al. **FASEB J** 1997 Aug; 11(10):817–23

The interaction between Alzheimer amyloid beta(1–40) peptide and ganglioside GM1-containing membranes. Choo-Smith LP, et al. **FEBS Lett** 1997 Feb 3;402(2–3):95–8

Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. Russo C, et al. **FEBS Lett** 1997 Jun 16;409(3):411–6

X-ray diffraction and far-UV CD studies of filaments formed by a leucine-rich repeat peptide: structural similarity to the amyloid fibrils of prions and Alzheimer's disease beta-protein. Symmons MF, et al. **FEBS Lett** 1997 Jul 28; 412(2):397-403

All-D-enantiomers of beta-amyloid exhibit similar biological properties to all-L-beta-amyloids. Cribbs DH, et al. **J Biol Chem** 1997 Mar 14;272(11):7431-6

Soluble amyloid Abeta-(1-40) exists as a stable dimer at low concentrations. Garzon-Rodriguez W, et al. **J Biol Chem** 1997 Aug 22;272(34):21037-44

Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. Walsh DM, et al. **J Biol Chem** 1997 Aug 29;272(35):22364-72

The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. Wang R, et al. **J Biol Chem** 1996 Dec 13;271(50):31894-902

Fibrillogenesis of Alzheimer Abeta peptides studied by fluorescence energy transfer. Huang TH, et al. **J Mol Biol** 1997 Jun 6;269(2):214-24

Conformations of beta-amyloid in solution [letter; comment] el-Agnaf OM, et al. **J Neurochem** 1997 Jan;68(1):437-9. Comment on: J Neurochem 1995 Dec;65(6):2585-93.

Amyloid precursor protein truncated at any of the gamma-secretase sites is not cleaved to beta-amyloid. Paganetti PA, et al. **J Neurosci Res** 1996 Nov 1; 46(3):283-93

The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy. Stine WB Jr, et al. **J Protein Chem** 1996 Feb;15(2):193-203

The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. Seilheimer B, et al. **J Struct Biol** 1997 Jun;119(1):59-71

Radical changes in beta-amyloid form and function. Vitek MP. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):49-55 (10 ref.)

Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Velazquez P, et al. **Nat Med** 1997 Jan;3(1):77-9

Media from rhabdomyosarcoma and neuroblastoma cell cultures stimulate in vitro aggregation and fibrillization of amyloid beta-protein. Chauhan A, et al. **Neurochem Res** 1997 Feb;22(2):227-32

A beta 42 is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury. Gentleman SM, et al. **Neuroreport** 1997 Apr 14; 8(6):1519-22

Alzheimer's beta-amyloid peptide is conformationally modified by apolipoprotein E in vitro. Soto C, et al. **Neuroreport** 1996 Feb 29;7(3):721-5

Kinetic theory of fibrillogenesis of amyloid beta-protein. Lomakin A, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):7942-7

The interaction of beta-amyloid protein fragment (12-28) with lipid environments. Fletcher TG, et al. **Protein Sci** 1997 Mar;6(3):666-75

Investigation of beta-amyloid peptide by on-line high-performance liquid chromatography coupled to electrospray ionization mass spectrometry. Hamdan M, et al. **Rapid Commun Mass Spectrom** 1996;10(14):1739-42

Protein conformation and disease. Nandi PK. **Vet Res** 1996; 27(4-5):373-82 (61 ref.)

DRUG EFFECTS

Specific modulation of the fusogenic properties of the Alzheimer beta-amyloid peptide by apolipoprotein E isoforms. Pillot T, et al. **Eur J Biochem** 1997 Feb 1; 243(3):650-9

Metal cations defibrillize the amyloid beta-protein fibrils. Chauhan VP, et al. **Neurochem Res** 1997 Jul;22(7):805-9

Laminin inhibits amyloid-beta-peptide fibrillation. Bronfman FC, et al. **Neurosci Lett** 1996 Nov 8;218(3):201-3

GENETICS

Inconstant apolipoprotein E (ApoE)-like immunoreactivity in amyloid beta protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease. Uchihara T, et al. **Acta Neuropathol (Berl)** 1996 Aug;92(2):180-5

Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. Kaplitt M, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:42-9

Amyloid (Abeta) deposition in chromosome 1-linked Alzheimer's disease: the Volga German families. Mann DM, et al. **Ann Neurol** 1997 Jan;41(1):52-7

Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence. Esler WP, et al. **Biochemistry** 1996 Nov 5;35(44):13914-21

Neurotoxicity of beta-amyloid and prion peptides. Forloni G. **Curr Opin Neurol** 1996 Dec;9(6):492-500 (111 ref.)

Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions [see comments] Plassman BL, et al. **J Am Geriatr Soc** 1996 Oct;44(10):1242-50 (150 ref.). Comment in: J Am Geriatr Soc 1996 Oct;44(10):1261-2.

Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. Giulian D, et al. **J Neurosci** 1996 Oct 1;16(19):6021-37

Amyloid hypothesis of Alzheimer's rides high--for now [news] Schehr RS. **Nat Biotechnol** 1997 Jan;15(1):19-20

The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Kosaka T, et al. **Neurology** 1997 Mar; 48(3):741-5

Microtubule-associated protein tau in human fibroblasts with the Swedish Alzheimer mutation. Ingelson M, et al. **Neurosci Lett** 1996 Dec 6;220(1):9-12

Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Mann DM, et al. **Neurosci Lett** 1997 Jan 17;221(2-3):81-4

IMMUNOLOGY

Inconstant apolipoprotein E (ApoE)-like immunoreactivity in amyloid beta protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease. Uchihara T, et al. **Acta Neuropathol (Berl)** 1996 Aug;92(2):180-5

Monoclonal antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains. Schmidt ML, et al. **Am J Pathol** 1997 Jul;151(1):69-80

Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates. Kordower JH, et al. **Exp Neurol** 1997 Jun;145(2 Pt 1):586-91

Beta-protein immunoreactivity in the human brain after cardiac arrest. Wiśniewski HM, et al. **Folia Neuropathol** 1996;34(2):65-71

Interactions of the Alzheimer beta amyloid fragment (25-35) with peripheral blood dendritic cells. Schmitt TL, et al. **Mech Ageing Dev** 1997 Mar;94(1-3):223-32

Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Xu S, et al. **Mech Ageing Dev** 1997 Mar;94(1-3):213-22

Chloroquine administration in mice increases beta-amyloid immunoreactivity and attenuates kainate-induced blood-brain barrier dysfunction. Mielke JG, et al. **Neurosci Lett** 1997 May 23;227(3):169-72

Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Solomon B, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):4109-12

ISOLATION & PURIFICATION

Micropreparative gel electrophoresis of low-molecular-weight peptides: purification of highly insoluble amyloid peptide fragments. Baumann M, et al. **Anal Biochem** 1996 May 1;236(2):191-8

METABOLISM

Distribution of amyloid deposits in the cerebral white matter of the Alzheimer's disease brain: relationship to blood vessels. Iwamoto N, et al. **Acta Neuropathol (Berl)** 1997 Apr;93(4):334-40

Immunohistochemical study of constituents other than beta-protein in canine senile plaques and cerebral amyloid angiopathy. Uchida K, et al. **Acta Neuropathol (Berl)** 1997 Mar;93(3):277-84

Molecular basis of Alzheimer's disease. Gooch MD, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1545-57; quiz 1603-4 (122 ref.)

Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Iwatsubo T, et al. **Am J Pathol** 1996 Dec; 149(6):1823-30

Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Webster S, et al. **Am J Pathol** 1997 May;150(5):1531-6

Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Wilson DM, et al. **Am J Pathol** 1997 Jun;150(6):2181-95

Presenilin-1 is associated with Alzheimer's disease amyloid. Wisniewski T, et al. **Am J Pathol** 1997 Aug;151(2):601-10

A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. Gómez-Isla T, et al. **Ann Neurol** 1997 Jun;41(6):809-13

Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer beta (1-40) amyloid fibrils. LeVine H 3rd. **Arch Biochem Biophys** 1997 Jun 15;342(2):306-16

Reduction of plasma glutamyl aminopeptidase activity in sporadic Alzheimer's disease. Kuda T, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):526-30

Elevated amyloid beta protein(1-40) level induces CREB phosphorylation at serine-133 via p44/42 MAP kinase (Erk1/2)-dependent pathway in rat pheochromocytoma PC12 cells. Sato N, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):637-42

Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions. Walter MF, et al. **Biochem Biophys Res Commun** 1997 Apr 28; 233(3):760-4

Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Aleshkov S, et al. **Biochemistry** 1997 Aug 26;36(34):10571-80

Nicotine inhibits amyloid formation by the beta-peptide. Salomon AR, et al. **Biochemistry** 1996 Oct 22; 35(42):13568-78

Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Münch G, et al. **Biochim Biophys Acta** 1997 Feb 27;1360(1):17-29

Modulation of fibrin assembly and polymerization by the beta-amyloid of Alzheimer's disease. Merkle DL, et al. **Blood Coagul Fibrinolysis** 1996 Sep;7(6):650-8

Composition of white matter bovine brain coated vesicles: evidence that several components influence beta-amyloid peptide to form oligomers and aggregates in vitro. Berg MJ, et al. **Brain Res** 1997 Mar 28;752(1-2):72-80

Human A beta-amyloid and amyloid precursor protein accumulates in rat brain cells after cultured human leptomeningeal fibroblast implants. DeGiorgio LA, et al. **Brain Res** 1997 Mar 28;752(1-2):35-44

Co-localization of beta-amyloid peptides, apolipoprotein E and glial markers in senile plaques in the prefrontal cortex of old rhesus monkeys. Härtig W, et al. **Brain Res** 1997 Mar 21;751(2):315-22

Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Ishii K, et al. **Brain Res** 1997 Feb 14; 748(1-2):250-2

Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-alpha. Klegeris A, et al. **Brain Res** 1997 Jan 30; 747(1):114-21

Isoform-specific binding of human apolipoprotein E to the non-amyloid beta component of Alzheimer's disease amyloid. Olesen OF, et al. **Brain Res Mol Brain Res** 1997 Feb;44(1):105-12

Amyloid beta protein and Alzheimer disease. Square D. **Can Med Assoc J** 1997 Apr 1;156(7):1040-2

An ApoE-Abeta inhibition complex in Abeta fibril extension. Wood SJ, et al. **Chem Biol** 1996 Nov;3(11):949-56

beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Butterfield DA. **Chem Res Toxicol** 1997 May;10(5):495-506 (113 ref.)

Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal. Sayre LM, et al. **Chem Res Toxicol** 1997 May;10(5):518-26 (141 ref.)

Beta-amyloid protein and Alzheimer's disease. Bao X. **Chin Med J (Engl)** 1996 Jan;109(1):41-3 (0 ref.)

Alzheimer's disease: genesis of amyloid. Beyreuther K, et al. **Ciba Found Symp** 1996;199:119-27; discussion 127-31

Apolipoprotein E and amyloidogenesis. Frangione B, et al. **Ciba Found Symp** 1996;199:132-41; discussion 141-5

Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation. Schwarzman AL, et al. **Ciba Found Symp** 1996;199:146-60; discussion 160-4

Subpial amyloid plaques in the cerebellum in a case of Alzheimer's disease. Takamatsu J, et al. **Dement Geriatr Cogn Disord** 1997 May-Jun;8(3):157-62

Vascular variant of Alzheimer's disease characterized by severe plaque-like beta protein angiopathy. Yamada M, et al. **Dement Geriatr Cogn Disord** 1997 May-Jun;8(3):163-8

Interrelationship between beta-amyloid deposition and complement-activated oligodendroglia. Yamada T, et al. **Dement Geriatr Cogn Disord** 1997 Sep-Oct;8(5):267-72

Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes. McLaurin J, et al. **Eur J Biochem** 1997 Apr 15; 245(2):355-63

Dystrophic neurite formation associated with age-related beta amyloid deposition in the neocortex: clues to the genesis of neurofibrillary pathology. Vickers JC, et al. **Exp Neurol** 1996 Sep;141(1):1-11

The interaction between Alzheimer amyloid beta(1-40) peptide and ganglioside GM1-containing membranes. Choo-Smith LP, et al. **FEBS Lett** 1997 Feb 3;402(2-3):95-8

A beta-amyloid peptide variant related with familial Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis is poorly eliminated by cathepsin D. Hamazaki H. **FEBS Lett** 1996 Nov 18;397(2-3):313-5

Cathepsin D is involved in the clearance of Alzheimer's beta-amyloid protein. Hamazaki H. **FEBS Lett** 1996 Nov 4;396(2-3):139-42

Rapid cellular uptake of Alzheimer amyloid betaA4 peptide by cultured human neuroblastoma cells. Ida N, et al. **FEBS Lett** 1996 Sep 30;394(2):174-8

Mechanochemical mechanism for peptidyl free radical generation by amyloid fibrils. Kay CJ. **FEBS Lett** 1997 Feb 24;403(3):230-5

Novel purification and detailed characterization of perlecan isolated from the Engelbreth-Holm-Swarm tumor for use in an animal model of fibrillar A beta amyloid persistence in brain. Castillo GM, et al. **J Biochem (Tokyo)** 1996 Aug; 120(2):433-44

Abeta(1-40) prevents heparanase-catalyzed degradation of heparan sulfate glycosaminoglycans and proteoglycans in vitro. A role for heparan sulfate proteoglycan turnover in Alzheimer's disease. Bame KJ, et al. **J Biol Chem** 1997 Jul 4;272(27):17005-11

Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. Choo-Smith LP, et al. **J Biol Chem** 1997 Sep 12;272(37):22987-90

Binding of amyloid beta protein to the 20 S proteasome. Gregori L, et al. **J Biol Chem** 1997 Jan 3;272(1):58-62

Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. Hammad SM, et al. **J Biol Chem** 1997 Jul 25;272(30):18644-9

The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells. Ho L, et al. **J Biol Chem** 1996 Nov 29;271(48):30929-34

The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities. Klafki H, et al. **J Biol Chem** 1996 Nov 8;271(45):28655-9

The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. Lalowski M, et al. **J Biol Chem** 1996 Dec 27; 271(52):33623-31

Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. Little SP, et al. **J Biol Chem** 1997 Oct 3;272(40):25135-42

Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. McLaurin J, et al. **J Biol Chem** 1996 Oct 25;271(43):26482-9

Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide. Pillot T, et al. **J Biol Chem** 1996 Nov 15;271(46):28757-65

Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. Qiu WQ, et al. **J Biol Chem** 1997 Mar 7; 272(10):6641-6

Controlling amyloid beta-peptide fibril formation with protease-stable ligands [published erratum appears in J Biol Chem 1997 Jul 11;272(28):17894] Tjernberg LO, et al. **J Biol Chem** 1997 May 9;272(19):12601-5

Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. Wild-Bode C, et al. **J Biol Chem** 1997 Jun 27;272(26):16085-8

Extracellular deposition of beta-amyloid upon p53-dependent neuronal cell death in transgenic mice. LaFerla FM, et al. **J Clin Invest** 1996 Oct 1;98(7):1626-32

Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. LaFerla FM, et al. **J Clin Invest** 1997 Jul 15;100(2):310-20

Neurobiology of Alzheimer's disease. Peskind ER. **J Clin Psychiatry** 1996;57 Suppl 14:5-8 (53 ref.)

alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein. Du Y, et al. **J Neurochem** 1997 Jul; 69(1):299-305

Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. Keller JN, et al. **J Neurochem** 1997 Jul;69(1):273-84

Aggregation of beta-amyloid peptide is promoted by membrane phospholipid metabolites elevated in Alzheimer's disease brain. Klunk WE, et al. **J Neurochem** 1997 Jul;69(1):266-72

Amyloid beta protein (25-35) stimulation of phospholipase C in LA-N-2 cells. Singh IN, et al. **J Neurochem** 1997 Jul;69(1):252-8

Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. Yang DS, et al. **J Neurochem** 1997 Feb;68(2):721-5

Effect of cerebrospinal fluid from normal and Alzheimer's patients with different apolipoprotein E phenotypes on in vitro aggregation of amyloid beta-protein. Chauhan A, et al. **J Neurol Sci** 1996 Sep 15;141(1-2):54-8

The mean A beta load in the hippocampus correlates with duration and severity of dementia in subgroups of Alzheimer disease. Bartoo GT, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):531-40

Amyloid beta-protein (A beta) accumulation in the leptomeninges during aging and in Alzheimer disease. Hamano T, et al. **J Neuropathol Exp Neurol** 1997 Aug; 56(8):922-32

APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. Irizarry MC, et al. **J Neuropathol Exp Neurol** 1997 Sep; 56(9):965-73

Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer disease. Verbeek MM, et al. **J Neuropathol Exp Neurol** 1997 Jul;56(7):751-61 (88 ref.)

Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). Backstrom JR, et al. **J Neurosci** 1996 Dec 15;16(24):7910-9

Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. Cataldo AM, et al. **J Neurosci** 1997 Aug 15;17(16):6142-51

Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. Giulian D, et al. **J Neurosci** 1996 Oct 1;16(19):6021-37

Late compartments of amyloid precursor protein transport in SY5Y cells are involved in beta-amyloid secretion. Peraus GC, et al. **J Neurosci** 1997 Oct 15;17(20):7714-24

Scavenging of Alzheimer's amyloid beta-protein by microglia in culture. Ard MD, et al. **J Neurosci Res** 1996 Jan 15;43(2):190-202

Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. LaDu MJ, et al. **J Neurosci Res** 1997 Jul 1;49(1):9-18

Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. Webster S, et al. **J Neurosci Res** 1996 Oct 1;46(1):58-66

A synthetic substrate assay for the gamma-secretase of the beta-A4 amyloid of Alzheimer's disease. Evin G, et al. **J Pept Sci** 1995 Mar-Apr;1(2):132-9

Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Urmoneit B, et al. **Lab Invest** 1997 Aug;77(2):157-66

Pinning the suspect to the crime in Alzheimer's [news] Finkel E. **Lancet** 1996 Nov 30;348(9040):1506

Pharmacologic inhibition of transglutaminase-induced cross-linking of Alzheimer's amyloid beta-peptide. Zhang W, et al. **Life Sci** 1997;60(25):2323-32

Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Zlokovic BV. **Life Sci** 1996; 59(18):1483-97 (83 ref.)

Effects of cadmium, copper, and zinc and beta APP processing and turnover in COS-7 and PC12 cells. Relationship to Alzheimer disease pathology. Smedman M, et al. **Mol Chem Neuropathol** 1997 May;31(1):13-28

Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Zhou Z, et al. **Mol Med** 1996 Mar;2(2):175-80

Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments [news] Inestrosa NC, et al. **Mol Psychiatry** 1996 Nov;1(5):359-61

Glia-derived cytokines and the biogenesis of amyloid plaques in Alzheimer's disease. Patel AJ, et al. **Mol Psychiatry** 1997 Mar;2(2):130-2 (20 ref.)

Amyloid hypothesis of Alzheimer's rides high--for now [news] Schehr RS. **Nat Biotechnol** 1997 Jan;15(1):19-20

Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice [see comments] Citron M, et al. **Nat Med** 1997 Jan;3(1):67-72. Comment in: Nat Med 1997 Jan;3(1):28-9.

Presenilins, amyloid-beta and Alzheimer's disease [news; comment] Lamb BT. **Nat Med** 1997 Jan;3(1):28-9. Comment on: Nat Med 1997 Jan;3(1):67-72.

The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Lemere CA, et al. **Nat Med** 1996 Oct; 2(10):1146-50

Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Velazquez P, et al. **Nat Med** 1997 Jan;3(1):77-9

Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Duff K, et al. **Nature** 1996 Oct 24; 383(6602):710-3

Alzheimer's disease. Short precursor shortens memory [news; comment] Mattson MP, et al. **Nature** 1997 May 29; 387(6632):457-8. Comment on: Nature 1997 May 29;387(6632):500-5.

beta-Amyloid (A beta) deposition in the brains of aged orangutans. Gearing M, et al. **Neurobiol Aging** 1997 Mar-Apr;18(2):139-46

Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains. Pirttilä T, et al. **Neurobiol Aging** 1997 Jan-Feb;18(1):121-7

Beta-amyloid (beta/A4) deposition in the medial temporal lobe in Down's syndrome: effects of brain region and patient age. Armstrong RA, et al. **Neurobiol Dis** 1994 Dec; 1(3):139-44

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Lemere CA, et al. **Neurobiol Dis** 1996 Feb;3(1):16-32

Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier [see comments] Poduslo JF, et al. **Neurobiol Dis** 1997;4(1):27-34. Comment in: Neurobiol Dis 1997 ;4(1):23-6.

Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology [editorial; comment] Zlokovic B. **Neurobiol Dis** 1997; 4(1):23-6 (19 ref.). Comment on: Neurobiol Dis 1997 ;4(1):27-34.

Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. McDermott JR, et al. **Neurochem Res** 1997 Jan; 22(1):49-56

Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Paresce DM, et al. **Neuron** 1996 Sep;17(3):553-65

Accumulation of apolipoprotein E and beta-amyloid-like protein in a trace of the hippocampal CA1 pyramidal cell layer after ischaemic delayed neuronal death. Ishimaru H, et al. **Neuroreport** 1996 Nov 25;7(18):3063-7

Degradation of Alzheimer's beta-amyloid protein by human cathepsin D. McDermott JR, et al. **Neuroreport** 1996 Sep 2;7(13):2163-6

Is amyloid beta-protein glycated in Alzheimer's disease? Tabaton M, et al. **Neuroreport** 1997 Mar 3;8(4):907-9

Presenilin-1 polymorphism and amyloid beta-protein deposition in fatal head injury. Zunarelli E, et al. **Neuroreport** 1996 Dec 20;8(1):45-8

Increased A beta 42(43)-plaque deposition in early-onset familial Alzheimer's disease brains with the deletion of exon 9 and the missense point mutation (H163R) in the PS-1 gene. Ishii K, et al. **Neurosci Lett** 1997 May 30;228(1):17-20

Comparable amyloid beta-protein (A beta) 42(43) and A beta 40 deposition in the aged monkey brain. Kanemaru K, et al. **Neurosci Lett** 1996 Aug 23;214(2-3):196-8

Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Mann DM, et al. **Neurosci Lett** 1997 Jan 17;221(2-3):81-4

Enhanced aggregation of beta-amyloid-containing peptides by extracellular matrix and their degradation by the 68 kDa serine protease prepared from human brain. Matsumoto A, et al. **Neurosci Lett** 1996 Dec 20; 220(3):159-62

Aluminum-sensitive degradation of amyloid beta-protein 1-40 by murine and human intracellular enzymes [published erratum appears in Neurotoxicol Teratol 1997 Jan-Feb;19(1):73] Banks WA, et al. **Neurotoxicol Teratol** 1996 Nov-Dec;18(6):671-7

Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Du Yan S, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):5296-301

Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Johnson-Wood K, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1550-5

Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Xu H, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3748-52

Is the binding of beta-amyloid protein to antichymotrypsin in Alzheimer plaques mediated by a beta-strand insertion? Lukacs CM, et al. **Proteins** 1996 Aug;25(4):420-4

Dissecting how presinilins function--and malfunction [news] Marx J. **Science** 1996 Dec 13;274(5294):1838-40

Alzheimer's disease: genotypes, phenotypes, and treatments. Selkoe DJ. **Science** 1997 Jan 31;275(5300):630-1 (17 ref.)

Amyloid, the presenilins and Alzheimer's disease. Hardy J. **Trends Neurosci** 1997 Apr;20(4):154-9 (53 ref.)

PHARMACOLOGY

A putative tetrapeptide antagonist prevents beta-amyloid-induced long-term elevation of [Ca2+]i in rat astrocytes. Laskay G, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):479-81

Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions. Walter MF, et al. **Biochem Biophys Res Commun** 1997 Apr 28; 233(3):760-4

Alzheimer's disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Kawahara M, et al. **Biophys J** 1997 Jul;73(1):67-75

The neurochemical and behavioral effects of beta-amyloid peptide(25-35). Chen SY, et al. **Brain Res** 1996 May 13; 720(1-2):54-60

beta-Amyloid peptide-induced morphological changes coincide with increased K+ and Cl- channel activity in rat cortical astrocytes. Jalonen TO, et al. **Brain Res** 1997 Jan 23;746(1-2):85-97

Mechanisms underlying the vascular activity of beta-amyloid protein fragment (beta A(4)25-35) at the level of skin microvasculature. Khalil Z, et al. **Brain Res** 1996 Oct 14; 736(1-2):206-16

Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates beta-amyloid protein activation of complement in vitro. McGeer PL, et al. **Brain Res** 1997 Feb 21; 749(1):135-8

Basic FGF attenuates amyloid beta-peptide-induced oxidative stress, mitochondrial dysfunction, and impairment of Na+/K+-ATPase activity in hippocampal neurons. Mark RJ, et al. **Brain Res** 1997 May 9;756(1-2):205-14

Reversion of beta 25-35-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists. Maurice T, et al. **Brain Res** 1996 Aug 26;731(1-2):249-53

The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes. Parpura-Gill A, et al. **Brain Res** 1997 Apr 18;754(1-2):65-71

Aggregates of a beta-amyloid peptide are required to induce calcium currents in neuron-like human teratocarcinoma cells: relation to Alzheimer's disease. Sanderson KL, et al. **Brain Res** 1997 Jan 2;744(1):7-14

Chlorpromazine reduces toxicity and Ca2+ uptake induced by amyloid beta protein (25-35) in vitro. Ueda K, et al. **Brain Res** 1997 Feb 14;748(1-2):184-8

Amyloid beta-protein(25-35) increases cellular APP and inhibits the secretion of APPs in human extraneuronal cells. Schmitt TL, et al. **Exp Cell Res** 1997 Aug 1;234(2):336-40

beta-amyloid-induced endothelial necrosis and inhibition of nitric oxide production. Sutton ET, et al. **Exp Cell Res** 1997 Feb 1;230(2):368-76

Amyloid beta-protein induces necrotic cell death mediated by ICE cascade in PC12 cells. Suzuki A. **Exp Cell Res** 1997 Aug 1;234(2):507-11

Beta-amyloid peptides initiate the complement cascade

without producing a comparable effect on the terminal pathway in vitro. Cadman ED, et al. **Exp Neurol** 1997 Aug; 146(2):388–94

Multiple inhibitory effects of Alzheimer's peptide Abeta1–40 on lipid biosynthesis in cultured human HepG2 cells. Koudinova NV, et al. **FEBS Lett** 1996 Oct 21; 395(2–3):204–6

Activation of LA–N–2 cell phospholipases by single alanine substitution analogs of amyloid beta peptide (25–35). Singh IN, et al. **FEBS Lett** 1997 Mar 17;405(1):65–7

A promising rat model of Alzheimer's disease–like neuropathology. Pluta R, et al. **Folia Morphol (Warsz)** 1996; 55(4):417–9

Increase of cerebral blood flow in rats after human b–amyloid peptide infusion. Pluta R, et al. **Folia Morphol (Warsz)** 1996; 55(4):420–1

Possible different mechanism between amyloid–beta (25–35)–and substance P–induced chemotaxis of murine microglia. Maeda K, et al. **Gerontology** 1997;43 Suppl 1:11–5

Nontoxic amyloid beta peptide 1–42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer's disease. Hoshi M, et al. **J Biol Chem** 1997 Jan 24;272(4):2038–41

Glutamine synthetase–induced enhancement of beta–amyloid peptide A beta (1–40) neurotoxicity accompanied by abrogation of fibril formation and A beta fragmentation. Aksenov MY, et al. **J Neurochem** 1996 May;66(5):2050–6

Amyloid beta–peptides increase annular and bulk fluidity and induce lipid peroxidation in brain synaptic plasma membranes. Avdulov NA, et al. **J Neurochem** 1997 May; 68(5):2086–91

Isoform–specific modulation by apolipoprotein E of the activities of secreted beta–amyloid precursor protein. Barger SW, et al. **J Neurochem** 1997 Jul;69(1):60–7

Amyloid beta–peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. Blanc EM, et al. **J Neurochem** 1997 May;68(5):1870–81

Increased activity–regulating and neuroprotective efficacy of alpha–secretase–derived secreted amyloid precursor protein conferred by a C–terminal heparin–binding domain [published erratum appears in J Neurochem 1997 Mar;68(3):1331] Furukawa K, et al. **J Neurochem** 1996 Nov; 67(5):1882–96

Dysfunction of cholinergic and dopaminergic neuronal systems in beta–amyloid protein––infused rats. Itoh A, et al. **J Neurochem** 1996 Mar;66(3):1113–7

Role of calpain– and interleukin–1 beta converting enzyme–like proteases in the beta–amyloid–induced death of rat hippocampal neurons in culture. Jordán J, et al. **J Neurochem** 1997 Apr;68(4):1612–21

Nanomolar amyloid beta protein–induced inhibition of cellular redox activity in cultured astrocytes. Kato M, et al. **J Neurochem** 1997 May;68(5):1889–95

A role for 4–hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta–peptide. Mark RJ, et al. **J Neurochem** 1997 Jan;68(1):255–64

The amyloid beta–protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. Sberna G, et al. **J Neurochem** 1997 Sep;69(3):1177–84

beta 25–35 alters calcium homeostasis and induces neurotoxicity in cerebellar granule cells. Scorziello A, et al. **J Neurochem** 1996 May;66(5):1995–2003

Amyloid beta protein potentiates Ca2+ influx through L–type voltage–sensitive Ca2+ channels: a possible involvement of free radicals. Ueda K, et al. **J Neurochem** 1997 Jan;68(1):265–71

Rapid degeneration of cultured human brain pericytes by amyloid beta protein. Verbeek MM, et al. **J Neurochem** 1997 Mar;68(3):1135–41

Aggregation state–dependent activation of the classical complement pathway by the amyloid beta peptide. Webster S, et al. **J Neurochem** 1997 Jul;69(1):388–98

Amyloid beta–mediated oxidative and metabolic stress in rat cortical neurons: no direct evidence for a role for H2O2 generation. Zhang Z, et al. **J Neurochem** 1996 Oct; 67(4):1595–606

Actions of neurotoxic beta–amyloid on calcium homeostasis and viability of PC12 cells are blocked by antioxidants but not by calcium channel antagonists. Zhou Y, et al. **J Neurochem** 1996 Oct;67(4):1419–25

Activation of nuclear factor–kappa B by beta–amyloid peptides and interferon–gamma in murine microglia. Bonaiuto C, et al. **J Neuroimmunol** 1997 Jul;77(1):51–6

Laterality in the histological effects of injections of amyloid–beta 25–35 into the amygdala of young Fischer rats. Sigurdsson EM, et al. **J Neuropathol Exp Neurol** 1997 Jun;56(6):714–25

Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta–peptide: involvement of calcium and oxyradicals. Guo Q, et al. **J Neurosci** 1997 Jun 1; 17(11):4212–22

beta–amyloid protein enhances macrophage production of oxygen free radicals and glutamate. Klegeris A, et al. **J Neurosci Res** 1997 Jul 15;49(2):229–35

beta–Amyloid peptide induced cytoskeletal reorganization in cultured astrocytes. Salinero O, et al. **J Neurosci Res** 1997 Jan 15;47(2):216–23

Amyloid–beta proteins activate Ca(2+)–permeable channels through calcium–sensing receptors. Ye C, et al. **J Neurosci Res** 1997 Mar 1;47(5):547–54

The toxicity of the Alzheimer's beta–amyloid peptide correlates with a distinct fiber morphology. Seilheimer B, et al. **J Struct Biol** 1997 Jun;119(1):59–71

beta–Amyloid–induced IL–1 beta release from an activated human monocyte cell line is calcium– and G–protein–dependent. Lorton D. **Mech Ageing Dev** 1997 Mar;94(1–3):199–211

Changes in gene transcription during a beta–mediated cell death. Iwasaki K, et al. **Mol Psychiatry** 1996 Mar;1(1):65–71

Intrahippocampal injections of exogenous beta–amyloid induce postdelay errors in an eight–arm radial maze. Sweeney WA, et al. **Neurobiol Learn Mem** 1997 Jul; 68(1):97–101

Cellular MTT reduction distinguishes the mechanism of action of beta–amyloid from that of tachykinin receptor peptides. Shearman MS. **Neuropeptides** 1996 Apr; 30(2):125–32

beta–Amyloid produces a delayed NMDA receptor–dependent reduction in synaptic transmission in rat hippocampus. Cullen WK, et al. **Neuroreport** 1996 Dec 20;8(1):87–92

beta–Amyloid induction of gelatinase B secretion in cultured microglia: inhibition by dexamethasone and indomethacin. Gottschall PE. **Neuroreport** 1996 Nov 25;7(18):3077–80

beta Amyloid does not activate the antioxidant pentose phosphate pathway within the B12 neural cell line. Kopp A, et al. **Neuroreport** 1997 Mar 24;8(5):1197–201

Cerebrovascular endothelial dysfunction mediated by beta–amyloid. Thomas T, et al. **Neuroreport** 1997 Apr 14; 8(6):1387–91

alpha–1–antichymotrypsin interaction with A beta (1–40) inhibits fibril formation but does not affect the peptide toxicity. Aksenova MV, et al. **Neurosci Lett** 1996 Jun 14; 211(1):45–8

Physiological levels of beta–amyloid peptide promote PC12 cell proliferation. Luo Y, et al. **Neurosci Lett** 1996 Oct 18;217(2–3):125–8

Priming of monocyte respiratory burst by beta–amyloid fragment (25–35). Meda L, et al. **Neurosci Lett** 1996 Nov 22;219(2):91–4

Injections of okadaic acid, but not beta–amyloid peptide, induce Alz–50 immunoreactive dystrophic neurites in the cerebral cortex of sheep. Nelson PT, et al. **Neurosci Lett** 1996 Apr 19;208(2):77–80

Amyloid beta proteins reduce the GABA–induced Cl– current in identified Aplysia neurons. Sawada M, et al. **Neurosci Lett** 1996 Aug 9;213(3):213–5

Administration of amyloid beta–peptides in the rat medial septum causes memory deficits: reversal by SR 57746A, a non–peptide neurotrophic compound. Terranova JP, et al. **Neurosci Lett** 1996 Aug 2;213(2):79–82

Amyloid–beta peptide–receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage–colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Du Yan S, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):5296–301

Effect of beta–amyloid block of the fast–inactivating K+ channel on intracellular Ca2+ and excitability in a modeled neuron. Good TA, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15130–5

Transcription factor NF–kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Kaltschmidt B, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2642–7

Amyloid beta–protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Pedersen WA, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8068–71

Amyloid beta–peptides injection into the cholinergic nuclei: morphological, neurochemical and behavioral effects. Pepeu G, et al. **Prog Brain Res** 1996;109:273–82

Amyloid beta peptides stimulate tissue–type plasminogen activator but not recombinant prourokinase. Wnendt S, et al. **Thromb Res** 1997 Feb 1;85(3):217–24

PHYSIOLOGY

The beta–amyloid peptide, peptide self–assembly, and the emergence of biological activities. A new principle in peptide function and the induction of neuropathology. Cotman CW. **Ann N Y Acad Sci** 1997 Apr 24;814:1–16 (55 ref.)

Alzheimer's disease amyloid beta–protein forms Zn(2+)–sensitive, cation–selective channels across excised membrane patches from hypothalamic neurons. Kawahara M, et al. **Biophys J** 1997 Jul;73(1):67–75

Human amylin mimics amyloid beta protein–induced reactive gliosis and inhibition of cellular redox activity in cultured astrocytes. Abe K, et al. **Brain Res** 1997 Jul 11; 762(1–2):285–8

beta–Amyloid protein–dependent nitric oxide production from microglial cells and neurotoxicity. Ii M, et al. **Brain Res** 1996 May 13;720(1–2):93–100

Amyloid precursor protein, A beta and amyloid–associated proteins involved in chloroquine retinopathy in rats––immunopathological studies. Yoshida T, et al. **Brain Res** 1997 Aug 1;764(1–2):283–8

beta–Amyloid regulates gene expression of glial trophic substance S100 beta in C6 glioma and primary astrocyte cultures. Peña LA, et al. **Brain Res Mol Brain Res** 1995 Dec 1;34(1):118–26

Specific modulation of the fusogenic properties of the Alzheimer beta–amyloid peptide by apolipoprotein E isoforms. Pillot T, et al. **Eur J Biochem** 1997 Feb 1; 243(3):650–9

Alzheimer's, ageing and amyloid: an absurd allegory? Fowler CJ, et al. **Gerontology** 1997;43(1–2):132–42 (97 ref.)

The length of amyloid–beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid–beta 1–42 in Alzheimer's disease. Castaño EM, et al. **J Biol Chem** 1996 Dec 13; 271(50):32185–91

Glutamine synthetase–induced enhancement of beta–amyloid peptide A beta (1–40) neurotoxicity accompanied by abrogation of fibril formation and A beta fragmentation. Aksenov MY, et al. **J Neurochem** 1996 May;66(5):2050–6

Aggregated amyloid–beta protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction. Estus S, et al. **J Neurosci** 1997 Oct 15; 17(20):7736–45

Amyloid beta–peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. Mark RJ, et al. **J Neurosci** 1997 Feb 1;17(3):1046–54

First–order kinetic model of Alzheimer's beta–amyloid fibril extension in vitro. Naiki H, et al. **Lab Invest** 1996 Feb; 74(2):374–83

Radical changes in beta–amyloid form and function. Vitek MP. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):49–55 (10 ref.)

Amyloid beta–peptide and oxidative cellular injury in Alzheimer's disease. Mark RJ, et al. **Mol Neurobiol** 1996 Jun;12(3):211–24 (91 ref.)

Inflammatory mechanisms in Alzheimer disease: the role of beta–amyloid/glial interactions. Pachter JS. **Mol Psychiatry** 1997 Mar;2(2):91–5 (58 ref.)

beta–Amyloid converts an acute phase injury response to chronic injury responses. Cotman CW, et al. **Neurobiol Aging** 1996 Sep–Oct;17(5):723–31 (96 ref.)

Oxidative mechanisms in beta–amyloid cytotoxicity. Davis JB. **Neurodegeneration** 1996 Dec;5(4):441–4 (29 ref.)

[New approach for the studies on Alzheimer's disease: a beta 1–42 and acetylcholine] Hoshi M. **Seikagaku** 1997 Mar; 69(3):181–7 (19 ref.) **(Jpn)**

POISONING

Chlorpromazine reduces toxicity and Ca2+ uptake induced by amyloid beta protein (25–35) in vitro. Ueda K, et al. **Brain Res** 1997 Feb 14;748(1–2):184–8

Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta–peptide toxicity in hippocampal neurons. Goodman Y, et al. **J Neurochem** 1996 May;66(5):1836–44

SECRETION

Specific increase in amyloid beta–protein 42 secretion ratio by calpain inhibition. Yamazaki T, et al. **Biochemistry** 1997 Jul 8;36(27):8377–83

Examination of the role of endopeptidase 3.4.24.15 in A beta secretion by human transfected cells. Chevallier N, et al. **Br J Pharmacol** 1997 Jun;121(3):556–62

Alzheimer's soluble amyloid beta protein is secreted by HepG2 cells as an apolipoprotein. Koudinov AR, et al. **Cell Biol Int** 1997 May;21(5):265–71

Isoform–specific modulation by apolipoprotein E of the activities of secreted beta–amyloid precursor protein. Barger SW, et al. **J Neurochem** 1997 Jul;69(1):60–7

Insertion of lysosomal targeting sequences to the amyloid precursor protein reduces secretion of beta A4. Schrader–Fischer G, et al. **J Neurochem** 1997 Apr; 68(4):1571–80

The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue [see comments] Tomita T, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):2025–30. Comment in: Proc Natl Acad Sci U S A 1997 Mar 18;94(6):2095–7.

TOXICITY

Nicotinic receptor stimulation protects neurons against beta–amyloid toxicity. Kihara T, et al. **Ann Neurol** 1997 Aug;42(2):159–63

Beta amyloid toxicity does not require RAGE protein. Liu Y, et al. **Biochem Biophys Res Commun** 1997 Aug 8; 237(1):37–40

Neuropathology of synthetic beta–amyloid peptide analogs in vivo. Chen SY, et al. **Brain Res** 1996 Apr 9; 715(1–2):44–50

IL–1 and anti–inflammatory drugs modulate A beta cytotoxicity in PC12 cells. Fagarasan MO, et al. **Brain Res** 1996 Jun 3;723(1–2):231–4

K+ channel openers protect hippocampal neurons against oxidative injury and amyloid beta–peptide toxicity. Goodman Y, et al. **Brain Res** 1996 Jan 15;706(2):328–32

beta–Amyloid protein–dependent nitric oxide production from microglial cells and neurotoxicity. Ii M, et al. **Brain Res** 1996 May 13;720(1–2):93–100

Influence of cell culture conditions on the protective effect of antioxidants against beta–amyloid toxicity: studies with

lazaroids. Lucca E, et al. **Brain Res** 1997 Aug 1; 764(1-2):293-8

Transforming growth factors-beta protect primary rat hippocampal neuronal cultures from degeneration induced by beta-amyloid peptide. Ren RF, et al. **Brain Res** 1996 Sep 2;732(1-2):16-24

Superoxide free radical and intracellular calcium mediate A beta(1-42) induced endothelial toxicity. Suo Z, et al. **Brain Res** 1997 Jul 11;762(1-2):144-52

PrP and beta-amyloid fragments activate different neurotoxic mechanisms in cultured mouse cells. Brown DR, et al. **Eur J Neurosci** 1997 Jun;9(6):1162-9

Serpins inhibit the toxicity of amyloid peptides. Schubert D. **Eur J Neurosci** 1997 Apr;9(4):770-7

In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat. Delobette S, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):1-4

Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line. Shen Y, et al. **J Biol Chem** 1997 Feb 7;272(6):3550-3

Amyloid beta toxicity consists of a Ca(2+)-independent early phase and a Ca(2+)-dependent late phase. Abe K, et al. **J Neurochem** 1996 Nov;67(5):2074-8

Beta-amyloid-induced neurotoxicity of a hybrid septal cell line associated with increased tau phosphorylation and expression of beta-amyloid precursor protein. Le WD, et al. **J Neurochem** 1997 Sep;69(3):978-85

Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion. Müller WE, et al. **J Neurochem** 1997 Jun;68(6):2371-7

Attenuation of beta-amyloid neurotoxicity in vitro by potassium-induced depolarization. Pike CJ, et al. **J Neurochem** 1996 Oct;67(4):1774-7

Effect of apolipoprotein E on neurite outgrowth and beta-amyloid-induced toxicity in developing rat primary hippocampal cultures. Puttfarcken PS, et al. **J Neurochem** 1997 Feb;68(2):760-9

Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. Pappolla MA, et al. **J Neurosci** 1997 Mar 1;17(5):1683-90

Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Nitta A, et al. **Jpn J Pharmacol** 1997 Jan;73(1):51-7

An experimental model to study the cytotoxic effects induced by beta-amyloid, histamine, LPS and serum from Alzheimer patients on cultured rat endothelial cells. Maneiro E, et al. **Methods Find Exp Clin Pharmacol** 1997 Jan-Feb;19(1):5-12

Apoptosis-mediated neurotoxicity induced by beta-amyloid and PrP fragments. Forloni G, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):163-71

Mechanism of amyloid beta-peptide (1-42) toxicity in PC12 cells. Fagarasan MO, et al. **Mol Psychiatry** 1996 Nov; 1(5):398-403

Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. Ma J, et al. **Neurobiol Aging** 1996 Sep-Oct; 17(5):773-80

Role of Leu(34)-Met(35) in neurotoxicity caused by human beta-amyloid (1-42) peptide in vitro. Pákáski M, et al. **Neurobiology (Bp)** 1996;4(3):273-4

Acetyl-L-carnitine arginine amide prevents beta 25-35-induced neurotoxicity in cerebellar granule cells. Scorziello A, et al. **Neurochem Res** 1997 Mar;22(3):257-65

High density lipoprotein decreases beta-amyloid toxicity in cortical cell culture. Farhangrazi ZS, et al. **Neuroreport** 1997 Mar 24;8(5):1127-30

Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. Guo Q, et al. **Neuroreport** 1996 Dec 20; 8(1):379-83

Nicotine modulates the neurotoxic effect of beta-amyloid protein(25-35)) in hippocampal cultures. Zamani MR, et al. **Neuroreport** 1997 Jan 20;8(2):513-7

Amyloid beta-induced neurotoxicity is associated with phospholipase D activation in cultured rat hippocampal cells. Cox DA, et al. **Neurosci Lett** 1997 Jun 20;229(1):37-40

Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Green PS, et al. **Neurosci Lett** 1996 Nov 8;218(3):165-8

Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity. Doré S, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4772-7

Inhibition of the electrostatic interaction between beta-amyloid peptide and membranes prevents beta-amyloid-induced toxicity. Hertel C, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9412-6

ULTRASTRUCTURE

Images in neuroscience. Alzheimer's disease: from genes to pathogenesis. Selkoe DJ. **Am J Psychiatry** 1997 Sep; 154(9):1198

Ca(2+)- and Al(3+)-induced conformational transitions of amyloid fragment H-Ile-Ile-Gly-Leu-Met-NH2. Laczkó I, et al. **Arch Biochem Biophys** 1996 Nov 15;335(2):381-7

In situ characterization of beta-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy. Choo LP, et al. **Biophys J** 1996 Oct; 71(4):1672-9

An ultrastructural and molecular perspective of the pathological hallmarks of Alzheimer's disease. Sobow T. **Folia Neuropathol** 1996;34(1):55-62 (74 ref.)

URINE

Alzheimer's soluble amyloid beta is a normal component of human urine. Ghiso J, et al. **FEBS Lett** 1997 May 12; 408(1):105-8

AMYLOID BETA-PROTEIN PRECURSOR

ADVERSE EFFECTS

Plaque formation in brain transplants exposed to human beta-amyloid precursor protein 695. Bayer TA, et al. **Acta Neuropathol (Berl)** 1996 Aug;92(2):130-7

ANALOGS & DERIVATIVES

Overexpressions of cDNAs for beta-amyloid precursor proteins 695, 751, and 770 enhance the secretion of beta-amyloid precursor protein derivatives and the survival of P19-derived neurons. Fukuchi K, et al. **J Neurochem** 1996 May;66(5):2201-4

Increased gene expression of beta-amyloid precursor protein and its homologues APLP1 and APLP2 in human neuroblastoma cells in response to retinoic acid. Beckman M, et al. **Neurosci Lett** 1997 Jan 17;221(2-3):73-6

ANALYSIS

The neurochemistry of Alzheimer's disease. Blennow K, et al. **Acta Neurol Scand Suppl** 1996;168:77-86 (129 ref.)

Accumulation of beta-amyloid precursor protein and ubiquitin in axons after spinal cord trauma in humans: immunohistochemical observations on autopsy material. Ahlgren S, et al. **Acta Neuropathol (Berl)** 1996 Jul; 92(1):49-55

Changes in microtubule-associated protein 2 and amyloid precursor protein immunoreactivity following traumatic brain injury in rat: influence of MK-801 treatment. Lewén A, et al. **Brain Res** 1996 May 6;719(1-2):161-71

The amyloid precursor protein of Alzheimer's disease is found on the surface of static but not activity motile portions of neurites. Storey E, et al. **Brain Res** 1996 Sep 30;735(1):59-66

Amyloid load and neural elements in Alzheimer's disease and nondemented individuals with high amyloid plaque density. Mochizuki A, et al. **Exp Neurol** 1996 Nov;142(1):89-102

Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. Ida N, et al. **J Biol Chem** 1996 Sep 13;271(37):22908-14

Increased expression of cathepsins E and D in neurons of the aged rat brain and their colocalization with lipofuscin and carboxy-terminal fragments of Alzheimer amyloid precursor protein. Nakanishi H, et al. **J Neurochem** 1997 Feb;68(2):739-49

Distribution of beta-amyloid precursor and B-cell lymphoma protooncogene proteins in the rat retina after optic nerve transection or vascular lesion. Chen ST, et al. **J Neuropathol Exp Neurol** 1996 Oct;55(10):1073-82

Alzheimer's beta-amyloid precursor protein is expressed on the surface of immediately ex vivo brain cells: a flow cytometric study. Jung SS, et al. **J Neurosci Res** 1996 Nov 1;46(3):336-48

Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. Biere AL, et al. **Neurobiol Dis** 1995 Jun; 2(3):177-87

Review. David Oppenheimer Memorial Lecture 1995: Some neuropathological aspects of Alzheimer's disease and its relevance to other disciplines. Wisniewski HM, et al. **Neuropathol Appl Neurobiol** 1996 Feb;22(1):3-11 (61 ref.)

Amyloid beta protein and transthyretin, sequestrating protein colocalize in normal human kidney. Tsuzuki K, et al. **Neurosci Lett** 1997 Feb 7;222(3):163-6

Characteristic neuropathology of leukomalacia in extremely low birth weight infants. Deguchi K, et al. **Pediatr Neurol** 1997 May;16(4):296-300

ANTAGONISTS & INHIBITORS

Metabotropic glutamate receptors increase amyloid precursor protein processing in astrocytes: inhibition by cyclic AMP. Lee RK, et al. **J Neurochem** 1997 May;68(5):1830-5

BIOSYNTHESIS

Differential pattern of beta-amyloid, amyloid precursor protein and apolipoprotein E expression in cortical senile plaques. Thal DR, et al. **Acta Neuropathol (Berl)** 1997 Sep; 94(3):255-65

Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. Schrader-Fischer G, et al. **Brain Res** 1996 Apr 15;716(1-2):91-100

Neuronal sorting and processing of amyloid precursor protein: implications for Alzheimer's disease. Tienari PJ, et al. **Cold Spring Harb Symp Quant Biol** 1996;61:575-85 (67 ref.)

Neurodegeneration and gliosis in transgenic mice overexpressing a carboxy-terminal fragment of Alzheimer amyloid-beta protein precursor. Sato M, et al. **Dement Geriatr Cogn Disord** 1997 Sep-Oct;8(5):296-307

Amyloid precursor protein fragment and acetylcholinesterase increase with cell confluence and differentiation in a neuronal cell line. Bronfman FC, et al. **Exp Cell Res** 1996 Nov 25;229(1):93-9

Amyloid beta-protein(25-35) increases cellular APP and inhibits the secretion of APPs in human extraneuronal cells. Schmitt TL, et al. **Exp Cell Res** 1997 Aug 1;234(2):336-40

Beta-amyloid protein protein precursor expression in lacrimal glands and tear fluid. Van Setten GB, et al. **Invest Ophthalmol Vis Sci** 1996 Dec;37(13):2585-93

Neuronal expression of beta-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid beta and cytoplasmic domains. McPhie DL, et al. **J Biol Chem** 1997 Oct 3;272(40):24743-6

Generation of Alzheimer amyloid beta peptide through nonspecific proteolysis. Tjernberg LO, et al. **J Biol Chem** 1997 Jan 17;272(3):1870-5

Beta-amyloid-induced neurotoxicity of a hybrid septal cell line associated with increased tau phosphorylation and expression of beta-amyloid precursor protein. Le WD, et al. **J Neurochem** 1997 Sep;69(3):978-85

Phorbol esters but not the cholinergic agonists oxotremorine-M and carbachol increase release of the amyloid precursor protein in cultured rat cortical neurons. Mills J, et al. **J Neurochem** 1996 Oct;67(4):1511-8

Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein [see comments] Nalbantoglu J, et al. **Nature** 1997 May 29; 387(6632):500-5. Comment in: Nature 1997 May 29;387(6632):457-8.

Expression of beta-amyloid precursor protein immunoreactivity in the retina of the rat during normal development and after neonatal optic tract lesion. Chen ST, et al. **Neuroreport** 1997 Feb 10;8(3):713-7

Glutamate responsiveness enhanced in neurones expressing amyloid precursor protein. Tominaga K, et al. **Neuroreport** 1997 May 27;8(8):2067-72

NMDA induces apoptosis and necrosis in neuronal cultures. Increased APP immunoreactivity is linked to apoptotic cells. Lesort M, et al. **Neurosci Lett** 1997 Jan 17; 221(2-3):213-6

Synaptic beta-amyloid precursor proteins increase with learning capacity in rats. Huber G, et al. **Neuroscience** 1997 Sep;80(2):313-20

Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. Efthimiopoulos S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8046-50

Stimulation of amyloid precursor protein synthesis by adrenergic receptors coupled to cAMP formation. Lee RKK, et al. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):5422-6

Expression of human amyloid precursor protein ectodomains in Pichia pastoris: analysis of culture conditions, purification, and characterization. Henry A, et al. **Protein Expr Purif** 1997 Jul;10(2):283-91

BLOOD

Collection and normal levels of the amyloid precursor protein in plasma. Whyte S, et al. **Ann Neurol** 1997 Jan;41(1):121-4

Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Di Luca M, et al. **Arch Neurol** 1996 Nov;53(11):1162-6

Lymphocyte content of amyloid precursor protein is increased in Down's syndrome and aging. Pallister C, et al. **Neurobiol Aging** 1997 Jan-Feb;18(1):97-103

CEREBROSPINAL FLUID

Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Haroutunian V, et al. **Brain Res Mol Brain Res** 1997 Jun;46(1-2):161-8

Selective aggregation of endogenous beta-amyloid peptide and soluble amyloid precursor protein in cerebrospinal fluid by zinc. Brown AM, et al. **J Neurochem** 1997 Sep; 69(3):1204-12

CHEMISTRY

Cerebral white matter damage in HIV infection demonstrated using beta-amyloid precursor protein immunoreactivity. Raja F, et al. **Acta Neuropathol (Berl)** 1997 Feb;93(2):184-9

Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein. Haas C, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):169-75

Solution conformations of a peptide containing the cytoplasmic domain sequence of the beta amyloid precursor protein. Kroenke CD, et al. **Biochemistry** 1997 Jul 1; 36(26):8145-52

Expression of Kunitz protease inhibitor--containing forms of amyloid beta-protein precursor within vascular thrombi. Lang IM, et al. **Circulation** 1996 Dec 1;94(11):2728-34

Alzheimer amyloid protein precursor is localized in nerve terminal preparations to Rab5-containing vesicular organelles distinct from those implicated in the synaptic vesicle pathway. Ikin AF, et al. **J Biol Chem** 1996 Dec 13;271(50):31783-6

Amyloid precursor protein truncated at any of the gamma-secretase sites is not cleaved to beta-amyloid.

Paganetti PA, et al. **J Neurosci Res** 1996 Nov 1; 46(3):283–93

The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Borg JP, et al. **Mol Cell Biol** 1996 Nov; 16(11):6229–41

DRUG EFFECTS

Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Pittel Z, et al. **Brain Res** 1996 Dec 2;742(1–2):299–304

Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Haroutunian V, et al. **Brain Res Mol Brain Res** 1997 Jun;46(1–2):161–8

A comprehensive study of the spatiotemporal pattern of beta-amyloid precursor protein mRNA and protein in the rat brain: lack of modulation by exogenously applied nerve growth factor. Neve RL, et al. **Brain Res Mol Brain Res** 1996 Jul;39(1–2):185–97

Intracortical glutamate perfusion in vivo induces cellular alterations in specific protein kinase C isoforms and amyloid precursor protein. Horsburgh K, et al. **Exp Neurol** 1997 Feb;143(2):207–18

Indomethacin and nordihydroguaiaretic acid inhibition of amyloid beta protein (25–35) activation of phospholipases A2 and D of LA–N–2 cells. Singh IN, et al. **Neurosci Lett** 1997 Jan 24;222(1):5–8

GENETICS

An inverse mammalian two-hybrid system for beta secretase and other proteases. Dixon EP, et al. **Anal Biochem** 1997 Jul 1;249(2):239–41

Genetic factors in Alzheimer's disease: a review of recent advances. Levy-Lahad E, et al. **Ann Neurol** 1996 Dec; 40(6):829–40 (146 ref.)

Familial Alzheimer's disease-linked mutations at Val717 of amyloid precursor protein are specific for the increased secretion of A beta 42(43). Maruyama K, et al. **Biochem Biophys Res Commun** 1996 Oct 23;227(3):730–5

Aluminium-induced changes in amyloid precursor protein mRNA expression. Sinclair MA, et al. **Biochem Soc Trans** 1996 Aug;24(3):500S

Amyloid precursor protein in guinea pigs—complete cDNA sequence and alternative splicing. Beck M, et al. **Biochim Biophys Acta** 1997 Mar 20;1351(1–2):17–21

Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA–D): I—A review of clinical, radiologic and genetic aspects. Bornebroek M, et al. **Brain Pathol** 1996 Apr;6(2):111–4 (43 ref.)

Beta-amyloid precursor protein and early-onset Alzheimer's disease. Hendriks L, et al. **Ciba Found Symp** 1996; 199:170–80

Mutational screening of APP gene in patients with early-onset Alzheimer disease utilizing mismatched PCR–RFLP. Nishiwaki Y, et al. **Clin Genet** 1996 Mar; 49(3):119–23

Cell biology of the beta-amyloid precursor protein and the genetics of Alzheimer's disease. Selkoe DJ. **Cold Spring Harb Symp Quant Biol** 1996;61:587–96 (100 ref.)

G protein betagamma complex-mediated apoptosis by familial Alzheimer's disease mutant of APP. Giambarella U, et al. **EMBO J** 1997 Aug 15;16(16):4897–907

Potential CRE suppression by familial Alzheimer's mutants of APP independent of adenylyl cyclase regulation. Giambarella U, et al. **FEBS Lett** 1997 Jul 21;412(1):97–101

Identification of cis-acting elements involved in an alternative splicing of the amyloid precursor protein (APP) gene. Shibata A, et al. **Gene** 1996 Oct 10;175(1–2):203–8

Molecular genetics of Alzheimer's disease. Goate AM. **Geriatrics** 1997 Sep;52 Suppl 2:S9–12 (11 ref.)

Expression of the APP gene family in brain cells, brain development and aging. Sandbrink R, et al. **Gerontology** 1997;43(1–2):119–31

cDNA cloning and chromosome mapping of the human Fe65 gene: interaction of the conserved cytoplasmic domains of the human beta-amyloid precursor protein and its homologues with the mouse Fe65 protein. Bressler SL, et al. **Hum Mol Genet** 1996 Oct;5(10):1589–98

Expression of amyloid precursor protein mRNA isoforms in rat brain is differentially regulated during postnatal maturation and by cholinergic activity. Apelt J, et al. **Int J Dev Neurosci** 1997 Feb;15(1):95–112

Deletion of an endosomal/lysosomal targeting signal promotes the secretion of Alzheimer's disease amyloid precursor protein (APP). Ono Y, et al. **J Biochem (Tokyo)** 1997 Mar;121(3):585–90

Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence. Reaume AG, et al. **J Biol Chem** 1996 Sep 20;271(38):23380–8

No founder effect in three novel Alzheimer's disease families with APP 717 Val—>Ile mutation. Clerget-darpoux. French Alzheimer's Disease Study Group. Campion D, et al. **J Med Genet** 1996 Aug;33(8):661–4

Beta-amyloid precursor protein (APP) and APP-RNA are rapidly affected by glutamate in cultured neurons: selective increase of mRNAs encoding a Kunitz protease inhibitor domain. Willoughby DA, et al. **J Mol Neurosci** 1995; 6(4):257–76

Defective neurite extension is caused by a mutation in amyloid beta/A4 (A beta) protein precursor found in familial Alzheimer's disease. Li HL, et al. **J Neurobiol** 1997 May;32(5):469–80

Identification of heparin-binding domains in the amyloid precursor protein of Alzheimer's disease by deletion mutagenesis and peptide mapping. Clarris HJ, et al. **J Neurochem** 1997 Mar;68(3):1164–72

Overexpressions of cDNAs for beta-amyloid precursor proteins 695, 751, and 770 enhance the secretion of beta-amyloid precursor protein derivatives and the survival of P19-derived neurons. Fukuchi K, et al. **J Neurochem** 1996 May;66(5):2201–4

Transcriptional regulation of amyloid precursor protein during dibutyryl cyclic AMP-induced differentiation of NG108–15 cells. Shekarabi M, et al. **J Neurochem** 1997 Mar;68(3):970–8

APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. Irizarry MC, et al. **J Neuropathol Exp Neurol** 1997 Sep; 56(9):965–73

Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. Oster-Granite ML, et al. **J Neurosci** 1996 Nov 1;16(21):6732–41

Expression of mutant amyloid precursor proteins induces apoptosis in PC12 cells. Zhao B, et al. **J Neurosci Res** 1997 Feb 1;47(3):253–63

Exploring the etiology of Alzheimer disease using molecular genetics. Lendon CL, et al. **JAMA** 1997 Mar 12; 277(10):825–31 (130 ref.)

Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and beta-amyloid precursor protein. Weidemann A, et al. **Nat Med** 1997 Mar; 3(3):328–32

APP gene family: unique age-associated changes in splicing of Alzheimer's betaA4-amyloid protein precursor. Sandbrink R, et al. **Neurobiol Dis** 1994 Nov;1(1–2):13–24

beta-Amyloid protein precursor in Microcebus murinus: genotyping and brain localization. Silhol S, et al. **Neurobiol Dis** 1996;3(3):169–82

Altered expression of amyloid protein precursor mRNA in the rat hippocampus following trimethyltin intoxication: an in situ hybridization study. O'Connell AW, et al. **Neurochem Int** 1997 Mar;30(3):313–20

Amyloid precursor protein mRNAs in Alzheimer's disease. Harrison PJ, et al. **Neurodegeneration** 1996 Dec;5(4):409–15 (51 ref.)

Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1–42/1–40 ratio in vitro and in vivo. Borchelt DR, et al. **Neuron** 1996 Nov;17(5):1005–13

Beta APP gene transfer into cultured human muscle induces inclusion-body myositis aspects. Askanas V, et al. **Neuroreport** 1997 Jul 7;8(9–10):2155–8

Allelic variability in D21S11, but not in APP or APOE, is associated with cognitive decline in Down syndrome. Farrer MJ, et al. **Neuroreport** 1997 May 6;8(7):1645–9

Differential regulation of adenylyl cyclase in fibroblasts from sporadic and familial Alzheimer's disease cases with PS1 and APP mutations. Vestling M, et al. **Neuroreport** 1997 May 27;8(8):2031–5

Conserved elements in the 5' regulatory region of the amyloid precursor protein gene in primates. Adroer R, et al. **Neurosci Lett** 1997 May 2;226(3):203–6

Relationships between beta-amyloid (A beta) deposits and blood vessels in patients with sporadic and familial Alzheimer's disease. Armstrong RA, et al. **Neurosci Lett** 1996 Apr 5;207(3):171–4

Increased beta-amyloid precursor protein mRNA in the rat cerebral cortex and hippocampus after chronic systemic atropine treatment. Beach TG, et al. **Neurosci Lett** 1996 May 24;210(1):13–6

Lack of effect of Presenilin 1, betaAPP and their Alzheimer's disease-related mutated forms on Xenopus oocytes membrane currents. Dauch P, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):85–8

Further evidence for an association between a mutation in the APP gene and Lewy body formation. Halliday G, et al. **Neurosci Lett** 1997 May 9;227(1):49–52

Mutation of potential N-linked glycosylation sites in the Alzheimer's disease amyloid precursor protein (APP). Yazaki M, et al. **Neurosci Lett** 1996 Dec 27;221(1):57–60

A novel method for making nested deletions and its application for sequencing of a 300 kb region of human APP locus. Hattori M, et al. **Nucleic Acids Res** 1997 May 1;25(9):1802–8

The Alzheimer family of diseases: many etiologies, one pathogenesis? [comment] Hardy J. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2095–7 (21 ref.). Comment on: Proc Natl Acad Sci U S A 1997 Mar 4;94(5):2025–30.

New 'Alzheimer's mouse' produced [news; comment] Marx J. **Science** 1996 Oct 11;274(5285):177–8. Comment on: Science 1996 Oct 4;274(5284):99–102.

Alzheimer's disease: genotypes, phenotypes, and treatments. Selkoe DJ. **Science** 1997 Jan 31;275(5300):630–1 (17 ref.)

[APP, the causal gene for Alzheimer's disease] Tamaoka A, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug;41(10):1453–9 (35 ref.) **(Jpn)**

IMMUNOLOGY

Mab22C11 antibody to amyloid precursor protein recognizes a protein associated with specific astroglial cells of the rat central nervous system characterized by their capacity to support axonal outgrowth. Chauvet N, et al. **J Comp Neurol** 1997 Jan 27;377(4):550–64

Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein. Philippe B, et al. **J Neurosci Res** 1996 Dec 15;46(6):709–19

ISOLATION & PURIFICATION

Expression of human amyloid precursor protein ectodomains in Pichia pastoris: analysis of culture conditions, purification, and characterization. Henry A, et al. **Protein Expr Purif** 1997 Jul;10(2):283–91

METABOLISM

Altered beta-APP metabolism after head injury and its relationship to the aetiology of Alzheimer's disease. Graham DI, et al. **Acta Neurochir Suppl (Wien)** 1996; 66:96–102 (53 ref.)

Accumulation of beta-amyloid precursor protein and ubiquitin in axons after spinal cord trauma in humans: immunohistochemical observations on autopsy material. Ahlgren S, et al. **Acta Neuropathol (Berl)** 1996 Jul; 92(1):49–55

Is beta-APP a marker of axonal damage in short-surviving head injury? McKenzie KJ, et al. **Acta Neuropathol (Berl)** 1996 Dec;92(6):608–13

Atypical amyloid (A beta) deposition in the cerebellum in Alzheimer's disease: an immunohistochemical study using end-specific A beta monoclonal antibodies. Mann DM, et al. **Acta Neuropathol (Berl)** 1996;91(6):647–53

Senile plaques in very aged cats. Nakamura S, et al. **Acta Neuropathol (Berl)** 1996;91(4):437–9

Differential expression of intercellular adhesion molecule-1 (ICAM-1) in the A beta-containing lesions in brains of patients with dementia of the Alzheimer type. Verbeek MM, et al. **Acta Neuropathol (Berl)** 1996;91(6):608–15

Expression and distribution of amyloid precursor protein-like protein-2 in Alzheimer's disease and in normal brain. Crain BJ, et al. **Am J Pathol** 1996 Oct;149(4):1087–95

Carboxyl-terminal fragments of beta-amyloid precursor protein bind to microtubules and the associated protein tau. Islam K, et al. **Am J Pathol** 1997 Jul;151(1):265–71

Beta-amyloid protein-containing inclusions in skeletal muscle of apolipoprotein-E-deficient mice. Robertson TA, et al. **Am J Pathol** 1997 Feb;150(2):417–27

Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities. Giometto B, et al. **Ann Neurol** 1997 Jul; 42(1):34–40

Plasma levels of amyloid beta proteins Abeta1–40 and Abeta1–42(43) are elevated in Down's syndrome. Tokuda T, et al. **Ann Neurol** 1997 Feb;41(2):271–3

Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. Almkvist O, et al. **Arch Neurol** 1997 May;54(5):641–4

Upregulation of actin gene expression in cells expressing exogenous beta-amyloid precursor protein. Ramakrishna N, et al. **Biochem Biophys Res Commun** 1997 Feb 24; 231(3):615–8

Processing of Alzheimer's amyloid precursor protein during H2O2-induced apoptosis in human neuronal cells. Zhang L, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):845–8

Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein. Haas C, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):169–75

Elevated intracellular calcium concentration increases secretory processing of the amyloid precursor protein by a tyrosine phosphorylation-dependent mechanism. Petryniak MA, et al. **Biochem J** 1996 Dec 15;320 (Pt 3):957–63

A novel metalloprotease in rat brain cleaves the amyloid precursor protein of Alzheimer's disease generating amyloidogenic fragments. Mok SS, et al. **Biochemistry** 1997 Jan 7;36(1):156–63

Phosphorylation of Alzheimer beta-amyloid precursor-like proteins. Suzuki T, et al. **Biochemistry** 1997 Apr 15; 36(15):4643–9

Reduction of histone cytotoxicity by the Alzheimer beta-amyloid peptide precursor. Currie JR, et al. **Biochim Biophys Acta** 1997 Mar 1;1355(3):248–58

Amyloid precursor protein, copper and Alzheimer's disease. Multhaup G. **Biomed Pharmacother** 1997;51(3):105–11 (72 ref.)

Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains. Arai Y, et al. **Brain Dev** 1997 Jun;19(4):290–4

Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, A beta 1–42, in differentiated PC12 cells. Burdick D, et al. **Brain Res** 1997 Jan 23;746(1–2):275–84

Cathepsin D displays in vitro beta-secretase-like specificity. Chevallier N, et al. **Brain Res** 1997 Mar 7;750(1–2):11–9

Human A beta-amyloid and amyloid precursor protein accumulates in rat brain cells after cultured human leptomeningeal fibroblast implants. DeGiorgio LA, et al.

Brain Res 1997 Mar 28;752(1-2):35-44

Cell surface APP751 forms complexes with protease nexin 2 ligands and is internalized via the low density lipoprotein receptor-related protein (LRP). Knauer MF, et al. **Brain Res** 1996 Nov 18;740(1-2):6-14

Alzheimer's disease amyloid precursor protein on the surface of cortical neurons in primary culture co-localizes with adhesion patch components. Storey E, et al. **Brain Res** 1996 Oct 7;735(2):217-31

Induction of neuroprotective kappa B-dependent transcription by secreted forms of the Alzheimer's beta-amyloid precursor. Barger SW, et al. **Brain Res Mol Brain Res** 1996 Aug;40(1):116-26

Proteolytical processing of mutated human amyloid precursor protein in transgenic mice. Czech C, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1-2):108-16

Two types of amyloid precursor protein (APP) mRNA in rat glioma cell lines: upregulation via a cyclic AMP-dependent pathway. Gegelashvili G, et al. **Brain Res Mol Brain Res** 1996 Apr;37(1-2):151-6

Quantification of APP and APLP2 mRNA in APOE genotyped Alzheimer's disease brains. Johnston JA, et al. **Brain Res Mol Brain Res** 1996 Dec 31;43(1-2):85-95

A new quantitative solution hybridisation-RNase protection assay for APP and APLP2 mRNA. Johnston JA, et al. **Brain Res Mol Brain Res** 1996 Dec 31;43(1-2):77-84

A comprehensive study of the spatiotemporal pattern of beta-amyloid precursor protein mRNA and protein in the rat brain: lack of modulation by exogenously applied nerve growth factor. Neve RL, et al. **Brain Res Mol Brain Res** 1996 Jul;39(1-2):185-97

Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes. Rohan de Silva HA, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1-2):147-56

Serum deprivation alters the expression and the splicing at exons 7, 8 and 15 of the beta-amyloid precursor protein in the C6 glioma cell line. Sudoh S, et al. **Brain Res Mol Brain Res** 1996 Jul;39(1-2):12-22

Beta-amyloid protein and Alzheimer's disease. Bao X. **Chin Med J (Engl)** 1996 Jan;109(1):41-3 (0 ref.)

Beta-amyloid precursor protein and early-onset Alzheimer's disease. Hendriks L, et al. **Ciba Found Symp** 1996; 199:170-80

Expression of Kunitz protease inhibitor—containing forms of amyloid beta-protein precursor within vascular thrombi. Lang IM, et al. **Circulation** 1996 Dec 1;94(11):2728-34

Beta-amyloid precursor protein accumulates in axons around hematogenous metastases of the human brain: immunohistochemical observations. Zhang M, et al. **Clin Neuropathol** 1996 Mar-Apr;15(2):74-8

Cell biology of the beta-amyloid precursor protein and the genetics of Alzheimer's disease. Selkoe DJ. **Cold Spring Harb Symp Quant Biol** 1996;61:587-96 (100 ref.)

The spatial pattern of discrete beta-amyloid deposits in Alzheimer's disease reflects synaptic disconnection. Armstrong RA. **Dementia** 1996 Mar-Apr;7(2):86-90

Analysis of amyloid precursor protein mRNAs in skin fibroblasts in Down's syndrome. Urakami K, et al. **Dementia** 1996 Mar-Apr;7(2):82-5

G protein betagamma complex-mediated apoptosis by familial Alzheimer's disease mutant of APP. Giambarella U, et al. **EMBO J** 1997 Aug 15;16(16):4897-907

The beta-amyloid domain is essential for axonal sorting of amyloid precursor protein. Tienari PJ, et al. **EMBO J** 1996 Oct 1;15(19):5218-29

A possible role for cathepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer's disease. Mackay EA, et al. **Eur J Biochem** 1997 Mar 1;244(2):414-25

Presenilin-1 immunoreactivity is localized intracellularly in Alzheimer's disease brain, but not detected in amyloid plaques. Weber LL, et al. **Exp Neurol** 1997 Jan;143(1):37-44

The intracellular cytoplasmic domain of the Alzheimer's disease amyloid precursor protein interacts with phosphotyrosine-binding domain proteins in the yeast two-hybrid system. McLoughlin DM, et al. **FEBS Lett** 1996 Nov 18;397(2-3):197-200

Cell surface receptor function of amyloid precursor protein that activates Ser/Thr kinases. Murayama Y, et al. **Gerontology** 1996;42 Suppl 1:2-11

Systemic overexpression of a C-terminal fragment of human amyloid beta-protein precursor causes accumulation of Alzheimer beta-amyloid fibrils in pancreas of transgenic mice. Shoji M, et al. **Gerontology** 1996;42 Suppl 1:48-56

Deleterious network: a testable pathogenetic concept of Alzheimer's disease. Ying W. **Gerontology** 1997; 43(4):242-53

Role of the juxtamembrane domains of the transforming growth factor-alpha precursor and the beta-amyloid precursor protein in regulated ectodomain shedding. Arribas J, et al. **J Biol Chem** 1997 Jul 4;272(27):17160-5

Processing of beta-amyloid precursor protein by cathepsin D. Higaki J, et al. **J Biol Chem** 1996 Dec 13; 271(50):31885-93

The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells. Ho L, et al. **J Biol Chem** 1996 Nov 29;271(48):30929-34

Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence. Reaume AG, et al. **J Biol Chem** 1996 Sep 20;271(38):23380-8

Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D. Saftig P, et al. **J Biol Chem** 1996 Nov 1;271(44):27241-4

Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations. Walter J, et al. **J Biol Chem** 1997 Jan 17;272(3):1896-903

Secreted glypican binds to the amyloid precursor protein of Alzheimer's disease (APP) and inhibits APP-induced neurite outgrowth. Williamson TG, et al. **J Biol Chem** 1996 Dec 6;271(49):31215-21

Interaction of the phosphotyrosine interaction/phosphotyrosine binding-related domains of Fe65 with wild-type and mutant Alzheimer's beta-amyloid precursor proteins. Zambrano N, et al. **J Biol Chem** 1997 Mar 7;272(10):6399-405

Beta-secretase processing of the beta-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes. Zhao J, et al. **J Biol Chem** 1996 Dec 6;271(49):31407-11

Interaction between Alzheimer's disease beta A4 precursor protein (APP) and the extracellular matrix: evidence for the participation of heparan sulfate proteoglycans. Cáceres J, et al. **J Cell Biochem** 1997 May;65(2):145-58

Novel beta-secretase cleavage of beta-amyloid precursor protein in the endoplasmic reticulum/intermediate compartment of NT2N cells. Chyung ASC, et al. **J Cell Biol** 1997 Aug 11;138(3):671-80

Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. Yamazaki T, et al. **J Cell Sci** 1996 May;109 (Pt 5):999-1008

Cytotoxic fragment of amyloid precursor protein accumulates in hippocampus after global forebrain ischemia. Yokota M, et al. **J Cereb Blood Flow Metab** 1996 Nov;16(6):1219-23

Diffuse Lewy body disease without amyloid plaques in a patient homozygous for apolipoprotein E allele epsilon 4: a case report. Seltzer B, et al. **J Geriatr Psychiatry Neurol** 1996 Oct;9(4):181-4

Stimulus responses and amyloid precursor protein processing in DAMI megakaryocytes [see comments] Davies TA, et al. **J Lab Clin Med** 1997 Jul;130(1):21-32. Comment in: J Lab Clin Med 1997 Jul;130(1):5-7.

Beta-amyloid precursor protein (APP) and APP-RNA are rapidly affected by glutamate in cultured neurons: selective increase of mRNAs encoding a Kunitz protease inhibitor domain. Willoughby DA, et al. **J Mol Neurosci** 1995; 6(4):257-76

Enhanced expression of amyloid precursor protein in response to dibutyryl cyclic AMP is not mediated by the transcription factor AP-2. Bourbonnière M, et al. **J Neurochem** 1997 Mar;68(3):909-16

Identification of heparin-binding domains in the amyloid precursor protein of Alzheimer's disease by deletion mutagenesis and peptide mapping. Clarris HJ, et al. **J Neurochem** 1997 Mar;68(3):1164-72

Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain [published erratum appears in J Neurochem 1997 Mar;68(3):1331] Furukawa K, et al. **J Neurochem** 1996 Nov; 67(5):1882-96

Processing of amyloid precursor protein in human primary neuron and astrocyte cultures. LeBlanc AC, et al. **J Neurochem** 1997 Mar;68(3):1183-90

Metabotropic glutamate receptors increase amyloid precursor protein processing in astrocytes: inhibition by cyclic AMP. Lee RK, et al. **J Neurochem** 1997 May;68(5):1830-5

Proteasome contributes to the alpha-secretase pathway of amyloid precursor protein in human cells. Marambaud P, et al. **J Neurochem** 1997 Feb;68(2):698-703

Insertion of lysosomal targeting sequences to the amyloid precursor protein reduces secretion of beta A4. Schrader-Fischer G, et al. **J Neurochem** 1997 Apr; 68(4):1571-80

Transcriptional regulation of amyloid precursor protein during dibutyryl cyclic AMP-induced differentiation of NG108-15 cells. Shekarabi M, et al. **J Neurochem** 1997 Mar;68(3):970-8

An etiological role of amyloidogenic carboxyl-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. Suh YH. **J Neurochem** 1997 May; 68(5):1781-91 (121 ref.)

An amyloid protein in familial cerebral amyloid angiopathy (British type) [letter] [see comments] Yamada M. **J Neurol Sci** 1996 Feb;135(2):181. Comment in: J Neurol Sci 1996 Jun;138(1-2):168.

Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. Li S, et al. **J Neuropathol Exp Neurol** 1997 Aug;56(8):901-11

Association of vascular amyloid beta and cells of the mononuclear phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer disease. Maat-Schieman ML, et al. **J Neuropathol Exp Neurol** 1997 Mar;56(3):273-84

Accumulation of Alzheimer amyloid-beta peptide in cultured myocytes is enhanced by serum and reduced by cerebrospinal fluid. Mazur-Kolecka B, et al. **J Neuropathol Exp Neurol** 1997 Mar;56(3):263-72

Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. Irizarry MC, et al. **J Neurosci** 1997 Sep 15;17(18):7053-9

Trafficking of cell-surface beta-amyloid precursor protein: evidence that a sorting intermediate participates in synaptic vesicle recycling. Marquez-Sterling NR, et al. **J Neurosci** 1997 Jan 1;17(1):140-51

Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. Masliah E, et al. **J Neurosci** 1996 Sep 15;16(18):5795-811

Late compartments of amyloid precursor protein transport in SY5Y cells are involved in beta-amyloid secretion. Peraus GC, et al. **J Neurosci** 1997 Oct 15;17(20):7714-24

Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. Zhang F, et al. **J Neurosci** 1997 Oct 15; 17(20):7655-61

Effect of aluminium on expression and processing of amyloid precursor protein. Neill D, et al. **J Neurosci Res** 1996 Nov 15;46(4):395-403

Metabolites of the beta-amyloid precursor protein generated by beta-secretase localise to the trans-Golgi network and late endosome in 293 cells. Stephens DJ, et al. **J Neurosci Res** 1996 Oct 15;46(2):211-25

Dehydroepiandrosterone (DHEA) increases production and release of Alzheimer's amyloid precursor protein. Danenboerg HD, et al. **Life Sci** 1996;59(19):1651-7

The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Borg JP, et al. **Mol Cell Biol** 1996 Nov; 16(11):6229-41

Phorbol esters affect multiple steps in beta-amyloid precursor protein trafficking and amyloid beta-protein production. Koo EH. **Mol Med** 1997 Mar;3(3):204-11

The cytoplasmic domain of Alzheimer's amyloid precursor protein is phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and cultured cells. Oishi M, et al. **Mol Med** 1997 Feb;3(2):111-23

Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Barger SW, et al. **Nature** 1997 Aug 28;388(6645):878-81

Beta AP deposition and head trauma. Adle-Biassette H, et al. **Neurobiol Aging** 1996 May-Jun;17(3):415-9

Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. Cummings BJ, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):653-9

Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Tamaoka A, et al. **Neurobiol Aging** 1996 May-Jun; 17(3):405-14

beta-Amyloid protein precursor in Microcebus murinus: genotyping and brain localization. Silhol S, et al. **Neurobiol Dis** 1996;3(3):169-82

Effect of hypocholinergic activity on the immunoreactivity of beta-amyloid precursor protein in the central nervous system. Kása P, et al. **Neurobiology (Bp)** 1996;4(1-2):119-21

Heparin promotes beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Leveugle B, et al. **Neurochem Int** 1997 Jun;30(6):543-8

Additive effects of basic fibroblast growth factor and phorbol ester on beta-amyloid precursor protein expression and secretion. Ringheim GE, et al. **Neurochem Int** 1997 Apr-May;30(4-5):475-81

Fibroblasts of patients affected by Down's syndrome oversecrete amyloid precursor protein and are hyporesponsive to protein kinase C stimulation. Govoni S, et al. **Neurology** 1996 Oct;47(4):1069-75

Correlations between the morphology of diffuse and primitive beta-amyloid (A beta) deposits and the frequency of associated cells in Down's syndrome. Armstrong RA. **Neuropathol Appl Neurobiol** 1996 Dec;22(6):527-30

Amyloid deposition is associated with c-Jun expression in Alzheimer's disease and amyloid angiopathy. Ferrer I, et al. **Neuropathol Appl Neurobiol** 1996 Dec;22(6):521-6

Ubiquitin and Alzheimer's amyloid beta precursor protein colocalize to endosomes-lysosomes in cultured human cells. Ali-Khan Z, et al. **Neuroreport** 1996 Dec 20; 8(1):385-9

Effect of increased glycogen synthase kinase-3 activity upon the maturation of the amyloid precursor protein in transfected cells. Aplin AE, et al. **Neuroreport** 1997 Feb 10;8(3):639-43

Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor protein. D'Hooge R, et al. **Neuroreport** 1996 Nov 4;7(15-17):2807-11

Factors secreted by activated microglia and monocytes reduce amyloidogenesis in vascular smooth muscle cells. Frackowiak J, et al. **Neuroreport** 1997 Jul 7;8(9-10):2259-63

Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. Ghilardi JR, et al. **Neuroreport** 1996 Nov 4;7(15-17):2607-11

Age-related changes in the expression of Alzheimer's beta APP in the brain of senescence accelerated mouse (SAM)-P/10. Jeong SJ, et al. **Neuroreport** 1997 May 6; 8(7):1733-7

Expression of beta-amyloid precursor protein mRNAs following transient focal ischaemia. Koistinaho J, et al. **Neuroreport** 1996 Nov 4;7(15-17):2727-31

Co-expression of APP with cNOS but not iNOS after cortical injury in rat. Lüth HJ, et al. **Neuroreport** 1997 Jul 7;8(9-10):2321-4

Ubiquitin (Ub) interacts non-covalently with Alzheimer amyloid precursor protein (betaPP): isolation of Ub-betaPP conjugates from brain extracts. Master E, et al. **Neuroreport** 1997 Aug 18;8(12):2781-6

The amino-terminally truncated forms of amyloid beta-protein in brain macrophages in the ischemic lesions of Alzheimer's disease patients. Akiyama H, et al. **Neurosci Lett** 1996 Nov 22;219(2):115-8

Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Gasparini L, et al. **Neurosci Lett** 1997 Aug 8;231(2):113-7

Screening for amyloid beta precursor protein codon 665, 670/671 and 717 mutations in Finnish patients with Alzheimer's disease. Helisalmi S, et al. **Neurosci Lett** 1996 Feb 16;205(1):68-70

An intronic polymorphism in the presenilin-1 gene does not influence the amount or molecular form of the amyloid beta protein deposited in Alzheimer's disease. Mann DM, et al. **Neurosci Lett** 1997 Jan 24;222(1):57-60

Expression of apolipoprotein E inhibits aggregation of the C-terminal fragments of beta-amyloid precursor protein. Ohman T, et al. **Neurosci Lett** 1996 May 24;210(1):65-8

Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Saido TC, et al. **Neurosci Lett** 1996 Sep 13;215(3):173-6

Changes in beta amyloid precursor protein secretion associated with the proliferative status of CNS derived progenitor cells. Salvietti N, et al. **Neurosci Lett** 1996 Jul 19;212(3):199-203

Promotion of synthetic amyloid beta-peptide fibrillization by cell culture media and cessation of fibrillization by serum. Wegiel J, et al. **Neurosci Lett** 1996 Jun 28;211(3):151-4

Mutation of potential N-linked glycosylation sites in the Alzheimer's disease amyloid precursor protein (APP). Yazaki M, et al. **Neurosci Lett** 1996 Dec 27;221(1):57-60

Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Citron M, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13170-5

Specific transcellular binding between membrane proteins crucial to Alzheimer disease. Dewji NN, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12575-80

Association of a novel human FE65-like protein with the cytoplasmic domain of the beta-amyloid precursor protein. Guénette SY, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10832-7

Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Johnson-Wood K, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1550-5

Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. Xia W, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8208-13

Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides. Forloni G, et al. **Prog Neurobiol** 1996 Jul;49(4):287-315 (273 ref.)

Dissecting how presinilins function--and malfunction [news] Marx J. **Science** 1996 Dec 13;274(5294):1838-40

Alzheimer's precursor protein and the use of bathocuproine for determining reduction of copper(II) [letter; comment] Sayre LM. **Science** 1996 Dec 13;274(5294):1933-4. Comment on: Science 1996 Mar 8;271(5254):1406-9.

Ionic effects of the Alzheimer's disease beta-amyloid precursor protein and its metabolic fragments. Fraser SP, et al. **Trends Neurosci** 1997 Feb;20(2):67-72 (91 ref.)

Function and dysfunction in the nervous system. Harmar AJ, et al. **Trends Neurosci** 1996 Nov;19(11):449-50

[Recent advances in Alzheimer's disease research--amyloid precursor protein trafficking, processing, and mutations in Alzheimer's disease linked genes] Fukatsu R, et al. **Hokkaido Igaku Zasshi** 1997 Jan;72(1):3-11 (44 ref.) (Eng. Abstr.) **(Jpn)**

[Biological characteristics of amyloid precursor protein and Alzheimer's disease] Fukatsu R, et al. **Rinsho Byori** 1996 Mar;44(3):213-24 (56 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Progress curve analysis of the kinetics with which blood coagulation factor Xla is inhibited by protease nexin-2. Scandura JM, et al. **Biochemistry** 1997 Jan 14;36(2):412-20

Reduction of histone cytotoxicity by the Alzheimer beta-amyloid peptide precursor. Currie JR, et al. **Biochim Biophys Acta** 1997 Mar 1;1355(3):248-58

Sprouting and abnormal contacts of nonmedullated axons, and deposition of extracellular material induced by the amyloid precursor protein (APP) and other protease inhibitors. Moreno RD, et al. **Brain Res** 1996 Apr 29; 718(1-2):13-24

Membrane currents induced in Xenopus oocytes by the C-terminal fragment of the beta-amyloid precursor protein. Fraser SP, et al. **J Neurochem** 1996 May;66(5):2034-40

Trypsin interaction with the senile plaques of Alzheimer disease is mediated by beta-protein precursor. Smith MA, et al. **Mol Chem Neuropathol** 1996 Feb;27(2):145-54

APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Trieb K, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):541-7

beta-Amyloid-mediated inhibition of redox activity (MTT reduction) is not an indicator of astroglial degeneration. Patel AJ, et al. **Neuroreport** 1996 Aug 12;7(12):2026-30

Cholesterol protects PC12 cells from beta-amyloid induced calcium disordering and cytotoxicity. Zhou Y, et al. **Neuroreport** 1996 Nov 4;7(15-17):2487-90

Lack of effect of Presenilin 1, betaAPP and their Alzheimer's disease-related mutated forms on Xenopus oocytes membrane currents. Dauch P, et al. **Neurosci Lett** 1997 Jan 17;221(2-3):85-8

Protein kinase inhibitor attenuates apoptotic cell death induced by amyloid beta protein in culture of the rat cerebral cortex. Ueda K, et al. **Neurosci Lett** 1996 Jan 26; 203(3):175-8

Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Masliah E, et al. **Neuroscience** 1997 May;78(1):135-46

PHYSIOLOGY

The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture. Ohsawa I, et al. **Biochem Biophys Res Commun** 1997 Jul 9;236(1):59-65

Amyloid precursor protein, A beta and amyloid-associated proteins involved in chloroquine retinopathy in rats--immunopathological studies. Yoshida T, et al. **Brain Res** 1997 Aug 1;764(1-2):283-8

Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Mattson MP, et al. **Brain Res Brain Res Rev** 1997 Feb; 23(1-2):47-61 (119 ref.)

Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. Koo EH, et al. **J Cell Sci** 1996 May;109 (Pt 5):991-8

Amyloid beta-protein precursor: a new anticoagulant? [editorial; comment] Schmaier AH. **J Lab Clin Med** 1997 Jul;130(1):5-7. Comment on: J Lab Clin Med 1997 Jul;130(1):21-32.

Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. Paradis E, et al. **J Neurosci** 1996 Dec 1;16(23):7533-9

Cell surface amyloid beta-protein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cells. Yamazaki T, et al. **J Neurosci** 1997 Feb 1;17(3):1004-10

Individual isoforms of the amyloid beta precursor protein demonstrate differential adhesive potentials to constituents of the extracellular matrix. Gillian AM, et al. **J Neurosci Res** 1997 Jul 15;49(2):154-60

Role of amyloid precursor protein in the mechanisms of neurodegeneration in Alzheimer's disease. Masliah E. **Lab Invest** 1997 Sep;77(3):197-209 (164 ref.)

Neurodegenerative mechanisms in Alzheimer disease. A role for oxidative damage in amyloid beta protein precursor-mediated cell death. Sopher BL, et al. **Mol Chem Neuropathol** 1996 Oct-Dec;29(2-3):153-68

Characterization of appican, the chondroitin sulfate proteoglycan form of the Alzheimer amyloid precursor protein. Pangalos MN, et al. **Neurodegeneration** 1996 Dec; 5(4):445-51 (57 ref.)

Secreted form of beta-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices. Ishida A, et al. **Neuroreport** 1997 Jul 7;8(9-10):2133-7

SECRETION

Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Racchi M, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):893-8

Amyloid beta-protein(25-35) increases cellular APP and inhibits the secretion of APPs in human extraneuronal cells. Schmitt TL, et al. **Exp Cell Res** 1997 Aug 1;234(2):336-40

Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. Itoh T, et al. **J Biol Chem** 1997 Sep 5;272(36):22389-92

Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. Lahiri DK, et al. **J Mol Neurosci** 1996 Spring;7(1):41-9

Increased secretion of the amino-terminal fragment of amyloid precursor protein in brains of rats with a constitutive up-regulation of protein kinase C. Caputi A, et al. **J Neurochem** 1997 Jun;68(6):2523-9

Metabotropic glutamate receptor subtype mGluR1alpha stimulates the secretion of the amyloid beta-protein precursor ectodomain. Nitsch RM, et al. **J Neurochem** 1997 Aug;69(2):704-12

Metabotropic glutamate receptor agonists increase release of soluble amyloid precursor protein derivatives from rat brain cortical and hippocampal slices. Ulus IH, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):149-54

Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Müller DM, et al. **Life Sci** 1997;60(13-14):985-91

Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. Kim SH, et al. **Mol Pharmacol** 1997 Sep;52(3):430-6

Glutamate-stimulated secretion of amyloid precursor protein from cortical rat brain slices. Kirazov L, et al. **Neurochem Int** 1997 Jun;30(6):557-63

TOXICITY

Beta-amyloid induces apoptosis in human-derived neurotypic SH-SY5Y cells. Li YP, et al. **Brain Res** 1996 Nov 4;738(2):196-204

Mechanism of amyloid beta protein induced neuronal cell death: current concepts and future perspectives. Behl C, et al. **J Neural Transm Suppl** 1997;49:125-34 (26 ref.)

A beta peptide enhances focal adhesion kinase/Fyn association in a rat CNS nerve cell line. Zhang C, et al. **Neurosci Lett** 1996 Jun 28;211(3):187-90

AMYLOID FIBRIL PROTEIN AA see **AMYLOID PROTEIN AA**

AMYLOID FIBRIL PROTEIN (ALZHEIMER'S) see **AMYLOID BETA-PROTEIN**

AMYLOID NEUROPATHIES

3rd International Symposium on Familial Amyloidotic Polyneuropathy and other TTR Related Disorders. 2nd International Workshop on Liver Transplantation in FAP. Lisbon, Portugal, October 27-29, 1995. Abstracts. **Neuromuscul Disord** 1996 Feb;6 Suppl 1:S3-94

Corino-Andrade disease (familial amyloidotic polineuropathy type I) in Spain: urological and andrological disorders. Hita Villaplana G, et al. **Neurourol Urodyn** 1997;16(1):55-61 (17 ref.)

[Familial amyloidotic polyneuropathy (FAP) type I and the therapies] Ando Y, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1430-2 (10 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Serum potassium concentrations after suxamethonium in patients with familial amyloid polyneuropathy type I. Viana JS, et al. **Acta Anaesthesiol Scand** 1997 Jun;41(6):750-3

Plasma beta-endorphin levels during liver transplantation in patients with familial amyloidotic polyneuropathy. Acosta F, et al. **Clin Biochem** 1996 Aug;29(4):393-5

Simple detection of abnormal serum transthyretin from patients with familial amyloidotic polyneuropathy by high-performance liquid chromatography/electrospray ionization mass spectrometry using material precipitated with specific antiserum [letter] Kishikawa M, et al. **J Mass Spectrom** 1996 Jan;31(1):112-4

COMPLICATIONS

Portuguese amyloidosis: a case of spontaneous bilateral corneal perforation. Frossard JL, et al. **Am J Med** 1996 Nov;101(5):562

Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up. Ando E, et al. **Br J Ophthalmol** 1997 Apr;81(4):295-8

Autonomic dysfunction and anemia in neurologic disorders. Ando Y, et al. **J Auton Nerv Syst** 1996 Nov 6;61(2):145-8

The neuroendocrine system and gastrointestinal complications in patients with familial amyloidosis and polyneuropathy. el-Salhy M, et al. **Scand J Gastroenterol** 1997 Sep;32(9):849-54 (55 ref.)

DIAGNOSIS

Portuguese amyloidosis: a case of spontaneous bilateral corneal perforation. Frossard JL, et al. **Am J Med** 1996 Nov;101(5):562

Technetium-99m (Tc-99m) diphosphono-propanedicarboxylic acid bone tracer uptake and Tc-99m sestamibi distribution in cardiac amyloidosis--a case report. Low YH, et al. **Ann Acad Med Singapore** 1995 Nov;24(6):898-901

Systemic amyloidosis with initial polyneuropathy. Lee DD, et al. **J Dermatol** 1996 Apr;23(4):296-8

The diagnosis of familial amyloid polyneuropathy [letter] Jiménez Escrig A, et al. **Neurologia** 1996 Oct;11(8):310-2

Late onset type I familial amyloidotic polyneuropathy: presentation of three autopsy cases in comparison with 19 autopsy cases of the ordinary type. Takahashi K, et al. **Pathol Int** 1997 Jun;47(6):353-9

[The natural history of cardiac involvement in Portuguese-type familial amyloid polyneuropathy] Fonseca C, et al. **Rev Port Cardiol** 1997 Jan;16(1):101-5 **(Por)**

DRUG THERAPY

Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine. Carvalho MJ, et al. **J Auton Nerv Syst** 1997 Jan 12;62(1-2):63-71

ETIOLOGY

A case of carpal tunnel syndrome due to dialysis-related amyloidosis in a patient undergoing long-term hemodialysis. Chung YJ, et al. **Korean J Intern Med** 1997 Jan;12(1):75-9

GENETICS

Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Sousa A, et al. **Am J Med Genet** 1995 Dec 18;60(6):512-21

Transthyretin amyloidosis: a new mutation associated with dementia. Petersen RB, et al. **Ann Neurol** 1997 Mar; 41(3):307-13

A new simple and rapid screening method for variant transthyretin-related amyloidosis. Ando Y, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):480-3

Peripheral nerve amyloidosis. Reilly MM, et al.

Brain Pathol 1996 Apr;6(2):163–77 (118 ref.)
Ethical aspects of CMJ articles [letter] de Silva D, et al. **Ceylon Med J** 1997 Jun;42(2):103
Familial amyloid polyneuropathy in a Sri Lankan family. Galappatthy P, et al. **Ceylon Med J** 1997 Mar;42(1):33–5
Familial amyloid polyneuropathy: new developments in genetics and treatment. Coelho T. **Curr Opin Neurol** 1996 Oct;9(5):355–9 (66 ref.)
A comment on: 'Molecular diagnosis of transthyretin Met30 mutation in an Italian family with familial amyloidotic polyneuropathy' by Paola Strocchi et al., FEBS Letters 359 (1995) 203–205 [letter; comment] Di Iorio G, et al. **FEBS Lett** 1996 Nov 18;397(2–3):357–8. Comment on: FEBS Lett 1995 Feb 13;359(2–3):203–5.
The diagnosis of familial amyloid polyneuropathy [letter] Jiménez Escrig A, et al. **Neurologia** 1996 Oct;11(8):310–2
A trinucleotide deletion in the transthyretin gene (delta V 122) in a kindred with familial amyloidotic polyneuropathy. Uemichi T, et al. **Neurology** 1997 Jun;48(6):1667–70
A European family with histidine 58 transthyretin mutation in familial amyloid polyneuropathy. Goebel HH, et al. **Neuromuscul Disord** 1997 Jun;7(4):229–30
No association between apolipoprotein E epsilon4 allele and the age of onset in type I familial amyloid polyneuropathy. Satoh S, et al. **Neurosci Lett** 1996 Feb 9;204(3):209–11
Comparison of amyloid deposition in two lines of transgenic mouse that model familial amyloidotic polyneuropathy, type I. Takaoka Y, et al. **Transgenic Res** 1997 Jul;6(4):261–9
[Orthotopic liver transplantation for familial Portuguese amyloidosis] Fournier B, et al.
Schweiz Med Wochenschr Suppl 1997;89:36S–40S (Eng. Abstr.) **(Fre)**
[Familial amyloidotic polyneuropathy with a transthyretin variant (Val30—>Leu)] Shimizu H, et al.
No To Shinkei 1996 Feb;48(2):175–8 (Eng. Abstr.) **(Jpn)**
[Variable clinical manifestations of familial amyloid polyneuropathy and living related liver transplantation] Ikeda S, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1433–5 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Protein and DNA sequencing analyses of transthyretin in familial amyloidotic polyneuropathy] Nakazato M.
Rinsho Shinkeigaku 1995 Dec;35(12):1436–7 (2 ref.) (Eng. Abstr.) **(Jpn)**
[A late onset familial amyloidotic polyneuropathy (FAP) with a novel variant transthyretin characterized by a basic-for-acidic amino acid substitution (Glu61—>Lys)] Yamamoto T, et al. **Rinsho Shinkeigaku** 1996 Sep; 36(9):1065–8 (Eng. Abstr.) **(Jpn)**

METABOLISM

Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Kohno K, et al. **Am J Pathol** 1997 Apr;150(4):1497–508
Reply to M. Yamada's letter to the editor: an amyloid protein in familial cerebral amyloid angiopathy (British type) [letter; comment] Plant GT. **J Neurol Sci** 1996 Jun; 138(1–2):168. Comment on: J Neurol Sci 1996 Feb;135(2):181.
Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous beta-sheet helix. Blake C, et al. **Structure** 1996 Aug 15;4(8):989–98
De novo amyloid synthesis in ocular tissue in familial amyloidotic polyneuropathy after liver transplantation [letter] Ando Y, et al. **Transplantation** 1996 Oct 15; 62(7):1037–8

MORTALITY

Impact of gastrointestinal dysfunction on survival after liver transplantation for familial amyloidotic polyneuropathy. Suhr O, et al. **Dig Dis Sci** 1996 Oct;41(10):1909–14

PATHOLOGY

Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Kohno K, et al. **Am J Pathol** 1997 Apr;150(4):1497–508
Peripheral nerve amyloidosis. Reilly MM, et al.
Brain Pathol 1996 Apr;6(2):163–77 (118 ref.)
Depleted cutaneous innervation in familial amyloid. Ramsey B, et al. **Clin Exp Dermatol** 1996 Nov;21(6):449–50
Muscle fiber splitting, capillary internalization, and target-like fiber formation in familial amyloidotic polyneuropathy. Fiori MG, et al. **Clin Neuropathol** 1996 Jul–Aug;15(4):240–7
Endocrine cells in rectal biopsy specimens from patients with familial amyloidotic polyneuropathy. El-Salhy M, et al. **Scand J Gastroenterol** 1996 Jan;31(1):68–73
Charcot knee arthropathy with articular amyloid deposition in familial amyloidotic polyneuropathy. Shiraishi M, et al. **Scand J Rheumatol** 1997;26(1):61–4
Comparison of amyloid deposition in two lines of transgenic mouse that model familial amyloidotic polyneuropathy, type I. Takaoka Y, et al. **Transgenic Res** 1997 Jul;6(4):261–9

PHYSIOPATHOLOGY

Neurophysiological evaluation of sexual dysfunction in familial amyloidotic polyneuropathy—Portuguese type. Alves M, et al. **Acta Neurol Scand** 1997 Sep;96(3):163–6
Bronchial hyperreactivity in patients with familial amyloidotic polyneuropathy and autonomic neuropathy. Kawano O, et al. **Am J Respir Crit Care Med** 1997 Apr; 155(4):1465–8
Peripheral nerves regenerated in familial amyloid polyneuropathy after liver transplantation. Ikeda S, et al. **Ann Intern Med** 1997 Oct 15;127(8 (Pt 1)):618–20
Electromyographic findings in transthyretin (TTR)-related familial amyloid polyneuropathy (FAP). Montagna P, et al. **Electroencephalogr Clin Neurophysiol** 1996 Oct; 101(5):423–30
Non-neurogenic periodic fluctuations in heart rate and vasomotion appearing in familial amyloid polyneuropathy (FAP) Type I (Met30). Abe M, et al.
J Auton Nerv Syst 1996 Aug 27;60(1–2):71–5
[Circadian patterns of heart rate variability in patients with dysautonomia] Freitas J, et al. **Rev Port Cardiol** 1997 Mar; 16(3):313–5 **(Por)**

RADIONUCLIDE IMAGING

Scan findings of various myocardial SPECT agents in a case of amyloid polyneuropathy with suspected myocardial involvement. Arbab AS, et al. **Ann Nucl Med** 1997 May; 11(2):139–41
Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. Tanaka M, et al. **J Am Coll Cardiol** 1997 Jan;29(1):168–74

SURGERY

Peripheral nerves regenerated in familial amyloid polyneuropathy after liver transplantation. Ikeda S, et al. **Ann Intern Med** 1997 Oct 15;127(8 (Pt 1)):618–20
Impact of gastrointestinal dysfunction on survival after liver transplantation for familial amyloidotic polyneuropathy. Suhr O, et al. **Dig Dis Sci** 1996 Oct;41(10):1909–14
Liver transplantation in Japanese patients with familial amyloidotic polyneuropathy [letter] Ando Y, et al. **Lancet** 1997 Aug 23;350(9077):593–4
Sequential liver transplantation. Furtado A, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):467–8
Long-term results of liver transplantation in familial amyloidotic polyneuropathy type I. Parrilla P, et al. **Transplantation** 1997 Aug 27;64(4):646–9
Impact of autonomic neuropathy on circulatory instability during liver transplantation for familial amyloidotic polyneuropathy. Suhr OB, et al. **Transplantation** 1997 Mar 15;63(5):675–9
[Liver transplantation in familial amyloid polyneuropathy. Case report and review of the literature] Krüger M, et al. **Internist (Berl)** 1997 Jul;38(7):692–700 (41 ref.) (Eng. Abstr.) **(Ger)**
[Liver transplantation in familial amyloid polyneuropathy (letter)] Krüger M, et al. **Nervenarzt** 1997 Feb;68(2):150–1 **(Ger)**

THERAPY

Early pacemaker implantation in patients with familial amyloidotic polyneuropathy [letter] Ando Y, et al. **Muscle Nerve** 1996 Dec;19(12):1640–1
Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Bergethon PR, et al. **Neurology** 1996 Oct;47(4):944–51
Three cases of liver transplantation for type I familial amyloid polyneuropathy. Fournier B, et al. **Transplant Proc** 1997 Aug;29(5):2416–7

AMYLOID P COMPONENT

ANALYSIS

Female protein, amyloidosis, and hormonal carcinogenesis in Turkish hamster: differences from Syrian hamster. Coe JE, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R934–41
Serum amyloid P component level in Alzheimer's disease. Nishiyama E, et al. **Dementia** 1996 Sep–Oct;7(5):256–9
Effects of hormone replacement therapy on serum amyloid P component in postmenopausal women. Hashimoto S, et al. **Maturitas** 1997 Mar;26(2):113–9
Elastic fiber-associated proteins of skin in development and photoaging. Werth VP, et al. **Photochem Photobiol** 1996 Mar;63(3):308–13

ANTAGONISTS & INHIBITORS

Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy. Pepys MB, et al. **Ciba Found Symp** 1996;199:73–81; discussion 81–9

BIOSYNTHESIS

Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Vouret-Craviari V, et al. **Infect Immun** 1997 Apr;65(4):1345–50

CHEMISTRY

Amyloid P immunoreactivity precedes C4d deposition on extracellular neurofibrillary tangles. Schwab C, et al. **Acta Neuropathol (Berl)** 1997 Jan;93(1):87–92
Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP. Hohenester E, et al. **J Mol Biol** 1997 Jun 20;269(4):570–8

DIAGNOSTIC USE

Potential for imaging cerebral amyloid deposits using 123I-labelled serum amyloid P component and SPET. Bornebroek M, et al. **Nucl Med Commun** 1996 Nov; 17(11):929–33

GENETICS

Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. Basile A, et al. **J Biol Chem** 1997 Mar 28;272(13):8172–8
Absence of coding sequence polymorphism in the serum amyloid P component gene (Sap) in autoimmune New Zealand black mice. Drake CG, et al. **Mamm Genome** 1996 Jun;7(6):466–7
Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Botto M, et al. **Nat Med** 1997 Aug;3(8):855–9

IMMUNOLOGY

The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Du Clos TW.
Mol Biol Rep 1996;23(3–4):253–60 (40 ref.)

ISOLATION & PURIFICATION

Selective removal of human serum amyloid P component from rat blood by use of an immunoaffinity membrane in an extracorporeal circulation system. Adachi T, et al.
J Chromatogr B Biomed Appl 1996 Jun 28;682(1):47–54

METABOLISM

Calcium-dependent and -independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: enhanced binding at slightly acid pH. Danielsen B, et al.
Biochim Biophys Acta 1997 Apr 25;1339(1):73–8
Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy. Pepys MB, et al. **Ciba Found Symp** 1996;199:73–81; discussion 81–9
Characterization of the binding of serum amyloid P to laminin. Zahedi K. **J Biol Chem** 1997 Jan 24;272(4):2143–8
Serum amyloid P component forms a stable complex with human C5b6. Barbashov SF, et al. **J Immunol** 1997 Apr 15;158(8):3830–5
Binding of complement proteins C1q and C4bp to serum amyloid P component (SAP) in solid contra liquid phase. Sørensen IJ, et al. **Scand J Immunol** 1996 Oct;44(4):401–7
[Change of serum amyloid P component concentrations in women] Katou M. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jul;48(7):481–7 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

The role of serum amyloid P (SAP) component in Alzheimer's disease. Urbányi Z. **Neurobiology (Bp)** 1996; 4(3):283–4
[The regulation of blood neutrophil functions by C-reactive protein and serum amyloid P] Polevshchikov AV, et al. **Fiziol Zh Im I M Sechenova** 1996 Aug–Sep;82(8–9):67–72 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Long pentraxins: an emerging group of proteins with diverse functions. Goodman AR, et al.
Cytokine Growth Factor Rev 1996 Aug;7(2):191–202 (76 ref.)
The role of serum amyloid P (SAP) component in Alzheimer's disease. Urbányi Z. **Neurobiology (Bp)** 1996; 4(3):283–4

AMYLOID POLYNEUROPATHIES see **AMYLOID NEUROPATHIES**

AMYLOID PROTEIN AA

Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Migita K, et al. **Lab Invest** 1996 Sep;75(3):371–5

ANALYSIS

Detection of serum amyloid A-derived proteins in formalin-fixed paraffin-embedded tissues: reliability of the method and expansion of its spectrum. Shtrasburg S, et al. **Am J Clin Pathol** 1997 Sep;108(3):289–94
Measurement of serum amyloid A by commonly used automated analysers [letter] Wada A, et al.
Ann Clin Biochem 1997 Sep;34 (Pt 5):569–70
Serum amyloid A remains at physiological concentrations in coronary atherosclerosis [letter] Yamada T, et al.
Clin Chem 1997 Jan;43(1):193
Acute-phase proteins in perinatal human plasma. Liberatori S, et al. **Electrophoresis** 1997 Mar–Apr;18(3–4):520–6
Central nervous system involvement in amyloid A type amyloidosis. Arakawa K, et al. **J Neurol Sci** 1996 Oct; 142(1–2):157–9
Pancreas-specific protein (PASP), serum amyloid A (SAA), and neopterin (NEOP) in the diagnosis of rejection after simultaneous pancreas and kidney transplantation. Müller TF, et al. **Transpl Int** 1997;10(3):185–91

[Day to day changes in SAA (serum amyloid A) values of healthy subjects and the effect of dexamethasone administration] Yamada T, et al. **Rinsho Byori** 1997 Jul; 45(7):696–8 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

An in vitro cellular system for generation of AA–amyloid. Palm M, et al. **APMIS** 1997 Aug;105(8):603–8

Messenger RNA deadenylylation precedes decapping in mammalian cells. Couttet P, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5628–33

Regulation of extrahepatic apolipoprotein serum amyloid A (ApoSAA) gene expression by interleukin–1 alpha alone: synthesis and secretion of ApoSAA by cultured aortic smooth muscle cells. Kumon Y, et al. **Scand J Immunol** 1997 Sep;46(3):284–91

[Production of inflammatory markers by HepG 2 cells stimulated with monocyte conditioned media: the effects of corticosteroid and other immunosuppressants] Shimetani N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Jun; 20(3):166–77 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Generalized AA–amyloidosis in Siamese and Oriental cats. van der Linde–Sipman JS, et al. **Vet Immunol Immunopathol** 1997 May;56(1–2):1–10

DRUG EFFECTS

Brefeldin A inhibits experimentally induced AA amyloidosis. Stenstad T, et al. **J Rheumatol** 1996 Jan;23(1):93–100

GENETICS

Involvement of an SAF–like transcription factor in the activation of serum amyloid A gene in monocyte/macrophage cells by lipopolysaccharide. Ray BK, et al. **Biochemistry** 1997 Apr 15;36(15):4662–8

Serum amyloid A gene expression in rabbit, mink and mouse. Marhaug G, et al. **Clin Exp Immunol** 1997 Feb; 107(2):425–34

C–reactive protein and serum amyloid A mRNA stability following induction by cytokines. Lozanski G, et al. **Cytokine** 1996 Jul;8(7):534–40

Serum amyloid A gene expression level in liver in response to different inflammatory agents is dependent upon the nature of activated transcription factors. Ray A, et al. **DNA Cell Biol** 1997 Jan;16(1):1–7

Mapping of the mouse serum amyloid A gene cluster by long–range polymerase chain reaction. Butler A, et al. **Immunogenetics** 1996;44(6):468–74

Efficient in vitro cleavage of mouse acute phase serum amyloid A mRNA mediated by a synthetic hammerhead ribozyme. Gaughan DJ, et al. **Scand J Immunol** 1997 Jul; 46(1):51–8

[Alzheimer's disease precipitating mutations in presenile genes result in increased production of amyloid peptide A beta(42)] Jensen PH, et al. **Ugeskr Laeger** 1997 May 12; 159(20):3025–6 **(Dan)**

IMMUNOLOGY

Generalised AA–amyloidosis in a bat (Pipistrellus pipistrellus). Gruber AD, et al. **Vet Pathol** 1996 Jul; 33(4):428–30

ISOLATION & PURIFICATION

Isolation of serum amyloid A protein by small–scale hydrophobic interaction chromatography and two–dimensional electrophoresis. Bruun CF, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25;685(2):360–3

METABOLISM

Acute phase proteins, C–reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. Hogarth MB, et al. **Age Ageing** 1997 Mar;26(2):153–8

Extracellular matrix–anchored serum amyloid A preferentially induces mast cell adhesion. Hershkoviz R, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C179–87

Increased plasma concentrations of serum amyloid A: an indicator of the acute–phase response after cardiopulmonary bypass. Berendes E, et al. **Crit Care Med** 1997 Sep;25(9):1527–33

Effect of serum amyloid A on cellular affinity of low density lipoprotein. Yamada T, et al. **Eur J Clin Chem Clin Biochem** 1997 Jun;35(6):421–6

Long–term survival in systemic amyloid A amyloidosis complicating Crohn's disease [see comments] Lovat LB, et al. **Gastroenterology** 1997 Apr;112(4):1362–5. Comment in: Gastroenterology 1997 Aug;113(2):731.

Binding of human serum amyloid A (hSAA) and its high–density lipoprotein3 complex (hSAA–HDL3) to human neutrophils. Possible implication to the function of a protein of an unknown physiological role. Preciado–Patt L, et al. **Int J Pept Protein Res** 1996 Dec;48(6):503–13

Characterization of high affinity binding between laminin and the acute–phase protein, serum amyloid A. Ancsin JB, et al. **J Biol Chem** 1997 Jan 3;272(1):406–13

Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin. Yamada T, et al. **J Immunol** 1996 Jul 15;157(2):901–7

Vascular renal AA amyloidosis in adult Still's disease. Rivera F, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1714–6

Diagnostic value of bone marrow biopsy in patients with AA–type renal amyloidosis secondary to ankylosing spondylitis [letter; comment] Sungur C, et al. **Nephrol Dial Transplant** 1996 Dec;11(12):2520–1. Comment on: Nephrol Dial Transplant 1996 Jun;11(6):1172–5.

Complete clinical remission and subsequent relapse of bronchiectasis–related (AA) amyloid induced nephrotic syndrome. Goldsmith DJ, et al. **Nephron** 1996;74(3):572–6

Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Liang JS, et al. **Neurosci Lett** 1997 Apr 4;225(2):73–6

Characterisation of the acute phase response of heifers to a prolonged low dose infusion of lipopolysaccharide. Werling D, et al. **Res Vet Sci** 1996 Nov;61(3):252–7

PHARMACOLOGY

Extracellular matrix–anchored serum amyloid A preferentially induces mast cell adhesion. Hershkoviz R, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C179–87

Serum amyloid A has little effect on high density lipoprotein (HDL) binding to U937 monocytes but may influence HDL mediated cholesterol transfer. Hayat S, et al. **Biochem Soc Trans** 1997 May;25(2):348S

AMYLOID PROTEIN A4 see **AMYLOID BETA–PROTEIN**

AMYLOID PROTEIN PRECURSOR see **AMYLOID BETA–PROTEIN PRECURSOR**

AMYLOID PROTEIN SAA

ANALYSIS

Sandwich enzyme–linked immunosorbent assay for quantitative measurement of serum amyloid A protein in horses. Satoh M, et al. **Am J Vet Res** 1995 Oct; 56(10):1286–91

Characterization of serum amyloid A4 as a plasma apolipoprotein. Yamada T, et al. **Clin Chim Acta** 1996 Jul 15;251(1):105–12

Characterization of human serum amyloid A protein isoforms separated by two–dimensional electrophoresis by liquid chromatography/electrospray ionization tandem mass spectrometry. Ducret A, et al. **Electrophoresis** 1996 May; 17(5):866–76

Human serum amyloid A (SAA) protein: a prominent acute–phase reactant for clinical practice. Malle E, et al. **Eur J Clin Invest** 1996 Jun;26(6):427–35 (76 ref.)

Rheumatoid arthritis exhibits reduced acute phase and enhanced constitutive serum amyloid A protein in synovial fluid relative to serum. A comparison with C–reactive protein. Kumon Y, et al. **J Rheumatol** 1997 Jan;24(1):14–9

Enzyme–linked immunosorbent assay for detection of feline serum amyloid A protein by use of immunological cross–reactivity of polyclonal anti–canine serum amyloid A protein antibody. Kajikawa T, et al. **J Vet Med Sci** 1996 Nov;58(11):1141–3

Both acute phase and constitutive serum amyloid A are present in atherosclerotic lesions. Yamada T, et al. **Pathol Int** 1996 Oct;46(10):797–800

BIOSYNTHESIS

Generation of soluble recombinant human acute phase serum amyloid A2 (A–SAA2) protein and its use in development of an A–SAA specific ELISA. McCormack CC, et al. **J Immunol Methods** 1996 Oct 30;198(1):101–10

Expression and regulation of constitutive and acute phase serum amyloid A mRNAs in hepatic and non–hepatic cell lines. Steel DM, et al. **Scand J Immunol** 1996 Nov; 44(5):493–500

CHEMISTRY

The acute phase serum amyloid A protein (SAA) in the horse: isolation and characterization of three isoforms. Hultén C, et al. **Vet Immunol Immunopathol** 1997 Jul;57(3–4):215–27

CLASSIFICATION

Both acute phase and constitutive serum amyloid A are present in atherosclerotic lesions. Yamada T, et al. **Pathol Int** 1996 Oct;46(10):797–800

GENETICS

Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high–density lipoprotein binding and amyloid fibril formation by site–directed mutagenesis. Patel H, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):1041–9

Polymorphism of acute–phase serum amyloid A isoforms and amyloid resistance in wild–type Mus musculus czech. Cathcart ES, et al. **Clin Immunol Immunopathol** 1996 Oct; 81(1):22–6

Structure of the mouse Saa4 gene and its linkage to the serum amyloid A gene family. de Beer MC, et al. **Genomics** 1996 May 15;34(1):139–42

Use of the acute phase serum amyloid A2 (SAA2) gene promoter in the analysis of pro– and anti–inflammatory mediators: differential kinetics of SAA2 promoter induction by IL–1 beta and TNF–alpha compared to IL–6. Uhlar CM, et al. **J Immunol Methods** 1997 Apr 25;203(2):123–30

Characterization of serum amyloid A protein mRNA expression and secondary amyloidosis in the domestic duck. Guo JT, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10; 93(25):14548–53

Structure of the mouse serum amyloid A 5 (Saa5) gene: relationship to other members of the serum amyloid A family. Butler A, et al. **Scand J Immunol** 1997 Feb; 45(2):160–5

IMMUNOLOGY

Generation of soluble recombinant human acute phase serum amyloid A2 (A–SAA2) protein and its use in development of an A–SAA specific ELISA. McCormack CC, et al. **J Immunol Methods** 1996 Oct 30;198(1):101–10

Enzyme–linked immunosorbent assay for detection of feline serum amyloid A protein by use of immunological cross–reactivity of polyclonal anti–canine serum amyloid A protein antibody. Kajikawa T, et al. **J Vet Med Sci** 1996 Nov;58(11):1141–3

ISOLATION & PURIFICATION

The acute phase serum amyloid A protein (SAA) in the horse: isolation and characterization of three isoforms. Hultén C, et al. **Vet Immunol Immunopathol** 1997 Jul;57(3–4):215–27

METABOLISM

Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high–density lipoprotein binding and amyloid fibril formation by site–directed mutagenesis. Patel H, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):1041–9

Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. Liang JS, et al. **J Lipid Res** 1996 Oct; 37(10):2109–16

Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection. Hartmann A, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):161–6

Degradation of amyloid A precursor protein SAA by macrophage cell lines obtained from amyloid resistant and susceptible strains of mice. Ham D, et al. **Scand J Immunol** 1997 Apr;45(4):354–60

PHARMACOKINETICS

Differential plasma clearance of murine acute–phase serum amyloid A proteins SAA1 and SAA2. Kluve–Beckerman B, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):663–9

PHARMACOLOGY

Mast cell adhesion to extracellular matrix: local effects of acute phase reactants. Hershkoviz R, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):295–6

AMYLOID SERUM PROTEIN SAA see **AMYLOID PROTEIN SAA**

AMYLOIDOSIS

Inhibition of Alzheimer's amyloidosis by peptides that prevent beta–sheet conformation. Soto C, et al. **Biochem Biophys Res Commun** 1996 Sep 24;226(3):672–80

The nature and origin of amyloid fibrils. Proceedings of a symposium. Oeiras, Portugal, 23–25 October 1995. **Ciba Found Symp** 1996;199:1–253

Amyloidosis. Friman C, et al. **Curr Opin Rheumatol** 1996 Jan;8(1):62–71 (69 ref.)

Amyloid and the gut. Lovat LB, et al. **Dig Dis** 1997 May–Jun; 15(3):155–71 (105 ref.)

Immunohistochemical localization of apolipoprotein E in renal amyloidosis. Taniguchi Y, et al. **Hiroshima J Med Sci** 1996 Mar;45(1):11–4

The amyloidoses. Buxbaum J. **Mt Sinai J Med** 1996 Jan; 63(1):16–23 (19 ref.)

Aging, amyloid, and cardiomyopathy [editorial; comment] Benson MD. **N Engl J Med** 1997 Feb 13;336(7):502–4. Comment on: N Engl J Med 1997 Feb 13;336(7):466–73.

The systemic amyloidoses. Falk RH, et al. **N Engl J Med** 1997 Sep 25;337(13):898–909 (94 ref.)

[Amyloid goiter] Scandroglio I, et al. **Minerva Chir** 1996 Jul–Aug;51(7–8):603–5 (Eng. Abstr.) **(Ita)**

[Arrhythmias in patients with metabolic disease] Yotsukura M, et al. **Nippon Rinsho** 1996 Aug;54(8):2202–6 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Amyloidosis] Morishita T. **Ryoikibetsu Shokogun Shirizu** 1996;(15):391–4 (17 ref.) **(Jpn)**

[Cardiac amyloidosis: review of the literature] Gouveia D, et al. **Rev Port Cardiol** 1996 Sep;15(9):657–64, 613 (45 ref.) (Eng. Abstr.) **(Por)**

[Tracheobronchial amyloidosis: apropos of 3 cases] Ruiz LA, et al. **Arch Bronconeumol** 1996 Oct;32(8):424–6 (Eng. Abstr.) **(Spa)**

BLOOD

High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. Hasegawa H, et al. **Arthritis Rheum** 1996 Oct;39(10):1728–32

The importance of the peripheral blood film in systemic amyloidosis. Hawkins C, et al. **Clin Lab Haematol** 1996 Sep;18(3):219–20

AMYLOIDOSIS

Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Migita K, et al. **Lab Invest** 1996 Sep;75(3):371–5

CHEMICALLY INDUCED

Development of amyloidosis as an unrecognized side effect of gold therapy: comment on the article by Shapiro and Spiera [letter; comment] Michels H, et al.
Arthritis Rheum 1996 Nov;39(11):1932–4. Comment on: Arthritis Rheum 1995 Dec;38(12):1851–4.

CLASSIFICATION

[Amyloidosis—primary or secondary? (letter)] Pettersson T.
Duodecim 1995;111(11):1066 **(Fin)**

COMPLICATIONS

Abdominal visceral calcification in primary amyloidosis: CT findings. Jacobs JE, et al. **Abdom Imaging** 1997 Sep–Oct; 22(5):519–21 (8 ref.)

Primary localised amyloidosis of the ureter. Van Cleynenbreugel B, et al. **Acta Urol Belg** 1996 Sep;64(3):43–5 (13 ref.)

Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Patel AR, et al.
Am J Cardiol 1997 Aug 15;80(4):486–92

Spontaneous rupture of the spleen in amyloidosis [letter] Cubo T, et al. **Am J Emerg Med** 1997 Jul;15(4):443–4

Spontaneous rupture of the liver in amyloidosis. Bujanda L, et al. **Am J Gastroenterol** 1997 Aug;92(8):1385–6 (8 ref.)

Hyperlipidemia as the first biochemical manifestation of primary hepatic amyloidosis. Couture P, et al.
Am J Gastroenterol 1997 Jun;92(6):1046–7

Extracapillary glomerulonephritis and renal amyloidosis. Moroni G, et al. **Am J Kidney Dis** 1996 Nov;28(5):695–9

Study of neuromyopathy in amyloid kidney transplant patients. Sobh M, et al. **Am J Nephrol** 1996;16(2):114–7

Aortic valve replacement in a patient with cardiac amyloidosis [letter] Terada Y, et al. **Ann Thorac Surg** 1996 Nov;62(5):1571–2

High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. Hasegawa H, et al. **Arthritis Rheum** 1996 Oct;39(10):1728–32

Salivary gland lymphoplasmacytoid lymphoma with nodular cutaneous amyloid deposition and lambda chain paraproteinaemia. Badell A, et al. **Br J Dermatol** 1996 Aug; 135(2):327–9

Coexistence of diffuse plane normolipaemic xanthoma and amyloidosis in a patient with monoclonal gammopathy. Buezo GF, et al. **Br J Dermatol** 1996 Sep;135(3):460–2

High attenuation lymphadenopathy caused by amyloidosis. Fukuda T, et al. **Br J Radiol** 1997 Feb;70:213–4

Cutaneous macular amyloidosis associated with multiple endocrine neoplasia 2A. de Argila D, et al.
Clin Exp Dermatol 1996 Jul;21(4):313–4

Systemic lupus erythematosus and amyloidosis. Al-Hoqail I, et al. **Clin Rheumatol** 1997 Jun;16(4):422–4

Systemic amyloidosis complicating inflammatory bowel disease [letter; comment] Meyers S. **Gastroenterology** 1997 Aug;113(2):731. Comment on: Gastroenterology 1997 Apr;112(4):1362–5.

Primary amyloidosis complicated by systemic necrotizing arteritis [letter] Uyama H, et al. **Histopathology** 1997 Aug; 31(2):203–4

Primary amyloidosis and syncope. Rodriguez Reguero J, et al. **Int J Cardiol** 1997 Jan 31;58(2):185–7

Etiologies of the sicca syndrome: primary systemic amyloidosis and others. Richey TK, et al.
Int J Dermatol 1996 Aug;35(8):553–7

Fatal diarrhea in a patient with Castleman's disease associated with intestinal amyloidosis. Miura A, et al. **Intern Med** 1995 Nov;34(11):1106–9

Diffuse pulmonary amyloidosis with monoclonal IgG-kappa gammopathy. Takashi S, et al. **Intern Med** 1997 May; 36(5):357–9

Localized cutaneous amyloidosis associated with mycosis fungoides. Romero LS, et al. **J Am Acad Dermatol** 1997 Jul;37(1):124–7

Primary systemic amyloidosis—pleural involvement with exudative pleural effusion. Mathews V, et al.
J Assoc Physicians India 1996 May;44(5):345–6

Destructive bone lesion in primary amyloidosis. Venkatachalam S, et al. **J Assoc Physicians India** 1996 May; 44(5):351–3

The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1–42 in Alzheimer's disease. Castaño EM, et al. **J Biol Chem** 1996 Dec 13; 271(50):32185–91

Pneumatosis cystoides intestinalis: an unusual complication of systemic amyloidosis. Pearson DC, et al.
J Clin Gastroenterol 1996 Jan;22(1):74–6

99mTc-HSA-D scintigraphy in the diagnosis of protein-losing gastroenteropathy due to secondary amyloidosis. Suzuki C, et al. **J Gastroenterol** 1997 Feb; 32(1):78–82

Central nervous system involvement in amyloid A type amyloidosis. Arakawa K, et al. **J Neurol Sci** 1996 Oct; 142(1-2):157–9

Amyloidaceous ulcerated gingival hyperplasia: a newly described entity related to ligneous conjunctivitis. Gokbuget AY, et al. **J Oral Pathol Med** 1997 Feb; 26(2):100–4

Psoriatic spondyloarthropathy with secondary amyloidosis. Ahmed Q, et al. **J Rheumatol** 1996 Jun;23(6):1107–10 (28 ref.)

Temporal artery involvement revealing AL amyloidosis and IgD monoclonal gammopathy. Rodon P, et al.
J Rheumatol 1996 Jan;23(1):189–90 (17 ref.)

Bladder dysfunction secondary to spinal cord amyloidosis. Sakamoto K, et al. **J Urol** 1997 Mar;157(3):949

Neuromyotonia and type I myofiber predominance in amyloidosis. Gutmann L, et al. **Muscle Nerve** 1996 Oct; 19(10):1338–41

Restrictive cardiomyopathy [letter; comment] Reisinger J, et al. **N Engl J Med** 1997 Jun 26;336(26):1917; discussion 1917–8. Comment on: N Engl J Med 1997 Jan 23;336(4):267–76.

Renal failure in a patient with two renal diseases: renal amyloidosis and rapidly progressive glomerulonephritis. Andreu FJ, et al. **Nephrol Dial Transplant** 1997 Feb; 12(2):341–3

Popliteal cysts from advanced amyloidosis in long-term haemofiltration/haemodiafiltration. Dantoine T, et al.
Nephrol Dial Transplant 1997 Jul;12(7):1512–5

Prolonged treatment with granulocyte colony-stimulating factor in a patient with Felty's syndrome and chronic renal failure from secondary amyloidosis. Del Pozo C, et al.
Nephrol Dial Transplant 1997 Aug;12(8):1727–9

Primary amyloidosis with severe nephrotic syndrome and acquired factor X deficiency. Gloy J, et al.
Nephrol Dial Transplant 1997 Mar;12(3):588–90

Fatal spontaneous liver rupture in a renal transplant patient with amyloidosis [letter] Satue JA, et al. **Nephron** 1996; 73(2):355–6

Primary localized nodular tongue amyloidosis associated with Sjögren's syndrome. Haraguchi H, et al.
ORL J Otorhinolaryngol Relat Spec 1997 Jan–Feb; 59(1):60–3

Octreotide therapy for diarrhoea [letter] Gilanders IA, et al. **Postgrad Med J** 1997 Jan;73(855):62

Rheumatic manifestations of dysproteinemias and lymphoproliferative disorders. Duna GF, et al.
Rheum Dis Clin North Am 1996 Feb;22(1):39–51 (107 ref.)

Endoscopic hydrostatic balloon dilation of ulcer-induced pyloric stenosis in rheumatoid arthritis and secondary amyloidosis. Hizawa K, et al. **Surg Endosc** 1997 Jun; 11(6):673–5

A case of type I Gaucher disease with cardiopulmonary amyloidosis and chitotriosidase deficiency. Hřebíček M, et al. **Virchows Arch** 1996 Nov;429(4–5):305–9

[A severe complication in chronic hemodialysis: intestinal pseudo-obstruction due to amyloidosis (letter)] Versini P, et al. **Ann Pathol** 1997 Jul;17(3):215–6 **(Fre)**

[Generalized amyloidosis associated with Hashimoto's thyroiditis and hypothyroidism] Nemr R, et al.
J Med Liban 1996;44(4):233–5 (Eng. Abstr.) **(Fre)**

[An unusual case of cardiac insufficiency] Ezingeard E, et al. **Rev Mal Respir** 1996 Dec;13(6):591–3 (Eng. Abstr.) **(Fre)**

[At a glance—joint amyloidosis in a dialysis patient]
Schweiz Med Wochenschr 1996 Dec 28;126(51–52):2244 **(Ger)**

[Polyneuropathy, diarrhea (clinical conference)] Koopmann F, et al. **Schweiz Rundsch Med Prax** 1996 Nov 26; 85(48):1553–8 (Eng. Abstr.) **(Ger)**

[Case report: secondary amyloidosis in ulcerative colitis—successful treatment with colchicine (letter)] Swarowsky B. **Z Gastroenterol** 1997 Jan;35(1):XVIII **(Ger)**

[Progress in diagnosis and treatment of renal diseases. II. nephropathies associated with systemic diseases. 3. Amyloidosis] Gejo F. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1663–7 (7 ref.) **(Jpn)**

[Case of renal cell carcinoma metastasis to the muscles with secondary amyloidosis] Nakajima K, et al.
Nippon Naika Gakkai Zasshi 1994 Jan 10;83(1):130–2 **(Jpn)**

[Case of factor VII deficiency with systemic amyloidosis having a unique clinical course such as splenic rupture] Uematsu M, et al. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):314–6 **(Jpn)**

[A case of gastric, pulmonary, and submandibular gland mucosa-associated lymphoid tissue lymphomas with colon and submandibular gland amyloidosis] Shirasaka D, et al.
Nippon Shokakibyo Gakkai Zasshi 1997 Jun;94(6):402–6 **(Jpn)**

[Myelopathy caused by hypertrophy of the posterior longitudinal ligament of the cervical spine in a patient with long-term hemodialysis] Mizuno J, et al.
No Shinkei Geka 1996 Jul;24(7):655–9 (Eng. Abstr.) **(Jpn)**

[Primary amyloidosis complicated with chronic myelomonocytic leukemia] Okuda T, et al.
Rinsho Ketsueki 1996 Sep;37(9):858–62 (Eng. Abstr.) **(Jpn)**

[The effect of a water-cooled vest on heat intolerance in a patient with anhidrosis due to familial amyloidosis of Finnish type] Ohnishi A, et al. **Rinsho Shinkeigaku** 1996 Oct;36(10):1183–5 (Eng. Abstr.) **(Jpn)**

[Tubulo-interstitial nephritis associated with abnormal immune system] Kawaguchi K.
Ryoikibetsu Shokogun Shirizu 1997;(16 Pt 1):281–3 (9 ref.) **(Jpn)**

[A clinical case of restrictive myocarditis due to senile-type amyloidosis] Martins M, et al. **Rev Port Cardiol** 1997 Apr; 16(4):383–9, 352 (12 ref.) (Eng. Abstr.) **(Por)**

[Systemic amyloidosis associated with common variable hypogammaglobulinemia and intestinal lymphoid nodular hyperplasia] Sánchez-Pobre P, et al.
Gastroenterol Hepatol 1996 Aug-Sep;19(7):351–5 (38 ref.) (Eng. Abstr.) **(Spa)**

[HIV nephropathy and amyloidosis (letter—] Caminal Montero L, et al. **Med Clin (Barc)** 1997 May 24; 108(20):797–8 **(Spa)**

[Diffuse fatty infiltration of the thyroid gland associated to amyloidosis in a patient with chronic renal failure] Téllez R, et al. **Rev Med Chil** 1996 Oct;124(10):1251–5 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

MR appearances of urinary bladder in amyloidosis associated with multiple myeloma. Amano Y, et al.
Abdom Imaging 1996 Sep–Oct;21(5):468–9

Diagnostic screening of systemic amyloidosis by abdominal fat aspiration: an analysis of 100 cases. Masouye I.
Am J Dermatopathol 1997 Feb;19(1):41–5

Cardiomyopathy, nephropathy, and death in a 44-year-old man [clinical conference] **Am J Med** 1997 May; 102(5):496–502

The premortem recognition of systemic senile amyloidosis with cardiac involvement. Kyle RA, et al. **Am J Med** 1996 Oct;101(4):395–400

Primary localised amyloidosis of the orbit. Murdoch IE, et al. **Br J Ophthalmol** 1996 Dec;80(12):1083–6

Erosive amyloidosis of the wrist and knee associated with oligoclonal bands. Bukhari M, et al. **Br J Rheumatol** 1997 Apr;36(4):494–7

Subpopulation of dogs with severe brain parenchymal beta amyloidosis distinguished with cluster analysis. Węgiel J, et al. **Brain Res** 1996 Jul 22;728(1):20–6

A 58-year-old man with shortness of breath, ascites, and leg edema [clinical conference] Kronzon I, et al.
Circulation 1996 Sep 15;94(6):1483–8

Nonsecretory immunoglobulin-derived amyloidosis of the heart: diagnosis by immunohistochemistry of the endomyocardium. Chau EM, et al. **Clin Cardiol** 1997 May; 20(5):494–6

Case report: focal amyloidosis of the maxillary antrum: plain film, CT and MR appearances. Birchall D, et al.
Clin Radiol 1997 May;52(5):392–4

Atypical hypergammaglobulinaemia D syndrome with amyloidosis: an overlap with familial Mediterranean fever? Ostuni P, et al. **Clin Rheumatol** 1996 Nov;15(6):610–2

Cytodiagnosis of amyloid deposition within the breast. Gupta RK, et al. **Cytopathology** 1996 Apr;7(2):136–40

Primary systemic amyloidosis. A report of 2 cases. Dézfoulian B, et al. **Dermatology** 1996;192(4):413–5

Lichen amyloidosis presenting as a papular pruritus syndrome in a human-immunodeficiency-virus-infected man. Goller MM, et al. **Dermatology** 1997;194(1):62–4

Diffuse mesenteric amyloidosis. Mohan V, et al.
Dig Dis Sci 1997 May;42(5):1079–82 (17 ref.)

MR findings of plasmacytoma with calcified amyloid deposition. Soler R, et al. **Eur J Radiol** 1995 Dec 15; 21(2):152–4

CT and MRI of amyloidoma of the CNS. Caerts B, et al. **Eur Radiol** 1997;7(4):474–6

Amyloidosis of the seminal vesicles simulating tumor invasion of prostatic carcinoma on endorectal MR images. Jager GJ, et al. **Eur Radiol** 1997;7(4):552–4

Primary solitary amyloidoma of the lung: findings on CT and MRI. Matsumoto K, et al. **Eur Radiol** 1997;7(4):586–8

Primary diffuse alveolar septal amyloidosis with multiple cysts and calcification. Ohdama S, et al. **Eur Respir J** 1996 Jul;9(7):1569–71

Amyloid colitis mimicking collagenous colitis. Groisman GM, et al. **Histopathology** 1997 Aug;31(2):201–2

Primary localized nasopharyngeal amyloidosis. A case report. Domínguez S, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jun;36(1):61–7

Hepatic amyloidosis presenting with severe intrahepatic cholestasis. Goenka MK, et al. **J Clin Gastroenterol** 1996 Sep;23(2):134–6

AL-type amyloidosis presenting with rapidly deteriorating liver involvement [letter] Linardaki G, et al.
J Clin Gastroenterol 1997 Jun;24(4):297–8

Primary systemic amyloidosis with giant hepatomegaly and a swiftly progressive course. Mainenti PP, et al.
J Clin Gastroenterol 1997 Apr;24(3):173–5

Senile seminal vesicle amyloidosis associated with hematospermia: demonstration by endorectal MRI. Botash RJ, et al. **J Comput Assist Tomogr** 1997 Sep–Oct; 21(5):748–9

MR finding of primary amyloid arthropathy associated with multiple myeloma. Shim JC, et al.
J Comput Assist Tomogr 1997 Sep–Oct;21(5):800–2

Systemic amyloidosis with initial polyneuropathy. Lee DD, et al. **J Dermatol** 1996 Apr;23(4):296–8

Amyloidosis localized in the sigmoid colon. Matsui H, et al. **J Gastroenterol** 1996 Aug;31(4):607–11 (15 ref.)

Amyloid deposits in labial salivary glands identified by electron microscopy. Delgado WA, et al.
J Oral Pathol Med 1997 Jan;26(1):51–2

A case of amyloidosis due to multiple myeloma that resembled systemic sclerosis [letter] Sabadini L, et al.

J Rheumatol 1997 May;24(5):1018

Nodular pulmonary amyloidosis. Podbielski FJ, et al. **J Thorac Cardiovasc Surg** 1997 Aug;114(2):289–91

Diagnostic aspects of beta 2–microglobulin amyloidosis. Schaeffer J, et al. **Nephrol Dial Transplant** 1996;11 Suppl 2:144–6 (28 ref.)

Cerebral amyloid angiopathy presenting as a nonhemorrhagic, infiltrating mass. Ortiz O, et al. **Neuroradiology** 1996 Jul;38(5):449–52

Systemic amyloidosis with temporal artery involvement mimicking temporal arteritis. Ing EB, et al. **Ophthalmic Surg Lasers** 1997 Apr;28(4):328–31

Amyloidosis. Smith MS, et al. **Otolaryngol Head Neck Surg** 1997 Jun;116(6 Pt 1):699–700

'Localized amyloidosis': 123I-labelled SAP component scintigraphy and labial salivary gland biopsy. Maulin L, et al. **QJM** 1997 Jan;90(1):45–50

Image interpretation session: 1996. Tracheal amyloidoma. **Radiographics** 1997 Jan–Feb;17(1):243–6

Solitary amyloid nodule in the lung. Yoshino I, et al. **Scand Cardiovasc J** 1997;31(2):121–2

Magnetic resonance imaging of dialysis-related amyloidosis of the shoulder and hip. Escobedo EM, et al. **Skeletal Radiol** 1996 Jan;25(1):41–8

[Heart failure and arterial hypertension disclosing amyloidosis] Habbal R, et al. **Nephrologie** 1997;18(3):91–4 (Eng. Abstr.) **(Fre)**

[Organ-specific nodular pulmonary amyloidosis of the A lambda type in Sjogren syndrome] Schneider F, et al. **Z Arztl Fortbild (Jena)** 1997 Jan;90(8):719–23 (Eng. Abstr.) **(Ger)**

[Primary amyloidosis of the gastrointestinal tract and liver—two case reports] Halm U, et al. **Z Gastroenterol** 1997 Feb;35(2):131–7 (35 ref.) (Eng. Abstr.) **(Ger)**

[Pleural amyloidosis] Kanoh T. **Rinsho Ketsueki** 1996 Nov; 37(11):1293–6 (Eng. Abstr.) **(Jpn)**

[Difficulties in the diagnosis of hereditary familial amyloidosis] Anokhin IM, et al. **Ter Arkh** 1995;67(12):56–7 (Eng. Abstr.) **(Rus)**

[Primary pulmonary nodular amyloidosis] Antolín García MT, et al. **Arch Bronconeumol** 1997 May;33(5):251–3 (24 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Comenzo RL, et al. **Blood** 1996 Oct 1; 88(7):2801–6

Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy. Pepys MB, et al. **Ciba Found Symp** 1996;199:73–81; discussion 81–9

Remission of lichen amyloidosus after treatment with acitretin [letter] Reider N, et al. **Dermatology** 1997; 194(3):309–11

Primary systemic amyloidoses: possible new directions in prophylaxis and therapy. Oken RJ. **Med Hypotheses** 1996 Jun;46(6):505–6

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. Kyle RA, et al. **N Engl J Med** 1997 Apr 24;336(17):1202–7

[Local DMSO treatment of macular and papular amyloidosis] Ozkaya-Bayazit E, et al. **Hautarzt** 1997 Jan;48(1):31–7 (Eng. Abstr.) **(Ger)**

[Secondary amyloidosis in ulcerative colitis—successful treatment with colchicine] Menges M, et al. **Z Gastroenterol** 1996 Nov;34(11):753–6 (Eng. Abstr.) **(Ger)**

[The treatment of secondary amyloidosis in rheumatoid arthritis] Lukina GV, et al. **Ter Arkh** 1996;68(5):18–21 (25 ref.) **(Rus)**

[Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis] Podorol'skaia LV, et al. **Vopr Med Khim** 1996 Oct–Dec;42(4):322–7 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

The structure, stability, and folding process of amyloidogenic mutant human lysozyme. Funahashi J, et al. **J Biochem (Tokyo)** 1996 Dec;120(6):1216–23

EPIDEMIOLOGY

Female protein, amyloidosis, and hormonal carcinogenesis in Turkish hamster: differences from Syrian hamster. Coe JE, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R934–41

Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. Jadoul M, et al. **Kidney Int** 1997 Jun;51(6):1928–32

ETHNOLOGY

Clinicohistopathological findings of gelatinous droplike corneal dystrophy among Asians. Li S, et al. **Cornea** 1996 Jul;15(4):355–62

ETIOLOGY

Notalgia paresthetica, macular posterior pigmentary incontinence, macular amyloidosis and pruritus [letter; comment] Bernhard JD. **Acta Derm Venereol** 1997 Mar; 77(2):164. Comment on: Acta Derm Venereol 1996 Jul;76(4):302–4.

Severe gastrointestinal complications of dialysis-related amyloidosis in two patients on long-term hemodialysis. Araki H, et al. **Am J Nephrol** 1996;16(2):149–53

High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Küchle C, et al. **Am J Nephrol** 1996;16(6):484–8

Structural and functional characterization of three human immunoglobulin kappa light chains with different pathological implications. Bellotti V, et al. **Biochim Biophys Acta** 1996 Dec 16;1317(3):161–7

Condyloma-like lesions as the presenting sign of multiple myeloma associated amyloidosis [letter] Buezo GF, et al. **Br J Dermatol** 1996 Oct;135(4):665–6

Metabolism of amyloid proteins. Benson MD, et al. **Ciba Found Symp** 1996;199:104–13; discussion 113–8

FAP mutations destabilize transthyretin facilitating conformational changes required for amyloid formation. Colon W, et al. **Ciba Found Symp** 1996;199:228–38; discussion 239–42

Apolipoprotein E and amyloidogenesis. Frangione B, et al. **Ciba Found Symp** 1996;199:132–41; discussion 141–5

Proteoglycans and amyloid fibrillogenesis. Kisilevsky R, et al. **Ciba Found Symp** 1996;199:58–67; discussion 68–72, 90–103

Ageing and amyloid fibrillogenesis: lessons from apolipoprotein AI, transthyretin and islet amyloid polypeptide. Westermark P, et al. **Ciba Found Symp** 1996; 199:205–18; discussion 218–22

Urticaria, arthralgia, and nephropathy without amyloidosis: another variant of the Muckle-Wells syndrome? Throssell D, et al. **Clin Genet** 1996 Mar;49(3):130–3

Goitre and severe autonomic neuropathy due to secondary amyloidosis in a renal transplant patient [letter] Ok E, et al. **Clin Nephrol** 1996 May;45(5):361–2

Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Saatçi U, et al. **Eur J Pediatr** 1997 Aug; 156(8):619–23

Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease [see comments] Lovat LB, et al. **Gastroenterology** 1997 Apr;112(4):1362–5. Comment in: Gastroenterology 1997 Aug;113(2):731.

Secondary amyloidosis following juvenile chronic arthritis. Sarkar B, et al. **Indian Pediatr** 1996 Feb;33(2):125–7

Upper extremity musculoskeletal manifestations of dialysis-associated amyloidosis. Fitzpatrick DC, et al. **Iowa Orthop J** 1996;16:135–8 (28 ref.)

Performance characteristics of a dialysis-related amyloidosis questionnaire. Chertow GM, et al. **J Am Soc Nephrol** 1996 Aug;7(8):1235–40

Beta 2-microglobulin amyloidosis in chronic dialysis patients: a case report and review of the literature. Farrell J, et al. **J Am Soc Nephrol** 1997 Mar;8(3):509–14 (26 ref.)

Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. Mourad G, et al. **J Am Soc Nephrol** 1996 May;7(5):798–804

Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. Couce M, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1267–72

Renal amyloidosis complicating Crohn's disease. Case report and review of the literature. Efstratiadis G, et al. **J Clin Gastroenterol** 1996 Jun;22(4):308–10

The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. Miyata T, et al. **J Clin Invest** 1996 Sep 1;98(5):1088–94

Light chain myeloma with oro-pharyngeal amyloidosis presenting as bulbar paralysis. Finsterer J, et al. **J Neurol Sci** 1997 Apr 15;147(2):205–8

Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. Gratacos J, et al. **J Rheumatol** 1997 May; 24(5):912–5

Giant cell (temporal) arteritis and secondary renal amyloidosis: report of 2 cases. Monteagudo M, et al. **J Rheumatol** 1997 Mar;24(3):605–7

Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Hou FF, et al. **Kidney Int** 1997 May; 51(5):1514–9

Dialysis-related amyloidosis of the tongue in long-term hemodialysis patients. Matsuo K, et al. **Kidney Int** 1997 Sep;52(3):832–8

Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis. Niwa T, et al. **Kidney Int** 1996 Oct; 50(4):1303–9

Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Migita K, et al. **Lab Invest** 1996 Sep;75(3):371–5

Renal-cell carcinoma [letter; comment] Grateau G, et al. **N Engl J Med** 1997 Mar 13;336(11):809–10; discussion 810–1. Comment on: N Engl J Med 1996 Sep 19;335(12):865–75.

Current concepts on the pathogenesis of systemic amyloidosis. Bellotti V, et al. **Nephrol Dial Transplant** 1996; 11 Suppl 9:53–62 (117 ref.)

Dialysis amyloidosis: clinical aspects and therapeutic approach. Brancaccio D, et al. **Nephrol Dial Transplant** 1996;11 Suppl 3:102–5 (22 ref.)

Dialysis-related amyloidosis: visceral involvement and protein constituents. Campistol JM, et al. **Nephrol Dial Transplant** 1996;11 Suppl 3:142–5 (44 ref.)

beta 2-microglobulin and amyloidosis: who is at risk? Davison AM. **Nephrol Dial Transplant** 1995;10 Suppl 10:48–51 (22 ref.)

Does dialysis-related amyloidosis regress after transplantation? [editorial] Jadoul M, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):655–7 (14 ref.)

Prevalence of dialysis-related amyloidosis in diabetic patients. Diabetes Amyloid Study Group. Lehnert H, et al. **Nephrol Dial Transplant** 1996 Oct;11(10):2004–7

New aspects in the pathogenesis of dialysis-related amyloidosis: role of beta 2-microglobulin modified with advanced glycation end products in bone and joint destruction. Miyata T, et al. **Nephrol Dial Transplant** 1996; 11 Suppl 2:140–3 (17 ref.)

Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis. Miyata T, et al. **Nephrol Dial Transplant** 1996; 11 Suppl 3:86–90 (37 ref.)

Vascular renal AA amyloidosis in adult Still's disease. Rivera F, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1714–6

Diagnostic value of bone marrow biopsy in patients with AA-type renal amyloidosis secondary to ankylosing spondylitis [letter; comment] Sungur C, et al. **Nephrol Dial Transplant** 1996 Dec;11(12):2520–1. Comment on: Nephrol Dial Transplant 1996 Jun;11(6):1172–5.

beta 2-Microglobulin amyloidosis: effect of ESRF treatment modality and dialysis membrane type. Van Ypersele de Strihou C. **Nephrol Dial Transplant** 1996;11 Suppl 2:147–9

May colchicine therapy be of value in the prevention of dialysis amyloidosis? [letter] Arik N, et al. **Nephron** 1996; 73(2):365–6

A case of renal amyloidosis associated with hepatic adenoma: the pathogenetic role of tumor necrosis factor-alpha. Shibasaki T, et al. **Nephron** 1997;75(3):350–3

Malignant lymphoma of mucosa associated lymphoid tissue: a new etiology of amyloidosis. Caulet S, et al. **Pathol Res Pract** 1995 Dec;191(12):1203–7

Renal, gastric and thyroidal amyloidosis due to familial Mediterranean fever. Kavukçu S, et al. **Pediatr Nephrol** 1997 Apr;11(2):210–2

Degradation of amyloid A precursor protein SAA by macrophage cell lines obtained from amyloid resistant and susceptible strains of mice. Ham D, et al. **Scand J Immunol** 1997 Apr;45(4):354–60

Hemodialysis-related amyloidosis of the sternoclavicular joint. Cameron EW, et al. **Skeletal Radiol** 1997 Jul; 26(7):428–30

Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Kelly JW. **Structure** 1997 May 15;5(5):595–600 (73 ref.)

[Type AA renal amyloidosis in sarcoidosis] Tchénio X, et al. **Rev Mal Respir** 1996 Dec;13(6):601–2 (Eng. Abstr.) **(Fre)**

[A case of necrotizing crescentic glomerulonephritis with arteritis due to secondary amyloidosis following rheumatoid arthritis] Watanabe M, et al. **Nippon Jinzo Gakkai Shi** 1997 May;39(4):421–5 (Eng. Abstr.) **(Jpn)**

[Amyloidosis secondary to bronchiectasis] Takeuchi S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 May; 34(5):601–4 (Eng. Abstr.) **(Jpn)**

[Hemodialysis-associated amyloidosis] Maeda K, et al. **Nippon Naika Gakkai Zasshi** 1996 Sep 10;85(9):1590–4 (14 ref.) **(Jpn)**

[A case of perforated appendix caused by secondary amyloidosis associated with rheumatoid arthritis] Kawashima I, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):569–72 **(Jpn)**

[Sézary syndrome associated with small intestinal amyloidosis] Takimoto Y, et al. **Rinsho Ketsueki** 1996 Dec; 37(12):1422–4 (Eng. Abstr.) **(Jpn)**

[A case of secondary amyloidosis in Hodgkin's disease] Bienia A, et al. **Pol Tyg Lek** 1996 May;51(19–22):297–8 (Eng. Abstr.) **(Pol)**

[Secondary amyloidosis as possible complication of psoriasis] Gemke GR, et al. **Klin Med (Mosk)** 1997;75(2):55–6 **(Rus)**

[Laryngeal amyloidosis and multiple myeloma: a case report] Lasso Luis O, et al. **An Otorrinolaringol Ibero Am** 1996; 23(5):511–24 (Eng. Abstr.) **(Spa)**

GENETICS

Presenilin-1 polymorphism and hereditary cerebral hemorrhage with amyloidosis, Dutch type. Bornebroek M, et al. **Ann Neurol** 1997 Jul;42(1):108–10

Monoclonal origin of localised orbital amyloidosis detected by molecular analysis. Pasternak S, et al. **Br J Ophthalmol** 1996 Nov;80(11):1013–7 (33 ref.)

Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): I—A review of clinical, radiologic and genetic aspects. Bornebroek M, et al. **Brain Pathol** 1996 Apr;6(2):111–4 (43 ref.)

The molecular pathology of hereditary cystatin C amyloid angiopathy causing brain hemorrhage. Olafsson I, et al. **Brain Pathol** 1996 Apr;6(2):121–6 (45 ref.)

A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. Seri M, et al.

Clin Genet 1997 Feb;51(2):86–90

Polymorphism of acute-phase serum amyloid A isoforms and amyloid resistance in wild-type Mus musculus czech. Cathcart ES, et al. **Clin Immunol Immunopathol** 1996 Oct; 81(1):22–6

Tissue distribution and levels of gelsolin mRNA in normal individuals and patients with gelsolin-related amyloidosis. Paunio T, et al. **FEBS Lett** 1997 Apr 7;406(1-2):49–55

In vitro expression analysis shows that the secretory form of gelsolin is the sole source of amyloid in gelsolin-related amyloidosis. Kangas H, et al. **Hum Mol Genet** 1996 Sep; 5(9):1237–43

Screening and biochemical characterization of transthyretin variants in the Portuguese population. Alves IL, et al. **Hum Mutat** 1997;9(3):226–33

Transthyretin ILE20, a new variant associated with late-onset cardiac amyloidosis. Jacobson DR, et al. **Hum Mutat** 1997;9(1):83–5

Familial amyloidosis in one Chinese family: clinical, immunological, and molecular genetic analysis. Chou CT, et al. **J Intern Med** 1997 Apr;241(4):327–31

RET mutation screening in familial cutaneous lichen amyloidosis and in skin amyloidosis associated with multiple endocrine neoplasia. Hofstra RM, et al. **J Invest Dermatol** 1996 Aug;107(2):215–8

Genetic heterogeneity of familial primary cutaneous amyloidosis: lack of evidence for linkage with the chromosome 10 pericentromeric region in Chinese families. Lee DD, et al. **J Invest Dermatol** 1996 Jul;107(1):30–3

Ultrastructural immunolabelling of amyloid fibrils in acquired and hereditary amyloid neuropathies. Adams D, et al. **J Neurol** 1996 Jan;243(1):63–7

Detection of three transthyretin gene mutations in familial amyloidotic polyneuropathy by analysis of DNA extracted from formalin-fixed and paraffin-embedded tissues. Date Y, et al. **J Neurol Sci** 1997 Sep 10;150(2):143–8

Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans [see comments] Jacobson DR, et al. **N Engl J Med** 1997 Feb 13; 336(7):466–73. Comment in: N Engl J Med 1997 Feb 13;336(7):502–4.

Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis [see comments] Booth DR, et al. **Nature** 1997 Feb 27;385(6619):787–93. Comment in: Nature 1997 Feb 27;385(6619):773, 775.

Amyloid fibrils. Mutations make enzyme polymerize [news; comment] Perutz MF. **Nature** 1997 Feb 27;385(6619):773, 775. Comment on: Nature 1997 Feb 27;385(6619):787–93.

Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene. Herrick MK, et al. **Neurology** 1996 Oct;47(4):988–92

The molecular basis of renal amyloidosis in Irish-American and Polish-Canadian kindreds. Uemichi T, et al. **QJM** 1996 Oct;89(10):745–50

Molecular basis for amyloidosis related to hereditary brain hemorrhage. Abrahamson M. **Scand J Clin Lab Invest Suppl** 1996;226:47–56 (44 ref.)

Transthyretin Ile 122 and cardiac amyloidosis in African-Americans. 2 case reports. Jacobson DR, et al. **Tex Heart Inst J** 1997;24(1):45–52

[Clinical characteristics of Hungarian-type familial meningo-cerebrovascular amyloidosis] Garzuly F. **Orv Hetil** 1996 Oct 27;137(43):2393–9 (50 ref.) (Eng. Abstr.) **(Hun)**

[The effect of a water-cooled vest on heat intolerance in a patient with anhidrosis due to familial amyloidosis of Finnish type] Ohnishi A, et al. **Rinsho Shinkeigaku** 1996 Oct;36(10):1183–5 (Eng. Abstr.) **(Jpn)**

[Difficulties in the diagnosis of hereditary familial amyloidosis] Anokhin IM, et al. **Ter Arkh** 1995;67(12):56–7 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Nodular localized cutaneous amyloidosis: detection of monoclonality of infiltrating plasma cells by polymerase chain reaction. Hagari Y, et al. **Br J Dermatol** 1996 Oct; 135(4):630–3

Macular amyloidosis [letter] Mattheou-Vakali G, et al. **Br J Dermatol** 1996 Sep;135(3):489–91

Erosive amyloidosis of the wrist and knee associated with oligoclonal bands. Bukhari M, et al. **Br J Rheumatol** 1997 Apr;36(4):494–7

Primary localized amyloidosis of the eyelid: two cases of immunoglobulin light chain-derived proteins, subtype lambda V respectively lambda VI. Olsen KE, et al. **Clin Exp Immunol** 1996 Nov;106(2):362–6 (27 ref.)

IgE lambda monoclonal gammopathy and amyloidosis. Jako JM, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):415–21 (49 ref.)

Identification of lambda light chain amyloid in eight canine and two feline extramedullary plasmacytomas. Platz SJ, et al. **J Comp Pathol** 1997 Jan;116(1):45–54

Increased acute-phase response and renal amyloidosis in aged CD2-fas-transgenic mice. Hsu HC, et al. **J Immunol** 1997 Jun 15;158(12):5988–96

Immunohistochemical study with anti-advanced glycation end-products antibody in murine amyloidosis. Hoshii Y, et al. **Pathol Int** 1996 Oct;46(10):738–42

Localized amyloidosis of the seminal vesicle: identification of lactoferrin immunoreactivity in the amyloid material. Tsutsumi Y, et al. **Pathol Int** 1996 Jul;46(7):491–7

Degradation of amyloid A precursor protein SAA by macrophage cell lines obtained from amyloid resistant and susceptible strains of mice. Ham D, et al. **Scand J Immunol** 1997 Apr;45(4):354–60

Generalised AA-amyloidosis in a bat (Pipistrellus pipistrellus). Gruber AD, et al. **Vet Pathol** 1996 Jul; 33(4):428–30

METABOLISM

Oxidative stress is found in amyloid deposits in systemic amyloidosis. Ando Y, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):497–502

Alpha 2-macroglobulin protects some of the protein constituents of dialysis-associated amyloidosis from protease degradation. Gouin-Charnet A, et al. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):48–51

Accumulation of pro-apolipoprotein A-II in mouse senile amyloid fibrils. Higuchi K, et al. **Biochem J** 1997 Aug 1; 325 (Pt 3):653–9

Progressive dementia and leucoencephalopathy as the initial presentation of late onset hereditary cystatin-C amyloidosis. Clinicopathological presentation of two cases. Sveinbjörnsdóttir S, et al. **J Neurol Sci** 1996 Sep 1; 140(1-2):101–8

Association of vascular amyloid beta and cells of the mononuclear phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer disease. Maat-Schieman ML, et al. **J Neuropathol Exp Neurol** 1997 Mar;56(3):273–84

Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease. Chargé SB, et al. **J Pathol** 1996 Aug;179(4):443–7

Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. Jadoul M, et al. **Kidney Int** 1997 Jun;51(6):1928–32

Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Niwa T, et al. **Kidney Int** 1997 Jan; 51(1):187–94

Three-dimensional cultures of keratinocytes and an application to in vitro-amyloid production of cutaneous amyloidosis. Horiguchi Y, et al. **Microsc Res Tech** 1997 Aug 15;38(4):387–93

Elevated pentosidine content in amyloid deposits and in insoluble amyloid fibrils from patients with beta 2-microglobulin amyloidosis [letter] Argilés A, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2371–2

Beta-2-microglobulin-associated amyloidosis. Floege J, et al. **Nephron** 1996;72(1):9–26

Beta2-Microglobulin dialysis amyloid and its formation: role of 3-deoxyglucosone and advanced glycation end products [editorial] Niwa T. **Nephron** 1997;76(4):373–91 (238 ref.)

Factors secreted by activated microglia and monocytes reduce amyloidogenesis in vascular smooth muscle cells. Frackowiak J, et al. **Neuroreport** 1997 Jul 7;8(9–10):2259–63

Ultrastructural evidence for colocalization of kappa light chain- and beta 2-microglobulin-derived amyloids using double labelling immunogold electron microscopy. Takahashi M, et al. **Virchows Arch** 1996 Dec;429(6):383–8

[Levels of procollagen III in bronchial alveolar lavage fluid in patients with sarcoidosis] Ziora D, et al. **Pneumonol Alergol Pol** 1997;65(5–6):343–7 (Eng. Abstr.) **(Pol)**

MORTALITY

Hepatic amyloidosis: clinical appraisal in 77 patients. Gertz MA, et al. **Hepatology** 1997 Jan;25(1):118–21

PATHOLOGY

Macular posterior pigmentary incontinence: its relation to macular amyloidosis and notalgia paresthetica [see comments] Westermark P, et al. **Acta Derm Venereol** 1996 Jul;76(4):302–4. Comment in: Acta Derm Venereol 1997 Mar;77(2):164.

Immunohistochemical characterization of amyloid fibril precursors in renal tissue. Wągrowska-Danilewicz M, et al. **Acta Histochem** 1996 Jul;98(3):301–8

Distribution of amyloid deposits in the cerebral white matter of the Alzheimer's disease brain: relationship to blood vessels. Iwamoto N, et al. **Acta Neuropathol (Berl)** 1997 Apr;93(4):334–40

Endomyocardial biopsy-proven light chain amyloidosis (AL) without echocardiographic features of infiltrative cardiomyopathy. Gertz MA, et al. **Am J Cardiol** 1997 Jul 1;80(1):93–5

Solitary "amyloid ulcer" localized in the sigmoid colon without evidence of systemic amyloidosis. Hirata K, et al. **Am J Gastroenterol** 1997 Feb;92(2):356–7 (11 ref.)

Amyloidoma of bone, a plasma cell/plasmacytoid neoplasm. Report of three cases and review of the literature. Pambuccian SE, et al. **Am J Surg Pathol** 1997 Feb; 21(2):179–86 (55 ref.)

Primary amyloidosis of the bladder: a case report. Tan SM, et al. **Ann Acad Med Singapore** 1996 Jul;25(4):612–3

A hyperpigmented, rippled eruption in a Hispanic woman. Macular amyloidosis. Lines RR 3rd, et al. **Arch Dermatol** 1997 Mar;133(3):383, 386

Nodular amyloidosis of the lip mimicking an infiltrating neoplasm. Yu LL, et al. **Australas J Dermatol** 1997 May; 38(2):91–2

Pathological aging in Africans: a benign form of cerebral amyloidosis vs. pre-clinical Alzheimer's disease? [editorial; comment] Dickson DW. **Brain Pathol** 1996 Apr;6(2):107–8 . Comment on: Brain Pathol 1996 Apr;6(2):101–7.

Prion protein amyloidosis. Ghetti B, et al. **Brain Pathol** 1996 Apr;6(2):127–45 (90 ref.)

Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): II--A review of histopathological aspects. Maat-Schieman ML, et al. **Brain Pathol** 1996 Apr; 6(2):115–20 (54 ref.)

The molecular pathology of hereditary cystatin C amyloid angiopathy causing brain hemorrhage. Olafsson I, et al. **Brain Pathol** 1996 Apr;6(2):121–6 (45 ref.)

Clinicohistopathological findings of gelatinous droplike corneal dystrophy among Asians. Li S, et al. **Cornea** 1996 Jul;15(4):355–62

Bilateral plantar amyloidosis: a unique presentation of localized cutaneous amyloidosis. Helm TN, et al. **Cutis** 1997 Mar;59(3):142–4

Cytodiagnosis of amyloid deposition within the breast. Gupta RK, et al. **Cytopathology** 1996 Apr;7(2):136–40

Localized primary amyloidosis of axillary lymph nodes. Lanzafame S, et al. **Histopathology** 1996 Apr;28(4):369–71 (6 ref.)

The classification of amyloid deposits in clinicopathological practice. Röcken C, et al. **Histopathology** 1996 Oct; 29(4):325–35

Histomorphological patterns of renal amyloidosis: a correlation between histology and chemical type of amyloidosis. Looi LM, et al. **Hum Pathol** 1997 Jul; 28(7):847–9

Renal amyloidosis--a clinicopathologic study. Shah VB, et al. **Indian J Pathol Microbiol** 1996 Jul;39(3):179–85

Primary localized cutaneous amyloidosis: a clinicopathologic study from Saudi Arabia. al-Ratrout JT, et al. **Int J Dermatol** 1997 Jun;36(6):428–34

Isolated amyloidosis of the colon. Threlkeld C, et al. **J Am Osteopath Assoc** 1996 Mar;96(3):188–90

Disseminated superficial porokeratosis with amyloid deposition. Yasuda K, et al. **J Dermatol** 1996 Feb; 23(2):111–5

Ultrastructural immunolabelling of amyloid fibrils in acquired and hereditary amyloid neuropathies. Adams D, et al. **J Neurol** 1996 Jan;243(1):63–7

Progressive dementia and leucoencephalopathy as the initial presentation of late onset hereditary cystatin-C amyloidosis. Clinicopathological presentation of two cases. Sveinbjörnsdóttir S, et al. **J Neurol Sci** 1996 Sep 1; 140(1-2):101–8

Fibrillary deposits: amyloids and tactoids. Looi LM. **Malays J Pathol** 1995 Jun;17(1):1–10 (54 ref.)

A new form of primary, localized, corneal amyloidosis: a case report with confocal microscopy. Kaufman SC, et al. **Metab Pediatr Syst Ophthalmol** 1995;18(1-4):1–4

Primary amyloid tumor of the breast: a case report and review of the literature. Luo JH, et al. **Mod Pathol** 1997 Jul;10(7):735–8 (18 ref.)

Complete clinical remission and subsequent relapse of bronchiectasis-related (AA) amyloid induced nephrotic syndrome. Goldsmith DJ, et al. **Nephron** 1996;74(3):572–6

Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology [editorial; comment] Zlokovic B. **Neurobiol Dis** 1997; 4(1):23–6 (19 ref.). Comment on: Neurobiol Dis 1997 ;4(1):27–34.

Localized amyloidosis of the seminal vesicle: identification of lactoferrin immunoreactivity in the amyloid material. Tsutsumi Y, et al. **Pathol Int** 1996 Jul;46(7):491–7

Amyloid tumors of the lung--an immunocytoma? Ihling C, et al. **Pathol Res Pract** 1996 May;192(5):446–52

Generalized AA-amyloidosis in Siamese and Oriental cats. van der Linde-Sipman JS, et al. **Vet Immunol Immunopathol** 1997 May;56(1-2):1–10

Generalised AA-amyloidosis in a bat (Pipistrellus pipistrellus). Gruber AD, et al. **Vet Pathol** 1996 Jul; 33(4):428–30

Visceral organ involvement and extracellular matrix changes in beta 2-microglobulin amyloidosis--a comparative study with systemic AA and AL amyloidosis. Ohashi K, et al. **Virchows Arch** 1997 Jun;430(6):479–87

Senile amyloidoses of the pituitary and adrenal glands. Morphological and statistical investigations. Röcken C, et al. **Virchows Arch** 1996 Nov;429(4–5):293–9

[Fibrillary glomerulopathy. Amyloidosis and non-amyloidosis] Wullbrand A, et al. **Dtsch Med Wochenschr** 1997 Mar 7;122(10):302–8 (71 ref.) **(Ger)**

[Laryngeal amyloidosis: a case report] Motta M, et al. **Acta Otorhinolaryngol Ital** 1996 Oct;16(5):455–9 (Eng. Abstr.) **(Ita)**

[A case of primary localized amyloidosis of the urinary bladder] Takahashi A, et al. **Hinyokika Kiyo** 1996 Nov; 42(11):903–5 (Eng. Abstr.) **(Jpn)**

[Histopathological study of valvular deposits of amyloid protein in cardiac amyloidosis] Hisaki R, et al. **J Cardiol** 1996;27 Suppl 2:31–7; discussion 38 (Eng. Abstr.) **(Jpn)**

[Anatomo-clinical correlation. Case 1/96. Instituto do Coração do Hospital das Clínicas FMUSP (clinical conference)] **Arq Bras Cardiol** 1996 Mar;66(3):161–5 **(Por)**

[Nephropathic variant of AL-amyloidosis] Siliaeva NF, et al. **Arkh Patol** 1997 May-Jun;59(3):60–2 (Eng. Abstr.) **(Rus)**

[The cellular aspects of amyloid angiopathies of the iris in open-angle glaucoma] Ziangirova GG, et al. **Izv Akad Nauk Ser Biol** 1997 Mar-Apr;(2):218-23 (Eng. Abstr.) **(Rus)**

[Heart block in a 75-year-old patient (clinical conference)] Abadal L, et al. **Med Clin (Barc)** 1996 Oct 5;107(11):429-36 **(Spa)**

PHYSIOPATHOLOGY

Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): I--A review of clinical, radiologic and genetic aspects. Bornebroek M, et al. **Brain Pathol** 1996 Apr;6(2):111-4 (43 ref.)

Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study. Sasaki A, et al. **Brain Res** 1997 May 2;755(2):193-201

Thyroid dysfunction in patients with amyloid goitre. Kimura H, et al. **Clin Endocrinol (Oxf)** 1997 Jun;46(6):769-74

Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease [see comments] Lovat LB, et al. **Gastroenterology** 1997 Apr;112(4):1362-5. Comment in: Gastroenterology 1997 Aug;113(2):731.

Low voltage, Q waves, and congestive heart failure. Hancock EW. **Hosp Pract (Off Ed)** 1997 Jun 15;32(6):21-2

Renal amyloidosis--a clinicopathologic study. Shah VB, et al. **Indian J Pathol Microbiol** 1996 Jul;39(3):179-85

Transmissible cerebral amyloidosis. Brown P. **J Neural Transm Suppl** 1996;47:219-29 (38 ref.)

The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis [see comments] Terry RD. **J Neuropathol Exp Neurol** 1996 Oct;55(10):1023-5 (25 ref.) . Comment in: J Neuropathol Exp Neurol 1997 Feb;56(2):213. Comment in: J Neuropathol Exp Neurol 1997 Feb;56(2):214-5. Comment in: J Neuropathol Exp Neurol 1997 Feb;56(2):216. Comment in: J Neuropathol Exp Neurol 1997 Feb;56(2);217.

Primary systemic amyloidoses: possible new directions in prophylaxis and therapy. Oken RJ. **Med Hypotheses** 1996 Jun;46(6):505-6

Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology [editorial; comment] Zlokovic B. **Neurobiol Dis** 1997; 4(1):23-6 (19 ref.). Comment on: Neurobiol Dis 1997 ;4(1):27-34.

Efficient in vitro cleavage of mouse acute phase serum amyloid A mRNA mediated by a synthetic hammerhead ribozyme. Gaughan DJ, et al. **Scand J Immunol** 1997 Jul; 46(1):51-8

[Reactive amyloidosis: advances in understanding its basic mechanisms] Yakar S, et al. **Harefuah** 1996 May 15; 130(10):688-93 (45 ref.) **(Heb)**

[Laryngeal amyloidosis and multiple myeloma: a case report] Lasso Luis O, et al. **An Otorrinolaringol Ibero Am** 1996; 23(5):511-24 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Brefeldin A inhibits experimentally induced AA amyloidosis. Stenstad T, et al. **J Rheumatol** 1996 Jan;23(1):93-100

May colchicine therapy be of value in the prevention of dialysis amyloidosis? [letter] Arik N, et al. **Nephron** 1996; 73(2):365-6

RADIOGRAPHY

Primary isolated urethral amyloidosis. Noone TC, et al. **Abdom Imaging** 1997 Jul-Aug;22(4):448-9

Calcified amyloidoma of the larynx. Rodríguez-Romero R, et al. **AJNR Am J Neuroradiol** 1996 Sep;17(8):1491-3

Amyloidosis of the thyroid [letter] Chong VF. **AJR Am J Roentgenol** 1997 Mar;168(3):845-6

Primary pulmonary amyloidosis as a cause of interlobular septal thickening [letter] Geusens EA, et al. **AJR Am J Roentgenol** 1997 Apr;168(4):1116-7

Thoracic cross-sectional imaging of amyloidosis. Pickford HA, et al. **AJR Am J Roentgenol** 1997 Feb;168(2):351-5

The case of the torpid thoracic tumor. Leu CY, et al. **Chest** 1997 Aug;112(2):535-7

Benign pulmonary lymphocytic infiltration and amyloidosis: computed tomographic and pathologic features in three cases. Desai SR, et al. **J Thorac Imaging** 1997 Jul; 12(3):215-20

[A patient with multiple intrapulmonary coin lesions (clinical conference)] Hessling J, et al. **Med Klin** 1996 Sep 15; 91(9):570-3 **(Ger)**

RADIONUCLIDE IMAGING

Technetium-99m (Tc-99m) diphosphono-propanedicarboxylic acid bone tracer uptake and Tc-99m sestamibi distribution in cardiac amyloidosis--a case report. Low YH, et al. **Ann Acad Med Singapore** 1995 Nov;24(6):898-901

Scan findings of various myocardial SPECT agents in a case of amyloid polyneuropathy with suspected myocardial involvement. Arbab AS, et al. **Ann Nucl Med** 1997 May; 11(2):139-41

Tc-99m DMSA (V) uptake in multiorgan amyloidosis. Bhatnagar A, et al. **Clin Nucl Med** 1996 Sep;21(9):733-4

Scintigraphy using iodine 123-labeled serum amyloid P component in ten patients with secondary AA type amyloidosis. A descriptive study [letter] Feutrie ML, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):866-9

SURGERY

The efficacy of dermabrasion in the treatment of nodular amyloidosis. Lien MH, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 2):315-6

Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Dubrey SW, et al. **Transplantation** 1997 Jul 15;64(1):74-80

[Primary localized amyloidosis of the urinary bladder: a case report] Maeda N, et al. **Hinyokika Kiyo** 1997 Jan;43(1):53-5 (Eng. Abstr.) **(Jpn)**

[Anesthetic implications of amyloidosis (letter)] Suárez-Delgado JM, et al. **Rev Esp Anestesiol Reanim** 1996 Dec;43(10):380 **(Spa)**

THERAPY

Effectiveness of cardiac transplantation for primary (AL) cardiac amyloidosis. Pelosi F Jr, et al. **Am J Cardiol** 1997 Feb 15;79(4):532-5

Normalization of plasma factor X levels in amyloidosis after plasma exchange. Beardell FV, et al. **Am J Hematol** 1997 Jan;54(1):68-71

Long-term clinical evaluation of an adsorbent column (BM-01) of direct hemoperfusion type for beta 2-microglobulin on the treatment of dialysis-related amyloidosis. Gejyo F, et al. **Artif Organs** 1995 Dec; 19(12):1222-6

Atrioventricular sequential pacing in cardiac amyloidosis: an acute Doppler echocardiographic and catheterization hemodynamic study. Mathew V, et al. **Clin Cardiol** 1997 Aug;20(8):723-5

Advances in the treatment of plasma cell diseases. Comenzo RL. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):67-70, 73-4, 79-84 passim (11 ref.)

Treatment of beta 2-microglobulin amyloidosis by extracorporeal therapies other than haemodialysis, by medication and by surgery. Drüeke TB. **Nephrol Dial Transplant** 1996;11 Suppl 2:150-3 (25 ref.)

Does dialysis-related amyloidosis regress after transplantation? [editorial] Jadoul M, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):655-7 (14 ref.)

Clinical and therapeutic aspects of renal amyloidosis. Schena FP, et al. **Nephrol Dial Transplant** 1996;11 Suppl 9:63-8 (27 ref.)

Dialysis treatment in children with amyloidosis due to juvenile rheumatoid arthritis. Sieniawska M, et al. **Turk J Pediatr** 1996 Jan-Mar;38(1):59-66

[Amyloidosis of a coral reef infrarenal aorta] Combe J, et al. **J Mal Vasc** 1997;22(1):43-7 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Sonographic findings in patients with dialysis-related amyloidosis [letter; comment] Malghem J, et al. **AJR Am J Roentgenol** 1997 Mar;168(3):844-5. Comment on: AJR Am J Roentgenol 1996 Jan;166(1):153-6.

QT interval in cardiac amyloidosis [see comments] Parthenakis FI, et al. **Clin Cardiol** 1996 Jan;19(1):51-4. Comment in: Clin Cardiol 1996 May;19(5):A22, 442.

Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Dubrey SW, et al. **Heart** 1997 Jul;78(1):74-82

Clinical value of a new Doppler index in cardiac amyloidosis [letter; comment] Reisinger J, et al. **J Am Coll Cardiol** 1997 Feb;29(2):471-2. Comment on: J Am Coll Cardiol 1996 Sep;28(3):658-64.

[Ultrasound diagnosis of soft tissue changes in dialysis-associated amyloidosis] Rapp-Bernhardt U, et al. **Ultraschall Med** 1997 Apr;18(2):91-4 (Eng. Abstr.) **(Ger)**

[Isolated cardiac amyloidosis. Presentation of a clinical case] Tiberti G, et al. **Minerva Cardioangiol** 1997 Mar;45(3):115-9 (Eng. Abstr.) **(Ita)**

URINE

Decreased excretion of urine glycosaminoglycans as marker in renal amyloidosis. Tencer J, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1161-6

VETERINARY

Conjunctival and nasal amyloidosis in a horse. Mould JR, et al. **Equine Vet J Suppl** 1990 Sep;(10):8-11

Identification of lambda light chain amyloid in eight canine and two feline extramedullary plasmacytomas. Platz SJ, et al. **J Comp Pathol** 1997 Jan;116(1):45-54

Renal amyloidosis in related English foxhounds. Mason NJ, et al. **J Small Anim Pract** 1996 Jun;37(6):255-60

Characterization of serum amyloid A protein mRNA expression and secondary amyloidosis in the domestic duck. Guo JT, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10; 93(25):14548-53

Generalized AA-amyloidosis in Siamese and Oriental cats. van der Linde-Sipman JS, et al. **Vet Immunol Immunopathol** 1997 May;56(1-2):1-10

Light microscopic, immunohistochemical, and electron microscopic features of amyloid arthropathy in chickens. Peperkamp NH, et al. **Vet Pathol** 1997 Jul;34(4):271-8

Systemic amyloidosis in cats [letter] Irwin PJ. **Vet Rec** 1996 Nov 30;139(22):552

VIROLOGY

Detection of Epstein-Barr virus in primary cutaneous amyloidosis. Chang YT, et al. **Br J Dermatol** 1997 Jun; 136(6):823-6

AMYLOPECTIN

Development of tricalcium phosphate/amylopectin paste combined with recombinant human transforming growth factor beta 1 as a bone defect filler. Ongpipattanakul B, et al. **J Biomed Mater Res** 1997 Sep 5;36(3):295-305

CHEMISTRY

Diffusion of mixed micelles of bile salt-lecithin in amylopectin gels: a Fourier transform infrared microspectroscopy approach. Sun L, et al. **Biophys Chem** 1996 Oct 30;61(2-3):143-50

The effects of ageing of amylopectin gels on the diffusion of BSA. Sun L, et al. **Int J Biol Macromol** 1997 Jun; 20(3):205-7

METABOLISM

Structure of the cyclic glucan produced from amylopectin by Bacillus stearothermophilus branching enzyme. Takata H, et al. **Carbohydr Res** 1996 Dec 13;295:91-101

Resistant starch as energy. Behall KM, et al. **J Am Coll Nutr** 1996 Jun;15(3):248-54

Soluble amylose cornstarch is more digestible than soluble amylopectin potato starch in rats. Zhou X, et al. **J Nutr** 1997 Jul;127(7):1349-56

AMYLOPECTIN BRANCHING ENZYME see **1,4-ALPHA-GLUCAN BRANCHING ENZYME**

AMYLOPECTINOSIS see **GLYCOGEN STORAGE DISEASE TYPE IV**

AMYLOSE

ANALOGS & DERIVATIVES

Enantiomeric resolution by HPLC of axial chiral amides using amylose tris[(S)-1-phenylethylcarbamate]. Cass QB, et al. **Chirality** 1997;9(2):109-12

ANALYSIS

Near-infrared diffuse reflectance spectroscopic analysis of the amounts of moisture, protein, starch, amylose, and tannin in buckwheat flours. Hong JH, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Aug;42(4):359-66

CHEMISTRY

Preparation of silica gel-bonded amylose through enzyme-catalyzed polymerization and chiral recognition ability of its phenylcarbamate derivative in HPLC. Enomoto N, et al. **Anal Chem** 1996 Sep 1;68(17):2798-804

The chemical structure of amylose and amylopectin fractions of starch from tobacco leaves during development and diurnally-nocturnally. Matheson NK. **Carbohydr Res** 1996 Mar 18;282(2):247-62

Molecular weight distribution of amylose fractions obtained by aqueous leaching of corn starch. Roger P, et al. **Int J Biol Macromol** 1996 Jul;19(1):51-61

GENETICS

Molecular analysis of the intergenic region of the duplicated Amy genes of Drosophila melanogaster and Drosophila teissieri. Okuyama E, et al. **J Mol Evol** 1997 Jul;45(1):32-42

METABOLISM

Resistant starch as energy. Behall KM, et al. **J Am Coll Nutr** 1996 Jun;15(3):248-54

Cyclodextrins are not the major cyclic alpha-1,4-glucans produced by the initial action of cyclodextrin glucanotransferase on amylose. Terada Y, et al. **J Biol Chem** 1997 Jun 20;272(25):15729-33

Soluble amylose cornstarch is more digestible than soluble amylopectin potato starch in rats. Zhou X, et al. **J Nutr** 1997 Jul;127(7):1349-56

PHARMACOLOGY

Breath-hydrogen production and amylose content of the diet. Behall KM, et al. **Am J Clin Nutr** 1997 Jun;65(6):1783-9

Effect of high-amylose starch and oat bran on metabolic variables and bowel function in subjects with hypertriglyceridemia. Noakes M, et al. **Am J Clin Nutr** 1996 Dec;64(6):944-51

Fecal numbers of bifidobacteria are higher in pigs fed Bifidobacterium longum with a high amylose cornstarch than with a low amylose cornstarch. Brown I, et al. **J Nutr** 1997 Sep;127(9):1822-7

A high amylose (amylomaize) starch raises proximal large bowel starch and increases colon length in pigs. Topping DL, et al. **J Nutr** 1997 Apr;127(4):615-22

Effects of amylose and wheat bran on the levels of blood serum urea nitrogen (BUN), other blood parameters, growth and fecal characteristics in rats. Mongeau R, et al. **Plant Foods Hum Nutr** 1995 Sep;48(2):95-105

AMYOPLASIA CONGENITA

AMYOPLASIA CONGENITA see **ARTHROGRYPOSIS**

AMYOTONIA CONGENITA see **NEUROMUSCULAR DISEASES**

AMYOTROPHIC LATERAL SCLEROSIS

Paraneoplastic primary lateral sclerosis and amyotrophic lateral sclerosis [comment] Rowland LP. **Ann Neurol** 1997 Jun;41(6):703–5 (32 ref.). Comment on: Ann Neurol 1997 Jun;41(6):722–30.

Motor neuron disease: etiology, pathogenesis and treatment—a review. Donohoe DJ, et al. **Ir J Med Sci** 1996 Jul–Sep;165(3):200–9 (91 ref.)

Amyotrophic lateral sclerosis: from pathological mechanisms to patient care. Scarlato G. **J Neurol** 1997 May;244 Suppl 2:S1–2

Proceedings of the 6th International Symposium on Motor Neuron Disease and Amyotrophic Lateral Sclerosis. Dublin, Ireland, 30 October–1 November 1995. **J Neurol Sci** 1996 Aug;139 Suppl:vi, 1–141

Advances in ALS. Gutmann L, et al. **Neurology** 1996 Oct; 47(4 Suppl 2):S17–8

[Amyotrophic lateral sclerosis] **Wien Med Wochenschr** 1996; 146(9–10):181–220 **(Ger)**

BLOOD

Copper and zinc levels in familial amyotrophic lateral sclerosis patients with CuZnSOD gene mutations [letter] Radunović A, et al. **Ann Neurol** 1997 Jul;42(1):130–1

Relationship between respiratory failure and plasma noradrenaline levels in amyotrophic lateral sclerosis. Yamashita A, et al. **Clin Auton Res** 1997 Aug;7(4):173–7

Amyotrophic lateral sclerosis immunoglobulins increase intracellular calcium in a motoneuron cell line. Colom LV, et al. **Exp Neurol** 1997 Aug;146(2):354–60

Lead, cadmium, and selenium in the blood of patients with sporadic amyotrophic lateral sclerosis. Vinceti M, et al. **Ital J Neurol Sci** 1997 Apr;18(2):87–92

Serum Cu/Zn superoxide dismutase activity is reduced in sporadic amyotrophic lateral sclerosis patients. Cohen O, et al. **J Neurol Sci** 1996 Nov;143(1–2):118–20

Essential trace element alterations in amyotrophic lateral sclerosis. Kapaki E, et al. **J Neurol Sci** 1997 Apr 15; 147(2):171–5

Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amiotrophic lateral sclerosis patients. Oteiza PI, et al. **Neurochem Res** 1997 Apr;22(4):535–9

Amyotrophic lateral sclerosis immunoglobulins are ineffective in altering calcium influx through presynaptic voltage-sensitive calcium channels. Thomas MM, et al. **Neurol Res** 1997 Apr;19(2):129–34

Increased CSF glutamate following injection of ALS immunoglobulins. La Bella V, et al. **Neurology** 1997 May; 48(5):1270–2

CEREBROSPINAL FLUID

Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. Rosengren LE, et al. **J Neurochem** 1996 Nov;67(5):2013–8

Essential trace element alterations in amyotrophic lateral sclerosis. Kapaki E, et al. **J Neurol Sci** 1997 Apr 15; 147(2):171–5

Cerebrospinal fluid from amyotrophic lateral sclerosis has no effect on intracellular free calcium in cultured cortical neurons. Gredal O, et al. **Mol Chem Neuropathol** 1996 Oct–Dec;29(2–3):141–52

CLASSIFICATION

[Clinical classification of ALS patients based on the total course of ALS—proposal of respiratory motor paralysis-preceded type and its significance] Hayashi H, et al. **No To Shinkei** 1997 May;49(5):435–41 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Amyotrophic lateral sclerosis. Successful treatment of mucous plugging by mechanical insufflation–exsufflation. Hanayama K, et al. **Am J Phys Med Rehabil** 1997 Jul–Aug; 76(4):338–9

Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Aboussouan LS, et al. **Ann Intern Med** 1997 Sep 15;127(6):450–3

Coexistent entrapment neuropathies in patients with amyotrophic lateral sclerosis. Kothari MJ, et al. **Arch Phys Med Rehabil** 1996 Nov;77(11):1186–8

The clinical measurement of swallowing in health and in neurogenic dysphagia. **Dysphagia** 1996 Fall;11(4):270–1

Management of oral-pharyngeal dysphagia symptoms in amyotrophic lateral sclerosis. Strand EA, et al. **Dysphagia** 1996 Spring;11(2):129–39

Autonomic dysfunction and anemia in neurologic disorders. Ando Y, et al. **J Auton Nerv Syst** 1996 Nov 6;61(2):145–8

Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis. Abrahams S, et al. **J Neurol Neurosurg Psychiatry** 1997 May;62(5):464–72

Pick's disease with amyotrophic lateral sclerosis (ALS): report of two autopsy cases and literature review. Niizato K, et al. **J Neurol Sci** 1997 May 1;148(1):107–12 (9 ref.)

Spasmodic dysphonia symptoms as initial presentation of amyotrophic lateral sclerosis. Roth CR, et al. **J Voice** 1996 Dec;10(4):362–7

Acoustic analysis of voice in individuals with amyotrophic lateral sclerosis and perceptually normal vocal quality. Silbergleit AK, et al. **J Voice** 1997 Jun;11(2):222–31

Familial childhood primary lateral sclerosis with associated gaze paresis. Gascon GG, et al. **Neuropediatrics** 1995 Dec; 26(6):313–9

[Amyotrophic lateral sclerosis and cognition disorders. Neuropsychological study of a population of 26 patients] Dary-Auriol M, et al. **Rev Neurol (Paris)** 1997 May; 153(4):244–50 (Eng. Abstr.) **(Fre)**

[Amyotrophic lateral sclerosis in a patient with Waldenstrom's macroglobulinemia] Vannucci P, et al. **Minerva Med** 1997 Apr;88(4):167–70 (Eng. Abstr.) **(Ita)**

[A case of bilateral pneumothorax successfully treated with surgery associated with amyotrophic lateral sclerosis having been controlled with artificial ventilation] Morita H, et al. **Kyobu Geka** 1997 Jun;50(6):511–3 (Eng. Abstr.) **(Jpn)**

[A case of amyotrophic lateral sclerosis with apraxia of eyelid opening] Terakawa H, et al. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):757–8 **(Jpn)**

[Reappraisal of amyotrophic lateral sclerosis with dementia] Murakami N, et al. **Rinsho Shinkeigaku** 1995 Dec; 35(12):1560–2 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Dysphagia in amyotrophic lateral sclerosis—the mechanism and managements] Tayama N. **Rinsho Shinkeigaku** 1995 Dec;35(12):1557–9 (7 ref.) (Eng. Abstr.) **(Jpn)**

CONGENITAL

Coexistence of Huntington's disease and familial amyotrophic lateral sclerosis: case presentation. Rubio A, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):421–7 (41 ref.)

DIAGNOSIS

Relation of neuropsychological and magnetic resonance findings in amyotrophic lateral sclerosis: evidence for subgroups. Frank B, et al. **Clin Neurol Neurosurg** 1997 May; 99(2):79–86

Hypovitaminosis D and decreased bone mineral density in amyotrophic lateral sclerosis. Sato Y, et al. **Eur Neurol** 1997;37(4):225–9

Cognition, language, and speech in amyotrophic lateral sclerosis: a review. Strong MJ, et al. **J Clin Exp Neuropsychol** 1996 Apr;18(2):291–303 (70 ref.)

A self report measure of affective lability. Moore SR, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):89–93

A comparison of three measures of disease progression in ALS. Andres PL, et al. **J Neurol Sci** 1996 Aug;139 Suppl:64–70

The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its repercussions. Belsh JM, et al. **J Neurol Sci** 1996 Aug;139 Suppl:110–6

Motor neuron disease presenting with respiratory failure. de Carvalho M, et al. **J Neurol Sci** 1996 Aug;139 Suppl:117–22

Motor neuropathies mimicking amyotrophic lateral sclerosis/motor neuron disease. Evangelista T, et al. **J Neurol Sci** 1996 Aug;139 Suppl:95–8

Identification of brain metabolites by magnetic resonance spectroscopy in MND/ALS. Knight JM, et al. **J Neurol Sci** 1996 Aug;139 Suppl:104–9

Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. Moulard B, et al. **J Neurol Sci** 1996 Aug;139 Suppl:34–7

Serial MRI and SPECT in amyotrophic lateral sclerosis: a case report. Waragai M, et al. **J Neurol Sci** 1997 May 1; 148(1):117–20

The relative value of facial, glossal, and masticatory muscles in the electrodiagnosis of amyotrophic lateral sclerosis. Preston DC, et al. **Muscle Nerve** 1997 Mar;20(3):370–2

Reorganization of motor units in amyotrophic lateral sclerosis. Emeryk-Szajewska B, et al. **Neurol Neurochir Pol** 1996;30 Suppl 3:81–90

Diagnostic criteria in clinical trials. Brooke MH. **Neurology** 1996 Oct;47(4 Suppl 2):S67–9; discussion S70 (5 ref.)

Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Gredal O, et al. **Neurology** 1997 Apr; 48(4):878–81

Spinobulbar muscular atrophy can mimic ALS: the importance of genetic testing in male patients with atypical ALS. Parboosingh JS, et al. **Neurology** 1997 Aug; 49(2):568–72

[Magnetic resonance tomography of the brain in amyotrophic lateral sclerosis] Fazekas G, et al. **Wien Med Wochenschr** 1996;146(9–10):204–6 (Eng. Abstr.) **(Ger)**

[Multifocal motor neuropathy with conduction block—a clinico-neuropathologic case report] Urbanits S, et al. **Wien Med Wochenschr** 1996;146(9–10):206–9 (Eng. Abstr.) **(Ger)**

[Clinical aspects of amyotrophic lateral sclerosis] Zeitlhofer J. **Wien Med Wochenschr** 1996;146(9–10):182–5 (7 ref.) (Eng. Abstr.) **(Ger)**

[The diagnosis of amyotrophic lateral sclerosis supported by motor evoked potential and brain MRI studies] Matsunaga K, et al. **Rinsho Shinkeigaku** 1997 Mar;37(3):233–8 (Eng. Abstr.) **(Jpn)**

[Electrophysiologic assessment in motor neuron diseases] Espadaler-Gamissans JM. **Neurologia** 1996 Dec;11 Suppl 5:20–8 (34 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Gredal O, et al. **Acta Neurol Scand** 1997 Jul; 96(1):8–13

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Miller RG, et al. **Ann Neurol** 1996 Feb;39(2):256–60

Riluzole—what is its impact in our treatment and understanding of amyotrophic lateral sclerosis? [comment] Mitsumoto H. **Ann Pharmacother** 1997 Jun;31(6):779–81. Comment on: Ann Pharmacother 1997 Jun;31(6):738–44.

Riluzole: a new agent for amyotrophic lateral sclerosis [see comments] Wagner ML, et al. **Ann Pharmacother** 1997 Jun; 31(6):738–44 (51 ref.). Comment in: Ann Pharmacother 1997 Jun;31(6):779–81.

Riluzole and amyotrophic lateral sclerosis: did potential market size bias pharmaceutical research? [letter] Riggs JE, et al. **Arch Neurol** 1996 Nov;53(11):1093–4

Potential utility of rhIGF-1 in neuromuscular and/or degenerative disease. Vaught JL, et al. **Ciba Found Symp** 1996;196:18–27; discussion 27–38

Riluzole for amyotrophic lateral sclerosis. **Drug Ther Bull** 1997 Feb;35(2):11–2 (12 ref.)

Amyotrophic lateral sclerosis: current and future treatment strategies [published erratum appears in Drugs 1996 Jul;52(1):92] Festoff BW. **Drugs** 1996 Jan;51(1):28–44 (120 ref.)

Therapeutic advances: riluzole for the treatment of motor neurone disease. Clark W, et al. **J Clin Pharm Ther** 1996 Dec;21(6):373–6 (9 ref.)

Impact of riluzole on the relationship between patient and physician. Dengler R, et al. **J Neurol** 1997 May;244 Suppl 2:S30–2 (11 ref.)

The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III. Meininger V, et al. **J Neurol** 1997 May;244 Suppl 2:S22–5

Glutamate, excitotoxicity and amyotrophic lateral sclerosis. Shaw PJ, et al. **J Neurol** 1997 May;244 Suppl 2:S3–14 (130 ref.)

Increase of flexor reflex latency in patients with amyotrophic lateral sclerosis treated with riluzole [letter] Riepe MW, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):427

A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit. Aisen ML, et al. **J Neurol Sci** 1996 Jun;138(1–2):93–6

Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis. Gourie-Devi M, et al. **J Neurol Sci** 1997 Sep 10; 150(2):167–72

The control of oral secretions in bulbar ALS/MND. Newall AR, et al. **J Neurol Sci** 1996 Aug;139 Suppl:43–4

The quality of care and symptom control—the effects on the terminal phase of ALS/MND. Oliver D. **J Neurol Sci** 1996 Aug;139 Suppl:134–6

Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. Vyth A, et al. **J Neurol Sci** 1996 Aug;139 Suppl:99–103

Rilutek (Riluzole) may extend survival in amyotrophic lateral sclerosis [news] **J Neurosci Nurs** 1996 Aug;28(4):275

Effects of riluzole on symptom progression in amyotrophic lateral sclerosis [letter] Sojka P, et al. **Lancet** 1997 Jan 18; 349(9046):176–7

Riluzole [see comments] Wokke J. **Lancet** 1996 Sep 21; 348(9030):795–9 (38 ref.). Comment in: Lancet 1996 Dec 14;348(9042):1660; discussion 1660–1. Comment in: Lancet 1996 Dec 14;348(9042):1661.

Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment—botulinum toxin A injections of the parotid glands. Bushara KO. **Med Hypotheses** 1997 Apr; 48(4):337–9

Encapsulated xenogeneic cells: delivering CNTF to motor neurons [news] O'Brien C. **Mol Med Today** 1996 Nov; 2(11):448–9

Controversies about amyotrophic lateral sclerosis. Rowland LP. **Neurologia** 1996 Dec;11 Suppl 5:72–4 (9 ref.)

Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. **Neurology** 1997 Sep;49(3):657–9

Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study. Cudkowicz ME, et al. **Neurology** 1997 Jul;49(1):213–22

Motor neuron growth factors. Elliott JL, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S47–53 (70 ref.)

ALS therapy: targets for the future. Hugon J. **Neurology** 1996 Dec;47(6 Suppl 4):S251–4

A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Lacomblez L, et al. **Neurology** 1996 Dec;47(6 Suppl 4):S242–50

Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study.

North American ALS/IGF-I Study Group. Lange DJ, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S93–4; discussion S94–5

Therapeutic advances in ALS. Miller R, et al. **Neurology** 1996 Dec;47(6 Suppl 4):S217

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Miller RG, et al. **Neurology** 1996 Dec;47(6):1383–8

Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group–II. Miller RG, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S86–90; discussion S90–2

Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Miller RG, et al. **Neurology** 1996 Nov; 47(5):1329–31

Drug combination treatment in patients with ALS: current status and future directions. Mitsumoto H, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S103–7 (15 ref.)

The impact of the approval of riluzole. Sufit R, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S117

A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Tandan R, et al. **Neurology** 1996 Nov;47(5):1220–6

Antioxidant drugs block in vitro the neurotoxicity of CSF from patients with amyotrophic lateral sclerosis. Terro F, et al. **Neuroreport** 1996 Aug 12;7(12):1970–2

Therapeutic advances in amyotrophic lateral sclerosis. Louvel E, et al. **Trends Pharmacol Sci** 1997 Jun; 18(6):196–203 (84 ref.)

Riluzole and ALS therapy. Hugon J. **Wien Med Wochenschr** 1996;146(9–10):185–7 (27 ref.)

[Riluzole treatment in amyotrophic lateral sclerosis] Wokke JH. **Ned Tijdschr Geneeskd** 1996 Nov 16;140(46):2265–8 **(Dut)**

[Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)] Yanagisawa N, et al. **Rinsho Shinkeigaku** 1996 Dec; 36(12):1329–30 (Eng. Abstr.) **(Jpn)**

[Riluzole for everybody or for nobody] Martí-Fàbregas J. **Neurologia** 1996 Jan;11(1):44–5 **(Spa)**

ECONOMICS

The economic impact of ALS. Klein LM, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S126–9

ENZYMOLOGY

Do posttranslational modifications of CuZnSOD lead to sporadic amyotrophic lateral sclerosis? Bredesen DE, et al. **Ann Neurol** 1997 Aug;42(2):135–7 (25 ref.)

CNS distribution of free-radical inactivating enzymes in amyotrophic lateral sclerosis [letter] Mitchell JD, et al. **Ann Neurol** 1996 Oct;40(4):689–90

Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis. Przedborski S, et al. **Ann Neurol** 1996 Feb;39(2):158–65

Immunohistochemical study on superoxide dismutases in spinal cords from autopsied patients with amyotrophic lateral sclerosis. Shibata N, et al. **Dev Neurosci** 1996; 18(5–6):492–8

Expression of a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH–SY5Y cells. Carrì MT, et al. **FEBS Lett** 1997 Sep 8;414(2):365–8

Instability of expressed Cu/Zn superoxide dismutase with 2 bp deletion found in familial amyotrophic lateral sclerosis. Watanabe Y, et al. **FEBS Lett** 1997 Jan 2;400(1):108–12

A familial amyotrophic lateral sclerosis-associated A4V Cu, Zn-superoxide dismutase mutant has a lower Km for hydrogen peroxide. Correlation between clinical severity and the Km value. Yim HS, et al. **J Biol Chem** 1997 Apr 4;272(14):8861–3

Colocalization of NOS and SOD1 in neurofilament accumulation within motor neurons of amyotrophic lateral sclerosis: an immunohistochemical study. Chou SM, et al. **J Chem Neuroanat** 1996 Jun;10(3–4):249–58

Normal binding and reactivity of copper in mutant superoxide dismutase isolated from amyotrophic lateral sclerosis patients. Marklund SL, et al. **J Neurochem** 1997 Aug;69(2):675–81

Enhanced superoxide dismutase-2 immunoreactivity of astrocytes and occasional neurons in amyotrophic lateral sclerosis. Blaauwgeers HG, et al. **J Neurol Sci** 1996 Sep 1;140(1–2):21–9

Serum Cu/Zn superoxide dismutase activity is reduced in sporadic amyotrophic lateral sclerosis patients. Cohen O, et al. **J Neurol Sci** 1996 Nov;143(1–2):118–20

An update on superoxide dismutase 1 in familial amyotrophic lateral sclerosis. Cudkowicz ME, et al. **J Neurol Sci** 1996 Aug;139 Suppl:10–5 (60 ref.)

Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis. Hoffman EK, et al. **J Neurol Sci** 1996 Jul;139(1):15–20

Cytoplasmic, lysosomal and matrix protease activities in spinal cord tissue from amyotrophic lateral sclerosis (ALS) and control patients. Shaw PJ, et al. **J Neurol Sci** 1996 Aug;139 Suppl:71–5

Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. Durham HD, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):523–30

Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis. Fujita K, et al. **J Neurosci Res** 1996 Aug 1; 45(3):276–81

Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Tu PH, et al. **Lab Invest** 1997 Apr;76(4):441–56 (144 ref.)

Alteration of transglutaminase activity in rat and human spinal cord after neuronal degeneration. Fujita K, et al. **Neurochem Res** 1995 Oct;20(10):1195–201

Cyclin-dependent kinase 5 in Lewy body-like inclusions in anterior horn cells of a patient with sporadic amyotrophic lateral sclerosis. Nakamura S, et al. **Neurology** 1997 Jan; 48(1):267–70

Instability of mutant Cu/Zn superoxide dismutase (Ala4Thr) associated with familial amyotrophic lateral sclerosis. Nakano R, et al. **Neurosci Lett** 1996 Jun 21;211(2):129–31

Immunohistochemical study on choline acetyltransferase in the spinal cord of patients with amyotrophic lateral sclerosis. Oda Y, et al. **Pathol Int** 1995 Dec;45(12):933–9

Mutations in copper-zinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redox behavior of the protein. Lyons TJ, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12240–4

[Amyotrophic lateral sclerosis and superoxide dismutase--a review (see comments)] Binzer MN, et al. **Ugeskr Laeger** 1997 Mar 10;159(11):1593–6 (17 ref.) (Eng. Abstr.). Comment in: Ugeskr Laeger 1997 Jun 2;159(23):3619. **(Dan)**

EPIDEMIOLOGY

Epidemiological and clinical characteristics of ALS in Belgrade, Yugoslavia. Alčaz S, et al. **Acta Neurol Scand** 1996 Oct;94(4):264–8

Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. McGuire V, et al. **Am J Epidemiol** 1997 Jun 15;145(12):1076–88

Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis [see comments] Cudkowicz ME, et al. **Ann Neurol** 1997 Feb;41(2):210–21. Comment in: Ann Neurol 1997 Aug;42(2):273–4.

Trace elements, age, and sex in amyotrophic lateral sclerosis disease. Kanias GD, et al. **Biol Trace Elem Res** 1997 Feb; 56(2):187–201

Epidemiology of ALS. Nelson LM. **Clin Neurosci** 1995–96; 3(6):327–31

Amyotrophic lateral sclerosis after long-term exposure to drinking water with high selenium content. Vinceti M, et al. **Epidemiology** 1996 Sep;7(5):529–32

Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. McGuire V, et al. **Neurology** 1996 Aug;47(2):571–3

[Disappearance of ALS from Guam: implications for exogenous causes] Chen KM. **Rinsho Shinkeigaku** 1995 Dec;35(12):1549–53 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Amyotrophic lateral sclerosis in a defined population in Belgrade--an epidemiologic study] Alčaz S, et al. **Vojnosanit Pregl** 1997 Jan–Feb;54(1):19–26 (Eng. Abstr.) **(Scr)**

ETIOLOGY

Amyotrophic lateral sclerosis and occupational exposure to electromagnetic fields. Davanipour Z, et al. **Bioelectromagnetics** 1997;18(1):28–35

Amyotrophic lateral sclerosis after long-term exposure to drinking water with high selenium content. Vinceti M, et al. **Epidemiology** 1996 Sep;7(5):529–32

Conjugal amyotrophic lateral sclerosis: toxic clustering or change? Poloni M, et al. **Ital J Neurol Sci** 1997 Apr; 18(2):109–12

ALS. Jerusalem F, et al. **Neurology** 1996 Dec;47(6 Suppl 4):S218–20 (36 ref.)

[Familial amyotrophic lateral sclerosis and mutations in the Cu/Zn superoxide dismutase gene] Nakano R. **Rinsho Shinkeigaku** 1995 Dec;35(12):1546–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Deficiency of human ciliary neurotropic factor (CNTF) is not causally related to amyotrophic lateral sclerosis (ALS)] Takahashi R. **Rinsho Shinkeigaku** 1995 Dec;35(12):1543–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Absence of the mutant SOD1 in familial amyotrophic lateral sclerosis (FALS) with two base pair deletion in the SOD1 gene. Watanabe Y, et al. **Acta Neurol Scand** 1997 Mar; 95(3):167–72

Apolipoprotein E in Guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex: genotype analysis and relationships to neuropathological changes. Buée L, et al. **Acta Neuropathol (Berl)** 1996;91(3):247–53

A low expressor line of transgenic mice carrying a mutant human Cu,Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Dal Canto MC, et al. **Acta Neuropathol (Berl)** 1997 Jun;93(6):537–50

Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Ince PG, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):395–403 (28 ref.)

Absence of SOD1 gene abnormalities in familial amyotrophic lateral sclerosis with posterior column involvement without Lewy-body-like hyaline inclusions. Kato S, et al. **Acta Neuropathol (Berl)** 1996 Nov;92(5):528–33

A specific superoxide dismutase mutation is on the same genetic background in sporadic and familial cases of amyotrophic lateral sclerosis [letter] Hayward C, et al. **Am J Hum Genet** 1996 Nov;59(5):1165–7

Do posttranslational modifications of CuZnSOD lead to sporadic amyotrophic lateral sclerosis? Bredesen DE, et al. **Ann Neurol** 1997 Aug;42(2):135–7 (25 ref.)

Superoxide dismutase and familial amyotrophic lateral sclerosis: new insights into mechanisms and treatments [editorial; comment] Brown RH Jr. **Ann Neurol** 1996 Feb; 39(2):145–6. Comment on: Ann Neurol 1996 Feb;39(2):147–57.

Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis [see comments] Cudkowicz ME, et al. **Ann Neurol** 1997 Feb;41(2):210–21. Comment in: Ann Neurol 1997 Aug;42(2):273–4.

Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis [see comments] Gurney ME, et al. **Ann Neurol** 1996 Feb; 39(2):147–57. Comment in: Ann Neurol 1996 Feb;39(2):145–6.

The glial glutamate transporter complementary DNA in patients with amyotrophic lateral sclerosis. Meyer T, et al. **Ann Neurol** 1996 Sep;40(3):456–9

Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Mu X, et al. **Ann Neurol** 1996 Sep;40(3):379–86

Expression of the copper-zinc superoxide dismutase gene in amyotrophic lateral sclerosis. Nishiyama K, et al. **Ann Neurol** 1997 Apr;41(4):551–6

CuZnSOD-associated amyotrophic lateral sclerosis [letter; comment] Radunović A, et al. **Ann Neurol** 1997 Aug; 42(2):273–4. Comment on: Ann Neurol 1997 Feb;41(2):210–21.

Copper and zinc levels in familial amyotrophic lateral sclerosis patients with CuZnSOD gene mutations [letter] Radunović A, et al. **Ann Neurol** 1997 Jul;42(1):130–1

Sequence variants in human neurofilament proteins: absence of linkage to familial amyotrophic lateral sclerosis. Vechio JD, et al. **Ann Neurol** 1996 Oct;40(4):603–10

Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Andersen PM, et al. **Brain** 1996 Aug;119 (Pt 4):1153–72

Inherited neurodegenerative diseases and transgenic models. Price DL, et al. **Brain Pathol** 1996 Oct;6(4):467–80 (220 ref.)

Familial amyotrophic lateral sclerosis. Siddique T, et al. **Clin Neurosci** 1995–96;3(6):338–47 (68 ref.)

Superoxide dismutase and oxygen radical neurotoxicity. Hosler BA, et al. **Curr Opin Neurol** 1996 Dec;9(6):486–91 (49 ref.)

The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Hottinger AF, et al. **Eur J Neurosci** 1997 Jul;9(7):1548–51

Genetics of amyotrophic lateral sclerosis. Siddique T, et al. **Hum Mol Genet** 1996;5 Spec No:1465–70 (68 ref.)

Novel G16S (GGC-AGC) mutation in the SOD-1 gene in a patient with apparently sporadic young-onset amyotrophic lateral sclerosis. Kawamata J, et al. **Hum Mutat** 1997;9(4):356–8

Familial amyotrophic lateral sclerosis. Siddique T, et al. **J Neural Transm Suppl** 1997;49:219–33 (66 ref.)

Disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC) is a non-Alzheimer's frontotemporal dementia. Wilhelmsen KC. **J Neural Transm Suppl** 1997;49:269–75 (35 ref.)

Transgenic animal models of familial amyotrophic lateral sclerosis. Gurney ME. **J Neurol** 1997 May;244 Suppl 2:S15–20

Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. Radunovic A, et al. **J Neurol Neurosurg Psychiatry** 1996 Dec;61(6):565–72 (82 ref.)

An update on superoxide dismutase 1 in familial amyotrophic lateral sclerosis. Cudkowicz ME, et al. **J Neurol Sci** 1996 Aug;139 Suppl:10–5 (60 ref.)

Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. Moulard B, et al. **J Neurol Sci** 1996 Aug;139 Suppl:34–7

The relationship of spinal muscular atrophy to motor neuron disease: investigation of SMN and NAIP gene deletions in sporadic and familial ALS. Orrell RW, et al. **J Neurol Sci** 1997 Jan;145(1):55–61

Familial amyotrophic lateral sclerosis with a two base pair deletion in superoxide dismutase 1: gene multisystem degeneration with intracytoplasmic hyaline inclusions in astrocytes. Kato S, et al. **J Neuropathol Exp Neurol** 1996 Oct;55(10):1089–101

Progressive motor neuron impairment in an animal model of familial amyotrophic lateral sclerosis. Azzouz M, et al. **Muscle Nerve** 1997 Jan;20(1):45–51

Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel protein interactions. Kunst CB, et al.

Nat Genet 1997 Jan;15(1):91–4
Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase. Juneja T, et al. **Neurology** 1997 Jan;48(1):55–7
Familial nature and continuing morbidity of the amyotrophic lateral sclerosis–parkinsonism dementia complex of Guam. McGeer PL, et al. **Neurology** 1997 Aug;49(2):400–9
Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for copper–zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis. Orrell RW, et al. **Neurology** 1997 Mar;48(3):746–51
Spinobulbar muscular atrophy can mimic ALS: the importance of genetic testing in male patients with atypical ALS. Parboosingh JS, et al. **Neurology** 1997 Aug; 49(2):568–72
D90A heterozygosity in the SOD1 gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis. Robberecht W, et al. **Neurology** 1996 Nov; 47(5):1336–9
Molecular genetic basis of familial ALS. Siddique T, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S27–34; discussion S34–5 (66 ref.)
A novel SOD1 mutation in an Austrian family with amyotrophic lateral sclerosis. Bereznai B, et al. **Neuromuscul Disord** 1997 Mar;7(2):113–6
Three novel mutations and two variants in the gene for Cu/Zn superoxide dismutase in familial amyotrophic lateral sclerosis. Hosler BA, et al. **Neuromuscul Disord** 1996 Oct; 6(5):361–6
Familial childhood primary lateral sclerosis with associated gaze paresis. Gascon GG, et al. **Neuropediatrics** 1995 Dec; 26(6):313–9
Evidence of reduced DNA repair in amyotrophic lateral sclerosis brain tissue. Kisby GE, et al. **Neuroreport** 1997 Apr 14;8(6):1337–40
A novel two-base mutation in the Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis in Japan. Morita M, et al. **Neurosci Lett** 1996 Feb 23;205(2):79–82
Instability of mutant Cu/Zn superoxide dismutase (Ala4Thr) associated with familial amyotrophic lateral sclerosis. Nakano R, et al. **Neurosci Lett** 1996 Jun 21;211(2):129–31
Pathogenic mechanisms in familial amyotrophic lateral sclerosis due to mutation of Cu, Zn superoxide dismutase. Gurney ME, et al. **Pathol Biol (Paris)** 1996 Jan;44(1):51–6 (38 ref.)
[Clinical study of familial forms of amyotrophic lateral sclerosis. Review of the literature] Moulard B, et al. **Rev Neurol (Paris)** 1997 Jun;153(5):314–24 (72 ref.) (Eng. Abstr.) **(Fre)**
[X chromosomal bulbospinal neuropathy (X-BSN, Kennedy syndrome): an illness with repetitive triplet sequences. Case report, differential diagnosis and molecular genetics aspects] Abel A, et al. **Nervenarzt** 1996 Dec;67(12):1011–9 (44 ref.) (Eng. Abstr.) **(Ger)**
[Clinical characteristics of familial amyotrophic lateral sclerosis with Cu/Zn superoxide dismutase gene mutations in Japan] Hasegawa T, et al. **Nippon Rinsho** 1996 Nov; 54(11):3157–62 (21 ref.) **(Jpn)**
[A case of familial amyotrophic lateral sclerosis with markedly decreased accumulation on 123I-MIBG myocardiac scintigraphy and atonic bladder] Yamamoto T, et al. **Rinsho Shinkeigaku** 1996 Feb;36(2):341–4 (Eng. Abstr.) **(Jpn)**

HISTORY

Amyotrophic lateral sclerosis and vitamin E. Keane JR. **Ann Neurol** 1996 Sep;40(3):480
Lou Gehrig and amyotrophic lateral sclerosis. Is vitamin E to be revisited? Reider CR, et al. **Arch Neurol** 1997 May; 54(5):527–8

IMMUNOLOGY

Autoimmunity and ALS: studies on antibodies to acetylcholinesterase in sera. Häggström B, et al. **Acta Neurol Scand** 1997 Feb;95(2):111–4
Distinct distribution of apolipoprotein E and beta-amyloid immunoreactivity in the hippocampus of Parkinson dementia complex of Guam. Schwab C, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):378–85
Immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum [see comments] Arsac C, et al. **Ann Neurol** 1996 Nov; 40(5):695–700. Comment in: Ann Neurol 1996 Nov;40(5):691–3.
Proteolytic activity in amyotrophic lateral sclerosis IgG preparations [see comments] Nyormoi O. **Ann Neurol** 1996 Nov;40(5):701–6. Comment in: Ann Neurol 1996 Nov;40(5):691–3.
Amyotrophic lateral sclerosis and antibodies to voltage-gated calcium channels—new doubts [editorial; comment] Vincent A, et al. **Ann Neurol** 1996 Nov;40(5):691–3 (15 ref.). Comment on: Ann Neurol 1996 Nov;40(5):695–700. Comment on: Ann Neurol 1996 Nov;40(5):701–6.
Amyotrophic lateral sclerosis with anti-acetylcholine receptor antibody. Okuyama Y, et al. **Intern Med** 1997 Apr; 36(4):312–5
Uptake of immunoglobulin G from amyotrophic lateral sclerosis patients by motor nerve terminals in mice. Fratantoni SA, et al. **J Neurol Sci** 1996 May;137(2):97–102
Altered calcium homeostasis and ultrastructure in motoneurons of mice caused by passively transferred anti-motoneuronal IgG. Engelhardt JI, et al. **J Neuropathol Exp Neurol** 1997 Jan;56(1):21–39
IgG subclasses in neurological disorders. Losy J, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:17–24 (16 ref.)
Autoimmunity and ALS. Smith RG, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S40–5; discussion S45–6 (65 ref.)

METABOLISM

Comparative study of ubiquitin immunoreactivity of hippocampal granular cells in amyotrophic lateral sclerosis with dementia, Guamanian amyotrophic lateral sclerosis and Guamanian parkinsonism–dementia complex. Ikemoto A, et al. **Acta Neuropathol (Berl)** 1997 Mar;93(3):265–70
The glial glutamate transporter complementary DNA in patients with amyotrophic lateral sclerosis. Meyer T, et al. **Ann Neurol** 1996 Sep;40(3):456–9
Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Siklós L, et al. **Ann Neurol** 1996 Feb;39(2):203–16
Immunocytochemical studies of neurotrophins in cerebral motor cortex in Amyotrophic Lateral Sclerosis. Duberley RM, et al. **Brain Res** 1997 Jul 25;763(2):259–63
Distribution of the N-methyl-D-aspartate glutamate receptor subunit NR2A in control and amyotrophic lateral sclerosis spinal cord. Samarasinghe S, et al. **Brain Res** 1996 Jul 15;727(1–2):233–7
Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients. Doré S, et al. **Brain Res Mol Brain Res** 1996 Sep 5;41(1–2):128–33
Increased intracellular calcium triggered by immune mechanisms in amyotrophic lateral sclerosis. Appel SH, et al. **Clin Neurosci** 1995–96;3(6):368–74 (60 ref.)
Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Rothstein JD. **Clin Neurosci** 1995–96;3(6):348–59 (79 ref.)
Differential abundance of glutamate transporter subtypes in amyotrophic lateral sclerosis (ALS)–vulnerable versus ALS–resistant brain stem motor cell groups. Medina L, et al. **Exp Neurol** 1996 Dec;142(2):287–95
FAC1 expression and localization in motor neurons of developing, adult, and amyotrophic lateral sclerosis spinal cord. Mu X, et al. **Exp Neurol** 1997 Jul;146(1):17–24
Synaptophysin in spinal anterior horn in aging and ALS: an immunohistological study. Cruz-Sánchez FF, et al. **J Neural Transm** 1996;103(11):1317–29
Hyaluronic acid is increased in the skin and urine in patients with amyotrophic lateral sclerosis. Ono S, et al. **J Neurol** 1996 Oct;243(10):693–9
Role of SOD-1 and nitric oxide/cyclic GMP cascade on neurofilament aggregation in ALS/MND. Chou SM, et al. **J Neurol Sci** 1996 Aug;139 Suppl:16–26
Neurotrophin-3-like immunoreactivity and Trk C expression in human spinal motoneurones in amyotrophic lateral sclerosis. Duberley RM, et al. **J Neurol Sci** 1997 May 1; 148(1):33–40
Muscarinic, N-methyl-D-aspartate (NMDA) and benzodiazepine receptor binding sites in cortical membranes from amyotrophic lateral sclerosis patients. Gredal O, et al. **J Neurol Sci** 1996 Nov;143(1–2):121–5
Evidence against increased oxidative stress in fibroblasts from patients with non-superoxide-dismutase-1 mutant familial amyotrophic lateral sclerosis. Jansen GA, et al. **J Neurol Sci** 1996 Aug;139 Suppl:91–4
Identification of brain metabolites by magnetic resonance spectroscopy in MND/ALS. Knight JM, et al. **J Neurol Sci** 1996 Aug;139 Suppl:104–9
Expression of ciliary neurotrophic factor is maintained in spinal motor neurons of amyotrophic lateral sclerosis. Schorr M, et al. **J Neurol Sci** 1996 Sep 1;140(1–2):117–22
Identification of phosphorylation sites in PHF-TAU from patients with Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex. Mawal-Dewan M, et al. **J Neuropathol Exp Neurol** 1996 Oct;55(10):1051–9
Glucocorticoid receptors and actions in the spinal cord of the Wobbler mouse, a model for neurodegenerative diseases. González Deniselle MC, et al. **J Steroid Biochem Mol Biol** 1997 Feb;60(3–4):205–13
Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Abe K, et al. **Neurol Res** 1997 Apr;19(2):124–8
Cell death mechanisms in ALS. Bredesen DE, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S36–8; discussion S38–9 (20 ref.)
Advances in ALS workshop summary: Research and future goals. Brooke MH, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S108–12
Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease. Cleveland DW, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S54–61; discussion S61–2 (37 ref.)
Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Curti D, et al. **Neurology** 1996 Oct;47(4):1060–4
Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Gredal O, et al. **Neurology** 1997 Apr; 48(4):878–81
Excitotoxicity in ALS. Leigh PN, et al. **Neurology** 1996 Dec; 47(6 Suppl 4):S221–7 (87 ref.)
Excitotoxicity hypothesis. Rothstein JD. **Neurology** 1996 Oct; 47(4 Suppl 2):S19–25; discussion S26 (40 ref.)
Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Sasaki S, et al. **Neurology** 1996 Aug;47(2):535–40
SGPG in ALS [letter; comment] Steck A, et al. **Neurology** 1996 Apr;46(4):1195–6. Comment on: Neurology 1995 Apr;45(4):827–9.
ALS IgGs suppress [Ca2+]i rise through P/Q-type calcium channels in central neurones in culture. Andjus PR, et al. **Neuroreport** 1996 Aug 12;7(12):1914–6
Analysis of AMPA receptor subunit mRNA expression in control and ALS spinal cord. Virgo L, et al. **Neuroreport** 1996 Nov 4;7(15–17):2507–11
Induction of c-Jun immunoreactivity in spinal cord and brainstem neurons in a transgenic mouse model for amyotrophic lateral sclerosis. Jaarsma D, et al. **Neurosci Lett** 1996 Nov 29;219(3):179–82
Expression of glial cell line-derived growth factor mRNA in the spinal cord and muscle in amyotrophic lateral sclerosis. Yamamoto M, et al. **Neurosci Lett** 1996 Feb 2; 204(1–2):117–20
Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Bruijn LI, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7606–11
Neuroscientists seek answers to brain function and disease. Faulty protein linked to ALS [news] Vogel G. **Science** 1996 Dec 6;274(5293):1612–3
Amyotrophic lateral sclerosis: the involvement of intracellular Ca2+ and protein kinase C. Krieger C, et al. **Trends Pharmacol Sci** 1996 Mar;17(3):114–20 (70 ref.)
[Similarities in calcium and magnesium metabolism between amyotrophic lateral sclerosis and calcification of the spinal cord in the Kii Peninsula ALS focus] Yasui M, et al. **No To Shinkei** 1997 Aug;49(8):745–51 (Eng. Abstr.) **(Jpn)**
[Neurotransmitter changes in amyotrophic lateral sclerosis] Barkhatova VP, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(4):78–85 (37 ref.) (Eng. Abstr.) **(Rus)**

MORTALITY

Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. **Dysphagia** 1997 Summer;12(3):174–5 (5 ref.)
Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. Vyth A, et al. **J Neurol Sci** 1996 Aug;139 Suppl:99–103
Amyotrophic lateral sclerosis in Mexico: validation of two predictive scales. Otero-Siliceo E, et al. **Muscle Nerve** 1997 Sep;20(9):1181–3
Epidemiological survey of amyotrophic lateral sclerosis in the province of Reggio Emilia, Italy: influence of environmental exposure to lead. Guidetti D, et al. **Neuroepidemiology** 1996;15(6):301–12

PATHOLOGY

Apolipoprotein E in Guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex: genotype analysis and relationships to neuropathological changes. Buée L, et al. **Acta Neuropathol (Berl)** 1996;91(3):247–53
A low expressor line of transgenic mice carrying a mutant human Cu,Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Dal Canto MC, et al. **Acta Neuropathol (Berl)** 1997 Jun;93(6):537–50
Comparative immunohistochemical study on synaptophysin expression in the anterior horn of post-poliomyelitis and sporadic amyotrophic lateral sclerosis. Ikemoto A, et al. **Acta Neuropathol (Berl)** 1996 Nov;92(5):473–8
Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Ince PG, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):395–403 (28 ref.)
Eosinophilic intranuclear inclusions in the hippocampal pyramidal neurons of a patient with amyotrophic lateral sclerosis. Kakita A, et al. **Acta Neuropathol (Berl)** 1997 May;93(5):532–6
Absence of SOD1 gene abnormalities in familial amyotrophic lateral sclerosis with posterior column involvement without Lewy-body-like hyaline inclusions. Kato S, et al. **Acta Neuropathol (Berl)** 1996 Nov;92(5):528–33
Golgi apparatus and intraneuronal inclusions of anterior horn cells in amyotrophic lateral sclerosis: an immunohistochemical study. Matsumoto S, et al. **Acta Neuropathol (Berl)** 1996;91(6):603–7
Coexistence of Huntington's disease and familial amyotrophic lateral sclerosis: case presentation. Rubio A, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):421–7 (41 ref.)
Dendritic synapses of anterior horn neurons in amyotrophic lateral sclerosis: an ultrastructural study. Sasaki S, et al. **Acta Neuropathol (Berl)** 1996;91(3):278–83
Amyotrophic lateral sclerosis with numerous axonal spheroids in the corticospinal tract and massive degeneration of the cortex. Takahashi T, et al. **Acta Neuropathol (Berl)** 1997 Sep;94(3):294–9
Comparative study of chronic aluminum-induced

neurofilamentous aggregates with intracytoplasmic inclusions of amyotrophic lateral sclerosis. Wakayama I, et al. **Acta Neuropathol (Berl)** 1996 Dec;92(6):545–54

Pathological characterization of astrocytic hyaline inclusions in familial amyotrophic lateral sclerosis. Kato S, et al. **Am J Pathol** 1997 Aug;151(2):611–20

Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Siklós L, et al. **Ann Neurol** 1996 Feb;39(2):203–16

Mouse inoculation studies reveal no transmissible agent in amyotrophic lateral sclerosis [see comments] Fraser H, et al. **Brain Pathol** 1996 Apr;6(2):89–99. Comment in: Brain Pathol 1996 Apr;6(2):99–100.

The search for a transmissible agent in ALS [editorial; comment] Love S. **Brain Pathol** 1996 Apr;6(2):99–100 (21 ref.). Comment on: Brain Pathol 1996 Apr;6(2):89–99.

Amyotrophic lateral sclerosis: occurrence of Bunina bodies in the locus ceruleus pigmented neurons. Iwanaga K, et al. **Clin Neuropathol** 1997 Jan–Feb;16(1):23–6

Sporadic amyotrophic lateral sclerosis with dementia and Cu/Zn superoxide dismutase–positive Lewy body–like inclusions. Matsumoto S, et al. **Clin Neuropathol** 1996 Jan–Feb;15(1):41–6

Comparison of pathological alterations in ALS and a murine transgenic model: pathogenetic implications. Dal Canto MC. **Clin Neurosci** 1995–96;3(6):332–7

Animal models of ALS. Pioro EP, et al. **Clin Neurosci** 1995–96;3(6):375–85 (95 ref.)

ALS: molecular clues to the jigsaw puzzle of neuronal degeneration. Siddique T. **Cold Spring Harb Symp Quant Biol** 1996;61:699–708 (79 ref.)

Differential vulnerability of two subsets of spinal motor neurons in amyotrophic lateral sclerosis. Wetts R, et al. **Exp Neurol** 1996 Oct;141(2):248–55

Neuropathology of amyotrophic lateral sclerosis: new perspectives on an old disease. Chou SM. **J Formos Med Assoc** 1997 Jul;96(7):488–98 (74 ref.)

High signal intensity on T1 weighted MRI of the anterolateral column of the spinal cord in amyotrophic lateral sclerosis. Waragai M, et al. **J Neurol Neurosurg Psychiatry** 1997 Jan;62(1):88–91

Relationships between motor-unit number estimates and isometric strength in distal muscles in ALS/MND. Bromberg MB, et al. **J Neurol Sci** 1996 Aug;139 Suppl:38–42

Neuropathology of sporadic amyotrophic lateral sclerosis of long duration. Iwanaga K, et al. **J Neurol Sci** 1997 Mar 10;146(2):139–43

Guamanian neurodegenerative disease: ultrastructural studies of skin. Ono S, et al. **J Neurol Sci** 1997 Feb 27;146(1):35–40

Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. Schiffer D, et al. **J Neurol Sci** 1996 Aug;139 Suppl:27–33

Distinct pathological features of the gallyas- and tau-positive glia in the Parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Oyanagi K, et al. **J Neuropathol Exp Neurol** 1997 Mar;56(3):308–16

A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Felice KJ. **Muscle Nerve** 1997 Feb;20(2):179–85

The use of upper extremity anthropometrics in the clinical assessment of patients with amyotrophic lateral sclerosis. Kasarskis EJ, et al. **Muscle Nerve** 1997 Mar;20(3):330–5

Reduced brain N-acetyl-aspartate in frontal lobes suggests neuronal loss in patients with amyotrophic lateral sclerosis. Giroud M, et al. **Neurol Res** 1996 Jun;18(3):241–3

Neuropathology of ALS: an overview. Hirano A. **Neurology** 1996 Oct;47(4 Suppl 2):S63–6 (44 ref.)

Cyclin-dependent kinase 5 in Lewy body–like inclusions in anterior horn cells of a patient with sporadic amyotrophic lateral sclerosis. Nakamura S, et al. **Neurology** 1997 Jan; 48(1):267–70

Longitudinal study of fiber density and motor unit number estimate in patients with amyotrophic lateral sclerosis. Yuen EC, et al. **Neurology** 1997 Aug;49(2):573–8

Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease. Bruijn LI, et al. **Neuropathol Appl Neurobiol** 1996 Oct; 22(5):373–87 (87 ref.)

Ultrastructural study of synapses in the anterior horn neurons of patients with amyotrophic lateral sclerosis. Sasaki S, et al. **Neurosci Lett** 1996 Feb 2;204(1–2):53–6

Neuronal inclusions in the dentate fascia in patients with multiple system atrophy. Takeda A, et al. **Neurosci Lett** 1997 May 23;227(3):157–60

[Sporadic juvenile amyotrophic lateral sclerosis with neuronal basophil inclusion bodies--a nosologic entity?] Schmidbauer M, et al. **Wien Med Wochenschr** 1996; 146(9–10):201–2 (12 ref.) (Eng. Abstr.) **(Ger)**

[Spinal pathology in spinal muscular atrophy in comparison with amyotrophic lateral sclerosis] Urbanits S, et al. **Wien Med Wochenschr** 1996;146(9–10):199–200 (Eng. Abstr.) **(Ger)**

[An autopsy case of amyotrophic lateral sclerosis with concomitant Alzheimer's and incidental Lewy body diseases] Su M, et al. **No To Shinkei** 1996 Oct;48(10):931–6 (Eng. Abstr.) **(Jpn)**

[MR imaging of the brain of amyotrophic lateral sclerosis] Yagishita A. **Rinsho Shinkeigaku** 1995 Dec;35(12):1554–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Physiopathology of amyotrophic lateral sclerosis: the contribution from transcranial magnetic stimulation] Gómez-Fernández L, et al. **Rev Neurol** 1997 Jun; 25(142):839–42 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Epidemiological and clinical characteristics of ALS in Belgrade, Yugoslavia. Alčaz S, et al. **Acta Neurol Scand** 1996 Oct;94(4):264–8

Physical activity, trauma, and ALS: a case–control study. Strickland D, et al. **Acta Neurol Scand** 1996 Jul;94(1):45–50

Epidural anesthesia and pulmonary function in a patient with amyotrophic lateral sclerosis. Hara K, et al. **Anesth Analg** 1996 Oct;83(4):878–9

Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis. Kostic V, et al. **Ann Neurol** 1997 Apr;41(4):497–504

CNS distribution of free-radical inactivating enzymes in amyotrophic lateral sclerosis [letter] Mitchell JD, et al. **Ann Neurol** 1996 Oct;40(4):689–90

Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Abrahams S, et al. **Brain** 1996 Dec;119 (Pt 6):2105–20

Amyotrophic lateral sclerosis with hypertensive attacks: blood pressure changes in response to drug administration. Shimizu T, et al. **Clin Auton Res** 1996 Aug;6(4):241–4

Relationship between respiratory failure and plasma noradrenaline levels in amyotrophic lateral sclerosis. Yamashita A, et al. **Clin Auton Res** 1997 Aug;7(4):173–7

Oxidative stress and mitochondrial dysfunction in neurodegeneration. Schapira AH. **Curr Opin Neurol** 1996 Aug;9(4):260–4 (49 ref.)

Towards a neurophysiological marker of amyotrophic lateral sclerosis as revealed by changes in cortical excitability. Desiato MT, et al. **Electroencephalogr Clin Neurophysiol** 1997 Feb;105(1):1–7

Somatosensory evoked potentials elicited by stimulation of lower-limb nerves in amyotrophic lateral sclerosis. Georgesco M, et al. **Electroencephalogr Clin Neurophysiol** 1997 Jul; 104(4):333–42

Magnetic stimulation in ALS--a single motor unit study. Kohara N, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1996;46:327–36

Motor evoked potentials (MEPs): evaluation of the different types of responses in amyotrophic lateral sclerosis and primary lateral sclerosis. Salerno A, et al. **Electromyogr Clin Neurophysiol** 1996 Sep;36(6):361–8

Breathing pattern and respiratory mechanics in patients with amyotrophic lateral sclerosis. Vitacca M, et al. **Eur Respir J** 1997 Jul;10(7):1614–21

White matter injury in amyotrophic lateral sclerosis (ALS). Rafałowska J, et al. **Folia Neuropathol** 1996;34(2):87–91

The roles of free radicals in amyotrophic lateral sclerosis. Liu D. **J Mol Neurosci** 1996 Fall;7(3):159–67 (100 ref.)

Sleep in patients with amyotrophic lateral sclerosis. Hetta J, et al. **J Neurol** 1997 Apr;244(4 Suppl 1):S7–9 (10 ref.)

Glutamate, excitotoxicity and amyotrophic lateral sclerosis. Shaw PJ, et al. **J Neurol** 1997 May;244 Suppl 2:S3–14 (130 ref.)

Entrapment of motor nerves in motor neuron disease: does double crush occur? Chaudhry V, et al. **J Neurol Neurosurg Psychiatry** 1997 Jan;62(1):71–6

Needle EMG of the tongue: motor unit action potential versus peak ratio analysis in limb and bulbar onset amyotrophic lateral sclerosis. Finsterer J, et al. **J Neurol Neurosurg Psychiatry** 1997 Aug;63(2):175–80

Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. Massman PJ, et al. **J Neurol Neurosurg Psychiatry** 1996 Nov;61(5):450–5

Increase of flexor reflex latency in patients with amyotrophic lateral sclerosis treated with riluzole [letter] Riepe MW, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):427

Double cortical stimulation in amyotrophic lateral sclerosis. Yokota T, et al. **J Neurol Neurosurg Psychiatry** 1996 Dec; 61(6):596–600

Cognitive function in amyotrophic lateral sclerosis. Abe K, et al. **J Neurol Sci** 1997 May 1;148(1):95–100

A comparison of three measures of disease progression in ALS. Andres PL, et al. **J Neurol Sci** 1996 Aug;139 Suppl:64–70

Expression of different metallothionein messenger ribonucleic acids in motor cortex, spinal cord and liver from patients with amyotrophic lateral sclerosis. Blaauwgeers HG, et al. **J Neurol Sci** 1996 Oct;142(1–2):39–44

Pitfalls in the evaluation of isometric strength (TQNE) data in ALS. Conradi S, et al. **J Neurol Sci** 1996 Aug;139 Suppl:60–3

Involvement of Onuf's nucleus in amyotrophic lateral sclerosis. Kihira T, et al. **J Neurol Sci** 1997 Mar 20; 147(1):81–8

Amyotrophic lateral sclerosis: recent advances in understanding disease mechanisms. de Belleroche J, et al. **J Neuropathol Exp Neurol** 1996 Jul;55(7):747–57 (60 ref.)

Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment--botulinum toxin A injections of the parotid glands. Bushara KO. **Med Hypotheses** 1997 Apr; 48(4):337–9

Ascorbate availability and neurodegeneration in amyotrophic lateral sclerosis. Kok AB. **Med Hypotheses** 1997 Apr; 48(4):281–96 (171 ref.)

Motor unit number estimates and quantitative muscle strength measurements of distal muscles in patients with amyotrophic lateral sclerosis. Armon C, et al. **Muscle Nerve** 1997 Apr;20(4):499–501

Abnormalities of cortical inhibitory neurons in amyotrophic lateral sclerosis. Enterzari-Taher M, et al. **Muscle Nerve** 1997 Jan;20(1):65–71

Longitudinal tracking of the same single motor unit in amyotrophic lateral sclerosis. Gooch CL, et al. **Muscle Nerve** 1997 Apr;20(4):511–3

Sensitivity of twitch interpolation [letter; comment] Herbert RD, et al. **Muscle Nerve** 1997 Apr;20(4):521–3. Comment on: Muscle Nerve 1996 Jul;19(7):861–9.

Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis. Syntex/Synergen Neuroscience Joint Venture rhCNTF ALS Study Group. Hoagland RJ, et al. **Muscle Nerve** 1997 Jun;20(6):691–5

The use of upper extremity anthropometrics in the clinical assessment of patients with amyotrophic lateral sclerosis. Kasarskis EJ, et al. **Muscle Nerve** 1997 Mar;20(3):330–5

Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis. Mills KR, et al. **Muscle Nerve** 1997 Sep;20(9):1137–41

Electrical and mechanical properties of skeletal muscle underlying increased fatigue in patients with amyotrophic lateral sclerosis. Sharma KR, et al. **Muscle Nerve** 1996 Nov; 19(11):1391–400

ALS care: a resource for measuring and improving ALS outcomes. Anderson FA Jr, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S113–5; discussion S115–6

Comparing composite scores based on maximal voluntary isometric contraction and on semiquantitative manual motor testing in measuring limb strength in patients with ALS. Armon C, et al. **Neurology** 1996 Dec;47(6):1586–7

Issues in clinical trial design. II: Selection of end point measures. Bromberg MB, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S100–2

Natural history of ALS: symptoms, strength, pulmonary function, and disability. Brooks BR. **Neurology** 1996 Oct; 47(4 Suppl 2):S71–81; discussion S81–2 (21 ref.)

Improving education for physicians and for patients. Chad DA, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S121–2

Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase. Juneja T, et al. **Neurology** 1997 Jan;48(1):55–7

Development of measurement techniques. Munsat TL. **Neurology** 1996 Oct;47(4 Suppl 2):S83–5 (11 ref.)

Issues in clinical trial design I: Use of natural history controls. A protagonist view. Munsat TL. **Neurology** 1996 Oct;47(4 Suppl 2):S96–7

Reduced corticomotoneuronal excitatory postsynaptic potentials (EPSPs) with normal Ia afferent EPSPs in amyotrophic lateral sclerosis. Nakajima M, et al. **Neurology** 1996 Dec;47(6):1555–61

Issues in clinical trial design I: Use of natural history controls. An antagonist view. Sufit RL. **Neurology** 1996 Oct;47(4 Suppl 2):S98–9

ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Bruijn LI, et al. **Neuron** 1997 Feb;18(2):327–38

Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: an electromyographic study. Kennel PF, et al. **Neuroreport** 1996 May 31;7(8):1427–31

Goldblatt's syndrome: relapsing-remitting amyotrophic lateral sclerosis. Goldblatt D. **Semin Neurol** 1996 Mar; 16(1):95–8

[Alterations of various parameters of evoked motor potentials in amyotrophic lateral sclerosis] Salerno A, et al. **Neurophysiol Clin** 1996;26(4):227–35 (Eng. Abstr.) **(Fre)**

[Effect of motor neuron density on the curve of motor neuron impoverishment in amyotrophic lateral sclerosis] Pinelli P, et al. **Ann Ist Super Sanita** 1996;32(3):345–50 (Eng. Abstr.) **(Ita)**

[Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis] Oda E, et al. **No To Shinkei** 1996 Nov;48(11):999–1007 (Eng. Abstr.) **(Jpn)**

[Electrophysiologic assessment in motor neuron diseases] Espadaler-Gamissans JM. **Neurologia** 1996 Dec;11 Suppl 5:20–8 (34 ref.) (Eng. Abstr.) **(Spa)**

[Motor neuron diseases. Present] Pou A. **Neurologia** 1996 Dec;11 Suppl 5:1–6 (44 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Hottinger AF, et al. **Eur J Neurosci** 1997 Jul;9(7):1548–51

PSYCHOLOGY

Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Abrahams S, et al. **Brain** 1996 Dec;119 (Pt 6):2105–20

Impact of riluzole on the relationship between patient and physician. Dengler R, et al. **J Neurol** 1997 May;244 Suppl 2:S30–2 (11 ref.)

Health outcome and quality-of-life measurements in amyotrophic lateral sclerosis. Swash M. **J Neurol** 1997 May;244 Suppl 2:S26–9 (22 ref.)

AMYOTROPHIC LATERAL SCLEROSIS

Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. Massman PJ, et al. **J Neurol Neurosurg Psychiatry** 1996 Nov;61(5):450–5

A self report measure of affective lability. Moore SR, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):89–93

The online patient meeting. Feenberg AL, et al. **J Neurol Sci** 1996 Aug;139 Suppl:129–31 (20 ref.)

Freedom through a single switch: coping and communicating with artificial ventilation. Gryfe P, et al. **J Neurol Sci** 1996 Aug;139 Suppl:132–3

[Managing life and death wishes of invasively ventilated amyotrophic lateral sclerosis patients] Winterholler M, et al. **Med Klin** 1997 Apr 28;92 Suppl 1:90–2 (Eng. Abstr.) **(Ger)**

[Legal limits of assisted death: exemplified by amyotrophic lateral sclerosis] Bernat E. **Wien Med Wochenschr** 1996; 146(9–10):195–8 (50 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Nigrostriatal dopaminergic function in familial amyotrophic lateral sclerosis patients with and without copper/zinc superoxide dismutase mutations. Przedborski S, et al. **Neurology** 1996 Dec;47(6):1546–51

SURGERY

Carpal tunnel syndrome in amyotrophic lateral sclerosis and late onset cerebellar ataxia. Mondelli M, et al. **J Hand Surg [Br]** 1996 Aug;21(4):553–8

THERAPY

An attempt to inhibit the course of amyotrophic lateral sclerosis (ALS) by suppressor factor. Nevsimal O, et al. **Biotherapy** 1996;9(1–3):139–41

Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF. Tan SA, et al. **Cell Transplant** 1996 Sep–Oct;5(5):577–87

Emerging directions in ALS therapeutics: palliative therapies at the advent of the twenty-first century. Brooks BR. **Clin Neurosci** 1995–96;3(6):386–92 (97 ref.)

Therapeutic horizons for amyotrophic lateral sclerosis. Rothstein JD. **Curr Opin Neurobiol** 1996 Oct;6(5):679–87 (66 ref.)

Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Aebischer P, et al. **Hum Gene Ther** 1996 May 1;7(7):851–60

Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. Meucci N, et al. **J Neurol** 1996 Feb;243(2):117–20

Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. Brinkmann JR, et al. **J Neurol Sci** 1997 Mar 20;147(1):97–111

Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy–intermittent positive pressure ventilation. Cazzolli PA, et al. **J Neurol Sci** 1996 Aug;139 Suppl:123–8

Inhibition of ICE slows ALS in mice [letter] Friedlander RM, et al. **Nature** 1997 Jul 3;388(6637):31

Controversies about amyotrophic lateral sclerosis. Rowland LP. **Neurologia** 1996 Dec;11 Suppl 5:72–4 (9 ref.)

Management of ALS: respiratory care. Hopkins LC, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S123–5

Management of ALS: nutritional care. Kasarskis EJ, et al. **Neurology** 1996 Oct;47(4 Suppl 2):S118–20

Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Penn RD, et al. **Neurosurgery** 1997 Jan;40(1):94–9; discussion 99–100

Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Kostic V, et al. **Science** 1997 Jul 25;277(5325):559–62

[Ambulatory intensive therapy in the bulbar form of amyotrophic lateral sclerosis] Kirisits H, et al. **Wien Med Wochenschr** 1996;146(9–10):202–3 (Eng. Abstr.) **(Ger)**

[Medical intensive care aspects in treatment of amyotrophic lateral sclerosis] Mamoli B. **Wien Med Wochenschr** 1996; 146(9–10):188–90 (Eng. Abstr.) **(Ger)**

[Patient education—support—help with decisions: ethical aspects in treatment of amyotrophic lateral sclerosis] Meran JG, et al. **Wien Med Wochenschr** 1996;146(9–10):190–4 (21 ref.) (Eng. Abstr.) **(Ger)**

[Amyotrophic lateral sclerosis] Moriwaka F. **Hokkaido Igaku Zasshi** 1997 Jan;72(1):21–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Therapeutic potentials of neurotrophic factors for neurodegenerative disorders] Okazawa H. **No To Shinkei** 1996 Sep;48(9):795–802 (45 ref.) **(Jpn)**

[Physiopathology of amyotrophic lateral sclerosis: the contribution from transcranial magnetic stimulation] Gómez-Fernández L, et al. **Rev Neurol** 1997 Jun; 25(142):839–42 (Eng. Abstr.) **(Spa)**

VIROLOGY

The search for a transmissible agent in ALS [editorial; comment] Love S. **Brain Pathol** 1996 Apr;6(2):99–100 (21 ref.). Comment on: Brain Pathol 1996 Apr;6(2):89–99.

Amyotrophic lateral sclerosis and viruses. Salazar-Grueso EF, et al. **Clin Neurosci** 1995–96;3(6):360–7 (90 ref.)

AMYXIN see **TILORONE**

ANABAENA

CHEMISTRY

Overexpression in E. coli of the complete petH gene product from Anabaena: purification and properties of a 49 kDa ferredoxin–NADP+ reductase. Martínez-Júlvez M, et al. **Biochim Biophys Acta** 1996 Oct 17;1297(2):200–6

Electrostatic effects in electron transfer reactions of [2Fe-2S] ferredoxins with inorganic reagents. Vidakovic M, et al. **Protein Sci** 1996 Sep;5(9):1793–9

ENZYMOLOGY

Glucose-6-phosphate dehydrogenase from the cyanobacterium, Anabaena sp. PCC 7120: purification and kinetics of redox modulation. Gleason FK. **Arch Biochem Biophys** 1996 Oct 15;334(2):277–83

Anabaena flos-aquae and other cyanobacteria possess diadenosine 5',5'''-P1,P4-tetraphosphate (Ap4A) phosphorylase activity. McLennan AG, et al. **Biochem J** 1996 Dec 15;320 (Pt 3):795–800

The cyanobacterium Anabaena flos-aquae possesses diadenosine 5',5'''-P1,P4-tetraphosphate (Ap4A) phosphorylase activity. McLennan AG, et al. **Biochem Soc Trans** 1996 Aug;24(3):417S

Evidence for propeptide-assisted folding of the calcium-dependent protease of the cyanobacterium Anabaena [published erratum appears in 1997 Apr 1;245(1):214] Baier K, et al. **Eur J Biochem** 1996 Nov 1; 241(3):750–5

Cloning, analysis and inactivation of the ndhK gene encoding a subunit of NADH quinone oxidoreductase from Anabaena PCC 7120. Howitt CA, et al. **Eur J Biochem** 1996 Aug 15;240(1):173–80

Nitrate assimilation gene cluster from the heterocyst-forming cyanobacterium Anabaena sp. strain PCC 7120. Frías JE, et al. **J Bacteriol** 1997 Jan;179(2):477–86

Oxidative inactivation of glutamine synthetase from the cyanobacterium Anabaena variabilis. Martin G, et al. **J Bacteriol** 1997 Feb;179(3):730–4

The nuiA gene from Anabaena sp. encoding an inhibitor of the NucA sugar-non-specific nuclease. Muro-Pastor AM, et al. **J Mol Biol** 1997 May 9;268(3):589–98

X-ray structure of the ferredoxin:NADP+ reductase from the cyanobacterium Anabaena PCC 7119 at 1.8 A resolution, and crystallographic studies of NADP+ binding at 2.25 A resolution. Serre L, et al. **J Mol Biol** 1996 Oct 18;263(1):20–39

Bacterial signalling involving eukaryotic-type protein kinases. Zhang CC. **Mol Microbiol** 1996 Apr;20(1):9–15 (32 ref.)

Sucrose biosynthesis in a prokaryotic organism: Presence of two sucrose-phosphate synthases in Anabaena with remarkable differences compared with the plant enzymes. Porchia AC, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13600–4

GENETICS

Heterocyst formation. Wolk CP. **Annu Rev Genet** 1996; 30:59–78 (143 ref.)

Charge reversal mutations in a conserved acidic patch in Anabaena ferredoxin can attenuate or enhance electron transfer to ferredoxin:NADP+ reductase by altering protein/protein orientation within the intermediate complex. Hurley JK, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):243–50

Amplification of DNA from whole cells of cyanobacteria using PCR. Howitt CA. **Biotechniques** 1996 Jul;21(1):32–4

Genes encoding proteins homologous to halobacterial Gvps N, J, K, F & L are located downstream of gvpC in the cyanobacterium Anabaena flos-aquae. Kinsman R, et al. **DNA Seq** 1997;7(2):97–106

Cloning, analysis and inactivation of the ndhK gene encoding a subunit of NADH quinone oxidoreductase from Anabaena PCC 7120. Howitt CA, et al. **Eur J Biochem** 1996 Aug 15;240(1):173–80

Suppression of heterocyst differentiation in Anabaena PCC 7120 by a cosmid carrying wild-type genes encoding enzymes for fatty acid synthesis. Bauer CC, et al. **FEMS Microbiol Lett** 1997 Jun 1;151(1):23–30

Nitrogen deprivation of Anabaena sp. strain PCC 7120 elicits rapid activation of a gene cluster that is essential for uptake and utilization of nitrate. Cai Y, et al. **J Bacteriol** 1997 Jan;179(1):258–66

Anabaena sp. strain PCC 7120 responds to nitrogen deprivation with a cascade-like sequence of transcriptional activations. Cai Y, et al. **J Bacteriol** 1997 Jan;179(1):267–71

Reduction of conjugal transfer efficiency by three restriction activities of Anabaena sp. strain PCC 7120. Elhai J, et al. **J Bacteriol** 1997 Mar;179(6):1998–2005

Isolation and characterization of multiple adenylate cyclase genes from the cyanobacterium Anabaena sp. strain PCC 7120. Katayama M, et al. **J Bacteriol** 1997 Jun; 179(11):3588–93

Maximum activity of recombinant ribulose 1,5-bisphosphate carboxylase/oxygenase of Anabaena sp. strain CA requires the product of the rbcX gene. Li LA, et al. **J Bacteriol** 1997 Jun;179(11):3793–6

Identification and characterization of the nifV-nifZ-nifT gene region from the filamentous cyanobacterium Anabaena sp. strain PCC 7120. Stricker O, et al. **J Bacteriol** 1997 May;179(9):2930–7

Characterization of genes for a second Mo-dependent nitrogenase in the cyanobacterium Anabaena variabilis. Thiel T, et al. **J Bacteriol** 1997 Aug;179(16):5222–5

Cell-type specificity of the Anabaena fdxN-element rearrangement requires xisH and xisI. Ramaswamy KS, et al. **Mol Microbiol** 1997 Mar;23(6):1241–9

Disruption analysis of the gene for a cold-regulated RNA-binding protein, rbpA1, in Anabaena: cold-induced initiation of the heterocyst differentiation pathway. Sato N, et al. **Plant Cell Physiol** 1996 Dec;37(8):1150–60

Differential regulation by low temperature of the gene for an RNA-binding protein, rbpA3, in the cyanobacterium Anabaena variabilis strain M3. Sato N, et al. **Plant Cell Physiol** 1997 Jan;38(1):81–6

METABOLISM

Variation of microcystins, cyanobacterial hepatotoxins, in Anabaena spp. as a function of growth stimuli. Rapala J, et al. **Appl Environ Microbiol** 1997 Jun;63(6):2206–12

Charge reversal mutations in a conserved acidic patch in Anabaena ferredoxin can attenuate or enhance electron transfer to ferredoxin:NADP+ reductase by altering protein/protein orientation within the intermediate complex. Hurley JK, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):243–50

Dechlorination of lindane by the cyanobacterium Anabaena sp. strain PCC7120 depends on the function of the nir operon. Kuritz T, et al. **J Bacteriol** 1997 May; 179(10):3368–70

Protein tyrosine phosphorylation in the cyanobacterium Anabaena sp. strain PCC 7120. McCartney B, et al. **J Bacteriol** 1997 Apr;179(7):2314–8

Kinetic and cross-linking studies on the interactions of negative patch mutant plastocyanin from Silene pratensis with photosystem I complexes from cyanobacteria, green algae, and plants. Hibino T, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):556–63

Negatively charged anabaena flavodoxin residues (Asp144 and Glu145) are important for reconstitution of cytochrome P450 17alpha-hydroxylase activity. Jenkins CM, et al. **J Biol Chem** 1997 Sep 5;272(36):22509–13

PHYSIOLOGY

Lipopolysaccharide dependence of cyanophage sensitivity and aerobic nitrogen fixation in Anabaena sp. strain PCC 7120. Xu X, et al. **J Bacteriol** 1997 May;179(9):2884–91

The heterocyst-specific fdxH gene product of the cyanobacterium Anabaena sp. PCC 7120 is important but not essential for nitrogen fixation. Masepohl B, et al. **Mol Gen Genet** 1997 Feb 27;253(6):770–6

ANABASINE

ANALOGS & DERIVATIVES

Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex. Summers KL, et al. **Jpn J Pharmacol** 1997 Jun;74(2):139–46

ANABOLIC STEROIDS

Anabolic steroid use among adolescents in Nebraska schools. Scott DM, et al. **Am J Health Syst Pharm** 1996 Sep 1; 53(17):2068–72

Intervention and prevention of steroid use in adolescents. Elliot D, et al. **Am J Sports Med** 1996;24(6 Suppl):S46–7

Use of anabolic steroids has been reported by 9% of men attending gymnasiums [letter; comment] Korkia P. **BMJ** 1996 Oct 19;313(7063):1009. Comment on: BMJ 1996 Jul 13;313(7049):100–1.

Cardiac tamponade in a 21-year-old body builder with anabolica abuse [letter] Roeggia M, et al. **Br J Clin Pract** 1996 Oct–Nov;50(7):411–2

Gym and tonic: a profile of 100 male steroid users. Evans NA. **Br J Sports Med** 1997 Mar;31(1):54–8

Echocardiography in fraternal twin bodybuilders with one abusing anabolic steroids [letter] Dickerman RD, et al. **Cardiology** 1997 Jan–Feb;88(1):50–1

Detection of anabolic steroid administration: ratio of urinary testosterone to epitestosterone vs the ratio of urinary testosterone to luteinizing hormone. Perry PJ, et al. **Clin Chem** 1997 May;43(5):731–5

The use of anabolic-androgenic steroids by Canadian students. Melia P, et al. **Clin J Sport Med** 1996 Jan;6(1):9–14

Anabolic-androgenic steroid use among 133 prisoners. Pope HG Jr, et al. **Compr Psychiatry** 1996 Sep–Oct;37(5):322–7

Natural sex steroids and their xenobiotic analogs in animal production: growth, carcass quality, pharmacokinetics, metabolism, mode of action, residues, methods, and epidemiology. Lone KP. **Crit Rev Food Sci Nutr** 1997 Mar; 37(2):93–209 (1177 ref.)

Steroid abuse in female athletes. Honour JW. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):181–6 (29 ref.)

Peripheral arterial thrombosis in two young men using anabolic steroids. Falkenberg M, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):223–6

Personality profile of men using anabolic androgenic steroids. Galligani N, et al. **Horm Behav** 1996 Jun;30(2):170–5

Body composition, cardiovascular risk factors and liver function in long-term androgenic-anabolic steroids using

bodybuilders three months after drug withdrawal. Hartgens F, et al. **Int J Sports Med** 1996 Aug;17(6):429–33

Examining athletes' attitudes toward using anabolic steroids and their knowledge of the possible effects. Anshel MH, et al. **J Drug Educ** 1997;27(2):121–45

Validity of self-report in identifying anabolic steroid use among weightlifters. Ferenchick GS. **J Gen Intern Med** 1996 Sep;11(9):554–6

Androgenic--anabolic steroids and body dysmorphia in young men. Wroblewska AM. **J Psychosom Res** 1997 Mar; 42(3):225–34 (75 ref.)

Effects of a multidimensional anabolic steroid prevention intervention. The Adolescents Training and Learning to Avoid Steroids (ATLAS) Program. Goldberg L, et al. **JAMA** 1996 Nov 20;276(19):1555–62

Anabolic steroids in sport [letter] [see comments] Moriarty HJ. **N Z Med J** 1997 Feb 14;110(1037):42. Comment in: N Z Med J 1997 Apr 25;110(1042):154–5.

Adolescents and anabolic steroids: a subject review. American Academy of Pediatrics. Committee on Sports Medicine and Fitness. **Pediatrics** 1997 Jun;99(6):904–8 (33 ref.)

Psychological and behavioural effects of endogenous testosterone and anabolic–androgenic steroids. An update. Bahrke MS, et al. **Sports Med** 1996 Dec;22(6):367–90 (157 ref.)

ADMINISTRATION & DOSAGE

Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height. Haeusler G, et al. **Acta Paediatr** 1996 Dec; 85(12):1408–14

Oxandrolone in AIDS–wasting myopathy. Berger JR, et al. **AIDS** 1996 Dec;10(14):1657–62

A 6–month study of low–dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Gaughan WJ, et al. **Am J Kidney Dis** 1997 Oct; 30(4):495–500

Effect of low dose oxandrolone and testosterone treatment on the pituitary–testicular and GH axes in boys with constitutional delay of growth and puberty. Crowne EC, et al. **Clin Endocrinol (Oxf)** 1997 Feb;46(2):209–16

Changes in lipoprotein–lipid levels in normal men following administration of increasing doses of testosterone cypionate. Kouri EM, et al. **Clin J Sport Med** 1996 Jul; 6(3):152–7

Growth promotion and Turner–specific bone age after therapy with growth hormone and in combination with oxandrolone: when should therapy be started in Turner syndrome? Joss EE, et al. **Horm Res** 1997;47(3):102–9

Nutritional status and lipid profiles of trained steroid–using bodybuilders. Keith RE, et al. **Int J Sport Nutr** 1996 Sep; 6(3):247–54

A comparative study of an estradiol–releasing vaginal ring versus tibolone in postmenopausal women: a transvaginal color Doppler study. Botsis D, et al. **Maturitas** 1997 May; 27(1):77–83

Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low–dose estrogen or tibolone treatment: a comparison. Botsis D, et al. **Maturitas** 1997 Jan;26(1):57–62

Effect on sexual life--a comparison between tibolone and a continuous estradiol–norethisterone acetate regimen. Nathorst–Böös J, et al. **Maturitas** 1997 Jan;26(1):15–20

Drugs in sports medicine [letter; comment] Milne C. **N Z Med J** 1997 Apr 25;110(1042):154–5. Comment on: N Z Med J 1997 Feb 14;110(1037):42.

Effects of androgen therapy on prostatic markers in hemodialyzed patients. Teruel JL, et al. **Scand J Urol Nephrol** 1996 Apr;30(2):129–31

ADVERSE EFFECTS

Child sexual abuse associated with anabolic androgenic steroid use [letter] Driessen M, et al. **Am J Psychiatry** 1996 Oct;153(10):1369

Steroids [letter; comment] Uzych L. **Am J Psychiatry** 1996 Dec;153(12):1653–4. Comment on: Am J Psychiatry 1995 Nov;152(11):1672–4.

Steroids [letter; comment] Yates WR, et al. **Am J Psychiatry** 1996 Dec;153(12):1653. Comment on: Am J Psychiatry 1995 Nov;152(11):1672–4.

The adverse effects of anabolic steroids on serum lipids. Labib M, et al. **Ann Clin Biochem** 1996 May;33 (Pt 3):263–4

A high prevalence of abnormal personality traits in chronic users of anabolic–androgenic steroids. Cooper CJ, et al. **Br J Sports Med** 1996 Sep;30(3):246–50

Spontaneous rupture of the anterior cruciate ligament after anabolic steroids. Freeman BJ, et al. **Br J Sports Med** 1995 Dec;29(4):274–5 (8 ref.)

Anabolic steroid use as the possible precipitant of dilated cardiomyopathy. Ferrera PC, et al. **Cardiology** 1997 Mar–Apr;88(2):218–20

Manifestation of severe coronary heart disease after anabolic drug abuse. Mewis C, et al. **Clin Cardiol** 1996 Feb; 19(2):153–5

Endocrine aspects of anabolic steroids. Wu FC. **Clin Chem** 1997 Jul;43(7):1289–92 (17 ref.)

Gymnasium acne [letter] Collins P, et al. **Clin Exp Dermatol** 1995 Nov;20(6):509

Left ventricular size and function in elite bodybuilders using anabolic steroids. Dickerman RD, et al. **Clin J Sport Med** 1997 Apr;7(2):90–3

Anticardiolipin (aCL) antibodies in a patient with Behçet's syndrome with vena cava inferior thrombosis. Ebo DG, et al. **Clin Rheumatol** 1997 Jan;16(1):96–8 (15 ref.)

Withdrawal from anabolic steroids. Brower KJ. **Curr Ther Endocrinol Metab** 1997;6:338–43 (8 ref.)

Beliefs about steroids: user vs. non–user comparisons. Schwerin MJ, et al. **Drug Alcohol Depend** 1996 Mar; 40(3):221–5

Cardiovascular complications and anabolic steroids [letter] Dickerman RD, et al. **Eur Heart J** 1996 Dec;17(12):1912 (6 ref.)

Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Nieminen MS, et al. **Eur Heart J** 1996 Oct;17(10):1576–83

Basilar artery occlusion associated with anabolic steroid abuse in a 17–year–old bodybuilder. Pálfi S, et al. **Eur Neurol** 1997;37(3):190–1

Cardiovascular effects of anabolic steroids in weight–trained subjects. Palatini P, et al. **J Clin Pharmacol** 1996 Dec; 36(12):1132–40

Commentary on Leong GB and Silva JA. A psychiatric–legal analysis of psychotic criminal defendants charged with murder (J Forensic Sci 1995;40(3):4045–448) [letter; comment] Uzych L. **J Forensic Sci** 1996 Mar;41(2):187–8 . Comment on: J Forensic Sci 1995 May;40(3):445–8.

Cause of vaginal bleeding in postmenopausal women taking tibolone. Ginsburg J, et al. **Maturitas** 1996 May; 24(1–2):107–10

Anabolic steroids and the mind [letter; comment] Byrne AJ. **Med J Aust** 1997 Feb 17;166(4):224. Comment on: Med J Aust 1996 Aug 19;165(4):222–6.

Exposure to anabolic–androgenic steroids shortens life span of male mice. Bronson FH, et al. **Med Sci Sports Exerc** 1997 May;29(5):615–9

Falsification of Thai dianabol. van der Kuy PH, et al. **Pharm World Sci** 1997 Aug;19(4):208–9

Serum lipoprotein patterns in long–term anabolic steroid users. Sachtleben TR, et al. **Res Q Exerc Sport** 1997 Mar; 68(1):110–5

ANALYSIS

Comparison of the possibilities of gas chromatography–mass spectrometry and tandem mass spectrometry systems for the analysis of anabolics in biological material. De Brabander HF, et al. **J Chromatogr A** 1996 Oct 25; 750(1–2):105–14

Determination of anabolic steroids by HPLC with UV–vis–particle beam mass spectrometry. Mesmer MZ, et al. **J Chromatogr Sci** 1997 Jan;35(1):38–42

[Anabolic steroids on the German black market] Musshoff F, et al. **Arch Kriminol** 1997 May–Jun;199(5–6):152–8 (Eng. Abstr.) **(Ger)**

[Detection of doping compounds in the racing pigeon] Hagedorn HW, et al. **Berl Munch Tierarztl Wochenschr** 1996 Sep;109(9):344–7 (Eng. Abstr.) **(Ger)**

BLOOD

Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5–androstene–3 beta, 17 beta–diol to risk of breast cancer in postmenopausal women. Dorgan JF, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Mar; 6(3):177–81

HISTORY

Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Franke WW, et al. **Clin Chem** 1997 Jul;43(7):1262–79

ISOLATION & PURIFICATION

Supercritical fluid extraction of selected pharmaceuticals from water and serum. Simmons BR, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):291–302

METABOLISM

Detection of stanozolol in hair by negative ion chemical ionization mass spectrometry. Höld KM, et al. **J Anal Toxicol** 1996 Oct;20(6):345–49

Endocrine regulation of the immune response to influenza virus infection with a metabolite of DHEA–androstenediol. Padgett DA, et al. **J Neuroimmunol** 1997 Sep; 78(1–2):203–11

Identification of a specific binding site for the anabolic steroid stanozolol in male rat liver microsomes. Boada LD, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1123–9

PHARMACOKINETICS

Excretion of the anabolic steroid boldenone by racing pigeons. Hagedorn HW, et al. **Am J Vet Res** 1997 Mar; 58(3):224–7

Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. Minto CF, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):93–102

PHARMACOLOGY

Effect of 19–norandrostenololylaurate on semen characteristics of colts. Koskinen E, et al. **Acta Vet Scand** 1997;38(1):41–50

Effect of 19–norandrostenololylaurate on testicular growth in colts. Koskinen E, et al. **Acta Vet Scand** 1997;38(1):51–7

Comparison of the effects of 17 alpha–methyltestosterone, methandrostenolone, and nandrolone decanoate on the sexual behavior of castrated male rats. Clark AS, et al. **Behav Neurosci** 1996 Dec;110(6):1478–86

Spatial working memory is preserved in rats treated with anabolic–androgenic steroids. Smith ST, et al. **Brain Res** 1996 Oct 21;737(1–2):313–6

Long–term chronic treatment with stanozolol lacks significant effects on aggression and activity in young and adult male laboratory mice. Martínez–Sanchis S, et al. **Gen Pharmacol** 1996 Mar;27(2):293–8

Modulation of immune responses by anabolic androgenic steroids. Hughes TK, et al. **Int J Immunopharmacol** 1995 Nov;17(11):857–63

Anabolic implant effects on steer performance, carcass traits, subprimal yields, and longissimus muscle properties. Foutz CP, et al. **J Anim Sci** 1997 May;75(5):1256–65

Late–gestation treatment of pregnant cows with trenbolone acetate does not increase subsequent growth of heifer calves. Harting MA, et al. **J Anim Sci** 1997 May; 75(5):1190–4

Implant program effects on performance and carcass quality of steer calves finished for 212 days. Samber JA, et al. **J Anim Sci** 1996 Jul;74(7):1470–6

Effects of nandrolone decanoate on respiratory and peripheral muscles in male and female rats. Bisschop A, et al. **J Appl Physiol** 1997 Apr;82(4):1112–8

High–dose anabolic androgenic steroids modulate concentrations of nerve growth factor and expression of its low affinity receptor (p75–NGFr) in male rat brain. Tirassa P, et al. **J Neurosci Res** 1997 Jan 15;47(2):198–207

Effects of the androgenic/anabolic steroid stanozolol on GABAA receptor function: GABA–stimulated 36Cl–influx and [35S] TBPS binding. Masonis AE, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):186–93

Anabolic steroids and lymphocyte function in sedentary and exercise–trained rats. Ferrández MD, et al. **J Steroid Biochem Mol Biol** 1996 Oct;59(2):225–32

Direct interactions of androgenic/anabolic steroids with the peripheral benzodiazepine receptor in rat brain: implications for the psychological and physiological manifestations of androgenic/anabolic steroid abuse. Masonis AE, et al. **J Steroid Biochem Mol Biol** 1996 Aug; 58(5–6):551–5

Bone histomorphometry of ovariectomized or orchiectomized rats fed a moderately magnesium–deficient fructose diet and treated with exogenous oestrogen or testosterone. Koh ET, et al. **Magnes Res** 1996 Mar; 9(1):13–21

Exogenous oestrogen affects calcium metabolism differently from exogenous testosterone in ovariectomized or orchiectomized rats fed a high fructose diet severely deficient in magnesium. Koh ET, et al. **Magnes Res** 1996 Mar;9(1):23–31

The effect of tibolone on cardiac flow in postmenopausal women with non–insulin dependent diabetes mellitus. Prelevic GM, et al. **Maturitas** 1997 May;27(1):85–90

Anabolic androgenic steroids increase beta–endorphin levels in the ventral tegmental area in the male rat brain. Johansson P, et al. **Neurosci Res** 1997 Feb;27(2):185–9

Anabolic–androgenic steroid induced alterations in choline acetyltransferase messenger RNA levels of spinal cord motoneurons in the male rat. Blanco CE, et al. **Neuroscience** 1997 Jun;78(3):873–82

Effects of prolonged exposure to anabolic steroids on the behavior of male and female mice. Bronson FH. **Pharmacol Biochem Behav** 1996 Feb;53(2):329–34

The effects of 17 alpha–methyltestosterone, methandrostenolone, and nandrolone decanoate on the rat estrous cycle. Blasberg ME, et al. **Physiol Behav** 1997 Feb; 61(2):265–72

The effect of anabolic–androgenic steroids on sexual behavior and reproductive tissues in male rats. Feinberg MJ, et al. **Physiol Behav** 1997 Jul;62(1):23–30

Anabolic–androgenic steroid exposure during adolescence and aggressive behavior in golden hamsters. Melloni RH Jr, et al. **Physiol Behav** 1997 Mar;61(3):359–64

The effects of cocaine and nandrolone co–administration on aggression in male rats. Long SF, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jul; 20(5):839–56

[A patient with an unexplained low level of high density lipoprotein cholesterol (see comments)] Castro Cabezas M, et al. **Ned Tijdschr Geneeskd** 1997 Jan 25;141(4):200–2 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1997 Mar 29;141(13):651–2. **(Dut)**

[A patient with an unexplained low level of high–density–lipoprotein cholesterol (letter; comment)] Gebhardt DO. **Ned Tijdschr Geneeskd** 1997 Mar 29; 141(13):651–2. Comment on: Ned Tijdschr Geneeskd 1997 Jan 25;141(4):200–2. **(Dut)**

[The results of experimental study of phytoecdysteroids as erythropoiesis stimulators in laboratory animals] Syrov VN, et al. **Eksp Klin Farmakol** 1997 May–Jun;60(3):41–4 (Eng. Abstr.) **(Rus)**

[The effect of ovariectomy and estradiol on DNA, RNA and protein metabolism in the adrenal cortex of rats] Kovzun OI. **Fiziol Zh** 1996;42(1–2):53–8 (Eng. Abstr.) **(Ukr)**

ANABOLIC STEROIDS

THERAPEUTIC USE

Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Teruel JL, et al. **Am J Kidney Dis** 1997 Apr;29(4):569–75

Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two–year randomized, placebo–controlled study. Berning B, et al. **Bone** 1996 Oct;19(4):395–9

The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bjarnason NH, et al. **Bone** 1997 Feb;20(2):151–5

The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys. Jerome CP, et al. **Bone** 1997 Apr;20(4):355–64

Substitution of testosterone in a HIV–1 positive patient with hypogonadism and Wasting–syndrome led to a reduced rate of apoptosis. Klein SA, et al. **Eur J Med Res** 1997 Jan; 2(1):30–2

Immunohistochemical and hysteroscopic assessment of postmenopausal women with uterine bleeding whilst taking Tibolone. Habiba M, et al.
Eur J Obstet Gynecol Reprod Biol 1996 May;66(1):45–9

Final height outcome in girls with Turner syndrome treated with a combination of low dose oestrogen and oxandrolone. Bareille P, et al. **Eur J Pediatr** 1997 May;156(5):358–62

The influence of growth hormone monotherapy and growth hormone in combination with oxandrolone or testosterone on thyroxid hormone parameters and thyroxine binding globulin in patients with Ullrich–Turner syndrome. Schmitt K, et al. **Eur J Pediatr** 1997 Feb;156(2):99–103

Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Taskin O, et al. **Fertil Steril** 1997 Jan; 67(1):40–5

Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta–estradiol and dydrogesterone. Lippuner K, et al. **J Bone Miner Res** 1997 May; 12(5):806–12

Age–associated sarcopenia—issues in the use of testosterone as an anabolic agent in older men [editorial; comment] Bhasin S, et al. **J Clin Endocrinol Metab** 1997 Jun; 82(6):1659–60. Comment on: J Clin Endocrinol Metab 1997 Jun;82(6):1661–7.

Commentary on article by Hobbs, Jones, and Plymate [letter; comment] Roberts HJ. **J Clin Endocrinol Metab** 1997 May; 82(5):1649. Comment on: J Clin Endocrinol Metab 1996 Apr;81(4):1582–5.

Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. Demling RH, et al. **J Trauma** 1997 Jul;43(1):47–51

Effects of short–term stanozolol administration on serum lipoproteins in hepatic lipase deficiency. Bausserman LL, et al. **Metabolism** 1997 Sep;46(9):992–6

A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study. Fenichel G, et al. **Neurology** 1997 May;48(5):1225–6

Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Flicker L, et al.
Osteoporos Int 1997;7(1):29–35

Changes in lipidic and hemostatic parameters induced by tibolone treatment. Rosati D, et al. **Thromb Res** 1997 Feb 1;85(3):273–8

[Isometric muscle exercise and anabolic steroid administration for prevention of regressive muscular atrophy] Yamauchi H. **Nippon Seirigaku Zasshi** 1996; 58(7–8):331–40 **(Jpn)**

TOXICITY

Anabolic steroids induce injury and apoptosis of differentiated skeletal muscle. Abu–Shakra S, et al.
J Neurosci Res 1997 Jan 15;47(2):186–97

URINE

Evaluation of selected–ion storage ion–trap mass spectrometry for detecting urinary anabolic agents [see comments] Bowers LD, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):1033–9. Comment in: Clin Chem 1997 Jun;43(6 Pt 1):915.

Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes' urine. Catlin DH, et al. **Clin Chem** 1997 Jul;43(7):1280–8 (56 ref.)

Effects of drugs which influence renal transport systems on the urinary excretion of the beta 2–adrenoceptor agonist clenbuterol and the anabolic steroids ethinylestradiol and methyltestosterone. Gleixner A, et al.
Food Addit Contam 1997 Feb–Mar;14(2):143–50

Testing for natural and synthetic anabolic agents in human urine. Ayotte C, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6;687(1):3–25

Direct determination of anabolic steroid conjugates in human urine by combined high–performance liquid chromatography and tandem mass spectrometry. Bean KA, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7; 690(1–2):65–75

Separation and confirmation of anabolic steroids with quadrupole ion trap tandem mass spectrometry. Bowers LD, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6; 687(1):69–78

Simultaneous determination, in calf urine, of twelve anabolic agents as heptafluorobutyryl derivatives by capillary gas chromatography–mass spectrometry. Casademont G, et al. **J Chromatogr B Biomed Appl** 1996 Nov 15;686(2):189–98

Comparison and evaluation of the specificity and binding capacity of commercial and in house affinity columns used in sample preparation for analysis of growth–promoting drugs. Crooks SR, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):161–72

Excretion study of furazabol, an anabolic steroid, in human urine. Kim T, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6;687(1):79–83

Long–term detection and identification of metandienone and stanozolol abuse in athletes by gas chromatography–high–resolution mass spectrometry. Schänzer W, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6;687(1):93–108

Biotransformation of 17–alkylsteroids in the equine: gas chromatographic–mass spectral identification of ten intermediate metabolites of methyltestosterone. Stanley SM, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7; 690(1–2):55–64

Gas chromatographic–mass spectrometric identification of main metabolites of stanozolol in cattle after oral and subcutaneous administration. Ferchaud V, et al.
J Chromatogr B Biomed Sci Appl 1997 Aug 1;695(2):269–77

Direct determination of anabolic steroids in human urine by on–line solid–phase extraction/liquid chromatography/mass spectrometry. Barrón D, et al.
J Mass Spectrom 1996 Mar;31(3):309–19

ANACONDA see **BOIDAE**

ANAEROBIC BACTERIA see **BACTERIA, ANAEROBIC**

ANAEROBIC THRESHOLD

Effect of training on the aerobic power and anaerobic performance of prepubertal girls. McManus AM, et al.
Acta Paediatr 1997 May;86(5):456–9

Identification of the anaerobic threshold using double product in patients with coronary artery disease. Brubaker PH, et al. **Am J Cardiol** 1997 Feb 1;79(3):360–2

A new approach to the assessment of anaerobic metabolism: measurement of lactate in saliva. Segura R, et al.
Br J Sports Med 1996 Dec;30(4):305–9

Dangerous curves. A perspective on exercise, lactate, and the anaerobic threshold. Myers J, et al. **Chest** 1997 Mar; 111(3):787–95 (105 ref.)

Threshold increases in plasma growth hormone in relation to plasma catecholamine and blood lactate concentrations during progressive exercise in endurance–trained athletes. Chwalbinska–Moneta J, et al. **Eur J Appl Physiol** 1996; 73(1–2):117–20

Influence of test duration and event specificity on maximal accumulated oxygen deficit of high performance track cyclists. Craig NP, et al. **Int J Sports Med** 1995 Nov; 16(8):534–40

Training level comparison study. Effect of high and low intensity exercise on ventilatory threshold in men with coronary artery disease. Jensen BE, et al.
J Cardiopulm Rehabil 1996 Jul–Aug;16(4):227–32

Oxygen consumption during recovery from prolonged submaximal cycling below the anaerobic threshold. Dawson B, et al. **J Sports Med Phys Fitness** 1996 Jun; 36(2):77–84

A short communication regarding the article by M. Kara et al. "Determination of the heart rate deflection point by the Dmax method." (J Sports Med Phys Fitness 1996;36(1):31–4) [letter; comment] Hofmann P, et al.
J Sports Med Phys Fitness 1997 Jun;37(2):151–5. Comment on: J Sports Med Phys Fitness 1996 Mar;36(1):31–4.

Detection of ventilatory threshold using near infrared spectroscopy in men and women. Bhambhani YN, et al.
Med Sci Sports Exerc 1997 Mar;29(3):402–9

Gender effect on the relationship of time limit at 100% VO2max with other bioenergetic characteristics. Billat V, et al. **Med Sci Sports Exerc** 1996 Aug;28(8):1049–55

Comparison of anaerobic components of the Wingate and Critical Power tests in males and females. Bulbulian R, et al. **Med Sci Sports Exerc** 1996 Oct;28(10):1336–41

Wingate test performance in children with asthma: aerobic or anaerobic limitation? Counil FP, et al.
Med Sci Sports Exerc 1997 Apr;29(4):430–5

The efficacy of the one–leg cycling test for determining the anaerobic threshold (AT) of lower limb amputees. Chin T, et al. **Prosthet Orthot Int** 1997 Aug;21(2):141–6

A treadmill test of sprint running. Falk B, et al.
Scand J Med Sci Sports 1996 Oct;6(5):259–64

[Study on anaerobic threshold in normal pregnant women] Matsushita M, et al.
Nippon Sanka Fujinka Gakkai Zasshi 1996 Jul; 48(7):495–500 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Creatine ingestion increases anaerobic capacity and maximum accumulated oxygen deficit. Jacobs I, et al.
Can J Appl Physiol 1997 Jun;22(3):231–43

PHYSIOLOGY

Exercise capacity during and after spaceflight. Stegemann J, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):812–7

Reliability for a walk/run test to estimate aerobic capacity in a brain–injured population. Vitale AE, et al.
Brain Inj 1997 Jan;11(1):67–76

Oxygen deficit: a measure of the anaerobic energy production during intense exercise? [see comments] Bangsbo J.
Can J Appl Physiol 1996 Oct;21(5):350–63; discussion 364–9 (26 ref.). Comment in: Can J Appl Physiol 1996 Oct;21(5):347–9.

Is the maximal accumulated oxygen deficit an adequate measure of the anaerobic capacity? [see comments] Medbø JI. **Can J Appl Physiol** 1996 Oct;21(5):370–83; discussion 384–8 (37 ref.). Comment in: Can J Appl Physiol 1996 Oct;21(5):347–9.

Maximal accumulated oxygen deficit of resistance–trained men. Pizza FX, et al. **Can J Appl Physiol** 1996 Oct; 21(5):391–402

Electromyographic response to exercise in cardiac transplant patients: a new method for anaerobic threshold determination? Lucía A, et al. **Chest** 1997 Jun;111(6):1571–6

Quantitative evaluation of blood flow distribution to exercising and resting skeletal muscles in patients with cardiac dysfunction using whole–body thallium–201 scintigraphy. Wada O, et al. **Clin Cardiol** 1997 Sep; 20(9):785–90

Verification of the heart rate threshold. Coen B, et al.
Eur J Appl Physiol 1996;72(3):281–2

Significance of time to exhaustion during exercise at the velocity associated with VO2max. Hill DW, et al.
Eur J Appl Physiol 1996;72(4):383–6

The anaerobic energy system in human performance. Cahill BR. **Instr Course Lect** 1994;43:5–9 (53 ref.)

A macro–driven Excel template for determining the anaerobic capacity using an air–braked ergometer. Finn JP, et al. **Int J Clin Monit Comput** 1996 Aug;13(3):179–89

The Conconi test: methodology after 12 years of application. Conconi F, et al. **Int J Sports Med** 1996 Oct;17(7):509–19 (65 ref.)

The Conconi test [letter] Hofmann P, et al.
Int J Sports Med 1997 Jul;18(5):397–9

The Conconi test [letter] Jeukendrup AE, et al.
Int J Sports Med 1997 Jul;18(5):393–6

Lack of reliability in Conconi's heart rate deflection point. Jones AM, et al. **Int J Sports Med** 1995 Nov;16(8):541–4

Role of aerobic capacity and body mass index in the age–associated decline in heart rate variability. Byrne EA, et al. **J Appl Physiol** 1996 Aug;81(2):743–50

Anaerobic capacity and muscle activation during horizontal and uphill running. Sloniger MA, et al. **J Appl Physiol** 1997 Jul;83(1):262–9

Effects of erythrocyte infusion on VO2max at high altitude. Young AJ, et al. **J Appl Physiol** 1996 Jul;81(1):252–9

Excessive anaerobic metabolism during exercise after repair of aortic coarctation [see comments] Rhodes J, et al.
J Pediatr 1997 Aug;131(2):210–4. Comment in: J Pediatr 1997 Aug;131(2):178–9.

Interpreting energy expenditure for anaerobic exercise and recovery: an anaerobic hypothesis. Scott CB.
J Sports Med Phys Fitness 1997 Mar;37(1):18–23

The Conconi test in not valid for estimation of the lactate turnpoint in runners. Jones AM, et al. **J Sports Sci** 1997 Aug;15(4):385–94

Monitoring high–intensity endurance exercise with heart rate and thresholds. Boulay MR, et al.
Med Sci Sports Exerc 1997 Jan;29(1):125–32

Left ventricular function in response to the transition from aerobic to anaerobic metabolism. Pokan R, et al.
Med Sci Sports Exerc 1997 Aug;29(8):1040–7

Effects of moderate–intensity endurance and high–intensity intermittent training on anaerobic capacity and VO2max. Tabata I, et al. **Med Sci Sports Exerc** 1996 Oct; 28(10):1327–30

The relationship between aerobic fitness and recovery from high–intensity exercise in infantry soldiers. Hoffman JR. **Mil Med** 1997 Jul;162(7):484–8

Lack of ventilatory threshold in patients with chronic obstructive pulmonary disease. Midorikawa J, et al.
Respiration 1997;64(1):76–80

Omega–3 fatty acid supplementation does not improve maximal aerobic power, anaerobic threshold and running performance in well–trained soccer players. Raastad T, et al. **Scand J Med Sci Sports** 1997 Feb;7(1):25–31

Aerobic and anaerobic work capacities and leg muscle characteristics in elite orienteers. Rolf C, et al.
Scand J Med Sci Sports 1997 Feb;7(1):20–4

[Effect of a three month training period on the maximal oxygen deficiency in high level performance sprinters] Heugas AM, et al. **Can J Appl Physiol** 1997 Apr; 22(2):171–81 (Eng. Abstr.) **(Fre)**

[An intrapatient comparison of adaptation to aerobic and anaerobic exertion during 3 types of physiological cardiac stimulation in chronotropic failure of the sinus node: DDD, VVIR and DDDR] Occhetta E, et al. **Cardiologia** 1997 Jan;42(1):51–7 (Eng. Abstr.) **(Ita)**

[Anaerobic threshold detected using "V–slope analysis" in chronic chagasic disease] Pedrosa RC, et al.
Rev Soc Bras Med Trop 1997 Mar–Apr;30(2):129–38 (Eng. Abstr.) **(Por)**

[Mechanism of development of the dead point and threshold of anaerobic metabolism in physical work of a dynamics character] Agadzhanian NA, et al. **Fiziol Cheloveka** 1996 Jan–Feb;22(1):98–103 **(Rus)**

ANAEROBIOSIS

The Art of Anaerobes Conference. Athens, Georgia, USA, August 15–16, 1996. Abstracts. **Biofactors** 1997;6(1):53–81

ANAL DRUG ADMINISTRATION see **ADMINISTRATION, RECTAL**

ANAL FISSURE see **FISSURE IN ANO**

ANAL FISTULA see **RECTAL FISTULA**

ANAL GLAND see **ANUS**

ANAL GLAND NEOPLASMS

GENETICS

Canine tumour suppressor gene p53—mutation in a case of adenoma of circumanal glands. Mayr B, et al. **Vet Res Commun** 1997 Jul;21(5):369–73

PATHOLOGY

Perianal mucinous adenocarcinoma. Anthony T, et al. **J Surg Oncol** 1997 Mar;64(3):218–21

THERAPY

Perianal mucinous adenocarcinoma. Anthony T, et al. **J Surg Oncol** 1997 Mar;64(3):218–21

VIROLOGY

The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Galloway DA, et al. **Semin Cancer Biol** 1996 Dec;7(6):309–15 (49 ref.)

ANAL SACS

SECRETION

Fel d I levels in cat anal glands. De Andrade AD, et al. **Clin Exp Allergy** 1996 Feb;26(2):178–80

ANAL SPHINCTER see **ANUS**

ANAL STAGE see **PSYCHOSEXUAL DEVELOPMENT**

ANAL ULCER see **FISSURE IN ANO**

ANALEPTICS see **CENTRAL NERVOUS SYSTEM STIMULANTS**

ANALGESIA

Wound infiltration with liposomal bupivacaine prolongs analgesia in rats. Grant GJ, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):204–7

Intraperitoneal bupivacaine for analgesia after laparoscopic cholecystectomy. Mraović B, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):193–6

Is the need for analgesia influenced by the time of day? [letter] Steinbrook RA. **Acta Anaesthesiol Scand** 1997 Aug; 41(7):950

A clinical study on physiological response in electroacupuncture analgesia and meperidine analgesia for colonoscopy. Wang HH, et al. **Am J Chin Med** 1997; 25(1):13–20

Metabolic correlates of selection for swim stress-induced analgesia in laboratory mice. Konarzewski M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R337–43

Postoperative analgesia reduces mortality and morbidity after esophagectomy. Tsui SL, et al. **Am J Surg** 1997 Jun; 173(6):472–8

A comparison of the efficacy of ketorolac and indomethacin for postoperative analgesia following laparoscopic surgery in day patients. Murrell GC, et al. **Anaesth Intensive Care** 1996 Apr;24(2):237–40

Comparison of the efficacy of paracetamol versus paracetamol, codeine and promethazine (Painstop) for premedication and analgesia for myringotomy in children. Ragg P, et al. **Anaesth Intensive Care** 1997 Feb;25(1):29–32

Single injection field block of tonsillar fossa [letter] Spence AG. **Anaesth Intensive Care** 1996 Oct;24(5):621–3

Analgesia after day case laparoscopic sterilisation. A comparison of tramadol with paracetamol/dextropropoxyphene and paracetamol/codeine combinations. Crighton IM, et al. **Anaesthesia** 1997 Jul;52(7):649–52

International Anesthesia Research Society 71st Clinical and Scientific Congress. San francisco, California, March 14–18, 1997. Abstracts. **Anesth Analg** 1997 Feb;84(2 Suppl):S1–662

Effect on postoperative analgesia of small-dose lysine acetylsalicylate added to prilocaine during intravenous regional anesthesia. Corpataux JB, et al. **Anesth Analg** 1997 May;84(5):1081–5

Is there a place for intrathecal clonidine for clinical analgesia? [letter; comment] Goudas LC, et al. **Anesth Analg** 1996 Oct;83(4):891. Comment on: Anesth Analg 1996 Mar;82(3):627–35.

A comparison of intrathecal morphine-6-glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement. Grace D, et al. **Anesth Analg** 1996 Nov; 83(5):1055–9

Effect of midazolam on development of acute tolerance to alfentanil: the role of pharmacokinetic interactions. Kissin I, et al. **Anesth Analg** 1997 Jul;85(1):182–7

Intravenous ketamine or fentanyl prolongs postoperative analgesia after intrathecal neostigmine. Lauretti GR, et al. **Anesth Analg** 1996 Oct;83(4):766–70

Comparison of tenoxicam by intramuscular injection or wound infiltration for analgesia after inguinal herniorrhaphy [see comments] Mikkelsen SS, et al. **Anesth Analg** 1996 Dec;83(6):1239–43. Comment in: Anesth Analg 1997 May;84(5):1168–9.

Comparison of the time course of morphine's analgesic and immunologic effects. Nelson CJ, et al. **Anesth Analg** 1997 Sep;85(3):620–6

The effects of different monoaminergic antidepressants on the analgesia induced by spinal cord adrenal medullary transplants in the formalin test in rats. Ortega-Alvaro A, et al. **Anesth Analg** 1997 Apr;84(4):816–20

Postoperative analgesia after peripheral nerve block for podiatric surgery: clinical efficacy and chemical stability of lidocaine alone versus lidocaine plus clonidine. Reinhart DJ, et al. **Anesth Analg** 1996 Oct;83(4):760–5

Local analgesia effect of nonsteroidal antiinflammatory drugs [letter; comment] Reuben SS, et al. **Anesth Analg** 1997 May; 84(5):1168–9. Comment on: Anesth Analg 1996 Dec;83(6):1239–43.

Spinal neostigmine diminishes, but does not abolish, hypotension from spinal bupivacaine in sheep. Rose G, et al. **Anesth Analg** 1996 Nov;83(5):1041–5

A minimum dose of clonidine added to mepivacaine prolongs the duration of anesthesia and analgesia after axillary brachial plexus block. Singelyn FJ, et al. **Anesth Analg** 1996 Nov;83(5):1046–50

Intrathecal adenosine analog administration reduces substance P in cerebrospinal fluid along with behavioral effects that suggest antinociception in rats. Sjölund KF, et al. **Anesth Analg** 1997 Sep;85(3):627–32

Preemptive analgesia implies prevention [letter; comment] Carr DB. **Anesthesiology** 1996 Dec;85(6):1498–9. Comment on: Anesthesiology 1996 May;84(5):1015–9.

Ketamine attenuates and reverses morphine tolerance in rodents. Shimoyama N, et al. **Anesthesiology** 1996 Dec; 85(6):1357–66

Shoulder reduction without anesthesia [letter; comment] Kolb JC, et al. **Ann Emerg Med** 1996 Nov;28(5):581–2. Comment on: Ann Emerg Med 1996 Jan;27(1):92–4.

Ten years of sedoanalgesia and how it has affected urological practice. Miller RA. **Arch Ital Urol Androl** 1997 Feb; 69(1):29–33

Preemptive analgesia in patients undergoing appendectomy. Ko CY, et al. **Arch Surg** 1997 Aug;132(8):874–7; discussion 877–8

Rectal diclofenac analgesia after abdominal hysterectomy. Scott RM, et al. **Aust N Z J Obstet Gynaecol** 1997 Feb; 37(1):112–4

Measurement of methemoglobin after EMLA analgesia for newborn circumcision. Law RM, et al. **Biol Neonate** 1996; 70(4):213–7

Antidepressants and chronic pain [editorial; comment] McQuay HJ, et al. **BMJ** 1997 Mar 15;314(7083):763–4. Comment on: BMJ 1997 Mar 15;314(7083):827.

Glutamate: a role in normal brain function, anaesthesia, analgesia and CNS injury. Hudspith MJ. **Br J Anaesth** 1997 Jun;78(6):731–47 (232 ref.)

Analgesia and analgesic drugs in paediatrics. Ball AJ, et al. **Br J Hosp Med** 1996 May 1–14;55(9):586–90 (27 ref.)

Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Tian JH, et al. **Br J Pharmacol** 1997 Feb;120(4):676–80

A prospective, randomized, double-blind study comparing lignocaine gel and plain lubricating gel in relieving pain during flexible cystoscopy. Choong S, et al. **Br J Urol** 1997 Jul;80(1):69–71

Opioid receptors in the ventral tegmental area contribute to stress-induced analgesia in the formalin test for tonic pain. Altier N, et al. **Brain Res** 1996 Apr 29;718(1-2):203–6

Antisense mapping DOR-1 in mice: further support for delta receptor subtypes. Rossi GC, et al. **Brain Res** 1997 Apr 4;753(1):176–9

Antinociceptive effects of stimulation of discrete sites in the rat hypothalamus: evidence for the participation of the lateral hypothalamus area in descending pain suppression mechanisms. Franco AC, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1531–41

Analgesia after otoplasty: regional nerve blockade vs local anaesthetic infiltration of the ear. Cregg N, et al. **Can J Anaesth** 1996 Feb;43(2):141–7

Epidural fentanyl improves the onset and spread of epidural mepivacaine analgesia. Kasaba T, et al. **Can J Anaesth** 1996 Dec;43(12):1211–5

Anaesthesia and analgesia in the emergency department. Murphy MF. **Can J Anaesth** 1997 May;44(5 Pt 2):R52–66 (33 ref.) **(Eng, Fre)**

Improved postoperative analgesia with preoperative piroxicam [see comments] O'Hanlon JJ, et al. **Can J Anaesth** 1996 Feb;43(2):102–5. Comment in: Can J Anaesth 1996 Feb;43(2):97–101.

Sedation, analgesia and muscle relaxation and the critically ill patient. Park GR. **Can J Anaesth** 1997 May;44(5 Pt 2):R40–51 (21 ref.) **(Eng, Fre)**

Pre-emptive analgesia: what does it mean to the clinical anaesthetist? [editorial; comment] [see comments] Penning JP. **Can J Anaesth** 1996 Feb;43(2):97–101. Comment on: Can J Anaesth 1996 Feb;43(2):102–5. Comment in: Can J Anaesth 1997 Jan;44(1):101–2.

Anesthetic considerations in chest trauma. Fouché Y, et al. **Chest Surg Clin N Am** 1997 May;7(2):227–38 (22 ref.)

Temporal variation in the interaction between calcium channel blockers and morphine-induced analgesia. Hodoğlugil U, et al. **Chronobiol Int** 1996 Aug;13(3):227–34

Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. Pande AC, et al. **Clin Neuropharmacol** 1996 Oct;19(5):451–6

Sedation, analgesia, and anesthesia issues in the pediatric patient. Goad RN, et al. **Clin Podiatr Med Surg** 1997 Jan; 14(1):131–48 (30 ref.)

EMLA cream for renal extracorporeal shock wave lithotripsy in ambulatory patients. Bárcena M, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):373–6

Pain treatment in the ICU: intravenous, regional or both? Kröll W, et al. **Eur J Anaesthesiol Suppl** 1997 May;15:49–52

Analgesic effects of propyphenazone in comparison to its combination with caffeine. Kraetsch HG, et al. **Eur J Clin Pharmacol** 1996;49(5):377–82

Conscious sedation for endoscopy. McCloy R, et al. **Eur J Gastroenterol Hepatol** 1996 Dec;8(12):1233–40

Reducing pain of first trimester abortion under local anaesthesia. Donati S, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec 27;70(2):145–9

Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice. Bernardi M, et al. **Eur J Pharmacol** 1996 Feb 29; 298(1):51–5

Further evidence for a peripheral component in the enhanced antinociceptive effect of systemic morphine in mononeuropathic rats: involvement of kappa-, but not delta-opioid receptors. Catheline G, et al. **Eur J Pharmacol** 1996 Nov 14;315(2):135–43

Naloxonazine antagonism of levorphanol-induced antinociception and respiratory depression in rhesus monkeys [published erratum appears in Eur J Pharmacol 1996 Oct 3;312(3):389] Gatch MB, et al. **Eur J Pharmacol** 1996 Feb 29;298(1):31–6

Central antinociceptive effect of L-ornithine, a metabolite of L-arginine, in rats and mice. Kawabata A, et al. **Eur J Pharmacol** 1996 Jan 18;296(1):23–31

Enhanced kappa-opioid receptor-mediated analgesia by antisense targeting the sigma1 receptor. King M, et al. **Eur J Pharmacol** 1997 Jul 16;331(1):R5–6

Modulation of opioid analgesia by agmatine. Kolesnikov Y, et al. **Eur J Pharmacol** 1996 Jan 18;296(1):17–22

Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors. Reche I, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):11–6

Naloxone sensitive orphanin FQ-induced analgesia in mice. Rossi GC, et al. **Eur J Pharmacol** 1996 Sep 12; 311(2-3):R7–8

Corticotropin-releasing factor in antinociception and inflammation. Schäfer M, et al. **Eur J Pharmacol** 1997 Mar 26;323(1):1–10 (152 ref.)

The mu-opioid receptor is necessary for [D-Pen2,D-Pen5]enkephalin-induced analgesia. Sora I, et al. **Eur J Pharmacol** 1997 Apr 18;324(2-3):R1–2

Inhibition of dynorphin-converting enzymes prolongs the antinociceptive effect of intrathecally administered dynorphin in the mouse formalin test. Tan-No K, et al. **Eur J Pharmacol** 1996 Oct 24;314(1-2):61–7

Similar involvement of several brain areas in the antinociception of endogenous and exogenous opioids. Valverde O, et al. **Eur J Pharmacol** 1996 Sep 19; 312(1):15–25

Repeated cold water swim produces delayed nociceptive responses, but not analgesia, for tonic pain in the rat. Fuchs PN, et al. **Exp Neurol** 1997 May;145(1):303–7

Influence of opiate tolerance and calcium channel antagonists on the antinociceptive effects of L-arginine and NG-nitro L-arginine. Contreras E, et al. **Gen Pharmacol** 1997 Mar; 28(3):443–8

Effect of aspartate and glutamate on nociception, catalepsy and core temperature in rats. Singh J, et al. **Indian J Physiol Pharmacol** 1997 Apr;41(2):123–8

Sucrose: is it not only sweet, but also an analgesic? Jain P. **Indian Pediatr** 1997 Mar;34(3):271–3

H3-histamine receptors and clonidine analgesia in rats. Chiechio S, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S43–4

Assessment of sedation, analgesia, and neuromuscular blockade in the perioperative period. Habibi S, et al. **Int Anesthesiol Clin** 1996 Summer;34(3):215–41 (68 ref.)

A protocol to improve analgesia use in the accident and emergency department. Goodacre SW, et al. **J Accid Emerg Med** 1996 May;13(3):177–9

Recent trends in the management of acute pain in children. Litman RS. **J Am Osteopath Assoc** 1996 May;96(5):290–6 (44 ref.)

A pharmacokinetic-pharmacodynamic model of tolerance to morphine analgesia during infusion in rats. Ouellet DM, et al. **J Pharmacokinet Biopharm** 1995 Dec;23(6):531–49

Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. Kolesnikov YA, et al.

J Pharmacol Exp Ther 1996 Nov;279(2):502–6

The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. Pugh G Jr, et al. **J Pharmacol Exp Ther** 1996 Nov; 279(2):608–16

Participation of AT1 and AT2 receptors in the differential interaction between angiotensin II or III and alpha-2 adrenoceptors in the nucleus reticularis gigantocellularis in cardiovascular regulation and antinociception in rats. Yang CH, et al. **J Pharmacol Exp Ther** 1996 Nov; 279(2):795–802

Penile block timing for postoperative analgesia of hypospadias repair in children. Chhibber AK, et al. **J Urol** 1997 Sep;158(3 Pt 2):1156–9

Implication of ATP-sensitive K+ channels in various stress-induced analgesia (SIA) in mice. Nakao K, et al. **Jpn J Pharmacol** 1996 Jul;71(3):269–72

Cardiopulmonary and analgesic effects of xylazine, detomidine, medetomidine, and the antagonist atipamezole in isoflurane-anesthetized swine. Tendillo FJ, et al. **Lab Anim Sci** 1996 Apr;46(2):215–9

Failure to demonstrate any hypoalgesic effect of low intensity laser irradiation (830nm) of Erb's point upon experimental ischaemic pain in humans. Lowe AS, et al. **Lasers Surg Med** 1997;20(1):69–76

Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors. Matsumoto K, et al. **Life Sci** 1996;59(14):1149–55

A study on the involvement of GABAB receptor ligands in stress-induced antinociception in male mice. Houston AJ, et al. **Methods Find Exp Clin Pharmacol** 1997 Apr; 19(3):167–71

Circumcision circumspection [editorial; comment] [see comments] Wiswell TE. **N Engl J Med** 1997 Apr 24; 336(17):1244–5. Comment on: N Engl J Med 1997 Apr 24;336(17):1197–201. Comment in: N Engl J Med 1997 Aug 21;337(8):569; discussion 570.

Acute pain services in New Zealand hospitals; a survey. Merry A, et al. **N Z Med J** 1997 Jun 27;110(1046):233–5

Sex, drugs and...[news; comment] Berkley KJ. **Nat Med** 1996 Nov;2(11):1184–5. Comment on: Nat Med 1996 Nov;2(11):1248–50.

Kappa-opioids produce significantly greater analgesia in women than in men [see comments] Gear RW, et al. **Nat Med** 1996 Nov;2(11):1248–50. Comment in: Nat Med 1996 Nov;2(11):1184–5.

Differential effects of forskolin and phorbol-13-myristate injected intrathecally or intracerebroventricularly on antinociception induced by morphine or beta-endorphin administered intracerebroventricularly in the mouse. Suh HW, et al. **Neuropeptides** 1996 Apr;30(2):177–85

L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: electrophysiological and behavioural studies. Xu XJ, et al. **Neuropeptides** 1996 Apr;30(2):203–6

Stress-induced analgesia. The role of hormones produced by the hypophyseal-adrenocortical system. Filaretov AA, et al. **Neurosci Behav Physiol** 1996 Nov-Dec;26(6):572–8

Does warming of anesthetic solutions improve analgesia and akinesia in retrobulbar anesthesia? [letter] Hamilton RC. **Ophthalmology** 1997 Oct;104(10):1528–30

Does warming of anesthetic solutions improve analgesia and akinesia in retrobulbar anesthesia? Krause M, et al. **Ophthalmology** 1997 Mar;104(3):429–32

Comparison of postoperative emesis, recovery profile, and analgesia in pediatric strabismus repair. Rectal acetaminophen versus intravenous fentanyl-droperidol. Padda GS, et al. **Ophthalmology** 1997 Mar;104(3):419–24

The use of ondansetron to treat pruritus associated with intrathecal morphine in two paediatric patients. Arai L, et al. **Paediatr Anaesth** 1996;6(4):337–9

Diclofenac vs oxybuprocaine eyedrops for analgesia in paediatric strabismus surgery. Morton NS, et al. **Paediatr Anaesth** 1997;7(3):221–6

The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Benedetti F. **Pain** 1996 Mar;64(3):535–43

Estrogen and progesterone activate spinal kappa-opiate receptor analgesic mechanisms. Dawson-Basoa ME, et al. **Pain** 1996 Jan;64(1):169–77

Peripheral morphine analgesia [editorial] Stein C, et al. **Pain** 1997 Jun;71(2):119–21

Additional comments on non-steroidal anti-inflammatory drugs and topical analgesia (PAIN, 61 (1995) 494–495). Willoughby DA, et al. **Pain** 1996 Jan;64(1):205

Analgesia for dying infants whose life support is withdrawn or withheld. Partridge JC, et al. **Pediatrics** 1997 Jan; 99(1):76–9

Pulsed magnetic field induced "analgesia" in the land snail, Cepaea nemoralis, and the effects of mu, delta, and kappa opioid receptor agonists/antagonists. Thomas AW, et al. **Peptides** 1997;18(5):703–9

Interactions between vasopressin and food restriction on stress-induced analgesia. Wideman CH, et al. **Peptides** 1996; 17(1):63–6

Nitric oxide synthase inhibition attenuates tolerance to morphine but not to [D-Ala2, Glu4] deltorphin II, a delta 2-opioid receptor agonist in mice. Zhao GM, et al. **Peptides** 1996;17(4):619–23

High intensity social conflict in the Swiss albino mouse induces analgesia modulated by 5-HT1A receptors. Canto de Souza A, et al. **Pharmacol Biochem Behav** 1997 Mar; 56(3):481–6

Alpha 2-adrenoceptor agonists and stress-induced analgesia in rats: influence of stressors and methods of analysis. De Kock M, et al. **Pharmacol Biochem Behav** 1997 Sep; 58(1):109–17

Differential sensitivity of mice bred for stress-induced analgesia to morphine and ACEA-1011 in the formalin test. Lutfy K, et al. **Pharmacol Biochem Behav** 1996 Jun; 54(2):495–500

Sex and genotype determine the selective activation of neurochemically-distinct mechanisms of swim stress-induced analgesia. Mogil JS, et al. **Pharmacol Biochem Behav** 1997 Jan;56(1):61–6

The analgesia-enhancing component of ingested amniotic fluid does not affect nicotine-induced antinociception in naltrexone-treated rats. Robinson-Vanderwerf TM, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):147–51

RU 486 reduces morphine-induced analgesia in mice, but steroid receptors are not involved. Bianchi M, et al. **Pharmacology** 1996 Jun;52(6):387–91

Influence of dynorphin A (1-13) and dynorphin A (1-10) amide on stress-induced analgesia. Starec M, et al. **Physiol Res** 1996;45(6):433–8

Influence of serotonergic drugs on restraint stress induced analgesia. Korzeniewska I, et al. **Pol J Pharmacol** 1995 Sep-Oct;47(5):381–5

Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: evidence for opposing NO actions on morphine analgesia and tolerance. Kolesnikov YA, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8220–5

Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Sora I, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1544–9

Sensory and sympathetic block during interpleural analgesia. Pettersson N, et al. **Reg Anesth** 1997 Jul-Aug;22(4):313–7

Evaluation of intercostal cryoanalgesia versus conventional analgesia in postthoracotomy pain. Pastor J, et al. **Respiration** 1996;63(4):241–5

The double-way effects of naloxone and clonidine on experimental stress analgesia. Cristea A, et al. **Rom J Physiol** 1995 Jan-Dec;32(1-4):137–43

Sedation and analgesia in the ICU—what evidence-based medicine is there? [editorial] Burrows RC, et al. **S Afr Med J** 1997 Aug;87(8):982

[Sedation and analgesia in ventilator-treated children] Hansen TG, et al. **Ugeskr Laeger** 1996 Dec 30;159(1):31–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Analgesic effects of natural growth hormone release inhibitors and their synthetic analogs. Intraspinal administration] Beltrutti D, et al. **Minerva Med** 1997 Jan-Feb;88(1-2):39–47 (86 ref.) (Eng. Abstr.) **(Ita)**

[Nicorandil, as ATP-sensitive K+ channel opener, potentiated morphine analgesia] Asano T, et al. **Masui** 1996 Nov;45(11):1342–6 (Eng. Abstr.) **(Jpn)**

[A review of pregnancy-induced analgesia] Iwasaki H, et al. **Masui** 1997 May;46(5):598–606 (62 ref.) (Eng. Abstr.) **(Jpn)**

[Regional technics for postoperative analgesia] Pjević M. **Med Pregl** 1997 Jan-Feb;50(1-2):27–31 (Eng. Abstr.) **(Scr)**

[Topical anesthesia with the EMLA cream: application in pediatric urology] Xavier B, et al. **Actas Urol Esp** 1996 Nov-Dec;20(10):883–5 (15 ref.) (Eng. Abstr.) **(Spa)**

[Pain relief. A new medical specialty focused on prolonged pain] Sjölund B. **Lakartidningen** 1997 May 21;94(21):1984 **(Swe)**

ADVERSE EFFECTS

Complication after interpleural analgesia [letter] Milliet N, et al. **Anesth Analg** 1996 Oct;83(4):890

Risk factors for unpleasant paresthesiae induced by paresthesiae-producing deep brain stimulation. Vilela Filho O. **Arq Neuropsiquiatr** 1996 Mar;54(1):57–63

Analgesic rebound as a cause of hemicrania continua. Warner JS. **Neurology** 1997 Jun;48(6):1540–1

Masked mischief. Bromage PR. **Reg Anesth** 1996 Nov-Dec; 21(6 Suppl):62–3 (6 ref.)

ECONOMICS

Cost-effectiveness and cost/benefit ratio of acute pain management. Rauck RL. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):139–43 (18 ref.)

HISTORY

Anesthesia & Analgesia: seventy-five years of publication. Craig DB, et al. **Anesth Analg** 1997 Aug;85(2):237–47

INSTRUMENTATION

Atheromatous aortic plaque as a cause of resistance to needle passage during transaortic celiac plexus block. Naveira FA, et al. **Anesth Analg** 1996 Dec;83(6):1327–9

METHODS

Pain relief and clinical outcome: from opioids to balanced analgesia. Kehlet H. **Acta Anaesthesiol Belg** 1996; 47(3):111–4 (19 ref.)

Oral sweet solution reduces pain-related behaviour in preterm infants. Abad F, et al. **Acta Paediatr** 1996 Jul; 85(7):854–8

Analgesia in newborns given oral glucose. Skogsdal Y, et al. **Acta Paediatr** 1997 Feb;86(2):217–20

Using balanced analgesia for postoperative pain. Pasero CL, et al. **Am J Nurs** 1996 Dec;96(12):17

Preemptive analgesia: it starts before surgery [published erratum appears in Am J Nurs 1997 Feb;97(2):16] Pasero CL, et al. **Am J Nurs** 1996 Dec;96(12):17–8

Prevention of phantom limb pain by infusion of local anaesthetic into the sciatic nerve [see comments] Pavy TJ, et al. **Anaesth Intensive Care** 1996 Oct;24(5):599–600. Comment in: Anaesth Intensive Care 1997 Apr;25(2):200.

Analgesia for removal of chest drains [letter; comment] Mackenzie JW, et al. **Anaesthesia** 1997 Jul;52(7):718. Comment on: Anaesthesia 1997 Feb;52(2):173–5.

Paravertebral block in head injured patient with chest trauma [letter] Williamson S, et al. **Anaesthesia** 1997 Mar; 52(3):284–5

The effect of intradermal administration of lidocaine and morphine on the response to thermal stimulation. Atanassoff PG, et al. **Anesth Analg** 1997 Jun;84(6):1340–3

Intraarticular morphine analgesia in chronic pain patients with osteoarthritis. Likar R, et al. **Anesth Analg** 1997 Jun; 84(6):1313–7

A comparison of remifentanil and morphine sulfate for acute postoperative analgesia after total intravenous anesthesia with remifentanil and propofol. Yarmush J, et al. **Anesthesiology** 1997 Aug;87(2):235–43

Comparison of diclofenac sodium and morphine sulphate for postoperative analgesia after day case inguinal hernia surgery [letter; comment] Anyanwu A. **Ann R Coll Surg Engl** 1997 Mar;79(2):155. Comment on: Ann R Coll Surg Engl 1996 Jul;78(4):363–6.

Treating acute pain in hospital. McQuay H, et al. **BMJ** 1997 May 24;314(7093):1531–5 (31 ref.)

Postoperative regional analgesia following basilic vein transposition for vascular access. Butterworth PC, et al. **Br J Surg** 1997 Apr;84(4):561

Spermatic-cord block improves analgesia for day-case testicular surgery. Burden RJ, et al. **Br J Urol** 1997 Sep; 80(3):472–5

Serum bupivacaine concentrations during continuous extrapleural infusion. Dauphin A, et al. **Can J Anaesth** 1997 Apr;44(4):367–70

Is wound infiltration with anesthetic effective as pre-emptive analgesia? A clinical trial in appendectomy patients [see comments] Willard PT, et al. **Can J Surg** 1997 Jun; 40(3):213–7. Comment in: Can J Surg 1997 Jun;40(3):166.

Analgesia in the elderly. Practical treatment recommendations. Drage MP, et al. **Drugs Aging** 1996 Nov; 9(5):311–8 (42 ref.)

Popliteal sciatic nerve block for postoperative analgesia. Rongstad K, et al. **Foot Ankle Int** 1996 Jul;17(7):378–82

Patient attitudes to perioperative suppository administration for postoperative analgesia. Carroll M, et al. **Ir J Med Sci** 1996 Oct-Dec;165(4):286–8

Pain relief following cardiac surgery: a review. Taylor A, et al. **Ir J Med Sci** 1996 Jan-Mar;165(1):1–9 (68 ref.)

Titrated intravenous opioids from the same syringe: an infection risk? Taylor M, et al. **J Accid Emerg Med** 1997 Jan;14(1):33–5

Postoperative analgesia and intraoperative inhalational anesthetic requirements during umbilical herniorrhaphy in children: postincisional local infiltration versus preincisional caudal epidural block. Tobias JD. **J Clin Anesth** 1996 Dec;8(8):634–8

Improved respiratory function and analgesia control after endovascular AAA repair. Boyle JR, et al. **J Endovasc Surg** 1997 Feb;4(1):62–5

Analgesia during circumcision. Dake P, et al. **J Fam Pract** 1997 Aug;45(2):100–1

Battlefield analgesia—a basic approach. Hocking G, et al. **J R Army Med Corps** 1996 Oct;142(3):101–2

Transverse tripolar spinal cord stimulation: theoretical performance of a dual channel system. Struijk JJ, et al. **Med Biol Eng Comput** 1996 Jul;34(4):273–9

Para-umbilical block: a new concept for regional anaesthesia in children. Courreges P, et al. **Paediatr Anaesth** 1997; 7(3):211–4

Postoperative pain management. Tobias JD. **Pediatr Ann** 1997 Aug;26(8):490–500 (23 ref.)

Sedation and analgesia for minor pediatric procedures. Algren JT, et al. **Pediatr Emerg Care** 1996 Dec;12(6):435–41 (6 ref.)

Anaesthetic experience with isolated limb perfusion with melphalan for melanoma. Kam PC, et al. **Perfusion** 1996 Sep;11(5):395–9

Blockade of tolerance to stress-induced analgesia by MK-801 in mice. Vaccarino AL, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):435–9

Alternative neuraxial pain management techniques. Abram SE. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):129–34 (59 ref.)

Importance of preincisional analgesia. Abram SE. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):117–21 (31 ref.)

Analgesic brachial plexus block for reduction of shoulder dislocation [letter] Agostoni M, et al. **Reg Anesth** 1996 Jul-Aug;21(4):373

50 Years on the wrong side of the reflex arc [editorial] Bromage PR. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):1–4

Providing perioperative analgesia care: a special unit or a special program? Brown DL. **Reg Anesth** 1996 Nov-Dec;

21(6 Suppl):105–7 (17 ref.)
Future directions for outcome research in acute pain management: design of clinical trials. Carpenter RL. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):137–8 (11 ref.)
Consensus statement on acute pain management. Carpenter RL, et al. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):152–6 (0 ref.)
Subarachnoid sufentanil for extracorporeal shock lithotripsy. Eaton MP, et al. **Reg Anesth** 1997 Jan–Feb;22(1):86–8
New agents to clinical practice: introduction to clinical trials. Eisenach JC. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):135–6 (14 ref.)
New technique for piriformis muscle injection using a nerve stimulator [letter] Hanania M. **Reg Anesth** 1997 Mar–Apr; 22(2):200–2
Preemptive analgesia in children. Does it exist? Ho JW, et al. **Reg Anesth** 1997 Mar–Apr;22(2):125–30
Organizing postoperative accelerated recovery programs. Kehlet H. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):149–51 (20 ref.)
Effect of pain relief on the surgical stress response. Kehlet H. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):35–7 (3 ref.)
General outcome improvement overview. Kehlet H. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):5–8
Interpleural analgesia in the management of esophageal perforation. Main A. **Reg Anesth** 1997 Mar–Apr; 22(2):185–7
An observational study of combined continuous lumbar plexus and single–shot sciatic nerve blocks for post–knee surgery analgesia. Mansour NY, et al. **Reg Anesth** 1996 Jul–Aug;21(4):287–91
Is an ounce of preoperative local anesthetic better than a pound of postoperative analgesic? [editorial; comment] Raja SN. **Reg Anesth** 1996 Jul–Aug;21(4):277–80. Comment on: Reg Anesth 1996 Jul–Aug;21(4):281–6.
Continuous spinal analgesia. Comparison between patient–controlled and bolus administration of plain bupivacaine for postoperative pain relief. Rundshagen I, et al. **Reg Anesth** 1997 Mar–Apr;22(2):150–6
Pain and sleep [editorial] Friedrichs ES. **Wis Med J** 1997 Feb;96(2):8–9
[Problems of postoperative drug analgesia in proctological surgery] Khinev S, et al. **Khirurgiia (Sofiia)** 1996;49(6):40–1 (Eng. Abstr.) **(Bul)**
[Analgesia in traumatism in childhood] Kostova S, et al. **Khirurgiia (Sofiia)** 1996;49(3):30–2 (Eng. Abstr.) **(Bul)**
[Treatment of cancer pain in Denmark. A questionnaire survey] Jensen NH, et al. **Ugeskr Laeger** 1997 Mar 31; 159(14):2086–90 (Eng. Abstr.) **(Dan)**
[Electrotherapy of pain] Dumoulin J, et al. **J Belge Med Phys Rehabil** 1980;3(3):231–8 (15 ref.) **(Fre)**
[Pain treatment: current status and perspectives] Buchser E, et al. **Rev Med Suisse Romande** 1997 Mar;117(3):175–84 (10 ref.) **(Fre)**
[What do adolescents desire for the postoperative pain relief?—a speculation from an interview with a patient] Horimoto Y, et al. **Masui** 1996 Sep;45(9):1160–3 (Eng. Abstr.) **(Jpn)**
[Radiofrequency treatment] Bell RF, et al. **Tidsskr Nor Laegeforen** 1997 Aug 10;117(18):2650 **(Nor)**
[Preventive analgesia: true of preventing the postoperative pain syndrome] Ovechkin AM, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):35–9 (Eng. Abstr.) **(Rus)**
[Analgesia in pancreatic cancer. Achievements and perspectives] Shalimov SO, et al. **Klin Khir** 1997;(1):38–42 (53 ref.) **(Ukr)**

NURSING

Managing postoperative pain in the elderly. Pasero CL, et al. **Am J Nurs** 1996 Oct;96(10):38–45; quiz 46 (19 ref.)

PSYCHOLOGY

The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Benedetti F, et al. **Prog Neurobiol** 1997 Jun;52(2):109–25 (135 ref.)

STANDARDS

Baseline pain as a moderator of hypnotic analgesia for burn injury treatment. Patterson DR, et al. **J Consult Clin Psychol** 1997 Feb;65(1):60–7
Consensus statement on acute pain management. Carpenter RL, et al. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):152–6 (0 ref.)

UTILIZATION

The undertreatment of pain in ambulatory AIDS patients. Breitbart W, et al. **Pain** 1996 May–Jun;65(2–3):243–9
Good patients cope with their pain: postoperative analgesia and nurses' perceptions of their patients' pain. Salmon P, et al. **Pain** 1996 Nov;68(1):63–8
Pediatric emergency department analgesic practice. Friedland LR, et al. **Pediatr Emerg Care** 1997 Apr; 13(2):103–6

VETERINARY

Local and regional anesthesia and analgesia. Pascoe P. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):94–105 (88 ref.)
Preliminary investigations of pain and analgesia assessment in horses administered phenylbutazone or placebo after arthroscopic surgery. Raekallio M, et al. **Vet Surg** 1997 Mar–Apr;26(2):150–5
Postoperative analgesia for stifle surgery: a comparison of intra–articular bupivacaine, morphine, or saline. Sammarco JL, et al. **Vet Surg** 1996 Jan–Feb;25(1):59–69
[Evaluation of the antinociceptive effect of xylazine after epidural administration in dogs under general anesthesia with isoflurane] Rector E, et al. **Berl Munch Tierarztl Wochenschr** 1997 Jan;110(1):15–23 (Eng. Abstr.) **(Ger)**

ANALGESIA, ACUPUNCTURE see **ACUPUNCTURE ANALGESIA**

ANALGESIA, CONGENITAL see **PAIN INSENSITIVITY, CONGENITAL**

ANALGESIA, EPIDURAL

Does epidural sufentanil provide effective analgesia per– and postoperatively for abdominal aortic surgery? Broekema AA, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):20–5
Does morphine premedication influence the pain and consumption of postoperative analgesics after total knee arthroplasty? Hendolin H, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):81–5
2–Chloroprocaine antagonism of epidural morphine analgesia. Karambelkar DJ, et al. **Acta Anaesthesiol Scand** 1997 Jun;41(6):774–8
Neuroendocrine response to mid and upper abdominal surgery [letter; comment] Richardson J, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):433–4. Comment on: Acta Anaesthesiol Scand 1996 Jul;40(6):691–6.
Postoperative epidural infusion of morphine and bupivacaine is safe on surgical wards. Organisation of the treatment, effects and side–effects in 2000 consecutive patients. Rygnestad T, et al. **Acta Anaesthesiol Scand** 1997 Aug; 41(7):868–76
Introducing epidural fentanyl for on–ward pain relief after major surgery. Salomäki TE, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):704–9
Myoelectric activity in the stomach and duodenum after epidural administration of morphine or bupivacaine. Thörn SE, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):773–8
Maintained unilateral epidural analgesia [letter] Van Gessel E, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):135–6
Prolonged postoperative epidural analgesia: how to make it work safely and effectively. Breivik H. **Acta Anaesthesiol Scand Suppl** 1996;109:173–4
Additives in neuraxial anesthesia: opioids, alpha–2 adrenergic agonists, and neostigmine as a possible future drug for perioperative pain management. Klimscha W, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:176–8
Epidural coadministration of ketamine, morphine and bupivacaine attenuates post–herpetic neuralgia—a case report. Wong CS, et al. **Acta Anaesthesiol Sin** 1996 Sep; 34(3):151–5
Quantitative sensory examination of epidural anaesthesia and analgesia in man. Brennum J. **Acta Physiol Scand Suppl** 1996;634:1–27
Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience. Gramling–Babb P, et al. **Am Heart J** 1997 Jun;133(6):648–55
Positional effects on maternal cardiac output during labor with epidural analgesia. Danilenko–Dixon DR, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):867–72
Evaluation of continuous intraspinal narcotic analgesia for chronic pain from benign causes. Yoshida GM, et al. **Am J Orthop** 1996 Oct;25(10):693–4
Increased intrapartum antibiotic administration associated with epidural analgesia in labor. Mayer DC, et al. **Am J Perinatol** 1997 Feb;14(2):83–6
The antinociceptive effect of epidural lignocaine and fentanyl during lithotripsy. Fredman B, et al. **Anaesth Intensive Care** 1997 Feb;25(1):11–4
Postoperative epidural ropivacaine [letter] Knuth S, et al. **Anaesth Intensive Care** 1997 Aug;25(4):435
Epidural steroids for sciatica [letter; comment] McQuay HJ, et al. **Anaesth Intensive Care** 1996 Apr;24(2):284–5. Comment on: Anaesth Intensive Care 1995 Oct;23(5):564–9.
The Cochrane collaboration [letter; comment] Murrell G, et al. **Anaesth Intensive Care** 1996 Apr;24(2):286–7. Comment on: Anaesth Intensive Care 1995 Oct;23(5):564–9.
Comparison of patient–controlled epidural analgesia with patient–controlled intravenous analgesia using pethidine or fentanyl. Ngan Kee WD, et al. **Anaesth Intensive Care** 1997 Apr;25(2):126–32
Back pain following postoperative epidural analgesia: an indicator of possible spinal infection. Tham EJ, et al. **Anaesth Intensive Care** 1997 Jun;25(3):297–301
Epidural ropivacaine 0.2% infusion for postoperative pain relief [letter] Watts DW. **Anaesth Intensive Care** 1997 Apr; 25(2):200–1
Thoracic epidural analgesia in cardiac surgery [editorial] [see comments] Desborough JP. **Anaesthesia** 1996 Sep; 51(9):805–7. Comment in: Anaesthesia 1997 Feb;52(2):186–7.
Neonatal welfare and placental transfer of fentanyl and bupivacaine during ambulatory combined spinal epidural analgesia for labour. Fernando R, et al. **Anaesthesia** 1997 Jun;52(6):517–24
Epidurals for cardiac surgery [letter; comment] Ponte J. **Anaesthesia** 1997 Feb;52(2):186–7. Comment on: Anaesthesia 1996 Sep;51(9):805–7.
Uterine rupture and epidural analgesia during trial of labour. Rowbottom SJ, et al. **Anaesthesia** 1997 May;52(5):486–8
A comparison of opioid solutions for patient–controlled epidural analgesia. Smith AJ, et al. **Anaesthesia** 1996 Nov; 51(11):1013–7
Safe epidural analgesia in thirty parturients with platelet counts between 69,000 and 98,000 mm(–3). Beilin Y, et al. **Anesth Analg** 1997 Aug;85(2):385–8
Orthostatic hypotension during postoperative continuous thoracic epidural bupivacaine–morphine in patients undergoing abdominal surgery. Crawford ME, et al. **Anesth Analg** 1996 Nov;83(5):1028–32
Postoperative epidural opioid analgesia: what are the choices? [see comments] de Leon–Casasola OA, et al. **Anesth Analg** 1996 Oct;83(4):867–75 (69 ref.). Comment in: Anesth Analg 1997 Jun;84(6):1390–1.
Postoperative epidural fentanyl analgesia [letter] dos Santos JE. **Anesth Analg** 1997 Aug;85(2):463–4
Continuous epidural ropivacaine 0.2% for analgesia after lower abdominal surgery. Etches RC, et al. **Anesth Analg** 1997 Apr;84(4):784–90
A randomized, double–blind, dose–response comparison of epidural fentanyl versus sufentanil analgesia after cesarean section. Grass JA, et al. **Anesth Analg** 1997 Aug; 85(2):365–71
Studies on the safety of glucose and paraben–containing neostigmine for intrathecal administration. Gurun MS, et al. **Anesth Analg** 1997 Aug;85(2):317–23
Intrathecal neostigmine for post–cesarean section analgesia: dose response. Krukowski JA, et al. **Anesth Analg** 1997 Jun;84(6):1269–75
The dose–response pharmacology of intrathecal sufentanil in female volunteers. Lu JK, et al. **Anesth Analg** 1997 Aug; 85(2):372–9
Epidural meperidine after cesarean section: the effect of diluent volume. Ngan Kee WD, et al. **Anesth Analg** 1997 Aug;85(2):380–4
Fetal heart rate changes after intrathecal sufentanil or epidural bupivacaine for labor analgesia: incidence and clinical significance. Nielsen PE, et al. **Anesth Analg** 1996 Oct;83(4):742–6
Patient–controlled epidural analgesia: interactions between nalbuphine and hydromorphone. Parker RK, et al. **Anesth Analg** 1997 Apr;84(4):757–63
The effect of epidural fentanyl on the minimum local analgesic concentration of epidural chloroprocaine in labor. Polley LS, et al. **Anesth Analg** 1996 Nov;83(5):987–90
Intrathecal sufentanil for labor analgesia: do sensory changes predict better analgesia and greater hypotension? Riley ET, et al. **Anesth Analg** 1997 Feb;84(2):346–51
Epidural bolus clonidine/morphine versus epidural patient–controlled bupivacaine/sufentanil: quality of postoperative analgesia and cost–identification analysis. Rockemann MG, et al. **Anesth Analg** 1997 Oct;85(4):864–9
Duration of intrathecal labor analgesia: early versus advanced labor. Viscomi CM, et al. **Anesth Analg** 1997 May; 84(5):1108–12
The effects of adding sufentanil to bupivacaine for postoperative patient–controlled epidural analgesia. Wiebalck A, et al. **Anesth Analg** 1997 Jul;85(1):124–9
Postcesarean analgesia with both epidural morphine and intravenous patient–controlled analgesia: neurobehavioral outcomes among nursing neonates. Wittels B, et al. **Anesth Analg** 1997 Sep;85(3):600–6
Epidural analgesia and the incidence of cesarean section: time for another close look [editorial] Chestnut DH. **Anesthesiology** 1997 Sep;87(3):472–6
Epidural clonidine used as the sole analgesic agent during and after abdominal surgery. A dose–response study. De Kock M, et al. **Anesthesiology** 1997 Feb;86(2):285–92
Nitric oxide synthase inhibition modulates the ventilatory depressant and antinociceptive actions of fourth ventricular infusions of morphine in the awake dog. Pelligrino DA, et al. **Anesthesiology** 1996 Dec;85(6):1367–77
Cesarean delivery: a randomized trial of epidural versus patient–controlled meperidine analgesia during labor. Sharma SK, et al. **Anesthesiology** 1997 Sep;87(3):487–94
Normal saline i.v. fluid load decreases uterine activity in active labour. Cheek TG, et al. **Br J Anaesth** 1996 Nov; 77(5):632–5
Extradural morphine gives better pain relief than patient–controlled i.v. morphine after hysterectomy. Eriksson–Mjöberg M, et al. **Br J Anaesth** 1997 Jan; 78(1):10–6
Ambulatory extradural analgesia in labour and mode of delivery [letter] Jenkins JG. **Br J Anaesth** 1997 Jun; 78(6):776–7
Plasma bupivacaine concentrations associated with continuous extradural infusions in babies. Peutrell JM, et al. **Br J Anaesth** 1997 Feb;78(2):160–2
Blood pressure and fetal heart rate changes with patient–controlled combined spinal epidural analgesia while ambulating in labour. al–Mufti R, et al. **Br J Obstet Gynaecol** 1997 May;104(5):554–8
Calmodulin inhibitors induce spinal analgesia in rats. Menendez L, et al. **Brain Res** 1996 Aug 26;731(1–2):114–21
Labour analgesia with intrathecal fentanyl decreases maternal

stress. Cascio M, et al. **Can J Anaesth** 1997 Jun;44(6):605–9

Perioperative ischaemia in aortic surgery: combined epidural/general anaesthesia and epidural analgesia vs general anaesthesia and i.v. analgesia [see comments] Garnett RL, et al. **Can J Anaesth** 1996 Aug;43(8):769–77 . Comment in: Can J Anaesth 1996 Aug;43(8):759–63. Comment in: Can J Anaesth 1997 Apr;44(4):452–3.

Epidural and intravenous bolus morphine for postoperative analgesia in infants. Haberkern CM, et al. **Can J Anaesth** 1996 Dec;43(12):1203–10

Epidural morphine vs hydromorphone in post–caesarean section patients. Halpern SH, et al. **Can J Anaesth** 1996 Jun;43(6):595–8

Epidural administered buprenorphine in the perioperative period. Miwa Y, et al. **Can J Anaesth** 1996 Sep;43(9):907–13

Bupivacaine decreases epidural meperidine requirements after abdominal surgery. St–Onge S, et al. **Can J Anaesth** 1997 Apr;44(4):360–6

Comparative assessment of the anaesthetic and analgesic effects of intramuscular and epidural clonidine in humans [see comments] Samsó E, et al. **Can J Anaesth** 1996 Dec; 43(12):1195–202. Comment in: Can J Anaesth 1996 Dec;43(12):1191–4.

Epidural analgesia for labour in a patient with Charcot–Marie–Tooth disease. Scull T, et al. **Can J Anaesth** 1996 Nov;43(11):1150–2

Pre–emptive analgesia with ketamine, morphine and epidural lidocaine prior to total knee replacement. Wong CS, et al. **Can J Anaesth** 1997 Jan;44(1):31–7

Treatment of postoperative pain with thoracic epidural morphine in oral malignant tumor patients. Sakuramoto C, et al. **Clin J Pain** 1996 Jun;12(2):142–4

Effect of epidural analgesia on venous blood flow after hip arthroplasty. Markel DC, et al. **Clin Orthop** 1997 Jan; (334):168–74

Thoracic epidural anaesthesia and analgesia with bupivacaine for transsternal thymectomy for myasthenia gravis. Akpolat N, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):220–3

Transition to post–operative epidural or patient–controlled intravenous analgesia following total intravenous anaesthesia with remifentanil and propofol for abdominal surgery. Bowdle TA, et al. **Eur J Anaesthesiol** 1997 Jul; 14(4):374–9

Maternal and fetal effects of adrenaline with bupivacaine (0.25%) for epidural analgesia during labour. Dounas M, et al. **Eur J Anaesthesiol** 1996 Nov;13(6):594–8

Effects of thoracic epidural analgesia on pulmonary function after coronary artery bypass surgery. Stenseth R, et al. **Eur J Cardiothorac Surg** 1996;10(10):859–65; discussion 866

Effect of second–stage 0.25% epidural bupivacaine on the outcome of labor. Luxman D, et al. **Gynecol Obstet Invest** 1996;42(3):167–70

Epidural analgesia in Scotland: a survey of extradural opioid practice. Carson D, et al. **Health Bull (Edinb)** 1996 Jan; 54(1):51–62

Effect of epidural buprenorphine and clonidine on vesical functions in women. Batra YK, et al. **Int J Clin Pharmacol Ther** 1996 Jul;34(7):309–11

Parity, prolonged labor and epidural analgesia [letter] Witter FR, et al. **Int J Gynaecol Obstet** 1996 Jun;53(3):269–70

Comparison of lumbar and thoracic epidural narcotics for postoperative analgesia in patients undergoing abdominal aortic aneurysm repair [see comments] Gold MS, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):137–40. Comment in: J Cardiothorac Vasc Anesth 1997 Apr;11(2):127–8.

The epidural space: is it the place to be during vascular surgery? [editorial; comment] Kahn RA, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):127–8. Comment on: J Cardiothorac Vasc Anesth 1997 Apr;11(2):129–36. Comment on: J Cardiothorac Vasc Anesth 1997 Apr;11(2):137–40.

Lumbar epidural morphine infusions for children undergoing cardiac surgery. Shayevitz JR, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):217–24

Comparison of epidural morphine and oxycodone for pain after abdominal surgery. Backlund M, et al. **J Clin Anesth** 1997 Feb;9(1):30–5

Pulse oxygen saturation in parturients receiving epidural versus opioid analgesia for labor [letter] Lurie S, et al. **J Clin Anesth** 1997 Feb;9(1):87

Postoperative analgesia and intraoperative inhalational anesthetic requirements during umbilical herniorrhaphy in children: postincisional local infiltration versus preincisional caudal epidural block. Tobias JD. **J Clin Anesth** 1996 Dec;8(8):634–8

New concepts in postoperative pain management: is there more beyond pain control? de Leon–Casasola OA. **J Fla Med Assoc** 1996 Dec;83(10):695–700 (72 ref.)

Epidural opioid therapy for chronic nonmalignant pain: critique of current experience. Bedder MD. **J Pain Symptom Manage** 1996 Jun;11(6):353–6 (14 ref.)

Epidural and subarachnoid administration of opioids for nonmalignant pain: technical issues, current approaches and novel treatments. Hassenbusch SJ. **J Pain Symptom Manage** 1996 Jun;11(6):357–62 (23 ref.)

High–dose epidural infusion of opioids for cancer pain: cost issues. Manfredi PL, et al. **J Pain Symptom Manage** 1997 Feb;13(2):118–21

The inappropriate use of the epidural route in cancer pain. Mercadante S, et al. **J Pain Symptom Manage** 1997 Apr; 13(4):233–7

Monitoring practices following epidural analgesics for pain management: a follow–up survey. Muir MR, et al. **J Pain Symptom Manage** 1997 Jul;14(1):36–44

Opioids in labor [letter; comment] Kingdom J, et al. **Lancet** 1997 Mar 8;349(9053):726; discussion 727–8. Comment on: Lancet 1997 Jan 4;349(9044):4–5.

Reduction in thermal hyperalgesia by intrathecal administration of glycine and related compounds. Simpson RK Jr, et al. **Neurochem Res** 1997 Jan;22(1):75–9

Accidental intrathecal injection of ionic water–soluble contrast medium: report of a case, including treatment. Salvolini U, et al. **Neuroradiology** 1996 May;38(4):349–51

Analgesic effect of epidural morphine in lumbar disc surgery. Sepehrnia A, et al. **Neurosurg Rev** 1996;19(4):227–30

Association of epidural analgesia with cesarean delivery in nulliparas. Lieberman E, et al. **Obstet Gynecol** 1996 Dec; 88(6):993–1000

The effect of instituting an elective labor epidural program on the operative delivery rate. Lyon DS, et al. **Obstet Gynecol** 1997 Jul;90(1):135–41

Patients can manage intraspinal analgesia at home. Racolin AA. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):22

Intraoperative continuous epidural lidocaine for early postoperative analgesia. Mizutani K, et al. **Osaka City Med J** 1996 Dec;42(2):125–34

The effect of perioperative and postoperative caudal block on pain control in children. Goodarzi M. **Paediatr Anaesth** 1996;6(6):475–7

Comments on Richardson, PAIN, 65 (1996) 277–278 [letter; comment] Devulder J. **Pain** 1997 Apr;70(2–3):291–2. Comment on: Pain 1996 May–Jun;65(2–3):277–8.

Facilitation of spinal cord stimulator implantation with epidural analgesia [see comments] Richardson J. **Pain** 1996 May–Jun;65(2–3):277–8. Comment in: Pain 1997 Apr;70(2–3):291–2.

Isobolographic analysis of the interaction between epidural sufentanil and bupivacaine in rats. Vercauteren M, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):237–42

Single–injection lumbar epidural morphine for postoperative analgesia in children: a report of 175 cases [see comments] Bozkurt P, et al. **Reg Anesth** 1997 May–Jun;22(3):212–7. Comment in: Reg Anesth 1997 May–Jun;22(3):205–8.

Gastrointestinal benefits of regional anesthesia/analgesia. Carpenter RL. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):13–7 (29 ref.)

Clinical outcome after epidural anesthesia and analgesia in high–risk surgical patients. de Leon–Casasola OA. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):144–8 (53 ref.)

Immunomodulation and epidural anesthesia and analgesia. de Leon–Casasola OA. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):24–5 (16 ref.)

Epidurograms in the management of patients with long–term epidural catheters. Du Pen SL, et al. **Reg Anesth** 1996 Jan–Feb;21(1):61–7

Regional anesthesia and analgesia in the patient receiving thromboprophylaxis [editorial; comment] Horlocker TT. **Reg Anesth** 1996 Nov–Dec;21(6):503–7. Comment on: Reg Anesth 1996 Nov–Dec;21(6):517–24.

Essential thrombocythemia and epidural analgesia in the parturient. Does thromboelastography help? Lowenwirt I, et al. **Reg Anesth** 1996 Nov–Dec;21(6):525–8

Epidural analgesia improves outcome following pediatric fundoplication. A retrospective analysis. McNeely JK, et al. **Reg Anesth** 1997 Jan–Feb;22(1):16–23

Ketamine potentiates analgesic effect of morphine in postoperative epidural pain control [see comments] Wong CS, et al. **Reg Anesth** 1996 Nov–Dec;21(6):534–41. Comment in: Reg Anesth 1996 Nov–Dec;21(6):508–13.

Epidural ketamine: a useful, mechanistically novel adjuvant for epidural morphine? [editorial; comment] Yaksh TL. **Reg Anesth** 1996 Nov–Dec;21(6):508–13. Comment on: Reg Anesth 1996 Nov–Dec;21(6):534–41.

The effect of continuous lumbar epidural infusion of ropivacaine (0.1%, 0.2%, and 0.3%) and 0.25% bupivacaine on sensory and motor block in volunteers: a double–blind study. Zaric D, et al. **Reg Anesth** 1996 Jan–Feb;21(1):14–25

Postoperative pain control after lumbar spine fusion. Patient–controlled analgesia versus continuous epidural analgesia. Cohen BE, et al. **Spine** 1997 Aug 15; 22(16):1892–6; discussion 1896–7

Thoracic versus lumbar epidural anesthesia's effect on pain control and ileus resolution after restorative proctocolectomy. Scott AM, et al. **Surgery** 1996 Oct; 120(4):688–95; discussion 695–7

Administration of epidural bupivacaine combined with epidural morphine after esophageal surgery. Terai T, et al. **Surgery** 1997 Apr;121(4):359–65

[Pre– and intra–operative administration of epidural morphine provides good postoperative pain relief after laminectomy] Kuo TC, et al. **Acta Anaesthesiol Sin** 1996 Jun;34(2):69–74 (Eng. Abstr.) **(Chi)**

[Combined spinal and epidural analgesia for labor (letter; comment)] Guedj P. **Ann Fr Anesth Reanim** 1996; 15(7):1135–7. Comment on: Ann Fr Anesth Reanim 1996;15(3):263–5. **(Fre)**

[Epidural analgesia in the surgery of scoliosis (letter)] Baracco E, et al. **Cah Anesthesiol** 1996;44(4):389 **(Fre)**

[Obstetrical epidural analgesia: an epidemiological in Bourgogne and Franche–Comté 1993] Vattaï P, et al. **Cah Anesthesiol** 1996;44(3):207–13 (Eng. Abstr.) **(Fre)**

[Intra– and postoperative catheter epidural analgesia. Combination of epidural analgesia and general anesthesia] Seeling W, et al. **Anaesthesist** 1997 Mar;46(3):237–52 (13 ref.) **(Ger)**

[Epidural administration of opioids in labor: contra] Biscoping J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Apr; 32(4):256–7 **(Ger)**

[Epidural administration of opioids in labor: pro] Gogarten W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Apr; 32(4):253–5 **(Ger)**

[Continuous intra– and postoperative peridural analgesia with combined low dose sufentanil, clonidine and bupivacaine] Hering R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Nov; 31(9):550–5 (Eng. Abstr.) **(Ger)**

[Conversion from peridural to transdermal opiate analgesia in abdominal tumor pain syndrome] Schuler M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 May; 32(5):322–4 (Eng. Abstr.) **(Ger)**

[Treatment of pain with peridural administration of opiates. Comment on the contribution by S. Chrubasik et al (letter; comment)] Brodner G, et al. **Chirurg** 1997 Jan;68(1):94–5 . Comment on: Chirurg 1996 Jul;67(7):665–70. **(Ger)**

[Treatment of pain with peridural administration of opioids (see comments)] Chrubasik S, et al. **Chirurg** 1996 Jul; 67(7):665–70 (24 ref.) (Eng. Abstr.). Comment in: Chirurg 1997 Jan;68(1):94–5. **(Ger)**

[Patient–controlled postoperative analgesia in orthopedic surgery: epidural PCA versus intravenous PCA] Bertini L, et al. **Minerva Anestesiol** 1995 Jul–Aug;61(7–8):319–28 (Eng. Abstr.) **(Ita)**

[Plasma levels of beta–endorphins and ACTH in labor with continuous peridural analgesia] Borgia ML, et al. **Minerva Anestesiol** 1996 May;62(5):183–6 (Eng. Abstr.) **(Ita)**

[Epidural fentanyl provide sufficient analgesia for extracorporeal shock wave lithotripsy (ESWL)] Abe T, et al. **Masui** 1997 May;46(5):694–9 (Eng. Abstr.) **(Jpn)**

[Epidural administration of buprenorphine after combined spinal epidural anesthesia] Endoh M, et al. **Masui** 1996 Nov; 45(11):1396–9 (Eng. Abstr.) **(Jpn)**

[Effective treatment of a man with head injury and multiple rib fractures with epidural analgesia] Kariya N, et al. **Masui** 1996 Feb;45(2):223–6 (Eng. Abstr.) **(Jpn)**

[Two cases of crush syndrome associated with intractable pain] Kurita S, et al. **Masui** 1997 Apr;46(4):511–4 (Eng. Abstr.) **(Jpn)**

[Intraoperative continuous epidural block influences postoperative changes in breathing pattern and thoracoabdominal movement associated with upper abdominal surgery] Mitsuhashi S, et al. **Masui** 1996 Jul; 45(7):813–7 (Eng. Abstr.) **(Jpn)**

[A case of reflex sympathetic dystrophy following a retinous surgery] Morimoto Y, et al. **Masui** 1997 Apr;46(4):549–51 (Eng. Abstr.) **(Jpn)**

[Effects of continuous epidural administration of fentanyl and morphine on postcesarean pain] Oda A, et al. **Masui** 1996 Dec;45(12):1511–5 (Eng. Abstr.) **(Jpn)**

[Postoperative epidural fentanyl administration in patients for hysterectomy with para–aortic lymph node resection] Sugimoto M, et al. **Masui** 1997 May;46(5):628–34 (Eng. Abstr.) **(Jpn)**

[Postoperative continuous epidural infusion of morphine in a patient with myotonic dystrophy] Takeda T, et al. **Masui** 1996 Nov;45(11):1384–7 (Eng. Abstr.) **(Jpn)**

[Epidural electric nerve stimulation] Brusin VI, et al. **Anesteziol Reanimatol** 1995 Nov–Dec;(6):26–31 (67 ref.) **(Rus)**

[Analgesic effectiveness and repercussions on the progress of labor of small doses of bupivacaine and fentanyl in continuous peridural perfusion] García–Muñoz M, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):135–9 (Eng. Abstr.) **(Spa)**

[Postoperative analgesia with epidural methadone in patients operated for hernia of the lumbar disc] Hernández–Palazón J, et al. **Rev Esp Anestesiol Reanim** 1997 May;44(5):182–5 (Eng. Abstr.) **(Spa)**

[MUltiple sclerosis and obstetric epidural analgesia] Salvador M, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):33–5 (Eng. Abstr.) **(Spa)**

[Pharmacokinetics of lidocaine in obstetric patients after its epidural single–dose administration] Sánchez–Alcaraz A, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):13–5 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Dural puncture: the patients' perspective. A patient survey of cases at a DGH maternity unit 1983–1993. Costigan SN, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):710–4

Pneumocephalus and respiratory depression after accidental dural puncture during epidural analgesia––a case report. Lin HY, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):119–23

Complications of epidural infusions for analgesia in postoperative and trauma patients. Kurek SJ, et al. **Am Surg** 1997 Jun;63(6):543–6

Postdural puncture symptoms in a child. McHale J, et al. **Anaesthesia** 1997 Jul;52(7):688–90

The effect of epidural opioids on maternal oxygenation during labour and delivery [see comments] Porter JS, et al. **Anaesthesia** 1996 Oct;51(10):899–903. Comment in: Anaesthesia 1997 Mar;52(3):276–8.

Epidural blood patch for atypical headache following obstetric epidural analgesia. Yentis SM, et al. **Anaesthesia** 1997 Jan;52(1):62–4

An epidural abscess due to resistant Staphylococcus aureus following epidural catheterisation. Yuste M, et al. **Anaesthesia** 1997 Feb;52(2):163–5

A comparison of multiport and uniport epidural catheters in laboring patients. D'Angelo R, et al. **Anesth Analg** 1997 Jun;84(6):1276–9

Epidural fibrin glue injection stops persistent cerebrospinal fluid leak during long-term intrathecal catheterization. Gerritse BM, et al. **Anesth Analg** 1997 May;84(5):1140–1

Epidural abscess in a one-year-old boy after continuous epidural analgesia. Larsson BA, et al. **Anesth Analg** 1997 Jun;84(6):1245–7

Skin abscess with lumbar epidural catheterization in infants: is it dangerous? Report of two cases. Meunier JF, et al. **Anesth Analg** 1997 Jun;84(6):1248–9

Three sudden postoperative respiratory arrests associated with epidural opioids in patients with sleep apnea. Ostermeier AM, et al. **Anesth Analg** 1997 Aug;85(2):452–60 (45 ref.)

Neurologic symptoms after accidental administration of epidural glucose. Whiteley MH, et al. **Anesth Analg** 1997 Jan;84(1):216–7

Do culture results tell us anything about the risk of infection with spinal catheters? [letter] Bevacqua BK. **Anesthesiology** 1997 Jul;87(1):179

Incidence of neurologic complications related to thoracic epidural catheterization. Giebler RM, et al. **Anesthesiology** 1997 Jan;86(1):55–63

Epidural catheter reconnection. Safe and unsafe practice. Langevin PB, et al. **Anesthesiology** 1996 Oct;85(4):883–8

Extradural analgesia: does it affect progress and outcome in labour? [editorial] McGrady EM. **Br J Anaesth** 1997 Feb;78(2):115–7

Pre-anaesthetic assessment of coagulation abnormalities in obstetric patients: usefulness, timing and clinical implications. Simon L, et al. **Br J Anaesth** 1997 Jun; 78(6):678–83

Do epidurals cause back pain? Buggy D, et al. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):99–101 (18 ref.)

Neuropathies masquerading as an epidural complication. Kahn L. **Can J Anaesth** 1997 Mar;44(3):313–6

Epidurals and fever: association or cause? [letter] Gray D, et al. **CMAJ** 1997 Sep 1;157(5):511–2

Accidental subdural injection of local anaesthetic: diagnosis by pressure measurement and response to aspiration of injectate. Tripathi M, et al. **Eur J Anaesthesiol** 1997 Jul; 14(4):455–7

Iatrogenic spinal epidural abscesses: early diagnosis essential for good outcome. Lindner A, et al. **Eur J Med Res** 1997 May 28;2(5):201–5

Fetal and maternal transcutaneous PCO2 levels during labour and the influence of epidural analgesia. Bergmans MG, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug; 67(2):127–32

Post-partum urinary retention: a comparison between two methods of epidural analgesia. Olofsson CI, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jan;71(1):31–4

Effect of epidural analgesia on duration and outcome of induced labor. Rojansky N, et al. **Int J Gynaecol Obstet** 1997 Mar;56(3):237–44

Compartment syndromes associated with postoperative epidural analgesia. A case report [letter; comment] Schmitz ML, et al. **J Bone Joint Surg Am** 1997 Aug;79(8):1271–2 . Comment on: J Bone Joint Surg Am 1996 Apr;78(4):597–9.

Maternal fever after epidural analgesia. Douglas M, et al. **J Fam Pract** 1997 Jun;44(6):529–30

Appropriate precautions for insertion of epidural catheters [letter; comment] Bowler IC. **J Hosp Infect** 1996 Aug; 33(4):302–4. Comment on: J Hosp Infect 1996 Jan;32(1):79–81.

Epidural catheter insertion and operating theatre standards [letter; comment] [see comments] Catchpole CR, et al. **J Hosp Infect** 1996 Jan;32(1):79–81. Comment on: J Hosp Infect 1995 Aug;30(4):245–52. Comment in: J Hosp Infect 1996 Aug;33(4):302–4.

Epidural analgesia [letter; comment] Walker M. **J Obstet Gynecol Neonatal Nurs** 1996 Oct;25(8):650. Comment on: J Obstet Gynecol Neonatal Nurs 1996 May;25(4):350–4.

Spinal epidural metastasis: implications for spinal analgesia to treat "refractory" cancer pain. Appelgren L, et al. **J Pain Symptom Manage** 1997 Jan;13(1):25–42

Compartment syndrome associated with bupivacaine and fentanyl epidural analgesia in pediatric orthopaedics [see comments] Dunwoody JM, et al. **J Pediatr Orthop** 1997 May–Jun;17(3):285–8. Comment in: J Pediatr Orthop 1997 May–Jun;17(3):282–4.

Compartment syndromes and epidural analgesia [editorial; comment] Mubarak SJ, et al. **J Pediatr Orthop** 1997 May–Jun;17(3):282–4 (9 ref.). Comment on: J Pediatr Orthop 1997 May–Jun;17(3):285–8.

Neurologic complications of lumbar epidural analgesia: spinal and paraspinal abscess. Bertol V, et al. **Neurology** 1997 Jun; 48(6):1732–3

Convulsions associated with epidural analgesia during sevoflurane anaesthesia. Saitoh K, et al. **Paediatr Anaesth** 1996;6(6):495–7

Respiratory depression following epidural morphine in an infant of three months of age. Vilà R, et al. **Paediatr Anaesth** 1997;7(1):61–4

Epidural analgesia, intrapartum fever, and neonatal sepsis evaluation. Lieberman E, et al. **Pediatrics** 1997 Mar; 99(3):415–9

Bupivacaine toxicity secondary to continuous epidural infusion [letter] Aldrete JA. **Reg Anesth** 1996 Sep–Oct; 21(5):498–9

Where should advocacy for pediatric patients end and concerns for patient safety begin? [editorial; comment] Broadman LM. **Reg Anesth** 1997 May–Jun;22(3):205–8. Comment on: Reg Anesth 1997 May–Jun;22(3):212–7.

Postoperative Guillain–Barré syndrome, arachnoiditis, and epidural analgesia. Rosenberg SK, et al. **Reg Anesth** 1996 Sep–Oct;21(5):486–9

Pressure sores as a complication of patient-controlled epidural analgesia after cesarean delivery. Case report. Smet IG, et al. **Reg Anesth** 1996 Jul–Aug;21(4):338–41

[Infections in connection with epidural catheterization (letter)] Clemensen SE, et al. **Ugeskr Laeger** 1996 Nov 18; 158(47):6785–6 **(Dan)**

[Paravertebral abscess with secondary meningomyelitis after infiltration therapy. A brief case report] Ohlmann D, et al. **Wien Klin Wochenschr** 1996;108(14):442–3 **(Ger)**

[Evaluation of the blood patch using magnetic resonance (letter)] Catalá-Bauset JC, et al. **Rev Esp Anestesiol Reanim** 1996 Jun–Jul;43(6):222–3 **(Spa)**

[General convulsive crisis related to pneumocephalus after inadvertant dural puncture in an obstetric patient] Rodrigo P, et al. **Rev Esp Anestesiol Reanim** 1997 Jun–Jul; 44(6):247–9 (Eng. Abstr.) **(Spa)**

ECONOMICS

Comparison of accuracy and cost of disposable, nonmechanical pumps used for epidural infusions. Valente M, et al. **Reg Anesth** 1997 May–Jun;22(3):260–6

INSTRUMENTATION

Metallic microparticle formation using the needle–through–needle technique [letter] Eldor J. **Acta Anaesthesiol Scand** 1997 Feb;41(2):326–7

Epidural catheter design: holes and flows [letter; comment] Collier CB. **Anaesthesia** 1997 Feb;52(2):183. Comment on: Anaesthesia 1996 Aug;51(8):757–63.

Dangerous faulty loss of resistance syringe [letter] Dark A. **Anaesthesia** 1997 Aug;52(8):804

Evaluation of thoracic epidural catheter position and migration using radio–opaque catheters. Hendriks GW, et al. **Anaesthesia** 1997 May;52(5):457–9

Some suggestions for simplifying subcutaneous tunneling [letter] Ramaioli F, et al. **Anesth Analg** 1997 Sep;85(3):705–6

Epidural catheter reconnection. Safe and unsafe practice. Langevin PB, et al. **Anesthesiology** 1996 Oct;85(4):883–8

Another way to solve the problem of catheter displacement [letter] Ramaioli F, et al. **Anesthesiology** 1996 Sep;85(3):682

Superiority of multi–orifice over single–orifice epidural catheters for labor analgesia and cesarean delivery. Segal S, et al. **J Clin Anesth** 1997 Mar;9(2):109–12

The effect of needle size and type in paediatric caudal analgesia. Newman PJ, et al. **Paediatr Anaesth** 1996; 6(6):459–61

Experience with arrow flextip epidural catheters [letter; comment] Ananthanarayan C. **Reg Anesth** 1996 Nov–Dec; 21(6):607. Comment on: Reg Anesth 1996 Jan–Feb;21(1):75–7.

Knotted epidural catheters [letter; comment] Stuart AL, et al. **Reg Anesth** 1996 Nov–Dec;21(6):606. Comment on: Reg Anesth 1996 Jan–Feb;21(1):71–3.

Comparison of accuracy and cost of disposable, nonmechanical pumps used for epidural infusions. Valente M, et al. **Reg Anesth** 1997 May–Jun;22(3):260–6

[Epiduritis after long–term pain therapy with an epidural catheter—review of the literature with a current case report] Michel H, et al. **Anaesthesiol Reanim** 1997; 22(3):69–79 (105 ref.) (Eng. Abstr.) **(Ger)**

[Peridural catheter for postoperative long–term analgesia in children] Boos K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):362–7 (Eng. Abstr.) **(Ger)**

[Effectiveness, side effects and costs of postoperative pain therapy: intravenous and epidural patient–controlled analgesia (PCA)] Rockemann MG, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jul; 32(7):414–9 (Eng. Abstr.) **(Ger)**

[Epidural catheter infection. A forgotten prosthetic device? (letter; comment)] Morano Amado LE, et al. **Rev Clin Esp** 1996 Nov;196(11):801–2. Comment on: Rev Clin Esp 1995 Jul;195(7):497–506. **(Spa)**

METHODS

Epidural analgesia for labor pain: (still) the method of choice? Vercauteren M. **Acta Anaesthesiol Belg** 1996;47(4):163–9 (28 ref.)

Continuous thoracic epidural analgesia versus combined spinal/thoracic epidural analgesia on pain, pulmonary function and the metabolic response following colonic resection [see comments] Scott NB, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):691–6. Comment in: Acta Anaesthesiol Scand 1997 Mar;41(3):433–4.

Thoracic epidural analgesia started after cardiopulmonary bypass. Adrenergic, cardiovascular and respiratory sequelae. Fawcett WJ, et al. **Anaesthesia** 1997 Apr; 52(4):294–9

Epidural opioids in labour—do we need them? [letter; comment] Thomas EO. **Anaesthesia** 1997 Mar;52(3):276–8 . Comment on: Anaesthesia 1996 Oct;51(10):899–903.

A simple system to prevent epidural catheter hub disconnections [letter] Breznick D, et al. **Anesth Analg** 1997 May;84(5):1167

Intrathecal and epidural anesthesia and analgesia for cardiac surgery. Chaney MA. **Anesth Analg** 1997 Jun;84(6):1211–21 (84 ref.)

Epidural morphine plus ketamine for upper abdominal surgery: improved analgesia from preincisional versus postincisional administration. Choe H, et al. **Anesth Analg** 1997 Mar;84(3):560–3

Determination of the dose–response relationship for intrathecal sufentanil in laboring patients. Herman NL, et al. **Anesth Analg** 1997 Jun;84(6):1256–61

Postoperative epidural opioid analgesia: what are the choices? [letter; comment] Ngan Kee WD. **Anesth Analg** 1997 Jun; 84(6):1390–1. Comment on: Anesth Analg 1996 Oct;83(4):867–75.

Postoperative epidural infusion: a randomized, double–blind, dose–finding trial of clonidine in combination with bupivacaine and fentanyl. Paech MJ, et al. **Anesth Analg** 1997 Jun;84(6):1323–8

Effects of ketorolac versus bupivacaine coadministration during patient–controlled hydromorphone epidural analgesia after thoracotomy procedures. Singh H, et al. **Anesth Analg** 1997 Mar;84(3):564–9

Epidural catheter insertion and satisfactory analgesia—the mobile versus the immobile patient [letter; comment] Moore DC. **Anesthesiology** 1997 Mar;86(3):747–9. Comment on: Anesthesiology 1996 Jun;84(6):1524–5.

Continuous extradural infusion of ropivacaine 2 mg ml–1 for pain relief during labour. Benhamou D, et al. **Br J Anaesth** 1997 Jun;78(6):748–50

Extradural clonidine combined with sufentanil and 0.0625% bupivacaine for analgesia in labour. Chassard D, et al. **Br J Anaesth** 1996 Oct;77(4):458–62

Extradural pain relief in labour: bupivacaine sparing by extradural fentanyl is dose dependent. Lyons G, et al. **Br J Anaesth** 1997 May;78(5):493–7

Intrathecal analgesia for labor. Wildman KM, et al. **J Fam Pract** 1997 Jun;44(6):535–40 (16 ref.)

Intraspinal morphine for chronic pain: a retrospective, multicenter study. Paice JA, et al. **J Pain Symptom Manage** 1996 Feb;11(2):71–80

The safety of continuous epidural infusion for postoperative analgesia in pediatric spine surgery. Shaw BA, et al. **J Pediatr Orthop** 1996 May–Jun;16(3):374–7

The use of additives to local anaesthetic solutions for caudal epidural blockade. Cook B, et al. **Paediatr Anaesth** 1996; 6(5):353–9 (54 ref.)

A simple technique to avoid epidural catheter disconnection from connector (Portex) [letter] Alam S, et al. **Reg Anesth** 1996 Nov–Dec;21(6):607

Extended epidural catheter infusions with analgesics for patients with noncancer pain at their homes. Aldrete JA. **Reg Anesth** 1997 Jan–Feb;22(1):35–42

Postoperative pain management in opioid–tolerant patients. de Leon–Casasola OA. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):114–6 (22 ref.)

Continuous infusion epidural analgesia during labor [letter] Eldor J. **Reg Anesth** 1996 Jul–Aug;21(4):373–4

Ambulatory combined spinal–epidural analgesia for labor. Influence of epinephrine on bupivacaine–sufentanil combination. Gautier PE, et al. **Reg Anesth** 1997 Mar–Apr; 22(2):143–9

Cervical epidural analgesia for management of pain associated with digital vasculitis secondary to rheumatoid arthritis. Green CR, et al. **Reg Anesth** 1997 Mar–Apr; 22(2):188–91

Epidural opioid delivery methods: bolus, continuous infusion, and patient–controlled epidural analgesia. Mulroy MF. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):100–4 (38 ref.)

Anesthetic management of a parturient with an incompletely resected cerebral arteriovenous malformation. Viscomi CM, et al. **Reg Anesth** 1997 Mar–Apr;22(2):192–7

[Balanced spinal analgesia in the treatment of oncologic pain. Review of the literature] Polati E, et al. **Minerva Anestesiol** 1996 Nov;62(11):363–75 (155 ref.) (Eng. Abstr.) **(Ita)**

[The effect of continuous epidural infusion of combination of buprenorphine and bupivacaine for postoperative pain relief using a portable 0.5 ml.h–1 type infuser with patient control module] Komatsu H, et al. **Masui** 1996 Jun; 45(6):735–40 (Eng. Abstr.) **(Jpn)**

STANDARDS

Audit of postoperative pain control. Influence of a dedicated acute pain nurse [see comments] Coleman SA, et al. **Anaesthesia** 1996 Dec;51(12):1093–6. Comment in: Anaesthesia 1997 Apr;52(4):388–9.

A two–year experience of an acute pain service in Singapore. Wong LT, et al. **Singapore Med J** 1997 May;38(5):209–13

TRENDS

[Epidural analgesia in labor. An area of continuous progress

ANALGESIA, EPIDURAL

(editorial)] Vilaplana-Birba J.
Rev Esp Anestesiol Reanim 1997 Apr;44(4):133-4 **(Spa)**

UTILIZATION

Epidural analgesia following upper abdominal surgery: United Kingdom practice. Cook TM, et al.
Acta Anaesthesiol Scand 1997 Jan;41(1 Pt 1):18-24

Epidural service implications of a feeding policy in labour [letter] Armstrong TS, et al. **Anaesthesia** 1997 Aug; 52(8):798-9

Epidural analgesia after thoracotomy: United Kingdom practice [letter] Cook TM, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):108-11

VETERINARY

Comparison of antinociceptive, cardiovascular, and respiratory effects, head ptosis, and position of pelvic limbs in mares after caudal epidural administration of xylazine and detomidine hydrochloride solution. Skarda RT, et al.
Am J Vet Res 1996 Sep;57(9):1338-45

Evaluation of analgesia and cardiorespiratory effects of epidurally administered butorphanol in isoflurane-anesthetized dogs. Troncy E, et al.
Am J Vet Res 1996 Oct;57(10):1478-82

A comparison of epidural saline, morphine, and bupivacaine for pain relief after abdominal surgery in goats. Hendrickson DA, et al. **Vet Surg** 1996 Jan-Feb;25(1):83-7

ANALGESIA, OBSTETRICAL

Weight gain during pregnancy does not influence the spread of spinal analgesia in the term parturient. Ekeløf NP, et al. **Acta Anaesthesiol Scand** 1997 Aug;41(7):884-7

2-Chloroprocaine antagonism of epidural morphine analgesia. Karambelkar DJ, et al.
Acta Anaesthesiol Scand 1997 Jun;41(6):774-8

Patient-controlled analgesia with morphine and droperidol following caesarean section under spinal anaesthesia. Russell D, et al. **Acta Anaesthesiol Scand** 1996 May; 40(5):600-5

Effects of routinely given pethidine during labour on infants' developing breastfeeding behaviour. Effects of dose-delivery time interval and various concentrations of pethidine/norpethidine in cord plasma. Nissen E, et al.
Acta Paediatr 1997 Feb;86(2):201-8

Increased intrapartum antibiotic administration associated with epidural analgesia in labor. Mayer DC, et al.
Am J Perinatol 1997 Feb;14(2):83-6

Spinal morphine in remote practice [letter] [see comments] Goldblatt M. **Anaesth Intensive Care** 1996 Oct;24(5):615-6 . Comment in: Anaesth Intensive Care 1997 Apr;25(2):198.

Comparison of patient-controlled epidural analgesia with patient-controlled intravenous analgesia using pethidine or fentanyl. Ngan Kee WD, et al. **Anaesth Intensive Care** 1997 Apr;25(2):126-32

Spinal morphine for caesarean section [letter; comment] Taylor R, et al. **Anaesth Intensive Care** 1997 Apr;25(2):198 . Comment on: Anaesth Intensive Care 1996 Oct;24(5):615-6.

Neonatal welfare and placental transfer of fentanyl and bupivacaine during ambulatory combined spinal epidural analgesia for labour. Fernando R, et al. **Anaesthesia** 1997 Jun;52(6):517-24

Uterine rupture and epidural analgesia during trial of labour. Rowbottom SJ, et al. **Anaesthesia** 1997 May;52(5):486-8

Safe epidural analgesia in thirty parturients with platelet counts between 69,000 and 98,000 mm(-3). Beilin Y, et al. **Anesth Analg** 1997 Aug;85(2):385-8

Does dextrose affect analgesia or the side effects of intrathecal sufentanil? Gage JC, et al. **Anesth Analg** 1997 Oct;85(4):826-30

A randomized, double-blind, dose-response comparison of epidural fentanyl versus sufentanil analgesia after cesarean section. Grass JA, et al. **Anesth Analg** 1997 Aug; 85(2):365-71

A comparison of the effect of intrathecal and extradural fentanyl on gastric emptying in laboring women. Kelly MC, et al. **Anesth Analg** 1997 Oct;85(4):834-8

Intrathecal neostigmine for post-cesarean section analgesia: dose response. Krukowski JA, et al. **Anesth Analg** 1997 Jun;84(6):1269-75

Epidural meperidine after cesarean section: the effect of diluent volume. Ngan Kee WD, et al. **Anesth Analg** 1997 Aug;85(2):380-4

Fetal heart rate changes after intrathecal sufentanil or epidural bupivacaine for labor analgesia: incidence and clinical significance. Nielsen PE, et al. **Anesth Analg** 1996 Oct;83(4):742-6

Patient-controlled epidural analgesia: interactions between nalbuphine and hydromorphone. Parker RK, et al.
Anesth Analg 1997 Apr;84(4):757-63

The effect of epidural fentanyl on the minimum local analgesic concentration of epidural chloroprocaine in labor. Polley LS, et al. **Anesth Analg** 1996 Nov;83(5):987-90

Maternal posture influences the extent of sensory block produced by intrathecal dextrose-free bupivacaine with fentanyl for labor analgesia. Richardson MG, et al.
Anesth Analg 1996 Dec;83(6):1229-33

Intrathecal sufentanil for labor analgesia: do sensory changes predict better analgesia and greater hypotension? Riley ET, et al. **Anesth Analg** 1997 Feb;84(2):346-51

Duration of intrathecal labor analgesia: early versus advanced labor. Viscomi CM, et al. **Anesth Analg** 1997 May; 84(5):1108-12

Postcesarean analgesia with both epidural morphine and intravenous patient-controlled analgesia: neurobehavioral outcomes among nursing neonates. Wittels B, et al.
Anesth Analg 1997 Sep;85(3):600-6

Epidural analgesia and the incidence of cesarean section: time for another close look [editorial] Chestnut DH.
Anesthesiology 1997 Sep;87(3):472-6

Cesarean delivery: a randomized trial of epidural versus patient-controlled meperidine analgesia during labor. Sharma SK, et al. **Anesthesiology** 1997 Sep;87(3):487-94

Efficacy of bupivacaine delivered by wound catheter for post-Caesarean section analgesia. Mecklem DW, et al.
Aust N Z J Obstet Gynaecol 1995 Nov;35(4):416-21

Normal saline i.v. fluid load decreases uterine activity in active labour. Cheek TG, et al. **Br J Anaesth** 1996 Nov; 77(5):632-5

Blood pressure and fetal heart rate changes with patient-controlled combined spinal epidural analgesia while ambulating in labour. al-Mufti R, et al.
Br J Obstet Gynaecol 1997 May;104(5):554-8

Lack of analgesic effect of systemically administered morphine or pethidine on labour pain [see comments] Olofsson C, et al. **Br J Obstet Gynaecol** 1996 Oct; 103(10):968-72. Comment in: Br J Obstet Gynaecol 1997 May;104(5):643.

Labour analgesia with intrathecal fentanyl decreases maternal stress. Cascio M, et al. **Can J Anaesth** 1997 Jun;44(6):605-9

Epidural morphine vs hydromorphone in post-caesarean section patients. Halpern SH, et al. **Can J Anaesth** 1996 Jun;43(6):595-8

Double-blind comparison of epidural ropivacaine 0.25% and bupivacaine 0.25%, for the relief of childbirth pain. Muir HA, et al. **Can J Anaesth** 1997 Jun;44(6):599-604

Peri-operative multimodal pain therapy for caesarean section: analgesia and fitness for discharge. Rosaeg OP, et al.
Can J Anaesth 1997 Aug;44(8):803-9

Epidural analgesia for labour in a patient with Charcot-Marie-Tooth disease. Scull T, et al.
Can J Anaesth 1996 Nov;43(11):1150-2

Fetal movements following intrapartum maternal opiate administration. Farrell T, et al.
Clin Exp Obstet Gynecol 1996;23(3):144-6

Maternal and fetal effects of adrenaline with bupivacaine (0.25%) for epidural analgesia during labour. Dounas M, et al. **Eur J Anaesthesiol** 1996 Nov;13(6):594-8

Effect of second-stage 0.25% epidural bupivacaine on the outcome of labor. Luxman D, et al.
Gynecol Obstet Invest 1996;42(3):167-70

Acute pain and the obstetric patient: recent developments in analgesia for labor and delivery. Ward ME.
Int Anesthesiol Clin 1997 Spring;35(2):83-103 (115 ref.)

ACOG technical bulletin. Obstetric analgesia and anesthesia. Number 225--July 1996 (replaces No. 112, January 1988). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists.
Int J Gynaecol Obstet 1996 Sep;54(3):281-92

Parity, prolonged labor and epidural analgesia [letter] Witter FR, et al. **Int J Gynaecol Obstet** 1996 Jun;53(3):269-70

Pulse oxygen saturation in parturients receiving epidural versus opioid analgesia for labor [letter] Lurie S, et al.
J Clin Anesth 1997 Feb;9(1):87

Pain management for labor and delivery in the 90s. James CF. **J Fla Med Assoc** 1997 Jan;84(1):28-36 (19 ref.)

Association of epidural analgesia with cesarean delivery in nulliparas. Lieberman E, et al. **Obstet Gynecol** 1996 Dec; 88(6):993-1000

The effect of instituting an elective labor epidural program on the operative delivery rate. Lyon DS, et al.
Obstet Gynecol 1997 Jul;90(1):135-41

Subarachnoid meperidine-morphine combination. An effective perioperative analgesic adjunct for cesarean delivery. Chung JH, et al. **Reg Anesth** 1997 Mar-Apr; 22(2):119-24

Essential thrombocythemia and epidural analgesia in the parturient. Does thromboelastography help? Lowenwirt I, et al. **Reg Anesth** 1996 Nov-Dec;21(6):525-8

[Epidural anaesthesia around the clock? (letter)] Ginsbourger F. **Cah Anesthesiol** 1996;44(3):271 **(Fre)**

[Morphine in cesarean section and postoperative analgesia] Milon D, et al. **Cah Anesthesiol** 1996;44(3):241-44 (Eng. Abstr.) **(Fre)**

[Epidural administration of opioids in labor: contra] Biscoping J.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Apr; 32(4):256-7 **(Ger)**

[Epidural administration of opioids in labor: pro] Gogarten W, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Apr; 32(4):253-5 **(Ger)**

[Plasma levels of beta-endorphins and ACTH in labor with continuous peridural analgesia] Borgia ML, et al.
Minerva Anestesiol 1996 May;62(5):183-6 (Eng. Abstr.) **(Ita)**

[Analgesic effectiveness and repercussions on the progress of labor of small doses of bupivacaine and fentanyl in continuous peridural perfusion] García-Muñoz M, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):135-9 (Eng. Abstr.) **(Spa)**

[MUltiple sclerosis and obstetric epidural analgesia] Salvador M, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):33-5 (Eng. Abstr.) **(Spa)**

[Pharmacokinetics of lidocaine in obstetric patients after its epidural single-dose administration] Sánchez-Alcaraz A, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):13-5 (Eng. Abstr.) **(Spa)**

[Unequal distribution of obstetrical analgesia] Ahlenius I, et al. **Lakartidningen** 1997 Apr 2;94(14):1269-73, 1275 (36 ref.) **(Swe)**

ADVERSE EFFECTS

Dural puncture: the patients' perspective. A patient survey of cases at a DGH maternity unit 1983-1993. Costigan SN, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):710-4

Extradural abscess complicating lumbar extradural anaesthesia and analgesia in an obstetric patient. Kindler C, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):858-61

The effect of epidural opioids on maternal oxygenation during labour and delivery [see comments] Porter JS, et al. **Anaesthesia** 1996 Oct;51(10):899-903. Comment in: Anaesthesia 1997 Mar;52(3):276-8.

Epidural blood patch for atypical headache following obstetric epidural analgesia. Yentis SM, et al.
Anaesthesia 1997 Jan;52(1):62-4

A comparison of multiport and uniport epidural catheters in laboring patients. D'Angelo R, et al. **Anesth Analg** 1997 Jun;84(6):1276-9

Extradural analgesia: does it affect progress and outcome in labour? [editorial] McGrady EM. **Br J Anaesth** 1997 Feb;78(2):115-7

Unexpected high spinal block in obstetrics [letter; comment] Richardson MG, et al. **Br J Anaesth** 1996 Dec;77(6):806-7 . Comment on: Br J Anaesth 1996 Feb;76(2):322-4.

Pre-anaesthetic assessment of coagulation abnormalities in obstetric patients: usefulness, timing and clinical implications. Simon L, et al. **Br J Anaesth** 1997 Jun; 78(6):678-83

Do epidurals cause back pain? Buggy D, et al.
Br J Hosp Med 1996 Jul 10-Aug 20;56(2-3):99-101 (18 ref.)

Epidurals and fever: association or cause? [letter] Gray D, et al. **CMAJ** 1997 Sep 1;157(5):511-2

Post-partum urinary retention: a comparison between two methods of epidural analgesia. Olofsson CI, et al.
Eur J Obstet Gynecol Reprod Biol 1997 Jan;71(1):31-4

Maternal fever after epidural analgesia. Douglas M, et al.
J Fam Pract 1997 Jun;44(6):529-30

Epidural analgesia [letter; comment] Walker M.
J Obstet Gynecol Neonatal Nurs 1996 Oct;25(8):650. Comment on: J Obstet Gynecol Neonatal Nurs 1996 May;25(4):350-4.

Epidural analgesia, intrapartum fever, and neonatal sepsis evaluation. Lieberman E, et al. **Pediatrics** 1997 Mar; 99(3):415-9

Labor analgesia and infant brain development. Golub MS.
Pharmacol Biochem Behav 1996 Dec;55(4):619-28 (95 ref.)

Fetal bradycardia and uterine hyperactivity following subarachnoid administration of fentanyl during labor. Friedlander JD, et al. **Reg Anesth** 1997 Jul-Aug; 22(4):378-81

Pressure sores as a complication of patient-controlled epidural analgesia after cesarean delivery. Case report. Smet IG, et al. **Reg Anesth** 1996 Jul-Aug;21(4):338-41

[General convulsive crisis related to pneumocephalus after inadvertant dural puncture in an obstetric patient] Rodrigo P, et al. **Rev Esp Anestesiol Reanim** 1997 Jun-Jul; 44(6):247-9 (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Epidural catheter design: holes and flows [letter; comment] Collier CB. **Anaesthesia** 1997 Feb;52(2):183. Comment on: Anaesthesia 1996 Aug;51(8):757-63.

Dangerous faulty loss of resistance syringe [letter] Dark A.
Anaesthesia 1997 Aug;52(8):804

Superiority of multi-orifice over single-orifice epidural catheters for labor analgesia and cesarean delivery. Segal S, et al. **J Clin Anesth** 1997 Mar;9(2):109-12

METHODS

Intrathecal narcotics for labor analgesia. Stephens MB, et al. **Am Fam Physician** 1997 Aug;56(2):463-70 (27 ref.)

Epidural service implications of a feeding policy in labour [letter] Armstrong TS, et al. **Anaesthesia** 1997 Aug; 52(8):798-9

Intrathecal administration of morphine for elective Caesarean section. A comparison between 0.1 mg and 0.2 mg [see comments] Milner AR, et al. **Anaesthesia** 1996 Sep; 51(9):871-3. Comment in: Anaesthesia 1997 Mar;52(3):278.

Intrathecal morphine for caesarean section: an assessment of pain relief, satisfaction and side-effects. Swart M, et al.
Anaesthesia 1997 Apr;52(4):373-7

Epidural opioids in labour--do we need them? [letter; comment] Thomas EO. **Anaesthesia** 1997 Mar;52(3):276-8 . Comment on: Anaesthesia 1996 Oct;51(10):899-903.

Determination of the dose-response relationship for intrathecal sufentanil in laboring patients. Herman NL, et al. **Anesth Analg** 1997 Jun;84(6):1256-61

Addition of epinephrine to intrathecal bupivacaine and sufentanil for ambulatory labor analgesia. Campbell DC, et al. **Anesthesiology** 1997 Mar;86(3):525-31

Baricity, needle direction, and intrathecal sufentanil labor

analgesia. Ferouz F, et al. **Anesthesiology** 1997 Mar; 86(3):592–8

Continuous extradural infusion of ropivacaine 2 mg ml–1 for pain relief during labour. Benhamou D, et al. **Br J Anaesth** 1997 Jun;78(6):748–50

Extradural clonidine combined with sufentanil and 0.0625% bupivacaine for analgesia in labour. Chassard D, et al. **Br J Anaesth** 1996 Oct;77(4):458–62

Ambulatory extradural analgesia in labour and mode of delivery [letter] Jenkins JG. **Br J Anaesth** 1997 Jun; 78(6):776–7

Extradural pain relief in labour: bupivacaine sparing by extradural fentanyl is dose dependent. Lyons G, et al. **Br J Anaesth** 1997 May;78(5):493–7

Epidural bupivacaine/fentanyl infusions vs. intermittent top-ups: a retrospective study of the effects on mode of delivery in primiparous women. Driver I, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):515–20

Intrathecal analgesia for labor. Wildman KM, et al. **J Fam Pract** 1997 Jun;44(6):535–40 (16 ref.)

Use of intrathecal analgesia in a rural hospital. Case studies. Kurokawa JS, et al. **J Nurse Midwifery** 1996 Jul–Aug; 41(4):338–42

Opioids in labor [letter; comment] Kingdom J, et al. **Lancet** 1997 Mar 8;349(9053):726; discussion 727–8. Comment on: Lancet 1997 Jan 4;349(9044):4–5.

Opioids in labour [letter; comment] Liston WA. **Lancet** 1997 Mar 8;349(9053):727; discussion 727–8. Comment on: Lancet 1997 Jan 4;349(9044):4–5.

Opioids in labour [letter; comment] Littler C, et al. **Lancet** 1997 Mar 8;349(9053):727; discussion 727–8. Comment on: Lancet 1997 Jan 4;349(9044):4–5.

Opioids in labour—no analgesic effect [see comments] Reynolds F, et al. **Lancet** 1997 Jan 4;349(9044):4–5. Comment in: Lancet 1997 Mar 8;349(9053):726; discussion 727–8. Comment in: Lancet 1997 Mar 8;349(9053):726–7; discussion 727–8. Comment in: Lancet 1997 Mar 8;349(9053):727; discussion 727–8.

Opioids in labour [letter; comment] Twycross R. **Lancet** 1997 Mar 8;349(9053):726–7; discussion 727–8. Comment on: Lancet 1997 Jan 4;349(9044):4–5.

Continuous infusion epidural analgesia during labor [letter] Eldor J. **Reg Anesth** 1996 Jul–Aug;21(4):373–4

Ambulatory combined spinal–epidural analgesia for labor. Influence of epinephrine on bupivacaine–sufentanil combination. Gautier PE, et al. **Reg Anesth** 1997 Mar–Apr; 22(2):143–9

Anesthetic management of a parturient with an incompletely resected cerebral arteriovenous malformation. Viscomi CM, et al. **Reg Anesth** 1997 Mar–Apr;22(2):192–7

Analgesic efficacy and side effects of subarachnoid sufentanil–bupivacaine administered to women in advanced labor. Viscomi CM, et al. **Reg Anesth** 1996 Sep–Oct; 21(5):424–9

Labor analgesia and anesthesia in a patient with spinal muscular atrophy and vocal cord paralysis. A rare and unusual case report. Weston LA, et al. **Reg Anesth** 1996 Jul–Aug;21(4):350–4 (11 ref.)

[Postoperative analgesia in cesarean section] Radev R. **Khirurgiia (Sofiia)** 1996;49(4):33–6 (Eng. Abstr.) **(Bul)**

[Obstetrical epidural analgesia: an epidemiological in Bourgogne and Franche-Comté 1993] Vattaï P, et al. **Cah Anesthesiol** 1996;44(3):207–13 (Eng. Abstr.) **(Fre)**

TRENDS

[Epidural analgesia in labor. An area of continuous progress (editorial)] Vilaplana–Birba J. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):133–4 **(Spa)**

UTILIZATION

[The current standing of obstetrical analgesia and anesthesia. A survey of North Rhein–Westfalia] Meuser T, et al. **Anaesthesist** 1997 Jun;46(6):532–5 (Eng. Abstr.) **(Ger)**

VETERINARY

Evaluation of extradural xylazine injection for caesarean operation in ovine dystocia cases. Scott PR, et al. **Vet J** 1997 Jul;154(1):63–7

ANALGESIA, PATIENT-CONTROLLED

Patient-controlled analgesia with morphine and droperidol following caesarean section under spinal anaesthesia. Russell D, et al. **Acta Anaesthesiol Scand** 1996 May; 40(5):600–5

Patient-controlled analgesia in children. Rieberer ML. **Acta Anaesthesiol Scand Suppl** 1996;109:104–7

Comparison of patient-controlled epidural analgesia with patient-controlled intravenous analgesia using pethidine or fentanyl. Ngan Kee WD, et al. **Anaesth Intensive Care** 1997 Apr;25(2):126–32

The efficacy, applicability and side-effects of postoperative intravenous patient-controlled morphine analgesia: an audit of 1233 Chinese patients. Tsui SL, et al. **Anaesth Intensive Care** 1996 Dec;24(6):658–64

Magnetic mayhem [letter] Leeson-Payne CG, et al. **Anaesthesia** 1996 Nov;51(11):1081–2

A comparison of opioid solutions for patient-controlled epidural analgesia. Smith AJ, et al. **Anaesthesia** 1996 Nov; 51(11):1013–7

Pain following craniotomy: a preliminary study comparing PCA morphine with intramuscular codeine phosphate [see comments] Stoneham MD, et al. **Anaesthesia** 1996 Dec; 51(12):1176–8. Comment in: Anaesthesia 1997 Jun;52(6):604–5.

The addition of continuous intravenous infusion of ketorolac to a patient-controlled analgetic morphine regime reduced postoperative myocardial ischemia in patients undergoing elective total hip or knee arthroplasty [see comments] Beattie WS, et al. **Anesth Analg** 1997 Apr;84(4):715–22. Comment in: Anesth Analg 1997 Apr;84(4):709–11.

A comparison of variable-dose patient-controlled analgesia with fixed-dose patient-controlled analgesia. Love DR, et al. **Anesth Analg** 1996 Nov;83(5):1060–4

Patient-controlled epidural analgesia: interactions between nalbuphine and hydromorphone. Parker RK, et al. **Anesth Analg** 1997 Apr;84(4):757–63

Morphine patient-controlled analgesia is superior to meperidine patient-controlled analgesia for postoperative pain. Plummer JL, et al. **Anesth Analg** 1997 Apr;84(4):794–9

Epidural bolus clonidine/morphine versus epidural patient-controlled bupivacaine/sufentanil: quality of postoperative analgesia and cost-identification analysis. Rockemann MG, et al. **Anesth Analg** 1997 Oct;85(4):864–9

Management of patient-controlled analgesia: a comparison of primary surgeons and a dedicated pain service. Stacey BR, et al. **Anesth Analg** 1997 Jul;85(1):130–4

Effect of the intensity of transcutaneous acupoint electrical stimulation on the postoperative analgesic requirement. Wang B, et al. **Anesth Analg** 1997 Aug;85(2):406–13

The effects of adding sufentanil to bupivacaine for postoperative patient-controlled epidural analgesia. Wiebalck A, et al. **Anesth Analg** 1997 Jul;85(1):124–9

Postcesarean analgesia with both epidural morphine and intravenous patient-controlled analgesia: neurobehavioral outcomes among nursing neonates. Wittels B, et al. **Anesth Analg** 1997 Sep;85(3):600–6

Cesarean delivery: a randomized trial of epidural versus patient-controlled meperidine analgesia during labor. Sharma SK, et al. **Anesthesiology** 1997 Sep;87(3):487–94

Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. Mercadante S, et al. **Ann Oncol** 1996 Aug;7(6):613–7

Patient-controlled analgesia versus patient-controlled analgesia plus continuous infusion after hip replacement surgery. Smythe MA, et al. **Ann Pharmacother** 1996 Mar; 30(3):224–7

Pain treatment after thoracotomy: is it a special problem? Salzer GM, et al. **Ann Thorac Surg** 1997 May;63(5):1411–4

Extradural morphine gives better pain relief than patient-controlled i.v. morphine after hysterectomy. Eriksson-Mjöberg M, et al. **Br J Anaesth** 1997 Jan; 78(1):10–6

Blood pressure and fetal heart rate changes with patient-controlled combined spinal epidural analgesia while ambulating in labour. al-Mufti R, et al. **Br J Obstet Gynaecol** 1997 May;104(5):554–8

Use of patient-controlled analgesia in extracorporeal shockwave lithotripsy. Chin CM, et al. **Br J Urol** 1997 Jun;79(6):848–51

Use of patient-controlled analgesia with alfentanil for burns dressing procedures: a preliminary report of five patients. Sim KM, et al. **Burns** 1996 May;22(3):238–41

Bolus size and PCA morphine requirements [letter] Delire V, et al. **Can J Anaesth** 1997 Aug;44(8):902

Patient maintained alfentanil target-controlled infusion for analgesia during extracorporeal shock wave lithotripsy. Irwin MG, et al. **Can J Anaesth** 1996 Sep;43(9):919–24

Comparison of tramadol and tramadol/droperidol mixture for patient-controlled analgesia. Ng KF, et al. **Can J Anaesth** 1997 Aug;44(8):810–5

Patient-controlled epidural analgesia after caesarean section using meperidine. Ngan Kee WD, et al. **Can J Anaesth** 1997 Jul;44(7):702–6

Oral clonidine reduces postoperative PCA morphine requirements. Park J, et al. **Can J Anaesth** 1996 Sep; 43(9):900–6

Immediate recovery of psychomotor function after patient-administered nitrous oxide/oxygen inhalation for colonoscopy. Trojan J, et al. **Endoscopy** 1997 Jan; 29(1):17–22

Transition to post-operative epidural or patient-controlled intravenous analgesia following total intravenous anaesthesia with remifentanil and propofol for abdominal surgery. Bowdle TA, et al. **Eur J Anaesthesiol** 1997 Jul; 14(4):374–9

Potentiation of sufentanil by clonidine in PCEA with or without basal infusion. Vercauteren MP, et al. **Eur J Anaesthesiol** 1996 Nov;13(6):571–6

How effective is patient-controlled analgesia? A randomized comparison of two protocols for pain relief during oocyte recovery. Bhattacharya S, et al. **Hum Reprod** 1997 Jul; 12(7):1440–2

Patient-controlled analgesia after spinal fusion for idiopathic scoliosis. Beaulieu P, et al. **Int Orthop** 1996;20(5):295–9

Patient controlled analgesia and intramuscular injections: a comparisons of patient pain experiences and postoperative outcomes. Snell CC, et al. **J Adv Nurs** 1997 Apr; 25(4):681–90

Effect of varying intravenous patient-controlled analgesia dose and lockout interval while maintaining a constant hourly maximum dose. Badner NH, et al. **J Clin Anesth** 1996 Aug;8(5):382–5

Respiratory monitoring during postoperative analgesia [letter; comment] Ladner E, et al. **J Clin Monit** 1996 Sep; 12(5):417. Comment on: J Clin Monit 1995 Nov;11(6):365–72.

Patient-controlled sedation and analgesia during SWL. Uyar M, et al. **J Endourol** 1996 Oct;10(5):407–10

A comparison of patient-controlled and fixed schedule analgesia after orthognathic surgery. Precious DS, et al. **J Oral Maxillofac Surg** 1997 Jan;55(1):33–9; discussion 40

Patient-controlled analgesia with nitrous oxide in cancer pain. Keating HJ 3rd, et al. **J Pain Symptom Manage** 1996 Feb;11(2):126–30

Comparison of patient-controlled analgesia with and without nighttime morphine infusion following lower extremity surgery in children. McNeely JK, et al. **J Pain Symptom Manage** 1997 May;13(5):268–73

Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. Collins JJ, et al. **J Pediatr** 1996 Nov; 129(5):722–8

Current status of patient-controlled analgesia in cancer patients. Ripamonti C, et al. **Oncology (Huntingt)** 1997 Mar; 11(3):373–80, 383–4; discussion 384–6 (102 ref.)

Variation in opioid use during PCA in adolescents [letter; comment] Marsh DF, et al. **Paediatr Anaesth** 1996; 6(5):429–30. Comment on: Paediatr Anaesth 1996;6(1):33–8.

Patient controlled analgesia (PCA) in paediatric surgery: a prospective study following laparoscopic and open appendicectomy. Till H, et al. **Paediatr Anaesth** 1996; 6(1):29–32

Variation in opioid use during PCA in adolescents [see comments] Tyler DC, et al. **Paediatr Anaesth** 1996;6(1):33–8 . Comment in: Paediatr Anaesth 1996;6(5):420–30.

Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA. Dunbar PJ, et al. **Pain** 1996 Dec;68(2–3):265–70

The effect of ethnicity on prescriptions for patient-controlled analgesia for post-operative pain. Ng B, et al. **Pain** 1996 Jul;66(1):9–12

A comparison of morphine, pethidine and fentanyl in the postsurgical patient-controlled analgesia environment. Woodhouse A, et al. **Pain** 1996 Jan;64(1):115–21

Iliac crest bone graft pain: simplicity revisited [letter] Green DM. **Reg Anesth** 1996 Jan–Feb;21(1):77

Ketorolac as an adjunct to patient-controlled morphine in postoperative spine surgery patients. Reuben SS, et al. **Reg Anesth** 1997 Jul–Aug;22(4):343–6

The effect of spinal versus general anesthesia on postoperative pain and analgesic requirements in patients undergoing lower abdominal surgery [see comments] Wang JJ, et al. **Reg Anesth** 1996 Jul–Aug;21(4):281–6. Comment in: Reg Anesth 1996 Jul–Aug;21(4):277–80.

Postoperative pain control after lumbar spine fusion. Patient-controlled analgesia versus continuous epidural analgesia. Cohen BE, et al. **Spine** 1997 Aug 15; 22(16):1892–6; discussion 1896–7

Treatment of pain in chronic bowel subobstruction with self-administration of methadone. Mercadante S, et al. **Support Care Cancer** 1997 Jul;5(4):327–9

Sublingual buprenorphine compared to morphine delivered by a patient-controlled analgesia system as postoperative analgesia after prostatectomy. Gaitini L, et al. **Urol Int** 1996;57(4):227–9

[Postoperative analgesia, self-controlled by aged patients (letter)] Badaoui R, et al. **Ann Fr Anesth Reanim** 1996; 15(7):1133 **(Fre)**

[Research of preferential indications of patient-controlled analgesia in orthopedics and traumatology (letter)] Grouille D, et al. **Ann Fr Anesth Reanim** 1996;15(2):228 **(Fre)**

[Analgesia after knee surgery (letter)] Mahoudeau G, et al. **Ann Fr Anesth Reanim** 1996;15(5):690–1 **(Fre)**

[Self-controlled analgesia and ambulatory palliative care (letter)] Bouffet E, et al. **Arch Pediatr** 1996 Jun;3(6):611–2 **(Fre)**

[What organizational structure is needed to carry out patient-controlled or continuous opioid analgesia?] Jage J. **Anaesthesist** 1996 Dec;45 Suppl 3:S74–5 **(Ger)**

[Two years experience with patient-controlled analgesia (PCA) in a general hospital] Ladner E, et al. **Anaesthesist** 1996 Dec;45 Suppl 3:S85–7 **(Ger)**

[Patient acceptance of patient-controlled intranasal analgesia (PCINA)] Schwagmeier R, et al. **Anaesthesist** 1996 Mar; 45(3):231–4 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

PCA: for patients only. Pasero CL. **Am J Nurs** 1996 Sep; 96(9):22–3

Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient [letter] Morley AD. **Anaesth Intensive Care** 1996 Apr;24(2):287

Antiemetic efficacy of ondansetron with patient-controlled analgesia [see comments] Davies PR, et al. **Anaesthesia** 1996 Sep;51(9):880–2. Comment in: Anaesthesia 1997 Jan;52(1):90–1.

Nausea and vomiting in the postoperative patient-controlled analgesia environment. Woodhouse A, et al. **Anaesthesia** 1997 Aug;52(8):770–5 (46 ref.)

Pressure sores as a complication of patient-controlled epidural analgesia after cesarean delivery. Case report. Smet IG, et al. **Reg Anesth** 1996 Jul–Aug;21(4):338–41

ANALGESIA, PATIENT-CONTROLLED

[Analgesia controlled by the patient in pediatrics (letter)] Veyckemans F. **Arch Pediatr** 1997 Mar;4(3):289 **(Fre)**

ECONOMICS

Patient attitudes regarding pca and associated costs. Badner NH, et al. **Can J Anaesth** 1997 Mar;44(3):255–8

INSTRUMENTATION

Morphine overdose from patient–controlled analgesia pumps. Kwan A. **Anaesth Intensive Care** 1996 Apr;24(2):254–6

Patient actuation of PCA [letter] McLaren P, et al. **Anaesth Intensive Care** 1996 Apr;24(2):284

Preliminary clinical use of a patient–controlled intranasal analgesia (PCINA) device. O'Neil G, et al. **Anaesth Intensive Care** 1997 Aug;25(4):408–12

Patient controlled oral analgesia with morphine. Striebel HW, et al. **Can J Anaesth** 1996 Jul;43(7):749–53

On–demand analgesia with piritramide in children. A study on dosage specification and safety. Petrat G, et al. **Eur J Pediatr Surg** 1997 Feb;7(1):38–41

Overinfusion caused by gravity free–flow from a damaged prefilled glass syringe. **Health Devices** 1996 Dec; 25(12):476–7

[Effectiveness, side effects and costs of postoperative pain therapy: intravenous and epidural patient–controlled analgesia (PCA)] Rockemann MG, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jul; 32(7):414–9 (Eng. Abstr.) **(Ger)**

[Postoperative pain therapy using on–demand analgesia after external ear reconstruction with rib cartilage harvesting] Lindig M, et al. **Laryngorhinootologie** 1997 Jun; 76(6):379–83 (Eng. Abstr.) **(Ger)**

[Peri– and postoperative pain therapy with mechanical patient–controlled disposable analgesia pumps in general surgery. Report of initial trial] Fieseler HG, et al. **Zentralbl Chir** 1996;121(7):552–6 (Eng. Abstr.) **(Ger)**

[Use of new elastomeric pumps and PCA in postoperative pain control in thoraco–abdominal surgery] Testa G, et al. **Ann Ital Chir** 1996 Mar–Apr;67(2):257–63 (Eng. Abstr.) **(Ita)**

[Postoperative pain relief for a patient with elective mutism by patient controlled analgesia] Onaka M, et al. **Masui** 1997 Jan;46(1):73–6 (Eng. Abstr.) **(Jpn)**

METHODS

Alternative use of PCA. Pasero CL, et al. **Am J Nurs** 1996 Oct;96(10):66–8

Isoflurane for removal of chest drains after cardiac surgery [see comments] Bryden FM, et al. **Anaesthesia** 1997 Feb; 52(2):173–5. Comment in: Anaesthesia 1997 Jul;52(7):718.

Interscalene patient–controlled analgesia [see comments] Lucas MA, et al. **Anaesthesia** 1997 Mar;52(3):263–4. Comment in: Anaesthesia 1997 Jul;52(7):715.

Patient–controlled regional anaesthesia [letter; comment] Mackenzie JW, et al. **Anaesthesia** 1997 Jul;52(7):715. Comment on: Anaesthesia 1997 Mar;52(3):263–4.

Morphine blood concentrations in elderly postoperative patients following administration via an indwelling subcutaneous cannula. Semple TJ, et al. **Anaesthesia** 1997 Apr;52(4):318–23

Propofol sedation during awake craniotomy for seizures: patient–controlled administration versus neurolept analgesia. Herrick IA, et al. **Anesth Analg** 1997 Jun; 84(6):1285–91

Patient–controlled intranasal analgesia [letter] Joly LM, et al. **Anesth Analg** 1997 Aug;85(2):465

Bone marrow harvesting using local anaesthesia and PCA–alfentanil: a feasible alternative to general or regional anaesthesia. Sim KM, et al. **Bone Marrow Transplant** 1996 Oct;18(4):787–90

The opiate–sparing effect of dipyrone in post–operative pain therapy with morphine using a patient–controlled analgesic system. Tempel G, et al. **Intensive Care Med** 1996 Oct; 22(10):1043–7

Patients can manage intraspinal analgesia at home. Racolin AA. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):22

Epidural opioid delivery methods: bolus, continuous infusion, and patient–controlled epidural analgesia. Mulroy MF. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):100–4 (38 ref.)

Continuous spinal analgesia. Comparison between patient–controlled and bolus administration of plain bupivacaine for postoperative pain relief. Rundshagen I, et al. **Reg Anesth** 1997 Mar–Apr;22(2):150–6

An evaluation of patient–controlled analgesia in adults undergoing cardiac surgery. Turner RE. **S Afr Med J** 1994 Nov;84(11 Suppl):807–11

[Analgesia controlled by the patient in pediatrics] Colcanap O, et al. **Arch Pediatr** 1996 Oct;3(10):1032–7 (43 ref.) (Eng. Abstr.) **(Fre)**

[Patient–controlled postoperative analgesia in orthopedic surgery: epidural PCA versus intravenous PCA] Bertini L, et al. **Minerva Anestesiol** 1995 Jul–Aug;61(7–8):319–28 (Eng. Abstr.) **(Ita)**

[Clinical use of sublingual buprenorphine hydrochloride for analgesia in the early postoperative period] Lebedeva RN, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):22–5 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Patient–controlled analgesia—who benefits? [editorial] Hall GM, et al. **Anaesthesia** 1997 May;52(5):401–2

Is patient–controlled analgesia controlled by the patient? Taylor N, et al. **Soc Sci Med** 1996 Oct;43(7):1137–43

STANDARDS

Audit of postoperative pain control. Influence of a dedicated acute pain nurse [see comments] Coleman SA, et al. **Anaesthesia** 1996 Dec;51(12):1093–6. Comment in: Anaesthesia 1997 Apr;52(4):388–9.

A two–year experience of an acute pain service in Singapore. Wong LT, et al. **Singapore Med J** 1997 May;38(5):209–13

ANALGESIA TESTS see **PAIN MEASUREMENT**

ANALGESIC CUTANEOUS ELECTROSTIMULATION see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

ANALGESICS

Calming minds or killing pain in newborn infants? [comment] Lindahl S. **Acta Paediatr** 1997 Aug;86(8):787–8. Comment on: Acta Paediatr 1997 Aug;86(8):837–42.

The efficacy of sucrose for relieving procedural pain in neonates—a systematic review and meta–analysis [see comments] Stevens B, et al. **Acta Paediatr** 1997 Aug; 86(8):837–42. Comment in: Acta Paediatr 1997 Aug;86(8):787–8.

Synergistic antinociceptive interactions of morphine and clonidine in rats with nerve–ligation injury. Ossipov MH, et al. **Anesthesiology** 1997 Jan;86(1):196–204

Effects of dopaminergic agents on visceral pain measured by the mouse writhing test. Frussa–Filho R, et al. **Arch Int Pharmacodyn Ther** 1996 Jan–Feb;331(1):74–93

Calcitonin treatment in reflex sympathetic dystrophy: a preliminary study. Hamamci N, et al. **Br J Clin Pract** 1996 Oct–Nov;50(7):373–5

Analgesics: a comparison of therapeutic knowledge and inter–professional liaison between general practitioners and community pharmacists. Briggs A, et al. **Br J Gen Pract** 1997 Jun;47(419):378–9

The mu–opioid receptor is necessary for [D–Pen2,D–Pen5]enkephalin–induced analgesia. Sora I, et al. **Eur J Pharmacol** 1997 Apr 18;324(2–3):R1–2

Opioid and benzodiazepine tolerance and dependence: application of theory to critical care practice. Puntillo K, et al. **Heart Lung** 1997 Jul–Aug;26(4):317–24 (32 ref.)

Determination of nalbuphine by high–performance liquid chromatography with ultraviolet detection: application to human and rabbit pharmacokinetic studies. Ho ST, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):289–96

Adolescents' use of prescribed drugs and over–the–counter preparations. Dengler R, et al. **J Public Health Med** 1996 Dec;18(4):437–42

Lack of local anaesthetic efficacy of Sarapin in the abaxial sesamoid block model. Harkins JD, et al. **J Vet Pharmacol Ther** 1997 Jun;20(3):229–32

Immobilization of domestic goats (Capra hircus) using orally administered carfentanil citrate and detomidine hydrochloride. Sleeman JM, et al. **J Zoo Wildl Med** 1997 Jun;28(2):158–65

Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine. Appendino G, et al. **Life Sci** 1997;60(10):681–96 (87 ref.)

Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors. Matsumoto K, et al. **Life Sci** 1996;59(14):1149–55

Papillary necrosis in a ballet dancer with no history of analgesic abuse. Brenke B, et al. **Nephrol Dial Transplant** 1996 Dec;11(12):2501–3

Milk–induced hypoalgesia in human newborns. Blass EM. **Pediatrics** 1997 Jun;99(6):825–9

Relationships between patient attitudes, subjective norms, perceived control, and analgesic use following elective orthopedic surgery. Pellino TA. **Res Nurs Health** 1997 Apr; 20(2):97–105

An investigation into the prescribing of analgesics. Truter I, et al. **S Afr Med J** 1996 Nov;86(11):1394–7

[Analgesics: their role in current therapeutics] Semaoun R, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(2):83–5 (Eng. Abstr.) **(Fre)**

[Clofelin in the anesthesiological support system for surgical operations] Mikhaĭlovich VA, et al. **Khirurgiia (Mosk)** 1996; (6):78–81 (Eng. Abstr.) **(Rus)**

[Characteristics of pain and its treatment in patients at a nursing home] Cañellas Arsegol M, et al. **An Med Interna** 1996 Sep;13(9):423–9 (Eng. Abstr.) **(Spa)**

[Selective inhibitors of cyclooxygenase–2. New agents against pain and inflammation] Oliw E. **Lakartidningen** 1997 May 7;94(19):1797–801 (14 ref.) (Eng. Abstr.) **(Swe)**

ADMINISTRATION & DOSAGE

No additional analgesic effect of intra–articular morphine or bupivacaine compared with placebo after elective knee arthroscopy. Aasbø V, et al. **Acta Anaesthesiol Scand** 1996 May;40(5):585–8

N–methyl–D–aspartate receptor antagonists potentiate morphine's antinociceptive effect in the rat. Grass S, et al. **Acta Physiol Scand** 1996 Nov;158(3):269–73

Effects of centrally administered opioid agonists on macrophage nitric oxide production and splenic lymphocyte proliferation. Schneider GM, et al. **Adv Exp Med Biol** 1996;402:81–8

Twelve pitfalls of adequate pain control [editorial; comment] Siwek J. **Am Fam Physician** 1997 Sep 1;56(3):726, 731–2 . Comment on: Am Fam Physician 1997 Sep 1;56(3):835–44, 847–50.

Managing postoperative pain in the elderly. Pasero CL, et al. **Am J Nurs** 1996 Oct;96(10):38–45; quiz 46 (19 ref.)

Epidural bolus clonidine/morphine versus epidural patient–controlled bupivacaine/sufentanil: quality of postoperative analgesia and cost–identification analysis. Rockemann MG, et al. **Anesth Analg** 1997 Oct;85(4):864–9

Factors associated with suboptimal analgesic use in community–dwelling elderly. Hanlon JT, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):739–44

Development and implementation of a pain management program. Campese C. **AORN J** 1996 Dec;64(6):931–5, 937–40

Use of sucrose as a treatment for infant colic. Markestad T. **Arch Dis Child** 1997 Apr;76(4):356–7; discussion 357–8

Paracetamol–codeine combinations versus paracetamol alone [letter; comment] Li Wan Po A, et al. **BMJ** 1996 Nov 9; 313(7066):1209. Comment on: BMJ 1996 Aug 10;313(7053):321–5.

Paracetamol–codeine combinations versus paracetamol alone. Intention to treat approach is not popular [letter; comment] Skoglund LA. **BMJ** 1996 Nov 9;313(7066):1209. Comment on: BMJ 1996 Aug 10;313(7053):321–5.

Caution is required when using new analgesics by the spinal route in children [letter; comment] Wildsmith JA. **BMJ** 1997 Apr 19;314(7088):1203. Comment on: BMJ 1997 Jan 18;314(7075):201–3.

Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Combe B, et al. **Calcif Tissue Int** 1997 Jul;61(1):10–5

Intrathecal ketorolac tromethamine produces analgesia after chronic constriction injury of sciatic nerve in rat. Parris WC, et al. **Can J Anaesth** 1996 Aug;43(8):867–70

Peri–operative multimodal pain therapy for caesarean section: analgesia and fitness for discharge. Rosaeg OP, et al. **Can J Anaesth** 1997 Aug;44(8):803–9

Analgesia for emergency centers' orthopaedic patients: does an ethnic bias exist? Karpman RR, et al. **Clin Orthop** 1997 Jan;(334):270–5

The effect of intrathecal midazolam on post–operative pain. Valentine JM, et al. **Eur J Anaesthesiol** 1996 Nov; 13(6):589–93

Postoperative pain management in children has been improved, but can be further optimized. Kart T, et al. **Eur J Pediatr Surg** 1996 Oct;6(5):259–64

In mononeuropathic rats, the enhancement of morphine antinociception by L–365,260, a selective CCK(B) receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics. Idänpään–Heikkilä JJ, et al. **Eur J Pharmacol** 1997 May 1;325(2–3):155–64

Repeated doses of combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine. Hugues FC, et al. **Headache** 1997 Jul–Aug;37(7):452–4

Topical analgesics: are they underused? Kuritzky L. **Hosp Pract (Off Ed)** 1997 Jan 15;32(1):131–2

Preoperative hypnotic techniques reduce consumption of analgesics after surgical removal of third mandibular molars: a brief communication. Enqvist B, et al. **Int J Clin Exp Hypn** 1997 Apr;45(2):102–8

Superiority of oral ketamine as an analgesic and sedative for wound care procedures in the pediatric patient with burns. Humphries Y, et al. **J Burn Care Rehabil** 1997 Jan–Feb; 18(1 Pt 1):34–6

Intrathecal neostigmine for postoperative analgesia after orthopedic surgery. Lauretti GR, et al. **J Clin Anesth** 1997 Sep;9(6):473–7

Re: Use of rectal medications in palliative care [letter; comment] Remon JP. **J Pain Symptom Manage** 1997 Jun; 13(6):313–4. Comment on: J Pain Symptom Manage 1996 Jun;11(6):378–87.

Inadequate pain management and associated morbidity in children at home after tonsillectomy. Sutters KA, et al. **J Pediatr Nurs** 1997 Jun;12(3):178–85

The safety of continuous epidural infusion for postoperative analgesia in pediatric spine surgery. Shaw BA, et al. **J Pediatr Orthop** 1996 May–Jun;16(3):374–7

What we don't know about over–the–counter analgesics [editorial] Abbott FV. **J Psychiatry Neurosci** 1997 May; 22(3):165–7

Chronopharmacological study of KE–SI–TO in mice. Ogawa N, et al. **Life Sci** 1997;60(23):2091–8

Chronic pain control in the elderly. Keay TJ. **Md Med J** 1996 Mar;45(3):226–8

Burn management. Psychosocial interventions: pharmacologic and psychologic modalities. Davis ST, et al. **Nurs Clin North Am** 1997 Jun;32(2):331–42 (56 ref.)

Reply to Sarantopoulos and Fassoulaki, PAIN, 65 (1996) 273–276 [letter; comment] Katz J, et al. **Pain** 1997 Apr; 70(2–3):292–3. Comment on: Pain 1996 May–Jun;65(2–3):273–6.

The utilization of syringe drivers at a teaching hospital [letter] McQuillan R, et al. **Palliat Med** 1996 Jan;10(1):52

Liposomal formulation of mirfentanil hydrochloride. Betageri GV, et al. **PDA J Pharm Sci Technol** 1996 Jul–Aug; 50(4):219–22

Pediatric emergency department analgesic practice.

Friedland LR, et al. **Pediatr Emerg Care** 1997 Apr; 13(2):103–6

Prescribing analgesics: the effect of patient age and physician specialty. Hauswald M, et al. **Pediatr Emerg Care** 1997 Aug; 13(4):262–3

Pharmacokinetic–pharmacodynamic relationships of bromfenac in mice and humans. Chiang ST, et al. **Pharmacotherapy** 1996 Nov–Dec;16(6):1179–87

A substance P antagonist, RP–67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. Kennedy PG, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):4167–70

Comparison of accuracy and cost of disposable, nonmechanical pumps used for epidural infusions. Valente M, et al. **Reg Anesth** 1997 May–Jun;22(3):260–6

Chronic pain states: pathophysiology and medical therapy. Garcia J, et al. **Semin Arthritis Rheum** 1997 Aug;27(1):1–16 (53 ref.)

Recent advances in our understanding of pain: how should they affect management? Raffe M. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):75–9 (17 ref.)

Salmon calcitonin and calcium in the treatment of male osteoporosis: the effect on bone mineral density. Erlacher L, et al. **Wien Klin Wochenschr** 1997 Apr 25;109(8):270–4

[Effect of sublingual nitroglycerin on pain following ERCP] Christensen MH, et al. **Ugeskr Laeger** 1997 Mar 24; 159(13):1954–5 (Eng. Abstr.) **(Dan)**

[Pain and treatment of pain in patients with AIDS] Frich LM, et al. **Ugeskr Laeger** 1996 Nov 11;158(46):6595–9 (Eng. Abstr.) **(Dan)**

[Sedation and analgesia in ventilator–treated children] Hansen TG, et al. **Ugeskr Laeger** 1996 Dec 30;158(1):31–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Comparison between effects of morning and evening administration of effervescent calcium carbasalate (equivalent of 160 mg aspirin) on the gastroduodenal mucosa in healthy volunteers] Berlin I, et al. **Pathol Biol (Paris)** 1997 Jun;45(6):514–20 (Eng. Abstr.) **(Fre)**

[Patient acceptance of patient–controlled intranasal analgesia (PCINA)] Schwagmeier R, et al. **Anaesthesist** 1996 Mar; 45(3):231–4 (Eng. Abstr.) **(Ger)**

[Long–term pain therapy] Hildebrandt J, et al. **Chirurg** 1996 Jul;67(7):681–7 (28 ref.) (Eng. Abstr.) **(Ger)**

[Postoperative pain therapy in inpatient treatment] Holthausen U, et al. **Chirurg** 1996 Jul;67(7):671–80 (30 ref.) (Eng. Abstr.) **(Ger)**

[A fixed combination of acetylsalicylic acid and paracetamol is absolutely effective (interview by Dr. rer. nat. Anita Schweiger)] Schweiger A. **Fortschr Med** 1996 Feb 10; 114(4):46–7 **(Ger)**

[Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double–blind study] Wörz R, et al. **Fortschr Med** 1996 Dec 20;114(35–36):500–4 (Eng. Abstr.) **(Ger)**

[Analgesic and antipyretic drugs in pregnancy] Berkowitch M, et al. **Harefuah** 1997 Mar 2;132(5):354–7 (38 ref.) **(Heb)**

[Patient–controlled postoperative analgesia in orthopedic surgery: epidural PCA versus intravenous PCA] Bertini L, et al. **Minerva Anestesiol** 1995 Jul–Aug;61(7–8):319–28 (Eng. Abstr.) **(Ita)**

[Continuous epidural blockade as a method of treatment of low back pain syndrome in the course of disk pathology. Introductory research] Wolny T, et al. **Neurol Neurochir Pol** 1996 May–Jun;30(3):409–18 (Eng. Abstr.) **(Pol)**

[The problem of acute pain in postoperative period] Malinovskii NN, et al. **Khirurgiia (Mosk)** 1996;(5):30–5 (41 ref.) (Eng. Abstr.) **(Rus)**

[Fuzzy logic and postoperative pain] Carregal A, et al. **Rev Esp Anestesiol Reanim** 1997 Jun–Jul;44(6):215–7 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

WD–40 and arthritic pain: the squeaky joint gets the grease [letter] Ramratham B, et al. **Am Fam Physician** 1997 Apr; 55(5):1584

Commentary on the National Kidney Foundation position paper on analgesics and the kidney. Delzell E, et al. **Am J Kidney Dis** 1996 Nov;28(5):783–5

Analgesic nephropathy in Belgium: confusion between prevalence and incidence [letter; comment] Michielsen P, et al. **Am J Kidney Dis** 1996 Dec;28(6):958–9; discussion 960–2. Comment on: Am J Kidney Dis 1996 Jan;27(1):162–5.

Combination analgesic involvement in the pathogenesis of analgesic nephropathy [letter; comment] Michielsen P, et al. **Am J Kidney Dis** 1996 Dec;28(6):959–60; discussion 960–2. Comment on: Am J Kidney Dis 1996 Jul;28(1 Suppl 1):S48–55.

Combination analgesic involvement in the pathogenesis of analgesic nephropathy [letter] Reyniers G, et al. **Am J Kidney Dis** 1997 Jun;29(6):982–3

Psychomotor agitation following gabapentin use in brain injury. Childers MK, et al. **Brain Inj** 1997 Jul;11(7):537–40

Strategies for diagnosing and managing medication–induced headache. Edmeads JG, et al. **Can Fam Physician** 1997 Jul; 43:1249–54 (42 ref.)

Amitriptyline and dexamethasone combined treatment in drug–induced headache. Bonuccelli U, et al. **Cephalalgia** 1996 May;16(3):198–200

Serotonin and analgesic–related headache [comment] Joseph R. **Cephalalgia** 1996 Oct;16(6):405. Comment on: Cephalalgia 1996 Oct;16(6):419–22. Comment on: Cephalalgia 1996 Oct;16(6):423–6.

Long–term outcome of patients with headache and drug abuse after inpatient withdrawal: five–year follow–up. Schnider P, et al. **Cephalalgia** 1996 Nov;16(7):481–5; discussion 461

Serotonin receptor adaptation in patients with analgesic–induced headache [see comments] Srikiatkhachorn A, et al. **Cephalalgia** 1996 Oct;16(6):419–22 . Comment in: Cephalalgia 1996 Oct;16(6):405.

Platelet serotonin in patients with analgesic–induced headache [see comments] Srikiatkhachorn A, et al. **Cephalalgia** 1996 Oct;16(6):423–6. Comment in: Cephalalgia 1996 Oct;16(6):405.

Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia. Skeith KJ, et al. **Clin Rheumatol** 1997 May;16(3):291–5

Fixed drug eruption induced by ethenzamide. Kawada A, et al. **Contact Dermatitis** 1996 May;34(5):369–70

Airborne contact dermatitis from propacetamol. Mathelier–Fusade P, et al. **Contact Dermatitis** 1997 May; 36(5):267–8

Occupational contact dermatitis from propacetamol. Szczurko C, et al. **Contact Dermatitis** 1996 Nov; 35(5):299–301

Analgesics and chronic renal disease. Klag MJ, et al. **Curr Opin Nephrol Hypertens** 1996 May;5(3):236–41 (42 ref.)

Increased risk of ischaemic heart disease mortality in elderly men using anxiolytics–hypnotics and analgesics. Results of the 10–year follow–up of the prospective population study "Men born in 1914", Malmo, Sweden. Merlo J, et al. **Eur J Clin Pharmacol** 1996;49(4):261–5

Precipitated kappa–opioid receptor agonist withdrawal increase glutamate in rat locus coeruleus. Hoshi K, et al. **Eur J Pharmacol** 1996 Oct 31;314(3):301–6

Hepatotoxicity of analgesics and anti–inflammatory agents. Fry SW, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):875–905 (171 ref.)

Central nervous system toxicity in a patient receiving continuous intrapleural bupivacaine. Kreitzer JM, et al. **J Clin Anesth** 1996 Dec;8(8):666–8

Granulomatous hepatitis induced by aspirin–kodein analgesics. Elzouki AN, et al. **J Intern Med** 1996 Mar; 239(3):279–81

Analgesics and the kidney: recommendations of the National Kidney Foundation for the use of analgesics. Birbari AE. **J Med Liban** 1996;44(3):144–5

Re: The ethics of death–hastening or death–causing palliative analgesic administration [letter; comment] Aldrete JA. **J Pain Symptom Manage** 1997 Jul;14(1):2–4. Comment on: J Pain Symptom Manage 1996 Oct;12(4):248–54.

Re: The ethics of death–hastening or death–causing palliative analgesic administration [letter; comment] Miller FG. **J Pain Symptom Manage** 1997 Jul;14(1):2. Comment on: J Pain Symptom Manage 1996 Oct;12(4):248–54.

Analgesic nephropathy. De Broe ME, et al. **Nephrol Dial Transplant** 1996 Dec;11(12):2407–8

No proof for a particular role of combination analgesics causing end–stage renal failure [letter; comment] Fox JM. **Nephrol Dial Transplant** 1996 Dec;11(12):2519–20. Comment on: Nephrol Dial Transplant 1994;9(1):41–6.

Incidence of analgesic nephropathy among patients undergoing renal replacement therapy in Czech Republic and Slovak Republic. The Group of Czech and Slovak Nephrologists. Matoušovic K, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):1048–51

Increase in the incidence of analgesic nephropathy in Hungary [letter] Mátyus J, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1774–5

Transformed migraine, analgesic rebound, and other chronic daily headaches. Mathew NT. **Neurol Clin** 1997 Feb; 15(1):167–186 (54 ref.)

Labor analgesia and infant brain development. Golub MS. **Pharmacol Biochem Behav** 1996 Dec;55(4):619–28 (95 ref.)

Spinal cord toxicity of epidural and subarachnoid analgesics. Abram SE. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):84–8 (44 ref.)

Is there a relationship between the use of analgesics and non–steroidal anti–inflammatory drugs and acute upper gastrointestinal bleeding? A Finnish case–control prospective study. Matikainen M, et al. **Scand J Gastroenterol** 1996 Sep;31(9):912–6

[Terminal care. II. Easing of symptoms of cancer patients. 3. Indications for and adverse effects of analgesics other than morphine] Hiraga K, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2021–6 **(Jpn)**

ANTAGONISTS & INHIBITORS

An antisense oligonucleotide on the mouse Shaker–like potassium channel Kv1.1 gene prevents antinociception induced by morphine and baclofen. Galeotti N, et al. **J Pharmacol Exp Ther** 1997 May;281(2):941–9

Involvement of supraspinal GABA receptors in majonoside–R2 suppression of clonidine–induced antinociception in mice. Nguyen TT, et al. **Life Sci** 1997; 61(4):427–36

Cellular mechanism for anti–analgesic action of agonists of the kappa–opioid receptor. Pan ZZ, et al. **Nature** 1997 Sep 25;389(6649):382–5

Effects of brain natriuretic peptide on effects of morphine in mice. Babarczy E, et al. **Neuropeptides** 1996 Oct; 30(5):438–42

Effects of intrathecally injected histamine receptor antagonists on the antinociception induced by morphine, beta–endorphin, and U50, 488H administered intrathecally in the mouse. Suh HW, et al. **Neuropeptides** 1996 Oct; 30(5):485–90

Inhibition of spinal nitric oxide synthase by N(omega)–nitro–L–arginine blocks the release of Met–enkephalin and antinociception induced by supraspinally administered beta–endorphin in the rat. Tseng LF, et al. **Neuroscience** 1997 May;78(2):461–7

Effects of some 7–arylidene and 7–heteroarylidene morphinan–6–ones on the antinociceptive activity of [D–Pen2, D–Pen5]enkephalin and [D–Ala2, Glu4]deltorphin II and on multiple opioid receptors. Bhargava HN, et al. **Peptides** 1997;18(5):695–701

The selective cannabinoid antagonist SR 141716A blocks cannabinoid–induced antinociception in rats. Lichtman AH, et al. **Pharmacol Biochem Behav** 1997 May–Jun; 57(1–2):7–12

BLOOD

Effects of routinely given pethidine during labour on infants' developing breastfeeding behaviour. Effects of dose–delivery time interval and various concentrations of pethidine/norpethidine in cord plasma. Nissen E, et al. **Acta Paediatr** 1997 Feb;86(2):201–8

Development of a capillary zone electrophoresis assay to examine the disposition of [D–pen2,5]enkephalin in rats. Chen C, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7; 681(2):363–73

Mass spectrometric quantification of the mu opioid receptor agonist Tyr–D–Arg–Phe–Lys–NH2 (DALDA) in high–performance liquid chromatography–purified ovine plasma. Grigoriants OO, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1;695(2):287–98

Plasma level monitoring of nasal salmon calcitonin in the rat by a heterogeneous two–site enzyme immunoassay. Nakamuta H, et al. **J Clin Lab Anal** 1997;11(3):129–31

CHEMICAL SYNTHESIS

Studies on analgesic and anti–inflammatory activities of 1–dialkylaminomethyl–2–(p–substituted phenyl)–5–substituted benzimidazole derivatives. Ersan S, et al. **Arzneimittelforschung** 1997 Jul;47(7):834–6

Synthesis, anticonvulsant and analgesic activities of some 6–substituted imidazo(2,1–b)–1,3,4–thiadiazole–2–sulfonamides and their 5–bromo derivatives. Khazi IA, et al. **Arzneimittelforschung** 1996 Oct;46(10):949–52

Synthesis and antinociceptive activity of peptides related to interleukin–1 beta 193–195 Lys–Pro–Thr. Caliendo G, et al. **Biopolymers** 1996;40(5):479–84

Design of potent dynorphin A–(1–9) analogues devoid of supraspinal motor effects in mice. Le HT, et al. **Can J Physiol Pharmacol** 1997 Jan;75(1):9–14

Synthesis and pharmacological evaluation in mice of new non–classical antinociceptive agents, 5–(4–arylpiperazin–1–yl)–4–benzyl–1,2–oxazin–6–ones. Bebot M, et al. **Chem Pharm Bull (Tokyo)** 1997 Apr; 45(4):659–67

Chiral synthesis and pharmacological evaluation of the enantiomers of SM32, a new analgesic and cognition–enhancing agent. Romanelli MN, et al. **Chirality** 1996;8(8):579–84

Structure–activity relationships defining the ACD–tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity. Melvin LS, et al. **Drug Des Discov** 1995 Nov; 13(2):155–66

Preparation and pharmacological activities of spiro[3,4–dihydro–6/7–R–1,2,4–benzotriazine–3,4'–(1'–substituted)piperi dines] Novelli F, et al. **Farmaco** 1996 Aug–Sep;51(8–9):541–50

Synthesis and SAR study of imidazo[2,1–b]benzothiazole acids and some related compounds with anti–inflammatory and analgesic activities. Palagiano F, et al. **Farmaco** 1996 Jul;51(7):483–91

Antinociceptive activity of chromophoric chain substituted hemicyaninocolourants. Gupta RK, et al. **Indian J Physiol Pharmacol** 1997 Apr;41(2):144–8

Anti–inflammatory and analgesic activities of 1–[2–(substituted benzothiazole)]–1,3–diethyl–4–aryl guanidines [letter] Naik PR, et al. **Indian J Physiol Pharmacol** 1996 Apr;40(2):189–90

Brain–targeted delivery of a leucine–enkephalin analogue by retrometabolic design. Prokai–Tatrai K, et al. **J Med Chem** 1996 Nov 22;39(24):4775–82

Synthesis, antiinflammatory, and cytotoxic activities of 2–alkyl and 2–benzyl–2–dimethylaminomethyl–5–(E)–arylidene cyclopentanone hydrochlorides. Chen H, et al. **Pharm Res** 1996 Oct;13(10):1482–7

Analgesic and antiinflammatory effects of some 2–mercaptobenzoxazole derivatives. Safak C, et al. **Pharmazie** 1996 Mar;51(3):180–2

[Evaluation of the synthesis and action of O– and

N-aryl-piperazine propyl derivatives of ethyl ester acid 3-cyano-2-hydroxy-6-methylpyridine-4-carboxyl] Sladowska H. **Acta Pol Pharm** 1992;49(1-2):61-5 (Eng. Abstr.) **(Pol)**

CHEMISTRY

The analgesic domain of IL-2. Wang Y, et al. **Biochem Biophys Res Commun** 1997 Jan 23;230(3):542-5

Chemical and pharmacological studies on fixed oil of Ocimum sanctum. Singh S, et al. **Indian J Exp Biol** 1996 Dec;34(12):1212-5

Pharmacist compounding of analgesic medication: the risk of a little-known practice [editorial] Johnson P, et al. **J Fla Med Assoc** 1997 Jan;84(1):13-5

Structure-activity relationship of biphalin. The synthesis and biological activities of new analogues with modifications in positions 3 and 4. Misicka A, et al. **Life Sci** 1997; 60(15):1263-9

Solution structure of vasoactive intestinal polypeptide (11-28)-NH2, a fragment with analgesic properties. Haghjoo K, et al. **Pept Res** 1996 Nov-Dec;9(6):327-31

CLASSIFICATION

[Management of facial pain resulting from cancer in oral and maxillofacial surgery] Chiarini L, et al. **Minerva Stomatol** 1997 Jan-Feb;46(1-2):27-38 (Eng. Abstr.) **(Ita)**

ECONOMICS

Combination analgesics with meprobamate as constituent [letter] Truter I. **S Afr Med J** 1996 Aug;86(8):973

METABOLISM

Intestinal transport and metabolism of analgesic dipeptide, kyotorphin: rate-limiting factor in intestinal absorption of peptide as drug. Mizuma T, et al. **Biochim Biophys Acta** 1997 Apr 17;1335(1-2):111-9

Stereoselective metabolism of famprofazone in humans: N-dealkylation and beta- and p-hydroxylation. Shin HS. **Chirality** 1997;9(1):52-8

Multiplicity of kappa opioid receptor binding in the rat cardiac sarcolemma. Zhang WM, et al. **J Mol Cell Cardiol** 1996 Jul;28(7):1547-54

Rapid in vivo metabolism of a methylether derivative of (+/-)-BW373U86: the metabolic fate of [3H]SNC121 in rats. Schetz JA, et al. **J Pharmacol Exp Ther** 1996 Dec; 279(3):1069-76

A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor. Minami M, et al. **Mol Pharmacol** 1996 Nov;50(5):1413-22

Laminar distribution of the multiple opioid receptors in the human cerebral cortex. Hiller JM, et al. **Neurochem Res** 1996 Nov;21(11):1333-45

Opioid binding profile of morphiceptin, Tyr-MIF-1 and dynorphin-related peptides in rat brain membranes. Sartania N, et al. **Neuropeptides** 1996 Jun;30(3):225-30

Kyotorphin (L-tyrosyl-L-arginine) as a possible substrate for inducible nitric oxide synthase in rat glial cells. Arima T, et al. **Neurosci Lett** 1996 Jul 5;212(1):1-4

Differential biotransformation of dynorphin A (1-17) and dynorphin A (1-13) peptides in human blood, ex vivo. Chou JZ, et al. **Peptides** 1996;17(6):983-90

Formation of meprobamate from carisoprodol is catalysed by CYP2C19. Dalén P, et al. **Pharmacogenetics** 1996 Oct; 6(5):387-94

Comparison of covalent binding of acetaminophen and the regioisomer 3'-hydroxyacetanilide to mouse liver protein. Matthews AM, et al. **Toxicol Lett** 1997 Jan 15;90(1):77-82

PHARMACOKINETICS

Effects of age and gender on the pharmacokinetics of bromfenac in healthy volunteers. Boni JP, et al. **Ann Pharmacother** 1997 Apr;31(4):400-5

Absolute bioavailability of bromfenac in humans. Gumbhir-Shah K, et al. **Ann Pharmacother** 1997 Apr; 31(4):395-9

Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine. Shyu WC, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):513-7

Pharmacokinetics of lysine clonixinate in children in postoperative care. González-Martin G, et al. **Int J Clin Pharmacol Ther** 1996 Sep;34(9):396-9

Pharmacokinetic-pharmacodynamic relationships for analgesics. Suri A, et al. **Int J Clin Pharmacol Ther** 1997 Aug;35(8):307-23 (140 ref.)

Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. Suri A, et al. **Int J Clin Pharmacol Ther** 1997 Jan;35(1):1-8

Evaluation of pharmacokinetic interaction between bromfenac and phenytoin in healthy males. Gumbhir-Shah K, et al. **J Clin Pharmacol** 1997 Feb;37(2):160-8

Brain and spinal cord distribution of biphalin: correlation with opioid receptor density and mechanism of CNS entry. Abbruscato TJ, et al. **J Neurochem** 1997 Sep;69(3):1236-45

Extensive biliary excretion of the model opioid peptide [D-PEN2,5] enkephalin in rats. Chen C, et al. **Pharm Res** 1997 Mar;14(3):345-50

Pharmacokinetic-pharmacodynamic relationships of bromfenac in mice and humans. Chiang ST, et al. **Pharmacotherapy** 1996 Nov-Dec;16(6):1179-87

Comparison of nicotinic receptor binding and biotransformation of coniine in the rat and chick. Forsyth CS, et al. **Toxicol Lett** 1996 Dec 31;89(3):175-83

PHARMACOLOGY

Interaction between sufentanil and U-50488H with respect to antinociception and respiratory depression in rats. Verborgh CM, et al. **Acta Anaesthesiol Scand** 1997 Aug; 41(7):895-902

Analgesic and psychomotor effects of thiopental at subanesthetic concentrations in human volunteers. Young CJ, et al. **Acta Anaesthesiol Scand** 1997 Aug;41(7):903-10

Update on spinal cord pharmacology in pain. Eisenach J. **Acta Anaesthesiol Scand Suppl** 1997;110:124-6 (21 ref.)

Ultrastructural changes in rat locus coeruleus induced by chronic opioids. Miao H, et al. **Acta Neuropathol (Berl)** 1997 Aug;94(2):109-15

Actions of xylazine in young swine. Gómez de Segura IA, et al. **Am J Vet Res** 1997 Jan;58(1):99-102

Comparative cardiopulmonary effects of intramuscularly administered etorphine and carfentanil in goats. Heard DJ, et al. **Am J Vet Res** 1996 Jan;57(1):87-96

RB 101, a purported pro drug inhibitor of enkephalin metabolism, is antinociceptive in pregnant mice. Jayaram A, et al. **Anesth Analg** 1997 Feb;84(2):355-8

Antinociceptive response to nitrous oxide is mediated by supraspinal opiate and spinal alpha 2 adrenergic receptors in the rat. Guo TZ, et al. **Anesthesiology** 1996 Oct; 85(4):846-52

Antinociceptive interaction of intrathecal alpha2-adrenergic agonists, tizanidine and clonidine, with lidocaine in rats. Kawamata T, et al. **Anesthesiology** 1997 Aug;87(2):436-48

Sympatholytic and minimum anesthetic concentration-sparing responses are preserved in rats rendered tolerant to the hypnotic and analgesic action of dexmedetomidine, a selective alpha(2)-adrenergic agonist. Rabin BC, et al. **Anesthesiology** 1996 Sep;85(3):565-73

Effects of R-84760, a selective kappa-opioid receptor agonist, on nociception, locomotion and respiration in rats. Fujibayashi K, et al. **Arch Int Pharmacodyn Ther** 1996 Mar-Apr;331(2):153-62

Reduced flexibility analogs of analgesic and cognition enhancing alpha-tropanyl esters. Manetti D, et al. **Arch Pharm (Weinheim)** 1996 Feb;329(2):105-11

New analgesics derived from the phencyclidine analogue thienylcyclidine. al-Deeb OA. **Arzneimittelforschung** 1996 May;46(5):505-8

Pro- and antinociceptive actions of serotonin (5-HT)1A agonists and antagonists in rodents: relationship to algesiometric paradigm. Millan MJ, et al. **Behav Brain Res** 1996;73(1-2):69-77

Processing of nux vomica. VII. Antinociceptive effects of crude alkaloids from the processed and unprocessed seeds of Strychnos nux-vomica in mice. Cai B, et al. **Biol Pharm Bull** 1996 Jan;19(1):127-31

Antinociceptive activities of 70% methanol extract of evodiae fructus (fruit of Evodia rutaecarpa var. bodinieri) and its alkaloidal components. Matsuda H, et al. **Biol Pharm Bull** 1997 Mar;20(3):243-8

Effects of mitragynine on cAMP formation mediated by delta-opiate receptors in NG108-15 cells. Tohda M, et al. **Biol Pharm Bull** 1997 Apr;20(4):338-40

Synthesis and antinociceptive activity of peptides related to interleukin-1 beta 193-195 Lys-Pro-Thr. Caliendo G, et al. **Biopolymers** 1996;40(5):479-84

Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover. Schlemmer A, et al. **Bone** 1997 Jan;20(1):63-7

Antinociception by intrathecal midazolam involves endogenous neurotransmitters acting at spinal cord delta opioid receptors. Goodchild CS, et al. **Br J Anaesth** 1996 Dec;77(6):758-63

Antinociceptive profile of the pseudopeptide B2 bradykinin receptor antagonist NPC 18688 in mice. Corrêa CR, et al. **Br J Pharmacol** 1996 Feb;117(3):552-558

Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues. Gouardères C, et al. **Br J Pharmacol** 1996 Feb;117(3):493-501

Inhibition of nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole (TRIM) in vitro: antinociceptive and cardiovascular effects. Handy RL, et al. **Br J Pharmacol** 1996 Sep;119(2):423-31

Differential antinociceptive effects of spinal opioids on foot withdrawal responses evoked by C fibre or A delta nociceptor activation. Lu Y, et al. **Br J Pharmacol** 1997 Jul;121(6):1210-6

Role of protein kinase C in desensitization of spinal delta-opioid-mediated antinociception in the mouse. Narita M, et al. **Br J Pharmacol** 1996 Aug;118(7):1829-35

Central B2 receptor involvement in the antinociceptive effect of bradykinin in rats. Pelá IR, et al. **Br J Pharmacol** 1996 Jul;118(6):1488-92

Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Pertwee RG, et al. **Br J Pharmacol** 1996 Aug;118(8):2199-205

Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Pertwee RG, et al. **Br J Pharmacol** 1996 Aug;118(8):2053-8

The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man. Ur E, et al. **Br J Pharmacol** 1997 Mar;120(5):781-4

The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration. Wilson JL, et al. **Br J Pharmacol** 1996 Aug; 118(7):1754-60

Alpha 2 adrenoceptor agonists in the horse--a review. England GC, et al. **Br Vet J** 1996 Nov;152(6):641-57 (105 ref.)

Modification of the binding of [3H]MK-801 to brain regions and spinal cord of rats treated chronically with U-50,488H, a kappa-opioid receptor agonist. Bhargava HN, et al. **Brain Res** 1997 Feb 28;749(2):347-50

Involvement of cholinergic neurons in the release of dopamine elicited by stimulation of mu-opioid receptors in striatum. Dourmap N, et al. **Brain Res** 1997 Feb 28; 749(2):295-300

Analgesic effects of the neurosteroid 3 alpha-androstanediol. Frye CA, et al. **Brain Res** 1996 Feb 12;709(1):1-9

Antinociception induced by opioid or 5-HT agonists microinjected into the anterior pretectal nucleus of the rat. Mamede Rosa ML, et al. **Brain Res** 1997 May 16; 757(1):133-8

Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Schröder U, et al. **Brain Res** 1996 Feb 26; 710(1-2):121-4

Galanin receptor antagonists attenuate spinal antinociceptive effects of DAMGO, tramadol and non-opioid drugs in rats. Selve N, et al. **Brain Res** 1996 Oct 7;735(2):177-87

Biphalin, an enkephalin analog with unexpectedly high antinociceptive potency and low dependence liability in vivo, selectively antagonizes excitatory opioid receptor functions of sensory neurons in culture. Shen KF, et al. **Brain Res** 1995 Dec 1;701(1-2):158-66

mu-Opioid receptor activation decreases N-type Ca2+ current in magnocellular neurons of the rat basal forebrain. Soldo BL, et al. **Brain Res** 1997 May 30;758(1-2):118-26

Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Tersigni TJ, et al. **Brain Res** 1996 Sep 16;733(2):184-92

Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Rubino T, et al. **Brain Res Mol Brain Res** 1997 Mar;44(2):191-7

Anti-inflammatory and analgesic activity of a water-soluble fraction from shark cartilage. Fontenele JB, et al. **Braz J Med Biol Res** 1996 May;29(5):643-6

Design of potent dynorphin A-(1-9) analogues devoid of supraspinal motor effects in mice. Le HT, et al. **Can J Physiol Pharmacol** 1997 Jan;75(1):9-14

Chiral synthesis and pharmacological evaluation of the enantiomers of SM32, a new analgesic and cognition-enhancing agent. Romanelli MN, et al. **Chirality** 1996;8(8):579-84

Pharmacotherapeutics in the management of orofacial pain. Reisner-Keller LA. **Dent Clin North Am** 1997 Apr; 41(2):259-78 (62 ref.)

Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Welch SP. **Drug Alcohol Depend** 1997 Apr 14;45(1-2):39-45

The effect of ipriflavone and its main metabolites on theophylline biotransformation. Monostory K, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jan-Mar;21(1):61-6

Effects of the kappa-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat. Bolanos CA, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):1-8

Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. Costa B, et al. **Eur J Pharmacol** 1996 Oct 10;313(1-2):17-24

Involvement of delta- and mu-opioid receptors in the potentiation of brain-stimulation reward. Duvauchelle CL, et al. **Eur J Pharmacol** 1996 Dec 5;316(2-3):137-43

Analgesic effects of Tyr-W-MIF-1: a mixed mu2-opioid receptor agonist/mu1-opioid receptor antagonist. Gergen KA, et al. **Eur J Pharmacol** 1996 Nov 28;316(1):33-8

Possible role of nitric oxide in the antinociceptive action of intraventricular bradykinin in mice. Germany A, et al. **Eur J Pharmacol** 1996 Aug 29;310(2-3):123-7

Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. Gifford AN, et al. **Eur J Pharmacol** 1997 Apr 18;324(2-3):187-92

Supraspinal delta 1-opioid receptor-mediated antinociceptive properties of (-)-TAN-67 in diabetic mice. Kamei J, et al. **Eur J Pharmacol** 1997 Mar 12;322(1):27-30

The role of spinal delta1-opioid receptors in inhibiting the formalin-induced nociceptive response in diabetic mice. Kamei J, et al. **Eur J Pharmacol** 1997 May 12;326(1):31-6

Peripheral kappa 1-opioid receptor-mediated analgesia in mice. Kolesnikov Y, et al. **Eur J Pharmacol** 1996 Aug 29; 310(2-3):141-3

Effect of caffeine coadministration and of nitric oxide synthesis inhibition on the antinociceptive action of ketorolac. López-Muñoz FJ, et al. **Eur J Pharmacol** 1996 Jul 25;308(3):275-7

Tachykinin NK1 receptor antagonist RP67580 attenuates progressive hypersensitivity of flexor reflex during experimental inflammation in rats. Ma QP, et al.

Eur J Pharmacol 1997 Mar 19;322(2-3):165-71

Different roles of alpha 2-adrenoceptors of the medulla versus the spinal cord in modulation of mustard oil-induced central hyperalgesia in rats. Mansikka H, et al. **Eur J Pharmacol** 1996 Feb 15;297(1-2):19-26

Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. Matsumoto K, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):75-81

The depletion of substance P by diclofenac in the mouse. Papworth J, et al. **Eur J Pharmacol** 1997 May 1; 325(2-3):R1-R2

A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice. Reche I, et al. **Eur J Pharmacol** 1996 Apr 22; 301(1-3):75-81

Tyr-D-Arg2-Phe-sarcosine4 activates phospholipase C-coupled mu2-opioid receptors in SH-SY5Y cells. Smart D, et al. **Eur J Pharmacol** 1996 Jun 3;305(1-3):235-8

Gastric effects of mu-, delta- and kappa-opioid receptor agonists on brainstem unitary responses in the neonatal rat. Yuan CS. **Eur J Pharmacol** 1996 Oct 24;314(1-2):27-32

Polysaccharopeptide from the mushroom Coriolus versicolor possesses analgesic activity but does not produce adverse effects on female reproductive or embryonic development in mice. Ng TB, et al. **Gen Pharmacol** 1997 Aug; 29(2):269-73

Antinociceptive mechanisms of dipsacus saponin C administered intracerebroventricularly in the mouse. Suh HW, et al. **Gen Pharmacol** 1996 Oct;27(7):1167-72

Mirfentanil antagonizes morphine-induced suppression of splenic NK activity in mice. Carr DJ, et al. **Immunopharmacology** 1996 Aug;34(1):9-16

Central modulation of Brewer's yeast-induced peripheral inflammation by neuropeptides bradykinin and substance P. Hore SK, et al. **Indian J Physiol Pharmacol** 1996 Oct; 40(4):367-71

Electroacupuncture, morphine and clonidine: a comparative study of analgesic effects. Shankar N, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):225-30

Pharmacokinetic-pharmacodynamic relationships for analgesics. Suri A, et al. **Int J Clin Pharmacol Ther** 1997 Aug;35(8):307-23 (140 ref.)

Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. Suri A, et al. **Int J Clin Pharmacol Ther** 1997 Jan;35(1):1-8

Cross-tolerance to acute administration of mu and kappa opioid agonists at the spinal cord level in the rat. Laurido C, et al. **Int J Neurosci** 1996 Nov;87(3-4):191-9

7th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators. Geneva, Switzerland, 19-21 May 1997. Abstracts. **Int J Tissue React** 1997;19(1-2):17-128

Anti-inflammatory activity of 2,3-dihydrophthalazine-1,4-diones in CF1 mice. Butner L, et al. **Int J Tissue React** 1996;18(2-3):47-55

Induction of apoptosis in cultured human retinal pigment epithelial cells is counteracted by flupirtine. Osborne NN, et al. **Invest Ophthalmol Vis Sci** 1997 Jun;38(7):1390-400

New insights into the site and mode of antinociceptive action of flurbiprofen enantiomers. Geisslinger G, et al. **J Clin Pharmacol** 1996 Jun;36(6):513-20 (85 ref.)

Opioid receptor ligand binding in the human striatum: II. Heterogeneous distribution of kappa opioid receptor labeled with [3H]bremazocine. Vonkeman HE, et al. **J Comp Neurol** 1996 Oct 14;374(2):223-9

Antiinflammatory effect of petroleum ether extract of leaves of Litchi chinensis Gaertn. (Sapindaceae). Besra SE, et al. **J Ethnopharmacol** 1996 Oct;54(1):1-6

Preliminary studies of analgesic and anti-inflammatory properties of Caesalpinia ferrea crude extract. Carvalho JC, et al. **J Ethnopharmacol** 1996 Sep;53(3):175-8

Investigation of antifungal and analgesic activities of extracts from Sium nodiflorum. Larhsini M, et al. **J Ethnopharmacol** 1996 Aug;53(2):105-10

Antinociceptive activity of Channa striatus (haruan) extracts in mice. Mat Jais AM, et al. **J Ethnopharmacol** 1997 Jul; 57(2):125-30

Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. Prokai-Tatrai K, et al. **J Med Chem** 1996 Nov 22;39(24):4775-82

Analogues of capsaicin with agonist activity as novel analgesic agents: structure-activity studies. 4. Potent, orally active analgesics. Wrigglesworth R, et al. **J Med Chem** 1996 Dec 6;39(25):4942-51

Nociceptin (orphanin FQ), an endogenous ligand for the QRL1 (opioid-receptor-like1) receptor; modulates responses of trigeminal neurons evoked by excitatory amino acids and somatosensory stimuli. Wang XM, et al. **J Neurophysiol** 1996 Nov;76(5):3568-72

Dissociation of tolerance and dependence for opioid peripheral antinociception in rats. Aley KO, et al. **J Neurosci** 1997 May 15;17(10):3907-12

Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat. Aley KO, et al. **J Neurosci** 1997 Oct 15;17(20):8018-23

Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. Martin WJ, et al. **J Neurosci** 1996 Oct 15;16(20):6601-11

Ocular action of an opioid peptide, DPDPE. Wang D, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):131-9

Chemical and pharmacological studies of Phyllanthus caroliniensis in mice. Cechinel Filho V, et al. **J Pharm Pharmacol** 1996 Dec;48(12):1231-6

Reversible inhibition of cholinesterases by opioids: possible pharmacological consequences. Galli A, et al. **J Pharm Pharmacol** 1996 Nov;48(11):1164-8

Mechanisms involved in the antinociceptive effect in mice of the hydroalcoholic extract of Siphocampylus verticillatus. Trentin AP, et al. **J Pharm Pharmacol** 1997 May;49(5):567-72

Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. Chaplan SR, et al. **J Pharmacol Exp Ther** 1997 Feb; 280(2):829-38

Pharmacological investigation of (+)- and (-)-cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo-[3,2-h]isoq uinoline, a bridged-nicotine analog. Damaj MI, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1425-34

Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys. Gatch MB, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1282-9

Antinociceptive profile of 3-alpha-tropanyl-(2-Cl)-acid phenoxybutyrate (SM-21): a novel analgesic with a presynaptic cholinergic mechanism of action. Ghelardini C, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):430-9

Putative kappa-2 opioid agonists are antihyperalgesic in a rat model of inflammation. Ho J, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):136-41

Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats. Honore P, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):208-17

Mutual antagonism between nerve growth factor and substance P N-terminal activity on nociceptive activity in mice. Larson AA, et al. **J Pharmacol Exp Ther** 1997 Sep; 282(3):1345-50

Antiinflammatory and analgesic activity of an inhibitor of neuropeptide amidation. Ogonowski AA, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):846-53

The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. Pugh G Jr, et al. **J Pharmacol Exp Ther** 1996 Nov; 279(2):608-16

Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. Pugh G Jr, et al. **J Pharmacol Exp Ther** 1997 May;281(2):730-7

Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride. Raffa RB, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1098-104

Pharmacological characterization of orphanin FQ/nociceptin and its fragments. Rossi GC, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):858-65

Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity. Shannon HE, et al. **J Pharmacol Exp Ther** 1997 May;281(2):884-94

M1 receptor agonist activity is not a requirement for muscarinic antinociception. Sheardown MJ, et al. **J Pharmacol Exp Ther** 1997 May;281(2):868-75

Effect of the highly selective and nonpeptide delta opioid receptor agonist TAN-67 on the morphine-induced place preference in mice. Suzuki T, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):177-85

Butylthio[2.2.2] (NNC 11-1053/LY297802): an orally active muscarinic agonist analgesic. Swedberg MD, et al. **J Pharmacol Exp Ther** 1997 May;281(2):876-83

Insulin attenuates formalin-induced nociceptive response in mice through a mechanism that is deranged by diabetes mellitus. Takeshita N, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):315-21

Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)TAN-67, in the mouse spinal cord. Tseng LF, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):600-5

Descending antinociceptive mechanisms in the brainstem: their role in the animal's defensive system. Harris JA. **J Physiol Paris** 1996;90(1):15-25 (146 ref.)

Analgesic effects on endogenous melatonin secretion. Lapwood KR, et al. **J Pineal Res** 1997 Jan;22(1):20-5

Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? Kotaniemi A, et al. **J Rheumatol** 1996 Nov;23(11):1875-9

Cardiovascular and respiratory effects of detomidine in isoflurane-anaesthetised horses. Still J, et al. **J S Afr Vet Assoc** 1996 Dec;67(4):199-203

Cardiopulmonary and analgesic effects of xylazine, detomidine, medetomidine, and the antagonist atipamezole in isoflurane-anesthetized swine. Tendillo FJ, et al. **Lab Anim Sci** 1996 Apr;46(2):215-9

Reversal by kappa-agonists of peritoneal irritation-induced ileus and visceral pain in rats. Friese N, et al. **Life Sci** 1997; 60(9):625-34

An examination of the relationship between mu-opioid antinociceptive efficacy and G-protein coupling using pertussis and cholera toxins. Goode TL, et al. **Life Sci** 1997; 60(7):PL107-13

Structure-activity relationship of biphalin. The synthesis and biological activities of new analogues with modifications in positions 3 and 4. Misicka A, et al. **Life Sci** 1997; 60(15):1263-9

Involvement of supraspinal GABA-ergic systems in clonidine-induced antinociception in the tail-pinch test in mice. Nguyen TT, et al. **Life Sci** 1997;61(11):1097-103

Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Takai S, et al. **Life Sci** 1996;59(21):PL331-6

Tolerance-like phenomenon of nifedipine-induced antinociception. Wong CH, et al. **Life Sci** 1996; 59(18):PL277-81

Antinociceptive effect of nifedipine and verapamil tested on rats chronically exposed to nicotine and after its withdrawal. Zbuzek VK, et al. **Life Sci** 1997;60(19):1651-8

Pain control. Sidebotham DA, et al. **N Z Med J** 1997 Mar 14;110(1039):65-7 (27 ref.)

Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene [see comments] Matthes HW, et al. **Nature** 1996 Oct 31;383(6603):819-23. Comment in: Nature 1996 Oct 31;383(6603):759-60.

Effects of two histamine-N-methyltransferase inhibitors, SKF 91488 and BW 301 U, in rodent antinociception. Malmberg-Aiello P, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Mar; 355(3):354-60

Differential modulation by muscimol and baclofen on antinociception induced by morphine, beta-endorphin, D-Pen2,5-enkephalin and U50,488H administered intracerebroventricularly in the mouse. Suh HW, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec; 352(6):614-9

The role of vasopressin on the effect of U-50,488 to block the development of morphine tolerance and physical dependence. Tao PL, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):281-7

Anti-inflammatory and antinociceptive effect of different somatostatin-analogs. Helyes Z, et al. **Neurobiology (Bp)** 1996;4(1-2):115-7

Sigma binding in a human neuroblastoma cell line. Ryan-Moro J, et al. **Neurochem Res** 1996 Nov; 21(11):1309-14

mu-Opioid agonists stimulate growth hormone secretion in immature rats. Eason MG, et al. **Neuroendocrinology** 1996 Jun;63(6):489-97

Differential mechanisms of ovine fetal pituitary stimulation by a selective kappa-opioid agonist and by dynorphin. Taylor CC, et al. **Neuroendocrinology** 1996 Dec; 64(6):419-24

Effect of nitric oxide synthase inhibition on tolerance to the analgesic action of D-Pen2, D-Pen5 enkephalin and morphine in the mouse. Bhargava HN, et al. **Neuropeptides** 1996 Jun;30(3):219-23

Nicotine enhances morphine- and beta-endorphin-induced antinociception at the supraspinal level in the mouse. Suh HW, et al. **Neuropeptides** 1996 Oct;30(5):479-84

Intrathecally injected nicotine enhances the antinociception induced by morphine but not beta-endorphin, D-Pen2,5-enkephalin and U50,488H administered intrathecally in the mouse. Suh HW, et al. **Neuropeptides** 1996 Aug;30(4):373-8

Substance P(6-11) and natural tachykinins interact with septide-sensitive tachykinin receptors coupled to a phospholipase C in the rat urinary bladder. Torrens Y, et al. **Neuropeptides** 1997 Jun;31(3):243-51

Effect of central administration of the kappa-opiate receptor agonist U 69.593 on neurohypophyseal hormone levels in blood and cerebrospinal fluid. van Wimersma Greidanus TB, et al. **Neuropeptides** 1996 Oct;30(5):452-5

The effects of Na+ channel blockers on somatosensory processing by rat dorsal horn neurones. Blackburn-Munro G, et al. **Neuroreport** 1997 May 6;8(7):1549-54

Ultrasonic vocalization (22-28 kHz) in a model of chronic pain, the arthritic rat: effects of analgesic drugs. Calvino B, et al. **Neuroreport** 1996 Jan 31;7(2):581-4

Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. Edsall SA, et al. **Neuroreport** 1996 Jan 31;7(2):593-6

Gabapentin, ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation. Stanfa LC, et al. **Neuroreport** 1997 Feb 10;8(3):587-90

Analgesic effects of fibroblast growth factor in the rat. Cuevas P, et al. **Neurosci Lett** 1996 Apr 5;207(3):175-8

DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro. Gold MS, et al. **Neurosci Lett** 1996 Jul 12;212(2):83-6

A mu-receptor opioid agonist induces AP-1 and NF-kappa B transcription factor activity in primary cultures of rat cortical neurons. Hou YN, et al. **Neurosci Lett** 1996 Jul 19;212(3):159-62

Spinal analgesic activity of orphanin FQ/nociceptin and its fragments. King MA, et al. **Neurosci Lett** 1997 Feb 21; 223(2):113-6

Ketamine enhances local anesthetic and analgesic effects of bupivacaine by peripheral mechanism: a study in postoperative patients. Tverskoy M, et al. **Neurosci Lett** 1996 Aug 30;215(1):5-8

Opposite role of delta 1- and delta 2-opioid receptors activated by endogenous or exogenous opioid agonists on the endogenous cholecystokinin system: further evidence for delta-opioid receptor heterogeneity. Noble F, et al. **Neuroscience** 1996 Dec;75(3):917-26

Blockade of capsaicin-induced reduction of GABA-immunoreactivity by spantide in cat spinal superficial dorsal horn. Wei F, et al. **Neuroscience** 1996 Mar;71(1):277-83

Comments on Detweiler et al. (Pain 63 (1995) 251-254) [letter; comment] Abbott FV, et al. **Pain** 1996 Sep; 67(1):220-5. Comment on: Pain 1995 Nov;63(2):251-4.

Endothelin-1 in periaqueductal gray area of mice induces analgesia via glutamatergic receptors. D'Amico M, et al. **Pain** 1996 May-Jun;65(2-3):205-9

Nitric oxide mediates long-term hyperalgesic and antinociceptive effects of the N-terminus of substance P in the formalin assay in mice. Goettl VM, et al. **Pain** 1996 Oct;67(2-3):435-41

Response to Lariviere and Melzack, PAIN, 66 (1996) 271-277 [letter] Jurna I. **Pain** 1997 May;71(1):113-4

Effects of morphine-3-glucuronide on the antinociceptive activity of peptide and nonpeptide opioid receptor agonists in mice. Bian JT, et al. **Peptides** 1996;17(8):1415-9

Cholecystokinin-induced antinociception is not blocked by CCK-A or CCK-B receptor antagonists. Williams CL, et al. **Peptides** 1997;18(3):409-14

Synthesis, antiinflammatory, and cytotoxic activities of 2-alkyl and 2-benzyl-2-dimethylaminomethyl-5-(E)-arylidene cyclopentanone hydrochlorides. Chen H, et al. **Pharm Res** 1996 Oct;13(10):1482-7

Inhibition of nitric oxide synthase by isothioureas: cardiovascular and antinociceptive effects. Handy RL, et al. **Pharmacol Biochem Behav** 1996 Oct;55(2):179-84

Differential sensitivity of mice bred for stress-induced analgesia to morphine and ACEA-1011 in the formalin test. Lutfy K, et al. **Pharmacol Biochem Behav** 1996 Jun; 54(2):495-500

Aversive effects of the synthetic cannabinoid CP 55,940 in rats. McGregor IS, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):657-64

The antinociceptive effects of branched-chain amino acids: evidence for their ability to potentiate morphine analgesia. Manner T, et al. **Pharmacol Biochem Behav** 1996 Feb; 53(2):449-54

Suppressive effect of mitragynine on the 5-methoxy-N,N-dimethyltryptamine-induced head-twitch response in mice. Matsumoto K, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):319-23

The analgesia-enhancing component of ingested amniotic fluid does not affect nicotine-induced antinociception in naltrexone-treated rats. Robinson-Vanderwerf TM, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):147-51

Antinociceptive effects of repeated systemic injections of calcitonin in formalin-induced hyperalgesic rats. Umeno H, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):151-6

Effects of cold acclimation and central opioid processes on thermoregulation in rats. Wilson JR, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):317-25

Antinociception induced by SM 32 depends on a central cholinergic mechanism. Ghelardini C, et al. **Pharmacol Res** 1997 Feb;35(2):141-7

Pharmacological studies of cardamom oil in animals. al-Zuhair H, et al. **Pharmacol Res** 1996 Jul-Aug; 34(1-2):79-82

Opposite influences of different adrenoceptors on baclofen-induced antinociception in mice. Sabetkasai M, et al. **Pharmacol Toxicol** 1997 Jan;80(1):6-10

A possible central antinociceptive effect of dipyrone in mice. Akman H, et al. **Pharmacology** 1996 Aug;53(2):71-8

The influence of bromfenac on the pharmacokinetics and pharmacodynamic responses to glyburide in diabetic subjects. Boni JP, et al. **Pharmacotherapy** 1997 Jul-Aug; 17(4):783-90

An analytical study, anti-inflammatory and analgesic effects of Harpagophytum procumbens and Harpagophytum zeyheri. Baghdikian B, et al. **Planta Med** 1997 Apr; 63(2):171-6

Investigation of anti-inflammatory and antinociceptive activities of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara. Part 1. Carvalho JC, et al. **Planta Med** 1996 Oct;62(5):402-4

Analgesic, anti-inflammatory, antipyretic and haematological effects of aethiopinone, an o-naphthoquinone diterpenoid from Salvia aethiopis roots and two hemisynthetic derivatives. Hernández-Pérez M, et al. **Planta Med** 1995 Dec;61(6):505-9

Anti-inflammatory and anti-nociceptive activity of disodium glycyrrhetinic acid hemiphthalate. Khaksa G, et al. **Planta Med** 1996 Aug;62(4):326-8

Antinociceptive components of Ganoderma lucidum. Koyama K, et al. **Planta Med** 1997 Jun;63(3):224-7

Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Lakhlani PP, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9950-5

Effects of the delta opioid against BW373U86 in pigeons trained to discriminate fentanyl, bremazocine and water in a three-choice drug discrimination procedure. Negus SS, et al. **Psychopharmacology (Berl)** 1996 Aug; 126(3):199-205

The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Singh L, et al. **Psychopharmacology (Berl)** 1996 Sep;127(1):1-9

Future epidural or subarachnoid analgesics: local anesthetics. Carpenter RL. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):75-80 (27 ref.)

Three novel spinal analgesics: clonidine, neostigmine, amitriptyline. Eisenach JC. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):81-3 (8 ref.)

Effect of chronic administration of dihydropyridine Ca2+ channel ligands on sufentanil-induced tolerance to mu- and kappa-opioid agonists in the guinea pig ileum myenteric plexus. Garaulet JV, et al. **Regul Pept** 1996 May 7;63(1):1-8

Effect of 2,4-disubstituted thiazol-5yl-aminoketones on inflammation. In vitro and in vivo biological studies: a structure-activity approach. Hadjipavlou-Litina DJ, et al. **Res Commun Mol Pathol Pharmacol** 1997 Jun;96(3):307-18

Peripherally active analgesia of aminopeptidase-resistant sugar-coupled leucine enkephalin. Mizuma T, et al. **Res Commun Mol Pathol Pharmacol** 1997 Jan;95(1):83-91

Potentiation of acetaminophen hepatotoxicity by acute physical exercise in rats. Yoon MY, et al. **Res Commun Mol Pathol Pharmacol** 1997 Apr;96(1):35-44

Effect of mu, delta and kappa opioid receptor agonists on a reactive oxygen species mediated model of skin inflammation. Earl JR, et al. **Skin Pharmacol** 1996; 9(4):250-8

Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Maneuf YP, et al. **Synapse** 1996 Apr;22(4):382-5

Interactions between the mu opioid agonist DAMGO and substance P in regulation of the ventral pallidum. Mitrovic I, et al. **Synapse** 1996 Jul;23(3):142-51

The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. Geisslinger G, et al. **Thromb Haemost** 1996 Oct;76(4):592-7

Effects of four analgesic treatments on the behavioural and cortisol responses of 3-week-old lambs to tail docking. Graham MJ, et al. **Vet J** 1997 Jan;153(1):87-97

Systemic and local effects associated with long-term epidural catheterization and morphine-detomidine administration in horses. Sysel AM, et al. **Vet Surg** 1997 Mar-Apr; 26(2):141-9

[Comparison between effects of morning and evening administration of effervescent calcium carbasalate (equivalent of 160 mg aspirin) on the gastroduodenal mucosa in healthy volunteers] Berlin I, et al. **Pathol Biol (Paris)** 1997 Jun;45(6):514-20 (Eng. Abstr.) **(Fre)**

[Evaluation of the antinociceptive effect of xylazine after epidural administration in dogs under general anesthesia with isoflurane] Rector E, et al. **Berl Munch Tierarztl Wochenschr** 1997 Jan;110(1):15-23 (Eng. Abstr.) **(Ger)**

[Anti-inflammatory and analgesic actions of of long-chain phenyl substituted alpha-aminoketones] Schulz E, et al. **Pharmazie** 1996 Aug;51(8):591-3 (Eng. Abstr.) **(Ger)**

[Analgesic mechanism of ketamine] Sonoda H, et al. **Masui** 1996 Jun;45(6):689-97 (Eng. Abstr.) **(Jpn)**

[Antinociceptive effects of Kami-kihi-to in mice] Yanase T, et al. **Nippon Yakurigaku Zasshi** 1996 Aug;108(2):77-83 (Eng. Abstr.) **(Jpn)**

[Chronopharmacological features of the pain-relieving effects of analgesics] Kubynin AN, et al. **Anesteziol Reanimatol** 1996 Jul-Aug;(4):7-9 (Eng. Abstr.) **(Rus)**

[The interaction of dialkylaminoacyl derivatives of phenothiazine, dibenzazepine and dibenzdiazepine with opiate receptors] Brusova EG, et al. **Eksp Klin Farmakol** 1996 Mar-Apr;59(2):20-3 (Eng. Abstr.) **(Rus)**

[The effect of calcium-regulating hormones on pain sensitivity in rats] Butakov SS, et al. **Eksp Klin Farmakol** 1996 Mar-Apr;59(2):9-11 (Eng. Abstr.) **(Rus)**

[Selective inhibitors of COX-2: new anti-inflammatory agents without gastric-damaging effects (editorial)] Clària J. **Gastroenterol Hepatol** 1997 Jun-Jul;20(6):309-11 **(Spa)**

POISONING

Are suicide rates in Sweden associated with changes in the prescribing of medicines? Carlsten A, et al. **Acta Psychiatr Scand** 1996 Aug;94(2):94-100

Drugs taken in fatal and non-fatal self-poisoning: a study in south London. Neeleman J, et al. **Acta Psychiatr Scand** 1997 Apr;95(4):283-7

[Gc-globulin in paracetamol poisoning] Schiødt FV, et al. **Ugeskr Laeger** 1996 Nov 11;158(46):6609-12 (Eng. Abstr.) **(Dan)**

SUPPLY & DISTRIBUTION

[What drugs should be kept at the "home pharmacy" for fever and pain? (letter)] Simon T. **Orv Hetil** 1997 Feb 16; 138(7):448 **(Hun)**

THERAPEUTIC USE

Research can be a pain in the neck [editorial; comment] Levitt MA. **Acad Emerg Med** 1996 Jun;3(6):563-4. Comment on: Acad Emerg Med 1996 Jun;3(6):568-73.

Determining the effectiveness of a clinical-practice intervention in improving the control of pain in outpatients with cancer. Trowbridge R, et al. **Acad Med** 1997 Sep; 72(9):798-800

Pharmacological approaches other than opioids in chronic non-cancer pain management. Merskey H. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):187-90

Adenosine for pain control. Sollevi A. **Acta Anaesthesiol Scand Suppl** 1997;110:135-6 (14 ref.)

Ketorolac tromethamine in cancer pain. Yalçin S, et al. **Acta Oncol** 1997;36(2):231-2

Painful neuropathy of the lateral cutaneous nerve of the thigh in patients with AIDS: successful treatment by injection with bupivacaine and triamcinolone [letter] Myers KG, et al. **AIDS** 1996 Sep;10(11):1302-3

Is decreased use of analgesics in Alzheimer disease due to a change in the affective component of pain? Scherder EJ, et al. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):171-4

Treating chronic pain [published erratum appears in Am Fam Physician 1997 Apr;55(5):1586] Montauk SL, et al. **Am Fam Physician** 1997 Mar;55(4):1151-60, 1165-6 (15 ref.)

Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience. Gramling-Babb P, et al. **Am Heart J** 1997 Jun;133(6):648-55

Age as a risk factor for inadequate emergency department analgesia. Jones JS, et al. **Am J Emerg Med** 1996 Mar; 14(2):157-60

Analgesic prescriptions for ED patients with pelvic or dental pain [letter] Plewa MC. **Am J Emerg Med** 1997 May; 15(3):326-8

Measurement methods of drug consumption as a secondary judgment criterion for clinical trials in chronic rheumatic diseases. Constant F, et al. **Am J Epidemiol** 1997 May 1; 145(9):826-33

No harm was done [letter] Dies DF, et al. **Am J Gastroenterol** 1997 Mar;92(3):541-2

Managing pain in addicted patients. Pasero CL, et al. **Am J Nurs** 1997 Apr;97(4):17-8

Phantom limb pain [letter; comment] Baylis R, et al. **Anaesth Intensive Care** 1996 Apr;24(2):288-9. Comment on: Anaesth Intensive Care 1995 Oct;23(5):620-2.

Acute pain management in Australia and New Zealand [letter; comment] Baylis RJ, et al. **Anaesth Intensive Care** 1996 Apr;24(2):287-8. Comment on: Anaesth Intensive Care 1995 Dec;23(6):715-7.

Comparison of the efficacy of paracetamol versus paracetamol, codeine and promethazine (Painstop) for premedication and analgesia for myringotomy in children. Ragg P, et al. **Anaesth Intensive Care** 1997 Feb;25(1):29-32

The effect of pretreatment with ketorolac on pain during intravenous injection of propofol [see comments] Smith AJ, et al. **Anaesthesia** 1996 Sep;51(9):883-5. Comment in: Anaesthesia 1997 Jan;52(1):94.

Is there a place for intrathecal clonidine for clinical analgesia? [letter; comment] Goudas LC, et al. **Anesth Analg** 1996 Oct;83(4):891. Comment on: Anesth Analg 1996 Mar;82(3):627-35.

Studies on the safety of glucose and paraben-containing neostigmine for intrathecal administration. Gurun MS, et al. **Anesth Analg** 1997 Aug;85(2):317-23

Postoperative analgesia after peripheral nerve block for podiatric surgery: clinical efficacy and chemical stability of lidocaine alone versus lidocaine plus clonidine. Reinhart DJ, et al. **Anesth Analg** 1996 Oct;83(4):760-5

Erythromelalgia pain managed with gabapentin. McGraw T, et al. **Anesthesiology** 1997 Apr;86(4):988-90

Analgesia in renal colic [letter; comment] Smally AJ. **Ann Emerg Med** 1997 Feb;29(2):296; discussion 297-9. Comment on: Ann Emerg Med 1996 Aug;28(2):151-8.

Acute pain management: operative or medical procedures and trauma. Follin SL, et al. **Ann Pharmacother** 1997 Sep; 31(9):1068-76 (63 ref.)

Comment: capsaicin for pain relief in Guillain-Barré syndrome [letter; comment] Jacknowitz AI. **Ann Pharmacother** 1997 Apr;31(4):500. Comment on: Ann Pharmacother 1996 Feb;30(2):173-80.

Sedatives, analgesics, and paralytics in the ICU. Watling SM, et al. **Ann Pharmacother** 1997 Feb;31(2):148-53

Use of gabapentin in pain management. Wetzel CH, et al. **Ann Pharmacother** 1997 Sep;31(9):1082-3 (8 ref.)

Tizanidine for chronic cluster headache [letter] D'Alessandro R. **Arch Neurol** 1996 Nov;53(11):1093

Tiger Balm as a treatment of tension headache. A clinical trial in general practice. Schattner P, et al. **Aust Fam Physician** 1996 Feb;25(2):216, 218, 220 passim

Salmon calcitonin in the prevention of bone loss at perimenopause. Arnala I, et al. **Bone** 1996 Jun;18(6):629-32

Analgesia and analgesic drugs in paediatrics. Ball AJ, et al. **Br J Hosp Med** 1996 May 1-14;55(9):586-90 (27 ref.)

Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism. Ruiz F, et al. **Br J Pharmacol** 1996 Sep; 119(1):174-82

Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Adachi JD, et al. **Br J Rheumatol** 1997 Feb;36(2):255-9

Preventive not pre-emptive analgesia with piroxicam [letter; comment] Futter M. **Can J Anaesth** 1997 Jan;44(1):101-2 . Comment on: Can J Anaesth 1996 Feb;43(2):97-101.

Dose-response of flurbiprofen on postoperative pain and

emesis after paediatric strabismus surgery. Mikawa K, et al. **Can J Anaesth** 1997 Jan;44(1):95–8
Comparison of tramadol and tramadol/droperidol mixture for patient-controlled analgesia. Ng KF, et al. **Can J Anaesth** 1997 Aug;44(8):810–5
Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. Pryse-Phillips WE, et al. **Can Med Assoc J** 1997 May 1; 156(9):1273–87 (160 ref.)
Postoperative use of analgesics in dogs and cats by Canadian veterinarians. Dohoo SE, et al. **Can Vet J** 1996 Sep; 37(9):546–51
Is a central action of acute antimigraine drugs essential? Goadsby PJ. **Cephalalgia** 1997 Jun;17 Suppl 17:10–1
What is lacking in the treatment of paediatric and adolescent migraine? Massiou H. **Cephalalgia** 1997 Jun;17 Suppl 17:21–3; discussion 23–4
Measuring central action of acute antimigraine drugs in humans. Schoenen J. **Cephalalgia** 1997 Jun;17 Suppl 17:12–5; discussion 15–6
How to define the best efficacy parameters for migraine. Tfelt-Hansen P. **Cephalalgia** 1997 Jun;17 Suppl 17:6–8; discussion 8–9
Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study. Gonnelli S, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):55–61
Analgesic drugs for neuropathic and sympathetically maintained pain. Lipman AG. **Clin Geriatr Med** 1996 Aug; 12(3):501–15 (30 ref.)
Glycosaminoglycan polysulfate injections for lateral humeral epicondylalgia. Mohtadi NG. **Clin J Sport Med** 1996 Jan; 6(1):65
Pain management in the pediatric intensive care unit. Chambliss CR, et al. **Curr Opin Pediatr** 1997 Jun; 9(3):246–53 (54 ref.)
Current guidelines for the treatment of acute pain in children. Bhatt-Mehta V. **Drugs** 1996 May;51(5):760–76 (160 ref.)
Peppers and pain. The promise of capsaicin. Fusco BM, et al. **Drugs** 1997 Jun;53(6):909–14 (37 ref.)
The therapeutic potential of neuropeptide Y. Analgesic, anxiolytic and antihypertensive. Munglani R, et al. **Drugs** 1996 Sep;52(3):371–89 (213 ref.)
Comparison of detomidine, butorphanol, flunixin meglumine and xylazine in clinical cases of equine colic. Jochle W, et al. **Equine Vet J Suppl** 1989 Jun;(7):111–6
Field trial evaluation of detomidine as a sedative and analgesic in horses with colic. Jöchle W. **Equine Vet J Suppl** 1989 Jun;(7):117–20
Comparative study of the efficacy of lysine acetylsalicylate, indomethacin and pethidine in acute renal colic. al-Sahlawi KS, et al. **Eur J Emerg Med** 1996 Sep;3(3):183–6
U-50488H, a selective kappa-opioid receptor agonist, improves carbon monoxide-induced delayed amnesia in mice. Hiramatsu M, et al. **Eur J Pharmacol** 1996 Nov 14; 315(2):119–25
The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Hunter JC, et al. **Eur J Pharmacol** 1997 Apr 18;324(2–3):153–60
Antinociceptive effects of oral clonidine and S12813–4 in acute colon inflammation in rats. Miampamba M, et al. **Eur J Pharmacol** 1996 Jul 25;308(3):251–9
Can a pharmacological pain analysis in patients with chronic low back pain predict the outcome of lumbar fusion? Preliminary report. Sörensen J, et al. **Eur Spine J** 1996; 5(5):326–31
Intravenous ketorolac tromethamine versus meperidine for adjunctive sedation in upper gastrointestinal endoscopy: a pilot study. Dies DF, et al. **Gastrointest Endosc** 1996 Jan; 43(1):6–9
Utilization of pain medications in hospitalized psychiatric patients. Wise TN, et al. **Gen Hosp Psychiatry** 1996 Nov; 18(6):422–5
Analgesic drug taking: beliefs and behavior among headache patients. Ferrari A, et al. **Headache** 1997 Feb;37(2):88–94
Prescribing practices for the management of headache in Newfoundland and Labrador. Furlong S, et al. **Headache** 1996 Oct;36(9):542–6
Incomplete analgesic effect of lanreotide in acromegaly [letter] Maffei P, et al. **Headache** 1997 May;37(5):299–300
Capsaicin--an effective topical treatment in pain. Markovits E, et al. **Int J Dermatol** 1997 Jun;36(6):401–4 (24 ref.)
A chart audit reviewing the prescription and administration trends of analgesia and the documentation of pain, after surgery. Lellan KM. **J Adv Nurs** 1997 Aug;26(2):345–50
Evaluation of a survey of the diplomates of the American College of Laboratory Animal Medicine on use of analgesic agents in animals used in biomedical research. Hubbell JA, et al. **J Am Vet Med Assoc** 1996 Sep 1;209(5):918–21
Anesthesia practices in the United States common to in vitro fertilization (IVF) centers. Ditkoff EC, et al. **J Assist Reprod Genet** 1997 Mar;14(3):145–7
Relation of cognitive coping and catastrophizing to acute pain and analgesic use following breast cancer surgery. Jacobsen PB, et al. **J Behav Med** 1996 Feb;19(1):17–29
A sequential trial of pain killers in arthritis: issues of multiple comparisons with control and of interval-censored survival data. Whitehead J, et al. **J Biopharm Stat** 1997 Jul; 7(3):333–53
Effect of pretreatment with ketorolac tromethamine on post-operative pain following periodontal surgery. Trombelli L, et al. **J Clin Periodontol** 1996 Feb; 23(2):128–32
Patterns of analgesic prescribing in a South African primary care setting. Truter I. **J Clin Pharm Ther** 1997 Feb; 22(1):33–7
Generalized use of over-the-counter analgesics: relationship to premenstrual symptoms. Hart KE, et al. **J Clin Psychol** 1997 Apr;53(3):197–200
Emergency department management of pain [editorial; comment] Catapano MS. **J Emerg Med** 1997 Mar-Apr; 15(2):245–6. Comment on: J Emerg Med 1997 Mar-Apr;15(2):247–8.
Pain and symptom management in cancer patients. Kori S. **J Fla Med Assoc** 1996 Dec;83(10):679–94 (75 ref.)
Antiparkinsonian effect of flupirtine in monoamine-depleted rats. Schwarz M, et al. **J Neural Transm Gen Sect** 1996; 103(5):581–90
Summary of the Mayday Fund Survey: public attitudes about pain and analgesics. Bostrom M. **J Pain Symptom Manage** 1997 Mar;13(3):166–8
Public attitudes about pain and analgesics: clinical implications. Fins JJ. **J Pain Symptom Manage** 1997 Mar; 13(3):169–71
Pharmacologic management of cancer pain in rural Minnesota. Lichtblau L, et al. **J Pain Symptom Manage** 1996 Nov;12(5):283–9
Improving analgesic prescribing in a general teaching hospital. McQuillan R, et al. **J Pain Symptom Manage** 1996 Mar;11(3):172–80
Management of postoperative pain in children undergoing orthopaedic surgery. Kart T, et al. **J Pediatr Orthop** 1996 Jul-Aug;16(4):545–8
Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. Bowersox SS, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1243–9
Evaluation of gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain. Field MJ, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1242–6
Carprofen as an analgesic for postoperative pain in cats: dose titration and assessment of efficacy in comparison to pethidine hydrochloride. Lascelles BD, et al. **J Small Anim Pract** 1995 Dec;36(12):535–41
Pain management. Foster RL. **J Soc Pediatr Nurs** 1996 Jul-Sep;1(2):93–4 (16 ref.)
A crossover comparison of bromfenac sodium, naproxen sodium, and placebo for relief of pain from primary dysmenorrhea. Mehlisch DR, et al. **J Womens Health** 1997 Feb;6(1):83–92
An analgesic effect of synthetic human calcitonin in patients with primary osteoporosis. Kapuściński P, et al. **Mater Med Pol** 1996 Jul-Sep;28(3):83–6
The management of cancer pain. Rhodes DJ, et al. **Md Med J** 1997 Mar;46(3):141–6 (13 ref.)
Anesthesiology. Second of two parts. Wiklund RA, et al. **N Engl J Med** 1997 Oct 23;337(17):1215–9 (151 ref.)
Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin. Samkoff LM, et al. **Neurology** 1997 Jul;49(1):304–5
Gabapentin for idiopathic trigeminal neuralgia: report of two cases. Sist T, et al. **Neurology** 1997 May;48(5):1467
Analgesic effects of adenosine during exercise-provoked myocardial ischaemia. Sylvén C, et al. **Neuroreport** 1996 Jun 17;7(9):1521–5
Pharmacologic approaches to chronic pain in the older adult. Dellasega C, et al. **Nurse Pract** 1997 May;22(5):20–4, 26, 31–2 passim; quiz 36–7 (21 ref.)
Pain relievers in first aid cabinets [letter] Lloyd K. **Occup Health Saf** 1996 Nov;65(11):10
Use of adjuvant analgesics profiled at pain conference. **Oncology (Huntingt)** 1997 Jun;11(6):808–10
Comparison of postoperative emesis, recovery profile, and analgesia in pediatric strabismus repair. Rectal acetaminophen versus intravenous fentanyl-droperidol. Padda GS, et al. **Ophthalmology** 1997 Mar;104(3):419–24
Pain and activity disturbance after paediatric day case adenoidectomy. Kokki H, et al. **Paediatr Anaesth** 1997; 7(3):227–31
Ro 15-8081 in osteoarthritis of hip and knee: a double-blind placebo-controlled multicentre dose-ranging study on analgesia. Bolnot-Delmas D, et al. **Pain** 1996 Jan; 64(1):99–105
Primum non nocere--a paradoxical ally in defense of placebos in analgesic trials? [letter] Burt RA. **Pain** 1997 Aug;72(1-2):291–2
Lamotrigine control of central pain. Canavero S, et al. **Pain** 1996 Nov;68(1):179–81
Intravenous morphine-6-glucuronide (M6G) is devoid of analgesic activity in man [letter; comment] Geisslinger G, et al. **Pain** 1997 Apr;70(2–3):289–90. Comment on: Pain 1996 Apr;65(1):25–30.
Antinociception induced by civamide, an orally active capsaicin analogue. Hua XY, et al. **Pain** 1997 Jul; 71(3):313–22
Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics. Moore A, et al. **Pain** 1996 Aug;66(2–3):229–37
Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: use of pain intensity and visual analogue scales. Moore A, et al. **Pain** 1997 Feb;69(3):311–5
Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: verification from independent data. Moore A, et al. **Pain** 1997 Jan;69(1-2):127–30
Experimental evaluation of the analgesic effect of ibuprofen on primary and secondary hyperalgesia. Petersen KL, et al. **Pain** 1997 Apr;70(2-3):167–74 (50 ref.)
Pain management in the emergency department: patterns of analgesic utilization. Petrack EM, et al. **Pediatrics** 1997 May;99(5):711–4
The effects of central and peripheral angiotensin on hypertension and nociception in rats. Irvine RJ, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):37–41
Biochemical aspects of chronic pain and its relationship to treatment. Pleuvry BJ, et al. **Pharmacol Ther** 1996; 71(3):313–24 (128 ref.)
Effects of various analgesic and anti-inflammatory drugs on endotoxin-induced hyperalgesia in rats and mice. Kanaan SA, et al. **Pharmacology** 1997 Jun;54(6):285–97
Cancer pain treatment insights. Barkin RL. **Pharmacotherapy** 1997 Mar-Apr;17(2):397–8
Analgesics prescribed and administered to intensive care cardiac surgery patients: does patient age make a difference? Lay TD, et al. **Prog Cardiovasc Nurs** 1996 Fall; 11(4):17–24
Pain management in home care. Magrum LC, et al. **Semin Oncol Nurs** 1996 Aug;12(3):202–18 (53 ref.)
Pain and ideology in human and veterinary medicine. Rollin BE. **Semin Vet Med Surg (Small Anim)** 1997 May; 12(2):56–60
Lamotrigine reduces total postoperative analgesic requirement: a randomized double-blind, placebo-controlled pilot study. Bonicalzi V, et al. **Surgery** 1997 Sep;122(3):567–70
Management of nonobstructive idiopathic feline lower urinary tract disease. Kruger JM, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):571–88 (65 ref.)
Options for management of acute pain in the rat. Abbott FV, et al. **Vet Rec** 1997 May 24;140(21):553–7
Survey of perioperative analgesic use in small animals [letter] Lascelles BD, et al. **Vet Rec** 1995 Dec 23–30;137(26):676
[Abdominal syndromes and analgesia] Camus-Kerebel C, et al. **Cah Anesthesiol** 1996;44(4):335–9 (Eng. Abstr.) **(Fre)**
[Analgesics in the treatment of chronic pelvic pain] Erny R, et al. **Contracept Fertil Sex** 1996 Oct;24(10):732–8 (2 ref.) **(Fre)**
[Antiaggregant effect and tolerance of calcium carbasalate administrated immediately after aorto-coronary bypass. Results of a double-blind versus placebo study] Mathieu P, et al. **Pathol Biol (Paris)** 1996 Jun;44(6):571–80 (Eng. Abstr.) **(Fre)**
[Comparative trial of lysine acetylsalicylate and paracetamol on pain in daily medical practice] Cabane J, et al. **Presse Med** 1996 Oct 12;25(30):1367–71 (Eng. Abstr.) **(Fre)**
[Analgesics in pediatrics. Drugs for pain relief in children] Fournier-Charrière E, et al. **Presse Med** 1997 Jun 7; 26(19):925–32 (28 ref.) (Eng. Abstr.) **(Fre)**
[Results of an acute pain service for effectiveness and treatment of complications of pain therapy at a general nursing station] Maier C. **Anaesthesist** 1996 Dec;45 Suppl 3:S78–9 **(Ger)**
[Patient acceptance of patient-controlled intranasal analgesia (PCINA)] Schwagmeier R, et al. **Anaesthesist** 1996 Mar; 45(3):231–4 (Eng. Abstr.) **(Ger)**
[Who is responsible for pain therapy? (editorial)] Hempel K, et al. **Chirurg** 1996 Jul;67(7):663–4 **(Ger)**
[Which hurdles in general practice actually prevent improved pain management? Experiences of a general practitioner with pain patients (interview by Dr. rer. nat. Anita Schweiger)] Engl F. **Fortschr Med** 1996 May 10; 114(13):16–8 **(Ger)**
[Pain therapy in ophthalmology] Wölfelschneider P, et al. **Klin Monatsbl Augenheilkd** 1996 Nov;209(5):261–8 (50 ref.) (Eng. Abstr.) **(Ger)**
[Postoperative pain control] Persico Stella L, et al. **Minerva Chir** 1997 Jan-Feb;52(1-2):69–74 (Eng. Abstr.) **(Ita)**
[Effects of ipriflavone on bone loss induced by GnRH analog] Pellicano M, et al. **Minerva Ginecol** 1996 Oct;48(10):435–9 (Eng. Abstr.) **(Ita)**
[Terminal care. II. Easing of symptoms of cancer patients. 3. Indications for and adverse effects of analgesics other than morphine] Hiraga K, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2021–6 **(Jpn)**
[Continuous epidural blockade as a method of treatment of low back pain syndrome in the course of disk pathology. Introductory research] Wolny T, et al. **Neurol Neurochir Pol** 1996 May-Jun;30(3):409–18 (Eng. Abstr.) **(Pol)**
[Differential combined drug therapy of phantom pain syndrome after amputation of extremity] Kukushkin ML, et al. **Anesteziol Reanimatol** 1996 Jul-Aug;(4):39–42 (Eng. Abstr.) **(Rus)**
[The effect of hydrocortisone on a neurogenic pain syndrome in rats] Igon'kina SI, et al. **Eksp Klin Farmakol** 1997 Jan-Feb;60(1):13–5 (Eng. Abstr.) **(Rus)**
[The place of Miacalcic (synthetic salmon calcitonin) in the treatment and prevention of osteoporosis] Nasonov EL, et al. **Ter Arkh** 1997;69(5):86–8 (67 ref.) **(Rus)**
[The treatment of the phantom pain syndrome with tizanidine] Vorobeichik IaM, et al.

ANALGESICS

Zh Nevropatol Psikhiatr Im S S Korsakova 1997;97(3):36–9 (Eng. Abstr.) **(Rus)**

[Analgesics in the postoperative period of abdominal interventions. The Study Group on Postoperative Analgesia of the Spanish Society of Clinical Pharmacology] Aguilera C, et al. **Med Clin (Barc)** 1997 Feb 1;108(4):136–40 (Eng. Abstr.) **(Spa)**

[Fuzzy logic and postoperative pain] Carregal A, et al. **Rev Esp Anestesiol Reanim** 1997 Jun–Jul;44(6):215–7 (Eng. Abstr.) **(Spa)**

TOXICITY

NO–naproxen vs. naproxen: ulcerogenic, analgesic and anti–inflammatory effects. Davies NM, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):69–79

Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid, paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys. Lehmann H, et al. **Arzneimittelforschung** 1996 Sep;46(9):895–905

Protein arylation precedes acetaminophen toxicity in a dynamic organ slice culture of mouse kidney. Hoivik DJ, et al. **Fundam Appl Toxicol** 1996 Nov;34(1):99–104

[The effect of guanfacine on the background and nociceptive stimulation–induced activity of spinal cord neurons in rats] Ivanov VE. **Eksp Klin Farmakol** 1997 May–Jun;60(3):12–5 (Eng. Abstr.) **(Rus)**

URINE

The detection and characterization of analgesics and anti–inflammatory drugs on high performance thin–layer chromatography plates using tandem mass spectrometry: application to drugs and metabolites in urine. Morden W, et al. **Rapid Commun Mass Spectrom** 1996;10(15):1951–5

ANALGESICS, ADDICTIVE see **ANALGESICS, OPIOID**

ANALGESICS, ANTI–INFLAMMATORY see **ANTI–INFLAMMATORY AGENTS, NON–STEROIDAL**

ANALGESICS, NARCOTIC see **ANALGESICS, OPIOID**

ANALGESICS, NON–NARCOTIC

Dexamethasone administered into organum vasculosum laminae terminalis of rabbits induced antipyresis via inhibiting nitric oxide pathway in situ. Lin MT, et al. **Neurosci Lett** 1997 Jul 11;230(1):53–6

Risk factors between analgesic use and chronic nephropathy in Thailand. Kantachuvesiri S, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):350–5

[Study of authorized chronic medication in a basic health area (letter; comment)] Formento Tirado JA. **Aten Primaria** 1996 Sep 30;18(5):271. Comment on: Aten Primaria 1996 Mar 15;17(4):251–6. **(Spa)**

ADMINISTRATION & DOSAGE

Antinociceptive effect of perioperative adenosine infusion in abdominal hysterectomy. Segerdahl M, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):473–9

Preoperative ketorolac administration has no preemptive analgesic effect for minor orthopaedic surgery. Vanlersberghe C, et al. **Acta Anaesthesiol Scand** 1996 Sep; 40(8 Pt 1):948–52

Effect of intramuscular intraoperative pain medication on narcotic usage after laparoscopic cholecystectomy. Lane GE, et al. **Am Surg** 1996 Nov;62(11):907–10

Analgesic efficacy of paracetamol in children using tonsillectomy as a pain model. Anderson B, et al. **Anaesth Intensive Care** 1996 Dec;24(6):669–73

A comparison of intramuscular ketorolac with indomethacin suppositories in the treatment of pain after oral surgery. Turner GA, et al. **Anaesth Intensive Care** 1996 Dec; 24(6):665–8

Postarthroscopic meniscus repair analgesia with intraarticular ketorolac or morphine [letter; comment] Cook TM, et al. **Anesth Analg** 1997 Feb;84(2):466–7. Comment on: Anesth Analg 1996 May;82(5):1036–9.

Analgesic doses of intrathecal but not intravenous clonidine increase acetylcholine in cerebrospinal fluid in humans. De Kock M, et al. **Anesth Analg** 1997 Apr;84(4):800–3

Effects of ketorolac versus bupivacaine coadministration during patient–controlled hydromorphone epidural analgesia after thoracotomy procedures. Singh H, et al. **Anesth Analg** 1997 Mar;84(3):564–9

A comparison of oral ketorolac and hydrocodone–acetaminophen for analgesia after ambulatory surgery: arthroscopy versus laparoscopic tubal ligation. White PF, et al. **Anesth Analg** 1997 Jul;85(1):37–43

Epidural clonidine used as the sole analgesic agent during and after abdominal surgery. A dose–response study. De Kock M, et al. **Anesthesiology** 1997 Feb;86(2):285–92

Tylenol Extended Relief overdose. Cetaruk EW, et al. **Ann Emerg Med** 1997 Jul;30(1):104–8

Fever revisited [editorial; comment] Bass LW. **Arch Pediatr Adolesc Med** 1997 Jul;151(7):647. Comment on: Arch Pediatr Adolesc Med 1997 Jul;151(7):654–6.

Concomitant i.v. and oral clodronate in the relief of bone pain––a double–blind placebo–controlled study in patients with prostate cancer. Kylmälä T, et al. **Br J Cancer** 1997; 76(7):939–42

Transdermal fentanyl system plus im ketorolac for the treatment of postoperative pain. Reinhart DJ, et al. **Can J Anaesth** 1997 Apr;44(4):377–84

Comparative assessment of the anaesthetic and analgesic effects of intramuscular and epidural clonidine in humans [see comments] Samsó E, et al. **Can J Anaesth** 1996 Dec; 43(12):1195–202. Comment in: Can J Anaesth 1996 Dec;43(12):1191–4.

Comparison of electromotive drug administration with ketorolac or with placebo in patients with pain from rheumatic disease: a double–masked study. Saggini R, et al. **Clin Ther** 1996 Nov–Dec;18(6):1169–74

Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Muir N, et al. **Curr Med Res Opin** 1997; 13(9):491–500

Continuous intravenous dihydroergotamine in the treatment of intractable headache. Ford RG, et al. **Headache** 1997 Mar;37(3):129–36

Dosing and administration of ergotamine tartrate and dihydroergotamine. Mathew NT. **Headache** 1997;37 Suppl 1:S26–32 (48 ref.)

Assessment of nurses' judgement for analgesic requirements of postoperative children. Rømsing J. **J Clin Pharm Ther** 1996 Jun;21(3):159–63

A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. Ernst DS, et al. **J Pain Symptom Manage** 1997 Jun;13(6):319–26

Ketorolac: continuous subcutaneous infusion for cancer pain [letter; comment] Hughes A, et al. **J Pain Symptom Manage** 1997 Jun;13(6):315–6. Comment on: J Pain Symptom Manage 1996 Sep;12(3):190–4.

Ketorolac continuous infusion: a case report and review of the literature [see comments] Middleton RK, et al. **J Pain Symptom Manage** 1996 Sep;12(3):190–4 (15 ref.). Comment in: J Pain Symptom Manage 1997 Jun;13(6):315–6.

Chronopharmacological study of KE–SI–TO in mice. Ogawa N, et al. **Life Sci** 1997;60(23):2091–8

Acetaminophen or ketorolac for post myringotomy pain in children? A prospective, double–blinded comparison. Bean–Lijewski JD, et al. **Paediatr Anaesth** 1997;7(2):131–7

Plasma concentration profiles after pre–operative rectal administration of a solution of paracetamol in children. Kolliöffel WJ, et al. **Pharm World Sci** 1996 Jun;18(3):105–8

Discrepancy among dissolution rates of commercial tables as a function of the dissolution method.Part 7: Aspirin. Ammar HA, et al. **Pharmazie** 1997 Feb;52(2):145–9

Evaluation of an aqueous injection of ketoprofen. Singhai AK, et al. **Pharmazie** 1997 Feb;52(2):149–51

Comparison of wound infiltration with ketorolac versus intravenous regional anesthesia with ketorolac for postoperative analgesia following ambulatory hand surgery. Reuben SS, et al. **Reg Anesth** 1996 Nov–Dec; 21(6):565–8

Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report. Ripamonti C, et al. **Tumori** 1996 Jul–Aug;82(4):413–5

Postoperative analgesic and cardiopulmonary effects in dogs of oxymorphone administered epidurally and intramuscularly, and medetomidine administered epidurally: a comparative clinical study. Vesal N, et al. **Vet Surg** 1996 Jul–Aug;25(4):361–9

[Combination preparations of codeine and paracetamol] Ostergaard HT, et al. **Ugeskr Laeger** 1997 Sep 15; 159(38):5685–6 **(Dan)**

[Veterinary dentistry (13). The use of the combination medetomidine/ketamine in dogs for anesthesia in dental procedures: evaluation of its clinical application] Sap R, et al. **Tijdschr Diergeneeskd** 1997 May 1;122(9):248–51 (Eng. Abstr.) **(Dut)**

[Focus on the safety of ibuprofen at the analgesic–antipyretic dose] Moore N, et al. **Therapie** 1996 Jul–Aug;51(4):458–63 (13 ref.) (Eng. Abstr.) **(Fre)**

[Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type] Göbel H, et al. **Nervenarzt** 1996 Aug;67(8):672–81 (Eng. Abstr.) **(Ger)**

[Comment on the contribution: "Usefulness of fixed analgesic combinations exemplified by thomapyrin" (letter; comment)] Hörl WH. **Wien Klin Wochenschr** 1997 Apr 11; 109(7):255–6. Comment on: Wien Klin Wochenschr 1996;108(8):219–33. **(Ger)**

[Analgesic and antipyretic drugs in pregnancy] Berkowitch M, et al. **Harefuah** 1997 Mar 2;132(5):354–7 (38 ref.) **(Heb)**

[Use of new elastomeric pumps and PCA in postoperative pain control in thoraco–abdominal surgery] Testa G, et al. **Ann Ital Chir** 1996 Mar–Apr;67(2):257–63 (Eng. Abstr.) **(Ita)**

[Reduce the dosage of ketorolac! Following EEC recommendations reduces the risk of hemorrhage with a marginal reduction of the analgesic effect] Lagerkranser M, et al. **Lakartidningen** 1996 Dec 4;93(49):4543–4 **(Swe)**

ADVERSE EFFECTS

Acetaminophen–induced hepatotoxicity: predisposing factors and treatments. Makin AJ, et al. **Adv Intern Med** 1997; 42:453–83 (143 ref.)

Postoperative acute liver failure after therapeutic paracetamol administration. Gould TH, et al. **Anaesth Intensive Care** 1997 Apr;25(2):153–5

The effect of pretreatment with ketorolac on pain during intravenous injection of propofol [letter; comment] Dexter TJ. **Anaesthesia** 1997 Jan;52(1):94. Comment on: Anaesthesia 1996 Sep;51(9):883–5.

Phase I human safety assessment of intrathecal neostigmine containing methyl– and propylparabens. Eisenach JC, et al. **Anesth Analg** 1997 Oct;85(4):842–6

Analgesia in renal colic [letter; comment] Mofenson HC, et al. **Ann Emerg Med** 1997 Feb;29(2):296–7; discussion 297–9 . Comment on: Ann Emerg Med 1996 Aug;28(2):151–8.

Parenteral ketorolac: the risk for acute renal failure. Feldman HI, et al. **Ann Intern Med** 1997 Feb 1;126(3):193–9

Agranulocytosis, plasmacytosis, and thrombocytosis followed by a leukemoid reaction due to acute acetaminophen toxicity. Gürsoy M, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):762–5

Nonnarcotic analgesics: prevalence and estimated economic impact of toxicities [see comments] McGoldrick MD, et al. **Ann Pharmacother** 1997 Feb;31(2):221–7 (50 ref.). Comment in: Ann Pharmacother 1997 Feb;31(2):245–8.

Clinical consequences of nonnarcotic analgesic use [editorial; comment] Matzke GR. **Ann Pharmacother** 1997 Feb; 31(2):245–8. Comment on: Ann Pharmacother 1997 Feb;31(2):221–7.

Acute. psychosis associated with abrupt withdrawal of carbamazepine following intoxication. Darbar D, et al. **Br J Clin Pract** 1996 Sep;50(6):350–1

Carbamazepine–related ejaculatory failure. Leris AC, et al. **Br J Urol** 1997 Mar;79(3):485

Tonsillectomies, ketorolac, and the march of progress [editorial; comment] Hall SC. **Can J Anaesth** 1996 Jun; 43(6):544–8. Comment on: Can J Anaesth 1996 Jun;43(6):560–3. **(Eng, Fre)**

Preoperative ketorolac increases bleeding after tonsillectomy in children [see comments] Splinter WM, et al. **Can J Anaesth** 1996 Jun;43(6):560–3. Comment in: Can J Anaesth 1996 Jun;43(6):544–8.

Paracetamol–induced pancreatitis and fulminant hepatitis in a hemodialysis patient. Farrell J, et al. **Clin Nephrol** 1997 Aug;48(2):132–3

Carbamazepine–induced drug rashes: diagnostic value of patch tests depends on clinico–pathologic presentation. Puig L, et al. **Contact Dermatitis** 1996 Jun;34(6):435–7

Acute generalized exanthematous pustulosis induced by paracetamol. A case with severe hemodynamic disturbances. De Coninck AL, et al. **Dermatology** 1996; 193(4):338–41 (35 ref.)

Acetaminophen and renal and bladder cancer. Derby LE, et al. **Epidemiology** 1996 Jul;7(4):358–62

Bradycardia following intravenous ketorolac in children [see comments] Foster PN, et al. **Eur J Anaesthesiol** 1997 May; 14(3):307–9. Comment in: Eur J Anaesthesiol 1997 May;14(3):231–5.

Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans. Delcker A, et al. **Eur Neuropsychopharmacol** 1997 Aug;7(3):213–8

Headache caused by a sphenoid mucocele but presenting as an ergotamine–induced headache. Bauer B, et al. **Headache** 1997 Jul–Aug;37(7):460–2

Antipyretics induced erythema multiforme. Dubey NK, et al. **Indian Pediatr** 1995 Oct;32(10):1117–9

Fixed drug eruption induced by acetaminophen in a 12–year–old girl [letter] Kawada A, et al. **Int J Dermatol** 1996 Feb;35(2):148–9

Acetaminophen–induced urticaria and tolerance of ibuprofen in an eight–year–old child. Ownby DR. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):151–2

Renal papillary necrosis following emergency department treatment of migraine. Witting MD. **J Emerg Med** 1996 May–Jun;14(3):373–6

Paracetamol–induced acute liver failure: prevention and management. O'Grady JG. **J Hepatol** 1997;26 Suppl 1:41–6 (45 ref.)

Paracetamol–induced cholestatic and granulomatous liver injuries. Lindgren A, et al. **J Intern Med** 1997 May; 241(5):435–9

Acetaminophen use in children: more is not better [editorial; comment] [published erratum appears in J Pediatr 1997 Apr;130(4):682] Heubi JE, et al. **J Pediatr** 1997 Feb; 130(2):175–7 (17 ref.). Comment on: J Pediatr 1997 Feb;130(2):300–4.

Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity [see comments] Rivera–Penera T, et al. **J Pediatr** 1997 Feb;130(2):300–4. Comment in: J Pediatr 1997 Feb;130(2):175–7.

Gastrointestinal bleeding following ketorolac administration in a pediatric patient. Alcaraz A, et al. **J Pediatr Gastroenterol Nutr** 1996 Nov;23(4):479–81

Biochemical basis for deficient paracetamol glucuronidation in cats: an interspecies comparison of enzyme constraint in liver microsomes. Court MH, et al. **J Pharm Pharmacol** 1997 Apr;49(4):446–9

Ibuprofen and paracetamol: relative safety in non–prescription dosages. Rainsford KD, et al. **J Pharm Pharmacol** 1997 Apr;49(4):345–76 (234 ref.)

Physiological, immunohistochemical and molecular aspects of gastric adaptation to stress, aspirin and to H. pylori–derived gastrotoxins. Konturek PC. **J Physiol Pharmacol** 1997 Mar;48(1):3–42 (89 ref.)

Pediatric subacute acetaminophen toxicity. Dunlevy TM, et al. **Otolaryngol Head Neck Surg** 1997 Jan;116(1):134–6

Hepatic necrosis masquerading as trauma. Anderson B, et al. **Pediatr Radiol** 1997 Jan;27(1):82–3

Relationship between upper gastrointestinal bleeding and non steroidal anti-inflammatory drugs in children. Li Voti G, et al. **Pediatr Surg Int** 1997 Apr;12(4):264–5

Acetaminophen-related acute renal failure without fulminant liver failure. Eguia L, et al. **Pharmacotherapy** 1997 Mar–Apr;17(2):363–70

Environmental hazard assessment of pharmaceuticals. Henschel KP, et al. **Regul Toxicol Pharmacol** 1997 Jun; 25(3):220–5

[Focus on the safety of ibuprofen at the analgesic-antipyretic dose] Moore N, et al. **Therapie** 1996 Jul–Aug;51(4):458–63 (13 ref.) (Eng. Abstr.) **(Fre)**

[Oral exposure testing in non-aspirin-induced analgesic intolerance] Wiedow O, et al. **Hautarzt** 1996 Dec; 47(12):901–8 (Eng. Abstr.) **(Ger)**

[Nephrotoxicity of analgesic combination preparations (letter; comment)] Schwarz A. **Wien Klin Wochenschr** 1997 Apr 11;109(7):247–8; discussion 249–54. Comment on: Wien Klin Wochenschr 1996;108(8):219–33. **(Ger)**

ANALYSIS

Application of high-performance liquid chromatography with diode-array detection and on-line post-column photochemical derivatization to the determination of analgesics. Di Pietra AM, et al. **J Chromatogr A** 1996 Apr 5;729(1–2):355–61

Determination of a new non-narcotic analgesic, DA-5018, in plasma, urine and bile by high-performance liquid chromatography. Shim HJ, et al. **J Chromatogr B Biomed Appl** 1997 Feb 21;689(2):422–6

Determination of paracetamol in pure form and in dosage forms using N,N-dibromo dimethylhydantoin. Kumar KG, et al. **J Pharm Biomed Anal** 1997 Jul;15(11):1725–8

Simultaneous determination of acetaminophen, dipyrone and caffeine in pharmaceutical preparations by the absorbance ratio technique. Doğan HN. **Pharmazie** 1996 Oct; 51(10):773–4

ANTAGONISTS & INHIBITORS

Protective effect of S-(1,2-dicarboxyethyl)glutathione, an intrinsic tripeptide in liver, heart and lens, and its esters on acetaminophen-induced hepatotoxicity in rats. Sakaue T, et al. **Biol Pharm Bull** 1996 Sep;19(9):1216–9

Antinociception produced by systemic R(+)-baclofen hydrochloride is attenuated by CGP 35348 administered to the spinal cord or ventromedial medulla of rats. Thomas DA, et al. **Brain Res** 1996 Apr 29;718(1–2):129–37

Tropisetron inhibits the antinociceptive effect of intrathecally administered paracetamol and serotonin. Alloui A, et al. **Fundam Clin Pharmacol** 1996;10(4):406–7

The selective capsaicin antagonist capsazepine abolishes the antinociceptive action of eugenol and guaiacol. Ohkubo T, et al. **J Dent Res** 1997 Apr;76(4):848–51

Protection by clofibrate against acetaminophen hepatotoxicity in male CD-1 mice is associated with an early increase in biliary concentration of acetaminophen-glutathione adducts. Manautou JE, et al. **Toxicol Appl Pharmacol** 1996 Sep;140(1):30–8

BLOOD

Advantage of high-surface-area charcoal for gastrointestinal decontamination in a human acetaminophen ingestion model [see comments] Roberts JR, et al. **Acad Emerg Med** 1997 Mar;4(3):167–74. Comment in: Acad Emerg Med 1997 Mar;4(3):161. Comment in: Acad Emerg Med 1997 Mar;4(3):162–3.

Acetaminophen plasma level after oral administration in liver cirrhotic patients suffering from schistosomal infection. el-Azab G, et al. **Int J Clin Pharmacol Ther** 1996 Jul; 34(7):299–303

Simultaneous determination of acetylsalicylic acid and salicylic acid in human plasma by high-performance liquid chromatography. Kees F, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23;677(1):172–7

Simplified solid-phase extraction method for determination of dihydroergotamine in rabbit and human serum using high-performance liquid chromatography with fluorescence detection. Romeijn SG, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):227–32

An indirect (derivatization) and a direct HPLC method for the determination of the enantiomers of ketorolac in plasma. Tsina I, et al. **J Pharm Biomed Anal** 1996 Dec;15(3):403–17

Dynorphin A (1–8) analog, E-2078, is stable in human and rhesus monkey blood. Yu J, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1147–51

CHEMICAL SYNTHESIS

Modulation of pharmacological profile of diphenylethane (lefetamine-type) derivatives. Carrara M, et al. **Arzneimittelforschung** 1997 Jul;47(7):803–9

Synthesis, analgesic and anti-inflammatory activities of some 1-acyl/aracyl-5-aminopyrazole derivatives. Gadad AK, et al. **Arzneimittelforschung** 1996 Nov;46(11):1082–5

Some new 1,2-benzothiazine derivatives with analgesic and anti-inflammatory activities. Kwon SK, et al. **Arzneimittelforschung** 1996 Oct;46(10):966–71

Synthesis of peripherally acting analgesic 3-arylpiperazinyl-5-benzyl-pyridazines. Moreau S, et al. **Arzneimittelforschung** 1996 Aug;46(8):800–5

2-Aryl-6-methyl-3-phenylamino-6,7-dihydropyrano[4,3-c]pyrazol-4(2H)-ones with analgesic activity. Bruno O, et al. **Farmaco** 1996 Nov;51(11):721–4

3,4-Dimethoxy cinnamic acid tertiary amides: synthesis and evaluation of antiinflammatory and analgesic activities. Yeşilada A, et al. **Farmaco** 1996 Aug-Sep;51(8–9):595–9

Synthesis and analgesic properties of new 4-arylhydrazone 1-H pyrazole [3,4-b] pyridine derivatives. Gaston MA, et al. **Pharm Acta Helv** 1996 Aug;71(3):213–9

CHEMISTRY

Characterization of acetaminophen: molecular microanalysis with Raman microprobe spectroscopy. Pestaner JP, et al. **J Forensic Sci** 1996 Nov;41(6):1060–3

ECONOMICS

Clinical consequences of nonnarcotic analgesic use [editorial; comment] Matzke GR. **Ann Pharmacother** 1997 Feb; 31(2):245–8. Comment on: Ann Pharmacother 1997 Feb;31(2):221–7.

ISOLATION & PURIFICATION

Preliminary studies on the antiinflammatory, analgesic and diuretic activity of stagninol, a sesquiterpene isolated from Persicaria stagnina. Ahmed M, et al. **Pharmazie** 1997 Jun; 52(6):472–5

METABOLISM

Paracetamol metabolism in two ethnically different Spanish populations. Esteban A, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jul–Sep;21(3):233–9

Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. Yeung JH, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct–Dec; 20(4):287–92

Evidence suggesting the 58-kDa acetaminophen binding protein is a preferential target for acetaminophen electrophile. Hoivik DJ, et al. **Fundam Appl Toxicol** 1996 Jul;32(1):79–86

Covalent binding of acetaminophen to N-10-formyltetrahydrofolate dehydrogenase in mice. Pumford NR, et al. **J Pharmacol Exp Ther** 1997 Jan; 280(1):501–5

Role of glutathione conjugation in protection of weanling rat liver against acetaminophen-induced hepatotoxicity. Allameh A, et al. **Mech Ageing Dev** 1997 Apr;95(1–2):71–9

Abnormalities in the metabolism of acetaminophen in patients infected with the human immunodeficiency virus (HIV). Esteban A, et al. **Methods Find Exp Clin Pharmacol** 1997 Mar;19(2):129–32

Metabolic changes of acetaminophen after intravenous administration to rats pretreated with a hepatoprotective agent, YH-439. Cho E, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jan;91(1):3–16

Stability, blood partition, and protein binding of DA-5018, a new nonnarcotic analgesic. Shim HJ, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jan;91(1):97–108

PHARMACOKINETICS

Transfer of clonidine and dexmedetomidine across the isolated perfused human placenta. Ala-Kokko TI, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):313–9

Effect of guaiazulene on some cytochrome P450 activities. Implication in the metabolic activation and hepatotoxicity of paracetamol. Kourounakis AP, et al. **Arch Pharm (Weinheim)** 1997 Jan-Feb;330(1–2):7–11

Biopharmaceutical studies on drug/conjugated-metabolite interactions. III. Effect of acetaminophen sulfate and its positional isomers on the pharmacokinetics of acetaminophen in rats. Nakayama T, et al. **Biol Pharm Bull** 1997 May;20(5):522–9

Pharmacokinetics of acetaminophen sulfate after oral administration in rats: analysis of plasma profiles exhibiting a non-linear second peak. Sawamoto T, et al. **Biol Pharm Bull** 1996 Jan;19(1):77–82

Carbamazepine and L-type calcium channel inhibitors: a binding assay study. Ngan ET, et al. **Biol Psychiatry** 1996 Jun 1;39(11):979–81

Oral paracetamol bioavailability in rats subjected to experimental spinal cord injury. García-López P, et al. **Biopharm Drug Dispos** 1997 Apr;18(3):203–11

Paracetamol and its metabolites in saliva and plasma in chronic dialysis patients. Lee HS, et al. **Br J Clin Pharmacol** 1996 Jan;41(1):41–7

Impaired absorption of paracetamol in vegetarians. Prescott LF, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):237–40

Bioavailability of two clodronate formulations. Lapham G, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):231–3

Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Spina E, et al. **Clin Pharmacokinet** 1996 Sep;31(3):198–214 (214 ref.)

Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Chien JY, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):24–34

Bromfenac disposition in patients with impaired kidney function. Ermer JC, et al. **Clin Pharmacol Ther** 1997 Mar; 61(3):312–8

Human pharmacokinetics of dihydroergotamine administered by nasal spray. Humbert H, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):265–75

The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Sarich T, et al. **Clin Pharmacol Ther** 1997 Jul;62(1):21–8

Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Muir N, et al. **Curr Med Res Opin** 1997; 13(9):491–500

Paracetamol (acetominophen) sulphoconjugation in man: no correlation with tyramine sulphoconjugation. Hannah P, et al. **Drug Metabol Drug Interact** 1996;13(2):119–28

Human metabolism of paracetamol (acetaminophen) at different dose levels. Steventon GB, et al. **Drug Metabol Drug Interact** 1996;13(2):111–7

Bioavailability study of paracetamol tablets in saliva and urine. Retaco P, et al. **Eur J Drug Metab Pharmacokinet** 1996 Oct–Dec; 21(4):295–300

Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. De Mey C, et al. **Int J Clin Pharmacol Ther** 1996 May;34(1 Suppl):S58–66

Pharmacokinetics of ketorolac in children after abdominal surgery. González-Martin G, et al. **Int J Clin Pharmacol Ther** 1997 Apr;35(4):160–3

A model of gastric emptying using paracetamol absorption in intensive care patients [see comments] Tarling MM, et al. **Intensive Care Med** 1997 Mar;23(3):256–60. Comment in: Intensive Care Med 1997 Mar;23(3):243–5.

Pooling of clodronate urinary excretion data: a new pharmacokinetic method to study drugs with highly variable gastrointestinal absorption. Castrén-Kortekangas P, et al. **J Bone Miner Res** 1997 Jan;12(1):66–71

Pharmacokinetics of samarium-153-EDTMP in disseminated skeletal metastases. Pusuwan P, et al. **J Med Assoc Thai** 1996 Sep;79(9):579–84

Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. Jang SH, et al. **J Pharm Sci** 1994 Jun;83(6):810–4

Dynorphin A (1–8) analog, E-2078, crosses the blood-brain barrier in rhesus monkeys. Yu J, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):633–8

Comparative pharmacokinetics of paracetamol (acetaminophen) and its sulphate and glucuronide metabolites in desert camels and goats. Ali BH, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):238–44

Removal of clodronate by haemodialysis in end-stage renal disease patients. Beigel AE, et al. **Nephrol Dial Transplant** 1995 Dec;10(12):2266–8

Rectal administration of paracetamol: a comparison of a solution and suppositories in adult volunteers. Kolllöffel WJ, et al. **Pharm World Sci** 1996 Jan;18(1):26–9

Discrepancy among dissolution rates of commercial tables as a function of the dissolution method.Part 7: Aspirin. Ammar HA, et al. **Pharmazie** 1997 Feb;52(2):145–9

Alteration in the biliary and urinary excretion of acetaminophen metabolites by nephrotoxicants in rats. Seo KW, et al. **Res Commun Mol Pathol Pharmacol** 1997 Mar; 95(3):305–17

[The relative bioavailability of paracetamol in suppositories in comparison to tablets] Blume H, et al. **Arzneimittelforschung** 1996 Oct;46(10):975–80 (Eng. Abstr.) **(Ger)**

[An experimental study of the pharmacokinetics of a new pediatric drug form—Paravit tablets] Shapovalova VA. **Eksp Klin Farmakol** 1996 Nov-Dec;59(6):29–30 (Eng. Abstr.) **(Rus)**

[Paracetamol pharmacokinetics in the blood plasma of sexually immature rabbits with the use of the new Paravit preparation] Shapovalova VO. **Fiziol Zh** 1995 Sep–Dec; 41(5–6):57–60 (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

Alleviation of the peripheral hemodynamic effects of dexmedetomidine by the calcium channel blocker isradipine. Roekaerts PM, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):364–70

Peroperative adenosine infusion reduces isoflurane concentrations during general anesthesia for shoulder surgery. Segerdahl M, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):792–7

Paw pressure test in the rabbit: a new animal model for the study of pain. Hu OY, et al. **Acta Anaesthesiol Sin** 1996 Mar;34(1):1–8

Do sodium nitroprusside and L-NAME affect pyrogen fever in rabbits? Gagalo IT, et al. **Acta Physiol Hung** 1996; 84(3):289–90

A comparative study of the antinociceptive action of xenon and nitrous oxide in rats. Ohara A, et al. **Anesth Analg** 1997 Oct;85(4):931–6

Antinociceptive response to nitrous oxide is mediated by supraspinal opiate and spinal alpha 2 adrenergic receptors in the rat. Guo TZ, et al. **Anesthesiology** 1996 Oct; 85(4):846–52

In vivo imaging of nitrous oxide-induced changes in cerebral activation during noxious heat stimuli. Gyulai FE, et al. **Anesthesiology** 1997 Mar;86(3):538–48

The effect of acetaminophen, ibuprofen, and misoprostol on

prostaglandin E2 synthesis and the degree and rate of orthodontic tooth movement. Kehoe MJ, et al. **Angle Orthod** 1996;66(5):339–49

The effect of acetaminophen on tooth movement in rabbits. Roche JJ, et al. **Angle Orthod** 1997;67(3):231–6

Long-term tolerability of nimesulide and acetaminophen in nonsteroidal antiinflammatory drug-intolerant patients. Quaratino D, et al. **Ann Allergy Asthma Immunol** 1997 Jul; 79(1):47–50

Modulation of pharmacological profile of diphenylethane (lefetamine-type) derivatives. Carrara M, et al. **Arzneimittelforschung** 1997 Jul;47(7):803–9

Role of caffeine in combined analgesic drugs from the point of view of experimental pharmacology. Engelhardt G, et al. **Arzneimittelforschung** 1997 Aug;47(8):917–27

Effect of acetylsalicylic acid, paracetamol, caffeine and a combination of these substances on the renal prostaglandin E2, 6-keto-prostaglandin F1 alpha, water, creatinine and electrolyte excretion of the rat. Engelhardt G. **Arzneimittelforschung** 1996 May;46(5):509–12

Effects of acetylsalicylic acid, paracetamol and caffeine and a combination of these substances on kidney glutathione levels. Engelhardt G, et al. **Arzneimittelforschung** 1996 May;46(5):513–8

Antipyretic effect of Lumbricus spencer in acetylsalicylic acid-induced asthma. Kurosawa M, et al. **Arzneimittelforschung** 1996 Feb;46(2):172–4

The thermal potentiation of acetaminophen-inhibited PMN oxidative metabolism in vitro. Shalabi EA, et al. **Biopharm Drug Dispos** 1996 Aug;17(6):501–9

The effects of clodronate on increased bone turnover and bone loss due to ovariectomy in rats. Kippo K, et al. **Bone** 1995 Dec;17(6):533–42

Effect of naloxone on nitrous oxide analgesia [letter; comment] Gillman MA, et al. **Br J Anaesth** 1996 Sep; 77(3):435–6. Comment on: Br J Anaesth 1995 Jun;74(6):670–3.

The dose-related effects of paracetamol on hyperalgesia and nociception in the rat. Bianchi M, et al. **Br J Pharmacol** 1996 Jan;117(1):130–2

Effects of naltrexone and histamine antagonists on the antinociceptive activity of the cimetidine analog SKF92374 in rats. Li BY, et al. **Brain Res** 1997 Feb 14;748(1–2):168–74

Ontogenetic development of the response to anandamide and delta 9-tetrahydrocannabinol in mice. Fride E, et al. **Brain Res Dev Brain Res** 1996 Aug 20;95(1):131–4

Antinociceptive effects of ONO-9902, an enkephalinase inhibitor, after visceral stress condition in rats. Yamamori Y, et al. **Can J Anaesth** 1996 Nov;43(11):1175–9

Population pharmacodynamic model for ketorolac analgesia. Mandema JW, et al. **Clin Pharmacol Ther** 1996 Dec; 60(6):619–35

Interaction between carbamazepine and bromperidol. Otani K, et al. **Eur J Clin Pharmacol** 1997;52(3):219–22

A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates. Chan CC, et al. **Eur J Pharmacol** 1997 May 30; 327(2–3):221–5

Influence of pentoxifylline on fevers induced by bacterial lipopolysaccharide and tumor necrosis factor-alpha in guinea pigs. Goldbach JM, et al. **Eur J Pharmacol** 1997 Jan 29;319(2–3):273–8

Behavioural analysis of changes in nociceptive thresholds produced by remoxipride in sheep and rats. Main DC, et al. **Eur J Pharmacol** 1995 Dec 20;287(3):221–31

Carbamazepine normalizes the altered behavioral and neurochemical response to stress in benzodiazepine-withdrawn rats. Martijena ID, et al. **Eur J Pharmacol** 1997 Jul 9;330(2–3):101–8

Flupirtine increases the levels of glutathione and Bcl-2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect. Perovic S, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):157–64

The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Pini LA, et al. **Eur J Pharmacol** 1996 Jul 11;308(1):31–40

Spinal administration of adrenergic agents produces analgesia in amphibians. Stevens CW, et al. **Eur J Pharmacol** 1996 Dec 5;316(2–3):205–10

Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide. Taniguchi Y, et al. **Eur J Pharmacol** 1997 Jul 9;330(2–3):221–9

Selective protective effect of an extract from Fumaria parviflora on paracetamol-induced hepatotoxicity. Gilani AH, et al. **Gen Pharmacol** 1996 Sep;27(6):979–83

The pharmacology of ergotamine and dihydroergotamine. Silberstein SD. **Headache** 1997;37 Suppl 1:S15–25 (57 ref.)

Antipyretic activity of Nelumbo nucifera rhizome extract. Mukherjee PK, et al. **Indian J Exp Biol** 1996 Mar; 34(3):275–6

GABAergic agents modify imipramine analgesia. Ballal PM, et al. **Indian J Physiol Pharmacol** 1996 Jan;40(1):95–7

Analgesic efficacy of two derivatives of O-hydroxy-naphthoquinone [letter] Mattu S, et al. **Indian J Physiol Pharmacol** 1996 Jan;40(1):103–4

Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties. Moore PF, et al. **Inflamm Res** 1996 Feb;45(2):54–61

Response of the methionine synthase system to short-term culture with homocysteine and nitrous oxide and its relation to methionine dependence. Fiskerstrand T, et al. **Int J Cancer** 1997 Jul 17;72(2):301–6

Antiinflammatory effect of petroleum ether extract of leaves of Litchi chinensis Gaertn. (Sapindaceae). Besra SE, et al. **J Ethnopharmacol** 1996 Oct;54(1):1–6

Evidence of the involvement of biogenic amines in the antinociceptive effect of a vouacapan extracted from Pterodon polygalaeflorus Benth. Duarte ID, et al. **J Ethnopharmacol** 1996 Dec;55(1):13–8

Antipyretic role of endogenous melanocortins mediated by central melanocortin receptors during endotoxin-induced fever. Huang QH, et al. **J Neurosci** 1997 May 1; 17(9):3343–51

Opioid and opioid-like drug effects on whole-gut transit measured by scintigraphy. Maurer AH, et al. **J Nucl Med** 1996 May;37(5):818–22

Pharmacological studies of 1-(p-chlorophenyl)propanol and 2-(1-hydroxy-3-butenyl)phenol: two new non-narcotic analgesics designed by molecular connectivity. García-March FJ, et al. **J Pharm Pharmacol** 1997 Jan; 49(1):10–5

Common quantitative trait loci for alcohol-related behaviors and central nervous system neurotensin measures: hypnotic and hypothermic effects. Erwin VG, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):911–8

The central cholinergic system has a role in the antinociception induced in rodents and guinea pigs by the antimigraine drug sumatriptan. Ghelardini C, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):884–90

Antinociceptive properties of propofol: involvement of spinal cord gamma-aminobutyric acid(A) receptors. Nadeson R, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1181–6

In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist. Shannon HE, et al. **Life Sci** 1997;60(13–14):969–76 (24 ref.)

Cyclooxygenase-independent mechanisms are not involved in the antipyretic action of indomethacin in the prepubertal pig. Parrott RF, et al. **Methods Find Exp Clin Pharmacol** 1996 Jun;18(5):321–6

Inherited, selective hyporesponsiveness to the analgesic action of nicotine in mice. Seale TW, et al. **Neuroreport** 1996 Dec 20;8(1):191–5

The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Herzberg U, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):157–60

Reversal of spinal cord non-opiate analgesia by conditioned anti-analgesia in the rat. Watkins LR, et al. **Pain** 1997 Jul; 71(3):237–47

Behavioral and analgesic effects induced by administration of nifedipine and nimodipine. Martín MI, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):93–8

Anti-inflammatory, antipyretic, and analgesic effects of Lawsonia inermis L. (henna) in rats. Ali BH, et al. **Pharmacology** 1995 Dec;51(6):356–63

Effects of carbamazepine treatment on pain threshold values and brain serotonin levels in rats. Pinelli A, et al. **Pharmacology** 1997 Mar;54(3):113–7

Serotonin and opiate involvement in the antinociceptive effect of acetylsalicylic acid. Pini LA, et al. **Pharmacology** 1997 Feb;54(2):84–91

Antipyretic activity of carboxylatocopper(II) complexes with salicylate skeleton. Sokolík J, et al. **Pharmazie** 1996 Aug; 51(8):610–1

Analgesic, anti-inflammatory, antipyretic and haematological effects of aethiopinone, an o-naphthoquinone diterpenoid from Salvia aethiopis roots and two hemisynthetic derivatives. Hernández-Pérez M, et al. **Planta Med** 1995 Dec;61(6):505–9

[The physiological properties of the action of a new analgesic and antipyretic preparation] Shapovalova VO, et al. **Fiziol Zh** 1997;43(1–2):117–21 (Eng. Abstr.) **(Ukr)**

POISONING

Late increase in acetaminophen concentration after overdose of Tylenol Extended Relief. Bizovi KE, et al. **Ann Emerg Med** 1996 Nov;28(5):549–51

Tylenol Extended Relief overdose. Cetaruk EW, et al. **Ann Emerg Med** 1997 Jul;30(1):104–8

Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient [letter] Caballero-Granado FJ, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1207

Adverse reactions to N-acetylcysteine in Inuit to paracetamol (acetaminophen) overdose. Nielsen PT, et al. **Arctic Med Res** 1996 Oct;55(4):204–5

Should methionine be added to every paracetamol tablet? Jones AL, et al. **BMJ** 1997 Aug 2;315(7103):301–4

Reducing paracetamol overdoses. Proposals will have negative effects [letter; comment] O'Connell S. **BMJ** 1997 Mar 8;314(7082):751. Comment on: BMJ 1996 Dec 7;313(7070):1417–8.

Reducing paracetamol overdoses. Paracetamol is wrongly blamed [letter; comment] Pounder D, et al. **BMJ** 1997 Mar 8;314(7082):751. Comment on: BMJ 1996 Dec 7;313(7070):1417–8.

Reducing paracetamol overdoses. Methionine should be included in all paracetamol preparations [letter; comment] Spender Q. **BMJ** 1997 Mar 8;314(7082):751. Comment on: BMJ 1996 Dec 7;313(7070):1417–8.

Reducing paracetamol overdoses. Provide hurdles to overdosing [letter; comment] [see comments] Taylor SJ. **BMJ** 1997 Mar 8;314(7082):750–1. Comment on: BMJ 1996 Dec 7;313(7070):1417–8. Comment in: BMJ 1997 Jul 26;315(7102):255.

Public should know of efficacy of early hospital treatment of paracetamol overdose [letter; comment] Wannan G, et al. **BMJ** 1997 Jul 26;315(7102):255. Comment on: BMJ 1997 Mar 8;314(7082):750–1.

N-acetylcysteine (NAC)--a safe antidote in paracetamol poisoning? [letter; comment] Casey PB, et al. **Ir Med J** 1997 Jan-Feb;90(1):38. Comment on: Ir Med J 1996 Sep-Oct;89(5):156, 158.

Paracetamol poisoning: the action line and the timing of acetylcysteine therapy [editorial] [see comments] Delanty N, et al. **Ir Med J** 1996 Sep-Oct;89(5):156, 158 (20 ref.) . Comment in: Ir Med J 1997 Jan-Feb;90(1):38.

Status epilepticus following intravenous N-acetylcysteine therapy. Hershkovitz E, et al. **Isr J Med Sci** 1996 Nov; 32(11):1102–4

Use of paracetamol for suicide and non-fatal poisoning in the UK and France: are restrictions on availability justified? Gunnell D, et al. **J Epidemiol Community Health** 1997 Apr; 51(2):175–9

A fatal case of methotrimeprazine overdose. Avis SP, et al. **J Forensic Sci** 1996 Nov;41(6):1080–1

Paracetamol hepatotoxicity: how to prevent. O'Grady JG. **J R Soc Med** 1997 Jul;90(7):368–70 (12 ref.)

Acetaminophen poisoning in late pregnancy. A case report. Wang PH, et al. **J Reprod Med** 1997 Jun;42(6):367–71

Heart donation after fatal acetaminophen poisoning [letter] Hantson P, et al. **J Toxicol Clin Toxicol** 1997;35(3):325–6

Placental transfer of N-acetylcysteine following human maternal acetaminophen toxicity. Horowitz RS, et al. **J Toxicol Clin Toxicol** 1997;35(5):447–51

Transplantation in patients with paracetamol-induced fulminant hepatic failure [letter] Gow PJ, et al. **Lancet** 1997 Mar 1;349(9052):651–2

Unusual complications of paracetamol poisoning. Jones AL, et al. **QJM** 1997 Mar;90(3):161–8 (148 ref.)

Classification, etiology, and considerations of outcome in acute liver failure. Williams R. **Semin Liver Dis** 1996 Nov; 16(4):343–8 (39 ref.)

Factors responsible for continuing morbidity after paracetamol poisoning in Chinese patients in Hong Kong. Chan TY, et al. **Singapore Med J** 1996 Jun;37(3):275–7

The epidemiology of acetaminophen (paracetamol) poisoning in Hong Kong. Chan TY. **Vet Hum Toxicol** 1996 Dec; 38(6):443–4

Outpatient N-acetylcysteine treatment for acetaminophen poisoning: an ethical dilemma or a new financial mandate? Dean BS, et al. **Vet Hum Toxicol** 1996 Jun;38(3):222–4

[Recommendations for treatment of paracetamol poisoning. Danish Medical Society, Study of the Liver] Clemmesen JO, et al. **Ugeskr Laeger** 1996 Nov 25;158(48):6892–5 (20 ref.) (Eng. Abstr.) **(Dan)**

[Acetaminophen poisoning] Washio M. **Fukuoka Igaku Zasshi** 1997 Mar;88(3):41–3 (4 ref.) **(Jpn)**

[Anaphylactic reaction to N-acetylcysteine after poisoning with paracetamol] Stavem K. **Tidsskr Nor Laegeforen** 1997 May 30;117(14):2038–9 (Eng. Abstr.) **(Nor)**

[Ergotamine poisoning and peripheral arterial ischemia (letter)] Martínez León JI, et al. **Aten Primaria** 1996 Nov 15;18(8):468–9 **(Spa)**

SUPPLY & DISTRIBUTION

Bioavailability of two clodronate formulations. Lapham G, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):231–3

THERAPEUTIC USE

Evaluation of ketorolac in children with forearm fractures. Pierce MC, et al. **Acad Emerg Med** 1997 Jan;4(1):22–6

Analgesic efficacy of ketorolac. Wheatley RG. **Acta Anaesthesiol Belg** 1996;47(3):135–42 (38 ref.)

Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article. Strang P. **Acta Oncol** 1996; 35 Suppl 5:50–4 (30 ref.)

Evaluation of sponging and antipyretic medication to reduce body temperature in febrile children. Aksoylar S, et al. **Acta Paediatr Jpn** 1997 Apr;39(2):215–7

Paracetamol. D'Arcy PF. **Adverse Drug React Toxicol Rev** 1997 Mar;16(1):9–14 (14 ref.)

The efficacy of tepid sponge bathing to reduce fever in young children. Sharber J. **Am J Emerg Med** 1997 Mar; 15(2):188–92

A prospective comparison of transnasal butorphanol and acetaminophen with codeine for the relief of acute musculoskeletal pain [letter] Wolford R, et al. **Am J Emerg Med** 1997 Jan;15(1):101–3

A comparison of the efficacy of ketorolac and indomethacin for postoperative analgesia following laparoscopic surgery in day patients. Murrell GC, et al. **Anaesth Intensive Care** 1996 Apr;24(2):237–40

Pain relief with oral cannabinoids in familial Mediterranean fever. Holdcroft A, et al. **Anaesthesia** 1997 May;52(5):483–6

Effect of dexmedetomidine on lumbar cerebrospinal fluid pressure in humans. Talke P, et al. **Anesth Analg** 1997 Aug; 85(2):358–64

Analgesia in renal colic [letter; comment] Benson DM. **Ann Emerg Med** 1997 Feb;29(2):297; discussion 297–9. Comment on: Ann Emerg Med 1996 Aug;28(2):151–8.

A controlled, randomized, double-blind study of ketorolac for postoperative analgesia after plastic surgery.

Marín-Bertolín S, et al. **Ann Plast Surg** 1997 May; 38(5):478–84

Restless legs syndrome [letter; comment] Hindmarsh JT. **Arch Intern Med** 1996 Nov 11;156(20):2390. Comment on: Arch Intern Med 1996 Feb 12;156(3):243–8.

Efficacy of nefopam for the prevention and treatment of amphotericin B-induced shivering. Rosa G, et al. **Arch Intern Med** 1997 Jul 28;157(14):1589–92

Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Gómez-Pérez FJ, et al. **Arch Med Res** 1996 Winter; 27(4):525–9

Managing measles. Giving paracetamol for fever is unnecessary [letter; comment] Havinga WH. **BMJ** 1997 Jun 7;314(7095):1692; discussion 1692–3. Comment on: BMJ 1997 Feb 1;314(7077):316–7.

Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Kanis JA, et al. **Bone** 1996 Dec; 19(6):663–7

Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Rizzoli R, et al. **Bone** 1996 Jun;18(6):531–7

Morphine consumption in patients receiving rectal paracetamol and diclofenac alone and in combination. Montgomery JE, et al. **Br J Anaesth** 1996 Oct;77(4):445–7

The efficacy of ketoprofen and paracetamol (acetaminophen) in postoperative pain after third molar surgery. Seymour RA, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):581–5

Role of dopamine mesolimbic system in opioid action of psychotropic analgesic nitrous oxide in alcohol and drug withdrawal. Lichtigfeld FJ, et al. **Clin Neuropharmacol** 1996 Jun;19(3):246–51 (43 ref.)

Ketorolac versus meperidine for pain relief after orthopaedic surgery. DeAndrade JR, et al. **Clin Orthop** 1996 Apr; (325):301–12

A randomized double-blind study of carbamazepine in the treatment of cocaine abuse. Halikas JA, et al. **Clin Pharmacol Ther** 1997 Jul;62(1):89–105

Bromfenac sodium, acetaminophen/oxycodone, ibuprofen, and placebo for relief of postoperative pain. Johnson GH, et al. **Clin Ther** 1997 May-Jun;19(3):507–19

Ketorolac for postoperative pain management in children. Forrest JB, et al. **Drug Saf** 1997 May;16(5):309–29 (113 ref.)

Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Gillis JC, et al. **Drugs** 1997 Jan;53(1):139–88 (293 ref.)

Premedication with controlled release diclofenac sodium reduces post-operative pain after minor gynaecological surgery. Bamber MJ, et al. **Eur J Anaesthesiol** 1997 Jul; 14(4):421–7

'Off-label' use of prescription drugs: legal, clinical and policy considerations [editorial; comment] Cohen PJ. **Eur J Anaesthesiol** 1997 May;14(3):231–5. Comment on: Eur J Anaesthesiol 1997 May;14(3):307–9.

Diazepam for relief of irrigation pain after transurethral resection of the prostate. Nott MR, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):197–200

A comparison of the effect of intramuscular diclofenac, ketorolac or piroxicam on post-operative pain following laparoscopy. O'Hanlon JJ, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):404–7

Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever. Autret E, et al. **Eur J Clin Pharmacol** 1997;51(5):367–71

A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Lundkvist J, et al. **Eur J Pharmacol** 1996 Aug 8;309(2):195–200

Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Cleland PG, et al. **Eur Neurol** 1997;38(1):31–8

A randomized, double-blind, multicentre controlled trial of ibuprofen versus acetaminophen and placebo for symptoms of acute otitis media in children. Bertin L, et al. **Fundam Clin Pharmacol** 1996;10(4):387–92

Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Becker WJ, et al. **Headache** 1996 Mar;36(3):144–8

Ketoprofen versus paracetamol in the treatment of acute migraine. Karabetsos A, et al. **Headache** 1997 Jan; 37(1):12–4

Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Lipton RB. **Headache** 1997;37 Suppl 1:S33–41 (33 ref.)

Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives. Young WB. **Headache** 1997;37 Suppl 1:S42–5

Nonopioid and opioid analgesic pharmacotherapy of cancer pain. Cherny NI, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):79–102 (125 ref.)

Adjuvant analgesic agents. Portenoy RK. **Hematol Oncol Clin North Am** 1996 Feb;10(1):103–19 (66 ref.)

Comparison of the analgesic effects of diflunisal and paracetamol in the treatment of postoperative dental pain. Selçuk E, et al. **Int J Clin Pharmacol Res** 1996; 16(2-3):57–65

Use of tolfenamic acid in febrile children with and without glucose-6-phosphate dehydrogenase deficiency. Haliotis FA, et al. **Int J Clin Pharmacol Ther** 1997 Mar;35(3):103–6

Acetaminophen-induced urticaria and tolerance of ibuprofen in an eight-year-old child. Ownby DR. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):151–2

Carbamazepine trial for Lesch-Nyhan self-mutilation. Roach ES, et al. **J Child Neurol** 1996 Nov;11(6):476–8

Assessment of nurses' judgement for analgesic requirements of postoperative children. Rømsing J. **J Clin Pharm Ther** 1996 Jun;21(3):159–63

Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain--a meta-analysis. Zhang WY, et al. **J Clin Pharm Ther** 1996 Aug;21(4):261–82

Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache. Schachtel BP, et al. **J Clin Pharmacol** 1996 Dec;36(12):1120–5

Analgesic efficacy of controlled-release oxycodone in postoperative pain. Sunshine A, et al. **J Clin Pharmacol** 1996 Jul;36(7):595–603

IV ketorolac for the treatment of ureteral and biliary colic [letter] [see comments] Feldman ML. **J Emerg Med** 1997 Mar-Apr;15(2):247–8. Comment in: J Emerg Med 1997 Mar-Apr;15(2):245–6.

Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome. Mitch CH, et al. **J Med Chem** 1997 Feb 14;40(4):538–46

Analgesia for venepuncture in a paediatric surgery centre. Brislin RP, et al. **J Paediatr Child Health** 1995 Dec; 31(6):542–4

Acetaminophen in the management of background pain in children post-burn. Meyer WJ 3rd, et al. **J Pain Symptom Manage** 1997 Jan;13(1):50–5

Ibuprofen and/or acetaminophen: what price for "euthermia"? [letter] Block S. **J Pediatr** 1997 Aug;131(2):332–3

Ibuprofen and/or acetaminophen: what price for "euthermia"? [letter] Melis R. **J Pediatr** 1997 Aug;131(2):332; discussion 333

Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Brandts CH, et al. **Lancet** 1997 Sep 6;350(9079):704–9

Samarium-153 lexidronam for painful bone metastases. **Med Lett Drugs Ther** 1997 Aug 29;39(1008):83–4

Paracetamol prescribing habits in a children's hospital. Anderson B, et al. **N Z Med J** 1996 Oct 11;109(1031):376–8

A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient. St. Charles CS, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):76–82

Ketorolac does not depress ventilation in children [letter] Hamunen K, et al. **Paediatr Anaesth** 1996;6(1):79

Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Benedetti F, et al. **Pain** 1997 Jun; 71(2):135–40

Peripheral analgesic effect of intra-articular clonidine. Gentili M, et al. **Pain** 1996 Mar;64(3):593–6

Paracetamol with and without codeine in acute pain: a quantitative systematic review. Moore A, et al. **Pain** 1997 Apr;70(2-3):193–201 (18 ref.)

Antipyretic effect of parenteral paracetamol (propacetamol) in pediatric oncologic patients: a randomized trial. Reymond D, et al. **Pediatr Hematol Oncol** 1997 Jan-Feb; 14(1):51–7

Varicella and necrotizing fasciitis [letter; comment] Rosefsky JB. **Pediatr Infect Dis J** 1996 Jun;15(6):556–7. Comment on: Pediatr Infect Dis J 1995 Jul;14(7):588–94.

Oral dihydroergotamine for therapy-resistant migraine attacks in children. Hämäläinen ML, et al. **Pediatr Neurol** 1997 Feb;16(2):114–7

Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer. Kylmälä T, et al. **Pharmacol Toxicol** 1996 Sep;79(3):157–60

Analgesic effect of ceruletide in men is limited to specific pain qualities. Pause BM, et al. **Physiol Behav** 1996 Jun; 59(6):1025–31

Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Hwang JH, et al. **Reg Anesth** 1997 May-Jun; 22(3):249–56

Tramadol and beta-cyclodextrin piroxicam: effective multimodal balanced analgesia for the intra- and postoperative period. Lauretti GR, et al. **Reg Anesth** 1997 May-Jun;22(3):243–8

Floctafenin versus acetaminophen for pain control in patients with osteoarthritis in the lower limbs. Franco-Belgian Task Force. Lequesne M, et al. **Rev Rhum Engl Ed** 1997 May; 64(5):327–33

Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug. Evidence for chronic encephalopathic processes following ischemia. Coimbra C, et al. **Stroke** 1996 Sep;27(9):1578–85

Should bisphosphonates be standard therapy for bone pain? Paterson AH. **Support Care Cancer** 1997 May;5(3):200–4 (21 ref.)

Preemptive analgesia in the laparoscopic patient. Mixter CG 3rd, et al. **Surg Endosc** 1997 Apr;11(4):351–3

[Familial erythermalgia treated with pizotifen] Guillet MH, et al. **Ann Dermatol Venereol** 1995;122(11-12):777–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[Multiple myeloma and bone manifestations. Role of clodronate] Bauduer F, et al. **Bull Cancer** 1996 Jul; 83(7):542–7 (42 ref.) (Eng. Abstr.) **(Fre)**

[Pain in cancer patients. Practical attitude] Pichard-Léandri E. **J Chir (Paris)** 1997 May;134(1):14–21 (29 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of pain at a community pharmacy] Malonne H, et al. **J Pharm Belg** 1996 Nov-Dec;51(6):305–15 (0 ref.) (Eng. Abstr.) **(Fre)**

[Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks] Pradalier A, et al. **Pathol Biol (Paris)** 1995 Nov; 43(9):806–13 (Eng. Abstr.) **(Fre)**

[Comparative trial of lysine acetylsalicylate and paracetamol on pain in daily medical practice] Cabane J, et al. **Presse Med** 1996 Oct 12;25(30):1367–71 (Eng. Abstr.) **(Fre)**

[Analgesic effect and clinical tolerability of the combination of paracetamol 500 mg and caffeine 50 mg versus paracetamol 400 mg and dextropropoxyphene 30 mg in back pain] Kuntz D, et al. **Presse Med** 1996 Sep 7; 25(25):1171–4 (Eng. Abstr.) **(Fre)**

[The preemptive action of ketoprofen. Randomized, double-blind study with gynecologic operations] Likar R, et al. **Anaesthesist** 1997 Mar;46(3):186–90 (Eng. Abstr.) **(Ger)**

[Paracetamol--the safe analgesic] Gleiter CH. **Internist (Berl)** 1997 Jul;38(7):707–11; discussion 712 (31 ref.) **(Ger)**

[Trigeminal neuralgia and other facial pain--diagnosis and therapy] Siegfried J. **Ther Umsch** 1997 Feb;54(2):83–6 (Eng. Abstr.) **(Ger)**

[Evaluation of the synergism between ketorolac and morphine in the treatment of postoperative pain] Casali R, et al. **Minerva Anestesiol** 1995 Dec;61(12):501–7 (Eng. Abstr.) **(Ita)**

[Ketorolac for prevention of acute postoperative pain] Peduto VA, et al. **Minerva Anestesiol** 1995 Sep; 61(9):367–72 (Eng. Abstr.) **(Ita)**

[Effectiveness of Ge-132 to relieve pain and smooth home care administration for the terminal cancer patient] Dozono H, et al. **Gan To Kagaku Ryoho** 1996 Dec;23 Suppl 3:291–5 (Eng. Abstr.) **(Jpn)**

[Study of the analgesic effect of the semax preparation] Koroleva MV, et al. **Biull Eksp Biol Med** 1996 Nov; 122(11):527–9 **(Rus)**

[Nationally produced 153SmEDTMP in the palliative treatment of metastatic bone cancer pain] Olea E, et al. **Rev Med Chil** 1996 Jul;124(7):805–12 (Eng. Abstr.) **(Spa)**

TOXICITY

Immunochemical detection of drug-protein adducts in acetaminophen hepatotoxicity. Hinson JA, et al. **Adv Exp Med Biol** 1996;387:47–55

Acetaminophen predisposes to renal and hepatic injury from compound A in the fasting rat. Laster MJ, et al. **Anesth Analg** 1997 Jan;84(1):169–72

Effect of guaiazulene on some cytochrome P450 activities. Implication in the metabolic activation and hepatotoxicity of paracetamol. Kourounakis AP, et al. **Arch Pharm (Weinheim)** 1997 Jan-Feb;330(1-2):7–11

Increased resistance to acetaminophen-induced hepatotoxicity in retrovirus-infected mice. Chow HH, et al. **Biopharm Drug Dispos** 1996 Nov;17(8):661–74

Selective protein arylation and acetaminophen-induced hepatotoxicity. Cohen SD, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):59–77 (111 ref.)

Histocytological study on the possible mechanism of acetaminophen cataractogenesis in mouse eye. Zhao C, et al. **Exp Mol Pathol** 1995 Oct;63(2):118–28

Effects of fructose-induced hypertriglyceridemia on hepatorenal toxicity of acetaminophen in rats. II. Role of enhancement of fructose metabolism and overproduction of triglyceride in the liver and kidney on hepatorenal toxicity of acetaminophen. Ishida K, et al. **Exp Toxicol Pathol** 1997 Feb;49(1-2):39–46

Protective effects of diallyl sulfide on acetaminophen-induced toxicities. Hu JJ, et al. **Food Chem Toxicol** 1996 Oct;34(10):963–9

Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells. Nicod L, et al. **Hum Exp Toxicol** 1997 Jan;16(1):28–34

Respiratory functions in kidney mitochondria following paracetamol administration to young-adult & old rats. Satav JG, et al. **Indian J Med Res** 1997 Mar;105:131–5

Interaction of ciprofloxacin with diclofenac and paracetamol in relation to it's epileptogenic effect. Shrivastava MP, et al. **Indian J Physiol Pharmacol** 1997 Apr;41(2):164–6

Protective effect of diallyl sulfone against acetaminophen-induced hepatotoxicity in mice. Lin MC, et al. **J Biochem Toxicol** 1996;11(1):11–20

Acetaminophen-induced hepatotoxicity is associated with early changes in NF-kB and NF-IL6 DNA binding activity. Blazka ME, et al. **J Inflamm** 1995-96;47(3):138–50

Role of macrophages in acetaminophen (paracetamol)-induced hepatotoxicity. Goldin RD, et al. **J Pathol** 1996 Aug;179(4):432–5

Is activation of lysosomal enzymes responsible for paracetamol-induced hepatotoxicity and nephrotoxicity? Khandkar MA, et al. **J Pharm Pharmacol** 1996 Apr; 48(4):437–40

Differential heat shock protein induction by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver. Salminen WF Jr, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1533–40

ANALGESICS, NON-NARCOTIC

Nephrotoxicity of acetaminophen in male Wistar rats: role of hepatically derived metabolites. Trumper L, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):548–54

Role of glutathione conjugation in protection of weanling rat liver against acetaminophen-induced hepatotoxicity. Allameh A, et al. **Mech Ageing Dev** 1997 Apr;95(1–2):71–9

Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Selander KS, et al. **Mol Pharmacol** 1996 Nov;50(5):1127–38

Paracetamol-induced spindle disturbances in V79 cells with and without expression of human CYP1A2. Jensen KG, et al. **Pharmacol Toxicol** 1996 Apr;78(4):224–8

Role of CYP3A in ethanol-mediated increases in acetaminophen hepatotoxicity. Kostrubsky VE, et al. **Toxicol Appl Pharmacol** 1997 Apr;143(2):315–23

Histopathology of acetaminophen-induced liver changes: role of interleukin 1 alpha and tumor necrosis factor alpha. Blazka ME, et al. **Toxicol Pathol** 1996 Mar–Apr;24(2):181–9

Influence of acetaminophen treatment and hydrogen peroxide treatment on the release of a CINC-related protein and TNF-alpha from rat hepatocyte cultures. Horbach M, et al. **Toxicology** 1997 Aug 15;121(2):117–26

Inhibition of DNA synthesis by paracetamol in different tissues of the rat in vivo. Lister CF, et al. **Toxicology** 1997 Jan 15;116(1–3):49–57

Cimetidine enhances the hepatoprotective action of N-acetylcysteine in mice treated with toxic doses of paracetamol. Al-Mustafa ZH, et al. **Toxicology** 1997 Sep 5;121(3):223–8

URINE

On-line liquid chromatography coupled with high field NMR and mass spectrometry (LC-NMR-MS): a new technique for drug metabolite structure elucidation. Burton KI, et al. **J Pharm Biomed Anal** 1997 Aug;15(12):1903–12

NMR and HPLC-NMR spectroscopic studies of futile deacetylation in paracetamol metabolites in rat and man. Nicholls AW, et al. **J Pharm Biomed Anal** 1997 Apr; 15(7):901–10

ANALGESICS, OPIOID

see related

NARCOTICS

Morphine metabolites. Christrup LL. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):116–22 (80 ref.)

Local anaesthesia and propofol–fentanyl sedation for carotid artery surgery. Nordström O, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):724–8

A clinical study on physiological response in electroacupuncture analgesia and meperidine analgesia for colonoscopy. Wang HH, et al. **Am J Chin Med** 1997; 25(1):13–20

When does 'drug-seeking' behavior signal addiction? Pasero CL, et al. **Am J Nurs** 1997 May;97(5):17–8

Analgesia after day case laparoscopic sterilisation. A comparison of tramadol with paracetamol/dextropropoxyphene and paracetamol/codeine combinations. Crighton IM, et al. **Anaesthesia** 1997 Jul;52(7):649–52

Contamination of opioids during preparation for regional anaesthesia [letter; comment] Mulvein JT. **Anaesthesia** 1997 Feb;52(2):183. Comment on: Anaesthesia 1996 Nov;51(11):1079–80.

A comparison of remifentanil and alfentanil in patients undergoing major abdominal surgery [see comments] Schüttler J, et al. **Anaesthesia** 1997 Apr;52(4):307–17. Comment in: Anaesthesia 1997 Apr;52(4):291–3.

Intrathecal morphine for caesarean section: an assessment of pain relief, satisfaction and side-effects. Swart M, et al. **Anaesthesia** 1997 Apr;52(4):373–7

The use of absorbent materials for the disposal of controlled drugs. Tarling MM, et al. **Anaesthesia** 1996 Sep;51(9):836–8

A randomized multicenter study of remifentanil compared with alfentanil, isoflurane, or propofol in anesthetized pediatric patients undergoing elective strabismus surgery. Davis PJ, et al. **Anesth Analg** 1997 May;84(5):982–9

Propofol sedation during awake craniotomy for seizures: patient-controlled administration versus neurolept analgesia. Herrick IA, et al. **Anesth Analg** 1997 Jun; 84(6):1285–91

Nitric oxide synthase inhibition modulates the ventilatory depressant and antinociceptive actions of fourth ventricular infusions of morphine in the awake dog. Pelligrino DA, et al. **Anesthesiology** 1996 Dec;85(6):1367–77

A method to produce sedation in critically ill patients [see comments] Watling SM, et al. **Ann Pharmacother** 1996 Nov; 30(11):1227–31. Comment in: Ann Pharmacother 1997 May;31(5):647–8.

Local anesthesia for arthroscopic surgery of the ankle using pethidine or prilocaine. Westman L, et al. **Arthroscopy** 1997 Jun;13(3):307–12

A comparative study of midazolam to meperidine/promethazine as an IM sedative technique for the pediatric dental patient. Downs AT, et al. **ASDC J Dent Child** 1997 May–Jun;64(3):197–200, 165, 228

Lack of analgesic effect of systemically administered morphine or pethidine on labour pain [see comments] Olofsson C, et al. **Br J Obstet Gynaecol** 1996 Oct; 103(10):968–72. Comment in: Br J Obstet Gynaecol 1997 May;104(5):643.

Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors. Chabal C, et al. **Clin J Pain** 1997 Jun;13(2):150–5

Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. Pande AC, et al. **Clin Neuropharmacol** 1996 Oct;19(5):451–6

Hemodynamic effects of intravenous morphine infusion in ventilated preterm babies. Sabatino G, et al. **Early Hum Dev** 1997 Feb 20;47(3):263–70

Potent reinforcing effects of dihydroetorphine in rats. Martin TJ, et al. **Eur J Pharmacol** 1997 Apr 18;324(2–3):141–5

Stages and processes of change as predictors of drug use among methadone maintenance patients. Belding MA, et al. **Exp Clin Psychopharmacol** 1997 Feb;5(1):65–73

Sedation and analgesia for colonoscopy: patient tolerance, pain, and cardiorespiratory parameters. Froehlich F, et al. **Gastrointest Endosc** 1997 Jan;45(1):1–9

Limited cutaneous scleroderma induced by pentazocine abuse [letter] Wanchu A, et al. **J Assoc Physicians India** 1995 Feb;43(2):145

Caudal epidural butorphanol plus bupivacaine versus bupivacaine in pediatric outpatient genitourinary procedures. Lawhorn CD, et al. **J Clin Anesth** 1997 Mar; 9(2):103–8

Pulse oxygen saturation in parturients receiving epidural versus opioid analgesia for labor [letter] Lurie S, et al. **J Clin Anesth** 1997 Feb;9(1):87

Opioid availability in Latin America: the Santo Domingo report progress since the Declaration of Florianopolis. De Lima L, et al. **J Pain Symptom Manage** 1997 Apr; 13(4):213–9

Immobilization of domestic goats (Capra hircus) using orally administered carfentanil citrate and detomidine hydrochloride. Sleeman JM, et al. **J Zoo Wildl Med** 1997 Jun;28(2):158–65

Butorphanol (Stadol): a study in problems of current drug information and control. Fisher MA, et al. **Neurology** 1997 May;48(5):1156–60

L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: electrophysiological and behavioural studies. Xu XJ, et al. **Neuropeptides** 1996 Apr;30(2):203–6

Remifentanil: the paediatric anaesthetist's opiate? [editorial] Lynn AM. **Paediatr Anaesth** 1996;6(6):433–5

Unusual problem with pain relief in an opium addict. Vas L. **Pain** 1997 Jan;69(1–2):203–4

System theory of pain and of opiate analgesia: no tolerance to opiates. Colpaert FC. **Pharmacol Rev** 1996 Sep; 48(3):355–402 (408 ref.)

The effects of pain on opioid tolerance: how do we resolve the controversy? Gutstein HB. **Pharmacol Rev** 1996 Sep; 48(3):403–7; discussion 409–11 (23 ref.)

Subarachnoid meperidine-morphine combination. An effective perioperative analgesic adjunct for cesarean delivery. Chung JH, et al. **Reg Anesth** 1997 Mar–Apr; 22(2):119–24

Ambulatory combined spinal-epidural analgesia for labor. Influence of epinephrine on bupivacaine-sufentanil combination. Gautier PE, et al. **Reg Anesth** 1997 Mar–Apr; 22(2):143–9

Phantom pain with probable reflex sympathetic dystrophy: efficacy of fentanyl infiltration of the stellate ganglion. Wassef MR. **Reg Anesth** 1997 May–Jun;22(3):287–90

Modern use of neuraxial opioids in acute pain. Shipton EA. **S Afr J Surg** 1996 Nov;34(4):180–5

A comparison of epidural saline, morphine, and bupivacaine for pain relief after abdominal surgery in goats. Hendrickson DA, et al. **Vet Surg** 1996 Jan–Feb;25(1):83–7

Postoperative analgesia for stifle surgery: a comparison of intra-articular bupivacaine, morphine, or saline. Sammarco JL, et al. **Vet Surg** 1996 Jan–Feb;25(1):59–69

A comparative study of medetomidine-butorphanol-ketamine and medetomidine-ketamine anaesthesia in dogs. Tomizawa N, et al. **Zentralbl Veterinarmed A** 1997 Jun;44(4):189–94

[Epidural administration of opioids in labor: pro] Gogarten W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Apr; 32(4):253–5 **(Ger)**

[Dyspnea in terminal patients--opioid inhalation?] Lozober Z, et al. **Harefuah** 1997 Jan 15;132(2):120–4 (32 ref.) **(Heb)**

[Combined general anesthesia using moradol in children] Agzamkhodzhaev TS, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):39–41 (Eng. Abstr.) **(Rus)**

[New aspects of learning addictive effects of narcotic analgesics] Zvartau EE, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):13–6 (20 ref.) **(Rus)**

[Opioid drugs in neonatal anesthesia] Cvejanov M. **Med Pregl** 1997 Mar–Apr;50(3–4):94–9 (Eng. Abstr.) **(Scr)**

[The choice of anesthesia methods in abdominal surgery is decisive for patients' recovery when it comes to eating again. Opinion should be avoided] Wattwil M, et al. **Lakartidningen** 1997 Apr 9;94(15):1376, 1379–80 (15 ref.) **(Swe)**

ADMINISTRATION & DOSAGE

The need for analgesia in elective cholecystectomies influenced by the time of day the operation is performed [letter] Anastasopoulou-Sampani D, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):955

The combination of morphine with local anaesthetic in rhinoplasty--no evidence of a peripheral morphine effect. Ben-David B, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):892–7

Analgesic effect of intraarticular morphine. A controlled, randomised and double-blind study. Christensen O, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):842–6

Inclusion of pethidine in lidocaine for infiltration improves analgesia following tonsillectomy in children. Elhakim M, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):214–7

Long-term intrathecal infusion of morphine in the home care of patients with advanced cancer. Gestin Y, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 1):12–7

Does morphine premedication influence the pain and consumption of postoperative analgesics after total knee arthroplasty? Hendolin H, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):81–5

Pharmacokinetics and pharmacodynamics of controlled-release opioids. Kaiko RF. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):166–74

Comparison of continuous epidural infusion of fentanyl and bupivacaine with intermittent epidural administration of morphine for postoperative pain management in children. Kart T, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):461–5

Differential effects of pre-treatment with intrathecal or intravenous morphine on the prevention of spinal cord hyperexcitability following sciatic nerve section in the rat. Luo L, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):91–5

Intravenous regional analgesia using morphine. The effect on postoperative pain following total knee arthroplasty. McSwiney M, et al. **Acta Anaesthesiol Scand** 1997 Mar; 41(3):345–7

Anesthetic quality during cesarean section following subarachnoid or epidural administration of bupivacaine with or without fentanyl. Olofsson C, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):332–8

Epidural and intrathecal opioids for postoperative pain management in Europe--a 17-nation questionnaire study of selected hospitals. Euro Pain Study Group on Acute Pain. Rawal N, et al. **Acta Anaesthesiol Scand** 1996 Oct; 40(9):1119–26

Patient-controlled analgesia with morphine and droperidol following caesarean section under spinal anaesthesia. Russell D, et al. **Acta Anaesthesiol Scand** 1996 May; 40(5):600–5

Postoperative epidural infusion of morphine and bupivacaine is safe on surgical wards. Organisation of the treatment, effects and side-effects in 2000 consecutive patients. Rygnestad T, et al. **Acta Anaesthesiol Scand** 1997 Aug; 41(7):868–76

Introducing epidural fentanyl for on-ward pain relief after major surgery. Salomäki TE, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):704–9

Analgesia following arthroscopy--a comparison of intra-articular morphine, pethidine and fentanyl. Söderlund A, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 1):6–11

Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Takala A, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):309–12

Epidural vs. intravenous infusion of alfentanil in the management of postoperative pain following laparotomies. van den Nieuwenhuyzen MC, et al. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1112–8

Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Wong JO, et al. **Acta Anaesthesiol Sin** 1997 Mar;35(1):25–32

Overdoses of pethidine given to two preterm neonates. Pokela ML. **Acta Paediatr** 1997 Mar;86(3):323–5

Changes in HIV risk behavior among injecting drug users: the impact of 21 versus 90 days of methadone detoxification. Iguchi MY, et al. **AIDS** 1996 Dec; 10(14):1719–28

Optimizing postoperative pain management [see comments] Carpenter RL. **Am Fam Physician** 1997 Sep 1;56(3):835–44, 847–50 (23 ref.). Comment in: Am Fam Physician 1997 Sep 1;56(3):726, 731–2.

Quicker dosage adjustment for transdermal fentanyl. Fudin J, et al. **Am J Health Syst Pharm** 1997 Jan 1;54(1):87–8

Don't overlook directions. Lilley LL, et al. **Am J Nurs** 1996 Dec;96(12):14–5

Using balanced analgesia for postoperative pain. Pasero CL, et al. **Am J Nurs** 1996 Dec;96(12):17

Preemptive analgesia: it starts before surgery [published erratum appears in Am J Nurs 1997 Feb;97(2):16] Pasero CL, et al. **Am J Nurs** 1996 Dec;96(12):17–8

Reluctance to order opioids in elders. Pasero CL, et al. **Am J Nurs** 1997 Sep;97(9):20, 23

Alternative use of PCA. Pasero CL, et al. **Am J Nurs** 1996 Oct;96(10):66–8

Central trigeminal effects of somatostatin and etorphine on adrenal and autonomic function in the cat. Bereiter DA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):R636–44

Effect of intramuscular intraoperative pain medication on narcotic usage after laparoscopic cholecystectomy. Lane GE, et al. **Am Surg** 1996 Nov;62(11):907–10

Morphine for postoperative analgesia. A comparison of intramuscular and subcutaneous routes of administration [see comments] Cooper IM. **Anaesth Intensive Care** 1996 Oct;24(5):574–8. Comment in: Anaesth Intensive Care 1997 Feb;25(1):95–6.

Comparison of patient-controlled epidural analgesia with patient-controlled intravenous analgesia using pethidine or fentanyl. Ngan Kee WD, et al. **Anaesth Intensive Care** 1997

Apr;25(2):126–32
Spinal morphine for caesarean section [letter; comment] Taylor R, et al. **Anaesth Intensive Care** 1997 Apr;25(2):198 . Comment on: Anaesth Intensive Care 1996 Oct;24(5):615–6.
The efficacy, applicability and side-effects of postoperative intravenous patient-controlled morphine analgesia: an audit of 1233 Chinese patients. Tsui SL, et al. **Anaesth Intensive Care** 1996 Dec;24(6):658–64
Intrathecal morphine dose for caesarean section [letter; comment] Buggy D. **Anaesthesia** 1997 Mar;52(3):278. Comment on: Anaesthesia 1996 Sep;51(9):871–3.
Pretreatment with controlled-release morphine for pain after hysterectomy. Cruickshank RH, et al. **Anaesthesia** 1996 Dec;51(12):1097–101
Remifentanil in the critically ill [letter] Evane TN, et al. **Anaesthesia** 1997 Aug;52(8):800–1
An investigation of the potential morphine sparing effect of midazolam [see comments] Gilliland HE, et al. **Anaesthesia** 1996 Sep;51(9):808–11. Comment in: Anaesthesia 1997 Apr;52(4):389.
A double-blind comparison of codeine and morphine for postoperative analgesia following intracranial surgery. Goldsack C, et al. **Anaesthesia** 1996 Nov;51(11):1029–32
Audit of opioid prescribing: the effect of hospital guidelines. Humphries CA, et al. **Anaesthesia** 1997 Aug;52(8):745–9
Epidural morphine and postherpetic neuralgia [letter; comment] Mayne CC, et al. **Anaesthesia** 1996 Dec; 51(12):1190. Comment on: Anaesthesia 1996 Jul;51(7):647–51.
Intrathecal administration of morphine for elective Caesarean section. A comparison between 0.1 mg and 0.2 mg [see comments] Milner AR, et al. **Anaesthesia** 1996 Sep; 51(9):871–3. Comment in: Anaesthesia 1997 Mar;52(3):278.
Potential morphine sparing effect of midazolam [letter] Mirakhur RK. **Anaesthesia** 1997 Aug;52(8):803–4
Pre-operative oral administration of morphine in day-case gynaecological laparoscopy. Rasanayagam R, et al. **Anaesthesia** 1996 Dec;51(12):1179–81
A comparison of opioid solutions for patient-controlled epidural analgesia. Smith AJ, et al. **Anaesthesia** 1996 Nov; 51(11):1013–7
Potential morphine sparing effect of midazolam [lctter; comment] Verheecke G. **Anaesthesia** 1997 Apr;52(4):389. Comment on: Anaesthesia 1996 Sep;51(9):808–11.
Lack of efficacy of intra-articular opioids for analgesia after day-case arthroscopy. Wrench IJ, et al. **Anaesthesia** 1996 Oct;51(10):920–2
The minimum effective doses of pethidine and doxapram in the treatment of post-anaesthetic shivering. Wrench IJ, et al. **Anaesthesia** 1997 Jan;52(1):32–6
The effect of intradermal administration of lidocaine and morphine on the response to thermal stimulation. Atanassoff PG, et al. **Anesth Analg** 1997 Jun;84(6):1340–3
Use of alfentanil and propofol for outpatient monitored anesthesia care: determining the optimal dosing regimen. Avramov MN, et al. **Anesth Analg** 1997 Sep;85(3):566–72
Intrathecal fentanyl with small-dose dilute bupivacaine: better anesthesia without prolonging recovery. Ben-David B, et al. **Anesth Analg** 1997 Sep;85(3):560–5
Intrathecal morphine for coronary artery bypass grafting and early extubation. Chaney MA, et al. **Anesth Analg** 1997 Feb;84(2):241–8
Postarthroscopic meniscus repair analgesia with intraarticular ketorolac or morphine [letter; comment] Cook TM, et al. **Anesth Analg** 1997 Feb;84(2):466–7. Comment on: Anesth Analg 1996 May;82(5):1036–9.
The safety and efficacy of oral transmucosal fentanyl citrate for preoperative sedation in young children. Epstein RH, et al. **Anesth Analg** 1996 Dec;83(6):1200–5
Determination of the dose-response relationship for intrathecal sufentanil in laboring patients. Herman NL, et al. **Anesth Analg** 1997 Jun;84(6):1256–61
Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses. Inagaki Y, et al. **Anesth Analg** 1997 Jan;84(1):100–5
Patient-controlled intranasal analgesia [letter] Joly LM, et al. **Anesth Analg** 1997 Aug;85(2):465
A comparison of the effect of intrathecal and extradural fentanyl on gastric emptying in laboring women. Kelly MC, et al. **Anesth Analg** 1997 Oct;85(4):834–8
Preemptive epidural morphine for postoperative pain relief after lumbar laminectomy. Kundra P, et al. **Anesth Analg** 1997 Jul;85(1):135–8
Intravenous ketamine or fentanyl prolongs postoperative analgesia after intrathecal neostigmine. Lauretti GR, et al. **Anesth Analg** 1996 Oct;83(4):766–70
Nalbuphine coadministered with morphine prevents tolerance and dependence. Lee SC, et al. **Anesth Analg** 1997 Apr;84(4):810–5
Intraarticular morphine analgesia in chronic pain patients with osteoarthritis. Likar R, et al. **Anesth Analg** 1997 Jun; 84(6):1313–7
A comparison of variable-dose patient-controlled analgesia with fixed-dose patient-controlled analgesia. Love DR, et al. **Anesth Analg** 1996 Nov;83(5):1060–4
Patient-controlled epidural analgesia: interactions between nalbuphine and hydromorphone. Parker RK, et al. **Anesth Analg** 1997 Apr;84(4):757–63
Morphine patient-controlled analgesia is superior to meperidine patient-controlled analgesia for postoperative pain. Plummer JL, et al. **Anesth Analg** 1997 Apr;84(4):794–9
Some suggestions for simplifying subcutaneous tunneling [letter] Ramaioli F, et al. **Anesth Analg** 1997 Sep;85(3):705–6
Maternal posture influences the extent of sensory block produced by intrathecal dextrose-free bupivacaine with fentanyl for labor analgesia. Richardson MG, et al. **Anesth Analg** 1996 Dec;83(6):1229–33
Intrathecal sufentanil for labor analgesia: do sensory changes predict better analgesia and greater hypotension? Riley ET, et al. **Anesth Analg** 1997 Feb;84(2):346–51
The use of 0.25% lidocaine with fentanyl and pancuronium for intravenous regional anesthesia. Sztark F, et al. **Anesth Analg** 1997 Apr;84(4):777–9
A comparison of oral ketorolac and hydrocodone-acetaminophen for analgesia after ambulatory surgery: arthroscopy versus laparoscopic tubal ligation. White PF, et al. **Anesth Analg** 1997 Jul;85(1):37–43
The effect of tourniquet release time on the analgesic efficacy of intraarticular morphine after arthroscopic knee surgery. Whitford A, et al. **Anesth Analg** 1997 Apr;84(4):791–3
The effects of adding sufentanil to bupivacaine for postoperative patient-controlled epidural analgesia. Wiebalck A, et al. **Anesth Analg** 1997 Jul;85(1):124–9
Postcesarean analgesia with both epidural morphine and intravenous patient-controlled analgesia: neurobehavioral outcomes among nursing neonates. Wittels B, et al. **Anesth Analg** 1997 Sep;85(3):600–6
Baricity, needle direction, and intrathecal sufentanil labor analgesia. Ferouz F, et al. **Anesthesiology** 1997 Mar; 86(3):592–8
Isobolographic analysis of interactions between intravenous morphine, propacetamol, and diclofenac in carrageenin-injected rats. Fletcher D, et al. **Anesthesiology** 1997 Aug;87(2):317–26
Remifentanil versus remifentanil/midazolam for ambulatory surgery during monitored anesthesia care. Gold MI, et al. **Anesthesiology** 1997 Jul;87(1):51–7
Effect of flumazenil on ventilatory drive during sedation with midazolam and alfentanil. Gross JB, et al. **Anesthesiology** 1996 Oct;85(4):713–20
Effect of systemic and intrathecal morphine in a rat model of postoperative pain [see comments] Zahn PK, et al. **Anesthesiology** 1997 May;86(5):1066–77. Comment in: Anesthesiology 1997 May;86(5):1015–7.
Comparison of oral transmucosal fentanyl citrate and intramuscular meperidine, promethazine, and chlorpromazine for conscious sedation of children undergoing laceration repair. Schutzman SA, et al. **Ann Emerg Med** 1996 Oct;28(4):385–90
Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. Mercadante S, et al. **Ann Oncol** 1996 Aug;7(6):613–7
Compatibility of hydromorphone and prochlorperazine, and irritation due to subcutaneous prochlorperazine infusion [letter] Trinkle R. **Ann Pharmacother** 1997 Jun;31(6):789–90
Comparison of diclofenac sodium and morphine sulphate for postoperative analgesia after day case inguinal hernia surgery [letter; comment] Alberts JC. **Ann R Coll Surg Engl** 1997 Mar;79(2):155–6. Comment on: Ann R Coll Surg Engl 1996 Jul;78(4):363–6.
Pharmacokinetics and drug input characteristics for a diclofenac-codeine phosphate combination following oral and rectal administration. Hanses A, et al. **Arzneimittelforschung** 1996 Jan;46(1):57–63
Chemical immobilisation of giraffe to facilitate short procedures. Vogelnest L, et al. **Aust Vet J** 1997 Mar; 75(3):180–2
Bone marrow harvesting using local anaesthesia and PCA-alfentanil: a feasible alternative to general or regional anaesthesia. Sim KM, et al. **Bone Marrow Transplant** 1996 Oct;18(4):787–90
Extradural morphine gives better pain relief than patient-controlled i.v. morphine after hysterectomy. Eriksson-Mjöberg M, et al. **Br J Anaesth** 1997 Jan; 78(1):10–6
Extradural pain relief in labour: bupivacaine sparing by extradural fentanyl is dose dependent. Lyons G, et al. **Br J Anaesth** 1997 May;78(5):493–7
Analgesia: dose-effect or pre-emptive effect? [letter; comment] Mallick A, et al. **Br J Anaesth** 1996 Aug; 77(2):297–8. Comment on: Br J Anaesth 1996 Mar;76(3):358–61.
Target-controlled infusion of alfentanil for postoperative analgesia: a feasibility study and pharmacodynamic evaluation in the early postoperative period. Van den Nieuwenhuyzen MC, et al. **Br J Anaesth** 1997 Jan; 78(1):17–23
Continuous brachial plexus infusion of butorphanol-mepivacaine mixtures for analgesia after upper extremity surgery. Wajima Z, et al. **Br J Anaesth** 1997 Jan;78(1):83–5
Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Mandema JW, et al. **Br J Clin Pharmacol** 1996 Dec;42(6):747–56
Lack of analgesic effect of systemically administered morphine or pethidine on labour pain [letter; comment] Lucas MJ, et al. **Br J Obstet Gynaecol** 1997 May;104(5):643 . Comment on: Br J Obstet Gynaecol 1996 Oct;103(10):968–72.
Use of patient-controlled analgesia in extracorporeal shockwave lithotripsy. Chin CM, et al. **Br J Urol** 1997 Jun;79(6):848–51
Labour analgesia with intrathecal fentanyl decreases maternal stress. Cascio M, et al. **Can J Anaesth** 1997 Jun;44(6):605–9
Bolus size and PCA morphine requirements [letter] Delire V, et al. **Can J Anaesth** 1997 Aug;44(8):902
Epidural and intravenous bolus morphine for postoperative analgesia in infants. Haberkern CM, et al. **Can J Anaesth** 1996 Dec;43(12):1203–10
Patient maintained alfentanil target-controlled infusion for analgesia during extracorporeal shock wave lithotripsy. Irwin MG, et al. **Can J Anaesth** 1996 Sep;43(9):919–24
Epidural fentanyl improves the onset and spread of epidural mepivacaine analgesia. Kasaba T, et al. **Can J Anaesth** 1996 Dec;43(12):1211–5
Epidural administered buprenorphine in the perioperative period. Miwa Y, et al. **Can J Anaesth** 1996 Sep;43(9):907–13
Transdermal fentanyl system plus im ketorolac for the treatment of postoperative pain. Reinhart DJ, et al. **Can J Anaesth** 1997 Apr;44(4):377–84
Antinociceptive synergistic interaction between morphine and n omega-nitro l-arginine methyl ester on thermal nociceptive tests in the rats. Yamaguchi H, et al. **Can J Anaesth** 1996 Sep;43(9):975–81
Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Hagen NA, et al. **Cancer** 1997 Apr 1; 79(7):1428–37
Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Scholz J, et al. **Clin Pharmacokinet** 1996 Oct;31(4):275–92 (136 ref.)
Relationship between behavioral and physiological indicators of pain, critical care patients' self-reports of pain, and opioid administration. Puntillo KA, et al. **Crit Care Med** 1997 Jul;25(7):1159–66
Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Jeal W, et al. **Drugs** 1997 Jan;53(1):109–38 (105 ref.)
Epidural bupivacaine/fentanyl infusions vs. intermittent top-ups: a retrospective study of the effects on mode of delivery in primiparous women. Driver I, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):515–20
Potentiation of sufentanil by clonidine in PCEA with or without basal infusion. Vercauteren MP, et al. **Eur J Anaesthesiol** 1996 Nov;13(6):571–6
Administration of rectal indomethacin does not reduce the requirement for intravenous narcotic analgesia in acute renal colic. Ginifer C, et al. **Eur J Emerg Med** 1996 Jun; 3(2):92–4
On-demand analgesia with piritramide in children. A study on dosage specification and safety. Petrat G, et al. **Eur J Pediatr Surg** 1997 Feb;7(1):38–41
Effect of pertussis toxin on morphine, diphenhydramine, baclofen, clomipramine and physostigmine antinociception. Galeotti N, et al. **Eur J Pharmacol** 1996 Jul 18; 308(2):125–33
Supraspinal administration of opioids with selectivity for mu-, delta- and kappa-opioid receptors produces analgesia in amphibians. Stevens CW, et al. **Eur J Pharmacol** 1997 Jul 16;331(1):15–21
Cost of administering controlled drugs in a hospice ward. McGettrick S, et al. **Health Bull (Edinb)** 1996 Nov; 54(6):441–2
How effective is patient-controlled analgesia? A randomized comparison of two protocols for pain relief during oocyte recovery. Bhattacharya S, et al. **Hum Reprod** 1997 Jul; 12(7):1440–2
Dilatation of radiation-induced esophageal strictures under sublingual buprenorphine analgesia: a pilot study. Desai DC, et al. **Indian J Gastroenterol** 1997 Jan;16(1):14–5
Intratracheal administration of fentanyl: pharmacokinetics and local tissue effects. Irazuzta JE, et al. **Intensive Care Med** 1996 Feb;22(2):129–33
Intranasal diamorphine for paediatric analgesia: assessment of safety and efficacy. Wilson JA, et al. **J Accid Emerg Med** 1997 Mar;14(2):70–2
Patient controlled analgesia and intramuscular injections: a comparisons of patient pain experiences and postoperative outcomes. Snell CC, et al. **J Adv Nurs** 1997 Apr; 25(4):681–90
A study of the use of a transdermal fentanyl patch in cats. Scherk-Nixon M. **J Am Anim Hosp Assoc** 1996 Jan-Feb; 32(1):19–24
Chronic opioids for chronic low back pain--solution or problem? [comment] [see comments] Murphy TM. **J Am Board Fam Pract** 1996 May-Jun;9(3):225–8. Comment on: J Am Board Fam Pract 1996 May-Jun;9(3):191–204. Comment in: J Am Board Fam Pract 1996 Sep-Oct;9(5):386; discussion 387–8. Comment in: J Am Board Fam Pract 1996 Sep-Oct;9(5):386–7; discussion 387–8. Comment in: J Am Board Fam Pract 1996 Sep-Oct;9(5):388; discussion 387–8. Comment in: J Am Board Fam Pract 1996 Sep-Oct;9(5):388–9; discussion 387–8.
Intra-articular morphine and/or bupivacaine in the management of pain after total knee arthroplasty. Mauerhan DR, et al. **J Arthroplasty** 1997 Aug;12(5):546–52
The effect of local infiltration with morphine before carpal tunnel release. Stahl S, et al. **J Bone Joint Surg Am** 1997 Apr;79(4):551–4
High-dose intrathecal morphine for thoracoabdominal aneurysm repair [letter] Chaney MA. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):306–7

Anesthesia supplemented with subarachnoid bupivacaine and morphine for coronary artery bypass surgery in a child with Kawasaki disease. Kowalewski R, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):243–6

Intrathecal morphine: one year's experience in cardiac surgical patients. Taylor A, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):225–8

Effect of varying intravenous patient-controlled analgesia dose and lockout interval while maintaining a constant hourly maximum dose. Badner NH, et al. **J Clin Anesth** 1996 Aug;8(5):382–5

Intrathecal morphine for neuropathic pain in a pregnant cancer patient. Wen YR, et al. **J Formos Med Assoc** 1996 Mar;95(3):252–4

A comparison of patient-controlled and fixed schedule analgesia after orthognathic surgery. Precious DS, et al. **J Oral Maxillofac Surg** 1997 Jan;55(1):33–9; discussion 40

Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. Ahmedzai S, et al. **J Pain Symptom Manage** 1997 May;13(5):254–61

Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. Broomhead A, et al. **J Pain Symptom Manage** 1997 Aug;14(2):63–73

Combined administration of opioids with selected drugs to manage pain and other cancer symptoms: initial safety screening for compatibility. Chandler SW, et al. **J Pain Symptom Manage** 1996 Sep;12(3):168–71

Re: Use of rectal medications in palliative care [letter; comment] Darke AC, et al. **J Pain Symptom Manage** 1997 Jun;13(6):314–5. Comment on: J Pain Symptom Manage 1996 Jun;11(6):378–87.

Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. Hagen N, et al. **J Pain Symptom Manage** 1997 Jul;14(1):51–8

Epidural and subarachnoid administration of opioids for nonmalignant pain: technical issues, current approaches and novel treatments. Hassenbusch SJ. **J Pain Symptom Manage** 1996 Jun;11(6):357–62 (23 ref.)

Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. Korte W, et al. **J Pain Symptom Manage** 1996 Mar;11(3):139–46

Intraspinal opioid therapy for chronic nonmalignant pain: current practice and clinical guidelines. Krames ES. **J Pain Symptom Manage** 1996 Jun;11(6):333–52 (78 ref.)

Subcutaneous cannulae for morphine boluses in children: assessment of a technique. Lamacraft G, et al. **J Pain Symptom Manage** 1997 Jan;13(1):43–9

High-dose epidural infusion of opioids for cancer pain: cost issues. Manfredi PL, et al. **J Pain Symptom Manage** 1997 Feb;13(2):118–21

Opioid-sparing effect of diclofenac in cancer pain. Mercadante S, et al. **J Pain Symptom Manage** 1997 Jul; 14(1):15–20

Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. Mercadante S, et al. **J Pain Symptom Manage** 1997 Apr;13(4):241–4

Similar pain in different countries [letter; comment] Mercadante S. **J Pain Symptom Manage** 1996 Nov; 12(5):270–1. Comment on: J Pain Symptom Manage 1995 Nov;10(8):632–8.

Re: control of cancer-related pain with MS contin [letter; comment] O'Bryan-Tear CG, et al. **J Pain Symptom Manage** 1996 Sep;12(3):145–6. Comment on: J Pain Symptom Manage 1995 Aug;10(6):416–22.

Edmonton injector: use in Córdoba, Argentina. Pruvost M, et al. **J Pain Symptom Manage** 1996 Dec;12(6):372–5

Reduction in hyperalgesia and intrathecal morphine requirements by low-dose ketamine infusion [letter] Walker SM, et al. **J Pain Symptom Manage** 1997 Sep;14(3):129–33

How should we use transdermal fentanyl (TF) for pain management in palliative care patients? Fainsinger RL, et al. **J Palliat Care** 1996 Spring;12(1):48–53 (30 ref.)

Morphine drips, terminal sedation, and slow euthanasia: definitions and facts, not anecdotes [comment] [see comments] Mount B. **J Palliat Care** 1996 Winter;12(4):31–7 . Comment on: J Palliat Care 1996 Winter;12(4):21–30. Comment in: J Palliat Care 1997 Spring;13(1):52.

Morphine infusions at the end of life: the pitfalls in reasoning from anecdote [comment] [see comments] Portenoy RK. **J Palliat Care** 1996 Winter;12(4):44–6. Comment on: J Palliat Care 1996 Winter;12(4):21–30. Comment in: J Palliat Care 1997 Spring;13(1):52.

Transdermal fentanyl administration in children and adolescents with sickle cell pain crisis. Christensen ML, et al. **J Pediatr Hematol Oncol** 1996 Nov;18(4):372–6

Comparison of continuous infusion of fentanyl to bolus dosing in neonates after surgery. Vaughn PR, et al. **J Pediatr Surg** 1996 Dec;31(12):1616–23

Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. Kolesnikov YA, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):502–6

Inhalation exposure to volatilized opioids produces antinociception in mice. Lichtman AH, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):69–76

Spinal morphine/clonidine antinociceptive synergism: involvement of G proteins and N-type voltage-dependent calcium channels. Wei ZY, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1392–407

Battlefield analgesia [letter] de Mello WF, et al. **J R Army Med Corps** 1997 Jun;143(2):129

Intravesical morphine analgesia after bladder surgery [see comments] Duckett JW, et al. **J Urol** 1997 Apr; 157(4):1407–9. Comment in: J Urol 1997 Apr;157(4):1414–5.

Postoperative analgesic effects of an external cooling system and intra-articular bupivacaine/morphine after arthroscopic cruciate ligament surgery. Brandsson S, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(4):200–5

Opioids in labor [letter; comment] Kingdom J, et al. **Lancet** 1997 Mar 8;349(9053):726; discussion 727–8. Comment on: Lancet 1997 Jan 4;349(9044):4–5.

Opioids in labour [letter; comment] Liston WA. **Lancet** 1997 Mar 8;349(9053):727; discussion 727–8. Comment on: Lancet 1997 Jan 4;349(9044):4–5.

Opioids in labour [letter; comment] Littler C, et al. **Lancet** 1997 Mar 8;349(9053):727; discussion 727–8. Comment on: Lancet 1997 Jan 4;349(9044):4–5.

Opioids in labour—no analgesic effect [see comments] Reynolds F, et al. **Lancet** 1997 Jan 4;349(9044):4–5. Comment in: Lancet 1997 Mar 8;349(9053):726; discussion 727–8. Comment in: Lancet 1997 Mar 8;349(9053):726–7; discussion 727–8. Comment in: Lancet 1997 Mar 8;349(9053):727; discussion 727–8.

Opioids in labour [letter; comment] Twycross R. **Lancet** 1997 Mar 8;349(9053):726–7; discussion 727–8. Comment on: Lancet 1997 Jan 4;349(9044):4–5.

Chronic pain control in the elderly. Keay TJ. **Md Med J** 1996 Mar;45(3):226–8

Pharmacologic treatment of cancer pain [letter; comment] Bruera E, et al. **N Engl J Med** 1997 Mar 27;336(13):962–3; discussion 963. Comment on: N Engl J Med 1996 Oct 10;335(15):1124–32.

Chronic intrathecal morphine treatment does not cause down-regulation of spinal adenosine A1 receptors in rats. Tao PL, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jul;354(2):187–91

Intraventricular administration of morphine for control of intractable cancer pain in 90 patients. Karavelis A, et al. **Neurosurgery** 1996 Jul;39(1):57–61; discussion 61–2

Discrepancies exist between dosage conversion calculators. Pennoni M. **Oncol Nurs Forum** 1996 Jun;23(5):847

Current status of patient-controlled analgesia in cancer patients. Ripamonti C, et al. **Oncology (Huntingt)** 1997 Mar; 11(3):373–80, 383–4; discussion 384–6 (102 ref.)

Transnasal butorphanol: pain relief in the head and neck patient. Cannon CR. **Otolaryngol Head Neck Surg** 1997 Feb;116(2):197–200

Intrathecal morphine for postoperative analgesia in an infant with bronchopulmonary dysplasia following upper abdominal surgery [see comments] Krechel SW, et al. **Paediatr Anaesth** 1996;6(5):423–6. Comment in: Paediatr Anaesth 1997;7(3):262.

Variation in opioid use during PCA in adolescents [letter; comment] Marsh DF, et al. **Paediatr Anaesth** 1996; 6(5):429–30. Comment on: Paediatr Anaesth 1996;6(1):33–8.

Intrathecal morphine for a child with bronchopulmonary dysplasia [letter; comment] Mayhew JF. **Paediatr Anaesth** 1997;7(3):262. Comment on: Paediatr Anaesth 1996;6(5):423–6.

Comparison of diclofenac and tenoxicam for postoperative analgesia with and without fentanyl in children undergoing adenotonsillectomy or tonsillectomy. Mendham JE, et al. **Paediatr Anaesth** 1996;6(6):467–73

Variation in opioid use during PCA in adolescents [see comments] Tyler DC, et al. **Paediatr Anaesth** 1996;6(1):33–8 . Comment in: Paediatr Anaesth 1996;6(5):420–30.

Systemic physostigmine increases the antinociceptive effect of spinal morphine. Beilin B, et al. **Pain** 1997 Apr; 70(2–3):217–21

Differences among patients in opioid self-administration during bone marrow transplantation. Chapman CR, et al. **Pain** 1997 Jul;71(3):213–23

Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Kalso E, et al. **Pain** 1996 Oct;67(2–3):443–9

Pain relief from intra-articular morphine after knee surgery: a qualitative systematic review. Kalso E, et al. **Pain** 1997 Jun;71(2):127–34 (47 ref.)

Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Manfredi PL, et al. **Pain** 1997 Mar;70(1):99–101

Peripheral morphine analgesia [editorial] Stein C, et al. **Pain** 1997 Jun;71(2):119–21

Morphine and clonazepam combinations in the Springfusor 30 infusion device [letter] Dean A, et al. **Palliat Med** 1997 May;11(3):256

Opioid rotation: does it have a role? [editorial] Fallon M. **Palliat Med** 1997 May;11(3):177–8

Drug combinations in syringe drivers: the compatibility and stability of diamorphine with cyclizine and haloperidol. Grassby PF, et al. **Palliat Med** 1997 May;11(3):217–24

Transdermal fentanyl for severe cancer-related pain. Yeo W, et al. **Palliat Med** 1997 May;11(3):233–9

The effect of cumulative dosing on the analgesic potency of morphine in mice. Duttaroy A, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):67–71

Ethnic differences in analgesic consumption for postoperative pain. Ng B, et al. **Psychosom Med** 1996 Mar–Apr; 58(2):125–9

Analgesic dosing strategies for chronic pain [letter; comment] Gregory RJ. **Psychosomatics** 1997 Mar–Apr;38(2):158–9. Comment on: Psychosomatics 1996 May–Jun;37(3):223–35.

Can meta-analysis rescue knowledge from a sea of unintelligible data? [editorial; comment] Abram SE, et al. **Reg Anesth** 1996 Nov–Dec;21(6):514–6. Comment on: Reg Anesth 1996 Nov–Dec;21(6):542–56.

Addition of morphine to intra-articular bupivacaine does not improve analgesia following knee joint replacement. Badner NH, et al. **Reg Anesth** 1997 Jul–Aug;22(4):347–50

Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer [see comments] Ballantyne JC, et al. **Reg Anesth** 1996 Nov–Dec;21(6):542–56. Comment in: Reg Anesth 1996 Nov–Dec;21(6):514–6.

Pain relief after knee arthroscopy: intra-articular morphine, intra-articular bupivacaine, or subcutaneous morphine? Cepeda MS, et al. **Reg Anesth** 1997 May–Jun;22(3):233–8

Subarachnoid sufentanil for extracorporeal shock lithotripsy. Eaton MP, et al. **Reg Anesth** 1997 Jan–Feb;22(1):86–8

Transdermal fentanyl in postoperative pain. Lehmann LJ, et al. **Reg Anesth** 1997 Jan–Feb;22(1):24–8

Epidural analgesia improves outcome following pediatric fundoplication. A retrospective analysis. McNeely JK, et al. **Reg Anesth** 1997 Jan–Feb;22(1):16–23

Epidural opioid delivery methods: bolus, continuous infusion, and patient-controlled epidural analgesia. Mulroy MF. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):100–4 (38 ref.)

Detection of intravascular epidural catheters using 2-chloroprocaine. Influence of local anesthetic dose and nalbuphine premedication. Rathmell JP, et al. **Reg Anesth** 1997 Mar–Apr;22(2):113–8

Ketamine potentiates analgesic effect of morphine in postoperative epidural pain control [see comments] Wong CS, et al. **Reg Anesth** 1996 Nov–Dec;21(6):534–41. Comment in: Reg Anesth 1996 Nov–Dec;21(6):508–13.

Epidural ketamine: a useful, mechanistically novel adjuvant for epidural morphine? [editorial; comment] Yaksh TL. **Reg Anesth** 1996 Nov–Dec;21(6):508–13. Comment on: Reg Anesth 1996 Nov–Dec;21(6):534–41.

Management of pain in the critically ill patient. Faggella AM. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):115–21 (28 ref.)

Treatment of pain in chronic bowel subobstruction with self-administration of methadone. Mercadante S, et al. **Support Care Cancer** 1997 Jul;5(4):327–9

Intrathecal granuloma after implantation of a morphine pump: case report and review of the literature. Bejjani GK, et al. **Surg Neurol** 1997 Sep;48(3):288–91 (23 ref.)

Nebulised drugs in palliative care. Ahmedzai S, et al. **Thorax** 1997 Apr;52 Suppl 2:S75–7

Sublingual buprenorphine compared to morphine delivered by a patient-controlled analgesia system as postoperative analgesia after prostatectomy. Gaitini L, et al. **Urol Int** 1996;57(4):227–9

Postoperative analgesic and cardiopulmonary effects in dogs of oxymorphone administered epidurally and intramuscularly, and medetomidine administered epidurally: a comparative clinical study. Vesal N, et al. **Vet Surg** 1996 Jul–Aug;25(4):361–9

Experiences with morphine injected into the subarachnoid space in sheep. Wagner AE, et al. **Vet Surg** 1996 May–Jun; 25(3):256–60

[The use of dihydrocodeine for postoperative analgesia in gynecological operations] Traĭkova V, et al. **Akush Ginekol (Sofiia)** 1996;35(1–2):24–6 (Eng. Abstr.) **(Bul)**

[Pre- and intra-operative administration of epidural morphine provides good postoperative pain relief after laminectomy] Kuo TC, et al. **Acta Anaesthesiol Sin** 1996 Jun;34(2):69–74 (Eng. Abstr.) **(Chi)**

[Treatment of severe cancer pain via spinal catheters] Andersen JS, et al. **Ugeskr Laeger** 1996 Nov 11; 158(46):6613–6 (Eng. Abstr.) **(Dan)**

[Prescription of strong analgesics in the out-of-hours general practice in the county of Aarhus] Christensen MB, et al. **Ugeskr Laeger** 1997 Apr 14;159(16):2381–5 (Eng. Abstr.) **(Dan)**

[Combination preparations of codeine and paracetamol] Ostergaard HT, et al. **Ugeskr Laeger** 1997 Sep 15; 159(38):5685–6 **(Dan)**

[Malignant bone pain] Thomsen CB, et al. **Ugeskr Laeger** 1997 Apr 14;159(16):2364–9 (40 ref.) (Eng. Abstr.) **(Dan)**

[Transdermal opioid administration: the pain plaster] Vecht CJ, et al. **Ned Tijdschr Geneeskd** 1997 Apr 26;141(17):821–3 (10 ref.) (Eng. Abstr.) **(Dut)**

[Evaluation of 2 dosages of fentanyl in caudal anesthesia. A prospective randomized double-blind study] Gharsallah A, et al. **Cah Anesthesiol** 1996;44(5):419–21 (Eng. Abstr.) **(Fre)**

[Morphine in cesarean section and postoperative analgesia] Milon D, et al. **Cah Anesthesiol** 1996;44(3):241–44 (Eng. Abstr.) **(Fre)**

[What organizational structure is needed to carry out patient-controlled or continuous opioid analgesia?] Jage J. **Anaesthesist** 1996 Dec;45 Suppl 3:S74–5 **(Ger)**

[Treatment of pain with peridural administration of opiates. Comment on the contribution by S. Chrubasik et al (letter; comment)] Brodner G, et al. **Chirurg** 1997 Jan;68(1):94–5 . Comment on: Chirurg 1996 Jul;67(7):665–70. **(Ger)**

[Treatment of pain with peridural administration of opioids (see comments)] Chrubasik S, et al. **Chirurg** 1996 Jul;

67(7):665–70 (24 ref.) (Eng. Abstr.). Comment in: Chirurg 1997 Jan;68(1):94–5. **(Ger)**

[Postoperative pain therapy in inpatient treatment] Holthausen U, et al. **Chirurg** 1996 Jul;67(7):671–80 (30 ref.) (Eng. Abstr.) **(Ger)**

[Tumor pain. Fentanyl TTS: a transdermal system for tumor pain therapy] **Dtsch Med Wochenschr** 1995 Oct 13;120(41 Suppl):1–4 **(Ger)**

[Peri- and postoperative pain therapy with mechanical patient-controlled disposable analgesia pumps in general surgery. Report of initial trial] Fieseler HG, et al. **Zentralbl Chir** 1996;121(7):552–6 (Eng. Abstr.) **(Ger)**

[Treatment of pain in oncology] De Conno F, et al. **Tumori** 1997;83(2 Suppl):S20–4 (49 ref.) (Eng. Abstr.) **(Ita)**

[Epidural fentanyl provide sufficient analgesia for extracorporeal shock wave lithotripsy (ESWL)] Abe T, et al. **Masui** 1997 May;46(5):694–9 (Eng. Abstr.) **(Jpn)**

[Epidural administration of buprenorphine after combined spinal epidural anesthesia] Endoh M, et al. **Masui** 1996 Nov; 45(11):1396–9 (Eng. Abstr.) **(Jpn)**

[Effective treatment of a man with head injury and multiple rib fractures with epidural analgesia] Kariya N, et al. **Masui** 1996 Feb;45(2):223–6 (Eng. Abstr.) **(Jpn)**

[Pre-emptive analgesia from intravenous administration of opioid: no effect with pentazocine] Nagasaka H, et al. **Masui** 1996 Jun;45(6):750–5 (Eng. Abstr.) **(Jpn)**

[Effects of continuous epidural administration of fentanyl and morphine on postcesarean pain] Oda A, et al. **Masui** 1996 Dec;45(12):1511–5 (Eng. Abstr.) **(Jpn)**

[Postoperative pain relief for a patient with elective mutism by patient controlled analgesia] Onaka M, et al. **Masui** 1997 Jan;46(1):73–6 (Eng. Abstr.) **(Jpn)**

[Postoperative epidural fentanyl administration in patients for hysterectomy with para-aortic lymph node resection] Sugimoto M, et al. **Masui** 1997 May;46(5):628–34 (Eng. Abstr.) **(Jpn)**

[Postoperative continuous epidural infusion of morphine in a patient with myotonic dystrophy] Takeda T, et al. **Masui** 1996 Nov;45(11):1384–7 (Eng. Abstr.) **(Jpn)**

[Intraoperative continuous epidural lidocaine combined with preoperative administration of epidural morphine for post-hepatectomy pain relief] Terai T, et al. **Masui** 1997 Jan;46(1):100–4 (Eng. Abstr.) **(Jpn)**

[Epidural buprenorphine and epidural droperidol for post-operative nausea or vomiting] Yokoyama K, et al. **Masui** 1997 Jun;46(6):798–802 (Eng. Abstr.) **(Jpn)**

[Reflections on pain treatment (letter)] Moi H. **Tidsskr Nor Laegeforen** 1997 Apr 20;117(10):1511 **(Nor)**

[General anesthesia with use of nubain and clopheline in myocardial revascularization surgery] Grishin VV, et al. **Anesteziol Reanimatol** 1996 Jul-Aug;(4):25–30 **(Rus)**

[Use of morphine after surgery of lower limbs under subarachnoid anesthesia] Mikhnevich KG. **Klin Khir** 1996; (4):33–5 **(Rus)**

[Is morphine not used sufficiently in cancer pain? Opiophobia in Sweden] Rane A. **Lakartidningen** 1997 Jan 29;94(5):321–3 **(Swe)**

ADVERSE EFFECTS

Side effects of opioids in postoperative pain treatment. Camu F. **Acta Anaesthesiol Belg** 1996;47(3):105–9 (28 ref.)

Tolerance and dependence to opiates. Jasinski DR. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):184–6 (16 ref.)

Psychomotor and cognitive functioning in cancer patients. Sjøgren P. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):159–61

Should people taking opioids for medical reasons be allowed to work and drive? [editorial] Zacny JP. **Addiction** 1996 Nov;91(11):1581–4 (16 ref.)

Safety profiles of tramadol, lindane, and astemizole updated [news] **Am J Health Syst Pharm** 1996 May 15;53(10):1116, 1122

Don't overlook directions. Lilley LL, et al. **Am J Nurs** 1996 Dec;96(12):14–5

Morphine overdose from patient-controlled analgesia pumps. Kwan A. **Anaesth Intensive Care** 1996 Apr;24(2):254–6

Profound respiratory depression with morphine patient-controlled analgesia in an elderly patient [letter] Morley AD. **Anaesth Intensive Care** 1996 Apr;24(2):287

The effect of epidural opioids on maternal oxygenation during labour and delivery [see comments] Porter JS, et al. **Anaesthesia** 1996 Oct;51(10):899–903. Comment in: Anaesthesia 1997 Mar;52(3):276–8.

Epidural opioids in labour—do we need them? [letter; comment] Thomas EO. **Anaesthesia** 1997 Mar;52(3):276–8 . Comment on: Anaesthesia 1996 Oct;51(10):899–903.

The effect of subhypnotic doses of propofol on the incidence of pruritus after intrathecal morphine for caesarean section. Warwick JP, et al. **Anaesthesia** 1997 Mar;52(3):270–5

Nausea and vomiting in the postoperative patient-controlled analgesia environment. Woodhouse A, et al. **Anaesthesia** 1997 Aug;52(8):770–5 (46 ref.)

Orthostatic hypotension during postoperative continuous thoracic epidural bupivacaine-morphine in patients undergoing abdominal surgery. Crawford ME, et al. **Anesth Analg** 1996 Nov;83(5):1028–32

The effects of a nonsteroidal antiinflammatory drug (ketoprofen) on morphine respiratory depression: a double-blind, randomized study in volunteers. Moren J, et al. **Anesth Analg** 1997 Aug;85(2):400–5

Three sudden postoperative respiratory arrests associated with epidural opioids in patients with sleep apnea. Ostermeier AM, et al. **Anesth Analg** 1997 Aug;85(2):452–60 (45 ref.)

Intravenous ondansetron for postsurgical opioid-induced nausea and vomiting. S3A-255 Study Group. Rung GW, et al. **Anesth Analg** 1997 Apr;84(4):832–8

Interactions between midazolam and remifentanil during monitored anesthesia care. Avramov MN, et al. **Anesthesiology** 1996 Dec;85(6):1283–9

Opiate-induced respiratory depression in pediatric patients. Gill AM, et al. **Ann Pharmacother** 1996 Feb;30(2):125–9

Possible serotonin syndrome associated with tramadol and sertraline coadministration. Mason BJ, et al. **Ann Pharmacother** 1997 Feb;31(2):175–7

Comment: opioid-induced muscle activity [letter; comment] Pereira JL, et al. **Ann Pharmacother** 1996 Sep;30(9):1042–3 . Comment on: Ann Pharmacother 1995 Nov;29(11):1118–21.

Potential interaction between tramadol and warfarin [letter] Scher ML, et al. **Ann Pharmacother** 1997 May;31(5):646–7

Localized indurated brown plaques on arms and right buttock. Pentazocine-induced morphea. Bellman B, et al. **Arch Dermatol** 1996 Nov;132(11):1366–7, 1368–9

The dangers of dextropropoxyphene. Dore GM. **Aust N Z J Psychiatry** 1996 Dec;30(6):864–6

Acute pancreatitis complicating a bone marrow harvest. Beamish N, et al. **Bone Marrow Transplant** 1997 Mar; 19(5):525–6

Respiratory depression after low-dose caudal morphine. Karl HW, et al. **Can J Anaesth** 1996 Oct;43(10):1065–7

Terbutaline inhalation suppresses fentanyl-induced coughing. Lui PW, et al. **Can J Anaesth** 1996 Dec;43(12):1216–9

Respiratory arrest precipitated by codeine in a child with chronic renal failure. Talbott GA, et al. **Clin Pediatr (Phila)** 1997 Mar;36(3):171–3

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Yuan CS, et al. **Clin Pharmacol Ther** 1997 Apr; 61(4):467–75

Comparison of metoclopramide and ondansetron for the prevention of nausea and vomiting after intrathecal morphine. Pitkänen MT, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):172–7

Muscle rigidity causing life-threatening hypercapnia following fentanyl administration in a premature infant [letter] Lemmen RJ, et al. **Eur J Pediatr** 1996 Dec; 155(12):1067

Chronic inhibition of intracellular Ca2+ release or protein kinase C activation significantly reduces the development of morphine dependence. Fundytus ME, et al. **Eur J Pharmacol** 1996 Apr 11;300(3):173–81

Serotonin syndrome attributed to tramadol addition to paroxetine therapy. Egberts AC, et al. **Int Clin Psychopharmacol** 1997 May;12(3):181–2

Effect of epidural buprenorphine and clonidine on vesical functions in women. Batra YK, et al. **Int J Clin Pharmacol Ther** 1996 Jul;34(7):309–11

Opioid therapy and chronic low back pain [letter; comment] Troncale JA. **J Am Board Fam Pract** 1996 Sep-Oct; 9(5):386; discussion 387–8. Comment on: J Am Board Fam Pract 1996 May-Jun;9(3):191–204. Comment on: J Am Board Fam Pract 1996 May-Jun;9(3):225–8.

Local opioid withdrawal in rat single periaqueductal gray neurons in vitro. Chieng B, et al. **J Neurosci** 1996 Nov 15;16(22):7128–36

Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. Devulder J. **J Neurosurg Anesthesiol** 1997 Apr;9(2):146–8

The ethics of death-hastening or death-causing palliative analgesic administration to the terminally ill [see comments] Cavanaugh TA. **J Pain Symptom Manage** 1996 Oct; 12(4):248–54 (18 ref.). Comment in: J Pain Symptom Manage 1997 Jul;14(1):2. Comment in: J Pain Symptom Manage 1997 Jul;14(1):2–4.

Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines. Dunteman E, et al. **J Pain Symptom Manage** 1996 Oct;12(4):255–60

Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. Hagen N, et al. **J Pain Symptom Manage** 1997 Jul;14(1):51–8

Can transdermal fentanyl cause diarrhea? [letter] Hardy JR, et al. **J Pain Symptom Manage** 1997 Apr;13(4):188–9

Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. Maddocks I, et al. **J Pain Symptom Manage** 1996 Sep;12(3):182–9

Compartment syndrome associated with bupivacaine and fentanyl epidural analgesia in pediatric orthopaedics [see comments] Dunwoody JM, et al. **J Pediatr Orthop** 1997 May-Jun;17(3):285–8. Comment in: J Pediatr Orthop 1997 May-Jun;17(3):282–4.

Compartment syndromes and epidural analgesia [editorial; comment] Mubarak SJ, et al. **J Pediatr Orthop** 1997 May-Jun;17(3):282–4 (9 ref.). Comment on: J Pediatr Orthop 1997 May-Jun;17(3):285–8.

Polymyositis developing after prolonged injections of pentazocine. Kim HA, et al. **J Rheumatol** 1996 Sep; 23(9):1644–6

Pica behavior associated with buprenorphine administration in the rat. Clark JA Jr, et al. **Lab Anim Sci** 1997 Jun; 47(3):300–3

Comparison of effect of an anti-inflammatory drug and a narcotic analgesic on renal function in sickle cell anemia [letter] Paydas S, et al. **Nephron** 1996;73(3):498

Opiate modulation of striatal dopamine and hippocampal norepinephrine release following morphine withdrawal. Grasing K, et al. **Neurochem Res** 1997 Mar;22(3):239–48

The use of ondansetron to treat pruritus associated with intrathecal morphine in two paediatric patients. Arai L, et al. **Paediatr Anaesth** 1996;6(4):337–9

Respiratory depression following epidural morphine in an infant of three months of age. Vilà R, et al. **Paediatr Anaesth** 1997;7(1):61–4

Respiratory depression following administration of low dose buprenorphine as postoperative analgesic after fentanyl balanced anaesthesia. Zanette G, et al. **Paediatr Anaesth** 1996;6(5):419–22

Respiratory depression following oral tramadol in a patient with impaired renal function. Barnung SK, et al. **Pain** 1997 May;71(1):111–2

Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Bruera E, et al. **Pain** 1997 Jan; 69(1-2):199–201

A case of uncommon withdrawal symptoms after a short period of spinal morphine administration. Devulder J, et al. **Pain** 1996 Mar;64(3):589–91

Effect of transient naloxone antagonism on tolerance development in rats receiving continuous spinal morphine infusion. Ibuki T, et al. **Pain** 1997 Apr;70(2-3):125–32

Acute neurotoxicity of meperidine in an infant. Saneto RP, et al. **Pediatr Neurol** 1996 May;14(4):339–41

Blockade of morphine-induced hindlimb myoclonic seizures in mice by ketamine. Kolesnikov Y, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):423–5

Involvement of delta 1 and delta 2 opioid receptor subtypes in the development of physical dependence on morphine in mice. Suzuki T, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):293–9

Withdrawal syndrome is not precipitated when butorphanol is added to opiate or opioid therapy. A comment on intranasal butorphanol-induced apraxia reversed by naloxone [comment] Barkin RL. **Pharmacotherapy** 1996 Sep-Oct;16(5):969. Comment on: Pharmacotherapy 1995 Nov-Dec;15(6):798–800.

Treatment of opioid-induced pruritus with ondansetron: report of four patients. Larijani GE, et al. **Pharmacotherapy** 1996 Sep-Oct;16(5):958–60

Fetal bradycardia and uterine hyperactivity following subarachnoid administration of fentanyl during labor. Friedlander JD, et al. **Reg Anesth** 1997 Jul-Aug; 22(4):378–81

Inhibition of epidural morphine-induced pruritus by intravenous droperidol. The effect of increasing the doses of morphine and of droperidol. Horta ML, et al. **Reg Anesth** 1996 Jul-Aug;21(4):312–7

Opioid effects and adverse effects. Lema MJ. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):38–42 (24 ref.)

Monitoring opioids. Mulroy MF. **Reg Anesth** 1996 Nov-Dec; 21(6 Suppl):89–93 (27 ref.)

Respiratory depression in a child unintentionally exposed to transdermal fentanyl patch. Hardwick WE Jr, et al. **South Med J** 1997 Sep;90(9):962–4

Meperidine-induced generalized seizures with normal renal function. Marinella MA. **South Med J** 1997 May; 90(5):556–8

Seizure after overdose of tramadol. Tobias JD. **South Med J** 1997 Aug;90(8):826–7

Galactorrhoea induced by a pharmacodynamic interaction between citalopram, alprazolam and tramadol: a case report [letter] Bondolfi G, et al. **Therapie** 1997 Jan-Feb;52(1):76–7

[Dependence after treatment with tramadol] Jensen JB. **Ugeskr Laeger** 1997 Feb 3;159(6):785 **(Dan)**

[Interaction between tramadol and oral anticoagulants] Jensen K. **Ugeskr Laeger** 1997 Feb 3;159(6):785–6 **(Dan)**

[Neurotoxicity of intrathecally administrated agents] Malinovsky JM, et al. **Ann Fr Anesth Reanim** 1996; 15(5):647–58 (128 ref.) (Eng. Abstr.) **(Fre)**

[Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance] Cossmann M, et al. **Drugs** 1997;53 Suppl 2:50–62 (68 ref.) (Eng. Abstr.) **(Fre)**

[Cardiorespiratory arrest following ingestion of morphine sulfate in a patient with chronic renal failure (letter)] Moreau K, et al. **Presse Med** 1997 May 3-10;26(15):713 **(Fre)**

[Pharmacoepidemiological study of methadone in a center of addiction management: adverse effects and combined drug consumption (letter)] Riotte C, et al. **Therapie** 1996 Sep-Oct;51(5):557–9 **(Fre)**

[Opioid intoxication. Inappropriate administration of transdermal fentanyl] Klockgether-Radke A, et al. **Anaesthesist** 1997 May;46(5):428–9 (Eng. Abstr.) **(Ger)**

[Treament of morphine-induced constipation with oral naloxone] Latasch L, et al. **Anaesthesist** 1997 Mar; 46(3):191–4 (Eng. Abstr.) **(Ger)**

[Epidural administration of opioids in labor: contra] Biscoping J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Apr; 32(4):256–7 **(Ger)**

[Myoclonus resulting from high-dose epidural and intravenous morphine infusion] Radbruch L, et al. **Med Klin** 1997 May 15;92(5):296–9 (Eng. Abstr.) **(Ger)**

[Practical problems associated with long-term opioid therapy] Bell RF. **Tidsskr Nor Laegeforen** 1997 May 10;

117(12):1786–7 (Eng. Abstr.) **(Nor)**

ANALYSIS

Evaluation of the online immunoassay for propoxyphene: comparison to EMIT II and GC–MS. McNally AJ, et al. **J Anal Toxicol** 1996 Nov–Dec;20(7):537–40

Determination of dihydroetorphine in biological fluids by gas chromatography–mass spectrometry using selected–ion monitoring. Liu F, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1–2):113–8

HPLC/MS determination of buprenorphine and norbuprenorphine in biological fluids and hair samples. Tracqui A, et al. **J Forensic Sci** 1997 Jan;42(1):111–4

Comparison of aqueous and non–aqueous capillary electrophoresis for quantitative determination of morphine in pharmaceuticals. Bjørnsdottir I, et al. **J Pharm Biomed Anal** 1997 May;15(8):1083–9

Profiling impurities and degradants of butorphanol tartrate using liquid chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry substructural techniques. Volk KJ, et al. **J Pharm Biomed Anal** 1996 Sep;14(12):1663–74

ANTAGONISTS & INHIBITORS

Ketamine attenuates and reverses morphine tolerance in rodents. Shimoyama N, et al. **Anesthesiology** 1996 Dec; 85(6):1357–66

Studies on the abstinence–like overshoot following reversal of the potent 19–isoamyl derivative of etorphine with naloxone. A comparison with the opioids fentanyl and alfentanil. Freye E, et al. **Arzneimittelforschung** 1997 Jan; 47(1):6–9

Reversal by naloxone of the spinal antinociceptive actions of a systemically–administered NSAID. Herrero JF, et al. **Br J Pharmacol** 1996 Jun;118(4):968–72

Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine. Singh L, et al. **Br J Pharmacol** 1996 Jul;118(5):1317–25

Opioid antagonists in the periaqueductal gray inhibit morphine and beta–endorphin analgesia elicited from the amygdala of rats. Pavlovic ZW, et al. **Brain Res** 1996 Nov 25;741(1–2):13–26

Neuropeptide FF receptors control morphine–induced analgesia in the parafascicular nucleus and the dorsal raphe nucleus. Dupouy V, et al. **Eur J Pharmacol** 1997 Jul 9; 330(2–3):129–37

Naloxonazine antagonism of levorphanol–induced antinociception and respiratory depression in rhesus monkeys [published erratum appears in Eur J Pharmacol 1996 Oct 3;312(3):389] Gatch MB, et al. **Eur J Pharmacol** 1996 Feb 29;298(1):31–6

Omega–agatoxin IVA blocks spinal morphine/clonidine antinociceptive synergism. Roerig SC, et al. **Eur J Pharmacol** 1996 Oct 31;314(3):293–300

Pretreatment with pertussis toxin blocks morphine– but not beta–endorphin–induced antinociception in the mouse. Tseng LF, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):345–8

Mirfentanil antagonizes morphine–induced suppression of splenic NK activity in mice. Carr DJ, et al. **Immunopharmacology** 1996 Aug;34(1):9–16

Efficacy and safety of naltrexone hydrochloride for antagonizing carfentanil citrate immobilization in captive Rocky Mountain elk (Cervus elaphus nelsoni). Miller MW, et al. **J Wildl Dis** 1996 Apr;32(2):234–9

Selective blockade of peripheral delta opioid agonist induced antinociception by intrathecal administration of delta receptor antisense oligodeoxynucleotide. Bilsky EJ, et al. **Neurosci Lett** 1996 Dec 20;220(3):155–8

Prolonged antagonism of morphine–induced locomotor stimulation by kappa opioid agonists: enhancement by prior morphine exposure. Pearl SM, et al. **Neurosci Lett** 1996 Jul 26;213(1):5–8

Excitatory amino acid antagonists in the rostral ventromedial medulla inhibit mesencephalic morphine analgesia in rats. Spinella M, et al. **Pain** 1996 Mar;64(3):545–52

Antagonism of morphine–like discriminative effects by beta–funaltrexamine. Holtzman SG. **Pharmacol Biochem Behav** 1997 Aug;57(4):771–7

Majonoside–R2, a major constituent of Vietnamese ginseng, attenuates opioid–induced antinociception. Huong NT, et al. **Pharmacol Biochem Behav** 1997 May–Jun; 57(1–2):285–91

Antagonistic effect of MR2266 and MR2267 on morphine or nalbuphine analgesia at the spinal levels in rats. Kmieciak–Kolada K, et al. **Pol J Pharmacol** 1995 Nov–Dec;47(6):509–18

BLOOD

Neonatal welfare and placental transfer of fentanyl and bupivacaine during ambulatory combined spinal epidural analgesia for labour. Fernando R, et al. **Anaesthesia** 1997 Jun;52(6):517–24

Morphine blood concentrations in elderly postoperative patients following administration via an indwelling subcutaneous cannula. Semple TJ, et al. **Anaesthesia** 1997 Apr;52(4):318–23

Changes of plasma dynorphin levels before and after percutaneous balloon mitral commissurotomy in patients with mitral stenosis. Yin R, et al. **Chin Med Sci J** 1995 Dec;10(4):214–9

Applicability of various brands of mixed–phase extraction columns for opiate extraction from blood and serum. Bogusz MJ, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30;683(2):177–88

Determination of nalbuphine in human plasma by high–performance liquid chromatography with electrochemical detection. Application to a pharmacokinetic study. de Cazanove F, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):203–10

Highly sensitive gas chromatographic–mass spectrometric method for morphine determination in plasma that is suitable for pharmacokinetic studies. Fryirs B, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):51–7

Determination of subnanogram concentrations of fentanyl in plasma by gas chromatography–mass spectrometry: comparison with standard radioimmunoassay. Fryirsa B, et al. **J Chromatogr B Biomed Appl** 1997 Jan 10;688(1):79–85

Determination of tramadol in human plasma by capillary gas chromatography–mass spectrometry using solid–phase extraction. Merslavic M, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):222–7

Modified method of nalbuphine determination in plasma: validation and application to pharmacokinetics of the rectal route. Nicolle E, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):89–97

High–performance liquid chromatographic determination of tramadol in human plasma. Nobilis M, et al. **J Chromatogr B Biomed Appl** 1996 May 31;681(1):177–83

Determination of morphine and codeine in plasma by HPLC following solid phase extraction. Freiermuth M, et al. **J Pharm Biomed Anal** 1997 Mar;15(6):759–64

Determination of remifentanil, an ultra–short–acting opioid anesthetic, in rat blood by high performance liquid chromatography with ultraviolet detection. Haidar SH, et al. **J Pharm Biomed Anal** 1996 Sep;14(12):1727–32

A sensitive assay for the simultaneous measurement of alfentanil and fentanyl in plasma. Kumar K, et al. **J Pharm Biomed Anal** 1996 Apr;14(6):667–73

Stereoselective determination of methadone in serum by HPLC following solid–phase extraction on disk. Rudaz S, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1271–9

Morphine, morphine–6–glucuronide, and morphine–3–glucuronide in cerebrospinal fluid and plasma after epidural administration of morphine. Kalman S, et al. **Reg Anesth** 1997 Mar–Apr;22(2):131–6

[Systematic analysis of basic drugs in plasma using X–5 solid–phase extraction GC–FID and GC–MS] Qiu FH, et al. **Yao Hsueh Hsueh Pao** 1996;31(4):296–9 (Eng. Abstr.) **(Chi)**

CEREBROSPINAL FLUID

Cerebrospinal fluid distribution of opioids after intraventricular & lumbar subarachnoid administration in sheep. Payne R, et al. **Life Sci** 1996;59(16):1307–21

Morphine, morphine–6–glucuronide, and morphine–3–glucuronide in cerebrospinal fluid and plasma after epidural administration of morphine. Kalman S, et al. **Reg Anesth** 1997 Mar–Apr;22(2):131–6

CHEMICAL SYNTHESIS

Synthesis and analgesic effects of 3–substituted 4,6–diarylpyridazine derivatives of the arylpiperazine class. Rohet F, et al. **Bioorg Med Chem** 1997 Apr;5(4):655–9

Synthesis and pharmacological activity of deltorphin and dermorphin–related glycopeptides. Tomatis R, et al. **J Med Chem** 1997 Aug 29;40(18):2948–52

Neoglycopeptide synthesis and purification in multi–gram scale: preparation of O–(2,3,4,6–tetra–O–acetyl–beta–D–galactopyranosyl)–N alpha–fluoren–9–yl–methoxycarbonyl–hydroxyproline and its use in the pilot–scale synthesis of the potent analgesic glycopeptide O1.5–beta–D–galactopyranosyl [DMet2, Hyp5]enkephalinamide. Torres JL, et al. **J Pept Sci** 1997 Mar–Apr;3(2):99–109

CHEMISTRY

Compatibility of ketamine hydrochloride and meperidine hydrochloride [letter] Ambados F. **Am J Health Syst Pharm** 1997 Jan 15;54(2):205

21–day compatibility of hydromorphone hydrochloride and promethazine hydrochloride in a cassette [letter] Henderson F. **Am J Health Syst Pharm** 1996 Oct 1; 53(19):2338–9

Compatibility of bupivacaine hydrochloride and morphine sulfate. Johnson CE, et al. **Am J Health Syst Pharm** 1997 Jan 1;54(1):61–4

Stability of cefazolin sodium and meperidine hydrochloride [letter] Lee DK, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1608, 1610

Densities of dextrose–free intrathecal local anesthetics, opioids, and combinations measured at 37 degrees C. Richardson MG, et al. **Anesth Analg** 1997 Jan;84(1):95–9

Rapid loss of fentanyl citrate admixed with fluorouracil in polyvinyl chloride containers. Xu QA, et al. **Ann Pharmacother** 1997 Mar;31(3):297–302

Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride. Xu QA, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):756–61

Molecular mechanics calculations of opioid ligands of the 4–arylpiperidine class [published erratum appears in Indian J Biochem Biophys 1996 Dec;33(6):534–7] Kamath S, et al. **Indian J Biochem Biophys** 1996 Oct;33(5):391–7

Stability of high–dose morphine chloride injection upon heat sterilization: comparison of UV–spectroscopy and HPLC. Steger PJ, et al. **J Clin Pharm Ther** 1996 Apr;21(2):73–8

Conformationally constrained deltorphin analogs with 2–aminotetralin–2–carboxylic acid in position 3. Tóth G, et al. **J Med Chem** 1997 Mar 14;40(6):990–5

[Endomorphins in pain relief. New endogenous peptides a sensational discovery] Nyberg F. **Lakartidningen** 1997 Sep 3;94(36):3019–21 (15 ref.) **(Swe)**

IMMUNOLOGY

Production and characterization of site–directed antibodies against dermorphin and dermorphin–related peptides. Cucumel K, et al. **Peptides** 1996;17(6):973–82

ISOLATION & PURIFICATION

Neoglycopeptide synthesis and purification in multi–gram scale: preparation of O–(2,3,4,6–tetra–O–acetyl–beta–D–galactopyranosyl)–N alpha–fluoren–9–yl–methoxycarbonyl–hydroxyproline and its use in the pilot–scale synthesis of the potent analgesic glycopeptide O1.5–beta–D–galactopyranosyl [DMet2, Hyp5]enkephalinamide. Torres JL, et al. **J Pept Sci** 1997 Mar–Apr;3(2):99–109

A potent and selective endogenous agonist for the mu–opiate receptor [see comments] Zadina JE, et al. **Nature** 1997 Apr 3;386(6624):499–502. Comment in: Nature 1997 Apr 3;386(6624):442.

METABOLISM

Remifentanil and cholinesterase [letter; comment] Djaiani G. **Anaesthesia** 1997 Jul;52(7):714. Comment on: Anaesthesia 1997 Mar;52(3):244–60.

Remifentanil [editorial; comment] Smith MA, et al. **Anaesthesia** 1997 Apr;52(4):291–3. Comment on: Anaesthesia 1997 Apr;52(4):307–17.

Fentanyl and alfentanil plasma protein binding in preterm and term neonates. Wilson AS, et al. **Anesth Analg** 1997 Feb;84(2):315–8

Attenuation of c–Fos expression in the rat lumbosacral spinal cord by morphine or tramadol following noxious colorectal distention. Traub RJ, et al. **Brain Res** 1995 Dec 1; 701(1–2):175–82

Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Feierman DE, et al. **Drug Metab Dispos** 1996 Sep;24(9):932–9

Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds. King CD, et al. **Drug Metab Dispos** 1997 Feb;25(2):251–5

Codeine disposition in human hair after single and multiple doses. Rollins DE, et al. **Eur J Clin Pharmacol** 1996; 50(5):391–7

Quantitative autoradiography of peripheral opioid binding sites in rat lung. Cabot PJ, et al. **Eur J Pharmacol** 1996 Aug 22;310(1):47–53

Comparison of binding parameters of sigma 1 and sigma 2 binding sites in rat and guinea pig brain membranes: novel subtype–selective trishomocubanes. Nguyen VH, et al. **Eur J Pharmacol** 1996 Sep 12;311(2–3):233–40

A gas chromatographic–positive ion chemical ionization–mass spectrometric method for the determination of I–alpha–acetylmethadol (LAAM), norLAAM, and dinorLAAM in plasma, urine, and tissue. Moody DE, et al. **J Anal Toxicol** 1995 Oct;19(6):343–51

Receptor–induced internalization of selective peptidic mu and delta opioid ligands. Gaudriault G, et al. **J Biol Chem** 1997 Jan 31;272(5):2880–8

High–performance liquid chromatographic assay for the simultaneous determination of tramadol and its metabolites in microsomal fractions of human liver. Paar WD, et al. **J Chromatogr B Biomed Appl** 1996 Nov 15;686(2):221–7

Helix–inducing alpha–aminoisobutyric acid in opioid mimetic deltorphin C analogues. Bryant SD, et al. **J Med Chem** 1997 Aug 1;40(16):2579–87

Increased mu opioid receptor binding detected by PET in cocaine–dependent men is associated with cocaine craving. Zubieta JK, et al. **Nat Med** 1996 Nov;2(11):1225–9

[3H]1,3–di(2–tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Bouchard P, et al. **Neuroscience** 1997 Jan;76(2):467–77

The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3–dimethylamino–1,1–diphenylbutene. Kristensen K, et al. **Pharmacol Toxicol** 1996 Aug;79(2):103–4

PHARMACOKINETICS

Pharmacokinetics of piritramide after an intravenous bolus in surgical patients. Kietzmann D, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):898–903

Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Takala A, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):309–12

Opioid drug disposition. Müller CM. **Acta Anaesthesiol Scand Suppl** 1996;109:102–3

Remifentanil and pulmonary extraction during and after cardiac anesthesia. Duthie DJ, et al. **Anesth Analg** 1997 Apr;84(4):740–4

The placental transfer of sufentanil: effects of fetal pH, protein binding, and sufentanil concentration. Johnson RF,

et al. **Anesth Analg** 1997 Jun;84(6):1262–8
Effect of midazolam on development of acute tolerance to alfentanil: the role of pharmacokinetic interactions. Kissin I, et al. **Anesth Analg** 1997 Jul;85(1):182–7
Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Hoke JF, et al. **Anesthesiology** 1997 Sep; 87(3):533–41
Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Kharasch ED, et al. **Anesthesiology** 1997 Jul;87(1):26–35
Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Minto CF, et al. **Anesthesiology** 1997 Jan;86(1):10–23
The cerebral pharmacokinetics of meperidine and alfentanil in conscious sheep. Upton RN, et al. **Anesthesiology** 1997 Jun;86(6):1317–25
Site-specific pharmacokinetics and pharmacodynamics of intramuscular meperidine in elderly postoperative patients. Erstad BL, et al. **Ann Pharmacother** 1997 Jan;31(1):23–8
Pharmacokinetics and drug input characteristics for a diclofenac–codeine phosphate combination following oral and rectal administration. Hanses A, et al. **Arzneimittelforschung** 1996 Jan;46(1):57–63
Transdermal prodrug concepts: permeation of buprenorphine and its alkyl esters through hairless mouse skin and influence of vehicles. Imoto H, et al. **Biol Pharm Bull** 1996 Feb;19(2):263–7
Combination effects of alpha–cyclodextrin and xanthan gum on rectal absorption and metabolism of morphine from hollow–type suppositories in rabbits. Kondo T, et al. **Biol Pharm Bull** 1996 Feb;19(2):280–6
The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans. Vachharajani NN, et al. **Biopharm Drug Dispos** 1997 Apr; 18(3):191–202
The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. Barrett DA, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):215–9
Characterization and validation of a pharmacokinetic model for controlled–release oxycodone. Mandema JW, et al. **Br J Clin Pharmacol** 1996 Dec;42(6):747–56
Dose dependent time course of the analgesic effect of a sustained–release preparation of tramadol on experimental phasic and tonic pain. Thürauf N, et al. **Br J Clin Pharmacol** 1996 Feb;41(2):115–23
Opioid analgesics. Rushton AR, et al. **Br J Hosp Med** 1997 Feb 5–18;57(3):105–6 (10 ref.)
Pharmacokinetics of opioids in renal dysfunction. Davies G, et al. **Clin Pharmacokinet** 1996 Dec;31(6):410–22 (93 ref.)
Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Scholz J, et al. **Clin Pharmacokinet** 1996 Oct;31(4):275–92 (136 ref.)
Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine–6–glucuronide in healthy volunteers. Lötsch J, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):316–25
The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment. Vachharajani NN, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):283–94
The effect of food intake on the pharmacokinetics of sustained–release morphine sulfate capsules. Kaiko RF. **Clin Ther** 1997 Mar–Apr;19(2):296–303
Steady–state bioavailability of controlled–release oxycodone in normal subjects. Reder RF, et al. **Clin Ther** 1996 Jan–Feb;18(1):95–105
The pharmacokinetics and extra–hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions. Chism JP, et al. **Drug Metab Dispos** 1996 Jan;24(1):34–40
The influence of surgery and anaesthesia on the pharmacokinetics of pethidine in the horse. Waterman AE, et al. **Equine Vet J Suppl** 1992 Feb;(11):56–8
Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. Borenstein M, et al. **Eur J Clin Pharmacol** 1997;51(5):359–66
Replacement of (R)–methadone by a double dose of (R,S)–methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eap CB, et al. **Eur J Clin Pharmacol** 1996;50(5):385–9
Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Poulsen L, et al. **Eur J Clin Pharmacol** 1996; 51(3–4):289–95
Tramadol distribution in four postmortem cases. Levine B, et al. **Forensic Sci Int** 1997 Apr 18;86(1–2):43–8
Pharmacokinetics of intrarectal nalbuphine in children undergoing general anaesthesia. Bessard G, et al. **Fundam Clin Pharmacol** 1997;11(2):133–7
Intratracheal administration of fentanyl: pharmacokinetics and local tissue effects. Irazuzta JE, et al. **Intensive Care Med** 1996 Feb;22(2):129–33
Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. Kuhlman JJ Jr, et al. **J Anal Toxicol** 1996 Oct;20(6):369–78
Gas chromatographic–mass spectrometry and gas chromatographic–Fourier transform infrared spectroscopy assay for the simultaneous identification of fentanyl metabolites. Guitton J, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):59–70
High–performance liquid chromatographic determination of tramadol in human plasma. Nobilis M, et al. **J Chromatogr B Biomed Appl** 1996 May 31;681(1):177–83
The pharmacokinetics of remifentanil. Michelsen LG, et al. **J Clin Anesth** 1996 Dec;8(8):679–82 (16 ref.)
Pharmacokinetic and pharmacodynamic interactions between opioids and propofol. Vuyk J. **J Clin Anesth** 1997 Sep;9(6 Suppl):23S–26S (13 ref.)
Rectal controlled–release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg. Campbell WI. **J Clin Pharm Ther** 1996 Apr;21(2):65–71
Bioavailability of sublingual buprenorphine. Mendelson J, et al. **J Clin Pharmacol** 1997 Jan;37(1):31–7
Pharmacokinetics of meperidine in healthy volunteers after short– and long–term exposure to high altitude. Ritschel WA, et al. **J Clin Pharmacol** 1996 Jul;36(7):610–6
A pharmacokinetic/pharmacodynamic study of controlled–release oxycodone. Benziger DP, et al. **J Pain Symptom Manage** 1997 Feb;13(2):75–82
Excretion of ketobemidone in human breast milk. Gerdin E, et al. **J Perinat Med** 1996;24(3):293–5
A pharmacokinetic study of sublingual aerosolized morphine in healthy volunteers. Watson NW, et al. **J Pharm Pharmacol** 1996 Dec;48(12):1256–9
Differential effects of food on the bioavailability of controlled–release oxycodone tablets and immediate–release oxycodone solution. Benziger DP, et al. **J Pharm Sci** 1996 Apr;85(4):407–10
Influence of Escherichia coli endotoxin on the pharmacokinetics and respiratory depressant effect of alfentanil in rabbits. Björkman S, et al. **J Pharm Sci** 1996 Jul;85(7):680–4
Intranasal absorption of oxymorphone. Hussain MA, et al. **J Pharm Sci** 1997 Aug;86(8):975–6
Pulmonary distribution of alfentanil and sufentanil studied with system dynamics analysis. Boer F, et al. **J Pharmacokinet Biopharm** 1996 Apr;24(2):197–218
Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. Hoke JF, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):226–32
Disposition of morphine in the rat isolated perfused kidney: concentration ranging studies. Shanahan KM, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1518–25
Pharmacokinetics of epidural butorphanol in isoflurane–anaesthetized dogs. Troncy E, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):268–73
Recommended use of morphine in neonates, infants and children based on a literature review: Part 1––Pharmacokinetics. Kart T, et al. **Paediatr Anaesth** 1997; 7(1):5–11 (38 ref.)
Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA. Dunbar PJ, et al. **Pain** 1996 Dec;68(2–3):265–70
Loss of analgesic effect of morphine due to coadministration of rifampin. Fromm MF, et al. **Pain** 1997 Aug;72(1–2):261–7
The effect of old age on the disposition and antinociceptive response of morphine and morphine–6 beta–glucuronide in the rat. Van Crugten JT, et al. **Pain** 1997 Jun; 71(2):199–205
Problems of sweating and transdermal fentanyl [letter] Catterall RA. **Palliat Med** 1997 Mar;11(2):169–70
Diminished effect of transdermal fentanyl in the terminal phase? [letter] Davies A, et al. **Palliat Med** 1997 Mar; 11(2):168–9
Dextromoramide pharmacokinetics following sublingual administration. Jones TE, et al. **Palliat Med** 1996 Oct; 10(4):313–7
Comparison of the disposition of hepatically–generated morphine–3–glucuronide and morphine–6–glucuronide in isolated perfused liver from the guinea pig. Milne RW, et al. **Pharm Res** 1997 Aug;14(8):1014–8
Fentanyl pharmacokinetics in patients undergoing renal transplantation. Koehntop DE, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):746–52
Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. Bertschy G, et al. **Ther Drug Monit** 1996 Oct;18(5):570–2
Stereoselective pharmacokinetics of methadone in chronic pain patients. Kristensen K, et al. **Ther Drug Monit** 1996 Jun;18(3):221–7
Remifentanil: an esterase–metabolized opioid. Egan TD. **West J Med** 1997 Mar;166(3):202

PHARMACOLOGY

Haemodynamic interaction of high–dose fentanyl and increasing doses of vecuronium in patients undergoing myocardial revascularization. Couture P, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):32–8
NMDA receptor antagonists: interactions with opioids. Dickenson AH. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):112–5
Effects of pH and buffer capacity modulation on the analgesic efficacy of lignocaine and pethidine solutions. Dyhre H, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):86–90
Effects of subarachnoid lidocaine, meperidine and fentanyl on somatosensory and motor evoked responses in awake humans. Fernandez–Galinski SM, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):39–46
Opioids in the brain: supraspinal mechanisms in pain control. Jensen TS. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):123–32 (61 ref.)
Pharmacokinetics and pharmacodynamics of controlled–release opioids. Kaiko RF. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):166–74
Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. Kietzmann D, et al. **Acta Anaesthesiol Scand** 1997 Aug;41(7):888–94
Is sufentanil a useful opioid for laryngomicroscopy? Steinfath M, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):883–8
Myoelectric activity in the stomach and duodenum after epidural administration of morphine or bupivacaine. Thörn SE, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):773–8
Pharmacology and mechanisms of opioid analgesic activity. Yaksh TL. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):94–111 (183 ref.)
A comparison of lidocaine, fentanyl, and esmolol for attenuation of cardiovascular response to laryngoscopy and tracheal intubation. Feng CK, et al. **Acta Anaesthesiol Sin** 1996 Jun;34(2):61–7
Paw pressure test in the rabbit: a new animal model for the study of pain. Hu OY, et al. **Acta Anaesthesiol Sin** 1996 Mar;34(1):1–8
Effects of morphine and naloxone on cerebral blood flow and metabolism in experimental subarachnoid hemorrhage. Hauerberg J, et al. **Acta Neurol Scand** 1997 Sep; 96(3):187–93
Peptide and nonpeptide ligands for opioid receptors. Misicka A. **Acta Pol Pharm** 1995 Sep–Oct;52(5):349–63 (128 ref.)
Morphine affects the brain–immune axis by modulating an interleukin–1 beta dependent pathway. Chang SL, et al. **Adv Exp Med Biol** 1996;402:35–42 (34 ref.)
On the evolution of opioid mechanisms and immune defenses. Renaud FL, et al. **Adv Exp Med Biol** 1996;402:63–9
The effect of ethanol drinking on opioid analgesia and receptors in mice. Shah S, et al. **Alcohol** 1997 Jul–Aug; 14(4):361–6
Effects of a carfentanil–xylazine combination on cardiopulmonary function and plasma catecholamine concentrations in female bongo antelopes. Schumacher J, et al. **Am J Vet Res** 1997 Feb;58(2):157–61
Evaluation of analgesia and cardiorespiratory effects of epidurally administered butorphanol in isoflurane–anesthetized dogs. Troncy E, et al. **Am J Vet Res** 1996 Oct;57(10):1478–82
Fentanyl and the interleukin–6 response to surgery. Taylor NM, et al. **Anaesthesia** 1997 Feb;52(2):112–5
Regional brain activity changes associated with fentanyl analgesia elucidated by positron emission tomography [published erratum appears in Anesth Analg 1997 May;84(5):949] Adler LJ, et al. **Anesth Analg** 1997 Jan; 84(1):120–6
Does dextrose affect analgesia or the side effects of intrathecal sufentanil? Gage JC, et al. **Anesth Analg** 1997 Oct;85(4):826–30
The influence of three L–type calcium channel blockers on morphine effects in healthy volunteers. Hasegawa AE, et al. **Anesth Analg** 1997 Sep;85(3):633–8
Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses. Inagaki Y, et al. **Anesth Analg** 1997 Jan;84(1):100–5
A comparison of the local anesthetic effects of meperidine, fentanyl, and sufentanil on dorsal root axons. Jaffe RA, et al. **Anesth Analg** 1996 Oct;83(4):776–81
The effect of skull–pin insertion on cerebrospinal fluid pressure and cerebral perfusion pressure: influence of sufentanil and fentanyl. Jamali S, et al. **Anesth Analg** 1997 Jun;84(6):1292–6
Comparison of the time course of morphine's analgesic and immunologic effects. Nelson CJ, et al. **Anesth Analg** 1997 Sep;85(3):620–6
Influences of morphine on the ventilatory response to isocapnic hypoxia. Berkenbosch A, et al. **Anesthesiology** 1997 Jun;86(6):1342–9
A physiologic assessment of intrathecal amitriptyline in sheep. Cerda SE, et al. **Anesthesiology** 1997 May; 86(5):1094–103
Alfentanil, but not amitriptyline, reduces pain, hyperalgesia, and allodynia from intradermal injection of capsaicin in humans. Eisenach JC, et al. **Anesthesiology** 1997 Jun; 86(6):1279–87
Meperidine decreases the shivering threshold twice as much as the vasoconstriction threshold. Kurz A, et al. **Anesthesiology** 1997 May;86(5):1046–54
Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Minto CF, et al. **Anesthesiology** 1997 Jan;86(1):10–23
Nitric oxide synthase inhibition modulates the ventilatory depressant and antinociceptive actions of fourth ventricular infusions of morphine in the awake dog. Pelligrino DA, et al. **Anesthesiology** 1996 Dec;85(6):1367–77
The effect of opioids on thermoregulatory responses in humans and the special antishivering action of meperidine. Ikeda T, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:792–8
Site–specific pharmacokinetics and pharmacodynamics of intramuscular meperidine in elderly postoperative patients. Erstad BL, et al. **Ann Pharmacother** 1997 Jan;31(1):23–8
Influence of tramadol on neurotransmitter systems of the rat brain. Frink MC, et al. **Arzneimittelforschung** 1996 Nov; 46(11):1029–36
Premedication with the opioid analgesic butorphanol raises the threshold for ischemic preconditioning in dogs.

Schwartz LM, et al. **Basic Res Cardiol** 1997 Apr; 92(2):106–14

Effects of the kappa-opioid dynorphin A(1–13) on learning and memory in mice. Ukai M, et al. **Behav Brain Res** 1997 Feb;83(1–2):169–72

The endogenous mu-opioid receptor agonists endomorphins 1 and 2 have novel hypotensive activity in the rabbit. Champion HC, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):567–70

Antinociceptive effect of dihydroetorphine following various routes of administration: a comparative study with morphine. Tokuyama S, et al. **Biol Pharm Bull** 1996 Mar; 19(3):477–9

Does intrathecal fentanyl produce acute cross-tolerance to i.v. morphine? Cooper DW, et al. **Br J Anaesth** 1997 Mar; 78(3):311–3

Synergistic interactions between midazolam and alfentanil in isolated neonatal rat spinal cord. Feng J, et al. **Br J Anaesth** 1996 Sep;77(3):375–80

Extradural buprenorphine suppresses breast feeding after caesarean section. Hirose M, et al. **Br J Anaesth** 1997 Jul; 79(1):120–1

Effects of fentanyl, nitrous oxide, or both, on baroreceptor reflex regulation in the cat. Lennander O, et al. **Br J Anaesth** 1996 Sep;77(3):399–403

Psychophysical and electrophysiological responses to experimental pain may be influenced by sedation: comparison of the effects of a hypnotic (propofol) and an analgesic (alfentanil). Petersen-Felix S, et al. **Br J Anaesth** 1996 Aug;77(2):165–71

Effects of acute administration of morphine on right atrial catecholamine content and heart rate in chronically morphine-treated rats. Rabadan JV, et al. **Br J Anaesth** 1997 Apr;78(4):439–41

Effects of alfentanil on cerebral haemodynamics in an experimental model of traumatic brain injury. Souter MJ, et al. **Br J Anaesth** 1997 Jul;79(1):97–102

Alfentanil-mediated analgesia during propofol injection: no evidence for a peripheral action. Wrench IJ, et al. **Br J Anaesth** 1996 Aug;77(2):162–4

Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. Barrett DA, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):531–7

Contribution of monoaminergic modulation to the analgesic effect of tramadol. Desmeules JA, et al. **Br J Clin Pharmacol** 1996 Jan;41(1):7–12

The analgesic tramadol has minimal effect on gastrointestinal motor function. Wilder-Smith CH, et al. **Br J Clin Pharmacol** 1997 Jan;43(1):71–5

Effects of competitive and noncompetitive antagonists of the N-methyl-D-aspartate receptor on the analgesic action of delta 1- and delta 2-opioid receptor agonists in mice. Bharagava HN, et al. **Br J Pharmacol** 1996 Dec; 119(8):1586–90

Depression of A and C fibre-evoked segmental reflexes by morphine and clonidine in the in vitro spinal cord of the neonatal rat. Faber ES, et al. **Br J Pharmacol** 1997 Apr; 120(7):1390–6

The effect of pretreatment with a delta 2-opioid receptor antisense oligodeoxynucleotide on the recovery from acute antinociceptive tolerance to delta 2-opioid receptor agonist in the mouse spinal cord. Narita M, et al. **Br J Pharmacol** 1997 Feb;120(4):587–92

Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Tian JH, et al. **Br J Pharmacol** 1997 Feb;120(4):676–80

Potentiation of fentanyl suppression of the jaw-opening reflex by transcranial electrical stimulation. Alantar A, et al. **Brain Res** 1997 Jul 18;763(1):14–20

Neuropeptide FF in the VTA blocks the analgesic effects of both intra-VTA morphine and exposure to stress. Altier N, et al. **Brain Res** 1997 May 30;758(1–2):250–4

Modulation of morphine-induced antinociception by ibogaine and noribogaine. Bagal AA, et al. **Brain Res** 1996 Nov 25;741(1–2):258–62

Effects of N-methyl-D-aspartate receptor antagonists on the analgesia and tolerance to D-Ala2, Glu4 deltorphin II, a delta 2-opioid receptor agonist in mice. Bhargava HN, et al. **Brain Res** 1996 May 6;719(1–2):56–61

N(G)-nitro-L-arginine reverses L-arginine induced changes in morphine antinociception and distribution of morphine in brain regions and spinal cord of the mouse. Bhargava HN, et al. **Brain Res** 1997 Feb 28;749(2):351–3

Induction of Fos-like immunoreactivity by opioids in guinea-pig brain. Bot G, et al. **Brain Res** 1996 Aug 26; 731(1–2):45–56

Distribution of c-Fos in guinea-pig brain following morphine withdrawal. Chahl LA, et al. **Brain Res** 1996 Apr 22; 717(1–2):127–34

Etorphine elicits anomalous excitatory opioid effects on sensory neurons treated with GM1 ganglioside or pertussis toxin in contrast to its potent inhibitory effects on naive or chronic morphine-treated cells. Crain SM, et al. **Brain Res** 1996 Nov 25;741(1–2):275–83

Chronic escapable footshock causes a reduced response to morphine in rats as assessed by local cerebral metabolic rates. Gescuk BD, et al. **Brain Res** 1995 Dec 1; 701(1–2):279–87

When is the maximal effect of pre-administered systemic morphine on carrageenin evoked spinal c-Fos expression in the rat? Honoré P, et al. **Brain Res** 1995 Dec 24; 705(1–2):91–6

Alteration of local cerebral glucose utilization following intravenous administration of heroin in Fischer 344 rats. Martin TJ, et al. **Brain Res** 1997 May 2;755(2):313–8

Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia. Pick CG, et al. **Brain Res** 1997 Jan 2;744(1):41–6

Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: decrease in activity after chronic morphine treatment. Selley DE, et al. **Brain Res** 1997 Jan 23; 746(1–2):10–8

Galanin receptor antagonists attenuate spinal antinociceptive effects of DAMGO, tramadol and non-opioid drugs in rats. Selve N, et al. **Brain Res** 1996 Oct 7;735(2):177–87

Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Shen KF, et al. **Brain Res** 1997 May 23;757(2):176–90

Opioid stimulation in the ventral tegmental area facilitates the onset of maternal behavior in rats. Thompson AC, et al. **Brain Res** 1996 Dec 16;743(1–2):184–201

Opioids modulate N-methyl-D-aspartic acid (NMDA)-evoked responses of neurons in the superficial and deeper dorsal horn of the medulla (trigeminal nucleus caudalis). Zhang KM, et al. **Brain Res** 1996 May 6; 719(1–2):229–33

Effects of multiple intracerebroventricular injections of [D-Pen2,D-Pen5]enkephalin and [D-Ala2,Glu4]deltorphin II on tolerance to their analgesic action and on brain delta-opioid receptors. Zhao GM, et al. **Brain Res** 1997 Jan 16;745(1–2):243–7

Descending inhibition in neonatal rat spinal cord: actions of pentobarbital and morphine. Tarasiuk A, et al. **Brain Res Bull** 1996;41(1):39–45

Opiate effects on 5-fluorouracil disposition in mice. Li Y, et al. **Cancer Chemother Pharmacol** 1997;39(3):273–7

Alertness, cognition and morphine in patients with advanced cancer. Clemons M, et al. **Cancer Treat Rev** 1996 Nov; 22(6):451–68

Fetal movements following intrapartum maternal opiate administration. Farrell T, et al. **Clin Exp Obstet Gynecol** 1996;23(3):144–6

Concentration-effect relationships of morphine and morphine-6 beta-glucuronide in the rat. van Crugten JT, et al. **Clin Exp Pharmacol Physiol** 1997 May;24(5):359–64

Antinociceptive effects of the kappa-opioid receptor agonist RP 60180 compared with pentazocine in an experimental human pain model. Lötsch J, et al. **Clin Neuropharmacol** 1997 Jun;20(3):224–33

Kappa opioids: therapeutic considerations in epilepsy and CNS injury. Tortella FC, et al. **Clin Neuropharmacol** 1994 Oct;17(5):403–16 (77 ref.)

Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Mikus G, et al. **Clin Pharmacol Ther** 1997 Apr;61(4):459–66

The hypoalgesic effect of tramadol in relation to CYP2D6. Poulsen L, et al. **Clin Pharmacol Ther** 1996 Dec; 60(6):636–44

Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Tallgren M, et al. **Clin Pharmacol Ther** 1997 Jun;61(6):655–61

The effects of a cold-water immersion stressor on the reinforcing and subjective effects of fentanyl in healthy volunteers. Zacny JP, et al. **Drug Alcohol Depend** 1996 Oct; 42(2):133–42

Pharmacology and clinical experience with tramadol in osteoarthritis. Katz WA. **Drugs** 1996;52 Suppl 3:39–47 (49 ref.)

Interaction between Ukrain and morphine in their ten-day treatment in mice in the writhing syndrome test. Jagiello-Wojtowicz E, et al. **Drugs Exp Clin Res** 1996; 22(3–5):205–6

Antinociceptive effect of ten day administration of Ukrain in mice and interaction of the treatment with morphine. Jagiello-Wojtowicz E, et al. **Drugs Exp Clin Res** 1996; 22(3–5):201–3

Effects of chronic treatment with methadone and naltrexone on sleep in addicts. Staedt J, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(6):305–9

The effect of alfentanil on cerebrospinal fluid pressure in human volunteers. Pühringer F, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):211–4

Mechanisms of actions of opioids and non-steroidal anti-inflammatory drugs. Bovill JG. **Eur J Anaesthesiol Suppl** 1997 May;15:9–15 (42 ref.)

Assessment of analgesia in man: tramadol controlled release formula vs. tramadol standard formulation. Hummel T, et al. **Eur J Clin Pharmacol** 1996;51(1):31–8

MK-801 blocks the expression but not the development of tolerance to morphine in the isolated spinal cord of the neonatal rat. Bell JA, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):289–96

Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice. Bernardi M, et al. **Eur J Pharmacol** 1996 Feb 29; 298(1):51–5

The antinociceptive activity of kappa- but not delta-opioid receptor agonists is maintained in morphine-tolerant neuropathic rats. Catheline G, et al. **Eur J Pharmacol** 1996 Dec 30;318(2–3):273–81

(-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Chien CC, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):303–8

Neuropeptide FF receptors control morphine-induced analgesia in the parafascicular nucleus and the dorsal raphe nucleus. Dupouy V, et al. **Eur J Pharmacol** 1997 Jul 9; 330(2–3):129–37

Modulation of opioid analgesia by agmatine. Kolesnikov Y, et al. **Eur J Pharmacol** 1996 Jan 18;296(1):17–22

Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors. Reche I, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):11–6

Attenuation of memory with Tyr-D-Arg-Phe-beta-Ala-NH2, a novel dermorphin analog with high affinity for mu-opioid receptors. Ukai M, et al. **Eur J Pharmacol** 1995 Dec 20;287(3):245–9

Similar involvement of several brain areas in the antinociception of endogenous and exogenous opioids. Valverde O, et al. **Eur J Pharmacol** 1996 Sep 19; 312(1):15–25

Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at mu-opioid receptors. Wong CS, et al. **Eur J Pharmacol** 1996 Feb 15; 297(1–2):27–33

Nicotine potentiates morphine antinociception: a possible cholinergic mechanism. Zarrindast MR, et al. **Eur Neuropsychopharmacol** 1996 May;6(2):127–33

Sex differences in effects of predictable and unpredictable footshock on fentanyl self-administration in rats. Klein LC, et al. **Exp Clin Psychopharmacol** 1997 May;5(2):99–106

Effects of morphine microinjections into the trigeminal sensory complex on the formalin test in the rat. Duale C, et al. **Exp Neurol** 1996 Dec;142(2):331–9

Differences in epinephrine levels in rat brains after administered morphine. Anasiewicz A, et al. **Folia Morphol (Warsz)** 1996;55(4):204–5

Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Penagini R, et al. **Gastroenterology** 1997 Aug;113(2):409–14

Opioid effects on macrovascular dopamine release. Scholz S, et al. **Gen Comp Endocrinol** 1997 Feb;105(2):239–45

Enhancement of morphine actions in morphine-naive and morphine-tolerant mice by LY 235959, a competitive antagonist of the NMDA receptor. Bhargava HN. **Gen Pharmacol** 1997 Jan;28(1):61–4

Influence of opiate tolerance and calcium channel antagonists on the antinociceptive effects of L-arginine and NG-nitro L-arginine. Contreras E, et al. **Gen Pharmacol** 1997 Mar; 28(3):443–8

The dermorphin peptide family. Melchiorri P, et al. **Gen Pharmacol** 1996 Oct;27(7):1099–107 (95 ref.)

Caerulein may potentiate morphine-induced antinociception by cholecystokinin-A and/or cholecystokinin-B receptor mechanisms. Rezayat M, et al. **Gen Pharmacol** 1997 Feb; 28(2):337–40

The reduction of antinociceptive effect of morphine administered intraventricularly is correlated with the decrease of serotonin release from the spinal cord in streptozotocin-induced diabetic rats. Suh HW, et al. **Gen Pharmacol** 1996 Apr;27(3):445–50

Assessment of fetal well-being in methadone-maintained pregnancies: abnormal nonstress tests. Anyaegbunam A, et al. **Gynecol Obstet Invest** 1997;43(1):25–8

Felodipine potentiates morphine analgesia in control and streptozotocin diabetic female rats. Rani MA, et al. **Indian J Exp Biol** 1996 Jul;34(7):663–6

Involvement of dopaminergic mechanisms in racemate pentazocine induced stereotyped behaviour in rats. Bhosale BB, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):271–3

Exogenous gaseous superoxide potentiates the antinociceptive effect of opioid analgesic agents. Goldstein N, et al. **Inflamm Res** 1996 Sep;45(9):473–8

The analgesic drug buprenorphine inhibits osteoclastic bone resorption in vitro, but is proinflammatory in rat adjuvant arthritis. Hall TJ, et al. **Inflamm Res** 1996 Jun;45(6):299–302

Effect of mu-opioids morphine and buprenorphine on the development of adjuvant arthritis in rats. Walker JS, et al. **Inflamm Res** 1996 Nov;45(11):557–63

New opioid analgesics: an update. Minto CF, et al. **Int Anesthesiol Clin** 1997 Spring;35(2):49–65 (95 ref.)

Role of prolactin in the modulation of NK and LAK cell activity after short- or long-term morphine administration in neoplastic patients. Provinciali M, et al. **Int J Immunopharmacol** 1996 Oct;18(10):577–86

Cross-tolerance to acute administration of mu and kappa opioid agonists at the spinal cord level in the rat. Laurido C, et al. **Int J Neurosci** 1996 Nov;87(3–4):191–9

Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties. Schmidt R, et al. **Int J Pept Protein Res** 1996 Nov;48(5):411–9

Drug interactions: volatile anesthetics and opioids. Glass PS, et al. **J Clin Anesth** 1997 Sep;9(6 Suppl):18S–22S (18 ref.)

Pharmacodynamic evaluation of codeine using tooth pulp evoked potentials. Suri A, et al. **J Clin Pharmacol** 1996 Dec;36(12):1126–31

Methadone block of K+ current in squid giant fiber lobe neurons. Horrigan FT, et al. **J Gen Physiol** 1996 Feb; 107(2):243–60

Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. Tomatis R, et al. **J Med Chem** 1997 Aug 29;40(18):2948–52

Intracerebroventricular galanin and N-terminal galanin fragment enhance the morphine-induced analgesia in the rat. Przewłocka B, et al. **J Neural Transm Gen Sect** 1995; 102(3):229-35

Preparation and binding properties of radioiodinated analogues of dermorphin and deltorphin with high specificity for the mu- and delta-opioid receptors. Gaudriault G, et al. **J Neurochem** 1997 Feb;68(2):813-9

Monoamine metabolism in the locus coeruleus measured concurrently with behavior during opiate withdrawal: an in vivo microdialysis study in freely moving rats. Javelle N, et al. **J Neurochem** 1997 Feb;68(2):683-90

Opioid effects on 45Ca2+ uptake and glutamate release in rat cerebral cortex in primary culture. Vlaskovska M, et al. **J Neurochem** 1997 Feb;68(2):517-24

Potentiation of NMDA receptor-mediated responses by dynorphin at low extracellular glycine concentrations. Zhang L, et al. **J Neurophysiol** 1997 Aug;78(2):582-90

The effects of fentanyl and sufentanil on cerebral hemodynamics. Hänel F, et al. **J Neurosurg Anesthesiol** 1997 Jul;9(3):223-7

Opioid and opioid-like drug effects on whole-gut transit measured by scintigraphy. Maurer AH, et al. **J Nucl Med** 1996 May;37(5):818-22

Analgesic response to stress is reduced in perinatally undernourished rats. Gutiérrez AC, et al. **J Nutr** 1997 May; 127(5):765-9

Effect of intrathecal morphine on blood glucose, glucagon and tissue glycogen in rat: comparison with the effect of xanthan gum on blood glucose. el Daly ES. **J Pharm Belg** 1996 Jul-Aug;51(4):195-9

Reversible inhibition of cholinesterases by opioids: possible pharmacological consequences. Galli A, et al. **J Pharm Pharmacol** 1996 Nov;48(11):1164-8

Influence of plasma-protein binding on analgesic effect of methadone in rats with spontaneous withdrawal. Garrido MJ, et al. **J Pharm Pharmacol** 1996 Mar;48(3):281-4

Influence of Escherichia coli endotoxin on the pharmacokinetics and respiratory depressant effect of alfentanil in rabbits. Björkman S, et al. **J Pharm Sci** 1996 Jul;85(7):680-4

Chronic morphine treatment increases stimulatory beta-2 adrenoceptor signaling in A431 cells stably expressing the mu opioid receptor. Ammer H, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):512-20

Sex differences in opioid antinociception. Bartok RE, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):769-78

Mechanism of attenuation of morphine antinociception by chronic treatment with L-arginine. Bhargava HN, et al. **J Pharmacol Exp Ther** 1997 May;281(2):707-12

Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys. Butelman ER, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):934-8

Gender-related differences in the antinociceptive properties of morphine. Cicero TJ, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):767-73

Sex-related differences in morphine's antinociceptive activity: relationship to serum and brain morphine concentrations. Cicero TJ, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):939-44

Acute tolerance to spinally administered morphine compares mechanistically with chronically induced morphine tolerance. Fairbanks CA, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1408-17

Butorphanol-mediated antinociception in mice: partial agonist effects and mu receptor involvement. Garner HR, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1253-61

Changes in sensitivity to the rate-decreasing effects of opioids in pigeons treated acutely or chronically with l-alpha-acetylmethadol. Gerak LR, et al. **J Pharmacol Exp Ther** 1997 May;281(2):799-809

Enhancement of analgesia from systemic opioid in humans by spinal cholinesterase inhibition. Hood DD, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):86-92

Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin-B receptor antagonist in a rat model of peripheral neuropathy. Idänpään-Heikkilä JJ, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1366-72

Analgesia by dihydrocodeine is not due to formation of dihydromorphine: evidence from nociceptive activity in rat thalamus. Jurna I, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1164-70

Chronic morphine treatment of guinea pigs induces nonspecific sensitivity changes in the nucleus tractus solitarius in vitro. Malanga CJ, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):16-23

Chronic exposure to morphine increases corticosteroid-binding globulin. Nock B, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1262-8

Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. Ohtani M, et al. **J Pharmacol Exp Ther** 1997 Apr; 281(1):428-33

Pharmacodynamics and tolerance development during multiple intravenous bolus morphine administration in rats. Ouellet DM, et al. **J Pharmacol Exp Ther** 1997 May; 281(2):713-20

Ventilation in morphine-maintained rhesus monkeys. II: Tolerance to the antinociceptive but not the ventilatory effects of morphine. Paronis CA, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):355-62

Changes in opioid receptor density on murine splenocytes induced by in vivo treatment with morphine and methadone. Patrini G, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):172-6

Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. Picker MJ, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1130-41

Effects of chronic morphine treatment on catecholamines content and mechanical response in the rat hearts. Rabadán JV, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):32-7

Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6beta-glucuronide antinociception. Rossi GC, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):109-14

Dose-dependent pain-facilitatory and -inhibitory actions of neurotensin are revealed by SR 48692, a nonpeptide neurotensin antagonist: influence on the antinociceptive effect of morphine. Smith DJ, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):899-908

Early nociceptive events influence the temporal profile, but not the magnitude, of the tonic response to subcutaneous formalin: effects with remifentanil. Taylor BK, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):876-83

Structure-activity relationships of a series of [D-Ala2]deltorphin I and II analogues; in vitro blood-brain barrier permeability and stability. Thomas SA, et al. **J Pharmacol Exp Ther** 1997 May;281(2):817-25

Characterization of neonatal rat fentanyl tolerance and dependence. Thornton SR, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):514-21

Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse. Tseng LF, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):39-46

Body temperature and analgesic effects of selective mu and kappa opioid receptor agonists microdialyzed into rat brain. Xin L, et al. **J Pharmacol Exp Ther** 1997 Apr; 281(1):499-507

N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist. Xu JY, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):539-47

Comparing the subjective, psychomotor and physiological effects of intravenous nalbuphine and morphine in healthy volunteers. Zacny JP, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1159-69

Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. Zacny JP, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1187-97

An assessment of the peripheral antinociceptive potential of remoxipride, clonidine and fentanyl in sheep using the forelimb tourniquet. Main DC, et al. **J Vet Pharmacol Ther** 1997 Jun;20(3):220-8

Cardiopulmonary effects of carfentanil in dama gazelles (Gazella dama). Schumacher J, et al. **J Zoo Wildl Med** 1997 Jun;28(2):166-70

Intracisternal injection of opioids induces itch-associated response through mu-opioid receptors in mice. Tohda C, et al. **Jpn J Pharmacol** 1997 May;74(1):77-82

A potent mu-opioid receptor agonist, dihydroetorphine, fails to produce the conditioned place preference in mice. Tokuyama S, et al. **Jpn J Pharmacol** 1996 Aug;71(4):357-60

Role of atrial natriuretic factor, hemodynamic changes and renal nerves in the renal effects of intraperitoneal morphine in conscious rats. Flores O, et al. **Kidney Blood Press Res** 1997;20(1):18-24

Interaction between tramadol and phenprocoumon [letter] Madsen H, et al. **Lancet** 1997 Aug 30;350(9078):637

Interactions between different antidepressants and morphine alter gastrointestinal transit in mice. Backer MM, et al. **Life Sci** 1997;61(9):PL109-13

Antinociceptive activity of deltorphin analogs in the formalin test. Chiba T, et al. **Life Sci** 1996;59(20):1717-22

Effects of oral treatment with sustained release morphine tablets on hypothalamic-pituitary-adrenal axis. Palm S, et al. **Methods Find Exp Clin Pharmacol** 1997 May; 19(4):269-73

Phytohemagglutinin-dependent T-cell proliferation is not impaired by morphine. Palm S, et al. **Methods Find Exp Clin Pharmacol** 1996 Apr;18(3):159-65

Prevention of morphine discontinuation phenomenon in mice by ondansetron, a selective 5-HT3 antagonist. Roychoudhury M, et al. **Methods Find Exp Clin Pharmacol** 1996 Dec;18(10):677-83

Kappa-opioids produce significantly greater analgesia in women than in men [see comments] Gear RW, et al. **Nat Med** 1996 Nov;2(11):1248-50. Comment in: Nat Med 1996 Nov;2(11):1184-5.

How does morphine work? [news; comment] Iversen LL. **Nature** 1996 Oct 31;383(6603):759-60. Comment on: Nature 1996 Oct 31;383(6603):819-23.

Prevention by morphine of apomorphine- and oxytocin-induced penile erection and yawning: involvement of nitric oxide. Melis MR, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 May; 355(5):595-600

Effects of Psychotria colorata alkaloids in brain opioid system. Amador TA, et al. **Neurochem Res** 1996 Jan; 21(1):97-102

Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Crain SM, et al. **Neurochem Res** 1996 Nov;21(11):1347-51 (59 ref.)

Chronic administration of Org2766 and morphine counteracts isolation-induced increase in social interest: implication of endogenous opioid systems. Hol T, et al. **Neuropeptides** 1996 Jun;30(3):283-91

Intrathecally injected nicotine enhances the antinociception induced by morphine but not beta-endorphin, D-Pen2,5-enkephalin and U50,488H administered intrathecally in the mouse. Suh HW, et al. **Neuropeptides** 1996 Aug;30(4):373-8

Involvement of dopamine D2 receptor-mediated functions in the modulation of morphine-induced antinociception in diabetic mouse. Kamei J, et al. **Neuropharmacology** 1996 Mar;35(3):273-8

Influence of inheritance and fostering on sensitivity to effects of morphine on nociception and locomotor activity in two inbred rat strains. Sudakov SK, et al. **Neuropharmacology** 1996;35(8):1131-4

Dextromethorphan potentiates morphine antinociception, but does not reverse tolerance in rats. Hoffmann O, et al. **Neuroreport** 1996 Feb 29;7(3):838-40

Chronic morphine increases biosynthesis of nitric oxide synthase in the rat spinal cord. Machelska H, et al. **Neuroreport** 1997 Aug 18;8(12):2743-7

Propofol potentiates the depressant effect of alfentanil in isolated neonatal rat spinal cord and blocks naloxone-precipitated hyperresponsiveness. Feng JQ, et al. **Neurosci Lett** 1997 Jun 20;229(1):9-12

Gender difference in analgesic response to the kappa-opioid pentazocine. Gear RW, et al. **Neurosci Lett** 1996 Mar 1; 205(3):207-9

Lack of cross-tolerance between the antinociceptive effect of intrathecal orphanin FQ and morphine in the rat. Hao JX, et al. **Neurosci Lett** 1997 Feb 14;223(1):49-52

Agonist and antagonist properties of dihydroetorphine for mu-opioid receptors in mice. Kamei J, et al. **Neurosci Lett** 1996 Sep 6;215(2):87-90

Downregulation of mu-opioid receptor mRNA in the mediobasal hypothalamus of the female guinea pig following morphine treatment. Rønnekleiv OK, et al. **Neurosci Lett** 1996 Sep 27;216(2):129-32

Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia. Rossi GC, et al. **Neurosci Lett** 1996 Sep 20;216(1):1-4

Morphine modulation of GABA- and glutamate-induced changes of ventral pallidal neuronal activity. Johnson PI, et al. **Neuroscience** 1997 Mar;77(1):187-97

Gender-related differences exist in cortical [3H]nisoxetine binding and are not affected by prenatal morphine exposure. Vathy I, et al. **Neuroscience** 1997 Jan;76(2):331-4

[Met]enkephalin in the spinal cord is involved in the antinociception induced by intracerebroventricularly-administered etorphine in the mouse. Xu JY, et al. **Neuroscience** 1997 Sep;80(2):579-85

Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Abbadie C, et al. **Pain** 1997 Jan;69(1-2):101-10

The effect of lesions of the dorsolateral funiculus on formalin pain and morphine analgesia: a dose-response analysis. Abbott FV, et al. **Pain** 1996 Apr;65(1):17-23

The opioid ketobemidone has a NMDA blocking effect. Andersen S, et al. **Pain** 1996 Oct;67(2-3):369-74

Sensitization of the tail-flick reflex following exposure to either a single prolonged test trial or behavioral testing under the analgesic influence of morphine. Baldwin AE, et al. **Pain** 1996 Sep;67(1):163-72

Comments on Andersen et al., Pain, 67 (1996) 369 [letter] Caudle RM. **Pain** 1997 Aug;72(1-2):283-4

Hydromorphone analgesia after intravenous bolus administration. Coda B, et al. **Pain** 1997 May;71(1):41-8

Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved? [see comments] Faura CC, et al. **Pain** 1996 Apr;65(1):25-30 . Comment in: Pain 1997 Apr;70(2-3):289-90.

Inhibition of noxious stimulus-evoked pain behaviors and neuronal fos-like immunoreactivity in the spinal cord of the rat by supraspinal morphine. Gogas KR, et al. **Pain** 1996 Apr;65(1):9-15

Chronic treatment with systemic morphine induced tolerance to the systemic and peripheral antinociceptive effects of morphine on both carrageenin induced mechanical hyperalgesia and spinal c-Fos expression in awake rats. Honoré P, et al. **Pain** 1997 May;71(1):99-108

Effect of transient naloxone antagonism on tolerance development in rats receiving continuous spinal morphine infusion. Ibuki T, et al. **Pain** 1997 Apr;70(2-3):125-32

Individual differences in the hotplate test and effects of habituation on sensitivity to morphine. Plone MA, et al. **Pain** 1996 Aug;66(2-3):265-70

Cholecystokinin antisense RNA increases the analgesic effect induced by electroacupuncture or low dose morphine: conversion of low responder rats into high responders. Tang NM, et al. **Pain** 1997 May;71(1):71-80

The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat. Van Crugten JT, et al. **Pain** 1997 Jun; 71(2):199-205

Differential activities of intrathecal MK-801 or morphine to alter responses to thermal and mechanical stimuli in normal

or nerve-injured rats. Wegert S, et al. **Pain** 1997 May; 71(1):57–64

Effects of systemic morphine on responses of primates to first or second pain sensations. Yeomans DC, et al. **Pain** 1996 Aug;66(2–3):253–63

beta-Casomorphin causes hypoalgesia in 10-day-old rats: evidence for central mediation. Blass EM, et al. **Pediatr Res** 1996 Feb;39(2):199–203

Morphine stimulates adrenocorticotropin and cortisol release in the late-term ovine fetus. Taylor CC, et al. **Pediatr Res** 1997 Mar;41(3):411–5

Downregulation of mu-opioid binding sites following chronic administration of neuropeptide FF (NPFF) and morphine. Goodman CB, et al. **Peptides** 1996;17(3):389–97

Influence of continuous levels of fentanyl in rats on the mu-opioid receptor in the central nervous system. Albrecht E, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):189–94

Cholera toxin effects on body temperature changes induced by morphine. Basilico L, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):499–505

High intensity social conflict in the Swiss albino mouse induces analgesia modulated by 5-HT1A receptors. Canto de Souza A, et al. **Pharmacol Biochem Behav** 1997 Mar; 56(3):481–6

Associative and nonassociative tolerance: the effects of dose and interdose interval. Cox LS, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1–2):31–6

Beyond sweet taste: saccharin, sucrose, and polycose differ in their effects upon morphine-induced analgesia. D'Anci KE, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):341–5

The effect of cumulative dosing on the analgesic potency of morphine in mice. Duttaroy A, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):67–71

Prenatal exposure to morphine alters analgesic responses and preference for sweet solutions in adult rats. Gagin R, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):629–34

Effects of acute and chronic morphine on DOPAC and glutamate at subcortical DA terminals in awake rats. Huang NK, et al. **Pharmacol Biochem Behav** 1997 Mar; 56(3):363–71

Dosage choices of rats for morphine, for heroin, and between morphine and heroin. Hutto CW Jr, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):133–40

Dietary modulation of mu and kappa opioid receptor-mediated analgesia. Kanarek RB, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):43–9

Induction of sensitization to hyperactivity caused by morphine in mice: effects of post-drug environments. Kuribara H. **Pharmacol Biochem Behav** 1997 May-Jun; 57(1–2):341–6

Differential sensitivity of mice bred for stress-induced analgesia to morphine and ACEA-1011 in the formalin test. Lutfy K, et al. **Pharmacol Biochem Behav** 1996 Jun; 54(2):495–500

The antinociceptive effects of branched-chain amino acids: evidence for their ability to potentiate morphine analgesia. Manner T, et al. **Pharmacol Biochem Behav** 1996 Feb; 53(2):449–54

Involvement of opioid mu 1 receptors in morphine-induced conditioned place preference in rats. Piepponen TP, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):275–9

Supraspinal delta 2 opioid agonist analgesia in Swiss-Webster mice involves spinal GABAA receptors. Rady JJ, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):363–9

Spinal delta opioid receptor subtype activity of 6-monoacetylmorphine in Swiss Webster mice. Rady JJ, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):243–9

Interaction of morphine and haloperidol on agonistic and motor behaviors of male mice. Rodriguez-Arias M, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):153–8

Time-dependent effects of in vivo pertussis toxin on morphine analgesia and G-proteins in mice. Shah S, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):465–9

Perinatal exposure to morphine disrupts brain norepinephrine, ovarian cyclicity, and sexual receptivity in rats. Siddiqui A, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):243–8

Isobolographic analysis of the interaction between epidural sufentanil and bupivacaine in rats. Vercauteren M, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):237–42

Midazolam does not influence intravenous fentanyl-induced analgesia in healthy volunteers. Zacny JP, et al. **Pharmacol Biochem Behav** 1996 Oct;55(2):275–80

Effects of caerulein and CCK antagonists on tolerance induced to morphine antinociception in mice. Zarrindast MR, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):173–8

Insights into opioid action in the intestinal tract. De Luca A, et al. **Pharmacol Ther** 1996;69(2):103–15 (164 ref.)

Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. Hasselström J, et al. **Pharmacol Toxicol** 1996 Jul;79(1):40–6

Differential effect of central versus parenteral administration of morphine sulfate on regional concentrations of reduced glutathione in rat brain. Goudas LC, et al. **Pharmacology** 1997 Feb;54(2):92–7

Influence of dynorphin A (1-13) and dynorphin A (1-10) amide on stress-induced analgesia. Starec M, et al. **Physiol Res** 1996;45(6):433–8

Peripheral opioid analgesia--facts and mechanisms. Herz A. **Prog Brain Res** 1996;110:95–104 (47 ref.)

Modulating effects of a cold water stimulus on opioid effects in volunteers. Conley KM, et al. **Psychopharmacology (Berl)** 1997 Jun;131(4):313–20

Isolation impairs place preference conditioning to morphine but not aversive learning in mice. Coudereau JP, et al. **Psychopharmacology (Berl)** 1997 Mar;130(2):117–23

Motivational properties of buprenorphine as assessed by place and taste conditioning in rats. Gaiardi M, et al. **Psychopharmacology (Berl)** 1997 Mar;130(2):104–8

Associative and non-associative mechanisms of morphine analgesic tolerance are neurochemically distinct in the rat spinal cord. Grisel JE, et al. **Psychopharmacology (Berl)** 1996 Dec;128(3):248–55

Loss of tolerance to morphine after a change in route of administration: control of within-session tolerance by interoceptive conditioned stimuli. Mucha RF, et al. **Psychopharmacology (Berl)** 1996 Apr;124(4):365–72

The role of serotonergic receptors in the effects of mu opioids in squirrel monkeys responding under a titration procedure. Powell KR, et al. **Psychopharmacology (Berl)** 1996 Jul; 126(1):42–9

Interactions between H1-antagonists and opioids: a drug discrimination study. Suzuki T, et al. **Psychopharmacology (Berl)** 1997 Jun;131(4):346–53

The effect of a peripherally-acting opioid on sensory nerve function. Garland L. **Pulm Pharmacol** 1995 Aug-Oct; 8(4-5):231–6 (9 ref.)

The hypothesis that antagonism of fentanyl analgesia by 2-chloroprocaine is mediated by direct action on opioid receptors. Coda B, et al. **Reg Anesth** 1997 Jan-Feb; 22(1):43–52

Immunomodulation and epidural anesthesia and analgesia. de Leon-Casasola OA. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):24–5 (16 ref.)

Postoperative pain management in opioid-tolerant patients. de Leon-Casasola OA. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):114–6 (22 ref.)

Opioid effects and adverse effects. Lema MJ. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):38–42 (24 ref.)

Effect of intrathecal opioids on somatosensory-evoked potentials during spinal fusion in children. Goodarzi M, et al. **Spine** 1996 Jul 1;21(13):1565–8

Effect of drugs and cocaine metabolites on cocaine and cocaethylene binding to human serum in vitro. Bailey DN. **Ther Drug Monit** 1997 Aug;19(4):427–30

[Effect of dihydroetorphini hydrochloride on mice parturition] Wang A, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 May;31(5):299–301 (Eng. Abstr.) **(Chi)**

[Use of a mix of lidocaine and butorphanol as a caudal epidural anesthesia in a mare] Csik-Salmon J, et al. **Can J Vet Res** 1996 Oct;60(4):288–95 (Eng. Abstr.) **(Fre)**

[Pharmacology of tramadol] Dayer P, et al. **Drugs** 1997;53 Suppl 2:18–24 (39 ref.) (Eng. Abstr.) **(Fre)**

[Principles of pharmacology] Taeger K. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 May; 32(5):307–21 (29 ref.) **(Ger)**

[Nicorandil, as ATP-sensitive K+ channel opener, potentiated morphine analgesia] Asano T, et al. **Masui** 1996 Nov;45(11):1342–6 (Eng. Abstr.) **(Jpn)**

[Differentiation of antinociceptive effects of mu, delta and kappa agonists using heat, chemical and mechanical nociception] Murakawa K, et al. **Masui** 1996 Aug; 45(8):937–42 (Eng. Abstr.) **(Jpn)**

[Assessment of central hemodynamics during long microsurgical interventions using beforal in children] Medvedeva EA, et al. **Anesteziol Reanimatol** 1996 Nov-Dec;(6):43–4 (Eng. Abstr.) **(Rus)**

[Neurophysiological analysis of analgesic effect of phentanyl and moradol] Meizerov EE, et al. **Anesteziol Reanimatol** 1996 Jul-Aug;(4):10–3 (Eng. Abstr.) **(Rus)**

[Tolerance to opiate analgesia: a complex effect of antagonists of excitatory amino acid receptors] Bespalov AIu, et al. **Biull Eksp Biol Med** 1994 May;117(5):494–6 **(Rus)**

[The effect of sedatin--a synthetic analog of dermorphin--on cell division in cornea and tongue epithelium of albino rats] Fleĭshman MIu, et al. **Biull Eksp Biol Med** 1996 Jun; 121(6):641–4 **(Rus)**

[Transcription in nerve cells and hepatocytes of WAG and F344 rats of different ages] Iarygin VN, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):427–31 **(Rus)**

[Catabolism of phosphoinositides after treatment with opioid agonist phenaridin and its antagonist in brain synaptosomes of albion rats in vitro] Vartanian GS, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):405–6 **(Rus)**

[Ritanserin prolongs the analgesic effect of morphine and slows the development of tolerance] Verbitskaia EV, et al. **Eksp Klin Farmakol** 1997 Mar-Apr;60(2):10–3 (Eng. Abstr.) **(Rus)**

[The effect of Moradol (butorphanol tartrate) on immunity] Byshovets SN, et al. **Lik Sprava** 1997 Jan-Feb;(1):92–8 (Eng. Abstr.) **(Rus)**

[Opioid mechanisms of the analgesic action of cocaine] Litvinova SV, et al. **Patol Fiziol Eksp Ter** 1996 Oct-Dec; (4):39–41 (Eng. Abstr.) **(Rus)**

POISONING

Accidental overdosing with intraspinal morphine caused by misprogrammation of a Synchromed pump: a report of two cases. Belmans L, et al. **Acta Anaesthesiol Belg** 1997; 48(2):93–7

Tramadol overdose requiring prolonged opioid antagonism [letter] Sachdeva DK, et al. **Am J Emerg Med** 1997 Mar; 15(2):217–8

Disposal of used fentanyl patches. Yerasi AB, et al. **Am J Health Syst Pharm** 1997 Jan 1;54(1):85–6

A cluster of fentanyl-related deaths among drug addicts in Sweden. Kronstrand R, et al. **Forensic Sci Int** 1997 Aug 22;88(3):185–93

Fatal fentanyl intoxication following excessive transdermal application. Edinboro LE, et al. **J Forensic Sci** 1997 Jul; 42(4):741–3

Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. Lawlor P, et al. **J Pain Symptom Manage** 1997 Jun;13(6):356–61

Prospective multicenter evaluation of tramadol exposure. Spiller HA, et al. **J Toxicol Clin Toxicol** 1997;35(4):361–4

Outpatient detoxification of a drug abuser: the case of Dr. A. Winchell C. **Md Med J** 1997 Jan;46(1):31

[Who dies of morphine and dextropropoxyphene intoxication? Danish experiences from the period 1979–1992] Leander P, et al. **Ugeskr Laeger** 1997 Apr 14; 159(16):2370–4 (Eng. Abstr.) **(Dan)**

THERAPEUTIC USE

Intravenous morphine for early pain relief in patients with acute abdominal pain [see comments] Pace S, et al. **Acad Emerg Med** 1996 Dec;3(12):1086–92. Comment in: Acad Emerg Med 1996 Dec;3(12):1081–2.

Power error [letter] Weinberger M, et al. **Acad Emerg Med** 1997 Aug;4(8):838–9

The relative risks [letter] Williams ER, et al. **Acad Emerg Med** 1997 Aug;4(8):838–9

Challenging dogma--analgesia in abdominal pain [editorial; comment] Yealy DM, et al. **Acad Emerg Med** 1996 Dec; 3(12):1081–2. Comment on: Acad Emerg Med 1996 Dec;3(12):1086–92.

Side effects of opioids in postoperative pain treatment. Camu F. **Acta Anaesthesiol Belg** 1996;47(3):105–9 (28 ref.)

Opioids in pain management. Proceedings of the 1st International Pain Center Symposium. Copenhagen, May 4–5, 1996. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):93–190

Does epidural sufentanil provide effective analgesia per- and postoperatively for abdominal aortic surgery? Broekema AA, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):20–5

Cancer pain management. Bruera E, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):146–53 (68 ref.)

International opioid consumption. Clausen TG. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):162–5

Tramadol in the treatment of postanesthetic shivering. de Witte J, et al. **Acta Anaesthesiol Scand** 1997 Apr; 41(4):506–10

Opioids in pain management [editorial] Eriksen J, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 1):1–3

Opioid responsiveness. Hanks GW, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):154–8

Opioid use in chronic pain. McQuay HJ. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):175–83

Intrathecal morphine for post-sternotomy pain in patients with myasthenia gravis: effects on respiratory function. Nilsson E, et al. **Acta Anaesthesiol Scand** 1997 May; 41(5):549–56

Opioids in regional anaesthesia. Ilias WK. **Acta Anaesthesiol Scand Suppl** 1996;109:103–4

Additives in neuraxial anesthesia: opioids, alpha-2 adrenergic agonists, and neostigmine as a possible future drug for perioperative pain management. Klimscha W, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:176–8

Comparison of epidural butorphanol plus clonidine with butorphanol alone for postoperative pain relief. Tan PH, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):91–6

Use of morphine sulfate for acute pulmonary edema [letter; comment] Adams FB Jr. **Am Fam Physician** 1997 Apr; 55(5):1561. Comment on: Am Fam Physician 1996 Jul;54(1):245–54, 258–60.

A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. O'Connor PG, et al. **Am J Drug Alcohol Abuse** 1996 Nov;22(4):523–31

Retention in methadone maintenance is associated with reductions in different HIV risk behaviors for women and men. Wells EA, et al. **Am J Drug Alcohol Abuse** 1996 Nov; 22(4):509–21

Transnasal butorphanol in the emergency department management of migraine headache. Melanson SW, et al. **Am J Emerg Med** 1997 Jan;15(1):57–61

A prospective comparison of transnasal butorphanol and acetaminophen with codeine for the relief of acute musculoskeletal pain [letter] Wolford R, et al. **Am J Emerg Med** 1997 Jan;15(1):101–3

No harm was done [letter] Dies DF, et al. **Am J Gastroenterol** 1997 Mar;92(3):541–2

Are opioids right for chronic nonmalignant pain? Pasero CL, et al. **Am J Nurs** 1997 Jun;97(6):20, 22

Evaluation of continuous intraspinal narcotic analgesia for chronic pain from benign causes. Yoshida GM, et al. **Am J Orthop** 1996 Oct;25(10):693–4

Evaluation of pain after arthroscopically assisted anterior cruciate ligament reconstruction. Brown DW, et al. **Am J Sports Med** 1997 Mar-Apr;25(2):182–6

The antinociceptive effect of epidural lignocaine and fentanyl during lithotripsy. Fredman B, et al. **Anaesth Intensive Care** 1997 Feb;25(1):11–4

Spinal morphine in remote practice [letter] [see comments] Goldblatt M. **Anaesth Intensive Care** 1996 Oct;24(5):615–6 . Comment in: Anaesth Intensive Care 1997 Apr;25(2):198.
Remifentanil for major abdominal surgery [letter] Evans TN, et al. **Anaesthesia** 1997 Jun;52(6):606
Pain following craniotomy: a preliminary study comparing PCA morphine with intramuscular codeine phosphate [see comments] Stoneham MD, et al. **Anaesthesia** 1996 Dec; 51(12):1176–8. Comment in: Anaesthesia 1997 Jun;52(6):604–5.
A multicenter evaluation of remifentanil for early postoperative analgesia. Bowdle TA, et al. **Anesth Analg** 1996 Dec;83(6):1292–7
Postoperative epidural opioid analgesia: what are the choices? [see comments] de Leon–Casasola OA, et al. **Anesth Analg** 1996 Oct;83(4):867–75 (69 ref.). Comment in: Anesth Analg 1997 Jun;84(6):1390–1.
Postoperative epidural fentanyl analgesia [letter] dos Santos JE. **Anesth Analg** 1997 Aug;85(2):463–4
A comparison of intrathecal morphine–6–glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement. Grace D, et al. **Anesth Analg** 1996 Nov; 83(5):1055–9
A randomized, double–blind, dose–response comparison of epidural fentanyl versus sufentanil analgesia after cesarean section. Grass JA, et al. **Anesth Analg** 1997 Aug; 85(2):365–71
The dose–response pharmacology of intrathecal sufentanil in female volunteers. Lu JK, et al. **Anesth Analg** 1997 Aug; 85(2):372–9
Transcutaneous cranial electrical stimulation (Limoge's currents) decreases early buprenorphine analgesic requirements after abdominal surgery. Mignon A, et al. **Anesth Analg** 1996 Oct;83(4):771–5
Epidural meperidine after cesarean section: the effect of diluent volume. Ngan Kee WD, et al. **Anesth Analg** 1997 Aug;85(2):380–4
Fetal heart rate changes after intrathecal sufentanil or epidural bupivacaine for labor analgesia: incidence and clinical significance. Nielsen PE, et al. **Anesth Analg** 1996 Oct;83(4):742–6
The effect of epidural fentanyl on the minimum local analgesic concentration of epidural chloroprocaine in labor. Polley LS, et al. **Anesth Analg** 1996 Nov;83(5):987–90
Opioid treatment of chronic nonmalignant pain. Stein C. **Anesth Analg** 1997 Apr;84(4):912–4 (30 ref.)
Recovery after propofol with and without intraoperative fentanyl in patients undergoing ambulatory gynecologic laparoscopy. Sukhani R, et al. **Anesth Analg** 1996 Nov; 83(5):975–81
Postischemic brain injury is affected stereospecifically by pentazocine in rats. Takahashi H, et al. **Anesth Analg** 1997 Aug;85(2):353–7
Effect of the intensity of transcutaneous acupoint electrical stimulation on the postoperative analgesic requirement. Wang B, et al. **Anesth Analg** 1997 Aug;85(2):406–13
Cesarean delivery: a randomized trial of epidural versus patient–controlled meperidine analgesia during labor. Sharma SK, et al. **Anesthesiology** 1997 Sep;87(3):487–94
Pain treatment after thoracotomy: is it a special problem? Salzer GM, et al. **Ann Thorac Surg** 1997 May;63(5):1411–4
Alfentanil as procedural pain relief in newborn infants. Saarenmaa E, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Sep;75(2):F103–7
Comparison of caudal bupivacaine and diamorphine with caudal bupivacaine alone for repair of hypospadias. Kelleher AA, et al. **Br J Anaesth** 1996 Nov;77(5):586–90
A randomized, double–blind, placebo–controlled trial comparing pethidine to metamizol for treatment of post–anaesthetic shivering. Monsó A, et al. **Br J Clin Pharmacol** 1996 Sep;42(3):307–11
Dose dependent time course of the analgesic effect of a sustained–release preparation of tramadol on experimental phasic and tonic pain. Thürauf N, et al. **Br J Clin Pharmacol** 1996 Feb;41(2):115–23
Management of chronic non–malignant pain. Andersen S, et al. **Br J Clin Pract** 1996 Sep;50(6):324–30 (27 ref.)
Morphine: yesterday's drug or yardstick for the future? Kurowska A, et al. **Br J Hosp Med** 1996 Sep 18–Oct 1; 56(6):256–9
The effect of tramadol on dento–alveolar surgical pain. Collins M, et al. **Br J Oral Maxillofac Surg** 1997 Feb; 35(1):54–8
Use of patient–controlled analgesia with alfentanil for burns dressing procedures: a preliminary report of five patients. Sim KM, et al. **Burns** 1996 May;22(3):238–41
Chronic non–malignant pain. Consider using opioids [news] Kermode–Scott B. **Can Fam Physician** 1997 May;43:1011–3 **(Eng, Fre)**
Fentanyl transdermal system. Pain management at home. Woodroffe MA, et al. **Can Fam Physician** 1997 Feb; 43:268–72
Epidural morphine vs hydromorphone in post–caesarean section patients. Halpern SH, et al. **Can J Anaesth** 1996 Jun;43(6):595–8
Bupivacaine decreases epidural meperidine requirements after abdominal surgery. St–Onge S, et al. **Can J Anaesth** 1997 Apr;44(4):360–6
Pre–emptive analgesia with ketamine, morphine and epidural lidocaine prior to total knee replacement. Wong CS, et al. **Can J Anaesth** 1997 Jan;44(1):31–7
A comparison of N–butylscopolammonium bromide and butorphanol tartrate for analgesia using a balloon model of abdominal pain in ponies. Boatwright CE, et al. **Can J Vet Res** 1996 Jan;60(1):65–8
Modifying prescribing of regulated analgesics [letter; comment] Anderson JF, et al. **Can Med Assoc J** 1997 Mar 1;156(5):636. Comment on: Can Med Assoc J 1996 Jan 1;154(1):31–9.
Factors influencing the postoperative use of analgesics in dogs and cats by Canadian veterinarians. Dohoo SE, et al. **Can Vet J** 1996 Sep;37(9):552–6
A comparison of ketorolac with flunixin, butorphanol, and oxymorphone in controlling postoperative pain in dogs. Mathews KA, et al. **Can Vet J** 1996 Sep;37(9):557–67
Nurses' knowledge about equianalgesia and opioid dosing. Ferrell BR, et al. **Cancer Nurs** 1997 Jun;20(3):201–12
Opioid analgesic drugs in the elderly. Forman WB. **Clin Geriatr Med** 1996 Aug;12(3):489–500 (44 ref.)
The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. **Clin J Pain** 1997 Mar;13(1):6–8
Treatment of postoperative pain with thoracic epidural morphine in oral malignant tumor patients. Sakuramoto C, et al. **Clin J Pain** 1996 Jun;12(2):142–4
Opioids and chronic pain [editorial] Wilson PR. **Clin J Pain** 1997 Mar;13(1):1–2
Ketorolac versus meperidine for pain relief after orthopaedic surgery. DeAndrade JR, et al. **Clin Orthop** 1996 Apr; (325):301–12
Nonsteroidal anti–inflammatory drugs, traditional opioids, and tramadol: contrasting therapies for the treatment of chronic pain. Aronson MD. **Clin Ther** 1997 May–Jun; 19(3):420–32; discussion 367–8 (38 ref.)
Bromfenac sodium, acetaminophen/oxycodone, ibuprofen, and placebo for relief of postoperative pain. Johnson GH, et al. **Clin Ther** 1997 May–Jun;19(3):507–19
Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine–maintained patients. Eissenberg T, et al. **Drug Alcohol Depend** 1997 Apr 14;45(1–2):81–91
A risk–benefit assessment of tramadol in the management of pain. Radbruch L, et al. **Drug Saf** 1996 Jul;15(1):8–29 (128 ref.)
Opioid analgesics: comparative features and prescribing guidelines. Cherny NI. **Drugs** 1996 May;51(5):713–37 (210 ref.)
Remifentanil. Patel SS, et al. **Drugs** 1996 Sep;52(3):417–27; discussion 428 (53 ref.)
Do terminally ill patients receive adequate pain management? Rousseau P. **Drugs Aging** 1996 Apr;8(4):233–6
Effects of chronic treatment with methadone and naltrexone on sleep in addicts. Staedt J, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(6):305–9
Intraarticular morphine administration provides pain relief after knee arthroscopy. Kanbak M, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):153–6
Post–operative pain relief in children following extraction of carious deciduous teeth under general anaesthesia: a comparison of nalbuphine and diclofenac. Littlejohn IH, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):359–63
A comparison of ibuprofen arginine with morphine sulphate for pain relief after orthopaedic surgery. Mansfield M, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):492–7
Comparison of tramadol with morphine for post–operative pain following abdominal surgery [letter; comment] Stubhaug A. **Eur J Anaesthesiol** 1996 Jul;13(4):416–8. Comment on: Eur J Anaesthesiol 1995 May;12(3):265–71.
Comparative study of the efficacy of lysine acetylsalicylate, indomethacin and pethidine in acute renal colic. al–Sahlawi KS, et al. **Eur J Emerg Med** 1996 Sep;3(3):183–6
Pain relief during and following outpatient curettage and hysterosalpingography: a double blind study to compare the efficacy and safety of tramadol versus naproxen. Cobra Research Group. Peters AA, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 May;66(1):51–6
Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. Noseda A, et al. **Eur Respir J** 1997 May;10(5):1079–83
Epidural analgesia in Scotland: a survey of extradural opioid practice. Carson D, et al. **Health Bull (Edinb)** 1996 Jan; 54(1):51–62
Nonopioid and opioid analgesic pharmacotherapy of cancer pain. Cherny NI, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):79–102 (125 ref.)
Adjuvant analgesic agents. Portenoy RK. **Hematol Oncol Clin North Am** 1996 Feb;10(1):103–19 (66 ref.)
Pain relief in chronic pancreatitis with epidural buprenorphine injection. Desai PM. **Indian J Gastroenterol** 1997 Jan;16(1):12–3
Oral tramadol and buprenorphine in tumour pain. An Italian multicentre trial. Brema F, et al. **Int J Clin Pharmacol Res** 1996;16(4–5):109–16
Pre–incisional caudal epidural blockade and the relief of pain after lumbar spine operations. Kakiuchi M, et al. **Int Orthop** 1997;21(1):62–6
The opiate–sparing effect of dipyrone in post–operative pain therapy with morphine using a patient–controlled analgesic system. Tempel G, et al. **Intensive Care Med** 1996 Oct; 22(10):1043–7
Drug–seeking patients. Eckstat S. **Iowa Med** 1997 Jan; 87(1):31
Cancer pain management [editorial] O'Brien T. **Ir Med J** 1997 Mar;90(2):48
Chronic opioid analgesic therapy for chronic low back pain [see comments] Brown RL, et al. **J Am Board Fam Pract** 1996 May–Jun;9(3):191–204 (63 ref.) . Comment in: J Am Board Fam Pract 1996 May–Jun;9(3):225–8. Comment in: J Am Board Fam Pract 1996 Sep–Oct;9(5):386; discussion 387–8. Comment in: J Am Board Fam Pract 1996 Sep–Oct;9(5):386–7; discussion 387–8. Comment in: J Am Board Fam Pract 1996 Sep–Oct;9(5):388; discussion 387–8. Comment in: J Am Board Fam Pract 1996 Sep–Oct;9(5):388–9; discussion 387–8.
Opioid therapy and chronic low back pain [letter; comment] Ellis J. **J Am Board Fam Pract** 1996 Sep–Oct;9(5):386–7; discussion 387–8. Comment on: J Am Board Fam Pract 1996 May–Jun;9(3):191–204. Comment on: J Am Board Fam Pract 1996 May–Jun;9(3):225–8.
Opioid therapy and low back pain [letter; comment] Gillette RD. **J Am Board Fam Pract** 1996 Sep–Oct;9(5):388–9; discussion 387–8. Comment on: J Am Board Fam Pract 1996 May–Jun;9(3):191–204. Comment on: J Am Board Fam Pract 1996 May–Jun;9(3):225–8.
Opioid therapy and low back pain [letter; comment] Ryan J. **J Am Board Fam Pract** 1996 Sep–Oct;9(5):388; discussion 387–8. Comment on: J Am Board Fam Pract 1996 May–Jun;9(3):191–204. Comment on: J Am Board Fam Pract 1996 May–Jun;9(3):225–8.
Opioid therapy and chronic low back pain [letter; comment] Troncale JA. **J Am Board Fam Pract** 1996 Sep–Oct; 9(5):386; discussion 387–8. Comment on: J Am Board Fam Pract 1996 May–Jun;9(3):191–204. Comment on: J Am Board Fam Pract 1996 May–Jun;9(3):225–8.
Lumbar epidural morphine infusions for children undergoing cardiac surgery. Shayevitz JR, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):217–24
Comparison of epidural morphine and oxycodone for pain after abdominal surgery. Backlund M, et al. **J Clin Anesth** 1997 Feb;9(1):30–5
Postoperative opioid analgesia—reconsider, don't reject [editorial] Goudas LC, et al. **J Clin Anesth** 1996 Sep; 8(6):439–40
Postoperative opioid analgesia: time for a reconsideration? Kehlet H, et al. **J Clin Anesth** 1996 Sep;8(6):441–5 (54 ref.)
Postthyroidectomy analgesia: morphine, buprenorphine, or bupivacaine? Lacoste L, et al. **J Clin Anesth** 1997 May; 9(3):189–93
Postoperative analgesia with parenteral opioids: does continuous delivery utilizing a transdermal opioid preparation affect analgesic efficacy or patient safety? Sevarino FB, et al. **J Clin Anesth** 1997 May;9(3):173–8
Intrathecal morphine for postoperative analgesia following repair of frontal encephaloceles in children: comparison with intermittent, on–demand dosing of nalbuphine. Tobias JD, et al. **J Clin Anesth** 1997 Jun,9(4):280–4
Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. De Conno F, et al. **J Clin Oncol** 1996 Oct;14(10):2836–42
Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain—a meta–analysis. Zhang WY, et al. **J Clin Pharm Ther** 1996 Aug;21(4):261–82
Analgesic efficacy of controlled–release oxycodone in postoperative pain. Sunshine A, et al. **J Clin Pharmacol** 1996 Jul;36(7):595–603
Pain relief for renal colic. Bergus GR. **J Fam Pract** 1996 Nov;43(5):438–40
Opioids for chronic non–malignant pain. Conigliaro DA. **J Fla Med Assoc** 1996 Dec;83(10):708–11 (30 ref.)
New concepts in postoperative pain management: is there more beyond pain control? de Leon–Casasola OA. **J Fla Med Assoc** 1996 Dec;83(10):695–700 (72 ref.)
Narcotic prescription for pain management in Florida: the physician and the law [editorial] Mackey DC, et al. **J Fla Med Assoc** 1996 Dec;83(10):673–4
Management of cancer–related pain with transdermal fentanyl. Leelanuntakit S. **J Med Assoc Thai** 1996 Jun; 79(6):341–6
No cancer patient has to live in pain, but many still do [news] McNeil C. **J Natl Cancer Inst** 1997 Sep 3;89(17):1250–2
Epidural opioid therapy for chronic nonmalignant pain: critique of current experience. Bedder MD. **J Pain Symptom Manage** 1996 Jun;11(6):353–6 (14 ref.)
Intrathecal morphine for analgesia in children undergoing selective dorsal rhizotomy. Dews TE, et al. **J Pain Symptom Manage** 1996 Mar;11(3):188–94
Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases. Dunbar SA, et al. **J Pain Symptom Manage** 1996 Mar; 11(3):163–71
Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open–label pilot study. Hammack JE, et al. **J Pain Symptom Manage** 1996 Oct;12(4):234–40
Clinical realities and economic considerations: economics of intrathecal therapy. Hassenbusch SJ, et al. **J Pain Symptom Manage** 1997 Sep;14(3 Suppl):S36–48 (12 ref.)
Epidural and subarachnoid administration of opioids for nonmalignant pain: technical issues, current approaches and novel treatments. Hassenbusch SJ. **J Pain Symptom Manage** 1996 Jun;11(6):357–62 (23 ref.)
The pharmacologic management of pain and discomfort in persons with AIDS near the end of life: use of opioid analgesia in the hospice setting. Kimball LR, et al.

J Pain Symptom Manage 1996 Feb;11(2):88–94

Re: formal treatment agreements for opioids in nonmalignant pain [letter; comment] King SA. **J Pain Symptom Manage** 1996 Oct;12(4):205–6. Comment on: J Pain Symptom Manage 1995 Oct;10(7):556–63.

Day–to–day titration to initiate transdermal fentanyl in patients with cancer pain: short– and long–term experiences in a prospective study of 39 patients. Korte W, et al. **J Pain Symptom Manage** 1996 Mar;11(3):139–46

Clinical realities and economic considerations: patient selection in intrathecal therapy. Krames ES, et al. **J Pain Symptom Manage** 1997 Sep;14(3 Suppl):S3–13 (31 ref.)

Intraspinal opioid therapy for chronic nonmalignant pain: current practice and clinical guidelines. Krames ES. **J Pain Symptom Manage** 1996 Jun;11(6):333–52 (78 ref.)

Intraspinal morphine for chronic pain: a retrospective, multicenter study. Paice JA, et al. **J Pain Symptom Manage** 1996 Feb;11(2):71–80

Clinical realities and economic considerations: efficacy of intrathecal pain therapy. Paice JA, et al. **J Pain Symptom Manage** 1997 Sep;14(3 Suppl):S14–26 (36 ref.)

Clinical realities and economic considerations: introduction. Portenoy RK. **J Pain Symptom Manage** 1997 Sep;14(3 Suppl):S1–2

Clinical realities and economic considerations: special therapeutic issues in intrathecal therapy––tolerance and addiction. Portenoy RK, et al. **J Pain Symptom Manage** 1997 Sep;14(3 Suppl):S27–35 (19 ref.)

Edmonton injector: use in Córdoba, Argentina. Pruvost M, et al. **J Pain Symptom Manage** 1996 Dec;12(6):372–5

Re: formal treatment agreements for opioids in nonmalignant pain [letter; comment] Rose HL. **J Pain Symptom Manage** 1996 Oct;12(4):206–7. Comment on: J Pain Symptom Manage 1995 Oct;10(7):556–63.

The Edmonton Staging System [letter; comment] Walker P, et al. **J Pain Symptom Manage** 1996 Nov;12(5):269. Comment on: J Pain Symptom Manage 1995 Nov;10(8):632–8.

Hanging a morphine drip [letter; comment] Fins JJ, et al. **J Palliat Care** 1997 Spring;13(1):52. Comment on: J Palliat Care 1996 Winter;12(4):21–30. Comment on: J Palliat Care 1996 Winter;12(4):31–7. Comment on: J Palliat Care 1996 Winter;12(4):44–6.

Patient–controlled analgesia for mucositis pain in children: a three–period crossover study comparing morphine and hydromorphone. Collins JJ, et al. **J Pediatr** 1996 Nov; 129(5):722–8

Routine use of fentanyl infusions for pain and stress reduction in infants with respiratory distress syndrome [see comments] Orsini AJ, et al. **J Pediatr** 1996 Jul;129(1):140–5 . Comment in: J Pediatr 1997 Mar;130(3):498–9.

Analgesic use in the neonatal intensive care unit [letter; comment] Templeton KE. **J Pediatr** 1997 Mar;130(3):498–9 . Comment on: J Pediatr 1996 Jul;129(1):140–5.

Conscious sedation of pediatric oncology patients for painful procedures: development and implementation of a clinical practice protocol. Macpherson CF, et al. **J Pediatr Oncol Nurs** 1997 Jan;14(1):33–42; quiz 43–4 (16 ref.)

Post–operative pain relief in children following caudal bupivacaine and buprenorphine––a comparative study. Anilkumar TK, et al. **J Postgrad Med** 1994 Apr–Jun; 40(2):61–4

Carprofen as an analgesic for postoperative pain in cats: dose titration and assessment of efficacy in comparison to pethidine hydrochloride. Lascelles BD, et al. **J Small Anim Pract** 1995 Dec;36(12):535–41

Mapping–enhanced drug abuse counseling: urinalysis results in the first year of methadone treatment. Dees SM, et al. **J Subst Abuse Treat** 1997 Jan–Feb;14(1):45–54

Motivating methadone patients to include drug–free significant others in treatment: a behavioral intervention. Kidorf M, et al. **J Subst Abuse Treat** 1997 Jan–Feb; 14(1):23–8

Patterns of service use and treatment involvement of methadone maintenance patients. Widman M, et al. **J Subst Abuse Treat** 1997 Jan–Feb;14(1):29–35

Pain management and chemical dependency. Evolving perspectives. Portenoy RK, et al. **JAMA** 1997 Aug 20; 278(7):592–3

Randomised double–blind active–placebo–controlled crossover trial of intravenous fentanyl in neuropathic pain. Dellemijn PL, et al. **Lancet** 1997 Mar 15;349(9054):753–8

Ganglionic local opioid analgesia for refractory trigeminal neuralgia [letter] Spacek A, et al. **Lancet** 1997 May 24; 349(9064):1521

Australian trends in opioid prescribing for chronic non–cancer pain, 1986–1996[see comments] Bell JR. **Med J Aust** 1997 Jul 7;167(1):26–9. Comment in: Med J Aust 1997 Jul 7;167(1):9–10.

The ACT heroin trial proposal: an overview [letter; comment] Gaughwin PC. **Med J Aust** 1997 Feb 17; 166(4):221–2. Comment on: Med J Aust 1996 Jun 3;164(11):690–2.

The use of oral opioids in patients with chronic non–cancer pain. Management strategies [see comments] Graziotti PJ, et al. **Med J Aust** 1997 Jul 7;167(1):30–4 (20 ref.). Comment in: Med J Aust 1997 Jul 7;167(1):9–10.

Role of opioids in chronic non–cancer pain [editorial; comment] Molloy AR, et al. **Med J Aust** 1997 Jul 7; 167(1):9–10 (14 ref.). Comment on: Med J Aust 1997 Jul 7;167(1):26–9. Comment on: Med J Aust 1997 Jul 7;167(1):30–4.

Respiratory and analgesic effects of meperidine and tramadol in patients undergoing orthopedic surgery. Tarradell R, et al. **Methods Find Exp Clin Pharmacol** 1996 Apr; 18(3):211–8

Reduction of propofol pain––fentanyl vs lidocaine. Alyafi WA, et al. **Middle East J Anesthesiol** 1996 Oct;13(6):613–9

Opiates for chronic nonmalignant pain? [see comments] Grosshandler S, et al. **N C Med J** 1996 Sep–Oct; 57(5):288–90 (7 ref.). Comment in: N C Med J 1997 Jan–Feb;58(1):8.

Can we manage pain? Cornell DH. **N J Med** 1997 May; 94(5):41–4

Sex, drugs and...[news; comment] Berkley KJ. **Nat Med** 1996 Nov;2(11):1184–5. Comment on: Nat Med 1996 Nov;2(11):1248–50.

Opioids in headache treatment. Is there a role? Ziegler DK. **Neurol Clin** 1997 Feb;15(1):199–207 (53 ref.)

Intravenous morphine attenuates pain induced changes in skin blood flow in newborn infants. Moustogiannis AN, et al. **Neurol Res** 1996 Oct;18(5):440–4

Correcting misconceptions about pain assessment and use of opioid analgesics: educational strategies aimed at public concerns. McCaffery M, et al. **Nurs Outlook** 1996 Jul–Aug; 44(4):184–90 (28 ref.)

Oral morphine termed narcotic standard in severe cancer pain. **Oncology (Huntingt)** 1996 Feb;10(2):186, 189

A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient. St. Charles CS, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):76–82

Recommended use of morphine in neonates, infants and children based on a literature review: Part 2––Clinical use. Kart T, et al. **Paediatr Anaesth** 1997;7(2):93–101 (82 ref.)

Antinociceptive effects of dynorphin peptides in a model of inflammatory pain. Beyer A, et al. **Pain** 1997 Apr; 70(2–3):141–7

Competitive and non–competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. Bilsky EJ, et al. **Pain** 1996 Dec;68(2–3):229–37

Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Donner B, et al. **Pain** 1996 Mar;64(3):527–34

Comments on Cherry et al. PAIN, 69 (1995) 119–121 [letter; comment] Edmonds PM, et al. **Pain** 1996 Apr;65(1):114–5 . Comment on: Pain 1995 Jul;62(1):119–21.

Benzodiazepine mediated antagonism of opioid analgesia. Gear RW, et al. **Pain** 1997 May;71(1):25–9

Pharmacokinetics and pharmacodynamics of twenty–four–hourly Kapanol compared to twelve–hourly MS Contin in the treatment of severe cancer pain. Gourlay GK, et al. **Pain** 1997 Feb;69(3):295–302

Transdermal fentanyl in the long–term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Grond S, et al. **Pain** 1997 Jan;69(1–2):191–8

Pain relief from intra–articular morphine after knee surgery: a qualitative systematic review. Kalso E, et al. **Pain** 1997 Jun;71(2):127–34 (47 ref.)

High dose alfentanil pre–empts pain after abdominal hysterectomy. Katz J, et al. **Pain** 1996 Nov;68(1):109–18

Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain. Kawamata M, et al. **Pain** 1996 Mar; 64(3):597–602

Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Lawlor P, et al. **Pain** 1997 Aug;72(1–2):79–85

In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain. Lesser GJ, et al. **Pain** 1996 May–Jun;65(2–3):265–72

Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Manfredi PL, et al. **Pain** 1997 Mar;70(1):99–101

Paracetamol with and without codeine in acute pain: a quantitative systematic review. Moore A, et al. **Pain** 1997 Apr;70(2–3):193–201 (18 ref.)

Single–patient data meta–analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Moore RA, et al. **Pain** 1997 Feb; 69(3):287–94

Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1–13) or MK–801 in a nerve–ligation model of peripheral neuropathy. Nichols ML, et al. **Pain** 1997 Feb;69(3):317–22

Pain control after dental surgery: a double–blind, randomised trial of lornoxicam versus morphine. Nørholt SE, et al. **Pain** 1996 Oct;67(2–3):335–43

An update on the clinical use of methadone for cancer pain. Ripamonti C, et al. **Pain** 1997 Apr;70(2–3):109–15 (70 ref.)

Nimodipine fails to enhance the analgesic effect of slow release morphine in the early phases of cancer pain treatment. Roca G, et al. **Pain** 1996 Dec;68(2–3):239–43

Sufentanil does not preempt pain after abdominal hysterectomy [see comments] Sarantopoulos C, et al. **Pain** 1996 May–Jun;65(2–3):273–6. Comment in: Pain 1997 Apr;70(2–3):292–3.

Peripheral morphine analgesia [editorial] Stein C, et al. **Pain** 1997 Jun;71(2):119–21

Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn–induced secondary hyperalgesia in man: a double–blind, cross–over comparison with morphine and placebo. Warncke T, et al. **Pain** 1997 Aug;72(1–2):99–106

Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients. Wolff T, et al. **Pain** 1996 Dec;68(2–3):209–16

Transdermal fentanyl and the opioid withdrawal syndrome [letter] Davies AN, et al. **Palliat Med** 1996 Oct;10(4):348

Transdermal fentanyl and the opioid withdrawal syndrome [letter] Hunt R. **Palliat Med** 1996 Oct;10(4):347–8

Analgesia for dying infants whose life support is withdrawn or withheld. Partridge JC, et al. **Pediatrics** 1997 Jan; 99(1):76–9

Ethnic differences in analgesic consumption for postoperative pain. Ng B, et al. **Psychosom Med** 1996 Mar–Apr; 58(2):125–9

Single–injection lumbar epidural morphine for postoperative analgesia in children: a report of 175 cases [see comments] Bozkurt P, et al. **Reg Anesth** 1997 May–Jun;22(3):212–7. Comment in: Reg Anesth 1997 May–Jun;22(3):205–8.

Gastrointestinal benefits of regional anesthesia/analgesia. Carpenter RL. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):13–7 (29 ref.)

Pain relief after knee arthroscopy: intra–articular morphine, intra–articular bupivacaine, or subcutaneous morphine? Cepeda MS, et al. **Reg Anesth** 1997 May–Jun;22(3):233–8

Tramadol and beta–cyclodextrin piroxicam: effective multimodal balanced analgesia for the intra– and postoperative period. Lauretti GR, et al. **Reg Anesth** 1997 May–Jun;22(3):243–8

Ketorolac as an adjunct to patient–controlled morphine in postoperative spine surgery patients. Reuben SS, et al. **Reg Anesth** 1997 Jul–Aug;22(4):343–6

Nalmefene, an intravenous alternative to naltrexone for extradural morphine prophylaxis [letter] Stuart AL, et al. **Reg Anesth** 1997 May–Jun;22(3):291

The effect of methadone prescribing in a clinic setting on the criminal activity of drug users. Bates M, et al. **Scott Med J** 1996 Dec;41(6):173–5

Management of acute and surgical pain. Hellyer PW. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):106–14 (55 ref.)

Principles of analgesic drug therapy. Papich MG. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):80–93 (111 ref.)

Cancer pain management and rectal opioids [letter; comment] Rousseau P. **South Med J** 1997 Mar;90(3):365–6. Comment on: South Med J 1996 Aug;89(8):744–60; quiz 761.

Postoperative pain control after lumbar spine fusion. Patient–controlled analgesia versus continuous epidural analgesia. Cohen BE, et al. **Spine** 1997 Aug 15; 22(16):1892–6; discussion 1896–7

Swiss Cancer League launches campaign against cancer pain: living with cancer and without pain [news] **Support Care Cancer** 1996 Jul;4(4):263–4

Analgesia for severe postoperative pain: a comparison of two methods. Amata AO, et al. **Trop Doct** 1997 Jul;27(3):133–4

Efficacy of an epidural combination of morphine and detomidine in alleviating experimentally induced hindlimb lameness in horses. Sysel AM, et al. **Vet Surg** 1996 Nov–Dec;25(6):511–8

Using opioids to control suffering: a painstaking approach. Kennedy M. **Wis Med J** 1997 Feb;96(2):20–2

[Opiates in oncology] Mühlbachová E, et al. **Ceska Gynekol** 1996 Jun;61(3):191–4 **(Cze)**

[Use of opiates for chronic pain] Larue F. **Bull Acad Natl Med** 1996 Nov;180(8):1967–78; discussion 1979–85 (27 ref.) (Eng. Abstr.) **(Fre)**

[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine] Bono AV, et al. **Drugs** 1997;53 Suppl 2:40–9 (Eng. Abstr.) **(Fre)**

[Treatment of post–herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine] Göbel H, et al. **Drugs** 1997;53 Suppl 2:34–9 (Eng. Abstr.) **(Fre)**

[Tramadol in acute pain] Lehmann KA. **Drugs** 1997;53 Suppl 2:25–33 (32 ref.) (Eng. Abstr.) **(Fre)**

[Pain in cancer patients. Practical attitude] Pichard–Léandri E. **J Chir (Paris)** 1997 May;134(1):14–21 (29 ref.) (Eng. Abstr.) **(Fre)**

[Analgesic effect and clinical tolerability of the combination of paracetamol 500 mg and caffeine 50 mg versus paracetamol 400 mg and dextropropoxyphene 30 mg in back pain] Kuntz D, et al. **Presse Med** 1996 Sep 7; 25(25):1171–4 (Eng. Abstr.) **(Fre)**

[One year follow–up of methadone maintenance patients] Facy F. **Rev Epidemiol Sante Publique** 1997 Jun;45(3):260–1 **(Fre)**

[Current therapeutics: tramadol] Sternon J, et al. **Rev Med Brux** 1996 Dec;17(6):397–9 (Eng. Abstr.) **(Fre)**

[What organizational structure is needed to carry out patient–controlled or continuous opioid analgesia?] Jage J. **Anaesthesist** 1996 Dec;45 Suppl 3:S74–5 **(Ger)**

[A transdermal method for the therapy of cancer pain. Status quo of cancer pain therapy in Germany] **Chirurg** 1995 Sep; 66(9 Suppl):1–4 **(Ger)**

[Morphine] Mignat C. **Dtsch Med Wochenschr** 1996 Nov 22; 121(47):1473–4 **(Ger)**

[Which hurdles in general practice actually prevent improved

pain management? Experiences of a general practitioner with pain patients (interview by Dr. rer. nat. Anita Schweiger)] Engl F. **Fortschr Med** 1996 May 10; 114(13):16–8 **(Ger)**

[Evaluation of the synergism between ketorolac and morphine in the treatment of postoperative pain] Casali R, et al. **Minerva Anestesiol** 1995 Dec;61(12):501–7 (Eng. Abstr.) **(Ita)**

[Clinical use of sublingual buprenorphine hydrochloride for analgesia in the early postoperative period] Lebedeva RN, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):22–5 (Eng. Abstr.) **(Rus)**

[Arrest of the painful syndrome by moradol and nubain in patients with ischemic heart disease] Litovchenko VS, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):30–1 (Eng. Abstr.) **(Rus)**

[Preventive analgesia: true of preventing the postoperative pain syndrome] Ovechkin AM, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):35–9 (Eng. Abstr.) **(Rus)**

[Case of prolonged use of high doses of opiates and opioids by oncologic surgical patient] Petrova VV, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):21–2 **(Rus)**

[Comparative assessment of chronic pain syndrome treatment methods in patients with small pelvis neoplasms] Vaisman MA, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):31–5 **(Rus)**

[The antinociceptive effect of tramal when combined with nonsteroidal anti–inflammatory preparations] Stanislavchuk NA, et al. **Eksp Klin Farmakol** 1997 Jan–Feb;60(1):22–4 (Eng. Abstr.) **(Rus)**

[Tramadol (Tramal) in the treatment of rheumatic diseases—comparative study] Vlak T. **Reumatizam** 1996;43(2):1–10 (Eng. Abstr.) **(Scr)**

[Tramadol chlorhydrate in the management of gyneco–obstetric pain] López Rosales C, et al. **Ginecol Obstet Mex** 1997 Apr;65:152–4 (Eng. Abstr.) **(Spa)**

[Analgesic effectiveness and repercussions on the progress of labor of small doses of bupivacaine and fentanyl in continuous peridural perfusion] García–Muñoz M, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):135–9 (Eng. Abstr.) **(Spa)**

[Postoperative analgesia with epidural methadone in patients operated for hernia of the lumbar disc] Hernández–Palazón J, et al. **Rev Esp Anestesiol Reanim** 1997 May;44(5):182–5 (Eng. Abstr.) **(Spa)**

[Use of opioid analgesics to alleviate pain in cancer] De Lima L. **Rev Panam Salud Publica** 1997 Aug;2(2):142–5 (Eng. Abstr.) **(Spa)**

TOXICITY

Morphine induces sepsis in mice. Hilburger ME, et al. **J Infect Dis** 1997 Jul;176(1):183–8

Involvement of mu– and delta–opioid receptors in the effects of systemic and locally perfused morphine on extracellular levels of dopamine, DOPAC and HVA in the nucleus accumbens of the halothane–anaesthetized rat. Borg PJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 May; 355(5):582–8

Preprothyrotropin–releasing hormone mRNA in the rat central gray is strongly and persistently induced during morphine withdrawal. Gahn LG, et al. **Neuropeptides** 1996 Jun;30(3):207–12

Effect of chronic administration of dihydropyridine Ca2+ channel ligands on sufentanil–induced tolerance to mu– and kappa–opioid agonists in the guinea pig ileum myenteric plexus. Garaulet JV, et al. **Regul Pept** 1996 May 7;63(1):1–8

URINE

A simple thin–layer chromatographic method for the analysis of buprenorphine in urine. Alemany G, et al. **Biomed Chromatogr** 1996 May–Jun;10(3):146–7

Gas chromatographic quantitation of dextropropoxyphene and norpropoxyphene in urine after solid–phase extraction. Amalfitano G, et al. **J Anal Toxicol** 1996 Nov–Dec; 20(7):547–54

Determination of phase II drug metabolites in equine urine by micellar electrokinetic capillary chromatography. Taylor MR, et al. **J Chromatogr A** 1996 Sep 20; 745(1–2):155–63

Gas chromatographic–mass spectrometric quantitation of urinary buprenorphine and norbuprenorphine after derivatization by direct extractive alkylation. Lisi AM, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):67–77

[The detection of tramadol and its metabolites in urine by chromatographic methods] Veselovskaia NV, et al. **Sud Med Ekspert** 1996 Oct–Dec;39(4):38–43 (Eng. Abstr.) **(Rus)**

ANALGIN see **DIPYRONE**

ANALOG–DIGITAL CONVERSION

Simultaneous digital imaging analysis of cytosolic calcium and morphological change in platelets activated by surface contact. Ikeda M, et al. **J Cell Biochem** 1996 May; 61(2):292–300

ANALOGUE PAIN SCALE see **PAIN MEASUREMENT**

ANALPHALIPOPROTEINEMIA see **TANGIER DISEASE**

ANALYSIS OF VARIANCE

Variance–component modeling in the analysis of receiver operating characteristic index estimates. Roe CA, et al. **Acad Radiol** 1997 Aug;4(8):587–600

Dorfman–Berbaum–Metz method for statistical analysis of multireader, multimodality receiver operating characteristic data: validation with computer simulation. Roe CA, et al. **Acad Radiol** 1997 Apr;4(4):298–303

Approximate variance of the standardized measure of gametic disequilibrium D' [letter] Zapata C, et al. **Am J Hum Genet** 1997 Sep;61(3):771–4

Extension of the Haseman–Elston method to multiple alleles and multiple loci: theory and practice for candidate genes. Stoesz MR, et al. **Ann Hum Genet** 1997 May;61 (Pt 3):263–74

What is a variable? Beyea SC, et al. **AORN J** 1997 Sep; 66(3):500–1

Changepoint statistics for assessing a treatment–covariate interaction. Koziol JA, et al. **Biometrics** 1996 Sep; 52(3):1147–52

Assessing reproducibility by the within–subject coefficient of variation with random effects models. Quan H, et al. **Biometrics** 1996 Dec;52(4):1195–203

Detecting skewness from summary information. Altman DG, et al. **BMJ** 1996 Nov 9;313(7066):1200

Statistics notes. Interaction 2: Compare effect sizes not P values. Matthews JN, et al. **BMJ** 1996 Sep 28;313(7060):808

Test of linear trend in eigenvalues of a covariance matrix with application to data analysis. Bentler PM, et al. **Br J Math Stat Psychol** 1996 Nov;49 (Pt 2):299–312

Design of crossover microcomputer program and application on drug bioequivalence data. Abdullah ME, et al. **Comput Methods Programs Biomed** 1995 Dec;48(3):237–9

Design III with marker loci. Cockerham CC, et al. **Genetics** 1996 Jul;143(3):1437–56

Realized sampling variances of estimates of genetic parameters and the difference between genetic and phenotypic correlations. Koots KR, et al. **Genetics** 1996 Jul;143(3):1409–16

Analysis of molecular variance (AMOVA) of Y–chromosome–specific microsatellites in two closely related human populations [published erratum appears in Hum Mol Genet 1997 May;6(5):828] Roewer L, et al. **Hum Mol Genet** 1996 Jul;5(7):1029–33

Two statistical methods for analyzing multiple neuronal data. Takahashi T. **Int J Neurosci** 1996 Nov;88(1–2):11–26

The likelihood of detecting differences between groups of sheep following deliberate infection with Ostertagia circumcincta. Stear MJ, et al. **Int J Parasitol** 1996 Jun; 26(6):657–60

Least squares Lehmann–Scheffé estimation of variances and covariances with mixed linear models. Slanger WD. **J Anim Sci** 1996 Nov;74(11):2577–85

Multiple–trait Gibbs sampler for animal models: flexible programs for Bayesian and likelihood–based (co)variance component inference. Van Tassell CP, et al. **J Anim Sci** 1996 Nov;74(11):2586–97

A summary statistic for measuring change from baseline. Donahue RM. **J Biopharm Stat** 1997 May;7(2):287–99

False–positive error rates in routine application of repeated measurements ANOVA. Overall JE, et al. **J Biopharm Stat** 1996 Mar;6(1):69–81

Comparison of two procedures to estimate the hospital stay attributable to nosocomial infection: matched cohort study versus analysis of covariance of the total unmatched cohort. Delgado–Rodríguez M, et al. **J Clin Epidemiol** 1997 Jul; 50(7):773–8

Now you see it, now you don't: a comparison of traditional versus random–effects regression models in the analysis of longitudinal follow–up data from a clinical trial. Nich C, et al. **J Consult Clin Psychol** 1997 Apr;65(2):252–61

Post hoc analysis: use and dangers in perspective. Elliott HL. **J Hypertens Suppl** 1996 Sep;14(2):S21–4; discussion S24–5 (25 ref.)

Bias/variance analyses of mixtures–of–experts architectures. Jacobs RA. **Neural Comput** 1997 Feb 15;9(2):369–83

Issues in classification in meta–analysis in substance abuse prevention research. Hansen WB, et al. **NIDA Res Monogr** 1997;170:183–201

Use of the Johnson–Neyman technique as an alternative to analysis of covariance. Dorsey SG, et al. **Nurs Res** 1996 Nov–Dec;45(6):363–6

Entry IV.D. 1: Analysis of variance: basic aspects of the one–way model. De Land PN, et al. **Optom Vis Sci** 1996 Feb;73(2):127–32

The use and interpretation of the Friedman test in the analysis of ordinal–scale data in repeated measures designs. Sheldon MR, et al. **Physiother Res Int** 1996;1(4):221–8 (28 ref.)

Overcoming feelings of powerlessness in "aging" researchers: a primer on statistical power in analysis of variance designs. Levin JR. **Psychol Aging** 1997 Mar;12(1):84–106 (45 ref.)

Non–iterative robust estimators of variance components in within–subject designs. Mehrotra DV. **Stat Med** 1997 Jul 15;16(13):1465–79

Non–normal variation and regression to the mean. Chesher A. **Stat Methods Med Res** 1997 Jun;6(2):147–66

[The center effect in multicenter studies: fixed or random?] Falissard B, et al. **Rev Epidemiol Sante Publique** 1996 Oct; 44(5):455–64 (Eng. Abstr.) **(Fre)**

ANALYZERS, NEURAL see **NEURAL ANALYZERS**

ANANKASTIC PERSONALITY see **COMPULSIVE PERSONALITY DISORDER**

ANAPHASE

A telomerase mutant defective in sister chromatid separation at mitosis. Nakaseko Y, et al. **Bioessays** 1997 Jul;19(7):557–9 (22 ref.)

Meiotic behaviour of holocentric chromosomes: orientation and segregation of autosomes in Triatoma infestans (Heteroptera). Pérez R, et al. **Chromosome Res** 1997 Feb; 5(1):47–56

Anaphase initiation in Saccharomyces cerevisiae is controlled by the APC–dependent degradation of the anaphase inhibitor Pds1p. Cohen–Fix O, et al. **Genes Dev** 1996 Dec 15;10(24):3081–93

Kinetochore fiber maturation in PtK1 cells and its implications for the mechanisms of chromosome congression and anaphase onset. McEwen BF, et al. **J Cell Biol** 1997 Jun 30;137(7):1567–80

Identification of a mid–anaphase checkpoint in budding yeast. Yang SS, et al. **J Cell Biol** 1997 Jan 27;136(2):345–54

Distinct subunit functions and cell cycle regulated phosphorylation of 20S APC/cyclosome required for anaphase in fission yeast. Yamada H, et al. **J Cell Sci** 1997 Aug;110 (Pt 15):1793–804

Centromere position in budding yeast: evidence for anaphase A. Guacci V, et al. **Mol Biol Cell** 1997 Jun;8(6):957–72

A ubiquitin–conjugating enzyme in fission yeast that is essential for the onset of anaphase in mitosis. Osaka F, et al. **Mol Cell Biol** 1997 Jun;17(6):3388–97

Relationship between chromatin bridges in anaphase and chromosomal aberrations induced by TMP + UVA (365 nm) in CHO cells. Botta R, et al. **Mutat Res** 1997 Mar 21;374(2):253–9

Real time observation of anaphase in vitro [see comments] Murray AW, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12327–32. Comment in: Proc Natl Acad Sci U S A 1996 Oct 29;93(22):12076–7.

APC–mediated proteolysis of Ase1 and the morphogenesis of the mitotic spindle. Juang YL, et al. **Science** 1997 Feb 28;275(5304):1311–4

Block in anaphase chromosome separation caused by a telomerase template mutation [see comments] Kirk KE, et al. **Science** 1997 Mar 7;275(5305):1478–81. Comment in: Science 1997 Mar 7;275(5305):1441–3.

Identification of BIME as a subunit of the anaphase–promoting complex. Peters JM, et al. **Science** 1996 Nov 15;274(5290):1199–201

Mitosis in living budding yeast: anaphase A but no metaphase plate. Straight AF, et al. **Science** 1997 Jul 25; 277(5325):574–8

Identification of subunits of the anaphase–promoting complex of Saccharomyces cerevisiae. Zachariae W, et al. **Science** 1996 Nov 15;274(5290):1201–4

DRUG EFFECTS

Mitotic arrest and anaphase aberrations induced by vinorelbine in hamster cells in vitro. González–Cid M, et al. **Anticancer Drugs** 1997 Jun;8(5):529–32

C–anaphases (common variant) are unrelated to colchicine and phytohemagglutinin. Domínguez MG, et al. **Arch Med Res** 1997 Spring;28(1):25–7

GENETICS

The kinesin–like protein CENP–E is kinetochore–associated throughout poleward chromosome segregation during anaphase–A. Brown KD, et al. **J Cell Sci** 1996 May;109 (Pt 5):961–9

The Schizosaccharomyces pombe spindle checkpoint protein mad2p blocks anaphase and genetically interacts with the anaphase–promoting complex. He X, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):7965–70

PHYSIOLOGY

Forces on chromosomal DNA during anaphase. Jannink G, et al. **Biophys J** 1996 Jul;71(1):451–65 (87 ref.)

Chromatid segregation at anaphase requires the barren product, a novel chromosome–associated protein that interacts with Topoisomerase II. Bhat MA, et al. **Cell** 1996 Dec 13;87(6):1103–14

Forces acting on the fission yeast anaphase spindle. Hagan IM, et al. **Cell Motil Cytoskeleton** 1996;34(1):69–75

A class of nonribosomal nucleolar components is located in chromosome periphery and in nucleolus–derived foci during anaphase and telophase. Dundr M, et al. **Chromosoma** 1997 Jun;105(7–8):407–17

The Saccharomyces cerevisiae kinesin–related motor Kar3p acts at preanaphase spindle poles to limit the number and length of cytoplasmic microtubules. Saunders W, et al. **J Cell Biol** 1997 Apr 21;137(2):417–31

CDK1 inactivation regulates anaphase spindle dynamics and cytokinesis in vivo. Wheatley SP, et al. **J Cell Biol** 1997 Jul 28;138(2):385–93

TPR proteins required for anaphase progression mediate ubiquitination of mitotic B–type cyclins in yeast. Zachariae W, et al. **Mol Biol Cell** 1996 May;7(5):791–801

Anaphase in vitro [comment] Cande WZ, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12076–7 (20

ANAPHASE

ref.). Comment on: Proc Natl Acad Sci U S A 1996 Oct 29;93(22):12327–32.

RADIATION EFFECTS

Coordinated movements between autosomal half–bivalents in crane–fly spermatocytes: evidence that 'stop' signals are sent between partner half–bivalents. Yin B, et al. **J Cell Sci** 1996 Jan;109 (Pt 1):155–63

ANAPHYLACTOID PURPURA see **PURPURA, SCHOENLEIN–HENOCH**

ANAPHYLATOXINS

ANALYSIS

Anaphylatoxins in fresh–frozen plasma. Sonntag J, et al. **Transfusion** 1997 Aug;37(8):798–803

ANTAGONISTS & INHIBITORS

Inhibition of anaphylatoxin C3a– and C5a– but not nerve stimulation– or Noradrenaline–dependent increase in glucose output and reduction of flow in Kupffer cell–depleted perfused rat livers. Püschel GP, et al. **Hepatology** 1996 Sep;24(3):685–90

BIOSYNTHESIS

Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. Maruo K, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):253–60

CHEMISTRY

Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. Tempero RM, et al. **J Immunol** 1997 Feb 1;158(3):1377–82

GENETICS

Nucleotide and corrected amino acid sequence of the functional recombinant rat anaphylatoxin C5a. Rothermel E, et al. **Biochim Biophys Acta** 1997 Mar 20;1351(1–2):9–12

METABOLISM

Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis. Hoffmann JN, et al. **Intensive Care Med** 1996 Dec; 22(12):1360–7

ANAPHYLAXIS

see related
SRS–A

Fetal encephalopathy after maternal anaphylaxis. Case report. Luciano R, et al. **Biol Neonate** 1997;71(3):190–3

Idiopathic anaphylaxis. Patterson R, et al. **Compr Ther** 1996 Jun;22(6):360–2 (8 ref.)

Idiopathic anaphylaxis. Bourke J, et al. **Ir Med J** 1997 Mar; 90(2):62

Multiphasic anaphylaxis: report of a case with prehospital and emergency department considerations. Brady WJ Jr, et al. **J Emerg Med** 1997 Jul–Aug;15(4):477–81 (19 ref.)

When food can kill. McKevitt KV. **Mich Med** 1997 Feb; 96(2):16–9

Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient [letter] Maruyama H, et al. **Nephron** 1996;74(2):468–9

[Anaphylactic reaction to N–acetylcysteine after poisoning with paracetamol] Stavem K. **Tidsskr Nor Laegeforen** 1997 May 30;117(14):2038–9 (Eng. Abstr.) **(Nor)**

CHEMICALLY INDUCED

Nitric oxide and toxicity of contrast material. Lasser EC, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S204–6

Predictable and unpredictable adverse reactions to uroangiographic contrast media. Spinazzi A, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S210–3

Anaphylactoid symptoms due to oral minocycline [letter] Okano M, et al. **Acta Derm Venereol** 1996 Mar;76(2):164 (6 ref.)

Anaphylactoid reaction to oral contrast agent [letter] Marik PE, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1623–4

Anaphylactoid reaction after oral administration of diatrizoate meglumine and diatrizoate sodium solution [see comments] Miller SH. **AJR Am J Roentgenol** 1997 Apr; 168(4):959–61. Comment in: AJR Am J Roentgenol 1997 Apr;168(4):962–4.

Re: Anaphylactic shock during a routine upper gastrointestinal series [letter; comment] Miller SH. **AJR Am J Roentgenol** 1997 Sep;169(3):912–3. Comment on: AJR Am J Roentgenol 1997 Apr;168(4):957–8.

Anaphylactic shock during a routine upper gastrointestinal series [see comments] Seymour PC, et al. **AJR Am J Roentgenol** 1997 Apr;168(4):957–8. Comment in: AJR Am J Roentgenol 1997 Apr;168(4):962–4. Comment in: AJR Am J Roentgenol 1997 Sep;169(3):912–3.

Anaphylactoid reactions with gastrointestinal contrast media [comment] Skucas J. **AJR Am J Roentgenol** 1997 Apr; 168(4):962–4. Comment on: AJR Am J Roentgenol 1997 Apr;168(4):957–8. Comment on: AJR Am J Roentgenol 1997 Apr;168(4):959–61.

Anaphylactic reaction to hydroxycobalamin. Branco–Ferreira M, et al. **Allergy** 1997 Jan;52(1):118–9

Anaphylactic–type reaction to hymecromone. Gonzalo–Garijo MA, et al. **Allergy** 1996 Jun;51(6):442–3

Anaphylaxis from cow's milk casein. Tabar AI, et al. **Allergy** 1996 May;51(5):343–5

Psyllium laxative–induced anaphylaxis, asthma, and rhinitis. Vaswani SK, et al. **Allergy** 1996 Apr;51(4):266–8

Anaphylactic bronchoconstriction in immunized guinea pigs provoked by inhalation and intravenous administration of hexahydrophthalic anhydride and methyltetrahydrophthalic anhydride. Zhao H, et al. **Allergy** 1997 Jan;52(1):18–26

Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles. Ciesielski–Carlucci C, et al. **Am J Clin Oncol** 1997 Aug; 20(4):373–5 (14 ref.)

Fatal anaphylactic reaction to hair dye. Belton AL, et al. **Am J Forensic Med Pathol** 1997 Sep;18(3):290–2

Anaphylaxis to mivacurium. Baird MB, et al. **Anaesth Intensive Care** 1996 Aug;24(4):486–8

Anaphylactic reaction to rocuronium bromide. Yee R, et al. **Anaesth Intensive Care** 1996 Oct;24(5):601–4

Anaphylactic reaction after cisatracurium. Clendenen SR, et al. **Anesthesiology** 1997 Sep;87(3):690–2

Anaphylaxis to erythromycin. Jorro G, et al. **Ann Allergy Asthma Immunol** 1996 Dec;77(6):456–8

Anaphylactoid reactions due to nonsteroidal antiinflammatory drugs: clinical and cross–reactivity studies. Quiralte J, et al. **Ann Allergy Asthma Immunol** 1997 Mar;78(3):293–6

Acetaminophen anaphylaxis with aspirin and sodium salicylate sensitivity: a case report. Schwarz N, et al. **Ann Allergy Asthma Immunol** 1996 Dec;77(6):473–4

Prophylaxis of anaphylactoid reaction to antituberculous drugs [letter] [see comments] Kévorkian JP, et al. **Ann Pharmacother** 1997 Mar;31(3):373–4. Comment in: Ann Pharmacother 1997 Jul–Aug;31(7–8):928–9.

Anaphylactic reaction to liposomal amphotericin B in children [letter] Torre I, et al. **Ann Pharmacother** 1996 Sep; 30(9):1036–7

Anaphylactic shock after aprotinin reexposure: time course of aprotinin–specific antibodies. Scheule AM, et al. **Ann Thorac Surg** 1997 Jan;63(1):242–4

Sensitivity of human cutaneous mast cells to anaphylactic and nonimmunological stimuli. Brzezińska–Błaszczyk E, et al. **Arch Immunol Ther Exp (Warsz)** 1997;45(1):55–9

Nitritoid reaction in a patient on ACE inhibitor and Myocrisin treatments [letter] Ching DW, et al. **Aust N Z J Med** 1997 Jun;27(3):343

Latex anaphylaxis in a myasthenic child undergoing thymectomy. Beaulieu P, et al. **Can J Surg** 1996 Dec; 39(6):490–3

Refractory anaphylactoid shock potentiated by beta–blockers. Javeed N, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):383–4 (8 ref.)

Anaphylaxis to penicillins after non–therapeutic exposure: an immunological investigation. Blanca M, et al. **Clin Exp Allergy** 1996 Mar;26(3):335–40

Keeping up with drug allergy [editorial; comment] Coleman JW. **Clin Exp Allergy** 1996 Dec;26(12):1341–2 (16 ref.). Comment on: Clin Exp Allergy 1996 Dec;26(12):1355–63.

Drug–associated anaphylaxis: 20 years of reporting in The Netherlands (1974–1994) and review of the literature [see comments] van der Klauw MM, et al. **Clin Exp Allergy** 1996 Dec;26(12):1355–63 (55 ref.). Comment in: Clin Exp Allergy 1996 Dec;26(12):1341–2.

Anaphylaxis from cefotiam hexetil hydrochloride (CTM–HE) in an atopic nurse [letter] Mizutani H, et al. **Clin Exp Dermatol** 1996 May;21(3):246

Contact anaphylaxis due to para–phenylenediamine. Fukunaga T, et al. **Contact Dermatitis** 1996 Sep;35(3):185–6

Perioperative collapse: prevalence of latex allergy in patients sensitive to anaesthetic agents. Tan BB, et al. **Contact Dermatitis** 1997 Jan;36(1):47–50

Acute laryngeal obstruction—reaction to intravenous hydrocortisone? [letter] Srinivasan V, et al. **Eur J Anaesthesiol** 1997 May;14(3):342

Anaphylactic shock during hysteroscopy using Hyskon solution: case report and review of adverse reactions and their treatment. Perlitz Y, et al. **Gynecol Obstet Invest** 1996; 41(1):67–9 (21 ref.)

Ventricular fibrillation after intrapleural urokinase [letter] Alfageme I, et al. **Intensive Care Med** 1997 Mar;23(3):352

Non cholinergic toxicity of Sarin [editorial; comment] Ishikawa S. **Intern Med** 1997 Jul;36(7):447. Comment on: Intern Med 1997 Jul;36(7):466–70.

Acute urticaria caused by subcutaneous recombinant hirudin: evidence for an IgG–mediated hypersensitivity reaction. Bircher AJ, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):994–6

An adverse reaction to angiotensin–converting enzyme inhibitors in a patient with neglected C1 esterase inhibitor deficiency. Ebo DG, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):425–6

Epileptic attacks associated with wasp sting–induced anaphylaxis. Gonzalo Garijo MA, et al. **J Investig Allergol Clin Immunol** 1996 Jul–Aug;6(4):277–9

Factor IX inhibitors and anaphylaxis in hemophilia B. Warrier I, et al. **J Pediatr Hematol Oncol** 1997 Jan–Feb; 19(1):23–7

Anaphylactic shock induced by intraarticular injection of methylprednisolone acetate. Mace S, et al. **J Rheumatol** 1997 Jun;24(6):1191–4 (37 ref.)

Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty–eight reexposures to aprotinin in heart operations. Dietrich W, et al. **J Thorac Cardiovasc Surg** 1997 Jan;113(1):194–201

Anaphylactoid reaction, angioedema, and urticaria associated with lamivudine [letter] Kainer MA, et al. **Lancet** 1996 Nov 30;348(9040):1519

Severe penicillin allergy precipitated by inhalation and topical exposure to co–amoxiclav (Augmentin) [letter] Jarrett P, et al. **N Z Med J** 1996 Sep 27;109(1030):366

Nurses can prepare to manage anaphylaxis in the home infusion patient. Anani HG. **Oncol Nurs Forum** 1996 Sep; 23(8):1336–7

Prophylaxis for anaphylactoid reactions in high risk patients receiving radiopaque contrast media. Robertson PS, et al. **Surg Neurol** 1997 Sep;48(3):292–3

Fluoroquinolones and anaphylaxis. Blayac JP, et al. **Therapie** 1996 Jul–Aug;51(4):417–8

[Anaphylactic or anaphylactoid reactions to paracetamol. Report of 3 cases] Sabbah A, et al. **Allerg Immunol (Paris)** 1997 Mar;29(3):60–2 (Eng. Abstr.) **(Fre)**

[Apropos of drug allergy (editorial)] Sabbah A. **Allerg Immunol (Paris)** 1996 Sep;28(7):230, 233 (Eng. Abstr.) **(Fre)**

[Anaphylactic reactions after intravenous injection of gadolinium for pituitary or cerebral magnetic resonance imaging (letter)] Bertherat J, et al. **Presse Med** 1996 Dec 21;25(40):2050 **(Fre)**

[Anaphylactic shock related to the treatment of malaria with halofantrine (letter)] Fourcade L, et al. **Presse Med** 1997 Apr 12;26(12):559 **(Fre)**

[Anaphylactic shock caused by application of fluorescein on the ocular conjunctiva] el Harrar N, et al. **Presse Med** 1996 Oct 26;25(32):1546–7 (Eng. Abstr.) **(Fre)**

[Pathophysiologic and immunologic mechanisms of contrast medium–induced anaphylactoid immediate hypersensitivity—an overview] Amon U. **Aktuelle Radiol** 1997 May;7(3):145–8 (28 ref.) (Eng. Abstr.) **(Ger)**

[Life threatening anaphylaxis after repeated cisplatin administration: case report and neu therapy concepts] Berg K, et al. **Zentralbl Gynakol** 1996;118(12):684–8 (Eng. Abstr.) **(Ger)**

[A case of life–threatening anaphylactoid reaction caused by povidone–iodine] Nakao M, et al. **Masui** 1997 Jan; 46(1):105–9 (Eng. Abstr.) **(Jpn)**

[Bronchospasm due to anaphylactic reaction to Hydroxyethyl starch (HESPANDER)] Takada M, et al. **Masui** 1997 Mar; 46(3):397–400 (Eng. Abstr.) **(Jpn)**

[The antidiphtheria immunization of a child with an anaphylactic reaction to DTP] Brumboiu I, et al. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jul–Dec; 41(3–4):119–21 **(Rum)**

[Allergic reactions during anesthesia] Escolano F, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):17–26 (56 ref.) (Eng. Abstr.) **(Spa)**

[Noncardiogenic pulmonary edema associated with hydrochlorothiazide use] Saldaña A, et al. **Rev Med Chil** 1996 Jun;124(6):720–4 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Allergy to pine nuts in a bird fancier. Jansen A, et al. **Allergy** 1996 Oct;51(10):741–4

Hyperthermia after cardiac surgery. Abe K, et al. **Can J Anaesth** 1997 Jun;44(6):662–5

Acute and delayed cerebral infarction after wasp sting anaphylaxis. Riggs JE, et al. **Clin Neuropharmacol** 1994 Aug;17(4):384–8

Recurrent hearing impairment and nystagmus induced by repeated antigen exposure in actively sensitized guinea pigs. Minoda R, et al. **Int Arch Allergy Immunol** 1996 Oct; 111(2):166–72

Bilateral massive adrenal haemorrhage complicating anaphylactic shock: a case report [see comments] Lefevre N, et al. **Intensive Care Med** 1996 May;22(5):447–9. Comment in: Intensive Care Med 1997 Feb;23(2):235–6.

Epileptic attacks associated with wasp sting–induced anaphylaxis. Gonzalo Garijo MA, et al. **J Investig Allergol Clin Immunol** 1996 Jul–Aug;6(4):277–9

DIAGNOSIS

Tryptase—at last a useful diagnostic marker for anaphylactic death. Edston E, et al. **Allergy** 1996 Jun;51(6):443–5

Anaphylaxis to dexamethasone. Figueredo E, et al. **Allergy** 1997 Aug;52(8):877

Honey allergy and rhinitis in Ankara, Turkey. Kalyoncu AF. **Allergy** 1997 Aug;52(8):876–7

Serum tryptase measurement in diagnosis of intraoperative anaphylaxis caused by hydatid cyst. Blanco I, et al. **Anaesth Intensive Care** 1996 Aug;24(4):489–91

Anaphylaxis and stinging insect reactions. Dykewicz MS. **Compr Ther** 1996 Sep;22(9):579–85 (9 ref.)

Pediatric idiopathic anaphylaxis: experience with 22 patients. Ditto AM, et al. **J Allergy Clin Immunol** 1997 Sep; 100(3):320–6

An adverse reaction to angiotensin–converting enzyme inhibitors in a patient with neglected C1 esterase inhibitor deficiency. Ebo DG, et al. **J Allergy Clin Immunol** 1997

Mar;99(3):425–6
Exercise–induced anaphylaxis after food contaminant ingestion in double–blinded, placebo–controlled, food–exercise challenge. Fiocchi A, et al. **J Allergy Clin Immunol** 1997 Sep;100(3):424–5
Anaphylaxis and coronary disease [letter] Roth A. **N Engl J Med** 1996 Dec 19;335(25):1925
[Emergency medicine for the practitioner: shock] Schaller MD, et al. **Rev Med Suisse Romande** 1997 Apr;117(4):321–4 **(Fre)**
[Recurrent losses of consciousness in anaphylactic reactions] Woltsche–Kahr I, et al. **Dtsch Med Wochenschr** 1997 Jun 6;122(23):747–50 (30 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Idiopathic anaphylaxis: long–term follow–up, cost, and outlook. Krasnick J, et al. **Allergy** 1996 Oct;51(10):724–31
Antihistamines and pregnancy [editorial] Schatz M, et al. **Ann Allergy Asthma Immunol** 1997 Feb;78(2):157–9
Methylene blue in anaphylactic shock [letter] Evora PR, et al. **Ann Emerg Med** 1997 Aug;30(2):240
Fatal intracranial bleeding associated with prehospital use of epinephrine. Horowitz BZ, et al. **Ann Emerg Med** 1996 Dec;28(6):725–7
Anaphylaxis and stinging insect reactions. Dykewicz MS. **Compr Ther** 1996 Sep;22(9):579–85 (9 ref.)
Insect & fire ant hypersensitivity: what the primary care physician needs to know. Freeman TM. **Compr Ther** 1997 Jan;23(1):38–43
Effect of TYB–2285 on lung anaphylaxis in actively sensitized rats. Watanabe A, et al. **Gen Pharmacol** 1997 Feb; 28(2):305–9
Antianaphylactic activity of Poncirus trifoliata fruit extract. Lee YM, et al. **J Ethnopharmacol** 1996 Nov;54(2–3):77–84
Preventing death from anaphylactic reaction [letter] Frazier CA. **J Ky Med Assoc** 1996 Feb;94(2):72
Zinc and intestinal anaphylaxis to cow's milk proteins in malnourished guinea pigs. Darmon N, et al. **Pediatr Res** 1997 Aug;42(2):208–13
An inhibitor of poly(adenosine 5'–diphosphoribose) synthetase, 3–aminobenzamide, does not improve cardiovascular depression, bronchospasm, or survival associated with systemic anaphylaxis in rabbits in vivo [see comments] Takeuchi H, et al. **Shock** 1997 Aug;8(2):147–52 . Comment in: Shock 1997 Aug;8(2):153–4.
[An anaphylactic shock case after hepatic arterial infusion of zinostatin stimalamer suspension improved by anti–histaminics] Fukuhara K, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):1023–6 (Eng. Abstr.) **(Jpn)**
[The effect of a protein concentrate from milk whey and its fractions on the macromolecular permeability of the intestinal barrier in rats with experimental food anaphylaxis] Gmoshinskiĭ IV, et al. **Vopr Pitan** 1996;(1):3–6 (Eng. Abstr.) **(Rus)**
[Anaphylaxis in severe food allergy. Adrenaline injection is safer than inhalation] Foucard T, et al. **Lakartidningen** 1997 Apr 16;94(16):1478, 1483 **(Swe)**

ENZYMOLOGY

Fate of two mast cell tryptases in V3 mastocytosis and normal BALB/c mice undergoing passive systemic anaphylaxis: prolonged retention of exocytosed mMCP–6 in connective tissues, and rapid accumulation of enzymatically active mMCP–7 in the blood. Ghildyal N, et al. **J Exp Med** 1996 Sep 1;184(3):1061–73

EPIDEMIOLOGY

Incidence and impact on outcome of streptokinase allergy in the GUSTO–I trial. Global Utilization of Streptokinase and t–PA in Occluded Coronary Arteries. Tsang TS, et al. **Am J Cardiol** 1997 May 1;79(9):1232–5
[Anaphylactic shock in hepatic hydatid cyst] Popovici A, et al. **Chirurgia (Bucur)** 1997 Jan–Feb;92(1):67–72 **(Rum)**

ETIOLOGY

Exercise–induced egg anaphylaxis. Asero R, et al. **Allergy** 1997 Jun;52(6):687–9
Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin. Blanco C, et al. **Allergy** 1996 Jun;51(6):421–4
Anisakis simplex, a relevant etiologic factor in acute urticaria. Del Pozo MD, et al. **Allergy** 1997 May;52(5):576–9
Anaphylaxis to topical bacitracin. Dyck ED, et al. **Allergy** 1997 Aug;52(8):870–1
Anaphylactic reaction caused by cherry ingestion. Escribano MM, et al. **Allergy** 1996 Oct;51(10):756–7
Anaphylactoid reaction in relation to sialolithiasis. Jorro Martinez G, et al. **Allergy** 1996 Aug;51(8):590–2
Anaphylactic reaction caused by neoallergens in heated pecan nut. Malanin K, et al. **Allergy** 1995 Dec;50(12):988–91
Anaphylaxis due to a red harvest ant bite. Schmid–Grendelmeier P, et al. **Allergy** 1997 Feb; 52(2):230–1
Drug–dependent exercise–induced anaphylaxis. van Wijk RG, et al. **Allergy** 1995 Dec;50(12):992–4
Allergy to the ornamental indoor green plant Tradescantia (Albiflоxia). Wüthrich B, et al. **Allergy** 1997 May; 52(5):556–9
Anaphylaxis to saffron. Wüthrich B, et al. **Allergy** 1997 Apr; 52(4):476–7
Anaphylaxis induced by exercise and related to multiple food intake. Caffarelli C, et al. **Allergy Asthma Proc** 1997 Jul–Aug;18(4):245–8
Food plus exercise plus anaphylaxis: theories and challenge [editorial] Fink JN. **Allergy Asthma Proc** 1997 Jul–Aug; 18(4):249
Anaphylaxis to the ingestion and inhalation of Tenebrio molitor (mealworm) and Zophobas morio (superworm). Freye HB, et al. **Allergy Asthma Proc** 1996 Jul–Aug; 17(4):215–9
Spontaneous systemic anaphylaxis as an unusual presentation of hydatid cyst: report of two cases. Mooraki A, et al. **Am J Trop Med Hyg** 1996 Sep;55(3):302–3
Serum tryptase measurement in diagnosis of intraoperative anaphylaxis caused by hydatid cyst. Blanco I, et al. **Anaesth Intensive Care** 1996 Aug;24(4):489–91
Idiopathic anaphylaxis: a series of 335 cases. Ditto AM, et al. **Ann Allergy Asthma Immunol** 1996 Oct;77(4):285–91
Exercise–induced anaphylaxis: useful screening of food sensitization. Guinnepain MT, et al. **Ann Allergy Asthma Immunol** 1996 Dec;77(6):491–6
Anaphylaxis induced by lentils. Kalogeromitros D, et al. **Ann Allergy Asthma Immunol** 1996 Dec;77(6):480–2
Severe hypersensitivity reaction during hemodialysis. Kraske GK, et al. **Ann Allergy Asthma Immunol** 1997 Feb; 78(2):217–20
Malignant and corticosteroid–dependent idiopathic anaphylaxis: successful responses to ketotifen. Patterson R, et al. **Ann Allergy Asthma Immunol** 1997 Aug;79(2):138–44
A nurse with anaphylaxis to stone fruits and latex sensitivity: potential diagnostic difficulties to consider. Weiss SJ, et al. **Ann Allergy Asthma Immunol** 1996 Dec;77(6):504–8
Anaphylaxis and cerebral hyadatidic disease [letter] Diaz de Durana MD, et al. **Ann Intern Med** 1997 May 1;126(9):745
Food related, exercise induced anaphylaxis. Caffarelli C, et al. **Arch Dis Child** 1996 Aug;75(2):141–4
Allergic reactions to oral, surgical and topical bovine collagen. Anaphylactic risk for surgeons. Mullins RJ, et al. **Aust N Z J Ophthalmol** 1996 Aug;24(3):257–60
Anaphylaxis during autologous peripheral blood progenitor cell infusion. Essayan DM, et al. **Bone Marrow Transplant** 1997 Apr;19(7):749–52
Anaphylaxis associated with, but not caused by, extradural bupivacaine. Rae SM, et al. **Br J Anaesth** 1997 Feb; 78(2):224–6
Allergies and anaesthesia [letter] Seigne R. **Br J Anaesth** 1997 Jun;78(6):778
Food–dependent exercise–induced anaphylaxis due to matsutake mushrooms [letter] Okano M, et al. **Br J Dermatol** 1997 May;136(5):805
The clinical spectrum of anaphylaxis in north–west England. Pumphrey RS, et al. **Clin Exp Allergy** 1996 Dec; 26(12):1364–70
Asthma and anaphylaxis induced by royal jelly. Thien FC, et al. **Clin Exp Allergy** 1996 Feb;26(2):216–22
Life–threatening, recurrent anaphylaxis caused by allergy to gliadin and exercise. Varjonen E, et al. **Clin Exp Allergy** 1997 Feb;27(2):162–6
Wheatburger anaphylaxis due to hidden buckwheat [letter] Wüthrich B, et al. **Clin Exp Allergy** 1995 Dec;25(12):1263
Urticarial anaphylactoid reaction following metoprolol [letter] Mora–Fernández C, et al. **Clin Nephrol** 1997 Mar; 47(3):203
Acute and delayed cerebral infarction after wasp sting anaphylaxis. Riggs JE, et al. **Clin Neuropharmacol** 1994 Aug;17(4):384–8
Post–Norplant implants insertion anaphylactoid reaction: a case report. Gbolade BA. **Contraception** 1997 May; 55(5):319–20
Exercise–induced anaphylaxis related to cuttlefish intake. Caffarelli C, et al. **Eur J Pediatr** 1996 Dec;155(12):1025–6
Micrococcus luteus cells and cell walls induce anaphylactoid reactions accompanied by early death and serum cytokines in mice primed with muramyl dipeptide. Monodane T, et al. **FEMS Immunol Med Microbiol** 1997 Jan;17(1):49–55
Anaphylactic shock in a female patient due to a spontaneous rupture of a hepatic hydatid cyst: a case report. Horzic M, et al. **Hepatogastroenterology** 1996 Nov–Dec; 43(12):1601–2
The renin–angiotensin system in patients with repeated anaphylactic reactions during hymenoptera venom hyposensitization and sting challenge. Hermann K, et al. **Int Arch Allergy Immunol** 1997 Mar;112(3):251–6
Risk factors associated with the severity of systemic insect sting reactions. Tamir R, et al. **Isr J Med Sci** 1996 Dec; 32(12):1192–7
Cumin anaphylaxis: a case report. Boxer M, et al. **J Allergy Clin Immunol** 1997 May;99(5):722–3
Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. Goldberg A, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):182–4
Anaphylaxis to ackee fruit. Lebo DB, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):997–8
Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. Oude Elberink JN, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):153–4
Development of IgE antibody to gelatin in children with systemic immediate–type reactions to vaccines. Sakaguchi M, et al. **J Allergy Clin Immunol** 1997 May;99(5):720–1
Mite–contaminated foods as a cause of anaphylaxis. Sanchez–Borges M, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):738–43
Anaphylaxis: multiple etiologies–focused therapy. James JM. **J Ark Med Soc** 1996 Nov;93(6):281–7 (10 ref.)
Insect stings [letter] Frazier CA. **J Fla Med Assoc** 1996 Jan; 83(1):53
Anaphylaxis induced by ingestion of a pollen compound. Chivato T, et al. **J Investig Allergol Clin Immunol** 1996 May–Jun;6(3):208–9
Experimental methods for immunization and challenge in antigenicity studies in guinea pigs. Nagami K, et al. **J Toxicol Sci** 1995 Nov;20(5):579–94
Exercise–induced urticaria and anaphylaxis. Volcheck GW, et al. **Mayo Clin Proc** 1997 Feb;72(2):140–7 (32 ref.)
Balloon–induced latex anaphylaxis [letter] Hawkins CA, et al. **Med J Aust** 1997 Aug 4;167(3):173–4
Anaphylaxis with Anisakis simplex in the gastric mucosa [letter] Alonso A, et al. **N Engl J Med** 1997 Jul 31; 337(5):350–1
Anaphylactoid reactions during dextran apheresis may occur even in the absence of ACE–inhibitor administration [letter] Schwarzbeck A, et al. **Nephrol Dial Transplant** 1997 May; 12(5):1083–4
Anaphylactic reaction to latex during cesarean delivery. Deusch E, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):727
Laboratory animal allergy: anaphylaxis from a needle injury. Watt AD, et al. **Occup Environ Med** 1996 Aug;53(8):573–4
The impact of Hymenoptera venom allergy on occupational activities. Kahan E, et al. **Occup Med (Oxf)** 1997 Jul; 47(5):273–6
Latex allergy and anaphylaxis in a child undergoing craniofacial surgery. Peng C, et al. **Plast Reconstr Surg** 1996 Dec;98(7):1290–2
The incidence, aetiology and management of anaphylaxis presenting to an accident and emergency department. Stewart AG, et al. **QJM** 1996 Nov;89(11):859–64
Latex allergy: a South Dakota problem. Bubak ME. **S D J Med** 1996 Apr;49(4):119–20
Transvaginal ultrasound may cause latex anaphylaxis [letter] Bronshtein M, et al. **Ultrasound Obstet Gynecol** 1996 May; 7(5):379–80
[Allergy to human semen] Dijkstra AT, et al. **Ned Tijdschr Geneeskd** 1997 Apr 5;141(14):690–2 (Eng. Abstr.) **(Dut)**
[Immediate and late complications of human albumin use] Quaranta JF. **Ann Fr Anesth Reanim** 1996;15(4):553–9 (Eng. Abstr.) **(Fre)**
[Risk factors for acute hypersensitivity reactions in hemodialysis] Simon P, et al. **Nephrologie** 1996;17(3):163–70 (Eng. Abstr.) **(Fre)**
[Anaphylaxis: role of a hormonal cofactor (letter)] Drouet M, et al. **Presse Med** 1997 Jan 18–25;26(1):17 **(Fre)**
[Anaphylactoid manifestations after ingestion of tuna: think about scombroid intoxication (letter)] Maury E, et al. **Presse Med** 1997 May 17;26(16):759 **(Fre)**
[Apropos of anaphylactic shock caused by application of fluorescein on the ocular conjunctiva (letter)] Moneret–Vautrin DA. **Presse Med** 1997 Mar 22;26(9):420 **(Fre)**
[Anaphylactic shock. Principles and acute therapy] Flesche CW, et al. **Hautarzt** 1996 Aug;47(8):650–60; quiz 660 **(Ger)**
[Hymenoptera venom allergy] Meier P, et al. **Schweiz Med Wochenschr** 1997 Mar 8;127(10):395–7 (Eng. Abstr.) **(Ger)**
[Severe allergic–immunologic reactions] Müller UR. **Schweiz Rundsch Med Prax** 1997 Feb 18;86(8):314–8 (23 ref.) (Eng. Abstr.) **(Ger)**
[Clinical and experimental aspect of latex allergy] Akasawa A. **Arerugi** 1997 Apr;46(4):349–53 (11 ref.) **(Jpn)**
[A case of food–dependent exercise–induced anaphylaxis induced by shrimp] Tokunaga H, et al. **Arerugi** 1995 Nov; 44(11):1297–304 (Eng. Abstr.) **(Jpn)**
[Case of food–dependent exercise–induced anaphylaxis caused by wheat] Murakami R, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):138–9 **(Jpn)**
[A case report of exercise–induced anaphylaxis] Kato Y, et al. **Rinsho Shinkeigaku** 1996 May;36(5):680–2 (Eng. Abstr.) **(Jpn)**
[Anaphylaxis due to the rupture of a hydatid cyst in the right ventricle (letter)] Valdovinos Mahave MC, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):238–9 (7 ref.) **(Spa)**

IMMUNOLOGY

Anaphylactoid reaction in relation to sialolithiasis. Jorro Martinez G, et al. **Allergy** 1996 Aug;51(8):590–2
Chickpea–induced anaphylaxis. Niphadkar PV, et al. **Allergy** 1997 Jan;52(1):115–6
Anaphylaxis from cow's milk casein. Tabar AI, et al. **Allergy** 1996 May;51(5):343–5
Anaphylactoid syndrome of pregnancy [letter; comment] Benson MD. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):749 . Comment on: Am J Obstet Gynecol 1995 Apr;172(4 Pt 1):1158–67; discussion 1167–9.
Amniotic fluid embolism, anaphylaxis, and tryptase. Benson MD, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):737 (5 ref.)
Sensitivity of human cutaneous mast cells to anaphylactic and nonimmunological stimuli. Brzezińska–Błaszczyk E, et al. **Arch Immunol Ther Exp (Warsz)** 1997;45(1):55–9
Anaphylactic IgE and IgG1 production for hapten can be

enhanced by contrast media. Miyauchi T, et al. **Br J Radiol** 1996 Oct;69(826):920–4

Characterization of proliferative responses and cytokine mRNA profiles induced by Vespula venom in patients with severe reactions to wasp stings. Bonay M, et al. **Clin Exp Immunol** 1997 Aug;109(2):342–50

Intraoperative anaphylaxis due to allergy to latex in children who have cerebral palsy: a report of six cases. Delfico AJ, et al. **Dev Med Child Neurol** 1997 Mar;39(3):194–7

Heterogeneity of drug susceptibility of mouse active anaphylactic shock [published erratum appears in Immunol Invest 1997 Apr;26(3):395] Kimura S, et al. **Immunol Invest** 1996 Sep–Nov;25(5–6):425–34

Eosinophil-derived proteins in postprandial (food-dependent) exercise-induced anaphylaxis. Romano A, et al. **Int Arch Allergy Immunol** 1997 Aug;113(4):505–11

Anaphylaxis after ingestion of wheat flour contaminated with mites. Blanco C, et al. **J Allergy Clin Immunol** 1997 Mar; 99(3):308–13

Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. Goldberg A, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):182–4

Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. Nelson HS, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):744–51

Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. Sakaguchi M, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1058–61

Anaphylactic reaction after bites by Glossina morsitans (tsetse fly) in a laboratory worker. Stevens WJ, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):700–1

Absence of Fc epsilonRI alpha chain results in upregulation of Fc gammaRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between Fc epsilonRI and Fc gammaRIII for limiting amounts of FcR beta and gamma chains. Dombrowicz D, et al. **J Clin Invest** 1997 Mar 1;99(5):915–25

Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. Miyajima I, et al. **J Clin Invest** 1997 Mar 1;99(5):901–14

Anti-IL-4 antibody inhibits antigen specific IgE response but fails to prevent chicken gamma globulin-induced active systemic anaphylaxis: evidence for the involvement of IgG antibodies. Lee HK, et al. **J Korean Med Sci** 1996 Apr; 11(2):111–7

A serendipitous peek at tobacco. Hornsby RP. **J Tenn Med Assoc** 1996 Mar;89(3):90–1

Bronchial and alveolar allergen-induced anaphylaxis and the stimulation of bronchial mucociliary clearance in ragweed-sensitized dogs. Yeates DB, et al. **Proc Assoc Am Physicians** 1997 Jul;109(4):440–52

[Antagonistic effect of oleanolic acid on anaphylactic shock] Zhang LR, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Nov; 16(6):527–30 (Eng. Abstr.) **(Chi)**

[Allergy to mosquitoes and use of new immunobiological parameters] Sabbah A, et al. **Allerg Immunol (Paris)** 1997 May;29(5):126–8 (Eng. Abstr.) **(Fre)**

[Anaphylactic shock after tourniquet removal in orthopedic surgery] Laxenaire MC, et al. **Ann Fr Anesth Reanim** 1996; 15(2):179–84 (Eng. Abstr.) **(Fre)**

METABOLISM

Intestinal anaphylaxis induces Fos immunoreactivity in myenteric plexus of rat small intestine. Miampamba M, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):G181–9

Human lung anaphylaxis results in rapid release of interleukin-4. Erger RA, et al. **Ann Allergy Asthma Immunol** 1997 Jun;78(6):566–8

Nitric oxide: a mediator in anaphylactic shock in guinea-pigs. Abend Y, et al. **J Basic Clin Physiol Pharmacol** 1996; 7(1):57–69

Release of calcitonin gene-related peptide in cardiac anaphylaxis. Schuligoi R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):224–9

Nitric oxide, perioxynitrite and poly(ADP-ribose) synthetase in anaphylactic shock [editorial; comment] Szabó C. **Shock** 1997 Aug;8(2):153–4. Comment on: Shock 1997 Aug;8(2):147–52.

[Importance of plasma (histamine and tryptase) and urinary (methylhistamine) in peri-anesthetic anaphylactic and/or anaphylactoid reactions] Cottineau C, et al. **Allerg Immunol (Paris)** 1996 Oct;28(8):270, 273–6 (Eng. Abstr.) **(Fre)**

[Oxygen consumption during anaphylactic shock] Catalá JC, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):154–6 (Eng. Abstr.) **(Spa)**

[The characteristics of tissue lipid peroxidation of the internal organs in anaphylaxis under the action of a hypo- or hypermagnetic field] Babych VI. **Fiziol Zh** 1996; 42(5–6):66–71 (Eng. Abstr.) **(Ukr)**

MORTALITY

Micrococcus luteus cells and cell walls induce anaphylactoid reactions accompanied by early death and serum cytokines in mice primed with muramyl dipeptide. Monodane T, et al. **FEMS Immunol Med Microbiol** 1997 Jan;17(1):49–55

NURSING

Emergency! Anaphylaxis. Lisanti P. **Am J Nurs** 1996 Nov; 96(11):51

Nurses can prepare to manage anaphylaxis in the home infusion patient. Anani HG. **Oncol Nurs Forum** 1996 Sep; 23(8):1336–7

PATHOLOGY

Hypothesis for synergistic toxicity of organophosphorus poisoning-induced cholinergic crisis and anaphylactoid reactions. Cowan FM, et al. **J Appl Toxicol** 1996 Jan–Feb; 16(1):25–33 (79 ref.)

Apoptotic cell death of neutrophils in development of skin lesions of patients with anaphylactoid purpura. Banno S, et al. **J Dermatol** 1997 Feb;24(2):94–9

PHYSIOPATHOLOGY

Multiphasic anaphylaxis: an uncommon event in the emergency department. Brady WJ Jr, et al. **Acad Emerg Med** 1997 Mar;4(3):193–7

Exercise-induced egg anaphylaxis. Asero R, et al. **Allergy** 1997 Jun;52(6):687–9

A rapid increase in foot tissue temperature predicts cardiovascular collapse during anaphylactic and anaphylactoid reactions. Kotani N, et al. **Anesthesiology** 1997 Sep;87(3):559–68

Hypersensitivity anaphylactoid reaction to pefloxacin in a patient with AIDS. al-Hedaithy MA, et al. **Ann Pharmacother** 1996 Jun;30(6):612–4

Effects of 1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3-(1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid with thromboxane A2 synthetase inhibitory and H1-blocking activities on anaphylactic bronchospasm. Nakamura S, et al. **Arzneimittelforschung** 1996 Nov; 46(11):1067–71

Reevaluation of the effect of a high alpha-linolenate and a high linoleate diet on antigen-induced antibody and anaphylactic responses in mice. Oh-hashi K, et al. **Biol Pharm Bull** 1997 Mar;20(3):217–23

Mediation of altered motility in food protein induced intestinal anaphylaxis in Hooded-Lister rat. Scott RB, et al. **Can J Physiol Pharmacol** 1996 Mar;74(3):320–30

The effects of a kinin antagonist on changes in lung function and plasma extravasation into the airways following challenge of sensitized guinea-pigs. Featherstone RL, et al. **Clin Exp Allergy** 1996 Feb;26(2):235–40

Paroxysmal atrial fibrillation after insect sting. Ferrari S, et al. **J Allergy Clin Immunol** 1996 Oct;98(4):759–61

Absence of Fc epsilonRI alpha chain results in upregulation of Fc gammaRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between Fc epsilonRI and Fc gammaRIII for limiting amounts of FcR beta and gamma chains. Dombrowicz D, et al. **J Clin Invest** 1997 Mar 1;99(5):915–25

Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. Miyajima I, et al. **J Clin Invest** 1997 Mar 1;99(5):901–14

Anaphylaxis and coronary disease [letter; comment] Levy JH, et al. **N Engl J Med** 1996 Dec 19;335(25):1925; discussion 1925. Comment on: N Engl J Med 1996 Aug 1;335(5):340–1.

In vivo production of nitric oxide in the canine heart in IgE-mediated anaphylaxis. Saitoh J, et al. **Shock** 1996 Jul; 6(1):66–70

[Anaphylactic shock] Müller-Werdan U, et al. **Anaesthesist** 1997 Jun;46(6):549–63 (14 ref.) **(Ger)**

[Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)] Cannas S, et al. **G Ital Cardiol** 1997 Mar;27(3):278–80 (Eng. Abstr.) **(Ita)**

[Cardiac anaphylaxis] Watanabe S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):560–3 (10 ref.) **(Jpn)**

[Changes in electroencephalograms and brain blood filling in guinea pigs in experimental bronchospasm] Karashurov SE. **Patol Fiziol Eksp Ter** 1996 Apr–Jun;(2):9–11 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

A novel submandibular gland peptide protects against endotoxic and anaphylactic shock. Mathison RD, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1017–23

Syringes and latex allergy [letter] Rao AM, et al. **Anaesthesia** 1997 May;52(5):506

A variety of clinical applicabilities of immobilized dextran sulphate as lipoprotein adsorbent and avoidance of anaphylactoid (anion-blood contact) reaction in its use. Agishi T, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1996 Jan; 24(1):11–7

Prevention of dextran anaphylaxis. Ten years experience with hapten dextran. Hedin H, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):358–9

Anti-IL-4 monoclonal antibody prevents antibiotics-induced active fatal anaphylaxis. Park JS, et al. **J Immunol** 1997 May 15;158(10):5002–6

The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. Yanni JM, et al. **J Ocul Pharmacol Ther** 1996 Winter; 12(4):389–400

Preventing insect sting anaphylaxis. Hollingsworth H. **JAMA** 1997 Apr 16;277(15):1196–7

Prophylaxis for anaphylactoid reactions in high risk patients receiving radiopaque contrast media. Robertson PS, et al. **Surg Neurol** 1997 Sep;48(3):292–3

[Portable emergency kits prescribed for patients allergic to hymenoptera venoms] Wessel F. **Allerg Immunol (Paris)** 1996 Oct;28(8):282–7 (Eng. Abstr.) **(Fre)**

[Lung edema and erosive gastroduodenitis as a sequela of inappropriate use of an adrenaline dose aerosol after wasp sting] Balda BR, et al. **Hautarzt** 1997 Mar;48(3):195–8 (Eng. Abstr.) **(Ger)**

[A case of life-threatening anaphylactoid reaction caused by povidone-iodine] Nakao M, et al. **Masui** 1997 Jan; 46(1):105–9 (Eng. Abstr.) **(Jpn)**

REHABILITATION

[The characteristics of tissue lipid peroxidation of the internal organs in anaphylaxis under the action of a hypo- or hypermagnetic field] Babych VI. **Fiziol Zh** 1996; 42(5–6):66–71 (Eng. Abstr.) **(Ukr)**

THERAPY

Current status of immunotherapy for allergies and anaphylactic reactions. Norman PS. **Adv Intern Med** 1996; 41:681–713 (129 ref.)

Intraosseous infusion in an emergency situation: a case report. Nafiu OO, et al. **Ann Trop Paediatr** 1997 Jun;17(2):175–7

Management of children with potential anaphylactic reactions in the community: a training package and proposal for good practice. Vickers DW, et al. **Clin Exp Allergy** 1997 Aug;27(8):898–903

Bilateral massive adrenal haemorrhage complicating anaphylactic shock: a case report [letter; comment] Waldhausen E. **Intensive Care Med** 1997 Feb;23(2):235–6 . Comment on: Intensive Care Med 1996 May;22(5):447–9.

Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. Fricker M, et al. **J Allergy Clin Immunol** 1997 Jul;100(1):11–5

Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. Nelson HS, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):744–51

Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. Oude Elberink JN, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):153–4

[Anaphylactic shock. From prevention to treatment] Questel F. **Presse Med** 1996 Oct 19;25(31):1507–15 (24 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

A Staphylococcus aureus enterotoxin-B induced type 1 immediate hypersensitivity reaction in a goat. Schofield LN, et al. **Microbios** 1997;89(358):29–30

ANAPHYLAXIS, PASSIVE CUTANEOUS see **PASSIVE CUTANEOUS ANAPHYLAXIS**

ANAPLASIA

METABOLISM

A high ratio of insulin-like growth factor II/insulin-like growth factor binding protein 2 messenger RNA as a marker for anaplasia in meningiomas. Nordqvist AC, et al. **Cancer Res** 1997 Jul 1;57(13):2611–4

PATHOLOGY

Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor. Re GG, et al. **Mod Pathol** 1997 Feb;10(2):129–36

ANAPLASMA

GENETICS

Anaplasma marginale major surface protein 3 is encoded by a polymorphic, multigene family. Alleman AR, et al. **Infect Immun** 1997 Jan;65(1):156–63

IMMUNOLOGY

Effect on intraerythrocytic Anaplasma marginale of soluble factors from infected calf blood mononuclear cells. Wyatt CR, et al. **Infect Immun** 1996 Nov;64(11):4846–9

Antibody against an Anaplasma marginale MSP5 epitope common to tick and erythrocyte stages identifies persistently infected cattle. Knowles D, et al. **J Clin Microbiol** 1996 Sep;34(9):2225–30

Peripheral blood lymphocyte proliferative responses in cattle infected with or vaccinated against Anaplasma marginale. Gale KR, et al. **Parasitol Res** 1996;82(6):551–62

Development and validation of an indirect enzyme immunoassay for detection of antibody to Anaplasma marginale in bovine sera. Nielsen K, et al.

Vet Parasitol 1996 Dec 31;67(3–4):133–42

ISOLATION & PURIFICATION

Anaplasma marginale: detection of carrier cattle by PCR–ELISA. Gale KR, et al. **Int J Parasitol** 1996 Oct; 26(10):1103–9

Developmental studies of Anaplasma marginale (Rickettsiales:Anaplasmataceae) in male Dermacentor andersoni (Acari:Ixodidae) infected as adults by using nonradioactive in situ hybridization and microscopy. Ge NL, et al. **J Med Entomol** 1996 Nov;33(6):911–20

Transmission of Anaplasma marginale with adult Boophilus microplus ticks fed as nymphs on calves with different levels of rickettsaemia. Aguirre DH, et al. **Parasite** 1994 Dec;1(4):405–7

PATHOGENICITY

Effect of breed of cattle on innate resistance to infection with Babesia bovis, B bigemina and Anaplasma marginale. Bock RE, et al. **Aust Vet J** 1997 May;75(5):337–40

Comparison of the infectivity of Babesia bovis, Babesia bigemina and Anaplasma centrale for cattle after cryopreservation in either dimethylsulphoxide (DMSO) or polyvinylpyrrolidone (PVP). Standfast NF, et al. **Aust Vet J** 1997 Jan;75(1):62–3

PHYSIOLOGY

Anaplasma marginale: effect of challenge of cattle with varying doses of infected erythrocytes. Gale KR, et al. **Int J Parasitol** 1996 Dec;26(12):1417–20

ULTRASTRUCTURE

Ultrastructure of Anaplasma marginale with an inclusion appendage, isolated in Minas Gerais State, Brazil. Ribeiro MF, et al. **Vet Parasitol** 1997 Jul 1;70(4):271–7

ANAPLASMATACEAE

GENETICS

Western immunoblot analysis of Haemobartonella muris and comparison of 16S rRNA gene sequences of H. muris, H. felis, and Eperythrozoon suis. Rikihisa Y, et al. **J Clin Microbiol** 1997 Apr;35(4):823–9

ANAPLASMATACEAE INFECTIONS

VETERINARY

Treatment for Haemobartonella felis in cats [letter] Stevenson M. **Vet Rec** 1997 May 10;140(19):512

[What is your diagnosis? Haemobartonellosis in a cat] Amberger C. **Schweiz Arch Tierheilkd** 1996;138(9):441–2 **(Fre)**

ANAPLASMOSIS

DIAGNOSIS

Anaplasma marginale: detection of carrier cattle by PCR–ELISA. Gale KR, et al. **Int J Parasitol** 1996 Oct; 26(10):1103–9

Use of a nonradioactive DNA probe for detection of Anaplasma marginale infection in field cattle: comparison with complement fixation serology and microscopic examination. Ge NL, et al. **J Vet Diagn Invest** 1997 Jan; 9(1):39–43

Development and validation of an indirect enzyme immunoassay for detection of antibody to Anaplasma marginale in bovine sera. Nielsen K, et al. **Vet Parasitol** 1996 Dec 31;67(3–4):133–42

EPIDEMIOLOGY

The distribution of Dermacentor hunteri and Anaplasma sp. in desert bighorn sheep (Ovis canadensis). Crosbie PR, et al. **J Parasitol** 1997 Feb;83(1):31–7

A winter outbreak of anaplasmosis in a nonendemic area of Oklahoma: a possible role for Dermacentor albipictus. Ewing SA, et al. **J Vet Diagn Invest** 1997 Apr;9(2):206–8

Different seasonal occurrence of anaplasmosis outbreaks in beef and diary cattle in an area of Argentina free of Boophilus microplus ticks. Guglielmone AA, et al. **Vet Q** 1997 Mar;19(1):32–3

Variations in seroprevalence and host factors for bovine anaplasmosis in Illinois. Hungerford LL, et al. **Vet Res Commun** 1997 Jan;21(1):9–18

IMMUNOLOGY

Effect on intraerythrocytic Anaplasma marginale of soluble factors from infected calf blood mononuclear cells. Wyatt CR, et al. **Infect Immun** 1996 Nov;64(11):4846–9

Antibody against an Anaplasma marginale MSP5 epitope common to tick and erythrocyte stages identifies persistently infected cattle. Knowles D, et al. **J Clin Microbiol** 1996 Sep;34(9):2225–30

Peripheral blood lymphocyte proliferative responses in cattle infected with or vaccinated against Anaplasma marginale. Gale KR, et al. **Parasitol Res** 1996;82(6):551–62

PHYSIOPATHOLOGY

Anaplasma marginale: effect of challenge of cattle with varying doses of infected erythrocytes. Gale KR, et al. **Int J Parasitol** 1996 Dec;26(12):1417–20

PREVENTION & CONTROL

Immunisation of smallholder dairy cattle against anaplasmosis and babesiosis in Malawi. Tjornehoj K, et al. **Trop Anim Health Prod** 1997 May;29(2):77–82

TRANSMISSION

Transmission of Anaplasma marginale with adult Boophilus microplus ticks fed as nymphs on calves with different levels of rickettsaemia. Aguirre DH, et al. **Parasite** 1994 Dec;1(4):405–7

ANASTOMOSIS, ROUX-EN-Y

Endoscopic access to the papilla of Vater for endoscopic retrograde cholangiopancreatography in patients with billroth II or Roux-en-Y gastrojejunostomy. Hintze RE, et al. **Endoscopy** 1997 Feb;29(2):69–73

Endoscopic sphincterotomy using an S-shaped sphincterotome in patients with a Billroth II or Roux-en-Y gastrojejunostomy. Hintze RE, et al. **Endoscopy** 1997 Feb; 29(2):74–8

The gastric pump [letter; comment] Frankel LA. **J Am Coll Surg** 1997 Apr;184(4):435–6. Comment on: J Am Coll Surg 1996 Sep;183(3):243–8.

Decreased constitutive hepatic nitric oxide synthase expression in secondary biliary fibrosis and its changes after Roux-en-Y choledocho-jejunostomy in the rat. Zimmermann H, et al. **J Hepatol** 1996 Oct;25(4):567–73

Cutaneous stoma in the roux limb of hepaticojejunostomy (hepaticocutaneous jejunostomy): useful access for intrahepatic stone extraction. Saing H, et al. **J Pediatr Surg** 1996 Feb;31(2):247–50

Roux-en-Y biliary diversion: a worthwhile procedure? Skinner PP, et al. **J R Coll Surg Edinb** 1996 Feb;41(1):14–6

Bacteremia following liver biopsy in transplant recipients with Roux-en-Y choledochojejunostomy. de Diego Lorenzo A, et al. **Rev Esp Enferm Dig** 1997 Apr; 89(4):289–95 **(Eng, Spa)**

Transdiaphragmatic cyst-jejunostomy with Roux-en-Y loop for an exclusively mediastinal pancreatic pseudocyst. Kotsis L, et al. **Scand J Thorac Cardiovasc Surg** 1996;30(3–4):181–3

Biliary reconstruction during liver transplantation in patients with primary sclerosing cholangitis. Feith MP, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):560–1

HISTORY

History of reconstruction after total gastrectomy. Catarci M, et al. **J R Coll Surg Edinb** 1997 Apr;42(2):73–81

METHODS

Functional results after total gastrectomy with enteric pouch reconstruction. A review of 34 cases. Michielsen D, et al. **Acta Chir Belg** 1996 Jul-Aug;96(4):155–7

A new reconstructive method after pancreaticoduodenectomy: the triple Roux on a "P" loop. Rationale and radionuclide scanning evaluation. Pescio G, et al. **HPB Surg** 1996;9(4):223–7

Roux-en-Y jejunostomy in the pediatric population. Yoshida NR, et al. **J Pediatr Surg** 1996 Jun;31(6):791–3

[Cysto-ileal diversion by Y loop of a compressive pseudocyst after segmental pancreatic transplantation] Masson B, et al. **J Chir (Paris)** 1996 Nov;133(7):342–5 (Eng. Abstr.) **(Fre)**

VETERINARY

Evaluation of a biofragmentable anastomosis ring for small intestinal anastomosis in ponies. Bleyaert HF, et al. **Vet Surg** 1996 Jul-Aug;25(4):327–35

ANASTOMOSIS, SURGICAL

Protection of intestinal anastomoses in septic environment with peritoneal graft and polyglycolic acid mesh: an experimental study. Dilek ON, et al. **Acta Chir Belg** 1996 Nov-Dec;96(6):261–5

Fibrin glue-assisted end-to-side anastomosis of rat femoral vessels: comparison with conventional suture method. Padubidri AN, et al. **Ann Plast Surg** 1996 Jul;37(1):41–7

Scanning electron microscopic analysis of the stapled microvascular anastomosis in the rabbit. Boeckx WD, et al. **Ann Thorac Surg** 1997 Jun;63(6 Suppl):S128–34

Morphometry of the small intestine in pigs with ileo-rectal anastomosis. Redlich J, et al. **Can J Vet Res** 1997 Jan; 61(1):21–7

Recurrent femoral anastomotic false aneurysms: is long term repair possible? Melliere D, et al. **Cardiovasc Surg** 1996 Aug;4(4):480–2

Ultrastructural features of progressive intimal hyperplasia at the distal end-to-side anastomosis of vein grafts. Shiroma H, et al. **Cardiovasc Surg** 1996 Jun;4(3):393–8

Intraoperative transesophageal echocardiographic assessment of vascular anastomoses in lung transplantation. A report on 18 cases. Michel-Cherqui M, et al. **Chest** 1997 May; 111(5):1229–35

Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft. Chen C, et al. **Circulation** 1996 Oct 15;94(8):1989–95

The use of the rat facial nerve model to assess the effect of differing nerve anastomotic agents on the facial nerve. Murray JA, et al. **Clin Otolaryngol** 1993 Dec;18(6):492–5

Percutaneous occlusion of the entry to a leaking false aneurysm after ascending aortic replacement for aortic dissection type A facilitating surgical repair. Henriques JP, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):381–3

Salvage of Soave-Boley endorectal pull-through by conversion to a classical Soave procedure. Laberge JM, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):362–3

Motility studies of the esophagus in a case of esophageal atresia before primary anastomosis and in experimental models. Shono T, et al. **Eur J Pediatr Surg** 1997 Jun; 7(3):138–42

Relationship between peritoneal adhesion phenomena and the experimental resistance of colonic anastomoses: influence of omentoplasty. García-Olmo D, et al. **Eur Surg Res** 1996 Jul-Aug;28(4):315–22

Influence of intraperitoneal 5-fluorouracil plus folinic acid on the healing of colonic anastomoses in rats. Kanellos I, et al. **Eur Surg Res** 1996;28(5):374–9

Fertility outcome after laparoscopic microsurgical tubal anastomosis. Yoon TK, et al. **Fertil Steril** 1997 Jan; 67(1):18–22

Effect of collateral circulation on healing of small intestinal anastomosis in rabbits. Altan A, et al. **Hepatogastroenterology** 1997 Jul-Aug;44(16):1046–50

Proximal tubal occlusion: is there an alternative to microsurgery? Dubuisson JB, et al. **Hum Reprod** 1997 Apr; 12(4):692–8

Bidirectional Glenn shunt: a step in the right direction. Narayan R, et al. **Indian Heart J** 1996 Jul-Aug;48(4):375–80

Laparoscopic-assisted tubal anastomosis. Frishman GN, et al. **J Am Assoc Gynecol Laparosc** 1995 Aug;2(4):411–5

Influence of age on the effect of bidirectional cavopulmonary anastomosis on left ventricular volume, mass and ejection fraction. Forbes TJ, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1301–7

Effects of geometry and flow division on flow structures in models of the distal end-to-side anastomosis. Hughes PE, et al. **J Biomech** 1996 Jul;29(7):855–72

MR measurement and numerical simulation of steady flow in an end-to-side anastomosis model. Steinman DA, et al. **J Biomech** 1996 Apr;29(4):537–42

Compliance and diameter mismatch affect the wall shear rate distribution near an end-to-end anastomosis. Weston MW, et al. **J Biomech** 1996 Feb;29(2):187–98

Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage. Meddahi A, et al. **J Biomed Mater Res** 1996 Jul;31(3):293–7

Cavo atriopulmonary anastomosis via a nonprosthetic medial tunnel. Kreutzer C, et al. **J Card Surg** 1997 Jan-Feb; 12(1):37–40

Laparoscopic fibrin glue ureteral anastomosis: experimental study in the porcine model. Anidjar M, et al. **J Endourol** 1996 Feb;10(1):51–6

Regeneration of nerve fibres across a colonic anastomosis in the guinea-pig. Brookes SJ, et al. **J Gastroenterol Hepatol** 1996 Apr;11(4):325–34

Pulmonary artery thrombolysis and stenting after a bilateral sequential lung transplantation. Bousamra M 2nd, et al. **J Heart Lung Transplant** 1997 Jun;16(6):678–80

Animal model of the univentricular heart and single ventricular physiology. Randsbaek F, et al. **J Invest Surg** 1996 Sep-Oct;9(5):375–84

Experimental study on neurorrhaphy of the recurrent laryngeal nerve in dogs. Rubio A, et al. **J Laryngol Otol** 1996 Aug;110(8):748–53

Chronic perioperative steroids and colonic anastomotic healing in rats. Del Rio JV, et al. **J Surg Res** 1996 Dec; 66(2):138–42

Intestinal anastomotic healing at varying times after irradiation. Dominguez JM, et al. **J Surg Res** 1996 Feb 15;61(1):293–9

Collagen deposition and mechanical strength of colon anastomoses and skin incisional wounds of rats. Oxlund H, et al. **J Surg Res** 1996 Nov;66(1):25–30

Gastric acid secretion and gastroduodenal pH after pancreaticogastrostomy in dogs. Shinchi H, et al. **J Surg Res** 1996 Feb 15;61(1):152–8

Sepsis impairs anastomotic collagen gene expression and synthesis: a possible role for nitric oxide. Thornton FJ, et al. **J Surg Res** 1997 Apr;69(1):81–6

Computational design of a bypass graft that minimizes wall shear stress gradients in the region of the distal anastomosis. Lei M, et al. **J Vasc Surg** 1997 Apr;25(4):637–46

In vivo microarterial freezing: experimental study. Cavadas PC, et al. **Microsurgery** 1996;17(3):109–14

In vivo microvascular freezing in veins: experimental study. Cavadas PC, et al. **Microsurgery** 1996;17(3):115–20

Axon reflexes or ephaptic responses simulating blink reflex R1 after XII-VII nerve anastomosis. Montero J, et al. **Muscle Nerve** 1996 Jul;19(7):848–52

Lumboperitoneal shunting for pseudotumor cerebri. Burgett RA, et al. **Neurology** 1997 Sep;49(3):734–9

Role of immediate postoperative feeding on colonic anastomoses resistance. An experimental study in a rat model. García-Olmo D, et al. **Nutr Hosp** 1996 Sep-Oct; 11(5):279–85

Hypoglossal-facial nerve anastomosis after acoustic neuroma resection: influence of the time anastomosis on recovery of facial movement. Kunihiro T, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Jan-Feb; 58(1):32-5

Sphincter-saving surgery for rectal and colorectal disorders. Van Tets WF, et al. **Scand J Gastroenterol Suppl** 1996; 218:34-7

Penile dorsal vein arterialization in managing venogenic impotence. Knoll LD. **Tech Urol** 1995 Fall;1(3):157-61

Bile duct splintage in liver transplantation: is it necessary? Ferraz-Neto BH, et al. **Transpl Int** 1996;9 Suppl 1:S185-7

Effective surface cooling of the kidney during vascular anastomosis decreases the risk of delayed kidney function after transplantation. Szostek M, et al. **Transpl Int** 1996;9 Suppl 1:S84-5

Ureterovesical anastomosis in renal transplants: fewer complications with the extravesical technique. Butterworth PC, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):151

Biliary reconstruction during liver transplantation in patients with primary sclerosing cholangitis. Feith MP, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):560-1

Effect of cyclosporine A on the healing process of ileal anastomosis in rats. Guatelli R, et al. **Transplant Proc** 1996 Oct;28(5):2589

Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation. Kaden J, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):344-7

Pancreas transplantation: four vascular anastomoses. Szmidt J, et al. **Transplant Proc** 1996 Dec;28(6):3511-3

[Cervical venous anastomoses of pulmonary lymphatic origin] Le Pimpec Barthes F, et al. **Bull Assoc Anat (Nancy)** 1996 Jun;80(249):11-6 (Eng. Abstr.) **(Fre)**

[False anastomotic aneurysms after aorto-femoral prosthesis. Detection, prevention and treatment] Melliere D, et al. **J Mal Vasc** 1996;21(3):158-64 (Eng. Abstr.) **(Fre)**

[Value of percutaneous catheter cholangiography in postoperative biliodigestive and bilio-biliary anastomoses] Barkhausen J, et al. **Aktuelle Radiol** 1996 Sep;6(5):239-42 (Eng. Abstr.) **(Ger)**

[66-year-old man with an unusual anastomosis ulcer after Billroth II stomach resection] Baniewicz W, et al. **Internist (Berl)** 1997 Mar;38(3):255-8 **(Ger)**

[Radiologic interventions in anastomosis complications after lung transplantation] Berger H, et al. **Radiologe** 1997 Mar; 37(3):220-4 (Eng. Abstr.) **(Ger)**

[Magnetic resonance tomography and magnetic resonance angiography in diagnosis of complicated popliteal artery aneurysm] Kolb M, et al. **Radiologe** 1997 Feb;37(2):145-51 (Eng. Abstr.) **(Ger)**

[Perioperative standards for prevention of anastomotic insufficiency] Waldner H, et al. **Zentralbl Chir** 1997; 122(1):25-8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Concepts for recognition and securing anastomotic wound dehiscence of the gastrointestinal tract] Zirngibl H, et al. **Zentralbl Chir** 1997;122(1):20-4 (21 ref.) (Eng. Abstr.) **(Ger)**

[Sutures without sutures in digestive surgery. Experimental study of the rat intestine] Trignano M, et al. **Ann Ital Chir** 1996 May-Jun;67(3):419-23; discussion 423-4 (Eng. Abstr.) **(Ita)**

[Differential types of pulmonary flow in bidirectional cavo-pulmonary anastomosis with an additional flow source] Borini I, et al. **G Ital Cardiol** 1997 Jun;27(6):577-82 (Eng. Abstr.) **(Ita)**

[Advantages and disadvantages of stomach resection with PU anastomosis in treatment of gastric and duodenal peptic ulcers] Maiorova IV, et al. **Khirurgiia (Mosk)** 1996;(5):61-6 (120 ref.) **(Rus)**

[Advantages of compression biliodigestive anastomoses (an experimental-morphological study)] Tatarshaov MKh, et al. **Klin Khir** 1996;(5):36-8 **(Rus)**

[Comparative hydrodynamic evaluation of variants of the cavopulmonary anastomosis] Roeva LA, et al. **Med Tekh** 1996 Sep-Oct;(5):18-24 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Treatment of colorectal and ileoanal anastomotic sinuses. Whitlow CB, et al. **Dis Colon Rectum** 1997 Jul;40(7):760-3

Small bowel volvulus following ileal pouch-anal anastomosis: CT demonstration. Catalano O. **Eur J Radiol** 1996 Sep; 23(2):115-7

Antegrade dilatation over a string for the management of anastomotic complications after a pull-through procedure. Langer JC, et al. **J Am Coll Surg** 1996 Oct;183(4):411-2

Case 3--1997. Bilateral pulmonary edema after left modified Blalock-Taussing shunt [clinical conference] Waikar HD, et al. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):657-60

Effect of E5510 on anastomotic intimal hyperplasia and platelet aggregation in dogs. Fujioka K, et al. **J Cardiovasc Pharmacol** 1996 Jun;27(6):824-30

Endourologic management of ureterosigmoidostomy anastomotic stricture. McDougall EM, et al. **J Endourol** 1997 Apr;11(2):135-7

Chylous ascites associated with atrioventricular valve regurgitation after Blalock-Taussig shunt. Ogasawara M, et al. **J Pediatr Gastroenterol Nutr** 1996 Nov;23(4):501-3

Electrophrenic respiration after intercostal to phrenic nerve anastomosis on a patient with anterior spinal artery syndrome: technical case report. Fodstad H. **Neurosurgery** 1996 Feb;38(2):420

[Anastomotic leakage after low anterior resection for rectal cancer (see comments)] Bülow S, et al. **Ugeskr Laeger** 1997 Jan 13;159(3):297-301 (Eng. Abstr.). Comment in: Ugeskr Laeger 1997 May 19;159(21):3194. **(Dan)**

[Anastomosis leakage--risk factors (letter; comment)] Jensen LS. **Ugeskr Laeger** 1997 May 19;159(21):3194. Comment on: Ugeskr Laeger 1997 Jan 13;159(3):297-301. **(Dan)**

[Endobronchial complications in lung and heart-lung transplantation] Bonnette P. **Rev Mal Respir** 1996 Nov;13(5 Suppl):S49-56 (51 ref.) (Eng. Abstr.) **(Fre)**

[Early gastric cancer in the remnant stomach. Case report] Castro D, et al. **G E N** 1995 Oct-Dec;49(4):314-6 (Eng. Abstr.) **(Spa)**

HISTORY

Early history of the therapy of Hirschsprung's disease: facts and personal observations over 50 years [letter; comment] Vrsansky P, et al. **J Pediatr Surg** 1997 Jun;32(6):935-6. Comment on: J Pediatr Surg 1996 Aug;31(8):1003-8.

INSTRUMENTATION

Nonsuture end-to-end microvascular anastomosis using intravascular stents. Mikaelsson C, et al. **Ann Chir Gynaecol** 1996;85(1):36-9

Nonpenetrating clips for coronary anastomosis. Nataf P, et al. **Ann Thorac Surg** 1997 Jun;63(6 Suppl):S135-7

Randomized trial of a biofragmentable bowel anastomosis ring in high-risk colonic resection. Påhlman L, et al. **Br J Surg** 1997 Sep;84(9):1291-4

Valtrac-secured intracolonic bypass device: an experimental study. Chen TC, et al. **Dis Colon Rectum** 1997 Sep; 40(9):1063-7

Intracolonic bypass procedure [letter; comment] Ravo B. **Dis Colon Rectum** 1997 May;40(5):628-9. Comment on: Dis Colon Rectum 1994 Oct;37(10):1046-7. Comment on: Dis Colon Rectum 1995 Oct;38(10):1108-9.

Neonatal intestinal obstruction: reducing short-term complications by surgical refinements. Bagolan P, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):354-7

Reconstruction of the pharyngo-oesophagus after pharyngo-oesophagectomy with a free bowel autograft using ATOM tube-guided vascular anastomosis. Natsugoe S, et al. **Eur J Surg** 1996 May;162(5):413-4

Technical devices in jejunal pouch reconstruction following total gastrectomy, including postoperative results. Takeshita K, et al. **Hepatogastroenterology** 1997 Mar-Apr; 44(14):588-98

Laparoscopic intracorporeal anastomosis in the colon using the biofragmentable anastomotic ring--an animal study. Köckerling F, et al. **Int J Colorectal Dis** 1996;11(6):299-302

Colorectal surgery using a biofragmentable anastomotic ring. Wang SM, et al. **J Formos Med Assoc** 1996 Oct; 95(10):798-801

Sliding, absorbable, reinforced ring and an axially driven stent placement device for sutureless fibrin glue gastrointestinal anastomosis. Detweiler MB, et al. **J Invest Surg** 1996 Nov-Dec;9(6):495-504

Venous microanastomosis with the Unilink system, sleeve, and suture techniques: a comparative study in the rat. Zhang L, et al. **J Reconstr Microsurg** 1997 May; 13(4):257-61; discussion 261-2

Colorectal resection and anal anastomosis with an intraluminal stapler in Hirschsprung's disease. Hedlund H. **Pediatr Surg Int** 1997 Feb;12(2-3):142-4

[Insertion of autografts after acute damage of the common carotid artery. Experimental microvascular anastomoses after balloon dilatation] Friedrich RE, et al. **Unfallchirurgie** 1997 Feb;23(1):1-9 (Eng. Abstr.) **(Ger)**

[Secure anastomoses of the large intestine (especially with transanal drainage] Klein P, et al. **Zentralbl Chir** 1997; 122(7):528-32; discussion 533-4 (Eng. Abstr.) **(Ger)**

[Use of compression anastomosis devices in digestive surgery] Fantini C, et al. **Minerva Chir** 1996 May;51(5):265-72 (Eng. Abstr.) **(Ita)**

[Use of Valtrac in digestive surgery. Initial clinical experience] Monaco A, et al. **Minerva Chir** 1997 Jun; 52(6):857-61 (Eng. Abstr.) **(Ita)**

[Use of a biofragmentable anastomosis ring Valtrac in surgery of the colon] Lavrik AS, et al. **Klin Khir** 1996;(5):3-5 **(Rus)**

METHODS

The modification of the new type of end-to-side anastomosis between carotid arteries in rats: a technical and scanning electron microscopic study. Imer M, et al. **Acta Neurochir (Wien)** 1996;138(10):1246-9

An improved technique for a stapled transabdominal esophagojejunostomy. Guerra JP, et al. **Am J Surg** 1997 Jul;174(1):61-2

Treatment of a degloved hand injury by arteriovenous anastomosis: a case report. Takeuchi M, et al. **Ann Plast Surg** 1997 Aug;39(2):174-7

End-on-side microvascular anastomosis: an experimental study. Tellioğlu AT. **Ann Plast Surg** 1997 Aug;39(2):137-40

Review of facilitated approaches to vascular anastomosis surgery. Werker PM, et al. **Ann Thorac Surg** 1997 Jun;63(6 Suppl):S122-7

Open distal anastomosis in retrograde cerebral perfusion for repair of ascending aortic dissection. Yamashita C, et al. **Ann Thorac Surg** 1997 Sep;64(3):665-9

Using a cytoscope sheath to perform urethrovesical anastomosis [letter; comment] Fourcade RO. **Br J Urol** 1997 May;79(5):819. Comment on: Br J Urol 1996 Oct;78(4):641.

Progressive release of the left colon for a tension-free colorectal or coloanal anastomosis. Sugarbaker PH. **Cancer Treat Res** 1996;82:255-61

Hairline reconstruction utilizing modified winged V-plastic hair-bearing flaps and focal anastomotic line excisions. Field LM. **Dermatol Surg** 1996 Nov;22(11):937-40

Repair of aortic arch interruption by direct anastomosis. Bogers AJ, et al. **Eur J Cardiothorac Surg** 1997 Jan; 11(1):100-4

Comparison of long-term patency of "horseshoe" saphenous vein grafts with and without valves. Lajos TZ, et al. **Eur J Cardiothorac Surg** 1996;10(10):846-51

Our modification of duodeno-jejuno-anastomosis; comment upon article duodenal atresia: a comparison of three modes of treatment [letter; comment] Vrsansky P. **Eur J Pediatr Surg** 1996 Dec;6(6):381. Comment on: Eur J Pediatr Surg 1996 Apr;6(2):75-7.

Endoscopic removal of a "floating" biliary Gianturco Z stent five years after placement for a benign anastomotic stricture in a liver transplant patient. Baron TH, et al. **Gastrointest Endosc** 1997 Jul;46(1):80-2

Transcolonic approach for a stapled end-to-end colorectal anastomosis in low anterior resection. Korenaga D, et al. **Hepatogastroenterology** 1996 Jul-Aug;43(10):832-4

Mechanically stapled esophagojejunostomy. Results of a prospective series of 176 cases. Pol B, et al. **Hepatogastroenterology** 1997 Mar-Apr;44(14):458-66

Duodenum-sparing resection of the pancreatic head combined with pancreatogastroanastomosis in the treatment of chronic pancreatitis--surgical technique. Ruzicka M, et al. **Hepatogastroenterology** 1997 Mar-Apr; 44(14):564-6

Long-term follow-up of Hirschsprung's disease: review of early and late complications. Agarwala S, et al. **Indian Pediatr** 1996 May;33(5):382-6

Approaches to postoperative blood flow monitoring after free tissue transfer. Which is the best? Berger A, et al. **Int Angiol** 1995 Sep;14(3):288-96 (92 ref.)

The effect of exposure time on microsurgical anastomoses of experimentally crushed arteries. Su WF, et al. **Int Angiol** 1995 Sep;14(3):243-7

Clinico-physiological results after sphincter-saving resection for rectal carcinoma. Ikeuchi H, et al. **Int J Colorectal Dis** 1996;11(4):172-6

Maxillary augmentation with a microvascularly anastomosed fibula: a preliminary report. Bähr W. **Int J Oral Maxillofac Implants** 1996 Nov-Dec;11(6):719-27

Stapled anastomotic leaks [editorial; comment] Kodner IJ. **J Am Coll Surg** 1997 Aug;185(2):185-6. Comment on: J Am Coll Surg 1997 Aug;185(2):105-13.

Geometric design improvements for femoral graft-artery junctions mitigating restenosis. Lei M, et al. **J Biomech** 1996 Dec;29(12):1605-14

Intestinal anastomosis with valtrac biofragmentable ring. Our experience. Annessi P, et al. **J Chemother** 1997 Apr;9(2):146

Endoluminal graft exclusion of a proximal para-anastomotic pseudoaneurysm following aortobifemoral bypass. White RA, et al. **J Endovasc Surg** 1997 Feb;4(1):88-94

Surgical and arteriographic results of bronchial artery revascularization in lung and heart lung transplantation. Nørgaard MA, et al. **J Heart Lung Transplant** 1997 Mar; 16(3):302-12

Direct bronchial artery revascularization and en bloc double lung transplantation--surgical techniques and early outcome. Pettersson G, et al. **J Heart Lung Transplant** 1997 Mar;16(3):320-33

Single-stage repair of Hirschsprung's disease: a comparison of 109 patients over 5 years. Hackam DJ, et al. **J Pediatr Surg** 1997 Jul;32(7):1028-31; discussion 1031-2

Experience with distal circular myotomy for long-gap esophageal atresia. Lai JY, et al. **J Pediatr Surg** 1996 Nov; 31(11):1503-8

Functional bowel stasis in the dilated segment of proximal bowel among newborns presenting with duodenal or jejunal atresia [letter; comment] Tanyel FC. **J Pediatr Surg** 1997 Jun;32(6):936. Comment on: J Pediatr Surg 1996 Oct;31(10):1405-6.

Duhamel-Martin procedure for Hirschsprung's disease in neonates and infants: one-stage operation. van der Zee DC, et al. **J Pediatr Surg** 1996 Jul;31(7):901-2

Distal anastomotic vein cuff and the use of an internal vessel occluder. Chalmers RT, et al. **J R Coll Surg Edinb** 1997 Jun;42(3):171-2

Anastomoses involving the colon and rectum: an 8 year experience [letter] Cripps NP. **J R Coll Surg Edinb** 1997 Jun;42(3):206-7

End-to-side neurorrhaphy: a histologic and morphometric study of axonal sprouting into an end-to-side nerve graft. Noah EM, et al. **J Reconstr Microsurg** 1997 Feb; 13(2):99-106

Venous microanastomosis with the Unilink system, sleeve, and suture techniques: a comparative study in the rat. Zhang L, et al. **J Reconstr Microsurg** 1997 May; 13(4):257-61; discussion 261-2

Nerve regeneration after terminolateral neurorrhaphy: experimental study in rats. Zhao JZ, et al. **J Reconstr Microsurg** 1997 Jan;13(1):31-7

Anastomotic intimal hyperplasia: a comparison between conventional and endovascular stent graft techniques. Ohki T, et al. **J Surg Res** 1997 May;69(2):255–67

Anastomoses in recurrent epistaxis. Hacein-Bey L, et al. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):535–8

The anastomotic stoma: a useful procedure in emergency bowel surgery. Lange R, et al. **Langenbecks Arch Chir** 1996; 381(6):333–6

Classification and comparison of five techniques of end-to-end microarterial anastomoses in rats: a new proposed technique. Gahankari DR, et al. **Microsurgery** 1995;16(12):793–802

End-to-side anastomosis in heterotopic rat organ transplantation. Marni A, et al. **Microsurgery** 1996; 17(1):21–4

Comparison of end-to-end and end-to-side venous anastomosis in free-tissue transfer following resection of head and neck tumors. Ueda K, et al. **Microsurgery** 1996; 17(3):146–9

New four-stitch sleeve anastomosis: an experimental study in rats with reports of clinical use. Zhang L, et al. **Microsurgery** 1996;17(6):291–4

Recognition of the Martin-Gruber anastomosis. van Dijk JG, et al. **Muscle Nerve** 1997 Jul;20(7):887–9

Silicone intubation with tissue glue anastomosis in the treatment of congenital nasolacrimal duct obstruction. Liao CL, et al. **Ophthalmic Surg Lasers** 1996 Mar;27(3):197–9

Extension of the Taylor patch concept to infrainguinal sequential arterial bypass. Mukherjee D. **Panminerva Med** 1997 Jun;39(2):132–5

Management of esophageal perforations after therapeutic upper gastrointestinal endoscopy. Adamek HE, et al. **Scand J Gastroenterol** 1997 May;32(5):411–4

Laparoscopic-assisted abdominoperineal proctosigmoidectomy for rectal prolapse. A new technique. Allam M, et al. **Surg Endosc** 1997 Feb;11(2):150–1

Intracorporeal colorectal anastomosis following laparoscopic left colon resection. Bergamaschi R, et al. **Surg Endosc** 1997 Aug;11(8):800–1

Laparoscopically assisted colorectal anastomose post-Hartmann's procedure. Regadas FS, et al. **Surg Laparosc Endosc** 1996 Feb;6(1):1–4

Experimental technique for (laparoscopic) bowel anastomosis: transient endoluminally stented anastomosis (TESA). Schmid RA, et al. **Surg Laparosc Endosc** 1997 Aug;7(4):281–4

Comparison of laparoscopic handsewn suture techniques for experimental small-bowel anastomoses. Waninger J, et al. **Surg Laparosc Endosc** 1996 Aug;6(4):282–9

Extraperitonealization of the anastomosis and sacral drain in restorative surgery for rectal carcinoma: a safety mechanism in the absence of a covering stoma. Jatzko GR, et al. **Surg Today** 1996;26(8):591–6

A simpler and more reliable technique of pancreatojejunal anastomosis. Kakita A, et al. **Surg Today** 1996;26(7):532–5

A new pedicled seromuscular flap technique for high-risk intestinal anastomoses. Moriura S, et al. **Surg Today** 1997; 27(4):379–81

Stapled versus sutured esophagogastric anastomoses [letter] Urschel JD, et al. **Surgery** 1997 Sep;122(3):643–4

Appendiceal cecoplication: a modification of the Malone antegrade colonic enema procedure. Stock JA, et al. **Tech Urol** 1996 Spring;2(1):40–2

Hepato-venous outflow complications following orthotopic liver transplantation with various techniques for hepato-venous reconstruction in adults and children. Hesse UJ, et al. **Transpl Int** 1996;9 Suppl 1:S182–4

A prospective randomised trial of bile duct reconstruction at liver transplantation: T tube or no T tube? Vougas V, et al. **Transpl Int** 1996;9(4):392–5

Alternative techniques for arterialization in multivisceral grafting. Lodge JP, et al. **Transplant Proc** 1997 May; 29(3):1850

Biliary tract reconstruction after liver transplantation: with or without T-tube? Nuño J, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):564–5

An easy and physiologic arterial reconstruction method (sleeve technique) for orthotopic rat liver transplantation. Sato Y, et al. **Transplant Proc** 1996 Dec;28(6):3649–51

[Vena saphena magna in situ bypass to the ankel and foot. A prospective assessment of results of 101 procedures in 94 patients with threatening amputation] Røder OC, et al. **Ugeskr Laeger** 1997 Aug 4;159(32):4846–9 (Eng. Abstr.) **(Dan)**

[Total and partial cavo-pulmonary anastomosis for univentricular hearts] Stenbøg EV, et al. **Ugeskr Laeger** 1997 Feb 10;159(7):946–51 (Eng. Abstr.) **(Dan)**

[Results of deep rectum resection and intersphincteric rectum excision] Bruch HP, et al. **Chirurg** 1997 Jul;68(7):689–92 (Eng. Abstr.) **(Ger)**

[Restorative proctectomy. A comparison of direct colo-anal and colon-pouch-anal anastomoses for reconstructing continuity] Kienle P, et al. **Chirurg** 1997 Jun;68(6):630–2 (Eng. Abstr.) **(Ger)**

[Intersphincteric rectum resection with radical mesorectum excision and colo-anal anastomosis] Schumpelick V, et al. **Chirurg** 1996 Feb;67(2):110–20 (Eng. Abstr.) **(Ger)**

[Cattell-Warren anastomosis in soft pancreatic remnant after q pancreas resection] Chikh-Torab F, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:249–51 (Eng. Abstr.) **(Ger)**

[Living related kidney transplantation in children younger than 5 years of age--intraperitoneal or extraperitoneal surgical procedure?] Fangmann J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:396–8 (Eng. Abstr.) **(Ger)**

[Palliative therapy of inoperable malignant occlusive jaundice--stent implantation or biliodigestive anastomosis] Truong S, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:762–6 (20 ref.) (Eng. Abstr.) **(Ger)**

[Pancreatic duct occlusion with fibrin (glue) to protect the pancreatico-digestive anastomosis after resection of the head of the pancreas in oncologic surgery] Waclawiczek HW, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:252–4 (Eng. Abstr.) **(Ger)**

[Biliary and gastrointestinal bypass: laparoscopic possibilities] Schöb O, et al. **Swiss Surg** 1996;Suppl 4:29–32 (Eng. Abstr.) **(Ger)**

[Ileal neobladder with anastomosis to the female urethra] de Petriconi R, et al. **Urologe A** 1996 Jul;35(4):284–90 (Eng. Abstr.) **(Ger)**

[Cervical mechanical anastomosis by transhiatal approach with a new circular stapler, Ehicon ECS 21] Gasparri G, et al. **Minerva Chir** 1996 Dec;51(12):1135–7 (Eng. Abstr.) **(Ita)**

[Bowel anastomosis using valtrac in urologic surgery] Okaneya T, et al. **Hinyokika Kiyo** 1996 Aug;42(8):569–72 (Eng. Abstr.) **(Jpn)**

[An operative case of bilateral partial anomalous pulmonary venous return using a direct anastomosis between the right atrial appendage and the superior vena cava] Sakurai H, et al. **Kyobu Geka** 1996 Sep;49(10):851–4 (Eng. Abstr.) **(Jpn)**

[Experimental study of hypoglossal facial anastomosis and accessory-facial anastomosis in guinea pigs] Horiuchi J. **Nippon Jibiinkoka Gakkai Kaiho** 1997 Mar;100(3):299–306 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of complicated forms of cancer of the right side of the colon] Bulynin VI, et al. **Khirurgiia (Mosk)** 1997;(5):14–7 (Eng. Abstr.) **(Rus)**

[Non-reflux esophago-gastric anastomosis] Bulynin VI, et al. **Khirurgiia (Mosk)** 1997;(6):64–5 (Eng. Abstr.) **(Rus)**

VETERINARY

Peritonitis following intestinal anastomosis and enteroplication in a kitten with intussusception. Culvenor JA. **Aust Vet J** 1997 Mar;75(3):175–7

Management and complications following trigonal-colonic anastomosis in a dog: five-year evaluation. Smith JD, et al. **J Am Anim Hosp Assoc** 1996 Jan-Feb;32(1):29–35

ANATOMIC MODELS see **MODELS, ANATOMIC**

ANATOMY

see related
DISSECTION

Experimental Morphology, the 1st International Symposium. Sofia, May 24–26, 1996. Abstracts. **Anat Anz** 1997 Apr; 179(2):177–200

Asia-Pacific Anatomical Conference. Singapore, 17–20 December 1995. Abstracts. **Aust N Z J Med** 1996 Jun; 26(3):439–86

Membership list. **Bull Assoc Anat (Nancy)** 1996 Dec; 80(251):VIII–XV

Association of Anatomists, membership list. **Bull Assoc Anat (Nancy)** 1995 Dec;79(247):VI–XIV

Clinical anatomy in China [editorial] Gao XH. **Clin Anat** 1996;9(5):350–3

Understanding anatomical terms. Mehta LA, et al. **Clin Anat** 1996;9(5):330–6

Towards a new terminology for clinical anatomy, with special reference to the heart. Message MA, et al. **Clin Anat** 1996;9(5):317–29

Making planes plain. O'Rahilly R. **Clin Anat** 1997;10(2):128–9

Confessions of an American clinical anatomist. Seifert MF. **Clin Anat** 1997;10(3):208–9

Patients' knowledge of anatomical location of major organs within the human body: a comparison between Asians and non-Asians. Rashid A, et al. **Fam Pract** 1996 Oct; 13(5):450–4

Papers presented during the 17th Congress of the Polish Anatomical Society. Gdansk, 1996. **Folia Morphol (Warsz)** 1996;55(4):191–474

XLIX National Congress of the Italian Society of Anatomy. Bari, 2–5 October 1995. Abstracts. **Ital J Anat Embryol** 1995 Oct;100 Suppl:1–256

L National Congress of the Italian Society of Anatomy. Catania, 24–27 September 1996. Abstracts. **Ital J Anat Embryol** 1996 Oct;101 Suppl:1–246

The Digital Anatomist distributed framework and its applications to knowledge-based medical imaging [see comments] Brinkley JF, et al. **J Am Med Inform Assoc** 1997 May-Jun;4(3):165–83 (55 ref.). Comment in: J Am Med Inform Assoc 1997 May-Jun;4(3):252–3.

Symbolic anatomic knowledge representation in the Read Codes version 3: structure and application. Schulz EB, et al. **J Am Med Inform Assoc** 1997 Jan-Feb;4(1):38–48

In defence of human anatomy--a commentary [editorial] Bouchet A. **Surg Radiol Anat** 1996;18(3):159–65

Employment of the anatomical terminology of the Nomina Anatomica in the radiologic literature. Grignon B, et al. **Surg Radiol Anat** 1995;17(4):289–91

[78th Congress of The Association of Anatomists. Madrid, Spain, 24–28 September 1996. Abstracts] **Bull Assoc Anat (Nancy)** 1996 Dec;80(251):1–70 **(Fre)**

[77th Congress of the Association of Anatomists. Marseille, France, 21–25 May 1995. Abstracts] **Bull Assoc Anat (Nancy)** 1995 Dec;79(247):1–68 **(Fre)**

[In memoriam Klaus Volquardt Hinrichsen (1927–19997)] Christ B. **Anat Anz** 1997 Aug;179(4):297–301 **(Ger)**

[Science in anatomy or anatomy in science?] Zilles K. **Anat Anz** 1996 Aug;178(4):305–8 **(Ger)**

[Dictionary of frequently used anatomic and pathomorphologic nomenclature] Szymaś J, et al. **Pol J Pathol** 1994;45(3 Suppl):1–53 **(Pol)**

[The semantic transformations of Greek and Latin words in the process of creating anatomical names] Krakovetskaia GA. **Arkh Anat Gistol Embriol** 1981 Dec;81(12):89–92 **(Rus)**

[The Museum of the Department of Normal Anatomy of the I. P. Pavlov 1st Leningrad Medical Institute] Muratikova VA, et al. **Arkh Anat Gistol Embriol** 1968 Nov; 55(11):91–8 **(Rus)**

[Bibliographical index of papers of the journals Archive of Anatomy, Histology and Embryology, volumes 92–101, and Morphology, volumes 102–110] **Morfologiia** 1997; 111(3):5–119 **(Rus)**

CLASSIFICATION

Anatomical characterisation of surgical procedures in the Read Thesaurus. Price C, et al. **Proc AMIA Annu Fall Symp** 1996;:110–4

EDUCATION

The unclaimed cadaver. Coelho DH, et al. **Acad Med** 1997 Sep;72(9):741–3

Students' use of anatomy modules in problem-based medical education at McMaster University. Zehr CL, et al. **Acad Med** 1996 Sep;71(9):1015–7

Sheet plastination as a clinically based teaching aid at the University of Auckland. Cook P. **Acta Anat (Basel)** 1997; 158(1):33–6

Plastinated canine gastrointestinal tracts used to facilitate teaching of endoscopic technique and anatomy. Janick L, et al. **Acta Anat (Basel)** 1997;158(1):48–53

Learning relational anatomy by correlating thin plastinated sections and magnetic resonance images: preparation of specimens. Magiros M, et al. **Acta Anat (Basel)** 1997; 158(1):37–43

Setting up and features of a database of images of plastinated materials. Masuda Y, et al. **Acta Anat (Basel)** 1997; 158(1):10–20

The potentially best stereographic presentation of the plastinated anatomical specimen. Taguchi M, et al. **Acta Anat (Basel)** 1997;158(1):21–5

Treatment of spinal injuries. On relating anatomical facts to clinical practice. Crock HV. **Acta Orthop Scand** 1997 Aug; 68(4):315–8 (13 ref.)

The place of basic science in the training of surgeons: a personal view. Whitaker RH. **Ann R Coll Surg Engl** 1996 Nov;78(6 Suppl):276–7

Aspiring surgeons and temporary lecturer posts in anatomy [letter] [see comments] Willan P, et al. **Br J Surg** 1996 Nov; 83(11):1656–7. Comment in: Br J Surg 1997 Jun;84(6):889.

A clinical anatomy curriculum for the medical student of the 21st century: gross anatomy [letter] Anderson J. **Clin Anat** 1997;10(2):143–4

Survey of the educational roles of the faculty of anatomy departments. Bourguet CC, et al. **Clin Anat** 1997; 10(4):264–71

A special anatomic preparation for teaching central venous catheterization. Buithieu J, et al. **Clin Anat** 1996;9(4):219–26

Common questions regarding anatomical bequests [editorial] Cahill DR, et al. **Clin Anat** 1997;10(3):218–9

The role of computers and dissection in teaching anatomy: a comment [editorial] Cahill DR, et al. **Clin Anat** 1997; 10(2):140–1

Anatomy departments and anatomy education: reflections and myths [letter; comment] Carraway KL. **Clin Anat** 1997; 10(1):60. Comment on: Clin Anat 1997;10(1):34–40.

Testing knowledge of human gross anatomy in medical school: an applied contextual-learning theory method. Clough RW, et al. **Clin Anat** 1996;9(4):263–8

Detached concern and death anxiety of first-year medical students: before and after the gross anatomy course. Dickinson GE, et al. **Clin Anat** 1997;10(3):201–7

Clinical anatomy [letter; comment] Graney DO. **Clin Anat** 1996;9(1):61. Comment on: Clin Anat 1996;9(1):53–6.

Clinical anatomy instruction in the operating room. Hubbeli DS, et al. **Clin Anat** 1996;9(6):405–7

Anatomy departments and anatomy education: reflections and myths [see comments] Jones DG. **Clin Anat** 1997; 10(1):34–40 (2 ref.). Comment in: Clin Anat 1997;10(1):60.

Reassessing the importance of dissection: a critique and elaboration. Jones DG. **Clin Anat** 1997;10(2):123–7

Re: "PBL" in medical education during the cultural revolution at Norman Bethune University of Medical Sciences, Changchun, China [letter] Lozanoff S. **Clin Anat** 1996;9(4):281

Human anatomy: a foundation for education about death and dying in medicine. Marks SC Jr, et al. **Clin Anat** 1997; 10(2):118–22

ANATOMY

Clinical anatomy [letter; comment] Marks SC Jr. **Clin Anat** 1996;9(1):60. Comment on: Clin Anat 1996;9(1):53–6.

Catching up [see comments] Mutyala S, et al. **Clin Anat** 1996; 9(1):53–6. Comment in: Clin Anat 1996;9(1):60. Comment in: Clin Anat 1996;9(1):61.

A controlled trial of peer-teaching in practical gross anatomy. Nnodim JO. **Clin Anat** 1997;10(2):112–7

A follow-up comparative study of two modes of learning human anatomy: by dissection and from prosections. Nnodim JO, et al. **Clin Anat** 1996;9(4):258–62

Aide-mémoire in anatomy [editorial] O'Rahilly R. **Clin Anat** 1996;9(6):424

How to reduce the time needed to learn anatomy in postgraduate training for surgery in different countries [letter] Pabst R. **Clin Anat** 1997;10(2):142

Anatomy into the next millennium: quo vadis, or simply where to? Satyapal KS, et al. **Clin Anat** 1997;10(1):41–3; discussion 44–6 (8 ref.)

A clinical anatomy curriculum for the medical student of the 21st century: gross anatomy [letter; comment] Tavares MA, et al. **Clin Anat** 1997;10(1):59. Comment on: Clin Anat 1996;9(2):71–99.

A laboratory exercise in the study of the gross structure of the eye. Waring GO, et al. **Clin Anat** 1996;9(1):46–9

Learning gross anatomy: dissection and prosection. Yeager VL. **Clin Anat** 1996;9(1):57–9

A computer program to aid in visual concept development in dentistry. Wallen ES, et al. **Comput Methods Programs Biomed** 1997 Feb;52(2):105–15

Modern techniques in teaching of anatomy. Jędrzejewski KS, et al. **Folia Morphol (Warsz)** 1996;55(4):301–2

The integration of clinical skills and clinical anatomy in medical education. Kasuya RT, et al. **Hawaii Med J** 1997 Apr;56(4):89

Clinical anatomy: a review course for emergency medicine residents. MacLean TA, et al. **J Emerg Med** 1996 May–Jun; 14(3):383–7

Anatomy training for surgeons—a personal viewpoint [editorial] Kaufman MH. **J R Coll Surg Edinb** 1997 Aug; 42(4):215–6

"I actually don't mind the bone saw": narratives of gross anatomy. Reifler DR. **Lit Med** 1996 Fall;15(2):183–99

Language as a barrier to the acquisition of anatomical knowledge. Lucas P, et al. **Med Educ** 1997 Mar;31(2):81–6

Ultrasound anatomy: a practical teaching system in human gross anatomy. Teichgräber UK, et al. **Med Educ** 1996 Jul; 30(4):296–8

The modern teaching of modern anatomy. Chevrel JP. **Surg Radiol Anat** 1995;17(4):285–6

[Practical ultrasound skills in the anatomy course—a future oriented curriculum concept?] Teichgräber UK, et al. **Med Klin** 1996 Dec 15;91(12):796–7 **(Ger)**

[Windmill principle versus clockwork principle—tradition and interaction in academic lectures. A. N. S. A. Radiologica] Leppek R, et al. **Z Arztl Fortbild (Jena)** 1996 Aug;90(5):406–13 (Eng. Abstr.) **(Ger)**

[Interactive atlas with magnetic resonance on CD-ROM for Macintosh] Montanari N, et al. **Radiol Med (Torino)** 1996 Nov;92(5):610–3 (Eng. Abstr.) **(Ita)**

[Freedom from regulation for curriculum and variety in laboratory program of gross anatomy—report of the 1994–5 Committee of Teaching in Japanese Association of Anatomists] Kohno K, et al. **Kaibogaku Zasshi** 1996 Jun; 71(3):219–28 **(Jpn)**

[Is it allowed to have a public open exhibition of human plastinated specimens in Japan?] Masuda Y, et al. **Kaibogaku Zasshi** 1997 Feb;72(1):61–71 (Eng. Abstr.) **(Jpn)**

[Once more on integration, only for real] Sapin MR. **Morfologiia** 1997;111(1):104–5 **(Rus)**

[Technical means in the study of the structure of the human being] Simbirtsev SA. **Morfologiia** 1997;111(1):106–10 **(Rus)**

HISTORY

The Flemish anatomist Andreas Vesalius (1514–1564) and the kidney. DeBroe ME, et al. **Am J Nephrol** 1997; 17(3–4):252–60

Marcello Malpighi (1628–1694). Mezzogiorno A, et al. **Am J Nephrol** 1997;17(3–4):269–73

So who was Gerdy... and how did he get his own tubercle? Beals TC. **Am J Orthop** 1996 Nov;25(11):750–2

A tribute to Berta Scharrer. Wissig SL. **Anat Rec** 1997 Sep; 249(1):1–5

Changing interpretations of the human cortical pattern. Maudgil DD. **Arch Neurol** 1997 Jun;54(6):769–75

Frederic Wood Jones: his major books and how they were reviewed. Christophers BE. **Aust N Z J Surg** 1997 Sep; 67(9):645–59

William Cheselden (1688–1752): humane anatomist and master surgeon. Guest J. **Aust N Z J Surg** 1997 Aug; 67(8):524–7

Nom et lumière: enlightenment through nomenclature (the 1996 Kenneth F. Russell Memorial Lecture). Pearn J. **Aust N Z J Surg** 1997 Aug;67(8):508–11

Play it again Sam [editorial] Cahill DR, et al. **Clin Anat** 1997; 10(5):364

Philatelic introduction to the history of anatomy. O'Rahilly R. **Clin Anat** 1997;10(5):337–40

Nerve supply of the breast with special reference to the nipple and areola: Sir Astley Cooper revisited. Sarhadi NS, et al. **Clin Anat** 1997;10(4):283–8

The discovery of vasomotor nerves. Montastruc JL, et al. **Clin Auton Res** 1996 Jun;6(3):183–7

Jaap Dubbeldam: professor of neurobehavioural morphology. Zweers GA. **Eur J Morphol** 1997 Oct;35(4):209–15

Giovanni Domenico Santorini (1681–1737) Charles-Pierre Denonvilliers (1808–1872). First description of urosurgically relevant structures in the small pelvis. Dietrich H. **Eur Urol** 1997;32(1):124–7

A short history of the wrist joint. Dobyns JH, et al. **Hand Clin** 1997 Feb;13(1):1–12

Jackson has a fright. Curtis EK. **J Am Coll Dent** 1996 Spring; 63(1):43–4

The bone called luz. Reichman E, et al. **J Hist Med Allied Sci** 1996 Jan;51(1):52–65

The ideas of Thomas Kuhn in relation to medical advances in the sixteenth and seventeenth centuries [see comments] Quin CE. **J R Soc Med** 1997 Apr;90(4):225–8. Comment in: J R Soc Med 1997 Jun;90(6):356.

The anatomy and embryological origins of the fascia of Denonvilliers: a medico-historical debate. van Ophoven A, et al. **J Urol** 1997 Jan;157(1):3–9 (45 ref.)

John Banister lecturing on anatomy by anonymous. Salcman M. **Neurosurgery** 1996 Nov;39(5):1068–9

Andreas Vesalius 1514–1564. Benini A, et al. **Spine** 1996 Jun 1;21(11):1388–93

Philosophical anatomy revisited [editorial] Masquelet AC. **Surg Radiol Anat** 1997;19(2):57–8

The Hyrtl skull collection. Worden G. **Trans Stud Coll Physicians Phila** 1995 Dec;17:94–113

[Jacobus van Rees (1854–1928); an outsider in the university] James J. **Ned Tijdschr Geneeskd** 1996 Dec 21; 140(51):2554–60 **(Dut)**

[Articles published in the Archives d'Anatomie, d'Histologie et d'Embryologie from volume 1 (1922) to volume 74 (1991–92)] Le Minor JM. **Arch Anat Histol Embryol** 1993–94;75:111–50 (Eng. Abstr.) **(Fre)**

[Illustration of humans in the anatomy of ther Renaissance: Andrea Vesalius' De humani corporis fabrica libri septem, Basel 1543] Hildebrand R. **Anat Anz** 1996 Aug; 178(4):375–84 (Eng. Abstr.) **(Ger)**

[Russian and German scholars of the 17th and 18th century] Speranski VS. **Anat Anz** 1996 Aug;178(4):385–8 **(Ger)**

[An apparent letter by Herophilos to King Antiochos, from a Brussels handwritten collection published for the first time] Fischer KD, et al. **Sudhoffs Arch Z Wissenschaftsgesch** 1996;80(1):86–98 **(Ger)**

[Albrecht von Haller (1708–1777)] Birtalan G. **Orv Hetil** 1996 Jun 16;137(24):1319–21 **(Hun)**

[Anatomical references in Homer's Iliad] Urso C. **Pathologica** 1997 Feb;89(1):26–30 (Eng. Abstr.) **(Ita)**

[General views in history of anatomy] Fujita H. **Kaibogaku Zasshi** 1997 Feb;72(1):25–43 **(Jpn)**

[Outline of historical view of human anatomy: Part 2] Fujita H. **Kaibogaku Zasshi** 1997 Apr;72(2):99–122 **(Jpn)**

[Scarce anatomical textbook by professor Buntaro Adachi] Shimada K. **Kaibogaku Zasshi** 1996 Apr;71(2):133–4 **(Jpn)**

[The 75th anniversary of the Department of Anatomy of the Minsk Medical Institute] Dobko PI, et al. **Morfologiia** 1996; 110(5):103–5 **(Rus)**

[Founded by Lesgaft (on the centenary of the Department of Anatomy and Sports Morphology of the P. F. Lesgaft Academy of Physical Education)] Sudzilovskiĭ FV. **Morfologiia** 1996;109(3):93–100 **(Rus)**

[The contribution of Leningrad anatomists and histologists to the training of scientific, teaching and medical personnel in the Soviet Union] Sudzilovskiĭ FV. **Morfologiia** 1996; 109(2):114–6 **(Rus)**

[The journal Morfologiia is 80 years old (editorial)] Sudzilovskiĭ FV. **Morfologiia** 1996;110(6):7–13 **(Rus)**

[Anatomy instruction at the Medical Faculty of Moscow University in the XVIII century] Stochik AM, et al. **Probl Sotsialnoi Gig Istor Med** 1996 Mar–Apr;(2):55–9 **(Rus)**

METHODS

Neutron anatomy. Bacon GE. **Basic Life Sci** 1996;64:17–27

Analysis of contemporary methods of anatomical structures visualisation in Imtron 2000 system, Image C package. Kędzia A, et al. **Folia Morphol (Warsz)** 1996;55(4):321–3

TRENDS

Recent advances in microsurgical anatomy. Zhong S. **Chin Med J (Engl)** 1996 Jan;109(1):64–5 (0 ref.)

Information technology, medical education, and anatomy for the twenty-first century. Marks SC Jr. **Clin Anat** 1996; 9(5):343–8 (47 ref.)

The concept of anatomy—classical topographic anatomy [editorial] Anderhuber F. **Surg Radiol Anat** 1996; 18(4):253–6

Clinical applied anatomy: a current assessment [editorial] Herrmann M. **Surg Radiol Anat** 1997;19(1):2–4

[The status and problems of research in applied anatomy] Bol'shakov OP. **Morfologiia** 1995;108(3):101–3 **(Rus)**

[Immunomorphology—yesterday, today and tomorrow] Trufakin Va, et al. **Vestn Ross Akad Med Nauk** 1996; (6):38–42 (48 ref.) (Eng. Abstr.) **(Rus)**

ANATOMY, ARTISTIC

Surface-based labeling of cortical anatomy using a deformable atlas. Sandor S, et al. **IEEE Trans Med Imaging** 1997 Feb;16(1):41–54

Distribution of neurotensin-containing neurons in the central nervous system of the pigeon and the chicken. Atoji Y, et al. **J Comp Neurol** 1996 Nov 11;375(2):187–211

Standard atlas of the gross anatomy of the developing inner ear of the chicken. Bissonnette JP, et al. **J Comp Neurol** 1996 May 13;368(4):620–30

A reliable system of ventricular coordinates for the cartography and stereotaxy of the amygdala (and anterior hippocampus) in macaques. Percheron G. **J Neurosci Methods** 1997 Jul 18;75(1):5–14

[Product of the month: the Schering Atlas. Sectional anatomy of CT and MRI images] Ludwig K, et al. **Radiologe** 1996 Feb;36(2):172–3 (Eng. Abstr.) **(Ger)**

[Interactive atlas with magnetic resonance on CD-ROM for Macintosh] Montanari N, et al. **Radiol Med (Torino)** 1996 Nov;92(5):610–3 (Eng. Abstr.) **(Ita)**

HISTORY

Realdo Colombo (1516–1559). A reappraisal. Eknoyan G, et al. **Am J Nephrol** 1997;17(3–4):261–8

Depictions of the kidney through the ages. Purkerson ML, et al. **Am J Nephrol** 1997;17(3–4):340–6

Some personal reflections on anatomic illustration with particular regard to regional anesthesia. Vandam LD. **Anesth Analg** 1997 Sep;85(3):691–6

Professor Raymond Jack Last, MB, BS, FRCS, FRACS, HonFMAA (1903–1993). Archer P. **J Audiov Media Med** 1996 Sep;19(3):131–3

Origins of the Pernkopf anatomy atlas [letter] Cutler DS. **JAMA** 1997 Apr 9;277(14):1122; discussion 1123–4

Nazi origins of an anatomy text: the Pernkopf atlas [letter] Israel HA, et al. **JAMA** 1996 Nov 27;276(20):1633; discussion 1634

Nazi origins of an anatomy text: the Pernkopf atlas [letter] Panush RS. **JAMA** 1996 Nov 27;276(20):1633–4; discussion 1634

Origins of the Pernkopf anatomy atlas [letter] Weissmann G. **JAMA** 1997 Apr 9;277(14):1122; discussion 1123–4

Vesalius and Calcar [editorial; comment] Chase RA. **Pharos** 1996 Summer;59(3):43. Comment on: Pharos 1996 Summer;59(3):8–13.

A historical enigma: the artist responsible for the illustrations of Andreas Vesalius's De Humani Corporis Fabrica [see comments] McLeod IK. **Pharos** 1996 Summer;59(3):8–13. Comment in: Pharos 1996 Summer;59(3):43.

Upon finding a Nazi anatomy atlas: the lessons of Nazi medicine [see comments] Panush RS. **Pharos** 1996 Fall; 59(4):18–22. Comment in: Pharos 1996 Fall;59(4):33.

Haeckel's embryos: fraud rediscovered [news] Pennisi E. **Science** 1997 Sep 5;277(5331):1435

[The skull and brain according to Leonardo: a survey on 4 pages by de Vinci and analogy of the onion. The scientific philosophy of the domino theory (editorial)] Castan P. **J Neuroradiol** 1997 Aug;24(2):79–82 **(Fre)**

ANATOMY, COMPARATIVE

Comparative ureteral microanatomy. Wolf JS Jr, et al. **J Endourol** 1996 Dec;10(6):527–31

HISTORY

Home away from home. Beasley AW. **Aust N Z J Surg** 1997 Aug;67(8):547–50

William Turner's lectures on the comparative anatomy of the placenta. Haig D. **Placenta** 1997 May;18(4):371–4

Professor Struthers and the Tay whale. Williams MJ. **Scott Med J** 1996 Jun;41(3):92–4

ANATOMY, CROSS-SECTIONAL

see related
MAGNETIC RESONANCE IMAGING
TOMOGRAPHY
ULTRASONOGRAPHY

Design of a Web interface for anatomical images. Barker TM, et al. **Australas Phys Eng Sci Med** 1997 Mar;20(1):33–8

The visible embryo project: embedded program objects for knowledge access, creation and management through the World Wide Web. Doyle MD, et al. **Comput Med Imaging Graph** 1996 Nov–Dec;20(6):423–31

An Internet atlas of mouse development. Williams BS, et al. **Comput Med Imaging Graph** 1996 Nov–Dec; 20(6):433–47

Build for future technology when building for the future: a lesson from the visible human project [editorial] **J Am Med Inform Assoc** 1996 Jul–Aug;3(4):300–1

A new simple method for conservation and demonstration of body sections for teaching clinically oriented courses in gross anatomy [letter] Post H, et al. **J Anat** 1996 Dec; 189 (Pt 3):685–8

Sectional anatomy using the personal computer. Cahill DR, et al. **J Digit Imaging** 1997 Aug;10(3 Suppl 1):227

An Internet-connected, patient-specific, deformable brain atlas integrated into a surgical navigation system. Levy AL, et al. **J Digit Imaging** 1997 Aug;10(3 Suppl 1):231–7

Comparison of image processing techniques (magnetic

resonance imaging, computed tomography scan and ultrasound) for 3D modeling and analysis of the human bones. Mehta BV, et al. **J Digit Imaging** 1997 Aug;10(3 Suppl 1):203–6

Visible humans give doctors a stage for surgical rehearsals [news; comment] Law C. **J Natl Cancer Inst** 1996 Dec 18;88(24):1799–801. Comment on: J Natl Cancer Inst 1996 Dec 18;88(24):1828–33. Comment on: J Natl Cancer Inst 1996 Dec 18;88(24):1834–9.

Concentrating the mind [letter; comment] Martin S. **Nature** 1996 Oct 3;383(6599):381. Comment on: Nature 1996 Aug 22;382(6593):657.

Concentrating the mind [letter; comment] Wassersug R. **Nature** 1996 Oct 3;383(6599):381. Comment on: Nature 1996 Aug 22;382(6593):657.

Determination of the mean cross-sectional area of the thoracic aorta using a double indicator dilution technique. Kornet L, et al. **Pflugers Arch** 1996 Oct;432(6):1069–73

Visible woman meets visible man [news] **Public Health Rep** 1996 Sep–Oct;111(5):385

EDUCATION

Toward virtual anatomy: a stereoscopic 3-D interactive multimedia computer program for cranial osteology. Trelease RB. **Clin Anat** 1996;9(4):269–72

METHODS

Application of rapid scanning retinal thickness analysis in retinal diseases. Asrani S, et al. **Ophthalmology** 1997 Jul; 104(7):1145–51

ANATOMY, SECTIONAL see **ANATOMY, CROSS-SECTIONAL**

ANATOMY, VETERINARY

HISTORY

The bursa of Hieronymus Fabrici d'Acquapendente: past and present of an anatomical structure. Antonello A, et al. **Am J Nephrol** 1997;17(3–4):248–51

ANATOXINS see **TOXOIDS**

ANCA see **ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC**

ANCHORED PCR see **POLYMERASE CHAIN REACTION**

ANCHORIN CII see **ANNEXIN V**

ANCIENT HISTORY see **HISTORY OF MEDICINE, ANCIENT**

ANCIENT HISTORY (MEDICINE) see **HISTORY OF MEDICINE, ANCIENT**

ANCIENT HISTORY OF MEDICINE see **HISTORY OF MEDICINE, ANCIENT**

ANCIENT MEDICINE see **HISTORY OF MEDICINE, ANCIENT**

ANCILLARY INFORMATION SYSTEMS see **INFORMATION SYSTEMS**

ANCILLARY SERVICES, HOSPITAL

Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. Saxon AJ, et al. **Addiction** 1996 Aug;91(8):1197–209

ECONOMICS

Physician variations and the ancillary costs of neonatal intensive care. Perlstein PH, et al. **Health Serv Res** 1997 Aug;32(3):299–311

UTILIZATION

Services to general practitioners [letter] Fisk P, et al. **Genitourin Med** 1996 Aug;72(4):301

ANCITABINE

PHARMACOLOGY

Exocytosis from rat submandibular granular tubules during cyclocytidine stimulation shows unusual features, including changes in the granule membrane. Thomopoulos GN, et al. **Microsc Res Tech** 1996 Dec 1;35(5):365–76

ANCROD

ADMINISTRATION & DOSAGE

Adhesion prevention with ancrod released via a tissue-adherent hydrogel. Chowdhury SM, et al. **J Surg Res** 1996 Feb 15;61(1):58–64

Sensitivity of experimental venous and arterial thrombosis and bleeding to ancrod-induced defibrinogenation. Schumacher WA, et al. **Thromb Res** 1996 Jan 15; 81(2):187–94

PHARMACOLOGY

Integrin alpha v beta 3 and phospholipase C regulate prostacyclin formation of endothelial cells caused by ancrod-generated fibrin. Chang MC, et al. **Eur J Pharmacol** 1996 Feb 15;297(1–2):129–36

Ancrod: understanding the agent. Illig KA, et al. **Semin Vasc Surg** 1996 Dec;9(4):303–14 (95 ref.)

THERAPEUTIC USE

Magnetic resonance imaging studies on the effect of the fibrinogen-lowering agent ancrod on cerebral lesions in two rat models of acute stroke. Elger B, et al. **Arzneimittelforschung** 1997 Aug;47(8):895–9

Ancrod: the use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting: nursing management. Lathan LO, et al. **Heart Lung** 1996 Nov–Dec; 25(6):451–60; quiz 461–2 (27 ref.)

Hematologic changes in a patient with heparin-induced thrombocytopenia who underwent cardiopulmonary bypass after ancrod defibrinogenation. Spiess BD, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):918–21

Ancrod: clinical indications and methods of use. Wright JG, et al. **Semin Vasc Surg** 1996 Dec;9(4):315–28 (87 ref.)

Functional outcome of discordant xenoislet grafts from a large animal donor after recipient defibrinogenation with Ancrod. Troppmann C, et al. **Transplant Proc** 1997 Jun; 29(4):2170–2

ANCYLOSTOMA

Hookworms to treat haemachromatosis? [letter] Simon D, et al. **Postgrad Med J** 1997 Apr;73(858):254–5

[New interpretation of the quantitative fecal examination in humans] Pino LA, et al. **Acta Cient Venez** 1994;45(4):292–5 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Acasp, a gene encoding a cathepsin D-like aspartic protease from the hookworm Ancylostoma caninum. Harrop SA, et al. **Biochem Biophys Res Commun** 1996 Oct 3; 227(1):294–302

Structural analysis of the catalytic site of AcCP-1, a cysteine proteinase secreted by the hookworm Ancylostoma caninum. Brinkworth RI, et al. **Biochim Biophys Acta** 1996 Nov 14;1298(1):4–8

GENETICS

Ancylostoma caninum anticoagulant peptide: cloning by PCR and expression of soluble, active protein in E. coli. Cappello M, et al. **Mol Biochem Parasitol** 1996 Sep; 80(1):113–7

IMMUNOLOGY

Correlation between degree of protection and humoral antibody response in hamsters immunized with somatic and excretory secretory antigens of Ancylostoma ceylanicum. Khan AM, et al. **Indian J Exp Biol** 1996 Oct;34(10):1015–8

Expression of acquired immunity to the hookworm Ancylostoma ceylanicum in hamsters. Behnke IM, et al. **Parasite Immunol** 1997 Jul;19(7):309–18

Molecular approaches to vaccinating against hookworm disease. Hotez PJ, et al. **Pediatr Res** 1996 Oct;40(4):515–21 (82 ref.)

ISOLATION & PURIFICATION

An itchy serpiginous lesion. Golledge CL. **Aust Fam Physician** 1996 Apr;25(4):587

PATHOGENICITY

An itchy serpiginous lesion. Golledge CL. **Aust Fam Physician** 1996 Apr;25(4):587

Pathogenesis of human hookworm infection: insights from a 'new' zoonosis. Prociv P. **Chem Immunol** 1997;66:62–98 (167 ref.)

PHYSIOLOGY

Hookworm: developmental biology of the infectious process. Hawdon JM, et al. **Curr Opin Genet Dev** 1996 Oct; 6(5):618–23 (33 ref.)

Enterobius, trichuris, capillaria, and hookworm including ancylostoma caninum. Grencis RK, et al. **Gastroenterol Clin North Am** 1996 Sep;25(3):579–97 (90 ref.)

Cutaneous larva migrans and enteric hookworm infections. Hendrix CM, et al. **J Am Vet Med Assoc** 1996 Nov 15; 209(10):1763–7

Aberrant migration of Ancylostoma caninum to the os penis of a dog. Bolton LA, et al. **J S Afr Vet Assoc** 1996 Sep; 67(3):161–2

ANCYLOSTOMA CANINUM see **ANCYLOSTOMA**

ANCYLOSTOMA DUODENALE see **ANCYLOSTOMA**

ANCYLOSTOMATOIDEA

Cryopreservation of sheathed third-stage larvae of Ancylostoma caninum (hookworm of dogs) and Ancylostoma tubaeforme (hookworm of cats). Titoy GA, et al. **Onderstepoort J Vet Res** 1996 Jun;63(2):181

GENETICS

Genetic markers in ribosomal DNA for hookworm identification. Gasser RB, et al. **Acta Trop** 1996 Sep; 62(1):15–21

ISOLATION & PURIFICATION

Field evaluation of an improved Kato-Katz thick smear technique for quantitative determination of helminth eggs in faeces. Odongo-Aginya EI, et al. **Trop Med Parasitol** 1995 Dec;46(4):275–7

PHYSIOLOGY

Epidemiology of iron deficiency anemia in Zanzibari schoolchildren: the importance of hookworms. Stoltzfus RJ, et al. **Am J Clin Nutr** 1997 Jan;65(1):153–9

ANCYLOSTOMIASIS

Human enteric infection with Ancylostoma caninum: hookworms reappraised in the light of a "new" zoonosis. Prociv P, et al. **Acta Trop** 1996 Sep;62(1):23–44 (105 ref.)

A distinctive aphthous ileitis linked to Ancylostoma caninum. Croese J, et al. **J Gastroenterol Hepatol** 1996 Jun; 11(6):524–31

COMPLICATIONS

The prevalence of hookworm infection, iron deficiency and anaemia in an aboriginal community in north-west Australia. Hopkins RM, et al. **Med J Aust** 1997 Mar 3; 166(5):241–4

EPIDEMIOLOGY

The distribution of Necator americanus and Ancylostoma duodenale among schoolchildren in Lagos, Nigeria. Adenusi AA. **Trans R Soc Trop Med Hyg** 1997 May–Jun; 91(3):270

ETHNOLOGY

The prevalence of hookworm infection, iron deficiency and anaemia in an aboriginal community in north-west Australia. Hopkins RM, et al. **Med J Aust** 1997 Mar 3; 166(5):241–4

ETIOLOGY

Pathogenesis of human hookworm infection: insights from a 'new' zoonosis. Prociv P. **Chem Immunol** 1997;66:62–98 (167 ref.)

HISTORY

Saint Gotthard's unwanted burden. Aronson SM. **Med Health R I** 1997 May;80(5):138–40

IMMUNOLOGY

Molecular approaches to vaccinating against hookworm disease. Hotez PJ, et al. **Pediatr Res** 1996 Oct;40(4):515–21 (82 ref.)

PARASITOLOGY

Hookworm: developmental biology of the infectious process. Hawdon JM, et al. **Curr Opin Genet Dev** 1996 Oct; 6(5):618–23 (33 ref.)

Enterobius, trichuris, capillaria, and hookworm including ancylostoma caninum. Grencis RK, et al. **Gastroenterol Clin North Am** 1996 Sep;25(3):579–97 (90 ref.)

PREVENTION & CONTROL

Vaccination with alum-precipitated recombinant Ancylostoma-secreted protein 1 protects mice against challenge infections with infective hookworm (Ancylostoma caninum) larvae. Ghosh K, et al. **J Infect Dis** 1996 Dec;174(6):1380–3

Hookworm control as a strategy to prevent iron deficiency. Stoltzfus RJ, et al. **Nutr Rev** 1997 Jun;55(6):223–32 (54 ref.)

[Impact of improved sanitary conditions and domestic hygiene on the incidence of ascaridiasis and ancylostomiasis in children two to four years old in the rural zones of Ivory Coast] Messou E, et al. **Bull Soc Pathol Exot** 1997; 90(1):48–50 (Eng. Abstr.) **(Fre)**

VETERINARY

Aberrant migration of Ancylostoma caninum to the os penis of a dog. Bolton LA, et al. **J S Afr Vet Assoc** 1996 Sep; 67(3):161–2

A primary health care approach to an outbreak of cutaneous larva migrans [letter] van Wyk JA. **J S Afr Vet Assoc** 1997 Mar;68(1):6–7

The efficacy of doramectin on arrested larvae of Ancylostoma caninum in early pregnancy of bitches. Schnieder T, et al. **Zentralbl Veterinarmed [B]** 1996 Aug;

ANCYLOSTOMIASIS

43(6):351–6

ANDERSEN'S DISEASE see **GLYCOGEN STORAGE DISEASE TYPE IV**

ANDERSON–FABRY DISEASE see **FABRY'S DISEASE**

ANDRESEN APPLIANCE see **ACTIVATOR APPLIANCES**

ANDROBLASTOMA

PHYSIOPATHOLOGY

Clinical features and hormonal characteristics in a case of ovarian arrhenoblastoma. Tita P, et al. **J Endocrinol Invest** 1996 Jul–Aug;19(7):484–7

ANDROGEN ANALOGS see **ANDROGENS, SYNTHETIC**

ANDROGEN ANTAGONISTS

The role of neoadjuvant androgen deprivation prior to radical prostatectomy. Fradet Y. **Urol Clin North Am** 1996 Nov;23(4):575–85 (47 ref.)

Antiandrogen withdrawal syndrome with nilutamide. Huan SD, et al. **Urology** 1997 Apr;49(4):632–4

ADMINISTRATION & DOSAGE

Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. Figg WD, et al. **Acta Oncol** 1996; 35(6):763–5

Low dose ketoconazole is an effective and a relatively safe alternative in the treatment of hirsutism. Işik AZ, et al. **Aust N Z J Obstet Gynaecol** 1996 Nov;36(4):487–9

Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma. Figg WD, et al. **Cancer** 1997 May 15;79(10):1964–8

Antiandrogen microimplants into the rostral medial preoptic area decrease gamma-aminobutyric acidergic neuronal activity and increase luteinizing hormone secretion in the intact male rat. Grattan DR, et al. **Endocrinology** 1996 Oct; 137(10):4167–73

Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (Permixon) supplemented with [1–14C]–lauric acid, [1–14C]–oleic acid or [4–14C]–beta–sitosterol. Chevalier G, et al. **Eur J Drug Metab Pharmacokinet** 1997 Jan–Mar; 22(1):73–83

The antiandrogen withdrawal syndrome in relapsed prostate cancer. Scher HI, et al. **Eur Urol** 1997;31 Suppl 2:3–7; discussion 24–7

Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal [letter; comment] Small EJ. **J Urol** 1997 Aug;158(2):552. Comment on: J Urol 1996 Feb;155(2):620–3.

Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy. Teruel JL, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1262–3

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Iversen P, et al. **Scand J Urol Nephrol** 1996 Apr;30(2):93–8

Combined androgen blockade in the treatment of advanced prostate cancer—an overview. The Scandinavian Prostatic Cancer Group. Iversen P. **Scand J Urol Nephrol** 1997 Jun; 31(3):249–54 (33 ref.)

Testotoxicosis proved by immunohistochemical analysis and successfully treated with cyproterone acetate. Itoh K, et al. **Urol Int** 1996;57(3):199–202

Intermittent androgen deprivation after PSA–complete response as a strategy to reduce induction of hormone–resistant prostate cancer. Oliver RT, et al. **Urology** 1997 Jan;49(1):79–82

[Chlormadinone acetate alone as therapy (letter)] Zaun H. **Hautarzt** 1996 Jan;47(1):66 **(Ger)**

[Ovulation induction with adjuvant antiandrogen treatment in Stein–Leventhal syndrome] Koloszár S, et al. **Orv Hetil** 1996 Nov 17;137(46):2569–71 (Eng. Abstr.) **(Hun)**

ADVERSE EFFECTS

Severe hepatitis and liver failure induced by cyproterone acetate [letter] Murphy BJ, et al. **Aust N Z J Med** 1996 Oct;26(5):724

The effects of pre– and postnatal exposure to the nonsteroidal antiandrogen flutamide on testis descent and morphology in the Albino Swiss rat. Kassim NM, et al. **J Anat** 1997 May;190 (Pt 4):577–88

Antiandrogen withdrawal syndrome with nilutamide. Gomella LG, et al. **J Urol** 1997 Apr;157(4):1366

Flutamide induced methemoglobinemia. Khan AM, et al. **J Urol** 1997 Apr;157(4):1363 (3 ref.)

Re: Osteoporosis after orchiectomy for prostate cancer [letter] Krongrad A, et al. **J Urol** 1997 Oct;158(4):1529–30

Flutamide photosensitivity. Leroy D, et al. **Photodermatol Photoimmunol Photomed** 1996 Oct; 12(5):216–8

Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Suzuki H, et al. **Prostate** 1996 Sep; 29(3):153–8

Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Kelly WK, et al. **Urol Clin North Am** 1997 May;24(2):421–31

The antiandrogen withdrawal syndrome. Wirth MP, et al. **Urol Res** 1997;25 Suppl 2:S67–71 (28 ref.)

Finasteride and flutamide as potency–sparing androgen–ablative therapy for advanced adenocarcinoma of the prostate. Brufsky A, et al. **Urology** 1997 Jun; 49(6):913–20

Fulminant hepatic failure associated with bicalutamide. Dawson LA, et al. **Urology** 1997 Feb;49(2):283–4

A case of flutamide–induced acute cholestatic hepatitis—a case report. Lee HW, et al. **Yonsei Med J** 1996 Jun; 37(3):225–9

[Fatal fulminating hepatitis caused by nilutamide. A new case (letter)] Marty F, et al. **Gastroenterol Clin Biol** 1996; 20(8–9):710–1 **(Fre)**

[An equivalent of anti–androgen withdrawal syndrome: decrease of prostate specific antigen and clinical response to estramustine phosphate withdrawal (letter)] Levy R, et al. **Presse Med** 1997 Apr 19;26(13):611 **(Fre)**

[The effective therapy of the hot flashes during hormone withdrawal treatment in patients with advanced prostatic carcinoma] Kliesch S, et al. **Dtsch Med Wochenschr** 1997 Jul 25;122(30):940–5 (64 ref.) **(Ger)**

[A case of fulminant hepatitis caused by antiandrogen, flutamide in a patient with prostate cancer] Satoh T, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 Jul;88(7):694–6 (Eng. Abstr.) **(Jpn)**

[Liver failure caused by flutamide] Guzmán Martínez–Valls PL, et al. **Actas Urol Esp** 1997 Mar;21(3):278–82 (Eng. Abstr.) **(Spa)**

[Hepatoxicity caused by flutamide increased by hypotensive situation?] Serrano Hernández N, et al. **An Med Interna** 1996 Nov;13(11):552–4 (Eng. Abstr.) **(Spa)**

BLOOD

New and validated high–performance liquid chromatographic method for determination of hydroxyflutamide in human plasma. Leibinger J, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1377–81

CHEMICAL SYNTHESIS

Antiandrogen. IV. C–17 spiro 2–oxasteroids. Koizumi N, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2162–4

METABOLISM

Studies on the formation of hepatic DNA adducts by the antiandrogenic and gestagenic drug, cyproterone acetate: 1. adduct levels in various species including man and 2. persistence and accumulation in the rat. Werner S, et al. **Adv Exp Med Biol** 1996;387:253–7

Non–steroidal L–245,976 acts as a classical antiandrogen in vitro. Toney JH, et al. **J Steroid Biochem Mol Biol** 1997 Jan;60(1–2):131–6

Enantioselective binding of Casodex to the androgen receptor. Mukherjee A, et al. **Xenobiotica** 1996 Feb; 26(2):117–22

PHARMACOKINETICS

Bioequivalence evaluation of two flutamide preparations in healthy female subjects. Doser K, et al. **Arzneimittelforschung** 1997 Feb;47(2):213–7

The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. Cockshott ID, et al. **Biopharm Drug Dispos** 1997 Aug;18(6):499–507

Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (Permixon) supplemented with [1–14C]–lauric acid, [1–14C]–oleic acid or [4–14C]–beta–sitosterol. Chevalier G, et al. **Eur J Drug Metab Pharmacokinet** 1997 Jan–Mar; 22(1):73–83

Importance of sebaceous glands in cutaneous penetration of an antiandrogen: target effect of liposomes. Bernard E, et al. **J Pharm Sci** 1997 May;86(5):573–8

PHARMACOLOGY

Marked symptom reduction in two women with bulimia nervosa treated with the testosterone receptor antagonist flutamide. Bergman L, et al. **Acta Psychiatr Scand** 1996 Aug;94(2):137–9

Absence of hepatic enzyme induction in prostate cancer patients receiving 'Casodex' (bicalutamide). Kaisary A, et al. **Anticancer Drugs** 1996 Jan;7(1):54–9

Ornithine decarboxylase activity and polyamine levels in the epididymis of prepubertal rat after antiandrogen administration. Rulli SB, et al. **Arch Androl** 1997 Mar–Apr; 38(2):163–71

Alteration by flutamide of neutrophil response to stimulation. Implications for tissue injury. Srinivasan R, et al. **Biochem Pharmacol** 1997 Apr 25;53(8):1179–85

Effect of antiandrogens casodex and epitestosterone on bone composition in mice. Broulik PD, et al. **Bone** 1997 May; 20(5):473–5

Casodex (a nonsteroidal antiandrogen) reduces cancellous, endosteal, and periosteal bone formation in estrogen–replete female rats. Lea C, et al. **Calcif Tissue Int** 1996 Apr;58(4):268–72

Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Klus GT, et al. **Cancer Res** 1996 Nov 1;56(21):4956–64

The influence of Microgynon and Diane–35, two sub–fifty ovulation inhibitors, on voice function in women. Wendler J, et al. **Contraception** 1995 Dec;52(6):343–8

Antiandrogenic effect of RU–486 in the mouse kidney. Tovar A, et al. **Int J Biochem Cell Biol** 1997 Feb;29(2):361–6

Induction of liver cytochrome P–450 (CYP) 3A in male and female rats by a steroidal androgen receptor antagonist, zanoterone. Roberts AE, et al. **J Biochem Toxicol** 1996; 11(3):101–10

A new synthetic steroid, osaterone acetate (TZP–4238), increases cortical bone mass and strength by enhancing bone formation in ovariectomized rats. Fuse H, et al. **J Bone Miner Res** 1997 Apr;12(4):590–7

Topical spironolactone reduces sebum secretion rates in young adults. Yamamoto A, et al. **J Dermatol** 1996 Apr; 23(4):243–6

Endocrine mechanisms of suppressive effect of low dose estrogen–antiandrogen treatment on androgen–dependent organs of male rats. Reznikov AG, et al. **J Endocrinol Invest** 1996 Nov;19(10):654–8

Antiandrogenic effect of Striga orobanchioides. Hiremath SP, et al. **J Ethnopharmacol** 1997 Mar;56(1):55–60

Inhibition of growth and induction of TGF–beta 1 in human hepatocellular carcinoma with androgen receptor by cyproterone acetate in male nude mice. Nagasue N, et al. **J Hepatol** 1996 Oct;25(4):554–62

The influence of the anti–androgen flutamide on early sexual differentiation of the marsupial male. Lucas JC, et al. **J Reprod Fertil** 1997 Mar;109(2):205–12

Non–steroidal L–245,976 acts as a classical antiandrogen in vitro. Toney JH, et al. **J Steroid Biochem Mol Biol** 1997 Jan;60(1–2):131–6

Hydroxyflutamide may not always be a pure antiandrogen [letter] Yeh S, et al. **Lancet** 1997 Mar 22;349(9055):852–3

Pesticides: multiple mechanisms of demasculinization. LeBlanc GA, et al. **Mol Cell Endocrinol** 1997 Jan 3; 126(1):1–5 (72 ref.)

Immunological and biological activities of pituitary FSH isoforms in prepubertal male rats: effect of antiandrogens. Rulli SB, et al. **Neuroendocrinology** 1996 Jun;63(6):514–21

Inhibition of male sex behavior by androgen receptor blockade in preoptic area or hypothalamus, but not amygdala or septum. McGinnis MY, et al. **Physiol Behav** 1996 Sep;60(3):783–9

The suppressive effects of testosterone on growth in young chickens appears to be mediated via a peripheral androgen receptor; studies of the anti–androgen ICI 176,334. Fennell MJ, et al. **Poult Sci** 1996 Jun;75(6):763–6

Effects of gonadal steroids and their antagonists on the humoral immune response of immune–selected broiler chicks. Leitner G, et al. **Poult Sci** 1996 Nov;75(11):1373–82

The antiangiogenic agent linomide inhibits tumor necrosis factor–alpha secretion via inhibition of its synthesis. Joseph IB, et al. **Prostate** 1996 Sep;29(3):183–90

Relative potency of antiandrogens with reference to intracellular testosterone in the rat prostate. Kondo Y, et al. **Prostate** 1996 Sep;29(3):146–52

Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Ravenna L, et al. **Prostate** 1996 Oct;29(4):219–30

Vinclozolin and p,p'–DDE alter androgen–dependent gene expression: in vivo confirmation of an androgen receptor–mediated mechanism. Kelce WR, et al. **Toxicol Appl Pharmacol** 1997 Jan;142(1):192–200

Comparison of in vitro effects of the pure antiandrogens OH–flutamide, Casodex, and nilutamide on androgen–sensitive parameters. Simard J, et al. **Urology** 1997 Apr;49(4):580–6; discussion 586–9

[Does interferon–alpha enhance the effect of tamoxifen–medroxyprogesterone acetate and hydroxyflutamide on in vitro tumor cells? Werner A, et al. **Zentralbl Gynakol** 1996;118(11):616–21 (Eng. Abstr.) **(Ger)**

[The effect of antiandrogens cyproterone acetate and niftolide on free radical oxidation indices in model biological systems in vitro] Chukaev SA. **Biull Eksp Biol Med** 1996 Nov;122(11):524–6 **(Rus)**

THERAPEUTIC USE

Treatment of female hyperandrogenism: estroprogestinic therapy at low dose in an inversal sequential scheme. Ragonesi FP, et al. **Acta Eur Fertil** 1995 Jul–Aug; 26(4):141–3

Marked symptom reduction in two women with bulimia nervosa treated with the testosterone receptor antagonist flutamide. Bergman L, et al. **Acta Psychiatr Scand** 1996 Aug;94(2):137–9

Maximal androgen blockade versus total androgen suppression. Dumez H, et al. **Acta Urol Belg** 1997 Mar; 65(1):49–54

Nilutamide approved for metastatic prostate cancer [news] **Am J Health Syst Pharm** 1996 Dec 1;53(23):2784

Nilutamide: an antiandrogen for the treatment of prostate cancer. Dole EJ, et al. **Ann Pharmacother** 1997 Jan; 31(1):65–75 (64 ref.)

Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. Blackledge G, et al. **Anticancer Drugs** 1996 Jan;7(1):27–34 (38 ref.)

Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy. Lee F, et al. **Anticancer Res** 1997 May-Jun; 17(3A):1507-10

Successful treatment of hirsutism in HAIR-AN syndrome using flutamide, spironolactone, and birth control therapy. Zemtsov A, et al. **Arch Dermatol** 1997 Apr;133(4):431-3

Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Theyer G, et al. **Br J Cancer** 1997;75(10):1515-8

Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Lucker GP, et al. **Br J Dermatol** 1997 Jan;136(1):71-5

Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Fleshner NE, et al. **Br J Urol** 1996 Dec;78(6):907-10

Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer. Hellström M, et al. **Br J Urol** 1997 Mar;79(3):421-6

Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy. Kurita Y, et al. **Br J Urol** 1997 Jul;80(1):78-83

Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment. Palmberg C, et al. **Br J Urol** 1997 May;79(5):808-9

Neoadjuvant androgen deprivation therapy before radical prostatectomy: who is unlikely to benefit? Rabbani F, et al. **Br J Urol** 1997 Feb;79(2):221-5

Androgen-receptor blockade does not impair bone mineral density in adolescent females. Bertelloni S, et al. **Calcif Tissue Int** 1997 Jul;61(1):1-5

Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Civantos F, et al. **Cancer** 1995 Apr 1;75(7):1634-41

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Schellhammer PF, et al. **Cancer** 1996 Nov 15;78(10):2164-9

Bicalutamide ('Casodex') development: from theory to therapy [see comments] Kolvenbag GJ, et al. **Cancer J Sci Am** 1997 Jul-Aug;3(4):192-203 (86 ref.). Comment in: Cancer J Sci Am 1997 Jul-Aug;3(4):204-8. 'Casodex': defining the role of antiandrogens [comment] McCaffrey JA, et al. **Cancer J Sci Am** 1997 Jul-Aug; 3(4):204-8 (47 ref.). Comment on: Cancer J Sci Am 1997 Jul-Aug;3(4):192-203.

Total androgen blockade for prostate cancer: the end does not justify the means. Javle M, et al. **Cancer Treat Res** 1996;88:201-10 (61 ref.)

Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Gibbs SJ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(6):346-52 (44 ref.)

Pulmonary metastases, an occult prostatic adenocarcinoma and delayed administration of antiandrogens. Harris SJ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(2):118-9

Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Vinorelbine: an update and review of activity [letter] Macbeth F. **Clin Oncol (R Coll Radiol)** 1997;9(3):197

Investigations in the assessment and management of patients with hirsutism. Barth JH. **Curr Opin Obstet Gynecol** 1997 Jun;9(3):187-92 (44 ref.)

Familial male precocious puberty. Leschek EW, et al. **Curr Ther Endocrinol Metab** 1997;6:343-5 (6 ref.)

Antiandrogen and hormonal treatment of acne. Shaw JC. **Dermatol Clin** 1996 Oct;14(4):803-11 (51 ref.)

Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Plosker GL, et al. **Drugs Aging** 1996 Nov;9(5):379-95 (86 ref.)

Androgens and prostate cancer: biology, pathology and hormonal therapy. Galbraith SM, et al. **Eur J Cancer** 1997 Apr;33(4):545-54 (78 ref.)

Spironolactone therapy in hypertrichosis. Darendeliler F, et al. **Eur J Endocrinol** 1996 Nov;135(5):604-8

Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Andriole GL. **Eur Urol** 1997;32 Suppl 3:65-9 (59 ref.)

Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Blackledge GR, et al. **Eur Urol** 1997;31 Suppl 2:30-9 (44 ref.)

Maximum androgen blockade in 1996. Boccon-Gibod L. **Eur Urol** 1996;30 Suppl 1:15-8; discussion 19-21 (10 ref.)

Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Griffiths K, et al. **Eur Urol** 1997;32 Suppl 3:24-40 (82 ref.)

Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Imada S, et al. **Eur Urol** 1997;31(3):360-4

Antiandrogen monotherapy in the management of advanced prostate cancer. Kaisary AV. **Eur Urol** 1997;31 Suppl 2:14-9; discussion 24-7

Combined androgen blockade: the gold standard for metastatic prostate cancer. McLeod DG, et al. **Eur Urol** 1997;32 Suppl 3:70-7 (43 ref.)

Clinical assessment and management of stage T3 prostate cancer. Newling DW. **Eur Urol** 1997;32 Suppl 3:55-9 (15 ref.)

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Palmberg C, et al. **Eur Urol** 1997;31(2):216-9

Effects of neoadjuvant androgen deprivation therapy on prostatic cancer. Polito M, et al. **Eur Urol** 1996;30 Suppl 1:26-31; discussion 38-9

Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Pummer K, et al. **Eur Urol** 1997;32 Suppl 3:81-5

Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Roach M 3rd. **Eur Urol** 1997;32 Suppl 3:48-54 (34 ref.)

Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and open questions. Schulman CC, et al. **Eur Urol** 1997;32 Suppl 3:41-7 (62 ref.)

Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate. Smith JA Jr, et al. **Eur Urol** 1997;31 Suppl 3:25-9

Innovative approaches to the hormonal treatment of advanced prostate cancer. Trachtenberg J. **Eur Urol** 1997; 32 Suppl 3:78-80 (5 ref.)

Progress in complete androgen blockade. Trachtenberg J. **Eur Urol** 1997;31 Suppl 2:8-10; discussion 24-7

Intermittent endocrine therapy of prostate cancer. Tunn UW. **Eur Urol** 1996;30 Suppl 1:22-5; discussion 38-9

Androgen receptors in untreated and treated prostatic intraepithelial neoplasia. van der Kwast TH, et al. **Eur Urol** 1996;30(2):265-8

Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia. Wheeler TM. **Eur Urol** 1996; 30(2):261-4 (20 ref.)

Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. Falsetti L, et al. **Gynecol Endocrinol** 1997 Aug;11(4):251-7

Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gökmen O, et al. **Gynecol Endocrinol** 1996 Aug;10(4):249-55

What is the optimal patient selection for combined androgen ablative and radiation therapy? The role of combined modality staging. D'Amico AV. **Hematol Oncol Clin North Am** 1996 Jun;10(3):643-51 (13 ref.)

Is there a role for induction androgen deprivation prior to radical prostatectomy? Watson R, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):627-41 (62 ref.)

Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Kauli R, et al. **Horm Res** 1997;47(2):54-61

Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Carmina E, et al. **Hum Reprod** 1997 Apr;12(4):663-6

Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Pantel K, et al. **Int J Cancer** 1997 May 16;71(4):521-5

Antiandrogen therapy in dermatology. Shaw JC. **Int J Dermatol** 1996 Nov;35(11):770-8 (86 ref.)

Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. Lawton CA, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15;38(5):931-9

Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy [editorial; comment] Zietman AL, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):245-6. Comment on: Int J Radiat Oncol Biol Phys 1997 Jan 15;37(2):247-52.

Cyproterone acetate monotherapy in advanced prostatic carcinoma. Kayigil O, et al. **Int Urol Nephrol** 1997; 29(2):213-20

The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. Moghetti P, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):952-60

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Scher HI, et al. **J Clin Oncol** 1997 Aug;15(8):2928-38

The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma. Vainas G, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):119-26

Antiandrogen treatment of aggressivity in men suffering from dementia. Amadeo M. **J Geriatr Psychiatry Neurol** 1996 Jul;9(3):142-5

Androgen deprivation as a strategy for prostate cancer chemoprevention. Aquilina JW, et al. **J Natl Cancer Inst** 1997 May 21;89(10):689-96

Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate? [see comments] Datta SN, et al. **J Urol** 1997 Jul;158(1):175-7. Comment in: J Urol 1997 Jul;158(1):178.

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group [see comments] Dijkman GA, et al. **J Urol** 1997 Jul;158(1):160-3. Comment in: J Urol 1997 Jul;158(1):178.

Re: Editorial comment [letter] Goldenberg SL, et al. **J Urol** 1997 Jun;157(6):2267

Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate [see comments] Smith JA Jr, et al. **J Urol** 1997 Apr;157(4):1329-34. Comment in: J Urol 1997 Apr;157(4):1335-6.

Re: Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer [letter; comment] Walsh PC. **J Urol** 1997 Mar;157(3):965 . Comment on: J Urol 1996 Sep;156(3):873-7.

New approaches to the treatment of congenital adrenal hyperplasia [clinical conference] Merke DP, et al. **JAMA** 1997 Apr 2;277(13):1073-6

Role for androgen withdrawal prior to radiation and surgery for prostate cancer? [news] **Oncology (Huntingt)** 1997 May; 11(5):738

Prostate cancer clinical trials of the Southwest Oncology Group. Crawford ED, et al. **Oncology (Huntingt)** 1997 Aug; 11(8):1154-63; discussion 1163-70 (54 ref.)

Combinations of hormones and local therapies in locally advanced prostate carcinoma. Eulau SM, et al. **Oncology (Huntingt)** 1996 Aug;10(8):1193-202; discussion 1207-14 (60 ref.)

Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Paubert-Braquet M, et al. **Pharmacol Res** 1996 Sep-Oct;34(3-4):171-9

Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Asbell SO, et al. **Prostate** 1996 Oct; 29(4):243-8

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Carraro JC, et al. **Prostate** 1996 Oct;29(4):231-40; discussion 241-2

Maximal androgen blockade in prostate cancer: a theory put into practice [letter; comment] Denis LJ. **Prostate** 1996 Sep; 29(3):194. Comment on: Prostate 1995 Nov;27(5):233-40.

Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies. Duchesne GM, et al. **Radiother Oncol** 1996 Jan;38(1):7-12

Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Koivisto P, et al. **Scand J Clin Lab Invest Suppl** 1996;226:57-63 (19 ref.)

Morphometry of benign prostatic hyperplasia during androgen suppressive therapy. Relationships among epithelial content, PSA density, and clinical outcome. Svindland A, et al. **Scand J Urol Nephrol Suppl** 1996; 179:113-7

Secondary hormonal therapy. Smith DC. **Semin Urol Oncol** 1997 Feb;15(1):3-12 (95 ref.)

Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Abbas F, et al. **Urol Clin North Am** 1996 Nov;23(4):587-604 (121 ref.)

The role of neoadjuvant androgen deprivation prior to radical prostatectomy. Fradet Y. **Urol Clin North Am** 1996 Nov;23(4):575-85 (47 ref.)

Combination treatment versus LHRH alone in advanced prostatic cancer. Ferrari P, et al. **Urol Int** 1996;56 Suppl 1:13-7

Effects of androgen deprivation prior to radical prostatectomy in 375 patients. Tunn UW, et al. **Urol Int** 1996;56 Suppl 1:6-12

Intermittent androgen deprivation in advanced prostate cancer. de Reijke TM. **Urol Res** 1997;25 Suppl 2:S63-6 (35 ref.)

Neo-adjuvant hormonal therapy of prostate cancer. Tunn UW. **Urol Res** 1997;25 Suppl 2:S57-62

Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Bazinet M, et al. **Urology** 1997 May; 49(5):721-5

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Caubet JF, et al. **Urology** 1997 Jan;49(1):71-8

The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Fair WR, et al. **Urology** 1997 Mar;49(3A Suppl):46-55

Hormonal therapy in the management of prostate cancer: from Huggins to the present. Garnick MB. **Urology** 1997 Mar;49(3A Suppl):5-15 (35 ref.)

Neoadjuvant hormonal therapy: the Canadian experience. Labrie F, et al. **Urology** 1997 Mar;49(3A Suppl):56-64

Estimated potency of Casodex: a problematic design [letter; comment] Labrie F, et al. **Urology** 1997 Aug;50(2):309-13 . Comment on: Urology 1995 May;45(5):745-52.

Flutamide plus castration in patients with previously untreated prostate cancer [letter] Labrie F. **Urology** 1997 Sep;50(3):479

ANDROGEN ANTAGONISTS

PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group. McLeod DG, et al. **Urology** 1997 Mar;49(3A Suppl):70–3

Neoadjuvant androgen–deprivation therapy prior to radical prostatectomy: con [editorial] Paulson DF. **Urology** 1996 Oct;48(4):539–40

Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Su SL, et al. **Urology** 1997 Mar;49(3A Suppl):95–101 (37 ref.)

Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Zelefsky MJ, et al. **Urology** 1997 Mar;49(3A Suppl):38–45

Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Zietman AL, et al. **Urology** 1997 Mar;49(3A Suppl):74–83 (43 ref.)

[The treatment of prostatic carcinoma with cyproterone acetate] Tsvetkov M, et al. **Khirurgiia (Sofiia)** 1996; 49(1):12–5 (Eng. Abstr.) **(Bul)**

[Total androgen blockade for prostate cancer] Kagebayashi Y, et al. **Hinyokika Kiyo** 1997 Mar;43(3):197–201 (Eng. Abstr.) **(Jpn)**

[Neoadjuvant endocrine therapy in patients with locally advanced prostate cancer] Maeda O, et al. **Hinyokika Kiyo** 1996 Oct;42(10):821–7 (Eng. Abstr.) **(Jpn)**

[Immunohistochemical study of androgen receptor in adenocarcinoma of the human prostatic cancer] Yoshikawa H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jul; 87(7):956–63 (Eng. Abstr.) **(Jpn)**

[Mechanism on androgen–independent progression of prostate cancer] Shimazaki J, et al. **Nippon Rinsho** 1997 May;55(5):1143–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Maximal androgen blockade in metastatic prostatic carcinoma (see comments)] Jørgensen T, et al. **Tidsskr Nor Laegeforen** 1997 Jan 30;117(3):381–3 (17 ref.) (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1997 Mar 20;117(8):1187. **(Nor)**

[Androgenic blockade in metastasizing prostatic carcinoma (letter; comment)] Tveter KJ. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1187. Comment on: Tidsskr Nor Laegeforen 1997 Jan 30;117(3):381–3. **(Nor)**

[The use of serpens for treating patients with benign prostatic hyperplasia] Mazo EB, et al. **Ter Arkh** 1996;68(10):47–9 (Eng. Abstr.) **(Rus)**

[The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer] Sivko AV, et al. **Urol Nefrol (Mosk)** 1997 May–Jun;(3):49–52 (83 ref.) **(Rus)**

[Effect of complete androgen block before radical prostatectomy for cancer of the prostate] Gómez Veiga F, et al. **Arch Esp Urol** 1997 May;50(4):355–63 (Eng. Abstr.) **(Spa)**

[Histologic regression of localized prostatic tumor with neoadjuvant hormonal therapy] López López C, et al. **Arch Esp Urol** 1996 Oct;49(8):819–23 (Eng. Abstr.) **(Spa)**

TOXICITY

Studies on the formation of hepatic DNA adducts by the antiandrogenic and gestagenic drug, cyproterone acetate: 1. adduct levels in various species including man and 2. persistence and accumulation in the rat. Werner S, et al. **Adv Exp Med Biol** 1996;387:253–7

Effects of short–term exposure to hydroxyflutamide in utero on the development of the reproductive tract in male mice. Silversides DW, et al. **Can J Physiol Pharmacol** 1995 Nov; 73(11):1582–8

Cyproterone acetate: is it hepato– or genotoxic? Rabe T, et al. **Drug Saf** 1996 Jan;14(1):25–38 (60 ref.)

Environmental antiandrogens: developmental effects, molecular mechanisms, and clinical implications. Kelce WR, et al. **J Mol Med** 1997 Mar;75(3):198–207 (110 ref.)

An overview of animal toxicology studies with bicalutamide (ICI 176,334). Iswaran TJ, et al. **J Toxicol Sci** 1997 May; 22(2):75–88 (38 ref.)

Latent effects of pesticides and toxic substances on sexual differentiation of rodents. Gray LE Jr, et al. **Toxicol Ind Health** 1996 May–Aug;12(3–4):515–31 (38 ref.)

ANDROGEN–BINDING PROTEINS

BIOSYNTHESIS

Androgens transcriptionally regulate the expression of cystatin–related protein and the C3 component of prostatic binding protein in rat ventral prostate and lacrimal gland. Vercaeren I, et al. **Endocrinology** 1996 Nov;137(11):4713–20

Androgenic induction of cystatin–related protein and the C3 component of prostatic binding protein in primary cultures from the rat lacrimal gland. Vanaken H, et al. **Mol Cell Endocrinol** 1996 Aug 9;121(2):197–205

DRUG EFFECTS

Environmental xenobiotics may disrupt normal endocrine function by interfering with the binding of physiological ligands to steroid receptors and binding proteins. Danzo BJ. **Environ Health Perspect** 1997 Mar;105(3):294–301

GENETICS

Expression and distribution of androgen–binding protein/sex hormone–binding globulin in the female rodent reproductive system. Joseph DR, et al. **Biol Reprod** 1997 Jan;56(1):14–20

Overexpression of androgen–binding protein/sex hormone–binding globulin in male transgenic mice: tissue distribution and phenotypic disorders. Joseph DR, et al. **Biol Reprod** 1997 Jan;56(1):21–32

The microevolution of mouse salivary androgen–binding protein (ABP) paralleled subspeciation of Mus musculus. Hwang JM, et al. **J Hered** 1997 Mar–Apr;88(2):93–7

Exon skipping and circular RNA formation in transcripts of the human cytochrome P–450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Zaphiropoulos PG. **Mol Cell Biol** 1997 Jun;17(6):2985–93

DNA sequences and their binding proteins required for Sertoli cell–specific transcription of the rat androgen–binding protein gene. Fenstermacher DA, et al. **Mol Endocrinol** 1997 Aug;11(9):1387–400

Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Yan Y, et al. **Prostate** 1997 Jul 1;32(2):129–39

[Alteration of mRNA transcripts of rat Sertoli cell secreted proteins and Leydig cell LH/CG–R protein following glycosides of Tripterigium Wilfordii Hook administration] Zheng W, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Apr; 18(2):104–10 (Eng. Abstr.) **(Chi)**

METABOLISM

Distribution of immunoreactive androgen–binding protein/sex hormone–binding globulin in tissues of the fetal rat. Becchis M, et al. **Steroids** 1996 Jul;61(7):392–400

PHARMACOLOGY

Growth response of adult germ cells to rat androgen–binding protein and human sex hormone–binding globulin. Gérard A, et al. **Horm Res** 1996;45(3–5):218–21

ANDROGEN RECEPTORS see **RECEPTORS, ANDROGEN**

ANDROGENS

see related
ANDROGEN ANTAGONISTS
RECEPTORS, ANDROGEN

Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen–responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC–SPES. Hsieh T, et al. **Biochem Mol Biol Int** 1997 Jul;42(3):535–44

The effect of androgen deprivation and radiation therapy on an androgen–sensitive murine tumor: an in vitro and in vivo study. Zietman AL, et al. **Cancer J Sci Am** 1997 Jan–Feb;3(1):31–6

Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down–regulation of vascular endothelial growth factor in human androgen–responsive prostatic cancers. Joseph IB, et al. **Cancer Res** 1997 Mar 15;57(6):1054–7

Effects of social housing condition on the response of the Shionogi mouse mammary carcinoma (SC115) to chemotherapy. Kerr LR, et al. **Cancer Res** 1997 Mar 15; 57(6):1124–8

Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Stanford JL, et al. **Cancer Res** 1997 Mar 15;57(6):1194–8

Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Zietman AL, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15; 38(5):1067–70

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Scher HI, et al. **J Clin Oncol** 1997 Aug;15(8):2928–38

Androgenic–anabolic steroids and body dysmorphia in young men. Wroblewska AM. **J Psychosom Res** 1997 Mar; 42(3):225–34 (75 ref.)

Establishment and characterization of three androgen–independent, metastatic carcinoma cell lines from 3,2'–dimethyl–4–aminobiphenyl–induced prostatic tumors in F344 rats. Nakanishi H, et al. **Jpn J Cancer Res** 1996 Dec;87(12):1218–26

ADMINISTRATION & DOSAGE

Androgen use by athletes: a reevaluation of the health risks. Street C, et al. **Can J Appl Physiol** 1996 Dec;21(6):421–40 (82 ref.)

Androgen replacement therapy in women: myths and realities. Casson PR, et al. **Int J Fertil Menopausal Stud** 1996 Jul–Aug;41(4):412–22 (79 ref.)

Effects of hormone deficiency, androgen therapy and calcium supplementation on bone mineral density in female transsexuals. Goh HH, et al. **Maturitas** 1997 Jan;26(1):45–52

ADVERSE EFFECTS

Androgen and estrogen–androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Gelfand MM, et al. **Clin Ther** 1997 May–Jun;19(3):383–404; discussion 367–8 (107 ref.)

The pharmacology and effectiveness of specific lipid–active drugs: estrogen/sex steroids. LaRosa JC. **Coron Artery Dis** 1996 Sep;7(9):683–8 (37 ref.)

Hormones and health. Eubanks MW. **Environ Health Perspect** 1997 May;105(5):482–6 (0 ref.)

Side effects of long–term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. Cicardi M, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):194–6

The effects of chronic high dose androgen or estrogen treatment on the human prostate [corrected] [published erratum appears in J Clin Endocrinol Metab 1997 Feb;82(2):413] Jin B, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4290–5

ANALOGS & DERIVATIVES see **ANDROGENS, SYNTHETIC**

ANALYSIS

Evaluation of hormonal function in a series of incidentally discovered adrenal masses. Bondanelli M, et al. **Metabolism** 1997 Jan;46(1):107–13

Endocrine Screening Methods Workshop report: detection of estrogenic and androgenic hormonal and antihormonal activity for chemicals that act via receptor or steroidogenic enzyme mechanisms. Gray LE Jr, et al. **Reprod Toxicol** 1997 Sep–Oct;11(5):719–50

ANTAGONISTS & INHIBITORS see **ANDROGEN ANTAGONISTS**

BIOSYNTHESIS

Sertoli cell conditioned media modulate the androgen biosynthetic pathways in rat Leydig cell primary cultures. Herrera J, et al. **Arch Androl** 1996 Sep–Oct;37(2):127–33

Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Klus GT, et al. **Cancer Res** 1996 Nov 1;56(21):4956–64

Forskolin treatment directs steroid production towards the androgen pathway in the NCI–H295R adrenocortical tumour cell line. Cobb VJ, et al. **Endocr Res** 1996 Nov; 22(4):545–50

Adrenal androgen production in response to adrenocorticotropin infusions in men. Parker CR Jr, et al. **Endocr Res** 1996 Nov;22(4):717–22

Hepatocyte growth factor regulates ovarian theca–interstitial cell differentiation and androgen production. Zachow RJ, et al. **Endocrinology** 1997 Feb;138(2):691–7

Rapid down–regulation of testicular androgen biosynthesis at increased environmental temperature is due to cytochrome P450c17 (CYP17) thermolability in Leydig cells, but not in endoplasmic reticulum membranes. Kühn–Velten WN. **Exp Clin Endocrinol Diabetes** 1996; 104(3):243–9

Effect of ovarian stimulation on adrenal androgenesis? [letter; comment] Cumming DC, et al. **Fertil Steril** 1996 Dec; 66(6):1042–3. Comment on: Fertil Steril 1996 May;65(5):950–3.

Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin–releasing hormone agonist testing. Ibáñez L, et al. **Fertil Steril** 1997 May;67(5):849–55

Androgen biosynthesis and secretion in developing Xenopus laevis. Kang L, et al. **Gen Comp Endocrinol** 1995 Dec; 100(3):293–307

Interaction of histamine with adrenocorticotropic hormone: a local modulatory role for adrenocortical androgen synthesis? Orsó E, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S57–8

Insulin–like growth factors augment steroid production and expression of steroidogenic enzymes in human fetal adrenal cortical cells: implications for adrenal androgen regulation. Mesiano S, et al. **J Clin Endocrinol Metab** 1997 May; 82(5):1390–6

Use of gas chromatographic–mass spectrometric techniques in studies of androst–16–ene and androgen biosynthesis in human testis; cytosolic specific binding of 5alpha–androst–16–en–3–one. Kwan TK, et al. **J Steroid Biochem Mol Biol** 1997 Jan;60(1–2):137–46

In vitro effects of beta–endorphin on testicular release of androgens in the lizard Podarcis sicula Raf. Ciarcia G, et al. **Mol Reprod Dev** 1996 Nov;45(3):308–12

Regulation of androgen synthesis: the late steroidogenic pathway. Dufau ML, et al. **Steroids** 1997 Jan;62(1):128–32

[Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer] Gleave M, et al. **Prog Urol** 1996 Jun;6(3):375–85 (Eng. Abstr.) **(Fre)**

[Hormonal control of sexual behavior in males and endocrinologic causes of sexual dysfunction] Manieri C, et al. **Minerva Endocrinol** 1997 Jun;22(2):37–43 (Eng. Abstr.) **(Ita)**

BLOOD

Androgen–sensitive period of humoral immune reactivity

development in male mice. Nikonenko IR, et al. **Acta Physiol Pharmacol Bulg** 1995;21(4):99–104

Kaposi's sarcoma and sex hormones [letter] Bouscarat F, et al. **AIDS** 1997 Apr;11(5):687–8

Effects of dietary fat and fiber on plasma and urine androgens and estrogens in men: a controlled feeding study. Dorgan JF, et al. **Am J Clin Nutr** 1996 Dec;64(6):850–5

Endocrine profiles of male workers with exposure to trichloroethylene. Chia SE, et al. **Am J Ind Med** 1997 Sep; 32(3):217–22

Anthropometrical measurements and androgen levels in males, females, and hormonally untreated female-to-male transsexuals. Bosinski HA, et al. **Arch Sex Behav** 1997 Apr; 26(2):143–57

Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa [letter; comment] Farrell AM, et al. **Br J Dermatol** 1997 May;136(5):802–3. Comment on: Br J Dermatol 1996 Jun;134(6):1057–9.

Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Dorgan JF, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jul;5(7):533–9

Serum androgens and prostate cancer. Nomura AM, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):621–5

Androgens and the menopause; a study of 40–60-year-old women. Bancroft J, et al. **Clin Endocrinol (Oxf)** 1996 Nov; 45(5):577–87

Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women [see comments] Barth JH, et al. **Clin Endocrinol (Oxf)** 1997 Feb;46(2):123–8. Comment in: Clin Endocrinol (Oxf) 1997 Feb;46(2):129–30.

Growth hormone substitution in adult growth hormone-deficient men augments androgen effects on the skin. Blok GJ, et al. **Clin Endocrinol (Oxf)** 1997 Jul; 47(1):29–36

17 beta-hydroxysteroid dehydrogenase deficiency with minimal virilization and spontaneous reduction of serum androgens to normal female levels. Duncan SL, et al. **Clin Endocrinol (Oxf)** 1997 Mar;46(3):369–72

Role of progesterone deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome. Fiad TM, et al. **Eur J Endocrinol** 1996 Sep;135(3):335–9

Cigarette smoking, sex hormones and bone density in women. Law MR, et al. **Eur J Epidemiol** 1997 Jul;13(5):553–8

Prevalence of hyperandrogenemia among nonhirsute oligo-ovulatory women. Allen SE, et al. **Fertil Steril** 1997 Mar;67(3):569–72

Premature plasma progesterone and androgen elevation are not prevented by adrenal suppression in in vitro fertilization. Fanchin R, et al. **Fertil Steril** 1997 Jan; 67(1):115–9

Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome. Koskinen P, et al. **Fertil Steril** 1996 Mar;65(3):517–22

Androgen-behavior correlations in hypogonadal men and eugonadal men. I. Mood and response to auditory sexual stimuli. Alexander GM, et al. **Horm Behav** 1997 Apr; 31(2):110–9

Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome. Buyalos RP, et al. **Hum Reprod** 1997 Jun;12(6):1138–41

Testicular gamma-aminobutyric acid and circulating androgens in Syrian and Djungarian hamsters during sexual development. Frungieri MB, et al. **Int J Androl** 1996 Jun; 19(3):164–70

Evaluation of plasma androgen and estrogen concentrations in ferrets with hyperadrenocorticism. Rosenthal KL, et al. **J Am Vet Med Assoc** 1996 Sep 15;209(6):1097–102

Pulsatile intravenous gonadotropin-releasing hormone administration averts fasting-induced hypogonadotropism and hypoandrogenemia in healthy, normal weight men. Aloi JA, et al. **J Clin Endocrinol Metab** 1997 May; 82(5):1543–8

Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. Andersson B, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):638–43

Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. Grinspoon S, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4051–8

17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss [see comments] Jakubowicz DJ, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):556–60. Comment in: J Clin Endocrinol Metab 1997 Jun;82(6):2014–5.

Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. Labrie F, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2396–402

Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. Labrie F, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2403–9

Prostate-specific antigen in female serum, a potential new marker of androgen excess. Melegos DN, et al. **J Clin Endocrinol Metab** 1997 Mar;82(3):777–80

Effect of interferon alpha on high serum androgen concentrations in HIV positive men with Kaposi's sarcoma. Christeff N, et al. **J Clin Pathol** 1997 Apr;50(4):341–5

Mild insulin resistance during oral glucose tolerance test (OGTT) in women with acne. Aizawa H, et al. **J Dermatol** 1996 Aug;23(8):526–9

Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women. Stomati M, et al. **J Endocrinol Invest** 1996 Sep;19(8):535–41

Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer. Vijayakumar S, et al. **J Natl Med Assoc** 1995 Nov;87(11):813–9

A simple, differential extraction method for the simultaneous direct radioimmunoassay of androgens and androgen glucuronides in human serum. Brind J, et al. **Steroids** 1996 Jul;61(7):429–32

[Current treatment of androgenetic male and female alopecia (with the exception of hormone treatment)] Bouhanna P. **Schweiz Rundsch Med Prax** 1997 Jun 4;86(23):996–9 (12 ref.) (Eng. Abstr.) **(Fre)**

[Possible effect of hormones on immune and inflammatory processes in female patients with chronic polyarthritis] Kullich W, et al. **Acta Med Austriaca** 1996;23(4):119–23 (Eng. Abstr.) **(Ger)**

[Pathogenesis and diagnosis of androgenetic manifestations] Imthurn B. **Schweiz Rundsch Med Prax** 1997 Jun 4; 86(23):993–5 (7 ref.) (Eng. Abstr.) **(Ger)**

[Isolated ovarian metastasis of primary gallbladder carcinoma with estrogen and androgen production] Hamm W, et al. **Zentralbl Gynakol** 1996;118(12):676–8 (Eng. Abstr.) **(Ger)**

[Osteogenic sarcoma and androgens] Trapeznikov NN, et al. **Biull Eksp Biol Med** 1996 Sep;122(9):305–10 **(Rus)**

[Androgen response in women with polycystic ovary syndrome and hyperinsulinemia during stimulation with corticotrophin and inhibition with dexamethasone] Espinosa de los Monteros A, et al. **Rev Invest Clin** 1996 Jul-Aug;48(4):267–73 (Eng. Abstr.) **(Spa)**

DEFICIENCY

hCG stimulation test for diagnosis of androgen deficiency. Tzvetkova P, et al. **Arch Androl** 1997 Sep–Oct;39(2):163–71

Delayed epiphyseal closure attributable to androgen deficiency. Van de Wiele C, et al. **Clin Nucl Med** 1997 Aug;22(8):567–8

The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage. Weinstein RS, et al. **Endocrinology** 1997 Sep;138(9):4013–21

Is there a role for induction androgen deprivation prior to radical prostatectomy? Watson R, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):627–41 (62 ref.)

GENETICS

A twin study of polycystic ovary syndrome and lipids. Jahanfar S, et al. **Gynecol Endocrinol** 1997 Apr;11(2):111–7

Interaction of androgen receptors with androgen response element in intact cells. Roles of amino- and carboxyl-terminal regions and the ligand. Karvonen U, et al. **J Biol Chem** 1997 Jun 20;272(25):15973–9

HISTORY

Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Franke WW, et al. **Clin Chem** 1997 Jul;43(7):1262–79

METABOLISM

Androgen producing luteinized granulosa cell tumor. Martinez L, et al. **Acta Obstet Gynecol Scand** 1997 Mar; 76(3):285–6

An investigation of hyperandrogenism and obesity presenting during late childhood. Wallace AM, et al. **Ann Clin Biochem** 1997 Sep;34 (Pt 5):564–8

Relationship of carnitine transport across the epididymis to blood carnitine and androgens in rats. Radigue C, et al. **Arch Androl** 1996 Jul-Aug;37(1):27–31

Increased scalp skin and serum 5 alpha-reductase reduced androgens in a man relevant to the acquired progressive kinky hair disorder and developing androgenetic alopecia. Boudou P, et al. **Arch Dermatol** 1997 Sep;133(9):1129–33 (44 ref.)

Regulation of growth and prostatic marker expression by activin A in an androgen-sensitive prostate cancer cell line LNCAP. Zhang Z, et al. **Biochem Biophys Res Commun** 1997 May 19;234(2):362–5

Changes in the forward and reverse metabolism of aromatizable androgens during the development of large ovarian cysts in the pregnant rat. Bogovich K. **Biol Reprod** 1997 Jul;57(1):148–57

The age-related decline of androgen levels in men: clinically significant? Gooren LI. **Br J Urol** 1996 Nov;78(5):763–8 (49 ref.)

Molecular and cellular biology of the prostate: is it clinically relevant? Habib FK, et al. **Br J Urol** 1996 Oct;78(4):546–51 (55 ref.)

Secondary alcohol dehydrogenase as a marker of the conversion between progestagens and androgens in the rat testis. de Oliveira JA, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 May;43(3):305–11

Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Habib FK, et al. **Clin Endocrinol (Oxf)** 1997 Feb;46(2):137–44

Polycystic ovary syndrome, hyperthecosis and the menopause [comment] Rittmaster RS. **Clin Endocrinol (Oxf)** 1997 Feb;46(2):129–30. Comment on: Clin Endocrinol (Oxf) 1997 Feb;46(2):123–8.

Clinical and biochemical investigations and molecular analysis of subjects with mutations in the androgen receptor gene. Weidemann W, et al. **Clin Endocrinol (Oxf)** 1996 Dec; 45(6):733–9

Androgen metabolism as it affects hair growth in androgenetic alopecia. Kaufman KD. **Dermatol Clin** 1996 Oct;14(4):697–711 (67 ref.)

Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract. George FW. **Endocrinology** 1997 Mar; 138(3):871–7

Androgens and prostate cancer: biology, pathology and hormonal therapy. Galbraith SM, et al. **Eur J Cancer** 1997 Apr;33(4):545–54 (78 ref.)

The presence of a transcription activation function in the hormone-binding domain of androgen receptor is revealed by studies in yeast cells. Moilanen A, et al. **FEBS Lett** 1997 Jul 28;412(2):355–8

Insulin-like growth factors and insulin-like growth factor binding proteins in androgen-dominant ovarian follicles from testosterone-treated female-to-male trans-sexuals. Yap OW, et al. **Fertil Steril** 1997 Aug;68(2):252–8

Metabolism of estrogens and androgens by embryonic tissues of Arctic charr, Salvelinus alpinus. Khan MN, et al. **Gen Comp Endocrinol** 1997 Jul;107(1):118–27

Androgen metabolism in the brain of the green anole lizard (Anolis carolinensis). Wade J. **Gen Comp Endocrinol** 1997 Apr;106(1):127–37

Effects of physiological and supraphysiological doses of insulin on adrenal androgen levels. Polderman KH, et al. **Horm Metab Res** 1996 Mar;28(3):152–5

Antiandrogenic effect of RU-486 in the mouse kidney. Tovar A, et al. **Int J Biochem Cell Biol** 1997 Feb;29(2):361–6

Characterization of apoptosis in prostatic androgen-independent cell lines. Salido M, et al. **Int J Dev Biol** 1996;Suppl 1:191S–192S

Successful diagnosis and surgical laparoscopic treatment of a woman with complete androgen insensitivity syndrome [letter] Batzer FR. **J Am Assoc Gynecol Laparosc** 1996 Nov; 4(1):112

Laparoscopic removal of gonads containing on occult seminoma in a woman with complete androgen resistance. Chantilis SJ, et al. **J Am Assoc Gynecol Laparosc** 1994 May; 1(3):277–82 (35 ref.)

Prostate-specific and androgen-dependent expression of a novel homeobox gene. Bieberich CJ, et al. **J Biol Chem** 1996 Dec 13;271(50):31779–82

Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. Sato N, et al. **J Biol Chem** 1997 Jul 11;272(28):17485–94

Sexual differences in 5'-deiodinase activity in the Harderian gland of Syrian hamsters and the effect of pinealectomy: regulation by androgens. Rubio A, et al. **J Cell Biochem** 1996 Sep 1;62(3):397–404

A novel missense mutation in the amino-terminal domain of the human androgen receptor gene in a family with partial androgen insensitivity syndrome causes reduced efficiency of protein translation. Choong CS, et al. **J Clin Invest** 1996 Sep 15;98(6):1423–31

Down syndrome in association with features of the androgen insensitivity syndrome. Viner RM, et al. **J Med Genet** 1996 Jul;33(7):574–7

Post-transcriptional regulation of gene expression by androgens: recent observations from the epidermal growth factor gene. Pascall JC. **J Mol Endocrinol** 1997 Jun; 18(3):177–80 (25 ref.)

The synthesis of 5-alpha-dihydrotestosterone from androgens by human gingival tissues and fibroblasts in culture in response to TGF-beta and PDGF. Kasasa SC, et al. **J Periodontal Res** 1996 Jul;31(5):313–22

Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma. Akakura K, et al. **J Steroid Biochem Mol Biol** 1996 Dec;59(5–6):501–11

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. Sato N, et al. **J Steroid Biochem Mol Biol** 1996 May;58(2):139–46

Androgen deprivation causes up-regulation of androgen receptor transcript in the rat prostate. Kumar VL, et al. **Mol Cell Biochem** 1997 Jun;171(1–2):133–8

Androgen insensitivity syndrome due to new mutations in the DNA-binding domain of the androgen receptor. Imasaki K, et al. **Mol Cell Endocrinol** 1996 Jun 18; 120(1):15–24

Characterization of an androgen response element within the promoter of the epididymis-specific murine glutathione peroxidase 5 gene. Lareyre JJ, et al. **Mol Cell Endocrinol** 1997 Apr 25;129(1):33–46

Contextual dependence of steroid receptor function on an androgen-responsive enhancer. Scheller A, et al.

Mol Cell Endocrinol 1996 Jul 23;121(1):75–86

An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Cleutjens KB, et al. **Mol Endocrinol** 1997 Feb;11(2):148–61

Two androgen response elements in the androgen receptor coding region are required for cell-specific up-regulation of receptor messenger RNA. Dai JL, et al. **Mol Endocrinol** 1996 Dec;10(12):1582–94

Identification of a functional androgen-response element in the exon 1-coding sequence of the cystatin-related protein gene crp2. Devos A, et al. **Mol Endocrinol** 1997 Jul; 11(8):1033–43

Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Klein KA, et al. **Nat Med** 1997 Apr;3(4):402–8

Biochemical selection of prepubertal patients with androgen insensitivity syndrome by sex hormone-binding globulin response to the human chorionic gonadotropin test. Bertelloni S, et al. **Pediatr Res** 1997 Feb;41(2):266–71

The heat shock-induced hyperphosphorylation of tau is estrogen-independent and prevented by androgens: implications for Alzheimer disease. Papasozomenos SC. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6612–7

Are ovine Leydig cells able to aromatize androgens? Bilińska B, et al. **Reprod Fertil Dev** 1997;9(2):193–9

Steroid-growth factor interaction in human prostate cancer. 2. Effects of transforming growth factors on androgen metabolism of prostate cancer cells. Carruba G, et al. **Steroids** 1996 Jan;61(1):41–6

[The mechanism of the effect of insulin on the interhormonal relations of androgens and glucocorticoids in the body] Pavlovs'kyĭ MP, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):100–4 (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

Germ-line and somatic mosaicism in the androgen insensitivity syndrome: implications for genetic counseling [letter] Boehmer AL, et al. **Am J Hum Genet** 1997 Apr; 60(4):1003–6

Effects of serotonergic1A and 1B agonists in androgenic versus estrogenic systems for aggression. Cologer-Clifford A, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:339–42

Apoptosis of androgen-independent mammary and prostate cell lines induced by topoisomerase inhibitors: common pathway of gene regulation. Furuya Y, et al. **Anticancer Res** 1997 May–Jun;17(3C):2089–93

Inhibitors of collagen synthesis and hypophysectomy: effects on androgen induced growth of ventral prostate in rats. Izumiya K, et al. **Arch Androl** 1997 May–Jun;38(3):231–41

Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1alpha,25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells. Hsieh T, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):539–44

The effects of insulin, transferrin and androgens on rat prostate explants in serum-free organ culture. Nguyen-Le XK, et al. **Biofactors** 1997;6(3):339–49

An androgen-regulated homeobox gene expressed in rat testis and epididymis. Lindsey JS, et al. **Biol Reprod** 1996 Nov; 55(5):975–83

Maintenance of decidual cell reaction by androgens in the mouse. Zhang X, et al. **Biol Reprod** 1996 Sep;55(3):519–24

Absence of androgen-mediated transcriptional effects in osteoblastic cells despite presence of androgen receptors. Czerwiec FS, et al. **Bone** 1997 Jul;21(1):49–56

Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Zarghami N, et al. **Br J Cancer** 1997;75(4):579–88

Androgens stimulate the morphological maturation of embryonic hypothalamic aromatase-immunoreactive neurons in the mouse. Beyer C, et al. **Brain Res Dev Brain Res** 1997 Jan 2;98(1):74–81

Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase. Burak WE Jr, et al. **Breast Cancer Res Treat** 1997 May;44(1):57–64

Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Culig Z, et al. **Cancer Detect Prev** 1996;20(1):68–75

Alteration in gamma-glutamyl transpeptidase activity and messenger RNA of human prostate carcinoma cells by androgen. Ripple MO, et al. **Cancer Res** 1997 Jun 15; 57(12):2428–33

Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Swinnen JV, et al. **Cancer Res** 1997 Mar 15;57(6):1086–90

Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Bello D, et al. **Carcinogenesis** 1997 Jun;18(6):1215–23

Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. Dalkin AC, et al. **Endocrinology** 1996 Dec;137(12):5230–5

Androgens modulate nitric oxide synthase messenger ribonucleic acid expression in neurons of the major pelvic ganglion in the rat. Schirar A, et al. **Endocrinology** 1997 Aug;138(8):3093–102

Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Swinnen JV, et al. **Endocrinology** 1996 Oct; 137(10):4468–74

Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Szelei J, et al. **Endocrinology** 1997 Apr;138(4):1406–12

Interaction of mouse placental lactogens and androgens in regulating progesterone release in cultured mouse luteal cells. Thordarson G, et al. **Endocrinology** 1997 Aug; 138(8):3236–41

Androgens transcriptionally regulate the expression of cystatin-related protein and the C3 component of prostatic binding protein in rat ventral prostate and lacrimal gland. Vercaeren I, et al. **Endocrinology** 1996 Nov;137(11):4713–20

Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Wang QF, et al. **Endocrinology** 1996 Dec; 137(12):5476–83

1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Zhao XY, et al. **Endocrinology** 1997 Aug;138(8):3290–8

Interactions of androgens and estradiol on sex accessory ducts of larval tiger salamanders, Ambystoma tigrinum. Norris DO, et al. **Gen Comp Endocrinol** 1997 Jun; 106(3):348–55

Long-term effects of androgen treatment on fear reactions in ewes. Bouissou MF, et al. **Horm Behav** 1996 Mar; 30(1):93–9

Anabolic-androgenic steroid effects on the sexual behavior of intact male rats. Clark AS, et al. **Horm Behav** 1997 Feb; 31(1):35–46

Androgen spares androgen-insensitive motoneurons from apoptosis in the spinal nucleus of the bulbocavernosus in rats. Freeman LM, et al. **Horm Behav** 1996 Dec; 30(4):424–33

Effects of androgens on male sexual behavior and secondary sex characters in the explosively breeding spadefoot toad, Scaphiopus couchii. Harvey LA, et al. **Horm Behav** 1997 Feb;31(1):89–96

Androgenic effects on hypothalamic asymmetry in a sexually differentiated nucleus related to vocal behavior in Mongolian gerbils. Holman SD, et al. **Horm Behav** 1996 Dec;30(4):662–72

Androgen regulation of hypothalamic neurons containing gonadotropin-releasing hormone in a cichlid fish: integration with social cues. Soma KK, et al. **Horm Behav** 1996 Sep;30(3):216–26

Androgen induction of male sexual behaviors in female goldfish. Stacey N, et al. **Horm Behav** 1996 Dec; 30(4):434–45

Androgen exposure and reproductive behavior of an induced ovulator, the pine vole (Microtus pinetorum). Wekesa KS, et al. **Horm Behav** 1996 Dec;30(4):416–23

Functional analysis of six androgen receptor mutations identified in patients with partial androgen insensitivity syndrome. Bevan CL, et al. **Hum Mol Genet** 1996 Feb; 5(2):265–73

Direct non-genomic effects of follicular steroids on maturing human oocytes: oestrogen versus androgen antagonism. Tesarik J, et al. **Hum Reprod Update** 1997 Mar–Apr; 3(2):95–100 (20 ref.)

LNCaP-OM, a new androgen-resistant prostate cancer subline [letter] Platica M, et al. **In Vitro Cell Dev Biol Anim** 1997 Mar;33(3):147–9

Induction of apoptosis in androgen-independent mouse mammary cell line by 1, 25-dihydroxyvitamin D3. Furuya Y, et al. **Int J Cancer** 1996 Sep 27;68(1):143–8

Modulation of immune responses by anabolic androgenic steroids. Hughes TK, et al. **Int J Immunopharmacol** 1995 Nov;17(11):857–63

Effects of methylcobalamin on the proliferation of androgen-sensitive or estrogen-sensitive malignant cells in culture and in vivo. Nishizawa Y, et al. **Int J Vitam Nutr Res** 1997;67(3):164–70

Effect of androgen substrates on the steroidogenic pattern of cumulus cells: correlation with cumulus culture morphology. Bar-Ami S, et al. **J Assist Reprod Genet** 1997 May;14(5):270–6

Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. Schneikert J, et al. **J Biol Chem** 1996 Sep 27; 271(39):23907–13

Gender-related differences in androgen regulation of thromboxane A2 receptors in rat aortic smooth-muscle cells. Higashiura K, et al. **J Cardiovasc Pharmacol** 1997 Mar;29(3):311–5

Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women--a clinical research center study. Lovejoy JC, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2198–203

Androgen insensitivity with mental retardation: a contiguous gene syndrome? Davies HR, et al. **J Med Genet** 1997 Feb; 34(2):158–60

Androgen control of vocal control region volumes in a wild migratory songbird (Junco hyemalis) is region and possibly age dependent. Gulledge CC, et al. **J Neurobiol** 1997 Apr; 32(4):391–402

Sexual differentiation of the surge mode of gonadotropin secretion: prenatal androgens abolish the gonadotropin-releasing hormone surge in the sheep. Herbosa CG, et al. **J Neuroendocrinol** 1996 Aug;8(8):627–33

Androgens modulate glucocorticoid receptor mRNA, but not mineralocorticoid receptor mRNA levels, in the rat hippocampus. Kerr JE, et al. **J Neuroendocrinol** 1996 Jun; 8(6):439–47

Prenatal androgens defeminize activation of GnRH neurons in response to estradiol stimulation. Wood RI, et al. **J Neuroendocrinol** 1996 Aug;8(8):617–25

Complete androgen insensitivity syndrome. Molecular characterization in two Chinese women. Ko TM, et al. **J Reprod Med** 1997 Jul;42(7):424–8

Androgen stimulation of lacrimal gland function in mouse models of Sjögren's syndrome. Sullivan DA, et al. **J Steroid Biochem Mol Biol** 1997 Feb;60(3–4):237–45

Influence of gender and brain region on neurosteroid modulation of GABA responses in rats. Wilson MA, et al. **Life Sci** 1997;60(19):1679–91

Effects of androgens on haemostasis. Winkler UH. **Maturitas** 1996 Jul;24(3):147–55 (61 ref.)

Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Heisler LE, et al. **Mol Cell Endocrinol** 1997 Jan 3;126(1):59–73

Androgens stimulate gonadotropin-II beta-subunit in eel pituitary cells in vitro. Huang YS, et al. **Mol Cell Endocrinol** 1997 Aug 8;131(2):157–66

Androgenic induction of cystatin-related protein and the C3 component of prostatic binding protein in primary cultures from the rat lacrimal gland. Vanaken H, et al. **Mol Cell Endocrinol** 1996 Aug 9;121(2):197–205

Human androgenic steroids affect growth of dermatophytes in vitro. Brasch J, et al. **Mycoses** 1996 Sep–Oct; 39(9–10):387–92

Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response. Soto AM, et al. **Oncol Res** 1995; 7(10–11):545–58

Anabolic-androgenic steroids and brain reward. Clark AS, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):741–5

Effects of progesterone, estrogen, and androgen on progesterone receptor binding in hen oviduct uterus (shell gland). Kawashima M, et al. **Poult Sci** 1996 Feb; 75(2):257–60

Regulation of S100P expression by androgen. Averboukh L, et al. **Prostate** 1996 Dec;29(6):350–5

Comparison of androgen-independent growth and androgen-dependent growth in BPH and cancer tissue from the same radical prostatectomies in sponge-gel matrix histoculture. Geller J, et al. **Prostate** 1997 Jun 1;31(4):250–4

Androgen independence of primary epithelial cultures of the prostate is associated with a down-regulation of androgen receptor gene expression. Grant ES, et al. **Prostate** 1996 Dec;29(6):339–49

Extended culturing of androgen-responsive human primary epithelial prostate cell isolates by continuous treatment with interstitial collagenase. Mitchen J, et al. **Prostate** 1997 Jan 1;30(1):7–19

Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research. Pousette A, et al. **Prostate** 1997 May 15; 31(3):198–203

Bone extracellular matrix induces homeobox proteins independent of androgens: possible mechanism for androgen-independent growth in human prostate cancer cells. Robbins SE, et al. **Prostate** 1996 Dec;29(6):362–70

Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells. Dai JL, et al. **Steroids** 1996 Sep;61(9):531–9

Androgen modulates N-methyl-D-aspartate-mediated depolarization in CA1 hippocampal pyramidal cells. Pouliot WA, et al. **Synapse** 1996 May;23(1):10–9

PHYSIOLOGY

Influence of androgens and pituitary hormones on the structural profile and secretory activity of the lacrimal gland. Sullivan DA, et al. **Acta Ophthalmol Scand** 1996 Oct;74(5):421–35

Androgens and alcohol [letter] Wiseman EJ. **Am J Psychiatry** 1997 Jul;154(7):1040–1

Perturbations of hypothalamic-pituitary-gonadal (HPG) axis and adrenal androgen (AA) functions in rheumatoid arthritis. Masi AT, et al. **Baillieres Clin Rheumatol** 1996 May;10(2):295–332 (142 ref.)

Isolation and characterization of the androgen-dependent mouse cysteine-rich secretory protein-1 (CRISP-1) gene. Schwidetzky U, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):325–32

Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. Penson DF, et al. **Biol Reprod** 1996 Sep;55(3):567–74

Neither testicular androgens nor embryonic aromatase activity alters morphology of the neural song system in zebra finches. Wade J, et al. **Biol Reprod** 1996 Nov; 55(5):1126–32

Cellular interactions in prostate cancer. Lee C. **Br J Urol** 1997 Mar;79 Suppl 1:21–7 (47 ref.)

Neonatal androgen manipulation differentially affects the development of monoamine systems in rat cerebral cortex, amygdala and hypothalamus. Siddiqui A, et al. **Brain Res Dev Brain Res** 1997 Feb 20;98(2):247–52

Casodex (a nonsteroidal antiandrogen) reduces cancellous, endosteal, and periosteal bone formation in estrogen-replete female rats. Lea C, et al. **Calcif Tissue Int** 1996 Apr;58(4):268–72

Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Chang GT, et al.

Cancer Res 1997 Sep 15;57(18):4075–81

Basement membrane associated changes in the rat ventral prostate following castration. de Carvalho HF, et al. **Cell Biol Int** 1996 Dec;20(12):809–19

Androgenic regulation of protein kinase CK1 in the prostatic cell. Ahmed K, et al. **Cell Mol Biol Res** 1995;41(5):421–4

Androgen–resistance syndromes: considerations of gender assignment. Gooren LJ. **Curr Ther Endocrinol Metab** 1997; 6:380–4 (6 ref.)

Androgen function after age 50 and treatment of hypogonadism. Korenman SG. **Curr Ther Endocrinol Metab** 1997;6:621–4 (10 ref.)

The 5 alpha–reductase system and its inhibitors. Recent development and its perspective in treating androgen–dependent skin disorders. Chen W, et al. **Dermatology** 1996;193(3):177–84 (58 ref.)

Androgen induces ornithine decarboxylase gene expression in colonic cell line HT–29. Cintron JR, et al. **Dis Colon Rectum** 1996 Apr;39(4):406–9

Involvement of an octamer–like sequence within a crucial region of the androgen–dependent Slp enhancer. Scarlett CO, et al. **DNA Cell Biol** 1997 Jan;16(1):45–57

Gonadal steroids and immunity. Olsen NJ, et al. **Endocr Rev** 1996 Aug;17(4):369–84 (163 ref.)

Androgen support of lacrimal gland function. Azzarolo AM, et al. **Endocrine** 1997 Feb;6(1):39–45

Immunohistochemical analysis of androgen effects on androgen receptor expression in developing Leydig and Sertoli cells. Shan LX, et al. **Endocrinology** 1997 Mar; 138(3):1259–66

Androgen receptor gene expression in rat granulosa cells: the role of follicle–stimulating hormone and steroid hormones. Tetsuka M, et al. **Endocrinology** 1996 Oct; 137(10):4392–7

Hormones and health. Eubanks MW. **Environ Health Perspect** 1997 May;105(5):482–6 (0 ref.)

Steroid hormones and cancer: IV. Prostate cancer. Habib FK. **Eur J Surg Oncol** 1997 Jun;23(3):264–8 (36 ref.)

Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Griffiths K, et al. **Eur Urol** 1997;32 Suppl 3:24–40 (82 ref.)

The role of androgens in opportunistic breeding, tropical frogs. Emerson SB, et al. **Gen Comp Endocrinol** 1996 Aug; 103(2):220–30

Is "off–protocol" chemotherapy for androgen–independent carcinoma of prostate warranted? Mani S, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):749–68 (106 ref.)

How is androgen–dependent metastatic prostate cancer best treated? Robson M, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):727–47 (149 ref.)

Effects of androgens and estrogens on sexual differentiation of sex behavior, scent marking, and the sexually dimorphic area of the gerbil hypothalamus. Ulibarri C, et al. **Horm Behav** 1996 Jun;30(2):107–30

Androgens and their role in skeletal homeostasis. Vanderschueren D. **Horm Res** 1996;46(2):95–8 (20 ref.)

Decline in renal hemodynamic function in aging SHR: role of androgens. Reckelhoff JF, et al. **Hypertension** 1997 Sep; 30(3 Pt 2):677–81

Hormonal profile of acne vulgaris: new aspects of the androgen–dependent cutaneous syndrome: syndrome X. Vignale R, et al. **Int J Dermatol** 1996 Feb;35(2):94–5

Sites of androgenic regulation of cavernosal blood pressure during penile erection in the rat. Mills TM, et al. **Int J Impot Res** 1996 Mar;8(1):29–34

The hormonal control of testicular descent. Levy JB, et al. **J Androl** 1995 Nov–Dec;16(6):459–63 (16 ref.)

Testosterone and spermatogenesis: evidence that androgens regulate cellular secretory mechanisms in stage VI–VIII seminiferous tubules from adult rats. McKinnell C, et al. **J Androl** 1995 Nov–Dec;16(6):499–509

Androgens and penile erection: a review. Mills TM, et al. **J Androl** 1996 Nov–Dec;17(6):633–8 (45 ref.)

Androgen ablation leads to an upregulation and intranuclear accumulation of deoxyribonuclease I in rat prostate epithelial cells paralleling their apoptotic elimination. Rauch F, et al. **J Cell Biol** 1997 May 19;137(4):909–23

Clinical review 82: Androgens and the postmenopausal woman. Davis SR, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2759–63 (59 ref.)

Different phenotypes in a family with androgen insensitivity caused by the same M780I point mutation in the androgen receptor gene. Rodien P, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2994–8

The promoter of an androgen dependent gene in the hamster flank organ. Aoki H, et al. **J Dermatol Sci** 1997 May; 15(1):36–43

Human genital melanocytes as androgen target cells. Tadokoro T, et al. **J Invest Dermatol** 1997 Oct;109(4):513–7

Androgen–induced redox changes in prostate cancer cells: what are causes and effects? [editorial; comment] Liehr JG. **J Natl Cancer Inst** 1997 Jan 1;89(1):3–4. Comment on: J Natl Cancer Inst 1997 Jan 1;89(1):40–8.

Prooxidant–antioxidant shift induced by androgen treatment of human prostate carcinoma cells [see comments] Ripple MO, et al. **J Natl Cancer Inst** 1997 Jan 1;89(1):40–8. Comment in: J Natl Cancer Inst 1997 Jan 1;89(1):3–4.

Short– and long–term effects of ciliary neurotrophic factor on androgen–sensitive motoneurons in the lumbar spinal cord. Bengston L, et al. **J Neurobiol** 1996 Oct;31(2):263–73

Expression of androgen–activating enzymes in cultured cells of developing rat brain. Poletti A, et al. **J Neurochem** 1997 Mar;68(3):1298–303

Androgenic regulation of androgen receptor immunoreactivity in motoneurons of the spinal nucleus of the bulbocavernosus of male rats. Matsumoto A, et al. **J Neuroendocrinol** 1996 Jul;8(7):553–9

Regulation of mouse epididymal epithelium in vitro by androgens, temperature and fibroblasts. Carballada R, et al. **J Reprod Fertil** 1997 May;110(1):171–81

The androgen–dependent mouse seminal vesicle secretory protein of 99 amino acids (MSVSP99): regulation of the mRNA and preliminary characterization of the promoter. Simon AM, et al. **J Steroid Biochem Mol Biol** 1997 Apr; 61(1–2):87–95

Androgen regulation of growth hormone binding protein. Keenan BS, et al. **Metabolism** 1996 Dec;45(12):1521–6

Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays. Markiewicz L, et al. **Methods Find Exp Clin Pharmacol** 1997 May;19(4):215–22

Hormones and the control of porphyrin biosynthesis and structure in the hamster harderian gland. Payne AP, et al. **Microsc Res Tech** 1996 Jun 1;34(2):123–32 (84 ref.)

Androgen regulation of the messenger RNA encoding diazepam–binding inhibitor/acyl–CoA–binding protein in the rat. Swinnen JV, et al. **Mol Cell Endocrinol** 1996 Apr 19;118(1–2):65–70

Keratinocyte growth factor expression in hormone insensitive prostate cancer. Leung HY, et al. **Oncogene** 1997 Aug 28; 15(9):1115–20

Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen–mediated proliferative response. Soto AM, et al. **Oncol Res** 1995; 7(10–11):545–58

Bone extracellular matrix induces homeobox proteins independent of androgens: possible mechanism for androgen–independent growth in human prostate cancer cells. Robbins SE, et al. **Prostate** 1996 Dec;29(6):362–70

Adrenal androgens, insulin resistance, and cardiovascular disease. Casson PR, et al. **Semin Reprod Endocrinol** 1996 Feb;14(1):29–34 (54 ref.)

A clinician looks at androgen resistance. Balducci R, et al. **Steroids** 1996 Apr;61(4):205–11 (66 ref.)

[Mutations of the androgen receptor gene a possible role in prostate cancer] Mowszowicz I, et al. **Bull Cancer** 1997 Feb;84(2):183–8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Hormones and male sexuality] Saltiel H. **Rev Med Interne** 1997;18 Suppl 1:14s–16s (Eng. Abstr.) **(Fre)**

[Benign prostatic hyperplasia—the outcome of age–induced alteration of androgen–estrogen balance?] Weisser H, et al. **Urologe A** 1997 Jan;36(1):3–9 (28 ref.) (Eng. Abstr.) **(Ger)**

[Mechanism on androgen–independent progression of prostate cancer] Shimazaki J, et al. **Nippon Rinsho** 1997 May;55(5):1143–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

SECRETION

Adrenal androgen–secreting carcinoma in a fertile woman. Falsetti L, et al. **Acta Eur Fertil** 1995 May–Jun;26(3):117–21

Hypersecretion of androgens by polycystic ovaries: the role of genetic factors in the regulation of cytochrome P450c17 alpha. Franks S, et al. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):193–203 (33 ref.)

Changes in androgen secretion and luteinizing hormone pulse amplitude are associated with the recruitment and growth of ovarian follicles during the luteal phase of the bovine estrous cycle. Evans AC, et al. **Biol Reprod** 1997 Aug; 57(2):394–401

Lack of an ovarian function influence on the increased adrenal androgen secretion present in women with functional ovarian hyperandrogenism. Escobar–Morreale HF, et al. **Fertil Steril** 1997 Apr;67(4):654–62

Androgen biosynthesis and secretion in developing Xenopus laevis. Kang L, et al. **Gen Comp Endocrinol** 1995 Dec; 100(3):293–307

The steroidogenic effects of beta–endorphin and joining peptide: a potential role in the modulation of adrenal androgen production. Clarke D, et al. **J Endocrinol** 1996 Nov;151(2):301–7

An unusual case of bilateral virilizing adrenal adenoma co–secreting androgens and cortisol. Delgrange E, et al. **J Endocrinol Invest** 1996 Jun;19(6):377–81

Steroid cell tumor of the ovary as a rare cause of virilization. Azizlerli H, et al. **Mt Sinai J Med** 1997 Mar;64(2):130–5

[An adrenal carcinoma producing androgens, estrogens and cortisol] De Pablos Velasco PL, et al. **An Med Interna** 1997 Apr;14(4):190–2 (12 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Androgen function after age 50 and treatment of hypogonadism. Korenman SG. **Curr Ther Endocrinol Metab** 1997;6:621–4 (10 ref.)

Androgen replacement therapy. Wang C, et al. **Curr Ther Endocrinol Metab** 1997;6:331–7 (5 ref.)

The role of androgens in menopausal hormonal replacement. Kaunitz AM. **Endocrinol Metab Clin North Am** 1997 Jun; 26(2):391–7 (19 ref.)

Oral treatments for erectile dysfunction. Riley A. **Int J STD AIDS** 1996;7 Suppl 3:16–8 (12 ref.)

Characteristics of androgen–independent growth of androgen–responsive Shionogi carcinoma 115 cells. Tomioka S, et al. **Int J Urol** 1996 Jul;3(4):286–91

Side effects of long–term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. Cicardi M, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):194–6

Testosterone and the aging male. Tenover JL. **J Androl** 1997 Mar–Apr;18(2):103–6 (14 ref.)

Clinical review 85: Emerging issues in androgen replacement therapy. Bhasin S, et al. **J Clin Endocrinol Metab** 1997 Jan; 82(1):3–8 (28 ref.)

Another use of androgens: treatment of anemia of end–stage renal disease [letter] Navarro JF. **J Clin Endocrinol Metab** 1997 Sep;82(9):3176

Estrogen–androgen for hormone replacement. A review. Rosenberg MJ, et al. **J Reprod Med** 1997 Jul;42(7):394–404 (95 ref.)

Androgens in the elderly: will androgen replacement therapy improve mood, cognition, and quality of life in aging men and women. Morrison MF. **Psychopharmacol Bull** 1997; 33(2):293–6

Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era. Teruel JL, et al. **Scand J Urol Nephrol** 1996 Oct;30(5):403–8

Androgen replacement in postmenopausal women. Chin HG. **West J Med** 1996 Dec;165(6):373–4

[Treatment of aplastic anemia with cyclosporine, prednisolone and androgens (primary results apropos of 10 cases] Frikha M, et al. **Therapie** 1996 Nov–Dec; 51(6):627–9 (Eng. Abstr.) **(Fre)**

TOXICITY

Androgen–repressed phenotype in human prostate cancer. Zhau HY, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24; 93(26):15152–7

URINE

Combined profile of androgen glucuro– and sulfoconjugates in post–competition urine of sportsmen: a simple screening procedure using gas chromatography–mass spectrometry. Dehennin L, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6;687(1):85–91

ANDROGENS, SYNTHETIC

ADMINISTRATION & DOSAGE

Esterified estrogens with and without methyltestosterone decrease arterial LDL metabolism in cynomolgus monkeys. Wagner JD, et al. **Arterioscler Thromb Vasc Biol** 1996 Dec; 16(12):1473–80

METABOLISM

Wide variation in androgen receptor dysfunction in complete androgen insensitivity syndrome. Bevan CL, et al. **J Steroid Biochem Mol Biol** 1997 Apr;61(1–2):19–26

PHARMACOLOGY

Defining a functional androgen responsive element in the 5' far upstream flanking region of the prostate–specific antigen gene. Zhang S, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):784–8

Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display. Betts AM, et al. **FEBS Lett** 1997 Apr 1;405(3):328–32

Comparison of the response of rat testis and accessory sex organs to treatment with testosterone and the synthetic androgen methyltrienolone (R1881). van Roijen JH, et al. **J Androl** 1997 Jan–Feb;18(1):51–61

Aromatase inhibition in JAr choriocarcinoma cells by 7alpha–arylaliphatic androgens. Brueggemeier RW, et al. **J Steroid Biochem Mol Biol** 1997 Apr;61(1–2):73–7

Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study. Uyanik BS, et al. **Jpn Heart J** 1997 Jan; 38(1):73–82

Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays. Markiewicz L, et al. **Methods Find Exp Clin Pharmacol** 1997 May;19(4):215–22

Androgen and glucocorticoid regulation of androgen receptor cDNA expression. Burnstein KL, et al. **Mol Cell Endocrinol** 1995 Dec 29;115(2):177–86

Anabolic androgenic steroids increase beta–endorphin levels in the ventral tegmental area in the male rat brain. Johansson P, et al. **Neurosci Res** 1997 Feb;27(2):185–9

The effects of 17 alpha–methyltestosterone, methandrostenolone, and nandrolone decanoate on the rat estrous cycle. Blasberg ME, et al. **Physiol Behav** 1997 Feb; 61(2):265–72

[The effect of steroid hormone preparations on the persistence and growth characteristics of staphylococci] Ivanov IuB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jul–Aug;(4):92–5 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Effects of various modes of androgen substitution therapy on erythropoiesis. Jockenhövel F, et al. **Eur J Med Res** 1997 Jul 28;2(7):293–8

ANDROGENS, SYNTHETIC

The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia. Adamopoulos DA, et al. **Fertil Steril** 1997 Apr;67(4):756–62

Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. Morales A, et al. **J Urol** 1997 Mar;157(3):849–54

[The role of testosterone undecanoate in correcting disorders of the copulative function] Tiktinskiĭ OL, et al. **Urol Nefrol (Mosk)** 1996 Sep–Oct;(5):47–8 (Eng. Abstr.) **(Rus)**

TOXICITY

Dietary testosterone suppresses protective responsiveness to Plasmodium chabaudi malaria. Mossmann H, et al. **Life Sci** 1997;60(11):839–48

ANDROLOGY see **UROLOGY**

ANDROSTADIENES

ADMINISTRATION & DOSAGE

Fluticasone propionate in children with moderate asthma. Hoekstra MO, et al. **Am J Respir Crit Care Med** 1996 Oct; 154(4 Pt 1):1039–44

Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Olivieri D, et al. **Am J Respir Crit Care Med** 1997 Jun; 155(6):1864–71

Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Weersink EJ, et al. **Am J Respir Crit Care Med** 1997 Apr; 155(4):1241–6

Response to intranasal fluticasone propionate in perennial allergic rhinitis not associated with glucocorticoid receptor characteristics. Garrelds IM, et al. **Ann Allergy Asthma Immunol** 1997 Mar;78(3):319–24

Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Holmberg K, et al. **Ann Allergy Asthma Immunol** 1997 Mar;78(3):270–6

Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194–079 Study Group. Mandl M, et al. **Ann Allergy Asthma Immunol** 1997 Sep; 79(3):237–45

Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Pearlman DS, et al. **Ann Allergy Asthma Immunol** 1997 Apr;78(4):356–62

Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Balfour-Lynn IM, et al. **Arch Dis Child** 1997 Aug;77(2):124–30

Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus inhaler compared with the Turbohaler inhaler in paediatric patients. UK Study Group. Williams J, et al. **Br J Clin Pract** 1997 Apr–May; 51(3):147–53

First-line treatment of hay fever: what is the best option? [editorial; comment] Freedman SO. **Can Med Assoc J** 1997 Apr 15;156(8):1141–3. Comment on: Can Med Assoc J 1997 Apr 15;156(8):1123–31.

First-line treatment of seasonal (ragweed) rhinoconjunctivitis. A randomized management trial comparing a nasal steroid spray and a nonsedating antihistamine [see comments] Juniper EF, et al. **Can Med Assoc J** 1997 Apr 15;156(8):1123–31. Comment in: Can Med Assoc J 1997 Apr 15;156(8):1141–3.

The effect of fluticasone propionate aqueous nasal spray on eosinophils and cytokines in nasal secretions of patients with ragweed allergic rhinitis. Alvarado-Valdés CA, et al. **Clin Ther** 1997 Mar–Apr;19(2):273–81

The efficacy of fluticasone propionate aqueous nasal spray for allergic rhinitis and its relationship to topical effects. Howland WC 3rd, et al. **Clin Ther** 1996 Nov–Dec; 18(6):1106–17

The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Bajetta E, et al. **Eur J Cancer** 1997 Apr;33(4):587–91

A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Grahnén A, et al. **Eur J Clin Pharmacol** 1997;52(4):261–7

Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. Agertoft L, et al. **Eur Respir J** 1997 Jul;10(7):1507–12

Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Boorsma M, et al. **Eur Respir J** 1996 Jul;9(7):1427–32

Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Esmailpour N, et al. **Eur Respir J** 1997 Jul;10(7):1496–9

Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 microg x day(-1). Hoekx JC, et al. **Eur Respir J** 1996 Nov;9(11):2263–72

A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. Agertoft L, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):773–80

Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr. Lorentzen KA, et al. **Respir Med** 1996 Nov;90(10):609–17

The effect of intranasal fluticasone propionate on the diving reflex in patients with non-eosinophilic non-allergic rhinitis. Cook JA, et al. **Rhinology** 1996 Sep;34(3):144–6

Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Clark DJ, et al. **Thorax** 1996 Sep;51(9):941–3

Asthma guidelines [letter; comment] Todd G. **Thorax** 1997 Jul;52(7):665; discussion 665–6. Comment on: Thorax 1997 Feb;52 Suppl 1:S2–8, S11–5, S20–1.

[The most fastest-acting steroid—again (letter)] Heebøll-Nielsen NC. **Ugeskr Laeger** 1997 Feb 3;159(6):775 **(Dan)**

[Can inhaled corticosteroid used for asthma cure allergic rhinitis? (letter)] Säynävälammi P. **Duodecim** 1995; 111(18):1805 **(Fin)**

[Controlled clinical comparative evaluation of fluticasone powder inhalation versus flunisolide dose aerosol in patients with mild to moderate asthma] Bergmann KC. **Pneumologie** 1997 Jan;51(1):27–32 (Eng. Abstr.) **(Ger)**

[The effect of initial treatment by FP aqueous nasal spray in patients with Japanese cedar pollinosis] Nakabayashi S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Sep; 99(9):1162–71 (Eng. Abstr.) **(Jpn)**

[A new trend of inhaled corticosteroid therapy in Japan] Sano Y. **Nippon Rinsho** 1996 Nov;54(11):3004–10 (16 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

The kinetics of skin thinning induced by topical fluticasone propionate 0.05% cream in volunteer subjects. Dykes PJ, et al. **Clin Exp Dermatol** 1996 May;21(3):180–4

Fluticasone propionate and mometasone furoate have a low risk of contact sensitization. Wilkinson SM, et al. **Contact Dermatitis** 1996 May;34(5):365–6

Secrets about drugs are not healthy [editorial] **Lancet** 1996 Sep 21;348(9030):765

High-dose inhaled steroids in asthmatic children [letter; comment] Cade A, et al. **Lancet** 1996 Sep 21;348(9030):819 . Comment on: Lancet 1996 Jul 6;348(9019):27–9.

High-dose inhaled steroids in asthmatic children [letter; comment] Lenney W. **Lancet** 1996 Sep 21;348(9030):819–20 . Comment on: Lancet 1996 Jul 6;348(9019):27–9.

Knemometry, urine cortisol excretion, and measures of the insulin-like growth factor axis and collagen turnover in children treated with inhaled glucocorticosteroids. Wolthers OD, et al. **Pediatr Res** 1997 Jan;41(1):44–50

Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Clark DJ, et al. **Thorax** 1997 Jan;52(1):55–8

BLOOD

A radioimmunoassay for the determination of tipredane in human plasma. Bayliss MA, et al. **J Pharm Biomed Anal** 1996 Oct;15(1):21–31

CHEMISTRY

3-Carboxy-20-keto steroids are dual uncompetitive inhibitors of human steroid 5 alpha-reductase types 1 and 2. Yamashita DS, et al. **Bioorg Med Chem** 1996 Sep; 4(9):1481–5

Synthesis and in vitro evaluation of new wortmannin esters: potent inhibitors of phosphatidylinositol 3-kinase. Creemer LC, et al. **J Med Chem** 1996 Dec 6;39(25):5021–4

The S-oxidative degradation of a novel corticosteroid tipredane (INN) Part III. Detailed investigations into the disulphoxidation of tipredane. Euerby MR, et al. **J Pharm Biomed Anal** 1996 Dec;15(3):299–313

Structural studies of loteprednol etabonate and other analogs of prednisolone using NMR techniques. Rachwal S, et al. **Steroids** 1996 Sep;61(9):524–30

15 beta-hydroxysteroids (Part VI). steroids of the human perinatal period: the preparation and reactions of 3 beta-hydroxy-5,15-androstadien-17-one. The synthesis of 3 beta,15 beta-dihydroxy-5-androsten-17-one and derivatives. Reeder AY, et al. **Steroids** 1996 Jan;61(1):22–6

ECONOMICS

A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis. Kozma CM, et al. **Clin Ther** 1996 Mar–Apr; 18(2):334–46; discussion 302

METABOLISM

Wortmannin-mediated inhibition of phosphatidylinositol 3-kinase activity triggers apoptosis in normal and neoplastic B lymphocytes which are in cell cycle. Padmore L, et al. **Int Immunol** 1996 Apr;8(4):585–94

Determination of a major metabolite of tipredane in rat urine by high-performance liquid chromatography with column switching. Baker PR, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20;694(1):193–8

Determination of the two major human metabolites of tipredane in human urine by high-performance liquid chromatography with column switching. Bayliss MA, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20; 694(1):199–209

PHARMACOKINETICS

Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects. Benincosa LJ, et al. **Biopharm Drug Dispos** 1996 Apr;17(3):249–58

Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Mackie AE, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):539–42

Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Thorsson L, et al. **Br J Clin Pharmacol** 1997 Feb;43(2):155–61

Excretion and metabolism of tipredane, a novel glucocorticoid, in the rat, mouse, monkey, and human. Cooper AE, et al. **Drug Metab Dispos** 1996 Oct; 24(10):1071–80

Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Esmailpour N, et al. **Eur Respir J** 1997 Jul;10(7):1496–9

Flovent (fluticasone propionate inhalation aerosol) [letter] Levy DS. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):861–2

Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. Rohatagi S, et al. **J Clin Pharmacol** 1996 Oct;36(10):938–41

Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. Reddy IK, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):159–67

PHARMACOLOGY

PAF-induced MAPK activation is inhibited by wortmannin in neutrophils and macrophages. Ferby I, et al. **Adv Exp Med Biol** 1996;416:321–6

Wortmannin inhibits contraction without altering electrical activity in canine gastric smooth muscle. Burke EP, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1405–12

A comparison of aqueous suspensions of budesonide nasal spray (128 micrograms and 256 micrograms once daily) and fluticasone propionate nasal spray (200 micrograms once daily) in the treatment of adult patients with seasonal allergic rhinitis. Stern MA, et al. **Am J Rhinol** 1997 Jul–Aug;11(4):323–30

Inhibition of protein kinase C-dependent noradrenaline release by wortmannin in PC12 cells. Oda H, et al. **Arch Biochem Biophys** 1997 Jan 1;337(1):96–102

Adrenal function and high dose inhaled corticosteroids for asthma. Yiallouros PK, et al. **Arch Dis Child** 1997 May; 76(5):405–10

Gastric inhibitory polypeptide activates MAP kinase through the wortmannin-sensitive and -insensitive pathways. Kubota A, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):171–5

Wortmannin enhances CPP32-like activity during neuronal differentiation of P19 embryonal carcinoma cells induced by retinoic acid. Mukasa T, et al. **Biochem Biophys Res Commun** 1997 Mar 6;232(1):192–7

Wortmannin-sensitive activation of p70S6-kinase and MAP-kinase by the G protein-coupled receptor, G/CCKB. Seva C, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):202–6

Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase gamma: structure-activity analysis and interactions with wortmannin. Stoyanova S, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):489–95

Effect of wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) on N-formyl-methionyl-leucyl-phenylalanine-induced phospholipase D activation in differentiated HL60 cells: possible involvement of phosphatidylinositol 3-kinase in phospholipase D activation. Nakamura M, et al. **Biochem Pharmacol** 1997 Jun 15;53(12):1929–36

Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation. Adcock IM, et al. **Biochem Soc Trans** 1996 May;24(2):267S

Wortmannin inhibits IGF-dependent differentiation in the mouse myogenic cell line C2. Pinset C, et al. **C R Acad Sci III** 1997 May;320(5):367–74

Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells. Boulton S, et al. **Carcinogenesis** 1996 Nov; 17(11):2285–90

Phosphatidylinositol 3-kinase inhibitor wortmannin blocks mitogenic activation of the transferrin receptor gene promoter in late G1. Miskimins WK, et al. **Cell Growth Differ** 1997 May;8(5):565–70

Phosphatidylinositol 3'-kinase, but not p70 ribosomal S6 kinase, is involved in membrane protein recycling: wortmannin inhibits glucose transport and downregulates cell-surface transferrin receptor numbers independently of any effect on fluid-phase endocytosis in fibroblasts. Jess TJ, et al. **Cell Signal** 1996 Jun;8(4):297–304

The enhancement by wortmannin of protein kinase C-dependent activation of phospholipase D in vascular endothelial cells. Natarajan V, et al. **Chem Phys Lipids** 1997 Mar 28;86(1):65–74

Fluticasone propionate: topical or systemic effects? Howland WC 3rd. **Clin Exp Allergy** 1996 May;26 Suppl 3:18–22

Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. Brunn GJ, et al. **EMBO J** 1996 Oct 1;15(19):5256–67

Wortmannin-sensitive and -insensitive steps in

calcium-controlled exocytosis in pituitary gonadotrophs: evidence that myosin light chain kinase mediates calcium-dependent and wortmannin-sensitive gonadotropin secretion. Rao K, et al. **Endocrinology** 1997 Apr;138(4):1440–9

The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Blommaart EF, et al. **Eur J Biochem** 1997 Jan 15; 243(1–2):240–6

Distinct repression of translation by wortmannin and rapamycin. Pedersen S, et al. **Eur J Biochem** 1997 Jul 1; 247(1):449–56

Effects of short-term exposure to high-dose inhaled corticosteroids on novel markers of bone metabolism. Grove A, et al. **Eur J Clin Pharmacol** 1996;50(4):275–7

Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. Oikawa T, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):93–6

Nuclear translocation of PKC zeta during ischemia and its inhibition by wortmannin, an inhibitor of phosphatidylinositol 3-kinase. Mizukami Y, et al. **FEBS Lett** 1997 Jan 20;401(2–3):247–51

cAMP stimulates protein kinase B in a Wortmannin-insensitive manner. Sable CL, et al. **FEBS Lett** 1997 Jun 9;409(2):253–7

Wortmannin inhibits both insulin- and contraction-stimulated glucose uptake and transport in rat skeletal muscle. Wojtaszewski JF, et al. **J Appl Physiol** 1996 Oct; 81(4):1501–9

Wortmannin and Li+ specifically inhibit clathrin-independent endocytic internalization of bulk fluid. Sato SB, et al. **J Biochem (Tokyo)** 1996 May; 119(5):887–97

Isolation and molecular cloning of wortmannin-sensitive bovine type III phosphatidylinositol 4-kinases. Balla T, et al. **J Biol Chem** 1997 Jul 18;272(29):18358–66

Inhibition of calcium-independent mannose 6-phosphate receptor incorporation into trans-Golgi network-derived clathrin-coated vesicles by wortmannin. Gaffet P, et al. **J Biol Chem** 1997 Sep 26;272(39):24170–5

Two discrete regions of interleukin-2 (IL2) receptor beta independently mediate IL2 activation of a PD98059/rapamycin/wortmannin-insensitive Stat5a/b serine kinase. Kirken RA, et al. **J Biol Chem** 1997 Jun 13; 272(24):15459–65

Cloning and characterization of a wortmannin-sensitive human phosphatidylinositol 4-kinase. Meyers R, et al. **J Biol Chem** 1997 Feb 14;272(7):4384–90

Insulin stimulates guanine nucleotide exchange on Rab4 via a wortmannin-sensitive signaling pathway in rat adipocytes. Shibata H, et al. **J Biol Chem** 1997 Jun 6; 272(23):14542–6

Inhibition of MG-63 cell proliferation and PDGF-stimulated cellular processes by inhibitors of phosphatidylinositol 3-kinase. Thomas JE, et al. **J Cell Biochem** 1997 Feb; 64(2):182–95

Inhibition of neutrophil oxidative burst and granule secretion by wortmannin: potential role of MAP kinase and renaturable kinases. Sue-A-Quan AK, et al. **J Cell Physiol** 1997 Jul;172(1):94–108

Initiation and maintenance of NGF-stimulated neurite outgrowth requires activation of a phosphoinositide 3-kinase. Jackson TR, et al. **J Cell Sci** 1996 Feb;109 (Pt 2):289–300

The effect of wortmannin on the localisation of lysosomal type I integral membrane glycoproteins suggests a role for phosphoinositide 3-kinase activity in regulating membrane traffic late in the endocytic pathway. Reaves BJ, et al. **J Cell Sci** 1996 Apr;109 (Pt 4):749–62

Wortmannin, a phosphatidylinositol 3-kinase inhibitor, blocks antigen-mediated, but not CD3 monoclonal antibody-induced, activation of murine CD4+ T cells. Shi J, et al. **J Immunol** 1997 May 15;158(10):4688–95

Induction of alloantigen-specific T cell tolerance through the treatment of human T lymphocytes with wortmannin. Taub DD, et al. **J Immunol** 1997 Mar 15;158(6):2745–55

Inhibitory effect of wortmannin on phosphatidylinositol 3-kinase-mediated cellular events. Hazeki O, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):259–61 (8 ref.)

Inhibition of testosterone 5 alpha-reductase: evidence for tissue-specific regulation of thromboxane A2 receptors. Higashiura K, et al. **J Pharmacol Exp Ther** 1996 Dec; 279(3):1386–91

The effects of progesterone, 4,16-androstadien-3-one and MK-434 on the kinetics of pig testis microsomal testosterone-4-ene-5alpha-reductase activity. Cooke GM, et al. **J Steroid Biochem Mol Biol** 1997 Mar;60(5–6):353–9

7alpha-Arylaliphatic androsta-1,4-diene-3,17-diones as enzyme-activated irreversible inhibitors of aromatase. O'Reilly JM, et al. **J Steroid Biochem Mol Biol** 1996 Sep; 59(1):93–102

Effects of steroid 5alpha-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats. Yasuda N, et al. **Jpn J Pharmacol** 1997 Jul;74(3):243–52

High-dose inhaled steroids in asthmatic children [letter; comment] Brus RH, et al. **Lancet** 1996 Sep 21; 348(9030):820–1; discussion 821. Comment on: Lancet 1996 Jul 6;348(9019):27–9.

High-dose inhaled steroids in asthmatic children [letter; comment] Lipworth BJ, et al. **Lancet** 1996 Sep 21; 348(9030):820; discussion 821. Comment on: Lancet 1996 Jul 6;348(9019):27–9.

Wortmannin converts insulin but not oxytocin from an antilipolytic to a lipolytic agent in the presence of forskolin. Fain JN, et al. **Metabolism** 1997 Jan;46(1):62–6

Wortmannin alters the transferrin receptor endocytic pathway in vivo and in vitro. Spiro DJ, et al. **Mol Biol Cell** 1996 Mar;7(3):355–67

Inhibition of IGF II-induced redistribution of mannose 6-phosphate receptors by the phosphatidylinositol 3-kinase inhibitor, wortmannin. Körner C, et al. **Mol Cell Endocrinol** 1996 Apr 19;118(1–2):201–5

Effects of a myosin light chain kinase inhibitor, wortmannin, on cytoplasmic Ca2+ levels, myosin light chain phosphorylation and force in vascular smooth muscle. Takayama M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jul; 354(2):120–7

Wortmannin blocks goldfish retinal phosphatidylinositol 3-kinase and neurite outgrowth. Lavie Y, et al. **Neurochem Res** 1997 Apr;22(4):373–8

Effects of a new 5 alpha reductase inhibitor (epristeride) on human prostate cell cultures. Robinson EJ, et al. **Prostate** 1997 Sep 1;32(4):259–65

STANDARDS

Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Pearlman DS, et al. **Ann Allergy Asthma Immunol** 1997 Apr;78(4):356–62

THERAPEUTIC USE

Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Géhanno P, et al. **Allergy** 1997 Apr;52(4):445–50

A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Friedlaender MH, et al. **Am J Ophthalmol** 1997 Apr;123(4):455–64

IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: comparison with IL-4 expression and modulation by topical glucocorticoid therapy. Ghaffar O, et al. **Am J Respir Cell Mol Biol** 1997 Jul;17(1):17–24

Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. Mandl M, et al. **Ann Allergy Asthma Immunol** 1997 Sep; 79(3):237–45

Fluticasone propionate aqueous nasal spray treatment for perennial allergic rhinitis in children. Ngamphaiboon J, et al. **Ann Allergy Asthma Immunol** 1997 May;78(5):479–84

Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis. Weido AJ, et al. **Ann Allergy Asthma Immunol** 1996 Nov;77(5):407–15

Fluticasone [letter; comment] Birchall MA. **Arch Otolaryngol Head Neck Surg** 1997 Apr;123(4):449–50 . Comment on: Arch Otolaryngol Head Neck Surg 1996 Jul;122(7):729–31.

A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Asbell P, et al. **CLAO J** 1997 Jan;23(1):31–6

Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medicamentosa. Hallén H, et al. **Clin Exp Allergy** 1997 May; 27(5):552–8

Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Wolfe JD, et al. **Clin Ther** 1996 Jul-Aug;18(4):635–46

Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis. Elewski BE, et al. **Cutis** 1996 Oct;58(4):305–7

Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Wiseman LR, et al. **Drugs** 1997 May;53(5):885–907 (114 ref.)

Effects of fluticasone propionate on methacholine dose-response curves in nonsmoking atopic asthmatics. Overbeek SE, et al. **Eur Respir J** 1996 Nov;9(11):2256–62

Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma. Mahajan P, et al. **J Asthma** 1997;34(3):227–34

Treatment of hay fever. Pabian C, et al. **J Fam Pract** 1997 Sep;45(3):201

Fluticasone propionate aqueous nasal spray: a well-tolerated and effective treatment for children with perennial rhinitis. Richards DH, et al. **Pediatr Allergy Immunol** 1996 Feb; 7(1):35–43

Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Levy ML, et al. **Thorax** 1996 Nov;51(11):1087–92

[Fluticasone propionate in treatment of seasonal allergic rhinitis—open multicenter study] Kokot M, et al. **Pol Merkuriusz Lek** 1996 Jul;1(1):38–40 (Eng. Abstr.) **(Pol)**

[Fluticasone propionate—a new name common in asthma and rhinitis] Ulmeanu R, et al. **Pneumoftiziologia** 1997 Jan-Mar; 46(1):63–4 (8 ref.) **(Rum)**

TOXICITY

Wortmannin inhibits the production of reactive oxygen and nitrogen intermediates and the killing of the Saccharomyces cerevisiae by isolated chicken macrophages. Yang M, et al. **Immunopharmacol Immunotoxicol** 1996 Nov; 18(4):597–608

URINE

Determination of a major metabolite of tipredane in rat urine by high-performance liquid chromatography with column switching. Baker PR, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20;694(1):193–8

Determination of the two major human metabolites of tipredane in human urine by high-performance liquid chromatography with column switching. Bayliss MA, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20; 694(1):199–209

ANDROSTANAZOL see **STANOZOLOL**

5-ANDROSTANE-3,17-DIOL

ADMINISTRATION & DOSAGE

Progesterone and 3 alpha-androstanediol conjugated to bovine serum albumin affects estrous behavior when applied to the MBH and POA. Frye CA, et al. **Behav Neurosci** 1996 Jun;110(3):603–12

ANALOGS & DERIVATIVES

Serum 3 alpha-androstanediol-glucuronide is decreased in nonhirsute women with acne vulgaris. Joura EA, et al. **Fertil Steril** 1996 Dec;66(6):1033–5

Plasma 3 alpha-androstanediol glucuronide in normal children and in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Lopes LA, et al. **Horm Res** 1997;48(1):35–40

Androstane-3alpha,17beta-diol glucuronide as a steroid correlate of visceral obesity in men. Tchernof A, et al. **J Clin Endocrinol Metab** 1997 May;82(5):1528–34

Developmental patterns of serum 3 alpha-androstanediol glucuronide. Rittner HL, et al. **J Endocrinol Invest** 1997 Mar;20(3):138–43

[Gas chromatography-mass spectrometry determination of plasma 5 alpha-androstane-3 alpha,17 beta-diol and 5 alpha-androstane-3 alpha,17 beta-diol glucuronide in children with premature and normal puberty] Wudy SA, et al. **Klin Padiatr** 1996 Nov-Dec;208(6):334–8 (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Developmental response by Leydig cells to acidic and basic fibroblast growth factor. Laslett AL, et al. **J Steroid Biochem Mol Biol** 1997 Feb;60(3–4):171–9

BLOOD

Effects of paced and non-paced mating stimulation on plasma progesterone, 3 alpha-diol and corticosterone. Frye CA, et al. **Psychoneuroendocrinology** 1996 May;21(4):431–9

[Gas chromatography-mass spectrometry determination of plasma 5 alpha-androstane-3 alpha,17 beta-diol and 5 alpha-androstane-3 alpha,17 beta-diol glucuronide in children with premature and normal puberty] Wudy SA, et al. **Klin Padiatr** 1996 Nov-Dec;208(6):334–8 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Behavioral effects of 3 alpha-androstanediol. I: Modulation of sexual receptivity and promotion of GABA-stimulated chloride flux. Frye CA, et al. **Behav Brain Res** 1996 Sep; 79(1–2):109–18

Behavioral effects of 3 alpha-androstanediol. II: Hypothalamic and preoptic area actions via a GABAergic mechanism. Frye CA, et al. **Behav Brain Res** 1996 Sep; 79(1–2):119–30

Analgesic effects of the neurosteroid 3 alpha-androstanediol. Frye CA, et al. **Brain Res** 1996 Feb 12;709(1):1–9

URINE

Confirming testosterone administration by isotope ratio mass spectrometric analysis of urinary androstanediols. Shackleton CH, et al. **Steroids** 1997 Apr;62(4):379–87

ANDROSTANES

ADMINISTRATION & DOSAGE

The role of perceptual and structural similarity in cross-adaptation. Pierce JD Jr, et al. **Chem Senses** 1996 Apr;21(2):223–37

BLOOD

Androstanediol glucuronide in patients with pancreatic cancer and in those with chronic pancreatitis. Janša R, et al. **Horm Metab Res** 1996 Aug;28(8):381–3

CHEMICAL SYNTHESIS

Synthesis and in vitro study of 17

ANDROSTANES

beta-[N-ureylene-N,N'-disubstituted]-4-methyl-4-aza-5 alpha-androstan-3-ones as selective inhibitors of type I 5 alpha-reductase. Lourdusamy M, et al. **Bioorg Med Chem** 1997 Feb;5(2):305-10

CHEMISTRY

Studies directed toward a mechanistic evaluation of aromatase inhibition by androst-5-ene-7,17-dione. Time-dependent inactivation by the 19-nor and 5 beta, 6 beta-epoxy derivatives. Numazawa M, et al. **Steroids** 1997 Jul;62(7):516-22

Photoaffinity labeling of rat steroid 5 alpha-reductase (isozyme-1) by a benzophenone derivative of a 4-methyl-4-azasteroid. Taylor MF, et al. **Steroids** 1996 May;61(5):323-31

PHARMACOLOGY

Aromatase inactivation by a suicide substrate, androst-5-ene-4,7,17-trione: the 5beta,6beta-epoxy-19-oxo derivative, as a possible reactive electrophile irreversibly binding to the active site. Numazawa M, et al. **Biol Pharm Bull** 1997 May;20(5):490-5

Studies directed toward a mechanistic evaluation of aromatase inhibition by androst-5-ene-7,17-dione. Time-dependent inactivation by the 19-nor and 5 beta, 6 beta-epoxy derivatives. Numazawa M, et al. **Steroids** 1997 Jul;62(7):516-22

THERAPEUTIC USE

Anti-inflammatory 17beta-thioalkyl-16alpha,17alpha-ketal and -acetal androstanes: a new class of airway selective steroids for the treatment of asthma. Ashton MJ, et al. **J Med Chem** 1996 Dec 6;39(25):4888-96

ANDROSTANOLONE see **STANOLONE**

ANDROSTANOLS

Evaluation of the onset time and intubation conditions of rocuronium bromide in children. McDonald PF, et al. **Anaesth Intensive Care** 1997 Jun;25(3):260-1

Tracheal intubation conditions after one minute: rocuronium and vecuronium, alone and in combination. England AJ, et al. **Anaesthesia** 1997 Apr;52(4):336-40

Use of rocuronium in a pregnant patient receiving magnesium medication [letter; comment] James MF. **Br J Anaesth** 1997 Jun;78(6):772. Comment on: Br J Anaesth 1996 Nov;77(5):669-71.

Priming with rocuronium accelerates the onset of neuromuscular blockade. Griffith KE, et al. **J Clin Anesth** 1997 May;9(3):204-7

Rocuronium versus succinylcholine for rapid-sequence induction using a variation of the timing principle. Nelson JM, et al. **J Clin Anesth** 1997 Jun;9(4):317-20

A mixture of mivacurium and rocuronium is comparable in clinical onset to succinylcholine. Stevens JB, et al. **J Clin Anesth** 1996 Sep;8(6):486-90

Anaesthesia for appendicectomy in childhood: a survey of practice in Northern Ireland. Weir PS. **Ulster Med J** 1997 May;66(1):34-7

[Effect of rocuronium in sufentanil/isoflurane and sufentanil/propofol anesthesia] Klinzing S, et al. **Anaesthesiol Reanim** 1996;21(6):149-52 (Eng. Abstr.) **(Ger)**

[The effects of age on onset and recovery from atracurium, rocuronium and vecuronium blockade] de Almeida MC, et al. **Anaesthesist** 1996 Oct;45(10):903-6 (Eng. Abstr.) **(Ger)**

[New muscle relaxants. Update on mivacurium, rocuronium and cis-atracurium] Fuchs-Buder T. **Anaesthesist** 1997 Apr;46(4):350-9 (17 ref.) **(Ger)**

[The interaction between rocuronium and smoking. The effect of smoking on neuromuscular transmission after rocuronium] Latorre F, et al. **Anaesthesist** 1997 Jun; 46(6):493-5 (Eng. Abstr.) **(Ger)**

[Intubation conditions and the development of neuromuscular blockade with rocuronium in endoscopic ORL surgery] Lüllwitz E, et al. **Anaesthesist** 1997 Jan;46(1):14-20 (Eng. Abstr.) **(Ger)**

[Intubation requirements after rocuronium and succinylcholine] Latorre F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):470-3 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Prediction of infusion rates of rocuronium using the bolus test dose technique. Harrison MJ. **Anaesthesia** 1997 Jan; 52(1):37-40

The effect of priming with vecuronium and rocuronium on young and elderly patients. Aziz L, et al. **Anesth Analg** 1997 Sep;85(3):663-6

Thiopental-rocuronium versus ketamine-rocuronium for rapid-sequence intubation in parturients undergoing cesarean section. Baraka AS, et al. **Anesth Analg** 1997 May; 84(5):1104-7

Interactions between mivacurium, rocuronium, and vecuronium during general anesthesia. Kim DW, et al. **Anesth Analg** 1996 Oct;83(4):818-22

The effect of ephedrine on the onset time of rocuronium. Muñoz HR, et al. **Anesth Analg** 1997 Aug;85(2):437-40

Dose-response and time course of effect of rocuronium in male and female anesthetized patients. Xue FS, et al. **Anesth Analg** 1997 Sep;85(3):667-71

Intramuscular rocuronium [letter; comment] Szmuk P, et al. **Anesthesiology** 1997 Feb;86(2):506-7. Comment on: Anesthesiology 1996 Aug;85(2):231-9.

Low-dose rocuronium improves conditions for tracheal intubation after induction of anaesthesia with propofol and alfentanil. Barclay K, et al. **Br J Anaesth** 1997 Jan; 78(1):92-4

Intubating conditions and time course of rocuronium-induced neuromuscular block in children. Fuchs-Buder T, et al. **Br J Anaesth** 1996 Sep;77(3):335-8

Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. Sparr HJ, et al. **Br J Anaesth** 1997 Mar;78(3):267-73

Intubating conditions and neuromuscular block after divided dose mivacurium or single dose rocuronium. Patel N, et al. **Can J Anaesth** 1997 Jan;44(1):49-53

Dose-response and concentration-response relation of rocuronium infusion during propofol-nitrous oxide and isoflurane-nitrous oxide anaesthesia. Kansanaho M, et al. **Eur J Anaesthesiol** 1997 Sep;14(5):488-94

Rocuronium priming of atracurium-induced neuromuscular blockade: the use of short priming intervals. Abdulatif M, et al. **J Clin Anesth** 1996 Aug;8(5):376-81

Rocuronium in infants, children and adults during balanced anaesthesia. Taivainen T, et al. **Paediatr Anaesth** 1996; 6(4):271-5

[Rocuronium. A replacement for suxamethonium?] Larsen PB, et al. **Ugeskr Laeger** 1996 Sep 30;158(40):5641-4 **(Dan)**

[New muscle relaxants] Diefenbach C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Feb; 31(1):2-8 (57 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Anaphylactic reaction to rocuronium bromide. Yee R, et al. **Anaesth Intensive Care** 1996 Oct;24(5):601-4

Pain on injection of rocuronium bromide [letter; comment] Joshi GP, et al. **Anesth Analg** 1997 Jan;84(1):228. Comment on: Anesth Analg 1996 Jul;83(1):203.

Postoperative reparalysis after rocuronium following nebulized epinephrine. Arndt GA, et al. **Can J Anaesth** 1997 Mar;44(3):321-4

Failure of neuromuscular blockade reversal after rocuronium in a patient who received oral neomycin. Hasfurther DL, et al. **Can J Anaesth** 1996 Jun;43(6):617-20

[Apropos of drug allergy (editorial)] Sabbah A. **Allerg Immunol (Paris)** 1996 Sep;28(7):230, 233 (Eng. Abstr.) **(Fre)**

ANTAGONISTS & INHIBITORS

Dose-response relationships for neostigmine antagonism of rocuronium-induced neuromuscular block in children and adults. Abdulatif M, et al. **Br J Anaesth** 1996 Dec; 77(6):710-5

BLOOD

Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. Wierda JM, et al. **Br J Anaesth** 1997 Jun;78(6):690-5

CHEMICAL SYNTHESIS

17 beta-(3-furyl)-5 beta-androstane-3 beta, 14 beta, 17 alpha-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. Quadri L, et al. **J Med Chem** 1997 May 23;40(11):1561-4

METABOLISM

Glucocorticoid (type II) receptors in the olfactory mucosa of the guinea-pig: RU 28362. Kern RC, et al. **Chem Senses** 1997 Jun;22(3):313-9

PHARMACOKINETICS

Pharmacokinetics of rocuronium during the three stages of liver transplantation. Fisher DM, et al. **Anesthesiology** 1997 Jun;86(6):1306-16

The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. van Miert MM, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):139-44

Rocuronium and cisatracurium. Pollard BJ. **Br J Hosp Med** 1997 Apr 2-15;57(7):346-8

Clinical pharmacokinetics of rocuronium bromide. Khuenl-Brady KS, et al. **Clin Pharmacokinet** 1996 Sep; 31(3):174-83 (53 ref.)

[The effects of cimetidine on the pharmacodynamics of rocuronium] Latorre F, et al. **Anaesthesist** 1996 Oct; 45(10):900-2 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Factors influencing the profile of onset of relaxation. De Mey JC, et al. **Acta Anaesthesiol Belg** 1997;48(1):7-10

Comparison of neuromuscular block of atracurium and rocuronium in adults. Hans P, et al. **Acta Anaesthesiol Belg** 1996;47(2):53-8

The haemodynamic effects of rocuronium and vecuronium are different under balanced anaesthesia. Stevens JB, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):502-5

The interaction between mivacurium and rocuronium during onset and recovery [letter; comment] England AJ, et al. **Anaesthesia** 1997 Mar;52(3):279-80. Comment on: Anaesthesia 1996 Oct;51(10):929-31.

Potency and onset time of neuromuscular relaxants [letter] Feldman SA. **Anaesthesia** 1997 Apr;52(4):387-8

Dose-response relationship and effective time to satisfactory intubation conditions after rocuronium in children. Hopkinson JM, et al. **Anaesthesia** 1997 May;52(5):428-32

Neuromuscular and cardiovascular advantages of combinations of mivacurium and rocuronium over either drug alone [see comments] Kim SY, et al. **Anaesthesia** 1996 Oct;51(10):929-31. Comment in: Anaesthesia 1997 Mar;52(3):279-80. Comment in: Anaesthesia 1997 Mar;52(3):280.

A comparison of acceleromyography and mechanomyography for determination of the dose-response curve of rocuronium in children. McCluskey A, et al. **Anaesthesia** 1997 Apr;52(4):345-9

The interaction between mivacurium and rocuronium during onset and recovery [letter; comment] Mirakhur RK. **Anaesthesia** 1997 Mar;52(3):280. Comment on: Anaesthesia 1996 Oct;51(10):929-31.

Duration of rocuronium-induced neuromuscular block during liver transplantation: a predictor of primary allograft function. Marcel RJ, et al. **Anesth Analg** 1997 Apr; 84(4):870-4

Extended duration of action of rocuronium in postpartum patients. Pühringer FK, et al. **Anesth Analg** 1997 Feb; 84(2):352-4

Use of rocuronium in a pregnant patient with an open eye injury, receiving magnesium medication, for preterm labour [see comments] Gaiser RR, et al. **Br J Anaesth** 1996 Nov; 77(5):669-71. Comment in: Br J Anaesth 1997 Jun;78(6):772.

Potency and time course of action of rocuronium during desflurane and isoflurane anaesthesia. Kumar N, et al. **Br J Anaesth** 1996 Oct;77(4):488-91

Administration of magnesium sulphate before rocuronium: effects on speed of onset and duration of neuromuscular block. Kussman B, et al. **Br J Anaesth** 1997 Jul;79(1):122-4

Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs. Loan PB, et al. **Br J Anaesth** 1997 Jan;78(1):90-1

Rocuronium and vecuronium [letter; comment] Parr MJ, et al. **Br J Anaesth** 1997 Mar;78(3):342. Comment on: Br J Anaesth 1996 Nov;77(5):607-11.

Effects of rocuronium and vecuronium on intracranial pressure, mean arterial pressure and heart rate in neurosurgical patients [see comments] Schramm WM, et al. **Br J Anaesth** 1996 Nov;77(5):607-11. Comment in: Br J Anaesth 1997 Mar;78(3):342.

Influence of induction technique on intubating conditions after rocuronium in adults: comparison with rapid-sequence induction using thiopentone and suxamethonium. Sparr HJ, et al. **Br J Anaesth** 1996 Sep; 77(3):339-42

Cardiovascular effects of an intubating dose of rocuronium 0.6 mg kg-1 in anaesthetized patients, paralysed with vecuronium. Wierda JM, et al. **Br J Anaesth** 1997 May; 78(5):586-7

The effects of type I and type II corticosteroid receptor agonists on exploratory behavior and spatial memory in the Y-maze. Conrad CD, et al. **Brain Res** 1997 Jun 6; 759(1):76-83

Residual neuromuscular blockade after cardiac surgery: pancuronium vs rocuronium. McEwin L, et al. **Can J Anaesth** 1997 Aug;44(8):891-5

Rocuronium in paediatric ICU [letter; comment] Withington D. **Can J Anaesth** 1996 Nov;43(11):1183. Comment on: Can J Anaesth 1996 Apr;43(4):353-7.

Production of follistatin in porcine endothelial cells: differential regulation by bacterial compounds and the synthetic glucocorticoid RU 28362. Michel U, et al. **Endocrinology** 1996 Nov;137(11):4925-34

Is rocuronium an exception to the relation between onset and offset? A comparison with pipecuronium. England AJ, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):385-8

Duration of stabilization of control responses affects the onset and duration of action of rocuronium but not suxamethonium. Symington MJ, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):377-80

Potentiation of mivacurium by rocuronium is age- and time-dependent: a study in children, adolescents, and young and elderly adults. Goudsouzian N, et al. **J Clin Pharmacol** 1997 Jul;37(7):649-55

Resistance to rocuronium in an epileptic patient on long-term carbamazepine therapy--a case report. Baraka A, et al. **Middle East J Anesthesiol** 1996 Oct;13(6):561-4

Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia. Wittmer LL, et al. **Mol Pharmacol** 1996 Dec;50(6):1581-6

Glucocorticoid receptor agonist and antagonist administration into the basolateral but not central amygdala modulates memory storage. Roozendaal B, et al. **Neurobiol Learn Mem** 1997 Mar;67(2):176-9

Neuromuscular effects of rocuronium in children during halothane anaesthesia. Vuksanaj D, et al. **Paediatr Anaesth** 1996;6(4):277-81

URINE

Excretion study of furazabol, an anabolic steroid, in human urine. Kim T, et al. **J Chromatogr B Biomed Appl** 1996 Dec 6;687(1):79–83

ANDROSTATRIENES

PHARMACOLOGY

Neonatal inhibition of brain estrogen synthesis alters adult neural Fos responses to mating and pheromonal stimulation in the male rat. Bakker J, et al. **Neuroscience** 1996 Sep; 74(1):251–60

Quantitative estimation of estrogen and androgen receptor–immunoreactive cells in the forebrain of neonatally estrogen–deprived male rats. Bakker J, et al. **Neuroscience** 1997 Apr;77(3):911–9

5–ANDROSTENE–3,17–DIOL

BLOOD

Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5–androstene–3 beta, 17 beta–diol to risk of breast cancer in postmenopausal women. Dorgan JF, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Mar; 6(3):177–81

METABOLISM

Regulation of the immune response by dehydroepiandrosterone and its metabolites. Loria RM, et al. **J Endocrinol** 1996 Sep;150 Suppl:S209–20

Endocrine regulation of the immune response to influenza virus infection with a metabolite of DHEA–androstenediol. Padgett DA, et al. **J Neuroimmunol** 1997 Sep; 78(1–2):203–11

PHARMACOLOGY

Contrasting effects of alpha– and beta–androstenediol on oncogenic myeloid cell lines in vitro. Huynh PN, et al. **J Leukoc Biol** 1997 Aug;62(2):258–67

Diffusion–weighted MRI of myelination in the rat brain following treatment with gonadal hormones. Prayer D, et al. **Neuroradiology** 1997 May;39(5):320–5

ANDROSTENEDIOL DIPROPIONATE see **5–ANDROSTENE–3,17–DIOL**

ANDROSTENEDIOLS

PHARMACOLOGY

The effects of dehydroepiandrosterone (DHEA) and its metabolites on the polycystic ovarian condition (PCO): cystogenic changes of rat granulosa cells in vitro. Anderson E, et al. **Tissue Cell** 1996 Dec;28(6):673–85

ANDROSTENEDIONE

ANALOGS & DERIVATIVES

Proper sequence of endocrine therapies in advanced breast cancer. Rose C. **Acta Oncol** 1996;35 Suppl 5:44–9 (14 ref.)

A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. Bajetta E, et al. **Ann Oncol** 1997 Jul;8(7):649–54

Mechanism for aromatase inactivation by a suicide substrate, androst–4–ene–3,6,17–trione. The 4 beta, 5 beta–epoxy–19–oxo derivative as a reactive electrophile irreversibly binding to the active site. Numazawa M, et al. **Biochem Pharmacol** 1996 Oct 25;52(8):1253–9

Hypoglycaemia associated with formestane treatment. Brankin E, et al. **BMJ** 1997 Mar 22;314(7084):869

Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Wiseman LR, et al. **Drugs Aging** 1996 Oct; 9(4):292–306 (71 ref.)

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects. Geisler J, et al. **Eur J Cancer** 1996 May;32A(5):789–92

Novel 19–(cyclopropylamino)–androst–4–en–3,17–dione: a mechanism–based inhibitor of aromatase. Njar VC, et al. **J Enzyme Inhib** 1996;10(1):47–56

Aromatase inhibition in JAr choriocarcinoma cells by 7alpha–arylaliphatic androgens. Brueggemeier RW, et al. **J Steroid Biochem Mol Biol** 1997 Apr;61(1–2):73–7

Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double–blind, placebo–controlled, randomized clinical trial using two doses of the aromatase–inhibitor atamestane. Atamestane Study Group. Radlmaier A, et al. **Prostate** 1996 Oct; 29(4):199–208

Studies directed toward a mechanistic evaluation of aromatase inhibition by androst–5–ene–7,17–dione. Time–dependent inactivation by the 19–nor and 5 beta, 6 beta–epoxy derivatives. Numazawa M, et al. **Steroids** 1997 Jul;62(7):516–22

Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane. Martinetti A, et al. **Tumour Biol** 1997;18(4):197–205

ANALYSIS

Steroid content in endometrial tissue. Suri NK. **East Afr Med J** 1997 Apr;74(4):242–8

BIOSYNTHESIS

Seasonal and acute heat stress effects on steroid production by dominant follicles in cows. Wolfenson D, et al. **Anim Reprod Sci** 1997 May;47(1–2):9–19

Adiposity and androstenedione production in relation to delayed ovulation in the Indian bat, Scotophilus heathi. Abhilasha, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jan;116(1):97–101

Steroid release from two human epithelial ovarian tumors: evidence for an intrinsic production in vitro. Abrahamsson G, et al. **Gynecol Oncol** 1997 Jan;64(1):99–104

Insulin–like growth factor I enhancement of steroidogenesis by bovine granulosa cells and thecal cells: dependence on de novo cholesterol synthesis. Spicer LJ, et al. **J Endocrinol** 1996 Dec;151(3):365–73

The inhibition of androstenedione production in mature thecal cells from the ovary of the domestic hen (Gallus domesticus): evidence for the involvement of progestins. Woolveridge I, et al. **Steroids** 1997 Feb;62(2):214–20

BLOOD

Exercise during pregnancy and maternal and fetal plasma corticosterone and androstenedione in rats. Carlberg KA, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):E896–902

Umbilical cord androgens in infants of diabetic mothers. Gemer O, et al. **Arch Gynecol Obstet** 1997;259(3):139–41

Serum levels of androstenedione, testosterone and dehydroepiandrosterone sulfate in patients with premature ovarian failure to age–matched menstruating controls. Elias AN, et al. **Gynecol Obstet Invest** 1997;43(1):47–8

Daily variation of plasma testosterone, androstenedione, and corticosterone in rats under food restriction. Leal AM, et al. **Horm Behav** 1997 Feb;31(1):97–100

Serum alpha–inhibin levels in polycystic ovary syndrome: relationship to the serum androstenedione level. Pigny P, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1939–43

Seasonal changes in circulating serum concentration and in vitro testicular secretion of testosterone and androstenedione in the male vespertilionid bat (Scotophilus heathi). Singh K, et al. **J Exp Zool** 1996 Sep 1;276(1):43–52

Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Miller JG, et al. **Melanoma Res** 1997 Jun; 7(3):197–208

[Androstenedione conversion in human peripheral blood lymphocytes] Bershtein LM, et al. **Biull Eksp Biol Med** 1994 May;117(5):517–9 **(Rus)**

[Dexamethasone and dibutyryl–cyclic AMP stimulates conversion of androstenedione in human blood lymphocytes] Bershtein LM, et al. **Dokl Akad Nauk** 1997 Jan;352(2):276–7 **(Rus)**

METABOLISM

Gonadal and adrenal hormones. Developmental transitions and aggressive behavior. Susman EJ, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:18–30

5 alpha reductase activity in human gingiva and gingival fibroblasts in response to bacterial culture supernatants, using [14C]4–androstenedione as substrate. Soory M, et al. **Arch Oral Biol** 1997 Apr;42(4):255–62

Normal human follicle development: an evaluation of correlations with oestradiol, androstenedione and progesterone levels in individual follicles. van Dessel HJ, et al. **Clin Endocrinol (Oxf)** 1996 Feb;44(2):191–8

Steroid transformation by mutants of Mycobacterium sp. with altered response to antibiotics. Barthakur S, et al. **J Basic Microbiol** 1996;36(6):383–7

PHARMACOLOGY

Modulation of ovine fetal adrenocorticotropin secretion by androstenedione and 17beta–estradiol. Saoud CJ, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1128–34

Relationship between androstenedione–induced myometrial contractions and platelet–activating factor acetylhydrolase in late gestation in pregnant rhesus monkeys. Giussani DA, et al. **Biol Reprod** 1997 Jan;56(1):247–52

A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int–5/aromatase gene. Tekmal RR, et al. **Cancer Lett** 1997 Sep 16; 118(1):21–8

The oxytocin antagonist atosiban prevents androstenedione–induced myometrial contractions in the chronically instrumented, pregnant rhesus monkey. Giussani DA, et al. **Endocrinology** 1996 Aug;137(8):3302–7

Modulation of the effects of FSH, androstenedione, epidermal growth factor (EGF) and insulin–like growth factor I (IGF–I) on bovine granulosa cells by GCIF, a growth–inhibitory factor of low molecular mass from bovine follicular fluid. Hynes AC, et al. **J Reprod Fertil** 1996 Nov;108(2):193–7

Aromatase inhibition in JAr choriocarcinoma cells by 7alpha–arylaliphatic androgens. Brueggemeier RW, et al. **J Steroid Biochem Mol Biol** 1997 Apr;61(1–2):73–7

Dietary and hypothalamic changes in delta 4–androstenedione–treated Zucker rats. Hargrave KR, et al. **Physiol Behav** 1997 Apr;61(4):619–26

The effects of dehydroepiandrosterone (DHEA) and its metabolites on the polycystic ovarian condition (PCO): cystogenic changes of rat granulosa cells in vitro. Anderson E, et al. **Tissue Cell** 1996 Dec;28(6):673–85

SECRETION

Follicular dynamics and ovarian steroid secretion in sheep during the follicular and early luteal phases of the estrous cycle. Souza CJ, et al. **Biol Reprod** 1997 Feb;56(2):483–8

Involvement of adrenoceptors in the ovarian vascular pedicle in the regulation of counter current transfer of steroid hormones to the arterial blood supplying the oviduct and uterus of pigs. Stefańczyk–Krzymowska S, et al. **Br J Pharmacol** 1997 Mar;120(5):763–8

Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche. Weber A, et al. **Clin Endocrinol (Oxf)** 1997 Apr;46(4):431–7

The ovarian secretion of androstenedione and oestradiol during late pregnancy and the early postpartum period in sheep with an autotransplanted ovary. Scaramuzzi RJ, et al. **Reprod Nutr Dev** 1996;36(5):531–43

TOXICITY

Androstenedione synergizes with stress or prenatal drug exposure to retard fetal growth: role of IGF. McGivern RF, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):549–57

ANDROSTENES

ADMINISTRATION & DOSAGE

The role of perceptual and structural similarity in cross–adaptation. Pierce JD Jr, et al. **Chem Senses** 1996 Apr;21(2):223–37

CHEMICAL SYNTHESIS

Steroidal allylic fluorination using diethylaminosulfur trifluoride: a convenient method for the synthesis of 3 beta–acetoxy–7 alpha– and 7 beta–fluoroandrost–5–en–17–one. Marwah P, et al. **Steroids** 1996 Aug;61(8):453–60

15 beta–hydroxysteroids (Part VI). steroids of the human perinatal period: the preparation and reactions of 3 beta–hydroxy–5,15–androstadien–17–one. The synthesis of 3 beta,15 beta–dihydroxy–5–androsten–17–one and derivatives. Reeder AY, et al. **Steroids** 1996 Jan;61(1):22–6

CHEMISTRY

Andrastin D, novel protein farnesyltransferase inhibitor produced by Penicillium sp. FO–3929. Uchida R, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1278–80

METABOLISM

Mechanism for aromatase inactivation by a suicide substrate, androst–4–ene–3,6,17–trione. The 4 beta, 5 beta–epoxy–19–oxo derivative as a reactive electrophile irreversibly binding to the active site. Numazawa M, et al. **Biochem Pharmacol** 1996 Oct 25;52(8):1253–9

Transformations of steroid sulphates by human axillary bacteria. A mechanism for human odour formation? Gower DB, et al. **Biochem Soc Trans** 1997 Feb;25(1):16S

Use of gas chromatographic–mass spectrometric techniques in studies of androst–16–ene and androgen biosynthesis in human testis; cytosolic specific binding of 5alpha–androst–16–en–3–one. Kwan TK, et al. **J Steroid Biochem Mol Biol** 1997 Jan;60(1–2):137–46

PHARMACOLOGY

Mechanism for aromatase inactivation by a suicide substrate, androst–4–ene–3,6,17–trione. The 4 beta, 5 beta–epoxy–19–oxo derivative as a reactive electrophile irreversibly binding to the active site. Numazawa M, et al. **Biochem Pharmacol** 1996 Oct 25;52(8):1253–9

Aromatase inactivation by a suicide substrate, androst–5–ene–4,7,17–trione: the 5beta,6beta–epoxy–19–oxo derivative, as a possible reactive electrophile irreversibly binding to the active site. Numazawa M, et al. **Biol Pharm Bull** 1997 May;20(5):490–5

Chemoprevention of spontaneous tumorigenesis in nullizygous p53–deficient mice by dehydroepiandrosterone and its analog 16alpha–fluoro–5–androsten–17–one. Perkins SN, et al. **Carcinogenesis** 1997 May;18(5):989–94

Pemenone and androstenone do not cross–adapt reciprocally. Stevens DA, et al. **Chem Senses** 1996 Dec;21(6):711–7

The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Fuhrmann U, et al. **Contraception** 1996 Oct; 54(4):243–51

Comparison of the enhancing effects of dehydroepiandrosterone with the structural analog 16 alpha–fluoro–5–androsten–17–one on aflatoxin B1 hepatocarcinogenesis in rainbow trout. Orner GA, et al. **Fundam Appl Toxicol** 1996 Nov;34(1):132–40

Andrastin D, novel protein farnesyltransferase inhibitor

ANDROSTENES

produced by Penicillium sp. FO-3929. Uchida R, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1278–80

Quantitative analysis of hydrophobic amine inhibition of intracellular cholesterol transport. Underwood KW, et al. **J Lipid Res** 1996 Jul;37(7):1556–68

FCE 28260, a new 5 alpha-reductase inhibitor: in vitro and in vivo effects. Giudici D, et al. **J Steroid Biochem Mol Biol** 1996 Jun;58(3):299–305

The antiovulatory activity of progesterone antagonists is not correlated to their antiprogestational potency in the rat. Schubert C, et al. **J Steroid Biochem Mol Biol** 1996 Sep; 59(1):75–82

4-Methyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-N-aryl-carboxamides: an approach to combined androgen blockade [5alpha-reductase inhibition with androgen receptor binding in vitro]. Tolman RL, et al. **J Steroid Biochem Mol Biol** 1997 Mar;60(5–6):303–9

ANDROSTENOLS

ADMINISTRATION & DOSAGE

Inhibition and augmentation of progesterone production during pregnancy: effects on parturition in rhesus monkeys. Haluska GJ, et al. **Am J Obstet Gynecol** 1997 Mar; 176(3):682–91

Plasma protein changes induced by two orally administered androgen derivatives. Rannevik G, et al. **Scand J Clin Lab Invest** 1996 Apr;56(2):161–6

BLOOD

Laparoscopic ovarian treatment in infertile patients with polycystic ovarian syndrome (PCOS): endocrine changes and clinical outcome. Liguori G, et al. **Gynecol Endocrinol** 1996 Aug;10(4):257–64

ANDROSTERONE

ANALOGS & DERIVATIVES

Transformations of steroid sulphates by human axillary bacteria. A mechanism for human odour formation? Gower DB, et al. **Biochem Soc Trans** 1997 Feb;25(1):16S

Production and characterization of monoclonal antibodies to dehydroepiandrosterone sulfate: application to direct enzyme-linked immunosorbent assays of dehydroepiandrosterone sulfate and androsterone/epiandrosterone sulfates in plasma. Lewis JG, et al. **Steroids** 1996 Dec;61(12):682–7

BIOSYNTHESIS

Growth hormone stimulates androsterone synthesis by rat theca-interstitial cells. Apa R, et al. **Mol Cell Endocrinol** 1996 Apr 19;118(1–2):95–101

CHEMISTRY

Spectroscopic investigations of dehydroepiandrosterone. Part II: Photoelectron spectrum and electronic structure. Bhacca NS, et al. **Steroids** 1996 Sep;61(9):557–9

METABOLISM

Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. Beaulieu M, et al. **J Biol Chem** 1996 Sep 13; 271(37):22855–62

PHARMACOLOGY

Epiandrosterone and dehydroepiandrosterone affect glucose oxidation and interleukin-1 beta effects in pancreatic islets. Laychock SG, et al. **Endocrinology** 1996 Aug; 137(8):3375–85

ANECDOTES

Parking lot encounter. Wood JC. **Pharos** 1996 Winter; 59(1):16

[Methaphors and understanding of diseases] Mabeck CE, et al. **Ugeskr Laeger** 1996 Dec 16;158(51):7384–7 (12 ref.) (Eng. Abstr.) **(Dan)**

ANEMIA

Long-lasting effect of cyclosporin-A on anemia associated with idiopathic myelofibrosis. Pietrasanta D, et al. **Haematologica** 1997 Jul-Aug;82(4):458–9

Anemia of malignancy. Frenkel EP, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):861–73 (36 ref.)

Rethinking anaemia surveillance. Stoltzfus RJ. **Lancet** 1997 Jun 14;349(9067):1764–6

Clinical experience with Repotin, a locally produced recombinant human erythropoietin, in the treatment of anaemia of chronic renal failure in South Africa. Swanepoel CR, et al. **S Afr Med J** 1996 Oct;86(10):1266–9

Anaemia in pregnancy [letter; comment] Wiggin TR. **Trop Doct** 1997 Apr;27(2):123–4. Comment on: Trop Doct 1996 Jan;26(1):5–7.

[Causes, diagnosis, and treatment of anemia in the elderly] Takasaki M, et al. **Nippon Ronen Igakkai Zasshi** 1997 Mar; 34(3):171–9 (36 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Serum ferritin and other iron indices in adult Nigerians with chronic renal failure—review of management of anaemia. Oluboyede OA, et al. **Afr J Med Med Sci** 1995 Sep; 24(3):231–7 (52 ref.)

Observations of stillbirths, birthweight and maternal haemoglobin in teenage pregnancy in Ibadan, Nigeria. Onadeko MO, et al. **Afr J Med Med Sci** 1996 Mar; 25(1):81–6

Microcytic anemia. Shine JW. **Am Fam Physician** 1997 May 15;55(7):2455–62

Clinical significance of immature reticulocyte fraction determined by automated reticulocyte counting. Chang CC, et al. **Am J Clin Pathol** 1997 Jul;108(1):69–73

Lack of relationship between soluble erythropoietin receptor levels and erythroid parameters in anemic patients [letter; comment] Yoshida S, et al. **Blood** 1996 Oct 15;88(8):3246–7 . Comment on: Blood 1993 Oct 1;82(7):2088–95.

Inadequate erythropoietin response to anaemia in HIV patients: relationship to serum levels of tumour necrosis factor-alpha, interleukin-6 and their soluble receptors. Kreuzer KA, et al. **Br J Haematol** 1997 Feb;96(2):235–9

The disappearance of fetal and donor red blood cells in alloimmunised pregnancies: a reappraisal. Egberts J, et al. **Br J Obstet Gynaecol** 1997 Jul;104(7):818–24

Human erythrocyte CAI and CAII isoenzymes in hypoxemic and anemic fetuses. Akbar SA, et al. **Clin Biochem** 1996 Feb;29(1):57–62

Assessment of erythropoiesis following renal transplantation. Beshara S, et al. **Eur J Haematol** 1997 Mar;58(3):167–73

The effect of calcitriol on renal anaemia in patients undergoing long-term dialysis. Nazem AK, et al. **Int Urol Nephrol** 1997;29(1):119–27

Lipoperoxidation and glutathione-dependent enzymes in uremic anemia of CAPD patients [letter] Galli F, et al. **Nephron** 1997;76(3):363

Circulating transferrin receptor during erythropoietin medication of anemic patients with rheumatoid arthritis. Pettersson T, et al. **Scand J Rheumatol** 1996;25(5):321–4

Mixture models in haematology: a series of case studies [see comments] McLaren CE. **Stat Methods Med Res** 1996 Jun; 5(2):129–53 (83 ref.). Comment in: Stat Methods Med Res 1996 Jun;5(2):107–27.

Very anemic donors may pass copper sulfate screening tests [letter] Newman B. **Transfusion** 1997 Jun;37(6):670–1

[Survival of very severe hemorrhage-induced anemia in a Jehovah's Witness] Tessmann R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):501–4 **(Ger)**

[Oxygen supply and acid-base status in extreme anemia] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):492–4 (30 ref.) **(Ger)**

[Appearance of cytoplasmic processes of megakaryocytes in the peripheral blood in a Munchausen syndrome with factitious anemia] Komeno T, et al. **Rinsho Ketsueki** 1996 Sep;37(9):848–52 (Eng. Abstr.) **(Jpn)**

[Anemia with low serum cobalamin concentration. Problems of differential diagnosis] Berentsen S, et al. **Tidsskr Nor Laegeforen** 1996 Sep 20;116(22):2680–3 (Eng. Abstr.) **(Nor)**

[The characteristics of the course and outcome of pregnancy in women with anemia and a background of zinc deficiency] Krivoruchko IV, et al. **Fiziol Cheloveka** 1997 May-Jun;23(3):82–4 **(Rus)**

[The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia] Stojimirović B, et al. **Srp Arh Celok Lek** 1997 May-Jun;125(5–6):163–7 (Eng. Abstr.) **(Scc)**

[A single absolute critical threshold of oxygen transport and anemia in patients with isovolemic hypovolemia] Biliaiev AV. **Fiziol Zh** 1997;43(3–4):71–8 (Eng. Abstr.) **(Ukr)**

CHEMICALLY INDUCED

Effects of discontinuing coffee intake on iron status of iron-deficient Guatemalan toddlers: a randomized intervention study. Dewey KG, et al. **Am J Clin Nutr** 1997 Jul;66(1):168–76

Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia [letter] Finkelstein SN, et al. **Ann Pharmacother** 1997 Sep;31(9):1094–5

Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Sheffield R, et al. **Ann Pharmacother** 1997 Jan;31(1):15–22 (58 ref.)

Long-term cadmium exposure induces anemia in rats through hypoinduction of erythropoietin in the kidneys. Horiguchi H, et al. **Arch Toxicol** 1996;71(1–2):11–9

Interactive effect of combined exposure to glycol ethers and alcohols on toxicodynamic and toxicokinetic parameters. Morel G, et al. **Arch Toxicol** 1996;70(8):519–25

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Strum SB, et al. **Br J Urol** 1997 Jun;79(6):933–41

Dextran syndrome. Acute hypotension, noncardiogenic pulmonary edema, anemia, and coagulopathy following hysteroscopic surgery using 32% dextran 70. Ellingson TL, et al. **Chest** 1997 Feb;111(2):513–8

Effects of combinations of stem cell factor and hemin on erythropoiesis after azidothymidine treatment of immunosuppressed mice. Hamburger AW. **Eur J Haematol** 1996 Aug;57(2):128–33

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Kurz Ch, et al. **Gynecol Oncol** 1997 Jun;65(3):461–6

Delayed anemia and thrombocytopenia after treatment with gemcitabine [letter] Malayeri R, et al. **J Natl Cancer Inst** 1997 Aug 6;89(15):1164

Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Gossmann J, et al. **Kidney Int** 1996 Sep;50(3):973–8

Effects of ACE inhibitor on renal anemia in predialysis patients [letter] Nomura S, et al. **Nephron** 1996;73(2):336–7

Anemia associated with lamotrigine. Esfahani FE, et al. **Neurology** 1997 Jul;49(1):306–7

Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Asbell SO, et al. **Prostate** 1996 Oct; 29(4):243–8

[Optimization of the diagnosis and treatment of anemias under exposure to aromatic-type organic solvents] Shpagina LA, et al. **Ter Arkh** 1996;68(12):15–9 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Clinical application of recombinant human erythropoietin in anemic HIV patients [letter] Iacono R, et al. **AIDS** 1997 Jul 15;11(9):1189–91

Lactic acidosis secondary to severe anemia in a patient with paroxysmal nocturnal hemoglobinuria. Essex DW, et al. **Am J Hematol** 1997 Jun;55(2):110–1

Reversible uremic deafness: is it correlated with the degree of anemia? Shaheen FA, et al. **Ann Otol Rhinol Laryngol** 1997 May;106(5):391–3

Anemia worsens hyperdynamic circulation of patients with cirrhosis and portal hypertension. Cirera I, et al. **Dig Dis Sci** 1997 Aug;42(8):1697–702

Parvovirus B19 infections in patients with chronic anemia. Heegaard ED, et al. **Haematologica** 1997 Jul-Aug; 82(4):402–5

Mean electrical axis of heart in chronic severe anemia. Singh K, et al. **Indian J Med Sci** 1996 Oct;50(10):359–61

Autonomic dysfunction and anemia in neurologic disorders. Ando Y, et al. **J Auton Nerv Syst** 1996 Nov 6;61(2):145–8

Anemia and perioperative myocardial ischemia in a Jehovah's Witness patient. Botero C, et al. **J Clin Anesth** 1996 Aug; 8(5):386–91

Conjunctival pallor and the presence of anemia [letter] Mishriki YY. **J Gen Intern Med** 1997 Jul;12(7):455

Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Yellen SB, et al. **J Pain Symptom Manage** 1997 Feb;13(2):63–74

The diagnosis of iron deficiency in patients with rheumatoid arthritis and anemia: an algorithm using simple laboratory measures [see comments] Mulherin D, et al. **J Rheumatol** 1996 Feb;23(2):237–40. Comment in: J Rheumatol 1997 Apr;24(4):804–5.

Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Carson JL, et al. **Lancet** 1996 Oct 19;348(9034):1055–60

Pistachio-green stools and anaemia in infancy: early signs of cystic fibrosis? [letter] [see comments] Jakobson AM. **Lancet** 1997 May 17;349(9063):1452. Comment in: Lancet 1997 Jul 26;350(9073):295.

The relationship between maternal nutritional status and spontaneous abortion. Neela J, et al. **Natl Med J India** 1997 Jan-Feb;10(1):15–6

Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Dubray B, et al. **Radiology** 1996 Nov; 201(2):553–8

Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. Venkatesan J, et al. **Semin Nephrol** 1997 Jul;17(4):257–69 (125 ref.)

Laparoscopic splenectomy in a Jehovah's Witness with profound anemia. Ferzli GS, et al. **Surg Endosc** 1997 Aug; 11(8):850–1

Schistosomiasis mansoni in Kenya: relationship between infection and anaemia in schoolchildren at the community level. Sturrock RF, et al. **Trans R Soc Trop Med Hyg** 1996 Jan-Feb;90(1):48–54

Comparison between intravenous and subcutaneous recombinant human erythropoietin (Epoetin alfa) administration in presurgical autologous blood donation in anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Mercuriali F, et al. **Vox Sang** 1997; 72(2):93–100

[Cardiovascular manifestations of anemia] Fujii H. **Ryoikibetsu Shokogun Shirizu** 1996;(15):151–4 (2 ref.) **(Jpn)**

[Effect of low-dose recombinant humane erythropoietin therapy on the quality of life in patients with anemia in the course of end-stage renal failure treated with dialysis] Matuszkiewicz-Rowińska J, et al. **Pol Arch Med Wewn** 1996 Aug;96(2):143–52 (Eng. Abstr.) **(Pol)**

[Severity of acquired cystic kidney disease determines improvement in chronic kidney failure anemia] Bezerra HM, et al. **Rev Assoc Med Bras** 1997 Jan-Mar;43(1):4–8 (Eng. Abstr.) **(Por)**

CONGENITAL

Anemia and perinatal death result from loss of the murine ecotropic retrovirus receptor mCAT-1. Perkins CP, et al. **Genes Dev** 1997 Apr 1;11(7):914-25

New molecular diagnostic tests for two congenital forms of anemia. Auerbach AD, et al. **J Clin Lab Anal** 1997; 11(1):17-22 (27 ref.)

DIAGNOSIS

Laboratory diagnosis of anemia and related diseases using multivariate analysis. Shiga S, et al. **Am J Hematol** 1997 Feb;54(2):108-17

Difficulty in applying discriminant function to patients with HbE trait [letter; comment] Liu TC, et al. **Clin Lab Haematol** 1996 Jun;18(2):128-9. Comment on: Clin Lab Haematol 1995 Mar;17(1):31-3.

A case of Sheehan's syndrome associated with severe anemia and empty sella proved 48 years after postpartum hemorrhage. Ishikawa K, et al. **Endocr J** 1995 Dec; 42(6):803-9

An unexpected diagnosis. Chemlal K, et al. **Haematologica** 1997 Jul-Aug;82(4):503

New molecular diagnostic tests for two congenital forms of anemia. Auerbach AD, et al. **J Clin Lab Anal** 1997; 11(1):17-22 (27 ref.)

The relation of conjunctival pallor to the presence of anemia. Sheth TN, et al. **J Gen Intern Med** 1997 Feb;12(2):102-6

Transient erythroblastopenia of childhood (TEC) presenting as leukoerythroblastic anemia. Mupanomunda OK, et al. **J Pediatr Hematol Oncol** 1997 Mar-Apr;19(2):165-7

Audit of the investigation and outcome of iron-deficiency anaemia in one health district. Lucas CA, et al. **J R Coll Physicians Lond** 1996 Jan-Feb;30(1):33-6

Haemoglobin concentration and erythrocyte sedimentation rate in primary care patients [see comments] Kanfer EJ, et al. **J R Soc Med** 1997 Jan;90(1):16-8. Comment in: J R Soc Med 1997 Mar;90(3):179-80. Comment in: J R Soc Med 1997 Apr;90(4):236. Comment in: J R Soc Med 1997 Apr;90(4):236-7.

A practical guide for differentiating between iron deficiency anemia and anemia of chronic disease in children and adults. Richer S. **Nurse Pract** 1997 Apr;22(4):82, 85-6, 91-6 passim; quiz 102-3 (29 ref.)

Cost-effective on-site screening for anaemia in pregnancy [letter] Pistorius LR, et al. **S Afr Med J** 1997 Aug; 87(8):1024

The role of low level Plasmodium falciparum parasitaemia in anaemia among infants living in an area of intense and perennial transmission. Kitua AY, et al. **Trop Med Int Health** 1997 Apr;2(4):325-33

[Management of chronic anemia in the adult in tropical zones] Gras C, et al. **Med Trop (Mars)** 1996;56(3):241-3 (0 ref.) **(Fre)**

[MR relaxation times in diffuse bone marrow disorders: evaluation of their clinical usefulness in differentiation between leukemia and anemia] Tanaka O, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jul; 56(8):539-45 (Eng. Abstr.) **(Jpn)**

[Anemia: the principle of diagnosis and current topics] Dan K. **Nippon Ika Daigaku Zasshi** 1997 Apr;64(2):176-9 (10 ref.) **(Jpn)**

[Diagnostic limitations of the physical examination in the identification of children with anemia] Sdepanian VL, et al. **Rev Assoc Med Bras** 1996 Jul-Sep;42(3):169-74 (Eng. Abstr.) **(Por)**

[The problems of managing anemia patients in the therapist's practice] Berliner GB, et al. **Klin Med (Mosk)** 1996; 74(2):60-2 **(Rus)**

DIET THERAPY

The influence of cultural practice on puerperal anemia. Ekanem AD, et al. **Int J Gynaecol Obstet** 1996 Nov; 55(2):169-70

DRUG THERAPY

Recombinant erythropoietin for treatment of anaemia in HIV-infected children [letter] Caselli D, et al. **AIDS** 1996 Jul;10(8):929-31

Clinical application of recombinant human erythropoietin in anemic HIV patients [letter] Iacono R, et al. **AIDS** 1997 Jul 15;11(9):1189-91

Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Ahluwalia N, et al. **Am J Kidney Dis** 1997 Oct;30(4):532-41

Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? Cruz DN, et al. **Am J Kidney Dis** 1996 Oct; 28(4):535-40

A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Gaughan WJ, et al. **Am J Kidney Dis** 1997 Oct; 30(4):495-500

Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Teruel JL, et al. **Am J Kidney Dis** 1997 Apr;29(4):569-75

How erythropoietin affects bone marrow of uremic patients. Sikole A, et al. **Am J Nephrol** 1997;17(2):128-36

Impact of human recombinant erythropoietin on plasminogen activator inhibitor, and protein C and S activity [letter] Steffensen G, et al. **Am J Nephrol** 1996;16(5):453-4

Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy. Tarng DC, et al. **Am J Nephrol** 1997;17(2):158-64

Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Mak RH. **Am J Physiol** 1996 May;270(5 Pt 2):F839-44

Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Gasché C, et al. **Ann Intern Med** 1997 May 15;126(10):782-7

Reversible uremic deafness: is it correlated with the degree of anemia? Shaheen FA, et al. **Ann Otol Rhinol Laryngol** 1997 May;106(5):391-3

Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities. Suzuki M, et al. **Artif Organs** 1995 Dec;19(12):1258-61

Use of recombinant human erythropoietin outside the setting of uremia. Cazzola M, et al. **Blood** 1997 Jun 15; 89(12):4248-67 (179 ref.)

Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Nagao K, et al. **Can J Cardiol** 1997 Aug;13(8):747-53 (23 ref.)

Haemodynamic changes measured by transthoracic bioimpedance during treatment with recombinant human erythropoietin. Jones MA, et al. **Clin Exp Hypertens** 1996 Jan;18(1):51-64

Erythropoietin in the treatment of anaemia in a nephropathic pregnant woman. Case report. D'Anna R, et al. **Clin Exp Obstet Gynecol** 1996;23(4):252-4

Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Drüeke TB, et al. **Clin Nephrol** 1997 Jul;48(1):1-8 (69 ref.)

Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy [letter] Goicoechea M, et al. **Clin Nephrol** 1996 Jun; 45(6):420-1

Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin [letter] Kotaki M, et al. **Clin Nephrol** 1997 Jul;48(1):63-4

Recombinant human erythropoietin for anaemia in nephrotic syndrome with thalassemia [letter] Ng YY, et al. **Clin Nephrol** 1997 Apr;47(4):273-4

Effect of recombinant human erythropoietin on interleukin-1 beta and interleukin-6 in patients on maintenance hemodialysis [letter] Sayinalp N, et al. **Clin Nephrol** 1995 Dec;44(6):404

Intravenous iron is effective in treating the anaemia of rheumatoid arthritis and is not associated with flares of synovitis [letter] Cimmino MA, et al. **Clin Rheumatol** 1997 Mar;16(2):215-6

Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin. Jensen JD, et al. **Eur J Clin Pharmacol** 1996; 50(3):171-7

Perioperative use of recombinant human erythropoietin in patients refusing blood transfusions. Pathophysiological considerations based on 5 cases. Wolff M, et al. **Eur J Haematol** 1997 Mar;58(3):154-9

Erythropoietin for inflammatory bowel disease anemia. Sandborn W. **Gastroenterology** 1997 Feb;112(2):660-1

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Kurz Ch, et al. **Gynecol Oncol** 1997 Jun;65(3):461-6

Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Cazzola M, et al. **Haematologica** 1996 Sep-Oct;81(5):434-41

The effects of rHuEPO administration on pulmonary functions in haemodialysis patients. Uçok K, et al. **Int J Artif Organs** 1996 Jun;19(6):336-8

Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study. Teruel JL, et al. **J Am Soc Nephrol** 1996 Jan;7(1):140-4

Another use of androgens: treatment of anemia of end-stage renal disease [letter] Navarro JF. **J Clin Endocrinol Metab** 1997 Sep;82(9):3176

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. Glaspy J, et al. **J Clin Oncol** 1997 Mar; 15(3):1218-34

Fetal proteins and chronic treatment with low-dose erythropoietin [see comments] Bellizzi V, et al. **J Lab Clin Med** 1997 Feb;129(2):193-9. Comment in: J Lab Clin Med 1997 Feb;129(2):174-5.

Autologous blood collection in anemic patients using low-dose erythropoietin therapy. Mott LS, et al. **J Natl Med Assoc** 1997 Jun;89(6):381-4

Erythropoietin treatment in renal anemia. How high should the target hematocrit be? [editorial] Minetti L. **J Nephrol** 1997 May-Jun;10(3):117-9

Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. Mak RH. **J Pediatr** 1996 Jul;129(1):97-104

Renal disease. II. The clinical impact of recombinant human erythropoietin. Muirhead N. **J R Coll Physicians Lond** 1997 Mar-Apr;31(2):125-30 (39 ref.)

Does iron therapy benefit children with severe malaria-associated anaemia? A clinical trial with 12 weeks supplementation of oral iron in young children from the Turiani Division, Tanzania. van den Hombergh J, et al. **J Trop Pediatr** 1996 Aug;42(4):220-7

Subtherapeutic erythropoietin and insulin-like growth factor-1 correct the anemia of chronic renal failure in the mouse. Brox AG, et al. **Kidney Int** 1996 Sep;50(3):937-43

Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure [editorial] Erslev AJ, et al. **Kidney Int** 1997 Mar;51(3):622-30 (93 ref.)

Erythropoietin therapy. Goodnough LT, et al. **N Engl J Med** 1997 Mar 27;336(13):933-8 (56 ref.)

High-dose alfacalcidol improves anaemia in patients on haemodialysis. Albitar S, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):514-8

Recombinant human erythropoietin for anaemia in thalassaemia minor patients on dialysis [letter] Kagan A, et al. **Nephrol Dial Transplant** 1995 Dec;10(12):2375-6

Erythropoietin (r-HuEPO) for the treatment of anaemia in patients with multiple myeloma and end-stage renal failure [letter] Svára F, et al. **Nephrol Dial Transplant** 1995 Dec; 10(12):2374-5

Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Van Loo A, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1815-21

Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease [letter] Boran M, et al. **Nephron** 1996;73(2):314-5

Successful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction. Ishimitsu T, et al. **Nephron** 1996;74(3):607-10

Improvement of anemia and secondary hyperparathyroidism with erythropoietin treatment in hemodialysis patients [letter] Seyrek N, et al. **Nephron** 1996;73(2):338-9

Intravenous immunoglobulins modify the response to erythropoietin in a CAPD patient [letter] al Shohaib S, et al. **Nephron** 1996;73(4):720

Erythropoietin escape in five CAPD patients [letter] Williams P, et al. **Nephron** 1996;73(2):354

Low-dose erythropoietin is effective and safe in children on continuous ambulatory peritoneal dialysis. Yalçinkaya F, et al. **Pediatr Nephrol** 1997 Jun;11(3):350-2

Commentary: cardiomyopathy of anemia and the potential of erythropoietin [editorial; comment] Foley RN, et al. **Perit Dial Int** 1997 Mar-Apr;17(2):117-8. Comment on: Perit Dial Int 1997 Mar-Apr;17(2):129-35.

Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin. Beshara S, et al. **Prostate** 1997 May 15;31(3):153-60

Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis. Nordström D, et al. **Rheumatol Int** 1997;17(2):67-73

Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis. Salvarani C, et al. **Rheumatol Int** 1996;16(2):45-8

Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era. Teruel JL, et al. **Scand J Urol Nephrol** 1996 Oct;30(5):403-8

Effects of androgen therapy on prostatic markers in hemodialyzed patients. Teruel JL, et al. **Scand J Urol Nephrol** 1996 Apr;30(2):129-31

Epoetin alfa as an adjunct to autologous blood donation in patients with a low hematocrit scheduled for elective orthopedic surgery. Adamson J. **Semin Hematol** 1996 Apr; 33(2 Suppl 2):15-6; discussion 17

The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Glaspy J. **Semin Hematol** 1997 Jul;34(3 Suppl 2):20-6

Patient selection and predicting response to recombinant human erythropoietin in anemic cancer patients. Henry DH 3d, et al. **Semin Hematol** 1996 Jan;33(1 Suppl 1):2-5 (17 ref.)

Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia. Mercuriali F. **Semin Hematol** 1997 Apr;33(2 Suppl 2):18-20; discussion 21

Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia. Mercuriali F. **Semin Hematol** 1996 Apr;33(2 Suppl 2):18-20; discussion 21 (9 ref.)

Epoetin alfa plus autologous blood donation in patients with a low hematocrit scheduled to undergo orthopedic surgery. Tryba M. **Semin Hematol** 1996 Apr;33(2 Suppl 2):22-4; discussion 25-6

Use of erythropoietin, active vitamin D3 metabolites, and alkali agents in predialysis patients. Ismail N. **Semin Nephrol** 1997 Jul;17(4):270-84 (112 ref.)

[Anemia in chronic renal failure and erythropoietin] Rosenlöf K. **Duodecim** 1995;111(15):1489-95 (37 ref.) **(Fin)**

[Preliminary results of erythropoietin treatment of anemia in myelodysplastic syndromes and chronic lymphocytic leukemia] Gałęza-Obrępalska B, et al. **Pol Tyg Lek** 1996 May;51(19-22):285-8 (Eng. Abstr.) **(Pol)**

[The pathogenetic use of trace elements in treating anemia] Popova IIu, et al. **Eksp Klin Farmakol** 1996 May-Jun; 59(3):72-7 (102 ref.) **(Rus)**

[Erythropoietin treatment of anemia associated with human immunodeficiency virus infection] Moreno García M.

Med Clin (Barc) 1997 Feb 22;108(7):266–71 (87 ref.) **(Spa)**

[Single weekly dose of recombinant erythropoietin in children with chronic renal insufficiency] Guízar JM, et al. **Rev Invest Clin** 1996 May–Jun;48(3):173–7 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

[Intensity of lipid peroxidation processes and activity of antioxidant enzymes in erythrocytes during anemia in pregnancy] Riazantsev VV, et al. **Ukr Biokhim Zh** 1996 May–Jun;68(3):116–20 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Anemia and the transition of nomadic hunter–gatherers to a sedentary life–style: follow–up study of a Kalahari community. Kent S, et al. **Am J Phys Anthropol** 1996 Mar; 99(3):455–72 (46 ref.)

Seasonality, malaria, and impact of prophylaxis in a West African village I. Effect of anemia in pregnancy. Bouvier P, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):378–83

Risk of Alzheimer's disease among elderly patients with anemia: population–based investigations in Olmsted County, Minnesota. Beard CM, et al. **Ann Epidemiol** 1997 Apr;7(3):219–24

Continuation of decline in prevalence of anemia in low–income children: the Vermont experience. Sherry B, et al. **Arch Pediatr Adolesc Med** 1997 Sep;151(9):928–30

Marked reduction of anemia during pregnancy over a 10–year period in Montserrat. Simmons WK, et al. **Bull Pan Am Health Organ** 1996 Mar;30(1):18–23

Iron, folate and vitamin B12 status of an elderly South African population. Charlton KE, et al. **Eur J Clin Nutr** 1997 Jul;51(7):424–30

The prevalence of anaemia and mineral supplement use in a Swedish middle–aged population. Results from the Malmö Diet and Cancer Study. Elmståhl S, et al. **Eur J Clin Nutr** 1996 Jul;50(7):450–5

Anaemia among 6 year old children in the United Arab Emirates. Musaiger AO, et al. **Eur J Clin Nutr** 1996 Sep; 50(9):636–7

Incidence of anemia in older people: an epidemiologic study in a well defined population. Ania BJ, et al. **J Am Geriatr Soc** 1997 Jul;45(7):825–31

Malaria is an important cause of anaemia in primigravidae: evidence from a district hospital in coastal Kenya. Shulman CE, et al. **Trans R Soc Trop Med Hyg** 1996 Sep–Oct; 90(5):535–9

Asking questions about women's reproductive health: validity and reliability of survey findings from Istanbul. Filippi V, et al. **Trop Med Int Health** 1997 Jan;2(1):47–56

ETHNOLOGY

A comparative study of clinical and sociocultural aspects of anaemia among adolescent girls in rural Ghana. Agyepong IA, et al. **Acta Trop** 1997 May 30;65(3):123–38

Prevalence of anemia in First Nations children of northwestern Ontario. Whalen EA, et al. **Can Fam Physician** 1997 Apr;43:659–64

ETIOLOGY

Primary gastric lymphoma presenting with vitamin B12 deficiency and achlorhydria. Drake WM, et al. **Am J Gastroenterol** 1996 Dec;91(12):2605–6

Microcytic anemia with iron malabsorption [letter; comment] Haurani FI. **Am J Hematol** 1997 Feb;54(2):177. Comment on: Am J Hematol 1996 Apr;51(4):269–75.

Anemia related to ascorbic acid deficiency [letter] Ural AU. **Am J Hematol** 1997 Sep;56(1):69

Iron utilization after iron dextran administration for iron deficiency in patients with dialysis–associated anemia: a prospective analysis and comparison of two agents. Roe DJ, et al. **Am J Kidney Dis** 1996 Dec;28(6):855–60

On fetal intracranial hemorrhage [letter; comment] Rodgers BD. **Am J Obstet Gynecol** 1997 Mar;176(3):731–2. Comment on: Am J Obstet Gynecol 1996 Sep;175(3 Pt 1):536–43.

Intestinal perforation in a patient with severe ankylosing spondylitis. Leitch DN, et al. **Ann Rheum Dis** 1997 Aug; 56(8):458–60

Anemia severity and missed dialysis treatments in erythropoietin–treated hemodialysis patients. Ifudu O, et al. **ASAIO J** 1996 May–Jun;42(3):146–9

Erythroblastopenia associated with methylmalonic aciduria. Case report and in vitro studies. Corazza F, et al. **Biol Neonate** 1996;70(5):304–10

Disseminated BCG infection in severe combined immunodeficiency presenting with severe anaemia and associated with gross hypersplenism after bone marrow transplantation. Skinner R, et al. **Bone Marrow Transplant** 1996 May;17(5):877–80

Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production. Dowlati A, et al. **Br J Haematol** 1997 May;97(2):297–9

Levels of stem cell factor and interleukin–3 in serum in acute Plasmodium falciparum malaria. Burgmann H, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):226–8

Premature removal of uninfected erythrocytes during malarial infection of normal and immunodeficient mice. Salmon MG, et al. **Clin Exp Immunol** 1997 Jun;108(3):471–6

Anaemia in juvenile chronic arthritis. Kirel B, et al. **Clin Rheumatol** 1996 May;15(3):236–41

Anemia following renal transplantation: erythropoietin response and iron deficiency. Miles AM, et al. **Clin Transplant** 1997 Aug;11(4):313–5

Recombinant human erythropoietin in the treatment of cancer–related anaemia. Kasper C, et al. **Eur J Haematol** 1997 Apr;58(4):251–6

Iron therapy resistant microcytic anaemia in a 13–year–old girl with Castleman disease. De Heer–Groen TA, et al. **Eur J Pediatr** 1996 Dec;155(12):1015–7

Erythropoietin for inflammatory bowel disease anemia. Sandborn W. **Gastroenterology** 1997 Feb;112(2):660–1

Anemia of chronic disorders in systemic autoimmune diseases. Bertero MT, et al. **Haematologica** 1997 May–Jun; 82(3):375–81 (87 ref.)

Malaria in pregnancy in Nigerians: seasonality and relationship to splenomegaly and anaemia. Egwunyenga OA, et al. **Indian J Malariol** 1997 Mar;34(1):17–24

Anemias in Thai patients with cirrhosis. Intragumtornchai T, et al. **Int J Hematol** 1997 Jun;65(4):365–73

Another use of androgens: treatment of anemia of end–stage renal disease [letter] Navarro JF. **J Clin Endocrinol Metab** 1997 Sep;82(9):3176

Anemia in infants with congenital hypothyroidism diagnosed by neonatal screening. Franzese A, et al. **J Endocrinol Invest** 1996 Oct;19(9):613–9

Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. Abkowitz JL, et al. **J Infect Dis** 1997 Jul;176(1):269–73

Fetal proteins and chronic treatment with low–dose erythropoietin [see comments] Bellizzi V, et al. **J Lab Clin Med** 1997 Feb;129(2):193–9. Comment in: J Lab Clin Med 1997 Feb;129(2):174–5.

Cardiovascular responses to neuromuscular blockade in the anemic ovine fetus. Shields LE, et al. **J Matern Fetal Med** 1997 Jul–Aug;6(4):195–9

Thrombocytopenic purpura and anemia in a breast–fed infant whose mother was treated with valproic acid. Stahl MM, et al. **J Pediatr** 1997 Jun;130(6):1001–3

Hemodynamic significance of pediatric femur fractures. Lynch JM, et al. **J Pediatr Surg** 1996 Oct;31(10):1358–61

Renal disease. II. The clinical impact of recombinant human erythropoietin. Muirhead N. **J R Coll Physicians Lond** 1997 Mar–Apr;31(2):125–30 (39 ref.)

Anemia and serum protein deficiencies in patients with traumatic spinal cord injury. Lipetz JS, et al. **J Spinal Cord Med** 1997 Jul;20(3):335–40

Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure [editorial] Erslev AJ, et al. **Kidney Int** 1997 Mar;51(3):622–30 (93 ref.)

Erythropoietin production in rats with post–ischemic acute renal failure. Tan CC, et al. **Kidney Int** 1996 Dec; 50(6):1958–64

A man with a prosthetic valve, anaemia, fever, and splenomegaly [see comments] Mouallem M, et al. **Lancet** 1996 Nov 2;348(9036):1216. Comment in: Lancet 1997 Jan 11;349(9045):135–6. Comment in: Lancet 1997 Jan 11;349(9045):136.

Cystic fibrosis and anaemia in infancy [letter; comment] Savaşan S, et al. **Lancet** 1997 Jul 26;350(9073):295. Comment on: Lancet 1997 May 17;349(9063):1452.

Royal Marsden teaching cases. An elderly man with weight loss and anaemia. Durosinmi MA, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):181–3

Case report: severe microcytosis associated with the anemia of chronic disease. LoPresti PJ, et al. **Md Med J** 1996 Sep; 45(9):762–4

Sports anemia and gastrointestinal bleeding in endurance athletes. Mechrefe A, et al. **Med Health R I** 1997 Jul; 80(7):216–8 (7 ref.)

Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Van Loo A, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1815–21

Lipoperoxidation and glutathione–dependent enzymes in uremic anemia of CAPD patients [letter] Galli F, et al. **Nephron** 1997;76(3):363

Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism [letter] Garcia–Canton C, et al. **Nephron** 1996;74(2):444–5

Successful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction. Ishimitsu T, et al. **Nephron** 1996;74(3):607–10

Mechanism underlying early anaemia in children with familial juvenile nephronophthisis. Ala–Mello S, et al. **Pediatr Nephrol** 1996 Oct;10(5):578–81

Chronic anemia as a complication of parvovirus B19 infection in a pediatric kidney transplant patient. Mathias RS. **Pediatr Nephrol** 1997 Jun;11(3):355–7

Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin. Beshara S, et al. **Prostate** 1997 May 15;31(3):153–60

Symptoms and haematologic features in consecutive adult coeliac patients. Bodé S, et al. **Scand J Gastroenterol** 1996 Jan;31(1):54–60

Anaemia in the hospitalised elderly. Sahadevan S, et al. **Singapore Med J** 1995 Aug;36(4):375–8

Anaemia and serum protein alteration in patients with pressure ulcers. Fuoco U, et al. **Spinal Cord** 1997 Jan; 35(1):58–60

Changes in weight gain and anaemia attributable to malaria in Tanzanian children living under holoendemic conditions. Shiff C, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun; 90(3):262–5

Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Cohen BJ, et al. **Transfusion** 1997 Sep;37(9):947–52

Heavy hookworm infestation and severe anaemia in a 4–month–old girl in Jinja Hospital, Uganda. Odiit A. **Trop Doct** 1997 Oct;27(4):245–6

[Anemia In the elderly] Bornand–Rousselot A, et al. **Ann Biol Clin (Paris)** 1997 Jul–Aug;55(4):305–9 (17 ref.) (Eng. Abstr.) **(Fre)**

[Occlusive syndrome and hypersideremic anemia] Algayres JP, et al. **Rev Med Interne** 1997;18 Suppl 3:282s–284s **(Fre)**

[The effect of calcitriol on renal anemia in patients under chronic hemodialysis] Abou–Khalil N, et al. **Orv Hetil** 1996 Jul 7;137(27):1469–72 (Eng. Abstr.) **(Hun)**

[Anemia associated with chronic illness] Bindi M, et al. **Recenti Prog Med** 1997 Jun;88(6):276 **(Ita)**

[Perioperative management of a patient with severe anemia caused by rare Jr (a–) blood] Ehata T, et al. **Masui** 1997 Apr;46(4):525–30 (Eng. Abstr.) **(Jpn)**

[A case of crescentic glomerulonephritis with extensive hematuria resulting in severe anemia] Kodama K, et al. **Nippon Jinzo Gakkai Shi** 1996 Jan;38(1):22–6 (Eng. Abstr.) **(Jpn)**

[Anemia due to chronic lead poisoning] Tanaka K, et al. **Rinsho Ketsueki** 1996 Nov;37(11):1325–7 (Eng. Abstr.) **(Jpn)**

[Hemorrhagic diathesis in a 5–week–old infant with cystic fibrosis] Domagała Z, et al. **Pediatr Pol** 1996 Mar; 71(3):265–7 (Eng. Abstr.) **(Pol)**

[The importance of time intervals between childbirth and anemia in pregnancy] Lazović N, et al. **Srp Arh Celok Lek** 1996 Nov–Dec;124(11–12):307–10 (Eng. Abstr.) **(Scc)**

GENETICS

ABC of clinical haematology. The hereditary anaemias. Weatherall DJ. **BMJ** 1997 Feb 15;314(7079):492–6 (0 ref.)

Hb Seal Rock [(alpha 2)142 term–>Glu, codon 142 TAA–>GAA]: an extended alpha chain variant associated with anemia, microcytosis, and alpha–thalassemia–2 (–3.7 Kb). Merritt D, et al. **Hemoglobin** 1997 Jul;21(4):331–44

Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Fleming MD, et al. **Nat Genet** 1997 Aug;16(4):383–6

HISTORY

Anemia, genetic diseases, and malaria in prehistoric mainland Southeast Asia. Tayles N. **Am J Phys Anthropol** 1996 Sep; 101(1):11–27

IMMUNOLOGY

Increase of fetal hematocrit decreases the middle cerebral artery peak systolic velocity in pregnancies complicated by rhesus alloimmunization. Mari G, et al. **J Matern Fetal Med** 1997 Jul–Aug;6(4):206–8

METABOLISM

The expression of transferrin receptors on erythroblasts in anaemia of chronic disease, myelodysplastic syndromes and iron deficiency. Kuiper–Kramer PA, et al. **Acta Haematol** 1997;97(3):127–31

An alternative quantitative polymerase chain reaction method [published erratum appears in Anal Biochem 1996 Nov 1;242(1):164] Nicoletti A, et al. **Anal Biochem** 1996 May 1;236(2):229–41

Measurement of gastrointestinal intramucosal pH is a poor guide to tolerable levels of anemia during isovolemic hemodilution in a canine model of coronary stenosis. Layland M, et al. **Arch Surg** 1997 May;132(5):547–52

Dietary ascorbic acid raises iron absorption in anaemic rats through enhancing mucosal iron uptake independent of iron solubility in the digesta. Wienk KJ, et al. **Br J Nutr** 1997 Jan;77(1):123–31

Ferritin is not an indicator of available hepatic iron stores in anemia of copper deficiency in rats. Fields M, et al. **Clin Chem** 1997 Aug;43(8 Pt 1):1457–9

Small–dose oral iron absorption test in anaemic and non–anaemic elderly hospitalized patients. Joosten E, et al. **Eur J Haematol** 1997 Feb;58(2):99–103

Regulation of intestinal non–haem iron absorption. Lombard M, et al. **Gut** 1997 Apr;40(4):435–9

CO2 transport in normovolemic anemia: complete compensation and stability of blood CO2 tensions. Deem S, et al. **J Appl Physiol** 1997 Jul;83(1):240–6

Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease. Jongen–Lavrencic M, et al. **J Rheumatol** 1997 Aug; 24(8):1504–9

The diagnosis of iron deficiency in patients with rheumatoid arthritis and anemia: an algorithm using simple laboratory measures [see comments] Mulherin D, et al. **J Rheumatol** 1996 Feb;23(2):237–40. Comment in: J Rheumatol 1997 Apr;24(4):804–5.

Dysregulation of melatonin metabolism in chronic renal

insufficiency: role of erythropoietin-deficiency anemia. Vaziri ND, et al. **Kidney Int** 1996 Aug;50(2):653–6

Ironing out anaemia [news] Vulpe C, et al. **Nat Genet** 1997 Aug;16(4):319–20

Effect of anaemia correction on skeletal muscle metabolism in patients with end-stage renal disease: 31P magnetic resonance spectroscopy assessment. Thompson RT, et al. **Nephron** 1996;73(3):436–41

MORTALITY

Childhood mortality during and after hospitalization in western Kenya: effect of malaria treatment regimens [published erratum appears in Am J Trop Med Hyg 1997 Mar;56(3):358] Zucker JR, et al. **Am J Trop Med Hyg** 1996 Dec;55(6):655–60

[Anemia in elderly patients with malignant tumors] Kikuchi M, et al. **Nippon Ronen Igakkai Zasshi** 1996 Oct; 33(10):768–73 (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

Does iron therapy benefit children with severe malaria-associated anaemia? A clinical trial with 12 weeks supplementation of oral iron in young children from the Turiani Division, Tanzania. van den Hombergh J, et al. **J Trop Pediatr** 1996 Aug;42(4):220–7

Severe malaria in children and transmission intensity [letter] Lines J. **Lancet** 1997 Sep 13;350(9080):813

Seasonal differences and the role of shoe-wearing in western Ethiopia [letter] Adish AA, et al. **Trop Doct** 1996 Oct; 26(4):196–7

PATHOLOGY

Teaching cases from the Royal Marsden and St. Mary's Hospitals case 10 microcytic anaemia and thrombocytosis. Mercieca J, et al. **Leuk Lymphoma** 1996 Mar;21(1-2):185–6; 2 p following 186

Placental ratio--its relationship with mild maternal anaemia. Lao TT, et al. **Placenta** 1997 Sep;18(7):593–6

PHYSIOPATHOLOGY

Unusual anemias [clinical conference] Phatak PD, et al. **Am J Hematol** 1997 Mar;54(3):249–52

Changes in left thoracic duct lymph flow during progressive anemia in the ovine fetus. Davis LE, et al. **Am J Obstet Gynecol** 1996 May;174(5):1469–76

The effects of progressive anemia on jejunal mucosal and serosal tissue oxygenation in pigs. Haisjackl M, et al. **Anesth Analg** 1997 Mar;84(3):538–44

Anaemia is associated with reduced productivity of women workers even in less-physically-strenuous tasks. Scholz BD, et al. **Br J Nutr** 1997 Jan;77(1):47–57

Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Kelleher DK, et al. **Cancer Res** 1996 Oct 15;56(20):4728–34

Haemodynamic changes measured by transthoracic bioimpedance during treatment with recombinant human erythropoietin. Jones MA, et al. **Clin Exp Hypertens** 1996 Jan;18(1):51–64

Hyperdynamic sepsis depresses circulatory compensation to normovolemic anemia in conscious rats. Morisaki H, et al. **J Appl Physiol** 1996 Feb;80(2):656–64

Clinical assessment of autonomic functions in anemics. Lakhotia M, et al. **J Assoc Physicians India** 1996 Aug; 44(8):534–6

Paradoxical effect of cytotoxic chemotherapy on anemia in cancer patients with beta-thalassemia minor [letter] Del Mastro L, et al. **J Natl Cancer Inst** 1997 Mar 19;89(6):455–6

Hematological recovery in Sparus aurata after bleeding. A time course study. Montero D, et al. **Rev Esp Fisiol** 1995 Dec;51(4):219–26

The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Cella D. **Semin Hematol** 1997 Jul;34(3 Suppl 2):13–9

[Influence of anemia on hemodynamic changes in patients with cirrhosis] Denié C, et al. **Gastroenterol Clin Biol** 1997; 21(1):29–33 (Eng. Abstr.) **(Fre)**

[Anemia increases work of breathing in patients with lung disease] Schönhofer B, et al. **Med Klin** 1997 Apr 28;92 Suppl 1:108–10 (Eng. Abstr.) **(Ger)**

[Chronic anemia protects against gastric damage by alcohol and aspirin. The role of the toxic radicals and lipid peroxidation] Marroni NP, et al. **Gastroenterol Hepatol** 1996 Dec;19(10):497–502 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Effective community intervention to improve hemoglobin status in preschoolers receiving once-weekly iron supplementation. Palupi L, et al. **Am J Clin Nutr** 1997 Apr; 65(4):1057–61

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? [letter] Juliusson G. **Am J Hematol** 1996 Sep;53(1):49

Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Vannucchi AM, et al. **Bone Marrow Transplant** 1996 Apr;17(4):527–31

Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Dunphy FR, et al. **Cancer** 1997 Apr 15;79(8):1623–8

The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. Beusterien KM, et al. **J Am Soc Nephrol** 1996 May;7(5):763–73

Effects of recombinant human erythropoietin on porphyrin metabolism in uremic patients on hemodialysis. Fontanellas A, et al. **J Am Soc Nephrol** 1996 May;7(5):774–9

Cost-effective on-site screening for anaemia in pregnancy in primary care clinics. Wilkinson D, et al. **S Afr Med J** 1997 Apr;87(4):463–5

[Immunocorrecting, antianemia, and adaptogenic effects of polysaccharides from Melilotus officinalis] Podkolzin AA, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):661–3 **(Rus)**

[Erythropoietin in the prevention and treatment of anemias (a review of the literature)] Shevchenko IuL, et al. **Voen Med Zh** 1996 Nov;317(11):45–8 (38 ref.) **(Rus)**

PSYCHOLOGY

The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Cella D. **Semin Hematol** 1997 Jul;34(3 Suppl 2):13–9

RADIOGRAPHY

A novel neurological disorder with progressive CNS calcification, deafness, renal tubular acidosis, and microcytic anemia. Yoshimura M, et al. **Dev Med Child Neurol** 1997 Mar;39(3):198–201

THERAPY

Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Portolés J, et al. **Am J Kidney Dis** 1997 Apr;29(4):541–8

Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia [letter] Finkelstein SN, et al. **Ann Pharmacother** 1997 Sep;31(9):1094–5

Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Sheffield R, et al. **Ann Pharmacother** 1997 Jan;31(1):15–22 (58 ref.)

Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial. Peeters HR, et al. **Ann Rheum Dis** 1996 Oct;55(10):739–44

Effects of recombinant human erythropoietin and exercise training on exercise capacity in hemodialysis patients. Akiba T, et al. **Artif Organs** 1995 Dec;19(12):1262–8

Elective surgery in an anaemic Jehovah's Witness. Cooper R, et al. **Br J Hosp Med** 1996 Jul 10-Aug 20;56(2-3):107–8

Clinical needs for hematopoietic growth factors: old and new. Rusthoven JJ. **Cancer Invest** 1996;14(6):622–34 (163 ref.)

Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Kelleher DK, et al. **Cancer Res** 1996 Oct 15;56(20):4728–34

Clinical experience of recombinant human erythropoietin in uremic children: report of three cases. Chuang FR, et al. **Chang Keng I Hsueh** 1996 Mar;19(1):71–6

Use of recombinant human erythropoietin in combination with parenteral iron in the treatment of postpartum anaemia. Breymann C, et al. **Eur J Clin Invest** 1996 Feb; 26(2):123–30

Recombinant human erythropoietin in the treatment of cancer-related anaemia. Kasper C, et al. **Eur J Haematol** 1997 Apr;58(4):251–6

The effect of blood transfusion and haemodilution on cerebral oxygenation and haemodynamics in newborn infants investigated by near infrared spectrophotometry. Liem KD, et al. **Eur J Pediatr** 1997 Apr;156(4):305–10

Effect of blood transfusion on apnoea, bradycardia and hypoxaemia in preterm infants. Poets CF, et al. **Eur J Pediatr** 1997 Apr;156(4):311–6

Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery. Braga M, et al. **Hepatogastroenterology** 1997 May-Jun;44(15):685–90

Optimizing the approach to anemia in the preterm infant: is there a role for erythropoietin therapy? Asch J, et al. **J Perinatol** 1997 Jul-Aug;17(4):276–82

Gene transfer for erythropoiesis enhancement. Naffakh N, et al. **Mol Med Today** 1996 Aug;2(8):343–8 (30 ref.)

Drug-related low responsiveness to recombinant human erythropoietin therapy in three patients with end-stage renal disease [letter] Ikeda Y, et al. **Nephrol Dial Transplant** 1997 Feb;12(2):371–2

Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Taylor JE, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):1079–83

Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism [letter] Garcia-Canton C, et al. **Nephron** 1996;74(2):444–5

Effect of anaemia correction on skeletal muscle metabolism in patients with end-stage renal disease: 31P magnetic resonance spectroscopy assessment. Thompson RT, et al. **Nephron** 1996;73(3):436–41

Hyporesponsiveness to erythropoietin: overview, 1996 [see comments] Nissenson AR. **Perit Dial Int** 1996 Jul-Aug; 16(4):417–20. Comment in: Eur J Surg 1997 Jan-Feb;17(1):99–100.

Hyporesponsiveness to erythropoietin [letter; comment] Tarng DC, et al. **Perit Dial Int** 1997 Jan-Feb;17(1):99–100 . Comment on: Perit Dial Int 1996 Jul-Aug;16(4):417–20.

Renal anaemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischaemic heart disease. Linde T, et al. **Scand J Urol Nephrol** 1996 Apr;30(2):115–20

Transfusion requirements in patients with malignancy. Aledort LM, et al. **Semin Hematol** 1996 Jan;33(1 Suppl 1):6–9

Early changes in hemoglobin and hematocrit levels after packed red cell transfusion in patients with acute anemia. Elizalde JI, et al. **Transfusion** 1997 Jun;37(6):573–6

Human immunodeficiency virus type 1 activation after blood transfusion. Mudido PM, et al. **Transfusion** 1996 Oct; 36(10):860–5

AS-1 red cells for neonatal transfusions: a randomized trial assessing donor exposure and safety. Strauss RG, et al. **Transfusion** 1996 Oct;36(10):873–8

[The effect of acetate-free biofiltration on anemia and use of erythropoietin] Eiselt J, et al. **Cas Lek Cesk** 1996 Aug 21;135(16):525–9 (Eng. Abstr.) **(Cze)**

[Recombinant erythropoietin (r-HuEPO) in the treatment of anemia in multiple myeloma] Spička I, et al. **Cas Lek Cesk** 1996 Jul 14;135(14):450–3 (Eng. Abstr.) **(Cze)**

[Iron supplementation during erythropoietin therapy in patients on hemodialysis] Svára F, et al. **Vnitr Lek** 1996 Dec;42(12):849–52 (Eng. Abstr.) **(Cze)**

[Management of chronic anemia in the adult in tropical zones] Gras C, et al. **Med Trop (Mars)** 1996;56(3):241–3 (0 ref.) **(Fre)**

[Comment on the Mini-Symposium, "Extreme anemia in transfusion refusal" (letter)] Biscoping J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jul; 32(7):470, 472–3 **(Ger)**

[Administration of erythropoietin in extreme anemia] von Bormann B, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):497–8 (18 ref.) **(Ger)**

[A patient who recovered successfully from severe anemia which continued for one hour] Asao Y, et al. **Masui** 1997 May;46(5):700–3 (Eng. Abstr.) **(Jpn)**

[Clinical application of erythropoietin] Bessho M. **Nippon Naika Gakkai Zasshi** 1996 Jun 10;85(6):839–43 (5 ref.) **(Jpn)**

[Application and reality of erythrocyte transfusion] Yasukawa M. **Nippon Naika Gakkai Zasshi** 1996 Jun 10; 85(6):801–5 (3 ref.) **(Jpn)**

[Treatment with erythropoietin (EPO) of the anemia of patients with hematological diseases] Bessho M. **Rinsho Ketsueki** 1997 May;38(5):364–6 (8 ref.) **(Jpn)**

[Erythropoietin improved anemia in a case of multicentric Castleman's disease] Otsubo H, et al. **Rinsho Ketsueki** 1996 Dec;37(12):1425–7 (Eng. Abstr.) **(Jpn)**

[Does erythropoietin treatment influence the lipid status of patients on maintenance hemodialysis?] Król E, et al. **Pol Arch Med Wewn** 1995 Nov;94(5):410–7 (Eng. Abstr.) **(Pol)**

[Treatment of anemia in patients after long term hemodialysis with human recombinant erythropoietin] Boratyńska M, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):329–31 (Eng. Abstr.) **(Pol)**

[Treatment of non-renal anemia with human recombinant erythropoietin (rHU-EPO] Dyjas R, et al. **Przegl Lek** 1996; 53(6):486–90 (50 ref.) (Eng. Abstr.) **(Pol)**

[Clinical and metabolic effects of erythropoietin administration in hemodialyzed children] Dyras P, et al. **Przegl Lek** 1996;53(11):793–6 (Eng. Abstr.) **(Pol)**

[Requirement for blood in hemodialyzed patients with chronic renal failure in the period before and after introduction to erythropoietin (r-HuEPO) treatment] Więcek A, et al. **Przegl Lek** 1996;53(12):866–9 (Eng. Abstr.) **(Pol)**

[Thyroid function in patients with posthemorrhagic anemia against a background of ultraviolet irradiation of the blood] Desiaterik VI, et al. **Klin Khir** 1995;(1):44 **(Rus)**

[Correction of posthemorrhagic syndrome in patients with peptic gastrointestinal hemorrhage] Desiaterik VI. **Klin Khir** 1996;(8):7–8 **(Rus)**

[Treatment of anemia in patients with chronic renal insufficiency with recombinant human erythropoietin] Djukanović Lj, et al. **Srp Arh Celok Lek** 1996 Mar-Apr; 124(3-4):93–7 (Eng. Abstr.) **(Scc)**

[Use of erythropoietin in patients with chronic renal insufficiency and in hemodialysis] Cuero CJ, et al. **Rev Med Panama** 1996 Jan-May;21(1-2):55–9 (Eng. Abstr.) **(Spa)**

VETERINARY

Descriptive epidemiology of marine anemia in seapen-reared salmon in southern British Columbia. Stephen C, et al. **Can Vet J** 1996 Jul;37(7):420–5

Hemoglobin types, erythrocyte membrane skeleton and plasma iron concentration in calves with poikilocytosis. Okabe J, et al. **J Vet Med Sci** 1996 Jul;58(7):629–34

Genomic characterization of the virus causing infectious salmon anemia in Atlantic salmon (Salmo salar L.): an orthomyxo-like virus in a teleost. Mjaaland S, et al. **J Virol** 1997 Oct;71(10):7681–6

Clinical and epidemiological features of simian parvovirus infection in cynomolgus macaques with severe anemia. O'Sullivan MG, et al. **Lab Anim Sci** 1996 Jun;46(3):291–7

ANEMIA

Suspected nutritional deficiency causing anaemia in llamas (Lama glama). Andrews AH, et al. **Vet Rec** 1997 Feb 8; 140(6):153–4

Preliminary study of the effect of iron dextran on a non-regenerative anaemia of housed lambs. Green LE, et al. **Vet Rec** 1997 Mar 1;140(9):219–22

Transient hyperlipidaemia and anaemia in kittens. Gunn-Moore DA, et al. **Vet Rec** 1997 Apr 5;140(14):355–9

Anaemia and low viability in piglets infected with Eperythrozoon suis. Henderson JP, et al. **Vet Rec** 1997 Feb 8;140(6):144–6

VIROLOGY

Parvovirus B19 in anemic liver transplant recipients. Ndimbie OK, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):756–60

Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus. van Elsacker-Neile AM, et al. **Clin Infect Dis** 1996 Dec;23(6):1255–60 (28 ref.)

ANEMIA, ADDISON'S see **ANEMIA, PERNICIOUS**

ANEMIA, APLASTIC

Low drug attributability of aplastic anemia in Thailand. The Aplastic Anemia Study Group. Issaragrisil S, et al. **Blood** 1997 Jun 1;89(11):4034–9

Pregnancy associated aplastic anaemia. Pavithran K, et al. **J Assoc Physicians India** 1996 Apr;44(4):273

[Abnormalities in blood cell production] Kanamaru A. **Rinsho Ketsueki** 1996 Jun;37(6):478–82 (12 ref.) **(Jpn)**

BLOOD

Hypercoagulability and high lipoprotein(a) levels in patients with aplastic anemia receiving cyclosporine. Morishita E, et al. **Blood Coagul Fibrinolysis** 1996 Sep;7(6):609–14

Measurement of endogenous plasma thrombopoietin in patients with acquired aplastic anaemia by a sensitive enzyme-linked immunosorbent assay. Kojima S, et al. **Br J Haematol** 1997 Jun;97(3):538–43

Serum thrombopoietin levels in patients with aplastic anaemia. Marsh JC, et al. **Br J Haematol** 1996 Dec; 95(4):605–10

Membrane changes and metabolic disorders in erythrocytes of patients and rat models with aplastic anemia. Lu Y, et al. **Chin Med J (Engl)** 1996 Jan;109(1):49–51 (14 ref.)

Early hemopoietic progenitors in the peripheral blood of patients with severe aplastic anemia (SAA) after treatment with antilymphocyte globulin (ALG), cyclosporin-A and G-CSF. Bacigalupo A, et al. **Haematologica** 1997 Mar-Apr;82(2):133–7

Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis. Elghetany MT, et al. **Haematologica** 1997 Jan-Feb;82(1):21–4 (27 ref.)

Anti-thymocyte globulin treatment of a patient for paroxysmal nocturnal haemoglobinuria-aplastic anaemia syndrome: complement activation and transient decrease of the PNH clone. Ebenbichler CF, et al. **Immunobiology** 1996–97;196(5):513–21

Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Ichikawa N, et al. **Thromb Haemost** 1996 Aug;76(2):156–60

Suppression of haematopoiesis by sera from patients with aplastic anemia. Liu H, et al. **Tokushima J Exp Med** 1996 Dec;43(3–4):107–11

[Significance of thrombopoietin and its receptor c-Mpl in regulation of thrombocytopoiesis in thrombocytopenia] Strauss G, et al. **Klin Padiatr** 1996 Jul-Aug;208(4):168–71 (Eng. Abstr.) **(Ger)**

[Diagnostic value of hematopoietic stem cells] Gidáli J, et al. **Orv Hetil** 1997 May 11;138(19):1171–6 (47 ref.) (Eng. Abstr.) **(Hun)**

[Serum erythropoietin levels and bone marrow hematopoiesis in patients with aplastic anemia] Ogawa T. **Rinsho Ketsueki** 1996 Jul;37(7):604–9 (Eng. Abstr.) **(Jpn)**

[Use of diffractometry of blood smears in the diagnosis of rheological disorders and assessment of the course of blood system diseases] Tarlykov VA, et al. **Klin Lab Diagn** 1997 Apr;(4):8–11 **(Rus)**

CHEMICALLY INDUCED

Aplastic anemia during treatment with albendazole [letter] Fernández FJ, et al. **Am J Hematol** 1996 Sep;53(1):53–4

Methimazole-induced aplastic anemia? [letter] Bishara J, et al. **Ann Pharmacother** 1996 Jun;30(6):684

Widespread use of topical chloramphenicol [letter] Ursell P. **Br J Ophthalmol** 1996 Sep;80(9):854

Ocular chloramphenicol and aplastic anaemia. Is there a link? Rayner SA, et al. **Drug Saf** 1996 May;14(5):273–6 (27 ref.)

Epidemiology. **Eur J Haematol Suppl** 1996;60:126–7

Drugs in the aetiology of agranulocytosis and aplastic anaemia. Kaufman DW, et al. **Eur J Haematol Suppl** 1996; 60:23–30

Drug use and aplastic anaemia: the French experience. French Cooperative Group for the Epidemiological Study of Aplastic Anaemia. Mary JY, et al. **Eur J Haematol Suppl** 1996;60:35–41

Overview of benzene-induced aplastic anaemia. Smith MT. **Eur J Haematol Suppl** 1996;60:107–10 (48 ref.)

Drug-related blood dyscrasias in a Swedish reporting system, 1985–1994. Wiholm BE, et al. **Eur J Haematol Suppl** 1996; 60:42–6

Drug-related blood dyscrasias. Introduction. Young NS. **Eur J Haematol Suppl** 1996;60:6–8

Felbamate as add-on therapy. Li LM, et al. **Eur Neurol** 1996; 36(3):146–8

Aplastic anemia in a young coke plant worker. Molinini R, et al. **Int Arch Occup Environ Health** 1997;69(2):144–6

CAPRIE trial [letter; comment] Green D. **Lancet** 1997 Feb 1;349(9048):354–5; discussion 356. Comment on: Lancet 1996 Nov 16;348(9038):1329–39.

Agranulocytosis and bone marrow aplasia induced by second-line drugs for rheumatoid arthritis. Treatment with granulocyte colony-stimulating factor [letter; comment] Sayag-Boukris V, et al. **Rev Rhum Engl Ed** 1997 Jan; 64(1):66. Comment on: Rev Rhum Engl Ed 1995 Jul-Sep;62(7–8):477–86.

Methimazole-induced severe aplastic anemia: unsuccessful treatment with recombinant human granulocyte-monocyte colony-stimulating factor. Escobar-Morreale HF, et al. **Thyroid** 1997 Feb;7(1):67–70

[Complete remission of essential thrombocythemia after recovery from severe bone marrow aplasia induced by busulfan treatment] Yamamoto K, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):365–9 (Eng. Abstr.) **(Jpn)**

[Severe aplastic anemia as a complication of treatment with metizol] Swider G, et al. **Wiad Lek** 1996;49(7–12):136–9 (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Ohara A, et al. **Blood** 1997 Aug 1; 90(3):1009–13

PIG-A gene mutations in four Taiwanese patients with paroxysmal nocturnal haemoglobinuria following aplastic anaemia. Lin LI, et al. **Br J Haematol** 1997 May; 97(2):286–92

Retrieval of Silastic catheter fragment from heart in septic thromboembolism complicating aplastic anemia. Dakshinamurti S, et al. **Can J Cardiol** 1996 Sep;12(9):794–6

Could aplastic anaemia be considered a pre-pre-leukaemic disorder? Socié G. **Eur J Haematol Suppl** 1996;60:60–3 (39 ref.)

Aplastic anemia in eosinophilic fasciitis: responses to immunosuppression and marrow transplantation. Kim SW, et al. **Haematologia (Budap)** 1997;28(3):131–7

Association of seropositivity for hepatitis viruses and aplastic anemia in Thailand. Issaragrisil S, et al. **Hepatology** 1997 May;25(5):1255–7

Sequential development of myelodysplasia and paroxysmal nocturnal hemoglobinuria in a patient with preceding aplastic anemia [letter] Nagakura S, et al. **Int J Hematol** 1997 Feb;65(2):187–9

Aplastic anemia complicating Sjögren's syndrome. Matsumoto N, et al. **Intern Med** 1997 May;36(5):371–4

Progressive retinitis-encephalitis due to ganciclovir-resistant cytomegalovirus associated with aplastic anemia. Sasaki T, et al. **Intern Med** 1997 May;36(5):375–9

Trichoderma longibrachiatum infection in a pediatric patient with aplastic anemia. Munoz FM, et al. **J Clin Microbiol** 1997 Feb;35(2):499–503 (24 ref.)

Diagnostic and therapeutic thoracic surgery in leukemia and severe aplastic anemia. Habicht JM, et al. **J Thorac Cardiovasc Surg** 1997 Jun;113(6):982–8

Heterotopic auxiliary liver transplantation in a 3-year-old boy with acute liver failure and aplastic anemia. Roll C, et al. **Transplantation** 1997 Aug 27;64(4):658–60

[Anesthesia for a patient with severe aplastic anemia] Tanaka M, et al. **Masui** 1996 Jul;45(7):865–8 (Eng. Abstr.) **(Jpn)**

[Smoldering leukemia with CD7.CD34(+), immunoglobulin heavy chain rearrangement (+) and hypoplastic marrow with myelofibrosis] Hara T, et al. **Rinsho Ketsueki** 1997 Jan;38(1):21–7 (Eng. Abstr.) **(Jpn)**

[Detection of early cardiac dysfunction in patients with transfusion-dependent aplastic anemia and chronic iron overload in childhood. Stress-velocity relation as a sensitive index by echocardiography] Ohnuma K, et al. **Rinsho Ketsueki** 1996 Sep;37(9):825–32 (Eng. Abstr.) **(Jpn)**

[Acute appendicitis caused by mucorales in a patient with severe aplastic anemia: report of an autopsy case] Sasaki S, et al. **Rinsho Ketsueki** 1996 Feb;37(2):152–7 (Eng. Abstr.) **(Jpn)**

[Transformation of aplastic anemia to acute myeloid leukemia with myelofibrosis following treatment with granulocyte colony-stimulating factor and erythropoietin] Tsurumi H, et al. **Rinsho Ketsueki** 1996 Jul;37(7):630–2 (Eng. Abstr.) **(Jpn)**

[Hemorrhagic and neurological complications in aplastic anemia patients] Bessmel'tsev SS, et al. **Ter Arkh** 1996; 68(2):56–9 (Eng. Abstr.) **(Rus)**

[Spontaneous gas gangrene in a female patient with aplastic anemia] Budianskiĭ VM, et al. **Ter Arkh** 1996;68(2):70–1 (8 ref.) **(Rus)**

CONGENITAL

Analysis of 65 Turkish patients with congenital aplastic anemia (Fanconi anemia and non-Fanconi anemia): Hacettepe experience. Altay C, et al. **Clin Genet** 1997 May; 51(5):296–302

[Aase syndrome] Kondoh T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):232–3 (13 ref.) **(Jpn)**

DIAGNOSIS

Hypoplastic myelodysplasia (MDS) [letter; comment] Geary CG, et al. **Br J Haematol** 1996 Sep;94(3):582–3. Comment on: Br J Haematol 1995 Nov;91(3):612–7.

Hypoplastic anemia associated with ulcerative colitis in a child. Sharma BC, et al. **J Pediatr Gastroenterol Nutr** 1996 Oct;23(3):326–8

[MR imaging of hematopoietic regions in bone marrow of aplastic anemia : diagnostic usefulness of opposed phase T1-weighted images] Amano Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jan;56(1):9–13 (Eng. Abstr.) **(Jpn)**

[MR images of bone marrow in aplastic anemia and correlation between MR findings and age] Amano Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jul; 56(8):546–9 (Eng. Abstr.) **(Jpn)**

[Proton MR spectroscopy of hyperplastic hematopoietic marrow in aplastic anemia] Amano Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Apr; 57(5):253–7 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Liver function abnormality following treatment with antithymocyte globulin for aplastic anaemia. Killick SB, et al. **Bone Marrow Transplant** 1997 Feb;19(3):249–51

Use of hematopoietic growth factors for treatment of aplastic anemia. Kojima S. **Bone Marrow Transplant** 1996 Dec;18 Suppl 3:S36–8 (24 ref.)

Treatment of aplastic anemia in children with high dose methyl prednisolone. Agarwal BR, et al. **Indian Pediatr** 1995 Oct;32(10):1061–5

IFN-gamma in combination with IL-3 accelerates platelet recovery in mice with 5-fluorouracil-induced marrow aplasia. Tsuji-Takayama K, et al. **J Interferon Cytokine Res** 1996 Jun;16(6):447–51

Kaposi's Sarcoma of the intestine in an HIV-negative patient associated with immunosuppressive therapy for severe aplastic anemia [letter] Abhyankar SH, et al. **J Pediatr Hematol Oncol** 1997 Jan-Feb;19(1):86–8

One course versus two courses of antithymocyte globulin for the treatment of severe aplastic anemia in children. Matloub YH, et al. **J Pediatr Hematol Oncol** 1997 Mar-Apr;19(2):110–4

Methimazole-induced severe aplastic anemia: unsuccessful treatment with recombinant human granulocyte-monocyte colony-stimulating factor. Escobar-Morreale HF, et al. **Thyroid** 1997 Feb;7(1):67–70

[Treatment of aplastic anemia with cyclosporine, prednisolone and androgens (primary results apropos of 10 cases] Frikha M, et al. **Therapie** 1996 Nov-Dec; 51(6):627–9 (Eng. Abstr.) **(Fre)**

["Cyclosporin dependence" in the treatment of severe aplastic anemia in children] Bogacheva NIu, et al. **Gematol Transfuziol** 1996 Mar-Apr;41(2):18–21 (Eng. Abstr.) **(Rus)**

[The use of cyclophosphane in the immunodepressive therapy of severe aplastic anemia] Fedorovskaia NA, et al. **Ter Arkh** 1997;69(4):61–4 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Aplastic anemia in the northern region of England [letter] Tweddle DA, et al. **Acta Paediatr** 1996 Nov;85(11):1388–9

Aplastic anemia in rural Thailand: its association with grain farming and agricultural pesticide exposure. Aplastic Anemia Study Group. Issaragrisil S, et al. **Am J Public Health** 1997 Sep;87(9):1551–4

Widespread use of topical chloramphenicol [letter] Ursell P. **Br J Ophthalmol** 1996 Sep;80(9):854

Incidence and non-drug aetiologies of aplastic anaemia in Thailand. The Thai Aplastic Anaemia Study Group. Issaragrisil S, et al. **Eur J Haematol Suppl** 1996;60:31–4

An epidemiological study of aplastic anaemia: relationship of drug exposures to clinical features and outcome. Kelly JP, et al. **Eur J Haematol Suppl** 1996;60:47–52

Use of household pesticides and the risk of aplastic anaemia in Thailand. The Aplastic Anemia Study Group. Kaufman DW, et al. **Int J Epidemiol** 1997 Jun;26(3):643–50

Unusual incidence of aplastic anaemia due to B-19 parvovirus infection in renal transplant recipients. Bertoni E, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):818–9

ETIOLOGY

Aplastic anemia in rural Thailand: its association with grain farming and agricultural pesticide exposure. Aplastic Anemia Study Group. Issaragrisil S, et al. **Am J Public Health** 1997 Sep;87(9):1551–4

Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Keil F, et al. **Blood** 1997 May 1;89(9):3113–7

Lymphocytosis of donor origin in cerebrospinal fluid, and marrow aplasia after donor leukocyte infusion for EBV-lymphoproliferative disease. Gharpure V, et al. **Bone Marrow Transplant** 1996 Jul;18(1):221–4

Hematopoiesis research in aplastic anaemia induced by

accidental protracted radiation. Socié G, et al. **C R Acad Sci III** 1996 Aug;319(8):711–6

Aetiology of severe aplastic anaemia and outcome after allogeneic bone marrow transplantation or immunosuppression therapy. Working Party on Severe Aplastic Anaemia of the European Blood and Marrow Transplantation Group. Bacigalupo A. **Eur J Haematol Suppl** 1996;60:16–9

Aplastic anemia complicating orthotopic liver transplantation. Goss JA, et al. **Hepatology** 1997 Oct; 26(4):865–9

A human T-cell lymphotropic virus type-I carrier with chronic renal failure, aplastic anemia, myelopathy, uveitis, Sjögren's syndrome and panniculitis [see comments] Osato M, et al. **Intern Med** 1996 Sep;35(9):742–5. Comment in: Intern Med 1996 Sep;35(9):677–8.

Anemia of cancer: pathogenesis and treatment with recombinant erythropoietin. Mittelman M. **Isr J Med Sci** 1996 Dec;32(12):1201–6 (54 ref.)

Aplastic anemia due to B19 parvovirus infection in cadaveric renal transplant recipients: an underestimated infectious disease in the immunocompromised host. Bertoni E, et al. **J Nephrol** 1997 May–Jun;10(3):152–6

Hypoplastic anemia associated with ulcerative colitis in a child. Sharma BC, et al. **J Pediatr Gastroenterol Nutr** 1996 Oct;23(3):326–8

Hepatitis-associated aplastic anemia [see comments] Brown KE, et al. **N Engl J Med** 1997 Apr 10;336(15):1059–64. Comment in: N Engl J Med 1997 Aug 7;337(6):424–5.

Hepatitis-associated aplastic anemia [letter; comment] Kiem HP, et al. **N Engl J Med** 1997 Aug 7;337(6):424–5. Comment on: N Engl J Med 1997 Apr 10;336(15):1059–64.

Rapid progression of acquired amegakaryocytic thrombocytopenia to aplastic anemia. King JA, et al. **South Med J** 1997 Jan;90(1):91–4 (18 ref.)

[Immunoblastic lymphadenopathy-like T cell lymphoma associated with erythroid hypoplasia and thrombocytopenia] Shirakawa C, et al. **Rinsho Ketsueki** 1996 Aug;37(8):701–6 (Eng. Abstr.) **(Jpn)**

[The etiology of aplastic anemia] Abdulkadyrov KM, et al. **Lik Sprava** 1995 Sep–Dec;(9–12):16–21 (37 ref.) **(Rus)**

GENETICS

T-cell receptor beta chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia. Manz CY, et al. **Blood Cells Mol Dis** 1997;23(1):110–22

Analysis of c-kit gene integrity in aplastic anemia. Paquette RL, et al. **Blood Cells Mol Dis** 1996;22(2):159–68

Increased frequency of somatic mutations at glycophorin A loci in patients with aplastic anaemia, myelodysplastic syndrome and paroxysmal nocturnal haemoglobinuria. Hattori H, et al. **Br J Haematol** 1997 Aug;98(2):384–91

Analysis of T-cell clonality in bone marrow of patients with acquired aplastic anaemia. Melenhorst JJ, et al. **Br J Haematol** 1997 Jan;96(1):85–91

Differentiation of Fanconi anemia from aplastic anemia by chromosomal breakage test. Hou JW, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1997 Mar–Apr;38(2):121–6

Cytogenetic abnormalities in patients with severe aplastic anemia. Mikhailova N, et al. **Haematologica** 1996 Sep–Oct; 81(5):418–22

X-ray-sensitivity of lymphocytes of aplastic- and Diamond-Blackfan-anemia patients as detected by conventional cytogenetic and chromosome painting techniques. van Diemen PC, et al. **Mutat Res** 1997 Feb 3;373(2):225–35

IMMUNOLOGY

Autoimmunity and its treatment in aplastic anemia [editorial; comment] Young NS. **Ann Intern Med** 1997 Jan 15; 126(2):166–8. Comment on: Ann Intern Med 1997 Jan 15;126(2):107–15. Comment on: Ann Intern Med 1997 Jan 15;126(2):116–22.

Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Nakao S, et al. **Blood** 1997 May 15;89(10):3691–9

Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Huss R, et al. **Bone Marrow Transplant** 1996 Oct;18(4):767–76

Hematopoiesis research in aplastic anaemia induced by accidental protracted radiation. Socié G, et al. **C R Acad Sci III** 1996 Aug;319(8):711–6

Immune pathophysiology of acquired aplastic anaemia. Young NS. **Eur J Haematol Suppl** 1996;60:55–9 (39 ref.)

Immune mechanism of aplastic anemia. Nakao S. **Int J Hematol** 1997 Aug;66(2):127–34 (26 ref.)

Aplastic anemia in a cardiac transplant recipient. Thio K, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1139, 1141–2 (11 ref.)

[Development of deep vein thrombosis in an aplastic anemia patient with antiphospholipid antibodies] Okuda H, et al. **Rinsho Ketsueki** 1996 Nov;37(11):1283–8 (Eng. Abstr.) **(Jpn)**

METABOLISM

Glycosylphosphatidyl-inositol (GPI)-linked protein deficiency on the platelets of patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria: two distinct patterns correlating with expression on neutrophils. Jin JY, et al. **Br J Haematol** 1997 Mar;96(3):493–6

Iron metabolism in transgenic mice with hypoplastic anaemia due to incomplete deficiency of erythropoietin. Raja KB, et al. **Br J Haematol** 1997 Feb;96(2):248–53

MICROBIOLOGY

Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes. Mayer A, et al. **J Virol** 1997 Jun; 71(6):4589–98

PATHOLOGY

Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens [see comments] Orazi A, et al. **Am J Clin Pathol** 1997 Mar; 107(3):268–74. Comment in: Am J Clin Pathol 1997 Mar;107(3):261–4.

Quantitative analysis of cobblestone area-forming cells in bone marrow of patients with aplastic anemia by limiting dilution assay. Schrezenmeier H, et al. **Blood** 1996 Dec 15;88(12):4474–80

Increased apoptotic cells in bone marrow biopsies from patients with aplastic anaemia. Callera F, et al. **Br J Haematol** 1997 Jul;98(1):18–20

Development of minimally differentiated acute myeloblastic leukemia with novel isochromosome 18p and antecedent aplastic anemia. Keung YK, et al. **Cancer Genet Cytogenet** 1996 Nov;92(1):1–3

Long-term bone marrow cultures in aplastic anaemia. Marsh JC. **Eur J Haematol Suppl** 1996;60:75–9 (23 ref.)

Effect of flt3 ligand on in vitro growth and expansion of colony-forming bone marrow cells from patients with aplastic anemia. Wodnar-Filipowicz A, et al. **Exp Hematol** 1997 Jul;25(7):573–81

Proton MR imaging and spectroscopy evaluation of aplastic anemia: three bone marrow patterns. Amano Y, et al. **J Comput Assist Tomogr** 1997 Mar–Apr;21(2):286–92

[Acute leukemia after aplastic anemia in childhood] Pargac N, et al. **Klin Padiatr** 1996 Mar–Apr;208(2):68–72 (Eng. Abstr.) **(Ger)**

[Morphofunctional characteristics of stromal structures of bone marrow in aplastic anemia patients] Abdulkadyrov KM, et al. **Arkh Patol** 1996 Jan–Feb;58(1):25–8 (Eng. Abstr.) **(Rus)**

[Morphological and pathogenetic aspects of aplastic anemia] Abdulkadyrov KM, et al. **Morfologiia** 1995;108(3):58–62 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

A new syndrome of familial aplastic anemia and chronic liver disease. Qazilbash MH, et al. **Acta Haematol** 1997; 97(3):164–7

Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. Maciejewski JP, et al. **Blood** 1997 Feb 15; 89(4):1173–81

Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Wodnar-Filipowicz A, et al. **Blood** 1996 Dec 15;88(12):4493–9

Uncontrolled triggering of programmed cell death (apoptosis) in haematopoietic stem cells: a new hypothesis for the pathogenesis of aplastic anaemia. Laveder F, et al. **Immunol Cell Biol** 1996 Apr;74(2):159–62

The pathophysiology of acquired aplastic anemia. Young NS, et al. **N Engl J Med** 1997 May 8;336(19):1365–72 (72 ref.)

SURGERY

Giving the gift of time. Perrin KO. **Am J Nurs** 1996 Oct; 96(10):88

THERAPY

Treatment of aplastic anemia with antithymocyte globulin, cyclosporin A, methylprednisolone, danazol and recombinant human granulocyte-colony stimulating factor. Shichino H, et al. **Acta Paediatr Jpn** 1996 Dec;38(6):644–7

Allogenic bone marrow transplantation for leukemias and aplastic anemia. Tsai TW, et al. **Adv Intern Med** 1997; 42:423–51 (122 ref.)

Practical aspects in the diagnosis and management of aplastic anemia. Fonseca R, et al. **Am J Med Sci** 1997 Mar; 313(3):159–69 (184 ref.)

Primary transplantation of allogeneic peripheral blood stem cell for severe aplastic anemia. Hsu HC, et al. **Ann Hematol** 1997 Apr;74(4):191–2

Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team [see comments] Doney K, et al. **Ann Intern Med** 1997 Jan 15; 126(2):107–15. Comment in: Ann Intern Med 1997 Jan 15;126(2):166–8.

Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia [see comments] Hinterberger W, et al. **Ann Intern Med** 1997 Jan 15;126(2):116–22. Comment in: Ann Intern Med 1997 Jan 15;126(2):166–8.

Autoimmunity and its treatment in aplastic anemia [editorial; comment] Young NS. **Ann Intern Med** 1997 Jan 15; 126(2):166–8. Comment on: Ann Intern Med 1997 Jan 15;126(2):107–15. Comment on: Ann Intern Med 1997 Jan 15;126(2):116–22.

Antithymocyte immunoglobulin in severe aplastic anemia and bone marrow transplantation. Colby C, et al. **Ann Pharmacother** 1996 Oct;30(10):1164–74 (76 ref.)

Treatment results of 23 cases of severe aplastic anemia with lymphocytapheresis. Morales-Polanco MR, et al. **Arch Med Res** 1997 Spring;28(1):85–90

Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation. Gillio AP, et al. **Biol Blood Marrow Transplant** 1997 Apr;3(1):18–24

Marrow transplantation for hepatitis-associated aplastic anemia: a follow-up of long-term survivors. Kiem HP, et al. **Biol Blood Marrow Transplant** 1996 May;2(2):93–9

Bone marrow transplantation for severe aplastic anemia: has outcome improved? Passweg JR, et al. **Blood** 1997 Jul 15; 90(2):858–64

Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin [letter] Storb R, et al. **Blood** 1997 May 15;89(10):3890–1

Microangiopathy without hemolysis in a patient following allogeneic bone marrow transplantation. Akiyama H, et al. **Bone Marrow Transplant** 1997 Aug;20(3):261–3

Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia. Azuma E, et al. **Bone Marrow Transplant** 1997 Jun; 19(11):1085–7

Study of chimerism in long-term survivors after bone marrow transplantation for severe acquired aplastic anemia. Casado LF, et al. **Bone Marrow Transplant** 1996 Aug; 18(2):405–9

Fatal autoimmune pancytopenia following bone marrow transplantation for aplastic anaemia. De Lord C, et al. **Bone Marrow Transplant** 1996 Jul;18(1):237–9

Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors. Hamblin M, et al. **Bone Marrow Transplant** 1996 May;17(5):819–24

Renal Salmonella enteritidis abscess in a patient with severe aplastic anemia after allogeneic stem cell transplantation. Hashino S, et al. **Bone Marrow Transplant** 1996 Oct; 18(4):807–8

Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Huss R, et al. **Bone Marrow Transplant** 1996 Oct;18(4):767–76

Pancreatitis following allogeneic bone marrow transplantation in a patient with aplastic anemia [letter] Ikushima S, et al. **Bone Marrow Transplant** 1996 Aug; 18(2):485–6

What is the most effective treatment of children with severe aplastic anemia who lack a matched sibling donor? Johnson FL. **Bone Marrow Transplant** 1996 Dec;18 Suppl 3:S39–44 (66 ref.)

Bone marrow 'boosts' following T cell-depleted haploidentical bone marrow transplantation. Kline RM, et al. **Bone Marrow Transplant** 1996 Apr;17(4):543–8

BMT from unrelated (UD) or family donors other than HLA identical siblings (FDNS), GVHD prophylaxis, incidence and treatment. Ladenstein R, et al. **Bone Marrow Transplant** 1996 Nov;18 Suppl 2:86–91

Rejection of the second allogeneic graft in a patient with severe aplastic anemia reversed by antilymphocyte globulin and donor lymphocyte infusions. Ljungman P, et al. **Bone Marrow Transplant** 1996 Dec;18(6):1179–81

In vivo CAMPATH-1 followed by T cell-depleted bone marrow transplantation: a potential new mode of therapy for hepatitis-associated severe aplastic anemia (SAA). Nagler A, et al. **Bone Marrow Transplant** 1996 Aug; 18(2):475–8

Successful engraftment after primary graft failure in aplastic anemia using G-CSF mobilized peripheral stem cell transfusions. Redei I, et al. **Bone Marrow Transplant** 1997 Jan;19(2):175–7

Excellent long-term survival after allogeneic marrow transplantation in patients with severe aplastic anemia. Reiter E, et al. **Bone Marrow Transplant** 1997 Jun; 19(12):1191–6

Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome. Rubin CM, et al. **Bone Marrow Transplant** 1996 Sep;18(3):533–40

Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. Trede NS, et al. **Bone Marrow Transplant** 1997 Aug;20(3):257–60

CY/TBI-800 as a pretransplant regimen for allogeneic bone marrow transplantation for severe aplastic anemia using HLA-haploidentical family donors. Tzeng CH, et al. **Bone Marrow Transplant** 1996 Aug;18(2):273–7

Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow

transplantation. Yabe M, et al. **Bone Marrow Transplant** 1997 Feb;19(4):389–92

Treatment of dyskeratosis congenita with granulocyte colony-stimulating factor and erythropoietin. Alter BP, et al. **Br J Haematol** 1997 May;97(2):309–11

Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. Davies SM, et al. **Br J Haematol** 1997 Mar;96(4):749–56

Myelodysplasia following aplastic anaemia–paroxysmal nocturnal haemoglobinuria syndrome after treatment with immunosuppression and G-CSF: evidence for the emergence of a separate clone. Jin JY, et al. **Br J Haematol** 1996 Sep;94(3):510–2

Pilot study of HLA alloimmunization after transfusion with pre-storage leucodepleted blood products in aplastic anaemia. Killick SB, et al. **Br J Haematol** 1997 Jun; 97(3):677–84

Hepatitis GB virus C genome in the serum of aplastic anaemia patients receiving frequent blood transfusions [see comments] Moriyama K, et al. **Br J Haematol** 1997 Mar; 96(4):864–7. Comment in: Br J Haematol 1997 Aug;98(2):495.

Mechanism of action of antithymocyte globulin in the treatment of aplastic anaemia: in vitro evidence for the presence of immunosuppressive mechanism. Teramura M, et al. **Br J Haematol** 1997 Jan;96(1):80–4

Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group. Bessho M, et al. **Eur J Haematol** 1997 Apr;58(4):265–72

The role of second bone marrow transplant using a different donor for relapsed leukemia or graft failure [letter] Lipton JH, et al. **Eur J Haematol** 1997 Feb;58(2):133–6 (27 ref.)

Combined treatment with amphotericin-B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation. Catalano L, et al. **Haematologica** 1997 Jan–Feb;82(1):71–2

Successful bone marrow transplantation in sensitized aplastic anemia patients using total lymphoid irradiation for conditioning: long-term follow-up. Zapatero A, et al. **Hematol Oncol** 1996 Dec;14(4):165–72

Anti-thymocyte globulin treatment of a patient for paroxysmal nocturnal haemoglobinuria–aplastic anaemia syndrome: complement activation and transient decrease of the PNH clone. Ebenbichler CF, et al. **Immunobiology** 1996–97;196(5):513–21

Delivery after bone marrow transplantation with total lymphoid irradiation for severe aplastic anemia. Ashida T, et al. **Int J Hematol** 1996 Oct;64(3–4):279–81 (14 ref.)

Anemia of cancer: pathogenesis and treatment with recombinant erythropoietin. Mittelman M. **Isr J Med Sci** 1996 Dec;32(12):1201–6 (54 ref.)

Allogeneic peripheral blood stem cell transfusion from human leukocyte antigen–mismatched sibling for the treatment of engraftment failure after bone marrow transplantation for severe aplastic anemia. Takamatsu Y, et al. **J Clin Apheresis** 1997;12(2):100–2

Immunosuppressive therapy: a potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood? Lawlor ER, et al. **J Pediatr Hematol Oncol** 1997 Mar–Apr;19(2):115–23

Hematopoietic stem cell transplantation in nonmalignant diseases. Storb R. **J Rheumatol Suppl** 1997 May;48:30–5 (29 ref.)

A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood. Ladenstein R, et al. **Klin Padiatr** 1997 Jul–Aug;209(4):201–8

[Clinical observation on child aplastic anemia treated with integrated Chinese and Western medicine] Zhang ZM, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Dec; 15(12):713–5 (Eng. Abstr.) **(Chi)**

[Transplantation of hematopoietic stem cells] Hertenstein B, et al. **Internist (Berl)** 1996 Mar;37(3):295–303 (41 ref.) **(Ger)**

[Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis] Spraul CW, et al. **Klin Monatsbl Augenheilkd** 1996 Jul;209(1):31–6 (Eng. Abstr.) **(Ger)**

[Late effects of treatment with recombinant human granulocyte colony-stimulating factor in patients with aplastic anemia] Kojima S. **Rinsho Ketsueki** 1997 May; 38(5):371–4 (15 ref.) **(Jpn)**

[Sudden cardiac tamponade due to hemorrhagic myocarditis after preconditioning marrow transplantation with cyclophosphamide in a patient with aplastic anemia] Miura Y, et al. **Rinsho Ketsueki** 1997 Jun;38(6):526–31 (Eng. Abstr.) **(Jpn)**

[Aplastic anemia. Alternative treatment by bone marrow transplantation] Fonseca T, et al. **Acta Med Port** 1997 Jan; 10(1):99–102 (8 ref.) (Eng. Abstr.) **(Por)**

VETERINARY

[Cyclosporin A in aplastic anemia in dogs: first results] Barth T, et al. **Berl Munch Tierarztl Wochenschr** 1997 Feb; 110(2):60–7 (Eng. Abstr.) **(Ger)**

VIROLOGY

Prevalence of hepatitis G virus in patients with aplastic anemia [letter] Kiem HP, et al. **Blood** 1997 Aug 1; 90(3):1335–6

Prevalence of GBV-C/HGV, a novel 'hepatitis' virus, in patients with aplastic anaemia. Brown KE, et al. **Br J Haematol** 1997 May;97(2):492–6

Hepatitis GBV-C and aplastic anaemia [letter; comment] Harrison P, et al. **Br J Haematol** 1997 Aug;98(2):495. Comment on: Br J Haematol 1997 Mar;96(4):864–7.

Transient aplastic anemia caused by parvovirus B19 infection in a heart transplant recipient. Bergen GA, et al. **J Heart Lung Transplant** 1996 Aug;15(8):843–5

GBV-C/HGV infection and aplastic anaemia [letter; comment] Kao JH, et al. **Lancet** 1996 Oct 12; 348(9033):1032–3. Comment on: Lancet 1996 Aug 17;348(9025):471–2. Comment on: Lancet 1996 Aug 17;348(9025):472.

Pure red cell aplasia caused by B19 parvovirus infection after autologous blood stem cell transplantation in a patient with chronic lymphocytic leukemia [letter] Itälä M, et al. **Leukemia** 1997 Jan;11(1):171

Life-threatening anaemia caused by B19 parvovirus infection in a non-immunocompromised patient. Biesma DH, et al. **Neth J Med** 1997 Feb;50(2):81–4

Parvoviruses and bone marrow failure. Brown KE, et al. **Stem Cells** 1996 Mar;14(2):151–63 (95 ref.)

[Bone marrow aplasia and hepatitis G virus: what relation? (letter)] Lellouche F, et al. **Presse Med** 1997 Jan 18–25; 26(1):16 **(Fre)**

ANEMIA, COOLEY'S see **BETA-THALASSEMIA**

ANEMIA, DIAMOND-BLACKFAN see **FANCONI'S ANEMIA**

ANEMIA, DYSERYTHROPOIETIC, CONGENITAL

[Congenital dyserythropoietic anemia type III. A case report] Holm T, et al. **Tidsskr Nor Laegeforen** 1997 May 20; 117(13):1898–9 (Eng. Abstr.) **(Nor)**

COMPLICATIONS

Successful treatment of iron overload by phlebotomies in a patient with severe congenital dyserythropoietic anemia type II [letter] Hofmann WK, et al. **Blood** 1997 Apr 15; 89(8):3068–9

A severe transfusion-dependent congenital dyserythropoietic anaemia presenting as hydrops fetalis. Cantù-Rajnoldi A, et al. **Br J Haematol** 1997 Mar;96(3):530–3

[Restrictive cardiac involvement in a patient with dyserythropoietic anemia and secondary hemochromatosis] Barriales Alvarez V, et al. **Rev Esp Cardiol** 1996 Aug; 49(8):618–20 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Congenital dyserythropoietic anaemia: report of three cases. Ariffin WA, et al. **J Paediatr Child Health** 1996 Apr; 32(2):191– 3

Neonatal manifestations of congenital dyserythropoietic anemia type I. Shalev H, et al. **J Pediatr** 1997 Jul;131(1 Pt 1):95–7

ENZYMOLOGY

Alpha-mannosidase-II deficiency results in dyserythropoiesis and unveils an alternate pathway in oligosaccharide biosynthesis. Chui D, et al. **Cell** 1997 Jul 11;90(1):157–67

GENETICS

Non-haematological traits associated with congenital dyserythropoietic anaemia type 1: a new entity emerging. Sabry MA, et al. **Clin Dysmorphol** 1997 Jul;6(3):205–12

Congenital dyserythropoietic anemia type II: molecular basis and clinical aspects. Iolascon A, et al. **Haematologica** 1996 Nov–Dec;81(6):543–59 (86 ref.)

METABOLISM

Reduced interferon-alpha production by Epstein-Barr virus transformed B-lymphoblastoid cell lines and lectin-stimulated lymphocytes in congenital dyserythropoietic anaemia type I. Wickramasinghe SN, et al. **Br J Haematol** 1997 Aug;98(2):295–8

THERAPY

Congenital dyserythropoiesis type I and alpha-interferon therapy [letter; comment] Virjee S, et al. **Br J Haematol** 1996 Sep;94(3):581–2. Comment on: Br J Haematol 1995 Apr;89(4):929–32.

Response of CDA type I to alpha-interferon [letter] Wickramasinghe SN. **Eur J Haematol** 1997 Feb;58(2):121–3

ANEMIA, ERYTHROBLASTIC see **BETA-THALASSEMIA**

ANEMIA, FANCONI see **FANCONI'S ANEMIA**

ANEMIA, HEMOLYTIC

Severe anemia due to Kell alloimmunization. Giannacopoulou CH, et al. **Haematologia (Budap)** 1997; 28(3):173–5

Zieve's syndrome a potential surgical pitfall? Pilcher CR, et al. **J R Army Med Corps** 1996 Jun;142(2):84

BLOOD

Magnesium and iron contents of leukemic lymphocytes in acute leukemias and hemolytic anemia. Rzymowska J. **Biol Trace Elem Res** 1996 Summer;53(1–3):235–9

Abnormal erythrocyte endothelial adherence in hereditary stomatocytosis. Smith BD, et al. **Blood** 1997 May 1; 89(9):3451–6

The role of the oxidative state of glutathione and glutathione-related enzymes in anemia of hemodialysis patients. Paşaoğlu H, et al. **Clin Biochem** 1996 Dec; 29(6):567–72

Severe anemia due to Kell alloimmunization. Giannacopoulou CH, et al. **Haematologia (Budap)** 1997; 28(3):173–5

Erythropoietin response is blunted in critically ill patients [see comments] Rogiers P, et al. **Intensive Care Med** 1997 Feb;23(2):159–62. Comment in: Intensive Care Med 1997 Feb;23(2):137–8.

Experimental Babesia microti infection in golden hamsters: immunoglobulin G response and recovery from severe hemolytic anemia. Hu R, et al. **J Parasitol** 1996 Oct; 82(5):728–32

A family with chronic haemolysis and selective accumulation of erythrocyte CDP-choline [letter] Petersen A, et al. **Leukemia** 1997 Aug;11(8):1373–6

Targeted disruption of the murine erythroid band 3 gene results in spherocytosis and severe haemolytic anaemia despite a normal membrane skeleton. Southgate CD, et al. **Nat Genet** 1996 Oct;14(2):227–30

Liver alcoholic cirrhosis and spur-cell (acanthocytic) anaemia. A study of erythrocyte ghost composition and fluidity. Arienti G, et al. **Scand J Gastroenterol** 1995 Dec; 30(12):1204–9

[Study of auto-rosette formation in circulating blood] Belchenko DI. **Klin Lab Diagn** 1993 May–Jun;(3):58–62 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Cocaine-induced microangiopathic hemolytic anemia and thrombocytopenia simulating thrombotic thrombocytopenia purpura [letter] Keung YK, et al. **Ann Hematol** 1996 Mar;72(3):155–6

Diclofenac-induced immune haemolytic anaemia: simultaneous occurrence of red blood cell autoantibodies and drug-dependent antibodies. Salama A, et al. **Br J Haematol** 1996 Dec;95(4):640–4

Severe reversible reticulocytopenic anemia associated with quinupristin/dalfopristin RP59500 therapy. Launay O, et al. **Clin Infect Dis** 1997 Jul;25(1):156

A possible mechanism of heinz body hemolytic anemia induced by DQ-2511, a new gastroprokinetic drug, in dogs. Ohno H, et al. **Fundam Appl Toxicol** 1996 Aug;32(2):269–77

Follow-up study on 24 patients with nomifensine-induced immune haemolytic anaemia. Giers G, et al. **Transfus Med** 1991 Jun;1(2):115–9

[Drug induced hemolytic anemia associated with agranulocytosis] Satoh S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Oct; 19(5):498–504 (Eng. Abstr.) **(Jpn)**

[Drug-induced hemolytic anemia] Miura A. **Nippon Rinsho** 1996 Sep;54(9):2534–8 (5 ref.) (Eng. Abstr.) **(Jpn)**

[A case of hemolysis induced by lansoprazole] Suzuki T, et al. **Rinsho Ketsueki** 1996 Dec;37(12):1389–94 (Eng. Abstr.) **(Jpn)**

[Hemolytic anemia and thrombocytopenia induced by cimetidine: recurrence with ranitidine administration] Takimoto R, et al. **Rinsho Ketsueki** 1997 Feb;38(2):124–8 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

[Classification and diagnosis of hemolytic anemias] Muto Y. **Nippon Rinsho** 1996 Sep;54(9):2402–6 (6 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Extramammary Paget's disease associated with autoimmune hemolytic anemia [letter] Okuyama R, et al. **Acta Derm Venereol** 1997 May;77(3):241

Hereditary spastic paraplegia and Evans's syndrome. Ahmed FE, et al. **Acta Paediatr** 1996 Jul;85(7):879–81

Bilirubinuria, conjugated hyperbilirubinaemia and delta bilirubinaemia following acute haemolysis. Cummins D, et al. **Ann Clin Biochem** 1997 Jan;34 (Pt 1):109–10

Post-splenectomy thrombosis and haemolytic anaemias [letter; comment] Kemahli S, et al. **Br J Haematol** 1997 May;97(2):505. Comment on: Br J Haematol 1996 May;93(2):303–10.

Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans' syndrome. Cervera H, et al. **J Rheumatol** 1995 Oct;22(10):1867–71

A case report of simultaneous surgery for Wolff-Parkinson-White syndrome combined with hemolytic anemia and mitral stenosis. Ikeshita M, et al. **Jpn Circ J** 1996 Mar;60(3):171–6

Human/mouse radiation chimera generated from PBMC of B chronic lymphocytic leukemia patients with autoimmune

hemolytic anemia produce anti-human red cell antibodies. Marcus H, et al. **Leukemia** 1997 May;11(5):687-93

[Acute pancreatitis and Zieve syndrome: an uncommon association] Klisnick A, et al. **Ann Med Interne (Paris)** 1997; 148(3):292-3 **(Fre)**

CONGENITAL see ANEMIA, HEMOLYTIC, CONGENITAL

DIAGNOSIS

Pseudohyperkalaemia, pseudohyponatraemia and pseudohypoglycaemia in a patient with hereditary stomatocytosis. Kilpatrick ES, et al. **Ann Clin Biochem** 1997 Sep;34 (Pt 5):561-3

Cocaine-induced microangiopathic hemolytic anemia and thrombocytopenia simulating thrombotic thrombocytopenia purpura [letter] Keung YK, et al. **Ann Hematol** 1996 Mar;72(3):155-6

Wilson's disease presenting as haemolytic anaemia and its successful treatment with penicillamine and zinc. Kong HL, et al. **Singapore Med J** 1996 Dec;37(6):670-2

[Clinical investigation of hemolytic anemia] Hamasaki N. **Nippon Rinsho** 1996 Sep;54(9):2407-10 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Classification and diagnosis of hemolytic anemias] Muto Y. **Nippon Rinsho** 1996 Sep;54(9):2402-6 (6 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Autoimmune haemolytic anaemia responding to anti-tuberculous treatment. Siribaddana SH, et al. **Trop Doct** 1997 Oct;27(4):243-4

ENZYMOLOGY

Clinical, genetic, and biochemical features of G-6PD(West Virginia). Corey SJ, et al. **Am J Hematol** 1996 Sep; 53(1):35-6

Glucose phosphate isomerase deficiency: biochemical and molecular genetic studies on the enzyme variants of two patients with severe haemolytic anaemia. Huppke P, et al. **Eur J Pediatr** 1997 Aug;156(8):605-9

EPIDEMIOLOGY

Severe ABO hemolytic disease of newborn is infrequent among Hong Kong Chinese [letter] Wong HF, et al. **Vox Sang** 1996;70(1):45

ETIOLOGY

Delayed hemolytic transfusion reaction due to anti-Go(a), an antibody against the low-prevalence Gonzales antigen. Larson PJ, et al. **Am J Hematol** 1996 Dec;53(4):248-50

Hemolytic anemia precipitated by pregnancy in a patient with hereditary elliptocytosis [letter] Pajor A, et al. **Am J Hematol** 1996 Jul;52(3):240-1

Hemolysis due to the simultaneous occurrence of passenger lymphocyte syndrome and a delayed hemolytic transfusion reaction in a liver transplant patient. Jacobs LB, et al. **Arch Pathol Lab Med** 1996 Jul;120(7):684-6

Spur cell anaemia resolves after orthotopic liver transplantation (OLT) [letter] Thomson A, et al. **Aust N Z J Med** 1997 Apr;27(2):198-9

De novo chronic graft-versus-host disease presenting as hemolytic anemia following partially mismatched related donor bone marrow transplant. Godder K, et al. **Bone Marrow Transplant** 1997 Apr;19(8):813-7

Gastric adenocarcinoma with microangiopathic hemolytic anemia and disseminated intravascular coagulation: a case report. Jiang CF, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Mar;59(3):204-9

Prospective evaluation of haematological alterations following the transjugular intrahepatic portosystemic stent-shunt (TIPSS). Jalan R, et al. **Eur J Gastroenterol Hepatol** 1996 Apr;8(4):381-5

Relation of haemolytic anaemia and erythrocyte-bound IgG in alpha- and beta-thalassaemic syndromes. Chinprasertsuk S, et al. **Eur J Haematol** 1997 Feb;58(2):86-91

Combined use of detachable coil against persistent mechanical hemolysis after transcatheter occlusion using Rashkind umbrella device in adult patient with patent ductus arteriosus. Murakami H, et al. **Heart Vessels** 1997; 12(1):49-51

Transient hemolytic anemia after transjugular intrahepatic portosystemic stent shunt. Garcia-Rebollo S, et al. **HPB Surg** 1996;9(4):249-51

Unstable hemoglobin as a cause of congenital hemolytic anemia. Singh R, et al. **Indian Pediatr** 1996 Jul;33(7):587-9

Pulmonary veno-occlusive disease accompanied by microangiopathic hemolytic anemia 1 year after a second bone marrow transplantation for acute lymphoblastic leukemia. Kuga T, et al. **Int J Hematol** 1996 Aug; 64(2):143-50

Anemia of critical illness and erythropoietin deficiency [editorial; comment] Krafte-Jacobs B. **Intensive Care Med** 1997 Feb;23(2):137-8. Comment on: Intensive Care Med 1997 Feb;23(2):159-62.

Hemolytic anemia associated with myotonic muscular dystrophy. Komeno T, et al. **Intern Med** 1996 Sep; 35(9):746-8

Hyperreactive malarial syndrome. Ackerman L. **J Am Board Fam Pract** 1996 Sep-Oct;9(5):356-9 (12 ref.)

Malignancy-associated microangiopathic hemolytic anemia. Schiller D. **J Clin Oncol** 1997 Jun;15(6):2474-5

Hemolytic anemia provoked by recombinant alpha-interferon. Takase K, et al. **J Gastroenterol** 1995 Dec; 30(6):795-7

Severe hemolysis due to artificial chordae displacement. Kihara S, et al. **J Heart Valve Dis** 1997 Jan;6(1):69-70

Lipid peroxidation of erythrocytes in visceral leishmaniasis. Biswas T, et al. **J Parasitol** 1997 Feb;83(1):151-2

Blood glucose normalization-induced haemolysis in three adolescents with type 1 diabetes mellitus at onset and unknown G-6-PD deficiency. Vanelli M, et al. **J Pediatr Endocrinol Metab** 1996 Mar-Apr;9(2):193-6

Failure of partial splenectomy to ameliorate the anemia of pyruvate kinase deficiency. Sandoval C, et al. **J Pediatr Surg** 1997 Apr;32(4):641-2

Intravascular haemolysis after aluminium phosphide ingestion. Sood AK, et al. **J R Soc Med** 1997 Jan;90(1):47-8

Massive hemolysis: a rare complication of transcatheter coil embolization. Duszak R Jr, et al. **J Vasc Interv Radiol** 1996 Jul-Aug;7(4):603-6

Hemolytic anemia associated with intravenous immunoglobulin. Wilson JR, et al. **Muscle Nerve** 1997 Sep; 20(9):1142-5

Acute pancreatitis in a CAPD patient in association with hemolytic anemia [letter] Ubara Y, et al. **Perit Dial Int** 1997 Jan-Feb;17(1):96-8

Liver alcoholic cirrhosis and spur-cell (acanthocytic) anaemia. A study of erythrocyte ghost composition and fluidity. Arienti G, et al. **Scand J Gastroenterol** 1995 Dec; 30(12):1204-9

Rhabdomyolysis and hemolysis associated with sickle cell trait and glucose-6-phosphate dehydrogenase deficiency. Kimmick G, et al. **South Med J** 1996 Nov;89(11):1097-8

Successful management of hemolysis in ABO-nonidentical orthotopic liver transplantation by steroid therapy: a case report. Auwerda JJ, et al. **Transpl Int** 1996;9(5):509-12

Severe hemolytic anemia due to anti-E after renal transplantation [letter] Larrea L, et al. **Transplantation** 1997 Aug 15;64(3):550-1

[Anemia, abdominal pain and fatigue--lead can still be found] Laine O, et al. **Duodecim** 1995;111(12):1107-10 **(Fin)**

[Hemolytic anemia disclosing lead poisoning (letter)] Grosieux C, et al. **Ann Med Interne (Paris)** 1996; 147(7):515-6 **(Fre)**

[Sarcoidosis with hematologic involvement and hypogammaglobulinemia] Bader-Meunier B, et al. **Arch Pediatr** 1996 Jun;3(6):576-9 (Eng. Abstr.) **(Fre)**

[Hepatic involvement and hemolytic anemia disclosing adult onset Still disease (letter)] Dohin-Caplanne S, et al. **Rev Med Interne** 1997;18(4):339-40 **(Fre)**

[Microangiopathic hemolytic anemia associated with uterine sarcoma: report of a case. Review of the literature] Tsatsaris V, et al. **Rev Med Interne** 1996;17(9):749-53 (23 ref.) (Eng. Abstr.) **(Fre)**

[Hemolytic anemia as cause of a marked bilirubin increase in primary biliary cirrhosis] Mahl MA, et al. **Dtsch Med Wochenschr** 1996 Oct 4;121(40):1226-8 (Eng. Abstr.) **(Ger)**

[Acute hemolytic crisis as the initial manifestation of Wilson disease] Rath HC, et al. **Z Gastroenterol** 1997 Mar; 35(3):199-203 (Eng. Abstr.) **(Ger)**

[Hemolysis and multiple trauma. A clinical case report] Buzio M, et al. **Minerva Chir** 1997 Apr;52(4):485-7 (10 ref.) (Eng. Abstr.) **(Ita)**

[Serratia marcescens prosthetic mitral valve endocarditis associated with hemolytic anemia] Kochi K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):860-4 (Eng. Abstr.) **(Jpn)**

[Case of direct Coombs-test-positive hemolytic anemia with bleeding tendency due to prominent low activity of factor V] Miyachi K, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1934-7 **(Jpn)**

[Hemolytic anemias observed in SLE] Ichikawa Y, et al. **Nippon Rinsho** 1996 Sep;54(9):2528-33 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Hemolytic anemia in association with viral hepatitis] Kanematsu T, et al. **Nippon Rinsho** 1996 Sep;54(9):2539-44 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Rapid onset of hemolytic anemia after allogeneic bone marrow transplantation from an unrelated ABO major mismatched donor] Watanabe H, et al. **Rinsho Ketsueki** 1997 Jan;38(1):14-20 (Eng. Abstr.) **(Jpn)**

[Microangiopathic anemia and leukoerythroblastic reaction associated with a pulmonary adenocarcinoma (letter)] Calvo Villas JM, et al. **An Med Interna** 1996 Jul;13(7):356-7 (Eng. Abstr.) **(Spa)**

[Microangiopathic hemolytic anemia associated with acute brucellosis (letter)] Calvo Villas JM, et al. **Med Clin (Barc)** 1997 Jul 5;109(6):236 **(Spa)**

GENETICS

Molecular analysis of 29 pyruvate kinase-deficient patients from central Europe with hereditary hemolytic anemia. Lenzner C, et al. **Blood** 1997 Mar 1;89(5):1793-9

Interaction of hemoglobin E and pyrimidine 5' nucleotidase deficiency. Rees DC, et al. **Blood** 1996 Oct 1;88(7):2761-7

Abnormal erythrocyte endothelial adherence in hereditary stomatocytosis. Smith BD, et al. **Blood** 1997 May 1; 89(9):3451-6

Hematologically important mutations: red cell pyruvate kinase. Baronciani L, et al. **Blood Cells Mol Dis** 1996; 22(1):85-9

Familial relapsing thrombotic micro-angiopathy in two siblings. Hazani A, et al. **Eur J Pediatr** 1996 Feb; 155(2):99-101

Missense mutations in the human glutathione synthetase gene result in severe metabolic acidosis, 5-oxoprolinuria, hemolytic anemia and neurological dysfunction. Dahl N, et al. **Hum Mol Genet** 1997 Jul;6(7):1147-52

IMMUNOLOGY

Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. Sylvestre D, et al. **J Exp Med** 1996 Dec 1;184(6):2385-92

Female alloimmunization with antibodies known to cause hemolytic disease. Geifman-Holtzman O, et al. **Obstet Gynecol** 1997 Feb;89(2):272-5 (18 ref.)

METABOLISM

Pseudohyperkalaemia, pseudohyponatraemia and pseudohypoglycaemia in a patient with hereditary stomatocytosis. Kilpatrick ES, et al. **Ann Clin Biochem** 1997 Sep;34 (Pt 5):561-3

PATHOLOGY

Malignancy-associated microangiopathic hemolytic anemia. Schiller D. **J Clin Oncol** 1997 Jun;15(6):2474-5

Microangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension. Suzuki H, et al. **Tohoku J Exp Med** 1997 Mar;181(3):379-84

[Cytoskeleton of erythrocyte membranes in hemolytic anemia] Takakuwa Y. **Nippon Rinsho** 1996 Sep;54(9):2300-3 (4 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Clinical characterization of thrombotic microangiopathy in HIV infection [letter] Kado DM, et al. **AIDS** 1996 Dec; 10(14):1747-9

Hemolytic anemias due to disorders of red cell membrane skeleton. Bossi D, et al. **Mol Aspects Med** 1996 Apr; 17(2):171-88

Hemolytic anemias due to erythrocyte enzyme deficiencies. Jacobasch G, et al. **Mol Aspects Med** 1996 Apr;17(2):143-70

Hemolytic anemias due to hemoglobinopathies. Poyart C, et al. **Mol Aspects Med** 1996 Apr;17(2):129-42

PREVENTION & CONTROL

7E3 F(ab')2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli. Taylor FB, et al. **Blood** 1997 Jun 1;89(11):4078-84

SURGERY

Reoperation for hemolytic, anaemia complicating mitral valve repair. Cerfolio RJ, et al. **Eur J Cardiothorac Surg** 1997 Mar;11(3):479-84

Laparoscopic splenectomy versus open splenectomy: a comparative study. Delaitre B, et al. **Hepatogastroenterology** 1997 Jan-Feb;44(13):45-9

THERAPY

High-dose gamma-globulin responsive haemolysis due to cytomegalovirus in an immunocompetent adult [letter; comment] Juneja SK, et al. **Br J Haematol** 1996 Nov; 95(2):433-5. Comment on: Br J Haematol 1996 Jan;92(1):218-20.

Combined use of detachable coil against persistent mechanical hemolysis after transcatheter occlusion using Rashkind umbrella device in adult patient with patent ductus arteriosus. Murakami H, et al. **Heart Vessels** 1997; 12(1):49-51

Failure of partial splenectomy to ameliorate the anemia of pyruvate kinase deficiency. Sandoval C, et al. **J Pediatr Surg** 1997 Apr;32(4):641-2

VETERINARY

Vaccine-associated immune-mediated hemolytic anemia in the dog. Duval D, et al. **J Vet Intern Med** 1996 Sep-Oct; 10(5):290-5

Hemolytic anemia in wild seaducks caused by marine oil pollution. Yamato O, et al. **J Wildl Dis** 1996 Apr; 32(2):381-4

ANEMIA, HEMOLYTIC, ACQUIRED see ANEMIA, HEMOLYTIC

ANEMIA, HEMOLYTIC, AUTOIMMUNE

BLOOD

Abnormalities of membrane protein composition in patients with autoimmune haemolytic anaemia. De Angelis V, et al. **Br J Haematol** 1996 Nov;95(2):273-7

Inverse correlation between IgG-antihinge region and antierythrocyte autoantibody in chronic benign and

malignant cold agglutination. Terness P, et al. **J Clin Immunol** 1997 May;17(3):220–7

Gel test application for IgG subclass detection in auto–immune haemolytic anaemia. Fabijańska–Mitek J, et al. **Vox Sang** 1997;72(4):233–7

Autoimmune haemolytic anaemia in infancy with anti–Kpb specificity. Win N, et al. **Vox Sang** 1996;71(3):187–8

[Erythrophagocytosis as a transfusion parameter in a case of autoimmune hemolytic anemia (letter)] Biondi C, et al. **Sangre (Barc)** 1995 Dec;40(6):522–3 **(Spa)**

CHEMICALLY INDUCED

Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia [letter] Tsiara S, et al. **Am J Hematol** 1997 Apr;54(4):342

Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Bougie D, et al. **Blood** 1997 Jul 1;90(1):407–13

Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Tertian G, et al. **Hematol Cell Ther** 1996 Aug;38(4):359–60

Carboplatin–induced immune hemolytic anemia. Marani TM, et al. **Transfusion** 1996 Nov–Dec;36(11–12):1016–8

Immune complex–mediated haemolytic anaemia and Evans syndrome induced by diclofenac. de Quirós JF, et al. **Vox Sang** 1997;72(2):121–3

[Fludarabine and severe autoimmune hemolytic anemia: a new case (letter)] Crozat–Grosleron S, et al. **Rev Med Interne** 1996;17(8):701–2 **(Fre)**

[Case of acute immune hemolytic anemia developing during fluorouracil administration following surgery of colonic cancer] Nosaka S, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):687–8 **(Jpn)**

COMPLICATIONS

Primary biliary cirrhosis associated with mixed type autoimmune hemolytic anemia and sicca syndrome: a case report and review of literature. Chen CY, et al. **Am J Gastroenterol** 1997 Sep;92(9):1547–9 (21 ref.)

Autoimmune hemolytic anemia, primary adrenal insufficiency, and the antiphospholipid syndrome. Hsu B, et al. **Am J Med Sci** 1997 Jul;314(1):41–3

Successful control of refractory and life–threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with the primary antiphospholipid syndrome. Vandenberghe P, et al. **Ann Hematol** 1996 Nov;73(5):253–6

Systemic lupus erythematosus, thrombocytopenia, microangiopathic haemolytic anaemia and anti–CD36 antibodies [clinical conference] al–Shahi R, et al. **Br J Rheumatol** 1997 Jul;36(7):794–8

Unusual presentation of primary sclerosing cholangitis. Pineau BC, et al. **Can J Gastroenterol** 1997 Jan–Feb; 11(1):45–8 (34 ref.)

Autoimmune haemolytic anaemia associated with dermatomyositis. Hardman CM, et al. **Clin Exp Dermatol** 1996 Nov;21(6):437–9

Severe autoimmune hemolytic anemia in hairy cell leukemia [letter] Güler N, et al. **Eur J Haematol** 1997 Mar; 58(3):205–6

HIV infection with haemolytic anaemia [clinical conference] Sukthankar AD, et al. **Genitourin Med** 1997 Feb;73(1):66–9

Evans' syndrome associated with Graves' disease. Yashiro M, et al. **Intern Med** 1996 Dec;35(12):987–90 (13 ref.)

Autoimmune haemolytic anaemia associated with ulcerative colitis. Murphy PT, et al. **Ir Med J** 1996 Sep–Oct; 89(5):172–3 (15 ref.)

Cardiopulmonary bypass procedures in patients with cold–reactive hemagglutination. A case report and a literature review. Ko W, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):623–6 (15 ref.)

Case Report: a patient with primary biliary cirrhosis and autoimmune hemolytic anemia. Yoshida EM, et al. **J Gastroenterol Hepatol** 1996 May;11(5):439–42

A case of thymoma–associated autoimmune haemolytic anaemia. Rennenberg RJ, et al. **Neth J Med** 1997 Mar; 50(3):110–4 (23 ref.)

Craniocephalic disproportion with increased intracranial pressure and brain herniation: a new clinical syndrome in anemic patients: report of two cases. Rengachary SS, et al. **Neurosurgery** 1997 Jul;41(1):297–303; discussion 303–4

[Giant cell hepatitis and autoimmune hemolytic anemia: efficacy of splenectomy on hemolysis] Choulot JJ, et al. **Arch Pediatr** 1996 Aug;3(8):789–91 (Eng. Abstr.) **(Fre)**

[Autoimmune hemolytic anemia with eosinophilia in elderly patient] Tamura J, et al. **Nippon Ronen Igakkai Zasshi** 1996 Aug;33(8):603–6 (Eng. Abstr.) **(Jpn)**

[Chronic recurrent polyneuropathy in a patient with autoimmune hemolytic anemia associated with antibodies to gangliosides GM1, GA1, and GD1b] Nomura K, et al. **Rinsho Shinkeigaku** 1995 Oct;35(10):1131–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Intense icterus in the course of EBV infectious mononucleosis] Baudet Arteaga JS, et al. **Rev Esp Enferm Dig** 1996 Oct;88(10):709–11 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Autoimmune haemolytic anaemia: laboratory aspects. Gupte SC. **Indian J Med Sci** 1996 May;50(5):155–61

Autoimmune hemolytic anemia with warm antibodies complicated with an intercurrent attack of hemolysis with cold agglutinins in a case of Waldenström disease. Gologan R, et al. **Rom J Intern Med** 1996 Jan–Jun;34(1–2):149–54 (30 ref.)

DRUG THERAPY

Cold agglutinin hemolysis responding to fludarabine therapy [letter] Jacobs A. **Am J Hematol** 1996 Dec;53(4):279–80

The mode of action of treatment by IgG of haemolytic anaemia induced by an anti–erythrocyte monoclonal antibody. Pottier Y, et al. **Clin Exp Immunol** 1996 Oct; 106(1):103–7

High–dose intravenous immunoglobulin as single therapy in a child with autoimmune hemolytic anemia [letter] Otheo E, et al. **Pediatr Hematol Oncol** 1997 Sep–Oct;14(5):487–90

The Scripps Clinic experience with cladribine (2–CdA) in the treatment of chronic lymphocytic leukemia. Saven A. **Semin Hematol** 1996 Jan;33(1 Suppl 1):28–33 (31 ref.)

[Effective cyclosporine therapy to resistant–Evans syndrome] Tsudo M, et al. **Rinsho Ketsueki** 1996 Nov;37(11):1289–92 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A trial of treatment with thymus factor (TFX) for chronic autoimmune hemolytic anemias] Słomkowski M. **Pol Merkuriusz Lek** 1996 Nov;1(5):327–8 (Eng. Abstr.) **(Pol)**

ETIOLOGY

Concomitant onset of ulcerative colitis and autoimmune hemolytic anemia in an 83–yr–old woman. Collazzo JA, et al. **Am J Gastroenterol** 1996 Oct;91(10):2236–7

Hypofibrinogenemia induced by prednisolone therapy in a patient with chronic lymphocytic leukemia complicated with autoimmune hemolytic anemia [letter] Yokose N, et al. **Am J Hematol** 1997 Jul;55(3):166–7

Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Chen FE, et al. **Bone Marrow Transplant** 1997 Mar;19(5):491–5 (23 ref.)

Autoimmune hemolytic anemia following T cell–depleted allogeneic bone marrow transplantation. Drobyski WR, et al. **Bone Marrow Transplant** 1996 Jun;17(6):1093–9

Cold agglutininemia with acrocyanosis in multicentric Castleman's disease: a case report. Chuang SS, et al. **Chang Keng I Hsueh** 1995 Dec;18(4):378–82

The mode of action of treatment by IgG of haemolytic anaemia induced by an anti–erythrocyte monoclonal antibody. Pottier Y, et al. **Clin Exp Immunol** 1996 Oct; 106(1):103–7

Fludarabine and autoimmune hemolytic anemia in chronic lymphocytic leukemia [letter] Longo G, et al. **Eur J Haematol** 1997 Aug;59(2):124–5

Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2–chlorodeoxyadenosine (cladribine). Robak T, et al. **Eur J Haematol** 1997 Feb;58(2):109–13

Primary sinusoidal lymphoma of the liver revealed by autoimmune hemolytic anemia. Pouderoux P, et al. **Gastroenterol Clin Biol** 1997;21(6–7):514–8 (23 ref.)

Autoimmune hemolytic anemia with anti–DC specificity following a primary infection by Varicella virus [letter] Sanchis Cervera J, et al. **Haematologica** 1997 Jul–Aug; 82(4):508–9

Autoimmune hemolytic anemia in allergic granulomatous angitis (Churg–Strauss syndrome). Kojima K, et al. **Int J Hematol** 1996 Feb;63(2):149–54

Acceleration of thrombosis and hemolysis by fibrinolysis inhibiting factor and suppression by Ia antigen expressed on T cells in partially hepatectomized Lewis rats. Nakatsuji T. **Int J Hematol** 1996 Oct;64(3–4):181–8

Production of anti–erythrocyte antibodies by leukemic and nonleukemic B cells in chronic lymphocytic leukemia patients. Centola M, et al. **Leuk Lymphoma** 1996 Feb; 20(5–6):465–69

Resolution of autoimmune hemolytic anemia following splenectomy in CD3+ large granular lymphocyte leukemia. Gentile TC, et al. **Leuk Lymphoma** 1996 Oct; 23(3–4):405–8

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 13–1997. A 32–year–old man with IgG antibody and Coombs'–positive hemolytic anemia resistant to corticosteroid therapy [clinical conference] **N Engl J Med** 1997 Apr 24;336(17):1235–41

Anti–red blood cell autoantibody transgenic mice: murine model of autoimmune hemolytic anemia. Murakami M, et al. **Semin Immunol** 1996 Feb;8(1):3–9 (43 ref.)

Coombs–negative severe hemolysis associated with hepatitis A. Ibe M, et al. **Z Gastroenterol** 1997 Jul;35(7):567–9

[Autoimmune hemolytic anemia disclosing splenic lymphoma with villous lymphocyte (letter)] Bonichon N, et al. **Presse Med** 1997 Mar 1;26(6):270 **(Fre)**

[Sarcoidosis in a patient with autoimmune hemolytic anemia] Yasuda N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Aug;34(8):931–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Hemolytic anemias observed in SLE] Ichikawa Y, et al. **Nippon Rinsho** 1996 Sep;54(9):2528–33 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Mycoplasma infection and hemolytic anemia] Nasu K. **Nippon Rinsho** 1996 Sep;54(9):2545–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of primary biliary cirrhosis with autoimmune hemolytic anemia] Kobayashi N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug;94(8):552–7 **(Jpn)**

[Non–Hodgkin's lymphoma associated with cold agglutinin disease] Niitsu N, et al. **Rinsho Ketsueki** 1997 Jul; 38(7):587–92 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Autoimmune hemolytic anemia in common variable immunodeficiency (letter) (published erratum appears in Sangre (Barc) 1996 Dec;41(6):486)] Andón Saavedra C, et al. **Sangre (Barc)** 1996 Oct;41(5):404–5 **(Spa)**

[Variant hairy–cell leukemia and autoimmune hemolytic anemia (letter)] Galán P, et al. **Sangre (Barc)** 1996 Jun; 41(3):260–1 **(Spa)**

GENETICS

A myeloproliferative disorder with eosinophilia associated with a unique translocation (3;5). Shanske AL, et al. **Br J Haematol** 1996 Dec;95(3):524–6

Reduced frequency of HLA–DQ6 in individuals with a positive direct antiglobulin test. Wang–Rodriguez J, et al. **Transfusion** 1996 Nov–Dec;36(11–12):979–84

IMMUNOLOGY

Anti–red blood cell immunoglobulin transgenic mice. An experimental model of autoimmune hemolytic anemia. Nisitani S, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:246–52 (21 ref.)

Chronic cold agglutinin disease of the "idiopathic" type is a premalignant or low–grade malignant lymphoproliferative disease. Berentsen S, et al. **APMIS** 1997 May;105(5):354–62

Lymphocyte activation and cytokine production in autoimmune hemolytic anaemia (AIHA). Fagiolo E, et al. **Autoimmunity** 1996;24(3):147–56

Do plasma anti phospholipid antibodies in patients with autoimmune haemolytic anaemia correlate with reduced levels of erythrocyte complement receptor 1? Jones DR, et al. **Autoimmunity** 1996;23(1):45–51

Quantitation of erythrocyte–bound IgG subclass autoantibodies in murine autoimmune haemolytic anaemia. Mazza G, et al. **Autoimmunity** 1996;23(4):245–55

Rapid detection of IgG subclasses on DAT positive RBC membranes by flow cytometry (FC). Asmussen C, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:35–9

T–cell subsets in autoimmune haemolytic anaemia. Barker RN, et al. **Biochem Soc Trans** 1997 May;25(2):312S

Acute auto immune haemolytic anaemia secondary to hepatitis A infection. Tibble JA, et al. **Clin Lab Haematol** 1997 Mar;19(1):73–5

Autoimmune hemolytic anemia in multicentric Castleman's disease. Liberato NL, et al. **Haematologica** 1996 Jan–Feb; 81(1):40–43

The anti–erythrocyte autoimmune response of NZB mice. Identification of two distinct autoantigens. Diiulio NA, et al. **Immunology** 1997 Jun;91(2):246–51

T–helper 1 dominated responses to erythrocyte Band 3 in NZB mice. Shen CR, et al. **Immunology** 1996 Oct; 89(2):195–9

A patient with fatal cold haemagglutinins. Mandigers CM, et al. **Neth J Med** 1996 Nov;49(5):209–11

Severe autoimmune hemolytic anemia associated with IgM warm autoantibodies directed against determinants on or associated with glycophorin A. Garratty G, et al. **Vox Sang** 1997;72(2):124–30

[Autoimmune hemolytic anemia caused by cold agglutinins of the anti–Pr specificity after rubella infection] König AL, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:26–9 (Eng. Abstr.) **(Ger)**

[Human monoclonal antibody against enzyme treated erythrocytes] Wagner FF, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:40–2 **(Ger)**

[Anemia and hemorrhagic diathesis in autoimmune hemolysis and immune thrombocytopenia] Stemmler HJ, et al. **Internist (Berl)** 1996 Jan;37(1):78–81 **(Ger)**

[Detection and characterization of anti–red cell autoantibodies in autoimmune hemolytic anemias] Kamesaki T, et al. **Nippon Rinsho** 1996 Sep;54(9):2430–5 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Cold agglutinin disease and paroxysmal cold hemoglobinuria] Kannagi R, et al. **Nippon Rinsho** 1996 Sep; 54(9):2519–27 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Pathogenesis of erythrocyte destruction in autoimmune hemolytic anemia] Yatomi Y. **Nippon Rinsho** 1996 Sep; 54(9):2397–401 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Evan's syndrome with antiphospholipid–protein antibodies] Frolow M, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):344–5 (Eng. Abstr.) **(Pol)**

[Allo– and autoantibody in a case of autoimmune hemolytic anemia associated with a myelodysplastic syndrome (letter)] Iturbe T, et al. **Sangre (Barc)** 1996 Oct;41(5):403–4 **(Spa)**

METABOLISM

Lymphocyte activation and cytokine production in autoimmune hemolytic anaemia (AIHA). Fagiolo E, et al. **Autoimmunity** 1996;24(3):147–56

PATHOLOGY

The leukemic cells of chronic lymphocytic leukemia patients with autoimmune hemolytic anemia produce isotype–switched immunoglobulins that are preferentially encoded by the 51p1 and DP–50 VH genes. Efremov DG,

et al. **Ann N Y Acad Sci** 1997 Apr 5;815:443–7 (9 ref.)
[Hemolytic anemia by cryoagglutinins, leukopenia and repetead infections (clinical conference)]
Medicina (B Aires) 1995;55(6):697–704 **(Spa)**

PREVENTION & CONTROL

Successful control of refractory and life-threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with the primary antiphospholipid syndrome. Vandenberghe P, et al. **Ann Hematol** 1996 Nov;73(5):253–6

SURGERY

Resolution of autoimmune hemolytic anemia following splenectomy in CD3+ large granular lymphocyte leukemia. Gentile TC, et al. **Leuk Lymphoma** 1996 Oct; 23(3–4):405–8

THERAPY

Recurrent cold hemagglutinin disease following allogeneic bone marrow transplantation successfully treated with plasmapheresis, corticosteroid and cyclophosphamide. Azuma E, et al. **Bone Marrow Transplant** 1996 Jul; 18(1):243–6
Management of autoimmune hemolytic anemia. Pathare AV. **Indian J Med Sci** 1996 May;50(5):162–7
Plasmalymphacytapheresis in the treatment of cold autoimmune hemolytic anemia [letter] Shpakova AP, et al. **J Clin Apheresis** 1996;11(1):50
[Immune thrombocytopenia, anemia and leukopenia during pregnancy. Successful therapy with extracorporeal immunoadsorption] Julius U, et al.
Dtsch Med Wochenschr 1997 Feb 21;122(8):220–4 (Eng. Abstr.) **(Ger)**
[Primary autoimmune hemolytic anemia (warm antibody)] Wakasugi K, et al. **Nippon Rinsho** 1996 Sep;54(9):2513–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Compensated immune mediated haemolytic anaemia in a dog [published erratum appears in Aust Vet J 1997 Mar;75(3):177] Mills JN. **Aust Vet J** 1997 Jan;75(1):24–6
Intravenous administration of human immune globulin in dogs with immune-mediated hemolytic anemia. Scott-Moncrieff JC, et al. **J Am Vet Med Assoc** 1997 Jun 1;210(11):1623–7
Serial monitoring of clinical, haematological and immunological parameters in canine autoimmune haemolytic anaemia. Day MJ. **J Small Anim Pract** 1996 Nov;37(11):523–34
IgG subclasses of canine anti-erythrocyte, antinuclear and anti-thyroglobulin autoantibodies. Day MJ. **Res Vet Sci** 1996 Sep;61(2):129–35

VIROLOGY

Acute auto immune haemolytic anaemia secondary to hepatitis A infection. Tibble JA, et al.
Clin Lab Haematol 1997 Mar;19(1):73–5

ANEMIA, HEMOLYTIC, CONGENITAL

[Hemolytic anemia—recent findings—with special reference to erythrocyte membrane abnormalities] Yawata Y.
Nippon Naika Gakkai Zasshi 1997 Mar 10;86(3):481–90 (18 ref.)
[Characteristics of red cell membrane disorders in the Japanese population] Yawata Y. **Rinsho Byori** 1997 Apr; 45(4):367–76 (46 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Thrombopoietin in Upshaw-Schulman syndrome [letter] Miura M, et al. **Blood** 1997 Jun 15;89(12):4663–4
[Analysis of abnormal erythrocyte proteins and the etiological relation to hemolytic anemia] Fujioka S.
Nippon Rinsho 1996 Sep;54(9):2423–9 (5 ref.) (Eng. Abstr.) **(Jpn)**
[The complete band4.2 deficiency in human red cells] Kanzaki A, et al. **Nippon Rinsho** 1996 Sep;54(9):2492–501 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Hereditary high red cell membrane phosphatidylcholine hemolytic anemia (HPCHA)] Terada H. **Nippon Rinsho** 1996 Sep;54(9):2502–6 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Mechanisms of enhanced erythrocyte destruction in patients with erythrocyte membrane disorders] Yasunaga M, et al. **Nippon Rinsho** 1996 Sep;54(9):2390–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Hemolytic anemia in a female newborn infant whose mother inhaled naphthalene before delivery [letter; comment] Athanasiou M, et al. **J Pediatr** 1997 Apr;130(4):680–1. Comment on: J Pediatr 1995 Nov;127(5):807–8.

DIAGNOSIS

[Gene diagnosis of hemolytic anemia] Miyazaki S.
Nippon Rinsho 1996 Sep;54(9):2416–22 (12 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

[Hemolytic anemia due to abnormalities in erythrocyte nucleotide metabolism] Masuda M, et al. **Nippon Rinsho** 1996 Sep;54(9):2473–7 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Hereditary hemolytic anemia due to abnormal enzymes of the glycolytic pathway] Omine M. **Nippon Rinsho** 1996 Sep;54(9):2460–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Congenital 6-phosphogluconate dehydrogenase (6PGD) deficiency associated with chronic hemolytic anemia in a Spanish family. Vives Corrons JL, et al. **Am J Hematol** 1996 Dec;53(4):221–7
Spectrin St Claude, a splicing mutation of the human alpha-spectrin gene associated with severe poikilocytic anemia. Fournier CM, et al. **Blood** 1997 Jun 15; 89(12):4584–90
Hematologically important mutations: spectrin variants in hereditary elliptocytosis and hereditary pyropoikilocytosis. Gallagher PG, et al. **Blood Cells Mol Dis** 1996;22(3):254–8
Mutation of a highly conserved residue of betaI spectrin associated with fatal and near-fatal neonatal hemolytic anemia. Gallagher PG, et al. **J Clin Invest** 1997 Jan 15; 99(2):267–77

PREVENTION & CONTROL

ACP Broadsheet No 150. March 1997. Antenatal serological testing and prevention of haemolytic disease of the newborn. Duguid JK. **J Clin Pathol** 1997 Mar;50(3):193–6

ANEMIA, HEMOLYTIC, CONGENITAL NONSPHEROCYTIC

GENETICS

Frame shift mutation, exon skipping, and a two-codon deletion caused by splice site mutations account for pyruvate kinase deficiency. Kanno H, et al. **Blood** 1997 Jun 1;89(11):4213–8
Molecular characterization of PK-LR gene in pyruvate kinase-deficient Italian patients. Zanella A, et al. **Blood** 1997 May 15;89(10):3847–52
Glucose-6-phosphate dehydrogenase Durham: a de novo mutation associated with chronic hemolytic anemia. Zimmerman SA, et al. **J Pediatr** 1997 Aug;131(2):284–7

ANEMIA, HEMOLYTIC, IDIOPATHIC ACQUIRED see **ANEMIA, HEMOLYTIC, AUTOIMMUNE**

ANEMIA, HYPOCHROMIC

COMPLICATIONS

Evolving concepts in autologous blood procurement and transfusion: case reports of perisurgical anemia complicated by myocardial infarction. Goodnough LT, et al.
Am J Med 1996 Aug 26;101(2A):33S–37S (30 ref.)
Spondyloptotic fracture of the cervical spine in a pregnant, anemic Jehovah's Witness: technical and ethical considerations. Case report. Feigenbaum F, et al.
J Neurosurg 1997 Sep;87(3):458–63
Craniocephalic disproportion with increased intracranial pressure and brain herniation: a new clinical syndrome in anemic patients: report of two cases. Rengachary SS, et al. **Neurosurgery** 1997 Jul;41(1):297–303; discussion 303–4

DIAGNOSIS

Serum transferrin receptor levels in different stages of iron deficiency [letter] Gimferrer E, et al. **Blood** 1997 Aug 1; 90(3):1332–4

DIET THERAPY

Iron supplementation moderates but does not cure the Belgrade anemia. Garrick M, et al. **Biometals** 1997 Apr; 10(2):65–76

DRUG THERAPY

Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel. Yagil Y. **Isr J Med Sci** 1997 Jan; 33(1):36–44

EPIDEMIOLOGY

[Prevalence of iron deficiency in the female working population in the reproductive age] Bermejo B, et al.
Rev Clin Esp 1996 Jul;196(7):446–50 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Pathophysiology of anemia. Greenburg AG. **Am J Med** 1996 Aug 26;101(2A):7S–11S (21 ref.)
Profound anaemia secondary to an ulcerated basal cell carcinoma [letter] Higgins J, et al. **Clin Exp Dermatol** 1996 Sep;21(5):389–90
[Isolated jejunal Crohn disease] Jiménez Sáenz M, et al.
An Med Interna 1996 Jun;13(6):279–81 (Eng. Abstr.) **(Spa)**
[Hyperthyroidism as a cause of chronic anemia] Justo Firvida E, et al. **An Med Interna** 1995 Sep;12(9):442–4 (Eng. Abstr.) **(Spa)**
[Microcytic anemia and coproparasitologic findings in a 3-year-old boy] Pemán J, et al.
Enferm Infecc Microbiol Clin 1997 Feb;15(2):111–2 **(Spa)**

HISTORY

Saint Gotthard's unwanted burden. Aronson SM.
Med Health R I 1997 May;80(5):138–40

PHYSIOPATHOLOGY

Pathophysiology of anemia. Greenburg AG. **Am J Med** 1996 Aug 26;101(2A):7S–11S (21 ref.)

PREVENTION & CONTROL

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. Del Mastro L, et al. **J Clin Oncol** 1997 Jul; 15(7):2715–21
Anaemia among women of reproductive age in Burkina Faso. Meda N, et al. **World Health Forum** 1996;17(4):369–72

THERAPY

Therapy of anemia in patients with multiple myeloma. Adam Z, et al. **Acta Med Austriaca** 1995;22(4):59–64
New insights into the management of anemia in the surgical patient. Klein HG. **Am J Med** 1996 Aug 26; 101(2A):12S–15S (23 ref.)

ANEMIA, HYPOPLASTIC see **ANEMIA, APLASTIC**

ANEMIA, HYPOPLASTIC, CONGENITAL see **FANCONI'S ANEMIA**

ANEMIA, IRON-DEFICIENCY

Fetal iron status in maternal anemia. Singla PN, et al.
Acta Paediatr 1996 Nov;85(11):1327–30
ABC of clinical haematology. Iron deficiency anaemia [see comments] Frewin R, et al. **BMJ** 1997 Feb 1; 314(7077):360–3 (0 ref.). Comment in: BMJ 1997 Jun 14;314(7096):1759. Comment in: BMJ 1997 Jun 14;314(7096):1759; discussion 1760. Comment in: BMJ 1997 Jun 14;314(7096):1759–60. Comment in: BMJ 1997 Jun 14;314(7096):1760.
Pregnancy and iron deficiency: unresolved issues. Allen LH. **Nutr Rev** 1997 Apr;55(4):91–101 (93 ref.)
[An unusual case of anemia [letter] Paoletti R, et al.
Minerva Ginecol 1995 Nov;47(11):519–20 **(Ita)**

BLOOD

Serum transferrin receptor levels in the evaluation of iron deficiency in the neonate. Rusia U, et al.
Acta Paediatr Jpn 1996 Oct;38(5):455–9
Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Punnonen K, et al.
Blood 1997 Feb 1;89(3):1052–7
The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Major A, et al.
Br J Haematol 1997 Aug;98(2):292–4
One for tea, not two. Davis SG, et al.
Clin Lab Haematol 1996 Dec;18(4):289–90
Analytical and clinical implications of soluble transferrin receptors in serum. Kuiper-Kramer EP, et al.
Eur J Clin Chem Clin Biochem 1996 Aug;34(8):645–9
Iron status in young Danes. Evaluation by serum ferritin and haemoglobin in a population survey of 634 individuals aged 14–23 yr. Milman N, et al. **Eur J Haematol** 1997 Mar; 58(3):160–6
Iron deficiency anemia in pregnancy [letter; comment] Paul Y. **Indian Pediatr** 1996 Nov;33(11):969–70. Comment on: Indian Pediatr 1996 Jul;33(7):606.
Chicken extract stimulates haemoglobin restoration in iron deficient rats. Geissler C, et al. **Int J Food Sci Nutr** 1996 Jul;47(4):351–60
Erythropoietin response is blunted in critically ill patients [see comments] Rogiers P, et al. **Intensive Care Med** 1997 Feb;23(2):159–62. Comment in: Intensive Care Med 1997 Feb;23(2):137–8.
Subnormal serum vitamin B12 concentration [letter] Jolobe OM. **J Am Geriatr Soc** 1997 Sep;45(9):1158–9
RDW to detect iron deficiency [letter; comment] Eliason BC. **J Fam Pract** 1996 Sep;43(3):223–4. Comment on: J Fam Pract 1996 Mar;42(3):237–40.
Low MCV anemia [published erratum appears in J Fam Pract 1997 Feb;44(2):214] Govaker D. **J Fam Pract** 1996 Sep; 43(3):307
Serum ferritin, erythrocyte protoporphyrin and hemoglobin are valid indicators of iron status of school children in a malaria-holoendemic population. Stoltzfus RJ, et al.
J Nutr 1997 Feb;127(2):293–8
Iron status of Filipino infants and preschoolers using plasma ferritin and transferrin receptor levels. Kuizon MD, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):343–9
Subnormal plasma von Willebrand factor (ristocetin cofactor) and iron deficiency anaemia in menstruating women [letter] Beck EA, et al. **Thromb Haemost** 1996 Apr;75(4):693
[Erythrocyte zinc-protoporphyrin and characteristics of iron- deficiency anemia in parturient women and neonates]

Janoušek S, et al. **Ceska Gynekol** 1996 Oct;61(5):297–9 (Eng. Abstr.) **(Cze)**

[The blood gas-transport function in patients with iron-deficiency anemia under measured physical loading] Ivanov AO, et al. **Patol Fiziol Eksp Ter** 1997 Apr-Jun; (2):37–9 **(Rus)**

[The regulatory mechanisms of the blood respiratory function in iron-deficiency anemias] Lanovenko II, et al. **Fiziol Zh** 1997;43(3–4):64–70 (Eng. Abstr.) **(Ukr)**

COMPLICATIONS

Popcorn, pica, and impaction. Hoyt RE. **Am J Med** 1997 Jul;103(1):70

Iron deficiency anaemia in infancy and early childhood. Booth IW, et al. **Arch Dis Child** 1997 Jun;76(6):549–53; discussion 553–4 (42 ref.)

Anemia secondary to combined deficiencies of iron and cobalamin. Hash RB, et al. **Arch Fam Med** 1996 Nov-Dec; 5(10):585–8 (25 ref.)

Iron deficiency anaemia and febrile convulsions. ...and coeliac disease [letter; comment] Macdonald CE, et al. **BMJ** 1996 Nov 9;313(7066):1205. Comment on: BMJ 1996 Aug 10;313(7053):343.

Prevalence of concomitant disease in patients with iron deficiency anaemia. Till SH, et al. **BMJ** 1997 Jan 18; 314(7075):206–8

Iron deficiency anaemia and febrile convulsions. Possible confounding factors include lead toxicity....[letter; comment] Wike WM, et al. **BMJ** 1996 Nov 9; 313(7066):1205. Comment on: BMJ 1996 Aug 10;313(7053):343.

Iron nutrition and anaemia in a malaria-endemic environment: haematological investigation of the Gidra-speaking population in lowland Papua New Guinea. Nakazawa M, et al. **Br J Nutr** 1996 Sep;76(3):333–46

Prominent pigmented fungiform papillae of the tongue. Ahn SK, et al. **Cutis** 1996 Dec;58(6):410–2

Effect of maternal iron deficiency anaemia on foetal outcome. Rusia U, et al. **Indian J Pathol Microbiol** 1995 Jul; 38(3):273–9

Asymptomatic giardiasis does not affect iron absorption in children with iron deficiency anemia [see comments] De Morais MB, et al. **J Am Coll Nutr** 1996 Oct;15(5):434–8 . Comment in: J Am Coll Nutr 1996 Oct;15(5):421.

Anemia and zinc deficiency in the athlete [editorial; comment] Nishi Y. **J Am Coll Nutr** 1996 Aug;15(4):323–4 . Comment on: J Am Coll Nutr 1996 Aug;15(4):359–63.

Subnormal serum vitamin B12 concentration [letter] Jolobe OM. **J Am Geriatr Soc** 1997 Sep;45(9):1158–9

A randomized intervention study of the effects of discontinuing coffee intake on growth and morbidity of iron-deficient Guatemalan toddlers. Dewey KG, et al. **J Nutr** 1997 Feb;127(2):306–13

Anemia in children with breath-holding spells [letter; comment] Yilmaz S, et al. **J Pediatr** 1996 Mar;128(3):440–1 . Comment on: J Pediatr 1995 Mar;126(3):395–7.

Iron status of newborns born to iron deficient anaemic mothers. Hokama T, et al. **J Trop Pediatr** 1996 Apr; 42(2):75–7

Fetal growth in maternal anaemia. Singla PN, et al. **J Trop Pediatr** 1997 Apr;43(2):89–92

Psychomotor development and behavior in iron-deficient anemic infants. de Andraca I, et al. **Nutr Rev** 1997 Apr; 55(4):125–32 (46 ref.)

Iron deficiency and educational deficiency. Pollitt E. **Nutr Rev** 1997 Apr;55(4):133–41 (12 ref.)

Incomplete occlusion of central retinal artery in a girl with iron deficiency anemia. Matsuoka Y, et al. **Ophthalmologica** 1996;210(6):358–60

Iron deficiency anemia and hearing. Ozturan O, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 Mar-Apr; 59(2):73–8

Iron deficiency: a cause of stroke in infants and children. Hartfield DS, et al. **Pediatr Neurol** 1997 Jan;16(1):50–3

Celiac disease in childhood presenting with pica: case report. Santos JA, et al. **Wis Med J** 1996 Aug;95(8):581–2 (9 ref.)

[Cerebral venous thrombosis in a child with iron deficiency anemia caused by food allergy] Repetto T, et al. **Pediatr Med Chir** 1997 Mar-Apr;19(2):133–4 (Eng. Abstr.) **(Ita)**

CONGENITAL

Serum transferrin receptor levels in the evaluation of iron deficiency in the neonate. Rusia U, et al. **Acta Paediatr Jpn** 1996 Oct;38(5):455–9

DIAGNOSIS

The erythrocyte cell hemoglobin distribution width segregates thalassemia traits from other nonthalassemic conditions with microcytosis. Liu TC, et al. **Am J Clin Pathol** 1997 May;107(5):601–7

The value of the MCV index in the diagnosis of thalassemic and nonthalassemic microcytosis [letter; comment] Wentworth P, et al. **Am J Clin Pathol** 1997 May;107(5):619 . Comment on: Am J Clin Pathol 1996 Aug;106(2):201–5.

Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Ahluwalia N, et al. **Am J Kidney Dis** 1997 Oct;30(4):532–41

Anemia secondary to combined deficiencies of iron and cobalamin. Hash RB, et al. **Arch Fam Med** 1996 Nov-Dec; 5(10):585–8 (25 ref.)

Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Punnonen K, et al. **Blood** 1997 Feb 1;89(3):1052–7

Recognizing and investigating iron-deficiency anemia in hospitalized elderly people. Smieja MJ, et al. **Can Med Assoc J** 1996 Sep 15;155(6):691–6

Evaluation of new immunoenzymometric assay for measuring soluble transferrin receptor to detect iron deficiency in anemic patients. Suominen P, et al. **Clin Chem** 1997 Sep; 43(9):1641–6

Detection of iron-deficiency anemia in hospitalized patients by zinc protoporphyrin. Wong SS, et al. **Clin Chim Acta** 1996 Jan 15;244(1):91–101

The clinical value of serum ferritin tests in endurance athletes. Garza D, et al. **Clin J Sport Med** 1997 Jan;7(1):46–53 (54 ref.)

The evaluation of iron status in hemodialysis patients. Fishbane S, et al. **J Am Soc Nephrol** 1996 Dec;7(12):2654–7

RDW to detect iron deficiency [letter; comment] Eliason BC. **J Fam Pract** 1996 Sep;43(3):223–4. Comment on: J Fam Pract 1996 Mar;42(3):237–40.

Low MCV anemia [published erratum appears in J Fam Pract 1997 Feb;44(2):214] Govaker D. **J Fam Pract** 1996 Sep; 43(3):307

The diagnosis of iron deficiency in patients with rheumatoid arthritis and anemia: an algorithm using simple laboratory measures [see comments] Mulherin D, et al. **J Rheumatol** 1996 Feb;23(2):237–40. Comment in: J Rheumatol 1997 Apr;24(4):804–5.

Hypochromic red cells as an indicator of iron deficiency [letter; comment] Navarro JF, et al. **J Rheumatol** 1997 Apr; 24(4):804–5. Comment on: J Rheumatol 1996 Feb;23(2):237–40.

A practical guide for differentiating between iron deficiency anemia and anemia of chronic disease in children and adults. Richer S. **Nurse Pract** 1997 Apr;22(4):82, 85–6, 91–6 passim; quiz 102–3 (29 ref.)

Gastric as well as duodenal biopsies may be useful in the investigation of iron deficiency anaemia. Dickey W, et al. **Scand J Gastroenterol** 1997 May;32(5):469–72

[Manifestation of iron deficiency] Jaeger M, et al. **Med Klin** 1996 Sep 15;91(9):580–8 (75 ref.) **(Ger)**

[Hemoglobin, iron deficiency and anemia in pregnant women. Diagnostic aspects] Haram K, et al. **Tidsskr Nor Laegeforen** 1997 Mar 10;117(7):962–6 (37 ref.) (Eng. Abstr.) **(Nor)**

[Hematological analyzers in the diagnosis of iron-deficiency anemias] Lugovskaia SA, et al. **Klin Lab Diagn** 1996 Nov-Dec;(6):7–10 **(Rus)**

DIET THERAPY

Influence of iron supplementation frequency on absorption efficiency and mucosal ferritin in anaemic rats. Benito P, et al. **Br J Nutr** 1997 Sep;78(3):469–77

Treating anemia with iron-fortified formula [letter] Rauliuk M, et al. **Can Fam Physician** 1997 Sep;43:1497–9

Chicken extract stimulates haemoglobin restoration in iron deficient rats. Geissler C, et al. **Int J Food Sci Nutr** 1996 Jul;47(4):351–60

Strategies for the prevention of iron deficiency through foods in the household. Layrisse M, et al. **Nutr Rev** 1997 Jun; 55(6):233–9 (42 ref.)

DRUG THERAPY

Weekly micronutrient supplementation to build iron stores in female Indonesian adolescents. Angeles-Agdeppa I, et al. **Am J Clin Nutr** 1997 Jul;66(1):177–83

Meta-analysis of efficacy and tolerability data on iron proteinsuccinylate in patients with iron deficiency anemia of different severity. Köpcke W, et al. **Arzneimittelforschung** 1995 Nov;45(11):1211–6

Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Drüeke TB, et al. **Clin Nephrol** 1997 Jul;48(1):1–8 (69 ref.)

An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Markowitz GS, et al. **Clin Nephrol** 1997 Jul;48(1):34–40

Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. al-Momen AK, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Nov;69(2):121–4

Pregnancy associated anemia and iron: a pilot study. Rani NV, et al. **Indian J Pathol Microbiol** 1995 Jul;38(3):293–7

Effects of iron replenishment on iron, calcium, phosphorus and magnesium metabolism in iron-deficient rats. Pallarés I, et al. **Int J Vitam Nutr Res** 1996;66(2):158–65

Asymptomatic giardiasis does not affect iron absorption in children with iron deficiency anemia [see comments] De Morais MB, et al. **J Am Coll Nutr** 1996 Oct;15(5):434–8 . Comment in: J Am Coll Nutr 1996 Oct;15(5):421.

Supplementing iron intravenously in pregnancy. A way to avoid blood transfusions. Hallak M, et al. **J Reprod Med** 1997 Feb;42(2):99–103

Definition and prevalence of anemia in Bolivian women of childbearing age living at high altitudes: the effect of iron-folate supplementation. Berger J, et al. **Nutr Rev** 1997 Jun;55(6):247–56

Iron, anemia, and infection. Walter T, et al. **Nutr Rev** 1997 Apr;55(4):111–24 (89 ref.)

Iron deficiency anemia. When is parenteral therapy warranted? Swain RA, et al. **Postgrad Med** 1996 Nov; 100(5):181–2, 185, 188–93 (15 ref.)

Can licensed drug sellers contribute to safe motherhood? A survey of the treatment of pregnancy-related anaemia in Nepal. Kafle KK, et al. **Soc Sci Med** 1996 Jun; 42(11):1577–88

[How to evaluate the iron therapy (editorial)] Li R. **Chung Hua Nei Ko Tsa Chih** 1996 Feb;35(2):78–9 **(Chi)**

[Is there an indication for intravenous iron replacement in, for example, by autologous blood donation-induced iron deficiency and is there a theoretically possible indication for intravenous administration for the not approved Ferrum Hausmann preparation?] Kruse HJ, et al. **Internist (Berl)** 1996 Oct;37(10):1059 **(Ger)**

[Parenteral iron replacement (editorial)] Cynke E. **Schweiz Rundsch Med Prax** 1997 May 14;86(20):835–6 **(Ger)**

[Effectiveness and tolerability of oral liquid ferrous gluconate in iron-deficiency anemia in pregnancy and in the immediate post-partum period: comparison with other liquid or solid formulations containing bivalent or trivalent iron] Casparis D, et al. **Minerva Ginecol** 1996 Nov; 48(11):511–8 (Eng. Abstr.) **(Ita)**

[Reevaluation of administration dosage in parenteral iron therapy] Uchida T, et al. **Rinsho Ketsueki** 1996 Feb; 37(2):123–8 (Eng. Abstr.) **(Jpn)**

[Cost of the treatment of iron-deficiency anemia (letter; comment)] Muguruza Valdeolmillos A, et al. **Aten Primaria** 1996 Oct 31;18(7):403. Comment on: Aten Primaria 1996 Apr 30;17(7):480–2. **(Spa)**

[The antioxidant effects of emoxipin in patients with iron-deficiency anemia] Shved MI, et al. **Lik Sprava** 1995 Sep-Dec;(9–12):72–5 (Eng. Abstr.) **(Ukr)**

ECONOMICS

A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease. Hutchinson FN, et al. **Am J Kidney Dis** 1997 May; 29(5):651–7

ENZYMOLOGY

Abnormalities in adenosine triphosphatase of the erythrocyte membrane in iron deficiency anaemia. Ifere GO, et al. **J Trace Elem Med Biol** 1996 Sep;10(3):185–8

Up-regulation of renal and vascular nitric oxide synthase in iron-deficiency anemia. Ni Z, et al. **Kidney Int** 1997 Jul;52(1):195–201

EPIDEMIOLOGY

A method to estimate prevalence of iron deficiency and iron deficiency anemia in adolescent Jamaican girls [see comments] Himes JH, et al. **Am J Clin Nutr** 1997 Mar; 65(3):831–6. Comment in: Am J Clin Nutr 1997 Mar;65(3):887–8.

Early response to the effect of iron fortification in the Venezuelan population [see comments] Layrisse M, et al. **Am J Clin Nutr** 1996 Dec;64(6):903–7. Comment in: Am J Clin Nutr 1996 Dec;64(6):972–3.

Epidemiology of iron deficiency anemia in Zanzibari schoolchildren: the importance of hookworms. Stoltzfus RJ, et al. **Am J Clin Nutr** 1997 Jan;65(1):153–9

Iron status and anaemia in preschool children in Sydney. Karr M, et al. **Aust N Z J Public Health** 1996 Dec; 20(6):618–22

Iron deficiency anaemia in general practice: presentations and investigations. Stellon AJ, et al. **Br J Clin Pract** 1997 Mar; 51(2):78–80

Prevalence of anemia among school-children from Rio Acima (State of Minas Gerais, Brazil): use of the standardized prevalence method and evaluation of iron deficiency. Norton RC, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1617–24

Incidence of iron-deficiency anaemia and depleted iron stores among nine-month-old infants in Vancouver, Canada. Innis SM, et al. **Can J Public Health** 1997 Mar-Apr; 88(2):80–4

Iron deficiency anemia in pregnancy [letter] [see comments] Kapil U, et al. **Indian Pediatr** 1996 Jul;33(7):606. Comment in: Indian Pediatr 1996 Nov;33(11):969–70.

Iron deficiency and anaemia in children with a high prevalence of haemoglobinopathies: implications for screening. Linpisarn S, et al. **Int J Epidemiol** 1996 Dec; 25(6):1262–6

Iron deficiency and anemia in school children and adolescents. Shaw NS. **J Formos Med Assoc** 1996 Sep; 95(9):692–8

Iron deficiency anemia among Alaska Natives may be due to fecal loss rather than inadequate intake. Petersen KM, et al. **J Nutr** 1996 Nov;126(11):2774–83

Prevalence of iron deficiency in the United States. Looker AC, et al. **JAMA** 1997 Mar 26;277(12):973–6

Prevalence of anaemia in semi-urban areas of Peshawar, Pakistan: a challenge for health professionals and policy makers. Paracha PI, et al. **JPMA J Pak Med Assoc** 1997 Feb;47(2):49–53

Blood lead concentrations and iron status of preschool children from low income families [letter; comment] [see comments] Karr M, et al. **Med J Aust** 1997 Jan 6;166(1):53 . Comment on: Med J Aust 1996 Apr 1;164(7):399–402. Comment in: Med J Aust 1997 Jun 2;166(11):614.

Blood lead concentrations and iron status of preschool

children from low income families [letter; comment] McNeil AR, et al. **Med J Aust** 1997 Jun 2;166(11):614. Comment on: Med J Aust 1997 Jan 6;166(1):53.
Definition and prevalence of anemia in Bolivian women of childbearing age living at high altitudes: the effect of iron-folate supplementation. Berger J, et al. **Nutr Rev** 1997 Jun;55(6):247–56
Iron status of Filipino infants and preschoolers using plasma ferritin and transferrin receptor levels. Kuizon MD, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):343–9

ETHNOLOGY

Treating anemia with iron-fortified formula [letter] Rauliuk M, et al. **Can Fam Physician** 1997 Sep;43:1497–9

ETIOLOGY

Epidemiology of iron deficiency anemia in Zanzibari schoolchildren: the importance of hookworms. Stoltzfus RJ, et al. **Am J Clin Nutr** 1997 Jan;65(1):153–9
Role of small bowel biopsy in the endoscopic evaluation of adults with iron deficiency anemia. Ackerman Z, et al. **Am J Gastroenterol** 1996 Oct;91(10):2099–102
Lack of significant colonic pathology in patients with iron deficiency anemia who have had partial gastrectomy [letter] Chalasani N, et al. **Am J Gastroenterol** 1997 Apr; 92(4):727
Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy. Tarng DC, et al. **Am J Nephrol** 1997;17(2):158–64
Hemoquant determination of hookworm-related blood loss and its role in iron deficiency in African children. Stoltzfus RJ, et al. **Am J Trop Med Hyg** 1996 Oct;55(4):399–404
A prospective study of the gastroenterological causes of iron deficiency anaemia in a general hospital. Bampton PA, et al. **Aust N Z J Med** 1996 Dec;26(6):793–9
Iron deficiency anaemia. Patients must be screened for coeliac disease [letter; comment] Barton R. **BMJ** 1997 Jun 14;314(7096):1759–60. Comment on: BMJ 1997 Feb 1;314(7077):360–3.
Iron deficiency anaemia. Is important in young children [letter; comment] Salman M. **BMJ** 1997 Jun 14; 314(7096):1760. Comment on: BMJ 1997 Feb 1;314(7077):360–3.
Iron deficiency anaemia. Limit investigations if iron deficiency has no obvious cause [letter; comment] Scott B. **BMJ** 1997 Jun 14;314(7096):1759. Comment on: BMJ 1997 Feb 1;314(7077):360–3.
Systemic lupus erythematosus presenting as iron deficiency anemia due to pulmonary alveolar hemorrhage. Blanche P, et al. **Clin Exp Rheumatol** 1996 Mar-Apr;14(2):228
Jejunal lymphangioma. An unusual cause of chronic gastrointestinal bleeding. Barquist ES, et al. **Dig Dis Sci** 1997 Jun;42(6):1179–83
Choledochocele presenting with anaemia. Krepel HP, et al. **Eur J Gastroenterol Hepatol** 1997 Jun;9(6):641–3
Zinc status relates to hematological deficits in women endurance runners [see comments] Nishiyama S, et al. **J Am Coll Nutr** 1996 Aug;15(4):359–63. Comment in: J Am Coll Nutr 1996 Aug;15(4):323–4.
The evaluation of iron status in hemodialysis patients. Fishbane S, et al. **J Am Soc Nephrol** 1996 Dec;7(12):2654–7
Gastric antral vascular ectasia causing severe anemia. Toyota M, et al. **J Gastroenterol** 1996 Oct;31(5):710–3 (22 ref.)
Jejunal adenocarcinoma presenting as iron deficiency in a young man. Trowers EA, et al. **J Natl Med Assoc** 1997 Mar;89(3):205–7
Iron deficiency anemia among Alaska Natives may be due to fecal loss rather than inadequate intake. Petersen KM, et al. **J Nutr** 1996 Nov;126(11):2774–83
More than 10 years' follow-up to total colonic aganglionosis--severe iron deficiency anemia and growth retardation. Ikawa H, et al. **J Pediatr Surg** 1997 Jan; 32(1):25–7
A study of iron requirement during weaning by total body iron determined by haemoglobin, serum ferritin, and body weight [letter] Hokama T, et al. **J Trop Pediatr** 1996 Apr; 42(2):120
Iron deficiency in benign duodenal ulcer [letter; comment] Jolobe OM. **Lancet** 1997 Mar 15;349(9054):809–10. Comment on: Lancet 1997 Jan 18;349(9046):174.
Gastrointestinal smooth muscle tumors and iron deficiency anemia in children. Cordova Z, et al. **Med Pediatr Oncol** 1997 Jun;28(6):441–3
Clinical problem-solving--where did good old clinical diagnosis go? [letter] Greeno EW. **N Engl J Med** 1997 Sep 25;337(13):940–1; discussion 942
Use of diet history in the screening of iron deficiency. Boutry M, et al. **Pediatrics** 1996 Dec;98(6 Pt 1):1138–42
Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection. Marignani M, et al. **Scand J Gastroenterol** 1997 Jun;32(6):617–22
Iron deficiency anemia, backache, and abdominal pain attacks during sexual intercourse in a 42-year-old woman. Mulari S, et al. **Scand J Gastroenterol** 1996 Jun;31(6):622–3
[Iron deficiency anemia and occlusive syndrome caused by ovarian mucinous cystadenoma invading the small intestine (letter)] Kalinsky E, et al. **Presse Med** 1996 Sep 28; 25(28):1304 **(Fre)**
[Schistosomiasis--a rare cause of iron deficiency anemia] Laudage G, et al. **Leber Magen Darm** 1996 Jul;26(4):216–8 (Eng. Abstr.) **(Ger)**
[Iron-deficiency anemia in enteral nutrition: correlation with tube position] Baxter YC, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Nov-Dec; 50(6):330–3 (Eng. Abstr.) **(Por)**
[Addison-Biermer disease combined with chronic posthemorrhagic iron-deficiency anemia (dimorphic anemias)] Berliner GB, et al. **Ter Arkh** 1996;68(12):10–2 (Eng. Abstr.) **(Rus)**
[Prevalence of monosymptomatic celiac disease in patients with iron deficiency anemia] Garrido C, et al. **Gastroenterol Hepatol** 1997 Apr;20(4):172–4 (Eng. Abstr.) **(Spa)**

GENETICS

[Prassad syndrome--case report] Sayali E, et al. **Wien Med Wochenschr** 1996;146(12):261–3 (Eng. Abstr.) **(Ger)**

HISTORY

[Correlations between cribra orbitalia, archeometric findings on the skeleton and habitat conditions] Schutkowski H, et al. **Anthropol Anz** 1997 Jun;55(2):155–66 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Iron, anemia, and infection. Walter T, et al. **Nutr Rev** 1997 Apr;55(4):111–24 (89 ref.)

METABOLISM

Supplementation of a cereal-milk formula with haem iron palliates the adverse effects of iron deficiency on calcium and magnesium metabolism in rats. Pallarés I, et al. **Ann Nutr Metab** 1996;40(2):81–90
Small-dose oral iron absorption test in anaemic and non-anaemic elderly hospitalized patients. Joosten E, et al. **Eur J Haematol** 1997 Feb;58(2):99–103
Iron deficiency in distance runners. A reinvestigation using Fe-labelling and non-invasive liver iron quantification. Nachtigall D, et al. **Int J Sports Med** 1996 Oct;17(7):473–9
Effect of source of iron on duodenal absorption of iron, calcium, phosphorous, magnesium, copper and zinc in rats with ferropoenic anaemia. Gómez-Ayala AE, et al. **Int J Vitam Nutr Res** 1997;67(2):106–14
Tissue oxygenation in patients with hemoglobinopathy H [see comments] Papassotiriou I, et al. **Pediatr Hematol Oncol** 1997 Jul-Aug;14(4):323–34. Comment in: Pediatr Hematol Oncol 1997 Jul-Aug;14(4):295–7.
Effect of Egyptian cooking methods of faba beans on its nutritive value, dietary protein utilization and iron deficiency anemia. 1. The role of main technological pretreatments. Bakr AA. **Plant Foods Hum Nutr** 1996 Jan; 49(1):83–92

PARASITOLOGY

The prevalence of hookworm infection, iron deficiency and anaemia in an aboriginal community in north-west Australia. Hopkins RM, et al. **Med J Aust** 1997 Mar 3; 166(5):241–4

PATHOLOGY

Iron deficiency anaemia. Gastrointestinal endoscopy should always be used [letter; comment] Goddard WP, et al. **BMJ** 1997 Jun 14;314(7096):1759; discussion 1760. Comment on: BMJ 1997 Feb 1;314(7077):360–3.
Prominent pigmented fungiform papillae of the tongue. Ahn SK, et al. **Cutis** 1996 Dec;58(6):410–2
[Etiology of the cribra orbitalia: effect of amino acid profile in bone collagen and the iron content of bone minerals] Grupe G. **Z Morphol Anthropol** 1995 Dec;81(1):125–37 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Erythrocyte production in iron deficiency anemia. Sánchez-Medal L, et al. **Acta Haematol** 1996;96(3):146–9
The role of vitamin A in iron deficiency anemia and implications for interventions. Karyadi D, et al. **Biomed Environ Sci** 1996 Sep;9(2–3):316–24
Compensatory and adaptive changes in microcirculation and left ventricular function of patients with chronic iron-deficiency anaemia. Georgieva Z, et al. **Clin Hemorheol Microcirc** 1997 Jan-Feb;17(1):21–30
Iron and thermoregulation: a review. Brigham D, et al. **Crit Rev Food Sci Nutr** 1996 Dec;36(8):747–63 (91 ref.)
Anaemia in adolescent girls: effects on cognitive function and activity. Nelson M. **Proc Nutr Soc** 1996 Mar; 55(1B):359–67 (39 ref.)
[General pathology of trace element deficiency] Zhavoronkov AA, et al. **Arkh Patol** 1997 Mar-Apr; 59(2):8–11 (24 ref.) (Eng. Abstr.) **(Rus)**
[The behavior of rat progeny after prenatal benzene exposure in an iron-deficiency state of the mother] Senichenkova IN, et al. **Fiziol Zh Im I M Sechenova** 1996 May-Jun; 82(5–6):95–101 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Follow-on formula in the prevention of iron deficiency: a multicentre study. Gill DG, et al. **Acta Paediatr** 1997 Jul; 86(7):683–9
Breast feeding and other aspects of infant nutrition [letter; comment] Kazal LA Jr. **Am Fam Physician** 1997 Feb 15; 55(3):785–6. Comment on: Am Fam Physician 1996 Jul;54(1):138–44.
Iron fortification in Venezuela [editorial; comment] Beard J. **Am J Clin Nutr** 1996 Dec;64(6):972–3. Comment on: Am J Clin Nutr 1996 Dec;64(6):903–7.
Delayed clamping of the umbilical cord improves hematologic status of Guatemalan infants at 2 mo of age. Grajeda R, et al. **Am J Clin Nutr** 1997 Feb;65(2):425–31
Iron deficiency anaemia in infancy and early childhood. Booth IW, et al. **Arch Dis Child** 1997 Jun;76(6):549–53; discussion 553–4 (42 ref.)
Dietary education and iron deficiency anaemia in the inner city. Childs F, et al. **Arch Dis Child** 1997 Feb;76(2):144–7
Feasibility of screening toddlers for iron deficiency anaemia in general practice. James JA, et al. **BMJ** 1997 Jul 12; 315(7100):102–3
Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin [letter] Kotaki M, et al. **Clin Nephrol** 1997 Jul;48(1):63–4
Effect of timing of cord clamping on the iron status of infants at 3 months. Geethanath RM, et al. **Indian Pediatr** 1997 Feb;34(2):103–6
Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Menendez C, et al. **Lancet** 1997 Sep 20;350(9081):844–50
Strategies of the Pan American Health Organization/World Health Organization for the control of iron deficiency in Latin America. Freire WB. **Nutr Rev** 1997 Jun;55(6):183–8 (15 ref.)
Preventing iron deficiency through food fortification. Hurrell RF. **Nutr Rev** 1997 Jun;55(6):210–22 (97 ref.)
Strategies for the prevention of iron deficiency through foods in the household. Layrisse M, et al. **Nutr Rev** 1997 Jun; 55(6):233–9 (42 ref.)
Preventing iron deficiency in infants and preschool children in Argentina. O'Donnell AM, et al. **Nutr Rev** 1997 Jun; 55(6):189–94 (22 ref.)
Hookworm control as a strategy to prevent iron deficiency. Stoltzfus RJ, et al. **Nutr Rev** 1997 Jun;55(6):223–32 (54 ref.)
Iron supplementation for the control of iron deficiency in populations at risk. Viteri FE. **Nutr Rev** 1997 Jun; 55(6):195–209 (74 ref.)
[New aspects on preventive iron supplementation in normal pregnancy] Haram K, et al. **Tidsskr Nor Laegeforen** 1997 Mar 10;117(7):966–9 (32 ref.) (Eng. Abstr.) **(Nor)**
[Relationship of vitamins and microelements and their role in the prevention of iron deficiencies (review)] Nasolodin VV, et al. **Gig Sanit** 1996 Nov-Dec;(6):26–9 (41 ref.) **(Rus)**

PSYCHOLOGY

[Aspects of pica in adult psychiatric patients (letter; comment)] Haanen C. **Ned Tijdschr Geneeskd** 1996 Nov 30;140(48):2427. Comment on: Ned Tijdschr Geneeskd 1996 Oct 19;140(42):2069–70. **(Dut)**

SURGERY

Surgical treatment of anaemia in malignant melanoma. Parfitt A, et al. **J R Soc Med** 1996 Nov;89(11):646

THERAPY

Strategies to control nutritional anemia [editorial; comment] West CE. **Am J Clin Nutr** 1996 Nov;64(5):789–90. Comment on: Am J Clin Nutr 1996 Nov;64(5):694–9.
Parenteral iron increases serum erythropoietin concentration during the "early anaemia' of 10–20-day-old mice [see comments] Bechensteen AG, et al. **Br J Haematol** 1996 Sep;94(3):529–32. Comment in: Br J Haematol 1997 Jun;97(3):686–7.
Weight gain in children with asymptomatic giardiasis and iron-deficiency anaemia during oral iron therapy [letter] De Morais MB, et al. **J Trop Pediatr** 1997 Apr;43(2):121–2
Effect of iron-supplemented total parenteral nutrition in patients with iron deficiency anemia. Burns DL, et al. **Nutrition** 1996 Jun;12(6):411–5
[Anemia in chronic inflammatory bowel diseases: administration of erythropoietin] Niederau C. **Z Gastroenterol** 1996 Nov;34(11):779–80 **(Ger)**
[Fortification of fluid milk for the prevention and treatment of iron deficiency anemia in children under 4 years of age] Torres MA, et al. **Rev Saude Publica** 1996 Aug;30(4):350–7 (Eng. Abstr.) **(Por)**
[The effect of the use of milk fortified with iron and vitamin C on hemoglobin levels and nutritional status of children under 2] Torres MA, et al. **Rev Saude Publica** 1995 Aug; 29(4):301–7 (Eng. Abstr.) **(Por)**

ANEMIA, LEUKOERYTHROBLASTIC see **ANEMIA, MYELOPHTHISIC**

ANEMIA, MACROCYTIC

BLOOD

Benign familial macrocytosis. Sechi LA, et al. **Clin Lab Haematol** 1996 Mar;18(1):41–3

ANEMIA, MACROCYTIC

CHEMICALLY INDUCED

Dose-related thrombocytopenia and macrocytic anemia associated with valproate use in bipolar disorder [letter] Fawcett RG. **J Clin Psychiatry** 1997 Mar;58(3):125

Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia. Inoue T, et al. **Leukemia** 1997 Apr;11 Suppl 3:123-7

Azathioprine induced macrocytosis and red cell aplasia in renal transplant patients [letter] Zazgornik J. **Nephrol Dial Transplant** 1997 Mar;12(3):628

DIAGNOSIS

[Pancytopenic form of Biermer disease (letter)] Blanc PL, et al. **Rev Med Interne** 1996;17(11):951-2 **(Fre)**

[Hemoglobin, iron deficiency and anemia in pregnant women. Diagnostic aspects] Haram K, et al. **Tidsskr Nor Laegeforen** 1997 Mar 10;117(7):962-6 (37 ref.) (Eng. Abstr.) **(Nor)**

ETIOLOGY

Unexplained macrocytosis in elderly patients [see comments] Mahmoud MY, et al. **Age Ageing** 1996 Jul;25(4):310-2. Comment in: Age Ageing 1997 May;26(3):237-8.

Macrocytosis in elderly patients [letter; comment] Rizeq M, et al. **Age Ageing** 1997 May;26(3):237-8. Comment on: Age Ageing 1996 Jul;25(4):310-2.

ABC of clinical haematology. Macrocytic anaemias [see comments] Hoffbrand V, et al. **BMJ** 1997 Feb 8; 314(7078):430-3 (0 ref.). Comment in: BMJ 1997 May 24;314(7093):1552.

Scintigraphic diagnosis of intrathoracic extramedullary hematopoiesis in alcohol-related macrocytosis. De Geeter F, et al. **J Nucl Med** 1996 Mar;37(3):473-5

GENETICS

A novel form of hereditary sideroblastic anaemia with macrocytosis. Tuckfield A, et al. **Br J Haematol** 1997 May; 97(2):279-85

RADIONUCLIDE IMAGING

Scintigraphic diagnosis of intrathoracic extramedullary hematopoiesis in alcohol-related macrocytosis. De Geeter F, et al. **J Nucl Med** 1996 Mar;37(3):473-5

ANEMIA, MEDITERRANEAN see **BETA-THALASSEMIA**

ANEMIA, MEGALOBLASTIC

BLOOD

Infantile megaloblastosis secondary to maternal vitamin B12 deficiency. Monagle PT, et al. **Clin Lab Haematol** 1997 Mar;19(1):23-5

Megaloblastosis [letter; comment] Carr JM. **N Engl J Med** 1996 Dec 26;335(26):2000; discussion 2000-1 . Comment on: N Engl J Med 1996 Aug 1;335(5):323.

CHEMICALLY INDUCED

Megaloblastic anaemia and pancytopenia secondary to prophylactic cotrimoxazole therapy. Tapp H, et al. **J Paediatr Child Health** 1997 Apr;33(2):166-7

COMPLICATIONS

Thrombosis, megaloblastic anaemia, and sickle cell disease: a unified hypothesis [letter] Ballas SK, et al. **Br J Haematol** 1997 Mar;96(4):879-80

Leukaemoid reaction in megaloblastic anemia during puerperium. Lakhotia M, et al. **J Assoc Physicians India** 1996 Oct;44(10):744

Neurologic findings of vitamin B12 deficiency: presentation of 7 cases. Kalayci O, et al. **Turk J Pediatr** 1996 Jan-Mar; 38(1):67-72

DIAGNOSIS

Blood films in the diagnosis of anaemia [letter] Gråberger-Willcox G, et al. **Trans R Soc Trop Med Hyg** 1997 Mar-Apr;91(2):240

DRUG THERAPY

Efficacy of oral administration of high-dose cobamamide in a patient with Imerslund-Gräsbeck syndrome [letter] Gangarossa S, et al. **Pediatr Hematol Oncol** 1996 Jul-Aug; 13(4):387-9

ENZYMOLOGY

Functional methionine synthase deficiency due to cblG disorder: a report of two patients and a review. Harding CO, et al. **Am J Med Genet** 1997 Sep 5;71(4):384-90 (22 ref.)

EPIDEMIOLOGY

Megaloblastic anaemia among Somalis in north-eastern Kenya. Gråberger-Willcox G, et al. **Trans R Soc Trop Med Hyg** 1997 Mar-Apr;91(2):190

ETIOLOGY

Scurvy, osteoporosis and megaloblastic anaemia due to alleged food intolerance [letter] Barratt JA, et al. **Br J Rheumatol** 1996 Jul;35(7):701-2

Elevated deoxyuridine triphosphate nucleotidohydrolase (dUTPase) activity in the cobalamin-deficient megaloblastic bone marrow cells. Sugita Y, et al. **Int J Hematol** 1996 Oct;64(3-4):203-12

Nutritional vitamin B12 deficiency and folate deficiency in an adolescent patient presenting with anemia, weight loss, and poor school performance. Middleman AB, et al. **J Adolesc Health** 1996 Jul;19(1):76-9

Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy. Bellou A, et al. **J Intern Med** 1996 Sep;240(3):161-4

Management of megaloblastic anaemia [letter; comment] Rosner F. **Lancet** 1997 Jan 11;349(9045):136. Comment on: Lancet 1996 Nov 2;348(9036):1216.

[Megaloblastic anemia due to inadequate nutrition] Tschöp M, et al. **Dtsch Med Wochenschr** 1997 Jun 20; 122(25-26):820-4 (Eng. Abstr.) **(Ger)**

[A case of megaloblastic anemia in an 11-month-old infant fed with goat milk] Sołtyski J, et al. **Pediatr Pol** 1996 Aug; 71(8):709-11 (Eng. Abstr.) **(Pol)**

GENETICS

A case report of 46,XX,del(21)(q22) de novo deletion associated with Imerslund-Grasbeck syndrome. Celep F, et al. **Clin Genet** 1996 Oct;50(4):248-50

PATHOLOGY

Apoptosis of late-stage erythroblasts in megaloblastic anemia: association with DNA damage and macrocyte production. Koury MJ, et al. **Blood** 1997 Jun 15;89(12):4617-23

Evaluation of DNA analysis for evidence of apoptosis in megaloblastic anaemia. Ingram CF, et al. **Br J Haematol** 1997 Mar;96(3):576-83

THERAPY

Management of megaloblastic anaemia [letter; comment] Stern SC, et al. **Lancet** 1997 Jan 11;349(9045):135-6. Comment on: Lancet 1996 Nov 2;348(9036):1216.

ANEMIA, MICROANGIOPATHIC see **ANEMIA, HEMOLYTIC**

ANEMIA, MYELOPHTHISIC

DIAGNOSIS

Transient erythroblastopenia of childhood (TEC) presenting as leukoerythroblastic anemia. Mupanomunda OK, et al. **J Pediatr Hematol Oncol** 1997 Mar-Apr;19(2):165-7

ANEMIA, NEONATAL

Anemia in preterm infants. Roth P. **Pediatr Rev** 1996 Oct; 17(10):370

DIAGNOSIS

Do cardiac output and serum lactate levels indicate blood transfusion requirements in anemia of prematurity? Möller JC, et al. **Intensive Care Med** 1996 May;22(5):472-6

Ultrasonographic fetal cardiac measurement in isoimmunized pregnancies. Ouzounian JG, et al. **J Reprod Med** 1997 Jun; 42(6):342-6

DRUG THERAPY

Erythropoietin to treat anemia of prematurity [letter] Wandstrat TL, et al. **Ann Pharmacother** 1997 May; 31(5):645-6

Erythropoietin therapy for anemia of prematurity. Merchant RH, et al. **Indian Pediatr** 1996 Apr;33(4):323-6

[Randomized multi-center trial of the administration of erythropoietin in anemia of prematurity] Javier Manchón G, et al. **An Esp Pediatr** 1997 Jun;46(6):587-92 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The role of erythropoietin in the anemia of prematurity. Doyle JJ. **Semin Perinatol** 1997 Feb;21(1):20-7 (50 ref.)

THERAPY

Effect of low and moderate doses of recombinant human erythropoietin on the haematological response in premature infants on a high protein and iron intake. Bechensteen AG, et al. **Eur J Pediatr** 1997 Jan;156(1):56-61

ANEMIA, PERNICIOUS

see related **SCHILLING TEST**

BLOOD

Pernicious anaemia patients should be searched for iron deficiency during follow up [letter] Demiroğlu H, et al. **Br J Clin Pract** 1996 Oct-Nov;50(7):412

COMPLICATIONS

Pernicious anemia and gastric carcinoid tumor: case report and review. Sculco D, et al. **Am J Gastroenterol** 1997 Aug; 92(8):1378-80 (57 ref.)

Coronary artery bypass in a patient with pernicious anemia [letter] Sakakibara Y, et al. **Ann Thorac Surg** 1997 Jan; 63(1):303

IgA nephropathy and pernicious anemia [letter] Nunes JP, et al. **Clin Nephrol** 1997 Mar;47(3):204

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 9-1997. A 39-year-old woman with pernicious anemia and a gastric mass [clinical conference] **N Engl J Med** 1997 Mar 20;336(12):861-7

Pernicious anaemia patients should be screened for iron deficiency during follow up. Demiroğlu H, et al. **N Z Med J** 1997 Apr 25;110(1042):147-8

[Pernicious anemia and cancer risk (letter)] Christensen B. **Ugeskr Laeger** 1997 Sep 22;159(39):5812 **(Dan)**

[Pernicious anemia and risk of cancer in Denmark] Mellemkjoer L, et al. **Ugeskr Laeger** 1997 Aug 4; 159(32):4850-3 (Eng. Abstr.) **(Dan)**

[Influenza-virus associated hemophagocytic syndrome in a patient with pernicious anemia] Shirono K, et al. **Rinsho Ketsueki** 1996 Jun;37(6):511-3 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

The value of the MCV index in the diagnosis of thalassemic and nonthalassemic microcytosis [letter; comment] Wentworth P, et al. **Am J Clin Pathol** 1997 May;107(5):619 . Comment on: Am J Clin Pathol 1996 Aug;106(2):201-5.

IgA nephropathy and pernicious anemia [letter] Nunes JP, et al. **Clin Nephrol** 1997 Mar;47(3):204

MRI of the spine in cobalamin deficiency: the value of examining both spinal cord and bone marrow. Duprez TP, et al. **Neuroradiology** 1996 Aug;38(6):511-5

[Neurologic signs in Addison-Biermer disease (report of 3 cases)] Tutaj A, et al. **Neurol Neurochir Pol** 1997 Jan-Feb; 31(1):35-41 (Eng. Abstr.) **(Pol)**

ETHNOLOGY

Pernicious anemia in Arabs. Harakati MS. **Blood Cells Mol Dis** 1996;22(2):98-103

ETIOLOGY

What's new about an old disease? [editorial] Barlow JF. **S D J Med** 1997 May;50(5):151-2

[A case of rheumatoid arthritis associated with pernicious anemia and bronchiolitis obliterans organizing pneumonia] Itoh H, et al. **Ryumachi** 1995 Dec;35(6):920-6 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Addison-Biermer disease combined with chronic posthemorrhagic iron-deficiency anemia (dimorphic anemias)] Berliner GB, et al. **Ter Arkh** 1996;68(12):10-2 (Eng. Abstr.) **(Rus)**

HISTORY

Geriatrics photo quiz. Addison's anemia. Shua-Hasim J, et al. **Geriatrics** 1996 Oct;51(10):13, 51

METABOLISM

Gastrin biosynthesis in the antrum of patients with pernicious anemia. Varro A, et al. **Gastroenterology** 1997 Mar; 112(3):733-41

NURSING

Clinical snapshot: pernicious anemia. Hawley K. **Am J Nurs** 1996 Nov;96(11):52-3

PATHOLOGY

Anemia in a patient with panhypogammaglobulinemia [clinical conference] Ruddell DN, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):17-20

Ultrastructural aspects of the neuroendocrine complex in the stomach in patients with either pernicious anemia or the Zollinger-Ellison syndrome. Schmidt HG, et al. **Z Gastroenterol** 1996 Jul;34(7):428-33

RADIONUCLIDE IMAGING

Reversal of Ga-67 'bone scan' with vitamin B12 therapy in a patient with pernicious anemia. Suga K, et al. **Clin Nucl Med** 1997 Aug;22(8):561-2

ANEMIA, REFRACTORY

[Simple refractory anemia in remission after 15 years' evolution (letter)] Cos MC, et al. **Sangre (Barc)** 1996 Apr; 41(2):161-2 **(Spa)**

BLOOD

Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis. Elghetany MT, et al. **Haematologica** 1997 Jan-Feb;82(1):21-4 (27 ref.)

CLASSIFICATION

Mixed myelodysplastic and myeloproliferative syndromes.

Neuwirtová R, et al. **Leuk Res** 1996 Sep;20(9):717–26

COMPLICATIONS

Successful control of refractory and life-threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with the primary antiphospholipid syndrome. Vandenberghe P, et al. **Ann Hematol** 1996 Nov;73(5):253–6

Behçet's disease associated with myelodysplastic syndromes. A case report and a review of the literature. Ohno E, et al. **Cancer** 1997 Jan 15;79(2):262–8 (31 ref.)

[Diabetes insipidus associated with a refractory anemia (letter)] Fernández Abellán P, et al. **Rev Clin Esp** 1996 Sep;196(9):664–5 **(Spa)**

[Polyarteritis nodosa cutanea and refractory anemia with excessive blast cells. Apropos of a case (letter)] Martínez Albaladejo M, et al. **Rev Clin Esp** 1996 Jul;196(7):493 **(Spa)**

DRUG THERAPY

Androgen therapy in combination with granulocyte colony-stimulating factor and erythropoietin in a patient with refractory anemia. Katayama Y, et al. **Int J Hematol** 1996 Dec;65(1):89–92

ETIOLOGY

Refractory postpartum anemia due to vitamin B6 deficiency [letter] Orehek AJ, et al. **Ann Intern Med** 1997 May 15; 126(10):834–5

Systemic vasculitis and myelodysplastic syndromes. A report of two cases. Philippe B, et al. **Arthritis Rheum** 1997 Jan; 40(1):179–82 (16 ref.)

Severe anemia in a patient with isolated adrenocorticotropin deficiency. Ihara T, et al. **Intern Med** 1996 Nov; 35(11):898–901

Diaphragmatic hernia and associated anemia: response to surgical treatment. Trastek VF, et al. **J Thorac Cardiovasc Surg** 1996 Nov;112(5):1340–4; discussion 1344–5

[Malignant lymphoma complicating myelodysplastic syndrome with autoantibody for the thyroid gland] Kondo H, et al. **Rinsho Ketsueki** 1997 Jul;38(7):593–8 (Eng. Abstr.) **(Jpn)**

GENETICS

Isochromosome 14q in refractory anemia. Boavida MG, et al. **Cancer Genet Cytogenet** 1997 Sep;97(2):155–6

A novel chromosomal abnormality involving chromosomes 2 and 18 in a patient with myelodysplastic syndrome. Viniou N, et al. **Cancer Genet Cytogenet** 1997 Jul 1; 96(1):7–12

Constitutional trisomy 8 as first mutation in multistep carcinogenesis: clinical, cytogenetic, and molecular data on three cases. Seghezzi L, et al. **Genes Chromosomes Cancer** 1996 Oct;17(2):94–101

IMMUNOLOGY

Increased levels of soluble Fas antigen in the plasma of the patients with refractory anemia [letter] Shinohara K, et al. **Int J Hematol** 1997 Jun;65(4):413–4

PATHOLOGY

Interphase ribosomal RNA cistron silver staining in refractory anaemias with and without excess blasts. Mamaev NN, et al. **Mol Pathol** 1997 Apr;50(2):92–5

[Quantitative evaluation of juxtatrabecular fibrosis in myelodysplastic syndromes] Reissenweber N, et al. **Sangre (Barc)** 1995 Dec;40(6):479–83 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Successful control of refractory and life-threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with the primary antiphospholipid syndrome. Vandenberghe P, et al. **Ann Hematol** 1996 Nov;73(5):253–6

SURGERY

Diaphragmatic hernia and associated anemia: response to surgical treatment. Trastek VF, et al. **J Thorac Cardiovasc Surg** 1996 Nov;112(5):1340–4; discussion 1344–5

THERAPY

Invasive cutaneous mucormycosis caused by Absidia corymbifera after allogeneic bone marrow transplantation. Jantunen E, et al. **Bone Marrow Transplant** 1996 Jul; 18(1):229–30

A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes. Bernell P, et al. **Leuk Res** 1996 Aug;20(8):693–9

[Improvement of bleeding tendency and normalized platelet count increment following splenectomy in a patient with refractory anemia] Kawai Y, et al. **Rinsho Ketsueki** 1997 Jun;38(6):532–8 (Eng. Abstr.) **(Jpn)**

ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS

BLOOD

[Temporary changes and permanent changes in the erythrocyte blood-group antigens in malignant hemopathies] Hafner V, et al. **Rom J Intern Med** 1996 Jul-Dec;34(3–4):183–8 (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia [letter] Bseiso AW, et al. **Leukemia** 1997 Jan;11(1):168–9

COMPLICATIONS

Bullous pemphigoid in association with cutaneous lesions specific to a myelodysplastic syndrome. Modiano P, et al. **Br J Dermatol** 1997 Mar;136(3):402–5

Pyoderma gangrenosum. Takvorian T, et al. **J Clin Oncol** 1997 Jan;15(1):407

[Myelodysplasia and tuberculosis (clinical conference)] Ugo V, et al. **Bull Cancer** 1996 Jul;83(7):548–52 (Eng. Abstr.) **(Fre)**

GENETICS

Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Peeters P, et al. **Cancer Res** 1997 Feb 15;57(4):564–9

Hidden monosomy 7 in acute myeloid leukemia and myelodysplastic syndrome detected by interphase fluorescence in situ hybridization. Arif M, et al. **Leuk Res** 1996 Sep;20(9):709–16

Chromosome abnormalities of the short arm of chromosome 12 in hematopoietic malignancies: a report including three novel translocations involving the TEL/ETV6 gene. Berger R, et al. **Leukemia** 1997 Sep;11(9):1400–3

IMMUNOLOGY

[Allo- and autoantibody in a case of autoimmune hemolytic anemia associated with a myelodysplastic syndrome (letter)] Iturbe T, et al. **Sangre (Barc)** 1996 Oct;41(5):403–4 **(Spa)**

PATHOLOGY

Trilineage extramedullary myeloid cell tumor in myelodysplastic syndrome. Hancock JC, et al. **Arch Pathol Lab Med** 1997 May;121(5):520–3

Clonality switch in acute myeloid leukemia. Yin JA, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):125–30

Interphase ribosomal RNA cistron silver staining in refractory anaemias with and without excess blasts. Mamaev NN, et al. **Mol Pathol** 1997 Apr;50(2):92–5

THERAPY

Multiple autoimmune events after autologous bone marrow transplantation. Lambertenghi-Deliliers GL, et al. **Bone Marrow Transplant** 1997 Apr;19(7):745–7

Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation. Maschan AA, et al. **Bone Marrow Transplant** 1997 Feb;19(4):385–7

In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Carella AM, et al. **Br J Haematol** 1996 Oct;95(1):127–30

Myelodysplastic syndrome in childhood [letter; comment] Reman O, et al. **Br J Haematol** 1996 Oct;95(1):212–3. Comment on: Br J Haematol 1996 Feb;92(2):344–50.

ANEMIA, SICKLE CELL

see related

ANTISICKLING AGENTS

Factitious sickle cell acute painful episodes: a secondary type of Munchausen syndrome. Ballas SK. **Am J Hematol** 1996 Dec;53(4):254–8 (7 ref.)

Sickle cell anaemia in Jordan and its clinical patterns. al-Sheyyab M, et al. **Ann Trop Paediatr** 1996 Sep; 16(3):249–53

A transgenic mouse model of hemoglobin S Antilles disease. Popp RA, et al. **Blood** 1997 Jun 1;89(11):4204–12

Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias. Pászty C. **Curr Opin Hematol** 1997 Mar;4(2):88–93 (49 ref.)

Continuing care for adult patients with sickle cell disease. Koshy M, et al. **Hematol Oncol Clin North Am** 1996 Dec; 10(6):1265–73 (00 ref.)

Attitudes toward adult patients with sickle cell disease: silent prejudice or benign neglect? [letter] Ballas SK. **J Assoc Acad Minor Phys** 1996;7(3):62

Nutrition assessment in children with sickle cell disease. Williams R, et al. **J Assoc Acad Minor Phys** 1997;8(3):44–8

Anesthesia for the parturient with sickle cell disease. Danzer BI, et al. **J Clin Anesth** 1996 Nov;8(7):598–602 (17 ref.)

Is it reactivation of fetal hemoglobin synthesis after transplantation of cord blood stem cells from a donor with heterozygous sickle cell anemia or beta-thalassemia? [letter; comment] Ohnuma K, et al. **J Pediatr** 1997 Jun; 130(6):1008–9. Comment on: J Pediatr 1996 Feb;128(2):241–3.

Sickle-cell disease. Serjeant GR. **Lancet** 1997 Sep 6; 350(9079):725–30 (34 ref.)

Sickle-cell disease in sub-Saharan Africa--past, present and future status [letter] Aluoch J, et al. **S Afr Med J** 1996 Aug;86(8):982–3

BLOOD

Hemoglobin A2 levels in healthy persons, sickle cell disease, sickle cell trait, and beta-thalassemia by capillary isoelectric focusing. Craver RD, et al. **Am J Clin Pathol** 1997 Jan;107(1):88–91

Hb S/Hb Lepore with mild sickling symptoms: a hemoglobin variant with mostly delta-chain sequences ameliorates sickle-cell disease. Fairbanks VF, et al. **Am J Hematol** 1997 Feb;54(2):164–5

Factor V Leiden is not responsible for stroke in patients with sickling disorders and is uncommon in African Americans with sickle cell disease. Kahn MJ, et al. **Am J Hematol** 1997 Jan;54(1):12–5

Inhibition of plasma-mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD-containing peptides. Kumar A, et al. **Am J Hematol** 1996 Oct;53(2):92–8

Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease. Marcus SJ, et al. **Am J Hematol** 1997 Jan;54(1):40–6

Calpromotin, a cytoplasmic protein, is associated with the formation of dense cells in sickle cell anemia. Moore RB, et al. **Am J Hematol** 1997 Oct;56(2):100–6

Red blood cell alloimmunization in sickle cell disease: the influence of racial and antigenic pattern differences between donors and recipients in Brazil. Moreira Júnior G, et al. **Am J Hematol** 1996 Jul;52(3):197–200

Irreversibly sickled cell beta-actin: defective filament formation. Shartava A, et al. **Am J Hematol** 1997 Jun; 55(2):97–103

Effects of density and of dehydration of sickle cells on their adhesion to cultured endothelial cells. Stone PC, et al. **Am J Hematol** 1996 Jul;52(3):135–43

Homocysteine in sickle cell disease: relationship to stroke. Houston PE, et al. **Am J Med** 1997 Sep;103(3):192–6

K(86Rb) transport heterogeneity in the low-density fraction of sickle cell anemia red blood cells. Etzion Z, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1111–21

Sickle erythrocytes induce prostacyclin and thromboxane synthesis by isolated perfused rat lungs. Ibe BO, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):L597–602

Endothelin-1 production during the acute chest syndrome in sickle cell disease. Hammerman SI, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):280–5

Lipid, apolipoprotein AI and B levels in Ivorian patients with sickle cell anaemia. Monnet D, et al. **Ann Biol Clin (Paris)** 1996;54(7):285–8

Serum calcium and vitamin D status of patients with sickle cell disease in Curaçao. van der Dijs FP, et al. **Ann Clin Biochem** 1997 Mar;34 (Pt 2):170–2

Stable transduction of recombinant adeno-associated virus into hematopoietic stem cells from normal and sickle cell patients. Lubovy M, et al. **Biol Blood Marrow Transplant** 1996 Feb;2(1):24–30

Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease [letter] Selby R, et al. **Blood** 1997 Jul 15;90(2):891–3

Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Steinberg MH, et al. **Blood** 1997 Feb 1; 89(3):1078–88

Percentage of reversibly and irreversibly sickled cells are altered by the method of blood drawing and storage conditions. Asakura T, et al. **Blood Cells Mol Dis** 1996; 22(3):297–306

Activated protein C resistance in homozygous sickle cell disease. Wright JG, et al. **Br J Haematol** 1997 Mar; 96(4):854–6

Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Duits AJ, et al. **Clin Immunol Immunopathol** 1996 Oct; 81(1):96–8

Mean cell haemoglobin concentration in subjects with haemoglobin C, D, E and S traits. Hinchliffe RF, et al. **Clin Lab Haematol** 1996 Dec;18(4):245–8

Pulse oximetry in a cohort study of sickle cell disease. Homi J, et al. **Clin Lab Haematol** 1997 Mar;19(1):17–22

Platelet function in patients with sickle cell anaemia in Nairobi. Maina JM, et al. **East Afr Med J** 1996 Sep; 73(9):568–70

Antioxidant status and susceptibility of sickle erythrocytes to oxidative and osmotic stress. Tatum VL, et al. **Free Radic Res** 1996 Aug;25(2):133–9

Peroxidative damage in sickle-cell erythrocyte ghosts: protective effect of allopurinol. Sertac A, et al. **Gen Pharmacol** 1997 Mar;28(3):427–8

Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease. Nsiri B, et al. **Hematol Cell Ther** 1996 Jul;38(3):279–84

Gelation kinetics of dilute hemoglobin from sickle cell anemia patients. Fasanmade AA. **Hemoglobin** 1996 Nov; 20(4):415–28

5' hypersensitive site-2 and fetal hemoglobin in Brazilians.

Figueiredo MS, et al. **Hemoglobin** 1996 Nov;20(4):435–8

Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo [see comments] Head CA, et al. **J Clin Invest** 1997 Sep 1;100(5):1193–8. Comment in: J Clin Invest 1997 Sep 1;100(5):955–6.

Serum interleukin-6 levels in the steady state of sickle cell disease. Taylor SC, et al. **J Interferon Cytokine Res** 1995 Dec;15(12):1061–4

Platelet-activating factor in plasma of patients with sickle cell disease in steady state. Oh SO, et al. **J Lab Clin Med** 1997 Aug;130(2):191–6

Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. Wun T, et al. **J Lab Clin Med** 1997 May;129(5):507–16

The structural link between polymerization and sickle cell disease. Mirchev R, et al. **J Mol Biol** 1997 Feb 7; 265(5):475–9

Shear rate dependency of red cell sequestration in skin capillaries in sickle cell disease and its variation with vasoocclusive crisis. Lipowsky HH, et al. **Microcirculation** 1997 Jun;4(2):289–301

Protein C activity in Gabonese children with sickle cell disease. Blavy G, et al. **Nouv Rev Fr Hematol** 1995; 37(4):251–2

Prolactinemia in sickle cell disease [letter] Kedar A, et al. **Pediatr Hematol Oncol** 1997 May–Jun;14(3):289–90

Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia. Helley D, et al. **Thromb Haemost** 1996 Sep;76(3):322–7

Factor V Leiden and sickle cell disease [letter; comment] Laffan MA, et al. **Thromb Haemost** 1996 May;75(5):859–60 . Comment on: Thromb Haemost 1995 Sep;74(3):996. Comment on: Thromb Haemost 1995 Nov;74(5):1381–2.

Assessment of qualitative functional parameters of stored red blood cells from donors with sickle cell trait (AS) or with heterozygote (AC) status. Ould Amar AK, et al. **Transfus Clin Biol** 1996;3(4):225–33

Altered filterability of fresh sickle cell trait donor blood [letter] Ould Amar AK, et al. **Vox Sang** 1997;73(1):55–6

[Evaluation of atherogenic risk in homozygous sickle cell disease: study of lipid and apolipoprotein AI and B plasma levels] Monnet PD, et al. **Bull Soc Pathol Exot** 1996; 89(4):278–81 (Eng. Abstr.) **(Fre)**

[Sickle cell anemia] Sugihara T. **Nippon Rinsho** 1996 Sep; 54(9):2442–7 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Community-based programs for hereditary hemoglobinopathies in Brazilian high school students] Compri MB, et al. **Rev Saude Publica** 1996 Apr; 30(2):187–95 (Eng. Abstr.) **(Por)**

COMPLICATIONS

Nitric oxide metabolite levels in acute vaso-occlusive sickle-cell crisis. Lopez BL, et al. **Acad Emerg Med** 1996 Dec;3(12):1098–103

Management of nontraumatic subarachnoid hemorrhage in a patient with sickle-cell disease: a case report. Rinnert S, et al. **Acad Emerg Med** 1996 Sep;3(9):859–63 (37 ref.)

Reversal of multiorgan system dysfunction in sickle cell disease with plasma exchange. Geigel EJ, et al. **Acta Anaesthesiol Scand** 1997 May;41(5):647–50

Thyroid functions in mild and severe forms of sickle cell anemia. Evliyaoğlu N, et al. **Acta Paediatr Jpn** 1996 Oct; 38(5):460–3

How safe is tourniquet use in sickle-cell disease? Oginni LM, et al. **Afr J Med Med Sci** 1996 Mar;25(1):3–6

Malnutrition in sickle cell disease patients [editorial; comment] Prasad AS. **Am J Clin Nutr** 1997 Aug; 66(2):423–4. Comment on: Am J Clin Nutr 1997 Aug;66(2):386–90.

Cancer incidence rate and mortality rate in sickle cell disease patients at Howard University Hospital: 1986–1995. Dawkins FW, et al. **Am J Hematol** 1997 Aug;55(4):188–92

Pelvic osteomyelitis in a sickle-cell patient receiving deferoxamine [letter] McLean TW, et al. **Am J Hematol** 1996 Dec;53(4):284–5

Babesiosis in a patient with sickle cell anemia. Klein P, et al. **Am J Med** 1997 Apr;102(4):416

Multifocal heterotopic ossification in a patient with sickle cell disease: a case report. Fye MA, et al. **Am J Orthop** 1997 Mar;26(3):216–9

Perioperative complications in patients with sickle cell disease. An orthopedic perspective. Garden MS, et al. **Am J Orthop** 1996 May;25(5):353–6

Splenectomy in patients with sickle-cell disease. al-Salem AH, et al. **Am J Surg** 1996 Sep;172(3):254–8

Sickle cell disease and tonsillectomy. Preoperative management and postoperative complications. Halvorson DJ, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jul; 123(7):689–92

Thrombocytosis in sickle cell anemia [letter; comment] Ozsoylu S. **Arch Pediatr Adolesc Med** 1997 Aug;151(8):859 . Comment on: Arch Pediatr Adolesc Med 1996 Jul;150(7):763–4.

Liver involvement in white patients with sickle-cell disease. Samperi P, et al. **Arch Pediatr Adolesc Med** 1996 Nov; 150(11):1177–80

Successful use of extracorporeal membrane oxygenation in the treatment of acute chest syndrome in a child with severe sickle cell anemia. Trant CA Jr, et al. **ASAIO J** 1996 May–Jun;42(3):236–9

Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. French JA 2nd, et al. **Blood** 1997 Jun 15;89(12):4591–9

Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease [letter] Selby R, et al. **Blood** 1997 Jul 15;90(2):891–3

Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Vichinsky EP, et al. **Blood** 1997 Mar 1; 89(5):1787–92

Psychological adjustment and family functioning in a group of British children with sickle cell disease: preliminary empirical findings and a meta-analysis. Midence K, et al. **Br J Clin Psychol** 1996 Sep;35 (Pt 3):439–50

Osteomyelitis of the mandible in sickle cell disease. Olaitan AA, et al. **Br J Oral Maxillofac Surg** 1997 Jun;35(3):190–2

Cardiovascular autonomic dysfunction in sickle cell anemia: a possible risk factor for sudden death? Romero Mestre JC, et al. **Clin Auton Res** 1997 Jun;7(3):121–5

The stability of pain coping strategies in young children adolescents, and adults with sickle cell disease over an 18-month period. Gil KM, et al. **Clin J Pain** 1997 Jun; 13(2):110–5

Impact of bone scintigraphy on the clinical management of a patient with sickle cell anemia and recent chest pain. Sisayan R, et al. **Clin Nucl Med** 1996 Jul;21(7):523–6

Cytologic diagnosis of fat emboli in peripheral blood during sickle cell infarctive crisis. van Hoeven KH, et al. **Diagn Cytopathol** 1997 Jul;17(1):54–6

Sensorineural hearing loss in patients with sickle cell anaemia in Kenya. Tsibulevskaya G, et al. **East Afr Med J** 1996 Jul;73(7):471–3

Systemic fat embolism and pulmonary hypertension in sickle cell disease. Castro O. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1289–303 (76 ref.)

Eye disease in sickling disorders. Charache S. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1357–62 (22 ref.)

Leg ulcers in sickle cell disease. Eckman JR. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1333–44 (74 ref.)

Priapism. Powars DR, et al. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1363–72 (55 ref.)

Bone disorders in sickle cell disease. Smith JA. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1345–56 (43 ref.)

Pulmonary complications. Vichinsky E, et al. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1275–87 (77 ref.)

Renal failure in sickle cell anemia. Wong WY, et al. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1321–31 (69 ref.)

Case in point. Salmon patch-hemorrhages (nonproliferative retinopathy associated with sickle-cell disease). Saif MW, et al. **Hosp Pract (Off Ed)** 1997 Aug 15;32(8):239

Bipolar hip replacement in sickle cell disease. Sanjay BK, et al. **Int Orthop** 1996;20(4):222–6

Propionyl-L-carnitine in chronic leg ulcers of homozygous sickle cell disease: a pilot study. Serjeant BE, et al. **J Am Acad Dermatol** 1997 Sep;37(3 Pt 1):491–3

Sickle cell myonecrosis involving the plantar musculature. Groves J, et al. **J Am Podiatr Med Assoc** 1997 Aug; 87(8):384–8

Results and complications of total hip arthroplasties in patients with sickle-cell hemoglobinopathies. Role of cementless components. Hickman JM, et al. **J Arthroplasty** 1997 Jun;12(4):420–5

Multiple Salmonella typhi subcutaneous abscesses in a sickle cell anaemia patient. Sarma PS, et al. **J Assoc Physicians India** 1996 Aug;44(8):563–4

Hepatic sequestration crisis presenting with severe intrahepatic cholestatic jaundice. Singh NK, et al. **J Assoc Physicians India** 1996 Apr;44(4):283–4

Protein C and protein S activity in sickle cell disease and stroke. Tam DA. **J Child Neurol** 1997 Jan;12(1):19–21

Salmonella osteomyelitis in sickle cell disease children in the east end of London. Atkins BL, et al. **J Infect** 1997 Mar; 34(2):133–8

Emergence of ciprofloxacin resistance during treatment of Salmonella osteomyelitis in three patients with sickle cell disease. Workman MR, et al. **J Infect** 1996 Jan;32(1):27–32

Sarcoidosis presenting with prolonged fever in a patient with sickle cell anemia. Chan ED, et al. **J Natl Med Assoc** 1995 Nov;87(11):826–8

Parasitic infections in sickle cell crisis: Nigerian experience. Sodipo JO, et al. **J Natl Med Assoc** 1997 Apr;89(4):285–8

Scintigraphic evidence of pulmonary vascular occlusion in sickle cell disease. Lisbona R, et al. **J Nucl Med** 1997 Jul; 38(7):1151–3

Sickle cell-related pain: perceptions of medical practitioners. Shapiro BS, et al. **J Pain Symptom Manage** 1997 Sep; 14(3):168–74

Recurrent Streptococcus pneumoniae sepsis in children with sickle cell disease [see comments] Hongeng S, et al. **J Pediatr** 1997 May;130(5):814–6. Comment in: J Pediatr 1997 May;130(5):693–4.

Airway hyperreactivity in children with sickle cell disease. Leong MA, et al. **J Pediatr** 1997 Aug;131(2):278–83

Prevention of pneumococcal disease in sickle cell anemia [editorial; comment] Pearson HA. **J Pediatr** 1996 Dec; 129(6):788–9 (12 ref.). Comment on: J Pediatr 1996 Dec;129(6):821–7. Comment on: J Pediatr 1996 Dec;129(6):828–35.

The febrile child with sickle cell disease: a pediatrician's quandary [editorial; comment] Platt OS. **J Pediatr** 1997 May;130(5):693–4. Comment on: J Pediatr 1997 May;130(5):814–6.

Salmonella infection in sickle cell disease: a clear and present danger [editorial; comment] Ware RE. **J Pediatr** 1997 Mar; 130(3):350–1. Comment on: J Pediatr 1997 Mar;130(3):394–9.

Septicemia caused by Salmonella infection: an overlooked complication of sickle cell disease [see comments] Wright J, et al. **J Pediatr** 1997 Mar;130(3):394–9. Comment in: J Pediatr 1997 Mar;130(3):350–1.

Autoimmune liver disease and sickle cell anemia in children: a report of three cases. Chuang E, et al. **J Pediatr Hematol Oncol** 1997 Mar–Apr;19(2):159–62

Helicobacter pylori gastritis in a child with sickle cell anemia and recurrent abdominal pain. Kennedy L, et al. **J Pediatr Hematol Oncol** 1997 Mar–Apr;19(2):163–4

Skull infarction and epidural hematomas in a patient with sickle cell anemia. Resar LM, et al. **J Pediatr Hematol Oncol** 1996 Nov;18(4):413–5

Influence of penicillin prophylaxis on antimicrobial resistance in nasopharyngeal S. pneumoniae among children with sickle cell anemia. The Ancillary Nasopharyngeal Culture Study of Prophylactic Penicillin Study II. Woods GM, et al. **J Pediatr Hematol Oncol** 1997 Jul–Aug;19(4):327–33

Bone infarction versus infection in sickle cell disease in children. Dalton GP, et al. **J Pediatr Orthop** 1996 Jul–Aug; 16(4):540–4

Osteonecrosis of the humeral head in sickle cell disease. Wingate J, et al. **J South Orthop Assoc** 1996 Summer; 5(2):101–7

Variation in the pattern of bacterial infection in patients with sickle cell disease requiring admission. Akuse RM. **J Trop Pediatr** 1996 Dec;42(6):318–23

Hepatitis E virus infection in patients from Saudi Arabia with sickle cell anaemia and beta-thalassemia major: possible transmission by blood transfusion. al-Fawaz I, et al. **J Viral Hepat** 1996 Jul;3(4):203–5

Sickle cell anemia causes a distinct pattern of glomerular dysfunction. Guasch A, et al. **Kidney Int** 1997 Mar; 51(3):826–33

Migraine and sickle-cell disorders: is there a cause for concern? Salman MS. **Med Hypotheses** 1996 Jun; 46(6):569–71

Management of sickle cell/beta thalassemia patient with severe odontogenic infection. Ziccardi VB, et al. **N Y State Dent J** 1996 Oct;62(8):28–32

Comparison of effect of an anti-inflammatory drug and a narcotic analgesic on renal function in sickle cell anemia [letter] Paydas S, et al. **Nephron** 1996;73(3):498

Nephrotic syndrome in two cases with sickle cell nephropathy [letter] Seyrek N, et al. **Nephron** 1996; 74(1):218

Life-threatening anaemia caused by B19 parvovirus infection in a non-immunocompromised patient. Biesma DH, et al. **Neth J Med** 1997 Feb;50(2):81–4

EC-IC bypass improves chronic ischemia in a patient with moyamoya disease secondary to sickle cell disease: an in vivo microdialysis study. Mendelowitsch A, et al. **Neurol Res** 1997 Feb;19(1):66–70

Comparison of magnetic resonance angiography and conventional angiography in sickle cell disease: clinical significance and reliability. Kandeel AY, et al. **Neuroradiology** 1996 Jul;38(5):409–16

Orbital compression syndrome in sickle cell disease. Curran EL, et al. **Ophthalmology** 1997 Oct;104(10):1610–5 (18 ref.)

Oral complications associated with sickle cell anemia: a review and case report. Kelleher M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Aug;82(2):225–8 (13 ref.)

Differentiation of bone infarct from infection in a child in sickle cell disease. Buchanan GR. **Pediatr Infect Dis J** 1996 Aug;15(8):725

Chronic osteomyelitis caused by Clostridium difficile in an adolescent with sickle cell disease. Gaglani MJ, et al. **Pediatr Infect Dis J** 1996 Nov;15(11):1054–6

Encephaloduroarterio-synangiosis in a child with sickle cell anemia and moyamoya disease. Vernet O, et al. **Pediatr Neurol** 1996 Apr;14(3):226–30

Fatal fat embolism syndrome in a child with undiagnosed hemoglobin S/beta+ thalassemia: a complication of acute parvovirus B19 infection. Kolquist KA, et al. **Pediatr Pathol Lab Med** 1996 Jan–Feb;16(1):71–82

Microangiopathic glomerulopathy in children with sickle cell anemia. Vogler C, et al. **Pediatr Pathol Lab Med** 1996 Mar–Apr;16(2):275–84

Acute chest syndrome of sickle cell disease: radiographic and clinical analysis of 70 cases. Martin L, et al. **Pediatr Radiol** 1997 Aug;27(8):637–41

Plastic bronchitis: an unusual complication associated with sickle cell disease and the acute chest syndrome. Raghuram N, et al. **Pediatrics** 1997 Jul;100(1):139–42

Screening the speech of young patients with sickle cell disease. Gentry B, et al. **Percept Mot Skills** 1997 Apr; 84(2):662

Surgical management of catheter tip thrombus: surgical therapy for right atrial thrombus and fungal endocarditis (Candida tropicalis) complicating paediatric sickle-cell disease. Hollingsed MJ, et al. **Perfusion** 1997 May;

12(3):197–201
Mental disorders in children and adolescents with sickle cell disease. Cepeda ML, et al. **South Med J** 1997 Mar; 90(3):284–7
Higher resistance to Plasmodium falciparum infection in patients with homozygous sickle cell disease in western Kenya. Aluoch JR. **Trop Med Int Health** 1997 Jun; 2(6):568–71
Psychiatric morbidity in patients with sickle cell anaemia. Udofia O, et al. **West Afr J Med** 1996 Oct–Dec; 15(4):196–200
Penicillin–resistant Streptococcus pneumoniae in a Jamaican patient with homozygous sickle–cell disease. Wierenga KJ, et al. **West Indian Med J** 1996 Sep;45(3):95–6
[Evaluation of atherogenic risk in homozygous sickle cell disease: study of lipid and apolipoprotein AI and B plasma levels] Monnet PD, et al. **Bull Soc Pathol Exot** 1996; 89(4):278–81 (Eng. Abstr.) **(Fre)**
[Acute pulmonary syndrome and cavernous pulmonary tuberculosis in a patient with sickle cell disease] Riehl J, et al. **Dtsch Med Wochenschr** 1996 Nov 1;121(44):1354, 1355–8 (Eng. Abstr.) **(Ger)**
[Drepanocytosis: acute osteomyelitis due to Salmonella and bone infarct. Difficulties for diagnosis] Casanova Matutano C, et al. **An Esp Pediatr** 1997 May;46(5):495–8 **(Spa)**

DIAGNOSIS

The complete blood count and reticulocyte count—are they necessary in the evaluation of acute vasoocclusive sickle–cell crisis? Lopez BL, et al. **Acad Emerg Med** 1996 Aug;3(8):751–7
Skull abnormalities on MR of children with sickle cell disease [letter; comment] Murphy KJ. **AJNR Am J Neuroradiol** 1997 Mar;18(3):596. Comment on: AJNR Am J Neuroradiol 1996 May;17(5):965–72.
The application of magnetic resonance techniques to the evaluation of the patient with sickle–cell disease. Terk MR, et al. **Biomed Instrum Technol** 1996 Jul–Aug;30(4):349–53 (12 ref.)
Validation of an automated HPLC method for quantification of hemoglobin S. Fisher SI, et al. **Clin Chem** 1997 Sep; 43(9):1667–9
Imaging in the diagnosis of musculoskeletal infections in children. Mandell GA. **Curr Probl Pediatr** 1996 Aug; 26(7):218–37 (46 ref.)
Multivariant confirmation of sickle cell disease using a non–radioactive minisequencing reaction. Tuuminen T, et al. **Hemoglobin** 1997 Jan;21(1):71–89
Quantitative MR imaging of children with sickle cell disease: striking T1 elevation in the thalamus. Steen RG, et al. **J Magn Reson Imaging** 1996 Jan–Feb;6(1):226–34
Newborn screening for sickle cell disease [letter; comment] Ballas SK, et al. **J Pediatr Hematol Oncol** 1996 Nov; 18(4):418–9. Comment on: J Pediatr Hematol Oncol 1996 Feb;18(1):36–41.
Fatal fat embolism syndrome in a child with undiagnosed hemoglobin S/beta+ thalassemia: a complication of acute parvovirus B19 infection. Kolquist KA, et al. **Pediatr Pathol Lab Med** 1996 Jan–Feb;16(1):71–82
Intrasplenic masses of "preserved" functioning splenic tissue in sickle cell disease: correlation of imaging findings (CT, ultrasound, MRI, and nuclear scintigraphy). Levin TL, et al. **Pediatr Radiol** 1996 Sep;26(9):646–9
Failure rates of young patients with sickle cell disease on a hearing screening test. Gentry B, et al. **Percept Mot Skills** 1997 Apr;84(2):434
Language and motor skills of preschool children with sickle cell disease. Gentry B, et al. **Percept Mot Skills** 1997 Apr; 84(2):486
Reproductive behaviour of couples at risk for sickle cell disease in Cuba: a follow–up study. Dorticós–Balea A, et al. **Prenat Diagn** 1997 Aug;17(8):737–42

DRUG THERAPY

Piracetam is useful in the treatment of children with sickle cell disease. el–Hazmi MA, et al. **Acta Haematol** 1996; 96(4):221–6
RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Adams–Graves P, et al. **Blood** 1997 Sep 1;90(5):2041–6
Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietary magnesium intake in transgenic SAD mouse. De Franceschi L, et al. **Blood** 1996 Oct 1;88(7):2738–44
Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Steinberg MH, et al. **Blood** 1997 Feb 1; 89(3):1078–88
Decrease of very late activation antigen–4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Styles LA, et al. **Blood** 1997 Apr 1; 89(7):2554–9
Thrombosis, megaloblastic anaemia, and sickle cell disease: a unified hypothesis [letter] Ballas SK, et al. **Br J Haematol** 1997 Mar;96(4):879–80
Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle–cell anaemia. Hackney AC, et al. **Clin Sci (Colch)** 1997 May;92(5):481–6
Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. Charache S, et al. **Control Clin Trials** 1995 Dec;16(6):432–46
Recurrent Streptococcus pneumoniae sepsis in children with sickle cell disease [see comments] Hongeng S, et al. **J Pediatr** 1997 May;130(5):814–6. Comment in: J Pediatr 1997 May;130(5):693–4.
Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. Jayabose S, et al. **J Pediatr** 1996 Oct;129(4):559–65
Transdermal fentanyl administration in children and adolescents with sickle cell pain crisis. Christensen ML, et al. **J Pediatr Hematol Oncol** 1996 Nov;18(4):372–6
Three–year follow–up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. de Montalembert M, et al. **J Pediatr Hematol Oncol** 1997 Jul–Aug;19(4):313–8
Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Charache S, et al. **Medicine (Baltimore)** 1996 Nov;75(6):300–26
Hydroxyurea, sickle cell disease and renal transplantation [letter] Allen A, et al. **Nephron** 1997;75(1):106–7

ECONOMICS

Cost of hospitalizations associated with sickle cell disease in the United States [see comments] Davis H, et al. **Public Health Rep** 1997 Jan–Feb;112(1):40–3. Comment in: Public Health Rep 1997 Jan–Feb;112(1):38–9.
Sickle cell disease expenditures and outcomes [comment] Schechter AN. **Public Health Rep** 1997 Jan–Feb; 112(1):38–9 (9 ref.). Comment on: Public Health Rep 1997 Jan–Feb;112(1):40–3. Comment on: Public Health Rep 1997 Jan–Feb;112(1):44–51. Comment on: Public Health Rep 1997 Jan–Feb;112(1):52–8.
Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Woods K, et al. **Public Health Rep** 1997 Jan–Feb;112(1):44–51

ENZYMOLOGY

Immunohistochemical localization of hepatic nitric oxide synthase in normal and transgenic sickle cell mice: the effect of hypoxia. Osei SY, et al. **Blood** 1996 Nov 1; 88(9):3583–8
Renal nitric oxide synthases in transgenic sickle cell mice. Bank N, et al. **Kidney Int** 1996 Jul;50(1):184–9

EPIDEMIOLOGY

Reproductive behaviour and natural selection for the sickle gene in the Baiga tribe of central India: the role of social parenting. Reddy PH, et al. **Ann Hum Genet** 1996 May; 60 (Pt 3):231–6
Milder clinical course of sickle cell disease in patients with alpha thalassemia in the Indian subcontinent [letter] Mukherjee MB, et al. **Blood** 1997 Jan 15;89(2):732
The prevalence of sickle cell trait in Sierra Leone. A laboratory profile. Wurie AT, et al. **West Afr J Med** 1996 Oct–Dec;15(4):201–3
[Neonatal screening for sickle–cell disease] Wierenga KJ. **Ned Tijdschr Geneeskd** 1997 Jan 25;141(4):184–7 (Eng. Abstr.) **(Dut)**
[Current aspects of sickle cell disease in children in Gabon] Thuilliez V, et al. **Arch Pediatr** 1996 Jul;3(7):668–74 (Eng. Abstr.) **(Fre)**

ETIOLOGY

The structural link between polymerization and sickle cell disease. Mirchev R, et al. **J Mol Biol** 1997 Feb 7; 265(5):475–9

GENETICS

Morbidity, beta S haplotype and alpha–globin gene patterns among sickle cell anemia patients in Kuwait. Adekile AD, et al. **Acta Haematol** 1996;96(3):150–4
Effect of alpha–thalassemia and beta–globin gene cluster haplotypes on the hematological and clinical features of sickle–cell anemia in Brazil. Figueiredo MS, et al. **Am J Hematol** 1996 Oct;53(2):72–6
Sickle cell disorder, beta–globin gene cluster haplotypes and alpha–thalassemia in neonates and adults from Guadeloupe. Kéclard L, et al. **Am J Hematol** 1997 May;55(1):24–7
Effect of alpha–thalassemia on sickle–cell anemia linked to the Arab–Indian haplotype in India. Mukherjee MB, et al. **Am J Hematol** 1997 Jun;55(2):104–9
Reproductive behaviour and natural selection for the sickle gene in the Baiga tribe of central India: the role of social parenting. Reddy PH, et al. **Ann Hum Genet** 1996 May; 60 (Pt 3):231–6
Activation of delta–globin gene expression by erythroid Krupple–like factor: a potential approach for gene therapy of sickle cell disease. Donze D, et al. **Blood** 1996 Nov 15; 88(10):4051–7
The relative importance of the X–linked FCP locus and beta–globin haplotypes in determining haemoglobin F levels: a study of SS patients homozygous for beta S haplotypes. Chang YP, et al. **Br J Haematol** 1997 Mar; 96(4):806–14
Ligase chain reaction assay for human mutations: the Sickle Cell by LCR assay. Reyes AA, et al. **Clin Chem** 1997 Jan; 43(1):40–4
The origin of the sickle cell gene [editorial] Aluoch JR. **East Afr Med J** 1996 Sep;73(9):565
Frequency of sickle cell gene in Arabia. el–Hazmi MA, et al. **Gene Geogr** 1996 Aug;10(2):87–91
DNA haplotypes in Africans and West Indians with sickle cell anaemia or SC disease. Konstantopoulos K, et al. **Gene Geogr** 1996 Apr;10(1):19–24
Efficiency of prenatal counselling for sickle cell disease in Guadeloupe. Alexandre L, et al. **Genet Couns** 1997; 8(1):25–32
Sickle cell gene in the population of Saudi Arabia. el–Hazmi MA, et al. **Hemoglobin** 1996 Aug;20(3):187–98
beta S haplotypes, alpha–globin gene status, and hematological data of sickle cell disease patients in Guadeloupe (F.W.I.). Kéclard L, et al. **Hemoglobin** 1996 Feb;20(1):63–74
Sequence polymorphisms of potential functional relevance in the beta–globin gene locus. Labie D, et al. **Hemoglobin** 1996 May;20(2):85–101 (53 ref.)
The sickle haplotypes in Guadeloupe and the African gene flow [editorial] Nagel RL. **Hemoglobin** 1996 Feb;20(1):v–vii
Modulation of the phenotypic diversity of sickle cell anemia. Steinberg MH. **Hemoglobin** 1996 Feb;20(1):1–19 (88 ref.)
Polymorphism in exon 10 of the human coagulation factor V gene in a population at risk for sickle cell disease. Helley D, et al. **Hum Genet** 1997 Aug;100(2):245–8
Genotype–phenotype analysis in HbS–beta–thalassemia. Altay C, et al. **Hum Hered** 1997 May–Jun;47(3):161–4
Distribution of composite CYP1A1 genotypes in Africans, African–Americans and Caucasians. Garte SJ, et al. **Hum Hered** 1996 May–Jun;46(3):121–7
Sickle cell trait & disease among tribal communities in Orissa, Madhya Pradesh & Kerala. Kaur M, et al. **Indian J Med Res** 1997 Mar;105:111–6
Magnetic resonance evidence of hypoxia in a homozygous alpha–knockout of a transgenic mouse model for sickle cell disease. Fabry ME, et al. **J Clin Invest** 1996 Dec 1; 98(11):2450–5
Sickle cell screening policies as portent: how will the human genome project affect public sector genetic services? Phoenix DD, et al. **J Natl Med Assoc** 1995 Nov; 87(11):807–12
Sickle cell and G–6–PD deficiency gene in cord blood samples: experience at King Khalid University Hospital, Riyadh. al–Nuaim L, et al. **J Trop Pediatr** 1997 Apr; 43(2):71–4
Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood [see comments] Cheung MC, et al. **Nat Genet** 1996 Nov;14(3):264–8. Comment in: Nat Genet 1996 Nov;14(3):239–40.
Sickle cell anemia research and a recombinant DNA technique [letter; comment] Stasiak A, et al. **Science** 1997 Jul 25;277(5325):460–2. Comment on: Science 1996 Sep 6;273(5280):1386–9.
Recombinant DNA technique and sickle cell anemia research [letter; comment] Thomas KR, et al. **Science** 1997 Mar 7; 275(5305):1404–5. Comment on: Science 1996 Sep 6;273(5280):1386–9.
[Sickle cell anemia and malaria—interferences] Năsçuţiu AM. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan–Jun; 42(1–2):11–4 (31 ref.) (Eng. Abstr.) **(Rum)**
[Anemia of falciform cells and the genetics of the Mexican population] Peñaloza R, et al. **Gac Med Mex** 1996 May–Jun;132(3):337–8 **(Spa)**

HISTORY

Genetic marker of segregation: sickle cell anemia, thalassemia, and racial ideology in American medical writing 1920–1950. Wailoo K. **Pubbl Stn Zool Napoli II** 1996;18(3):305–20
The second reported case of sickle cell anemia. Charlottesville, Virginia, 1911. Savitt TL. **Va Med Q** 1997 Spring;124(2):84–92

IMMUNOLOGY

Red blood cell alloimmunization in sickle cell disease: the influence of racial and antigenic pattern differences between donors and recipients in Brazil. Moreira Júnior G, et al. **Am J Hematol** 1996 Jul;52(3):197–200
Antibody responses to Haemophilus influenzae type b conjugate vaccine in sickle cell disease. Goldblatt D, et al. **Arch Dis Child** 1996 Aug;75(2):159–61
Alloimmunization to platelets in heavily transfused patients with sickle cell disease. Friedman DF, et al. **Blood** 1996 Oct 15;88(8):3216–22
Hemoglobin–specific antibody in a multiply transfused patient with sickle cell disease. Noronha PA, et al. **Blood** 1997 Mar 15;89(6):2155–8
Enhanced levels of soluble VCAM–1 in sickle cell patients and their specific increment during vasoocclusive crisis. Duits AJ, et al. **Clin Immunol Immunopathol** 1996 Oct; 81(1):96–8
Serotype–specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis [see comments] Bjornson AB, et al. **J Pediatr** 1996 Dec;129(6):828–35. Comment in: J Pediatr 1996 Dec;129(6):788–9.
[Immunologic aspects related to hemoglobinopathic diseases] Muñoz MA, et al. **Rev Med Panama** 1996 Sep;21(3):107–12 (Eng. Abstr.) **(Spa)**

ANEMIA, SICKLE CELL

METABOLISM

Is there an energy deficiency in homozygous sickle cell disease? [see comments] Singhal A, et al. **Am J Clin Nutr** 1997 Aug;66(2):386–90. Comment in: Am J Clin Nutr 1997 Aug;66(2):423–4.

Case report: splenomegaly and splenic sequestration in an adult with sickle cell anemia. Moll S, et al. **Am J Med Sci** 1996 Dec;312(6):299–302

Do HbSS erythrocytes lose KCl in physiological conditions? Godart H, et al. **Br J Haematol** 1997 Jul;98(1):25–31

Pulse oximetry in a cohort study of sickle cell disease. Homi J, et al. **Clin Lab Haematol** 1997 Mar;19(1):17–22

Increased red cell glutamine availability in sickle cell anemia: demonstration of increased active transport, affinity, and increased glutamate level in intact red cells. Niihara Y, et al. **J Lab Clin Med** 1997 Jul;130(1):83–90

Protein and energy metabolism in prepubertal children with sickle cell anemia. Salman EK, et al. **Pediatr Res** 1996 Jul; 40(1):34–40

MICROBIOLOGY

Pneumococcal colonization in children with sickle cell disease [see comment] Norris CF, et al. **J Pediatr** 1996 Dec; 129(6):821–7. Comment on: J Pediatr 1996 Dec;129(6):788–9.

Influence of penicillin prophylaxis on antimicrobial resistance in nasopharyngeal S. pneumoniae among children with sickle cell anemia. The Ancillary Nasopharyngeal Culture Study of Prophylactic Penicillin Study II. Woods GM, et al. **J Pediatr Hematol Oncol** 1997 Jul–Aug;19(4):327–33

MORTALITY

Cancer incidence rate and mortality rate in sickle cell disease patients at Howard University Hospital: 1986–1995. Dawkins FW, et al. **Am J Hematol** 1997 Aug;55(4):188–92

National trends in the mortality of children with sickle cell disease, 1968 through 1992. Davis H, et al. **Am J Public Health** 1997 Aug;87(8):1317–22

Geographic differences in mortality of young children with sickle cell disease in the United States [published erratum appears in Public Health Rep 1997 Mar–Apr;112(2):89] Davis H, et al. **Public Health Rep** 1997 Jan–Feb;112(1):52–8

NURSING

Emergency! Sickle cell crisis. Chiocca EM. **Am J Nurs** 1996 Sep;96(9):49

Caring for the pregnant woman with sickle cell disease. Montgomery KS. **MCN Am J Matern Child Nurs** 1996 Sep–Oct;21(5):224–8 (10 ref.)

PATHOLOGY

Inhibition of sickle erythrocyte adhesion to immobilized thrombospondin by von Willebrand factor under dynamic flow conditions. Barabino GA, et al. **Blood** 1997 Apr 1; 89(7):2560–7

Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. Hebbel RP. **J Clin Invest** 1997 Jun 1; 99(11):2561–4 (17 ref.)

Stochastic nature and red cell population distribution of the sickling–induced Ca2+ permeability. Lew VL, et al. **J Clin Invest** 1997 Jun 1;99(11):2727–35

Alveolar bone patterns in sickle cell anemia and non–sickle cell anemia adolescent Nigerians: a comparative study. Arowojolu MO, et al. **J Periodontol** 1997 Mar;68(3):225–8

PHYSIOPATHOLOGY

Diagnostic evaluation for infectious etiology of sickle cell pain crisis. Ander DS, et al. **Am J Emerg Med** 1997 May; 15(3):290–2

Influence of alpha–thalassemia trait on spleen function in sickle cell anemia patients with high HbF. Adekile AD, et al. **Am J Hematol** 1996 Sep;53(1):1–5

Hb S/Hb Lepore with mild sickling symptoms: a hemoglobin variant with mostly delta–chain sequences ameliorates sickle–cell disease. Fairbanks VF, et al. **Am J Hematol** 1997 Feb;54(2):164–5

Assessment of painful episode frequency in sickle–cell disease. Westerman MP, et al. **Am J Hematol** 1997 Mar; 54(3):183–8

Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Pegelow CH, et al. **Am J Med** 1997 Feb;102(2):171–7

The pathophysiology of vascular obstruction in the sickle syndromes. Kaul DK, et al. **Blood Rev** 1996 Mar; 10(1):29–44 (153 ref.)

Splenic regrowth in sickle cell anaemia following hypertransfusion. Campbell PJ, et al. **Br J Haematol** 1997 Jan;96(1):77–9

Twenty–four–hour pattern in emergency department presentation for sickle cell vaso–occlusive pain crisis. Auvil–Novak SE, et al. **Chronobiol Int** 1996 Dec; 13(6):449–56

Management of sickle pain. Ballas SK. **Curr Opin Hematol** 1997 Mar;4(2):104–11 (59 ref.)

Pathophysiology of vaso–occlusion. Ballas SK, et al. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1221–39 (132 ref.)

Pathophysiology of sickle cell anemia. Bookchin RM, et al. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1241–53 (61 ref.)

Radionuclide (MUGA) studies of left ventricular functional abnormalities in asymptomatic patients with sickle cell anemia. Pani S, et al. **Indian Heart J** 1995 Sep–Oct; 47(5):489–92

Pulmonary entrapment of sickle cells: the role of regional alveolar hypoxia. Aldrich TK, et al. **J Appl Physiol** 1996 Feb;80(2):531–9

Psickle, the temporary leaky link between sickling and cellular dehydration [editorial] Ranney HM. **J Clin Invest** 1997 Jun 1;99(11):2559–60

The endothelial biology of sickle cell disease. Hebbel RP, et al. **J Lab Clin Med** 1997 Mar;129(3):288–93 (59 ref.)

Oxidative activation of K–Cl cotransport by diamide in erythrocytes from humans with red cell disorders, and from several other mammalian species. Adragna NC, et al. **J Membr Biol** 1997 Feb 1;155(3):207–17

Renal abnormalities in patients with sickle cell–beta thalassemia. Katopodis KP, et al. **J Nephrol** 1997 May–Jun; 10(3):163–7

Sickle cell anemia causes a distinct pattern of glomerular dysfunction. Guasch A, et al. **Kidney Int** 1997 Mar; 51(3):826–33

A rat model for sickle cell–mediated vaso–occlusion in retina. Lutty GA, et al. **Microvasc Res** 1996 Nov;52(3):270–80

Pathogenesis and treatment of sickle cell disease. Bunn HF. **N Engl J Med** 1997 Sep 11;337(11):762–9 (73 ref.)

PREVENTION & CONTROL

Perception of sickle cell haemoglobinopathy among 'would–be' counsellors. Omotade OO. **Afr J Med Med Sci** 1995 Dec;24(4):315–20

Penicillin–resistant Aerococcus viridans bacteremia in a child receiving prophylaxis for sickle–cell disease. Swanson H, et al. **Clin Infect Dis** 1996 Feb;22(2):387–8

Neonatal screening for sickle cell disease in a metropolitan university hospital: efficacy and problems. Ballas SK, et al. **J Med Screen** 1994 Oct;1(4):229–32

Newborn metabolic disorder screening program: sickle cell disease and other hemoglobinopathies [news] Parkhurst J. **J Okla State Med Assoc** 1997 Jul–Aug;90(6):256–7

The role of preventive medicine in sickle cell disease. The Watson Smith lecture. Serjeant GR. **J R Coll Physicians Lond** 1996 Jan–Feb;30(1):37–41 (10 ref.)

[Neonatal detection of sickle cell disease in metropolitan France. Association française pour le dépistage et la prévention des handicaps de l'enfant (AFDPHE)] Galactéros F. **Arch Pediatr** 1996 Oct;3(10):1026–31 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Psychological adjustment and family functioning in a group of British children with sickle cell disease: preliminary empirical findings and a meta–analysis. Midence K, et al. **Br J Clin Psychol** 1996 Sep;35 (Pt 3):439–50

Psychiatric complications of homozygous sickle cell disease among young adults in the Jamaican Cohort Study. Hilton C, et al. **Br J Psychiatry** 1997 Jan;170:69–76

Depiction of pain in the self–drawings of children with sickle cell disease. Stefanatou A, et al. **Child Care Health Dev** 1997 Mar;23(2):135–55

The stability of pain coping strategies in young children adolescents, and adults with sickle cell disease over an 18–month period. Gil KM, et al. **Clin J Pain** 1997 Jun; 13(2):110–5

The adolescent with sickle cell anemia. Kinney TR, et al. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1255–64 (23 ref.)

A comparison study of children with sickle cell disease and their non–diseased siblings on hopelessness, depression, and perceived competence. Lee EJ, et al. **J Adv Nurs** 1997 Jan;25(1):79–86

Psychological adjustment of adults with sickle cell anemia: stability over 20 months, correlates, and predictors. Thompson RJ Jr, et al. **J Clin Psychol** 1996 May; 52(3):253–61

Empirically validated family interventions for pediatric psychology: sickle cell disease as an exemplar. Kaslow NJ, et al. **J Pediatr Psychol** 1997 Apr;22(2):213–27

Hope, coping, and adjustment among children with sickle cell disease: tests of mediator and moderator models. Lewis HA, et al. **J Pediatr Psychol** 1996 Feb;21(1):25–41

Academic performance among children with sickle cell disease: setting minimum standards for comparison groups. Richard HW, et al. **Psychol Rep** 1997 Aug;81(1):27–34

RADIOGRAPHY

Chest case of the day. Extramedullary hematopoiesis (EMH). Gilkeson RC, et al. **AJR Am J Roentgenol** 1997 Jul; 169(1):267, 270–3

RADIONUCLIDE IMAGING

Scintigraphy and ultrasonography in differentiating osteomyelitis from bone infarction in sickle cell disease. Rifai A, et al. **Acta Radiol** 1997 Jan;38(1):139–43 (12 ref.)

SURGERY

Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Preoperative Transfusion in Sickle Cell Disease Study Group. Haberkern CM, et al. **Blood** 1997 Mar 1;89(5):1533–42

The effect of splenectomy for hypersplenism on whole body protein turnover, resting metabolic rate and growth in sickle cell disease. Badaloo AV, et al. **Eur J Clin Nutr** 1996 Oct;50(10):672–5

Partial splenectomy in children with sickle cell disease and repeated episodes of splenic sequestration. Svarch E, et al. **Hemoglobin** 1996 Nov;20(4):393–400

Laparoscopic splenectomy in childhood hematologic disorders. Hicks BA, et al. **J Laparoendosc Surg** 1996 Mar; 6 Suppl 1:S31–4

THERAPY

American Academy of Pediatrics publishes guidelines on the management of sickle cell disease. **Am Fam Physician** 1997 Apr;55(5):1973–4, 1976

Review: sickle cell disease: present and future treatment. Steinberg MH. **Am J Med Sci** 1996 Oct;312(4):166–74 (103 ref.)

Case reports: delayed hemolytic transfusion reaction in sickle cell disease. Syed SK, et al. **Am J Med Sci** 1996 Oct; 312(4):175–81

Indications for blood transfusion in pregnancy with sickle cell disease. El–Shafei AM, et al. **Aust N Z J Obstet Gynaecol** 1995 Nov;35(4):405–8

Barriers to bone marrow transplantation for sickle cell anemia. Walters MC, et al. **Biol Blood Marrow Transplant** 1996 May;2(2):100–4

Hemoglobin–specific antibody in a multiply transfused patient with sickle cell disease. Noronha PA, et al. **Blood** 1997 Mar 15;89(6):2155–8

Blood transfusion in sickle cell disease. Davies SC, et al. **Blood Rev** 1997 Jun;11(2):57–71 (148 ref.)

Management of patients with sickle cell disease. Davies SC, et al. **BMJ** 1997 Sep 13;315(7109):656–60 (44 ref.)

Evaluation of fast track admission policy for children with sickle cell crises: questionnaire survey of parents' preferences. Fertleman CR, et al. **BMJ** 1997 Sep 13; 315(7109):650

Sickle cell disease is poorly managed [news] Westall J. **BMJ** 1997 Feb 8;314(7078):396

Automated red cell exchange in sickle cell disease. Janes SL, et al. **Br J Haematol** 1997 May;97(2):256–8

Chronic transfusion programmes in sickle cell disease: problem or panacea? Serjeant GR. **Br J Haematol** 1997 May;97(2):253–5

Management of sickling conditions in pregnancy. Howard RJ. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):7–10 (20 ref.)

Experience with the Port–A–Cath in sickle cell disease. McCready CE, et al. **Clin Lab Haematol** 1996 Jun; 18(2):79–82

New therapies and approaches to transfusion in sickle cell disease in children. Styles LA, et al. **Curr Opin Pediatr** 1997 Feb;9(1):41–5 (32 ref.)

Experimental therapy. Charache S. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1373–82 (67 ref.)

Treating anemia. King KE, et al. **Hematol Oncol Clin North Am** 1996 Dec;10(6):1305–20 (71 ref.)

A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study. Gonzalez P, et al. **J Investig Med** 1997 Jun; 45(5):258–64

The febrile child with sickle cell disease: a pediatrician's quandary [editorial; comment] Platt OS. **J Pediatr** 1997 May;130(5):693–4. Comment on: J Pediatr 1997 May;130(5):814–6.

Pathogenesis and treatment of sickle cell disease. Bunn HF. **N Engl J Med** 1997 Sep 11;337(11):762–9 (73 ref.)

Bone marrow transplantation for sickle cell disease [letter; comment] Rehman KL. **N Engl J Med** 1996 Dec 12; 335(24):1845–6. Comment on: N Engl J Med 1996 Aug 8;335(6):369–76.

Sickle cell anemia [letter] Telfair J. **Public Health Rep** 1997 May–Jun;112(3):177

Severe reactions associated with transfusion of patients with sickle cell disease [editorial; comment] Garratty G. **Transfusion** 1997 Apr;37(4):357–61. Comment on: Transfusion 1997 Apr;37(4):376–81. Comment on: Transfusion 1997 Apr;37(4):382–92.

Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells [see comments] King KE, et al. **Transfusion** 1997 Apr; 37(4):376–81. Comment in: Transfusion 1997 Apr;37(4):357–61.

The sickle cell hemolytic transfusion reaction syndrome [see comments] Petz LD, et al. **Transfusion** 1997 Apr; 37(4):382–92. Comment in: Transfusion 1997 Apr;37(4):357–61.

Screening with monoclonal anti–Fy3 to provide blood for phenotype–matched transfusions for patients with sickle cell disease. Sandler SG, et al. **Transfusion** 1997 Apr; 37(4):393–7

[Hepatitis C seropositivity after multiple transfusions in sickle cell anemia patients in Yaounde, Cameroon (letter)]

Kemmegne J, et al. **Med Trop (Mars)** 1996;56(3):309–10 **(Fre)**

[Pharma clinics. How I treat... Falciform anemia in children] Oury AP, et al. **Rev Med Liege** 1996 Oct;51(10):623–6 **(Fre)**

ULTRASONOGRAPHY

Scintigraphy and ultrasonography in differentiating osteomyelitis from bone infarction in sickle cell disease. Rifai A, et al. **Acta Radiol** 1997 Jan;38(1):139–43 (12 ref.)

Renal length in sickle cell disease: observations from a cohort study. Walker TM, et al. **Clin Nephrol** 1996 Dec;46(6):384–8

VIROLOGY

Hepatitis E virus infection in patients from Saudi Arabia with sickle cell anaemia and beta-thalassemia major: possible transmission by blood transfusion. al-Fawaz I, et al. **J Viral Hepat** 1996 Jul;3(4):203–5

ANEMIA, SIDEROBLASTIC

The naming of a syndrome. Pearson HA. **J Pediatr Hematol Oncol** 1997 Jul–Aug;19(4):271–3

CLASSIFICATION

Mixed myelodysplastic and myeloproliferative syndromes. Neuwirtová R, et al. **Leuk Res** 1996 Sep;20(9):717–26

COMPLICATIONS

Sideroblastic anemia terminating in chronic myeloid leukemia [letter] Bandieri E, et al. **Am J Hematol** 1997 Jan; 54(1):89–90

Primary acquired sideroblastic anemia, thrombocytosis, and trisomy 8. Patel K, et al. **Ann Hematol** 1997 Apr; 74(4):199–201

Haemochromatosis Cys282Tyr mutation in pyridoxine-responsive sideroblastic anaemia [letter; comment] Yaouanq J, et al. **Lancet** 1997 May 17; 349(9063):1475–6. Comment on: Lancet 1997 Feb 1;349(9048):296–7.

DIAGNOSIS

Unusual anemias [clinical conference] Phatak PD, et al. **Am J Hematol** 1997 Mar;54(3):249–52

DRUG THERAPY

Vitamin B6 responsive sideroblastic anaemia in a patient with tuberculosis. Demiroglu H, et al. **Br J Clin Pract** 1997 Jan–Feb;51(1):51–2

[Is chloroquine useful in the the treatment of sideroblastic refractory anemia? (letter)] García Pérez A, et al. **Sangre (Barc)** 1996 Apr;41(2):162 **(Spa)**

ENZYMOLOGY

Pyridoxine refractory X-linked sideroblastic anemia caused by a point mutation in the erythroid 5-aminolevulinate synthase gene. Furuyama K, et al. **Blood** 1997 Jul 15; 90(2):822–30

ETIOLOGY

Sideroblastic anemia recurring during two pregnancies. Jackson N, et al. **Int J Hematol** 1996 Dec;65(1):85–8

[Acquired sideroblastic anemia and cholestasis in a hyperthyroid patient treated with methimazole and atenolol] Mamianetti A, et al. **Medicina (B Aires)** 1995; 55(6):693–6 (Eng. Abstr.) **(Spa)**

GENETICS

Pyridoxine refractory X-linked sideroblastic anemia caused by a point mutation in the erythroid 5-aminolevulinate synthase gene. Furuyama K, et al. **Blood** 1997 Jul 15; 90(2):822–30

A novel form of hereditary sideroblastic anaemia with macrocytosis. Tuckfield A, et al. **Br J Haematol** 1997 May; 97(2):279–85

Identification of an arginine452 to histidine substitution in the erythroid 5-aminolaevulinate synthetase gene in a large pedigree with X-linked hereditary sideroblastic anaemia. Edgar AJ, et al. **Eur J Haematol** 1997 Jan;58(1):1–4

PATHOLOGY

Sideroblastic anemia: a mitochondrial disorder. Bridges KR. **J Pediatr Hematol Oncol** 1997 Jul–Aug;19(4):274–8 (51 ref.)

RADIONUCLIDE IMAGING

Localization of technetium-99m-sestamibi in diffuse myelodysplastic processes. Reiman RE, et al. **J Nucl Med** 1996 Mar;37(3):471–3

URINE

Phosphaturia, glycosuria and aminoaciduria associated with idiopathic acquired sideroblastic anemia. Hanson B, et al. **Clin Nephrol** 1995 Dec;44(6):382–8

ANEMIA, SPLENIC see **HYPERSPLENISM**

ANENCEPHALY

Comparative study of fetal behaviour in a case of monozygotic twins, one being anencephalic. Kurauchi O, et al. **Gynecol Obstet Invest** 1996;42(3):209–10

Infants with anencephaly, the ADA, and the Child Abuse Amendments. Crossley M. **Issues Law Med** 1996 Spring; 11(4):379–410

Anencephalic organ donation. Rhodes AM. **MCN Am J Matern Child Nurs** 1996 Jan–Feb;21(1):15

Testing the standards of death. Rhodes AM. **MCN Am J Matern Child Nurs** 1996 Mar–Apr;21(2):109

Anencephaly, dorsal hypermelia, and duplication of the vertebral column: a rare type of rachipagus conjoined twins. Spencer R, et al. **Teratology** 1996 Apr;53(4):253–60

Anencephalics as organ sources. Sytsma SE. **Theor Med** 1996 Mar;17(1):19–32

[A case of twin death with a co-twin of the acardius acephalus type] Alaniz-Sánchez A, et al. **Ginecol Obstet Mex** 1996 Oct;64:467–70 (Eng. Abstr.) **(Spa)**

BLOOD

Maternal serum alpha-fetoprotein in fetal neural tube and abdominal wall defects at 10 to 14 weeks of gestation. Sebire NJ, et al. **Br J Obstet Gynaecol** 1997 Jul; 104(7):849–51

DIAGNOSIS

Diagnostic dilemma with elevated level of alpha-fetoprotein in an undiagnosed twin pregnancy with a small discordant holoacardius acephalus. Entezami M, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):466–8

EMBRYOLOGY

Pituitary morphology in anencephalic human fetuses. Pilavdzic D, et al. **Neuroendocrinology** 1997 Mar; 65(3):164–72

[Effect of amniotic fluid on cell differentiation in neural tissue culture in pathologic embryo development (anencephaly)] Bobryshev IuV, et al. **Biull Eksp Biol Med** 1996 Jul; 122(7):87–90 **(Rus)**

EPIDEMIOLOGY

High incidence of anencephaly and legal rights. Nassaralla SM, et al. **Braz J Med Biol Res** 1996 Oct;29(10):1301–6

Analysis of seasonal data using the Lorenz curve and the associated Gini index. Lee WC. **Int J Epidemiol** 1996 Apr; 25(2):426–34

[A five years surveillance on neural system birth defects in rural areas of China] Hu YH, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Feb; 17(1):20–4 (Eng. Abstr.) **(Chi)**

[Preventive program of birth defects: incidence of anencephaly in Maracaibo, Venezuela. 1993–1996 period] Moreno-Fuenmayor H, et al. **Invest Clin** 1996 Dec; 37(4):271–8 (Eng. Abstr.) **(Spa)**

[High incidence of anencephaly in the East coast of the Maracaibo Lake: a myth (editorial)] Moreno-Fuenmayor H. **Invest Clin** 1996 Dec;37(4):207–8 **(Spa)**

ETIOLOGY

Lack of serologic evidence for an association between Cache Valley Virus infection and anencephaly and other neural tube defects in Texas. Edwards JF, et al. **Emerg Infect Dis** 1997 Apr–Jun;3(2):195–7 (19 ref.)

Is maternal obesity a risk factor for anencephaly and spina bifida? Watkins ML, et al. **Epidemiology** 1996 Sep; 7(5):507–12

GENETICS

A report of recurrent anencephaly with trisomy 2p23–2pter: additional evidence for the involvement of 2p24 in neural tube development and evaluation of the role for cytogenetic analysis. Winsor SH, et al. **Prenat Diagn** 1997 Jul; 17(7):665–9

MORTALITY

Sex differences in prevalence of congenital neural defects after periconceptional famine exposure. Brown AS, et al. **Epidemiology** 1997 Jan;8(1):55–8

NURSING

Stress and distress in pediatric nurses: lessons from Baby K. Perkin RM, et al. **Am J Crit Care** 1997 May;6(3):225–32

PATHOLOGY

Adrenal glands in anencephaly. Bocian-Sobkowska J, et al. **Folia Morphol (Warsz)** 1996;55(4):214–6

Comparative stereological study on zonation and cellular composition of adrenal glands of normal and anencephalic human fetuses. I. Zonation of the gland. Bocian-Sobkowska J, et al. **Histol Histopathol** 1997 Apr;12(2):311–7

Comparative stereological studies on zonation and cellular composition of adrenal glands of normal and anencephalic human fetuses. II. Cellular composition of the gland. Bocian-Sobkowska J, et al. **Histol Histopathol** 1997 Apr; 12(2):391–9

PHYSIOPATHOLOGY

Reactivity of skin blood flow and heart rate to external thermal stimulation in anencephaly. Jahnukainen T, et al. **Acta Paediatr** 1997 Apr;86(4):426–7

The diurnal rhythm in fetal heart rate in a twin pregnancy with discordant anencephaly: comparison with three normal twin pregnancies. Lunshof S, et al. **Early Hum Dev** 1997 Apr 25;48(1–2):47–57

PREVENTION & CONTROL

Doubling the number of women consuming vitamin supplement pills containing folic acid: an urgently needed birth defect prevention complement to the folic acid fortification of cereal grains. Oakley GP Jr. **Reprod Toxicol** 1997 Jul–Aug;11(4):579–81

Comparison of national policies on periconceptional use of folic acid to prevent spina bifida and anencephaly (SBA). Cornel MC, et al. **Teratology** 1997 Feb;55(2):134–7

THERAPY

Management of twin pregnancies discordant for anencephaly. Sebire NJ, et al. **Br J Obstet Gynaecol** 1997 Feb; 104(2):216–9

The Baby K case: a search for the elusive standard of medical care. Schneiderman LJ, et al. **Camb Q Healthc Ethics** 1997 Winter;6(1):9–18

ULTRASONOGRAPHY

Crown–chin length in normal and anencephalic fetuses at 10 to 14 weeks' gestation. Sepulveda W, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):852–5

Concordant anencephaly in monoamniotic twins and an analysis of maternal serum markers. Hansen LM, et al. **Prenat Diagn** 1997 May;17(5):471–3

Ultrasound screening for anencephaly at 10–14 weeks of gestation. Johnson SP, et al. **Ultrasound Obstet Gynecol** 1997 Jan;9(1):14–6

ANESTHESIA

Preparation of adult patients for anaesthesia and surgery. Arvidsson S. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):962–70 (40 ref.)

Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Bendixen D, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):480–4

Metabolic, ventilatory and circulatory effects of doxapram in anaesthetized pigs during normoxia and hypoxia. Björk L, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):919–26

A simple method of ventilation via the laryngeal mask during transportation and recovery from anaesthesia [letter] Brimacombe J, et al. **Acta Anaesthesiol Scand** 1996 Nov; 40(10):1258

Improvement of arterial oxygenation by selective infusion of prostaglandin E1 to ventilated lung during one-lung ventilation [see comments] Chen TL, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):7–13. Comment in: Acta Anaesthesiol Scand 1996 Jan;40(1):2–4.

Not another database paper? [editorial; comment] Davies JM. **Acta Anaesthesiol Scand** 1996 Nov;40(10):1169–70. Comment on: Acta Anaesthesiol Scand 1996 Nov;40(10):1173–83.

Fasting guidelines in different countries. Eriksson LI, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):971–4

Data recording of problems during anaesthesia: presentation of a well-functioning and simple system [see comments] Fasting S, et al. **Acta Anaesthesiol Scand** 1996 Nov; 40(10):1173–83. Comment in: Acta Anaesthesiol Scand 1996 Nov;40(10):1169–70.

Manipulating pulmonary blood flow during one-lung anaesthsia [editorial; comment] Hedenstierna G, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):2–4. Comment on: Acta Anaesthesiol Scand 1996 Jan;40(1):7–13.

Pre-anaesthetic evaluation and management of patients with cardiovascular disease. Hultman J. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):996–1003

Haemodynamic effects of high-dose vecuronium compared with pancuronium in beta-blocked patients with coronary artery disease during fentanyl-diazepam-nitrous oxide anaesthesia. Husby P, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):26–31

The influence of the duration of isoflurane anaesthesia on neuromuscular effects of mivacurium. Jalkanen L, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):248–51

The place of alpha-2-agonists in anaesthesiology of today [editorial] Kanto J. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 1):4–5

Preoperative evaluation of difficult intubation [letter; comment] Kessell G. **Acta Anaesthesiol Scand** 1997 Mar; 41(3):432. Comment on: Acta Anaesthesiol Scand 1996 Apr;40(4):421–4.

Perioperative management of children. Lindahl SG. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):975–81

Hepatic energy charge and adenine nucleotide status in rats anesthetized with halothane, isoflurane or enflurane. Mets B, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):252–5

Recovery and outcome after propofol and isoflurane anesthesia in patients undergoing laparoscopic hysterectomy. Nelskylä K, et al.

Acta Anaesthesiol Scand 1997 Mar;41(3):360–3

Basis of anaesthesia--what do we know after 150 years? [editorial] Raeder JC. **Acta Anaesthesiol Scand** 1996 Oct; 40(9):1068–72

Delayed elevation of plasma endothelin-1 during unilateral alveolar hypoxia without systemic hypoxemia in humans. Takeda S, et al. **Acta Anaesthesiol Scand** 1997 Feb; 41(2):274–80

Angiotensin-converting enzyme inhibitors and anaesthesia [letter] Tohmo H, et al. **Acta Anaesthesiol Scand** 1996 Jan; 40(1):132–3

The Radiometer Prize 1995 [editorial] Viby-Mogensen J. **Acta Anaesthesiol Scand** 1996 May;40(5):509

About the real prevalence of difficult laryngoscopy [letter; comment] Voyagis GS, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):430–1. Comment on: Acta Anaesthesiol Scand 1996 Apr;40(4):421–4.

Deliberate hypotensive anesthesia with labetalol in reconstructive surgery for scoliosis [published erratum appears in Acta Anaesthesiol Sin 19997 Mar;35(1):59] Sum DC, et al. **Acta Anaesthesiol Sin** 1996 Dec;34(4):203–7

Shortening and superlon-wrapping the downstream tube can increase the useful range of the blood warmer. Tseng CC, et al. **Acta Anaesthesiol Sin** 1996 Sep;34(3):123–8

Combined technique of anesthesia in early and late neck reconstruction. Jandová J, et al. **Acta Chir Plast** 1997; 39(2):56–9

Comparison of the analgesic effect of EMLA cream and EMLA patch on normal skin evaluated with laser-induced pain stimuli. Egekvist H, et al. **Acta Derm Venereol** 1997 May;77(3):214–6

Enhanced increase of plasma sodium pump inhibitory activity to saline expansion in vagosympathectomized and anaesthetized dogs. Rodríguez-Martínez M, et al. **Acta Physiol Scand** 1997 May;160(1):95–102

Mapping quantitative trait loci for ethanol-induced anesthesia in LSxSS recombinant inbred and F2 mice: methodology and results. Bennett B, et al. **Alcohol Alcohol Suppl** 1994; 2:79–86

Endothelium-dependent pulmonary vasodilation is selectively attenuated during isoflurane anesthesia. Gambone LM, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H290–8

Medullary vasomotor activity and hypoxic sympathoexcitation in pentobarbital-anesthetized rats. Sun MK, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):R348–55

Auto- and cross-spectral analysis of cardiovascular fluctuations during pentobarbital anesthesia in the rat. Yang CC, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):H575–82

Infection Control in Anesthesia. Proceedings of a symposium. November 1994. **Anaesth Intensive Care** 1996 Apr; 24(2):149–96

Abstracts of the combined scientific meeting of the Australian and New Zealand College of Anaesthetists, Faculty of Intensive Care and Australian Society of Anesthetists. Western Australia, October 26–30, 1996. **Anaesth Intensive Care** 1997 Apr;25(2):171–93

20 year cumulative index. Volumes 1–20, 1972–1992. **Anaesth Intensive Care** 1996;:1–104

The role of the anaesthetist during the transjugular intrahepatic porto-systemic stent shunt procedure (TIPPS). Kam PC, et al. **Anaesth Intensive Care** 1997 Aug; 25(4):385–9

Colour coded drug packaging [letter; comment] Adejumo SW. **Anaesthesia** 1996 Dec;51(12):1185. Comment on: Anaesthesia 1996 May;51(5):506–7.

Cholinesterase. Its significance in anaesthetic practice [see comments] Davis L, et al. **Anaesthesia** 1997 Mar; 52(3):244–60 (260 ref.). Comment in: Anaesthesia 1997 Jul;52(7):714.

Routine suxamethonium in children. A regional survey of current usage [see comments] Robinson AL, et al. **Anaesthesia** 1996 Sep;51(9):874–8. Comment in: Anaesthesia 1997 Feb;52(2):189.

End-tidal oxygraphy and safe duration of apnoea in young adults and elderly patients [letter; comment] Snowdon SL. **Anaesthesia** 1997 Jun;52(6):606–7. Comment on: Anaesthesia 1997 Feb;52(2):175–8.

Parental presence during induction of anaesthesia [letter; comment] Watts J. **Anaesthesia** 1997 Mar;52(3):284. Comment on: Anaesthesia 1996 Nov;51(11):1008–12.

International Anesthesia Research Society 71st Clinical and Scientific Congress. San francisco, California, March 14–18, 1997. Abstracts. **Anesth Analg** 1997 Feb;84(2 Suppl):S1–662

Propofol and early extubation after cardiac surgery [letter; comment] Chaney MA. **Anesth Analg** 1997 Jul;85(1):228–9 . Comment on: Anesth Analg 1997 Jan;84(1):12–9.

A randomized multicenter study of remifentanil compared with alfentanil, isoflurane, or propofol in anesthetized pediatric patients undergoing elective strabismus surgery. Davis PJ, et al. **Anesth Analg** 1997 May;84(5):982–9

Anesthesia patient information on the World Wide Web [letter; comment] Doyle DJ. **Anesth Analg** 1997 May; 84(5):1167–8. Comment on: Anesth Analg 1996 Dec;83(6):1314–21.

Remifentanil and pulmonary extraction during and after cardiac anesthesia. Duthie DJ, et al. **Anesth Analg** 1997 Apr;84(4):740–4

Intravenous clonidine decreases minimum end-tidal isoflurane for induction of electroencephalographic burst suppression. Entholzner EK, et al. **Anesth Analg** 1997 Jul; 85(1):193–8

Anesthetic potencies of n-alkanols: results of additivity and solubility studies suggest a mechanism of action similar to that for conventional inhaled anesthetics. Fang Z, et al. **Anesth Analg** 1997 May;84(5):1042–8

Anesthesia providers, patient outcomes, and costs [letter; comment] Gaba DM. **Anesth Analg** 1996 Dec;83(6):1347–8; discussion 1349–50. Comment on: Anesth Analg 1996 Jun;82(6):1273–83.

Anesthesia providers, patient outcomes, and costs [letter; comment] Hanna K. **Anesth Analg** 1996 Dec;83(6):1348; discussion 1349–50. Comment on: Anesth Analg 1996 Jun;82(6):1273–83.

Acute pulmonary edema in a young male after intravenous nalmefene. Henderson CA, et al. **Anesth Analg** 1997 Jan; 84(1):218–9

Clinical management of latex-allergic children. Holzman RS. **Anesth Analg** 1997 Sep;85(3):529–33

Ketamine in porphyria [letter; comment] Kanbak M. **Anesth Analg** 1997 Jun;84(6):1395. Comment on: Anesth Analg 1995 Mar;80(3):591–9.

The safety of dantrolene in a patient with a severe cardiomyopathy requiring a heart transplant [letter] Koehntop DE, et al. **Anesth Analg** 1997 Jul;85(1):229–30

Does midazolam cause retrograde amnesia, and can flumazenil reverse that amnesia? Koht A, et al. **Anesth Analg** 1997 Jul;85(1):211–2

Anesthesia providers, patient outcomes, and costs [letter; comment] Kremer M. **Anesth Analg** 1996 Dec;83(6):1348–9; discussion 1349–50. Comment on: Anesth Analg 1996 Jun;82(6):1117–8. Comment on: Anesth Analg 1996 Jun;82(6):1273–83.

Tenth annual meeting of the Society for Pediatric Anesthesia, New Orleans, Louisiana, October 18, 1996. Martin LD, et al. **Anesth Analg** 1997 Apr;84(4):934–7

Hemodynamic effects, myocardial ischemia, and timing of tracheal extubation with propofol-based anesthesia for cardiac surgery [see comments] Myles PS, et al. **Anesth Analg** 1997 Jan;84(1):12–9. Comment in: Anesth Analg 1997 Jul;85(1):228–9.

Hemodynamic effects of anesthesia in patients with ischemic heart failure chronically treated with angiotensin-converting enzyme inhibitors. Ryckwaert F, et al. **Anesth Analg** 1997 May;84(5):945–9

Propofol anesthesia increases dopamine and serotonin activities at the somatosensory cortex in rats: a microdialysis study. Shyr MH, et al. **Anesth Analg** 1997 Jun;84(6):1344–8

Anesthesia providers, patient outcomes, and costs [letter; comment] Stoelting RK. **Anesth Analg** 1996 Dec; 83(6):1347; discussion 1349–50. Comment on: Anesth Analg 1996 Jun;82(6):1273–83.

Dose-response and time course of effect of rocuronium in male and female anesthetized patients. Xue FS, et al. **Anesth Analg** 1997 Sep;85(3):667–71

Assessment of the potency and intrinsic activity of systemic versus intrathecal opioids in rats. Abram SE, et al. **Anesthesiology** 1997 Jul;87(1):127–34; discussion 27A–29A

Compound A concentrations during sevoflurane anesthesia in children depend on fresh gas flow [letter; comment] Aldrete JA. **Anesthesiology** 1996 Sep;85(3):684. Comment on: Anesthesiology 1996 Mar;84(3):566–71.

Response to "Ethical concerns in anesthetic care for patients with do-not-resusitate orders" [letter; comment] Berry JM, et al. **Anesthesiology** 1997 Jul;87(1):174; discussion 178–9. Comment on: Anesthesiology 1996 Nov;85(5):1190–3.

Response to "Ethical concerns in anesthetic care for patients with do-not-resuscitate orders" [letter; comment] Cohen CB, et al. **Anesthesiology** 1997 Jul;87(1):175–6; discussion 178–9. Comment on: Anesthesiology 1996 Nov;85(5):1190–3.

Elusive artifact and cost issues with computerized patient records for anesthesia (CPRA) [letter] Edsall DW, et al. **Anesthesiology** 1997 Sep;87(3):721–2

Remifentanil versus remifentanil/midazolam for ambulatory surgery during monitored anesthesia care. Gold MI, et al. **Anesthesiology** 1997 Jul;87(1):51–7

The ventilation-perfusion relation and gas exchange in mitral valve disease and coronary artery disease. Implications for anesthesia, extracorporeal circulation, and cardiac surgery. Hachenberg T, et al. **Anesthesiology** 1997 Apr;86(4):809–17

Response to "Ethical concerns in anesthetic care for patients with do-not-resuscitate orders" [letter; comment] Jackson SH. **Anesthesiology** 1997 Jul;87(1):176–8; discussion 178–9 . Comment on: Anesthesiology 1996 Nov;85(5):1190–3.

Nitric oxide, cyclic guanosine monophosphate, and the anesthetic state [editorial; comment] Johns RA. **Anesthesiology** 1996 Sep;85(3):457–9. Comment on: Anesthesiology 1996 Sep;85(3):544–50.

Microvascular oxygen delivery and interstitial oxygenation during sodium pentobarbital anesthesia. Kerger H, et al. **Anesthesiology** 1997 Feb;86(2):372–86

Sensing cold and producing heat [editorial; comment] Lindahl SG. **Anesthesiology** 1997 Apr;86(4):758–9. Comment on: Anesthesiology 1997 Apr;86(4):772–7.

Induction of anesthesia and tracheal intubation with sevoflurane in adults. Muzi M, et al. **Anesthesiology** 1996 Sep;85(3):536–43

How can we demonstrate that new developments in anesthesia are of real clinical importance? [letter; comment] Rigg JR, et al. **Anesthesiology** 1997 Apr;86(4):1008–11. Comment on: Anesthesiology 1996 Jan;84(1):1–2. Comment on: Anesthesiology 1996 Jan;84(1):3–13.

Effect of cranial surgery and brain tumor size on emergence from anesthesia. Schubert A, et al. **Anesthesiology** 1996 Sep; 85(3):513–21

Perioperative transfusion strategies: a national survey among anaesthetists. Loo S, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):193–9

Ten years of sedoanalgesia and how it has affected urological practice. Miller RA. **Arch Ital Urol Androl** 1997 Feb; 69(1):29–33

Continuous wavelet transform of aortic pressure oscillations in anesthetized dogs: effects of 45 degrees tilting. Jiménez RF, et al. **Biol Res** 1997;30(2):53–64

Paediatric anaesthesia [see comments] Russell SC, et al. **BMJ** 1997 Jan 18;314(7075):201–3 (35 ref.). Comment in: BMJ 1997 Apr 19;314(7088):1203.

European Society of Anaesthesiologists annual congress. Lausanne, 3–6 May 1997. Abstracts. **Br J Anaesth** 1997 May;78 Suppl 1:1–142

European Association of Cardiothoracic Anaesthesiologists 12th annual meeting. Thessaloniki, Greece, 25–28 Jun 1997. Abstracts. **Br J Anaesth** 1997 Jun;78 Suppl 2:1–53

Effect of amino acid infusion on body temperature during anaesthesia [letter; comment] Donmez A, et al. **Br J Anaesth** 1997 Mar;78(3):338–9. Comment on: Br J Anaesth 1996 Feb;76(2):227–34.

Calculation of drug dosage and body surface area of children. Lack JA, et al. **Br J Anaesth** 1997 May;78(5):601–5

Does anaesthesia have long-term consequences? [editorial] Masterson GR, et al. **Br J Anaesth** 1996 Nov;77(5):569–71

Cytokines in anaesthesia. Sheeran P, et al. **Br J Anaesth** 1997 Feb;78(2):201–19 (148 ref.)

Pharmacokinetics of thiopentone enantiomers following intravenous injection or prolonged infusion of rac-thiopentone. Cordato DJ, et al. **Br J Clin Pharmacol** 1997 Apr;43(4):355–62

Decreased dorsal raphe nucleus neuronal activity in adult chloral hydrate anesthetized rats following neonatal clomipramine treatment: implications for endogenous depression. Kinney GG, et al. **Brain Res** 1997 May 9; 756(1-2):68–75

Discharge patterns of dorsal and ventral respiratory group neurons during spontaneous augmented breaths observed in pentobarbital anesthetized rats. Takeda M, et al. **Brain Res** 1997 Feb 21;749(1):95–100

Relations between acetylcholine release and electrophysiological characteristics of theta rhythm: a microdialysis study in the urethane-anesthetized rat hippocampus. Monmaur P, et al. **Brain Res Bull** 1997; 42(2):141–6

Ketamine modulation of the temporal pattern of discharges and spike train interactions in the rat substantia nigra pars reticulata. Villa AE, et al. **Brain Res Bull** 1997;43(6):525–35

Detecting wakefulness in anaesthetised children. Byers GF, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):486–8

Public relations in anaesthesia. Eltringham R. **Can J Anaesth** 1997 May;44(5 Pt 2):R131–6 **(Eng, Fre)**

The myocardium. Foëx P, et al. **Can J Anaesth** 1997 May; 44(5 Pt 2):R67–76 (53 ref.) **(Eng, Fre)**

Novel targets of pain modulation in anaesthesia: preventing painful memories [editorial; comment] Gilron I, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):457–62. Comment on: Can J Anaesth 1997 May;44(5 Pt 1):543–9. **(Eng, Fre)**

Alpha-2 adrenergic agonists. Kamibayashi T, et al. **Can J Anaesth** 1997 May;44(5 Pt 2):R13–22 (50 ref.) **(Eng, Fre)**

Use and misuse of syringes in anaesthesia [editorial] Lessard MR, et al. **Can J Anaesth** 1997 Aug;44(8):793–7 **(Eng, Fre)**

Heart rate and cardiac output after atropine in anaesthetised infants and children. McAuliffe G, et al. **Can J Anaesth** 1997 Feb;44(2):154–9

Stethoscopy during anaesthesia. McIntyre JW. **Can J Anaesth** 1997 May;44(5 Pt 1):535–42 (88 ref.)

Anaesthesia and analgesia in the emergency department. Murphy MF. **Can J Anaesth** 1997 May;44(5 Pt 2):R52–66 (33 ref.) **(Eng, Fre)**

Ciguatera and the anesthesiologist [letter] Ortega RA, et al. **Can J Anaesth** 1996 Oct;43(10):1080

Heat conservation vs convective warming in adults undergoing elective surgery. Patel N, et al. **Can J Anaesth** 1997 Jun;44(6):669–73

Anaesthesia in Barbados. Shankar KB, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):559–68

Airway management in neuroanaesthesia. Spiekermann BF, et al. **Can J Anaesth** 1996 Aug;43(8):820–34 (93 ref.)

Misleading end-tidal CO2 tensions. Wahba RW, et al. **Can J Anaesth** 1996 Aug;43(8):862–6 (23 ref.)

The barbarism of managed care, revisited [letter; comment] Bittar DA. **Chest** 1996 Dec;110(6):1623. Comment on: Chest 1996 Jul;110(1):1–2.

Local anesthesia with thoracoscopic talc poudrage pleurodesis [letter] Kavuru MS, et al. **Chest** 1996 Oct; 110(4):1126–7

Anesthetic considerations in chest trauma. Fouché Y, et al. **Chest Surg Clin N Am** 1997 May;7(2):227–38 (22 ref.)

Sedation, analgesia, and anesthesia issues in the pediatric patient. Goad RN, et al. **Clin Podiatr Med Surg** 1997 Jan; 14(1):131–48 (30 ref.)

Anesthesia is not dreamland. Peluso A. **Conn Med** 1997 Jun; 61(6):351–2

Hemodynamic effects of carcinine in the anesthetized,

instrumented, open-chest rat. Steinberg C, et al. **Crit Care Med** 1996 Dec;24(12):2042-5

Noninvasive endoscopical measurement of gastric mucosal blood flow in the anesthetized rat. Yamamoto Y, et al. **Digestion** 1996 Nov-Dec;57(6):420-3

Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice. Bryson HM, et al. **Drugs** 1997 May;53(5):848-66 (66 ref.)

The effects of cortical stimulation, anesthesia and recording site on somatosensory evoked potentials in the rat. Koyanagi I, et al. **Electroencephalogr Clin Neurophysiol** 1996 Dec;101(6):534-42

Attenuation of the haemodynamic responses to noxious stimuli in patients undergoing cataract surgery. A comparison of magnesium sulphate, esmolol, lignocaine, nitroglycerine and placebo given i.v. with induction of anaesthesia. van den Berg AA, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):134-47

Propofol neuroprotection in a rat model of ischaemia reperfusion injury. Young Y, et al. **Eur J Anaesthesiol** 1997 May;14(3):320-6

How to manage drug interactions. Glass PS, et al. **Eur J Anaesthesiol Suppl** 1997 May;15:33-9

Monitoring depth of anaesthesia. Schneider G, et al. **Eur J Anaesthesiol Suppl** 1997 May;15:21-8 (106 ref.)

Early enhancement but no late changes of motor responses induced by intracortical microstimulation in the ketamine-anesthetized rat. Gu X, et al. **Exp Brain Res** 1996 Feb;108(1):119-28

Anesthesia ventilators with descending bellows: the need for appropriate monitoring. **Health Devices** 1996 Oct; 25(10):391-3

The effect of anesthesia on intravenous glucose tolerance test in the rat [letter; comment] Leow CK. **Hepatology** 1997 Mar;25(3):782-3. Comment on: Hepatology 1996 Mar;23(3):582-8.

Effects of catecholamines and diazepam in chloroquine poisoning in barbiturate anaesthetised rats. Buckley NA, et al. **Hum Exp Toxicol** 1996 Nov;15(11):909-14

Anaesthetic management of patients undergoing surgery for tachyarrhythmias. Initial experience with 16 patients. Tempe DK, et al. **Indian Heart J** 1997 Mar-Apr; 49(2):173-8

Anesthetic management for surgical ablation of giant cerebral aneurysms. Larson CP Jr. **Int Anesthesiol Clin** 1996 Fall; 34(4):151-60

Surgical intervention and anesthetic management of the patient with Parkinson's disease. Mason LJ, et al. **Int Anesthesiol Clin** 1996 Fall;34(4):133-50 (75 ref.)

1st International Symposium on Decision Support in Anaesthesia and Intensive Care. Mainz, Germany, September 25-28, 1996. Abstracts. **Int J Clin Monit Comput** 1997 Feb;14(1):49-68

A modified Trigg's Tracking Variable as an 'advisory' alarm during anaesthesia. Kennedy RR. **Int J Clin Monit Comput** 1995;12(4):197-204

Pulsed laser treatment in children and the use of anesthesia. Grevelink JM, et al. **J Am Acad Dermatol** 1997 Jul; 37(1):75-81

Noxious stimuli do not determine reflex cardiorespiratory effects in anesthetized rabbits. Raimondi G, et al. **J Appl Physiol** 1996 Dec;81(6):2421-7

Increased activity of bulbospinal cardiovascular neurons in the rat rostral ventrolateral medulla upon emergence from anaesthesia. Frugière A, et al. **J Auton Nerv Syst** 1996 Oct 7;61(1):87-95

Anesthesia and thermal injury [letter; comment] Sjöberg F, et al. **J Burn Care Rehabil** 1996 May-Jun;17(3):285-6. Comment on: J Burn Care Rehabil 1994 May-Jun;15(3):224-31.

Positive end-expiratory pressure during one-lung ventilation improves oxygenation in patients with low arterial oxygen tensions. Cohen E, et al. **J Cardiothorac Vasc Anesth** 1996 Aug;10(5):578-82

Heart rate variability as an assessment of cardiovascular status. Fleisher LA. **J Cardiothorac Vasc Anesth** 1996 Aug; 10(5):659-71 (96 ref.)

Computerized data collection in the operating room during coronary artery bypass surgery: a comparison to the hand-written anesthesia record. Hollenberg JP, et al. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):545-51

Perioperative cardiovascular care [editorial] Murray MJ. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):173-4

Computerized recordkeeping and information management in cardiothoracic and vascular anesthesia [editorial] Reich DL. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):543-4

Is there a role for the Carlen's double-lumen tube in cardiothoracic anesthesia? [letter; comment] Thangathurai D, et al. **J Cardiothorac Vasc Anesth** 1996 Aug;10(5):693. Comment on: J Cardiothorac Vasc Anesth 1995 Feb;9(1):116.

Fuzzy logic: theory and medical applications. Vitez TS, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):800-8 (33 ref.)

Anesthesia and minimally invasive thoracoscopically assisted coronary artery bypass: a brief clinical report. Wasnick JD, et al. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):552-5

A comparison of the endobronchial segment of modern left-sided double-lumen tubes in anesthesia for bilateral sequential lung transplantation. Watterson LM, et al. **J Cardiothorac Vasc Anesth** 1996 Aug;10(5):583-5

Gas chromatography in anaesthesia. I. A brief review of analytical methods and gas chromatographic detector and column systems. Uyanik A. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):1-9 (62 ref.)

Desire for perioperative information in adult patients: a cross-sectional study. Kain ZN, et al. **J Clin Anesth** 1997 Sep;9(6):467-72

Intraoperative management of distal tracheal rupture with selective bronchial intubation. Lobato EB, et al. **J Clin Anesth** 1997 Mar;9(2):155-8

Pipecuronium revisited: dose-response and maintenance requirement in infants, children, and adults. Meretoja OA, et al. **J Clin Anesth** 1997 Mar;9(2):125-9

Rocuronium versus succinylcholine for rapid-sequence induction using a variation of the timing principle. Nelson JM, et al. **J Clin Anesth** 1997 Jun;9(4):317-20

Preoperative anesthetic concerns of men and women in the ambulatory surgical setting [letter] Zvara DA, et al. **J Clin Anesth** 1997 Feb;9(1):88-9

The implementation and acceptance of an intra-operative anesthesia information management system. Coleman RL, et al. **J Clin Monit** 1997 Mar;13(2):121-8

APSF grants support key safety research [news] Cooper JB. **J Clin Monit** 1997 Jan;13(1):59-65

Computerized pre-anesthetic evaluation results in additional abstracted comorbidity diagnoses. Gibby GL, et al. **J Clin Monit** 1997 Jan;13(1):35-41

Basic principles of optical radiation and some common applications in anesthesia. Gravenstein D, et al. **J Clin Monit** 1996 Nov;12(6):445-54 (75 ref.)

Will "cost containment" decrease safety? Noted observer considers relative safety risks [news] Gravenstein JS [news]. **J Clin Monit** 1996 Mar;12(2):199-202

OR reading debate continues in my opinion: lack of outcome data makes reading a personal decision, states OR investigator [news] Weinger MB. **J Clin Monit** 1996 Jan; 12(1):109-10

Safe anaesthesia in infants and children [letter] Sarangi BK, et al. **J Indian Med Assoc** 1996 Jan;94(1):34,36

The role of anesthesia in the advancement of surgical technique. Loucks EB. **J Invest Surg** 1997 May-Jun; 10(3):iii-iv

Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors. Anderson A, et al. **J Med Chem** 1997 May 23;40(11):1668-81

Cutaneous responsiveness of lumbar spinal neurons in awake and halothane-anesthetized sheep. Herrero JF, et al. **J Neurophysiol** 1995 Oct;74(4):1549-62

Changes in oxygenation variables during progressive hypothermia in anesthetized patients. Bacher A, et al. **J Neurosurg Anesthesiol** 1997 Jul;9(3):205-10

Anesthesia for carotid endarterectomy: a survey. Cheng MA, et al. **J Neurosurg Anesthesiol** 1997 Jul;9(3):211-6

Specific modulation of two neuronal digitalis receptors by anaesthesia. Gerbi A, et al. **J Recept Signal Transduct Res** 1997 Jan-May; 17(1-3):137-47

Anesthesia type does not influence early graft patency or limb salvage rates of lower extremity arterial bypass. Pierce ET, et al. **J Vasc Surg** 1997 Feb;25(2):226-32; discussion 232-3

The effect of epidural xylazine on halothane minimum alveolar concentration in ponies. Doherty TJ, et al. **J Vet Pharmacol Ther** 1997 Jun;20(3):246-8

The use of isoflurane anaesthesia in studies of carnitine metabolism in the laboratory rat. Davis AT. **Lab Anim** 1996 Oct;30(4):377-82

Cardiopulmonary and analgesic effects of xylazine, detomidine, medetomidine, and the antagonist atipamezole in isoflurane-anesthetized swine. Tendillo FJ, et al. **Lab Anim Sci** 1996 Apr;46(2):215-9

Arterial to end-tidal CO2 gradient as an adjunct to unmasking silent pulmonary embolism [letter] Taniguchi S, et al. **Lancet** 1996 Dec 21-28;348(9043):1733

Java's abstract window toolkit and the automated anesthesia record. Gage JS. **MD Comput** 1997 Mar-Apr;14(2):94-6, 99

Day ophthalmic surgery: aspects of perioperative care [letter; comment] Siebert S. **Med J Aust** 1997 May 5;166(9):511-2. Comment on: Med J Aust 1996 Oct 7;165(7):379-81.

Awareness during anesthesia. Azar N. **Middle East J Anesthesiol** 1997 Feb;14(1):65-70 (7 ref.)

Mivacurium in an obese patient with myotonic dystrophy--a case report. Yazigi A, et al. **Middle East J Anesthesiol** 1997 Jun;14(2):77-82

Compatibility of reduced glutathione (GSH) with different solutions currently used in anesthesia and reanimation. Mangiameli S, et al. **Minerva Anestesiol** 1995 Oct; 61(10):407-9

The effect of a preanaesthetic information booklet on patient understanding and satisfaction. Courtney MJ. **N Z Med J** 1997 Jun 13;110(1045):212-4

NK1 and CGRP receptor-mediated dilatation of the carotid arterial bed of the anaesthetized rabbit. Perren MJ, et al. **Neuropeptides** 1996 Apr;30(2):141-8

NADPH-diaphorase reactivity is reduced in the molecular layer but increased in the granular layer of primate cerebellum after prolonged anaesthesia. Yan XX, et al. **Neurosci Lett** 1997 Jul 18;230(2):125-8

The tenth annual meeting of the Society for Pediatric Anesthesia, held at the New Orleans Marriott hotel, New Orleans, Louisiana, USA, October 18 1996. Bush GH. **Paediatr Anaesth** 1997;7(1):59-60

Joint meeting of the Association of Paediatric Anaesthetists of Great Britain and Ireland and the Belgian Association of Paediatric Anaesthetists. Bush GH. **Paediatr Anaesth** 1996;6(1):50

Unsuspected subglottic stenosis in a two-year-old. Chhibber AK, et al. **Paediatr Anaesth** 1997;7(1):65-7

Difficult intubation in paediatrics. Frei FJ, et al. **Paediatr Anaesth** 1996;6(4):251-63 (166 ref.)

Difficulty with a preformed tube in a neonate [letter] McDonald DS, et al. **Paediatr Anaesth** 1997;7(1):87

Haemothorax following central line placement [letter] Margolis JO, et al. **Paediatr Anaesth** 1997;7(2):178

Paediatric anaesthesiologist, the winds of change' [letter; comment] Smith RM. **Paediatr Anaesth** 1996;6(4):342. Comment on: Paediatr Anaesth 1995;5(5):277-8. Comment on: Paediatr Anaesth 1995;5(5):279-80.

Rocuronium in infants, children and adults during balanced anaesthesia. Taivainen T, et al. **Paediatr Anaesth** 1996; 6(4):271-5

Respiratory depression following administration of low dose buprenorphine as postoperative analgesic after fentanyl balanced anaesthesia. Zanette G, et al. **Paediatr Anaesth** 1996;6(5):419-22

Pentobarbital alters the response of cerebrospinal fluid pressure evoked by two provocative tests in rats. Searles RV, et al. **Pharmacology** 1996 Feb;52(2):78-85

Influence of selected antiarrhythmic drugs on the hemodynamic parameters in rabbits during anesthesia. Part III. Ketamine anesthesia. Orszulak-Michalak D. **Pol J Pharmacol** 1995 Sep-Oct;47(5):407-16

Cough and other reflexes on irritation of airway mucosa in man. Nishino T, et al. **Pulm Pharmacol** 1996 Oct-Dec; 9(5-6):285-92

Patterns of anesthesia and nursing care for interventional radiology procedures: a national survey of physician practices and preferences. Mueller PR, et al. **Radiology** 1997 Feb;202(2):339-43

American Society of Regional Anesthesia Future Directions of Acute Pain Management. Consensus conference. Orlando, Florida, May 31-June 2, 1996. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):1-159 (0 ref.)

Ventral medullary surface activity during hypoxia in awake and anesthetized goats. Forster HV, et al. **Respir Physiol** 1996 Jan;103(1):45-56

Anaesthesia for appendicectomy in childhood: a survey of practice in Northern Ireland. Weir PS. **Ulster Med J** 1997 May;66(1):34-7

Intra-articular anesthesia of the distal interphalangeal joint alleviates lameness associated with the navicular bursa in horses. Pleasant RS, et al. **Vet Surg** 1997 Mar-Apr; 26(2):137-40

[The incidence of double-lumen tubes displacement after positioning of patients during anesthesia] Cheng KS, et al. **Acta Anaesthesiol Sin** 1996 Jun;34(2):75-80 (Eng. Abstr.) **(Chi)**

[Summary of national symposium on anesthesia and perioperative management for critically ill patients] **Chung Hua I Hsueh Tsa Chih** 1996 Oct;76(10):725-7 **(Chi)**

[Advances in the study of anesthesia in patients with carcinoid syndrome] Huang YG, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jul;76(7):536-8 (15 ref.) (Eng. Abstr.) **(Chi)**

[Critically ill patients: anesthesia and perioperative management (editorial)] Jin Q, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Oct;76(10):723-4 **(Chi)**

[Progresses in anesthesiology in China, 1996] Luo A, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):914-6 (0 ref.) **(Chi)**

[Importance of plasma (histamine and tryptase) and urinary (methylhistamine) in peri-anesthetic anaphylactic and/or anaphylactoid reactions] Cottineau C, et al. **Allerg Immunol (Paris)** 1996 Oct;28(8):270, 273-6 (Eng. Abstr.) **(Fre)**

[The anesthetist's point of view in the surgical treatment of morbid obesity] Munsch Y, et al. **Ann Chir** 1997;51(2):183-8 (Eng. Abstr.) **(Fre)**

[Anesthesia-resuscitation in surgery for pheochromocytoma] Tavernier B, et al. **Ann Chir** 1997;51(4):352-60 (84 ref.) (Eng. Abstr.) **(Fre)**

[Consensus conference. Use of human albumin solutions in surgical anesthesia and surgical intensive care of adults. Saint-Mandé, France, 15 December 1995] **Ann Fr Anesth Reanim** 1996;15(4):407-568 (0 ref.) **(Fre)**

[Use of human albumin solutions in surgical anesthesia and critical care in adults] **Ann Fr Anesth Reanim** 1996; 15(4):414-23 **(Fre)**

[Anesthesia-resuscitation in war situations. Apropos of 43 cases] Escarment J, et al. **Chirurgie** 1997;122(3):207-11 (Eng. Abstr.) **(Fre)**

[Upper endoscopy, sedation and anesthesia: what needs? what conditions? (editorial)] Vallot T, et al. **Gastroenterol Clin Biol** 1996;20(6-7):561-3 **(Fre)**

[Pain, anesthesia and drug addiction] Carpentier M. **Rev Stomatol Chir Maxillofac** 1997 Aug;98(2):120-2 (Eng. Abstr.) **(Fre)**

[The clinical pharmacology of mivacurium] Diefenbach C, et al. **Anaesthesist** 1997 May;46(5):385-8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Anesthesia in endovascular treatment of aortic aneurysm. Results and perioperative risks] Eberle B, et al. **Anaesthesist** 1996 Oct;45(10):931–40 (Eng. Abstr.) **(Ger)**

[New muscle relaxants. Update on mivacurium, rocuronium and cis-atracurium] Fuchs-Buder T. **Anaesthesist** 1997 Apr;46(4):350–9 (17 ref.) **(Ger)**

[Automated anesthesia record systems] Heinrichs W, et al. **Anaesthesist** 1997 Jul;46(7):574–82 (37 ref.) (Eng. Abstr.) **(Ger)**

[NO inhalation in heart surgery procedures: relevance for right heart function?] Knothe C, et al. **Anaesthesist** 1996 Mar;45(3):240–8 (Eng. Abstr.) **(Ger)**

[The effects of cimetidine on the pharmacodynamics of rocuronium] Latorre F, et al. **Anaesthesist** 1996 Oct; 45(10):900–2 (Eng. Abstr.) **(Ger)**

[Ethical conflicts during anesthesia. "Do not resuscitate" orders in the operating room] Mohr M. **Anaesthesist** 1997 Apr;46(4):267–74 (36 ref.) (Eng. Abstr.) **(Ger)**

[The laryngeal mask--a valuable instrument for cases of difficult intubation in children. Anesthesiologic management in the presence of Pierre-Robin syndrome (see comments)] Ofer R, et al. **Anaesthesist** 1996 Mar; 45(3):268–70 (Eng. Abstr.). Comment in: Anaesthesist 1997 Apr;46(4):362–3. **(Ger)**

[Intraoperative airway obstruction during use of a laryngeal mask. A case report and fiber optic findings] Rieger A, et al. **Anaesthesist** 1996 Mar;45(3):278–83 (Eng. Abstr.) **(Ger)**

[The interaction of nitrous oxide and enflurane on the EEG median of 2-3 additive, but weaker than at 1.0 MAC. Remarks on the work of H. Ropcke and H. Schwilden. Anaesthesist (1996) 45:819–825 (letter; comment)] Rothhammer A. **Anaesthesist** 1997 Jun;46(6):566–7. Comment on: Anaesthesist 1996 Sep;45(9):819–25. **(Ger)**

[Remarks on the work of J. Rathgeber et al. Respiratory gas acclimatization with an efficient HME (heat and moisture exchanger)--an effective and cost saving alternative to active humidifying of the ventilated patient. Anaesthesist (1996) 45: 518–525 (letter; comment)] Thäle H, et al. **Anaesthesist** 1996 Dec;45(12):1270–2. Comment on: Anaesthesist 1996 Jun;45(6):518–25. **(Ger)**

[Remarks on the work of J. Rathgeber et al. Warming and humidification for acclimatization of intubated inspiratory air in patients in intensive care. Anaesthesist (1995) 44:274–83] Tontschev G, et al. **Anaesthesist** 1996 Mar; 45(3):284–7 **(Ger)**

[Preoperative evaluation for anesthesia] Wilhelm W, et al. **Anaesthesist** 1997 Jul;46(7):629–39 (10 ref.) **(Ger)**

[Data collection in anesthesia. Experiences with the inauguration of a new information system] Zbinden AM, et al. **Anaesthesist** 1997 Jun;46(6):496–503 (Eng. Abstr.) **(Ger)**

[External quality assurance in anesthesia] Heinrichs W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jun;32(6):361–4 **(Ger)**

[Principles of pharmacology] Taeger K. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 May; 32(5):307–21 (29 ref.) **(Ger)**

[Comment on Deusch et al.: Patient knowledge about anesthesia practice and responsibilities of the anesthetist (letter; comment)] Walz R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Apr; 32(4):263. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Sep;31(7):409–13. **(Ger)**

[Anesthesia and postoperative management management of patients with Duchenne's dystrophy] Ben Abraham R, et al. **Harefuah** 1996 Nov 15;131(10):435–7 (20 ref.) **(Heb)**

[Separation of conjoined twins: the anesthesiologist's perspective] Grunwald Z, et al. **Harefuah** 1997 Feb 16; 132(4):241–5, 312 (Eng. Abstr.) **(Heb)**

[Thoracoscopic bilateral sympathectomy in Raynaud's syndrome. Anesthesiology problems] Delogu G, et al. **Ann Ital Chir** 1996 May-Jun;67(3):405–8; discussion 409 (Eng. Abstr.) **(Ita)**

[Unexpected accumulation of nitrogen in a circuit during low-flow anesthesia. Presentation of two clinical cases] Bonetti L, et al. **Minerva Anestesiol** 1995 Dec;61(12):515–7 (Eng. Abstr.) **(Ita)**

[Myorelaxants in pediatric anesthesia] Curreri G, et al. **Minerva Anestesiol** 1996 Apr;62(4):125–30 (Eng. Abstr.) **(Ita)**

[Prevalence and incidence. These (almost) unknowns] De Amici D. **Minerva Anestesiol** 1996 Oct;62(10):343–8 (11 ref.) (Eng. Abstr.) **(Ita)**

[Vecuronium for anesthesia in developing countries] Di Filippo A, et al. **Minerva Anestesiol** 1995 Sep;61(9):381–5 (Eng. Abstr.) **(Ita)**

[Anesthesiology problems for implant and explant of left ventricular Novacor systems] Domenegati E, et al. **Minerva Anestesiol** 1996 Jun;62(6):219–27 (Eng. Abstr.) **(Ita)**

[The laryngeal mask in pediatric anesthesia] Frediani M, et al. **Minerva Anestesiol** 1996 Mar;62(3):65–71 (Eng. Abstr.) **(Ita)**

[Clinical pharmacology of pipecuronium; a comparative study of its duration of action in balanced anesthesia (propofol/fentanyl) vs isoflurane] Melloni C. **Minerva Anestesiol** 1995 Dec;61(12):491–500 (Eng. Abstr.) **(Ita)**

[Infusion constituents in pediatric anesthesia] Pigna A, et al. **Minerva Anestesiol** 1996 Apr;62(4):137–41 (Eng. Abstr.) **(Ita)**

[Monitoring in pediatric anesthesia] Sarti A, et al. **Minerva Anestesiol** 1996 Apr;62(4):119–23 (Eng. Abstr.) **(Ita)**

[Anesthesiologic problems in abdominal mini-invasive surgery (editorial)] Moscato S. **Minerva Chir** 1996 Jul–Aug; 51(7–8):507–10 (Eng. Abstr.) **(Ita)**

[Anesthesia in videolaparoscopic cholecystectomy. Our experience] Verardo T, et al. **Minerva Chir** 1997 Jan–Feb; 52(1–2):17–9 (Eng. Abstr.) **(Ita)**

[Anesthesia for patients with heart diseases] Aze M. **Masui** 1996 Dec;45 Suppl:S179–86 (21 ref.) **(Jpn)**

[Preventive effect of anesthesia to surgical stress] Fujita T. **Masui** 1996 Dec;45 Suppl:S49–50 (4 ref.) **(Jpn)**

[Local immune response to surgical stress] Hosokawa T. **Masui** 1996 Dec;45 Suppl:S31–7 (27 ref.) **(Jpn)**

[Preoperative evaluation of patients and informed consent] Inada E. **Masui** 1996 Dec;45 Suppl:S137–8 (8 ref.) **(Jpn)**

[Assessment of left ventricular contractility during intravenous induction of anesthesia by echocardiographic automated border detection] Kobayashi T, et al. **Masui** 1996 Nov;45(11):1335–41 (Eng. Abstr.) **(Jpn)**

[Surgical stress and nervous systems] Komatsu T, et al. **Masui** 1996 Dec;45 Suppl:S16–24 (36 ref.) **(Jpn)**

[Anesthetic managements for pericardiectomy of three patients with constrictive pericarditis] Kurokawa S, et al. **Masui** 1997 Apr;46(4):515–20 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Possibility of rice porridge for preoperative feeding in children] Kushikata T, et al. **Masui** 1996 Aug;45(8):943–7 (Eng. Abstr.) **(Jpn)**

[Intraoperative monitoring during anesthesia in children] Miyasaka K. **Masui** 1996 Dec;45 Suppl:S6–13 (18 ref.) **(Jpn)**

[Examples of pitfalls in statistical analysis--6. Evaluation of data consisting of the elapsed time between two events] Nagata O. **Masui** 1997 Feb;46(2):244–50 (Eng. Abstr.) **(Jpn)**

[Measurement of stress response during surgery and anesthesia] Ninomiya S, et al. **Masui** 1996 Dec;45 Suppl:S38–43 (4 ref.) **(Jpn)**

[Thermoregulatory research in the field of anesthesia and intensive care: a review] Ozaki M. **Masui** 1996 Jul; 45(7):804–12 (45 ref.) (Eng. Abstr.) **(Jpn)**

[Biological response to surgical stress--endocrine response] Sakai T. **Masui** 1996 Dec;45 Suppl:S25–30 (14 ref.) **(Jpn)**

[Anesthesia and heart function] Suga H. **Masui** 1996 Dec;45 Suppl:S1–5 (18 ref.) **(Jpn)**

[Anesthesia mechanisms: nerve excitation and temperature] Suzuki A, et al. **Masui** 1996 Jun;45(6):670–5 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Experience of Anesthesia in northern Iraq after the Gulf War] Suzuki T. **Masui** 1996 Jun;45(6):769–73 (Eng. Abstr.) **(Jpn)**

[Anesthesia and postoperative care in respiratory tract surgery] Takachi T. **Masui** 1996 Dec;45 Suppl:S88–92 **(Jpn)**

[Anesthetic management of ten Jehovah's Witness patients] Tsubokawa K, et al. **Masui** 1996 Jan;45(1):111–4 (Eng. Abstr.) **(Jpn)**

[Anesthesia and intraoperative care of patients with heart dysfunction] Ueda N, et al. **Masui** 1996 Dec;45 Suppl:S114–21 (24 ref.) **(Jpn)**

[Result of biological response to surgical stress] Yuge T. **Masui** 1996 Dec;45 Suppl:S44–8 (14 ref.) **(Jpn)**

[Anesthesiological and intensive care in war trauma] Bakeev RF. **Anesteziol Reanimatol** 1997 Jan–Feb;(1):20–3 **(Rus)**

[Choice of the method of anesthesia in long and traumatic surgery] Likhvantsev VV, et al. **Anesteziol Reanimatol** 1997 Jan–Feb;(1):53–6 **(Rus)**

[The state of the hypophyseal-adrenal system during surgical correction of heart diseases under conditions of different anesthesia and in distant periods after surgery] Litasova EE, et al. **Anesteziol Reanimatol** 1997 Jan–Feb;(1):58–60 (Eng. Abstr.) **(Rus)**

[Use of diprivan in anesthesiology of angiographic studies and x-ray endovascular methods of treatment in children] Mikhelson VA, et al. **Anesteziol Reanimatol** 1996 Nov–Dec; (6):14–7 (Eng. Abstr.) **(Rus)**

[The use of Instenon to correct a postanesthesia consciousness disorder in surgical patients] Rumiantseva SA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(6):88–9 **(Rus)**

[Opioid drugs in neonatal anesthesia] Cvejanov M. **Med Pregl** 1997 Mar–Apr;50(3–4):94–9 (Eng. Abstr.) **(Scr)**

[Allergic reactions during anesthesia] Escolano F, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):17–26 (56 ref.) (Eng. Abstr.) **(Spa)**

[Anesthetic considerations of osteopetrosis. Apropos of a case (letter)] Granados LM, et al. **Rev Esp Anestesiol Reanim** 1996 Dec;43(10):379 **(Spa)**

[Anesthesia in a patient with Klippel-Trenaunay-Weber syndrome (letter)] López-Moreno JA, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):127 **(Spa)**

[Anesthesia with low flow of fresh gases and closed circuit (editorial)] Martín-Larrauri Camarillo R. **Rev Esp Anestesiol Reanim** 1997 May;44(5):173–5 **(Spa)**

[Anesthesia implications in Klippel-Trenaunay syndrome (letter)] Martínez-Ubieto J, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):127–8 **(Spa)**

[Anesthetic implications in Morquio syndrome (letter)] Moya J, et al. **Rev Esp Anestesiol Reanim** 1996 May;43(5):189–90 **(Spa)**

[Changes in the immunologic status related to the duration of the anesthesia/surgery procedure] Muriel C, et al. **Rev Esp Anestesiol Reanim** 1996 May;43(5):160–3 (Eng. Abstr.) **(Spa)**

[Anesthesia in Kearns-Sayre syndrome (mitochondrial myopathy)] Sabaté S, et al. **Rev Esp Anestesiol Reanim** 1996 Aug-Sep;43(7):255–7 (Eng. Abstr.) **(Spa)**

[Pulmonary lymphangiomyomatosis. Report of a case (letter; comment)] Saludes J, et al. **Rev Esp Anestesiol Reanim** 1996 May;43(5):190–1. Comment on: Rev Esp Anestesiol Reanim 1995 Mar;42(3):109. **(Spa)**

ADVERSE EFFECTS

Tramadol in the treatment of postanesthetic shivering. de Witte J, et al. **Acta Anaesthesiol Scand** 1997 Apr; 41(4):506–10

Routine preoperative gastric emptying is seldom indicated. A study of 85,594 anaesthetics with special focus on aspiration pneumonia. Mellin-Olsen J, et al. **Acta Anaesthesiol Scand** 1996 Nov;40(10):1184–8

Morbidity and mortality associated with anaesthesia. Sigurdsson GH, et al. **Acta Anaesthesiol Scand** 1996 Sep; 40(8 Pt 2):1057–63 (41 ref.)

An audit of perioperative aspiration pneumonitis in gynaecological and obstetric patients. Soreide E, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):14–9

Measuring anaesthetic outcomes. Lee A, et al. **Anaesth Intensive Care** 1996 Dec;24(6):685–93 (82 ref.)

Anaesthetic disasters: handling the aftermath. Aitkenhead AR. **Anaesthesia** 1997 May;52(5):477–82

Relationship between complications of pediatric anesthesia and volume of pediatric anesthetics [letter] Auroy Y, et al. **Anesth Analg** 1997 Jan;84(1):234–5

Intraoperative hypoxia from nitrogen tanks with oxygen fittings. Bernstein DB, et al. **Anesth Analg** 1997 Jan; 84(1):225–7

Juvenile papillomatosis and airway obstruction [letter; comment] Berry FA. **Anesth Analg** 1997 Jun;84(6):1395–6 . Comment on: Anesth Analg 1996 Dec;83(6):1332–4.

Parental desire for perioperative information and informed consent: a two-phase study. Kain ZN, et al. **Anesth Analg** 1997 Feb;84(2):299–306

Ventricular fibrillation during anesthetic induction in a child with undiagnosed mitral valve prolapse. Moritz HA, et al. **Anesth Analg** 1997 Jul;85(1):59–61

Anesthesia for patients with asthma. Low risk but not no risk [editorial; comment] Bishop MJ, et al. **Anesthesiology** 1996 Sep;85(3):455–6. Comment on: Anesthesiology 1996 Sep;85(3):460–7.

Self-reporting can be a reliable means of tracking adverse perioperative events [letter] Lagasse RS. **Anesthesiology** 1997 Sep;87(3):722–5

Perioperative respiratory complications in patients with asthma [see comments] Warner DO, et al. **Anesthesiology** 1996 Sep;85(3):460–7. Comment in: Anesthesiology 1996 Sep;85(3):455–6.

ASA classification and perioperative variables: graded anaesthesia score? [letter; comment] Lake AP, et al. **Br J Anaesth** 1997 Feb;78(2):228–9. Comment on: Br J Anaesth 1996 Aug;77(2):217–22.

A randomized, double-blind, placebo-controlled trial comparing pethidine to metamizol for treatment of post-anaesthetic shivering. Monsó A, et al. **Br J Clin Pharmacol** 1996 Sep;42(3):307–11

Watch your surgeon [letter] Wong DH. **Can J Anaesth** 1997 Jun;44(6):679

Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Larach MG, et al. **Clin Pediatr (Phila)** 1997 Jan;36(1):9–16

Incidence, prevalence and anaesthesia: a troubled marriage? [letter] De Amici D, et al. **Eur J Anaesthesiol** 1997 Jan; 14(1):107

Physostigmine: going ... going ... gone? Two cases of central anticholinergic syndrome following anaesthesia and its treatment with physostigmine. Martin B, et al. **Eur J Anaesthesiol** 1997 Jul;14(4):467–70

A perspective on studies of anaesthesia morbidity and mortality. Desmonts JM, et al. **Eur J Anaesthesiol Suppl** 1993;7:33–41 (27 ref.)

The standards formulation process. Eichhorn JH. **Eur J Anaesthesiol Suppl** 1993;7:9–11

Average spectrum of cochlear activity: a possible synchronized firing, its olivo-cochlear feedback and alterations under anesthesia. Cazals Y, et al. **Hear Res** 1996 Nov 1;101(1-2):81–92

A prospective analysis of critical incidents attributable to anaesthesia. Spittal MJ, et al. **Int J Qual Health Care** 1995 Dec;7(4):363–71

Unfavorable influence of anesthesia and surgery on Doberman pinschers with occult cardiomyopathy. Calvert CA, et al. **J Am Anim Hosp Assoc** 1996 Jan-Feb; 32(1):57–62

Appropriate thermal manipulations eliminate tremors in rats recovering from halothane anesthesia. Grahn DA, et al. **J Appl Physiol** 1996 Dec;81(6):2547–54

Severe hypoxemia after suction of the nonventilated lung via the bronchial blocker lumen of the univent tube [letter] Baraka A, et al. **J Cardiothorac Vasc Anesth** 1996 Aug; 10(5):694–5

An unusual electrocardiographic tracing [letter] Ceriana P,

et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):834–6
A risk index for pregnancy during anesthesia. Kempen PM, et al. **J Clin Anesth** 1997 May;9(3):194–9
Prolonged surgery increases the likelihood of admission of scheduled ambulatory surgery patients. Mingus ML, et al. **J Clin Anesth** 1997 Sep;9(6):446–50
Effect of intraoperative anesthetic events on postoperative patient satisfaction. Brown DL, et al. **Mayo Clin Proc** 1997 Jan;72(1):20–5
Ocular explosion after peribulbar anesthesia: case report and experimental study. Magnante DO, et al. **Ophthalmology** 1997 Apr;104(4):608–15
The incidence of minor sequelae following anaesthesia in children. Selby IR, et al. **Paediatr Anaesth** 1996; 6(4):293–302
Anesthesia with sodium pentobarbital enhances lipopolysaccharide-induced cardiovascular dysfunction in rats. Hoque AM, et al. **Shock** 1996 Nov;6(5):365–70
[Claims related to anesthesia at the University Hospitals of Paris] Lienhart A, et al. **Ann Fr Anesth Reanim** 1996; 15(2):215–9 (Eng. Abstr.) **(Fre)**
[Interaction of frequency-adaptive pacemakers and anesthetic management. Discussion of current literature and two case reports] von Knobelsdorff G, et al. **Anaesthesist** 1996 Sep;45(9):856–60 (Eng. Abstr.) **(Ger)**
[Human error in the anesthesiological field. Up to what point is it possible to speak of prevention?] De Amici D, et al. **Epidemiol Prev** 1997 Jan–Mar;21(1):19–29 (51 ref.) (Eng. Abstr.) **(Ita)**
[Iatrogenic accidents and anesthesia] Soares EL. **Rev Bras Anestesiol** 1968 Oct–Dec;18(4):374–90 (Eng. Abstr.) **(Por)**

CLASSIFICATION

The bigger picture [editorial; comment] Jones RL. **J Clin Anesth** 1997 Mar;9(2):91–2. Comment on: J Clin Anesth 1997 Mar;9(2):93–6.

ECONOMICS

Anesthesia practices in the United States common to in vitro fertilization (IVF) centers. Ditkoff EC, et al. **J Assist Reprod Genet** 1997 Mar;14(3):145–7
[Documentation and therapeutic standards in anesthesia and intensive care medicine—means for quality assurance and cost control] Bach A, et al. **Zentralbl Chir** 1996; 121(7):521–8 (35 ref.) (Eng. Abstr.) **(Ger)**

EDUCATION see ANESTHESIOLOGY/education

HISTORY

Towards a new chronology of ether anesthesia in Europe. Franco A, et al. **Acta Anaesthesiol Belg** 1997;48(2):107–9
The history of anaesthesia in Australia—150 years [editorial] Cooper MG. **Anaesth Intensive Care** 1997 Jun;25(3):221
Nathan P. Rice and Trials of a Public Benefactor, 1859—historical notes on the facsimile of 1995. Cooper MG. **Anaesth Intensive Care** 1997 Jun;25(3):289–91
An early anaesthetic in Papua New Guinea. Phillips GD. **Anaesth Intensive Care** 1997 Jun;25(3):286–8
Anesthesia & Analgesia: seventy-five years of publication. Craig DB, et al. **Anesth Analg** 1997 Aug;85(2):237–47
Arabs were skilled in anaesthesia [letter] al-Fallouji M. **BMJ** 1997 Apr 12;314(7087):1128
History of neuroanesthesia: a contemporary review. Samuels SI. **Int Anesthesiol Clin** 1996 Fall;34(4):1–20
History of automated delivery of anesthetic agents. Smith BE. **Int Anesthesiol Clin** 1995 Summer;33(3):1–10
Lexicographic history of "anesthesia". Sanchez GC. **J Clin Anesth** 1996 Sep;8(6):435–8
Will the anesthesia question always remain debatable? Vandam LD. **J Clin Anesth** 1996 Sep;8(6):429–30
The last days of William Thomas Green Morton. Vandam LD. **J Clin Anesth** 1996 Sep;8(6):431–4
The Journal 150 & 100 years ago. December 1846 and 1896. Colon GA. **J La State Med Soc** 1996 Dec;148(12):517–9
Sesquicentennial of the ether dome. Newsom B. **J S C Med Assoc** 1996 Oct;92(10):441
Perspectives of the history of anesthesia [editorial] Haddad FS. **Middle East J Anesthesiol** 1997 Feb;14(1):3–6
Middle Eastern history of anesthesia. Takrouri MS, et al. **Middle East J Anesthesiol** 1997 Feb;14(1):7–23
[We are finally repaying our debt (F.C. Opitz, 1810–1866)] Tošovský V. **Sb Lek** 1996;97(3):437–40 **(Cze)**
[The 150th anniversary of of he birth of anesthesia (editorial)] Lassner J. **Cah Anesthesiol** 1996;44(5):397–401 **(Fre)**
["A discovery in surgery" 150 years of anesthesia] Brandt L, et al. **Anaesthesist** 1996 Oct;45(10):970–5 **(Ger)**
[Thoughts on the 150th anniversary of anesthesia (editorial)] Mayrhofer O. **Anaesthesist** 1996 Oct;45(10):881–3 **(Ger)**
[SMW 100 years ago. William Thomas Green Morton and the discovery of anesthesia (classical article)] Morton WT. **Schweiz Med Wochenschr** 1996 Nov 23;126(47):2040–2 **(Ger)**
[What is anesthesia? Some reflections on the definition, measuring methods and mechanisms at the 150th anniversary] Raeder JC. **Tidsskr Nor Laegeforen** 1996 Oct 20;116(25):3015–9 (Eng. Abstr.) **(Nor)**
["Gentlemen, this is not a humbug". The 150th anniversary of anesthesia] Strømskag KE. **Tidsskr Nor Laegeforen** 1996 Dec 10;116(30):3622–4 (Eng. Abstr.) **(Nor)**
[The 150th anniversary of using narcosis in Russia] Sorokina TS. **Probl Sotsialnoi Gig Istor Med** 1997 Jul–Aug;(4):56–8 **(Rus)**
[The start of a new age in Russian surgery (on the 150th anniversary of the first use of anesthesia in Russia)] Galin LL, et al. **Voen Med Zh** 1997 Apr;318(4):60–3 **(Rus)**
[Anesthesia history, historiology, and historiography in Spain (editorial)] Franco Grande A. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):267–8 **(Spa)**
[On the 150th anniversary of the introduction of anesthesia in Spain: the role of dentists] Hervás C, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):16–22 (Eng. Abstr.) **(Spa)**

INSTRUMENTATION see ANESTHESIOLOGY/instrumentation

METHODS

Esmolol for hypotensive anesthesia in middle ear surgery. Pilli G, et al. **Acta Anaesthesiol Belg** 1996;47(2):85–91
Perianaesthetic management of patients with endocrine disease. Breivik H. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):1004–15 (41 ref.)
Use of the Univent System tube for difficult intubation and for achieving one-lung anaesthesia. García-Aguado R, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):765–7
Anesthesia of a patient with an obstructing tracheal mass: a new way to manage the airway. Licker M, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 1):84–6
Long QT interval syndrome with increased QT dispersion. Michaloudis D, et al. **Acta Anaesthesiol Scand** 1997 Apr; 41(4):541–4
Prediction of difficult intubation. Randell T. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):1016–23 (28 ref.)
Anaesthesia for children with mucopolysaccharidoses [letter; comment] Walker RW, et al. **Anaesth Intensive Care** 1997 Apr;25(2):197–8. Comment on: Anaesth Intensive Care 1996 Aug;24(4):459–63.
Anaesthesia for cardioversion in children [letter; comment] Abengochea A, et al. **Anaesthesia** 1996 Dec;51(12):1192. Comment on: Anaesthesia 1996 Jun;51(6):565–70.
Intrapulmonary shunt during one-lung anaesthesia [letter] Dingley J, et al. **Anaesthesia** 1997 Jun;52(6):613
Intrapulmonary shunt during one-lung anaesthesia [letter; comment] Foley KN, et al. **Anaesthesia** 1997 Jan;52(1):95 . Comment on: Anaesthesia 1996 Jul;51(7):654–7.
The anaesthetist and the antiphospholipid syndrome [see comments] Madan R, et al. **Anaesthesia** 1997 Jan;52(1):72–6 (32 ref.). Comment in: Anaesthesia 1997 Jun;52(6):612.
Intrathecal sufentanil for extracorporeal shock wave lithotripsy provides earlier discharge of the outpatient than intrathecal lidocaine. Lau WC, et al. **Anesth Analg** 1997 Jun;84(6):1227–31
Percutaneous dilational tracheostomy: anesthetic considerations for a growing trend. Schwann NM. **Anesth Analg** 1997 Apr;84(4):907–11
Video-assisted thoracoscopic volume reduction surgery in patients with diffuse pulmonary emphysema: gas exchange and anesthesiological management. Zollinger A, et al. **Anesth Analg** 1997 Apr;84(4):845–51
Early tracheal extubation after coronary artery bypass graft surgery reduces costs and improves resource use. A prospective, randomized, controlled trial. Cheng DC, et al. **Anesthesiology** 1996 Dec;85(6):1300–10
Propofol requirements versus stimulus intensity [editorial; comment] Hug CC Jr. **Anesthesiology** 1997 Aug; 87(2):201–2. Comment on: Anesthesiology 1997 Aug;87(2):213–27.
Anesthesia preoperative evaluation clinic [letter; comment] Kempen PM. **Anesthesiology** 1997 Jan;86(1):259, discussion 261–3. Comment on: Anesthesiology 1996 Jul;85(1):196–206.
Parental presence not necessary during induction of anesthesia [letter; comment] Pond WW, et al. **Anesthesiology** 1996 Nov;85(5):1212–3. Comment on: Anesthesiology 1996 May;84(5):1060–7.
Warming devices in pediatric anesthesia. Leben J, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:812–7
Recovery after major surgery: does the anaesthetic make any difference? [editorial] Chumbley GM, et al. **Br J Anaesth** 1997 Apr;78(4):347–9
Anaesthesia for porphyria. Ashley EM. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):37–42 (22 ref.)
Management of a boy with extensive burns and a partly closed tracheostomy. Cray S. **Br J Hosp Med** 1997 Mar 19–Apr 1;57(6):292
Adult cardiac anaesthesia. Freeman JM, et al. **Br J Hosp Med** 1994 Jan 19–Feb 1;51(1–2):40–3 (3 ref.)
Anaesthesia for day-case surgery [letter; comment] Susay SR. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):50. Comment on: Br J Hosp Med 1995 Sep 6–19;54(5):202–6.
Hypotensive anaesthesia [letter; comment] Young PN, et al. **Br J Hosp Med** 1997 Apr 2–15;57(7):352. Comment on: Br J Hosp Med 1996 Apr 17–30;55(8):482–5.
Anaesthetic managements for conjoined twins with complex cardiac anomalies. Chen TL, et al. **Can J Anaesth** 1996 Nov;43(11):1161–7
The drug addicted patient. Cheng DC. **Can J Anaesth** 1997 May;44(5 Pt 2):R101–11 (46 ref.) **(Eng, Fre)**
Lower airway injuries and anaesthesia [see comments] Devitt JH, et al. **Can J Anaesth** 1996 Feb;43(2):148–59 (63 ref.) . Comment in: Can J Anaesth 1996 Nov;43(11):1181–2.
Anaesthesia for patients after lung transplantation. Haddow GR. **Can J Anaesth** 1997 Feb;44(2):182–97 (103 ref.)
Anaesthesia for phaeochromocytoma in pregnancy. Hamilton A, et al. **Can J Anaesth** 1997 Jun;44(6):654–7
The anaesthetic management of a patient with Emery-Dreifuss muscular dystrophy. Jensen V. **Can J Anaesth** 1996 Sep;43(9):968–71
Anaesthesia for balloon dilatation for congenital tracheal stenosis in an infant [letter] Kinouchi K, et al. **Can J Anaesth** 1996 Oct;43(10):1081
Anaesthesia for neuroradiology. Manninen PH. **Can J Anaesth** 1997 May;44(5 Pt 2):R34–9 (17 ref.) **(Eng, Fre)**
The patient with reactive airways disease. Moudgil GC. **Can J Anaesth** 1997 May;44(5 Pt 2):R77–89 (35 ref.) **(Eng, Fre)**
Anaesthesia for carotid artery surgery. Mutch WA. **Can J Anaesth** 1997 May;44(5 Pt 2):R90–100 (37 ref.) **(Eng, Fre)**
Postoperative anaesthesia care [editorial; comment] Ralley FE. **Can J Anaesth** 1996 Aug;43(8):759–63. Comment on: Can J Anaesth 1996 Aug;43(8):769–77. **(Eng, Fre)**
Anaesthetizing children in remote locations: necessary expeditions or anaesthetic misadventures? [editorial; comment] Roy WL. **Can J Anaesth** 1996 Aug;43(8):764–8 . Comment on: Can J Anaesth 1996 Aug;43(8):835–9. **(Eng, Fre)**
Perioperative anaesthetic considerations for patients undergoing lung transplantation. Singh H, et al. **Can J Anaesth** 1997 Mar;44(3):284–99 (100 ref.)
Chewing gum prior to anaesthesia—is not age restricted [letter] Tays R, et al. **Can J Anaesth** 1996 Oct;43(10):1080
Anaesthetic management of a patient with familial normokalaemic periodic paralysis. Walsh F, et al. **Can J Anaesth** 1996 Jul;43(7):684–6
Sedation and anesthesia for pediatric bronchoscopy. Tobias JD. **Curr Opin Pediatr** 1997 Jun;9(3):198–206 (23 ref.)
Monitoring of neuromuscular transmission by electromyography during anaesthesia. A comparison with mechanomyography in cat and man. Engbaek J. **Dan Med Bull** 1996 Sep;43(4):301–16 (188 ref.)
Anaesthesia in the elderly. Special considerations. Jones AG, et al. **Drugs Aging** 1996 Nov;9(5):319–31 (73 ref.)
Topical pharyngeal anesthesia improves tolerance of upper gastrointestinal endoscopy: a randomized double-blind study. Campo R, et al. **Endoscopy** 1995 Nov;27(9):659–64
Anaesthesia and diaphragmatic pacing in patients with tetraplegia. A review of peri-operative management in patients over a 10-year period. Devine A, et al. **Eur J Anaesthesiol** 1996 Nov;13(6):553–61
A new route, jet-injection for anesthetic induction in children – II. ketamine dose-range finding studies. Zsigmond EK, et al. **Int J Clin Pharmacol Ther** 1996 Feb;34(2):84–8
Prehospital emergency rapid sequence induction of anaesthesia. Graham CA, et al. **J Accid Emerg Med** 1997 Jul;14(4):219–21
Anesthesia practices in the United States common to in vitro fertilization (IVF) centers. Ditkoff EC, et al. **J Assist Reprod Genet** 1997 Mar;14(3):145–7
ACC/AHA task force report. Special report: guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):540–52
The adult patient with congenital heart disease. Baum VC. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):261–82 (221 ref.)
Cardiorespiratory changes in patients undergoing pulmonary resection using different anesthetic management techniques. Boldt J, et al. **J Cardiothorac Vasc Anesth** 1996 Dec; 10(7):854–9
Lung transplantation: historical perspective, current concepts, and anesthetic considerations. Bracken CA, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):220–41 (167 ref.)
Submitral left ventricular aneurysms: anesthetic considerations. Cooper A, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):922–5
The MIDCAB experience: a current look at evolving surgical and anesthetic approaches. Gayes JM, et al. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):625–8 (31 ref.)
Anesthetic considerations for patients undergoing minimally invasive coronary artery bypass surgery: mini-sternotomy and mini-thoracotomy approaches [see comments] Gayes JM, et al. **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):531–5 . Comment in: J Cardiothorac Vasc Anesth 1996 Jun;10(4):445–50. Comment in: J Cardiothorac Vasc Anesth 1996 Dec;10(7):975. Comment in: J Cardiothorac Vasc Anesth 1997 Feb;11(1):123–4.
Minimally invasive direct coronary artery bypass (MIDCAB): surgical techniques and anesthetic considerations. Greenspun HG, et al. **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):507–9
Minimally invasive coronary artery surgery: anesthetic considerations [letter; comment] Juneja R, et al. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):123–4. Comment on: J Cardiothorac Vasc Anesth 1996 Jun;10(4):445–6. Comment on: J Cardiothorac Vasc Anesth 1996 Jun;10(4):531–5.
Anesthesia supplemented with subarachnoid bupivacaine and

morphine for coronary artery bypass surgery in a child with Kawasaki disease. Kowalewski R, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):243–6

Anesthetic management of patients undergoing unilateral video-assisted lung reduction for treatment of end-stage emphysema. Krucylak PE, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):850–3

Anesthesia for bilateral sequential lung transplantation: experience of 64 cases. Myles PS, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):177–83

Frequent sudden reexpansion of deflated lung during one-lung ventilation under thoracoscopic procedure [letter] Takahisa M, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):831–2

Carotid endarterectomy: perioperative and anesthetic considerations. Wilke HJ 2nd, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):928–49 (212 ref.)

A combined stereotaxic adaptor and anaesthesia apparatus for microdialysis studies in small rodents. Vandebroek I, et al. **J Neurosci Methods** 1996 Sep;68(1):81–6

Anaesthesia for laparoscopic surgery [letter] Falk GL. **J R Coll Surg Edinb** 1996 Feb;41(1):61–2; discussion 62

Anaesthesia for laparoscopic surgery [letter] Goggin P, et al. **J R Coll Surg Edinb** 1996 Feb;41(1):62–3

A method for long duration anaesthesia for a new hindlimb ischaemia-reperfusion model in mice. Wiersema AM, et al. **Lab Anim** 1997 Apr;31(2):151–6

Apneic anesthesia with intermittent ventilation for microsurgery of the upper airway. Weisberger EC, et al. **Laryngoscope** 1996 Sep;106(9 Pt 1):1099–102

Combinations of drugs for induction and maintenance of anesthesia and sedation of the critically ill. Garforth R, et al. **Middle East J Anesthesiol** 1996 Jun;13(5):545–57

Site of service, anesthesia, and postoperative practice patterns for oculoplastic and orbital surgeries. Bartamian M, et al. **Ophthalmology** 1996 Oct;103(10):1628–33

Efficacy of unanesthetized spiral computed tomography scanning in initial evaluation of childhood leukocoria. O'Brien JM, et al. **Ophthalmology** 1995 Sep;102(9):1345–50

Anaesthetic management of a child undergoing thoracoscopic removal of a lung cyst. Armstrong T, et al. **Paediatr Anaesth** 1997;7(2):159–61

Preparation and intraoperative management of the pediatric patient. Hata T. **Pediatr Ann** 1997 Aug;26(8):471–81; quiz 501–3 (28 ref.)

Malignant hyperthermia susceptibility: anaesthetic implications and risk stratification. Ben Abraham R, et al. **QJM** 1997 Jan;90(1):13–8 (67 ref.)

50 Years on the wrong side of the reflex arc [editorial] Bromage PR. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):1–4

Effect of type of anesthesia and lower-abdominal laparotomy in mice on the cytokine response to acute stress. Fu ES, et al. **Reg Anesth** 1996 Sep-Oct;21(5):470–3

Effect of pain relief on the surgical stress response. Kehlet H. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):35–7 (3 ref.)

Preoperative anesthesia and postoperative considerations in laser resurfacing. Fitzpatrick RE, et al. **Semin Cutan Med Surg** 1996 Sep;15(3):170–6 (11 ref.)

Anesthetic considerations in damage control surgery. Ham AA, et al. **Surg Clin North Am** 1997 Aug;77(4):909–20 (13 ref.)

Transcranial Doppler ultrasonography in neurosurgery: effects of intracranial tumour on right middle cerebral artery flow velocity during induction of anaesthesia. Dong ML, et al. **Ultrasound Med Biol** 1996;22(9):1163–8

[Current anesthesia problems in minor proctological operations] Khinev S, et al. **Khirurgiia (Sofiia)** 1996; 49(6):38–9 (Eng. Abstr.) **(Bul)**

[9th meeting of the Anesthesia-Intensive Care in Otorhinolaryngology Club. Paris, 1 December 1995] Boisson-Bertrand D. **Ann Fr Anesth Reanim** 1996; 15(2):234–5 **(Fre)**

[Pulmonary tuberculosis in 1996. Recent data and practical consequences for the anesthesiologist] Veber B. **Ann Fr Anesth Reanim** 1996;15(7):1080–7 (Eng. Abstr.) **(Fre)**

[Postoperative analgesia after surgery of the knee] Fletcher D. **Can Anesthesiol** 1996;44(3):253–9 (74 ref.) (Eng. Abstr.) **(Fre)**

[The AIDS patient in anesthesia] Jalowy A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):87–97 (109 ref.) (Eng. Abstr.) **(Ger)**

[Anesthesiologic and intensive care requirements in liver transplantation] Bobek I, et al. **Orv Hetil** 1996 Oct 20; 137(42 Suppl 1):2375–7 (Eng. Abstr.) **(Hun)**

[Recommendations for anesthesiologic treatment in non-cardiac surgery in congenital cardiopathy in neonatal and pediatric age. Italian Society of Anesthesia, Resuscitation and Intensive Therapy Group. Anesthesia and Resuscitation in Cardiothoracic Surgery] **Minerva Anestesiol** 1996 Nov;62(11):385–8 **(Ita)**

[Experience with one-lung anesthesia using balloon catheter for patients with terminal tracheostomy] Matsumura Y, et al. **Kyobu Geka** 1996 Dec;49(13):1078–80 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a patient with esophageal hiatal hernia accompanied with chest pain] Fukushima A, et al. **Masui** 1996 Nov;45(11):1393–5 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of 6 cases with dilated cardiomyopathy for non-cardiac surgery] Hase K, et al. **Masui** 1996 Jun;45(6):741–5 (Eng. Abstr.) **(Jpn)**

[Anesthetic problems in a 480 g infant for ventriculo-peritoneal shunt surgery] Mizushima A, et al. **Masui** 1996 Jan;45(1):86–90 (Eng. Abstr.) **(Jpn)**

[Prostaglandin E1 at low-doses improved right ventricular ejection fraction in anesthetic management for CABG] Oohata H, et al. **Masui** 1996 Oct;45(10):1272–7 (Eng. Abstr.) **(Jpn)**

[Anesthesia for a patient with pheochromocytoma associated with chronic renal failure] Sagara M, et al. **Masui** 1996 Oct;45(10):1256–9 (Eng. Abstr.) **(Jpn)**

[The risk of surgical treatment in elderly patients] Swiątkowski J. **Pol Merkuriusz Lek** 1996 Oct;1(4):261–3 (Eng. Abstr.) **(Pol)**

[Choice of optimal anesthesia in outpatient treatment of varicose veins] Larin SI, et al. **Khirurgiia (Mosk)** 1997; (6):51–5 **(Rus)**

[The problem of acute pain in postoperative period] Malinovskii NN, et al. **Khirurgiia (Mosk)** 1996;(5):30–5 (41 ref.) (Eng. Abstr.) **(Rus)**

[The initial status of patients with insulinoma as a factor in selecting the method of anesthesia] Kostenko AA. **Klin Khir** 1996;(11–12):32–4 **(Rus)**

[The characteristics of the anesthesiological support for surgical interventions in patients earlier operated on the heart] Polushin IuS, et al. **Vestn Khir Im I I Grek** 1997; 156(2):97–103 (Eng. Abstr.) **(Rus)**

[Acquired neuromyotonia (Isaacs' syndrome): clinical characteristics and anesthesia implications] Hernández-Palazón J, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):120–3 **(Spa)**

[Hyperbaric medicine and anesthesiology] Manubens E, et al. **Rev Esp Anestesiol Reanim** 1996 Nov;43(9):321–6 (14 ref.) **(Spa)**

MORTALITY

Morbidity and mortality associated with anaesthesia [letter] Warden JC, et al. **Acta Anaesthesiol Scand** 1997 Aug; 41(7):949

Report of the Anaesthetic Mortality Committee of Western Australia 1990–1995. Eagle CC, et al. **Anaesth Intensive Care** 1997 Feb;25(1):51–9

Urgent non-emergency surgery and death attributable to anaesthetic factors. Horan BF, et al. **Anaesth Intensive Care** 1996 Dec;24(6):694–8

Mortality associated with anaesthesia [letter; comment] Coetzee A. **S Afr Med J** 1996 Aug;86(8):973, 976. Comment on: S Afr Med J 1996 Apr;86(4):325–6. Comment on: S Afr Med J 1996 Apr;86(4):338–42.

NURSING

An approach to pediatric perioperative care. Parent-present induction. LaRosa-Nash PA, et al. **Nurs Clin North Am** 1997 Mar;32(1):183–99

PSYCHOLOGY

[A psychological burden on patients with clinical trials during anesthesia] Otsuka H, et al. **Masui** 1997 Jun;46(6):860–6 (Eng. Abstr.) **(Jpn)**

STANDARDS

Anesthesia care and comprehensive quality management. Belani KG. **Acta Anaesthesiol Scand Suppl** 1996;109:13–5

The effect of the National Confidential Enquiry into Perioperative Deaths on clinical practice. Report of a postal survey of a sample of consultant anaesthetists. Derrington MC, et al. **Anaesthesia** 1997 Jan;52(1):3–8

The value of continuous practice [letter; comment] Fletcher R. **Anaesthesia** 1997 Jul;52(7):713. Comment on: Anaesthesia 1997 Feb;52(2):191.

Ethical concerns in anesthetic care for patients with do-not-resuscitate orders [see comments] Bastron RD. **Anesthesiology** 1996 Nov;85(5):1190–3. Comment in: Anesthesiology 1997 Jul;87(1):174; discussion 178–9. Comment in: Anesthesiology 1997 Jul;87(1):175–6; discussion 178–9. Comment in: Anesthesiology 1997 Jul;87(1):176–8; discussion 178–9.

The role of the anesthesia care coordinator in preadmission testing [see comments] Swanson HL, et al. **AORN J** 1996 Nov;64(5):776–80. Comment in: AORN J 1997 Jun;65(6):1038.

Sedation and anaesthesia in radiology [letter] Warwick RJ, et al. **Clin Radiol** 1997 Mar;52(3):246

Risk assessment in the formulation of anaesthesia safety standards. Runciman WB. **Eur J Anaesthesiol Suppl** 1993; 7:26–32 (26 ref.)

[Safe use of anesthetic drugs outside the operating room] Rudich Z, et al. **Harefuah** 1996 Jun 2;130(11):784–6 (11 ref.) **(Heb)**

[Quality in anesthetic management during hepatic transplant. Hepatic Transplant Anesthesia Group] Sabaté A, et al. **Rev Esp Anestesiol Reanim** 1996 Dec;43(10):354–9 (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

A survey of anaesthetic manpower and training in the south-west Pacific region. Kinnear SB. **Anaesth Intensive Care** 1996 Aug;24(4):477–82

TRENDS

The Geoffrey Kaye Oration. ASA/ANZCA combined scientific meeting, Perth, W.A. October 30, 1996. Wotherspoon GP. **Anaesth Intensive Care** 1997 Jun; 25(3):304–8

Science from the patient's point of view [letter; comment] Bliss MR. **Lancet** 1997 Feb 22;349(9051):573–4. Comment on: Lancet 1996 Dec 21–28;348 Suppl 2:sIII.

Anaesthesia. Starved, sleepless, cold, and in pain [see comments] Simini B. **Lancet** 1996 Dec 21–28;348 Suppl 2:sII1 (5 ref.). Comment in: Lancet 1997 Feb 22;349(9051):573–4.

Advances in pediatric anesthesia. Burns LS. **Nurs Clin North Am** 1997 Mar;32(1):45–71 (159 ref.)

Anaesthesia in Nepal: present and future aims. Donaldson MD. **Trop Doct** 1997 Apr;27(2):100–3

[Ambulatory anesthesia: towards what future? (editorial)] Ravussin P, et al. **Rev Med Suisse Romande** 1997 May; 117(5):369–70 (7 ref.) **(Fre)**

[Anesthesia--after 150 years on the threshold to the next century] Van Aken H. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Dec; 31(10):589–91 **(Ger)**

UTILIZATION

Anesthesia for neonatal circumcision. is it state of the art? hristian RM, et al. **N C Med J** 1996 Mar-Apr;57(2):106–7

VETERINARY

Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs. Martinez EA, et al. **Am J Vet Res** 1996 Nov;57(11):1623–6

Cortisol suppression in cats after induction of anesthesia with etomidate, compared with ketamine-diazepam combination. Moon PF. **Am J Vet Res** 1997 Aug; 58(8):868–71

Monitoring techniques and equipment for small animal anaesthesia. Nicholson A. **Aust Vet J** 1996 Aug; 74(2):114–23 (32 ref.)

Feline anesthesia. Brock N. **Can Vet J** 1996 Dec;37(12):751–2

Anesthesia for North American cervids. Caulkett NA. **Can Vet J** 1997 Jun;38(6):389–90 (3 ref.)

A comparison of romifidine and xylazine when used with diazepam/ketamine for short duration anesthesia in the horse. Kerr CL, et al. **Can Vet J** 1996 Oct;37(10):601–9

Anaesthetic problems caused by diaphragmatic hernia in the horse: a review of four cases. Clutton RE, et al. **Equine Vet J Suppl** 1992 Feb;(11):30–3 (30 ref.)

Equine anaesthesiology [editorial] Steffey EP. **Equine Vet J Suppl** 1992 Feb;(11):2–3

A retrospective survey of anaesthesia in horses with colic. Trim CM, et al. **Equine Vet J Suppl** 1989 Jun;(7):84–90

The influence of surgery and anaesthesia on the pharmacokinetics of pethidine in the horse. Waterman AE, et al. **Equine Vet J Suppl** 1992 Feb;(11):56–8

Unfavorable influence of anesthesia and surgery on Doberman pinschers with occult cardiomyopathy. Calvert CA, et al. **J Am Anim Hosp Assoc** 1996 Jan-Feb; 32(1):57–62

Use of xylazine, butorphanol, tiletamine-zolazepam, and isoflurane for induction and maintenance of anesthesia in ratites. Lin HC, et al. **J Am Vet Med Assoc** 1997 Jan 15; 210(2):244–8

Arterial blood pressure monitoring in anesthetized animals. Wagner AE, et al. **J Am Vet Med Assoc** 1997 May 1; 210(9):1279–85 (74 ref.)

Ketamine and its use in the pig. Recommendations of the Consensus meeting on Ketamine Anaesthesia in Pigs, Bergen 1994. Ketamine Consensus Working Group. Boschert K, et al. **Lab Anim** 1996 Jul;30(3):209–19 (28 ref.)

Rapid increase in inspired desflurane concentration does not elicit a hyperdynamic circulatory response in the pig. Karzai W, et al. **Lab Anim** 1997 Jul;31(3):279–82

Evaluation of anaesthetic regimens in guineapigs. Radde GR, et al. **Lab Anim** 1996 Jul;30(3):220–7

Orbital bleeding in rats while under diethylether anaesthesia does not influence telemetrically determined heart rate, body temperature, locomotor and eating activity when compared with anaesthesia alone. Van Herck H, et al. **Lab Anim** 1997 Jul;31(3):271–8

Effect of thiopental, saffan, and propofol anesthesia on cardiovascular parameters and bronchial smooth muscle in the rhesus monkey. Foster A, et al. **Lab Anim Sci** 1996 Jun;46(3):327–34

Anaesthesia and basic experimental surgery of minipigs. A practical exercise. Svendsen P. **Pharmacol Toxicol** 1997;80 Suppl 2:23–6

Equithesin without chloral hydrate as an anaesthetic for rats [letter] Deacon RM, et al. **Psychopharmacology (Berl)** 1996 Apr;124(3):288–90

Postanesthetic hemorrhagic myelopathy or myelomalacia. Trim CM. **Vet Clin North Am Equine Pract** 1997 Apr; 13(1):73–7 (23 ref.)

Physiologic and pathophysiologic considerations for ruminant and swine anesthesia. Jorgensen JS, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov; 12(3):481–500 (64 ref.)

Management and emergency intervention during anesthesia. Kruse-Elliott KT. **Vet Clin North Am Food Anim Pract**

1996 Nov;12(3):563–78 (29 ref.)
General principles of anesthesia and sedation in food animals. Lee DD, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):473–80 (23 ref.)
Supplies and technical considerations for ruminant and swine anesthesia. Tobin E, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):531–62 (24 ref.)
Pharmacology of drugs used for anesthesia and sedation. Tranquilli WJ, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):501–29 (68 ref.)
The effects of verapamil and lidocaine on the duration of propofol and xylazine–ketamine anesthesia in broiler chickens. Roder JD, et al. **Vet Hum Toxicol** 1996 Jun; 38(3):181–3
Induction of anaesthesia by veterinary nurses [letter] Beardshall RM. **Vet Rec** 1996 Nov 2;139(18):452
[Medetomidine] Hellebrekers LJ. **Tijdschr Diergeneeskd** 1996 Nov 1;121(21):634 **(Dut)**
[Sedation and anesthesia in dogs and cats with cardiovascular diseases. III. Ventilation, respiratory monitoring, treatment for postoperative pain] Skarda RT, et al. **Schweiz Arch Tierheilkd** 1996;138(6):312–8 (Eng. Abstr.) **(Ger)**
[Anesthesia in domestic animals (small mammals, psittacines and reptiles)] Kuntze A. **Tierarztl Prax** 1996 Dec; 24(6):600–3 (24 ref.) (Eng. Abstr.) **(Ger)**

ANESTHESIA, ACUPUNCTURE see **ACUPUNCTURE ANESTHESIA**

ANESTHESIA ADJUVANTS

Intravenous regional anesthesia. Evaluation of 4 different additives to prilocaine. Hoffmann V, et al. **Acta Anaesthesiol Belg** 1997;48(2):71–6
Effect of low dose fentanyl–droperidol administration on respiratory drive, respiratory pattern and gas exchange in ASA 1 spontaneously breathing patients. Pierdominici S, et al. **Acta Anaesthesiol Belg** 1997;48(2):85–91
Spinal anesthesia with meperidine. Effects of added alpha–adrenergic agonists: epinephrine versus clonidine. Acalovschi I, et al. **Anesth Analg** 1997 Jun;84(6):1333–9
Propofol sedation during awake craniotomy for seizures: patient–controlled administration versus neurolept analgesia. Herrick IA, et al. **Anesth Analg** 1997 Jun; 84(6):1285–91
The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Wang B, et al. **Anesth Analg** 1997 Sep;85(3):675–80
Parental presence plus oral midazolam decreases frequency of 5% halothane inductions in children. Gillerman RG, et al. **J Clin Anesth** 1996 Sep;8(6):480–5
Is intravenous lidocaine an effective adjuvant for endotracheal intubation in children undergoing induction of anesthesia with halothane–nitrous oxide? Warner LO, et al. **J Clin Anesth** 1997 Jun;9(4):270–4
No suppression of respiratory function of mitochondrial isolated from the hearts of anesthetized rats with high–dose pentobarbital sodium. Takaki M, et al. **Jpn J Physiol** 1997 Feb;47(1):87–92
Mivacurium in infants and children. Goudsouzian NG. **Paediatr Anaesth** 1997;7(3):183–90 (53 ref.)
Effect of addition of hyaluronidase and epinephrine on the pH of local anesthetic solutions [letter] England AJ, et al. **Reg Anesth** 1996 Nov–Dec;21(6):605–6
[Effect of rocuronium in sufentanil/isoflurane and sufentanil/propofol anesthesia] Klinzing S, et al. **Anaesthesiol Reanim** 1996;21(6):149–52 (Eng. Abstr.) **(Ger)**
[Postoperative observations following intraoperative fentanyl administration] Albrecht DM, et al. **Anaesthesist** 1997 Jun; 46(6):564–5 **(Ger)**
[Age–related correlation between EEG parameters and depth of anesthesia under propofol. Effect of fentanyl] Werry C, et al. **Anaesthesist** 1996 Aug;45(8):722–30 (Eng. Abstr.) **(Ger)**
[Comparative study of pethidine and clonidine for prevention of postoperative shivering. A prospective, randomized, placebo–controlled double–blind study] Grundmann U, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan;32(1):36–42 (Eng. Abstr.) **(Ger)**
[The effect of epidural anesthesia with combined use of vasodilator on hemodynamics and stress hormone levels during hepatectomy] Arai M, et al. **Masui** 1997 Feb; 46(2):158–65 (Eng. Abstr.) **(Jpn)**
[Usefulness of alpha 2–adrenoceptor agonists and practical problems associated with their use in clinical anesthesia—1. Premedication, anesthetic adjuvants, and hemodynamic effects] Nishikawa T, et al. **Masui** 1996 Dec; 45(12):1490–502 (113 ref.) (Eng. Abstr.) **(Jpn)**
[Anesthesia with Inoval and Valium in combined use] Narvaes C, et al. **Rev Bras Anestesiol** 1968 Oct–Dec; 18(4):447–61 (Eng. Abstr.) **(Por)**

ADMINISTRATION & DOSAGE

Additives in neuraxial anesthesia: opioids, alpha–2 adrenergic agonists, and neostigmine as a possible future drug for perioperative pain management. Klimscha W, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:176–8
The effects of epidural fentanyl on hemodynamic responses during emergence from isoflurane anesthesia and tracheal extubation: a comparison with intravenous fentanyl. Inagaki Y, et al. **Anesth Analg** 1997 Aug;85(2):328–35
Intrathecal sufentanil for extracorporeal shock wave lithotripsy provides earlier discharge of the outpatient than intrathecal lidocaine. Lau WC, et al. **Anesth Analg** 1997 Jun;84(6):1227–31
Early extubation after coronary bypass [letter; comment] Das T, et al. **Ann Thorac Surg** 1997 Apr;63(4):1219. Comment on: Ann Thorac Surg 1996 Oct;62(4):1164–71.
Hyaluronidase and peribulbar block. Dempsey GA, et al. **Br J Anaesth** 1997 Jun;78(6):671–4
Premedication with midazolam is more effective by the sublingual than oral route. Lim TW, et al. **Can J Anaesth** 1997 Jul;44(7):723–6
Patient–controlled epidural analgesia after caesarean section using meperidine. Ngan Kee WD, et al. **Can J Anaesth** 1997 Jul;44(7):702–6
Preoperative glycopyrrolate: oral, intramuscular, or intravenous administration. Bernstein CA, et al. **J Clin Anesth** 1996 Sep;8(6):515–8
Oral midazolam compared with diazepam–droperidol and trimeprazine as premedicants in children. Patel D, et al. **Paediatr Anaesth** 1997;7(4):287–93
Oral premedication with midazolam in paediatric anaesthesia. Effects on sedation and gastric contents. Riva J, et al. **Paediatr Anaesth** 1997;7(3):191–6

ADVERSE EFFECTS

Potential morphine sparing effect of midazolam [letter; comment] Verheecke G. **Anaesthesia** 1997 Apr;52(4):389. Comment on: Anaesthesia 1996 Sep;51(9):808–11.
Respiratory arrest after spinal anesthesia with lidocaine and fentanyl. Cornish PB. **Anesth Analg** 1997 Jun;84(6):1387–8
Interactions between midazolam and remifentanil during monitored anesthesia care. Avramov MN, et al. **Anesthesiology** 1996 Dec;85(6):1283–9
Anesthesia with sodium pentobarbital enhances lipopolysaccharide–induced cardiovascular dysfunction in rats. Hoque AM, et al. **Shock** 1996 Nov;6(5):365–70

BLOOD

Gas chromatographic determination of midazolam in low–volume plasma samples. Podkowik BI, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):405–11
Determination of droperidol in plasma by liquid chromatography. Kumar K, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1529–33

PHARMACOKINETICS

Age–related changes in the pharmacokinetic disposition of diazepam in foals. Norman WM, et al. **Am J Vet Res** 1997 Aug;58(8):878–80
Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Ahonen J, et al. **Anesthesiology** 1996 Dec;85(6):1246–52
Fentanyl pharmacokinetics in patients undergoing renal transplantation. Koehntop DE, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):746–52
Single–dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity. Yasui N, et al. **Ther Drug Monit** 1997 Aug; 19(4):371–4
Drug residue considerations for anesthetics and adjunctive drugs in food–producing animals. Papich MG. **Vet Clin North Am Food Anim Pract** 1996 Nov; 12(3):693–706 (29 ref.)
[RO 48–6791—a short acting benzodiazepine. Pharmacokinetics and pharmacodynamics in young and old subjects in comparison to midazolam] Hering W, et al. **Anaesthesist** 1996 Dec;45(12):1211–4 (Eng. Abstr.) **(Ger)**
[Kinetics of elimination of diazepam after intravenous injection in horses] Shini S, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Jan;104(1):22–5 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Cardiopulmonary and gastrointestinal motility effects of xylazine/ketamine–induced anesthesia in horses previously treated with glycopyrrolate. Singh S, et al. **Am J Vet Res** 1996 Dec;57(12):1762–70
Thiopentone requirements in adults after varying pre–induction doses of fentanyl. Wang LP, et al. **Anaesthesia** 1996 Sep;51(9):831–5
Intravenous clonidine decreases minimum end–tidal isoflurane for induction of electroencephalographic burst suppression. Entholzner EK, et al. **Anesth Analg** 1997 Jul; 85(1):193–8
The influence of three L–type calcium channel blockers on morphine effects in healthy volunteers. Hasegawa AE, et al. **Anesth Analg** 1997 Sep;85(3):633–8
Dexmedetomidine as an anesthetic adjunct in coronary artery bypass grafting. Jalonen J, et al. **Anesthesiology** 1997 Feb; 86(2):331–45
Alteration of the cardiac effects of midazolam by hypothermia in rat isolated atria. Melnikov AL, et al. **Arch Int Pharmacodyn Ther** 1996 May–Jun;331(3):263–72
Modification of cardiopulmonary and intestinal motility effects of xylazine with glycopyrrolate in horses. Singh S, et al. **Can J Vet Res** 1997 Apr;61(2):99–107
A comparison of romifidine and xylazine when used with diazepam/ketamine for short duration anesthesia in the horse. Kerr CL, et al. **Can Vet J** 1996 Oct;37(10):601–9
Clonidine inhibits gastric motility in the rat. Asai T, et al. **Eur J Anaesthesiol** 1997 May;14(3):316–9
Effects of pentobarbital and etomidate on plasma catecholamine levels and spectral analysis of blood pressure and heart rate in dogs. Mazerolles M, et al. **Fundam Clin Pharmacol** 1996;10(3):298–303
The effects of midazolam and flumazenil on psychomotor function. Gupta A, et al. **J Clin Anesth** 1997 Feb;9(1):21–5
Sodium pentobarbitone and the suppression of luteinizing hormone pulses in the female rat: the role of hypothermia. Strutton PH, et al. **J Neuroendocrinol** 1996 Dec;8(12):941–6
Comparative effects of propofol, pentobarbital, and isoflurane on cerebral blood flow and blood volume. Todd MM, et al. **J Neurosurg Anesthesiol** 1996 Oct;8(4):296–303
Inhibitory effect of pentobarbital on biliary excretion of diclofenac in a rat liver perfusion system. Fukuyama T, et al. **J Pharm Pharmacol** 1996 Jul;48(7):734–7
Influence of pentobarbitone on in–vivo local disposition of diclofenac in rat liver. Tabata K, et al. **J Pharm Pharmacol** 1996 Aug;48(8):866–9
Midazolam and ketamine induction before halothane anaesthesia in ponies: cardiorespiratory, endocrine and metabolic changes. Luna SP, et al. **J Vet Pharmacol Ther** 1997 Apr;20(2):153–9
Gamma–hydroxybutyric acid decreases thalamic sensory excitatory postsynaptic potentials by an action on presynaptic GABAB receptors. Emri Z, et al. **Neurosci Lett** 1996 Sep 27;216(2):121–4
Lack of effect of gamma–hydroxybutyrate on mu, delta and kappa opioid receptor binding. Feigenbaum JJ, et al. **Neurosci Lett** 1996 Jul 5;212(1):5–8
Comparison of three injectable anaesthetic techniques in pigs. Clutton RE, et al. **Vet Rec** 1997 Aug 9;141(6):140–6
[RO 48–6791—a short acting benzodiazepine. Pharmacokinetics and pharmacodynamics in young and old subjects in comparison to midazolam] Hering W, et al. **Anaesthesist** 1996 Dec;45(12):1211–4 (Eng. Abstr.) **(Ger)**
[Acid–base equilibrium in anesthesia with the Valium–Inoval combination] do Amaral RV, et al. **Rev Bras Anestesiol** 1968 Oct–Dec;18(4):462–71 (Eng. Abstr.) **(Por)**

THERAPEUTIC USE

Preserved sympathetic response to hypotension despite perioperative alpha2 agonist administration. Dodd–o JM, et al. **Anesth Analg** 1997 Jun;84(6):1208–10
Effect of dexmedetomidine on lumbar cerebrospinal fluid pressure in humans. Talke P, et al. **Anesth Analg** 1997 Aug; 85(2):358–64
Value of sedative premedication in female sterilization via minilaparotomy: a prospective study of two local anaesthesia regimen. Ruminjo JK, et al. **East Afr Med J** 1995 Oct;72(10):678–83
Intravenous ketorolac tromethamine versus meperidine for adjunctive sedation in upper gastrointestinal endoscopy: a pilot study. Dies DF, et al. **Gastrointest Endosc** 1996 Jan; 43(1):6–9
Use of atropine during endoscopy: benefit during photodynamic therapy [letter] Van de Mierop F, et al. **Gastrointest Endosc** 1996 Oct;44(4):512
Inhibition of epidural morphine–induced pruritus by intravenous droperidol. The effect of increasing the doses of morphine and of droperidol. Horta ML, et al. **Reg Anesth** 1996 Jul–Aug;21(4):312–7
Options for management of acute pain in the rat. Abbott FV, et al. **Vet Rec** 1997 May 24;140(21):553–7
[Use of the vegetative index in optimization of premedication in patients with stomach and duodenal ulcer] Spitsyn ON, et al. **Klin Khir** 1996;(8):15–6 **(Rus)**

ANESTHESIA ASSISTANTS see **PHYSICIAN ASSISTANTS**

ANESTHESIA, CAUDAL

Caudal clonidine and bupivacaine for combined epidural and general anaesthesia in children. Motsch J, et al. **Acta Anaesthesiol Scand** 1997 Aug;41(7):877–83
Experience with caudal blocks in children over a period of 3.5 years. Breschan C, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:174–6
Comparison of subcutaneous ring block of the penis with caudal epidural block for post–circumcision analgesia in children. Irwin MG, et al. **Anaesth Intensive Care** 1996 Jun;24(3):365–7
The optimal dose of ketamine for caudal epidural blockade in children. Semple D, et al. **Anaesthesia** 1996 Dec; 51(12):1170–2
Reducing pain after inguinal hernia repair in children: caudal anesthesia versus ketorolac tromethamine. Splinter WM, et al. **Anesthesiology** 1997 Sep;87(3):542–6
Pre–incisional caudal epidural blockade and the relief of pain after lumbar spine operations. Kakiuchi M, et al. **Int Orthop** 1997;21(1):62–6
Post–operative pain relief in children following caudal bupivacaine and buprenorphine—a comparative study. Anilkumar TK, et al. **J Postgrad Med** 1994 Apr–Jun; 40(2):61–4
One explanation why Spiegel's formula gives us a larger dose for small children [letter] Ying Y, et al.

ANESTHESIA, CAUDAL

Paediatr Anaesth 1996;6(4):341
Use of epidural anesthesia in non-cardiac surgery in two cases complicated by hypertrophic cardiomyopathy. Takaya T, et al. **Tokai J Exp Clin Med** 1996 Oct;21(3):113-5
[Caudal and spinal anesthesia in sub-umbilical surgery in children. Apropos of 1875 cases] Aguemon AR, et al. **Cah Anesthesiol** 1996;44(5):455-63 (22 ref.) (Eng. Abstr.) **(Fre)**
[Arthrogryposis multiplex congenita: special anesthesiological aspects] Standl T, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Feb; 31(1):53-7 (Eng. Abstr.) **(Ger)**
[Combined caudal and general anesthesia in clubfoot surgery] Nelitz M, et al. **Z Orthop Ihre Grenzgeb** 1996 Nov-Dec; 134(6):537-40 (Eng. Abstr.) **(Ger)**
[Anesthetic management of a pediatric patient with non-Fukuyama type congenital muscular dystrophy] O'Higashi T, et al. **Masui** 1997 Jan;46(1):83-6 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Caudal anesthesia and urinary retention in ambulatory surgery [letter] Pappas AL, et al. **Anesth Analg** 1997 Sep; 85(3):706

METHODS

Identifying the caudal space--if it doesn't itch don't scratch [letter; comment] Ball AJ. **Anaesthesia** 1997 May;52(5):506 . Comment on: Anaesthesia 1996 Dec;51(12):1190-1.
A method of identifying the caudal space--a 'scratch' test [letter] [see comments] Kamath BS. **Anaesthesia** 1996 Dec; 51(12):1190-1. Comment in: Anaesthesia 1997 May;52(5):506.
Randomized comparison of agents for caudal anaesthesia in anal surgery [letter; comment] Chan MT, et al. **Br J Surg** 1996 Sep;83(9):1300. Comment on: Br J Surg 1996 Mar;83(3):364-5.
Topical anaesthesia for bladder biopsies and cautery: intravesical lidocaine versus caudal anaesthesia. Amano T, et al. **Int Urol Nephrol** 1995;27(5):533-7
Use of spinal or continuous caudal anesthesia for inguinal hernia repair in premature infants: are there advantages? Broadman LM. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):108-13 (27 ref.)
[Evaluation of 2 dosages of fentanyl in caudal anesthesia. A prospective randomized double-blind study] Gharsallah A, et al. **Cah Anesthesiol** 1996;44(5):419-21 (Eng. Abstr.) **(Fre)**

VETERINARY

Evaluation of caudal epidural lignocaine injection during dystocia correction in ewes. Scott PR, et al. **Vet Rec** 1996 Jan 6;138(1):19-20

ANESTHESIA, CLOSED-CIRCUIT

Gas leakage and the laryngeal mask airway. A comparison with the tracheal tube and facemask during spontaneous ventilation using a circle breathing system. Cameron AE, et al. **Anaesthesia** 1996 Dec;51(12):1117-9
The loss of sevoflurane from a closed breathing system. Vagts DA, et al. **Anaesthesia** 1997 Jul;52(7):636-9
Complexities overlooked: things may not be what they seem [editorial; comment] Eger EI 2nd. **Anesth Analg** 1997 Feb; 84(2):239-40. Comment on: Anesth Analg 1997 Feb;84(2):413-8.
Uptake of desflurane and isoflurane during closed-circuit anesthesia with spontaneous and controlled mechanical ventilation [see comments] Hendrickx JF, et al. **Anesth Analg** 1997 Feb;84(2):413-8. Comment in: Anesth Analg 1997 Feb;84(2):239-40.
A source of nitrogen in the breathing circuit during closed system anesthesia [letter] Stevens WC, et al. **Anesthesiology** 1996 Dec;85(6):1492-3
Quantitative study of Lowe's square-root-of-time method of closed-system anaesthesia. da Silva JM, et al. **Br J Anaesth** 1997 Jul;79(1):103-12
[Low flow anesthesia with xenon] Baum J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):51-5 **(Ger)**
[Xenon (editorial; comment)] Georgieff M. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):43. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):268-75. **(Ger)**
[Low-flow anesthetic systems. Closed circuit] Bermejo-Díaz de Rábago R, et al. **Rev Esp Anestesiol Reanim** 1997 Mar; 44(3):108-11; quiz 111 (26 ref.) **(Spa)**
[Do the new volatile anesthetics approximate the ideal anesthetic?] Coriat P. **Rev Esp Anestesiol Reanim** 1996 Aug-Sep;43(7):233-4 **(Spa)**

ADVERSE EFFECTS

Carboxyhemoglobin concentrations during desflurane and isoflurane closed-circuit anesthesia. Hendrickx JF, et al. **Acta Anaesthesiol Belg** 1996;47(2):67-72
Hepatitis C nosocomial infection [letter; comment] Greene ES. **Anaesth Intensive Care** 1997 Feb;25(1):86-7. Comment on: Anaesth Intensive Care 1996 Apr;24(2):169-72.

INSTRUMENTATION

Barriers to hepatitis C transmission within breathing systems: efficacy of a pleated hydrophobic filter. Lloyd G, et al. **Anaesth Intensive Care** 1997 Jun;25(3):235-8
The effect of a heat and moisture exchanger on humidity in a low-flow anaesthesia system. Henriksson BA, et al. **Anaesthesia** 1997 Feb;52(2):144-9
An alternative method of nitrous oxide delivery into a minimal-flow circle breathing system. Nel MR, et al. **Anaesthesia** 1997 Jan;52(1):57-61
An unpredictable and possibly dangerous hazard of an anaesthetic scavenging system [letter] Sivalingam P, et al. **Anaesthesia** 1997 Jun;52(6):609-10
An uncommon leak in the anesthesia breathing circuit [letter] Bromley HR, et al. **Anesth Analg** 1997 Sep;85(3):707
Food and Drug Administration guidelines for machine checkout need modification [letter; comment] Dunn SM, et al. **Anesth Analg** 1997 Feb;84(2):468-9. Comment on: Anesth Analg 1996 Aug;83(2):425-6.
Effects of ThermH2Osorb carbon dioxide absorber on temperature and humidity in the anesthetic circuit [letter] Mosca PJ, et al. **Anesth Analg** 1997 May;84(5):1164-5
Obstruction due to retained carbon dioxide absorber canister wrapping [letter; comment] Ransom ES, et al. **Anesth Analg** 1997 Mar;84(3):703. Comment on: Anesth Analg 1996 Aug;83(2):425-6.
Prevention of patient bacterial contamination of anaesthesia-circle-systems: a clinical study of the contamination risk and performance of different heat and moisture exchangers with electret filter (HMEF). Rathgeber J, et al. **Eur J Anaesthesiol** 1997 Jul;14(4):368-73
The anesthesia machine valve tester: a new device and method for evaluating the competence of unidirectional anesthetic valves. Eappen S, et al. **J Clin Monit** 1996 Jul; 12(4):305-9
Use of the laryngeal mask for closed circuit anesthesia. Stacey MR, et al. **Middle East J Anesthesiol** 1996 Oct; 13(6):593-604
Anaesthetic breathing systems for children [letter; comment] Meakin G, et al. **Paediatr Anaesth** 1996;6(4):346. Comment on: Paediatr Anaesth 1996;6(1):1-5.
[The temperature-humidity profile of the PhysioFlex. Studies on a model] Wissing H, et al. **Anaesthesist** 1997 Mar; 46(3):201-6 (Eng. Abstr.) **(Ger)**
[Anesthetic gas conditioning using the anesthetic device PhysioFlex] Wissing H, et al. **Anaesthesist** 1997 Jul; 46(7):613-5 **(Ger)**
[Reclaiming volatile and gaseous anesthetics] Bäder S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):46-8 **(Ger)**
[Behm's T-piece for reducing anesthesia gas pollution at the anesthesia work site] Salomon F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):425-6 (Eng. Abstr.) **(Ger)**
[Clinical evaluation of low flow anesthesia machine ACOMA ACM-10] Igarashi M, et al. **Masui** 1997 Apr;46(4):560-4 (Eng. Abstr.) **(Jpn)**
[Anesthesia with low flow of fresh gases and closed circuit (editorial)] Martín-Larrauri Camarillo R. **Rev Esp Anestesiol Reanim** 1997 May;44(5):173-5 **(Spa)**

METHODS

New agents, the circle system and short procedures. Nel MR, et al. **Anaesthesia** 1997 Apr;52(4):364-7
[Adaptive lung ventilation (AVL). Evaluation of new closed loop regulated respiration algorithm for operation in the hyperextended lateral position] Weiler N, et al. **Anaesthesist** 1996 Oct;45(10):950-6 (Eng. Abstr.) **(Ger)**
[Simple, practical closed-circuit anesthesia] Lin CY. **Masui** 1997 Apr;46(4):498-505 (19 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Priming of anesthesia circuit with xenon for closed circuit anesthesia. Saito H, et al. **Artif Organs** 1997 Jan;21(1):70-2

VETERINARY

[Minimal-flow anesthesia in the dog] Gantke S, et al. **Tierarztl Prax** 1997 Apr;25(2):156-63 (Eng. Abstr.) **(Ger)**
[Isoflurane anesthesia in rabbits in a closed anesthetic system] Henke J, et al. **Tierarztl Prax** 1996 Dec;24(6):604-9 (Eng. Abstr.) **(Ger)**

ANESTHESIA, CONDUCTION

Intravenous regional anesthesia. Evaluation of 4 different additives to prilocaine. Hoffmann V, et al. **Acta Anaesthesiol Belg** 1997;48(2):71-6
Thromboprophylaxis, coagulation disorders, and regional anaesthesia. Haljamäe H. **Acta Anaesthesiol Scand** 1996 Sep; 40(8 Pt 2):1024-40 (94 ref.)
Intra-arterial regional anaesthesia for hand surgery: a dose-finding study. Koscielniak-Nielsen ZJ, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):197-203
The effects of simulated Bier block IVRA on intracompartmental tissue pressure. Mabee JR, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):208-13
Cardiac risk patient--intraoperative contribution: anaesthetic management. Boldt J. **Acta Anaesthesiol Scand Suppl** 1996; 109:133-4
Opioids in regional anaesthesia. Ilias WK. **Acta Anaesthesiol Scand Suppl** 1996;109:103-4
Regional anesthesia for the pregnant cardiac patient. Mitterschiffthaler G. **Acta Anaesthesiol Scand Suppl** 1996; 109:180-4
General or regional anaesthesia--pro regional. Raeder J. **Acta Anaesthesiol Scand Suppl** 1997;110:56-8
General or regional anaesthesia. Stefansson T. **Acta Anaesthesiol Scand Suppl** 1997;110:52-3
Regional anaesthesia for emergency caesarean section in a patient with lepromatous leprosy. Hempenstall K, et al. **Anaesth Intensive Care** 1997 Apr;25(2):168-70
Bier's block--under pressure? [letter] [see comments] Hunt SJ, et al. **Anaesthesia** 1997 Feb;52(2):188-9. Comment in: Anaesthesia 1997 Jul;52(7):713.
Contamination of opioids during preparation for regional anaesthesia [letter] [see comments] McConaghy P, et al. **Anaesthesia** 1996 Nov;51(11):1079-80. Comment in: Anaesthesia 1997 Feb;52(2):183. Comment in: Anaesthesia 1997 Mar;52(3):290.
Contamination of opioids during preparation for regional anaesthesia [letter; comment] Mulvein JT. **Anaesthesia** 1997 Feb;52(2):183. Comment on: Anaesthesia 1996 Nov;51(11):1079-80.
Regional anesthesia in children: what have we learned? [editorial; comment] Berde C. **Anesth Analg** 1996 Nov; 83(5):897-900. Comment on: Anesth Analg 1996 Nov;83(5):904-12.
Effect on postoperative analgesia of small-dose lysine acetylsalicylate added to prilocaine during intravenous regional anesthesia. Corpataux JB, et al. **Anesth Analg** 1997 May;84(5):1081-5
A North American survey of intravenous regional anesthesia. Henderson CL, et al. **Anesth Analg** 1997 Oct;85(4):858-63
Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Horlocker TT, et al. **Anesth Analg** 1997 Oct;85(4):874-85 (78 ref.)
Regional anesthesia for thyroidectomy in two patients with amiodarone-induced hyperthyroidism. Klein SM, et al. **Anesth Analg** 1997 Jul;85(1):222-4
Electroencephalographic bispectral index correlates with intraoperative recall and depth of propofol-induced sedation. Liu J, et al. **Anesth Analg** 1997 Jan;84(1):185-9
alpha(2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Eisenach JC, et al. **Anesthesiology** 1996 Sep;85(3):655-74 (169 ref.)
Local and regional anesthesia for functional endoscopic sinus surgery. Lee WC, et al. **Ann Otol Rhinol Laryngol** 1997 Sep;106(9):767-9
Music therapy for patients undergoing regional anesthesia. Eisenman A, et al. **AORN J** 1995 Dec;62(6):947-50
Prophylaxis of venous thromboembolism. Regional anaesthesia reduces thromboembolic morbidity [letter; comment] Cook TM, et al. **BMJ** 1997 Apr 26; 314(7089):1282; discussion 1282-3. Comment on: BMJ 1997 Jan 11;314(7074):123-5.
Soft tissue anatomy within the vertebral canal in pregnant women. Hirabayashi Y, et al. **Br J Anaesth** 1996 Aug; 77(2):153-6
Low-dose mivacurium supplementation of prilocaine i.v. regional anaesthesia. Torrance JM, et al. **Br J Anaesth** 1997 Feb;78(2):222-3
Emergency laparoscopy in a patient with severe asthma. Arrowsmith JE, et al. **Br J Hosp Med** 1996 May 1-14; 55(9):593
Eschew the achoo! [letter] Elwood T, et al. **Can J Anaesth** 1996 Feb;43(2):192-3
The addition of clonidine to prilocaine for intravenous regional anaesthesia. Kleinschmidt S, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):40-6
Fasting before Bier's block [letter; comment] Nandwani N, et al. **J Accid Emerg Med** 1997 Jan;14(1):59; discussion 60 . Comment on: J Accid Emerg Med 1996 Mar;13(2):105-7.
Fasting before Bier's block [letter; comment] Stokes JM, et al. **J Accid Emerg Med** 1997 Jan;14(1):59-60. Comment on: J Accid Emerg Med 1996 Mar;13(2):105-7.
Successful regional anesthesia for a woman with a single ventricle presenting for labor and delivery. Ammar T, et al. **J Cardiothorac Vasc Anesth** 1996 Aug;10(5):640-2
Role of regional anaesthesia and a modified technique of fish-hook removal. Abid SA, et al. **J Indian Med Assoc** 1996 Aug;94(8):323
A comparison of regional and general anesthesia in patients undergoing carotid endarterectomy. Rockman CB, et al. **J Vasc Surg** 1996 Dec;24(6):946-53; discussion 953-6
Prevention of phantom limb pain by regional anaesthesia. Katz J. **Lancet** 1997 Feb 22;349(9051):519-20
Post-discharge deep-vein thrombosis after orthopaedic surgery [letter; comment] Simini B. **Lancet** 1996 Oct 26; 348(9035):1179; discussion 1179-80. Comment on: Lancet 1996 Jul 27;348(9022):224-8.
Regional/local anesthesia: a safe and reasonable choice for patients undergoing carotid endarterectomy. Buchbinder D, et al. **Md Med J** 1997 Mar;46(3):125-30
Higher rate of fetal acidemia after regional anesthesia for elective cesarean delivery. Mueller MD, et al. **Obstet Gynecol** 1997 Jul;90(1):131-4
Regional anesthesia for pain associated with terminal pediatric malignancy. Collins JJ, et al. **Pain** 1996 Apr; 65(1):63-9

Intravenous regional anesthesia for management of children's extremity fractures in the emergency department. Blasier RD, et al. **Pediatr Emerg Care** 1996 Dec;12(6):404–6

1996 Annual meeting of the American Society of Regional Anesthesia. San Diego, California, March 28–31, 1996. Abstracts. **Reg Anesth** 1996 Mar–Apr;21(2 Suppl):1–119

1997 Annual meeting of the American Society of Regional Anesthesia. Atlanta, Georgia, April 10–13 1997. Abstracts. **Reg Anesth** 1997 Mar–Apr;22(2 Suppl):1–124

Survey of regional anesthetic practice among French residents at time of certification [see comments] Bouaziz H, et al. **Reg Anesth** 1997 May–Jun;22(3):218–22. Comment in: Reg Anesth 1997 May–Jun;22(3):209–11.

Gastrointestinal benefits of regional anesthesia/analgesia. Carpenter RL. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):13–7 (29 ref.)

A different approach in demonstrating the mechanism of intravenous regional anesthesia [letter] Celebi H, et al. **Reg Anesth** 1997 Jul–Aug;22(4):387

Respiratory benefits of regional anesthesia. Clergue F, et al. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):18–23 (39 ref.)

Regional anesthesia and analgesia in the patient receiving thromboprophylaxis [editorial; comment] Horlocker TT. **Reg Anesth** 1996 Nov–Dec;21(6):503–7. Comment on: Reg Anesth 1996 Nov–Dec;21(6):517–24.

QA in regional anesthesia training: quantity or quality? [editorial; comment] Kopacz D. **Reg Anesth** 1997 May–Jun; 22(3):209–11. Comment on: Reg Anesth 1997 May–Jun;22(3):218–22.

"No paresthesias–no anesthesia," the nerve stimulator or neither? [letter; comment] Moore DC. **Reg Anesth** 1997 Jul–Aug;22(4):388–90. Comment on: Reg Anesth 1997 Jul–Aug;22(4):387–8.

Comparison of wound infiltration with ketorolac versus intravenous regional anesthesia with ketorolac for postoperative analgesia following ambulatory hand surgery. Reuben SS, et al. **Reg Anesth** 1996 Nov–Dec; 21(6):565–8

Intravenous regional anesthesia with ketorolac–lidocaine for the management of sympathetically–mediated pain. Connelly NR, et al. **Yale J Biol Med** 1995 May–Aug; 68(3–4):95–9

[Combined loco–regional anesthesia and intravenous anesthesia with propofol (Diprivan––Zeneca)] Badeva B, et al. **Khirurgiia (Sofiia)** 1996;49(4):12–3 (Eng. Abstr.) **(Bul)**

[Locoregional anesthesia in obstetrics: benefits and risks] Benhamou D. **Chirurgie** 1997;122(1):43–6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Locoregional anesthesia in children: benefit/risk ratio] Ecoffey C. **Chirurgie** 1997;122(1):39–42 (23 ref.) (Eng. Abstr.) **(Fre)**

[Locoregional anesthesia in digestive surgery] Eledjam JJ, et al. **Chirurgie** 1997;122(1):47–54 (30 ref.) (Eng. Abstr.) **(Fre)**

[Spinal and regional anesthesia in bacteremia] Beland B, et al. **Anaesthesist** 1997 Jun;46(6):536–47 (117 ref.) (Eng. Abstr.) **(Ger)**

[Which regional anesthesia methods for pain therapy are suitable for acheivement of normalization?] Hempel V. **Anaesthesist** 1996 Dec;45 Suppl 3:S77–8 **(Ger)**

[Optimal regional anesthesia procedure in cesarean section] Hempelmann G, et al. **Anaesthesist** 1996 Oct;45(10):996–7 **(Ger)**

[Hypnosis––a side effect–free alternative to medical sedation in regional anesthesia] Schulz–Stübner S. **Anaesthesist** 1996 Oct;45(10):965–9 (Eng. Abstr.) **(Ger)**

[Perioperative monitoring of the course of anesthesia, the postanesthesia visit and inquiry of patient satisfaction. A prospective study of parameters in process and outcome quality in anesthesia] Bothner U, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Dec; 31(10):608–14 (Eng. Abstr.) **(Ger)**

[Anesthesia and analgesia in intravenous drug dependent patients with injection abscesses of the upper extremity. Case report] Ebert B, et al. **Handchir Mikrochir Plast Chir** 1997 Jan;29(1):38–41 (Eng. Abstr.) **(Ger)**

[Usefulness of alpha 2–adrenoceptor agonists and practical problems associated with their use in clinical anesthesia––II. Effects in regional anesthesia and analgesic effects for pain relief] Nishikawa T, et al. **Masui** 1997 Jan;46(1):64–72 (209 ref.) (Eng. Abstr.) **(Jpn)**

[Regional (conduction) anesthesia: new solutions of old problems] Svetlov VA, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):53–62 (107 ref.) (Eng. Abstr.) **(Rus)**

[Analysis of regional anesthetic efficacy in pediatric postop pain] Martínez–Tellería A, et al. **Cir Pediatr** 1997 Jan; 10(1):18–20 (Eng. Abstr.) **(Spa)**

[Subarachnoid anesthesia with minimal doses of lidocaine in ambulatory arthroscopic surgery of the knee] Raich–Brufau M, et al. **Rev Esp Anestesiol Reanim** 1997 May;44(5):204–6 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Serious complications related to regional anesthesia: results of a prospective survey in France [see comments] Auroy Y, et al. **Anesthesiology** 1997 Sep;87(3):479–86. Comment in: Anesthesiology 1997 Sep;87(3):469–72.

Regional anesthesia: vintage Bordeaux (and Napa Valley) [editorial] Eisenach JC. **Anesthesiology** 1997 Sep; 87(3):467–9

Effects of regional anesthesia on perioperative outcome. Atanassoff PG. **J Clin Anesth** 1996 Sep;8(6):446–55 (106 ref.)

Mild perioperative hypothermia. Sessler DI. **N Engl J Med** 1997 Jun 12;336(24):1730–7 (60 ref.)

Tumescent liposuction complicated by pulmonary edema. Gilliland MD, et al. **Plast Reconstr Surg** 1997 Jan; 99(1):215–9

Complications of pediatric regional anesthesia. Broadman LM. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):64–70 (46 ref.)

Long–tapered double needle used to reduce needle stick nerve injury. Maruyama M. **Reg Anesth** 1997 Mar–Apr; 22(2):157–60

Can regional anesthesia worsen outcome? Medicolegal risk. Wedel DJ. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):71–4 (13 ref.)

Anaesthetic complications in the recovery room [see comments] Norsidah AM, et al. **Singapore Med J** 1997 May; 38(5):200–4. Comment in: Singapore Med J 1997 May;38(5):190–1.

ECONOMICS

[Cost effectiveness of local regional anesthesia in a remote area] Faisy C, et al. **Med Trop (Mars)** 1996;56(4):367–72 (Eng. Abstr.) **(Fre)**

HISTORY

Some personal reflections on anatomic illustration with particular regard to regional anesthesia. Vandam LD. **Anesth Analg** 1997 Sep;85(3):691–6

Emery A. Rovenstine and regional anesthesia. Bacon DR, et al. **Reg Anesth** 1997 May–Jun;22(3):273–9

INSTRUMENTATION

Regional anesthesia in knee arthroscopy: a new technique involving femoral and sciatic nerve blocks in knee arthroscopy. Cappellino A, et al. **Arthroscopy** 1996 Feb; 12(1):120–3

Lateral decubitus and the nonaxillary roll [letter] Ben–David B, et al. **Reg Anesth** 1997 Jul–Aug;22(4):390–2

Long–tapered double needle used to reduce needle stick nerve injury. Maruyama M. **Reg Anesth** 1997 Mar–Apr; 22(2):157–60

METHODS

Prolonged peribulbar anaesthesia with indwelling catheter: a preliminary report of 217 cases. Bernard JM, et al. **Br J Anaesth** 1997 Jan;78(1):81–2

A comparison of three regional anaesthesia techniques for outpatient knee arthroscopy. Goranson BD, et al. **Can J Anaesth** 1997 Apr;44(4):371–6

Paravertebral block for breast cancer surgery. Greengrass R, et al. **Can J Anaesth** 1996 Aug;43(8):858–61

Regional anaesthesia and reactive airway disease [letter; comment] Mercier FJ, et al. **Can J Anaesth** 1997 Mar; 44(3):339–40. Comment on: Can J Anaesth 1996 Jul;43(7):700–13.

Patient sedation: technical problems and developments. Kenny GN. **Eur J Anaesthesiol Suppl** 1996 Jul;13:18–21; discussion 22–5

Sedation during regional anaesthesia: indications, advantages and methods. Mackenzie N. **Eur J Anaesthesiol Suppl** 1996 Jul;13:2–7; discussion 22–5

Choices in sedation: the balanced sedation technique. Tryba M. **Eur J Anaesthesiol Suppl** 1996 Jul;13:8–12; discussion 22–5

A prospective trial to compare three anaesthetic techniques used for the reduction of fractures of the distal radius. Funk L. **Injury** 1997 Apr;28(3):209–12

Regional anesthesia for endovascular treatment of abdominal aortic aneurysms. Aadahl P, et al. **J Endovasc Surg** 1997 Feb;4(1):56–61

Regional anesthesia in foot and ankle surgery. Lee TH, et al. **Orthopedics** 1996 Jul;19(7):577–80

Para–umbilical block: a new concept for regional anaesthesia in children. Courreges P, et al. **Paediatr Anaesth** 1997; 7(3):211–4

Special situations for regional anesthesia: trauma. Brown DL. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):122–5 (28 ref.)

Benefits of regional anesthesia on thromboembolic complications following surgery. Rosenfeld BA. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):9–12 (40 ref.)

Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double–blind randomized clinical study. Simon MA, et al. **Reg Anesth** 1997 Jan–Feb; 22(1):29–34

[Locoregional anesthesia for injuries of the lower limbs] Barré J, et al. **Cah Anesthesiol** 1996;44(3):197–201 (Eng. Abstr.) **(Fre)**

[Local and regional anesthesia for ambulatory surgery] Ecoffey C, et al. **Rev Med Suisse Romande** 1997 May; 117(5):379–82 (25 ref.) **(Fre)**

[Local anesthetics––maximum recommended doses] Niesel HC. **Anaesthesiol Reanim** 1997;22(3):60–2 (15 ref.) (Eng. Abstr.) **(Ger)**

[Comparison of dosage relations of prilocaine and bupivacaine for axillary plexus anesthesia] Voges O, et al. **Anaesthesiol Reanim** 1997;22(3):63–8 (Eng. Abstr.) **(Ger)**

[Anesthesia in ophthalmology] Ştefăniu I, et al. **Oftalmologia** 1996 Oct–Dec;40(4):340–8 (5 ref.) (Eng. Abstr.) **(Rum)**

[Intravenous regional anesthesia using low doses of lidocaine for hand surgery (letter)] Aznar IM, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):77–8 **(Spa)**

STATISTICS & NUMERICAL DATA

Epidemiology and morbidity of regional anesthesia in children: a one–year prospective survey of the French–Language Society of Pediatric Anesthesiologists [see comments] Giaufré E, et al. **Anesth Analg** 1996 Nov; 83(5):904–12. Comment in: Anesth Analg 1996 Nov;83(5):897–900.

UTILIZATION

The use of central regional anesthesia techniques in Sweden: results of a nation–wide survey. Swedish Association of Anesthesia and Intensive care. Holmström B, et al. **Acta Anaesthesiol Scand** 1997 May;41(5):565–72

VETERINARY

Innervation and anesthesia of the antler pedicle in wapiti and fallow deer. Woodbury MR, et al. **Can Vet J** 1996 Aug;37(8):486–9

Radiological appearance of air introduced during equine regional limb anaesthesia. Kirberger RM, et al. **Equine Vet J** 1996 Jul;28(4):298–305

Local and regional anesthesia and analgesia. Pascoe P. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):94–105 (88 ref.)

Local and regional anesthesia in ruminants and swine. Skarda RT. **Vet Clin North Am Food Anim Pract** 1996 Nov; 12(3):579–626 (140 ref.)

ANESTHESIA, DENTAL

Anaesthetic management of a pregnant, post liver transplant patient for dental surgery. Avraamides EJ, et al. **Anaesth Intensive Care** 1997 Feb;25(1):68–70

Laryngeal mask insertion following inhalational induction in children: a comparison between halothane and sevoflurane. Kwek TK, et al. **Anaesth Intensive Care** 1997 Aug; 25(4):413–6

Adverse response to sevoflurane induction followed by enflurane maintenance [letter] MacLeod A, et al. **Anaesthesia** 1997 Jun;52(6):603–4

Clinical outcomes for nursing caries treated using general anesthesia. Berkowitz RJ, et al. **ASDC J Dent Child** 1997 May–Jun;64(3):210–1, 228

Evidence for safety margins of lignocaine local anaesthetics for peri–oral use. Cannell H. **Br Dent J** 1996 Oct 5; 181(7):243–9 (43 ref.)

Safety margins for lignocaine local anaesthetic [letter] Feirn D. **Br Dent J** 1996 Dec 7–21;181(11–12):398

General anaesthesia [letter; comment] Greenan J. **Br Dent J** 1996 Oct 5;181(7):241. Comment on: Br Dent J 1996 Jun 22;180(12):448.

General anaesthesia in dentistry [letter] Greenan J. **Br Dent J** 1996 Mar 23;180(6):206

Is general anaesthesia for orthodontic extractions in children necessary? [letter; comment] [published erratum appears in Br Dent J 1996 Oct 19;181(8):283] [see comments] Jack WA, et al. **Br Dent J** 1996 Sep 7;181(5):165. Comment on: Br Dent J 1996 Jul 6;181(1):6–7. Comment in: Br Dent J 1996 Nov 9;181(9):319.

A survey of general anaesthesia, sedation and resuscitation in general dental practice. Macpherson LM, et al. **Br Dent J** 1996 Sep 21;181(6):199–203

The use of lignocaine local anaesthetic [letter] Preshaw PM, et al. **Br Dent J** 1996 Oct 5;181(7):240

General anaesthesia [letter; comment] Prince AT. **Br Dent J** 1996 Sep 21;181(6):196. Comment on: Br Dent J 1996 Jul 6;181(1):6–7.

Epileptic fits under intravenous midazolam sedation [see comments] Robb ND. **Br Dent J** 1996 Sep 7;181(5):178–9 . Comment in: Br Dent J 1996 Dec 7–21;181(11–12):399. Comment in: Br Dent J 1997 Jan 25;182(2):50.

Bilateral block: is it safe and more efficient during removal of third molars? [see comments] Holland IS, et al. **Br J Oral Maxillofac Surg** 1996 Jun;34(3):243–7. Comment in: Br J Oral Maxillofac Surg 1997 Feb;35(1):74.

The role of pre–general anaesthetic assessment for patients referred by general dental practitioners to the Community Dental Service. Landes DP, et al. **Community Dent Health** 1996 Sep;13(3):169–71

A quality assurance review of the patient referral process and user satisfaction of outpatient general anaesthesia services for dental treatment. Podesta JR, et al. **Community Dent Health** 1996 Dec;13(4):228–31

Post–operative pain relief in children following extraction of carious deciduous teeth under general anaesthesia: a comparison of nalbuphine and diclofenac. Littlejohn IH, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):359–63

Anaesthesia for dental conservation in a patient with tuberous sclerosis. Nott MR, et al. **Eur J Anaesthesiol** 1996 Jul; 13(4):413–5

The use of lignocaine in dental practice: results of a survey of a group of general and hospital dental practitioners. Rowson JE, et al. **J Dent** 1997 Sep;25(5):431–3

Pain control in recovering alcoholics: effects of local anesthesia. Fiset L, et al. **J Stud Alcohol** 1997 May; 58(3):291–6

ANESTHESIA, DENTAL

Local anesthetic safety in pediatric patients. Davis MJ, et al. **N Y State Dent J** 1996 Feb;62(2):32–5

Relationship of tonsil size on an airway blockage maneuver in children during sedation. Fishbaugh DF, et al. **Pediatr Dent** 1997 May–Jun;19(4):277–81

Effects of nitrous oxide on diazepam sedation of young children. Houpt MI, et al. **Pediatr Dent** 1996 May–Jun; 18(3):236–41

A history of sedation guidelines: where we are headed in the future. Wilson S, et al. **Pediatr Dent** 1996 May–Jun; 18(3):194–9

[Intravenous sedation in implantology] Chanavaz M, et al. **Rev Stomatol Chir Maxillofac** 1997 Jan;98(1):57–61 (Eng. Abstr.) **(Fre)**

[Anesthetic preparation of patients with generalized diseases for maxillofacial surgery. Authors' experience] Tartaro GP, et al. **Minerva Stomatol** 1997 Jul–Aug;46(7–8):391–8 **(Ita)**

ADVERSE EFFECTS

A case report or a cautionary tale? [letter; comment] Dixon M, et al. **Br Dent J** 1997 Jan 25;182(2):50. Comment on: Br Dent J 1996 Sep 7;181(5):178–9.

Epileptic fits [letter; comment] Garton R. **Br Dent J** 1996 Dec 7–21;181(11–12):399. Comment on: Br Dent J 1996 Sep 7;181(5):178–9.

Bless you [letter] Ngeow WC. **Br Dent J** 1996 Apr 6; 180(7):246

Permanent neurologic deficit after inferior alveolar nerve block: a case report. Shenkman Z, et al. **Int J Oral Maxillofac Surg** 1996 Oct;25(5):381–2

Transient diplopia as a result of block injections. Mandibular and posterior superior alveolar. Goldenberg AS. **N Y State Dent J** 1997 May;63(5):29–31

Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Luchetti W, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jan;81(1):21–5

ECONOMICS

Anaesthetic fees [letter] Jack WA. **Br Dent J** 1997 May 24; 182(10):371

HISTORY

Horace Wells (1815–1848). Westhorpe R. **Anaesth Intensive Care** 1996 Aug;24(4):415

[On the 150th anniversary of the introduction of anesthesia in Spain: the role of dentists] Hervás C, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):16–22 (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Sterilising anaesthetic cartridges [letter] [see comments] Gordon P. **Br Dent J** 1997 Feb 8;182(3):87. Comment in: Br Dent J 1997 May 24;182(10):370.

Reducing the risk of needlesticks: methods used to reload syringes. Drelich EV. **J Am Dent Assoc** 1997 Jan; 128(1):55–9

METHODS

A comparison of the nasal mask and the nasopharyngeal airway in paediatric chair dental anaesthesia. Bagshaw ON, et al. **Anaesthesia** 1997 Aug;52(8):786–9

Anaesthesia for simple exodontia in the dental chair [letter; comment] Bricker SR. **Anaesthesia** 1997 May;52(5):507–8 . Comment on: Anaesthesia 1996 Jul;51(7):713. Comment on: Anaesthesia 1997 Jan;52(1):89.

General anaesthesia versus inhalational sedation for children's exodontia [letter; comment] [see comments] Girdler NM. **Anaesthesia** 1997 Jan;52(1):89. Comment on: Anaesthesia 1996 Jul;51(7):713. Comment in: Anaesthesia 1997 May;52(5):507–8.

The effectiveness of midazolam and hydroxyzine as sedative agents for young pediatric dental patients. Shapira J, et al. **ASDC J Dent Child** 1996 Nov–Dec;63(6):421–5

Is general anaesthesia necessary? [letter; comment] Girdler NM. **Br Dent J** 1996 Nov 9;181(9):319. Comment on: Br Dent J 1996 Jul 6;181(1):6–7. Comment on: Br Dent J 1996 Sep 7;181(5):165.

Palatal injection technique [letter; comment] [see comments] Greenwood I. **Br Dent J** 1997 Apr 12;182(7):245. Comment on: Br Dent J 1997 Jan 25;182(2):50. Comment in: Br Dent J 1997 Jun 28;182(12):453.

What injection? [letter; comment] [see comments] Harker T. **Br Dent J** 1997 Jan 25;182(2):50. Comment on: Br Dent J 1996 Nov 9;181(9):333–5. Comment in: Br Dent J 1997 Apr 12;182(7):245.

Is GA for orthodontic extractions in children necessary? [letter; comment] Healy A. **Br Dent J** 1996 Nov 9; 181(9):319. Comment on: Br Dent J 1996 Sep 7;181(5):165.

Is general anaesthesia really necessary? [letter; comment] Lee P. **Br Dent J** 1996 Nov 9;181(9):319. Comment on: Br Dent J 1996 Sep 7;181(5):165.

A comparison of topical anaesthesia and electronic nerve stimulation for reducing the pain of intra-oral injections [see comments] Meechan JG, et al. **Br Dent J** 1996 Nov 9;181(9):333–5. Comment in: Br Dent J 1997 Jan 25;182(2):50.

Postgraduate education in sedation—a new development. Robb ND, et al. **Br Dent J** 1997 Jan 25;182(2):45–7

General anaesthesia [letter; comment] Taylor MS. **Br Dent J** 1996 Oct 19;181(8):284. Comment on: Br Dent J 1996 Jul 6;181(1):6–7.

Comparison of induction and recovery between sevoflurane and halothane supplementation of anaesthesia in children undergoing outpatient dental extractions. Ariffin SA, et al. **Br J Anaesth** 1997 Feb;78(2):157–9

Bilateral block: is it safe and more efficient during removal of third molars? [letter] Adatia AK, et al. **Br J Oral Maxillofac Surg** 1997 Aug;35(4):299

Bilateral block: is it safe and more efficient during the removal of third molars? [letter; comment] Appiah-Anane S. **Br J Oral Maxillofac Surg** 1997 Feb;35(1):74. Comment on: Br J Oral Maxillofac Surg 1996 Jun;34(3):243–7.

Analgesic efficacy and safety of an intraoral lidocaine patch. Hersh EV, et al. **J Am Dent Assoc** 1996 Nov; 127(11):1626–34; quiz 1665–6

Painless palatal anesthesia. McArdle BF. **J Am Dent Assoc** 1997 May;128(5):647

Desflurane for outpatient general anesthesia in third molar extraction cases. Bandrowsky T, et al. **J Oral Maxillofac Surg** 1997 Feb;55(2):129–32; discussion 132–3

Effects of sedation with midazolam or propofol on cognition and psychomotor functions. Sarasin DS, et al. **J Oral Maxillofac Surg** 1996 Oct;54(10):1187–93

Outpatient anesthetic management of a patient with Wolff-Parkinson-White syndrome. Schmitz JP, et al. **J Oral Maxillofac Surg** 1997 Feb;55(2):175–9

Comparison of sublingually and orally administered triazolam for premedication before oral surgery. Berthold CW, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Aug;84(2):119–24

Anesthetic efficacy of the intraosseous injection in maxillary and mandibular teeth. Coggins R, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jun;81(6):634–41

Multidrug intravenous sedation: determinants of the sedative dose of midazolam. Moore PA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):5–10

Effects of midazolam on pain sensations in the face. Nakanishi O, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):11–5

Anesthetic efficacy of the intraosseous injection of 2% lidocaine (1:100,000 epinephrine) and 3% mepivacaine in mandibular first molars. Replogle K, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):30–7

Intrapulpal injection: factors related to effectiveness. VanGheluwe J, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):38–40

The effectiveness of mandibular infiltration compared to mandibular block anesthesia in treating primary molars in children. Oulis CJ, et al. **Pediatr Dent** 1996 Jul–Aug; 18(4):301–5

A comparison of two oral ketamine–diazepam regimens for sedating anxious pediatric dental patients. Reinemer HC, et al. **Pediatr Dent** 1996 Jul–Aug;18(4):294–300

[The use of hypnosis in stomatology] Kelemen P, et al. **Fogorv Sz** 1997 Apr;90(4):107–10 (Eng. Abstr.) **(Hun)**

[General anesthesia in Prader-Willi syndrome] Cavaliere F, et al. **Minerva Anestesiol** 1996 Oct;62(10):327–32 (Eng. Abstr.) **(Ita)**

[Diprivan (propofol) in the anesthesiological support of outpatient dental interventions] Gritsuk SF, et al. **Stomatologiia (Mosk)** 1997;76(1):63–4 **(Rus)**

[The characteristics of local anesthesia in children] Vasmanova EV, et al. **Stomatologiia (Mosk)** 1997;76(1):44–9 **(Rus)**

MORTALITY

Mortality incidence in outpatient anesthesia for dentistry in Ontario. Nkansah PJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jun;83(6):646–51

PSYCHOLOGY

Four dimensions of fear of dental injections. Milgrom P, et al. **J Am Dent Assoc** 1997 Jun;128(6):756–66

STANDARDS

The efficacy of local anaesthetics administered by general dental practitioners. Matthews R, et al. **Br Dent J** 1997 Mar 8;182(5):175–8

STATISTICS & NUMERICAL DATA

A survey of the American Academy of Pediatric Dentistry membership: nitrous oxide and sedation. Wilson S. **Pediatr Dent** 1996 Jul–Aug;18(4):287–93

ANESTHESIA DEPARTMENT, HOSPITAL

The prevalence of latex sensitivity among anesthesiology staff. Konrad C, et al. **Anesth Analg** 1997 Mar;84(3):629–33

Cognitive integration of data in intensive care and anaesthesia. Cole WG. **Int J Clin Monit Comput** 1996 May; 13(2):77–9

General anaesthesia in accident and emergency departments. Teale KF, et al. **J Accid Emerg Med** 1995 Dec;12(4):259–61

Acute pain services in New Zealand hospitals; a survey. Merry A, et al. **N Z Med J** 1997 Jun 27;110(1046):233–5

[Treatment of chronic pain syndromes in surgery units with an acute pain service] Griessinger N, et al. **Anaesthesist** 1996 Dec;45 Suppl 3:S79–81 **(Ger)**

ECONOMICS

Cost containment in anesthesiology: a survey of department activities [see comments] Valenzuela RC, et al. **J Clin Anesth** 1997 Mar;9(2):93–6. Comment in: J Clin Anesth 1997 Mar;9(2):91–2.

LEGISLATION & JURISPRUDENCE

Physicians. Going to court for clout. Nordhaus-Bike AM. **Hosp Health Netw** 1997 Jun 5;71(11):41–2

MANPOWER

Work force planning for anesthesia care. Orkin FK. **Int Anesthesiol Clin** 1995 Fall;33(4):69–101 (51 ref.)

ORGANIZATION & ADMINISTRATION

Involving anesthesiology in drug control. Lennon DB, et al. **Am J Health Syst Pharm** 1997 Jun 15;54(12):1392–3

The operating rooms: cost center management in a managed care environment. DeRiso B, et al. **Int Anesthesiol Clin** 1995 Fall;33(4):133–50 (11 ref.)

In-house approach to develop a complete information management system for an anaesthesia department. Conze P, et al. **Int J Clin Monit Comput** 1996 May;13(2):93–4

When will managed care come to anesthesia? Klein JD. **J Health Care Finance** 1997 Spring;23(3):62–86 (61 ref.)

A two-year experience of an acute pain service in Singapore. Wong LT, et al. **Singapore Med J** 1997 May;38(5):209–13

STANDARDS

A prospective analysis of critical incidents attributable to anaesthesia. Spittal MJ, et al. **Int J Qual Health Care** 1995 Dec;7(4):363–71

ANESTHESIA, ELECTRIC see **ELECTRONARCOSIS**

ANESTHESIA, EPIDURAL

2-Chloroprocaine antagonism of epidural morphine analgesia. Karambelkar DJ, et al. **Acta Anaesthesiol Scand** 1997 Jun;41(6):774–8

Atropine premedication attenuates heart rate variability during high thoracic epidural anesthesia. Kawamoto M, et al. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1132–7

Anesthetic quality during cesarean section following subarachnoid or epidural administration of bupivacaine with or without fentanyl. Olofsson C, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):332–8

Subcutaneous blood flow in man during sleep with continuous epidural anaesthesia. Sindrup JH, et al. **Acta Anaesthesiol Scand** 1996 May;40(5):636–40

Additives in neuraxial anesthesia: opioids, alpha-2 adrenergic agonists, and neostigmine as a possible future drug for perioperative pain management. Klimscha W, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:176–8

The preemptive effect of pre-incisional bupivacaine infiltration on postoperative analgesia following lower abdominal surgery under epidural anesthesia. Huang SJ, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):97–102

Epidural anesthesia for emergency caesarean section in a patient with single ventricle and aortic stenosis. Peng TC, et al. **Acta Anaesthesiol Sin** 1997 Mar;35(1):39–44

Quantitative sensory examination of epidural anaesthesia and analgesia in man. Brennum J. **Acta Physiol Scand Suppl** 1996;634:1–27

Recent epidural anesthesia: a relative contraindication to thrombolysis. Smith RE, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):445–6

The effects of epidural anesthesia on the neuroendocrine response to major surgical stress: a randomized prospective trial. Norman JG, et al. **Am Surg** 1997 Jan;63(1):75–80

Retrospective review of 100 cases of endoluminal aortic stent-graft surgery from an anaesthetic perspective. Baker AB, et al. **Anaesth Intensive Care** 1997 Aug;25(4):378–84

Pain associated with 2% lignocaine epidural anaesthesia [letter] Clarke JP, et al. **Anaesth Intensive Care** 1997 Aug; 25(4):435–6

Failed spinal anaesthesia in combined spinal-epidural anaesthesia [letter] Eldor J, et al. **Anaesth Intensive Care** 1997 Jun;25(3):311–2

Comparison of 0.5% ropivacaine and 0.5% bupivacaine in lumbar epidural anaesthesia for lower limb orthopaedic surgery. McGlade DP, et al. **Anaesth Intensive Care** 1997 Jun;25(3):262–6

The reproducibility of the iliac crest as a marker of lumbar spine level. Render CA. **Anaesthesia** 1996 Nov; 51(11):1070–1

Effect of epidural block on the lag time of pulse oximeter response. Xue FS, et al. **Anaesthesia** 1996 Dec; 51(12):1102–5

Safe epidural analgesia in thirty parturients with platelet

counts between 69,000 and 98,000 mm(-3). Beilin Y, et al. **Anesth Analg** 1997 Aug;85(2):385-8

Maternal experience during epidural or combined spinal-epidural anesthesia for cesarean section: a prospective, randomized trial. Davies SJ, et al. **Anesth Analg** 1997 Sep;85(3):607-13

Biphasic drug absorption from the epidural space of the dog may limit the utility of a slow release medium molecular weight hyaluronic acid-lidocaine ionic complex formulation. Doherty MM, et al. **Anesth Analg** 1996 Dec; 83(6):1244-50

Epidural anesthesia and pulmonary function in a patient with amyotrophic lateral sclerosis. Hara K, et al. **Anesth Analg** 1996 Oct;83(4):878-9

The Zavanelli maneuver does not preclude regional anesthesia. Hepner DL, et al. **Anesth Analg** 1997 May; 84(5):1145-6

The effects of epidural fentanyl on hemodynamic responses during emergence from isoflurane anesthesia and tracheal extubation: a comparison with intravenous fentanyl. Inagaki Y, et al. **Anesth Analg** 1997 Aug;85(2):328-35

The effect of intravenous lidocaine on somatosensory evoked potentials during scoliosis surgery [letter; comment] Klasen J. **Anesth Analg** 1997 Jul;85(1):228. Comment on: Anesth Analg 1996 Nov;83(5):1122-5.

Hysterical paraplegia as a cause of transient paraplegia after epidural anesthesia. Laraki M, et al. **Anesth Analg** 1996 Oct;83(4):876-7

The efficacy of epinephrine test doses during spinal anesthesia in volunteers: implications for combined spinal-epidural anesthesia. Liu SS, et al. **Anesth Analg** 1997 Apr;84(4):780-3

Thoracic epidural anesthesia and the patient with heart disease: benefits, risks, and controversies. Meissner A, et al. **Anesth Analg** 1997 Sep;85(3):517-28 (137 ref.)

Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia. Pan PH, et al. **Anesth Analg** 1996 Nov;83(5):982-6

Thoracic epidural anesthesia improves functional recovery from myocardial stunning in conscious dogs [see comments] Rolf N, et al. **Anesth Analg** 1996 Nov;83(5):935-40. Comment in: Anesth Analg 1997 Aug;85(2):465-6.

The effects of thoracic epidural anesthesia on functional recovery from myocardial stunning in propofol-anesthetized dogs. Rolf N, et al. **Anesth Analg** 1997 Apr;84(4):723-9

Thoracic epidural anesthesia reduces the severity of myocardial ischemia in conscious dogs [letter; comment] Schlack W, et al. **Anesth Analg** 1997 Aug;85(2):465-6. Comment on: Anesth Analg 1996 Nov;83(5):935-40.

Alteration of renal blood flow during epidural anesthesia in normal subjects. Suleiman MY, et al. **Anesth Analg** 1997 May;84(5):1076-80

The effect of dopamine on hepatic blood flow in patients undergoing epidural anesthesia. Tanaka N, et al. **Anesth Analg** 1997 Aug;85(2):286-90

Epidural anesthesia enhances sympathetic nerve activity in the unanesthetized segments in cats. Taniguchi M, et al. **Anesth Analg** 1997 Feb;84(2):391-7

Quantitative assessment of differential sensory blockade after lumbar epidural lidocaine. Tay B, et al. **Anesth Analg** 1997 May;84(5):1071-5

Dural puncture with a 26-gauge spinal needle affects spread of epidural anesthesia [letter] Walker S, et al. **Anesth Analg** 1997 Jan;84(1):228

Comparison of continuous spinal with combined spinal-epidural anesthesia using plain bupivacaine 0.5% in trauma patients. Wilhelm S, et al. **Anesth Analg** 1997 Jul; 85(1):69-74

Continuous epidural blockade arrests the postoperative decrease in muscle protein fractional synthetic rate in surgical patients. Carli F, et al. **Anesthesiology** 1997 May; 86(5):1033-40

Severe maternal hypotension and fetal bradycardia after a combined spinal epidural anesthetic. D'Angelo R, et al. **Anesthesiology** 1997 Jul;87(1):166-8

Epidural and intrathecal n-butyl-p-aminobenzoate solution in the rat. Comparison with bupivacaine. Grouls RJ, et al. **Anesthesiology** 1997 Jan;86(1):181-7

Combined spinal and epidural anesthesia in a parturient with idiopathic hypertrophic subaortic stenosis. Ho KM, et al. **Anesthesiology** 1997 Jul;87(1):168-9

Sympathetic and mesenteric venous responses to baroreceptor or chemoreceptor stimulation during epidural anesthesia in rabbits. Hogan QH, et al. **Anesthesiology** 1996 Dec;85(6):1413-21

Injection volume of saline with loss of resistance method may affect the spread of epidural anesthesia [letter] Iwama H. **Anesthesiology** 1997 Feb;86(2):507-8

Arterial pressure and neurologic morbidity during carotid surgery under peridural anesthesia. Chaillou P, et al. **Ann Vasc Surg** 1996 May;10(3):228-32

The effect of epidural bupivacaine on the fetal electrocardiogram [letter; comment] Murray H. **Aust N Z J Obstet Gynaecol** 1997 May;37(2):248-50. Comment on: Aust N Z J Obstet Gynaecol 1996 Aug;36(3):272-4.

The lumbar extradural structure changes with increasing age. Igarashi T, et al. **Br J Anaesth** 1997 Feb;78(2):149-52

Processed electroencephalogram during combined extradural and general anaesthesia. Kiyama S, et al. **Br J Anaesth** 1997 Jun;78(6):751-3

Comparison of extradural and general anaesthesia on the fibrinolytic response to total knee arthroplasty. Sharrock NE, et al. **Br J Anaesth** 1997 Jul;79(1):29-34

Removal of extradural catheters [letter; comment] Trikha A. **Br J Anaesth** 1996 Aug;77(2):295. Comment on: Br J Anaesth 1994 Dec;73(6):833-5. Comment on: Br J Anaesth 1995 Jun;74(6):722.

Combined epidural/general anaesthesia [letter; comment] Carli F, et al. **Can J Anaesth** 1997 Apr;44(4):452-3. Comment on: Can J Anaesth 1996 Aug;43(8):769-77.

Epidural anaesthesia for ureteral reimplantation in an infant with congenital tracheal stenosis. Concha M, et al. **Can J Anaesth** 1997 Jun;44(6):666-8

Perioperative ischaemia in aortic surgery: combined epidural/general anaesthesia and epidural analgesia vs general anaesthesia and i.v. analgesia [see comments] Garnett RL, et al. **Can J Anaesth** 1996 Aug;43(8):769-77 . Comment in: Can J Anaesth 1996 Aug;43(8):759-63. Comment in: Can J Anaesth 1997 Apr;44(4):452-3.

Surgical anaesthesia for Caesarean section with a subdural catheter. Gershon RY. **Can J Anaesth** 1996 Oct; 43(10):1068-71

Spinal somatosensory evoked potentials after epidural isoproterenol in awake sheep. Marcus MA, et al. **Can J Anaesth** 1997 Jan;44(1):85-9

Anaesthetic management in patients with asthma [letter] Mercier FJ, et al. **Can J Anaesth** 1996 Feb;43(2):195-6

Patient-controlled epidural analgesia after caesarean section using meperidine. Ngan Kee WD, et al. **Can J Anaesth** 1997 Jul;44(7):702-6

Combined spinal and epidural anaesthesia for major abdominal surgery in infants. Williams RK, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):511-4

Pre-emptive analgesia with ketamine, morphine and epidural lidocaine prior to total knee replacement. Wong CS, et al. **Can J Anaesth** 1997 Jan;44(1):31-7

Randomized trial of epidural versus general anesthesia: outcomes after primary total knee replacement. Williams-Russo P, et al. **Clin Orthop** 1996 Oct; (331):199-208

Use of epidural anesthesia and spontaneous ventilation during transabdominal colon and rectal procedures in selected high-risk patient groups. Kolker AR, et al. **Dis Colon Rectum** 1997 Mar;40(3):339-43

Effect of epidural anesthesia on colorectal anastomosis: a tonometric assessment. Sala C, et al. **Dis Colon Rectum** 1997 Aug;40(8):958-61

Thoracic epidural anaesthesia and analgesia with bupivacaine for transsternal thymectomy for myasthenia gravis. Akpolat N, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):220-3

Haemodynamic monitoring during alkalinized lignocaine epidural block: a comparison with subarachnoid anaesthesia. Casati A, et al. **Eur J Anaesthesiol** 1997 May; 14(3):300-6

High spinal block following an inadequate continuous spinal anaesthetic. Serpell MG. **Eur J Anaesthesiol** 1996 Sep; 13(5):530-3

The feasibility of epidural anesthesia without endotracheal intubation for abdominal surgery in patients with collagen diseases. Nakashima H, et al. **Hepatogastroenterology** 1997 Jan-Feb;44(13):121-6

Cholecystectomy under regional anesthesia in a patient with total Kartagener's syndrome. Kapoor R, et al. **Indian J Gastroenterol** 1997 Apr;16(2):64-5

Epidural anesthesia and cesarean section [letter; comment] Morrow JG 3d. **J Am Board Fam Pract** 1996 May-Jun; 9(3):231. Comment on: J Am Board Fam Pract 1995 Nov-Dec;8(6):494-6.

Hormonal and metabolic responses to electrically induced cycling during epidural anesthesia in humans. Kjaer M, et al. **J Appl Physiol** 1996 Jun;80(6):2156-62

Effects of anesthetic technique on myocardial wall motion abnormalities during abdominal aortic surgery [see comments] Dodds TM, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):129-36. Comment in: J Cardiothorac Vasc Anesth 1997 Apr;11(2):127-8.

Effects of thoracic epidural anesthesia on changes in ischemic myocardial metabolism induced by intracoronary injection of endothelin in dogs. Fujita S, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):903-8

The epidural space: is it the place to be during vascular surgery? [editorial; comment] Kahn RA, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):127-8. Comment on: J Cardiothorac Vasc Anesth 1997 Apr;11(2):129-36. Comment on: J Cardiothorac Vasc Anesth 1997 Apr;11(2):137-40.

Con: thoracic epidural anesthesia is not indicated in the treatment of unstable angina. Kleinman B. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):109-11

Pro: the anesthesiologist should provide epidural anesthesia in the coronary care unit for patients with severe angina. Staats PS, et al. **J Cardiothorac Vasc Anesth** 1997 Feb; 11(1):105-8

Neuraxial anesthesia is contraindicated in patients undergoing heparinization for surgery. Con: neuraxial block is useful in patients undergoing heparinization for surgery. Turnbull KW. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):961-2

Active warming, not passive heat retention, maintains normothermia during combined epidural-general anesthesia for hip and knee arthroplasty. Berti M, et al. **J Clin Anesth** 1997 Sep;9(6):482-6

Control of blood pressure and heart rate in patients randomized to epidural or general anesthesia for lower extremity vascular surgery. Perioperative Ischemia Randomized Anesthesia Trial (PIRAT) Study Group. Christopherson R, et al. **J Clin Anesth** 1996 Nov; 8(7):578-84

Anesthesia for the parturient with sickle cell disease. Danzer BI, et al. **J Clin Anesth** 1996 Nov;8(7):598-602 (17 ref.)

Comparison of general anesthesia with and without lumbar epidural for total hip arthroplasty: effects of epidural block on hip arthroplasty. Dauphin A, et al. **J Clin Anesth** 1997 May;9(3):200-3

Caudal epidural butorphanol plus bupivacaine versus bupivacaine in pediatric outpatient genitourinary procedures. Lawhorn CD, et al. **J Clin Anesth** 1997 Mar; 9(2):103-8

Echocardiographic evaluation of global left ventricular function during high thoracic epidural anesthesia. Niimi Y, et al. **J Clin Anesth** 1997 Mar;9(2):118-24

Hemodynamic effects of intrathecal sufentanil compared with epidural bupivacaine in laboring parturients. Pham LH, et al. **J Clin Anesth** 1996 Sep;8(6):497-501; discussion 502-3

The efficacy of epidural anesthesia for endoscopic preperitoneal herniorrhaphy: a prospective study. Azurin DJ, et al. **J Laparoendosc Surg** 1996 Dec;6(6):369-73

Effects of narcotic and non-narcotic continuous epidural anesthesia on intrapartum fetal heart rate tracings as measured by computer analysis. Hoffman CT 3rd, et al. **J Matern Fetal Med** 1997 Jul-Aug;6(4):200-5

Comparison of general and epidural anesthesia in patients undergoing primary unilateral THR. Brinker MR, et al. **Orthopedics** 1997 Feb;20(2):109-15

Left ventricular functions are not impaired after lumbar epidural anaesthesia in young children. Tsuji MH, et al. **Paediatr Anaesth** 1996;6(5):405-9

Effects of extradural anesthesia on microcirculatory blood flow in free latissimus dorsi musculocutaneous flaps in pigs. Banic A, et al. **Plast Reconstr Surg** 1997 Sep;100(4):945-55; discussion 956

Modulation of protein metabolism in the surgical patient. Effect of 48-hour continuous epidural block with local anesthetics on leucine kinetics. Carli F, et al. **Reg Anesth** 1996 Sep-Oct;21(5):430-5

Immunomodulation and epidural anesthesia and analgesia. de Leon-Casasola OA. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):24-5 (16 ref.)

Clinical outcome after epidural anesthesia and analgesia in high-risk surgical patients. de Leon-Casasola OA. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):144-8 (53 ref.)

Successful epidural anesthesia in a patient with an arachnoid cyst, preeclampsia, and triplets. Gaiser RR, et al. **Reg Anesth** 1996 Nov-Dec;21(6):592-4

Preemptive analgesia in children. Does it exist? Ho JW, et al. **Reg Anesth** 1997 Mar-Apr;22(2):125-30

Effect of thoracic epidural anesthesia on spontaneous postinfarction ventricular dysrhythmia in awake dogs. Hogan QH, et al. **Reg Anesth** 1997 Jul-Aug;22(4):318-24

Oral anticoagulant prophylaxis and epidural catheter removal [see comments] Wu CL, et al. **Reg Anesth** 1996 Nov-Dec; 21(6):517-24. Comment in: Reg Anesth 1996 Nov-Dec;21(6):503-7.

Reduction of blood loss during spinal surgery by epidural blockade under normotensive general anesthesia. Kakiuchi M. **Spine** 1997 Apr 15;22(8):889-94

Thoracic versus lumbar epidural anesthesia's effect on pain control and ileus resolution after restorative proctocolectomy. Scott AM, et al. **Surgery** 1996 Oct; 120(4):688-95; discussion 695-7

Postpartum back pain, so what! Avery JK. **Tenn Med** 1996 Sep;89(9):322-3

Laparoscopic ligation of bilateral spermatic varices under epidural anesthesia. Chiu AW, et al. **Urol Int** 1996; 57(2):80-4

[Spinal or epidural anesthesia?] Tuominen M. **Duodecim** 1995; 111(13):1232-4 (7 ref.) **(Fin)**

[Comparison of the efficacy of 2 antiseptic solutions in the prevention of infection from peridural catheters] Adam MN, et al. **Cah Anesthesiol** 1996;44(5):465-7 (Eng. Abstr.) **(Fre)**

[Epidural anesthesia in children under 3 months of age. Apropos of 49 cases] Courrèges P, et al. **Cah Anesthesiol** 1996;44(5):403-8 (Eng. Abstr.) **(Fre)**

[Epidural anaesthesia around the clock? (letter)] Ginsbourger F. **Cah Anesthesiol** 1996;44(3):271 **(Fre)**

[Hepatobiliopancreatic surgery in patients over 70 years old: which anesthesia?] Barzoi G, et al. **Chir Ital** 1995;47(4):44-8 (Eng. Abstr.) **(Ita)**

[A study of surgical treatment in lung cancer over 75 years of age-effect of epidural anesthesia for protection of postoperative coughing disturbance] Tabata T, et al. **Kyobu Geka** 1996 May;49(5):347-51; discussion 351-2 (Eng. Abstr.) **(Jpn)**

[Addition of fentanyl to epidural lidocaine raises the toe temperature] Akiyoshi H, et al. **Masui** 1996 Oct; 45(10):1278-80 (Eng. Abstr.) **(Jpn)**

[The effect of epidural anesthesia with combined use of vasodilator on hemodynamics and stress hormone levels during hepatectomy] Arai M, et al. **Masui** 1997 Feb; 46(2):158-65 (Eng. Abstr.) **(Jpn)**

[Thoracic epidural anesthesia for cholecystectomy in a patient after Fontan procedure] Arai M, et al. **Masui** 1997 Feb;46(2):271-5 (Eng. Abstr.) **(Jpn)**

[The effect of low-dose prostaglandin E1 on intra- and post-operative renal function] Hayashida M, et al. **Masui** 1997 Apr;46(4):464-70 (Eng. Abstr.) **(Jpn)**

[The effect of low-dose prostaglandin E1 on intra- and post-operative liver function] Hayashida M, et al. **Masui** 1997 May;46(5):618-27 (Eng. Abstr.) **(Jpn)**

[The effect of low-dose prostaglandin E1 on serum and urinary fluoride concentrations in patients anesthetized with sevoflurane] Hayashida M, et al. **Masui** 1997 Jun; 46(6):736-42 (Eng. Abstr.) **(Jpn)**

[Merit of surgical stress suppression--special reference to epidural and intravenous anesthesia in view of endocrine systems] Ishihara H. **Masui** 1996 Dec;45 Suppl:S51-5 (13 ref.) **(Jpn)**

[The effect of hypertonic saline infusion on lumbar epidural anesthesia] Ishikawa G. **Masui** 1996 Feb;45(2):205-14 (Eng. Abstr.) **(Jpn)**

[Cesarean section in a patient with uncontrolled hyperthyroidism, preeclampsia, and congestive heart failure] Kagawa T, et al. **Masui** 1996 Feb;45(2):230-4 (Eng. Abstr.) **(Jpn)**

[Epidural anesthesia for patients with bronchial asthma] Kasaba T, et al. **Masui** 1996 Oct;45(10):1260-4 (Eng. Abstr.) **(Jpn)**

[The effects of cervical epidural anesthesia on epidural somatosensory evoked potentials and phrenic nerve activities] Kasaba T, et al. **Masui** 1997 Mar;46(3):321-5 (Eng. Abstr.) **(Jpn)**

[The level of analgesia with epidural injection of 2% mepivacaine using combined spinal and epidural analgesia] Kasaba T, et al. **Masui** 1996 Sep;45(9):1078-82 (Eng. Abstr.) **(Jpn)**

[Fatal pulmonary embolism during knee surgery under epidural anesthesia] Kato S, et al. **Masui** 1997 Mar; 46(3):393-6 (Eng. Abstr.) **(Jpn)**

[Comparison of analgesic effect of lidocaine tape versus eutectic mixture of lidocaine and tetracaine during infiltration of local anesthetics before epidural block] Kawano T, et al. **Masui** 1996 Sep;45(9):1074-7 (Eng. Abstr.) **(Jpn)**

[Anesthetic management for a patient with pure autonomic failure] Kida K, et al. **Masui** 1997 Jun;46(6):813-7 (Eng. Abstr.) **(Jpn)**

[Does the difference in anesthetic methods influence postoperative nitrogen balance?] Kim C. **Masui** 1996 Feb; 45(2):215-22 (Eng. Abstr.) **(Jpn)**

[Cesarean section in a morbidly obese parturient under epidural anesthesia] Konishi R, et al. **Masui** 1996 Dec; 45(12):1503-6 (Eng. Abstr.) **(Jpn)**

[Combined spinal-epidural anesthesia for intra-abdominal gynecological surgeries] Nagashima N, et al. **Masui** 1996 Sep;45(9):1153-9 (Eng. Abstr.) **(Jpn)**

[Comparison of epidural fentanyl versus bupivacaine in maintaining intraoperative liver function] Nishiyama M. **Masui** 1997 Jun;46(6):743-9 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a pediatric patient with non-Fukuyama type congenital muscular dystrophy] O'Higashi T, et al. **Masui** 1997 Jan;46(1):83-6 (Eng. Abstr.) **(Jpn)**

[Perioperative care of patients with heart dysfunction--influence of epidural anesthesia] Shibata K, et al. **Masui** 1996 Dec;45 Suppl:S122-7 (18 ref.) **(Jpn)**

[Cerebral blood volume, cerebral hemoglobin and cytochrome AA3 during hypotension induced by prostaglandin E1 or epidural anesthesia under general anesthesia] Shinohara M, et al. **Masui** 1996 Aug;45(8):961-6 (Eng. Abstr.) **(Jpn)**

[Epidural anesthesia for herniorrhaphy in a patient with severe dilated cardiomyopathy (DCM) under pimobendan control] Shiraishi M, et al. **Masui** 1997 Jan;46(1):114-8 (Eng. Abstr.) **(Jpn)**

[Comparison of epidural versus intravenous administration of fentanyl during epidural block] Shirasaka T, et al. **Masui** 1997 Mar;46(3):358-62 (Eng. Abstr.) **(Jpn)**

[Bronchospasm due to anaphylactic reaction to Hydroxyethyl starch (HESPANDER)] Takada M, et al. **Masui** 1997 Mar; 46(3):397-400 (Eng. Abstr.) **(Jpn)**

[Surgical stress suppressive effect of epidural anesthesia and the limitation] Takasaki M, et al. **Masui** 1996 Dec;45 Suppl:S73-8 (20 ref.) **(Jpn)**

[Obstetric anesthesia for cesarean section of patients with bronchial asthma] Ueda K. **Masui** 1996 Dec;45 Suppl:S208-11 (1 ref.) **(Jpn)**

[The spread of contrast medium in the epidural space and the analgesic area in epidural anesthesia in elderly patients] Yokoyama M, et al. **Masui** 1996 Sep;45(9):1067-73 (Eng. Abstr.) **(Jpn)**

[Hemodynamic changes during laparoscopic cholecystectomy under different anesthesia methods] Yokoyama M, et al. **Masui** 1996 Feb;45(2):160-6 (Eng. Abstr.) **(Jpn)**

[Combined spinal and epidural anesthesia for laparotomy in a geriatric patient with severe obstructive lung disease] Yokoyama T, et al. **Masui** 1997 Mar;46(3):409-12 (Eng. Abstr.) **(Jpn)**

[Somatosensory evoked potentials (SEPs) as an intraoperative monitor in lower abdominal surgery during lumbar epidural anesthesia] Dong WY, et al. **Nippon Ika Daigaku Zasshi** 1997 Jun;64(3):264-7 **(Jpn)**

[Epidural electric neurostimulation in the protocols of anesthesia in plastic and reconstructive surgery] Brusin VI, et al. **Anesteziol Reanimatol** 1997 Jan-Feb;(1):61-4 **(Rus)**

[State of lipid peroxidation in patients with ischemic heart disease during aortocoronary bypass surgery using epidural anesthesia] Kornienko AN, et al. **Anesteziol Reanimatol** 1997 Jan-Feb;(1):42-5 (Eng. Abstr.) **(Rus)**

[Epidural anesthesia in cardiac anesthesiology (a review of the literature)] Nemytin IuV, et al. **Voen Med Zh** 1997 Mar;318(3):34-40 (33 ref.) **(Rus)**

[Combined intradural-epidural anesthesia in a case of Steinert's disease (letter)] Alagón-Abad MC, et al. **Rev Esp Anestesiol Reanim** 1997 May;44(5):209 **(Spa)**

[Anesthetic management in unilateral lung transplantation] Lluch M, et al. **Rev Esp Anestesiol Reanim** 1996 Jun-Jul; 43(6):212-5 (Eng. Abstr.) **(Spa)**

[Peridural anesthesia for subcostal cholecystectomy in patients with dilated cardiomyopathy. Apropos of 2 cases] Ornaque I, et al. **Rev Esp Anestesiol Reanim** 1996 Jun-Jul; 43(6):216-8 (Eng. Abstr.) **(Spa)**

[Thoracic epidural anesthesia combined with general anesthesia with propofol for thymectomy in myasthenia gravis (letter)] Quintana-Villamandos B, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):130 **(Spa)**

[Anesthesia for cesarean section in patients with mitral valve prolapse (see comments)] Ruiz-Castro M, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):291-3 (Eng. Abstr.). Comment in: Rev Esp Anestesiol Reanim 1997 Mar;44(3):128-9. Comment in: Rev Esp Anestesiol Reanim 1997 Apr;44(4):165-6. **(Spa)**

[Anesthesia for cesarean section in a case of Emery-Dreifuss muscular dystrophy] Sariego M, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):288-90 (Eng. Abstr.) **(Spa)**

[The effects of carbonation on 2% mepivacaine in epidural anesthesia] Tisner ML, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):140-3 (Eng. Abstr.) **(Spa)**

[Epidural anesthesia combined with general anesthesia in ischemic cardiomyopathy (letter)] Tormos P, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):75-6 **(Spa)**

ADVERSE EFFECTS

Severe complications associated with epidural and spinal anaesthesias in Finland 1987-1993. A study based on patient insurance claims [see comment] Aromaa U, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):445-52. Comment on: Acta Anaesthesiol Scand 1997 Apr;41(4):439-44.

Neurological complications of subarachnoid and epidural anaesthesia [editorial; comment] Bromage PR. **Acta Anaesthesiol Scand** 1997 Apr;41(4):439-44. Comment on: Acta Anaesthesiol Scand 1997 Apr;41(4):445-52. Comment on: Acta Anaesthesiol Scand 1997 Apr;41(4):453-60.

Peripheral neurologic deficits in relation to subarachnoid or epidural administration of local anesthetics for surgery. A survey of 21 cases [see comments] Pleym H, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):453-60. Comment in: Acta Anaesthesiol Scand 1997 Apr;41(4):439-44.

Prevention of maternal hypotension by epidural administration of ephedrine sulfate during lumbar epidural anesthesia for cesarean section. Fong J, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):985-90

Does station of the fetal head at epidural placement affect the position of the fetal vertex at delivery? Robinson CA, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):991-4

Complete heart block during laparotomy under combined thoracic epidural and general anaesthesia. Ng KP. **Anaesth Intensive Care** 1996 Apr;24(2):257-60

Through the needle approach for difficult epidurals [letter; comment] Ahmed AB. **Anaesthesia** 1996 Sep;51(9):893. Comment on: Anaesthesia 1996 May;51(5):513.

Immediate postdural puncture headache [letter] Collard E, et al. **Anaesthesia** 1997 Mar;52(3):288, 290

Epidural abscess following epidural steroid and local anaesthetic injection. Knight JW, et al. **Anaesthesia** 1997 Jun;52(6):576-8

Epidural anaesthesia, ephedrine and phenylephrine in a patient taking moclobemide, a new monoamine oxidase inhibitor. Martyr JW, et al. **Anaesthesia** 1996 Dec; 51(12):1150-2

Sciatic nerve palsy following childbirth [see comments] Silva M, et al. **Anaesthesia** 1996 Dec;51(12):1144-8 (53 ref.). Comment in: Anaesthesia 1997 Jun;52(6):605-6.

Time to abandon loss of resistance to air [letter] Yentis SM. **Anaesthesia** 1997 Feb;52(2):184

Factors associated with hypotension and bradycardia after epidural blockade. Curatolo M, et al. **Anesth Analg** 1996 Nov;83(5):1033-40

Spinal epidural hematoma detected by lumbar epidural puncture. Harvey SC, et al. **Anesth Analg** 1997 May; 84(5):1136-9

Intradural herniation of a thoracic disc causing paraplegia coincident with epidural anesthesia. Matsuura JA, et al. **Anesth Analg** 1997 Apr;84(4):922-3

Magnetic resonance imaging of cerebrospinal fluid leak and tamponade effect of blood patch in postdural puncture headache. Vakharia SB, et al. **Anesth Analg** 1997 Mar; 84(3):585-90

Epidural dexamethasone reduces the incidence of backache after lumbar epidural anesthesia. Wang YL, et al. **Anesth Analg** 1997 Feb;84(2):376-8

Cardiac arrest during segmental thoracic epidural anesthesia. Chan KK, et al. **Anesthesiology** 1997 Feb;86(2):503-5

Clinical and bacteriologic survey of epidural analgesia in patients in the intensive care unit. Darchy B, et al. **Anesthesiology** 1996 Nov;85(5):988-98

Delayed subarachnoid migration of an epidural Arrow FlexTip Plus catheter [letter] Jaeger JM, et al. **Anesthesiology** 1997 Sep;87(3):718-9

Epidural catheter reconnection. Safe and unsafe practice. Langevin PB, et al. **Anesthesiology** 1996 Oct;85(4):883-8

Asystole and severe bradycardia during epidural anesthesia in orthopedic patients. Liguori GA, et al. **Anesthesiology** 1997 Jan;86(1):250-7

Human skin flora as a potential source of epidural abscess. Sato S, et al. **Anesthesiology** 1996 Dec;85(6):1276-82

Human chest wall function during epidural anesthesia. Warner DO, et al. **Anesthesiology** 1996 Oct;85(4):761-73

Monoplegia following obstetric epidural anaesthesia. Loo CC, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):232-4 (10 ref.)

Finding of relation between epidural anaesthesia and long-term backache remains valid [letter] MacArthur C, et al. **BMJ** 1997 Sep 13;315(7109):679

Time course of increased haemodilution in hypotension induced by extradural anaesthesia [see comments] Drobin D, et al. **Br J Anaesth** 1996 Aug;77(2):223-6. Comment in: Br J Anaesth 1997 Jan;78(1):111.

Conservative management of extradural abscess complicating spinal-extradural anaesthesia for caesarean section. Dysart RH, et al. **Br J Anaesth** 1997 May;78(5):591-3

Inflammatory changes after extradural anaesthesia may affect the spread of local anaesthetic within the extradural space. Igarashi T, et al. **Br J Anaesth** 1996 Sep;77(3):347-51

Lumbovertebral syndrome after repeat extradural blood patch. Palmer JH, et al. **Br J Anaesth** 1997 Mar;78(3):334-6

Haemoglobin changes during anaesthesia [letter; comment] Wildsmith JA. **Br J Anaesth** 1997 Jan;78(1):111. Comment on: Br J Anaesth 1996 Aug;77(2):223-6.

Aseptic meningitis using the needle-through-needle technique [letter; comment] Eldor J. **Can J Anaesth** 1996 Nov;43(11):1183-4. Comment on: Can J Anaesth 1996 Apr;43(4):399-402.

Detection of intravascular injection of regional anaesthetics in children [see comments] Fisher QA, et al. **Can J Anaesth** 1997 Jun;44(6):592-8. Comment in: Can J Anaesth 1997 Jun;44(6):582-6.

Local anaesthetics belong in the caudal/epidural space, not in the veins! [editorial; comment] Lerman J. **Can J Anaesth** 1997 Jun;44(6):582-6. Comment on: Can J Anaesth 1997 Jun;44(6):592-8. **(Eng, Fre)**

Epidural abscess after combined spinal-epidural block [see comments] Schröter J, et al. **Can J Anaesth** 1997 Mar; 44(3):300-4. Comment in: Can J Anaesth 1997 Mar;44(3):235-8.

Infection after central neuraxial block [editorial; comment] Smedstad KG. **Can J Anaesth** 1997 Mar;44(3):235-8. Comment on: Can J Anaesth 1997 Mar;44(3):300-4. **(Eng, Fre)**

Epidural anaesthesia and spinal haematoma. Wulf H. **Can J Anaesth** 1996 Dec;43(12):1260-71 (103 ref.)

Epidural hematoma complicating cholestasis of pregnancy. Yarnell RW, et al. **Curr Opin Obstet Gynecol** 1996 Jun; 8(3):239-42

Iatrogenic spinal infection following epidural anaesthesia: case report. Dunn LT, et al. **Eur Spine J** 1996;5(6):418-20

Spinal epidural abscess associated with epidural anesthesia: gadolinium-enhanced magnetic resonance imaging and its usefulness in diagnosis and treatment. Higuchi T, et al. **Intern Med** 1996 Nov;35(11):902-4

Major neurological sequelae of lumbar epidural anesthesia. Report of three cases [see comments] Barontini F, et al. **Ital J Neurol Sci** 1996 Oct;17(5):333-9. Comment in: Ital J Neurol Sci 1997 Feb;18(1);63.

Neurologic complications of epidural anesthesia [letter; comment] Sghirlanzoni A, et al. **Ital J Neurol Sci** 1997 Feb;18(1):63. Comment on: Ital J Neurol Sci 1996 Oct;17(5):333-9.

Epidural hematoma in an ambulatory surgical patient. Porterfield WR, et al. **J Clin Anesth** 1997 Feb;9(1):74-7

Episiotomy [letter; comment] McMillan MH. **J Obstet Gynecol Neonatal Nurs** 1997 Jul-Aug;26(4):373. Comment on: J Obstet Gynecol Neonatal Nurs 1997 Mar-Apr;26(2):155-61.

Acute myofascial pain after regional anesthesia [letter] Prasanna A. **J Pain Symptom Manage** 1997 Jul;14(1):4-5

Epidural anaesthesia and urinary dysfunction [letter; comment] Collier C. **J R Soc Med** 1996 Dec;89(12):727. Comment on: J R Soc Med 1995 Dec;88(12):699p-701p.

Incidence of postdural puncture headache following spinal anaesthesia for lower segment caesarean section with the 25 gauge polymedic spinal needle. Ahsan S, et al. **JPMA J Pak Med Assoc** 1996 Dec;46(12):278-81

Use of head-up tilt testing to determine a possible cause of unexpected cardiac asystole during epidural anesthesia. Takase B, et al. **Jpn Circ J** 1997 Jun;61(6):525-30

Incidence of back pain after lumbar epidural anaesthesia for non-obstetric surgery--a preliminary report. Chan ST. **Med J Malaysia** 1995 Sep;50(3):241-5

Epidural anesthesia [letter; comment] Jerez A, et al. **Neurology** 1997 Jan;48(1):294; discussion 294-5. Comment on: Neurology 1995 Oct;45(10):1795-801.

Epidural anesthesia [letter; comment] Sghirlanzoni A, et al. **Neurology** 1997 Jan;48(1):293-4; discussion 294-5. Comment on: Neurology 1995 Oct;45(10):1795-801.

Epidural anesthesia [letter; comment] Steiner I, et al.

Neurology 1997 Jan;48(1):293; discussion 294–5. Comment on: Neurology 1995 Oct;45(10):1795–801.

Sedation for therapeutic and diagnostic procedures in children [letter] Hargus EP. **Pediatrics** 1997 Oct; 100(4):732–3

The extent of the subdural space [letter] Collier CB. **Reg Anesth** 1996 Jan–Feb;21(1):75

Back pain following epidural anesthesia with 2–chloroprocaine (EDTA–free) or lidocaine [see comments] Drolet P, et al. **Reg Anesth** 1997 Jul–Aug; 22(4):303–7. Comment in: Reg Anesth 1997 Jul–Aug;22(4):299–302.

Status epilepticus amauroticus secondary to meningitis as a cause of postpartum cortical blindness. Goldstein MJ, et al. **Reg Anesth** 1996 Nov–Dec;21(6):595–8

Safety of spinal and epidural anesthesia in parturients with chorioamnionitis. Goodman EJ, et al. **Reg Anesth** 1996 Sep–Oct;21(5):436–41

Removal of knotted epidural catheters [see comments] Gozal D, et al. **Reg Anesth** 1996 Jan–Feb;21(1):71–3. Comment in: Reg Anesth 1996 Nov–Dec;21(6):606.

Epidural hematoma after epidural anesthesia in a patient with peripheral vascular disease. Case report. Martínez–Palli G, et al. **Reg Anesth** 1996 Jul–Aug;21(4):342–6

Identification of the epidural space: is loss of resistance to air a safe technique? A review of the complications related to the use of air [see comments] Saberski LR, et al. **Reg Anesth** 1997 Jan–Feb;22(1):3–15 (58 ref.). Comment in: Reg Anesth 1997 Jan–Feb;22(1):1–2.

Back pain following epidural anesthesia with 2–chloroprocaine [editorial; comment] Stevens RA. **Reg Anesth** 1997 Jul–Aug;22(4):299–302. Comment on: Reg Anesth 1997 Jul–Aug;22(4):303–7.

Bilateral radicular pain after epidural lidocaine [letter] Wong CA, et al. **Reg Anesth** 1996 Nov–Dec;21(6):600–1

[Infections in connection with epidural catheterization (letter)] Clemensen SE, et al. **Ugeskr Laeger** 1996 Nov 18; 158(47):6785–6 **(Dan)**

[Bacterial meningitis after combined spinal and epidural anesthesia in obstetrics (letter)] Aldebert S, et al. **Ann Fr Anesth Reanim** 1996;15(5):687–8 **(Fre)**

[Limits of sumatriptan in the treatment of headache after dura mater puncture (letter; comment)] Freiherr Von Hornstein W, et al. **Ann Fr Anesth Reanim** 1996; 15(2):229–31. Comment on: Ann Fr Anesth Reanim 1995;14(2):237. **(Fre)**

[Apropos of blood patch after thoracic epidural anesthesia (letter; comment)] Kuhlman G, et al. **Ann Fr Anesth Reanim** 1996;15(2):229. Comment on: Ann Fr Anesth Reanim 1995;14(5):435–7. **(Fre)**

[Neurological accidents after epidural anesthesia in obstetrics] Pujol S, et al. **Cah Anesthesiol** 1996;44(4):341–5 (Eng. Abstr.) **(Fre)**

[Infectious complications after peridural obstetric anesthesia] Marsaudon E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):159–62 (20 ref.) (Eng. Abstr.) **(Fre)**

[Spinal para–medullary conduction anesthesia in therapy with anticoagulant drugs] Hesse T, et al. **Anaesthesiol Reanim** 1996;21(5):116–21 (74 ref.) (Eng. Abstr.) **(Ger)**

[Neurologic complications following total endoprothesis implantation of the hip under peridural catheter anesthesia] Christ F, et al. **Anaesthesist** 1996 Dec;45(12):1192–5 (Eng. Abstr.) **(Ger)**

[Post dural puncture headache (PDPH) which occurred after the removal of an epidural catheter] Kaetsu H, et al. **Masui** 1996 Oct;45(10):1285–8 (Eng. Abstr.) **(Jpn)**

[Dorsal subdural spinal abscess after epidural anesthesia] Barón M, et al. **Neurologia** 1997 Jun–Jul;12(6):262–4 (Eng. Abstr.) **(Spa)**

[Indication for spinal anesthesia for cesarean section in HELLP syndrome coagulopathy] Blasi A, et al. **Rev Esp Anestesiol Reanim** 1997 Feb;44(2):79–82 (Eng. Abstr.) **(Spa)**

[Chronic subdural hematoma secondary to an accidental dural puncture during lumbar epidural anesthesia] García–Sánchez MJ, et al. **Rev Esp Anestesiol Reanim** 1996 Nov;43(9):327–9 (Eng. Abstr.) **(Spa)**

[Use of low molecular weight heparins (letter; comment)] Llau JV, et al. **Rev Esp Anestesiol Reanim** 1997 Feb; 44(2):88–9. Comment on: Rev Esp Anestesiol Reanim 1996 Aug–Sep;43(7):258–60. **(Spa)**

CONTRAINDICATIONS

Neuraxial anesthesia is contraindicated in patients undergoing heparinization for surgery. Pro: neuraxial anesthesia should not be used in patients undergoing heparinization for surgery. Ralley FE. **J Cardiothorac Vasc Anesth** 1996 Dec; 10(7):957–60

ECONOMICS

Comparison of accuracy and cost of disposable, nonmechanical pumps used for epidural infusions. Valente M, et al. **Reg Anesth** 1997 May–Jun;22(3):260–6

HISTORY

Torrieri and combined spinal–epidural technique [letter] Aldrete JA. **Reg Anesth** 1996 Nov–Dec;21(6):599–600

The evolution of combined spinal–epidural anesthesia needles [letter] Eldor J. **Reg Anesth** 1997 May–Jun;22(3):294–6

[In memoriam Fidel Pagés Miravé (1886–1923) on the 75th anniversary of the publication of "Anesthesia metamérica"] Herrera A, et al. **Rev Esp Anestesiol Reanim** 1996 Feb; 43(2):59–66 (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Eldor needle's advantage over the needle–through–needle technique [letter] Gozal D. **Acta Anaesthesiol Scand** 1997 May;41(5):656

Intraoperative epidural catheter malfunction in two obese patients. Leith P, et al. **Acta Anaesthesiol Scand** 1997 May; 41(5):651–3

Fractured 27 gauge Whitacre spinal needle [letter] Crowhurst JA. **Anaesth Intensive Care** 1997 Jun;25(3):317–8

A new combined spinal–epidural apparatus: measurement of the distance to the epidural and subarachnoid spaces. Hoffmann VL, et al. **Anaesthesia** 1997 Apr;52(4):350–5

Intravascular migration of epidural catheter during cesarean section [letter] Lee BB, et al. **Anesth Analg** 1996 Dec; 83(6):1350

Epidural catheter reconnection. Safe and unsafe practice. Langevin PB, et al. **Anesthesiology** 1996 Oct;85(4):883–8

Continuous thoracic epidural anesthesia for breast augmentation. Lai CS, et al. **Ann Plast Surg** 1996 Feb; 36(2):113–6

Epidural catheter connector [letter; comment] Alam S. **Can J Anaesth** 1996 Jun;43(6):642. Comment on: Can J Anaesth 1991 May;38(4 Pt 1):544.

Powder contamination of extradural catheters and implications for infection risk. Green M. **Eur J Surg Suppl** 1997;(579):39–40

Infections following epidural catheters [letter; comment] Holt HM, et al. **J Hosp Infect** 1997 Mar;35(3):245. Comment on: J Hosp Infect 1995 Aug;30(4):253–60.

An alternative adapter–connector for epidural catheters [letter] Alam S. **Reg Anesth** 1996 Sep–Oct;21(5):492–3

Experience with arrow flextip epidural catheters [letter; comment] Ananthanarayan C. **Reg Anesth** 1996 Nov–Dec; 21(6):607. Comment on: Reg Anesth 1996 Jan–Feb;21(1):75–7.

Stretching of epidural nylon catheters on removal [letter] Caldwell M, et al. **Reg Anesth** 1996 Jul–Aug;21(4):379–80

Dural puncture with arrow Flex Tip plus catheter [letter] [see comments] Cherala SR. **Reg Anesth** 1996 Jan–Feb; 21(1):75–7. Comment in: Reg Anesth 1996 Nov–Dec;21(6):607.

The seven–holed epidural catheter—too much of a good thing? [letter; comment] Collier C, et al. **Reg Anesth** 1997 Mar–Apr;22(2):199–200. Comment on: Reg Anesth 1996 May–Jun;21(3):271–2.

A new type of spinal introducer [letter] Gurmarnik S. **Reg Anesth** 1997 May–Jun;22(3):296

Defective nylon epidural catheter [letter] Stacey BR, et al. **Reg Anesth** 1996 Jul–Aug;21(4):377

Knotted epidural catheters [letter; comment] Stuart AL, et al. **Reg Anesth** 1996 Nov–Dec;21(6):606. Comment on: Reg Anesth 1996 Jan–Feb;21(1):71–3.

Comparison of accuracy and cost of disposable, nonmechanical pumps used for epidural infusions. Valente M, et al. **Reg Anesth** 1997 May–Jun;22(3):260–6

Comparison of the flow rates of 27–gauge Whitacre and Sprotte needles for combined spinal and epidural anesthesia [letter] Waldman SA, et al. **Reg Anesth** 1996 Jul–Aug; 21(4):378–9

Use of auditory feedback to aid identification of the epidural space [letter; comment] Chantler J, et al. **Anaesthesia** 1997 Jun;52(6):608. Comment on: Anaesthesia 1997 Feb;52(2):141–3.

A dual technique for identification of the epidural space [see comments] Jacob S, et al. **Anaesthesia** 1997 Feb;52(2):141–3 . Comment in: Anaesthesia 1997 Jun;52(6):608.

Is it not dangerous to push epidural needles all the way to the hub? [letter; comment] Rao CS. **Anaesthesia** 1996 Nov; 51(11):1077. Comment on: Anaesthesia 1996 May;51(5):513.

Anaesthesia for laparoscopic cholecystectomy in myasthenia gravis: a non–muscle relaxant technique [letter] Tortosa JA, et al. **Anaesthesia** 1997 Aug;52(8):807–8

Mathematical formulae for assessing the depth of the epidural space in children [letter] Yamashita M. **Anaesthesia** 1997 Jan;52(1):94–5

Intrathecal and epidural anesthesia and analgesia for cardiac surgery. Chaney MA. **Anesth Analg** 1997 Jun;84(6):1211–21 (84 ref.)

The plasma concentrations of lidocaine after slow versus rapid administration of an initial dose of epidural anesthesia. Jiang X, et al. **Anesth Analg** 1997 Mar;84(3):570–3

Plasma concentrations of bupivacaine in neonates after continuous epidural infusion. Larsson BA, et al. **Anesth Analg** 1997 Mar;84(3):501–5

Thoracic epidural anesthesia as the last option for treating angina in a patient before coronary artery bypass surgery. Overdyk FJ, et al. **Anesth Analg** 1997 Jan;84(1):213–5

Reduced postoperative analgesic demand after inhaled anesthesia in comparison to combined epidural–inhaled anesthesia in patients undergoing abdominal surgery. Rockemann MG, et al. **Anesth Analg** 1997 Mar;84(3):600–5

Comparison of lidocaine and saline for epidural top–up during combined spinal–epidural anesthesia in volunteers. Trautman WJ 3rd, et al. **Anesth Analg** 1997 Mar;84(3):574–7

Epidural anesthesia and acutely increased intracranial pressure. Lumbar epidural space hydrodynamics in a porcine model. Grocott HP, et al. **Anesthesiology** 1996 Nov; 85(5):1086–91

Effects of concentration and volume of 2–chloroprocaine on epidural anesthesia in volunteers. Liu SS, et al. **Anesthesiology** 1997 Jun;86(6):1288–93; discussion 7A

Sedation for the conduct of lumbar epidural anaesthesia: a study using subanaesthetic dose of ketamine in combination with midazolam. Loo CC, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):200–4

Combined spinal–extradural anaesthesia for preterm and term caesarean section: is there a difference in local anaesthetic requirements? James KS, et al. **Br J Anaesth** 1997 May; 78(5):498–501

Single bolus compared with a fractionated dose injection technique of bupivacaine for extradural Caesarean section: effect on uteroplacental and fetal haemodynamic state. Karinen J, et al. **Br J Anaesth** 1996 Aug;77(2):140–4

Extradural anaesthesia for caesarean section in a patient with moyamoya disease. Kee WD, et al. **Br J Anaesth** 1996 Oct; 77(4):550–2

Influence of patient position on withdrawal forces during removal of lumbar extradural catheters. Morris GN, et al. **Br J Anaesth** 1996 Sep;77(3):419–20

Ropivacaine 0.75% for extradural anaesthesia in elective caesarean section: an open clinical and pharmacokinetic study in mother and neonate. Morton CP, et al. **Br J Anaesth** 1997 Jul;79(1):3–8

Anaesthetic management of a parturient with severe muscular dystrophy, lumbar lordosis and a difficult airway. Pash MP, et al. **Can J Anaesth** 1996 Sep;43(9):959–63

Epidural bupivacaine/fentanyl infusions vs. intermittent top–ups: a retrospective study of the effects on mode of delivery in primiparous women. Driver I, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):515–20

Thoracolumbar epidural blockade as adjunct to high dose fentanyl/midazolam anesthesia in coronary surgery: effects of sternotomy. Thorelius J, et al. **Eur J Cardiothorac Surg** 1996;10(9):754–62

Does sympathetic blockade prevent the physiologic changes associated with tourniquet use in children? Goodarzi M, et al. **J Pediatr Orthop** 1997 May–Jun;17(3):289–92

A simple technique to avoid epidural catheter disconnection from connector (Portex) [letter] Alam S, et al. **Reg Anesth** 1996 Nov–Dec;21(6):607

Spinal–epidural–general anesthesia [letter; comment] Alam S. **Reg Anesth** 1996 Nov–Dec;21(6):608–9. Comment on: Reg Anesth 1994 Sep–Oct;19(5):365–6.

A clinical measure of the posterior epidural space depth [see comments] Bevacqua BK, et al. **Reg Anesth** 1996 Sep–Oct; 21(5):456–60. Comment in: Reg Anesth 1997 May–Jun;22(3):297.

Spread of local anesthetic into the epidural caudal space for two rates of injection in children. Blanco D, et al. **Reg Anesth** 1996 Sep–Oct;21(5):442–5

The seven–holed epidural catheter—too much of a good thing? [letter; comment] Collier C, et al. **Reg Anesth** 1997 Mar–Apr;22(2):199–200. Comment on: Reg Anesth 1996 May–Jun;21(3):271–2.

Verification of sensory block during regional anesthesia. de Leon–Casasola OA. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):126–8 (11 ref.)

Effectiveness and safety of combined epidural and general anesthesia for laparoscopic cholecystectomy. Luchetti M, et al. **Reg Anesth** 1996 Sep–Oct;21(5):465–9

A chronic model for experimental investigation of epidural anesthesia in the rabbit. Malinovsky JM, et al. **Reg Anesth** 1997 Jan–Feb;22(1):80–5

Epidural anesthesia for extracorporeal shock wave lithotripsy in an achondroplastic dwarf. Nguyen TT, et al. **Reg Anesth** 1997 Jan–Feb;22(1):102–4

Detection of intravascular epidural catheters using 2–chloroprocaine. Influence of local anesthetic dose and nalbuphine premedication. Rathmell JP, et al. **Reg Anesth** 1997 Mar–Apr;22(2):113–8

The anticoagulated patient. Rauck RL. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):51–6 (28 ref.)

Epidural space as a Starling resistor and elevation of inflow resistance in a diseased epidural space. Rocco AG, et al. **Reg Anesth** 1997 Mar–Apr;22(2):167–77

A multivariate model to predict the distance from the skin to the epidural space in an obstetric population. Segal S, et al. **Reg Anesth** 1996 Sep–Oct;21(5):451–5

Labor analgesia and anesthesia in a patient with spinal muscular atrophy and vocal cord paralysis. A rare and unusual case report. Weston LA, et al. **Reg Anesth** 1996 Jul–Aug;21(4):350–4 (11 ref.)

[Epidural anesthesia in the treatment of severe neuropathic pain in diabetic patients (letter)] Tiainen P, et al. **Duodecim** 1995;111(12):1120–1 **(Fin)**

[Value of combined spinal and epidural anesthesia in the

management of peroperative analgesia in prosthetic surgery of the lower limb. Prospective study of 68 cases] Cazeneuve JF, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(8):705–8 (Eng. Abstr.) **(Fre)**

[Epidural administration of buprenorphine after combined spinal epidural anesthesia] Endoh M, et al. **Masui** 1996 Nov; 45(11):1396–9 (Eng. Abstr.) **(Jpn)**

[High epidural anesthesia for asthmatic patients—case reports and philological Investigation] Enguchi T. **Masui** 1997 Mar;46(3):401–5 (Eng. Abstr.) **(Jpn)**

[Anesthesia for bilateral volume reduction surgery in a patient with severe bullous emphysema] Ito T, et al. **Masui** 1996 Nov;45(11):1410–2 (Eng. Abstr.) **(Jpn)**

[Anesthetic management for a patient with pheochromocytoma using magnesium sulfate and epidural block] Sakamoto T, et al. **Masui** 1996 Nov;45(11):1400–5 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a child with pheochromocytoma using sevoflurane, diltiazem and continuous epidural blockade] Takahashi K, et al. **Masui** 1996 Oct;45(10):1252–5 (Eng. Abstr.) **(Jpn)**

NURSING

Use of caudal epidural blocks to relieve lumbar canal stenotic pain in elderly patients. Galindo-Ciocon D. **AORN J** 1996 Jan;63(1):254–7

STATISTICS & NUMERICAL DATA

[Lumbar and thoracic epidural anesthesia in children's hospitals in Japan] Kitahara Y, et al. **Masui** 1996 Jan; 45(1):115–8 (Eng. Abstr.) **(Jpn)**

UTILIZATION

National audit of anaesthesia for major abdominal surgery. Rigg JR, et al. **Anaesth Intensive Care** 1997 Jun;25(3):282–5

Hemostasis-altering drugs and central neural block. A survey of anesthetic practice in Scotland and the United Kingdom. Millar FA, et al. **Reg Anesth** 1996 Nov-Dec;21(6):529–33

VETERINARY

Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. Lacoste L, et al. **Lab Anim** 1996 Jul;30(3):228–33

[Use of a mix of lidocaine and butorphanol as a caudal epidural anesthesia in a mare] Csik-Salmon J, et al. **Can J Vet Res** 1996 Oct;60(4):288–95 (Eng. Abstr.) **(Fre)**

[Observations on epidural anesthesia in cats from the anatomical viewpoint] Maierl J, et al. **Tierarztl Prax** 1997 May;25(3):267–70 (Eng. Abstr.) **(Ger)**

ANESTHESIA, EXTRADURAL see **ANESTHESIA, EPIDURAL**

ANESTHESIA, GENERAL

Ketamine safety profile in the developing world: survey of practitioners. Green SM, et al. **Acad Emerg Med** 1996 Jun; 3(6):598–604

Anaesthesia and systemic oxygenation. Bacher A, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):869–75

Intravenous induction of general anaesthesia with eltanolone in children 6–15 years of age. Beskow A, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):242–7

Cardiovascular effects of desflurane and isoflurane in patients with coronary artery disease. Grundmann U, et al. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1101–7

Awareness in anaesthesia: incidence, consequences and prevention. Heier T, et al. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1073–86 (216 ref.)

Caudal clonidine and bupivacaine for combined epidural and general anaesthesia in children. Motsch J, et al. **Acta Anaesthesiol Scand** 1997 Aug;41(7):877–83

Bupivacaine does not suppress cardiac sympathetic nerve activity during halothane anesthesia in the cat. Nishikawa K, et al. **Acta Anaesthesiol Scand** 1997 May;41(5):595–601

Metoclopramide reduces the induction dose of propofol. Page VJ, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):256–9

The claims of compensation for awareness with recall during general anaesthesia in Finland. Ranta S, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):356–9

Recall of awareness during cardiac anaesthesia: influence of feedback information to the anaesthesiologist. Ranta S, et al. **Acta Anaesthesiol Scand** 1996 May;40(5):554–60

Perioperative respiratory events in smokers and nonsmokers undergoing general anaesthesia. Schwilk B, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):348–55

Tourniquet release: systemic and metabolic effects. Townsend HS, et al. **Acta Anaesthesiol Scand** 1996 Nov; 40(10):1234–7

Cardiac risk patient—intraoperative contribution: anaesthetic management. Boldt J. **Acta Anaesthesiol Scand Suppl** 1996; 109:133–4

The nervous system at risk—an overview. Gelb AW. **Acta Anaesthesiol Scand Suppl** 1996;109:48–50 (8 ref.)

Patients with congenital heart malformations for noncardiac surgery. Jonmarker C. **Acta Anaesthesiol Scand Suppl** 1997; 110:104–5

Acute renal failure—implications for the anesthesia management. Kröll W. **Acta Anaesthesiol Scand Suppl** 1996; 109:20–2

Thermoregulatory vasoconstriction and perianesthetic heat transfer. Kurz A, et al. **Acta Anaesthesiol Scand Suppl** 1996; 109:30–3

Pharmacological neuronal protection. Michalek-Sauberer A, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:57–8

Balanced anaesthesia in children. Semsroth M, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:101–2

Anesthesia for patients with liver failure. Spiss CK, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:17–20

General or regional anaesthesia. Stefansson T. **Acta Anaesthesiol Scand Suppl** 1997;110:52–3

General or regional anaesthesia—pro general. Wattwil M. **Acta Anaesthesiol Scand Suppl** 1997;110:54–5

Comparative study of the effects of nitric oxide synthase and cyclo-oxygenase inhibition on duodenal functions in rats anaesthetized with inactin, urethane or alpha-chloralose. Sababi M, et al. **Acta Physiol Scand** 1996 Sep;158(1):45–52

Parathyroid surgery using monitored anesthesia care as an alternative to general anesthesia. Ditkoff BA, et al. **Am J Surg** 1996 Dec;172(6):698–700

Effect of anesthesia and surgery on energy expenditure determined by indirect calorimetry in dogs with malignant and nonmalignant conditions. Ogilvie GK, et al. **Am J Vet Res** 1996 Sep;57(9):1321–6

Retrospective review of 100 cases of endoluminal aortic stent-graft surgery from an anaesthetic perspective. Baker AB, et al. **Anaesth Intensive Care** 1997 Aug;25(4):378–84

Anaesthesia information—what patients want to know. Garden AL, et al. **Anaesth Intensive Care** 1996 Oct; 24(5):594–8

Anaesthesia for laparoscopic surgery in myotonic dystrophy [letter] Merefield DC, et al. **Anaesth Intensive Care** 1997 Feb;25(1):93–4

Anaesthesia for children with mucopolysaccharidoses [see comments] Moores C, et al. **Anaesth Intensive Care** 1996 Aug;24(4):459–63. Comment in: Anaesth Intensive Care 1997 Apr;25(2):197–8.

Jaw thrust as a sign of anaesthetic depth [letter] Bukht D. **Anaesthesia** 1997 Aug;52(8):803

The airways and anaesthesia—I. Anatomy, physiology and fluid mechanics. Burwell DR, et al. **Anaesthesia** 1996 Sep; 51(9):849–57 (40 ref.)

Carboxyhaemoglobin-corrected oxygen saturation [letter; comment] Caranza R. **Anaesthesia** 1996 Sep;51(9):894. Comment on: Anaesthesia 1996 Apr;51(4):324–6.

The hazards of anaesthetic gas scavenging systems. Farquhar-Thomson DR, et al. **Anaesthesia** 1996 Sep; 51(9):860–2

Spontaneous remission of left bundle branch block during anaesthesia. Garcia EJ, et al. **Anaesthesia** 1997 Jul; 52(7):684–7

Simulated difficult intubation. Comparison of the gum elastic bougie and the stylet [see comments] Gataure PS, et al. **Anaesthesia** 1996 Oct;51(10):935–8. Comment in: Anaesthesia 1997 Apr;52(4):386.

End-tidal carbon dioxide measurement and breathing system filters. Hardman JG, et al. **Anaesthesia** 1997 Jul;52(7):646–8

A new critical incident monitor for use with the paediatric T-piece. In vitro evaluation and clinical experience with the Magtrak Infanta Electronic Respirometer [see comments] Hatch DJ, et al. **Anaesthesia** 1996 Sep; 51(9):839–42. Comment in: Anaesthesia 1997 Feb;52(2):185.

Intra-ocular pressure changes during gynaecological laparoscopy. Lentschener C, et al. **Anaesthesia** 1996 Dec; 51(12):1106–8

Safety and efficacy of the laryngeal mask airway. A prospective survey of 1400 children. Lopez-Gil M, et al. **Anaesthesia** 1996 Oct;51(10):969–72

Torsade de pointes ventricular tachycardia following coronary artery spasm during general anaesthesia. Mizutani K, et al. **Anaesthesia** 1996 Sep;51(9):858–60

On the dangers of monitoring. Or, primum non nocere revisited [editorial] Saunders DA. **Anaesthesia** 1997 May; 52(5):399–400

Feasibility of day case laparoscopic cholecystectomy in unselected patients. Tuckey JP, et al. **Anaesthesia** 1996 Oct; 51(10):965–8

Choice of tracheal tube size for children: finger size or age-related formula? van den Berg AA, et al. **Anaesthesia** 1997 Jul;52(7):701–3

The oldest patient? [letter] Wraight WJ. **Anaesthesia** 1997 May;52(5):509

Thiopental-rocuronium versus ketamine-rocuronium for rapid-sequence intubation in parturients undergoing cesarean section. Baraka AS, et al. **Anesth Analg** 1997 May; 84(5):1104–7

Anesthetic management of cesarean delivery complicated by ex utero intrapartum treatment of the fetus. Gaiser RR, et al. **Anesth Analg** 1997 May;84(5):1150–3

Minimally invasive aortic valve surgery: anesthetic considerations. Hearn CJ, et al. **Anesth Analg** 1996 Dec; 83(6):1342–4

Use of the laryngeal mask airway as an alternative to the tracheal tube during ambulatory anesthesia. Joshi GP, et al. **Anesth Analg** 1997 Sep;85(3):573–7

Anesthetic considerations in myelopathy associated with human T-cell lymphotropic virus type I (HTLV-I-associated myelopathy: HAM). Kanmura Y, et al. **Anesth Analg** 1996 Nov;83(5):1120–1

Interactions between mivacurium, rocuronium, and vecuronium during general anesthesia. Kim DW, et al. **Anesth Analg** 1996 Oct;83(4):818–22

Current understanding of patients' attitudes toward and preparation for anesthesia: a review [see comments] Klafta JM, et al. **Anesth Analg** 1996 Dec;83(6):1314–21 (40 ref.) . Comment in: Anesth Analg 1997 May;84(5):1167–8.

The effects of general anesthesia and surgery on basal and interferon stimulated natural killer cell activity of humans. Kutza J, et al. **Anesth Analg** 1997 Oct;85(4):918–23

Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2O-O2-opioid anesthesia. Lepage JY, et al. **Anesth Analg** 1996 Oct;83(4):823–9

Computer-assisted auscultation of a bronchopleurocutaneous fistula during general anesthesia. Manecke GR Jr, et al. **Anesth Analg** 1996 Oct;83(4):880–2

The effects of midazolam on propofol-induced anesthesia: propofol dose requirements, mood profiles, and perioperative dreams. Oxorn DC, et al. **Anesth Analg** 1997 Sep;85(3):553–9

The effects of sevoflurane anesthesia on insulin secretion and glucose metabolism in pigs. Saho S, et al. **Anesth Analg** 1997 Jun;84(6):1359–65

Midlatency auditory evoked potentials predict movements during anesthesia with isoflurane or propofol. Schwender D, et al. **Anesth Analg** 1997 Jul;85(1):164–73

The effect of anesthetic techniques on blood coagulability in parturients as measured by thromboelastography. Sharma SK, et al. **Anesth Analg** 1997 Jul;85(1):82–6

Simulation of an epidural test dose with intravenous isoproterenol in isoflurane-anesthetized adults. Tanaka M. **Anesth Analg** 1997 Sep;85(3):639–43

Reduction of the minimum alveolar concentration of isoflurane by dexmedetomidine. Aantaa R, et al. **Anesthesiology** 1997 May;86(5):1055–60

Cardiac outcomes after regional or general anesthesia: do we know the question? [letter; comment] Beattie C, et al. **Anesthesiology** 1996 Nov;85(5):1207–9. Comment on: Anesthesiology 1996 Jan;84(1):1–2.

Continuous epidural blockade arrests the postoperative decrease in muscle protein fractional synthetic rate in surgical patients. Carli F, et al. **Anesthesiology** 1997 May; 86(5):1033–40

Learning and memory during general anesthesia: an update. Ghoneim MM, et al. **Anesthesiology** 1997 Aug; 87(2):387–410 (152 ref.)

Anesthesia for transjugular intrahepatic portosystemic shunt placement [letter; comment] Pivalizza EG, et al. **Anesthesiology** 1996 Oct;85(4):946–7. Comment on: Anesthesiology 1996 Jan;84(1);231–3.

Effects of general anesthesia and paralysis on upper airway changes due to head position in humans. Sivarajan M, et al. **Anesthesiology** 1996 Oct;85(4):787–93

A prospective trial of local versus general anaesthesia for arthroscopic surgery of the knee. Williams CR, et al. **Ann R Coll Surg Engl** 1997 Sep;79(5):345–8

Use of methohexital for elective intubation in neonates. Naulaers G, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Jul;77(1):F61–4

Clinical outcomes for nursing caries treated using general anesthesia. Berkowitz RJ, et al. **ASDC J Dent Child** 1997 May-Jun;64(3):210–1, 228

Rapid opiate detoxification. Acute withdrawal of opiates is indication for anaesthesia [letter] Laban MM, et al. **BMJ** 1997 Sep 13;315(7109):682–3

General anaesthesia does not usually affect the fetus [letter] Raftery S. **BMJ** 1997 Aug 23;315(7106):488

General anaesthesia [letter; comment] Greenan J. **Br Dent J** 1996 Oct 5;181(7):241. Comment on: Br Dent J 1996 Jun 22;180(12):448.

General anaesthesia in dentistry [letter] Greenan J. **Br Dent J** 1996 Mar 23;180(6):206

Is general anaesthesia for orthodontic extractions in children necessary? [letter; comment] [published erratum appears in Br Dent J 1996 Oct 19;181(8):283] [see comments] Jack WA, et al. **Br Dent J** 1996 Sep 7;181(5):165. Comment on: Br Dent J 1996 Jul 6;181(1):6–7. Comment in: Br Dent J 1996 Nov 9;181(9):319.

A survey of general anaesthesia, sedation and resuscitation in general dental practice. Macpherson LM, et al. **Br Dent J** 1996 Sep 21;181(6):199–203

General anaesthesia [letter; comment] Prince AT. **Br Dent J** 1996 Sep 21;181(6):196. Comment on: Br Dent J 1996 Jul 6;181(1):6–7.

Efficacy of intraoperative heat administration by ventilation with warm humidified gases and an oesophageal warming system [see comments] Beck E, et al. **Br J Anaesth** 1996 Oct;77(4):530–3. Comment in: Br J Anaesth 1997 Mar;78(3):343.

Preoxygenation in children using expired oxygraphy. Butler PJ, et al. **Br J Anaesth** 1996 Sep;77(3):333–4

Calcium homeostasis during i.v. infusion of 1.5% glycine in anaesthetized pigs [see comments] Chassard D, et al. **Br J Anaesth** 1996 Aug;77(2):271–3. Comment in: Br J Anaesth 1996 Dec;77(6):810–1.

Volumetric analysis of aeration in the lungs during general anaesthesia [letter; comment] Drummond GB. **Br J Anaesth** 1996 Nov;77(5):697–8. Comment on: Br J Anaesth 1996 Jun;76(6):760–6.

Transoesophageal echocardiography in anaesthesia and intensive care [letter; comment] George SJ. **Br J Anaesth** 1996 Nov;77(5):700. Comment on: Br J Anaesth 1996 Aug;77(2):137–9.

Absence of memory for intraoperative information [letter] Hooper MB. **Br J Anaesth** 1997 Jul;79(1):143

Processed electroencephalogram during combined extradural and general anaesthesia. Kiyama S, et al. **Br J Anaesth** 1997 Jun;78(6):751–3

Prevention of cardiovascular response to tracheal intubation [letter; comment] Mallick A, et al. **Br J Anaesth** 1996 Aug; 77(2):296–7. Comment on: Br J Anaesth 1996 Feb;76(2):221–6.

Effect of anaesthesia on lung function in children with asthma. May HA, et al. **Br J Anaesth** 1996 Aug;77(2):200–2

Sternomental distance as the sole predictor of difficult laryngoscopy in obstetric anaesthesia [see comments] [published erratum appears in Br J Anaesth 1996 Nov;77(5):701] Al Ramadhani S, et al. **Br J Anaesth** 1996 Sep;77(3):312–6. Comment in: Br J Anaesth 1996 Sep;77(3):309–11. Comment in: Br J Anaesth 1997 Mar;78(3):338. Comment in: Br J Anaesth 1997 May;78(5):626–7.

Beneficial effects of dexmedetomidine on ischaemic myocardium of anaesthetized dogs. Roekaerts PM, et al. **Br J Anaesth** 1996 Sep;77(3):427–9

Fuzzy logic control of mechanical ventilation during anaesthesia. Schäublin J, et al. **Br J Anaesth** 1996 Nov; 77(5):636–41

Comparison of extradural and general anaesthesia on the fibrinolytic response to total knee arthroplasty. Sharrock NE, et al. **Br J Anaesth** 1997 Jul;79(1):29–34

Measurement of cardiac output by transoesophageal Doppler echocardiography in anaesthetized horses: comparison with thermodilution. Young LE, et al. **Br J Anaesth** 1996 Dec; 77(6):773–80

Phasic relationship between the activity of basal forebrain neurons and cortical EEG in urethane–anesthetized rat. Détári L, et al. **Brain Res** 1997 Jun 6;759(1):112–21

Anaesthetic management of patients with sleep apnoea syndrome [published erratum appears in Can J Anaesth 1996 Nov;43(11):1184] Boushra NN. **Can J Anaesth** 1996 Jun;43(6):599–616 (139 ref.)

Anticholinergics improve fibreoptic intubating conditions during general anaesthesia. Brookman CA, et al. **Can J Anaesth** 1997 Feb;44(2):165–7

Combined epidural/general anaesthesia [letter; comment] Carli F, et al. **Can J Anaesth** 1997 Apr;44(4):452–3. Comment on: Can J Anaesth 1996 Aug;43(8):769–77.

Perioperative ischaemia in aortic surgery: combined epidural/general anaesthesia and epidural analgesia vs general anaesthesia and i.v. analgesia [see comments] Garnett RL, et al. **Can J Anaesth** 1996 Aug;43(8):769–77 . Comment in: Can J Anaesth 1996 Aug;43(8):759–63. Comment in: Can J Anaesth 1997 Apr;44(4):452–3.

Ketamine sedation obviates the need for general anaesthesia in children having laser ablation of facial port–wine stains [letter] Pullerits J, et al. **Can J Anaesth** 1996 Jul;43(7):755–6

Awareness during general anesthesia. Sebel PS. **Can J Anaesth** 1997 May;44(5 Pt 2):R124–30 (16 ref.) **(Eng, Fre)**

Carbon monoxide and general anesthesia [letter] [see comments] Hampson NB, et al. **Chest** 1996 Nov;110(5):1375 . Comment in: Chest 1996 Feb;109(2):592.

Randomized trial of epidural versus general anesthesia: outcomes after primary total knee replacement. Williams–Russo P, et al. **Clin Orthop** 1996 Oct; (331):199–208

Augmented thermic effect of amino acids under general anaesthesia occurs predominantly in extra–splanchnic tissues. Selldén E, et al. **Clin Sci (Colch)** 1996 Oct; 91(4):431–9

Changes in vitamin E concentration after surgery and anesthesia. Zunić J, et al. **Coll Antropol** 1997 Jun; 21(1):327–34

A quality assurance review of the patient referral process and user satisfaction of outpatient general anaesthesia services for dental treatment. Podesta JR, et al. **Community Dent Health** 1996 Dec;13(4):228–31

Ketamine anesthesia in electroconvulsive therapy. Rasmussen KG, et al. **Convuls Ther** 1996 Dec;12(4):217–23

Gustatory sweating associated with diabetes: a general anaesthetic gives clues to potential treatments [letter] Davies MJ, et al. **Diabet Med** 1996 Jun;13(6):595–7

Safety considerations in the use of drug combinations during general anaesthesia. Ransom ES, et al. **Drug Saf** 1997 Feb; 16(2):88–103 (129 ref.)

Event–related potential measures of information processing during general anesthesia. van Hooff JC, et al. **Electroencephalogr Clin Neurophysiol** 1997 Aug; 103(2):268–81

Is eye enucleation or evisceration possible under peribulbar anaesthesia? [letter] Calenda E, et al. **Eur J Anaesthesiol** 1997 Sep;14(5):551–2

Learning during anaesthesia [editorial] Jelicic M, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):311–3

Nitrous oxide inhalation as an adjunct to intravenous induction of general anaesthesia with propofol for day surgery. Johnson GW, et al. **Eur J Anaesthesiol** 1997 May; 14(3):295–9

Dose–response and concentration–response relation of rocuronium infusion during propofol–nitrous oxide and isoflurane–nitrous oxide anaesthesia. Kansanaho M, et al. **Eur J Anaesthesiol** 1997 Sep;14(5):488–94

Some studies of the complement system during total hip replacement using bone cement under general anaesthesia. Lewis RN. **Eur J Anaesthesiol** 1997 Jan;14(1):35–9

Post–operative pain relief in children following extraction of carious deciduous teeth under general anaesthesia: a comparison of nalbuphine and diclofenac. Littlejohn IH, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):359–63

The effect of general anaesthesia on breathing patterns in elderly patients during the early post–operative period. Loick HM, et al. **Eur J Anaesthesiol** 1997 May;14(3):258–65

An investigation of the effect of ondansetron on time to induction of anaesthesia with thiopentone and propofol. Mansfield M, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):24–8

Anaesthesia for dental conservation in a patient with tuberous sclerosis. Nott MR, et al. **Eur J Anaesthesiol** 1996 Jul; 13(4):413–5

Magnetic resonance imaging in children: role of the anaesthesiologist [editorial] Wouters PF, et al. **Eur J Anaesthesiol** 1997 May;14(3):236–8

Local versus general anaesthesia in carotid endarterectomy: a systematic review of the evidence. Tangkanakul C, et al. **Eur J Vasc Endovasc Surg** 1997 May;13(5):491–9

Guinea–pig tracheal responsiveness in vitro following general anaesthesia with halothane. Mercier FJ, et al. **Eur Respir J** 1996 Jul;9(7):1451–5

Pharmacokinetics of intrarectal nalbuphine in children undergoing general anaesthesia. Bessard G, et al. **Fundam Clin Pharmacol** 1997;11(2):133–7

A controlled study of the effect of balanced general anaesthesia on cognitive functions in hypertensives on propranolol. Sharma S, et al. **Indian J Med Res** 1995 Aug; 102:77–86

A prospective trial to compare three anaesthetic techniques used for the reduction of fractures of the distal radius. Funk L. **Injury** 1997 Apr;28(3):209–12

Anesthetics and cerebroprotection: experimental aspects. Kirsch JR, et al. **Int Anesthesiol Clin** 1996 Fall;34(4):73–93 (186 ref.)

The effect of skin incision followed by alfentanil on catecholamine levels and on the T–wave amplitude of ECG during isoflurane anaesthesia. Annila PA, et al. **Int J Clin Monit Comput** 1995;12(4):205–11

Implicit memory during anaesthesia attempt at replication. Hugdahl K, et al. **Int J Neurosci** 1996 Oct;87(1–2):63–9

Lipolysis in human fat cells obtained under local and general anesthesia. Large V, et al. **Int J Obes Relat Metab Disord** 1997 Jan;21(1):78–82

Is general anaesthesia necessary for URS in women? Yalçinkaya F, et al. **Int Urol Nephrol** 1996;28(2):153–6

Urethan anesthesia protects rats against lethal endotoxemia and reduces TNF–alpha release. Kotanidou A, et al. **J Appl Physiol** 1996 Nov;81(5):2305–11

V/Q distribution and correlation to atelectasis in anesthetized paralyzed humans. Tokics L, et al. **J Appl Physiol** 1996 Oct;81(4):1822–33

Effects of anesthetic technique on myocardial wall motion abnormalities during abdominal aortic surgery [see comments] Dodds TM, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):129–36. Comment in: J Cardiothorac Vasc Anesth 1997 Apr;11(2):127–8.

Electrophysiological mechanisms for ventricular arrhythmias in patients with myocardial ischemia: anesthesiologic considerations, Part 1. Gallagher JD. **J Cardiothorac Vasc Anesth** 1997 Jun;11(4):495–505 (80 ref.)

Glucose: enough versus too much [editorial; comment] Nicolson SC. **J Cardiothorac Vasc Anesth** 1997 Jun; 11(4):409–10. Comment on: J Cardiothorac Vasc Anesth 1997 Jun;11(4):411–4.

Minimally invasive anesthesia should accompany minimally invasive surgery [letter] Pawlowski J, et al. **J Cardiothorac Vasc Anesth** 1997 Jun;11(4):536–7

Intravenous sedation for placement of automatic implantable cardioverter–defibrillators. Pinosky ML, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):764–6

Effects of enflurane and isoflurane on splanchnic oxygenation in humans. Berendes E, et al. **J Clin Anesth** 1996 Sep; 8(6):456–68

Active warming, not passive heat retention, maintains normothermia during combined epidural–general anesthesia for hip and knee arthroplasty. Berti M, et al. **J Clin Anesth** 1997 Sep;9(6):482–6

Control of blood pressure and heart rate in patients randomized to epidural or general anesthesia for lower extremity vascular surgery. Perioperative Ischemia Randomized Anesthesia Trial (PIRAT) Study Group. Christopherson R, et al. **J Clin Anesth** 1996 Nov; 8(7):578–84

Comparison of general anesthesia with and without lumbar epidural for total hip arthroplasty: effects of epidural block on hip arthroplasty. Dauphin A, et al. **J Clin Anesth** 1997 May;9(3):200–3

Spinal ignorance [letter; comment] Eldor J. **J Clin Anesth** 1996 Sep;8(6):533–4. Comment on: J Clin Anesth 1995 Aug;7(5):389–94.

Parental presence plus oral midazolam decreases frequency of 5% halothane inductions in children. Gillerman RG, et al. **J Clin Anesth** 1996 Sep;8(6):480–5

A comparison: the efficacy of sevoflurane–nitrous oxide or propofol–nitrous oxide for the induction and maintenance of general anesthesia. Lien CA, et al. **J Clin Anesth** 1996 Dec;8(8):639–43

Anesthetic management and outcome following noncardiac surgery in nonparturients with Eisenmenger's physiology. Raines DE, et al. **J Clin Anesth** 1996 Aug;8(5):341–7 (33 ref.)

Outpatient general anesthesia: a comparison of a combination of midazolam plus propofol and propofol alone. Reinhart DJ, et al. **J Clin Anesth** 1997 Mar;9(2):130–7

Use of propofol anesthesia during outpatient radiographic imaging studies in patients with Lesch–Nyhan syndrome. Williams KS, et al. **J Clin Anesth** 1997 Feb;9(1):61–5

Computer simulation of cerebrovascular circulation: assessment of intracranial hemodynamics during induction of anesthesia. Bekker A, et al. **J Clin Monit** 1996 Nov; 12(6):433–44

EEG Predicts movement response to surgical stimuli during general anesthesia with combinations of isoflurane, 70% N2O, and fentanyl. Dutton RC, et al. **J Clin Monit** 1996 Mar;12(2):127–39

Neural network–based detection of esophageal intubation in anesthetized patients. León MA, et al. **J Clin Monit** 1996 Mar;12(2):165–9

Simulators for anesthesia. Norman J, et al. **J Clin Monit** 1996 Jan;12(1):91–9

Recurrent issues prompt call for continued effort [news] Pierce EC Jr. **J Clin Monit** 1996 Jan;12(1):103

Fluoroscopy–assisted intubation of a child with an unstable subluxation of C1/C2. Morell RC, et al. **J Neurosurg Anesthesiol** 1997 Jan;9(1):25–8

The use of ketamine or etomidate to supplement sufentanil/N2O anesthesia does not disrupt monitoring of myogenic transcranial motor evoked responses. Ubags LH, et al. **J Neurosurg Anesthesiol** 1997 Jul;9(3):228–33

Anesthetic management for laparoscopic cholecystectomy in children with decreased myocardial function: two case reports. Tobias JD, et al. **J Pediatr Surg** 1997 May; 32(5):743–6

Effect of chronic cocaine administration on the hemodynamic response to acute hemorrhage in awake and anesthetized sheep. Bernards CM, et al. **J Trauma** 1997 Jan;42(1):42–8

A comparison of regional and general anesthesia in patients undergoing carotid endarterectomy. Rockman CB, et al. **J Vasc Surg** 1996 Dec;24(6):946–53; discussion 953–6

Effects of repeated ether stress on the hypothalamic–pituitary–testes axis in adult rats with special reference to inhibin secretion. Tohei A, et al. **J Vet Med Sci** 1997 May;59(5):329–34

Experts debate merits of 1–day opiate detoxification under anesthesia [news] Stephenson J. **JAMA** 1997 Feb 5; 277(5):363–4

No suppression of respiratory function of mitochondrial isolated from the hearts of anesthetized rats with high–dose pentobarbital sodium. Takaki M, et al. **Jpn J Physiol** 1997 Feb;47(1):87–92

Optimal concentration of epinephrine for vasoconstriction in neck surgery. Dunlevy TM, et al. **Laryngoscope** 1996 Nov;106(11):1412–4

Immediate response to inspiratory resistive loading in anesthetized patients with kyphoscoliosis: spirometric and neural effects. Baydur A, et al. **Lung** 1996;174(2):99–118

Bilateral total knee arthroplasty under one anesthesia: a safe protocol [editorial; comment] Vince KG. **Mayo Clin Proc** 1997 Sep;72(9):883–5. Comment on: Mayo Clin Proc 1997 Sep;72(9):799–805.

The relationship among brain, spinal cord and anesthetic requirements. Antognini JF. **Med Hypotheses** 1997 Jan; 48(1):83–7

General anesthesia, respiratory and cardiac standstill triggered by the extra–integumentary mechanical stimulation of foreign bodies in the airways. Baggot MG. **Med Hypotheses** 1997 Jul;49(1):93–100

Natural killer and lymphokine–activated cytotoxicity following anaesthesia in patients with uveal malignant melanoma. Richardson PS, et al. **Melanoma Res** 1997 Apr; 7(2):129–37

Is antacid treatment necessary in obstetric anesthesia? Al Mazrooa AA, et al. **Middle East J Anesthesiol** 1995 Oct; 13(3):335–40

Anesthesia during a mass–casualty disaster: the Army's experience at Fort Bragg, North Carolina, March 23, 1994. Phillips WJ, et al. **Mil Med** 1997 Jun;162(6):371–3

Transcranial high–frequency repetitive electrical stimulation for recording myogenic motor evoked potentials with the patient under general anesthesia. Pechstein U, et al. **Neurosurgery** 1996 Aug;39(2):335–43; discussion 343–4

Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia. Ascaso FJ, et al. **Ophthalmologica** 1997;211(5):292–5

General anaesthesia may improve the success rate of hydrostatic reductions of intussusception. Brenn BR, et al. **Paediatr Anaesth** 1997;7(1):77–81

Moebius syndrome: a review of the anaesthetic implications. Ferguson S. **Paediatr Anaesth** 1996;6(1):51–6

Duchenne muscular dystrophy: a challenge for the anaesthetist [editorial] Morris P. **Paediatr Anaesth** 1997; 7(1):1–4

Convulsions associated with epidural analgesia during sevoflurane anaesthesia. Saitoh K, et al. **Paediatr Anaesth** 1996;6(6):495–7

Recovery of psychomotor function following general anaesthesia in children: a comparison of propofol and thiopentone/halothane. Schröter J, et al. **Paediatr Anaesth** 1996;6(4):317–24

Pulmonary aspiration of gastric contents after a priming dose of vecuronium. Shorten GD, et al. **Paediatr Anaesth** 1997;

7(2):167–9
Bronchoscopic airway evaluation facilitated by the laryngeal mask airway in pediatric patients [published erratum appears in Pediatr Pulmonol 1996 Aug;22(2):140] Badr A, et al. **Pediatr Pulmonol** 1996 Jan;21(1):57–61
Anesthesia and pain management in pediatric burn patients. Beushausen T, et al. **Pediatr Surg Int** 1997 Jul; 12(5–6):327–33 (75 ref.)
The effect of tobacco smoke on children undergoing general anesthesia and surgery [letter] Setzer N. **Pediatrics** 1997 Oct;100(4):731
Delayed arousal from anesthesia: a further similarity between stress and beta-1 adrenoceptor blockade. Stone EA, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):131–3
How has molecular pharmacology contributed to our understanding of the mechanism(s) of general anesthesia? Little HJ. **Pharmacol Ther** 1996;69(1):37–58 (218 ref.)
Breast reduction under local anesthesia with intravenous sedation [letter; comment] Stryker AK.
Plast Reconstr Surg 1997 Jan;99(1):256–7. Comment on: Plast Reconstr Surg 1996 Apr;97(5):952–6; discussion 957–8.
Influence of lidocaine on the hemodynamic parameters in rabbits during general anesthesia. Orszulak-Michalak D. **Pol J Pharmacol** 1996 Mar–Apr;48(2):153–62
The effect of spinal versus general anesthesia on postoperative pain and analgesic requirements in patients undergoing lower abdominal surgery [see comments] Wang JJ, et al. **Reg Anesth** 1996 Jul–Aug;21(4):281–6. Comment in: Reg Anesth 1996 Jul–Aug;21(4):277–80.
Ankle arthroscopy under local and general anaesthesia for diagnostic evaluation and treatment. Rolf C, et al.
Scand J Med Sci Sports 1996 Aug;6(4):255–8
Reduction of blood loss during spinal surgery by epidural blockade under normotensive general anesthesia. Kakiuchi M. **Spine** 1997 Apr 15;22(8):889–94
Hemodynamic and metabolic effects of transjugular intrahepatic portosystemic shunt (TIPS) during anesthesia for orthotopic liver transplantation. Antonini M, et al. **Transpl Int** 1996;9(4):403–7 (9 ref.)
[Clinical experience of laryngeal mask airway combined with continuous intravenous propofol infusion during general anesthesia] Chen KP, et al. **Acta Anaesthesiol Sin** 1996 Dec; 34(4):209–12 (Eng. Abstr.) **(Chi)**
[Study on combined acupunctural and general anesthesia in pneumonectomy] Kuang X, et al.
Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1996 Feb; 16(2):84–6 (Eng. Abstr.) **(Chi)**
[Changes in intraocular pressure during anesthesia with intratracheal intubation or laryngeal mask] Blanchard N, et al. **Ann Fr Anesth Reanim** 1996;15(7):1008–12 (Eng. Abstr.) **(Fre)**
[Argyria and anesthesia (letter)] Donnard G, et al.
Ann Fr Anesth Reanim 1996;15(2):226 **(Fre)**
[Drug onset time of atracurium after pancuronium priming in elderly patients] Geldner G, et al.
Anaesthesiol Reanim 1997;22(2):46–9 (Eng. Abstr.) **(Ger)**
[Mivacurium in pediatric anesthesia] Hofmockel VR, et al. **Anaesthesiol Reanim** 1996;21(1):11–3 (25 ref.) (Eng. Abstr.) **(Ger)**
[Effect of rocuronium in sufentanil/isoflurane and sufentanil/propofol anesthesia] Klinzing S, et al.
Anaesthesiol Reanim 1996;21(6):149–52 (Eng. Abstr.) **(Ger)**
[Comparison of the effect of desflurane and isoflurane on neuromuscular blockage with vecuronium on geriatric patients] Mielke VL, et al. **Anaesthesiol Reanim** 1996; 21(1):4–10 (Eng. Abstr.) **(Ger)**
[Neostigmine and edrophonium. Antagonism of profound and shallow mivacurium blockade] Bartunek A, et al.
Anaesthesist 1997 Feb;46(2):96–100 (Eng. Abstr.) **(Ger)**
[Cost aspects in anesthesia. Propofol versus isoflurane anesthesia] Boldt J, et al. **Anaesthesist** 1996 Aug;45(8):731–6 (Eng. Abstr.) **(Ger)**
[Combination anesthesia and bronchial tranport velocity. Effects of anesthesia with isoflurane, fentanyl, vecuronium and oxygen–nitrous oxide breathing on bronchial mucus transport] Konrad F, et al. **Anaesthesist** 1997 May; 46(5):403–7 (Eng. Abstr.) **(Ger)**
[Monitoring intraoperative awareness. Vegetative signs, isolated forearm technique, electroencephalogram, and acute evoked potentials] Schwender D, et al.
Anaesthesist 1996 Aug;45(8):708–21 (66 ref.) (Eng. Abstr.) **(Ger)**
[Intra- and postoperative catheter epidural analgesia. Combination of epidural analgesia and general anesthesia] Seeling W, et al. **Anaesthesist** 1997 Mar;46(3):237–52 (13 ref.) **(Ger)**
[Craniosynostosis operations in childhood] Berg K, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Mar; 32(3):138–50 (107 ref.) (Eng. Abstr.) **(Ger)**
[Perioperative monitoring of the course of anesthesia, the postanesthesia visit and inquiry of patient satisfaction. A prospective study of parameters in process and outcome quality in anesthesia] Bothner U, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Dec; 31(10):608–14 (Eng. Abstr.) **(Ger)**
[Patient knowledge concerning anesthesia general practice and the responsibilities of the anesthetist (see comments)] Deusch E, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Sep; 31(7):409–13 (Eng. Abstr.). Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Sep;31(7):399–400. Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Apr;32(4):263. **(Ger)**
[New muscle relaxants] Diefenbach C, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Feb; 31(1):2–8 (57 ref.) (Eng. Abstr.) **(Ger)**
[Comparative study of pethidine and clonidine for prevention of postoperative shivering. A prospective, randomized, placebo-controlled double-blind study] Grundmann U, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan;32(1):36–42 (Eng. Abstr.) **(Ger)**
[Anesthesiologic management of ankle joint osteosynthesis in the 35th week of pregnancy in a patient with Charcot-Marie-Tooth syndrome] Kirmayer UJ, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Nov; 31(9):582–4 (Eng. Abstr.) **(Ger)**
[Mucociliary clearance function and medicamentous modification] Konrad F.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Sep; 31(7):404–8 (38 ref.) (Eng. Abstr.) **(Ger)**
[Echocardiography values in the halothane uptake phase--measurement by acoustic quantification and manual evaluation] Laux G, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Jan; 32(1):30–5 (Eng. Abstr.) **(Ger)**
[High frequency jet ventilation during tracheal resection in children and infants] Männle C, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Jan; 32(1):21–6 (Eng. Abstr.) **(Ger)**
[Effects of different kinds of ventilation and positioning measures on blood flow velocity in the middle cerebral artery] Mühling J, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Oct; 31(8):474–80 (Eng. Abstr.) **(Ger)**
[Perioperative management of the patient with atypical Parkinson disease] Rundshagen I.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Feb; 31(1):49–52 (Eng. Abstr.) **(Ger)**
[Effect of endoscopic surgery techniques in children on ventilation] Schäfer R, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Jun; 32(6):343–7 (Eng. Abstr.) **(Ger)**
[Use of the laryngeal mask in adenoidectomy in childhood--a comparison with endotracheal intubation] Schnurer U, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Mar;32(3):155–63 (Eng. Abstr.) **(Ger)**
[Alpha 2-adrenoreceptor agonists--horse or donkey? (editorial)] Scholz J, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Sep; 31(7):401–3 **(Ger)**
[Is remifentanil an ideal opioid for anesthesiologic management in the 21st century?] Scholz J, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Dec; 31(10):592–607 (96 ref.) (Eng. Abstr.) **(Ger)**
[The laryngeal mask--an expanding concept in airway safety (editorial)] Schulte am Esch J, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Mar; 32(3):135–7 **(Ger)**
[Damage due to patient positioning in anesthesia and surgical medicine (1)] Ullrich W, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Jan; 32(1):4–20 (0 ref.) (Eng. Abstr.) **(Ger)**
[Special anesthesiological aspects in patients with Niikawa-Kuroki ("Kabuki Make-Up") syndrome] Wappler F, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Mar; 32(3):197–200 (Eng. Abstr.) **(Ger)**
[Experiences with use of the laryngeal mask with flexible, wire reinforced tube for ENT interventions in childhood] Wehrle HJ, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Mar; 32(3):151–4 (Eng. Abstr.) **(Ger)**
[Does propofol have advantages over isoflurane for sufentanil supplemented anesthesia in children for strabismus surgery?] Wilhelm S, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Sep; 31(7):414–9 (Eng. Abstr.) **(Ger)**
[Burst suppression detection in pEEG] Litscher G, et al.
Biomed Tech (Berl) 1997 Jan–Feb;42(1–2):12–5 (Eng. Abstr.) **(Ger)**
[Drug withdrawal under anesthesia--an alternative to substitution therapy. Model project in a Bavarian district hospital (interview by Dr. rer. nat. Anita Schweiger)] Reiss J. **Fortschr Med** 1996 Aug 30;114(24):12–3 **(Ger)**
[Anesthesia and high frequency jet ventilation (HFJV) for surgical interventions on the larynx and trachea] Biro P, et al. **HNO** 1997 Jan;45(1):43–52 **(Ger)**
[Hypoglossal nerve paralysis after endonasal paranasal sinus operation in intubation narcosis] Bachmann G, et al.
Laryngorhinootologie 1996 Oct;75(10):623–4 (Eng. Abstr.) **(Ger)**
[Opiate withdrawal in anesthesia (forced narcotic withdrawal, "turbo withdrawal") in narcotic dependence. Changes in withdrawal treatment--wishes and reality] Dettling M, et al. **Nervenarzt** 1996 Sep;67(9):805–10 **(Ger)**
[Effect of locally applied lidocaine on expression of the oculocardiac reflex] Ruta U, et al. **Ophthalmologe** 1997 May;94(5):354–9 (Eng. Abstr.) **(Ger)**
[Pre-anesthesiologic preparation for urologic operations. I: Screening for anesthesia] Wilhelm W, et al. **Urologe A** 1996 Sep;35(5):W427–36 (0 ref.) **(Ger)**
[Anesthesiologic preparation for urologic operations. II: Procedure in concomitant diseases] Wilhelm W, et al.
Urologe A 1996 Nov;35(6):497–510 (10 ref.) **(Ger)**
[Intraoperative hypothermia: pathophysiology and clinical sequelae (see comments)] Kurz A.
Wien Klin Wochenschr 1997 Apr 25;109(8):261–9 (36 ref.) (Eng. Abstr.). Comment in: Wien Klin Wochenschr 1997 Apr 25;109(8):250–60. **(Ger)**
["Brother of sleep". The operating room and temperature (editorial; comment)] Lackner FX.
Wien Klin Wochenschr 1997 Apr 25;109(8):259–60. Comment on: Wien Klin Wochenschr 1997 Apr 25;109(8):261–9. **(Ger)**
[Severe protracted cholestasis after general anesthesia in a patient with Alagille syndrome] Müller C, et al.
Z Gastroenterol 1996 Dec;34(12):809–12 (Eng. Abstr.) **(Ger)**
[Combined caudal and general anesthesia in clubfoot surgery] Nelitz M, et al. **Z Orthop Ihre Grenzgeb** 1996 Nov–Dec; 134(6):537–40 (Eng. Abstr.) **(Ger)**
[Anesthetic management in pheochromocytoma] Strecker U, et al. **Zentralbl Chir** 1997;122(6):460–6 (44 ref.) (Eng. Abstr.) **(Ger)**
[Hepatobiliopancreatic surgery in patients over 70 years old: which anesthesia?] Barzoi G, et al. **Chir Ital** 1995;47(4):44–8 (Eng. Abstr.) **(Ita)**
[Difficult intubation in paediatric cardiac surgery. Significance of age. Association with Down's syndrome] Bevilacqua S, et al. **Minerva Anestesiol** 1996 Jul–Aug; 62(7–8):259–64 (Eng. Abstr.) **(Ita)**
[Mechanical ventilation with laryngeal mask in anesthesia. Personal experience] D'Apote AL. **Minerva Anestesiol** 1995 Jul–Aug;61(7–8):313–8 (Eng. Abstr.) **(Ita)**
[Variations of esophageal temperature during general anesthesia with a low-flow circuit] Di Filippo A, et al. **Minerva Anestesiol** 1995 Sep;61(9):351–7 (Eng. Abstr.) **(Ita)**
[Artificial ventilation in children during anesthesia] Marraro G, et al. **Minerva Anestesiol** 1996 Apr;62(4):131–6 (12 ref.) (Eng. Abstr.) **(Ita)**
[The laryngeal mask in pediatric anesthesia] Piana R, et al. **Minerva Anestesiol** 1996 Jan–Feb;62(1–2):17–23 (Eng. Abstr.) **(Ita)**
[Use of the laryngeal mask in general anesthesia. Clinical experience] Viviani M, et al. **Minerva Anestesiol** 1996 Nov; 62(11):349–55 (Eng. Abstr.) **(Ita)**
[Evaluation of percutaneous microwave hepatic tumor coagulation therapy (PMTC) under general anesthesia from viewpoint of quality of life (QOL)] Niinobu T, et al.
Gan To Kagaku Ryoho 1996 Sep;23(11):1600–2 (Eng. Abstr.) **(Jpn)**
[A child of malignant lymphoma diagnosed by transbronchial aspiration cytology under general anesthesia with a laryngeal mask] Sakurada A, et al. **Kyobu Geka** 1997 Jul; 50(7):585–8 (Eng. Abstr.) **(Jpn)**
[Bacterial contamination of anesthesiologists' hands and the efficacy of handwashing] Fukada T, et al. **Masui** 1996 Aug; 45(8):1026–30 (Eng. Abstr.) **(Jpn)**
[Importance of instructing anesthesiologists in handwashing against bacterial contamination] Fukada T, et al. **Masui** 1997 Apr;46(4):552–5 (Eng. Abstr.) **(Jpn)**
[Pediatric fiberoptic bronchoscopy via the laryngeal mask airway] Fukushima Y, et al. **Masui** 1996 Dec; 45(12):1519–24 (Eng. Abstr.) **(Jpn)**
[Prolonged neuromuscular blockade with vecuronium in patient with triple pregnancy treated with magnesium sulfate] Hino H, et al. **Masui** 1997 Feb;46(2):266–70 (Eng. Abstr.) **(Jpn)**
[Anesthetic management of a patient with dilated cardiomyopathy] Kadoi Y, et al. **Masui** 1996 Aug; 45(8):1002–4 (Eng. Abstr.) **(Jpn)**
[Post dural puncture headache (PDPH) which occurred after the removal of an epidural catheter] Kaetsu H, et al.
Masui 1996 Oct;45(10):1285–8 (Eng. Abstr.) **(Jpn)**
[Placental transfer of vecuronium administered with priming principle regimen in patients undergoing cesarean section] Kaneko T, et al. **Masui** 1997 Jun;46(6):750–4 (Eng. Abstr.) **(Jpn)**
[Anesthetic management for a patient with pure autonomic failure] Kida K, et al. **Masui** 1997 Jun;46(6):813–7 (Eng. Abstr.) **(Jpn)**
[Does the difference in anesthetic methods influence postoperative nitrogen balance?] Kim C. **Masui** 1996 Feb; 45(2):215–22 (Eng. Abstr.) **(Jpn)**
[Difficult tracheal intubation and abnormal response to thiopental in a patient with arthrogryposis multiplex congenita] Kimura F, et al. **Masui** 1996 Aug;45(8):1022–5 (Eng. Abstr.) **(Jpn)**
[Evaluation of postoperative hypoxemia with a pulse oximeter] Kobayashi Y, et al. **Masui** 1996 Feb;45(2):183–8 (Eng. Abstr.) **(Jpn)**
[Anesthetic problems in a very low birth weight infant with Kasabach-Merritt syndrome] Mizushima A, et al. **Masui** 1996 Aug;45(8):1009–14 (Eng. Abstr.) **(Jpn)**
[Drug-induced laryngospasm] Nishikawa T, et al. **Masui** 1997 Feb;46(2):276–8 (Eng. Abstr.) **(Jpn)**
[Usefulness of alpha 2-adrenoceptor agonists and practical problems associated with their use in clinical anesthesia--1. Premedication, anesthetic adjuvants, and hemodynamic effects] Nishikawa T, et al. **Masui** 1996 Dec; 45(12):1490–502 (113 ref.) (Eng. Abstr.) **(Jpn)**
[Anesthetic management using transesophageal

echocardiography during removal of a cardiac myxoma] Nomura T, et al. **Masui** 1997 May;46(5):684–8 (Eng. Abstr.) **(Jpn)**

[Anesthetic management for AICD (automatic implantable cardioverter defibrillator) implant surgery] Ohnishi Y, et al. **Masui** 1996 Feb;45(2):239–43 (Eng. Abstr.) **(Jpn)**

[Emergency internal carotid artery ligation using near infrared spectroscopy] Saitoh K, et al. **Masui** 1996 Aug; 45(8):1015–7 (Eng. Abstr.) **(Jpn)**

[Cerebral blood volume, cerebral hemoglobin and cytochrome AA3 during hypotension induced by prostaglandin E1 or epidural anesthesia under general anesthesia] Shinohara M, et al. **Masui** 1996 Aug;45(8):961–6 (Eng. Abstr.) **(Jpn)**

[Anesthesia for a patient with HELLP syndrome] Takahashi H, et al. **Masui** 1996 Nov;45(11):1380–3 (Eng. Abstr.) **(Jpn)**

[Rhabdomyolysis induced by succinylcholine chloride and sevoflurane in an elderly man] Takamatsu F, et al. **Masui** 1996 Nov;45(11):1406–9 (Eng. Abstr.) **(Jpn)**

[Tizanidine for preanesthetic medication] Takenaka M, et al. **Masui** 1996 Aug;45(8):971–5 (Eng. Abstr.) **(Jpn)**

[Anesthesia for a patient with severe aplastic anemia] Tanaka M, et al. **Masui** 1996 Jul;45(7):865–8 (Eng. Abstr.) **(Jpn)**

[Surgical stress and the suppression] Tanaka Y, et al. **Masui** 1996 Dec;45 Suppl:S56–67 **(Jpn)**

[A patient who manifested various symptoms following severe accidental hypercapnia] Yano M. **Masui** 1996 Sep; 45(9):1140–4 (Eng. Abstr.) **(Jpn)**

[Tonsillectomy in a boy liver transplant] Yamaguchi K, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Feb;99(2):314–19 (Eng. Abstr.) **(Jpn)**

[Anesthesia during the past 150 years—where are we aiming now?] Gisvold SE. **Tidsskr Nor Laegeforen** 1996 Oct 20; 116(25):3032–4 **(Nor)**

[Combined general anesthesia using moradol in children] Agzamkhodzhaev TS, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):39–41 (Eng. Abstr.) **(Rus)**

[Induction anesthesia with fluothane and calipsol in children] Babaev BD, et al. **Anesteziol Reanimatol** 1996 Nov–Dec; (6):41–3 (Eng. Abstr.) **(Rus)**

[State of the hypophyseal–adrenal system during surgical correction of heart defects under various anesthesiological methods and at distant periods after surgery] Litasova EE, et al. **Anesteziol Reanimatol** 1997 Mar–Apr;(2):33–6 (Eng. Abstr.) **(Rus)**

[The initial experience of using Celeston in anesthesia and resuscitation practice] Malyshev VD, et al. **Anesteziol Reanimatol** 1996 May–Jun;(3):46–8 **(Rus)**

[Assessment of central hemodynamics during long microsurgical interventions using beforal in children] Medvedeva EA, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):43–4 (Eng. Abstr.) **(Rus)**

[General anesthesia in minor surgical interventions in children] Ostreĭkov IF, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):45–8 (Eng. Abstr.) **(Rus)**

[Anesthesia in surgery involving blood loss of different volume in children] Stepanova NA, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):35–8 (Eng. Abstr.) **(Rus)**

[Anesthetic agents and visual evoked potentials in patients undergoing transphenoidal or breast reconstruction surgery] Damiani Cavero S, et al. **Neurologia** 1997 Feb; 12(2):51–5 (Eng. Abstr.) **(Spa)**

[The need for alfentanyl in total intravenous anesthesia. Comparison between laparoscopic cholecystectomy and subcostal laparotomy] Figueredo–Gaspari E, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):103–7 (Eng. Abstr.) **(Spa)**

[Anesthetic management in unilateral lung transplantation] Lluch M, et al. **Rev Esp Anestesiol Reanim** 1996 Jun–Jul; 43(6):212–5 (Eng. Abstr.) **(Spa)**

[Anesthetic treatment of periodic familial hypokalemic paralysis. Report of a case] Martínez de Guereñu A, et al. **Rev Esp Anestesiol Reanim** 1996 May;43(5):185–6 (Eng. Abstr.) **(Spa)**

[Impact of anesthetic technic (general anesthesia versus intradural anesthesia) on the immune status] Muriel C, et al. **Rev Esp Anestesiol Reanim** 1996 May;43(5):164–6 (Eng. Abstr.) **(Spa)**

[Thoracic epidural anesthesia combined with general anesthesia with propofol for thymectomy in myasthenia gravis (letter)] Quintana–Villamandos B, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):130 **(Spa)**

[Total intravenous anesthesia with propofol in orthotopic liver transplantation in swine] Ramírez A, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):98–102 (Eng. Abstr.) **(Spa)**

[Quantification of dehydration of soda lime in clinical circumstances] Soro–Domingo M, et al. **Rev Esp Anestesiol Reanim** 1997 May;44(5):186–90 (Eng. Abstr.) **(Spa)**

[Anesthetic implications of amyloidosis (letter)] Suárez–Delgado JM, et al. **Rev Esp Anestesiol Reanim** 1996 Dec;43(10):380 **(Spa)**

[Narcosis 150 years ago and today. High efficiency for general anesthesia] Jonsson L. **Lakartidningen** 1996 Oct 30; 93(44):3897–902 **(Swe)**

[Euthanasia or long–term anesthesia? (letter; comment)] Lindqvist B. **Lakartidningen** 1997 May 21;94(21):1972. Comment on: Lakartidningen 1997 Mar 12;94(11):926, 931–2. **(Swe)**

[Revised guidelines on fasting prior to anesthesia: now is the patient allowed to drink. Swedish Society of Anesthesiology] Sandin R, et al. **Lakartidningen** 1997 Apr 9;94(15):1380–1 **(Swe)**

ADVERSE EFFECTS

Atelectasis and pulmonary shunting during induction of general anaesthesia—can they be avoided? Rothen HU, et al. **Acta Anaesthesiol Scand** 1996 May;40(5):524–9

Cerebral dysfunction after anaesthesia. Møller JT. **Acta Anaesthesiol Scand Suppl** 1997;110:13–6

New pharmacological aspects of postoperative nausea and vomiting (PONV). Tolksdorf W. **Acta Anaesthesiol Scand Suppl** 1996;109:168–70

A child of suspected malignant hyperthermia during general anesthesia for dental surgery. Chen LW, et al. **Acta Anaesthesiol Sin** 1996 Sep;34(3):167–71

Effect of anesthesia on cerebral tissue oxygen and cardiopulmonary parameters in rats. Liu KJ, et al. **Adv Exp Med Biol** 1997;411:33–9

The role of irrigation in the development of hypothermia during laparoscopic surgery. Moore SS, et al. **Am J Obstet Gynecol** 1997 Mar;176(3):598–602

Complete heart block during laparotomy under combined thoracic epidural and general anaesthesia. Ng KP. **Anaesth Intensive Care** 1996 Apr;24(2):257–60

Anaesthesia for simple exodontia in the dental chair [letter; comment] Bricker SR. **Anaesthesia** 1997 May;52(5):507–8 . Comment on: Anaesthesia 1996 Jul;51(7):713. Comment on: Anaesthesia 1997 Jan;52(1):89.

The airways and anaesthesia II. Pathophysiology. Burwell DR, et al. **Anaesthesia** 1996 Oct;51(10):943–54 (108 ref.)

Postanesthetic polyuria attributable to central diabetes insipidus. Otsuka F, et al. **Anesth Analg** 1997 Oct; 85(4):940–3

Small–dose propofol by continuous infusion does not prevent postoperative vomiting in females undergoing outpatient laparoscopy. Scuderi PE, et al. **Anesth Analg** 1997 Jan; 84(1):71–5

Fatal acute myocardial infarction during general anesthesia in a 7–yr–old boy associated with total intramural coronary arteries. Iwama H, et al. **Anesthesiology** 1997 Aug; 87(2):426–9

Hemodynamic response to anesthesia and pneumoperitoneum in orthotopic cardiac transplant recipients [see comments] Joshi GP, et al. **Anesthesiology** 1996 Oct;85(4):929–33. Comment in: Anesthesiology 1997 Jun;86(6):1425–7.

Assessment of low–flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity [see comments] Kharasch ED, et al. **Anesthesiology** 1997 Jun;86(6):1238–53. Comment in: Anesthesiology 1997 Jun;86(6):1225–7.

Association between latex sensitization and repeated latex exposure in children. Porri F, et al. **Anesthesiology** 1997 Mar;86(3):599–602

Dental injuries during general anaesthesia [see comments] Chadwick RG, et al. **Br Dent J** 1996 Apr 6;180(7):255–8 (21 ref.). Comment in: Br Dent J 1996 Jul 6;181(1):11.

Failed tracheal intubation [letter; comment] Norman B. **Br J Anaesth** 1996 Oct;77(4):559. Comment on: Br J Anaesth 1996 May;76(5):680–4.

Body temperature control and anaesthesia. Desborough JP. **Br J Hosp Med** 1997 May 7–20;57(9):440–2 (14 ref.)

Clonidine at induction reduces shivering after general anaesthesia. Buggy D, et al. **Can J Anaesth** 1997 Mar; 44(3):263–7

The LMA for the application of postoperative CPAP [letter] Glaisyer HR, et al. **Can J Anaesth** 1997 Jul;44(7):784–5

Components of the blood acid–base disturbance that accompanies urethane anaesthesia in rats during normothermia and hypothermia. Alfaro V, et al. **Clin Exp Pharmacol Physiol** 1997 Jul;24(7):498–502

Use of epidural anesthesia and spontaneous ventilation during transabdominal colon and rectal procedures in selected high–risk patient groups. Kolker AR, et al. **Dis Colon Rectum** 1997 Mar;40(3):339–43

Post–operative central anticholinergic syndrome [editorial] Cook B, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):1–2

Distinct central anticholinergic syndrome following general anaesthesia. Link J, et al. **Eur J Anaesthesiol** 1997 Jan; 14(1):15–23

General anaesthesia versus cervical block and perioperative complications in carotid artery surgery. Fiorani P, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):37–42

Suppression of cytokine–induced neutrophil accumulation in rat mesenteric venules in vivo by general anesthesia. Miller LS, et al. **Int J Microcirc Clin Exp** 1996 May–Jun; 16(3):147–54

Effects of regional anesthesia on perioperative outcome. Atanassoff PG. **J Clin Anesth** 1996 Sep;8(6):446–55 (106 ref.)

Cardiovascular collapse during anesthesia in a patient with preoperatively discontinued chronic MAO inhibitor therapy. Sprung J, et al. **J Clin Anesth** 1996 Dec;8(8):662–5

Patient awareness during general anesthesia: a shocking outcome. Watkins–Pitchford M, et al. **J Clin Monit** 1997 Jan;13(1):51–2

Morbidity and mortality with outpatient anesthesia: the experience of a residency training program. Hunter MJ, et al. **J Oral Maxillofac Surg** 1997 Jul;55(7):684–7; discussion 687–8

The effect of a 4–mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery. Rodrigo C, et al. **J Oral Maxillofac Surg** 1996 Oct;54(10):1171–5

Surgery and the tiny baby: sensorineural outcome at 5 years of age. The Victorian Infant Collaborative Study Group. **J Paediatr Child Health** 1996 Apr;32(2):167–72

Sudden sensorineural hearing loss after general anesthesia for nonotologic surgery. Evan KE, et al. **Laryngoscope** 1997 Jun;107(6):747–52 (40 ref.)

Fluctuations in serum magnesium levels during total intravenous anaesthesia with propofol. Nastou H, et al. **Magnes Res** 1996 Mar;9(1):47–53

Masseter muscle rigidity and nondepolarizing neuromuscular blocking agents. Albrecht A, et al. **Mayo Clin Proc** 1997 Apr;72(4):329–32

Mild perioperative hypothermia. Sessler DI. **N Engl J Med** 1997 Jun 12;336(24):1730–7 (60 ref.)

Anaesthetic management of children with Joubert syndrome. Habre W, et al. **Paediatr Anaesth** 1997;7(3):251–3

Regurgitation and aspiration of gastric contents in a child during general anaesthesia using the laryngeal mask airway. Ismail–Zade IA, et al. **Paediatr Anaesth** 1996;6(4):325–8

Perioperative considerations in a newly described subtype of congenital long QT syndrome. Joseph–Reynolds AM, et al. **Paediatr Anaesth** 1997;7(3):237–41 (25 ref.)

Neonatal cleft lip repair: a retrospective review of anaesthetic complications. Stephens P, et al. **Paediatr Anaesth** 1997; 7(1):33–6

Rhabdomyolysis and anesthesia: a report of two cases and review of the literature. Pedrozzi NE, et al. **Pediatr Neurol** 1996 Oct;15(3):254–7 (52 ref.)

Masked mischief. Bromage PR. **Reg Anesth** 1996 Nov–Dec; 21(6 Suppl):62–3 (6 ref.)

Pulmonary microvascular injury following general anaesthesia with volatile anaesthetics—halothane and isoflurane: a comparative clinical and experimental study. Gunaydin B, et al. **Respir Med** 1997 Jul;91(6):351–60

Anaesthetic complications in the recovery room [see comments] Norsidah AM, et al. **Singapore Med J** 1997 May; 38(5):200–4. Comment in: Singapore Med J 1997 May;38(5):190–1.

Platelet functions and haemostasis parameters in pigs: absence of side effects of a procedure of general anaesthesia. Roussi J, et al. **Thromb Res** 1996 Feb 1;81(3):297–305

[Angiotensin–converting enzyme inhibitors and anesthesia] Larsen JK, et al. **Ugeskr Laeger** 1996 Oct 21;158(43):6081–4 (Eng. Abstr.) **(Dan)**

[Duchenne muscular dystrophy and anesthesia. A retrospective study] Petersen CT, et al. **Ugeskr Laeger** 1996 Oct 28;158(44):6274–6 (Eng. Abstr.) **(Dan)**

[Awareness anesthesia—an anesthesiologic dilemma] Schierbeck J, et al. **Ugeskr Laeger** 1997 Jun 2; 159(23):3567–71 (38 ref.) (Eng. Abstr.) **(Dan)**

[Sleep apnea and anesthesia] Lindgren L. **Duodecim** 1995; 111(12):1131–3 (17 ref.) **(Fin)**

[Sedation and sleep induction instead of anesthesia in infants and young children during CT and MRI examinations] Weisenbach J, et al. **Orv Hetil** 1996 Mar 24;137(12):629–32 (Eng. Abstr.) **(Hun)**

[Transitory swelling of a parotid gland following general anesthesia. Description of a case] Valenti M, et al. **Minerva Anestesiol** 1995 Sep;61(9):393–5 (Eng. Abstr.) **(Ita)**

[Aspiration pneumonia during the endotracheal intubation on the occasion of bladder perforation by TUR] Fukuhara H, et al. **Masui** 1997 Mar;46(3):384–7 (Eng. Abstr.) **(Jpn)**

[Hypertension in general anesthesia] Koyama T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):114–7 (20 ref.) **(Jpn)**

[The risk of surgical treatment in elderly patients] Swiątkowski J. **Pol Merkuriusz Lek** 1996 Oct;1(4):261–3 (Eng. Abstr.) **(Pol)**

[Comparative characterization of damaging mental effect of general anesthesia using fluothane and ketamine in surgery of the face in children with congenital facial and palatal clefts] Egorov VM, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):31–3 (Eng. Abstr.) **(Rus)**

[Pneumothorax during anesthesia complicating needle aspiration of microcalcifications in the breast. Presentation of a case] Flo A, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):161 **(Spa)**

CONTRAINDICATIONS

Effect of an upper respiratory tract infection on upper airway reactivity. Nandwani N, et al. **Br J Anaesth** 1997 Apr; 78(4):352–5

Clinical significance of methohexital, meperidine, and diazepam in breast milk. Borgatta L, et al. **J Clin Pharmacol** 1997 Mar;37(3):186–92

[Are there contraindications for anesthesia in laparoscopic surgery? (editorial)] Duvaldestin P. **J Chir (Paris)** 1996; 133(8):355 **(Fre)**

ECONOMICS

Knee arthroscopy: a cost analysis of general and local anesthesia. Trieshmann HW Jr. **Arthroscopy** 1996 Feb; 12(1):60–3

A comparison of the cost of local versus general anesthesia for laparoscopic sterilization in an operating room setting. Lipscomb GH, et al. **J Am Assoc Gynecol Laparosc** 1996

Feb;3(2):277–81

[Cost effectiveness of local regional anesthesia in a remote area] Faisy C, et al. **Med Trop (Mars)** 1996;56(4):367–72 (Eng. Abstr.) **(Fre)**

[Economic control in anesthesia and intensive care medicine—do we need new muscle relaxants? Pro] Diefenbach C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Feb; 31(1):44–5 **(Ger)**

[Economic control in anesthesia and intensive care medicine—do we need new muscle relaxants? Contra] Plötz J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Feb;31(1):42–3 **(Ger)**

HISTORY

The successful introduction of general anaesthesia [letter] Conacher ID. **Lancet** 1997 Jan 25;349(9047):290

Paediatric anaesthesia in Australia: origins and developments. Cass NM, et al. **Paediatr Anaesth** 1996;6(1):69–78

Triumph over pain: the discovery of surgical anesthesia. Anderson EF. **S D J Med** 1996 Oct;49(10):369–72

[The 16th October 1846 and its outcome] Röse W. **Anaesthesiol Reanim** 1996;21(6):144–8 (Eng. Abstr.) **(Ger)**

[The recommendation by Menzel in 1877 for statistical assessment of anesthesia performance] Röse W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):432–3 **(Ger)**

[Maria Oliveras: pioneer of neuroanesthesia in Catalonia] Unzueta-Merino MC, et al. **Rev Esp Anestesiol Reanim** 1996 Dec;43(10):360–3 (Eng. Abstr.) **(Spa)**

[Malignant hyperthermia. History of a serious complication after general anesthesia (see comments)] Appelgren LK. **Lakartidningen** 1997 Feb 12;94(7):534, 539–44. Comment in: Lakartidningen 1997 May 21;94(21):1972. **(Swe)**

[The 150th anniversary of narcosis. An intoxicating, varied and noisy time] Appelgren LK. **Lakartidningen** 1996 Nov 6;93(45):4004, 4007–8 **(Swe)**

INSTRUMENTATION

Adult face mask for neonatal anaesthesia and resuscitation [letter] Chan YW. **Anaesthesia** 1997 Aug;52(8):807

Personnel and facilities for electroconvulsive therapy [letter; comment] Farnsworth G. **Anaesthesia** 1996 Dec; 51(12):1189. Comment on: Anaesthesia 1996 Jun;51(6):583–4.

Syringes and latex allergy [letter] Rao AM, et al. **Anaesthesia** 1997 May;52(5):506

Comparison of cuffed and uncuffed endotracheal tubes in young children during general anesthesia. Khine HH, et al. **Anesthesiology** 1997 Mar;86(3):627–31; discussion 27A

The reinforced laryngeal mask airway for dento-alveolar surgery. Quinn AC, et al. **Br J Anaesth** 1996 Aug; 77(2):185–8

The Humphrey ADE block [letter; comment] Milner Q. **Trop Doct** 1997 Jul;27(3):190–1. Comment on: Trop Doct 1995;25 Suppl 1:34–9.

[Evaluation of the usefulness of the laryngeal mask for general anesthesia in eye microsurgery—preliminary results] Poloch A, et al. **Klin Oczna** 1996 Jan;98(1):45–9 (Eng. Abstr.) **(Pol)**

METHODS

Assessment of anaesthesia depth. Heier T, et al. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1087–100 (186 ref.)

A comparison of the nasal mask and the nasopharyngeal airway in paediatric chair dental anaesthesia. Bagshaw ON, et al. **Anaesthesia** 1997 Aug;52(8):786–9

Local or general anaesthesia for cataract surgery [letter; comment] Denha RF, et al. **Anaesthesia** 1996 Dec; 51(12):1191–2. Comment on: Anaesthesia 1996 May;51(5):435–7.

Anaesthetic management of childhood thyrotoxicosis and the use of esmolol. Knighton JD, et al. **Anaesthesia** 1997 Jan; 52(1):67–70

Central airway compression. Anaesthetic and intensive care consequences. McMahon CC, et al. **Anaesthesia** 1997 Feb; 52(2):158–62

Anaesthesia in a patient with Conradi's disease [letter] Pandit JJ, et al. **Anaesthesia** 1996 Oct;51(10):992–3

A comparison of remifentanil and alfentanil in patients undergoing major abdominal surgery [see comments] Schüttler J, et al. **Anaesthesia** 1997 Apr;52(4):307–17. Comment in: Anaesthesia 1997 Apr;52(4):291–3.

Anaesthesia for laparoscopic cholecystectomy in myasthenia gravis: a non-muscle relaxant technique [letter] Tortosa JA, et al. **Anaesthesia** 1997 Aug;52(8):807–8

Rapid atrial pacing for detecting provokable demand ischemia in anesthetized patients [see comments] Seeberger MD, et al. **Anesth Analg** 1997 Jun;84(6):1180–5. Comment in: Anesth Analg 1997 Jun;84(6):1177–9.

Effects of low-flow sevoflurane anesthesia on renal function: comparison with high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia [see comments] Bito H, et al. **Anesthesiology** 1997 Jun;86(6):1231–7. Comment in: Anesthesiology 1997 Jun;86(6):1225–7.

Recovery of consciousness after thiopental or propofol. Bispectral index and isolated forearm technique. Flaishon R, et al. **Anesthesiology** 1997 Mar;86(3):613–9

Xenon provides faster emergence from anesthesia than does nitrous oxide–sevoflurane or nitrous oxide–isoflurane. Goto T, et al. **Anesthesiology** 1997 Jun;86(6):1273–8

Comparison of remifentanil and fentanyl in patients undergoing craniotomy for supratentorial space-occupying lesions. Guy J, et al. **Anesthesiology** 1997 Mar;86(3):514–24

Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity [see comments] Kharasch ED, et al. **Anesthesiology** 1997 Jun;86(6):1238–53. Comment in: Anesthesiology 1997 Jun;86(6):1225–7.

Comparison of cuffed and uncuffed endotracheal tubes in young children during general anesthesia. Khine HH, et al. **Anesthesiology** 1997 Mar;86(3):627–31; discussion 27A

Sevoflurane inhalation induction for emergency cesarean section in a parturient with no intravenous access. Schaut DJ, et al. **Anesthesiology** 1997 Jun;86(6):1392–4

Reduction in the incidence of carbon monoxide exposures in humans undergoing general anesthesia [see comments] Woehlck HJ, et al. **Anesthesiology** 1997 Aug;87(2):228–34 . Comment in: Anesthesiology 1997 Aug;87(2):202–3.

Tubeless spontaneous respiration technique for pediatric microlaryngeal surgery. Quintal MC, et al. **Arch Otolaryngol Head Neck Surg** 1997 Feb;123(2):209–14

Unrecognized "crack" cocaine abuse in pregnancy. Campbell D, et al. **Br J Anaesth** 1996 Oct;77(4):553–5

Congenital heart disease in adults. Findlow D, et al. **Br J Anaesth** 1997 Apr;78(4):416–30 (130 ref.)

Thorascopic sympathectomy in the treatment of palmar hyperhidrosis: anaesthetic implications. Fredman B, et al. **Br J Anaesth** 1997 Jul;79(1):113–9 (55 ref.)

Orthotopic liver transplantation in two patients with hypertrophic obstructive cardiomyopathy. Harley ID, et al. **Br J Anaesth** 1996 Nov;77(5):675–7

Anaesthetic management of a patient with an automatic implantable cardioverter defibrillator in situ. Kam PC. **Br J Anaesth** 1997 Jan;78(1):102–6

General anaesthesia for caesarean section in a parturient with Noonan's syndrome. McLure HA, et al. **Br J Anaesth** 1996 Nov;77(5):665–8

Influence of induction technique on intubating conditions after rocuronium in adults: comparison with rapid-sequence induction using thiopentone and suxamethonium. Sparr HJ, et al. **Br J Anaesth** 1996 Sep; 77(3):339–42

General anaesthesia of a bullous pemphigoid patient [letter] Yaniv R, et al. **Can J Anaesth** 1996 Nov;43(11):1181

Initial experience with implantation of internal cardioverter/defibrillators under local anaesthesia by electrophysiologists. Schmitt C, et al. **Eur Heart J** 1996 Nov;17(11):1710–6

Safe and simple, an alternative technique for anaesthesia during magnetic resonance imaging (MRI) [letter; comment] ten Broecke P, et al. **Eur J Anaesthesiol** 1997 May;14(3):343–5. Comment on: Eur J Anaesthesiol 1996 Jul;13(4):400–3.

One-lung ventilation in a patient with a fresh tracheostomy using the tracheostomy tube and a Univent endobronchial blocker [letter] Dhamee MS. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):124–5

General or topical anesthesia? [letter] Hayashi JD. **J Cataract Refract Surg** 1997 Jun;23(5):696–7

Comparison of general anesthesia and intravenous sedation-analgesia for SWL. Zommick J, et al. **J Endourol** 1996 Dec;10(6):489–91

Prolonged general anesthesia for experimental craniofacial surgery in fetal swine. Sims CD, et al. **J Invest Surg** 1997 Jan-Apr;10(1-2):53–7

General anesthesia using the laryngeal mask airway during brief, laparoscopic inspection of the peritoneum in children. Tobias JD, et al. **J Laparoendosc Surg** 1996 Jun;6(3):175–80

Desflurane for outpatient general anesthesia in third molar extraction cases. Bandrowsky T, et al. **J Oral Maxillofac Surg** 1997 Feb;55(2):129–32; discussion 132–3

Evaluation of five agents/methods for anesthesia of neonatal rats. Danneman PJ, et al. **Lab Anim Sci** 1997 Aug; 47(4):386–95

Severe neck burns and laryngeal mask airway for frequent general anesthetics. Karam R, et al. **Middle East J Anesthesiol** 1996 Jun;13(5):527–35

Anaesthesia for Hecht Beals syndrome [letter] Geva D, et al. **Paediatr Anaesth** 1997;7(2):178–9

Anaesthetic management of children with Joubert syndrome. Habre W, et al. **Paediatr Anaesth** 1997;7(3):251–3

Spinal-epidural-general anesthesia [letter; comment] Alam S. **Reg Anesth** 1996 Nov-Dec;21(6):608–9. Comment on: Reg Anesth 1994 Sep-Oct;19(5):365–6.

Effectiveness and safety of combined epidural and general anesthesia for laparoscopic cholecystectomy. Luchetti M, et al. **Reg Anesth** 1996 Sep-Oct;21(5):465–9

Anesthetic management of a parturient with an incompletely resected cerebral arteriovenous malformation. Viscomi CM, et al. **Reg Anesth** 1997 Mar-Apr;22(2):192–7

Anesthetic regimen effects on a pediatric porcine model of asphyxial arrest. Jasani MS, et al. **Resuscitation** 1997 Aug; 35(1):69–75

General anaesthesia for cleft lip and palate surgery team activities in Cambodia. Ishizawa Y, et al. **Trop Doct** 1997 Jul;27(3):153–5

[Gynecologic laparoscopy with or without curare] Chassard D, et al. **Ann Fr Anesth Reanim** 1996;15(7):1013–7 (Eng. Abstr.) **(Fre)**

[Anesthetic problems of epidermolysis bullosa dystrophica. Apropos of a case] Gozal Y, et al. **Can Anesthesiol** 1996; 44(4):361–3 (Eng. Abstr.) **(Fre)**

[Clinical study of a mivacurium-propofol combination for laparoscopic surgery in children] Hermonville E, et al. **Can Anesthesiol** 1996;44(3):261–5 (Eng. Abstr.) **(Fre)**

[Protective efficacy of 3 anesthetic methods with reference to surgical stress in children] Ivani G, et al. **Can Anesthesiol** 1996;44(4):297–302 (Eng. Abstr.) **(Fre)**

[Anesthesia for magnetic resonance tomography in neonates, infants and young children] Funk W, et al. **Radiologe** 1997 Feb;37(2):159–64 (10 ref.) (Eng. Abstr.) **(Ger)**

[General anesthesia in Prader-Willi syndrome] Cavaliere F, et al. **Minerva Anestesiol** 1996 Oct;62(10):327–32 (Eng. Abstr.) **(Ita)**

[Anesthesiologic problems in patients with Launois-Bensaude-Madelung disease. Clinical case] Da Broi U, et al. **Minerva Anestesiol** 1996 Oct;62(10):333–7 (Eng. Abstr.) **(Ita)**

[Anesthetic management of a patient with thymoma presenting superior vena cava syndrome] Furuya A, et al. **Masui** 1996 Jan;45(1):107–10 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a patient with erythroderma] Hattori S, et al. **Masui** 1996 Sep;45(9):1127–30 (Eng. Abstr.) **(Jpn)**

[Intra-operative management during laparotomy for patients under hemodialysis] Horibe M, et al. **Masui** 1996 Sep; 45(9):1135–9 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a pediatric patient with Cornelia de Lange syndrome] Nagai H, et al. **Masui** 1996 Jan; 45(1):99–101 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a patient complicated with restrictive cardiomyopathy for gastrectomy] Nishida T, et al. **Masui** 1996 Oct;45(10):1265–8 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a patient with tuberous sclerosis] Sugi Y, et al. **Masui** 1996 Feb;45(2):227–9 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of a patient with renal cell carcinoma extending into the right atrium] Tashiro T, et al. **Masui** 1996 Jul;45(7):861–4 (Eng. Abstr.) **(Jpn)**

[Perioperative management of a patient with bilateral renal cell cancer and large vena caval tumor thrombosis] Yokoyama T, et al. **Masui** 1996 Sep;45(9):1149–52 (Eng. Abstr.) **(Jpn)**

[Anesthesia in ophthalmology] Stefăniu I, et al. **Oftalmologia** 1996 Oct-Dec;40(4):340–8 (5 ref.) (Eng. Abstr.) **(Rum)**

[Anesthesia in interventions for diabetic cataract] Zolog I, et al. **Oftalmologia** 1996 Oct-Dec;40(4):389–92 (Eng. Abstr.) **(Rum)**

[General anesthesia with use of nubain and clopheline in myocardial revascularization surgery] Grishin VV, et al. **Anesteziol Reanimatol** 1996 Jul-Aug;(4):25–30 **(Rus)**

[The use of general anesthesia with Etran and a low flow of the medical gases during prolonged and traumatic operations] Likhvantsev VV, et al. **Anesteziol Reanimatol** 1996 May-Jun;(3):68–9 **(Rus)**

[Preoperative intensive therapy and surgical anesthesia for patients with diffuse toxic goiter] Neĭmark MI, et al. **Anesteziol Reanimatol** 1996 May-Jun;(3):38–40 **(Rus)**

[A system of individual psycho- and immunotherapy in neuroanesthesiological practice] Starchenko AA, et al. **Anesteziol Reanimatol** 1996 May-Jun;(3):53–7 (Eng. Abstr.) **(Rus)**

[The characteristics of the functional activity of cellular immunity factors in relation to the use of general anesthetics from different pharmacological groups in operations for optic nerve neurolysis] Starchenko AA, et al. **Anesteziol Reanimatol** 1996 May-Jun;(3):32–4 (Eng. Abstr.) **(Rus)**

[Preoperative care and anesthesia in patients with diffuse suppurative peritonitis] Ismailov IS, et al. **Khirurgiia (Mosk)** 1997;(3):42–4 **(Rus)**

[Anesthesia in 3 cases of Marfan's syndrome] Puebla G, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):30–4 (15 ref.) (Eng. Abstr.) **(Spa)**

[Anesthesia for thoracoscopy (see comments)] Unzueta MC, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):67–9 (Eng. Abstr.). Comment in: Rev Esp Anestesiol Reanim 1996 Oct;43(8):298–9. **(Spa)**

[Anesthesia in lung transplantation] Vicente R, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):23–9 (86 ref.) **(Spa)**

MORTALITY

Mortality incidence in outpatient anesthesia for dentistry in Ontario. Nkansah PJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jun;83(6):646–51

NURSING

General anesthesia and elderly surgical patients. Hazen SE, et al. **AORN J** 1997 Apr;65(4):815–9, 821–2

PSYCHOLOGY

Please tell children the truth [letter] Cartwright P. **Anaesthesia** 1996 Sep;51(9):895

Investigations of hypesthesia: using anesthetics to explore relationships between consciousness, learning, and memory. Andrade J. **Conscious Cogn** 1996 Dec;5(4):562–80 (42 ref.)

Memory during general anesthesia: practical and methodological aspects [see comments] Bonebakker AE,

et al. **Conscious Cogn** 1996 Dec;5(4):542–61. Comment in: Conscious Cogn 1996 Dec;5(4):525–41.
Memory for unconsciously perceived events: evidence from anesthetized patients [see comments] Merikle PM, et al. **Conscious Cogn** 1996 Dec;5(4):525–41. Comment in: Conscious Cogn 1996 Dec;5(4):542–61.
Parental presence during induction of anesthesia: the surgeon's perspective. Kain ZN, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):323–7
Effect of elective surgery under general anesthesia on mental status variables in elderly women and men: 10–month follow–up. Goldstein MZ, et al. **Int Psychogeriatr** 1996 Spring;8(1):135–49
Patient awareness during general anesthesia: a legal guide. Grinblat TS. **J Contemp Health Law Policy** 1996 Fall; 13(1):137–67
[Is the patient under general anesthesia able to process information? (editorial)] Moix Queraltó J. **Med Clin (Barc)** 1996 Oct 5;107(11):416–7 **(Spa)**

STANDARDS

Toward one standard of care: sedation of pediatric patients. Kingston F, et al. **J Pediatr Nurs** 1996 Feb;11(1):69–70

TRENDS

Failed intubation during obstetric anaesthesia [letter; comment] Jenkins JG. **Br J Anaesth** 1996 Nov;77(5):698. Comment on: Br J Anaesth 1996 May;76(5):680–4.

UTILIZATION

Is general anaesthesia necessary? [letter; comment] Girdler NM. **Br Dent J** 1996 Nov 9;181(9):319. Comment on: Br Dent J 1996 Jul 6;181(1):6–7. Comment on: Br Dent J 1996 Sep 7;181(5):165.
Is GA for orthodontic extractions in children necessary? [letter; comment] Healy A. **Br Dent J** 1996 Nov 9; 181(9):319. Comment on: Br Dent J 1996 Sep 7;181(5):165.
Is general anaesthesia really necessary? [letter; comment] Lee P. **Br Dent J** 1996 Nov 9;181(9):319. Comment on: Br Dent J 1996 Sep 7;181(5):165.
General anaesthesia [letter; comment] Taylor MS. **Br Dent J** 1996 Oct 19;181(8):284. Comment on: Br Dent J 1996 Jul 6;181(1):6–7.
The role of pre–general anaesthetic assessment for patients referred by general dental practitioners to the Community Dental Service. Landes DP, et al. **Community Dent Health** 1996 Sep;13(3):169–71
General anaesthesia in accident and emergency departments. Teale KF, et al. **J Accid Emerg Med** 1995 Dec;12(4):259–61

VETERINARY

Effects of additional premedication on romifidine and ketamine anaesthesia in horses. Marntell S, et al. **Acta Vet Scand** 1996;37(3):315–25
Physiologic effects of anesthesia induced and maintained by intravenous administration of a climazolam–ketamine combination in ponies premedicated with acepromazine and xylazine. Bettschart–Wolfensberger R, et al. **Am J Vet Res** 1996 Oct;57(10):1472–7
Induction and maintenance of anesthesia in dogs by intravenous administration of methohexital. Gentry WB, et al. **Am J Vet Res** 1996 Jul;57(7):1044–9
Cardiopulmonary and gastrointestinal motility effects of xylazine/ketamine–induced anesthesia in horses previously treated with glycopyrrolate. Singh S, et al. **Am J Vet Res** 1996 Dec;57(12):1762–70
Acute paraplegia in a thoroughbred racehorse after general anaesthesia. Raidal SR, et al. **Aust Vet J** 1997 Mar; 75(3):178–9
Ultrasonography of the equine triceps muscle before and after general anaesthesia and in post anaesthetic myopathy. Smith RK, et al. **Equine Vet J** 1996 Jul;28(4):311–9
Midazolam and ketamine induction before halothane anaesthesia in ponies: cardiorespiratory, endocrine and metabolic changes. Luna SP, et al. **J Vet Pharmacol Ther** 1997 Apr;20(2):153–9
A comparison between medetomidine–ketamine and medetomidine–propofol anaesthesia in rabbits. Hellebrekers LJ, et al. **Lab Anim** 1997 Jan;31(1):58–69
Evaluation of five agents/methods for anesthesia of neonatal rats. Danneman PJ, et al. **Lab Anim Sci** 1997 Aug; 47(4):386–95
General anesthetic techniques in ruminants [published erratum appears in Vet Clin North Am Food Anim Pract 1997 Mar;13(1):XI] Carroll GL, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):627–61 (125 ref.)
General anesthetic techniques in swine. Moon PF, et al. **Vet Clin North Am Food Anim Pract** 1996 Nov;12(3):663–91 (61 ref.)
Maintenance of anaesthesia in Equidae [letter] Johnston GM. **Vet Rec** 1997 Mar 22;140(12):319
A comparative study of medetomidine–butorphanol–ketamine and medetomidine–ketamine anaesthesia in dogs. Tomizawa N, et al. **Zentralbl Veterinarmed A** 1997 Jun;44(4):189–94
[Evaluation of the antinociceptive effect of xylazine after epidural administration in dogs under general anesthesia with isoflurane] Rector E, et al. **Berl Munch Tierarztl Wochenschr** 1997 Jan;110(1):15–23 (Eng. Abstr.) **(Ger)**
[Clinical investigations of an i.m. combination anesthesia with fentanylclimazolam/xylazine and postoperative i.v. antagonism with naloxone/sarmazenil/yohimbine in guinea pigs] Henke J, et al. **Tierarztl Prax** 1996 Feb;24(1):85–7 (Eng. Abstr.) **(Ger)**
[Total intravenous anesthesia (TIVA) with alphaxolon/alphadolon (Saffan) for permanent restraint of two cats with severe dyspnea] Tacke S. **Tierarztl Prax** 1996 Oct;24(5):484–8 (Eng. Abstr.) **(Ger)**
[Study of long–term anesthesia in rabbits] Troitzsch D, et al. **Tierarztl Prax** 1996 Oct;24(5):519–21 (Eng. Abstr.) **(Ger)**

ANESTHESIA, INFILTRATION see **ANESTHESIA, LOCAL**

ANESTHESIA, INHALATION

Anesthetic management of a patient combining myotonic dystrophy and obesity. Perilli V, et al. **Acta Anaesthesiol Belg** 1997;48(2):101–5
Effects of thoracic vs. lumbar epidural anaesthesia on systemic haemodynamics and coronary circulation in sevoflurane anaesthetized dogs. Hirabayashi Y, et al. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1127–31
The efficacy of clonidine for reducing perioperative haemodynamic changes and volatile anaesthetic requirements in children. Nishina K, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):746–51
The haemodynamic effects of rocuronium and vecuronium are different under balanced anaesthesia. Stevens JB, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):502–5
Inhalation vs. i.v. anesthesia and intensive care medicine. List WF. **Acta Anaesthesiol Scand Suppl** 1996;109:161–3
Anaesthesia and trisomy 3p syndrome [letter] Allen DL, et al. **Anaesth Intensive Care** 1996 Oct;24(5):615
Modification of the Benjamin Jet Tube [letter] Rechtman I. **Anaesth Intensive Care** 1997 Jun;25(3):309–10
Fatal hepatic necrosis following cardiac surgery and enflurane anaesthesia [letter; comment] Schneider M. **Anaesth Intensive Care** 1996 Apr;24(2):289. Comment on: Anaesth Intensive Care 1995 Dec;23(6):755–6.
The Mapleson breathing systems [letter; comment] Dorrington KL. **Anaesthesia** 1996 Oct;51(10):988. Comment on: Anaesthesia 1996 Apr;51(4):371–85.
Factors affecting neostigmine reversal of vecuronium block during sevoflurane anaesthesia. Morita T, et al. **Anaesthesia** 1997 Jun;52(6):538–43
Turbulence in the Magill and Lack breathing systems [letter; comment] Nott MR, et al. **Anaesthesia** 1996 Oct; 51(10):988–9. Comment on: Anaesthesia 1980 Apr;35(4):393–4.
Total intravenous anaesthesia with propofol or inhalational anaesthesia with isoflurane for major abdominal surgery. Recovery characteristics and postoperative oxygenation—an international multicentre study. Phillips AS, et al. **Anaesthesia** 1996 Nov;51(11):1055–9
Comparison of sufentanil/propofol versus isoflurane/nitrous oxide anaesthesia on mesenteric artery blood flow. Zwijsen JH, et al. **Anaesthesia** 1996 Nov;51(11):1060–3
Awakening, clinical recovery, and psychomotor effects after desflurane and propofol anesthesia. Apfelbaum JL, et al. **Anesth Analg** 1996 Oct;83(4):721–5
Immediate 8% sevoflurane induction in children: a comparison with incremental sevoflurane and incremental halothane. Baum VC, et al. **Anesth Analg** 1997 Aug; 85(2):313–6
Total airway obstruction by papillomas during induction of general anesthesia [see comments] Dalmeida RE, et al. **Anesth Analg** 1996 Dec;83(6):1332–4. Comment in: Anesth Analg 1997 Jun;84(6):1395–6.
Anesthetic and convulsant properties of aromatic compounds and cycloalkanes: implications for mechanisms of narcosis. Fang Z, et al. **Anesth Analg** 1996 Nov;83(5):1097–104
The effects of epidural fentanyl on hemodynamic responses during emergence from isoflurane anesthesia and tracheal extubation: a comparison with intravenous fentanyl. Inagaki Y, et al. **Anesth Analg** 1997 Aug;85(2):328–35
Single breath induction technique: comparison of sevoflurane and isoflurane [letter; comment] Lewis MC, et al. **Anesth Analg** 1996 Oct;83(4):890–1. Comment on: Anesth Analg 1996 Mar;82(3):528–32.
Laser Doppler skin blood flow and sympathetic nervous responses to surgical incision during halothane and isoflurane anesthesia. Mashimo T, et al. **Anesth Analg** 1997 Aug;85(2):291–8
Dobutamine infusion modifies thermoregulation during general anesthesia. Shitara T, et al. **Anesth Analg** 1996 Dec; 83(6):1154–9
Intramuscular atropine sulfate in children: comparison of injection sites. Sullivan KJ, et al. **Anesth Analg** 1997 Jan; 84(1):54–8
Sevoflurane depresses myocardial contractility less than halothane during induction of anesthesia in children. Holzman RS, et al. **Anesthesiology** 1996 Dec;85(6):1260–7
Sympathetic nervous system does not mediate reflex pupillary dilation during desflurane anesthesia. Larson MD, et al. **Anesthesiology** 1996 Oct;85(4):748–54
Sevoflurane degradation to compound A in anaesthesia breathing systems. Cunningham DD, et al. **Br J Anaesth** 1996 Oct;77(4):537–43
Absence of memory for intraoperative information during surgery under adequate general anaesthesia. Russell IF, et al. **Br J Anaesth** 1997 Jan;78(1):3–9
Low and minimal flow inhalational anaesthesia. Baxter AD. **Can J Anaesth** 1997 Jun;44(6):643–52; quiz 652–3
Pattern of ventilation during halothane anaesthesia in infants less than two months of age. Brown KA. **Can J Anaesth** 1996 Feb;43(2):121–8
Inhalation induction of anaesthesia [editorial] Goresky GV, et al. **Can J Anaesth** 1996 Nov;43(11):1085–9 **(Eng, Fre)**
Xenon is another laughing gas [letter] Kawaguchi T, et al. **Can J Anaesth** 1996 Jun;43(6):641–2
Echocardiographic assessment of left ventricular filling during isoflurane anaesthesia. Oxorn D, et al. **Can J Anaesth** 1996 Jun;43(6):569–74
Living related small bowel transplantation: anaesthesia and peri–operative care. Bellamy MC, et al. **Eur J Anaesthesiol** 1997 Jul;14(4):450–4
Deep halothane anaesthesia compared with halothane–suxamethonium anaesthesia for tracheal intubation in young children. Hansen D, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):29–34
Nitrous oxide reduces the cost of intravenous anaesthesia. Heath KJ, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):369–72
Anaesthesia during laparoscopic gynaecological surgery: a comparison between desflurane and isoflurane. Jakobsson J, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):148–52
Anaesthesia for children and infants undergoing magnetic resonance imaging: a prospective study [see comments] Young AE, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):400–3 . Comment in: Eur J Anaesthesiol 1997 May;14(3):343–5.
Ventilatory response to helium–oxygen breathing during exercise: effect of airway anesthesia. Krishnan BS, et al. **J Appl Physiol** 1997 Jul;83(1):82–8
Anesthesia for laser transmyocardial revascularization. Thrush DN. **J Cardiothorac Vasc Anesth** 1997 Jun; 11(4):481–4
Laryngotracheal anesthesia device as jet ventilation cannula for removal of fragmented intratracheal T–tube. Brown MM, et al. **J Clin Anesth** 1997 May;9(3):239–42
A phase III, multicenter, open–label, randomized, comparative study evaluating the effect of sevoflurane versus isoflurane on the maintenance of anesthesia in adult ASA class I, II, and III inpatients. Campbell C, et al. **J Clin Anesth** 1996 Nov;8(7):557–63
Priming with rocuronium accelerates the onset of neuromuscular blockade. Griffith KE, et al. **J Clin Anesth** 1997 May;9(3):204–7
Is management of anesthesia in achondroplastic dwarfs really a challenge? Monedero P, et al. **J Clin Anesth** 1997 May; 9(3):208–12
Removal of the laryngeal mask airway in children: deep anesthesia versus awake. Splinter WM, et al. **J Clin Anesth** 1997 Feb;9(1):4–7
Is intravenous lidocaine an effective adjuvant for endotracheal intubation in children undergoing induction of anesthesia with halothane–nitrous oxide? Warner LO, et al. **J Clin Anesth** 1997 Jun;9(4):270–4
Linear approximation of Brody's equation to predict oxygen consumption [letter; comment] Kennedy R. **J Clin Monit** 1996 Jan;12(1):111–2. Comment on: J Clin Monit 1995 May;11(3):165–7.
A study of electroencephalographic descriptors and end–tidal concentration in estimating depth of anesthesia. Muthuswamy J, et al. **J Clin Monit** 1996 Sep;12(5):353–64
Changes in cerebral blood flow velocity in children during sevoflurane and halothane anesthesia. Berkowitz RA, et al. **J Neurosurg Anesthesiol** 1996 Jul;8(3):194–8
Does sympathetic blockade prevent the physiologic changes associated with tourniquet use in children? Goodarzi M, et al. **J Pediatr Orthop** 1997 May–Jun;17(3):289–92
The anesthetic management of a patient with pemphigus vulgaris—a case report. Aktürk G, et al. **Middle East J Anesthesiol** 1997 Jun;14(2):91–7
Brain–stem auditory evoked potentials comparison between 1.3 and 1.5 MAC of isoflurane–nitrous oxide anesthesia. el–Dawlatly AA, et al. **Middle East J Anesthesiol** 1997 Jun;14(2):107–16
Comparison of laryngeal mask airway with endotracheal tube for airway control. Voyagis GS. **Middle East J Anesthesiol** 1997 Feb;14(1):25–31
Comparison of general and epidural anesthesia in patients undergoing primary unilateral THR. Brinker MR, et al. **Orthopedics** 1997 Feb;20(2):109–15
Anaesthetic management of a neonate with nesidioblastosis. Bellwoar C, et al. **Paediatr Anaesth** 1996;6(1):61–3 (12 ref.)
Anaesthesia in children with viral respiratory tract infections (Paediatric Anaesthesia 5: 257–262) [letter] Donnelly J. **Paediatr Anaesth** 1997;7(4):353–4
Anaesthetic management for Klippel–Trenaunay–Weber syndrome [letter] Ezri T, et al. **Paediatr Anaesth** 1996; 6(1):81–2
A comparison of sevoflurance to halothane in paediatric surgical patients: results of a multicentre international study. Kataria B, et al. **Paediatr Anaesth** 1996;6(4):283–92
Freeman–Sheldon (whistling face) syndrome. Anaesthetic and airway management. Munro HM, et al. **Paediatr Anaesth** 1997;7(4):345–8
Neuromuscular effects of rocuronium in children during halothane anaesthesia. Vuksanaj D, et al. **Paediatr Anaesth** 1996;6(4):277–81
Effects of intravenous mepivacaine on renal sympathetic

nerve activity in the cat during nitrous oxide and nitrous oxide–halothane anesthesia. Morimoto O, et al. **Reg Anesth** 1996 Jan–Feb;21(1):41–8

[Anesthesia with the laryngeal mask during the treatment of fractures of the nose. A study of a group of 53 patients] Villain M, et al. **Rev Stomatol Chir Maxillofac** 1997 Jan; 98(1):16–8 (Eng. Abstr.) **(Fre)**

[Serum cytokines and cytokine receptors in children after small or larger surgical interventions with halothane anesthesia] Burkhardt U, et al. **Anaesthesiol Reanim** 1997; 22(2):50–4 (Eng. Abstr.) **(Ger)**

[Comparison of the effect of desflurane and isoflurane on neuromuscular blockage with vecuronium on geriatric patients] Mielke VL, et al. **Anaesthesiol Reanim** 1996; 21(1):4–10 (Eng. Abstr.) **(Ger)**

[Critical evaluation of the new inhalational anesthetics desflurane and sevoflurane] Scholz J, et al. **Anaesthesiol Reanim** 1997;22(1):15–20 (39 ref.) (Eng. Abstr.) **(Ger)**

[Low-flow anesthesia with desflurane] Baum J, et al. **Anaesthesist** 1997 Apr;46(4):287–93 (Eng. Abstr.) **(Ger)**

[New inhalation anesthetics] Conzen P, et al. **Anaesthesist** 1996 Aug;45(8):674–93 (82 ref.) (Eng. Abstr.) **(Ger)**

[The effects of age on onset and recovery from atracurium, rocuronium and vecuronium blockade] de Almeida MC, et al. **Anaesthesist** 1996 Oct;45(10):903–6 (Eng. Abstr.) **(Ger)**

[The laryngeal mask--a valuable instrument for difficult intubation in children. Remarks on the work of R. Ofer and H. Dworzak. Anaesthesist (1996) 45:268–270 (letter; comment)] Erb T, et al. **Anaesthesist** 1997 Apr;46(4):362–3 . Comment on: Anaesthesist 1996 Mar;45(3):268–70. **(Ger)**

[The difficult intubation in adults. Remarks on the work of H. Langenstein and G. Cunitz Anaesthesist (1996) 45:372–383 (letter; comment)] Kiefer G. **Anaesthesist** 1997 Apr;46(4):364–5. Comment on: Anaesthesist 1996 Apr;45(4):372–83. **(Ger)**

[The effect of a heat and moisture exchanger (HME) on bronchial mucus transport in a closed inhalation anesthesia system] Konrad F, et al. **Anaesthesist** 1996 Sep;45(9):802–6 (Eng. Abstr.) **(Ger)**

[Safe handling of the laryngeal mask airway in eye surgery] Langenstein H, et al. **Anaesthesist** 1997 May;46(5):389–97 (Eng. Abstr.) **(Ger)**

[The effect of anesthetic method on enflurane air pollution in non-air conditioned operating rooms] Marx T, et al. **Anaesthesist** 1996 Dec;45(12):1167–70 (Eng. Abstr.) **(Ger)**

[Comparative study of the efficiency of bacterial filters in long-term mechanical ventilation (comment) (see comments)] Nielsen HJ, et al. **Anaesthesist** 1996 Sep; 45(9):814–8 (Eng. Abstr.). Comment on: Anaesthesist 1996 Sep;45(9):814–8. Comment in: Anaesthesist 1997 Jun;46(6):568–9. **(Ger)**

[Is reduction of intraoperative heat loss and management of hypothermic patients with anesthetic gas climate control advisable? Heat and humidity exchangers vs. active humidifiers ina functional lung model] Rathgeber J, et al. **Anaesthesist** 1996 Sep;45(9):807–13 (Eng. Abstr.) **(Ger)**

[The interaction of nitrous oxide and enflurane on the EEG median of 2–3 Hz is additive, but weaker than at 1.0 MAC (see comments)] Röpcke H, et al. **Anaesthesist** 1996 Sep; 45(9):819–25 (Eng. Abstr.). Comment in: Anaesthesist 1997 Jun;46(6):566–7. **(Ger)**

[Transcranial doppler sonography. Effect of sevoflurane in comparison to isoflurane] Thiel A, et al. **Anaesthesist** 1997 Jan;46(1):29–33 (Eng. Abstr.) **(Ger)**

[Severe aspiration pneumonia with the laryngeal mask] Lussmann RF, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Mar; 32(3):194–6 (Eng. Abstr.) **(Ger)**

[Environmental and work site contamination in anesthesia] Marx T. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):44–6 **(Ger)**

[Blood supply to the liver in the human after 1 MAC desflurane in comparison with isoflurane and halothane] Schindler E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):344–8 (Eng. Abstr.) **(Ger)**

[N2O-induced acute funicular myelosis in latent vitamin B 12 deficiency] Takács J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):525–8 (Eng. Abstr.) **(Ger)**

[Effects of anesthesia with inhalation anesthetics on excitation, conduction and refractory parameters of the heart. Experiments in dogs] Hahn N, et al. **Arzneimittelforschung** 1996 Mar;46(3):251–6 (Eng. Abstr.) **(Ger)**

[The Harrington scoliosis operation: the anesthesiological problems in the perioperative phase] Koch HJ. **Rom J Intern Med** 1996 Jan–Jun;34(1–2):127–36 (Eng. Abstr.) **(Ger)**

[The effect of low-dose prostaglandin E1 on intra- and post-operative liver function] Hayashida M, et al. **Masui** 1997 May;46(5):618–27 (Eng. Abstr.) **(Jpn)**

[The effect of low-dose prostaglandin E1 on serum and urinary fluoride concentrations in patients anesthetized with sevoflurane] Hayashida M, et al. **Masui** 1997 Jun; 46(6):736–42 (Eng. Abstr.) **(Jpn)**

[The effect of low-dose prostaglandin E1 on intra- and post-operative renal function] Hayashida M, et al. **Masui** 1997 Apr;46(4):464–70 (Eng. Abstr.) **(Jpn)**

[Effects of halothane and sevoflurane on reversal of neuromuscular blockade induced by vecuronium in man] Izawa H, et al. **Masui** 1997 Feb;46(2):177–83 (Eng. Abstr.) **(Jpn)**

[Perioperative management for partial resection of a lymphangioma of the tongue] Kanai M, et al. **Masui** 1996 Jul;45(7):869–72 (Eng. Abstr.) **(Jpn)**

[The effect of cerebral perfusion pressure on cerebral blood flow in the rhesus monkey during sevoflurane anesthesia] Kaneko T, et al. **Masui** 1997 Feb;46(2):166–72 (Eng. Abstr.) **(Jpn)**

[Anesthetic management in a child with Drash syndrome] Mizushima A, et al. **Masui** 1997 Feb;46(2):262–5 (Eng. Abstr.) **(Jpn)**

[Perioperative risk factors and anesthetic management of patients for carotid endarterectomy] Niinai H, et al. **Masui** 1997 May;46(5):689–93 (Eng. Abstr.) **(Jpn)**

[Anesthetic management for AICD (automatic implantable cardioverter defibrillator) implant surgery] Ohnishi Y, et al. **Masui** 1996 Feb;45(2):239–43 (Eng. Abstr.) **(Jpn)**

[Anesthesia for pediatric open heart surgery without transfusion] Ohnishi Y, et al. **Masui** 1997 Feb;46(2):199–204 (Eng. Abstr.) **(Jpn)**

[Repeated low-flow sevoflurane anesthesia: effects on hepatic and renal function in beagles] Sun L, et al. **Masui** 1997 Mar;46(3):351–7 (Eng. Abstr.) **(Jpn)**

[Preanesthetic meals in elective surgical patients] Tanabe T, et al. **Masui** 1997 Jun;46(6):788–92 (Eng. Abstr.) **(Jpn)**

[Surgical stress and the suppression] Tanaka Y, et al. **Masui** 1996 Dec;45 Suppl:S56–67 **(Jpn)**

[The effect of nicardipine hydrochloride upon the pulmonary arterial pressure] Terashima M, et al. **Masui** 1997 Jan; 46(1):110–3 (Eng. Abstr.) **(Jpn)**

[Hemodynamic changes during laparoscopic cholecystectomy under different anesthesia methods] Yokoyama M, et al. **Masui** 1996 Feb;45(2):160–6 (Eng. Abstr.) **(Jpn)**

[Components of anesthesiological provision and central hemodynamics in hypothermia without perfusion] Naumenko SE, et al. **Anesteziol Reanimatol** 1997 Mar–Apr; (2):22–5 (Eng. Abstr.) **(Rus)**

[Comparative study of recovery from general anesthesia with halothane or sevoflurane in pediatrics] Calderón E, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):272–5 (Eng. Abstr.) **(Spa)**

[Respiratory changes during laparoscopic cholecystectomy. A comparative study of three techniques] Gándara MV, et al. **Rev Esp Anestesiol Reanim** 1997 May;44(5):177–81 (Eng. Abstr.) **(Spa)**

[A neonate with a large cystic hygroma: management of the airway (letter)] Puebla G, et al. **Rev Esp Anestesiol Reanim** 1997 May;44(5):210–1 **(Spa)**

[Anesthesia in laparoscopic cholecystectomy with CO2: comparison of the hemodynamic and respiratory behavior using 2 different anesthetic techniques (see comments)] Rubio-Martínez CJ, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):12–6 (Eng. Abstr.). Comment in: Rev Esp Anestesiol Reanim 1996 Jun–Jul;43(6):227–8. **(Spa)**

[Intraoperative anesthetic management of kidney failure in adult liver transplantation. Conventional hemodialysis] Sevillano A, et al. **Rev Esp Anestesiol Reanim** 1997 Feb; 44(2):62–9 (Eng. Abstr.) **(Spa)**

[Narcosis 150 years ago and today. High efficiency for general anesthesia] Jonsson L. **Lakartidningen** 1996 Oct 30; 93(44):3897–902 **(Swe)**

ADVERSE EFFECTS

Influence of anesthetic technique on early postoperative hypoxemia. Georgiou LG, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):75–80

Late intraoperative clonidine administration prevents postanesthetic shivering after total intravenous or volatile anesthesia. Horn EP, et al. **Anesth Analg** 1997 Mar; 84(3):613–7

Glucose intolerance during prolonged sevoflurane anaesthesia. Iwasaka H, et al. **Can J Anaesth** 1996 Oct; 43(10):1059–61

Quadriparesia following permissive hypercapnia and inhalational anesthesia in a patient with severe status asthmaticus [letter] Zender HO, et al. **Intensive Care Med** 1996 Sep;22(9):1001

Surgeon or system--malpractice. Avery JK. **J Ark Med Soc** 1997 Aug;94(3):121–2

Speaking for itself: the doctrine of res ipsa loquitur in a case of pediatric anesthesia. Liang BA, et al. **J Clin Anesth** 1996 Aug;8(5):398–401

Cardiorespiratory, endocrine and metabolic changes in ponies undergoing intravenous or inhalation anaesthesia. Luna SP, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):251–8

Hyperthermia during sevoflurane anaesthesia in arthrogryposis multiplex congenita with central nervous system dysfunction [letter] Kanaya N, et al. **Paediatr Anaesth** 1996;6(5):428–9

Halothane hepatitis in a South African population--frequency and the influence of gender and ethnicity [see comments] Voigt MD, et al. **S Afr Med J** 1997 Jul;87(7):882–5. Comment in: S Afr Med J 1997 Jul;87(7):880–3.

[Duchenne muscular dystrophy and anesthesia. A retrospective study] Petersen CT, et al. **Ugeskr Laeger** 1996 Oct 28;158(44):6274–6 (Eng. Abstr.) **(Dan)**

[Myoglobinuria following anesthesia with enflurane and succinylcholine in an asthmatic child on theophylline] Shono S, et al. **Masui** 1996 Jan;45(1):91–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Aspiration pneumonia during cesarean section (letter)] Benito MC, et al. **Rev Esp Anestesiol Reanim** 1997 Feb; 44(2):89–90 **(Spa)**

[Changes in the concentrations of catecholamines and cortisol in balanced anesthesia and total intravenous anesthesia] Castillo V, et al. **Rev Esp Anestesiol Reanim** 1997 Feb; 44(2):52–5 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Paediatric anaesthetic breathing systems [editorial] [see comments] Lin YC, et al. **Paediatr Anaesth** 1996;6(1):1–5 . Comment in: Paediatr Anaesth 1996;6(4):346.

ECONOMICS

Cost-effectiveness of inhalational, balanced and total intravenous anaesthesia for ambulatory knee surgery. Alhashemi JA, et al. **Can J Anaesth** 1997 Feb;44(2):118–25

[Economic aspects of modern inhalation anesthetics with sevoflurane as an example] Bach A, et al. **Anaesthesist** 1997 Jan;46(1):21–8 (Eng. Abstr.) **(Ger)**

HISTORY

Clearing the airway--mouth gags, wedges and openers. Ball C, et al. **Anaesth Intensive Care** 1997 Aug;25(4):335

Bellamy Gardner's mask [letter] Roberts FW. **Anaesth Intensive Care** 1996 Oct;24(5):623–4

William Morton and the first successful demonstration of anaesthesia. Westhorpe R. **Anaesth Intensive Care** 1996 Oct; 24(5):529

Ether inhaler, 1847. Westhorpe R. **Anaesth Intensive Care** 1997 Jun;25(3):213

Did the use of chloroform by Queen Victoria influence its acceptance in obstetric practice? Connor H, et al. **Anaesthesia** 1996 Oct;51(10):955–7

America's greatest medical discovery: 150 years later, who gets the credit? Rutledge RH. **J Am Coll Surg** 1996 Dec; 183(6):625–36

Singular experiences--the early history of anaesthesia in the Royal Navy 1847 to 1854. Glew PA. **J R Nav Med Serv** 1997;83(1):42–4

Humphry Davy's small circle of Bristol friends. Wright AJ. **Middle East J Anesthesiol** 1995 Oct;13(3):233–79

[150th anniversary of inhalation anesthesia. Le Comité de Redaction des AFAR (editorial)] **Ann Fr Anesth Reanim** 1996;15(7):1003 **(Fre)**

[1846–1847: starting inhalation anesthesia in Paris] Juvin P. **Ann Fr Anesth Reanim** 1996;15(7):1111–12 **(Fre)**

[The 16th October 1846 and its outcome] Röse W. **Anaesthesiol Reanim** 1996;21(6):144–8 (Eng. Abstr.) **(Ger)**

[150th anniversary of ether narcosis] Incze F. **Orv Hetil** 1997 Jan 12;138(2):87–8 **(Hun)**

["Gentlemen, this is not a humbug". The 150th anniversary of anesthesia] Strømskag KE. **Tidsskr Nor Laegeforen** 1996 Dec 10;116(30):3622–4 (Eng. Abstr.) **(Nor)**

[The discovery of surgical anesthesia and its arrival in Europe. Apropos of the 150th anniversary of the clinical introduction of ether] Franco A, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):281–7 (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Inspired oxygen concentrations with or without an oxygen economizer during ether draw-over anaesthesia. Khaing TT, et al. **Anaesth Intensive Care** 1997 Aug;25(4):417–9

Faulty nitrous oxide Schraeder valve [letter] Barnor E, et al. **Anaesthesia** 1997 Apr;52(4):392–3

The Oxyvent. An anaesthetic machine designed to be used in developing countries and difficult situations. Eltringham RJ, et al. **Anaesthesia** 1997 Jul;52(7):668–72

An unusual and dangerous anaesthetic machine failure [letter] Ferguson S, et al. **Anaesthesia** 1997 Mar;52(3):283–4

Monitoring failure and awareness hazard during prolonged surgery [letter] Girgis Y, et al. **Anaesthesia** 1997 May; 52(5):504–5

Breathing system terminology [letter; comment] Lowe DM, et al. **Anaesthesia** 1997 May;52(5):506–7. Comment on: Anaesthesia 1996 Dec;51(12):1089–92.

A non-rebreathing coaxial anaesthesia system: dependence of end-tidal gas concentrations on fresh gas flow and tidal volume. Tweed WA. **Anaesthesia** 1997 Mar;52(3):237–41

Use of the 'AeroChamber' during induction of anaesthesia [letter] Wandless JG. **Anaesthesia** 1996 Dec;51(12):1193

An antique turn-off [letter; comment] Welsh BE. **Anaesthesia** 1997 Apr;52(4):394. Comment on: Anaesthesia 1996 Oct;51(10):939–42.

Comparison of tests for detecting leaks in the low-pressure system of anesthesia gas machines. Myers JA, et al. **Anesth Analg** 1997 Jan;84(1):179–84

Rehydration of desiccated Baralyme prevents carbon monoxide formation from desflurane in an anesthesia machine. Baxter PJ, et al. **Anesthesiology** 1997 May; 86(5):1061–5

Oxygen flow through nasal cannulae. Henderson CL, et al. **Can J Anaesth** 1996 Jun;43(6):636–9

Halothane consumption under varying breathing circuit designs. Wambani JO. **East Afr Med J** 1996 Dec; 73(12):827–9

Which volatile setting for sevoflurane? [letter] Gaspar L, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):535

A massive gas leak: missing O-ring and a plastic band [letter] Jayamaha S, et al. **Eur J Anaesthesiol** 1996 Nov; 13(6):627–30

Patient safety and scented pediatric anesthesia facemasks [letter] Hinkle AJ. **J Clin Anesth** 1997 Sep;9(6):521–2

Pro: there is nothing wrong with old anesthesia machines and equipment [see comments] Arens JF. **J Clin Monit** 1996 Jan;12(1):37–8. Comment in: J Clin Monit 1996 Jan;12(1):39–41.

Cardiogenic oscillations may be masked by the breathing system configuration. Haridas RP, et al. **J Clin Monit** 1997 Jul;13(4):269–72

Con: there is nothing wrong with old anesthesia machines and equipment [comment] Schreiber PJ. **J Clin Monit** 1996 Jan;12(1):39–41. Comment on: J Clin Monit 1996 Jan;12(1):37–8.

Study of clinical anaesthesia with pedius A anaesthesia system using ketamine or halothane with muscle relaxant. Das SK, et al. **J Indian Med Assoc** 1995 Oct;93(10):377–9

Use of the laryngeal mask airway in oral and maxillofacial surgery. Bennett J, et al. **J Oral Maxillofac Surg** 1996 Nov; 54(11):1346–51 (38 ref.)

Sevoflurane concentration available from the universal drawover vaporizer. Pylman ML, et al. **Mil Med** 1997 Jun; 162(6):405–6

Apparatus for endtidal carbon dioxide measurement for neonatal anaesthesia [letter] Goldsmith AL, et al. **Paediatr Anaesth** 1996;6(1):80

Usefulness of self made introducer for laryngeal mask airway in paediatric anaesthesia. Ishikawa T, et al. **Paediatr Anaesth** 1997;7(2):117–20

The benefit of using a heat and moisture exchanger during short operations in young children. Monrigal JP, et al. **Paediatr Anaesth** 1997;7(4):295–300

[The Ombredanne equipment] Lassner J. **Cah Anesthesiol** 1996;44(5):469–78 **(Fre)**

[Ventilation via a transnasally placed pharyngeal tube. Comparison with mask ventilation] Bund M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):420–4 (Eng. Abstr.) **(Ger)**

[Behm's T-piece for reducing anesthesia gas pollution at the anesthesia work site] Salomon F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):425–6 (Eng. Abstr.) **(Ger)**

[The Bird Mark-8 in inhalation anesthesia] Portella AA. **Rev Bras Anestesiol** 1968 Oct–Dec;18(4):482–5 **(Por)**

[The standardization of equipment for artificial pulmonary ventilation and inhalation anesthesia in Russia] Burlakov RI, et al. **Med Tekh** 1996 Jan–Feb;(1):15–8 (Eng. Abstr.) **(Rus)**

METHODS

Difficult intubation and muscle relaxants. Vandermeersch E. **Acta Anaesthesiol Belg** 1997;48(1):3–6

Anaesthetic considerations in exomphalos repair: a report of 2 cases. Amata AO. **Afr J Med Med Sci** 1995 Dec; 24(4):403–6

Adult inhalational induction [letter] Edwards RM. **Anaesth Intensive Care** 1997 Apr;25(2):198–9

A simple manoeuvre to aid inhalation induction in a patient with a supraglottic mass [letter] Riley RH, et al. **Anaesth Intensive Care** 1996 Dec;24(6):727–8

Sevoflurane induction and difficult airway management [letter] [see comments] Fenlon S, et al. **Anaesthesia** 1997 Mar;52(3):285–6. Comment in: Anaesthesia 1997 Jul;52(7):710.

Economics of low-flow anaesthesia in children [see comments] Perkins R, et al. **Anaesthesia** 1996 Dec; 51(12):1089–92. Comment in: Anaesthesia 1997 May;52(5):506–7.

Reduced postoperative analgesic demand after inhaled anesthesia in comparison to combined epidural-inhaled anesthesia in patients undergoing abdominal surgery. Rockemann MG, et al. **Anesth Analg** 1997 Mar;84(3):600–5

Positron emission tomography study of regional cerebral metabolism in humans during isoflurane anesthesia. Alkire MT, et al. **Anesthesiology** 1997 Mar;86(3):549–57

High carboxyhemoglobin concentrations occur in swine during desflurane anesthesia in the presence of partially dried carbon dioxide absorbents [see comments] Frink EJ Jr, et al. **Anesthesiology** 1997 Aug;87(2):308–16. Comment in: Anesthesiology 1997 Aug;87(2):202–3.

Keep the blood red...the right way [editorial; comment] Kharasch ED. **Anesthesiology** 1997 Aug;87(2):202–3. Comment on: Anesthesiology 1997 Aug;87(2):228–34. Comment on: Anesthesiology 1997 Aug;87(2):308–16.

Pott's disease of the spine. Parmar M, et al. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):52

Repetitive inhalation endotracheal anaesthesia for cobalt radiotherapy in a child [see comments] LeDez KM, et al. **Can J Anaesth** 1996 Aug;43(8):835–9. Comment in: Can J Anaesth 1996 Aug;43(8):764–8.

Low-flow anaesthesia [editorial] Baum JA. **Eur J Anaesthesiol** 1996 Sep;13(5):432–5

Low-flow and minimal-flow anaesthesia using the laryngeal mask airway. Möllhoff T, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):456–62

Vital capacity induction with sevoflurane in adult surgical patients [letter] Philip BK, et al. **J Clin Anesth** 1996 Aug; 8(5):426

Humane and practical implications of using carbon dioxide mixed with oxygen for anesthesia or euthanasia of rats. Danneman PJ, et al. **Lab Anim Sci** 1997 Aug;47(4):376–85

Parent-assisted anaesthesia [letter] Shaikh L, et al. **Paediatr Anaesth** 1997;7(3):262

Haemodynamic response to tracheal intubation or laryngeal mask insertion in hypertensive patients. Rooke GO, et al. **S Afr J Surg** 1997 Feb;35(1):24–6

[Volatile agents in ambulatory anesthesia] Clergue F. **Rev Med Suisse Romande** 1997 May;117(5):383–8 (16 ref.) **(Fre)**

[General anesthesia in a patient homozygous for the atypical variant of plasma pseudocholinesterase (letter)] Bermejo MA, et al. **Rev Esp Anestesiol Reanim** 1996 Jun-Jul; 43(6):224–5 **(Spa)**

[Evaluation and management of the difficult airway (see comments)] Rodrigo MP, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):34–41 (25 ref.) . Comment in: Rev Esp Anestesiol Reanim 1997 Apr;44(4):167–9. **(Spa)**

STANDARDS

[The standardization of equipment for artificial pulmonary ventilation and inhalation anesthesia in Russia] Burlakov RI, et al. **Med Tekh** 1996 Jan–Feb;(1):15–8 (Eng. Abstr.) **(Rus)**

VETERINARY

Endocrine changes in cerebrospinal fluid, pituitary effluent, and peripheral plasma of anesthetized ponies. Luna SP, et al. **Am J Vet Res** 1997 Jul;58(7):765–70

Distribution of technetium 99m-labeled red blood cells during isoflurane anesthesia in ferrets. Marini RP, et al. **Am J Vet Res** 1997 Jul;58(7):781–5

An evaluation of the influence of medetomidine hydrochloride and atipamezole hydrochloride on the arrhythmogenic dose of epinephrine in dogs during halothane anesthesia. Pettifer GR, et al. **Can J Vet Res** 1996 Jan;60(1):1–6

Intranasal phenylephrine reduces post anesthetic upper airway obstruction in horses. Lukasik VM, et al. **Equine Vet J** 1997 May;29(3):236–8

Ultrasonographic pregnancy detection and inhalation anesthesia in the gray short-tailed opossum (Monodelphis domestica). Miles KG, et al. **Lab Anim Sci** 1997 Jun; 47(3):280–2

Effects of anesthesia and open-thorax surgery on coronary vascular reserve in swine. Rogers IT, et al. **Lab Anim Sci** 1997 Aug;47(4):396–400

Comparisons of sevoflurane, isoflurane, and halothane anesthesia in spontaneously breathing cats. Hikasa Y, et al. **Vet Surg** 1996 May-Jun;25(3):234–43

Anesthesia in sheep with propofol or with xylazine-ketamine followed by halothane. Lin HC, et al. **Vet Surg** 1997 May-Jun;26(3):247–52

Metabolic, hormonal, and hemodynamic changes during dopamine infusions in halothane anesthetized horses. Robertson SA, et al. **Vet Surg** 1996 Jan-Feb;25(1):88–97

ANESTHESIA, INTRATRACHEAL

Continuous gastric suctioning decreases measured esophageal temperature during general anesthesia. Nelson EJ, et al. **J Clin Monit** 1996 Nov;12(6):429–32

[New muscle relaxants] Diefenbach C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Feb; 31(1):2–8 (57 ref.) (Eng. Abstr.) **(Ger)**

[Intubation requirements after rocuronium and succinylcholine] Latorre F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):470–3 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Hypoglossal paralysis after septum correction with intubation anesthesia] Baumgarten V, et al. **Anaesthesist** 1997 Jan;46(1):34–7 (Eng. Abstr.) **(Ger)**

[Conservative treatment of 2 tracheal lesions secondary to anesthetic intubation] Buitrago LJ, et al. **Arch Bronconeumol** 1997 Mar;33(3):151–3 (16 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Failure to ventilate due to glass ampule fragment occlusion of the breathing circuit [letter] Gallacher BP, et al. **Anesthesiology** 1997 Jul;87(1):180

METHODS

[Atypical tracheal intubation] Bianco F, et al. **G Chir** 1996 Aug-Sep;17(8–9):416–7 **(Ita)**

[Anesthesia for angiocardiography. A review of cases] Ferreira FC, et al. **Rev Bras Anestesiol** 1968 Oct–Dec; 18(4):472–7 (Eng. Abstr.) **(Por)**

ANESTHESIA, INTRAVENOUS

Intravenous regional anesthesia. Evaluation of 4 different additives to prilocaine. Hoffmann V, et al. **Acta Anaesthesiol Belg** 1997;48(2):71–6

Effect of low dose fentanyl-droperidol administration on respiratory drive, respiratory pattern and gas exchange in ASA 1 spontaneously breathing patients. Pierdominici S, et al. **Acta Anaesthesiol Belg** 1997;48(2):85–91

The effect of topical lignocaine on intubating conditions after propofol-alfentanil induction. Bülow K, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):752–6

Propofol anaesthesia in spontaneously breathing paediatric patients during magnetic resonance imaging. Levati A, et al. **Acta Anaesthesiol Scand** 1996 May;40(5):561–5

The effects of simulated Bier block IVRA on intracompartmental tissue pressure. Mabee JR, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):208–13

Ketamine anesthesia in children with acute burns and scalds. Maldini B. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1108–11

Inhalation vs. i.v. anesthesia and intensive care medicine. List WF. **Acta Anaesthesiol Scand Suppl** 1996;109:161–3

Anesthesia and surgery influences regional net release and uptake rates of tissue-type plasminogen activator. An experimental study in the intact pig. Seeman-Lodding H, et al. **Acta Anaesthesiol Scand Suppl** 1997;110:151–3

A new method to evaluate central sensitization to pain following surgery. Effect of ketamine. Stubhaug A. **Acta Anaesthesiol Scand Suppl** 1997;110:154–5

Anaesthesia and trisomy 3p syndrome [letter] Allen DL, et al. **Anaesth Intensive Care** 1996 Oct;24(5):615

Bier's block--under pressure? [letter] [see comments] Hunt SJ, et al. **Anaesthesia** 1997 Feb;52(2):188–9. Comment in: Anaesthesia 1997 Jul;52(7):713.

Total intravenous anaesthesia with propofol or inhalational anaesthesia with isoflurane for major abdominal surgery. Recovery characteristics and postoperative oxygenation--an international multicentre study. Phillips AS, et al. **Anaesthesia** 1996 Nov;51(11):1055–9

Osteogenesis imperfecta and malignant hyperthermia. Is there a relationship? Porsborg P, et al. **Anaesthesia** 1996 Sep; 51(9):863–5

Comparison of sufentanil/propofol versus isoflurane/nitrous oxide anaesthesia on mesenteric artery blood flow. Zwijsen JH, et al. **Anaesthesia** 1996 Nov;51(11):1060–3

The arterial blood propofol concentration preventing movement in 50% of healthy women after skin incision. Andrews DT, et al. **Anesth Analg** 1997 Aug;85(2):414–9

Awakening, clinical recovery, and psychomotor effects after desflurane and propofol anesthesia. Apfelbaum JL, et al. **Anesth Analg** 1996 Oct;83(4):721–5

Effect on postoperative analgesia of small-dose lysine acetylsalicylate added to prilocaine during intravenous regional anesthesia. Corpataux JB, et al. **Anesth Analg** 1997 May;84(5):1081–5

A North American survey of intravenous regional anesthesia. Henderson CL, et al. **Anesth Analg** 1997 Oct;85(4):858–63

The effects of epidural fentanyl on hemodynamic responses during emergence from isoflurane anesthesia and tracheal extubation: a comparison with intravenous fentanyl. Inagaki Y, et al. **Anesth Analg** 1997 Aug;85(2):328–35

Midazolam premedication increases sedation but does not prolong discharge times after brief outpatient general anesthesia for laparoscopic tubal sterilization. Richardson MG, et al. **Anesth Analg** 1997 Aug;85(2):301–5

The use of 0.25% lidocaine with fentanyl and pancuronium for intravenous regional anesthesia. Sztark F, et al. **Anesth Analg** 1997 Apr;84(4):777–9

Propofol and alfentanil prevent the increase in intraocular pressure caused by succinylcholine and endotracheal intubation during a rapid sequence induction of anesthesia. Zimmerman AA, et al. **Anesth Analg** 1996 Oct;83(4):814–7

Regional metabolism of articaine in 10 patients undergoing intravenous regional anaesthesia during day case surgery. Vree TB, et al. **Br J Clin Pharmacol** 1997 Jul;44(1):29–34

Midazolam and awareness with recall during total intravenous anaesthesia. Miller DR, et al. **Can J Anaesth** 1996 Sep;43(9):946–53

Intravenous anaesthesia and leukocytes [letter; comment] Morisaki H, et al. **Can J Anaesth** 1997 Jan;44(1):100. Comment on: Can J Anaesth 1993 Aug;40(8):770–4.

Ketamine anesthesia in electroconvulsive therapy. Rasmussen KG, et al. **Convuls Ther** 1996 Dec;12(4):217–23

Transition to post-operative epidural or patient-controlled intravenous analgesia following total intravenous anaesthesia with remifentanil and propofol for abdominal surgery. Bowdle TA, et al. **Eur J Anaesthesiol** 1997 Jul; 14(4):374–9

Uneventful total intravenous anaesthesia with ketamine for schizophrenic surgical patients. Ishihara H, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):47–51

The addition of clonidine to prilocaine for intravenous regional anaesthesia. Kleinschmidt S, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):40–6

Update in intravenous anaesthesia. Proceedings of the 7th International Symposium on Intravenous Anaesthesia. Lausanne, Switzerland, 2–3 May 1997. **Eur J Anaesthesiol Suppl** 1997 May;15:1–60

How safe is Biers Block in the accident and emergency department? Thamizhavell RC, et al. **Eur J Emerg Med** 1996 Mar;3(1):56–8

Coronary vasoconstriction by endothelin-1 in anesthetized goats: role of endothelin receptors, nitric oxide and prostanoids. Garcia JL, et al. **Eur J Pharmacol** 1996 Nov 14;315(2):179–86

Computer-controlled infusions in anesthesia. Kenny GN, et

al. **Int Anesthesiol Clin** 1995 Summer;33(3):101–9 (17 ref.)

Total intravenous anesthesia and high-frequency jet ventilation during transthoracic endoscopic sympathectomy for treatment of essential hyperhidrosis palmaris: a new approach. D'Haese J, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):767–71

Anesthesia for laser transmyocardial revascularization. Thrush DN. **J Cardiothorac Vasc Anesth** 1997 Jun; 11(4):481–4

Safe anesthetic management of patients undergoing a novel method of treating human hepatocellular cancer. Dougherty TB, et al. **J Clin Anesth** 1997 May;9(3):220–7

The Society for Intravenous Anesthesia: aims and goals [editorial] Glass PS, et al. **J Clin Anesth** 1997 Sep;9(6 Suppl):1S–2S

Etomidate and thiopental-based anesthetic induction: comparisons between different titrated levels of electrophysiologic cortical depression and response to laryngoscopy. Jellish WS, et al. **J Clin Anesth** 1997 Feb; 9(1):36–41

Propofol decreases ocular pressure in outpatients undergoing trabeculectomy. Lauretti GR, et al. **J Clin Anesth** 1997 Jun;9(4):289–92

Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery. McKenzie R, et al. **J Clin Anesth** 1997 Feb;9(1):15–20

Study of the safe threshold of apneic period in children during anesthesia induction. Xue FS, et al. **J Clin Anesth** 1996 Nov;8(7):568–74

Propofol anesthesia for transvaginal ultrasound guided oocyte retrieval. Tontisirin O, et al. **J Med Assoc Thai** 1996 Oct;79(10):618–23

Increase in antioxidant capacity of plasma during propofol anesthesia. Hans P, et al. **J Neurosurg Anesthesiol** 1997 Jul; 9(3):234–6

Computer-controlled infusion of propofol for long neurosurgical procedures. Lim TA, et al. **J Neurosurg Anesthesiol** 1997 Jul;9(3):242–9

Evaluation of the safety and efficacy of deep sedation for electrophysiology procedures administered in the absence of an anesthetist. Geiger MJ, et al. **Pacing Clin Electrophysiol** 1997 Jul;20(7):1808–14

Changes in carbon dioxide tension and oxygen saturation during deep sedation for paediatric cardiac catheterization. Friesen RH, et al. **Paediatr Anaesth** 1996;6(1):15–20

Anaesthetic management of a girls with chondrodysplasia punctata [letter] García Miguel FJ, et al. **Paediatr Anaesth** 1997;7(4):355–6

The Bland-White-Garland syndrome. Clinical picture and anaesthesiological management. Kleinschmidt S, et al. **Paediatr Anaesth** 1996;6(1):65–8

Breast reduction under intravenous sedation: a review of 50 cases [letter; comment] Aldo Mottura A. **Plast Reconstr Surg** 1997 Jun;99(7):2113–4. Comment on: Plast Reconstr Surg 1996 Apr;97(5):952–6; discussion 957–8.

A different approach in demonstrating the mechanism of intravenous regional anesthesia [letter] Celebi H, et al. **Reg Anesth** 1997 Jul–Aug;22(4):387

Comparison of wound infiltration with ketorolac versus intravenous regional anesthesia with ketorolac for postoperative analgesia following ambulatory hand surgery. Reuben SS, et al. **Reg Anesth** 1996 Nov–Dec; 21(6):565–8

Patient sedation for routine genital examination [letter] Dehaeck K, et al. **S Afr Med J** 1996 Aug;86(8):973

Where there is no anaesthetist: a study of 282 consecutive patients using intravenous, spinal and local infiltration anaesthetic techniques. Adesunkanmi AR. **Trop Doct** 1997 Apr;27(2):79–82

Intravenous regional anesthesia with ketorolac-lidocaine for the management of sympathetically-mediated pain. Connelly NR, et al. **Yale J Biol Med** 1995 May–Aug; 68(3–4):95–9

[Combined loco-regional anesthesia and intravenous anesthesia with propofol (Diprivan—Zeneca)] Badeva B, et al. **Khirurgiia (Sofiia)** 1996;49(4):12–3 (Eng. Abstr.) **(Bul)**

[Propofol (Diprivan) in emergency anesthesia] Badeva B, et al. **Khirurgiia (Sofiia)** 1996;49(4):31–3 (Eng. Abstr.) **(Bul)**

[Intravenous sedation in implantology] Chanavaz M, et al. **Rev Stomatol Chir Maxillofac** 1997 Jan;98(1):57–61 (Eng. Abstr.) **(Fre)**

[Total intravenous anesthesia with propofol and sufentanil for resection of pheochromocytoma] Kreienmeyer J. **Anaesthesiol Reanim** 1997;22(3):80–2 (Eng. Abstr.) **(Ger)**

[New intravenous anesthetics. Remifentanil, S(+)-ketamine, eltanolone and target controlled infusion] Albrecht S, et al. **Anaesthesist** 1996 Dec;45(12):1129–41 (85 ref.) (Eng. Abstr.) **(Ger)**

[The effect of total intravenous anesthesia with S-(+)-ketamine/propofol on hemodynamic, endocrine and metabolic stress reactions in comparison to alfentanil/propofol in laparotomy] Crozier TA, et al. **Anaesthesist** 1996 Nov;45(11):1015–23 (Eng. Abstr.) **(Ger)**

[Comparison of sufentanil-propofol-anesthesia with fentanyl-propofol in major abdominal surgery] Kietzmann D, et al. **Anaesthesist** 1996 Dec;45(12):1151–7 (Eng. Abstr.) **(Ger)**

[The interaction between rocuronium and smoking. The effect of smoking on neuromuscular transmission after rocuronium] Latorre F, et al. **Anaesthesist** 1997 Jun; 46(6):493–5 (Eng. Abstr.) **(Ger)**

[Intravenous anesthesia—which way are we going?] Schüttler J, et al. **Anaesthesist** 1996 Dec;45(12):1127–8 **(Ger)**

[Cisatracurium—is the stereoisomer an "ideal" relaxant? Histamine liberation and tryptase determination after bolus administration of cistracurium: a comparison with vecuronium] Soukup J, et al. **Anaesthesist** 1997 Jun; 46(6):486–91 (Eng. Abstr.) **(Ger)**

[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery] Wilhelm W, et al. **Anaesthesist** 1997 Apr;46(4):335–8 (Eng. Abstr.) **(Ger)**

[High frequency jet ventilation during tracheal resection in children and infants] Männle C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):21–6 (Eng. Abstr.) **(Ger)**

[Is remifentanil an ideal opioid for anesthesiologic management in the 21st century?] Scholz J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Dec; 31(10):592–607 (96 ref.) (Eng. Abstr.) **(Ger)**

[Sedation, combined anesthesia, and total intravenous anesthesia (TIVA) with propofol in the pediatric surgical patient] Ivani G, et al. **Minerva Anestesiol** 1996 Apr; 62(4):113–7 (Eng. Abstr.) **(Ita)**

[Merit of surgical stress suppression—special reference to epidural and intravenous anesthesia in view of endocrine systems] Ishihara H. **Masui** 1996 Dec;45 Suppl:S51–5 (13 ref.) **(Jpn)**

[Protective effect of intravenous anesthesia using propofol from surgical stress] Kazama T. **Masui** 1996 Dec;45 Suppl:S68–72 (4 ref.) **(Jpn)**

[The on-line simulation of blood propofol concentration by personal computer transmitting settings of the syringe pump via a digital port] Nakao M. **Masui** 1997 Feb; 46(2):279–83 (Eng. Abstr.) **(Jpn)**

[Anesthesia induction for laryngeal mask insertion—comparison of propofol with midazolam and propofol with thiopental] Nishiyama T, et al. **Masui** 1997 Feb;46(2):188–92 (Eng. Abstr.) **(Jpn)**

[Rapid induction of anesthesia with propofol—comparison with thiopental] Nishiyama T, et al. **Masui** 1996 Dec; 45(12):1469–72 (Eng. Abstr.) **(Jpn)**

[Living related liver transplantation for patients with ornithine transcarbamylase deficiency] Tazuke M, et al. **Masui** 1997 Jun;46(6):783–7 (Eng. Abstr.) **(Jpn)**

[Intraoperative monitoring for functional neurosurgery during intravenous anesthesia with propofol] Fukuda M, et al. **No Shinkei Geka** 1997 Mar;25(3):231–7 (Eng. Abstr.) **(Jpn)**

[The content of beta-endorphin, met-enkephalin and ACTH in the blood plasma during electric and drug anesthesia] Alisov AP, et al. **Anesteziol Reanimatol** 1996 May-Jun; (3):9–14 (Eng. Abstr.) **(Rus)**

[Readaptation after total intravenous anesthesia in one-day surgery] Buravtsev VA, et al. **Anesteziol Reanimatol** 1997 Jan–Feb;(1):67–9 (Eng. Abstr.) **(Rus)**

[Features of anesthesia in surgery of liver cirrhosis in children] Lekmanov AU, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):33–5 (Eng. Abstr.) **(Rus)**

[The use of propofol in carotid surgery] Asuero de Lis MS, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):144–9 (Eng. Abstr.) **(Spa)**

[The need for alfentanyl in total intravenous anesthesia. Comparison between laparoscopic cholecystectomy and subcostal laparotomy] Figueredo-Gaspari E, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):103–7 (Eng. Abstr.) **(Spa)**

[Effect of acute intestinal obstruction on infrared systems for measuring anesthetic gases (letter)] Martinéz A, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):74 **(Spa)**

[The risk of severe bradycardia from the use of adenosine triphosphate in pheochromocytoma surgery under total intravenous anesthesia with propofol (letter)] Munar F, et al. **Rev Esp Anestesiol Reanim** 1997 Jun–Jul;44(6):254–5 **(Spa)**

[Total intravenous anesthesia with propofol in orthotopic liver transplantation in swine] Ramirez A, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):98–102 (Eng. Abstr.) **(Spa)**

[Anesthesia in laparoscopic cholecystectomy with CO2: comparison of the hemodynamic and respiratory behavior using 2 different anesthetic techniques (see comments)] Rubio-Martínez CJ, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):12–6 (Eng. Abstr.). Comment in: Rev Esp Anestesiol Reanim 1996 Jun–Jul;43(6):227–8. **(Spa)**

[Epidural anesthesia combined with general anesthesia in ischemic cardiomyopathy (letter)] Tormos P, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):75–6 **(Spa)**

ADVERSE EFFECTS

Influence of anesthetic technique on early postoperative hypoxemia. Georgiou LG, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):75–80

Postoperative nausea and vomiting. Propofol or thiopentone: does choice of induction agent affect outcome? Myles PS, et al. **Anaesth Intensive Care** 1996 Jun;24(3):355–9

Late intraoperative clonidine administration prevents postanesthetic shivering after total intravenous or volatile anesthesia. Horn EP, et al. **Anesth Analg** 1997 Mar; 84(3):613–7

Epileptic fits [letter; comment] Garton R. **Br Dent J** 1996 Dec 7–21;181(11–12):399. Comment on: Br Dent J 1996 Sep 7;181(5):178–9.

The effects of anesthesia with thiopental on T lymphocyte responses to antigen and mitogens in vivo and in vitro. Corrêa-Sales C, et al. **Int J Immunopharmacol** 1997 Feb; 19(2):117–28

Cardiorespiratory, endocrine and metabolic changes in ponies undergoing intravenous or inhalation anaesthesia. Luna SP, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):251–8

[Changes in the concentrations of catecholamines and cortisol in balanced anesthesia and total intravenous anesthesia] Castillo V, et al. **Rev Esp Anestesiol Reanim** 1997 Feb; 44(2):52–5 (Eng. Abstr.) **(Spa)**

[Prolactinemia in children anesthetized with propofol] del Campo-Martín MD, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):7–11 (Eng. Abstr.) **(Spa)**

ECONOMICS

Cost effectiveness of administration of intravenous anesthetics for direct-current cardioversion by nonanesthesiologists. Tobin MG, et al. **Am J Cardiol** 1997 Mar 1;79(5):686–8

Cost-effectiveness of inhalational, balanced and total intravenous anaesthesia for ambulatory knee surgery. Alhashemi JA, et al. **Can J Anaesth** 1997 Feb;44(2):118–25

Nitrous oxide reduces the cost of intravenous anaesthesia. Heath KJ, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):369–72

INSTRUMENTATION

Induction stand [letter] Lim W, et al. **Anaesth Intensive Care** 1996 Oct;24(5):613–4

A prospective clinical comparison of two intravenous polyurethane cannulae. Russell WJ, et al. **Anaesth Intensive Care** 1996 Dec;24(6):705–9

Recall after total intravenous anaesthesia due to an equipment misuse [see comments] Tong D, et al. **Can J Anaesth** 1997 Jan;44(1):73–7. Comment in: Can J Anaesth 1997 Jan;44(1):4–8.

Food and drug administration regulations and computer-controlled infusion pumps. Bazaral MG, et al. **Int Anesthesiol Clin** 1995 Summer;33(3):45–63 (42 ref.)

Clinical drug level predictions and practice. Howell S, et al. **Int Anesthesiol Clin** 1995 Summer;33(3):91–100

Infusion rate control algorithms for pharmacokinetic model-driven drug infusion devices. Jacobs JR. **Int Anesthesiol Clin** 1995 Summer;33(3):65–82 (20 ref.)

METHODS

The difficult airway: propofol infusion as an alternative to gaseous induction. Ludbrook GL, et al. **Anaesth Intensive Care** 1997 Feb;25(1):71–3

Bier's block [letter; comment] Bannister M. **Anaesthesia** 1997 Jul;52(7):713. Comment on: Anaesthesia 1997 Feb;52(2):188–9.

Bier's block [letter; comment] de May JC. **Anaesthesia** 1997 Jul;52(7):713. Comment on: Anaesthesia 1997 Feb;52(2):188–9.

Jaw thrusting as a clinical test to assess the adequate depth of anaesthesia for insertion of the laryngeal mask. Drage MP, et al. **Anaesthesia** 1996 Dec;51(12):1167–70

Influence of induction technique on intubating conditions after rocuronium in adults: comparison with rapid-sequence induction using thiopentone and suxamethonium. Sparr HJ, et al. **Br J Anaesth** 1996 Sep; 77(3):339–42

Target-controlled anaesthesia: concepts and first clinical experiences. Kenny GN. **Eur J Anaesthesiol Suppl** 1997 May;15:29–31

Titrated total intravenous anaesthesia (TIVA) in war. Bačić A, et al. **J R Army Med Corps** 1996 Oct;142(3):103–5

The efficacy and safety of the hematoma block for fracture reduction in closed, isolated fractures. Furia JP, et al. **Orthopedics** 1997 May;20(5):423–6

Haemodynamic response to tracheal intubation or laryngeal mask insertion in hypertensive patients. Rooke GO, et al. **S Afr J Surg** 1997 Feb;35(1):24–6

[Propofol in combination with etomidate for anesthesia induction] Bovianska N. **Khirurgiia (Sofiia)** 1996;49(4):37–9 (Eng. Abstr.) **(Bul)**

[Total intravenous anesthesia (TIVA) with propofol/ketamine as an alternative for patients at risk in abdominal surgery] Vankov I, et al. **Khirurgiia (Sofiia)** 1996; 49(4):17–9 (Eng. Abstr.) **(Bul)**

[Combination of propofol-ketamine-vecuronium for total intravenous anesthesia under hazardous conditions] Escarment J, et al. **Can Anesthesiol** 1996;44(5):447–50 (Eng. Abstr.) **(Fre)**

[Intravenous anesthetic agents in ambulatory anesthesia] Servin F. **Rev Med Suisse Romande** 1997 May;117(5):375–7 (15 ref.) **(Fre)**

[Intravenous anesthesia by continuous administration of midazolam and fentanyl] Yoshida Y, et al. **Masui** 1997 Mar; 46(3):326–30 (Eng. Abstr.) **(Jpn)**

[Acid-base equilibrium in anesthesia with the Valium-Inoval combination] do Amaral RV, et al. **Rev Bras Anestesiol** 1968 Oct–Dec;18(4):462–71 (Eng. Abstr.) **(Por)**

[Total intravenous anesthesia in patients with postburn deformations of the face and neck] Beliakov VA, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):50–2 (Eng. Abstr.) **(Rus)**

[Diprivan (propofol) in the anesthesiological support of outpatient dental interventions] Gritsuk SF, et al. **Stomatologiia (Mosk)** 1997;76(1):63–4 **(Rus)**

[Intravenous regional anesthesia using low doses of lidocaine for hand surgery (letter)] Aznar IM, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):77–8 **(Spa)**

STANDARDS

Autoregressive modeling with exogenous input of middle-latency auditory-evoked potentials to measure rapid changes in depth of anesthesia. Jensen EW, et al. **Methods Inf Med** 1996 Sep;35(3):256–60

TRENDS

[Recent progress in intravenous anesthesia] Dundee JW. **Rev Bras Anestesiol** 1968 Oct-Dec;18(4):391–8 (10 ref.) (Eng. Abstr.) **(Por)**

VETERINARY

Clinical perspectives of intravenous ketamine anaesthesia in peafowl (Pavo cristatus). Athar M, et al. **Acta Vet Hung** 1996;44(3):357–61

Endocrine changes in cerebrospinal fluid, pituitary effluent, and peripheral plasma of anesthetized ponies. Luna SP, et al. **Am J Vet Res** 1997 Jul;58(7):765–70

Cardiopulmonary and anesthetic effects of propofol in wild turkeys. Schumacher J, et al. **Am J Vet Res** 1997 Sep; 58(9):1014–7

A comparison of injectable anaesthetic regimens in mules. Matthews NS, et al. **Equine Vet J Suppl** 1992 Feb;(11):34–6

A comparison of injectable anaesthetic regimens in Mammoth asses. Matthews NS, et al. **Equine Vet J Suppl** 1992 Feb; (11):37–40

Median effective dose of propofol required for induction of anaesthesia in goats. Pablo LS, et al. **J Am Vet Med Assoc** 1997 Jul 1;211(1):86–8

Technical note: reversible re-entrant cannulation of the parotid duct in cattle using a new injection anesthesia regimen. Nørgaard P, et al. **J Anim Sci** 1996 Jul; 74(7):1716–9

Cardiopulmonary effects of lying position in anesthetized and mechanically ventilated dogs. Bornscheuer A, et al. **J Exp Anim Sci** 1996 Aug;38(1):20–7

Cardiopulmonary effects of desflurane in ponies, after induction of anaesthesia with xylazine and ketamine. Clarke KW, et al. **Vet Rec** 1996 Aug 24;139(8):180–5

Effects of tiletamine/zolazepam premedication on propofol anaesthesia in dogs. Cullen LK, et al. **Vet Rec** 1997 Apr 5;140(14):363–6

Medetomidine as a premedicant for ketamine, propofol or fentanyl anaesthesia in dogs. Hellebrekers LJ, et al. **Vet Rec** 1997 May 24;140(21):545–8

Anesthesia in sheep with propofol or with xylazine-ketamine followed by halothane. Lin HC, et al. **Vet Surg** 1997 May-Jun;26(3):247–52

[Veterinary dentistry (13). The use of the combination medetomidine/ketamine in dogs for anesthesia in dental procedures: evaluation of its clinical application] Sap R, et al. **Tijdschr Diergeneeskd** 1997 May 1;122(9):248–51 (Eng. Abstr.) **(Dut)**

[Total intravenous anesthesia (TIVA) with alphaxolon/alphadolon (Saffan) for permanent restraint of two cats with severe dyspnea] Tacke S. **Tierarztl Prax** 1996 Oct;24(5):484–8 (Eng. Abstr.) **(Ger)**

ANESTHESIA, LOCAL

see related

ANESTHETICS, LOCAL

Intravenous infusions of nifedipine: an alternative for the prevention of hypertension in eye surgery under local anesthesia. Nastou H, et al. **Acta Anaesthesiol Belg** 1997; 48(2):77–83

Pre-emptive effect of pre-incisional versus post-incisional infiltration of local anaesthesia on children undergoing hernioplasty. Dahl V, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):847–51

Inclusion of pethidine in lidocaine for infiltration improves analgesia following tonsillectomy in children. Elhakim M, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):214–7

Local anaesthesia and propofol-fentanyl sedation for carotid artery surgery. Nordström O, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):724–8

The Schirmer test with topical anaesthesia. A latent learning effect? [letter] Patel S, et al. **Acta Ophthalmol Scand** 1995 Dec;73(6):574–5

Comparison of etidocaine and bupivacaine + lidocaine in retrobulbar anaesthesia. Ruusuvaara P, et al. **Acta Ophthalmol Scand** 1995 Dec;73(6):563–6

Use of sedation and local anesthesia to prepare children for procedures. Sectish TC. **Am Fam Physician** 1997 Feb 15; 55(3):909–16 (24 ref.)

Upper airway anesthesia reduces phasic genioglossus activity during sleep apnea. Berry RB, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):127–32

Local anesthesia for infrainguinal arterial reconstruction. Barkmeier LD, et al. **Am J Surg** 1997 Aug;174(2):202–4

Parathyroid surgery using monitored anesthesia care as an alternative to general anesthesia. Ditkoff BA, et al. **Am J Surg** 1996 Dec;172(6):698–700

Midazolam-flumazenil topical anaesthesia for microlaryngoscopy with jet ventilation. Rushatamukayanunt W, et al. **Anaesth Intensive Care** 1997 Aug;25(4):358–64

Oxygenation of patients undergoing ophthalmic surgery under local anaesthesia. Risdall JE, et al. **Anaesthesia** 1997 May;52(5):492–5

Use of alfentanil and propofol for outpatient monitored anesthesia care: determining the optimal dosing regimen. Avramov MN, et al. **Anesth Analg** 1997 Sep;85(3):566–72

Medial canthus (caruncle) single injection periocular anesthesia. Ripart J, et al. **Anesth Analg** 1996 Dec; 83(6):1234–8

Interactions between midazolam and remifentanil during monitored anesthesia care. Avramov MN, et al. **Anesthesiology** 1996 Dec;85(6):1283–9

Cardiac outcomes after regional or general anesthesia: do we know the question? [letter; comment] Beattie C, et al. **Anesthesiology** 1996 Nov;85(5):1207–9. Comment on: Anesthesiology 1996 Jan;84(1):1–2.

Local anesthesia in posterior cervical surgery. Nygaard OP, et al. **Anesthesiology** 1997 Jan;86(1):242–3

Shoulder reduction without anesthesia [letter; comment] Kolb JC, et al. **Ann Emerg Med** 1996 Nov;28(5):581–2. Comment on: Ann Emerg Med 1996 Jan;27(1):92–4.

Prevention of flash fires during facial surgery performed under local anesthesia. Howard BK, et al. **Ann Otol Rhinol Laryngol** 1997 Mar;106(3):248–51

Local and regional anesthesia for functional endoscopic sinus surgery. Lee WC, et al. **Ann Otol Rhinol Laryngol** 1997 Sep;106(9):767–9

Anesthetic efficacy of eutectic prilocaine-lidocaine cream in pediatric oncology patients undergoing lumbar puncture. Juárez Gimenez JC, et al. **Ann Pharmacother** 1996 Nov; 30(11):1235–7

A study of the effects of epinephrine infiltration on delayed bleeding in a rat flap model. Rey RM Jr, et al. **Ann Plast Surg** 1996 Oct;37(4):406–10

Extended V-Y flap: patient reports and reconsideration. Terashi H, et al. **Ann Plast Surg** 1997 Feb;38(2):147–50

Is an outpatient appointment required for patients referred for a minor operation under local anaesthetic? Johnson RC, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5 Suppl):223–5

Surgical treatment of cystic swellings of the scrotum under local anaesthesia. Lavelle MA. **Ann R Coll Surg Engl** 1996 Nov;78(6):541–3

A prospective trial of local versus general anaesthesia for arthroscopic surgery of the knee. Williams CR, et al. **Ann R Coll Surg Engl** 1997 Sep;79(5):345–8

Simultaneous repair of bilateral inguinal hernias under local anesthesia [letter; comment] Celdrán A, et al. **Ann Surg** 1997 Jul;226(1):113–4. Comment on: Ann Surg 1996 Mar;223(3):249–52.

Simultaneous repair of bilateral inguinal hernias under local anesthesia [letter; comment] Voeller GR, et al. **Ann Surg** 1997 Feb;225(2):240–1. Comment on: Ann Surg 1996 Mar;223(3):249–52.

Local anesthesia in outpatient knee arthroscopy: a comparison of efficacy and cost. Lintner S, et al. **Arthroscopy** 1996 Aug;12(4):482–8

Local anesthesia for arthroscopic surgery of the ankle using pethidine or prilocaine. Westman L, et al. **Arthroscopy** 1997 Jun;13(3):307–12

Local anaesthesia to the airway reduces sedation requirements in patients undergoing artificial ventilation [see comments] Mallick A, et al. **Br J Anaesth** 1996 Dec; 77(6):731–4. Comment in: Br J Anaesth 1997 Apr;78(4):479–80.

Patient-controlled sedation for cataract surgery using peribulbar block. Pac-Soo CK, et al. **Br J Anaesth** 1996 Sep;77(3):370–4

One stage vertical rectus muscle recession using adjustable sutures under local anaesthesia. Rauz S, et al. **Br J Ophthalmol** 1996 Aug;80(8):713–8

Local anaesthetic for lower-limb revascularization in high-risk patients. Mackay CA, et al. **Br J Surg** 1997 Aug; 84(8):1096–8

The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. The United Kingdom and Eire Bladder Tumour Antigen Study Group. **Br J Urol** 1997 Mar;79(3):362–6

Airway anaesthesia during fibreoptic endoscopy [letter] Jones M, et al. **Can J Anaesth** 1997 Jul;44(7):785

Middle ear surgery under local anaesthesia and sedation. Edussuriya B, et al. **Ceylon Med J** 1997 Jun;42(2):75–7

Local anesthesia with thoracoscopic talc poudrage pleurodesis [letter; comment] Aelony Y, et al. **Chest** 1996 Oct;110(4):1126–7. Comment on: Chest 1995 Sep;108(3):828–41.

Pain during arterial puncture. Giner J, et al. **Chest** 1996 Dec; 110(6):1443–5

Thoracoscopic wedge resection of blebs under local anesthesia with sedation for treatment of a spontaneous pneumothorax [see comments] Nezu K, et al. **Chest** 1997 Jan;111(1):230–5. Comment in: Chest 1997 Jun;111(6):1785.

Therapeutic thoracoscopy under local anesthesia [letter; comment] Yim AP, et al. **Chest** 1997 Jun;111(6):1785. Comment on: Chest 1997 Jan;111(1):230–5.

Local anaesthesia in middle ear surgery: survey of patients and surgeons. Yung MW. **Clin Otolaryngol** 1996 Oct; 21(5):404–8

Tumescent anesthesia with a lidocaine dose of 55 mg/kg is safe for liposuction [editorial] Coleman WP 3rd. **Dermatol Surg** 1996 Nov;22(11):919

Topical anesthetic agents in dermatologic surgery. A review. Lener EV, et al. **Dermatol Surg** 1997 Aug;23(8):673–83 (58 ref.)

Tumescent anesthesia with a lidocaine dose of 55 mg/kg is safe for liposuction. Ostad A, et al. **Dermatol Surg** 1996 Nov;22(11):921–7

Removal of femoral Kuntscher nails in selected cases under local anaesthesia. Onwuanyi ON, et al. **East Afr Med J** 1996 Dec;73(12):835–7

A simple test for predicting patients' tolerance of upper gastrointestinal endoscopy [letter] Ladas SD, et al. **Endoscopy** 1997 Jun;29(5):430

Gastrointestinal endoscopy: to sedate or not to sedate? [editorial; comment] Quine MA, et al. **Endoscopy** 1996 Mar; 28(3):306–7. Comment on: Endoscopy 1996 Mar;28(3):277–82.

Sedation for upper gastrointestinal endoscopy: as much as possible, or without? [editorial] Rey JF. **Endoscopy** 1996 Mar;28(3):308–9

Throat spray for upper gastrointestinal endoscopy is quite acceptable to patients [see comments] Tan CC, et al. **Endoscopy** 1996 Mar;28(3):277–82. Comment in: Endoscopy 1996 Mar;28(3):306–7.

A comparison of topical Emla cream with Bonain's solution for anesthesia of the tympanic membrane during tympanocentesis. Jyväkorpi M. **Eur Arch Otorhinolaryngol** 1996;253(4–5):234–6

Implantation of a unipolar cardioverter/defibrillator system under local anaesthesia [see comments] Stix G, et al. **Eur Heart J** 1996 May;17(5):764–8. Comment in: Eur Heart J 1996 May;17(5):653–5.

Unipolar cardioverter/defibrillator systems implanted under local anaesthesia--a further step to feasibility and safety [editorial; comment] Weismüller P, et al. **Eur Heart J** 1996 May;17(5):653–5. Comment on: Eur Heart J 1996 May;17(5):764–8.

Reducing pain of first trimester abortion under local anaesthesia. Donati S, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec 27;70(2):145–9

Pattern of anesthetic diffusion during peribulbar infiltration: a CT evaluation. Neuschuler R, et al. **Eur J Ophthalmol** 1996 Jul-Sep;6(3):336–9

Local versus general anaesthesia in carotid endarterectomy: a systematic review of the evidence. Tangkanakul C, et al. **Eur J Vasc Endovasc Surg** 1997 May;13(5):491–9

Transurethral ureteroscopy: is local anesthesia with intravenous sedation sufficiently effective and safe? Miroglu C, et al. **Eur Urol** 1997;31(1):36–9

The effectiveness of peri-operative cardiac monitoring and pulse oximetry. Jayamanne DG, et al. **Eye** 1996;10 (Pt 1):130–2

Testing for anaesthesia following peribulbar block [letter] Pathmanathan T, et al. **Eye** 1995;9 (Pt 6):810

Pre-operative assessment and investigation of ophthalmic patients [letter; comment] Walters G. **Eye** 1997;11 (Pt 1):143. Comment on: Eye 1996;10 (Pt 1):138–40.

Office laparoscopy under local anesthesia for gamete intrafallopian transfer: technique and tolerance. Milki AA, et al. **Fertil Steril** 1997 Jul;68(1):128–32

Comparison of intra-articular lignocaine and a suprascapular nerve block for acute anterior shoulder dislocation. Gleeson AP, et al. **Injury** 1997 Mar;28(2):141–2

Lipolysis in human fat cells obtained under local and general anesthesia. Large V, et al. **Int J Obes Relat Metab Disord** 1997 Jan;21(1):78–82

The use of EMLA cream and 1% lidocaine infiltration in men for relief of pain associated with the removal of genital warts by cryotherapy. Menter A, et al. **J Am Acad Dermatol** 1997 Jul;37(1):96–100

Topical anesthesia for hysteroscopy in postmenopausal women. Cicinelli E, et al. **J Am Assoc Gynecol Laparosc** 1996 Nov;4(1):9–12

Serum bupivacaine levels during laparoscopic sterilization using local anesthesia. Lipscomb GH, et al. **J Am Assoc Gynecol Laparosc** 1994 Nov;2(1):27–30

The effect of nitrous oxide and carbon dioxide pneumoperitoneum on operative and postoperative pain during laparoscopic sterilization under local anesthesia. Lipscomb GH, et al. **J Am Assoc Gynecol Laparosc** 1994 Nov;2(1):57–60

Anesthesia for neonatal circumcision [letter; comment] Cold CJ, et al. **J Am Board Fam Pract** 1997 Jul-Aug;10(4):310–1 . Comment on: J Am Board Fam Pract 1997 Jan-Feb;10(1):13–9.

Buffered lidocaine decreases the pain of digital anesthesia in the foot. Friedman HE, et al. **J Am Podiatr Med Assoc** 1997 May;87(5):219–23

Anesthetic management and outcome following noncardiac surgery in nonparturients with Eisenmenger's physiology. Raines DE, et al. **J Clin Anesth** 1996 Aug;8(5):341–7 (33 ref.)

A comparison of propofol and remifentanil during monitored anesthesia care. Smith I, et al. **J Clin Anesth** 1997 Mar; 9(2):148–54

The use of lignocaine in dental practice: results of a survey of a group of general and hospital dental practitioners. Rowson JE, et al. **J Dent** 1997 Sep;25(5):431–3

Lidocaine anesthesia. Richards JW Jr. **J Fam Pract** 1996 Nov; 43(5):502

Carpal tunnel decompression under local anaesthetic and

tourniquet control. Baguneid MS, et al. **J Hand Surg [Br]** 1997 Jun;22(3):322–4

Flexible transnasal endoscopy: is local anaesthetic necessary? Singh V, et al. **J Laryngol Otol** 1997 Jul;111(7):616–8

Methods for X-ray microanalysis of epidermis: the effect of local anaesthesia. Grängsjö A, et al. **J Microsc** 1997 Apr; 186 (Pt 1):23–7

Randomized double-blind trial of low- and moderate-dose lidocaine regional anesthesia for forearm fractures in childhood. Bratt HD, et al. **J Pediatr Orthop** 1996 Sep–Oct; 16(5):660–3

Effects of clonidine pretreatment on the local anaesthetic activity of bupivacaine in mice. Attolini L, et al. **J Pharm Pharmacol** 1995 Dec;47(12A):994–6

Pain control in recovering alcoholics: effects of local anesthesia. Fiset L, et al. **J Stud Alcohol** 1997 May; 58(3):291–6

Lack of local anaesthetic efficacy of Sarapin in the abaxial sesamoid block model. Harkins JD, et al. **J Vet Pharmacol Ther** 1997 Jun;20(3):229–32

Extraction of Kuntscher (femoral) implant under local anaesthesia: an appraisal of patients tolerance and merits. Onwuanyi ON, et al. **JPMA J Pak Med Assoc** 1997 Jun; 47(6):153–5

Neonatal circumcision [letter; comment] Cold CJ. **Lancet** 1997 Apr 26;349(9060):1257–8. Comment on: Lancet 1997 Mar 1;349(9052):599–603.

Regional/local anesthesia: a safe and reasonable choice for patients undergoing carotid endarterectomy. Buchbinder D, et al. **Md Med J** 1997 Mar;46(3):125–30

Efficacy and safety of lidocaine-prilocaine cream for pain during circumcision [see comments] Taddio A, et al. **N Engl J Med** 1997 Apr 24;336(17):1197–201. Comment in: N Engl J Med 1997 Apr 24;336(17):1244–5. Comment in: N Engl J Med 1997 Aug 21;337(8):568; discussion 569–70. Comment in: N Engl J Med 1997 Aug 21;337(8):568–9; discussion 569–70. Comment in: N Engl J Med 1997 Aug 21;337(8):569; discussion 569–70.

Local anesthetic safety in pediatric patients. Davis MJ, et al. **N Y State Dent J** 1996 Feb;62(2):32–5

Effects of ketoprofen and mesosalpinx infiltration on postoperative pain after laparoscopic sterilization. Van Ee R, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):568–72

Influence of topical anesthesia on tests diagnostic of blepharitis-associated dry eye syndrome. Herreras JM, et al. **Ocul Immunol Inflamm** 1997 Mar;5(1):33–41

Laser-uvulopalatoplasty (LUPP) under local anesthesia: effective, safe and comfortable. Haraldsson PO, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Mar–Apr; 58(2):99–104

An anatomic approach to local anesthesia for surgery of the nose and paranasal sinuses. Rontal M, et al. **Otolaryngol Clin North Am** 1997 Jun;30(3):403–20

Anaesthetic management during awake craniotomy in a 12-year-old boy. Tobias JD, et al. **Paediatr Anaesth** 1997; 7(4):341–4

Breast reduction under intravenous sedation: a review of 50 cases [letter; comment] Aldo Mottura A. **Plast Reconstr Surg** 1997 Jun;99(7):2113–4. Comment on: Plast Reconstr Surg 1996 Apr;97(5):952–6; discussion 957–8.

Breast reduction under local anesthesia with intravenous sedation [letter; comment] Stryker AK. **Plast Reconstr Surg** 1997 Jan;99(1):256–7. Comment on: Plast Reconstr Surg 1996 Apr;97(5):952–6; discussion 957–8.

Local anaesthesia for major general surgical procedures. A review of 116 cases over 12 years. Dennison A, et al. **Postgrad Med J** 1996 Feb;72(844):105–8

Patients undergoing vitreous surgery under local anesthesia [letter] Willis AW. **Retina** 1997;17(2):169

Ankle arthroscopy under local and general anaesthesia for diagnostic evaluation and treatment. Rolf C, et al. **Scand J Med Sci Sports** 1996 Aug;6(4):255–8

Where there is no anaesthetist: a study of 282 consecutive patients using intravenous, spinal and local infiltration anaesthetic techniques. Adesunkanmi AR. **Trop Doct** 1997 Apr;27(2):79–82

[Combined loco-regional anesthesia and intravenous anesthesia with propofol (Diprivan—Zeneca)] Badeva B, et al. **Khirurgiia (Sofiia)** 1996;49(4):12–3 (Eng. Abstr.) **(Bul)**

[Local anesthesia] Meley M, et al. **Ann Chir** 1997;51(3):289–91 (Eng. Abstr.) **(Fre)**

[Role of topical anesthesia in strabismus surgery] Paris V, et al. **Bull Soc Belge Ophtalmol** 1995;259:155–64 (Eng. Abstr.) **(Fre)**

[Tubal ligation using minilaparotomy under local anesthesia. Apropos of 800 cases at the University Hospital Center in Dakar] Cisse CT, et al. **Contracept Fertil Sex** 1997 Apr; 25(4):X–XV **(Fre)**

[Parathyroidectomy under local anesthesia. First two cases in Lebanon and review of the literature] Abboud B, et al. **J Med Liban** 1997;45(2):107–11 (31 ref.) (Eng. Abstr.) **(Fre)**

[Use of percutaneous anesthesia in cardiac pacemaker implantation] Trigano JA, et al. **Presse Med** 1996 Jul 6–13; 25(24):1097–100 (Eng. Abstr.) **(Fre)**

[Remarks on the work of G. Hege-Scheuing et al. Analgesia with intra-articular morphine after knee joint arthroscopy? Anaesthesist (1995) 44:351–358 (comment)] Stein C, et al. **Anaesthesist** 1996 Mar;45(3):287–8. Comment on: Anaesthesist 1995 May;44(5):351–8. **(Ger)**

[Comment on the contribution by K.A. Strub et al. On the local infiltration of epinephrine and bupivacaine before tonsillectomy (letter)] Plath P. **HNO** 1997 Jun;45(6):432 **(Ger)**

[Local infiltration of epinephrine and bupivacaine before tonsillectomy] Strub KA, et al. **HNO** 1996 Dec; 44(12):672–6 (Eng. Abstr.) **(Ger)**

[Superficial sponge anesthesia in cataract surgery (with scleral tunnel incision)] Pham DT, et al. **Klin Monatsbl Augenheilkd** 1996 Dec;209(6):347–53 (Eng. Abstr.) **(Ger)**

[Local anesthesia in operations of the head-neck area] Grevers G, et al. **Laryngorhinootologie** 1996 Jul;75(7):433–6 (10 ref.) (Eng. Abstr.) **(Ger)**

[Damage to sense of smell and taste following xylocaine administration? Process before the expert evaluation committee for medical malpractice of the North Rhine Physicians Organization in 1995 (Az. 91/588)] Wienke A. **Laryngorhinootologie** 1996 Feb;75(2):109–10 **(Ger)**

[Vitreoretinal operations with local anesthesia] Mutsch A, et al. **Ophthalmologe** 1996 Dec;93(6):719–23 (Eng. Abstr.) **(Ger)**

[Eyedrop anesthesia in cataract surgery] Strobel I, et al. **Ophthalmologe** 1996 Feb;93(1):68–72 (Eng. Abstr.) **(Ger)**

[Our experience with prostatic incision (TUIP) with local anesthesia] Del Boca C, et al. **Arch Ital Urol Androl** 1997 Feb;69(1):23–8 (Eng. Abstr.) **(Ita)**

[Surgical treatment of inguinal hernia using a "tension-free" technique and local anesthesia. Initial experience] Gianetta E, et al. **Minerva Chir** 1996 Jun;51(6):405–12 (Eng. Abstr.) **(Ita)**

[The role of transdermal anesthesia with EMLA in urologic surgery] Tedeschi D, et al. **Minerva Urol Nefrol** 1997 Jun; 49(2):87–9 (Eng. Abstr.) **(Ita)**

[Video-assisted bedside pleuroscopy under local anesthesia: use of a rigid cystoureteroscope in patients with undiagnosed pleural effusion] Sakurai S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:148–54 (Eng. Abstr.) **(Jpn)**

[Local anesthesia in inguinoscrotal pathology] López Cubillana P, et al. **Actas Urol Esp** 1996 May;20(5):459–64 (Eng. Abstr.) **(Spa)**

[Analysis of regional anesthetic efficacy in pediatric postop pain] Martínez-Tellería A, et al. **Cir Pediatr** 1997 Jan; 10(1):18–20 (Eng. Abstr.) **(Spa)**

[Subconjunctival anesthesia: an alternative for vitrectomy in mitochondrial myopathy] Ortiz M, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):159–60 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Optic nerve injury after retrobulbar anesthesia [letter; comment] Devoto MH, et al. **Arch Ophthalmol** 1997 May; 115(5):687–8. Comment on: Arch Ophthalmol 1996 Mar;114(3):351–3.

Subperiosteal orbital hemorrhage from retrobulbar injection resulting in blindness [letter; comment] Girard LJ. **Arch Ophthalmol** 1997 Aug;115(8):1085–6. Comment on: Arch Ophthalmol 1997 Jan;115(1):123–4.

Subperiosteal orbital hemorrhage from retrobulbar injection resulting in blindness [see comments] Mootha VV, et al. **Arch Ophthalmol** 1997 Jan;115(1):123–4. Comment in: Arch Ophthalmol 1997 Aug;115(8):1085–6.

Brainstem anaesthesia after peribulbar anaesthesia. Gomez RS, et al. **Can J Anaesth** 1997 Jul;44(7):732–4

Vitreous hemorrhage following retrobulbar anesthesia. Labelle PF, et al. **Can J Ophthalmol** 1996 Feb;31(1):21–4

Brain-stem anesthesia following retrobulbar anesthesia: case report and possible pathophysiologic mechanism. Mandelcorn MS, et al. **Can J Ophthalmol** 1996 Feb; 31(1):24–6

Post-Norplant implants insertion anaphylactoid reaction: a case report. Gbolade BA. **Contraception** 1997 May; 55(5):319–20

Adverse effects of class I antiarrhythmic drugs. Caron J, et al. **Drug Saf** 1997 Jul;17(1):8–36 (366 ref.)

Local anaesthesia revisited [editorial; comment] Boase DL. **Eye** 1996;10 (Pt 5):531–2. Comment on: Eye 1996;10(Pt 5):533–6.

Ocular perforation during peribulbar anaesthesia [see comments] Gillow JT, et al. **Eye** 1996;10 (Pt 5):533–6. Comment in: Eye 1996;10(P6 5):531–2.

A survey of ocular perforation during ophthalmic local anaesthesia in the United Kingdom. Gillow JT, et al. **Eye** 1996;10 (Pt 5):537–8

Experimental study on necrotizing sialometaplasia of the palate in rats. Role of local anesthetic injections. Shigematsu H, et al. **Int J Oral Maxillofac Surg** 1996 Jun; 25(3):239–41

Globe rupture during digital massage after peribulbar anesthesia. Rathi V, et al. **J Cataract Refract Surg** 1997 Mar;23(2):297–9

Methemoglobinemia complicating topical anesthesia during bronchoscopic procedures. Clary B, et al. **J Thorac Cardiovasc Surg** 1997 Aug;114(2):293–5

Restrictive strabismus after retrobulbar anesthesia. Ando K, et al. **Jpn J Ophthalmol** 1997 Jan–Feb;41(1):23–6

Orbital hemorrhage after the administration of sub-Tenon's infusion anesthesia. Olitsky SE, et al. **Ophthalmic Surg Lasers** 1997 Feb;28(2):145–6

Corneal endothelial toxicity of topical anesthesia. Judge AJ, et al. **Ophthalmology** 1997 Sep;104(9):1373–9

Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Luchetti W, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jan;81(1):21–5

[Tension pneumothorax after intercostal blockade] Bjerre J. **Ugeskr Laeger** 1997 Aug 18;159(34):5103–4 (Eng. Abstr.) **(Dan)**

[Comparison of analgesic effect of lidocaine tape versus eutectic mixture of lidocaine and tetracaine during infiltration of local anesthetics before epidural block] Kawano T, et al. **Masui** 1996 Sep;45(9):1074–7 (Eng. Abstr.) **(Jpn)**

ECONOMICS

Knee arthroscopy: a cost analysis of general and local anesthesia. Trieshmann HW Jr. **Arthroscopy** 1996 Feb; 12(1):60–3

A comparison of the cost of local versus general anesthesia for laparoscopic sterilization in an operating room setting. Lipscomb GH, et al. **J Am Assoc Gynecol Laparosc** 1996 Feb;3(2):277–81

INSTRUMENTATION

Astra's plastic cartridges [letter] Balfry GK. **Br Dent J** 1996 Nov 9;181(9):318

New sheath for vascular access and subcutaneous drug administration: multicenter clinical trial for pain prevention after cardiac catheterization [see comments] Lambert CR, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):81–3. Comment in: Cathet Cardiovasc Diagn 1997 Jan;40(1):84.

Reducing the risk of needlesticks: methods used to reload syringes. Drelich EV. **J Am Dent Assoc** 1997 Jan; 128(1):55–9

Anesthesia blocks of the lower extremity. Comparing the Biojector with needle and syringe. Gerbert J, et al. **J Am Podiatr Med Assoc** 1996 May;86(5):195–204

Computerized local anesthetic delivery vs. traditional syringe technique. Subjective pain response. Hochman M, et al. **N Y State Dent J** 1997 Aug–Sep;63(7):24–9

A disposable needle for frontalis suspension surgery in congenital ptosis. Daví G, et al. **Ophthalmic Surg Lasers** 1997 Jul;28(7):607–8

METHODS

A double-blind randomized trial of low-dose versus high-dose topical anaesthesia in unsedated upper gastrointestinal endoscopy. Mulcahy HE, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):975–9

Informed consent and parental choice of anesthesia and sedation for the repair of small lacerations in children. Yamamoto LG, et al. **Am J Emerg Med** 1997 May; 15(3):285–9

Single quadrant sub-Tenon's block. Evaluation of a new local anaesthetic technique for eye surgery. Guise PA. **Anaesth Intensive Care** 1996 Apr;24(2):241–4

Anaesthesia for a patient with a mediastinal mass presenting with acute stridor. Lewer BM, et al. **Anaesth Intensive Care** 1996 Oct;24(5):605–8

Postoperative morbidity following cataract surgery [letter; comment] Francis JG. **Anaesthesia** 1996 Sep;51(9):888–9. Comment on: Anaesthesia 1996 May;51(5):435–7.

The rectus sheath block—well worth remembering [letter] [see comments] Muir J, et al. **Anaesthesia** 1996 Sep; 51(9):893–4. Comment in: Anaesthesia 1997 Mar;52(3):287.

Airway management and rigid spine syndrome. Kitayama M, et al. **Anesth Analg** 1997 Mar;84(3):690–1

Medial canthus (caruncle) single injection periocular anesthesia [letter] Loken RG, et al. **Anesth Analg** 1997 Sep; 85(3):707–8

EMLA versus TAC for topical anesthesia of extremity wounds in children. Zempsky WT, et al. **Ann Emerg Med** 1997 Aug;30(2):163–6

Clinical parameters of tumescent anesthesia in skin cancer reconstructive surgery. A review of 86 patients. Acosta AE. **Arch Dermatol** 1997 Apr;133(4):451–4

The effectiveness of sub-Tenon's infiltration of local anaesthesia for cataract surgery. Verghese I, et al. **Aust N Z J Ophthalmol** 1996 May;24(2):117–20

Bone marrow harvesting using local anaesthesia and PCA-alfentanil: a feasible alternative to general or regional anaesthesia. Sim KM, et al. **Bone Marrow Transplant** 1996 Oct;18(4):787–90

Palatal injection technique [letter; comment] [see comments] Greenwood I. **Br Dent J** 1997 Apr 12;182(7):245. Comment on: Br Dent J 1997 Jan 25;182(2):50. Comment in: Br Dent J 1997 Jun 28;182(12):453.

Hyaluronidase and peribulbar block. Dempsey GA, et al. **Br J Anaesth** 1997 Jun;78(6):671–4

Intraocular pressure changes after peribulbar injections with and without ocular compression [letter; comment] Ellis J, et al. **Br J Ophthalmol** 1997 May;81(5):421. Comment on: Br J Ophthalmol 1996 May;80(5):394–7.

Re-evaluation of hyaluronidase in peribulbar anaesthesia. Prosser DP, et al. **Br J Ophthalmol** 1996 Sep;80(9):827–30

Cataract surgery with 0.75% bupivacaine [letter; comment] Heston JP, et al. **Can J Ophthalmol** 1996 Oct;31(6):328. Comment on: Can J Ophthalmol 1995 Aug;30(5):264–6.

Some observations concerning visual perception during vitrectomy after retrobulbar anesthesia. Mandelcorn MS,

et al. **Can J Ophthalmol** 1997 Jun;32(4):255–6
Intranasal application of lidocaine jelly preoperatively in patients undergoing dacryocystorhinostomy. Pelletier CR, et al. **Can J Ophthalmol** 1996 Aug;31(5):245
Local anaesthesia in inguinal herniorrhaphy: our experience in Ile-Ife, Nigeria. Agbakwuru E, et al. **Cent Afr J Med** 1995 Dec;41(12):405–9
Anesthesia for lip augmentation [letter] Elson ML. **Dermatol Surg** 1997 May;23(5):405
Harvesting split-thickness grafts with tumescent anesthesia [letter] Field LM, et al. **Dermatol Surg** 1997 Jan;23(1):62
Bilevel tumescent anesthetic infiltration for hair transplantation. Field LM, et al. **Dermatol Surg** 1997 Apr; 23(4):289–90 (07 ref.)
Problems of tumescent anesthesia for dermabrasion [letter; comment] Field LM. **Dermatol Surg** 1997 Jun;23(6):497–9 . Comment on: J Dermatol Surg Oncol 1994 Dec;20(12):802–7.
Evaluation of solution temperature for local tumescent anesthesia [letter; comment] Shiffman M. **Dermatol Surg** 1997 Apr;23(4):309. Comment on: Dermatol Surg 1996 Aug;22(8):707–9.
Technique of local anesthesia for anorectal surgery [letter] Nivatvongs S. **Dis Colon Rectum** 1997 Sep;40(9):1128–9
Hook-needle puncture. A new technique of local anesthesia for anorectal surgery. Sobrado CW, et al. **Dis Colon Rectum** 1996 Nov;39(11):1330–1
Value of sedative premedication in female sterilization via minilaparotomy: a prospective study of two local anaesthesia regimen. Ruminjo JK, et al. **East Afr Med J** 1995 Oct;72(10):678–83
Initial experience with implantation of internal cardioverter/defibrillators under local anaesthesia by electrophysiologists. Schmitt C, et al. **Eur Heart J** 1996 Nov;17(11):1710–6
Cocaine or phenylephrine/lignocaine for nasal fibreoptic intubation? Latorre F, et al. **Eur J Anaesthesiol** 1996 Nov; 13(6):577–81
One quadrant sub-Tenon's capsule anesthesia in anterior segment surgery. Kapran Z, et al. **Eur J Ophthalmol** 1996 Apr-Jun;6(2):131–6
Oral low-dose midazolam as premedication for intraocular surgery in retrobulbar anesthesia: cardiovascular effects and relief of perioperative anxiety. Kiefer RT, et al. **Eur J Ophthalmol** 1997 Apr-Jun;7(2):185–92
Topical anesthesia for phacoemulsification surgery [letter; comment] Lindley-Jones M. **Eye** 1996;10 (Pt 5):650. Comment on: Eye 1995;9 (Pt 4):456–9.
Trabeculectomy in subconjunctival anesthesia [letter] Pfeiffer N, et al. **Ger J Ophthalmol** 1996 May;5(3):182–3
A comparison of blood pressure changes in phacoemulsification cataract surgery with topical and retrobulbar block local anesthesia. Suzuki R, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 May;235(5):277–82
Dilatation of radiation-induced esophageal strictures under sublingual buprenorphine analgesia: a pilot study. Desai DC, et al. **Indian J Gastroenterol** 1997 Jan;16(1):14–5
Topical pharyngeal anesthesia without intravenous sedation during upper gastrointestinal endoscopy. Dhir V, et al. **Indian J Gastroenterol** 1997 Jan;16(1):10–1
An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. Ulmsten U, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(2):81–5; discussion 85–6
Topical anaesthesia for bladder biopsies and cautery: intravesical lidocaine versus caudal anaesthesia. Amano T, et al. **Int Urol Nephrol** 1995;27(5):533–7
The use of topical anesthesia in diagnostic hysteroscopy and endometrial biopsy. Zupi E, et al. **J Am Assoc Gynecol Laparosc** 1994 May;1(3):249–52
Local anesthesia for circumcision: which technique is most effective? [see comments] Lenhart JG, et al. **J Am Board Fam Pract** 1997 Jan-Feb;10(1):13–9. Comment in: J Am Board Fam Pract 1997 Jul-Aug;10(4):310–1.
Painless palatal anesthesia. McArdle BF. **J Am Dent Assoc** 1997 May;128(5):647
Consultation section. Cataract surgery and ocular anesthesia. **J Cataract Refract Surg** 1996 Nov;22(9):1135–42
Circumferential perilimbal anesthesia [see comments] Anderson CJ. **J Cataract Refract Surg** 1996 Oct; 22(8):1009–12. Comment in: J Cataract Refract Surg 1997 Jan-Feb;23(1):6–7.
Is topical anesthesia adequate? [letter; comment] Bernstein RM. **J Cataract Refract Surg** 1997 Jan-Feb;23(1):6–7. Comment on: J Cataract Refract Surg 1996 Oct;22(8):1009–12.
Surgical repair of multiple ruptures of radial and transverse incisions under topical anesthesia [letter] Eggleston RJ. **J Cataract Refract Surg** 1996 Dec;22(10):1394
Use of topical anesthesia alone in cataract surgery. Fichman RA. **J Cataract Refract Surg** 1996 Jun;22(5):612–4
Indicators of patient suitability for topical anesthesia. Fraser SG, et al. **J Cataract Refract Surg** 1997 Jun;23(5):781–3
Intracameral preserved lidocaine [letter] Fry LL. **J Cataract Refract Surg** 1997 Jan-Feb;23(1):10
Retrobulbar block revisited and revised. Hamilton RC. **J Cataract Refract Surg** 1996 Nov;22(9):1147–50
General or topical anesthesia? [letter] Hayashi JD. **J Cataract Refract Surg** 1997 Jun;23(5):696–7
Patient comfort during cataract surgery with modified topical and peribulbar anesthesia. Maclean H, et al. **J Cataract Refract Surg** 1997 Mar;23(2):277–83
Patient comfort with topical and peribulbar anesthesia [letter] Percival P. **J Cataract Refract Surg** 1997 Jul-Aug;23(6):818
Topical versus peribulbar anesthesia in cataract surgery. Roman S, et al. **J Cataract Refract Surg** 1996 Oct; 22(8):1121–4
Retrobulbar block revised [letter] Spak KE. **J Cataract Refract Surg** 1997 Jun;23(5):697
Lidocaine anesthesia. Richards JW Jr. **J Fam Pract** 1996 Nov; 43(5):502
Maxillary antral lavage using inferior meatal cannula anaesthesia. Mochloulis G, et al. **J Laryngol Otol** 1996 Aug; 110(8):763–4
Prolonged oculocardiac reflex during strabismus surgery under topical anesthesia. Arnold RW, et al. **J Pediatr Ophthalmol Strabismus** 1997 Jul-Aug;34(4):252–4
Visual acuity immediately following phacoemulsification with subconjunctival anesthesia. Brothers Arbisser L, et al. **Ophthalmic Surg Lasers** 1996 Jul;27(7):640–2
Approaching a 100% success rate using topical anesthesia with mild intravenous sedation in phacoemulsification procedures. Dinsmore SC. **Ophthalmic Surg Lasers** 1996 Nov;27(11):935–8
Topical anesthesia with benoxinate 0.4% for pterygium surgery. Frucht-Pery J. **Ophthalmic Surg Lasers** 1997 Mar; 28(3):219–22
Combined peribulbar and retrobulbar block anesthesia and antibiotic-steroid injection: a simple method to prevent retrobulbar hemorrhage, globe perforation, or infection. Girard LJ, et al. **Ophthalmic Surg Lasers** 1997 Mar; 28(3):251–4
Sub-Tenon's versus retrobulbar anesthesia for cataract surgery. Khoo BK, et al. **Ophthalmic Surg Lasers** 1996 Sep; 27(9):773–7
Lidocaine-prilocaine cream for local-anesthesia chalazion incision in children. Wessels IF, et al. **Ophthalmic Surg Lasers** 1996 Jun;27(6):431–3
Does warming of anesthetic solutions improve analgesia and akinesia in retrobulbar anesthesia? [letter] Hamilton RC. **Ophthalmology** 1997 Oct;104(10):1528–30
Does warming of anesthetic solutions improve analgesia and akinesia in retrobulbar anesthesia? Krause M, et al. **Ophthalmology** 1997 Mar;104(3):429–32
Retrobulbar blocks [letter; comment] Rockwood EJ. **Ophthalmology** 1995 Sep;102(9):1258. Comment on: Ophthalmology 1995 May;102(5):824–6.
Parabulbar anesthesia for primary vitreoretinal surgery. Sharma T, et al. **Ophthalmology** 1997 Mar;104(3):425–8
The effects of phacoemulsification cataract surgery via local anesthesia on preoperative and postoperative blood pressure levels. Suzuki R, et al. **Ophthalmology** 1997 Feb; 104(2):216–22
Retrobulbar needles during retrobulbar block [letter; comment] Wilson RS. **Ophthalmology** 1995 Sep;102(9):1260 . Comment on: Ophthalmology 1995 May;102(5):824–6.
Anesthetic efficacy of the intraosseous injection in maxillary and mandibular teeth. Coggins R, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jun;81(6):634–41
Intrapulpal injection: factors related to effectiveness. VanGheluwe J, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):38–40
The efficacy and safety of the hematoma block for fracture reduction in closed, isolated fractures. Furia JP, et al. **Orthopedics** 1997 May;20(5):423–6
The effectiveness of mandibular infiltration compared to mandibular block anesthesia in treating primary molars in children. Oulis CJ, et al. **Pediatr Dent** 1996 Jul-Aug; 18(4):301–5
When the surgeon is gloved and the patient needs more local anesthesia [letter] Meyer TN. **Plast Reconstr Surg** 1996 Nov;98(6):1114
Expanded utilization of the tumescent technique for mastectomy [letter] Worland RG. **Plast Reconstr Surg** 1996 Dec;98(7):1321
Is an ounce of preoperative local anesthetic better than a pound of postoperative analgesic? [editorial; comment] Raja SN. **Reg Anesth** 1996 Jul-Aug;21(4):277–80. Comment on: Reg Anesth 1996 Jul-Aug;21(4):281–6.
Extended unilateral anesthesia. New technique or paravertebral anesthesia? Saito T, et al. **Reg Anesth** 1996 Jul-Aug;21(4):304–7
Use of iontophoretic anaesthesia in urologic surgery: a preliminary experience. Png DJ, et al. **Singapore Med J** 1996 Dec;37(6):636–8
The effect and timing of local anesthesia in laparoscopic cholecystectomy. Sarac AM, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):362–6
[Peribulbar anesthesia and intraocular lens implantation] Yang W, et al. **Chung Hua Yen Ko Tsa Chih** 1995 Jul; 31(4):271–3 (Eng. Abstr.) **(Chi)**
[Treatment of inguinal hernias by classical approach and under local anesthesia] Lerut JP, et al. **Ann Chir** 1996; 50(9):747–54 (Eng. Abstr.) **(Fre)**
[Local and regional anesthesia for ambulatory surgery] Ecoffey C, et al. **Rev Med Suisse Romande** 1997 May; 117(5):379–82 (25 ref.) **(Fre)**
[Local anesthetics—maximum recommended doses] Niesel HC. **Anaesthesiol Reanim** 1997;22(3):60–2 (15 ref.) (Eng. Abstr.) **(Ger)**
[Transcutaneous or transconjunctival peribulbar anesthesia?] Bohlender T, et al. **Ophthalmologe** 1997 May;94(5):324–6 (Eng. Abstr.) **(Ger)**
[Local anesthesia in the surgery of inguinal hernia. Technical notes] Palumbo P, et al. **Minerva Chir** 1997 Apr; 52(4):509–12 (Eng. Abstr.) **(Ita)**
[Anesthesia in interventions for diabetic cataract] Zolog I, et al. **Oftalmologia** 1996 Oct-Dec;40(4):389–92 (Eng. Abstr.) **(Rum)**
[The characteristics of local anesthesia in children] Vasmanova EV, et al. **Stomatologiia (Mosk)** 1997;76(1):44–9 **(Rus)**
[Ultracaine anesthesia in surgical otorhinolaryngology] Aniutin RG, et al. **Vestn Otorinolaringol** 1996 Nov-Dec; (6):38–40 (Eng. Abstr.) **(Rus)**
[Leocaine – local anesthetic of new generation in otorhinolaryngology] Karneeva OV, et al. **Vestn Otorinolaringol** 1997;(1):42–3 **(Rus)**
[Diagnostic thoracoscopy (letter; comment)] García-Aguado R, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):298–9 . Comment on: Rev Esp Anestesiol Reanim 1996 Feb;43(2):67–9. **(Spa)**
[Anesthesia for thoracoscopy (see comments)] Unzueta MC, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):67–9 (Eng. Abstr.). Comment in: Rev Esp Anestesiol Reanim 1996 Oct;43(8):298–9. **(Spa)**

PSYCHOLOGY

Patient acceptability of transurethral incision of the prostate under local anaesthesia. Irani I, et al. **Br J Urol** 1996 Dec; 78(6):904–6
Four dimensions of fear of dental injections. Milgrom P, et al. **J Am Dent Assoc** 1997 Jun;128(6):756–66

STANDARDS

The efficacy of local anaesthetics administered by general dental practitioners. Matthews R, et al. **Br Dent J** 1997 Mar 8;182(5):175–8

VETERINARY

Effect of castration method and the provision of local anesthesia on plasma cortisol, scrotal circumference, growth, and feed intake of bull calves. Fisher AD, et al. **J Anim Sci** 1996 Oct;74(10):2336–43
Local and regional anesthesia and analgesia. Pascoe P. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):94–105 (88 ref.)
Local and regional anesthesia in ruminants and swine. Skarda RT. **Vet Clin North Am Food Anim Pract** 1996 Nov; 12(3):579–626 (140 ref.)
[Basis and use of neural therapy in diagnosis and treatment] Zohmann A. **Schweiz Arch Tierheilkd** 1997;139(3):117–25 (58 ref.) (Eng. Abstr.) **(Ger)**

ANESTHESIA, OBSTETRICAL

Preanaesthetic management of the obstetric patient. Alahuhta S. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 2):991–5 (39 ref.)
Anesthetic quality during cesarean section following subarachnoid or epidural administration of bupivacaine with or without fentanyl. Olofsson C, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):332–8
Pre-eclampsia: the effect of intravenous fluid preload on atrial natriuretic peptide secretion during caesarean section under spinal anaesthesia. Pouta A, et al. **Acta Anaesthesiol Scand** 1996 Nov;40(10):1203–9
How to maintain uteroplacental perfusion during obstetric anaesthesia. Alahuhta S, et al. **Acta Anaesthesiol Scand Suppl** 1997;110:106–8
Regional anesthesia for the pregnant cardiac patient. Mitterschiffthaler G. **Acta Anaesthesiol Scand Suppl** 1996; 109:180–4
Anaesthetic management of the pre-eclamptic woman. Rocke A. **Acta Anaesthesiol Scand Suppl** 1997;110:27–8
Prevention of aspiration pneumonitis in the obstetric patient. Søreide E. **Acta Anaesthesiol Scand Suppl** 1997;110:23–4
Anaesthetic lessons to be learnt from confidential inquiries into maternal death. Willatts S. **Acta Anaesthesiol Scand Suppl** 1997;110:25–6
Intravenous infusion of low dose propofol for conscious sedation in cesarean section before spinal anesthesia. Cheng YJ, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):79–84
Prophylaxis against acid aspiration in regional anesthesia for elective cesarean section: a comparison between oral single-dose ranitidine, famotidine and omeprazole assessed with fiberoptic gastric aspiration. Lin CJ, et al. **Acta Anaesthesiol Sin** 1996 Dec;34(4):179–84
Is conscious sedation possible during cesarean delivery under spinal anesthesia? [editorial; comment] Liu CC. **Acta Anaesthesiol Sin** 1996 Sep;34(3):i. Comment on: Acta Anaesthesiol Sin 1996 Sep;34(3):109–15. Comment on: Acta Anaesthesiol Sin 1996 Sep;34(3):117–21. Comment on: Acta Anaesthesiol Sin 1996 Sep;34(3):141–9.
Epidural anesthesia for emergency caesarean section in a patient with single ventricle and aortic stenosis. Peng TC, et al. **Acta Anaesthesiol Sin** 1997 Mar;35(1):39–44
Conscious sedation by low dose propofol infusion during spinal anesthesia for cesarean section [see comments] [published erratum appears in Acta Anaesthesiol Sin 1996 Dec;34(4):252] Wang YP, et al. **Acta Anaesthesiol Sin** 1996 Sep;34(3):117–21. Comment in: Acta Anaesthesiol Sin 1996 Sep;34(3):i.

ANESTHESIA, OBSTETRICAL

Anesthesia in peripartum cardiomyopathy [letter; comment] Perkins V. **Am Heart J** 1996 Dec;132(6):1320. Comment on: Am Heart J 1995 Oct;130(4):860–70.

Prevention of maternal hypotension by epidural administration of ephedrine sulfate during lumbar epidural anesthesia for cesarean section. Fong J, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):985–90

Does station of the fetal head at epidural placement affect the position of the fetal vertex at delivery? Robinson CA, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):991–4

Anaesthetic management of a pregnant, post liver transplant patient for dental surgery. Avraamides EJ, et al. **Anaesth Intensive Care** 1997 Feb;25(1):68–70

Pain associated with 2% lignocaine epidural anaesthesia [letter] Clarke JP, et al. **Anaesth Intensive Care** 1997 Aug; 25(4):435–6

Peripartum cardiomyopathy: four case histories and a commentary on anaesthetic management. George LM, et al. **Anaesth Intensive Care** 1997 Jun;25(3):292–6 (17 ref.)

Uterine rupture and scar dehiscence [letter] Gudgeon CW. **Anaesth Intensive Care** 1997 Aug;25(4):434

Regional anaesthesia for emergency caesarean section in a patient with lepromatous leprosy. Hempenstall K, et al. **Anaesth Intensive Care** 1997 Apr;25(2):168–70

Recovery from mivacurium block with or without anticholinesterase following continuous infusion in obstetric patients. Jan GS, et al. **Anaesth Intensive Care** 1996 Oct;24(5):585–9

Blood loss during suction termination of pregnancy with two different anaesthetic techniques. Kumarasinghe N, et al. **Anaesth Intensive Care** 1997 Feb;25(1):48–50

Management of malignant hyperthermia susceptible parturients. Pollock NA, et al. **Anaesth Intensive Care** 1997 Aug;25(4):398–407

Breakage of Whitacre 27 gauge needle during performance of spinal anaesthesia for caesarean section [letter] Teh J. **Anaesth Intensive Care** 1997 Feb;25(1):96

Anaesthetic management of a quadriplegic patient with severe respiratory insufficiency undergoing caesarean section. Ahmed AB, et al. **Anaesthesia** 1996 Nov; 51(11):1043–5

Ethics in obstetric anaesthesia [letter; comment] Chrispin P. **Anaesthesia** 1996 Dec;51(12):1182–3. Comment on: Anaesthesia 1996 Aug;51(8):717–8.

Ethics in obstetric anaesthesia [letter; comment] Davies AG. **Anaesthesia** 1996 Dec;51(12):1182. Comment on: Anaesthesia 1996 Aug;51(8):717–8.

Repeat dose after an inadequate spinal block [letter] [see comments] Deshpande S, et al. **Anaesthesia** 1996 Sep; 51(9):892. Comment in: Anaesthesia 1997 Feb;52(2):188.

Classification of caesarean section [letter; comment] Dowson S. **Anaesthesia** 1996 Dec;51(12):1183. Comment on: Anaesthesia 1996 Aug;51(8):791–2.

Respiratory effects of spinal anaesthesia for caesarean section. Kelly MC, et al. **Anaesthesia** 1996 Dec;51(12):1120–2

Classification of caesarean sections [letter; comment] Lack JA. **Anaesthesia** 1996 Dec;51(12):1184. Comment on: Anaesthesia 1996 Aug;51(8):791–2.

Inadequate spinal block [letter; comment] Render CA. **Anaesthesia** 1997 Feb;52(2):188. Comment on: Anaesthesia 1996 Sep;51(9):892.

Ethics in obstetric anaesthesia [letter; comment] Spears FD. **Anaesthesia** 1997 Jan;52(1):85. Comment on: Anaesthesia 1996 Aug;51(8):717–8.

Spinal anesthesia for cesarean section in a case of pemphigus foliaceous. Abouleish EI, et al. **Anesth Analg** 1997 Feb; 84(2):449–50

The self-inflating bulb versus end-tidal capnography for confirming tracheal intubation in the parturient undergoing cesarean section [letter] Baraka A, et al. **Anesth Analg** 1997 Oct;85(4):944

Thiopental–rocuronium versus ketamine–rocuronium for rapid-sequence intubation in parturients undergoing cesarean section. Baraka AS, et al. **Anesth Analg** 1997 May; 84(5):1104–7

Practice patterns of anesthesiologists regarding situations in obstetric anesthesia where clinical management is controversial. Beilin Y, et al. **Anesth Analg** 1996 Oct; 83(4):735–41

Safe epidural analgesia in thirty parturients with platelet counts between 69,000 and 98,000 mm(–3). Beilin Y, et al. **Anesth Analg** 1997 Aug;85(2):385–8

Maternal experience during epidural or combined spinal–epidural anesthesia for cesarean section: a prospective, randomized trial. Davies SJ, et al. **Anesth Analg** 1997 Sep;85(3):607–13

Anesthetic management of cesarean delivery complicated by ex utero intrapartum treatment of the fetus. Gaiser RR, et al. **Anesth Analg** 1997 May;84(5):1150–3

The Zavanelli maneuver does not preclude regional anesthesia. Hepner DL, et al. **Anesth Analg** 1997 May; 84(5):1145–6

Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia. Pan PH, et al. **Anesth Analg** 1996 Nov;83(5):982–6

Spinal anesthesia in a patient with prekallikrein deficiency. Pasricha SK, et al. **Anesth Analg** 1996 Dec;83(6):1325–6

The effect of anesthetic techniques on blood coagulability in parturients as measured by thromboelastography. Sharma SK, et al. **Anesth Analg** 1997 Jul;85(1):82–6

Severe maternal hypotension and fetal bradycardia after a combined spinal epidural anesthetic. D'Angelo R, et al. **Anesthesiology** 1997 Jul;87(1):166–8

Changes in the position of epidural catheters associated with patient movement. Hamilton CL, et al. **Anesthesiology** 1997 Apr;86(4):778–84; discussion 29A

Obstetric anesthesia work force survey, 1981 versus 1992 [see comments] Hawkins JL, et al. **Anesthesiology** 1997 Jul; 87(1):135–43. Comment in: Anesthesiology 1997 Jul;87(1):4–5.

Combined spinal and epidural anesthesia in a parturient with idiopathic hypertrophic subaortic stenosis. Ho KM, et al. **Anesthesiology** 1997 Jul;87(1):168–9

Obstetric anesthesia coverage. The problem in perspective [editorial; comment] Lagasse RS, et al. **Anesthesiology** 1997 Jul;87(1):4–5 (7 ref.). Comment on: Anesthesiology 1997 Jul;87(1):135–43.

Women's autonomy in childbirth. Courts should also take evidence from obstetric anaesthetists [letter] Holdcroft A. **BMJ** 1997 Aug 23;315(7106):488

General anaesthesia does not usually affect the fetus [letter] Raftery S. **BMJ** 1997 Aug 23;315(7106):488

Do fetuses feel pain? Surgical terminations of pregnancy take place under general anaesthesia [letter; comment] Savage W. **BMJ** 1997 Apr 19;314(7088):1201. Comment on: BMJ 1997 Jan 25;314(7076):302–3. Comment on: BMJ 1997 Jan 25;314(7076):303.

CSF progesterone and spread of subarachnoid anaesthesia in pregnancy [letter; comment] Chan MT, et al. **Br J Anaesth** 1996 Aug;77(2):293–4. Comment on: Br J Anaesth 1995 Dec;75(6):683–7.

Does intrathecal fentanyl produce acute cross-tolerance to i.v. morphine? Cooper DW, et al. **Br J Anaesth** 1997 Mar; 78(3):311–3

Soft tissue anatomy within the vertebral canal in pregnant women. Hirabayashi Y, et al. **Br J Anaesth** 1996 Aug; 77(2):153–6

Acid–base state of cerebrospinal fluid during pregnancy and its effect on spread of spinal anaesthesia. Hirabayashi Y, et al. **Br J Anaesth** 1996 Sep;77(3):352–5

Anaphylaxis associated with, but not caused by, extradural bupivacaine. Rae SM, et al. **Br J Anaesth** 1997 Feb; 78(2):224–6

Sternomental distance as the sole predictor of difficult laryngoscopy in obstetric anaesthesia [see comments] [published erratum appears in Br J Anaesth 1996 Nov;77(5):701] Al Ramadhani S, et al. **Br J Anaesth** 1996 Sep;77(3):312–6. Comment in: Br J Anaesth 1996 Sep;77(3):309–11. Comment in: Br J Anaesth 1997 Mar;78(3):338. Comment in: Br J Anaesth 1997 May;78(5):626–7.

Quality and retrieval of obstetrical anaesthesia randomized controlled trials [see comments] Bender JS, et al. **Can J Anaesth** 1997 Jan;44(1):14–8. Comment in: Can J Anaesth 1997 Jan;44(1):1–3.

Surgical anaesthesia for Caesarean section with a subdural catheter. Gershon RY. **Can J Anaesth** 1996 Oct; 43(10):1068–71

Direction of injection does not affect the spread of spinal bupivacaine in parturients. Massé E, et al. **Can J Anaesth** 1997 Aug;44(8):816–9

Patient-controlled epidural analgesia after caesarean section using meperidine. Ngan Kee WD, et al. **Can J Anaesth** 1997 Jul;44(7):702–6

Spinal anaesthesia for Caesarean section in a patient with a cervical arteriovenous malformation. Ong BY, et al. **Can J Anaesth** 1996 Oct;43(10):1052–8

Difficult intubation in obstetrics [letter] Pogulanik J, et al. **Can J Anaesth** 1996 Aug;43(8):879

Anaesthesia for caesarean section in a Marfan patient with recurrent aortic dissection. Tritapepe L, et al. **Can J Anaesth** 1996 Nov;43(11):1153–5

Observations on database design for improving clinical care. McGhee TD. **Int J Clin Monit Comput** 1996 Aug; 13(3):143–5

ACOG technical bulletin. Obstetric analgesia and anesthesia. Number 225—July 1996 (replaces No. 112, January 1988). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Sep;54(3):281–92

Comparison of 0.5% and 1.0% lidocaine for abortions. Wiebe ER, et al. **Int J Gynaecol Obstet** 1996 Oct;55(1):71–2

Epidural anesthesia and cesarean section [letter; comment] Morrow JG 3d. **J Am Board Fam Pract** 1996 May–Jun; 9(3):231. Comment on: J Am Board Fam Pract 1995 Nov–Dec;8(6):494–6.

Successful regional anesthesia for a woman with a single ventricle presenting for labor and delivery. Ammar T, et al. **J Cardiothorac Vasc Anesth** 1996 Aug;10(5):640–2

Anesthesia for the parturient with sickle cell disease. Danzer BI, et al. **J Clin Anesth** 1996 Nov;8(7):598–602 (17 ref.)

Hemodynamic effects of intrathecal sufentanil compared with epidural bupivacaine in laboring parturients. Pham LH, et al. **J Clin Anesth** 1996 Sep;8(6):497–501; discussion 502–3

Pregnancy induced hypertension--anaesthetic considerations. Zubair NA. **JPMA J Pak Med Assoc** 1996 Sep;46(9):206–13 (70 ref.)

Is antacid treatment necessary in obstetric anesthesia? Al Mazrooa AA, et al. **Middle East J Anesthesiol** 1995 Oct; 13(3):335–40

Nitrous oxide inhalation: effects on the maternal and fetal circulations at term [letter] Tsen LC, et al. **Obstet Gynecol** 1996 Nov;88(5):899–900

Nitrous oxide inhalation: effects on maternal and fetal circulations at term [letter; comment] Yun EM, et al. **Obstet Gynecol** 1996 Nov;88(5):899; discussion 900. Comment on: Obstet Gynecol 1996 Jun;87(6):1045–8.

Successful epidural anesthesia in a patient with an arachnoid cyst, preeclampsia, and triplets. Gaiser RR, et al. **Reg Anesth** 1996 Nov–Dec;21(6):592–4

Anesthesia for cesarean delivery in a patient with Ehlers–Danlos syndrome type II. Goldstein M, et al. **Reg Anesth** 1997 May–Jun;22(3):280–3

The effect of head-down tilt position on arterial blood pressure after spinal anesthesia for cesarean delivery. Miyabe M, et al. **Reg Anesth** 1997 May–Jun;22(3):239–42

How anesthesiologists practice obstetric anesthesia: responses of practicing obstetric anesthesiologists at the 1993 meeting of the Society for Obstetric Anesthesia and Perinatology. Plumer MH, et al. **Reg Anesth** 1996 Jan–Feb;21(1):49–60

Postpartum back pain, so what! Avery JK. **Tenn Med** 1996 Sep;89(9):322–3

Simplified care of women with prolonged or persistent retention of the placenta: the use of paracervical block. Mola G, et al. **Trop Doct** 1996 Jul;26(3):116–8

[Locoregional anesthesia in obstetrics: benefits and risks] Benhamou D. **Chirurgie** 1997;122(1):43–6 (10 ref.) (Eng. Abstr.) **(Fre)**

[An empty stomach is necessary in the delivery room] Bleyl JU, et al. **Anaesthesist** 1997 May;46(5):465 **(Ger)**

[Optimal regional anesthesia procedure in cesarean section] Hempelmann G, et al. **Anaesthesist** 1996 Oct;45(10):996–7 **(Ger)**

[Autonomic hyperreflexia, pregnancy and delivery in para-tetraplegia. The obstetric anesthesiologic viewpoint on a case] Plötz J, et al. **Anaesthesist** 1996 Dec; 45(12):1179–83 (Eng. Abstr.) **(Ger)**

[Spinal anesthesia in cesarean section: 1% versus 0.5% hyperbaric bupivacaine] Gallo F, et al. **Minerva Anestesiol** 1996 Jan–Feb;62(1–2):9–15 (Eng. Abstr.) **(Ita)**

[Cesarean section under spinal anesthesia for a patient with chronic renal failure] Azuma K, et al. **Masui** 1996 Jul; 45(7):880–3 (Eng. Abstr.) **(Jpn)**

[Anesthesia for cesarean section: drug transfer to fetus during anesthesia] Higashi T, et al. **Masui** 1996 Jan;45(1):96–8 (Eng. Abstr.) **(Jpn)**

[Prolonged neuromuscular blockade with vecuronium in patient with triple pregnancy treated with magnesium sulfate] Hino H, et al. **Masui** 1997 Feb;46(2):266–70 (Eng. Abstr.) **(Jpn)**

[Cesarean section in a patient with uncontrolled hyperthyroidism, preeclampsia, and congestive heart failure] Kagawa T, et al. **Masui** 1996 Feb;45(2):230–4 (Eng. Abstr.) **(Jpn)**

[Placental transfer of vecuronium administered with priming principle regimen in patients undergoing cesarean section] Kaneko T, et al. **Masui** 1997 Jun;46(6):750–4 (Eng. Abstr.) **(Jpn)**

[The spread of subarachnoid hyperbaric dibucaine in the term parturient] Konishi R, et al. **Masui** 1997 Feb;46(2):184–7 (Eng. Abstr.) **(Jpn)**

[Cesarean section in a morbidly obese parturient under epidural anesthesia] Konishi R, et al. **Masui** 1996 Dec; 45(12):1503–6 (Eng. Abstr.) **(Jpn)**

[Combined spinal–epidural anesthesia for intra-abdominal gynecological surgeries] Nagashima N, et al. **Masui** 1996 Sep;45(9):1153–9 (Eng. Abstr.) **(Jpn)**

[Anesthesia for a patient with HELLP syndrome] Takahashi H, et al. **Masui** 1996 Nov;45(11):1380–3 (Eng. Abstr.) **(Jpn)**

[Obstetric anesthesia for cesarean section of patients with bronchial asthma] Ueda K. **Masui** 1996 Dec;45 Suppl:S208–11 (1 ref.) **(Jpn)**

[HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome and acute pancreatitis complicated with severe preeclampsia] Yamada K, et al. **Masui** 1997 Mar; 46(3):373–5 (Eng. Abstr.) **(Jpn)**

[Effect of the local anesthetic on visceral pain in cesarean sections done under intradural anesthesia] Echevarría M, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):2–6 (Eng. Abstr.) **(Spa)**

[Anesthesia for cesarean section in patients with mitral valve prolapse (letter; comment)] García-Romero J, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):128–9. Comment on: Rev Esp Anestesiol Reanim 1996 Oct;43(8):291–3. **(Spa)**

[Anesthesia for cesarean section in patients with mitral valve prolapse (see comments)] Ruiz-Castro M, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):291–3 (Eng. Abstr.). Comment in: Rev Esp Anestesiol Reanim 1997 Mar;44(3):128–9. Comment in: Rev Esp Anestesiol Reanim 1997 Apr;44(4):165–6. **(Spa)**

[Anesthesia for cesarean section in a case of Emery–Dreifuss muscular dystrophy] Sariego M, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):288–90 (Eng. Abstr.) **(Spa)**

[Cesarean section in pregnancy with undiagnosed pheochromocytoma (letter)] Tortosa JA, et al. **Rev Esp Anestesiol Reanim** 1996 May;43(5):191–2 **(Spa)**

[Unequal distribution of obstetrical analgesia] Ahlenius I, et al. **Lakartidningen** 1997 Apr 2;94(14):1269–73, 1275 (36 ref.) **(Swe)**

[Local anesthesia is effective in Cesarean section] Bakos O, et al. **Lakartidningen** 1997 Sep 10;94(37):3160–2 **(Swe)**

ADVERSE EFFECTS

Extradural abscess complicating lumbar extradural anaesthesia and analgesia in an obstetric patient. Kindler C, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):858–61

Post dural puncture headache in cesarean section: comparison of 25-gauge Whitacre with 25- and 26-gauge Quincke needles. Hwang JJ, et al. **Acta Anaesthesiol Sin** 1997 Mar; 35(1):33–7

The incidence of post dural puncture headache in Taiwanese patients undergoing cesarean section. Hwang JJ, et al. **Acta Anaesthesiol Sin** 1997 Mar;35(1):1–6

Through the needle approach for difficult epidurals [letter; comment] Ahmed AB. **Anaesthesia** 1996 Sep;51(9):893. Comment on: Anaesthesia 1996 May;51(5):513.

Fluid preload and atrial natriuretic peptide [letter; comment] Rout CC. **Anaesthesia** 1996 Sep;51(9):889–90. Comment on: Anaesthesia 1996 Feb;51(2):128–32.

Sciatic nerve palsy following childbirth [see comments] Silva M, et al. **Anaesthesia** 1996 Dec;51(12):1144–8 (53 ref.). Comment in: Anaesthesia 1997 Jun;52(6):605–6.

Time to abandon loss of resistance to air [letter] Yentis SM. **Anaesthesia** 1997 Feb;52(2):184

Acupressure versus intravenous metoclopramide to prevent nausea and vomiting during spinal anesthesia for cesarean section. Stein DJ, et al. **Anesth Analg** 1997 Feb;84(2):342–5

Monoplegia following obstetric epidural anaesthesia. Loo CC, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):232–4 (10 ref.)

Finding of relation between epidural anaesthesia and long-term backache remains valid [letter] MacArthur C, et al. **BMJ** 1997 Sep 13;315(7109):679

Cardiac arrest after caesarean section under subarachnoid block [letter; comment] Burns R, et al. **Br J Anaesth** 1997 Jan;78(1):110. Comment on: Br J Anaesth 1996 Aug;77(2):274–6.

Conservative management of extradural abscess complicating spinal–extradural anaesthesia for caesarean section. Dysart RH, et al. **Br J Anaesth** 1997 May;78(5):591–3

Cardiac arrest after caesarean section under subarachnoid block [letter; comment] Gambling DR. **Br J Anaesth** 1997 Jan;78(1):109–10. Comment on: Br J Anaesth 1996 Aug;77(2):274–6.

Lumbovertebral syndrome after repeat extradural blood patch. Palmer JH, et al. **Br J Anaesth** 1997 Mar;78(3):334–6

Cardiac arrest after Caesarean section under subarachnoid block [see comments] Scull TJ, et al. **Br J Anaesth** 1996 Aug;77(2):274–6. Comment in: Br J Anaesth 1997 Jan;78(1):109. Comment in: Br J Anaesth 1997 Jan;78(1):109–10. Comment in: Br J Anaesth 1997 Jan;78(1):110. Comment in: Br J Anaesth 1997 Feb;78(2):230.

Cardiac arrest after caesarean section under subarachnoid block [letter; comment] Trotter C, et al. **Br J Anaesth** 1997 Jan;78(1):109. Comment on: Br J Anaesth 1996 Aug;77(2):274–6.

Aseptic meningitis using the needle-through-needle technique [letter; comment] Eldor J. **Can J Anaesth** 1996 Nov;43(11):1183–4. Comment on: Can J Anaesth 1996 Apr;43(4):399–402.

Hearing loss following spinal anaesthesia with bupivacaine. Hussain SS, et al. **Clin Otolaryngol** 1996 Oct;21(5):449–54

Effect of epidural analgesia on duration and outcome of induced labor. Rojansky N, et al. **Int J Gynaecol Obstet** 1997 Mar;56(3):237–44

Episiotomy [letter; comment] McMillan MH. **J Obstet Gynecol Neonatal Nurs** 1997 Jul–Aug;26(4):373. Comment on: J Obstet Gynecol Neonatal Nurs 1997 Mar–Apr;26(2):155–61.

Incidence of postdural puncture headache following spinal anaesthesia for lower segment caesarean section with the 25 gauge polymedic spinal needle. Ahsan S, et al. **JPMA J Pak Med Assoc** 1996 Dec;46(12):278–81

Safety of spinal and epidural anesthesia in parturients with chorioamnionitis. Goodman EJ, et al. **Reg Anesth** 1996 Sep–Oct;21(5):436–41

Role of needle gauge and tip configuration in the production of lumbar puncture headache. Lambert DH, et al. **Reg Anesth** 1997 Jan–Feb;22(1):66–72

Postpartum bilateral subdural hematomas following spinal anesthesia: case report. Cohen JE, et al. **Surg Neurol** 1997 Jan;47(1):6–8

[An alternative method for treating headache after spinal anesthesia in cesarean section] Tsenov D. **Akush Ginekol (Sofiia)** 1996;35(4):6–7 (Eng. Abstr.) **(Bul)**

[Bacterial meningitis after combined spinal and epidural anesthesia in obstetrics (letter)] Aldebert S, et al. **Ann Fr Anesth Reanim** 1996;15(5):687–8 **(Fre)**

[Problems caused by spinal sufentanil analgesia at the end of labor (letter)] Mercier FJ, et al. **Ann Fr Anesth Reanim** 1996;15(5):688–90 **(Fre)**

[Neurological accidents after epidural anesthesia in obstetrics] Pujol S, et al. **Cah Anesthesiol** 1996;44(4):341–5 (Eng. Abstr.) **(Fre)**

[Infectious complications after peridural obstetric anesthesia] Marsaudon E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):159–62 (20 ref.) (Eng. Abstr.) **(Fre)**

[Aspiration pneumonia during cesarean section (letter)] Benito MC, et al. **Rev Esp Anestesiol Reanim** 1997 Feb; 44(2):89–90 **(Spa)**

[Indication for spinal anesthesia for cesarean section in HELLP syndrome coagulopathy] Blasi A, et al. **Rev Esp Anestesiol Reanim** 1997 Feb;44(2):79–82 (Eng. Abstr.) **(Spa)**

[Use of low molecular weight heparins (letter; comment)] Llau JV, et al. **Rev Esp Anestesiol Reanim** 1997 Feb; 44(2):88–9. Comment on: Rev Esp Anestesiol Reanim 1996 Aug–Sep;43(7):258–60. **(Spa)**

HISTORY

Strategies for labor pain relief—past, present and future. Cohen S. **Acta Anaesthesiol Scand Suppl** 1997;110:17–21

James Young Simpson, 1811–1870. Ball C. **Anaesth Intensive Care** 1996 Dec;24(6):639

Did the use of chloroform by Queen Victoria influence its acceptance in obstetric practice? Connor H, et al. **Anaesthesia** 1996 Oct;51(10):955–7

Dr John Snow (1813–58) of London: pioneer of obstetric anaesthesia. Dunn PM. **Arch Dis Child Fetal Neonatal Ed** 1996 Sep;75(2):F141–2

One hundred and fifty years of anaesthesia in obstetrics—Irish connections. O'Dowd MJ. **Ir J Med Sci** 1997 Jul–Sep; 166(3):139–40

The journal 100 & 150 years ago. New Orleans Medical and Surgical Journal. July 1847 & 1897. Colon G. **J La State Med Soc** 1997 Jul;149(6):231–3

James Young Simpson and the introduction of chloroform anesthesia in obstetric practice. Kyle RA, et al. **Mayo Clin Proc** 1997 Apr;72(4):372

Doctor James Young Simpson, Rabbi Abraham De Sola, and Genesis Chapter 3, verse 16. Cohen J. **Obstet Gynecol** 1996 Nov;88(5):895–8

INSTRUMENTATION

Intravascular migration of epidural catheter during cesarean section [letter] Lee BB, et al. **Anesth Analg** 1996 Dec; 83(6):1350

Changes in the position of epidural catheters associated with patient movement. Hamilton CL, et al. **Anesthesiology** 1997 Apr;86(4):778–84; discussion 29A

METHODS

Epidural analgesia for labor pain: (still) the method of choice? Vercauteren M. **Acta Anaesthesiol Belg** 1996;47(4):163–9 (28 ref.)

The influence of anaesthetic techniques and type of delivery on peripartum serum interleukin-6 concentrations. De Jongh RF, et al. **Acta Anaesthesiol Scand** 1997 Aug; 41(7):853–60

Anesthetic management of a parturient implanted with a permanent pacemaker—a case report. Ng YT, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):107–11

Effective obstetric paracervical block with reduced dose of bupivacaine. A prospective randomized double-blind study comparing 25 mg (0.25%) and 12.5 mg (0.125%) of bupivacaine. Nieminen K, et al. **Acta Obstet Gynecol Scand** 1997 Jan;76(1):50–4

Caesarean section in a parturient with respiratory failure caused by cystic fibrosis. Bose D, et al. **Anaesthesia** 1997 Jun;52(6):578–82

Intrathecal morphine dose for caesarean section [letter; comment] Buggy D. **Anaesthesia** 1997 Mar;52(3):278. Comment on: Anaesthesia 1996 Sep;51(9):871–3.

Management of Caesarean delivery in the presence of a large pelvic vascular malformation. Gray C, et al. **Anaesthesia** 1996 Oct;51(10):961–4

Caesarean section and sleep apnoea syndrome [letter] Mercer M. **Anaesthesia** 1996 Oct;51(10):992

Contamination of opioids during preparation for regional anaesthesia [letter; comment] Tunstall ME, et al. **Anaesthesia** 1997 Mar;52(3):290. Comment on: Anaesthesia 1996 Nov;51(11):1079–80.

Ethics in obstetric anaesthesia [letter; comment] Urquhart J. **Anaesthesia** 1996 Dec;51(12):1183. Comment on: Anaesthesia 1996 Aug;51(8):717–8.

Pregnancy complicated by severe preeclampsia and thrombocytopenia in a patient with scleroderma. D'Angelo R, et al. **Anesth Analg** 1997 Oct;85(4):839–41

Sevoflurane inhalation induction for emergency cesarean section in a parturient with no intravenous access. Schaut DJ, et al. **Anesthesiology** 1997 Jun;86(6):1392–4

Spinal anaesthesia with 0.25% hyperbaric bupivacaine for caesarean section: effects of volume [letter; comment] Bell R, et al. **Br J Anaesth** 1997 Mar;78(3):339–40. Comment on: Br J Anaesth 1996 Aug;77(2):145–9.

Unrecognized "crack" cocaine abuse in pregnancy. Campbell D, et al. **Br J Anaesth** 1996 Oct;77(4):553–5

Spinal anaesthesia with 0.25% hyperbaric bupivacaine for Caesarean section: effects of volume [see comments] Chung CJ, et al. **Br J Anaesth** 1996 Aug;77(2):145–9. Comment in: Br J Anaesth 1997 Mar;78(3):339–40.

Failed intubation drill [letter] Dean VS, et al. **Br J Anaesth** 1997 Feb;78(2):231

Spinal anaesthesia for Caesarean section [letter; comment] Foster RN, et al. **Br J Anaesth** 1996 Aug;77(2):301–2. Comment on: Br J Anaesth 1996 Mar;76(3):476.

Blood loss during first trimester termination of pregnancy: comparison of two anaesthetic techniques. Hall JE, et al. **Br J Anaesth** 1997 Feb;78(2):172–4

Spinal anaesthesia for Caesarean section: effect of Sprotte needle orientation [see comments] James KS, et al. **Br J Anaesth** 1996 Aug;77(2):150–2. Comment in: Br J Anaesth 1997 Feb;78(2):229–30.

Combined spinal–extradural anaesthesia for preterm and term caesarean section: is there a difference in local anaesthetic requirements? James KS, et al. **Br J Anaesth** 1997 May; 78(5):498–501

Single bolus compared with a fractionated dose injection technique of bupivacaine for extradural Caesarean section: effect on uteroplacental and fetal haemodynamic state. Karinen J, et al. **Br J Anaesth** 1996 Aug;77(2):140–4

Extradural anaesthesia for caesarean section in a patient with moyamoya disease. Kee WD, et al. **Br J Anaesth** 1996 Oct; 77(4):550–2

Failed tracheal intubation [letter; comment] Kessell G. **Br J Anaesth** 1996 Oct;77(4):560. Comment on: Br J Anaesth 1996 May;76(5):680–4.

Regional anaesthesia in moyamoya disease [letter] Llorente de la Fuente A, et al. **Br J Anaesth** 1997 Apr;78(4):478–9

Failed tracheal intubation [letter; comment] McBrien ME. **Br J Anaesth** 1996 Oct;77(4):559–60. Comment on: Br J Anaesth 1996 May;76(5):680–4.

General anaesthesia for caesarean section in a parturient with Noonan's syndrome. McLure HA, et al. **Br J Anaesth** 1996 Nov;77(5):665–8

Influence of patient position on withdrawal forces during removal of lumbar extradural catheters. Morris GN, et al. **Br J Anaesth** 1996 Sep;77(3):419–20

Ropivacaine 0.75% for extradural anaesthesia in elective caesarean section: an open clinical and pharmacokinetic study in mother and neonate. Morton CP, et al. **Br J Anaesth** 1997 Jul;79(1):3–8

Failed tracheal intubation [letter; comment] Norman B. **Br J Anaesth** 1996 Oct;77(4):559. Comment on: Br J Anaesth 1996 May;76(5):680–4.

Spinal anaesthesia for Caesarean section [letter; comment] Vickers R, et al. **Br J Anaesth** 1996 Aug;77(2):301–2. Comment on: Br J Anaesth 1996 Mar;76(3):476.

A difficult obstetric anaesthesia problem. Wheatley EC, et al. **Br J Hosp Med** 1996 Nov 20–Dec 10;56(10):553

Anaesthetic management of a parturient with severe muscular dystrophy, lumbar lordosis and a difficult airway. Pash MP, et al. **Can J Anaesth** 1996 Sep;43(9):959–63

Valvular heart disease [letter; comment] Thomas TA. **J R Coll Physicians Lond** 1997 Jan–Feb;31(1):113–4. Comment on: J R Coll Physicians Lond 1996 Jul–Aug;30(4):309–15.

Testing sensory level of anesthesia [letter] Fishman EB. **Reg Anesth** 1997 Mar–Apr;22(2):200

Continuous spinal anesthesia for cesarean delivery in a patient with arthrogryposis multiplex congenita. A clinical report. Rozkowski A, et al. **Reg Anesth** 1996 Sep–Oct;21(5):477–9

A multivariate model to predict the distance from the skin to the epidural space in an obstetric population. Segal S, et al. **Reg Anesth** 1996 Sep–Oct;21(5):451–5

Labor analgesia and anesthesia in a patient with spinal muscular atrophy and vocal cord paralysis. A rare and unusual case report. Weston LA, et al. **Reg Anesth** 1996 Jul–Aug;21(4):350–4 (11 ref.)

[Combined spinal and epidural analgesia for labor (letter; comment)] Guedj P. **Ann Fr Anesth Reanim** 1996; 15(7):1135–7. Comment on: Ann Fr Anesth Reanim 1996;15(3):263–5. **(Fre)**

[Difficult deliveries treated with sufentanil spinal anesthesia at the end of labor (letter)] Van Elstraete AC, et al. **Ann Fr Anesth Reanim** 1996;15(2):231–2 **(Fre)**

[Acute fetal distress. The anesthesiologist's point of view] Hamza J. **Cah Anesthesiol** 1996;44(4):309–26 (104 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

Maternal mortality—is it still relevant? [editorial] Harmer M. **Anaesthesia** 1997 Feb;52(2):99–100

Anesthesia and maternal mortality [editorial; comment] Chestnut DH. **Anesthesiology** 1997 Feb;86(2):273–6. Comment on: Anesthesiology 1997 Feb;86(2):277–84.

Anesthesia-related deaths during obstetric delivery in the United States, 1979–1990 [see comments] Hawkins JL, et al. **Anesthesiology** 1997 Feb;86(2):277–84. Comment in: Anesthesiology 1997 Feb;86(2):273–6.

TRENDS

Failed intubation during obstetric anaesthesia [letter; comment] Jenkins JG. **Br J Anaesth** 1996 Nov;77(5):698. Comment on: Br J Anaesth 1996 May;76(5):680–4.

UTILIZATION

[The current standing of obstetrical analgesia and anesthesia. A survey of North Rhein-Westfalia] Meuser T, et al. **Anaesthesist** 1997 Jun;46(6):532–5 (Eng. Abstr.) **(Ger)**

ANESTHESIA, PERIDURAL see **ANESTHESIA, EPIDURAL**

ANESTHESIA, REBREATHING see **ANESTHESIA, CLOSED-CIRCUIT**

ANESTHESIA RECOVERY PERIOD

see related

POSTANESTHESIA NURSING

Recovery from neuromuscular block and vital function testing. Eriksson LI. **Acta Anaesthesiol Belg** 1997;48(1):45–8

Response to double-burst appears before response to train-of-four stimulation during recovery from non-depolarizing neuromuscular blockade. Kirkegaard-Nielsen H, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):719-23

Recovery and outcome after propofol and isoflurane anesthesia in patients undergoing laparoscopic hysterectomy. Nelskylä K, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):360-3

Airway management in the recovery room [editorial] Vaughan RS. **Anaesthesia** 1997 Jul;52(7):617-8

Awakening, clinical recovery, and psychomotor effects after desflurane and propofol anesthesia. Apfelbaum JL, et al. **Anesth Analg** 1996 Oct;83(4):721-5

The impact of choice of muscle relaxant on postoperative recovery time: a retrospective study [see comments] Ballantyne JC, et al. **Anesth Analg** 1997 Sep;85(3):476-82 . Comment in: Anesth Analg 1997 Sep;85(3):473-5.

Intrathecal fentanyl with small-dose dilute bupivacaine: better anesthesia without prolonging recovery. Ben-David B, et al. **Anesth Analg** 1997 Sep;85(3):560-5

Midazolam premedication delays recovery after propofol without modifying involuntary movements. Bevan JC, et al. **Anesth Analg** 1997 Jul;85(1):50-4

The effects of epidural fentanyl on hemodynamic responses during emergence from isoflurane anesthesia and tracheal extubation: a comparison with intravenous fentanyl. Inagaki Y, et al. **Anesth Analg** 1997 Aug;85(2):328-35

Emergence of elderly patients from prolonged desflurane, isoflurane, or propofol anesthesia. Juvin P, et al. **Anesth Analg** 1997 Sep;85(3):647-51

A comparison of cisatracurium and atracurium: onset of neuromuscular block after bolus injection and recovery after subsequent infusion. Mellinghoff H, et al. **Anesth Analg** 1996 Nov;83(5):1072-5

Recovery after propofol with and without intraoperative fentanyl in patients undergoing ambulatory gynecologic laparoscopy. Sukhani R, et al. **Anesth Analg** 1996 Nov; 83(5):975-81

Comparison of emergence and recovery characteristics of sevoflurane, desflurane, and halothane in pediatric ambulatory patients. Welborn LG, et al. **Anesth Analg** 1996 Nov;83(5):917-20

Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxide-isoflurane. Goto T, et al. **Anesthesiology** 1997 Jun;86(6):1273-8

Ultrasonography of the equine triceps muscle before and after general anaesthesia and in post anaesthetic myopathy. Smith RK, et al. **Equine Vet J** 1996 Jul;28(4):311-9

Upper-airway obstruction and prolonged recovery from anesthesia following intranasal clotrimazole administration. Caulkett N, et al. **J Am Anim Hosp Assoc** 1997 May-Jun; 33(3):264-7

Sleeping time after phenobarbital treatment and the brain levels of gamma-aminobutyric acid and phenobarbital at the regaining of righting response point in ethionine-induced liver-disordered mice. Noguchi M, et al. **J Toxicol Sci** 1996 May;21(2):113-23

Does thiopentone delay recovery in children premedicated with midazolam? Morley-Forster P, et al. **Paediatr Anaesth** 1997;7(4):279-85

Parental perceptions, expectations and preferences for the postanaesthetic recovery of children. Sikich N, et al. **Paediatr Anaesth** 1997;7(2):139-42

Emergence and recovery from anesthesia for pediatrics patients in the post-anesthesia care unit. Lee B, et al. **Pediatr Ann** 1997 Aug;26(8):461-9 (19 ref.)

Recovery parameters after sevoflurane and isoflurane anesthesia. Cantillo J, et al. **Pharmacotherapy** 1997 Jul-Aug; 17(4):779-82

Accelerated recovery from brachial plexus block by dilution [letter] Elias MA. **Reg Anesth** 1996 Nov-Dec;21(6):600

Complications in the recovery room [editorial; comment] Dhara SS. **Singapore Med J** 1997 May;38(5):190-1 (5 ref.) . Comment on: Singapore Med J 1997 May;38(5):200-4.

Anaesthetic complications in the recovery room [see comments] Norsidah AM, et al. **Singapore Med J** 1997 May; 38(5):200-4. Comment in: Singapore Med J 1997 May;38(5):190-1.

Negative pressure pulmonary edema as a post-anesthetic complication associated with upper airway obstruction in a horse. Tute AS, et al. **Vet Surg** 1996 Nov-Dec; 25(6):519-23

[Early postoperative hypoxemia in infants, children and adults undergoing elective plastic surgery] Xue F, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 May;12(3):208-11 (Eng. Abstr.) **(Chi)**

[Arrhythmia during the recovery phase in a child. Another ampoule story, a human error... (letter)] Paqueron X, et al. **Ann Fr Anesth Reanim** 1996;15(7):1134-5 **(Fre)**

[Is early extubation after surgery for esophageal cancer possible?] Le Mée J, et al. **Cah Anesthesiol** 1996; 44(5):409-13 (Eng. Abstr.) **(Fre)**

[Recovery and psychomimetic reactions following S-(+)-ketamine] Engelhardt W. **Anaesthesist** 1997 Mar;46 Suppl 1:S38-42 (20 ref.) (Eng. Abstr.) **(Ger)**

[Perioperative monitoring of the course of anesthesia, the postanesthesia visit and inquiry of patient satisfaction. A prospective study of parameters in process and outcome quality in anesthesia] Bothner U, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Dec; 31(10):608-14 (Eng. Abstr.) **(Ger)**

[Examples of pitfalls in statistical analysis—6. Evaluation of data consisting of the elapsed time between two events] Nagata O. **Masui** 1997 Feb;46(2):244-50 (Eng. Abstr.) **(Jpn)**

[Post-anesthesia recovery. How can it be evaluated? (editorial)] Aguilera L. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):47-48 **(Spa)**

[Comparative study of recovery from general anesthesia with halothane or sevoflurane in pediatrics] Calderón E, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):272-5 (Eng. Abstr.) **(Spa)**

-Atypical pseudocholinesterase and clinical error with train-of-four visual monitoring (letter)- Fraile JR, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):45-6 **(Spa)**

[Utilization of a post-anesthetic recovery index] Navas E, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):53-8 (Eng. Abstr.) **(Spa)**

[Apnea and retarded awakening following oral premedication with midazolam (letter)] Rufino-Ruiz J, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):129 **(Spa)**

[The choice of anesthesia methods in abdominal surgery is decisive for patients' recovery when it comes to eating again. Opinion should be avoided] Wattwil M, et al. **Lakartidningen** 1997 Apr 9;94(15):1376, 1379-80 (15 ref.) **(Swe)**

ANESTHESIA, REFRIGERATION see **HYPOTHERMIA, INDUCED**

ANESTHESIA, REGIONAL see **ANESTHESIA, CONDUCTION**

ANESTHESIA, SACRAL EPIDURAL see **ANESTHESIA, CAUDAL**

ANESTHESIA, SPINAL

Spinal anesthesia: some considerations. Vandenbroucke G. **Acta Anaesthesiol Belg** 1997;48(2):63-9 (45 ref.)

Weight gain during pregnancy does not influence the spread of spinal analgesia in the term parturient. Ekeløf NP, et al. **Acta Anaesthesiol Scand** 1997 Aug;41(7):884-7

Emergency spinal anaesthesia in the prone position. Larsen JR. **Acta Anaesthesiol Scand** 1997 Jun;41(6):790-1

Pre-eclampsia: the effect of intravenous fluid preload on atrial natriuretic peptide secretion during caesarean section under spinal anaesthesia. Pouta A, et al. **Acta Anaesthesiol Scand** 1996 Nov;40(10):1203-9

Neuroendocrine response to mid and upper abdominal surgery [letter; comment] Richardson J, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):433-4. Comment on: Acta Anaesthesiol Scand 1996 Jul;40(6):691-6.

Motor power pharmacodynamics of subarachnoid hyperbaric 5% lidocaine in the sitting position. Rushmer J, et al. **Acta Anaesthesiol Scand** 1997 May;41(5):557-64

Patient-controlled analgesia with morphine and droperidol following caesarean section under spinal anaesthesia. Russell D, et al. **Acta Anaesthesiol Scand** 1996 May; 40(5):600-5

Continuous thoracic epidural analgesia versus combined spinal/thoracic epidural analgesia on pain, pulmonary function and the metabolic response following colonic resection [see comments] Scott NB, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):691-6. Comment in: Acta Anaesthesiol Scand 1997 Mar;41(3):433-4.

Intravenous infusion of low dose propofol for conscious sedation in cesarean section before spinal anesthesia. Cheng YJ, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):79-84

Prophylaxis against acid aspiration in regional anesthesia for elective cesarean section: a comparison between oral single-dose ranitidine, famotidine and omeprazole assessed with fiberoptic gastric aspiration. Lin CJ, et al. **Acta Anaesthesiol Sin** 1996 Dec;34(4):179-84

Is conscious sedation possible during cesarean delivery under spinal anesthesia? [editorial; comment] Liu CC. **Acta Anaesthesiol Sin** 1996 Sep;34(3):i. Comment on: Acta Anaesthesiol Sin 1996 Sep;34(3):109-15. Comment on: Acta Anaesthesiol Sin 1996 Sep;34(3):117-21. Comment on: Acta Anaesthesiol Sin 1996 Sep;34(3):141-9.

Conscious sedation by low dose propofol infusion during spinal anesthesia for cesarean section [see comments] [published erratum appears in Acta Anaesthesiol Sin 1996 Dec;34(4):252] Wang YP, et al. **Acta Anaesthesiol Sin** 1996 Sep;34(3):117-21. Comment in: Acta Anaesthesiol Sin 1996 Sep;34(3):i.

Failed spinal anaesthesia in combined spinal-epidural anaesthesia [letter] Eldor J, et al. **Anaesth Intensive Care** 1997 Jun;25(3):311-2

Radicular irritation with 2% lignocaine spinal [letter; comment] Grange C, et al. **Anaesth Intensive Care** 1997 Feb;25(1):89-90. Comment on: Anaesth Intensive Care 1996 Aug;24(4):508-10.

Transient dysaesthesia following spinal anaesthesia with 2% lignocaine [letter] Ramasamy D, et al. **Anaesth Intensive Care** 1997 Feb;25(1):90-1

Breakage of Whitacre 27 gauge needle during performance of spinal anaesthesia for caesarean section [letter] Teh J. **Anaesth Intensive Care** 1997 Feb;25(1):96

Repeat dose after an inadequate spinal block [letter] [see comments] Deshpande S, et al. **Anaesthesia** 1996 Sep; 51(9):892. Comment in: Anaesthesia 1997 Feb;52(2):188.

Spinal anaesthesia in a patient with Huntington's chorea [letter] Fernandez IG, et al. **Anaesthesia** 1997 Apr;52(4):391

Respiratory effects of spinal anaesthesia for caesarean section. Kelly MC, et al. **Anaesthesia** 1996 Dec;51(12):1120-2

Postoperative analgesic effect of intrathecal neostigmine and its influence on spinal anaesthesia. Klamt JG, et al. **Anaesthesia** 1997 Jun;52(6):547-51

Inadequate spinal block [letter; comment] Render CA. **Anaesthesia** 1997 Feb;52(2):188. Comment on: Anaesthesia 1996 Sep;51(9):892.

Failed spinal anaesthesia [letter] Stace JD, et al. **Anaesthesia** 1996 Sep;51(9):892-3

Spinal anesthesia for cesarean section in a case of pemphigus foliaceous. Abouleish EI, et al. **Anesth Analg** 1997 Feb; 84(2):449-50

Intrathecal fentanyl with small-dose dilute bupivacaine: better anesthesia without prolonging recovery. Ben-David B, et al. **Anesth Analg** 1997 Sep;85(3):560-5

Spinal bupivacaine in ambulatory surgery: the effect of saline dilution. Ben-David B, et al. **Anesth Analg** 1996 Oct; 83(4):716-20

Small-dose hypobaric lidocaine-fentanyl spinal anesthesia for short duration outpatient laparoscopy. II. Optimal fentanyl dose. Chilvers CR, et al. **Anesth Analg** 1997 Jan;84(1):65-70

Maternal experience during epidural or combined spinal-epidural anesthesia for cesarean section: a prospective, randomized trial. Davies SJ, et al. **Anesth Analg** 1997 Sep;85(3):607-13

A comparison of propofol with a propofol-ketamine combination for sedation during spinal anesthesia. Frizelle HP, et al. **Anesth Analg** 1997 Jun;84(6):1318-22

Spinal anesthesia for a patient with a calcium channel mutation causing hypokalemic periodic paralysis. Hecht ML, et al. **Anesth Analg** 1997 Feb;84(2):461-4

Spinal conduction block by intrathecal ketamine in dogs. Iida H, et al. **Anesth Analg** 1997 Jul;85(1):106-10

The effects of solution concentration and epinephrine on lateral distribution of hyperbaric tetracaine spinal anesthesia. Iselin-Chaves IA, et al. **Anesth Analg** 1996 Oct; 83(4):755-9

Intravenous ketamine or fentanyl prolongs postoperative analgesia after intrathecal neostigmine. Lauretti GR, et al. **Anesth Analg** 1996 Oct;83(4):766-70

The efficacy of epinephrine test doses during spinal anesthesia in volunteers: implications for combined spinal-epidural anesthesia. Liu SS, et al. **Anesth Analg** 1997 Apr;84(4):780-3

Spinal anesthesia in a patient with prekallikrein deficiency. Pasricha SK, et al. **Anesth Analg** 1996 Dec;83(6):1325-6

Hemodynamic response and change in organ blood volume during spinal anesthesia in elderly men with cardiac disease. Rooke GA, et al. **Anesth Analg** 1997 Jul;85(1):99-105

Isobaric spinal anesthesia for lumbar disk surgery [letter; comment] Rung GW, et al. **Anesth Analg** 1997 May; 84(5):1165-6. Comment on: Anesth Analg 1996 Sep;83(3):559-64.

The effect of anesthetic techniques on blood coagulability in parturients as measured by thromboelastography. Sharma SK, et al. **Anesth Analg** 1997 Jul;85(1):82-6

Small-dose hypobaric lidocaine-fentanyl spinal anesthesia for short duration outpatient laparoscopy. I. A randomized comparison with conventional dose hyperbaric lidocaine. Vaghadia H, et al. **Anesth Analg** 1997 Jan;84(1):59-64

Duration of intrathecal labor analgesia: early versus advanced labor. Viscomi CM, et al. **Anesth Analg** 1997 May; 84(5):1108-12

Femoral and genitofemoral nerve blocks versus spinal anesthesia for outpatients undergoing long saphenous vein stripping surgery. Vloka JD, et al. **Anesth Analg** 1997 Apr; 84(4):749-52

Comparison of continuous spinal with combined spinal-epidural anesthesia using plain bupivacaine 0.5% in trauma patients. Wilhelm S, et al. **Anesth Analg** 1997 Jul; 85(1):69-74

Changes in the position of epidural catheters associated with patient movement. Hamilton CL, et al. **Anesthesiology** 1997 Apr;86(4):778-84; discussion 29A

Combined spinal and epidural anesthesia in a parturient with idiopathic hypertrophic subaortic stenosis. Ho KM, et al. **Anesthesiology** 1997 Jul;87(1):168-9

Maternal respiratory arrests, severe hypotension, and fetal distress after administration of intrathecal, sufentanil, and bupivacaine after intravenous fentanyl. Lu JK, et al. **Anesthesiology** 1997 Jul;87(1):170-2

Population pharmacodynamic modeling and covariate detection for central neural blockade. Schnider TW, et al. **Anesthesiology** 1996 Sep;85(3):502-12

Ambulatory surgical management of breast carcinoma using a paravertebral block [letter; comment] Dalton EP. **Ann Surg** 1997 Mar;225(3):341. Comment on: Ann Surg 1995 Jul;222(1):19-26.

CSF progesterone and spread of subarachnoid anaesthesia in pregnancy [letter; comment] Chan MT, et al. **Br J Anaesth** 1996 Aug;77(2):293-4. Comment on: Br J Anaesth 1995 Dec;75(6):683-7.

Does intrathecal fentanyl produce acute cross-tolerance to i.v. morphine? Cooper DW, et al. **Br J Anaesth** 1997 Mar; 78(3):311-3

Spinal anaesthesia inhibits central temporal summation. Curatolo M, et al. **Br J Anaesth** 1997 Jan;78(1):88-9

Acid-base state of cerebrospinal fluid during pregnancy and its effect on spread of spinal anaesthesia. Hirabayashi Y, et al. **Br J Anaesth** 1996 Sep;77(3):352-5

Low molecular weight heparin associated with spinal

anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group. Samama CM, et al. **Br J Anaesth** 1997 Jun;78(6):660–5

Calmodulin inhibitors induce spinal analgesia in rats. Menendez L, et al. **Brain Res** 1996 Aug 26;731(1–2):114–21

Spinal anaesthesia with midazolam in the rat. Bahar M, et al. **Can J Anaesth** 1997 Feb;44(2):208–15

Cardiac performance during unilateral lumbar spinal block after crystalloid preload. Casati A, et al. **Can J Anaesth** 1997 Jun;44(6):623–8

Delayed bilateral spinal anaesthesia [letter; comment] Dilger JA. **Can J Anaesth** 1997 May;44(5 Pt 1):572. Comment on: Can J Anaesth 1996 Mar;43(3):303–5.

Direction of injection does not affect the spread of spinal bupivacaine in parturients. Massé E, et al. **Can J Anaesth** 1997 Aug;44(8):816–9

Wound infiltration with lidocaine prolongs postoperative analgesia after haemorrhoidectomy with spinal anaesthesia. Morisaki H, et al. **Can J Anaesth** 1996 Sep;43(9):914–8

Spinal anaesthesia for Caesarean section in a patient with a cervical arteriovenous malformation. Ong BY, et al. **Can J Anaesth** 1996 Oct;43(10):1052–8

Comparison of glucose 7.5% and 0.75% with or without phenylephrine for tetracaine spinal anaesthesia. Sumi M, et al. **Can J Anaesth** 1996 Nov;43(11):1138–43

Combined spinal and epidural anaesthesia for major abdominal surgery in infants. Williams RK, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):511–4

Haemodynamic monitoring during alkalinized lignocaine epidural block: a comparison with subarachnoid anaesthesia. Casati A, et al. **Eur J Anaesthesiol** 1997 May; 14(3):300–6

Respiratory complications of bone cement insertion during total hip replacement under spinal anaesthesia. Lewis RN. **Eur J Anaesthesiol** 1997 Jan;14(1):52–4

High spinal block following an inadequate continuous spinal anaesthetic. Serpell MG. **Eur J Anaesthesiol** 1996 Sep; 13(5):530–3

Activation of the arginine–nitric oxide pathway in primary sensory neurons contributes to dipyrone–induced spinal and peripheral analgesia. Lorenzetti BB, et al. **Inflamm Res** 1996 Jun;45(6):308–11

A numerical investigation into factors affecting anesthetic distribution during spinal anesthesia. Myers MR. **J Biomech** 1996 Feb;29(2):139–49

High spinal anesthesia does not alter experimental myocardial infarction size or ischemic preconditioning. Haessler R, et al. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):72–9

Anesthesia supplemented with subarachnoid bupivacaine and morphine for coronary artery bypass surgery in a child with Kawasaki disease. Kowalewski R, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):243–6

Neuraxial anesthesia is contraindicated in patients undergoing heparinization for surgery. Con: neuraxial block is useful in patients undergoing heparinization for surgery. Turnbull KW. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):961–2

Spinal ignorance [letter; comment] Eldor J. **J Clin Anesth** 1996 Sep;8(6):533–4. Comment on: J Clin Anesth 1995 Aug;7(5):389–94.

Efficacy and safety of single injection peribulbar block performed by anesthesiologists prior to cataract surgery. Hendrick SW, et al. **J Clin Anesth** 1997 Jun;9(4):285–8

Subcutaneous cysts: another cause of "failed" spinal anesthesia? Kelly D, et al. **J Clin Anesth** 1996 Nov; 8(7):603–4

What needs to be said? Informed consent in the context of spinal anesthesia. Liang BA, et al. **J Clin Anesth** 1996 Sep; 8(6):525–7

A case of resident malpractice administering spinal anesthesia. Liang BA. **J Clin Anesth** 1997 Jun;9(4):341–4

Postoperative oxygen desaturation requiring clinical intervention in premature infants receiving spinal anesthesia for inguinal herniorrhaphy [letter] Sukhani R, et al. **J Clin Anesth** 1997 Sep;9(6):520–1

Safety of 5% lidocaine heavily defended [news; letter] Blitt CD. **J Clin Monit** 1996 Jan;12(1):107

Bilateral cervical plexus block for thyroidectomy and parathyroidectomy in healthy and high risk patients. Kulkarni RS, et al. **J Endocrinol Invest** 1996 Dec; 19(11):714–8

The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic–opioid synergy. Stone LS, et al. **J Neurosci** 1997 Sep 15;17(18):7157–65

Post–spinal hypotension at cesarean section: the denial of evidence. van Bogaert LJ. **Med Hypotheses** 1997 Mar; 48(3):201–4

Preanesthetic wrapping of legs for prevention of spinal induced hypotension. Ghabash M, et al. **Middle East J Anesthesiol** 1997 Jun;14(2):117–24

Spinal anaesthesia for a paediatric patient undergoing an image guided invasive procedure in the Open Configuration Magnetic Resonance Imaging Unit. Corn SB. **Paediatr Anaesth** 1997;7(2):155–7

Spinal anaesthesia [letter] Gallagher TM, et al. **Paediatr Anaesth** 1996;6(1):82

Anesthesia for cesarean delivery in a patient with Ehlers–Danlos syndrome type II. Goldstein M, et al. **Reg Anesth** 1997 May–Jun;22(3):280–3

Subarachnoid neostigmine does not affect blood pressure or heart rate during bupivacaine spinal anesthesia. Lauretti GR, et al. **Reg Anesth** 1996 Nov–Dec;21(6):586–91

The effect of head–down tilt position on arterial blood pressure after spinal anesthesia for cesarean delivery. Miyabe M, et al. **Reg Anesth** 1997 May–Jun;22(3):239–42

Microscopic analysis of the tips of thin spinal needles after subarachnoid puncture [see comments] Rosenberg H, et al. **Reg Anesth** 1996 Jan–Feb;21(1):35–40. Comment in: Reg Anesth 1997 Jan–Feb;22(1):105–6.

EMLA cream effectively reduces the pain of spinal needle insertion. Sharma SK, et al. **Reg Anesth** 1996 Nov–Dec; 21(6):561–4

Spinal anesthesia reduces oxygen consumption in diabetic patients prior to peripheral vascular surgery. Stanley GD, et al. **Reg Anesth** 1997 Jan–Feb;22(1):53–8

Sympathetic block during spinal anesthesia in volunteers using lidocaine, tetracaine, and bupivacaine. Stevens RA, et al. **Reg Anesth** 1997 Jul–Aug;22(4):325–31

The effect of spinal versus general anesthesia on postoperative pain and analgesic requirements in patients undergoing lower abdominal surgery [see comments] Wang JJ, et al. **Reg Anesth** 1996 Jul–Aug;21(4):281–6. Comment in: Reg Anesth 1996 Jul–Aug;21(4):277–80.

Oral anticoagulant prophylaxis and epidural catheter removal [see comments] Wu CL, et al. **Reg Anesth** 1996 Nov–Dec; 21(6):517–24. Comment in: Reg Anesth 1996 Nov–Dec;21(6):503–7.

Where there is no anaesthetist: a study of 282 consecutive patients using intravenous, spinal and local infiltration anaesthetic techniques. Adesunkanmi AR. **Trop Doct** 1997 Apr;27(2):79–82

[Removal of femoral interlocking nail–induced pulmonary embolism under spinal anesthesia––a case report] Chen FC, et al. **Acta Anaesthesiol Sin** 1996 Dec;34(4):247–51 (Eng. Abstr.) **(Chi)**

[Spinal or epidural anesthesia?] Tuominen M. **Duodecim** 1995; 111(13):1232–4 (7 ref.) **(Fin)**

[Combined spinal and epidural analgesia for labor (letter; comment)] Guedj P. **Ann Fr Anesth Reanim** 1996; 15(7):1135–7. Comment on: Ann Fr Anesth Reanim 1996;15(3):263–5. **(Fre)**

[Problems posed by spinal anesthesia in a patient with Gélineau disease] Pasteau F, et al. **Ann Fr Anesth Reanim** 1996;15(5):669–72 (Eng. Abstr.) **(Fre)**

[Caudal and spinal anesthesia in sub–umbilical surgery in children. Apropos of 1875 cases] Aguemon AR, et al. **Cah Anesthesiol** 1996;44(5):455–63 (22 ref.) (Eng. Abstr.) **(Fre)**

[Should we give up combining spinal anesthesia and anticoagulants?] Samama CM. **Cah Anesthesiol** 1996; 44(5):437–40 (Eng. Abstr.) **(Fre)**

[10 years of spinal anesthesia in infants and children for orthopedic surgery. Our clinical experience] Bang–Vojdanovski B. **Anaesthesist** 1996 Mar;45(3):271–7 (Eng. Abstr.) **(Ger)**

[Spinal and regional anesthesia in bacteremia] Beland B, et al. **Anaesthesist** 1997 Jun;46(6):536–47 (117 ref.) (Eng. Abstr.) **(Ger)**

[Single–dose spinal anesthesia with a mixture of isobaric bupivacaine 0.5% and hyperbaric mepivacaine 4%] Eckert S, et al. **Anaesthesist** 1997 Feb;46(2):121–5 (Eng. Abstr.) **(Ger)**

[Spinal anesthesia for ambulatory arthroscopy. The view of the patients: results and patient's viewpoint] Fritz KW, et al. **Anaesthesist** 1997 May;46(5):430–3 (Eng. Abstr.) **(Ger)**

[Continuous spinal anesthesia] Möllmann M. **Anaesthesist** 1997 Jul;46(7):616–21 (27 ref.) (Eng. Abstr.) **(Ger)**

[Ropivacaine for spinal anesthesia. A dose–finding study] Wahedi W, et al. **Anaesthesist** 1996 Aug;45(8):737–44 (Eng. Abstr.) **(Ger)**

[Perioperative physiological and cognitive functions following oral premedication with 3.75 mg midazolam in operations with retrobulbar anesthesia] Weindler J, et al. **Anaesthesist** 1996 Sep;45(9):826–33 (Eng. Abstr.) **(Ger)**

[Spinal anesthesia for ambulatory interventions: pro and contra (letter)] Van Damme E. **Anaesthesiol Intensivmed Notfallmed Schmerzther** 1997 Apr; 32(4):263 **(Ger)**

[Spinal anesthesia in cesarean section: 1% versus 0.5% hyperbaric bupivacaine] Gallo F, et al. **Minerva Anestesiol** 1996 Jan–Feb;62(1–2):9–15 (Eng. Abstr.) **(Ita)**

[Cesarean section under spinal anesthesia for a patient with chronic renal failure] Azuma K, et al. **Masui** 1996 Jul; 45(7):880–3 (Eng. Abstr.) **(Jpn)**

[Effect of injection speed on sensory blockade in spinal anesthesia with 0.5% hyperbaric tetracaine] Hanazaki M, et al. **Masui** 1997 Jun;46(6):777–82 (Eng. Abstr.) **(Jpn)**

[The level of analgesia with epidural injection of 2% mepivacaine using combined spinal and epidural analgesia] Kasaba T, et al. **Masui** 1996 Sep;45(9):1078–82 (Eng. Abstr.) **(Jpn)**

[The spread of subarachnoid hyperbaric dibucaine in the term parturient] Konishi R, et al. **Masui** 1997 Feb;46(2):184–7 (Eng. Abstr.) **(Jpn)**

[The use of low dose midazolam for the management of spinal anesthesia] Nagahama H, et al. **Masui** 1997 Jun;46(6):803–8 (Eng. Abstr.) **(Jpn)**

[Combined spinal–epidural anesthesia for intra–abdominal gynecological surgeries] Nagashima N, et al. **Masui** 1996 Sep;45(9):1153–9 (Eng. Abstr.) **(Jpn)**

[Serial changes of atrial natriuretic peptide and brain natriuretic peptide during cesarean section under spinal anesthesia] Ohara R, et al. **Masui** 1996 Oct;45(10):1209–11 (Eng. Abstr.) **(Jpn)**

[Spinal anesthesia with 2% plain lidocaine for ultrasonically guided vaginal oocyte retrieval] Omi S, et al. **Masui** 1996 Dec;45(12):1507–10 (Eng. Abstr.) **(Jpn)**

[Combined spinal and epidural anesthesia for laparotomy in a geriatric patient with severe obstructive lung disease] Yokoyama T, et al. **Masui** 1997 Mar;46(3):409–12 (Eng. Abstr.) **(Jpn)**

[Spinal anesthesia in ambulatory surgery?] Flaatten H. **Tidsskr Nor Laegeforen** 1997 Apr 10;117(9):1265–6 **(Nor)**

[Spinal anesthesia in ambulatory surgery. Extent, routines and patient satisfaction] Wisborg T, et al. **Tidsskr Nor Laegeforen** 1997 Apr 10;117(9):1267–9 (Eng. Abstr.) **(Nor)**

[Use of morphine after surgery of lower limbs under subarachnoid anesthesia] Mikhnevich KG. **Klin Khir** 1996; (4):33–5 **(Rus)**

[Combined intradural–epidural anesthesia in a case of Steinert's disease (letter)] Alagón–Abad MC, et al. **Rev Esp Anestesiol Reanim** 1997 May;44(5):209 **(Spa)**

[Effect of the local anesthetic on visceral pain in cesarean sections done under intradural anesthesia] Echevarría M, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):2–6 (Eng. Abstr.) **(Spa)**

[Impact of anesthetic technic (general anesthesia versus intradural anesthesia) on the immune status] Muriel C, et al. **Rev Esp Anestesiol Reanim** 1996 May;43(5):164–6 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Transient radicular irritation followed by meningitis after spinal anesthesia. Mardirosoff C, et al. **Acta Anaesthesiol Belg** 1996;47(4):207–10

Severe complications associated with epidural and spinal anaesthesias in Finland 1987–1993. A study based on patient insurance claims [see comment] Aromaa U, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):445–52. Comment on: Acta Anaesthesiol Scand 1997 Apr;41(4):439–44.

Intracranial subdural haematoma––a rare complication following spinal anaesthesia. Bjärnhall M, et al. **Acta Anaesthesiol Scand** 1996 Nov;40(10):1249–51

Neurological complications of subarachnoid and epidural anaesthesia [editorial; comment] Bromage PR. **Acta Anaesthesiol Scand** 1997 Apr;41(4):439–44. Comment on: Acta Anaesthesiol Scand 1997 Apr;41(4):445–52. Comment on: Acta Anaesthesiol Scand 1997 Apr;41(4):453–60.

Grading of severity of postdural puncture headache after 27–gauge Quincke and Whitacre needles. Corbey MP, et al. **Acta Anaesthesiol Scand** 1997 Jun;41(6):779–84

Peripheral neurologic deficits in relation to subarachnoid or epidural administration of local anesthetics for surgery. A survey of 21 cases [see comments] Pleym H, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):453–60. Comment in: Acta Anaesthesiol Scand 1997 Apr;41(4):439–44.

Transient radicular irritation after spinal anaesthesia [letter; comment] Van Elstraete AC, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):864–5. Comment on: Acta Anaesthesiol Scand 1995 Oct;39(7):881–4.

The incidence of post dural puncture headache in Taiwanese patients undergoing cesarean section. Hwang JJ, et al. **Acta Anaesthesiol Sin** 1997 Mar;35(1):1–6

Post dural puncture headache in cesarean section: comparison of 25–gauge Whitacre with 25– and 26–gauge Quincke needles. Hwang JJ, et al. **Acta Anaesthesiol Sin** 1997 Mar; 35(1):33–7

Intravenous pretreatment of hypertonic saline can prevent systemic hypotension induced by spinal anesthesia. Wang BW, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):85–90

Neurotoxicity after spinal anaesthesia induced by serial intrathecal injections of magnesium sulphate. An experimental study in a rat model. Chanimov M, et al. **Anaesthesia** 1997 Mar;52(3):223–8

Hypotension, subarachnoid block and the elderly patient. Critchley LA. **Anaesthesia** 1996 Dec;51(12):1139–43 (37 ref.)

Serious spinal cord injury due to haematomyelia caused by spinal anaesthesia in a patient treated with low–dose heparin [see comments] Greaves JD. **Anaesthesia** 1997 Feb; 52(2):150–4. Comment in: Anaesthesia 1997 Jul;52(7):716.

The use of sumatriptan in the treatment of postdural puncture headache [letter] Hodgson C, et al. **Anaesthesia** 1997 Aug; 52(8):808

Heparin prophylaxis and central neural blocking techniques [letter; comment] Knowles P. **Anaesthesia** 1997 Jul; 52(7):716. Comment on: Anaesthesia 1997 Feb;52(2):150–4.

Absence of transient radicular irritation after 5000 spinal anaesthetics with prilocaine [letter] König W, et al. **Anaesthesia** 1997 Feb;52(2):182–3

Fluid preload and atrial natriuretic peptide [letter; comment] Rout CC. **Anaesthesia** 1996 Sep;51(9):889–90. Comment on: Anaesthesia 1996 Feb;51(2):128–32.

Spinal cord injury due to haematomyelia [letter; comment] Tan J, et al. **Anaesthesia** 1997 Jul;52(7):716. Comment on: Anaesthesia 1997 Feb;52(2):150–4.

Prevention of spinal anesthesia–induced hypotension in the elderly: comparison between preanesthetic administration of crystalloids, colloids, and no prehydration. Buggy D, et al. **Anesth Analg** 1997 Jan;84(1):106–10

Respiratory arrest after spinal anesthesia with lidocaine and

fentanyl. Cornish PB. **Anesth Analg** 1997 Jun;84(6):1387–8
A similar incidence of transient neurologic symptoms after spinal anesthesia with 2% and 5% lidocaine [see comments] Hampl KF, et al. **Anesth Analg** 1996 Nov;83(5):1051–4. Comment in: Anesth Analg 1997 Jun;84(6):1392–3.
Transient radicular irritation: a misnomer? [letter; comment] Hartrick CT. **Anesth Analg** 1997 Jun;84(6):1392–3. Comment on: Anesth Analg 1996 Nov;83(5):1051–4.
Neurologic complications of 603 consecutive continuous spinal anesthetics using macrocatheter and microcatheter techniques. Perioperative Outcomes Group. Horlocker TT, et al. **Anesth Analg** 1997 May;84(5):1063–70
A retrospective review of 4767 consecutive spinal anesthetics: central nervous system complications. Perioperative Outcomes Group. Horlocker TT, et al. **Anesth Analg** 1997 Mar;84(3):578–84
Transient radicular irritation after spinal anesthesia with hyperbaric 4% mepivacaine. Lynch J, et al. **Anesth Analg** 1997 Oct;85(4):872–3
Transient neurologic toxicity? [letter; comment] Naveira FA, et al. **Anesth Analg** 1996 Oct;83(4):887–8. Comment on: Anesth Analg 1996 May;82(5):1076–7.
Spinal neostigmine diminishes, but does not abolish, hypotension from spinal bupivacaine in sheep. Rose G, et al. **Anesth Analg** 1996 Nov;83(5):1041–5
Prevention of hypotension during spinal anesthesia: a comparison of intravascular administration of hetastarch versus lactated Ringer's solution. Sharma SK, et al. **Anesth Analg** 1997 Jan;84(1):111–4
Acupressure versus intravenous metoclopramide to prevent nausea and vomiting during spinal anesthesia for cesarean section. Stein DJ, et al. **Anesth Analg** 1997 Feb;84(2):342–5
Magnetic resonance imaging of cerebrospinal fluid leak and tamponade effect of blood patch in postdural puncture headache. Vakharia SB, et al. **Anesth Analg** 1997 Mar; 84(3):585–90
Treatment of hypotension after hyperbaric tetracaine spinal anesthesia. A randomized, double-blind, cross-over comparison of phenylephrine and epinephrine. Brooker RF, et al. **Anesthesiology** 1997 Apr;86(4):797–805
Drawing conclusions from Pollock et al.: limitations imposed study design [letter; comment] Drasner K. **Anesthesiology** 1996 Dec;85(6):1494–6 (16 ref.). Comment on: Anesthesiology 1996 Jun;84(6):1361–7.
Lidocaine spinal anesthesia: a vanishing therapeutic index? [editorial; comment] Drasner K. **Anesthesiology** 1997 Sep; 87(3):469–72. Comment on: Anesthesiology 1997 Sep;87(3):479–86. Comment on: Anesthesiology 1997 Sep;87(3):687–9.
Cauda equina syndrome following a single spinal administration of 5% hyperbaric lidocaine through a 25-gauge Whitacre needle [see comments] Gerancher JC. **Anesthesiology** 1997 Sep;87(3):687–9. Comment in: Anesthesiology 1997 Sep;87(3):469–72.
Transient paraparesis after postdural puncture spinal hematoma in a patient receiving ketorolac. Gerancher JC, et al. **Anesthesiology** 1997 Feb;86(2):490–4 (26 ref.)
Ruptured aortic aneurysm and cardiac arrest associated with spinal anesthesia. Joshi GP, et al. **Anesthesiology** 1997 Jan; 86(1):244–7
Radicular irritation after spinal anesthesia [letter; comment] Lambert DH, et al. **Anesthesiology** 1996 Nov;85(5):1216–7. Comment on: Anesthesiology 1996 Jun;84(6):1361–7.
Distinguishing cerebrospinal fluid from saline used to identify the extradural space. el-Behesy BA, et al. **Br J Anaesth** 1996 Dec;77(6):784–5
Meningitis after spinal anaesthesia [editorial] Burke D, et al. **Br J Anaesth** 1997 Jun;78(6):635–6
Cardiac arrest after caesarean section under subarachnoid block [letter; comment] Burns R, et al. **Br J Anaesth** 1997 Jan;78(1):110. Comment on: Br J Anaesth 1996 Aug;77(2):274–6.
Conservative management of extradural abscess complicating spinal-extradural anaesthesia for caesarean section. Dysart RH, et al. **Br J Anaesth** 1997 May;78(5):591–3
Cardiac arrest after caesarean section under subarachnoid block [letter; comment] Gambling DR. **Br J Anaesth** 1997 Jan;78(1):109–10. Comment on: Br J Anaesth 1996 Aug;77(2):274–6.
Cardiac arrest after Caesarean section under subarachnoid block [see comments] Scull TJ, et al. **Br J Anaesth** 1996 Aug;77(2):274–6. Comment in: Br J Anaesth 1997 Jan;78(1):109. Comment in: Br J Anaesth 1997 Jan;78(1):109–10. Comment in: Br J Anaesth 1997 Jan;78(1):110. Comment in: Br J Anaesth 1997 Feb;78(2):230.
Cardiac arrest after caesarean section under subarachnoid block [letter; comment] Trotter C, et al. **Br J Anaesth** 1997 Jan;78(1):109. Comment on: Br J Anaesth 1996 Aug;77(2):274–6.
Hypotension during subarachnoid anaesthesia [letter; comment] Watters M. **Br J Anaesth** 1996 Dec;77(6):808–9. Comment on: Br J Anaesth 1996 May;76(5):734–6.
Aseptic meningitis using the needle-through-needle technique [letter; comment] Eldor J. **Can J Anaesth** 1996 Nov;43(11):1183–4. Comment on: Can J Anaesth 1996 Apr;43(4):399–402.
Brainstem anaesthesia after peribulbar anaesthesia. Gomez RS, et al. **Can J Anaesth** 1997 Jul;44(7):732–4
Failed spinal anaesthesia: cause identified by MRI. Hirabayashi Y, et al. **Can J Anaesth** 1996 Oct;43(10):1072–5
Graduated compression stocking prevents hypotension during spinal anaesthesia [letter] Iwama H. **Can J Anaesth** 1996 Sep;43(9):984–5
Epidural abscess after combined spinal-epidural block [see comments] Schröter J, et al. **Can J Anaesth** 1997 Mar; 44(3):300–4. Comment in: Can J Anaesth 1997 Mar;44(3):235–8.
Infection after central neuraxial block [editorial; comment] Smedstad KG. **Can J Anaesth** 1997 Mar;44(3):235–8. Comment on: Can J Anaesth 1997 Mar;44(3):300–4. **(Eng, Fre)**
Hearing loss following spinal anaesthesia with bupivacaine. Hussain SS, et al. **Clin Otolaryngol** 1996 Oct;21(5):449–54
Development of a midline lumbar lipoma following spinal anesthesia: complications or coincidence? [letter] Cohen SP, et al. **J Clin Anesth** 1997 Mar;9(2):170–1
A case of coronary artery spasm during spinal anesthesia. Imamura M, et al. **J Clin Anesth** 1996 Sep;8(6):522–4
Conus medullaris injury following both tetracaine and lidocaine spinal anesthesia. Waters JH, et al. **J Clin Anesth** 1996 Dec;8(8):656–8
Complications of super-selective subarachnoid anesthesia (SSA) with hyperbaric bupivacaine: experiences with 355 patients in general and orthopaedic surgery. Pappalardo GB, et al. **Panminerva Med** 1997 Mar;39(1):41–5
Unexpected neurologic deficit following spinal anesthesia. Chhibber AK, et al. **Reg Anesth** 1996 Jul–Aug;21(4):355–7
Postdural puncture headache [letter; comment] Glazener EL. **Reg Anesth** 1996 Jul–Aug;21(4):375. Comment on: Reg Anesth 1995 Jul–Aug;20(4):329–36.
Safety of spinal and epidural anesthesia in parturients with chorioamnionitis. Goodman EJ, et al. **Reg Anesth** 1996 Sep–Oct;21(5):436–41
Postdural puncture headache: the betadine factor [letter] [see comments] Gurmarnik S, et al. **Reg Anesth** 1996 Jul–Aug; 21(4):375–6. Comment in: Reg Anesth 1997 May–Jun;22(3):297.
Venous capacitance changes in the lower extremities during spinal anesthesia [letter; comment] Hogan QH. **Reg Anesth** 1996 Jul–Aug;21(4):376–7. Comment on: Reg Anesth 1995 Sep–Oct;20(5):402–6.
Role of needle gauge and tip configuration in the production of lumbar puncture headache. Lambert DH, et al. **Reg Anesth** 1997 Jan–Feb;22(1):66–72
Postdural puncture headache and back pain after spinal anesthesia with 27-gauge Quincke and 26-gauge Atraucan needles. Schultz AM, et al. **Reg Anesth** 1996 Sep–Oct; 21(5):461–4
Transient radicular irritation after bupivacaine spinal anesthesia. Tarkkila P, et al. **Reg Anesth** 1996 Jan–Feb; 21(1):26–9
Risks of regional anesthesia—infectious, septic. Wedel DJ, et al. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):57–61 (30 ref.)
Proximal paraparesis following spinal anesthesia. Toussirot E, et al. **Rev Rhum Engl Ed** 1996 Jun;63(6):450–2
Postpartum bilateral subdural hematomas following spinal anesthesia: case report. Cohen JE, et al. **Surg Neurol** 1997 Jan;47(1):6–8
[An alternative method for treating headache after spinal anesthesia in cesarean section] Tsenov D. **Akush Ginekol (Sofiia)** 1996;35(4):6–7 (Eng. Abstr.) **(Bul)**
[Bacterial meningitis after combined spinal and epidural anesthesia in obstetrics (letter)] Aldebert S, et al. **Ann Fr Anesth Reanim** 1996;15(5):687–8 **(Fre)**
[Neurotoxicity of intrathecally administrated agents] Malinovsky JM, et al. **Ann Fr Anesth Reanim** 1996; 15(5):647–58 (128 ref.) (Eng. Abstr.) **(Fre)**
[Problems caused by spinal sufentanil analgesia at the end of labor (letter)] Mercier FJ, et al. **Ann Fr Anesth Reanim** 1996;15(5):688–90 **(Fre)**
[Spinal para-medullary conduction anesthesia in therapy with anticoagulant drugs] Hesse T, et al. **Anaesthesiol Reanim** 1996;21(5):116–21 (74 ref.) (Eng. Abstr.) **(Ger)**
[Circulatory reactions under spinal anesthesia. The catheter technique versus the single dose procedure] Holst D, et al. **Anaesthesist** 1997 Jan;46(1):38–42 (Eng. Abstr.) **(Ger)**
[Two cases of asthmatic attack caused by spinal anesthesia] Kawabata KM. **Masui** 1996 Jan;45(1):102–6 (Eng. Abstr.) **(Jpn)**
[Evaluation of postoperative hypoxemia after spinal anesthesia with a pulse oximeter] Kobayashi Y, et al. **Masui** 1997 Jun;46(6):818–22 (Eng. Abstr.) **(Jpn)**
[Sudden syncope during spinal block under sitting position: a report of three cases] Masuda R, et al. **Masui** 1996 Jul; 45(7):876–9 (Eng. Abstr.) **(Jpn)**
[Neurologic sequelae of spinal anesthesia: local anesthetic toxicity] Sakura S, et al. **Masui** 1996 Jul;45(7):846–51 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Leg pain under spinal anesthesia in leprosy patients] Tsuji C, et al. **Masui** 1997 May;46(5):704–7 (Eng. Abstr.) **(Jpn)**
[Indication for spinal anesthesia for cesarean section in HELLP syndrome coagulopathy] Blasi A, et al. **Rev Esp Anestesiol Reanim** 1997 Feb;44(2):79–82 (Eng. Abstr.) **(Spa)**
[Hearing loss after spinal anesthesia (letter; comment)] de la Linde-Valverde CM. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):42. Comment on: Rev Esp Anestesiol Reanim 1996 Jun–Jul;43(6):229–30. **(Spa)**
[Transient global amnesia during subarachnoid anesthesia (letter)] Domingo I, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):74–5 **(Spa)**
[Pain in the lower extremities after subarachnoid block with lidocaine] Saludes J, et al. **Rev Esp Anestesiol Reanim** 1996 Nov;43(9):330–2 (Eng. Abstr.) **(Spa)**
[Transient bilateral hearing loss after spinal anesthesia (letter) (see comments)] Sánchez-Conde P, et al. **Rev Esp Anestesiol Reanim** 1996 Jun–Jul;43(6):229–30. Comment in: Rev Esp Anestesiol Reanim 1997 Jan;44(1):42. **(Spa)**
[Benign intracranial hypertension after meningitis as a complication of subarachnoid anesthesia (letter)] Sánchez-Conde P, et al. **Rev Esp Anestesiol Reanim** 1996 Aug–Sep;43(7):263–4 **(Spa)**

CONTRAINDICATIONS

Spinal anaesthesia and spina-bifida occulta. Davies PR, et al. **Anaesthesia** 1996 Dec;51(12):1158–60
Neuraxial anesthesia is contraindicated in patients undergoing heparinization for surgery. Pro: neuraxial anesthesia should not be used in patients undergoing heparinization for surgery. Ralley FE. **J Cardiothorac Vasc Anesth** 1996 Dec; 10(7):957–60
[Thromboembolism prevention with low dose heparin and spinal anesthesia--a risky combination?] Keser C, et al. **Anaesthesist** 1996 Dec;45(12):1203–10 (Eng. Abstr.) **(Ger)**
[Spinal anesthesia for ambulatory interventions--contra] Bachmann-Mennenga B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Nov; 31(9):573–4 **(Ger)**
[Spinal anesthesia for ambulatory interventions--pro] Hempel V. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Nov; 31(9):575–6 **(Ger)**
[Patients with coronary heart disease and post-myocardial infarct status] van Aken H, et al. **Internist (Berl)** 1997 Feb; 38(2):165–6 **(Ger)**

HISTORY

Magnesium sulphate spinal anaesthesia [letter; comment] Diba A, et al. **Anaesthesia** 1997 Feb;52(2):187–8. Comment on: Anaesthesia 1996 Jul;51(7):627–33.
Tait and Caglieri. The first spinal anesthetic in America. Larson MD. **Anesthesiology** 1996 Oct;85(4):913–9
Torrieri and combined spinal-epidural technique [letter] Aldrete JA. **Reg Anesth** 1996 Nov–Dec;21(6):599–600
The evolution of combined spinal-epidural anesthesia needles [letter] Eldor J. **Reg Anesth** 1997 May–Jun;22(3):294–6
[Jonnesco total spinal anesthesia] Goerig M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Feb; 31(1):46–8 **(Ger)**

INSTRUMENTATION

Eldor needle's advantage over the needle-through-needle technique [letter] Gozal D. **Acta Anaesthesiol Scand** 1997 May;41(5):656
Deformed spinal needle tips and associated dural perforations examined by scanning electron microscopy. Jokinen MJ, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):687–90
Spinal needle damage during routine clinical practice. Benham M. **Anaesthesia** 1996 Sep;51(9):843–5
A new combined spinal-epidural apparatus: measurement of the distance to the epidural and subarachnoid spaces. Hoffmann VL, et al. **Anaesthesia** 1997 Apr;52(4):350–5
Flow dynamics through spinal needles. Serpell MG, et al. **Anaesthesia** 1997 Mar;52(3):229–36
Broken small-gauge spinal needle [letter; comment] Thomsen AF, et al. **Anesth Analg** 1997 Jul;85(1):230–1. Comment on: Anesth Analg 1996 Jan;82(1):217–8.
Incidence of tissue coring with the 25-gauge Quincke and Whitacre spinal needles. Campbell DC, et al. **Reg Anesth** 1996 Nov–Dec;21(6):582–5
Double-hole pencil-point spinal needle [letter] Eldor J. **Reg Anesth** 1996 Jan–Feb;21(1):74–5
A new type of spinal introducer [letter] Gurmarnik S. **Reg Anesth** 1997 May–Jun;22(3):296
Comments on study of spinal needle tips by Rosenberg et al [letter; comment] Haindl H. **Reg Anesth** 1997 Jan–Feb; 22(1):105–6. Comment on: Reg Anesth 1996 Jan–Feb;21(1):35–40.
Postdural puncture headache and back pain after spinal anesthesia with 27-gauge Quincke and 26-gauge Atraucan needles. Schultz AM, et al. **Reg Anesth** 1996 Sep–Oct; 21(5):461–4
Comparison of the flow rates of 27-gauge Whitacre and Sprotte needles for combined spinal and epidural anesthesia [letter] Waldman SA, et al. **Reg Anesth** 1996 Jul–Aug; 21(4):378–9
[Electron microscopy of the lesions produced in the human dura mater by Quincke beveled and Whitacre needles] Reina MA, et al. **Rev Esp Anestesiol Reanim** 1997 Feb; 44(2):56–61 (Eng. Abstr.) **(Spa)**

METHODS

Intrathecal morphine dose for caesarean section [letter; comment] Buggy D. **Anaesthesia** 1997 Mar;52(3):278. Comment on: Anaesthesia 1996 Sep;51(9):871–3.
The reproducibility of the iliac crest as a marker of lumbar spinal level [letter] Thavasothy M. **Anaesthesia** 1997 Aug; 52(8):811

Contamination of opioids during preparation for regional anaesthesia [letter; comment] Tunstall ME, et al. **Anaesthesia** 1997 Mar;52(3):290. Comment on: Anaesthesia 1996 Nov;51(11):1079–80.
Spinal anesthesia with meperidine. Effects of added alpha-adrenergic agonists: epinephrine versus clonidine. Acalovschi I, et al. **Anesth Analg** 1997 Jun;84(6):1333–9
Comparison of lidocaine and saline for epidural top-up during combined spinal-epidural anesthesia in volunteers. Trautman WJ 3rd, et al. **Anesth Analg** 1997 Mar;84(3):574–7
The direction of the Whitacre needle aperture affects the extent and duration of isobaric spinal anesthesia. Urmey WF, et al. **Anesth Analg** 1997 Feb;84(2):337–41
Dose-response characteristics of spinal bupivacaine in volunteers. Clinical implications for ambulatory anesthesia. Liu SS, et al. **Anesthesiology** 1996 Oct;85(4):729–36
Spinal anaesthesia with 0.25% hyperbaric bupivacaine for caesarean section: effects of volume [letter; comment] Bell R, et al. **Br J Anaesth** 1997 Mar;78(3):339–40. Comment on: Br J Anaesth 1996 Aug;77(2):145–9.
Spinal anaesthesia with 0.25% hyperbaric bupivacaine for Caesarean section: effects of volume [see comments] Chung CJ, et al. **Br J Anaesth** 1996 Aug;77(2):145–9. Comment in: Br J Anaesth 1997 Mar;78(3):339–40.
Spinal anaesthesia for Caesarean section [letter; comment] Foster RN, et al. **Br J Anaesth** 1996 Aug;77(2):301–2. Comment on: Br J Anaesth 1996 Mar;76(3):476.
Spinal anaesthesia for Caesarean section: effect of Sprotte needle orientation [see comments] James KS, et al. **Br J Anaesth** 1996 Aug;77(2):150–2. Comment in: Br J Anaesth 1997 Feb;78(2):229–30.
Combined spinal–extradural anaesthesia for preterm and term caesarean section: is there a difference in local anaesthetic requirements? James KS, et al. **Br J Anaesth** 1997 May; 78(5):498–501
Spinal anaesthesia: effect of the site of injection on the spread of analgesia [letter] Kamenik M. **Br J Anaesth** 1997 Jul; 79(1):144–5
Regional anaesthesia in moyamoya disease [letter] Llorente de la Fuente A, et al. **Br J Anaesth** 1997 Apr;78(4):478–9
Effect of Sprotte needle orientation on spinal anaesthesia [letter; comment] Serpell MG. **Br J Anaesth** 1997 Feb; 78(2):229–30. Comment on: Br J Anaesth 1996 Aug;77(2):150–2.
Spinal anaesthesia with 0.5% hyperbaric bupivacaine in elderly patients: effect of site of injection on spread of analgesia. Veering BT, et al. **Br J Anaesth** 1996 Sep; 77(3):343–6
Spinal anaesthesia for Caesarean section [letter; comment] Vickers R, et al. **Br J Anaesth** 1996 Aug;77(2):301–2. Comment on: Br J Anaesth 1996 Mar;76(3):476.
A difficult obstetric anaesthesia problem. Wheatley EC, et al. **Br J Hosp Med** 1996 Nov 20–Dec 10;56(10):553
Use of intrathecal analgesia in a rural hospital. Case studies. Kurokawa JS, et al. **J Nurse Midwifery** 1996 Jul–Aug; 41(4):338–42
Reporting levels of spinal blockade. Van Bogaert LJ. **Med Hypotheses** 1997 Jun;48(6):485–8 (31 ref.)
High spinal anaesthesia for repair of patent ductus arteriosus in neonates. Williams RK, et al. **Paediatr Anaesth** 1997; 7(3):205–9
Spinal–epidural–general anesthesia [letter; comment] Alam S. **Reg Anesth** 1996 Nov–Dec;21(6):608–9. Comment on: Reg Anesth 1994 Sep–Oct;19(5):365–6.
Use of spinal or continuous caudal anesthesia for inguinal hernia repair in premature infants: are there advantages? Broadman LM. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):108–13 (27 ref.)
Comparison between hemodynamic changes after single-dose and incremental subarachnoid anesthesia. Casati A, et al. **Reg Anesth** 1996 Jul–Aug;21(4):298–303
Testing sensory level of anesthesia [letter] Fishman EB. **Reg Anesth** 1997 Mar–Apr;22(2):200
The peripheral nerve stimulator: a monitor during continuous spinal anesthesia. Case report. Gerancher JC, et al. **Reg Anesth** 1996 Sep–Oct;21(5):480–1
Spinal clonidine fails to provide surgical anesthesia for transurethral resection of prostate. A dose-finding pilot study. Malinovsky JM, et al. **Reg Anesth** 1996 Sep–Oct; 21(5):419–23
The anticoagulated patient. Rauck RL. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):51–6 (28 ref.)
Continuous spinal anesthesia for cesarean delivery in a patient with arthrogryposis multiplex congenita. A clinical report. Rozkowski A, et al. **Reg Anesth** 1996 Sep–Oct;21(5):477–9
[Difficult deliveries treated with sufentanil spinal anesthesia at the end of labor (letter)] Van Elstraete AC, et al. **Ann Fr Anesth Reanim** 1996;15(2):231–2 **(Fre)**
[Value of combined spinal and epidural anesthesia in the management of peroperative analgesia in prosthetic surgery of the lower limb. Prospective study of 68 cases] Cazeneuve JF, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(8):705–8 (Eng. Abstr.) **(Fre)**
[Circulatory reactions under spinal anesthesia. The catheter technique versus the single dose procedure] Holst D, et al. **Anaesthesist** 1997 Jan;46(1):38–42 (Eng. Abstr.) **(Ger)**
[Selective subarachnoid anesthesia for intervention for hip fracture] Porcelli P, et al. **Minerva Anestesiol** 1996 Nov; 62(11):357–61 (Eng. Abstr.) **(Ita)**
[Superselective spinal anesthesia for saphenectomy intervention. Comparison of 2 concentrations of hyperbaric bupivacaine] Santagostino G, et al. **Minerva Anestesiol** 1996 Dec;62(12):389–94 (Eng. Abstr.) **(Ita)**
[Epidural administration of buprenorphine after combined spinal epidural anesthesia] Endoh M, et al. **Masui** 1996 Nov; 45(11):1396–9 (Eng. Abstr.) **(Jpn)**
[Anesthesia in a case of benign symmetrical lipomatosis type Launois-Bensaude (letter)] García-Miguel FJ, et al. **Rev Esp Anestesiol Reanim** 1996 Aug–Sep;43(7):264–5 **(Spa)**

UTILIZATION

National audit of anaesthesia for major abdominal surgery. Rigg JR, et al. **Anaesth Intensive Care** 1997 Jun;25(3):282–5
Hemostasis-altering drugs and central neural block. A survey of anesthetic practice in Scotland and the United Kingdom. Millar FA, et al. **Reg Anesth** 1996 Nov–Dec;21(6):529–33

ANESTHESIOLOGY

Proceedings of the Vienna International Anesthesiology and Intensive Care Congress. Vienna, Austria, October 2–5, 1996. **Acta Anaesthesiol Scand Suppl** 1996;109:1–271
Proceedings and abstracts from the Scandinavian Society of Anaesthesiologists 24th Congress. Stockholm, Sweden, June 10–13, 1997. **Acta Anaesthesiol Scand Suppl** 1997; 110:7–202
Intraoperative care of the high risk patient: the role of the anaesthesiologist. Hammerle AF, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:15–6
The impact of health care reform [editorial; comment] Chan KH. **Acta Anaesthesiol Sin** 1996 Mar;34(1):i–iii. Comment on: Acta Anaesthesiol Sin 1996 Mar;34(1):27–32.
The impact of health care reform on anesthesiologists and their patients in the United States: an ergonomic perspective [see comments] Weinger MB. **Acta Anaesthesiol Sin** 1996 Mar;34(1):27–32 (31 ref.). Comment in: Acta Anaesthesiol Sin 1996 Mar;34(1):i–iii.
Recent advances in airway management in anesthesiology: an update for otolaryngologists. American Society of Anesthesiologists. Gonzalez RM, et al. **Am J Otolaryngol** 1996 May–Jun;17(3):145–60 (74 ref.)
Abstracts of the combined scientific meeting of the Australian and New Zealand College of Anaesthetists, Faculty of Intensive Care and Australian Society of Anesthetists. Western Australia, October 26–30, 1996. **Anaesth Intensive Care** 1997 Apr;25(2):171–93
American Society of Anesthesiologists infection control policy [letter] Berry AJ. **Anaesth Intensive Care** 1996 Oct; 24(5):618
Anaesthesia and emerging infectious diseases. Dwyer DE. **Anaesth Intensive Care** 1996 Apr;24(2):184–90 (51 ref.)
Infection control [letter] Holland R. **Anaesth Intensive Care** 1996 Oct;24(5):619
Revision of the anaesthetic aspects of an infection control policy following reporting of hepatitis C nosocomial infection [see comments] Knoblanche GK. **Anaesth Intensive Care** 1996 Apr;24(2):169–72. Comment in: Anaesth Intensive Care 1996 Aug;24(4):514. Comment in: Anaesth Intensive Care 1997 Feb;25(1):86–7.
Response times to visual and auditory alarms during anaesthesia. Morris RW, et al. **Anaesth Intensive Care** 1996 Dec;24(6):682–4
Transfer of adenovirus infection from patient to anaesthetist during emergency tracheal intubation. Sidebotham D, et al. **Anaesth Intensive Care** 1997 Feb;25(1):83–5
Detection of accidental oesophageal intubation. Role of the anaesthetic assistant. Cameron AE, et al. **Anaesthesia** 1997 Aug;52(8):733–5
Ease of insertion of the laryngeal mask airway by inexperienced personnel when using an introducer. Dingley J, et al. **Anaesthesia** 1997 Aug;52(8):756–60
Managing the dysfunctional doctor [editorial] Hatch DJ. **Anaesthesia** 1997 Mar;52(3):193–4
Music in theatre: not so harmonious. A survey of attitudes to music played in the operating theatre. Hawksworth C, et al. **Anaesthesia** 1997 Jan;52(1):79–83
Labelling and drug administration error [letter; comment] Merry AF, et al. **Anaesthesia** 1996 Oct;51(10):987–8. Comment on: Anaesthesia 1996 Jan;51(1):1–2.
Anaesthesia, anaesthetics and anaesthesiology [letter] Tierney E. **Anaesthesia** 1997 Jun;52(6):615
Is Hartmann's the solution? White SA, et al. **Anaesthesia** 1997 May;52(5):422–7
Association of Anaesthetists recommendations on filters to prevent cross infection in anaesthetic breathing systems [letter] Wilkes AR, et al. **Anaesthesia** 1996 Nov; 51(11):1080–1
International Anesthesia Research Society 71st Clinical and Scientific Congress. San francisco, California, March 14–18, 1997. Abstracts. **Anesth Analg** 1997 Feb;84(2 Suppl):S1–662
Society of Cardiovascular Anesthesiologists 19th annual meeting. Baltimore, Maryland, May 10–14, 1997. Abstracts. **Anesth Analg** 1997 Apr;84(4 Suppl):SCA1–143
Practice patterns of anesthesiologists regarding situations in obstetric anesthesia where clinical management is controversial. Beilin Y, et al. **Anesth Analg** 1996 Oct; 83(4):735–41
Anesthesia providers, patient outcomes, and costs [letter; comment] Gaba DM. **Anesth Analg** 1996 Dec;83(6):1347–8; discussion 1349–50. Comment on: Anesth Analg 1996 Jun;82(6):1273–83.
Anesthesia providers, patient outcomes, and costs [letter; comment] Hanna K. **Anesth Analg** 1996 Dec;83(6):1348; discussion 1349–50. Comment on: Anesth Analg 1996 Jun;82(6):1273–83.
More or better—educating the patient about the anesthesiologist's role as perioperative physician [editorial; comment] Klock PA, et al. **Anesth Analg** 1996 Oct; 83(4):671–2. Comment on: Anesth Analg 1996 Oct;83(4):793–7.
Anesthesia providers, patient outcomes, and costs [letter; comment] Kremer M. **Anesth Analg** 1996 Dec;83(6):1348–9; discussion 1349–50. Comment on: Anesth Analg 1996 Jun;82(6):1117–8. Comment on: Anesth Analg 1996 Jun;82(6):1273–83.
Non-operating room emergency airway management and endotracheal intubation practices: a survey of anesthesiology program directors. Nayyar P, et al. **Anesth Analg** 1997 Jul;85(1):62–8
Should we be aggressive anesthesiologists? [letter] Norman J. **Anesth Analg** 1997 Sep;85(3):706–7
Anesthesia providers, patient outcomes, and costs [letter; comment] Stoelting RK. **Anesth Analg** 1996 Dec; 83(6):1347; discussion 1349–50. Comment on: Anesth Analg 1996 Jun;82(6):1273–83.
Occupational transmission of tuberculosis: implications for anesthesiologists. Tait AR. **Anesth Analg** 1997 Aug; 85(2):444–51 (74 ref.)
The importance of the postoperative anesthetic visit: do repeated visits improve patient satisfaction or physician recognition? [see comments] Zvara DA, et al. **Anesth Analg** 1996 Oct;83(4):793–7. Comment in: Anesth Analg 1996 Oct;83(4):671–2.
Annual meeting of the American Society of Anesthesiologists. New Orleans, Louisiana, October 19–23, 1996. Abstracts. **Anesthesiology** 1996 Sep;85(3A Suppl):A1–1343
1997 Annual meeting of the American Society of Anesthesiologists. San Diego, California, October 18–22, 1997. Abstracts. **Anesthesiology** 1997 Sep;87(3A Suppl):A1–1261
Navigation in uncharted waters. Is anesthesiology on course for the 21st century? Longnecker DE. **Anesthesiology** 1997 Mar;86(3):736–42
Bears, academia, and anaesthesia: a controlled study. Curran J, et al. **BMJ** 1996 Dec 21–28;313(7072):1643–4
Infant and neonatal pain: anaesthetists' perceptions and prescribing patterns. de Lima J, et al. **BMJ** 1996 Sep 28; 313(7060):787
Anaesthetists are younger than other doctors [letter; comment] McMamus C. **BMJ** 1997 Aug 2;315(7103):314. Comment on: BMJ 1996 Dec 21–28;313(7072):1581–2. Comment on: BMJ 1997 Apr 12;314(7087):1132.
European Society of Anaesthesiologists annual congress. Lausanne, 3–6 May 1997. Abstracts. **Br J Anaesth** 1997 May;78 Suppl 1:1–142
European Association of Cardiothoracic Anaesthesiologists 12th annual meeting. Thessaloniki, Greece, 25–28 Jun 1997. Abstracts. **Br J Anaesth** 1997 Jun;78 Suppl 2:1–53
Personal reflections [editorial] Smith G. **Br J Anaesth** 1997 Jul;79(1):1–2
CJA—metamorphosis [editorial; comment] Bevan D. **Can J Anaesth** 1997 Jan;44(1):1–3. Comment on: Can J Anaesth 1997 Jan;44(1):14–8. **(Eng, Fre)**
Electronic publishing [letter; comment] Doyle DJ. **Can J Anaesth** 1996 Jun;43(6):640–1. Comment on: Can J Anaesth 1995 Dec;42(12):1177.
Anaesthesia technology: friend and foe [editorial; comment] Malm D. **Can J Anaesth** 1997 Jan;44(1):4–8. Comment on: Can J Anaesth 1997 Jan;44(1):73–7. **(Eng, Fre)**
The value of the Internet to anaesthetists. Oyston JP, et al. **Can J Anaesth** 1997 Apr;44(4):439–44
Canadian Anaesthetists' Society Gold Medal. Sellery GR. **Can J Anaesth** 1996 Dec;43(12):1273–4 **(Eng, Fre)**
An analysis of review articles published in four anaesthesia journals [see comments] Smith AF. **Can J Anaesth** 1997 Apr;44(4):405–9. Comment in: Can J Anaesth 1997 Apr;44(4):350–3.
The James Young Simpson Legacy, 4–6 September 1997. Abstracts. **Eur J Anaesthesiol** 1997 Sep;14(5):521–50
Anaesthesiological manpower in Europe [letter; comment] Dejonckheere M, et al. **Eur J Anaesthesiol** 1997 May; 14(3):345. Comment on: Eur J Anaesthesiol 1996 Jul;13(4):314–5.
Exposure of anesthesiologists to nitrous oxide during pediatric anesthesia. Chang WP, et al. **Ind Health** 1997; 35(1):112–8
Technology and health system reform. Lang AC. **Int Anesthesiol Clin** 1995 Fall;33(4):119–32 (19 ref.)
Con: anesthesia societies should not consider endorsement of patient care guidelines written by other societies. Arens JF. **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):538–9
Anesthesia information-management systems: their role in risk-versus cost assessment and outcomes research. Gibby GL. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2 Suppl 1):2–5; discussion 24–5 (22 ref.)
Pro: anesthesia societies should consider endorsement of patient care guidelines written by other societies. Roizen MF. **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):536–7
New surgical techniques: implications for the cardiac anesthesiologist: mini-thoracotomy for coronary revascularization without cardiopulmonary bypass. Schaff HV. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2 Suppl 1):6–9; discussion 24–5 (17 ref.)

ANESTHESIOLOGY

Drug packaging similarities require extraordinary vigilance [letter] Thielmeier KA. **J Clin Anesth** 1996 Dec;8(8):688–9

Use of data from a hospital online medical records system by physicians during preanesthetic evaluation. Gibby GL, et al. **J Clin Monit** 1996 Sep;12(5):405–8

IARS annual meeting includes safety topics [news] Guyton D. **J Clin Monit** 1996 Jan;12(1):105–6

Research grant report: how does night call affect next-day performance in anesthesia? [news] Lichtor JL, et al. **J Clin Monit** 1996 May;12(3):277–8

Recurrent issues prompt call for continued effort [news] Pierce EC Jr. **J Clin Monit** 1996 Jan;12(1):103

OR reading debate continues in my opinion: lack of outcome data makes reading a personal decision, states OR investigator [news] Weinger MB. **J Clin Monit** 1996 Jan; 12(1):109–10

Quotation accuracy in neuroanesthesiologic research. Kolbitsch C, et al. **J Neurosurg Anesthesiol** 1997 Jan; 9(1):8–10

The caesarean section. Gow DN. **Med J Aust** 1996 Dec 2–16; 165(11–12):680–1

Universal precautions: attitudes of Australian and New Zealand [letter] Horan B. **Med J Aust** 1997 May 19; 166(10):566; discussion 566–7

Universal precautions and anaesthetists: time for a rethink? [comment] Kerridge RK. **Med J Aust** 1997 Feb 3; 166(3):142. Comment on: Med J Aust 1997 Feb 3;166(3):138–40.

Universal precautions and anaesthetists: personalising the message [comment] Phillips GD. **Med J Aust** 1997 Feb 3;166(3):141. Comment on: Med J Aust 1997 Feb 3;166(3):138–40.

Universal precautions: attitudes of Australian and New Zealand anaesthetists [see comments] Richards MJ, et al. **Med J Aust** 1997 Feb 3;166(3):138–40. Comment in: Med J Aust 1997 Feb 3;166(3):141. Comment in: Med J Aust 1997 Feb 3;166(3):142.

The Internet and paediatric anaesthesia [editorial] Tibbals J, et al. **Paediatr Anaesth** 1997;7(4):265–6

The anaesthetist as determinant factor of quality of surgical antimicrobial prophylaxis. A survey in a university hospital. Gyssens IC, et al. **Pharm World Sci** 1997 Apr;19(2):89–92

Annual congress of the Swiss Society of Anesthesiology and Resuscitation. Interlaken, 7–9 November 1996. Abstracts. **Schweiz Med Wochenschr Suppl** 1996;83:3S–14S **(Eng, Fre, Ger)**

Role of the anesthesiologist in the early diagnosis of life-threatening complications during laparoscopic surgery. Noga J, et al. **Surg Laparosc Endosc** 1997 Feb;7(1):63–5

[38th National Congress of Anesthesiology and Resuscitation. Paris, 26–29 September 1996. Abstracts] **Ann Fr Anesth Reanim** 1996;15(6):719–994 **(Fre)**

[89th Annual meeting of the Swiss Society of Pediatrics in association with the Swiss Society of Infant Surgery and The Swiss Society of Pediatric Anesthesiology. Bienne, 20–22 June 1996. Abstracts] **Schweiz Med Wochenschr Suppl** 1996;78:1S–43S **(Fre, Ger)**

[Disorders of organ perfusion. IV. Interdisciplinary Symposium of Clinical Physiological Anesthesiology. V., 9/20–21/1996, Heidelberg] Weigand MA. **Anaesthesist** 1996 Dec;45(12):1239–43 **(Ger)**

German Congress on Anesthesiology. Yearly Meeting of the German Societyfor Anesthesiology and Intensive Care. Symposium: Sufentanil in anesthesia and intensive care. Nürnberg, 15 June 1994] **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Apr; 30(2 Suppl):1–8 **(Ger)**

[The role of the anesthetist or what do patients know about us? (editorial; comment)] Krier C. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):399–400. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Sep;31(7):409–13. **(Ger)**

[The problem with assessing quality (editorial)] Möllenberg O, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jun; 32(6):331–2 **(Ger)**

[Comment on Deusch et al.: Patient knowledge about anesthesia practice and responsibilities of the anesthetist (letter; comment)] Walz R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Apr; 32(4):263. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Sep;31(7):409–13. **(Ger)**

[Questionnaires on preoperative evaluation of patients] Irita K, et al. **Masui** 1996 Dec;45 Suppl:S147–54 (9 ref.) **(Jpn)**

[Problems in preoperative evaluation of patients—differences in viewpoint among physicians] Katayama H, et al. **Masui** 1996 Dec;45 Suppl:S139–42 (0 ref.) **(Jpn)**

[Participation of anesthesiologists in the Internet] Mori T. **Masui** 1996 Dec;45(12):1480–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Anesthesiologists and information resources on the Internet] Mori T. **Masui** 1997 Jan;46(1):49–63 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Anesthesiologists and the Internet: the Internet and the Masui Discussion List] Mori T. **Masui** 1996 Nov; 45(11):1372–9 (Eng. Abstr.) **(Jpn)**

[Accepted low hemoglobin levels in the perioperative period. A questionnaire survey among Norwegian anesthesiologists] Kongsgaard UE, et al. **Tidsskr Nor Laegeforen** 1996 Nov 10;116(27):3219–21 (Eng. Abstr.) **(Nor)**

[Feedback monitoring systems in anesthesiology] Drozdov AV, et al. **Anesteziol Reanimatol** 1997 Jan–Feb;(1):48–53 **(Rus)**

[Anesthesiological practice in Scotland] Polovinkin PV. **Anesteziol Reanimatol** 1997 Mar–Apr;(2):68–72 **(Rus)**

[Anesthesiology and Internet (editorial)] Campos JM. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):91–2 **(Spa)**

[The Spanish edition of "Educational Synopsis in Anesthesia." The 1st electronic anesthesiology periodical (letter)] Campos-Suárez JM. **Rev Esp Anestesiol Reanim** 1997 Jan; 44(1):41–2 **(Spa)**

[Can we change the patient's image of the anesthesiologist? (see comments)] García-Sánchez MJ, et al. **Rev Esp Anestesiol Reanim** 1996 Jun–Jul;43(6):204–7 (Eng. Abstr.). Comment in: Rev Esp Anestesiol Reanim 1996 Dec;43(10):380–1. **(Spa)**

[The Internet web in anesthesiology-recovery] Gil-Cebrián J, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):112–6 (39 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Economics of anesthesia care. A call to arms! [editorial; comment] Fisher DM, et al. **Anesthesiology** 1997 May; 86(5):1018–9. Comment on: Anesthesiology 1997 May;86(5):1145–60. Comment on: Anesthesiology 1997 May;86(5):1161–9. Comment on: Anesthesiology 1997 May;86(5):1170–96. Comment on: Anesthesiology 1997 May;86(5):1197–205.

The successful implementation of pharmaceutical practice guidelines. Analysis of associated outcomes and cost savings. SWiPE Group. Systematic Withdrawal of Perioperative Expenses [see comments] Lubarsky DA, et al. **Anesthesiology** 1997 May;86(5):1145–60. Comment in: Anesthesiology 1997 May;86(5):1018–9. Comment in: Anesthesiology 1997 May;86(5):1020–2.

Why must the practice of anesthesiology change? It's economics, doctor! [editorial; comment] Shapiro BA. **Anesthesiology** 1997 May;86(5):1020–2. Comment on: Anesthesiology 1997 May;86(5):1145–60. Comment on: Anesthesiology 1997 May;86(5):1161–9. Comment on: Anesthesiology 1997 May;86(5):1170–96. Comment on: Anesthesiology 1997 May;86(5):1197–205.

Principles of economic analysis [see comments] Sperry RJ. **Anesthesiology** 1997 May;86(5):1197–205. Comment in: Anesthesiology 1997 May;86(5):1018–9. Comment in: Anesthesiology 1997 May;86(5):1020–2.

Economics of anesthetic practice [see comments] Watcha MF, et al. **Anesthesiology** 1997 May;86(5):1170–96 (177 ref.) . Comment in: Anesthesiology 1997 May;86(5):1018–9. Comment in: Anesthesiology 1997 May;86(5):1020–2.

Does the method of payment affect anaesthetic practice? An evaluation of an alternate payment plan. Duncan PG, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):503–10

What really happens when capitation arrives? Strategies for successful integration into anesthesia practices. Dritz RA. **Int Anesthesiol Clin** 1995 Fall;33(4):151–62

Efficacy and financial benefit of an anesthesiologist-directed university preadmission evaluation center. Starsnic MA, et al. **J Clin Anesth** 1997 Jun;9(4):299–305

Health care financing outlook. Thomas SJ. **Reg Anesth** 1996 Sep–Oct;21(5):474–6

EDUCATION

A dual technique for identification of the epidural space [letter] Baylis RJ, et al. **Anaesthesia** 1997 Aug;52(8):805–6

Academic anaesthetists—an endangered species? [editorial] [see comments] Feldman S. **Anaesthesia** 1997 Jan;52(1):1–2 . Comment in: Anaesthesia 1997 May;52(5):501–2. Comment in: Anaesthesia 1997 May;52(5):502.

Academic anaesthetists [letter; comment] Forrest AL. **Anaesthesia** 1997 May;52(5):502. Comment on: Anaesthesia 1997 Jan;52(1):1–2.

Learning curves for fibreoptic nasotracheal intubation when using the endoscopic video camera. Smith JE, et al. **Anaesthesia** 1997 Feb;52(2):101–6

Academic anaesthetists [letter; comment] Snowdon SL. **Anaesthesia** 1997 May;52(5):501–2. Comment on: Anaesthesia 1997 Jan;52(1):1–2.

An aid to learning to use the fiberoptic bronchoscope for intubation [letter] Colley PS, et al. **Anesth Analg** 1997 Aug; 85(2):464–5

Cricoid pressure: teaching the recommended level. Herman NL, et al. **Anesth Analg** 1996 Oct;83(4):859–63

A comparison of traditional textbook and interactive computer learning of neuromuscular block. Ohrn MA, et al. **Anesth Analg** 1997 Mar;84(3):657–61

Preoperative anxiety and fear: a comparison of assessments by patients and anesthesia and surgery residents. Shafer A, et al. **Anesth Analg** 1996 Dec;83(6):1285–91

Resident education and unreviewed material [letter] [see comments] Shapira Y, et al. **Anesth Analg** 1996 Oct; 83(4):886. Comment in: Anesth Analg 1997 Mar;84(3):701.

Resident accountability [letter; comment] Buchwald IP. **Anesthesiology** 1996 Oct;85(4):945. Comment on: Anesthesiology 1996 Mar;84(3):700–11.

Relationship between NIH dollars and percentage of residents matched through the National Residency Matching Program [letter] Wu CL, et al. **Anesthesiology** 1997 Aug;87(2):454–6

Aesthetic surgical training: the Lenox Hill model. Schulman NH. **Ann Plast Surg** 1997 Apr;38(4):309–13; discussion 313–4

Using patient simulators to train surgical team members. Bower JO. **AORN J** 1997 Apr;65(4):805–8

Simulator training in anesthesiology: an answer? King PH, et al. **Biomed Instrum Technol** 1996 Jul–Aug;30(4):341–5

Postgraduate education in sedation—a new development. Robb ND, et al. **Br Dent J** 1997 Jan 25;182(2):45–7

Use of a mechanical simulator for training in applying cricoid pressure. Ashurst N, et al. **Br J Anaesth** 1996 Oct; 77(4):468–72

Inaccurate reporting of simulated critical anaesthetic incidents [see comments] Byrne AJ, et al. **Br J Anaesth** 1997 Jun;78(6):637–41. Comment in: Br J Anaesth 1997 Jun;78(6):633–4.

Responses to simulated anaesthetic emergencies by anaesthetists with different durations of clinical experience. Byrne AJ, et al. **Br J Anaesth** 1997 May;78(5):553–6

Cusum: a statistical method to evaluate competence in practical procedures [letter; comment] Hammond EJ, et al. **Br J Anaesth** 1996 Oct;77(4):562. Comment on: Br J Anaesth 1995 Dec;75(6):805–9.

The expanding role of simulators in risk management [editorial; comment] Spence AA. **Br J Anaesth** 1997 Jun; 78(6):633–4. Comment on: Br J Anaesth 1997 Jun;78(6):637–41.

Lead by example [letter] White R. **Br J Anaesth** 1997 May; 78(5):628–9

The day unit as a teaching environment. Jarrett PE. **Br J Hosp Med** 1996 Sep 18–Oct 1;56(6):279–81

So you want to train in anaesthetics. Willatts SM. **Br J Hosp Med** 1996 Dec 11–1997 Jan 14;56(11):592–3

Characteristics of good anaesthesia teachers [see comments] Cleave-Hogg D, et al. **Can J Anaesth** 1997 Jun;44(6):587–91 . Comment in: Can J Anaesth 1997 Jun;44(6):577–81.

The characteristics of excellent clinical teachers [editorial; comment] Shysh AJ, et al. **Can J Anaesth** 1997 Jun; 44(6):577–81. Comment on: Can J Anaesth 1997 Jun;44(6):587–91. **(Eng, Fre)**

A comparison of simple tests to distinguish cerebrospinal fluid from saline. Walker DS, et al. **Can J Anaesth** 1997 May; 44(5 Pt 1):494–7

Education in pain management. Taylor I, et al. **Int Anesthesiol Clin** 1997 Spring;35(2):197–206

PatSim—simulator for practising anaesthesia and intensive care. Development and observations. Arne R, et al. **Int J Clin Monit Comput** 1996 Aug;13(3):147–52

The Sophus anaesthesia simulator v. 2.0. A Windows 95 control-center of a full-scale simulator. Christensen UJ, et al. **Int J Clin Monit Comput** 1997 Feb;14(1):11–6

Simulator training in anesthesia growing rapidly; LORAL model born in Florida [news] Euliano T, et al. **J Clin Monit** 1997 Jan;13(1):53–7

Simulators for anesthesia. Norman J, et al. **J Clin Monit** 1996 Jan;12(1):91–9

Are we dancing alone? Matching medical operational readiness training with potential future conflict. Olsen JC. **Mil Med** 1997 Feb;162(2):75–8

"This doesn't hurt, does it Johnny?" [editorial] Altemeier WA, et al. **Pediatr Ann** 1997 Aug;26(8):448, 450–1

QA in regional anesthesia training: quantity or quality? [editorial; comment] Kopacz D. **Reg Anesth** 1997 May–Jun; 22(3):209–11. Comment on: Reg Anesth 1997 May–Jun;22(3):218–22.

General anaesthesia for cleft lip and palate surgery team activities in Cambodia. Ishizawa Y, et al. **Trop Doct** 1997 Jul;27(3):153–5

The Humphrey ADE block [letter; comment] Milner Q. **Trop Doct** 1997 Jul;27(3):190–1. Comment on: Trop Doct 1995;25 Suppl 1:34–9.

[Continuing medical education via questionnaire studies. Three pilot projects for anesthesiology, cardiology and neurology] Mortensen P, et al. **Ugeskr Laeger** 1997 May 19;159(21):3140–5 (Eng. Abstr.) **(Dan)**

[Continuing education in anesthesiology and intensive care: an ethical obligation (editorial)] Scherpereel P, et al. **Ann Fr Anesth Reanim** 1996;15(2):123–4 **(Fre)**

[Specialist graduate education in accordance with the recommendations of DGAI and OGARI. Preoperative anesthesiologic patient visit, outpatient anesthesia. Risk assessment, patient preparation and planing perioperative procedures] Madler C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Dec; 31(10):633–53 **(Ger)**

[A report on the present status of education in cardiopulmonary resuscitation] **Masui** 1996 Jun; 45(6):774–81 **(Jpn)**

[Educational training simulator systems in anesthesiology] Morita K. **Masui** 1996 Dec;45 Suppl:S164–7 (9 ref.) **(Jpn)**

[Desk-top simulation of crisis management in anesthesiology] Ozaki M. **Masui** 1996 Dec;45 Suppl:S161–3 (0 ref.) **(Jpn)**

[Evaluation of the training of the anesthesiologist] Sugiura Y, et al. **Masui** 1996 Jun;45(6):766–8 (Eng. Abstr.) **(Jpn)**

[Experience of Anesthesia in northern Iraq after the Gulf War] Suzuki T. **Masui** 1996 Jun;45(6):769–73 (Eng. Abstr.) **(Jpn)**

[Crisis management training using anesthesia simulator] Tominaga M, et al. **Masui** 1996 Dec;45 Suppl:S156–60 (1 ref.) **(Jpn)**

[The teaching of anesthesiology and the title of specialist

in anesthesiology (editorial)] Maia JC.
Rev Bras Anestesiol 1968 Oct-Dec;18(4):371-3 **(Por)**

HISTORY

History of infection control in anaesthesia. Bowring D.
Anaesth Intensive Care 1996 Apr;24(2):150-3

The World Federation of Societies of Anesthesiologists: McMechan's final legacy? Bacon DR. **Anesth Analg** 1997 May;84(5):1130-5

Response to "Iconography in anesthesiology: the importance of society seals in the 1920s and 1930s" [letter; comment] Ichim S. **Anesthesiology** 1997 Jun;86(6):1427; discussion 1428. Comment on: Anesthesiology 1996 Aug;85(2):414-9.

Response to "Iconography in anesthesiology: the importance of society seals in the 1920s and 1930s" [letter; comment] Welsh B. **Anesthesiology** 1997 Jun;86(6):1428. Comment on: Anesthesiology 1996 Aug;85(2):414-9.

Dr John Snow (1813-58) of London: pioneer of obstetric anaesthesia. Dunn PM.
Arch Dis Child Fetal Neonatal Ed 1996 Sep;75(2):F141-2

Narcosis and nightshade. Carter AJ. **BMJ** 1996 Dec 21-28; 313(7072):1630-2

A curious moment: the proposal to certify nurse anesthetists by the American Board of Anesthesiology [see comments] Bacon DR. **J Clin Anesth** 1996 Nov;8(7):614-9. Comment in: J Clin Anesth 1996 Dec;8(8):683-7.

Lexicographic history of "anesthesia". Sanchez GC.
J Clin Anesth 1996 Sep;8(6):435-8

The copper kettle: a historical perspective. Sands RP Jr, et al. **J Clin Anesth** 1996 Sep;8(6):528-32

The last days of William Thomas Green Morton. Vandam LD. **J Clin Anesth** 1996 Sep;8(6):431-4

Will the anesthesia question always remain debatable? Vandam LD. **J Clin Anesth** 1996 Sep;8(6):429-30

Virginia Apgar (1909-1974). Morishima HO. **J Pediatr** 1996 Nov;129(5):768-70

Sesquicentennial of first publicly performed surgery under anesthesia [news] Skolnick AA. **JAMA** 1996 Oct 16; 276(15):1205

Anaesthesia--150 years strong. Phillips GD. **Med J Aust** 1997 Jun 2;166(11):602-3

Emery A. Rovenstine and regional anesthesia. Bacon DR, et al. **Reg Anesth** 1997 May-Jun;22(3):273-9

["A discovery in surgery" 150 years of anesthesia] Brandt L, et al. **Anaesthesist** 1996 Oct;45(10):970-5 **(Ger)**

[Thoughts on the 150th anniversary of anesthesia (editorial)] Mayrhofer O. **Anaesthesist** 1996 Oct;45(10):881-3 **(Ger)**

[Helmut Schmidt--a protagonist of modern anesthesia in Germany] Goerig M, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Dec; 31(10):621-31 (Eng. Abstr.) **(Ger)**

[One hundred-fifty years of general anesthesia (1846-1996)] Bellucci G. **Minerva Anestesiol** 1997 Mar;63(3):59-60 **(Ita)**

[50 years with anesthesiologists in Norway] Flaatten H.
Tidsskr Nor Laegeforen 1996 Oct 20;116(25):2991-2 **(Nor)**

[An anniversary article on a non-anniversary date] Likhvantsev VV. **Khirurgiia (Mosk)** 1996;(2):145-6 **(Rus)**

[Milestones in the origin and development of anesthesiology and resuscitation (on the 150th anniversary of the first use of ether anesthesia)] Prilmak VP. **Voen Med Zh** 1996 Nov; 317(11):74-6 **(Rus)**

[In memoriam Fidel Pagés Miravé (1886-1923) on the 75th anniversary of the publication of "Anesthesia metamérica"] Herrera A, et al. **Rev Esp Anestesiol Reanim** 1996 Feb; 43(2):59-66 (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Hepatitis C and anaesthetic breathing systems [letter; comment] Grange C. **Anaesth Intensive Care** 1996 Aug; 24(4):514. Comment on: Anaesth Intensive Care 1995 Apr;24(2):169-72.

Datex AS3 monitor failure [letter] Ho S, et al.
Anaesth Intensive Care 1996 Aug;24(4):516-7

Anaesthetic machine and breathing system contamination and the efficacy of bacterial/viral filters. Hogarth I.
Anaesth Intensive Care 1996 Apr;24(2):154-63 (74 ref.)

Disposable and autoclavable anaesthetic circuits: the future is now. Komesaroff D. **Anaesth Intensive Care** 1996 Apr; 24(2):173-5

Narkomed 4E power failure [letter] Ng KP, et al.
Anaesth Intensive Care 1997 Jun;25(3):309

Monitoring in anaesthesia and alarm systems [letter] Shirley PJ. **Anaesth Intensive Care** 1997 Aug;25(4):432-3

Needleless and sharp-free anaesthesia. Tomkins DP, et al. **Anaesth Intensive Care** 1996 Apr;24(2):164-8 (17 ref.)

The use of surrogate gases for anaesthetic monitor calibration [letter] Troughear R. **Anaesth Intensive Care** 1996 Aug; 24(4):513

Digital assistance for the anaesthetist [letter] Hargrave C, et al. **Anaesthesia** 1997 Jun;52(6):610-1

An evaluation of the SCOTI device. Haridas RP, et al.
Anaesthesia 1997 May;52(5):453-6

Carbon monoxide within circle systems. Harrison N, et al. **Anaesthesia** 1996 Nov;51(11):1037-40

Rubber gloves and anaesthetic gas leak [letter] Lam WH, et al. **Anaesthesia** 1996 Nov;51(11):1075-6

My anaesthetic machine's on fire [letter] Rogers S, et al.
Anaesthesia 1997 May;52(5):505

Leaks from breathing system gas sampling points fitted with Luer connections [letter] Smith PJ, et al. **Anaesthesia** 1997 Jul;52(7):707-8

Monitoring dangers and apparatus safety [letter] Snowdon SL. **Anaesthesia** 1997 Aug;52(8):799-800

Intraoperative hypoxia from nitrogen tanks with oxygen fittings. Bernstein DB, et al. **Anesth Analg** 1997 Jan; 84(1):225-7

Mistaken connection of scavenging tube to mask [letter] Nathan B, et al. **Anesth Analg** 1997 Sep;85(3):704

Monitoring techniques and equipment for small animal anaesthesia. Nicholson A. **Aust Vet J** 1996 Aug; 74(2):114-23 (32 ref.)

Prevention of occlusion of sampling tubes in side-steam capnographs [letter] Shankar KB, et al. **Can J Anaesth** 1997 Apr;44(4):453

COVERS for anaesthetic machines: an audit and standard. Krimmer M, et al. **Eur J Anaesthesiol** 1997 Sep; 14(5):505-13

Technology and the growth of anaesthesiology as a specialty. Gravenstein JS. **Eur J Anaesthesiol Suppl** 1993;7:42-4 (12 ref.)

Future areas for recommendations. Gravenstein JS.
Eur J Anaesthesiol Suppl 1993;7:24-5

Commentary on equipment recommendations. Runciman WB. **Eur J Anaesthesiol Suppl** 1993;7:16-8

Adapting to new technology in the operating room. Cook RI, et al. **Hum Factors** 1996 Dec;38(4):593-613

Design of a recognition system to predict movement during anesthesia. Sharma A, et al. **IEEE Trans Biomed Eng** 1997 Jun;44(6):505-11

Ventilators in the operating room. Eisenkraft JB, et al.
Int Anesthesiol Clin 1997 Winter;35(1):87-108 (25 ref.)

Feedback control in anaesthesia. Asbury AJ.
Int J Clin Monit Comput 1997 Feb;14(1):1-10 (11 ref.)

Auditory alarms during anesthesia monitoring with an integrated monitoring system. Block FE Jr, et al.
Int J Clin Monit Comput 1996 May;13(2):81-4

Medical waste in the environment: do anesthesia personnel have a role to play? Goldberg ME, et al.
J Clin Anesth 1996 Sep;8(6):475-9

The copper kettle: a historical perspective. Sands RP Jr, et al. **J Clin Anesth** 1996 Sep;8(6):528-32

Latex exposure from anesthesia equipment [letter; comment] Williams T. **J Clin Anesth** 1997 May;9(3):259. Comment on: J Clin Anesth 1996 Mar;8(2):161-7.

Response time studies of a new, portable mass spectrometer. Delaney PA, et al. **J Clin Monit** 1997 May;13(3):181-9

Performance of anesthesia machines' devices that are not part of the Food and Drug Administration's daily checkout. Dexter F, et al. **J Clin Monit** 1997 May;13(3):171-9

In my opinion: to obsolete or not [letter] Gravenstein JS. **J Clin Monit** 1997 Mar;13(2):131-2

An integrated graphic data display improves detection and identification of critical events during anesthesia. Michels P, et al. **J Clin Monit** 1997 Jul;13(4):249-59

The aging anesthetic machine [letter] Petty WC.
J Clin Monit 1997 Mar;13(2):129

Response to question of machine obsolescence [letter] Schreiber PJ. **J Clin Monit** 1997 Mar;13(2):133-6

A method of testing the compliance of 15 and 22 mm conical connectors on heat and moisture exchangers to ISO 5356-1:1987. Wilkes AR, et al. **J Med Eng Technol** 1997 May-Aug;21(3-4):147-50

[The effect of a heat and moisture exchanger (HME) on bronchial mucus transport in a closed inhalation anesthesia system] Konrad F, et al. **Anaesthesist** 1996 Sep;45(9):802-6 (Eng. Abstr.) **(Ger)**

[Transesophageal echocardiography in anesthesia and intensive care. The diagnostic importance of transesophageal echocardiography] Loick HM, et al.
Anaesthesist 1997 Jun;46(6):504-14 (123 ref.) (Eng. Abstr.) **(Ger)**

[Is reduction of intraoperative heat loss and management of hypothermic patients with anesthetic gas climate control advisable? Heat and humidity exchangers vs. active humidifiers ina functional lung model] Rathgeber J, et al. **Anaesthesist** 1996 Sep;45(9):807-13 (Eng. Abstr.) **(Ger)**

[Anesthetic gas conditioning using the anesthetic device PhysioFlex] Wissing H, et al. **Anaesthesist** 1997 Jul; 46(7):613-5 **(Ger)**

[Unexpected accumulation of nitrogen in a circuit during low-flow anesthesia. Presentation of two clinical cases] Bonetti L, et al. **Minerva Anestesiol** 1995 Dec;61(12):515-7 (Eng. Abstr.) **(Ita)**

[Variations of esophageal temperature during general anesthesia with a low-flow circuit] Di Filippo A, et al. **Minerva Anestesiol** 1995 Sep;61(9):351-7 (Eng. Abstr.) **(Ita)**

[Usefulness of "Valve Checker" for inspecting anesthesia machine and respiratory circuit] Ozaki K, et al. **Masui** 1996 Jul;45(7):901-3 (Eng. Abstr.) **(Jpn)**

[An anesthesia machine malfunction due to dew condensation produced by abnormally high humidity in the electronically-controlled panel] Ushijima K, et al.
Masui 1997 Mar;46(3):406-8 (Eng. Abstr.) **(Jpn)**

[A new valve-less circuit with gas circulation] Takaoka K, et al. **Rev Bras Anestesiol** 1968 Oct-Dec;18(4):478-82 **(Por)**

[Monitoring neuromuscular conduction by the accelerometric method in anesthesiology] Flerov EV, et al. **Anesteziol Reanimatol** 1997 Mar-Apr;(2):62-5 **(Rus)**

[Safety monitoring. 5-year experience of use in anesthesiology and intensive care] Shvedov EP.
Anesteziol Reanimatol 1997 Mar-Apr;(2):65-8 **(Rus)**

[The creation and manufacture of anesthetic respiratory equipment based on a complex systems approach] Viktorov VA, et al. **Med Tekh** 1996 Jan-Feb;(1):9-15 (Eng. Abstr.) **(Rus)**

[Anesthesia with low flow of fresh gases and closed circuit (editorial)] Martín-Larrauri Camarillo R.
Rev Esp Anestesiol Reanim 1997 May;44(5):173-5 **(Spa)**

[Clinical circumstances of desiccation of soda lime (letter; comment)] Soro M, et al. **Rev Esp Anestesiol Reanim** 1996 Aug-Sep;43(7):261-2. Comment on: Rev Esp Anestesiol Reanim 1996 Jan;43(1):42. **(Spa)**

LEGISLATION & JURISPRUDENCE

The claims of compensation for awareness with recall during general anaesthesia in Finland. Ranta S, et al.
Acta Anaesthesiol Scand 1997 Mar;41(3):356-9

Ethics in obstetric anaesthesia [letter; comment] Chrispin P. **Anaesthesia** 1996 Dec;51(12):1182-3. Comment on: Anaesthesia 1996 Aug;51(8):717-8.

Women's autonomy in childbirth. Courts should also take evidence from obstetric anaesthetists [letter] Holdcroft A. **BMJ** 1997 Aug 23;315(7106):488

General anaesthesia [letter; comment] Greenan J.
Br Dent J 1996 Oct 5;181(7):241. Comment on: Br Dent J 1996 Jun 22;180(12):448.

General anaesthesia in dentistry [letter] Greenan J.
Br Dent J 1996 Mar 23;180(6):206

A primer of malpractice law for the neuroanesthesiologist. Molton L. **Int Anesthesiol Clin** 1996 Fall;34(4):195-206

Speaking for itself: the doctrine of res ipsa loquitur in a case of pediatric anesthesia. Liang BA, et al. **J Clin Anesth** 1996 Aug;8(5):398-401

Frankly my dear, I don't give a damn [editorial] Monks P. **Med Sci Law** 1996 Jul;36(3):185-7

Death under anaesthetic: the case of Dr Adomako. Williams, et al. **Med Sci Law** 1996 Jul;36(3):188-93

Letter from North America. Medical practice and criminal law [news] Silva YJ. **Natl Med J India** 1996 Jan-Feb; 9(1):41-2

Can regional anesthesia worsen outcome? Medicolegal risk. Wedel DJ. **Reg Anesth** 1996 Nov-Dec;21(6 Suppl):71-4 (13 ref.)

[Medical liability, professional specialty standards and health legislation] Dudziak R. **Anaesthesist** 1996 Sep;45(9):787-8 **(Ger)**

[Principles of physician's liability as it applies to the anesthetist (see comments)] Schlund GH. **Anaesthesist** 1996 Sep;45(9):789-97 (61 ref.) (Eng. Abstr.). Comment in: Anaesthesist 1997 May;46(5):462-4. Comment in: Anaesthesist 1997 Jul;46(7):627-8. **(Ger)**

[Principles of physician's liability as it applies to the anesthetist. Remarks on the work of G. H. Schlund, Anaesthesist (1996) 45:789-97 (letter; comment)] Sold M. **Anaesthesist** 1997 May;46(5):462-4. Comment on: Anaesthesist 1996 Sep;45(9):789-97. **(Ger)**

[Basic principles of medical liability for the anesthetist. Remarks on the work of G. H. Schlund (letter; comment)] Spahn DR, et al. **Anaesthesist** 1997 Jul;46(7):627-8. Comment on: Anaesthesist 1996 Sep;45(9):789-97. **(Ger)**

[Consent and patient education in anesthesia. Legal principles and forensic consequences] Biermann E.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Jul; 32(7):427-52 (108 ref.) **(Ger)**

[Medico-legal aspects of anesthesia and intensive care medicine. 1: The treatment error] Biermann E.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Mar; 32(3):175-93 (62 ref.) **(Ger)**

[Legal problems in the activities of the anesthesia-resuscitation specialist] Vanevskii VL.
Anesteziol Reanimatol 1995 Nov-Dec;(6):60-3 **(Rus)**

MANPOWER

Anaesthesia workforce in Australia and New Zealand. Baker AB. **Anaesth Intensive Care** 1997 Feb;25(1):60-7

A survey of anaesthetic manpower and training in the south-west Pacific region. Kinnear SB.
Anaesth Intensive Care 1996 Aug;24(4):477-82

Attitudes of consultant anaesthetists to the Calman proposals: a questionnaire survey [see comments] Dempsey GA, et al. **Anaesthesia** 1996 Oct;51(10):975-7. Comment in: Anaesthesia 1997 Feb;52(2):181-2.

The value of continuous practice [letter; comment] Diamond AW. **Anaesthesia** 1997 Feb;52(2):191. Comment on: Anaesthesia 1997 Jul;52(7):713.

Anaesthesiology manpower in Europe [letter] Krimmer MH. **Eur J Anaesthesiol** 1997 Jul;14(4):477

Anaesthesiological manpower in Europe [see comments] Rolly G, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):325-32. Comment in: Eur J Anaesthesiol 1996 Jul;13(4):314-5.

Anaesthesiological manpower in Europe [editorial; comment] [see comments] Zorab JS, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):314-5. Comment on: Eur J Anaesthesiol 1996 Jul;13(4):325-32. Comment in: Eur J Anaesthesiol 1997 May;14(3):345.

Work force planning for anesthesia care. Orkin FK.
Int Anesthesiol Clin 1995 Fall;33(4):69-101 (51 ref.)

Where there is no anaesthetist: a study of 282 consecutive patients using intravenous, spinal and local infiltration anaesthetic techniques. Adesunkanmi AR. **Trop Doct** 1997

Apr;27(2):79–82

METHODS

Bite blocks and the LMA [letter] Chikungwa M. **Anaesth Intensive Care** 1997 Aug;25(4):433

Anesthetic implications of chronic disease of the cervical spine. Popitz MD. **Anesth Analg** 1997 Mar;84(3):672–83 (78 ref.)

The lower limit of autoregulation: time to revise our thinking? [letter] Drummond JC. **Anesthesiology** 1997 Jun; 86(6):1431–3

Anesthesia preoperative evaluation clinic [letter; comment] Hannenberg AA. **Anesthesiology** 1997 Jan;86(1):259–60, discussion 261–3. Comment on: Anesthesiology 1996 Jul;85(1):196–206.

Anesthesia preoperative evaluation clinic [letter; comment] Lee A, et al. **Anesthesiology** 1997 Jan;86(1):260–3. Comment on: Anesthesiology 1996 Jul;85(1):196–206.

Anesthesia preoperative evaluation clinic [letter; comment] Silverman R. **Anesthesiology** 1997 Jan;86(1):261–3. Comment on: Anesthesiology 1996 Jul;85(1):1–3.

Measurement and reduction of nitrous oxide in operating rooms. Schuyt HC, et al. **J Occup Environ Med** 1996 Oct; 38(10):1036–40

Evaluating the difficult airway. An epidemiological study. Voyagis GS, et al. **Minerva Anestesiol** 1995 Dec; 61(12):483–9

Anesthesiology. Second of two parts. Wiklund RA, et al. **N Engl J Med** 1997 Oct 23;337(17):1215–9 (151 ref.)

Anesthesiology. First of two parts. Wiklund RA, et al. **N Engl J Med** 1997 Oct 16;337(16):1132–41 (100 ref.)

Where does science end and reality begin? [editorial] Neal JM. **Reg Anesth** 1997 Mar–Apr;22(2):109–12

Identification of the epidural space: loss of resistance to air or saline? [editorial; comment] Scott DB. **Reg Anesth** 1997 Jan–Feb;22(1):1–2. Comment on: Reg Anesth 1997 Jan–Feb;22(1):3–15.

New technique to confirm placement in the epidural space [letter] Soderman M. **Reg Anesth** 1996 Sep–Oct;21(5):498

Laryngeal mask airway. Wat LI. **West J Med** 1997 Mar; 166(3):201–2

[Specificity of the anesthetic consultation for ambulatory surgery] Forster A, et al. **Rev Med Suisse Romande** 1997 May;117(5):371–3 (1 ref.) **(Fre)**

[The difficult intubation] Kleemann PP. **Anaesthesist** 1996 Dec;45(12):1248–67 (11 ref.) **(Ger)**

[Comparative study of the efficiency of bacterial filters in long–term mechanical ventilation (comment) (see comments)] Nielsen HJ, et al. **Anaesthesist** 1996 Sep; 45(9):814–8 (Eng. Abstr.). Comment on: Anaesthesist 1996 Sep;45(9):814–8. Comment in: Anaesthesist 1997 Jun;46(6):568–9. **(Ger)**

ORGANIZATION & ADMINISTRATION

Anaesthetists and the Calman proposals [letter; comment] Haldane G, et al. **Anaesthesia** 1997 Feb;52(2):181–2. Comment on: Anaesthesia 1996 Oct;51(10):975–7.

Back seat driving [letter] Martin LV. **Anaesthesia** 1997 May; 52(5):509

Using an anesthesia information management system as a cost containment tool. Description and validation [see comments] Lubarsky DA, et al. **Anesthesiology** 1997 May; 86(5):1161–9. Comment in: Anesthesiology 1997 May;86(5):1018–9. Comment in: Anesthesiology 1997 May;86(5):1020–2.

An algorithm for assessing intraoperative mean arterial pressure lability. Reich DL, et al. **Anesthesiology** 1997 Jul; 87(1):156–61

The effect of electronic record keeping and transesophageal echocardiography on task distribution, workload, and vigilance during cardiac anesthesia. Weinger MB, et al. **Anesthesiology** 1997 Jul;87(1):144–55; discussion 29A–30A

Toward the paperless hospital? Harper RH, et al. **Br J Anaesth** 1997 Jun;78(6):762–7

Efficacy and financial benefit of an anesthesiologist–directed university preadmission evaluation center. Starsnic MA, et al. **J Clin Anesth** 1997 Jun;9(4):299–305

When will managed care come to anesthesia? Klein JD. **J Health Care Finance** 1997 Spring;23(3):62–86 (61 ref.)

STANDARDS

A survey of the ASA physical status classification: significant variation in allocation among Finnish anaesthesiologists. Ranta S, et al. **Acta Anaesthesiol Scand** 1997 May; 41(5):629–32

Airway management practices in emergency medicine [letter; comment] Tayal V. **Am J Emerg Med** 1997 Mar;15(2):211 . Comment on: Am J Emerg Med 1995 Sep;13(5):501–4.

Guidelines and cardiac anaesthetists. Not in my back yard. Alston RP. **Anaesthesia** 1997 Apr;52(4):328–31

Is voluntary reporting of critical events effective for quality assurance? [editorial; comment] Cooper JB. **Anesthesiology** 1996 Nov;85(5):961–4. Comment on: Anesthesiology 1996 Nov;85(5):977–87.

What is the transfusion trigger? What is the message? [letter] Miller RD. **Anesthesiology** 1997 Mar;86(3):750

Variation in expert opinion in medical malpractice review [published erratum appears in Anesthesiology 1997 Mar;86(3):754] Posner KL, et al. **Anesthesiology** 1996 Nov; 85(5):1049–54

Detection of intraoperative incidents by electronic scanning of computerized anesthesia records. Comparison with voluntary reporting [see comments] Sanborn KV, et al. **Anesthesiology** 1996 Nov;85(5):977–87. Comment in: Anesthesiology 1996 Nov;85(5):961–4.

An introduction to ethics. Waisel DB, et al. **Anesthesiology** 1997 Aug;87(2):411–7 (42 ref.)

"At least a nurse anesthetist" may not be enough! [letter] Field LM. **Dermatol Surg** 1997 Sep;23(9):847–8

The standards formulation process. Eichhorn JH. **Eur J Anaesthesiol Suppl** 1993;7:9–11

Future areas for recommendations. Gravenstein JS. **Eur J Anaesthesiol Suppl** 1993;7:24–5

Comparison of self–reporting of deficiencies in airway management with video analyses of actual performance. LOTAS Group. Level One Trauma Anesthesia Simulation. Mackenzie CF, et al. **Hum Factors** 1996 Dec;38(4):623–35

Practice parameters for anesthesiology. Arens JF. **Int Anesthesiol Clin** 1995 Fall;33(4):103–17 (12 ref.)

Control and quality assurance in anaesthesia with a PDMS. Wagner F. **Int J Clin Monit Comput** 1997 Feb;14(1):43–8

Unindicated preoperative testing: ASA physical status and financial implications [see comments] Vogt AW, et al. **J Clin Anesth** 1997 Sep;9(6):437–41. Comment in: J Clin Anesth 1997 Sep;9(6):435–6.

[Modifying our image depends of our interest in it (letter; comment)] Onrubia X, et al. **Rev Esp Anestesiol Reanim** 1996 Dec;43(10):380–1. Comment on: Rev Esp Anestesiol Reanim 1996 Jun–Jul;204–7. **(Spa)**

STATISTICS & NUMERICAL DATA

Paediatric anaesthesia––who should do it? The view from the specialist hospital [editorial] McNicol R. **Anaesthesia** 1997 Jun;52(6):513–5

Early death amongst anaesthetists [letter] Milner QJ, et al. **Anaesthesia** 1997 Aug;52(8):797–8

Paediatric anaesthesia––who should do it? The view from the district general hospital [editorial] Rollin AM. **Anaesthesia** 1997 Jun;52(6):515–6

[Evaluation of anesthetic activity in the operating room. Use of beta relative cost index] Eon B, et al. **Ann Fr Anesth Reanim** 1996;15(5):608–16 (Eng. Abstr.) **(Fre)**

[Towards the search of an optimal indicator of anesthetic activity (editorial)] Marty J, et al. **Ann Fr Anesth Reanim** 1996;15(5):579–80 **(Fre)**

TRENDS

After 150 years of anaesthesia––it is time to expand [editorial] Gisvold SE. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1065–7

The image of the anaesthetist. Duncan PG. **Eur J Anaesthesiol Suppl** 1993;7:3–7

Technology and the growth of anaesthesiology as a specialty. Gravenstein JS. **Eur J Anaesthesiol Suppl** 1993;7:42–4 (12 ref.)

How controversial are anesthetic controversies? Poterack KA. **J Clin Anesth** 1997 Jun;9(4):266–9

Anesthesiology. Todd MM. **JAMA** 1997 Jun 18; 277(23):1842–3

Recent developments in anesthesiology. Matjasko MJ. **Md Med J** 1997 Sep;46(8):401–4

Survey of NC anesthesiologists regarding nature of fasting before elective surgery. Bowman MA. **N C Med J** 1997 Jan–Feb;58(1):33–4

Anaesthesia in Nepal: present and future aims. Donaldson MD. **Trop Doct** 1997 Apr;27(2):100–3

[Anesthesia between tradition and renewal. The 44th annual meeting of the German Society for Anesthesiology and Intensive Care, April 23–26, 1997, Hamburg] Fatehi S, et al. **Anaesthesist** 1997 Jul;46(7):640–6 **(Ger)**

[Palliative treatment. A medically and ethically relevant field of activity for the anesthetist] Kettler D. **Anaesthesist** 1997 Mar;46(3):175–6 **(Ger)**

[The magic of impact factors––the unmasking of a phenomenon (editorial)] Lindner UK, et al. **Anaesthesist** 1997 Jan;46(1):1–2 **(Ger)**

[Anesthesia on the Internet] Schäfer N, et al. **Anaesthesist** 1997 Jan;46(1):60–4 (19 ref.) **(Ger)**

[What is the state of neuroanesthesia?] Schregel W, et al. **Anaesthesist** 1997 Mar;46(3):231–2 **(Ger)**

[New developments in anesthesiology and intensive care. IX. International Heidelberg Symposium, Heidelberg, 14–16, 1996] Weigand MA, et al. **Anaesthesist** 1997 May; 46(5):451–6 **(Ger)**

[Pain and anesthesiologists (editorial)] Torres–Morera LM. **Rev Esp Anestesiol Reanim** 1996 May;43(5):159 **(Spa)**

ANESTHETIC GAS SCAVENGERS see **GAS SCAVENGERS**

ANESTHETICS

see related

ANESTHESIA ADJUVANTS

Basis of anaesthesia––what do we know after 150 years? [editorial] Raeder JC. **Acta Anaesthesiol Scand** 1996 Oct; 40(9):1068–72

Effects of additional premedication on romifidine and ketamine anaesthesia in horses. Marntell S, et al. **Acta Vet Scand** 1996;37(3):315–25

Breaking glass vials [letter] Cohen Y, et al. **Anesthesiology** 1997 May;86(5):1215

Perioperative cardiovascular optimization: importance and relevance for anaesthesia. Boyd O. **Br J Hosp Med** 1997 Mar 5–18;57(5):219–23

Blood oxygen saturation measured in the presence of a mixture of cyclopropane, sulfur hexafluoride, and ethane. Forte VA Jr, et al. **Eur J Appl Physiol** 1997;75(1):68–74

Ketamine–midazolam versus meperidine–midazolam for painful procedures in pediatric oncology patients. Marx CM, et al. **J Clin Oncol** 1997 Jan;15(1):94–102

Alleviation of the temperature–sensitive paralytic phenotype of shibire(ts) mutants in Drosophila by sub–anesthetic concentrations of carbon dioxide. Krishnan KS, et al. **J Neurogenet** 1996 Sep;10(4):221–38

In vivo 125I–erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. Widness JA, et al. **J Pharmacol Exp Ther** 1996 Dec; 279(3):1205–10

Anesthesiology. First of two parts. Wiklund RA, et al. **N Engl J Med** 1997 Oct 16;337(16):1132–41 (100 ref.)

The effects of verapamil and lidocaine on the duration of propofol and xylazine–ketamine anesthesia in broiler chickens. Roder JD, et al. **Vet Hum Toxicol** 1996 Jun; 38(3):181–3

Intravenous regional anesthesia with ketorolac–lidocaine for the management of sympathetically–mediated pain. Connelly NR, et al. **Yale J Biol Med** 1995 May–Aug; 68(3–4):95–9

[Esters and stereoisomers] Nigrovic V, et al. **Anaesthesist** 1997 Apr;46(4):282–6 (9 ref.) (Eng. Abstr.) **(Ger)**

[Anesthesia and intraoperative care of patients with heart dysfunction] Ueda N, et al. **Masui** 1996 Dec;45 Suppl:S114–21 (24 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Labelling and drug administration error [letter; comment] Merry AF, et al. **Anaesthesia** 1996 Oct;51(10):987–8. Comment on: Anaesthesia 1996 Jan;51(1):1–2.

Relationship between complications of pediatric anesthesia and volume of pediatric anesthetics [letter] Auroy Y, et al. **Anesth Analg** 1997 Jan;84(1):234–5

Thiopental–rocuronium versus ketamine–rocuronium for rapid–sequence intubation in parturients undergoing cesarean section. Baraka AS, et al. **Anesth Analg** 1997 May; 84(5):1104–7

Laryngotracheal lidocaine administration [letter; comment] Burton AW, et al. **Anesthesiology** 1997 Jul;87(1):185–6. Comment on: Anesthesiology 1996 Sep;85(3):691.

Parental presence not necessary during induction of anesthesia [letter; comment] Pond WW, et al. **Anesthesiology** 1996 Nov;85(5):1212–3. Comment on: Anesthesiology 1996 May;84(5):1060–7.

Synthesis of an anaesthetic agent administration system using fuzzy inductive reasoning. Nebot A, et al. **Artif Intell Med** 1996 May;8(2):147–66

Comparative assessment of the anaesthetic and analgesic effects of intramuscular and epidural clonidine in humans [see comments] Samsó E, et al. **Can J Anaesth** 1996 Dec; 43(12):1195–202. Comment in: Can J Anaesth 1996 Dec;43(12):1191–4.

Managing chronic neuropathic pain with implanted anesthetic reservoirs. Monsivais JJ, et al. **Hand Clin** 1996 Nov;12(4):781–6 (8 ref.)

Fundamentals of feedback control: PID, fuzzy logic, and neural networks. Westenskow DR. **J Clin Anesth** 1997 Sep; 9(6 Suppl):33S–35S (23 ref.)

Combinations of drugs for induction and maintenance of anesthesia and sedation of the critically ill. Garforth R, et al. **Middle East J Anesthesiol** 1996 Jun;13(5):545–57

The efficacy and safety of the hematoma block for fracture reduction in closed, isolated fractures. Furia JP, et al. **Orthopedics** 1997 May;20(5):423–6

One explanation why Spiegel's formula gives us a larger dose for small children [letter] Ying Y, et al. **Paediatr Anaesth** 1996;6(4):341

Local and regional anesthesia and analgesia. Pascoe P. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):94–105 (88 ref.)

Evaluation of extradural xylazine injection for caesarean operation in ovine dystocia cases. Scott PR, et al. **Vet J** 1997 Jul;154(1):63–7

ADVERSE EFFECTS

Eye injuries after nonocular surgery. A study of 60,965 anesthetics from 1988 to 1992. Roth S, et al. **Anesthesiology** 1996 Nov;85(5):1020–7

The link between exposure to volatile anesthetics and damage to health of operating room (OR) staff [letter] De Amici D, et al. **Arch Environ Health** 1997 Mar–Apr;52(2):149

Intradermal compared with prick testing in the diagnosis of anaesthetic allergy. Fisher MM, et al. **Br J Anaesth** 1997 Jul;79(1):59–63

Retinopathy of prematurity: systemic complications associated with different anaesthetic techniques at treatment. Haigh PM, et al. **Br J Ophthalmol** 1997 Apr; 81(4):283–7

Methods for bursting Foley catheter balloons [letter; comment] Kamat NN. **Br J Urol** 1997 Jul;80(1):192. Comment on: Br J Urol 1996 May;77(5):716–8.

MAOIs and anesthesia [letter] Clark AG. **Can J Anaesth** 1996 Jun;43(6):641

Perioperative collapse: prevalence of latex allergy in patients sensitive to anaesthetic agents. Tan BB, et al. **Contact Dermatitis** 1997 Jan;36(1):47–50

Hepatotoxicity of anesthetics and other central nervous system drugs. Holt C, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):853–74 (165 ref.)

Adverse drug interactions in anesthesia. Bovill JG. **J Clin Anesth** 1997 Sep;9(6 Suppl):3S–13S (104 ref.)

Low frequency of adenylate kinase release into cerebrospinal fluid during balanced, normotensive anaesthesia and a non-orthognathic surgical procedure. Enlund M, et al. **J Int Med Res** 1997 Mar–Apr;25(2):92–7

Loss prevention case of the month. Cardiovascular warning signs ignored. Avery JK. **Tenn Med** 1997 Mar;90(3):92–3

[Postoperative nausea and vomiting (see comments)] Jensen LB, et al. **Ugeskr Laeger** 1997 Jan 13;159(3):269–74 (40 ref.) (Eng. Abstr.). Comment in: Ugeskr Laeger 1997 May 19;159(21):3191–2. **(Dan)**

[Allergic reactions during anesthesia] Escolano F, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):17–26 (56 ref.) (Eng. Abstr.) **(Spa)**

[Prevention of nausea and vomiting in the postoperative period (editorial)] Muriel C. **Rev Esp Anestesiol Reanim** 1996 Dec;43(10):343–4 **(Spa)**

ANALYSIS

The use of high-resolution solid-state NMR spectroscopy and differential scanning calorimetry to study interactions of anaesthetic steroids with membrane. Mavromoustakos T, et al. **Biochim Biophys Acta** 1997 Aug 14;1328(1):65–73

Gas chromatography in anaesthesia. I. A brief review of analytical methods and gas chromatographic detector and column systems. Uyanik A. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):1–9 (62 ref.)

ANTAGONISTS & INHIBITORS

The anti-anesthetic action of idazoxan. Majeed AB. **Biol Pharm Bull** 1996 Feb;19(2):203–8

Use of yohimbine to reverse prolonged effects of xylazine hydrochloride in a horse being treated with chloramphenicol. Grubb TL, et al. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1771–3

CHEMICAL SYNTHESIS

Anesthetic activity of novel water-soluble 2 beta-morpholinyl steroids and their modulatory effects at GABAA receptors. Anderson A, et al. **J Med Chem** 1997 May 23;40(11):1668–81

CHEMISTRY

Contrasting membrane localization and behavior of halogenated cyclobutanes that follow or violate the Meyer–Overton hypothesis of general anesthetic potency. North C, et al. **Biophys J** 1997 Apr;72(4):1754–61

ECONOMICS

The successful implementation of pharmaceutical practice guidelines. Analysis of associated outcomes and cost savings. SWiPE Group. Systematic Withdrawal of Perioperative Expenses [see comments] Lubarsky DA, et al. **Anesthesiology** 1997 May;86(5):1145–60. Comment in: Anesthesiology 1997 May;86(5):1018–9. Comment in: Anesthesiology 1997 May;86(5):1020–2.

HISTORY

[Thoughts on the 150th anniversary of anesthesia (editorial)] Mayrhofer O. **Anaesthesist** 1996 Oct;45(10):881–3 **(Ger)**

METABOLISM

Entropy-driven interactions of anesthetics with membrane proteins. Lopez MM, et al. **Biochemistry** 1997 Jul 22; 36(29):8864–72

Different distribution of fluorinated anesthetics and nonanesthetics in model membrane: a 19F NMR study. Tang P, et al. **Biophys J** 1997 Apr;72(4):1676–82

Titration calorimetry of anesthetic-protein interaction: negative enthalpy of binding and anesthetic potency. Ueda I, et al. **Biophys J** 1997 Apr;72(4):1812–7

PHARMACOKINETICS

Opioid drug disposition. Müller CM. **Acta Anaesthesiol Scand Suppl** 1996;109:102–3

(Almost) everything you learned about pharmacokinetics was (somewhat) wrong! [editorial; comment] Fisher DM. **Anesth Analg** 1996 Nov;83(5):901–3. Comment on: Anesth Analg 1996 Nov;83(5):1065–71.

Drug residue considerations for anesthetics and adjunctive drugs in food-producing animals. Papich MG. **Vet Clin North Am Food Anim Pract** 1996 Nov; 12(3):693–706 (29 ref.)

PHARMACOLOGY

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part III. Propranolol. Orszulak-Michalak D. **Acta Pol Pharm** 1995 Jul–Aug;52(4):309–13

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part IV. Lidocaine. Orszulak-Michalak D. **Acta Pol Pharm** 1995 Jul–Aug;52(4):315–9

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part I. Procainamide and its active metabolite-N-acetylprocainamide. Orszulak-Michalak D. **Acta Pol Pharm** 1995 Mar–Apr;52(2):141–6

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part II. N-acetylprocainamide. Orszulak-Michalak D. **Acta Pol Pharm** 1995 Mar–Apr; 52(2):147–51

Anesthetics alter relative contributions of NO and EDHF in rat cremaster muscle microcirculation. Loeb AL, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H618–27

Actions of xylazine in young swine. Gómez de Segura IA, et al. **Am J Vet Res** 1997 Jan;58(1):99–102

Cardiopulmonary and gastrointestinal motility effects of xylazine/ketamine-induced anesthesia in horses previously treated with glycopyrrolate. Singh S, et al. **Am J Vet Res** 1996 Dec;57(12):1762–70

Effects of sedation, anesthesia, and endotracheal intubation on respiratory mechanics in adult horses. Tomasic M, et al. **Am J Vet Res** 1997 Jun;58(6):641–6

Postanesthetic vasoconstriction slows peripheral-to-core transfer of cutaneous heat, thereby isolating the core thermal compartment. Plattner O, et al. **Anesth Analg** 1997 Oct;85(4):899–906

A multicenter study of bispectral electroencephalogram analysis for monitoring anesthetic effect. Sebel PS, et al. **Anesth Analg** 1997 Apr;84(4):891–9

The anesthetic effect of dexmedetomidine does not adhere to the Meyer–Overton rule but is reversed by hydrostatic pressure. Tonner PH, et al. **Anesth Analg** 1997 Mar; 84(3):618–22

A technique for population pharmacodynamic analysis of concentration-binary response data. Bailey JM, et al. **Anesthesiology** 1997 Apr;86(4):825–35

Supersensitive sites in the central nervous system. Anesthetics block brain nicotinic receptors [editorial; comment] Evers AS, et al. **Anesthesiology** 1997 Apr;86(4):760–2. Comment on: Anesthesiology 1997 Apr;86(4):859–65. Comment on: Anesthesiology 1997 Apr;86(4):866–74.

Alpha 4 beta 2 neuronal nicotinic acetylcholine receptors in the central nervous system are inhibited by isoflurane and propofol, but alpha 7-type nicotinic acetylcholine receptors are unaffected [see comments] Flood P, et al. **Anesthesiology** 1997 Apr;86(4):859–65. Comment in: Anesthesiology 1997 Apr;86(4):760–2.

Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane, and alfentanil in healthy volunteers. Glass PS, et al. **Anesthesiology** 1997 Apr; 86(4):836–47

Riluzole anesthesia: use-dependent block of presynaptic glutamate fibers. MacIver MB, et al. **Anesthesiology** 1996 Sep;85(3):626–34

Sympatholytic and minimum anesthetic concentration-sparing responses are preserved in rats rendered tolerant to the hypnotic and analgesic action of dexmedetomidine, a selective alpha(2)-adrenergic agonist. Rabin BC, et al. **Anesthesiology** 1996 Sep;85(3):565–73

Differential sensitivities of mammalian neuronal and muscle nicotinic acetylcholine receptors to general anesthetics [see comments] Violet JM, et al. **Anesthesiology** 1997 Apr; 86(4):866–74. Comment in: Anesthesiology 1997 Apr;86(4):760–2.

Comparison of response properties of neurons in the inferior colliculus of guinea pigs under different anesthetics. Astl J, et al. **Audiology** 1996 Nov–Dec;35(6):335–45

Dose-response curve for anaesthetics based on the Monod–Wyman–Changeux model [letter; comment] Mapleson WW. **Br J Anaesth** 1997 Feb;78(2):230–1. Comment on: Br J Anaesth 1996 Oct;77(4):517–21.

Does anaesthesia have long-term consequences? [editorial] Masterson GR, et al. **Br J Anaesth** 1996 Nov;77(5):569–71

Effects of inhalational general anaesthetics on native glycine receptors in rat medullary neurones and recombinant glycine receptors in Xenopus oocytes. Downie DL, et al. **Br J Pharmacol** 1996 Jun;118(3):493–502

The effects of the muscle relaxant, CS-722, on synaptic activity of cultured neurones. Marszalec W, et al. **Br J Pharmacol** 1996 Sep;119(1):126–32

Enhancement of homomeric glycine receptor function by long-chain alcohols and anaesthetics. Mascia MP, et al. **Br J Pharmacol** 1996 Dec;119(7):1331–6

Effects of intravenous anaesthetic agents on fast inhibitory oscillations in the rat hippocampus in vitro [published erratum appears in Br J Pharmacol 1996 Nov;119(6):1291] Whittington MA, et al. **Br J Pharmacol** 1996 Aug; 118(8):1977–86

Discontinuing drugs before surgery. Doak GJ. **Can J Anaesth** 1997 May;44(5 Pt 2):R112–23 (25 ref.) **(Eng, Fre)**

Cerebrospinal fluid constituents collected at the atlanto-occipital site of xylazine hydrochloride sedated, healthy 8-week-old Holstein calves. St Jean G, et al. **Can J Vet Res** 1997 Apr;61(2):108–12

Modification of cardiopulmonary and intestinal motility effects of xylazine with glycopyrrolate in horses. Singh S, et al. **Can J Vet Res** 1997 Apr;61(2):99–107

A comparison of romifidine and xylazine when used with diazepam/ketamine for short duration anesthesia in the horse. Kerr CL, et al. **Can Vet J** 1996 Oct;37(10):601–9

Effects of anaesthetics and trauma on stimulated gastric acid secretion in chronic fistula dogs. Bastaki SM, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul;23(6–7):532–6

The effects of general anesthesia on human peripheral immune cell distribution and cytokine production. Brand JM, et al. **Clin Immunol Immunopathol** 1997 May; 83(2):190–4

Investigations of hypesthesia: using anesthetics to explore relationships between consciousness, learning, and memory. Andrade J. **Conscious Cogn** 1996 Dec;5(4):562–80 (42 ref.)

The suppression of formalin-induced fos expression by different anesthetic agents in the infant rat. Yi DK, et al. **Dev Psychobiol** 1996 Sep;29(6):497–506

Effect of neuroleptics on ethanol-treated rats. Popović MR, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jul–Sep; 21(3):247–50

Allopregnanolone (THP) mediates anesthetic effects of progesterone in rat brain. Korneyev A, et al. **Horm Behav** 1996 Mar;30(1):37–43

Anesthetics and cerebroprotection: experimental aspects. Kirsch JR, et al. **Int Anesthesiol Clin** 1996 Fall;34(4):73–93 (186 ref.)

Genetic models in the study of anesthetic drug action. Simpson VJ, et al. **Int Rev Neurobiol** 1996;39:223–41 (59 ref.)

Electrophysiological mechanisms for ventricular arrhythmias in patients with myocardial ischemia: anesthesiologic considerations, Pt II. Gallagher JD. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):641–56 (139 ref.)

Influence of anesthetics on the incidence of reperfusion-induced arrhythmias and sudden death in rats. Baczkó I, et al. **J Cardiovasc Pharmacol** 1997 Feb; 29(2):196–201

Pharmacology of serotonin as related to anesthesia. Gyermek L. **J Clin Anesth** 1996 Aug;8(5):402–25 (232 ref.)

Kinetics of the inhibition of acetylcholinesterase from desert cobra (Walterinnesia aegyptia) venom by local anesthetics: procaine and tetracaine. al-Jafari AA, et al. **J Enzyme Inhib** 1996 Oct;11(2):123–34

K(ATP) channels contribute to the cardioprotection of preconditioning independent of anaesthetics in rabbit hearts. Morita Y, et al. **J Mol Cell Cardiol** 1997 Apr; 29(4):1267–76

Difference in response of D2 receptor binding between 11C-N-methylspiperone and 11C-raclopride against anesthetics in rhesus monkey brain. Kobayashi K, et al. **J Neural Transm Gen Sect** 1995;100(2):147–51

Effects of regional anesthesia on phantom limb pain are mirrored in changes in cortical reorganization. Birbaumer N, et al. **J Neurosci** 1997 Jul 15;17(14):5503–8

Delta subunit inhibits neurosteroid modulation of GABAA receptors. Zhu WJ, et al. **J Neurosci** 1996 Nov 1; 16(21):6648–56

Parameter estimability of biphasic response models. Dutta S, et al. **J Pharm Sci** 1997 Jan;86(1):44–51

Renal excretory responses produced by central administration of opioid agonists in ketamine and xylazine-anesthetized rats. Cabral AM, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):609–16

Inhibition of 5-hydroxytryptamine type 2A receptor-induced currents by n-alcohols and anesthetics. Minami K, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1136–43

Evaluation of five agents/methods for anesthesia of neonatal rats. Danneman PJ, et al. **Lab Anim Sci** 1997 Aug; 47(4):386–95

Effect of in vivo administration of anesthetics on GABAA receptor function. Engel SR, et al. **Lab Anim Sci** 1996 Aug; 46(4):425–9

Effects of two injectable anesthetic agents on coagulation assays in the rat. Stringer SK, et al. **Lab Anim Sci** 1996 Aug;46(4):430–3

Reduced anesthetic requirements in aged rats: association with altered brain synaptic plasma membrane Ca(2+)-ATPase pump and phospholipid methyltransferase I activities. Horn JL, et al. **Life Sci** 1996;59(17):PL263–8

Differential subunit dependence of the actions of the general anesthetics alphaxalone and etomidate at gamma-aminobutyric acid type A receptors expressed in Xenopus laevis oocytes. Sanna E, et al. **Mol Pharmacol** 1997 Mar;51(3):484–90

The anaesthetic action and modulation of GABAA receptor activity by the novel water-soluble aminosteroid Org 20599. Hill-Venning C, et al. **Neuropharmacology** 1996; 35(9–10):1209–22

Recovery of psychomotor function following general anaesthesia in children: a comparison of propofol and thiopentone/halothane. Schröter J, et al. **Paediatr Anaesth** 1996;6(4):317–24

Development of tolerance in mice to the sedative effects of the neuroactive steroid minaxolone following chronic exposure. Marshall FH, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):1–8

Dissociation of hypnotic-anesthetic actions of alpha 2 agonists from cyclic AMP in the rat. Rabin BC, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):23–9

Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in

vivo. Lakhlani PP, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9950–5

Maintenance of muscimol–induced long–term depression by neurosteroids. Akhondzadeh S, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1996 Feb; 20(2):277–89

Benefits of regional anesthesia on thromboembolic complications following surgery. Rosenfeld BA.
Reg Anesth 1996 Nov–Dec;21(6 Suppl):9–12 (40 ref.)

Adrenoceptor mechanism involved in thiopental–induced potentiation of halothane–epinephrine arrhythmias in dogs. Kamibayashi T, et al.
Res Commun Mol Pathol Pharmacol 1996 Aug;93(2):225–34

Cardiac effects of methylmethacrylate in the rat heart–lung preparation with or without volatile anesthetics. Kashimoto S, et al. **Resuscitation** 1995 Dec;30(3):269–73

Schistosoma mansoni Sambon, 1907: effects of dilation and constricting anesthetics drugs on adult worms localization in Swiss mice. Machado–Silva JR, et al.
Rev Inst Med Trop Sao Paulo 1996 Jul–Aug;38(4):307–8

Hyperglycemia and the vascular effects of cerebral ischemia. Kawai N, et al. **Stroke** 1997 Jan;28(1):149–54

Allosteric modulation of 5–HT3 receptors: focus on alcohols and anaesthetic agents. Parker RM, et al.
Trends Pharmacol Sci 1996 Mar;17(3):95–9 (38 ref.)

Pharmacology of drugs used for anesthesia and sedation. Tranquilli WJ, et al.
Vet Clin North Am Food Anim Pract 1996 Nov;12(3):501–29 (68 ref.)

Stimulation of food intake by xylazine in sheep. Mohammad FK, et al. **Zentralbl Veterinarmed A** 1996 Sep;43(7):387–91

Xylazine impairs the anticonvulsant activity of conventional antiepileptic drugs in mice. Wlaź P, et al.
Zentralbl Veterinarmed A 1996 Oct;43(8):495–500

[Possible applications of the "patch–clamp" method in anesthesiologic research; comment] Bräu ME, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Nov; 31(9):537–42 (21 ref.) (Eng. Abstr.). Comment on: Anasthesiol Intensivmed Notfallmed Schmer 1996 Nov;31(9):535–6. **(Ger)**

[Principles of pharmacology] Taeger K.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 May; 32(5):307–21 (29 ref.) **(Ger)**

[Molecular anesthesiologic research—the way out of isolation (editorial; comment)] Urban BW.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Nov; 31(9):535–6. Comment on: Anasthesiol Intensivmed Notfallmed Schmer 1996 Nov;31(9):537–42. **(Ger)**

[The evaluation of isoflurane's effect on the cochlear blood flow by laser doppler flowmetry] Albera R, et al.
Acta Otorhinolaryngol Ital 1995 Aug;15(4):289–93 (Eng. Abstr.) **(Ita)**

[Ventilatory management during anesthesia in the patient with congenital cardiopathy undergoing non–cardiac surgery (letter; comment)] Reinoso–Barbero F.
Rev Esp Anestesiol Reanim 1996 Jun–Jul;43(6):222. Comment on: Rev Esp Anestesiol Reanim 1995 Oct;42(8):336–40. **(Spa)**

[Botulinum toxin: clinical uses and anesthetic implications] Vidal–Marcos A, et al. **Rev Esp Anestesiol Reanim** 1996 Jun–Jul;43(6):208–11 (52 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Specialists criticise treatment for heroin addiction [news] Mayor S. **BMJ** 1997 May 10;314(7091):1365

Should we reassess the susceptibility of MH patients? [editorial; comment] Larach MG. **Can J Anaesth** 1997 Jul; 44(7):685–8. Comment on: Can J Anaesth 1997 Jul;44(7):696–701. **(Eng, Fre)**

Determinants of success and failure of EMLA. Lander J, et al. **Pain** 1996 Jan;64(1):89–97

Anaesthesia and basic experimental surgery of minipigs. A practical exercise. Svendsen P. **Pharmacol Toxicol** 1997;80 Suppl 2:23–6

Equithesin without chloral hydrate as an anaesthetic for rats [letter] Deacon RM, et al. **Psychopharmacology (Berl)** 1996 Apr;124(3):288–90

Diagnosis and treatment of status epilepticus on a neurological intensive care unit. Walker MC, et al.
QJM 1996 Dec;89(12):913–20

Pain and ideology in human and veterinary medicine. Rollin BE. **Semin Vet Med Surg (Small Anim)** 1997 May; 12(2):56–60

TOXICITY

Increasing or decreasing nervous activity modulates the severity of the glio–vascular lesions of 1,3–dinitrobenzene in the rat: effects of the tremorgenic pyrethroid, Bifenthrin, and of anaesthesia. Holton JL, et al.
Acta Neuropathol (Berl) 1997 Feb;93(2):159–65

Neurotoxicity after spinal anaesthesia induced by serial intrathecal injections of magnesium sulphate. An experimental study in a rat model. Chanimov M, et al.
Anaesthesia 1997 Mar;52(3):223–8

ANESTHETICS, COMBINED

Midazolam–flumazenil topical anaesthesia for microlaryngoscopy with jet ventilation.
Rushatamukayanunt W, et al. **Anaesth Intensive Care** 1997 Aug;25(4):358–64

Co–induction and laryngeal mask insertion. A comparison of thiopentone versus propofol. Driver I, et al.
Anaesthesia 1997 Jul;52(7):698–700

Single–breath inhalation induction of sevoflurane anaesthesia with and without nitrous oxide: a feasibility study in adults and comparison with an intravenous bolus of propofol. Hall JE, et al. **Anaesthesia** 1997 May;52(5):410–5

Anaesthesia for laparoscopic cholecystectomy in myasthenia gravis: a non–muscle relaxant technique [letter] Tortosa JA, et al. **Anaesthesia** 1997 Aug;52(8):807–8

Small–dose hypobaric lidocaine–fentanyl spinal anesthesia for short duration outpatient laparoscopy. II. Optimal fentanyl dose. Chilvers CR, et al. **Anesth Analg** 1997 Jan;84(1):65–70

The threshold for thermoregulatory vasoconstriction during nitrous oxide/sevoflurane anesthesia is reduced in the elderly. Ozaki M, et al. **Anesth Analg** 1997 May; 84(5):1029–33

Small–dose hypobaric lidocaine–fentanyl spinal anesthesia for short duration outpatient laparoscopy. I. A randomized comparison with conventional dose hyperbaric lidocaine. Vaghadia H, et al. **Anesth Analg** 1997 Jan;84(1):59–64

Sedation for the conduct of lumbar epidural anaesthesia: a study using subanaesthetic dose of ketamine in combination with midazolam. Loo CC, et al.
Ann Acad Med Singapore 1997 Mar;26(2):200–4

Low–dose rocuronium improves conditions for tracheal intubation after induction of anaesthesia with propofol and alfentanil. Barclay K, et al. **Br J Anaesth** 1997 Jan; 78(1):92–4

Halothane–propofol anaesthesia for tracheal intubation in young children. Hansen D, et al. **Br J Anaesth** 1997 Apr; 78(4):366–9

Comparison of topical anesthetics with lidocaine infiltration during laceration repair in children. Smith GA, et al.
Clin Pediatr (Phila) 1997 Jan;36(1):17–23

Nitrous oxide inhalation as an adjunct to intravenous induction of general anaesthesia with propofol for day surgery. Johnson GW, et al. **Eur J Anaesthesiol** 1997 May; 14(3):295–9

Dose–response and concentration–response relation of rocuronium infusion during propofol–nitrous oxide and isoflurane–nitrous oxide anaesthesia. Kansanaho M, et al.
Eur J Anaesthesiol 1997 Sep;14(5):488–94

How to manage drug interactions. Glass PS, et al.
Eur J Anaesthesiol Suppl 1997 May;15:33–9

Sedation and analgesia for colonoscopy: patient tolerance, pain, and cardiorespiratory parameters. Froehlich F, et al.
Gastrointest Endosc 1997 Jan;45(1):1–9

Ability of flumazenil, butorphanol, and naloxone to reverse the anesthetic effects of oxymorphone–diazepam in dogs. Lemke KA, et al. **J Am Vet Med Assoc** 1996 Aug 15; 209(4):776–9

Use of xylazine, butorphanol, tiletamine–zolazepam, and isoflurane for induction and maintenance of anesthesia in ratites. Lin HC, et al. **J Am Vet Med Assoc** 1997 Jan 15; 210(2):244–8

A comparison between medetomidine–ketamine and medetomidine–propofol anaesthesia in rabbits. Hellebrekers LJ, et al. **Lab Anim** 1997 Jan;31(1):58–69

A comparison of thiopentone–isoflurane anaesthesia vs propofol infusion in children having repeat minor haematological procedures. Harling DW, et al.
Paediatr Anaesth 1997;7(1):19–23

Cisatracurium during halothane and balanced anaesthesia in children. Meretoja OA, et al. **Paediatr Anaesth** 1996; 6(5):373–8

Anesthetic regimen effects on a pediatric porcine model of asphyxial arrest. Jasani MS, et al. **Resuscitation** 1997 Aug; 35(1):69–75

[Propofol in combination with etomidate for anesthesia induction] Bovianska N. **Khirurgiia (Sofiia)** 1996;49(4):37–9 (Eng. Abstr.) **(Bul)**

[The use of Diprivan in combination with the local use of lidocaine/adrenaline in operations on the neck area] Tomova M. **Khirurgiia (Sofiia)** 1996;49(4):40–1 (Eng. Abstr.) **(Bul)**

[Total intravenous anesthesia (TIVA) with propofol/ketamine as an alternative for patients at risk in abdominal surgery] Vankov I, et al. **Khirurgiia (Sofiia)** 1996; 49(4):17–9 (Eng. Abstr.) **(Bul)**

[Age–related correlation between EEG parameters and depth of anesthesia under propofol. Effect of fentanyl] Werry C, et al. **Anaesthesist** 1996 Aug;45(8):722–30 (Eng. Abstr.) **(Ger)**

[Comparison of analgesic effect of lidocaine tape versus eutectic mixture of lidocaine and tetracaine during infiltration of local anesthetics before epidural block] Kawano T, et al. **Masui** 1996 Sep;45(9):1074–7 (Eng. Abstr.) **(Jpn)**

[Combined spinal–epidural anesthesia for intra–abdominal gynecological surgeries] Nagashima N, et al. **Masui** 1996 Sep;45(9):1153–9 (Eng. Abstr.) **(Jpn)**

[Living related liver transplantation for patients with ornithine transcarbamylase deficiency] Tazuke M, et al.
Masui 1997 Jun;46(6):783–7 (Eng. Abstr.) **(Jpn)**

[Anesthesia with Inoval and Valium in combined use] Narvaes C, et al. **Rev Bras Anestesiol** 1968 Oct–Dec; 18(4):447–61 (Eng. Abstr.) **(Por)**

ADMINISTRATION & DOSAGE

The optimal dose of ketamine for caudal epidural blockade in children. Semple D, et al. **Anaesthesia** 1996 Dec; 51(12):1170–2

Is wound infiltration with anesthetic effective as pre–emptive analgesia? A clinical trial in appendectomy patients [see comments] Willard PT, et al. **Can J Surg** 1997 Jun; 40(3):213–7. Comment in: Can J Surg 1997 Jun;40(3):166.

Prilocaine/lidocaine patch as a local premedication for skin biopsy in children. de Waard–van der Spek FB, et al.
J Am Acad Dermatol 1997 Sep;37(3 Pt 1):418–21

Humane and practical implications of using carbon dioxide mixed with oxygen for anesthesia or euthanasia of rats. Danneman PJ, et al. **Lab Anim Sci** 1997 Aug;47(4):376–85

Multidrug intravenous sedation: determinants of the sedative dose of midazolam. Moore PA, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jul;84(1):5–10

A comparison of two oral ketamine–diazepam regimens for sedating anxious pediatric dental patients. Reinemer HC, et al. **Pediatr Dent** 1996 Jul–Aug;18(4):294–300

[Total intravenous anesthesia in patients with postburn deformations of the face and neck] Beliakov VA, et al.
Anesteziol Reanimatol 1996 Jul–Aug;(4):50–2 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Adverse response to sevoflurane induction followed by enflurane maintenance [letter] MacLeod A, et al.
Anaesthesia 1997 Jun;52(6):603–4

Severe maternal hypotension and fetal bradycardia after a combined spinal epidural anesthetic. D'Angelo R, et al.
Anesthesiology 1997 Jul;87(1):166–8

Maternal respiratory arrests, severe hypotension, and fetal distress after administration of intrathecal, sufentanil, and bupivacaine after intravenous fentanyl. Lu JK, et al.
Anesthesiology 1997 Jul;87(1):170–2

ANTAGONISTS & INHIBITORS

Safety considerations in the use of drug combinations during general anaesthesia. Ransom ES, et al. **Drug Saf** 1997 Feb; 16(2):88–103 (129 ref.)

BLOOD

Venous levels of lignocaine and bupivacaine after peribulbar block. Gao F, et al. **Anaesthesia** 1996 Dec;51(12):1109–12

CHEMISTRY

Densities of dextrose–free intrathecal local anesthetics, opioids, and combinations measured at 37 degrees C. Richardson MG, et al. **Anesth Analg** 1997 Jan;84(1):95–9

PHARMACOKINETICS

Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. Lacoste L, et al.
Lab Anim 1996 Jul;30(3):228–33

PHARMACOLOGY

A concept for assessing interactions of general anesthetics. Kissin I. **Anesth Analg** 1997 Jul;85(1):204–10

Processed electroencephalogram during combined extradural and general anaesthesia. Kiyama S, et al. **Br J Anaesth** 1997 Jun;78(6):751–3

Comparison of the effects of ketamine–midazolam with those of fentanyl–midazolam on cortical somatosensory evoked potentials during major spine surgery. Langeron O, et al.
Br J Anaesth 1997 Jun;78(6):701–6

Regional cerebral blood flow (SPECT) during anaesthesia with isoflurane and nitrous oxide in humans. Reinstrup P, et al. **Br J Anaesth** 1997 Apr;78(4):407–11

Auditory evoked response, median frequency and 95% spectral edge during anaesthesia with desflurane and nitrous oxide. Sharpe RM, et al. **Br J Anaesth** 1997 Mar;78(3):282–5

A risk–benefit assessment of topical percutaneous local anaesthetics in children. Russell SC, et al. **Drug Saf** 1997 Apr;16(4):279–87 (65 ref.)

The effect of nitrous oxide on the measurement of single–breath transfer factor. Phillips CL, et al.
Eur Respir J 1997 Jan;10(1):200–1

Anesthetic interactions following bolus injections. Kissin I.
J Clin Anesth 1997 Sep;9(6 Suppl):14S–17S

Anesthetic drug interaction: an overview. Rosow CE.
J Clin Anesth 1997 Sep;9(6 Suppl):27S–32S (37 ref.)

Steady–state minute volume determination by body–only plethysmography in juvenile rhesus monkeys. Besch TK, et al. **Lab Anim Sci** 1996 Oct;46(5):539–44

The influence of midazolam and nitrous oxide on respiratory depression in laboratory rats. Henry RJ, et al.
Pediatr Dent 1996 Jul–Aug;18(4):281–6

Comparison of three injectable anaesthetic techniques in pigs. Clutton RE, et al. **Vet Rec** 1997 Aug 9;141(6):140–6

[Acid–base equilibrium in anesthesia with the Valium–Inoval combination] do Amaral RV, et al. **Rev Bras Anestesiol** 1968 Oct–Dec;18(4):462–71 (Eng. Abstr.) **(Por)**

THERAPEUTIC USE

EMLA versus TAC for topical anesthesia of extremity wounds in children. Zempsky WT, et al.
Ann Emerg Med 1997 Aug;30(2):163–6

ANESTHETICS, CONDUCTION–BLOCKING see **ANESTHETICS, LOCAL**

ANESTHETICS, DISSOCIATIVE

Ketamine anesthesia in children with acute burns and scalds. Maldini B. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1108–11

Anaesthesia with the difficult airway [letter; comment] Cormack RS. **Anaesthesia** 1997 Jul;52(7):710. Comment on: Anaesthesia 1997 Mar;52(3):285–6.

A comparison of propofol with a propofol–ketamine combination for sedation during spinal anesthesia. Frizelle HP, et al. **Anesth Analg** 1997 Jun;84(6):1318–22

Sedation for the conduct of lumbar epidural anaesthesia: a study using subanaesthetic dose of ketamine in combination with midazolam. Loo CC, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):200–4

Ketamine modulation of the temporal pattern of discharges and spike train interactions in the rat substantia nigra pars reticulata. Villa AE, et al. **Brain Res Bull** 1997;43(6):525–35

Ketamine anesthesia in electroconvulsive therapy. Rasmussen KG, et al. **Convuls Ther** 1996 Dec;12(4):217–23

Hemodynamic effects of carcinine in the anesthetized, instrumented, open–chest rat. Steinberg C, et al. **Crit Care Med** 1996 Dec;24(12):2042–5

Uneventful total intravenous anaesthesia with ketamine for schizophrenic surgical patients. Ishihara H, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):47–51

Coronary vasoconstriction by endothelin–1 in anesthetized goats: role of endothelin receptors, nitric oxide and prostanoids. García JL, et al. **Eur J Pharmacol** 1996 Nov 14;315(2):179–86

Ketamine in the field: the use of ketamine for induction of anaesthesia before intubation in injured patients in the field. Gofrit ON, et al. **Injury** 1997 Jan;28(1):41–3

Sedation with ketamine during cataract surgery. Cugini U, et al. **J Cataract Refract Surg** 1997 Jun;23(5):784–6

Illicit use of ketamine in Scotland. Dalgarno PJ, et al. **J Psychoactive Drugs** 1996 Apr–Jun;28(2):191–9

Cardiopulmonary effects of desflurane in ponies, after induction of anaesthesia with xylazine and ketamine. Clarke KW, et al. **Vet Rec** 1996 Aug 24;139(8):180–5

Anesthesia in sheep with propofol or with xylazine–ketamine followed by halothane. Lin HC, et al. **Vet Surg** 1997 May–Jun;26(3):247–52

A comparative study of medetomidine–butorphanol–ketamine and medetomidine–ketamine anaesthesia in dogs. Tomizawa N, et al. **Zentralbl Veterinarmed A** 1997 Jun;44(4):189–94

[Combination of propofol–ketamine–vecuronium for total intravenous anesthesia under hazardous conditions] Escarment J, et al. **Cah Anesthesiol** 1996;44(5):447–50 (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

A new method to evaluate central sensitization to pain following surgery. Effect of ketamine. Stubhaug A. **Acta Anaesthesiol Scand Suppl** 1997;110:154–5

The optimal dose of ketamine for caudal epidural blockade in children. Semple D, et al. **Anaesthesia** 1996 Dec; 51(12):1170–2

Spinal conduction block by intrathecal ketamine in dogs. Iida H, et al. **Anesth Analg** 1997 Jul;85(1):106–10

Intravenous ketamine or fentanyl prolongs postoperative analgesia after intrathecal neostigmine. Lauretti GR, et al. **Anesth Analg** 1996 Oct;83(4):766–70

Intravenous ketamine sedation of pediatric patients in the emergency department. Dachs RJ, et al. **Ann Emerg Med** 1997 Jan;29(1):146–50

Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Malinovsky JM, et al. **Br J Anaesth** 1996 Aug;77(2):203–7

Oral ketamine premedication in children (placebo controlled double–blind study). Sekerci C, et al. **Eur J Anaesthesiol** 1996 Nov;13(6):606–11

Development of a pharmacokinetic model–based infusion system for ketamine analgesia [letter] Mason DG, et al. **Int J Clin Monit Comput** 1996 Aug;13(3):139–42

A new route, jet–injection for anesthetic induction in children – II. ketamine dose–range finding studies. Zsigmond EK, et al. **Int J Clin Pharmacol Ther** 1996 Feb;34(2):84–8

Chemical restraint of African lions (Panthera leo) with medetomidine–ketamine. Tomizawa N, et al. **J Vet Med Sci** 1997 Apr;59(4):307–10

Oral transmucosal ketamine: an effective premedication in children. Cioacă R, et al. **Paediatr Anaesth** 1996;6(5):361–5

Intranasal ketamine preinduction of paediatric outpatients. Diaz JH. **Paediatr Anaesth** 1997;7(4):273–8

A comparison of two oral ketamine–diazepam regimens for sedating anxious pediatric dental patients. Reinemer HC, et al. **Pediatr Dent** 1996 Jul–Aug;18(4):294–300

Continuous ketamine infusion for the treatment of refractory asthma in a mechanically ventilated infant: case report and review of the pediatric literature. Nehama J, et al. **Pediatr Emerg Care** 1996 Aug;12(4):294–7 (20 ref.)

Ketamine potentiates analgesic effect of morphine in postoperative epidural pain control [see comments] Wong CS, et al. **Reg Anesth** 1996 Nov–Dec;21(6):534–41. Comment in: Reg Anesth 1996 Nov–Dec;21(6):508–13.

Epidural ketamine: a useful, mechanistically novel adjuvant for epidural morphine? [editorial; comment] Yaksh TL. **Reg Anesth** 1996 Nov–Dec;21(6):508–13. Comment on: Reg Anesth 1996 Nov–Dec;21(6):534–41.

Effects of tiletamine/zolazepam premedication on propofol anaesthesia in dogs. Cullen LK, et al. **Vet Rec** 1997 Apr 5;140(14):363–6

[Veterinary dentistry (13). The use of the combination medetomidine/ketamine in dogs for anesthesia in dental procedures: evaluation of its clinical application] Sap R, et al. **Tijdschr Diergeneeskd** 1997 May 1;122(9):248–51 (Eng. Abstr.) **(Dut)**

[Analgesic effect of ketamine in a patient with neuropathic pain] Oye I, et al. **Tidsskr Nor Laegeforen** 1996 Oct 30; 116(26):3130–1 (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Ketamine safety profile in the developing world: survey of practitioners. Green SM, et al. **Acad Emerg Med** 1996 Jun; 3(6):598–604

Transient apnea with intramuscular ketamine [letter; comment] Green SM, et al. **Am J Emerg Med** 1997 Jul; 15(4):440–1. Comment on: Am J Emerg Med 1993 Mar;22(3):613–5. Comment on: Am J Emerg Med 1996 Oct;14(6):580–1.

Apnea and oxyhemoglobin desaturation after intramuscular ketamine administration in a 2–year–old child [letter; comment] Litman RS. **Am J Emerg Med** 1997 Sep; 15(5):547–8. Comment on: Am J Emerg Med 1996 Oct;14(6):580–1.

Respiratory arrest after intramuscular ketamine in a 2–year–old child [see comments] Mitchell RK, et al. **Am J Emerg Med** 1996 Oct;14(6):580–1. Comment in: Am J Emerg Med 1997 Jul;15(4):440–1. Comment in: Am J Emerg Med 1997 Sep;15(5):547–8.

Adverse cardiovascular effects of ketamine infusion in patients with catecholamine–dependent heart failure. Christ G, et al. **Anaesth Intensive Care** 1997 Jun;25(3):255–9

Unexpected interaction of methylphenidate (Ritalin) with anaesthetic agents. Ririe DG, et al. **Paediatr Anaesth** 1997; 7(1):69–72

Sedation for therapeutic and diagnostic procedures in children [letter] McGraw T, et al. **Pediatrics** 1997 Oct; 100(4):732–3

BLOOD

Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Malinovsky JM, et al. **Br J Anaesth** 1996 Aug;77(2):203–7

Ketamine concentrations during cardiopulmonary bypass. McLean RF, et al. **Can J Anaesth** 1996 Jun;43(6):580–4

Determination of ketamine and norketamine enantiomers in plasma by solid–phase extraction and high–performance liquid chromatography. Svensson JO, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):373–6

PHARMACOKINETICS

Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. Nolan A, et al. **Res Vet Sci** 1996 May;60(3):262–6

The influence of ionophores on the duration of xylazine–ketamine anestheisa and the hepatic cytochrome P–450 content of broiler chickens. Roder JD, et al. **Vet Hum Toxicol** 1996 Oct;38(5):353–5

PHARMACOLOGY

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part V. Verapamil. Orszulak–Michalak D. **Acta Pol Pharm** 1996 Jan–Feb;53(1):57–61

Contrasting effects of urethane, ketamine, and thiopental anesthesia on ethanol–clonidine hemodynamic interaction. el–Mas MM, et al. **Alcohol Clin Exp Res** 1997 Feb; 21(1):19–27

The effects of ketamine on Ca2+ movements in A7r5 vascular smooth muscle cells. Kanmura Y, et al. **Anesth Analg** 1996 Nov;83(5):1105–9

The relaxing effect of ketamine on isolated rabbit lower esophageal sphincter. Kohjitani A, et al. **Anesth Analg** 1997 Feb;84(2):433–7

The relaxant effect of ketamine on guinea pig airway smooth muscle is epithelium–independent. Sato T, et al. **Anesth Analg** 1997 Mar;84(3):641–7

Ketamine relaxes airway smooth muscle contracted by endothelin. Sato T, et al. **Anesth Analg** 1997 Apr; 84(4):900–6

Ketamine blocks currents through mammalian nicotinic acetylcholine receptor channels by interaction with both the open and the closed state. Scheller M, et al. **Anesth Analg** 1996 Oct;83(4):830–6

Blocking mechanisms of ketamine and its enantiomers in enzymatically demyelinated peripheral nerve as revealed by single–channel experiments. Bräu ME, et al. **Anesthesiology** 1997 Feb;86(2):394–404

Blockade of myocardial ATP–sensitive potassium channels by ketamine. Ko SH, et al. **Anesthesiology** 1997 Jul; 87(1):68–74

Multiple mechanisms of ketamine blockade of N–methyl–D–aspartate receptors. Orser BA, et al. **Anesthesiology** 1997 Apr;86(4):903–17

Calcium concentration–dependent mechanisms through which ketamine relaxes canine airway smooth muscle. Pabelick CM, et al. **Anesthesiology** 1997 May;86(5):1104–11

Ketamine attenuates and reverses morphine tolerance in rodents. Shimoyama N, et al. **Anesthesiology** 1996 Dec; 85(6):1357–66

Effect of racemic mixture and the (S+)–isomer of ketamine on temporal and spatial summation of pain. Arendt–Nielsen L, et al. **Br J Anaesth** 1996 Nov;77(5):625–31

Ketamine: its mechanism(s) of action and unusual clinical uses [editorial] Hirota K, et al. **Br J Anaesth** 1996 Oct; 77(4):441–4

Effects of ketamine and pentobarbitone on acetylcholine release from the rat frontal cortex in vivo. Kikuchi T, et al. **Br J Anaesth** 1997 Jul;79(1):128–30

Comparison of the effects of ketamine–midazolam with those of fentanyl–midazolam on cortical somatosensory evoked potentials during major spine surgery. Langeron O, et al. **Br J Anaesth** 1997 Jun;78(6):701–6

Ketamine increases the amplitude of the 40–Hz auditory steady–state response in humans. Plourde G, et al. **Br J Anaesth** 1997 May;78(5):524–9

Differential effects of ketamine and pentobarbitone on acetylcholine release from the rat hippocampus and striatum. Sato K, et al. **Br J Anaesth** 1996 Sep;77(3):381–4

Ketamine inhibits nitric oxide production in mouse–activated macrophage–like cells. Shimaoka M, et al. **Br J Anaesth** 1996 Aug;77(2):238–42

Effects of ketamine on dopamine metabolism during anesthesia in discrete brain regions in mice: comparison with the effects during the recovery and subanesthetic phases. Irifune M, et al. **Brain Res** 1997 Jul 25;763(2):281–4

Magnesium deficiency increases ketamine sensitivity in rats. Orser B, et al. **Can J Anaesth** 1997 Aug;44(8):883–90

A comparison of romifidine and xylazine when used with diazepam/ketamine for short duration anesthesia in the horse. Kerr CL, et al. **Can Vet J** 1996 Oct;37(10):601–9

An abnormal ketamine response in mutants defective in the ryanodine receptor gene ryr–1 (unc–68) of Caenorhabditis elegans. Sakube Y, et al. **J Mol Biol** 1997 Apr 11; 267(4):849–64

The effect of intravenous administration of variable–dose midazolam after fixed–dose ketamine in healthy awake cats. Ilkiw JE, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):217–24

Interaction of cyclophosphamide and ketamine in vivo. Rojavin MA, et al. **Neuroimmunomodulation** 1996 Nov–Dec;3(6):333–5

Dizocilpine–like discriminative stimulus effects of low–affinity uncompetitive NMDA antagonists. Grant KA, et al. **Neuropharmacology** 1996;35(12):1709–19

The effect of Ketamine on stimulation of primary and secondary hyperalgesic areas induced by capsaicin—a double–blind, placebo–controlled, human experimental study [published erratum appears in Pain 1996 Dec;68(2–3):439] Andersen OK, et al. **Pain** 1996 Jul; 66(1):51–62

Effects of an anaesthetic on plasma levels of histamine and tele–methylhistamine in the cat. Irman–Florjanc T. **Pflugers Arch** 1996;431(6 Suppl 2):R221–2

Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Hustveit O, et al. **Pharmacol Toxicol** 1995 Dec;77(6):355–9

Venom yields from several species of colubrid snakes and differential effects of ketamine. Hill RE, et al. **Toxicon** 1997 May;35(5):671–8

Comparison of three injectable anaesthetic techniques in pigs. Clutton RE, et al. **Vet Rec** 1997 Aug 9;141(6):140–6

[S(+)–ketamine bases and clinical application. Symposium as part of the German Anesthesia Congress. Hamburg, 23 April 1997] **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jul; 32(7 Suppl Ketamin):1–4 **(Ger)**

[The mechanisms of action of ketamine] Tarakanov AV, et al. **Eksp Klin Farmakol** 1996 Nov–Dec;59(6):56–61 (95 ref.) (Eng. Abstr.) **(Rus)**

[The interaction of clofelin and ketamine in the body of patients] Byshovets SN. **Lik Sprava** 1996 Jul–Sep; (7–9):157–60 (Eng. Abstr.) **(Rus)**

STANDARDS

Ketamine and its use in the pig. Recommendations of the Consensus meeting on Ketamine Anaesthesia in Pigs, Bergen 1994. Ketamine Consensus Working Group. Boschert K, et al. **Lab Anim** 1996 Jul;30(3):209–19 (28 ref.)

THERAPEUTIC USE

Phantom limb pain [letter; comment] Baylis R, et al. **Anaesth Intensive Care** 1996 Apr;24(2):288–9. Comment on: Anaesth Intensive Care 1995 Oct;23(5):620–2.

Diazepam [letter; comment] Lott DB. **AORN J** 1996 Feb; 63(2):349. Comment on: AORN J 1995 Oct;62(4):638–45.

Pre–emptive analgesia with ketamine, morphine and epidural lidocaine prior to total knee replacement. Wong CS, et al. **Can J Anaesth** 1997 Jan;44(1):31–7

Ketamine as an anaesthetic agent for tubal sterilisation. Weerasekera DS, et al. **Ceylon Med J** 1996 Sep;41(3):102–3

Continuous infusion of ketamine in mechanically ventilated children with refractory bronchospasm. Youssef–Ahmed MZ, et al. **Intensive Care Med** 1996 Sep;22(9):972–6

Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. Krupitsky EM, et al. **J Psychoactive Drugs** 1997 Apr–Jun;29(2):165–83 (55 ref.)

Fibromyalgia—are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. Sörensen J, et al. **J Rheumatol** 1997 Aug;24(8):1615–21

Comments on Cherry et al. PAIN, 69 (1995) 119–121 [letter;

ANESTHETICS, DISSOCIATIVE

comment] Edmonds PM, et al. **Pain** 1996 Apr;65(1):114–5 . Comment on: Pain 1995 Jul;62(1):119–21.

Ketamine: relief from chronic pain through actions at the NMDA receptor? [letter] Meller ST. **Pain** 1996 Dec; 68(2–3):435–6

Efficacy and safety of intravenous midazolam and ketamine as sedation for therapeutic and diagnostic procedures in children. Parker RI, et al. **Pediatrics** 1997 Mar;99(3):427–31

ANESTHETICS, GENERAL

The lateral pressure profile in membranes: a physical mechanism of general anesthesia. Cantor RS. **Biochemistry** 1997 Mar 4;36(9):2339–44 (33 ref.)

Administration of sufentanil and nitrous oxide blunts cardiovascular effects of desflurane but does not prevent an increase in middle cerebral artery blood flow velocity. Tonner PH, et al. **Eur J Anaesthesiol** 1997 Jul;14(4):389–96

Urethan anesthesia protects rats against lethal endotoxemia and reduces TNF-alpha release. Kotanidou A, et al. **J Appl Physiol** 1996 Nov;81(5):2305–11

Effects of enflurane and isoflurane on splanchnic oxygenation in humans. Berendes E, et al. **J Clin Anesth** 1996 Sep; 8(6):456–68

Parental presence plus oral midazolam decreases frequency of 5% halothane inductions in children. Gillerman RG, et al. **J Clin Anesth** 1996 Sep;8(6):480–5

Outpatient general anesthesia: a comparison of a combination of midazolam plus propofol and propofol alone. Reinhart DJ, et al. **J Clin Anesth** 1997 Mar;9(2):130–7

Use of propofol anesthesia during outpatient radiographic imaging studies in patients with Lesch–Nyhan syndrome. Williams KS, et al. **J Clin Anesth** 1997 Feb;9(1):61–5

Electrographic tachyphylaxis to etomidate and ketamine used for refractory status epilepticus controlled with isoflurane. Kofke WA, et al. **J Neurosurg Anesthesiol** 1997 Jul; 9(3):269–72

The use of ketamine or etomidate to supplement sufentanil/N2O anesthesia does not disrupt monitoring of myogenic transcranial motor evoked responses. Ubags LH, et al. **J Neurosurg Anesthesiol** 1997 Jul;9(3):228–33

Anaesthetics: cracking a nut without a sledgehammer [news] Bonn D. **Lancet** 1997 Jun 28;349(9069):1892

[Recovery and psychomimetic reactions following S-(+)-ketamine] Engelhardt W. **Anaesthesist** 1997 Mar;46 Suppl 1:S38–42 (20 ref.) (Eng. Abstr.) **(Ger)**

[Clinical significance of S-(+)-ketamine] Hempelmann G, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S3–7 (26 ref.) (Eng. Abstr.) **(Ger)**

[Anesthesia with sevoflurane vs propofol in elective extracavity surgery] Cetica P, et al. **Minerva Anestesiol** 1997 Jan–Feb;63(1–2):47–56 (Eng. Abstr.) **(Ita)**

[Propofol in coronary diseases. Haemodynamic evaluation of some anesthetic regimes] Procaccini B, et al. **Minerva Anestesiol** 1996 Jul–Aug;62(7–8):249–57 (Eng. Abstr.) **(Ita)**

[Narcosis 150 years ago and today. High efficiency for general anesthesia] Jonsson L. **Lakartidningen** 1996 Oct 30; 93(44):3897–902 **(Swe)**

[The choice of anesthesia methods in abdominal surgery is decisive for patients' recovery when it comes to eating again. Opinion should be avoided] Wattwil M, et al. **Lakartidningen** 1997 Apr 9;94(15):1376, 1379–80 (15 ref.) **(Swe)**

ADMINISTRATION & DOSAGE

History of automated delivery of anesthetic agents. Smith BE. **Int Anesthesiol Clin** 1995 Summer;33(3):1–10

ADVERSE EFFECTS

Magnesium sulfate stops postanesthetic shivering. Kizilirmak S, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:799–806

Alfentanil mediated activation of epileptiform activity in the electrocorticogram during resection of epileptogenic foci. Keene DL, et al. **Can J Neurol Sci** 1997 Feb;24(1):37–9

Monoamine oxidase inhibitors and cardiac anesthesia revisited. Noorily SH, et al. **South Med J** 1997 Aug; 90(8):836–8

[Angiotensin–converting enzyme inhibitors and anesthesia] Larsen JK, et al. **Ugeskr Laeger** 1996 Oct 21;158(43):6081–4 (Eng. Abstr.) **(Dan)**

[Ocular complications in connection with general anesthesia] Laursen RJ, et al. **Ugeskr Laeger** 1997 Jan 20;159(4):409–13 (39 ref.) (Eng. Abstr.) **(Dan)**

[S-(+)-Ketamine and circulation] Zielmann S, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S43–6 (15 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Amphiphilic sites for general anesthetic action? Evidence from 129Xe-[1H] intermolecular nuclear Overhauser effects. Xu Y, et al. **Biochim Biophys Acta** 1997 Jan 14; 1323(1):154–62

Stereochemistry in anaesthesia. Sidebotham DA, et al. **Clin Exp Pharmacol Physiol** 1997 Feb;24(2):126–30 (42 ref.)

Interaction of alcohols and anesthetics with protein kinase Calpha. Slater SJ, et al. **J Biol Chem** 1997 Mar 7; 272(10):6167–73

HISTORY

Triumph over pain: the discovery of surgical anesthesia. Anderson EF. **S D J Med** 1996 Oct;49(10):369–72

PHARMACOKINETICS

[The pharmacodynamics of general anesthetics. The neurological and cardiovascular aspects] Vale FM. **Rev Port Cardiol** 1997 Jan;16(1):41–50, 8 (34 ref.) (Eng. Abstr.) **(Por)**

PHARMACOLOGY

The perturbations of various CNS functions by anaesthetic drugs. Halsey M. **Acta Anaesthesiol Scand Suppl** 1997; 110:11–2

Multiple cellular and subcellular actions of general anaesthetics on cultured molluscan neurones. Winlow W, et al. **Acta Biol Hung** 1995;46(2–4):381–93

A possible role for phospholipase A2 in the action of general anesthetics. Denson DD, et al. **Am J Physiol** 1996 Feb; 270(2 Pt 1):C636–44

Patients' memories of events during general anaesthesia. Bailey AR, et al. **Anaesthesia** 1997 May;52(5):460–76 (102 ref.)

A concept for assessing interactions of general anesthetics. Kissin I. **Anesth Analg** 1997 Jul;85(1):204–10

Learning and memory during general anesthesia: an update. Ghoneim MM, et al. **Anesthesiology** 1997 Aug; 87(2):387–410 (152 ref.)

Amphiphilic sites for general anesthetic action? Evidence from 129Xe-[1H] intermolecular nuclear Overhauser effects. Xu Y, et al. **Biochim Biophys Acta** 1997 Jan 14; 1323(1):154–62

Midlatency auditory evoked potentials as indicators of perceptual processing during general anaesthesia. de Beer NA, et al. **Br J Anaesth** 1996 Nov;77(5):617–24

Detection of inspiratory resistive loads after anaesthesia for minor surgery. Drummond GB, et al. **Br J Anaesth** 1997 Mar;78(3):308–10

Cardioventilatory coupling during anaesthesia. Galletly DC, et al. **Br J Anaesth** 1997 Jul;79(1):35–40

Glutamate: a role in normal brain function, anaesthesia, analgesia and CNS injury. Hudspith MJ. **Br J Anaesth** 1997 Jun;78(6):731–47 (232 ref.)

A model of the electrocortical effects of general anaesthesia. Sleigh JW, et al. **Br J Anaesth** 1997 Mar;78(3):260–3

Modulation by general anaesthetics of rat GABAA receptors comprised of alpha 1 beta 3 and beta 3 subunits expressed in human embryonic kidney 293 cells. Davies PA, et al. **Br J Pharmacol** 1997 Mar;120(5):899–909

The site of general anaesthesia and cytochrome P450 oxygenases: similarities defined by straight chain and cyclic alcohols. LaBella FS, et al. **Br J Pharmacol** 1997 Mar; 120(6):1158–64

Ultrasonography of the equine triceps muscle before and after general anaesthesia and in post anaesthetic myopathy. Smith RK, et al. **Equine Vet J** 1996 Jul;28(4):311–9

Ethanol as a general anesthetic: actions in spinal cord. Wong SM, et al. **Eur J Pharmacol** 1997 Jun 25;329(2–3):121–7

Correlation of effects of general anesthetics on somatosensory neurons in the primate thalamus and cortical EEG power. Dougherty PM, et al. **J Neurophysiol** 1997 Mar; 77(3):1375–92

Enhancement by lanthanide of general anesthetic-induced GABAA-receptor current in rat septal cholinergic neurons in culture. Kumamoto E, et al. **J Neurophysiol** 1996 Jun; 75(6):2294–9

Selectivity of general anesthetics: a new dimension [news] Franks NP, et al. **Nat Med** 1997 Apr;3(4):377–8

Inhibitory synapses. Anaesthetics set their sites on ion channels [news; comment] Franks NP, et al. **Nature** 1997 Sep 25;389(6649):334–5. Comment on: Nature 1997 Sep 25;389(6649):385–9.

Daily rhythms of heart rate, temperature and locomotor activity are modified by anaesthetics in rats: a telemetric study. Prudian F, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jun; 355(6):774–8

Modulation of human recombinant GABAA receptors by pregnanediols. Belelli D, et al. **Neuropharmacology** 1996; 35(9–10):1223–31

Midbrain raphe cell firing and hippocampal theta rhythm in urethane-anaesthetized rats. Kocsis B, et al. **Neuroreport** 1996 Nov 25;7(18):2867–72

Mechanisms of etomidate potentiation of GABAA receptor-gated currents in cultured postnatal hippocampal neurons. Yang J, et al. **Neuroscience** 1996 Jul;73(1):69–78

Halothane and isoflurane dose-dependently inhibit the cyclic GMP increase caused by N-methyl-D-aspartate in rat cerebellum: novel localization and quantitation by in vitro autoradiography. Zuo Z, et al. **Neuroscience** 1996 Oct; 74(4):1069–75

How has molecular pharmacology contributed to our understanding of the mechanism(s) of general anesthesia? Little HJ. **Pharmacol Ther** 1996;69(1):37–58 (218 ref.)

Propofol-induced ataxia and hypnosis in rat lines selected for differential alcohol sensitivity. Yildirim Y, et al. **Pharmacol Toxicol** 1997 Jan;80(1):44–8

Influence of general anesthetics on a specific neural pathway in Drosophila melanogaster. Lin M, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10446–51

[Endocrine reactions following S-(+)-ketamine] Adams HA. **Anaesthesist** 1997 Mar;46 Suppl 1:S30–7 (33 ref.) (Eng. Abstr.) **(Ger)**

[S-(+)-Ketamine--today and tomorrow] Adams HA, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S1–2 **(Ger)**

[Effects of ketamine on CNS-function] Detsch O, et al. **Anaesthesist** 1997 Mar;46 Suppl 1:S20–9 (98 ref.) (Eng. Abstr.) **(Ger)**

[Combination anesthesia and bronchial tranport velocity. Effects of anesthesia with isoflurane, fentanyl, vecuronium and oxygen-nitrous oxide breathing on bronchial mucus transport] Konrad F, et al. **Anaesthesist** 1997 May; 46(5):403–7 (Eng. Abstr.) **(Ger)**

[Mechanisms of action of ketamine] Kress HG. **Anaesthesist** 1997 Mar;46 Suppl 1:S8–19 (120 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Characterization of the humoral immune response and hepatotoxicity after multiple halothane exposures in guinea pigs. Chen M, et al. **Drug Metab Rev** 1997 Feb–May; 29(1–2):103–22

Selective toxicity of the general anesthetic propofol for GABAergic neurons in rat brain cell cultures. Honegger P, et al. **J Neurosci Res** 1996 Sep 1;45(5):631–6

ANESTHETICS, INHALATION

Effects of thoracic vs. lumbar epidural anaesthesia on systemic haemodynamics and coronary circulation in sevoflurane anaesthetized dogs. Hirabayashi Y, et al. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1127–31

New horizons in inhalation anesthetics. White PF, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:164–5

Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs. Martinez EA, et al. **Am J Vet Res** 1996 Nov;57(11):1623–6

Evaluation of analgesia and cardiorespiratory effects of epidurally administered butorphanol in isoflurane-anesthetized dogs. Troncy E, et al. **Am J Vet Res** 1996 Oct;57(10):1478–82

Inspired oxygen concentrations with or without an oxygen economizer during ether draw-over anaesthesia. Khaing TT, et al. **Anaesth Intensive Care** 1997 Aug;25(4):417–9

Laryngeal mask insertion following inhalational induction in children: a comparison between halothane and sevoflurane. Kwek TK, et al. **Anaesth Intensive Care** 1997 Aug; 25(4):413–6

Faulty nitrous oxide Schraeder valve [letter] Barnor E, et al. **Anaesthesia** 1997 Apr;52(4):392–3

Isoflurane for removal of chest drains after cardiac surgery [see comments] Bryden FM, et al. **Anaesthesia** 1997 Feb; 52(2):173–5. Comment in: Anaesthesia 1997 Jul;52(7):718.

Gas leakage and the laryngeal mask airway. A comparison with the tracheal tube and facemask during spontaneous ventilation using a circle breathing system. Cameron AE, et al. **Anaesthesia** 1996 Dec;51(12):1117–9

Single-breath inhalation induction of sevoflurane anaesthesia with and without nitrous oxide: a feasibility study in adults and comparison with an intravenous bolus of propofol. Hall JE, et al. **Anaesthesia** 1997 May;52(5):410–5

Sevoflurane--an alternative to routine use of suxamethonium in children [letter; comment] Jackson D, et al. **Anaesthesia** 1997 Feb;52(2):189. Comment on: Anaesthesia 1996 Sep;51(9):874–8.

The effect of clonidine on sevoflurane requirements for anaesthesia and hypnosis. Katoh T, et al. **Anaesthesia** 1997 Apr;52(4):377–81

Rubber gloves and anaesthetic gas leak [letter] Lam WH, et al. **Anaesthesia** 1996 Nov;51(11):1075–6

Induction with sevoflurane; an olfactory opinion [letter] Mehta S. **Anaesthesia** 1997 Apr;52(4):391–2

Sevoflurane induction and acute epiglottitis [letter] Milligan K. **Anaesthesia** 1997 Aug;52(8):810

Anesthetic potencies of n-alkanols: results of additivity and solubility studies suggest a mechanism of action similar to that for conventional inhaled anesthetics. Fang Z, et al. **Anesth Analg** 1997 May;84(5):1042–8

Emergence of elderly patients from prolonged desflurane, isoflurane, or propofol anesthesia. Juvin P, et al. **Anesth Analg** 1997 Sep;85(3):647–51

The threshold for thermoregulatory vasoconstriction during nitrous oxide/sevoflurane anesthesia is reduced in the elderly. Ozaki M, et al. **Anesth Analg** 1997 May; 84(5):1029–33

The effects of sevoflurane anesthesia on insulin secretion and glucose metabolism in pigs. Saho S, et al. **Anesth Analg** 1997 Jun;84(6):1359–65

Midlatency auditory evoked potentials predict movements during anesthesia with isoflurane or propofol. Schwender D, et al. **Anesth Analg** 1997 Jul;85(1):164–73

Simulation of an epidural test dose with intravenous isoproterenol in isoflurane-anesthetized adults. Tanaka M. **Anesth Analg** 1997 Sep;85(3):639–43

Xenon provides faster emergence from anesthesia than does nitrous oxide–sevoflurane or nitrous oxide–isoflurane. Goto T, et al. **Anesthesiology** 1997 Jun;86(6):1273–8

Sevoflurane inhalation induction for emergency cesarean section in a parturient with no intravenous access. Schaut DJ, et al. **Anesthesiology** 1997 Jun;86(6):1392–4

Priming of anesthesia circuit with xenon for closed circuit

anesthesia. Saito H, et al. **Artif Organs** 1997 Jan;21(1):70–2
Long-term sedation with isoflurane in postoperative intensive care in cardiac surgery. Tanigami H, et al. **Artif Organs** 1997 Jan;21(1):21–3
Comparison of induction and recovery between sevoflurane and halothane supplementation of anaesthesia in children undergoing outpatient dental extractions. Ariffin SA, et al. **Br J Anaesth** 1997 Feb;78(2):157–9
Effect of domperidone on the ventilatory response to transient hyperoxia in patients anaesthetized with isoflurane. Foo IT, et al. **Br J Anaesth** 1997 Jul;79(1):41–6
Ether in an isoflurane vaporizer and the use of vapour analysers in safe anaesthesia [letter; comment] Green AC. **Br J Anaesth** 1997 Jun;78(6):774. Comment on: Br J Anaesth 1997 Jan;78(1):107–8.
Halothane-propofol anaesthesia for tracheal intubation in young children. Hansen D, et al. **Br J Anaesth** 1997 Apr; 78(4):366–9
Isoflurane for sedation in a case of congenital myasthenia gravis. McBeth C, et al. **Br J Anaesth** 1996 Nov;77(5):672–4
Rapid inhalation induction in children: 8% sevoflurane compared with 5% halothane. Sigston PE, et al. **Br J Anaesth** 1997 Apr;78(4):362–5
Inhalation induction with sevoflurane: a double-blind comparison with propofol. Thwaites A, et al. **Br J Anaesth** 1997 Apr;78(4):356–61
The arrhythmogenic dose of epinephrine in halothane and isoflurane anesthetized dogs: an assessment of repeatability. Pettifer G, et al. **Can J Vet Res** 1997 Jul;61(3):221–6
Deep halothane anaesthesia compared with halothane–suxamethonium anaesthesia for tracheal intubation in young children. Hansen D, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):29–34
Anaesthesia during laparoscopic gynaecological surgery: a comparison between desflurane and isoflurane. Jakobsson J, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):148–52
Administration of sufentanil and nitrous oxide blunts cardiovascular effects of desflurane but does not prevent an increase in middle cerebral artery blood flow velocity. Tonner PH, et al. **Eur J Anaesthesiol** 1997 Jul;14(4):389–96
Leaching of the plasticizer from PVC tubing in heart–lung bypass unit tubing circuits. **Health Devices** 1996 Oct; 25(10):393–5
Exposure of anesthesiologists to nitrous oxide during pediatric anesthesia. Chang WP, et al. **Ind Health** 1997; 35(1):112–8
The effect of skin incision followed by alfentanil on catecholamine levels and on the T-wave amplitude of ECG during isoflurane anaesthesia. Annila PA, et al. **Int J Clin Monit Comput** 1995;12(4):205–11
Commentary and recommendations on control of waste anesthetic gases in the workplace. American College of Veterinary Anesthesiologists. **J Am Vet Med Assoc** 1996 Jul 1;209(1):75–7
Response to avian sedation evaluation [letter; comment] Harrison GJ. **J Am Vet Med Assoc** 1996 Dec 15; 209(12):1992–3. Comment on: J Am Vet Med Assoc 1996 Sep 1;209(5):969–71.
Catecholamine and renin–angiotensin response during controlled hypotension induced by prostaglandin E1 combined with hemodilution during isoflurane anesthesia. Fukusaki M, et al. **J Clin Anesth** 1997 Jun;9(4):321–7
Is intravenous lidocaine an effective adjuvant for endotracheal intubation in children undergoing induction of anesthesia with halothane–nitrous oxide? Warner LO, et al. **J Clin Anesth** 1997 Jun;9(4):270–4
Performance of erroneously filled sevoflurane, enflurane and other agent-specific vaporizers. Abel M, et al. **J Clin Monit** 1996 Mar;12(2):119–25
EEG Predicts movement response to surgical stimuli during general anesthesia with combinations of isoflurane, 70% N2O, and fentanyl. Dutton RC, et al. **J Clin Monit** 1996 Mar;12(2):127–39
The response of anesthetic agent monitors to trifluoromethane warns of the presence of carbon monoxide from anesthetic breakdown. Woehlck HJ, et al. **J Clin Monit** 1997 May;13(3):149–55
Study of clinical anaesthesia with pedius A anaesthesia system using ketamine or halothane with muscle relaxant. Das SK, et al. **J Indian Med Assoc** 1995 Oct;93(10):377–9
Furosemide decreases cerebrospinal fluid formation during desflurane anesthesia in rabbits. Artru AA, et al. **J Neurosurg Anesthesiol** 1997 Apr;9(2):166–74
Intact cerebral blood flow reactivity during remifentanil/nitrous oxide anesthesia. Baker KZ, et al. **J Neurosurg Anesthesiol** 1997 Apr;9(2):134–40
Desflurane and sevoflurane are valuable additions to the practice of neuroanesthesiology: pro. Baker KZ. **J Neurosurg Anesthesiol** 1997 Jan;9(1):66–8 (24 ref.)
Effects of normo- and hypocapnic nitrous-oxide-inhalation on cerebral blood flow velocity in patients with brain tumors. Hörmann C, et al. **J Neurosurg Anesthesiol** 1997 Apr;9(2):141–5
The new inhalational anesthetics desflurane and sevoflurane are valuable additions to the practice of neuroanesthesia: con. Tempelhoff R. **J Neurosurg Anesthesiol** 1997 Jan; 9(1):69–71 (19 ref.)
Desflurane for outpatient general anesthesia in third molar extraction cases. Bandrowsky T, et al. **J Oral Maxillofac Surg** 1997 Feb;55(2):129–32; discussion 132–3
Closed anesthesia with nitrous oxide. Li S, et al. **J Tongji Med Univ** 1996;16(2):126–8
Brain-stem auditory evoked potentials comparison between 1.3 and 1.5 MAC of isoflurane-nitrous oxide anesthesia. el-Dawlatly AA, et al. **Middle East J Anesthesiol** 1997 Jun;14(2):107–16
The safety and efficacy of desflurane. Naguib K, et al. **Middle East J Anesthesiol** 1997 Feb;14(1):33–44
Anaesthesia for insertion of ear tubes in children: comparison of propofol, thiopentone and halothane. Carpenter RD, et al. **Paediatr Anaesth** 1997;7(1):25–31
A comparison of sevoflurance to halothane in paediatric surgical patients: results of a multicentre international study. Kataria B, et al. **Paediatr Anaesth** 1996;6(4):283–92
Spontaneous breathing with the use of a laryngeal mask airway in children: comparison of sevoflurane and isoflurane. Komatsu H, et al. **Paediatr Anaesth** 1997; 7(2):111–5
Cisatracurium during halothane and balanced anaesthesia in children. Meretoja OA, et al. **Paediatr Anaesth** 1996; 6(5):373–8
Convulsions associated with epidural analgesia during sevoflurane anaesthesia. Saitoh K, et al. **Paediatr Anaesth** 1996;6(6):495–7
Neuromuscular effects of rocuronium in children during halothane anaesthesia. Vuksanaj D, et al. **Paediatr Anaesth** 1996;6(4):277–81
Anesthesia in sheep with propofol or with xylazine–ketamine followed by halothane. Lin HC, et al. **Vet Surg** 1997 May–Jun;26(3):247–52
Metabolic, hormonal, and hemodynamic changes during dopamine infusions in halothane anesthetized horses. Robertson SA, et al. **Vet Surg** 1996 Jan–Feb;25(1):88–97
[Evaluation of sevoflurane, new anesthetic agent during pediatric cardiac catheterization] Bazin JE, et al. **Arch Mal Coeur Vaiss** 1997 May;90(5):657–60 (Eng. Abstr.) **(Fre)**
[Effect of rocuronium in sufentanil/isoflurane and sufentanil/propofol anesthesia] Klinzing S, et al. **Anaesthesiol Reanim** 1996;21(6):149–52 (Eng. Abstr.) **(Ger)**
[Comparison of the effect of desflurane and isoflurane on neuromuscular blockage with vecuronium on geriatric patients] Mielke VL, et al. **Anaesthesiol Reanim** 1996; 21(1):4–10 (Eng. Abstr.) **(Ger)**
[Critical evaluation of the new inhalational anesthetics desflurane and sevoflurane] Scholz J, et al. **Anaesthesiol Reanim** 1997;22(1):15–20 (39 ref.) (Eng. Abstr.) **(Ger)**
[Low-flow anesthesia with desflurane] Baum J, et al. **Anaesthesist** 1997 Apr;46(4):287–93 (Eng. Abstr.) **(Ger)**
[Cost aspects in anesthesia. Propofol versus isoflurane anesthesia] Boldt J, et al. **Anaesthesist** 1996 Aug;45(8):731–6 (Eng. Abstr.) **(Ger)**
[New inhalation anesthetics] Conzen P, et al. **Anaesthesist** 1996 Aug;45(8):674–93 (82 ref.) (Eng. Abstr.) **(Ger)**
[The interaction of nitrous oxide and enflurane on the EEG median of 2–3 Hz is additive, but weaker than at 1.0 MAC (see comments)] Röpcke H, et al. **Anaesthesist** 1996 Sep; 45(9):819–25 (Eng. Abstr.). Comment in: Anaesthesist 1997 Jun;46(6):566–7. **(Ger)**
[Transcranial doppler sonography. Effect of sevoflurane in comparison to isoflurane] Thiel A, et al. **Anaesthesist** 1997 Jan;46(1):29–33 (Eng. Abstr.) **(Ger)**
[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery] Wilhelm W, et al. **Anaesthesist** 1997 Apr;46(4):335–8 (Eng. Abstr.) **(Ger)**
[Low flow anesthesia with xenon] Baum J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):51–5 **(Ger)**
[Xenon as inhalation anesthetic] Fröba G. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):48–51 (40 ref.) **(Ger)**
[Xenon (editorial; comment)] Georgieff M. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):43. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):268–75. **(Ger)**
[Echocardiography values in the halothane uptake phase—measurement by acoustic quantification and manual evaluation] Laux G, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan; 32(1):30–5 (Eng. Abstr.) **(Ger)**
[Blood supply to the liver in the human after 1 MAC desflurane in comparison with isoflurane and halothane] Schindler E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):344–8 (Eng. Abstr.) **(Ger)**
[Does propofol have advantages over isoflurane for sufentanil supplemented anesthesia in children for strabismus surgery?] Wilhelm S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):414–9 (Eng. Abstr.) **(Ger)**
[Effects of anesthesia with inhalation anesthetics on excitation, conduction and refractory parameters of the heart. Experiments in dogs] Hahn N, et al. **Arzneimittelforschung** 1996 Mar;46(3):251–6 (Eng. Abstr.) **(Ger)**
[Minimal-flow anesthesia in the dog] Gantke S, et al. **Tierarztl Prax** 1997 Apr;25(2):156–63 (Eng. Abstr.) **(Ger)**
[Isoflurane anesthesia in rabbits in a closed anesthetic system] Henke J, et al. **Tierarztl Prax** 1996 Dec;24(6):604–9 (Eng. Abstr.) **(Ger)**
[Anesthesia with sevoflurane vs propofol in elective extracavity surgery] Cetica P, et al. **Minerva Anestesiol** 1997 Jan–Feb;63(1–2):47–56 (Eng. Abstr.) **(Ita)**
[The effect of low-dose prostaglandin E1 on serum and urinary fluoride concentrations in patients anesthetized with sevoflurane] Hayashida M, et al. **Masui** 1997 Jun; 46(6):736–42 (Eng. Abstr.) **(Jpn)**
[Effects of halothane and sevoflurane on reversal of neuromuscular blockade induced by vecuronium in man] Izawa H, et al. **Masui** 1997 Feb;46(2):177–83 (Eng. Abstr.) **(Jpn)**
[Evaluation of vaporizers by anesthetic gas monitors corrected with a new method for preparation of calibration gases] Kurashiki T. **Masui** 1996 Nov;45(11):1354–66 (Eng. Abstr.) **(Jpn)**
[Anesthetic management of a pediatric patient with Cornelia de Lange syndrome] Nagai H, et al. **Masui** 1996 Jan; 45(1):99–101 (Eng. Abstr.) **(Jpn)**
[Anesthetic management of a child with pheochromocytoma using sevoflurane, diltiazem and continuous epidural blockade] Takahashi K, et al. **Masui** 1996 Oct;45(10):1252–5 (Eng. Abstr.) **(Jpn)**
[The use of general anesthesia with Etran and a low flow of the medical gases during prolonged and traumatic operations] Likhvantsev VV, et al. **Anesteziol Reanimatol** 1996 May–Jun;(3):68–9 **(Rus)**
[The efficacy of using alpha-tocopherol during ftorotan anesthesia] Abidova SS, et al. **Eksp Klin Farmakol** 1996 Jul–Aug;59(4):3–4 (Eng. Abstr.) **(Rus)**
[Comparative study of recovery from general anesthesia with halothane or sevoflurane in pediatrics] Calderón E, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):272–5 (Eng. Abstr.) **(Spa)**
[Anesthesia in laparoscopic cholecystectomy with CO2: comparison of the hemodynamic and respiratory behavior using 2 different anesthetic techniques (see comments)] Rubio-Martínez CJ, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):12–6 (Eng. Abstr.). Comment in: Rev Esp Anestesiol Reanim 1996 Jun–Jul;43(6):227–8. **(Spa)**
[Narcosis 150 years ago and today. High efficiency for general anesthesia] Jonsson L. **Lakartidningen** 1996 Oct 30; 93(44):3897–902 **(Swe)**

ADMINISTRATION & DOSAGE

Prolonged isoflurane anesthesia in a case of catastrophic asthma. Miyagi T, et al. **Acta Paediatr Jpn** 1997 Jun; 39(3):375–8
Comparison of isoflurane, halothane and fentanyl in patients with decreased ejection fraction undergoing coronary surgery. Urzua J, et al. **Anaesth Intensive Care** 1996 Oct; 24(5):579–84
The estimation of inspired desflurane concentration in a low-flow system. Gowrie-Mohan S, et al. **Anaesthesia** 1996 Oct;51(10):904–7
Effects of a single pre-operative dexmedetomidine dose on isoflurane requirements and peri-operative haemodynamic stability. Lawrence CJ, et al. **Anaesthesia** 1997 Aug; 52(8):736–44
Factors affecting neostigmine reversal of vecuronium block during sevoflurane anaesthesia. Morita T, et al. **Anaesthesia** 1997 Jun;52(6):538–43
New agents, the circle system and short procedures. Nel MR, et al. **Anaesthesia** 1997 Apr;52(4):364–7
An alternative method of nitrous oxide delivery into a minimal-flow circle breathing system. Nel MR, et al. **Anaesthesia** 1997 Jan;52(1):57–61
Economics of low-flow anaesthesia in children [see comments] Perkins R, et al. **Anaesthesia** 1996 Dec; 51(12):1089–92. Comment in: Anaesthesia 1997 May;52(5):506–7.
Anaesthesia with the Boyle's bottle vaporizer [see comments] White SA, et al. **Anaesthesia** 1996 Oct;51(10):939–42. Comment in: Anaesthesia 1997 Apr;52(4):394.
Awakening, clinical recovery, and psychomotor effects after desflurane and propofol anesthesia. Apfelbaum JL, et al. **Anesth Analg** 1996 Oct;83(4):721–5
Immediate 8% sevoflurane induction in children: a comparison with incremental sevoflurane and incremental halothane. Baum VC, et al. **Anesth Analg** 1997 Aug; 85(2):313–6
A comparison of isoflurane versus fentanyl as primary anesthetics for mitral valve surgery. Howie MB, et al. **Anesth Analg** 1996 Nov;83(5):941–8
The effects of epidural fentanyl on hemodynamic responses during emergence from isoflurane anesthesia and tracheal extubation: a comparison with intravenous fentanyl. Inagaki Y, et al. **Anesth Analg** 1997 Aug;85(2):328–35
Multiple but different genetic factors underlie enflurane and isoflurane requirements studied through backcross analysis in C57BL and ddN mice. Kuratani N, et al. **Anesth Analg** 1996 Oct;83(4):798–803
Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2O–O2–opioid anesthesia. Lepage JY, et al. **Anesth Analg** 1996 Oct;83(4):823–9
Single breath induction technique: comparison of sevoflurane and isoflurane [letter; comment] Lewis MC, et al. **Anesth Analg** 1996 Oct;83(4):890–1. Comment on: Anesth Analg 1996 Mar;82(3):528–32.
May cardiovascular stability be achieved with both sevoflurane and desflurane? [letter; comment]

Martinez-Laborde FE. **Anesth Analg** 1996 Dec; 83(6):1351-2. Comment on: Anesth Analg 1995 Dec;81(6):1186-90.

Laser Doppler skin blood flow and sympathetic nervous responses to surgical incision during halothane and isoflurane anesthesia. Mashimo T, et al. **Anesth Analg** 1997 Aug;85(2):291-8

The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Wang B, et al. **Anesth Analg** 1997 Sep;85(3):675-80

Comparison of emergence and recovery characteristics of sevoflurane, desflurane, and halothane in pediatric ambulatory patients. Welborn LG, et al. **Anesth Analg** 1996 Nov;83(5):917-20

Reduction of the minimum alveolar concentration of isoflurane by dexmedetomidine. Aantaa R, et al. **Anesthesiology** 1997 May;86(5):1055-60

Effects of low-flow sevoflurane anesthesia on renal function: comparison with high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia [see comments] Bito H, et al. **Anesthesiology** 1997 Jun;86(6):1231-7. Comment in: Anesthesiology 1997 Jun;86(6):1225-7.

Minimum alveolar concentration of halothane and enflurane are decreased in early pregnancy. Chan MT, et al. **Anesthesiology** 1996 Oct;85(4):782-6

Effects of sevoflurane with and without nitrous oxide on human cerebral circulation. Transcranial Doppler study. Cho S, et al. **Anesthesiology** 1996 Oct;85(4):755-60

High carboxyhemoglobin concentrations occur in swine during desflurane anesthesia in the presence of partially dried carbon dioxide absorbents [see comments] Frink EJ Jr, et al. **Anesthesiology** 1997 Aug;87(2):308-16. Comment in: Anesthesiology 1997 Aug;87(2):202-3.

Effects of blood glucose changes and physostigmine on anesthetic requirements of halothane in rats. Ishizawa Y, et al. **Anesthesiology** 1997 Aug;87(2):354-60

Keep the blood red...the right way [editorial; comment] Kharasch ED. **Anesthesiology** 1997 Aug;87(2):202-3. Comment on: Anesthesiology 1997 Aug;87(2):228-34. Comment on: Anesthesiology 1997 Aug;87(2):308-16.

Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity [see comments] Kharasch ED, et al. **Anesthesiology** 1997 Jun;86(6):1238-53. Comment in: Anesthesiology 1997 Jun;86(6):1225-7.

Reduction of isoflurane minimal alveolar concentration by remifentanil. Lang E, et al. **Anesthesiology** 1996 Oct; 85(4):721-8

Low-flow (1 l/min) sevoflurane: is it safe? [editorial; comment] Mazze RI, et al. **Anesthesiology** 1997 Jun; 86(6):1225-7. Comment on: Anesthesiology 1997 Jun;86(6):1231-7. Comment on: Anesthesiology 1997 Jun;86(6):1238-53.

Nitric oxide synthase inhibitors, 7-nitro indazole and nitroG-L-arginine methyl ester, dose dependently reduce the threshold for isoflurane anesthesia. Pajewski TN, et al. **Anesthesiology** 1996 Nov;85(5):1111-9

The threshold for thermoregulatory vasoconstriction during nitrous oxide/sevoflurane anesthesia is lower in elderly than in young patients. Ozaki M, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:789-91

Minimum alveolar concentration of desflurane for tracheal extubation in deeply anaesthetized, unpremedicated children. Cranfield KA, et al. **Br J Anaesth** 1997 Apr; 78(4):370-1

Quantitative study of Lowe's square-root-of-time method of closed-system anaesthesia. da Silva JM, et al. **Br J Anaesth** 1997 Jul;79(1):103-12

Occupational exposure to desflurane and isoflurane during cardiopulmonary bypass: is the gas outlet of the membrane oxygenator an operating theatre pollution hazard? Hoerauf K, et al. **Br J Anaesth** 1997 Apr;78(4):378-80

Fuzzy logic control of inspired volatile anaesthetic concentrations [letter; comment] Wissing H, et al. **Br J Anaesth** 1996 Dec;77(6):807-8. Comment on: Br J Anaesth 1996 Feb;76(2):245-50.

Output from a Drager Vapor 19.1 on a moving trolley [letter] Garden AL, et al. **Can J Anaesth** 1997 Feb;44(2):227-8

Xenon is another laughing gas [letter] Kawaguchi T, et al. **Can J Anaesth** 1996 Jun;43(6):641-2

Echocardiographic assessment of left ventricular filling during isoflurane anaesthesia. Oxorn D, et al. **Can J Anaesth** 1996 Jun;43(6):569-74

Halothane consumption under varying breathing circuit designs. Wambani JO. **East Afr Med J** 1996 Dec; 73(12):827-9

Which volatile setting for sevoflurane? [letter] Gaspar L, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):535

Nitrous oxide reduces the cost of intravenous anaesthesia. Heath KJ, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):369-72

Nitrous oxide inhalation as an adjunct to intravenous induction of general anaesthesia with propofol for day surgery. Johnson GW, et al. **Eur J Anaesthesiol** 1997 May; 14(3):295-9

Dose-response and concentration-response relation of rocuronium infusion during propofol-nitrous oxide and isoflurane-nitrous oxide anaesthesia. Kansanaho M, et al. **Eur J Anaesthesiol** 1997 Sep;14(5):488-94

Role of adenosine in the ethanol-induced potentiation of the effects of general anesthetics in rats. Campisi P, et al. **Eur J Pharmacol** 1997 May 1;325(2-3):165-72

Drawover vaporizers for sedation in intensive care. McIndoe AK, et al. **Intensive Care Med** 1997 Jun;23(6):704-7

Reduction of infarct volume by halothane: effect on cerebral blood flow or perifocal spreading depression-like depolarizations. Saito R, et al. **J Cereb Blood Flow Metab** 1997 Aug;17(8):857-64

A phase III, multicenter, open-label, randomized, comparative study evaluating the effect of sevoflurane versus isoflurane on the maintenance of anesthesia in adult ASA class I, II, and III inpatients. Campbell C, et al. **J Clin Anesth** 1996 Nov;8(7):557-63

The minimum alveolar concentration (MAC) of sevoflurane with and without nitrous oxide in elderly versus young adults. Fragen RJ, et al. **J Clin Anesth** 1996 Aug;8(5):352-6

Prolonged respiratory depression after anesthesia for parathyroidectomy in a patient with juvenile type of acid maltase deficiency [letter] Kotani N, et al. **J Clin Anesth** 1996 Nov;8(7):620

A comparison: the efficacy of sevoflurane-nitrous oxide or propofol-nitrous oxide for the induction and maintenance of general anesthesia. Lien CA, et al. **J Clin Anesth** 1996 Dec;8(8):639-43

Vital capacity induction with sevoflurane in adult surgical patients [letter] Philip BK, et al. **J Clin Anesth** 1996 Aug; 8(5):426

The copper kettle: a historical perspective. Sands RP Jr, et al. **J Clin Anesth** 1996 Sep;8(6):528-32

Postoperative analgesia and intraoperative inhalational anesthetic requirements during umbilical herniorrhaphy in children: postincisional local infiltration versus preincisional caudal epidural block. Tobias JD. **J Clin Anesth** 1996 Dec;8(8):634-8

Linear approximation of Brody's equation to predict oxygen consumption [letter; comment] Kennedy R. **J Clin Monit** 1996 Jan;12(1):111-2. Comment on: J Clin Monit 1995 May;11(3):165-7.

New anesthetic requires new vaporizers for safety [news] Petty WC. **J Clin Monit** 1996 Nov;12(6):483

Propofol vs isoflurane for neurosurgical anesthesia in Thai patients. Ittichaikulthol W, et al. **J Med Assoc Thai** 1997 Jul;80(7):454-60

Dose-sparing effects of romifidine premedication for thiopentone and halothane anaesthesia in the dog. England GC, et al. **J Small Anim Pract** 1997 Apr;38(4):141-6

A method for long duration anaesthesia for a new hindlimb ischaemia-reperfusion model in mice. Wiersema AM, et al. **Lab Anim** 1997 Apr;31(2):151-6

Increased anesthetic requirements for isoflurane, halothane, enflurane and desflurane in obese Zucker rats are associated with insulin-induced stimulation of plasma membrane Ca(2+)-ATPase. Janicki PK, et al. **Life Sci** 1996; 59(17):PL269-75

The hemodynamic effects of isoflurane before and after sternotomy in patients undergoing coronary artery bypass grafting. Baraka A, et al. **Middle East J Anesthesiol** 1995 Oct;13(3):307-14

Sevoflurane concentration available from the universal drawover vaporizer. Pylman ML, et al. **Mil Med** 1997 Jun; 162(6):405-6

A comparison of thiopentone-isoflurane anaesthesia vs propofol infusion in children having repeat minor haematological procedures. Harling DW, et al. **Paediatr Anaesth** 1997;7(1):19-23

Effects of nitrous oxide on diazepam sedation of young children. Houpt MI, et al. **Pediatr Dent** 1996 May-Jun; 18(3):236-41

A survey of the American Academy of Pediatric Dentistry membership: nitrous oxide and sedation. Wilson S. **Pediatr Dent** 1996 Jul-Aug;18(4):287-93

Halothane and cardiac autonomic control in infants: assessment with quantitative respiratory sinus arrhythmia. Oberlander TF, et al. **Pediatr Res** 1996 Nov;40(5):710-7

Halothane administration during liquid ventilation. Kimless-Garber DB, et al. **Respir Med** 1997 May; 91(5):255-62

[A case of bronchial asthma for whose status asthmaticus an anticholinergic drug was effective in weaning from inhaled anesthesia] Takizawa T, et al. **Arerugi** 1997 Apr; 46(4):391-4 **(Jpn)**

[Sevoflurane inhalation reduced bronchospasm after extubation] Hamanaka N, et al. **Masui** 1996 Sep; 45(9):1131-4 (Eng. Abstr.) **(Jpn)**

[Anesthesia for bilateral volume reduction surgery in a patient with severe bullous emphysema] Ito T, et al. **Masui** 1996 Nov;45(11):1410-2 (Eng. Abstr.) **(Jpn)**

[Enzyme saturation of sevoflurane in piglets at clinically-used concentrations] Kadota Y, et al. **Masui** 1996 Feb; 45(2):167-72 (Eng. Abstr.) **(Jpn)**

[Status asthmaticus treated with inhaled isoflurane and intravenous isoproterenol] Nakahara Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 May; 35(5):536-40 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Postoperative seizure-like activity following sevoflurane anesthesia. Terasako K, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):953-4

Isoflurane hepatotoxicity: a case report and review of the literature. Sinha A, et al. **Am J Gastroenterol** 1996 Nov; 91(11):2406-9 (12 ref.)

Acute hepatitis following enflurane anaesthesia. Reeves M. **Anaesth Intensive Care** 1997 Feb;25(1):80-2

Fatal hepatic necrosis following cardiac surgery and enflurane anaesthesia [letter; comment] Schneider M. **Anaesth Intensive Care** 1996 Apr;24(2):289. Comment on: Anaesth Intensive Care 1995 Dec;23(6):755-6.

Tachypnoea following vital capacity induction with sevoflurane [letter] Hall JE, et al. **Anaesthesia** 1996 Sep; 51(9):890

Adverse response to sevoflurane induction followed by enflurane maintenance [letter] MacLeod A, et al. **Anaesthesia** 1997 Jun;52(6):603-4

Criticism of Hartung's analysis [letter; comment] Allen IE, et al. **Anesth Analg** 1997 May;84(5):1169-70. Comment on: Anesth Analg 1996 Jul;83(1):4-5. Comment on: Anesth Analg 1996 Jul;83(1):114-6.

There is no evidence of sevoflurane nephrotoxicity [letter; comment] DeSouza GJ, et al. **Anesth Analg** 1997 Mar; 84(3):700. Comment on: Anesth Analg 1996 Jun;82(6):1268-72.

Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers. Eger EI 2nd, et al. **Anesth Analg** 1997 Jan; 84(1):160-8

Fading of a port-wine stain associated with sevoflurane anesthesia. Emhardt JD, et al. **Anesth Analg** 1997 Apr; 84(4):929-30

A case of suspected malignant hyperthermia during desflurane administration. Michalek-Sauberer A, et al. **Anesth Analg** 1997 Aug;85(2):461-2

If nitrous oxide induces emesis, maybe 100% oxygen is an antiemetic [letter; comment] Overdyk FJ, et al. **Anesth Analg** 1997 Jan;84(1):231-2. Comment on: Anesth Analg 1996 Jul;83(1):4-5. Comment on: Anesth Analg 1996 Jul;83(1):114-6.

Omission of nitrous oxide during anesthesia reduces the incidence of postoperative nausea and vomiting. A meta-analysis. Divatia JV, et al. **Anesthesiology** 1996 Nov; 85(5):1055-62

Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity [see comments] Kharasch ED, et al. **Anesthesiology** 1997 Jun;86(6):1238-53. Comment in: Anesthesiology 1997 Jun;86(6):1225-7.

Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats. Kharasch ED, et al. **Anesthesiology** 1997 Jan;86(1):160-71

Generalized seizures associated with nitrous oxide in an infant. Lannes M, et al. **Anesthesiology** 1997 Sep;87(3):705-8

Low-flow (1 l/min) sevoflurane: is it safe? [editorial; comment] Mazze RI, et al. **Anesthesiology** 1997 Jun; 86(6):1225-7. Comment on: Anesthesiology 1997 Jun;86(6):1231-7. Comment on: Anesthesiology 1997 Jun;86(6):1238-53.

Malignant hyperthermia induced by general anesthesia for bone marrow harvesting. Hosoya N, et al. **Bone Marrow Transplant** 1997 Mar;19(5):509-11

Sevoflurane [letter; comment] Daniel M. **Br J Anaesth** 1996 Aug;77(2):294-5. Comment on: Br J Anaesth 1996 Mar;76(3):435-45.

Hazards of nitrous oxide exposure [letter] Girdler NM. **Br J Hosp Med** 1996 Nov 6-19;56(9):488

Humidification reduces coughing and breath-holding during inhalation induction with isoflurane in children. Cregg N, et al. **Can J Anaesth** 1996 Nov;43(11):1090-4

Malignant hyperthermia involving the administration of desflurane. Fu ES, et al. **Can J Anaesth** 1996 Jul; 43(7):687-90

Untoward risk of nitrous oxide in hair transplantation surgery--or any other surgery [letter] Field LM. **Dermatol Surg** 1997 Sep;23(9):847

Comparative tolerability profiles of the inhaled anaesthetics. Fee JP, et al. **Drug Saf** 1997 Mar;16(3):157-70 (158 ref.)

Hepatic injury associated with halogenated anaesthetics: cross-sensitization and its clinical implications. Mikatti NE, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):7-14 (57 ref.)

Marked increases in heart rate associated with sevoflurane but not with halothane following suxamethonium administration in children. Rieger A, et al. **Eur J Anaesthesiol** 1996 Nov;13(6):616-21

Differential diagnosis of postoperative liver failure in a 12-year-old child. Hausmann R, et al. **Int J Legal Med** 1996;109(4):210-2

Nitrous oxide safety [letter] Johnsen KG. **J Am Dent Assoc** 1997 Aug;128(8):1066-7

Speaking for itself: the doctrine of res ipsa loquitur in a case of pediatric anesthesia. Liang BA, et al. **J Clin Anesth** 1996 Aug;8(5):398-401

Effects of sevoflurane anaesthesia on renal function. Nishimori A, et al. **J Int Med Res** 1997 Mar-Apr; 25(2):87-91

Rapid increase in inspired desflurane concentration does not elicit a hyperdynamic circulatory response in the pig. Karzai W, et al. **Lab Anim** 1997 Jul;31(3):279-82

Orbital bleeding in rats while under diethylether anaesthesia does not influence telemetrically determined heart rate, body temperature, locomotor and eating activity when compared with anaesthesia alone. Van Herck H, et al. **Lab Anim** 1997 Jul;31(3):271-8

Desflurane and the sensitivity of upper airway reflexes. Park GR. **Middle East J Anesthesiol** 1995 Oct;13(3):281-9

Hazards of nitrous oxide administration in presence of venous air embolism. Sibai AN, et al. **Middle East J Anesthesiol** 1996 Oct;13(6):565-71

Risk of spontaneous abortion in women occupationally exposed to anaesthetic gases: a meta-analysis. Boivin JF.

Occup Environ Med 1997 Aug;54(8):541–8

Hyperthermia during sevoflurane anaesthesia in arthrogryposis multiplex congenita with central nervous system dysfunction [letter] Kanaya N, et al. **Paediatr Anaesth** 1996;6(5):428–9

Anisocoria during isoflurane anaesthesia in a six-year-old girl. Kuhn I, et al. **Paediatr Anaesth** 1996;6(5):411–3

Pulmonary microvascular injury following general anaesthesia with volatile anaesthetics—halothane and isoflurane: a comparative clinical and experimental study. Gunaydin B, et al. **Respir Med** 1997 Jul;91(6):351–60

[Environmental and work site contamination in anesthesia] Marx T.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Jan; 32(1):44–6 **(Ger)**

[Behm's T-piece for reducing anesthesia gas pollution at the anesthesia work site] Salomon F, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Sep; 31(7):425–6 (Eng. Abstr.) **(Ger)**

[N2O-induced acute funicular myelosis in latent vitamin B 12 deficiency] Takács J.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Oct; 31(8):525–8 (Eng. Abstr.) **(Ger)**

[Exposure to anesthetic gases at the work site (comment)] Hogrefe G, et al. **HNO** 1996 Oct;44(10):554–5. Comment on: HNO 1996 Oct;44(10):567–71. **(Ger)**

[Sevoflurane comparably decreases the threshold for thermoregulatory vasoconstriction as isoflurane] Atarashi K, et al. **Masui** 1996 Jul;45(7):818–23 (Eng. Abstr.) **(Jpn)**

[Involvement of enhanced glutamate release in halogenated volatile anesthetic-induced excitation in mouse brain] Hirose T, et al. **Masui** 1997 Mar;46(3):338–43 (Eng. Abstr.) **(Jpn)**

[Relationship among the heart, vasculature and blood volume at perioperative period: the influence of volatile anesthetics] Hoka S. **Masui** 1996 Jun;45(6):707–16 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Rhabdomyolysis induced by succinylcholine chloride and sevoflurane in an elderly man] Takamatsu F, et al.
Masui 1996 Nov;45(11):1406–9 (Eng. Abstr.) **(Jpn)**

[Hepatologic parameters in health personnel after several years of occupational exposure to anesthetic gases] Prokeš B. **Med Pregl** 1997 Mar–Apr;50(3–4):103–7 (Eng. Abstr.) **(Scr)**

[Atypical malignant hyperthermia. A higher incidence than expected (letter)] Herrero E, et al.
Rev Esp Anestesiol Reanim 1996 Jan;43(1):42–3 **(Spa)**

[Safety of sevoflurane in humans (letter; comment)] Martínez A, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):78–9 . Comment on: Rev Esp Anestesiol Reanim 1995 Feb;42(2):77–8. **(Spa)**

ANALYSIS

Occupational exposure to sevoflurane, halothane and nitrous oxide during paediatric anaesthesia. Waste gas exposure during paediatric anaesthesia [see comments] Hoerauf K, et al. **Anaesthesia** 1997 Mar;52(3):215–9. Comment in: Anaesthesia 1997 Jul;52(7):714.

Halothane or halitosis? [letter] Scott PV. **Anaesthesia** 1997 Aug;52(8):811

Occupational exposure to inhalational anaesthetics [letter; comment] Sweeney B. **Anaesthesia** 1997 Jul;52(7):714. Comment on: Anaesthesia 1997 Mar;52(3):215–9.

Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses. Inagaki Y, et al. **Anesth Analg** 1997 Jan;84(1):100–5

Waste anesthetic nitrous oxide suspected to be frequent contaminant in medical practices worldwide [letter] Chang WP, et al. **Arch Environ Health** 1997 Mar–Apr;52(2):149

Simple method for simultaneous determination of halothane, enflurane, and isoflurane in Krebs solution using capillary gas chromatography. Farthing D, et al.
Biomed Chromatogr 1997 Jan–Feb;11(1):29–32

Isoflurane waste gas exposure during general anaesthesia: the laryngeal mask compared with tracheal intubation. Hoerauf KH, et al. **Br J Anaesth** 1996 Aug;77(2):189–93

Safety issues and volatile agent analysers [letter; comment] Shirley PJ. **Br J Anaesth** 1997 Jun;78(6):773–4. Comment on: Br J Anaesth 1997 Jan;78(1):107–8.

Ether in an isoflurane vaporizer and the use of vapour analysers in safe anaesthesia [see comments] Strachan AN, et al. **Br J Anaesth** 1997 Jan;78(1):107–8. Comment in: Br J Anaesth 1997 Jun;78(6):773–4. Comment in: Br J Anaesth 1997 Jun;78(6):774.

Occupational exposure to sevoflurane and nitrous oxide in operating room personnel. Hoerauf KH, et al.
Int Arch Occup Environ Health 1997;69(2):134–8

Can the "old" vapor monitors measure new vapor anesthetics? [letter] Gyermek L. **J Clin Anesth** 1997 Mar;9(2):171–2

Effects of gas flow management on postintubation end-tidal anesthetic concentration and operating room pollution. Siker D, et al. **J Clin Anesth** 1997 May;9(3):228–32

Focal heat stimulation for the determination of the minimum alveolar concentration of halothane in the rabbit. Sobair AT, et al. **Vet Res Commun** 1997 Apr;21(3):149–59

[The effect of anesthetic method on enflurane air pollution in non-air conditioned operating rooms] Marx T, et al. **Anaesthesist** 1996 Dec;45(12):1167–70 (Eng. Abstr.) **(Ger)**

[Reclaiming volatile and gaseous anesthetics] Bäder S, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Jan; 32(1):46–8 **(Ger)**

[Effectiveness of anesthetic gas scavengers fulfilling EN 740 requirements with reference to equipment leakage and fresh gas flow] Marx T, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1997 Feb; 32(2):101–4 (Eng. Abstr.) **(Ger)**

[Exposure of operating room personnel to anesthetic gases during ENT interventions (see comments)] Hoerauf K, et al. **HNO** 1996 Oct;44(10):567–71 (Eng. Abstr.). Comment in: HNO 1996 Oct;44(10):554–5. **(Ger)**

[Evaluation of a protocol of health surveillance for the personnel exposed to inhalation anesthetics in a sample of 3 operating rooms] Domenegati E, et al.
Minerva Anestesiol 1996 Sep;62(9):297–305 (Eng. Abstr.) **(Ita)**

[A study of waste anesthetic gases monitoring and working environmental controls in hospital operating rooms] Koda S, et al. **Sangyo Eiseigaku Zasshi** 1997 Jan;39(1):38–45 (Eng. Abstr.) **(Jpn)**

[Effect of acute intestinal obstruction on infrared systems for measuring anesthetic gases (letter)] Martinéz A, et al.
Rev Esp Anestesiol Reanim 1996 Feb;43(2):74 **(Spa)**

BLOOD

A new method for measurement of anaesthetic partial pressure in blood. Smith MA, et al. **Br J Anaesth** 1997 Apr;78(4):449–52

CHEMISTRY

The loss of sevoflurane from a closed breathing system. Vagts DA, et al. **Anaesthesia** 1997 Jul;52(7):636–9

Compound A: solubility in saline and olive oil; destruction by blood. Eger EI 2nd, et al. **Anesth Analg** 1996 Oct; 83(4):849–53

The saturated vapor pressure of desflurane at various temperatures. Susay SR, et al. **Anesth Analg** 1996 Oct; 83(4):864–6

Rehydration of desiccated Baralyme prevents carbon monoxide formation from desflurane in an anesthesia machine. Baxter PJ, et al. **Anesthesiology** 1997 May; 86(5):1061–5

Sevoflurane degradation to compound A in anaesthesia breathing systems. Cunningham DD, et al.
Br J Anaesth 1996 Oct;77(4):537–43

The dehydrofluorinated product of sevoflurane by soda lime reacts with ethanol to produce two products. Fujü K, et al. **Drug Metabol Drug Interact** 1996;13(2):137–44

Approach to the thermodynamics of enantiomer separation by gas chromatography. Enantioselectivity between the chiral inhalation anesthetics enflurane, isoflurane and desflurane and a diluted gamma-cyclodextrin derivative. Schurig V, et al. **J Chromatogr A** 1997 Jan 3; 757(1–2):119–35

[Degradation of halothane, enflurane, and isoflurane by dry soda lime to give carbon monoxide] Strauss JM, et al.
Anaesthesist 1996 Sep;45(9):798–801 (Eng. Abstr.) **(Ger)**

[Production of carbon monoxide in soda lime (letter) (see comments)] Ponz L. **Rev Esp Anestesiol Reanim** 1996 Jan; 43(1):42. Comment in: Rev Esp Anestesiol Reanim 1996 Aug;Sep;43(7):261–2. **(Spa)**

ECONOMICS

Cost of volatile anaesthetic agents [letter; comment] Daniel M. **Br J Anaesth** 1996 Sep;77(3):437. Comment on: Br J Anaesth 1996 May;76(5):749.

The economics of using isoflurane in small animal practice. Harasen GL. **Can Vet J** 1996 Aug;37(8):498

Total intravenous or inhalational anaesthesia--a cost comparison [letter] Blaine EM. **S Afr Med J** 1996 Dec; 86(12):1564–6

Total intravenous or inhalational anaesthesia--a cost comparison [letter] Garratt RM. **S Afr Med J** 1997 Jun; 87(6):772–3

[Economic aspects of modern inhalation anesthetics with sevoflurane as an example] Bach A, et al. **Anaesthesist** 1997 Jan;46(1):21–8 (Eng. Abstr.) **(Ger)**

HISTORY

Towards a new chronology of ether anesthesia in Europe. Franco A, et al. **Acta Anaesthesiol Belg** 1997;48(2):107–9

James Young Simpson, 1811–1870. Ball C.
Anaesth Intensive Care 1996 Dec;24(6):639

150 years of ether anaesthesia and what is next? [editorial] Wilkinson DJ. **Anaesthesia** 1996 Dec;51(12):1087–8

The "Dumfries claim" [letter; comment] Baillie TW.
Br J Anaesth 1997 Jun;78(6):777–8. Comment on: Br J Anaesth 1996 Dec;77(6):705–6.

Ether anaesthesia comes to London. December 1846 [editorial] [see comments] Spence AA. **Br J Anaesth** 1996 Dec;77(6):705–6. Comment in: Br J Anaesth 1997 Jun;78(6):777–8.

America's greatest medical discovery: 150 years later, who gets the credit? Rutledge RH. **J Am Coll Surg** 1996 Dec; 183(6):625–36

Ether Day and the first ether anaesthetics in South Africa. Haridas RP. **S Afr J Surg** 1997 May;35(2):54–8

[The 150th anniversary of of he birth of anesthesia (editorial)] Lassner J. **Cah Anesthesiol** 1996;44(5):397–401 **(Fre)**

[The discovery of surgical anesthesia and its arrival in Europe. Apropos of the 150th anniversary of the clinical introduction of ether] Franco A, et al.
Rev Esp Anestesiol Reanim 1996 Oct;43(8):281–7 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Preparative enantiomer separation of the inhalation anesthetics enflurane, isoflurane and desflurane by gas chromatography on a derivatized gamma-cyclodextrin stationary phase. Juza M, et al. **J Chromatogr A** 1997 May 2;769(1):119–27

METABOLISM

Carboxyhemoglobin concentrations during desflurane and isoflurane closed-circuit anesthesia. Hendrickx JF, et al.
Acta Anaesthesiol Belg 1996;47(2):67–72

Metabolic characteristics and enflurane defluorination of cytochrome P450-dependent monooxygenases in human hepatocellular carcinoma. Chen TL, et al.
Acta Anaesthesiol Sin 1997 Mar;35(1):7–14

Baralyme dehydration increases and soda lime dehydration decreases the concentration of compound A resulting from sevoflurane degradation in a standard anesthetic circuit. Eger EI 2nd, et al. **Anesth Analg** 1997 Oct;85(4):892–8

The relationship between cytochrome P4502E1 activity and plasma fluoride levels after sevoflurane anesthesia in humans. Wandel C, et al. **Anesth Analg** 1997 Oct; 85(4):924–30

Compound A concentrations during sevoflurane anesthesia in children depend on fresh gas flow [letter; comment] Aldrete JA. **Anesthesiology** 1996 Sep;85(3):684. Comment on: Anesthesiology 1996 Mar;84(3):566–71.

P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product. Kharasch ED, et al. **Drug Metab Dispos** 1996 Jun; 24(6):649–54

Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Spracklin DK, et al.
Drug Metab Dispos 1996 Sep;24(9):976–83

Binding of the volatile anesthetic halothane to the hydrophobic core of a tetra-alpha-helix-bundle protein. Johansson JS, et al. **J Pharmacol Exp Ther** 1996 Oct; 279(1):56–61

Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. Spracklin DK, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):400–11

The effect of epidural xylazine on halothane minimum alveolar concentration in ponies. Doherty TJ, et al.
J Vet Pharmacol Ther 1997 Jun;20(3):246–8

Reductive metabolism of halothane by cytochrome P450 isoforms in rats and humans. Chow T, et al.
Res Commun Mol Pathol Pharmacol 1996 Sep;93(3):363–74

[Carbon monoxide can be generated from halogenated anesthetics in connection with dry soda lime] Jørgensen BC. **Ugeskr Laeger** 1997 Jan 20;159(4):445–7 **(Dan)**

PHARMACOKINETICS

Minimum alveolar concentration of sevoflurane for tracheal extubation in children. Higuchi H, et al.
Acta Anaesthesiol Scand 1997 Aug;41(7):911–3

Comparison of the respiratory and systemic kinetics of nitrous oxide in the sheep. Reid MA, et al.
Acta Anaesthesiol Scand 1996 Aug;40(7):809–14

Sevoflurane induction and difficult airway management [letter] [see comments] Fenlon S, et al. **Anaesthesia** 1997 Mar;52(3):285–6. Comment in: Anaesthesia 1997 Jul;52(7):710.

Uptake of desflurane [letter; comment] Lin CY.
Anaesthesia 1997 May;52(5):502–3. Comment on: Anaesthesia 1996 Jan;51(1):33–36.

A non-rebreathing coaxial anaesthesia system: dependence of end-tidal gas concentrations on fresh gas flow and tidal volume. Tweed WA. **Anaesthesia** 1997 Mar;52(3):237–41

Context-sensitive half-times and other decrement times of inhaled anesthetics. Bailey JM. **Anesth Analg** 1997 Sep; 85(3):681–6

Minimum alveolar anesthetic concentration values for the enantiomers of isoflurane differ minimally. Eger EI 2nd, et al. **Anesth Analg** 1997 Jul;85(1):188–92

Complexities overlooked: things may not be what they seem [editorial; comment] Eger EI 2nd. **Anesth Analg** 1997 Feb; 84(2):239–40. Comment on: Anesth Analg 1997 Feb;84(2):413–8.

Maturation decreases ethanol minimum alveolar anesthetic concentration in mice as previously demonstrated in rats: there is no species difference. Fang Z, et al.
Anesth Analg 1997 Jul;85(1):160–3

Uptake of desflurane and isoflurane during closed-circuit anesthesia with spontaneous and controlled mechanical ventilation [see comments] Hendrickx JF, et al.
Anesth Analg 1997 Feb;84(2):413–8. Comment in: Anesth Analg 1997 Feb;84(2):239–40.

Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Njoku D, et al. **Anesth Analg** 1997 Jan;84(1):173–8

Area under the compound A concentration curve (compound A AUC) analysis [letter] Bito H, et al. **Anesthesiology** 1997 Sep;87(3):715–6

Minimum alveolar concentration of halothane and enflurane are decreased in early pregnancy. Chan MT, et al. **Anesthesiology** 1996 Oct;85(4):782–6

Recovery and kinetic characteristics of desflurane and sevoflurane in volunteers after 8–h exposure, including kinetics of degradation products. Eger EI 2nd, et al. **Anesthesiology** 1997 Sep;87(3):517–26

Cysteine conjugate beta–lyase–dependent biotransformation of the cysteine S–conjugates of the sevoflurane degradation product compound A in human, nonhuman primate, and rat kidney cytosol and mitochondria. Iyer RA, et al. **Anesthesiology** 1996 Dec;85(6):1454–61

Reduction of isoflurane minimal alveolar concentration by remifentanil. Lang E, et al. **Anesthesiology** 1996 Oct; 85(4):721–8

Concentration and second gas effects: can the accepted explanation be improved? Korman B, et al. **Br J Anaesth** 1997 May;78(5):618–25 (37 ref.)

Low and minimal flow inhalational anaesthesia. Baxter AD. **Can J Anaesth** 1997 Jun;44(6):643–52; quiz 652–3

Determination of end–tidal sevoflurane concentration for tracheal intubation in children with the rapid method. Inomata S, et al. **Can J Anaesth** 1996 Aug;43(8):806–11

Intrathecally administered NMDA receptor antagonists reduce the MAC of isoflurane in rats. Ishizaki K, et al. **Can J Anaesth** 1996 Jul;43(7):724–30

Intrathecal neurokinin–1 receptor antagonist reduces isoflurane MAC in rats [see comments] Ishizaki K, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):543–9. Comment in: Can J Anaesth 1997 May;44(5 Pt 1):457–62.

Adsorption of inhalational anesthetics and hydrochlorofluorocarbons on activated carbons as a biological model. Tanada S, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb;45(2):231–5

The minimum alveolar concentration of sevoflurane in rats. Kashimoto S, et al. **Eur J Anaesthesiol** 1997 Jul; 14(4):359–61

Influence of closed head injury on isoflurane MAC in the rat. Shapira Y, et al. **J Neurosurg Anesthesiol** 1997 Jan; 9(1):51–7

Characterization of the cerebral distribution of general anesthetics in vivo by two–dimensional 19F chemical shift imaging. Venkatasubramanian PN, et al. **Magn Reson Med** 1996 Apr;35(4):626–30

Clinical characteristics and biotransformation of sevoflurane in paediatric patients during antiepileptic drug therapy. Komatsu H, et al. **Paediatr Anaesth** 1996;6(5):379–82

[Adsorption of volatile anesthetics on activated charcoal. Efficiency of an experimental filter during low–flow circuit ventilation] Romano E, et al. **Minerva Anestesiol** 1995 Oct; 61(10):437–40 (Eng. Abstr.) **(Ita)**

[Simple, practical closed–circuit anesthesia] Lin CY. **Masui** 1997 Apr;46(4):498–505 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of nitrous oxide at sub–MAC concentrations on sevoflurane MAC in adults] Nakahara T, et al. **Masui** 1997 May;46(5):607–12 (Eng. Abstr.) **(Jpn)**

[Do the new volatile anesthetics approximate the ideal anesthetic?] Coriat P. **Rev Esp Anestesiol Reanim** 1996 Aug–Sep;43(7):233–4 **(Spa)**

PHARMACOLOGY

Hemodynamic, sympathetic and angiotensin II responses to PEEP ventilation before and during administration of isoflurane. Aneman A, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 1):41–8

Effect of temperature variation (22 degrees C–44 degrees C) on halothane and caffeine contracture testing in normal humans. Antognini JF, et al. **Acta Anaesthesiol Scand** 1997 May;41(5):639–42

Effects of volatile anesthetics on the calcium ionophore A23187–mediated alterations in hepatic flow and metabolism in the perfused liver in fasted rats. Araki M, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 1):55–61

Cardiovascular effects of desflurane and isoflurane in patients with coronary artery disease. Grundmann U, et al. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1101–7

In vivo effects of halothane, enflurane, and isoflurane on hepatic sinusoidal microcirculation. Grundmann U, et al. **Acta Anaesthesiol Scand** 1997 Jun;41(6):760–5

Haemodynamics during inhalation of a 50% nitrous–oxide–in–oxygen mixture with and without hypovolaemia. Hahn RG, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):485–91

Effects of halothane and isoflurane on left ventricular diastolic function during surgical stress in patients with coronary artery disease. Houltz E, et al. **Acta Anaesthesiol Scand** 1997 Aug;41(7):931–8

Effects of halothane, isoflurane and sevoflurane on ischemia–reperfusion injury in the perfused liver of fasted rats. Imai M, et al. **Acta Anaesthesiol Scand** 1996 Nov; 40(10):1242–8

The influence of the duration of isoflurane anaesthesia on neuromuscular effects of mivacurium. Jalkanen L, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):248–51

The effect of halothane on mivacurium infusion requirements in adult surgical patients. Kansanaho M, et al. **Acta Anaesthesiol Scand** 1997 Jun;41(6):754–9

Hepatic energy charge and adenine nucleotide status in rats anesthetized with halothane, isoflurane or enflurane. Mets B, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):252–5

Blockade of ATP–sensitive K+ channel abolishes the anti–ischemic effects of isoflurane in dog hearts. Nakayama M, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):531–5

alpha 1–adrenoceptor stimulation is able to reverse halothane–induced cardiac depression in isolated rat hearts. Okuyama T, et al. **Acta Anaesthesiol Scand** 1997 Aug; 41(7):939–44

Nitrous oxide has different effects on the EEG and somatosensory evoked potentials during isoflurane anaesthesia in patients. Porkkala T, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):497–501

Hemodilution significantly decreases tolerance to isoflurane–induced cardiovascular depression. Schou H, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):218–28

Peroperative adenosine infusion reduces isoflurane concentrations during general anesthesia for shoulder surgery. Segerdahl M, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):792–7

Effects of desflurane on systemic, preportal and renal circulatory responses to infra–renal aortic cross–clamping in the pig. Sundeman H, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):876–82

Different effects of halothane, isoflurane and sevoflurane on sarcoplasmic reticulum of vascular smooth muscle in dog mesenteric artery. Yamamoto M, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):376–80

The interaction between nitrous oxide and isoflurane on suppression of learning: a study using classical conditioning in rabbits. El–Zahaby HM, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):798–803

Effects of halothane, isoflurane and sevoflurane on calcium–related contraction in porcine coronary arteries. Zhang XP, et al. **Acta Anaesthesiol Scand** 1996 Aug; 40(7):815–9

Comparison of sevoflurane with halothane in pediatric ambulatory anesthesia: an experience in Taiwan. Chong ZK, et al. **Acta Anaesthesiol Sin** 1997 Mar;35(1):21–4

Priming technique accelerates the onset time of mivacurium in children during halothane anesthesia. Chu YC, et al. **Acta Anaesthesiol Sin** 1997 Mar;35(1):15–20

Is desflurane a better inhalational anesthetic for our health insurance? [editorial] Wong CS. **Acta Anaesthesiol Sin** 1997 Jun;35(2):i–ii

The effect of chronic nicotine and its withdrawal on ED50 inspired halothane requirement in rats. Yang CY, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):73–7

Effects of inhalation anesthetics on parasympathetic reflex vasodilation in the lower lip and palate of the cat. Izumi H, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R168–74

Effects of sevoflurane on inward rectifier K+ current in guinea pig ventricular cardiomyocytes. Stadnicka A, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H324–32

Cardiopulmonary effects of sevoflurane, compared with halothane, enflurane, and isoflurane, in dogs. Mutoh T, et al. **Am J Vet Res** 1997 Aug;58(8):885–90

Effects of halothane and sevoflurane on the electroretinogram of dogs. Yanase J, et al. **Am J Vet Res** 1997 Aug;58(8):904–9

Temporal effects of an infusion of dopexamine hydrochloride in horses anesthetized with halothane. Young LE, et al. **Am J Vet Res** 1997 May;58(5):516–23

Blood loss during suction termination of pregnancy with two different anaesthetic techniques. Kumarasinghe N, et al. **Anaesth Intensive Care** 1997 Feb;25(1):48–50

Serum glutathione S–transferase concentrations and creatinine clearance after sevoflurane anaesthesia. Darling JR, et al. **Anaesthesia** 1997 Feb;52(2):121–6

The effects of desflurane on splanchnic hemodynamics and oxygenation in the anesthetized pig. Armbruster K, et al. **Anesth Analg** 1997 Feb;84(2):271–7

Intracranial pressure, middle cerebral artery flow velocity, and plasma inorganic fluoride concentrations in neurosurgical patients receiving sevoflurane or isoflurane. Artru AA, et al. **Anesth Analg** 1997 Sep;85(3):587–92

Systemic vascular effects of isoflurane versus propofol anesthesia in dogs [see comments] Deryck YL, et al. **Anesth Analg** 1996 Nov;83(5):958–64. Comment in: Anesth Analg 1997 Apr;84(4):940–1.

Hypothesis: inhaled anesthetics produce immobility and amnesia by different mechanisms at different sites. Eger EI 2nd, et al. **Anesth Analg** 1997 Apr;84(4):915–8

Intravenous clonidine decreases minimum end–tidal isoflurane for induction of electroencephalographic burst suppression. Entholzner EK, et al. **Anesth Analg** 1997 Jul; 85(1):193–8

Anesthetic and convulsant properties of aromatic compounds and cycloalkanes: implications for mechanisms of narcosis. Fang Z, et al. **Anesth Analg** 1996 Nov;83(5):1097–104

Effects of isoflurane and propofol on arterial mechanical properties [letter; comment] Hettrick DA, et al. **Anesth Analg** 1997 Apr;84(4):940–1. Comment on: Anesth Analg 1996 Nov;83(5):958–64.

Isoflurane and halothane produce similar alterations in aortic distensibility and characteristic aortic impedance. Hettrick DA, et al. **Anesth Analg** 1996 Dec;83(6):1166–72

The effects of sevoflurane on population spikes in CA1 and dentate gyrus of the rat hippocampus in vitro. Hirota K, et al. **Anesth Analg** 1997 Aug;85(2):426–30

Effects and interactions of nitrous oxide, myocardial ischemia, and reperfusion on left ventricular diastolic function. Marsch SC, et al. **Anesth Analg** 1997 Jan; 84(1):39–45

The effects of sevoflurane on recovery of brain energy metabolism after cerebral ischemia in the rat: a comparison with isoflurane and halothane. Nakajima Y, et al. **Anesth Analg** 1997 Sep;85(3):593–9

Isoflurane and halothane attenuate endothelium–dependent vasodilation in rat coronary microvessels. Park KW, et al. **Anesth Analg** 1997 Feb;84(2):278–84

The effects of halothane and isoflurane on the phosphoenergetic state of the liver during hemorrhagic shock in rats: an in vivo 31P nuclear magnetic resonance spectroscopic study. Takahashi K, et al. **Anesth Analg** 1997 Aug;85(2):347–52

Efficacy of simulated intravascular test dose during sevoflurane anesthesia [letter] Takahashi S, et al. **Anesth Analg** 1997 Oct;85(4):946

Halothane inhalation inhibits the metabolism of chlorzoxazone, a substrate for CYP2E1, in rabbits. Tateishi T, et al. **Anesth Analg** 1997 Jul;85(1):199–203

The effect of xenon on spinal dorsal horn neurons: a comparison with nitrous oxide. Utsumi J, et al. **Anesth Analg** 1997 Jun;84(6):1372–6

The effects of halothane pretreatment on manganese influx induced by muscarinic stimulation of airway smooth muscle. Warner DO, et al. **Anesth Analg** 1997 Jun; 84(6):1366–71

Voltage–dependent effects of volatile anesthetics on cardiac sodium current. Weigt HU, et al. **Anesth Analg** 1997 Feb; 84(2):285–93

Isoflurane reduces K+ current in single smooth muscle cells of guinea pig portal vein. Wilde DW. **Anesth Analg** 1996 Dec;83(6):1307–13

Positron emission tomography study of regional cerebral metabolism in humans during isoflurane anesthesia. Alkire MT, et al. **Anesthesiology** 1997 Mar;86(3):549–57

Nitrous oxide impairs electrophysiologic recovery after severe hypoxia in rat hippocampal slices. Amorim P, et al. **Anesthesiology** 1997 Sep;87(3):642–51

Halothane attenuation of calcium sensitivity in airway smooth muscle. Mechanisms of action during muscarinic receptor stimulation. Bremarich DH, et al. **Anesthesiology** 1997 Jul; 87(1):94–101

Differential inhibition of lysophosphatidate signaling by volatile anesthetics. Chan CK, et al. **Anesthesiology** 1997 Mar;86(3):660–9

Behavioral effects of volatile anesthetics in Caenorhabditis elegans. Crowder CM, et al. **Anesthesiology** 1996 Oct; 85(4):901–12

Role of adenosine triphosphate–sensitive potassium channels in coronary vasodilation by halothane, isoflurane, and enflurane. Crystal GJ, et al. **Anesthesiology** 1997 Feb; 86(2):448–58

Hypothermia and isoflurane similarly inhibit glutamate release evoked by chemical anoxia in rat cortical brain slices. Eilers H, et al. **Anesthesiology** 1996 Sep;85(3):600–7

Isoflurane anesthesia attenuates endothelium–dependent pulmonary vasorelaxation by inhibiting the synergistic interaction between nitric oxide and prostacyclin. Gambone LM, et al. **Anesthesiology** 1997 Apr;86(4):936–44

Halothane prevents postischemic production of hydroxyl radicals in the canine heart. Glantz L, et al. **Anesthesiology** 1997 Feb;86(2):440–7

Effects of desflurane in rat myocardium: comparison with isoflurane and halothane. Gueugniaud PY, et al. **Anesthesiology** 1997 Sep;87(3):599–609

Prevention of methacholine–induced changes in respiratory mechanics in piglets: a comparison of sevoflurane and halothane. Habre W, et al. **Anesthesiology** 1997 Sep; 87(3):585–90

Interaction of halothane with alpha– and beta–adrenoceptor stimulations in rat myocardium. Hanouz JL, et al. **Anesthesiology** 1997 Jan;86(1):147–59

Halothane–induced dilatation of intraparenchymal arterioles in rat brain slices: a comparison to sodium nitroprusside. Harkin CP, et al. **Anesthesiology** 1997 Apr;86(4):885–94

Sevoflurane inhibits human platelet aggregation and thromboxane A2 formation, possibly by suppression of cyclooxygenase activity. Hirakata H, et al. **Anesthesiology** 1996 Dec;85(6):1447–53

Sevoflurane depresses myocardial contractility less than halothane during induction of anesthesia in children. Holzman RS, et al. **Anesthesiology** 1996 Dec;85(6):1260–7

Hyperlocomotion during recovery from isoflurane anesthesia is associated with increased dopamine turnover in the nucleus accumbens and striatum in mice. Irifune M, et al. **Anesthesiology** 1997 Feb;86(2):464–75

Effect of isoflurane on motor–evoked potentials induced by direct electrical stimulation of the exposed motor cortex with single, double, and triple stimuli in rats. Kawaguchi M, et al. **Anesthesiology** 1996 Nov;85(5):1176–83

Role of adenosine in isoflurane–induced cardioprotection. Kersten JR, et al. **Anesthesiology** 1997 May;86(5):1128–39

Isoflurane mimics ischemic preconditioning via activation of K(ATP) channels: reduction of myocardial infarct size with an acute memory phase. Kersten JR, et al. **Anesthesiology** 1997 Aug;87(2):361–70

Mechanism of myocardial protection by isoflurane. Role of adenosine triphosphate–regulated potassium (KATP) channels. Kersten JR, et al. **Anesthesiology** 1996 Oct; 85(4):794–807; discussion 27A

Lack of inhibition by inhalational anesthetics of myocardial contraction dependent on intracellular sodium activity. Komai H, et al. **Anesthesiology** 1996 Nov;85(5):1139–46

Isoflurane attenuates early neutrophil–independent

hypoxia–reoxygenation injuries in the reperfused liver in fasted rats. Kon S, et al. **Anesthesiology** 1997 Jan; 86(1):128–36

Inhibition of plasma membrane Ca(2+)-ATPase by volatile anesthetics [letter] Kosk-Kosicka D. **Anesthesiology** 1996 Nov;85(5):1211–2

Halothane, isoflurane, and sevoflurane reduce postischemic adhesion of neutrophils in the coronary system. Kowalski C, et al. **Anesthesiology** 1997 Jan;86(1):188–95

Blood flow velocity of middle cerebral artery during prolonged anesthesia with halothane, isoflurane, and sevoflurane in humans. Kuroda Y, et al. **Anesthesiology** 1997 Sep;87(3):527–32

Sympathetic nervous system does not mediate reflex pupillary dilation during desflurane anesthesia. Larson MD, et al. **Anesthesiology** 1996 Oct;85(4):748–54

Pulmonary vascular effects of isoflurane anesthesia after left lung autotransplantation in chronically instrumented dogs. Lennon PF, et al. **Anesthesiology** 1996 Sep;85(3):592–9

Volatile anesthetics reduce low-voltage-activated calcium currents in a thyroid C-cell line. McDowell TS, et al. **Anesthesiology** 1996 Nov;85(5):1167–75

Volatile anesthetics depress glutamate transmission via presynaptic actions. MacIver MB, et al. **Anesthesiology** 1996 Oct;85(4):823–34

Increase of glutamate uptake in astrocytes: a possible mechanism of action of volatile anesthetics. Miyazaki H, et al. **Anesthesiology** 1997 Jun;86(6):1359–66; discussion 8A

Leukocyte-endothelium interaction in the rat mesenteric microcirculation during halothane or sevoflurane anesthesia. Morisaki H, et al. **Anesthesiology** 1997 Sep; 87(3):591–8

Site(s) mediating sympathetic activation with desflurane. Muzi M, et al. **Anesthesiology** 1996 Oct;85(4):737–47

Induction of anesthesia and tracheal intubation with sevoflurane in adults. Muzi M, et al. **Anesthesiology** 1996 Sep;85(3):536–43

Mechanoenergetics of the negative inotropism of isoflurane in the canine left ventricle. No O2 wasting effect. Nakayama Y, et al. **Anesthesiology** 1997 Jul;87(1):82–93

Isoflurane-induced cerebral hyperemia in neuronal nitric oxide synthase gene deficient mice. Okamoto H, et al. **Anesthesiology** 1997 Apr;86(4):875–84

Isoflurane, but not halothane, improves indices of diastolic performance in dogs with rapid ventricular, pacing-induced cardiomyopathy. Pagel PS, et al. **Anesthesiology** 1996 Sep;85(3):644–54

Volatile anesthetics affect calcium mobilization in bovine endothelial cells. Pajewski TN, et al. **Anesthesiology** 1996 Nov;85(5):1147–56

Isoflurane- and halothane-mediated dilation of distal bronchi in the rat depends on the epithelium. Park KW, et al. **Anesthesiology** 1997 May;86(5):1078–87; discussion 23A–24A

Direct vasomotor effects of isoflurane in subepicardial resistance vessels from collateral-dependent and normal coronary circulation of pigs. Park KW, et al. **Anesthesiology** 1996 Sep;85(3):584–91

Halothane blocks synaptic excitation of inhibitory interneurons. Perouansky M, et al. **Anesthesiology** 1996 Dec;85(6):1431–8; discussion 29A

Halothane interactions with nicotinic acetylcholine receptor membranes. Steady-state and kinetic studies of intrinsic fluorescence quenching. Raines DE, et al. **Anesthesiology** 1997 Feb;86(2):476–86

Inhalational anesthetic effects on rat cerebellar nitric oxide and cyclic guanosine monophosphate production. Rengasamy A, et al. **Anesthesiology** 1997 Mar;86(3):689–98

The effect of isoflurane, halothane, sevoflurane, and thiopental/nitrous oxide on respiratory system resistance after tracheal intubation. Rooke GA, et al. **Anesthesiology** 1997 Jun;86(6):1294–9

Halothane and isoflurane differentially affect the regulation of dopamine and gamma-aminobutyric acid release mediated by presynaptic acetylcholine receptors in the rat striatum. Salord F, et al. **Anesthesiology** 1997 Mar; 86(3):632–41

Halothane and enflurane attenuate pulmonary vasodilation mediated by adenosine triphosphate-sensitive potassium channels compared to the conscious state. Seki S, et al. **Anesthesiology** 1997 Apr;86(4):923–35

Halothane attenuates endothelium-dependent pulmonary vasorelaxant response to lemakalim, an adenosine triphosphate (ATP)-sensitive potassium channel agonist. Seki S, et al. **Anesthesiology** 1997 Sep;87(3):625–34

Desflurane and isoflurane increase lumbar cerebrospinal fluid pressure in normocapnic patients undergoing transsphenoidal hypophysectomy. Talke P, et al. **Anesthesiology** 1996 Nov;85(5):999–1004

Initial contractile response of isolated rat heart cells to halothane, enflurane, and isoflurane. Wheeler DM, et al. **Anesthesiology** 1997 Jan;86(1):137–46

Volatile general anesthetics produce hyperpolarization of Aplysia neurons by activation of a discrete population of baseline potassium channels. Winegar BD, et al. **Anesthesiology** 1996 Oct;85(4):889–900

Spinal cord motoneuron excitability during isoflurane and nitrous oxide anesthesia. Zhou HH, et al. **Anesthesiology** 1997 Feb;86(2):302–7

Isoflurane produces marked and nonlinear decreases in the vasoconstriction and shivering thresholds. Kurz A, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:778–85

A comparison of the body temperature during sevoflurane anesthesia and isoflurane anesthesia. Saito T. **Ann N Y Acad Sci** 1997 Mar 15;813:786–8

Effects of volatile anesthetic isoflurane on ATP-sensitive K+ channels in rabbit ventricular myocytes. Han J, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):852–6

Electrophysiologic effects of nitrous oxide, a volatile anesthetic, in dogs following myocardial infarction in comparison with other anesthetics. Hashimoto H, et al. **Biol Pharm Bull** 1997 Jan;20(1):82–5

Effect of nitrous oxide on cerebral blood velocity while reclining and standing. Mathew RJ, et al. **Biol Psychiatry** 1997 May 1;41(9):979–84

Effects of magnesium sulphate on atrioventricular conduction times and surface electrocardiogram in dogs anaesthetized with sevoflurane. Akazawa S, et al. **Br J Anaesth** 1997 Jan;78(1):75–80

Volatile anaesthetic effects on calcium conductance of planar lipid bilayers formed with synthetic lipids or extracted lipids from sarcoplasmic reticulum. Andoh T, et al. **Br J Anaesth** 1997 Jan;78(1):66–74

Effect of halothane on K+ and carbachol stimulated [3H]noradrenaline release and increased [Ca2+]i in SH-SY5Y human neuroblastoma cells. Atcheson R, et al. **Br J Anaesth** 1997 Jul;79(1):78–83

Effect of halothane, isoflurane and desflurane on lower oesophageal sphincter tone. Chassard D, et al. **Br J Anaesth** 1996 Dec;77(6):781–3

In vivo and in vitro dose–response curves [letter; comment] Cormack RS. **Br J Anaesth** 1997 Jun;78(6):776. Comment on: Br J Anaesth 1996 Oct;77(4):517–21.

Role of prostaglandins and nitric oxide on halothane-induced arteriolar dilatation in rat diaphragm. de Larminat V, et al. **Br J Anaesth** 1996 Aug;77(2):232–7

Visual evoked potentials and nitrous oxide-induced neuronal depression: role for benzodiazepine receptors. Dzoljic M, et al. **Br J Anaesth** 1996 Oct;77(4):522–5

Effects of volatile anaesthetics on human neutrophil oxidative response to the bacterial peptide FMLP. Fröhlich D, et al. **Br J Anaesth** 1997 Jun;78(6):718–23

Propofol or halothane anaesthesia for children with asthma: effects on respiratory mechanics. Habre W, et al. **Br J Anaesth** 1996 Dec;77(6):739–43

Effect of halothane on conventional protein kinase C translocation and down-regulation in rat cerebrocortical synaptosomes. Hemmings HC Jr, et al. **Br J Anaesth** 1997 Feb;78(2):189–96

Sevoflurane modulates both GABAA and GABAB receptors in area CA1 of rat hippocampus. Hirota K, et al. **Br J Anaesth** 1997 Jan;78(1):60–5

Atrioventricular conduction during adenosine-induced hypotension in dogs anaesthetized with sevoflurane. Ishii R, et al. **Br J Anaesth** 1996 Sep;77(3):393–8

Dose–response curve for anaesthetics based on the Monod–Wyman–Changeux model [see comments] Iwai T, et al. **Br J Anaesth** 1996 Oct;77(4):517–21. Comment in: Br J Anaesth 1997 Feb;78(2):230–1. Comment in: Br J Anaesth 1997 Jun;78(6):776.

Nitrous oxide produces a non-linear reduction in thiopentone requirements. Katoh T, et al. **Br J Anaesth** 1996 Aug; 77(2):265–7

Role of endothelium in the modulation of isoflurane-induced vasodilatation in rat thoracic aorta. Kirstetter P, et al. **Br J Anaesth** 1997 Jul;79(1):84–7

Increase in serum creatine phosphokinase concentrations after suxamethonium during sevoflurane or isoflurane anaesthesia in children. Kudoh A, et al. **Br J Anaesth** 1997 Apr;78(4):372–4

Potency and time course of action of rocuronium during desflurane and isoflurane anaesthesia. Kumar N, et al. **Br J Anaesth** 1996 Oct;77(4):488–91

Isoflurane increases the uptake of glutamate in synaptosomes from rat cerebral cortex. Larsen M, et al. **Br J Anaesth** 1997 Jan;78(1):55–9

Effects of fentanyl, nitrous oxide, or both, on baroreceptor reflex regulation in the cat. Lennander O, et al. **Br J Anaesth** 1996 Sep;77(3):399–403

Effects on haemodynamics and catecholamine release of xenon anaesthesia compared with total i.v. anaesthesia in the pig. Marx T, et al. **Br J Anaesth** 1997 Mar;78(3):326–7

Influence of 0.2 minimum alveolar concentration of enflurane on the ventilatory response to sustained hypoxia in humans. Nagyova B, et al. **Br J Anaesth** 1997 Jun;78(6):707–13

Anaesthetic potency of inhalation agents is independent of membrane microviscosity. Norman RI, et al. **Br J Anaesth** 1997 Mar;78(3):290–5

Adequate general anaesthesia--what are we trying to achieve? [letter; comment] O'Connor TC, et al. **Br J Anaesth** 1996 Aug;77(2):299–301. Comment on: Br J Anaesth 1996 Jan;76(1):1–4. Comment on: Br J Anaesth 1996 Jan;76(1):99–105.

Effects of desflurane and isoflurane on splanchnic microcirculation during major surgery. O'Riordan J, et al. **Br J Anaesth** 1997 Jan;78(1):95–6

Effect of sevoflurane anaesthesia on plasma concentrations of glutathione S-transferase. Ray DC, et al. **Br J Anaesth** 1996 Sep;77(3):404–7

Hepatocellular integrity after inhalation anaesthesia [letter; comment] Ray DC, et al. **Br J Anaesth** 1997 Jun; 78(6):772–3. Comment on: Br J Anaesth 1996 Dec;77(6):744–7.

Regional cerebral blood flow (SPECT) during anaesthesia with isoflurane and nitrous oxide in humans. Reinstrup P, et al. **Br J Anaesth** 1997 Apr;78(4):407–11

Spectral edge frequency of the electroencephalogram to monitor "depth" of anaesthesia with isoflurane or propofol. Schwender D, et al. **Br J Anaesth** 1996 Aug;77(2):179–84

Auditory evoked response, median frequency and 95% spectral edge during anaesthesia with desflurane and nitrous oxide. Sharpe RM, et al. **Br J Anaesth** 1997 Mar;78(3):282–5

Quantitative EEG in assessment of anaesthetic depth: comparative study of methodology. Thomsen CE, et al. **Br J Anaesth** 1996 Aug;77(2):172–8

Hepatocellular integrity during and after isoflurane and halothane anaesthesia in surgical patients [see comments] Tiainen P, et al. **Br J Anaesth** 1996 Dec;77(6):744–7. Comment in: Br J Anaesth 1997 Jun;78(6):772–3.

Volatile anaesthetics and neuromuscular block [letter; comment] Wright PM. **Br J Anaesth** 1996 Oct;77(4):561–2 . Comment on: Br J Anaesth 1996 Mar;76(3):389–95.

Volatile general anaesthetic actions on recombinant nACh alpha 7, 5-HT3 and chimeric nACh alpha 7-5-HT3 receptors expressed in Xenopus oocytes. Zhang L, et al. **Br J Pharmacol** 1997 Feb;120(3):353–5

Effects of two volatile anesthetics (sevoflurane and halothane) on the hypothalamic noradrenaline release in rat brain. Chave S, et al. **Brain Res** 1996 Jan 15;706(2):293–6

Inhalation anesthetics suppress the expression of c-Fos protein evoked by noxious somatic stimulation in the deeper layer of the spinal cord in the rat. Hagihira S, et al. **Brain Res** 1997 Mar 14;751(1):124–30

Isoflurane enhances glutamatergic agonist-stimulated nitric oxide synthesis in cultured neurons. Loeb AL, et al. **Brain Res** 1996 Sep 23;734(1-2):295–300

Effects of volatile anesthetics on hippocampal slice metabolism, response to anoxia with and without glucose. Raley-Susman KM, et al. **Brain Res** 1997 Apr 25;755(1):1–8

Chronic cocaine administration does not modify haemodynamic responses to isoflurane anaesthesia in sheep. Bernards CM, et al. **Can J Anaesth** 1997 Feb;44(2):202–7

Do enflurane and isoflurane interfere with the release, action, or stability of endothelium-derived relaxing factors? Blaise G, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):550–8

Comparison of nifedipine and metoprolol on collateral coronary blood flow in a swine model of chronic coronary obstruction and acute ischaemia during isoflurane anaesthesia. Cheng DC, et al. **Can J Anaesth** 1996 Feb; 43(2):160–8

Reduction in post-intubation respiratory resistance by isoflurane and albuterol. Choi JH, et al. **Can J Anaesth** 1997 Jul;44(7):717–22

Haemodynamic comparison of sevoflurane and isoflurane anaesthesia in surgical patients. Inada T, et al. **Can J Anaesth** 1997 Feb;44(2):140–5

Changes in the cerebral arteriovenous oxygen content difference by surgical incision are similar during sevoflurane and isoflurane anaesthesia. Inada T, et al. **Can J Anaesth** 1996 Oct;43(10):1019–24

Sevoflurane anaesthesia for a patient with adult polyglucosan body disease. Inoue S, et al. **Can J Anaesth** 1996 Dec; 43(12):1257–9

Ventilatory parameters in children during propofol anaesthesia: a comparison with halothane. Kulkarni P, et al. **Can J Anaesth** 1996 Jul;43(7):653–9

Sevoflurane and isoflurane impair edrophonium reversal of vecuronium-induced neuromuscular block. Morita T, et al. **Can J Anaesth** 1996 Aug;43(8):799–805

Halothane and isoflurane enhance melanoma tumour metastasis in mice. Moudgil GC, et al. **Can J Anaesth** 1997 Jan;44(1):90–4

Cerebrovascular CO2 reactivity in elderly and younger adult patients during sevoflurane anaesthesia. Nishiyama T, et al. **Can J Anaesth** 1997 Feb;44(2):160–4

Volatile anaesthetics attenuate hypocapnia-induced constriction in isolated dog cerebral arteries. Ogawa K, et al. **Can J Anaesth** 1997 Apr;44(4):426–32

Comparison of sevoflurane/fentanyl and isoflurane/fentanyl during elective coronary artery bypass surgery. Sevoflurane Venture Group [see comments] Searle NR, et al. **Can J Anaesth** 1996 Sep;43(9):890–9. Comment in: Can J Anaesth 1996 Sep;43(9):825–7.

New volatile anaesthetics in cardiovascular anaesthesia: one step forward, two steps back? [editorial; comment] Thomson IR. **Can J Anaesth** 1996 Sep;43(9):883–9. Comment on: Can J Anaesth 1996 Sep;43(9):890–9. **(Eng, Fre)**

Anesthetics modulate phospholipase C hydrolysis of monolayer phospholipids by surface pressure. Goodman DM, et al. **Chem Phys Lipids** 1996 Nov 1;84(1):57–64

UDP-glucose:glycoprotein glucosyltransferase associates with endoplasmic reticulum chaperones and its activity is decreased in vivo by the inhalation anesthetic halothane. Amouzadeh HR, et al. **Chem Res Toxicol** 1997 Jan; 10(1):59–63

The reinforcing effects of brief exposures to nitrous oxide in healthy volunteers. Zacny JP, et al. **Drug Alcohol Depend** 1996 Nov;42(3):197–200

A study of the effect of isoflurane anaesthesia on equine skeletal muscle perfusion. Goetz TE, et al. **Equine Vet J Suppl** 1989 Jun;(7):133–7

The haemodynamic effects of milrinone HCl in halothane anaesthetised horses. Muir WW. **Equine Vet J Suppl** 1995 Sep;(19):108–13

The inhibition of serotonin evoked bovine coronary artery

contraction by halothane, isoflurane and sevoflurane is endothelium-independent. Xiaoping Z, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):352–8

Halothane inhibits endothelium-dependent relaxation elicited by acetylcholine in human isolated pulmonary arteries. Higueras J, et al. **Eur J Pharmacol** 1997 May 20; 326(2–3):175–81

Guinea-pig tracheal responsiveness in vitro following general anaesthesia with halothane. Mercier FJ, et al. **Eur Respir J** 1996 Jul;9(7):1451–5

The effect of nitrous oxide on the measurement of single-breath transfer factor. Phillips CL, et al. Eur Respir J 1997 Jan;10(1):200–1

The effect of anaesthesia on the intraocular volume of the C3F8 gas bubble. Briggs M, et al. **Eye** 1997;11 (Pt 1):47–52

Strain and sex differences in the effect of enflurane and isoflurane on heme metabolism in mice. Buzaleh AM, et al. **Gen Pharmacol** 1996 Sep;27(6):1009–12

Effect of chronic anesthesia on the drug-metabolizing enzyme system and heme pathway regulation. Buzaleh AM, et al. **Gen Pharmacol** 1997 Apr;28(4):577–82

Influence of inhalational, neuroleptic and local anaesthesia on lymphocyte subset distribution. Corsi M, et al. **Int J Tissue React** 1995;17(5–6):211–7

Effects of N2O narcosis on breathing and effort sensations during exercise and inspiratory resistive loading. Fothergill DM, et al. **J Appl Physiol** 1996 Oct;81(4):1562–71

Cocaine toxicity and isoflurane anesthesia: hemodynamic, myocardial metabolic, and regional blood flow effects in swine. Boylan JF, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):772–7

In vivo direct measurement of the bronchodilating effect of sevoflurane using a superfine fiberoptic bronchoscope: comparison with enflurane and halothane. Hashimoto Y, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):213–6

A comparison of the effects of propofol-alfentanil versus isoflurane anesthesia on arterial oxygenation during one-lung ventilation. Reid CW, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):860–3

Effects of desflurane and isoflurane on systemic vascular resistance during hypothermic cardiopulmonary bypass. Rödig G, et al. **J Cardiothorac Vasc Anesth** 1997 Feb; 11(1):54–7

Effects of isoflurane on cardiovascular system and sympathovagal balance in New Zealand white rabbits. Marano G, et al. **J Cardiovasc Pharmacol** 1996 Oct; 28(4):513–8

Drug interactions: volatile anesthetics and opioids. Glass PS, et al. **J Clin Anesth** 1997 Sep;9(6 Suppl):18S–22S (18 ref.)

Interactions between neuronal histamine and halothane anesthesia in rats. Mammoto T, et al. **J Neurochem** 1997 Jul;69(1):406–11

Effects of the volatile anesthetic enflurane on spontaneous discharge rate and GABA(A)-mediated inhibition of Purkinje cells in rat cerebellar slices. Antkowiak B, et al. **J Neurophysiol** 1997 May;77(5):2525–38

Modulation of forebrain electroencephalographic activity in halothane-anesthetized rat via actions of noradrenergic beta-receptors within the medial septal region. Berridge CW, et al. **J Neurosci** 1996 Nov 1;16(21):7010–20

Comparative effects of propofol, pentobarbital, and isoflurane on cerebral blood flow and blood volume. Todd MM, et al. **J Neurosurg Anesthesiol** 1996 Oct;8(4):296–303

Folate depletion induced by methotrexate affects methionine synthase activity and its susceptibility to inactivation by nitrous oxide. Fiskerstrand T, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1305–11

Cardiovascular and respiratory effects of detomidine in isoflurane-anaesthetised horses. Still J, et al. **J S Afr Vet Assoc** 1996 Dec;67(4):199–203

Effect of isofluorane anesthesia on serum levels of Zn, Cu, Fe, Mn and Co in humans. Alarcón OM, et al. **J Trace Elem Med Biol** 1996 Sep;10(3):180–4

Halothane anesthesia and serum electrolytes. Alarcón OM, et al. **J Trace Elem Med Biol** 1996 Apr;10(1):46–9

Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. Troncy E, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):268–73

Effects of isoflurane versus halothane on myocardial contractility in rabbits: assessment with transthoracic two-dimensional echocardiography. Marano G, et al. **Lab Anim** 1997 Apr;31(2):144–50

Middle ear pressure variation: effect of nitrous oxide. Chinn K, et al. **Laryngoscope** 1997 Mar;107(3):357–63

Effects of halothane, alpha-chloralose, and pCO2 on injury volume and CSF beta-endorphin levels in focal cerebral ischemia. Browning JL, et al. **Mol Chem Neuropathol** 1997 May;31(1):29–42

Gene knockout of the alpha6 subunit of the gamma-aminobutyric acid type A receptor: lack of effect on responses to ethanol, pentobarbital, and general anesthetics. Homanics GE, et al. **Mol Pharmacol** 1997 Apr; 51(4):588–96

Effects of volatile anesthetics on the G protein-regulated muscarinic potassium channel. Magyar J, et al. **Mol Pharmacol** 1996 Dec;50(6):1520–8

Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors [see comments] Mihic SJ, et al. **Nature** 1997 Sep 25;389(6649):385–9. Comment in: Nature 1997 Sep 25;389(6649):384–5.

Nitrous oxide depresses somatocardiac sympathetic A- and C-reflexes in anesthetized rats. Adachi T, et al. **Neurosci Lett** 1996 Jul 26;213(1):57–60

Cellular mechanisms of gamma rhythms in rat neocortical brain slices probed by the volatile anaesthetic isoflurane. Antkowiak B, et al. **Neurosci Lett** 1997 Aug 8;231(2):87–90

Halothane alters electrical activity and calcium dynamics in cultured mouse cortical, spinal cord, and dorsal root ganglion neurons. Wamil AW, et al. **Neurosci Lett** 1996 Sep 27;216(2):93–6

Effect of nitrous oxide and propofol on amino acid metabolism in neoplasic patients. Crespo ML, et al. **Nutr Cancer** 1997;27(1):80–3

Nitrous oxide inhalation: effects on the maternal and fetal circulations at term [letter] Tsen LC, et al. **Obstet Gynecol** 1996 Nov;88(5):899–900

Nitrous oxide inhalation: effects on maternal and fetal circulations at term [letter; comment] Yun EM, et al. **Obstet Gynecol** 1996 Nov;88(5):899; discussion 900. Comment on: Obstet Gynecol 1996 Jun;87(6):1045–8.

Effects of isoflurane on electrophysiological measurements in children with the Wolff-Parkinson-White syndrome. Chang RK, et al. **Pacing Clin Electrophysiol** 1996 Jul; 19(7):1082–8

The influence of midazolam and nitrous oxide on respiratory depression in laboratory rats. Henry RJ, et al. **Pediatr Dent** 1996 Jul-Aug;18(4):281–6

Desflurane, enflurane, isoflurane and ether produce ethanol-like discriminative stimulus effects in mice. Bowen SE, et al. **Pharmacol Biochem Behav** 1997 May-Jun; 57(1–2):191–8

Lack of acute tolerance development to the subjective, cognitive, and psychomotor effects of nitrous oxide in healthy volunteers. Yajnik S, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):501–8

Quantitative trait loci controlling halothane sensitivity in Caenorhabditis elegans. van Swinderen B, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8232–7

Role of L-type calcium channels on halothane-induced myocardial depression in cultured rat ventricular myocytes. Kanaya N, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jan;91(1):85–96

Cardiopulmonary effects of desflurane in the dog during spontaneous and artificial ventilation. Clarke KW, et al. **Res Vet Sci** 1996 Jul;61(1):82–6

Influence of nitrous oxide on motor-evoked potentials. Zentner J, et al. **Spine** 1997 May 1;22(9):1002–6

Stimulatory effect of anesthetics on dechlorination of carbon tetrachloride in guinea-pig liver microsomes. Fujii K. **Toxicology** 1996 Dec 2;114(2):147–53

Cardiopulmonary effects of desflurane in ponies, after induction of anaesthesia with xylazine and ketamine. Clarke KW, et al. **Vet Rec** 1996 Aug 24;139(8):180–5

A comparison of the effects of halothane and isoflurane in combination with nitrous oxide on lower oesophageal sphincter pressure and barrier pressure in anaesthetised dogs. Hashim MA, et al. **Vet Rec** 1995 Dec 23–30; 137(26):658–61

Sufentanil and nitrous oxide anaesthesia for the recording of transcranial magnetic motor evoked potentials in dogs. Van Ham LM, et al. **Vet Rec** 1996 Jun 29;138(26):642–5

Cardiovascular and pulmonary effects of sevoflurane anesthesia in horses. Aida H, et al. **Vet Surg** 1996 Mar-Apr; 25(2):164–70

Comparisons of sevoflurane, isoflurane, and halothane anesthesia in spontaneously breathing cats. Hikasa Y, et al. **Vet Surg** 1996 May-Jun;25(3):234–43

Cardiovascular effects of 1.0, 1.5, and 2.0 minimum alveolar concentrations of isoflurane in experimentally induced hypothyroidism in dogs. McMurphy RM, et al. **Vet Surg** 1996 Mar-Apr;25(2):171–8

Differences in quantitated electroencephalographic variables during surgical stimulation of horses anesthetized with isoflurane. Otto KA, et al. **Vet Surg** 1996 May-Jun; 25(3):249–55

Anesthetic potency of desflurane in the horse: determination of the minimum alveolar concentration. Tendillo FJ, et al. **Vet Surg** 1997 Jul-Aug;26(4):354–7

[The effect of droperidol and sevoflurane on serotonin-induced bronchoconstriction in dog] Nakaoji T, et al. **Masui** 1996 Jun;45(6):698–706 (Eng. Abstr.) **(Jpn)**

[The effect of volatile anesthetics on EEG, auditory evoked potentials and somatosensory evoked potentials in dogs] Ono K, et al. **Masui** 1997 Apr;46(4):471–7 (Eng. Abstr.) **(Jpn)**

[Effects of halothane, isoflurane, enflurane, and sevoflurane on the monosynaptic reflex response in the isolated spinal cord of newborn rats] Tsutahara S, et al. **Masui** 1996 Jul; 45(7):829–36 (Eng. Abstr.) **(Jpn)**

[The effect of sevoflurane on regional cerebral metabolism and cerebral blood flow in rhesus monkeys] Yoshikawa T, et al. **Masui** 1997 Feb;46(2):237–43 (Eng. Abstr.) **(Jpn)**

[Ultrastructural changes in the encapsulated nerve endings of the tibial nerve under the action of diethyl ether in 2 strains of rats selected for their threshold of nervous system excitability] Vshivtseva VV, et al. **Morfologiia** 1996; 109(3):22–6 (Eng. Abstr.) **(Rus)**

[Cardiocirculatory effects of halothane and isoflurane in respiratory distress caused by oleic acid] Cobreces-García MJ, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):3–6 (Eng. Abstr.) **(Spa)**

[Sevoflurane] Gilsanz F, et al. **Rev Esp Anestesiol Reanim** 1996 Aug-Sep;43(7):243–8 (75 ref.) (Eng. Abstr.) **(Spa)**

[Desflurane: a new inhalation anesthetic] Roigé J, et al. **Rev Esp Anestesiol Reanim** 1996 Aug-Sep;43(7):249–54 (Eng. Abstr.) **(Spa)**

STANDARDS

The use of isoflurane to anaesthetise koalas (Phascolarctus cinereus). McGowan MR, et al. **Aust Vet J** 1995 Dec; 72(12):472–3

THERAPEUTIC USE

Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Cope DK, et al. **Anesthesiology** 1997 Mar; 86(3):699–709

Beneficial effect of concomitant administration of isoflurane and nicorandil. Piriou V, et al. **Br J Anaesth** 1997 Jul; 79(1):68–77

Sevoflurane or halothane for paediatric endoscopy [letter] Plowman A, et al. **Br J Anaesth** 1997 Jul;79(1):143–4

Halothane reduces reperfusion injury after regional ischaemia in the rabbit heart in vivo. Schlack W, et al. **Br J Anaesth** 1997 Jul;79(1):88–96

Sevoflurane. Grounds RM, et al. **Br J Hosp Med** 1997 Jan 15–Feb 5;57(1–2):43–6 (21 ref.)

Isoflurane and propofol block neurotoxicity caused by MK-801 in the rat posterior cingulate/retrosplenial cortex. Jevtović-Todorović V, et al. **J Cereb Blood Flow Metab** 1997 Feb;17(2):168–74

Changes in cerebral blood flow velocity in children during sevoflurane and halothane anesthesia. Berkowitz RA, et al. **J Neurosurg Anesthesiol** 1996 Jul;8(3):194–8

Therapeutic options for severe, refractory status asthmaticus: inhalational anaesthetic agents, extracorporeal membrane oxygenation and helium/oxygen ventilation. Tobias JD, et al. **Paediatr Anaesth** 1997;7(1):47–57

Recovery parameters after sevoflurane and isoflurane anesthesia. Cantillo J, et al. **Pharmacotherapy** 1997 Jul-Aug; 17(4):779–82

[Volatile agents in ambulatory anesthesia] Clergue F. **Rev Med Suisse Romande** 1997 May;117(5):383–8 (16 ref.) **(Fre)**

TOXICITY

Spectrum and subcellular determinants of fluorinated anesthetic-mediated proximal tubular injury. Lochhead KM, et al. **Am J Pathol** 1997 Jun;150(6):2209–21

Acetaminophen predisposes to renal and hepatic injury from compound A in the fasting rat. Laster MJ, et al. **Anesth Analg** 1997 Jan;84(1):169–72

compound A induces sister chromatid exchanges in Chinese hamster ovary cells. Eger EI 2nd, et al. **Anesthesiology** 1997 Apr;86(4):918–22

Comparison of the effects of controlled ventilation with 100% oxygen, 50% oxygen in nitrogen, and 50% oxygen in nitrous oxide on responses to venous air embolism in pigs. Kyttä J, et al. **Br J Anaesth** 1996 Nov;77(5):658–61

Halothane hepatotoxicity and hepatic free radical metabolism in guinea pigs; the effects of vitamin E. Durak I, et al. **Can J Anaesth** 1996 Jul;43(7):741–8

Interaction of lymphocytes with Kupffer cells from halothane-exposed guinea pigs. Furst SM, et al. **Int Arch Allergy Immunol** 1997 Sep;114(1):46–53

Postnatal hepatic and renal consequences of in utero exposure to halothane or its oxidative metabolite trifluoroacetic acid in the rat. Saillenfait AM, et al. **J Appl Toxicol** 1997 Jan-Feb;17(1):1–8

In vivo study of halothane hepatotoxicity in the rat using magnetic resonance imaging and 31P spectroscopy. Noseworthy MD, et al. **J Biochem Biophys Methods** 1997 Mar 27;34(2):107–22

Ageing potentiates anaesthetic-induced synaptic depression in hippocampal slices. el-Beheiry H, et al. **Neuroreport** 1996 Jan 31;7(2):502–4

Effects of antidepressants on thyroid stimulating hormone release in rats under ether stress. Kadono Y, et al. **Psychiatry Clin Neurosci** 1995 Aug;49(4):231–6

Demonstration of a cellular immune response in halothane-exposed guinea pigs. Furst SM, et al. **Toxicol Appl Pharmacol** 1997 Apr;143(2):245–55

Kupffer cells from halothane-exposed guinea pigs carry trifluoroacetylated protein adducts. Furst SM, et al. **Toxicology** 1997 Jun 27;120(2):119–32

[Repeated low-flow sevoflurane anesthesia: effects on hepatic and renal function in beagles] Sun L, et al. **Masui** 1997 Mar;46(3):351–7 (Eng. Abstr.) **(Jpn)**

URINE

Interferences of urinary tract infection in the measurement of urinary nitrous oxide. Apostoli P, et al. **Occup Environ Med** 1996 Sep;53(9):591–4

ANESTHETICS, INTRAVENOUS

Intravenous regional anesthesia. Evaluation of 4 different additives to prilocaine. Hoffmann V, et al. **Acta Anaesthesiol Belg** 1997;48(2):71–6

Effect of low dose fentanyl-droperidol administration on respiratory drive, respiratory pattern and gas exchange in ASA 1 spontaneously breathing patients. Pierdominici S, et al. **Acta Anaesthesiol Belg** 1997;48(2):85–91

Recovery and outcome after propofol and isoflurane

anesthesia in patients undergoing laparoscopic hysterectomy. Nelskylä K, et al. **Acta Anaesthesiol Scand** 1997 Mar;41(3):360–3

Clinical perspectives of intravenous ketamine anaesthesia in peafowl (Pavo cristatus). Athar M, et al. **Acta Vet Hung** 1996;44(3):357–61

Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Galloway GP, et al. **Addiction** 1997 Jan;92(1):89–96

The difficult airway: propofol infusion as an alternative to gaseous induction. Ludbrook GL, et al. **Anaesth Intensive Care** 1997 Feb;25(1):71–3

Anaesthesia for laparoscopic surgery in myotonic dystrophy [letter] Merefield DC, et al. **Anaesth Intensive Care** 1997 Feb;25(1):93–4

Anaesthesia for children with mucopolysaccharidoses [see comments] Moores C, et al. **Anaesth Intensive Care** 1996 Aug;24(4):459–63. Comment in: Anaesth Intensive Care 1997 Apr;25(2):197–8.

Midazolam-flumazenil topical anaesthesia for microlaryngoscopy with jet ventilation. Rushatamukayanunt W, et al. **Anaesth Intensive Care** 1997 Aug;25(4):358–64

Co-induction and laryngeal mask insertion. A comparison of thiopentone versus propofol. Driver I, et al. **Anaesthesia** 1997 Jul;52(7):698–700

Propofol anaesthesia and vomiting after myringoplasty in children. Habre W, et al. **Anaesthesia** 1997 Jun;52(6):544–6

Warmed propofol, a cautionary note [letter] Hall AP. **Anaesthesia** 1996 Nov;51(11):1083

One ampoule, two expiry dates [letter] Nel MR, et al. **Anaesthesia** 1997 Mar;52(3):287–8

Remote controlled prolonged conscious sedation for gynaecological radiotherapy. Oei-Lim VL, et al. **Anaesthesia** 1996 Sep;51(9):866–8

A persistent problem with glass ampoules [letter] Stewart PC. **Anaesthesia** 1997 May;52(5):509–10

Contamination of opioids during preparation for regional anaesthesia [letter; comment] Tunstall ME, et al. **Anaesthesia** 1997 Mar;52(3):290. Comment on: Anaesthesia 1996 Nov;51(11):1079–80.

Midazolam premedication delays recovery after propofol without modifying involuntary movements. Bevan JC, et al. **Anesth Analg** 1997 Jul;85(1):50–4

Propofol and early extubation after cardiac surgery [letter; comment] Chaney MA. **Anesth Analg** 1997 Jul;85(1):228–9 . Comment on: Anesth Analg 1997 Jan;84(1):12–9.

A randomized multicenter study of remifentanil compared with alfentanil, isoflurane, or propofol in anesthetized pediatric patients undergoing elective strabismus surgery. Davis PJ, et al. **Anesth Analg** 1997 May;84(5):982–9

Emergence of elderly patients from prolonged desflurane, isoflurane, or propofol anesthesia. Juvin P, et al. **Anesth Analg** 1997 Sep;85(3):647–51

Hemodynamic effects, myocardial ischemia, and timing of tracheal extubation with propofol-based anesthesia for cardiac surgery [see comments] Myles PS, et al. **Anesth Analg** 1997 Jan;84(1):12–9. Comment in: Anesth Analg 1997 Jul;85(1):228–9.

Postoperative epidural infusion: a randomized, double-blind, dose-finding trial of clonidine in combination with bupivacaine and fentanyl. Paech MJ, et al. **Anesth Analg** 1997 Jun;84(6):1323–8

Midlatency auditory evoked potentials predict movements during anesthesia with isoflurane or propofol. Schwender D, et al. **Anesth Analg** 1997 Jul;85(1):164–73

Propofol anesthesia increases dopamine and serotonin activities at the somatosensory cortex in rats: a microdialysis study. Shyr MH, et al. **Anesth Analg** 1997 Jun;84(6):1344–8

Addition of epinephrine to intrathecal bupivacaine and sufentanil for ambulatory labor analgesia. Campbell DC, et al. **Anesthesiology** 1997 Mar;86(3):525–31

Recovery of consciousness after thiopental or propofol. Bispectral index and isolated forearm technique. Flaishon R, et al. **Anesthesiology** 1997 Mar;86(3):613–9

Sedation for the conduct of lumbar epidural anaesthesia: a study using subanaesthetic dose of ketamine in combination with midazolam. Loo CC, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):200–4

Propofol compatibility with other intravenous drug products: two new methods of evaluating IV emulsion compatibility. Michaels MR, et al. **Ann Pharmacother** 1996 Mar; 30(3):228–32

Use of methohexital for elective intubation in neonates. Naulaers G, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Jul;77(1):F61–4

Low-dose rocuronium improves conditions for tracheal intubation after induction of anaesthesia with propofol and alfentanil. Barclay K, et al. **Br J Anaesth** 1997 Jan; 78(1):92–4

Halothane-propofol anaesthesia for tracheal intubation in young children. Hansen D, et al. **Br J Anaesth** 1997 Apr; 78(4):366–9

Inhalation induction with sevoflurane: a double-blind comparison with propofol. Thwaites A, et al. **Br J Anaesth** 1997 Apr;78(4):356–61

Strychnine-dependent allodynia in the urethane-anesthetized rat is segmentally distributed and prevented by intrathecal glycine and betaine. Sherman SE, et al. **Can J Physiol Pharmacol** 1995 Dec;73(12):1698–705

A comparison of injectable anaesthetic regimens in mules. Matthews NS, et al. **Equine Vet J Suppl** 1992 Feb;(11):34–6

A comparison of injectable anaesthetic regimens in Mammoth asses. Matthews NS, et al. **Equine Vet J Suppl** 1992 Feb; (11):37–40

In-use contamination of propofol. A clinical study. Bach A, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):178–83

Transition to post-operative epidural or patient-controlled intravenous analgesia following total intravenous anaesthesia with remifentanil and propofol for abdominal surgery. Bowdle TA, et al. **Eur J Anaesthesiol** 1997 Jul; 14(4):374–9

An investigation of the effect of ondansetron on time to induction of anaesthesia with thiopentone and propofol. Mansfield M, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):24–8

A comparison of eltanolone and propofol anaesthesia for minor gynaecological surgery. Whyte JA, et al. **Eur J Anaesthesiol** 1997 Sep;14(5):499–504

Update in intravenous anaesthesia. Proceedings of the 7th International Symposium on Intravenous Anaesthesia. Lausanne, Switzerland, 2–3 May 1997. **Eur J Anaesthesiol Suppl** 1997 May;15:1–60

Propofol: pro- or anticonvulsant? Borgeat A. **Eur J Anaesthesiol Suppl** 1997 May;15:17–20 (32 ref.)

Remifentanil: when and how to use it. Servin F. **Eur J Anaesthesiol Suppl** 1997 May;15:41–4 (24 ref.)

Sedation and analgesia for colonoscopy: patient tolerance, pain, and cardiorespiratory parameters. Froehlich F, et al. **Gastrointest Endosc** 1997 Jan;45(1):1–9

Infections linked to anesthetic [letter] Bach A. **Infect Control Hosp Epidemiol** 1996 Nov;17(11):712

The effect of skin incision followed by alfentanil on catecholamine levels and on the T-wave amplitude of ECG during isoflurane anaesthesia. Annila PA, et al. **Int J Clin Monit Comput** 1995;12(4):205–11

Response to avian sedation evaluation [letter; comment] Harrison GJ. **J Am Vet Med Assoc** 1996 Dec 15; 209(12):1992–3. Comment on: J Am Vet Med Assoc 1996 Sep 1;209(5):969–71.

Etomidate and thiopental-based anesthetic induction: comparisons between different titrated levels of electrophysiologic cortical depression and response to laryngoscopy. Jellish WS, et al. **J Clin Anesth** 1997 Feb; 9(1):36–41

Propofol decreases ocular pressure in outpatients undergoing trabeculectomy. Lauretti GR, et al. **J Clin Anesth** 1997 Jun;9(4):289–92

Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery. McKenzie R, et al. **J Clin Anesth** 1997 Feb;9(1):15–20

Hemodynamic effects of intrathecal sufentanil compared with epidural bupivacaine in laboring parturients. Pham LH, et al. **J Clin Anesth** 1996 Sep;8(6):497–501; discussion 502–3

A comparison of propofol and remifentanil during monitored anesthesia care. Smith I, et al. **J Clin Anesth** 1997 Mar; 9(2):148–54

EEG Predicts movement response to surgical stimuli during general anesthesia with combinations of isoflurane, 70% N2O, and fentanyl. Dutton RC, et al. **J Clin Monit** 1996 Mar;12(2):127–39

Visual laser coagulation of the prostate using intraurethral gel anesthesia and light intravenous analgesia and sedation. Karlsen SJ, et al. **J Endourol** 1996 Aug;10(4):389–91

Comparison of general anesthesia and intravenous sedation-analgesia for SWL. Zommick J, et al. **J Endourol** 1996 Dec;10(6):489–91

Intact cerebral blood flow reactivity during remifentanil/nitrous oxide anesthesia. Baker KZ, et al. **J Neurosurg Anesthesiol** 1997 Apr;9(2):134–40

Increase in antioxidant capacity of plasma during propofol anesthesia. Hans P, et al. **J Neurosurg Anesthesiol** 1997 Jul; 9(3):234–6

Computer-controlled infusion of propofol for long neurosurgical procedures. Lim TA, et al. **J Neurosurg Anesthesiol** 1997 Jul;9(3):242–9

The use of ketamine or etomidate to supplement sufentanil/N2O anesthesia does not disrupt monitoring of myogenic transcranial motor evoked responses. Ubags LH, et al. **J Neurosurg Anesthesiol** 1997 Jul;9(3):228–33

Comparison of intubation conditions under propofol in children--alfentanil vs atracurium. Senel AC, et al. **Middle East J Anesthesiol** 1996 Oct;13(6):605–11

Approaching a 100% success rate using topical anesthesia with mild intravenous sedation in phacoemulsification procedures. Dinsmore SC. **Ophthalmic Surg Lasers** 1996 Nov;27(11):935–8

Safe pediatric outpatient sedation: the chloral hydrate debate revisited. Malis DJ, et al. **Otolaryngol Head Neck Surg** 1997 Jan;116(1):53–7

Anaesthesia for insertion of ear tubes in children: comparison of propofol, thiopentone and halothane. Carpenter RD, et al. **Paediatr Anaesth** 1997;7(1):25–31

Medetomidine as a premedicant for ketamine, propofol or fentanyl anaesthesia in dogs. Hellebrekers LJ, et al. **Vet Rec** 1997 May 24;140(21):545–8

Anesthesia in sheep with propofol or with xylazine-ketamine followed by halothane. Lin HC, et al. **Vet Surg** 1997 May-Jun;26(3):247–52

[Is propofol (Diprivan) indicated in emergency surgery?] Badeva B, et al. **Khirurgiia (Sofiia)** 1996;49(4):24–7 (Eng. Abstr.) **(Bul)**

[Propofol (Diprivan) in emergency anesthesia] Badeva B, et al. **Khirurgiia (Sofiia)** 1996;49(4):31–3 (Eng. Abstr.) **(Bul)**

[Propofol in combination with etomidate for anesthesia induction] Bovianska N. **Khirurgiia (Sofiia)** 1996;49(4):37–9 (Eng. Abstr.) **(Bul)**

[Diprivan anesthesia in a case with intraoperative corticography] Karadimov D, et al. **Khirurgiia (Sofiia)** 1996;49(4):46–7 **(Bul)**

[The use of Diprivan in combination with the local use of lidocaine/adrenaline in operations on the neck area] Tomova M. **Khirurgiia (Sofiia)** 1996;49(4):40–1 (Eng. Abstr.) **(Bul)**

[Clinical study of a mivacurium-propofol combination for laparoscopic surgery in children] Hermonville E, et al. **Cah Anesthesiol** 1996;44(3):261–5 (Eng. Abstr.) **(Fre)**

[Effect of rocuronium in sufentanil/isoflurane and sufentanil/propofol anesthesia] Klinzing S, et al. **Anaesthesiol Reanim** 1996;21(6):149–52 (Eng. Abstr.) **(Ger)**

[Total intravenous anesthesia with propofol and sufentanil for resection of pheochromocytoma] Kreienmeyer J. **Anaesthesiol Reanim** 1997;22(3):80–2 (Eng. Abstr.) **(Ger)**

[New intravenous anesthetics. Remifentanil, S(+)-ketamine, eltanolone and target controlled infusion] Albrecht S, et al. **Anaesthesist** 1996 Dec;45(12):1129–41 (85 ref.) (Eng. Abstr.) **(Ger)**

[Cost aspects in anesthesia. Propofol versus isoflurane anesthesia] Boldt J, et al. **Anaesthesist** 1996 Aug;45(8):731–6 (Eng. Abstr.) **(Ger)**

[Comparison of sufentanil-propofol-anesthesia with fentanyl-propofol in major abdominal surgery] Kietzmann D, et al. **Anaesthesist** 1996 Dec;45(12):1151–7 (Eng. Abstr.) **(Ger)**

[Propofol and etomidate-Lipuro for induction of general anesthesia. Hemodynamics, vascular compatibility, subjective findings and postoperative nausea] Mayer M, et al. **Anaesthesist** 1996 Nov;45(11):1082–4 (Eng. Abstr.) **(Ger)**

[Intravenous anesthesia--which way are we going?] Schüttler J, et al. **Anaesthesist** 1996 Dec;45(12):1127–8 **(Ger)**

[Age-related correlation between EEG parameters and depth of anesthesia under propofol. Effect of fentanyl] Werry C, et al. **Anaesthesist** 1996 Aug;45(8):722–30 (Eng. Abstr.) **(Ger)**

[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery] Wilhelm W, et al. **Anaesthesist** 1997 Apr;46(4):335–8 (Eng. Abstr.) **(Ger)**

[Is remifentanil an ideal opioid for anesthesiologic management in the 21st century?] Scholz J, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Dec; 31(10):592–607 (96 ref.) (Eng. Abstr.) **(Ger)**

[Does propofol have advantages over isoflurane for sufentanil supplemented anesthesia in children for strabismus surgery?] Wilhelm S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Sep; 31(7):414–9 (Eng. Abstr.) **(Ger)**

[Sedation, combined anesthesia, and total intravenous anesthesia (TIVA) with propofol in the pediatric surgical patient] Ivani G, et al. **Minerva Anestesiol** 1996 Apr; 62(4):113–7 (Eng. Abstr.) **(Ita)**

[Clinical pharmacology of pipecuronium; a comparative study of its duration of action in balanced anesthesia (propofol/fentanyl) vs isoflurane] Melloni C. **Minerva Anestesiol** 1995 Dec;61(12):491–500 (Eng. Abstr.) **(Ita)**

[Protective effect of intravenous anesthesia using propofol from surgical stress] Kazama T. **Masui** 1996 Dec;45 Suppl:S68–72 (4 ref.) **(Jpn)**

[Difficult tracheal intubation and abnormal response to thiopental in a patient with arthrogryposis multiplex congenita] Kimura F, et al. **Masui** 1996 Aug;45(8):1022–5 (Eng. Abstr.) **(Jpn)**

[Comparison of epidural fentanyl versus bupivacaine in maintaining intraoperative liver function] Nishiyama M. **Masui** 1997 Jun;46(6):743–9 (Eng. Abstr.) **(Jpn)**

[Rapid induction of anesthesia with propofol--comparison with thiopental] Nishiyama T, et al. **Masui** 1996 Dec; 45(12):1469–72 (Eng. Abstr.) **(Jpn)**

[Anesthesia induction for laryngeal mask insertion--comparison of propofol with midazolam and propofol with thiopental] Nishiyama T, et al. **Masui** 1997 Feb;46(2):188–92 (Eng. Abstr.) **(Jpn)**

[Living related liver transplantation for patients with ornithine transcarbamylase deficiency] Tazuke M, et al. **Masui** 1997 Jun;46(6):783–7 (Eng. Abstr.) **(Jpn)**

[Intraoperative monitoring for functional neurosurgery during intravenous anesthesia with propofol] Fukuda M, et al. **No Shinkei Geka** 1997 Mar;25(3):231–7 (Eng. Abstr.) **(Jpn)**

[Anesthesia with Inoval and Valium in combined use] Narvaes C, et al. **Rev Bras Anestesiol** 1968 Oct-Dec; 18(4):447–61 (Eng. Abstr.) **(Por)**

[Use of diprivan in anesthesiology of angiographic studies and x-ray endovascular methods of treatment in children] Mikhelson VA, et al. **Anesteziol Reanimatol** 1996 Nov-Dec; (6):14–7 (Eng. Abstr.) **(Rus)**

[New trends in pediatric anesthesiology: diprivan and laryngeal mask (preliminary communication)] Mizikov VM, et al. **Anesteziol Reanimatol** 1996 Nov-Dec;(6):10–4 **(Rus)**

[Propofol (diprivan): clinical and pharmacological characteristics and use in pediatric anesthesiology]

Voskerchian AE. **Anesteziol Reanimatol** 1996 Nov–Dec; (6):72–5 (8 ref.) **(Rus)**

[Diprivan (propofol) in the anesthesiological support of outpatient dental interventions] Gritsuk SF, et al. **Stomatologiia (Mosk)** 1997;76(1):63–4 **(Rus)**

[The use of propofol in carotid surgery] Asuero de Lis MS, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):144–9 (Eng. Abstr.) **(Spa)**

[Use of propofol as an anesthetic agent in a pediatric patient with Steinert's myotonic dystrophy (letter)] Cano JM, et al. **Rev Esp Anestesiol Reanim** 1996 Jun–Jul;43(6):227 **(Spa)**

[Effectiveness of propofol in pediatric magnetic resonance (letter)] Edo–Cebollada L, et al. **Rev Esp Anestesiol Reanim** 1996 May;43(5):187–8 **(Spa)**

[The need for alfentanyl in total intravenous anesthesia. Comparison between laparoscopic cholecystectomy and subcostal laparotomy] Figueredo–Gaspari E, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):103–7 (Eng. Abstr.) **(Spa)**

[The risk of severe bradycardia from the use of adenosine triphosphate in pheochromocytoma surgery under total intravenous anesthesia with propofol (letter)] Munar F, et al. **Rev Esp Anestesiol Reanim** 1997 Jun–Jul;44(6):254–5 **(Spa)**

[Thoracic epidural anesthesia combined with general anesthesia with propofol for thymectomy in myasthenia gravis (letter)] Quintana–Villamandos B, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):130 **(Spa)**

[Total intravenous anesthesia with propofol in orthotopic liver transplantation in swine] Ramírez A, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):98–102 (Eng. Abstr.) **(Spa)**

[Anesthesia in laparoscopic cholecystectomy with CO2: comparison of the hemodynamic and respiratory behavior using 2 different anesthetic techniques (see comments)] Rubio–Martínez CJ, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):12–6 (Eng. Abstr.). Comment in: Rev Esp Anestesiol Reanim 1996 Jun–Jul;43(6):227–8. **(Spa)**

ADMINISTRATION & DOSAGE

Sufentanil with and without diazepam for coronary artery bypass graft surgery. Lina AA, et al. **Acta Anaesthesiol Belg** 1996;47(4):177–85

Potentiation of atracurium by pancuronium during propofol–fentanyl–N2O anesthesia. Nathan N, et al. **Acta Anaesthesiol Belg** 1996;47(4):187–93

Intravenous induction of general anaesthesia with eltanolone in children 6–15 years of age. Beskow A, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):242–7

Influence of body compartments on propofol induction dose in female patients. Chassard D, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):889–91

Metoclopramide reduces the induction dose of propofol. Page VJ, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):256–9

The use of remifentanil in clinical anesthesia. Philip BK. **Acta Anaesthesiol Scand Suppl** 1996;109:170–3

Co–administration of midazolam decreases propofol dose during anesthesia in endoscopic laryngeal microsurgery. Lai HC, et al. **Acta Anaesthesiol Sin** 1996 Dec;34(4):191–6

EMLA cream and lidocaine local injection in the treatment of extravenous thiopental injection––a case report. Mao CC, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):103–6

Conscious sedation by low dose propofol infusion during spinal anesthesia for cesarean section [see comments] [published erratum appears in Acta Anaesthesiol Sin 1996 Dec;34(4):252] Wang YP, et al. **Acta Anaesthesiol Sin** 1996 Sep;34(3):117–21. Comment in: Acta Anaesthesiol Sin 1996 Sep;34(3):i.

Effectiveness of a manually controlled infusion scheme of propofol and alfentanil mixture for endotracheal intubation in hypertensive patients: in comparison with thiamylal and nifedipine plus thiamylal. Wei TT, et al. **Acta Anaesthesiol Sin** 1996 Mar;34(1):9–16

Cost effectiveness of administration of intravenous anesthetics for direct–current cardioversion by nonanesthesiologists. Tobin MG, et al. **Am J Cardiol** 1997 Mar 1;79(5):686–8

Rapid opiate detoxification. Bartter T, et al. **Am J Drug Alcohol Abuse** 1996 Nov;22(4):489–95

Compatibility of propofol injectable emulsion with selected drugs during simulated Y–site administration. Trissel LA, et al. **Am J Health Syst Pharm** 1997 Jun 1;54(11):1287–92

Induction and maintenance of anesthesia in dogs by intravenous administration of methohexital. Gentry WB, et al. **Am J Vet Res** 1996 Jul;57(7):1044–9

The taste of intravenous thiopentone. Nor NB, et al. **Anaesth Intensive Care** 1996 Aug;24(4):483–5

Comparison of isoflurane, halothane and fentanyl in patients with decreased ejection fraction undergoing coronary surgery. Urzua J, et al. **Anaesth Intensive Care** 1996 Oct; 24(5):579–84

Intubation without muscle relaxant: an alternative technique for rapid tracheal intubation. Wong AK, et al. **Anaesth Intensive Care** 1996 Apr;24(2):224–30

Spontaneous movement after injection of propofol [letter; comment] Malkan DJ, et al. **Anaesthesia** 1997 Jun;52(6):614 . Comment on: Anaesthesia 1996 Jul;51(7):663–6.

Comparison of computer–controlled administration of propofol with two manually controlled infusion techniques. Struys M, et al. **Anaesthesia** 1997 Jan;52(1):41–50

Awakening, clinical recovery, and psychomotor effects after desflurane and propofol anesthesia. Apfelbaum JL, et al. **Anesth Analg** 1996 Oct;83(4):721–5

A comparison of isoflurane versus fentanyl as primary anesthetics for mitral valve surgery. Howie MB, et al. **Anesth Analg** 1996 Nov;83(5):941–8

Intravenous ketamine or fentanyl prolongs postoperative analgesia after intrathecal neostigmine. Lauretti GR, et al. **Anesth Analg** 1996 Oct;83(4):766–70

The effects of midazolam on propofol–induced anesthesia: propofol dose requirements, mood profiles, and perioperative dreams. Oxorn DC, et al. **Anesth Analg** 1997 Sep;85(3):553–9

Recovery after propofol with and without intraoperative fentanyl in patients undergoing ambulatory gynecologic laparoscopy. Sukhani R, et al. **Anesth Analg** 1996 Nov; 83(5):975–81

Propofol and alfentanil prevent the increase in intraocular pressure caused by succinylcholine and endotracheal intubation during a rapid sequence induction of anesthesia. Zimmerman AA, et al. **Anesth Analg** 1996 Oct;83(4):814–7

Remifentanil versus remifentanil/midazolam for ambulatory surgery during monitored anesthesia care. Gold MI, et al. **Anesthesiology** 1997 Jul;87(1):51–7

Multicenter study of target–controlled infusion of propofol–sufentanil or sufentanil–midazolam for coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Jain U, et al. **Anesthesiology** 1996 Sep;85(3):522–35

Esmolol reduces anesthetic requirement for skin incision during propofol/nitrous oxide/morphine anesthesia. Johansen JW, et al. **Anesthesiology** 1997 Feb;86(2):364–71

Epileptic fits under intravenous midazolam sedation [see comments] Robb ND. **Br Dent J** 1996 Sep 7;181(5):178–9 . Comment in: Br Dent J 1996 Dec 7–21;181(11–12):399. Comment in: Br Dent J 1997 Jan 25;182(2):50.

Induction characteristics of 2% propofol in children. Borgeat A, et al. **Br J Anaesth** 1997 Apr;78(4):433–5

Comparison of patient–controlled sedation with either methohexitone or propofol. Hamid SK, et al. **Br J Anaesth** 1996 Dec;77(6):727–30

Nitrous oxide produces a non–linear reduction in thiopentone requirements. Katoh T, et al. **Br J Anaesth** 1996 Aug; 77(2):265–7

Local anaesthesia to the airway reduces sedation requirements in patients undergoing artificial ventilation [see comments] Mallick A, et al. **Br J Anaesth** 1996 Dec; 77(6):731–4. Comment in: Br J Anaesth 1997 Apr;78(4):479–80.

Rectus sheath bupivacaine analgesia after aortic surgery [letter; comment] Cuschieri RJ, et al. **Br J Surg** 1997 Jul; 84(7):1033–4. Comment on: Br J Surg 1996 Nov;83(11);1558.

Comparison of propofol versus thiopentone with midazolam or lidocaine to facilitate laryngeal mask insertion [see comments] Bapat P, et al. **Can J Anaesth** 1996 Jun; 43(6):564–8. Comment in: Can J Anaesth 1997 May;44(5 Pt 1):569.

Conscious sedation for interventional neuroradiology: a comparison of midazolam and propofol infusion. Manninen PH, et al. **Can J Anaesth** 1997 Jan;44(1):26–30

Optimal dose of thiamylal in combination with midazolam for induction of anaesthesia. Nishiyama T, et al. **Can J Anaesth** 1996 Nov;43(11):1134–7

High–dose thiopentone for open–chamber cardiac surgery: a retrospective review. Pascoe EA, et al. **Can J Anaesth** 1996 Jun;43(6):575–9

Dose–response to anaesthetic induction with sufentanil: haemodynamic and electroencephalographic effects. Sareen J, et al. **Can J Anaesth** 1997 Jan;44(1):19–25

Recall after total intravenous anaesthesia due to an equipment misuse [see comments] Tong D, et al. **Can J Anaesth** 1997 Jan;44(1):73–7. Comment in: Can J Anaesth 1997 Jan;44(1):4–8.

Intravenous sedation prior to peribulbar anaesthesia for cataract surgery in elderly patients. Wong DH, et al. **Can J Anaesth** 1996 Nov;43(11):1115–20

Nitrous oxide inhalation as an adjunct to intravenous induction of general anaesthesia with propofol for day surgery. Johnson GW, et al. **Eur J Anaesthesiol** 1997 May; 14(3):295–9

Dose–response and concentration–response relation of rocuronium infusion during propofol–nitrous oxide and isoflurane–nitrous oxide anaesthesia. Kansanaho M, et al. **Eur J Anaesthesiol** 1997 Sep;14(5):488–94

Target–controlled anaesthesia: concepts and first clinical experiences. Kenny GN. **Eur J Anaesthesiol Suppl** 1997 May;15:29–31

No effect of age on the dose requirement of thiopental in the rat. Harashima H, et al. **Exp Gerontol** 1997 May–Jun; 32(3):315–24

Clinical drug level predictions and practice. Howell S, et al. **Int Anesthesiol Clin** 1995 Summer;33(3):91–100

Computer–controlled infusions in anesthesia. Kenny GN, et al. **Int Anesthesiol Clin** 1995 Summer;33(3):101–9 (17 ref.)

Median effective dose of propofol required for induction of anaesthesia in goats. Pablo LS, et al. **J Am Vet Med Assoc** 1997 Jul 1;211(1):86–8

Administration of propofol by target–controlled infusion in patients undergoing coronary artery surgery. Barvais L, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):877–83

Propofol–alfentanil versus fentanyl–midazolam in coronary artery surgery. Collard E, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):869–76

Early extubation after mitral valve surgery: a target–controlled infusion of propofol and low–dose sufentanil. D'Attellis N, et al. **J Cardiothorac Vasc Anesth** 1997 Jun;11(4):467–73

A comparison of the effects of propofol–alfentanil versus isoflurane anesthesia on arterial oxygenation during one–lung ventilation. Reid CW, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):860–3

A comparison: the efficacy of sevoflurane–nitrous oxide or propofol–nitrous oxide for the induction and maintenance of general anesthesia. Lien CA, et al. **J Clin Anesth** 1996 Dec;8(8):639–43

Propofol and alfentanil for sedation during placement of retrobulbar block for cataract surgery. Yee JB, et al. **J Clin Anesth** 1996 Dec;8(8):623–6

Patient–controlled sedation and analgesia during SWL. Uyar M, et al. **J Endourol** 1996 Oct;10(5):407–10

Propofol vs isoflurane for neurosurgical anesthesia in Thai patients. Ittichaikulthol W, et al. **J Med Assoc Thai** 1997 Jul;80(7):454–60

Propofol anesthesia for transvaginal ultrasound guided oocyte retrieval. Tontisirin O, et al. **J Med Assoc Thai** 1996 Oct;79(10):618–23

Variation of functional MRI signal in response to frequency of somatosensory stimulation in alpha–chloralose anesthetized rats. Gyngell ML, et al. **Magn Reson Med** 1996 Jul;36(1):13–5

Multidrug intravenous sedation: determinants of the sedative dose of midazolam. Moore PA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):5–10

Effects of midazolam on pain sensations in the face. Nakanishi O, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):11–5

Changes in carbon dioxide tension and oxygen saturation during deep sedation for paediatric cardiac catheterization. Friesen RH, et al. **Paediatr Anaesth** 1996;6(1):15–20

A comparison of thiopentone–isoflurane anaesthesia vs propofol infusion in children having repeat minor haematological procedures. Harling DW, et al. **Paediatr Anaesth** 1997;7(1):19–23

Does thiopentone delay recovery in children premedicated with midazolam? Morley–Forster P, et al. **Paediatr Anaesth** 1997;7(4):279–85

Plasma levels of intranasal midazolam at 0.4 mg/kg and 0.2 mg/kg doses. Sayany Z, et al. **Pediatr Dent** 1996 Jul–Aug; 18(4):320–1

Extended epidural catheter infusions with analgesics for patients with noncancer pain at their homes. Aldrete JA. **Reg Anesth** 1997 Jan–Feb;22(1):35–42

Neuroendocrine blockade in coronary surgery. A clinical study with reference to myocardial metabolism and performance. Thorelius J. **Scand Cardiovasc J** 1997; 31(3):185

[Combined loco–regional anesthesia and intravenous anesthesia with propofol (Diprivan––Zeneca)] Badeva B, et al. **Khirurgiia (Sofiia)** 1996;49(4):12–3 (Eng. Abstr.) **(Bul)**

[Clinical experience of laryngeal mask airway combined with continuous intravenous propofol infusion during general anesthesia] Chen KP, et al. **Acta Anaesthesiol Sin** 1996 Dec; 34(4):209–12 (Eng. Abstr.) **(Chi)**

German Congress on Anesthesiology. Yearly Meeting of the German Societyfor Anesthesiology and Intensive Care. Symposium: Sufentanil in anesthesia and intensive care. Nürnberg, 15 June 1994] **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Apr; 30(2 Suppl):1–8 **(Ger)**

[Experiences with propofol as an injection narcotic for radiotherapy of cats and dogs] Fodor G, et al. **Tierarztl Prax** 1996 Feb;24(1):62–7 (Eng. Abstr.) **(Ger)**

[Clinical investigations of an i.m. combination anesthesia with fentanylclimazolam/xylazine and postoperative i.v. antagonism with naloxone/sarmazenil/yohimbine in guinea pigs] Henke J, et al. **Tierarztl Prax** 1996 Feb;24(1):85–7 (Eng. Abstr.) **(Ger)**

[Premixing lidocaine reduces the incidence and severity of pain on injection of propofol] Inoue S, et al. **Masui** 1997 Apr;46(4):543–6 (Eng. Abstr.) **(Jpn)**

[Comparison of epidural versus intravenous administration of fentanyl during epidural block] Shirasaka T, et al. **Masui** 1997 Mar;46(3):358–62 (Eng. Abstr.) **(Jpn)**

[Intravenous anesthesia by continuous administration of midazolam and fentanyl] Yoshida Y, et al. **Masui** 1997 Mar; 46(3):326–30 (Eng. Abstr.) **(Jpn)**

[Total intravenous anesthesia in patients with postburn deformations of the face and neck] Beliakov VA, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):50–2 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Infectious risks associated with the use of propofol. Bach A, et al. **Acta Anaesthesiol Scand** 1996 Nov;40(10):1189–96 (67 ref.)

Propofol reduces emesis after sufentanil supplemented anaesthesia in paediatric squint surgery. Standl T, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):729–33

Multiple seizures following re–exposure to propofol. Harrigan PW, et al. **Anaesth Intensive Care** 1996 Apr; 24(2):261–4

Postoperative nausea and vomiting. Propofol or thiopentone: does choice of induction agent affect outcome? Myles PS, et al. **Anaesth Intensive Care** 1996 Jun;24(3):355–9

Pain on injection of propofol [letter; comment] Borgeat A. **Anaesthesia** 1997 Apr;52(4):390. Comment on: Anaesthesia 1996 Sep;51(9):878–80.

Injection pain with propofol. Reduction with aspiration of blood [see comments] McDonald DS, et al. **Anaesthesia** 1996 Sep;51(9):878–80. Comment in: Anaesthesia 1997 Apr;52(4):390.

Pain on injection of propofol [letter; comment] Seddon SJ. **Anaesthesia** 1997 Mar;52(3):288. Comment on: Anaesthesia 1996 Sep;51(9):815–8.

The effect of pretreatment with ketorolac on pain during intravenous injection of propofol [see comments] Smith AJ, et al. **Anaesthesia** 1996 Sep;51(9):883–5. Comment in: Anaesthesia 1997 Jan;52(1):94.

Does midazolam cause retrograde amnesia, and can flumazenil reverse that amnesia? Koht A, et al. **Anesth Analg** 1997 Jul;85(1):211–2

Pretreatment with topical 60% lidocaine tape reduces pain on injection of propofol. Yokota S, et al. **Anesth Analg** 1997 Sep;85(3):672–4

Maternal respiratory arrests, severe hypotension, and fetal distress after administration of intrathecal, sufentanil, and bupivacaine after intravenous fentanyl. Lu JK, et al. **Anesthesiology** 1997 Jul;87(1):170–2

Cardiovascular collapse resulting from thiopental-induced histamine release [letter; comment] Sprung J, et al. **Anesthesiology** 1997 Apr;86(4):1006–7. Comment on: Anesthesiology 1982 Jan;56(1):64–7.

Do anxiety or hypocapnia predispose to apnoea after induction of anaesthesia? Drummond GB, et al. **Br J Anaesth** 1997 Feb;78(2):153–6

Effect of lignocaine and pH on propofol-induced pain. Eriksson M, et al. **Br J Anaesth** 1997 May;78(5):502–6

Propofol and bradycardia: causation, frequency and severity. Tramèr MR, et al. **Br J Anaesth** 1997 Jun;78(6):642–51 (103 ref.)

Alfentanil-mediated analgesia during propofol injection: no evidence for a peripheral action. Wrench IJ, et al. **Br J Anaesth** 1996 Aug;77(2):162–4

Prolonged delirium after propofol [letter] Gadalla F, et al. **Can J Anaesth** 1996 Aug;43(8):877

Prevention of hypotension after propofol for rapid sequence intubation [letter; comment] Gin T. **Can J Anaesth** 1996 Aug;43(8):877–8. Comment on: Can J Anaesth 1995 Oct;42(10):875–8.

No lipid droplets in blood during propofol anaesthesia [letter] Iwama H, et al. **Can J Anaesth** 1996 Oct;43(10):1081

Refractory dystonia during propofol anaesthesia in a patient with torticollis-dystonia disorder. Zabani I, et al. **Can J Anaesth** 1996 Oct;43(10):1062–4

The role of ascorbic acid and xylitol in etomidate-induced adrenocortical suppression in humans. Schraag S, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):346–51

Muscle rigidity causing life-threatening hypercapnia following fentanyl administration in a premature infant [letter] Lemmen RJ, et al. **Eur J Pediatr** 1996 Dec; 155(12):1067

The effect of propofol on parthenogenetic activation, in vitro fertilization and early development of mouse oocytes. Janssenswillen C, et al. **Fertil Steril** 1997 Apr;67(4):769–74

Flumazenil reversal of psychomotor impairment due to midazolam or diazepam for conscious sedation for upper endoscopy. Kankaria A, et al. **Gastrointest Endosc** 1996 Oct;44(4):416–21

The effects of anesthesia with thiopental on T lymphocyte responses to antigen and mitogens in vivo and in vitro. Corrêa-Sales C, et al. **Int J Immunopharmacol** 1997 Feb; 19(2):117–28

On the putative mechanistic basis for intraoperative propofol-induced penile erections. Staerman F, et al. **Int J Impot Res** 1997 Mar;9(1):1–9

Excitatory movements in a dog following propofol anesthesia. Smedile LE, et al. **J Am Anim Hosp Assoc** 1996 Jul-Aug;32(4):365–8

Myocardial effect of propofol infusions in humans: more questions than answers [letter; comment] Vuylsteke A, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):264. Comment on: J Cardiothorac Vasc Anesth 1995 Aug;9(4):368–72. Comment on: J Cardiothorac Vasc Anesth 1996 Jun;10(4):568.

Reduction of propofol injection pain with a double lumen i.v. set. Angst MS, et al. **J Clin Anesth** 1997 Sep;9(6):462–6

Preventing pain during injection of propofol: the optimal dose of lidocaine. Gajraj NM, et al. **J Clin Anesth** 1996 Nov;8(7):575–7

Reduction of propofol pain--fentanyl vs lidocaine. Alyafi WA, et al. **Middle East J Anesthesiol** 1996 Oct;13(6):613–9

Cognitive sequelae of propofol anaesthesia. Sanou J, et al. **Neuroreport** 1996 Apr 26;7(6):1130–2

Opioid-induced rigidity after intravenous fentanyl. Viscomi CM, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):822–4

Clonic convulsions in a neonate after propofol anaesthesia [letter] Gelber O, et al. **Paediatr Anaesth** 1997;7(1):88

Muscle rigidity due to fentanyl infusion in the pediatric patient. Glick C, et al. **South Med J** 1996 Nov; 89(11):1119–20 (11 ref.)

[The effect of total intravenous anesthesia with S-(+)-ketamine/propofol on hemodynamic, endocrine and metabolic stress reactions in comparison to alfentanil/propofol in laparotomy] Crozier TA, et al. **Anaesthesist** 1996 Nov;45(11):1015–23 (Eng. Abstr.) **(Ger)**

[Effect of lidocaine administration mode on decreasing injection pain caused by propofol] Goldmann R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):98–100 (Eng. Abstr.) **(Ger)**

[Severe protracted cholestasis after general anesthesia in a patient with Alagille syndrome] Müller C, et al. **Z Gastroenterol** 1996 Dec;34(12):809–12 (Eng. Abstr.) **(Ger)**

[Prolactinemia in children anesthetized with propofol] del Campo-Martín MD, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):7–11 (Eng. Abstr.) **(Spa)**

ANALYSIS

Analysis of fentanyl and sufentanil in hair by GC/MS/MS. Sachs H, et al. **Int J Legal Med** 1996;109(4):213–5

Propofol assay in biological fluids in pregnant women. Ragno G, et al. **J Pharm Biomed Anal** 1997 Jul;15(11):1633–40

BLOOD

Serum protein binding of propofol in patients with renal failure or hepatic cirrhosis. Costela JL, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):741–5

Changes of propofol levels in isolated cardiopulmonary bypass circuit. Su HB, et al. **Acta Anaesthesiol Sin** 1996 Mar;34(1):17–20

Brain and blood concentrations of propofol after rapid intravenous injection in sheep, and their relationships to cerebral effects. Ludbrook GL, et al. **Anaesth Intensive Care** 1996 Aug;24(4):445–52

The arterial blood propofol concentration preventing movement in 50% of healthy women after skin incision. Andrews DT, et al. **Anesth Analg** 1997 Aug;85(2):414–9

Relationship between calculated blood concentration of propofol and electrophysiological variables during emergence from anaesthesia: comparison of bispectral index, spectral edge frequency, median frequency and auditory evoked potential index. Doi M, et al. **Br J Anaesth** 1997 Feb;78(2):180–4

Cardiopulmonary bypass-induced changes in plasma concentrations of propofol and in auditory evoked potentials. Hammarén E, et al. **Br J Anaesth** 1996 Sep; 77(3):360–4

The effects of cardiopulmonary bypass on total and unbound plasma concentrations of propofol and midazolam. Dawson PJ, et al. **J Cardiothorac Vasc Anesth** 1997 Aug; 11(5):556–61

Determination of eltanolone in human plasma by high-performance liquid chromatography. Jones DJ, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):467–70

Simultaneous determination of midazolam and its metabolites 1-hydroxymidazolam and 4-hydroxymidazolam in human serum using gas chromatography-mass spectrometry. Martens J, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):95–100

High-performance liquid chromatographic assay for thiopental in human plasma. Application to pharmacokinetic studies. Russo H, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20;694(1):239–45

Determination of propofol in rat whole blood and plasma by high-performance liquid chromatography. Yeganeh MH, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11; 691(2):478–82

Microdetermination of propofol in plasma by a rapid and sensitive liquid chromatographic method. el-Yazigi A, et al. **J Pharm Biomed Anal** 1996 Oct;15(1):99–104

A rapid high-performance liquid chromatographic method for the measurement of midazolam plasma concentrations during long-term infusion in ICU patients. Van Brandt N, et al. **Ther Drug Monit** 1997 Jun;19(3):352–7

[The on-line simulation of blood propofol concentration by personal computer transmitting settings of the syringe pump via a digital port] Nakao M. **Masui** 1997 Feb; 46(2):279–83 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Compatibility of ketamine hydrochloride and meperidine hydrochloride [letter] Ambados F. **Am J Health Syst Pharm** 1997 Jan 15;54(2):205

Stability of thiopental sodium and propofol in polypropylene syringes at 23 and 4 degrees C. Chernin EL, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1576–9

Physicochemical compatibility of propofol with thiopental sodium. Prankerd RJ, et al. **Am J Health Syst Pharm** 1996 Nov 1;53(21):2606–10

The effect of the addition of lignocaine on propofol emulsion stability [see comments] Lilley EM, et al. **Anaesthesia** 1996 Sep;51(9):815–8. Comment in: Anaesthesia 1997 Mar;52(3):288.

Propofol is a peroxynitrite scavenger. Kahraman S, et al. **Anesth Analg** 1997 May;84(5):1127–9

Myocardial uptake of thiopental enantiomers by the isolated perfused rat heart. Nguyen KT, et al. **Chirality** 1996; 8(7):477–80

CONTRAINDICATIONS

Use of methohexital in cardiac patients [letter; comment] Schabes GA. **J Oral Maxillofac Surg** 1996 Oct;54(10):1263. Comment on: J Oral Maxillofac Surg 1996 May;54(5):578–81; discussion 581–2.

[Longterm sedation with propofol is contraindicated in children (letter)] Vos GD, et al. **Ned Tijdschr Geneeskd** 1997 May 24;141(21):1072 **(Dut)**

ECONOMICS

Total intravenous or inhalational anaesthesia--a cost comparison [letter] Blaine EM. **S Afr Med J** 1996 Dec; 86(12):1564–6

Total intravenous or inhalational anaesthesia--a cost comparison [letter] Garratt RM. **S Afr Med J** 1997 Jun; 87(6):772–3

HISTORY

[Tomás Alday and the chemical synthesis of somnifen (letter)] Hervás Puyal C. **Rev Esp Anestesiol Reanim** 1996 Nov; 43(9):340 **(Spa)**

ISOLATION & PURIFICATION

Clinical significance of methohexital, meperidine, and diazepam in breast milk. Borgatta L, et al. **J Clin Pharmacol** 1997 Mar;37(3):186–92

METABOLISM

Hepatic disposition of alfentanil and sufentanil in patients undergoing orthotopic liver transplantation. Raucoules-Aimé M, et al. **Anesth Analg** 1997 May; 84(5):1019–24

I.v. anaesthetic agents do not interact with the verapamil binding site on L-type voltage-sensitive Ca2+ channels. Hirota K, et al. **Br J Anaesth** 1996 Sep;77(3):385–6

Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Ghosal A, et al. **Drug Metab Dispos** 1996 Sep;24(9):940–7

Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. von Moltke LL, et al. **J Clin Pharmacol** 1996 Sep;36(9):783–91

PHARMACOKINETICS

Age-dependent development of acute tolerance to propofol and its distribution in a pharmacokinetic compartment-independent rat model. Larsson JE, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):734–40

Pharmacokinetics and concentration-effect relationship after propofol infusion [see comments] Lim TA, et al. **Acta Anaesthesiol Sin** 1996 Sep;34(3):109–15. Comment in: Acta Anaesthesiol Sin 1996 Sep;34(3):i.

Brain and blood concentrations of propofol after rapid intravenous injection in sheep, and their relationships to cerebral effects. Ludbrook GL, et al. **Anaesth Intensive Care** 1996 Aug;24(4):445–52

Recovery from anaesthesia: which is the best kinetic descriptor of a drug's recovery profile? [editorial] Sear JW. **Anaesthesia** 1996 Nov;51(11):997–9

Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Ahonen J, et al. **Anesthesiology** 1996 Dec;85(6):1246–52

Pharmacokinetic model-driven infusion of fentanyl in children. Ginsberg B, et al. **Anesthesiology** 1996 Dec; 85(6):1268–75

Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Kharasch ED, et al. **Anesthesiology** 1997 Jul;87(1):26–35

The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Kharasch ED, et al. **Anesthesiology** 1997 Jul;87(1):36–50

Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Minto CF, et al. **Anesthesiology** 1997 Jan;86(1):10–23

Pharmacokinetics of thiopentone enantiomers following intravenous injection or prolonged infusion of rac-thiopentone. Cordato DJ, et al. **Br J Clin Pharmacol** 1997 Apr;43(4):355–62

Myocardial uptake of thiopental enantiomers by the isolated perfused rat heart. Nguyen KT, et al. **Chirality** 1996; 8(7):477–80

Infusion rate control algorithms for pharmacokinetic model-driven drug infusion devices. Jacobs JR. **Int Anesthesiol Clin** 1995 Summer;33(3):65–82 (20 ref.)

Why pharmacokinetic model drug delivery? Reves JG, et al. **Int Anesthesiol Clin** 1995 Summer;33(3):29–43 (42 ref.)

Pharmacokinetics without calculus--an introduction. Smith BE. **Int Anesthesiol Clin** 1995 Summer;33(3):11–28 (108 ref.)

Gas chromatographic-mass spectrometry and gas chromatographic-Fourier transform infrared spectroscopy assay for the simultaneous identification of fentanyl metabolites. Guitton J, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):59–70

Pharmacokinetic and pharmacodynamic interactions between opioids and propofol. Vuyk J. **J Clin Anesth** 1997 Sep;9(6 Suppl):23S–26S (13 ref.)

Computer simulation of cerebrovascular circulation: assessment of intracranial hemodynamics during induction of anesthesia. Bekker A, et al. **J Clin Monit** 1996 Nov; 12(6):433–44

Predictive accuracy of continuous propofol infusions in neurosurgical patients: comparison of pharmacokinetic models. Hans P, et al. **J Neurosurg Anesthesiol** 1997 Apr; 9(2):112–7

Pharmacokinetics of continuous infusion fentanyl in newborns. Santeiro ML, et al. **J Perinatol** 1997 Mar–Apr; 17(2):135–9

Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation [letter] Dutta S, et al. **J Pharm Sci** 1997 Aug;86(8):967–9

The systemic and cerebral kinetics of thiopental in sheep: enantiomeric analysis. Mather LE, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):291–7

Applications of pharmacokinetic/pharmacodynamic research in rational drug development. Danhof M. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:53–4 (12 ref.)

Pharmacokinetic profile of the induction dose of propofol in chronic renal failure patients undergoing renal transplantation. de Gasperi A, et al. **Minerva Anestesiol** 1996 Jan–Feb;62(1–2):25–31

In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. Raoof AA, et al. **Pharm Res** 1996 Jun;13(6):891–5

Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. Correia D, et al. **Res Vet Sci** 1996 May; 60(3):213–7

Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. Nolan A, et al. **Res Vet Sci** 1996 May;60(3):262–6

PHARMACOLOGY

The effect of cortisol suppression on interleukin–6 and white blood cell responses to surgery. Jameson P, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):304–8

Propofol induces a lowering of free cytosolic calcium in myocardial cells. Li YC, et al. **Acta Anaesthesiol Scand** 1997 May;41(5):633–8

Analgesic and psychomotor effects of thiopental at subanesthetic concentrations in human volunteers. Young CJ, et al. **Acta Anaesthesiol Scand** 1997 Aug;41(7):903–10

Intravenous infusion of low dose propofol for conscious sedation in cesarean section before spinal anesthesia. Cheng YJ, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):79–84

The role of labetalol and propofol in the management of HELLP syndrome––a case report. Chu YL, et al. **Acta Anaesthesiol Sin** 1996 Mar;34(1):43–6

Propofol anesthesia in a patient with myasthenia gravis––a case report. Lin CC, et al. **Acta Anaesthesiol Sin** 1996 Jun; 34(2):89–92

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part V. Verapamil. Orszulak–Michalak D. **Acta Pol Pharm** 1996 Jan–Feb;53(1):57–61

Contrasting effects of urethane, ketamine, and thiopental anesthesia on ethanol–clonidine hemodynamic interaction. el–Mas MM, et al. **Alcohol Clin Exp Res** 1997 Feb; 21(1):19–27

Physiologic effects of anesthesia induced and maintained by intravenous administration of a climazolam–ketamine combination in ponies premedicated with acepromazine and xylazine. Bettschart–Wolfensberger R, et al. **Am J Vet Res** 1996 Oct;57(10):1472–7

Cardiopulmonary effects of propofol infusion in llamas. Duke T, et al. **Am J Vet Res** 1997 Feb;58(2):153–6

Cardiopulmonary and anesthetic effects of propofol in wild turkeys. Schumacher J, et al. **Am J Vet Res** 1997 Sep; 58(9):1014–7

Adverse cardiovascular effects of ketamine infusion in patients with catecholamine–dependent heart failure. Christ G, et al. **Anaesth Intensive Care** 1997 Jun;25(3):255–9

Blood loss during suction termination of pregnancy with two different anaesthetic techniques. Kumarasinghe N, et al. **Anaesth Intensive Care** 1997 Feb;25(1):48–50

The taste of intravenous thiopentone. Nor NB, et al. **Anaesth Intensive Care** 1996 Aug;24(4):483–5

Spontaneous movement after propofol: relationship to dopamine receptors [letter; comment] Akpek EA. **Anaesthesia** 1997 Apr;52(4):390–1. Comment on: Anaesthesia 1996 Jul;51(7):663–6.

Propofol, fluoxetine and spontaneous movement [letter] Armstrong TS, et al. **Anaesthesia** 1997 Aug;52(8):809–10

Spontaneous movement, propofol and dopamine receptors [letter] Borgeat A, et al. **Anaesthesia** 1997 Aug;52(8):808–9

Dreams, images and emotions associated with propofol anaesthesia. Brandner B, et al. **Anaesthesia** 1997 Aug; 52(8):750–5

Effects of propofol emulsion and thiopentone on T helper cell type–1/type–2 balance in vitro. Salo M, et al. **Anaesthesia** 1997 Apr;52(4):341–4

Thiopentone requirements in adults after varying pre–induction doses of fentanyl. Wang LP, et al. **Anaesthesia** 1996 Sep;51(9):831–5

Propofol inhibits in vitro platelet aggregation in human whole blood. De La Cruz JP, et al. **Anesth Analg** 1997 Apr; 84(4):919–21

Systemic vascular effects of isoflurane versus propofol anesthesia in dogs [see comments] Deryck YL, et al. **Anesth Analg** 1996 Nov;83(5):958–64. Comment in: Anesth Analg 1997 Apr;84(4):940–1.

The direct effects of propofol on myocyte contractile function after hypothermic cardioplegic arrest. Hebbar L, et al. **Anesth Analg** 1996 Nov;83(5):949–57

Effects of isoflurane and propofol on arterial mechanical properties [letter; comment] Hettrick DA, et al. **Anesth Analg** 1997 Apr;84(4):940–1. Comment on: Anesth Analg 1996 Nov;83(5):958–64.

Inhibitory effect of the intravenous anesthetic, ketamine, on rat mesangial cell proliferation. Jimi N, et al. **Anesth Analg** 1997 Jan;84(1):190–5

Propofol attenuates ischemia–reperfusion injury in the isolated rat heart. Ko SH, et al. **Anesth Analg** 1997 Oct; 85(4):719–24

Uric acid excretion increases during propofol anesthesia. Masuda A, et al. **Anesth Analg** 1997 Jul;85(1):144–8

Metabolic pattern and lipid oxidation during abdominal surgery: midazolam versus propofol. Pestaña D, et al. **Anesth Analg** 1996 Oct;83(4):837–43

The effects of thoracic epidural anesthesia on functional recovery from myocardial stunning in propofol–anesthetized dogs. Rolf N, et al. **Anesth Analg** 1997 Apr;84(4):723–9

Interactions between propofol and lipid mediator receptors: inhibition of lysophosphatidate signaling. Rossi MA, et al. **Anesth Analg** 1996 Nov;83(5):1090–6

Eltanolone as an alternative to propofol for ambulatory anesthesia. Tang J, et al. **Anesth Analg** 1997 Oct;85(4):801–7

Age–related propofol effects on electrophysiological properties of isolated hearts. Wu MH, et al. **Anesth Analg** 1997 May;84(5):964–71

Effects of midazolam on contractions in smooth muscle of the rabbit mesenteric artery. Yamaguchi S, et al. **Anesth Analg** 1997 Jan;84(1):199–205

Role of the endocardial endothelium in the negative inotropic effects of thiopental. Bettens KM, et al. **Anesthesiology** 1996 Nov;85(5):1100–10

Differential effects of etomidate, propofol, and midazolam on calcium and potassium channel currents in canine myocardial cells. Buljubasic N, et al. **Anesthesiology** 1996 Nov;85(5):1092–9

Effect of intravenous anesthetics on inward rectifier potassium current in rat and human ventricular myocytes. Carnes CA, et al. **Anesthesiology** 1997 Aug;87(2):327–34

Negative and selective effects of propofol on isolated swine myocyte contractile function in pacing–induced congestive heart failure. Hebbar L, et al. **Anesthesiology** 1997 Mar; 86(3):649–59

Alterations in canine left ventricular–arterial coupling and mechanical efficiency produced by propofol. Hettrick DA, et al. **Anesthesiology** 1997 May;86(5):1088–93

Propofol requirements versus stimulus intensity [editorial; comment] Hug CC Jr. **Anesthesiology** 1997 Aug; 87(2):201–2. Comment on: Anesthesiology 1997 Aug;87(2):213–27.

Effects of intracoronary fentanyl on left ventricular mechanoenergetics in the excised cross–circulated canine heart. Kohno K, et al. **Anesthesiology** 1997 Jun; 86(6):1350–8; discussion 7A–8A

Effects of intracoronary fentanyl on left ventricular mechanoenergetics in the excised cross–circulated canine heart (revised publication). Kohno K, et al. **Anesthesiology** 1997 Sep;87(3):658–66

Mild and moderate hypothermia provide better protection than a burst–suppression dose of thiopental against ischemic spinal cord injury in rabbits. Matsumoto M, et al. **Anesthesiology** 1997 May;86(5):1120–7

Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Minto CF, et al. **Anesthesiology** 1997 Jan;86(1):10–23

Lack of nonshivering thermogenesis in infants anesthetized with fentanyl and propofol [see comments] Plattner O, et al. **Anesthesiology** 1997 Apr;86(4):772–7. Comment in: Anesthesiology 1997 Apr;86(4):758–9.

Effects of propofol on sodium channel–dependent sodium influx and glutamate release in rat cerebrocortical synaptosomes. Ratnakumari L, et al. **Anesthesiology** 1997 Feb;86(2):428–39

Mechanisms whereby propofol mediates peripheral vasodilation in humans. Sympathoinhibition or direct vascular relaxation? Robinson BJ, et al. **Anesthesiology** 1997 Jan;86(1):64–72

The effect of isoflurane, halothane, sevoflurane, and thiopental/nitrous oxide on respiratory system resistance after tracheal intubation. Rooke GA, et al. **Anesthesiology** 1997 Jun;86(6):1294–9

Consequences of electroencephalographic–suppressive doses of propofol in conjunction with deep hypothermic circulatory arrest. Stone JG, et al. **Anesthesiology** 1996 Sep; 85(3):497–501

Pulmonary blood flow distribution in sheep: effects of anesthesia, mechanical ventilation, and change in posture. Walther SM, et al. **Anesthesiology** 1997 Aug;87(2):335–42

Role of nitric oxide–mediated signal transduction in hypothermia induced by intravenous anesthetics. Bansinath M, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:818–26

Isoflurane produces marked and nonlinear decreases in the vasoconstriction and shivering thresholds. Kurz A, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:778–85

In vitro modulation of hippocampal pyramidal cell response by quinolones: effects of HA 966 and gamma–hydroxybutyric acid. Dimpfel W, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2573–6

Hypnotic effect of i.v. propofol is enhanced by i.m. administration of either lignocaine or bupivacaine. Ben–Shlomo I, et al. **Br J Anaesth** 1997 Apr;78(4):375–7

Flow cytometry [letter; comment] Galley HF, et al. **Br J Anaesth** 1997 Feb;78(2):227–8. Comment on: Br J Anaesth 1996 Sep;77(3):387–92.

Propofol or halothane anaesthesia for children with asthma: effects on respiratory mechanics. Habre W, et al. **Br J Anaesth** 1996 Dec;77(6):739–43

Flow cytometry evaluation of the in vitro influence of four i.v. anaesthetics on respiratory burst of neutrophils [see comments] Heine J, et al. **Br J Anaesth** 1996 Sep; 77(3):387–92. Comment in: Br J Anaesth 1997 Feb;78(2):227–8.

I.v. anaesthetic agents inhibit dihydropyridine binding to L–type voltage–sensitive Ca2+ channels in rat cerebrocortical membranes [see comments] Hirota K, et al. **Br J Anaesth** 1996 Aug;77(2):248–53. Comment in: Br J Anaesth 1997 Apr;78(4):481–2.

Propofol attenuates formation of lipid peroxides in tourniquet–induced ischaemia–reperfusion injury. Kahraman S, et al. **Br J Anaesth** 1997 Mar;78(3):279–81

Is inhibition of dopamine uptake relevant to the hypnotic action of i.v. anaesthetics? Keita H, et al. **Br J Anaesth** 1996 Aug;77(2):254–6

Thiobarbiturates suppress depolarization–induced contraction of vascular smooth muscle without suppression of calcium influx. Kitamura R, et al. **Br J Anaesth** 1996 Oct;77(4):503–7

Effects on haemodynamics and catecholamine release of xenon anaesthesia compared with total i.v. anaesthesia in the pig. Marx T, et al. **Br J Anaesth** 1997 Mar;78(3):326–7

Changes in extracellular brain ascorbate in rat striatum in response to administration of non–volatile anaesthetic agents. Miele M, et al. **Br J Anaesth** 1997 May;78(5):588–90

Myocardial effects of eltanolone in hamsters with hypertrophic cardiomyopathy. Ruel P, et al. **Br J Anaesth** 1996 Nov;77(5):653–7

Comparative actions of propofol and thiopentone on cell membranes of isolated guineapig ventricular myocytes. Sakai F, et al. **Br J Anaesth** 1996 Oct;77(4):508–16

Spectral edge frequency of the electroencephalogram to monitor "depth" of anaesthesia with isoflurane or propofol. Schwender D, et al. **Br J Anaesth** 1996 Aug;77(2):179–84

Midlatency auditory evoked potentials and motor signs of wakefulness during anaesthesia with midazolam. Schwender D, et al. **Br J Anaesth** 1997 Jul;79(1):53–8

Ventilatory effects of eltanolone during induction of anaesthesia: comparison with propofol and thiopentone. Spens HJ, et al. **Br J Anaesth** 1996 Aug;77(2):194–9

Effect of lipid and propofol on oxidation of haemoglobin by reactive oxygen species. Stratford N, et al. **Br J Anaesth** 1997 Mar;78(3):320–2

Comparison of propofol and a propofol–methohexitone mixture for induction of day–case anaesthesia. Thompson N, et al. **Br J Anaesth** 1996 Aug;77(2):213–6

Concentration–related effects of propofol on the auditory evoked response. Tooley MA, et al. **Br J Anaesth** 1996 Dec;77(6):720–6

Effect of propofol on isolated human omental arteries and veins. Wallerstedt SM, et al. **Br J Anaesth** 1997 Mar; 78(3):296–300

Pregnenolone sulphate and pregnenolone do not interact with 5 beta–pregnanolone– and hexobarbitone–induced anaesthesia in the rat. Wang MD, et al. **Br J Anaesth** 1997 Mar;78(3):328–31

I.v. anaesthetics and binding to calcium channels [letter; comment] Wilkinson PR. **Br J Anaesth** 1997 Apr; 78(4):481–2. Comment on: Br J Anaesth 1996 Aug;77(2):248–53.

Subunit–dependent interaction of the general anaesthetic etomidate with the gamma–aminobutyric acid type A receptor. Hill–Venning C, et al. **Br J Pharmacol** 1997 Mar; 120(5):749–56

Inhibition by propofol of [3H]–batrachotoxinin–A 20–alpha–benzoate binding to voltage–dependent sodium channels in rat cortical synaptosomes. Ratnakumari L, et al. **Br J Pharmacol** 1996 Dec;119(7):1498–504

Comparative direct electrophysiological effects of propofol on the conduction system and ionic channels of rabbit hearts. Wu MH, et al. **Br J Pharmacol** 1997 Jun; 121(4):617–24

Propofol regulation of calcium entry pathways in cultured A10 and rat aortic smooth muscle cells. Xuan YT, et al. **Br J Pharmacol** 1996 Jan;117(1):5–12

Spinal anaesthesia with midazolam in the rat. Bahar M, et al. **Can J Anaesth** 1997 Feb;44(2):208–15

Thiopentone or propofol for LMA insertion? [letter; comment] Cook TM, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):569. Comment on: Can J Anaesth 1996 Jun;43(6):564–8.

Ventilatory parameters in children during propofol anaesthesia: a comparison with halothane. Kulkarni P, et al. **Can J Anaesth** 1996 Jul;43(7):653–9

Midazolam and awareness with recall during total intravenous anaesthesia. Miller DR, et al. **Can J Anaesth** 1996 Sep;43(9):946–53

Intravenous anaesthesia and leukocytes [letter; comment] Morisaki H, et al. **Can J Anaesth** 1997 Jan;44(1):100. Comment on: Can J Anaesth 1993 Aug;40(8):770–4.

Droperidol inhibits tracheal contraction induced by serotonin, histamine or carbachol in guinea pigs. Sato T, et al. **Can J Anaesth** 1996 Feb;43(2):172–8

New induction agents. Sear JW. **Can J Anaesth** 1997 May; 44(5 Pt 2):R3–12 (25 ref.) **(Eng, Fre)**

Propofol inhibits medullary pressor mechanisms in cats. Yang CY, et al. **Can J Anaesth** 1997 Jul;44(7):775–81

Electrophysiological effects of propofol on the normal cardiac conduction system. Pires LA, et al. **Cardiology** 1996 Jul–Aug;87(4):319–24

Effects of midazolam on the differentiation of murine myeloid leukemia cells. Mak NK, et al. **Chemotherapy** 1997 Jul–Aug; 43(4):272–81

The effects of midazolam and ephedrine on post–exercise autonomic chronotropic control of the heart in normal subjects. Lindqvist A, et al. **Clin Auton Res** 1996 Dec; 6(6):343–9

A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect. Billard V, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):45–58

Propofol inhibits epileptiform activity in rat hippocampal slices. Rasmussen PA, et al. **Epilepsy Res** 1996 Nov; 25(3):169–75

Thiopentone and propofol, but not methohexitone nor midazolam, inhibit neutrophil oxidative responses to the bacterial peptide FMLP. Fröhlich D, et al. **Eur J Anaesthesiol** 1996 Nov;13(6):582–8

The effect of propofol and thiopentone on impairment by reactive oxygen species of endothelium–dependent relaxation in rat aortic rings. Kelicen P, et al. **Eur J Anaesthesiol** 1997 May;14(3):310–5

The effects of midazolam or propofol followed by suxamethonium on the QT interval in humans. Michaloudis DG, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):364–8

The effect of propofol on the neutrophil respiratory burst. Murphy PG, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):471–3

Propofol does not affect platelet aggregation. Türkan H, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):408–9

Propofol neuroprotection in a rat model of ischaemia reperfusion injury. Young Y, et al. **Eur J Anaesthesiol** 1997 May;14(3):320–6

Intravenous anaesthetics: some cellular sites of action. Dzoljic M, et al. **Eur J Anaesthesiol Suppl** 1997 May;15:3–7 (50 ref.)

Effects of anaesthetic agents on basal and histamine–stimulated acid secretion in the fistula rat. Bastaki SM, et al. **Eur J Gastroenterol Hepatol** 1995 Dec; 7(12):1199–202

Propofol and flurazepam act synergistically to potentiate GABAA receptor activation in human recombinant receptors. Reynolds JN, et al. **Eur J Pharmacol** 1996 Oct 24;314(1–2):151–6

Effects of pentobarbital and etomidate on plasma catecholamine levels and spectral analysis of blood pressure and heart rate in dogs. Mazerolles M, et al. **Fundam Clin Pharmacol** 1996;10(3):298–303

Alteration of tissue carnitine content following anaesthesia with barbiturate and surgery in rat. Pessotto P, et al. **Int J Clin Pharmacol Res** 1995;15(5–6):191–9

Negative inotropic effect of low–dose propofol infusion in cardiac–compromised patients [letter; comment] [see comments] Guarracino F, et al. **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):568. Comment on: J Cardiothorac Vasc Anesth 1995 Aug;9(4):368–72. Comment in: J Cardiothorac Vasc Anesth 1997 Apr;11(2):264.

Bolus administration of eltanolone, thiopental, or etomidate does not affect systemic vascular resistance during cardiopulmonary bypass. Tassani P, et al. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):562–4

Changes in heart rate variability during induction of anesthesia with fentanyl and midazolam. Zickmann B, et al. **J Cardiothorac Vasc Anesth** 1996 Aug;10(5):609–13

Anesthetic interactions following bolus injections. Kissin I. **J Clin Anesth** 1997 Sep;9(6 Suppl):14S–17S

Propofol at conscious sedation doses produces mild analgesia to cold pressor–induced pain in healthy volunteers. Zacny JP, et al. **J Clin Anesth** 1996 Sep;8(6):469–74

Comparison of alfentanil and fentanyl for anesthesia in short gynecologic procedures. Tan PP, et al. **J Formos Med Assoc** 1996 Jul;95(7):540–4

Anti–serotonergic effects of urethane and chloral hydrate may not be mediated by a blockade of 5–HT2 receptors. Short communication. Dringenberg HC, et al. **J Neural Transm Gen Sect** 1996;103(6):693–8

Distinct loci mediate the direct and indirect actions of the anesthetic etomidate at GABA(A) receptors. Moody EJ, et al. **J Neurochem** 1997 Sep;69(3):1310–3

Neuroprotection by propofol in acute mechanical injury: role of GABAergic inhibition. Hollrigel GS, et al. **J Neurophysiol** 1996 Oct;76(4):2412–22

The effect of isoflurane on biochemical changes during and electrophysiological recovery after anoxia in rat hippocampal slices. Kass IS, et al. **J Neurosurg Anesthesiol** 1997 Jul;9(3):280–6

Effects of propofol on cerebral blood flow, metabolism, and cerebral autoregulation in the anesthetized pig. Lagerkranser M, et al. **J Neurosurg Anesthesiol** 1997 Apr; 9(2):188–93

Comparative effects of propofol, pentobarbital, and isoflurane on cerebral blood flow and blood volume. Todd MM, et al. **J Neurosurg Anesthesiol** 1996 Oct;8(4):296–303

Role of the endothelium in the relaxation induced by propofol and thiopental in isolated arteries from man. Moreno L, et al. **J Pharm Pharmacol** 1997 Apr;49(4):430–2

Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation [letter] Dutta S, et al. **J Pharm Sci** 1997 Aug;86(8):967–9

Concentration–EEG effect relationship of propofol in rats. Dutta S, et al. **J Pharm Sci** 1997 Jan;86(1):37–43

Antinociceptive properties of propofol: involvement of spinal cord gamma–aminobutyric acid(A) receptors. Nadeson R, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1181–6

Continuous total intravenous anesthesia, using propofol and fentanyl in an open–thorax rabbit model: evaluation of cardiac contractile function and biochemical assessment. De Mulder PA, et al. **Lab Anim Sci** 1997 Aug;47(4):367–75

Effect of thiopental, saffan, and propofol anesthesia on cardiovascular parameters and bronchial smooth muscle in the rhesus monkey. Foster A, et al. **Lab Anim Sci** 1996 Jun;46(3):327–34

The effects of propofol on cerebral high energy metabolites, lactate, and glucose in normoxic and severely hypoxic rats. Ori C, et al. **Life Sci** 1997;60(16):1349–57

Fluctuations in serum magnesium levels during total intravenous anaesthesia with propofol. Nastou H, et al. **Magnes Res** 1996 Mar;9(1):47–53

Effects of halothane, alpha–chloralose, and pCO2 on injury volume and CSF beta–endorphin levels in focal cerebral ischemia. Browning JL, et al. **Mol Chem Neuropathol** 1997 May;31(1):29–42

Respiratory effects of intravenous midazolam. Zacharias M, et al. **N Z Dent J** 1996 Sep;92(409):76–9

Insensitivity to anaesthetic agents conferred by a class of GABA(A) receptor subunit. Davies PA, et al. **Nature** 1997 Feb 27;385(6619):820–3

Effect of chloral hydrate on in vivo KCl–induced striatal dopamine release in the rat. Chen HT, et al. **Neurochem Res** 1996 Jun;21(6):695–700

Effect of the intravenous anesthetic 2,6–diisopropylphenol on respiration and energy production by rat brain synaptosomes. Marian M, et al. **Neurochem Res** 1997 Mar; 22(3):287–92

Cerebral blood flow and metabolic response to etomidate and ischemia. Hoffman WE, et al. **Neurol Res** 1997 Feb; 19(1):41–4

Alpha subunit isoform influences GABA(A) receptor modulation by propofol. Krasowski MD, et al. **Neuropharmacology** 1997 Jul;36(7):941–9

Pharmacological characterisation of multiple components in the enhancement by pregnanolone and propofol of [3H]flunitrazepam binding to GABAA receptors. Zhong Y, et al. **Neuropharmacology** 1996;35(9–10):1193–8

Propofol potentiates the depressant effect of alfentanil in isolated neonatal rat spinal cord and blocks naloxone–precipitated hyperresponsiveness. Feng JQ, et al. **Neurosci Lett** 1997 Jun 20;229(1):9–12

Effect of nitrous oxide and propofol on amino acid metabolism in neoplasic patients. Crespo ML, et al. **Nutr Cancer** 1997;27(1):80–3

Neurone–specific enolase and Sangtec 100 assays during cardiac surgery: Part I—The effects of heparin, protamine and propofol. Gao F, et al. **Perfusion** 1997 May;12(3):163–5

Responses to propofol in relation to GABA functionality of discrete parts of the brain of rats. Dirksen R, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):727–35

Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Hustveit O, et al. **Pharmacol Toxicol** 1995 Dec;77(6):355–9

Excitatory action of angiotensins II and IV on hippocampal neuronal activity in urethane anesthetized rats. Albrecht D, et al. **Regul Pept** 1997 Jun 18;70(2–3):105–9

Effects of intravenous anesthetics on the contraction and response of rat trachea to phosphatidylinositol. Tsujita T, et al. **Res Commun Mol Pathol Pharmacol** 1997 Mar; 95(3):287–303

Comparison of three injectable anaesthetic techniques in pigs. Clutton RE, et al. **Vet Rec** 1997 Aug 9;141(6):140–6

Sufentanil and nitrous oxide anaesthesia for the recording of transcranial magnetic motor evoked potentials in dogs. Van Ham LM, et al. **Vet Rec** 1996 Jun 29;138(26):642–5

[Effects of propofol on blood concentration of cyclosporine] Pertek JP, et al. **Ann Fr Anesth Reanim** 1996;15(5):589–94 (Eng. Abstr.) **(Fre)**

[Prolongation of fentanyl–induced decreased arousal by clonidine] Walz R, et al. **Anaesthesiol Reanim** 1997; 22(2):42–5 (Eng. Abstr.) **(Ger)**

[Etomidate inhibits neuronal potassium channels in humans] Friederich P, et al. **Anaesthesist** 1997 May;46(5):434–6 (Eng. Abstr.) **(Ger)**

[Concentration–effect relationship, hemodynamics and respiration after infusion of the steroid anesthetic eltanolone in healthy subjects] Hering W, et al. **Anaesthesist** 1996 Dec; 45(12):1142–50 (Eng. Abstr.) **(Ger)**

[Interaction of nimodipine and propofol in dogs. Hemodynamics and cardiodynamics] Rolf N, et al. **Anaesthesist** 1997 May;46(5):398–402 (Eng. Abstr.) **(Ger)**

[Effects of midazolam and propofol on dopamine release from rat striatal slice using a fast–cyclic voltammetry system] Hotta O, et al. **Masui** 1997 Jun;46(6):755–63 (Eng. Abstr.) **(Jpn)**

[Inhibitory effect of ketamine on depolarization–induced norepinephrine release in the rat ventral hippocampus investigated by in vivo microdialysis] Mae T, et al. **Masui** 1997 Mar;46(3):331–7 (Eng. Abstr.) **(Jpn)**

[Acid–base equilibrium in anesthesia with the Valium–Inoval combination] do Amaral RV, et al. **Rev Bras Anestesiol** 1968 Oct–Dec;18(4):462–71 (Eng. Abstr.) **(Por)**

[Effects of induction propofol mono–narcosis on the central and cerebral hemodynamics] Grinberg BI, et al. **Anesteziol Reanimatol** 1997 Jan–Feb;(1):56–8 (Eng. Abstr.) **(Rus)**

[Safety of sevoflurane in humans (letter; comment)] Martínez A, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):78–9 . Comment on: Rev Esp Anestesiol Reanim 1995 Feb;42(2):77–8. **(Spa)**

THERAPEUTIC USE

Remifentanil approved for anesthesia use [news] **Am J Health Syst Pharm** 1996 Oct 1;53(19):2250

Tracheal intubation using alfentanil and no muscle relaxant: is the choice of hypnotic important? Stevens JB, et al. **Anesth Analg** 1997 Jun;84(6):1222–6

Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Cope DK, et al. **Anesthesiology** 1997 Mar; 86(3):699–709

Meta–analytic comparison of prophylactic antiemetic efficacy for postoperative nausea and vomiting: propofol anaesthesia vs omitting nitrous oxide vs total i.v. anaesthesia with propofol. Tramèr M, et al. **Br J Anaesth** 1997 Mar; 78(3):256–9

Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies. Tramèr M, et al. **Br J Anaesth** 1997 Mar; 78(3):247–55

Comparative effects of thiopentone and propofol on respiratory resistance after tracheal intubation. Wu RS, et al. **Br J Anaesth** 1996 Dec;77(6):735–8

Intravenous agents and intraoperative neuroprotection. Beyond barbiturates. Cheng MA, et al. **Crit Care Clin** 1997 Jan;13(1):185–99 (90 ref.)

Remifentanil. Patel SS, et al. **Drugs** 1996 Sep;52(3):417–27; discussion 428 (53 ref.)

Thoracolumbar epidural blockade as adjunct to high dose fentanyl/midazolam anesthesia in coronary surgery: effects of sternotomy. Thorelius J, et al. **Eur J Cardiothorac Surg** 1996;10(9):754–62

Variation of serum potassium and creatinine phosphokinase levels in suxamethonium–induced muscle relaxation. Guha A, et al. **J Indian Med Assoc** 1996 Feb;94(2):45–6

Conscious sedation with high–dose midazolam for pediatric gastrointestinal endoscopy. Gremse DA, et al. **South Med J** 1997 Aug;90(8):821–5

Comparison of propofol and methohexitone as an induction agent in anaesthesia for electroconvulsive therapy. Lim SK, et al. **West Afr J Med** 1996 Oct–Dec;15(4):186–9

[Intravenous anesthetic agents in ambulatory anesthesia] Servin F. **Rev Med Suisse Romande** 1997 May;117(5):375–7 (15 ref.) **(Fre)**

[Anesthetic agents and visual evoked potentials in patients undergoing transphenoidal or breast reconstruction surgery] Damiani Cavero S, et al. **Neurologia** 1997 Feb; 12(2):51–5 (Eng. Abstr.) **(Spa)**

TOXICITY

Negative and selective effects of propofol on isolated swine myocyte contractile function in pacing–induced congestive heart failure. Hebbar L, et al. **Anesthesiology** 1997 Mar; 86(3):649–59

Influence of urethane anesthesia on neural processing in the auditory cortex analogue of a songbird. Capsius B, et al. **Hear Res** 1996 Jul;96(1–2):59–70

The effect of the anaesthetic, Propofol, on in–vitro oocyte maturation, fertilization and cleavage in mice. Alsalili M, et al. **Hum Reprod** 1997 Jun;12(6):1271–4

[Propofol is toxic for immature GABAergic neurons] Matthieu JM, et al. **Rev Med Suisse Romande** 1996 Dec; 116(12):971–3 **(Fre)**

URINE

Determination of diprivan in urine by a supported liquid membrane technique and liquid chromatography–electrochemical detection. Trocewicz J, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11; 685(1):129–34

ANESTHETICS, LOCAL

Motor power pharmacodynamics of subarachnoid hyperbaric 5% lidocaine in the sitting position. Rushmer J, et al. **Acta Anaesthesiol Scand** 1997 May;41(5):557–64

Comparison of the analgesic effect of EMLA cream and EMLA patch on normal skin evaluated with laser–induced pain stimuli. Egekvist H, et al. **Acta Derm Venereol** 1997 May;77(3):214–6

Presumed herpetic keratitis and topical anesthetic abuse [letter] Solomon A, et al. **Acta Ophthalmol Scand** 1996 Oct; 74(5):518–9

Stability of ceftriaxone sodium reconstituted with lidocaine hydrochloride and stored in polypropylene syringes. Plumridge RJ, et al. **Am J Health Syst Pharm** 1996 Oct 1;53(19):2323–5

Tetracaine versus lidocaine–prilocaine for preventing venipuncture–induced pain in children. van Kan HJ, et al. **Am J Health Syst Pharm** 1997 Feb 15;54(4):388–92

Using local anesthetics to control procedural pain. Wong D, et al. **Am J Nurs** 1997 Jan;97(1):17

Postoperative epidural ropivacaine [letter] Knuth S, et al. **Anaesth Intensive Care** 1997 Aug;25(4):435

Comparison of 0.5% ropivacaine and 0.5% bupivacaine in lumbar epidural anaesthesia for lower limb orthopaedic surgery. McGlade DP, et al. **Anaesth Intensive Care** 1997 Jun;25(3):262–6

Axillary brachial plexus block in two hundred consecutive patients. Pearce H, et al. **Anaesth Intensive Care** 1996 Aug; 24(4):453–8

Laryngeal mask lubrication. A comparative study of saline versus 2% lignocaine gel with cuff pressure control. Keller C, et al. **Anaesthesia** 1997 Jun;52(6):592–7

Failed spinal anaesthesia [letter] Stace JD, et al. **Anaesthesia** 1996 Sep;51(9):892–3

Postoperative epidural infusion: a randomized, double-blind, dose-finding trial of clonidine in combination with bupivacaine and fentanyl. Paech MJ, et al. **Anesth Analg** 1997 Jun;84(6):1323–8

Local analgesia effect of nonsteroidal antiinflammatory drugs [letter; comment] Reuben SS, et al. **Anesth Analg** 1997 May; 84(5):1168–9. Comment on: Anesth Analg 1996 Dec;83(6):1239–43.

Addition of epinephrine to intrathecal bupivacaine and sufentanil for ambulatory labor analgesia. Campbell DC, et al. **Anesthesiology** 1997 Mar;86(3):525–31

Effects of concentration and volume of 2-chloroprocaine on epidural anesthesia in volunteers. Liu SS, et al. **Anesthesiology** 1997 Jun;86(6):1288–93; discussion 7A

N-butyl tetracaine as a neurolytic agent for ultralong sciatic nerve block. Wang GK, et al. **Anesthesiology** 1996 Dec; 85(6):1386–94

Anesthetic efficacy of eutectic prilocaine-lidocaine cream in pediatric oncology patients undergoing lumbar puncture. Juárez Gimenez JC, et al. **Ann Pharmacother** 1996 Nov; 30(11):1235–7

Catheterisation technique: overcoming gel blockage. Graham AJ, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5):439

Effectiveness of lidocaine hydrochloride on venipuncture sites. Hussey VM, et al. **AORN J** 1997 Sep;66(3):472–4, 476, 479–80

Preemptive analgesia in patients undergoing appendectomy. Ko CY, et al. **Arch Surg** 1997 Aug;132(8):874–7; discussion 877–8

Local anesthesia for arthroscopic surgery of the ankle using pethidine or prilocaine. Westman L, et al. **Arthroscopy** 1997 Jun;13(3):307–12

Efficacy of bupivacaine delivered by wound catheter for post-Caesarean section analgesia. Mecklem DW, et al. **Aust N Z J Obstet Gynaecol** 1995 Nov;35(4):416–21

Measurement of methemoglobin after EMLA analgesia for newborn circumcision. Law RM, et al. **Biol Neonate** 1996; 70(4):213–7

A comparison of topical anaesthesia and electronic nerve stimulation for reducing the pain of intra-oral injections [see comments] Meechan JG, et al. **Br Dent J** 1996 Nov 9;181(9):333–5. Comment in: Br Dent J 1997 Jan 25;182(2):50.

Ropivacaine 0.75% for extradural anaesthesia in elective caesarean section: an open clinical and pharmacokinetic study in mother and neonate. Morton CP, et al. **Br J Anaesth** 1997 Jul;79(1):3–8

Transcervical analgesia for laparoscopic sterilisation [letter; comment] Kelly MC, et al. **Br J Obstet Gynaecol** 1996 Oct;103(10):1051. Comment on: Br J Obstet Gynaecol 1996 Apr;103(4):378–80.

Topical anaesthesia with oxybuprocaine versus sub-Tenon's infiltration with 2% lignocaine for small incision cataract surgery. Chittenden HB, et al. **Br J Ophthalmol** 1997 Apr; 81(4):288–90

Re-evaluation of hyaluronidase in peribulbar anaesthesia. Prosser DP, et al. **Br J Ophthalmol** 1996 Sep;80(9):827–30

Removal of skin staples and the use of EMLA cream [letter] Banwell P, et al. **Br J Plast Surg** 1997 Feb;50(2):144–5

Rectus sheath bupivacaine analgesia after aortic surgery [letter; comment] Chester JF, et al. **Br J Surg** 1997 May; 84(5):728. Comment on: Br J Surg 1996 Nov;83(11):1558.

Randomized trial of periportal peritoneal bupivacaine for pain relief after laparoscopic cholecystectomy [letter; comment] Lotz JC. **Br J Surg** 1997 May;84(5):730. Comment on: Br J Surg 1996 Sep;83(9):1223–5.

Spermatic-cord block improves analgesia for day-case testicular surgery. Burden RJ, et al. **Br J Urol** 1997 Sep; 80(3):472–5

A prospective, randomized, double-blind study comparing lignocaine gel and plain lubricating gel in relieving pain during flexible cystoscopy. Choong S, et al. **Br J Urol** 1997 Jul;80(1):69–71

Patient acceptability of transurethral incision of the prostate under local anaesthesia. Irani I, et al. **Br J Urol** 1996 Dec; 78(6):904–6

Decreased cocaine- and lidocaine-induced seizure response by dextromethorphan and DNQX in rat. Barat SA, et al. **Brain Res** 1997 May 9;756(1-2):179–83

Ca(2+)-antagonistic action of bevantolol on hypothalamic neurons in vitro: its comparison with those of other beta-adrenoceptor antagonists, a local anesthetic and a Ca(2+)-antagonist. Omura T, et al. **Brain Res** 1996 Jan 15;706(2):289–92

Conscious sedation: what an internist needs to know. Higgins TL, et al. **Cleve Clin J Med** 1996 Oct;63(6):355–61 (22 ref.)

Comparison of topical anesthetics with lidocaine infiltration during laceration repair in children. Smith GA, et al. **Clin Pediatr (Phila)** 1997 Jan;36(1):17–23

Saturated phenol as a local anesthetic for manual dermabrasion. Ruiz-Maldonado R. **Dermatol Surg** 1997 Mar;23(3):187–89; discussion 190

Preliminary risk-benefit analysis of ropivacaine in labour and following surgery. Cederholm I. **Drug Saf** 1997 Jun; 16(6):391–402 (60 ref.)

A comparison of topical Emla cream with Bonain's solution for anesthesia of the tympanic membrane during tympanocentesis. Jyväkorpi M. **Eur Arch Otorhinolaryngol** 1996;253(4–5):234–6

Thoracic epidural anaesthesia and analgesia with bupivacaine for transsternal thymectomy for myasthenia gravis. Akpolat N, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):220–3

Readiness for surgery after axillary block: single or multiple injection techniques. Koscielniak-Nielsen ZJ, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):164–71

Development of a sedation policy for upper GI endoscopy based on an audit of patients' perception of the procedure [see comments] Martin JP, et al. **Eur J Gastroenterol Hepatol** 1996 Apr;8(4):355–7. Comment in: Eur J Gastroenterol Hepatol 1996 Sep;8(9):933.

Warming lignocaine reduces the pain of injection during local anaesthetic eyelid surgery. Bell RW, et al. **Eye** 1996;10 (Pt 5):558–60

A simple method of warming local anaesthetic solutions [letter] Fuller JR, et al. **Eye** 1995;9 (Pt 6):809–10

Preparation and local anaesthetic activity of N-[2-(tert-amino)ethyl]- and N-(lupinyl)-benzotriazol-1/2-ylacetamides. Vazzana I, et al. **Farmaco** 1997 Mar;52(3):131–9

Popliteal sciatic nerve block for postoperative analgesia. Rongstad K, et al. **Foot Ankle Int** 1996 Jul;17(7):378–82

Topical anesthesia and urease tests [letter] Rey E, et al. **Gastrointest Endosc** 1996 Dec;44(6):760

Endosonography-guided celiac plexus neurolysis. Wiersema MJ, et al. **Gastrointest Endosc** 1996 Dec;44(6):656–62

Comparison of intra-articular lignocaine and a suprascapular nerve block for acute anterior shoulder dislocation. Gleeson AP, et al. **Injury** 1997 Mar;28(2):141–2

Hyaluronidase (Hyalase): a useful addition in haematoma block? London NJ, et al. **J Accid Emerg Med** 1996 Sep; 13(5):337–8

Fasting before Bier's block [letter; comment] Nandwani N, et al. **J Accid Emerg Med** 1997 Jan;14(1):59; discussion 60 . Comment on: J Accid Emerg Med 1996 Mar;13(2):105–7.

Fasting before Bier's block [letter; comment] Stokes JM, et al. **J Accid Emerg Med** 1997 Jan;14(1):59–60. Comment on: J Accid Emerg Med 1996 Mar;13(2):105–7.

Caudal epidural butorphanol plus bupivacaine versus bupivacaine in pediatric outpatient genitourinary procedures. Lawhorn CD, et al. **J Clin Anesth** 1997 Mar; 9(2):103–8

Hemodynamic effects of intrathecal sufentanil compared with epidural bupivacaine in laboring parturients. Pham LH, et al. **J Clin Anesth** 1996 Sep;8(6):497–501; discussion 502–3

Is intravenous lidocaine an effective adjuvant for endotracheal intubation in children undergoing induction of anesthesia with halothane-nitrous oxide? Warner LO, et al. **J Clin Anesth** 1997 Jun;9(4):270–4

Visual laser coagulation of the prostate using intraurethral gel anesthesia and light intravenous analgesia and sedation. Karlsen SJ, et al. **J Endourol** 1996 Aug;10(4):389–91

Analgesia during circumcision. Dake P, et al. **J Fam Pract** 1997 Aug;45(2):100–1

Flexible transnasal endoscopy: is local anaesthetic necessary? Singh V, et al. **J Laryngol Otol** 1997 Jul;111(7):616–8

Postoperative pain management. d'Amours RH, et al. **J Orthop Sports Phys Ther** 1996 Oct;24(4):227–36 (65 ref.)

Nerve blocks with local anesthetics and corticosteroids in chronic pain: a clinical follow-up study. Johansson A, et al. **J Pain Symptom Manage** 1996 Mar;11(3):181–7

Effects of clonidine pretreatment on the local anaesthetic activity of bupivacaine in mice. Attolini L, et al. **J Pharm Pharmacol** 1995 Dec;47(12A):994–6

Penile block timing for postoperative analgesia of hypospadias repair in children. Chhibber AK, et al. **J Urol** 1997 Sep;158(3 Pt 2):1156–9

Bupivacaine for postoperative analgesia following endoscopic sinus surgery. Friedman M, et al. **Laryngoscope** 1996 Nov;106(11):1382–5

Sphenopalatine blocks in the treatment of pain in fibromyalgia and myofascial pain syndrome. Janzen VD, et al. **Laryngoscope** 1997 Oct;107(10):1420–2

Ropivacaine--a new local anesthetic. **Med Lett Drugs Ther** 1997 Aug 15;39(1007):80

Digital blocks [letter] Tountas CP. **Minn Med** 1996 Sep; 79(9):6

Anesthesiology. Second of two parts. Wiklund RA, et al. **N Engl J Med** 1997 Oct 23;337(17):1215–9 (151 ref.)

Sphenopalatine ganglion block relieves symptoms of trigeminal neuralgia: a case report. Manahan AP, et al. **Nebr Med J** 1996 Sep;81(9):306–9

Para-umbilical block: a new concept for regional anaesthesia in children. Courreges P, et al. **Paediatr Anaesth** 1997; 7(3):211–4

Diclofenac vs oxybuprocaine eyedrops for analgesia in paediatric strabismus surgery. Morton NS, et al. **Paediatr Anaesth** 1997;7(3):221–6

High spinal anaesthesia for repair of patent ductus arteriosus in neonates. Williams RK, et al. **Paediatr Anaesth** 1997; 7(3):205–9

Facilitation of spinal cord stimulator implantation with epidural analgesia [see comments] Richardson J. **Pain** 1996 May-Jun;65(2-3):277–8. Comment in: Pain 1997 Apr;70(2-3):291–2.

Effect of addition of hyaluronidase and epinephrine on the pH of local anesthetic solutions [letter] England AJ, et al. **Reg Anesth** 1996 Nov-Dec;21(6):605–6

Failure of meperidine to anesthetize human median nerve. A blinded comparison with lidocaine and saline. Flanagan MT, et al. **Reg Anesth** 1997 Jan-Feb;22(1):73–9

Preemptive analgesia in children. Does it exist? Ho JW, et al. **Reg Anesth** 1997 Mar-Apr;22(2):125–30

Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. Simon MA, et al. **Reg Anesth** 1997 Jan-Feb; 22(1):29–34

Reduction of blood loss during spinal surgery by epidural blockade under normotensive general anesthesia. Kakiuchi M. **Spine** 1997 Apr 15;22(8):889–94

Preemptive analgesia in the laparoscopic patient. Mixter CG 3rd, et al. **Surg Endosc** 1997 Apr;11(4):351–3

A comparison of epidural saline, morphine, and bupivacaine for pain relief after abdominal surgery in goats. Hendrickson DA, et al. **Vet Surg** 1996 Jan-Feb;25(1):83–7

Postoperative analgesia for stifle surgery: a comparison of intra-articular bupivacaine, morphine, or saline. Sammarco JL, et al. **Vet Surg** 1996 Jan-Feb;25(1):59–69

[The use of Diprivan in combination with the local use of lidocaine/adrenaline in operations on the neck area] Tomova M. **Khirurgiia (Sofiia)** 1996;49(4):40–1 (Eng. Abstr.) **(Bul)**

[Peribulbar anesthesia and intraocular lens implantation] Yang W, et al. **Chung Hua Yen Ko Tsa Chih** 1995 Jul; 31(4):271–3 (Eng. Abstr.) **(Chi)**

[Use of an anesthetic cream in the surgical treatment of phimosis] Passaro U, et al. **Ann Urol (Paris)** 1997; 31(2):101–2 (Eng. Abstr.) **(Fre)**

[Use of percutaneous anesthesia in cardiac pacemaker implantation] Trigano JA, et al. **Presse Med** 1996 Jul 6–13; 25(24):1097–100 (Eng. Abstr.) **(Fre)**

[Single-dose spinal anesthesia with a mixture of isobaric bupivacaine 0.5% and hyperbaric mepivacaine 4%] Eckert S, et al. **Anaesthesist** 1997 Feb;46(2):121–5 (Eng. Abstr.) **(Ger)**

[Combined 3-in-1 sciatic block. Prilocaine 500 mg vs. 650 mg] Wagner F, et al. **Anaesthesist** 1997 Mar;46(3):195–200 (Eng. Abstr.) **(Ger)**

[Ropivacaine for spinal anesthesia. A dose-finding study] Wahedi W, et al. **Anaesthesist** 1996 Aug;45(8):737–44 (Eng. Abstr.) **(Ger)**

[EMLA for anesthesia of puncture sites for large lumen indwelling venous catheters for autologous plasma and erythrocyte concentrate donation] Gelowicz-Maurer M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jan;32(1):27–9 (Eng. Abstr.) **(Ger)**

[Treatment of tinnitus with lidocaine? (comment)] Kellerhals B. **HNO** 1997 Feb;45(2):63–4. Comment on: HNO 1997 Feb;45(2):69–73. **(Ger)**

[Superficial sponge anesthesia in cataract surgery (with scleral tunnel incision)] Pham DT, et al. **Klin Monatsbl Augenheilkd** 1996 Dec;209(6):347–53 (Eng. Abstr.) **(Ger)**

[The role of transdermal anesthesia with EMLA in urologic surgery] Tedeschi D, et al. **Minerva Urol Nefrol** 1997 Jun; 49(2):87–9 (Eng. Abstr.) **(Ita)**

[Comparison of analgesic effect of lidocaine tape versus eutectic mixture of lidocaine and tetracaine during infiltration of local anesthetics before epidural block] Kawano T, et al. **Masui** 1996 Sep;45(9):1074–7 (Eng. Abstr.) **(Jpn)**

[The spread of subarachnoid hyperbaric dibucaine in the term parturient] Konishi R, et al. **Masui** 1997 Feb;46(2):184–7 (Eng. Abstr.) **(Jpn)**

[Combined spinal-epidural anesthesia for intra-abdominal gynecological surgeries] Nagashima N, et al. **Masui** 1996 Sep;45(9):1153–9 (Eng. Abstr.) **(Jpn)**

[Local anesthetics] Namiki A, et al. **Masui** 1996 Dec;45 Suppl:S192–8 (19 ref.) **(Jpn)**

[Comparison of epidural fentanyl versus bupivacaine in maintaining intraoperative liver function] Nishiyama M. **Masui** 1997 Jun;46(6):743–9 (Eng. Abstr.) **(Jpn)**

[Spinal anesthesia with 2% plain lidocaine for ultrasonically guided vaginal oocyte retrieval] Omi S, et al. **Masui** 1996 Dec;45(12):1507–10 (Eng. Abstr.) **(Jpn)**

[A case of severe hypertension caused by stellate ganglion block in a patient with facial palsy] Yokota S, et al. **Masui** 1996 Sep;45(9):1123–6 (Eng. Abstr.) **(Jpn)**

[The use of Categel with lidocaine in urology] Kadyrov ZA, et al. **Urol Nefrol (Mosk)** 1997 May-Jun;(3):29–31 (Eng. Abstr.) **(Rus)**

[Ultracaine anesthesia in surgical otorhinolaryngology] Aniutin RG, et al. **Vestn Otorinolaringol** 1996 Nov-Dec; (6):38–40 (Eng. Abstr.) **(Rus)**

[Topical anesthesia with the EMLA cream: application in pediatric urology] Xavier B, et al. **Actas Urol Esp** 1996 Nov-Dec;20(10):883–5 (15 ref.) (Eng. Abstr.) **(Spa)**

[Effect of the local anesthetic on visceral pain in cesarean sections done under intradural anesthesia] Echevarría M, et al. **Rev Esp Anestesiol Reanim** 1996 Jan;43(1):2–6 (Eng. Abstr.) **(Spa)**

[Subarachnoid anesthesia with minimal doses of lidocaine in

ambulatory arthroscopic surgery of the knee] Raich-Brufau M, et al. **Rev Esp Anestesiol Reanim** 1997 May;44(5):204-6 (Eng. Abstr.) **(Spa)**

[The effects of carbonation on 2% mepivacaine in epidural anesthesia] Tisner ML, et al.
Rev Esp Anestesiol Reanim 1997 Apr;44(4):140-3 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Topical tetracaine attenuates the pain of infiltration of buffered lidocaine. Bartfield JM, et al.
Acad Emerg Med 1996 Nov;3(11):1001-5

Subcutaneous lidocaine does not affect the success rate of intravenous access in children less than 24 months of age. Sacchetti AD, et al. **Acad Emerg Med** 1996 Nov; 3(11):1016-9

The combination of morphine with local anaesthetic in rhinoplasty--no evidence of a peripheral morphine effect. Ben-David B, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):892-7

The effect of topical lignocaine on intubating conditions after propofol-alfentanil induction. Bülow K, et al.
Acta Anaesthesiol Scand 1996 Jul;40(6):752-6

Prevention of hypertension during trans-sphenoidal surgery--the effect of bilateral maxillary nerve block with local anaesthetics. Chadha R, et al.
Acta Anaesthesiol Scand 1997 Jan;41(1 Pt 1):35-40

Inclusion of pethidine in lidocaine for infiltration improves analgesia following tonsillectomy in children. Elhakim M, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):214-7

Preoperative infiltration of bupivacaine--effects on pain relief and trauma response (cortisol and interleukin-6). Eriksson-Mjöberg M, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):466-72

Wound infiltration with liposomal bupivacaine prolongs analgesia in rats. Grant GJ, et al.
Acta Anaesthesiol Scand 1997 Feb;41(2):204-7

Comparison of continuous epidural infusion of fentanyl and bupivacaine with intermittent epidural administration of morphine for postoperative pain management in children. Kart T, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):461-5

Streptomycin/lignocaine local infiltration in the treatment of hypertrophic scar pain. A preliminary report [letter] Kumar A, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):546

Effect of pre- vs postoperative tonsillar infiltration with local anesthetics on postoperative pain after tonsillectomy. Molliex S, et al. **Acta Anaesthesiol Scand** 1996 Nov; 40(10):1210-5

Caudal clonidine and bupivacaine for combined epidural and general anaesthesia in children. Motsch J, et al.
Acta Anaesthesiol Scand 1997 Aug;41(7):877-83

Intraperitoneal bupivacaine for analgesia after laparoscopic cholecystectomy. Mraović B, et al.
Acta Anaesthesiol Scand 1997 Feb;41(2):193-6

Preoperative application of piroxicam gel compared to a local anaesthetic field block for postoperative analgesia. O'Hanlon JJ, et al. **Acta Anaesthesiol Scand** 1996 Jul; 40(6):715-8

Anesthetic quality during cesarean section following subarachnoid or epidural administration of bupivacaine with or without fentanyl. Olofsson C, et al.
Acta Anaesthesiol Scand 1997 Mar;41(3):332-8

Postoperative epidural infusion of morphine and bupivacaine is safe on surgical wards. Organisation of the treatment, effects and side-effects in 2000 consecutive patients. Rygnestad T, et al. **Acta Anaesthesiol Scand** 1997 Aug; 41(7):868-76

Postoperative pain relief by topical lidocaine in the surgical wound of hysterectomized patients. Sinclair R, et al.
Acta Anaesthesiol Scand 1996 May;40(5):589

Nebulized tetracaine attenuates the hemodynamic response to tracheal intubation. Stevens JB, et al.
Acta Anaesthesiol Scand 1996 Jul;40(6):757-9

Interpleural bupivacaine for pain relief after transthoracic endoscopic sympathectomy for primary hyperhidrosis. Lieou FJ, et al. **Acta Anaesthesiol Sin** 1996 Mar;34(1):21-5

EMLA cream and lidocaine local injection in the treatment of extravenous thiopental injection--a case report. Mao CC, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):103-6

Effective obstetric paracervical block with reduced dose of bupivacaine. A prospective randomized double-blind study comparing 25 mg (0.25%) and 12.5 mg (0.125%) of bupivacaine. Nieminen K, et al.
Acta Obstet Gynecol Scand 1997 Jan;76(1):50-4

Influence of auxiliary substances on the release of heptacaine from the drug form. Vitková Z, et al.
Acta Pharm Hung 1996 Sep;66(5):191-5

Using local anesthetics to expel foreign objects in the foot [letter] Ahearn MA. **Am Fam Physician** 1997 Mar; 55(4):1073

Preemptive analgesia: it starts before surgery [published erratum appears in Am J Nurs 1997 Feb;97(2):16] Pasero CL, et al. **Am J Nurs** 1996 Dec;96(12):17-8

Using balanced analgesia for postoperative pain. Pasero CL, et al. **Am J Nurs** 1996 Dec;96(12):17

Plasma lignocaine concentration following nebulization for awake intubation. Parkes SB, et al.
Anaesth Intensive Care 1997 Aug;25(4):369-71

Prevention of phantom limb pain by infusion of local anaesthetic into the sciatic nerve [see comments] Pavy TJ, et al. **Anaesth Intensive Care** 1996 Oct;24(5):599-600. Comment in: Anaesth Intensive Care 1997 Apr;25(2):200.

Single injection field block of tonsillar fossa [letter] Spence AG. **Anaesth Intensive Care** 1996 Oct;24(5):621-3

Epidural ropivacaine 0.2% infusion for postoperative pain relief [letter] Watts DW. **Anaesth Intensive Care** 1997 Apr; 25(2):200-1

Repeat dose after an inadequate spinal block [letter] [see comments] Deshpande S, et al. **Anaesthesia** 1996 Sep; 51(9):892. Comment in: Anaesthesia 1997 Feb;52(2):188.

Topical lignocaine for laryngeal mask airway insertion [letter; comment] Glaisyer HR, et al. **Anaesthesia** 1996 Dec; 51(12):1187. Comment on: Anaesthesia 1996 Aug;51(8):787-90.

Patient-controlled regional anaesthesia [letter; comment] Mackenzie JW, et al. **Anaesthesia** 1997 Jul;52(7):715. Comment on: Anaesthesia 1997 Mar;52(3):263-4.

Lignocaine toxicity--a surgical surprise [letter] Seigne R. **Anaesthesia** 1997 Jan;52(1):91

The effect of intradermal administration of lidocaine and morphine on the response to thermal stimulation. Atanassoff PG, et al. **Anesth Analg** 1997 Jun;84(6):1340-3

Intrathecal fentanyl with small-dose dilute bupivacaine: better anesthesia without prolonging recovery. Ben-David B, et al. **Anesth Analg** 1997 Sep;85(3):560-5

Spinal bupivacaine in ambulatory surgery: the effect of saline dilution. Ben-David B, et al. **Anesth Analg** 1996 Oct; 83(4):716-20

Effect on postoperative analgesia of small-dose lysine acetylsalicylate added to prilocaine during intravenous regional anesthesia. Corpataux JB, et al. **Anesth Analg** 1997 May;84(5):1081-5

Continuous epidural ropivacaine 0.2% for analgesia after lower abdominal surgery. Etches RC, et al.
Anesth Analg 1997 Apr;84(4):784-90

Antinociceptive effect of bupivacaine encapsulated in poly(D,L)-lactide-co-glycolide microspheres in the acute inflammatory pain model of carrageenin-injected rats. Fletcher D, et al. **Anesth Analg** 1997 Jan;84(1):90-4

The effects of solution concentration and epinephrine on lateral distribution of hyperbaric tetracaine spinal anesthesia. Iselin-Chaves IA, et al. **Anesth Analg** 1996 Oct; 83(4):755-9

Intrathecal sufentanil for extracorporeal shock wave lithotripsy provides earlier discharge of the outpatient than intrathecal lidocaine. Lau WC, et al. **Anesth Analg** 1997 Jun;84(6):1227-31

Differential sensory block after spinal bupivacaine in volunteers. Liu SS, et al. **Anesth Analg** 1997 Jan;84(1):115-9

Medial canthus (caruncle) single injection periocular anesthesia [letter] Loken RG, et al. **Anesth Analg** 1997 Sep; 85(3):707-8

Maternal posture influences the extent of sensory block produced by intrathecal dextrose-free bupivacaine with fentanyl for labor analgesia. Richardson MG, et al.
Anesth Analg 1996 Dec;83(6):1229-33

A minimum dose of clonidine added to mepivacaine prolongs the duration of anesthesia and analgesia after axillary brachial plexus block. Singelyn FJ, et al. **Anesth Analg** 1996 Nov;83(5):1046-50

The use of 0.25% lidocaine with fentanyl and pancuronium for intravenous regional anesthesia. Sztark F, et al.
Anesth Analg 1997 Apr;84(4):777-9

Quantitative assessment of differential sensory blockade after lumbar epidural lidocaine. Tay B, et al. **Anesth Analg** 1997 May;84(5):1071-5

The direction of the Whitacre needle aperture affects the extent and duration of isobaric spinal anesthesia. Urmey WF, et al. **Anesth Analg** 1997 Feb;84(2):337-41

The effects of adding sufentanil to bupivacaine for postoperative patient-controlled epidural analgesia. Wiebalck A, et al. **Anesth Analg** 1997 Jul;85(1):124-9

Pretreatment with topical 60% lidocaine tape reduces pain on injection of propofol. Yokota S, et al. **Anesth Analg** 1997 Sep;85(3):672-4

Dyclonine hydrochloride for airway anesthesia: awake endotracheal intubation in a patient with suspected local anesthetic allergy. Bacon GS, et al. **Anesthesiology** 1997 May;86(5):1206-7

Dose-range effects of clonidine added to lidocaine for brachial plexus block. Bernard JM, et al. **Anesthesiology** 1997 Aug;87(2):277-84

Prevention of lidocaine aerosol-induced bronchoconstriction with intravenous lidocaine. Bulut Y, et al.
Anesthesiology 1996 Oct;85(4):853-9

Epidural and intrathecal n-butyl-p-aminobenzoate solution in the rat. Comparison with bupivacaine. Grouls RJ, et al. **Anesthesiology** 1997 Jan;86(1):181-7

Dose-response characteristics of spinal bupivacaine in volunteers. Clinical implications for ambulatory anesthesia. Liu SS, et al. **Anesthesiology** 1996 Oct;85(4):729-36

Liposomal bupivacaine. Extended duration nerve blockade using large unilamellar vesicles that exhibit a proton gradient. Mowat JJ, et al. **Anesthesiology** 1996 Sep; 85(3):635-43

Local anesthetic administration for awake direct laryngoscopy. Are glossopharyngeal nerve blocks superior? Sitzman BT, et al. **Anesthesiology** 1997 Jan;86(1):34-40

Concentration-effect relations for intravenous lidocaine infusions in human volunteers: effects on acute sensory thresholds and capsaicin-evoked hyperpathia. Wallace MS, et al. **Anesthesiology** 1997 Jun;86(6):1262-72

Safe and effective method for application of tetracaine, adrenaline, and cocaine to oral lacerations. Bonadio WA. **Ann Emerg Med** 1996 Oct;28(4):396-8

Effects of peritonsillar infiltration on post-tonsillectomy pain. A double-blind study. Goldsher M, et al.
Ann Otol Rhinol Laryngol 1996 Nov;105(11):868-70

Intranasal lidocaine for migraine and cluster headaches. Mills TM, et al. **Ann Pharmacother** 1997 Jul-Aug;31(7-8):914-5

Warmed local anesthetic reduces pain of infiltration. Fialkov JA, et al. **Ann Plast Surg** 1996 Jan;36(1):11-3

Lidocaine for lumbar punctures. A help not a hindrance. Carraccio C, et al. **Arch Pediatr Adolesc Med** 1996 Oct; 150(10):1044-6

Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia [see comments] Hong CZ, et al. **Arch Phys Med Rehabil** 1996 Nov;77(11):1161-6. Comment in: Arch Phys Med Rehabil 1997 Jun;78(6):676.

Comparing preincisional with postincisional bupivacaine infiltration in the management of postoperative pain. Bourget JL, et al. **Arch Surg** 1997 Jul;132(7):766-9

Local and intra-articular infiltration of bupivacaine before surgery: effect on postoperative pain after anterior cruciate ligament reconstruction. Höher J, et al. **Arthroscopy** 1997 Apr;13(2):210-7

The effectiveness of sub-Tenon's infiltration of local anaesthesia for cataract surgery. Verghese I, et al.
Aust N Z J Ophthalmol 1996 May;24(2):117-20

Evidence for safety margins of lignocaine local anaesthetics for peri-oral use. Cannell H. **Br Dent J** 1996 Oct 5; 181(7):243-9 (43 ref.)

Safety margins for lignocaine local anaesthetic [letter] Feirn D. **Br Dent J** 1996 Dec 7-21;181(11-12):398

The use of lignocaine local anaesthetic [letter] Preshaw PM, et al. **Br Dent J** 1996 Oct 5;181(7):240

Spinal anaesthesia with 0.25% hyperbaric bupivacaine for caesarean section: effects of volume [letter; comment] Bell R, et al. **Br J Anaesth** 1997 Mar;78(3):339-40. Comment on: Br J Anaesth 1996 Aug;77(2):145-9.

Continuous extradural infusion of ropivacaine 2 mg ml-1 for pain relief during labour. Benhamou D, et al.
Br J Anaesth 1997 Jun;78(6):748-50

Prolonged peribulbar anaesthesia with indwelling catheter: a preliminary report of 217 cases. Bernard JM, et al.
Br J Anaesth 1997 Jan;78(1):81-2

Serum concentrations of bupivacaine during prolonged continuous paravertebral infusion in young infants. Cheung SL, et al. **Br J Anaesth** 1997 Jul;79(1):9-13

Spinal anaesthesia with 0.25% hyperbaric bupivacaine for Caesarean section: effects of volume [see comments] Chung CJ, et al. **Br J Anaesth** 1996 Aug;77(2):145-9. Comment in: Br J Anaesth 1997 Mar;78(3):339-40.

Wound infiltration with local anaesthetic after abdominal hysterectomy. Cobby TF, et al. **Br J Anaesth** 1997 Apr; 78(4):431-2

Combined spinal-extradural anaesthesia for preterm and term caesarean section: is there a difference in local anaesthetic requirements? James KS, et al. **Br J Anaesth** 1997 May; 78(5):498-501

Spinal anaesthesia: effect of the site of injection on the spread of analgesia [letter] Kamenik M. **Br J Anaesth** 1997 Jul; 79(1):144-5

Single bolus compared with a fractionated dose injection technique of bupivacaine for extradural Caesarean section: effect on uteroplacental and fetal haemodynamic state. Karinen J, et al. **Br J Anaesth** 1996 Aug;77(2):140-4

Effect of Sprotte needle orientation on spinal anaesthesia [letter; comment] Serpell MG. **Br J Anaesth** 1997 Feb; 78(2):229-30. Comment on: Br J Anaesth 1996 Aug;77(2):150-2.

Spinal anaesthesia with 0.5% hyperbaric bupivacaine in elderly patients: effect of site of injection on spread of analgesia. Veering BT, et al. **Br J Anaesth** 1996 Sep; 77(3):343-6

Topical anaesthesia for diagnostic hysteroscopy and endometrial biopsy in postmenopausal women: a randomised placebo-controlled double-blind study. Cicinelli E, et al. **Br J Obstet Gynaecol** 1997 Mar; 104(3):316-9

Evaluation of post-operative analgesia following laparoscopic application of Filshie clips. Fiddes TM, et al. **Br J Obstet Gynaecol** 1996 Nov;103(11):1143-7

Use of epidural catheter for postoperative pain relief for bone harvesting from iliac crest. Dunstan SP, et al.
Br J Oral Maxillofac Surg 1996 Oct;34(5):436-7

The use of pH adjusted lignocaine in controlling operative pain in the day surgery unit: a prospective, randomised trial. Fitton AR, et al. **Br J Plast Surg** 1996 Sep;49(6):404-8

Randomized trial of periportal peritoneal bupivacaine for pain relief after laparoscopic cholecystectomy [see comments] Alexander DJ, et al. **Br J Surg** 1996 Sep; 83(9):1223-5. Comment in: Br J Surg 1997 Jan;84(1):138. Comment in: Br J Surg 1997 May;84(5):730.

Rectus sheath bupivacaine analgesia after aortic surgery [see comments] Curley P, et al. **Br J Surg** 1996 Nov;83(11):1558 . Comment in: Br J Surg 1997 May;84(5):728. Comment in: Br J Surg 1997 Jul;84(7):1033-4.

Rectus sheath bupivacaine analgesia after aortic surgery [letter; comment] Cuschieri RJ, et al. **Br J Surg** 1997 Jul; 84(7):1033-4. Comment on: Br J Surg 1996 Nov;83(11):1558.

Randomized trial of periportal peritoneal bupivacaine for pain relief after laparoscopic cholecystectomy [letter; comment] Wong C, et al. **Br J Surg** 1997 Jan;84(1):138.

Comment on: Br J Surg 1996 Sep;83(9):1223–5.

Bladder and urethral anaesthesia with electromotive drug administration (EMDA): a technique for invasive endoscopic procedures. Fontanella UA, et al. **Br J Urol** 1997 Mar;79(3):414–20

Injections and low back pain: outcome and randomized controlled trials. Balagué F. **Bull Hosp Jt Dis** 1996; 55(4):185–90 (49 ref.)

Fibromyalgia and trigger point injections. Jayson MI. **Bull Hosp Jt Dis** 1996;55(4):176–7

Epidural injection for the treatment of low back pain. Moskovich R. **Bull Hosp Jt Dis** 1996;55(4):178–84 (46 ref.)

Comparison of propofol versus thiopentone with midazolam or lidocaine to facilitate laryngeal mask insertion [see comments] Bapat P, et al. **Can J Anaesth** 1996 Jun; 43(6):564–8. Comment in: Can J Anaesth 1997 May;44(5 Pt 1):569.

Analgesia after otoplasty: regional nerve blockade vs local anaesthetic infiltration of the ear. Cregg N, et al. **Can J Anaesth** 1996 Feb;43(2):141–7

Detection of intravascular injection of regional anaesthetics in children [see comments] Fisher QA, et al. **Can J Anaesth** 1997 Jun;44(6):592–8. Comment in: Can J Anaesth 1997 Jun;44(6):582–6.

Comparative topical anaesthesia of EMLA and liposome–encapsulated tetracaine. Hung OR, et al. **Can J Anaesth** 1997 Jul;44(7):707–11

Lidocaine tape relieves pain due to needle insertion during stellate ganglion block. Inada T, et al. **Can J Anaesth** 1997 Mar;44(3):259–62

Epidural fentanyl improves the onset and spread of epidural mepivacaine analgesia. Kasaba T, et al. **Can J Anaesth** 1996 Dec;43(12):1211–5

Local anaesthetics belong in the caudal/epidural space, not in the veins! [editorial; comment] Lerman J. **Can J Anaesth** 1997 Jun;44(6):582–6. Comment on: Can J Anaesth 1997 Jun;44(6):592–8. **(Eng, Fre)**

Direction of injection does not affect the spread of spinal bupivacaine in parturients. Massé E, et al. **Can J Anaesth** 1997 Aug;44(8):816–9

Double–blind comparison of epidural ropivacaine 0.25% and bupivacaine 0.25%, for the relief of childbirth pain. Muir HA, et al. **Can J Anaesth** 1997 Jun;44(6):599–604

Bupivacaine decreases epidural meperidine requirements after abdominal surgery. St–Onge S, et al. **Can J Anaesth** 1997 Apr;44(4):360–6

Comparison of glucose 7.5% and 0.75% with or without phenylephrine for tetracaine spinal anaesthesia. Sumi M, et al. **Can J Anaesth** 1996 Nov;43(11):1138–43

EMLA patch for intravenous cannulation in adult surgical outpatients. Vaghadia H, et al. **Can J Anaesth** 1997 Aug; 44(8):798–802

Cataract surgery with 0.75% bupivacaine [letter; comment] Heston JP, et al. **Can J Ophthalmol** 1996 Oct;31(6):328. Comment on: Can J Ophthalmol 1995 Aug;30(5):264–6.

Intranasal application of lidocaine jelly preoperatively in patients undergoing dacryocystorhinostomy. Pelletier CR, et al. **Can J Ophthalmol** 1996 Aug;31(5):245

Is wound infiltration with anesthetic effective as pre–emptive analgesia? A clinical trial in appendectomy patients [see comments] Willard PT, et al. **Can J Surg** 1997 Jun; 40(3):213–7. Comment in: Can J Surg 1997 Jun;40(3):166.

New sheath for vascular access and subcutaneous drug administration: multicenter clinical trial for pain prevention after cardiac catheterization [see comments] Lambert CR, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):81–3. Comment in: Cathet Cardiovasc Diagn 1997 Jan;40(1):84.

Cluster headache [letter; comment] Olin JS. **Cleve Clin J Med** 1997 Jan;64(1):53. Comment on: Cleve Clin J Med 1996 Jul–Aug;63(4):237–44.

Iontophoretic administration of 2% lidocaine HCl and 1:100,000 epinephrine in humans. Ashburn MA, et al. **Clin J Pain** 1997 Mar;13(1):22–6

Steroid injection technique [letter; comment] Weber PC. **Clin Orthop** 1997 Jan;(334):383–4. Comment on: Clin Orthop 1995 Aug;(317):185–7.

Safe and effective topical application dose of lidocaine for surgery with laryngomicroscopy. Kotaki H, et al. **Clin Pharmacol Ther** 1996 Aug;60(2):229–35 (15 ref.)

Tumescent anesthesia with a lidocaine dose of 55 mg/kg is safe for liposuction [editorial] Coleman WP 3rd. **Dermatol Surg** 1996 Nov;22(11):919

Anesthesia for lip augmentation [letter] Elson ML. **Dermatol Surg** 1997 May;23(5):405

Topical anesthetic agents in dermatologic surgery. A review. Lener EV, et al. **Dermatol Surg** 1997 Aug;23(8):673–83 (58 ref.)

Tumescent anesthesia with a lidocaine dose of 55 mg/kg is safe for liposuction. Ostad A, et al. **Dermatol Surg** 1996 Nov;22(11):921–7

EMLA cream for renal extracorporeal shock wave lithotripsy in ambulatory patients. Bárcena M, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):373–6

Epidural bupivacaine/fentanyl infusions vs. intermittent top–ups: a retrospective study of the effects on mode of delivery in primiparous women. Driver I, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):515–20

The addition of clonidine to prilocaine for intravenous regional anaesthesia. Kleinschmidt S, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):40–6

Cocaine or phenylephrine/lignocaine for nasal fibreoptic intubation? Latorre F, et al. **Eur J Anaesthesiol** 1996 Nov; 13(6):577–81

The optimal dose of local anaesthetic in the orthogonal two–needle technique. Extent of sensory block after the injection of 20, 30 and 40 mL of anaesthetic solution. Rucci FS, et al. **Eur J Anaesthesiol** 1997 May;14(3):281–6

The value of continuous blockade of the lumbar plexus as an adjunct to acetylsalicyclic acid for pain relief after surgery for femoral neck fractures. Spansberg NL, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):410–2

The blocking effect of iontophoretic administration of lidocaine on neurogenic vascular reactions in rat dental pulp. Kostouros GD, et al. **Eur J Oral Sci** 1996 Oct–Dec; 104(5–6):577–82

Preoperative local infiltration with ropivacaine for postoperative pain relief after inguinal hernia repair. A randomised controlled trial. Johansson B, et al. **Eur J Surg** 1997 May;163(5):371–8

Topical anesthesia for phacoemulsification surgery [letter; comment] Lindley–Jones M. **Eye** 1996;10 (Pt 5):650. Comment on: Eye 1995;9 (Pt 4):456–9.

Lignocaine aerosol spray in outpatient hysteroscopy: a randomized double–blind placebo–controlled trial. Davies A, et al. **Fertil Steril** 1997 Jun;67(6):1019–23

Trabeculectomy in subconjunctival anesthesia [letter] Pfeiffer N, et al. **Ger J Ophthalmol** 1996 May;5(3):182–3

A comparison of blood pressure changes in phacoemulsification cataract surgery with topical and retrobulbar block local anesthesia. Suzuki R, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 May;235(5):277–82

Topical pharyngeal anesthesia without intravenous sedation during upper gastrointestinal endoscopy. Dhir V, et al. **Indian J Gastroenterol** 1997 Jan;16(1):10–1

Tumescent infiltrators for the installation of dilute steroid suspensions or anaesthetic solutions [letter] Field LM. **Int J Dermatol** 1997 Feb;36(2):158–9

Comparison of 0.5% and 1.0% lidocaine for abortions. Wiebe ER, et al. **Int J Gynaecol Obstet** 1996 Oct;55(1):71–2

Local bupivacaine infusion following bone graft harvest from the iliac crest. Hahn M, et al. **Int J Oral Maxillofac Surg** 1996 Oct;25(5):400–1

Topical anaesthesia for bladder biopsies and cautery: intravesical lidocaine versus caudal anaesthesia. Amano T, et al. **Int Urol Nephrol** 1995;27(5):533–7

Topical analgesia for children [letter; comment] Nathan B, et al. **J Accid Emerg Med** 1997 Jan;14(1):59. Comment on: J Accid Emerg Med 1996 Mar;13(2):119–22.

Surgical pearl: bacteriostatic sodium chloride injection USP 0.9%. Daniel CR 3rd, et al. **J Am Acad Dermatol** 1997 Jan;36(1):92

Prilocaine/lidocaine patch as a local premedication for skin biopsy in children. de Waard–van der Spek FB, et al. **J Am Acad Dermatol** 1997 Sep;37(3 Pt 1):418–21

The use of EMLA cream and 1% lidocaine infiltration in men for relief of pain associated with the removal of genital warts by cryotherapy. Menter A, et al. **J Am Acad Dermatol** 1997 Jul;37(1):96–100

The use of topical anesthesia in diagnostic hysteroscopy and endometrial biopsy. Zupi E, et al. **J Am Assoc Gynecol Laparosc** 1994 May;1(3):249–52

Analgesic efficacy and safety of an intraoral lidocaine patch. Hersh EV, et al. **J Am Dent Assoc** 1996 Nov; 127(11):1626–34; quiz 1665–6

Anesthesia blocks of the lower extremity. Comparing the Biojector with needle and syringe. Gerbert J, et al. **J Am Podiatr Med Assoc** 1996 May;86(5):195–204

Intra–articular morphine and/or bupivacaine in the management of pain after total knee arthroplasty. Mauerhan DR, et al. **J Arthroplasty** 1997 Aug;12(5):546–52

Continuous postoperative infusion of a regional anesthetic after an amputation of the lower extremity. A randomized clinical trial. Pinzur MS, et al. **J Bone Joint Surg Am** 1996 Oct;78(10):1501–5

Continuous infusion is superior to bolus doses with thoracic paravertebral blocks after thoracotomies. Català E, et al. **J Cardiothorac Vasc Anesth** 1996 Aug;10(5):586–8

The effects of carotid sinus nerve blockade on hemodynamic stability after carotid endarterectomy. Gottlieb A, et al. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):67–71

Anesthesia supplemented with subarachnoid bupivacaine and morphine for coronary artery bypass surgery in a child with Kawasaki disease. Kowalewski R, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):243–6

Circumferential perilimbal anesthesia [see comments] Anderson CJ. **J Cataract Refract Surg** 1996 Oct; 22(8):1009–12. Comment in: J Cataract Refract Surg 1997 Jan–Feb;23(1):6–7.

Is topical anesthesia adequate? [letter; comment] Bernstein RM. **J Cataract Refract Surg** 1997 Jan–Feb;23(1):6–7. Comment on: J Cataract Refract Surg 1996 Oct;22(8):1009–12.

Use of topical anesthesia alone in cataract surgery. Fichman RA. **J Cataract Refract Surg** 1996 Jun;22(5):612–4

Indicators of patient suitability for topical anesthesia. Fraser SG, et al. **J Cataract Refract Surg** 1997 Jun;23(5):781–3

Intracameral preserved lidocaine [letter] Fry LL. **J Cataract Refract Surg** 1997 Jan–Feb;23(1):10

Anterior chamber irrigation with unpreserved lidocaine 1% for anesthesia during cataract surgery. Koch PS. **J Cataract Refract Surg** 1997 May;23(4):551–4

Patient comfort during cataract surgery with modified topical and peribulbar anesthesia. Maclean H, et al. **J Cataract Refract Surg** 1997 Mar;23(2):277–83

Patient comfort with topical and peribulbar anesthesia [letter] Percival P. **J Cataract Refract Surg** 1997 Jul–Aug;23(6):818

Globe rupture during digital massage after peribulbar anesthesia. Rathi V, et al. **J Cataract Refract Surg** 1997 Mar;23(2):297–9

Topical versus peribulbar anesthesia in cataract surgery. Roman S, et al. **J Cataract Refract Surg** 1996 Oct; 22(8):1121–4

Preventing pain during injection of propofol: the optimal dose of lidocaine. Gajraj NM, et al. **J Clin Anesth** 1996 Nov;8(7):575–7

Postoperative analgesia and intraoperative inhalational anesthetic requirements during umbilical herniorrhaphy in children: postincisional local infiltration versus preincisional caudal epidural block. Tobias JD. **J Clin Anesth** 1996 Dec;8(8):634–8

Safety of 5% lidocaine heavily defended [news; letter] Blitt CD. **J Clin Monit** 1996 Jan;12(1):107

Transtracheal injection of local anesthetic: an intratracheal view. Doyle DJ, et al. **J Clin Monit** 1996 Sep;12(5):409

Use of streptomycin–lidocaine injections in the treatment of the cluster–tic syndrome. Clinical perspectives and a case report. Kreiner M. **J Craniomaxillofac Surg** 1996 Oct; 24(5):289–92 (48 ref.)

The use of lignocaine in dental practice: results of a survey of a group of general and hospital dental practitioners. Rowson JE, et al. **J Dent** 1997 Sep;25(5):431–3

Topical liposomal system for localized and controlled drug delivery. Singh R, et al. **J Dermatol Sci** 1996 Nov; 13(2):107–11

Electromotive administration of intravesical lidocaine in patients with interstitial cystitis. Gürpinar T, et al. **J Endourol** 1996 Oct;10(5):443–7

Lidocaine anesthesia. Richards JW Jr. **J Fam Pract** 1996 Nov; 43(5):502

Modified transthecal digital block. Whetzel TP, et al. **J Hand Surg [Am]** 1997 Mar;22(2):361–3

In vitro controlled release kinetics of local anaesthetics from poly(D,L–lactide) and poly(lactide–co–glycolide) microspheres. Le Corre P, et al. **J Microencapsul** 1997 Mar–Apr;14(2):243–55

Topical application of lidocaine–prilocaine (EMLA) cream reduces the pain of intramuscular infiltration of saline solution. Himelstein BP, et al. **J Pediatr** 1996 Nov; 129(5):718–21

Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic. Creamer P, et al. **J Rheumatol** 1996 Jun;23(6):1031–6

Postoperative analgesic effects of an external cooling system and intra–articular bupivacaine/morphine after arthroscopic cruciate ligament surgery. Brandsson S, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(4):200–5

Neonatal circumcision [letter; comment] Ramet J, et al. **Lancet** 1997 Apr 26;349(9060):1257. Comment on: Lancet 1997 Mar 1;349(9052):599–603.

Local anesthetic safety in pediatric patients. Davis MJ, et al. **N Y State Dent J** 1996 Feb;62(2):32–5

Computerized local anesthetic delivery vs. traditional syringe technique. Subjective pain response. Hochman M, et al. **N Y State Dent J** 1997 Aug–Sep;63(7):24–9

Influence of topical anesthesia on tests diagnostic of blepharitis–associated dry eye syndrome. Herreras JM, et al. **Ocul Immunol Inflamm** 1997 Mar;5(1):33–41

Visual acuity immediately following phacoemulsification with subconjunctival anesthesia. Brothers Arbisser L, et al. **Ophthalmic Surg Lasers** 1996 Jul;27(7):640–2

Approaching a 100% success rate using topical anesthesia with mild intravenous sedation in phacoemulsification procedures. Dinsmore SC. **Ophthalmic Surg Lasers** 1996 Nov;27(11):935–8

Topical anesthesia with benoxinate 0.4% for pterygium surgery. Frucht–Pery J. **Ophthalmic Surg Lasers** 1997 Mar; 28(3):219–22

Sub–Tenon's versus retrobulbar anesthesia for cataract surgery. Khoo BK, et al. **Ophthalmic Surg Lasers** 1996 Sep; 27(9):773–7

Lidocaine–prilocaine cream for local–anesthesia chalazion incision in children. Wessels IF, et al. **Ophthalmic Surg Lasers** 1996 Jun;27(6):431–3

Dilute topical proparacaine for pain relief after photorefractive keratectomy. Shahinian L Jr, et al. **Ophthalmology** 1997 Aug;104(8):1327–32

The effects of phacoemulsification cataract surgery via local anesthesia on preoperative and postoperative blood pressure levels. Suzuki R, et al. **Ophthalmology** 1997 Feb; 104(2):216–22

A prospective, randomized, double–masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Verma S, et al. **Ophthalmology** 1995 Dec;102(12):1918–24

Anesthetic efficacy of the intraosseous injection in maxillary and mandibular teeth. Coggins R, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jun;81(6):634–41

Anesthetic efficacy of the intraosseous injection of 2% lidocaine (1:100,000 epinephrine) and 3% mepivacaine in mandibular first molars. Replogle K, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jan;83(1):30–7

Intrapulpal injection: factors related to effectiveness. VanGheluwe J, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997

Jan;83(1):38–40
Local injection therapy in 107 patients with myofascial pain syndrome of the head and neck. Tschopp KP, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Nov–Dec; 58(6):306–10
The use of additives to local anaesthetic solutions for caudal epidural blockade. Cook B, et al. **Paediatr Anaesth** 1996; 6(5):353–9 (54 ref.)
Effective pain relief with continuous intrapleural bupivacaine after thoracotomy in infants and children. Semsroth M, et al. **Paediatr Anaesth** 1996;6(4):303–10
Comments on Sotgiu et al (PAIN, 62 (1995) 250) [letter; comment] Jaffe RA. **Pain** 1996 May–Jun;65(2–3):286–7. Comment on: Pain 1995 Aug;62(2):250–1.
Comments on Luo and Wiesenfeld–Hallin (Pain 63 (1995) 173–179) [letter; comment] Katz J. **Pain** 1996 Sep; 67(1):212–4. Comment on: Pain 1995 Nov;63(2):173–9.
Lidocaine patch: double–blind controlled study of a new treatment method for post–herpetic neuralgia. Rowbotham MC, et al. **Pain** 1996 Apr;65(1):39–44
Controlled systemic absorption and increased anesthetic effect of bupivacaine following epidural administration of bupivacaine–hydroxypropyl–beta–cyclodextrin complex. Fréville JC, et al. **Pharm Res** 1996 Oct;13(10):1576–80
Where's the point? [letter] Keyser JJ. **Plast Reconstr Surg** 1997 Feb;99(2):593
Extended epidural catheter infusions with analgesics for patients with noncancer pain at their homes. Aldrete JA. **Reg Anesth** 1997 Jan–Feb;22(1):35–42
Addition of morphine to intra–articular bupivacaine does not improve analgesia following knee joint replacement. Badner NH, et al. **Reg Anesth** 1997 Jul–Aug;22(4):347–50
Spread of local anesthetic into the epidural caudal space for two rates of injection in children. Blanco D, et al. **Reg Anesth** 1996 Sep–Oct;21(5):442–5
Low–volume interscalene brachial plexus block for perioperative shoulder pain [letter] Bruin G, et al. **Reg Anesth** 1996 Jul–Aug;21(4):371
Comparison of two application techniques of EMLA and pain assessment in pediatric oncology patients. Calamandrei M, et al. **Reg Anesth** 1996 Nov–Dec;21(6):557–60
Comparison between hemodynamic changes after single–dose and incremental subarachnoid anesthesia. Casati A, et al. **Reg Anesth** 1996 Jul–Aug;21(4):298–303
Pain relief after knee arthroscopy: intra–articular morphine, intra–articular bupivacaine, or subcutaneous morphine? Cepeda MS, et al. **Reg Anesth** 1997 May–Jun;22(3):233–8
What causes different pain sensations on intradermal injection of local anesthetics? [letter; comment] Eckstein KL, et al. **Reg Anesth** 1996 Jul–Aug;21(4):374. Comment on: Reg Anesth 1994 Jan–Feb;19(1):48–51.
Local anesthetic infusion through nerve sheath catheters for analgesia following upper extremity amputation. Clinical report. Enneking FK, et al. **Reg Anesth** 1997 Jul–Aug; 22(4):351–6
Iliac crest bone graft pain: simplicity revisited [letter] Green DM. **Reg Anesth** 1996 Jan–Feb;21(1):77
Plasma bupivacaine concentrations following epidural administration in kidney transplant recipients. Hammouda GE, et al. **Reg Anesth** 1996 Jul–Aug;21(4):308–11
Continuous axillary brachial plexus block for postoperative pain relief. Intermittent bolus versus continuous infusion. Mezzatesta JP, et al. **Reg Anesth** 1997 Jul–Aug;22(4):357–62
Lidocaine–clonidine retrobulbar block for cataract surgery in the elderly. Mjahed K, et al. **Reg Anesth** 1996 Nov–Dec; 21(6):569–75
Subarachnoid bupivacaine increases human cerebrospinal fluid concentration of serotonin. Naesh O, et al. **Reg Anesth** 1996 Sep–Oct;21(5):446–50
Where does science end and reality begin? [editorial] Neal JM. **Reg Anesth** 1997 Mar–Apr;22(2):109–12
Detection of intravascular epidural catheters using 2–chloroprocaine. Influence of local anesthetic dose and nalbuphine premedication. Rathmell JP, et al. **Reg Anesth** 1997 Mar–Apr;22(2):113–8
Continuous spinal analgesia. Comparison between patient–controlled and bolus administration of plain bupivacaine for postoperative pain relief. Rundshagen I, et al. **Reg Anesth** 1997 Mar–Apr;22(2):150–6
Patient–administered sphenopalatine ganglion block. Saade E, et al. **Reg Anesth** 1996 Jan–Feb;21(1):68–70
Extended unilateral anesthesia. New technique or paravertebral anesthesia? Saito T, et al. **Reg Anesth** 1996 Jul–Aug;21(4):304–7
EMLA cream effectively reduces the pain of spinal needle insertion. Sharma SK, et al. **Reg Anesth** 1996 Nov–Dec; 21(6):561–4
A prospective randomized controlled study of 4% lignocaine solution in Merocel nasal pack removal. Lavy JA, et al. **Rhinology** 1996 Dec;34(4):219–21
The effect and timing of local anesthesia in laparoscopic cholecystectomy. Sarac AM, et al. **Surg Laparosc Endosc** 1996 Oct;6(5):362–6
Use of subdiaphragmatic bupivacaine instillation to control postoperative pain after laparoscopic surgery. Weber A, et al. **Surg Laparosc Endosc** 1997 Feb;7(1):6–8
Local wound infiltration with bupivacaine in lumbar laminectomy. Cherian MN, et al. **Surg Neurol** 1997 Feb; 47(2):120–2; discussion 122–3
Nebulised drugs in palliative care. Ahmedzai S, et al. **Thorax** 1997 Apr;52 Suppl 2:S75–7
Intra–articular anesthesia of the distal interphalangeal joint alleviates lameness associated with the navicular bursa in horses. Pleasant RS, et al. **Vet Surg** 1997 Mar–Apr; 26(2):137–40
[Analgesia after laparoscopic cholecystectomy by intraperitoneal administration of bupivacaine] Fuhrer Y, et al. **Ann Fr Anesth Reanim** 1996;15(2):128–34 (Eng. Abstr.) **(Fre)**
[Application of EMLA cream without an adhesive film (letter)] Carbajal R, et al. **Arch Pediatr** 1997 Apr;4(4): 84–5 **(Fre)**
[Local anesthetics––maximum recommended doses] Niesel HC. **Anaesthesiol Reanim** 1997;22(3):60–2 (15 ref.) (Eng. Abstr.) **(Ger)**
[Comparison of dosage relations of prilocaine and bupivacaine for axillary plexus anesthesia] Voges O, et al. **Anaesthesiol Reanim** 1997;22(3):63–8 (Eng. Abstr.) **(Ger)**
[Circulatory reactions under spinal anesthesia. The catheter technique versus the single dose procedure] Holst D, et al. **Anasthesist** 1997 Jan;46(1):38–42 (Eng. Abstr.) **(Ger)**
[Effect of lidocaine administration mode on decreasing injection pain caused by propofol] Goldmann R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):98–100 (Eng. Abstr.) **(Ger)**
[Treatment of tinnitus with lidocaine? A report of clinical experiences (see comments)] Rudack C, et al. **HNO** 1997 Feb;45(2):69–73 (Eng. Abstr.). Comment in: HNO 1997 Feb;45(2):63–4. **(Ger)**
[Injection therapy in cervical syndromes] Grifka J. **Orthopade** 1996 Nov;25(6):524–32 (26 ref.) (Eng. Abstr.) **(Ger)**
[Long–term therapeutic effect of different intra–articular injection treatments of the painful shoulder––effect on pain, mobility and work capacity] Ströbel G. **Rehabilitation (Stuttg)** 1996 Aug;35(3):176–8 (Eng. Abstr.) **(Ger)**
[Paravertebral abscess with secondary meningomyelitis after infiltration therapy. A brief case report] Öhlmann D, et al. **Wien Klin Wochenschr** 1996;108(14):442–3 **(Ger)**
[Superselective spinal anesthesia for saphenectomy intervention. Comparison of 2 concentrations of hyperbaric bupivacaine] Santagostino G, et al. **Minerva Anestesiol** 1996 Dec;62(12):389–94 (Eng. Abstr.) **(Ita)**
[The use of intraoperative topical bupivacaine in the control of postoperative pain following laparoscopic cholecystectomy] Fornari M, et al. **Minerva Chir** 1996 Oct; 51(10):881–5 (Eng. Abstr.) **(Ita)**
[Efficacy of lidocaine tape for venous cannulation in children] Fukuda M, et al. **Masui** 1997 Jun;46(6):793–7 (Eng. Abstr.) **(Jpn)**
[Effect of injection speed on sensory blockade in spinal anesthesia with 0.5% hyperbaric tetracaine] Hanazaki M, et al. **Masui** 1997 Jun;46(6):777–82 (Eng. Abstr.) **(Jpn)**
[Premixing lidocaine reduces the incidence and severity of pain on injection of propofol] Inoue S, et al. **Masui** 1997 Apr;46(4):543–6 (Eng. Abstr.) **(Jpn)**
[The level of analgesia with epidural injection of 2% mepivacaine using combined spinal and epidural analgesia] Kasaba T, et al. **Masui** 1996 Sep;45(9):1078–82 (Eng. Abstr.) **(Jpn)**
[Relationship between the dose of lidocaine administered endotracheally in small children and the serum lidocaine level––recommended dose prior to endotracheal intubation] Takaya T, et al. **Masui** 1997 Jun;46(6):764–9 (Eng. Abstr.) **(Jpn)**
[Intraoperative continuous epidural lidocaine combined with preoperative administration of epidural morphine for post–hepatectomy pain relief] Terai T, et al. **Masui** 1997 Jan;46(1):100–4 (Eng. Abstr.) **(Jpn)**
[The author's own method of local anesthesia for skin incision around implants during limb lengthening] Rajewski F, et al. **Chir Narzadow Ruchu Ortop Pol** 1997;62(2):155–8 (Eng. Abstr.) **(Pol)**
[The epidural administration of steroids and local anesthetics as the basis for the pathogenetic therapy of a radicular pain syndrome in the stages of its development] Gnezdilov AV, et al. **Anesteziol Reanimatol** 1996 May–Jun;(3):28–32 (Eng. Abstr.) **(Rus)**
[Effect of sufan, lidocaine and their combination on the course of early occlusive and reperfusion arrhythmias in cats] Galenko–Iaroshevskiĭ Pa, et al. **Biull Eksp Biol Med** 1997 May;123(5):545–7 **(Rus)**
[Intravenous regional anesthesia using low doses of lidocaine for hand surgery (letter)] Aznar IM, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):77–8 **(Spa)**
[Sciatic nerve block at the popliteal fossa for foot surgery] Monsó A, et al. **Rev Esp Anestesiol Reanim** 1996 Jan; 43(1):27–9 (Eng. Abstr.) **(Spa)**
[More flexible reposition with local analgesia. Intra–articular analgesia tested in shoulder dislocation] Gröndal L, et al. **Lakartidningen** 1997 May 21;94(21):1997–8 **(Swe)**

ADVERSE EFFECTS

Peripheral neurologic deficits in relation to subarachnoid or epidural administration of local anesthetics for surgery. A survey of 21 cases [see comments] Pleym H, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):453–60. Comment in: Acta Anaesthesiol Scand 1997 Apr;41(4):439–44.
Transient radicular irritation after spinal anaesthesia [letter; comment] Van Elstraete AC, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):864–5. Comment on: Acta Anaesthesiol Scand 1995 Oct;39(7):881–4.
Lidocaine–induced CNS toxicity––a case report. Chiang YY, et al. **Acta Anaesthesiol Sin** 1996 Dec;34(4):243–6
Transient radicular irritation as a complication of spinal anaesthesia with hyperbaric 5% lignocaine [see comments] Albrecht A, et al. **Anaesth Intensive Care** 1996 Aug; 24(4):508–10. Comment in: Anaesth Intensive Care 1997 Feb;25(1):89–90.
Pain associated with 2% lignocaine epidural anaesthesia [letter] Clarke JP, et al. **Anaesth Intensive Care** 1997 Aug; 25(4):435–6
Angioedema following prilocaine [see comments] Ferguson S. **Anaesth Intensive Care** 1996 Jun;24(3):398–400. Comment in: Anaesth Intensive Care 1997 Feb;25(1):87–9.
Radicular irritation with 2% lignocaine spinal [letter; comment] Grange C, et al. **Anaesth Intensive Care** 1997 Feb;25(1):89–90. Comment on: Anaesth Intensive Care 1996 Aug;24(4):508–10.
Transient femoral nerve palsy after ilioinguinal block––comment [letter; comment] Johnson CM. **Anaesth Intensive Care** 1996 Jun;24(3):402. Comment on: Anaesth Intensive Care 1996 Feb;24(1):115.
Transient dysaesthesia following spinal anaesthesia with 2% lignocaine [letter] Ramasamy D, et al. **Anaesth Intensive Care** 1997 Feb;25(1):90–1
Angioedema following prilocaine [letter; comment] Wildsmith JA. **Anaesth Intensive Care** 1997 Feb;25(1):87–9 . Comment on: Anaesth Intensive Care 1996 Jun;24(3):398–400.
Absence of transient radicular irritation after 5000 spinal anaesthetics with prilocaine [letter] König W, et al. **Anaesthesia** 1997 Feb;52(2):182–3
Respiratory arrest after spinal anesthesia with lidocaine and fentanyl. Cornish PB. **Anesth Analg** 1997 Jun;84(6):1387–8
Orthostatic hypotension during postoperative continuous thoracic epidural bupivacaine–morphine in patients undergoing abdominal surgery. Crawford ME, et al. **Anesth Analg** 1996 Nov;83(5):1028–32
Polymyoclonus resulting from possible accidental subdural injection of local anesthetic. Dreskin S, et al. **Anesth Analg** 1997 Mar;84(3):692–3
A similar incidence of transient neurologic symptoms after spinal anesthesia with 2% and 5% lidocaine [see comments] Hampl KF, et al. **Anesth Analg** 1996 Nov;83(5):1051–4. Comment in: Anesth Analg 1997 Jun;84(6):1392–3.
Transient radicular irritation after spinal anesthesia with hyperbaric 4% mepivacaine. Lynch J, et al. **Anesth Analg** 1997 Oct;85(4):872–3
Transient neurologic toxicity? [letter; comment] Naveira FA, et al. **Anesth Analg** 1996 Oct;83(4):887–8. Comment on: Anesth Analg 1996 May;82(5):1076–7.
Effects of topical nitroglycerin and intravenous lidocaine on propofol–induced pain on injection. O'Hara JR Jr, et al. **Anesth Analg** 1997 Apr;84(4):865–9
Spinal neostigmine diminishes, but does not abolish, hypotension from spinal bupivacaine in sheep. Rose G, et al. **Anesth Analg** 1996 Nov;83(5):1041–5
NG–nitro–L–arginine methyl ester (L–NAME) prevents tachyphylaxis to local anesthetics in a dose–dependent manner. Wilder RT, et al. **Anesth Analg** 1996 Dec; 83(6):1251–5
Comparison of continuous spinal with combined spinal–epidural anesthesia using plain bupivacaine 0.5% in trauma patients. Wilhelm S, et al. **Anesth Analg** 1997 Jul; 85(1):69–74
Treatment of hypotension after hyperbaric tetracaine spinal anesthesia. A randomized, double–blind, cross–over comparison of phenylephrine and epinephrine. Brooker RF, et al. **Anesthesiology** 1997 Apr;86(4):797–805
Prevention of lidocaine aerosol–induced bronchoconstriction with intravenous lidocaine. Bulut Y, et al. **Anesthesiology** 1996 Oct;85(4):853–9
Lidocaine spinal anesthesia: a vanishing therapeutic index? [editorial; comment] Drasner K. **Anesthesiology** 1997 Sep; 87(3):469–72. Comment on: Anesthesiology 1997 Sep;87(3):479–86. Comment on: Anesthesiology 1997 Sep;87(3):687–9.
Cauda equina syndrome following a single spinal administration of 5% hyperbaric lidocaine through a 25–gauge Whitacre needle [see comments] Gerancher JC. **Anesthesiology** 1997 Sep;87(3):687–9. Comment in: Anesthesiology 1997 Sep;87(3):469–72.
Understanding allergic reactions to local anesthetics. Eggleston ST, et al. **Ann Pharmacother** 1996 Jul–Aug; 30(7–8):851–7 (38 ref.)
Methemoglobinemia induced by an over–the–counter medication. Tush GM, et al. **Ann Pharmacother** 1996 Nov; 30(11):1251–4
Injection injury to the median nerve. Fremling MA, et al. **Ann Plast Surg** 1996 Nov;37(5):561–7
Delayed–type hypersensitivity after subcutaneous administration of amide anesthetic [letter] Whalen JD, et al. **Arch Dermatol** 1996 Oct;132(10):1256–7
Cardiovascular toxicity following preincisional intra–articular injection of bupivicaine [letter] Abbott PJ Jr, et al. **Arthroscopy** 1997 Apr;13(2):282
Bless you [letter] Ngeow WC. **Br Dent J** 1996 Apr 6; 180(7):246
Handle with care [letter; comment] Seward GR. **Br Dent J** 1997 May 24;182(10):370. Comment on: Br Dent J 1997 Feb 8;182(3):87.
Cardiac arrest after caesarean section under subarachnoid block [letter; comment] Burns R, et al. **Br J Anaesth** 1997 Jan;78(1):110. Comment on: Br J Anaesth 1996

Aug;77(2):274–6.
Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Knudsen K, et al. **Br J Anaesth** 1997 May;78(5):507–14
Mechanism of femoral nerve palsy complicating percutaneous ilioinguinal field block. Rosario DJ, et al. **Br J Anaesth** 1997 Mar;78(3):314–6
Serial angiography in cocaine-induced myocardial infarction. Williams MJ, et al. **Chest** 1997 Mar;111(3):822–4
Hearing loss following spinal anaesthesia with bupivacaine. Hussain SS, et al. **Clin Otolaryngol** 1996 Oct;21(5):449–54
Methemoglobinemia associated with a prilocaine–lidocaine cream. Kumar AR, et al. **Clin Pediatr (Phila)** 1997 Apr; 36(4):239–40
Safe and effective topical application dose of lidocaine for surgery with laryngomicroscopy. Kotaki H, et al. **Clin Pharmacol Ther** 1996 Aug;60(2):229–35 (15 ref.)
Delayed-type hypersensitivity to subcutaneous lidocaine with tolerance to articaine: confirmation by in vivo and in vitro tests. Bircher AJ, et al. **Contact Dermatitis** 1996 Jun;34(6):387–9
Purpura caused by Emla is of toxic origin. de Waard-van der Spek FB, et al. **Contact Dermatitis** 1997 Jan;36(1):11–3
Simultaneous contact sensitivity due to lidocaine and crotamiton. Kawada A, et al. **Contact Dermatitis** 1997 Jul; 37(1):45
Fixed drug eruption induced by lidocaine. Kawada A, et al. **Contact Dermatitis** 1996 Dec;35(6):375
Patch testing in suspected allergic contact dermatitis due to Emla cream in haemodialyzed patients. le Coz CJ, et al. **Contact Dermatitis** 1996 Nov;35(5):316–7
Topical anesthetic abuse ring keratitis: report of four cases. Varga JH, et al. **Cornea** 1997 Jul;16(4):424–9
Transient facial palsy in sphenoidal electrode placement. Iriarte J, et al. **Epilepsia** 1996 Dec;37(12):1239–41
Accidental subdural injection of local anaesthetic: diagnosis by pressure measurement and response to aspiration of injectate. Tripathi M, et al. **Eur J Anaesthesiol** 1997 Jul; 14(4):455–7
An assessment of intraocular pressure during fractionated peribulbar anaesthesia. Joshi N, et al. **Eye** 1996;10 (Pt 5):565–8
Experimental study on necrotizing sialometaplasia of the palate in rats. Role of local anesthetic injections. Shigematsu H, et al. **Int J Oral Maxillofac Surg** 1996 Jun; 25(3):239–41
Fatal intracerebral hemorrhage during dental treatment. Massalha R, et al. **Isr J Med Sci** 1996 Sep;32(9):774–6
Alkalinisation of lignocaine to reduce the pain of digital nerve blockade. Cornelius P, et al. **J Accid Emerg Med** 1996 Sep; 13(5):339–40
Allergic reaction caused by local anesthetic agents belonging to the amide group. Cuesta-Herranz J, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):427–8
Toxic methemoglobinemia after topical anesthesia for transesophageal echocardiography. Grauer SE, et al. **J Am Soc Echocardiogr** 1996 Nov-Dec;9(6):874–6
Lignocaine toxicity following pleurodesis [letter; comment] Goel A, et al. **J Assoc Physicians India** 1996 Apr;44(4):288 . Comment on: J Assoc Physicians India 1995 Jun;43(6):437–8.
Transient no light perception visual acuity after intracameral lidocaine injection. Hoffman RS, et al. **J Cataract Refract Surg** 1997 Jul-Aug;23(6):957–8
Keratitis from corneal anesthetic abuse after photorefractive keratectomy. Kim JY, et al. **J Cataract Refract Surg** 1997 Apr;23(3):447–9
Central nervous system toxicity in a patient receiving continuous intrapleural bupivacaine. Kreitzer JM, et al. **J Clin Anesth** 1996 Dec;8(8):666–8
Conus medullaris injury following both tetracaine and lidocaine spinal anesthesia. Waters JH, et al. **J Clin Anesth** 1996 Dec;8(8):656–8
Compartment syndrome associated with bupivacaine and fentanyl epidural analgesia in pediatric orthopaedics [see comments] Dunwoody JM, et al. **J Pediatr Orthop** 1997 May-Jun;17(3):285–8. Comment in: J Pediatr Orthop 1997 May-Jun;17(3):282–4.
Compartment syndromes and epidural analgesia [editorial; comment] Mubarak SJ, et al. **J Pediatr Orthop** 1997 May-Jun;17(3):282–4 (9 ref.). Comment on: J Pediatr Orthop 1997 May-Jun;17(3):285–8.
Seizures after ureteral stone manipulation with lidocaine. Pantuck AJ, et al. **J Urol** 1997 Jun;157(6):2248
Restrictive strabismus after retrobulbar anesthesia. Ando K, et al. **Jpn J Ophthalmol** 1997 Jan-Feb;41(1):23–6
Circumcision blues [letter] Prineas S, et al. **Med J Aust** 1997 Jun 2;166(11):615
Transient diplopia as a result of block injections. Mandibular and posterior superior alveolar. Goldenberg AS. **N Y State Dent J** 1997 May;63(5):29–31
Orbital hemorrhage after the administration of sub-Tenon's infusion anesthesia. Olitsky SE, et al. **Ophthalmic Surg Lasers** 1997 Feb;28(2):145–6
Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Luchetti W, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jan;81(1):21–5
Convulsions associated with epidural analgesia during sevoflurane anaesthesia. Saitoh K, et al. **Paediatr Anaesth** 1996;6(6):495–7
Neurological impairment during long-term intrathecal infusion of bupivacaine in cancer patients: a sign of spinal cord compression. van Dongen RT, et al. **Pain** 1997 Jan; 69(1-2):205–9
Bupivacaine toxicity secondary to continuous epidural infusion [letter] Aldrete JA. **Reg Anesth** 1996 Sep-Oct; 21(5):498–9
Cutaneous application of ethyl chloride spray [letter] Anyanwu-Okoli I. **Reg Anesth** 1996 Jan-Feb;21(1):77–8
Unexpected neurologic deficit following spinal anesthesia. Chhibber AK, et al. **Reg Anesth** 1996 Jul-Aug;21(4):355–7
Back pain following epidural anesthesia with 2-chloroprocaine (EDTA-free) or lidocaine [see comments] Drolet P, et al. **Reg Anesth** 1997 Jul-Aug; 22(4):303–7. Comment in: Reg Anesth 1997 Jul-Aug;22(4):299–302.
What causes different pain sensations on intradermal injection of local anesthetics? [letter; comment] Eckstein KL, et al. **Reg Anesth** 1996 Jul-Aug;21(4):374. Comment on: Reg Anesth 1994 Jan-Feb;19(1):48–51.
Back pain following epidural anesthesia with 2-chloroprocaine [editorial; comment] Stevens RA. **Reg Anesth** 1997 Jul-Aug;22(4):299–302. Comment on: Reg Anesth 1997 Jul-Aug;22(4):303–7.
Transient radicular irritation after bupivacaine spinal anesthesia. Tarkkila P, et al. **Reg Anesth** 1996 Jan-Feb; 21(1):26–9
Ethyl chloride for assessing sensory block [letter] Wace JR. **Reg Anesth** 1996 Jan-Feb;21(1):78
Accidental ocular perforation from self-inflicted facial palsy. O'Halloran HS, et al. **Retina** 1997;17(2):164–6
Toxicology of topical local anesthetics. Bangha E, et al. **Skin Pharmacol** 1996;9(6):376–80 (28 ref.)
Methemoglobinemia caused by benzocaine topical spray. Cooper HA. **South Med J** 1997 Sep;90(9):946–8 (15 ref.)
Methemoglobinemia secondary to benzocaine topical anesthetic. Lee E, et al. **Surg Laparosc Endosc** 1996 Dec; 6(6):492–3
[Neurotoxicity of intrathecally administrated agents] Malinovsky JM, et al. **Ann Fr Anesth Reanim** 1996; 15(5):647–58 (128 ref.) (Eng. Abstr.) **(Fre)**
[Immediate allergy to anesthetics of the amide group (letter)] Bourezane Y, et al. **Gastroenterol Clin Biol** 1997;21(4):344–5 **(Fre)**
[Toxicity of local anesthetics] Mazoit JX, et al. **Rev Med Suisse Romande** 1997 May;117(5):389–92 (0 ref.) **(Fre)**
[Side effects of mesotherapy] Doutre MS, et al. **Therapie** 1997 Mar-Apr;52(2):93–6 (15 ref.) **(Fre)**
[Circulatory reactions under spinal anesthesia. The catheter technique versus the single dose procedure] Holst D, et al. **Anaesthesist** 1997 Jan;46(1):38–42 (Eng. Abstr.) **(Ger)**
[Local anesthesia in operations of the head-neck area] Grevers G, et al. **Laryngorhinootologie** 1996 Jul;75(7):433–6 (10 ref.) (Eng. Abstr.) **(Ger)**
[Damage to sense of smell and taste following xylocaine administration? Process before the expert evaluation committee for medical malpractice of the North Rhine Physicians Organization in 1995 (Az. 91/588)] Wienke A. **Laryngorhinootologie** 1996 Feb;75(2):109–10 **(Ger)**
[Transient myocardial ischemia secondary to the use of cocaine-like anesthetic drug] Elia LR, et al. **Ann Ital Med Int** 1996 Apr-Jun;11(2):140–3 (Eng. Abstr.) **(Ita)**
[Clinical study of patients with positive reactions in patch tests with local anesthetics] Amano K. **Nippon Ika Daigaku Zasshi** 1997 Apr;64(2):139–46 (Eng. Abstr.) **(Jpn)**
[Neurotoxicity of 5% hyperbaric lidocaine in subarachnoid anesthesia? (editorial)] de Andrés JA. **Rev Esp Anestesiol Reanim** 1996 Nov;43(9):303–4 **(Spa)**
[Pain in the lower extremities after subarachnoid block with lidocaine] Saludes J, et al. **Rev Esp Anestesiol Reanim** 1996 Nov;43(9):330–2 (Eng. Abstr.) **(Spa)**

ANALYSIS

Determination of ester-type local anesthetic drugs (procaine, tetracaine, and T-caine) in human serum by wide-bore capillary gas chromatography with nitrogen-phosphorus detection. Terada M, et al. **J Anal Toxicol** 1996 Sep; 20(5):318–22
Validation of high-performance liquid chromatographic methods on two silica base-deactivated reversed phases for the determination of chloroprocaine and bupivacaine. Brun F, et al. **J Pharm Biomed Anal** 1996 Jun; 14(8-10):1251–9
A chiral capillary electrophoresis method for ropivacaine hydrochloride in pharmaceutical formulations: validation and comparison with chiral liquid chromatography. Sänger-van de Griend CE, et al. **J Pharm Biomed Anal** 1997 May;15(8):1051–61
Validation of a capillary electrophoresis method for the enantiomeric purity testing of ropivacaine, a new local anaesthetic compound. Sänger-van de Griend CE, et al. **J Pharm Biomed Anal** 1996 Jan;14(3):295–304

BLOOD

Study of local anaesthetics. Part 133. Determination of diperodon in blood serum in vitro by the HPLC method. Cižmárik J, et al. **Acta Pol Pharm** 1996 May-Jun; 53(3):167–9
Plasma lignocaine concentration following nebulization for awake intubation. Parkes SB, et al. **Anaesth Intensive Care** 1997 Aug;25(4):369–71
Neonatal welfare and placental transfer of fentanyl and bupivacaine during ambulatory combined spinal epidural analgesia for labour. Fernando R, et al. **Anaesthesia** 1997 Jun;52(6):517–24
Venous levels of lignocaine and bupivacaine after peribulbar block. Gao F, et al. **Anaesthesia** 1996 Dec;51(12):1109–12
Plasma concentrations of lidocaine and bupivacaine after cervical plexus block for carotid surgery. Tissot S, et al. **Anesth Analg** 1997 Jun;84(6):1377–9
Rapid and specific precolumn extraction high-performance liquid chromatographic assay for bupivacaine in human serum. Emara S, et al. **Biomed Chromatogr** 1996 May-Jun; 10(3):131–4
Plasma bupivacaine concentrations associated with continuous extradural infusions in babies. Peutrell JM, et al. **Br J Anaesth** 1997 Feb;78(2):160–2
Serum bupivacaine concentrations during continuous extrapleural infusion. Dauphin A, et al. **Can J Anaesth** 1997 Apr;44(4):367–70
Serum bupivacaine concentrations and transplacental transfer following repeated epidural administrations in term parturients during labour. Decocq G, et al. **Fundam Clin Pharmacol** 1997;11(4):365–70
Serum bupivacaine levels during laparoscopic sterilization using local anesthesia. Lipscomb GH, et al. **J Am Assoc Gynecol Laparosc** 1994 Nov;2(1):27–30
Direct injection of large volumes of plasma in a column-switching system for the analysis of local anaesthetics. I. Optimization of semi-permeable surface precolumns in the system and characterization of some interference peaks. Yu Z, et al. **J Chromatogr A** 1996 Feb 19;725(1):137–47
Direct injection of large volumes of plasma in a column-switching system for the analysis of local anaesthetics. II. Determination of bupivacaine in human plasma with an alkyldiol silica precolumn. Yu Z, et al. **J Chromatogr A** 1996 Feb 19;725(1):149–55
High-performance liquid chromatographic method for an automated determination of local anaesthetics in human plasma. Drewe J, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):105–10
Capillary gas chromatographic method for the determination of n-butyl-p-aminobenzoate and lidocaine in plasma samples. Grouls RJ, et al. **J Chromatogr B Biomed Appl** 1995 Nov 3;673(1):51–7
Rapid determination of chloroprocaine and its major metabolite, 2-chloroaminobenzoic acid, in plasma by high-performance liquid chromatography. Janicki PK, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26;675(2):336–41
Stereoselective determination of R-(-)- and S-(+)-prilocaine in human serum by capillary electrophoresis using a derivatized cyclodextrin and ultraviolet detection. Siluveru M, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):205–10
Stereoselective determination of mepivacaine in human serum using a brush-type chiral stationary phase and solid-phase extraction. Siluveru M, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1-2):359–62
High-performance liquid chromatographic assay of mepivacaine enantiomers in human plasma in the nanogram per milliliter range. Vletter AA, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):369–72
Lidocaine plasma levels following two techniques of obturator nerve block. Atanassoff PG, et al. **J Clin Anesth** 1996 Nov;8(7):535–9
Stereoselective determination of R(-)- and S(+)-prilocaine in human serum using a brush-type chiral stationary phase, solid-phase extraction and UV detection. Siluveru M, et al. **J Pharm Biomed Anal** 1996 Dec;15(3):389–92
HPCE determination of R(+) and S(-) mepivacaine in human serum using a derivatized cyclodextrin and ultraviolet detection. Siluveru M, et al. **J Pharm Biomed Anal** 1997 Jul;15(11):1751–6
Comparative study of the determination of bupivacaine in human plasma by gas chromatography-mass spectrometry and high-performance liquid chromatography. Tahraoui A, et al. **J Pharm Biomed Anal** 1996 Nov;15(2):251–7
Plasma concentrations of different local anesthetics after facial nerve block. Schimek F, et al. **Ophthalmic Surg Lasers** 1996 Oct;27(10):862–8
Effects of calcium antagonists on binding of local anesthetics to plasma proteins and erythrocytes in mice. Jacob D, et al. **Pharmacology** 1996 Oct;53(4):219–23
Plasma bupivacaine concentrations following epidural administration in kidney transplant recipients. Hammouda GE, et al. **Reg Anesth** 1996 Jul-Aug;21(4):308–11

CHEMICAL SYNTHESIS

Modulation of pharmacological profile of diphenylethane (lefetamine-type) derivatives. Carrara M, et al. **Arzneimittelforschung** 1997 Jul;47(7):803–9
Synthesis, local anaesthetic and antiarrhythmic activity of methyl N-(2-substituted aminopropanoyl)-3-cyanoanthranilates. al-Obaid AR. **Boll Chim Farm** 1996 Jul-Aug;135(7):415–20
Synthesis and local anaesthetic activity of some 7-amino-2-dialkylaminoalkylpyrrolo[3,4-c]pyridine derivatives. Da Settimo F, et al. **Farmaco** 1996 Nov; 51(11):725–8

Synthesis and local anaesthetic activities of N,N-diethyl-3-allyloxy-2-(2-alkoxyphenylcarbamoyloxy) -propylammonium chlorides. Csöllei J. **Pharmazie** 1997 Aug;52(8):639-40

CHEMISTRY

The influence of glycerol, propylene glycol and sorbitol on surface tension, partition coefficient and diffusion of pyrrolidinoethylester of 3-heptyloxy phenylcarbamic acid (drug XX Z). Vitková Z, et al. **Acta Pol Pharm** 1995 Nov-Dec;52(6):483-5

Compatibility of bupivacaine hydrochloride and morphine sulfate. Johnson CE, et al. **Am J Health Syst Pharm** 1997 Jan 1;54(1):61-4

The effect of the addition of lignocaine on propofol emulsion stability [see comments] Lilley EM, et al. **Anaesthesia** 1996 Sep;51(9):815-8. Comment in: Anaesthesia 1997 Mar;52(3):288.

Structure-affinity relationships and stereospecificity of several homologous series of local anesthetics for the beta2-adrenergic receptor. Butterworth J, et al. **Anesth Analg** 1997 Aug;85(2):336-42

Densities of dextrose-free intrathecal local anesthetics, opioids, and combinations measured at 37 degrees C. Richardson MG, et al. **Anesth Analg** 1997 Jan;84(1):95-9

Interaction of local anesthetic heptacaine homologs with phosphatidylcholine bilayers: spin label ESR study. Gallová J, et al. **Biochim Biophys Acta** 1997 Apr 26; 1325(2):189-96

Light-induced reversible local fusions of thylakoid membranes in the presence of dibucaine or tetracaine. Semenova GA, et al. **Biochim Biophys Acta** 1996 Nov 13; 1285(1):29-37

Locations of local anesthetic dibucaine in model membranes and the interaction between dibucaine and a Na+ channel inactivation gate peptide as studied by 2H- and 1H-NMR spectroscopies. Kuroda Y, et al. **Biophys J** 1996 Sep; 71(3):1191-207

Direct inhibition of the actomyosin motility by local anesthetics in vitro. Tsuda Y, et al. **Biophys J** 1996 Nov; 71(5):2733-41

Molecular and physicochemical aspects of local anesthetic-membrane interaction. de-Paula E, et al. **Braz J Med Biol Res** 1996 Jul;29(7):877-94 (199 ref.)

Stereochemistry in anaesthesia. Sidebotham DA, et al. **Clin Exp Pharmacol Physiol** 1997 Feb;24(2):126-30 (42 ref.)

Partition coefficients (n-octanol/water) of N-butyl-p-aminobenzoate and other local anesthetics measured by reversed-phase high-performance liquid chromatography. Grouls RJ, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):421-5

[Do "lefthanders" make better local anesthetics? The relevance of stereoisomerism in clinical practice as shown by new local anesthetics] Wulf H. **Anaesthesist** 1997 Jul; 46(7):622-6 (32 ref.) (Eng. Abstr.) **(Ger)**

CONTRAINDICATIONS

[The systemic problems in the dental treatment of the elderly patients] Matsuura H. **Nippon Ronen Igakkai Zasshi** 1996 Jul;33(7):505-7 (0 ref.) **(Jpn)**

DIAGNOSTIC USE

Liver function tests and lidocaine metabolism (MEGX test) during i.v. CMF therapy in breast cancer. Rizzi V, et al. **Anticancer Drugs** 1996 Nov;7(8):846-50

Early assessment of transplanted liver function: lignocaine clearance test (MEGX). Freys G, et al. **Eur J Anaesthesiol** 1997 Jul;14(4):397-405

Peroneal tendon bupivacaine injection: utility of concomitant injection of contrast material. Mizel MS, et al. **Foot Ankle Int** 1996 Sep;17(9):566-8

Irritable bowel syndrome: a study to investigate the mechanism(s) of visceral hypersensitivity. Greenwood B, et al. **J Okla State Med Assoc** 1996 Feb;89(2):47-50

Treatment of spinal pain syndromes [editorial; comment] North RB. **N Engl J Med** 1996 Dec 5;335(23):1763-4. Comment on: N Engl J Med 1996 Dec 5;335(23):1721-6.

Specificity of lumbar medial branch and L5 dorsal ramus blocks. A computed tomography study. Dreyfuss P, et al. **Spine** 1997 Apr 15;22(8):895-902

Chronic cervical zygapophysial joint pain after whiplash. A placebo-controlled prevalence study [see comments] Lord SM, et al. **Spine** 1996 Aug 1;21(15):1737-44; discussion 1744-5. Comment in: Spine 1997 Jun 15;22(12):1420-1.

HISTORY

["Coca-Koller" and hist friends. On the 140th birthday of the Vienna Jewish trio: Carl Koller (1857-1944), Sigmund Lustgarten (1857-1911) and Sigmund Freud (1856-1939)] Amm M, et al. **Wien Klin Wochenschr** 1997 Mar 14; 109(5):170-5 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Allergic reaction caused by local anesthetic agents belonging to the amide group. Cuesta-Herranz J, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):427-8

Fixed drug eruption induced by lidocaine and patch testing. García JC, et al. **J Investig Allergol Clin Immunol** 1997 Mar-Apr;7(2):127-8

ISOLATION & PURIFICATION

Enantioseparation of local anaesthetic drugs by capillary zone electrophoresis with cyclodextrins as chiral selectors using a partial filling technique. Amini A, et al. **Electrophoresis** 1997 Jun;18(6):1019-25

HPLC separation of enantiomers of carbisocaine. Study of local anaesthetics, part 138. Cižmárik J, et al. **Pharmazie** 1997 May;52(5):402-3

METABOLISM

Do local anaesthetics interact with dihydropyridine binding sites on neuronal L-type Ca2+ channels? Hirota K, et al. **Br J Anaesth** 1997 Feb;78(2):185-8

Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Ekström G, et al. **Drug Metab Dispos** 1996 Sep;24(9):955-61

Metabolism and excretion of ropivacaine in humans. Halldin MM, et al. **Drug Metab Dispos** 1996 Sep;24(9):962-8

Extrahepatic metabolism of 4-methylumbelliferone and lidocaine in the anhepatic rabbit. Nyberg SL, et al. **Drug Metab Dispos** 1996 Jun;24(6):643-8

Pattern of anesthetic diffusion during peribulbar infiltration: a CT evaluation. Neuschuler R, et al. **Eur J Ophthalmol** 1996 Jul-Sep;6(3):336-9

Metabolism of benzocaine during percutaneous absorption in the hairless guinea pig: acetylbenzocaine formation and activity. Kraeling ME, et al. **Skin Pharmacol** 1996; 9(3):221-30

Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease. Shiffman ML, et al. **Ther Drug Monit** 1996 Aug;18(4):372-7

PHARMACOKINETICS

Ropivacaine gel in active distal ulcerative colitis and proctitis -- a pharmacokinetic and exploratory clinical study. Arlander E, et al. **Aliment Pharmacol Ther** 1996 Feb; 10(1):73-81

Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. Burm AG, et al. **Anesth Analg** 1997 Jan;84(1):85-9

Biphasic drug absorption from the epidural space of the dog may limit the utility of a slow release medium molecular weight hyaluronic acid-lidocaine ionic complex formulation. Doherty MM, et al. **Anesth Analg** 1996 Dec; 83(6):1244-50

Comparative pharmacokinetics of ropivacaine and bupivacaine in nonpregnant and pregnant ewes. Santos AC, et al. **Anesth Analg** 1997 Jul;85(1):87-93

Hyperbaric dye solution distribution characteristics after pencil-point needle injection in a spinal cord model. Holman SJ, et al. **Anesthesiology** 1997 Apr;86(4):966-73

Effects of fetal pH on local anesthetic transfer across the human placenta. Johnson RF, et al. **Anesthesiology** 1996 Sep;85(3):608-15

Comment: bioavailability and safety of two ceftriaxone formulations--exposure to lidocaine questioned [letter; comment] Seay RE. **Ann Pharmacother** 1997 Apr; 31(4):501-2. Comment on: Ann Pharmacother 1996 Nov;30(11):1223-6.

Regional distribution of 11C-labeled lidocaine, bupivacaine, and ropivacaine in the heart, lungs, and skeletal muscle of pigs studied with positron emission tomography. Feldman HS, et al. **Biopharm Drug Dispos** 1997 Mar; 18(2):151-64

Differences in steady-state inactivation between Na channel isoforms affect local anesthetic binding affinity. Wright SN, et al. **Biophys J** 1997 Aug;73(2):779-88

Myocardial extraction of bupivacaine in anaesthetized sheep and by hearts of sheep and rats in vitro. Foth H, et al. **Br J Anaesth** 1996 Aug;77(2):257-64

Anatomical configuration of the spinal column as determined by magnetic resonance imaging [letter] Hirabayashi Y, et al. **Br J Anaesth** 1997 Mar;78(3):339

Acid-base state of cerebrospinal fluid during pregnancy and its effect on spread of spinal anaesthesia. Hirabayashi Y, et al. **Br J Anaesth** 1996 Sep;77(3):352-5

Inflammatory changes after extradural anaesthesia may affect the spread of local anaesthetic within the extradural space. Igarashi T, et al. **Br J Anaesth** 1996 Sep;77(3):347-51

A model of the first pass passage of drugs from i.v. injection site to the heart--parameter estimates for lignocaine in the sheep. Upton RN. **Br J Anaesth** 1996 Dec;77(6):764-72

Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. Mazoit JX, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):242-5

Regional metabolism of articaine in 10 patients undergoing intravenous regional anaesthesia during day case surgery. Vree TB, et al. **Br J Clin Pharmacol** 1997 Jul;44(1):29-34

Wound infiltration with lidocaine prolongs postoperative analgesia after haemorrhoidectomy with spinal anaesthesia. Morisaki H, et al. **Can J Anaesth** 1996 Sep;43(9):914-8

Metabolism and excretion of ropivacaine in humans. Halldin MM, et al. **Drug Metab Dispos** 1996 Sep;24(9):962-8

Effect of phenobarbital on the pharmacokinetics of lidocaine, monoethylglycinexylidide and 3-hydroxylidocaine in the rat: correlation with P450 isoform levels. Nakamoto T, et al. **Drug Metab Dispos** 1997 Mar;25(3):296-300

Early assessment of transplanted liver function: lignocaine clearance test (MEGX). Freys G, et al. **Eur J Anaesthesiol** 1997 Jul;14(4):397-405

Systemic absorption and toxicity from topically administered lidocaine during transesophageal echocardiography. Sharma SC, et al. **J Am Soc Echocardiogr** 1996 Sep-Oct; 9(5):710-1

A numerical investigation into factors affecting anesthetic distribution during spinal anesthesia. Myers MR. **J Biomech** 1996 Feb;29(2):139-49

Comparison of systemic absorption of aqueous and liposomal lidocaine following intra-articular injection in rabbits. Hou SM, et al. **J Formos Med Assoc** 1997 Feb;96(2):141-3

Kinetics of bupivacaine after levcromakalim treatment in mice. Gantenbein M, et al. **J Pharm Pharmacol** 1997 Mar; 49(3):293-5

Kinetics of bupivacaine after nicorandil treatment in mice. Gantenbein M, et al. **J Pharm Pharmacol** 1996 Jul; 48(7):749-52

Epidural metabolism of articaine to its metabolite articainic acid in five patients after epidural administration of 600 mg articaine. Vree TB, et al. **J Pharm Pharmacol** 1997 Feb; 49(2):158-63

Dermal and underlying tissue pharmacokinetics of lidocaine after topical application. Singh P, et al. **J Pharm Sci** 1994 Jun;83(6):774-82

Tissue distribution kinetics as determinant of transit time dispersion of drugs in organs: application of a stochastic model to the rat hindlimb. Weiss M, et al. **J Pharmacokinet Biopharm** 1996 Apr;24(2):173-96

Effects of cholestyramine and parenteral nutrition on hepatic metabolism of lidocaine: a study using isolated rat liver perfusion. Zaman N, et al. **JPEN J Parenter Enteral Nutr** 1996 Sep-Oct;20(5):349-56

Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. Lacoste L, et al. **Lab Anim** 1996 Jul;30(3):228-33

Absorption of topical cocaine in rhinologic procedures. Greinwald JH Jr, et al. **Laryngoscope** 1996 Oct; 106(10):1223-5

Effects of tobacco smoke exposure on the kinetics of bupivacaine in mice. Attolini L, et al. **Life Sci** 1997; 60(10):725-34

Plasma bupivacaine levels after fascia iliaca compartment block with and without adrenaline. Doyle E, et al. **Paediatr Anaesth** 1997;7(2):121-4

Controlled systemic absorption and increased anesthetic effect of bupivacaine following epidural administration of bupivacaine-hydroxypropyl-beta-cyclodextrin complex. Fréville JC, et al. **Pharm Res** 1996 Oct;13(10):1576-80

Alcohol pretreatment does not affect bupivacaine pharmacokinetics in the pig. Mets B, et al. **Pharmacol Res** 1996 Apr-May;33(4-5):291-5

Spread of local anesthetic into the epidural caudal space for two rates of injection in children. Blanco D, et al. **Reg Anesth** 1996 Sep-Oct;21(5):442-5

Distribution of local anesthetic solution in retromediastinal block. Preliminary experimental results. Kull K, et al. **Reg Anesth** 1997 Jul-Aug;22(4):308-12

Saturable in vitro metabolism of articaine by serum esterases. Does it contribute to the persistence of the local anesthetic effect? Oertel R, et al. **Reg Anesth** 1996 Nov-Dec; 21(6):576-81

Intraneural lidocaine uptake compared with analgesic differences between pregnant and nonpregnant rats. Popitz-Bergez FA, et al. **Reg Anesth** 1997 Jul-Aug; 22(4):363-71

Toxicology of topical local anesthetics. Bangha E, et al. **Skin Pharmacol** 1996;9(6):376-80 (28 ref.)

Intraindividual and interindividual variability in the disposition of the local anesthetic ropivacaine in healthy subjects. Emanuelsson BM, et al. **Ther Drug Monit** 1997 Apr;19(2):126-31

[The spread of contrast medium in the epidural space and the analgesic area in epidural anesthesia in elderly patients] Yokoyama M, et al. **Masui** 1996 Sep;45(9):1067-73 (Eng. Abstr.) **(Jpn)**

[Anatomic distribution of anesthetic solutions in the orbit after subconjuctival, parabulbar and retrobulbar administration] Zváč J, et al. **Cesk Slov Oftalmol** 1996 Sep; 52(4):238-42 (Eng. Abstr.) **(Slo)**

[Pharmacokinetics of lidocaine in obstetric patients after its epidural single-dose administration] Sánchez-Alcaraz A, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):13-5 (Eng. Abstr.) **(Spa)**

[The pharmacokinetic determinants of the analgesic effect of benzofurocaine in patients with burns and wounds of the joints] Stanislavchuk MA, et al. **Lik Sprava** 1996 Jul-Sep;(7-9):154-7 (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

Effects of pH and buffer capacity modulation on the analgesic efficacy of lignocaine and pethidine solutions. Dyhre H, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):86-90

Effects of subarachnoid lidocaine, meperidine and fentanyl on somatosensory and motor evoked responses in awake humans. Fernandez-Galinski SM, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):39-46

Methylprednisolone shortens the effects of bupivacaine on sensory nerve fibers in vivo. Johansson A. **Acta Anaesthesiol Scand** 1996 May;40(5):595-99

2-Chloroprocaine antagonism of epidural morphine analgesia. Karambelkar DJ, et al. **Acta Anaesthesiol Scand** 1997 Jun;41(6):774-8

Inhibitory effect of local anaesthetics on reactive oxygen

species production by human neutrophils. Mikawa K, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):524–8

Bupivacaine does not suppress cardiac sympathetic nerve activity during halothane anesthesia in the cat. Nishikawa K, et al. **Acta Anaesthesiol Scand** 1997 May;41(5):595–601

Myoelectric activity in the stomach and duodenum after epidural administration of morphine or bupivacaine. Thörn SE, et al. **Acta Anaesthesiol Scand** 1996 Aug;40(7):773–8

Lidocaine-induced hemodynamic effects are enhanced by the inhibition of endothelium-derived relaxing factor in dogs. Toyoyama H, et al. **Acta Anaesthesiol Scand** 1997 Jun; 41(6):766–73

Effect of lidocaine on histamine release and Ca2+ mobilization from mast cells and basophils. Yanagi H, et al. **Acta Anaesthesiol Scand** 1996 Oct;40(9):1138–44

A comparison of lidocaine, fentanyl, and esmolol for attenuation of cardiovascular response to laryngoscopy and tracheal intubation. Feng CK, et al. **Acta Anaesthesiol Sin** 1996 Jun;34(2):61–7

The preemptive effect of pre-incisional bupivacaine infiltration on postoperative analgesia following lower abdominal surgery under epidural anesthesia. Huang SJ, et al. **Acta Anaesthesiol Sin** 1997 Jun;35(2):97–102

Effects of local anaesthetics on the gross receptor potentials in the guinea pig cochlea. Jäger W, et al. **Acta Otolaryngol (Stockh)** 1997 Jan;117(1):49–54

Intravenous lidocaine and oral mexiletine block reflex bronchoconstriction in asthmatic subjects. Groeben H, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):885–8

Airway anesthesia and respiratory adaptations to dead space loading and exercise. Krishnan BS, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):459–65

Antimicrobial properties of bupivacaine [letter; comment] Meyer RJ. **Anaesth Intensive Care** 1997 Apr;25(2):200. Comment on: Anaesth Intensive Care 1996 Oct;24(5):599–600.

The effect of intravenous lidocaine on intraoperative somatosensory evoked potentials during scoliosis surgery [see comments] Chaves-Vischer V, et al. **Anesth Analg** 1996 Nov;83(5):1122–5. Comment in: Anesth Analg 1997 Jul;85(1):228.

Blunting the hemodynamic response to skull-pin placement [letter; comment] Colley PS. **Anesth Analg** 1997 Apr; 84(4):942. Comment on: Anesth Analg 1996 Dec;83(6):1256–61.

The inhibitory effects of local anesthetics on superoxide generation of neutrophils correlate with their partition coefficients. Hattori M, et al. **Anesth Analg** 1997 Feb; 84(2):405–12

The effects of topical and intravenous ropivacaine on canine pial microcirculation. Ishiyama T, et al. **Anesth Analg** 1997 Jul;85(1):75–81

A comparison of the local anesthetic effects of meperidine, fentanyl, and sufentanil on dorsal root axons. Jaffe RA, et al. **Anesth Analg** 1996 Oct;83(4):776–81

The effect of intravenous lidocaine on somatosensory evoked potentials during scoliosis surgery [letter; comment] Klasen J. **Anesth Analg** 1997 Jul;85(1):228. Comment on: Anesth Analg 1996 Nov;83(5):1122–5.

The effects of bupivacaine and ropivacaine on baroreflex sensitivity with or without respiratory acidosis and alkalosis in rats. Watanabe Y, et al. **Anesth Analg** 1997 Feb; 84(2):398–404

Bupivacaine preferentially blocks ventral root axons in rats. Dietz FB, et al. **Anesthesiology** 1997 Jan;86(1):172–80

Pregnancy does not increase susceptibility to bupivacaine in spinal root axons. Dietz FB, et al. **Anesthesiology** 1997 Sep; 87(3):610–6

Stereospecific effect of bupivacaine isomers on atrioventricular conduction in the isolated perfused guinea pig heart. Graf BM, et al. **Anesthesiology** 1997 Feb; 86(2):410–9

Sympathetic and mesenteric venous responses to baroreceptor or chemoreceptor stimulation during epidural anesthesia in rabbits. Hogan QH, et al. **Anesthesiology** 1996 Dec;85(6):1413–21

Direct effects of ropivacaine and bupivacaine on spinal pial vessels in canine. Assessment with closed spinal window technique. Iida H, et al. **Anesthesiology** 1997 Jul;87(1):75–81

Inhibition of lysophosphatidate signaling by lidocaine and bupivacaine. Nietgen GW, et al. **Anesthesiology** 1997 May; 86(5):1112–9

Influence of lidocaine on endotoxin-induced leukocyte-endothelial cell adhesion and macromolecular leakage in vivo. Schmidt W, et al. **Anesthesiology** 1997 Sep; 87(3):617–24

Effects of ropivacaine on a potassium channel (hKv1.5) cloned from human ventricle. Valenzuela C, et al. **Anesthesiology** 1997 Mar;86(3):718–28

Third-degree heart block complicating supraclavicular brachial plexus block. Vyas A, et al. **Anesthesiology** 1996 Sep;85(3):675–7

Visual acuity after topical application of proparacaine. Bossart PJ, et al. **Ann Emerg Med** 1997 Jan;29(1):158–60

Injection injury to the median nerve. Fremling MA, et al. **Ann Plast Surg** 1996 Nov;37(5):561–7

Modulation of pharmacological profile of diphenylethane (lefetamine-type) derivatives. Carrara M, et al. **Arzneimittelforschung** 1997 Jul;47(7):803–9

The effect of epidural bupivacaine on the fetal electrocardiogram [letter; comment] Murray H. **Aust N Z J Obstet Gynaecol** 1997 May;37(2):248–50. Comment on: Aust N Z J Obstet Gynaecol 1996 Aug;36(3):272–4.

The effect of epidural bupivacaine on the fetal electrocardiogram [see comments] Phillips K, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):272–4. Comment in: Aust N Z J Obstet Gynaecol 1997 May;37(2):248–50.

Effect of intrathecally administered local anesthetics on protein phosphorylation in the spinal cord. Nivarthi RN, et al. **Biochem Pharmacol** 1997 Apr 4;53(7):979–86

Monocarboxylic acids enhance the anesthetic action of procaine by decreasing intracellular pH. Katsuki H, et al. **Biochim Biophys Acta** 1997 Mar 15;1334(2–3):273–82

Effects of pressure and local anesthetic tetracaine on dipalmitoylphosphatidylcholine bilayers. Maruyama S, et al. **Biochim Biophys Acta** 1997 Apr 26;1325(2):272–80

The action of local anesthetics on myelin structure and nerve conduction in toad sciatic nerve. Mateu L, et al. **Biophys J** 1997 Jun;72(6):2581–7

Local anaesthesia to the airway reduces sedation requirements in patients undergoing artificial ventilation [letter; comment] Bapat P, et al. **Br J Anaesth** 1997 Apr; 78(4):479–80. Comment on: Br J Anaesth 1996 Dec;77(6):731–4.

Hypnotic effect of i.v. propofol is enhanced by i.m. administration of either lignocaine or bupivacaine. Ben-Shlomo I, et al. **Br J Anaesth** 1997 Apr;78(4):375–7

Spinal anaesthesia inhibits central temporal summation. Curatolo M, et al. **Br J Anaesth** 1997 Jan;78(1):88–9

Potentiation of local lignocaine-induced sensory block by calcium channel blockers in rats. Iwasaki H, et al. **Br J Anaesth** 1996 Aug;77(2):243–7

Low-dose mivacurium supplementation of prilocaine i.v. regional anaesthesia. Torrance JM, et al. **Br J Anaesth** 1997 Feb;78(2):222–3

In vivo quantification of muscle damage in dogs after intramuscular administration of drugs. Aktas M, et al. **Br Vet J** 1995 Mar–Apr;151(2):189–96

Procaine microinjection into the lower midbrain increases brown fat and body temperatures in anesthetized rats. Shibata M, et al. **Brain Res** 1996 Apr 15;716(1–2):171–9

Eutectic mixture of local anaesthetics is not effective for extracorporeal shock wave lithotripsy. Ganapathy S, et al. **Can J Anaesth** 1996 Oct;43(10):1030–4

Potassium channel agonists modify the local anaesthetic activity of bupivacaine in mice. Gantenbein M, et al. **Can J Anaesth** 1996 Aug;43(8):871–6

Inhibition of nicotinic cholinoceptor mediated current in vagal motor neurons by local anesthetics. Lu WY, et al. **Can J Physiol Pharmacol** 1996 Nov;74(11):1265–9

The effects of lidocaine on cardiac parasympathetic control in normal subjects and in subjects after myocardial infarction. Abramovich-Sivan S, et al. **Clin Auton Res** 1996 Dec;6(6):313–9

A risk–benefit assessment of topical percutaneous local anaesthetics in children. Russell SC, et al. **Drug Saf** 1997 Apr;16(4):279–87 (65 ref.)

Effects of intratympanically delivered lidocaine on the auditory system in humans. Laurikainen EA, et al. **Ear Hear** 1996 Feb;17(1):49–54

Centrally mediated hemodynamic effects of cocaine in rabbits: the role of local anesthetic actions and biogenic amine re-uptake blockage. Bernards CM. **Eur J Pharmacol** 1996 Jun 20;307(1):33–9

Mazindol and lidocaine are antinociceptives in the mouse formalin model: involvement of dopamine receptor. Bittencourt AL, et al. **Eur J Pharmacol** 1997 Jul 9; 330(2–3):109–13

Tetracaine stimulates extracellular Ca2+-independent insulin release. Bordin S, et al. **Eur J Pharmacol** 1997 May 30; 327(2–3):257–62

The local anesthetic, n-butyl-p-aminobenzoate, reduces rat sensory neuron excitability by differential actions on fast and slow Na+ current components. Van den Berg RJ, et al. **Eur J Pharmacol** 1996 Nov 28;316(1):87–95

Induction of apoptotic cell death in a neuroblastoma cell line by dibucaine. Kim M, et al. **Exp Cell Res** 1997 Mar 15; 231(2):235–41

Synthesis and local anesthetic activity—lipophilicity relationships for a homological series of phenylcarbamic acid esters. Note II. Gregáň F, et al. **Farmaco** 1996 Oct; 51(10):669–72

The effects of systemic procaine, lidocaine and dimethocaine on nociception in mice. Rigon AR, et al. **Gen Pharmacol** 1996 Jun;27(4):647–50

Effects of lidocaine on salicylate-induced discharge of neurons in the inferior colliculus of the guinea pig. Manabe Y, et al. **Hear Res** 1997 Jan;103(1–2):192–8

Influence of inhalational, neuroleptic and local anaesthesia on lymphocyte subset distribution. Corsi M, et al. **Int J Tissue React** 1995;17(5–6):211–7

Platelet-activating factor induces histamine release from human skin mast cells in vivo, which is reduced by local nerve blockade. Petersen LJ, et al. **J Allergy Clin Immunol** 1997 May;99(5):640–7

Antiviral activity of local anaesthetic agents [letter] De Amici D, et al. **J Antimicrob Chemother** 1996 Mar;37(3):635

Changes in serum enzyme activities after injection of bupivacaine into rat tibialis anterior. Nosaka K. **J Appl Physiol** 1996 Aug;81(2):876–84

Has nicotine a local anaesthetic action? Erenmemisoglu A, et al. **J Basic Clin Physiol Pharmacol** 1994 Apr–Jun; 5(2):125–31

Comparative effects of plain and epinephrine-containing bupivacaine on the hemodynamic response to cervical plexus anesthesia in patients undergoing carotid endarterectomy. McGlade DP, et al. **J Cardiothorac Vasc Anesth** 1996 Aug;10(5):593–7

Local anesthetics as effectors of allosteric gating. Lidocaine effects on inactivation-deficient rat skeletal muscle Na channels. Balser JR, et al. **J Clin Invest** 1996 Dec 15; 98(12):2874–86

Mechanism of tetracaine block of cyclic nucleotide-gated channels. Fodor AA, et al. **J Gen Physiol** 1997 Jan; 109(1):3–14

Concentration-dependent effects of tetracaine on excitation-contraction coupling in frog skeletal muscle fibres. Sárközi S, et al. **J Muscle Res Cell Motil** 1996 Dec; 17(6):647–56

The recovery of long-term denervated rat muscles after Marcaine treatment and grafting. Billington L, et al. **J Neurol Sci** 1996 Dec;144(1–2):147–55

Intracellular QX-314 inhibits calcium currents in hippocampal CA1 pyramidal neurons. Talbot MJ, et al. **J Neurophysiol** 1996 Sep;76(3):2120–4

Intravenous lidocaine decreases but cocaine does not alter the rate of cerebrospinal fluid formation in anesthetized rabbits. Artru AA, et al. **J Neurosurg Anesthesiol** 1997 Jan; 9(1):31–43

The effect of the sodium channel blocker QX-314 on recovery after acute spinal cord injury. Agrawal SK, et al. **J Neurotrauma** 1997 Feb;14(2):81–8

Susceptibility to lidocaine of impulses in different somatosensory afferent fibers of rat sciatic nerve. Huang JH, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):802–11

Two human paramyotonia congenita mutations have opposite effects on lidocaine block of Na+ channels expressed in a mammalian cell line. Fan Z, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):275–86

Dual effects of tetracaine on spontaneous calcium release in rat ventricular myocytes. Györke S, et al. **J Physiol (Lond)** 1997 Apr 15;500 (Pt 2):297–309

Dual actions of tetracaine on intramembrane charge in amphibian striated muscle. Huang CL. **J Physiol (Lond)** 1997 Jun 15;501 (Pt 3):589–606

Randomized, prospective, double-blind study of the effects on pain perception of lidocaine jelly versus plain lubricant during outpatient rigid cystoscopy. Goldfischer ER, et al. **J Urol** 1997 Jan;157(1):90–4

Re: Efficacy of prilocaine-lidocaine cream in the treatment of premature ejaculation [letter; comment] Sahin H, et al. **J Urol** 1996 Nov;156(5):1783–4. Comment on: J Urol 1995 Oct;154(4):1360–1.

The heart sodium channel phenotype for inactivation and lidocaine block. Makielski JC. **Jpn Heart J** 1996 Sep; 37(5):733–9

Regional cutaneous differences in the duration of bupivacaine local anesthesia in mice. Smith FL. **Life Sci** 1997; 60(18):1613–21

Effectiveness of sodium hydroxide as a pleural sclerosing agent in rabbits: influence of concomitant intrapleural lidocaine. Teixeira LR, et al. **Lung** 1996;174(5):325–32

Further validation of a simple biochemical method for evaluation of local anesthetic effects at sodium channels. Tiger G, et al. **Methods Find Exp Clin Pharmacol** 1996 Sep;18(7):431–5

Effects of local anaesthetics and phenothiazines on 32P-incorporation into the inositol phospholipids and glycosyl phosphatidylinositol of Tetrahymena pyriformis GL. Kovács P, et al. **Microbios** 1996;87(352):149–59

The beta 1 sodium channel subunit modifies the interactions of neurotoxins and local anesthetics with the rat brain IIA alpha sodium channel in isolated membranes but not in intact cells. Bonhaus DW, et al. **Neuropharmacology** 1996 May;35(5):605–13

Local anaesthetics potentiate GABA-mediated Cl- currents by inhibiting GABA uptake. Nordmark J, et al. **Neuroreport** 1997 Jan 20;8(2):465–8

Ketamine enhances local anesthetic and analgesic effects of bupivacaine by peripheral mechanism: a study in postoperative patients. Tverskoy M, et al. **Neurosci Lett** 1996 Aug 30;215(1):5–8

Fast Na+ spike generation in dendrites of guinea-pig substantia nigra pars compacta neurons. Nedergaard S, et al. **Neuroscience** 1996 Jul;73(2):381–96

Changes in membrane potential induced by local anesthetic bupivacaine on mitochondria within Ehrlich ascites tumor cells. Pulselli R, et al. **Oncol Res** 1996;8(7–8):267–71

Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Abbadie C, et al. **Pain** 1997 Jan;69(1–2):101–10

Distinct electrophysiological effects of two spinally administered membrane stabilising drugs, bupivacaine and lamotrigine. Chapman V, et al. **Pain** 1997 Jul;71(3):285–95

Isobolographic analysis of the interaction between epidural sufentanil and bupivacaine in rats. Vercauteren M, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):237–42

Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Ragsdale DS, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9270–5

Stimulant activities of dimethocaine in mice: reinforcing and anxiogenic effects. Rigon AR, et al.

Psychopharmacology (Berl) 1996 Oct;127(4):323–7

Future epidural or subarachnoid analgesics: local anesthetics. Carpenter RL. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):75–80 (27 ref.)

The hypothesis that antagonism of fentanyl analgesia by 2-chloroprocaine is mediated by direct action on opioid receptors. Coda B, et al. **Reg Anesth** 1997 Jan–Feb; 22(1):43–52

Monitoring epidural local anesthetic action during the postoperative period. Lema MJ. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):94–9 (15 ref.)

Effects of intravenous mepivacaine on renal sympathetic nerve activity in the cat during nitrous oxide and nitrous oxide–halothane anesthesia. Morimoto O, et al. **Reg Anesth** 1996 Jan–Feb;21(1):41–8

Sympathetic block during spinal anesthesia in volunteers using lidocaine, tetracaine, and bupivacaine. Stevens RA, et al. **Reg Anesth** 1997 Jul–Aug;22(4):325–31

Effects of lidocaine on pulmonary circulation during hyperoxia and hypoxia in the dog. Yukioka H, et al. **Reg Anesth** 1996 Jul–Aug;21(4):327–37

The effect of continuous lumbar epidural infusion of ropivacaine (0.1%, 0.2%, and 0.3%) and 0.25% bupivacaine on sensory and motor block in volunteers: a double-blind study. Zaric D, et al. **Reg Anesth** 1996 Jan–Feb;21(1):14–25

[Use of a mix of lidocaine and butorphanol as a caudal epidural anesthesia in a mare] Csik-Salmon J, et al. **Can J Vet Res** 1996 Oct;60(4):288–95 (Eng. Abstr.) **(Fre)**

[Chronopharmacology. Time of day variations in the action of bupivacaine are not manifested in nerves] Holthusen H, et al. **Anaesthesist** 1997 Jul;46(7):588–91 (Eng. Abstr.) **(Ger)**

[Do "lefthanders" make better local anesthetics? The relevance of stereoisomerism in clinical practice as shown by new local anesthetics] Wulf H. **Anaesthesist** 1997 Jul; 46(7):622–6 (32 ref.) (Eng. Abstr.) **(Ger)**

[Potentiation of procaine-induced local sensory block by verapamil in rats] Ohmori H, et al. **Masui** 1996 Sep; 45(9):1100–4 (Eng. Abstr.) **(Jpn)**

[Effect of dibucaine and lidocaine on histamine release from mouse bone marrow-derived cultured mast cells] Yanagi H, et al. **Masui** 1997 Jan;46(1):16–22 (Eng. Abstr.) **(Jpn)**

[Regional (conduction) anesthesia: new solutions of old problems] Svetlov VA, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):53–62 (107 ref.) (Eng. Abstr.) **(Rus)**

[Effect of lidocaine on ultrastructural changes in jejunum, kidney medulla and lungs of suckling rabbits, caused by vibrio cholerae] Bardakhch'ian ÉA, et al. **Biull Eksp Biol Med** 1997 Jun;123(6):632–7 **(Rus)**

[Comparative anti-arrhythmia activity of rinocaine and lidocaine] Galenko-Iaroshevskiĭ PA, et al. **Biull Eksp Biol Med** 1996 Nov;122(11):517–20 **(Rus)**

[The effect of CO2 on conduction blocking in nerve fibers by trimecaine and anestezin] Mangusheva NA, et al. **Eksp Klin Farmakol** 1997 Mar–Apr;60(2):14–5 (Eng. Abstr.) **(Rus)**

[The effect of CO2 on the blocking of excitation conduction by local anesthetics in feline A-delta and C fibers] Mangusheva NA, et al. **Fiziol Zh Im I M Sechenova** 1995 Oct;81(10):15–9 (Eng. Abstr.) **(Rus)**

[Leocaine – local anesthetic of new generation in otorhinolaryngology] Karneeva OV, et al. **Vestn Otorinolaringol** 1997;(1):42–3 **(Rus)**

POISONING

Fatal accidental dibucaine poisoning in children. Dayan PS, et al. **Ann Emerg Med** 1996 Oct;28(4):442–5

Protracted methemoglobinemia after phenazopyridine overdose in an infant. Christensen CM, et al. **J Clin Pharmacol** 1996 Feb;36(2):112–6 (11 ref.)

STANDARDS

Evaluation of caudal epidural lignocaine injection during dystocia correction in ewes. Scott PR, et al. **Vet Rec** 1996 Jan 6;138(1):19–20

THERAPEUTIC USE

Is EMLA effective in Dercum's disease? [letter] Reggiani M, et al. **Acta Derm Venereol** 1996 Mar;76(2):170–1

Intradiscal glycerol or bupivacaine in the treatment of low back pain. Kotilainen E, et al. **Acta Neurochir (Wien)** 1997; 139(6):541–5

Tinnitus remission by lidocaine demonstrated by auditory-evoked magnetoencephalogram. A preliminary report. Shiomi Y, et al. **Acta Otolaryngol (Stockh)** 1997 Jan;117(1):31–4

Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience. Gramling-Babb P, et al. **Am Heart J** 1997 Jun;133(6):648–55

Comparison of wound infection rates using plain versus buffered lidocaine for anesthesia of traumatic wounds. Brogan GX, et al. **Am J Emerg Med** 1997 Jan;15(1):25–8

The antinociceptive effect of epidural lignocaine and fentanyl during lithotripsy. Fredman B, et al. **Anaesth Intensive Care** 1997 Feb;25(1):11–4

The application of EMLA and glyceryl trinitrate ointment prior to venepuncture. Michael A, et al. **Anaesth Intensive Care** 1996 Jun;24(3):360–4

Complication after interpleural analgesia [letter] Milliet N, et al. **Anesth Analg** 1996 Oct;83(4):890

Fetal heart rate changes after intrathecal sufentanil or epidural bupivacaine for labor analgesia: incidence and clinical significance. Nielsen PE, et al. **Anesth Analg** 1996 Oct;83(4):742–6

The effect of epidural fentanyl on the minimum local analgesic concentration of epidural chloroprocaine in labor. Polley LS, et al. **Anesth Analg** 1996 Nov;83(5):987–90

Postoperative analgesia after peripheral nerve block for podiatric surgery: clinical efficacy and chemical stability of lidocaine alone versus lidocaine plus clonidine. Reinhart DJ, et al. **Anesth Analg** 1996 Oct;83(4):760–5

EMLA cream for pain reduction in diagnostic allergy skin testing: effects on wheal and flare responses. Sicherer SH, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):64–8

EMLA versus TAC for topical anesthesia of extremity wounds in children. Zempsky WT, et al. **Ann Emerg Med** 1997 Aug;30(2):163–6

Use of Emla prior to circumcision. Puthoff TD, et al. **Ann Pharmacother** 1996 Nov;30(11):1327–30

Phenazopyridine in urinary tract infections. Zelenitsky SA, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):866–8 (10 ref.)

Comparison of physiotherapy, manipulation, and corticosteroid injection for treating shoulder complaints in general practice: randomised, single blind study. Winters JC, et al. **BMJ** 1997 May 3;314(7090):1320–5

Intrathecal infusion of bupivacaine with or without morphine for postoperative analgesia after hip and knee arthroplasty. Bachmann M, et al. **Br J Anaesth** 1997 Jun;78(6):666–70

Effects of local anaesthetics on carrageenan-evoked inflammatory nociceptive processing in the rat. Buritova J, et al. **Br J Anaesth** 1996 Nov;77(5):645–52

Effect of lignocaine and pH on propofol-induced pain. Eriksson M, et al. **Br J Anaesth** 1997 May;78(5):502–6

Effect of percutaneous local anaesthetics on pain reduction during pulse dye laser treatment of portwine stains. McCafferty DF, et al. **Br J Anaesth** 1997 Mar;78(3):286–9

Evaluation of the usefulness of intrathecal bupivacaine infusion for analgesia after hip and knee arthroplasty. Niemi L, et al. **Br J Anaesth** 1996 Oct;77(4):544–5

Intraperitoneal lignocaine for pain relief after total abdominal hysterectomy. Williamson KM, et al. **Br J Anaesth** 1997 Jun;78(6):675–7

Efficacy and safety of promethazine hydrochloride as a local anaesthetic agent for inguinal hernia repair: a pilot study. Kumar S, et al. **Br J Clin Pract** 1997 Jan–Feb;51(1):33–5

Vitiligo [letter; comment] Juhlin L, et al. **Br J Dermatol** 1996 Nov;135(5):852. Comment on: Br J Dermatol 1996 Feb;134(2):373.

Pain relief with Emla of ulcerating lesions in mycosis fungoides [letter] Robins G, et al. **Br J Dermatol** 1997 Feb; 136(2):287

Novel therapies for Crohn disease and colitis [letter] Saibil F. **Can Med Assoc J** 1997 Mar 1;156(5):634, 636

Treating refractory cough with aerosols of mepivacaine [letter; comment] Almansa-Pastor A. **Chest** 1996 Nov; 110(5):1374–5. Comment on: Chest 1994 May;105(5):1592–3.

Intractable hiccups. Consider nebulized lidocaine [letter] Neeno TA, et al. **Chest** 1996 Oct;110(4):1129–30

Drug management in skin surgery. Lawrence C. **Drugs** 1996 Dec;52(6):805–17 (109 ref.)

Ropivacaine. A review of its pharmacology and therapeutic use in regional anaesthesia. Markham A, et al. **Drugs** 1996 Sep;52(3):429–49 (90 ref.)

Effects of intratympanically delivered lidocaine on the auditory system in humans. Laurikainen EA, et al. **Ear Hear** 1996 Feb;17(1):49–54

Topical pharyngeal anesthesia improves tolerance of upper gastrointestinal endoscopy: a randomized double-blind study. Campo R, et al. **Endoscopy** 1995 Nov;27(9):659–64

Peribulbar anaesthesia for cataract surgery: prilocaine versus lignocaine and bupivacaine. Henderson TR, et al. **Eye** 1996; 10 (Pt 4):497–500

Chronic paroxysmal hemicrania and hemicrania continua: anaesthetic blockades of pericranial nerves. Antonaci F, et al. **Funct Neurol** 1997 Jan–Feb;12(1):11–5

Inhibition of the neurogenic inflammatory response by lidocaine in rat skin. Dux M, et al. **Inflamm Res** 1996 Jan; 45(1):10–3

Topical lidocaine for postoperative analgesia following myringotomy and tube placement. Lawhorn CD, et al. **Int J Pediatr Otorhinolaryngol** 1996 Mar;35(1):19–24

Pre-incisional caudal epidural blockade and the relief of pain after lumbar spine operations. Kakiuchi M, et al. **Int Orthop** 1997;21(1):62–6

Effect of topical pramoxine on experimentally induced pruritus in humans. Yosipovitch G, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 1):278–80

The effect of wound irrigation with bupivacaine on postoperative analgesia of the feline onychectomy patient. Winkler KP, et al. **J Am Anim Hosp Assoc** 1997 Jul–Aug; 33(4):346–52

Local anesthetics. Is there an advantage to mixing solutions? Ribotsky BM, et al. **J Am Podiatr Med Assoc** 1996 Oct; 86(10):487–91

Unpreserved lidocaine to control discomfort during cataract surgery using topical anesthesia. Gills JP, et al. **J Cataract Refract Surg** 1997 May;23(4):545–50

Effects of intravenous lidocaine and/or esmolol on hemodynamic responses to laryngoscopy and intubation: a double-blind, controlled clinical trial. Kindler CH, et al. **J Clin Anesth** 1996 Sep;8(6):491–6

Postthyroidectomy analgesia: morphine, buprenorphine, or bupivacaine? Lacoste L, et al. **J Clin Anesth** 1997 May; 9(3):189–93

Breaking the cycle: lidocaine therapy for habit cough. Sherman JM. **J Fla Med Assoc** 1997 Jun–Jul;84(5):308–9

The effect of postinjury administration of polyethylene glycol-conjugated superoxide dismutase (pegorgotein, Dismutec) or lidocaine on behavioral function following fluid-percussion brain injury in rats. Hamm RJ, et al. **J Neurotrauma** 1996 Jun;13(6):325–32

Analgesia for venepuncture in a paediatric surgery centre. Brislin RP, et al. **J Paediatr Child Health** 1995 Dec; 31(6):542–4

Pilot study evaluating local anesthetics administered systemically for treatment of pain in patients with advanced cancer. Chong SF, et al. **J Pain Symptom Manage** 1997 Feb;13(2):112–7

Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. Galer BS, et al. **J Pain Symptom Manage** 1996 Sep; 12(3):161–7

Randomized double-blind trial of low- and moderate-dose lidocaine regional anesthesia for forearm fractures in childhood. Bratt HD, et al. **J Pediatr Orthop** 1996 Sep–Oct; 16(5):660–3

Does sympathetic blockade prevent the physiologic changes associated with tourniquet use in children? Goodarzi M, et al. **J Pediatr Orthop** 1997 May–Jun;17(3):289–92

Post-operative pain relief in children following caudal bupivacaine and buprenorphine--a comparative study. Anilkumar TK, et al. **J Postgrad Med** 1994 Apr–Jun; 40(2):61–4

Experimental free tissue transfer over perivascular-injured vessels: effect of in vivo freezing. Cavadas PC, et al. **Microsurgery** 1996;17(6):295–300

Reduction of propofol pain--fentanyl vs lidocaine. Alyafi WA, et al. **Middle East J Anesthesiol** 1996 Oct;13(6):613–9

Efficacy and safety of lidocaine-prilocaine cream for pain during circumcision [see comments] Taddio A, et al. **N Engl J Med** 1997 Apr 24;336(17):1197–201. Comment in: N Engl J Med 1997 Apr 24;336(17):1244–5. Comment in: N Engl J Med 1997 Aug 21;337(8):568; discussion 569–70. Comment in: N Engl J Med 1997 Aug 21;337(8):568–9; discussion 569–70. Comment in: N Engl J Med 1997 Aug 21;337(8):569; discussion 569–70.

Patients can be pain-free while undergoing implanted port assessment. Hawn M, et al. **Oncol Nurs Forum** 1997 Jun; 24(5):801–2

The use of lidocaine in microvascular reconstruction. Chafin JB, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):93–8

The influence of the timing of bupivacaine infiltration on the time course of inflammation induced by two carrageenin injections seven days apart. Fletcher D, et al. **Pain** 1997 Feb;69(3):303–9

Blockade of peripheral neuronal barrage reduces postoperative pain. Gordon SM, et al. **Pain** 1997 Apr; 70(2–3):209–15

Use of EMLA cream in a department of neonatology. Gourrier E, et al. **Pain** 1996 Dec;68(2–3):431–4

Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Rowbotham MC, et al. **Pain** 1996 Apr;65(1):39–44

Resolution of tumor pain with EMLA cream. Stegman MB, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):694–7

Pain relief after knee arthroscopy: intra-articular morphine, intra-articular bupivacaine, or subcutaneous morphine? Cepeda MS, et al. **Reg Anesth** 1997 May–Jun;22(3):233–8

EMLA cream as a topical anesthetic before office phlebotomy in children. Young SS, et al. **South Med J** 1996 Dec;89(12):1184–7

Results of sacroiliac joint double block and value of sacroiliac pain provocation tests in 54 patients with low back pain. Maigne JY, et al. **Spine** 1996 Aug 15;21(16):1889–92

Management of post-partum cervical uterine or rectal prolapses in ewes using caudal epidural xylazine and lignocaine injection. Scott PR, et al. **Vet J** 1997 Jan; 153(1):115–6

[Surgical treatment of inguinal hernia. Which criteria to be used for assessment?] Fingerhut A, et al. **Ann Chir** 1996; 50(9):832–7 (62 ref.) **(Fre)**

[Apropos of the use of Emla cream in ophthalmology (letter)] Borgo J, et al. **Ann Fr Anesth Reanim** 1996;15(5):694–5 **(Fre)**

[Comparative evaluation of the anti-arrhythmia effect of KLN-93, dicaine, and lidocaine during neurogenic atrial fibrillation] Leonidov NB, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):77–80 **(Rus)**

[Digital ischemia of the lower limb: reversion via sympathetic blockage] Valdivielso Serna A, et al. **An Esp Pediatr** 1997 Feb;46(2):202–4 **(Spa)**

[Analgesic effectiveness and repercussions on the progress of labor of small doses of bupivacaine and fentanyl in continuous peridural perfusion] García-Muñoz M, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):135–9 (Eng. Abstr.) **(Spa)**

TOXICITY

Amrinone reverses bupivacaine-induced regional myocardial dysfunction. Fujita Y. **Acta Anaesthesiol Scand** 1996 Jan;

40(1):47–52
Modification of bupivacaine toxicity by nonselective versus neuronal nitric oxide synthesis inhibition. Shi B, et al. **Anesth Analg** 1997 Apr;84(4):804–9
Differential effects of lidocaine infusions into the ventral CA1/subiculum or the nucleus accumbens on the acquisition and retention of spatial information. Floresco SB, et al. **Behav Brain Res** 1996 Nov;81(1–2):163–71
The comparative genotoxicological study of new local anesthetics, 3-(2-alkoxyphenylcarbamoyloxy)quinuclidium chlorides, on Salmonella typhimurium, Saccharromyces cerevisiae, Vicia faba, Hordeum vulgare and Drosophila melanogaster. Miadoková E, et al. **Cell Biol Toxicol** 1996 Jun;12(3):135–45
Leukocyte hydrogen peroxide production in a surgical wound in mice. The effects of an amide local anaesthetic. Eriksson AS, et al. **Inflammation** 1996 Oct;20(5):569–79
Systemic absorption and toxicity from topically administered lidocaine during transesophageal echocardiography. Sharma SC, et al. **J Am Soc Echocardiog.** 1996 Sep–Oct; 9(5):710–1
Ocular toxicity following topical application of anesthetic cream to the eyelid skin [published erratum appears in Ophthalmic Surg Lasers 1996 Jul;27(7):594] Cohen RG, et al. **Ophthalmic Surg Lasers** 1996 May;27(5):374–7
Corneal endothelial toxicity of topical anesthesia. Judge AJ, et al. **Ophthalmology** 1997 Sep;104(9):1373–9
Pharmacological analysis of local anaesthetic tolycaine-induced convulsions by modification of monoamines in rat brain. Satoh T, et al. **Pharmacol Toxicol** 1996 Dec;79(6):305–11
Local anesthetic toxicity: an update. Hogan Q. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):43–50 (78 ref.)
Cleavage and development in cultured preimplantation mouse embryos exposed to lidocaine. Del Valle LJ, et al. **Reprod Toxicol** 1996 Nov–Dec;10(6):491–6
[Neurologic sequelae of spinal anesthesia: local anesthetic toxicity] Sakura S, et al. **Masui** 1996 Jul;45(7):846–51 (25 ref.) (Eng. Abstr.) **(Jpn)**

ANESTRUS

Normal or induced secretory patterns of luteinising hormone and follicle-stimulating hormone in anoestrous gonadotrophin-releasing hormone-immunised and cyclic control heifers. Prendiville DJ, et al. **Anim Reprod Sci** 1996 Dec 16;45(3):177–90
Changes in ovarian function and gonadotropin secretion preceding the onset of nutritionally induced anestrus in Bos indicus heifers. Rhodes FM, et al. **Biol Reprod** 1996 Dec; 55(6):1437–43
Effect of thyroidectomy on maintenance of seasonal reproductive suppression in the ewe. Thrun LA, et al. **Biol Reprod** 1997 Apr;56(4):1035–40
Sire breed of calf influences peripartum endocrine profiles and postpartum anestrus in Brahman cows. Browning R Jr, et al. **Domest Anim Endocrinol** 1996 Nov;13(6):511–7

BLOOD

Serum progesterone levels in mares in winter and during transitional periods. Koskinen E, et al. **Acta Vet Scand** 1996; 37(4):409–14

DRUG EFFECTS

Comparison of the effects of N-methyl-DL-aspartic acid on gonadotropin and prolactin secretion in anestrous mares and mares exhibiting estrous cycles during anestrus. Fitzgerald BP, et al. **Biol Reprod** 1997 Jul;57(1):36–42
Estradiol acts locally within the retrochiasmatic area to inhibit pulsatile luteinizing-hormone release in the female sheep during anestrus. Gallegos-Sánchez J, et al. **Biol Reprod**, 1997 Jun;56(6):1544–9
Extracellular monoamines and their metabolites in the mediobasal hypothalamus--median eminence of anestrous and estrous ewes during CRF treatment. Tomaszewska D, et al. **Exp Clin Endocrinol Diabetes** 1997;105(3):175–81

METABOLISM

Time-course of thyroid hormone involvement in the development of anestrus in the ewe. Thrun LA, et al. **Biol Reprod** 1996 Oct;55(4):833–7

PHYSIOLOGY

Some effects of adding p-LH in defined amounts to purified p-FSH to modify FSH/LH ratios during the superovulatory treatment of anestrous ewes. D'Alessandro A, et al. **Anim Reprod Sci** 1997 May;47(1–2):91–8
The arena test and cortisol response of sheep as indirect selection criteria for the improvement of lamb survival. Kilgour RJ, et al. **Anim Reprod Sci** 1997 Mar; 46(1–2):97–108
Comparison of the effects of N-methyl-DL-aspartic acid on gonadotropin and prolactin secretion in anestrous mares and mares exhibiting estrous cycles during anestrus. Fitzgerald BP, et al. **Biol Reprod** 1997 Jul;57(1):36–42
Estradiol acts locally within the retrochiasmatic area to inhibit pulsatile luteinizing-hormone release in the female sheep during anestrus. Gallegos-Sánchez J, et al. **Biol Reprod** 1997 Jun;56(6):1544–9
Dopaminergic A14/A15 neurons are activated during estradiol negative feedback in anestrous, but not breeding season, ewes. Lehman MN, et al. **Endocrinology** 1996 Oct; 137(10):4443–50
Use of melengestrol acetate-based treatments to induce and synchronize estrus in seasonally anestrous ewes. Powell MR, et al. **J Anim Sci** 1996 Oct;74(10):2292–302
Prolactin administration to seasonally anestrous mares: reproductive, metabolic, and hair-shedding responses. Thompson DL Jr, et al. **J Anim Sci** 1997 Apr;75(4):1092–9
Food supplementation during lactation shortens anestrus and elevates gonadotropins in rats. Gournis E, et al. **J Nutr** 1997 May;127(5):785–90
Dopaminergic regulation of gonadotrophin secretion in seasonally anoestrous mares. Besognet B, et al. **J Reprod Fertil** 1996 Sep;108(1):55–61
Ovarian follicular dynamics in ewes during the transition from anoestrus to the breeding season. Ravindra JP, et al. **J Reprod Fertil** 1997 Jul;110(2):279–89
Follicular dynamics and ovarian steroid secretion in sheep during anoestrus. Souza CJ, et al. **J Reprod Fertil** 1996 Sep;108(1):101–6
[Endocrine function of the testicle in the Mexican crossbred ram at different times of the year and its opioidergic control during anoestrus] Fuentes V, et al. **Zentralbl Veterinarmed A** 1997 Jul;44(5):259–63 (Eng. Abstr.) **(Spa)**

ANETHOLE TRITHIONE

ANALYSIS

Determination of noscapine, hexylresorcinol and anethole in cough lozenges by liquid chromatography. Lucangioli S, et al. **Boll Chim Farm** 1996 Jun;135(6):387–90

PHARMACOLOGY

Anethole dithiolethione prevents oxidative damage in glutathione-depleted astrocytes. Drukarch B, et al. **Eur J Pharmacol** 1997 Jun 25;329(2–3):259–62
Chemopreventive efficacy of anethole trithione, N-acetyl-L-cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model. Lubet RA, et al. **Int J Cancer** 1997 Jul 3;72(1):95–101

THERAPEUTIC USE

A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs. Bagheri H, et al. **Eur J Clin Pharmacol** 1997;52(5):339–42

ANETHOLTRITHION see **ANETHOLE TRITHIONE**

ANEUPLOIDY

Aneuploid correction and confined placental mosaicism. Simoni G, et al. **Acta Genet Med Gemellol (Roma)** 1996; 45(1–2):153–61 (24 ref.)
Preoperative fine needle aspiration from human breast cancer is a valuable sampling material for progesterone receptor and cytometric DNA analysis. Fernö M, et al. **Acta Oncol** 1996;35 Suppl 8:19–25
Proliferation and DNA aneuploidy in mild dysplasia imply early steps of cervical carcinogenesis. Steinbeck RG. **Acta Oncol** 1997;36(1):3–12
Prenatal detection of chromosome aneuploidies in uncultured chorionic villus samples by FISH. Bryndorf T, et al. **Am J Hum Genet** 1996 Oct;59(4):918–26
Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Cook EH Jr, et al. **Am J Hum Genet** 1997 Apr;60(4):928–34
Meiotic segregation, recombination, and gamete aneuploidy assessed in a t(1;10)(p22.1;q22.3) reciprocal translocation carrier by three- and four-probe multicolor FISH in sperm. Van Hummelen P, et al. **Am J Hum Genet** 1997 Sep; 61(3):651–9
Paternal uniparental disomy for chromosome 14: a case report and review. Cotter PD, et al. **Am J Med Genet** 1997 May 2;70(1):74–9 (27 ref.)
Aneuploidy detection in human sperm nuclei using PRINS technique. Girardet A, et al. **Am J Med Genet** 1996 Aug 23;64(3):488–92
Incidence of aneuploid spermatozoa among infertile men studied by multicolor fluorescence in situ hybridization. Lähdetie J, et al. **Am J Med Genet** 1997 Jul 11;71(1):115–21
Mosaic tetrasomy 15q25-->qter in a newborn infant with multiple anomalies [published erratum appears in Am J Med Genet 1996 Aug 23;64(3):528] Van den Enden A, et al. **Am J Med Genet** 1996 Jun 14;63(3):482–5
First-trimester growth restriction and fetal aneuploidy: the effect of type of aneuploidy and gestational age. Bahado-Singh RO, et al. **Am J Obstet Gynecol** 1997 May; 176(5):976–80
Defining the role of fluorescence in situ hybridization on uncultured amniocytes for prenatal diagnosis of aneuploidies. D'Alton ME, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):769–74; discussion 774–6
Abnormal nuchal findings on screening ultrasonography: aneuploidy stratification on the basis of ultrasonographic anomaly and gestational age at detection. Landwehr JB Jr, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):995–9
Relevance of forward scatter and side scatter in aneuploidy detection by flow cytometry. Pétriz J, et al. **Anal Cell Pathol** 1996 May;10(3):243–52
Flow cytometric DNA analyses of 105 fresh hydatidiform moles, with correlations to prognosis. Sunde L, et al. **Anal Cell Pathol** 1996 Nov;12(2):99–114
Flow cytometry analysis of malignant tumors of the head and neck--differences between two methods in the recognition of aneuploidy. Wennerberg J, et al. **Anal Cell Pathol** 1996 Dec;12(3):125–36
Aneuploidy of human granulosa cells in follicular fluids from in vitro fertilization patients. Melsheimer P, et al. **Anal Quant Cytol Histol** 1997 Feb;19(1):75–9
Uniparental disomy (UPD). Genomic imprinting and a case for new genetics (prenatal and clinical implications: the "Likon" concept). Engel E. **Ann Genet** 1997;40(1):24–34 (74 ref.)
Non-tumorigenic SV40T immortalized human buccal epithelial cells show aneuploidy and genetic instability. Kalkarni Schmidt-Kastner PS, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2681–6
The inhibitory effect of selenium on induction of tetraploidy by dimethylarsinic acid in Chinese hamster cells. Ueda H, et al. **Anticancer Res** 1997 May–Jun;17(3C):1939–43
Aetiopathology and genetic basis of neonatal diabetes. Shield JP, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Jan; 76(1):F39–42
Polysomies of chromosomes 7 and 17 in head and neck squamous cell carcinomas. Choi G, et al. **Arch Otolaryngol Head Neck Surg** 1996 Oct;122(10):1062–7
First trimester aneuploidy screening using nuchal translucency, free beta human chorionic gonadotrophin and maternal age. Scott F, et al. **Aust N Z J Obstet Gynaecol** 1996 Nov;36(4):381–4
1,2-propanediol-induced premature centromere separation in mouse oocytes and aneuploidy in one-cell zygotes. Mailhes JB, et al. **Biol Reprod** 1997 Jul;57(1):92–8
Uncultured blood samples can be labeled by PRINS and ready for chromosome enumeration analysis 1 H after collection. Gosden J, et al. **Biotechniques** 1996 Jul; 21(1):88–91
Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. Winter JN, et al. **Blood** 1996 Nov 15;88(10):3919–25
Simultaneous effects of aneuploidy and oncogenic human papillomavirus on histological grade of cervical intraepithelial neoplasia. Monsonego J, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):723–7
Genomic heterogeneity in bladder cancer as detected by fluorescence in situ hybridization. Yokogi H, et al. **Br J Urol** 1996 Nov;78(5):699–703
S-phase fraction identifies high-risk subgroups among DNA-diploid breast cancers. Romero H, et al. **Breast Cancer Res Treat** 1996;38(3):265–75
S-phase fraction and tumor aneuploidy in colorectal carcinoma of young patients. Cascinu S, et al. **Cancer** 1996 Nov 1;78(9):1857–60
The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study. Cohn KH, et al. **Cancer** 1997 Jan 15;79(2):233–44
Flow cytometric DNA content analysis of 185 soft tissue neoplasms indicates that S-phase fraction is a prognostic factor for sarcomas. French Federation of Cancer Centers (FNCLCC) Sarcoma Group. Collin F, et al. **Cancer** 1997 Jun 15;79(12):2371–9
The value of DNA flow cytometry in predicting the development of lymph node metastasis and survival in patients with locally recurrent oral squamous cell carcinoma. Hemmer J, et al. **Cancer** 1997 Jun 15; 79(12):2309–13
Evidence of clonal divergence in colorectal carcinoma. Tollenaar RA, et al. **Cancer** 1997 Apr 1;79(7):1304–14
Tandem triplication and quadruplication of chromosome 21 in childhood acute lymphoblastic leukemia. Baialardo EM, et al. **Cancer Genet Cytogenet** 1996 Nov;92(1):43–5
Tetrasomy 8 detected by interphase cytogenetics in a child with acute lymphocytic leukemia. Shao J, et al. **Cancer Genet Cytogenet** 1996 Dec;92(2):135–40
In vitro proliferative advantage of bone marrow cells with tetrasomy 8 in Ewing sarcoma. Trakhtenbrot L, et al. **Cancer Genet Cytogenet** 1996 Sep;90(2):176–8
Cytogenetic study of neuroendocrine carcinoma of Merkel cells. Vázquez-Mazariego Y, et al. **Cancer Genet Cytogenet** 1996 Nov;92(1):79–81
Detection of p53 gene mutations in fine-needle aspiration biopsied breast cancer specimens: correlations with nuclear p53 accumulations and tumor DNA aneuploidy patterns. Sato T, et al. **Cancer Lett** 1997 May 1;115(1):47–55
Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Boige V, et al. **Cancer Res** 1997 May 15;57(10):1986–90
Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells). Styles JA, et al. **Carcinogenesis** 1997 Feb; 18(2):303–13
The effect of environmental aneuploidy-inducing agents on the microtubule architecture of mitotic meristematic root cells in Hordeum vulgare. Voutsinas G, et al. **Cell Biol Int** 1997 Jul;21(7):411–8
Cytological identification of an isotetrasomic in rice and its

application to centromere mapping. Cheng ZK, et al. **Cell Res** 1997 Jun;7(1):31–8

Detection of chromosomal aneuploidy by interphase fluorescence in situ hybridization in bronchoscopically gained cells from lung cancer patients. Schenk T, et al. **Chest** 1997 Jun;111(6):1691–6

Aneuploid epididymal sperm detected in chromosomally normal and Robertsonian translocation–bearing mice using a new three–chromosome FISH method. Lowe X, et al. **Chromosoma** 1996 Oct;105(4):204–10

Heterogeneity of nuclear DNA pattern and its relationship with cell cycle activity parameters in multinodular goitre [see comments] Francia G, et al. **Clin Endocrinol (Oxf)** 1997 Jun;46(6):649–54. Comment in: Clin Endocrinol (Oxf) 1997 Jun;46(6):655.

Hyperproliferation and aneuploidy in multinodular goitre and thyroid follicular neoplasia: causal or incidental relationship?[comment] Jasani B. **Clin Endocrinol (Oxf)** 1997 Jun;46(6):655. Comment on: Clin Endocrinol (Oxf) 1997 Jun;46(6):649–54.

Identification of the parental origin of polysomy in two 49,XXXXY cases. Celik A, et al. **Clin Genet** 1997 Jun; 51(6):426–9

Primed IN situ labelling (PRINS) as a rational procedure for identification of marker chromosomes using a panel of primers differentially tagging the human chromosomes. Hindkjaer J, et al. **Clin Genet** 1996 Dec;50(6):437–41

Clinical variability of tetrasomy 12p. Schaefer GB, et al. **Clin Genet** 1997 Feb;51(2):102–8

Moving towards a syndrome: a review of 20 cases and a new case of non–mosaic tetrasomy 9p with long–term survival. Tonk VS. **Clin Genet** 1997 Jul;52(1):23–9 (26 ref.)

Parental origin and mechanisms of formation of three cases of 12p tetrasomy. Turleau C, et al. **Clin Genet** 1996 Jul; 50(1):41–6

Progress in the genetic analysis of fetal cells circulating in maternal blood. Bianchi DW. **Curr Opin Obstet Gynecol** 1997 Apr;9(2):121–5 (33 ref.)

Increased aneuploid frequency in spermatozoa from a Hodgkin's disease patient after chemotherapy and radiotherapy. Monteil M, et al. **Cytogenet Cell Genet** 1997; 76(3–4):134–8

Simultaneous enumeration of chromosomes 13, 18, 21, X, and Y in interphase cells for preimplantation genetic diagnosis of aneuploidy. Munné S, et al. **Cytogenet Cell Genet** 1996;75(4):263–70

Complex chromosomal mechanisms lead to APRT loss of heterozygosity in heteroploid cells. Shao C, et al. **Cytogenet Cell Genet** 1996;75(4):216–21

An analysis of human sperm chromosome aneuploidy. Templado C, et al. **Cytogenet Cell Genet** 1996;74(3):194–200

Objective aneuploidy detection for fetal and neonatal screening using comparative genomic hybridization (CGH). Yu LC, et al. **Cytometry** 1997 Jul 1;28(3):191–7

Detection of aneuploidy in mesothelioma cell lines by fluorescence in situ hybridization (FISH) [letter] Abati A, et al. **Diagn Cytopathol** 1997 Apr;16(4):375–7

Use of fluorescent in situ hybridization to detect aneuploidy in cervical dysplasia. Kurtycz D, et al. **Diagn Cytopathol** 1996 Jul;15(1):46–51

Recent Advances in Prenatal Diagnosis for Aneuploidy. Proceedings of a meeting. Amsterdam, The Netherlands, May 1–3, 1996. **Early Hum Dev** 1996 Dec 30;47 Suppl:S1–109

Early prenatal diagnosis of fetal aneuploidy using coelomic fluid. Atkinson G, et al. **Early Hum Dev** 1996 Dec 30;47 Suppl:S103–4

Second trimester ultrasound markers for fetal aneuploidy. Bilardo C. **Early Hum Dev** 1996 Dec 30;47 Suppl:S31–3 (4 ref.)

Isolation of fetal trophoblasts and nucleated erythrocytes from the peripheral blood of pregnant women for prenatal diagnosis of fetal aneuploides. Durrant LG, et al. **Early Hum Dev** 1996 Dec 30;47 Suppl:S79–83

Detection of aneuploidy in human spermatozoa of normal semen donors by fluorescence in situ hybridization. Lähdetie J, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:629–32

Interphase cytogenetics of workers exposed to benzene. Zhang L, et al. **Environ Health Perspect** 1996 Dec;104 Suppl 6:1325–9

Aneuploidy in germ cells: etiologies and risk factors. Bishop JB, et al. **Environ Mol Mutagen** 1996;28(3):159–66

Parental age–related aneuploidy in human germ cells and offspring: a story of past and present. Eichenlaub–Ritter U. **Environ Mol Mutagen** 1996;28(3):211–36 (200 ref.)

Meiotic recombination and germ cell aneuploidy. Ferguson LR, et al. **Environ Mol Mutagen** 1996;28(3):192–210 (178 ref.)

The aneuploidy issue in germ cell mutagenesis. Generoso WM. **Environ Mol Mutagen** 1996;28(3):265–6

Human aneuploidy: incidence, origin, and etiology. Hassold T, et al. **Environ Mol Mutagen** 1996;28(3):167–75 (39 ref.)

Effects of the DNA topoisomerase II inhibitor merbarone in male mouse meiotic divisions in vivo: cell cycle arrest and induction of aneuploidy. Kallio M, et al. **Environ Mol Mutagen** 1997;29(1):16–27

Thiabendazole–induced cytogenetic abnormalities in mouse oocytes. Mailhes JB, et al. **Environ Mol Mutagen** 1997; 29(4):367–71

Research on the mechanisms of action of aneugenic chemicals and regulatory approaches for their control in the European Communities. Parry JM. **Environ Mol Mutagen** 1996;28(3):248–53

Aneuploidy in germ cells: disruption of chromosome mover components. Preston RJ. **Environ Mol Mutagen** 1996; 28(3):176–81

Detection of hyperdiploidy and breakage affecting the 1cen–1q12 region of cultured interphase human lymphocytes treated with various genotoxic agents. Rupa DS, et al. **Environ Mol Mutagen** 1997;29(2):161–7

Chromosomal differences in susceptibility to meiotic aneuploidy. Warburton D, et al. **Environ Mol Mutagen** 1996;28(3):237–47 (52 ref.)

Mechanisms and targets involved in maternal and paternal age effects on numerical aneuploidy. Wyrobek AJ, et al. **Environ Mol Mutagen** 1996;28(3):254–64

Viable aneuploidy in the horse [editorial; comment] Chandley AC. **Equine Vet J** 1997 Jan;29(1):3–4. Comment on: Equine Vet J 1997 Jan;29(1):60–2.

Prognostic significance of DNA ploidy in mucoepidermoid carcinoma. Gemryd P, et al. **Eur Arch Otorhinolaryngol** 1997;254(4):180–5

Maternal origin of inv dup(15) chromosomes in infantile autism. Martinsson T, et al. **Eur Child Adolesc Psychiatry** 1996 Dec;5(4):185–92

Premature separation of centromere and aneuploidy: an indicator of high risk in unaffected individuals from familial breast cancer families? Rao NM, et al. **Eur J Cancer Prev** 1996 Oct;5(5):343–50

Tetrasomy 18p de novo: parental origin and different mechanisms of formation [published erratum appears in Eur J Hum Genet 1996;4(5):291] Bugge M, et al. **Eur J Hum Genet** 1996;4(3):160–7

Tetrasomy 18p caused by paternal meiotic nondisjunction. Eggermann T, et al. **Eur J Hum Genet** 1997 May–Jun; 5(3):175–7

Flow cytometric DNA analysis of gastric cancer that is invading the muscularis propria. Mizunuma H, et al. **Eur J Surg** 1996 Nov;162(11):889–94

A longitudinal study of human age–related chromosomal analysis in skin fibroblasts. Mukherjee AB, et al. **Exp Cell Res** 1997 Aug 25;235(1):161–9

Age–related decline in fertility: a link to degenerative oocytes? Lim AS, et al. **Fertil Steril** 1997 Aug;68(2):265–71

Estimation of aneuploidy levels for 8, 15, 18, X and Y chromosomes in 97 human sperm samples using fluorescence in situ hybridization. Morel F, et al. **Fertil Steril** 1997 Jun;67(6):1134–9

Birth of healthy children after preimplantation diagnosis of common aneuploidies by polar body fluorescent in situ hybridization analysis. Preimplantation Genetics Group. Verlinsky Y, et al. **Fertil Steril** 1996 Jul;66(1):126–9

Abnormal biochemical serum screening versus 2nd–trimester ultrasound–detected minor anomalies as predictors of aneuploidy in low–risk patients. Drugan A, et al. **Fetal Diagn Ther** 1996 Sep–Oct;11(5):301–5

Raised level of amniotic endothelin in pregnancies with fetal aneuploidy. Vesce F, et al. **Fetal Diagn Ther** 1996 Mar–Apr; 11(2):94–8

Argyrophilic nucleolar organizer regions, bromodeoxyuridine labelling index and DNA ploidy in squamous cell carcinoma of the uterine cervix. Gasińska A, et al. **Folia Histochem Cytobiol** 1996;34(2):95–101

DNA–aneuploidy as marker for neoplasia in G1–urothelial carcinomas. Planz B, et al. **Gen Diagn Pathol** 1996 Oct; 142(2):69–73

Mapping of chromosomal gains and losses in primitive neuroectodermal tumors by comparative genomic hybridization. Schütz BR, et al. **Genes Chromosomes Cancer** 1996 Jul;16(3):196–203

Aneuploid marker assignment in hexaploid oat with the C genome as a reference for determining remnant homoeology. Kianian SF, et al. **Genome** 1997 Jun; 40(3):386–96

Detection of numerical aberrations in hematologic neoplasias by fluorescence in situ hybridization. Cuneo A, et al. **Haematologica** 1997 Jan–Feb;82(1):85–90 (61 ref.)

Comparison of chromosome 1 aneusomy detected by interphase cytogenetics and DNA ploidy in carcinoma of the breast. Harrison MM, et al. **Histopathology** 1997 Mar; 30(3):221–6

Detection of chromosomal aneuploidy in endometriosis by multi–color fluorescence in situ hybridization (FISH). Shin JC, et al. **Hum Genet** 1997 Sep;100(3–4):401–6

Activation status of the X chromosome in human micronucleated lymphocytes. Tucker JD, et al. **Hum Genet** 1996 Apr;97(4):471–5

Progress in the autosomal segmental aneusomy syndromes (SASs): single or multi–locus disorders? Budarf ML, et al. **Hum Mol Genet** 1997;6(10):1657–65 (121 ref.)

Spindle cell carcinoma of the larynx: review of 26 cases including DNA content and immunohistochemistry. Lewis JE, et al. **Hum Pathol** 1997 Jun;28(6):664–73

Chromosomal and DNA ploidy characterization of salivary gland neoplasms by combined FISH and flow cytometry. El–Naggar AK, et al. **Hum Pathol** 1997 Aug;28(8):881–6

Preimplantation diagnosis in older patients--but of course! [see comments] Munné S, et al. **Hum Reprod** 1997 Mar; 12(3):413–4 (11 ref.). Comment in: Hum Reprod 1997 Apr;12(4):870–1. Comment in: Hum Reprod 1997 Apr;12(4):871.

Preimplantation diagnosis of common aneuploidies in infertile couples of advanced maternal age. Verlinsky Y, et al. **Hum Reprod** 1996 Oct;11(10):2076–7

Transfection of human mutated K–ras in mouse NIH–3T3 cells is associated with increased cloning efficiency and DNA aneuploidization. Nigro S, et al. **Int J Cancer** 1996 Sep 17;67(6):871–5

17beta–estradiol, diethylstilbestrol, tamoxifen, toremifene and ICI 164,384 induce morphological transformation and aneuploidy in cultured Syrian hamster embryo cells. Tsutsui T, et al. **Int J Cancer** 1997 Jan 17;70(2):188–93

DNA aneuploidy in benign tumors and normal tissues of the female genital tract. Lai CH, et al. **Int J Gynecol Pathol** 1996 Jan;15(1):63–8

Hyperdiploid myeloma cell as an indicator of poor prognosis and drug refractoriness. Hata H, et al. **Int J Hematol** 1997 Aug;66(2):219–26

Detection of aneuploidy in human oocytes and corresponding first polar bodies by fluorescent in situ hybridization. Dyban A, et al. **J Assist Reprod Genet** 1996 Jan;13(1):73–8

Rapid chromosome detection in human gametes, zygotes, and preimplantation embryos using the PRINS technique. Pellestor F, et al. **J Assist Reprod Genet** 1996 Sep; 13(8):675–80

Mosaicism and aneuploidy in human preembryos [editorial; comment] Strom CM. **J Assist Reprod Genet** 1996 Aug; 13(7):592–3. Comment on: J Assist Reprod Genet 1996 Aug;13(7):586–91.

Comparative genomic hybridization (CGH) discloses chromosomal and subchromosomal copy number changes in Merkel cell carcinomas. Härle M, et al. **J Cutan Pathol** 1996 Oct;23(5):391–7

Identification of aneuploidy in recurrent clear cell hidradenoma by DNA image cytometry (ICM–DNA). Kiehl P, et al. **J Cutan Pathol** 1997 May;24(5):314–21

Double aneuploidy with Down's–Klinefelter's syndrome. Hou JW, et al. **J Formos Med Assoc** 1996 Apr;95(4):350–2

Aneusomy of chromosome 18 is associated with the development of colorectal carcinoma. Nanashima A, et al. **J Gastroenterol** 1997 Aug;32(4):487–91

Prenatal detection of fetal aneuploidies using transcervical cell samples. Sherlock J, et al. **J Med Genet** 1997 Apr; 34(4):302–5

Early asymmetric IUGR and aneuploidy. Anandakumar C, et al. **J Obstet Gynaecol Res** 1996 Aug;22(4):365–70

Chromosomal aneuploidy associated with spontaneous abortions and neonatal losses in cattle. Schmutz SM, et al. **J Vet Diagn Invest** 1996 Jan;8(1):91–5

Detection of aneuploidy in human spermatozoa using fluorescence in situ hybridization (FISH). Hu H, et al. **Jpn J Hum Genet** 1996 Dec;41(4):381–9

Retrieval of aneuploidy by FISH–technique in a case with 46,XX/47,XXX/47,XX,+8. Verma RS, et al. **Jpn J Hum Genet** 1996 Mar;41(1):215–9

Routine fetal echocardiography and detection of congenital heart disease [letter; comment] Kingdom J, et al. **Lancet** 1996 Dec 21–28;348(9043):1732; discussion 1732–3 . Comment on: Lancet 1996 Sep 28;348(9031):854–7.

Tetrasomy 8 and t(1;11)(p32;q24) in acute myelo–monocytic leukemia with extensive leukemic cutaneous involvement. Ferrara F, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):513–5

Detection of newborn aneuploidy by interphase fluorescence in situ hybridization. Jalal SM, et al. **Mayo Clin Proc** 1997 Aug;72(8):705–10

Age–related aneuploidy analysis of human blood cells in vivo by fluorescence in situ hybridization (FISH). Mukherjee AB, et al. **Mech Ageing Dev** 1996 Sep 18;90(2):145–56

Analysis of sperm aneuploidy by PRINS. Pellestor F, et al. **Methods Mol Biol** 1997;71:23–9 (12 ref.)

WO–2, a stable aneuploid derivative of Candida albicans strain WO–1, can switch from white to opaque and form hyphae. Magee BB, et al. **Microbiology** 1997 Feb;143 (Pt 2):289–95

Correspondence re: Fleischhacker M, Lee S, Spira S, Takeuchi S, Koeffler HP: DNA aneuploidy in morphologically normal colons from patients with colon cancer. Mod Pathol 8:360, 1995 [letter; comment] Bauer KD, et al. **Mod Pathol** 1996 Apr;9(4):457–8. Comment on: Mod Pathol 1995 May;8(4):360–5.

Comparison of gonosomal aneuploidy in spermatozoa of normal fertile men and those with severe male factor detected by in–situ hybridization. Bernardini L, et al. **Mol Hum Reprod** 1997 May;3(5):431–8

Detection of chromosomes and estimation of aneuploidy in human spermatozoa using fluorescence in–situ hybridization. Downie SE, et al. **Mol Hum Reprod** 1997 Jul;3(7):585–98 (108 ref.)

The oxidizing agent tertiary butyl hydroperoxide induces disturbances in spindle organization, c–meiosis, and aneuploidy in mouse oocytes. Tarin JJ, et al. **Mol Hum Reprod** 1996 Dec;2(12):895–901

Rapid chromosomal analysis of germ–line cells by FISH: an investigation of an infertile male with large–headed spermatozoa. Yurov YB, et al. **Mol Hum Reprod** 1996 Sep; 2(9):665–8

Indication for thresholds of chromosome non–disjunction versus chromosome lagging induced by spindle inhibitors in vitro in human lymphocytes. Elhajouji A, et al. **Mutagenesis** 1997 May;12(3):133–40

Induction and persistence of cytogenetic damage in mouse splenocytes following whole–body X–irradiation analysed by fluorescence in situ hybridization. III. Chromosome malsegregation/aneuploidy. Hande MP, et al. **Mutagenesis** 1997 May;12(3):125–31

ANEUPLOIDY

Spontaneous rates of sex chromosomal aneuploidies in sperm and offspring of mice: a validation of the detection of aneuploid sperm by fluorescence in situ hybridization. Adler ID, et al. **Mutat Res** 1996 Dec;372(2):259–68

Chemical induction of mitotic checkpoint override in mammalian cells results in aneuploidy following a transient tetraploid state. Andreassen PR, et al. **Mutat Res** 1996 Dec; 372(2):181–94

Evidence for a parent–of–origin effect on sperm aneuploidy in mice carrying Robertsonian translocations as analyzed by fluorescence in situ hybridization. Baulch JE, et al. **Mutat Res** 1996 Dec;372(2):269–78

A study of the aneugenic activity of trichlorfon detected by centromere–specific probes in human lymphoblastoid cell lines. Doherty AT, et al. **Mutat Res** 1996 Dec; 372(2):221–31

Mechanisms of spontaneous and chemically–induced aneuploidy in mammalian oogenesis: basis of sex–specific differences in response to aneugens and the necessity for further tests. Eichenlaub–Ritter U, et al. **Mutat Res** 1996 Dec;372(2):279–94

A new possible parameter for the detection of aneuploidy inducing substances: the analysis of qualitative and quantitative abnormalities of the spindle apparatus. Kochendörfer U, et al. **Mutat Res** 1996 Dec 12; 361(2–3):55–66

Fluorescence in situ hybridisation with chromosome–specific centromeric probes: a sensitive method to detect aneuploidy. Marshall RR, et al. **Mutat Res** 1996 Dec; 372(2):233–45

Disruption of microtubule assembly and spindle formation as a mechanism for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide. Ramírez P, et al. **Mutat Res** 1997 Jun;386(3):291–8

PRINS localization of centromeres and telomeres in micronuclei indicates that in mouse splenocytes chromatid non–disjunction is a major mechanism of aneuploidy. Russo A, et al. **Mutat Res** 1996 Dec;372(2):173–80

A critical evaluation of centromeric labeling to distinguish micronuclei induced by chromosomal loss and breakage in vitro. Schuler M, et al. **Mutat Res** 1997 Aug 1; 392(1–2):81–95

Benzene–, catechol–, hydroquinone– and phenol–induced cell transformation, gene mutations, chromosome aberrations, aneuploidy, sister chromatid exchanges and unscheduled DNA synthesis in Syrian hamster embryo cells. Tsutsui T, et al. **Mutat Res** 1997 Jan 3;373(1):113–23

Utility of a test for chromosomal malsegregation in Saccharomyces cerevisiae strain D61.M for the detection of antianeugens: test of the model combination of chlorophyllin and nocodazole. Verma A, et al. **Mutat Res** 1996 Oct 28;358(1):73–80

Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Robbins WA, et al. **Nat Genet** 1997 May;16(1):74–8

Genetic instability in colorectal cancers. Lengauer C, et al. **Nature** 1997 Apr 10;386(6625):623–7

Aneuploidy in twin gestations: when is maternal age advanced? Meyers C, et al. **Obstet Gynecol** 1997 Feb; 89(2):248–51

Fluorescence in situ hybridization for the detection of aneuploidy from archived fetal cells. Wilkins–Haug LE, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):684–7

Noninvasive first–trimester screening for fetal aneuploidy. Sherer DM, et al. **Obstet Gynecol Surv** 1997 Feb; 52(2):123–9 (89 ref.)

Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Chen J, et al. **Oncogene** 1996 Oct 3; 13(7):1395–403

Aneuploidy in sclerosing adenosis may predict an increased risk of malignancy. A study using the AgNOR silver stain. Mourad WA. **Pathology** 1997 Aug;29(3):255–9

Structural instability of a transgene locus in tobacco is associated with aneuploidy [published erratum appears in Plant J 1997 Jan;11(1):167] Papp I, et al. **Plant J** 1996 Sep; 10(3):469–78

Prenatal detection of chromosome aneuploidies by fluorescence in situ hybridization: experience with 2000 uncultured amniotic fluid samples in a prospective preclinical trial. Bryndorf T, et al. **Prenat Diagn** 1997 Apr; 17(4):333–41

Urinary beta–core–hCG screening in the first trimester [letter; comment] Cuckle HS, et al. **Prenat Diagn** 1996 Nov; 16(11):1057–9. Comment on: Prenat Diagn 1994 Oct;14(10):953–8. Comment on: Prenat Diagn 1995 Aug;15(8):739–44. Comment on: Prenat Diagn 1995 Aug;15(8):745–51.

Aneuploidy risk with isolated choroid plexus cysts [letter] Cuckle HS, et al. **Prenat Diagn** 1996 Oct;16(10):967–8

Serum screening in complete triploidy 69,XXX [letter] Dormeier A, et al. **Prenat Diagn** 1996 Jun;16(6):578

Fetal biometric ratios by transvaginal sonography as a marker for aneuploidies in early pregnancy. Guariglia L, et al. **Prenat Diagn** 1997 May;17(5):415–22

Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice. Kornman LH, et al. **Prenat Diagn** 1996 Sep;16(9):797–805

Urinary beta–core hCG: screening for aneuploidies in early pregnancy (11–14 weeks' gestation). Macintosh MC, et al. **Prenat Diagn** 1997 May;17(5):401–5

Confirmation of fetal aneuploidy with primed in situ hybridization on amniotic fluid during selective fetal reduction [letter] Phillips OP, et al. **Prenat Diagn** 1997 Jun; 17(6):586–8

First–trimester growth patterns of aneuploid fetuses. Schemmer G, et al. **Prenat Diagn** 1997 Feb;17(2):155–9

Fetal choroid plexus cysts—is a genetic evaluation indicated? Sharony R. **Prenat Diagn** 1997 Jun;17(6):519–24 (43 ref.)

The sonographic finding of persistent umbilical cord cystic masses is associated with lethal aneuploidy and/or congenital anomalies. Smith GN, et al. **Prenat Diagn** 1996 Dec;16(12):1141–7 (17 ref.)

Prenatal diagnosis of a tetraploid fetus. Teyssier M, et al. **Prenat Diagn** 1997 May;17(5):474–8 (21 ref.)

Chromosomal localization of the proteasome Z subunit gene reveals an ancient chromosomal duplication involving the major histocompatibility complex. Kasahara M, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9096–101

Studies on locus content mapping. Teague JW, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11814–8

The significance of DNA–ploidy and S–phase fraction in node–positive (stage D1) prostate cancer treated with androgen ablation. Pollack A, et al. **Prostate** 1997 Apr 1; 31(1):21–8

Preferential sensitivity of acrocentric chromosomes to the aneugenic effect of colchicine. Caria H, et al. **Teratog Carcinog Mutagen** 1996;16(5):243–52

Susceptibility to vinblastine–induced aneuploidy and preferential chromosome segregation during meiosis I in Robertsonian heterozygous mice. Pacchierotti F, et al. **Teratog Carcinog Mutagen** 1995;15(5):217–30

[Prenatal serum screening of aneuploidy and of neural tube defects in the second trimester of pregnancy among the population of Luxembourg. Evaluation of risk by the triple test (AFP+THCG+UE3)] Thix J. **Bull Soc Sci Med Grand Duche Luxemb** 1997;134(1):25–9 (Eng. Abstr.) **(Fre)**

[Prenatal chromosome analysis using the FISH technique allows fetal aneuploidy detection within a few hours] Steinborn A, et al. **Z Geburtshilfe Neonatol** 1996 Sep–Oct; 200(5):186–90 (Eng. Abstr.) **(Ger)**

[Significance of hyper–echogenic yolk sac in first–trimester screening for chromosome aneuploidy] Szabó J, et al. **Orv Hetil** 1996 Oct 20;137(42):2313–5 (Eng. Abstr.) **(Hun)**

[Flow cytometry in the determination of DNA aneuploidy in patients with acute leukemias] Shmarov DA, et al. **Ter Arkh** 1996;68(7):11–4 (Eng. Abstr.) **(Rus)**

[Flow–cytometric study of aneuploidy and proliferative activity of colonic cancer cells] Bychkova NV, et al. **Vopr Onkol** 1996;42(5):40–4 (Eng. Abstr.) **(Rus)**

[Aneuploidy and proliferative activity in breast cancer (flow–cytometric investigation)] Bychkova NV, et al. **Vopr Onkol** 1997;43(2):171–5 (Eng. Abstr.) **(Rus)**

[Detection of aneuploidies using in situ hybridization in cells of the oral mucosa] Frías S, et al. **Rev Invest Clin** 1996 Sep–Oct;48(5):355–60 (Eng. Abstr.) **(Spa)**

ANEURIN see **THIAMINE**

ANEURYSM

Aneurysms of the portal vein and superior mesenteric vein. Fulcher A, et al. **Abdom Imaging** 1997 May–Jun; 22(3):287–92

Pulmonary artery aneurysm [letter; comment] Mastroroberto P, et al. **Ann Thorac Surg** 1997 Aug;64(2):585–6. Comment on: Ann Thorac Surg 1996 Jul;62(1):272–4.

Aneurysm of pulmonary trunk [letter; comment] Shimokawa S, et al. **Ann Thorac Surg** 1997 Aug;64(2):586–7. Comment on: Ann Thorac Surg 1996 Jul;62(1):272–4.

Common splanchnic artery aneurysms: splenic, hepatic, and celiac. Shanley CJ, et al. **Ann Vasc Surg** 1996 May; 10(3):315–22 (124 ref.)

Uncommon splanchnic artery aneurysms: pancreaticoduodenal, gastroduodenal, superior mesenteric, inferior mesenteric, and colic. Shanley CJ, et al. **Ann Vasc Surg** 1996 Sep;10(5):506–15 (147 ref.)

Atherosclerotic popliteal aneurysm. Dawson I, et al. **Br J Surg** 1997 Mar;84(3):293–9 (82 ref.)

Arterial wall mechanical characteristics after treatment in collagenase: an in vitro aneurysm model. Dadgar L, et al. **Clin Invest Med** 1997 Feb;20(1):25–34

Aneurysm of aberrant right subclavian [correction of subdavian] artery arising from diverticulum of Kommerell. Report of a case with tracheal compression. Aoyagi S, et al. **Eur J Cardiothorac Surg** 1997 Jul;12(1):138–40

Extracranial carotid artery aneurysms. Neelakandhan KS, et al. **Int Angiol** 1996 Dec;15(4):316–20

An aneurysm of the right gastroepiploic artery. Funahashi S, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):385–8 (11 ref.)

Extracranial carotid artery aneurysms. Pulli R, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):339–46

Visceral artery aneurysms secondary to collateral circulation. Porcellini M, et al. **Minerva Cardioangiol** 1996 Sep; 44(9):443–5

True aneurysm of non–functional renal allograft artery. Balaji V, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2344–6

The diagnosis and management of splanchnic artery aneurysms. Røkke O, et al. **Scand J Gastroenterol** 1996 Aug; 31(8):737–43 (89 ref.)

Aneurysms of the great vessels and their branches. Bower TC. **Semin Vasc Surg** 1996 Jun;9(2):134–46

Diseases of the brachiocephalic arteries and their management. Overview. Bower TC, et al. **Semin Vasc Surg** 1996 Jun;9(2):71–6

Splenic artery aneurysms. Hallett JW Jr. **Semin Vasc Surg** 1995 Dec;8(4):321–6

Visceral artery aneurysms. Messina LM, et al. **Surg Clin North Am** 1997 Apr;77(2):425–42 (40 ref.)

Observations on the development of mural thrombi in chronic experimental aneurysms in sheep. Stehbens WE. **Thromb Haemost** 1997 Aug;78(2):952–7

[Arteriomegaly in the aorto–iliac–femoral area with or without associated aneurysm] D'Andrea V, et al. **Ann Ital Chir** 1996 May–Jun;67(3):411–5 (Eng. Abstr.) **(Ita)**

[Bilateral aneurysm of the common iliac vein: a case report] Alatri A, et al. **Ann Ital Med Int** 1997 Apr–Jun;12(2):92–3 (Eng. Abstr.) **(Ita)**

[Bilateral aneurysm of the popliteal vein. A case report and review of the literature] Corsi M, et al. **Minerva Cardioangiol** 1996 Nov;44(11):591–3 (Eng. Abstr.) **(Ita)**

[Arteriosclerotic aneurysms of the subclavian artery] Porcellini M, et al. **Minerva Cardioangiol** 1996 Sep; 44(9):433–6 (Eng. Abstr.) **(Ita)**

[Subclavian artery aneurysm] Ito M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):476–8 (14 ref.) **(Jpn)**

[Renal artery aneurysm] Kato T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):338–40 (9 ref.) **(Jpn)**

[Multiple aneurysms] Yamaguchi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):527–30 (18 ref.) **(Jpn)**

[Isolated peripheral arterial aneurysm] Yasuda I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):535–9 (20 ref.) **(Jpn)**

[Aneurysms of the carotid arteries] Lotina S, et al. **Srp Arh Celok Lek** 1997 May–Jun;125(5–6):141–53 (121 ref.) (Eng. Abstr.) **(Scc)**

[Aneurysms of the popliteal artery] Davidović L, et al. **Acta Chir Iugosl** 1995;42(1):41–7 (Eng. Abstr.) **(Scr)**

[Extrahepatic aneurysm of the portal vein. Apropos of 2 cases] Querol Borrás V, et al. **Gastroenterol Hepatol** 1996 Mar;19(3):153–5 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Ruptured aneurysm of the profunda femoral artery associated with polyaneurysmal disease. Defraigne JO, et al. **Acta Chir Belg** 1997 Apr;97(2):93–6 (32 ref.)

Primary saphenous vein aneurysm presenting as a femoral hernia: radiographic findings [letter] Gilkeson RC, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1621–2

Rupture of splenic artery aneurysm in a pregnant patient with portal hypertension. Hillemanns P, et al. **Am J Obstet Gynecol** 1996 May;174(5):1665–6

A case of Behçet's disease with an abdominal aortic aneurysm and two aneurysms in the common carotid artery. A case report. Tuzuner A, et al. **Angiology** 1996 Dec; 47(12):1173–80

A rare complication of splenic artery aneurysm: mesenteric steal syndrome [letter; comment] Long SI. **Arch Surg** 1996 Oct;131(10):1116. Comment on: Arch Surg 1995 Jun;130(6):669–72.

Upper extremity ischemia from subclavian artery aneurysm caused by bony abnormalities of the thoracic outlet. Nehler MR, et al. **Arch Surg** 1997 May;132(5):527–32

Rupture as the exceptional complication of popliteal aneurysm. Gawenda M, et al. **Eur J Surg** 1997 Jan; 163(1):69–71 (17 ref.)

Infrainguinal saphenous vein graft aneurysm and aortic aneurysm. Casha A, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):380–2

Fatal haemoptysis due to pulmonary artery aneurysm in Behçet's disease. Gebitekin C, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):233–6

A case of splenic artery aneurysm with Cushing's syndrome. Yoshitomi Y, et al. **Int J Cardiol** 1996 Jun;54(3):263–5 (5 ref.)

Digital ischemia associated with a thrombosed aneurysm of the dorsal interosseous artery. A case report. O'Farrell DA, et al. **J Bone Joint Surg Am** 1997 Mar;79(3):441–3

Coarctation of the abdominal aorta with left renal artery and splenic artery aneurysms. Dogan R, et al. **J Cardiovasc Surg (Torino)** 1996 Oct;37(5):457–61

Persistent sciatic artery aneurysm with ruptured internal iliac artery aneurysm. Kuwabara M, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):169–72

Porto–hepatic venous shunt via portal vein aneurysm with splenomegaly. Hanatate F, et al. **J Gastroenterol** 1995 Dec; 30(6):786–9 (21 ref.)

Brachial plexus compression by venous aneurysms. Case illustration. Gabriel EM, et al. **J Neurosurg** 1997 Feb; 86(2):311

Carotid aneurysm: a rare cause of cervical swelling. Lyons AJ, et al. **J Oral Maxillofac Surg** 1997 Jan;55(1):77–9

Massive upper gastrointestinal haemorrhage due to direct visceral erosion of splenic artery aneurysm. Shahani RB, et al. **J Postgrad Med** 1994 Oct–Dec;40(4):220–2

Ischemia of the throwing hand in major league baseball pitchers: embolic occlusion from aneurysms of axillary

artery branches. Kee ST, et al. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6):979-82

Thorotrast-associated oropharyngeal hemorrhage: treatment by means of carotid occlusion with use of flow arrest and fibered coils. Kesava PP, et al. **J Vasc Interv Radiol** 1996 Sep-Oct;7(5):709-12

Visceral artery aneurysms in Von Recklinghausen's neurofibromatosis. Hassen-Khodja R, et al. **J Vasc Surg** 1997 Mar;25(3):572-5

Periarticular aneurysm formation in haemophilia. Saris DB, et al. **Lancet** 1997 Mar 15;349(9054):766-8

Renal artery aneurysm and fibromuscular dysplasia. Krumme B, et al. **Nephrol Dial Transplant** 1997 May;12(5):1067-9

Subclavian artery aneurysm associated with absence of the ipsilateral internal carotid artery. Mikami C, et al. **Neurol Res** 1996 Apr;18(2):140-4

Coats' disease and central nervous system venous malformation. Robitaille JM, et al. **Ophthalmic Genet** 1996 Dec;17(4):215-8

Popliteal aneurysm presenting as chronic exertional compartment syndrome. Knight JL, et al. **Orthopedics** 1997 Feb;20(2):166-9

Inferior suprarenal artery aneurysm in polyarteritis nodosa. Oğuzkurt L, et al. **Pediatr Radiol** 1997 Mar;27(3):234-5

Idiopathic polypoidal choroidal vasculopathy associated with retinal arterial macroaneurysm and hypertensive retinopathy. Ross RD, et al. **Retina** 1996;16(2):105-11

Aneurysm of the innominate artery with aberrant origin of the left carotid artery. Case report. Villegas-Cabello O, et al. **Tex Heart Inst J** 1996;23(4):298-300

A major renal artery aneurysm as the cause of a hydronephrosis with renovascular hypertension. Bernhardt J, et al. **Urol Int** 1996;57(4):237-9

Carotid artery aneurysm as a rare cause for aspiration pneumonia. A case report. Decrinis M, et al. **Vasa** 1996; 25(4):362-7

[Aneurysm of an anomalous common celiac-mesenteric trunk] Simána J, et al. **Rozhl Chir** 1997 Jun;76(6):284-6 (Eng. Abstr.) **(Cze)**

[Arterial complications of Behcet's disease. Report of 13 cases] Bensaid Y, et al. **J Mal Vasc** 1997;22(1):24-8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Embolic infarction in the anterior cerebral artery in a patient with aneurysm of the interatrial septum (letter)] Burbaud P, et al. **Rev Med Interne** 1997;18(3):259-61 **(Fre)**

[Acute compartment syndrome of the tibia--complication of popliteal artery aneurysm] Dellanna M, et al. **Zentralbl Chir** 1997;122(3):193-6 (Eng. Abstr.) **(Ger)**

[Renal cell carcinoma associated with renal artery aneurysm] Yazawa K, et al. **Hinyokika Kiyo** 1997 May;43(5):343-5 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Isolated iliac artery aneurysms associated with disseminated intravascular coagulation (DIC)] Ichihara H, et al. **Nippon Ronen Igakkai Zasshi** 1995 Dec;32(12):822-4 (Eng. Abstr.) **(Jpn)**

[A case of acquired intrahepatic portosystemic shunt via portal vein aneurysm] Kounoura K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb;93(2):126-30 **(Jpn)**

[Clinicoimmunological characteristics of aneurysmic lesion in nonspecific aortic arteritis] Sugraliev AB, et al. **Klin Med (Mosk)** 1996;74(8):35-7 (Eng. Abstr.) **(Rus)**

[Aneurysm of the left hepatic artery--a rare cause of hemobilia after laparoscopic cholecystectomy: case report] Mráz P Jr, et al. **Rozhl Chir** 1996 Oct;75(10):496-8 (Eng. Abstr.) **(Slo)**

CONGENITAL

Congenital mesenteric aneurysm and mesenteric arterioportal fistula. Paşaoğlu E, et al. **Abdom Imaging** 1996 Sep-Oct; 21(5):451-2 (10 ref.)

Clinicopathologic findings in congenital aneurysms of the great vessels. Adès LC, et al. **Am J Med Genet** 1996 Dec 18;66(3):289-99 (37 ref.)

Superior mesenteric venous aneurysm. Lerch R, et al. **Ann Vasc Surg** 1996 Nov;10(6):582-8

Unruptured aneurysm of the sinus of Valsalva. Malcolm I. **Can J Cardiol** 1996 Sep;12(9):783-5

Aneurysmal dilatation of pulmonary artery and pulmonary valve hypoplasia: a pointer to agenesis of ductus arteriosus. Indrani S, et al. **Indian Heart J** 1997 Jan-Feb;49(1):90-2

Congenital internal jugular venous aneurysm: diagnosis and treatment. Bosshardt TL, et al. **Mil Med** 1996 Apr; 161(4):246-7 (10 ref.)

[What is your diagnosis? congenital, partially calcified saccular aneurysm of the superior vena cava and bilateral brachiocephalic veins] Hauser M, et al. **Schweiz Rundsch Med Prax** 1997 Feb 4;86(6):177-81 **(Ger)**

DIAGNOSIS

Venous aneurysm of the distal forearm: MR imaging findings. Morrison J, et al. **AJR Am J Roentgenol** 1996 Dec; 167(6):1552-4

Asymptomatic large coronary artery saphenous vein bypass graft aneurysm: a case report and review of the literature. Wight JN Jr, et al. **Am Heart J** 1997 Apr;133(4):454-60 (37 ref.)

Saphenous vein graft aneurysm presenting as a large mediastinal mass compressing the right atrium. Ferreira AC, et al. **Am J Cardiol** 1997 Mar 1;79(5):706-7

Failure of pre-operative imaging to distinguish renal artery aneurysm from renal cell carcinoma. Padmore D, et al. **Br J Urol** 1996 Nov;78(5):794-5

Pseudoaneurysm of the gastroduodenal artery: an unusual cause of painless jaundice. Hilborn MD, et al. **Can Assoc Radiol J** 1996 Dec;47(6):413-6

Thrombosed fusiform basilar aneurysm associated with Klippel-Trenaunay-Weber syndrome: case report. Ouellet MC, et al. **Can Assoc Radiol J** 1997 Feb;48(1):28-32

Idiopathic right pulmonary artery aneurysm with pulmonary valve insufficiency. Onorato E, et al. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):162-5

Superior mesenteric artery aneurysm in systemic lupus erythematosus. Ko SF, et al. **Clin Imaging** 1997 Jan-Feb; 21(1):13-6

An image-processing strategy for the segmentation and quantification of microaneurysms in fluorescein angiograms of the ocular fundus. Spencer T, et al. **Comput Biomed Res** 1996 Aug;29(4):284-302

Large iliac venous aneurysm simulating a retroperitoneal soft tissue tumour. Petrunić M, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):221-2

Spontaneous rupture of an internal carotid artery aneurysm diagnosed as a peritonsillar abscess, a tonsillar and epipharyngeal carcinoma with metastasis. Karov I. **Folia Med (Plovdiv)** 1996;38(2):65-7

Identification of individual microaneurysms: a comparison between fluorescein angiograms and red-free and colour photographs. Hellstedt T, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234 Suppl 1:S13-7

The management of extrahepatic portal vein aneurysms: observe or treat? Feliciano PD, et al. **HPB Surg** 1996; 10(2):113-6 (22 ref.)

Mitral valve aneurysm without infective endocarditis. Saxena A, et al. **Indian Heart J** 1995 Sep-Oct;47(5):501-2

Venous aneurysms: MR diagnosis with the "layered gadolinium" sign. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul-Aug;21(4):623-7 (12 ref.)

Idiopathic pulmonary artery aneurysm. Fang CC, et al. **J Formos Med Assoc** 1996 Nov;95(11):873-6

A fatal illness presenting as an S1 radiculopathy. Vascular causes of lumbar radicular pain. Shields RE, et al. **J Ky Med Assoc** 1997 Jul;95(7):268-70

Bilateral iliac artery aneurysms and pancake kidney: a case report. Eckes D, et al. **J Vasc Surg** 1997 May;25(5):927-30 (18 ref.)

True aneurysms of the palmar arch of the hand: a report of two cases. Rieck B, et al. **Microsurgery** 1996;17(2):102-5

Congenital internal jugular venous aneurysm: diagnosis and treatment. Bosshardt TL, et al. **Mil Med** 1996 Apr; 161(4):246-7 (10 ref.)

Vascular lesions in the orbit. Forbes G. **Neuroimaging Clin N Am** 1996 Feb;6(1):113-22 (22 ref.)

Topographic anatomy of paraclinoid carotid artery aneurysms: usefulness of MR angiographic source images. Nagasawa S, et al. **Neuroradiology** 1997 May;39(5):341-3

Subretinal fibrovascular proliferation in retinal arteritis with multiple aneurysmal dilatations: a case report. Salvador F, et al. **Ophthalmologica** 1996;210(2):129-31

Indocyanine green videoangiography of hemorrhagic retinal arterial macroaneurysms. Schneider U, et al. **Ophthalmologica** 1997;211(2):115-8

Case of possible true aneurysm of the posterior tibial artery. Iwamoto K, et al. **Osaka City Med J** 1994 Jul;40(1):31-5

Mesenteric artery aneurysm simulating a tumor in the head of the pancreas. Report of a case [letter] Herman P, et al. **Pancreas** 1996 Aug;13(2):215-7

Atherosclerotic femoral artery aneurysms: increase in deep femoral aneurysms? Levi N, et al. **Panminerva Med** 1996 Sep;38(3):164-6

Early versus late staining of microaneurysms in fluorescein angiography. Jalli PY, et al. **Retina** 1997;17(3):211-5

Case of the season. Sada PN. **Semin Roentgenol** 1996 Jan; 31(1):2-3

Current management of visceral artery aneurysms. Carr SC, et al. **Surgery** 1996 Oct;120(4):627-33; discussion 633-4

[Peripheral artery aneurysms. I. Aneurysms of the lower limbs] Defraigne JO, et al. **Rev Med Liege** 1996 Dec; 51(12):771-81 (31 ref.) **(Fre)**

[Hydrocalicosis caused by a large renal artery aneurysm] Groell R, et al. **Aktuelle Radiol** 1997 Mar;7(2):100-2 (Eng. Abstr.) **(Ger)**

[Magnetic resonance tomography and magnetic resonance angiography in diagnosis of complicated popliteal artery aneurysm] Kolb M, et al. **Radiologe** 1997 Feb;37(2):145-51 (Eng. Abstr.) **(Ger)**

[Aneurysms of the iliac artery in fibromuscular dysplasia as differential diagnostic consideration in acute lower abdominal pain] Tsatalpas P, et al. **Zentralbl Chir** 1997; 122(5):413-7 (Eng. Abstr.) **(Ger)**

[A posttraumatic venous aneurysm simulating a strangulated femoral hernia] Borzenko BV, et al. **Klin Khir** 1996;(7):44-5 **(Rus)**

[The late results of the surgical treatment of gigantic carotid-ophthalmic aneurysms of the internal carotid artery (2 cases)] Tropinskaia OF, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct-Dec; (4):35-7 (10 ref.) **(Rus)**

DRUG THERAPY

Intra-arterial thrombolysis followed by elective surgery for thrombo-embolic popliteal aneurysms. Debing E, et al. **Acta Chir Belg** 1997 Jun;97(3):137-40

Effects of corticosteroid and chlorambucil on multiple pulmonary artery aneurysms in Behcet's syndrome. A case report. Park JY, et al. **J Korean Med Sci** 1995 Dec; 10(6):470-3

EPIDEMIOLOGY

Portal vein aneurysm: report of six cases and review of the literature. Ohnami Y, et al. **Abdom Imaging** 1997 May-Jun; 22(3):281-6 (38 ref.)

ETIOLOGY

Vascular complications of lumbar disc surgery. Fruhwirth J, et al. **Acta Neurochir (Wien)** 1996;138(8):912-6

Right hepatic artery pseudoaneurysm after laparoscopic cholecystectomy. Ibrarullah M, et al. **Am J Gastroenterol** 1997 Mar;92(3):528-9

Interaction between fibrillin genotype and blood pressure and the development of aneurysmal disease. Powell JT, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:198-207

Aneurysm of the radial artery following blunt trauma to the wrist. Turowski GA, et al. **Ann Plast Surg** 1997 May; 38(5):527-30

Popliteal aneurysm due to fibromuscular dysplasia. Neukirch C, et al. **Ann Vasc Surg** 1996 Nov;10(6):578-81

Two unusual variants of internal carotid artery aneurysms due to fibromuscular dysplasia. Rhee RY, et al. **Ann Vasc Surg** 1996 Sep;10(5):481-5

Multiple intraabdominal aneurysms--getting to the heart of the matter. Davies RS, et al. **Br J Radiol** 1997 Jun; 70(834):659-60

Fibromuscular dysplasia of the renal artery--rapid progression with formation of aneurysm: case report. Langis P, et al. **Can Assoc Radiol J** 1997 Feb;48(1):8-10

The pathogenesis of arterial aneurysms and associated lesions [letter; comment] Stehbens WE. **Cardiovasc Res** 1997 May; 34(2):431-4. Comment on: Cardiovasc Res 1996 Feb;31(2):222-30.

The effect of pregnancy on mild diabetic retinopathy. Hellstedt T, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Jul;235(7):437-41

Surgical repair of aneurysm in the transplanted kidney following a percutaneous needle biopsy. Yagisawa T, et al. **Int Urol Nephrol** 1996;28(5):729-32

Pseudoaneurysm of the gastrointestinal artery. Maes RM, et al. **J Belge Radiol** 1996 Dec;79(6):273

Arteriosclerotic femoral artery aneurysms. A short review. Levi N, et al. **J Cardiovasc Surg (Torino)** 1997 Aug; 38(4):335-8 (31 ref.)

Traumatic aneurysm of the temporal artery: a report of five cases. Inoue Y, et al. **J Dermatol** 1997 Apr;24(4):246-8

False aneurysm presenting as delayed posterior interosseus nerve palsy. Weinstein RN. **J Orthop Trauma** 1996; 10(8):583-5

Aneurysm of the posterior tibial vein. A case report. Otto S, et al. **Mater Med Pol** 1996 Apr-Jun;28(2):71-2

Arterial injuries following diagnostic, therapeutic, and accidental arterial cannulation in haemodialysis patients. Cina G, et al. **Nephrol Dial Transplant** 1997 Jul; 12(7):1448-52

Early changes in the choroidal vasculature of rats occurring with experimentally induced hypertension. Fulcher T, et al. **Ophthalmic Res** 1996;28(4):255-9

Embolization of multiple pulmonary arterial aneurysms in Behçet's disease. Mouas H, et al. **Scand J Rheumatol** 1996; 25(1):58-60

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Lindahl P, et al. **Science** 1997 Jul 11;277(5323):242-5

Thrombotic obstruction of a reinforced ringed expanded polytetrafluoroethylene graft caused by formation of a pseudoaneurysm at a nonanastomotic site: report of a case. Akiyama K, et al. **Surg Today** 1996;26(11):936-9

Failure patterns of cryopreserved vein grafts in liver transplantation. Kuang AA, et al. **Transplantation** 1996 Sep 27;62(6):742-7 (21 ref.)

[Rupture to the skin of atheromatous aneurysm on a femoropopliteal venous bypass using an in situ vein] Fukui S, et al. **Presse Med** 1996 Nov 9;25(34):1631-2 (Eng. Abstr.) **(Fre)**

[Aneurysm of the celiac trunk. Etiopathogenic role of the arcuate ligament] Hadjadj S, et al. **Presse Med** 1997 Feb 8;26(3):115-7 (Eng. Abstr.) **(Fre)**

[Aneurysms of the peripheral arteries. II. Aneurysms of the upper limbs] Defraigne JO, et al. **Rev Med Liege** 1997; 52(1):27-30 (23 ref.) **(Fre)**

[Hemoptysis caused by pulmonary arterial aneurysm, disclosing Behçet disease. Apropos of 2 cases] Kooli C, et al. **Rev Pneumol Clin** 1997;53(1):51-6 (Eng. Abstr.) **(Fre)**

[Aneurysms of the pulmonary artery in Behçet disease. Apropos of 5 new cases] Yassine N, et al. **Rev Pneumol Clin** 1997;53(1):42-8 (24 ref.) (Eng. Abstr.) **(Fre)**

[CT angiography in peripheral bypass "aneurysmosis": a case report] Rodenwaldt J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Oct;165(4):409-11 **(Ger)**

ANEURYSM

GENETICS

Non-Marfan idiopathic medionecrosis (cystic medial necrosis) presenting with multiple visceral artery aneurysms and diffuse connective tissue fragility: two brothers. Kubota J, et al. **Cardiovasc Intervent Radiol** 1997 May-Jun;20(3):225-7

Recurrent COL3A1 mutation results in EDS IV or familial aneurysms. Anderson DW, et al. **Hum Mutat** 1997;9(5):475

HISTORY

The earliest case of extracranial aneurysm of the vertebral artery. Vaswani M, et al. **Br J Neurosurg** 1997 Apr; 11(2):164-5

PATHOLOGY

Scanning electron microscopic findings in a basilar tip aneurysm embolized with Guglielmi detachable coils. Horowitz MB, et al. **AJNR Am J Neuroradiol** 1997 Apr; 18(4):688-90

Left ventricular aneurysm caused by blunt chest trauma. Arcudi G, et al. **Am J Forensic Med Pathol** 1996 Sep; 17(3):194-6 (11 ref.)

Venous aneurysm, arterial dysplasia, and near-fatal hemorrhages in neurofibromatosis type 1. Nopajaroonsri C, et al. **Hum Pathol** 1996 Sep;27(9):982-5

Bilateral extracranial aneurysms of the internal carotid artery. A case report. Rossi P, et al.
J Cardiovasc Surg (Torino) 1997 Feb;38(1):27-31

Paraclinoid carotid artery aneurysms with the dome eroding the anterior clinoid process: preoperative depiction of topography and surgical tactics--two case reports. Nagasawa S, et al. **Neurol Med Chir (Tokyo)** 1996 Sep; 36(9):639-43

Idiopathic retinal vasculitis, aneurysms, and neuro-retinitis. Retinal Vasculitis Study. Chang TS, et al.
Ophthalmology 1995 Jul;102(7):1089-97

Ductus arteriosus aneurysm [letter; comment] Laurin S.
Pediatr Radiol 1996 Nov;26(11):830-1. Comment on: Pediatr Radiol 1996;26(3):207-9.

Portal vein aneurysm: a rare but important vascular condition. Brock PA, et al. **Surgery** 1997 Jan;121(1):105-8

Varicose veins combined with mucoid degeneration of the venous wall. Fischer R, et al. **Vasa** 1996;25(1):76-80

[Imaging with magnetic resonance in a case of post-traumatic aneurysm of the radial artery] Magarelli N, et al.
Radiol Med (Torino) 1997 Mar;93(3):298-300 **(Ita)**

[Visual prognosis and macular pathology in eyes with retinal macroaneurysms] Saito K, et al.
Nippon Ganka Gakkai Zasshi 1997 Feb;101(2):148-51 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Inflammation and cytokine signaling in aneurysms. McMillan WD, et al. **Ann Vasc Surg** 1997 Sep;11(5):540-5 (36 ref.)

Modeling of flow in a straight stented and nonstented side wall aneurysm model. Aenis M, et al. **J Biomech Eng** 1997 May;119(2):206-12

Thrombosed superficial femoral artery aneurysms in a child: failure of limb salvage with catheter-directed thrombolysis. Leyendecker JR, et al. **J Vasc Interv Radiol** 1996 Sep-Oct; 7(5):691-4

Pulsation-pressure relationship in experimental aneurysms: observation of aneurysmal hysteresis. Novak P, et al.
Neurol Res 1996 Aug;18(4):377-82

[Combined cardiac surgery and aneurysm of subrenal abdominal aorta] Saccani S, et al.
Acta Biomed Ateneo Parmense 1995;66(5):209-15 (Eng. Abstr.) **(Ita)**

[Visual prognosis and macular pathology in eyes with retinal macroaneurysms] Saito K, et al.
Nippon Ganka Gakkai Zasshi 1997 Feb;101(2):148-51 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Difficulties in the diagnosis of popliteal vein aneurysm. Deblier I, et al. **Acta Chir Belg** 1996 Jul-Aug;96(4):177-8

Vertebrobasilar dolichoectasia: evaluation with CT angiography. Vieco PT, et al. **AJNR Am J Neuroradiol** 1997 Aug;18(7):1385-8

Saphenous vein graft aneurysm after coronary artery bypass surgery. Doyle MT, et al. **AJR Am J Roentgenol** 1997 Mar; 168(3):747-9

Angiography/interventional case of the day. Polyarteritis nodosa (PAN). LiPuma JP, et al.
AJR Am J Roentgenol 1997 Jul;169(1):260, 264-5

Aneurysms of the visceral and renal arteries. Panayiotopoulos YP, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5):412-9 (85 ref.)

Paracardiac masses caused by a right coronary artery aneurysm and a saphenous vein graft aneurysm. Chalasani P, et al. **Clin Cardiol** 1997 Jan;20(1):79-81

Expanding aneurysm of aberrant right subclavian artery. Case report and imaging evaluation. Hogg JP, et al.
Clin Imaging 1997 May-Jun;21(3):195-9 (8 ref.)

Hepatic artery aneurysms: evaluation using three-dimensional spiral CT angiography. Howling SJ, et al. **Clin Radiol** 1997 Mar;52(3):227-30

Ductus arteriosus aneurysm in the adult: role of computed tomography in diagnosis. Taneja K, et al. **Clin Radiol** 1997 Mar;52(3):231-4

Aneurysms complicating inflammatory diseases in immunocompromised hosts: value of contrast-enhanced CT. Heussel CP, et al. **Eur Radiol** 1997;7(3):316-9

Aneurysms of proximal pulmonary arteries: CT diagnosis and preoperative assessment. Iula G, et al. **Eur Radiol** 1996; 6(5):730-3 (16 ref.)

Radiological case of the month. Hypothenar hammer syndrome. Avva R, et al. **J Ark Med Soc** 1996 Nov; 93(6):303-4

Saccular aneurysm of the external jugular vein, an unusual cause of neck swelling. Verbeeck N, et al.
J Belge Radiol 1997 Apr;80(2):63-4

The radiological appearance of atherosclerotic popliteal artery aneurysms: the "dog-leg" sign. Holdsworth RJ, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):181-2

Gas inclusion as an unusual complication in a case of giant aneurysm. Schneider JF, et al. **J Comput Assist Tomogr** 1997 Sep-Oct;21(5):842-4

Bronchial artery aneurysms in association with Mycobacterium avium intracellulare complex. Siegler CM, et al. **J Thorac Imaging** 1996 Spring;11(2):155-7 (15 ref.)

Portal vein aneurysm: a rare but important vascular condition. Brock PA, et al. **Surgery** 1997 Jan;121(1):105-8

[Calcified aneurysm of the right renal artery] Delval O, et al. **J Radiol** 1997 Apr;78(4):317-9 **(Fre)**

[Pseudoaneurysm of the right hepatic artery with an arterio-biliary fistula]
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997 Jun;166(6):586-7 **(Ger)**

[True aneurysm of the femoral profunda artery] Flückiger R, et al. **Vasa** 1996;25(3):279-86 (36 ref.) (Eng. Abstr.) **(Ger)**

[Combined imaging of hepatic artery aneurysm: report of 2 cases] Garribba AP, et al. **Radiol Med (Torino)** 1996 Oct; 92(4):486-9 **(Ita)**

SURGERY

Intra-arterial thrombolysis followed by elective surgery for thrombo-embolic popliteal aneurysms. Debing E, et al.
Acta Chir Belg 1997 Jun;97(3):137-40

Aneurysm clips made of titanium: magnetic characteristics and artifacts in MR. Wichmann W, et al.
AJNR Am J Neuroradiol 1997 May;18(5):939-44

Results of surgical management of internal carotid artery aneurysm by the cervical approach. Coffin O, et al.
Ann Vasc Surg 1997 Sep;11(5):482-90

Endovascular repair of peripheral aneurysms, pseudoaneurysms, and arteriovenous fistulas. Criado E, et al. **Ann Vasc Surg** 1997 May;11(3):256-63

Two unusual variants of internal carotid artery aneurysms due to fibromuscular dysplasia. Rhee RY, et al.
Ann Vasc Surg 1996 Sep;10(5):481-5

Hepatic artery aneurysm: two case reports and review of the literature. Ibach EG, et al. **Aust N Z J Surg** 1997 Feb-Mar;67(2-3):143-7

Prophylaxis of graft infection with rifampicin-bonded Gelseal graft: 2-year follow-up of a prospective clinical trial. Italian Investigators Group. D'Addato M, et al.
Cardiovasc Surg 1996 Apr;4(2):200-4

Coeliac artery aneurysm: a case report. Ghoddousi I, et al.
Cardiovasc Surg 1996 Aug;4(4):555-6

Coeliac artery aneurysm: a case report. Gupta R, et al.
Cardiovasc Surg 1996 Aug;4(4):550-2

Renal artery aneurysm: a report of 28 cases. Lumsden AB, et al. **Cardiovasc Surg** 1996 Apr;4(2):185-9

Surgical aspects of fusiform and saccular extracranial carotid artery aneurysms. Miksić K, et al. **Cardiovasc Surg** 1997 Apr;5(2):190-5

Aneurysm of the coeliac artery. Saliou C, et al.
Cardiovasc Surg 1996 Aug;4(4):552-5

Femoral artery aneurysms: long-term follow-up and results of surgical treatment. Sapienza P, et al. **Cardiovasc Surg** 1996 Apr;4(2):181-84

True aneurysms of infrainguinal vein bypass grafts: the need for active, not passive management. Barker SG, et al.
Eur J Vasc Endovasc Surg 1996 Oct;12(3):378-9

Femoral pseudoaneurysms in drug addicts. Levi N, et al.
Eur J Vasc Endovasc Surg 1997 Apr;13(4):361-2

Aneurysm of the inferior mesenteric artery: case report and review of the literature. Sallou C, et al.
Eur J Vasc Endovasc Surg 1997 Jul;14(1):71-4 (26 ref.)

Aneurysms of the lower limbs: evaluation and management. Porcellini M, et al. **G Chir** 1996 Jun-Jul;17(6-7):314-9

Late arteriovenous fistulas and pseudoaneurysms of the extremity secondary to civilian firearms. Porcellini M, et al. **G Chir** 1997 Mar;18(3):91-6

Ex vivo surgery for renal artery aneurysms. Toshino A, et al. **Int J Urol** 1996 Nov;3(6):421-5

Surgical repair of aneurysm in the transplanted kidney following a percutaneous needle biopsy. Yagisawa T, et al. **Int Urol Nephrol** 1996;28(5):729-32

Modeling of flow in a straight stented and nonstented side wall aneurysm model. Aenis M, et al. **J Biomech Eng** 1997 May;119(2):206-12

Surgical treatment of recurrence of an aneurysm of aberrant right subclavian artery. Luciani N, et al. **J Card Surg** 1997 Jan-Feb;12(1):51-4

Inferior pancreaticoduodenal artery aneurysm associated with common hepatic artery occlusion. Bracale G, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):579-81

Exclusion of an internal carotid aneurysm by a covered stent. Ruebben A, et al. **J Cardiovasc Surg (Torino)** 1997 Jun; 38(3):301-3

Surgical treatment of popliteal artery aneurysm. A 20 year experience. Sarcina A, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):347-54

The successful management of a non-atherosclerotic ilio-femoro-popliteal aneurysm. Case report. al Zahrani H.
J Cardiovasc Surg (Torino) 1997 Apr;38(2):157-9

Endoluminal grafting for aneurysmal and occlusive disease in the superficial femoral artery: early experience. Diethrich EB, et al. **J Endovasc Surg** 1995 Aug;2(3):225-39

Endoluminal grafting for percutaneous aneurysm exclusion in an aortocoronary saphenous vein graft: the first clinical experience. Heuser RR, et al. **J Endovasc Surg** 1995 Feb; 2(1):81-8

Endovascular repair of an ascending aorta-to-left common femoral artery graft with aneurysmal degeneration. Jaff MR, et al. **J Endovasc Surg** 1995 May;2(2):189-95

Ethical and legal issues related to endovascular graft investigation and early usage [editorial] Veith FJ, et al.
J Endovasc Surg 1997 Feb;4(1):66-71

A new nonstented balloon-expandable graft for straight or bifurcated endoluminal bypass. White GH, et al.
J Endovasc Surg 1994 Sep;1:16-24

Treatment of thrombosed thumb artery aneurysm: a report of four cases. Adham MN, et al. **J Hand Surg [Am]** 1997 Jul;22(4):750-2

Hepatic artery aneurysm: a case report. Sunthornlekhla B, et al. **J Med Assoc Thai** 1996 Jan;79(1):60-4

Aberrant right subclavian artery aneurysm--a surgical review. Jebara VA, et al. **J Med Liban** 1995;43(3):157-61 (32 ref.)

Successful resection of a massive hepatic artery aneurysm. Andrew DR, et al. **J R Army Med Corps** 1994 Oct; 140(3):138-40

Management of coarctation with multiple calcified aneurysms of the intercostal arteries in adults. Sethi GK, et al.
J Thorac Cardiovasc Surg 1975 Jun;69(6):909-11

Experience with revascularizing renal artery aneurysms: is it feasible, safe and worth attempting? Seki T, et al.
J Urol 1997 Aug;158(2):357-62

Percutaneous treatment of a collapsed stent-graft. Ahmad AA, et al. **J Vasc Interv Radiol** 1997 Jul-Aug;8(4):637-9

Multiple idiopathic arterial aneurysms in children: a case report and review of the literature. Halpern V, et al.
J Vasc Surg 1997 May;25(5):949-56 (22 ref.)

Aneurysms of anomalous splenomesenteric trunk: clinical features and surgical management in two cases. Settembrini PG, et al. **J Vasc Surg** 1996 Oct;24(4):687-92

Microembolization during endovascular and conventional aneurysm repair. Thompson MM, et al. **J Vasc Surg** 1997 Jan;25(1):179-86

Magnetic field gradients in the MRI suite and their effects on aneurysm clips. Dujovny M, et al. **Neurol Res** 1996 Dec;18(6):483-6

Aneurysm of the intradural artery of Adamkiewicz treated with muslin wrapping: technical case report. Vishteh AG, et al. **Neurosurgery** 1997 Jan;40(1):207-9

Atherosclerotic femoral artery aneurysms: increase in deep femoral aneurysms? Levi N, et al. **Panminerva Med** 1996 Sep;38(3):164-6

Occlusive and aneurysmal peripheral arterial disease: assessment of a stent-graft system. Henry M, et al.
Radiology 1996 Dec;201(3):717-24

Magnetic characteristics of Yaşargil aneurysm clips. Dujovny M, et al. **Surg Neurol** 1997 Jun;47(6):547-50

The immunogenicity of the extracellular matrix in arterial xenografts. Allaire E, et al. **Surgery** 1997 Jul;122(1):73-81

A first case report of the successful laparoscopic repair of a splenic artery aneurysm. Matsumoto K, et al. **Surgery** 1997 Apr;121(4):462-4

Management of aneurysms in Behçet's syndrome: an analysis of 24 patients. Tüzün H, et al. **Surgery** 1997 Feb; 121(2):150-6

[Popliteal aneurysm: surgical treatment is mandatory before complications occur] Poirier NC, et al. **Ann Chir** 1996; 50(8):613-8 (Eng. Abstr.) **(Fre)**

[Popliteal aneurysms--surgical management versus conservative procedure] Schröder A, et al.
Langenbecks Arch Chir Suppl Kongressbd 1996;113:857-63 (Eng. Abstr.) **(Ger)**

[Combined cardiac surgery and aneurysm of subrenal abdominal aorta] Saccani S, et al.
Acta Biomed Ateneo Parmense 1995;66(5):209-15 (Eng. Abstr.) **(Ita)**

[Bilateral aneurysms of the popliteal artery] Ritucci V, et al. **Ann Ital Chir** 1996 Sep-Oct;67(5):683-6; discussion 687 (Eng. Abstr.) **(Ita)**

[Aneurysm of the hepatic artery. Case report and review of the literature] Oddi A, et al. **G Chir** 1997 May; 18(5):277-82 (Eng. Abstr.) **(Ita)**

[Aneurysm of the popliteal artery. A case contribution of a 15-year surgical experience] D'Angelo F, et al.
Minerva Cardioangiol 1996 Oct;44(10):499-509 (Eng. Abstr.) **(Ita)**

[Aneurysms of the popliteal artery. Our experience apropos of 37 cases] Vettorello G, et al. **Minerva Cardioangiol** 1996 Sep;44(9):437-42 (Eng. Abstr.) **(Ita)**

[Aneurysms of the splanchnic arteries] Masciariello S, et al.
Minerva Chir 1997 Jan-Feb;52(1-2):45-52 (Eng. Abstr.) **(Ita)**

[Use of the Cragg stent in the treatment of popliteal artery aneurysm: report of a case] Maglione F, et al.

Radiol Med (Torino) 1996 Nov;92(5):662–4 **(Ita)**

[An operative case of bilateral peripheral pulmonary arterial aneurysms] Inaba H, et al. **Kyobu Geka** 1997 Apr; 50(4):331–4 (5 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of surgical treatment for aneurysm of the brachiocephalic artery associated with tracheal stenosis] Matsushita T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):754–8 (Eng. Abstr.) **(Jpn)**

[Simultaneous surgical treatment for distal aortic arch aneurysm associated with innominate artery aneurysm and coronary artery disease] Nakashima S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):778–82 (Eng. Abstr.) **(Jpn)**

[A case report of primary repair for thoracic and thoracoabdominal and iliac artery aneurysms associated with severe visceral artery occlusive diseases—a redo operation for thoracoabdominal aortic aneurysm after infrarenal abdominal aortic aneurysm repair] Takigami K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr; 45(4):577–81 (Eng. Abstr.) **(Jpn)**

[Surgical management of extracranial internal carotid artery aneurysms] Nagasawa S, et al. **No Shinkei Geka** 1997 Feb; 25(2):143–9 (Eng. Abstr.) **(Jpn)**

[A case of a surgically treated extracranial internal carotid artery saccular aneurysm] Yamaguchi S, et al. **No Shinkei Geka** 1997 Feb;25(2):181–5 (Eng. Abstr.) **(Jpn)**

[The microsurgical treatment of large and giant aneurysms of the internal carotid artery located parasphenoidally] Eliava ShSh, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct–Dec;(4):3–6 (Eng. Abstr.) **(Rus)**

[Aneurysms of the extracranial part of the carotid artery] Lovričević I, et al. **Lijec Vjesn** 1996 Nov–Dec; 118(11–12):272–7 (Eng. Abstr.) **(Scr)**

THERAPY

Re: embolization of pancreaticoduodenal aneurysms associated with occlusive disease of the celiac artery [letter; comment] Savastano S, et al. **Abdom Imaging** 1996 Sep–Oct; 21(5):475–6. Comment on: Abdom Imaging 1995 Sep–Oct;20(5):470–3.

Endovascular treatment of ophthalmic segment aneurysms with Guglielmi detachable coils. Roy D, et al. **AJNR Am J Neuroradiol** 1997 Aug;18(7):1207–15

Initial experience with collagen-filled Guglielmi detachable coils for endovascular treatment of experimental aneurysms. Szikora I, et al. **AJNR Am J Neuroradiol** 1997 Apr;18(4):667–72

Endovascular extraction of malpositioned fibered platinum microcoils from the aneurysm sac during endovascular therapy. Zoarski GH, et al. **AJNR Am J Neuroradiol** 1997 Apr;18(4):691–5

Aneurysms of the visceral and renal arteries. Panayiotopoulos YP, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5):412–9 (85 ref.)

Endovascular treatment of renal artery aneurysms with conventional non-detachable microcoils and Guglielmi detachable coils. Klein GE, et al. **Br J Urol** 1997 Jun; 79(6):852–60

Transseptal mitral balloon valvotomy in patients with atrial septal aneurysms. Rittoo D, et al. **Cardiology** 1997 May–Jun;88(3):300–4

Embolization of pulmonary catheter-induced pulmonary artery pseudoaneurysms. Ray CE Jr, et al. **Chest** 1996 Nov; 110(5):1370–3

Two giant bronchial aneurysms: effect of preoperative embolisation. case report. Nakajima H, et al. **Eur J Surg** 1995 Nov;161(11):855–6

Successful management of eleven splanchnic artery aneurysms. Røkke O, et al. **Eur J Surg** 1997 Jun; 163(6):411–7

Treatment of an aneurysm of the coeliac axis by transluminal steel wire occlusion. Rengo M, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):88–90

Non-surgical treatment of aneurysms of bilateral persistent sciatic artery. Sogaro F, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):503–5

The management of extrahepatic portal vein aneurysms: observe or treat? Feliciano PD, et al. **HPB Surg** 1996; 10(2):113–6 (22 ref.)

Successful embolization of a renal artery aneurysm with preservation of renal blood flow. Tateno T, et al. **Int Urol Nephrol** 1996;28(3):283–7

Endoleak—a proposed new terminology to describe incomplete aneurysm exclusion by an endoluminal graft [letter] White GH, et al. **J Endovasc Surg** 1996 Feb; 3(1):124–5

Angiographic analysis and results of endovascular therapy of aneurysm of vein of Galen. Rao VR, et al. **J Neuroradiol** 1994 Apr;21(3):213–22

Endovascular treatment of traumatic aneurysms of the superficial temporal artery. Komiyama M, et al. **J Trauma** 1997 Sep;43(3):545–8

Percutaneous treatment of peripheral aneurysms with the Cragg EndoPro System. Rousseau H, et al. **J Vasc Interv Radiol** 1996 Jan–Feb;7(1):35–9

Embolization and percutaneous aspiration of hepatic artery aneurysm for relief of obstructive jaundice. Sakamoto I, et al. **J Vasc Interv Radiol** 1996 Jul–Aug;7(4):557–60

Bilateral cavernous carotid artery aneurysms in a 4-year-old child: endovascular treatment with mechanically detachable coils. Cekirge S, et al. **Neuroradiology** 1997 May; 39(5):367–70

Endovascular embolization of superior hypophyseal artery aneurysms. Gurian JH, et al. **Neurosurgery** 1996 Dec; 39(6):1150–4; discussion 1154–6

Endovascular treatment of experimental aneurysms with liquid polymers: the protective potential of stents. Szikora I, et al. **Neurosurgery** 1996 Feb;38(2):339–47

Extracranial aneurysm and arteriovenous fistula: embolization with the Guglielmi detachable coil. Klein GE, et al. **Radiology** 1996 Nov;201(2):489–94

Embolization of multiple pulmonary arterial aneurysms in Behçet's disease. Mouas H, et al. **Scand J Rheumatol** 1996; 25(1):58–60

Management of renal artery aneurysms. Cinat M, et al. **Semin Vasc Surg** 1996 Sep;9(3):236–44 (50 ref.)

Current management of visceral artery aneurysms. Carr SC, et al. **Surgery** 1996 Oct;120(4):627–33; discussion 633–4

Endoluminal exclusion of an iliac artery aneurysm by Wallstent endoprosthesis and PTFE vascular graft. Krajcer Z, et al. **Tex Heart Inst J** 1997;24(1):11–4

[Emergency treatment of hemobilia using embolization] Abada HT, et al. **J Belge Radiol** 1996 Nov;79(5):221–3 (Eng. Abstr.) **(Fre)**

[Endovascular therapy of visceral aneurysms] Kramann B, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:878–81 (Eng. Abstr.) **(Ger)**

[Pseudoaneurysm of the lingual artery. Report of a case treated with embolization] Liessi G, et al. **Radiol Med (Torino)** 1997 May;93(5):631–2 **(Ita)**

[Percutaneous embolization with tungsten coils of a splenic artery aneurysm: report of a case] Molani L, et al. **Radiol Med (Torino)** 1997 Apr;93(4):477–9 **(Ita)**

ULTRASONOGRAPHY

Renal vein aneurysm: diagnosis with color Doppler sonography. Kabaalioğlu A, et al. **AJR Am J Roentgenol** 1997 Mar;168(3):645–6 (8 ref.)

Poststenotic aneurysm of the paraumbilical collateral vein: Doppler sonography findings [letter] Killi RM, et al. **AJR Am J Roentgenol** 1997 Feb;168(2):571–2

Hepatic artery aneurysm: a case report. Sunthornlekhla B, et al. **J Med Assoc Thai** 1996 Jan;79(1):60–4

Renal artery aneurysm manifested as parapelvic cyst on abdominal sonography [letter] Kwon HS, et al. **Nephron** 1996;74(1):229

[Asymptomatic aneurysm of the ileocolic artery] Hundertmark C, et al. **Aktuelle Radiol** 1997 Mar;7(2):98–9 (Eng. Abstr.) **(Ger)**

[Aneurysm of the popliteal artery: diagnostic error in duplex ultrasonography] Vogl W, et al. **Rontgenpraxis** 1996 Jan; 49(1):1–3 **(Ger)**

[Aneurysm of the left intrahepatic branch of the portal vein: occasional finding. A case] D'Andrea P, et al. **Radiol Med (Torino)** 1996 Dec;92(6):804–5 **(Ita)**

[A case of celiac aneurysm exposed to the ulcer base of the remnant stomach: an usefulness of miniature ultrasonic probe] Imada Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Apr;94(4):268–71 **(Jpn)**

[Echographic diagnosis of inferior pancreatoduodenal artery aneurysm (letter)] Córdoba López A, et al. **Med Clin (Barc)** 1997 Jun 28;109(5):199 **(Spa)**

[Aneurysm of the hepatic artery and echography (letter)] Arzua E, et al. **Rev Esp Enferm Dig** 1997 Jul;89(7):572–3 **(Spa)**

ANEURYSM, ARTERIOVENOUS see **ARTERIOVENOUS FISTULA**

ANEURYSM, BACTERIAL see **ANEURYSM, INFECTED**

ANEURYSM, CORONARY see **CORONARY ANEURYSM**

ANEURYSM, DISSECTING

Immunohistochemical abnormalities of fibrillin in cardiovascular tissues in Marfan's syndrome. Fleischer KJ, et al. **Ann Thorac Surg** 1997 Apr;63(4):1012–7

Spontaneous dissection of the celiac artery. Chaillou P, et al. **Ann Vasc Surg** 1997 Jul;11(4):413–5

Aortic dissection. Braverman AC. **Curr Opin Cardiol** 1997 Jul;12(4):389–90 (4 ref.)

Carotid and vertebral artery dissections. Stahmer SA, et al. **Emerg Med Clin North Am** 1997 Aug;15(3):677–98 (99 ref.)

Geriatrics photo quiz. Thoracic aortic aneurysm. Shua-Haim JR, et al. **Geriatrics** 1997 Sep;52(9):35, 90

Spontaneous internal carotid artery dissection. Review. Karacagil S, et al. **Int Angiol** 1996 Dec;15(4):291–4 (55 ref.)

Thoracic aortic dissection or aneurysm: clinical presentation, diagnostic imaging and initial management in a tertiary referral centre. Hennessy TG, et al. **Ir J Med Sci** 1996 Oct–Dec;165(4):259–62

Progress report: evaluation and treatment of ascending and aortic arch aneurysm/dissection. Meadors FA. **J Ark Med Soc** 1997 Mar;93(10):481–3 (7 ref.)

Spontaneous and isolated dissection of the common iliac artery. Fernández AL, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):377–9

Iliac artery dissection originating in a true aneurysm. A case report. Miyamoto S, et al. **J Cardiovasc Surg (Torino)** 1996 Oct;37(5):453–6

Acute aortic dissection without intimal tear. Utoh J, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):419–20

Cardiac tamponade during transesophageal echocardiography in the patient of circumferential aortic dissection. Kim CM, et al. **J Korean Med Sci** 1997 Jun; 12(3):266–8

Spontaneous dissection of the internal carotid artery: a nineteen-year clinical experience. Treiman GS, et al. **J Vasc Surg** 1996 Oct;24(4):597–605; discussion 605–7

Aortic dissection. Prêtre R, et al. **Lancet** 1997 May 17; 349(9063):1461–4 (65 ref.)

Aortic and other arterial dissections associated with pregnancy. Rutherford RB, et al. **Semin Vasc Surg** 1995 Dec;8(4):299–305 (29 ref.)

Recurrence of cervical artery dissection. A prospective study of 81 patients. Bassetti C, et al. **Stroke** 1996 Oct; 27(10):1804–7

[Isolated dissection of the posterior cerebral artery] Le Tu PT, et al. **Rev Neurol (Paris)** 1996 Aug–Sep;152(8–9):542–7 (17 ref.) (Eng. Abstr.) **(Fre)**

[Aortic dissection: new diagnostic and therapeutic trends] Marra L, et al. **Clin Ter** 1996 Jun;147(6):333–7 (Eng. Abstr.) **(Ita)**

[Triple-barrel(ed) or three channeled aortic dissection] Fujiwara K, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (14):375–7 (13 ref.) **(Jpn)**

[Spontaneous cervical artery dissection] Kiyama M. **Ryoikibetsu Shokogun Shirizu** 1996;(14):485–7 (17 ref.) **(Jpn)**

[Aortic dissection, dissecting aortic aneurysm] Matsco H. **Ryoikibetsu Shokogun Shirizu** 1996;(14):303–6 (12 ref.) **(Jpn)**

[Thrombosed type aortic dissection] Matsuo H. **Ryoikibetsu Shokogun Shirizu** 1996;(14):341–4 (16 ref.) **(Jpn)**

[Coronary artery dissection] Tada H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):584–8 (27 ref.) **(Jpn)**

[Primary coronary artery dissection] Tada H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):645–50 (25 ref.) **(Jpn)**

[Aortic dissection: clinical evaluation, comparison of diagnostic techniques and treatment election] San Román JA, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:2–12 (84 ref.) (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Cerebral spinal fluid drainage and distal aortic perfusion decrease the incidence of neurological deficit: the results of 343 descending and thoracoabdominal aortic aneurysm repairs. Safi HJ, et al. **Eur J Vasc Endovasc Surg** 1997 Aug; 14(2):118–24

CHEMICALLY INDUCED

Cocaine-induced aortic dissection. Rashid J, et al. **Am Heart J** 1996 Dec;132(6):1301–4 (20 ref.)

Thoracic aortic dissection secondary to crack cocaine ingestion. Perron AD, et al. **Am J Emerg Med** 1997 Sep; 15(5):507–9

Acute dissection of the aorta with amphetamine misuse. Dihmis WC, et al. **BMJ** 1997 Jun 7;314(7095):1665

Aortic dissection and use of the nicotine patch: a case involving a temporal relationship. Ropchan GV, et al. **Can J Cardiol** 1997 May;13(5):525–8

CLASSIFICATION

Aortic dissection type A versus type B: a different post-surgical death hazard? Rizzoli G, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):202–8

[Aortic dissection] Mészáros I. **Orv Hetil** 1997 Apr 6; 138(14):843–9 (53 ref.) (Eng. Abstr.) **(Hun)**

COMPLICATIONS

Stent angioplasty for renovascular disease associated with acute aortic dissection. Hata M, et al. **Ann Thorac Surg** 1997 Jan;63(1):244–6

Thoracoabdominal fenestration for aortic dissection with ischemic colonic perforation. Howell JF, et al. **Ann Thorac Surg** 1997 Jul;64(1):242–4

Stroke due to arterial disease in cogenital heart disease [letter] Ganesan V, et al. **Arch Dis Child** 1997 Feb;76(2):175

Cervical carotid or vertebral artery dissection [editorial; comment] Blunt SB, et al. **BMJ** 1997 Jan 25;314(7076):243 . Comment on: BMJ 1997 Jan 25;314(7076):291–2.

Aorto-pulmonary fistula: a rare event in the evolution of a dissecting aneurysm of the thoracic aorta. Massetti M, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):994–6

Obstruction of the superior vena cava due to aortic dissection: CT findings of collateral venous flow via the bronchial veins. Schepers-Bok R, et al. **Eur Radiol** 1996;6(5):753–5

Back pain in a 43-year-old man. Archer TP, et al. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):104–6

Spontaneous dissection of coronary artery causing anterior myocardial infarction in a young man. Kumar PR, et al. **Indian Heart J** 1996 Nov–Dec;48(6):699–700

Rupture of a dissecting aneurysm into the superior vena cava in Marfan's syndrome. Toyoda Y, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):411–3

Atypical manifestations in a patient with systemic lupus erythematosus. Lam KY, et al. **J Clin Pathol** 1997 Feb;

50(2):174–6
Brachial plexus palsy and carotid artery dissection. Edmunds I, et al. **J Hand Surg [Br]** 1996 Oct;21(5):695
Aortic dissection in puerperium: a case report. Scalia D, et al. **J Heart Valve Dis** 1996 May;5(3):251–3
Fatal stroke in a patient with carotid and middle cerebral artery dissection associated with cystic medial necrosis [letter] Bähr M, et al. **J Neurol** 1996 Oct;243(10):722–3
Cerebral microembolism and extracranial internal carotid artery dissection. Babikian VL, et al. **J Ultrasound Med** 1996 Dec;15(12):863–6
The dissected aorta: percutaneous treatment of ischemic complications—principles and results. Williams DM, et al. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):605–25
A surgeon with a nasty taste in his mouth. Schievink WI. **Lancet** 1997 Jul 26;350(9073):260
Acute subdural hematoma without subarachnoid hemorrhage due to ruptured intracranial aneurysm—case report. Ishibashi A, et al. **Neurol Med Chir (Tokyo)** 1997 Jul; 37(7):533–7
Cerebellar infarction with hydrocephalus caused by spontaneous extracranial vertebral artery dissection—case report. Sagoh M, et al. **Neurol Med Chir (Tokyo)** 1997 Jul; 37(7):538–41
Posterior cervical spinal cord infarction following vertebral artery dissection. Bergqvist CA, et al. **Neurology** 1997 Apr; 48(4):1112–5
Paraparesis due to syphilitic aortic dissection. Kellett MW, et al. **Neurology** 1997 Jan;48(1):221–3
Rash in an elderly woman presenting with collapse. Prajapati C, et al. **Postgrad Med J** 1997 Mar;73(857):175–6
CT scanning as a helpful tool for decision-making during CPR [letter] Ladner E, et al. **Resuscitation** 1996 Apr; 31(2):171–3
Regression of ST segment elevation after thrombolysis in acute aortic dissection. Safi J Jr, et al. **South Med J** 1996 Nov;89(11):1091–3
Bilateral vertebral artery dissection in a patient with afibrinogenemia. García-Moncó JC, et al. **Stroke** 1996 Dec; 27(12):2325–7
Ruptured dissecting aneurysm as a cause of subarachnoid hemorrhage of unverified etiology. Nakatomi H, et al. **Stroke** 1997 Jun;28(6):1278–82
Vertebral artery occlusion after subarachnoid hemorrhage from a dissecting aneurysm of the vertebral artery: case report. Yasui T, et al. **Surg Neurol** 1997 Feb;47(2):149–52; discussion 152–3
Global renal infarction secondary to a dissecting thoracic aneurysm. Frank RG, et al. **Urology** 1996 Dec;48(6):930–1
[Peripheral and coronary artery dissections in a young woman. A rare case of type IV Ehlers-Danlos syndrome] Eltchaninoff H, et al. **Arch Mal Coeur Vaiss** 1997 Jun; 90(6):841–4 (Eng. Abstr.) **(Fre)**
[Acute myocardial infarction in pregnancy in a patient with pseudoaneurysm of the left main coronary artery] Manari A, et al. **G Ital Cardiol** 1996 Dec;26(12):1437–43 (Eng. Abstr.) **(Ita)**
[A case report of closing aortic dissection with cardiac tamponade] Yoshimura N, et al. **Kyobu Geka** 1996 Oct; 49(11):943–6 (Eng. Abstr.) **(Jpn)**
[Pathophysiology and complications of aortic dissection] Matsuo H. **Nippon Geka Gakkai Zasshi** 1996 Oct; 97(10):879–83 (11 ref.) (Eng. Abstr.) **(Jpn)**
[A case report of Stanford type A acute thrombosed aortic dissection complicating cardiac tamponade] Morimoto K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep; 44(9):1805–8 (Eng. Abstr.) **(Jpn)**
[A successful surgical case report of impending rupture of the true thoraco-abdominal aortic aneurysm induced by thrombosed-type acute aortic dissection (Stanford type A)] Ohnishi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):649–54 (Eng. Abstr.) **(Jpn)**
[A successful surgical case of a dissecting aortic aneurysm with right-sided aortic arch and right-sided descending aorta] Osako M, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Aug;44(8):1145–50 (Eng. Abstr.) **(Jpn)**
[Usefulness of Dumon-type endotracheal stent for left main bronchial obstruction caused by thoracic aortic aneurysm—a case report] Watanabe S, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Sep;44(9):1776–80 (Eng. Abstr.) **(Jpn)**
[A case of acute thrombosed aortic dissection (Stanford type A) in association with a true aortic arch aneurysm] Yamamoto H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct;44(10):1945–8 (Eng. Abstr.) **(Jpn)**
[Spinal cord ischemia caused by dissecting aortic aneurysm in a patient with acute exacerbation of pulmonary emphysema] Yanagisawa N, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1997 Jan;35(1):77–81 (Eng. Abstr.) **(Jpn)**
[Case of aortic occlusion caused by aortic dissection: recanalization by multiple fenestrations] Kihira Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2081–2 **(Jpn)**
[A case of middle cerebral artery occlusion caused by dissecting aneurysm] Fu Y, et al. **No Shinkei Geka** 1996 Oct;24(10):955–9 (Eng. Abstr.) **(Jpn)**
[Intracerebral hemorrhage secondary to dissecting aneurysm of the anterior cerebral artery] Hayashi N, et al.
No To Shinkei 1996 Nov;48(11):1053–6 (19 ref.) (Eng. Abstr.) **(Jpn)**
[A case of cerebral infarction due to dissection in a branch of the middle cerebral artery] Gotoh T, et al.
Rinsho Shinkeigaku 1996 Feb;36(2):312–7 (Eng. Abstr.) **(Jpn)**
[A case of vertebral artery dissection with lateral inferior pontine syndrome and lateral medullary syndrome] Hashimoto Y, et al. **Rinsho Shinkeigaku** 1997 Mar; 37(3):253–6 (Eng. Abstr.) **(Jpn)**
[Medullary infarction due to vertebral dissecting aneurysm in a patient with Behçet's disease] Itoh K, et al.
Rinsho Shinkeigaku 1996 Aug;36(8):986–9 (Eng. Abstr.) **(Jpn)**
[Acute anterior myocardial wall infarct caused by aortic dissection] Panić G, et al. **Med Pregl** 1996;49(11–12):493–6 (Eng. Abstr.) **(Scr)**
[Right pleural effusion as first manifestation of dissecting aneurysm of the aorta (letter)] Marcos Sánchez F, et al. **An Med Interna** 1996 Nov;13(11):562–3 **(Spa)**
[Brown-Sequard syndrome secondary to dissecting aortic aneurysm (letter)] Blanco Jiménez J, et al.
Rev Clin Esp 1997 Apr;197(4):299–301 **(Spa)**
[Dissection of the internal carotid artery with subarachnoid hemorrhage] Martín-Bermúdez R, et al. **Rev Neurol** 1997 Jun;25(142):882–3 (Eng. Abstr.) **(Spa)**

CONGENITAL

Unruptured congenital aneurysm of the right sinus of Valsalva. Dissecting into the interventricular septum. Kalimanovska-Oštrić D, et al. **Tex Heart Inst J** 1996; 23(3):217–21

DIAGNOSIS

Postcoital vertebral artery dissection [letter] Chang GY, et al. **Am Fam Physician** 1996 Nov 15;54(7):2195–6
Thrombolytic therapy in aortic dissection [letter] Cheng TO. **Am Fam Physician** 1997 Sep 1;56(3):738, 741
A case report of carotid artery dissection presenting as cluster headache. Rosebraugh CJ, et al. **Am J Med** 1997 Apr; 102(4):418–9
Horner syndrome as an isolated manifestation of an intrapetrous internal carotid artery dissection. Bilbao R, et al. **Am J Ophthalmol** 1997 Apr;123(4):562–4
Dissection of retroesophageal aortic diverticulum and descending aorta in a patient with right aortic arch: magnetic resonance demonstration. Ko SF, et al.
Cardiovasc Intervent Radiol 1996 Nov–Dec;19(6):438–41
Plaque rupture as a cause of apparent coronary aneurysm formation following directional coronary atherectomy. Moriuchi M, et al. **Cathet Cardiovasc Diagn** 1997 May; 41(1):48–50
Chronic aortic dissection presenting as a prolonged febrile disease and arterial embolization. Schattner A, et al.
Chest 1996 Oct;110(4):1111–4 (13 ref.)
Follow-up of aortic dissection: contribution of MR angiography for evaluation of the abdominal aorta and its branches. Bogaert J, et al. **Eur Radiol** 1997;7(5):695–702
Retrograde extension of a chronic type III aortic dissection. Leon M, et al. **J Ark Med Soc** 1997 Jul;94(2):78
Aneurysm of the arch of aorta presenting as an opaque hemithorax. Avasthi G, et al. **J Assoc Physicians India** 1995 Jun;43(6):435–6
Nontraumatic intracranial internal carotid artery dissection: a case report. Newton KI, et al. **J Emerg Med** 1997 Jan–Feb;15(1):19–22
Artifact in SE phase images can mimic aortic dissection. den Boer JA, et al. **J Magn Reson Imaging** 1996 Nov–Dec; 6(6):964–5
Immediate postgadolinium spoiled gradient-echo MRI for evaluating the abdominal aorta in the setting of abdominal MR examination. Kelekis NL, et al.
J Magn Reson Imaging 1997 Jul–Aug;7(4):652–6
Carotid artery dissections presenting as isolated posterior cerebral artery infarctions. Küker W, et al. **J Neurol** 1997 May;244(5):324–7
Extracranial and intracranial vertebrobasilar dissections: diagnosis and prognosis. de Bray JM, et al.
J Neurol Neurosurg Psychiatry 1997 Jul;63(1):46–51
MRI- and MRA-guided therapy of carotid and vertebral artery dissections. Jacobs A, et al. **J Neurol Sci** 1997 Mar 20;147(1):27–34
A young woman fainted. Avery JK. **J Tenn Med Assoc** 1996 Mar;89(3):87–8
Biochemical diagnosis of aortic dissection by raised concentrations of creatine kinase BB-isozyme [letter] Suzuki T, et al. **Lancet** 1997 Sep 13;350(9080):784–5
MRI postoperative monitoring in patients surgically treated for aortic dissection. Di Cesare E, et al.
Magn Reson Imaging 1996;14(10):1149–56
Fibromuscular dysplasia with dissection of basilar artery presenting as "locked-in-syndrome". Arunodaya GR, et al. **Neurology** 1997 Jun;48(6):1605–8
MRI and MR angiography of vertebral artery dissection. Mascalchi M, et al. **Neuroradiology** 1997 May;39(5):329–40
Intracranial aneurysms and cervicocephalic arterial dissections associated with congenital heart disease. Schievink WI, et al. **Neurosurgery** 1996 Oct;39(4):685–9; discussion 689–90
Otologic manifestations of vertebral artery dissection. Strome SE, et al. **Otolaryngol Head Neck Surg** 1997 Feb; 116(2):262–4
Vertebral artery dissection: issues in diagnosis and management. Khurana DS, et al. **Pediatr Neurol** 1996 Apr; 14(3):255–8
Case of intracranial vertebral artery dissection in young age. Tekin S, et al. **Pediatr Neurol** 1997 Jan;16(1):67–70
Prevalence of vertebral artery dissection in Wallenberg syndrome: neuroradiological analysis of 93 patients in the Tohoku District, Japan. Hosoya T, et al. **Radiat Med** 1996 Sep–Oct;14(5):241–6
Review of techniques used to image aortic dissection. Dowd SB, et al. **Radiol Technol** 1996 Jan–Feb;67(3):223–30; quiz 231–2 (34 ref.)
Definitive diagnosis of intramural hematoma of the thoracic aorta with MR imaging [editorial; comment] Bluemke DA. **Radiology** 1997 Aug;204(2):319–21. Comment on: Radiology 1997 Aug;204(2):349–55.
Intramural hematoma of the thoracic aorta: MR image findings and their prognostic implications [see comments] Murray JG, et al. **Radiology** 1997 Aug;204(2):349–55. Comment in: Radiology 1997 Aug;204(2):319–21.
Natural history of a spontaneous dissecting aneurysm of the proximal superior mesenteric artery: report of a case. Nakamura K, et al. **Surg Today** 1997;27(3):272–4
[Dissection of the intracranial arteries. Apropos of 10 cases] Ferro P, et al. **J Neuroradiol** 1996 Dec;23(3):139–48 (Eng. Abstr.) **(Fre)**
[Spontaneous dissection of the internal carotid artery: apropos of a case] Lefebvre P, et al. **Rev Med Brux** 1996 Oct;17(5):342–5 (18 ref.) (Eng. Abstr.) **(Fre)**
[Acute thoracic aortic dissection with occlusion of the left coronary artery] Weber M, et al. **Herz** 1997 Apr; 22(2):104–10 (Eng. Abstr.) **(Ger)**
[Magnetic resonance angiography and magnetic resonance tomography in dissection of the vertebral artery] Felber S, et al. **Radiologe** 1996 Nov;36(11):872–83 (Eng. Abstr.) **(Ger)**
[CT and PRI angiographic findings in dissection of the neck arteries] Link J, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Sep;165(3):244–8 (Eng. Abstr.) **(Ger)**
[Increased serum concentration of myosin heavy chain in aortic dissection: discussion of 2 cases] von Kodolitsch Y, et al. **Z Kardiol** 1997 Jun;86(6):469–73 (Eng. Abstr.) **(Ger)**
[Familial aortic dissection in a young woman. A clinical case and review of the literature] Cucchi G. **Cardiologia** 1997 Feb;42(2):211–3 (22 ref.) (Eng. Abstr.) **(Ita)**
[Diagnostic techniques useful to surgical treatment] Monaca V, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):595–7 **(Ita)**
[Computerized tomography and magnetic resonance in the study of aortic dissection] Sardanelli F, et al.
Cardiologia 1995 Dec;40(12 Suppl 1):583–94 **(Ita)**
[Recent progress of diagnostic imaging for aortic dissection] Takamiya M, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct; 97(10):884–9 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Role of noninvasive graphic diagnosis in acute type A aortic dissection and selection of the adjunct for cerebral protection] Sueda T, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Aug;44(8):1130–5 (Eng. Abstr.) **(Jpn)**
[Localized abdominal aortic dissection] Iino M, et al.
Ryoikibetsu Shokogun Shirizu 1996;(14):411–4 (14 ref.) **(Jpn)**
[A difficult case for the intravital diagnosis of an aortic aneurysm (notes from practice)] Iakimova OG, et al.
Ter Arkh 1996;68(12):75–6 **(Rus)**
[Superior cava vena syndrome, infrequent form of presentation of aortic dissecting aneurysm (letter)] Marcos Sánchez F, et al. **An Med Interna** 1996 Dec;13(12):612 **(Spa)**
[Primary spontaneous bilateral coronary dissection associated with arterial calcinosis] Acoltzin C, et al.
Gac Med Mex 1997 Mar–Apr;133(2):149–50 **(Spa)**

DRUG THERAPY

Successful management of acute aortic dissection in a heart transplant recipient. Defraigne JO, et al. **Acta Chir Belg** 1997 Jun;97(3):141–4 (15 ref.)
Thrombolytic therapy in aortic dissection [letter] Cheng TO. **Am Fam Physician** 1997 Sep 1;56(3):738, 741
Results of long-term medical treatment of patients with arterial hypertension complicated by aortic dissection. Grajek S, et al. **J Hum Hypertens** 1995 Dec;9(12):987–92
Vertebral artery dissection: issues in diagnosis and management. Khurana DS, et al. **Pediatr Neurol** 1996 Apr; 14(3):255–8
[Natural history and prognosis of medical treatment for the patients with aortic dissections] Masuda Y, et al.
Nippon Geka Gakkai Zasshi 1996 Oct;97(10):890–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Traumatic type B aortic dissection. Goverde P, et al.
Acta Chir Belg 1996 Sep–Oct;96(5):233–6
Angiographic evolution of intracoronary thrombus and dissection following percutaneous transluminal coronary angioplasty (the Thrombolysis and Angioplasty in Unstable Angina [TAUSA] trial). Ambrose JA, et al.
Am J Cardiol 1997 Mar 1;79(5):559–63
Traumatic carotid artery dissection. Opeskin K.
Am J Forensic Med Pathol 1997 Sep;18(3):251–7 (44 ref.)

Posttraumatic left ventricular pseudoaneurysm due to intramyocardial dissecting hematoma. Maselli D, et al. **Ann Thorac Surg** 1997 Sep;64(3):830–1

Aortic dissection extending from the left coronary artery during percutaneous coronary angioplasty. Ochi M, et al. **Ann Thorac Surg** 1996 Oct;62(4):1180–2

Marfanoid aneurysm in donor aorta after transplantation. Pathi VL, et al. **Ann Thorac Surg** 1997 Jun;63(6):1770–1

Dissection of the ascending aorta: a late complication of coronary artery bypass grafting. Yaku H, et al. **Ann Thorac Surg** 1996 Dec;62(6):1834–5

Carotid dissection causing stroke in a child with migraine [see comments] Ganesan V, et al. **BMJ** 1997 Jan 25; 314(7076):291–2. Comment in: BMJ 1997 Jan 25;314(7076):243.

Spontaneous coronary artery dissection in young women. Almahmeed WA, et al. **Cathet Cardiovasc Diagn** 1996 Feb; 37(2):201–5

Stenting within a stent for treatment of residual dissection. Hamon M, et al. **Cathet Cardiovasc Diagn** 1997 Mar; 40(3):319–21

Successful repair of intimal dissection following coronary angioplasty with a 48–hour inflation of spiral inflation coil and local delivery of heparin. Shimabukuro M, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):103–5

Persistent cauda equina syndrome following bilateral aortoiliac dissection as a complication of cardiac angiography. Verneuil A, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):377–9

Cardiac involvement in seat belt–related and direct sternal trauma: a prospective study in management implications. Erbel R. **Eur Heart J** 1995 Nov;16(11):1742–3

Effect of balloon angioplasty in femoropopliteal arteries assessed by intravascular ultrasound. van der Lugt A, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):549–56

Cervical artery dissections. Leys D, et al. **Eur Neurol** 1997; 37(1):3–12 (134 ref.)

The risk of aortic dissection in women with Turner syndrome [letter] Birdsall M, et al. **Hum Reprod** 1996 Jul;11(7):1587

Aortic dissection during directional coronary atherectomy. Ohmoto Y, et al. **Int J Cardiol** 1996 Aug;55(3):289–91

Long–term follow–up of coronary artery dissection due to blunt chest trauma with spontaneous healing in a young woman. Masuda T, et al. **Intensive Care Med** 1996 May; 22(5):450–2

Marfan syndrome presenting as fatal ruptured dissecting aneurysm of aorta. Kale MM, et al. **J Assoc Physicians India** 1996 Oct;44(10):734–5

Internal carotid artery dissection following bronchoscopy [letter] Mercier B, et al. **J Neurol** 1996 Apr;243(4):368–9

Dissecting aneurysm of the internal carotid artery after a mandibular osteotomy. Suzuki H, et al. **J Oral Maxillofac Surg** 1997 Jul;55(7):747–50

Aortic dissection after trauma: case report and review of the literature. Rogers FB, et al. **J Trauma** 1996 Nov; 41(5):906–8 (16 ref.)

An unfortunate consequence of being tickled. Nance J, et al. **Lancet** 1997 Apr 19;349(9059):1142

Stroke after a visit to the hairdresser [letter] Nwokolo N, et al. **Lancet** 1997 Sep 20;350(9081):866

Carotid–artery dissection after a prolonged telephone call [letter] Mourad JJ, et al. **N Engl J Med** 1997 Feb 13; 336(7):516

Thoracic aortic dissection complicating autosomal dominant polycystic kidney disease. Paynter HE, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1711–3

Spontaneous dissections [letter; comment] Gilbert GJ. **Neurology** 1997 May;48(5):1475. Comment on: Neurology 1996 Aug;47(2):552–6.

Dissection of the descending aorta after balloon angioplasty of native coarctation. Beitzke A, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):222–5

Image interpretation session: 1996. Traumatic dissection of the internal carotid artery (mural arterial dissection). **Radiographics** 1997 Jan–Feb;17(1):253–6

Infection–associated cervical artery dissection. Three cases. Grau AJ, et al. **Stroke** 1997 Feb;28(2):453–5

Unruptured intracranial vertebral artery dissection. Clinical course and serial radiographic imagings. Yoshimoto Y, et al. **Stroke** 1997 Feb;28(2):370–4 (30 ref.)

Leaking giant aneurysm of the aortic root due to cystic medial necrosis with pericardial tamponade mimicking type–A aortic dissection. Attenhofer CH, et al. **Thorac Cardiovasc Surg** 1996 Apr;44(2):103–4

[Manipulations of cervical vertebrae and trauma of the vertebral artery. Report of two cases] Alimi Y, et al. **J Mal Vasc** 1996;21(5):320–3 (Eng. Abstr.) **(Fre)**

[Carotid dissection during childbirth] Bruninx G, et al. **J Mal Vasc** 1996;21(2):92–4 (Eng. Abstr.) **(Fre)**

[Incidence and management of acute left main coronary artery dissection as a complication of acute transluminal coronary angioplasty] Dittel M, et al. **Z Kardiol** 1996 Sep; 85(9):635–9 (Eng. Abstr.) **(Ger)**

[Acute retrograde dissection of the aorta is a formidable complication in retrograde perfusion through the femoral artery] Matsuzaki K, et al. **Kyobu Geka** 1997 Jun; 50(6):463–5 (Eng. Abstr.) **(Jpn)**

[Aortic dissection after weaning from extracorporeal circulation] Ohashi Y, et al. **Masui** 1996 Oct;45(10):1281–4 (Eng. Abstr.) **(Jpn)**

[Investigation of complications of bronchial artery embolization using superselective catheter system and platinum coil–major complications as vascular detachment] Adachi T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):846–50 (Eng. Abstr.) **(Jpn)**

[Case of thrombotic–occlusive type dissecting aneurysm appeared during the course of thoracic aortic aneurysm] Fukushima S, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):118–20 **(Jpn)**

[Extracranial vertebral artery aneurysm complicating Klippel–Feil syndrome: case report] Shimizu S, et al. **No Shinkei Geka** 1996 Oct;24(10):933–7 (Eng. Abstr.) **(Jpn)**

GENETICS

Familial thoracic aortic dilatations and dissections: a case control study. Biddinger A, et al. **J Vasc Surg** 1997 Mar; 25(3):506–11

Spontaneous multivessel cervical artery dissection in a patient with a substitution of alanine for glycine (G13A) in the alpha 1 (I) chain of type I collagen [see comments] Mayer SA, et al. **Neurology** 1996 Aug;47(2):552–6. Comment in: Neurology 1997 May;48(5):1475.

[Aortic aneurysms in Ullrich–Turner syndrome] Buheitel G, et al. **Klin Padiatr** 1996 Jan–Feb;208(1):42–5 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Review and hypothesis: the eosinophil and peripartum heart disease (myocarditis and coronary artery dissection)—coincidence or pathogenetic significance? Borczuk AC, et al. **Cardiovasc Res** 1997 Mar;33(3):527–32 (54 ref.)

MICROBIOLOGY

Aortic dissection due to Clostridium septicum infection. Monsen T, et al. **Eur J Vasc Endovasc Surg** 1997 May; 13(5):517–8

PARASITOLOGY

A rare case of hydatid cyst perceived as false aneurysm of thoracic aorta. Zakhariev T, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):792–3

PATHOLOGY

Cerebral infarction and intracranial arterial dissection in closed head injury. Rutherfoord GS, et al. **Am J Forensic Med Pathol** 1996 Mar;17(1):53–7

Carotid artery dissection in a young adult: cystic medial necrosis associated with an increased elastase content. Thal DR, et al. **Clin Neuropathol** 1997 Jul–Aug;16(4):180–4

Morphological changes after percutaneous transluminal coronary angioplasty of unstable plaques. Insights from serial angioscopic follow–up [see comments] Bauters C, et al. **Eur Heart J** 1996 Oct;17(10):1554–9. Comment in: Eur Heart J 1996 Oct;17(10):1461–2.

Rupture of dissecting aneurysm in a China Airlines co–pilot. Shaw KP, et al. **Forensic Sci Int** 1996 Aug 15; 81(2–3):157–64

Dissecting aneurysm of the pulmonary artery associated with a large facial cavernous haemangioma. Shanks JH, et al. **Histopathology** 1997 Apr;30(4):390–2

Spontaneous carotid dissection. Israsena N, et al. **J Med Assoc Thai** 1997 Jun;80(6):406–10

Dissection of the vertebral artery with cervical nerve root lesions. Hetzel A, et al. **J Neurol** 1996 Feb;243(2):121–5

Follow–up evaluation of dissecting aneurysms of the vertebrobasilar circulation by using gadolinium–enhanced magnetic resonance imaging. Nagahiro S, et al. **J Neurosurg** 1997 Sep;87(3):385–90

Images in clinical medicine. Traumatic carotid–artery dissection. Matsumura JS, et al. **N Engl J Med** 1996 Oct 31;335(18):1368

Non–aneurysmal subarachnoid hemorrhage associated with basilar artery dissection—autopsy case report. Ogiichi T, et al. **Neurol Med Chir (Tokyo)** 1997 Aug;37(8):612–5

[Helicoidal mode scanning of an aortic dissecting aneurysm] Andreassian B, et al. **Ann Cardiol Angeiol (Paris)** 1997 Mar; 46(3):171 **(Fre)**

[Dissecting aneurysm of the external iliac artery. An unusual course of endofibrosis in an athlete] Del Gallo G, et al. **J Mal Vasc** 1996;21(2):95–7 (Eng. Abstr.) **(Fre)**

[Pathology of aortic dissection] Hosoda Y. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):873–8 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Cystic medial necrosis] Imakita M. **Ryoikibetsu Shokogun Shirizu** 1996;(14):405–7 (18 ref.) **(Jpn)**

[Dissection of the internal carotid artery with subarachnoid hemorrhage] Martín–Bermúdez R, et al. **Rev Neurol** 1997 Jun;25(142):882–3 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The pulsatile pain of acute aortic dissection: a neurosurgeon's personal experience. Hunt WE, et al. **Am Heart J** 1996 Dec;132(6):1267–8

Usefulness of transesophageal echocardiography in detecting changes in flow dynamics responsible for malperfusion phenomena observed during surgery of aortic dissection. Yamada E, et al. **Am J Cardiol** 1997 Apr 15;79(8):1149–52

Aortic root dilatation in patients with spontaneous cervical artery dissection. Tzourio C, et al. **Circulation** 1997 May 20;95(10):2351–3

Evaluation of blood flow patterns of true and false lumens in dissecting aneurysms using MR phase–contrast techniques. Inoue T, et al. **Clin Imaging** 1996 Oct–Dec; 20(4):262–8

Natural history of descending and thoracoabdominal aortic aneurysms. Coselli JS, et al. **J Card Surg** 1997 Mar–Apr; 12(2 Suppl):285–9; discussion 289–91 (24 ref.)

Circadian rhythmicity in the occurrence of spontaneous acute dissection and rupture of thoracic aorta. Gallerani M, et al. **J Thorac Cardiovasc Surg** 1997 Mar;113(3):603–4

Otologic manifestations of vertebral artery dissection. Strome SE, et al. **Otolaryngol Head Neck Surg** 1997 Feb; 116(2):262–4

[Pathophysiology and complications of aortic dissection] Matsuo H. **Nippon Geka Gakkai Zasshi** 1996 Oct; 97(10):879–83 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Isolated hypoglossal nerve palsy as a manifestation of carotid artery dissection. Letter] Carod–Artal J, et al. **Rev Neurol** 1997 Feb;25(138):313–4 **(Spa)**

PREVENTION & CONTROL

Aortic wall structural strengthening by intraluminal net prosthesis to arrest aneurysm progression and to prevent dissection and rupture. Nazari S, et al. **Eur J Cardiothorac Surg** 1996;10(4):264–72

RADIOGRAPHY

Three–dimensional CT imaging of an isolated dissecting aneurysm of the superior mesenteric artery. Hyodoh H, et al. **Abdom Imaging** 1996 Nov–Dec;21(6):515–6

Dual origin of the vertebral artery mimicking dissection. Nogueira TE, et al. **AJNR Am J Neuroradiol** 1997 Feb; 18(2):382–4

Intramural aortic dissection. Wambeek ND, et al. **Australas Radiol** 1996 Nov;40(4):442–6

Fast CT for aortic dissection. Small JH, et al. **Br J Radiol** 1996 Oct;69(826):900–5

Bilateral spontaneous dissecting aneurysm of the internal carotid arteries: report of two cases. Grosman H, et al. **Can Assoc Radiol J** 1996 Oct;47(5):365–9

Prevalence of motion artifact simulating aortic dissection on spiral CT using a 180 degree linear interpolation algorithm for reconstruction of the images. Loubeyre P, et al. **Eur Radiol** 1997;7(3):320–2

Case in point. Chronic aortic dissection. Hariharan R, et al. **Hosp Pract (Off Ed)** 1997 Jul 15;32(7):24

Radiological case of the month. Motion artifact simulating aortic dissection. Nokes SR, et al. **J Ark Med Soc** 1997 Feb;93(9):459–60

Diagnosis and endovascular treatment of midbasilar dissecting aneurysm. Boulanger TH, et al. **J Belge Radiol** 1996 Aug;79(4):171–4

A 52–year–old woman complaining of back pain. Hada Y. **J Cardiol** 1996 Feb;27(2):85–87

Chest pain in an elderly patient. Vilke GM. **J Emerg Med** 1997 Jul–Aug;15(4):523

Angiography in the evaluation of head and neck trauma. Gaskill–Shipley MF, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):607–24 (69 ref.)

Carotid dissection [letter] Janati A. **Neurology** 1996 Aug; 47(2):610–1

Electron–beam CT angiography for thoracic aortic aneurysm and dissection: application of continuous volume scan and electrocardiographically triggered scan. Nakanishi T, et al. **Radiat Med** 1997 May–Jun;15(3):155–61

Spiral CT artifact that simulates aortic dissection: image reconstruction with use of 180 degrees and 360 degrees linear–interpolation algorithms. Loubeyre P, et al. **Radiology** 1997 Oct;205(1):153–7

The dissected aorta: part III. Anatomy and radiologic diagnosis of branch–vessel compromise. Williams DM, et al. **Radiology** 1997 Apr;203(1):37–44

CT scanning as a helpful tool for decision–making during CPR [letter] Ladner E, et al. **Resuscitation** 1996 Apr; 31(2):171–3

[Dissecting hematoma of the thoracic aorta] Fossati P, et al. **J Radiol** 1997 Jul;78(7):517–8 **(Fre)**

[Dissecting aneurysm of an aberrant right subclavian artery: diagnosis with ultrafast–CT] Reittner P, et al. **Aktuelle Radiol** 1996 Jan;6(1):38–40 (8 ref.) (Eng. Abstr.) **(Ger)**

[Traumatically–induced closure with spontaneous recanalization of the internal carotid artery] Bauer KF, et al. **Chirurg** 1997 Feb;68(2):187–9 (Eng. Abstr.) **(Ger)**

[Spiral computerized tomography of acute abdominal aortic aneurysm with optimal 3–D image reconstruction] Holland BR, et al. **Chirurg** 1996 Jan;67(1):44–52 (Eng. Abstr.) **(Ger)**

[CT angiography in dissections of the internal carotid artery. Value of a new examination technique in comparison with DSA and Doppler ultrasound] Egelhof T, et al. **Radiologe** 1996 Nov;36(11):850–4 (Eng. Abstr.) **(Ger)**

[Conventional therapeutic strategy in PTCA–induced dissection: long–term re–PTCA, early re–coronary angiography] Jacksch R, et al. **Z Kardiol** 1996;85 Suppl 1:49–57 (Eng. Abstr.) **(Ger)**

[Imaging techniques in aortic dissection. Diagnosis with angiography] Orzan F, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):579–82 **(Ita)**

[A 71-year-old woman complaining of right arm and shoulder pain followed by fever] Hashimoto S, et al. **J Cardiol** 1997 Mar;29(3):177–8 **(Jpn)**

[Chest radiographic diagnosis of dissecting thoracic descending aorta] Momiyama Y, et al. **J Cardiol** 1997 Mar; 29(3):157–62 (Eng. Abstr.) **(Jpn)**

[A 69-year-old woman with unconsciousness] Morimoto K, et al. **J Cardiol** 1996 Aug;28(2):113–4 **(Jpn)**

[A case of DeBakey type IIIb acute aortic dissection extending through an atherosclerotic abdominal aortic aneurysm] Iino M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Nov; 56(13):985–7 (Eng. Abstr.) **(Jpn)**

[A case of spontaneous cervical internal carotid artery dissection] Shimada J, et al. **No Shinkei Geka** 1997 Jan; 25(1):67–71 (Eng. Abstr.) **(Jpn)**

[Traumatic dissecting aneurysm] Hayashi T. **Ryoikibetsu Shokogun Shirizu** 1996;(14):322–4 (9 ref.) **(Jpn)**

[Acute occlusion of aortic aneurysms] Yasuda K. **Ryoikibetsu Shokogun Shirizu** 1996;(14):395–8 (13 ref.) **(Jpn)**

[Computerized tomography in aortic pathology] Lecumberri Olaverri F, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:27–36 (54 ref.) (Eng. Abstr.) **(Spa)**

[Asymptomatic aortic dissection in a patient with aortic valve prosthesis] Sánchez Calle JM, et al. **Rev Esp Cardiol** 1997 Apr;50(4):287–9 (Eng. Abstr.) **(Spa)**

[Angiography of the aorta] Soto B, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:52–62 (31 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Detection of a dissecting aortic aneurysm by renal transplant imaging. Andreas J, et al. **Clin Nucl Med** 1997 Mar; 22(3):182

SURGERY

High frequency jet ventilation for severe pulmonary hemorrhage during aortic dissection operation--a case report. Cheng KS, et al. **Acta Anaesthesiol Sin** 1997 Mar; 35(1):51–4

Treatment of dissecting basilar artery aneurysm by flow reversal. Amin-Hanjani S, et al. **Acta Neurochir (Wien)** 1997;139(1):44–51 (38 ref.)

Demonstration of false lumen perfusion during repair of type A aortic dissection. Voci P, et al. **Anesthesiology** 1996 Oct; 85(4):926–8

Paraplegia after thoracoabdominal aortic aneurysm repair: is dissection a risk factor? Coselli JS, et al. **Ann Thorac Surg** 1997 Jan;63(1):28–35; discussion 35–6

Treatment of aortic dissection and ruptured abdominal aneurysm with coronary bypass. Ghalili KC, et al. **Ann Thorac Surg** 1997 Jan;63(1):223–5

1989: New technique for repair of ascending thoracic aortic dissections. Updated in 1997. Hammond GL. **Ann Thorac Surg** 1997 Jan;63(1):287

Successful surgical repair of aortic dissection presenting with complete heart block. Jessen ME, et al. **Ann Thorac Surg** 1996 Oct;62(4):1202–3

Recurrent aortic dissection after orthotopic heart transplantation. Mullen JC, et al. **Ann Thorac Surg** 1996 Dec;62(6):1830–1

Surgical treatment of acute type B aortic dissection using an endoprosthesis (elephant trunk). Palma JH, et al. **Ann Thorac Surg** 1997 Apr;63(4):1081–4

Operation for type B aortic dissection using hypothermic selective cerebral perfusion. Tayama K, et al. **Ann Thorac Surg** 1997 Feb;63(2):535–7

Long-term results of flow reversal and thromboexclusion method for thoracic aortic aneurysm. Urayama H, et al. **Ann Thorac Surg** 1997 Mar;63(3):716–20

Surgical treatment of dissecting aneurysm of the interventricular septum. Wu Q. **Ann Thorac Surg** 1997 Feb; 63(2):545–7

Open distal anastomosis in retrograde cerebral perfusion for repair of ascending aortic dissection. Yamashita C, et al. **Ann Thorac Surg** 1997 Sep;64(3):665–9

Successful treatment of an iatrogenic infrarenal aortic dissection with serial Wallstents. Johnson MS, et al. **Ann Vasc Surg** 1997 May;11(3):295–9

Use of percutaneous cardiopulmonary support system with rotary blood pump in graft replacement of the descending thoracic and thoracoabdominal aorta. Watanabe S, et al. **Artif Organs** 1997 Jul;21(7):846–51

Temporary left external axillofemoral bypass during repair of a leaking type B aortic dissection. Taylor PR, et al. **Br J Surg** 1997 Mar;84(3):423

Surgical management of type A aortic dissection: evaluation of predisposing factors for postoperative neurologic complication and late reoperation. Ahn H, et al. **Cardiovasc Surg** 1997 Feb;5(1):104–11

Surgical treatment for acute aortic arch dissection. Suda H, et al. **Cardiovasc Surg** 1996 Jun;4(3):315–9

Circulatory management with retrograde cerebral perfusion for acute type A aortic dissection. Bavaria JE, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II173–6

New graft-implanting method for thoracic aortic aneurysm or dissection with a stented graft. Kato M, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II188–93

A rare case of gastrointestinal hemorrhage: aortoesophageal fistula following repair of aortic dissection. Kirchgatterer A, et al. **Endoscopy** 1997 Feb;29(2):137–8

Pacemaker twiddler's syndrome: delayed transection of permanent ventricular lead [letter] Said SA, et al. **Eur Heart J** 1996 Dec;17(12):1914–5

Protection of the spinal cord during surgery of thoraco-abdominal aortic aneurysms. Bachet J, et al. **Eur J Cardiothorac Surg** 1996;10(10):817–25

Radical replacement of the aortic root in acute type A dissection: indications and outcome. Ergin MA, et al. **Eur J Cardiothorac Surg** 1996;10(10):840–4; discussion 845

Late complications after surgical exclusion of the thoracic aorta. Gontijo B, et al. **Eur J Cardiothorac Surg** 1996; 10(7):590–2

Early and late outcome of operated and non-operated acute dissection of the descending aorta. Gysi J, et al. **Eur J Cardiothorac Surg** 1997 Jun;11(6):1163–9; discussion 1169–70

Percutaneous occlusion of the entry to a leaking false aneurysm after ascending aortic replacement for aortic dissection type A facilitating surgical repair. Henriques JP, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):381–3

Aortic root replacement in type A dissection [letter] Moriyama Y, et al. **Eur J Cardiothorac Surg** 1997 Aug; 12(2):325–6

Surgery for aortic dissection with intimal tear in the transverse aortic arch. Okita Y, et al. **Eur J Cardiothorac Surg** 1996;10(9):784–90

Surgery of the thoracic aorta with hypothermic circulatory arrest: experience with retrograde perfusion via the superior vena cava and demonstration of cerebral perfusion. Pagano D, et al. **Eur J Cardiothorac Surg** 1996;10(10):833–8; discussion 839

Aprotinin and deep hypothermic circulatory arrest: there are no benefits even when appropriate amounts of heparin are given. Parolari A, et al. **Eur J Cardiothorac Surg** 1997 Jan; 11(1):149–56

Aortic dissection type A versus type B: a different post-surgical death hazard? Rizzoli G, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):202–8

Retrograde cerebral perfusion through antero-axillary thoracotomy in the aortic arch surgery. Sasaguri S, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):657–60

Composite graft in annulo-aortic ectasia. Nineteen years' experience without graft inclusion. Savunen T, et al. **Eur J Cardiothorac Surg** 1996;10(6):428–32

Surgery of the thoracic aorta using deep hypothermic total circulatory arrest. Are there neurological consequences other than frank cerebral defects? Welz A, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):650–6

Four-channeled aortic dissection and rupture. Yagyu K, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):315–8

Ambulatory follow-up of aortic dissection: comparison between computed tomography and biplane transesophageal echocardiography [see comments] Maffei S, et al. **Int J Card Imaging** 1996 Jun;12(2):105–11. Comment in: Int J Card Imaging 1996 Jun;12(2):137–8.

Clinical and echocardiographical study of the aortic homograft implantations in patients with Marfan syndrome. Podolec P, et al. **Int J Cardiol** 1997 Jun 27;60(1):41–7

Spontaneous dissection of the left main coronary artery: a case report and review of the literature. Atay Y, et al. **J Card Surg** 1996 Sep-Oct;11(5):371–5 (49 ref.)

Current practice in Marfan's syndrome and annulo-aortic ectasia: aortic root replacement with a composite graft over a twenty-year period. Bachet J, et al. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):157–66

The proper use of glue: a 20-year experience with the GRF glue in acute aortic dissection. Bachet J, et al. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):243–53; discussion 253–5 (30 ref.)

Diagnosis and management of cerebral malperfusion phenomena during aortic dissection repair by transesophageal Doppler echocardiographic monitoring. Coletti G, et al. **J Card Surg** 1996 Sep-Oct;11(5):355–8

Current practice in Marfan's aortic root surgery: reconstruction with aortic valve preservation or replacement? What to do with the mitral valve? David TE. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):147–50

Identification of risk factors in patients undergoing thoracoabdominal aneurysm repair. Galla JD, et al. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):292–9

Aortic root surgery in Marfan syndrome: current practice and evolving techniques. LeMaire SA, et al. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):137–41 (38 ref.)

The Bentall procedure in patients with Marfan's syndrome. Nguyen KH, et al. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):142–6

Operative results of thoracoabdominal repair for chronic type B aortic dissection. Dudra J, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):147–51

A case of Turner's syndrome associated with partial anomalous pulmonary venous return complicated by dissecting aortic aneurysm and aortic regurgitation. Shiroma K, et al. **J Cardiovasc Surg (Torino)** 1997 Jun; 38(3):257–9

Directly visualized cerebral circulation during retrograde cerebral perfusion. Yoshimura N, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):553–6

Clinical endovascular placement of branched graft for type B aortic dissection. Inoue K, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):1111–3

Extended aortic replacement for acute type A dissection with the tear in the descending aorta. Kazui T, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):973–8

Surgical treatment of ascending aortic dissecting aneurysm--clinical application of modified Cabrol's operation. Yang C, et al. **J Tongji Med Univ** 1996;16(2):96–8

Use of a stone basket as a target during fenestration of aortic dissection. Trerotola SO. **J Vasc Interv Radiol** 1996 Sep-Oct;7(5):687–90

Regarding "Endoluminal repair of atypical dissecting aneurysm of descending thoracic aorta and fusiform aneurysm of the abdominal aorta" [letter; comment] Sandmann W. **J Vasc Surg** 1996 Oct;24(4):698–700. Comment on: J Vasc Surg 1995 Aug;22(2):167–72.

Abdominal aortic tailoring for renal, visceral, and lower extremity malperfusion resulting from acute aortic dissection. Webb TH, et al. **J Vasc Surg** 1997 Sep; 26(3):474–80; discussion 480–1

Non clamping anastomosis of the ascending and arch aneurysm using retrograde cerebral perfusion. Yamashita C, et al. **Kobe J Med Sci** 1996 Aug;42(4):261–70

Acute dissecting aortic aneurysm in an operational environment. Henning KS. **Mil Med** 1997 Aug;162(8):573–4 (5 ref.)

Endovascular stenting of a traumatic dissecting aneurysm of the extracranial internal carotid artery--case report. Miyachi S, et al. **Neurol Med Chir (Tokyo)** 1997 Mar; 37(3):270–4

Dissecting aneurysms of the anterior cerebral artery and accessory middle cerebral artery. Case report. Otawara Y, et al. **Neurosurg Rev** 1997;20(2):145–8

Cervical-to-petrous internal carotid artery saphenous vein in situ bypass for the treatment of a high cervical dissecting aneurysm: technical case report. Candon E, et al. **Neurosurgery** 1996 Oct;39(4):863–6

Dissection of an aneurysmic ascending aorta in a child with atresia of the aortic isthmus. Lindinger A, et al. **Pediatr Cardiol** 1997 Mar-Apr;18(2):146–8

Acute dissection of ascending aortic aneurysm in a patient with previous coronary artery bypass grafting. Savunen T, et al. **Scand Cardiovasc J** 1997;31(3):161–3

Spontaneous double vessel coronary artery dissection. A case report and surgical management. Singh RS, et al. **Scand Cardiovasc J** 1997;31(3):181–3

Surgical implication of aortic dissection on long-term outcome in Marfan patients. Hayashi J, et al. **Surg Today** 1996;26(12):980–4 (19 ref.)

Modified Bentall operation with concomitant total aortic arch replacement for DeBakey type I aortic dissection: report of a case. Katoh T, et al. **Surg Today** 1997; 27(4):373–5

Extensive replacement of the aorta from the ascending aorta to the supraceliac abdominal aorta during a one-stage operation. Murashita T, et al. **Surg Today** 1997;27(4):368–72

Emergency aortic arch replacement in a patient with idiopathic thrombocytopenic purpura. Usui A, et al. **Surg Today** 1996;26(10):828–30

Repair of acute dissection of the ascending aorta associated with aortic coarctation. Tesler UF, et al. **Tex Heart Inst J** 1996;23(2):170–3

Use of the retrograde "pull-through" technique. Vitali E, et al. **Tex Heart Inst J** 1997;24(2):114–7

[Causes of failure in surgical treatment of acute dissection of the ascending aorta (type A)] Hejnal J, et al. **Vnitr Lek** 1996 Aug;42(8):524–7 (Eng. Abstr.) **(Cze)**

[Abdominal aortic aneurysm: surgery, indications, technique, outcome] Prager M, et al. **Acta Med Austriaca** 1997; 24(1):10–4 (Eng. Abstr.) **(Ger)**

[Early results in the surgical treatment of type B aortic dissection] Genoni M, et al. **Schweiz Med Wochenschr** 1997 Feb 8;127(6):208–13 (Eng. Abstr.) **(Ger)**

[Directional coronary atherectomy in coronary dissection?] Höfling B. **Z Kardiol** 1996;85 Suppl 1:59–66 (Eng. Abstr.) **(Ger)**

[Direct coronary bypass operation in complicated coronary dissection] Reidemeister JC, et al. **Z Kardiol** 1996;85 Suppl 1:67–72 (30 ref.) (Eng. Abstr.) **(Ger)**

[Acute type A dissection of the ascending aorta after aortocoronary bypass operation] Staubach P, et al. **Z Kardiol** 1996 Sep;85(9):668–72 (Eng. Abstr.) **(Ger)**

[Extracranial carotid aneurysms] Hepp W. **Zentralbl Chir** 1996;121(12):1058–62 (Eng. Abstr.) **(Ger)**

[Total proximal reconstruction of chronic aortic dissection in patients with Marfan syndrome] Szabolcs Z, et al. **Orv Hetil** 1997 Mar 16;138(11):681–5 (Eng. Abstr.) **(Hun)**

[Our experience in the surgery of thoracic aorta] Fesani F, et al. **Acta Biomed Ateneo Parmense** 1995;66(5):217–22 (Eng. Abstr.) **(Ita)**

[Diagnostic techniques useful to surgical treatment] Monaca V, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):595–7 **(Ita)**

[Surgery of the ascending aorta: the 1984–1995 experience of the cardiac surgery teaching unit in the University of Milan. Multivariate analysis of its risk factors for hospital mortality and reduced long-term survival] Spirito R, et al. **G Ital Cardiol** 1997 Aug;27(8):775–85 (Eng. Abstr.) **(Ita)**

[Surgery of the descending thoracic and thoraco-abdominal arteries. Report of 105 cases] Zanetti PP, et al. **G Ital Cardiol** 1997 Jul;27(7):682–5 (Eng. Abstr.) **(Ita)**

[A multi-center study on medical and surgical management

in patients with aortic aneurysm and dissection from 1988 through 1993] Hayashi J, et al. **J Cardiol** 1996 Jun; 27(6):335–8 **(Jpn)**

[Surgical treatment of aortic dissection (Stanford type A) using hypothermic retrograde cerebral perfusion in patients older than 70 years of age] Ataka K, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):641–4 (Eng. Abstr.) **(Jpn)**

[Surgery for acute type A aortic dissection associated with Marfan syndrome] Furukawa K, et al. **Kyobu Geka** 1996 Jul;49(7):548–51 (Eng. Abstr.) **(Jpn)**

[A successful case of infrarenal abdominal aortic replacement against acute abdominal organ failures and ischemia of bilateral lower limbs following the operation of DeBakey IIIb–type dissecting aneurysm] Gu K, et al. **Kyobu Geka** 1996 Dec;49(13):1100–3 (Eng. Abstr.) **(Jpn)**

[A case report of coronary artery bypass grafting (CABG) and graft replacement of the ascending aorta for coronary artery disease associated with dissection of the ascending aorta] Hanada T, et al. **Kyobu Geka** 1997 Jul;50(7):557–9 (Eng. Abstr.) **(Jpn)**

[Concomitant composite graft replacement of the aortic root and the aortic arch for type A aortic dissection] Kikuchi Y, et al. **Kyobu Geka** 1997 Jun;50(6):469–74 (Eng. Abstr.) **(Jpn)**

[The surgical results of aged thoracic aortic aneurysm] Kunihara T, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):627–31 (Eng. Abstr.) **(Jpn)**

[Surgical treatment for recrudescent Stanford type A early closing dissection] Kuwabara M, et al. **Kyobu Geka** 1996 Jul;49(7):575–8 (Eng. Abstr.) **(Jpn)**

[A case report of type A dissection of the aorta presenting as a superior vena cava syndrome 10 years after aortic valve replacement] Murai N, et al. **Kyobu Geka** 1997 Feb; 50(2):146–9 (Eng. Abstr.) **(Jpn)**

[A case of redo operation for ascending aortic aneurysm after modified Bentall operation for Marfan syndrome associated with type A acute dissecting aortic aneurysm] Murashita T, et al. **Kyobu Geka** 1996 Jul;49(7):579–82 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of thoracic aorta for elderly patient] Nakai M, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):622–6 (Eng. Abstr.) **(Jpn)**

[A case report of sudden death after Bentall's operation (Piehler's modification) due to left coronary occlusion] Nonoyama M, et al. **Kyobu Geka** 1997 Jul;50(7):569–72 (Eng. Abstr.) **(Jpn)**

[Constrictive pericarditis with dissecting aortic aneurysm (DeBakey type II)] Nosaka S, et al. **Kyobu Geka** 1996 Aug; 49(9):759–61 (Eng. Abstr.) **(Jpn)**

[Combined surgery for coronary artery disease and thoracic aortic disease] Ohashi H, et al. **Kyobu Geka** 1997 Apr; 50(4):263–7; discussion 267–9 (Eng. Abstr.) **(Jpn)**

[Redo operation after surgery for aortic aneurysm and dissection] Ohmi M, et al. **Kyobu Geka** 1997 Jul;50(7):523–8; discussion 528–30 (Eng. Abstr.) **(Jpn)**

[Abdominal aortic surgery in Stanford type B chronic dissecting aortic aneurysm] Sakurada T, et al. **Kyobu Geka** 1997 Apr;50(4):270–4 (Eng. Abstr.) **(Jpn)**

[A case of successful surgical treatment of recurrent Stanford type A thrombosed aortic dissection] Sakurada T, et al. **Kyobu Geka** 1997 Mar;50(3):223–5 (Eng. Abstr.) **(Jpn)**

[Obstruction of the true lumen by retrograde perfusion during repair of DeBakey type I aortic dissection: a case report] Tsuda K, et al. **Kyobu Geka** 1996 May;49(5):372–5 (Eng. Abstr.) **(Jpn)**

[Ascending aortic aneurysms operated through redo median sternotomy under selective cerebral perfusion] Yamazaki Y, et al. **Kyobu Geka** 1997 Mar;50(3):190–3 (Eng. Abstr.) **(Jpn)**

[The surgical treatment for acute aortic dissection and changing concept of surgical procedures] Nakajima N. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):900–5 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Recent progress in adjunctive methods during surgery of aortic dissection] Takamoto S. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):894–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A successful surgical treatment of dissecting thoracoabdominal aortic aneurysm using a heparin coated percutaneous cardiopulmonary support system] Tanaka H, et al. **Nippon Geka Gakkai Zasshi** 1997 May;98(5):524–8 (Eng. Abstr.) **(Jpn)**

[Operative results and long-term prognosis of aortic dissections] Ueda T, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):916–20 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Evolution and recent trends in patient selection and reconstruction method for chronic aortic dissection] Yasuda K, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct; 97(10):906–15 (30 ref.) (Eng. Abstr.) **(Jpn)**

[A case of extended surgery in acute aortic dissection by perfusion into extra anatomic bypass] Fujii H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul;44(7):1003–7 (Eng. Abstr.) **(Jpn)**

[Surgical strategy for Stanford type A aortic dissection with Marfan syndrome] Fukada J, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):724–8 (Eng. Abstr.) **(Jpn)**

[Surgical outcomes of transverse aortic arch replacement] Fukuda I, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):718–23 (Eng. Abstr.) **(Jpn)**

[Urgent replacement of aortic arch and descending aorta following replacement of ascending aorta for Stanford a aortic dissection--a case report] Hata H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jan;45(1):102–7 (Eng. Abstr.) **(Jpn)**

[Debakey IIIb aortic dissection from a distal arch atherosclerotic aneurysm--a case report] Hayashi S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):569–71 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical treatment of type A acute aortic dissection--experience of hypothermic circulatory arrest associated with the cerebroplegia] Hirotani T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):556–62 (Eng. Abstr.) **(Jpn)**

[A successful surgical case report of acute aortic dissection involving entire sinus of Valsalva] Jung E, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):913–8 (Eng. Abstr.) **(Jpn)**

[Stent graft treatment for two cases of DeBakey IIIb dissecting aortic aneurysm] Kawaguchi S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):926–33 (Eng. Abstr.) **(Jpn)**

[Two cases of annulo-aortic ectasia with type A aortic dissection reconstructed by reimplantation of the aortic valve] Konishi T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):611–4 (Eng. Abstr.) **(Jpn)**

[Extended total aortic arch replacement involving the proximal descending aorta through a median sternotomy] Kurimoto Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):661–5 (Eng. Abstr.) **(Jpn)**

[Surgical repair of a dissecting aortic aneurysm with entry at proximal descending aorta through left thoracotomy--a case report] Mitsumaru A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug;44(8):1163–7 (Eng. Abstr.) **(Jpn)**

[Clinical experience with the gelatin-resorcine-formol biological glue in acute type A aortic dissection] Moriyama Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May; 45(5):682–6 (Eng. Abstr.) **(Jpn)**

[A simultaneous operation of aortic root, arch replacement, and sternal elevation for Marfan's syndrome--a case report] Ohhira M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):759–63 (Eng. Abstr.) **(Jpn)**

[Surgical treatment for acute dissection associated with thoracic aneurysm--a case report and a review of Japanese literatures] Ohki S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug;44(8):1151–4 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Results and keypoints in emergency surgery of true and dissecting aortic aneurysms] Omi M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Mar;45(3):339–41 **(Jpn)**

[Successful surgical treatment of intraoperative aortic dissection complicating aortic valve replacement] Ozaki S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul; 44(7):1022–6 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of aortic dissection with ringed intraluminal graft--late results and fate of the false lumen] Sasaki K. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul; 44(7):923–35 (Eng. Abstr.) **(Jpn)**

[Successful surgical repair of acute DeBakey type I aortic dissection complicated by acute occlusion of the suprarenal abdominal aorta] Shiiya N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):682–6 (Eng. Abstr.) **(Jpn)**

[Subtotal aortic replacement in a patient with Marfan's syndrome--replacement of the ascending aorta and entire aortic arch for acute type I aortic dissection 4 years after the thoracoabdominal replacement] Shiiya N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Nov;44(11):2095–9 (Eng. Abstr.) **(Jpn)**

[Acute aortic dissection complicated with acute myocardial infarction--a case report of successful operation for the case of DOA] Tayama K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul;44(7):965–9 (Eng. Abstr.) **(Jpn)**

[Surgery for acute aortic dissection extending to the aortic root using gelatine-resorcine-formol biological glue--a case report] Uchida K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul;45(7):1024–7 (Eng. Abstr.) **(Jpn)**

[Bleeding from unruptured dissecting aneurysm in the vertebral artery after proximal clipping] Hirano A, et al. **No Shinkei Geka** 1995 Dec;23(12):1135–9 (Eng. Abstr.) **(Jpn)**

[A case of traumatic extracranial internal carotid artery dissecting aneurysm treated by proximal ligation and STA-MCA bypass] Ueyama T, et al. **No Shinkei Geka** 1997 Mar;25(3):253–8 (Eng. Abstr.) **(Jpn)**

[Management and long-term follow-up results in patients with carotid artery dissection] Uno M, et al. **No Shinkei Geka** 1997 May;25(5):417–23 (Eng. Abstr.) **(Jpn)**

[New coronary tube for Cabrol's technique] Yokoyama M, et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):160–2 (Eng. Abstr.) **(Jpn)**

[Clinical usefulness of intraoperative color Doppler sonography in the operation of the dissecting aortic aneurysm] Yozu R, et al. **Rinsho Kyobu Geka** 1989 Aug; 9(4):401–5 (Eng. Abstr.) **(Jpn)**

[Immediate and late results of the surgical treatment of the aneurysms and dissections of the ascending aorta] Couto WJ, et al. **Arq Bras Cardiol** 1996 Jun;66(6):349–52 (Eng. Abstr.) **(Por)**

[Surgery for acute type-A aortic dissection] Brazão A, et al. **Rev Port Cardiol** 1997 Jun;16(6):525–32, 507 (40 ref.) (Eng. Abstr.) **(Por)**

[A case of in vivo diagnosis of compound aortic aneurysm successfully treated surgically] Volkov GG, et al. **Klin Med (Mosk)** 1996;74(3):61–2 **(Rus)**

[Aortic valve prosthesis and the plication of a dissecting aneurysm of the ascending aorta in a patient with infectious endocarditis against a background of chronic kidney failure and its management by regular hemodialysis] Uglov FG, et al. **Vestn Khir Im I I Grek** 1996;155(2):9–14 (28 ref.) (Eng. Abstr.) **(Rus)**

[Surgery of type A acute aortic dissection. Past, present and future] Canestri A, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:77–84 (Eng. Abstr.) **(Spa)**

[Surgical treatment of the pathology of the descending aorta. Aneurysm and dissection] Lisbona Sabater C, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:85–91 (Eng. Abstr.) **(Spa)**

THERAPY

Dissecting aneurysms of all four cervicocranial arteries in fibromuscular dysplasia: treatment with self-expanding endovascular stents, coil embolization, and surgical ligation. Manninen HI, et al. **AJNR Am J Neuroradiol** 1997 Aug; 18(7):1216–20

Isolated dissecting aneurysm of the left posterior inferior cerebellar artery: endovascular treatment with a Guglielmi detachable coil. Tikkakoski T, et al. **AJNR Am J Neuroradiol** 1997 May;18(5):936–8

Percutaneous fenestration of aortic dissection: salvage of an ischemic solitary left kidney. Park JH, et al. **Cardiovasc Intervent Radiol** 1997 Mar-Apr;20(2):146–8

Stent treatment of obstructing dissection after percutaneous transluminal angioplasty of aortic stenosis caused by nonspecific aortitis. Sharma S, et al. **Cardiovasc Intervent Radiol** 1997 Sep-Oct;20(5):377–9

Treatment of spontaneous coronary artery dissection: report of three cases. Klutstein MW, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):372–6

New alternative for the treatment of spontaneous dissection [editorial] Satler LF. **Cathet Cardiovasc Diagn** 1996 Feb; 37(2):206–7

Coronary stenting for aortocoronary dissection following balloon angioplasty. Seifein HB, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):222–5

Successful repair of intimal dissection following coronary angioplasty with a 48-hour inflation of spiral inflation coil and local delivery of heparin. Shimabukuro M, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):103–5

Transcatheter Inoue endovascular graft for treatment of canine aortic dissection. Htay T, et al. **Heart Vessels** 1996; 11(2):80–5

Spontaneous coronary dissection: management by coronary angioplasty followed by successful renal transplantation. Kapoor A, et al. **Indian Heart J** 1997 Jan-Feb;49(1):71–2

Natural history of aneurysms of the descending and thoracoabdominal aorta. Svensson LG. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):279–84 (40 ref.)

Emergent interventional transcatheter revascularization in acute right coronary artery dissection after blunt chest trauma. Thorban S, et al. **J Trauma** 1997 Aug;43(2):365–7

Emergent treatment of iatrogenic dissection of the internal carotid artery with the Palmaz-Schatz stent--case report. Yamashita K, et al. **Neurol Med Chir (Tokyo)** 1997 Apr; 37(4):336–9

Endovascular treatment of a dissecting posteroinferior cerebellar artery aneurysm: case report. Lefkowitz MA, et al. **Neurosurgery** 1996 Nov;39(5):1036–8; discussion 1038–9

Treatment of dissecting pseudoaneurysm of the cervical internal carotid artery using a wall stent and detachable coils: case report. Perez-Cruet MJ, et al. **Neurosurgery** 1997 Mar;40(3):622–5; discussion 625–6

True lumen obliteration in complicated aortic dissection: endovascular treatment. Slonim SM, et al. **Radiology** 1996 Oct;201(1):161–6

[Implantation of coronary stent during the acute phase of myocardial infarction for treatment of dissection or partial result after angioplasty. Immediate results and angiographic follow-up] Maillard L, et al. **Arch Mal Coeur Vaiss** 1997 Feb;90(2):253–61 (Eng. Abstr.) **(Fre)**

[Intravascular ultrasound for monitoring percutaneous fenestration of a membrane from an aortic dissection] Görge G, et al. **Dtsch Med Wochenschr** 1996 Dec 20; 121(51-52):1598–602 (Eng. Abstr.) **(Ger)**

[Emergency stent implantation in the area of extensive muscle bridging of the anterior interventricular ramus after post-interventional dissection] Jeremias A, et al. **Z Kardiol** 1997 May;86(5):367–72 (Eng. Abstr.) **(Ger)**

[Interventional coronary revascularization in a patient with chronic dissection of the ascending aorta] von Kodolitsch Y, et al. **Z Kardiol** 1996 Sep;85(9):673–6 (Eng. Abstr.) **(Ger)**

[Retrograde aortic dissection during cardiopulmonary bypass a case report successfully treated by contralateral femoral cannulation] Saito T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct;44(10):1953–7 (Eng. Abstr.) **(Jpn)**

[Usefulness of the interlocking detachable coil for the

repeatedly ruptured dissecting aneurysm of the vertebral artery in the acute stage] Nakada M, et al. **No Shinkei Geka** 1997 Jan;25(1):57–60 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Acute aortic dissection: association with patent ductus arteriosus. Cusick DA, et al. **Am J Card Imaging** 1996 Jul; 10(3):200–3

Usefulness of transesophageal echocardiography in detecting changes in flow dynamics responsible for malperfusion phenomena observed during surgery of aortic dissection. Yamada E, et al. **Am J Cardiol** 1997 Apr 15;79(8):1149–52

Spontaneous dissections of the internal carotid artery: appearances on colour Doppler ultrasound. Sidhu PS, et al. **Br J Radiol** 1997 Jan;70:50–7

Opacification of the thoracic aorta after venous injection of sonicated albumin microbubbles. Implications for aortic dissection. Voci P. **Cardiologia** 1997 Mar;42(3):299–304

Multiplane transesophageal echocardiography in traumatic aortic dissection: a case report. Liao WB, et al. **Chang Keng I Hsueh** 1995 Dec;18(4):383–6

Use of transesophageal echocardiography for diagnosis of traumatic aortic injury. Goarin JP, et al. **Chest** 1997 Jul; 112(1):71–80

The aorta. Aortic aneurysm, trauma, and dissection. Erbel R, et al. **Crit Care Clin** 1996 Jul;12(3):733–66 (135 ref.)

Spontaneous echocardiographic contrast in the true lumen of a dissected aortic aneurysm. Allan JJ, et al. **J Am Soc Echocardiogr** 1997 Jul–Aug;10(6):673–6

Spectrum of acute dissection of the ascending aorta: a transesophageal echocardiographic study. Armstrong WF, et al. **J Am Soc Echocardiogr** 1996 Sep–Oct;9(5):646–56

Tortuosity of the descending thoracic aorta simulating dissection on transesophageal echocardiography. Katz ES, et al. **J Am Soc Echocardiogr** 1997 Jan–Feb;10(1):83–7

Echocardiographic diagnosis of right and left sinus of Valsalva aneurysms dissecting into the ventricular septum. Silance PG, et al. **J Am Soc Echocardiogr** 1996 Mar–Apr; 9(2):190–4 (12 ref.)

The role of echocardiography in the diagnosis of aortic dissection. Treasure T, et al. **J Heart Valve Dis** 1996 Nov; 5(6):623–9 (13 ref.)

The role of transcranial Doppler sonography in the identification of patients at risk of cerebral and brainstem ischemia. Terenzi TJ, et al. **J Manipulative Physiol Ther** 1996 Jul–Aug;19(6):406–14 (61 ref.)

False-positive diagnosis of ascending aorta dissection by single-plane transesophageal echocardiography. Neri E, et al. **J Thorac Cardiovasc Surg** 1996 Nov;112(5):1387–9

The dissected aorta: part II. Differentiation of the true from the false lumen with intravascular US. Lee DY, et al. **Radiology** 1997 Apr;203(1):32–6

The dissected aorta: part I. Early anatomic changes in an in vitro model. Williams DM, et al. **Radiology** 1997 Apr; 203(1):23–31

[Aortic intramural hematoma. A rare new clinical form of aortic dissection] Bolognesi R, et al. **Cardiologia** 1997 Aug; 42(8):789–94 (27 ref.) **(Ita)**

[Transesophageal and intravascular echocardiographic imaging in aortic dissection] Memmola C, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):575–8 **(Ita)**

[Recent progress in adjunctive methods during surgery of aortic dissection] Takamoto S. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):894–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical usefulness of intraoperative color Doppler sonography in the operation of the dissecting aortic aneurysm] Yozu R, et al. **Rinsho Kyobu Geka** 1989 Aug; 9(4):401–5 (Eng. Abstr.) **(Jpn)**

[A case report of thoracic aortic and common carotid artery dissecting aneurysm diagnosed by duplex ultrasound examination] Kimura K, et al. **Rinsho Shinkeigaku** 1996 Feb;36(2):348–51 (Eng. Abstr.) **(Jpn)**

[Extrinsic compression of the left atrium as an infrequent and fatal form of type B aortic dissection: value of ECG] Vicente T, et al. **Rev Esp Cardiol** 1997 Aug;50(8):590–2 (Eng. Abstr.) **(Spa)**

[Echocardiography and aortic dissection] Vilacosta I, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:13–26 (82 ref.) (Eng. Abstr.) **(Spa)**

ANEURYSM, FALSE

[Pseudoaneurysm] Koike A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):434–7 (28 ref.) **(Jpn)**

[Spontaneous perforation of the atherosclerotic aorta] Origuchi N, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (14):399–402 (22 ref.) **(Jpn)**

[Coronary pseudoaneurysm] Toyota F, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):633–5 (21 ref.) **(Jpn)**

CHEMICALLY INDUCED

Brachial plexopathy secondary to anticoagulant-induced hematoma as a complication of axillary arteriography. Shoup DW, et al. **J Am Osteopath Assoc** 1997 Feb; 97(2):102–5 (18 ref.)

COMPLICATIONS

Left ventricular pseudoaneurysm: a cause of unilateral pulmonary edema by compressing the left pulmonary artery. Cocina EG, et al. **Am Heart J** 1996 Dec; 132(6):1306–7

Hepatic artery pseudoaneurysm associated with amebic liver abscess presenting as upper GI hemorrhage. Gopanpallikar A, et al. **Am J Gastroenterol** 1997 Aug;92(8):1391–3

Coincidence of true and false left ventricular aneurysm. Das AK, et al. **Ann Thorac Surg** 1997 Sep;64(3):831–4 (10 ref.)

Mitral-aortic intervalvular fibrosa pseudoaneurysm complicating aortic valve endocarditis [letter] Cheong YM, et al. **Aust N Z J Med** 1997 Apr;27(2):193–4

A case of obstructive jaundice. Griffith JF, et al. **Br J Radiol** 1997 Jan;70:107–8

Pseudoaneurysm of the right lingual artery: an unusual cause of severe hemorrhage during tonsillectomy. Mitchell RB, et al. **Ear Nose Throat J** 1997 Aug;76(8):575–6

Ruptured aortic pseudo-aneurysm: a rare presentation as aortocaval fistula. Pagni S, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):165–8

Hemosuccus pancreaticus from a splenic artery pseudoaneurysm: an unusual cause of upper gastrointestinal bleeding. Hwang YT, et al. **J Formos Med Assoc** 1996 Mar; 95(3):247–51

Renal artery pseudoaneurysm: a cause of delayed hematuria in blunt trauma. Farrell TM, et al. **J Trauma** 1996 Dec; 41(6):1067–8

An unusual cause of haemobilia: biliary ascariasis. Corr P, et al. **Pediatr Radiol** 1997 Apr;27(4):348–9

Postoperative back pain. Worthy SA, et al. **Postgrad Med J** 1996 Nov;72(853):697–9

False aneurysm with median nerve palsy after iatrogenic brachial artery puncture. Yip KM, et al. **Postgrad Med J** 1997 Jan;73(855):43–4

Ruptured idiopathic left ventricular false aneurysm of the free wall associated with Takayasu's arteritis in a young child. Rose AG. **S Afr Med J** 1997 Jun;87 Suppl 3:C161–4

[A rare cause of obstructive jaundice: peripancreatic pseudoaneurysm] Bécheur H, et al. **Gastroenterol Clin Biol** 1996;20(12):1131–4 (Eng. Abstr.) **(Fre)**

[Hemosuccus pancreaticus--a rare cause of upper gastrointestinal bleeding. Successful treatment in two cases by radiologic-interventional embolization of the splenic artery] Allgaier HP, et al. **Dtsch Med Wochenschr** 1996 Sep 20;121(38):1158–62 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Traumatic aneurysm of the internal carotid artery: a late finding presenting as a mass in the sphenoid sinus. Ramos A, et al. **AJNR Am J Neuroradiol** 1996 Feb;17(2):222–5

Musculoskeletal case of the day. Pseudoaneurysm of the left superficial femoral artery. Hatem SF, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):283, 286–8

The validity of current vascular imaging methods in the evaluation of aortic anastomotic aneurysms developing after abdominal aortic aneurysm repair. Bastounis E, et al. **Ann Vasc Surg** 1996 Nov;10(6):537–45

A case of obstructive jaundice. Griffith JF, et al. **Br J Radiol** 1997 Jan;70:107–8

Dissection of retroesophageal aortic diverticulum and descending aorta in a patient with right aortic arch: magnetic resonance demonstration. Ko SF, et al. **Cardiovasc Intervent Radiol** 1996 Nov–Dec;19(6):438–41

MRI of pseudoaneurysm of a brachial venous coronary bypass graft. Duerinckx AJ, et al. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):281–6

Distinguishing left ventricular aneurysm from pseudoaneurysm. A review of the literature. Brown SL, et al. **Chest** 1997 May;111(5):1403–9 (44 ref.)

Pseudoaneurysm of the cystic artery. Maw A, et al. **Eur J Surg** 1997 Apr;163(4):307–9

False aneurysm of the thyrocervical trunk [letter; comment] Chalmers RT. **Eur J Vasc Endovasc Surg** 1997 Apr; 13(4):424–5. Comment on: Eur J Vasc Endovasc Surg 1996 Apr;11(3):373–4.

Fever and anorexia 10 years after major trauma. Ruiz W, et al. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):32, 34

Diagnosis and treatment of iatrogenic femoral artery pseudoaneurysm: a review. Kronzon I. **J Am Soc Echocardiogr** 1997 Apr;10(3):236–45 (24 ref.)

Aneurysms of the digital arteries: a case report and literature review. Abouzahr MK, et al. **J Hand Surg [Am]** 1997 Mar; 22(2):311–4 (19 ref.)

Optic chiasmal compression by venous aneurysm: magnetic resonance imaging diagnosis. Wolansky LJ, et al. **J Neuroimaging** 1997 Jan;7(1):46–7

Pseudoaneurysm of the lingual artery: a case report. Salgarelli A, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):860–4 (11 ref.)

Blunt popliteal artery injury: is physical examination alone enough for evaluation? Gable DR, et al. **J Trauma** 1997 Sep;43(3):541–4 (21 ref.)

False left ventricular aneurysm with ventriculo-bronchial fistula and massive haemoptysis. Camero LG, et al. **Scand Cardiovasc J** 1997;31(2):117–9

Case of the season. Infected false aneurysm of the aorta with aorto-enteric fistula. Kew J, et al. **Semin Roentgenol** 1996 Jul;31(3):182–4

Traumatic pseudoaneurysm of the superficial temporal artery. Pennington C, et al. **Tenn Med** 1997 Jul;90(7):284

[Combination of true and false left ventricular aneurysm. Cine-MRI diagnosis] Darremont O, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89(10):1311–5 (Eng. Abstr.) **(Fre)**

[False anastomotic aneurysms after aorto-femoral prosthesis. Detection, prevention and treatment] Melliere D, et al. **J Mal Vasc** 1996;21(3):158–64 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Escherichia coli endocarditis of a native mitral valve with paravalvular pseudoaneurysm formation and fatal hemopericardium. Oosterbosch L, et al. **Acta Cardiol** 1996; 51(6):535–40

False aneurysm of the pulmonary artery induced by a Swan-Ganz catheter: clinical presentation and radiologic management [see comments] Ferretti GR, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):941–5. Comment in: AJR Am J Roentgenol 1997 Aug;169(2):598.

Angiography/interventional case of the day. Splenic artery pseudoaneurysm associated with pancreatitis. LiPuma JP, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):259, 262–3

Pseudoaneurysm formation after catheter dissection of the common hepatic artery: report of two cases. Ahn J, et al. **Am J Gastroenterol** 1997 Apr;92(4):696–9 (23 ref.)

Delayed presentation of popliteal artery pseudoaneurysm following blunt trauma. Atta HM, et al. **Am Surg** 1997 Jun; 63(6):496–9

Nonoperative therapy for postcatheterization femoral artery pseudoaneurysms. Kazmers A, et al. **Am Surg** 1997 Feb; 63(2):199–204

An unusual complication of emergency tracheal intubation. Ooi GC, et al. **Anaesthesia** 1997 Feb;52(2):154–8

Traumatic chiasmal syndrome: a feature photograph. Goh KY, et al. **Ann Acad Med Singapore** 1996 Jul;25(4):614–5

Spontaneous rupture of the common carotid artery with pseudoaneurysm formation. Prendergast H, et al. **Ann Emerg Med** 1997 Aug;30(2):230–3

False aneurysm of an intercostal artery after thoracoscopic sympathectomy. Atherton WG, et al. **Ann R Coll Surg Engl** 1997 May;79(3):229–30

LVOT pseudoaneurysm: a late complication of extended aortic root replacement. Jaggers J, et al. **Ann Thorac Surg** 1996 Oct;62(4):1198–9

Posttraumatic left ventricular pseudoaneurysm due to intramyocardial dissecting hematoma. Maselli D, et al. **Ann Thorac Surg** 1997 Sep;64(3):830–1

Tuberculous pseudoaneurysm of the thoracic aorta. Ohtsuka T, et al. **Ann Thorac Surg** 1996 Dec;62(6):1831–4 (8 ref.)

Dual-inflow great vessel aneurysm: delayed presentation after penetrating trauma. Rossbach MM, et al. **Ann Thorac Surg** 1997 Jan;63(1):238–40

Posttraumatic aneurysm of the right atrium. von der Emde J, et al. **Ann Thorac Surg** 1996 Nov;62(5):1507–9

Enlarging mediastinal mass after cardiac transplantation. Weinstein S, et al. **Ann Thorac Surg** 1997 Sep;64(3):845–7

Infection of a chronically implanted iliac artery stent. Bunt TJ, et al. **Ann Vasc Surg** 1997 Sep;11(5):529–32

Pseudoaneursym of the external carotid artery after tonsillectomy. A rare complication. Karas DE, et al. **Arch Otolaryngol Head Neck Surg** 1997 Mar;123(3):345–7

Giant pseudoaneurysm of the extracranial vertebral artery: case report. Gallo P, et al. **Arq Neuropsiquiatr** 1996 Jun; 54(2):297–303 (53 ref.)

False aneurysm of the popliteal artery complicating acupuncture. Lord RV, et al. **Aust N Z J Surg** 1996 Sep; 66(9):645–7

Arterial complications of pancreatitis and their radiological management. Sawlani V, et al. **Australas Radiol** 1996 Nov; 40(4):381–6 (14 ref.)

Inadvertent rupture of a composite vein graft by angioplasty. Sandison A, et al. **Cardiovasc Intervent Radiol** 1997 Jul–Aug;20(4):305–7

False aneurysm of the inferior gluteal artery following penetrating buttock trauma: case report and review of the literature. Holland AJ, et al. **Cardiovasc Surg** 1996 Dec; 4(6):841–3

False aneurysm of the common femoral artery after total hip arthroplasty. A case report. Mallory TH, et al. **Clin Orthop** 1997 May;(338):105–8

Hemobilia: a rare complication following cholecystectomy. Jafarey AM, et al. **Endoscopy** 1997 Jan;29(1):53–4

Spontaneous obliteration of a pseudo-aneurysm complicating an aortic homograft. Federmann M, et al. **Eur J Cardiothorac Surg** 1996;10(8):705–6 (5 ref.)

Left ventricular false aneurysm after previous repair of acquired ventricular septal defect. Ridley PD, et al. **Eur J Cardiothorac Surg** 1996;10(1):68–70

Rupture of a popliteal artery pseudo-aneurysm secondary to a fibular osteochondroma. Ballaro A, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):151–2 (5 ref.)

Arteriovenous fistula and pseudoaneurysm formation following heel endoscopy. O'Brien SP, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):240–1

False aneurysm of a lumbar artery following vertebral biopsy. Stevens KJ, et al. **Eur Spine J** 1997;6(3):205–7

Pseudoaneurysm with an arteriovenous fistula of the tibial vessels after plantar fasciotomy: a case report. Nierenberg G, et al. **Foot Ankle Int** 1997 Aug;18(8):524–5

Pseudoaneurysm formation after ankle arthroscopy. O'Farrell D, et al. **Foot Ankle Int** 1997 Sep;18(9):578–9

Transcatheter repair of a large coronary pseudoaneurysm

using ultrasound guidance and vein-covered stents. Di Mario C, et al. **G Ital Cardiol** 1997 Jul;27(7):701-5

Femoral nerve palsy: a rare presentation of femoral artery pseudoaneurysm following cardiac catheterisation. Bapat VN, et al. **Indian Heart J** 1996 Nov-Dec;48(6):715-6

Hepatic artery pseudoaneurysm and hemobilia following laparoscopic cholecystectomy. Kapoor R, et al. **Indian J Gastroenterol** 1997 Jan;16(1):32-3

Management of the carotid artery following penetrating injuries of the soft palate. Suskind DL, et al. **Int J Pediatr Otorhinolaryngol** 1997 Feb 14;39(1):41-9

Left ventricular pseudoaneurysm with left atrium tamponade: a rare postinfarction complication. Delgado C, et al. **J Am Soc Echocardiogr** 1997 Jun;10(5):582-7

Traumatic pseudoaneurysm of the left sinus of Valsalva: a case report. Gharzuddine WS, et al. **J Am Soc Echocardiogr** 1997 May;10(4):377-80

Pseudoaneurysm of the left ventricle following repair for ventricular septal perforation. Watarida S, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):635-7

Aneurysmal arterial disease in a patient with Ehlers-Danlos syndrome. Case report and literature review. Witz M, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):161-3 (9 ref.)

Intercostal artery pseudoaneurysm after a percutaneous biliary procedure: diagnosis with CT and treatment with transarterial embolization. Casas JD, et al. **J Comput Assist Tomogr** 1997 Sep-Oct;21(5):729-30

Traumatic aneurysm of the temporal artery: a report of five cases. Inoue Y, et al. **J Dermatol** 1997 Apr;24(4):246-8

False aneurysm: a rare and potentially severe complication after pulmonary autograft operation. Metras D, et al. **J Heart Valve Dis** 1996 Jul;5(4):414-6; discussion 416-7

Pseudoaneurysm and splenic infarction in chronic pancreatitis--a case report. Lee HS, et al. **J Korean Med Sci** 1996 Apr;11(2):183-7

False aneurysm--a complication following an inversion ankle sprain: a case report. Bandy WD, et al. **J Orthop Sports Phys Ther** 1996 Apr;23(4):272-9

Splanchnic artery pseudo-aneurysms secondary to blunt abdominal trauma in children. Gow KW, et al. **J Pediatr Surg** 1996 Jun;31(6):812-5

Pseudoaneurysm formation is a known complication of both arterial manipulations and arterial injuries [letter] Tekinalp H, et al. **J Pediatr Surg** 1996 Aug;31(8):1197

Venous pseudoaneurysm as a complication of shoulder arthroscopy. Cameron SE. **J Shoulder Elbow Surg** 1996 Sep-Oct;5(5):404-6

Pseudoaneurysm of the brachial artery from blunt trauma. Crawford DL, et al. **J Trauma** 1997 Feb;42(2):327-9

Pseudoaneurysm of the superior gluteal arterial system: an unusual cause of pain after a pelvic fracture. Stephen DJ. **J Trauma** 1997 Jul;43(1):146-9

Traumatic abdominal aortic pseudoaneurysm causing biliary obstruction: a case report and review of the literature. Chase CW, et al. **J Vasc Surg** 1997 May;25(5):936-40 (21 ref.)

Tuberculous pseudoaneurysm of the descending thoracic aorta: a case report and literature review of surgically treated cases. Ikezawa T, et al. **J Vasc Surg** 1996 Oct; 24(4):693-7 (32 ref.)

Upper abdominal aortic injury during spinal surgery. Smythe WR, et al. **J Vasc Surg** 1997 Apr;25(4):774-7

Carotid pseudoaneurysm from inadvertent carotid artery catheterization for haemodialysis. Parry W, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1853-5

An ominous complication of acute myocardial infarction. El-Omar MM, et al. **Postgrad Med J** 1996 May; 72(847):309-11

Popliteal artery pseudoaneurysm caused by an osteochondroma--a traditional medicine massage sequelae. Kalinga MJ, et al. **Singapore Med J** 1996 Aug;37(4):443-5 (8 ref.)

False aneurysm of a hepatic artery branch [letter] Halpern NB. **Surg Endosc** 1997 Apr;11(4):402-3

False aneurysm of a hepatic artery branch and a recurrent subphrenic abscess: two unusual complications after laparoscopic cholecystectomy. Porte RJ, et al. **Surg Endosc** 1996 Feb;10(2):161-3

False aneurysm of the axillary artery caused by graft infection: report of a case. Yamamoto K, et al. **Surg Today** 1997;27(4):376-8

Left ventricular pseudoaneurysm after myocardial infarction. Usher BW. **Tenn Med** 1997 Apr;90(4):150-1

Delayed presentation of false abdominal aortic aneurysm following umbilical artery catheterisation. Bapat VN, et al. **Thorac Cardiovasc Surg** 1997 Jun;45(3):154-7

Pseudoaneurysm caused by disruption of an externally supported knitted Dacron graft for femoropopliteal bypass. Orii M, et al. **Tokai J Exp Clin Med** 1995 Dec;20(4-6):241-4

False aneurysm of the brachial artery in an infant following attempted venipuncture. Demircin M, et al. **Turk J Pediatr** 1996 Jul-Sep;38(3):389-91

Intrarenal pseudoaneurysm presenting 15 years after penetrating renal injury. Chazen MD, et al. **Urology** 1997 May;49(5):774-6

[Gastroduodenal arterial aneurysm and chronic pancreatitis. A case and review of the literature] Benoit L, et al. **Ann Chir** 1996;50(10):918-20 (17 ref.) (Eng. Abstr.) **(Fre)**

[False hydatic aneurysm of the thoraco-abdominal aorta] El Mesnaoui A, et al. **J Chir (Paris)** 1996 Jul;133(5):222-5 (Eng. Abstr.) **(Fre)**

[Ruptured pseudoaneurysm of the splenic artery. A complication of chronic pancreatitis] Kuhn R, et al. **Dtsch Med Wochenschr** 1996 Dec 13;121(50):1567-70 (Eng. Abstr.) **(Ger)**

[Formation, therapy and prevention of false aneurysm of the femoral artery following diagnostic and interventional heart catheterization] Rath J, et al. **Dtsch Med Wochenschr** 1997 Jun 13;122(24):771-7 (Eng. Abstr.) **(Ger)**

[Incidence and therapy of peripheral arterial vascular complications after heart catheter examinations] Heintzen MP, et al. **Z Kardiol** 1997 Apr;86(4):264-72 (Eng. Abstr.) **(Ger)**

[Pseudoaneurysm of the left ventricle after mitral valve replacement. Diagnosis 6 years after the intervention] Antonielli E, et al. **Minerva Cardioangiol** 1997 May; 45(5):251-6 (Eng. Abstr.) **(Ita)**

[A case report of multiple pseudoaneurysms of the left ventricle following acute myocardial infarction] Yasuda H, et al. **Kyobu Geka** 1996 May;49(5):392-4 (Eng. Abstr.) **(Jpn)**

[A case report of Takayasu's arteritis with aortic pseudoaneurysm caused by aortic perforation] Hachiya T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct; 44(10):1921-4 (Eng. Abstr.) **(Jpn)**

[A case report of hemobilia and biliary obstruction caused by a pseudoaneurysm as a complication of percutaneous placement of Wallstent] Murayama M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Feb;94(2):139-42 **(Jpn)**

[Pseudoaneurysm after anastomosis of a prosthesis with the femoral artery] Witkowski M, et al. **Pol Tyg Lek** 1996 Mar; 51(10-13):145-7 (Eng. Abstr.) **(Pol)**

[Pseudoaneurysm of the pancreas] Dąbrowski A, et al. **Wiad Lek** 1996;49(1-6):51-3 (Eng. Abstr.) **(Pol)**

[Posttraumatic pseudoaneurysm of the axillary artery after anterior dislocation of the shoulder: a case report] Gaspar M, et al. **Chirurgia (Bucur)** 1996 Nov-Dec;45(6):317-20 (Eng. Abstr.) **(Rum)**

[Current knowledge of posttraumatic AV fistulae and pseudoaneurysms] Davidović L. **Vojnosanit Pregl** 1997 Mar-Apr;54(2):155-60 (72 ref.) **(Scr)**

[Post-traumatic arteriovenous fistulae and pseudoaneurysms] Davidović L, et al. **Vojnosanit Pregl** 1997 Jan-Feb; 54(1):5-10 (Eng. Abstr.) **(Scr)**

[Lesions of the peripheral nerves associated with pseudoaneurysms of the major arteries caused by gunshot wounds] Roganović Z, et al. **Vojnosanit Pregl** 1996 Mar-Apr;53(2):101-6 (Eng. Abstr.) **(Scr)**

[Pseudoaneurysm of the splenic artery and chronic pancreatitis] Gabriel Botella F, et al. **An Med Interna** 1995 Aug;12(8):393-6 (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Multiple mycotic pseudoaneurysms due to Yersinia enterocolitica: report of a case and review of the literature. Donald K, et al. **Ann Vasc Surg** 1996 Nov;10(6):573-7

Salmonella aortitis with pseudoaneurysm formation diagnosed by transesophageal echocardiography. Kures P, et al. **J Am Soc Echocardiogr** 1996 Nov-Dec;9(6):885-7

PARASITOLOGY

A rare case of hydatid cyst perceived as false aneurysm of thoracic aorta. Zakhariev T, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):792-3

PATHOLOGY

[Pseudoaneurysm and aneurysm of the left ventricle. Discription of a case and long-term follow-up] Piccone U, et al. **Minerva Cardioangiol** 1997 May;45(5):245-50 (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Evaluation of blood flow patterns of true and false lumens in dissecting aneurysms using MR phase-contrast techniques. Inoue T, et al. **Clin Imaging** 1996 Oct-Dec; 20(4):262-8

Management of the carotid artery following penetrating injuries of the soft palate. Suskind DL, et al. **Int J Pediatr Otorhinolaryngol** 1997 Feb 14;39(1):41-9

PREVENTION & CONTROL

Do 5-F-catheters reduce the incidence of a pseudoaneurysm? Zahn R, et al. **Int Angiol** 1996 Sep;15(3):257-60

RADIOGRAPHY

Traumatic aneurysm of the basilar artery. Quintana F, et al. **AJNR Am J Neuroradiol** 1996 Feb;17(2):283-5

Sentinel transoral hemorrhage from a pseudoaneurysm of the internal maxillary artery: a complication of CT-guided biopsy of the masticator space. Walker AT, et al. **AJNR Am J Neuroradiol** 1996 Feb;17(2):377-81

Saphenous vein graft aneurysm after coronary artery bypass surgery. Doyle MT, et al. **AJR Am J Roentgenol** 1997 Mar; 168(3):747-9

Radiologic diagnosis and management of uterine artery pseudoaneurysm: case report. Bromley PJ, et al. **Can Assoc Radiol J** 1997 Apr;48(2):119-22 (17 ref.)

Ascending aortic pseudoaneurysm masquerading as pulmonary embolus: case report. Murphy JP, et al. **Can Assoc Radiol J** 1997 Aug;48(4):270-2

Case report. Aortic pseudoaneurysm with aortobronchial fistula: diagnosis with CT angiography. Ferretti GR, et al. **J Comput Assist Tomogr** 1996 Nov-Dec;20(6):975-8 (8 ref.)

Ultrafast computed tomography in infectious pseudoaneurysm of the left ventricular outflow tract. Berrizbeitia LD, et al. **J Thorac Cardiovasc Surg** 1997 Jul; 114(1):138-9

False aneurysm of the common carotid artery and injury of the brachial plexus due to trauma inflicted by an air gun pellet. van Alphen JC, et al. **J Trauma** 1996 Dec; 41(6):1044-6

Angiography in the evaluation of head and neck trauma. Gaskill-Shipley MF, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):607-24 (69 ref.)

A false traumatic giant aneurysm of the supraclinoid carotid artery. A case report and review of the literature. Baskaya MK, et al. **Neurol Res** 1996 Apr;18(2):135-9 (29 ref.)

[Vanishing aneurysm] Azencot M, et al. **Rev Med Interne** 1997;18(5):416-7 **(Fre)**

[Ventricular aneurysm or pseudoaneurysm?] Toussaint AC, et al. **Rev Med Liege** 1997;52(7):457-62 **(Fre)**

[Traumatically-induced closure with spontaneous recanalization of the internal carotid artery] Bauer KF, et al. **Chirurg** 1997 Feb;68(2):187-9 (Eng. Abstr.) **(Ger)**

[Diagnostic imaging of aortic pseudoaneurysm: study of 4 clinical cases] Fedriga E, et al. **Cardiologia** 1996 Jul; 41(7):661-5 (Eng. Abstr.) **(Ita)**

SURGERY

Pseudoaneurysms of the radial artery. Importance of microsurgery. Apropos of a case. Moufarrège R, et al. **Ann Chir Main** 1982;1(1):40-4 (13 ref.) **(Eng, Fre)**

False aneurysm of the superficial temporal artery: a surgical complication. Giele H, et al. **Ann Plast Surg** 1996 Feb; 36(2):219-20

Pseudoaneurysm of the anterior superficial temporal artery. Han K, et al. **Ann Plast Surg** 1996 Dec;37(6):650-3 (19 ref.)

Repair of aortobronchial fistula using extraanatomic grafts and hypothermic arrest. Lawrence WA, et al. **Ann Thorac Surg** 1997 Apr;63(4):1158-60

Recurrent left ventricular false aneurysm. Stanton MW, et al. **Ann Thorac Surg** 1997 May;63(5):1472-3

Infected false hepatic artery aneurysm after orthotopic liver transplantation treated by resection and reno-hepatic vein graft. Fichelle JM, et al. **Ann Vasc Surg** 1997 May; 11(3):300-3

Traumatic aneurysms of the carotid arteries. Doudle MW, et al. **Aust N Z J Surg** 1996 Dec;66(12):847-9

Recurrent femoral anastomotic false aneurysms: is long term repair possible? Melliere D, et al. **Cardiovasc Surg** 1996 Aug;4(4):480-2

Percutaneous occlusion of the entry to a leaking false aneurysm after ascending aortic replacement for aortic dissection type A facilitating surgical repair. Henriques JP, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):381-3

Successful surgical repair of a false aneurysm of the ascending aorta following orthotopic cardiac transplantation: a case report. Punjabi P, et al. **Eur J Cardiothorac Surg** 1997 Jun; 11(6):1174-5

Aneurysmatic arteriovenous fistula complicating splenic injury. Sarioğlu A, et al. **Eur J Pediatr Surg** 1996 Jun; 6(3):183-5

False aneurysm of the thyrocervical trunk [letter; comment] Chalmers RT. **Eur J Vasc Endovasc Surg** 1997 Apr; 13(4):424-5. Comment on: Eur J Vasc Endovasc Surg 1996 Apr;11(3):373-4.

Endovascular stenting of an aortopulmonary fistula presenting with hemoptysis. A case report. Campagna AC, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):643-6

Endoluminal graft exclusion of a proximal para-anastomotic pseudoaneurysm following aortobifemoral bypass. White RA, et al. **J Endovasc Surg** 1997 Feb;4(1):88-94

False aneurysm and brachial plexus palsy complicating a proximal humeral exostosis. Gerrand CH. **J Hand Surg [Br]** 1997 Jun;22(3):413-5

Pseudoaneurysm of the radial artery complicating excision of a wrist ganglion. Maw A, et al. **J Hand Surg [Br]** 1996 Dec;21(6):783-4

Pseudoaneurysm of the superficial temporal artery: report of a case. Webber CM, et al. **J Oral Maxillofac Surg** 1997 Feb;55(2):166-9 (22 ref.)

Posterior circulation cerebral infarcts associated with repair of thoracic aortic disruption using partial left heart bypass. Duke BJ, et al. **J Trauma** 1997 Jun;42(6):1135-9

Delayed presentation of 50 years after a World War II vascular injury with intraoperative localization by duplex ultrasound of a traumatic false aneurysm. Jackson MR, et al. **J Trauma** 1997 Jul;43(1):159-61

Direct repair of a giant extracranial vertebral artery pseudoaneurysm through the aneurysmal cavity. Lin TK, et al. **J Trauma** 1997 Jun;42(6):1140-3

Stent-graft failure in a patient with a connective tissue disorder. Hovsepian DM, et al. **J Vasc Interv Radiol** 1997 Sep-Oct;8(5):789-93

Aneurysm clipping after endovascular treatment with coils: a report of eight patients. Civit T, et al. **Neurosurgery** 1996 May;38(5):955-60; discussion 960-1

Determinants of success of color-flow duplex-guided

compression repair of femoral pseudoaneurysms. Hood DB, et al. **Surgery** 1996 Oct;120(4):585–8; discussion 588–90

Vascular injury during lumbar disc surgery. Report of two cases; a review of the literature. Sağdiç K, et al. **Vasa** 1996; 25(4):378–81 (21 ref.)

[Post-traumatic aneurysma spurium of the subclavian artery] Schwarz E, et al. **Unfallchirurg** 1996 Jan;99(1):73–5 (Eng. Abstr.) **(Ger)**

[Extracranial carotid aneurysms] Hepp W. **Zentralbl Chir** 1996;121(12):1058–62 (Eng. Abstr.) **(Ger)**

[Ascending aortic aneurysms operated through redo median sternotomy under selective cerebral perfusion] Yamazaki Y, et al. **Kyobu Geka** 1997 Mar;50(3):190–3 (Eng. Abstr.) **(Jpn)**

THERAPY

False aneurysms of the intracavernous carotid artery--report of 7 cases. Bavinzski G, et al. **Acta Neurochir (Wien)** 1997; 139(1):37–43

Endovascular occlusion of the carotid or vertebral artery with temporary proximal flow arrest and microcoils: clinical results. Graves VB, et al. **AJNR Am J Neuroradiol** 1997 Aug;18(7):1201–6

Posttraumatic extracranial aneurysm of the internal carotid artery: combined endovascular treatment with coils and stents. Klein GE, et al. **AJNR Am J Neuroradiol** 1997 Aug; 18(7):1261–4

Percutaneous repair of breast pseudoaneurysm: sonographically guided embolization. Beres RA, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):425–7

Angiography/interventional case of the day. Splenic artery pseudoaneurysm associated with pancreatitis. LiPuma JP, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):259, 262–3

Obliteration of femoral pseudoaneurysm complicating coronary intervention by direct puncture and permanent or removable coil insertion. Pan M, et al. **Am J Cardiol** 1997 Sep 15;80(6):786–8

Nonoperative therapy for postcatheterization femoral artery pseudoaneurysms. Kazmers A, et al. **Am Surg** 1997 Feb; 63(2):199–204

Duplex-guided compression of femoral artery false aneurysms reduces the need for surgery. Perkins JM, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5):473–5

Arteriographic embolization of visceral artery pseudoaneurysms. Stambo GW, et al. **Ann Vasc Surg** 1996 Sep;10(5):476–80

Arterial complications of pancreatitis and their radiological management. Sawlani V, et al. **Australas Radiol** 1996 Nov; 40(4):381–6 (14 ref.)

Percutaneous treatment of iliac aneurysms and pseudoaneurysms with Cragg Endopro System 1 stent-grafts. Gasparini D, et al. **Cardiovasc Intervent Radiol** 1997 Sep–Oct;20(5):348–52

False aneurysm of the inferior gluteal artery following penetrating buttock trauma: case report and review of the literature. Holland AJ, et al. **Cardiovasc Surg** 1996 Dec; 4(6):841–3

Ultrasound-guided compression repair and beyond [editorial; comment] Chatterjee T, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):16. Comment on: Cathet Cardiovasc Diagn 1997 Jan;40(1):9–15.

Use of a pneumatic compression system (FemoStop) as a treatment option for femoral artery pseudoaneurysms after percutaneous cardiac procedures. Dangas G, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):138–42

Closure of an iatrogenic femoral artery pseudoaneurysm by transcutaneous coil embolization. Jain SP, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):317–9

Delayed development of a pseudoaneurysm in the left circumflex artery following angioplasty and stent placement, treated with intravascular ultrasound-guided stenting. Kitzis I, et al. **Cathet Cardiovasc Diagn** 1997 Sep; 42(1):51–3

Pseudoaneurysm after cardiac catheterization: therapeutic interventions and their sequelae: experience in 86 patients [see comments] Zahn R, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):9–15. Comment in: Cathet Cardiovasc Diagn 1997 Jan;40(1):16.

Pseudoaneurysm of the left ventricle after mitral valve replacement. Surgical repair or medical follow-up [letter; comment] Demirtaş MM. **Chest** 1997 Feb;111(2):526–7. Comment on: Chest 1996 Feb;109(2):565–7. Comment on: Chest 1996 Feb;109(2):577–9.

Immediate transcatheter embolization of Swan-Ganz catheter-induced pulmonary artery pseudoaneurysm. Karak P, et al. **Chest** 1997 May;111(5):1450–2

Case report: delayed superficial femoral artery pseudoaneurysm rupture following successful compression therapy. Birchall D, et al. **Clin Radiol** 1997 Aug; 52(8):629–30

Technical report: an alternative mechanical technique of pseudoaneurysm compression therapy. McGlinchey I, et al. **Clin Radiol** 1997 Aug;52(8):621–4

Case report: intravascular stenting across a false aneurysm of the popliteal artery. Manns RA, et al. **Clin Radiol** 1997 Feb;52(2):151–3

Simplified method for compression of femoral false aneurysms. Coghlan JG, et al. **Eur Heart J** 1995 Nov; 16(11):1589–92

Endovascular treatment with microcoils of traumatic haemobilia: case report. Celdrán A, et al. **Eur J Surg** 1995 Nov;161(11):857–8

Endovascular stenting of internal carotid artery false aneurysm. Huang A, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):375–7

Successful non-surgical management of traumatic pseudoaneurysm of the axillary artery by duplex guided compression obliteration. Szendro G, et al. **Eur J Vasc Endovasc Surg** 1997 May;13(5):513–4

Multiple pulmonary artery pseudoaneurysms: intrasaccular embolization. Ghaye B, et al. **Eur Radiol** 1997;7(2):176–9 (18 ref.)

Hepatic artery pseudoaneurysm following laparoscopic cholecystectomy: transcatheter intraarterial embolization. Siablis D, et al. **Hepatogastroenterology** 1996 Sep–Oct; 43(11):1343–6

Management of 219 consecutive cases of postcatheterization pseudoaneurysm. Schaub F, et al. **J Am Coll Cardiol** 1997 Sep;30(3):670–5

Diagnosis and treatment of iatrogenic femoral artery pseudoaneurysm: a review. Kronzon I. **J Am Soc Echocardiogr** 1997 Apr;10(3):236–45 (24 ref.)

Combined surgical and endovascular treatment of a traumatic pseudo-aneurysm of the brachiocephalic trunk with anatomical anomaly. Ruebben A, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):173–6

Transbrachial endovascular exclusion of an axillary artery pseudoaneurysm with PTFE-covered stents. Marston WA, et al. **J Endovasc Surg** 1995 May;2(2):172–6

Endovascular graft repair of penetrating subclavian artery injuries. Patel AV, et al. **J Endovasc Surg** 1996 Nov; 3(4):382–8

Endovascular management of unusual aneurysms of the axillary and subclavian arteries. Sullivan TM, et al. **J Endovasc Surg** 1996 Nov;3(4):389–95

Traumatic intraparenchymal splenic pseudoaneurysms in a child: nonoperative management. Nagar H, et al. **J Trauma** 1997 Sep;43(3):552–5

Successful endovascular treatment of a celiac artery pseudoaneurysm complicating pancreatitis. Abbott GT, et al. **J Vasc Interv Radiol** 1996 Jan–Feb;7(1):103–6

Endovascular stent-graft exclusion of an aortobronchial fistula. Chuter TA, et al. **J Vasc Interv Radiol** 1996 May–Jun;7(3):357–9

Treatment of iatrogenic femoral artery pseudoaneurysm with percutaneous thrombin injection. Liau CS, et al. **J Vasc Surg** 1997 Jul;26(1):18–23

Treatment of dissecting pseudoaneurysm of the cervical internal carotid artery using a wall stent and detachable coils: case report. Perez-Cruet MJ, et al. **Neurosurgery** 1997 Mar;40(3):622–5; discussion 625–6

Ultrasound-guided compression for the treatment of iatrogenic femoral pseudoaneurysms. Weatherford DA, et al. **South Med J** 1997 Feb;90(2):223–6

Unusual pseudoaneurysms after catheterization: successful treatment by ultrasound-guided compression. Do DD, et al. **Ultrasound Med Biol** 1997;23(3):377–80

Ultrasound guided compression therapy in 134 patients with iatrogenic pseudo-aneurysms: advantage of routine duplex ultrasound control of the puncture site following transfemoral catheterization. Ugurluoglu A, et al. **Vasa** 1997 May;26(2):110–6

[Endovascular therapy of visceral aneurysms] Kramann B, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:878–81 (Eng. Abstr.) **(Ger)**

[The color Doppler-guided compression therapy of pseudoaneurysms. The authors' own experiences and a review of the literature] Oelerich M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):484–90 (34 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Chronic post-traumatic pseudoaneurysm of the abdominal aorta diagnosed by duplex Doppler ultrasonography. A case report. González Llorente J, et al. **Acta Radiol** 1997 Jan;38(1):121–3 (12 ref.)

Radiology for the surgeon. Case 12. Splenic laceration with pseudoaneurysm of the splenic artery. Tran CN, et al. **Can J Surg** 1996 Dec;39(6):450, 486

Ultrasound-guided compression repair for treatment of femoral artery pseudoaneurysm: acute and follow-up results. Chatterjee T, et al. **Cathet Cardiovasc Diagn** 1996 Aug;38(4):335–40

Use of transesophageal echocardiography for diagnosis of traumatic aortic injury. Goarin JP, et al. **Chest** 1997 Jul; 112(1):71–80

A closed hole. Barletta G, et al. **G Ital Cardiol** 1997 Jul; 27(7):720 **(Eng, Ita)**

Pseudoaneurysm of mitral-aortic intervalvular fibrosa in aortic valve endocarditis: transoesophageal echocardiographic diagnosis. Kothari SS, et al. **Indian Heart J** 1997 Jan–Feb;49(1):85–6

Transesophageal echocardiographic detection of complications after Cabrol's procedure. Davis G, et al. **J Am Soc Echocardiogr** 1997 May;10(4):375–6

Salmonella aortitis with pseudoaneurysm formation diagnosed by transesophageal echocardiography. Kures P, et al. **J Am Soc Echocardiogr** 1996 Nov–Dec;9(6):885–7

Pseudoaneurysm and ventricular septal rupture complicated with inferior myocardial infarction diagnosed by two-dimensional and Doppler echocardiography: case report. Kawai J, et al. **J Cardiol** 1996 Feb;27(2):77–83

Iatrogenic pseudoaneurysm of the axillary artery: the role of color Doppler sonography. Sustić A, et al. **J Clin Ultrasound** 1996 Jul–Aug;24(6):323–5

Pseudoaneurysm of the cystic artery associated with upper gastrointestinal bleeding. Nakajima M, et al. **J Gastroenterol** 1996 Oct;31(5):750–4 (16 ref.)

Traumatic aneurysm of a common digital artery. Cromheecke M, et al. **J Hand Surg [Br]** 1997 Jun;22(3):416–8

Delayed presentation of 50 years after a World War II vascular injury with intraoperative localization by duplex ultrasound of a traumatic false aneurysm. Jackson MR, et al. **J Trauma** 1997 Jul;43(1):159–61

Case of the day. Gastrodenal artery pseudoaneurysm complicating pancreatitis. Townsend R, et al. **J Ultrasound Med** 1997 Apr;16(4):303

Spontaneous closure of selected iatrogenic pseudoaneurysms and arteriovenous fistulae. Toursarkissian B, et al. **J Vasc Surg** 1997 May;25(5):803–8; discussion 808–9

Ultrasound-guided compression for the treatment of iatrogenic femoral pseudoaneurysms. Weatherford DA, et al. **South Med J** 1997 Feb;90(2):223–6

Determinants of success of color-flow duplex-guided compression repair of femoral pseudoaneurysms. Hood DB, et al. **Surgery** 1996 Oct;120(4):585–8; discussion 588–90

Unusual pseudoaneurysms after catheterization: successful treatment by ultrasound-guided compression. Do DD, et al. **Ultrasound Med Biol** 1997;23(3):377–80

[Reduction of puncture-induced complications after heart catheterization by optimized compression technique despite reduced compression time. A prospective, duplex ultrasound and pressure controlled study] Sotiriou M, et al. **Med Klin** 1996 Sep 15;91(9):557–63 (Eng. Abstr.) **(Ger)**

[The color Doppler-guided compression therapy of pseudoaneurysms. The authors' own experiences and a review of the literature] Oelerich M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):484–90 (34 ref.) (Eng. Abstr.) **(Ger)**

[Left ventricular pseudoaneurysm recognized 9 years after mitral valve replacement and repeated heart failure of 3 years duration: a case report] Emoto R, et al. **J Cardiol** 1996;27 Suppl 2:65–71; discussion 72 (Eng. Abstr.) **(Jpn)**

[A case report of a pseudoaneurysm of the thoracic aorta (thrombotic closure type) showing like a mediastinal tumor—value of endoscopic ultrasonography in differential diagnosis] Muraki S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct; 44(10):1917–20 (Eng. Abstr.) **(Jpn)**

ANEURYSM, INFECTED

Images in cardiovascular medicine. Mycotic aneurysm of the descending thoracic aorta. Oxorn D, et al. **Circulation** 1997 Apr 1;95(7):1972–3

Candida albicans mycotic abdominal aortic aneurysm. Barry MC, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):237–9

Aortic dissection due to Clostridium septicum infection. Monsen T, et al. **Eur J Vasc Endovasc Surg** 1997 May; 13(5):517–8

[Surgical treatment for active infective endocarditis : septic embolization and mycotic aneurysms] Suzuki S, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):652–5 (Eng. Abstr.) **(Jpn)**

[Mycotic aneurysm and mycotic aortitis] Yasuda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):325–8 (21 ref.) **(Jpn)**

COMPLICATIONS

Infected abdominal aortic aneurysm associated with a psoas abscess, aorto-duodenal and sigmoid fistulas. Case report and review of the literature. Louagie YA, et al. **Acta Chir Belg** 1997 Jan–Feb;97(1):39–43 (22 ref.)

Ruptured bacterial intracranial aneurysm in pregnancy. A case report. Powell S, et al. **J Reprod Med** 1997 Jul; 42(7):455–8

Multiple hepatic hemorrhagic mycotic pseudoaneurysms treated with embolization. Tharp RW, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6):876–8

Mycotic aneurysm of a coronary artery in SLE--a rare complication of salmonella infection. Howe HS, et al. **Lupus** 1997;6(4):404–7

[Surgical treatment of infective endocarditis associated with cerebral mycotic aneurysm] Minakata K, et al. **Kyobu Geka** 1997 Jul;50(7):544–8 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Rupture of the perivisceral aorta: atherosclerotic versus mycotic aneurysm. Quiñones-Baldrich WJ, et al. **Ann Vasc Surg** 1997 Jul;11(4):331–41

Infected aneurysms of the infrarenal abdominal aorta: diagnostic criteria and therapeutic strategy. Sessa C, et al. **Ann Vasc Surg** 1997 Sep;11(5):453–63

Campylobacter fetus-associated aneurysms: report of a case involving the popliteal artery and review of the literature. Montero A, et al. **Clin Infect Dis** 1997 May;24(5):1019–21 (9 ref.)

Mycotic thoracic aneurysm due to Clostridium septicum and occult adenocarcinoma of the cecum. Montoya FJ, et al. **Clin Infect Dis** 1997 May;24(5):785, 1007

Mycotic aneurysm of the aorta: MRI and MRA features. Walsh DW, et al. **J Magn Reson Imaging** 1997 Mar–Apr; 7(2):312–5

Mycotic common carotid artery aneurysm in an immunosuppressed pediatric patient: case report. Willemsen P, et al. **J Vasc Surg** 1997 Apr;25(4):784–5

Stereoscopic synthesized brain–surface imaging with MR angiography for localization of a peripheral mycotic aneurysm: case report. Kato Y, et al. **Minim Invasive Neurosurg** 1996 Dec;39(4):113–5

Case of the season. Infected false aneurysm of the aorta with aorto–enteric fistula. Kew J, et al. **Semin Roentgenol** 1996 Jul;31(3):182–4

[Aortitis and development of an aneurysm after PTA of distal aortic stenosis] Raschke R, et al. **Vasa** 1996;25(3):287–91 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Infected abdominal aortic aneurysm caused by spinal brucellar infection [letter] Yee N, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):1068–9

Infection of a chronically implanted iliac artery stent. Bunt TJ, et al. **Ann Vasc Surg** 1997 Sep;11(5):529–32

Evolution of salmonella aortitis towards the formation of abdominal aneurysm. Carreras M, et al. **Eur Radiol** 1997; 7(1):54–6

Neisseria elongata subsp. elongata, a case of human endocarditis complicated by pseudoaneurysm. Nawaz T, et al. **J Clin Microbiol** 1996 Mar;34(3):756–8

Mycotic aortic aneurysms after orthotopic heart transplantation: a three–case report and review of the literature. Knosalla C, et al. **J Heart Lung Transplant** 1996 Aug;15(8):827–39 (27 ref.)

Hepatic artery aneurysm in a 10–year–old boy as a complication of infective endocarditis. Senocak F, et al. **J Pediatr Surg** 1996 Nov;31(11):1570–2

Delayed presentation of false abdominal aortic aneurysm following umbilical artery catheterisation. Bapat VN, et al. **Thorac Cardiovasc Surg** 1997 Jun;45(3):154–7

[Selective embolization of ruptured mycotic aneurysm of the duodeno–pancreatic arcade disclosing infectious endocarditis] Staat P, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11):1431–5 (Eng. Abstr.) **(Fre)**

[Mycotic aneurysm of the external ilial artery: a very rare complication of coronary angioplasty] Karam BG, et al. **J Med Liban** 1996;44(3):165–7 (Eng. Abstr.) **(Fre)**

[A case report of postcoarctation mycotic aneurysm after surgical treatment for cerebral arterial aneurysms] Kido M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul; 45(7):1006–10 (7 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Mycotic aneurysm of the carotid artery. A case report and review of the literature. Michielsen D, et al. **Acta Chir Belg** 1997 Jan–Feb;97(1):44–6 (14 ref.)

Mycotic aneurysm of the thoracic aorta caused by Clostridium septicum. Murphy DP, et al. **Ann Thorac Surg** 1996 Dec;62(6):1835–7

Salmonella endocarditis of a ventricular aneurysm: a case report and review of the literature. Amyot R, et al. **Can J Cardiol** 1997 Mar;13(3):299–301 (07 ref.)

Mycotic aneurysm due to non–typhi salmonella: report of 16 cases. Wang JH, et al. **Clin Infect Dis** 1996 Oct; 23(4):743–7

Mycotic pulmonary artery aneurysm complicating bacterial endocarditis. Javid M, et al. **Indian Heart J** 1996 Jul–Aug; 48(4):403–4

Infectious arterial aneurysms: patterns and treatment. Illuminati G, et al. **Riv Eur Sci Med Farmacol** 1996 Mar–Apr;18(2):53–60

[Aortic aneurysms due to Yersinia enterocolitica: three new cases and a review of the literature] Mercié P, et al. **J Mal Vasc** 1996;21(2):68–71 (21 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Mycotic aneurysm of the abdominal aorta: CT finding in three patients. Parellada JA, et al. **Abdom Imaging** 1997 May–Jun;22(3):321–4

Evolution of the infected abdominal aortic aneurysm: CT observation of early aortitis. Rozenblit A, et al. **Abdom Imaging** 1996 Nov–Dec;21(6):512–4

Ultrafast computed tomography in infectious pseudoaneurysm of the left ventricular outflow tract. Berrizbeitia LD, et al. **J Thorac Cardiovasc Surg** 1997 Jul; 114(1):138–9

Mycotic aneurysm after aortic bifurcation prosthesis. Galema L, et al. **Neth J Med** 1996 Mar;48(3):105–8

SURGERY

Double mycotic aneurysms of the ascending aorta. Chen YF, et al. **Ann Thorac Surg** 1997 Feb;63(2):529–31

Infected false hepatic artery aneurysm after orthotopic liver transplantation treated by resection and reno–hepatic vein graft. Fichelle JM, et al. **Ann Vasc Surg** 1997 May; 11(3):300–3

Ruptured Salmonella mycotic aneurysm of the extracranial carotid artery. Rice HE, et al. **Ann Vasc Surg** 1997 Jul; 11(4):416–9

Infected aneurysms of the infrarenal abdominal aorta: diagnostic criteria and therapeutic strategy. Sessa C, et al. **Ann Vasc Surg** 1997 Sep;11(5):453–63

Surgical treatment of infected thoracic and abdominal aortic aneurysms. Chiba Y, et al. **Cardiovasc Surg** 1996 Aug; 4(4):476–9

Bilateral splenorenal bypass and axillofemoral graft for management of juxtarenal mycotic aneurysm. Marty–Ané C, et al. **Cardiovasc Surg** 1996 Jun;4(3):331–4

Images in cardio–thoracic surgery. Mycotic aneurysms of the thoracic aorta caused by Streptococcus pneumoniae. Berdat PA, et al. **Eur J Cardiothorac Surg** 1997 Jul; 12(1):154–5

Successful treatment of primary pneumococcal multilocular mycotic aneurysms. Grandmougin D, et al. **Eur J Cardiothorac Surg** 1997 Jul;12(1):133–7

Homograft replacement of thoraco–abdominal aorta for a leaking mycotic aneurysm. Pagano D, et al. **Eur J Cardiothorac Surg** 1996;10(5):383–5

Infected abdominal aortic aneurysms. Experience with 14 consecutive cases. Sriussadaporn S. **Int Surg** 1996 Oct–Dec; 81(4):395–9

The infected aorta. von Segesser LK, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):256–60; discussion 260–1

Infected abdominal aortic aneurysm: in situ replacement with cryopreserved arterial homograft. Alonso M, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):371–5

Infectious aneurysm of the interosseous artery at the forearm. Case report. Illuminati G, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):589–91

Surgical experience with Salmonella–infected aneurysms of the abdominal aorta. Luo CY, et al. **J Formos Med Assoc** 1997 May;96(5):346–52

Abdominal aortic aneurysms in children. Millar AJ, et al. **J Pediatr Surg** 1996 Dec;31(12):1624–8

Infectious arterial aneurysms: patterns and treatment. Illuminati G, et al. **Riv Eur Sci Med Farmacol** 1996 Mar–Apr;18(2):53–60

[Mycotic aortic aneurysm after appendectomy] Rhomberg M, et al. **Vasa** 1996;25(1):90–3 (Eng. Abstr.) **(Ger)**

[A case of mycotic ICA petrous portion aneurysm treated with endovascular surgery] Kawakami K, et al. **No Shinkei Geka** 1996 Mar;24(3):253–7 (Eng. Abstr.) **(Jpn)**

[A case of infective endocarditis with the mycotic aortic valve aneurysm] Aokage K, et al. **Rinsho Kyobu Geka** 1989 Jun;9(3):305–8 (Eng. Abstr.) **(Jpn)**

[Hepatic artery aneurysm: treatment with left hepatectomy. Report of a case] Chaib E, et al. **Arq Gastroenterol** 1995 Jul–Sep;32(3):116–20 (Eng. Abstr.) **(Por)**

THERAPY

Multiple pulmonary artery pseudoaneurysms: intrasaccular embolization. Ghaye B, et al. **Eur Radiol** 1997;7(2):176–9 (18 ref.)

Transcatheter embolization of mycotic iliac aneurysm after aortic valve replacement because of bacterial endocarditis. Akomea–Agyin C, et al. **J Thorac Cardiovasc Surg** 1996 Dec;112(6):1671–2

[A case of multiple cerebral mycotic aneurysms treated with endovascular surgery] Katakura K, et al. **No Shinkei Geka** 1995 Dec;23(12):1127–32 (22 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Coronary artery mycotic aneurysm discovered by transoesophageal echocardiography [letter] Gebuhrer V, et al. **Eur Heart J** 1997 Feb;18(2):352

Mycotic aneurysm of the descending thoracic aorta: the role of transesophageal echocardiography. Joffe II, et al. **J Am Soc Echocardiogr** 1996 Sep–Oct;9(5):663–7

[Clinical analysis of infective endocarditis with aneurysmal formation of the mitral or aortic valve] Kinoshita N, et al. **J Cardiol** 1997 Aug;30(2):79–87 (Eng. Abstr.) **(Jpn)**

ANEURYSM, MYCOTIC see **ANEURYSM, INFECTED**

ANEURYSM, RUPTURED

Ruptured visceral artery aneurysms. Wagner WH, et al. **Ann Vasc Surg** 1997 Jul;11(4):342–7

Infrarenal aortic aneurysms [letter; comment] Hoch RC. **N Engl J Med** 1997 Jun 12;336(24):1757; discussion 1757–8 . Comment on: N Engl J Med 1997 Jan 2;336(1):59–60.

Ruptured aneurysms of the thoracoabdominal aorta: a case series. Rampoldi V, et al. **Panminerva Med** 1995 Sep; 37(3):123–8

CHEMICALLY INDUCED

Intracranial aneurysms [letter; comment] Shacker PL. **N Engl J Med** 1997 Jun 12;336(24):1759. Comment on: N Engl J Med 1997 Jan 2;336(1):28–40.

CLASSIFICATION

A new subarachnoid hemorrhage grading system based on the Glasgow Coma Scale: a comparison with the Hunt and Hess and World Federation of Neurological Surgeons Scales in a clinical series. Oshiro EM, et al. **Neurosurgery** 1997 Jul;41(1):140–7; discussion 147–8

COMPLICATIONS

Ruptured aortic aneurysm and cardiac arrest associated with spinal anesthesia. Joshi GP, et al. **Anesthesiology** 1997 Jan; 86(1):244–7

Recurrent aneurysmal subarachnoid haemorrhage: bleeding pattern and incidence of posthaemorrhagic ischaemic infarction. Gruber A, et al. **Br J Neurosurg** 1997 Apr; 11(2):121–6

The effect of changes in barometric pressure on the risk of rupture of intracranial aneurysms. Landers AT, et al. **Br J Neurosurg** 1997 Jun;11(3):191–5

Subarachnoid haemorrhage secondary to ruptured cerebral aneurysm in a patient with osteogenesis imperfecta [letter] Narváez J, et al. **Br J Rheumatol** 1996 Dec;35(12):1332–3

Acute superior vena cava obstruction after rupture of a bronchial artery aneurysm. Hoffmann V, et al. **Chest** 1996 Nov;110(5):1356–8

Aneurysmal subarachnoid hemorrhage associated with weight training: three case reports. Haykowsky MJ, et al. **Clin J Sport Med** 1996 Jan;6(1):52–5 (21 ref.)

Ruptured popliteal artery aneurysm. An insidious complication. Sie RB, et al. **Eur J Vasc Endovasc Surg** 1997 May;13(5):432–8 (51 ref.)

Polyarteritis nodosa presenting with hemobilia and intestinal hemorrhage. Yazici Z, et al. **Eur Radiol** 1997;7(7):1059–61

Massive extra–enteric gastrointestinal hemorrhage secondary to splanchnic artery aneurysms. Yeh TS, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):1152–6

Ruptured aortic cusp aneurysm in infective endocarditis. Morelli S, et al. **Int J Cardiol** 1996 Nov 15;57(1):51–3

Persistent sciatic artery aneurysm with ruptured internal iliac artery aneurysm. Kuwabara M, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):169–72

Ruptured bacterial intracranial aneurysm in pregnancy. A case report. Powell S, et al. **J Reprod Med** 1997 Jul; 42(7):455–8

Familial intracranial aneurysms [letter; comment] Wakai S. **Lancet** 1997 May 17;349(9063):1478–9. Comment on: Lancet 1997 Feb 8;349(9049):380–4.

Mycotic aneurysm of a coronary artery in SLE--a rare complication of salmonella infection. Howe HS, et al. **Lupus** 1997;6(4):404–7

Pathogenesis of acute monocular blindness from leaking anterior communicating artery aneurysms: report of six cases. Chan JW, et al. **Neurology** 1997 Mar;48(3):680–3

Isolated trigeminal neuralgia secondary to distal anterior inferior cerebellar artery aneurysm. Ildan F, et al. **Neurosurg Rev** 1996;19(1):43–6

Detection of delayed cerebral vasospasm, after rupture of intracranial aneurysms, by magnetic resonance angiography. Tamatani S, et al. **Neurosurgery** 1997 Apr; 40(4):748–53; discussion 753–4

Large bilateral pulmonary artery aneurysms in Behçet's disease: rupture of the contralateral lesion after aneurysmorrhaphy. de Montpréville VT, et al. **Respiration** 1996;63(1):49–51

Ruptured dissecting aneurysm as a cause of subarachnoid hemorrhage of unverified etiology. Nakatomi H, et al. **Stroke** 1997 Jun;28(6):1278–82

Pathogenesis of hyponatremia following subarachnoid hemorrhage due to ruptured cerebral aneurysm. Kurokawa Y, et al. **Surg Neurol** 1996 Nov;46(5):500–7; discussion 507–8

Concurrent aneurysm rupture and thrombosis of high grade internal carotid artery stenosis: report of two cases. Porter RW, et al. **Surg Neurol** 1997 Jun;47(6):532–9; discussion 539–40 (44 ref.)

Subarachnoid hemorrhage: diagnosis and treatment. Standard SC, et al. **Tenn Med** 1997 May;90(5):187–8

[Agenesis of the internal carotid artery associated with an aneurysm of the anterior communicating artery] Armand JP, et al. **J Neuroradiol** 1996 Dec;23(3):164–7 (Eng. Abstr.) **(Fre)**

[Analysis and course of cognitive deficits after rupture of aneurysms of the anterior communicating artery] Rousseaux M, et al. **Rev Neurol (Paris)** 1996 Nov; 152(11):678–87 (Eng. Abstr.) **(Fre)**

[Sentinel headache: a premonitory symptom too often unrecognized in intracranial ruptured aneurysm] Regli L, et al. **Schweiz Med Wochenschr** 1997 Apr 19;127(16):668–74 (34 ref.) (Eng. Abstr.) **(Fre)**

[Comment on D. Moskopp and H. Wassmann: Subarachnoid hemorrhage from cerebral artery aneurysm subsequent to a fall: external or internal etiology? (letter)] Bratzke H. **Versicherungsmedizin** 1997 Feb 1;49(1):30 **(Ger)**

[Comment on D. Moskopp and H. Wassmann: Subarachnoid hemorrhage from cerebral artery aneurysm subsequent to a fall: external or internal etiology? (letter)] in der Schmitten J. **Versicherungsmedizin** 1997 Feb 1;49(1):30–1 **(Ger)**

[Comment on D. Moskopp and H. Wassmann: Subarachnoid hemorrhage from cerebral artery aneurysm subsequent to a fall: external or internal etiology? (letter) (published erratum appears in Versicherungsmedizin 1997 Apr 1;49(2):60)] Marx HH. **Versicherungsmedizin** 1997 Feb 1; 49(1):30; discussion 31 **(Ger)**

[Subarachnoid hemorrhage from cerebral artery aneurysm within the context of a fall: external or internal etiology?] Moskopp D, et al. **Versicherungsmedizin** 1996 Aug 1; 48(4):134–7 (Eng. Abstr.) **(Ger)**

[Acute brain expansion during emergency neck clipping surgery for cerebral aneurysms in a patient with dilated cardiomyopathy] Nakao M, et al. **Masui** 1996 Jun; 45(6):725–30 (Eng. Abstr.) **(Jpn)**

[Posterior cerebral aneurysm associated with complete occlusion of the middle cerebral artery caused

subarachnoid hemorrhage: a case report] Kawamura A, et al. **No Shinkei Geka** 1996 Dec;24(12):1107–11 (17 ref.) (Eng. Abstr.) **(Jpn)**

[A ruptured aneurysm of the distal posterior inferior cerebellar artery associated with acute subdural hematoma of the posterior fossa: a case report] Miyagi A, et al. **No Shinkei Geka** 1997 Jun;25(6):537–41 (Eng. Abstr.) **(Jpn)**

[Ruptured traumatic aneurysms of the peripheral anterior cerebral artery: study of delayed hemorrhage after closed head injury] Sasaoka Y, et al. **No Shinkei Geka** 1997 Apr; 25(4):337–44 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Basilar artery aneurysm associated with agenesis of unilateral internal carotid artery: two case reports] Sugiura Y, et al. **No Shinkei Geka** 1997 Apr;25(4):385–90 (Eng. Abstr.) **(Jpn)**

[Terson's syndrome which arose from ruptured right superior cerebellar artery aneurysm: a case report and 32 series investigations] Takeuchi T, et al. **No Shinkei Geka** 1997 Mar;25(3):259–64 (32 ref.) (Eng. Abstr.) **(Jpn)**

[A retrospective analysis of the outcomes of patients with aneurysmal subarachnoid hemorrhages: a focus on the prognostic factors] Yoshikai S, et al. **No Shinkei Geka** 1996 Aug;24(8):733–8 (Eng. Abstr.) **(Jpn)**

[Vitrectomy in Terson's Syndrome] Urbanowicz-Nowakowska J, et al. **Klin Oczna** 1996 Feb; 98(2):131–2 (Eng. Abstr.) **(Pol)**

[Mitral valve insufficiency caused by tendinous cord rupture and mitral valve aneurysm. Significance of the echocardiographic study] Pitta ML, et al. **Rev Port Cardiol** 1997 Mar;16(3):267–71, 242 (Eng. Abstr.) **(Por)**

[Severe neurogenic pulmonary edema as a result of rupture of a giant intracranial arterial aneurysm] Lubnin AIu. **Anesteziol Reanimatol** 1995 Nov-Dec;(6):57–60 (23 ref.) **(Rus)**

DIAGNOSIS

Induction and subsequent rupture of aneurysms of the circle of Willis after radiation therapy in Ehlers-Danlos syndrome: a plausible hypothesis. Holodny AI, et al. **AJNR Am J Neuroradiol** 1996 Feb;17(2):226–32

MR angiography of ruptured aneurysms in acute subarachnoid hemorrhage. Ida M, et al. **AJNR Am J Neuroradiol** 1997 Jun-Jul;18(6):1025–32

Infected aneurysms of the infrarenal abdominal aorta: diagnostic criteria and therapeutic strategy. Sessa C, et al. **Ann Vasc Surg** 1997 Sep;11(5):453–63

Ruptured renal artery aneurysm during pregnancy. Yang JC, et al. **Ann Vasc Surg** 1996 Jul;10(4):370–2

Magnetic resonance angiography for anterior midline aneurysms [see comments] Keogh AJ, et al. **Br J Neurosurg** 1996 Apr;10(2):143–7. Comment in: Br J Neurosurg 1996 Dec;10(6):621–2.

Haemodynamic consequences of embolizing aneurysms: a transcranial Doppler study. Rowe JG, et al. **Br J Neurosurg** 1995;9(6):749–57

Findings of negligence followed communication lapses in BC aneurysm case [see comments] Capen K. **Can Med Assoc J** 1997 Jan 1;156(1):49–51. Comment in: CMAJ 1997 Jul 1;157(1):18, 20.

Mycotic thoracic aneurysm due to Clostridium septicum and occult adenocarcinoma of the cecum. Montoya FJ, et al. **Clin Infect Dis** 1997 May;24(5):785, 1007

Spontaneous rupture of an internal carotid artery aneurysm diagnosed as a peritonsillar abscess, a tonsillar and epipharyngeal carcinoma with metastasis. Karov I. **Folia Med (Plovdiv)** 1996;38(2):65–7

Transient reactive lymphocytosis associated with acute middle cerebral artery aneurysmal rupture. Siddiqui MA, et al. **J Natl Med Assoc** 1997 Apr;89(4):283–4

Blunt popliteal artery injury: is physical examination alone enough for evaluation? Gable DR, et al. **J Trauma** 1997 Sep;43(3):541–4 (21 ref.)

Giant basilar artery aneurysm with intramural hemorrhage and then disastrous hemorrhage: case report. Koyama S, et al. **Neurosurgery** 1996 Jul;39(1):174–7; discussion 177–8

Evidence for breaches of the retinal vasculature in acquired immune deficiency syndrome angiopathy. A fluorescent microsphere study. Glasgow BJ. **Ophthalmology** 1997 May; 104(5):753–60

[Subarachnoid hemorrhage from the anterior communication artery in a sex offender. Considerations regarding liability] Mielke U, et al. **Nervenarzt** 1996 Sep;67(9):781–4 (Eng. Abstr.) **(Ger)**

[Aneurysms of the iliac artery in fibromuscular dysplasia as differential diagnostic consideration in acute lower abdominal pain] Tsatalpas P, et al. **Zentralbl Chir** 1997; 122(5):413–7 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Does nimodipine influence sex difference in outcome after aneurysmal subarachnoid haemorrhage? Hauerberg J, et al. **Acta Neurochir (Wien)** 1996;138(10):1168–71

ENZYMOLOGY

Activity of alpha 1-antitrypsin and cigarette smoking in subarachnoid haemorrhage from ruptured aneurysm. Gaetani P, et al. **J Neurol Sci** 1996 Sep 15;141(1-2):33–8

EPIDEMIOLOGY

Epidemiological study of reptured intracranial aneurysms in the Saguenay-Lac-Saint-Jean region (Quebec, Canada). Mathieu J, et al. **Can J Neurol Sci** 1996 Aug;23(3):184–8

ETIOLOGY

Ruptured aneurysm of the profunda femoral artery associated with polyaneurysmal disease. Defraigne JO, et al. **Acta Chir Belg** 1997 Apr;97(2):93–6 (32 ref.)

Secondary rupture of an iliac artery aneurysm after exclusion-bypass. Batt M, et al. **Ann Vasc Surg** 1996 May; 10(3):296–9

Late death from aneurysm rupture following balloon angioplasty for branch pulmonary artery stenosis. Zeevi B, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):284–6

Case report: delayed superficial femoral artery pseudoaneurysm rupture following successful compression therapy. Birchall D, et al. **Clin Radiol** 1997 Aug; 52(8):629–30

Rupture of splenic artery aneurysm after liver transplantation. Jovine E, et al. **Clin Transplant** 1996 Oct;10(5):451–4 (19 ref.)

Rupture of a popliteal artery pseudo-aneurysm secondary to a fibular osteochondroma. Ballaro A, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):151–2 (5 ref.)

Iatrogenic rupture of internal carotid artery aneurysm. A complication of CT-guided needle biopsy of the neck. Porcellini M, et al. **G Chir** 1996 Oct;17(10):531–3

Delayed presentation and rupture of a posttraumatic innominate artery aneurysm: case report and review of the literature. Hirose H, et al. **J Trauma** 1997 Jun;42(6):1187–95 (30 ref.)

Stent-graft failure in a patient with a connective tissue disorder. Hovsepian DM, et al. **J Vasc Interv Radiol** 1997 Sep-Oct;8(5):789–93

Rupture of a hepatic artery aneurysm caused by Wegener's granulomatosis. den Bakker MA, et al. **Pathol Res Pract** 1997;193(1):61–6

Fatal rupture of an acquired aneurysm of the pulmonary artery: rare complication after surgical palliation of tricuspid atresia. Boubaker A, et al. **Pediatr Cardiol** 1997 Sep-Oct;18(5):392–5 (9 ref.)

Neonatal intracranial hemorrhage due to rupture of arteriovenous malformation. Ozek E, et al. **Pediatr Neurol** 1996 Jul;15(1):53–6

Traction-induced rupture of an extracranial vertebral artery aneurysm associated with neurofibromatosis. A case report. Horsley M, et al. **Spine** 1997 Jan 15;22(2):225–7

Aortic aneurysm rupture after extracorporeal shock wave lithotripsy. Lazarides MK, et al. **Surgery** 1997 Jul; 122(1):112–3

[Selective embolization of ruptured mycotic aneurysm of the duodeno-pancreatic arcade disclosing infectious endocarditis] Staat P, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11):1431–5 (Eng. Abstr.) **(Fre)**

[Rupture of cerebral aneurysm associated with aortic coarctation (letter)] Gire C, et al. **Rev Neurol (Paris)** 1997 Jun;153(5):357–8 **(Fre)**

[The rupture of an iliac aneurysm after its endovascular elimination. The problems of stent infection (letter)] Kolvenbach R, et al. **Dtsch Med Wochenschr** 1997 Aug 22;122(34–35):1059–60 **(Ger)**

[Ruptured pseudoaneurysm of the splenic artery. A complication of chronic pancreatitis] Kuhn R, et al. **Dtsch Med Wochenschr** 1996 Dec 13;121(50):1567–70 (Eng. Abstr.) **(Ger)**

MORTALITY

A population-based study of prognosis of ruptured cerebral aneurysm: mortality and recurrence of subarachnoid hemorrhage. Olafsson E, et al. **Neurology** 1997 May; 48(5):1191–5

Long-term follow-up study of unruptured intracranial aneurysms. Yasui N, et al. **Neurosurgery** 1997 Jun; 40(6):1155–9; discussion 1159–60

PATHOLOGY

Aneurysm size: a prognostic factor for rupture. Orz Y, et al. **Br J Neurosurg** 1997 Apr;11(2):144–9

Expansion rates of abdominal aortic aneurysm: current limitations in evaluation. Wilson KA, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):521–6 (48 ref.)

Rupture of dissecting aneurysm in a China Airlines co-pilot. Shaw KP, et al. **Forensic Sci Int** 1996 Aug 15; 81(2-3):157–64

The influence of shape on the stresses in model abdominal aortic aneurysms. Elger DF, et al. **J Biomech Eng** 1996 Aug;118(3):326–32

Pathological consideration of a "blister-like" aneurysm at the superior wall of the internal carotid artery: case report. Ishikawa T, et al. **Neurosurgery** 1997 Feb;40(2):403–5; discussion 405–6

Fatal subarachnoid hemorrhage from the rupture of a totally intracavernous carotid artery aneurysm: case report. Lee AG, et al. **Neurosurgery** 1996 Mar;38(3):596–8; discussion 598–9

[Ruptured fusiform aneurysm of the basilar artery with minimal atherosclerosis--report of a case (published erratum appears in No To Shinkei 1997 Jul;49(7):645)] Takao M, et al. **No To Shinkei** 1997 Jun;49(6):553–7 (Eng. Abstr.) **(Jpn)**

[The morphology of the vascular spasm in cerebral aneurysm rupture] Krylov VV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1997 Apr-Jun; (2):8–10 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Flow dynamics in a fatal aneurysm of the basilar artery. Kerber CW, et al. **AJNR Am J Neuroradiol** 1996 Sep; 17(8):1417–21

Complement activation in the central nervous system following blood-brain barrier damage in man. Lindsberg PJ, et al. **Ann Neurol** 1996 Oct;40(4):587–96

Frontal tests do not detect frontal infarctions after ruptured intracranial aneurysm. Ahola K, et al. **Brain Cogn** 1996 Jun;31(1):1–16

Pathological false alarm rates following damage to the left frontal cortex. Parkin AJ, et al. **Brain Cogn** 1996 Oct; 32(1):14–27

On crossed apraxia. Description of a right-handed apraxic patient with right supplementary motor area damage. Marchetti C, et al. **Cortex** 1997 Jun;33(2):341–54

Influence of size, shape and properties on the mechanics of axisymmetric saccular aneurysms. Kyriacou SK, et al. **J Biomech** 1996 Aug;29(8):1015–22

A population-based study of prognosis of ruptured cerebral aneurysm: mortality and recurrence of subarachnoid hemorrhage. Olafsson E, et al. **Neurology** 1997 May; 48(5):1191–5

The relationship of blood velocity as measured by transcranial doppler ultrasonography to cerebral blood flow as determined by stable xenon computed tomographic studies after aneurysmal subarachnoid hemorrhage. Clyde BL, et al. **Neurosurgery** 1996 May;38(5):896–904; discussion 904–5

Computer modeling of intracranial saccular and lateral aneurysms for the study of their hemodynamics [letter; comment] Steiger HJ, et al. **Neurosurgery** 1997 Jul; 41(1):326–7. Comment on: Neurosurgery 1995 Oct;37(4):774–82; discussion 782–4.

[Changes in regional and local brain circulation in patients with subarachnoid hemorrhage due to ruptured aneurysm] Nemati MN, et al. **Schweiz Arch Neurol Psychiatr** 1995; 146(6):256–63 (Eng. Abstr.) **(Ger)**

[Effects of traumatic subarachnoid hemorrhage on pathological properties in diffuse brain injury: a comparison with aneurysmal subarachnoid hemorrhage] Fukuda T, et al. **No Shinkei Geka** 1996 Aug;24(8):723–31 (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Prospective study of the natural history of thoracic aortic aneurysms [published erratum appears in Ann Thorac Surg 1997 Aug;64(2):594] Juvonen T, et al. **Ann Thorac Surg** 1997 Jun;63(6):1533–45

RADIOGRAPHY

Digital subtraction rotational angiography for aneurysms of the intracranial anterior circulation: injection method and optimization. Tu RK, et al. **AJNR Am J Neuroradiol** 1996 Jun-Jul;17(6):1127–36

Patterns of hemorrhage with ruptured posterior inferior cerebellar artery aneurysms: CT findings in 44 cases. Kallmes DF, et al. **AJR Am J Roentgenol** 1997 Oct; 169(4):1169–71

Aneurysm of the right colic artery. Girishkumar H, et al. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):305–7

Radiology case of the month. Calcified mass and indistinct retroperitoneal landmarks on abdominal radiograph. Ruptured abdominal aortic aneurysm. Romano CC, et al. **J La State Med Soc** 1997 Aug;149(8):267–8

Extracranial distal aneurysm of posterior inferior cerebellar artery. Chen CJ, et al. **Neuroradiology** 1997 May; 39(5):344–7

Filling defect sign in CT diagnosis of ruptured aneurysm. Noguchi K, et al. **Neuroradiology** 1997 Jul;39(7):480–2

The role of computed tomographic angiography in the diagnosis of intracranial aneurysms and emergent aneurysm clipping. Hsiang JN, et al. **Neurosurgery** 1996 Mar; 38(3):481–7 discussion 487

Three-dimensional computed tomographic angiography in detection of cerebral aneurysms in acute subarachnoid hemorrhage. Zouaoui A, et al. **Neurosurgery** 1997 Jul; 41(1):125–30

Cause of perimesencephalic hyperattenuation in cases of ruptured vertebrobasilar aneurysm [letter; comment] Friedman D. **Radiology** 1997 Jun;203(3):884. Comment on: Radiology 1996 Dec;201(3):657–60.

Ruptured vertebrobasilar aneurysms: frequency of the nonaneurysmal perimesencephalic pattern of hemorrhage on CT scans [see comments] Kallmes DF, et al. **Radiology** 1996 Dec;201(3):657–60. Comment in: Radiology 1997 Jun;203(3):884.

[Recurrent hematemesis and hemobilia in ruptured hepatic artery aneurysm--differential diagnostic aspects of acute, upper gastrointestinal hemorrhage] Baartz T, et al. **Leber Magen Darm** 1996 Jan;26(1):42–6 (Eng. Abstr.) **(Ger)**

[Rectus sheath hematoma--detection of hemorrhage of ruptured aneurysm of the epigastric artery in CT] Weishaupt D, et al. **Vasa** 1997;26(1):55–7 (Eng. Abstr.) **(Ger)**

[Ruptured peripheral lenticulostriate artery aneurysm in a child: case report] Endo M, et al. **No Shinkei Geka** 1996 Oct;24(10):961–4 (Eng. Abstr.) **(Jpn)**

[Saccular aneurysm–like bleb formation after rupture of the internal carotid–posterior communicating artery aneurysm: a case with interesting angiographic findings] Hayashi T, et al. **No Shinkei Geka** 1997 Jan;25(1):85–8 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

SPECT with technetium–99m–HMPAO in relation to late cognitive outcome after surgery for ruptured cerebral aneurysms. Säveland H, et al. **Acta Neurochir (Wien)** 1996; 138(3):301–7

SURGERY

Aneurysm of the internal auditory artery: our experience and review of the literature. Banczerowski P, et al. **Acta Neurochir (Wien)** 1996;138(10):1157–62 (39 ref.)

Surgical approaches for vertebro–basilar trunk aneurysms located in the midline. Kawase T, et al. **Acta Neurochir (Wien)** 1996;138(4):402–10

Early aneurysm surgery and dehydration therapy in patients with severe subarachnoid haemorrhage without ICH. Oda S, et al. **Acta Neurochir (Wien)** 1996;138(9):1050–6

Thermal diffusion blood flow monitoring during aneurysm surgery. Ogata N, et al. **Acta Neurochir (Wien)** 1996; 138(6):726–31

Surgical outcome for multiple intracranial aneurysms. Orz Y, et al. **Acta Neurochir (Wien)** 1996;138(4):411–7

Loss and apoptosis of smooth muscle cells in intracranial aneurysms. Studies with in situ DNA end labeling and antibody against single–stranded DNA. Sakaki T, et al. **Acta Neurochir (Wien)** 1997;139(5):469–74; discussion 474–5

Ruptured cerebral aneurysm: influence of specialist and trainee–performed operations on outcome. Stranjalis G. **Acta Neurochir (Wien)** 1996;138(9):1067–9

The effect of endovascular therapy for cerebral arterial spasm, its limitation and pitfalls. Terada T, et al. **Acta Neurochir (Wien)** 1997;139(3):227–34

Intraarterial injection of amrinone for vasospasm induced by subarachnoid hemorrhage. Yoshida K, et al. **AJNR Am J Neuroradiol** 1997 Mar;18(3):492–6

False aneurysm of the superficial temporal artery: a surgical complication. Giele H, et al. **Ann Plast Surg** 1996 Feb; 36(2):219–20

Ruptured Salmonella mycotic aneurysm of the extracranial carotid artery. Rice HE, et al. **Ann Vasc Surg** 1997 Jul; 11(4):416–9

Infected aneurysms of the infrarenal abdominal aorta: diagnostic criteria and therapeutic strategy. Sessa C, et al. **Ann Vasc Surg** 1997 Sep;11(5):453–63

Indications for cisternal irrigation with urokinase in postoperative patients with aneurysmal subarachnoid haemorrhage. Hirashima Y, et al. **Br J Neurosurg** 1996 Oct; 10(5):477–81

Delayed surgery for ruptured intracranial aneurysms: a reappraisal. Maurice–Williams RS, et al. **Br J Neurosurg** 1997 Apr;11(2):104–9

Left ventricular endoaneurysmorrhaphy: effect on left ventricular size, shape and function. Çiçek S, et al. **Cardiology** 1997 Jul–Aug;88(4):340–5

Ruptured inferior mesenteric artery aneurysm due to segmental mediolytic arteritis. Kato T, et al. **Cardiovasc Surg** 1996 Oct;4(5):644–6 (10 ref.)

Kidney salvage in a case of ruptured renal artery aneurysm: case report and literature review. Schorn B, et al. **Cardiovasc Surg** 1997 Feb;5(1):134–6 (21 ref.)

Image guided excision of a ruptured feeding artery "pedicle aneurysm" associated with an arteriovenous malformation in a child: case report. Albert FK, et al. **Comput Aided Surg** 1997;2(1):5–10

Homograft replacement of thoraco–abdominal aorta for a leaking mycotic aneurysm. Pagano D, et al. **Eur J Cardiothorac Surg** 1996;10(5):383–5

Aneurysm of the membranous septum in adult patients with perimembranous ventricular septal defect. Yilmaz AT, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):307–11

Ruptured aneurysm of the renal artery in a woman with a solitary kidney. Witz M, et al. **Eur J Surg** 1996 Dec; 162(12):989–91

Risk factors for intestinal ischaemia after aortoiliac surgery: a combined cohort and case–control study of 2824 operations. Björck M, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):531–9

Endovascular repair of residual iliac artery aneurysms following surgery for ruptured abdominal aortic aneurysm. Panayiotopoulos YP, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):482–6

Aneurysm of the right colic artery. Girishkumar H, et al. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):305–7

Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy [see comments] Leipzig TJ, et al. **J Neurosurg** 1997 Feb; 86(2):220–5. Comment in: J Neurosurg 1997 Sep;87(3):486–7.

Endovascular treatment of ruptured posterior circulation aneurysms using electrolytically detachable coils. Nichols DA, et al. **J Neurosurg** 1997 Sep;87(3):374–80

Endovascular treatment of acutely ruptured and unruptured aneurysms of the basilar bifurcation. Raymond J, et al. **J Neurosurg** 1997 Feb;86(2):211–9

Orthotopic heart transplantation for Kawasaki disease after rupture of a giant coronary artery aneurysm. Koutlas TC, et al. **J Thorac Cardiovasc Surg** 1997 Jan;113(1):217–8

Infrarenal aortic aneurysms [letter; comment] Yusuf SW, et al. **N Engl J Med** 1997 Jun 12;336(24):1756; discussion 1757–8. Comment on: N Engl J Med 1997 Jan 2;336(1):59–60.

The outcome of early surgical management of ruptured posterior circulation aneurysms. Sagoh M, et al. **Neurol Res** 1997 Aug;19(4):385–8

Aneurysm of an azygos anterior cerebral artery: report of two cases and review of the literature. Baykal S, et al. **Neurosurg Rev** 1996;19(1):57–9 (10 ref.)

Intracranial arterial aneurysm complicating Behçet's disease. Ildan F, et al. **Neurosurg Rev** 1996;19(1):53–6

Intra–aortic balloon pump counterpulsation in the management of concomitant cerebral vasospasm and cardiac failure after subarachnoid hemorrhage: technical case report. Apostolides PJ, et al. **Neurosurgery** 1996 May; 38(5):1056–9; discussion 1059–60

Aneurysm clipping after endovascular treatment with coils: a report of eight patients. Civit T, et al. **Neurosurgery** 1996 May;38(5):955–60; discussion 960–1

Distal basilar perforator artery aneurysm: case report. Ghogawala Z, et al. **Neurosurgery** 1996 Aug;39(2):393–6

Glasgow Coma Scale in the prediction of outcome after early aneurysm surgery. Gotoh O, et al. **Neurosurgery** 1996 Jul; 39(1):19–24; discussion 24–5

Clinical grading and outcome after early surgery in aneurysmal subarachnoid hemorrhage. Hirai S, et al. **Neurosurgery** 1996 Sep;39(3):441–6; discussion 446–7

Subdural hemorrhage caused by de novo aneurysm complicating extracranial–intracranial bypass surgery: case report. Kohno K, et al. **Neurosurgery** 1996 May; 38(5):1051–5 (17 ref.)

The incidence of surgical complications is similar in good and poor grade patients undergoing repair of ruptured anterior circulation aneurysms: a retrospective review of 355 patients. Le Roux PD, et al. **Neurosurgery** 1996 May; 38(5):887–93; discussion 893–5

Ruptured distal accessory anterior cerebral artery aneurysm: case report. Morioka M, et al. **Neurosurgery** 1997 Feb; 40(2):399–401; discussion 401–2

Neurological and psychosocial outcome 4 to 7 years after subarachnoid hemorrhage. Ogden JA, et al. **Neurosurgery** 1997 Jul;41(1):25–34

Cerebral hemodynamic and metabolic changes caused by brain retraction after aneurysmal subarachnoid hemorrhage. Yundt KD, et al. **Neurosurgery** 1997 Mar; 40(3):442–50; discussion 450–1

Ruptured aneurysm of the superficial femoral artery. Farinon AM, et al. **Panminerva Med** 1995 Sep;37(3):155–8 (14 ref.)

Ruptured aneurysm of the internal iliac artery. Giordanengo F, et al. **Panminerva Med** 1995 Sep;37(3):150–4

A ruptured aneurysm at the distal end of the basilar artery fenestration associated with multiple fenestrations of the vertebrobasilar system: case report. Fujimura M, et al. **Surg Neurol** 1997 May;47(5):469–72 (22 ref.)

Coil embolization of ruptured vertebral dissection in acute stage with interlocking detachable coils. Manabe H, et al. **Surg Neurol** 1997 May;47(5):476–80 (25 ref.)

The effect of orbitozygomatic access for ruptured basilar and related aneurysms on management outcome. Neil–Dwyer G, et al. **Surg Neurol** 1997 Apr;47(4):354–8; discussion 358–9

Utilization of a mass–infusion system in the management of ruptured abdominal aortic aneurysms: an alternative application for devices employed in cardiopulmonary bypass. Katsumata T, et al. **Surg Today** 1996;26(10):852–3

Acute subdural hematoma associated with nontraumatic aneurysm rupture. Meyer F, et al. **Zentralbl Neurochir** 1997; 58(2):66–70 (31 ref.)

[Indications for surgical therapy of aneurysmic subarachnoid hemorrhage—current status] Pietilä TA, et al. **Wien Med Wochenschr** 1997;147(7–8):149–51 (21 ref.) (Eng. Abstr.) **(Ger)**

[Neurosurgical therapy of subarachnoid hemorrhage] Seifert V. **Wien Med Wochenschr** 1997;147(7–8):152–8 (20 ref.) (Eng. Abstr.) **(Ger)**

[A case report on graft replacement of ruptured aneurysm of the arch and the descending thoracic aorta associated with dense pulmonary adhesion] Hirai M, et al. **Kyobu Geka** 1996 May;49(5):367–71 (16 ref.) (Eng. Abstr.) **(Jpn)**

[An aged case of successful repair for the ruptured distal aortic arch aneurysm associated with aortic regurgitation: a case report] Kusuhara K, et al. **Kyobu Geka** 1996 Aug; 49(9):754–8 (Eng. Abstr.) **(Jpn)**

[A case of ruptured sinus of Valsalva aneurysm with bicuspid aortic valve] Ohkado A, et al. **Kyobu Geka** 1996 Jul; 49(7):567–9 (Eng. Abstr.) **(Jpn)**

[Management of aortoesophageal fistula due to thoracic aortic aneurysm] Sakurai T, et al. **Kyobu Geka** 1996 Sep; 49(10):815–20 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Acute brain expansion during emergency neck clipping surgery for cerebral aneurysms in a patient with dilated cardiomyopathy] Nakao M, et al. **Masui** 1996 Jun; 45(6):725–30 (Eng. Abstr.) **(Jpn)**

[A reconstruction of the left ventricle for post infarction left ventricular aneurysm complicated by ventricular septal perforation—a case report] Hata M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):792–5 (Eng. Abstr.) **(Jpn)**

[Postoperative olfactory dysfunction in interhemispheric approach for ruptured anterior communicating artery aneurysms] Ito S, et al. **No Shinkei Geka** 1996 Jul; 24(7):625–8 (Eng. Abstr.) **(Jpn)**

[A ruptured aneurysm of the distal posterior inferior cerebellar artery associated with acute subdural hematoma of the posterior fossa: a case report] Miyagi A, et al. **No Shinkei Geka** 1997 Jun;25(6):537–41 (Eng. Abstr.) **(Jpn)**

[A case report of a distal posterior cerebral artery (P3) aneurysm, not accessible through a subtemporal approach] Nishimura T, et al. **No Shinkei Geka** 1996 Nov; 24(11):1011–4 (Eng. Abstr.) **(Jpn)**

[Efficacy of MR angiographic original images on surgery for posterior communicating artery aneurysms] Takeichi Y, et al. **No Shinkei Geka** 1997 May;25(5):411–6 (Eng. Abstr.) **(Jpn)**

[Simultaneous rupture of multiple intracranial aneurysms: a case report] Tsurushima H, et al. **No Shinkei Geka** 1996 Apr;24(4):385–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Intraoperative aneurysmal rupture at the neck] Yasui T, et al. **No Shinkei Geka** 1997 Mar;25(3):271–6 (Eng. Abstr.) **(Jpn)**

[A retrospective analysis of the outcomes of patients with aneurysmal subarachnoid hemorrhages: a focus on the prognostic factors] Yoshikai S, et al. **No Shinkei Geka** 1996 Aug;24(8):733–8 (Eng. Abstr.) **(Jpn)**

[The procedure for the surgical treatment of intracranial arterial aneurysms in cerebral vascular spasm and ischemia] Krylov VV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Jul–Sep;(3):3–8 (Eng. Abstr.) **(Rus)**

THERAPY

MR artifacts, heat production, and ferromagnetism of Guglielmi detachable coils. Hartman J, et al. **AJNR Am J Neuroradiol** 1997 Mar;18(3):497–501

Retrievable versus nonretrievable coils [letter; comment] Higashida RT. **AJNR Am J Neuroradiol** 1997 Aug; 18(7):1390. Comment on: AJNR Am J Neuroradiol 1997 Aug;18(7):1389–90.

Does electrothrombosis occur immediately after embolization of an aneurysm with Guglielmi detachable coils? Horowitz M, et al. **AJNR Am J Neuroradiol** 1997 Mar;18(3):510–3

Haemodynamic consequences of embolizing aneurysms: a transcranial Doppler study. Rowe JG, et al. **Br J Neurosurg** 1995;9(6):749–57

Spontaneous recurrent hemarthrosis of the knee joint: endovascular treatment of a ruptured aneurysm with platinum microcoils. A case report. Klein GE, et al. **J Bone Joint Surg Am** 1997 Apr;79(4):594–6

Endovascular management of unusual aneurysms of the axillary and subclavian arteries. Sullivan TM, et al. **J Endovasc Surg** 1996 Nov;3(4):389–95

Management of poor–grade patients with ruptured intracranial aneurysm. Lee KC, et al. **Keio J Med** 1997 Jun;46(2):69–73

[Treatment of 315 intracranial aneurysms using electrically controlled detachable coils] Houdart E. **Bull Acad Natl Med** 1996 Jun–Jul;180(6):1173–83; discussion 1183–6 (Eng. Abstr.) **(Fre)**

[Forum: Clips and coils in aneurysm treatment] Spetzger U, et al. **Wien Med Wochenschr** 1997;147(7–8):172–7 (62 ref.) (Eng. Abstr.) **(Ger)**

[A case of multiple cerebral mycotic aneurysms treated with endovascular surgery] Katakura K, et al. **No Shinkei Geka** 1995 Dec;23(12):1127–32 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Usefulness of the interlocking detachable coil for the repeatedly ruptured dissecting aneurysm of the vertebral artery in the acute stage] Nakada M, et al. **No Shinkei Geka** 1997 Jan;25(1):57–60 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Echocardiographic diagnosis of subepicardial aneurysm ruptured into the right ventricle after inferior myocardial infarction. Hironaka E, et al. **J Am Soc Echocardiogr** 1997 Mar;10(2):192–6

Pseudoaneurysm and ventricular septal rupture complicated with inferior myocardial infarction diagnosed by two–dimensional and Doppler echocardiography: case report. Kawai J, et al. **J Cardiol** 1996 Feb;27(2):77–83

ANF see **ATRIAL NATRIURETIC FACTOR**

ANF RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ANGELMAN SYNDROME

Diagnostic testing for Prader–Willi and Angelman syndromes: response [letter; comment] Smith A, et al. **Am J Hum Genet** 1997 Jul;61(1):241–4. Comment on: Am J Hum Genet 1997 Jan;60(1):244–7.

Angelman syndrome in adulthood. Laan LA, et al. **Am J Med Genet** 1996 Dec 18;66(3):356–60

[Prader–Willi syndrome, Angelman syndrome] Narahara K. **Ryoikibetsu Shokogun Shirizu** 1996;(15):220–3 (22 ref.) **(Jpn)**

ANGELMAN SYNDROME

BLOOD

Elevated plasma gamma-aminobutyric acid (GABA) levels in individuals with either Prader-Willi syndrome or Angelman syndrome. Ebert MH, et al.
J Neuropsychiatry Clin Neurosci 1997 Winter;9(1):75-80

DIAGNOSIS

Diagnostic testing: a cost analysis for Prader-Willi and Angelman syndromes [letter] [see comments] Monaghan KG, et al. **Am J Hum Genet** 1997 Jan;60(1):244-7. Comment in: Am J Hum Genet 1997 Jul;61(1):241-4.

Evolution of epilepsy and EEG findings in Angelman syndrome. Laan LA, et al. **Epilepsia** 1997 Feb;38(2):195-9

Analysis of parent of origin specific DNA methylation at SNRPN and PW71 in tissues: implication for prenatal diagnosis. Kubota T, et al. **J Med Genet** 1996 Dec; 33(12):1011-4

An Angelman syndrome clinic: report on 24 patients. Leitner RP, et al. **J Paediatr Child Health** 1996 Apr;32(2):94-8

[EEG and early diagnosis of Angelman syndrome] Ostergaard JR, et al. **Ugeskr Laeger** 1997 Feb 24; 159(9):1273-6 (Eng. Abstr.) **(Dan)**

GENETICS

Molecular analysis of an extra inv dup(15)(q13) chromosome in two patients with Angelman syndrome. Buchholz T, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(1-2):217-20

Phenotype-karyotype-genotype correlations in Prader-Willi and Angelman syndromes: preliminary results. Cecconi A, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(1-2):227-31

A case of Angelman syndrome arising as a result of a de novo Robertsonian translocation. Ramsden S, et al.
Acta Genet Med Gemellol (Roma) 1996;45(1-2):255-61

Different mechanisms and recurrence risks of imprinting defects in Angelman syndrome. Bürger J, et al.
Am J Hum Genet 1997 Jul;61(1):88-93

Angelman syndrome associated with an inversion of chromosome 15q11.2q24.3. Greger V, et al.
Am J Hum Genet 1997 Mar;60(3):574-80

Detection of imprinting mutations in Angelman syndrome using a probe for exon alpha of SNRPN [letter] Beuten J, et al. **Am J Med Genet** 1996 May 17;63(2):414-5

Methylation analysis at three different loci within the imprinted region of chromosome 15q11-13 [letter] Buchholz T, et al. **Am J Med Genet** 1997 Oct 3;72(1):117-9

Phenotypic differences in Angelman syndrome patients: imprinting mutations show less frequently microcephaly and hypopigmentation than deletions. Bürger J, et al.
Am J Med Genet 1996 Dec 11;66(2):221-6

Unexpected familial recurrence in Angelman syndrome. Connerton-Moyer KJ, et al. **Am J Med Genet** 1997 Jun 13;70(3):253-60

Genotype and phenotype in Angelman syndrome caused by paternal UPD 15 [letter] Prasad C, et al.
Am J Med Genet 1997 Jun 13;70(3):328-9

Clinical spectrum and molecular diagnosis of Angelman and Prader-Willi syndrome patients with an imprinting mutation. Saitoh S, et al. **Am J Med Genet** 1997 Jan 20; 68(2):195-206

Manifestations in institutionalised adults with Angelman syndrome due to deletion. Sandanam T, et al.
Am J Med Genet 1997 Jun 27;70(4):415-20

FISH detection of chromosome 15 deletions in Prader-Willi and Angelman syndromes [published erratum appears in Am J Med Genet 1996 Aug 23;64(3):527] Teshima I, et al. **Am J Med Genet** 1996 Mar 29;62(3):217-23

Robertsonian (15q;15q) translocation in a child with Angelman syndrome: evidence of uniparental disomy. Tonk V, et al. **Am J Med Genet** 1996 Dec 30;66(4):426-8

Inherited unbalanced subtelomeric translocation in a child with 8p- and Angelman syndromes. Wenger SL, et al.
Am J Med Genet 1997 May 16;70(2):150-4

Imprint switch mechanism indicated by mutations in Prader-Willi and Angelman syndromes. Kelsey G, et al.
Bioessays 1997 May;19(5):361-5 (29 ref.)

A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. Zeschnigk M, et al.
Eur J Hum Genet 1997 Mar-Apr;5(2):94-8

The E6-Ap ubiquitin-protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region [letter] Sutcliffe JS, et al. **Genome Res** 1997 Apr; 7(4):368-77

Localization of the tight junction protein gene TJP1 to human chromosome 15q13, distal to the Prader-Willi/Angelman region, and to mouse chromosome 7. Mohandas TK, et al. **Genomics** 1995 Dec 10;30(3):594-7

Imprinted segments in the human genome: different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method. Zeschnigk M, et al. **Hum Mol Genet** 1997 Mar; 6(3):387-95

Unilateral cleft lip in a boy with Angelman syndrome. Rösby O, et al. **J Craniofac Genet Dev Biol** 1996 Apr-Jun; 16(2):122-5

Counselling dilemmas associated with the molecular characterisation of two Angelman syndrome families. Gilbert HL, et al. **J Med Genet** 1997 Aug;34(8):651-5

Familial translocations involving 15q11-q13 can give rise to interstitial deletions causing Prader-Willi or Angelman syndrome. Horsthemke B, et al. **J Med Genet** 1996 Oct; 33(10):848-51

Clinical features in four patients with Angelman syndrome resulting from paternal uniparental disomy. Smith A, et al. **J Med Genet** 1997 May;34(5):426-9

Genomic imprinting and its relevance to genetic diseases. Niikawa N. **Jpn J Hum Genet** 1996 Dec;41(4):351-61 (32 ref.)

A candidate model for Angelman syndrome in the mouse. Cattanach BM, et al. **Mamm Genome** 1997 Jul;8(7):472-8

Genes for Prader Willi syndrome/Angelman syndrome and fragile X syndrome are homologous, with genetic imprinting and unstable trinucleotide repeats causing mental retardation, autism and aggression. Fischer KM. **Med Hypotheses** 1996 Oct;47(4):289-98

Genomic imprinting: potential function and mechanisms revealed by the Prader-Willi and Angelman syndromes. Glenn CC, et al. **Mol Hum Reprod** 1997 Apr;3(4):321-32 (110 ref.)

Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Albrecht U, et al. **Nat Genet** 1997 Sep;17(1):75-8

Imprinting of the Angelman syndrome gene, UBE3A, is restricted to brain [letter] Hoffman AR. **Nat Genet** 1997 Sep;17(1):12-3

UBE3A/E6-AP mutations cause Angelman syndrome. Kishino T, et al. **Nat Genet** 1997 Jan;15(1):70-3

Methylation-specific PCR simplifies imprinting analysis [letter] Kubota T, et al. **Nat Genet** 1997 May;16(1):16-7

De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Matsuura T, et al. **Nat Genet** 1997 Jan;15(1):74-7

The Angelman syndrome candidate gene, UBE3A/E6-AP, is imprinted in brain [letter] Rougeulle C, et al.
Nat Genet 1997 Sep;17(1):14-5

Fishing out the Angelman syndrome gene [news] Donlon T. **Nat Med** 1997 Mar;3(3):281

Angelman syndrome assessed by neurological and molecular cytogenetic investigations. Hou JW, et al.
Pediatr Neurol 1997 Jan;16(1):17-22

Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior. Homanics GE, et al.
Proc Natl Acad Sci U S A 1997 Apr 15;94(8):4143-8

Minimal definition of the imprinting center and fixation of chromosome 15q11-q13 epigenotype by imprinting mutations. Saitoh S, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7811-5

[Genomic imprinting and its role in Prader-Willi and Angelman syndromes] Mglinets VA, et al. **Genetika** 1996 Dec;32(12):1605-15 (91 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Clinical features in 27 patients with Angelman syndrome resulting from DNA deletion. Smith A, et al.
J Med Genet 1996 Feb;33(2):107-12 (42 ref.)

PHYSIOPATHOLOGY

Angelman's syndrome: clinical and electroencephalographic findings. Rubin DI, et al.
Electroencephalogr Clin Neurophysiol 1997 Apr; 102(4):299-302

ANGER

Angry? Let's talk about it! Thomas SP. **Appl Nurs Res** 1997 May;10(2):80-5

Educational attainment, anger, and the risk of triggering myocardial infarction onset. The Determinants of Myocardial Infarction Onset Study Investigators. Mittleman MA, et al. **Arch Intern Med** 1997 Apr 14; 157(7):769-75

The expression of anger and its consequences. Deffenbacher JL, et al. **Behav Res Ther** 1996 Jul;34(7):575-90

Wrath. Chapman S. **BMJ** 1996 Dec 21-28;313(7072):1593-4

Anger over HIV questions cancels blood clinic at Ottawa university. Gray C. **Can Med Assoc J** 1997 Apr 15; 156(8):1181-3

Ethnic differences in circumstances of abuse and symptoms of depression and anger among sexually abused black and Latino boys. Moisan PA, et al. **Child Abuse Negl** 1997 May; 21(5):473-88

Parenting stress and anger expression as predictors of child abuse potential. Rodriguez CM, et al. **Child Abuse Negl** 1997 Apr;21(4):367-77

The interpersonal context of emotion: anger with close friends and classmates. Whitesell NR, et al. **Child Dev** 1996 Aug;67(4):1345-59

Anger and hostility in maritally violent men: conceptual distinctions, measurement issues, and literature review. Eckhardt CI, et al. **Clin Psychol Rev** 1997;17(4):333-58 (111 ref.)

"Missed, dissed, and pissed": making meaning of neighborhood risk, fear and anger management in urban black youth. Stevenson HC Jr.
Cult Divers Ment Health 1997;3(1):37-52

Influences of parental drug use, personality, and child rearing on the toddler's anger and negativity. Brook JS, et al.
Genet Soc Gen Psychol Monogr 1996 Feb;122(1):107-28

Children's responding to live interadult conflict: the role of form of anger expression. el-Sheikh M, et al.
J Abnorm Child Psychol 1996 Aug;24(4):401-15

Personality and symptom profiles of the angry hostile depressed patient. Bagby RM, et al. **J Affect Disord** 1997 Sep;45(3):155-60

Differential pharmacological treatment response in high angry hostile and low angry hostile depressed patients: a retrospective analysis. Bagby RM, et al.
J Affect Disord 1997 Sep;45(3):161-6

Prevalence and correlates of anger attacks: a two site study. Gould RA, et al. **J Affect Disord** 1996 Jun 20;39(1):31-8

Anger, patients, families, and risk management. Utley JR.
J Card Surg 1996 Nov-Dec;11(6):434-5

Blood pressure reactivity in urban youth during angry and normal talking. Liehr P, et al. **J Cardiovasc Nurs** 1997 Jul; 11(4):85-94

Cognitive-behavioral treatment for severe anger in posttraumatic stress disorder. Chemtob CM, et al.
J Consult Clin Psychol 1997 Feb;65(1):184-9

Cynicism, hostility, and suicidal ideation in depressed outpatients. Nierenberg AA, et al. **J Nerv Ment Dis** 1996 Oct;184(10):607-10

Escalation in response to persistent annoyance: groups versus individuals and gender effects. Mikolic JM, et al.
J Pers Soc Psychol 1997 Jan;72(1):151-63

Laboratory pain and styles of coping with anger. Gelkopf M. **J Psychol** 1997 Jan;131(1):121-3

Anger and depressed affect: interindividual and intraindividual perspectives. Robbins PR, et al.
J Psychol 1997 Sep;131(5):489-500

Cynical hostility, anger, and resting blood pressure. Spicer J, et al. **J Psychosom Res** 1996 Apr;40(4):359-68

Anger coping styles and perceived social support. Palfai TP, et al. **J Soc Psychol** 1997 Aug;137(4):405-11

Anger regulation deficits in combat-related posttraumatic stress disorder. Chemtob CM, et al. **J Trauma Stress** 1997 Jan;10(1):17-36 (28 ref.)

Impaired auditory recognition of fear and anger following bilateral amygdala lesions. Scott SK, et al. **Nature** 1997 Jan 16;385(6613):254-7

Brief aikido training versus karate and golf training and university students' scores on self-esteem, anxiety, and expression of anger. Foster YA. **Percept Mot Skills** 1997 Apr;84(2):609-10

Psychophysiology of anger and violent behavior. Scarpa A, et al. **Psychiatr Clin North Am** 1997 Jun;20(2):375-94 (96 ref.)

A meta-analytic review of research on hostility and physical health. Miller TQ, et al. **Psychol Bull** 1996 Mar; 119(2):322-48

Anger and drug addiction. De Mojá CA, et al.
Psychol Rep 1997 Aug;81(1):152-4

Expression of anger by Samoan adults. Steele MS, et al.
Psychol Rep 1996 Dec;79(3 Pt 2):1339-48

Anger attacks and treatment nonadherence in a perinatal psychiatry clinic. Mammen O, et al.
Psychopharmacol Bull 1997;33(1):105-8

Effects of cynical hostility, anger out, anxiety, and defensiveness on ambulatory blood pressure in black and white college students. Shapiro D, et al.
Psychosom Med 1996 Jul-Aug;58(4):354-64

Alexithymia, anger, and interpersonal behavior. Berenbaum H, et al. **Psychother Psychosom** 1996;65(4):203-8

Anger, impulsivity and suicide risk. Horesh N, et al.
Psychother Psychosom 1997;66(2):92-6

Generalized versus spouse-specific anger/hostility and men's violence against intimates. Boyle DJ, et al.
Violence Vict 1996 Winter;11(4):293-317

[Anger outbursts in unipolar depressive disorders] Fava M. **Encephale** 1997 Jun;23 Spec No 3:39-42 (19 ref.) (Eng. Abstr.) **(Fre)**

[Anger and risk of suicide. Study of elderly psychiatric patients] Hodapp V, et al. **Nervenarzt** 1997 Jan;68(1):55-61 (35 ref.) (Eng. Abstr.) **(Ger)**

[Relationship between psychosocial and cardiovascular variables in adolescents] Bretaña Casado ML, et al.
An Esp Pediatr 1996 Dec;45(6):603-8 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Fluoxetine treatment of anger attacks: a replication study. Fava M, et al. **Ann Clin Psychiatry** 1996 Mar;8(1):7-10

The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men--a clinical research center study. Tricker R, et al.
J Clin Endocrinol Metab 1996 Oct;81(10):3754-8

A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Fava M, et al. **Psychopharmacol Bull** 1997; 33(1):101-3

PHYSIOLOGY

Anger expression correlates with platelet aggregation. Wenneberg SR, et al. **Behav Med** 1997 Winter;22(4):174-7

Anger and myocardial infarction [letter; comment] Friedman EH. **Circulation** 1996 Oct 1;94(7):1788. Comment on: Circulation 1995 Oct 1;92(7):1720-5.

A prospective study of anger and coronary heart disease. The Normative Aging Study. Kawachi I, et al.
Circulation 1996 Nov 1;94(9):2090-5

Anger and myocardial infarction [letter; comment] Ketterer MW. **Circulation** 1996 Oct 1;94(7):1788-9. Comment on: Circulation 1995 Oct 1;92(7):1720-5.

Anger expression and cardiovascular reactivity to mental stress: a spectral analysis approach. Laude D, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):901–11

Facial EMG in an anger–provoking situation: individual differences in directing anger outwards or inwards. Jäncke L. **Int J Psychophysiol** 1996 Oct;23(3):207–14

Anger management style, degree of expressed anger, and gender influence cardiovascular recovery from interpersonal harassment. Faber SD, et al. **J Behav Med** 1996 Feb;19(1):31–53

Anger management training with mild essential hypertensive patients. Larkin KT, et al. **J Behav Med** 1996 Oct; 19(5):415–33

The outward expression of anger, the inward experience of anger and CVR: the role of vocal expression. Siegman AW, et al. **J Behav Med** 1997 Feb;20(1):29–45

Marital arguments lead to weakened immune system in older couples [news] **Oncology (Huntingt)** 1996 May;10(5):760

Anger management style, hostility and spouse responses: gender differences in predictors of adjustment among chronic pain patients. Burns JW, et al. **Pain** 1996 Mar; 64(3):445–53

The premenstrual phase and reactions to aversive events: a study of hormonal influences on emotionality. Van Goozen SH, et al. **Psychoneuroendocrinology** 1996 Jul;21(5):479–97

Cardiovascular responses during effortful active coping and acute experience of anger in women. Bongard S, et al. **Psychophysiology** 1997 Jul;34(4):459–66

Defensive hostility and anger expression: relationship to additional heart rate reactivity during active coping. Larson MR, et al. **Psychophysiology** 1997 Mar;34(2):177–84

Insulin and glucose: relationships with hassles, anger, and hostility in nondiabetic older adults. Vitaliano PP, et al. **Psychosom Med** 1996 Sep–Oct;58(5):489–99

Neurobiology of anger–hostility and coronary risk [letter] Friedman EH. **Psychother Psychosom** 1996;65(4):222

ANGIITIS see **VASCULITIS**

ANGIITIS, ALLERGIC CUTANEOUS see **VASCULITIS, ALLERGIC CUTANEOUS**

ANGIITIS, ALLERGIC GRANULOMATOUS see **CHURG–STRAUSS SYNDROME**

ANGIITIS, HYPERSENSITIVITY see **VASCULITIS, HYPERSENSITIVITY**

ANGIITIS, LEUKOCYTOCLASTIC see **VASCULITIS, HYPERSENSITIVITY**

ANGINA AT REST see **ANGINA, UNSTABLE**

ANGINA, MICROVASCULAR see **SYNDROME X**

ANGINA PECTORIS

Morbidity and use of medical resources in patients with chest pain and normal or near–normal coronary arteries. Albertsson P, et al. **Am J Cardiol** 1997 Feb 1;79(3):299–304

Angina pectoris and progressive fatigue in a 61–year–old man [clinical conference] Schäfer S, et al. **Circulation** 1996 Dec 15;94(12):3376–81

Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. **Eur Heart J** 1997 Mar;18(3):394–413 (121 ref.)

Angina in the elderly. Duprez DA. **Eur Heart J** 1996 Dec; 17 Suppl G:8–13 (28 ref.)

Evaluation of patients with minimally obstructive coronary artery disease and angina. Hasdai D, et al. **Int J Cardiol** 1996 Mar;53(3):203–8 (34 ref.)

[Angina pectoris (editorial)] Yasuse H. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):189–90 **(Jpn)**

[Organic angina] Hashimoto T. **Ryoikibetsu Shokogun Shirizu** 1996;(12):629–32 (9 ref.) **(Jpn)**

[Coronary thrombotic angina] Hirashima O, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):577–80 (11 ref.) **(Jpn)**

[Stable angina, effort angina, stable effort angina] Saitoh T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):561–5 (18 ref.) **(Jpn)**

[Preinfarction angina and postinfarction angina] Suzuki T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):700–3 (13 ref.) **(Jpn)**

[Mixed angina pectoris] Yasutake M. **Ryoikibetsu Shokogun Shirizu** 1996;(12):654–6 (6 ref.) **(Jpn)**

[Coronary spastic angina and its related disease] Yoshimura M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):621–4 (5 ref.) **(Jpn)**

[Prehospital delay in patients with ischemic chest pain in the Province of Alicante. Multicenter Study of Prehospital Delay in Patients with chest Pain (see comments)] Latour Pérez J, et al. **Med Clin (Barc)** 1996 Jun 15;107(3):81–5 (Eng. Abstr.). Comment in: Med Clin (Barc) 1996 Jun 15;107(3):93–4. **(Spa)**

[Delay in the diagnosis and treatment of patients with ischemic chest pain: how and why we should improve (editorial; comment)] Mont Girbau L. **Med Clin (Barc)** 1996 Jun 15;107(3):93–4. Comment on: Med Clin (Barc) 1996 Jun 15;107(3):81–5. **(Spa)**

BLOOD

Circulating endothelin–1 levels in type 2 diabetic patients with ischaemic heart disease. Donatelli M, et al. **Acta Diabetol** 1996 Sep;33(3):246–8

Insulin–like growth factor–I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X. Bøtker HE, et al. **Am J Cardiol** 1997 Apr 1;79(7):961–3

Relationship between plasma endothelin–1 levels and myocardial ischemia induced by exercise testing. Fontana F, et al. **Am J Cardiol** 1997 Apr 1;79(7):957–9

Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Verhoef P, et al. **Am J Cardiol** 1997 Mar 15;79(6):799–801

Twenty–four hour plasma profile of sustained–release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials. Baxter T, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):333–5

Local changes in the plasma endothelin level in the coronary artery immediately after percutaneous transluminal coronary angioplasty. Vojácek J, et al. **Cardiology** 1997 Jan–Feb;88(1):1–5

Increased serotonin release across the coronary bed during a nonischemic interval in patients with vasospastic angina. Murakami Y, et al. **Clin Cardiol** 1996 Jun;19(6):473–6

Effects of mental and physical stress on platelet function in patients with stable angina pectoris and healthy controls. Wallén NH, et al. **Eur Heart J** 1997 May;18(5):807–15

Concurrent development of hemiplegia and angina pectoris in a 46–year–old man with familial hypercholesterolemia and elevated serum Lp(a) concentrations. Kazumi T, et al. **J Atheroscler Thromb** 1994;1(2):129–31

Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study in Stockholm (APSIS). A comparison with healthy controls. Held C, et al. **J Intern Med** 1997 Jan;241(1):59–69

An index predicting coronary heart disease: LDL/HDL x 5. Kimata S, et al. **Jpn Heart J** 1997 Jan;38(1):1–9

Production of C–reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group [see comments] Haverkate F, et al. **Lancet** 1997 Feb 15;349(9050):462–6. Comment in: Lancet 1997 Apr 26;349(9060):1252–3. Comment in: Lancet 1997 Apr 26;349(9060):1253.

Suppressed anti–aggregating and cGMP–elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris. Chirkov YY, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Oct; 354(4):520–5

Enhanced platelet aggregability under high shear stress after treadmill exercise in patients with effort angina. Tokuue J, et al. **Thromb Haemost** 1996 May;75(5):833–7

[Behavior of plasma levels of endothelin 1 and noradrenaline in patients with stable angina during the cold pressor test] Letizia C, et al. **Recenti Prog Med** 1997 Jul–Aug; 88(7–8):312–6 (Eng. Abstr.) **(Ita)**

[Angina pectoris: the lipid profile and clinical practice] Diogo AN. **Acta Med Port** 1997 Apr;10(4):293–8 (25 ref.) (Eng. Abstr.) **(Por)**

CHEMICALLY INDUCED

Dipyridamole–induced angina pectoris during sestamibi stress test in patients with significant coronary artery disease: clinical, angiographic, and nuclear determinants. Rosseel M, et al. **Angiology** 1997 Apr;48(4):301–7

Chest symptoms after sumatriptan: a two–year clinical practice review in 735 consecutive migraine patients. Visser WH, et al. **Cephalalgia** 1996 Dec;16(8):554–9

Vasospastic angina induced by nonsteroidal anti–inflammatory drugs. Mori E, et al. **Clin Cardiol** 1997 Jul;20(7):656–8

Adenosine–induced chest pain: is it due to myocardial ischaemia? Clinical, electrocardiographic, haemodynamic and metabolic study. Mehta AB, et al. **Indian Heart J** 1997 May–Jun;49(3):267–70

Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer. Yano S, et al. **Jpn Circ J** 1996 Mar;60(3):185–8

A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography. Lewis PJ, et al. **Neurology** 1997 Jun; 48(6):1542–50

Beta–endorphin but not metenkephalin counteracts adenosine–provoked angina pectoris–like pain. Sylvén C, et al. **Neuroreport** 1996 Aug 12;7(12):1982–4

Iatrogenic chest pain—5–fluorouracil cardiotoxicity [letter] Cassidy J. **QJM** 1997 Apr;90(4):305–6

COMPLICATIONS

Association of preceding angina with in–hospital life–threatening ventricular tachyarrhythmias and late potentials in patients with a first acute myocardial infarction. Tamura K, et al. **Am Heart J** 1997 Mar; 133(3):297–301

Effects of short–term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia. de Divitiis M, et al. **Am J Cardiol** 1996 Oct 1;78(7):763–8

Echocardiographic prediction of complications in patients with chest pain. Fleischmann KE, et al. **Am J Cardiol** 1997 Feb 1;79(3):292–8

Prognostic significance of angina pectoris > or = 30 days before acute myocardial infarction in patients > or = 75 years of age. Jacquemin L, et al. **Am J Cardiol** 1997 Jul 15;80(2):198–200

Chest pain, congestive heart failure, and death in a 65–year–old man [clinical conference] **Am J Med** 1997 Jan; 102(1):118–25

Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine. Di Somma S, et al. **Cardiologia** 1996 Jul;41(7):635–43

The prognostic significance of angina pectoris experienced during the first month following acute myocardial infarction. Jespersen CM. **Clin Cardiol** 1997 Jul;20(7):623–6

Angina and left ventricular dysfunction. Dargie HJ. **Eur Heart J** 1996 Dec;17 Suppl G:2–7 (25 ref.)

Angina pectoris in patients with a history of myocardial infarction. Sellier P. **Eur Heart J** 1996 Dec;17 Suppl G:25–9 (30 ref.)

Angina in McArdle's disease. Nicholls DP, et al. **Heart** 1996 Oct;76(4):372–3

Plasma lipids, dehydroepiandosterone sulphate and insulin concentrations in elderly overweight angina patients, and effect of weight loss. Hankey CR, et al. **Int J Obes Relat Metab Disord** 1997 Jan;21(1):72–7

The relationship between resting systolic blood pressure and cutaneous pain perception in cardiac patients with angina pectoris and controls. Sheffield D, et al. **Pain** 1997 Jul; 71(3):249–55

Successful treatment of a patient with Graves' disease on hemodialysis complicated by antithyroid drug–induced granulocytopenia and angina pectoris. Miyasaka Y, et al. **Thyroid** 1997 Aug;7(4):621–4

[Antiarrhythmic effects of prajmaline (Neo–Gilurythmal) in stable angina pectoris in light of Holter electrocardiographic monitoring] Janicki K, et al. **Przegl Lek** 1995;52(10):485–491 (Eng. Abstr.) **(Pol)**

[Double origin of anterior descending artery—from the left and right coronary arteries—associated with anomalous origin of the circumflex artery] Bastos L de C, et al. **Arq Bras Cardiol** 1996 Dec;67(6):407–9 (Eng. Abstr.) **(Por)**

DIAGNOSIS

An intermittently volvulating paraoesophageal hernia mimicking angina pectoris. A case report. Tielliu I, et al. **Acta Chir Belg** 1997 Apr;97(2):81–3

Diagnostic value of exercise electrocardiography and angina after coronary artery stenting. Benestent Study Group. Legrand V, et al. **Am Heart J** 1997 Feb;133(2):240–8

Association of systolic blood pressure at time of myocardial ischemia with angina pectoris during exercise testing. Go BM, et al. **Am J Cardiol** 1997 Apr 1;79(7):954–6

Ischemic–like ST–segment changes during Holter monitoring in patients with angina pectoris and normal coronary arteries but negative exercise testing. Lanza GA, et al. **Am J Cardiol** 1997 Jan 1;79(1):1–6

QT dispersion ratio in patients with unstable angina pectoris (a new risk factor?). Cin VG, et al. **Clin Cardiol** 1997 Jun; 20(6):533–5

Coronary artery spasm in patients with normal or near normal coronary arteries. Long–term follow–up of 277 patients [see comments] Bory M, et al. **Eur Heart J** 1996 Jul;17(7):1015–21. Comment in: Eur Heart J 1996 Jul;17(7):980–2.

Gastro–oesophageal reflux in patients with coronary artery disease: how common is it and does it matter? Mehta AJ, et al. **Eur J Gastroenterol Hepatol** 1996 Oct;8(10):973–8

Geriatrics photo quiz. Angina pectoris. Gross JS, et al. **Geriatrics** 1996 Nov;51(11):19, 61

Chest discomfort and the region of cardiac ischemia [letter] Ilia R, et al. **Int J Cardiol** 1996 Jul 26;55(2):204

Troponin T in patients with cardiac chest pain [letter] Tarpey A, et al. **J Accid Emerg Med** 1997 May;14(3):200–1

Vitamin c status and undiagnosed angina. Ness AR, et al. **J Cardiovasc Risk** 1996 Aug;3(4):373–7

Angina pectoris by Rose questionnaire does not predict cardiovascular disease in treated hypertensive patients. Madhavan S, et al. **J Hypertens** 1995 Nov;13(11):1307–12

The correlation between everyday stress and angina pectoris: a longitudinal study. Verthein U, et al. **J Psychosom Res** 1997 Sep;43(3):241–5

Abnormalities of T waves in effort angina pectoris patients at rest evaluated by spatial velocity electrocardiogram. Sasaki A, et al. **Jpn Heart J** 1996 Nov;37(6):879–89

Angina for 14 years. Stöllberger C, et al. **Lancet** 1997 May 3;349(9061):1292

[The long–term prognosis of patients with acute chest pain of various origins] Launbjerg J, et al. **Ugeskr Laeger** 1997 Jan 6;159(2):175–9 (Eng. Abstr.) **(Dan)**

[A case–based and multi–media computer learning program on the topic of myocardial infarct, angina pectoris and mitral valve stenosis] Friedl R, et al. **Med Klin** 1996 Sep 15;91(9):564–9 (Eng. Abstr.) **(Ger)**

[Endothelin and big endothelin in coronary heart disease and acute coronary syndromes] Borries M, et al. **Z Kardiol** 1996 Oct;85(10):761–7 (Eng. Abstr.) **(Ger)**

[Quality of life in advanced coronary heart disease] Siegrist J, et al. **Z Kardiol** 1997;86 Suppl 1:1–7 (22 ref.) (Eng. Abstr.)

(Ger)
[Angina pectoris: progress in diagnosis and treatment. II. Progress in imaging diagnosis. 1. Key points in electrocardiographic diagnosis] Hirai T, et al. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):208–13 (9 ref.) (Jpn)
[Angina pectoris: progress in diagnosis and treatment. I. Physiopathology. 2. Symptoms most likely associated with angina pectoris] Noda T, et al. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):196–200 (4 ref.) (Jpn)
[The stress electrocardiogram in the evaluation of angina pectoris] Monteiro J. **Acta Med Port** 1997 Apr;10(4):249–53 (33 ref.) (Eng. Abstr.) (Por)
[The diverse aspects of angina pectoris (editorial)] Mota E. **Acta Med Port** 1997 Apr;10(4):225–6 (Por)
[Angina pectoris. Silent ischemia] Tuna JL. **Acta Med Port** 1997 Apr;10(4):267–75 (50 ref.) (Eng. Abstr.) (Por)
[The possibility for the presumed detection of the obstructive lesion of the coronary arteries in stenocardia patients by the data from circadian ECG monitoring and stress tests] Kuleshova EV, et al. **Ter Arkh** 1997;69(4):26–30 (Eng. Abstr.) (Rus)
[The importance of ambulatory ECG monitoring for determining the prognosis of patients with stable stenocardia] Shipilova T, et al. **Ter Arkh** 1997;69(4):31–4 (Eng. Abstr.) (Rus)
[Angina pectoris. The concept and its classification. The Angina Pectoris Study Group of the Ischemic Cardiopathy Section and Coronary Units of the Spanish Society of Cardiology] Azpitarte Almagro J, et al. **Rev Esp Cardiol** 1995 Jun;48(6):373–82 (37 ref.) (Eng. Abstr.) (Spa)
[Diagnostic methods in angina pectoris. The Angina Pectoris Study Group of the Ischemic Cardiopathy Section and Coronary Units of the Spanish Society of Cardiology] Cordo Mollar JC, et al. **Rev Esp Cardiol** 1995 Jun; 48(6):383–93 (62 ref.) (Eng. Abstr.) (Spa)

DIET THERAPY

The challenge of angina [letter] Ryde D. **Br J Gen Pract** 1996 Dec;46(413):759

DRUG THERAPY

Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem. Davies GJ, et al. **Am Heart J** 1997 Aug;134(2 Pt 1):220–8
Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience. Gramling-Babb P, et al. **Am Heart J** 1997 Jun;133(6):648–55
Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. Hansen JF, et al. **Am Heart J** 1997 Aug; 134(2 Pt 2):S48–52
Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris. Alpert JS, et al. **Am J Cardiol** 1997 Apr 15;79(8):1025–30
Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris. Alpert JS, et al. **Am J Cardiol** 1997 Aug 21;80(4B):20C–26C
Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. Chen JW, et al. **Am J Cardiol** 1997 Jul 1;80(1):32–8
Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists. Davies GJ, et al. **Am J Cardiol** 1997 Aug 21;80(4B):34C–39C
Effect of morning versus evening dosing of diltiazem on myocardial ischemia detected by ambulatory electrocardiographic monitoring in chronic stable angina pectoris. Dilacor XR Ambulatory Ischemia Study Group. Deedwania PC, et al. **Am J Cardiol** 1997 Aug 15; 80(4):421–5
Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Zatebradine Investigators. Glasser SP, et al. **Am J Cardiol** 1997 May 15;79(10):1401–5
Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. Kobrin I, et al. **Am J Cardiol** 1997 Aug 21;80(4B):40C–46C
Supersensitive dilator response to nitroglycerin but not to atrial natriuretic peptide in spastic coronary arteries in coronary spastic angina. Kugiyama K, et al. **Am J Cardiol** 1997 Mar 1;79(5):606–10
Response of symptomatic myocardial ischemia in ischemic cardiomyopathy to intensive vasodilator therapy. Levine TB, et al. **Am J Cardiol** 1997 Jul 15;80(2):212–4
Achieving sustained improvement in myocardial perfusion: role of isosorbide mononitrate. Lewin HC, et al. **Am J Cardiol** 1997 Jun 26;79(12B):31–5 (50 ref.)
Relation between dynamic midventricular obstruction and unexplained chest pain in patients with normal echocardiograms at rest. Murakami H, et al. **Am J Cardiol** 1996 Nov 1;78(9):1063–5
N-acetylcysteine attenuates nitroglycerin tolerance in patients with angina pectoris and normal left ventricular function. Pizzulli L, et al. **Am J Cardiol** 1997 Jan 1; 79(1):28–33
Management of patients with chronic stable angina at low risk for serious cardiac events. Thadani U. **Am J Cardiol** 1997 Jun 26;79(12B):24–30 (47 ref.)
Studies on the response of nitroglycerin oral spray compared with sublingual tablets for angina pectoris patients with dry mouth. A multicenter trial. Sato H, et al. **Arzneimittelforschung** 1997 Feb;47(2):128–31
The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator. Williams S, et al. **Blood Coagul Fibrinolysis** 1995 Dec;6(8):718–25
Buccaling under the pressure: influence of secondary care establishments on the prescribing of glyceryl trinitrate buccal tablets in primary care. Pryce AJ, et al. **BMJ** 1996 Dec 21–28;313(7072):1621–4
Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. Angina Prognosis Study in Stockholm. Rehnqvist N, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):301
Effect of gallopamil on myocardial microperfusion in patients with stable effort angina: a randomized, cross-over, double-blind, placebo-controlled trial. Acanfora D, et al. **Cardiology** 1997 Jul-Aug;88(4):353–60
Additional antiischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy. Bartels GL, et al. **Cardiovasc Drugs Ther** 1995 Dec;9(6):749–53
Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters. Silke B, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):573–80
Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Thadani U. **Cardiovasc Drugs Ther** 1997 Jan;10(6):735–42 (65 ref.)
Chronic oral dipyridamole as a 'novel' antianginal drug: the collateral hypothesis. Picano E, et al. **Cardiovasc Res** 1997 Mar;33(3):666–70
Dipyridamole and dobutamine–atropine stress echocardiography in the diagnosis of coronary artery disease. Comparison with exercise stress test, analysis of agreement, and impact of antianginal treatment. San Román JA, et al. **Chest** 1996 Nov;110(5):1248–54
Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: a randomized, double-blind, placebo-controlled trial. Chen YH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Nov;58(5):323–8
Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. Held C, et al. **Circulation** 1997 May 20; 95(10):2380–6
Prevastatin treatment in angina pectoris [letter; comment] Hellstrom HR. **Circulation** 1997 Aug 5;96(3):1059–60. Comment on: Circulation 1996 Oct 1;94(7):1503–5.
Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group [see comments] van Boven AJ, et al. **Circulation** 1996 Oct 1;94(7):1503–5 . Comment in: Circulation 1997 Aug 5;96(3):1059–60.
Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient Compliance. Detry JM. **Clin Cardiol** 1994 Sep;17(9 Suppl Iii):III12–6
A double-blind evaluation of amlodipine in patients with chronic, stable angina: sustained efficacy and lack of "withdrawal phenomenon" upon abrupt discontinuation. Mehta JL, et al. **Clin Cardiol** 1994 Sep;17(9 Suppl Iii):III17–22
Double-blind randomized multicenter study on the efficacy of trapidil versus isosorbide dinitrate in stable angina pectoris. Raubach KH, et al. **Clin Cardiol** 1997 May; 20(5):483–8
Chronic-intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris—a pilot study. Schoebel FC, et al. **Clin Cardiol** 1996 Feb;19(2):115–20
Improvement of exercise-induced ischaemia and myocardial perfusion after aminophylline. Roig E, et al. **Coron Artery Dis** 1996 Jan;7(1):69–73
Calcium-channel blockers in ischemic heart disease. Silvestry FE, et al. **Curr Opin Cardiol** 1996 Jul;11(4):434–9 (45 ref.)
Angina and left ventricular dysfunction. Dargie HJ. **Eur Heart J** 1996 Dec;17 Suppl G:2–7 (25 ref.)
Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Fatah K, et al. **Eur Heart J** 1996 Sep; 17(9):1362–6
How European cardiologists perceive the role of calcium antagonists in the treatment of stable angina. Fox KM, et al. **Eur Heart J** 1997 Jan;18 Suppl A:A113–6 (3 ref.)
Calcium antagonist drugs in hypertensive patients with angina pectoris. Just H, et al. **Eur Heart J** 1996 Dec;17 Suppl G:20–4 (27 ref.)
Felodipine in addition to beta-adrenergic blockade for angina pectoris. a multicentre, randomized, placebo-controlled trial. Rønnevik PK, et al. **Eur Heart J** 1995 Nov; 16(11):1535–41
Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris. Sedgwick ML, et al. **Eur Heart J** 1995 Nov;16(11):1641–6
Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Hauf-Zachariou U, et al. **Eur J Clin Pharmacol** 1997;52(2):95–100
Transdermal nitroglycerin: clinical and pharmacokinetic consequences of renewing the patch and the application site. Klemsdal TO, et al. **Eur J Clin Pharmacol** 1997; 52(5):379–81
Permutation distribution estimation applied to the comparison of the profile of the activity of two antianginal drugs. Harpey C, et al. **Fundam Clin Pharmacol** 1996;10(2):151–5
Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris. Schoebel FC, et al. **Heart** 1997 Jan;77(1):13–7 (53 ref.)
Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN). de Vries RJ, et al. **Int J Cardiol** 1996 Dec 6;57(2):143–50
Comments on 'A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily and isosorbide dinitrate twice daily in patients with stable angina' [letter; comment] Nyberg G. **Int J Cardiol** 1997 Jun 27; 60(1):107–10. Comment on: Int J Cardiol 1996 Feb;53(2):117–26.
Felodipine and amlodipine in stable angina pectoris: results of a randomized double-blind crossover trial. Koenig W, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):520–4
Safety and efficacy of monotherapy with fantofarone, a novel calcium channel antagonist, in patients with chronic stable angina pectoris. Fantofarone Study Group. Glasser SP, et al. **J Clin Pharmacol** 1997 Jan;37(1):53–7
Effect of diltiazem on intraarterial blood pressure and heart rate during stress testing in patients with angina: a gender comparison study. Klassen GA, et al. **J Clin Pharmacol** 1997 Apr;37(4):297–303
Clinical pharmacology of calcium antagonists as antihypertensive and anti-anginal drugs. van Zwieten PA. **J Hypertens Suppl** 1996 Oct;14(3):S3–9 (46 ref.)
Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis. Takahashi T, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1028–33
Exfoliative dermatitis associated with diltiazem. Odeh M. **J Toxicol Clin Toxicol** 1997;35(1):101–4 (19 ref.)
CPMP note for guidance: clinical investigation of anti-anginal drugs in stable angina pectoris. Morros R. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:35–6 (6 ref.)
Development of new drugs for chronic congestive heart failure and stable angina—a clinicians's view. Permanyer-Miralda G. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:39–40
NO-donors and angina pectoris: more than just symptomatic treatment? Cleophas TJ, et al. **Neth J Med** 1997 Apr; 50(4):180–3 (24 ref.)
Antianginal response to once-daily diltiazem CD in patients receiving concomitant beta-blockers, long-acting nitrates, or both. Diltiazem CD Study Group. Heller GV, et al. **Pharmacotherapy** 1997 Jul-Aug;17(4):760–6
Current approaches to stable angina. Jackson G. **Practitioner** 1996 Nov;240(1568):642–4, 647–8
Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris [see comments] de Maat MP, et al. **Thromb Haemost** 1996 Aug;76(2):166–70. Comment in: Thromb Haemost 1997 Mar;77(3):603–4.
[A clinical study of hehuantang in treating coronary heart disease] Cai PY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Apr; 16(4):204–6 (Eng. Abstr.) (Chi)
[Clinical study on the effect of shuxuening tablet in treatment of coronary heart disease] Chen K, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Jan; 16(1):24–6 (Eng. Abstr.) (Chi)
[Clinical observation on treatment of 45 angina pectoris patients of coronary heart disease with taponin] Liu KY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Nov;15(11):649–51 (Eng. Abstr.) (Chi)
[Clinical observation of wenxin decoction in treating 82 patients with spontaneous angina pectoris] Wang XF, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Apr; 16(4):201–3 (Eng. Abstr.) (Chi)
[Nifedipine and coronary insufficiency reasons for controversy] Lièvre M, et al. **Therapie** 1997 Jan-Feb; 52(1):37–45 (49 ref.) (Eng. Abstr.) (Fre)
[Nitric oxide in therapy of angina pectoris: nitrates or molsidomine?] Schächinger V, et al. **Internist (Berl)** 1997 May;38(5):438–47 (49 ref.) (Ger)
[Conservative treatment concepts for stable angina pectoris in coronary heart disease] Schoebel FC, et al. **Med Klin** 1996 Jul 15;91(7):458–65 (68 ref.) (Ger)
[Direct thrombin inhibitors] Bornkessel B. **Med Monatsschr Pharm** 1997 Apr;20(4):86–9 (3 ref.) (Ger)
[Chronic intermittent urokinase therapy: anti-ischemic and hemodynamic effects] Leschke M, et al. **Z Kardiol** 1997; 86 Suppl 1:85–94 (45 ref.) (Eng. Abstr.) (Ger)
[Clinical use of potassium channel activators in angina

pectoris: efficacy and tolerance] Specchia G, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):91–5 **(Ita)**

[Effectiveness of depot diltiazem in stable effort angina: a double-blind study compared with placebo] Baldi N, et al. **G Ital Cardiol** 1996 May;26(5):527–32 (Eng. Abstr.) **(Ita)**

[Reproducibility of spasm in patients with long-term remission of vasospastic angina by medical treatment] Byun T, et al. **J Cardiol** 1997 May;29(5):243–50 (Eng. Abstr.) **(Jpn)**

[Angina pectoris: progress in diagnosis and treatment. III. Progress in treatment. 2. Therapeutic guidelines for coronary spastic angina] Aizawa T. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):248–53 (5 ref.) **(Jpn)**

[The medical therapy of angina pectoris] Clara JG. **Acta Med Port** 1997 Apr;10(4):287–91 (32 ref.) (Eng. Abstr.) **(Por)**

[The effect of antianginal preparations on the hemodynamics and metabolism of the ischemic myocardium] Makolkin VI, et al. **Eksp Klin Farmakol** 1996 Jul–Aug;59(4):18–20 (Eng. Abstr.) **(Rus)**

[Efficacy of cordipin chronotherapy with reference to anginal patients' chronosensitivity] Zaslavskaia RM, et al. **Klin Med (Mosk)** 1997;75(3):41–3 (Eng. Abstr.) **(Rus)**

[A comparative evaluation of the antianginal action of commercially and noncommercially produced validol in neurocirculatory dystonia and stenocardia] Bondarenko IP, et al. **Lik Sprava** 1996 Mar–Apr;(3–4):110–3 (Eng. Abstr.) **(Rus)**

[A trial of the use of the transdermal preparation Deponit for treating stenocardia] Alliluev IG, et al. **Ter Arkh** 1996; 68(6):55–8 **(Rus)**

[A clinico-pharmacological study of the antianginal and anti-ischemic efficacy of a new drug form of diltiazem with delayed release] Belousov IuB, et al. **Ter Arkh** 1997; 69(3):61–3 **(Rus)**

[The anti-ischemic effect of angiotensin-converting enzyme inhibitors in treating stable stenocardia of effort in middle-aged and elderly patients] Lazebnik LB, et al. **Ter Arkh** 1996;68(4):40–2 **(Rus)**

[The neurohumoral and hemodynamic effect of aldizem in patients with stable and unstable angina pectoris] Malaia LT, et al. **Ter Arkh** 1993;65(2):55–8 (Eng. Abstr.) **(Rus)**

[The therapeutic and prophylactic use of Olicard-Retard under outpatient polyclinical conditions in stenocardia patients] Mikhallusova MP, et al. **Ter Arkh** 1997;69(1):17–20 (Eng. Abstr.) **(Rus)**

[The use of trimetazidine in the combined therapy of postinfarct stenocardia] Tereshchenko SN, et al. **Ter Arkh** 1997;69(1):68–9 **(Rus)**

[The anti-anginal efficacy of the drug forms of isosorbide-5-mononitrate--Monocinque, Monocinque retard and isosorbide dinitrate] Chernov SA, et al. **Voen Med Zh** 1997 Apr;318(4):39–41 **(Rus)**

[Interactions of the most frequently used drugs in the treatment of angina pectoris] Miljković M, et al. **Srp Arh Celok Lek** 1997 Mar–Apr;125(3–4):116–23 (Eng. Abstr.) **(Scc)**

ECONOMICS

Cost-effective management of chronic stable angina. O'Rourke RA. **Clin Cardiol** 1996 Jun;19(6):497–501 (22 ref.)

Is medical treatment for angina the most cost-effective option? Cleland JG, et al. **Eur Heart J** 1997 May;18 Suppl B:B35–42 (25 ref.)

Cost analysis of once-daily ISMN versus twice-daily ISMN or transdermal patch for nitrate prophylaxis. Brown RE, et al. **J Clin Pharm Ther** 1997 Feb;22(1):67–76

Cost effectiveness of personal health education in primary care for people with angina in the greater Belfast area of Northern Ireland. O'Neill C, et al. **J Epidemiol Community Health** 1996 Oct;50(5):538–40

EPIDEMIOLOGY

Anginal status and prediction of cardiac events in patients enrolled in the asymptomatic cardiac ischemia pilot (ACIP) study. ACIP investigators. Conti CR, et al. **Am J Cardiol** 1997 Apr 1;79(7):889–92

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Manzi S, et al. **Am J Epidemiol** 1997 Mar 1;145(5):408–15

Moderate alcohol consumption and risk for angina pectoris or myocardial infarction in U.S. male physicians. Camargo CA Jr, et al. **Ann Intern Med** 1997 Mar 1;126(5):372–5

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities [see comments] Juhan-Vague I, et al. **Circulation** 1996 Nov 1;94(9):2057–63. Comment in: Circulation 1996 Nov 1;94(9):2052–4.

Is worrying bad for your heart? A prospective study of worry and coronary heart disease in the Normative Aging Study. Kubzansky LD, et al. **Circulation** 1997 Feb 18;95(4):818–24

Methodology for assessing the prevalence of angina in primary care using practice based information in northern England. Bottomley A. **J Epidemiol Community Health** 1997 Feb;51(1):87–9

[Angina pectoris. The extent of the problem] Rocha E, et al. **Acta Med Port** 1997 Apr;10(4):243–8 (29 ref.) (Eng. Abstr.) **(Por)**

ETHNOLOGY

Psychosocial correlates of chest pain among African-American women. Fisher SG, et al. **Women Health** 1996;24(3):19–35

ETIOLOGY

Early and six-month outcome in patients with angina pectoris early after acute myocardial infarction (the GISSI-3 APPI [angina precoce post-infarto] study). The GISSI-3 APPI Study Group. **Am J Cardiol** 1996 Dec 1;78(11):1191–7

Effects of components of meals (carbohydrate, fat, protein) in causing postprandial exertional angina pectoris. Baliga RR, et al. **Am J Cardiol** 1997 May 15;79(10):1397–400

Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X. Bøtker HE, et al. **Am J Cardiol** 1997 Apr 1;79(7):961–3

Relation between dynamic midventricular obstruction and unexplained chest pain in patients with normal echocardiograms at rest. Murakami H, et al. **Am J Cardiol** 1996 Nov 1;78(9):1063–5

Variations in use of cardiology services in a health authority: comparison of coronary artery revascularisation rates with prevalence of angina and coronary mortality. Payne N, et al. **BMJ** 1997 Jan 25;314(7076):257–61

Angina pectoris occurring during granulocyte colony-stimulating factor-combined preparatory regimen for autologous peripheral blood stem cell transplantation in a patient with acute myelogenous leukaemia. Fukumoto Y, et al. **Br J Haematol** 1997 Jun;97(3):666–8

Recurrent angina after coronary artery bypass surgery. Ramsdale DR. **Br J Hosp Med** 1996 Oct 2–15;56(7):331–7 (15 ref.)

Prolonged impairment of regional contractile function after resolution of exercise-induced angina. Evidence of myocardial stunning in patients with coronary artery disease. Ambrosio G, et al. **Circulation** 1996 Nov 15; 94(10):2455–64

Allergic angina and allergic myocardial infarction [letter] Kounis NG, et al. **Circulation** 1996 Oct 1;94(7):1789

Hyperglycemia-induced angina pectoris in a patient with diabetes mellitus. Lickerman A, et al. **Clin Cardiol** 1997 Aug;20(8):736–7

Predictors for recurrent chest pain and relationship to myocardial ischaemia during long-term follow-up after coronary artery bypass grafting. Brandrup-Wognsen G, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):304–11

A woman with anginal pain despite normal coronary arteries. Javeed N, et al. **Hosp Pract (Off Ed)** 1997 Sep 15; 32(9):215–6

Neoplastic angina: a case report. White HL, et al. **Int J Cardiol** 1997 Apr 18;59(2):209–11

A case of rest angina due to microvascular spasm. Yamagishi H, et al. **Jpn Circ J** 1997 Jan;61(1):87–9

[Fibrous aortic valve tumor (Lambl's excrescence) trapped in the right coronary artery. Apropos of a case] Quinson P, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11):1419–23 (Eng. Abstr.) **(Fre)**

[Picture of the month. Spastic angina and moderate coronary lesion treated with stent angioplasty] Legrand V, et al. **Rev Med Liege** 1996 Dec;51(12):737–9 **(Fre)**

[Angina pectoris with normal coronary arteries (letter; comment)] Eisenlohr H, et al. **Dtsch Med Wochenschr** 1997 May 16;122(20):666–7. Comment on: Dtsch Med Wochenschr 1997 Jan 3;122(1–2):33–8. **(Ger)**

[Recurrent angina pectoris in stress caused by hemangioma of the heart] Wahba A, et al. **Z Kardiol** 1997 Jul;86(7):545–8 (Eng. Abstr.) **(Ger)**

[Angina pectoris and the severity of coronary artery stenosis] Ilia R, et al. **Harefuah** 1997 May 15;132(10):691–2, 744 (Eng. Abstr.) **(Heb)**

[A successful surgical treatment of coronary to pulmonary artery fistula with coronary steal phenomenon due to large volume of shunt: a case report] Ikeda M, et al. **Kyobu Geka** 1997 Mar;50(3):230–3 (Eng. Abstr.) **(Jpn)**

[Angina pectoris: progress in diagnosis and treatment. III. Progress in treatment. 1. Control of risk factors of angina pectoris] Teramoto T. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):242–7 (5 ref.) **(Jpn)**

[Exercise induced vasospastic angina] Hikita H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):570–2 (14 ref.) **(Jpn)**

[Postprandial angina] Kishida H. **Ryoikibetsu Shokogun Shirizu** 1996;(12):688–91 (15 ref.) **(Jpn)**

[Chronic angina pectoris in the patient with arterial hypertension] da Silva JD. **Acta Med Port** 1997 Apr; 10(4):277–82 (70 ref.) (Eng. Abstr.) **(Por)**

[The current concept of early postinfarct stenocardia and the procedure for patient management] Shumakov VA, et al. **Lik Sprava** 1997 Mar–Apr;(2):15–9 (39 ref.) **(Rus)**

[Thoracic pain of esophageal origin. Assessment of 125 consecutive patients with resting angina and angiographically normal coronary arteries] Ros E, et al. **Med Clin (Barc)** 1996 Jan 27;106(3):81–6 (Eng. Abstr.) **(Spa)**

[Coronary involvement in Takayasu's arteritis] Osa A, et al. **Rev Esp Cardiol** 1996 Nov;49(11):852–4 (Eng. Abstr.) **(Spa)**

HISTORY

Academic surgeons, take heart: the story of a student, his mentor, and the discovery of the etiology of angina pectoris. Manders EC, et al. **Am Surg** 1996 Dec; 62(12):1076–9

[Significance of cognitive processes in drug research in the 19th century--exemplified by nitroglycerin] Schüppel R. **Gesnerus** 1997;54(1–2):59–73 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[Postoperative immunological capacity after coronary artery bypass grafting in a patient with chronic hemodialysis: comparison with data from patients without chronic hemodialysis] Shirasawa B, et al. **Kyobu Geka** 1996 Sep; 49(10):809–12 (Eng. Abstr.) **(Jpn)**

METABOLISM

Levels of expression of P-selectin, E-selectin, and intercellular adhesion molecule-1 in coronary atherectomy specimens from patients with stable and unstable angina pectoris. Tenaglia AN, et al. **Am J Cardiol** 1997 Mar 15; 79(6):742–7

Muscle characteristics in effort angina before and after CABG. Karlsson J, et al. **Can J Cardiol** 1997 Jun; 13(6):577–82

Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina [see comments] Kugiyama K, et al. **Circulation** 1996 Aug 1;94(3):266–71. Comment in: Circulation 1997 Aug 5;96(3):1048–50.

Clinical evaluation of serum amlodipine level in patients with angina pectoris. Watanabe K, et al. **Gen Pharmacol** 1996 Mar;27(2):205–9

Changes in myocardial lactate metabolism during ramp exercise in patients with effort angina and microvascular angina. Nagayama M, et al. **Jpn Circ J** 1996 Nov; 60(11):876–88

Muscle ubiquinone in male effort angina patients. Karlsson J, et al. **Mol Cell Biochem** 1996 Mar 23;156(2):173–8

Muscle fibers, ubiquinone and exercise capacity in effort angina. Karlsson J, et al. **Mol Cell Biochem** 1996 Mar 23; 156(2):179–84

MORTALITY

Effect on survival of previous angina pectoris after acute myocardial infarction. Kobayashi Y, et al. **Am J Cardiol** 1997 Jun 1;79(11):1534–8

PATHOLOGY

Comparison of men versus women in cross-sectional area luminal narrowing, quantity of plaque, presence of calcium in plaque, and lumen location in coronary arteries by intravascular ultrasound in patients with stable angina pectoris. Kornowski R, et al. **Am J Cardiol** 1997 Jun 15; 79(12):1601–5

Neovascularization in human coronary atherosclerotic lesions [see comments] Depré C, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):215–20. Comment in: Cathet Cardiovasc Diagn 1996 Nov;39(3):221–3.

Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Moreno PR, et al. **Circulation** 1996 Dec 15;94(12):3090–7

Comparison of the histopathology of culprit lesions in chronic stable angina, unstable angina, and myocardial infarction. Haft JI, et al. **Clin Cardiol** 1997 Jul;20(7):651–5

Papillary endothelial hyperplasia in a TEC coronary atherectomy specimen. Crilley JG, et al. **Heart** 1997 Jun; 77(6):572–3

Clinically stable angina pectoris is not necessarily associated with histologically stable atherosclerotic plaques. van der Wal AC, et al. **Heart** 1996 Oct;76(4):312–6

[Histopathologic features in atherectomy samples obtained from patient with unstable angina, stable angina and restenosis. Directional Atherectomy Lombardi Group (see comments) (published erratum appears in G Ital Cardiol 1996 Aug;6(8):XII)] Arbustini E, et al. **G Ital Cardiol** 1996 Jun;26(6):623–33 (Eng. Abstr.). Comment in: G Ital Cardiol 1996 Jun;26(6):635–7. **(Ita)**

[Angina pectoris: progress in diagnosis and treatment. II. Progress in imaging diagnosis. 5. Angioscopic examination] Mizuno K. **Nippon Naika Gakkai Zasshi** 1997 Feb 10; 86(2):237–41 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Long-lasting abnormalities in cardiac sympathetic nervous system in patients with coronary spastic angina: quantitative analysis with iodine 123 metaiodobenzylguanidine myocardial scintigraphy. Inobe Y, et al. **Am Heart J** 1997 Jul;134(1):112–8

Flow-mediated, endothelium-dependent dilatation of the brachial arteries is impaired in patients with coronary spastic angina. Motoyama T, et al. **Am Heart J** 1997 Mar; 133(3):263–7

Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Ceremuzyński L, et al. **Am J Cardiol** 1997 Aug 1;80(3):331–3

Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Chirkov YY, et al. **Am J Cardiol** 1997 Jul 15;80(2):128–31

Analysis of phasic flow velocity dynamics in the left anterior descending coronary artery before and after angioplasty using transthoracic echocardiography in patients with stable angina pectoris. Crowley JJ, et al. **Am J Cardiol** 1997 Sep 1;80(5):614–7

Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Zatebradine Investigators. Glasser SP, et al. **Am J Cardiol** 1997 May 15;79(10):1401–5

Ischemic-like ST-segment changes during Holter monitoring in patients with angina pectoris and normal coronary arteries but negative exercise testing. Lanza GA, et al. **Am J Cardiol** 1997 Jan 1;79(1):1–6

Cardiac autonomic function and sensitivity to pain in postmenopausal women with angina and normal coronary arteries. Lanza GA, et al. **Am J Cardiol** 1997 May 1; 79(9):1174–9

Effects of acute alcohol ingestion on heart rate variability in patients with documented coronary artery disease and stable angina pectoris. Rossinen J, et al. **Am J Cardiol** 1997 Feb 15;79(4):487–91

Effect of endoscopic transthoracic sympathicotomy on heart rate variability in severe angina pectoris. Tygesen H, et al. **Am J Cardiol** 1997 Jun 1;79(11):1447–52

Effects of the new calcium antagonist efonidipine hydrochloride on resting and exercise hemodynamics in patients with stable effort angina. Saito T, et al. **Arzneimittelforschung** 1996 Sep;46(9):861–7

Platelet activation during provocation of coronary artery spasm by ergonovine and cold pressor testing in patients with angina pectoris. Gurevich VS, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):181–2

Role of coronary vasomotor tone in patients with stable angina pectoris. Kaufmann P, et al. **Cardiologia** 1996 Oct; 41(10):945–51 (63 ref.)

Age and gender differences in left ventricular function among patients with stable angina and a matched control group. A report from the Angina Prognosis Study in Stockholm. Eriksson SV, et al. **Cardiology** 1996 Jul–Aug;87(4):287–93

Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms. Yamabe H, et al. **Cardiovasc Drugs Ther** 1995 Dec; 9(6):755–61

Abnormal coronary flow reserve in patients with angina pectoris and hypertensive left ventricular hypertrophy. Shen W, et al. **Chin Med J (Engl)** 1996 May;109(5):376–80

Prolonged impairment of regional contractile function after resolution of exercise-induced angina. Evidence of myocardial stunning in patients with coronary artery disease. Ambrosio G, et al. **Circulation** 1996 Nov 15; 94(10):2455–64

Why angina pectoris in aortic stenosis [editorial; comment] Gould KL. **Circulation** 1997 Feb 18;95(4):790–2 (14 ref.). Comment on: Circulation 1997 Feb 18;95(4):892–8.

Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. Held C, et al. **Circulation** 1997 May 20; 95(10):2380–6

Angina pectoris in patients with aortic stenosis and normal coronary arteries. Mechanisms and pathophysiological concepts [see comments] Julius BK, et al. **Circulation** 1997 Feb 18;95(4):892–8. Comment in: Circulation 1997 Feb 18;95(4):790–2.

Both endothelium-dependent and endothelium-independent function is impaired in patients with angina pectoris and normal coronary angiograms. Chauhan A, et al. **Eur Heart J** 1997 Jan;18(1):60–8

Variant angina in patients without obstructive coronary atherosclerosis: a benign form of spasm [editorial; comment] Crea F. **Eur Heart J** 1996 Jul;17(7):980–2. Comment on: Eur Heart J 1996 Jul;17(7):1015–21.

Clinical validation of a quality of life questionnaire in angina pectoris patients. Marquis P, et al. **Eur Heart J** 1995 Nov; 16(11):1554–60

Mechanisms of angina pectoris in syndrome X assessed by myocardial perfusion dynamics and heart rate variability [see comments] Meeder JG, et al. **Eur Heart J** 1995 Nov; 16(11):1571–7. Comment in: Eur Heart J 1995 Nov;16(11):1455–6. Comment in: Eur Heart J 1996 Nov;17(11):1759–60.

Angina in patients with an active lifestyle. Mittleman MA. **Eur Heart J** 1996 Dec;17 Suppl G:30–5 (33 ref.)

Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris. Sedgwick ML, et al. **Eur Heart J** 1995 Nov;16(11):1641–6

Mechanisms of the warm-up phenomenon [see comments] Tomai F, et al. **Eur Heart J** 1996 Jul;17(7):1022–7. Comment in: Eur Heart J 1997 Feb;18(2):352–3.

Relative changes in regional cerebral blood flow during spinal cord stimulation in patients with refractory angina pectoris. Hautvast RW, et al. **Eur J Neurosci** 1997 Jun; 9(6):1178–83

Effects of acute coronary occlusion and previous ischaemic injury on left ventricular wall motion in humans. Henein MY, et al. **Heart** 1997 Apr;77(4):338–45

Salutary effects of myocardial ischemia in coronary artery disease. Fujita M. **Int J Cardiol** 1995 Dec;52(3):197–202 (51 ref.)

Chest discomfort and the region of cardiac ischemia [letter] Ilia R, et al. **Int J Cardiol** 1996 Jul 26;55(2):204

Tenuous link between ischaemic threshold and both ambulatory ischaemia and symptom status over time in stable angina: a 5-year follow-up study. Knight CJ, et al. **Int J Cardiol** 1996 Jul 5;55(1):61–5

Improvement in inducible ischemia during dobutamine stress echocardiography after transmyocardial laser revascularization in patients with refractory angina pectoris. Donovan CL, et al. **J Am Coll Cardiol** 1997 Sep; 30(3):607–12

William Heberden revisited: postprandial angina-interval between food and exercise and meal composition are important determinants of time to onset of ischemia and maximal exercise tolerance. Kearney MT, et al. **J Am Coll Cardiol** 1997 Feb;29(2):302–7

Cardioesophageal reflex: a mechanism for "linked angina" [letter; comment] Koelz HR, et al. **J Am Coll Cardiol** 1997 Mar 1;29(3):705. Comment on: J Am Coll Cardiol 1996 Jun;27(7):1621–8.

Clinical importance of late potential in patients with angina pectoris. Akiya T, et al. **J Cardiol** 1997 Apr;29(4):189–94

N-Acetylcysteine potentiates nitroglycerin-induced reversal of platelet aggregation. Chirkov YY, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):375–80

Giant negative U waves during acute myocardial infarction and ischemia. Yamaguchi T, et al. **J Electrocardiol** 1997 Apr;30(2):105–8

Coronary microvascular dysfunction is associated with ischemic-like electrocardiogram during exercise in patients with anginal chest pain and normal coronary angiograms. Chen JW, et al. **Jpn Heart J** 1996 Nov;37(6):865–78

Coronary stenosis dilatation induced by L-arginine [letter] Tousoulis D, et al. **Lancet** 1997 Jun 21;349(9068):1812–3

Spinal cord stimulation in severe angina pectoris. Augustinsson LE, et al. **Stereotact Funct Neurosurg** 1995; 65(1–4):136–41

Neurophysiological aspects of angina pectoris. Sylvén C. **Z Kardiol** 1997;86 Suppl 1:95–105 (80 ref.)

[Changed views on vasoconstriction of coronary vessels and angina pectoris] Spáčil J. **Vnitr Lek** 1996 Aug;42(8):564–7 (21 ref.) (Eng. Abstr.) **(Cze)**

[Effects of nicorandil on coronary collateral circulation depend on the donor arteries] Umezawa S, et al. **J Cardiol** 1996 Nov;28(5):257–66 (Eng. Abstr.) **(Jpn)**

[ST elevated angina pectoris] Kohno M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):553–6 (12 ref.) **(Jpn)**

[The physiopathology of angina pectoris] da Costa JT. **Acta Med Port** 1997 Apr;10(4):233–41 (56 ref.) (Eng. Abstr.) **(Por)**

[Ischemic changes in the electrocardiogram and their correction with drugs using a model of chronic angina] Pozin VM. **Biull Eksp Biol Med** 1994 Apr;117(4):435–8 **(Rus)**

[Immune and fibrinolytic system functions in the cardiac manifestations of atherosclerosis] Kamenev VF, et al. **Lik Sprava** 1997 Jan–Feb;(1):33–7 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Angioplasty and stenting of an unprotected left main bifurcation lesion. Morrison DA, et al. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):174–8

Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS). Aengevaeren WR, et al. **Circulation** 1997 Jul 15;96(2):429–35

Intractable vasospastic angina. Kurata C, et al. **Heart** 1997 Jul;78(1):93–4

Willingness to pay for reductions in angina pectoris attacks. Kartman B, et al. **Med Decis Making** 1996 Jul–Sep; 16(3):248–53

Analgesic effects of adenosine during exercise-provoked myocardial ischaemia. Sylvén C, et al. **Neuroreport** 1996 Jun 17;7(9):1521–5

PSYCHOLOGY

The SF-36 questionnaire: a convenient way to assess quality of life in angina pectoris patients. Charlier L, et al. **Acta Cardiol** 1997;52(3):247–60

Is worrying bad for your heart? A prospective study of worry and coronary heart disease in the Normative Aging Study. Kubzansky LD, et al. **Circulation** 1997 Feb 18;95(4):818–24

Relationship among depression scores, beta-endorphin, and angina pectoris during exercise in patients with coronary artery disease. Krittayaphong R, et al. **Clin J Pain** 1996 Jun;12(2):126–33

The cardiac health profile: content, reliability and validity of a new disease-specific quality of life questionnaire. Währborg P, et al. **Coron Artery Dis** 1996 Nov;7(11):823–9

Differences in cognitions during chest pain of patients with panic disorder and ischemic heart disease. Fraenkel YM, et al. **Depress Anxiety** 1996–97;4(5):217–22

Psychosocial variables in female vs male patients with stable angina pectoris and matched healthy controls [see comments] Billing E, et al. **Eur Heart J** 1997 Jun; 18(6):911–8. Comment in: Eur Heart J 1997 Jun;18(6):892–3.

Angina pectoris and the personality factor: the relevance of psychosocial factors in myocardial ischaemia [editorial; comment] Chierchia SL. **Eur Heart J** 1997 Jun;18(6):892–3 . Comment on: Eur Heart J 1997 Jun;18(6):911–8.

Prioritising the cardiac surgery waiting list: the angina patient's perspective. Kee F, et al. **Heart** 1997 Apr; 77(4):330–2

Predictors of quality of life after hospital admission for heart attack or angina. Heller RF, et al. **Int J Cardiol** 1997 Apr 18;59(2):161–6

Empirical psychological modeling of chest pain: a comparative study. Serlie AW, et al. **J Psychosom Res** 1996 Jun;40(6):625–35

Angina pectoris after recovery from an acute coronary event--the role of psychological factors in Japanese vs North American patients. Freedland KE, et al. **Jpn Circ J** 1997 Apr;61(4):299–307

Comorbidities and utility for angina symptoms [letter; comment] Nease RF Jr. **Med Decis Making** 1996 Jul–Sep; 16(3):300–2. Comment on: Med Decis Making 1996 Jan–Mar;16(1):78–85.

Prevalence and severity of anxiety, depression and Type A behaviors in angina pectoris. Smith DF, et al. **Scand J Psychol** 1996 Sep;37(3):249–58

[Psychophysiological approaches to assessing patients with painful and painless forms of ischemic heart disease] Lipovetskii BM, et al. **Ter Arkh** 1995;67(12):8–11 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Radial versus femoral approach for diagnostic coronary angiography in stable angina pectoris. Ludman PF, et al. **Am J Cardiol** 1997 May 1;79(9):1239–41

Coronary arteriography in the presence of dextrocardia and situs inversus. Shah RP, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):759–60 (10 ref.)

Causes of coronary events after successful coronary angioplasty. Ishiwata S, et al. **Coron Artery Dis** 1996 Aug; 7(8):573–7

Coronary stenosis progression differs in patients with stable angina pectoris with and without a previous history of unstable angina. Kaski JC, et al. **Eur Heart J** 1996 Oct; 17(10):1488–94

A case of effort angina pectoris with total obstruction of the left main coronary artery and extracardiac anastomose detected by angiography [letter] Ogawa K, et al. **Eur Heart J** 1997 Jun;18(6):1033

Cardiologists' use of clinical information for management decisions for patients with unstable angina: a policy analysis. van Miltenburg-van Zijl AJ, et al. **Med Decis Making** 1997 Jul–Sep;17(3):292–7

Impaction of foreign body in right coronary ostium. Dal A, et al. **Thorac Cardiovasc Surg** 1996 Jun;44(3):150–1

[Severity of angina pectoris and coronary angiographic imaging] Broda K, et al. **Przegl Lek** 1996;53(10):713–6 (Eng. Abstr.) **(Pol)**

[Coronary angiography in the outpatient with angina pectoris] Gomes RS. **Acta Med Port** 1997 Apr;10(4):263–6 (Eng. Abstr.) **(Por)**

RADIONUCLIDE IMAGING

Exercise myocardial perfusion and wall motion imaging to predict recurrence of angina pectoris after successful angioplasty. Dendale PA, et al. **Acta Cardiol** 1996; 51(5):409–23

Potential cost effectiveness of initial myocardial perfusion imaging for assessment of emergency department patients with chest pain. Radensky PW, et al. **Am J Cardiol** 1997 Mar 1;79(5):595–9

Slow coronary run-off in patients with angina pectoris: clinical significance and thallium-201 scintigraphic study. César LA, et al. **Braz J Med Biol Res** 1996 May; 29(5):605–13

Slow bolus injection of ribose in the identification of thallium-201 redistribution following combined adenosine/dynamic exercise stress. Gunning MG, et al. **Eur Heart J** 1996 Sep;17(9):1438–43

Altered myocardial perfusion during dobutamine stress testing in silent versus symptomatic myocardial ischaemia assessed by quantitative MIBI SPET imaging. Elhendy A, et al. **Eur J Nucl Med** 1996 Oct;23(10):1354–60

Clearance of thallium-201 from the peripheral blood: comparison of immediate and standard thallium-201 reinjection. van Eck-Smit BL, et al. **Eur J Nucl Med** 1996 Feb;23(2):188–94

Ninety-day follow-up of patients in the emergency department with chest pain who undergo initial single-photon emission computed tomographic perfusion scintigraphy with technetium 99m-labeled sestamibi. Hilton TC, et al. **J Nucl Cardiol** 1996 Jul–Aug;3(4):308–11

Quantitative analysis of defect reversibility after immediate and standard 201Tl reinjection. Van Eck-Smit BL, et al. **Nucl Med Commun** 1996 Oct;17(10):857–63

Myocardial SPET imaging with 99Tcm-tetrofosmin in clinical practice: comparison of a 1 day and a 2 day imaging protocol. van Eck-Smit BL, et al. **Nucl Med Commun** 1997 Jan;18(1):24–30

[Evaluation of myocardial damage using 123I-BMIPP imaging in patients with vasospastic angina] Abe M, et al. **Kaku Igaku** 1996 Jun;33(6):599–606 (Eng. Abstr.) **(Jpn)**

[Importance of the delayed 123I-BMIPP image for detecting myocardial metabolic abnormality induced by transient myocardial ischemia: a case of vasospastic angina] Tanaka K, et al. **Kaku Igaku** 1997 Apr;34(4):229–35 (Eng. Abstr.) **(Jpn)**

[Angina pectoris: progress in diagnosis and treatment. II. Progress in imaging diagnosis. 2. The role of nuclear medicine] Nishimura T. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):214–9 (3 ref.) **(Jpn)**

[Myocardial perfusion scintigraphy for diagnosis and risk stratification in stable angina pectoris] Gil VM. **Acta Med Port** 1997 Apr;10(4):255–61 (35 ref.) (Eng. Abstr.) **(Por)**

RADIOTHERAPY

[A comparative analysis of the results of using different methods of helium–neon laser therapy in patients with stable stenocardia] Iurlov VM, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):73–6 (Eng. Abstr.) **(Ukr)**

SURGERY

Reoperative coronary bypass grafting without cardiopulmonary bypass through a small thoracotomy. Boonstra PW, et al. **Ann Thorac Surg** 1997 Feb;63(2):405–7

Troponin–T in minimally invasive coronary operations [letter; comment] Hadjinikolaou LK, et al. **Ann Thorac Surg** 1997 May;63(5):1511–2. Comment on: Ann Thorac Surg 1996 Jan;61(1):10–1.

Angina pectoris treated by thoracoscopic sympathecotomy. Claes G, et al. **Cardiovasc Surg** 1996 Dec;4(6):830–1

Myocardial revascularization for severe left ventricular dysfunction. Factors influencing early and late survival. Louagie Y, et al. **Cardiovasc Surg** 1996 Oct;4(5):607–16

Myocardial revascularization in a hemophiliac. Nahas C, et al. **Cardiovasc Surg** 1996 Aug;4(4):557–8

Plasma endothelin–1 levels in adult patients undergoing coronary revascularization. St. Rammos K, et al. **Cardiovasc Surg** 1996 Dec;4(6):808–12

Emergency bypass surgery for failed coronary interventions. Topaz O, et al. **Cathet Cardiovasc Diagn** 1997 Jan; 40(1):55–65 (57 ref.)

A case of effort angina pectoris with total obstruction of the left main coronary artery and extracardiac anastomose detected by angiography [letter] Ogawa K, et al. **Eur Heart J** 1997 Jun;18(6):1033

Transluminal extraction atherectomy for stent restenosis in a saphenous vein bypass graft [letter] Virk SJ, et al. **Eur Heart J** 1997 Feb;18(2):350–1

Cardiac troponin T and troponin I release during coronary artery surgery using cold crystalloid and cold blood cardioplegia. Caputo M, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):254–60

Early coronary artery bypass graft thrombosis in a patient with protein S deficiency. De Paulis R, et al. **Eur J Cardiothorac Surg** 1996;10(6):470–2

Failure of gastroepiploic artery graft due to gastroduodenal artery stenosis. Kawasuji M, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):790–2

Coronary artery bypass surgery in women and in men; early and long–term results. A study of the Norwegian population adjusted by age and sex. Risum O, et al. **Eur J Cardiothorac Surg** 1997 Mar;11(3):539–46

Return to work and quality of life measurement in coronary artery bypass grafting. Speziale G, et al. **Eur J Cardiothorac Surg** 1996;10(10):852–8

Myocardial indium–111 antimyosin uptake after uncomplicated coronary artery bypass surgery. Astorri E, et al. **Int J Cardiol** 1996 Aug;55(3):239–44

Restenosis or rapid progression in non–dilated sites are not predictors of late spontaneous coronary events. Benchimol D, et al. **Int J Cardiol** 1997 Jul 25;60(2):201–11

Transmyocardial revascularization for intractable angina. Lansing AM, et al. **J Ky Med Assoc** 1996 Oct;94(10):432–6

Health technology assessment: TMR trials and tribulations [letter] Wallwork J, et al. **Lancet** 1996 Nov 16; 348(9038):1386

A 66–year–old man with severe angina and previous coronary artery bypass. Yaryura R, et al. **Lancet** 1997 Feb 8;349(9049):396

Outcome after coronary artery surgery in women and men in the north of England. Farrer M, et al. **QJM** 1997 Mar; 90(3):203–11

Helping heartache [news] Gibbs WW. **Sci Am** 1997 Jul; 277(1):34, 36

Coronary steal through anomalous internal mammary artery graft treated by ligation without sternotomy [letter; comment] Kern MJ. **Tex Heart Inst J** 1996;23(4):316–7. Comment on: Tex Heart Inst J 1996;23(3):226–8.

Late survival and predictors of recurrent angina after coronary artery reoperation. Dougenis D, et al. **Thorac Cardiovasc Surg** 1997 Jun;45(3):114–8

[The value of ultrafast computerized tomography in detection of the patency of coronary bypasses] Knez A, et al. **Z Kardiol** 1996 Sep;85(9):629–34 (Eng. Abstr.) **(Ger)**

[Transmyocardial revascularization] Moosdorf R. **Z Kardiol** 1997;86 Suppl 1:115–24 (Eng. Abstr.) **(Ger)**

[A case report on successful coronary artery bypass grafting (CABG) for angina pectoris combined with hypothyroidism] Furukawa K, et al. **Kyobu Geka** 1997 Apr; 50(4):275–8 (Eng. Abstr.) **(Jpn)**

[Surgical results of two cases of simultaneous carotid endarterectomy and coronary artery bypass grafting] Harada H, et al. **Kyobu Geka** 1996 Jul;49(7):557–61 (Eng. Abstr.) **(Jpn)**

[A case report of coronary artery bypass grafting in a patient with Sjögren's syndrome] Ingu A, et al. **Kyobu Geka** 1996 Sep;49(10):847–50 (Eng. Abstr.) **(Jpn)**

[Postoperative immunological capacity after coronary artery bypass grafting in a patient with chronic hemodialysis: comparison with data from patients without chronic hemodialysis] Shirasawa B, et al. **Kyobu Geka** 1996 Sep; 49(10):809–12 (Eng. Abstr.) **(Jpn)**

[Coronary artery bypass grafting using arterial grafts in a patient with rheumatoid arthritis requiring steroid therapy] Tsuji K, et al. **Kyobu Geka** 1997 Mar;50(3):218–21 (Eng. Abstr.) **(Jpn)**

[Case report of coronary artery bypass grafting using only arterial grafts in a patient with idiopathic thrombocytopenic purpura] Hayashi S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Nov;44(11):2091–4 (Eng. Abstr.) **(Jpn)**

[A case report of aorto–coronary artery bypass surgery in patient with essential thrombocythemia] Kohno K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jan;45(1):55–8 (Eng. Abstr.) **(Jpn)**

[Two cases of coronary artery bypass grafting following radical mastectomy using bilateral internal thoracic arterial grafts] Yoshida K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jan;45(1):64–6 (Eng. Abstr.) **(Jpn)**

[Angina pectoris: progress in diagnosis and treatment. III. Progress in treatment. 6. Timing for switching to surgical therapy for angina pectoris] Suma H. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):271–5 (5 ref.) **(Jpn)**

[Angina pectoris: the possibilities for surgical treatment. Recent progress] Queiroz e Melo J. **Acta Med Port** 1997 Apr;10(4):299–302 (8 ref.) (Eng. Abstr.) **(Por)**

THERAPY

Cost–benefit of combined use of acupuncture, Shiatsu and lifestyle adjustment for treatment of patients with severe angina pectoris. Ballegaard S, et al. **Acupunct Electrother Res** 1996 Jul–Dec;21(3–4):187–97

Effect of theophylline on adaptation of the heart to myocardial ischemia during percutaneous transluminal coronary angioplasty in patients with stable angina pectoris. Hashimura K, et al. **Am J Cardiol** 1997 Feb 15;79(4):475–7

Results of coronary stenting for unstable versus stable angina pectoris. Marzocchi A, et al. **Am J Cardiol** 1997 May 15; 79(10):1314–8

Experimental angina treatment rejected by the FDA [news] Josefson D. **BMJ** 1997 Aug 9;315(7104):328

Improved exercise tolerance following enhanced external counterpulsation: cardiac or peripheral effect? Lawson WE, et al. **Cardiology** 1996 Jul–Aug;87(4):271–5

Local changes in the plasma endothelin level in the coronary artery immediately after percutaneous transluminal coronary angioplasty. Vojácek J, et al. **Cardiology** 1997 Jan–Feb;88(1):1–5

Exaggerated luminal loss a few minutes after successful percutaneous transluminal coronary angioplasty in patients with recent myocardial infarction compared with stable angina: an intracoronary ultrasound study. Lee TM, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):32–9

Site–specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. Camenzind E, et al. **Circulation** 1997 Jul 1;96(1):154–65

Advertising of therapies for cardiovascular patients [editorial] [see comments] Conti CR. **Clin Cardiol** 1997 Jan;20(1):1. Comment in: Clin Cardiol 1997 May;20(5):506–7.

Angina pectoris refractory for conventional therapy—is neurostimulation a possible alternative treatment? Hautvast RW, et al. **Clin Cardiol** 1996 Jul;19(7):531–5 (68 ref.)

Cost–effective management of chronic stable angina. O'Rourke RA. **Clin Cardiol** 1996 Jun;19(6):497–501 (22 ref.)

Ischemic preconditioning: clinical relevance and investigative studies. Schlaifer JD, et al. **Clin Cardiol** 1997 Jul; 20(7):602–6 (24 ref.)

Management of stable & unstable angina in elderly patients. Brann WM, et al. **Compr Ther** 1997 Jan;23(1):49–56

Sequelae of spinal cord stimulation for refractory angina pectoris. Reliability and safety profile of long–term clinical application. Jessurun GA, et al. **Coron Artery Dis** 1997 Jan; 8(1):33–8

PTCA versus CABG for angina pectoris: a look at the randomized trials. Kalynych AM, et al. **Coron Artery Dis** 1995 Oct;6(10):788–96 (31 ref.)

Optimal treatment of angina in older patients. Doughty RN, et al. **Drugs Aging** 1996 May;8(5):349–57 (39 ref.)

Stable angina: drugs, angioplasty or surgery? Jackson G. **Eur Heart J** 1997 May;18 Suppl B:B2–10 (20 ref.)

Differences in the morphology of unstable and stable coronary lesions and their impact on the mechanisms of angioplasty. An in vivo study with intravascular ultrasound. Kearney P, et al. **Eur Heart J** 1996 May; 17(5):721–30

Angina in patients with an active lifestyle. Mittleman MA. **Eur Heart J** 1996 Dec;17 Suppl G:30–5 (33 ref.)

Geriatrics photo quiz. Angina pectoris. Gross JS, et al. **Geriatrics** 1996 Nov;51(11):19, 61

Articulation strut coronary restenosis in Palmaz–Schatz stents. Davis G, et al. **Int J Cardiol** 1996 Jun;54(3):266–71

Transbrachial coil occlusion of the first intercostal branch of an internal mammary artery bypass graft for angina. Soliotis F, et al. **Int J Cardiol** 1997 Apr 18;59(2):206–8

Managing stable angina: time to re–evaluate medical therapy [editorial] Jackson G. **Int J Clin Pract** 1997 Jun;51(4):203–4

Respiratory compromise: a rare complication of transcutaneous electrical nerve stimulation for angina pectoris. Mann CJ. **J Accid Emerg Med** 1996 Jan;13(1):68

Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty. Airaksinen KE, et al. **J Am Coll Cardiol** 1997 Apr;29(5):1035–8

Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double–vessel versus single–vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS [see comments] Folland ED, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1505–11. Comment in: J Am Coll Cardiol 1997 Jun;29(7):1512–4.

Fate of collateral vessels after successful coronary angioplasty in patients with effort angina. Fujita M, et al. **J Am Coll Cardiol** 1997 Mar 1;29(3):544–8

PTCA comes to the bifurcations in the road: what the VA has to offer [editorial; comment] Morrison DA, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1512–4. Comment on: J Am Coll Cardiol 1997 Jun;29(7):1505–11.

Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA–2) trial. RITA–2 trial participants. **Lancet** 1997 Aug 16;350(9076):461–8

Effect of gender on angioplasty outcome: are we closer to the answer? [editorial; comment] Alexander KP, et al. **Mayo Clin Proc** 1997 Jan;72(1):89–91. Comment on: Mayo Clin Proc 1997 Jan;72(1):5–12.

Comparison of immediate and long–term outcome of coronary angioplasty performed for unstable angina and rest pain in men and women [see comments] Keelan ET, et al. **Mayo Clin Proc** 1997 Jan;72(1):5–12. Comment in: Mayo Clin Proc 1997 Jan;72(1):89–91.

Comorbidities and utility for angina symptoms [letter; comment] Nease RF Jr. **Med Decis Making** 1996 Jul–Sep; 16(3):300–2. Comment on: Med Decis Making 1996 Jan–Mar;16(1):78–85.

Time dependent variation of stimulus requirements in spinal cord stimulation for angina pectoris. Andersen C. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 1):359–63

Spinal cord stimulation in severe angina pectoris—presentation of current studies, indications and clinical experience. Eliasson T, et al. **Pain** 1996 May–Jun; 65(2–3):169–79 (137 ref.)

Current views on neurostimulation in the treatment of cardiac ischemic syndromes. Jessurun GA, et al. **Pain** 1996 Aug; 66(2–3):109–16 (45 ref.)

Spinal cord stimulation in severe angina pectoris. Augustinsson LE, et al. **Stereotact Funct Neurosurg** 1995; 65(1–4):136–41

Spinal cord stimulation in refractory angina pectoris—clinical results and mechanisms. Oosterga M, et al. **Z Kardiol** 1997; 86 Suppl 1:107–13 (36 ref.)

[Accidental insertion of a temporary pacemaker electrode in the left ventricle: radiological and electrocardiographic diagnosis] Rickenbacher P, et al. **Schweiz Med Wochenschr** 1996 Oct 5;126(40):1688–92 (Eng. Abstr.) **(Ger)**

[Percutaneous "high risk" angioplasty with prophylactic cardiopulmonary support. High risk PTCA with mechanical circulatory support] Borges AC, et al. **Z Kardiol** 1996;85 Suppl 4:21–8 (Eng. Abstr.) **(Ger)**

[Therapy refractory end stage angina pectoris in coronary heart disease—a clinical and scientific challenge] Leschke M, et al. **Z Kardiol** 1997;86 Suppl 1:V–VI **(Ger)**

[Indication for percutaneous transluminal coronary angioplasty based on quality of life of patients with angina pectoris] Hayashi T, et al. **J Cardiol** 1997 Jan;29(1):13–22 (Eng. Abstr.) **(Jpn)**

[Effects of the time interval between the first and second balloon inflations on ischemic preconditioning during percutaneous transluminal coronary angioplasty] Tanaka T, et al. **J Cardiol** 1996 Jun;27(6):303–8 (Eng. Abstr.) **(Jpn)**

[Physiopathology and treatment of angina pectoris] Takeshita A. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):469–72 (0 ref.) **(Jpn)**

[Angina pectoris: progress in diagnosis and treatment. III. Progress in treatment. 5. Coronary artery intervention for angina pectoris] Yamaguchi T. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):265–70 (6 ref.) **(Jpn)**

[Analysis of elastic retraction in the 1st 15 minutes after coronary balloon angioplasty] Caixeta AM, et al. **Arq Bras Cardiol** 1996 Jan;66(1):5–9 (Eng. Abstr.) **(Por)**

[Coronary transluminal angioplasty in octogenarians] Moreira AE, et al. **Arq Bras Cardiol** 1996 Dec;67(6):389–93 (Eng. Abstr.) **(Por)**

["Running" pulse magnetic field in treating stenocardia] Orlov LL, et al. **Biofizika** 1996 Jul–Aug;41(4):949–52 (Eng. Abstr.) **(Rus)**

[Effectiveness of drug therapy alone or its combination with plasmapheresis in patients with severe angina pectoris] Sokolov AV, et al. **Klin Med (Mosk)** 1997;75(8):31–3 (Eng. Abstr.) **(Rus)**

[The current concept of early postinfarct stenocardia and the procedure for patient management] Shumakov VA, et al. **Lik Sprava** 1997 Mar–Apr;(2):15–9 (39 ref.) **(Rus)**

[Coronary angioplasty simultaneous with the "kissing" technique in a bifurcation lesion: use of a guidewire, and

ANGINA PECTORIS

2 monorail systems of rapid interchange] Escudero X. **Arch Inst Cardiol Mex** 1996 May–Jun;66(3):265–8 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Echocardiographic prediction of complications in patients with chest pain. Fleischmann KE, et al. **Am J Cardiol** 1997 Feb 1;79(3):292–8

Intracoronary ultrasound before coronary interventions: a prospective comparison of two different catheters. Alfonso F, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):33–9

Prognostic value of stress echocardiography in stable angina or after myocardial infarction [see comments] Nagueh SF, et al. **Curr Opin Cardiol** 1996 Nov;11(6):627–34 (28 ref.). Comment in: Curr Opin Cardiol 1996 Nov;11(6):611–2.

Value of intracoronary ultrasound and Doppler in the differentiation of angiographically normal coronary arteries: a prospective study in patients with angina pectoris. Erbel R, et al. **Eur Heart J** 1996 Jun;17(6):880–9

Differences in the morphology of unstable and stable coronary lesions and their impact on the mechanisms of angioplasty. An in vivo study with intravascular ultrasound. Kearney P, et al. **Eur Heart J** 1996 May; 17(5):721–30

[Intravascular ultrasound in determining the end point of percutaneous transluminal coronary angioplasty] Seo T, et al. **J Cardiol** 1996 Oct;28(4):183–9 (Eng. Abstr.) **(Jpn)**

ANGINA PECTORIS, VARIANT

BLOOD

Low density lipoprotein oxidation and variant angina: role of methodologic procedures in assessment of oxidizability of low density lipoprotein [letter; comment] Napoli C. **J Am Coll Cardiol** 1996 Nov 15;28(6):1637–8. Comment on: J Am Coll Cardiol 1995 Sep;26(3):632–8.

Characteristics of vasospastic angina with exercised-induced ischemia--analysis of parameters of hemostasis and fibrinolysis. Sakata K, et al. **Jpn Circ J** 1996 May; 60(5):277–84

CHEMICALLY INDUCED

Painless Prinzmetal's ST elevation related to propranolol: a case report. Lin YJ, et al. **Int J Cardiol** 1997 Aug 8; 60(3):311–4

COMPLICATIONS

Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X. Bøtker HE, et al. **Am J Cardiol** 1997 Apr 1;79(7):961–3

Neurocardiogenic syncope and Prinzmetal's angina associated with bronchogenic carcinoma. Angelini P, et al. **Chest** 1997 Mar;111(3):819–22

Vitamin E deficiency in variant angina. Miwa K, et al. **Circulation** 1996 Jul 1;94(1):14–8

Preconditioning by transient myocardial ischemia confers protection against ischemia-induced ventricular arrhythmias in variant angina. Pasceri V, et al. **Circulation** 1996 Oct 15;94(8):1850–6

Sudden death during Holter electrocardiogram monitoring in a patient with variant angina. Tsurukawa T, et al. **Intern Med** 1996 Dec;35(12):966–9

Autonomic changes associated with spontaneous coronary spasm in patients with variant angina. Lanza GA, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1249–56

DIAGNOSIS

Cases in electrocardiography. Zimmers T. **Am J Emerg Med** 1996 Mar;14(2):207–8

Comparison of clinical and laboratory findings between patients with diffuse three-vessel coronary artery spasm and other types of coronary artery spasm. Koh KK, et al. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):132–9

DRUG THERAPY

Calcium-channel blockers in ischemic heart disease. Silvestry FE, et al. **Curr Opin Cardiol** 1996 Jul;11(4):434–9 (45 ref.)

ETIOLOGY

Provocation of coronary spasm by dobutamine stress echocardiography in a patient with angiographically minimal coronary artery disease. Deligonul U, et al. **Clin Cardiol** 1996 Sep;19(9):755–8

Exercise-induced coronary spasm: comparison of treadmill and bicycle exercise in patients with vasospastic angina. Yamakado T, et al. **Coron Artery Dis** 1996 Nov; 7(11):819–22

Relation between severity of magnesium deficiency and frequency of anginal attacks in men with variant angina. Satake K, et al. **J Am Coll Cardiol** 1996 Oct;28(4):897–902

METABOLISM

Basal nitric oxide production by diseased coronary arteries [letter; comment] Tousoulis D, et al. **J Am Coll Cardiol** 1996 Nov 15;28(6):1639–40. Comment on: J Am Coll Cardiol 1996 May;27(6):1444–9.

PHYSIOPATHOLOGY

Insulin resistance in cardiac syndrome X and variant angina: influence of physical capacity and circulating lipids. Bøtker HE, et al. **Am Heart J** 1997 Aug;134(2 Pt 1):229–37

Comparison of coronary flow reserve between focal and diffuse vasoconstriction induced by ergonovine in patients with vasospastic angina. Akasaka T, et al. **Am J Cardiol** 1997 Sep 15;80(6):705–10

Left ventricular diastolic dysfunction in patients with angina decubitus. Chen J, et al. **Chin Med J (Engl)** 1996 Sep; 109(9):684–6

Re-evaluation of the mechanism and treatment of angina decubitus. Chen J, et al. **Chin Med Sci J** 1996 Mar; 11(1):8–12

Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Liuzzo G, et al. **Circulation** 1996 Nov 15;94(10):2373–80

Increased constrictor response to acetylcholine of the isolated coronary arteries from patients with variant angina. Kugiyama K, et al. **Int J Cardiol** 1995 Dec;52(3):223–33

Increased basal tone and hyperresponsiveness to acetylcholine and ergonovine in spasm-related coronary arteries in patients with variant angina. Lee SJ, et al. **Int J Cardiol** 1996 Jul 26;55(2):117–26

Response of conductance and resistance vessels of the coronary artery to intracoronary isosorbide dinitrate in patients with variant angina. Yamada T, et al. **Intern Med** 1996 Nov;35(11):844–8

Autonomic changes associated with spontaneous coronary spasm in patients with variant angina. Lanza GA, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1249–56

Vasospastic angina in a patient with Fabry's disease who showed normal coronary angiographic findings. Ogawa T, et al. **Jpn Circ J** 1996 May;60(5):315–8

Evolution of coronary vascular tone in vasospastic angina. Takamatsu T, et al. **Jpn Circ J** 1997 Mar;61(3):211–7

PREVENTION & CONTROL

Antianginal effect of RS-5773, a diltiazem congener, in the methacholine-induced anginal model in rats. Shiga H, et al. **Jpn J Pharmacol** 1996 Dec;72(4):365–74

RADIOGRAPHY

Endothelial dysfunction in the absence of coronary atheroma causing Prinzmetal's angina. Cox ID, et al. **Heart** 1997 Jun; 77(6):584

RADIONUCLIDE IMAGING

Assessment of regional sympathetic nerve activity in vasospastic angina: analysis of iodine 123-labeled metaiodobenzylguanidine scintigraphy. Sakata K, et al. **Am Heart J** 1997 Apr;133(4):484–9

Positron emission tomography in the diagnosis of variant angina. Jessurun GA, et al. **Clin Nucl Med** 1997 Jun; 22(6):442

Tl-201 scintigraphy in multivessel exercise-induced variant angina. Kruithoff WA, et al. **Clin Nucl Med** 1996 Sep; 21(9):675–8

Iodine-123 metaiodobenzylguanidine cardiac imaging to identify and localize vasospastic angina without significant coronary artery narrowing. Sakata K, et al. **J Am Coll Cardiol** 1997 Aug;30(2):370–6

THERAPY

Percutaneous transluminal angioplasty of internal mammary arteries in patients with rest angina. Crowley ST, et al. **Cathet Cardiovasc Diagn** 1996 Jul;38(3):256–62

ANGINA PECTORIS WITH NORMAL CORONARY ARTERIOGRAM see **SYNDROME X**

ANGINA, PREINFARCTION see **ANGINA, UNSTABLE**

ANGINA, UNSTABLE

Unstable angina: new insights into pathophysiologic characteristics, prognosis, and management strategies. Ribeiro PA, et al. **Curr Probl Cardiol** 1996 Oct; 21(10):669–731 (241 ref.)

Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. Hochman JS, et al. **J Am Coll Cardiol** 1997 Jul;30(1):141–8

The use of empiric clinical data in the evaluation of practice guidelines for unstable angina [see comments] Katz DA, et al. **JAMA** 1996 Nov 20;276(19):1568–74. Comment in: JAMA 1997 Mar 26;277(12):961; discussion 962. Comment in: JAMA 1997 Mar 26;277(12):961–2; discussion 962.

[Unstable angina] Ibuki C. **Ryoikibetsu Shokogun Shirizu** 1996;(12):766–70 (18 ref.) **(Jpn)**

[Definition and classification of unstable angina pectoris] Celikić S. **Vojnosanit Pregl** 1996 Jan–Feb;53(1):41–4 (28 ref.) **(Scr)**

BLOOD

Elevated levels of circulating soluble adhesion molecules in peripheral blood of patients with unstable angina. Ghaisas NK, et al. **Am J Cardiol** 1997 Sep 1;80(5):617–9

Usefulness of positive troponin-T and negative creatine kinase levels in identifying high-risk patients with unstable angina pectoris. Pettijohn TL, et al. **Am J Cardiol** 1997 Aug 15;80(4):510–1

Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Merlini PA, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1325–30

Association of neutrophils with platelet aggregates in unstable angina. Should we alter therapy? [editorial; comment] Entman ML, et al **Circulation** 1996 Sep 15; 94(6):1206–8. Comment on: Circulation 1996 Sep 15;94(6):1239–46.

Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Galvani M, et al. **Circulation** 1997 Apr 15;95(8):2053–9

Increased neutrophil-platelet adhesion in patients with unstable angina [see comments] Ott I, et al. **Circulation** 1996 Sep 15;94(6):1239–46. Comment in: Circulation 1996 Sep 15;94(6):1206–8.

Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. Rao AK, et al. **Circulation** 1996 Nov 15; 94(10):2389–95

Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment. Andersen K, et al. **Coron Artery Dis** 1996 Sep;7(9):673–81

Transmyocardial fibrinolytic activity in patients with unstable angina pectoris. Daniel WC, et al. **Coron Artery Dis** 1996 Jan;7(1):45–9

A prospective study of the role of lipoprotein(a) in the pathogenesis of unstable angina. Stubbs P, et al. **Eur Heart J** 1997 Apr;18(4):603–7

t-Plasminogen activator and von Willebrand factor in patients with unstable angina. Tousoulis D, et al. **Int J Cardiol** 1996 Apr 19;54(1):89–92

Cardiac troponin I levels in unstable angina and non-Q wave AMI. Graber MA. **J Fam Pract** 1997 Feb;44(2):135–6

Pathophysiological analysis of serum troponin T release kinetics in evolving ischemic myocardial injury. Seino Y, et al. **Jpn Circ J** 1996 May;60(5):265–76

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group [see comments] Haverkate F, et al. **Lancet** 1997 Feb 15;349(9050):462–6. Comment in: Lancet 1997 Apr 26;349(9060):1252–3. Comment in: Lancet 1997 Apr 26;349(9060):1253.

Increased plasma factor VIII:c activity in patients with unstable angina pectoris. Olinic D, et al. **Rom J Intern Med** 1996 Jan–Jun;34(1–2):65–71

On the regulation of monocyte tissue factor expression and activation of the coagulation cascade--cell studies and clinical studies on patients undergoing heart surgery and patients with unstable angina. Ernofsson M. **Scand Cardiovasc J** 1997;31(4):249–50

Gender difference in factor VII and in activated factor VII levels in unstable angina [letter] Benamer H, et al. **Thromb Haemost** 1996 Jun;75(6):981

Inactivation of factor Xia in vivo: studies in chimpanzees and in humans. Wuillemin WA, et al. **Thromb Haemost** 1996 Oct;76(4):549–55

Biochemical markers of myocardial damage for early diagnosis and prognosis in patients with acute coronary syndromes. Minireview based on a doctorial thesis. Lindahl B. **Ups J Med Sci** 1996;101(3):193–232 (210 ref.)

[Determination of cardiac troponin I on Stratus analyzer: prospective evaluation in unstable angina] Quillard M, et al. **Ann Biol Clin (Paris)** 1996;54(10–11):359–63 (Eng. Abstr.) **(Fre)**

[Cardiac troponin I and T in unstable angina: incidence, correlation, kinetics of release and prognostic value] Musso P, et al. **G Ital Cardiol** 1996 Sep;26(9):1013–23 (Eng. Abstr.) **(Ita)**

[Generation of active oxygen species by neutrophils in patients with unstable angina pectoris] Kowalski J, et al. **Przegl Lek** 1995;52(11):541–3 (Eng. Abstr.) **(Pol)**

[Hemostasis and pathogenetic therapy of unstable angina pectoris] Krashutskii VV, et al. **Klin Med (Mosk)** 1996; 74(7):18–21 (Eng. Abstr.) **(Rus)**

[The role of free-radical processes in determining immune disorders in unstable angina and the principles for their correction] Girina ON. **Lik Sprava** 1995 Sep–Dec; (9–12):37–41 (Eng. Abstr.) **(Rus)**

[Plasma fibrinogen during the acute stage of angina or myocardial infarct] de la Llata-Romero M, et al. **Gac Med Mex** 1997 May–Jun;133(3):175–80; discussion 181 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Predictive validity of the Braunwald classification of unstable angina for angiographic findings, short-term prognoses, and treatment selection. Owa M, et al. **Angiology** 1997 Aug; 48(8):663–71

COMPLICATIONS

Effects of renal artery stent implantation in patients with renovascular hypertension presenting with unstable angina or congestive heart failure. Khosla S, et al. **Am J Cardiol** 1997 Aug 1;80(3):363–6

Usefulness of the addition of heart rate variability to Holter monitoring in predicting in-hospital cardiac events in

patients with unstable angina pectoris. Lanza GA, et al. **Am J Cardiol** 1997 Aug 1;80(3):263–7

Usefulness of positive troponin–T and negative creatine kinase levels in identifying high–risk patients with unstable angina pectoris. Pettijohn TL, et al. **Am J Cardiol** 1997 Aug 15;80(4):510–1

Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. Biasucci LM, et al. **Circulation** 1996 Jun 15;93(12):2121–7

Comparison of usefulness of computer assisted continuous 48–h 3–lead with 12–lead ECG ischaemia monitoring for detection and quantitation of ischaemia in patients with unstable angina. Klootwijk P, et al. **Eur Heart J** 1997 Jun; 18(6):931–40

[Implanting of coronary stents in patients with unstable angina] Palmerini T, et al. **Cardiologia** 1997 Apr; 42(4):415–20 (Eng. Abstr.) **(Ita)**

[Emergency coronary artery bypass in an 84–year–old patient with severe left main disease and cardiogenic shock] Tomioka H, et al. **Kyobu Geka** 1996 Sep;49(10):863–7 (Eng. Abstr.) **(Jpn)**

[Impending myocardial infarction] Shibata M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):730–4 (23 ref.) **(Jpn)**

[Arrest of the painful syndrome by moradol and nubain in patients with ischemic heart disease] Litovchenko VS, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):30–1 (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Management of unstable angina pectoris and non–Q–wave acute myocardial infarction in the United States and Canada (the TIMI III Registry). Anderson HV, et al. **Am J Cardiol** 1997 Jun 1;79(11):1441–6

SGOT, LDH, HBD, CPK, CK–MB, MB1MB2, cTnT, cTnC, cTnI. Futterman LG, et al. **Am J Crit Care** 1997 Jul;6(4):333–8 (6 ref.)

Unstable angina: are we able to recognize high–risk patients? de Zwaan C, et al. **Chest** 1997 Jul;112(1):244–50 (53 ref.)

Unstable angina: can early decisions about diagnosis and therapy be made using troponin T values? [editorial] Conti CR. **Clin Cardiol** 1996 Jun;19(6):445–6

Ischaemia detected by continuous on–line vectorcardiographic monitoring predicts unfavourable outcome in patients admitted with probable unstable coronary disease. Andersen K, et al. **Coron Artery Dis** 1996 Oct;7(10):753–60

Recognition and treatment of unstable angina. Brunelli C, et al. **Drugs** 1996 Aug;52(2):196–208 (80 ref.)

Parallel testing: is it 'T–time'? [editorial; comment] Rodak DJ, et al. **Eur Heart J** 1997 May;18(5):716–8. Comment on: Eur Heart J 1997 May;18(5):762–70.

Troponin T: a diagnostic marker for myocardial infarction and minor cardiac cell damage. Rottbauer W, et al. **Eur Heart J** 1996 Dec;17 Suppl F:3–8 (40 ref.)

Variation in the use of coronary angiography in patients with unstable angina is related to differences in patient population and availability of angiography facilities, without affecting prognosis. van Miltenburg–van Zijl AJ, et al. **Eur Heart J** 1996 Dec;17(12):1828–35

The prognostic value of serum troponin T in unstable angina. Gökhan Cin V, et al. **Int J Cardiol** 1996 Mar;53(3):237–44

Rapid and specific immunoassay for cardiac troponin I in the diagnosis of myocardial damage. Panteghini M, et al. **Int J Clin Lab Res** 1997;27(1):60–4

Experience of a rapid access acute chest pain clinic. el Gaylani N, et al. **Ir Med J** 1997 Jun–Jul;90(4):139–40

Correlation of angiographic morphology and clinical presentation in unstable angina. Dangas G, et al. **J Am Coll Cardiol** 1997 Mar 1;29(3):519–25

Biochemical markers of myocardial damage for early diagnosis and prognosis in patients with acute coronary syndromes. Minireview based on a doctorial thesis. Lindahl B. **Ups J Med Sci** 1996;101(3):193–232 (210 ref.)

[Endothelin and big endothelin in coronary heart disease and acute coronary syndromes] Borries M, et al. **Z Kardiol** 1996 Oct;85(10):761–7 (Eng. Abstr.) **(Ger)**

[Qualifying patients with unstable angina for invasive tests based on electrocardiographic examinations] Petelenz T, et al. **Pol Merkuriusz Lek** 1996 Aug;1(2):87–90 (Eng. Abstr.) **(Pol)**

DIET THERAPY

[Diet for heart patients. A questionnaire study at Danish coronary care units] Jeppesen ET, et al. **Ugeskr Laeger** 1997 Jul 28;159(31):4751–5 (Eng. Abstr.) **(Dan)**

DRUG THERAPY

Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Bovill EG, et al. **Am J Cardiol** 1997 Feb 15; 79(4):391–6

Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb–IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Harrington RA. **Am J Cardiol** 1997 Aug 18; 80(4A):34B–38B (27 ref.)

Comparison of heparin therapy for < or = 48 hours to > 48 hours in unstable angina pectoris. Klein LW, et al. **Am J Cardiol** 1997 Feb 1;79(3):259–63

Fragmin in unstable angina pectoris or in non–Q–wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease. Klein W, et al. **Am J Cardiol** 1997 Sep 4;80(5A):30E–34E

Low–molecular–weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group. Swahn E, et al. **Am J Cardiol** 1997 Sep 4;80(5A):25E–29E

New frontiers in the management of unstable coronary artery disease. Turpie AG. **Am J Cardiol** 1997 Sep 4; 80(5A):21E–24E (30 ref.)

Increasing the stability of unstable angina [letter; comment] Ray J. **Arch Intern Med** 1997 Jan 27;157(2):246. Comment on: Arch Intern Med 1996 Jul 8;156(13):1382–94.

Tirofiban—spinning the data from fact to hype [editorial; comment] Jackson G. **Br J Clin Pract** 1997 Apr–May; 51(3):131–2. Comment on: Br J Clin Pract 1997 Apr–May;51(3):157–9.

Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Thadani U. **Cardiovasc Drugs Ther** 1997 Jan;10(6):735–42 (65 ref.)

Site–specific intravascular administration of drugs: history of a method applicable in humans. Camenzind E, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):342–7 (39 ref.)

Comparison of low–molecular–weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) [see comments] Klein W, et al. **Circulation** 1997 Jul 1;96(1):61–8. Comment in: Circulation 1997 Jul 1;96(1):3–5.

Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. Rao AK, et al. **Circulation** 1996 Nov 15; 94(10):2389–95

Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Schulman SP, et al. **Circulation** 1996 Nov 1; 94(9):2083–9

First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo–controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Simpfendorfer C, et al. **Circulation** 1997 Jul 1;96(1):76–81

Low–molecular–weight heparins for unstable angina. A better mousetrap? [editorial; comment] Waters D, et al. **Circulation** 1997 Jul 1;96(1):3–5. Comment on: Circulation 1997 Jul 1;96(1):61–8.

Refining the treatment of women with unstable angina—a randomized, double–blind, comparative safety and efficacy evaluation of Integrelin versus aspirin in the management of unstable angina. Goldschmidt–Clermont PJ, et al. **Clin Cardiol** 1996 Nov;19(11):869–74

Use of urokinase in unstable angina. Duvvuri S, et al. **Coron Artery Dis** 1996 Sep;7(9):630–6 (51 ref.)

Prolonged streptokinase infusion in patients with unstable angina: results of a randomized, placebo–controlled clinical trial. Oltrona L, et al. **Coron Artery Dis** 1996 May; 7(5):377–82

Potential advantages of direct–acting thrombin inhibitors. Philippides GJ, et al. **Coron Artery Dis** 1996 Jul; 7(7):497–507 (100 ref.)

Recognition and treatment of unstable angina. Brunelli C, et al. **Drugs** 1996 Aug;52(2):196–208 (80 ref.)

Clinical management of unstable angina: the place of antithrombins and platelet GP IIb/IIIa receptor blockers. Knudtson ML. **Eur Heart J** 1995 Nov;16 Suppl L:68–74 (105 ref.)

How european cardiologists perceive the role of calcium antagonists in the treatment of unstable angina. Pepine CJ, et al. **Eur Heart J** 1997 Jan;18 Suppl A:A117–24 (3 ref.)

Antiplatelet therapy in therapy–resistant unstable angina. A pilot study with REO PRO (c7E3). van den Brand MJ, et al. **Eur Heart J** 1995 Nov;16 Suppl L:36–42

Low molecular weight heparins: a valuable tool in the treatment of acute coronary syndromes. Wallentin L. **Eur Heart J** 1996 Oct;17(10):1470–6 (90 ref.)

Nucleoside transport inhibition by draflazine in unstable coronary disease. Andersen K, et al. **Eur J Clin Pharmacol** 1996;51(1):7–13

Comparison of clinical outcome of fixed–dose subcutaneous low molecular weight heparin (tinzaparin) with conventional heparin in unstable angina: a pilot study. Suvarna TT, et al. **Indian Heart J** 1997 Mar–Apr; 49(2):159–62

Dose–ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. **J Am Coll Cardiol** 1997 Jun;29(7):1474–82

Effect of transdermal nitroglycerin or N–acetylcysteine, or both, in the long–term treatment of unstable angina pectoris. Ardissino D, et al. **J Am Coll Cardiol** 1997 Apr; 29(5):941–7

Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators.Evaluation of 7E3 in Preventing Ischemic Complications. Lincoff AM, et al. **J Am Coll Cardiol** 1997 Jul;30(1):149–56

Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. Williams MJ, et al. **J Am Coll Cardiol** 1997 Aug;30(2):364–9

Glucose–insulin–potassium solutions enhance recovery after urgent coronary artery bypass grafting. Lazar HL, et al. **J Thorac Cardiovasc Surg** 1997 Feb;113(2):354–60; discussion 360–2

Benefit of heparin plus aspirin vs aspirin alone in unstable angina [letter; comment] Blankfield RP. **JAMA** 1996 Dec 18;276(23):1873–4; discussion 1874. Comment on: JAMA 1996 Sep 11;276(10):811–5.

Benefit of heparin plus aspirin vs aspirin alone in unstable angina [letter; comment] Brophy J. **JAMA** 1996 Dec 18; 276(23):1873; discussion 1874. Comment on: JAMA 1996 Sep 11;276(10):811–5.

Benefit of heparin plus aspirin vs aspirin alone in unstable angina [letter; comment] Collins R, et al. **JAMA** 1996 Dec 18;276(23):1873; discussion 1874. Comment on: JAMA 1996 Sep 11;276(10):811–5.

Randomised trial of roxithromycin in non–Q–wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group [see comments] Gurfinkel E, et al. **Lancet** 1997 Aug 9; 350(9075):404–7. Comment in: Lancet 1997 Aug 9;350(9075):378–9.

Heparin in acute coronary disease—requiem for a heavyweight? [editorial; comment] Armstrong PW. **N Engl J Med** 1997 Aug 14;337(7):492–4. Comment on: N Engl J Med 1997 Aug 14;337(7):447–52.

A comparison of low–molecular–weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q–Wave Coronary Events Study Group [see comments] Cohen M, et al. **N Engl J Med** 1997 Aug 14; 337(7):447–52. Comment in: N Engl J Med 1997 Aug 14;337(7):492–4.

Treatment of chronic unstable angina pectoris: use of a totally implantable programmable device for continuous intrathecal infusion of opiates: case report. Segal R, et al. **Neurosurgery** 1996 Feb;38(2):385–8

Relationship between plasma perhexiline concentration and symptomatic status during short–term perhexiline therapy. Stewart S, et al. **Ther Drug Monit** 1996 Dec;18(6):635–9

Coronary heart disease, unstable angina, PTCA: new indications for low molecular weight heparins? Breddin HK. **Thromb Res** 1996;81(2 Suppl):S47–51 (21 ref.)

[Current point of view on medical treatment of unstable angina] Col J. **Arch Mal Coeur Vaiss** 1996 Oct;89 Spec No 5:15–8 (Eng. Abstr.) **(Fre)**

[Linsidomine, direct donor of EDRF/NO: a new treatment for unstable angina] Delonca J, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89 Spec No 5:19–25 (Eng. Abstr.) **(Fre)**

[Low molecular weight heparin in unstable angina] Kher A, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1495–500 (Eng. Abstr.) **(Fre)**

[Modern "antiplatelet agents" in unstable angina] Vahanian A, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1521–6 (27 ref.) (Eng. Abstr.) **(Fre)**

[Calcium antagonists and ischemic heart disease] Simon K, et al. **Orv Hetil** 1996 Sep 29;137(39):2131–6 (66 ref.) (Eng. Abstr.) **(Hun)**

[Unstable angina in coronary intensive care units without hemodynamics: is admissible a strategy limiting the indications for coronarography?] Bonechi F, et al. **Cardiologia** 1996 Oct;41(10):987–94 (Eng. Abstr.) **(Ita)**

[The role of low–molecular–weight heparin in unstable angina, acute myocardial infarction and post–elective percutaneous transluminal coronary angioplasty (see comments)] Cláudio Correia LC, et al. **Arq Bras Cardiol** 1995 Dec;65(6):475–8 (Eng. Abstr.). Comment in: Arq Bras Cardiol 1995 Dec;65(5):517–8. **(Por)**

[The role of low–molecular–weight heparin in unstable angina, acute myocardial infarction and post–elective percutaneous transluminal coronary angioplasty (editorial; comment)] Pimentel Filho WA. **Arq Bras Cardiol** 1995 Dec; 65(6):517–8. Comment on: Arq Bras Cardiol 1995 Dec;65(6):475–8. **(Por)**

[Piracetam and tocopherol acetate ability to potentiate clinical effect of antianginal drugs in presenile and senile patients with ischemic heart disease (unstable angina)] Pimenov LT, et al. **Klin Med (Mosk)** 1997;75(1):32–5 (Eng. Abstr.) **(Rus)**

[The possibilities of arifon in the combined therapy of unstable stenocardia in persons with arterial hypertension] Iakovlev VM, et al. **Ter Arkh** 1997;69(6):53–5 (Eng. Abstr.) **(Rus)**

[The neurohumoral and hemodynamic effect of aldizem in patients with stable and unstable angina pectoris] Malaia LT, et al. **Ter Arkh** 1993;65(2):55–8 (Eng. Abstr.) **(Rus)**

[The antioxidant histochrome: its effect on lipid peroxidation and the blood rheological properties in patients with unstable stenocardia] Zakirova AN, et al. **Ter Arkh** 1996; 68(8):12–4 (Eng. Abstr.) **(Rus)**

[Thrombolysis in unstable angina. A perspective before and after TIMI IIIB] Jerjes–Sánchez C, et al. **Arch Inst Cardiol Mex** 1996 May–Jun;66(3):254–64 (Eng. Abstr.) **(Spa)**

ECONOMICS

Potential economic impact of glycoprotein IIb–IIIa inhibitors

in improving outcomes of patients with acute ischemic coronary syndromes. McElwee NE, et al. **Am J Cardiol** 1997 Aug 18;80(4A):39B–43B (16 ref.)

EPIDEMIOLOGY

A study of unplanned readmissions to a coronary care unit. Stewart S, et al. **Heart Lung** 1997 May–Jun;26(3):196–203

ETIOLOGY

Unstable angina--report from a Canadian expert roundtable. Cairns J, et al. **Can J Cardiol** 1996 Dec;12(12):1279–92 (116 ref.)

Family history and socioeconomic factors as predictors of myocardial infarction, unstable angina and stroke in an Italian population. PROGETTO 3A Investigators. Vitullo F, et al. **Eur J Epidemiol** 1996 Apr;12(2):177–85

Single (culprit) vessel disease in octogenarians with acute myocardial infarction and unstable angina. U KM, et al. **Md Med J** 1996 Jun;45(6):471–5

Coronary–plaque rupture in acute coronary syndromes triggered by snow shoveling [letter] [see comments] Hammoudeh AJ, et al. **N Engl J Med** 1996 Dec 26; 335(26):2001. Comment in: N Engl J Med 1997 Jun 5;336(23):1678; discussion 1678–9.

GENETICS

Normal prevalence of factor V Leiden gene mutation in patients with severe unstable angina [letter] Verheggen PW, et al. **Thromb Haemost** 1997 Jun;77(6):1218

IMMUNOLOGY

Role of inflammation in the pathogenesis of unstable coronary artery disease. Crea F, et al. **Am J Cardiol** 1997 Sep 4; 80(5A):10E–16E (66 ref.)

Acute T–cell activation is detectable in unstable angina. Neri Serneri GG, et al. **Circulation** 1997 Apr 1;95(7):1806–12

METABOLISM

Levels of expression of P–selectin, E–selectin, and intercellular adhesion molecule–1 in coronary atherectomy specimens from patients with stable and unstable angina pectoris. Tenaglia AN, et al. **Am J Cardiol** 1997 Mar 15; 79(6):742–7

Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Cipollone F, et al. **Circulation** 1997 Aug 19;96(4):1109–16

Coronary artery calcium in acute coronary syndromes: a comparative study of electron–beam computed tomography, coronary angiography, and intracoronary ultrasound in survivors of acute myocardial infarction and unstable angina. Schmermund A, et al. **Circulation** 1997 Sep 2;96(5):1461–9

MORTALITY

Non–invasive risk stratification within 48 h of hospital admission in patients with unstable coronary disease. Andersen K, et al. **Eur Heart J** 1997 May;18(5):780–8

Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre–discharge exercise tests. FRISK Study Group [see comments] Lindahl B, et al. **Eur Heart J** 1997 May; 18(5):762–70. Comment in: Eur Heart J 1997 May;18(5):716–8.

Comparison between Japan and North America in the post–hospital course after recovery from an acute coronary event. Nakamura Y, et al. **Int J Cardiol** 1996 Aug; 55(3):245–54

Cardiac troponin I levels in unstable angina and non–Q wave AMI. Graber MA. **J Fam Pract** 1997 Feb;44(2):135–6

Cardiac–specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes [see comments] Antman EM, et al. **N Engl J Med** 1996 Oct 31;335(18):1342–9. Comment in: N Engl J Med 1996 Oct 31;335(18):1388–9. Comment in: N Engl J Med 1997 Apr 24;336(17):1258; discussion 1258–9.

[The risk factors for sudden coronary death in patients with unstable angina] Sirenko IuN, et al. **Lik Sprava** 1995 Sep–Dec;(9–12):3–7 (38 ref.) **(Rus)**

PATHOLOGY

Electron microscopic studies of phenotypic modulation of smooth muscle cells in coronary arteries of patients with unstable angina pectoris and postangioplasty restenosis. Chen YH, et al. **Circulation** 1997 Mar 4;95(5):1169–75

Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell–mediated thrombogenicity in acute coronary syndromes. Moreno PR, et al. **Circulation** 1996 Dec 15;94(12):3090–7

Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Moreno PR, et al. **Circulation** 1996 Dec 15;94(12):3098–102

Angioscopic predictors of early adverse outcome after coronary angioplasty in patients with unstable angina and non–Q–wave myocardial infarction. Waxman S, et al. **Circulation** 1996 Jun 15;93(12):2106–13

Focal myocardial ischemic necroses associated with unstable angina pectoris. Dominitz I, et al. **J Am Coll Cardiol** 1996 Oct;28(4):910–4

PHYSIOPATHOLOGY

The inflammatory etiology of unstable angina [editorial] Azar RR, et al. **Am Heart J** 1996 Nov;132(5):1101–6 (45 ref.)

Ischemic chest pain and global T–wave inversion in women with normal coronary angiograms. Brscic E, et al. **Am J Cardiol** 1997 Jul 15;80(2):245–7

Circadian variation in the onset of unstable angina and non–Q–wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Cannon CP, et al. **Am J Cardiol** 1997 Feb 1;79(3):253–8

Platelet activation and inhibition in unstable coronary syndromes. Patrono C, et al. **Am J Cardiol** 1997 Sep 4; 80(5A):17E–20E (36 ref.)

Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. Biasucci LM, et al. **Circulation** 1996 Jun 15;93(12):2121–7

The role of CRP and IL–6 in unstable angina [letter] Erdogan O, et al. **Circulation** 1997 Sep 16;96(6):2099–101

Plasma protein acute–phase response in unstable angina is not induced by ischemic injury. Liuzzo G, et al. **Circulation** 1996 Nov 15;94(10):2373–80

Pathophysiology of transient myocardial ischemia in acute coronary syndromes. Characterization by continuous ST–segment monitoring. Patel DJ, et al. **Circulation** 1997 Mar 4;95(5):1185–92

Pathophysiology and initial management of the acute coronary syndromes. Giri S, et al. **Curr Opin Cardiol** 1996 Jul;11(4):351–60 (85 ref.)

Asynchronous left ventricular wall motion in unstable angina. Henein MY, et al. **Int J Cardiol** 1997 Mar;59(1):37–45

Detection of coronary artery disease using 12–lead electrocardiogram and simultaneous dual myocardial imaging with iodine–123–beta–methyl iodophenyl–pentadecanoic acid (BMIPP) and thallium–201 in patients with unstable angina. Saitoh M, et al. **Intern Med** 1995 Nov;34(11):1064–70

The electrocardiogram predicts one–year outcome of patients with unstable angina and non–Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. Cannon CP, et al. **J Am Coll Cardiol** 1997 Jul;30(1):133–40

[Physiopathology of unstable angina] Spaulding C, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89 Spec No 5:11–4 (Eng. Abstr.) **(Fre)**

[Femoral neuropathy in a patient with unstable angina] Bar–Dayan Y, et al. **Harefuah** 1997 Jun 15;132(12):903–4 **(Heb)**

[Inflammation and unstable angina] Leibovitz E, et al. **Harefuah** 1996 May 1;130(9):635–8 (38 ref.) **(Heb)**

[Circadian variation of the unstable phase in coronary disease] Szpot M, et al. **Przegl Lek** 1996;53(6):478–80 (Eng. Abstr.) **(Pol)**

[Hypoxia and vascular–platelet hemostasis in patients with acute coronary insufficiency] Shvarts IuG, et al. **Anesteziol Reanimatol** 1997 Jan–Feb;(1):18–20 (Eng. Abstr.) **(Rus)**

[Right ventricular function and the hemodynamic status of patients with unstable stenocardia] Tashchuk VK, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):54–7 (Eng. Abstr.) **(Ukr)**

PREVENTION & CONTROL

[Clinical studies of the effectiveness of aspirin in the prevention of major cardio–cerebrovascular occurrences] Mariani M, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):423–8 (43 ref.) **(Ita)**

PSYCHOLOGY

Heart rate and heart–rate variability in patients with acute coronary heart disease classified on Bortner's scale as type A and type B. Catipović–Veselica K, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):775–84

RADIOGRAPHY

Occipital infarction following coronary angiography [letter] Benito–León J, et al. **Cathet Cardiovasc Diagn** 1997 Jan; 40(1):117–8

Persistent cauda equina syndrome following bilateral aortoiliac dissection as a complication of cardiac angiography. Verneuil A, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):377–9

Coronary stenosis progression differs in patients with stable angina pectoris with and without a previous history of unstable angina. Kaski JC, et al. **Eur Heart J** 1996 Oct; 17(10):1488–94

Clinical predictors of unstable coronary lesion morphology. Rupprecht HJ, et al. **Eur Heart J** 1995 Nov;16(11):1526–34

Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. Chen L, et al. **J Am Coll Cardiol** 1996 Nov 15;28(6):1493–9

Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. Williams MJ, et al. **J Am Coll Cardiol** 1997 Aug;30(2):364–9

[Should all patients with unstable angina undergo routine coronary angiography? Arguments in favor] Alfonso F. **Rev Esp Cardiol** 1996 Sep;49(9):638–46 **(Spa)**

[Should all patients with unstable angina undergo routine coronary angiography? Arguments against] Bosch X, et al. **Rev Esp Cardiol** 1996 Sep;49(9):647–56 **(Spa)**

RADIONUCLIDE IMAGING

Detection of coronary artery disease using 12–lead electrocardiogram and simultaneous dual myocardial imaging with iodine–123–beta–methyl iodophenyl–pentadecanoic acid (BMIPP) and thallium–201 in patients with unstable angina. Saitoh M, et al. **Intern Med** 1995 Nov;34(11):1064–70

Relevance of increased lung thallium uptake on stress imaging in patients with unstable angina and non–Q wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI)–IIIB Study. Jain D, et al. **J Am Coll Cardiol** 1997 Aug;30(2):421–9

An effective tool to detect lesions causing unstable angina with multivessel disease: iodine–123–betamethyl–p–iodophenyl–pentadecanoic acid single photon emission computed tomography. Fukuzawa S, et al. **J Cardiol** 1996 Oct;28(4):191–8

Decision making with acute chest pain myocardial perfusion imaging. Padula L, et al. **J Nucl Cardiol** 1996 Sep–Oct; 3(5):446–7

Iodine–123–BMIPP imaging in unstable angina: a guide for interventional strategy. Takeishi Y, et al. **J Nucl Med** 1997 Sep;38(9):1407–11

Comparison of resting beta–methyl–iodophenyl pentadecanoic acid (BMIPP) and thallium–201 tomography using quantitative polar maps in patients with unstable angina. Suzuki A, et al. **Jpn Circ J** 1997 Feb;61(2):133–8

REHABILITATION

[The characteristics of the rehabilitative treatment of patients with a history of unstable stenocardia] Sledzevskaia IK, et al. **Lik Sprava** 1996 Mar–Apr;(3–4):108–10 (Eng. Abstr.) **(Rus)**

SURGERY

Relation of unstable angina and myocardial infarction to progression of coronary narrowing in patients undergoing coronary artery bypass grafting (utilizing an internal mammary artery). Lerakis S, et al. **Am J Cardiol** 1997 Jun 15;79(12):1683–5

Arterial autologous graft–stent for treatment of coronary artery disease: a new technique. Stefanadis C, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):302–7 (23 ref.)

Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Moreno PR, et al. **Circulation** 1996 Dec 15;94(12):3098–102

Unstable angina: the role of surgical revascularization. Burtt DM, et al. **Coron Artery Dis** 1995 Oct;6(10):780–7 (28 ref.)

Coronary angioplasty of rapidly progressive lesions--nothing to it or just too rare to be recognized as a problem? [editorial; comment] Meier B. **Eur Heart J** 1996 Nov; 17(11):1612–3. Comment on: Eur Heart J 1996 Nov;17(11):1671–7.

Coronary stenting in a hemophilic patient [letter] Helft G, et al. **Thromb Haemost** 1997 May;77(5):1044–5

[Current indications of myocardial revascularization in unstable angina] Danchin N, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89 Spec No 5:27–31 (Eng. Abstr.) **(Fre)**

[Myocardial revascularization in geriatric patients] Garachemani A, et al. **Schweiz Med Wochenschr** 1997 Mar 15;127(11):425–9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Effectiveness of the Palmaz Schatz stent in elderly patients with unstable angina: factors predictive of short–term and long–term events] Klugmann S, et al. **G Ital Cardiol** 1997 Jul;27(7):659–68 (35 ref.) (Eng. Abstr.) **(Ita)**

[Successful emergency coronary artery bypass grafting in a patient with systemic lupus erythematosus under hemodialysis therapy] Moriyama Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):195–7 (Eng. Abstr.) **(Jpn)**

THERAPY

New Frontiers in the Management of Unstable Coronary Artery Disease. Symposium proceedings. Uppsala, Sweden, February 14–15, 1997. **Am J Cardiol** 1997 Sep 4; 80(5A):1E–67E

Angiographic evolution of intracoronary thrombus and dissection following percutaneous transluminal coronary angioplasty (the Thrombolysis and Angioplasty in Unstable Angina [TAUSA] trial). Ambrose JA, et al. **Am J Cardiol** 1997 Mar 1;79(5):559–63

Management of unstable angina pectoris and non–Q–wave acute myocardial infarction in the United States and Canada (the TIMI III Registry). Anderson HV, et al. **Am J Cardiol** 1997 Jun 1;79(11):1441–6

Potential economic impact of glycoprotein IIb–IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes. McElwee NE, et al. **Am J Cardiol** 1997 Aug 18;80(4A):39B–43B (16 ref.)

Results of coronary stenting for unstable versus stable angina pectoris. Marzocchi A, et al. **Am J Cardiol** 1997 May 15; 79(10):1314–8

Percutaneous coronary angioscopic comparison of thrombus formation during percutaneous coronary angioplasty with ionic and nonionic low osmolality contrast media in unstable angina. Qureshi NR, et al. **Am J Cardiol** 1997 Sep 15;80(6):700–4

Roundtable panel discussion: the role of glycoprotein IIb–IIIa receptor inhibitors in acute ischemic coronary

syndromes. White HD. **Am J Cardiol** 1997 Aug 18; 80(4A):44B–48B

Thoracic epidural anesthesia as the last option for treating angina in a patient before coronary artery bypass surgery. Overdyk FJ, et al. **Anesth Analg** 1997 Jan;84(1):213–5

Cardiac troponin T in unstable angina. Does measurement of troponin T add to ability to stratify risk? [letter; comment] Kennedy RL. **BMJ** 1996 Nov 23;313(7068):1330; discussion 1330–1. Comment on: BMJ 1996 Aug 3;313(7052):262–4.

Cardiac troponin T in unstable angina. Troponin T could be used to identify patients needing early treatment [letter; comment] Wierzbicki AS, et al. **BMJ** 1996 Nov 23; 313(7068):1330; discussion 1330–1. Comment on: BMJ 1996 Aug 3;313(7052):262–4.

Angioplasty of a coronary artery via the translumbar approach in a patient with severe peripheral vascular disease [see comments] Chandler AH 3rd, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):202–4. Comment in: Cathet Cardiovasc Diagn 1996 Jun;38(2):205.

Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein–covered Palmaz stent [see comments] Gurbel PA, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):75–8 (12 ref.). Comment in: Cathet Cardiovasc Diagn 1997 Jan;40(1):79.

Embolization of a Wiktor stent within a stent: successful nonsurgical management. Kaul U, et al. **Cathet Cardiovasc Diagn** 1996 Jul;38(3):277–9

Obliteration of a coronary artery aneurysm with percutaneous transluminal coronary angioplasty and stent placement. Parmar RJ, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):51–2

Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans [see comments] Condado JA, et al. **Circulation** 1997 Aug 5;96(3):727–32. Comment in: Circulation 1997 Aug 5;96(3):709–12. Comment in: Circulation 1997 Aug 19;96(4):1067–8.

Association of neutrophils with platelet aggregates in unstable angina. Should we alter therapy? [editorial; comment] Entman ML, et al. **Circulation** 1996 Sep 15; 94(6):1206–8. Comment on: Circulation 1996 Sep 15;94(6):1239–46.

Angioscopic predictors of early adverse outcome after coronary angioplasty in patients with unstable angina and non–Q-wave myocardial infarction. Waxman S, et al. **Circulation** 1996 Jun 15;93(12):2106–13

Results of percutaneous transluminal coronary angioplasty in unstable angina and non–Q-wave myocardial infarction. Observations from the TIMI IIIB Trial. Williams DO, et al. **Circulation** 1996 Dec 1;94(11):2749–55

Unstable angina: can early decisions about diagnosis and therapy be made using troponin T values? [editorial] Conti CR. **Clin Cardiol** 1996 Jun;19(6):445–6

Enhanced external counterpulsation as an adjunct to revascularization in unstable angina. Lawson WE, et al. **Clin Cardiol** 1997 Feb;20(2):178–80

Importance of delaying balloon angioplasty in patients with unstable angina pectoris. Rozenman Y, et al. **Clin Cardiol** 1996 Feb;19(2):111–4

Infected pseudoaneurysm complicating percutaneous transluminal coronary angioplasty. Herchline TE, et al. **Clin Infect Dis** 1996 Mar;22(3):602, reply 603

Coronary stent placement as a bridge to coronary artery bypass surgery in an unstable, anemic Jehovah's Witness patient: a case report and review of bloodless surgery techniques. Dougherty JE, et al. **Conn Med** 1997 Apr; 61(4):195–9 (22 ref.)

Early coronary angioplasty as compared with delayed coronary angioplasty in patients with high-risk unstable angina pectoris. Antoniucci D, et al. **Coron Artery Dis** 1996 Jan;7(1):75–80

Unstable angina: the role of percutaneous coronary angioplasty. Piana RN, et al. **Coron Artery Dis** 1995 Oct; 6(10):774–9 (36 ref.)

Role of medical versus revascularization therapy in unstable angina. Rodak DJ, et al. **Coron Artery Dis** 1995 Oct; 6(10):765–73 (55 ref.)

Pathophysiology and initial management of the acute coronary syndromes. Giri S, et al. **Curr Opin Cardiol** 1996 Jul;11(4):351–60 (85 ref.)

Outcome of unstable angina in patients with diabetes mellitus. Fava S, et al. **Diabet Med** 1997 Mar;14(3):209–13

Morphological changes after percutaneous transluminal coronary angioplasty of unstable plaques. Insights from serial angioscopic follow-up [see comments] Bauters C, et al. **Eur Heart J** 1996 Oct;17(10):1554–9. Comment in: Eur Heart J 1996 Oct;17(10):1461–2.

Treatment of ischaemic heart disease. Role of drugs, surgery and angioplasty in unstable angina patients. Conti CR. **Eur Heart J** 1997 May;18 Suppl B:B11–5 (25 ref.)

Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study [see comments] Grip L, et al. **Eur Heart J** 1997 Mar;18(3):443–9. Comment in: Eur Heart J 1997 Mar;18(3):362–3.

Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris [see comments] Hafner G, et al. **Eur Heart J** 1996 Aug; 17(8):1207–15. Comment in: Eur Heart J 1996 Aug;17(8):1134–6.

Adjunctive infusion of antithrombin III during percutaneous transluminal coronary angioplasty [editorial; comment] Huber K, et al. **Eur Heart J** 1997 Mar;18(3):362–3. Comment on: Eur Heart J 1997 Mar;18(3):443–9.

Differences in the morphology of unstable and stable coronary lesions and their impact on the mechanisms of angioplasty. An in vivo study with intravascular ultrasound. Kearney P, et al. **Eur Heart J** 1996 May; 17(5):721–30

Percutaneous transluminal coronary angioplasty in refractory unstable angina pectoris: are new devices useful? Bertaglia E, et al. **Int J Cardiol** 1996 Nov 15;57(1):1–7

Complement activates neutrophils during PTCA procedure in patients with unstable angina pectoris. Kowalski J, et al. **Int J Cardiol** 1997 Feb;58(3):229–40

Coronary angioplasty for elderly patients with "high risk" unstable angina: short-term outcomes and long-term survival. Morrison DA, et al. **J Am Coll Cardiol** 1997 Feb; 29(2):339–44

Con: thoracic epidural anesthesia is not indicated in the treatment of unstable angina. Kleinman B. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):109–11

Pro: the anesthesiologist should provide epidural anesthesia in the coronary care unit for patients with severe angina. Staats PS, et al. **J Cardiothorac Vasc Anesth** 1997 Feb; 11(1):105–8

Effectiveness of percutaneous transluminal coronary angioplasty for patients with unstable angina. Mahanonda N, et al. **J Med Assoc Thai** 1996 Jul;79(7):454–9

Management of unstable angina: the role of noninvasive risk stratification. Brown KA. **J Nucl Cardiol** 1997 Mar–Apr; 4(2 Pt 2):S164–8 (24 ref.)

The AHCPR unstable angina algorithm in practice [letter; comment] Lloyd F, et al. **JAMA** 1997 Mar 26;277(12):961; discussion 962. Comment on: JAMA 1996 Nov 20;276(19):1568–74.

The AHCPR unstable angina algorithm in practice [letter; comment] Young RA. **JAMA** 1997 Mar 26;277(12):961–2; discussion 962. Comment on: JAMA 1996 Mar 26;277(12):961–2; discussion 962.

Randomised placebo–controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study [see comments] **Lancet** 1997 May 17;349(9063):1429–35. Comment in: Lancet 1997 May 17;349(9063):1409–10.

The CAPTURE trial [letter] Umans VA, et al. **Lancet** 1997 Aug 9;350(9075):445

Comparison of immediate and long-term outcome of coronary angioplasty performed for unstable angina and rest pain in men and women [see comments] Keelan ET, et al. **Mayo Clin Proc** 1997 Jan;72(1):5–12. Comment in: Mayo Clin Proc 1997 Jan;72(1):89–91.

Guidelines for managing patients with unstable angina. Rating the evidence and rationale for treatment. Tonkin AM, et al. **Med J Aust** 1997 Jun 16;166(12):644–7

[Management of unstable angina (editorial)] Broustet JP. **Arch Mal Coeur Vaiss** 1996 Oct;89 Spec No 5:7–10 **(Fre)**

[Unstable angina: new frontiers of research] Maseri A, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89 Spec No 5:33–4 **(Fre)**

[PTCA in unstable angina pectoris] Rupprecht HJ, et al. **Internist (Berl)** 1997 Jan;38(1):3–10 (58 ref.) **(Ger)**

[Interventional coronary revascularization in a patient with chronic dissection of the ascending aorta] von Kodolitsch Y, et al. **Z Kardiol** 1996 Sep;85(9):673–6 (Eng. Abstr.) **(Ger)**

[Coronary angioplasty in unstable angina at rest. Influence of the degree of clinical instability on the immediate and long-term results] Cavallini C, et al. **G Ital Cardiol** 1996 Jun;26(6):647–55 (Eng. Abstr.) **(Ita)**

[The importance of serum lipid level for restenosis following initial successful percutaneous transluminal coronary angioplasty in patients with unstable angina] Kishi K, et al. **J Cardiol** 1996 Aug;28(2):79–84 (Eng. Abstr.) **(Jpn)**

[Emergency coronary artery bypass in an 84-year-old patient with severe left main disease and cardiogenic shock] Tomioka H, et al. **Kyobu Geka** 1996 Sep;49(10):863–7 (Eng. Abstr.) **(Jpn)**

[Angina pectoris: progress in diagnosis and treatment. III. Progress in treatment. 3. Selection of treatment of unstable angina pectoris] Nonogi H. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):254–8 (6 ref.) **(Jpn)**

[Hemostasis and pathogenetic therapy of unstable angina pectoris] Krashutskii VV, et al. **Klin Med (Mosk)** 1996; 74(7):18–21 (Eng. Abstr.) **(Rus)**

[X-ray endovascular dilatation of coronary arteries in patients with unstable angina pectoris] Ianus VM, et al. **Vestn Rentgenol Radiol** 1997 Mar–Apr;(2):31–5 (Eng. Abstr.) **(Rus)**

[Percutaneous revascularization with coronary angioplasty in patients with refractory angina] Valdesuso Aguilar RM, et al. **Rev Esp Cardiol** 1996 Nov;49(11):826–33 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Documentation by intravascular ultrasound of thrombus overlying a small atheromatous plaque in a coronary artery in unstable angina pectoris and in acute myocardial infarction. Birnbaum Y, et al. **Am J Cardiol** 1997 Jun 1; 79(11):1568–70

Differences in the morphology of unstable and stable coronary lesions and their impact on the mechanisms of angioplasty. An in vivo study with intravascular ultrasound. Kearney P, et al. **Eur Heart J** 1996 May; 17(5):721–30

New insight into plaque healing after plaque rupture with subsequent thrombus formation detected by intravascular ultrasound. Jeremias A, et al. **Heart** 1997 Mar;77(3):293

ANGIOCARDIOGRAPHY

Iodixanol and the heart. Harnish P, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S437–9

On-line evaluation of systolic performance by densitometry in digital left ventriculography. Lehmkuhl H, et al. **Clin Cardiol** 1996 Sep;19(9):729–36

Is quantitative angiography sufficient to guide stent implantation? A comparison with three-dimensional reconstruction of intracoronary ultrasound images. Prati F, et al. **G Ital Cardiol** 1997 Apr;27(4):328–36

Determination of ventricular ejection fraction: a comparison of available imaging methods. The Cardiovascular Imaging Working Group. Rumberger JA, et al. **Mayo Clin Proc** 1997 Sep;72(9):860–70 (54 ref.)

[Standards concerning cardiac catheterization and angiocardiography in adults. Subcommittee for Catheterization and Angiography. Committee on Standards of the Canadian Society of Cardiology] Miller RM, et al. **Can J Cardiol** 1996 Aug;12(8):719–21 **(Fre)**

[Activation of blood coagulation and fibrinolysis after angiocardiography with ionic and non-ionic contrast media] Winkler UH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jun;166(6):539–43 (Eng. Abstr.) **(Ger)**

[Clinical evaluation of the use of ultravist in patients with coronary artery disease and in children during angiocardiography] Lapshina NV, et al. **Vestn Rentgenol Radiol** 1996 Sep–Oct;(5):51–3 **(Rus)**

[Angiographic correlation of ST segment depression in exercise test in precardial electrocardiography leads after inferior wall acute myocardial infarction] González Vilchez F, et al. **Rev Esp Cardiol** 1997 May;50(5):331–6 (Eng. Abstr.) **(Spa)**

HISTORY

[Opacification of the hepatic circulation (1947–1948). A Mexican priority] Quijano-Pitman F. **Gac Med Mex** 1997 Jan–Feb;133(1):43 **(Spa)**

INSTRUMENTATION

[Individual archiving of digital angiocardiograms] Stiel GM, et al. **Z Kardiol** 1996 Aug;85(8):553–60 (Eng. Abstr.) **(Ger)**

METHODS

The role of radionuclide angiocardiography in the treatment of patients receiving doxorubicin–based chemotherapy: a reassessment. Dreicer R, et al. **Am J Clin Oncol** 1997 Apr; 20(2):132–7

A general technique for automatic left ventricle boundary validation: relation between gray scale cardioangiograms and observed boundary errors. Suri JS, et al. **J Digit Imaging** 1997 Aug;10(3 Suppl 1):212–7

Assessment of left ventricular regional function by radionuclide angiography: effects of number of sectors on repeatability. Ciarmiello A, et al. **Nucl Med Biol** 1994 Aug; 21(6):883–7

[Anesthesia for angiocardiography. A review of cases] Ferreira FC, et al. **Rev Bras Anestesiol** 1968 Oct–Dec; 18(4):472–7 (Eng. Abstr.) **(Por)**

ANGIODYSPLASIA

Colonic angiodysplasia. Foutch PG. **Gastroenterologist** 1997 Jun;5(2):148–56 (82 ref.)

Gastrointestinal angiodysplasia. Dodda G, et al. **J Assoc Acad Minor Phys** 1997;8(1):16–9 (38 ref.)

COMPLICATIONS

Upper gastrointestinal bleeding in patients with chronic renal failure: role of vascular ectasia. Chalasani N, et al. **Am J Gastroenterol** 1996 Nov;91(11):2329–32

Sengstaken tube for bleeding rectal angiodysplasia [see comments] [published erratum appears in Br J Surg 1996 Oct;83(10):1477] Roy MK, et al. **Br J Surg** 1996 Aug; 83(8):1111. Comment in: Br J Surg 1996 Dec;83(12):1795.

Push enteroscopy and heater probe therapy for small bowel bleeding. Morris AJ, et al. **Gastrointest Endosc** 1996 Oct; 44(4):394–7

Gastrointestinal angiodysplasia in constitutional thrombocytopathies [letter; comment] Bellucci S, et al. **Int J Hematol** 1997 Jun;65(4):419–20. Comment on: Int J Hematol 1996 Dec;65(1):79–84.

Gastrointestinal angiodysplasia in congenital platelet dysfunction [see comments] Okamura T, et al. **Int J Hematol** 1996 Dec;65(1):79–84. Comment in: Int J Hematol 1997 Jun;65(4):419–20.

Somatostatin in the treatment of gastrointestinal bleeding caused by angiodysplasia. Andersen MR, et al. **Scand J Gastroenterol** 1996 Oct;31(10):1037–9

[Heyde syndrome] Larsen NH. **Ugeskr Laeger** 1997 Jul 21; 159(30):4628–30 (29 ref.) (Eng. Abstr.) **(Dan)**

ANGIODYSPLASIA

[Association of acquired Willebrand's disease, monoclonal gammopathy and angiodysplasia of the small bowel: a rare indication of high-dose intravenous immunoglobulins] Sailler L, et al. **Rev Med Interne** 1996;17(11):929-32 (Eng. Abstr.) **(Fre)**

[Veno-lymphatic angiodysplasia as the cause of recurrent inguinal varicose veins] Kohler A, et al. **Vasa** 1997; 26(1):52-4 (Eng. Abstr.) **(Ger)**

[Angiodysplasia as source of hemorrhage] Vajda K, et al. **Orv Hetil** 1997 Feb 9;138(6):355-7 (Eng. Abstr.) **(Hun)**

[Difficult digestive hemorrhage: angiodysplasia] Cristin A, et al. **Minerva Med** 1996 Oct;87(10):465-70 (Eng. Abstr.) **(Ita)**

[Diffuse gastrointestinal angiodysplasia associated with cryptogenic hepatic cirrhosis and coagulopathy simulating von Willebrand disease] Sebastián JJ, et al. **Rev Esp Enferm Dig** 1996 Sep;88(9):631-3 (Eng. Abstr.) **(Spa)**

CONGENITAL see ARTERIOVENOUS MALFORMATIONS

DIAGNOSIS

Enteroscopy in patients with gastrointestinal bleeding of obscure origin. Adrain AL, et al. **Dig Dis** 1996 Nov-Dec; 14(6):345-55 (27 ref.)

Diagnostic efficacy of push-enteroscopy and long-term follow-up of patients with small bowel angiodysplasias. Schmit A, et al. **Dig Dis Sci** 1996 Dec;41(12):2348-52

Watermelon stomach [letter; comment] van Blankenstein M. **Endoscopy** 1996 Mar;28(3):328. Comment on: Endoscopy 1995 Feb;27(2):203-6.

Rectal Dieulafoy's or angiodysplasia? [letter] Kalman DR, et al. **Gastrointest Endosc** 1997 Jul;46(1):91-2

Enhanced imaging of angiodysplasias using remote endoscopic digital spectroscopy. Krevsky B, et al. **Gastrointest Endosc** 1996 Nov;44(5):598-602

Detection and treatment of angiodysplasia. Krevsky B. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):509-24 (53 ref.)

Jejunal angiodysplasia confirmed by intravascular injection technique in vitro. Report of a case and review of the literature. Koga H, et al. **J Clin Gastroenterol** 1996 Sep; 23(2):139-44 (71 ref.)

ETIOLOGY

Angiodysplasia of the gastrointestinal tract. Williams CN. **Can J Gastroenterol** 1997 Mar;11(2):123

HISTORY

[An epicritical review on the pathology of angiodysplasias (editorial)] Giampalmo A. **Pathologica** 1996 Oct; 88(5):335-58 **(Ita)**

IMMUNOLOGY

Acquired von Willebrand disease in a patient with angiodysplasia resulting from immune-mediated clearance of von Willebrand factor. Inbal A, et al. **Br J Haematol** 1997 Jan;96(1):179-82

PATHOLOGY

Late stage congestive gastropathy. Leone O, et al. **J Clin Pathol** 1997 Apr;50(4):350-2

Gastric antral vascular ectasia in a patient on hemodialysis improved with CAPD [see comments] Yorioka N, et al. **Perit Dial Int** 1996 Mar-Apr;16(2):177-8. Comment in: Perit Dial Int 1996 Sep-Oct;16(5):536.

PHYSIOPATHOLOGY

Angiodysplasia, haemostasis and capillaries. A hypothesis [letter] O'Brien JR. **Thromb Res** 1996 Dec 1;84(5):385-7

RADIOGRAPHY

Jejunal angiodysplasia confirmed by intravascular injection technique in vitro. Report of a case and review of the literature. Koga H, et al. **J Clin Gastroenterol** 1996 Sep; 23(2):139-44 (71 ref.)

[Angiographic image of intestinal angiodysplasia of the duodenum in comparison with endoscopy--case report] Meindl S, et al. **Aktuelle Radiol** 1996 Jul;6(4):197-8 (Eng. Abstr.) **(Ger)**

[Preoperative angiographic marking of angiodysplasia of the small intestine with platinum coils] Pinocy J, et al. **Chirurg** 1996 Feb;67(2):195-8 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

[Recurrent rectorrhagia caused by angiodysplasia of the colon localized exclusively by scintigraphy with Tc-99m red blood cells] Martínez MN, et al. **Gastroenterol Hepatol** 1997 Mar;20(3):138-40 (Eng. Abstr.) **(Spa)**

[Ulcerative colitis and colonic angiodysplasia associated with a lower digestive hemorrhage. Their diagnosis by 99-technetium-labelled red blood cells] Martínez-Caballero A, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):51-4 (16 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Pulmonary angiodysplasia: a case report. Rizzo S, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):531-5

An endoscopic treatment for gastric angiodysplasia, using an endoscopic ligating device designed to treat esophageal varices. Baniukiewicz A, et al. **Endoscopy** 1996 Nov; 28(9):787

Enteroscopy and cautery for small intestinal angiodysplasia [letter; comment] Van Gossum A, et al. **Gastrointest Endosc** 1997 Feb;45(2):216-7. Comment on: Gastrointest Endosc 1996 Jun;43(6):580-3.

[Treatment of watermelon stomach (GAVE syndrome) with endoscopic argon plasma coagulation (APC). A new therapy approach] Focke G, et al. **Leber Magen Darm** 1996 Sep;26(5):254, 257-9 (Eng. Abstr.) **(Ger)**

THERAPY

Sengstaken tube for bleeding rectal angiodysplasia [letter; comment] Basso L, et al. **Br J Surg** 1996 Dec;83(12):1795 . Comment on: Br J Surg 1996 Aug;83(8):1111.

Push enteroscopic cauterization: long-term follow-up of 83 patients with bleeding small intestinal angiodysplasia [see comments] Askin MP, et al. **Gastrointest Endosc** 1996 Jun; 43(6):580-3. Comment in: Gastrointest Endosc 1997 Feb;45(2):216-7.

Detection and treatment of angiodysplasia. Krevsky B. **Gastrointest Endosc Clin N Am** 1997 Jul;7(3):509-24 (53 ref.)

ANGIOEDEMA see **ANGIONEUROTIC EDEMA**

ANGIOFIBROMA

Fibropapule multiplex of the nose: a variant of Cowden's disease? Yamamoto T, et al. **Dermatology** 1996; 192(4):379-81

BLOOD SUPPLY

Hypervascular tumor of the buccal space in an adult as a late recurrence of juvenile angiofibroma. Berger SB, et al. **AJNR Am J Neuroradiol** 1996 Aug;17(7):1384-7

COMPLICATIONS

A case of tuberous sclerosis with a giant angiofibroma. Wataya-Kaneda M, et al. **J Dermatol** 1997 Feb;24(2):132-4

DIAGNOSIS

Hypervascular tumor of the buccal space in an adult as a late recurrence of juvenile angiofibroma. Berger SB, et al. **AJNR Am J Neuroradiol** 1996 Aug;17(7):1384-7

Angiofibroma confined to the pterygoid muscle region: CT and MR demonstration. Seo CS, et al. **AJNR Am J Neuroradiol** 1996 Feb;17(2):374-6

Extranasopharyngeal angiofibroma of the inferior turbinate. Gaffney R, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jun 20;40(2-3):177-80

Extranasopharyngeal angiofibroma. Alvi A, et al. **J Otolaryngol** 1996 Oct;25(5):346-8

PATHOLOGY

Cellular angiofibroma: a benign neoplasm distinct from angiomyofibroblastoma and spindle cell lipoma. Nucci MR, et al. **Am J Surg Pathol** 1997 Jun;21(6):636-44

Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Darling TN, et al. **Arch Dermatol** 1997 Jul;133(7):853-7

Angiomyofibroblastoma of the spermatic cord. Siddiqui MT, et al. **Br J Urol** 1997 Mar;79(3):475-6

Immunohistochemical and electron microscopical characterization of stromal cells in nasopharyngeal angiofibromas. Beham A, et al. **Eur Arch Otorhinolaryngol** 1997;254(4):196-9

Angiofibroma-like nasosinus mass lesion [letter] Ertefai P, et al. **Eur Arch Otorhinolaryngol** 1997;254(3):163-4

Giant cell angiofibroma of the orbit. Ganesan R, et al. **Histopathology** 1997 Jan;30(1):93-6

Angiomyofibroblastoma of the female genital tract: analysis of 17 cases including a lipomatous variant. Laskin WB, et al. **Hum Pathol** 1997 Sep;28(9):1046-55

Cellular composition of the angiofibromas in tuberous sclerosis. Benjamin DR. **Pediatr Pathol Lab Med** 1996 Nov-Dec;16(6):893-9

[Juvenile angiofibroma as a diagnostic and therapeutic problem (from the materials of the ENT clinic in Warsaw in 1980-1990)] Balcerzak J. **Otolaryngol Pol** 1995; 49(6):560-5 (Eng. Abstr.) **(Pol)**

SURGERY

Endoscopic surgery for nasal and sinusal vascular tumours: about two cases of nasopharyngeal angiofibromas and one case of turbinate angioma. Zicot AF, et al. **Acta Otorhinolaryngol Belg** 1996;50(3):177-82

Transnasal endoscopic approach for juvenile nasopharyngeal angiofibroma. Tseng HZ, et al. **Am J Otolaryngol** 1997 Mar-Apr;18(2):151-4

Transfacial surgical access in the treatment of angiofibroma [letter; comment] Mellor TK, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jan;123(1):115-6 . Comment on: Arch Otolaryngol Head Neck Surg 1996 Feb;122(2):122-9.

Intracranial juvenile nasopharyngeal angiofibroma. Gupta AC, et al. **Aust N Z J Surg** 1997 Jul;67(7):477-82

Staging and treatment of nasopharyngeal angiofibroma. Ochoa-Carrillo FJ, et al. **Eur Arch Otorhinolaryngol** 1997; 254(4):200-4

Nasopharyngeal angiofibromas: selecting a surgical approach. Fagan JJ, et al. **Head Neck** 1997 Aug;19(5):391-9

Transnasal endoscopic surgery in juvenile nasopharyngeal angiofibroma. Kamel RH. **J Laryngol Otol** 1996 Oct; 110(10):962-8

Anterior transcranial (craniofacial) resection of tumors of the paranasal sinuses: surgical technique and results [letter; comment] Goel A. **Neurosurgery** 1997 Jan;40(1):218-9; discussion 219-20. Comment on: Neurosurgery 1996 Mar;38(3):471-9; discussion 479-80.

Midfacial degloving for the management of nasal, sinus, and skull-base neoplasms. Maniglia AJ, et al. **Otolaryngol Clin North Am** 1995 Dec;28(6):1127-43

Treatment of the facial angiofibromas of tuberous sclerosis. Verheyden CN. **Plast Reconstr Surg** 1996 Oct;98(5):777-83

THERAPY

Preoperative embolization of paragangliomas and angiofibromas. Measurement of intratumoral arteriovenous shunts. Schroth G, et al. **Arch Otolaryngol Head Neck Surg** 1996 Dec;122(12):1320-5

Juvenile nasopharyngeal angiofibroma: an update of therapeutic management. Ungkanont K, et al. **Head Neck** 1996 Jan-Feb;18(1):60-6

Creutzfeldt-Jakob disease after extracranial dura mater embolization for a nasopharyngeal angiofibroma. Antoine JC, et al. **Neurology** 1997 May;48(5):1451-3

ANGIOFOLLICULAR LYMPHOID HYPERPLASIA see **GIANT LYMPH NODE HYPERPLASIA**

ANGIOGENESIS FACTOR

[Molecular mechanism in cell migration] Claesson-Welsh L. **Nord Med** 1997 Jun;112(6):212-5 (Eng. Abstr.) **(Swe)**

ADMINISTRATION & DOSAGE

Chronic oral dipyridamole as a 'novel' antianginal drug: the collateral hypothesis. Picano E, et al. **Cardiovasc Res** 1997 Mar;33(3):666-70

ANALYSIS

Angiogenin: a marker for preterm delivery in midtrimester amniotic fluid. Spong CY, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):415-8

Detection, quantitation, and localization of bovine angiogenin by immunological assays. Chang SI, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):323-7

[Determination of angiogenin in cow's milk based on a competitive test "pancreatic RNAase/placental inhibitor of RNAase--angiogenin"] Rogov IA, et al. **Vopr Pitan** 1997; (2):35-7 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Development of antiangiogenin peptide using a phage-displayed peptide library. Gho YS, et al. **Cancer Res** 1997 Sep 1;57(17):3733-40

Description of an in vitro angiogenesis model designed to test antiangiogenic molecules. Vailhé B, et al. **Cell Biol Toxicol** 1996 Dec;12(4-6):341-4

Antiangiogenesis for cancer therapy. Harris AL. **Lancet** 1997 May;349 Suppl 2:SII13-5 (19 ref.)

Inhibition of motility and invasion of human lung cancer cells by invasion inhibiting factor 2. Han ZG, et al. **Surg Oncol** 1996 Apr;5(2):77-84

BIOSYNTHESIS

Juvenile hemangioma of the testis: analysis of expression of angiogenic factors. Uchida K, et al. **Urology** 1997 Feb; 49(2):285-6

BLOOD

Angiogenin plasma levels during pregnancy. Kolben M, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):37-41

GENETICS

Expression of angiogenic factors and structural proteins in central nervous system vascular malformations. Rothbart D, et al. **Neurosurgery** 1996 May;38(5):915-24; discussion 924-5

[Expression of synthetic gene for human angiogenin in E. coli cells] Nikonova AA, et al. **Bioorg Khim** 1996 Dec; 22(12):891-3 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

An angiogenic protein from bovine serum and milk--purification and primary structure of angiogenin-2. Strydom DJ, et al. **Eur J Biochem** 1997 Jul 15;247(2):535-44

[Purification of angiogenin from cow's milk] Rogov IA, et al. **Prikl Biokhim Mikrobiol** 1997 Jan-Feb;33(1):107-10 (Eng. Abstr.) **(Rus)**

METABOLISM

Pathogenetic implication of interleukin-2 expressed in preeclamptic decidual tissues: a possible mechanism of deranged vasculature of the placenta associated with preeclampsia. Hamai Y, et al. **Am J Reprod Immunol** 1997 Aug;38(2):83–8

Interaction of heparin with human angiogenin. Soncin F, et al. **J Biol Chem** 1997 Apr 11;272(15):9818–24

Angiogenin levels in the vitreous from patients with proliferative diabetic retinopathy. Ozaki H, et al. **Ophthalmic Res** 1996;28(6):356–60

PHARMACOLOGY

Description of an in vitro angiogenesis model designed to test antiangiogenic molecules. Vailhé B, et al. **Cell Biol Toxicol** 1996 Dec;12(4–6):341–4

Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Ziche M, et al. **Lab Invest** 1997 Apr; 76(4):517–31

[Reaction to antigenic information after treatment with elevated doses of angiogenin] Eliseeva LS, et al. **Biull Eksp Biol Med** 1997 Apr;123(4):427–30 **(Rus)**

PHYSIOLOGY

The role of angiogenic growth factors in breast cancer progression. Kern FG, et al. **Cancer Metastasis Rev** 1996 Jun;15(2):213–9 (38 ref.)

What, if anything, is an angiogenic factor? Risau W. **Cancer Metastasis Rev** 1996 Jun;15(2):149–51 (25 ref.)

Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. Blair RJ, et al. **J Clin Invest** 1997 Jun 1;99(11):2691–700

Vascular endothelial growth factor, a multifunctional polypeptide. Stephan CC, et al. **P R Health Sci J** 1996 Sep;15(3):169–78 (111 ref.)

THERAPEUTIC USE

[Local treatment of chronic arterial ulcera cruris with thrombocytogenic growth factors--a pilot project] Debus ES, et al. **Zentralbl Chir** 1996;121 Suppl:73–4 **(Ger)**

ANGIOGENESIS, PATHOLOGIC see **NEOVASCULARIZATION, PATHOLOGIC**

ANGIOGENESIS, PHYSIOLOGIC see **NEOVASCULARIZATION, PHYSIOLOGIC**

ANGIOGRANULOMA see **GRANULOMA, PYOGENIC**

ANGIOGRAPHY

Methodological assessment of combined spiral CT angiography and CT arterial portography. Kanematsu M, et al. **Abdom Imaging** 1997 Jul–Aug;22(4):404–9

Evaluation of a low-density gastrointestinal contrast agent: effect on computed tomography angiography. Alexander D, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S432–4

Renal effects of iodixanol in patients: a comparison with other radiographic contrast media. Andrew E, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S440–3

Measurement of a cross-sectional area of normal and stenotic arteries with videodensitometric quantitative arteriography and intravascular ultrasound. Molloi S, et al. **Acad Radiol** 1997 Apr;4(4):245–52

Osmolality of contrast media affects opacification during renal arteriography. Morris TW, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S251–3

Iodixanol and ioxaglate in adult aortography and peripheral arteriography: a phase III clinical trial. Rosenblum JD, et al. **Acad Radiol** 1996 Sep;3 Suppl 3:S514–8

Comparison of iodixanol and ioxaglate for adult aortography and renal/visceral angiography: a phase III clinical trial. Siegel EL, et al. **Acad Radiol** 1996 Sep;3 Suppl 3:S507–13

Predictable and unpredictable adverse reactions to uroangiographic contrast media. Spinazzi A, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S210–3

Cervical myelopathy associated with intracranial dural arteriovenous fistula: MR findings before and after treatment. Ernst RJ, et al. **AJNR Am J Neuroradiol** 1997 Aug;18(7):1330–4

Preoperative evaluation of pulmonary sequestration by helical CT angiography [letter] Amitai M, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):1069–70

Antibiotic prophylaxis in vascular and interventional radiology. McDermott VG, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):31–8 (66 ref.)

Anatomy and clinical importance of cholecystic venous drainage: helical CT observations during injection of contrast medium into the cholecystic artery. Yoshimitsu K, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):505–10

Advances in Ultrafast Computed Tomography: 1996. An International Symposium on Electron Beam Tomography. Lake Buena Vista, Florida, October 4–6, 1996. Abstracts. **Am J Card Imaging** 1996 Apr;10(2 Suppl 1):1–13

Reduced radiation during cardiac catheterization of infants using acquisition zoom technology. Ross RD, et al. **Am J Cardiol** 1997 Mar 1;79(5):691–3

Toxoplasmic retinochoroiditis: new insights provided by indocyanine green angiography. Auer C, et al. **Am J Ophthalmol** 1997 Jan;123(1):131–3

Completion angiography, is it really necessary? Ricotta JJ, et al. **Am J Surg** 1997 Aug;174(2):181–4

Selective use of preoperative lower extremity arteriography in free flap reconstruction. Dublin BA, et al. **Ann Plast Surg** 1997 Apr;38(4):404–7

Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Olieman AF, et al. **Ann Surg Oncol** 1997 Jan;4(1):64–9

Indocyanine green angiography in Vogt-Koyanagi-Harada-type disease [letter] Pece A, et al. **Arch Ophthalmol** 1997 Jun;115(6):804–6

Cost-effective evaluation and treatment for carotid disease. Ballard JL, et al. **Arch Surg** 1997 Mar;132(3):268–71

Bolus dynamics: theoretical and experimental aspects. Blomley MJ, et al. **Br J Radiol** 1997 Apr;70:351–9

JSAIR '96. The 6th International Symposium on Interventional Radiology and New Vascular Imaging and the 25th annual meeting of the Japanese Society of Angiography and Interventional Radiology. Aomori, Japan, April 23–26, 1996. Abstracts. **Cardiovasc Intervent Radiol** 1996;19 Suppl 1:S1–138

Traumatic first rib fracture: is angiography necessary? A review of 730 cases. Gupta A, et al. **Cardiovasc Surg** 1997 Feb;5(1):48–53 (21 ref.)

The Society of Cardiac Angiography and Interventions 20th annual meeting. Scottsdale, Arizona, May 13–17, 1997. Abstracts. **Cathet Cardiovasc Diagn** 1997 May;41(1):98–115

Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Miller BD, et al. **Circulation** 1996 Nov 1;94(9):2146–53

Primary mediastinal leiomyoma: an angiographic study and embolisation of the feeding vessels to improve the surgical approach. Baldó X, et al. **Eur J Cardiothorac Surg** 1997 Mar;11(3):574–6

Indocyanine green angiography (ICGA) in pathological myopia. Brancato R, et al. **Eur J Ophthalmol** 1996 Jan–Mar; 6(1):39–43

Value of duplex scanning in evaluation of crural and foot arteries in limbs with severe lower limb ischaemia--a prospective comparison with angiography. Karacagil S, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):300–3

Non-invasive assessment of arterial stenoses in angioplasty surveillance: a comparison with angiography. Nyamekye I, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):471–81

Role of angiography in carcinoma of the pancreas as a preoperative assessment. Mori M, et al. **Hepatogastroenterology** 1995 Sep–Oct;42(5):752–63

Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease. Woodburn KR, et al. **Int Angiol** 1995 Sep;14(3):219–25

Conventional and CT angiographic diagnosis of Takayasu arteritis. Park JH. **Int J Cardiol** 1997 Aug;54 Suppl:S165–71 (11 ref.)

Angiographic findings in Buerger disease. Suzuki S, et al. **Int J Cardiol** 1997 Aug;54 Suppl:S189–95

Management of angiogram positive lower gastrointestinal hemorrhage: long term follow-up of non-operative treatments. Pennoyer WP, et al. **Int J Colorectal Dis** 1996; 11(6):279–82

Comparison of centralized versus "site-based" measurement of angiographic stenosis for eligibility in the asymptomatic carotid atherosclerosis study. Dean BL, et al. **Invest Radiol** 1996 Jul;31(7):446–50

Angiographic detection of gastrointestinal bleeding. An experimental comparison of conventional screen-film angiography and digital subtraction angiography. Krüger K, et al. **Invest Radiol** 1996 Jul;31(7):451–7

Radiological case of the month. Matchett WJ, et al. **J Ark Med Soc** 1996 Mar;92(10):517–8

Left ventricular aneurysm: angiographic determinants. Jagtap PM, et al. **J Assoc Physicians India** 1995 May;43(5):331–3

Pseudoaneurysm of the gastrointestinal artery. Maes RM, et al. **J Belge Radiol** 1996 Dec;79(6):273

Surgical and arteriographic results of bronchial artery revascularization in lung and heart lung transplantation. Nørgaard MA, et al. **J Heart Lung Transplant** 1997 Mar; 16(3):302–12

Invasive evaluation of mitral regurgitation: the importance of hemodynamic measurements during exercise. Holm S, et al. **J Heart Valve Dis** 1997 Jul;6(4):383–6

Presurgical angiographic localization of small bowel bleeding site with methylene blue injection. Schrodt JF, et al. **J Ky Med Assoc** 1996 May;94(5):192–5

The limited value of preoperative angiography in microsurgical reconstruction of the lower limb. Isenberg JS, et al. **J Reconstr Microsurg** 1996 Jul;12(5):303–5; discussion 306

Pedal arterial imaging. Alson MD, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):9–18 (56 ref.)

Use of a collagen hemostatic closure device to achieve hemostasis after arterial puncture: a cost-effectiveness analysis [see comments] Bos JJ, et al. **J Vasc Interv Radiol** 1996 Jul–Aug;7(4):479–86. Comment in: J Vasc Interv Radiol 1997 Mar–Apr;8(2):299–300.

Development of a model angiography informed consent form based on a multiinstitutional survey of current forms. Briguglio J, et al. **J Vasc Interv Radiol** 1995 Nov–Dec; 6(6):971–8

Natural history of arterial injuries diagnosed with arteriography. Hoffer EK, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):43–53

Creation of a modified angiography (endovascular) suite for transluminal endograft placement and combined interventional-surgical procedures. Katzen BT, et al. **J Vasc Interv Radiol** 1996 Mar–Apr;7(2):161–7

Effects of vascular stent surface area and hemodynamics on intimal thickening [see comments] Newman VS, et al. **J Vasc Interv Radiol** 1996 May–Jun;7(3):387–93. Comment in: J Vasc Interv Radiol 1996 Nov–Dec;7(6):948–9.

Imaging of carotid artery disease. Conventional angiography. Dean BL, et al. **Neuroimaging Clin N Am** 1996 Nov; 6(4):843–51 (34 ref.)

Can noninvasive studies replace conventional angiography in the preoperative evaluation of carotid stenosis? De Marco JK, et al. **Neuroimaging Clin N Am** 1996 Nov; 6(4):911–29 (57 ref.)

The role of angiography in the assessment of atherosclerotic disease. Assessment of the carotid bifurcation. Fox AJ. **Neuroimaging Clin N Am** 1996 Aug;6(3):645–9 (16 ref.)

Angiography in the evaluation of head and neck trauma. Gaskill-Shipley MF, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):607–24 (69 ref.)

The role of angiography in the evaluation of vascular and neoplastic disease in the external carotid artery circulation. Hu WY, et al. **Neuroimaging Clin N Am** 1996 Aug; 6(3):625–44 (37 ref.)

Computed tomography angiography. Marks MP. **Neuroimaging Clin N Am** 1996 Nov;6(4):899–909 (22 ref.)

Vertebrospinal angiography in the evaluation of vertebral and spinal cord disease. Nelson PK, et al. **Neuroimaging Clin N Am** 1996 Aug;6(3):589–605 (61 ref.)

Intramedullary angiographically occult vascular malformations of the spinal cord. Furuya K, et al. **Neurosurgery** 1996 Dec;39(6):1123–30; discussion 1131–2

Angiographic determination of ventricular morphology: correlation with pathology in 36 hearts with single functional ventricles. Julsrud PR, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):208–12

Three-dimensional reconstruction of cutaneous arteries of the back by computer graphic imaging. Nakajima H, et al. **Plast Reconstr Surg** 1997 Aug;100(2):381–9

Renal cortical retention of contrast medium after angiography as assessed by delayed CT: a multivariate analysis. Yamazaki H, et al. **Radiat Med** 1996 Sep–Oct; 14(5):247–50

Exploratory and interventional angiography in severe trauma: present and future procedure of choice. Ben-Menachem Y. **Radiographics** 1996 Jul;16(4):963–70

Popliteal vascular disease: evaluation with spiral CT angiography. Beregi JP, et al. **Radiology** 1997 May; 203(2):477–83

Blood flow and liver imaging. Itai Y, et al. **Radiology** 1997 Feb;202(2):306–14 (80 ref.)

Papillary endolymphatic sac tumors: CT, MR imaging, and angiographic findings in 20 patients. Mukherji SK, et al. **Radiology** 1997 Mar;202(3):801–8

Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Spaide RF, et al. **Retina** 1996;16(3):203–13

Clinics in diagnostic imaging (9). Gestational trophoblastic disease with liver metastases. Helpert C, et al. **Singapore Med J** 1996 Feb;37(1):103–6

Comparison of preoperative selective spinal angiography and somatosensory-evoked potential monitoring with temporary occlusion of segmental vessels during anterior spinal surgery. Bassett G, et al. **Spine** 1996 Sep 1; 21(17):1996–9; discussion 2000

[Angiographic identification of spinal cord arteries before bronchial artery embolization] Mesurolle B, et al. **J Radiol** 1997 May;78(5):377–80 (Eng. Abstr.) **(Fre)**

[Evaluation of carboxy-angiography in the study of arteriopathy of the lower limbs] Rolland Y, et al. **J Radiol** 1997 Jan;78(1):41–7 (Eng. Abstr.) **(Fre)**

[Role of super selective arteriography with embolization in the treatment of severe epistaxis: our experience apropos of 16 cases] Mérol JC, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(5):363–6 (26 ref.) (Eng. Abstr.) **(Fre)**

[Angiographic image of intestinal angiodysplasia of the duodenum in comparison with endoscopy--case report] Meindl S, et al. **Aktuelle Radiol** 1996 Jul;6(4):197–8 (Eng. Abstr.) **(Ger)**

[Local fibrinolytic therapy of arterial occlusions of the lower extremity: initial success and clinical outcome] Müller-Lung U, et al. **Aktuelle Radiol** 1996 Nov;6(6):325–9 (Eng. Abstr.) **(Ger)**

[Semiquantitative detection of pain and heat sensations in evaluation of contrast media in pelvic/leg angiography. Intraindividual double-blind study with iomeprol 350 and iopentol 350] Mathias K, et al. **Radiologe** 1996 Feb; 36(2):164–8 (Eng. Abstr.) **(Ger)**

[CT angiography in peripheral bypass "aneurysmosis": a case report] Rodenwaldt J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Oct;165(4):409–11 **(Ger)**

[Conventional pelvis-leg arteriography with iomeprol 400. Does higher concentration contrast medium have a diagnostic advantage?] Körber HJ, et al. **Rontgenpraxis** 1997 Mar;50(3):67–9 **(Ger)**

[Value of Doppler color ultrasonography in diagnosis of arterial occlusive disease of the lower extremity. A direct

comparison with percutaneous angiography] Hendrickx P, et al. **Ultraschall Med** 1997 Jun;18(3):116–23 (Eng. Abstr.) **(Ger)**

[Significance of arterial anastomoses of the distal calf and proximal foot for compensation of peripheral arterial occlusive disease] Schwarzenbach BP, et al. **Vasa** 1996; 25(4):331–6 (Eng. Abstr.) **(Ger)**

[Radiology and geriatrics: limits between normal values and pathology exemplified by conventional thoracic roentgen image, cerebral CT and MRI and pelvic-leg angiography] Osterheider MA. **Z Gerontol Geriatr** 1997 May–Jun; 30(3):226–34 (17 ref.) (Eng. Abstr.) **(Ger)**

[Transesophageal Doppler echocardiography assessment of mitral valve insufficiency: Comparison of jet area, pulmonary venous flow profile, proximal jet diameter, maximal regurgitation flow rate and regurgitation orifice area with angiography] Frieske R, et al. **Z Kardiol** 1997 May;86(5):346–53 (Eng. Abstr.) **(Ger)**

[Carotid endarterectomy without angiography] Shifrin EG, et al. **Harefuah** 1996 Jul;131(1–2):4–7, 72 (Eng. Abstr.) **(Heb)**

[The role of angiography for the detection of early carcinomas] Isobe Y. **Nippon Rinsho** 1996 May;54(5):1273–5 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Anatomic and radiologic studies of of ovarian arteries in women of various ages] Czerwiński F, et al. **Ginekol Pol** 1996 Jun;67(6):296–300 (Eng. Abstr.) **(Pol)**

[Use of diprivan in anesthesiology of angiographic studies and x-ray endovascular methods of treatment in children] Mikhelson VA, et al. **Anesteziol Reanimatol** 1996 Nov–Dec; (6):14–7 (Eng. Abstr.) **(Rus)**

[Use of ionic and non-ionic contrast media in interventional radiology] Grakov LS, et al. **Vestn Rentgenol Radiol** 1996 Sep–Oct;(5):54–5 **(Rus)**

[Spiral computed tomography in the diagnosis of pathology of the vascular bed] Makarenko VN, et al. **Vestn Rentgenol Radiol** 1996 Sep–Oct;(5):21–5 (Eng. Abstr.) **(Rus)**

[Iodixanol: a new nonionic dimeric contrast medium for angio-cardiography-urography] Sviridov NK. **Vestn Rentgenol Radiol** 1997 Mar–Apr;(2):55–6 **(Rus)**

[Nephrotoxicity of radiographic contrast media] Vavić N, et al. **Srp Arh Celok Lek** 1996;124 Suppl 1:138–9 (Eng. Abstr.) **(Scc)**

ADVERSE EFFECTS

Effect of iomeprol on renal function immediately after abdominal angiography. Murakami R, et al. **Acta Radiol** 1996 Nov;37(6):962–5

Transbrachial arteriography [letter; comment] Raphael MJ. **Clin Radiol** 1996 Oct;51(10):742. Comment on: Clin Radiol 1996 Mar;51(3):205–9.

Brachial plexopathy secondary to anticoagulant-induced hematoma as a complication of axillary arteriography. Shoup DW, et al. **J Am Osteopath Assoc** 1997 Feb; 97(2):102–5 (18 ref.)

Multiple cholesterol embolism: a case report. Macheras A, et al. **J Cardiovasc Surg (Torino)** 1997 Feb;38(1):43–4

Safety of pulmonary angiography in the 1990s. Zuckerman DA, et al. **J Vasc Interv Radiol** 1996 Mar–Apr;7(2):199–205

Livedo reticularis, rhabdomyolysis, massive intestinal infarction, and death after carbon dioxide arteriography. Rundback JH, et al. **J Vasc Surg** 1997 Aug;26(2):337–40 (13 ref.)

Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. Bettmann MA, et al. **Radiology** 1997 Jun;203(3):611–20

Radiodermatitis after transjugular intrahepatic portosystemic shunt. Knautz MA, et al. **South Med J** 1997 Mar; 90(3):352–6

[Convulsions after renal angiography and angioplasty (letter)] Dumas S, et al. **Presse Med** 1997 Jun 21;26(21):1004 **(Fre)**

CONTRAINDICATIONS

What are the accepted guidelines for performing elective angiographic procedures on a hypertensive patient? Payne CS. **AJR Am J Roentgenol** 1997 Mar;168(3):839

INSTRUMENTATION

Detection of pancreatic adenocarcinoma: relative value of arterial and late phases of spiral CT. Choi BI, et al. **Abdom Imaging** 1997 Mar–Apr;22(2):199–203

Helical CT evaluation of arterial invasion in pancreatic tumors: comparison with angiography. Kaneko K, et al. **Abdom Imaging** 1997 Mar–Apr;22(2):204–7

Spiral CT angiography of the abdomen. Prokop M, et al. **Abdom Imaging** 1997 Mar–Apr;22(2):143–53

A new catheter type for superselective angiography and embolization. Hoogewoud HM. **Acta Radiol** 1997 Mar; 38(2):335–7

Fishing for the internal mammary artery: the rod or the net? [editorial; comment] Kaufmann UP, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):203. Comment on: Cathet Cardiovasc Diagn 1996 Oct;39(2):198–202.

Evaluation of colour images printed by a thermal dye diffusion process. Deldinne M, et al. **Eur Radiol** 1996; 6(5):762–4

Severity assessment of acute pulmonary embolism with spiral CT: evaluation of two modified angiographic scores and comparison with clinical data. Bankier AA, et al. **J Thorac Imaging** 1997 Apr;12(2):150–8

Pulmonary angiography: an 8-F double-curve pigtail catheter for universal use. Fisher RG, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6):983–4

Rule of 110. Nemcek A Jr. **J Vasc Interv Radiol** 1996 May–Jun;7(3):379

Small-vessel radiography in situ with monochromatic synchrotron radiation. Mori H, et al. **Radiology** 1996 Oct; 201(1):173–7

[Infarct of the lower renal artery segment: diagnosis with CT-angiography and 3-dimensional spatial representation] Gartenschläger M, et al. **Aktuelle Radiol** 1996 Nov; 6(6):334–7 (Eng. Abstr.) **(Ger)**

[Preoperative angiographic marking of angiodysplasia of the small intestine with platinum coils] Pinocy J, et al. **Chirurg** 1996 Feb;67(2):195–8 (Eng. Abstr.) **(Ger)**

[Invasive or noninvasive angiography? The role of "classical" catheter angiography] Hagen B. **Radiologe** 1997 Jul; 37(7):493–500 (50 ref.) (Eng. Abstr.) **(Ger)**

[Standardization of use of 4-F size catheter for selective transcatheter angiography and intervention of abdomen] Kiyosue H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Jan;56(1):32–6 (Eng. Abstr.) **(Jpn)**

[Trial of a detachable Y-shaped tube with two valves for serial examinations of CT arterial portography and CT hepatic arteriography] Murakami T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Jun;57(7):430–2 (Eng. Abstr.) **(Jpn)**

METHODS

Spiral CT angiography of the abdomen and pelvis: interventional applications. Brink JA. **Abdom Imaging** 1997 Jul–Aug;22(4):365–72 (26 ref.)

Image intensifier-based computed tomography volume scanner for angiography. Ning R, et al. **Acad Radiol** 1996 Apr;3(4):344–50

High-resolution three-dimensional imaging from subsecond helical CT data sets: applications in vascular imaging. Fishman EK. **AJR Am J Roentgenol** 1997 Aug;169(2):441–3

In cases of suspected pulmonary embolism, if the clinical symptoms and scintigraphic findings on lung scan point strongly to unilateral disease, is it always necessary to perform pulmonary angiography bilaterally if the angiogram on the more suspicious side is negative? Kee ST, et al. **AJR Am J Roentgenol** 1996 Nov;167(5):1339

Strategic arteriography: surgical approach and analysis of technique. Schneider PA. **Ann Vasc Surg** 1996 Sep; 10(5):493–505

The role of transradial diagnostic angiography. Cowling MG, et al. **Cardiovasc Intervent Radiol** 1997 Mar–Apr; 20(2):103–6

Use of synchrotron radiation microangiography to assess development of small collateral arteries in a rat model of hindlimb ischemia. Takeshita S, et al. **Circulation** 1997 Feb 18;95(4):805–8

Expanding aneurysm of aberrant right subclavian artery. Case report and imaging evaluation. Hogg JP, et al. **Clin Imaging** 1997 May–Jun;21(3):195–9 (8 ref.)

Magnetic resonance venography versus contrast venography to diagnose thrombosis after joint surgery. Larcom PG, et al. **Clin Orthop** 1996 Oct;(331):209–15

Helical/spiral computed body tomography. Brink JA, et al. **Clin Radiol** 1997 Jul;52(7):489–503 (102 ref.)

Prospective assessment of carotid bifurcation disease with spiral CT angiography in surface shaded display (SSD)-technique. Link J, et al. **Comput Med Imaging Graph** 1995 Nov–Dec;19(6):451–6

Left ventricular volume calculations using a multiplanar transoesophageal echoprobe; in vitro validation and comparison with biplane angiography. Krebs W, et al. **Eur Heart J** 1996 Aug;17(8):1279–88

Nonionic monomers and dimers. Stacul F, et al. **Eur Radiol** 1996;6(5):756–61 (45 ref.)

CT angiography: thoracic vascular imaging with interactive volume rendering technique. Johnson PT, et al. **J Comput Assist Tomogr** 1997 Jan–Feb;21(1):110–4

Preoperative sizing of grafts for transfemoral endovascular aneurysm management: a prospective comparative study of spiral CT angiography, arteriography, and conventional CT imaging. Broeders IA, et al. **J Endovasc Surg** 1997 Aug; 4(3):252–61

Posterior hip dislocations: a cadaveric angiographic study. Yue JJ, et al. **J Orthop Trauma** 1996;10(7):447–54

Peripheral ischemic occlusive arterial disease: comparison of color Doppler sonography and angiography. Pinto F, et al. **J Ultrasound Med** 1996 Oct;15(10):697–704; quiz 705–6

Obtaining arterial access in trauma patients. Sclafani SJ. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):593–4 (0 ref.)

Prospective evaluation of pulmonary artery pressures during pulmonary angiography performed with low-osmolar nonionic contrast media. Smith TP, et al. **J Vasc Interv Radiol** 1996 Mar–Apr;7(2):207–12

Determination of functional portal-systemic shunting in patients submitted to hepatic angiography. Molino G, et al. **Liver** 1996 Dec;16(6):347–52

A real vessel phantom for imaging experimentation. Dabrowski W, et al. **Med Phys** 1997 May;24(5):687–93

X-ray imaging technique for in vitro tissue composition measurements using saline/iodine displacement: technique optimization. Moreau M, et al. **Med Phys** 1997 Jan; 24(1):37–49

X-ray imaging technique for in vitro tissue composition measurements using saline/iodine displacement: experimental verification. Moreau M, et al. **Med Phys** 1997 Mar;24(3):351–60

New simplified radio-opaque injection technique for visualization of rat arteries. Ozek C, et al. **Microsurgery** 1996;17(6):321–3

Spiral CT angiography in an infant with severe hypoplasia of a long segment of the descending aorta. Brochhagen HG, et al. **Pediatr Radiol** 1997 Feb;27(2):181–3

Use of maximum intensity projections in CT angiography: a basic review. Prokop M, et al. **Radiographics** 1997 Mar–Apr;17(2):433–51 (26 ref.)

Small-vessel radiography in situ with monochromatic synchrotron radiation. Mori H, et al. **Radiology** 1996 Oct; 201(1):173–7

Changes in contrast enhancement of hepatocellular carcinoma and liver: effect of temporary occlusion of a hepatic vein evaluated with spiral CT. Murata S, et al. **Radiology** 1997 Mar;202(3):715–20

Renal artery origins: best angiographic projection angles. Verschuyl EJ, et al. **Radiology** 1997 Oct;205(1):115–20

Angiographic localization with methylene blue and radiopaque microcoil [letter] Leow CK, et al. **Surgery** 1997 Apr;121(4):477–8

Three-dimensional ultrasonic angiography using power-mode Doppler. Ritchie CJ, et al. **Ultrasound Med Biol** 1996;22(3):277–86

[Volume rendering technique in 3D vascular imaging] Marcus C, et al. **J Radiol** 1997 Jul;78(7):481–4 (11 ref.) (Eng. Abstr.) **(Fre)**

[CT-supported virtual intra-arterial endoscopy after stent implantation: phantom studies and the initial clinical results] Rodenwaldt J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):180–4 (Eng. Abstr.) **(Ger)**

[Recent changes and trends in angiographic techniques] Hasuo K. **Fukuoka Igaku Zasshi** 1997 Apr;88(4):77–83 (2 ref.) **(Jpn)**

[Clinical usefulness of trans-brachial angiography for abdominal diseases] Mutou H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Oct; 56(12):846–54 (Eng. Abstr.) **(Jpn)**

[Therapeutic angiography] Pisco JM. **Acta Med Port** 1996 Oct–Dec;9(10–12):361–6 (14 ref.) (Eng. Abstr.) **(Por)**

[Potentialities of contrast angiography and endovascular embolization in ent bleeding] Ovchinnikov IM, et al. **Vestn Otorinolaringol** 1997;(2):31–2 **(Rus)**

[Radiation diagnosis of spleen diseases] Vlasov PV, et al. **Vestn Rentgenol Radiol** 1997 May–Jun;(3):27–34 (28 ref.) (Eng. Abstr.) **(Rus)**

[A survey of early arteriosclerosis. New possibilities with angiography and ultrasound] Jogestrand T. **Lakartidningen** 1996 Oct 23;93(43):3783–4, 3787 (10 ref.) **(Swe)**

PSYCHOLOGY

MR and conventional angiography: work in progress toward assessing utility in radiology. Swan JS, et al. **Acad Radiol** 1997 Jul;4(7):475–82

STANDARDS

Comparison of MR angiography with contrast angiography for the diagnosis of carotid artery stenosis. Dadachanji MC, et al. **J Assoc Physicians India** 1995 Feb;43(2):92–5

Assessment of blunt aortic-brachiocephalic trauma: should angiography be supplanted by transesophageal echocardiography? [comment] Ben-Menachem Y. **J Trauma** 1997 May;42(5):969–72 (42 ref.). Comment on: J Trauma 1996 Mar;40(3):422–7. Comment on: J Trauma 1997 May;42(5):960–3.

Guidelines regarding HIV and other bloodborne pathogens in vascular/interventional radiology. SCVIR Technology Assessment Committee. Hansen ME, et al. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):667–76

An approach for the use of Doppler ultrasound as a screening tool for hemodynamically significant stenosis (despite heterogeneity of Doppler performance). A multicenter experience. Asymptomatic Carotid Atherosclerosis Study Investigators. Howard G, et al. **Stroke** 1996 Nov; 27(11):1951–7

STATISTICS & NUMERICAL DATA

Extension of receiver operating characteristic analysis to data concerning multiple signal detection tasks. Hajian-Tilaki KO, et al. **Acad Radiol** 1997 Mar;4(3):222–9

TRENDS

The future of vascular and interventional radiology. Lang EK. **Radiology** 1997 Sep;204(3):63A–65A; discussion 66A

[Recent changes and trends in angiographic techniques] Hasuo K. **Fukuoka Igaku Zasshi** 1997 Apr;88(4):77–83 (2 ref.) **(Jpn)**

VETERINARY

Histomorphometric and angiographic analysis of the humerus in pigeons. West PG, et al. **Am J Vet Res** 1996 Jul; 57(7):982–6

Ultrasonography and angiographic examination of normal canine liver vessels. Mwanza T, et al. **Jpn J Vet Res** 1996

Dec;44(3):179–88

Arteriography after ligation of the brachial and femoral artery in the dog. Butković V, et al. **Vet Med (Praha)** 1996 Oct;41(10):319–22

The arterial shift features in the equine proximal sesamoid bone. Cornelissen BP, et al. **Vet Q** 1996;18 Suppl 2:S110–6

ANGIOGRAPHY, CEREBRAL see **CEREBRAL ANGIOGRAPHY**

ANGIOGRAPHY, CORONARY see **CORONARY ANGIOGRAPHY**

ANGIOGRAPHY, DIGITAL SUBTRACTION

1996 AUR Memorial Award. Densitometric analysis of eccentric vascular stenoses: comparison of CO2 and iodinated contrast media. Black CM, et al. **Acad Radiol** 1996 Dec;3(12):985–93

Carotid artery stenosis: optimization of CT angiography with a combination of shaded surface display and source images. Papp Z, et al. **AJNR Am J Neuroradiol** 1997 Apr; 18(4):759–63

Anatomic evaluation of the circle of Willis: MR angiography versus intraarterial digital subtraction angiography. Stock KW, et al. **AJNR Am J Neuroradiol** 1996 Sep;17(8):1495–9

Examination of renal donors as outpatients using intraarterial digital subtraction angiography and a pigtail catheter. Caridi JG, et al. **AJR Am J Roentgenol** 1997 Aug; 169(2):537–9

Angiography/interventional case of the day. Arteriogenic impotence from posttraumatic bilateral proximal cavernosal artery occlusions. LiPuma JP, et al.
AJR Am J Roentgenol 1997 Jul;169(1):260, 263–4

Hepatic arteriography in patients with hepatocellular carcinoma under balloon occlusion of a hepatic vein draining the tumor–bearing liver parenchyma: useful for arterial infusion treatment? [letter; comment] Murata S, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):1063–4. Comment on: AJR Am J Roentgenol 1995 Dec;165(6):1415–9.

CT angiography versus intraarterial digital subtraction angiography for assessment of aortoiliac occlusive disease. Rieker O, et al. **AJR Am J Roentgenol** 1997 Oct; 169(4):1133–8

Intraoperative prebypass arteriography for infrageniculate revascularization. Huber TS, et al. **Am J Surg** 1997 Aug; 174(2):205–9

Comparison of two–dimensional time–of–flight dynamic magnetic resonance angiography with digital subtraction angiography in popliteal artery entrapment syndrome. Forster BB, et al. **Can Assoc Radiol J** 1997 Feb;48(1):11–8

Successful repeat transcatheter ablation of a mediastinal parathyroid adenoma 6 years after alcohol embolization. Cook GJ, et al. **Cardiovasc Intervent Radiol** 1997 Jul–Aug; 20(4):314–6

Percutaneous transluminal rotational atherectomy in the treatment of peripheral vascular disease using a transluminal endatherectomy catheter (TEC): initial results and angiographic follow–Up. Rilinger N, et al.
Cardiovasc Intervent Radiol 1997 Jul–Aug;20(4):263–7

Evaluation of distal run–off before femorodistal bypass. Davies AH, et al. **Cardiovasc Surg** 1996 Apr;4(2):161–4

Colour duplex ultrasonography versus angiography in the diagnosis of lower–extremity arterial disease. Lai DT, et al. **Cardiovasc Surg** 1996 Jun;4(3):384–8

Hemodynamic effects of nonionic contrast bolus injection and oxygen inhalation during pulmonary angiography in patients with chronic major–vessel thromboembolic pulmonary hypertension. Pitton MB, et al. **Circulation** 1996 Nov 15;94(10):2485–91

Congenital absence of the right common iliac artery: CT and angiographic demonstration. Llauger J, et al.
Eur J Radiol 1995 Dec 15;21(2):128–30

Duplex vs. angiography [letter; comment] Dodds S.
Eur J Vasc Endovasc Surg 1997 Feb;13(2):255–6. Comment on: Eur J Vasc Endovasc Surg 1996 Aug;12(2):238–42.

Accuracy of duplex sonography before carotid endarterectomy--a comparison with angiography. Hansen F, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):331–6

The measurement of internal carotid artery stenosis: comparison of duplex with digital subtraction angiography. Padayachee TS, et al. **Eur J Vasc Endovasc Surg** 1997 Feb; 13(2):180–5

Images in cardiology. Anomalous origin of the left coronary artery from the pulmonary artery. Grant S, et al. **Heart** 1996 Aug;76(2):136

The concept of archiving unedited and edited digital coronary angiograms. Stiel GM, et al.
Int J Card Imaging 1997 Feb;13(1):35–41

Angiographic detection of gastrointestinal bleeding. An experimental comparison of conventional screen–film angiography and digital subtraction angiography. Krüger K, et al. **Invest Radiol** 1996 Jul;31(7):451–7

Initial experience with helical CT and 3D reconstruction in therapeutic planning of cerebral AVMs: comparison with 3D time–of–flight MRA and digital subtraction angiography. Tanaka H, et al. **J Comput Assist Tomogr** 1997 Sep–Oct;21(5):811–7

Intraoperative digital subtraction angiography after thromboembolectomy: preliminary experience. Crolla RM, et al. **J Endovasc Surg** 1995 May;2(2):168–71

Incorporation of digital images into an interventional radiology procedure note. Ayoub DM, et al.
J Vasc Interv Radiol 1997 Jul–Aug;8(4):663–5

Use of intravenous digital subtraction angiography for imaging of the thoracic aorta [letter; comment] Haskal ZJ. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):720. Comment on: J Vasc Interv Radiol 1997 Mar–Apr;8(2):226–7.

Comparison of digital subtraction and cut film arteriography in the evaluation of suspected thoracic aortic injury. Johnson MS, et al. **J Vasc Interv Radiol** 1997 Sep–Oct; 8(5):799–807

Value of color duplex sonography for evaluation of tibioperoneal arteries in patients with femoropopliteal obstruction: a prospective comparison with anterograde intraarterial digital subtraction angiography. Larch E, et al. **J Vasc Surg** 1997 Apr;25(4):629–36

Wire–core tree technique for accurate three–dimensional modelling of arterial trees. Benjamin R.
Med Biol Eng Comput 1996 Nov;34(6):481–3

Diagnosis of renovascular hypertension: are i.v. digital subtraction angiography and the excretory urograms really outdated compared to captopril renography? [letter] Fournier A, et al. **Nephrol Dial Transplant** 1996 Jun; 11(6):1186–7

Intravenous angiography in brain death: report of 140 patients. Braum M, et al. **Neuroradiology** 1997 Jun; 39(6):400–5

The role of duplex sonography and angiography in the investigation of carotid artery disease. Worthy SA, et al. **Neuroradiology** 1997 Feb;39(2):122–6

Photodynamic therapy and digital angiography of experimental iris neovascularization using liposomal benzoporphyrin derivative. Husain D, et al.
Ophthalmology 1997 Aug;104(8):1242–50

Types of diaphragmatic motion during hepatic angiography. Katsuda T, et al. **Radiol Technol** 1997 Jul–Aug;68(6):481–6

Reducing misregistration of mask image in hepatic DSA. Katsuda T, et al. **Radiol Technol** 1997 Jul–Aug;68(6):487–90

Strip drip. Livett PP. **Radiol Technol** 1996 Jul–Aug;67(6):538

Renal artery stenosis: detection and quantification with spiral CT angiography versus optimized digital subtraction angiography. Kaatee R, et al. **Radiology** 1997 Oct; 205(1):121–7

Azotemia: gadopentetate dimeglumine as contrast agent at digital subtraction angiography. Matchett WJ, et al.
Radiology 1996 Nov;201(2):569–71

Hemodynamic significance of renal artery stenosis: digital subtraction angiography versus systolically gated three–dimensional phase–contrast MR angiography. Wasser MN, et al. **Radiology** 1997 Feb;202(2):333–8

Digital subtraction angiography for arteriovenous malformations in stereotactic radiosurgery. Piovan E, et al. **Stereotact Funct Neurosurg** 1996;66 Suppl 1:57–62

Morphological and hemodynamic assessments of carotid stenosis using quantitative digital subtraction angiography. Bladin CF, et al. **Stroke** 1996 Sep;27(9):1672–8

A comparison of intra–arterial digital subtraction angiography with Doppler sonography in the assessment of carotid arterial stenosis. Ellis PK, et al.
Ulster Med J 1996 Nov;65(2):137–41

Colour coded duplex sonography in ischemic finger artery disease--a comparison with hand arteriography. Langholz J, et al. **Vasa** 1997 May;26(2):85–90

[Cost–effectiveness of and morbidity from digital subtraction angiography. A study of 5,817 cases] Perendreu J, et al. **Ann Radiol (Paris)** 1996;39(3):153–60 (Eng. Abstr.) **(Fre)**

[Detection of subretinal neovessels with indocyanine green videoangiography] Atmaca L, et al. **J Fr Ophtalmol** 1997; 20(3):189–94 (Eng. Abstr.) **(Fre)**

[Comparison between iopamidol and ioxaglate in digital arteriography of the lower limbs] Cercueil JP, et al.
J Radiol 1996 Sep;77(9):643–7 (Eng. Abstr.) **(Fre)**

[Preoperative angiographic embolization of carotid glomus tumors. A method for improving operability] Fruhwirth J, et al. **HNO** 1996 Sep;44(9):510–3 (Eng. Abstr.) **(Ger)**

[CT angiography in dissections of the internal carotid artery. Value of a new examination technique in comparison with DSA and Doppler ultrasound] Egelhof T, et al.
Radiologe 1996 Nov;36(11):850–4 (Eng. Abstr.) **(Ger)**

[Possibilities and limitations of CT angiography in comparison to DSA in intracranial aneurysm] Dillo W, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Sep;165(3):227–31 (Eng. Abstr.) **(Ger)**

[Carotid vessels studied by Doppler color echography and digital angiography. Results of meta analysis] Cappetti P, et al. **Minerva Cardioangiol** 1996 Jul–Aug;44(7–8):373–6 (Eng. Abstr.) **(Ita)**

[Use of the inferior epigastric artery for coronary artery bypass grafting: preoperative digital subtraction angiography] Tanaka K, et al. **Kyobu Geka** 1996 Jul; 49(7):552–6 (Eng. Abstr.) **(Jpn)**

[Angiography of extremities] Yasuda K, et al.
Nippon Geka Gakkai Zasshi 1996 Jul;97(7):515–9 (5 ref.) (Eng. Abstr.) **(Jpn)**

[3D contrast MR angiography of lower extremity : additional imaging with subtraction] Ito K, et al.
Nippon Igaku Hoshasen Gakkai Zasshi 1996 Jan;56(1):66–7 (Eng. Abstr.) **(Jpn)**

[MR dynamic subtraction angiography (MRDSA)] Watanabe Y, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Jan; 57(1):61–3 (Eng. Abstr.) **(Jpn)**

[Renovascular arterial hypertension. Importance of subtraction digital angiography in its diagnosis] Machado FS, et al. **Rev Port Cardiol** 1996 Jun;15(6):465–71, 459 (33 ref.) (Eng. Abstr.) **(Por)**

[Renovascular arterial hypertension. Importance of subtraction digital angiography in its diagnosis] Telles EC, et al. **Rev Port Cardiol** 1996 Jul–Aug;15(7–8):555–61, 547 (Eng. Abstr.) **(Por)**

[MRA or DSA? A well–done multicenter study as a textbook example for evaluation of new medical technology] Ahlström H, et al. **Lakartidningen** 1996 Oct 9;93(41):3555–6 **(Swe)**

ADVERSE EFFECTS

CO2 digital subtraction angiography: potential complications and their prevention. Caridi JG, et al.
J Vasc Interv Radiol 1997 May–Jun;8(3):383–91 (33 ref.)

INSTRUMENTATION

Superselective angio–CT of brain tumors. Tomura N, et al. **AJNR Am J Neuroradiol** 1996 Jun–Jul;17(6):1073–80

Digital subtraction rotational angiography for aneurysms of the intracranial anterior circulation: injection method and optimization. Tu RK, et al. **AJNR Am J Neuroradiol** 1996 Jun–Jul;17(6):1127–36

Postmortem coronary subtraction angiography. Prahlow JA, et al. **Am J Forensic Med Pathol** 1996 Sep;17(3):225–30

Neuroradiological applications of a new system of stereoscopic biplane digital subtraction angiography. Hasuo K, et al. **Neuroradiology** 1996 Jul;38(5):430–2

What's new in ... medical physics. DeLuca PM Jr, et al.
Wis Med J 1997 May;96(5):51–8

[Studies of image quality and dose in digital subtraction angiography] Heckmann H, et al. **Aktuelle Radiol** 1997 Jul; 7(4):205–11 (Eng. Abstr.) **(Ger)**

[Digital dacryography after insertion of silicone probes after interruption of the lacrimal ducts in childhood] Ragozzino A, et al. **Aktuelle Radiol** 1997 May;7(3):149–51 (Eng. Abstr.) **(Ger)**

[New developments in parameter–oriented roentgen densitometry perfusion analysis within the scope of heart catheter studies] Haude M, et al. **Herz** 1997 Apr;22(2):72–86 (76 ref.) (Eng. Abstr.) **(Ger)**

[CT subtraction angiography (CTSA). Results with an automated "elastic" subtraction algorithm] Luboldt W, et al. **Radiologe** 1997 Jan;37(1):89–93 (Eng. Abstr.) **(Ger)**

[Digital subtraction angiography with carbon dioxide using a new gas dosage system] Schmitz–Rode T, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997 Jul;167(1):71–8 (Eng. Abstr.) **(Ger)**

[Development of rotational digital angiography system and new cone–beam 3 D CT] Kumazaki T.
Nippon Ika Daigaku Zasshi 1997 Feb;64(1):57–60 (6 ref.) **(Jpn)**

METHODS

Assessment of image intensifier and distortion for DSA localization studies. Coste E, et al. **Br J Radiol** 1997 Jan; 70:70–3

Analysis of the tumor staining obtained by preoperative IV–DSA for breast cancer patients: density and metastasis correlation. Haga S, et al. **Breast Cancer Res Treat** 1997 Apr;43(2):129–35

CT angiography of intracranial aneurysms: advantages and pitfalls. Ng SH, et al. **Eur J Radiol** 1997 Jul;25(1):14–9

Degree of carotid artery stenosis. Comparison of selective and non–selective angiographic findings with surgical specimens. Post K, et al. **Eur J Radiol** 1997 Jul;25(1):9–13

Assessment of accuracy of renal artery stenosis grading in helical CT angiography using maximum intensity projections. Van Hoe L, et al. **Eur Radiol** 1996;6(5):658–64

The clinical value of methods to measure carotid stenosis. Bladin CF, et al. **Int Angiol** 1996 Dec;15(4):295–9

Impact of various compression rates on interpretation of digital coronary angiograms. Silber S, et al.
Int J Cardiol 1997 Jul 25;60(2):195–200

CT angiography of Takayasu arteritis: comparison with conventional angiography. Park JH, et al.
J Vasc Interv Radiol 1997 May–Jun;8(3):393–400

Observer performance methodologies for evaluating blood vessel visibility in MR angiograms using accurate geometric registration to high resolution x–ray angiograms. Chapman BE, et al. **Magn Reson Med** 1997 Apr; 37(4):519–29

Velocity measurement based on bolus tracking with the aid of three–dimensional reconstruction from digital subtraction angiography. Huang SP, et al. **Med Phys** 1997 May;24(5):677–86

Intra–arterial digital subtraction angiography with extra–large fields using a computed radiography system in evaluating peripheral vascular disease. Hasuo K, et al. **Radiat Med** 1996 Sep–Oct;14(5):229–33

Computed radiography angiography using storage phosphor imaging plates: eight year's experience. Kudo S, et al.
Radiat Med 1997 May–Jun;15(3):137–42

Use of personal computers and digitized film angiograms to produce subtraction angiograms. Kofler JM Jr, et al.
Radiographics 1996 Mar;16(2):401–7

Clinical experience with stereotactic digital subtraction angiography with distortion correction software. Ericson K, et al. **Stereotact Funct Neurosurg** 1996;66 Suppl 1:63–70

ANGIOGRAPHY, DIGITAL SUBTRACTION

ROC analysis of noninvasive tests for peripheral arterial disease. Lijmer JG, et al. **Ultrasound Med Biol** 1996; 22(4):391–8

[Intravenous spiral CT angiography for assessment before orthotopic liver transplantation: comparisons between tomography, MIP, 3-dimensional surface imaging and intra-arterial DSA] Hidajat N, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Nov;165(5):445–51 (Eng. Abstr.) **(Ger)**

[3D-CT angiography and duplex sonography compared to arteriography in carotid stenoses] Link J, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997 Jan;166(1):30–5 (Eng. Abstr.) **(Ger)**

[Spiral CT angiography versus DSA in detection of carotid stenoses] Link J, et al. **Zentralbl Chir** 1996;121(12):1018–22 (Eng. Abstr.) **(Ger)**

[Digital subtraction arterioportography in the examination of patients with the portal hypertension syndrome] Zubarev PN, et al. **Vestn Khir Im I I Grek** 1997;156(3):81–5 (Eng. Abstr.) **(Rus)**

STANDARDS

Analysis of biliary drainage in the caudate lobe of the liver: comparison of three-dimensional CT cholangiography and rotating cine cholangiography. Furukawa H, et al.
Radiology 1997 Jul;204(1):113–7

ANGIOGRAPHY, GATED RADIONUCLIDE see **GATED BLOOD-POOL IMAGING**

ANGIOGRAPHY, MAGNETIC RESONANCE see **MAGNETIC RESONANCE ANGIOGRAPHY**

ANGIOGRAPHY, RADIONUCLIDE see **RADIONUCLIDE ANGIOGRAPHY**

ANGIOHEMOPHILIA see **VON WILLEBRAND'S DISEASE**

ANGIOID STREAKS

Understanding angioid streaks. Gurwood AS, et al.
J Am Optom Assoc 1997 May;68(5):309–24 (95 ref.)

COMPLICATIONS

Laser photocoagulation of choroidal neovascularization in angioid streaks. Pece A, et al. **Retina** 1997;17(1):12–6

DIAGNOSIS

Ophthaproblem. Angioid streaks. Sharma S.
Can Fam Physician 1997 Jul;43:1217, 1223

Hypofluorescent spots in indocyanine green angiography of peau d'orange and fundus. Shiraki K, et al.
Int Ophthalmol 1997;21(1):43–50

[Angioid streaks--case report] Dróbecka-Brydak E, et al. **Klin Oczna** 1995 Sep-Oct;97(9–10):303–4 (Eng. Abstr.) **(Pol)**

[Angioid streaks. Pathogenesis and the clinical picture] Janotka H, et al. **Klin Oczna** 1995 Sep-Oct; 97(9–10):299–302 (14 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

[Pseudoxanthoma elasticum. Skin changes as a marker of systemic illness] Jacobi H, et al. **Hautarzt** 1997 Mar; 48(3):191–4 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Indocyanine green angiography in angioid streaks. Pece A, et al. **Acta Ophthalmol Scand** 1997 Jun;75(3):261–5

Images in clinical medicine. Angioid streaks in pseudoxanthoma elasticum. Cheeseman EW Jr, et al.
N Engl J Med 1997 Sep 18;337(12):828

ANGIOIMMUNOBLASTIC LYMPHADENOPATHY see **IMMUNOBLASTIC LYMPHADENOPATHY**

ANGIOKERATOMA

Angiokeratomas: an update. Schiller PI, et al.
Dermatology 1996;193(4):275–82 (57 ref.)

COMPLICATIONS

Widespread angiokeratomas and tuberous sclerosis. Gil-Mateo MP, et al. **Br J Dermatol** 1996 Aug;135(2):280–2

PATHOLOGY

Scrotal angiokeratoma in a young man [letter] Hisa T, et al. **Acta Derm Venereol** 1996 May;76(3):248–9

Blue rubber bleb nevus syndrome associated with diffuse angiokeratoma. Trattner A, et al. **Cutis** 1997 May; 59(5):264–6

Solitary angiokeratoma of the oral cavity. Leung CS, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997 Jul;84(1):51–3

ANGIOKERATOMA CORPORIS DIFFUSUM see **FABRY'S DISEASE**

ANGIOLEIOMYOMA see **ANGIOMYOMA**

ANGIOLIPOMA

COMPLICATIONS

Intracranial angiolipoma: report of two cases. Prabu SS, et al. **Br J Neurosurg** 1995;9(6):793–7

DIAGNOSIS

Spinal angiolipomas revisited: two case reports. Trabulo A, et al. **Acta Neurochir (Wien)** 1996;138(11):1311–9 (21 ref.)

Spinal canal compromise in Proteus syndrome: case report and review of the literature. Ring D, et al.
Am J Orthop 1997 Apr;26(4):275–8 (14 ref.)

Spinal intramedullary angiolipoma. Maggi G, et al.
Childs Nerv Syst 1996 Jun;12(6):346–9

GENETICS

Cytogenetic analysis of subcutaneous angiolipoma: further evidence supporting its difference from ordinary pure lipomas: a report of the CHAMP Study Group. Sciot R, et al. **Am J Surg Pathol** 1997 Apr;21(4):441–4

[Genetic studies of differential fatty tissue tumor diagnosis] Belge G, et al. **Pathologe** 1997 Mar;18(2):160–6 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Intracranial angiolipoma: report of two cases. Prabu SS, et al. **Br J Neurosurg** 1995;9(6):793–7

Concurrent occurrence of solitary spinal epidural osteochondroma and angiolipoma. Shuangshoti S, et al.
Clin Neuropathol 1997 Mar-Apr;16(2):107–10

Combined myxoid liposarcoma and angiolipoma of the spermatic cord. Ikinger U, et al. **Urology** 1997 Apr; 49(4):635–7 (15 ref.)

SURGERY

Solitary gastric Peutz-Jeghers polyp and angiolipoma presenting as acute haemorrhage. Hunt J, et al.
Aust N Z J Surg 1996 Oct;66(10):713–5

ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA

[Kimura's disease] Nishimura M.
Ryoikibetsu Shokogun Shirizu 1996;(15):419–21 (13 ref.) **(Jpn)**

COMPLICATIONS

Kimura's disease: an unusual cause of cervical tumour. Chusid MJ, et al. **Arch Dis Child** 1997 Aug;77(2):153–4

Angiolymphoid hyperplasia with eosinophilia in the colon: a novel cause of rectal bleeding. Berney DM, et al.
J Clin Pathol 1997 Jul;50(7):611–3

DIAGNOSIS

Kimura disease: CT and MR findings. Takahashi S, et al.
AJNR Am J Neuroradiol 1996 Feb;17(2):382–5

Angiolymphoid hyperplasia with eosinophilia and vascular tumors of the head and neck. Don DM, et al.
Am J Otolaryngol 1996 Jul-Aug;17(4):240–5

Kimura's disease of the epiglottis. Cho MS, et al.
Histopathology 1997 Jun;30(6):592–4

Kimura's disease. A typical case of a rare disorder. Jani A, et al. **West J Med** 1997 Feb;166(2):142–4 (7 ref.)

[Parotid tumor. Kimura disease of the parotid gland] Woldag K, et al. **HNO** 1997 Jun;45(6):466–7 **(Ger)**

PATHOLOGY

Multiple angiolymphoid hyperplasia with eosinophilia of the hand: report of a case and review of the literature. Imbing FD Jr, et al. **Cutis** 1996 Nov;58(5):345–8 (13 ref.)

Kimura's disease in an Arab female. Jaber K.
Histopathology 1996 Jul;29(1):76–8

Kimura's disease. Lenk N, et al. **Int J Dermatol** 1997 Jun; 36(6):437–9

Kimura's disease. Pamaraju N, et al. **J Laryngol Otol** 1996 Nov;110(11):1084–7

Kimura's disease: a clinicopathologic study of 54 Chinese patients. Li TJ, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Nov;82(5):549–55

[A rare case of angiolymphoid intramasseteric hyperplasia] Bruno E, et al. **An Otorrinolaringol Ibero Am** 1997; 24(2):143–50 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Kimura's disease (angiolymphoid hyperplasia with eosinophilia) of the tympanic membrane. Fitzgerald DC, et al. **Ear Nose Throat J** 1996 Feb;75(2):94–6

Kimura's disease in an Arab female. Jaber K.
Histopathology 1996 Jul;29(1):76–8

RADIOGRAPHY

Computerized tomographic and ultrasonographic features of Kimura's disease. Goldenberg D, et al. **J Laryngol Otol** 1997 Apr;111(4):389–91

Radiological features in a patient with Kimura's disease. Lim WE, et al. **Singapore Med J** 1997 Mar;38(3):125–8 (9 ref.)

RADIOTHERAPY

Radiation treatment in patients with recurrent Kimura's disease. Kim GE, et al. **Int J Radiat Oncol Biol Phys** 1997 Jun 1;38(3):607–12

SURGERY

Pulsed dye laser treatment of angiolymphoid hyperplasia with eosinophilia lesions [letter] Lertzman BH, et al.
Arch Dermatol 1997 Jul;133(7):920–1

THERAPY

Kimura's disease. A typical case of a rare disorder. Jani A, et al. **West J Med** 1997 Feb;166(2):142–4 (7 ref.)

ULTRASONOGRAPHY

[Differential diagnosis of tumorous space-occupying lesions of the parotid gland: angiolymphoid hyperplasia with eosinophilia and Kimura disease] Ussmüller J, et al.
Laryngorhinootologie 1997 Feb;76(2):110–5 (Eng. Abstr.) **(Ger)**

ANGIOMA see **HEMANGIOMA**

ANGIOMA, SCLEROSING see **DERMATOFIBROMA**

ANGIOMATOSIS

see related
TELANGIECTASIA, HEREDITARY HEMORRHAGIC

COMPLICATIONS

Meningioangiomatosis is associated with neurofibromatosis 2 but not with somatic alterations of the NF2 gene. Stemmer-Rachamimov AO, et al.
J Neuropathol Exp Neurol 1997 May;56(5):485–9 (43 ref.)

Cerebral venous sinus thrombosis associated with systemic multiple hemangiomas manifesting as chronic subdural hematoma--case report. Takamura Y, et al.
Neurol Med Chir (Tokyo) 1996 Sep;36(9):650–3

[Congenital subfold hemangioma in combination with hemangiomatosis of the head, face and neck] Vodolazov SI, et al. **Vestn Otorinolaringol** 1996 Sep-Oct;(5):35–6 (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Acquired zosteriform naevus flammeus: a cutaneous marker of central nervous system angiomatosis [letter] Requena L, et al. **Acta Derm Venereol** 1996 Mar;76(2):165–6

January 1997--7 year old girl with seizures. al-Hindi H, et al. **Brain Pathol** 1997 Jul;7(3):1023–4 (6 ref.)

Diffuse skeletal cystic angiomatosis: MR and CT findings. Soler R, et al. **Eur J Radiol** 1996 May;22(2):149–51

Hereditary neurocutaneous angiomatosis. Report of four cases. Leblanc R, et al. **J Neurosurg** 1996 Dec; 85(6):1135–42

Gorham syndrome of the thorax and cervical spine: CT and MRI findings. Chung C, et al. **Skeletal Radiol** 1997 Jan; 26(1):55–9

Skeletal cystic angiomatosis. Lateur L, et al.
Skeletal Radiol 1996 Jan;25(1):92–5 (11 ref.)

[Disseminated neonatal angiomatosis: diagnosis and follow up of a case] Masala S, et al. **Radiol Med (Torino)** 1996 Oct;92(4):489–91 **(Ita)**

[Eruptive pseudoangiomatosis. A case report] González Enseñat MA, et al. **An Esp Pediatr** 1997 Jan;46(1):69–70 **(Spa)**

GENETICS

Meningioangiomatosis is associated with neurofibromatosis 2 but not with somatic alterations of the NF2 gene. Stemmer-Rachamimov AO, et al.
J Neuropathol Exp Neurol 1997 May;56(5):485–9 (43 ref.)

Hereditary neurocutaneous angiomatosis. Report of four cases. Leblanc R, et al. **J Neurosurg** 1996 Dec; 85(6):1135–42

PATHOLOGY

Dabska tumor developing within a preexisting vascular malformation. Quecedo E, et al. **Am J Dermatopathol** 1996 Jun;18(3):302–7 (14 ref.)

Cystic angiomatosis of bone: a case report. Goutoudi PC, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Jan;81(1):89–92

PHYSIOPATHOLOGY

[Eruptive pseudoangiomatosis. A case report] González Enseñat MA, et al. **An Esp Pediatr** 1997 Jan;46(1):69–70 **(Spa)**

ANGIOMATOSIS, BACILLARY

Bacillary angiomatosis: microbiology, histopathology, clinical presentation, diagnosis and management. Ramirez Ramírez CR, et al. **Bol Asoc Med P R** 1996 Apr-Jun; 88(4–6):46–51 (22 ref.)

COMPLICATIONS

Bacillary angiomatosis: a role for Phyllobacterium? [letter] Price DA, et al. **AIDS** 1997 Jul 15;11(9):1186–7

Bone bacillary angiomatosis in an HIV–infected patient. Olivé A, et al. **Br J Rheumatol** 1996 Sep;35(9):901–4

DIAGNOSIS

Molecular diagnosis of deep nodular bacillary angiomatosis and monitoring of therapeutic success. Schlüpen EM, et al. **Br J Dermatol** 1997 May;136(5):747–51

Bacillary angiomatosis in an HIV seronegative patient on systemic steroid therapy. Schwartz RA, et al. **Br J Dermatol** 1996 Dec;135(6):982–7

Isolation of Bartonella quintana from an HIV–positive patient with bacillary angiomatosis. Schmidt HU, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep;15(9):736–41 (21 ref.)

Serological cross–reactions between Bartonella quintana, Bartonella henselae, and Coxiella burnetii. La Scola B, et al. **J Clin Microbiol** 1996 Sep;34(9):2270–4

Bacillary angiomatosis of the cervix and vulva in a patient with AIDS. Long SR, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):709–11

[Illnesses caused by Bartonella. Cat–scratch disease, bacillary angiomatosis, bacillary peliosis hepatis, endocarditis] Nadal D, et al. **Internist (Berl)** 1996 Sep;37(9):890–4 (35 ref.) **(Ger)**

DRUG THERAPY

Experimentally induced Bartonella henselae infections followed by challenge exposure and antimicrobial therapy in cats. Regnery RL, et al. **Am J Vet Res** 1996 Dec; 57(12):1714–9

ETIOLOGY

Bacillary angiomatosis associated with extensive esophageal polyposis: a new mucocutaneous manifestation of acquired immunodeficiency disease (AIDS). Chang AD, et al. **Am J Gastroenterol** 1996 Oct;91(10):2220–3

Unraveling mysteries associated with cat–scratch disease, bacillary angiomatosis, and related syndromes. Regnery R, et al. **Emerg Infect Dis** 1995 Jan–Mar;1(1):16–21 (46 ref.)

Histological and ultrastructural study of one case of oral bacillary angiomatosis in HIV disease and review of the literature. Monteil RA, et al. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):65–71 (64 ref.)

Intrathoracic localization of bacillary angiomatosis. Finet JF, et al. **Histopathology** 1996 Feb;28(2):183–5

MICROBIOLOGY

Bacillary angiomatosis: a role for Phyllobacterium? [letter] Price DA, et al. **AIDS** 1997 Jul 15;11(9):1186–7

Prevalence of Bartonella henselae antibodies among human immunodeficiency virus–infected patients from Bahrain. Yousif A, et al. **Clin Infect Dis** 1996 Aug;23(2):398–9

PATHOLOGY

Bacillary angiomatosis in an immunocompetent child. Smith KJ, et al. **Am J Dermatopathol** 1996 Dec;18(6):597–600

Bacillary angiomatosis: presentation of six patients, some with unusual features. Schwartz RA, et al. **Br J Dermatol** 1997 Jan;136(1):60–5

Bacillary angiomatosis associated with myositis in a patient infected with human immunodeficiency virus. Whitfeld MJ, et al. **Clin Infect Dis** 1997 Apr;24(4):562–4

Intrathoracic localization of bacillary angiomatosis. Finet JF, et al. **Histopathology** 1996 Feb;28(2):183–5

Osseous manifestations of bacillary angiomatosis. Gomez–Jorge JT, et al. **Skeletal Radiol** 1996 Jul;25(5):505–8

PHYSIOPATHOLOGY

Bacillary angiomatosis, cat–scratch disease, and bartonellosis: what's the connection? Nosal JM. **Int J Dermatol** 1997 Jun; 36(6):405–11 (21 ref.)

VETERINARY

Experimentally induced Bartonella henselae infections followed by challenge exposure and antimicrobial therapy in cats. Regnery RL, et al. **Am J Vet Res** 1996 Dec; 57(12):1714–9

ANGIOMATOSIS, EPITHELIOID see **ANGIOMATOSIS, BACILLARY**

ANGIOMYOLIPOMA

[Renal angiomyolipoma] Baše J, et al. **Rozhl Chir** 1996 Dec; 75(12):569–72 (Eng. Abstr.) **(Cze)**

[Pararenal angiomyolipoma] Vesga Molina F, et al. **Arch Esp Urol** 1996 Oct;49(8):868–70 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Co–incidence of angioleiomyolipoma and renal cyst. Csata S, et al. **Acta Chir Hung** 1995–96;35(3–4):355–9

How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? [letter] Blute ML. **Am J Respir Crit Care Med** 1996 Nov;154(5):1580–1

Case quiz. Spontaneous rupture of a renal tumour with a perinephric haematoma. Ooi GC, et al. **Australas Radiol** 1997 Feb;41(1):79–81

Massive renal angiomyolipoma in tuberous sclerosis. Katz DS, et al. **Clin Imaging** 1997 May–Jun;21(3):200–2

Giant hepatic angiomyolipoma associated with disseminated intravascular coagulation. Ukai K, et al. **Intern Med** 1997 Mar;36(3):186–90

A cross sectional study of renal involvement in tuberous sclerosis. Cook JA, et al. **J Med Genet** 1996 Jun;33(6):480–4

Placental abruption and spontaneous rupture of renal angiomyolipoma in a pregnant woman with tuberous sclerosis. Forsnes EV, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):725

Hepatic angiomyolipoma developing during the follow–up of ulcerative colitis: report of a case and review of the literature. Suzuki S, et al. **Surg Today** 1996;26(8):635–9 (44 ref.)

Recurrent bleeding of angiomyolipomas in tuberous sclerosis. Chatterjee T, et al. **Urol Int** 1996;56(1):44–7

Spontaneous hemorrhage during pregnancy secondary to renal angiomyolipoma. Yanai H, et al. **Urol Int** 1996; 56(3):188–91

[Endovascular treatment of hemorrhagic renal angiomyolipoma with platinum microcoils] Beaujeux R, et al. **Prog Urol** 1996 Jun;6(3):424–8 (Eng. Abstr.) **(Fre)**

[Renal angiolipoma associated with bilateral double ureter. A clinical case] Verna C, et al. **Minerva Urol Nefrol** 1997 Mar;49(1):39–44 (28 ref.) (Eng. Abstr.) **(Ita)**

[Spontaneous retroperitoneal hemorrhage from renal angiomyolipoma. Report of 2 cases] Gibilisco G, et al. **Radiol Med (Torino)** 1996 Nov;92(5):660–2 **(Ita)**

[Renal angiomyolipoma and renal cell carcinoma associated with tuberous sclerosis: a case report] Sugimoto M, et al. **Hinyokika Kiyo** 1997 Jan;43(1):33–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Hemodialysis case of kidney failure due to ruptured renal angiomyolipoma associated with tuberous sclerosis] Inoue K, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10; 85(1):121–2 **(Jpn)**

[Spontaneous rupture of renal angiomyolipoma] Sarmentero E, et al. **Arch Esp Urol** 1996 Jun;49(5):527–8 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Giant retroperitoneal angiomyolipoma mimicking liposarcoma. Wang LJ, et al. **Br J Urol** 1997 Jun; 79(6):1001–2

Multiple organ involvement in tuberous sclerosis. Yagci C, et al. **Eur J Radiol** 1997 Jul;25(1):52–4

Multiple angiomyolipomas of the liver (case report). Kyokane T, et al. **Hepatogastroenterology** 1995 Sep–Oct;42(5):510–5

Three cases of renal angiomyolipoma. Itano S, et al. **Intern Med** 1997 Mar;36(3):206–10

Chemical shift GRE MRI of renal angiomyolipoma. Kido T, et al. **J Comput Assist Tomogr** 1997 Mar–Apr; 21(2):268–70

Small (< 1.5 cm) angiomyolipomas of the kidney: characterization by the combined use of in–phase and fat–attenuated MR techniques. Burdeny DA, et al. **Magn Reson Imaging** 1997;15(2):141–5

Hepatic angiomyolipoma with minimal fat content: MR demonstration. Worawattanakul S, et al. **Magn Reson Imaging** 1996;14(6):687–9

Unusual fat–containing tumors of the kidney: a diagnostic dilemma. Hélénon O, et al. **Radiographics** 1997 Jan–Feb; 17(1):129–44

Adult renal hamartomas. Wagner BJ, et al. **Radiographics** 1997 Jan–Feb;17(1):155–69

Imaging of angiomyolipomas. Lemaitre L, et al. **Semin Ultrasound CT MR** 1997 Apr;18(2):100–14 (70 ref.)

Extrarenal retroperitoneal angiomyolipoma. Fegan JE, et al. **South Med J** 1997 Jan;90(1):59–62 (22 ref.)

[Hepatic angiomyolipoma simulating hepatocytic tumor. 3 cases] Arblade S, et al. **Gastroenterol Clin Biol** 1996; 20(11):1022–6 (39 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic difficulties and value of partial surgery in multiple tumors of the kidney. Apropos of 4 cases] De la Taille A, et al. **J Urol (Paris)** 1996;102(4):139–43 (Eng. Abstr.) **(Fre)**

[Renal angiomyolipoma] Kikuchi K. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):481–3 (13 ref.) **(Jpn)**

[Case of life–time diagnosis of renal angiomyolipoma] Karmilov VA, et al. **Klin Med (Mosk)** 1996;74(4):55–7 **(Rus)**

[Renal incidentaloma and pregnancy] Pobil Moreno JL, et al. **Arch Esp Urol** 1996 Sep;49(7):755–7 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Renal manifestations of tuberous sclerosis complex. O'Hagan AR, et al. **Clin Pediatr (Phila)** 1996 Oct;35(10):483–9 (71 ref.)

GENETICS

Heterogeneity of DNA distribution pattern in renal tumours. Nenning H, et al. **Anal Cell Pathol** 1997;14(1):9–17

Clonal chromosome aberrations in three of five sporadic angiomyolipomas of the kidney. Wullich B, et al. **Cancer Genet Cytogenet** 1997 Jul 1;96(1):42–5

PATHOLOGY

Hepatic angiomyolipoma: a report of two cases. Lee PY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jan; 57(1):74–8

Angiomyolipoma of the liver: an unusual benign tumour identifiable on cytological material. Sempoux C, et al. **Cytopathology** 1997 Jun;8(3):196–202

Coexistence of renal cell carcinoma and renal angiomyolipoma developing in a kidney: a case report. Tsuboniwa N, et al. **Hinyokika Kiyo** 1997 Feb;43(2):131–5 (30 ref.)

Renal angiomyolipoma: a tumour with peculiar variants and associations [letter; comment] Csanaky G. **Histopathology** 1996 Nov;29(5):491–2. Comment on: Histopathology 1996 Mar;28(3):277–80.

Epithelioid cell variant of renal angiomyolipoma [see comments] Mai KT, et al. **Histopathology** 1996 Mar; 28(3):277–80. Comment in: Histopathology 1996 Nov;29(5):491–2.

Cutaneous angiomyolipoma. Val–Bernal JF, et al. **J Cutan Pathol** 1996 Aug;23(4):364–8

A histopathologic and immunohistochemical study of small nodules of renal angiomyolipoma: a comparison of small nodules with angiomyolipoma. Chowdhury PR, et al. **Mod Pathol** 1996 Nov;9(11):1081–8

Hepatic angiomyolipoma in childhood: association with tuberous sclerosis [letter] Ben–Izhak O, et al. **Pediatr Pathol Lab Med** 1995 Jan–Feb;15(1):213–7

Rare association of unilateral renal oncocytoma and angiomyolipoma. Talic RF, et al. **Scand J Urol Nephrol** 1997 Feb;31(1):91–3

[A case of huge renal angiomyolipoma calculated doubling time] Okihara K, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Oct;87(10):1197–200 (Eng. Abstr.) **(Jpn)**

[Angiomyolipoma renal in the child. Presentation of case] Urdangarain OO, et al. **Arch Esp Urol** 1996 Jul–Aug; 49(6):617–8 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

[Erratic course of bilateral renal angiomyolipomas] Guisgand M, et al. **J Radiol** 1996 Nov;77(11):1141–3 (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

"Aggressive" renal angiomyolipoma. Cittadini G Jr, et al. **Acta Radiol** 1996 Nov;37(6):927–32

Small (< or = 3 cm) hyperechoic renal masses: comparison of helical and convention CT for diagnosing angiomyolipoma. Silverman SG, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):877–81

Spontaneous rupture of a hepatic angiomyolipoma: CT findings and literature review. Guidi G, et al. **Eur Radiol** 1997;7(3):335–7 (32 ref.)

Cardiac angiomyolipoma: radiologic and pathologic correlation. Tsai CC, et al. **J Formos Med Assoc** 1997 Aug; 96(8):653–6

Hepatic angiomyo(myelo)lipoma: difficulties in radiological diagnosis and interest of fine needle aspiration biopsy. Messiaen T, et al. **Liver** 1996 Oct;16(5):338–41

Incidentally detected renal angiomyolipoma with tumour thrombus into the inferior vena cava. Rubio–Briones J, et al. **Scand J Urol Nephrol** 1997 Apr;31(2):189–91 (14 ref.)

[Renal angiomyolipoma] Merran S. **Presse Med** 1997 Jan 18–25;26(1):52 **(Fre)**

[Acute abdomen with palpable resistance in the pelvis and painful kidney region.Acute retroperitoneal hemorrhage from angiomyolipoma kidney in tuberous sclerosis (Bourneville–Pringle disease)] Hünerbein R, et al. **Radiologe** 1997 Apr;37(4):333–5 **(Ger)**

SURGERY

Renal angiomyolipoma—experience of 20 years in Taiwan. Chen SS, et al. **Eur Urol** 1997;32(2):175–8

Angiomyolipoma of the liver. Chaib E, et al. **Int Surg** 1996 Jul–Sep;81(3):320–2

Ruptured hepatic angiolipoma in tuberous sclerosis complex. Huber C, et al. **Langenbecks Arch Chir** 1996;381(1):7–9

THERAPY

Renal angiomyolipomas: long–term follow–up of embolization for acute hemorrhage. Hamlin JA, et al. **Can Assoc Radiol J** 1997 Jun;48(3):191–8

Renal angiomyolipoma: selective arterial embolization—effectiveness and changes in angiomyogenic components in long–term follow–up. Han YM, et al. **Radiology** 1997 Jul;204(1):65–70

[The management selection of renal angiomyolipoma] Meiri H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Oct; 87(10):1151–7 (Eng. Abstr.) **(Jpn)**

[Long–term effect of transcatheter arterial embolization therapy for renal angiomyolipoma] Sasaki M, et al. **Nippon Jinzo Gakkai Shi** 1996 Jun;38(6):273–7 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Characterization of renal angiomyolipoma by scanning acoustic microscopy. Sasaki H, et al. **J Pathol** 1997 Apr; 181(4):455–61

ANGIOMYOLIPOMA

Differentiation of renal cell carcinomas from angiomyolipomas by ultrasonic frequency dependent attenuation. Taniguchi N, et al. **J Urol** 1997 Apr; 157(4):1242–5

ANGIOMYOMA

Angioleiomyoma of the lower extremity. Hanft JR, et al. **J Am Podiatr Med Assoc** 1997 Aug;87(8):388–91

COMPLICATIONS

Gaze–evoked amaurosis heralding orbital angiomyoma. Case report. Salvi F, et al. **Ital J Neurol Sci** 1997 Feb;18(1):31–4

Intravenous leiomyomatosis complicated by Budd–Chiari syndrome. Kuenen BC, et al. **Postgrad Med J** 1996 Nov; 72(853):686–8

DIAGNOSIS

Vascular leiomyoma of the superior turbinate: first reported case. Nall AV, et al. **Head Neck** 1997 Jan;19(1):63–7 (15 ref.)

Angiomyoma of the lower extremity: MR findings. Kinoshita T, et al. **Skeletal Radiol** 1997 Jul;26(7):443–5

[Diagnostic difficulties in a degeneratively altered myoma] Raicheva R, et al. **Akush Ginekol (Sofiia)** 1997;36(1):26–7 **(Bul)**

PATHOLOGY

Vulval angiomyofibroblastoma. Clinicopathologic analysis of six cases. Fukunaga M, et al. **Am J Clin Pathol** 1997 Jan; 107(1):45–51

Genital angiomyofibroblastoma. Comparison with aggressive angiomyxoma and other myxoid neoplasms of skin and soft tissue. Ockner DM, et al. **Am J Clin Pathol** 1997 Jan; 107(1):36–44

Pleomorphic angioleiomyoma. Martínez JA, et al. **Am J Dermatopathol** 1996 Aug;18(4):409–12

Pleomorphic angioleiomyoma [letter] Rosai J. **Am J Dermatopathol** 1997 Aug;19(4):419

Angiomyofibroblastoma of the vulva with sarcomatous transformation ("angiomyofibrosarcoma"). Nielsen GP, et al. **Am J Surg Pathol** 1997 Sep;21(9):1104–8

Cellular angiofibroma: a benign neoplasm distinct from angiomyofibroblastoma and spindle cell lipoma. Nucci MR, et al. **Am J Surg Pathol** 1997 Jun;21(6):636–44

Angiomyofibroblastoma of the spermatic cord. Siddiqui MT, et al. **Br J Urol** 1997 Mar;79(3):475–6

Basal ganglionic angioleiomyoma. Ravikumar C, et al. **Clin Neurol Neurosurg** 1996 Aug;98(3):253–7

Aggressive angiomyxoma: reappraisal of its relationship to angiomyofibroblastoma in a series of 16 cases. Granter SR, et al. **Histopathology** 1997 Jan;30(1):3–10

Angiomyomatous hamartoma of a cervical lymph node combined with haemangiomatoids and vascular transformation of sinuses. Laeng RH, et al. **Histopathology** 1996 Jul;29(1):80–4

Angiomyofibroblastoma of the female genital tract: analysis of 17 cases including a lipomatous variant. Laskin WB, et al. **Hum Pathol** 1997 Sep;28(9):1046–55

Intravenous leiomyomatosis complicated by Budd–Chiari syndrome. Kuenen BC, et al. **Postgrad Med J** 1996 Nov; 72(853):686–8

SURGERY

Craniofacial resection for vascular leiomyoma of the nasal cavity. Nicolai P, et al. **Am J Otolaryngol** 1996 Sep–Oct; 17(5):340–4 (25 ref.)

Vascular leiomyoma of the superior turbinate: first reported case. Nall AV, et al. **Head Neck** 1997 Jan;19(1):63–7 (15 ref.)

Giant vascular leiomyoma in the hand. Kataoka M, et al. **Scand J Plast Reconstr Surg Hand Surg** 1997 Mar; 31(1):91–3

ANGIOMYXOMA see **MYXOMA**

ANGIONEUROTIC EDEMA

Acquired angioedema. Heymann WR. **J Am Acad Dermatol** 1997 Apr;36(4):611–5 (39 ref.)

Hereditary angioedema: case report and review of management. Karlis V, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Apr;83(4):462–4 (14 ref.)

BLOOD

Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin–converting enzyme inhibitor. Sigler C, et al. **Arch Dermatol** 1997 Aug;133(8):972–5

Activation of the coagulation cascade in C1–inhibitor deficiencies. Cugno M, et al. **Blood** 1997 May 1; 89(9):3213–8

Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1–inhibitor deficiencies. Cugno M, et al. **Immunopharmacology** 1996 Jun;33(1–3):361–4

CHEMICALLY INDUCED

Angioedema of ACE inhibitors. Ebo DG, et al. **Allergy** 1997 Mar;52(3):354–5

Angiotensin–converting enzyme inhibitor–induced angioedema: late onset, irregular course, and potential role of triggers. Schiller PI, et al. **Allergy** 1997 Apr;52(4):432–5

Angioedema following prilocaine [see comments] Ferguson S. **Anaesth Intensive Care** 1996 Jun;24(3):398–400. Comment in: Anaesth Intensive Care 1997 Feb;25(1):87–9.

Angioedema following prilocaine [letter; comment] Wildsmith JA. **Anaesth Intensive Care** 1997 Feb;25(1):87–9 . Comment on: Anaesth Intensive Care 1996 Jun;24(3):398–400.

Angioedema associated with angiotensin–converting enzyme inhibitors [letter] Eberhart G, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):80

Hair conditioner causes angioedema [letter] Stadtmauer G, et al. **Ann Allergy Asthma Immunol** 1997 Jun;78(6):602

Angioedema with oral N–acetylcysteine [letter] Mroz LS, et al. **Ann Emerg Med** 1997 Aug;30(2):240–1

Asymmetric angioneurotic edema associated with thrombolysis for acute stroke. Pancioli A, et al. **Ann Emerg Med** 1997 Aug;30(2):227–9

Epidemiological study of angioedema and ACE inhibitors. Gabb GM, et al. **Aust N Z J Med** 1996 Dec;26(6):777–82

Angioedema and acute asthma attack due to the unexpected occurrence of aspirin in an over–the–counter cold preparation [letter] Chan TY. **Br J Clin Pract** 1996 Oct–Nov;50(7):412–3

Angiotensin–converting enzyme (ACE) inhibitors and angio–oedema. Sabroe RA, et al. **Br J Dermatol** 1997 Feb; 136(2):153–8 (65 ref.)

Relevance of lymphoproliferative disorders and of anti–C1 inhibitor autoantibodies in acquired angio–oedema. Cicardi M, et al. **Clin Exp Immunol** 1996 Dec;106(3):475–80

Race and angioedema [letter; comment] Burkhart GA. **Clin Pharmacol Ther** 1997 Jun;61(6):700. Comment on: Clin Pharmacol Ther 1996 Jul;60(1):8–13.

Lisinopril–induced isolated visceral angioedema: review of ACE–inhibitor–induced small bowel angioedema. Abdelmalek MF, et al. **Dig Dis Sci** 1997 Apr;42(4):847–50 (15 ref.)

Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Pillans PI, et al. **Eur J Clin Pharmacol** 1996;51(2):123–6 (14 ref.)

Angioedema from oral polyethylene glycol electrolyte lavage solution [letter] Stollman N, et al. **Gastrointest Endosc** 1996 Aug;44(2):209–10

Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Agah R, et al. **Intensive Care Med** 1997 Jul;23(7):793–6

Angioedema after long–term use of an angiotensin–converting enzyme inhibitor. Pavletic AJ. **J Am Board Fam Pract** 1997 Sep–Oct;10(5):370–3

Paroxetine–induced angioedema and tongue swelling [letter] Mithani H, et al. **J Clin Psychiatry** 1996 Oct;57(10):486

Recurrent angiotensin–converting enzyme inhibitor—associated angioedema. Brown NJ, et al. **JAMA** 1997 Jul 16;278(3):232–3

A case report of angioedema during long–term (66 months) angiotensin converting enzyme inhibition therapy with enalapril. Shionoiri H, et al. **Jpn Circ J** 1996 Mar; 60(3):166–70

Anaphylactoid reaction, angioedema, and urticaria associated with lamivudine [letter] Kainer MA, et al. **Lancet** 1996 Nov 30;348(9040):1519

Visceral angioedema related to treatment with an ACE inhibitor. Mullins RJ, et al. **Med J Aust** 1996 Sep 16; 165(6):319–21

Angiodema of the intestine [letter] Gabb GM. **N Engl J Med** 1996 Nov 14;335(20):1534–5; discussion 1535

Angioedema of the intestine [letter] Marinella MA. **N Engl J Med** 1996 Nov 14;335(20):1535

Delayed onset of angioedema with angiotensin–converting enzyme inhibitors: case report and review of the literature. O'Mara NB, et al. **Pharmacotherapy** 1996 Jul–Aug; 16(4):675–9 (40 ref.)

Angioedema associated with angiotensin II receptor antagonist losartan. Sharma PK, et al. **South Med J** 1997 May;90(5):552–3

[Remarks on the work of C. Maier. The risk of postoperative angioedema following the use of ACE antagonists. Anesthesiet (1995) 44:875–879 (letter; comment)] Bircher AJ, et al. **Anaesthesist** 1996 Dec;45(12):1268–9. Comment on: Anaesthesist 1995 Dec;44(12):875–9. **(Ger)**

[Angioedema of the mucous membranes of the upper aerodigestive tract after administration of ACE inhibitors] Tisch M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):122–3 (Eng. Abstr.) **(Ger)**

[ACE–inhibitors and angioedema (letter; comment)] Dybendal T, et al. **Tidsskr Nor Laegeforen** 1996 Sep 30; 116(23):2817. Comment on: Tidsskr Nor Laegeforen 1996 Sep 20;116(22):2710. **(Nor)**

[ACE–inhibitors and angioedema (letter; comment)] Forslund T. **Tidsskr Nor Laegeforen** 1996 Sep 20; 116(22):2710. Comment on: Tidsskr Nor Laegeforen 1996 Sep 30;116(23):2817. **(Nor)**

[Angioedema and taking captopril (letter)] Râfola Crestani A, et al. **Aten Primaria** 1997 Mar 31;19(5):275–6 **(Spa)**

COMPLICATIONS

Successful pregnancy in a woman with cyclic angioedema and eosinophilia. Lorraine JK. **Ann Allergy Asthma Immunol** 1996 Dec;77(6):497–9

Association of hereditary angioedema and hereditary breast cancer. Christie DR, et al. **Cancer Genet Cytogenet** 1997 Jun;95(2):159–62

Late–onset life–threatening angioedema and upper airway obstruction caused by angiotensin–converting enzyme inhibitor: report of a case. Weng PK, et al. **Ear Nose Throat J** 1997 Jun;76(6):404–7

Cardiopulmonary by–pass in a patient with acquired C1 inhibitor deficiency. Castelli R, et al. **Int J Artif Organs** 1997 Mar;20(3):175–7

Hereditary angioedema with ascites [letter; comment] Laurent J, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):999. Comment on: J Allergy Clin Immunol 1995 Aug;96(2):259–61.

Hashimoto's thyroiditis associated with urticaria and angio–oedema: disappearance of cutaneous and mucosal manifestations after thyroidectomy. Amoroso A, et al. **J Clin Pathol** 1997 Mar;50(3):254–6

CONGENITAL

[Hereditary angioedema] Kohno Y. **Ryoikibetsu Shokogun Shirizu** 1996;(15):311–3 (17 ref.) **(Jpn)**

DIAGNOSIS

Type I hereditary angio–oedema. Variability of clinical presentation and course within two large kindreds. Winnewisser J, et al. **J Intern Med** 1997 Jan;241(1):39–46

Recurrent "unexplained" scalp swelling in an eighteen–month–old child: an atypical presentation of angioedema causing confusion with child abuse. Thakur BK, et al. **J Pediatr** 1996 Jul;129(1):163–5

Angioedema of the intestine [letter] Pavletic A. **N Engl J Med** 1996 Nov 14;335(20):1534; discussion 1535

[Deficiencies of C1 inhibitor: hereditary and acquired angioedema] Porcel–Pérez JM, et al. **Rev Clin Esp** 1996 Mar;196 Spec No:26–30 (30 ref.) **(Spa)**

DRUG THERAPY

Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin–converting enzyme inhibitor. Sigler C, et al. **Arch Dermatol** 1997 Aug;133(8):972–5

Acyclovir therapy for angioedema and chronic urticaria. Shelley WB, et al. **Cutis** 1997 Apr;59(4):185–8

Side effects of long–term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. Cicardi M, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):194–6

Interferon alpha 2a therapy for urticarial vasculitis with angioedema apparently following hepatitis A infection. Matteson EL. **J Rheumatol** 1996 Feb;23(2):382–4

EPIDEMIOLOGY

Epidemiological study of angioedema and ACE inhibitors. Gabb GM, et al. **Aust N Z J Med** 1996 Dec;26(6):777–82

ETHNOLOGY

Race and angioedema [letter; comment] Burkhart GA. **Clin Pharmacol Ther** 1997 Jun;61(6):700. Comment on: Clin Pharmacol Ther 1996 Jul;60(1):8–13.

ETIOLOGY

Sensitization to Anisakis simplex: an unusual presentation. Estrada Rodríguez JL, et al. **Allergol Immunopathol (Madr)** 1997 Mar–Apr;25(2):95–7

Anisakis simplex, a relevant etiologic factor in acute urticaria. Del Pozo MD, et al. **Allergy** 1997 May;52(5):576–9

Systemic contact dermatitis to copper–containing IUD. Purello D'Ambrosio F, et al. **Allergy** 1996 Sep;51(9):658–9

Angioneurotic edema as a reaction to angiotensin–converting enzyme inhibitors. Gunkel AR, et al. **Am J Otolaryngol** 1996 Mar–Apr;17(2):87–91

Acquired C 1–inhibitor deficiency with angioedema due to pleomorphic immunocytoma in a patient with three malignant tumors: long–term follow–up data and presentation of an additional case. Bohle W, et al. **Ann Hematol** 1996 Jun;72(6):383–6

Late–onset life–threatening angioedema and upper airway obstruction caused by angiotensin–converting enzyme inhibitor: report of a case. Weng PK, et al. **Ear Nose Throat J** 1997 Jun;76(6):404–7

The association of chronic urticaria and angioedema with autoimmune thyroiditis. Turktas I, et al. **Int J Dermatol** 1997 Mar;36(3):187–90

Anaphylaxis to ackee fruit. Lebo DB, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):997–8

Exercise–induced urticaria and angioedema: reports of two cases. Kato T, et al. **J Dermatol** 1997 Mar;24(3):189–92

Autoantibodies to C1 inhibitor in patients with lupus disease [letter] Ordi–Ros J, et al. **J Rheumatol** 1997 Sep; 24(9):1856–8

[Angioedema caused by splenectomy with malignant lymphoma followed by multiple myeloma 7 years later]

Shahar A, et al. **Harefuah** 1997 May 1;132(9):624–6, 679 (Eng. Abstr.) **(Heb)**

GENETICS

Association of Sjögren's syndrome with hereditary angioneurotic edema: report of a case. Suzuki Y, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):95–7

Type I hereditary angio–oedema. Variability of clinical presentation and course within two large kindreds. Winnewisser J, et al. **J Intern Med** 1997 Jan;241(1):39–46

Fresh frozen plasma prophylaxis for hereditary angioedema during pregnancy. A case report. Galan HL, et al. **J Reprod Med** 1996 Jul;41(7):541–4

Molecular defects in hereditary angioneurotic edema. Bissler JJ, et al. **Proc Assoc Am Physicians** 1997 Mar;109(2):164–73

[Deficiencies of C1 inhibitor: hereditary and acquired angioedema] Porcel–Pérez JM, et al. **Rev Clin Esp** 1996 Mar;196 Spec No:26–30 (30 ref.) **(Spa)**

IMMUNOLOGY

Absence of CD69 expression on peripheral eosinophils in episodic angioedema and eosinophilia. Kawano M, et al. **Am J Hematol** 1996 Sep;53(1):43–5

Association of Sjögren's syndrome with hereditary angioneurotic edema: report of a case. Suzuki Y, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):95–7

Antibody to C1–inhibitor in a patient receiving C1–inhibitor infusions for treatment of hereditary angioneurotic edema with systemic lupus erythematosus reacts with a normal allotype of residue 458 of C1–inhibitor. Donaldson VH, et al. **J Lab Clin Med** 1996 Oct;128(4):438–43

PHYSIOPATHOLOGY

Angioneurotic edema as a reaction to angiotensin–converting enzyme inhibitors. Gunkel AR, et al. **Am J Otolaryngol** 1996 Mar–Apr;17(2):87–91

Activation of the complement, coagulation, fibrinolytic and kallikrein–kinin systems during attacks of hereditary angioedema. Nielsen EW, et al. **Immunopharmacology** 1996 Jun;33(1–3):359–60

Immunological and genetic studies on hereditary angioedema. Madaliński K, et al. **Rocz Akad Med Bialymst** 1995;40(3):634–41

PREVENTION & CONTROL

Side effects of long–term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. Cicardi M, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):194–6

Fresh frozen plasma prophylaxis for hereditary angioedema during pregnancy. A case report. Galan HL, et al. **J Reprod Med** 1996 Jul;41(7):541–4

RADIOGRAPHY

Angioedema of the intestine [letter] Smith DC. **N Engl J Med** 1996 Nov 14;335(20):1535

THERAPY

Angioneurotic edema. Gaboriau HP, et al. **J La State Med Soc** 1997 Feb;149(2):50–2 (16 ref.)

[Hereditary angioneurotic edema in gynecology–obstetrics. Management] Khalife H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(6):559–67 (29 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Human parvovirus infection: rheumatic manifestations, angioedema, C1 esterase inhibitor deficiency, ANA positivity, and possible onset of systemic lupus erythematosus. Fawaz–Estrup F. **J Rheumatol** 1996 Jul; 23(7):1180–5

ANGIOPLASTY

see related

ENDARTERECTOMY

Serial angiographic follow–up after successful direct angioplasty for acute myocardial infarction. Nakagawa Y, et al. **Am J Cardiol** 1996 Nov 1;78(9):980–4

Coronary angiography and angioplasty after acute myocardial infarction. Bates DW, et al. **Ann Intern Med** 1997 Apr 1;126(7):539–50 (121 ref.)

Angioplasty for carotid disease. No. Ferguson GG. **Arch Neurol** 1996 Jul;53(7):698–700 (25 ref.)

Carotid angioplasty. In search of a worthy alternative to endarterectomy. Ferguson RD, et al. **Arch Neurol** 1996 Jul;53(7):696–8 (39 ref.)

Carotid angioplasty. Hachinski V. **Arch Neurol** 1996 Jul; 53(7):700–1

Platelet surface activation antigen expression at baseline and during elective angioplasty in patients with mild to moderate coronary artery disease. Cahill MR, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):165–8

Immediate sealing of arterial puncture site following femoropopliteal angioplasty: a prospective randomized trial. Beyer–Enke SA, et al. **Cardiovasc Intervent Radiol** 1996 Nov–Dec;19(6):406–10

Experimental evaluation of bleeding complications, thrombogenicity and neointimal characteristics of prosthetic patch materials used for carotid angioplasty. Rhee RY, et al. **Cardiovasc Surg** 1996 Dec;4(6):746–52

Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Wei GL, et al. **Circ Res** 1997 Mar;80(3):418–26

Problem of angioplasty in diabetics [editorial; comment] Ellis SG, et al. **Circulation** 1997 Sep 16;96(6):1707–10. Comment on: Circulation 1997 Sep 16;96(6):1761–9.

Can a viral serine proteinase inhibitor prevent postangioplasty restenosis? [editorial; comment] Haber E. **Circulation** 1996 Dec 1;94(11):2694–5. Comment on: Circulation 1996 Dec 1;94(11):2890–900.

Plaque sealing or plumbing for coronary artery stenoses? [letter] Meier B. **Circulation** 1997 Sep 16;96(6):2094–5

Subcutaneous infusion of r–hirudin does not inhibit neointimal proliferation after angioplasty of the subclavian artery in cholesterol–fed rabbits. Hadoke PW, et al. **Coron Artery Dis** 1996 Aug;7(8):599–608

Endovascular treatment for acute and chronic brain ischemia. Clark WM, et al. **Curr Opin Neurol** 1996 Feb;9(1):62–7 (48 ref.)

Coronary angioplasty of rapidly progressive lesions—nothing to it or just too rare to be recognized as a problem? [editorial; comment] Meier B. **Eur Heart J** 1996 Nov; 17(11):1612–3. Comment on: Eur Heart J 1996 Nov;17(11):1671–7.

Surgical angioplasty of the left main coronary artery. Dion R, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):857–64

Non–invasive assessment of arterial stenoses in angioplasty surveillance: a comparison with angiography. Nyamekye I, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):471–81

How epicardial U–wave changes are reflected in body surface precordial electrocardiograms in anterior or inferoposterior myocardial ischaemia during coronary angioplasty. Kataoka H, et al. **Heart** 1996 Nov; 76(5):397–405

Measurement of pressure and assessment of cavitation for a 22.5–kHz intra–arterial angioplasty device. Makin IR, et al. **J Acoust Soc Am** 1996 Sep;100(3):1855–64

Noninvasive method for measuring thrombus formation in patients after peripheral angioplasty using three–dimensional B–mode and color–coded Doppler ultrasonography. Eisert WG, et al. **J Clin Pharmacol** 1997 Jan;37(1 Suppl):79S–83S

Progressive renal dysfunction despite successful renal artery angioplasty in a single kidney [letter] Mikhail A, et al. **Lancet** 1997 Mar 29;349(9056):926

Repair of abdominal aortic aneurysms by the endoluminal method: outcome in the first 100 patients. May J, et al. **Med J Aust** 1996 Nov 18;165(10):549–51

Isolated tibial vessel disease: treatment options and outcome. Wilson YG, et al. **Panminerva Med** 1996 Jun;38(2):71–7

Simultaneous endoluminal dilatation and conventional surgery. Importance of programmed revascularization of the legs] Mellière D, et al. **J Mal Vasc** 1997 Jul;22(3):173–9; discussion 179–80 (Eng. Abstr.) **(Fre)**

[Endovascular closure of a foramen ovale after a right pneumonectomy] Bombaron P, et al. **Rev Mal Respir** 1997 Apr;14(2):133–5 (Eng. Abstr.) **(Fre)**

[Surgical treatment for tetralogy of Fallot with pulmonary atresia right ventricular outflow tract reconstruction with autologous pulmonary tissue and concomitant extensive pulmonary angioplasty] Matsuo K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct;44(10):1853–9 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Coronary occlusion post angioplasty associated with vasovagal reaction [letter] Ilia R. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):336

Thrombosis and restenosis after peripheral angioplasty: does acute 111indium–platelet accumulation predict angioplasty outcome? Nyamekye I, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):388–93

Ultrasound–based quantification of emboli during conventional and endovascular aneurysm repair. Thompson MM, et al. **J Endovasc Surg** 1997 Feb;4(1):33–8

[Coronary endoprosthesis (stents) implanted without coumadin administration: one year's experience] Pérez de Prado A, et al. **Rev Esp Cardiol** 1996 Jun;49(6):439–43 (Eng. Abstr.) **(Spa)**

ECONOMICS

Cost–effectiveness analysis of stents, balloon angioplasty, and surgery for the treatment of branch pulmonary artery stenosis. Trant CA Jr, et al. **Pediatr Cardiol** 1997 Sep–Oct; 18(5):339–44

HISTORY

Endoluminal treatment of arterial diseases using a stent–graft combination: reflections 20 years after the initial concept. Parodi JC. **J Endovasc Surg** 1997 Feb;4(1):3–4

INSTRUMENTATION

Remounted half–stents [letter; comment] Kern MJ, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):335. Comment on: Cathet Cardiovasc Diagn 1996 Sep;39(1):17–20.

European experience with a system for bifurcated stent–graft insertion. Chuter TA, et al. **J Endovasc Surg** 1997 Feb; 4(1):13–22

Inflammatory aneurysm treated by means of transfemoral endovascular graft insertion. Chuter T, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):39–41

Vascular stent prototype: in vivo swine studies. Fontaine AB, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):107–11

Repositioning of a malaligned aortic stent–graft [letter] Maclennan AC, et al. **J Vasc Interv Radiol** 1997 Jan–Feb; 8(1 Pt 1):151–2

Aortoesophageal fistula: repair with transluminal placement of a thoracic aortic stent–graft. Oliva VL, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):35–8

General principles for evaluation of new interventional technologies and devices. Technology Assessment Committee. Sacks D, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):133–6 (21 ref.)

METHODS

Minor amputations on the feet after revascularization for gangrene. A consecutive series of 95 limbs. Albrektsen SB, et al. **Acta Orthop Scand** 1997 Jun;68(3):291–3

Balloon versus patch angioplasty as an adjuvant treatment to surgical thrombectomy of hemodialysis grafts. Bitar G, et al. **Am J Surg** 1997 Aug;174(2):140–2

Endovascular aneurysm repair [editorial] Thompson MM, et al. **BMJ** 1997 Apr 19;314(7088):1139–40

Intracoronary stents [editorial] Uren NG, et al. **BMJ** 1996 Oct 12;313(7062):892–3

Recanalization of iliac artery occlusion by subintimal dissection using the ipsilateral and the contralateral approach. Bolia A, et al. **Clin Radiol** 1997 Sep;52(9):684–7

Patch angioplasty following carotid endarterectomy using the ipsilateral superior thyroid artery. Jenkins MP, et al. **Eur J Vasc Endovasc Surg** 1997 Jul;14(1):60–2

Increase in the lumen of the femoral artery in dogs with an arteriotomy encircled by glutaraldehyde–tanned calf pericardium. Sotelo J, et al. **Heart Vessels** 1996; 11(6):318–21

Regional anesthesia for endovascular treatment of abdominal aortic aneurysms. Aadahl P, et al. **J Endovasc Surg** 1997 Feb;4(1):56–61

Improved respiratory function and analgesia control after endovascular AAA repair. Boyle JR, et al. **J Endovasc Surg** 1997 Feb;4(1):62–5

A primer on common technical problems in endovascular surgery: know them to avoid them. Criado FJ, et al. **J Endovasc Surg** 1997 Feb;4(1):95–9 (6 ref.)

Will contrast aortography become obsolete in the preoperative evaluation of abdominal aortic aneurysm for endovascular exclusion? [editorial; comment] Diethrich EB. **J Endovasc Surg** 1997 Feb;4(1):5–12 (10 ref.). Comment on: J Endovasc Surg 1997 Feb;4(1):39–44.

The need for clinical trials of endovascular abdominal aortic aneurysm stent–graft repair: The EUROSTAR Project. EUROpean collaborators on Stent–graft Techniques for abdominal aortic Aneurysm Repair. Harris PL, et al. **J Endovasc Surg** 1997 Feb;4(1):72–7; discussion 78–9 (15 ref.)

Successful endoluminal repair of arterial aneurysms by Wallstent prosthesis and PTFE graft: preliminary results with a new technique. Krajcer Z, et al. **J Endovasc Surg** 1997 Feb;4(1):80–7

Changing aneurysmal morphology after endovascular grafting: relation to leakage or persistent perfusion [see comments] Malina M, et al. **J Endovasc Surg** 1997 Feb; 4(1):23–30. Comment in: J Endovasc Surg 1997 Feb;4(1):31–2.

Morphometry and classification in abdominal aortic aneurysms: patient selection for endovascular and open surgery [see comments] Schumacher H, et al. **J Endovasc Surg** 1997 Feb;4(1):39–44. Comment in: J Endovasc Surg 1997 Feb;4(1):5–12.

Intravascular ultrasound guidance for peripheral vascular interventions. Scoccianti M, et al. **J Endovasc Surg** 1994 Sep;1:71–80 (43 ref.)

Intravascular ultrasound: the ultimate tool for abdominal aortic aneurysm assessment and endovascular graft delivery. White RA, et al. **J Endovasc Surg** 1997 Feb; 4(1):45–55 (12 ref.)

Endoluminal graft exclusion of a proximal para–anastomotic pseudoaneurysm following aortobifemoral bypass. White RA, et al. **J Endovasc Surg** 1997 Feb;4(1):88–94

Transaortic patch angioplasty for left main coronary artery occlusion. Kao CL, et al. **J Formos Med Assoc** 1997 May; 96(5):379–81

Endovascular management of vertebral arteriovenous fistulas: the Toronto experience. Waitzman AA, et al. **J Otolaryngol** 1996 Oct;25(5):322–8

Superior approach to the left main coronary artery for surgical angioplasty. Eishi K, et al. **J Thorac Cardiovasc Surg** 1997 Mar;113(3):609–11

Lay–open pulmonary arterioplasty for postoperative hilar pulmonary artery stenosis. Kaneko Y, et al. **J Thorac Cardiovasc Surg** 1997 Sep;114(3):406–11; discussion 411–2

Percutaneous transvenous angioplasty of a stenosed bicaval anastomosis after orthotopic cardiac transplantation. Pedrazzini GB, et al. **J Thorac Cardiovasc Surg** 1996 Dec; 112(6):1667–9

Stent–graft repair of aorto–iliac occlusive disease coexisting with common femoral artery disease. Cynamon J, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):19–26

Aortic stents covering the renal arteries ostia: an animal

study. Desgranges P, et al. **J Vasc Interv Radiol** 1997 Jan-Feb;8(1 Pt 1):77-82

A program of operative angioplasty: endovascular intervention and the vascular surgeon. Silva MB Jr, et al. **J Vasc Surg** 1996 Dec;24(6):963-71; discussion 971-3

REHABILITATION

Cardiac rehabilitation: not just exercise anymore. Pashkow FJ. **Cleve Clin J Med** 1996 Mar-Apr;63(2):116-23 (28 ref.)

STANDARDS

Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. Technology Assessment Committee. Sacks D, et al. **J Vasc Interv Radiol** 1997 Jan-Feb;8(1 Pt 1):137-49 (77 ref.)

STATISTICS & NUMERICAL DATA

Delayed improvement in carotid artery diameter after carotid angioplasty. Crawley F, et al. **Stroke** 1997 Mar;28(3):574-9

ANGIOPLASTY, BALLOON

Biomechanical effects of experimental transluminal angioplasty. Keris V, et al. **Acta Neurochir (Wien)** 1996; 138(6):752-8

The effect of endovascular therapy for cerebral arterial spasm, its limitation and pitfalls. Terada T, et al. **Acta Neurochir (Wien)** 1997;139(3):227-34

Proliferative response in smooth muscle cells after angioplasty or insertion of self-expanding stents. An experimental study in pigs. Cwikiel W, et al. **Acta Radiol** 1997 Jan;38(1):124-8

Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor. Wallace RC, et al. **AJNR Am J Neuroradiol** 1997 Aug;18(7):1257-60

Treatment of renal angioplasty failure by percutaneous renal artery stenting with Palmaz stents: midterm technical and clinical results. Boisclair C, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):245-51

MR angiography of patients with peripheral arterial disease before and after transluminal angioplasty. Davis CP, et al. **AJR Am J Roentgenol** 1997 Apr;168(4):1027-34

Angioplasty treatment of portal vein stenosis in children with segmental liver transplants: mid-term results. Funaki B, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):551-4

A simple method to avoid vertebral artery embolism during subclavian percutaneous transluminal angioplasty: provocative maneuver [letter] Memis A, et al. **AJR Am J Roentgenol** 1997 Feb;168(2):569-70

Suprahepatic caval anastomotic stenosis complicating orthotopic liver transplantation: treatment with percutaneous transluminal angioplasty, Wallstent placement, or both. Pfammatter T, et al. **AJR Am J Roentgenol** 1997 Feb;168(2):477-80

After peripheral angioplasty should we prescribe both aspirin and Persantin (dipyridamole), or one of them, and how much? Regan JD. **AJR Am J Roentgenol** 1997 Mar; 168(3):839-40

Renal artery stenosis complicated by hypertensive heart disease in a young child: successful therapy by balloon angioplasty. Liang CD, et al. **Am Heart J** 1996 Nov; 132(5):1077-9

Excimer laser angioplasty versus balloon angioplasty in functional and total coronary occlusions [see comments] Appelman YE, et al. **Am J Cardiol** 1996 Oct 1;78(7):757-62 . Comment in: Am J Cardiol 1996 Oct 1:78(7):823-4.

Percutaneous transluminal angioplasty of the left subclavian artery to prevent or treat the coronary-subclavian steal syndrome. Marques KM, et al. **Am J Cardiol** 1996 Sep 15; 78(6):687-90

Comparison of results of intracoronary implantation of the Plamaz-Schatz stent with conventional balloon angioplasty in chronic total coronary arterial occlusion. Mori M, et al. **Am J Cardiol** 1996 Nov 1;78(9):985-9

Predictors of long-term event-free survival after percutaneous balloon mitral valvuloplasty. Pavlides GS, et al. **Am J Cardiol** 1997 May 15;79(10):1370-4

Balloon angioplasty by vascular surgeons. Madera FA, et al. **Am J Surg** 1997 Aug;174(2):152-6

Replicas of human aortic and iliac artery aneurysms for endovascular repair. Practice makes perfect. Wisselink W, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:258-9

Stent angioplasty for renovascular disease associated with acute aortic dissection. Hata M, et al. **Ann Thorac Surg** 1997 Jan;63(1):244-6

A comparison of angioplasty with stenting versus endarterectomy for the treatment of carotid artery stenosis. Jordan WD Jr, et al. **Ann Vasc Surg** 1997 Jan;11(1):2-8

Directional atherectomy and balloon angioplasty for lower extremity arterial disease. Osborn JJ, et al. **Ann Vasc Surg** 1997 May;11(3):278-83

Balloon angioplasty and stent placement during operative vascular reconstruction for lower extremity ischemia. Schneider PA. **Ann Vasc Surg** 1996 Nov;10(6):589-98

Cerebral angioplasty in a patient with vascular dementia. Maeshima S, et al. **Arch Phys Med Rehabil** 1997 Jun; 78(6):666-9

Local irrigation with tissue factor pathway inhibitor inhibits intimal hyperplasia induced by arterial interventions. Brown DM, et al. **Arch Surg** 1996 Oct;131(10):1086-90

Proliferative response of human and minipig smooth muscle cells after coronary angioplasty to growth factors and platelets. Unterberg C, et al. **Basic Res Cardiol** 1996 Nov-Dec;91(6):407-17

cDNA cloning of human allograft inflammatory factor-1: tissue distribution, cytokine induction, and mRNA expression in injured rat carotid arteries. Autieri MV. **Biochem Biophys Res Commun** 1996 Nov 1;228(1):29-37

Blood flow in the lower limb after balloon angioplasty of the superficial femoral artery [letter] Dodds SR. **Br J Surg** 1996 Nov;83(11):1657-8

Percutaneous transluminal angioplasty of the internal carotid artery [see comments] McGuinness CL, et al. **Br J Surg** 1996 Sep;83(9):1171-3 (10 ref.). Comment in: Br J Surg 1997 May;84(5):726. Comment in: Br J Surg 1997 May;84(5):729-30.

What can angiotensin antagonists do that converting-enzyme inhibition can't: the case of post-angioplastic restenosis. Pham D, et al. **Can J Physiol Pharmacol** 1996 Jul; 74(7):867-77

Attenuation of stunning by the calcium antagonist nisoldipine in patients with myocardial infarction and early percutaneous transluminal coronary angioplasty [comment] Heusch G. **Cardiovasc Drugs Ther** 1997 Mar;11(1):19-20. Comment on: Cardiovasc Drugs Ther 1997 Mar;11(1):5-16.

Clinical evidence that nisoldipine attenuates stunning in patients post infarction [comment] Kloner RA, et al. **Cardiovasc Drugs Ther** 1997 Mar;11(1):17-8. Comment on: Cardiovasc Drugs Ther 1997 Mar;11(1):5-16.

Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine [see comments] Sheiban I, et al. **Cardiovasc Drugs Ther** 1997 Mar;11(1):5-16 . Comment in: Cardiovasc Drugs Ther 1997 Mar;11(1):17-8. Comment in: Cardiovasc Drugs Ther 1997 Mar;11(1):19-20.

Contralateral loop snare removal of a ruptured and entrapped angioplasty balloon. Braun MA, et al. **Cardiovasc Intervent Radiol** 1996 Nov-Dec;19(6):428-30

The use of color-coded duplex scanning in the selection of patients with lower extremity arterial disease for percutaneous transluminal angioplasty: a prospective study. Elsman BH, et al. **Cardiovasc Intervent Radiol** 1996 Sep-Oct;19(5):313-6

The use of below-knee percutaneous transluminal angioplasty in arterial occlusive disease causing chronic critical limb ischemia. Löfberg AM, et al. **Cardiovasc Intervent Radiol** 1996 Sep-Oct;19(5):317-22

Percutaneous transluminal angioplasty for carotid artery stenosis in Takayasu arteritis: persistent benefit over 10 years. Murakami R, et al. **Cardiovasc Intervent Radiol** 1997 May-Jun;20(3):219-21

The predictive value of angiographic results for the outcome of percutaneous transluminal angioplasty in stenosed femoral bypass grafts. Spijkerboer AM, et al. **Cardiovasc Intervent Radiol** 1997 Mar-Apr;20(2):98-102

Intraarterial pressure gradients after randomized angioplasty or stenting of iliac artery lesions. Dutch Iliac Stent Trial Study Group. Tetteroo E, et al. **Cardiovasc Intervent Radiol** 1996 Nov-Dec;19(6):411-7

Intraaortic balloon pump insertion after percutaneous revascularization in patients with severe peripheral vascular disease [see comments] Colyer WR Jr, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):1-6. Comment in: Cathet Cardiovasc Diagn 1997 Sep;42(1):7.

"The stage has shifted!" [editorial; comment] Cumpston N. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):240. Comment on: Cathet Cardiovasc Diagn 1997 Mar;40(3):235-9.

Use of coronary Palmaz-Schatz stent in the percutaneous treatment of an intracranial carotid artery stenosis. Feldman RL, et al. **Cathet Cardiovasc Diagn** 1996 Jul;38(3):316-9

Treatment of coronary artery disease in an anomalous coronary artery by placement of an intracoronary stent. Lawton J, et al. **Cathet Cardiovasc Diagn** 1997 Jun; 41(2):185-8

Stent redilation in canine models of congenital heart disease: pulmonary artery stenosis and coarctation of the aorta. Mendelsohn AM, et al. **Cathet Cardiovasc Diagn** 1996 Aug; 38(4):430-40

Reduced distal embolization with transluminal extraction atherectomy compared to balloon angioplasty for saphenous vein graft disease. Misumi K, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):246-51

One balloon, one stent: an effective cost-containment strategy for elective stent deployment. Rocha-Singh KJ, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):17-20

Rupture of the arterial wall causes deflection in pressure time course during ex vivo balloon angioplasty. Steenhuijsen JL, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):92-101

Vascular turf wars: getting a leg up on iliac artery disease during intraaortic balloon pumping [editorial; comment] Turi ZG. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):7. Comment on: Cathet Cardiovasc Diagn 1997 Sep;42(1):1-6.

Retrospective comparative study of primary intracoronary stenting versus balloon angioplasty for acute myocardial infarction [see comments] Turi ZG, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):235-9. Comment in: Cathet Cardiovasc Diagn 1997 Mar;40(3):240.

Late death from aneurysm rupture following balloon angioplasty for branch pulmonary artery stenosis. Zeevi B, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):284-6

The efficacy of percutaneous transluminal angioplasty in the treatment of failing vascular access in chronic hemodialysis patients. Lio JY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Nov; 58(5):335-40

Arterial thrombin activity after angioplasty in an atherosclerotic rabbit model: time course and effect of hirudin. Barry WL, et al. **Circulation** 1996 Jul 1;94(1):88-93

The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty [see comments] Belch JJ, et al. **Circulation** 1997 Apr 15; 95(8):2027-31. Comment in: Circulation 1997 Apr 15;95(8):1986-8.

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Berkowitz SD, et al. **Circulation** 1997 Feb 18;95(4):809-13

Electron microscopic studies of phenotypic modulation of smooth muscle cells in coronary arteries of patients with unstable angina pectoris and postangioplasty restenosis. Chen YH, et al. **Circulation** 1997 Mar 4;95(5):1169-75

Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model. Coats WD Jr, et al. **Circulation** 1997 Mar 4;95(5):1293-300

Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial [see comments] Kastrati A, et al. **Circulation** 1997 Jul 15; 96(2):462-7. Comment in: Circulation 1997 Jul 15;96(2):383-5.

Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Kimura T, et al. **Circulation** 1997 Jul 15;96(2):475-83

Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty [see comments] Lucas A, et al. **Circulation** 1996 Dec 1;94(11):2890-900. Comment in: Circulation 1996 Dec 1;94(11):2694-5.

Late regression of the dilated site after coronary angioplasty: a 5-year quantitative angiographic study. Ormiston JA, et al. **Circulation** 1997 Jul 15;96(2):468-74

Comparison of coronary luminal quantification obtained from intracoronary ultrasound and both geometric and videodensitometric quantitative angiography before and after balloon angioplasty and directional atherectomy. Ozaki Y, et al. **Circulation** 1997 Jul 15;96(2):491-9

Arterial remodeling after balloon angioplasty or stenting in an atherosclerotic experimental model. Post MJ, et al. **Circulation** 1997 Aug 5;96(3):996-1003

Predictors of outcome of balloon angioplasty of native aortic coarctation [letter; comment] Rao PS, et al. **Circulation** 1997 Aug 5;96(3):1057-9. Comment on: Circulation 1996 Sep 1;94(5):1056-62.

Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Steg PG, et al. **Circulation** 1997 Jul 15;96(2):408-11

Transballoon intravascular ultrasound imaging during balloon angioplasty in animal models with coarctation and branch pulmonary stenosis. Stock JH, et al. **Circulation** 1997 May 20;95(10):2354-7

Beta-radiation to reduce restenosis. Too little, too soon? [editorial; comment] Teirstein P. **Circulation** 1997 Mar 4; 95(5):1095-7 (22 ref.). Comment on: Circulation 1997 Mar 4;95(5):1138-44.

Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery. Weintraub WS, et al. **Circulation** 1997 Feb 18;95(4):868-77

Anatomic variant of the posterior interventricular coronary artery: implications for coronary angioplasty in acute myocardial infarction. Topaz O, et al. **Clin Anat** 1997; 10(5):303-6

Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic implications. Schneider DJ, et al. **Clin Cardiol** 1997 May;20(5):433-40 (90 ref.)

Radionuclide inferior venocavagraphy in Budd-Chiari syndrome before and after angioplasty. Kao PF, et al. **Clin Nucl Med** 1997 Jul;22(7):485-7

Renal artery stent placement in renal artery stenosis: technical and early clinical results. Taylor A, et al. **Clin Radiol** 1997 Jun;52(6):451-7

A four-year audit of interventional treatment for atheromatous renal artery stenosis. Donohoe P, et al. **Contrib Nephrol** 1996;119:78-82

Late improvement of renal function in patients treated by percutaneous transluminal renal angioplasty. Zuccalà A, et al. **Contrib Nephrol** 1996;119:74-7

Role of leukocytes in neointimal formation after balloon angioplasty in the rabbit atherosclerotic model. Guzman LA, et al. **Coron Artery Dis** 1995 Sep;6(9):693-701

New interventions in cerebrovascular disease: the role of thrombolytic therapy and balloon angioplasty. Balousek PA, et al. **Curr Opin Cardiol** 1996 Sep;11(5):550-7 (67 ref.)

Feasibility and effectiveness of peripheral percutaneous transluminal balloon angioplasty in diabetic subjects with foot ulcers. Faglia E, et al. **Diabetes Care** 1996 Nov; 19(11):1261-4

Excimer laser vs balloon angioplasty: (AMRO study)--what is the relevance? [editorial] Margolis JR. **Eur Heart J** 1996 Jun;17(6):807-8

Asymptomatic carotid stenosis in patients undergoing major cardiac surgery: can percutaneous carotid angioplasty be

an alternative? [see comments] Babatasi G, et al. **Eur J Cardiothorac Surg** 1997 Mar;11(3):547–53. Comment in: Eur J Cardiothorac Surg 1997 Mar;11(3):554–6.

Carotid angioplasty before aorta coronary bypass. Prospect for a new randomised study? [editorial; comment] Vermeulen FE. **Eur J Cardiothorac Surg** 1997 Mar; 11(3):554–6. Comment on: Eur J Cardiothorac Surg 1997 Mar;11(3):547–53.

Balloon angioplasty and induction of non–endothelial nitric oxide synthase in rabbit carotid arteries. Bosmans JM, et al. **Eur J Pharmacol** 1996 Aug 29;310(2–3):163–74

The nature and importance of changes in toe–brachial pressure indices following percutaneous transluminal angioplasty for leg ischaemia. Ray SA, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):125–33

The relationship between the delayed improvement in ankle–brachial pressure index and changes in limb volume following balloon angioplasty for leg ischaemia. Ray SA, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):114–7

Evaluation of femoropopliteal arteries with duplex ultrasound after angioplasty. Can we predict results at one year? Spijkerboer AM, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):418–23

Quality of life following percutaneous transluminal angioplasty for claudication [letter; comment] Tisi PV, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):509–10. Comment on: Eur J Vasc Endovasc Surg 1995 Oct;10(3):356–61.

Septal coronary artery ablation for hypertrophic obstructive cardiomyopathy. Bahl VK, et al. **Indian Heart J** 1996 Nov–Dec;48(6):701–3

Follow–up results of balloon angioplasty for native coarctation of aorta. Biswas PK, et al. **Indian Heart J** 1996 Nov–Dec;48(6):673–6

A decade of subclavian angioplasty: aortoarteritis versus atherosclerosis. Tyagi S, et al. **Indian Heart J** 1996 Nov–Dec;48(6):667–71

Stent angioplasty for relief of chronic mesenteric ischemia in Takayasu arteritis. Tyagi S, et al. **Indian Heart J** 1997 May–Jun;49(3):315–8

Iliac transluminal angioplasty and distal surgical revascularisation can be performed in a one–step technique. Alimi Y, et al. **Int Angiol** 1997 Jun;16(2):83–7

The effects of platelet inhibitors on platelet uptake and restenosis after femoral angioplasty. Horrocks M, et al. **Int Angiol** 1997 Jun;16(2):101–6

Anticardiolipin antibodies are not associated with restenosis or endothelial activation after percutaneous transluminal angioplasty. Tsakiris DA, et al. **Int Angiol** 1997 Jun; 16(2):88–93

192IR endovascular brachytherapy for avoidance of intimal hyperplasia after percutaneous transluminal angioplasty and stent implantation in peripheral vessels: 6 years of experience. Schopohl B, et al. **Int J Radiat Oncol Biol Phys** 1996 Nov 1;36(4):835–40

The role of hyaluronan and its receptors in restenosis after balloon angioplasty: development of a potential therapy. Savani RC, et al. **Int J Tissue React** 1995;17(4):141–51 (53 ref.)

Angioplasty treatment for peripheral vascular disease. Iannone L, et al. **Iowa Med** 1996 Sep;86(7):281–3

Renal revascularisation by gastroduodenal–renal bypass as treatment of renal artery stenosis. Little DM, et al. **Ir Med J** 1997 Jan–Feb;90(1):23–4

Infrapopliteal transcatheter interventions for limb salvage in diabetic patients: importance of aggressive interventional approach and role of transcutaneous oximetry. Hanna GP, et al. **J Am Coll Cardiol** 1997 Sep;30(3):664–9

Acute results of balloon angioplasty of native coarctation versus recurrent aortic obstruction are equivalent. Valvuloplasty and Angioplasty of Congenital Anomalies (VACA) Registry Investigators. McCrindle BW, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1810–7

Successful treatment by percutaneous balloon angioplasty of Budd–Chiari syndrome caused by membranous obstruction of inferior vena cava: 8–year follow–up study. Yang XL, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1720–4

Balloon angioplasty of recurrent coarctation: a 12–year review. Yetman AT, et al. **J Am Coll Cardiol** 1997 Sep; 30(3):811–6

Radiological case of the month. Bilateral iliac artery atherosclerosis treated with balloon angioplasty and stent placement. Christy GW, et al. **J Ark Med Soc** 1997 Mar; 93(10):499–501

Strategies for effective patient education material design. Hussey LC. **J Cardiovasc Nurs** 1997 Jan;11(2):37–46

Local anesthesia in carotid angioplasty. Alessandri C, et al. **J Endovasc Surg** 1996 Feb;3(1):31–4

Iliac and femoropopliteal lesions: evaluation of balloon angioplasty and classical surgery. Becquemin JP, et al. **J Endovasc Surg** 1995 Feb;2(1):42–50

Carotid angioplasty: is it safe? [see comments] Becquemin JP, et al. **J Endovasc Surg** 1996 Feb;3(1):35–41 (31 ref.). Comment in: J Endovasc Surg 1996 Aug;3(3):359–60.

Long–term results with the Palmaz stent in the superficial femoral artery. Bergeron P, et al. **J Endovasc Surg** 1995 May;2(2):161–7

Recurrent carotid disease: will stents be an alternative to surgery? Bergeron P, et al. **J Endovasc Surg** 1996 Feb; 3(1):76–9

Strecker stents in the femoropopliteal arteries: value of duplex ultrasonography in restenosis assessment. Bray AE, et al. **J Endovasc Surg** 1995 May;2(2):150–60

Wound Healing: An endpoint for complex peripheral angioplasty. Crew JR, et al. **J Endovasc Surg** 1994 Sep; 1:88–91

Techniques for endovascular recanalization of supra–aortic trunks. Criado FJ, et al. **J Endovasc Surg** 1996 Nov; 3(4):405–13 (48 ref.)

Stenting in the carotid artery: initial experience in 110 patients. Diethrich EB, et al. **J Endovasc Surg** 1996 Feb; 3(1):42–62

Carotid angioplasty on trial [comment] Diethrich EB. **J Endovasc Surg** 1996 Feb;3(1):21. Comment on: J Endovasc Surg 1996 Feb;3(1):16–20.

Initial experience with the Cragg Endopro System 1 for intraluminal treatment of peripheral vascular disease. Henry M, et al. **J Endovasc Surg** 1994 Sep;1:31–43

Results of balloon angioplasty in the carotid arteries [see comments] Kachel R. **J Endovasc Surg** 1996 Feb;3(1):22–30 (47 ref.). Comment in: J Endovasc Surg 1996 Nov;3(4):484–6.

PTA and thrombolysis in leg salvage. Motarjeme A. **J Endovasc Surg** 1994 Sep;1:81–7

The role of endovascular surgery in carotid restenosis. Pratesi C, et al. **J Endovasc Surg** 1995 Feb;2(1):36–41

European carotid angioplasty trial [see comments] Sivaguru A, et al. **J Endovasc Surg** 1996 Feb;3(1):16–20. Comment in: J Endovasc Surg 1996 Feb;3(1):21.

Cerebral protection during carotid angioplasty [letter; comment] Théron J. **J Endovasc Surg** 1996 Nov;3(4):484–6 . Comment on: J Endovasc Surg 1996 Feb;3(1):22–30.

Utility of intravascular ultrasound in carotid stenting. Wilson EP, et al. **J Endovasc Surg** 1996 Feb;3(1):63–8

Percutaneous angioplasty, endothelial markers, and fibrin turnover. Woodburn KR, et al. **J Endovasc Surg** 1994 Sep; 1:53–60

Effect of transluminal angioplasty on cerebral blood flow in the management of symptomatic vasospasm following aneurysmal subarachnoid hemorrhage. Firlik AD, et al. **J Neurosurg** 1997 May;86(5):830–9

Hemodialysis access graft stenosis: percutaneous transluminal angioplasty. Lumsden AB, et al. **J Surg Res** 1997 Mar; 68(2):181–5

Treatment of ostial renal–artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. Novick AC. **J Urol** 1997 Sep;158(3 Pt 1):983

Percutaneous treatment of benign portal vein stenosis after liver transplantation. Godoy MA, et al. **J Vasc Interv Radiol** 1996 Mar–Apr;7(2):273–6

Assessment of the hemodynamic result of PTA with a Doppler guide wire: initial experience. Hoppe M, et al. **J Vasc Interv Radiol** 1996 Jan–Feb;7(1):89–93

Restenosis: pathophysiology and preventive strategies. Phillips–Hughes J, et al. **J Vasc Interv Radiol** 1996 May–Jun;7(3):321–33 (136 ref.)

Percutaneous transluminal angioplasty versus endovascular stent placement in the treatment of venous stenoses in patients undergoing hemodialysis: intermediate results. Quinn SF, et al. **J Vasc Interv Radiol** 1995 Nov–Dec; 6(6):851–5

Local thrombolytic therapy as part of a multidisciplinary approach to acute axillosubclavian vein thrombosis (Paget–Schroetter syndrome). Sheeran SR, et al. **J Vasc Interv Radiol** 1997 Mar–Apr;8(2):253–60

Local delivery of heparin with balloon angioplasty: results of a prospective randomized trial. Sheley RC, et al. **J Vasc Interv Radiol** 1996 Nov–Dec;7(6):853–8

Comparison of balloon angioplasty and Simpson atherectomy for lesions in the femoropopliteal artery: angiographic and clinical results of a prospective randomized trial. Tielbeek AV, et al. **J Vasc Interv Radiol** 1996 Nov–Dec;7(6):837–44

Propofol versus midazolam for sedation during percutaneous transluminal angioplasty. Wagner HJ, et al. **J Vasc Interv Radiol** 1996 Sep–Oct;7(5):673–80

The dissected aorta: percutaneous treatment of ischemic complications––principles and results. Williams DM, et al. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):605–25

Statement regarding carotid angioplasty and stenting. Society for Vascular Surgery. International Society for Cardiovascular Surgery, North American Chapter. **J Vasc Surg** 1996 Nov;24(5):900

High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long–segment superficial femoral artery disease after suboptimal angioplasty. Gray BH, et al. **J Vasc Surg** 1997 Jan;25(1):74–83

Regarding "Statement regarding carotid angioplasty and stenting" [letter] Hobson RW 2nd, et al. **J Vasc Surg** 1997 Jun;25(6):1117

Prophylactic balloon angioplasty fails to prolong the patency of expanded polytetrafluoroethylene arteriovenous grafts: results of a prospective randomized study. Lumsden AB, et al. **J Vasc Surg** 1997 Sep;26(3):382–90; discussion 390–2

Prospective randomized comparison of surgical versus endovascular management of thrombosed dialysis access grafts. Marston WA, et al. **J Vasc Surg** 1997 Sep; 26(3):373–80; discussion 380–1

Thrombolytic and endovascular treatment of peripartum iliac vein thrombosis: a case report. Patterson DE, et al. **J Vasc Surg** 1996 Dec;24(6):1030–3

Regarding "Impact of arterial surgery and balloon angioplasty on amputation: a population–based study of 1155 procedures between 1973 and 1992" [letter] Robicsek F. **J Vasc Surg** 1997 Aug;26(2):353

Percutaneous transluminal angioplasty and primary stenting of the iliac arteries in 288 patients. Sullivan TM, et al. **J Vasc Surg** 1997 May;25(5):829–38; discussion 838–9

Results of percutaneous transluminal angioplasty for atherosclerotic renal artery stenosis: a follow–up study with duplex ultrasonography. Tullis MJ, et al. **J Vasc Surg** 1997 Jan;25(1):46–54

Balloon angioplasty for aortic coarctation––report of a questionnaire survey by the Japanese Pediatric Interventional Cardiology Committee. Ino T, et al. **Jpn Circ J** 1997 May;61(5):375–83

Is pre–intervention intravascular ultrasound necessary in evaluating target lesion calcification in patients undergoing transcatheter therapy? Wang J, et al. **Jpn Circ J** 1996 Aug; 60(8):567–74

Carotid endarterectomy vs carotid angioplasty [letter; comment] [see comments] Brown MM, et al. **Lancet** 1997 Mar 22;349(9055):880–1. Comment on: Lancet 1997 Jan 18;349(9046):203–4. Comment in: Lancet 1997 May 3;349(9061):1324–5.

Carotid and Vertebral Artery Transluminal Angioplasty Study [letter; comment] Naylor AR, et al. **Lancet** 1997 May 3;349(9061):1324–5. Comment on: Lancet 1997 Mar 22;349(9055):880. Comment on: Lancet 1997 Mar 22;349(9055):880–1.

Carotid endarterectomy vs carotid angioplasty [letter; comment] [see comments] Warlow C, et al. **Lancet** 1997 Mar 22;349(9055):880. Comment on: Lancet 1997 Jan 18;349(9046):203–4. Comment in: Lancet 1997 May 3;349(9061):1324–5.

Treatment of ostial renal–artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty [see comments] Blum U, et al. **N Engl J Med** 1997 Feb 13; 336(7):459–65. Comment in: N Engl J Med 1997 Jul 10;337(2):132–3.

Permanent pacemaker wires causing subclavian vein stenosis in presence of AV fistula––is it ever wrong to try angioplasty and stenting? Konner K, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1735–8

Successful surgical revascularization of a kidney transplant after PTA–induced arterial dissection of the allograft renal artery. Renders L, et al. **Nephrol Dial Transplant** 1997 Jun; 12(6):1264–6

Reproducibility and validity of quality of life measurements in hypertensive patients on stable medication. Krijnen P, et al. **Neth J Med** 1997 Apr;50(4):137–52

Transcranial Doppler Sonographic monitoring during percutaneous transluminal angioplasty of the internal carotid artery. Eckert B, et al. **Neuroradiology** 1997 Mar; 39(3):229–34

Percutaneous transluminal angioplasty of atherosclerotic basilar artery stenosis. Houdart E, et al. **Neuroradiology** 1996 May;38(4):383–5

Percutaneous transluminal cerebral angioplasty: serial angiographic follow–up after successful dilatation. Mori T, et al. **Neuroradiology** 1997 Feb;39(2):111–6

Percutaneous transluminal angioplasty for total occlusion of middle cerebral arteries. Mori T, et al. **Neuroradiology** 1997 Jan;39(1):71–4

Endovascular treatment for acute thrombotic occlusion of the middle cerebral artery: local intra–arterial thrombolysis combined with percutaneous transluminal angioplasty. Ueda T, et al. **Neuroradiology** 1997 Feb;39(2):99–104

Carotid angioplasty and stent: an alternative to carotid endarterectomy. **Neurosurgery** 1997 Feb;40(2):344–5

Dissection of the descending aorta after balloon angioplasty of native coarctation. Beitzke A, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):222–5

Midterm clinical impact versus procedural success of balloon angioplasty for pulmonary artery stenosis. Zeevi B, et al. **Pediatr Cardiol** 1997 Mar–Apr;18(2):101–6

Percutaneous angioplasty of arteriovenous (Brescia–Cimino) fistulae in children. Lahoche A, et al. **Pediatr Nephrol** 1997 Aug;11(4):468–72

Percutaneous transluminal angioplasty increases thromboxane A2 production in claudicants. Rossi P, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 May; 56(5):369–72

Percutaneous vascular intervention: value of hemodynamic measurements [editorial; comment] Bonn J. **Radiology** 1996 Oct;201(1):18–20. Comment on: Radiology 1996 Oct;201(1):155–9.

Meta–analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Bosch JL, et al. **Radiology** 1997 Jul;204(1):87–96

Carotid angioplasty [editorial; comment] Hurst RW. **Radiology** 1996 Dec;201(3):613–6. Comment on: Radiology 1996 Dec;201(3):627–36.

MR imaging of soft–tissue changes after percutaneous transluminal angioplasty and stent placement. Kellner W, et al. **Radiology** 1997 Feb;202(2):327–31

True lumen obliteration in complicated aortic dissection: endovascular treatment. Slonim SM, et al. **Radiology** 1996 Oct;201(1):161–6

Stent placement after iliac angioplasty: comparison of hemodynamic and angiographic criteria. Dutch Iliac Stent Trial Study Group [see comments] Tetteroo E, et al. **Radiology** 1996 Oct;201(1):155–9. Comment in: Radiology 1996 Oct;201(1):18–20.

Routine coronary angioplasty with autoperfusion balloon catheter: Can prolonged inflations reduce myocardial ischemia and preserve myocardial function? Cremonesi A,

et al. **Riv Eur Sci Med Farmacol** 1995 Nov-Dec; 17(6):209-13

Limitations of percutaneous transluminal angioplasty with stenting for femoropopliteal arterial occlusive disease. Gray BH, et al. **Semin Vasc Surg** 1997 Mar;10(1):8-16

In vivo angioplasty prevents the development of vasospasm in canine carotid arteries. Pharmacological and morphological analyses. Megyesi JF, et al. **Stroke** 1997 Jun; 28(6):1216-24

Angioplasty and stenting for restenosis after carotid endarterectomy. Initial experience. Yadav JS, et al. **Stroke** 1996 Nov;27(11):2075-9

Percutaneous transluminal mesenteric angioplasty. Hackworth CA, et al. **Surg Clin North Am** 1997 Apr; 77(2):371-80

Balloon dilatation angioplasty of a stenotic Blalock-Taussig anastomosis. A case report. Saltik IL, et al. **Turk J Pediatr** 1996 Oct-Dec;38(4):515-9

Ultrasonic-pathologic comparison of postangioplasty myointimal hyperplasia and primary atheroma of the superficial femoral artery. Baumgartner I, et al. **Ultrasound Med Biol** 1996;22(7):815-21

Residual stenosis determined by intravascular ultrasound and duplex ultrasound after balloon angioplasty of the superficial femoral artery. Pasterkamp G, et al. **Ultrasound Med Biol** 1996;22(7):801-6

[The effect of heparan sulfate on percutaneous transluminal angioplasty in the vessels supplying the lower extremities] Bulvas M, et al. **Cas Lek Cesk** 1996 Jul 14;135(14):445-9 (Eng. Abstr.) **(Cze)**

[Angioplasty of three intracranial vertebro-basilar atherosclerotic stenoses] Houdart E. **Bull Acad Natl Med** 1997 Feb;181(2):333-9; discussion 339-40 (Eng. Abstr.) **(Fre)**

[Endovascular recanalization of primary thromboses of the iliac artery] Cardon JM, et al. **J Mal Vasc** 1996;21(2):107-10 **(Fre)**

[Associated carotid and coronary lesions: carotid endoluminal angioplasty before coronary surgery] Babatasi G, et al. **Presse Med** 1996 Nov 9;25(34):1623-6 (Eng. Abstr.) **(Fre)**

[Percutaneous angioplasty of the renal arteries. Long-term results of 222 operations] Lasry JL, et al. **Presse Med** 1996 Sep 14;25(26):1195-200 (Eng. Abstr.) **(Fre)**

[Only early invasive therapy can be curative (interview by Dr. rer. nat. Anita Schweiger)] Gain T. **Fortschr Med** 1997 Feb 28;115(6):34, 36 **(Ger)**

[Renal artery dilatation in renovascular hypertension. Acute and long-term outcome in a large patient sample] Lenz T, et al. **Med Klin** 1996 Jul 15;91(7):442-6 (Eng. Abstr.) **(Ger)**

[Restenosis after percutaneous transluminal angioplasty: I. Etiology and clinical significance] Alfke H, et al. **Vasa** 1996; 25(1):13-20 (58 ref.) (Eng. Abstr.) **(Ger)**

[Restenosis after percutaneous transluminal angioplasty: II. Possibilities for pharmacologic intervention] Böger RH, et al. **Vasa** 1996;25(1):21-31 (105 ref.) (Eng. Abstr.) **(Ger)**

[The effect of Taprostene on platelet activation and clinical course after percutaneous transluminal angioplasty] Heinz M, et al. **Vasa** 1996;25(1):65-72 (Eng. Abstr.) **(Ger)**

[Cystic degeneration of the adventitia of the popliteal artery after PTA of the superficial femoral artery] Lastdrager WB, et al. **Vasa** 1996;25(1):84-9 (Eng. Abstr.) **(Ger)**

[Aortitis and development of an aneurysm after PTA of distal aortic stenosis] Raschke R, et al. **Vasa** 1996;25(3):287-91 (Eng. Abstr.) **(Ger)**

[Therapy of renovascular hypertension in neurofibromatosis: surgical revascularization versus percutaneous transluminal angioplasty] Türler A, et al. **Vasa** 1996;25(4):368-72 (34 ref.) (Eng. Abstr.) **(Ger)**

[Angioplasty and stenting of the carotid artery] Atar E, et al. **Harefuah** 1997 Mar 16;132(6):388-91, 448 (Eng. Abstr.) **(Heb)**

[Percutaneous transluminal valvuloplasty in severe neonatal pulmonary stenosis] Masszi G, et al. **Orv Hetil** 1996 Apr 7;137(14):743-5 (Eng. Abstr.) **(Hun)**

[Management of aortic recoarctation by transluminal balloon angioplasty in childhood] Szatmári A, et al. **Orv Hetil** 1997 Aug 24;138(34):2127-31 (Eng. Abstr.) **(Hun)**

[Percutaneous mitral valvuloplasty] Boscarini M, et al. **Cardiologia** 1996 Jul;41(7):675-8 **(Ita)**

[Dilatation of congenital aortic stenosis] Carminati M. **Cardiologia** 1995 Dec;40(12 Suppl 1):409-11 **(Ita)**

[Percutaneous mitral valvuloplasty in mitral restinosis after surgical commissurotomy] Ramondo A, et al. **G Ital Cardiol** 1997 Apr;27(4):357-62 (Eng. Abstr.) **(Ita)**

[Balloon angioplasty and metallic stent] Nishimine K, et al. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):532-9 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Effectiveness of percutaneous transluminal angioplasty and intra-arterial papaverine infusion for symptomatic vasospasm after subarachnoid hemorrhage] Fujiwara N, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Jun; 57(7):412-7 (Eng. Abstr.) **(Jpn)**

[Case of bilateral renal artery stenosis with successful weaning from hemodialysis following percutaneous transluminal angioplasty] Nakae H, et al. **Nippon Naika Gakkai Zasshi** 1997 May 10;86(5):846-8 **(Jpn)**

[A case of acute occlusion of left middle cerebral artery due to an embolus treated successfully with percutaneous transluminal angioplasty] Watanabe M, et al. **No Shinkei Geka** 1996 Nov;24(11):1027-32 (Eng. Abstr.) **(Jpn)**

[Optimization of endovascular methods of the treatment of stenosing lesions of peripheral blood vessels by ultrasound scanning] Demidov IN, et al. **Vestn Rentgenol Radiol** 1996 Sep-Oct;(5):45-6 **(Rus)**

[Significance of intravascular ultrasound studies in the evaluation of the vascular lumen and wall in interventional radiological procedures] Ivanitskiĭ AV, et al. **Vestn Rentgenol Radiol** 1996 Sep-Oct;(5):26-34 (Eng. Abstr.) **(Rus)**

[Treatment of arterial stenosis of the kidney graft with transluminal angioplasty] Gómez dos Santos V, et al. **Arch Esp Urol** 1996 Jun;49(5):493-8 (Eng. Abstr.) **(Spa)**

[The long-term results on arterial pressure and kidney function after the percutaneous transluminal dilatation of renal artery stenosis] Rodríguez Pérez JC, et al. **Med Clin (Barc)** 1997 Mar 15;108(10):366-72 (Eng. Abstr.) **(Spa)**

[Early therapeutic intervention: thromboendarterectomy and percutaneous transluminal angioplasty] Gil-Peralta A. **Neurologia** 1995 Dec;10 Suppl 2:55-61 (30 ref.) (Eng. Abstr.) **(Spa)**

[Endovascular radiation and restinosis] Blanco Castiñeira J, et al. **Rev Esp Cardiol** 1997 Jul;50(7):520-8 (50 ref.) (Eng. Abstr.) **(Spa)**

[Stents and de novo coronary lesions. Meta-analysis] Masotti M, et al. **Rev Esp Cardiol** 1997;50 Suppl 2:3-9 (Eng. Abstr.) **(Spa)**

[The use of transesophageal echocardiography in the diagnosis of aortic hematoma after an aortic recoarctation angioplasty] Mercé J, et al. **Rev Esp Cardiol** 1997 May; 50(5):355-6 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Dilation mechanism, causes of restenosis and stenting in balloon coarctation angioplasty. Ino T, et al. **Acta Paediatr** 1997 Apr;86(4):367-71 (55 ref.)

Reopening of the ductal ampulla during balloon angioplasty of native aortic coarctation [letter] Wong JA, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):316-7

Autopsy findings of fatal complication of posterior cerebral circulation angioplasty. Volk EE, et al. **Arch Pathol Lab Med** 1997 Jul;121(7):738-40

Fibrin(ogen) and von Willebrand factor deposition are associated with intimal thickening after balloon angioplasty of the rabbit carotid artery. Bosmans JM, et al. **Arterioscler Thromb Vasc Biol** 1997 Apr;17(4):634-45

Importance of platelets in neutrophil adhesion and vasoconstriction after deep carotid arterial injury by angioplasty in pigs. Merhi Y, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1185-91

PDGF receptor protein tyrosine kinase expression in the balloon-injured rat carotid artery. Panek RL, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1283-8

Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Ueno H, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):898-904

Local alcohol delivery may reduce phenotype conversion of smooth muscle cells and neointimal formation in rabbit iliac arteries after balloon injury. Liu MW, et al. **Atherosclerosis** 1996 Dec 20;127(2):221-7

Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis. Miller DD, et al. **Atherosclerosis** 1996 Sep 27;126(1):1-14

Expression of platelet-derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Uchida K, et al. **Atherosclerosis** 1996 Jul; 124(1):9-23

Endocarditis after angiography and angioplasty of a subclavian artery stenosis. Casson RJ, et al. **Aust N Z J Surg** 1997 May;67(5):306-8

Inadvertent rupture of a composite vein graft by angioplasty. Sandison A, et al. **Cardiovasc Intervent Radiol** 1997 Jul-Aug;20(4):305-7

Stent treatment of obstructing dissection after percutaneous transluminal angioplasty of aortic stenosis caused by nonspecific aortitis. Sharma S, et al. **Cardiovasc Intervent Radiol** 1997 Sep-Oct;20(5):377-9

Stenting within a stent for treatment of residual dissection. Hamon M, et al. **Cathet Cardiovasc Diagn** 1997 Mar; 40(3):319-21

Palmaz stent compression in patients following carotid artery stenting. Mathur A, et al. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):137-40

Rupture of coronary artery and cardiac tamponade complicating Wallstent implantation. Mendzelevski B, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):368-71

Plaque prolapse between the struts of the intracoronary Palmaz-Schatz stent: report of two cases with a novel treatment of this unusual problem. Ponde CK, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):353-7

Stent thrombosis in a patient receiving chemotherapy. Smith SC, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):383-6 (24 ref.)

Use of intravascular ultrasound in evaluating repeated balloon rupture during coronary stenting. Zellner C, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):52-4 (10 ref.)

Expression of nonmuscle myosin heavy chain-B isoform in the vessel wall of porcine coronary arteries after balloon angioplasty. De Leon H, et al. **Circ Res** 1997 Apr; 80(4):514-9

The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Gunn J, et al. **Circ Res** 1997 Apr;80(4):520-31

Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries: a link between angiotensin II and intimal thickening. Abe J, et al. **Circulation** 1997 Sep 16;96(6):1906-13

Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Oparil S, et al. **Circulation** 1997 Mar 4;95(5):1301-7

Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury [see comments] Perlman H, et al. **Circulation** 1997 Feb 18;95(4):981-7. Comment in: Circulation 1997 Feb 18;95(4):782-6.

Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Schwarzacher SP, et al. **Circulation** 1997 Apr 1;95(7):1863-9

In vitro identification of angioplasty-induced injury by use of vascular acoustic emissions. Vonesh MJ, et al. **Circulation** 1997 Feb 18;95(4):1022-9

Effect of intravascular irradiation on cell proliferation, apoptosis, and vascular remodeling after balloon overstretch injury of porcine coronary arteries. Waksman R, et al. **Circulation** 1997 Sep 16;96(6):1944-52

Coronary artery and saphenous vein graft remodeling: a review of histologic findings after various interventional procedures--Part II. Waller BF, et al. **Clin Cardiol** 1996 Oct;19(10):817-23 (26 ref.)

Coronary artery and saphenous vein graft remodeling: a review of histologic findings after various interventional procedures--Part IV. Waller BF, et al. **Clin Cardiol** 1996 Dec;19(12):960-6 (41 ref.)

Phenotypic modification of arterial smooth muscle cells in response to medial dissection. Dufourcq P, et al. **Coron Artery Dis** 1997 Mar-Apr;8(3-4):163-70

Does sequential balloon injury of an artery lead to a different outcome than a single injury? An experimental study of angioplasty. Stadius ML, et al. **Coron Artery Dis** 1996 Mar; 7(3):247-55

Effect of balloon angioplasty in femoropopliteal arteries assessed by intravascular ultrasound. van der Lugt A, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):549-56

Vascular rupture complicating transluminal angioplasty applied on a failed dialysis vascular access in a patient under chronic steroid therapy. Melki PS, et al. **Eur Radiol** 1997; 7(3):313-5

Coronary artery perforation during coronary angioplasty. Kane GR, et al. **Indian Heart J** 1997 Jan-Feb;49(1):73-5

Articulation strut coronary restenosis in Palmaz-Schatz stents. Davis G, et al. **Int J Cardiol** 1996 Jun;54(3):266-71

Anterior ST segment elevation due to isolated right ventricular infarction during right coronary angioplasty. Koh TW, et al. **Int J Cardiol** 1996 Jun;54(3):201-6

Intracoronary radiation decreases the second phase of intimal hyperplasia in a repeat balloon angioplasty model of restenosis. Waksman R, et al. **Int J Radiat Oncol Biol Phys** 1997 Sep 1;39(2):475-80

Selective antagonism of the ET(A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs. Burke SE, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):33-41

Moderate alcohol feeding attenuates postinjury vascular cell proliferation in rabbit angioplasty model. Merritt R, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):19-25

Cerebral hyperperfusion injury after percutaneous transluminal angioplasty of extracranial arteries. Schoser BG, et al. **J Neurol** 1997 Feb;244(2):101-4

Leech therapy for massive scrotal hematoma following percutaneous transluminal angioplasty. Goessl C, et al. **J Urol** 1997 Aug;158(2):545

The influence of lesion length on intimal hyperplasia after Fogarty balloon injury in the rabbit carotid artery: role of endothelium. Doornekamp FN, et al. **J Vasc Res** 1997 Jul-Aug;34(4):260-6

Recombinant tissue plasminogen activator prevents intimal hyperplasia after balloon angioplasty in hypercholesterolemic rabbits. Kanamasa K, et al. **Jpn Circ J** 1996 Nov;60(11):889-94

A new single-injury model of balloon angioplasty in cholesterol-fed rabbits: beneficial effect of hirudin and comparison with double-injury model. Barry WL, et al. **Lab Invest** 1997 Jul;77(1):109-16

Cytomegalovirus and restenosis [news] Holzman DC. **Mol Med Today** 1996 Jul;2(7):270

Separation of the arterial wall from blood contact using hydrogel barriers reduces intimal thickening after balloon injury in the rat: the roles of medial and luminal factors in arterial healing. West JL, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13188-93

Eicosanoids, fatty acids and restenosis following coronary artery bypass graft surgery and balloon angioplasty. Jeremy JY, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Jun;54(6):385-402 (298 ref.)

[Compensatory enlargement versus chronic constriction. The two features of vascular remodelling after experimental angioplasty] Lafont A, et al. **Arch Mal Coeur Vaiss** 1997 Jun;90(6):827-34 (54 ref.) (Eng. Abstr.) **(Fre)**

[Convulsions after renal angiography and angioplasty (letter)] Dumas S, et al. **Presse Med** 1997 Jun 21;26(21):1004 **(Fre)**

[Papillary muscle rupture during subaortic membrane balloon dilatation] Frutos A, et al. **Rev Esp Cardiol** 1996 Feb; 49(2):146–8 (Eng. Abstr.) **(Spa)**

[Factors related to the appearance of peripheral vascular complications after taneous cardiovascular interventions] Navarro F, et al. **Rev Esp Cardiol** 1997 Jul;50(7):480–90 (Eng. Abstr.) **(Spa)**

ECONOMICS

Comparison of hospital charges for balloon angioplasty and surgical repair in children with native coarctation of the aorta. Shim D, et al. **Am J Cardiol** 1997 Apr 15;79(8):1143–6

Cost–effectiveness analysis of stents, balloon angioplasty, and surgery for the treatment of branch pulmonary artery stenosis. Trant CA Jr, et al. **Pediatr Cardiol** 1997 Sep–Oct; 18(5):339–44

INSTRUMENTATION

Arterial changes after thrombolysis and percutaneous transluminal angioplasty in vertebrobasilar thrombosis. Becker KJ, et al. **AJNR Am J Neuroradiol** 1997 Mar; 18(3):514–8

Reversal of abnormal ischemic vascular enhancement after intracerebral angioplasty. Kessler LS, et al. **AJNR Am J Neuroradiol** 1996 Feb;17(2):269–70

Preliminary results of intracranial angioplasty for vascular stenosis caused by atherosclerosis and vasculitis. McKenzie JD, et al. **AJNR Am J Neuroradiol** 1996 Feb;17(2):263–8

Percutaneous transluminal angioplasty of the internal carotid artery with a continuous–perfusion dilatation catheter. Tsurutani T, et al. **AJNR Am J Neuroradiol** 1997 Apr; 18(4):696–8

Arterial perforation during optimization of coronary stents using high–pressure balloon inflations. Alfonso F, et al. **Am J Cardiol** 1996 Nov 15;78(10):1169–72

Experimental trial of balloon–expandable, metallic Palmaz stent in the trachea. Fraga JC, et al. **Arch Otolaryngol Head Neck Surg** 1997 May;123(5):522–8

Angioplasty balloon catheters used for distraction of the ankle joint. Sartoretti C, et al. **Arthroscopy** 1996 Feb; 12(1):82–6

Popliteal artery thrombosis in a patient with Cogan syndrome: treatment with thrombolysis and percutaneous transluminal angioplasty. Bastug DE, et al. **Cardiovasc Intervent Radiol** 1997 Jan–Feb;20(1):57–9

Arteriovenous fistula at the site of balloon dilatation complicating femoropopliteal angioplasty. Malcolm PN, et al. **Cardiovasc Intervent Radiol** 1997 Jan–Feb;20(1):54–6

Percutaneous retrieval of a retained Jackson–Pratt drain fragment. Namyslowski J, et al. **Cardiovasc Intervent Radiol** 1996 Nov–Dec;19(6):446–8

Stent implantation in severely angulated lesions: safety, efficacy, and morphological remodelling. Abhyankar AD, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):261–4

The "Concorde" stent: a novel use of a stiff bent guidewire to facilitate stent deployment. Carlson TA, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):277–80

Balloon atrial septostomy using a new low–profile balloon catheter: initial clinical results. Hijazi ZM, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):187–90; discussion 191

Feasibility and efficacy of locally delivered enoxaparin via the Channeled Balloon catheter on smooth muscle cell proliferation following balloon injury in rabbits. Hong MK, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):241–5

Magnum Meier wires with Crag Fx wire catheter for total occlusive coronary arteries. Kitazume H, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):198–201

Successful treatment of chronic total peripheral occlusions that failed conventional techniques using the stiff backend of the Glidewire. Kjellgren O, et al. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):360–3

Angioplasty of chronic total coronary occlusions with the use of six French guiding catheters. Koch KT, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):255–60

Lumenology: intracoronary ultrasound in search of tenths of millimeters [editorial; comment] Linnemeier TJ. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):8. Comment on: Cathet Cardiovasc Diagn 1997 Jan;40(1):1–7.

Localized delivery of heparin to angioplasty sites with iontophoresis. Mitchel JF, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):315–23

Is intravascular ultrasound after coronary stenting a safe procedure? Three cases of stent damage attributable to ICUS in a tantalum coil stent [see comments] Nicosia A, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):265–70. Comment in: Cathet Cardiovasc Diagn 1997 Mar;40(3):271.

Time course of smooth muscle cell proliferation after local drug delivery of low–molecular–weight heparin using a porous balloon catheter. Oberhoff M, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):268–74

Endovascular stent implantation for severe recoarctation of the aorta: case report with angiographic and 18–month clinical follow–up. Pedulla DM, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):311–4

Plaque prolapse between the struts of the intracoronary Palmaz–Schatz stent: report of two cases with a novel treatment of this unusual problem. Ponde CK, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):353–7

Temporary arterial stenting: comparison to permanent stenting and conventional balloon injury in a rabbit carotid artery model. Rechavia E, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):85–92

Not all stents are created equal [editorial; comment] Tobis JM. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):271. Comment on: Cathet Cardiovasc Diagn 1997 Mar;40(3):265–70.

Vessel reconstruction in total coronary occlusions with a long subintimal wire pathway: use of multiple stents under guidance of intravascular ultrasound. Werner GS, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):46–51

Use of intravascular ultrasound in evaluating repeated balloon rupture during coronary stenting. Zellner C, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):52–4 (10 ref.)

Is anticoagulation for intracoronary stenting justified? [editorial; comment] Corr L. **Eur Heart J** 1996 Sep; 17(9):1296–8. Comment on: Eur Heart J 1996 Sep;17(9):1373–80.

Percutaneous stent implantation in an adult with left pulmonary artery stenosis and absent right pulmonary artery [letter] Dalvi BV, et al. **Eur Heart J** 1997 Apr; 18(4):700–1

Renal artery stenosis managed by Palmaz stent insertion: technical and clinical outcome. MacLeod M, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1791–5

Stent placement in the renal artery: three–year experience with the Palmaz stent. Henry M, et al. **J Vasc Interv Radiol** 1996 May–Jun;7(3):343–50

Plastic syringe shaft fracture as a risk for percutaneous injury during performance of interventional procedures [letter] Sandhu JS, et al. **J Vasc Interv Radiol** 1995 Nov–Dec; 6(6):987–8

Stent–grafts for revision of TIPS stenoses and occlusions: a clinical pilot study. Saxon RR, et al. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):539–48

Catheter–delivered ultrasound potentiates in vitro thrombolysis. Shlansky–Goldberg RD, et al. **J Vasc Interv Radiol** 1996 May–Jun;7(3):313–20

Luminal changes in downsteam arteries after percutaneous interventions in iliac arteries: implications for balloon or stent size determination. Strunk HM, et al. **J Vasc Interv Radiol** 1996 May–Jun;7(3):361–6

Percutaneous transluminal stent placement to treat subclavian steal syndrome. Sueoka BL. **J Vasc Interv Radiol** 1996 May–Jun;7(3):351–6

Superselective bronchial artery embolization for hemoptysis with a coaxial microcatheter system. Tanaka N, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):65–70

Emergent treatment of iatrogenic dissection of the internal carotid artery with the Palmaz–Schatz stent––case report. Yamashita K, et al. **Neurol Med Chir (Tokyo)** 1997 Apr; 37(4):336–9

The Doppler guide wire: clinical applications in neuroendovascular treatment. Benndorf G, et al. **Neuroradiology** 1997 Apr;39(4):286–91

Dual microcatheter and guidewire snare technique for retrieval of intravascular foreign body: technical note. Terada T, et al. **Neuroradiology** 1996 Oct;38(7):615–7

Thrombolysis of the cervical internal carotid artery before balloon angioplasty and stent placement: report of two cases. Guterman LR, et al. **Neurosurgery** 1996 Mar; 38(3):620–3; discussion 624

Successful percutaneous transluminal angioplasty for basilar artery stenosis: technical case report. Nakatsuka H, et al. **Neurosurgery** 1996 Jul;39(1):161–4

Stenting of stenosis of the abdominal aorta. Lim MC, et al. **Singapore Med J** 1995 Oct;36(5):562–5

[Management of iatrogenic hemorrhage after mechanical vascular recanalization] Görich J, et al. **Aktuelle Radiol** 1996 Jan;6(1):28–31 (Eng. Abstr.) **(Ger)**

[Current status of abdominal aortic aneurysm therapy (editorial)] Allenberg JR. **Langenbecks Arch Chir** 1997; 382(3):117–8 **(Ger)**

[Interventional pneumology: procedures for pulmonary hemorrhage and tumor–induced superior vena cava syndrome] Witt C, et al. **Pneumologie** 1996 Feb;50(2):202–8 (51 ref.) (Eng. Abstr.) **(Ger)**

[Percutaneous removal of a stripped–off Palmaz stent in the renal artery] Schmitz–Rode T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Sep;165(3):293–5 **(Ger)**

[Rashkind PDA occluder and detachable metal spiral for interventional occlusion of the ductus arteriosus Botalli. Indications, outcome and complications] Buheitel G, et al. **Z Kardiol** 1997 Jan;86(1):42–9 (Eng. Abstr.) **(Ger)**

[Quality criteria in using percutaneous transluminal angioplasty of supra–aortic arteries] Kachel R, et al. **Zentralbl Chir** 1996;121(12):1076–84 (Eng. Abstr.) **(Ger)**

[Difficulties and complications in transfemoral implantation of stent prostheses in infrarenal abdominal aortic aneurysms] Stelter WJ, et al. **Zentralbl Chir** 1996; 121(9):734–43 (Eng. Abstr.) **(Ger)**

[Mechanical endarterectomy: review of the literature and description of an original device] Terrinoni V, et al. **G Chir** 1997 Mar;18(3):122–6 (Eng. Abstr.) **(Ita)**

METHODS

A novel method to create atrial septal defect using a cutting balloon in piglets. Coe JY, et al. **Am J Cardiol** 1996 Dec 1;78(11):1323–6

Outpatient angioplasty: 4–year experience in one practice. Payne SP, et al. **Ann R Coll Surg Engl** 1997 Sep;79(5):331–4

Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? Maca T, et al. **Atherosclerosis** 1996 Nov 15;127(1):27–34

Brachial artery access for percutaneous renal artery interventions. Kaukanen ET, et al. **Cardiovasc Intervent Radiol** 1997 Sep–Oct;20(5):353–8

The "Concorde" stent: a novel use of a stiff bent guidewire to facilitate stent deployment. Carlson TA, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):277–80

Vigilate, not mea culpa [editorial; comment] Hildner FJ. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):139. Comment on: Cathet Cardiovasc Diagn 1997 Feb;40(2):133–8.

Transcatheter perforation of the right ventricular outflow tract as initial therapy for pulmonary valve atresia and intact ventricular septum in the newborn [see comments] Justo RN, et al. **Cathet Cardiovasc Diagn** 1997 Apr; 40(4):408–13. Comment in: Cathet Cardiovasc Diagn 1997 Apr;40(4):414–5.

New double wire technique to stent ostial lesions. Katoh O, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):400–2

Magnum Meier wires with Crag Fx wire catheter for total occlusive coronary arteries. Kitazume H, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):198–201

Simultaneous use of a diagnostic catheter to facilitate stent deployment in aorto–ostial artery stenosis: a case report. Lambros J, et al. **Cathet Cardiovasc Diagn** 1997 Feb; 40(2):210–1

Combined coronary and bilateral carotid stenting: a case report. Mathur A, et al. **Cathet Cardiovasc Diagn** 1997 Feb; 40(2):202–6

A method to eliminate articulation from the Palmaz–Schatz stent delivery system. Moussa I, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):212–6

Vessel tearing at the edge of intracoronary stents detected with intravascular ultrasound imaging. Schwarzacher SP, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):152–5

Brachial artery approach for transluminal angioplasty of the internal carotid artery. Sievert H, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):421–3

Autologous vein graft–coated stents for the treatment of thrombus–containing coronary artery lesions. Stefanadis C, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):217–22

Intracoronary stent implantation using a single high–pressure perfusion balloon catheter. Waksman R, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):140–3

Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study. Reifart N, et al. **Circulation** 1997 Jul 1; 96(1):91–8

The usage of heparin in vascular intervention [letter; comment] Randi ML, et al. **Clin Radiol** 1997 Mar; 52(3):247–8. Comment on: Clin Radiol 1996 Feb;51(2):113–6.

Treatment of peripheral arterial and venous diseases. Navarro F, et al. **Coron Artery Dis** 1996 Sep;7(9):649–55 (35 ref.)

Treatment of the Budd–Chiari syndrome by insertion of a wall–stent in the hepatic vein after percutaneous transluminal angioplasty: the necessity of follow–up. Weernink EE, et al. **Eur J Gastroenterol Hepatol** 1996 Jan; 8(1):85–8

Transhepatic venous angioplasty and stenting: a treatment option in bleeding from gastric varices secondary to pancreatic carcinoma. Ferguson JM, et al. **HPB Surg** 1997; 10(3):173–5

Procedural outcome and follow–up results of balloon angioplasty versus new device interventions for treatment of true bifurcation stenoses. Gambhir DS, et al. **Indian Heart J** 1996 Jul–Aug;48(4):389–94, 430

Self–expanding Wallstent deployment in an adult with coarctation of the aorta. Gambhir DS, et al. **Indian Heart J** 1996 Jul–Aug;48(4):409–11

Spontaneous coronary dissection: management by coronary angioplasty followed by successful renal transplantation. Kapoor A, et al. **Indian Heart J** 1997 Jan–Feb;49(1):71–2

Exclusion of an internal carotid aneurysm by a covered stent. Ruebben A, et al. **J Cardiovasc Surg (Torino)** 1997 Jun; 38(3):301–3

Peripheral transluminal angioplasty under ultrasound guidance: initial clinical experience and prevalence of lower limb lesions amenable to ultrasound–guided angioplasty. Ramaswami G, et al. **J Endovasc Surg** 1995 Feb;2(1):27–35

Percutaneous transluminal stent placement in the abdominal aorta. Sheeran SR, et al. **J Vasc Interv Radiol** 1997 Jan–Feb; 8(1 Pt 1):55–60

A program of operative angioplasty: endovascular intervention and the vascular surgeon. Silva MB Jr, et al. **J Vasc Surg** 1996 Dec;24(6):963–71; discussion 971–3

A case of acute massive pulmonary thromboembolism treated by mechanical clot fragmentation using a percutaneous transluminal angioplasty balloon. Isoda K, et al. **Jpn Circ J** 1997 Jun;61(6):531–5

Patency of percutaneous transluminal renal angioplasty: a prospective sonographic study. Baumgartner I, et al. **Kidney Int** 1997 Mar;51(3):798–803

Use of the internal jugular vein approach in balloon dilatation angioplasty of pulmonary artery stenosis in children. Senzaki H, et al. **Pediatr Cardiol** 1996 Mar–Apr;17(2):82–5

Percutaneous transluminal angioplasty for renovascular hypertension in children: initial and long–term results. Tyagi S, et al. **Pediatrics** 1997 Jan;99(1):44–9

Carotid artery stenosis: treatment with protected balloon

angioplasty and stent placement [see comments] Theron JG, et al. **Radiology** 1996 Dec;201(3):627–36. Comment in: Radiology 1996 Dec;201(3):613–6.

Carotid stent–assisted angioplasty. Smedema JP, et al. **S Afr Med J** 1997 Feb;87 Suppl 1:C9–14

In vitro validation of intravascular ultrasound imaging after balloon angioplasty of coronary artery stenoses. Peters RJ, et al. **Ultrasound Med Biol** 1996;22(8):999–1005

Interobserver reproducibility of qualitative and quantitative analysis of intravascular ultrasound images before and after peripheral balloon angioplasty. van der Lugt A, et al. **Ultrasound Med Biol** 1996;22(4):399–404

[Current possibilities for endoluminal arterial vascular procedures] Morin D, et al. **Rev Med Suisse Romande** 1997 Feb;117(2):117–25 (10 ref.) **(Fre)**

[Special technics for angioplasty of the brachiocephalic vessels] Schroth G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Aug;167(2):165–73 (Eng. Abstr.) **(Ger)**

[The successful percutaneous revascularization of a subacute renal artery obstruction] Weishaupt D, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):269–72 (15 ref.) **(Ger)**

[A case of acute occlusion of the cervical portion of the right internal carotid artery with successful stepwise vascular dilatation by rescue PTA and deferred PTA] Suga T, et al. **No Shinkei Geka** 1996 Dec;24(12):1101–6 (Eng. Abstr.) **(Jpn)**

NURSING

Reducing costs and improving processes for the interventional cardiology patient. Sullivan J, et al. **J Cardiovasc Nurs** 1997 Jan;11(2):22–36

STANDARDS

Prediction of outcome after femoropopliteal balloon angioplasty by intravascular ultrasound. Vogt KC, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):563–8

STATISTICS & NUMERICAL DATA

Cumulative risk of bypass, amputation or death following percutaneous transluminal angioplasty. Gutteridge W, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):134–9

UTILIZATION

Concerning Dr. Waters' and Dr. Kiernan's "The abuse of cardiovascular procedures" [letter; comment] Seltzer J. **Conn Med** 1997 Jul;61(7):443–4. Comment on: Conn Med 1997 May;61(5):259–62.

VETERINARY

Percutaneous balloon pericardiotomy for the management of malignant pericardial effusion in two dogs. Cobb MA, et al. **J Small Anim Pract** 1996 Nov;37(11):549–51

ANGIOPLASTY, BALLOON, CORONARY see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

ANGIOPLASTY, BALLOON, LASER-ASSISTED

Laser balloon angioplasty combined with local intracoronary heparin therapy: immediate and short-term follow-up results. Glazier JJ, et al. **Am Heart J** 1997 Aug;134(2 Pt 1):266–73

Excimer laser–facilitated angioplasty for undilatable coronary narrowings. Ahmed WH, et al. **Am J Cardiol** 1996 Nov 1;78(9):1045–6

Excimer laser angioplasty versus balloon angioplasty in functional and total coronary occlusions [see comments] Appelman YE, et al. **Am J Cardiol** 1996 Oct 1;78(7):757–62 . Comment in: Am J Cardiol 1996 Oct 1:78(7):823–4.

Excimer laser angioplasty: focus on total occlusions [editorial; comment] Bittl JA. **Am J Cardiol** 1996 Oct 1;78(7):823–4 . Comment on: Am J Cardiol 1996 Oct 1;78(7):757–62. Comment on: Am J Cardiol 1996 Oct 1;78(7):836–8.

Angioscopy variables predictive of early angiographic outcome after excimer laser–assisted coronary angioplasty. Larrazet FS, et al. **Am J Cardiol** 1997 May 15;79(10):1343–9

Excimer laser angioplasty vs. balloon angioplasty in saphenous vein bypass grafts: quantitative angiographic comparison of matched lesions. Natarajan MK, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):153–8

Excimer laser vs balloon angioplasty: (AMRO study)—what is the relevance? [editorial] Margolis JR. **Eur Heart J** 1996 Jun;17(6):807–8

Changes of fluid–dynamic parameters in peripheral stenoses with transcutaneous interventions. Wellnhofer E, et al. **Eur Heart J** 1995 Oct;16 Suppl J:60–70

Experimental study on the early efficacy of excimer laser with adjunctive balloon angioplasty in dog's femoral artery. Zeng H, et al. **J Tongji Med Univ** 1996;16(2):87–90

Solid-state mid–infrared laser facilitated coronary angioplasty: clinical and quantitative coronary angiographic results in 112 patients. Topaz O, et al. **Lasers Surg Med** 1996;19(3):260–72

[Percutaneous angioplasty (PTA) in the treatment of non–penetrating injuries to the subclavian artery. A clinical case] Giordanengo F, et al. **Minerva Cardioangiol** 1996 May;44(5):257–61 (Eng. Abstr.) **(Ita)**

[Laser coronary angioplasty] Kitazume H, et al. **Rinsho Kyobu Geka** 1988 Feb;8(1):42–6 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Early deterioration after excimer laser–assisted coronary angioplasty. Garcia–Cantu E, et al. **Am J Cardiol** 1997 May 1;79(9):1230–2

Ultrasound findings after ELCA [editorial; comment] Block PC. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):119. Comment on: Cathet Cardiovasc Diagn 1996 Feb;37(2):113–8.

Intravascular ultrasound findings after excimer laser coronary angioplasty [see comments] Mintz GS, et al. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):113–8. Comment in: Cathet Cardiovasc Diagn 1996 Feb;37(2):119.

Cell damage induced by Angiovist–370 and 308nm excimer laser radiation. Schomacker KT, et al. **Lasers Surg Med** 1997;20(2):111–8

INSTRUMENTATION

Recanalization of chronic coronary occlusions using a laser wire. Sievert H, et al. **Cathet Cardiovasc Diagn** 1996 Feb; 37(2):220–2

[The role of laser angioplasty in the spectrum of interventional therapy of coronary heart disease] Motz W. **Internist (Berl)** 1997 Jan;38(1):27–30 (16 ref.) **(Ger)**

METHODS

Percutaneous method of laser transmyocardial revascularization. Kim CB, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):223–8

Transmyocardial laser revascularisation as an adjunct to CABG. Trehan N, et al. **Indian Heart J** 1996 Jul–Aug; 48(4):381–8

ANGIOPLASTY, CORONARY BALLOON see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

ANGIOPLASTY, EXCIMER LASER see **ANGIOPLASTY, BALLOON, LASER-ASSISTED**

ANGIOPLASTY, LASER

A model of blood interaction with optical–fluid guide for laser angioplasty. Ilegbusi OJ, et al. **Ann Biomed Eng** 1997 Jul–Aug;25(4):653–64

Excimer laser angioplasty vs. balloon angioplasty in saphenous vein bypass grafts: quantitative angiographic comparison of matched lesions. Natarajan MK, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):153–8

Perspectives of coronary excimer laser angioplasty: multiplexing, saline flushing, and acoustic ablation control. Haase KK, et al. **Lasers Surg Med** 1997;21(1):72–8

[Experimental results of excimer–laser–PTA in an experimental ex vivo vascular model] Vogl TJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Dec;165(6):568–73 (Eng. Abstr.) **(Ger)**

[Clinical experience of laser angioplasty for the peripheral and coronary arterial diseases] Okada M, et al. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):526–31 (27 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

[Development and evaluation of a spectroscopy system for classification of laser–induced arterial fluorescence spectra] Morguet AJ, et al. **Biomed Tech (Berl)** 1997 Jun; 42(6):176–82 (Eng. Abstr.) **(Ger)**

[Coronary laser angioplasty: clinical value and experimental progress] Haase KK, et al. **Z Kardiol** 1996;85 Suppl 1:81–6 (21 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Single–laser approach for fluorescence guidance of excimer laser angioplasty at 308 nm: evaluation in vitro and during coronary angioplasty. Morguet AJ, et al. **Lasers Surg Med** 1997;20(4):382–93

MORTALITY

Comparative study of Nd:YAG laser angioplasty at 1.06 microns, 1.32 microns, and 1.44 microns wavelengths: decreased vascular spasm and early mortality with 1.44 microns laser ablation. Bauer J, et al. **Lasers Surg Med** 1996;19(3):299–310

REHABILITATION

Flying status and coronary revascularization procedures in military aviators. Khan MA, et al. **Aviat Space Environ Med** 1996 Feb;67(2):165–70 (32 ref.)

STATISTICS & NUMERICAL DATA

Light–guiding effect in a two–fluid model of laser angioplasty. Ilegbusi OJ, et al. **IEEE Trans Biomed Eng** 1997 Jul;44(7):592–600

UTILIZATION

The changing face of coronary interventional practice. The Mayo Clinic experience. Hasdai D, et al. **Arch Intern Med** 1997 Mar 24;157(6):677–82

ANGIOPLASTY, LASER-ASSISTED, BALLOON see **ANGIOPLASTY, BALLOON, LASER-ASSISTED**

ANGIOPLASTY, TRANSLUMINAL see **ANGIOPLASTY, BALLOON**

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY

Exercise myocardial perfusion and wall motion imaging to predict recurrence of angina pectoris after successful angioplasty. Dendale PA, et al. **Acta Cardiol** 1996; 51(5):409–23

Management of stable coronary artery disease [see comments] Gutstein DE, et al. **Am Fam Physician** 1997 Jul; 56(1):99–106, 111–3 (31 ref.). Comment in: Am Fam Physician 1997 Jul;56(1):31–2, 34, 37.

Quantitative Doppler tissue imaging for assessment of regional myocardial velocities during transient ischemia and reperfusion. Bach DS, et al. **Am Heart J** 1996 Oct; 132(4):721–5

Early exercise testing to stratify risk for development of restenosis after percutaneous transluminal coronary angioplasty. Coplan NL, et al. **Am Heart J** 1996 Dec; 132(6):1222–5 (37 ref.)

Stenting within a stent: treatment for repeat in–stent restenosis in a venous graft. Debbas N, et al. **Am Heart J** 1997 Apr;133(4):460–3

Angiographic predictors of neointimal thickening after successful coronary wall healing following percutaneous revascularization. de Lezo JS, et al. **Am Heart J** 1997 Feb; 133(2):210–20

Adaptation to myocardial ischemia during coronary angioplasty demonstrated by clinical, electrocardiographic, echocardiographic, and metabolic parameters. Eltchaninoff H, et al. **Am Heart J** 1997 Apr;133(4):490–6

Attenuation of the no–reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Ishihara M, et al. **Am Heart J** 1996 Nov;132(5):959–63

Postangioplasty restenosis: platelet activation and the coagulation–fibrinolysis system as possible factors in the pathogenesis of restenosis. Ishiwata S, et al. **Am Heart J** 1997 Apr;133(4):387–92

Repeat coronary angioplasty as the treatment of choice for restenosis. Kitazume H, et al. **Am Heart J** 1996 Oct; 132(4):711–5

Percutaneous transluminal coronary angioplasty in Takayasu's arteritis. Lee HY, et al. **Am Heart J** 1996 Nov; 132(5):1084–6

Acute myocardial infarction caused by blunt chest trauma: successful treatment by direct coronary angioplasty. Marcum JL, et al. **Am Heart J** 1996 Dec;132(6):1275–7

Angiographic deterioration of target coronary artery narrowing as a result of percutaneous balloon angioplasty. Rozenman Y, et al. **Am Heart J** 1997 May;133(5):575–9

Coronary stenting after unsuccessful emergency angioplasty in acute myocardial infarction: results in a series of consecutive patients. Steffenino G, et al. **Am Heart J** 1996 Dec;132(6):1115–8

Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Vlietstra RE, et al. **Am Heart J** 1996 Nov;132(5):1049–50

Short– and long–term outcome of narrowed saphenous vein bypass graft: a comparison of Palmaz–Schatz stent, directional coronary atherectomy, and balloon angioplasty. Waksman R, et al. **Am Heart J** 1997 Aug;134(2 Pt 1):274–81

Early and late assessment of the Micro Stent PL coronary stent for restenosis and suboptimal balloon angioplasty. Webb JG, et al. **Am Heart J** 1997 Mar;133(3):369–74

Causes of failed angioplasty for acute myocardial infarction assessed by intravascular ultrasound. Werner GS, et al. **Am Heart J** 1997 May;133(5):517–25

Rotational coronary atherectomy with adjunctive balloon angioplasty: evaluation of lumen enlargement by quantitative angiographic analysis. Zimarino M, et al. **Am Heart J** 1997 Feb;133(2):203–9

Excimer laser–facilitated angioplasty for undilatable coronary narrowings. Ahmed WH, et al. **Am J Cardiol** 1996 Nov 1;78(9):1045–6

Angiographic evolution of intracoronary thrombus and dissection following percutaneous transluminal coronary angioplasty (the Thrombolysis and Angioplasty in Unstable Angina [TAUSA] trial). Ambrose JA, et al. **Am J Cardiol** 1997 Mar 1;79(5):559–63

Comparison of stenting and balloon angioplasty for narrowings in aortocoronary saphenous vein conduits in place for more than five years. Brener SJ, et al. **Am J Cardiol** 1997 Jan 1;79(1):13–8

Timing and mechanism of death determined clinically after primary angioplasty for acute myocardial infarction. Brodie BR, et al. **Am J Cardiol** 1997 Jun 15;79(12):1586–91

Use of exercise echocardiography to evaluate patients after coronary angioplasty. Crouse LJ, et al. **Am J Cardiol** 1996 Nov 15;78(10):1163–6

Analysis of phasic flow velocity dynamics in the left anterior descending coronary artery before and after angioplasty using transthoracic echocardiography in patients with stable angina pectoris. Crowley JJ, et al. **Am J Cardiol**

1997 Sep 1;80(5):614–7

Changes in immediate outcome of percutaneous transluminal coronary angioplasty in multivessel coronary artery disease in 1990 to 1991 versus 1994 to 1995. Danchin N, et al. **Am J Cardiol** 1997 May 15;79(10):1389–91

Effect of late percutaneous angioplastic recanalization of total coronary artery occlusion on left ventricular remodeling, ejection fraction, and regional wall motion. Danchin N, et al. **Am J Cardiol** 1996 Oct 1;78(7):729–35

Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. Eisenberg MJ, et al. **Am J Cardiol** 1997 Apr 1;79(7):867–72

Are the results of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction different during the "off" hours? Garot P, et al. **Am J Cardiol** 1997 Jun 1;79(11):1527–9

Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. Gibson CM, et al. **Am J Cardiol** 1997 Jul 1;80(1):21–6

A new predictor of restenosis after successful percutaneous transluminal coronary angioplasty in patients with multivessel coronary artery disease. Hamasaki S, et al. **Am J Cardiol** 1997 Aug 15;80(4):411–5

Increase in the delta ST/delta heart rate (HR) index: a new predictor of restenosis after successful percutaneous transluminal coronary angioplasty. Hamasaki S, et al. **Am J Cardiol** 1996 Nov 1;78(9):990–5

ACE polymorphism, a genetic predictor of occlusion after coronary angioplasty. Hamon M, et al. **Am J Cardiol** 1996 Sep 15;78(6):679–81

Outcome > or = 10 years after successful percutaneous transluminal coronary angioplasty. Hasdai D, et al. **Am J Cardiol** 1997 Apr 15;79(8):1005–11

Effect of theophylline on adaptation of the heart to myocardial ischemia during percutaneous transluminal coronary angioplasty in patients with stable angina pectoris. Hashimura K, et al. **Am J Cardiol** 1997 Feb 15;79(4):475–7

Comparison of balloon angioplasty versus debulking devices versus stenting in right coronary ostial lesions. Jain SP, et al. **Am J Cardiol** 1997 May 15;79(10):1334–8

Community practice of primary angioplasty for myocardial infarction. Jhangiani AH, et al. **Am J Cardiol** 1997 Jul 15; 80(2):209–12

Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention. Kereiakes DJ, et al. **Am J Cardiol** 1997 Sep 1;80(5):633–4

Angioplasty or surgery for multivessel coronary artery disease: comparison of eligible registry and randomized patients in the EAST trial and influence of treatment selection on outcomes. Emory Angioplasty versus Surgery Trial Investigators. King SB 3rd, et al. **Am J Cardiol** 1997 Jun 1;79(11):1453–9

Increases in serum unbound free fatty acid levels following coronary angioplasty. Kleinfeld AM, et al. **Am J Cardiol** 1996 Dec 15;78(12):1350–4

Further ST elevation at reperfusion by direct percutaneous transluminal coronary angioplasty predicts poor recovery of left ventricular systolic function in anterior wall AMI. Kobayashi N, et al. **Am J Cardiol** 1997 Apr 1;79(7):862–6

Transient leftward QRS axis shift during treadmill exercise testing or percutaneous transluminal coronary angioplasty is a highly specific marker of proximal left anterior descending coronary artery disease. Kodama K, et al. **Am J Cardiol** 1997 Jun 1;79(11):1530–4

Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. Labinaz M, et al. **Am J Cardiol** 1996 Dec 15;78(12):1338–44

Angioscopy variables predictive of early angiographic outcome after excimer laser-assisted coronary angioplasty. Larrazet FS, et al. **Am J Cardiol** 1997 May 15;79(10):1343–9

Incidence and importance of thrombolysis in myocardial infarction grade 3 flow after primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Laster SB, et al. **Am J Cardiol** 1996 Sep 15; 78(6):623–6

Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). CAVEAT-I Investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial [see comments] Levine GN, et al. **Am J Cardiol** 1997 Mar 15; 79(6):748–55. Comment in: ACP J Club 1997 Sep-Oct;127(2):33.

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. Lincoff AM, et al. **Am J Cardiol** 1997 Feb 1;79(3):286–91

Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. Mehran R, et al. **Am J Cardiol** 1996 Sep 15;78(6):618–22

Comparison of outcome after stenting for de novo versus restenotic narrowings in native coronary arteries. Mittal S, et al. **Am J Cardiol** 1997 Sep 15;80(6):711–5

Relation of duration of ST reelevation at reperfusion and improvement of left ventricular function after successful primary angioplasty of the left anterior descending coronary artery in anterior wall acute myocardial infarction. Ochiai M, et al. **Am J Cardiol** 1997 Jun 15; 79(12):1667–70

Coronary flow reserve assessed by transesophageal echocardiography identifies early restenosis of the left anterior descending coronary artery angioplasty. Paraskevaidis IA, et al. **Am J Cardiol** 1997 Mar 15; 79(6):803–7

Percutaneous coronary angioscopic comparison of thrombus formation during percutaneous coronary angioplasty with ionic and nonionic low osmolality contrast media in unstable angina. Qureshi NR, et al. **Am J Cardiol** 1997 Sep 15;80(6):700–4

Comparison of myocardial contrast echocardiography and coronary angiography for assessing the acute protective effects of collateral recruitment during occlusion of the left anterior descending coronary artery at the time of elective angioplasty. Sakata Y, et al. **Am J Cardiol** 1997 May 15;79(10):1329–33

Rapid reduction of ST-segment elevation after successful direct angioplasty in acute myocardial infarction. Santoro GM, et al. **Am J Cardiol** 1997 Sep 15;80(6):685–9

Interprocedural interval as a predictor of stent restenosis after previous coronary angioplasty. The Palmaz-Schatz Stent Investigators. Savage MP, et al. **Am J Cardiol** 1996 Sep 15;78(6):683–4

Recanalization of chronic coronary artery occlusions using laser followed by balloon angioplasty [see comments] Schofer J, et al. **Am J Cardiol** 1996 Oct 1;78(7):836–8. Comment in: Am J Cardiol 1996 Oct 1;78(7):823–4.

Prognostic value of slow resolution of ST-segment elevation following successful direct percutaneous transluminal coronary angioplasty for recovery of left ventricular function. Somitsu Y, et al. **Am J Cardiol** 1997 Aug 15; 80(4):406–10

One-week and six-month angiographic controls of stent implantation after occlusive and nonocclusive dissection during primary balloon angioplasty for acute myocardial infarction. Spaulding C, et al. **Am J Cardiol** 1997 Jun 15; 79(12):1592–5

Frequency of pericardial friction rub ("pericarditis") after direct percutaneous transluminal coronary angioplasty in Q-wave acute myocardial infarction. Sugiura T, et al. **Am J Cardiol** 1997 Feb 1;79(3):362–4

Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Take S, et al. **Am J Cardiol** 1997 Apr 15;79(8):1097–9

Low-dose heparin for routine coronary angioplasty and stenting. Vainer J, et al. **Am J Cardiol** 1996 Oct 15; 78(8):964–6

Cardiologists' perception of risk of coronary revascularization procedures. Vaitkus PT, et al. **Am J Cardiol** 1997 Aug 1;80(3):338–41

Differences of regional coronary flow reserve assessed by adenosine thallium-201 scintigraphy early and six months after successful percutaneous transluminal coronary angioplasty or stent implantation. Versaci F, et al. **Am J Cardiol** 1996 Nov 15;78(10):1097–102

Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction. Ward SR, et al. **Am J Cardiol** 1997 Mar 1; 79(5):539–44

Effect of coronary angioplasty on precordial QT dispersion. Yunus A, et al. **Am J Cardiol** 1997 May 15;79(10):1339–42

Primary angioplasty versus thrombolysis in the treatment of acute myocardial infarction. ALKK Study Group. Zahn R, et al. **Am J Cardiol** 1997 Feb 1;79(3):264–9

Early management of acute myocardial infarction: thrombolysis, angioplasty, and adjunctive therapies. Selig MB. **Am J Emerg Med** 1996 Mar;14(2):209–17 (103 ref.)

Hemodynamic consequences of stenosis remodeling during coronary angioplasty. Back MR, et al. **Angiology** 1997 Feb; 48(2):99–109

Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Birand A, et al. **Angiology** 1997 May;48(5):413–22

Is there any association between dissection after successful percutaneous transluminal coronary angioplasty and late restenosis? An angiographic study. Ovünç K, et al. **Angiology** 1997 Feb;48(2):111–6

Patency and reinfarction in late-entry myocardial infarct patients treated with reperfusion therapy. van't Hof AW, et al. **Angiology** 1997 Mar;48(3):215–22

Percutaneous transluminal coronary angioplasty for morphologic left anterior descending artery lesion in a patient with dextrocardia. A case report and literature review. Yamazaki T, et al. **Angiology** 1997 May;48(5):451–6 (12 ref.)

Clinical trials to prevent restenosis after percutaneous coronary revascularization. Mak KH, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:255–84; discussion 284–8 (183 ref.)

ABCIXIMAB: a new antiaggregant used in angioplasty. Genetta TB, et al. **Ann Pharmacother** 1996 Mar;30(3):251–7 (28 ref.)

Angiographic correlates of graft patency and relationship to clinical outcomes. Alderman EL. **Ann Thorac Surg** 1996 Nov;62(5 Suppl):S22–5; discussion S31–2

Revascularization of patients with coronary artery disease: the interventional cardiologist's perspective. de Jaegere PP, et al. **Ann Thorac Surg** 1997 Jun;63(6 Suppl):S23–7

Predictors of CABG within one year of successful PTCA: a retrospective, case-control study. Johnson RG, et al. **Ann Thorac Surg** 1997 Jul;64(1):3–7; discussion 7–8

Coronary artery restenosis after balloon angioplasty in humans is associated with circumferential coronary constriction. Luo H, et al. **Arterioscler Thromb Vasc Biol** 1996 Nov;16(11):1393–8

Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis. Adachi H, et al. **Artif Organs** 1995 Dec;19(12):1243–7

The lack of effect of beta-carotene on restenosis in cholesterol-fed rabbits. Burchenal JE, et al. **Atherosclerosis** 1996 Jun;123(1-2):157–67

Molecular biology and post-angioplasty restenosis. Nikol S, et al. **Atherosclerosis** 1996 Jun;123(1-2):17–31 (79 ref.)

Apolipoprotein E polymorphism does not predict risk of restenosis after coronary angioplasty. Samani NJ, et al. **Atherosclerosis** 1996 Sep 6;125(2):209–16

Percutaneous transluminal coronary angioplasty (PTCA): long-term outcome and aeromedical implications. Moorman DL, et al. **Aviat Space Environ Med** 1996 Oct; 67(10):990–6 (45 ref.)

Systemic and cardiac catecholamines during elective PTCA and during immediate PTCA for acute myocardial infarction. Richardt G, et al. **Basic Res Cardiol** 1997 Feb; 92(1):52–60

Consent procedure for coronary angioplasty is haphazard [letter] Langford E, et al. **BMJ** 1997 Jun 14;314(7096):1762

Evaluation of body surface potential mapping changes after successful percutaneous transluminal coronary angioplasty. Boudík F, et al. **Can J Cardiol** 1996 Aug;12(8):745–9

Percutaneous transluminal angioplasty in coronary-internal thoracic-subclavian steal syndrome. Nguyen NH, et al. **Can J Cardiol** 1997 Mar;13(3):285–9 (34 ref.)

Percutaneous transluminal angioplasty in coronary-internal thoracic-subclavian steal syndrome [letter] Perrault LP, et al. **Can J Cardiol** 1997 Aug;13(8):729, 780

Stenting of the left main coronary artery in the setting of acute myocardial infarction. al-Saadon K, et al. **Can J Cardiol** 1997 Jul;13(7):681–4

Treatment of acute myocardial infarction: in which patients should primary percutaneous transluminal coronary angioplasty be preferred to thrombolysis? Topol EJ. **Cardiologia** 1996 Sep;41(9):843–7

Radiation catheter-based therapy for prevention of restenosis. Waksman R. **Cardiologia** 1996 Sep;41(9):849–54

Rescue PTCA for a totally occluded left main coronary artery in acute myocardial infarction with cardiogenic shock: technical success and long-term survival. La Vecchia L, et al. **Cardiology** 1997 Sep-Oct;88(5):482–5

Age- and gender-related differences in success, major and minor complication rates and the duration of hospitalization after percutaneous transluminal coronary angioplasty. Rozenman Y, et al. **Cardiology** 1996 Sep-Oct;87(5):396–401

Local changes in the plasma endothelin level in the coronary artery immediately after percutaneous transluminal coronary angioplasty. Vojácek J, et al. **Cardiology** 1997 Jan-Feb;88(1):1–5

Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study). Nakamura Y, et al. **Cardiovasc Drugs Ther** 1996 Sep;10(4):475–83

Altered resistive vessel function after coronary angioplasty is not due to reduced production of nitric oxide. Uren NG, et al. **Cardiovasc Res** 1996 Dec;32(6):1108–14

Angioplasty followed by coronary stenting at the anastomotic site of saphenous vein bypass graft with the native vessel: a case that needs special procedural strategy. Antonellis IP, et al. **Cathet Cardiovasc Diagn** 1997 Sep; 42(1):61–3

Understanding the "no-reflow" problem [editorial; comment] Baim DS, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):7–8. Comment on: Cathet Cardiovasc Diagn 1996 Sep;39(1):1–6.

Angioplasty decision making based on abnormal translesion hemodynamics for an intermediate stenosis: the dilemma of a high translesional pressure gradient and normal distal flow reserve. Carollo S, et al. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):184–7

Percutaneous transluminal angioplasty of internal mammary arteries in patients with rest angina. Crowley ST, et al. **Cathet Cardiovasc Diagn** 1996 Jul;38(3):256–62

Distal coronary hemoperfusion during percutaneous transluminal coronary angioplasty. de Muinck ED, et al. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):233–40; discussion 241–2 (56 ref.)

A single-step stent delivery, deployment, and expansion system. Duvvuri S, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):308–10

Acute coronary artery angioplasty during pregnancy. Eickman FM. **Cathet Cardiovasc Diagn** 1996 Aug; 38(4):369–72

Diffuse vasospasm following stenting of a free gastroepiploic artery graft: resolution with balloon angioplasty and intensive medical therapy. Feld S, et al. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):352–5

Use of coronary Palmaz-Schatz stent in the percutaneous treatment of vertebral artery stenoses. Feldman RL, et al.

Cathet Cardiovasc Diagn 1996 Jul;38(3):312–5
Improved technique for use of half-stents remounted on a stent delivery system [see comments] Feldman T, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):17–20. Comment in: Cathet Cardiovasc Diagn 1997 Mar;40(3):335.
Recurrent miscarriages as an indication for percutaneous tricuspid valvuloplasty during pregnancy. Gamra H, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):283–6
Coronary AVE micro stents: do we need another stent? [editorial; comment] Ganim MS, et al. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):225. Comment on: Cathet Cardiovasc Diagn 1997 Jun;41(2):213–24.
Recanalization of totally occluded saphenous vein grafts using local urokinase delivery with the Dispatch catheter. Glazier JJ, et al. **Cathet Cardiovasc Diagn** 1995 Dec; 36(4):326–32
Successful coronary pace-termination of ventricular tachycardia during coronary angioplasty [see comments] Goode G, et al. **Cathet Cardiovasc Diagn** 1997 Sep; 42(1):31–2. Comment in: Cathet Cardiovasc Diagn 1997 Sep;42(1):33.
Intracoronary stenting using slotted tubular stents with intravascular ultrasound and anticoagulation [see comments] Goods CM, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):341–5. Comment in: Cathet Cardiovasc Diagn 1996 Dec;39(4):346.
Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. Gottsauner-Wolf M, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):102–8
Percutaneous revascularization of an extensively diseased saphenous vein bypass graft with a saphenous vein-covered Palmaz stent [see comments] Gurbel PA, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):75–8 (12 ref.). Comment in: Cathet Cardiovasc Diagn 1997 Jan;40(1):79.
Recanalization of occluded SVGs: is there light at the end of the graft? [editorial] Heuser RR. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):333–4
Why we get out of bed to do infarct PTCA [editorial; comment] Kahn JK. **Cathet Cardiovasc Diagn** 1996 Dec; 39(4):340. Comment on: Cathet Cardiovasc Diagn 1996 Dec;39(4):333–9.
Culprit vessel angioplasty: it's a small world after all [editorial; comment] Kahn JK. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):262. Comment on: Cathet Cardiovasc Diagn 1996 Mar;37(3):258–61.
Embolization of a Wiktor stent within a stent: successful nonsurgical management. Kaul U, et al. **Cathet Cardiovasc Diagn** 1996 Jul;38(3):277–9
Angioplasty of isolated acute marginal coronary artery disease [see comments] Kirigin M, et al. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):258–61. Comment in: Cathet Cardiovasc Diagn 1996 Mar;37(3):262.
Exaggerated luminal loss a few minutes after successful percutaneous transluminal coronary angioplasty in patients with recent myocardial infarction compared with stable angina: an intracoronary ultrasound study. Lee TM, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):32–9
Creatine kinase release after catheter-based coronary intervention [editorial] Lim R, et al. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):117–9 (10 ref.)
Coronary vein flow velocity changes during transluminal balloon angioplasty: a study using the Doppler guide wire. Manginas A, et al. **Cathet Cardiovasc Diagn** 1997 Jan; 40(1):85–91 (23 ref.)
Pacing in the left heart—often forgotten because rarely needed [editorial; comment] Meier B. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):33. Comment on: Cathet Cardiovasc Diagn 1997 Sep;42(1):31–2.
Plaque sealing by coronary angioplasty [editorial] [see comments] Meier B, et al. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):295–7. Comment in: Cathet Cardiovasc Diagn 1996 Jun;38(2):226–7.
Is echocardiography or magnetic resonance imaging superior for precoarctation angioplasty evaluation? Mendelsohn AM, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):26–30
Emergent mitral percutaneous valvuloplasty before emergent liver transplantation [letter] Moreno R, et al. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):229–30
Angioplasty and stenting of an unprotected left main bifurcation lesion. Morrison DA, et al. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):174–8
Excimer laser angioplasty vs. balloon angioplasty in saphenous vein bypass grafts: quantitative angiographic comparison of matched lesions. Natarajan MK, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):153–8
Coronary hemodynamics before and after rotational atherectomy with adjunctive balloon angioplasty. Núñez BD, et al. **Cathet Cardiovasc Diagn** 1996;Suppl 3:40–9
Resolution of exercise intolerance secondary to ischemic sinus node dysfunction following percutaneous transluminal angioplasty. Osborn LA, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):44–7
Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time. Pesola GR, et al. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):140–4
Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty. Pitney MR, et al. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):145–50
Coronary AVE micro stents: serial quantitative angiography and histology in a canine model [see comments] Pomerantsev EV, et al. **Cathet Cardiovasc Diagn** 1997 Jun; 41(2):213–24. Comment in: Cathet Cardiovasc Diagn 1997 Jun;41(2):225.
How does the fairer sex fare after PTCA? [editorial; comment] Rabah MM, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):16. Comment on: Cathet Cardiovasc Diagn 1996 Sep;39(1):9–15.
New approach to quantitative angiographic assessment after stent implantation. Reimers B, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):343–7
Women fare no worse than men 10 years after attempted coronary angioplasty [see comments] Ruygrok PN, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):9–15. Comment in: Cathet Cardiovasc Diagn 1996 Sep;39(1):16.
Lysis of intracoronary thrombus prior to coronary stenting using the dispatch infusion catheter [editorial; comment] [see comments] Satler LF, et al. **Cathet Cardiovasc Diagn** 1996 Aug;38(4):415–6. Comment on: Cathet Cardiovasc Diagn 1996 Aug;38(4):410–4. Comment in: Cathet Cardiovasc Diagn 1996 Dec;39(4):438–9.
Facilitated advancement of the Palmaz-Schatz stent delivery system with the use of an adjacent 0.018" stiff wire. Saucedo JF, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):106–10
Distal vessel pullback angiography and pressure gradient measurement: an innovative diagnostic approach to evaluate the no-reflow phenomenon [see comments] Sherman JR, et al. **Cathet Cardiovasc Diagn** 1996 Sep; 39(1):1–6. Comment in: Cathet Cardiovasc Diagn 1996 Sep;39(1):7–8.
Sheath pulling immediately after PTCA: comparison of two different deployment techniques for the hemostatic puncture closure device: a prospective, randomized study [see comments] Silber S, et al. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):378–83. Comment in: Cathet Cardiovasc Diagn 1997 Aug;41(4):384–5.
Outcome of different reperfusion strategies in patients with former contraindications to thrombolytic therapy: a comparison of primary angioplasty and tissue plasminogen activator. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators [see comments] Stone GW, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):333–9. Comment in: Cathet Cardiovasc Diagn 1996 Dec;39(4):340.
Coronary angioplasty of a severe coronary stenosis at the site of a myocardial bridge. Takeuchi M, et al. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):416–20
Measurement of myocardial fractional flow reserve during coronary angioplasty in patients with old myocardial infarction. Takeuchi M, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):19–25
Coronary angioplasty of a posterolateral branch with severe proximal vessel tortuosity. Tishler S, et al. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):426–9
Coronary bypass on a catheter: sweeping the thrombus and friable material under a vein [editorial; comment] Turi ZG. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):79–80. Comment on: Cathet Cardiovasc Diagn 1997 Jan;40(1):75–8.
Reconsidering unprotected left main coronary angioplasty [editorial] Turi ZG. **Cathet Cardiovasc Diagn** 1995 Dec; 36(4):368–70
Acute infarction, intracoronary thrombolysis, and primary PTCA in pregnancy. Webber MD, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):38–43
Precision angioplasty [editorial; comment] White CJ. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):338. Comment on: Cathet Cardiovasc Diagn 1995 Dec;36(4):335–7.
The role of percutaneous revascularization in the treatment of ischemic heart disease: insights from published reports and randomized clinical trials. Levine GN, et al. **Chest** 1997 Sep;112(3):805–21 (95 ref.)
Emergency percutaneous transluminal coronary angioplasty in acute myocardial infarction complicated with cardiogenic shock. Gao R, et al. **Chin Med J (Engl)** 1996 Aug;109(8):583–7
Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) [see comments] **Circulation** 1997 Sep 16;96(6):1761–9. Comment in: Circulation 1997 Sep 16;96(6):1707–10.
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. **Circulation** 1997 Sep 2;96(5):1445–53
Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans [editorial; comment] **Circulation** 1997 Aug 19;96(4):1067–8. Comment on: Circulation 1997 Aug 5;96(3):727–32.
Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Abdelmeguid AE, et al. **Circulation** 1996 Oct 1; 94(7):1528–36
Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Berkowitz SD, et al. **Circulation** 1997 Feb 18;95(4):809–13
Effect of Rotablator atherectomy and adjunctive balloon angioplasty on coronary blood flow. Bowers TR, et al. **Circulation** 1997 Mar 4;95(5):1157–64
Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Cairns JA, et al. **Circulation** 1996 Oct 1;94(7):1553–60
Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics. Camenzind E, et al. **Circulation** 1997 Jul 1;96(1):154–65
Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans [see comments] Condado JA, et al. **Circulation** 1997 Aug 5;96(3):727–32. Comment in: Circulation 1997 Aug 5;96(3):709–12. Comment in: Circulation 1997 Aug 19;96(4):1067–8.
Clinical and prognostic usefulness of supine bicycle exercise echocardiography in the functional evaluation of patients undergoing elective percutaneous transluminal coronary angioplasty. Dagianti A, et al. **Circulation** 1997 Mar 4; 95(5):1176–84
Lipid lowering versus revascularization: an idea whose time (for testing) has come. Forrester JS, et al. **Circulation** 1997 Aug 19;96(4):1360–2
Lanreotide reduces serum free and total insulin-like growth factor-I after angioplasty. Frystyk J, et al. **Circulation** 1996 Nov 15;94(10):2465–71
Pacifying the infarct vessel [editorial; comment] Guetta V, et al. **Circulation** 1997 Aug 5;96(3):713–5. Comment on: Circulation 1997 Aug 5;96(3):748–55.
Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Guzman LA, et al. **Circulation** 1996 Sep 15;94(6):1441–8
Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty. Horie H, et al. **Circulation** 1997 Jul 1;96(1):166–73
Presence of a critical coronary artery stenosis does not abolish the protective effect of ischemic preconditioning. Kapadia SJ, et al. **Circulation** 1997 Mar 4;95(5):1286–92
Significance of CK values after coronary angioplasty [letter; comment] Karim MA. **Circulation** 1997 Mar 18; 95(6):1665–6. Comment on: Circulation 1996 Jan 15;93(2):397–8.
Histopathology of in-stent restenosis in patients with peripheral artery disease. Kearney M, et al. **Circulation** 1997 Apr 15;95(8):1998–2002
Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry [see comments] Kip KE, et al. **Circulation** 1996 Oct 15; 94(8):1818–25. Comment in: Circulation 1996 Oct 15;94(8):1804–6.
Dynamics of left ventricular apex rotation during angioplasty: a sensitive index of ischemic dysfunction. Knudtson ML, et al. **Circulation** 1997 Aug 5;96(3):801–8
Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem. Lablanche JM, et al. **Circulation** 1997 Jan 7;95(1):83–9
Does stenting prevent diabetic arterial shrinkage after percutaneous coronary revascularization? [editorial; comment] Lincoff AM. **Circulation** 1997 Sep 2;96(5):1374–7 . Comment on: Circulation 1997 Sep 2;96(5):1454–60.
Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction [see comments] Madsen JK, et al. **Circulation** 1997 Aug 5;96(3):748–55. Comment in: Circulation 1997 Aug 5;96(3):713–5.
Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Mintz GS, et al. **Circulation** 1996 Jul 1;94(1):35–43
Prediction of restenosis after coronary balloon angioplasty. Results of PICTURE (Post-IntraCoronary Treatment Ultrasound Result Evaluation), a prospective multicenter intracoronary ultrasound imaging study [see comments] Peters RJ, et al. **Circulation** 1997 May 6;95(9):2254–61. Comment in: Circulation 1997 May 6;95(9):2244–6.
Beta-radiation to reduce restenosis. Too little, too soon? [editorial; comment] Teirstein P. **Circulation** 1997 Mar 4; 95(5):1095–7 (22 ref.). Comment on: Circulation 1997 Mar 4;95(5):1138–44.
Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels [see comments] Van Belle E, et al. **Circulation** 1997 Sep 2;96(5):1454–60. Comment in: Circulation 1997 Sep 2;96(5):1374–7.
Platelet changes in patients with acute myocardial infarction treated with immediate PTCA [letter; comment] van der Loo B, et al. **Circulation** 1996 Dec 1;94(11):3001–2. Comment on: Circulation 1996 Jan 15;93(2):229–37.
Feasibility of intracoronary beta-irradiation to reduce restenosis after balloon angioplasty. A clinical pilot study [see comments] Verin V, et al. **Circulation** 1997 Mar 4; 95(5):1138–44. Comment in: Circulation 1997 Mar 4;95(5):1095–7.
Effects of octreotide treatment on restenosis after coronary angioplasty: results of the VERAS study. VErringerung der Restenoserate nach Angioplastie durch ein Somatostatin-analogon. von Essen R, et al. **Circulation** 1997 Sep 2;96(5):1482–7
Angioscopic predictors of early adverse outcome after

coronary angioplasty in patients with unstable angina and non–Q–wave myocardial infarction. Waxman S, et al. **Circulation** 1996 Jun 15;93(12):2106–13

Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease [news] Willerson JT. **Circulation** 1996 Sep 15;94(6):1194

Results of percutaneous transluminal coronary angioplasty in unstable angina and non–Q–wave myocardial infarction. Observations from the TIMI IIIB Trial. Williams DO, et al. **Circulation** 1996 Dec 1;94(11):2749–55

The Bypass Angioplasty Revascularization Investigation (BARI) trial: implications for clinical practice. Whitlow PL. **Cleve Clin J Med** 1997 Jan;64(1):17–20

Factors associated with the release of cardiac troponin T following percutaneous transluminal coronary angioplasty. Abbas SA, et al. **Clin Cardiol** 1996 Oct;19(10):782–6

Coronary artery stenting with high–pressure post–dilation followed by adjunctive thrombolysis after failed coronary angioplasty for acute myocardial infarction: report of three cases. Iwasaki K, et al. **Clin Cardiol** 1997 Apr;20(4):398–401

Echocardiographic assessment of wall motion in ST–segment alternans during coronary angioplasty. Kerensky RA, et al. **Clin Cardiol** 1996 Sep;19(9):749–50

Importance of delaying balloon angioplasty in patients with unstable angina pectoris. Rozenman Y, et al. **Clin Cardiol** 1996 Feb;19(2):111–4

Ischemic preconditioning: clinical relevance and investigative studies. Schlaifer JD, et al. **Clin Cardiol** 1997 Jul; 20(7):602–6 (24 ref.)

Abrupt (< 1 day), acute (< 1 week), and early (< 1 month) vessel closure at the angioplasty site. Morphologic observations and causes of closure in 130 necropsy patients undergoing coronary angioplasty. Waller BF, et al. **Clin Cardiol** 1996 Nov;19(11):857–68

Coronary artery and saphenous vein graft remodeling: A review of histologic findings after various interventional procedures—Part III. Waller BF, et al. **Clin Cardiol** 1996 Nov;19(11):895–901 (39 ref.)

Coronary artery and saphenous vein graft remodeling: a review of histologic findings after various interventional procedures—Part V. Waller BF, et al. **Clin Cardiol** 1997 Jan;20(1):67–74 (52 ref.)

Coronary artery and saphenous vein graft remodeling: a review of histologic findings after various interventional procedures—Part I. Waller BF, et al. **Clin Cardiol** 1996 Sep;19(9):744–8

Current approaches to coronary intervention. King SB 3rd. **Compr Ther** 1996 Nov;22(11):731–6 (24 ref.)

Coronary revascularization in the elderly: Florida multicenter consecutive case experience with coronary revascularization in patients age 75 years and older. The Program Committee Florida Chapter American College of Cardiology. Safford RE. **Compr Ther** 1996 Aug; 22(8):477–84

Successful coronary stenting without warfarin or intravascular ultrasound. Warner MF, et al. **Conn Med** 1997 Feb;61(2):91–4

Organizational structure and communication strategies of the bypass angioplasty revascularization investigation: a multicenter clinical trial. Naydeck BL, et al. **Control Clin Trials** 1996 Jun;17(3):226–34

Early coronary angioplasty as compared with delayed coronary angioplasty in patients with high–risk unstable angina pectoris. Antoniucci D, et al. **Coron Artery Dis** 1996 Jan;7(1):75–80

Acute results of directional coronary atherectomy in the Balloon Versus Optimal Atherectomy Trial (BOAT) pilot phase. Baim DS, et al. **Coron Artery Dis** 1996 Apr; 7(4):290–3

Clinical trials of Hirulog in patients undergoing high–risk percutaneous transluminal coronary angioplasty. Bittl JA. **Coron Artery Dis** 1996 Jun;7(6):449–54 (64 ref.)

Intravascular ultrasound assessment of direct percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. Bocksch W, et al. **Coron Artery Dis** 1997 May;8(5):265–73

Early detection of platelet activation after coronary angioplasty. Inoue T, et al. **Coron Artery Dis** 1996 Jul; 7(7):529–34

Causes of coronary events after successful coronary angioplasty. Ishiwata S, et al. **Coron Artery Dis** 1996 Aug; 7(8):573–7

PTCA versus CABG for angina pectoris: a look at the randomized trials. Kalynych AM, et al. **Coron Artery Dis** 1995 Oct;6(10):788–96 (31 ref.)

Acute myocardial infarction: role of medical therapy versus primary PTCA. Keeley EC, et al. **Coron Artery Dis** 1995 Oct;6(10):759–64 (30 ref.)

Coronary collateral blood–flow velocity improves with repeated coronary occlusions during angioplasty in patients with coronary artery disease and systemic hypertension. Kyriakides ZS, et al. **Coron Artery Dis** 1997 May; 8(5):275–81

Unstable angina: the role of percutaneous coronary angioplasty. Piana RN, et al. **Coron Artery Dis** 1995 Oct; 6(10):774–9 (36 ref.)

Effect of diabetes mellitus on outcome after percutaneous transluminal coronary angioplasty. St Claire DA Jr, et al. **Coron Artery Dis** 1996 Oct;7(10):744–52 (75 ref.)

Angioplasty or thrombolysis: misconstrued questions and misleading answers [editorial] Sobel BE. **Coron Artery Dis** 1996 Dec;7(12):933–4

'Tandem lesion' coronary angioplasty: ten years' experience. Tan KH, et al. **Coron Artery Dis** 1995 Oct;6(10):819–25

A review of randomized trials comparing coronary angioplasty and bypass grafting. Anderson WD, et al. **Curr Opin Cardiol** 1996 Nov;11(6):583–90 (32 ref.)

Restenosis after coronary angioplasty. Hong MK, et al. **Curr Probl Cardiol** 1997 Jan;22(1):1–36 (159 ref.)

Role of calcium channel blockers in reducing acute ischaemia and preventing restenosis in PTCA. Vahanian A, et al. **Drugs** 1996;52 Suppl 4:9–15; discussion 15–6 (35 ref.)

Management of acute myocardial infarction in the elderly. Forman DE, et al. **Drugs Aging** 1996 May;8(5):358–77 (149 ref.)

Recommendations for training and quality control in coronary angioplasty. The study group Clinical Issues, working group Coronary Circulation, of the European Society of Cardiology. **Eur Heart J** 1996 Oct; 17(10):1477–81

Quantification of collateral blood flow during PTCA by intravascular Doppler. Bach RG, et al. **Eur Heart J** 1995 Oct;16 Suppl J:74–7

Morphological changes after percutaneous transluminal coronary angioplasty of unstable plaques. Insights from serial angioscopic follow–up [see comments] Bauters C, et al. **Eur Heart J** 1996 Oct;17(10):1554–9. Comment in: Eur Heart J 1996 Oct;17(10):1461–2.

Coronary angioplasty as a model of ischaemic preconditioning: fact or fancy? [editorial; comment] Baxter GF. **Eur Heart J** 1996 Jun;17(6):812–4. Comment on: Eur Heart J 1996 Jun;17(6):846–53.

Complications prior to revascularization among patients waiting for coronary artery bypass grafting and percutaneous transluminal coronary angioplasty. Bengtson A, et al. **Eur Heart J** 1996 Dec;17(12):1846–51

A randomized trial of a fixed high dose vs a weight–adjusted low dose of intravenous heparin during coronary angioplasty. Boccara A, et al. **Eur Heart J** 1997 Apr; 18(4):631–5

Predictors of outcome of reperfusion therapy. Califf RM, et al. **Eur Heart J** 1997 May;18(5):728–35 (75 ref.)

Treatment of ischaemic heart disease. Role of drugs, surgery and angioplasty in unstable angina patients. Conti CR. **Eur Heart J** 1997 May;18 Suppl B:B11–5 (25 ref.)

Angioscopic morphological changes after coronary angioplasty of unstable plaques [editorial; comment] Conti CR. **Eur Heart J** 1996 Oct;17(10):1461–2. Comment on: Eur Heart J 1996 Oct;17(10):1554–9.

Late in–stent restenosis in coronary arteries and in grafts [letter] Debbas NM, et al. **Eur Heart J** 1997 Mar; 18(3):528–30

Angioplasty registries: wide open for audit? [editorial; comment] De Bono DP. **Eur Heart J** 1997 Jul;18(7):1042–3 . Comment on: Eur Heart J 1997 Jul;18(7):1110–4.

Angina in the elderly. Duprez DA. **Eur Heart J** 1996 Dec; 17 Suppl G:8–13 (28 ref.)

Multiple restenosis following PTCA. Eber B, et al. **Eur Heart J** 1995 Nov;16(11):1742

Multiple restenoses following PTCA [letter] Eber B, et al. **Eur Heart J** 1997 Jul;18(7):1189–90

Transoesophageal stress echocardiography. Flachskampf FA, et al. **Eur Heart J** 1997 Jun;18 Suppl D:D37–42 (19 ref.)

Functional assessment of PTCA results by stress echocardiography: when and how to test. Flachskampf FA, et al. **Eur Heart J** 1995 Oct;16 Suppl J:31–4 (29 ref.)

Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double–blind pilot study [see comments] Grip L, et al. **Eur Heart J** 1997 Mar;18(3):443–9. Comment in: Eur Heart J 1997 Mar;18(3):362–3.

Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris [see comments] Hafner G, et al. **Eur Heart J** 1996 Aug; 17(8):1207–15. Comment in: Eur Heart J 1996 Aug;17(8):1134–6.

Hypersensitivity of human coronary segments to ergonovine 6 months after injury by coronary angioplasty: a quantitative angiographic study in consecutive patients undergoing single–vessel angioplasty [see comments] Hamon M, et al. **Eur Heart J** 1996 Jun;17(6):890–5. Comment in: Eur Heart J 1996 Jun;17(6):814–5.

Evaluation of recombinant hirudin (CGP 39,393/TMREVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study. Herrman JP, et al. **Eur Heart J** 1995 Nov;16 Suppl L:56–62 (54 ref.)

Adjunctive infusion of antithrombin III during percutaneous transluminal coronary angioplasty [editorial; comment] Huber K, et al. **Eur Heart J** 1997 Mar;18(3):362–3. Comment on: Eur Heart J 1997 Mar;18(3):443–9.

Stable angina: drugs, angioplasty or surgery? Jackson G. **Eur Heart J** 1997 May;18 Suppl B:B2–10 (20 ref.)

Differences in the morphology of unstable and stable coronary lesions and their impact on the mechanisms of angioplasty. An in vivo study with intravascular ultrasound. Kearney P, et al. **Eur Heart J** 1996 May; 17(5):721–30

Description of patients undergoing high risk angioplasty. Analyses of various databases. Kleiman NS. **Eur Heart J** 1995 Nov;16 Suppl L:30–5 (50 ref.)

PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS) [see comments] Kolarov P, et al. **Eur Heart J** 1996 Aug;17(8):1216–22. Comment in: Eur Heart J 1996 Aug;17(8):1134–6.

Platelet activation and coronary interventions [editorial; comment] Kutryk MJ, et al. **Eur Heart J** 1996 Aug; 17(8):1134–6. Comment on: Eur Heart J 1996 Aug;17(8):1207–15. Comment on: Eur Heart J 1996 Aug;17(8):1216–22.

Percutaneous balloon mitral valvuloplasty in patients with mitral restenosis after previous surgical commissurotomy. A matched comparative study. Lau KW, et al. **Eur Heart J** 1996 Sep;17(9):1367–72

An unresolved, persisting challenge for percutaneous transluminal coronary angioplasty: how to identify the lesions that will not restenose [editorial; comment] Maseri A. **Eur Heart J** 1996 Jun;17(6):814–5. Comment on: Eur Heart J 1996 Jun;17(6):890–5.

Reproducibility of quantitative measurements from intracoronary ultrasound images. Beat–to–beat variability and influence of the cardiac cycle. Peters RJ, et al. **Eur Heart J** 1996 Oct;17(10):1593–9

Angiographic follow–up results of a randomized study on angioplasty versus bypass surgery (GABI trial). GABI Study Group [see comments] Rupprecht HJ, et al. **Eur Heart J** 1996 Aug;17(8):1192–8. Comment in: Eur Heart J 1996 Aug;17(8):1140–1.

Immediate outcome following coronary angioplasty. A contemporary single centre audit. Ruygrok PN, et al. **Eur Heart J** 1995 Nov;16 Suppl L:24–9

Interpretation of trials with drugs and devices; a double standard? Simoons ML. **Eur Heart J** 1996 Oct; 17(10):1463–5

Management of myocardial infarction: the proper priorities. Simoons ML, et al. **Eur Heart J** 1997 Jun;18(6):896–9 (31 ref.)

CABG v PTCA in multi–vessel disease: angiographic insights [editorial; comment] Stables RH, et al. **Eur Heart J** 1996 Aug;17(8):1140–1. Comment on: Eur Heart J 1996 Aug;17(8):1192–8.

Predictors of angiographic findings when chest pain recurs after successful coronary angioplasty. Tan KH, et al. **Eur Heart J** 1995 Nov;16(11):1593–602

Clinical promise of calcium antagonists in the angioplasty patient. Thaulow E, et al. **Eur Heart J** 1997 May;18 Suppl B:B21–6 (47 ref.)

Effects of A1 adenosine receptor blockade by bamiphylline on ischaemic preconditioning during coronary angioplasty [see comments] Tomai F, et al. **Eur Heart J** 1996 Jun; 17(6):846–53. Comment in: Eur Heart J 1996 Jun;17(6):812–4.

Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands. van Hout BA, et al. **Eur Heart J** 1995 Nov;16 Suppl L:81–5

PTCA registry of German community hospitals. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) Study Group [see comments] Vogt A, et al. **Eur Heart J** 1997 Jul;18(7):1110–4. Comment in: Eur Heart J 1997 Jul;18(7):1042–3.

The management of post–cardiac transplantation coronary artery disease. Parry A, et al. **Eur J Cardiothorac Surg** 1996; 10(7):528–32; discussion 53

Coronary angioplasty 1997: twenty years after. Angelini P. **G Ital Cardiol** 1997 Mar;27(3):300–3 (13 ref.)

Coronary restenosis after optimal (stent–like) initial angiographic results obtained by traditional balloon angioplasty. Di Luzio V, et al. **G Ital Cardiol** 1997 Jul; 27(7):645–53 (38 ref.)

Intracoronary stenting for thrombus–containing lesions in the setting of acute ischemic syndromes. Ramondo A, et al. **G Ital Cardiol** 1997 Jul;27(7):654–8

Factors affecting the therapeutic choice in patients with multivessel coronary artery disease. The Studio Lombardo Angiografia Multivasali (SLAM) Study Group. De Servi S, et al. **Heart** 1997 May;77(5):443–8

Prioritising the cardiac surgery waiting list: the angina patient's perspective. Kee F, et al. **Heart** 1997 Apr; 77(4):330–2

Does a waiting time for elective coronary angioplasty affect the primary success rate? Koch KT, et al. **Heart** 1997 May; 77(5):432–6

Safety of low dose heparin in elective coronary angioplasty. Koch KT, et al. **Heart** 1997 Jun;77(6):517–22

Effect of pre–treatment with transdermal glyceryl trinitrate on myocardial ischaemia during coronary angioplasty. Ramamurthy S, et al. **Heart** 1996 Dec;76(6):471–6

Chest pain is an unreliable measure of ischemia in men and women during PTCA. Caldwell MA, et al. **Heart Lung** 1996 Nov–Dec;25(6):423–9

Factors related to functional status after percutaneous transluminal coronary angioplasty. Fitzgerald ST, et al. **Heart Lung** 1996 Jan–Feb;25(1):24–30

A rare indication for stenting: persistent coronary artery spasm. Kültürsay H, et al. **Heart Vessels** 1996;11(3):165–8 (13 ref.)

Antiischemic effect of intracoronary diltiazem on myocardial ischemia during PTCA. Saito K, et al. **Heart Vessels** 1996; 11(2):92–9

National PTCA registry of India—1994. Sharma S, et al. **Indian Heart J** 1995 Sep–Oct;47(5):523–6

National PTCA registry of India data for 1996. Sharma S, et al. **Indian Heart J** 1997 Mar–Apr;49(2):213–7

Coronary embolism in a patient with mitral prosthesis treated

by coronary angioplasty--a case report. Sridhar K, et al. **Indian Heart J** 1997 Mar-Apr;49(2):181-2

Tissue Doppler echocardiography: a new method of evaluating perfusion-dependent myocardial function during PTCA. Nixdorff U, et al. **Int J Card Imaging** 1997 Apr;13(2):99-103

Detection of patients with restenosis after PTCA by dipyridamole-atropine-stress-echocardiography. Scherhag AW, et al. **Int J Card Imaging** 1997 Apr;13(2):115-23

Restenosis or rapid progression in non-dilated sites are not predictors of late spontaneous coronary events. Benchimol D, et al. **Int J Cardiol** 1997 Jul 25;60(2):201-11

Use of low molecular weight heparin in postangioplasty management. Chow WH, et al. **Int J Cardiol** 1997 Jan 3; 58(1):83-5

Thallium-201 myocardial perfusion imaging in patients before and after successful percutaneous transluminal coronary angioplasty. Kostkiewicz M, et al. **Int J Cardiol** 1996 Mar;53(3):299-304

Complement activates neutrophils during PTCA procedure in patients with unstable angina pectoris. Kowalski J, et al. **Int J Cardiol** 1997 Feb;58(3):229-40

Intracoronary cyclic-GMP and cyclic-AMP during percutaneous transluminal coronary angioplasty. Kremastinos DT, et al. **Int J Cardiol** 1996 Mar;53(3):227-32

Decreased vasomotor effect of endothelin on the coronary arteries during angioplasty in hypertensive patients. Kyriakides ZS, et al. **Int J Cardiol** 1996 Jul 5;55(1):41-8

No evidence for ischemic preconditioning during repeated vessel occlusion in coronary angioplasty. Ylitalo K, et al. **Int J Cardiol** 1996 Aug;55(3):227-37

Changes of some immune functions after percutaneous transluminal coronary angioplasty (PTCA). Pasqui AL, et al. **Int J Clin Pharmacol Res** 1995;15(4):139-44

Endovascular beta-irradiation after percutaneous transluminal coronary balloon angioplasty. Popowski Y, et al. **Int J Radiat Oncol Biol Phys** 1996 Nov 1;36(4):841-5

Severity of coronary artery calcification detected by electron beam computed tomography is related to the risk of restenosis after percutaneous transluminal coronary angioplasty. Takahashi M, et al. **Intern Med** 1997 Apr; 36(4):255-62

Acute myocardial infarction after extracorporeal shock-wave lithotripsy: a dilemma of management [clinical conference] Perouansky M, et al. **Isr J Med Sci** 1997 Jan;33(1):71-4

Coronary angioplasty versus coronary artery bypass surgery. Walter PJ, et al. **Isr J Med Sci** 1996 Oct;32(10):815-6 (8 ref.)

Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty. Airaksinen KE, et al. **J Am Coll Cardiol** 1997 Apr;29(5):1035-8

Influence of procedural success on immediate and long-term clinical outcome of patients undergoing percutaneous revascularization of occluded coronary artery bypass vein grafts. Berger PB, et al. **J Am Coll Cardiol** 1996 Dec; 28(7):1732-7

Ischemic preconditioning during coronary angioplasty [letter; comment] Bolli R, et al. **J Am Coll Cardiol** 1997 Feb; 29(2):469-70. Comment on: J Am Coll Cardiol 1996 May;27(6):1374-80.

Myocardial contrast echocardiography versus dobutamine echocardiography for predicting functional recovery after acute myocardial infarction treated with primary coronary angioplasty. Bolognese L, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1677-83

Growth factors released into the coronary circulation after vascular injury promote proliferation of human vascular smooth muscle cells in culture. Caplice NM, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1536-41

Coronary flow reserve during coronary angioplasty in patients with a recent myocardial infarction: relation to stenosis and myocardial viability. Claeys MJ, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1712-9

Contrast media: is there a preferable agent for coronary interventions? [letter; comment] Davidson CJ. **J Am Coll Cardiol** 1997 Apr;29(5):1122-3. Comment on: J Am Coll Cardiol 1996 May;27(6):1381-6.

Bailout and corrective use of Gianturco-Roubin flex stents after percutaneous transluminal coronary angioplasty: operator reports and angiographic core laboratory verification from the National Heart, Lung, and Blood Institute/New Approaches to Coronary Intervention Registry. Dean LS, et al. **J Am Coll Cardiol** 1997 Apr; 29(5):934-40

Alteration of left ventricular diastolic function during coronary angioplasty-induced ischemia: a color M-mode Doppler study. Duval-Moulin AM, et al. **J Am Coll Cardiol** 1997 May;29(6):1246-55

Susceptibility to pain during coronary angioplasty: usefulness of pulpal test. Falcone C, et al. **J Am Coll Cardiol** 1996 Oct;28(4):903-9

Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS [see comments] Folland ED, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1505-11. Comment in: J Am Coll Cardiol 1997 Jun;29(7):1512-4.

Fate of collateral vessels after successful coronary angioplasty in patients with effort angina. Fujita M, et al. **J Am Coll Cardiol** 1997 Mar 1;29(3):544-8

Predictors of success and major complications for primary percutaneous transluminal coronary angioplasty in acute myocardial infarction. An analysis of the 1990 to 1994 Society for Cardiac Angiography and Interventions registries. Grassman ED, et al. **J Am Coll Cardiol** 1997 Jul;30(1):201-8

Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. Gregorini L, et al. **J Am Coll Cardiol** 1997 Jan;29(1):13-20

Has the time come to seek and open all occluded infarct-related arteries after myocardial infarction? [editorial; comment] Hochman JS. **J Am Coll Cardiol** 1996 Oct;28(4):846-8. Comment on: J Am Coll Cardiol 1996 Oct;28(4):837-45.

Rule no. 7: nights and weekends [editorial; comment] Holmes DR. **J Am Coll Cardiol** 1997 Apr;29(5):913-4. Comment on: J Am Coll Cardiol 1997 Apr;29(5):908-12.

Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. Inoue T, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1127-33

Can we provide reperfusion therapy to all unselected patients admitted with acute myocardial infarction? Juliard JM, et al. **J Am Coll Cardiol** 1997 Jul;30(1):157-64

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. Karsch KR, et al. **J Am Coll Cardiol** 1996 Nov 15;28(6):1437-43

Role of coronary artery lumen enlargement in improving coronary blood flow after balloon angioplasty and stenting: a combined intravascular ultrasound Doppler flow and imaging study. Kern MJ, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1520-7

Outpatient coronary stent implantation. Kiemeneij F, et al. **J Am Coll Cardiol** 1997 Feb;29(2):323-7

Role of platelets in restenosis after percutaneous coronary revascularization. Le Breton H, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1643-51 (107 ref.)

Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators.Evaluation of 7E3 in Preventing Ischemic Complications. Lincoff AM, et al. **J Am Coll Cardiol** 1997 Jul;30(1):149-56

Coronary vasomotion after percutaneous transluminal coronary angioplasty depends on the severity of the culprit lesion. Mandinov L, et al. **J Am Coll Cardiol** 1997 Sep; 30(3):682-8

Coronary angioplasty for elderly patients with "high risk" unstable angina: short-term outcomes and long-term survival. Morrison DA, et al. **J Am Coll Cardiol** 1997 Feb; 29(2):339-44

PTCA comes to the bifurcations in the road: what the VA has to offer [editorial; comment] Morrison DA, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1512-4. Comment on: J Am Coll Cardiol 1997 Jun;29(7):1505-11.

Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. O'Brien JE, et al. **J Am Coll Cardiol** 1996 Nov 1; 28(5):1111-8

Estrogen replacement therapy after coronary angioplasty in women. O'Keefe JH Jr, et al. **J Am Coll Cardiol** 1997 Jan; 29(1):1-5

Comparison of collateral vascular responses in the donor and recipient coronary artery during transient coronary occlusion assessed by intracoronary blood flow velocity analysis in patients. Piek JJ, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1528-35

Coronary recanalization by elective angioplasty prevents ventricular dilation after anterior myocardial infarction [see comments] Pizzetti G, et al. **J Am Coll Cardiol** 1996 Oct; 28(4):837-45. Comment in: J Am Coll Cardiol 1996 Oct;28(4):846-8.

Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis. Reimers B, et al. **J Am Coll Cardiol** 1997 Jul;30(1):186-92

Do we require a cure for "stentmania"? [editorial; comment] Rodriguez A, et al. **J Am Coll Cardiol** 1996 Oct;28(4):827-9 . Comment on: J Am Coll Cardiol 1996 Oct;28(4):820-6.

Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. Serrano CV Jr, et al. **J Am Coll Cardiol** 1997 May;29(6):1276-83

Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. Sirnes PA, et al. **J Am Coll Cardiol** 1996 Nov 15;28(6):1444-51

Coronary angioplasty versus repeat coronary artery bypass grafting for patients with previous bypass surgery. Stephan WJ, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1140-6

A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial Investigators. Stone GW, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1459-67

Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance. Strauer BE, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1119-26

QRS changes during percutaneous transluminal coronary angioplasty and their possible mechanisms. Surawicz B, et al. **J Am Coll Cardiol** 1997 Aug;30(2):452-8

Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction [see comments] Zijlstra F, et al. **J Am Coll Cardiol** 1997 Apr;29(5):908-12. Comment in: J Am Coll Cardiol 1997 Apr;29(5):913-4.

Combined percutaneous transluminal angioplasty, iliac stent deployment, and femorofemoral bypass for bilateral aortoiliac occlusive disease. Lopez-Galarza LA, et al. **J Am Coll Surg** 1997 Mar;184(3):249-58

Flow rate-pressure drop relation in coronary angioplasty: catheter obstruction effect. Back LH, et al. **J Biomech Eng** 1996 Feb;118(1):83-9

Entrapment of a coronary stent in the left main trunk: an easy method for surgical removal. Benedetti M, et al. **J Card Surg** 1996 Jan-Feb;11(1):79-82

Pitfalls of intervention therapy in a patient with anomalous origin of the right coronary artery from the left sinus of Valsalva associated with organic stenosis [see comments] Sohara H, et al. **J Cardiol** 1997 Feb;29(2):111-5. Comment in: J Cardiol 1997 Jul;30(1):53-4.

Interventional cardiology: present and future. Chambers CE, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):211-9 (91 ref.)

Inhibition of neointimal proliferation after coronary angioplasty by low-molecular-weight heparin (clivarine) and polyethyleneglycol-hirudin. Buchwald AB, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):481-7

Association between pre-PTCA blood haemoglobin concentration and the risk of symptomatic restenosis after successful PTCA of primary coronary stenoses. Gustavsson CG, et al. **J Cardiovasc Risk** 1997 Feb;4(1):37-40

Methodology of serial ECG classification using an adaptation of the NOVACODE for Q wave myocardial infarction in the Bypass Angioplasty Revascularization Investigation (BARI). Chaitman BR, et al. **J Electrocardiol** 1996 Oct; 29(4):265-77

Coronary angioplasty vs thrombolysis in acute MI. Millard PS. **J Fam Pract** 1997 Jul;45(1):21-2

Bypass surgery vs angioplasty in multivessel CAD. Zamorski M. **J Fam Pract** 1997 Jun;44(6):527-8

Influence of continued smoking and some biological risk factors on restenosis after percutaneous transluminal coronary angioplasty. Kotamäki M, et al. **J Intern Med** 1996 Nov;240(5):293-301

Ticlopidine in the prevention of thrombus formation after percutaneous transluminal coronary angioplasty (PTCA). Chotinaiwattarakul C, et al. **J Med Assoc Thai** 1997 Feb; 80(2):76-80

Immediate angioplasty results of total coronary artery occlusion in Thai population. Mahanonda N, et al. **J Med Assoc Thai** 1996 Nov;79(11):698-702

Effectiveness of percutaneous transluminal coronary angioplasty for patients with unstable angina. Mahanonda N, et al. **J Med Assoc Thai** 1996 Jul;79(7):454-9

Coronary intervention 1996. Mahanonda N, et al. **J Med Assoc Thai** 1997 May;80(5):326-31 (39 ref.)

Stress radionuclide studies after acute myocardial infarction: changes with revascularization. Coma-Canella I, et al. **J Nucl Cardiol** 1996 Sep-Oct;3(5):403-9

Residual area at risk after anterior myocardial infarction: are ST segment changes during coronary angioplasty a reliable indicator? A comparison with technetium 99m-labeled sestamibi single-photon emission computed tomography. Faraggi M, et al. **J Nucl Cardiol** 1997 Jan-Feb;4(1 Pt 1):11-7

PET perfusion and vasodilator function after angioplasty for acute myocardial infarction. Stewart RE, et al. **J Nucl Med** 1997 May;38(5):770-7

Chronic coronary occlusions: age, morphology and chance of reopening. Vallbracht C, et al. **J R Soc Med** 1997 Apr; 90(4):209-11

A profile of candidates for repeat myocardial revascularization: implications for selection of treatment. Brener SJ, et al. **J Thorac Cardiovasc Surg** 1997 Aug; 114(2):153-61

Clinical significance of perioperative Q-wave myocardial infarction: the Emory Angioplasty versus Surgery Trial. Hodakowski GT, et al. **J Thorac Cardiovasc Surg** 1996 Dec; 112(6):1447-53; discussion 1453-4

Minimally invasive direct coronary artery bypass, percutaneous transluminal coronary angioplasty, and stent placement for left main stenosis. Liekweg WG, et al. **J Thorac Cardiovasc Surg** 1997 Feb;113(2):411-2

Minimally invasive coronary artery bypass grafting versus coronary angioplasty for isolated type C stenosis of the left anterior descending artery. Mariani MA, et al. **J Thorac Cardiovasc Surg** 1997 Sep;114(3):434-9

Emergent interventional transcatheter revascularization in acute right coronary artery dissection after blunt chest trauma. Thorban S, et al. **J Trauma** 1997 Aug;43(2):365-7

Restenosis: pathophysiology and preventive strategies. Phillips-Hughes J, et al. **J Vasc Interv Radiol** 1996 May-Jun;7(3):321-33 (136 ref.)

Five-year clinical and functional outcome comparing bypass

surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators [see comments] **JAMA** 1997 Mar 5;277(9):715–21. Comment in: JAMA 1997 Jul 9;278(2):114–5.

The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty [editorial; comment] Fischman DL, et al. **JAMA** 1997 Aug 13; 278(6):518–9. Comment on: JAMA 1997 Aug 13;278(6):479–84.

Angioplasty vs bypass surgery in patients with multivessel coronary artery disease [letter; comment] Guerra CE, et al. **JAMA** 1997 Jul 9;278(2):114–5. Comment on: JAMA 1997 Mar 5;277(9):715–21.

Prognostic implication of creatine kinase elevation following elective coronary artery interventions [see comments] Kong TQ, et al. **JAMA** 1997 Feb 12;277(6):461–6. Comment in: JAMA 1997 Feb 12;277(6):495–7. Comment in: JAMA 1997 May 28;277(20):1593.

Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. Importance and implications [editorial; comment] Ohman EM, et al. **JAMA** 1997 Feb 12;277(6):495–7. Comment on: JAMA 1997 Feb 12;277(6):461–6.

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication [see comments] Topol EJ, et al. **JAMA** 1997 Aug 13;278(6):479–84. Comment in: JAMA 1997 Aug 13;278(6):518–9.

Relationship between HLA-C locus and restenosis after coronary artery balloon angioplasty. Watanabe Y, et al. **JAMA** 1997 Mar 26;277(12):983–4

Long-term outcome of percutaneous transluminal coronary angioplasty and coronary bypass surgery for multivessel coronary artery disease. Hara K, et al. **Jpn Circ J** 1996 Dec;60(12):940–6

Coronary vasomotor response to acetylcholine late after angioplasty. Nishijima H, et al. **Jpn Circ J** 1996 Oct; 60(10):789–96

Long-term outcome in double-vessel coronary artery disease in Japanese patients. Nishiyama S, et al. **Jpn Heart J** 1997 Mar;38(2):181–9

The cause-effect relationship of sympathovagal activity and the outcome of percutaneous transluminal coronary angioplasty. Tseng CD, et al. **Jpn Heart J** 1996 Jul; 37(4):455–62

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study [see comments] **Lancet** 1997 May 17;349(9063):1429–35. Comment in: Lancet 1997 May 17;349(9063):1409–10.

Intracoronary-stent placement for coronary artery disease [letter] Schwartz L, et al. **Lancet** 1997 Jul 12; 350(9071):113–4

Stenting for acute myocardial infarction. Steinhubl SR, et al. **Lancet** 1997 Aug 23;350(9077):532–3

Single-laser approach for fluorescence guidance of excimer laser angioplasty at 308 nm: evaluation in vitro and during coronary angioplasty. Morguet AJ, et al. **Lasers Surg Med** 1997;20(4):382–93

Effect of gender on angioplasty outcome: are we closer to the answer? [editorial; comment] Alexander KP, et al. **Mayo Clin Proc** 1997 Jan;72(1):89–91. Comment on: Mayo Clin Proc 1997 Jan;72(1):5–12.

Pilot findings of a percutaneous transluminal coronary angioplasty-restenosis-prone prevention program [letter; comment] Goodman M. **Mayo Clin Proc** 1997 May; 72(5):487. Comment on: Mayo Clin Proc 1996 Aug;71(8):729–34.

Comparison of immediate and long-term outcome of coronary angioplasty performed for unstable angina and rest pain in men and women [see comments] Keelan ET, et al. **Mayo Clin Proc** 1997 Jan;72(1):5–12. Comment in: Mayo Clin Proc 1997 Jan;72(1):89–91.

Dosimetry of a radioactive coronary balloon dilatation catheter for treatment of neointimal hyperplasia. Amols HI, et al. **Med Phys** 1996 Oct;23(10):1783–8

A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators [published erratum appears in N Engl J Med 1997 Jul 24;337(4):287] **N Engl J Med** 1997 Jun 5;336(23):1621–8

A comparison of coronary-artery stenting with angioplasty [letter; comment] Adelman AG. **N Engl J Med** 1997 Jul 24;337(4):277–8. Comment on: N Engl J Med 1997 Mar 20;336(12):817–22.

Bypass angioplasty revascularization investigation [letter; comment] Berreklouw E. **N Engl J Med** 1997 Jan 9; 336(2):136; discussion 137–8. Comment on: N Engl J Med 1996 Jul 25;335(4):217–25.

Advances in coronary angioplasty [published erratum appears in N Engl J Med 1997 Feb 27;336(9):670] Bittl JA. **N Engl J Med** 1996 Oct 24;335(17):1290–302 (97 ref.)

More on "hybrid revascularization" [letter] Bonchek LI. **N Engl J Med** 1997 Sep 18;337(12):861–2

A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. Myocardial Infarction Triage and Intervention Investigators [see comments] Every NR, et al. **N Engl J Med** 1996 Oct 24;335(17):1253–60. Comment in: N Engl J Med 1997 Apr 10;336(15):1103; discussion 1104. Comment in: N Engl J Med 1997 Apr 10;336(15):1103–4; discussion 1104.

A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction [letter; comment] Fath-Ordoubadi F, et al. **N Engl J Med** 1997 Apr 10;336(15):1103–4; discussion 1104 . Comment on: N Engl J Med 1996 Oct 24;335(17):1253–60.

Preliminary experience with minimally invasive coronary-artery bypass surgery combined with coronary angioplasty [letter] Friedrich GJ, et al. **N Engl J Med** 1997 May 15;336(20):1454–5

Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Primary angioplasty—the strategy of choice [see comments] Grines CL. **N Engl J Med** 1996 Oct 24;335(17):1313–6; discussion 1316–7. Comment in: N Engl J Med 1997 Apr 10;336(15):1101; discussion 1102–3. Comment in: N Engl J Med 1997 Apr 10;336(15):1101–2; discussion 1102–3. Comment in: N Engl J Med 1997 Apr 10;336(15):1102; discussion 1102–3.

Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization [see comments] Hasdai D, et al. **N Engl J Med** 1997 Mar 13; 336(11):755–61. Comment in: ACP J Club 1997 Sep-Oct;127(2):52.

Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Thrombolysis--the preferred treatment [see comments] Lange RA, et al. **N Engl J Med** 1996 Oct 24;335(17):1311–2; discussion 1316–7. Comment in: N Engl J Med 1997 Apr 10;336(15):1101; discussion 1102–3. Comment in: N Engl J Med 1997 Apr 10;336(15):1101–2; discussion 1102–3. Comment in: N Engl J Med 1997 Apr 10;336(15):1102; discussion 1102–3.

Thrombolysis or primary angioplasty for acute myocardial infarction? [letter; comment] Leff B. **N Engl J Med** 1997 Apr 10;336(15):1102; discussion 1102–3. Comment on: N Engl J Med 1996 Oct 24;335(17):1311–2; discussion 1316–7. Comment on: N Engl J Med 1996 Oct 24;335(17):1313–6; discussion 1316–7.

Bypass angioplasty revascularization investigation [letter; comment] Madias JE. **N Engl J Med** 1997 Jan 9; 336(2):136–7; discussion 137–8. Comment on: N Engl J Med 1996 Jul 25;335(4):217–25.

Thrombolysis or primary angioplasty for acute myocardial infarction? [letter; comment] Magalski A, et al. **N Engl J Med** 1997 Apr 10;336(15):1101–2; discussion 1102–3. Comment on: N Engl J Med 1996 Oct 24;335(17):1311–2; discussion 1316–7. Comment on: N Engl J Med 1996 Oct 24;335(17):1313–6; discussion 1316–7.

Subarachnoid hemorrhage and acute myocardial infarction [letter; comment] Pasceri V. **N Engl J Med** 1996 Oct 24; 335(17):1320. Comment on: N Engl J Med 1996 Jun 6;334(23):1530–4.

Primary coronary angioplasty versus thrombolysis [letter] Pasceri V. **N Engl J Med** 1997 Oct 16;337(16):1169–70

Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. Savage MP, et al. **N Engl J Med** 1997 Sep 11;337(11):740–7

Primary coronary angioplasty versus thrombolysis [letter] Stone GW, et al. **N Engl J Med** 1997 Oct 16;337(16):1168–9; discussion 1170

Bypass angioplasty revascularization investigation [letter; comment] Taggart DP. **N Engl J Med** 1997 Jan 9; 336(2):137; discussion 137–8. Comment on: N Engl J Med 1996 Jul 25;335(4):217–25.

Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group [see comments] Tardif JC, et al. **N Engl J Med** 1997 Aug 7;337(6):365–72. Comment in: N Engl J Med 1997 Aug 7;337(6):418–9.

A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery [see comments] Versaci F, et al. **N Engl J Med** 1997 Mar 20;336(12):817–22. Comment in: N Engl J Med 1997 Jul 24;337(4):277–8. Comment in: ACP J Club 1997 Sep-Oct;127(2):32.

Thrombolysis or primary angioplasty for acute myocardial infarction? [letter; comment] Zijlstra F, et al. **N Engl J Med** 1997 Apr 10;336(15):1101; discussion 1102–3 . Comment on: N Engl J Med 1996 Oct 24;335(17):1311–2; discussion 1316–7. Comment on: N Engl J Med 1996 Oct 24;335(17):1313–6; discussion 1316–7.

Percutaneous coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG)—which is the appropriate therapy of coronary artery disease in uraemic patients? [editorial] Ivens K, et al. **Nephrol Dial Transplant** 1996 Oct; 11(10):1949–51 (23 ref.)

Dobutamine 99Tcm-MIBI SPET myocardial perfusion scintigraphy in the prediction of restenosis after percutaneous transluminal coronary angioplasty in patients unable to perform an exercise stress test. Elhendy A, et al. **Nucl Med Commun** 1997 Feb;18(2):122–8

Acute myocardial infarction during pregnancy managed with immediate percutaneous transluminal coronary angioplasty. Ascarelli MH, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):655–7

Effects of ischemia and reperfusion on QT dispersion during coronary angioplasty. Michelucci A, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1905–8

ST reelevation at reperfusion is associated with the occurrence of late potentials in patients with acute anterior infarction. Ochiai M, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1914–7

Spurious detection of ventricular fibrillation by a transvenous implantable cardioverter defibrillator during percutaneous transluminal coronary angioplasty. Rizk AB, et al. **Pacing Clin Electrophysiol** 1997 Jan;20(1 Pt 1):136–7

Percutaneous balloon aortoplasty for restenosis after extended aortic arch anastomosis for type B interrupted aortic arch. Sato S, et al. **Pediatr Cardiol** 1996 Jul-Aug; 17(4):275–7

Measurement of angioplasty lumen volume and wall compliance: a laboratory study. Murray A, et al. **Physiol Meas** 1997 Feb;18(1):39–47

Primary coronary angioplasty in acute myocardial infarction. Grech ED, et al. **Postgrad Med J** 1996 May;72(847):269–73 (38 ref.)

Intervention in coronary artery disease. Hubbard W. **Practitioner** 1995 Dec;239(1557):710–2 (0 ref.)

Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures. Landzberg BR, et al. **Prog Cardiovasc Dis** 1997 Jan-Feb;39(4):361–98 (355 ref.)

ST segment deviation during myocardial ischemia: are there gender differences? Pelter MM, et al. **Prog Cardiovasc Nurs** 1996 Summer;11(3):4–9

Treatment of hypercholesterolemia in patients undergoing multiple coronary angioplasties. Marques V, et al. **Rev Port Cardiol** 1996 Nov;15(11):787–91, 771–2

Percutaneous transluminal angioplasty and retransplantation due to transplant coronary artery disease. Fiane AE, et al. **Scand Cardiovasc J** 1997;31(4):223–7

Percutaneous transluminal coronary angioplasty or coronary artery bypass grafting for coronary artery disease? Währborg P. **Scand Cardiovasc J** 1997;31(4):201–11 (103 ref.)

Results of a Swiss consensus conference on coronary revascularization. Members of the Swiss Society of Cardiology, Swiss Society of Internal Medicine, Swiss Society of Thoracic and Cardiovascular Surgery. **Schweiz Med Wochenschr** 1997 Jul 8;127(27–28):1191–210 (9 ref.)

Management of renal artery aneurysms. Cinat M, et al. **Semin Vasc Surg** 1996 Sep;9(3):236–44 (50 ref.)

The indications and results of percutaneous transluminal angioplasty and stenting in renal artery stenosis. Kidney DD, et al. **Semin Vasc Surg** 1996 Sep;9(3):188–97 (54 ref.)

Safety and efficacy of percutaneous Inoue-balloon mitral commissurotomy. Gao W, et al. **Singapore Med J** 1996 Aug; 37(4):357–61

Percutaneous transluminal angioplasty of the symptomatic atherosclerotic carotid arteries. Results, complications, and follow-up. Gil-Peralta A, et al. **Stroke** 1996 Dec; 27(12):2271–3

Intracoronary electrocardiogram demonstrating ischemic preconditioning during coronary angioplasty. Bhargava B, et al. **Tex Heart Inst J** 1997;24(1):71

The potential thrombogenic action of a nonionic radiographic contrast medium used during coronary angiography is offset by heparin during coronary angioplasty. Mukherjee M, et al. **Thromb Haemost** 1996 Nov;76(5):679–81

Decrease in factor VII coagulant activity during percutaneous transluminal coronary angioplasty by heparin-mediated lipolytic action. Mukherjee M, et al. **Thromb Haemost** 1997 Apr;77(4):675–8

Activation of coagulation and fibrinolysis despite heparinization during successful elective coronary angioplasty. Peltonen S, et al. **Thromb Res** 1996 Jun 15; 82(6):459–68

Recurrent restenosis after percutaneous transluminal coronary angioplasty in a patient with congenital protein C deficiency and high activated factor VII level. Sakata T, et al. **Thromb Res** 1996 Mar 15;81(6):687–91

Coronary artery stenting during acute myocardial infarction in patients treated with IIb/IIIa anti-platelet antibodies: early outcome results. Murdock DK, et al. **Wis Med J** 1996 Dec;95(12):867–71

[Use of PTCA in a gastroepiploic aortocoronary graft] Kováč J, et al. **Vnitr Lek** 1997 Feb;43(2):98–101 (Eng. Abstr.) **(Cze)**

[Angiopeptin versus placebo for reductin of restenosis after PTCA treatment. A randomized, double-blind study] Eriksen UH, et al. **Ugeskr Laeger** 1996 Nov 11; 158(46):6605–8 (Eng. Abstr.) **(Dan)**

[Stents in the treatment of coronary artery diseases (editorial)] Saunamäki KI. **Ugeskr Laeger** 1997 Mar 10;159(11):1583 **(Dan)**

[Stent implantation in genuine coronary vessels--with and without guidance of intracoronary ultrasound] Thuesen L, et al. **Ugeskr Laeger** 1997 Mar 10;159(11):1597–601 (Eng. Abstr.) **(Dan)**

[Myocardial revascularization: surgery or angioplasty?] Goy JJ. **Ann Cardiol Angeiol (Paris)** 1996 Oct;45(8):427–9 (17 ref.) (Eng. Abstr.) **(Fre)**

[Prospects of prevention of restenosis after coronary angioplasty] Le Feuvre C, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jul-Sep;45(7):383–8 (36

ref.) (Eng. Abstr.) **(Fre)**

[Repeated angioplasties on the coronary artery (letter)] Lefeuvre C, et al. **Ann Med Interne (Paris)** 1996; 147(7):521–3 **(Fre)**

[Antiplatelet therapy during coronary endoprosthesis placement] Barragan P, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1515–20 (42 ref.) (Eng. Abstr.) **(Fre)**

[Endocoronary ultrasonography and quantitative coronary angiography. Correlations before and after transluminal coronary angioplasty] Boschat J, et al. **Arch Mal Coeur Vaiss** 1997 Mar;90(3):353–60 (Eng. Abstr.) **(Fre)**

[Clinical, experimental and physiopathological aspects of restenosis after coronary angioplasty] Brami M, et al. **Arch Mal Coeur Vaiss** 1997 Mar;90(3):385–91 (37 ref.) (Eng. Abstr.) **(Fre)**

[Predictive factors of coronary restenosis after optimal directional atherectomy. A multivariate analysis apropos of 102 patients] Coste P, et al. **Arch Mal Coeur Vaiss** 1997 Feb;90(2):225–31 (30 ref.) (Eng. Abstr.) **(Fre)**

[Angioplasty of the proximal left anterior descending artery outside the acute phase of myocardial infarction. Apropos of a series of 100 consecutive patients] Maillard JM, et al. **Arch Mal Coeur Vaiss** 1996 Jul;89(7):825–33 (30 ref.) (Eng. Abstr.) **(Fre)**

[Implantation of coronary stent during the acute phase of myocardial infarction for treatment of dissection or partial result after angioplasty. Immediate results and angiographic follow-up] Maillard L, et al. **Arch Mal Coeur Vaiss** 1997 Feb;90(2):253–61 (Eng. Abstr.) **(Fre)**

[Primary angioplasty in acute myocardial infarction. A one-year experience in a small urban community] Moquet B, et al. **Arch Mal Coeur Vaiss** 1997 Jan;90(1):11–5 (30 ref.) (Eng. Abstr.) **(Fre)**

[Standards for performing coronary angioplasty. Subcommittee on Coronary Angioplasty. Committee on Standards of the Canadian Society of Cardiology] Marquis JF, et al. **Can J Cardiol** 1996 Aug;12(8):721–2 **(Fre)**

[Percutaneous suture closure of the femoral artery access after diagnostic heart catheter examination or coronary intervention] Gerckens U, et al. **Dtsch Med Wochenschr** 1996 Nov 29;121(48):1487–91 (Eng. Abstr.) **(Ger)**

[Blood vessel occlusion in acute and chronic coronary syndromes—significance of PTCA] Schoebel FC, et al. **Dtsch Med Wochenschr** 1997 Mar 14;122(11):346–7 **(Ger)**

[Balloon dilatation or bypass surgery in coronary multi-vessel disease? Change of therapy following conclusion of randomized studies?] Seggewiss H, et al. **Dtsch Med Wochenschr** 1996 Sep 27;121(39):1204–6 **(Ger)**

[Evaluation of indications for PTCA] Kadel C. **Herz** 1996 Dec;21(6):347–58 (Eng. Abstr.) **(Ger)**

[Direct dilatation and emergency bypass operation of main branch occlusion in acute anterior wall infarct and cardiogenic shock] Zahn R, et al. **Herz** 1997 Apr; 22(2):111–5 (Eng. Abstr.) **(Ger)**

[Restenosis after angioplasty. Clinical significance, pathobiology, future developments for suppression of recurrent stenoses] Höfling B, et al. **Internist (Berl)** 1997 Jan;38(1):31–43 (48 ref.) **(Ger)**

[Surgical preparedness in coronary interventions] Meinertz T, et al. **Internist (Berl)** 1997 Jan;38(1):53–5 (5 ref.) **(Ger)**

[Percutaneous transluminal coronary angioplasty. Acute results and long-term follow-up] Reynen K. **Med Klin** 1996 Nov 15;91(11):711–8 (91 ref.) **(Ger)**

[Percutaneous transluminal angioplasty and restenosis—working hypothesis and treatment approaches] Roeren T. **Rontgenpraxis** 1996 Feb;49(2):31–4 (49 ref.) **(Ger)**

[Myocardial revascularization in geriatric patients] Garachemani A, et al. **Schweiz Med Wochenschr** 1997 Mar 15;127(11):425–9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients] Meyer BJ. **Schweiz Med Wochenschr** 1996 Nov 16;126(46):1961–9 (43 ref.) (Eng. Abstr.) **(Ger)**

[Secondary prevention in patients before and after percutaneous transluminal coronary angioplasty: 5-year follow-up] Muntwyler J, et al. **Schweiz Med Wochenschr** 1997 Apr 5;127(14):573–8 (Eng. Abstr.) **(Ger)**

[Interventional treatment of heart valve diseases] Garachemani A, et al. **Schweiz Rundsch Med Prax** 1997 Apr 16;86(16):666–71 (71 ref.) (Eng. Abstr.) **(Ger)**

[Restenosis after percutaneous transluminal angioplasty: II. Possibilities for pharmacologic intervention] Böger RH, et al. **Vasa** 1996;25(1):21–31 (105 ref.) (Eng. Abstr.) **(Ger)**

[Noninvasive coronary angiography with electron beam tomography: methods and clinical evaluation in post-PTCA follow-up] Achenbach S, et al. **Z Kardiol** 1997 Feb;86(2):121–30 (Eng. Abstr.) **(Ger)**

[Percutaneous "high risk" angioplasty with prophylactic cardiopulmonary support. High risk PTCA with mechanical circulatory support] Borges AC, et al. **Z Kardiol** 1996;85 Suppl 4:21–8 (Eng. Abstr.) **(Ger)**

[The significance of intravascular ultrasound in differential diagnosis and therapy of coronary stenoses] Görge G, et al. **Z Kardiol** 1996;85 Suppl 1:73–80 (41 ref.) (Eng. Abstr.) **(Ger)**

[Rate of restenosis after PTCA in patients with terminal renal failure. A quantitative coronary angiography study] Gradaus F, et al. **Z Kardiol** 1997 May;86(5):373–9 (Eng. Abstr.) **(Ger)**

[Conventional therapeutic strategy in PTCA-induced dissection: long-term re-PTCA, early re-coronary angiography] Jacksch R, et al. **Z Kardiol** 1996;85 Suppl 1:49–57 (Eng. Abstr.) **(Ger)**

[Cardiosurgical stand-by and acute interventions after interventional cardiologic procedures] Oelert H. **Z Kardiol** 1996;85 Suppl 6:303–8 (24 ref.) (Eng. Abstr.) **(Ger)**

[Direct coronary bypass operation in complicated coronary dissection] Reidemeister JC, et al. **Z Kardiol** 1996;85 Suppl 1:67–72 (30 ref.) (Eng. Abstr.) **(Ger)**

[Concepts for local therapy of restenosis] Riessen R, et al. **Z Kardiol** 1996;85 Suppl 1:87–98 (86 ref.) (Eng. Abstr.) **(Ger)**

[Value of dipyridamole-atropine stress echocardiography for detection of patients with restenosis after PTCA] Scherhag A, et al. **Z Kardiol** 1996 Aug;85(8):570–9 (Eng. Abstr.) **(Ger)**

[Treatment of recurrent stenosis by conventional re-PTCA] Schräder R. **Z Kardiol** 1996;85 Suppl 1:99–101 (7 ref.) (Eng. Abstr.) **(Ger)**

[Personal experiences with emergency coronary artery revascularization after failed PTCA--early and late results] Simic O, et al. **Zentralbl Chir** 1997;122(3):149–52 (Eng. Abstr.) **(Ger)**

[The use of coronary artery prostheses (letter; comment)] Lozsádi K. **Orv Hetil** 1997 Aug 10;138(32):2042. Comment on: Orv Hetil 1997 Feb 9;138(6):349–51. **(Hun)**

[Use of coronary vessel prosthesis. Complex coronary angioplasty under general anesthesia (see comments)] Szatmáry LJ, et al. **Orv Hetil** 1997 Feb 9;138(6):349–51 (Eng. Abstr.). Comment in: Orv Hetil 1997 Aug 10;138(32):2042. **(Hun)**

[Percutaneous aortic valvuloplasty in the adult. When and why is now useful?] Piovaccari G, et al. **Ann Ital Med Int** 1996 Oct–Dec;11(4):258–62 (Eng. Abstr.) **(Ita)**

[Cardiopulmonary support in high-risk percutaneous coronary angioplasty] Bartorelli AL. **Cardiologia** 1997 May; 42(5):533–9 (5 ref.) **(Ita)**

[Coronary angioplasty in acute myocardial infarction] Bertaglia E, et al. **Cardiologia** 1997 Jul;42(7):737–41 (Eng. Abstr.) **(Ita)**

[Implanting of coronary stents in patients with unstable angina] Palmerini T, et al. **Cardiologia** 1997 Apr; 42(4):415–20 (Eng. Abstr.) **(Ita)**

[Recurrent restenosis after angioplasty of anomalous right coronary artery] Sganzerla P, et al. **Cardiologia** 1996 Jul; 41(7):667–9 (Eng. Abstr.) **(Ita)**

[Coronary angioplasty in unstable angina at rest. Influence of the degree of clinical instability on the immediate and long-term results] Cavallini C, et al. **G Ital Cardiol** 1996 Jun;26(6):647–55 (Eng. Abstr.) **(Ita)**

[The choice between primary angioplasty and thrombolysis: is there any change after GUSTO-IIb?] Fazzini PF. **G Ital Cardiol** 1997 Jan;27(1):79–84 (39 ref.) **(Ita)**

[Coronary stenting for treatment of intimal dissection and occlusive thrombosis during primary PTCA in acute myocardial infarction] Galli M, et al. **G Ital Cardiol** 1997 Apr;27(4):370–3 (Eng. Abstr.) **(Ita)**

[Comparison of outcome of primary PTCA for acute myocardial infarction in patients younger and older than 70 years of age] Santoro GM, et al. **G Ital Cardiol** 1996 Oct;26(10):1111–22 (Eng. Abstr.) **(Ita)**

[The Registry for Angioplasty in Infarction (RAI): brief preliminary report on the main indicators and process of acute outcome] Steffenino G, et al. **G Ital Cardiol** 1997 Jun;27(6):563–8 (Eng. Abstr.) **(Ita)**

[Omniplane transesophageal echocardiography: an improvement in the monitoring of percutaneous pulmonary valvuloplasty] Tumbarello R, et al. **G Ital Cardiol** 1997 Feb;27(2):168–72 (Eng. Abstr.) **(Ita)**

[Initial outcome of coronary intervention in elderly patients] Hojo Y, et al. **J Cardiol** 1996 Jun;27(6):297–302 (Eng. Abstr.) **(Jpn)**

[The importance of serum lipid level for restenosis following initial successful percutaneous transluminal coronary angioplasty in patients with unstable angina] Kishi K, et al. **J Cardiol** 1996 Aug;28(2):79–84 (Eng. Abstr.) **(Jpn)**

[Identification of predictive factors associated with recurrent restenosis after second percutaneous transluminal coronary angioplasty] Kishi K, et al. **J Cardiol** 1997 Jan;29(1):7–12 (Eng. Abstr.) **(Jpn)**

[Ten-year follow-up of percutaneous transluminal coronary angioplasty] Kohzuma K, et al. **J Cardiol** 1996 Sep; 28(3):123–9 (Eng. Abstr.) **(Jpn)**

[Estimation of the length of coronary thrombi and prediction of the result of coronary thrombolytic therapy based on the angiographic findings] Mochida Y. **J Cardiol** 1996 Nov; 28(5):249–55 (Eng. Abstr.) **(Jpn)**

[Usefulness of directional coronary atherectomy as a bail-out device for acute closure after coronary angioplasty] Nishio R, et al. **J Cardiol** 1997 Jun;29(6):325–30 (Eng. Abstr.) **(Jpn)**

[Comparison of thrombolytic therapy and direct percutaneous transluminal coronary angioplasty for acute myocardial infarction: prospective multicenter trial at 16 clinical centers in Ibaraki prefecture TUGMI. Tsukuba University Group for Myocardial Infarction] Noguchi Y, et al. **J Cardiol** 1996 Mar;27(3):111–20 (Eng. Abstr.) **(Jpn)**

[Percutaneous transluminal coronary angioplasty in patients with multivessel coronary disease: does complete revascularization improve the long-term survival?] Ohta H, et al. **J Cardiol** 1997 May;29(5):251–9 (Eng. Abstr.) **(Jpn)**

[Lesion-related factors associated with restenosis after percutaneous transluminal coronary angioplasty in the absence of patient-related factors] Sakai Y, et al. **J Cardiol** 1997 Jan;29(1):1–6 (Eng. Abstr.) **(Jpn)**

[Intravascular ultrasound in determining the end point of percutaneous transluminal coronary angioplasty] Seo T, et al. **J Cardiol** 1996 Oct;28(4):183–9 (Eng. Abstr.) **(Jpn)**

[Successful coronary angioplasty in a patient with acute myocardial infarction caused by prosthetic valve endocarditis] Takimoto E, et al. **J Cardiol** 1996;27 Suppl 2:103–8; discussion 109–10 (Eng. Abstr.) **(Jpn)**

[Effects of the time interval between the first and second balloon inflations on ischemic preconditioning during percutaneous transluminal coronary angioplasty] Tanaka T, et al. **J Cardiol** 1996 Jun;27(6):303–8 (Eng. Abstr.) **(Jpn)**

[Usefulness of 99mTc-tetrofosmin myocardial scintigraphy before and after coronary intervention] Adachi I, et al. **Kaku Igaku** 1997 Jun;34(6):363–9 (Eng. Abstr.) **(Jpn)**

[Evaluation of myocardial perfusion by 99mTc-tetrofosmin SPECT before and after emergent percutaneous transluminal coronary angioplasty for acute myocardial infarction] Kawai Y, et al. **Kaku Igaku** 1997 Apr; 34(4):221–8 (Eng. Abstr.) **(Jpn)**

[Emergency coronary artery bypass grafting using the internal thoracic artery graft after percutaneous transluminal coronary angioplasty in a patient with left main coronary artery disease associated with acute myocardial infarction] Seki T, et al. **Kyobu Geka** 1997 Apr; 50(4):308–11 (Eng. Abstr.) **(Jpn)**

[Usefulness of percutaneous transluminal angioplasty of lesions in saphenous vein graft] Yasuda H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep;44(9):1729–34 (Eng. Abstr.) **(Jpn)**

[Angina pectoris: progress in diagnosis and treatment. III. Progress in treatment. 5. Coronary artery intervention for angina pectoris] Yamaguchi T. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):265–70 (6 ref.) **(Jpn)**

[Gene therapy for restenosis after angioplasty] Morishita R, et al. **Rinsho Byori** 1997 Feb;Suppl 104:224–31 (24 ref.) **(Jpn)**

[Comparison between CABG and PTCA complementary therapies] Endo M, et al. **Rinsho Kyobu Geka** 1988 Apr; 8(2):140–6 (Eng. Abstr.) **(Jpn)**

[Percutaneous transluminal coronary angioplasty--its primary success and prognosis] Kitazume H. **Rinsho Kyobu Geka** 1988 Apr;8(2):132–5 (Eng. Abstr.) **(Jpn)**

[Laser coronary angioplasty] Kitazume H, et al. **Rinsho Kyobu Geka** 1988 Feb;8(1):42–6 (Eng. Abstr.) **(Jpn)**

[Emergent aorto-coronary bypass surgery immediate or late after percutaneous transluminal coronary angioplasty] Kyo S, et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):147–51 (Eng. Abstr.) **(Jpn)**

[Restenosis and arterial remodelling after coronary angioplasty] Jørgensen B, et al. **Tidsskr Nor Laegeforen** 1996 Aug 30;116(20):2460–3 (34 ref.) (Eng. Abstr.) **(Nor)**

[Evaluation of efficacy and mechanism of action of angioplasty and directed atherectomy assisted by intravascular ultrasonography] Kubica J, et al. **Pol Merkuriusz Lek** 1996 Aug;1(2):104–7 (Eng. Abstr.) **(Pol)**

[The role of calcium antagonists on coronary artery spasm and prevention of restenosis after angioplasty] Kocurek A, et al. **Przegl Lek** 1997;54(1):37–42 (23 ref.) (Eng. Abstr.) **(Pol)**

[Analysis of elastic retraction in the 1st 15 minutes after coronary balloon angioplasty] Caixeta AM, et al. **Arq Bras Cardiol** 1996 Jan;66(1):5–9 (Eng. Abstr.) **(Por)**

[Ergometric test after surgical revascularization and mechanical recanalization of the myocardium] Chalela WA, et al. **Arq Bras Cardiol** 1996 Jul;67(1):59–62 (27 ref.) **(Por)**

[The role of low-molecular-weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty (see comments)] Cláudio Correia LC, et al. **Arq Bras Cardiol** 1995 Dec;65(6):475–8 (Eng. Abstr.). Comment in: Arq Bras Cardiol 1995 Dec;65(5):517–8. **(Por)**

[Coronary angioplasty in patients with restenosis. Characterization of clinical and angiographic profiles, hospital clinical course, and implications for the selection of patients [letter; comment]] de Godoy MF, et al. **Arq Bras Cardiol** 1996 May;66(5):325–7 **(Por)**

[Thrombolysis versus angioplasty in acute myocardial infarction] Ferreira Leite P, et al. **Arq Bras Cardiol** 1995 Oct;65(4):349–52 (35 ref.) **(Por)**

[Coronary transluminal angioplasty in octogenarians] Moreira AE, et al. **Arq Bras Cardiol** 1996 Dec;67(6):389–93 (Eng. Abstr.) **(Por)**

[High risk percutaneous transluminal coronary angioplasty

after mechanical recanalization of the unprotected left main stem coronary artery and during myocardial infarction] Moreira AE, et al. **Arq Bras Cardiol** 1996 Feb;66(2):75–8 (Eng. Abstr.) **(Por)**

[The role of low-molecular-weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty (editorial; comment)] Pimentel Filho WA. **Arq Bras Cardiol** 1995 Dec; 65(6):517–8. Comment on: Arq Bras Cardiol 1995 Dec;65(6):475–8. **(Por)**

[Efficacy of repeat coronary dilatation in patients with restenosis of the anterior descending artery] Prudêncio LA, et al. **Arq Bras Cardiol** 1995 Nov;65(5):399–402 (Eng. Abstr.) **(Por)**

[Coronary angioplasty of proximal lesions of the anterior descending artery (editorial)] Ribeiro JP, et al. **Arq Bras Cardiol** 1995 Nov;65(5):437–8 **(Por)**

[Coronary angioplasty at a center without heart surgery. The experience of the 1st year] Carvalho H, et al. **Rev Port Cardiol** 1997 Feb;16(2):197–200 **(Por)**

[Direct angioplasty and thrombolysis in acute myocardial infarct] Gottschall CA. **Rev Port Cardiol** 1997 Feb; 16(2):165–74 (60 ref.) **(Por)**

[The prognostic value of left ventricular dysfunction in patients undergoing percutaneous coronary angioplasty] Oliveira M, et al. **Rev Port Cardiol** 1997 Feb;16(2):203–6 **(Por)**

[Collateral circulation can influence the asymptomatic ST segment depression in stress tests performed after percutaneous coronary angioplasty] Oliveira M, et al. **Rev Port Cardiol** 1997 Feb;16(2):207–10 **(Por)**

[Will there be a place for incomplete myocardial revascularization in elective coronary angioplasty?] Oliveira M, et al. **Rev Port Cardiol** 1997 Feb;16(2):213–6 **(Por)**

[Direct coronary angioplasty: the time and therapeutic window] Sousa P, et al. **Rev Port Cardiol** 1997 Feb; 16(2):191–3 **(Por)**

[Intraoperative coronary angioscopy after unsuccessful percutaneous dilatation angioplasty and the implantation of an intracoronary stent] Busch T, et al. **Chirurgia (Bucur)** 1996 Mar-Apr;45(2):85–9 (Eng. Abstr.) **(Rum)**

[X-ray endovascular dilatation of coronary arteries in patients with unstable angina pectoris] Ianus VM, et al. **Vestn Rentgenol Radiol** 1997 Mar-Apr;(2):31–5 (Eng. Abstr.) **(Rus)**

[X-ray morphology of coronary artery restenosis] Savchenko AP, et al. **Vestn Rentgenol Radiol** 1996 Sep-Oct;(5):13–5 (Eng. Abstr.) **(Rus)**

[Usefulness of intracoronary ultrasound in percutaneous transluminal coronary angioplasty] Ledesma M, et al. **Arch Inst Cardiol Mex** 1996 Nov-Dec;66(6):467–75 (Eng. Abstr.) **(Spa)**

[Coronary stents. Results during the hospitalization phase] Villavicencio Fernández R, et al. **Arch Inst Cardiol Mex** 1997 Jan-Feb;67(1):24–8 (Eng. Abstr.) **(Spa)**

[Angioplasty in the acute coronary syndrome] Ambrose J. **Rev Clin Esp** 1996 Dec;196(4 Monografico):39–40 (12 ref.) **(Spa)**

[Blood coagulation, genetics and post-angioplasty restenosis] García-Ribes M, et al. **Rev Esp Cardiol** 1997 Jan; 50(1):26–30 (Eng. Abstr.) **(Spa)**

[Percutaneous revascularization with coronary angioplasty in patients with refractory angina] Valdesuso Aguilar RM, et al. **Rev Esp Cardiol** 1996 Nov;49(11):826–33 (Eng. Abstr.) **(Spa)**

[Hospital course of acute myocardial infarction: significance of the therapeutic procedures of early reperfusion] Almendares C, et al. **Rev Med Chil** 1995 Nov; 123(11):1365–71 (Eng. Abstr.) **(Spa)**

[Thrombolysis or angioplasty in acute heart infarct?] Emanuelsson H. **Nord Med** 1996 Feb;111(2):52–4 (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Iatrogenic coronary septal artery-to-right ventricular fistula complicating percutaneous transluminal coronary angioplasty with spontaneous resolution. Youssef M, et al. **Am Heart J** 1997 Feb;133(2):260–2 (9 ref.)

Comparison of standard and derived 12-lead electrocardiograms for diagnosis of coronary angioplasty-induced myocardial ischemia. Drew BJ, et al. **Am J Cardiol** 1997 Mar 1;79(5):639–44

Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Ellis SG, et al. **Am J Cardiol** 1996 Sep 15;78(6):642–6

Early deterioration after excimer laser-assisted coronary angioplasty. Garcia-Cantu E, et al. **Am J Cardiol** 1997 May 1;79(9):1230–2

Expected hemoglobin decrease following percutaneous transluminal coronary angioplasty. Jauch W, et al. **Am J Cardiol** 1997 Jul 1;80(1):71–4

Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Kleiman NS. **Am J Cardiol** 1997 Aug 18; 80(4A):29B–33B (17 ref.)

Absence of increased in-hospital complications with reused balloon catheters [see comments] Mak KH, et al. **Am J Cardiol** 1996 Sep 15;78(6):717–9. Comment in: Am J Cardiol 1996 Sep 15;78(6):673–4.

Frequency, risk factors, and outcome for bacteremia after percutaneous transluminal coronary angioplasty. Samore MH, et al. **Am J Cardiol** 1997 Apr 1;79(7):873–7

Frequency and outcome of development of coronary artery aneurysm after intracoronary stent placement and angioplasty. STRESS Trial Investigators. Slota PA, et al. **Am J Cardiol** 1997 Apr 15;79(8):1104–6

Cardiac troponin T concentration after coronary balloon angioplasty [letter; comment] Sribhen K, et al. **Am J Cardiol** 1997 May 15;79(10):1439. Comment on: Am J Cardiol 1995 Sep 1;76(7):521–3.

Possible prevention of postangioplasty restenosis by ascorbic acid. Tomoda H, et al. **Am J Cardiol** 1996 Dec 1; 78(11):1284–6

Myocardial infarction as a complication of new interventional devices. Waksman R, et al. **Am J Cardiol** 1996 Oct 1; 78(7):751–6

Restenosis following percutaneous revascularization--the potential role of thrombin and the thrombin receptor. Stouffer GA, et al. **Ann Hematol** 1996;73 Suppl 1:S39–41 (14 ref.)

Care of the patient and management of complications after percutaneous coronary artery interventions. O'Meara JJ, et al. **Ann Intern Med** 1997 Sep 15;127(6):458–71 (224 ref.)

Ticlopidine and aspirin therapy following implantation of coronary artery stents. Hobson AG, et al. **Ann Pharmacother** 1997 Jun;31(6):770–2 (16 ref.)

Aortic dissection extending from the left coronary artery during percutaneous coronary angioplasty. Ochi M, et al. **Ann Thorac Surg** 1996 Oct;62(4):1180–2

Tyrosine kinase inhibitor suppresses the (re) stenotic changes of the coronary artery after balloon injury in pigs. Fukumoto Y, et al. **Cardiovasc Res** 1996 Dec;32(6):1131–40

Erroneous pressure measurement due to artificially deformed vessel during angioplasty. Ahn J, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):281–2

The relentless pursuit of sustained patency after acute myocardial infarction [editorial; comment] Benzuly KH, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):155–6. Comment on: Cathet Cardiovasc Diagn 1996 Oct;39(2):149–59.

Cardiac tamponade following stent implantation with adjuvant platelet IIb/IIIa receptor inhibitor administration. Bottner RK, et al. **Cathet Cardiovasc Diagn** 1997 Apr; 40(4):380–2 (4 ref.)

"T"-shaped stent placement: a technique for the treatment of dissected bifurcation lesions [see comments] Carrie D, et al. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):311–3. Comment in: Cathet Cardiovasc Diagn 1996 Mar;37(3):314–6.

Coronary artery fistula complicating coronary angioplasty: interventional cardiology turns into invasive cardiology [editorial; comment] Cheng TO. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):37. Comment on: Cathet Cardiovasc Diagn 1997 Sep;42(1):34–6.

Successful management of Palmaz-Schatz stents deformed by inadvertent angioplasty outside the stents. Chu TN, et al. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):435–9

Use of a pneumatic compression system (FemoStop) as a treatment option for femoral artery pseudoaneurysms after percutaneous cardiac procedures. Dangas G, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):138–42

"Back-squeezing" of the clot: an unusual complication of primary coronary angioplasty. Desmet WJ, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):64–7

Placement of multiple and different stent types for very long dissections during coronary angioplasty. Eeckhout E, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):302–8

Intracoronary loss of balloon-mounted stents: successful retrieval with a 2 mm-"Microsnare"-device. Elsner M, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):271–6

Inoue balloon deformity and rupture during percutaneous balloon valvuloplasty. Ho YL, et al. **Cathet Cardiovasc Diagn** 1996 Aug;38(4):345–50; discussion 351

Repair of a coronary pseudoaneurysm with percutaneous placement of a saphenous vein allograft attached to a biliary stent. Kaplan BM, et al. **Cathet Cardiovasc Diagn** 1996 Feb; 37(2):208–12

Coronary air embolism: incidence, severity, and suggested approaches to treatment [see comments] Khan M, et al. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):313–8. Comment in: Cathet Cardiovasc Diagn 1995 Dec;36(4):319.

Use of multiple stent types to treat long dissections: a stentorian method to manage a strut? [editorial] Klein LW, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):309–10

Successful retrieval of unexpanded Palmaz-Schatz stent from left main coronary artery [see comments] Kobayashi Y, et al. **Cathet Cardiovasc Diagn** 1996 Aug;38(4):402–4. Comment in: Cathet Cardiovasc Diagn 1996 Aug;38(4):405.

Fatal infection of coronary stent implantation. Leroy O, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):168–70; discussion 171 (6 ref.)

LAD-right ventricular fistula complicating PTCA: another case [see comments] Marques KM, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):34–6. Comment in: Cathet Cardiovasc Diagn 1997 Sep;42(1):37.

Radiation exposure in the cardiac catheterization laboratory: an issue or a non-issue? [editorial; comment] Meier B. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):352. Comment on: Cathet Cardiovasc Diagn 1997 Apr;40(4):348–51.

Coronary aneurysms after catheter interventions: an exception to "bigger is better" [editorial; comment] Rodriguez O, et al. **Cathet Cardiovasc Diagn** 1997 Aug; 41(4):411–2. Comment on: Cathet Cardiovasc Diagn 1997 Aug;41(4):407–10.

Coronary stenting for failed angioplasty in acute myocardial infarction [see comments] el Setiha M, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):149–54. Comment in: Cathet Cardiovasc Diagn 1996 Oct;39(2):155–6.

Successful repair of intimal dissection following coronary angioplasty with a 48-hour inflation of spiral inflation coil and local delivery of heparin. Shimabukuro M, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):103–5

Incidence and outcome of radial artery occlusion following transradial artery coronary angioplasty. Stella PR, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):156–8

Emergency bypass surgery for failed coronary interventions. Topaz O, et al. **Cathet Cardiovasc Diagn** 1997 Jan; 40(1):55–65 (57 ref.)

Multicenter clinical experience with the development of a novel short coronary stent and its prototype device. Webb J, et al. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):120–4

Radiation exposure to patients and operators during diagnostic catheterization and coronary angioplasty [see comments] Zorzetto M, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):348–51. Comment in: Cathet Cardiovasc Diagn 1997 Apr;40(4):352.

The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Abdelmeguid AE, et al. **Circulation** 1996 Dec 15;94(12):3369–75 (43 ref.)

Redifferentiation of smooth muscle cells after coronary angioplasty determined via myosin heavy chain expression. Aikawa M, et al. **Circulation** 1997 Jul 1;96(1):82–90

Differences in outcomes between women and men associated with percutaneous transluminal coronary angioplasty. A regional prospective study of 13,061 procedures. Northern New England Cardiovascular Disease Study Group. Malenka DJ, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II99–104

Six-month clinical and angiographic outcome of the new, less shortening Wallstent in native coronary arteries. Ozaki Y, et al. **Circulation** 1996 Jun 15;93(12):2114–20

Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty. Boston DR, et al. **Clin Cardiol** 1996 Jul;19(7):536–42 (62 ref.)

Infected pseudoaneurysm complicating percutaneous transluminal coronary angioplasty. Herchline TE, et al. **Clin Infect Dis** 1996 Mar;22(3):602, reply 603

Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty. Shea KW, et al. **Clin Infect Dis** 1996 Mar;22(3):601

Posterior cerebral circulation infarct following cardiac catheterization and balloon angioplasty in an adolescent. Easley RB, et al. **Clin Pediatr (Phila)** 1997 Sep;36(9):535–8

Single bailout stenting for threatened coronary closure complicating balloon angioplasty: acute and mid-term outcome. Lau KW, et al. **Coron Artery Dis** 1996 Apr; 7(4):327–33

Reduction of thrombus formation without inhibiting coagulation factors does not inhibit intimal hyperplasia after balloon injury in pig coronary arteries. Liu MW, et al. **Coron Artery Dis** 1996 Sep;7(9):667–71

Coronary artery flow monitoring: the value of intravascular Doppler for detection of complications after interventions. Anderson HV, et al. **Eur Heart J** 1995 Nov;16 Suppl L:93–6 (20 ref.)

Mechanisms of luminal enlargement and quantification of vessel wall trauma following balloon coronary angioplasty and directional atherectomy. Baptista J, et al. **Eur Heart J** 1995 Nov;16(11):1603–12

Restenosis after coronary angioplasty for rapidly progressive coronary stenosis [see comments] Bauters C, et al. **Eur Heart J** 1996 Nov;17(11):1671–7. Comment in: Eur Heart J 1996 Nov;17(11):1612–3.

Iliacus haematoma--an unusual complication of the percutaneous trans-radial approach for coronary stent implantation [letter] Brown AS, et al. **Eur Heart J** 1996 Jun;17(6):964–5

An overview of the results of the EPIC trial. Califf RM, et al. **Eur Heart J** 1995 Nov;16 Suppl L:43–9

Successful treatment of coronary artery perforation during angioplasty using autologous vein graft-coated stent. Chae JK, et al. **Eur Heart J** 1997 Jun;18(6):1030–2

Coronary intervention: risk stratification and management of abrupt coronary occlusion. de Feyter PJ, et al. **Eur Heart J** 1995 Nov;16 Suppl L:97–103 (51 ref.)

Intravascular ultrasound: a guide for management of complications during intervention? Görge G, et al. **Eur Heart J** 1995 Nov;16 Suppl L:86–92 (57 ref.)

Prevention and management of thrombotic complications during coronary interventions. Combination therapy with antithrombins, antiplatelets, and/or thrombolytics: risks and benefits. Neuhaus KL, et al. **Eur Heart J** 1995 Nov;16 Suppl L:63–7 (41 ref.)

Prospects for prevention of graft stenosis and angioplasty restenosis. Chan P. **Eur J Vasc Endovasc Surg** 1997 May; 13(5):429–31

Lipid peroxidation-associated oxidative stress during percutaneous transluminal coronary angioplasty in humans. Oostenbrug GS, et al. **Free Radic Biol Med** 1997; 22(1-2):129–36

Role of endothelial cells in restenosis after coronary

angioplasty. Meurice T, et al. **Fundam Clin Pharmacol** 1996; 10(3):234–42 (76 ref.)

Bleeding complications with new antithrombotics used in ischaemic heart disease. Adgey AA. **Haemostasis** 1996 Sep–Oct;26(5):237–46 (35 ref.)

Effects of acute coronary occlusion and previous ischaemic injury on left ventricular wall motion in humans. Henein MY, et al. **Heart** 1997 Apr;77(4):338–45

Vascular complications of coronary interventions. Davis C, et al. **Heart Lung** 1997 Mar–Apr;26(2):118–27 (21 ref.)

Is the presence of hyperlipidemia associated with impairment of endothelium-dependent neointimal relaxation after percutaneous transluminal coronary angioplasty? Sakai A, et al. **Heart Vessels** 1996;11(5):255–61

Intravascular ultrasound evidence of angiographically undetected left main coronary artery disease and associated trauma during interventional procedures. Yamagishi M, et al. **Heart Vessels** 1996;11(5):262–8

Intravascular ultrasound detected classification of coronary lesions as a predictor of dissections after balloon angioplasty. Voigtländer T, et al. **Int J Card Imaging** 1996 Sep;12(3):179–83

Spontaneous regression of post-percutaneous transluminal coronary angioplasty aneurysm. Abhyankar AD, et al. **Int J Cardiol** 1997 Aug 8;60(3):233–8

Atheroembolic occlusion of the left axillary artery after percutaneous transluminal coronary angioplasty [letter] Chen GY, et al. **Int J Cardiol** 1997 Aug 29;61(1):97–8

Platelet aggregability and occurrence of restenosis following coronary angioplasty. Goel PK, et al. **Int J Cardiol** 1997 Aug 8;60(3):227–31

Coronary artery aneurysmal fistula: a late complication of stent deployment. Karim MA. **Int J Cardiol** 1996 Dec 13; 57(3):207–9

Restenosis is associated with decreased coronary artery nitric oxide synthase. Myers PR, et al. **Int J Cardiol** 1996 Jul 26;55(2):183–91

Troponin T, creatine kinase MB mass, and creatine kinase MB isoform ratio in the detection of myocardial damage during non-surgical coronary revascularization. Reimers B, et al. **Int J Cardiol** 1997 Jun 27;60(1):7–13

Arterial remodeling after experimental percutaneous injury is highly dependent on adventitial injury and histopathology. Staab ME, et al. **Int J Cardiol** 1997 Jan 3;58(1):31–40

Aminophylline reduces cardiac ischemic pain during percutaneous transluminal coronary angioplasty. Hashino T, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1725–31

Risk of major complications from coronary angioplasty performed immediately after diagnostic coronary angiography: results from the Registry of the Society for Cardiac Angiography and Interventions. Kimmel SE, et al. **J Am Coll Cardiol** 1997 Jul;30(1):193–200

Surgical treatment of acute myocardial ischaemia related to coronary angioplasty with special reference to use of perfusion balloon catheter and long-term outcome. Heikkinen L, et al. **J Cardiovasc Surg (Torino)** 1997 Apr; 38(2):101–6

Surgical treatment of coronary artery aneurysm after percutaneous transluminal coronary angioplasty (PTCA). Shiraishi S, et al. **J Cardiovasc Surg (Torino)** 1997 Jun; 38(3):217–21

Coronary artery perforation and delayed cardiac tamponade following balloon coronary angioplasty. Tseng CD, et al. **J Formos Med Assoc** 1996 Oct;95(10):789–92

Extracellular matrix collagen synthesis and degradation following coronary balloon angioplasty. Guarda E, et al. **J Mol Cell Cardiol** 1996 Apr;28(4):699–706

Deposition of PG-M/versican is a major cause of human coronary restenosis after percutaneous transluminal coronary angioplasty. Matsuura R, et al. **J Pathol** 1996 Nov;180(3):311–6

Prolonged dilation improves an unsatisfactory primary result of femoropopliteal artery angioplasty: usefulness of a perfusion balloon catheter. Manninen HI, et al. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):627–32

Fogarty and percutaneous transluminal coronary angioplasty balloon injury induce comparable damage to the arterial wall but lead to different healing responses. Doornekamp FN, et al. **J Vasc Surg** 1996 Nov;24(5):843–50

Effects of locally administration of argatroban using a hydrogel-coated balloon catheter on intimal thickening induced by balloon injury. Imanishi T, et al. **Jpn Circ J** 1997 Mar;61(3):256–62

Local delivery of antithrombotic drug prevents restenosis after balloon angioplasty in atherosclerotic rabbit artery. Tomaru T, et al. **Jpn Circ J** 1996 Dec;60(12):981–92

Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty. Tsutsui M, et al. **Jpn Circ J** 1996 Apr;60(4):207–15

Physicians' judgments of the risks of cardiac procedures. Differences between cardiologists and other internists. Poses RM, et al. **Med Care** 1997 Jun;35(6):603–17

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators [see comments] **N Engl J Med** 1997 Jun 12;336(24):1689–96. Comment in: N Engl J Med 1997 Jun 12;336(24):1748–9.

Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty [letter] Gambassi G, et al. **N Engl J Med** 1997 Oct 23;337(17):1243–4

Preventing coronary restenosis and complications [editorial; comment] Holmes DR Jr. **N Engl J Med** 1997 Jun 12; 336(24):1748–9. Comment on: N Engl J Med 1997 Jun 12;336(24):1689–96. Comment on: N Engl J Med 1997 Jun 12;336(24):1697–703.

Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty [letter] Khan SS, et al. **N Engl J Med** 1997 Oct 23;337(17):1243; discussion 1244–5

Smooth muscle cell diversity and the extracellular matrix in a rat model of restenosis. Majesky MW, et al. **P R Health Sci J** 1996 Sep;15(3):187–91

Coronary artery stents. Stewart AJ, et al. **Postgrad Med J** 1996 May;72(847):274–6 (18 ref.)

Concerns regarding carotid artery angioplasty and stenting [letter; comment] Ammar AD. **Stroke** 1996 Nov; 27(11):2143–4. Comment on: Stroke 1996 Feb;27(2):197–8.

Concern about safety of carotid angioplasty [letter] Callahan TJ, et al. **Stroke** 1996 Nov;27(11):2144–5

Coronary heart disease, unstable angina, PTCA: new indications for low molecular weight heparins? Breddin HK. **Thromb Res** 1996;81(2 Suppl):S47–51 (21 ref.)

Low molecular weight heparin in prevention of restenosis after PTCA. Preisack MB, et al. **Thromb Res** 1996;81(2 Suppl):S53–9

Unusual pseudoaneurysms after catheterization: successful treatment by ultrasound-guided compression. Do DD, et al. **Ultrasound Med Biol** 1997;23(3):377–80

[Loss of a stent in the left main coronary artery and secondary migration into the left circumflex artery needing surgical extraction. Apropos of a case] Bedossa M, et al. **Arch Mal Coeur Vaiss** 1996 Dec;89(12):1677–80 (10 ref.) (Eng. Abstr.) **(Fre)**

[A study of platelet activation following coronary angioplasty. Effect on acute occlusion and restenosis] Durrieu-Jaïs C, et al. **Arch Mal Coeur Vaiss** 1996 Oct; 89(10):1259–65 (Eng. Abstr.) **(Fre)**

[Mycotic aneurysm of the external ilial artery: a very rare complication of coronary angioplasty] Karam BG, et al. **J Med Liban** 1996;44(3):165–7 (Eng. Abstr.) **(Fre)**

[Comparative analysis of indications and results of percutaneous coronary angioplasties according to age] Nellessen E, et al. **Rev Med Liege** 1997 Apr;52(4):230–6 (18 ref.) **(Fre)**

[Troponin T, Troponin I and CK-MB (mass) in the detection of periprocedural myocardial damage after coronary angioplasty] La Vecchia L, et al. **Cardiologia** 1997 Apr; 42(4):405–13 (Eng. Abstr.) **(Ita)**

[Incidence of peripheral vascular complications in subjects undergoing coronary angioplasty] Petronio AS, et al. **Cardiologia** 1996 Oct;41(10):973–9 (Eng. Abstr.) **(Ita)**

[Prevention of left ventricular aneurysm formation and left ventricular remodeling caused by percutaneous transluminal coronary angioplasty performed 24–48 hours after onset of acute myocardial infarction] Kanamasa K, et al. **J Cardiol** 1996 Oct;28(4):199–205 (Eng. Abstr.) **(Jpn)**

[Fatty acid metabolic disorder detected by 123I-BMIPP SPECT shortly after elective percutaneous transluminal coronary angioplasty] Kuwabara Y, et al. **Kaku Igaku** 1996 Jan;33(1):9–17 (Eng. Abstr.) **(Jpn)**

[Retroperitoneal hematoma after percutaneous transluminal coronary angioplasty] Gómez Sánchez-Biedma C, et al. **An Med Interna** 1996 Aug;13(8):395–7 (Eng. Abstr.) **(Spa)**

[Intracoronary stents in the treatment of angioplasty complications] Cequier A, et al. **Rev Esp Cardiol** 1997;50 Suppl 2:21–30 (121 ref.) (Eng. Abstr.) **(Spa)**

CONTRAINDICATIONS

Radial access for primary PTCA in patients with acute myocardial infarction and contraindication or impossible femoral access. Steg G, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):424–6 (9 ref.)

ECONOMICS

A two-step program of competitive bidding and physician feedback to reduce coronary angioplasty equipment costs. Vaitkus PT, et al. **Am J Cardiol** 1996 Oct 1;78(7):829–32

Funding of coronary angioplasty in public hospitals [letter; comment] Batey RG. **Aust N Z J Med** 1996 Jun;26(3):430 . Comment on: Aust N Z J Med 1996 Feb;26(1):3–4.

Funding of coronary angioplasty in public hospitals [letter; comment] Eccleston DS, et al. **Aust N Z J Med** 1996 Jun; 26(3):430–1. Comment on: Aust N Z J Med 1996 Feb;26(1):3–4.

Funding of coronary angioplasty and coronary stenting in public hospitals [editorial; comment] [see comments] Harper RW. **Aust N Z J Med** 1996 Feb;26(1):3–4. Comment on: Aust N Z J Med 1996 Feb;26(1):20–6. Comment in: Aust N Z J Med 1996 Jun;26(3):430. Comment in: Aust N Z J Med 1996 Jun;26(3):430–1.

Cost-effectiveness of coronary angioplasty versus medical treatment: the impact of cost-shifting [see comments] Kinlay S. **Aust N Z J Med** 1996 Feb;26(1):20–6. Comment in: Aust N Z J Med 1996 Feb;26(1):3–4.

Is medical treatment for angina the most cost-effective option? Cleland JG, et al. **Eur Heart J** 1997 May;18 Suppl B:B35–42 (25 ref.)

Initial cost of primary angioplasty for acute myocardial infarction. Lieu TA, et al. **J Am Coll Cardiol** 1996 Oct; 28(4):882–9

Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators. Stone GW, et al. **J Am Coll Cardiol** 1997 Apr;29(5):901–7

Reimbursement for cardiac rehabilitation services [letter; comment] Wenger NK. **J Am Coll Cardiol** 1997 Feb; 29(2):473. Comment on: J Am Coll Cardiol 1986 Feb;7(2):451–3.

Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators [see comments] Hlatky MA, et al. **N Engl J Med** 1997 Jan 9;336(2):92–9. Comment in: N Engl J Med 1997 Jun 19;336(25):1840–1. Comment in: ACP J Club 1997 Jul–Aug;127(1):25.

Cost effectiveness of coronary bypass surgery versus angioplasty [letter; comment] Jacobson MW. **N Engl J Med** 1997 Jun 19;336(25):1840–1. Comment on: N Engl J Med 1997 Jan 9;336(2):92–9.

A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction [letter; comment] Lee JS. **N Engl J Med** 1997 Apr 10; 336(15):1103; discussion 1104. Comment on: N Engl J Med 1996 Oct 24;335(17):1253–60.

Average charges for coronary artery bypass grafts and percutaneous transluminal coronary angioplasties, 1995. Mushinski M. **Stat Bull Metrop Insur Co** 1997 Jan–Mar; 78(1):20–8

[Cost-effectiveness analysis of an invasive therapeutic approach to coronary disease] Urban P. **Schweiz Med Wochenschr** 1996 Sep 28;126(39):1661–4 (21 ref.) (Eng. Abstr.) **(Fre)**

[Abciximab (c7E3)--a new monoclonal antibody--from the pharmaco-economic viewpoint. Initial reports from the literature] Sturm C. **Med Klin** 1996 Nov 15;91(11):735–8 **(Ger)**

[Coronary angioplasty: use and cost] Bossi I, et al. **G Ital Cardiol** 1997 May;27(5):489–94 (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

Comparison of 6F with 7F and 8F guiding catheters for elective coronary angioplasty: results of a prospective, multicenter, randomized trial. Metz D, et al. **Am Heart J** 1997 Jul;134(1):131–7

Patient acceptance of reused angioplasty equipment. Vaitkus PT. **Am Heart J** 1997 Jul;134(1):127–30

Magnum wire for percutaneous coronary balloon angioplasty in 800 total chronic occlusions. Allemann Y, et al. **Am J Cardiol** 1997 Sep 1;80(5):634–7

The reuse of single-use balloon angioplasty catheters: is it now legitimate? [editorial; comment] Bourassa MG. **Am J Cardiol** 1996 Sep 15;78(6):673–4. Comment on: Am J Cardiol 1996 Sep 15;78(6):717–9.

Absence of increased in-hospital complications with reused balloon catheters [see comments] Mak KH, et al. **Am J Cardiol** 1996 Sep 15;78(6):717–9. Comment in: Am J Cardiol 1996 Sep 15;78(6):673–4.

Comfort and bleeding after percutaneous transluminal coronary angioplasty: comparison of a flexible sheath and a standard sheath. Mayer DM, et al. **Am J Crit Care** 1997 Sep;6(5):341–7

Endovascular stenting. Sullivan TM. **Am J Surg** 1997 Jan; 173(1):27–9; discussion 30–1 (17 ref.)

The changing face of coronary interventional practice. The Mayo Clinic experience. Hasdai D, et al. **Arch Intern Med** 1997 Mar 24;157(6):677–82

New technique for exchanging an "over-the-wire" balloon dilatation catheter. Agarwal R, et al. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):350–1

Angioplasty without the use of "Y connector": a new, easier, bloodless method. Antonellis IP, et al. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):445–8

Bailout coronary stenting without anticoagulation or intravascular ultrasound guidance: acute and six-month angiographic results in a series of 120 consecutive patients. Antoniucci D, et al. **Cathet Cardiovasc Diagn** 1997 May; 41(1):14–9

Local delivery of c-myb antisense oligonucleotides during balloon angioplasty. Azrin MA, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):232–40

Perfusion angioplasty: a rising or receding tide? [editorial; comment] Bach RG, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):90–1. Comment on: Cathet Cardiovasc Diagn 1997 Sep;42(1):84–9.

Comparing perfusion balloon systems: keeping flow in perspective [editorial; comment] Bach RG. **Cathet Cardiovasc Diagn** 1996 Aug;38(4):428–9. Comment on: Cathet Cardiovasc Diagn 1996 Aug;38(4):421–7.

PTCA in angulated segments: effects of balloon material, balloon length, and inflation sequence on straightening forces in an in vitro model. Barasch E, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):207–12; discussion 213

Infiltrator Angioplasty Balloon Catheter: a device for combined angioplasty and intramural site-specific treatment. Barath P, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):333–41

Efficacy of low-molecular-weight heparin delivery with the Dispatch catheter following balloon angioplasty in the rabbit iliac artery. Baumbach A, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):303–7

Clinical one-year outcomes after stenting in acute myocardial infarction [see comments] Berland G, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):337-41. Comment in: Cathet Cardiovasc Diagn 1997 Apr;40(4):342.

Evaluation of the cathetron system for recycling angioplasty catheters [see comments] Bryce EA, et al. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):132-5. Comment in: Cathet Cardiovasc Diagn 1997 Jun;41(2):136.

Site-specific intravascular administration of drugs: history of a method applicable in humans. Camenzind E, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):342-7 (39 ref.)

Angioplasty of a coronary artery via the translumbar approach in a patient with severe peripheral vascular disease [see comments] Chandler AH 3rd, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):202-4. Comment in: Cathet Cardiovasc Diagn 1996 Jun;38(2):205.

Utility of Pilot wire in angioplasty of tortuous and highly angulated coronary arteries. Chandra P, et al. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):268-70; discussion 271

Left main intervention revisited: early and late outcome of PTCA and stenting [see comments] Chauhan A, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):21-9. Comment in: Cathet Cardiovasc Diagn 1997 May;41(1):30-1.

Comparison of bailout versus elective stenting: time to reassess our benchmarks of outcome. Chauhan A, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):40-7

Pullback atherectomy for the treatment of intrastent restenosis [letter; comment] Chow WH, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):94-5. Comment on: Cathet Cardiovasc Diagn 1996 Dec;39(4):377-82.

Successful closure of a coronary vessel rupture with a vein graft stent: case report. Colombo A, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):172-4

Percutaneous bailout therapy of a perforated vein graft using a stent-autologous vein patch [see comments] Colon PJ 3rd, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):175-8. Comment in: Cathet Cardiovasc Diagn 1995 Jun;38(2):179.

Trifurcation triple balloon angioplasty in a dual left anterior descending coronary artery: the "Ménage à trois" revisited. Cusco JA, et al. **Cathet Cardiovasc Diagn** 1996 Jun; 38(2):214-7

Coronary artery stenting postcardiac transplant: a report of two cases. Cusick D, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):92-6

Comparison of clinical complications, angiographic results, and device usage of coronary angioplasty using low- and high-compliance balloons. Desmet WJ, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):5-11

Sustained local drug delivery to the arterial wall via biodegradable microspheres. Dev V, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):324-32

Jaws catheter exchange: an alternative method of exchanging coronary interventional devices. Feiring AJ. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):427-32

Evaluation of an active coronary perfusion balloon device using Doppler flow wire during PTCA [see comments] Ferrari M, et al. **Cathet Cardiovasc Diagn** 1997 Sep; 42(1):84-9. Comment in: Cathet Cardiovasc Diagn 1997 Sep;42(1):90-1.

Left main coronary angioplasty: is the Bastille of bypass surgery about to go down? [editorial; comment] Fleisch M, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):30-1. Comment on: Cathet Cardiovasc Diagn 1997 May;41(1):21-9.

Local delivery of heparin to balloon angioplasty sites with a new angiotherapy catheter: pharmacokinetics and effect on platelet deposition in the porcine model. Fram DB, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):275-86

Coronary artery perforation with subepicardial hematoma. Furushima H, et al. **Cathet Cardiovasc Diagn** 1997 May; 41(1):59-61

Treatment of thrombotic saphenous vein bypass grafts using local urokinase infusion therapy with the Dispatch catheter. Glazier JJ, et al. **Cathet Cardiovasc Diagn** 1997 Jul; 41(3):261-7

Site-specific intracoronary thrombolysis with urokinase-coated hydrogel balloons: acute and follow-up studies in 95 patients. Glazier JJ, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):246-53

Risks of reusing coronary angioplasty catheters: results of an experimental study [see comments] Grimandi G, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):123-30; discussion 131-2. Comment in: Cathet Cardiovasc Diagn 1996 Jun;38(2):133-4.

Back to our roots [editorial; comment] Grollman JH Jr. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):205. Comment on: Cathet Cardiovasc Diagn 1996 Jun;38(2):202-4.

New concept in coronary angioplasty: dilatation with a helical balloon that allows simultaneous autoperfusion. Gurbel PA, et al. **Cathet Cardiovasc Diagn** 1997 Jan; 40(1):109-16

Coronary artery angioplasty with a helical autoperfusion balloon catheter [see comments] Gurbel PA, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):179-85. Comment in: Cathet Cardiovasc Diagn 1997 Feb;40(2):186.

Local drug delivery with porous balloons in the rabbit: assessment of vascular injury for an improvement of application parameters. Herdeg C, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):308-14

Stents in jackets: the latest in endovascular haute couture [editorial; comment] Heuser RR. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):179. Comment on: Cathet Cardiovasc Diagn 1996 Jun;38(2):175-8.

Percutaneous revascularization using endoluminal prostheses: coming of age [editorial] Heuser RR. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):213-4

A disposable society: is it time for a change? [editorial; comment] Holmes DR. **Cathet Cardiovasc Diagn** 1997 Jun; 41(2):136. Comment on: Cathet Cardiovasc Diagn 1997 Jun;41(2):132-5.

Friction-free stenting [editorial] Kahn JK. **Cathet Cardiovasc Diagn** 1997 May;41(1):20

Confusion about perfusion [editorial; comment] Kahn JK. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):186. Comment on: Cathet Cardiovasc Diagn 1997 Feb;40(2):179-85.

Infarct artery stents: the first year [editorial; comment] Kahn JK. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):342. Comment on: Cathet Cardiovasc Diagn 1997 Apr;40(4):337-41.

Analysis of reproducibility of reference lumen quantitation with intravascular ultrasound in stented coronary arteries [see comments] Kearney PP, et al. **Cathet Cardiovasc Diagn** 1997 Jan;40(1):1-7. Comment in: Cathet Cardiovasc Diagn 1997 Jan;40(1):8.

Impact of stent size and indication for stent placement on immediate outcome [see comments] Keelan ET, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):145-51. Comment in: Cathet Cardiovasc Diagn 1996 Jun;38(2):152.

Conquering compliance [editorial] Kern MJ, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):12-3

Straightening a kinked guidewire extension. Koh TH. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):300-1

"Kissing balloon" technique in percutaneous transluminal coronary angiography: single-guide catheter, dual-wire, dual-balloon system with single inflation device. Krikorian RK, et al. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):331-3

Outcomes during stenting: risk, benefit, bad luck, and good judgement [editorial; comment] Laskey WK. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):152. Comment on: Cathet Cardiovasc Diagn 1996 Jun;38(2):145-51.

Refractory ventricular fibrillation complicating acute myocardial infarction terminated by intracoronary stenting. Le May MR, et al. **Cathet Cardiovasc Diagn** 1996 Feb; 37(2):174-7

Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Lewis BE, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):206-9

Stenting on a rail: propitious placement of permanent endoluminal prostheses [editorial; comment] Linnemeier TJ. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):144. Comment on: Cathet Cardiovasc Diagn 1996 Jun;38(2):135-43.

Left main coronary disease: is stenting an option? [editorial; comment] Linnemeier TJ. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):276. Comment on: Cathet Cardiovasc Diagn 1997 Mar;40(3):272-5.

Applications of a novel balloon catheter during coronary angioplasty. Mego DM, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):207-9

Catheter-based local thrombolysis with urokinase: comparative efficacy of intraluminal clot lysis with conventional urokinase infusion techniques in an in vivo porcine thrombus model. Mitchel JF, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):293-302

Localized delivery of heparin to angioplasty sites with iontophoresis. Mitchel JF, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):315-23

Local urokinase delivery with the Channel balloon: device safety, pharmacokinetics of intracoronary drug delivery, and efficacy of thrombolysis. Mitchel JF, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):254-60

PTCA procedure for Shepherd's Crook right coronary artery lesion with a new long soft-tip 6F guiding catheter. Morís de la Tassa C, et al. **Cathet Cardiovasc Diagn** 1997 Apr; 40(4):390-2

Time course of smooth muscle cell proliferation after local drug delivery of low-molecular-weight heparin using a porous balloon catheter. Oberhoff M, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):268-74

Coronary implantation of silicone-carbide-coated Palmaz-Schatz stents in patients with high risk of stent thrombosis without oral anticoagulation. Ozbek C, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):71-8

Obliteration of a coronary artery aneurysm with percutaneous transluminal coronary angioplasty and stent placement. Parmar RJ, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):51-2

Intramural drug delivery by direct injection within the arterial wall: first clinical experience with a novel intracoronary delivery-infiltrator system. Pavlides GS, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):287-92

Deep seating of six French guiding catheters for delivery of new Palmaz-Schatz stents. Peels HO, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):210-3

Endoluminal stenting for unprotected left main stenosis in Takayasu's arteritis [see comments] Punamiya K, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):272-5. Comment in: Cathet Cardiovasc Diagn 1997 Mar;40(3):276.

Endoluminal local delivery of PCNA/cdc2 antisense oligonucleotides by porous balloon catheter does not affect neointima formation or vessel size in the pig coronary artery model of postangioplasty restenosis. Robinson KA, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):348-53

Pharmacokinetics and tissue localization of antisense oligonucleotides in balloon-injured pig coronary arteries after local delivery with an iontophoretic balloon catheter. Robinson KA, et al. **Cathet Cardiovasc Diagn** 1997 Jul; 41(3):354-9

Stent implantation in a left anterior descending coronary artery through an internal mammary artery graft. Rubartelli P, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):311-3

Equipment-dependent mechanical distortion of a tortuous right coronary artery during PTCA. Schlaifer JD, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):281-3

Use of c7E3 Fab in conjunction with primary coronary stenting for acute myocardial infarctions complicated by cardiogenic shock. Schultz RD, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):143-8

Coronary stenting for aortocoronary dissection following balloon angioplasty. Seifein HB, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):222-5

Guide catheter exchange techniques: bi-coaxial and other methods. Selig MB, et al. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):442-4

Thrombotic occlusion of the coronary artery associated with accidental detachment of undeployed Palmaz-Schatz stent. Shiojima I, et al. **Cathet Cardiovasc Diagn** 1996 Aug; 38(4):360-2

Recanalization of chronic coronary occlusions using a laser wire. Sievert H, et al. **Cathet Cardiovasc Diagn** 1996 Feb; 37(2):220-2

In the same vein--a step backwards [editorial; comment] Smalling R. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):171. Comment on: Cathet Cardiovasc Diagn 1996 Jun;38(2):159-70.

Initial clinical experience with a novel low-profile integrated ultrasound-angioplasty catheter. Stone GW, et al. **Cathet Cardiovasc Diagn** 1996 Jul;38(3):303-7

Micro stent, quantitative coronary angiography, and procedural results [see comments] Tresukosol D, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):135-43. Comment in: Cathet Cardiovasc Diagn 1996 Jun;38(2):144.

Reuse of disposables: let's not embrace waste [editorial; comment] Turi ZG. **Cathet Cardiovasc Diagn** 1996 Jun; 38(2):133-4. Comment on: Cathet Cardiovasc Diagn 1996 Jun;38(2):123-30; discussion 131-2.

Use of Palmaz stents to palliate pulmonary atresia with ventricular septal defect and stenotic aortopulmonary collaterals. Vance MS. **Cathet Cardiovasc Diagn** 1997 Apr; 40(4):387-9

Comparison of passive and active perfusion catheters: an in vitro study in a pulsatile coronary flow model [see comments] Voelker W, et al. **Cathet Cardiovasc Diagn** 1996 Aug;38(4):421-7. Comment in: Cathet Cardiovasc Diagn 1996 Aug;38(4):428-9.

Stent recoil: comparison of the Wiktor-GX coil and the Palmaz-Schatz tubular coronary stent. White CJ. **Cathet Cardiovasc Diagn** 1997 May;41(1):1-3; discussion 4

Improved procedural results of coronary angioplasty with intravascular ultrasound-guided balloon sizing: the CLOUT Pilot Trial. Clinical Outcomes With Ultrasound Trial (CLOUT) Investigators. Stone GW, et al. **Circulation** 1997 Apr 15;95(8):2044-52

Porous balloon delivery of low molecular weight heparin in the dog coronary artery. Baumbach A, et al. **Eur Heart J** 1996 Oct;17(10):1538-45

Coronary stents--implantation of foreign bodies into stenotic human coronary arteries: dream or nightmare? Haase KK, et al. **Eur Heart J** 1997 Apr;18(4):552-3

Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management [see comments] Lablanche JM, et al. **Eur Heart J** 1996 Sep;17(9):1373-80. Comment in: Eur Heart J 1996 Sep;;17(9):1296-8.

Interventional cardiology in Europe 1993. Working Group on Coronary Circulation of the European Society of Cardiology. Meyer BJ, et al. **Eur Heart J** 1996 Sep; 17(9):1318-28

Identifying and tracking a guide wire in the coronary arteries during angioplasty from X-ray images. Palti-Wasserman D, et al. **IEEE Trans Biomed Eng** 1997 Feb;44(2):152-64

Percutaneous transluminal coronary angioplasty in refractory unstable angina pectoris: are new devices useful? Bertaglia E, et al. **Int J Cardiol** 1996 Nov 15;57(1):1-7

Magnum wire for angioplasty of total and non-total coronary lesions. Gunnes P, et al. **Int J Cardiol** 1997 Jun 27;60(1):1-6

Recanalization of chronic total coronary occlusions using a laser guide wire: a pilot study. Hamburger JN, et al. **J Am Coll Cardiol** 1997 Sep;30(3):649-56

Cost efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty [letter; comment] Lesh MD. **J Am Coll Cardiol** 1996 Nov 15;28(6):1640-1. Comment on: J Am Coll Cardiol 1996 Jul;28(1):106-11.

Antithrombotic therapy after intracoronary stenting. Spinler S, et al. **Pharmacotherapy** 1997 Jan-Feb;17(1):74-90 (68 ref.)

Hemodialysis fistulas and grafts: use of cutting balloons to dilate venous stenoses. Vorwerk D, et al. **Radiology** 1996 Dec;201(3):864-7

The role of intracoronary stents in the prevention of restenosis--facts and fallacies. Lau KW. **Singapore Med J** 1996 Oct;37(5):522-6 (31 ref.)

Efficacy of coronary angioplasty with a cutting balloon in a case of repeated coronary stenosis. Sakabe K, et al. **Tokushima J Exp Med** 1996 Dec;43(3-4):167-72 (10 ref.)

[Stent implantation in coronary arteries--current status] Frombach R, et al. **Gesundheitswesen** 1997 Jul;59(7):447-51 (27 ref.) (Eng. Abstr.) **(Ger)**

[Interventional therapy in acute myocardial infarct] Heintzen MP, et al. **Internist (Berl)** 1997 Jan;38(1):44-52 (63 ref.) **(Ger)**

[Alternatives to balloon angioplasty. Radio frequency angioplasty, directional coronary atherectomy, high frequency rational angioplasty and coronary extraction atherectomy] Hombach V, et al. **Internist (Berl)** 1997 Jan; 38(1):11-9 (41 ref.) **(Ger)**

[Current status of stent implantation] Kaufmann U, et al. **Internist (Berl)** 1997 Jan;38(1):20-6 (29 ref.) **(Ger)**

[Intravascular ultrasound imaging in coronary angioplasty] Mudra H. **Internist (Berl)** 1997 Jan;38(1):56-63 (52 ref.) **(Ger)**

[PTCA in unstable angina pectoris] Rupprecht HJ, et al. **Internist (Berl)** 1997 Jan;38(1):3-10 (58 ref.) **(Ger)**

[Stents: new studies--new trends] Dietz R, et al. **Z Kardiol** 1997 Feb;86(2):65-70 (53 ref.) (Eng. Abstr.) **(Ger)**

[Incidence and management of acute left main coronary artery dissection as a complication of acute transluminal coronary angioplasty] Dittel M, et al. **Z Kardiol** 1996 Sep; 85(9):635-9 (Eng. Abstr.) **(Ger)**

[High risk PTCA: prevention and treatment of cardiogenic shock with mechanical assist systems] Figulla HR, et al. **Z Kardiol** 1996;85 Suppl 1:33-7 (12 ref.) (Eng. Abstr.) **(Ger)**

[Emergency stent implantation in the area of extensive muscle bridging of the anterior interventricular ramus after post-interventional dissection] Jeremias A, et al. **Z Kardiol** 1997 May;86(5):367-72 (Eng. Abstr.) **(Ger)**

[Alternative techniques in coronary intervention--a new differential therapy?] Kober G. **Z Kardiol** 1996;85 Suppl 1:1-7 (48 ref.) (Eng. Abstr.) **(Ger)**

[Initial clinical and angiographic results with the AVE Micro-Stent] Köster R, et al. **Z Kardiol** 1996 Sep; 85(9):640-6 (Eng. Abstr.) **(Ger)**

[Primary balloon dilatation in every coronary stenosis?] Meier B. **Z Kardiol** 1996;85 Suppl 1:9-15 (17 ref.) (Eng. Abstr.) **(Ger)**

[Applications and value of intravascular ultrasound imaging in coronary interventions] Mudra H, et al. **Z Kardiol** 1996; 85 Suppl 1:39-47 (33 ref.) (Eng. Abstr.) **(Ger)**

[Visual assessment or quantitative measurement of coronary stenoses: significance for "prima vista"-PTCA] Stiel GM, et al. **Z Kardiol** 1997 Mar;86(3):189-95 (Eng. Abstr.) **(Ger)**

[Interventional coronary revascularization in a patient with chronic dissection of the ascending aorta] von Kodolitsch Y, et al. **Z Kardiol** 1996 Sep;85(9):673-6 (Eng. Abstr.) **(Ger)**

[The implantation of Palmaz-Schatz stents via 6F catheters without oral hypocoagulation] Carvalho H, et al. **Rev Port Cardiol** 1997 Feb;16(2):185-8 **(Por)**

[A cutting balloon for coronary angioplasty: a new trend in the prevention of restenosis] Izmailov BI, et al. **Vestn Rentgenol Radiol** 1996 Sep-Oct;(5):47-50 **(Rus)**

[Coronary angioplasty through 6 French guiding catheters] Moris de la Tassa C, et al. **Rev Esp Cardiol** 1996 Feb; 49(2):124-9 (Eng. Abstr.) **(Spa)**

METHODS

Prospects for gene therapy of postangioplasty restenosis. Steg PG, et al. **Adv Nephrol Necker Hosp** 1997;26:121-31 (57 ref.)

Results of coronary stenting for unstable versus stable angina pectoris. Marzocchi A, et al. **Am J Cardiol** 1997 May 15; 79(10):1314-8

Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. O'Keefe JH, et al. **Am J Cardiol** 1996 Oct 1; 78(7):747-50

Experience with the AVE Micro stent in native coronary arteries. Rozenman Y, et al. **Am J Cardiol** 1996 Sep 15; 78(6):685-7

Public policy and coronary stenting: report of an expert panel to the cardiac Care Network of Ontario. Cardiac Care Network of Ontario Expert Panel on Intracoronary Stents. **Can J Cardiol** 1997 Aug;13(8):731-46 (121 ref.)

Intravascular ultrasound and balloon percutaneous transluminal coronary angioplasty. Tenaglia AN. **Cardiol Clin** 1997 Feb;15(1):31-8 (30 ref.)

Intravascular ultrasound in the setting of directional coronary atherectomy and percutaneous transluminal coronary rotational atherectomy. Timmis SB, et al. **Cardiol Clin** 1997 Feb;15(1):39-48 (63 ref.)

Use and limitations of immediate postprocedural intracoronary Doppler blood flow measurements for predicting late result after coronary balloon angioplasty. Results of a pilot study. Lewis BS, et al. **Cardiology** 1997 Sep-Oct;88(5):433-40

Angioplasty without the use of "Y connector": a new, easier, bloodless method. Antonellis IP, et al. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):445-8

Brachial, radial, or femoral approach for elective Palmaz-Schatz stent implantation: a randomized comparison [see comments] Benit E, et al. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):124-30. Comment in: Cathet Cardiovasc Diagn 1997 Jun;41(2):131.

Management of resistant coronary lesions by the cutting balloon catheter: initial experience. Bertrand OF, et al. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):179-84

Minimally invasive coronary catheterization: western technology and eastern dexterity [editorial] Cheng TO. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):164-5

Mechanical versus manual compression of radial artery following percutaneous transradial approach for coronary arteriography and angioplasty [editorial; comment] Cheng TO. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):301. Comment on: Cathet Cardiovasc Diagn 1997 Mar;40(3):297-300.

Management of membranous obstruction of inferior vena cava by percutaneous balloon angioplasty with or without the use of a stent [letter; comment] Cheng TO. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):336. Comment on: Cathet Cardiovasc Diagn 1996 Nov;39(3):252-7.

PTCA of complex atherosclerotic lesion at site of LAD myocardial bridging. Cohen HM, et al. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):272-6 (14 ref.)

Simultaneous inflation of tandem (sequential) angioplasty balloons [letter; comment] Corcos T, et al. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):378. Comment on: Cathet Cardiovasc Diagn 1995 Apr;34(4):365-7.

Hugging perfusion balloon salvage of a right coronary artery angioplasty. Ebersole MD, et al. **Cathet Cardiovasc Diagn** 1996 Jul;38(3):308-11

Ulnar and radial coronary interventions: distal reaches of arterial access [editorial; comment] Feldman T. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):131. Comment on: Cathet Cardiovasc Diagn 1997 Jun;41(2):124-30.

Coronary angioplasty of branch vessels associated with an extreme angle take-off. Gershony G, et al. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):356-9

"Functional characteristics of a new perfusion balloon: comparison with the Flowtrack 40 in a closed chest swine" [letter; comment] Gurbel PA. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):377-8. Comment on: Cathet Cardiovasc Diagn 1995 Jun;35(2):176-80.

Half for me ... half for you! [editorial] Hodgson JM. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):377

Interventional cardiology and intracoronary stents--a changing practice: approved vs. nonapproved indications [see comments] Holmes DR Jr, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):133-8. Comment in: Cathet Cardiovasc Diagn 1997 Feb;40(2):139.

Trouser-like stenting: a new technique for bifurcation lesions. Khoja A, et al. **Cathet Cardiovasc Diagn** 1997 Jun; 41(2):192-6; discussion 197-9

"Kissing balloon" technique in percutaneous transluminal coronary angiography: single-guide catheter, dual-wire, dual-balloon system with single inflation device. Krikorian RK, et al. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):331-3

Investigational intervention: revisit the paradigm or make a new one? Laskey WK. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):469-70

Use of bare-mounted Palmaz-Schatz stents employing the stent saddle technique on the delivery balloon: a single center experience [see comments] Levine G, et al. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):361-8. Comment in: Cathet Cardiovasc Diagn 1997 Aug;41(4):369-70.

Coronary stenting with the half (disarticulated) Palmaz-Schatz stent: immediate results and six-month follow-up. Marzocchi A, et al. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):371-6

Single device approach to ultrasound-guided percutaneous transluminal coronary angioplasty and stenting: initial experience with a combined intracoronary ultrasound/variable diameter balloon. Müller C, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):393-9

Is balloon a challenge to scalpel in membranous pulmonary valve atresia or just a partner? [editorial; comment] Ruiz CE, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):414-5 . Comment on: Cathet Cardiovasc Diagn 1997 Apr;40(4):408-13.

New alternative for the treatment of spontaneous dissection [editorial] Satler LF. **Cathet Cardiovasc Diagn** 1996 Feb; 37(2):206-7

The V-stent: a novel technique for coronary bifurcation stenting. Schampaert E, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):320-6

Guide catheter exchange techniques: bi-coaxial and other methods. Selig MB, et al. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):442-4

U.S. experience of transradial coronary stenting utilizing Palmaz-Schatz stents. el-Shiekh RA, et al. **Cathet Cardiovasc Diagn** 1997 Feb;40(2):166-9

Radial access for primary PTCA in patients with acute myocardial infarction and contraindication or impossible femoral access. Steg G, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):424-6 (9 ref.)

Bare-mounted stents: a bare necessity? [editorial; comment] Topaz O. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):369-70 . Comment on: Cathet Cardiovasc Diagn 1997 Aug;41(4):361-8.

Transradial coronary angiography and angioplasty in Chinese patients. Wu CJ, et al. **Cathet Cardiovasc Diagn** 1997 Feb; 40(2):159-63

Preconditioning of human myocardium with adenosine during coronary angioplasty. Leesar MA, et al. **Circulation** 1997 Jun 3;95(11):2500-7

Immediate and chronic results of cutting balloon angioplasty: a matched comparison with conventional angioplasty. Kondo T, et al. **Clin Cardiol** 1997 May;20(5):459-63

Coronary arteriovenous fistulas: collective review and management of six new cases--changing etiology, presentation, and treatment strategy. Said SA, et al. **Clin Cardiol** 1997 Sep;20(9):748-52 (33 ref.)

Platelet activation and restenosis after coronary stenting: flow cytometric detection of wound-induced platelet activation. Markovitz JH, et al. **Coron Artery Dis** 1996 Sep;7(9):657-65

Cutting balloon angioplasty and stenting for aorto-ostial lesions. Kurbaan AS, et al. **Heart** 1997 Apr;77(4):350-2

Enhancement of coronary reactive hyperemia in patients with ischemic myocardial tolerance during angioplasty. Tanaka T, et al. **Heart Vessels** 1996;11(5):242-7

Immediate and six-month outcome of self-expanding Wallstent for long lesions in native coronary arteries. Gambhir DS, et al. **Indian Heart J** 1997 Jan-Feb;49(1):53-9

Treatment of ulcerated atherosclerotic carotid artery bifurcation stenosis using a self-expanding mesh stent. Joseph G, et al. **Indian Heart J** 1996 Jul-Aug;48(4):412-4

PTCA, thrombolysis or atherectomy: rational treatment of recently occluded saphenous vein grafts. Mehta S, et al. **Indian Heart J** 1995 Sep-Oct;47(5):481-4

Percutaneous balloon occlusion of post-infarction ventricular septal defect. Vajifdar B, et al. **Indian Heart J** 1996 Jul-Aug;48(4):407-8

Angioplasty through a stent side door. Abhyankar A, et al. **Int J Cardiol** 1996 Jul 5;55(1):107-10

Angioplasty of a left anterior descending artery originating from the right sinus of Valsalva (discussion in decision making). Antonellis J, et al. **Int J Cardiol** 1996 Sep; 56(1):86-9

Improved outcome of coronary stenting by utilizing a modified treatment protocol. Rozenman Y, et al. **Isr J Med Sci** 1996 Sep;32(9):722-5

A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the access study. Kiemeneij F, et al. **J Am Coll Cardiol** 1997 May;29(6):1269-75

Balloon dilatation of inferior vena cava stenosis in Budd-Chiari syndrome. Tyagi S, et al. **J Assoc Physicians India** 1996 Jun;44(6):378-80

Continuous ST-segment monitoring during coronary angioplasty using orthogonal ECG leads. Badir BF, et al. **J Electrocardiol** 1997 Jul;30(3):175-87

Comparison of high-resolution and standard ECG parameters of myocardial ischemia during PTCA. Lander P, et al. **J Electrocardiol** 1996;29 Suppl:167

Percutaneous transluminal coronary angioplasty of the left anterior descending artery through a left main coronary artery of anomalous origin. Ko WC, et al. **J Formos Med Assoc** 1997 Mar;96(3):222-4

Stents with high-pressure balloon inflations and intravascular ultrasonography--applicable in all patients? [editorial; comment] Berger PB. **Mayo Clin Proc** 1997 Feb; 72(2):185-7. Comment on: Mayo Clin Proc 1997 Feb;72(2):101-11.

[Should a main coronary artery be dilated when the controlateral vessel is occluded?] Lafont A, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89(10):1233-9 (Eng. Abstr.) **(Fre)**

[Elective coronary implantation of a newly developed stent without conventional anticoagulation] Markert T, et al. **Dtsch Med Wochenschr** 1996 Oct 4;121(40):1213-9 (Eng. Abstr.) **(Ger)**

[The radial artery as an approach to diagnostic coronary angiography] Kröger K, et al. **Z Kardiol** 1997 May; 86(5):363-6 (17 ref.) (Eng. Abstr.) **(Ger)**

[Evolution in coronary stenting: use of ticlopidine with and without oral anticoagulants] Zanini R, et al. **Cardiologia** 1997 Aug;42(8):837-43 (32 ref.) (Eng. Abstr.) **(Ita)**

[Coronary rotational atherectomy: initial experience at a hospital without a special department for heart surgery] Belli R, et al. **G Ital Cardiol** 1996 Jul;26(7):765-74 (Eng. Abstr.) **(Ita)**

[Carotid angioplasty with cerebral protection and endovascular prosthesis] Soler-Singla L, et al. **Rev Neurol** 1997 Feb;25(138):287-90 (12 ref.) **(Spa)**

MORTALITY

Explaining discrepant mortality results between primary percutaneous transluminal coronary angioplasty and thrombolysis for acute myocardial infarction [editorial] Anderson JL, et al. **Am J Cardiol** 1996 Oct 15;78(8):934-9

PTCA with the use of cardiac assist devices: risk stratification, short- and long-term results [see comments] Ferrari M, et al. **Cathet Cardiovasc Diagn** 1996 Jul; 38(3):242-8. Comment in: Cathet Cardiovasc Diagn 1996 Jul;38(3):249-50.

Supported angioplasty: another look [editorial; comment] Tommaso CL. **Cathet Cardiovasc Diagn** 1996 Jul; 38(3):249-50. Comment on: Cathet Cardiovasc Diagn 1996 Jul;38(3):242-8.

Relationship between physician and hospital coronary angioplasty volume and outcome in elderly patients [see comments] Jollis JG, et al. **Circulation** 1997 Jun 3; 95(11):2485-91. Comment in: Circulation 1997 Jun 3;95(11):2467-70.

[Coronary dilatation in geriatric patients--indications and results] Seggewiss H, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:1004-8 (19 ref.) (Eng. Abstr.) **(Ger)**

[The initial and long-term outcome of PTCA] Kimura T,

et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):119–24 (Eng. Abstr.) **(Jpn)**

NURSING

Survey of current practice patterns for percutaneous transluminal coronary angioplasty. SANDBAG Nursing Coordinators. Juran NB, et al. **Am J Crit Care** 1996 Nov; 5(6):442–8

Clinical pathway across tertiary and community care after an interventional cardiology procedure. Doran K, et al. **J Cardiovasc Nurs** 1997 Jan;11(2):1–14

Study of mechanical versus manual/mechanical compression following various interventional cardiology procedures. Rudisill PT, et al. **J Cardiovasc Nurs** 1997 Jan;11(2):15–21

PSYCHOLOGY

Patients' responses to the angioplasty experience: a qualitative study. Gulanick M, et al. **Am J Crit Care** 1997 Jan; 6(1):25–32

REHABILITATION

Determinants of improvement in exercise capacity in patients undergoing cardiac rehabilitation. Shiran A, et al. **Cardiology** 1997 Mar–Apr;88(2):207–13

Clinical pathway across tertiary and community care after an interventional cardiology procedure. Doran K, et al. **J Cardiovasc Nurs** 1997 Jan;11(2):1–14

[Work capacity of coronary disease patients after coronary balloon dilatation and coronary artery bypass] Leinonen H. **Duodecim** 1995;111(17):1667–9 **(Fin)**

[Indication for percutaneous transluminal coronary angioplasty based on quality of life of patients with angina pectoris] Hayashi T, et al. **J Cardiol** 1997 Jan;29(1):13–22 (Eng. Abstr.) **(Jpn)**

STANDARDS

Effect of continuous quality improvement analysis on the delivery of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Caputo RP, et al. **Am J Cardiol** 1997 May 1;79(9):1159–64

If youth but knew, if age but could...[letter] Corcos T, et al. **Cathet Cardiovasc Diagn** 1997 Jun;41(2):228

Relation of operator volume and experience to procedural outcome of percutaneous coronary revascularization at hospitals with high interventional volumes [see comments] Ellis SG, et al. **Circulation** 1997 Jun 3;95(11):2479–84. Comment in: Circulation 1997 Jun 3;95(11):2467–70.

Credentialing for coronary interventions. Practice makes perfect [editorial; comment] Teirstein PS. **Circulation** 1997 Jun 3;95(11):2467–70. Comment on: Circulation 1997 Jun 3;95(11):2479–84. Comment on: Circulation 1997 Jun 3;95(11):2485–91.

Requirements for quality assessment in coronary angiograph and angioplasty. Brennecke R, et al. **Eur Heart J** 1995 Nov; 16(11):1578–88 (94 ref.)

Why there should be constraints about who performs coronary angioplasty [comment] Boyle R. **Heart** 1996 Aug; 76(2):106. Comment on: Heart 1996 Apr;75(4):419–25.

Planning for coronary angioplasty: guidelines for training and continuing competence. Webb-Peploe MM. **Heart** 1996 Aug;76(2):105

Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. **Lancet** 1997 Aug 16;350(9076):461–8

Early experience of primary angioplasty at Waikato Hospital. Nunn C, et al. **N Z Med J** 1997 Apr 11;110(1041):116–8

Percutaneous transluminal coronary angioplasty in Singapore General Hospital in 1995: a medical audit. Chan CN, et al. **Singapore Med J** 1997 Apr;38(4):161–3

[Comparative analysis of indications and results of percutaneous coronary angioplasties according to age] Nellessen E, et al. **Rev Med Liege** 1997 Apr;52(4):230–6 (18 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

Coronary revascularization and cardiac catheterization in the United States: trends in racial differences. Gillum RF, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1557–62

[Cardiac interventions in Switzerland in 1994] Goerre S. **Schweiz Rundsch Med Prax** 1996 Sep 3;85(36):1071–80 (Eng. Abstr.) **(Ger)**

TRENDS

Quality control for invasive cardiology: Holland. Plokker HW. **Herz** 1996 Oct;21(5):288–90

Recent progress in coronary interventions--assessment by quantitative coronary angiography. Ozaki Y, et al. **Jpn Circ J** 1997 Jan;61(1):1–13 (77 ref.)

[Quality assurance in invasive cardiology: Switzerland] Goerre S, et al. **Herz** 1996 Oct;21(5):283–7 (Eng. Abstr.) **(Ger)**

[Quality assurance in invasive and interventional cardiology in Austria for the 1995 calendar year] Mühlberger V, et al. **Herz** 1996 Oct;21(5):291–8 (Eng. Abstr.) **(Ger)**

UTILIZATION

Racial and ethnic disparities in the use of cardiovascular procedures: associations with type of health insurance. Carlisle DM, et al. **Am J Public Health** 1997 Feb; 87(2):263–7

The changing face of coronary interventional practice. The Mayo Clinic experience. Hasdai D, et al. **Arch Intern Med** 1997 Mar 24;157(6):677–82

Impact of the 1991 NHS reforms on the availability and use of coronary revascularisation in the UK (1987–1995). Black N, et al. **Heart** 1996 Dec;76(4 Suppl 4):1–31

Quality control in the United States. Margolis JR. **Herz** 1996 Dec;21(6):359–63 (11 ref.)

The effects of health insurance on access to new medical technologies. Ramsey SD, et al. **Int J Technol Assess Health Care** 1997 Spring;13(2):357–67

Sex and ethnic differences in use of myocardial revascularization procedures in Mexican Americans and non-Hispanic whites: the Corpus Christi Heart Project. Ramsey DJ, et al. **J Clin Epidemiol** 1997 May;50(5):603–9

Racial differences in performance of invasive cardiac procedures in a Department of Veterans Affairs Medical Center. Sedlis SP, et al. **J Clin Epidemiol** 1997 Aug; 50(8):899–901

Do patient preferences contribute to racial differences in cardiovascular procedure use? Whittle J, et al. **J Gen Intern Med** 1997 May;12(5):267–73

Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. Hannan EL, et al. **JAMA** 1997 Mar 19;277(11):892–8

Measuring and averting underuse of necessary cardiac procedures: a summary of results and future directions. Kravitz RL, et al. **Jt Comm J Qual Improv** 1997 May; 23(5):268–76

Use of coronary artery bypass surgical procedure and coronary angioplasty in treatment of coronary artery disease: changes during a 10-year period at Mayo Clinic Rochester [see comments] Harris WO, et al. **Mayo Clin Proc** 1996 Oct;71(10):927–35. Comment in: Mayo Clin Proc 1996 Oct;71(10):1016–7.

Racial variation in the use of coronary-revascularization procedures [letter; comment] Barnhart JM, et al. **N Engl J Med** 1997 Jul 10;337(2):131–2. Comment on: N Engl J Med 1997 Feb 13;336(7):480–6.

Racial variation in the use of coronary-revascularization procedures [letter; comment] Fowler C. **N Engl J Med** 1997 Jul 10;337(2):132. Comment on: N Engl J Med 1997 Feb 13;336(7):480–6.

Cardiac procedures, outcomes, and accountability [editorial; comment] Krumholz HM. **N Engl J Med** 1997 May 22; 336(21):1522–3. Comment on: N Engl J Med 1997 May 22;336(21):1500–5.

Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? [see comments] Peterson ED, et al. **N Engl J Med** 1997 Feb 13;336(7):480–6. Comment in: N Engl J Med 1997 Jul 10;337(2):131–2. Comment in: N Engl J Med 1997 Jul 10;337(2):132.

Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada [see comments] [published erratum appears in N Engl J Med 1997 Jul 10;337(2):139] Tu JV, et al. **N Engl J Med** 1997 May 22;336(21):1500–5. Comment in: N Engl J Med 1997 May 22;336(21):1522–3.

[Heart surgery in Austria 1995] Unger F. **Herz** 1996 Dec; 21(6):397–404 (Eng. Abstr.) **(Ger)**

[Quality assurance in invasive and interventional cardiology in Austria in 1994. Commissioned by the Interventional Cardiology Working Group of the Austrian Cardiology Society] Mühlberger V, et al. **Z Kardiol** 1996 Sep; 85(9):647–55 (Eng. Abstr.) **(Ger)**

[Coronary angioplasty: use and cost] Bossi I, et al. **G Ital Cardiol** 1997 May;27(5):489–94 (Eng. Abstr.) **(Ita)**

ANGIOSARCOMA see **HEMANGIOSARCOMA**

ANGIOSCOPY

Angioscopic characteristics of coronary narrowing in patients with recurrent myocardial ischemia after myocardial infarction. Alfonso F, et al. **Am J Cardiol** 1997 May 15;79(10):1394–6

Angioscopic coronary macromorphology after thrombolysis in acute myocardial infarction. Arakawa K, et al. **Am J Cardiol** 1997 Jan 15;79(2):197–202

Angioscopic assessment of coronary lesions underlying thrombus. Waxman S, et al. **Am J Cardiol** 1997 Apr 15; 79(8):1106–9

Intraoperative vascular endoscopy: early and late results. Ahn SS, et al. **Ann Vasc Surg** 1996 Sep;10(5):443–51

Angioscopy of culprit lesions. Ueda Y, et al. **Cardiologia** 1997 Aug;42(8):827–32 (44 ref.)

Efficacy of angioscopy in determining the effectiveness of intracoronary urokinase and TEC atherectomy thrombus removal from an occluded saphenous vein graft prior to stent implantation [see comments] Kaplan BM, et al. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):335–7. Comment in: Cathet Cardiovasc Diagn 1995 Dec;36(4):338.

Angioscopic predictors of early adverse outcome after coronary angioplasty in patients with unstable angina and non-Q-wave myocardial infarction. Waxman S, et al. **Circulation** 1996 Jun 15;93(12):2106–13

Morphological changes after percutaneous transluminal coronary angioplasty of unstable plaques. Insights from serial angioscopic follow-up [see comments] Bauters C, et al. **Eur Heart J** 1996 Oct;17(10):1554–9. Comment in: Eur Heart J 1996 Oct;17(10):1461–2.

Angioscopic morphological changes after coronary angioplasty of unstable plaques [editorial; comment] Conti CR. **Eur Heart J** 1996 Oct;17(10):1461–2. Comment on: Eur Heart J 1996 Oct;17(10):1554–9.

Induction of thrombolysis and prevention of thrombus formation by local drug delivery with a double-occlusion balloon catheter. Tomaru T, et al. **Heart Vessels** 1996; 11(3):123–32

Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries. Tomaru T, et al. **Heart Vessels** 1996;11(3):133–44

Repeatability of intravital capillaroscopic measurement of capillary density. Lamah M, et al. **Int J Microcirc Clin Exp** 1996 Jan–Feb;16(1):23–9

Angioscopic evaluation of an endoluminal aortic graft: the first clinical experience. Hill BB, et al. **J Endovasc Surg** 1995 Aug;2(3):248–54

The role of routine angioscopy in vascular access surgery [see comments] Hölzenbein TJ, et al. **J Endovasc Surg** 1995 Feb;2(1):10–25. Comment in: J Endovasc Surg 1995 Feb;2(1):26.

A new light on vascular access surgery [comment] White RA. **J Endovasc Surg** 1995 Feb;2(1):26. Comment on: J Endovasc Surg 1995 Feb;2(1):10–25.

Influence of angioscopic vein graft preparation on development of neointimal hyperplasia in an organ culture model of human saphenous vein. Wilson YG, et al. **J Endovasc Surg** 1996 Nov;3(4):436–44

Clinical usefulness of 3-D CT endoscopic imaging of cerebral aneurysms. Kato Y, et al. **Neurol Res** 1996 Apr;18(2):98–102

[Initial experience with angioscopy in infrainguinal reconstruction using the in situ saphenous vein technique] Tošenovský P, et al. **Rozhl Chir** 1997 Jun;76(6):289–93 (Eng. Abstr.) **(Cze)**

[Coronary angioscopy] Lablanche JM, et al. **Arch Mal Coeur Vaiss** 1997 May;90 Spec No 2:29–33 (Eng. Abstr.) **(Fre)**

[Simultaneous echographic and endoscopic examination of morphologic anomalies of the valves of the internal saphenous vein] Chleir F, et al. **J Mal Vasc** 1997; 22(1):18–23 (Eng. Abstr.) **(Fre)**

[Intraoperative quality control after vascular surgery reconstruction of kidney and visceral arteries: personal experiences with intraoperative angioscopy] Reiher L, et al. **Vasa** 1996;25(4):349–51 (Eng. Abstr.) **(Ger)**

[Angioscopy in the diagnostic imaging of acute coronary syndrome] Guagliumi G, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):385–8 **(Ita)**

[Angina pectoris: progress in diagnosis and treatment. II. Progress in imaging diagnosis. 5. Angioscopic examination] Mizuno K. **Nippon Naika Gakkai Zasshi** 1997 Feb 10; 86(2):237–41 (5 ref.) **(Jpn)**

[Intraoperative coronary angioscopy after unsuccessful percutaneous dilatation angioplasty and the implantation of an intracoronary stent] Busch T, et al. **Chirurgia (Bucur)** 1996 Mar–Apr;45(2):85–9 (Eng. Abstr.) **(Rum)**

[Use of angioscopy in vascular surgery bypass with an in situ approach--first year experience] Lovričević I, et al. **Lijec Vjesn** 1997 Jan;119(1):22–6 (Eng. Abstr.) **(Scr)**

METHODS

Coronary angioscopy. Clinical applications. Annex BH. **Cardiol Clin** 1997 Feb;15(1):131–7 (33 ref.)

[Three-dimensional measurement of vascular lesions with virtual CT endoscopy "cruising eye view" method] Hayashi H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Oct; 56(12):880–2 (Eng. Abstr.) **(Jpn)**

ANGIOSTRONGYLUS

Angiostrongylus eosinophilic meningitis in Egypt [letter] Brown FM, et al. **Lancet** 1996 Oct 5;348(9032):964–5

Rupture of femoral artery in a dog infected with Angiostrongylus vasorum. Cury MC, et al. **Vet Parasitol** 1996 Oct 25;65(3–4):313–5

GROWTH & DEVELOPMENT

Angiostrongylus costaricensis life cycle: a new proposal. Mota EM, et al. **Mem Inst Oswaldo Cruz** 1995 Nov–Dec; 90(6):707–9

ISOLATION & PURIFICATION

Eosinophilic ileitis with perforation caused by Angiostrongylus (Parastrongylus) costaricensis. A case study and review. Wu SS, et al. **Arch Pathol Lab Med** 1997 Sep;121(9):989–91 (15 ref.)

Canine angiostrongylosis in south Wales [letter] Otter A, et al. **Vet Rec** 1997 Jun 14;140(24):635–6

Angiostrongylus vasorum infection in foxes (Vulpes vulpes) in Cornwall. Simpson VR. **Vet Rec** 1996 Nov 2; 139(18):443–45

PHYSIOLOGY

Evidences against a significant role of Mus musculus as natural host for Angiostrongylus costaricensis. dos Santos FT, et al. **Rev Inst Med Trop Sao Paulo** 1996 May–Jun;

38(3):171–5

ANGIOSTRONGYLUS CANTONENSIS

Induction of cerebrospinal fluid eosinophilia in rats by the intraventricular injection of Angiostrongylus cantonensis antigen. Sugaya H, et al. **Int J Parasitol** 1997 Jan; 27(1):113–7

Experimental infection of five subspecies of Oncomelania snails with Angiostrongylus cantonensis. Iwanaga Y. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):767–73

[Angiostrongylosis in infants in Reunion and Mayotte. Apropos of 3 cases of eosinophilic meningitis including 1 fatal radiculo-myeloencephalitis with hydrocephalus] Graber D, et al. **Arch Pediatr** 1997 May;4(5):424–9 (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Influence of PF1022A on the motility of Angiostrongylus cantonensis in vitro. Kachi S, et al. **Parasitol Res** 1997; 83(6):578–82

GENETICS

Stage-specific gene expression in Angiostrongylus cantonensis: characterisation and expression of an adult-specific gene. Bessarab IN, et al. **Mol Biochem Parasitol** 1997 Sep;88(1–2):73–84

IMMUNOLOGY

Detection of circulating antigen by monoclonal antibodies for immunodiagnosis of angiostrongyliasis. Chye SM, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):408–12

Role of T cell subpopulations in mice infected with Angiostrongylus cantonensis. Lee JD, et al. **J Helminthol** 1996 Sep;70(3):211–4

Cytokine responses in mice infected with Angiostrongylus cantonensis. Sugaya H, et al. **Parasitol Res** 1997;83(1):10–5

Eosinophilia and intracranial worm recovery in interleukin-5 transgenic and interleukin-5 receptor alpha chain-knockout mice infected with Angiostrongylus cantonensis. Sugaya H, et al. **Parasitol Res** 1997; 83(6):583–90

Detection of circulating antigens of Parastrongylus cantonensis in human sera by sandwich ELISA with specific monoclonal antibody. Eamsobhana P, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):712–5

The evaluation of the 29 and 31 kDa antigens in female Angiostrongylus cantonensis for serodiagnosis of human angiostrongyliasis. Nuamtanong S. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):291–6

Identification of Angiostrongylus cantonensis in infected rats with a coagglutination assay. Rojas Rivero L, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):716–8

PATHOGENICITY

Mediastinal lymph node cells of Angiostrongylus cantonensis-infected rats respond to antigens and release interleukin-5 in vitro. Sugaya H, et al. **Int J Parasitol** 1996 May;26(5):543–51

ANGIOTENSIN see **ANGIOTENSIN II**

ANGIOTENSIN I

Angiotensin receptor type 1 mRNA in human right ventricular endomyocardial biopsies: downregulation in heart failure. Regitz-Zagrosek V, et al. **Cardiovasc Res** 1997 Jul;35(1):99–105

[Irbesartan—a new AT1-receptor antagonist (AT1-blocker). Angiotensin-II-receptor antagonists: perspectives of a new therapeutic principle, Wiesbaden, 6 April 1997] **Dtsch Med Wochenschr** 1997 Sep;122(37 Suppl):1–4 **(Ger)**

ANALOGS & DERIVATIVES

Analysis of responses to angiotensin I-(3–10) in the hindlimb vascular bed of the cat. Garrison EA, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):H1172–7

Inhibition of angiotensin converting enzyme and potentiation of bradykinin by retro-inverso analogues of short peptides and sequences related to angiotensin I and bradykinin. Carmona AK, et al. **Biochem Pharmacol** 1996 Apr 26; 51(8):1051–60

Actions of D-amino acid-substituted analogues of des-Asp-angiotensin I on the central pressor action of angiotensin III. Radhakrishnan R, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):337–9

ANTAGONISTS & INHIBITORS

[What is the benefit of the new AT1 receptor antagonists?] Unger T. **Fortschr Med** 1997 Feb 28;115(6):31–3 **(Ger)**

BIOSYNTHESIS

Valvular interstitial cells express angiotensinogen and cathepsin D, and generate angiotensin peptides. Katwa LC, et al. **Int J Biochem Cell Biol** 1996 Jul;28(7):807–21

BLOOD

Plasma angiotensins and human forearm circulation: effects of sympatho-adrenal activation. Kahan T, et al. **Acta Physiol Scand** 1997 Feb;159(2):107–11

CHEMISTRY

In vitro reactivity of the antineoplastic drug carmustin and acrolein with model peptides. Carbone V, et al. **J Pept Res** 1997 Jun;49(6):586–95

DRUG EFFECTS

Modulatory role of nitric oxide on angiotensins vasoconstriction. Haulică I, et al. **Rom J Physiol** 1996 Jan-Dec;33(1–4):83–90

GENETICS

Human type-1 angiotensin II (AT1) receptor gene structure and function. Curnow KM. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S67–73 (40 ref.)

METABOLISM

The urinary bladder angiotensin system: response to infusions of angiotensin I and angiotensin-converting enzyme inhibitors. Weaver-Osterholtz D, et al. **Am J Kidney Dis** 1996 Oct;28(4):603–9

Forebrain angiotensin type 1 receptors and parabrachial serotonin in the control of NaCl and water intake. Colombari DS, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1470–6

Development of [11C]L-159,884: a radiolabelled, nonpeptide angiotensin II antagonist that is useful for angiotensin II, AT1 receptor imaging. Hamill TG, et al. **Appl Radiat Isot** 1996 Feb;47(2):211–8

Effect of new peptide inhibitors on the ratio of angiotensin I-converting and kinin-degrading activities of dipeptidyl carboxypeptidase (angiotensin-converting enzyme). Kalinina EV, et al. **Biochemistry (Mosc)** 1997 Mar; 62(3):247–50

Interaction of biphenylimidazole and imidazoleacrylic acid nonpeptide antagonists with valine 108 in TM III of the AT1 angiotensin receptor. Nirula V, et al. **Br J Pharmacol** 1996 Dec;119(8):1505–7

Effect of chronic treatment with ME3221 on blood pressure and mortality in aged stroke-prone spontaneously hypertensive rats. Nagura J, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S363–5

Gastric acid secretion after blockade of angiotensin AT1 receptors in the Na(+)-depleted rat. Chow L, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):309–17

Identification of nonconserved amino acids in the AT1 receptor which comprise a general binding site for biphenylimidazole antagonists. Nirula V, et al. **FEBS Lett** 1996 Oct 7;394(3):361–4

Recognition of tissue- and subtype-specific modulation of angiotensin II receptors using antibodies against AT1 and AT2 receptors. Rakugi H, et al. **Hypertens Res** 1997 Mar; 20(1):51–5

Angiotensin receptor 1 blockade does not prevent physiological cardiac hypertrophy in the adult rat. Geenen DL, et al. **J Appl Physiol** 1996 Aug;81(2):816–21

The conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. Balmforth AJ, et al. **J Biol Chem** 1997 Feb 14;272(7):4245–51

Down-regulation of angiotensin AT1 receptor by progesterone in human placenta. Kalenga MK, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):998–1002

Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. Dell'Italia LJ, et al. **J Clin Invest** 1997 Jul 15;100(2):253–8

Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. Hatton R, et al. **J Endocrinol** 1997 Jan;152(1):5–10

Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-formylmethionyl-leucyl-phenylalanine to neutrophil receptors. Raiden S, et al. **J Pharmacol Exp Ther** 1997 May; 281(2):624–8

Angiotensin II, via an action at AT1 receptors, may modulate the behavioural effects of ET-1 in conscious rats. D'Amico M, et al. **Life Sci** 1996;59(22):PL355–8

Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Michaud A, et al. **Mol Pharmacol** 1997 Jun;51(6):1070–6

Enhanced angiotensin receptor type 1 mRNA degradation and induction of polyribosomal mRNA binding proteins by angiotensin II in vascular smooth muscle cells. Nickenig G, et al. **Mol Pharmacol** 1996 Oct;50(4):743–51

Electrophysiological properties of paraventricular magnocellular neurons in rat brain slices: modulation of IA by angiotensin II. Li Z, et al. **Neuroscience** 1996 Mar; 71(1):133–45

The ligand binding site of the angiotensin AT1 receptor. Hunyady L, et al. **Trends Pharmacol Sci** 1996 Apr; 17(4):135–40 (52 ref.)

PHARMACOKINETICS

Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. de Lannoy LM, et al. **Hypertension** 1997 Jun;29(6):1240–51

PHARMACOLOGY

The urinary bladder angiotensin system: response to infusions of angiotensin I and angiotensin-converting enzyme inhibitors. Weaver-Osterholtz D, et al. **Am J Kidney Dis** 1996 Oct;28(4):603–9

Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Kennefick TM, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F595–602

Renal, hormonal, and cardiovascular responses to chronic angiotensin I infusion in the ovine fetus. Moritz KM, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1912–7

Serum angiotensin converting enzyme activity and response to angiotensin I in horses. Tillman LG, et al. **Equine Vet J Suppl** 1989 Jun;(7):80–3

Excess extrafetal fluid without demonstrable changes in placental concentration gradients after week-long infusions of angiotensin into fetal lambs. Anderson DF, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Dec;63(2):175–9

Analysis of responses to angiotensin I and angiotensin I-(3–10) in the mesenteric vascular bed of the cat. Champion HC, et al. **Eur J Pharmacol** 1996 Aug 15; 309(3):251–9

Pressor action of angiotensin I at the ventrolateral medulla: effect of selective angiotensin blockade. Lima DX, et al. **Immunopharmacology** 1996 Jun;33(1–3):305–7

Pressor and hormonal responses to angiotensin I infusion in healthy subjects of different angiotensin-converting enzyme genotypes. Chadwick IG, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):485–9

Angiotensin I modulates Ca-transport systems in the rat heart through angiotensin II. Krizanova O, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1739–46

Effects of angiotensin I and angiotensin II in blood vessels: greater influence of converting enzyme activity in the rabbit basilar artery. Zerrouk A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Oct; 354(4):466–73

A novel action of angiotensin peptides in inhibiting neurite outgrowth from isolated chick sympathetic neurons in culture. Reed G, et al. **Neurosci Lett** 1996 Jun 7; 210(3):209–12

ANGIOTENSIN II

see related
RENIN-ANGIOTENSIN SYSTEM

Effect of neonatal sympathectomy on development of angiotensin II-induced hypertension. Csiky B, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H648–56

Aortic medial necrosis with or without thrombosis in rabbits treated with Russell's viper venom and angiotensin II. Nakamura M, et al. **Atherosclerosis** 1997 Feb 10; 128(2):149–56

Pharmacodynamic, pharmacokinetic and clinical profile of the first orally active angiotensin II receptor antagonist. Reid JL. **Cardiologia** 1995 Dec;40(12 Suppl 1):187

Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta. Ishizaka N, et al. **Circulation** 1997 Sep 16;96(6):1923–9

Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension [see comments] Laursen JB, et al. **Circulation** 1997 Feb 4;95(3):588–93. Comment in: Circulation 1997 Feb 4;95(3):557–9.

Angiotensin AT1 Receptors: From Molecular Physiology to Therapeutics. Proceedings of a symposium. Melbourne, Australia, December 1995. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S57–154

Differential expression of angiotensin receptor subtypes in the myocardium: a hypothesis [editorial; comment] Dzau VJ, et al. **Eur Heart J** 1996 Jul;17(7):978–80. Comment on: Eur Heart J 1996 Jul;17(7):1112–20.

Association of angiotensin converting enzyme and angiotensin II type 1 receptor genotypes with left ventricular function and mass in patients with angiographically normal coronary arteries [see comments] Hamon M, et al. **Heart** 1997 Jun;77(6):502–5. Comment in: Heart 1997 Jun;77(6):489–90.

Bovine aortic endothelial cells contain an angiotensin-(1–7) receptor. Tallant EA, et al. **Hypertension** 1997 Jan;29(1 Pt 2):388–93

Localization of angiotensin II receptor subtypes AT1 and AT2 in the pancreas of rodents. Leung PS, et al. **J Endocrinol** 1997 May;153(2):269–74

Immunolocalisation of angiotensin II receptors in icefish (Chionodraco hamatus) tissues. Marsigliante S, et al. **J Endocrinol** 1997 Aug;154(2):193–200

Effect of induced hypertension with angiotensin II infusion on biodistribution of 111in-labeled monoclonal antibody. Kinuya S, et al. **Nucl Med Biol** 1996 Feb;23(2):137–40

Drug-induced antisynthetase syndrome. Thickett DR, et al. **Postgrad Med J** 1997 Mar;73(857):165–6

Studying the central actions of angiotensin using the expression of immediate-early genes: expectations and limitations. Herbert J. **Regul Pept** 1996 Oct 8;66(1–2):13–8 (26 ref.)

Localization and disposition of a non-peptide angiotensin II type 1 receptor antagonist, and its glucuronide metabolite, in rat. Kakiki M, et al. **Xenobiotica** 1997 Jul;27(7):723–32

The medicine of the month. Losartan (Cozaar)] Scheen AJ. **Rev Med Liege** 1997 May;52(5):367–9 (8 ref.) **(Fre)**

[Angiotensin–2 receptor blockade—new therapeutic approach to treatment of hypertension] Zimlichman R. **Harefuah** 1996 Jul;131(1–2):43–5 (27 ref.) **(Heb)**

[History of the pharmacologic therapy of arterial hypertension: from diuretics to angiotensin II receptor antagonists] Salvetti A, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):181–6 (30 ref.) **(Ita)**

[The first clinical experience in Italy with angiotensin II receptor antagonists: results of a multicenter study on the efficacy and tolerance in arterial hypertension] Trimarco B. **Cardiologia** 1995 Dec;40(12 Suppl 1):193–5 **(Ita)**

ADMINISTRATION & DOSAGE

Intrarenal administration of angiotensin II does not moderate afferent renal nerve mediated cardiovascular reflexes in the anaesthetized rabbit. Ashton N, et al. **Acta Physiol Scand** 1996 Nov;158(3):233–40

Relationship between the drinking response to angiotensin II and induction of Fos in the brain. Rowland NE, et al. **Adv Exp Med Biol** 1996;396:113–9 (35 ref.)

Influence of circulating angiotensin II and vasopressin on neurons of the nucleus of the solitary tract. Hegarty AA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):R675–81

Nitric oxide modulates angiotensin II– and norepinephrine–dependent vasoconstriction in rat kidney. Parekh N, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):R630–5

Calcium entry and mobilization signaling pathways in ANG II–induced renal vasoconstriction in vivo. Ruan X, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):F398–405

Effect of a non–peptide angiotensin receptor antagonist on water intake caused by centrally administered carbachol in the rat. Reis LC, et al. **Braz J Med Biol Res** 1996 Feb; 29(2):245–7

Chronic intrarenal infusion of low–dose angiotensin II in dogs increases arterial pressure without impairment of renal function. Stevenson KM, et al. **Clin Exp Pharmacol Physiol** 1997 Jun;24(6):439–41

Renal and hormonal actions of atrial natriuretic peptide during angiotensin II or noradrenaline infusion in man. Eiskjaer H, et al. **Eur J Clin Invest** 1996 Jul;26(7):584–95

Local renin–angiotensin system in sympathetic overactivity of spontaneously hypertensive rats. Nagase M, et al. **Hypertens Res** 1996 Sep;19(3):171–7

Modulation of target tissue response to angiotensin II and sodium sensitivity in Japanese patients with essential hypertension. Ozono R, et al. **Hypertens Res** 1996 Sep; 19(3):141–5

The response of renal plasma flow to angiotensin II infusion in a population–based sample and its association with the parental history of essential hypertension. Kardia SL, et al. **J Hypertens** 1997 May;15(5):483–93

Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. Hemmelder MH, et al. **Kidney Int** 1996 Jan;49(1):174–80

Changes of blood pressure responsiveness in rats exposed in utero and perinatally to a high–salt environment. Argüelles J, et al. **Regul Pept** 1996 Oct 8;66(1–2):113–5

Age–related decline in thirst and sodium appetite in rats related to kininase II inhibition. Rowland NE, et al. **Regul Pept** 1996 Oct 22;66(3):163–7

[A case of non–resectable pancreatic cancer surviving more than 4 years by intra–arterial infusion chemotherapy with angiotensin–II] Tsuji Y, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1617–20 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Orthostatic hypertension [letter; comment] Bell C. **Hypertension** 1997 Mar;29(3):835. Comment on: Hypertension 1996 Jul;28(1):42–6.

Vascular aldosterone. Biosynthesis and a link to angiotension II–induced hypertrophy of vascular smooth muscle cells. Gómez–Sánchez EP. **J Endocrinol Invest** 1995 Jul–Aug; 18(7):580–5 (22 ref.)

ANALOGS & DERIVATIVES

rho–Aminophenylalanine6 angiotensin II (AII) improves learning and memory in rats. Braszko JJ, et al. **Acta Physiol Hung** 1996;84(3):267–8

Receptors for (3–8) angiotensin in brain cells. AngIV binding in brain cells. Sernia C, et al. **Adv Exp Med Biol** 1996; 396:253–63

Angiotensins stimulate catecholamine release from the chromaffin tissue of the rainbow trout. Bernier NJ, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R49–57

Angiotensin IV stimulates the proliferation of rat anterior pituitary cells in vitro. Pawlikowski M, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):292–3

Modulation by nitric oxide and prostaglandin of the renal vascular response to angiotensin II (3–8). Yoshida M, et al. **Br J Pharmacol** 1996 Mar;117(5):885–90

Localization of angiotensin IV binding sites to motor and sensory neurons in the sheep spinal cord and hindbrain. Moeller I, et al. **Brain Res** 1995 Dec 1;701(1–2):301–6

Angiotensin IV inhibits neurite outgrowth in cultured embryonic chicken sympathetic neurones. Moeller I, et al. **Brain Res** 1996 Jun 24;725(1):61–6

Effects of LY231617 and angiotensin IV on ischemia–induced deficits in circular water maze and passive avoidance performance in rats. Wright JW, et al. **Brain Res** 1996 Apr 22;717(1–2):1–11

Nonpeptide angiotensin II receptor antagonists: in vivo inhibition of [125I–Sar1,Ile8]angiotensin II binding by losartan, EXP597 and L–159,282 in rats. Wong PC, et al. **Clin Exp Hypertens** 1996 Feb;18(2):189–200

Pharmacological characterization of a specific binding site for angiotensin IV in cultured porcine aortic endothelial cells. Riva L, et al. **Eur J Pharmacol** 1996 Jun 3; 305(1–3):193–9

Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein. Li Q, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):451–6

Effects of angiotensin II and its blockers Sar1–Ile8–angiotensin II and DuP 753 on drinking in ducks in relation to properties of subfornical organ neurons. Simon E, et al. **J Comp Physiol [B]** 1996;165(8):607–14

Design, synthesis, and biological activities of four angiotensin II receptor ligands with gamma–turn mimetics replacing amino acid residues 3–5. Schmidt B, et al. **J Med Chem** 1997 Mar 14;40(6):903–19

Identification and characterization of angiotensinIV binding sites in rat neurone and astrocyte cell cultures. Greenland K, et al. **J Neuroendocrinol** 1996 Sep;8(9):687–93

A specific binding site for angiotensin II(3–8), angiotensin IV, in rabbit cardiac fibroblasts. Wang L, et al. **J Recept Signal Transduct Res** 1995 Jan–Mar; 15(1–4):517–27

Evidence for angiotensin IV receptors in human collecting duct cells. Czekalski S, et al. **Kidney Int** 1996 Oct; 50(4):1125–31

Angiotensin II (3–8) induces long–term memory improvement in the crab Chasmagnathus. Delorenzi A, et al. **Neurosci Lett** 1997 May 2;226(3):143–6

Solid–phase synthesis of hydroxyethylamine angiotensin analogues. Chambers SL, et al. **Peptides** 1997;18(4):505–12

Production of [Asn1, Val5] angiotensin II and [Asp1, Val5] angiotensin II in kallikrein–treated trout plasma (T60K). Conlon JM, et al. **Peptides** 1996;17(3):527–30

Angiotensin III and IV activation of the brain AT1 receptor subtype in cardiovascular function. Wright JW, et al. **Peptides** 1996;17(8):1365–71

Excitatory action of angiotensins II and IV on hippocampal neuronal activity in urethane anesthetized rats. Albrecht D, et al. **Regul Pept** 1997 Jun 18;70(2–3):105–9

Angiotensin II– and IV–induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Kramár EA, et al. **Regul Pept** 1997 Jan 29;68(2):131–8

Characterization of the binding properties and physiological action of divalinal–angiotensin IV, a putative AT4 receptor antagonist. Krebs LT, et al. **Regul Pept** 1996 Dec 3; 67(2):123–30

Behavioural activity of angiotensin II (3–7)4Phe—analogue of natural fragment 3–7 of angiotensin II. Hoły Z, et al. **Rocz Akad Med Bialymst** 1996;41(2):191–201

[Angiotensin II analogue infusion test] Katsuragi M, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:321–4 (10 ref.) **(Jpn)**

ANALYSIS

Expression of angiotensinogen mRNA and localization of angiotensin II and renin in peripheral adrenergic neurons in primary culture. Wang JM, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):876–81

A comparison of the inactive urinary kallikrein: creatinine ratio and the angiotensin sensitivity test for the prediction of pre–eclampsia [letter; comment] Nisell H. **Br J Obstet Gynaecol** 1997 Aug;104(8):971. Comment on: Br J Obstet Gynaecol 1996 Oct;103(10):981–7.

Angiotensin II–receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction [see comments] Rogg H, et al. **Eur Heart J** 1996 Jul; 17(7):1112–20. Comment in: Eur Heart J 1996 Jul;17(7):978–80.

Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation. Delbaere A, et al. **Fertil Steril** 1997 Jun;67(6):1038–45

Atrial natriuretic peptide, bradykinin, and angiotensin II–like immunoreactivity in the harderian gland of the terrapin Pseudemys scripta: response to osmotic stress. Masini MA, et al. **J Exp Zool** 1996 Dec 15;276(6):425–31

Bioactive angiotensin (1–8) is the main component of angiotensin II immunoreactivity in human follicular fluid. Delbaere A, et al. **Peptides** 1996;17(7):1135–8

ANTAGONISTS & INHIBITORS

The role of vasopressin and angiotensin II in the hemodynamic response to dynamic exercise. Symons JD, et al. **Adv Exp Med Biol** 1995;381:215–21

Glucose and the insulin–releasing drug tolbutamide attenuate the effects of morphine and angiotensin on alcohol consumption. Grupp LA, et al. **Alcohol** 1997 Jan–Feb; 14(1):71–9

The renoprotective properties of angiotensin–converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. Zoja C, et al. **Am J Kidney Dis** 1997 Feb; 29(2):254–64

Chronic effects of ANG II antagonist in heart failure: improvement of cGMP generation from ANP. Maeda Y, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2139–45

Role of kinin and renal ANG II blockade in acute effects of ACE inhibitors in low–renin hypertension. Naitoh M, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H679–87

Inhibitors of angiotensin II: potential hazards for patients at risk for anaphylaxis? [editorial] Kemp SF, et al. **Ann Allergy Asthma Immunol** 1997 Jun;78(6):527–9

Development of [11C]L–159,884: a radiolabelled, nonpeptide angiotensin II antagonist that is useful for angiotensin II, AT1 receptor imaging. Hamill TG, et al. **Appl Radiat Isot** 1996 Feb;47(2):211–8

Angiotensin II receptor inhibition. A new therapeutic principle. Messerli FH, et al. **Arch Intern Med** 1996 Sep 23;156(17):1957–65 (100 ref.)

Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically–instrumented transgenic rats. van Meel JC, et al. **Arzneimittelforschung** 1996 Aug;46(8):755–9

Tranilast antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells. Miyazawa K, et al. **Atherosclerosis** 1996 Apr 5;121(2):167–73

3N–methylbiphenylsulfonylurea and –carbamate substituted imidazo[4,5–b]pyridines. Potent antagonists of the ANG II AT1 receptors. Heitsch H, et al. **Bioorg Med Chem** 1997 Apr;5(4):673–8

Angiotensin II antagonism: a new avenue of hypertension management. Gavras H. **Blood Press Suppl** 1997;1:42–6 (24 ref.)

Effect of the non peptide angiotensin II antagonist, GR117289C on the vasoconstrictor actions of angiotensin II in the human forearm. Lyons D, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):323–6

Modulation by nitric oxide and prostaglandin of the renal vascular response to angiotensin II (3–8). Yoshida M, et al. **Br J Pharmacol** 1996 Mar;117(5):885–90

Losartan and reversible psychosis [letter] Ahmad S. **Cardiology** 1996 Nov–Dec;87(6):569–70

Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type–1 receptor blockade. Hayashida W, et al. **Cardiovasc Res** 1997 Jan;33(1):54–62

Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Kiely DG, et al. **Cardiovasc Res** 1997 Jan; 33(1):201–8

Use of pulsed–wave Doppler echocardiography to measure changes in MPAP. Is further validation required? [letter; comment] Morrell NW. **Chest** 1997 May;111(5):1469–70. Comment on: Chest 1996 Sep;110(3):584–5. Comment on: Chest 1996 Sep;110(3):698–703.

Angiotensin II antagonism and pre–glomerular arterial wall dimensions in the kidney of the spontaneously hypertensive rat. Anderson WP, et al. **Clin Exp Hypertens** 1997 Jul–Aug; 19(5–6):965–79

Pharmacological demonstration of the additive effects of angiotensin–converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects. Azizi M, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):937–51

Structural changes in the renal vasculature in the spontaneously hypertensive rat: no effect of angiotensin II blockade. Kett MM, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S132–5 (35 ref.)

Experience with angiotensin II antagonists in hypertensive patients. Waeber B, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S142–6 (32 ref.)

Pharmacokinetic–pharmacodynamic profile of angiotensin II receptor antagonists. Csajka C, et al. **Clin Pharmacokinet** 1997 Jan;32(1):1–29 (112 ref.)

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Corea L, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):341–6

The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Morgan JM, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):35–44

The peroxynitrite product 3–nitro–L–tyrosine attenuates the hemodynamic responses to angiotensin II in vivo. Kooy NW, et al. **Eur J Pharmacol** 1996 Nov 14;315(2):165–70

Glomerular number and size following chronic angiotensin II blockade in the postnatal rat. McCausland JE, et al. **Exp Nephrol** 1997 May–Jun;5(3):201–9

Troglitazone inhibits angiotensin II–induced DNA synthesis and migration in vascular smooth muscle cells. Graf K, et al. **FEBS Lett** 1997 Jan 2;400(1):119–21

Effects of angiotensin converting enzyme inhibitor cilazapril and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit. Sahin Y, et al. **Gynecol Endocrinol** 1997 Aug;11(4):231–6

Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV–116) and other classes of antihypertensive drugs in spontaneously hypertensive rats. Wada T, et al. **Hypertens Res** 1996 Dec;19(4):247–54

Adrenomedullin is a potent inhibitor of angiotensin II–induced migration of human coronary artery smooth muscle cells. Kohno M, et al. **Hypertension** 1997 Jun; 29(6):1309–13

Angiotensin II blockade does not prevent renal effects of L–NAME in sodium–repleted humans. Montanari A, et al. **Hypertension** 1997 Sep;30(3 Pt 2):557–62

Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Price DA, et al. **Hypertension** 1997 Aug;30(2 Pt 1):240–6

Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen–Rosenthal diabetic hypertensive rat. Rosenthal T, et al. **Hypertension** 1997 Jun; 29(6):1260–4

Effects of angiotensin II receptor blockade on N–terminal proatrial natriuretic factor plasma levels in chronic heart failure. Klinge R, et al. **J Card Fail** 1997 Jun;3(2):75–81

Reduction by (–)–cicletanine of the vascular reactivity to angiotensin II in rats. Alvarez–Guerra M, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):564–70

Determination of 1–[5–(2–cyclopropyl–5,7–dimethyl–imidazo[4,5–b] pyridin–3–ylmethyl)thiophen–2–yl]cyclopent–3–enecarboxylic acid (CP–191,166), an angiotensin II antagonist, in dog and rat plasma by high–performance liquid chromatography. Allen MC, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26;675(2):265–71

Ouabain is a potent inhibitor of aldosterone secretion and angiotensin action in the human adrenal. Antonipillai I, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2335–7

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. Holwerda NJ, et al. **J Hypertens** 1996 Sep;14(9):1147–51

The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. Moan A, et al. **J Hypertens** 1996 Sep;14(9):1093–7

Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. Tikkanen I, et al. **J Hypertens** 1995 Nov;13(11):1343–51

Effects of losartan on cerebral arteries in stroke–prone spontaneously hypertensive rats. Vacher E, et al. **J Hypertens** 1996 Nov;14(11):1341–8

Pharmacological and pharmacokinetic evaluation of EXP3312, an orally–active non–peptide angiotensin II–receptor antagonist. Wong YN, et al. **J Pharm Pharmacol** 1996 May;48(5):492–7

HR 720, a novel angiotensin receptor antagonist inhibits the angiotensin II–induced trophic effects, fibronectin release and fibronectin–EIIIA+ expression in rat aortic vascular smooth muscle cells in vitro. Dunn FW, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):447–53

Modulation of plasminogen activator inhibitor–1 in vivo: a new mechanism for the anti–fibrotic effect of renin–angiotensin inhibition. Oikawa T, et al. **Kidney Int** 1997 Jan;51(1):164–72

Angiotensin II blockade decreases TGF–beta1 and matrix proteins in cyclosporine nephropathy. Shihab FS, et al. **Kidney Int** 1997 Sep;52(3):660–73

Renal effects of an angiotensin II antagonist in stroke–prone spontaneously hypertensive rat. Yo Y, et al. **Nephron** 1997; 76(4):466–71

Dizocilpine maleate, an N–methyl–D–aspartate antagonist, inhibits dipsogenic responses and C–Fos expression induced by intracerebral infusion of angiotensin II. Xu Z, et al. **Neuroscience** 1997 May;78(1):203–14

Nicotine blocks angiotensin II inhibition of LTP in the dentate gyrus. Wayner MJ, et al. **Peptides** 1996; 17(7):1127–33

Effects of the selective angiotensin II receptor antagonists losartan and PD123177 in animal models of anxiety and memory. Shepherd J, et al. **Psychopharmacology (Berl)** 1996 Aug;126(3):206–18

Effect of renin–angiotensin inhibition on glomerular injuries in DOCA–salt hypertensive rats. Oishi T, et al. **Regul Pept** 1996 Apr 23;62(2–3):89–95

The effect of Losartan, an angiotensin II antagonist, on cardiac function, mass and morphology in rats after repeated hyperbaric exposures. Stuhr LE, et al. **Scand J Clin Lab Invest** 1997 May;57(3):253–61

[Angiotensin II antagonists] Tikkanen I, et al. **Duodecim** 1995; 111(18):1733–5 **(Fin)**

[Angiotensin II antagonists: a distinct therapeutic class (editorial)] Waeber B, et al. **Presse Med** 1996 Oct 26; 25(32):1533–5 (Eng. Abstr.) **(Fre)**

[Tissue angiotensin 2—potential advantage in the therapeutic approach to the treatment of hypertension] Zimlichman E, et al. **Harefuah** 1997 Jan 15;132(2):113–6 (38 ref.) **(Heb)**

[ACE inhibitors and renal insufficiency] Marcantoni C, et al. **Cardiologia** 1997 Aug;42(8):783–7 **(Ita)**

[Angiotensin–II receptor blockers] Metelitsa VI. **Ter Arkh** 1996;68(8):64–7 **(Rus)**

BIOSYNTHESIS

Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro. Balcells E, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H417–21

Tissue repair and angiotensin II generated at sites of healing. Weber KT, et al. **Basic Res Cardiol** 1997 Apr;92(2):75–8 (10 ref.)

The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Noda K, et al. **Biochemistry** 1996 Dec 24;35(51):16435–42

Angiotensin II type 1 receptor expression in human breast tissues. Inwang ER, et al. **Br J Cancer** 1997;75(9):1279–83

Characterization of angiotensin II formation in human isolated bladder by selective inhibitors of ACE and human chymase: a functional and biochemical study. Waldeck K, et al. **Br J Pharmacol** 1997 Jul;121(6):1081–6

Inhaled nitric oxide does not change transpulmonary angiotensin II formation in patients with acute respiratory distress syndrome. Wenz M, et al. **Chest** 1997 Aug; 112(2):478–83

Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin–converting enzyme by Ang–(1–9) formed by heart carboxypeptidase A–like activity. Kokkonen JO, et al. **Circulation** 1997 Mar 18;95(6):1455–63

Angiotensin II–generating system in dog and monkey ocular tissues. Shiota N, et al. **Clin Exp Pharmacol Physiol** 1997 Mar–Apr;24(3–4):243–8

Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Ardaillou R. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):28–34 (73 ref.)

Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. Takai S, et al. **FEBS Lett** 1997 Jul 21;412(1):86–90

Valvular interstitial cells express angiotensinogen and cathepsin D, and generate angiotensin peptides. Katwa LC, et al. **Int J Biochem Cell Biol** 1996 Jul;28(7):807–21

Purification and characterization of a kinin– and angiotensin II–forming enzyme in the dog heart. Sasaguri M, et al. **J Hypertens** 1997 Jun;15(6):675–82

Activation of angiotensin II–forming chymase in the cardiomyopathic hamster heart. Shiota N, et al. **J Hypertens** 1997 Apr;15(4):431–40

Cultured myofibroblasts generate angiotensin peptides de novo. Katwa LC, et al. **J Mol Cell Cardiol** 1997 May; 29(5):1375–86

In situ production of angiotensin II by fibrosed rat pericardium. Ou R, et al. **J Mol Cell Cardiol** 1996 Jun; 28(6):1319–27

Renin stimulates decidual prostaglandin production via a novel mechanism that is independent of angiotensin II formation. Mitchell MD, et al. **Placenta** 1996 Jul–Aug; 17(5–6):299–305

BLOOD

Hemodynamic, sympathetic and angiotensin II responses to PEEP ventilation before and during administration of isoflurane. Aneman A, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 1):41–8

Plasma angiotensins and human forearm circulation: effects of sympatho–adrenal activation. Kahan T, et al. **Acta Physiol Scand** 1997 Feb;159(2):107–11

Angiotensin II: a humoral mediator for the gastric sodium monitor. Duggan KA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):F406–10

Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease. Jensen J, et al. **Am J Vet Res** 1997 May;58(5):535–40

Endogenous angiotensin II levels and the mechanism of action of angiotensin–converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Campbell DJ. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S125–31 (68 ref.)

Relationship between blood pressure and renin, angiotensin II and atrial natriuretic factor after renal transplantation. Hestin D, et al. **Clin Nephrol** 1997 Aug;48(2):98–103

Thromboxane is required for full expression of angiotensin hypertension in rats. Keen HL, et al. **Hypertension** 1997 Jan;29(1 Pt 2):310–4

Dose–ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS–186295) on blood pressure and neurohormonal effects in salt–deplete men. McIntyre M, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):101–6

Serum angiotensin–converting enzyme activity correlates positively with plasma angiotensin II: a population–based study of ambulatory blood pressure and the renin–angiotensin system. Nyström F, et al. **J Hum Hypertens** 1997 May;11(5):301–6

Effect of high–performance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients. Bragat AC, et al. **J Hypertens** 1997 May;15(5):459–65

Effects of captopril related to increased levels of prostacyclin and angiotensin–(1–7) in essential hypertension [see comments] Luque M, et al. **J Hypertens** 1996 Jun; 14(6):799–805. Comment in: J Hypertens 1996 Nov;14(11):1380–1.

Effects of captopril related to increased levels of prostacyclin and angiotensin–(1–7) in essential hypertension [letter; comment] Reneland R, et al. **J Hypertens** 1996 Nov; 14(11):1380–1. Comment on: J Hypertens 1996 Jun;14(6):799–805.

Elevated blood pressure in spontaneously hypertensive rats consuming a high sucrose diet is associated with elevated angiotensin II and is reversed by vanadium. Shi SJ, et al. **J Hypertens** 1997 Aug;15(8):857–62

The increase in the cardiodepressant activity and vasopressin concentration in the sella turcica venous blood during vagal afferents stimulation or after angiotensin II infusion. Gorąca A, et al. **J Physiol Pharmacol** 1996 Jun;47(2):257–67

Effects of reduced renal perfusion pressure and acute volume expansion on proximal tubule and whole kidney angiotensin II content in the rat. Boer WH, et al. **Kidney Int** 1997 Jan; 51(1):44–9

[Acute effects of human recombinant erythropoietin on cardiovascular dynamics and vasoactive substances] Suga M, et al. **Nippon Jinzo Gakkai Shi** 1996 Dec;38(12):634–9 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Monte–Carlo calculations of the solvent effects on the conformation of angiotensin II. Collet O, et al. **Int J Pept Protein Res** 1996 Apr;47(4):239–44

Angiotensin II receptor expression in the conduction system and arterial duct of neonatal and adult rat hearts. Bastien NR, et al. **Regul Pept** 1996 May 7;63(1):9–16

DIAGNOSTIC USE

[Clinical studies with angiotensin II and angiotensin III] Yamamoto K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:333–6 (11 ref.) **(Jpn)**

DRUG EFFECTS

Modulatory role of nitric oxide on angiotensins vasoconstriction. Haulică I, et al. **Rom J Physiol** 1996 Jan–Dec;33(1–4):83–90

[Angiotensin II antagonist for heart insufficiency] **Z Kardiol** 1997 Jun;86(6 Suppl):1–8 **(Ger)**

GENETICS

Human type–1 angiotensin II (AT1) receptor gene structure and function. Curnow KM. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S67–73 (40 ref.)

Regulation of vascular type 1 angiotensin receptors by cytokines. Sasamura H, et al. **Hypertension** 1997 Jul;30(1 Pt 1):35–41

Dietary salt intake modulates angiotensin II type 1 receptor gene expression. Schmid C, et al. **Hypertension** 1997 Apr; 29(4):923–9

Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Tsuzuki S, et al. **Hypertension** 1996 Nov;28(5):916–8

Tissue targeting of angiotensin peptides. Methot D, et al. **J Biol Chem** 1997 May 16;272(20):12994–9

Local stress, not systemic factors, regulate gene expression of the cardiac renin–angiotensin system in vivo: a comprehensive study of all its components in the dog. Lee YA, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1; 93(20):11035–40

ISOLATION & PURIFICATION

Subcellular localization of angiotensin II immunoreactivity in the rat cerebellar cortex. Erdmann B, et al. **Hypertension** 1996 Nov;28(5):818–24

METABOLISM

Regulation of the hypothalmic–pituitary–adrenal axis and vasopressin secretion. Role of angiotensin II. Aguilera G, et al. **Adv Exp Med Biol** 1996;396:105–12 (29 ref.)

Angiotensin receptor heterogeneity in the dorsal medulla oblongata as defined by angiotensin–(1–7). Diz DI, et al. **Adv Exp Med Biol** 1996;396:225–35 (65 ref.)

Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal cells via type 2 receptors in a pertussis toxin sensitive fashion. Huang XC, et al. **Adv Exp Med Biol** 1996;396:209–15 (25 ref.)

Interactions of angiotensin II with central dopamine. Jenkins TA, et al. **Adv Exp Med Biol** 1996;396:93–103 (94 ref.)

Cardiac effects of AII. AT1A receptor signaling, desensitization, and internalization. Thomas WG, et al. **Adv Exp Med Biol** 1996;396:59–69 (60 ref.)

The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension. Smith MC, et al. **Am J Hypertens** 1995 Dec; 8(12 Pt 1):1177–83

Effects of UP269–6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy. Villa E, et al. **Am J Hypertens** 1997 Mar; 10(3):275–81

Angiotensin II release from rabbit intrarenal arteries: a critical assessment. Zimmerman BG, et al. **Am J Hypertens** 1997 Mar;10(3):306–14

The urinary bladder angiotensin system: response to infusions of angiotensin I and angiotensin–converting enzyme inhibitors. Weaver–Osterholtz D, et al. **Am J Kidney Dis** 1996 Oct;28(4):603–9

Angiotensin–converting enzyme inhibitors regulate the Na(+)–K+ pump via effects on angiotensin metabolism. Hool LC, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C172–80

Proximal tubular fluid, kidney, and plasma levels of angiotensin II in hypertensive ren–2 transgenic rats. Mitchell KD, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F246–53

Role of central ANG II receptors in stress–induced cardiovascular and hyperthermic responses in rats. Saiki Y, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R26–33

Characterization of renin activity in brown adipose tissue. Shenoy U, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C989–99

Resistance to mineralocorticoids in Wistar–Furth rats. Ullian ME, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1454–61

Myocardial angiotensin II (Ang II) receptors in diabetic rats. Khatter JC, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:466–72

Angiotensin II receptor antagonists: the prototype losartan. Schaefer KL, et al. **Ann Pharmacother** 1996 Jun; 30(6):625–36 (81 ref.)

Platelet-derived growth factor mediates angiotensin II-induced DNA synthesis in vascular smooth muscle cells. Mangiarua EI, et al. **Arch Physiol Biochem** 1997 Apr; 105(2):151–7

Differential roles of AT1 and AT2 receptor subtypes in vascular trophic and phenotypic changes in response to stimulation with angiotensin II. Sabri A, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):257–64

General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions. Kito G, et al. **Arzneimittelforschung** 1996 Jul;46(7):681–6

Angiotensin type-1 (AT1) receptor gene expression in primarily cultured human arterial umbilical endothelial cells. Ko Y, et al. **Biochem Pharmacol** 1997 Feb 7; 53(3):417–21

Receptor-mediated endocytosis of angiotensin II in rat myometrial cells. Lázari MF, et al. **Biochem Pharmacol** 1997 Aug 1;54(3):399–408

Angiotensin II receptor type 1 on granulosa and thecal cells of rabbit preovulatory follicles. Féral C, et al. **Biochim Biophys Acta** 1996 Oct 23;1284(2):221–6

Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Urata H, et al. **Blood Press Suppl** 1996;2:22–8 (49 ref.)

A comparison of the inactive urinary kallikrein:creatinine ratio and the angiotensin sensitivity test for the prediction of pre-eclampsia [see comments] Kyle PM, et al. **Br J Obstet Gynaecol** 1996 Oct;103(10):981–7. Comment in: Br J Obstet Gynaecol 1997 Aug;104(8):971.

In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation. Virone-Oddos A, et al. **Br J Pharmacol** 1997 Feb;120(3):488–94

Expression of a novel angiotensin II receptor subtype in gerbil brain. de Oliveira AM, et al. **Brain Res** 1995 Dec 24;705(1-2):177–87

Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Jöhren O, et al. **Brain Res** 1997 May 23;757(2):218–27

Stimulation of angiotensin II AT1 receptors in rat median eminence increases phosphoinositide hydrolysis. Seltzer AM, et al. **Brain Res** 1995 Dec 24;705(1-2):24–30

Localization of AT2 angiotensin II receptor gene expression in rat brain by in situ hybridization histochemistry. Jöhren O, et al. **Brain Res Mol Brain Res** 1996 Apr;37(1-2):192–200

Potentiation of angiotensin II action by corticosteroids in vascular tissue. Ullian ME, et al. **Cardiovasc Res** 1996 Aug; 32(2):266–73

Effects of intracellular angiotensin II in vascular smooth muscle cells. Haller H, et al. **Circ Res** 1996 Oct;79(4):765–72

Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Wolny A, et al. **Circ Res** 1997 Feb;80(2):219–27

Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries: a link between angiotensin II and intimal thickening. Abe J, et al. **Circulation** 1997 Sep 16;96(6):1906–13

Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist. Ledingham JM, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):576–8

Angiotensin II receptors and renin in the porcine uterus: myometrial AT2 and endometrial AT1 receptors are down-regulated during gestation. Nielsen AH, et al. **Clin Exp Pharmacol Physiol** 1997 May;24(5):309–14

Down-regulation of angiotensin II receptors in hypertrophied human myocardium. Nozawa Y, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):514–8

Changes in angiotensin II metabolism contribute to the increased pressor response to angiotensin after chronic treatment with L-NAME in the spontaneously hypertensive rat. Yang Y, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):611–3

A study of angiotensin II receptors after chronic inhibition of nitric oxide synthase in the spontaneously hypertensive rat. Yang Y, et al. **Clin Exp Pharmacol Physiol** 1996 May; 23(5):441–3

Angiotensin receptors and development: the kidney. Alcorn D, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S88–92 (55 ref.)

Role of nitric oxide in impaired coronary circulation and improvement by angiotensin II receptor antagonist in spontaneously hypertensive rats. Fujita H, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S148–50

Molecular determinants of peptide and non-peptide binding to the AT1 receptor. Karnik SS, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S58–66 (35 ref.)

Cytokines and cardiac hypertrophy: roles of angiotensin II and basic fibroblast growth factor. Kaye DM, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S136–41 (71 ref.)

Effect of an angiotensin II receptor antagonist, TCV-116, on neointimal formation following balloon injury in the SHR carotid artery. Kino H, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S360–2

Differences in cultured cardiac fibroblast populations isolated from SHR and WKY rats. Klett CP, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S265–7

Mapping of angiotensin II receptor subtypes in peripheral tissues of spontaneously hypertensive rats by in vitro autoradiography. Song K, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S17–9

Molecular mechanisms of angiotensin II (AT1A) receptor endocytosis. Thomas WG, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S74–80 (60 ref.)

Presence of angiotensin II AT2 receptor binding sites in the adventitia of human kidney vasculature. Zhuo J, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S147–54

DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan. Goldberg MR, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):59–69

Pregnancy induces an increase in angiotensin II type-1 receptor expression in uterine but not systemic artery endothelium. Bird IM, et al. **Endocrinology** 1997 Jan; 138(1):490–8

Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Jones BH, et al. **Endocrinology** 1997 Apr; 138(4):1512–9

Tetralogy of Fallot repair results in activation of the renin-angiotensin-aldosterone system. Mainwaring RD, et al. **Eur Heart J** 1996 Sep;17(9):1421–5

Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Ojima M, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):137–46

Tissue angiotensin II and myocardial infarction. Sun Y, et al. **EXS** 1996;76:479–88 (54 ref.)

The presence of angiotensin II receptors in elasmobranchs. Tierney M, et al. **Gen Comp Endocrinol** 1997 Jan; 105(1):9–17

Effects of SC-52458, a new nonpeptide angiotensin II receptor antagonist, on increase in cytoplasmic Ca2+ concentrations and contraction induced by angiotensin II and K(+)-depolarization in guinea-pig taenia coli. Usune S, et al. **Gen Pharmacol** 1996 Oct;27(7):1179–85

Platelet angiotensin II receptor status during pregnancy in Chinese women at high-risk of developing pregnancy-induced hypertension. Rogers MS, et al. **Gynecol Obstet Invest** 1996;42(2):88–94

Recognition of tissue- and subtype-specific modulation of angiotensin II receptors using antibodies against AT1 and AT2 receptors. Rakugi H, et al. **Hypertens Res** 1997 Mar; 20(1):51–5

Renal immunocytochemical distribution and pharmacological properties of the dual angiotensin II/AVP receptor. Gonzalez CB, et al. **Hypertension** 1997 Apr;29(4):957–61

Brain "ouabain" and angiotensin II in salt-sensitive hypertension in spontaneously hypertensive rats. Huang BS, et al. **Hypertension** 1996 Dec;28(6):1005–12

Vascular angiotensin-converting enzyme expression regulates local angiotensin II. Müller DN, et al. **Hypertension** 1997 Jan;29(1 Pt 1):98–104

Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. van Kats JP, et al. **Hypertension** 1997 Jul;30(1 Pt 1):42–9

Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Weber KT, et al. **Int J Biochem Cell Biol** 1997 Jan; 29(1):31–42 (77 ref.)

Photochemical conjugation of peptides to carrier proteins using 1,2,3-thiadiazole-4-carboxylic acid. Immunoreactivity of free C-terminal epitope with specific antibodies. Hansen PR, et al. **Int J Pept Protein Res** 1996 Jun;47(6):419–26

Role of nitric oxide and angiotensin II in diabetes mellitus-induced glomerular hyperfiltration. Mathis KM, et al. **J Am Soc Nephrol** 1996 Jan;7(1):105–12

Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor. Ali MS, et al. **J Biol Chem** 1997 Sep 12;272(37):23382–8

Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. Liao DF, et al. **J Biol Chem** 1997 Mar 7;272(10):6146–50

Distinct multisite synergistic interactions determine substrate specificities of human chymase and rat chymase-1 for angiotensin II formation and degradation. Sanker S, et al. **J Biol Chem** 1997 Jan 31;272(5):2963–8

A domain for G protein coupling in carboxyl-terminal tail of rat angiotensin II receptor type 1A. Sano T, et al. **J Biol Chem** 1997 Sep 19;272(38):23631–6

Identification of angiotensin II-binding domains in the rat AT2 receptor with photolabile angiotensin analogs. Servant G, et al. **J Biol Chem** 1997 Mar 28;272(13):8653–9

Angiotensin and bradykinin peptides in rats with myocardial infarction. Duncan AM, et al. **J Card Fail** 1997 Mar; 3(1):41–52

Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. Duncan AM, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):746–54

Effects of losartan on renal function in patients with essential hypertension. Fauvel JP, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):259–63

Interactions of nonpeptide angiotensin II receptor antagonists at imidazoline/guanidinium receptor sites in rat forebrain. Li Z, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):425–31

Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. Noël B, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):252–8

Effects of angiotensin II receptor blockade during exercise: comparison of losartan and saralasin. Symons JD, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):223–31

Quantitation of a new potent angiotensin II receptor antagonist, TCV-116, and its metabolites in human serum and urine. Miyabayashi T, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23;677(1):123–32

Periovulatory elevation of angiotensin II in the peritoneal fluid during the human menstrual cycle. Delbaere A, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2810–5

Type 2 angiotensin II receptor is expressed in human myometrium and uterine leiomyoma and is down-regulated during pregnancy. Matsumoto T, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4366–72

Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. Ashizawa N, et al. **J Clin Invest** 1996 Nov 15;98(10):2218–27

Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. Dell'Italia LJ, et al. **J Clin Invest** 1997 Jul 15;100(2):253–8

Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. Okubo S, et al. **J Clin Invest** 1997 Mar 1; 99(5):855–60

Tissue-specific changes in angiotensin II receptors in streptozotocin-diabetic rats. Brown L, et al. **J Endocrinol** 1997 Aug;154(2):355–62

Characterization of the AT1 angiotensin II receptor expressed in guinea pig liver. García-Sáinz JA, et al. **J Endocrinol** 1997 Jul;154(1):133–8

Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. Hatton R, et al. **J Endocrinol** 1997 Jan;152(1):5–10

Agonist-induced internalisation of the angiotensin II-binding sites from plasma membranes of isolated rat hepatocytes. Montiel M, et al. **J Endocrinol** 1997 Mar;152(3):407–12

Hepatic angiotensin II nuclear receptors and transcription of growth-related factors. Eggena P, et al. **J Hypertens** 1996 Aug;14(8):961–8

Serine protease angiotensin II systems. Arakawa K. **J Hypertens Suppl** 1996 Dec;14(5):S3–7 (44 ref.)

Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization. Kondo T, et al. **J Mass Spectrom** 1996 Aug;31(8):873–8

Angiotensin I modulates Ca-transport systems in the rat heart through angiotensin II. Krizanova O, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1739–46

Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type 1 receptor in rats. Makino N, et al. **J Mol Cell Cardiol** 1996 Mar;28(3):507–17

Meet the "other" angiotensins [comment] Luft FC. **J Mol Med** 1997 Mar;75(3):157–9. Comment on: J Mol Med 1997 Mar;75(3):217–22.

Characterization of angiotensin receptors on human skin fibroblasts [see comments] Nickenig G, et al. **J Mol Med** 1997 Mar;75(3):217–22. Comment in: J Mol Med 1997 Mar;75(3):157–9.

The role of tyrosine phosphorylation in angiotensin II mediated intracellular signaling and cell growth. Schieffer B, et al. **J Mol Med** 1996 Feb;74(2):85–91 (57 ref.)

Presynaptic or postsynaptic location of receptors for angiotensin II and substance P in the medial solitary tract nucleus. Qu L, et al. **J Neurophysiol** 1996 Jun;75(6):2220–8

The effect of central angiotensin II receptor blockade on interleukin-1beta- and prostaglandin E-induced fevers in rats: possible involvement of brain angiotensin II receptor in fever induction. Watanabe T, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):873–81

A potential mechanism for proximal tubule angiotensin II-mediated sodium flux associated with receptor-mediated endocytosis and arachidonic acid release. Becker BN, et al. **Kidney Int Suppl** 1996 Dec;57:S66–72

Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers. Burnier M, et al. **Kidney Int Suppl** 1996 Jun;55:S24–9 (20 ref.)

Differential inducibility of angiotensin II AT2 receptor between SHR and WKY vascular smooth muscle cells. Ichiki T, et al. **Kidney Int Suppl** 1996 Jun;55:S14–7

Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Hein L, et al. **Mol Endocrinol** 1997 Aug; 11(9):1266–77

Inhibition of aminopeptidase A activity causes an acute albuminuria in mice: an angiotensin II-mediated effect? Mentzel S, et al. **Nephrol Dial Transplant** 1996 Nov; 11(11):2163–9

Nitric oxide and angiotensin II regulation of renal hemodynamics in the developing piglet. Solhaug MJ, et al. **Pediatr Res** 1996 Mar;39(3):527–33

The development of nonpeptide angiotensin II receptor antagonists: a success story. Höltje HD, et al. **Pharmazie** 1997 Feb;52(2):83–6 (22 ref.)

Central ANG II receptor involved in carotid sinus reflex

resetting in chronically stressed rats. Qian ZM, et al. **Physiol Behav** 1997 Aug;62(2):241–7

Blockade of AT1 receptors by specific antibody attenuated hypertension development in young spontaneously hypertensive rats. Železná B, et al. **Physiol Res** 1996; 45(6):475–7

Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Zini S, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11968–73

Angiotensin II receptor expression in the conduction system and arterial duct of neonatal and adult rat hearts. Bastien NR, et al. **Regul Pept** 1996 May 7;63(1):9–16

Effects of DOCA pretreatment on neuronal sensitivity and cell responsiveness to angiotensin II, in the bed nucleus of the stria terminalis in the rat. Liénard F, et al. **Regul Pept** 1996 Oct 8;66(1–2):59–63

Variation of intrarenal angiotensin II and angiotensin II receptors by acute renal ischemia in the aged rat. Lü X, et al. **Ren Fail** 1996 Jan;18(1):19–29

Purification and characterization of angiotensin II degradation factor from porcine endothelial cells. Fujioka H, et al. **Tohoku J Exp Med** 1995 Nov;177(3):183–92

Angiotensin II in the rabbit retina. Kohler K, et al. **Vis Neurosci** 1997 Jan–Feb;14(1):63–71

[Metabolism of angiotensin I in placenta tissue] Wang Q, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 May;31(5):275–7 (Eng. Abstr.) **(Chi)**

[Angiotensin II—receptor antagonists: a new action group for an established active principle] Pfaffendorf M. **Pharm Unserer Zeit** 1996 Jan;25(1):10–6 (15 ref.) **(Ger)**

PHARMACOKINETICS

Use of designed peptide linkers and recombinant hemoglobin mutants for drug delivery: in vitro release of an angiotensin II analog and kinetic modeling of delivery. Trimble SP, et al. **Bioconjug Chem** 1997 May–Jun;8(3):416–23

Urinary clearance of angiotensin II in Pekin ducks. Gray DA, et al. **Comp Biochem Physiol A Physiol** 1996 Dec; 115(4):335–9

Evidence for angiotensin IV receptors in human collecting duct cells. Czekalski S, et al. **Kidney Int** 1996 Oct; 50(4):1125–31

Plasma renin activity and metabolic clearance rate of angiotensin II in the unstressed aging rat. Baylis C, et al. **Mech Ageing Dev** 1997 Aug;97(2):163–72

PHARMACOLOGY

The role of NMDA receptors in central action of angiotensin II. Wiśniewski K, et al. **Acta Physiol Hung** 1996;84(3):347–8

Effects of angiotensin II on brain monoamine oxidase activity in non-hypoxic and hypoxic mice. Stancheva S, et al. **Acta Physiol Pharmacol Bulg** 1996;22(1):27–30

5-Hydroxytryptamine, angiotensin and bradykinin transiently increase intracellular calcium concentrations and PKC-alpha activity, but do not induce mitogenesis in human vascular smooth muscle cells. Assender JW, et al. **Acta Physiol Scand** 1997 Jul;160(3):207–17

Angiotensin II induces a tachyphylactic calcium response in the rabbit afferent arteriole. Kornfeld M, et al. **Acta Physiol Scand** 1997 Jun;160(2):165–73

Restoration of cardiac contraction by angiotensin II during raised [K+]O in the rabbit. Ryan DM, et al. **Acta Physiol Scand** 1996 Apr;156(4):419–27

Intracerebroventricular angiotensin II increases tolerance to blood loss in conscious sheep. Ullman JE, et al. **Acta Physiol Scand** 1996 Jun;157(2):265–74

AT1-receptors and cellular actions of angiotensin II in neuronal cultures of stroke prone-spontaneously hypertensive rat brain. Raizada MK, et al. **Adv Exp Med Biol** 1996;396:71–8

Effect of taurine on angiotensin II-induced expression of immediate early response genes in primary cultured neonatal rat heart cells. Takahashi K, et al. **Adv Exp Med Biol** 1996;403:297–304

Angiotensin II reduces alcohol intake and choice in water- or food-restricted rats. Kulkosky PJ, et al. **Alcohol** 1996 Jul–Aug;13(4):359–63

Modulation of ANF-R2/ANP-C receptors by angiotensin II in vascular smooth muscle cells. Palaparti A, et al. **Am J Hypertens** 1996 Sep;9(9):930–4

Role of nitric oxide in modulating the chronic renal and arterial pressure responses to angiotensin II. Schnackenberg C, et al. **Am J Hypertens** 1997 Feb;10(2):226–9

The effect of high dietary n-3 fatty acid supplementation on angiotensin II pressor response in human pregnancy. Adair CD, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):688–91

The effect of chronic nitric oxide synthesis inhibition on blood pressure and angiotensin II responsiveness in the pregnant rat. Lubarsky SL, et al. **Am J Obstet Gynecol** 1997 May;176(5):1069–76

Effects of chronic infusion of angiotensin II on renin and blood pressure in the late-gestation fetal sheep. Stanley JR, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):931–7

Effect of intravenous angiotensin II on Fos distribution and drinking behavior in rabbits. Badoer E, et al. **Am J Physiol** 1997 May;272(5 Pt 2):R1515–24

Effect of luminal angiotensin II and ANP on early and late cortical distal tubule HCO3- reabsorption. Barreto-Chaves ML, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):F977–84

Angiotensins stimulate catecholamine release from the chromaffin tissue of the rainbow trout. Bernier NJ, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R49–57

Chronic ANG II infusion and reflex control of norepinephrine and corticosterone in conscious rabbits. Brooks VL, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R487–96

Cholesterol feeding does not alter renal hemodynamic response to acetylcholine and angiotensin II in rabbits. Carroll JF, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R940–7

Afferent renal inputs onto subfornical organ neurons responsive to angiotensin II. Ciriello J. **Am J Physiol** 1997 May;272(5 Pt 2):R1684–9

Synergistic vascular effects of dietary sodium supplementation and angiotensin II administration. Csiky B, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1275–82

Acute depressor actions of angiotensin II in the nucleus of the solitary tract are mediated by substance P. Diz DI, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R28–34

Myogenic contribution to agonist-induced renal vasoconstriction during normoxia and hypoxia. Eichinger MR, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1945–51

Rapid elicitation of salt appetite by an intravenous infusion of angiotensin II in rats. Fitts DA, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R1092–8

Angiotensin II-induced Ca(2+)-oscillations in vascular myocytes from the rat pulmonary artery. Guibert C, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L637–42

Angiotensin II and the maturation of renal cortical Na+/H+ exchanger activity during fetal life in sheep. Guillery EN, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1507–13

Renal actions of angiotensin-(1–7): in vivo and in vitro studies. Handa RK, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):F141–7

Morphological heterogeneity of renal glomerular arterioles and distinct [Ca2+]i responses to ANG II. Helou CM, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):F84–96

ANG II modifies cardiomyocyte function via extracardiac and intracardiac neurons: in situ and in vitro studies. Horackova M, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R766–75

Basal nitric oxide production curtails arteriolar vasoconstrictor responses to ANG II in rat kidney. Ikenaga H, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F365–73

Afferent arteriolar responses to ANG II involve activation of PLA2 and modulation by lipoxygenase and P-450 pathways. Imig JD, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F274–82

Chloride is essential for contraction of afferent arterioles after agonists and potassium. Jensen BL, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):F389–96

ANG II prolongs splanchnic nerve-mediated inhibition of duodenal mucosal alkaline secretion in the rat. Johansson B, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R942–6

Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Kennefick TM, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F595–602

Angiotensin II-induced structural and functional alterations in spontaneously hypertensive rat kidney. Kost CK Jr, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):F229–36

Involvement of AT2 receptors at NRVL in tonic baroreflex suppression by endogenous angiotensins. Lin KS, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2204–10

Angiotensin II activation of Ca(2+)-permeant nonselective cation channels in rat adrenal glomerulosa cells. Lotshaw DP, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1705–15

Membrane potential measurements in renal afferent and efferent arterioles: actions of angiotensin II. Loutzenhiser R, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F307–14

Effects of angiotensin II on cultured rat renomedullary interstitial cells are mediated by AT1A receptors. Maric C, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):F1020–8

Functional evidence for L-type Ca2+ channels controlling ANG II-induced adrenal catecholamine release in vivo. Martineau D, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1713–9

Atrial natriuretic hormone inhibits angiotensin II-stimulated sympathetic nerve activity in humans. Matsukawa T, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):R464–71

Dissociation between positive inotropic and alkalinizing effects of angiotensin II in feline myocardium. Mattiazzi A, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1131–6

Baroreceptor-independent renal nerve inhibition by intracerebroventricular angiotensin II in conscious sheep. May CN, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R560–7

Endothelial vasoconstrictor prostanoids modulate contractions to acetylcholine and ANG II in Ren-2 rats. Noll G, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H493–500

Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation. Oliverio MI, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):F515–20

ANG II stimulates endothelial nitric oxide synthase expression in bovine pulmonary artery endothelium. Olson SC, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):L315–21

Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and ANG II. Oyekan A, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R293–300

Perfused skeletal muscle contraction and metabolism improved by angiotensin II-mediated vasoconstriction. Rattigan S, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):E96–103

Angiotensin II activates the beta 1 isoform of phospholipase C in vascular smooth muscle cells. Schelling JR, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1558–66

Verapamil abolishes the preglomerular response to ANG II during intrarenal nitric oxide synthesis inhibition. Schnackenberg CG, et al. **Am J Physiol** 1997 May;272(5 Pt 2):R1670–6

Modulation of Ca2+ transients in neonatal and adult rat cardiomyocytes by angiotensin II and endothelin-1. Touyz RM, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):H857–68

Mechanisms of ANG II-induced mitogenic responses: role of 12-lipoxygenase and biphasic MAP kinase. Wen Y, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1212–20

ANG II chronically supports renal and lumbar sympathetic activity in sodium-deprived, conscious rats. Xu L, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2591–8

Modulation of K+ and Ca2+ currents in cultured neurons by an angiotensin II type 1a receptor peptide. Zhu M, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C1040–8

Effects of chronic treatment with angiotensin II on thermoregulation in rats. Fregly MJ, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:211–5

Bimodal effects of angiotensin II on migration of human and rat smooth muscle cells. Direct stimulation and indirect inhibition via transforming growth factor-beta 1. Liu G, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1251–7

Differential roles of AT1 and AT2 receptor subtypes in vascular trophic and phenotypic changes in response to stimulation with angiotensin II. Sabri A, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):257–64

Effects of parathyroidectomy and calcium supplementation on the pressor response to angiotensin II in conscious rats. Maeda T, et al. **Artery** 1996;22(3):125–39

Effects of highly purified eicosapentaenoic acid on vascular reactivity to angiotensin II and norepinephrine in pregnant rabbits. Yoshimura T, et al. **Artery** 1997;22(5):242–50

Influence of mibefradil on Ca2+ influx induced by vasoactive hormones or depletion of intracellular calcium stores. Cheglakov IB, et al. **Arzneimittelforschung** 1997 Mar;47(3):244–7

Interleukin-2 modulates the responsiveness to angiotensin II in cultured vascular smooth muscle cells. Nabata T, et al. **Atherosclerosis** 1997 Aug;133(1):23–30

Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Hiruma Y, et al. **Biochem Biophys Res Commun** 1997 Jan 3;230(1):176–8

Angiotensin II increases monocyte binding to endothelial cells. Kim JA, et al. **Biochem Biophys Res Commun** 1996 Sep 24;226(3):862–8

The angiotensin II type 2 receptor primarily inhibits cell growth via pertussis toxin-sensitive G proteins. Ozawa Y, et al. **Biochem Biophys Res Commun** 1996 Nov 12; 228(2):328–33

Angiotensin II stimulates proliferation of primary human keratinocytes via a non-AT1, non-AT2 angiotensin receptor. Steckelings UM, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):329–33

Cytoplasmic Ca2+ signalling and reduction of mitochondrial pyridine nucleotides in adrenal glomerulosa cells in response to K+, angiotensin II and vasopressin. Rohács T, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):785–92

Regulation of thrombospondin-1 production by angiotensin II in rat heart endothelial cells. Chua CC, et al. **Biochim Biophys Acta** 1997 Jun 27;1357(2):209–14

Does angiotensin play a role in human fetal erythropoiesis? Anderson EM, et al. **Biol Neonate** 1997;71(3):194–7

Tissue-specific regulation of angiotensin-converting enzyme by angiotensin II and losartan in the rat. Metsärinne KP, et al. **Blood Press** 1996 Nov;5(6):363–70

Characterization of angiotensin-II effects on cerebral and ocular circulation by noninvasive methods. Krejcy K, et al. **Br J Clin Pharmacol** 1997 May;43(5):501–8

Reciprocal inhibition of nitric oxide and prostacyclin synthesis in human saphenous vein. Barker JE, et al. **Br J Pharmacol** 1996 Jun;118(3):643–8

Increase by adrenaline or angiotensin II of the accumulation of low density lipoprotein and fibrinogen by aortic walls in unrestrained conscious rats. Cardona-Sanclemente LE, et al. **Br J Pharmacol** 1996 Mar;117(6):1089–94

Alterations of cyclo-oxygenase products and NO in responses to angiotensin II of resistance arteries from the spontaneously hypertensive rat. Côrtes SD, et al. **Br J Pharmacol** 1996 Dec;119(8):1635–41

Angiotensin II receptors involved in the enhancement of noradrenergic transmission in the caudal artery of the spontaneously hypertensive rat. Cox SL, et al. **Br J Pharmacol** 1996 Nov;119(5):965–75

Multiple prejunctional actions of angiotensin II on noradrenergic transmission in the caudal artery of the rat. Cox SL, et al. **Br J Pharmacol** 1996 Nov;119(5):976–84

The stimulation of human neutrophil migration by angiotensin II: its dependence on Ca2+ and the involvement of cyclic GMP. Elferink JG, et al. **Br J Pharmacol** 1997 Jun;121(4):643–8

Modulation by locally produced luminal angiotensin II of proximal tubular sodium reabsorption via an AT1 receptor. Hiranyachattada S, et al. **Br J Pharmacol** 1996 Oct; 119(4):617–8

Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins-1 and -3 and angiotensin II in a rat sponge model. Hu DE, et al. **Br J Pharmacol** 1996

Feb;117(3):545–551

Direct positive chronotropic effects of angiotensin II and angiotensin III in pithed rats and in rat isolated atria. Li Q, et al. **Br J Pharmacol** 1996 Aug;118(7):1653–8

Trophic effect of angiotensin II in neonatal rat cardiomyocytes: role of endothelin-1 and non-myocyte cells. Pönicke K, et al. **Br J Pharmacol** 1997 May; 121(1):118–24

The effect of forskolin on 5-HT1-like and angiotensin II-induced vasoconstriction and cyclic AMP content of the rabbit isolated femoral artery. Randall VA, et al. **Br J Pharmacol** 1996 Jun;118(3):627–34

Effect of the Na+/H+ antiport inhibitor Hoe 694 on the angiotensin II-induced vascular smooth muscle cell growth. Sachinidis A, et al. **Br J Pharmacol** 1996 Nov; 119(5):787–96

Potentiation of purinergic transmission by angiotensin in prostatic rat vas deferens. Sum CS, et al. **Br J Pharmacol** 1996 Jul;118(6):1523–9

Cardiovascular effects produced by microinjection of angiotensins and angiotensin antagonists into the ventrolateral medulla of freely moving rats. Fontes MA, et al. **Brain Res** 1997 Mar 7;750(1–2):305–10

Arcuate nucleus inputs onto subfornical organ neurons that respond to plasma hypernatremia and angiotensin II. Rosas-Arellano MP, et al. **Brain Res** 1996 Jan 29; 707(2):308–13

Losartan inhibition of angiotensin-related drinking and Fos immunoreactivity in hypertensive and hypotensive contexts. Rowland NE, et al. **Brain Res** 1996 Dec 2; 742(1–2):253–9

Aminopeptidase A antiserum inhibits intracerebroventricular angiotensin II-induced dipsogenic and pressor responses. Song L, et al. **Brain Res** 1997 Jan 2;744(1):1–6

Excitotoxic lesions of the ventral anteroventral third ventricle and pressor responses to central sodium, ouabain and angiotensin II. Veerasingham SJ, et al. **Brain Res** 1997 Feb 21;749(1):157–60

Effects of unilateral or bilateral lesions within the anteroventral third ventricular region on c-fos expression induced by dehydration or angiotensin II in the supraoptic and paraventricular nuclei of the hypothalamus. Xu Z, et al. **Brain Res** 1996 Mar 25;713(1–2):36–43

Central antagonism of atrial natriuretic peptides on behavioral and hormonal responses to angiotensin II: mapping with c-fos. Zhu B, et al. **Brain Res** 1996 Sep 23; 734(1–2):55–60

Angiotensin II enhances long-term memory in the crab Chasmagnathus. Delorenzi A, et al. **Brain Res Bull** 1996; 41(4):211–20

Water versus salty taste and Iontophoretic ANGII responses of septopreoptic neurons in dehydrated and euhydrated awake rats. Mousseau MC, et al. **Brain Res Bull** 1996; 41(3):167–73

Central interaction between atrial natriuretic peptide and angiotensin II in the control of sodium intake and excretion in female rats. De-Angelis PR, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1671–4

Paraventricular nucleus administration of DuP753 or PD123319 inhibits the effects of angiotensin on water and sodium intake. do-Prado MH, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1499–502

Effects of chronic blockade of angiotensin II receptor on the maintenance of hypertension and vascular changes in spontaneously hypertensive rats. Gillies LK, et al. **Can J Physiol Pharmacol** 1996 Sep;74(9):1061–9

Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo. Krejcy K, et al. **Can J Physiol Pharmacol** 1996 Jan;74(1):9–14

Interactions between angiotensin II and adenosine 3':5'-cyclic monophosphate in the regulation of amino acid transport by vascular smooth muscle cells. McCumbee WD, et al. **Can J Physiol Pharmacol** 1996 Feb;74(2):173–81

Ventilatory effects of angiotensin and vasopressin in conscious rats. Walker JK, et al. **Can J Physiol Pharmacol** 1996 Nov;74(11):1258–64

Effect of angiotensin II on immunotoxin uptake in tumor and normal tissue. Elizondo FG Jr, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):113–21

Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers. Baan J Jr, et al. **Cardiovasc Res** 1996 Nov; 32(5):973–9

The influence of angiotensin II-induced increase in aortic wall mass on compliance in rats in vivo. Brouwers-Ceiler DL, et al. **Cardiovasc Res** 1997 Feb;33(2):478–84

Effects of low-flow ischemia on the positive inotropic action of angiotensin II in isolated rabbit and rat hearts. Libonati JR, et al. **Cardiovasc Res** 1997 Jan;33(1):71–81

Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Sun Y, et al. **Cardiovasc Res** 1997 Jul;35(1):138–47

Doxazosin blocks the angiotensin II-induced smooth muscle cell DNA synthesis in the media, but not in the neointima of the rat carotid artery after balloon injury. van Kleef EM, et al. **Cardiovasc Res** 1996 Feb;31(2):324–30

Oscillatory Cl- current induced by angiotensin II in rat pulmonary arterial myocytes: Ca2+ dependence and physiological implication. Guibert C, et al. **Cell Calcium** 1997 Jun;21(6):421–9

Different behavior of lactotroph cell subpopulations in response to angiotensin II and thyrotrophin-releasing hormone. De Paul A, et al. **Cell Mol Neurobiol** 1997 Apr; 17(2):245–58

Pressure and angiotensin II synergistically induce aortic fibronectin expression in organ culture model of rabbit aorta. Evidence for a pressure-induced tissue renin-angiotensin system. Bardy N, et al. **Circ Res** 1996 Jul;79(1):70–8

Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Kudoh S, et al. **Circ Res** 1997 Jan;80(1):139–46

Cross talk between angiotensin AT1 and alpha 1-adrenergic receptors: angiotensin II downregulates alpha 1a-adrenergic receptor subtype mRNA and density in neonatal rat cardiac myocytes. Li HT, et al. **Circ Res** 1997 Sep;81(3):396–403

Angiotensin II stimulates MAP kinase kinase kinase activity in vascular smooth muscle cells, Role of Raf. Liao DF, et al. **Circ Res** 1996 Nov;79(5):1007–14

Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Pollman MJ, et al. **Circ Res** 1996 Oct; 79(4):748–56

Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. Sadoshima J, et al. **Circ Res** 1997 Feb; 80(2):228–41

Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Saward I, et al. **Circ Res** 1997 Aug;81(2):249–57

Angiotensin II stimulates p90rsk in vascular smooth muscle cells. A potential Na(+)-H+ exchanger kinase. Takahashi E, et al. **Circ Res** 1997 Aug;81(2):268–73

Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Moreau P, et al. **Circulation** 1997 Sep 2; 96(5):1593–7

Angiotensin II inhibits protein kinase A-dependent chloride conductance in heart via pertussis toxin-sensitive G proteins. Obayashi K, et al. **Circulation** 1997 Jan 7; 95(1):197–204

Depletion of resistance vessel polyamines attenuates angiotensin II induced blood pressure rise in rats. Ibrahim J, et al. **Clin Exp Hypertens** 1996 Aug;18(6):811–30

Vascular reactivity to phenylephrine and angiotensin II in hypertensive rats associated with insulin resistance. Iyer SN, et al. **Clin Exp Hypertens** 1996 Feb;18(2):227–42

Effect of angiotensin II on striatal dopamine release in the spontaneous hypertensive rat. Jenkins TA, et al. **Clin Exp Hypertens** 1997 Jul-Aug;19(5–6):645–58

Angiotensin II activates pressor and depressor sites of the pontomedulla that react to glutamate. Chai CY, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):415–23

Angiotensin II-induced tyrosine phosphorylation in mesangial and vascular smooth muscle cells. Marrero MB, et al. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):83–8 (46 ref.)

Prolonged systemic and regional haemodynamic effects of intracerebroventricular angiotensin II in conscious sheep. May CN. **Clin Exp Pharmacol Physiol** 1996 Oct-Nov; 23(10–11):878–84

Slow pressor effect of angiotensin II in normotensive rats with renal artery stenosis. Melaragno MG, et al. **Clin Exp Pharmacol Physiol** 1996 Feb;23(2):140–4

Changes in angiotensin II metabolism contribute to the increased pressor response to angiotensin after chronic treatment with L-NAME in the spontaneously hypertensive rat. Yang Y, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6–7):611–3

Angiotensin II and the adrenal. Giacchetti G, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S119–24 (49 ref.)

Regulation of renal tubular sodium transport by angiotensin II and atrial natriuretic factor. Harris PJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S112–8 (74 ref.)

Role of AT1 receptors in the central control of sympathetic vasomotor function. Head GA. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S93–8

Subpressor doses of angiotensin II do not increase albumin excretion in humans. Erley CM, et al. **Clin Nephrol** 1996 Nov;46(5):312–8

Enhanced effects of insulin and angiotensin II on intracellular pH and free cytosolic calcium in fibroblasts from microalbuminuric patients with non-insulin-dependent diabetes mellitus. Trevisan R, et al. **Clin Sci (Colch)** 1996 Dec;91(6):703–10

Renal responses to antagonism of the renin-angiotensin system. Braam B, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):89–96 (69 ref.)

Regulation of glomerular epithelial cell production of fibronectin and transforming growth factor-beta by high glucose, not by angiotensin II. van Det NF, et al. **Diabetes** 1997 May;46(5):834–40

Effects of angiotensin II on insulin receptor binding and mRNA levels in normal and diabetic rats. Sechi LA, et al. **Diabetologia** 1997 Jul;40(7):770–7

ACTH angiotensin II and TGF beta participate in the regulation of steroidogenesis in bovine adrenal glomerulosa cells. Galtier A, et al. **Endocr Res** 1996 Nov;22(4):607–12

AT1 receptors and cell proliferation in rat adrenals: effects of angiotensin infusion, low sodium diet and losartan. McEwan PE, et al. **Endocr Res** 1996 Nov;22(4):369–71

The role of voltage-dependent calcium channels in angiotensin-stimulated glomerulosa cells. Spät A, et al. **Endocr Res** 1996 Nov;22(4):569–76

Role of the tissue renin-angiotensin system in the response of the rat adrenal to exogenous angiotensin II. Vinson GP, et al. **Endocr Res** 1996 Nov;22(4):589–93

Possible role for mitochondrial calcium in angiotensin II- and potassium-stimulated steroidogenesis in bovine adrenal glomerulosa cells. Brandenburger Y, et al. **Endocrinology** 1996 Dec;137(12):5544–51

Angiotensin-responsive adrenal glomerulosa cell proteins: characterization by protease mapping, species comparison, and specific angiotensin receptor antagonists. Elliott ME, et al. **Endocrinology** 1997 Jun;138(6):2530–6

Functional interactions between neuronal AT1 and AT2 receptors. Gelband CH, et al. **Endocrinology** 1997 May; 138(5):2195–8

Angiotensin II receptor subtypes AT1 and AT2 are down-regulated by angiotensin II through AT1 receptor by different mechanisms. Ouali R, et al. **Endocrinology** 1997 Feb;138(2):725–33

Desensitization of AT1 receptor-mediated cellular responses requires long term receptor down-regulation in bovine adrenal glomerulosa cells. Richard DE, et al. **Endocrinology** 1997 Sep;138(9):3828–35

Angiotensin II regulation of tyrosine hydroxylase gene expression in the neuronal cultures of normotensive and spontaneously hypertensive rats. Yu K, et al. **Endocrinology** 1996 Aug;137(8):3566–76

Effect of regional angiotensin II infusion on the relationship between tumour blood flow and fluorouracil uptake in a liver metastasis animal model. Dworkin MJ, et al. **Eur J Cancer** 1996 Aug;32A(9):1580–4

Mechanism of angiotensin II-induced arachidonic acid metabolite release in aortic smooth muscle cells: involvement of phospholipase D. Shinoda J, et al. **Eur J Endocrinol** 1997 Feb;136(2):207–12

Excess extrafetal fluid without demonstrable changes in placental concentration gradients after week-long infusions of angiotensin into fetal lambs. Anderson DF, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Dec;63(2):175–9

Angiotensin II-induced renal responses in anesthetized rabbits: effects of N omega-nitro-L-arginine methyl ester and losartan. Adachi Y, et al. **Eur J Pharmacol** 1996 Jul 18;308(2):165–71

Analysis of responses to angiotensin I and angiotensin I-(3–10) in the mesenteric vascular bed of the cat. Champion HC, et al. **Eur J Pharmacol** 1996 Aug 15; 309(3):251–9

Vascular reactivity to angiotensin II in blood-perfused kidneys of hypertensive diabetic rats. Farina NK, et al. **Eur J Pharmacol** 1996 Aug 29;310(2–3):185–91

Age-related differences and roles of endothelial nitric oxide and prostanoids in angiotensin II responses of isolated, perfused mesenteric arteries and veins of rats. Konishi C, et al. **Eur J Pharmacol** 1997 Feb 12;320(2–3):175–81

Effects of angiotensin II and angiotensin-converting enzyme inhibitors on human myocardium. Lenz O, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):17–27

Carbocyclic thromboxane A2 enhances the angiotensin II-induced DNA synthesis in smooth muscle cells. Sachinidis A, et al. **Eur J Pharmacol** 1996 Jun 20; 307(1):121–4

Intracisternally applied angiotensin II does not excite reticulospinal vasomotor neurons in anesthetized rats. Sun MK, et al. **Eur J Pharmacol** 1996 May 23;304(1–3):63–71

Angiotensin II activates programmed myocyte cell death in vitro. Cigola E, et al. **Exp Cell Res** 1997 Mar 15; 231(2):363–71

Selective antagonism of the AT1 receptor inhibits the effect of angiotensin II on DNA and protein synthesis of rat proximal tubular cells. Weerackody RP, et al. **Exp Nephrol** 1997 May-Jun;5(3):253–62

Increasing cAMP antagonizes hypertrophic response to angiotensin II without affecting Ras and MAP kinase activation in vascular smooth muscle cells. Takahashi T, et al. **FEBS Lett** 1996 Nov 11;397(1):89–92

Altered growth and lack of responsiveness to angiotensin II in aortic vascular smooth muscle cells from cirrhotic rats. Tazi KA, et al. **Gastroenterology** 1997 Jun; 112(6):2065–72

Effects of SC-52458, a new nonpeptide angiotensin II receptor antagonist, on increase in cytoplasmic Ca2+ concentrations and contraction induced by angiotensin II and K(+)-depolarization in guinea-pig taenia coli. Usune S, et al. **Gen Pharmacol** 1996 Oct;27(7):1179–85

6-OHDA lesions to the central amygdala abolish angiotensins facilitation of object recognition in rats. Winnicka MM, et al. **Gen Pharmacol** 1997 Aug;29(2):239–43

Angiotensin II activates distinct signal transduction pathways in astrocytes isolated from neonatal rat brain. Tallant EA, et al. **Glia** 1997 Apr;19(4):333–42

The influence of angiotensin II on prostanoid production in preterm human umbilical arteries. Haugen G, et al. **Gynecol Obstet Invest** 1996;42(3):159–62

Inhibition by somatostatin of the growth hormone, but not corticotropin response to angiotensin II in normal men. Volpi R, et al. **Horm Res** 1996;45(6):269–72

Angiotensin II activates endothelial constitutive nitric oxide synthase via AT1 receptors. Saito S, et al. **Hypertens Res** 1996 Sep;19(3):201–6

Angiotensin-(1–7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Abbas A, et al.

Hypertension 1997 Aug;30(2 Pt 1):217–21
Angiotensin II–stimulated phospholipase C responses of two vascular smooth muscle–derived cell lines. Role of cyclic GMP. Baines RJ, et al. **Hypertension** 1996 Nov;28(5):772–8
Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Balakrishnan SM, et al. **Hypertension** 1996 Nov;28(5):806–9
Increased brain transcription factor expression by angiotensin in genetic hypertension. Blume A, et al. **Hypertension** 1997 Feb;29(2):592–8
Role of type 1 and type 2 angiotensin receptors in angiotensin II–induced cardiomyocyte hypertrophy. Booz GW, et al. **Hypertension** 1996 Oct;28(4):635–40
Mechanical load opposes angiotensin–mediated decrease in vascular alpha 1–adrenoceptors. Clements ML, et al. **Hypertension** 1997 May;29(5):1165–72
Alterations in calcium stores in aortic myocytes from spontaneously hypertensive rats. Côrtes SF, et al. **Hypertension** 1997 Jun;29(6):1322–8
Hypothalamic substance P release. Attenuated angiotensin responses in mRen2(27) transgenic rats. Diz DI, et al. **Hypertension** 1997 Jan;29(1 Pt 2):510–3
Counterregulatory actions of angiotensin–(1–7). Ferrario CM, et al. **Hypertension** 1997 Sep;30(3 Pt 2):535–41 (63 ref.)
Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Gandhi SK, et al. **Hypertension** 1996 Dec;28(6):961–6
Role of renal nerves in afferent arteriolar reactivity in angiotensin–induced hypertension. Ichihara A, et al. **Hypertension** 1997 Jan;29(1 Pt 2):442–9
Afferent and efferent arteriolar vasoconstriction to angiotensin II and norepinephrine involves release of Ca2+ from intracellular stores. Inscho EW, et al. **Hypertension** 1997 Jan;29(1 Pt 2):222–7
Angiotensin II type 2 receptor subtype mediates phospholipase A2–dependent signaling in rabbit proximal tubular epithelial cells. Jacobs LS, et al. **Hypertension** 1996 Oct;28(4):663–8
Role of the lipoxygenase pathway in angiotensin II–induced vasoconstriction in the human placenta. Kisch ES, et al. **Hypertension** 1997 Mar;29(3):796–801
Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Laredo J, et al. **Hypertension** 1997 Jan;29(1 Pt 2):401–7
Angiotensin–(1–7) augments bradykinin–induced vasodilation by competing with ACE and releasing nitric oxide. Li P, et al. **Hypertension** 1997 Jan;29(1 Pt 2):394–400
Potentiation of the hypotensive effect of bradykinin by short–term infusion of angiotensin–(1–7) in normotensive and hypertensive rats. Lima CV, et al. **Hypertension** 1997 Sep;30(3 Pt 2):542–8
Change in pressor responsiveness to angiotensin II as a determinant of blood pressure after unclipping in two–kidney, one clip hypertensive rats. Melaragno MG, et al. **Hypertension** 1996 Oct;28(4):656–62
Reduced sensitivity of the renal circulation to angiotensin II in pregnant rats. Novak J, et al. **Hypertension** 1997 Sep; 30(3 Pt 2):580–4
Angiotensin II and myocyte growth: role of fibroblasts. Sil P, et al. **Hypertension** 1997 Aug;30(2 Pt 1):209–16
Intracellular Ca2+ modulation by angiotensin II and endothelin–1 in cardiomyocytes and fibroblasts from hypertrophied hearts of spontaneously hypertensive rats. Touyz RM, et al. **Hypertension** 1996 Nov;28(5):797–805
Opposite regulation of Gax homeobox expression by angiotensin II and C–type natriuretic peptide. Yamashita J, et al. **Hypertension** 1997 Jan;29(1 Pt 2):381–7
Receptor–mediated intrarenal angiotensin II augmentation in angiotensin II–infused rats. Zou LX, et al. **Hypertension** 1996 Oct;28(4):669–77
An immortalized rat mesangial cell line [letter] Nitta K, et al. **In Vitro Cell Dev Biol Anim** 1997 Mar;33(3):156–7
The effect of angiotensin II on myosin heavy chain expression in cultured myocardial cells. Shalitin N, et al. **In Vitro Cell Dev Biol Anim** 1996 Oct;32(9):573–8
Angiotensin–II–induced angiogenesis in sponge implants in mice. Andrade SP, et al. **Int J Microcirc Clin Exp** 1996 Nov–Dec;16(6):302–7
Effect of angiotensin II on the reactivity of isolated mesenteric vessels to norepinephrine in rats poisoned with cadmium. Skoczyńska A. **Int J Occup Med Environ Health** 1997;10(1):67–77
Suppression of CO2–induced relaxation of bovine retinal pericytes by angiotensin II. Matsugi T, et al. **Invest Ophthalmol Vis Sci** 1997 Mar;38(3):652–7
Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. Lapinski R, et al. **J Am Soc Nephrol** 1996 May;7(5):653–60
Differential effects of angiotensin II and transforming growth factor beta on the production of heparan sulfate proteoglycan by mesangial cells in vitro. van Det NF, et al. **J Am Soc Nephrol** 1996 Jul;7(7):1015–23
Effects of tumor necrosis factor and interleukin–1 on the constriction induced by angiotensin II in rat aorta. Vicaut E, et al. **J Appl Physiol** 1996 Jun;80(6):1891–7
Angiotensin II stimulates tyrosine phosphorylation and activation of insulin receptor substrate 1 and protein–tyrosine phosphatase 1D in vascular smooth muscle cells. Ali MS, et al. **J Biol Chem** 1997 May 9; 272(19):12373–9
Angiotensin II interferes with interleukin 6–induced Stat3 signaling by a pathway involving mitogen–activated protein kinase kinase 1. Bhat GJ, et al. **J Biol Chem** 1996 Sep 13;271(37):22447–52
Angiotensin II–induced down–regulation of inositol trisphosphate receptors in WB rat liver epithelial cells. Evidence for involvement of the proteasome pathway. Bokkala S, et al. **J Biol Chem** 1997 May 9;272(19):12454–61
Angiotensin II stimulates phosphorylation of the translational repressor 4E–binding protein 1 by a mitogen–activated protein kinase–independent mechanism. Fleurent M, et al. **J Biol Chem** 1997 Feb 14;272(7):4006–12
Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108–15 cells. Effect counteracted by the AT1 receptors. Laflamme L, et al. **J Biol Chem** 1996 Sep 13;271(37):22729–35
Role of Janus kinase/signal transducer and activator of transcription and mitogen–activated protein kinase cascades in angiotensin II– and platelet–derived growth factor–induced vascular smooth muscle cell proliferation. Marrero MB, et al. **J Biol Chem** 1997 Sep 26; 272(39):24684–90
Angiotensin II increases macrophage–mediated modification of low density lipoprotein via a lipoxygenase–dependent pathway. Scheidegger KJ, et al. **J Biol Chem** 1997 Aug 22;272(34):21609–15
Angiotensin II stimulates mitogen–activated protein kinases and protein synthesis by a Ras–independent pathway in vascular smooth muscle cells. Takahashi T, et al. **J Biol Chem** 1997 Jun 20;272(25):16018–22
Angiotensin II and vasopressin modulate intracellular free magnesium in vascular smooth muscle cells through Na+–dependent protein kinase C pathways. Touyz RM, et al. **J Biol Chem** 1996 Oct 4;271(40):24353–8
p22phox is a critical component of the superoxide–generating NADH/NADPH oxidase system and regulates angiotensin II–induced hypertrophy in vascular smooth muscle cells. Ushio–Fukai M, et al. **J Biol Chem** 1996 Sep 20; 271(38):23317–21
Angiotensin II activation of cyclin D1–dependent kinase activity. Watanabe G, et al. **J Biol Chem** 1996 Sep 13; 271(37):22570–7
Stimulated mitogen–activated protein kinase is necessary but not sufficient for the mitogenic response to angiotensin II. A role for phospholipase D. Wilkie N, et al. **J Biol Chem** 1996 Dec 13;271(50):32447–53
Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II–induced activation of Raf–1 kinase and extracellular signal–regulated protein kinases in cardiac myocytes. Zou Y, et al. **J Biol Chem** 1996 Dec 27;271(52):33592–7
Effects of endothelin–1 on [Ca2+]i–shortening trajectory and Ca2+ sensitivity in rabbit single ventricular cardiomyocytes loaded with indo–1/AM: comparison with the effects of phenylephrine and angiotensin II. Fujita S, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S45–57
Effects of long–term treatment with trandolapril on augmented vasoconstriction in rats with chronic heart failure. Okumura Y, et al. **J Card Fail** 1996 Dec;2(4):301–10
Role of calcium in angiotensin II–induced prostaglandin release and DNA synthesis in rat vascular smooth muscle cells. Catalioto RM, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):195–200
Effects of hypercholesterolemia on the contractions to angiotensin II in the isolated aorta and iliac artery of the rabbit: role of arachidonic acid metabolites. Dam JP, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):118–23
Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein. Li Q, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):451–6
Activation of protein kinase C by angiotensin II decreases beta 1–adrenergic receptor responsiveness in the rat heart. Schwartz DD, et al. **J Cardiovasc Pharmacol** 1997 Feb; 29(2):257–64
Renal and depressor activities of inhibitors of neutral endopeptidase and angiotensin converting enzyme in monkeys infused with angiotensin II. Seymour AA, et al. **J Cardiovasc Pharmacol** 1996 Nov;28(5):651–8
Angiotensin II–induced phosphoinositide production and atrial natriuretic peptide release in rat atrial tissue. Soualmia H, et al. **J Cardiovasc Pharmacol** 1997 May;29(5):605–11
Role of nitric oxide in the attenuated pressor responses of pregnant or sodium–deplete sheep. Tresham JJ, et al. **J Cardiovasc Pharmacol** 1996 Jun;27(6):908–15
Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. Takeda Y, et al. **J Clin Endocrinol Metab** 1996 Aug; 81(8):2797–800
Angiotensin II depolarizes podocytes in the intact glomerulus of the Rat. Gloy J, et al. **J Clin Invest** 1997 Jun 1; 99(11):2772–81
Stimulation of activin A expression in rat aortic smooth muscle cells by thrombin and angiotensin II correlates with neointimal formation in vivo. Pawlowski JE, et al. **J Clin Invest** 1997 Aug 1;100(3):639–48
The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. Siragy HM, et al. **J Clin Invest** 1997 Jul 15;100(2):264–9
Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. Wolf G, et al. **J Clin Invest** 1997 Sep 1;100(5):1047–58
Effects of angiotensin II and its blockers Sar1–Ile8–angiotensin II and DuP 753 on drinking in ducks in relation to properties of subfornical organ neurons. Simon E, et al. **J Comp Physiol [B]** 1996;165(8):607–14
Effect of angiotensin II on the apical K+ channel in the thick ascending limb of the rat kidney. Lu M, et al. **J Gen Physiol** 1996 Dec;108(6):537–47
Influence of nifedipine on pressor responses induced by different alpha–adrenoceptor agonists and angiotensin II in pithed diabetic hypertensive rats. Beenen OH, et al. **J Hypertens** 1996 Jul;14(7):847–53
Cytosolic calcium changes induced by angiotensin II in human peripheral blood mononuclear cells are mediated via angiotensin II subtype 1 receptors. Lijnen P, et al. **J Hypertens** 1997 Aug;15(8):871–6
Angiotensin II induces activation of phosphatidylinositol 3–kinase in cardiomyocytes. Rabkin SW, et al. **J Hypertens** 1997 Aug;15(8):891–9
Relationship between renal plasma flow response to angiotensin II and blood pressure in a population–based sample. Turner ST, et al. **J Hypertens** 1997 May; 15(5):495–502
Regulation of type 1 angiotensin II receptor and its subtype gene expression in kidney by sodium loading and angiotensin II infusion. Wang DH, et al. **J Hypertens** 1996 Dec;14(12):1409–15
Angiotensinogen messenger RNA stabilization by angiotensin II. Klett CP, et al. **J Hypertens Suppl** 1996 Dec; 14(5):S25–36
Kinetics of altered angiotensin II responses in experimental vein grafts. Davies MG, et al. **J Invest Surg** 1996 Nov–Dec; 9(6):423–32
Angiotensin II stimulated expression of transforming growth factor–beta1 in cardiac fibroblasts and myofibroblasts. Campbell SE, et al. **J Mol Cell Cardiol** 1997 Jul; 29(7):1947–58
Altered mRNA abundance of calcium transport genes in cardiac myocytes induced by angiotensin II. Ju H, et al. **J Mol Cell Cardiol** 1996 May;28(5):1119–28
Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. Kajstura J, et al. **J Mol Cell Cardiol** 1997 Mar;29(3):859–70
Cytokine– and endotoxin–induced nitric oxide synthase in rat astroglial cultures: differential modulation by angiotensin II. Kopnisky KL, et al. **J Neurochem** 1997 Mar; 68(3):935–44
Mechanisms underlying the chronotropic effect of angiotensin II on cultured neurons from rat hypothalamus and brain stem. Wang D, et al. **J Neurophysiol** 1997 Aug; 78(2):1013–20
Involvement of MAP kinase in angiotensin II–induced phosphorylation and intracellular targeting of neuronal AT1 receptors. Yang H, et al. **J Neurosci** 1997 Mar 1; 17(5):1660–9
Angiotensin II potentiates vasodilation of rat aorta by cAMP elevating agonists. Brizzolara–Gourdie A, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):354–9
Regulation of [Ca++]i in human neuroblastoma (SH–SY5Y) cells expressing recombinant rat angiotensin1A receptors by angiotensin II and carbachol. McDonald RL, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1257–63
Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. Thomas GP, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1090–7
The inhibitory effect of angiotensin II on stimulus–induced release of cAMP is augmented in the genetically hypertensive rat kidney. Vyas SJ, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):114–9
Participation of AT1 and AT2 receptors in the differential interaction between angiotensin II or III and alpha–2 adrenoceptors in the nucleus reticularis gigantocellularis in cardiovascular regulation and antinociception in rats. Yang CH, et al. **J Pharmacol Exp Ther** 1996 Nov; 279(2):795–802
Positive inotropic effect of angiotensin II. Increases in intracellular Ca2+ or changes in myofilament Ca2+ responsiveness? Mattiazzi A. **J Pharmacol Toxicol Methods** 1997 Jun;37(4):205–14 (80 ref.)
Angiotensin II activation of protein kinase C decreases delayed rectifier K+ current in rabbit vascular myocytes. Clément–Chomienne O, et al. **J Physiol (Lond)** 1996 Sep 15;495 (Pt 3):689–700
The action of angiotensin II on the intracellular sodium content of suspensions of rat proximal tubules. Wong PS, et al. **J Physiol (Lond)** 1996 Nov 15;497 (Pt 1):219–27
Increase in cardiodepressant factor release from the posterior pituitary lobe after angiotensin II infusion into the internal carotid artery. Gorąca A, et al. **J Physiol Pharmacol** 1997 Jun;48(2):225–37
Enhancement of potassium–, and angiotensin II–stimulated aldosterone production by the calcium chelator EGTA in bovine adrenal glomerulosa cells in vitro. Kigoshi T, et al. **J Steroid Biochem Mol Biol** 1997 Feb;60(3–4):215–20
Cardiac augmentation can be maintained by continuous exposure of intrinsic cardiac neurons to a beta–adrenergic agonist or angiotensin II. Levett JM, et al. **J Surg Res** 1996 Dec;66(2):167–73
Role of endothelial nitric oxide in the response to angiotensin II of small mesenteric arteries of the rat. Andriantsitohaina R, et al. **J Vasc Res** 1996 Sep–Oct;33(5):386–94

Angiotensin II induces media hypertrophy and hyperreactivity in mesenteric but not epigastric small arteries of the rat. Stassen FR, et al. **J Vasc Res** 1997 Jul–Aug;34(4):289–97

Immunohistochemical and molecular characterization of the differential response of the rat mesenteric microvasculature to angiotensin–II infusion. Wiener J, et al. **J Vasc Res** 1996 May–Jun;33(3):195–208

Insulin and angiotensin II are additive in stimulating TGF–beta 1 and matrix mRNAs in mesangial cells. Anderson PW, et al. **Kidney Int** 1996 Sep;50(3):745–53

Selective antagonism of the AT1 receptor inhibits angiotensin II stimulated DNA and protein synthesis in primary cultures of human proximal tubular cells. Chatterjee PK, et al. **Kidney Int** 1997 Sep;52(3):699–705

Alteration of cytosolic calcium induced by angiotensin II and norepinephrine in mesangial cells from diabetic rats. Hadad SJ, et al. **Kidney Int** 1997 Jan;51(1):87–93

Angiotensin II increases the cytosolic calcium activity in rat podocytes in culture. Henger A, et al. **Kidney Int** 1997 Sep;52(3):687–93

Signaling pathways in the biphasic effect of angiotensin II on apical Na/H antiport activity in proximal tubule. Houillier P, et al. **Kidney Int** 1996 Nov;50(5):1496–505

Contribution of tubuloglomerular feedback to renal arteriolar angiotensin II responsiveness. Ikenaga H, et al. **Kidney Int** 1996 Jan;49(1):34–9

Angiotensin II action in isolated microperfused rabbit afferent arterioles is modulated by flow. Juncos LA, et al. **Kidney Int** 1996 Feb;49(2):374–81

Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kagami S, et al. **Kidney Int** 1997 Mar;51(3):664–71

Ionic effects of angiotensin II and their role in the activation of the Na+/H+ antiporter. Flores G, et al. **Kidney Int Suppl** 1996 Jun;55:S122–5

Angiotensin II, via an action at AT1 receptors, may modulate the behavioural effects of ET–1 in conscious rats. D'Amico M, et al. **Life Sci** 1996;59(22):PL355–8

AT1 receptors mediate pressor responses induced by angiotensin II in the periaqueductal gray area of rats. D'Amico M, et al. **Life Sci** 1997;61(1):PL17–20

Effects of angiotensin–II infusion at pressor and subpressor doses on endothelin–1 plasma levels in healthy men. Jilma B, et al. **Life Sci** 1997;60(21):1859–66

Increased production of PDGF by angiotensin and high glucose in human vascular endothelium. Okuda Y, et al. **Life Sci** 1996;59(17):1455–61

Effect of angiotensin II on a spinal nociceptive reflex in the rat: receptor and mechanism of action. Toma N, et al. **Life Sci** 1997;61(5):503–13

Effects of age and gender on the AII–induced stimulation of prolactin release and inositol phosphate accumulation in rat anterior pituitary cells in vitro. Janik JM, et al. **Mech Ageing Dev** 1997 Apr;95(1–2):113–30

Sensitivity of the segmental renal arterioles to angiotensin II in the aging rat. Zhang XZ, et al. **Mech Ageing Dev** 1997 Aug;97(2):183–92

Dietary myo–inositol restores diabetic renal arteriolar reactivity to angiotensin II but not to norepinephrine. Inman SR, et al. **Microcirculation** 1996 Jun;3(2):191–8

Regulation of the gene–encoding angiotensin II receptor in vascular tissue. Wang DH, et al. **Microcirculation** 1996 Jun; 3(2):237–9 (22 ref.)

Angiotensin II stimulates rapid serine phosphorylation of transcription factor Stat3. Bhat GJ, et al. **Mol Cell Biochem** 1997 May;170(1–2):171–6

Effect of angiotensin II on myocardial collagen gene expression. Ju H, et al. **Mol Cell Biochem** 1996 Oct–Nov; 163–164:231–7

Role of vascular adrenergic mechanisms in the haemodynamic and PGI2 stimulating effects of angiotensin in diabetic dogs. Koltai MZ, et al. **Mol Cell Biochem** 1996 Oct–Nov;163–164:151–7

Demonstration of an angiotensin II–induced negative feedback effect on aldosterone synthesis in isolated rat adrenal zona glomerulosa cells. Aptel HB, et al. **Mol Cell Endocrinol** 1996 May 17;119(1):105–11

The steroidogenic acute regulatory protein is induced by angiotensin II and K+ in H295R adrenocortical cells. Clark BJ, et al. **Mol Cell Endocrinol** 1995 Dec 29; 115(2):215–19

Differential regulation of 11 beta–hydroxylase and aldosterone synthase in human adrenocortical H295R cells. Denner K, et al. **Mol Cell Endocrinol** 1996 Jul 23; 121(1):87–91

ACTH and AII differentially stimulate steroid hormone orphan receptor mRNAs in adrenal cortical cells. Enyeart JJ, et al. **Mol Cell Endocrinol** 1996 Nov 29;124(1–2):97–110

The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Meffert S, et al. **Mol Cell Endocrinol** 1996 Aug 30;122(1):59–67

Stimulation of the angiotensin II type I receptor on bovine adrenal glomerulosa cells activates a temperature–sensitive internalization–recycling pathway. Richard DE, et al. **Mol Cell Endocrinol** 1997 May 16;129(2):209–18

Insulin is required for angiotensin II–mediated hypertrophy of smooth muscle cells. Saward L, et al. **Mol Cell Endocrinol** 1996 Aug 30;122(1):93–100

Angiotensin II and potassium regulate human CYP11B2 transcription through common cis–elements. Clyne CD, et al. **Mol Endocrinol** 1997 May;11(5):638–49

Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor–kappaB p65) transcription factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Li J, et al. **Mol Endocrinol** 1996 Mar;10(3):252–64

Cell shape change reveals the cyclic AMP–mediated action of follicle stimulating hormone, human chorionic gonadotrophin and vasoactive intestinal peptide in primary cultured human granulosa–lutein cells. Furger C, et al. **Mol Hum Reprod** 1996 Apr;2(4):251–7

Enhanced angiotensin receptor type 1 mRNA degradation and induction of polyribosomal mRNA binding proteins by angiotensin II in vascular smooth muscle cells. Nickenig G, et al. **Mol Pharmacol** 1996 Oct;50(4):743–51

Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations. Perlman S, et al. **Mol Pharmacol** 1997 Feb; 51(2):301–11

ATP release by angiotensin II from segments and cultured smooth muscle cells of guinea–pig taenia coli. Katsuragi T, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Dec; 354(6):796–9

Pharmacological differentiation of synergistic contribution of L–type Ca2+ channels and Na+/H+ exchange to the positive inotropic effect of phenylephrine, endothelin–3 and angiotensin II in rabbit ventricular myocardium. Talukder MA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jan;355(1):87–96

Effects of angiotensin I and angiotensin II in blood vessels: greater influence of converting enzyme activity in the rabbit basilar artery. Zerrouk A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Oct; 354(4):466–73

Angiotensin II requires PDGF–BB to induce DNA synthesis in rat mesangial cells cultured in an exogenous insulin–free medium. Higueruelo S, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):694–700

Urinary albumin excretion rate during angiotensin II infusion in microalbuminuric patients with insulin and non–insulin–dependent diabetes mellitus. Spooren PF, et al. **Nephrol Dial Transplant** 1997 Feb;12(2):281–5

Modulation by angiotensin II of endothelial cell control of DNA synthesis in human mesangial cells. Essig M, et al. **Nephron** 1997;75(3):303–9

Cyclosporin–A– and angiotensin–II–induced vasoreactivity in isolated glomeruli and cultured mesangial cells, 4 and 24 h after renal mass reduction: role of vasodilatory prostaglandins. Forpomès O, et al. **Nephron** 1997; 76(3):337–44

Effect of sympathoadrenal blockade on the hyperglycemic action of angiotensin II. Mihessen–Neto I, et al. **Neuropeptides** 1996 Jun;30(3):303–8

Influence of nitric oxide on hypoglycemia—or angiotensin II–stimulated ACTH and GH secretion in normal men. Volpi R, et al. **Neuropeptides** 1996 Dec;30(6):528–32

Modulation of cerebral calcium homeostasis in rats by angiotensin II in vivo. Das N, et al. **Neurosci Lett** 1997 Feb 28;223(3):149–52

Angiotensin II as a stimulator of Na(+)–dependent Ca2+ efflux from freshly isolated adult rat cardiomyocytes. Fukuta Y, et al. **Neurosci Lett** 1996 Aug 2;213(2):95–8

Angiotensin II–induced inhibition and facilitation of calcium current subtypes in rat retinal ganglion cells. Guenther E, et al. **Neurosci Lett** 1997 Aug 8;231(2):71–4

Anti–apoptotic action of angiotensin fragments to neuronal cells from angiotensinogen knock–out mice. Kakinuma Y, et al. **Neurosci Lett** 1997 Sep 5;232(3):167–70

A novel action of angiotensin peptides in inhibiting neurite outgrowth from isolated chick sympathetic neurons in culture. Reed G, et al. **Neurosci Lett** 1996 Jun 7; 210(3):209–12

Electrophysiological properties of paraventricular magnocellular neurons in rat brain slices: modulation of IA by angiotensin II. Li Z, et al. **Neuroscience** 1996 Mar; 71(1):133–45

Angiotensin II interacts with nitric oxide–cyclic GMP pathway in the central control of drinking behaviour: mapping with c–fos and NADPH–diaphorase. Zhu B, et al. **Neuroscience** 1997 Jul;79(2):543–53

Angiotensin II blockade of long–term potentiation at the perforant path—granule cell synapse in vitro. Armstrong DL, et al. **Peptides** 1996;17(4):689–93

Interactions between angiotensin II and delta opioid receptor subtype agonists upon water intake in rats. Yu WZ, et al. **Peptides** 1997;18(2):241–5

The role of angiotensin II in the feedback control of renin gene expression. Shricker K, et al. **Pflugers Arch** 1997 Jun; 434(2):166–72

Losartan influences behavioural effects of angiotensin II in rats. Kulakowska A, et al. **Pharmacol Res** 1996 Sep–Oct; 34(3–4):109–15

Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17 beta–estradiol in human internal mammary arteries in vitro. Mügge A, et al. **Pharmacology** 1997 Mar;54(3):162–8

Ventromedial hypothalamus lesions increase the dipsogenic responses and reduce the pressor responses to median preoptic area activation. Bastos R, et al. **Physiol Behav** 1997 Aug;62(2):311–6

The dipsogen angiotensin II does not stimulate ethanol intake in mice. Blair–West JR, et al. **Physiol Behav** 1996 Aug; 60(2):481–7

Centrally mediated vasodilation of the rat's tail by angiotensin II. Fregly MJ, et al. **Physiol Behav** 1996 Sep;60(3):861–5

Comparison of changes in blood pressure and dipsogenic responsiveness to angiotensin II in male and female rats chronically exposed to cold. Sun Z, et al. **Physiol Behav** 1996 Dec;60(6):1543–9

Dependence of agonist activation on a conserved apolar residue in the third intracellular loop of the AT1 angiotensin receptor. Hunyady L, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10040–5

Protein kinase C mediates angiotensin II–induced contractions and the release of endothelin and prostacyclin in rat aortic rings. Oriji GK, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Aug; 57(2):135–41

Neurotensin attenuates the reduction in alcohol drinking produced by angiotensin II. Grupp LA, et al. **Psychopharmacology (Berl)** 1996 May;125(1):57–64

Effect of modulators of tyrosine kinase activity on agonist–induced contraction in the rat pulmonary vascular smooth muscle. Savineau JP, et al. **Pulm Pharmacol** 1996 Jun;9(3):189–95

Excitatory action of angiotensins II and IV on hippocampal neuronal activity in urethane anesthetized rats. Albrecht D, et al. **Regul Pept** 1997 Jun 18;70(2–3):105–9

Brain oxytocin receptor antagonism disinhibits sodium appetite in preweanling rats. Chow SY, et al. **Regul Pept** 1997 Jan 29;68(2):119–24

Whole cell patch recordings from forebrain slices demonstrate angiotensin II inhibits potassium currents in subfornical organ neurons. Ferguson AV, et al. **Regul Pept** 1996 Oct 8;66(1–2):55–8

Responses to systemic angiotensin II in lactating and non–lactating goats. Hossaini–Hilali J, et al. **Regul Pept** 1996 Oct 8;66(1–2):123–6

Angiotensin II– and IV–induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Kramár EA, et al. **Regul Pept** 1997 Jan 29;68(2):131–8

Angiotensin II receptor subtype antagonists can both stimulate and inhibit salt appetite in rats. Liénard F, et al. **Regul Pept** 1996 Oct 8;66(1–2):87–94

Angiotensin II and glutamate influence area postrema neurons in rat brain slices. Sun K, et al. **Regul Pept** 1996 Jul 5;63(2–3):91–8

Angiotensin II stimulates sperm motility. Vinson GP, et al. **Regul Pept** 1996 Dec 3;67(2):131–5

Behavioural activity of angiotensin II (3–7)4Phe—analogue of natural fragment 3–7 of angiotensin II. Holy Z, et al. **Rocz Akad Med Bialymst** 1996;41(2):191–201

Regulation of primary response and specific genes in adrenal cells by peptide hormones and growth factors. Penhoat A, et al. **Steroids** 1996 Apr;61(4):176–83

Angiotensin II increases plasminogen activator inhibitor–1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Nishimura H, et al. **Thromb Haemost** 1997 Jun; 77(6):1189–95

The effects of high glucose concentration on angiotensin II– or transforming growth factor–beta–induced DNA synthesis, hypertrophy and collagen synthesis in cultured rat mesangial cells. Choi KH, et al. **Yonsei Med J** 1996 Oct;37(5):302–11

[Contribution of the vascular interstitial matrix to induced contraction by angiotensin II. In vitro studies on the rabbit aorta, mesenteric artery and vein] Plante GE, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89(8):997–1001 (Eng. Abstr.) **(Fre)**

[Hormone–mediated calcium responses of rat and human hepatocytes. Study of multicellular systems by videomicroscopy] Tordjmann T, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):980–90 (24 ref.) (Eng. Abstr.) **(Fre)**

[Role of nitric oxide in the modulation of the vascular response to angiotensin II in hypertensive rats] Sánchez Mendoza A, et al. **Arch Inst Cardiol Mex** 1996 Jul–Aug; 66(4):306–12 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

The integrated effects of angiotensin II. Cody RJ. **Am J Cardiol** 1997 Mar 6;79(5A):9–11 (22 ref.)

Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose–fed rats. Iyer SN, et al. **Am J Hypertens** 1996 Jul;9(7):662–8

Respective role of humoral factors and blood pressure in aortic remodeling of DOCA hypertensive rats [see comments] Karam H, et al. **Am J Hypertens** 1996 Oct;9(10 Pt 1):991–8. Comment in: Am J Hypertens 1997 Jul;10(7 Pt 1):825–7.

The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Wolf G, et al. **Am J Kidney Dis** 1997 Jan;29(1):153–63 (126 ref.)

Role of endogenous angiotensin II on sympathetic reflexes in conscious rabbits. Bendle RD, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1816–25

Exaggerated tubuloglomerular feedback activity in genetic hypertension is mediated by ANG II and AT1 receptors. Brännström K, et al. **Am J Physiol** 1996 May;270(5 Pt 2):F749–55

Endogenous angiotensin II inhibits natriuresis after acute volume expansion in the neonatal rat. Chevalier RL, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):R393–7

ANGIOTENSIN II

Effect of endogenous angiotensin II on renal nerve activity and its arterial baroreflex regulation. DiBona GF, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):R361–7

Sympathoexcitatory and pressor responses to increased brain sodium and ouabain are mediated via brain ANG II. Huang BS, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H275–80

ANG II–dependent HCO3– reabsorption in surviving rat distal tubules: expression/activation of H(+)–ATPase. Levine DZ, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):F799–808

In the Lyon hypertensive rat, renal function alterations are angiotensin II dependent. Liu KL, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):R346–51

Evidence that centrally released arginine vasopressin is involved in central pressor action of angiotensin II. Loń S, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H167–73

Angiotensin II stimulates T–type Ca2+ channel currents via activation of a G protein, Gi. Lu HK, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1340–9

Brain angiotensinergic pathways mediate renal nerve inhibition by central hypertonic NaCl in conscious sheep. May CN, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R593–600

Role of ANG II in hypertension produced by chronic inhibition of nitric oxide synthase in conscious rats. Melaragno MG, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H806–11

Angiotensin II and bladder obstruction in the rat: influence on hypertrophic growth and contractility. Persson K, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1186–92

Pressure–independent effects of AT1–receptor antagonism on cardiovascular remodeling in aortic–banded rats. Regan CP, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2131–8

Brain angiotensin II tonically modulates sympathetic baroreflex in rabbit ventrolateral medulla. Saigusa T, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1015–21

Role of endogenous ANG II and AT1 receptors in regulating arterial baroreflex responses in newborn lambs. Segar JL, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1862–73

Role of brain angiotensin II in thirst and sodium appetite of sheep. Weisinger RS, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R187–96

AT1 receptor blockade and the sympathoadrenal response to insulin–induced hypoglycemia in humans. Worck RH, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):E415–21

Role of central angiotensin II in interleukin–1–induced fever in rats. Watanabe T, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:314–5

Radial artery has higher receptor–mediated contractility but similar endothelial function compared with mammary artery. He GW, et al. **Ann Thorac Surg** 1997 May; 63(5):1346–52

Biological functions of angiotensin and its receptors. Matsusaka T, et al. **Annu Rev Physiol** 1997;59:395–412 (99 ref.)

No evidence for involvement of angiotensin II in spatial learning in water maze in rats. Chalas A, et al. **Behav Brain Res** 1996 Nov;81(1–2):199–205

Role of intracellular calcium in the angiotensin II–mediated tyrosine phosphorylation and dephosphorylation of PLC–gamma 1. Harp JB, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):540–4

Role of endogenous angiotensin II in renal hemodynamic and excretory responses to L–arginine infusion. Urabe K, et al. **Biol Pharm Bull** 1996 Sep;19(9):1149–53

Involvement of angiotensin II in the process of gonadotropin–induced ovulation in rabbits. Kuji N, et al. **Biol Reprod** 1996 Nov;55(5):984–91

The neuronal role of angiotensin II in thirst, sodium appetite, cognition and memory. Mosimann R, et al. **Biol Rev Camb Philos Soc** 1996 Nov;71(4):545–59 (117 ref.)

Paracrine/autocrine regulation of anion secretion in the epididymis: role of angiotensin II. Chan HC, et al. **Biol Signals** 1996 Nov–Dec;5(6):309–16 (34 ref.)

The potential role of nitric oxide in angiotensin II–receptor blockade. Cachofeiro V, et al. **Blood Press Suppl** 1996; 2:29–35 (49 ref.)

Distribution and signal transduction of angiotensin II AT1 and AT2 receptors. Capponi AM. **Blood Press Suppl** 1996; 2:41–6 (55 ref.)

Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Chung O, et al. **Blood Press Suppl** 1996; 2:47–52 (48 ref.)

Angiotensin II receptors and renal hemodynamics and function. Ichikawa I. **Blood Press Suppl** 1996;2:19–21 (7 ref.)

Regulation of vascular smooth–muscle cell growth by angiotensin II. Pratt RE. **Blood Press Suppl** 1996;2:6–9 (31 ref.)

The diversified pharmacology of angiotensin II–receptor blockade. Timmermans PB, et al. **Blood Press Suppl** 1996; 2:53–61 (112 ref.)

Interactions between acute effect of angiotensin converting enzyme inhibition and salt balance on the renal function and urinary prostanoids. Studies in healthy women. Agnoli GC, et al. **Boll Soc Ital Biol Sper** 1996 Mar–Apr; 72(3–4):117–24

Temporal differences between the involvement of angiotensin II and endothelin in the cardiovascular responses to endotoxaemia in conscious rats. Gardiner SM, et al. **Br J Pharmacol** 1996 Dec;119(8):1619–27

Effects of captopril, losartan, and nifedipine on cell hypertrophy of cultured vascular smooth muscle from hypertensive Ren–2 transgenic rats. Peiró C, et al. **Br J Pharmacol** 1997 Aug;121(7):1438–44

Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung. Zhao L, et al. **Br J Pharmacol** 1996 Nov;119(6):1217–22

Role of the alpha 1–, and alpha 2– and beta–adrenoceptors of the median preoptic area on the water intake, renal excretion, and arterial pressure induced by ANG II. da Silva RK, et al. **Brain Res** 1996 Apr 22;717(1–2):38–43

Two–fold effect of Angiotensin II on voltage–dependent calcium currents in rat retinal ganglion cells. Guenther E, et al. **Brain Res** 1996 Apr 29;718(1–2):112–6

Blood pressure control by the renin–angiotensin system and its interaction with the sympathetic nervous system in fish. Platzack B. **Braz J Med Biol Res** 1995 Nov–Dec; 28(11–12):1227–31 (31 ref.)

Pathologic consequences of increased angiotensin II activity. Ferrario CM, et al. **Cardiovasc Drugs Ther** 1996 Nov; 10(5):511–8 (100 ref.)

Role of intracardiac angiotensin II in cardiac dysfunction of rat during septic shock. Ji Y, et al. **Chin Med J (Engl)** 1996 Nov;109(11):864–7

Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Berk BC, et al. **Circ Res** 1997 May; 80(5):607–16 (19 ref.)

Oxidative stress produced by angiotensin too. Implications for hypertension and vascular injury [editorial; comment] Oskarsson HJ, et al. **Circulation** 1997 Feb 4;95(3):557–9. Comment on: Circulation 1997 Feb 4;95(3):588–93.

Intracoronary angiotensin II potentiates coronary sympathetic vasoconstriction in humans. Saino A, et al. **Circulation** 1997 Jul 1;96(1):148–53

Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Schmieder RE, et al. **Circulation** 1996 Sep 15;94(6):1304–9

Angiotensin–II–receptors: new targets for antihypertensive therapy. Oliverio MI, et al. **Clin Cardiol** 1997 Jan;20(1):3–6 (19 ref.)

Effect of central endogenous angiotensin II on sympathetic activation induced by hypoxia. Gaudet EA, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):913–23

Role of angiotensin II in reflex tachycardia during hypotension caused by a calcium channel blocker. Sato K, et al. **Clin Exp Hypertens** 1996 Jul;18(5):607–24

Cardiac hypertrophy in diabetic spontaneously hypertensive rats: role of angiotensin II? Black MJ, et al. **Clin Exp Pharmacol Physiol** 1997 Jun;24(6):445–8

Interactions between angiotensin II and the sympathetic nervous system in the the long–term control of arterial pressure. Brooks VL. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):83–90 (86 ref.)

Actions of angiotensin in the subfornical organ and area postrema: implications for long term control of autonomic output. Ferguson AV, et al. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):96–101 (46 ref.)

Long–term sympatho–excitatory effect of angiotensin II: a mechanism of spontaneous and renovascular hypertension. Fink GD. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):91–5 (35 ref.)

Brain angiotensin and circulatory control. Muratani H, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul; 23(6–7):458–64 (74 ref.)

Postrenal transplant erythrosis: a direct role for angiotensin II [letter] Ducloux D, et al. **Clin Nephrol** 1997 Apr; 47(4):277–8

Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Ardaillou R. **Curr Opin Nephrol Hypertens** 1997 Jan;6(1):28–34 (73 ref.)

Angiotensin II mediates mechanical stress–induced cardiac hypertrophy. Yamazaki T, et al. **Diabetes Res Clin Pract** 1996 Feb;30 Suppl:107–11

Cigarette smoke increases gastric ulcer size in part by an angiotensin II–mediated mechanism in rats. Seno K, et al. **Dig Dis Sci** 1997 Jan;42(1):74–8

Extrarenal aspects of angiotensin II function. Csikós T, et al. **Eur J Endocrinol** 1997 Apr;136(4):349–58 (94 ref.)

Renal vasoconstrictor response to 5–hydroxytryptamine in the in situ autoperfused rat kidney: involvement of angiotensin II and the 5–HT2 receptor activation. Morán A, et al. **Eur J Pharmacol** 1997 Jul 9;330(2–3):205–11

p53 Induces myocyte apoptosis via the activation of the renin–angiotensin system. Pierzchalski P, et al. **Exp Cell Res** 1997 Jul 10;234(1):57–65

The renin–angiotensin–aldosterone system and cardiac ischaemia. Ikram H. **Heart** 1996 Nov;76(3 Suppl 3):60–7 (99 ref.)

The effect of angiotensin II receptor antagonists on diethylstilbestrol–induced vascular changes in the rat anterior pituitary gland: a quantitative evaluation. Pawllkowski M, et al. **Histol Histopathol** 1996 Oct; 11(4):909–13

Dual role of angiotensin II in the human endometrium. Li XF, et al. **Hum Reprod** 1996 Oct;11 Suppl 2:95–108 (74 ref.)

Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Alonso–Galicia M, et al. **Hypertension** 1996 Dec;28(6):1047–54

Role of angiotensin–(1–7) in the modulation of the baroreflex in renovascular hypertensive rats. Britto RR, et al. **Hypertension** 1997 Sep;30(3 Pt 2):549–56

Angiotensin II induction of osteopontin expression and DNA replication in rat arteries. deBlois D, et al. **Hypertension** 1996 Dec;28(6):1055–63

Possible participation of nitric oxide in the increase of norepinephrine release caused by angiotensin peptides in rat atria. Gironacci MM, et al. **Hypertension** 1997 Jun; 29(6):1344–50

Angiotensin II signaling in vascular smooth muscle. New concepts. Griendling KK, et al. **Hypertension** 1997 Jan;29(1 Pt 2):366–73

Heme oxygenase–1 is regulated by angiotensin II in rat vascular smooth muscle cells. Ishizaka N, et al. **Hypertension** 1997 Mar;29(3):790–5

Angiotensin II in the evolution of experimental heart failure. Luchner A, et al. **Hypertension** 1996 Sep;28(3):472–7

Angiotensin II blockade [corrected] enhances baroreflex control of sympathetic outflow in heart failure [published erratum appears in Hypertension 1997 May;29(5):1211] Murakami H, et al. **Hypertension** 1997 Feb;29(2):564–9

Role for endothelin–1 in angiotensin II–mediated hypertension. Rajagopalan S, et al. **Hypertension** 1997 Jul; 30(1 Pt 1):29–34

Angiotensin II regulates vascular smooth muscle cell pH, contraction, and growth via tyrosine kinase–dependent signaling pathways. Touyz RM, et al. **Hypertension** 1997 Aug;30(2 Pt 1):222–9

Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Tsuzuki S, et al. **Hypertension** 1996 Nov;28(5):916–8

Nerve–mediated antidiuresis and antinatriuresis after air–jet stress is modulated by angiotensin II. Veelken R, et al. **Hypertension** 1996 Nov;28(5):825–32

Thromboxane A2 does not mediate angiotensin II–dependent nonischemic peripheral vasoconstriction in healthy men: a pilot study. Gasic S, et al. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):56–60

Angiotensin in progressive renal diseases: theory and practice [editorial] Matsusaka T, et al. **J Am Soc Nephrol** 1996 Oct; 7(10):2025–43 (245 ref.)

Altered signal transduction system in hypertrophied myocardium: angiotensin II stimulates collagen synthesis in hypertrophied hearts. Kawaguchi H, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S13–9

Angiotensin II regulation of neuromodulation: downstream signaling mechanism from activation of mitogen–activated protein kinase. Lu D, et al. **J Cell Biol** 1996 Dec;135(6 Pt 1):1609–17

Angiotensin II–induced fluid phase endocytosis in human cerebromicrovascular endothelial cells is regulated by the inositol–phosphate signaling pathway. Stanimirovic D, et al. **J Cell Physiol** 1996 Dec;169(3):455–67

Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)–induced DNA synthesis and collagen gel contraction. Ashizawa N, et al. **J Clin Invest** 1996 Nov 15;98(10):2218–27

Angiotensin–independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. Okubo S, et al. **J Clin Invest** 1997 Mar 1; 99(5):855–60

Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels. Endlich K, et al. **J Hypertens** 1997 Jun;15(6):633–41

Characterization of angiotensin II–regulated K+ conductance in rat adrenal glomerulosa cells. Lotshaw DP. **J Membr Biol** 1997 Apr 1;156(3):261–77

AT1 receptor gene regulation in cardiac myocytes and fibroblasts. Everett AD, et al. **J Mol Cell Cardiol** 1996 Aug;28(8):1727–36

A–type K+ current in neurons cultured from neonatal rat hypothalamus and brain stem: modulation by angiotensin II. Wang D, et al. **J Neurophysiol** 1997 Aug;78(2):1021–9

Regulation of neuromodulatory actions of angiotensin II in the brain neurons by the Ras–dependent mitogen–activated protein kinase pathway. Yang H, et al. **J Neurosci** 1996 Jul 1;16(13):4047–58

The role of angiotensin II and prostaglandins in arcade formation in a developing microvascular network. le Noble FA, et al. **J Vasc Res** 1996 Nov–Dec;33(6):480–8

Hormonal regulation of cardiac cystic fibrosis transmembrane conductance regulator chloride channels. Horie M, et al. **Jpn Heart J** 1996 Sep;37(5):661–71 (72 ref.)

Angiotensin II signal transduction in vascular smooth muscle cells: role of tyrosine kinases. Ishida M, et al. **Keio J Med** 1997 Jun;46(2):61–8 (86 ref.)

Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies. Hilgers KF, et al. **Kidney Blood Press Res** 1996;19(5):254–62 (112 ref.)

Angiotensin II and L–arginine in tissue fibrosis: more than blood pressure. Peters H, et al. **Kidney Int** 1997 May; 51(5):1481–6 (63 ref.)

Involvement of angiotensin II in glomerulosclerosis of stroke–prone spontaneously hypertensive rats. Nakamura T, et al. **Kidney Int Suppl** 1996 Jun;55:S109–12

Role of the renin–angiotensin system on cardiac diseases. De Mello WC. **P R Health Sci J** 1996 Sep;15(3):193–4

Na depletion–induced Na appetite of sheep is independent of brain angiotensin II. Weisinger RS, et al. **Physiol Behav** 1997 Jul;62(1):43–51

Angiotensin mediated interaction of fetal kidney and placenta in the control of fetal arterial pressure and its role in hydrops fetalis. Faber JJ, et al. **Placenta** 1997 May; 18(4):313–26 (43 ref.)

Cross–talk between the insulin and angiotensin signaling

systems. Velloso LA, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12490-5

Interactions of angiotensin II and atrial natriuretic peptide in the brain: fish to rodent. Galli SM, et al. **Proc Soc Exp Biol Med** 1996 Nov;213(2):128-37 (65 ref.)

Angiotensin in thirst and hydromineral balance. Festschrift to honor James T. Fitzsimons, on the occasion of his retirement from the Department of Physiology at Cambridge University. **Regul Pept** 1996 Oct 8; 66(1-2):1-133

Complex activation of inducible transcription factors in the brain of normotensive and spontaneously hypertensive rats following central angiotensin II administration. Lebrun CJ, et al. **Regul Pept** 1996 Oct 8;66(1-2):19-23 (33 ref.)

The role of brain angiotensin in thirst and AVP release induced by hemorrhage. Phillips MI, et al. **Regul Pept** 1996 Oct 8;66(1-2):3-11

Angiotensin-related induction of immediate early genes in rat brain. Rowland NE, et al. **Regul Pept** 1996 Oct 8; 66(1-2):25-9 (35 ref.)

Interaction of vasopressin and angiotensin II in central control of blood pressure and thirst. Szczepańska-Sadowska E. **Regul Pept** 1996 Oct 8; 66(1-2):65-71 (60 ref.)

The role of angiotensin II in ingestive behaviour: a brief review of angiotensin II, thirst and Na appetite. Weisinger RS, et al. **Regul Pept** 1996 Oct 8;66(1-2):73-81 (100 ref.)

[Angiotensin II and the adrenal gland] Ying YR, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):70-2 (10 ref.) **(Chi)**

[Heart failure and circulatory control peptides] Takeshita A. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):138-42 (10 ref.) **(Jpn)**

[Tissue angiotensin II and its impact in the treatment of arterial hypertension] Escobar-Morreale HF, et al. **Med Clin (Barc)** 1997 Jan 25;108(3):105-8 (63 ref.) **(Spa)**

SECRETION

Drug actions in preeclampsia: aspirin, but not magnesium chloride or dihydralazine, differentially inhibits cultured human trophoblast release of thromboxane and prostacyclin without affecting angiotensin II, endothelin-1, or leukotriene B4 secretion. Cervar M, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):66-72

Regulation of bFGF expression and ANG II secretion in cardiac myocytes and microvascular endothelial cells. Fischer TA, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H958-68

Effects of long term stimulation of ACTH and angiotensin II-secretions on the rat adrenal cortex. Mitani F, et al. **Endocr Res** 1996 Nov;22(4):421-31

THERAPEUTIC USE

Effect of angiotensin II on arteriovenous shunting assessed by hepatic arterial perfusion scintigraphy. Inoue Y, et al. **Am J Clin Oncol** 1997 Jun;20(3):237-41

The effects of central and peripheral angiotensin on hypertension and nociception in rats. Irvine RJ, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):37-41

[Induced hypertensive chemotherapy with angiotensin-II for liver metastases from gastric cancer] Iwasaki Y, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1558-60 (Eng. Abstr.) **(Jpn)**

TOXICITY

Effects of nifedipine and TMB-8 on angiotensin II-induced antinatriuresis in anesthetized dogs. Takahara A, et al. **Arch Int Pharmacodyn Ther** 1995 Nov-Dec;330(3):309-18

Low dose angiotensin II infusions into the renal artery induce chronic hypertension in conscious dogs. Fitzgerald SM, et al. **Blood Press** 1997 Jan;6(1):52-61

Functions of angiotensin peptides in the rostral ventrolateral medulla. Dampney RA, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S105-11 (65 ref.)

Physiological actions of angiotensin II mediated by AT1 and AT2 receptors in the brain. McKinley MJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S99-104 (69 ref.)

Angiotensin II-induced pulmonary edema in a rabbit model. Yamamoto T, et al. **Jpn J Pharmacol** 1997 Jan;73(1):33-40

Angiotensin II-stimulated hypertrophy of LLC-PK1 cells depends on the induction of the cyclin-dependent kinase inhibitor p27Kip1. Wolf G, et al. **Kidney Int** 1996 Dec; 50(6):2112-9

ANGIOTENSIN III

DIAGNOSTIC USE

Aldosterone changes during angiotensin III and potassium infusions in patients with primary aldosteronism [letter; comment] Plouin PF, et al. **Clin Endocrinol (Oxf)** 1996 Aug; 45(2):243-4. Comment on: Clin Endocrinol (Oxf) 1995 Feb;42(2):111-9.

[Clinical studies with angiotensin II and angiotensin III] Yamamoto K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:333-6 (11 ref.) **(Jpn)**

METABOLISM

Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Zini S, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11968-73

PHARMACOLOGY

Direct positive chronotropic effects of angiotensin II and angiotensin III in pithed rats and in rat isolated atria. Li Q, et al. **Br J Pharmacol** 1996 Aug;118(7):1653-8

Actions of D-amino acid-substituted analogues of des-Asp-angiotensin I on the central pressor action of angiotensin III. Radhakrishnan R, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):337-9

Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein. Li Q, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):451-6

Participation of AT1 and AT2 receptors in the differential interaction between angiotensin II or III and alpha-2 adrenoceptors in the nucleus reticularis gigantocellularis in cardiovascular regulation and antinociception in rats. Yang CH, et al. **J Pharmacol Exp Ther** 1996 Nov; 279(2):795-802

Functional characterization of caudal hypoglossal neurons by spectral patterns of neuronal discharges in the rat. Yang CC, et al. **Neuroscience** 1997 Apr;77(3):813-27

Angiotensin III and IV activation of the brain AT1 receptor subtype in cardiovascular function. Wright JW, et al. **Peptides** 1996;17(8):1365-71

TOXICITY

Functions of angiotensin peptides in the rostral ventrolateral medulla. Dampney RA, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S105-11 (65 ref.)

ANGIOTENSIN BINDING SITES see **RECEPTORS, ANGIOTENSIN**

ANGIOTENSIN CONVERTING ENZYME see **PEPTIDYL-DIPEPTIDASE A**

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Angiotensin AT1 Receptors: From Molecular Physiology to Therapeutics. Proceedings of a symposium. Melbourne, Australia, December 1995. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S57-154

Once-daily monotherapy with trandolapril in the treatment of hypertension. Smith DH, et al. **J Hum Hypertens** 1996 Feb;10(2):129-34

Angiotensin converting enzyme inhibitors: basics (Part I). Mallat SG, et al. **J Med Liban** 1995;43(4):208-20 (181 ref.)

Lisinopril use in a large military medical center. Wirebaugh SR, et al. **Mil Med** 1997 Feb;162(2):113-7

Haematopoietic effects of ACE inhibitors and local bone marrow renin-angiotensin system: An hypothesis [letter; comment] Haznedaroğlu IC. **Nephrol Dial Transplant** 1996 Nov;11(11):2373. Comment on: Nephrol Dial Transplant 1996 Apr;11(4):749-751.

Cloning and sequence analysis of a Bothrops jararaca cDNA encoding a precursor of seven bradykinin-potentiating peptides and a C-type natriuretic peptide. Murayama N, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1189-93

[Trends--ACE inhibition improves coronary dysfunction. Symposium within the scope of the American Heart Association Congress, Anaheim, November 1995] Müller-Lissner S. **Internist (Berl)** 1996 Mar;37(3):328-9 **(Ger)**

ADMINISTRATION & DOSAGE

Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS). Pitt B, et al. **Am J Cardiol** 1996 Nov 15;78(10):1129-31

Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure: the Veratran Study. **Am J Hypertens** 1997 May;10(5 Pt 1):492-9

The effects of isradipine and spirapril as monotherapy and combined therapy on blood pressure, renal hemodynamics, natriuresis, and urinary kallikrein in hypertensive nephropathy. Maccariello ER, et al. **Am J Hypertens** 1997 May;10(5 Pt 1):541-5

Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Pool JL, et al. **Am J Hypertens** 1997 Jan;10(1):117-23

A case of renin-producing juxtaglomerular tumor: effect of ACE inhibitor or angiotensin II receptor antagonist. Kashiwabara H, et al. **Blood Press** 1997 May;6(3):147-53

Noncontinuous use of angiotensin converting enzyme inhibitors in the treatment of experimental bone marrow transplant nephropathy. Moulder JE, et al. **Bone Marrow Transplant** 1997 Apr;19(7):729-35

Fixed dose combinations of ACE inhibitors. Rangoonwala B, et al. **Br J Clin Pract** 1996 Dec;50(8):454-65 (70 ref.)

Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats. Mervaala EM, et al. **Br J Pharmacol** 1997 Jun;121(3):503-10

Is a combination of verapamil and an ACE-inhibitor the optimal solution in ischaemic heart failure? Jespersen CM. **Cardiologia** 1995 Dec;40(12 Suppl 1):307-10

Effects of enalapril on the exercise capacity and neurohumoral factors during exercise in patients with chronic heart failure. Ogino K, et al. **Cardiology** 1997 Jan-Feb;88(1):6-13

Moexipril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension. Stimpel M, et al. **Cardiology** 1996 Jul-Aug;87(4):313-8

Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Pfeffer MA, et al. **Circulation** 1997 Jun 17;95(12):2643-51

Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Vaughan DE, et al. **Circulation** 1997 Jul 15; 96(2):442-7

Reverse remodeling in heart failure with intensification of vasodilator therapy. Levine TB, et al. **Clin Cardiol** 1997 Aug;20(8):697-702

Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects. Azizi M, et al. **Clin Exp Hypertens** 1997 Jul-Aug;19(5-6):937-51

Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Wagstaff AJ, et al. **Drugs** 1996 May;51(5):777-91 (75 ref.)

Optimal dosage of ACE inhibitors in older patients. Tomlinson B. **Drugs Aging** 1996 Oct;9(4):262-73 (105 ref.)

Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure. Pacher R, et al. **Eur Heart J** 1996 Aug;17(8):1223-32

Assessing the clinical need for short-term conversion from oral to parenteral angiotensin converting enzyme inhibitor therapy in hypertensive patients. A quinapril to quinaprilat placebo-controlled model. Whelton A, et al. **Eur Heart J** 1997 Jan;18(1):140-7

Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Pinto YM, et al. **Eur J Clin Pharmacol** 1996; 50(4):265-8

Trandolapril plus verapamil inhibits the coronary vasospasm induced by hypoxia following ischemia-reperfusion injury in dogs. Lee JJ, et al. **Gen Pharmacol** 1996 Sep;27(6):1057-9

A paradoxical increase in circulating ACE (angiotensin converting enzyme) activity after long-term administration of alacepril (ACE inhibitor). Nishida S, et al. **Horm Metab Res** 1997 Mar;29(3):153-4

Induction of cardiac angiotensinogen mRNA and angiotensin converting enzyme (ACE) activity in isoproterenol-induced heart injury. Ogiku N, et al. **Hypertens Res** 1996 Sep;19(3):179-87

Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene. Wegner M, et al. **Hypertens Res** 1996 Sep;19(3):151-9

Potentiation of the biological efficacy of bradykinin by ACE inhibitors: a shift in the affinity of the B2 receptor? Hecker M, et al. **Immunopharmacology** 1996 Jun;33(1-3):93-4

Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients. Fillastre JP, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):269-74

Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. O'Driscoll G, et al. **J Clin Invest** 1997 Aug 1; 100(3):678-84

A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide. Chrysant SG, et al. **J Clin Pharmacol** 1996 Aug;36(8):701-6

Effects of fosinopril on the blood pressure and lipid profile of patients undergoing heart transplantation. Almenar L, et al. **J Heart Lung Transplant** 1997 Apr;16(4):454-9

Disparate effects of ACE-inhibitors and calcium antagonists on left ventricular structure and function in essential hypertension. Aepfelbacher FC, et al. **J Hum Hypertens** 1997 May;11(5):321-5

Antihypertensive treatment with moexipril plus HCTZ vs metoprolol plus HCTZ in patients with mild-to-moderate hypertension. Stimpel M, et al. **J Hum Hypertens** 1997 Feb; 11(2):133-7

Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. Küppers HE, et al. **J Hypertens** 1997 Jan;15(1):93-7

Fixed-dose combination of perindopril with indapamide in spontaneously hypertensive rats: haemodynamic, biological and structural effects. Richard V, et al. **J Hypertens** 1996 Dec;14(12):1447-54

Duration of inhibition of local microvascular ACE in spontaneously hypertensive rats. Vicaut E, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1758-63

Fixed low-dose combination of an angiotensin converting enzyme inhibitor and a calcium channel blocker drug in the treatment of essential hypertension. de Leeuw PW, et al. **J Hypertens Suppl** 1997 Mar;15(2):S39-42 (20 ref.)

Individual assessment of antihypertensive response by self-starting cumulative sums. Cornélissen G, et al. **J Med Eng Technol** 1997 May-Aug;21(3-4):111-20

Early treatment with low-dose enalapril after acute myocardial infarction: an equilibrium radionuclide angiographic study. Enalapril despues del Infarto (EDI) Trial Investigators. Bazzino O, et al. **J Nucl Cardiol** 1997

Mar-Apr;4(2 Pt 1):133-9
The effect of ACE inhibitors on atheroma formation is potentiated by association with a calcium channel blocker. A biochemical and ultrastructural study. Raicu M, et al. **J Submicrosc Cytol Pathol** 1997 Jul;29(3):317-28
Recovery of iodine-123 metaiodobenzylguanidine uptake associated with left ventricular functional recovery in a patient with dilated cardiomyopathy. Endomyocardial histological findings before and after the improvement of uptake. Ueda T, et al. **Jpn Heart J** 1997 Jan;38(1):145-50
A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation. Beckingham IJ, et al. **Nephrol Dial Transplant** 1995 Dec; 10(12):2316-20
Age-related decline in thirst and sodium appetite in rats related to kininase II inhibition. Rowland NE, et al. **Regul Pept** 1996 Oct 22;66(3):163-7
Protection from the nephrotoxicity of contrast dye. Louis BM, et al. **Ren Fail** 1996 Jul;18(4):639-46
Treatment of kidney transplants with chronic rejection using angiotensin-converting enzyme inhibitors. Paredes D, et al. **Transplant Proc** 1997 Sep;29(6):2587-8
Effects of atenolol as add-on therapy to fosinopril in heart failure. Pacher R, et al. **Wien Klin Wochenschr** 1997 Apr 11;109(7):232-8
[The effects of cardioplegia and reperfusional blood containing captopril on myocardial ultrastructure alterations after cardiac arrest] Guo X, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Oct;76(10):733-7 (Eng. Abstr.) **(Chi)**
[Dosage of ACE inhibitors in heart failure (letter; comment)] Jerie P. **Vnitr Lek** 1996 Nov;42(11):802-4. Comment on: Vnitr Lek 1996 Apr;42(4):290-6. **(Cze)**
[Angiotensin-converting enzyme inhibitor in the treatment of epirubicin-induced dilated cardiomyopathy] Jensen BV, et al. **Ugeskr Laeger** 1997 Mar 24;159(13):1945-9 (Eng. Abstr.) **(Dan)**
[ACE inhibitors and the kidney] Hörl WH. **Wien Med Wochenschr** 1996;146(16):450-3 (32 ref.) (Eng. Abstr.) **(Ger)**
[Hemodynamic and humoral effects of parenteral therapy with intravenously administered ACE inhibitor quinaprilat in patients with advanced heart failure] Mitrovic V, et al. **Z Kardiol** 1996 Nov;85(11):828-38 (Eng. Abstr.) **(Ger)**
[Early treatment of acute myocardial infarct: implementation of therapy guidelines in routine clinical practice, MITRA pilot phase] Schuster S, et al. **Z Kardiol** 1997 Apr; 86(4):273-83 (Eng. Abstr.) **(Ger)**
[Changes in venous tonus in rats with heart failure during acute and chronic perindopril administration] Moleva EB, et al. **Eksp Klin Farmakol** 1996 Jul-Aug;59(4):15-7 (Eng. Abstr.) **(Rus)**
[Administration of captopril (aceten++, ++"Vokhardt"++) in hypertension and congestive heart failure] Balakhonova NP, et al. **Klin Med (Mosk)** 1997; 75(1):42-3 **(Rus)**

ADVERSE EFFECTS

Angioedema of ACE inhibitors. Ebo DG, et al. **Allergy** 1997 Mar;52(3):354-5
Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers. Schiller PI, et al. **Allergy** 1997 Apr;52(4):432-5
Enalapril-associated acute pancreatitis: recurrence after rechallenge. Maringhini A, et al. **Am J Gastroenterol** 1997 Jan;92(1):166-7
Cancer risk with calcium-channel-blocker use examined [news] **Am J Health Syst Pharm** 1996 Sep 1;53(17):1999
Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? Cruz DN, et al. **Am J Kidney Dis** 1996 Oct; 28(4):535-40
Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors. Gunkel AR, et al. **Am J Otolaryngol** 1996 Mar-Apr;17(2):87-91
Exacerbation of respiratory symptoms in patients with panic disorder [letter] Bouwer CD, et al. **Am J Psychiatry** 1997 May;154(5):712-3
Angioedema associated with angiotensin-converting enzyme inhibitors [letter] Eberhart G, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):80
Hyperkalemia and trimethoprim-sulfamethoxazole [letter; comment] [published erratum appears in Ann Intern Med 1996 Dec 15;125(12):1015] Thomas RJ. **Ann Intern Med** 1996 Nov 1;125(9):778; discussion 779-80. Comment on: Ann Intern Med 1996 Feb 1;124(3):316-20.
Increased serum lithium concentration secondary to treatment with tiaprofenic acid and fosinopril. Alderman CP, et al. **Ann Pharmacother** 1996 Dec;30(12):1411-3
Cromolyn sodium for ACE inhibitor-induced cough. Allen TL, et al. **Ann Pharmacother** 1997 Jun;31(6):773-5 (31 ref.)
Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors. Dicpinigaitis PV. **Ann Pharmacother** 1996 Nov;30(11):1242-5
LDL apheresis with dextran sulfate and angiotension receptor antagonist (Losartan). Elicio N, et al. **Artif Organs** 1997 Apr;21(4):334-5
Hypertension medication and periodontosis [letter] Bowell GR. **Aust Dent J** 1997 Apr;42(2):140
Epidemiological study of angioedema and ACE inhibitors. Gabb GM, et al. **Aust N Z J Med** 1996 Dec;26(6):777-82
Ramipril-associated lichen planus pemphigoides. Ogg GS, et al. **Br J Dermatol** 1997 Mar;136(3):412-4
Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Sabroe RA, et al. **Br J Dermatol** 1997 Feb; 136(2):153-8 (65 ref.)
Ramipril-induced superficial pemphigus [letter] Vignes S, et al. **Br J Dermatol** 1996 Oct;135(4):657-8
Is there a role for bradykinin in the therapeutic and side effects of angiotensin-converting enzyme inhibitors? Marceau F. **Can J Cardiol** 1997 Feb;13(2):187-94 (71 ref.)
Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker. Rosenthal J, et al. **Cardiology** 1996 Sep-Oct;87(5):409-14
Potential proischemic effect of early enalapril in hypotension-prone patients with acute myocardial infarction. The CONSENSUS II Holter Substudy Group. Søgaard P, et al. **Cardiology** 1997 May-Jun;88(3):285-91
Brief treatment of SHR with an ace inhibitor fails to cause long-term normotension but markedly increases mortality. Lan L, et al. **Clin Exp Pharmacol Physiol Suppl** 1995; 1:S345-6
Postrenal transplant erythrocytosis, ACE inhibitors and a hypothetical local renin-angiotensin system in the bone marrow [letter; comment] Haznedaroğlu IC. **Clin Nephrol** 1997 Jul;48(1):60. Comment on: Clin Nephrol 1996 Sep;46(3):217.
Race and angioedema [letter; comment] Burkhart GA. **Clin Pharmacol Ther** 1997 Jun;61(6):700. Comment on: Clin Pharmacol Ther 1996 Jul;60(1):8-13.
Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Elliott WJ. **Clin Pharmacol Ther** 1996 Nov; 60(5):582-8
Problem drugs for the patient with asthma. Craig T, et al. **Compr Ther** 1996 Jun;22(6):339-44 (21 ref.)
Life-threatening hyperkalaemia caused by angiotensin-converting enzyme-inhibitor and diuretics [letter] Odawara M, et al. **Diabet Med** 1997 Feb; 14(2):169-70
Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema. Abdelmalek MF, et al. **Dig Dis Sci** 1997 Apr;42(4):847-50 (15 ref.)
Perindopril-induced acute pancreatitis. Gallego-Rojo FJ, et al. **Dig Dis Sci** 1997 Aug;42(8):1789-91 (13 ref.)
A risk-benefit assessment of ACE inhibitor therapy post-myocardial infarction. Borghi C, et al. **Drug Saf** 1996 May;14(5):277-87 (42 ref.)
ACE inhibitors and the kidney. A risk-benefit assessment. Navis G, et al. **Drug Saf** 1996 Sep;15(3):200-11 (110 ref.)
ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management [see comments] Overlack A. **Drug Saf** 1996 Jul;15(1):72-8 (71 ref.). Comment in: Drug Saf 1997 Feb;16(2):150-1.
Pharmacoepidemiology of ACE inhibitor--induced cough [letter; comment] Tomlinson B, et al. **Drug Saf** 1997 Feb; 16(2):150-1. Comment on: Drug Saf 1996 Jul;15(1):72-8.
Late-onset life-threatening angioedema and upper airway obstruction caused by angiotensin-converting enzyme inhibitor: report of a case. Weng PK, et al. **Ear Nose Throat J** 1997 Jun;76(6):404-7
Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Pillans PI, et al. **Eur J Clin Pharmacol** 1996;51(2):123-6 (14 ref.)
Perindopril-associated pneumonitis. Benard A, et al. **Eur Respir J** 1996 Jun;9(6):1314-6 (10 ref.)
Deterioration in renal function with enalapril but not losartan in a patient with renal artery stenosis in a solitary kidney [letter] Missouris CG, et al. **Heart** 1997 Apr;77(4):391-2
Effects of nifedipine and enalapril on cardiac autonomic nervous function during the tilt test in elderly patients with hypertension. Okabayashi J, et al. **Hypertens Res** 1997 Mar; 20(1):1-6
Neonatal angiotensin-converting enzyme inhibition in the rat induces persistent abnormalities in renal function and histology. Guron G, et al. **Hypertension** 1997 Jan;29(1 Pt 1):91-7
Enalapril-induced renal artery thrombosis in unilateral renal artery stenosis. Kothari SS, et al. **Indian Heart J** 1997 Mar-Apr;49(2):192-4
Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Agah R, et al. **Intensive Care Med** 1997 Jul;23(7):793-6
Hypoglycemia associated with the administration of angiotensin-converting enzyme inhibitor in a patient with diabetes mellitus [letter] Sakaguchi H, et al. **Intern Med** 1997 Jan;36(1):77
An adverse reaction to angiotensin-converting enzyme inhibitors in a patient with neglected C1 esterase inhibitor deficiency. Ebo DG, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):425-6
Angioedema after long-term use of an angiotensin-converting enzyme inhibitor. Pavletic AJ. **J Am Board Fam Pract** 1997 Sep-Oct;10(5):370-3
Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. Benz J, et al. **J Clin Pharmacol** 1997 Feb;37(2):101-7
Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. Chan P, et al. **J Clin Pharmacol** 1997 Mar;37(3):253-7
Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction. Finley PR, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):68-71
Cough--a common complication of ACE-inhibitor therapy. Kundu AK. **J Indian Med Assoc** 1997 Mar;95(3):82-3
Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs. Bugge JF. **J Intern Med** 1996 Oct;240(4):249-51
Gd-DOTA tubular transit asymmetry induced by angiotensin-converting enzyme inhibitor in experimental renovascular hypertension. Trillaud H, et al. **J Magn Reson Imaging** 1996 Jan-Feb;6(1):149-55
Congenital renal tubular dysplasia and skull ossification defects similar to teratogenic effects of angiotensin converting enzyme (ACE) inhibitors. Kumar D, et al. **J Med Genet** 1997 Jul;34(7):541-5
From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy--United States, Canada, and Israel, 1987-1995. **JAMA** 1997 Apr 16;277(15):1193-4
Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. Brown NJ, et al. **JAMA** 1997 Jul 16;278(3):232-3
Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Gossmann J, et al. **Kidney Int** 1996 Sep;50(3):973-8
Adverse event with first-dose perindopril in congestive heart failure [letter] [see comments] Bagger JP. **Lancet** 1997 Jun 7;349(9066):1671-2. Comment in: Lancet 1997 Aug 16;350(9076):520; discussion 521-2. Comment in: Lancet 1997 Aug 16;350(9076):520-1; discussion 521-2. Comment in: Lancet 1997 Aug 16;350(9076):521.
Adverse event with first-dose perindopril in congestive heart failure [letter; comment] Cleland JG. **Lancet** 1997 Aug 16; 350(9076):520-1; discussion 521-2. Comment on: Lancet 1997 Jun 7;349(9066):1671-2.
Tackling ACE inhibitor cough [letter] Goldsmith DJ. **Lancet** 1997 Sep 13;350(9080):814
Tackling ACE inhibitor cough [letter] Knox AJ, et al. **Lancet** 1997 Sep 13;350(9080):814
Adverse event with first-dose perindopril in congestive heart failure [letter; comment] Lees KR, et al. **Lancet** 1997 Aug 16;350(9076):520; discussion 521-2. Comment on: Lancet 1997 Jun 7;349(9066):1671-2.
Adverse event with first-dose perindopril in congestive heart failure [letter; comment] MacFadyen RJ. **Lancet** 1997 Aug 16;350(9076):520; discussion 521-2. Comment on: Lancet 1997 Jun 7;349(9066):1671-2.
Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor [see comments] Malini PL, et al. **Lancet** 1997 Jul 5;350(9070):15-8. Comment in: Lancet 1997 Jul 5;350(9070):3-4.
How to stop ACE-inhibitor-induced cough [comment] Robinson TD, et al. **Lancet** 1997 Jul 5;350(9070):3-4. Comment on: Lancet 1997 Jul 5;350(9070):15-8.
Adverse event with first-dose perindopril in congestive heart failure [letter; comment] Tan LB, et al. **Lancet** 1997 Aug 16;350(9076):521. Comment on: Lancet 1997 Jun 7;349(9066):1671-2.
Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors. Umemura K, et al. **Life Sci** 1997;60(18):1583-8
Visceral angioedema related to treatment with an ACE inhibitor. Mullins RJ, et al. **Med J Aust** 1996 Sep 16; 165(6):319-21
Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy--United States, Canada, and Israel, 1987-1995. **MMWR Morb Mortal Wkly Rep** 1997 Mar 21;46(11):240-2
Deaths in the Chicago heat wave [letter; comment] Cervantes J. **N Engl J Med** 1996 Dec 12;335(24):1848; discussion 1848-9. Comment on: N Engl J Med 1996 Jul 11;335(2):84-90.
Angiodema of the intestine [letter] Gabb GM. **N Engl J Med** 1996 Nov 14;335(20):1534-5; discussion 1535
Angioedema of the intestine [letter] Marinella MA. **N Engl J Med** 1996 Nov 14;335(20):1535
Angioedema of the intestine [letter] Pavletic A. **N Engl J Med** 1996 Nov 14;335(20):1534; discussion 1535
Angioedema of the intestine [letter] Smith DC. **N Engl J Med** 1996 Nov 14;335(20):1535
Acute renal failure following ACE inhibition in a patient with coarctation of the aorta. Sever MS, et al. **Nephrol Dial Transplant** 1996 Aug;11(8):1643-4
Pathogenesis of acute renal failure: new aspects. Bock HA. **Nephron** 1997;76(2):130-42
Neonatal anuria by ACE inhibitors during pregnancy [letter] Lavoratti G, et al. **Nephron** 1997;76(2):235-6
Effects of ACE inhibitor on renal anemia in predialysis patients [letter] Nomura S, et al. **Nephron** 1996;73(2):336-7
"Scalded mouth syndrome" caused by angiotensin converting enzyme inhibitors: two case reports. Brown RS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jun;83(6):665-7
Modulators of the renin-angiotensin-aldosterone system and cough in childhood [letter] Donati-Genet P, et al. **Pediatr Nephrol** 1996 Aug;10(4):545-6
Delayed onset of angioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature. O'Mara NB, et al. **Pharmacotherapy** 1996 Jul-Aug; 16(4):675-9 (40 ref.)

Role of substance P in cough. Sekizawa K, et al. **Pulm Pharmacol** 1996 Oct-Dec;9(5-6):323-8

Renal failure related to angiotensin-converting enzyme inhibitors. Textor SC. **Semin Nephrol** 1997 Jan;17(1):67-76 (49 ref.)

Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Morrone LF, et al. **Transplantation** 1997 Sep 27;64(6):913-8

[Angiotensin-converting enzyme inhibitors and anesthesia] Larsen JK, et al. **Ugeskr Laeger** 1996 Oct 21;158(43):6081-4 (Eng. Abstr.) **(Dan)**

[Remarks on the work of C. Maier. The risk of postoperative angioedema following the use of ACE antagonists. Anesthesist (1995) 44:875-879 (letter; comment)] Bircher AJ, et al. **Anaesthesist** 1996 Dec;45(12):1268-9. Comment on: Anaesthesist 1995 Dec;44(12):875-9. **(Ger)**

[Angioedema of the mucous membranes of the upper aerodigestive tract after administration of ACE inhibitors] Tisch M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):122-3 (Eng. Abstr.) **(Ger)**

[Renal side effects of angiotensin converting enzyme inhibitors] Schmidt A, et al. **Wien Med Wochenschr** 1996; 146(16):454-6 (28 ref.) (Eng. Abstr.) **(Ger)**

[The antagonistic effect of aspirin on the expression of prostaglandin participation in the antihypertensive activity of ACE inhibitors] Alimento M, et al. **Cardiologia** 1997 Jun;42(6):605-10 (Eng. Abstr.) **(Ita)**

[Extracardiovascular toxic effects of drugs used in cardiology] Zennaro RG. **Cardiologia** 1995 Dec;40(12 Suppl 1):99-104 **(Ita)**

[ACE-inhibitors and angioedema (letter; comment)] Dybendal T, et al. **Tidsskr Nor Laegeforen** 1996 Sep 30; 116(23):2817. Comment on: Tidsskr Nor Laegeforen 1996 Sep 20;116(22):2710. **(Nor)**

[ACE-inhibitors and angioedema (letter; comment)] Forslund T. **Tidsskr Nor Laegeforen** 1996 Sep 20; 116(22):2710. Comment on: Tidsskr Nor Laegeforen 1996 Sep 30;116(23):2817. **(Nor)**

[Angioedema and taking captopril (letter)] Râfola Crestani A, et al. **Aten Primaria** 1997 Mar 31;19(5):275-6 **(Spa)**

ANALYSIS

Observation of high and low molecular weight inhibitors of angiotensin-converting enzyme in rat lung. Brecher AS, et al. **Arch Int Pharmacodyn Ther** 1996 May-Jun; 331(3):301-12

TLC characterization of liposomes containing angiotensinogen, angiotensine I, angiotensine II and saralazin. Brailoiu E, et al. **Biomed Chromatogr** 1997 May-Jun;11(3):160-3

Determination of captopril and its disulphides in whole human blood and urine by high-performance liquid chromatography with ultraviolet detection and precolumn derivatization. Sypniewski S, et al. **J Chromatogr A** 1996 Apr 5;729(1-2):335-40

Identification of an antihypertensive peptide from casein hydrolysate produced by a proteinase from Lactobacillus helveticus CP790. Maeno M, et al. **J Dairy Sci** 1996 Aug; 79(8):1316-21

Radioimmunoassay for imidapril, a new angiotensin-converting enzyme inhibitor, and imidaprilat, its active metabolite, in human plasma and urine. Yamanaka K, et al. **J Pharm Biomed Anal** 1996 Jan;14(3):281-7

BLOOD

HPLC determination of captopril in human plasma and its pharmacokinetic study. Li K, et al. **Biomed Chromatogr** 1996 Sep-Oct;10(5):237-9

Determination of captopril in plasma by high-performance liquid chromatography for pharmacokinetic studies. Arroyo C, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):339-44

Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling. Kok RJ, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):181-9

Determination of captopril in human serum by high performance liquid chromatography using solid-phase extraction. Bahmaei M, et al. **J Pharm Biomed Anal** 1997 May;15(8):1181-6

Time-resolved fluoroimmunoassay for the determination of lisinopril and enalaprilat in human serum. Yuan AS, et al. **J Pharm Biomed Anal** 1996 May;14(7):773-81

Determination of captopril in human blood by an enzyme-linked immunosorbent assay. Jehanli AM, et al. **J Pharm Pharmacol** 1996 Sep;48(9):914-7

Steady-state pharmacokinetics and pharmacodynamics of imidaprilat, an active metabolite of imidapril, a new angiotensin-converting enzyme inhibitor in spontaneously hypertensive rats. Yamanaka K, et al. **J Pharm Sci** 1996 Nov;85(11):1234-7

CHEMICAL SYNTHESIS

Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors. Ksander GM, et al. **J Med Chem** 1997 Feb 14;40(4):506-14

Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Robl JA, et al. **J Med Chem** 1997 May 23;40(11):1570-7

CHEMISTRY

Antihypertensive peptides derived from food proteins. Yamamoto N. **Biopolymers** 1997;43(2):129-34 (67 ref.)

Synthesis and biological evaluation of proline derivatives as potential angiotensin converting enzyme inhibitor. Giugliano G, et al. **Boll Soc Ital Biol Sper** 1996 Jan-Feb; 72(1-2):29-36

Internal marker for quantitative analysis of mRNA by reverse transcriptase-polymerase chain reaction in pancreatic beta cells [letter] Yamato E, et al. **Diabetologia** 1996 Jun; 39(6):747-8

Identification of a novel angiotensin-I-converting enzyme inhibitory peptide corresponding to a tryptic fragment of bovine beta-lactoglobulin. Mullally MM, et al. **FEBS Lett** 1997 Feb 3;402(2-3):99-101

Screening of selected basidiomycetes for inhibitory activity on neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE). Melzig MF, et al. **Pharmazie** 1996 Jul;51(7):501-3

CONTRAINDICATIONS

Heart failure in the elderly [letter; comment] Jolobe OM. **Postgrad Med J** 1997 Mar;73(857):189-90. Comment on: Postgrad Med J 1996 Oct;72(852):577-80.

[Aortic stenosis] Figulla HR. **Internist (Berl)** 1997 May; 38(5):484 **(Ger)**

DIAGNOSTIC USE

Preliminary assessment of captopril sonography in screening for renal artery stenosis. Gottlieb RH, et al. **Acad Radiol** 1996 Jan;3(1):57-62

The captopril test in children with renovascular and renal hypertension. Fossali E, et al. **Acta Paediatr** 1996 Sep; 85(9):1129-31

Captopril renal scintigraphy in renovascular hypertension. Khairullah QT, et al. **Am Fam Physician** 1997 May 1; 55(6):2240-4 (19 ref.)

The place of renal scintigraphy in the diagnosis of renal artery stenosis. Fifteen years of clinical experience. van Jaarsveld BC, et al. **Arch Intern Med** 1997 Jun 9;157(11):1226-34

Diagnosis of renal artery branch stenosis using captopril intervention scintirenography. Prakash R, et al. **Australas Radiol** 1996 Aug;40(3):213-7

Consensus report on ACE inhibitor renography for detecting renovascular hypertension. Radionuclides in Nephrourology Group. Consensus Group on ACEI Renography. Taylor A, et al. **J Nucl Med** 1996 Nov; 37(11):1876-82

Angiotensin-converting enzyme inhibition-induced changes in hippurate renography and renal function in renovascular hypertension. Visscher CA, et al. **J Nucl Med** 1996 Mar; 37(3):482-8

ECONOMICS

Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients. Briscoe TA, et al. **Am J Health Syst Pharm** 1996 Sep 15;53(18):2191-3

A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Butler JR, et al. **Aust N Z J Med** 1996 Feb;26(1):89-95

An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Rodby RA, et al. **Diabetes Care** 1996 Oct;19(10):1051-61

Economic aspects of captopril treatment [letter; comment] Tsevat J, et al. **Eur Heart J** 1997 Jan;18(1):165. Comment on: Eur Heart J 1996 May;17(5):648-50. Comment on: Eur Heart J 1996 May;17(5):731-40.

The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment. Johannesson M. **J Hum Hypertens** 1996 Feb;10 Suppl 2:S23-6

Cost containment for treating hypertension in African Americans: impact of a combined ACE inhibitor-calcium channel blocker. Kountz DS. **J Natl Med Assoc** 1997 Jul; 89(7):457-60

Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. Hendry BM, et al. **QJM** 1997 Apr; 90(4):277-82

[Economical treatment of heart failure (editorial; comment)] Sonntag F. **Med Klin** 1996 Feb 15;91(2):111. Comment on: Med Klin 1996 Feb 15;91(2):112-8. **(Ger)**

[Cost effectiveness of captopril after myocardial infarct; comment] Szucs T, et al. **Med Klin** 1996 Feb 15;91(2):112-8 (Eng. Abstr.). Comment on: Med Klin 1996 Feb 15;91(2):111. **(Ger)**

[Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study] Szucs TD, et al. **Schweiz Med Wochenschr** 1997 Jul 22;127(29-30):1234-41 (Eng. Abstr.) **(Ger)**

[Cost-effectiveness analysis of the treatment with enalapril of chronic heart failure in Spain] Antoñanzas Villar F, et al. **Gac Sanit** 1996 May-Jun;10(54):135-42 (Eng. Abstr.) **(Spa)**

METABOLISM

Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo. Lew RA, et al. **Br J Pharmacol** 1996 Jul;118(5):1269-77

Characterization of angiotensin II formation in human isolated bladder by selective inhibitors of ACE and human chymase: a functional and biochemical study. Waldeck K, et al. **Br J Pharmacol** 1997 Jul;121(6):1081-6

Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries, and veins. Bevilacqua M, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):494-9

Kinetic analysis of the covalent binding of captopril to human serum albumin. Narazaki R, et al. **J Pharm Sci** 1997 Feb; 86(2):215-9

Glaucoma, capillaries and pericytes. 3. Peptide hormone binding and influence on pericytes. Ferrari-Dileo G, et al. **Ophthalmologica** 1996;210(5):269-75

PHARMACOKINETICS

Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril. Pidlich J, et al. **Acta Med Austriaca** 1997;24(1):15-8

Trough-to-peak ratio of angiotensin converting enzyme inhibitors and calcium antagonists [letter; comment] Myers MG. **Am J Hypertens** 1997 May;10(5 Pt 1):580-2. Comment on: Am J Hypertens 1996 Jul;9(7):633-43.

Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists [see comments] [published erratum appears in Am J Hypertens 1997 Apr;10(4 Pt 1):482] Zannad F, et al. **Am J Hypertens** 1996 Jul;9(7):633-43. Comment in: Am J Hypertens 1997 May;10(5 Pt 1):580-2.

Placental passage of angiotensin-converting enzyme inhibitors. Reisenberger K, et al. **Am J Obstet Gynecol** 1996 May;174(5):1450-5

Intestinal absorption of captopril and two thioester analogs in rats and dogs. Morrison RA, et al. **Biopharm Drug Dispos** 1997 Jan;18(1):25-39

Pharmacokinetic-pharmacodynamic modelling for captopril in healthy anaesthetized piglets. Pereira CM, et al. **Biopharm Drug Dispos** 1996 Jul;17(5):365-72

Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. Harder S, et al. **Br J Clin Pharmacol** 1997 May; 43(5):475-80

Pharmacokinetics and haemodynamic effects of the angiotensin converting enzyme inhibitor cilazapril in hypertensive patients with normal and impaired renal function. Kloke HJ, et al. **Br J Clin Pharmacol** 1996 Nov; 42(5):615-20

A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril. Macdonald NJ, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):201-4

The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. Macdonald NJ, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):205-9

Fosinopril. Clinical pharmacokinetics and clinical potential. Shionoiri H, et al. **Clin Pharmacokinet** 1997 Jun; 32(6):460-80 (95 ref.)

Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function. Hoogkamer JF, et al. **Eur J Clin Pharmacol** 1997;51(6):489-91

Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. Hutt V, et al. **Eur J Clin Pharmacol** 1996;51(3-4):339-44

Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach. Ribeiro W, et al. **Eur J Clin Pharmacol** 1996;50(5):399-405

Tight binding of ramiprilat to ACE: consequences for pharmacokinetic and pharmacodynamic measurements. Brockmeier D. **Int J Clin Pharmacol Ther** 1995 Dec; 33(12):631-8

Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure. Bellissant E, et al. **J Cardiovasc Pharmacol** 1997 Aug;30(2):253-60

Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. Bellissant E, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):470-8

Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients. Fillastre JP, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):269-74

Disposition of quinapril and quinaprilat in the isolated perfused rat kidney. Kugler AR, et al. **J Pharmacokinet Biopharm** 1995 Jun;23(3):287-305

Tubular transport mechanisms of quinapril and quinaprilat in the isolated perfused rat kidney: effect of organic anions and cations. Kugler AR, et al. **J Pharmacokinet Biopharm** 1996 Aug;24(4):349-68

Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). Ishizuka H, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1304-11

Sex-related pharmacokinetic and pharmacodynamic variations of lisinopril. Sáenz-Campos D, et al. **Methods Find Exp Clin Pharmacol** 1996 Oct;18(8):533-8

Reductive metabolism and its role in the disposition of the

hydroxamic angiotensin-converting enzyme inhibitor idrapril calcium in rat. Lippi A, et al. **Xenobiotica** 1996 May;26(5):551–8

[ACE inhibitors from the viewpoint of the clinical pharmacologist] Hitzenberger G. **Wien Med Wochenschr** 1996;146(11):225–7 (8 ref.) (Eng. Abstr.) **(Ger)**

[Bioanalytic examination and pharmacokinetics of captopril. Bioequivalence studies of different captopril-containing Tensiomin preparations] Klebovich I, et al. **Acta Pharm Hung** 1997 Jul;67(4):123–35 (Eng. Abstr.) **(Hun)**

PHARMACOLOGY

Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy. Stenvinkel P, et al. **Acta Diabetol** 1997 Mar;34(1):10–7

Converting enzyme inhibition and renal function of conscious uninephrectomized rats [correction of enzyme] MacLaughlin M, et al. **Acta Physiol Pharmacol Ther Latinoam** 1996;46(3):203–8

Effects of angiotensin-converting enzyme inhibition on arterial, venous and capillary functions in cat skeletal muscle in vivo. Ekelund U. **Acta Physiol Scand** 1996 Sep; 158(1):29–37

Effect of an intravenous angiotensin-converting enzyme inhibitor on the electrophysiologic features of normal and hypertrophied feline ventricles. Rials SJ, et al. **Am Heart J** 1996 Nov;132(5):989–94

Effects of nisoldipine and/or enalapril on left ventricular function and exercise capacity in patients with recent anterior myocardial infarction and mild cardiac dysfunction. Romano M, et al. **Am Heart J** 1997 Mar; 133(3):268–72

Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? Ruschitzka FT, et al. **Am Heart J** 1997 Aug;134(2 Pt 2):S31–47 (117 ref.)

Enalapril reduces QTc dispersion in mild congestive heart failure secondary to coronary artery disease. Barr CS, et al. **Am J Cardiol** 1997 Feb 1;79(3):328–33

Angiotensin-converting enzyme inhibitors promote nitric oxide production in coronary microvessels from failing explanted human hearts. Kichuk MR, et al. **Am J Cardiol** 1997 Aug 4;80(3A):137A–142A

Angiotensin-converting enzyme inhibitors in preventing remodeling and development of heart failure after acute myocardial infarction: results of the German multicenter study of the effects of captopril on cardiopulmonary exercise parameters (ECCE). Kleber FX, et al. **Am J Cardiol** 1997 Aug 4;80(3A):162A–167A

Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Minshall RD, et al. **Am J Cardiol** 1997 Aug 4;80(3A):132A–136A

Perfusion-independent effect of bradykinin and fosinoprilate on glucose transport in Langendorff rat hearts. Rett K, et al. **Am J Cardiol** 1997 Aug 4;80(3A):143A–147A

Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Zhu YC, et al. **Am J Cardiol** 1997 Aug 4;80(3A):110A–117A (65 ref.)

Effect of cilazapril and salt on Ca2+ extrusion in arterial smooth muscle of Dahl rats. Ashida T, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):107S–111S

Enalapril does not improve left ventricular diastolic dysfunction in young and mild hypertensives without concomitant hypertrophy [see comments] Chang NC, et al. **Am J Hypertens** 1996 Sep;9(9):909–14. Comment in: Am J Hypertens 1997 Mar;10(3):366.

Effects of chronic treatment with losartan and enalaprilat on [3H]-norepinephrine release from isolated atria of Wistar-Kyoto and spontaneously hypertensive rats. Foucart S, et al. **Am J Hypertens** 1996 Jan;9(1):61–9

Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade. Himmelmann A, et al. **Am J Hypertens** 1996 Sep;9(9):850–3

Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade [published erratum appears in Am J Hypertens 1996 Oct;9(10 Pt 1):1054] Hulthén UL, et al. **Am J Hypertens** 1996 Sep;9(9):895–901

Modulation of G-protein expression by the angiotensin converting enzyme inhibitor captopril in hearts from spontaneously hypertensive rats. Relationship with adenylyl cyclase. Pandey SK, et al. **Am J Hypertens** 1996 Aug;9(8):833–7

Elevation of von Willebrand factor levels in patients with IgA nephropathy: effect of ACE inhibition. Hernández E, et al. **Am J Kidney Dis** 1997 Sep;30(3):397–403

Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency. Mitchell HC, et al. **Am J Kidney Dis** 1997 Jun;29(6):897–906

The urinary bladder angiotensin system: response to infusions of angiotensin I and angiotensin-converting enzyme inhibitors. Weaver-Osterholtz D, et al. **Am J Kidney Dis** 1996 Oct;28(4):603–9

In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity. Barra JG, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H859–68

Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. Décarie A, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1340–7

Enalapril and captopril enhance antioxidant defenses in mouse tissues. de Cavanagh EM, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R514–8

Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Dell'Italia LJ, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H961–70

The persistent effect of long-term enalapril on pressure natriuresis in spontaneously hypertensive rats. Dukacz SA, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):F104–12

Converting enzyme inhibitors cause pressure-independent resetting of baroreflex control of sympathetic outflow. Heesch CM, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):R728–37

Angiotensin-converting enzyme inhibitors regulate the Na(+)-K+ pump via effects on angiotensin metabolism. Hool LC, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C172–80

ACE inhibitors and cardiac ACE mRNA in volume overload-induced cardiac hypertrophy. Lear W, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H641–6

Role of kinin and renal ANG II blockade in acute effects of ACE inhibitors in low-renin hypertension. Naitoh M, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H679–87

Effects of ACE inhibition and beta-blockade on skeletal muscle fiber types in dogs with moderate heart failure. Sabbah HN, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H115–20

Long-term captopril treatment restores natriuresis after carotid baroreceptor activation in the SHR. Valentin JP, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R70–9

NO synthesis is involved in structural and functional effects of ACE inhibitors in injured arteries. Van Belle E, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H298–305

Effects of angiotensin converting enzyme inhibition on crossbridge properties of diaphragm in cardiomyopathic hamsters of the dilated bio 53-58 strain. Lecarpentier Y, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):630–6

Effects of certain vasoactive agents on the long-term pattern of blood pressure, heart rate, and motor activity in cats. Brown SA, et al. **Am J Vet Res** 1997 Jun;58(6):647–52

Effect of spirapril and hydrochlorothiazide on platelet function and euglobulin clot lysis time in patients with mild hypertension. Gleerup G, et al. **Angiology** 1996 Oct; 47(10):951–5

Effect of enalapril maleate on cerebral blood flow in patients with chronic heart failure. Kamishirado H, et al. **Angiology** 1997 Aug;48(8):707–13

Angiotensin-converting enzyme inhibition with enalapril increases the cardiac concentration of vasoactive intestinal peptide. Duggan KA, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:713–6

Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Friehe H, et al. **Arzneimittelforschung** 1997 Feb;47(2):132–44

Possible involvement of ATP-dependent K-channel related mechanisms in the antihypertensive and cough suppressant effects of the novel ACE inhibitor (2S, 3aS, 7aS)-1-(N2-nicotinoyl-L-lysyl-gamma-D-glutamyl) octahydro-1H- indole-2-carboxylic acid. Nagata S, et al. **Arzneimittelforschung** 1997 Jun;47(6):726–30

Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically-instrumented transgenic rats. van Meel JC, et al. **Arzneimittelforschung** 1996 Aug;46(8):755–9

Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Hoshida S, et al. **Atherosclerosis** 1997 Apr;130(1-2):53–9

Impairment of endothelium-dependent relaxation of rabbit aortas by cigarette smoke extract--role of free radicals and attenuation by captopril. Ota Y, et al. **Atherosclerosis** 1997 Jun;131(2):195–202

ACE inhibition accelerates endothelial regrowth in vivo: a possible explanation for the benefit observed with ACE inhibitors following arterial injury. Van Belle E, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):577–81

Captopril reverses high glucose-induced effects on LLC-PK1 cells partly by enhancing facilitative glucose transporter messenger RNA expressions. Yang ML, et al. **Biochem Mol Biol Int** 1997 Mar;41(3):511–9

Interaction of oligonucleotide-conjugates with the dipeptide transporter system in Caco-2 cells. Moore VA, et al. **Biochem Pharmacol** 1997 May 9;53(9):1223–8

The involvement of catecholamines, in hypertension, alcohol and ACE-inhibition. Patel VB, et al. **Biochem Soc Trans** 1996 May;24(2):262S

Effect of new peptide inhibitors on the ratio of angiotensin I-converting and kinin-degrading activities of dipeptidyl carboxypeptidase (angiotensin-converting enzyme). Kalinina EV, et al. **Biochemistry (Mosc)** 1997 Mar; 62(3):247–50

Synthetic peptides corresponding to alpha-lactalbumin and beta-lactoglobulin sequences with angiotensin-I-converting enzyme inhibitory activity. Mullally MM, et al. **Biol Chem Hoppe Seyler** 1996 Apr; 377(4):259–60

Inhibitory effects of angiotensin-converting enzyme inhibitor on cefroxadine uptake by rabbit small intestinal brush border membrane vesicles. Kitagawa S, et al. **Biol Pharm Bull** 1997 Apr;20(4):449–51

Tuna muscle peptide, PTHIKWGD, inhibits leukocyte-mediated injury and leukocyte adhesion to cultured endothelial cells. Kohama Y, et al. **Biol Pharm Bull** 1996 Jan;19(1):139–41

Quinapril prevents hypertension and enhanced vascular reactivity in nitroarginine-treated rats. Charpie JR, et al. **Blood Press** 1997 Mar;6(2):117–24

Captopril does not blunt the sympathoadrenal response to cigarette smoking in normotensive humans. Ottesen MM, et al. **Blood Press** 1997 Jan;6(1):29–34

Interactions between acute effect of angiotensin converting enzyme inhibition and salt balance on the renal function and urinary prostanoids. Studies in healthy women. Agnoli GC, et al. **Boll Soc Ital Biol Sper** 1996 Mar-Apr; 72(3-4):117–24

Gut mucosal perfusion in infants undergoing cardiopulmonary bypass: effect of preoperative captopril. Booker PD, et al. **Br J Anaesth** 1997 Jul;79(1):14–8

Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid. Böger RH, et al. **Br J Clin Pharmacol** 1996 Dec;42(6):721–7

Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. Harder S, et al. **Br J Clin Pharmacol** 1997 May; 43(5):475–80

Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients? Pritchard G, et al. **Br J Clin Pharmacol** 1997 Aug; 44(2):145–9

Effects of acute and chronic angiotensin converting enzyme inhibition by spirapril on cardiovascular regulation in essential hypertensive patients. Assessment by spectral analysis and haemodynamic measurements. Veerman DP, et al. **Br J Clin Pharmacol** 1996 Jan;41(1):49–56

Influence of ACE inhibition on the kidney function of diabetics. Lewis EJ. **Br J Clin Pract Symp Suppl** 1996 Jul; 84:23–4

Comparison of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition in pregnant sheep during late gestation. Forhead AJ, et al. **Br J Pharmacol** 1996 Sep;119(2):393–401

Effects of moexiprilat on oestrogen-stimulated cardiac fibroblast growth. Grohé C, et al. **Br J Pharmacol** 1997 Aug;121(7):1350–4

ACE inhibitor potentiation of bradykinin-induced venoconstriction. Hecker M, et al. **Br J Pharmacol** 1997 Aug;121(7):1475–81

Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2. Henrion D, et al. **Br J Pharmacol** 1997 May;121(1):83–90

Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Kim S, et al. **Br J Pharmacol** 1996 Jun;118(3):549–56

Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat. Kirk JE, et al. **Br J Pharmacol** 1996 Nov;119(5):943–8

Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits. Tomoda F, et al. **Br J Pharmacol** 1996 Sep;119(2):365–73

Distribution of Fos-immunoreactivity in rat brain following a dipsogenic dose of captopril and effects of angiotensin receptor blockade. McKinley MJ, et al. **Brain Res** 1997 Jan 30;747(1):43–51

Effect of intracerebroventricular injection of ramipril on the drinking response caused by injection of noradrenaline into the third ventricle. Barros VM, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1503–5

Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Small W Jr, et al. **Breast Cancer Res Treat** 1997 Jul;44(3):217–24

Anti-free radical mechanisms in captopril protection against reperfusion injury in isolated rat hearts. Anderson B, et al. **Can J Cardiol** 1996 Oct;12(10):1099–104

Effects of lisinopril on intercellular resistance of guinea pig ventricular myocytes. Daleau P, et al. **Can J Physiol Pharmacol** 1997 May;75(5):363–7

Effects of the angiotensin converting enzyme (ACE) inhibitor, captopril, on the cardiovascular, endocrine, and renal responses to furosemide in conscious lambs. de Wildt SN, et al. **Can J Physiol Pharmacol** 1997 Apr;75(4):263–70

Effects of inhibition of the maternal renin-angiotensin system on maternal and fetal responses to drainage of fetal fluids. Lumbers ER, et al. **Can J Physiol Pharmacol** 1996 Aug; 74(8):973–82

Effect of ACE inhibitors on endothelial dysfunction: unanswered questions and implications for further investigation and therapy [editorial] Pitt B. **Cardiovasc Drugs Ther** 1996 Sep;10(4):469–73

Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition. Schmitt R, et al. **Cardiovasc Drugs Ther** 1996 May; 10(2):101–5

Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade. Hayashida W, et al. **Cardiovasc Res** 1997 Jan;33(1):54–62

Cocaine-stimulated endothelin-1 release is decreased by angiotensin-converting enzyme inhibitors in cultured endothelial cells. Hendricks-Munoz KD, et al. **Cardiovasc Res** 1996 Jan;31(1):117–23

Chronic ACE inhibition by quinapril modulates central vasopressinergic system. Muders F, et al. **Cardiovasc Res** 1997 Jun;34(3):575–81

Effects of renin inhibition compared to angiotensin converting enzyme inhibition in conscious dogs with pacing-induced heart failure. Shannon RP, et al. **Cardiovasc Res** 1997 Jun;34(3):464–72

Structural alterations of resistance vessels of spontaneously hypertensive rats and protective effects of captopril. Chen Y, et al. **Chin Med J (Engl)** 1996 Nov;109(11):873–6

Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Antony I, et al. **Circulation** 1996 Dec 15;94(12):3115–22

Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion. Brunner F, et al. **Circulation** 1996 Oct 1;94(7):1752–61

Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Grassi G, et al. **Circulation** 1997 Aug 19;96(4):1173–9

Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Guazzi M, et al. **Circulation** 1997 Apr 1;95(7):1930–6

Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Hernández-Presa M, et al. **Circulation** 1997 Mar 18;95(6):1532–41

Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Hornig B, et al. **Circulation** 1997 Mar 4;95(5):1115–8

Long-term angiotensin-converting enzyme inhibition with fosinopril improves depressed responsiveness to Ca2+ in myocytes from aortic-banded rats. Kagaya Y, et al. **Circulation** 1996 Dec 1;94(11):2915–22

Modulation of myocardial oxygen consumption through ACE inhibitors. NO effect? [editorial; comment] Laursen JB, et al. **Circulation** 1997 Jan 7;95(1):14–6. Comment on: Circulation 1997 Jan 7;95(1):176–82.

Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Love MP, et al. **Circulation** 1996 Nov 1;94(9):2131–7

ACE inhibition: postsynaptic adrenergic sympatholytic action in men. Lyons D, et al. **Circulation** 1997 Aug 5; 96(3):911–5

Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. Noll G, et al. **Circulation** 1997 May 6;95(9):2286–92

Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Wollert KC, et al. **Circulation** 1997 Apr 1;95(7):1910–7

Angiotensin-converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries: relationships to neointima formation. Wong J, et al. **Circulation** 1997 Sep 2;96(5):1631–40

ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption [see comments] Zhang X, et al. **Circulation** 1997 Jan 7;95(1):176–82. Comment in: Circulation 1997 Jan 7;95(1):14–6.

Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Zhuo JL, et al. **Circulation** 1997 Jul 1;96(1):174–82

Erythrocyte Na+, K+ and Ca2+, Mg(2+)-ATPase activities in hypertensives on angiotensin-converting enzyme inhibitors. Golik A, et al. **Clin Biochem** 1996 Jun; 29(3):249–54

Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group. Edner M, et al. **Clin Cardiol** 1996 Jul;19(7):543–8

Modifying influence of enalaprilat on mesangial cell DNA synthesis induced by hydrogen peroxide. D'Souza RJ, et al. **Clin Chim Acta** 1997 Mar 18;259(1-2):137–46

Effects of dietary salt and angiotensin-converting enzyme inhibitor on ATP-driven Ca pump and Na/Ca exchange in aortic rings of Dahl rats. Ashida T, et al. **Clin Exp Hypertens** 1996 Aug;18(6):851–71

Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor. Chen S, et al. **Clin Exp Hypertens** 1996 Jul;18(5):625–36

Renal tissue angiotensins during converting enzyme inhibition in the spontaneously hypertensive rat. Grima M, et al. **Clin Exp Hypertens** 1997 Jul-Aug;19(5–6):671–85

ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction. Linz W, et al. **Clin Exp Hypertens** 1996 Jul;18(5):691–712

The mechanisms of the improvement of insulin sensitivity by angiotensin converting enzyme inhibitor. Shimamoto K, et al. **Clin Exp Hypertens** 1996 Feb;18(2):257–66

Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study. Whitlock G, et al. **Clin Exp Hypertens** 1997 Jul-Aug;19(5–6):843–55

Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Management Committee on behalf of the High Blood Pressure Research Council of Australia. **Clin Exp Pharmacol Physiol** 1997 Feb; 24(2):188–92

Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Fennessy PA, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):S30–2 (14 ref.)

Acute but not chronic angiotensin-converting enzyme inhibition induces enzyme synthesis in the glomerulus of the spontaneously hypertensive rat. Hodge G, et al. **Clin Exp Pharmacol Physiol** 1997 Jun;24(6):460–2

Angiotensin converting enzyme inhibition in the postnatal rat results in decreased cell proliferation in the renal outer medulla. McCausland JE, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6–7):552–4

Effects of ACE inhibition and beta-blockade on collagen remodelling in the heart of Bio 14.6 hamsters. Mansoor AM, et al. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):43–9

Endothelium-dependent responses and inhibition of angiotensin-converting enzyme. Vanhoutte PM. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):S23–9 (56 ref.)

Increases in the myocardial concentration of vasoactive intestinal peptide may explain the positive inotropic effect of angiotensin converting enzyme inhibitors. Ye VZ, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6–7):617–8

Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Campbell DJ. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S125–31 (68 ref.)

Effect of angiotensin-converting enzyme inhibitors on fructose induced hypertension and hyperinsulinaemia in rats. Erlich Y, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S347–9

Suppression of vascular transforming growth factor-beta1 and extracellular matrix gene expressions by cilazapril and nifedipine in hypertensive rats. Kim S, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S355–6

Captopril-induced changes in effective renal plasma flow in hypertensive renal transplant recipients. Sud K, et al. **Clin Transplant** 1996 Aug;10(4):337–40

Amlodipine and benazeprilat differently affect the responses to endothelin-1 and bradykinin in porcine ciliary arteries: effects of a low and high dose combination. Lang MG, et al. **Curr Eye Res** 1997 Mar;16(3):208–13

Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research. Cleland JG, et al. **Curr Opin Cardiol** 1996 May;11(3):252–62 (101 ref.)

Renal responses to antagonism of the renin-angiotensin system. Braam B, et al. **Curr Opin Nephrol Hypertens** 1996 Jan;5(1):89–96 (69 ref.)

Effects of ACE inhibition on spontaneous and insulin-stimulated endothelin-1 secretion: in vitro and in vivo studies. Desideri G, et al. **Diabetes** 1997 Jan;46(1):81–6

ACE inhibition by enalaprilate stimulates duodenal mucosal alkaline secretion via a bradykinin pathway in the rat. Chen L, et al. **Dig Dis Sci** 1997 Sep;42(9):1908–13

Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure. Davis R, et al. **Drugs** 1997 Jul;54(1):103–16 (53 ref.)

Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus. Goa KL, et al. **Drugs** 1997 Jun;53(6):1081–105 (157 ref.)

Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Wagstaff AJ, et al. **Drugs** 1996 May;51(5):777–91 (75 ref.)

Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients. Langtry HD, et al. **Drugs Aging** 1997 Feb;10(2):131–66 (240 ref.)

Sex-related differences in the response of spontaneously hypertensive rats to angiotensin-converting enzyme inhibitor. Nigro D, et al. **Endothelium** 1997;5(1):63–71

Anti-adrenergic effects of angiotensin converting enzyme inhibitors. Bristow MR, et al. **Eur Heart J** 1995 Nov;16 Suppl K:37–41 (42 ref.)

Influence of angiotensin II blockade during exercise in the heat. Mittleman KD. **Eur J Appl Physiol** 1996; 72(5–6):542–7

Effects of ramipril on the hormone concentrations in serum of hypertensive patients. Grönroos PE, et al. **Eur J Clin Chem Clin Biochem** 1997 Jun;35(6):411–4

Effects of hydrochlorothiazide and captopril on lipoprotein lipid composition in patients with essential hypertension. Bagdade JD, et al. **Eur J Clin Pharmacol** 1996;49(5):355–9

Effect of enalapril and quinapril on forearm vascular ACE in man. Lyons D, et al. **Eur J Clin Pharmacol** 1997; 51(5):373–8

Effects of the antihypertensive drug captopril on human salivary secretion rate and composition. Nederfors T, et al. **Eur J Oral Sci** 1995 Dec;103(6):351–4

Blockade of angiotensin converting enzyme but not of angiotensin AT1 receptors improves glucose tolerance. Chow L, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):77–83

Imidapril inhibits increased transforming growth factor-beta1 expression in remnant kidney model. Hamaguchi A, et al. **Eur J Pharmacol** 1997 Jul 16;331(1):27–30

Effects of angiotensin II and angiotensin-converting enzyme inhibitors on human myocardium. Lenz O, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):17–27

Antihypertensive effect of angiotensin I-converting enzyme inhibitory peptides derived from hemoglobin. Mito K, et al. **Eur J Pharmacol** 1996 May 23;304(1-3):93–8

Nifedipine, losartan and captopril effects on hyperplasia of vascular smooth muscle from Ren-2 transgenic rats. Peiró C, et al. **Eur J Pharmacol** 1997 Apr 18;324(2-3):257–65

Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin. Pham I, et al. **Eur J Pharmacol** 1996 Feb 5;296(3):267–76

Dose-response studies with idrapril in the rat heart during acute myocardial ischaemia and reperfusion. Riva E, et al. **Eur J Pharmacol** 1996 Oct 3;312(3):293–300

Ramiprilat attenuates hypoxia/reoxygenation injury to cardiac myocytes via a bradykinin-dependent mechanism. Wall TM, et al. **Eur J Pharmacol** 1996 Jun 13; 306(1-3):165–74

Cellular protective action of angiotensin converting enzyme inhibitors. Tepel M, et al. **Exp Clin Endocrinol Diabetes** 1997;105 Suppl 2:61–3

Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects. Burnier M, et al. **Exp Nephrol** 1996;4 Suppl 1:41–6 (41 ref.)

The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes. Ruggenenti P, et al. **Exp Nephrol** 1996;4 Suppl 1:53–60 (42 ref.)

Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Wapstra FH, et al. **Exp Nephrol** 1996;4 Suppl 1:47–52 (48 ref.)

From converting enzyme inhibition to angiotensin II receptor blockade: new insight on angiotensin II receptor subtypes in the kidney. Wolf G, et al. **Exp Nephrol** 1996;4 Suppl 1:8–19 (133 ref.)

Changes in the maternal and fetal renin-angiotensin systems in response to angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition in pregnant sheep during late gestation. Forhead AJ, et al. **Exp Physiol** 1997 Jul;82(4):761–76

Identification of a novel angiotensin-I-converting enzyme inhibitory peptide corresponding to a tryptic fragment of bovine beta-lactoglobulin. Mullally MM, et al. **FEBS Lett** 1997 Feb 3;402(2-3):99–101

Antioxidant and prooxidant properties of captopril and enalapril. Bartosz M, et al. **Free Radic Biol Med** 1997; 23(5):729–35

Different effects of thiol and nonthiol ace inhibitors on copper-induced lipid and protein oxidative modification. Fernandes AC, et al. **Free Radic Biol Med** 1996; 20(4):507–14

Effect of angiotensin converting enzyme inhibitors on quality of life in hypertensive patients. Pharmacodynamic basis. Govantes C, et al. **Fundam Clin Pharmacol** 1996;10(4):400–5 (61 ref.)

Response of large and small vessels to alpha and beta adrenoceptor stimulation in heart failure: effect of angiotensin converting enzyme inhibition. Mulder P, et al. **Fundam Clin Pharmacol** 1997;11(3):221–30

Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system. Stephan D, et al. **Fundam Clin Pharmacol** 1996;10(5):474–83

Effects of angiotensin converting enzyme inhibitor cilazapril and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit. Sahin Y, et al. **Gynecol Endocrinol** 1997 Aug;11(4):231–6

KATP channel opening does not contribute significantly to the vasodilatory effect of SH-group-containing ACE inhibitors. Köppel H, et al. **Heart Vessels** 1996;11(4):192–6

Angiotensin-converting enzyme inhibition by enalapril: a novel approach to reduce ischemia/reperfusion damage after experimental liver transplantation. Anthuber M, et al. **Hepatology** 1997 Mar;25(3):648–51

Captopril increases renin release stimulated by furosemide and hypotension in isolated perfused guinea pig kidneys. Mokuda O, et al. **Horm Metab Res** 1996 May;28(5):227–9

Additive effects of losartan and enalapril on blood pressure and plasma active renin. Azizi M, et al. **Hypertension** 1997 Feb;29(2):634–40

Is the regulation of apoptosis altered in smooth muscle cells of adult spontaneously hypertensive rats? Díez J, et al. **Hypertension** 1997 Mar;29(3):776–80

Arthus C. Corcoran Memorial Lecture. Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Frohlich ED. **Hypertension** 1997 Jan;29(1 Pt 2):188–93

Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Gohlke P, et al. **Hypertension** 1997 Jan;29(1 Pt 2):478–82

Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Iwatsubo H, et al. **Hypertension** 1997 Jan;29(1 Pt 2):286–90

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Effects of renin-angiotensin blockade on sympathetic reactivity and beta-adrenergic pathway in the spontaneously hypertensive rat. K.-Laflamme A, et al. **Hypertension** 1997 Aug;30(2 Pt 1):278–87

Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Karam H, et al. **Hypertension** 1996 Sep; 28(3):379–85

Endothelin-1 upregulation in the kidney of uninephrectomized spontaneously hypertensive rats and its modification by the angiotensin-converting enzyme inhibitor quinapril. Largo R, et al. **Hypertension** 1997 May; 29(5):1178–85

Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat. Rosenthal T, et al. **Hypertension** 1997 Jun; 29(6):1260–4

Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure. Skov K, et al. **Hypertension** 1996 Sep;28(3):464–71 (62 ref.)

Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Fukuzawa M, et al. **Immunopharmacology** 1997 Apr; 36(1):49–55

Lack of contribution of circulatory kinin elevated by captopril to induce hypotension in normotensive and hypertensive rats. Majima M, et al. **Immunopharmacology** 1996 Jun;33(1–3):291–3

Effect of cadmium and captopril on serum angiotensin converting enzyme activity in rats. Puri VN. **Indian Heart J** 1997 May–Jun;49(3):297–9

Role of tachykinins in enhancement of bradykinin-induced bronchoconstriction by captopril. Arakawa M, et al. **Inflamm Res** 1996 Feb;45(2):75–82

A comparison of the effect of enalapril and metoprolol on renal function, potassium balance, lipid profile, cardiac function, exercise tolerance and quality of life in hypertensive dialysis patients. Wong KC, et al. **Int J Artif Organs** 1995 Dec;18(12):757–62

Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure. Khoury AM, et al. **Int J Cardiol** 1996 Nov 15; 57(1):21–9

Effect of alacepril on 24-hour blood pressure in elderly hypertensive patients. Kohara K, et al. **Int J Clin Pharmacol Ther** 1996 Sep;34(9):380–3

The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. Middeke M, et al. **Int J Clin Pharmacol Ther** 1997 Jun;35(6):231–4

Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation. Miki T, et al. **J Am Coll Cardiol** 1996 Nov 15;28(6):1616–22

Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. Morris SD, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1599–606

Captopril reverses high-glucose-induced growth effects on LLC-PK1 cells partly by decreasing transforming growth factor-beta receptor protein expressions. Guh JY, et al. **J Am Soc Nephrol** 1996 Aug;7(8):1207–15

Lifelong angiotensin-converting enzyme inhibition, pressure natriuresis, and renin-angiotensin system gene expression in transgenic (mRen-2)27 rats. Lippoldt A, et al. **J Am Soc Nephrol** 1996 Oct;7(10):2119–29

Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis. Ruiz-Ortega M, et al. **J Am Soc Nephrol** 1997 May;8(5):756–68

Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat. Verseput GH, et al. **J Am Soc Nephrol** 1997 Feb;8(2):249–59

Effects of renal denervation on cardiovascular and renal responses to ACE inhibition in conscious lambs. Smith FG, et al. **J Appl Physiol** 1997 Aug;83(2):414–9

Vascular health: the emerging appreciation of the endothelium. Talley JD. **J Ark Med Soc** 1997 Feb; 93(9):454–5

Electrophysiologic and morphologic abnormalities in the failing heart: effect of enalapril on the electrical properties. De Mello WC, et al. **J Card Fail** 1997 Mar;3(1):53–61

Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins. Tschöpe C, et al. **J Card Fail** 1997 Jun;3(2):133–48 (192 ref.)

Enalaprilat decreases plasma endothelin and atrial natriuretic peptide levels and preload in patients with left ventricular dysfunction after cardiac surgery. Tohmo H, et al. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):585–90

Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. Bellissant E, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):470–8

Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. Buikema H, et al. **J Cardiovasc Pharmacol** 1997 May;29(5):684–91

Inhibitor of angiotensin-converting enzyme modifies myointimal origin in an arterial autograft model. Buján J, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):285–93

Early captopril treatment reduces plasma endothelin concentrations in the acute and subacute phases of myocardial infarction: a pilot study. Di Pasquale P, et al. **J Cardiovasc Pharmacol** 1997 Feb;29(2):202–8

Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation. Erşahin C, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):96–101

Excretory responses to renal nerve stimulation during inhibition of neutral metalloendopeptidase and angiotensin-converting enzyme in the rat. Golin R, et al. **J Cardiovasc Pharmacol** 1996 Nov;28(5):665–71

Preservation of left ventricular mechanical function and energy metabolism in rats after myocardial infarction by the angiotensin-converting enzyme inhibitor quinapril. Horn M, et al. **J Cardiovasc Pharmacol** 1996 Feb; 27(2):201–10

Effects of a new angiotensin-converting enzyme inhibitor (idrapril) in rats with left ventricular dysfunction after myocardial infarction. Jeremic G, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):347–54

Low-dose but not high-dose captopril increases parasympathetic activity in patients with heart failure. Kamen PW, et al. **J Cardiovasc Pharmacol** 1997 Jul; 30(1):7–11

Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients. Keidar S, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):183–6

Captopril and norepinephrine-induced hypertrophy and haemodynamics in rats. Laycock SK, et al. **J Cardiovasc Pharmacol** 1996 May;27(5):667–72

Effect of calcium channel blockade or angiotensin-converting enzyme inhibition on structure of coronary, renal, and other small arteries in spontaneously hypertensive rats. Li JS, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):68–74

The practical assessment of compliance with ACE-inhibitor therapy--a novel approach. MacFadyen RJ, et al. **J Cardiovasc Pharmacol** 1997 Jan;29(1):119–24

Effect of captopril and losartan on blood pressure and accumulation of LDL and fibrinogen by aortic wall and other tissues in normotensive and hypertensive rats. Medina R, et al. **J Cardiovasc Pharmacol** 1997 Jan;29(1):125–9

Improved survival in rats administered NG-nitro L-arginine methyl ester due to converting enzyme inhibition. Michel JB, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):142–8

Alteration of cytochrome P-450 isozymes by captopril and idrapril in hepatic and renal microsomes of normotensive and spontaneously hypertensive rats. Moretti A, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):12–8

Prolonging action of imidapril on the lifespan expectancy of cardiomyopathic hamsters. Narita H, et al. **J Cardiovasc Pharmacol** 1996 Jun;27(6):861–71

Effects of ramipril and enalapril on cerebral blood flow in elderly patients with asymptomatic carotid artery occlusive disease. Patel RV, et al. **J Cardiovasc Pharmacol** 1996 Jul; 28(1):48–52

Acute and long-term dose-response study of quinapril on hormonal profile and tissue angiotensin-converting enzyme in Wistar rats. Schaison FH, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):11–8

Renal and depressor activities of inhibitors of neutral endopeptidase and angiotensin converting enzyme in monkeys infused with angiotensin II. Seymour AA, et al. **J Cardiovasc Pharmacol** 1996 Nov;28(5):651–8

In vivo pharmacology of dual neutral endopeptidase/angiotensin-converting enzyme inhibitors. Seymour AA, et al. **J Cardiovasc Pharmacol** 1996 Nov; 28(5):672–8

Renal and depressor activity of C-natriuretic peptide in conscious monkeys: effects of enzyme inhibitors. Seymour AA, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):397–401

Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure [published erratum appears in J Cardiovasc Pharmacol 1996 Sep;28(3):479] Squire IB, et al. **J Cardiovasc Pharmacol** 1996 May;27(5):657–66

Effects of angiotensin II receptor blockade during exercise: comparison of losartan and saralasin. Symons JD, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):223–31

Therapeutic, but not low-dose, angiotensin-converting enzyme inhibition causes regression of cardiovascular changes in spontaneously hypertensive rats. Wahlander H, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):327–34

Acute and chronic in vivo inhibition of angiotensin-converting enzyme by perindopril in the endothelium and adventitia of large arteries and organs of the rabbit. Zhuo J, et al. **J Cardiovasc Pharmacol** 1997 Mar; 29(3):297–310

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. Liu YH, et al. **J Clin Invest** 1997 Apr 15;99(8):1926–35

Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AIIRA) on renal function and glomerular injury in subtotal nephrectomized rats. Yamamoto M, et al. **J Clin Lab Anal** 1997;11(1):53–62

Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients. Simunic M, et al. **J Clin Pharmacol** 1995 Dec;35(12):1150–5

The correction of autonomic dysfunction in cirrhosis by captopril. Dillon JF, et al. **J Hepatol** 1997 Feb;26(2):331–5

Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. Bakris G, et al. **J Hum Hypertens** 1997 Jan;11(1):35–8 (35 ref.)

Effects of moderate salt restriction alone and in combination with cilazapril on office and ambulatory blood pressure. Uusitupa M, et al. **J Hum Hypertens** 1996 May;10(5):319–26

Effect of captopril on intracellular free calcium ([Ca2+]i) of thymocytes in spontaneously hypertensive rats. Xie L, et al. **J Hum Hypertens** 1996 Jun;10(6):425–7

A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. Chen S, et al. **J Hypertens** 1996 Nov;14(11):1325–30

Renal function in one-kidney, one clip sodium-restricted rats: influence of enalapril and losartan. Demeilliers B, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1764–6

The angiotensin converting enzyme inhibitors fosinopril and enalapril differ in their central nervous effects in humans. Derad I, et al. **J Hypertens** 1996 Nov;14(11):1309–15

Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels. Endlich K, et al. **J Hypertens** 1997 Jun;15(6):633–41

Kinins and the events influenced by an angiotensin-converting enzyme inhibitor during neointima formation in the rat carotid artery. Farhy RD, et al. **J Hypertens** 1997 Apr;15(4):421–9

Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. Hingorani AD, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1602–9

Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition. London GM, et al. **J Hypertens** 1996 Sep; 14(9):1139–46

Plasma renin activity levels influence the effect of converting enzyme inhibitors in preserving renal function in hypertension. Sanchez RA, et al. **J Hypertens** 1996 Aug; 14(8):1025–31

Effects of angiotensin converting enzyme inhibitor on renal haemodynamics during mental stress. Schmieder RE, et al. **J Hypertens** 1996 Oct;14(10):1201–7

Impaired renal haemodynamic response to amino acid infusion in essential hypertension during angiotensin converting enzyme inhibitor treatment. Tietze IN, et al. **J Hypertens** 1997 May;15(5):551–60

Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition. Zhang X, et al. **J Hypertens** 1995 Dec;13(12 Pt 1):1413–19

Effect of angiotensin-converting enzyme two-week inhibition on renal angiotensin II receptors and renal vascular reactivity in SHR. Haddad G, et al. **J Mol Cell Cardiol** 1997 Feb;29(2):813–22

Perindopril treatment prevents the loss of endothelial nitric oxide function and development of neo-intima in rabbits. Hickey H, et al. **J Mol Cell Cardiol** 1996 Sep;28(9):1985–94

Effects of chronic angiotensin-converting enzyme inhibition on left ventricular and myocyte structure and function during recovery from chronic rapid pacing. Melton DM, et al. **J Mol Cell Cardiol** 1997 Feb;29(2):697–710

Aspirin does not prevent the attenuation of myocardial stunning by the ACE inhibitor ramiprilat. Rose J, et al. **J Mol Cell Cardiol** 1996 Mar;28(3):603–13

Enalaprilat, an angiotensin-converting enzyme inhibitor, enhances functional preservation during long-term cardiac preservation. Possible involvement of bradykinin and PKC. Yang X, et al. **J Mol Cell Cardiol** 1996 Jul;28(7):1445–52

ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. Takeishi Y, et al. **J Nucl Med** 1997 Jul; 38(7):1085–9

Pharmacokinetic and pharmacodynamic study of imidapril, an active metabolite of imidapril, a new angiotensin-converting enzyme inhibitor, in spontaneously hypertensive rats. Yamanaka K, et al. **J Pharm Biomed Anal** 1997 Aug;15(12):1851–9

Electrical and mechanical modulations by oxygen-derived free-radical generating systems in guinea-pig heart muscles. Satoh H, et al. **J Pharm Pharmacol** 1997 May; 49(5):505–10

Studies on the magnitude and the mechanism of cough potentiation by angiotensin-converting enzyme inhibitors in guinea-pigs: involvement of bradykinin in the potentiation. Takahama K, et al. **J Pharm Pharmacol** 1996 Oct;48(10):1027–33

Steady-state pharmacokinetics and pharmacodynamics of imidaprilat, an active metabolite of imidapril, a new angiotensin-converting enzyme inhibitor in spontaneously hypertensive rats. Yamanaka K, et al. **J Pharm Sci** 1996 Nov;85(11):1234–7

Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. Brown NJ, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):703–12

Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats. Scheidegger KJ, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1276–81

Resistance and conduit arteries following converting enzyme inhibition in hypertension. Safar ME, et al. **J Vasc Res**

1997 Mar-Apr;34(2):67-81 (115 ref.)
Protective effect of the angiotensin-converting enzyme inhibitor captopril on postischemic myocardial damage in perfused rat heart. Takeda H, et al. **Jpn Circ J** 1997 Aug; 61(8):687-94
Effects of cilazapril on exercise tolerance in the chronic phase of acute myocardial infarction. Tanabe K, et al. **Jpn Circ J** 1996 Nov;60(11):831-40
Angiotensin-converting enzyme inhibitor up-regulates cardiac beta-receptors in cultured neonatal rat myocytes. Yonemochi H, et al. **Jpn Circ J** 1997 Feb;61(2):170-9
Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats. Kanagawa R, et al. **Jpn J Pharmacol** 1997 Mar;73(3):185-90
Altered prostaglandin metabolism induced by angiotensin-converting enzyme inhibitors in broncho-alveolar lavage fluid of the guinea pig. Umemura K, et al. **Jpn J Pharmacol** 1996 Sep;72(1):17-21
Inhibition of angiotensin-converting enzyme modulates structural and functional adaptation to loop diuretic-induced diuresis. Beck FX, et al. **Kidney Int** 1997 Jan;51(1):36-43
Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. De'Oliveira JM, et al. **Kidney Int** 1997 Sep; 52(3):771-7
The effect of ACE inhibitors on the expression of matrix genes and the role of p53 and p21 (WAF1) in experimental renal fibrosis. Morrissey JJ, et al. **Kidney Int Suppl** 1996 May;54:S83-7
The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Ziai F, et al. **Kidney Int Suppl** 1996 Dec;57:S132-6
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) [see comments] **Lancet** 1997 Jun 28; 349(9069):1857-63. Comment in: Lancet 1997 Jun 28;349(9069):1852-3.
Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study [letter] Porter AM. **Lancet** 1997 Sep 6;350(9079):736; discussion 736-7
Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Takai S, et al. **Life Sci** 1996;59(21):PL331-6
Effect of angiotensin-converting enzyme inhibition on Na+/H(+)-exchange and Ca(2+)-efflux in human erythrocytes. Lijnen P, et al. **Methods Find Exp Clin Pharmacol** 1997 Mar;19(2):125-8
Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Dixon IM, et al. **Mol Cell Biochem** 1996 Dec 6;165(1):31-45
Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy. Makino N, et al. **Mol Cell Biochem** 1996 Oct-Nov;163-164:239-45
Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Michaud A, et al. **Mol Pharmacol** 1997 Jun;51(6):1070-6
Potentiation of the pro-inflammatory effects of bradykinin by inhibition of angiotensin-converting enzyme and aminopeptidase P in rat paws. Damas J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):670-6
Influence of ACE inhibition on insulin resistance [letter] Dzúrik R, et al. **Nephrol Dial Transplant** 1995 Dec; 10(12):2373
Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis. Ebihara I, et al. **Nephrol Dial Transplant** 1997 May;12(5):1001-6
Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect? [editorial] Geiger H. **Nephrol Dial Transplant** 1997 Apr;12(4):640-2 (15 ref.)
Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients. Giordano M, et al. **Nephron** 1996;72(3):447-53
Renal hemodynamic changes induced by captopril and angictensin-converting enzyme gene polymorphism. Mizuiri S, et al. **Nephron** 1997;75(3):310-4
Investigation of inhibition angiotensin-converting enzyme (ACE) activity and opioid activity of two hemorphins, LVV-hemorphin-5 and VV-hemorphin-5, isolated from a defined peptic hydrolysate of bovine hemoglobin. Zhao Q, et al. **Neuropeptides** 1997 Apr;31(2):147-53
Influence of enalapril on experimental cyclosporin A nephrotoxicity. Anarat A, et al. **Pediatr Nephrol** 1996 Oct; 10(5):616-20
Effects of captopril and Icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-induced edema. Decarie A, et al. **Peptides** 1996;17(6):1009-15
Effects of captopril on responses to bradykinin in the hindquarters vascular bed of the rat. Nossaman BD, et al. **Peptides** 1997;18(4):491-4
Captopril alters schedule induced polydipsia, urination, and defecation in rats. Bowers RL, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):353-9
Short-term and long-term cardiovascular actions of different doses of perindopril in the rabbit. Fennessy PA, et al. **Pharmacol Res** 1996 Sep-Oct;34(3-4):135-41
Effects of chronic treatment with lisinopril on cardiovascular complications in streptozotocin diabetic and DOCA hypertensive rats. Sevak AR, et al. **Pharmacol Res** 1996 Nov-Dec;34(5-6):201-9
Effects of myocardial infarction and captopril therapy on anxiety-related behaviors in the rat. Prickaerts J, et al. **Physiol Behav** 1996 Jul;60(1):43-50
The inhibition of angiotensin converting enzyme attenuates the effects of chronic hypoxia on pulmonary blood vessels in the rat. Herget J, et al. **Physiol Res** 1996;45(3):221-6
Influence of captopril on the serotonin-induced vasopressor effect in tail artery isolated from two-kidney, one-clip renal hypertensive rats. Morelowska-Spierzak D, et al. **Pol J Pharmacol** 1995 Sep-Oct;47(5):417-22
Antithrombotic effect of enalapril, an angiotensin-converting enzyme inhibitor, on venous thrombosis in rats. Pawlak R, et al. **Pol J Pharmacol** 1996 Jan-Feb;48(1):117-20
Enhanced psychophysiological signs of attention after angiotensin-converting enzyme inhibition by captopril. Derad I, et al. **Psychophysiology** 1996 May;33(3):295-301
Angiotensin converting enzyme inhibitor captopril does not prevent acute gastrointestinal radiation damage in the rat. Moulder JE, et al. **Radiat Oncol Investig** 1997;5(2):50-3
Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism. Haddad G, et al. **Regul Pept** 1997 Jan 29;68(2):111-7
The angiotensin I-converting enzyme inhibitor, cilazapril inhibits the platelet-derived growth factor B chain expression in glomeruli of spontaneously hypertensive rats. Yamauchi T, et al. **Ren Physiol Biochem** 1995 Sep-Oct; 18(5):237-45
Free radical scavenging properties of alacepril metabolites and lisinopril. Noda Y, et al. **Res Commun Mol Pathol Pharmacol** 1997 May;96(2):125-36
PGE2 production after angiotensin-converting enzyme inhibition. Johnsen SA, et al. **Scand J Urol Nephrol** 1997 Feb;31(1):81-8
Effects of the angiotensin converting enzyme inhibitor enalapril on bacterial translocation after thermal injury and bacterial challenge. Gennari R, et al. **Shock** 1996 Aug; 6(2):95-100
Neointima formation in injured hamster carotid artery is effectively prevented by the combination G4120 and quinapril. Matsuno H, et al. **Thromb Haemost** 1996 Aug; 76(2):263-9
Impact of enalapril on microvascular perfusion and leukocyte adherence in a model of rat liver transplantation assessed by in vivo microscopy. Anthuber M, et al. **Transpl Int** 1996; 9 Suppl 1:S93-6
Losartan decreases hemoglobin in renal transplant recipients. Ducloux D, et al. **Transplant Proc** 1997 Aug;29(5):2402-3
Renal hemodynamic response to ureteral obstruction during converting enzyme inhibition. Frøkiaer J, et al. **Urol Res** 1996;24(4):217-27
[The influence of perindopril on intrarenal RAS in experimental diabetic rats] Liu Y, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jul;76(7):512-5 (Eng. Abstr.) **(Chi)**
[Reduction of incidence of ischemia-reperfusion induced ventricular fibrillation by captopril] Zhang M, et al. **Sheng Li Hsueh Pao** 1995 Dec;47(6):559-64 (Eng. Abstr.) **(Chi)**
[ACE inhibitors with SH groups have no effect of ATP-dependent K channels—a dissertation] Köppel H, et al. **Acta Med Austriaca** 1996;23(3):109-12 (Eng. Abstr.) **(Ger)**
[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors] Erley CM, et al. **Dtsch Med Wochenschr** 1997 Aug 1;122(31-32):953-8 (Eng. Abstr.) **(Ger)**
[Effect of the ACE inhibitor enalapril on development of chronic rejection after orthotopic rat kidney transplantation] Schleimer K, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:279-83 (Eng. Abstr.) **(Ger)**
[Effect of cilazapril in patients with essential hypertension: effect on cardiac hypertrophy] Abrahám G, et al. **Orv Hetil** 1996 Jul 21;137(29):1583-6 (Eng. Abstr.) **(Hun)**
[Anti-atherosclerotic action of angiotensin converting enzyme II. Effect on metabolism of kinin, free radical reaction, sensitivity to insulin and lipid metabolism] Stajszczyk M, et al. **Postepy Hig Med Dosw** 1996; 50(6):635-47 (71 ref.) (Eng. Abstr.) **(Pol)**
[Anti-atherosclerotic action of hypotensive drugs] Gmiński J, et al. **Wiad Lek** 1996;49(7-12):182-98 (0 ref.) (Eng. Abstr.) **(Pol)**
[Biochemical and physiological activity of new peptide inhibitors of angiotensin-converting enzyme] Gomazkov OA, et al. **Biull Eksp Biol Med** 1996 Sep;122(9):279-81 **(Rus)**
[A comparison of the effect of Capoten (captopril) and ramipril on the circadian profile of the arterial pressure and peripheral hemodynamics in patients with hypertension combined with diabetes mellitus] Filatova EV, et al. **Ter Arkh** 1996;68(5):67-70 (Eng. Abstr.) **(Rus)**
[Effect of captopril on angiotensin-converting enzyme activity and animal behavior in the "open field" test] Vernigora AN, et al. **Vopr Med Khim** 1996 Jan-Mar; 42(1):34-8 (Eng. Abstr.) **(Rus)**
[Hemodynamic effects of oral captopril in patients with critical aortic stenosis] Martínez Sánchez C, et al. **Arch Inst Cardiol Mex** 1996 Jul-Aug;66(4):322-30 (Eng. Abstr.) **(Spa)**
[Plausible pharmacologic interaction between fosinopril and acenocoumarol (letter)] de Tomás ME, et al. **Med Clin (Barc)** 1997 May 17;108(19):757 **(Spa)**
[Effect of cilazapril, a converting enzyme inhibitor, on cardiovascular hypertrophy in the hypertensive patient] Sesin J, et al. **Medicina (B Aires)** 1996;56(1):75-84 (Eng. Abstr.) **(Spa)**

POISONING

Captopril hepatotoxicity in a case of renal crisis due to systemic sclerosis. Deira JL, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1717-8

THERAPEUTIC USE

Regression of increased left ventricular masses in elderly hypertensive patients on lisinopril as assessed by magnetic resonance imaging. Handa S, et al. **Acad Radiol** 1996 Apr; 3(4):294-9
Angiotensin-converting enzyme inhibitors and anaesthesia [letter] Tohmo H, et al. **Acta Anaesthesiol Scand** 1996 Jan; 40(1):132-3
Clinical trials in progression of chronic renal failure. Striker GE, et al. **Adv Intern Med** 1997;42:555-95 (53 ref.)
Pharmacologic approaches to reperfusion injury. Willerson JT. **Adv Pharmacol** 1997;39:291-312 (120 ref.)
Clinical implications of alpha 1 adrenergic blockade and angiotensin converting enzyme inhibition 'cross talk' in heart failure in Nigerians [letter] Ajayi AA, et al. **Afr J Med Med Sci** 1996 Mar;25(1):95
Evaluation of treatment for congestive heart failure in patients aged 60 years and older using generic measures of health status (SF-36 and COOP charts). Jenkinson C, et al. **Age Ageing** 1997 Jan;26(1):7-13
Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. Hansen JF, et al. **Am Heart J** 1997 Aug; 134(2 Pt 2):S48-52
Treatment of acute myocardial infarction today. Maggioni AP, et al. **Am Heart J** 1997 Aug;134(2 Pt 2):S9-14 (29 ref.)
Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction. Patten RD, et al. **Am Heart J** 1997 Jul;134(1):37-43
Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Philbin EF, et al. **Am Heart J** 1997 Aug;134(2 Pt 1):188-95
The place of angiotensin-converting enzyme inhibition after acute myocardial infarction. Torp-Pedersen C, et al. **Am Heart J** 1997 Aug;134(2 Pt 2):S25-30 (24 ref.)
Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). **Am J Cardiol** 1996 Oct 15;78(8):902-7
Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension. Aepfelbacher FC, et al. **Am J Cardiol** 1997 Mar 15;79(6):826-8
Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Bart BA, et al. **Am J Cardiol** 1997 Apr 15; 79(8):1118-20
The time course of left ventricular remodeling after acute myocardial infarction [editorial] Glasser SP. **Am J Cardiol** 1997 Aug 15;80(4):506-7
Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction. Greaves SC, et al. **Am J Cardiol** 1997 Aug 15;80(4):442-8
Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group [see comments] Hansen JF, et al. **Am J Cardiol** 1997 Mar 15;79(6):738-41. Comment in: Am J Cardiol 1997 Mar 15;79(6):788-9.
Effect of ramipril on mitral regurgitation secondary to mitral valve prolapse. Høst U, et al. **Am J Cardiol** 1997 Sep 1; 80(5):655-8
Relation of functional improvement in congestive heart failure after quinapril therapy to peripheral limitation. Jondeau G, et al. **Am J Cardiol** 1997 Mar 1;79(5):635-8
Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons > or = 65 years of age. Krumholz HM, et al. **Am J Cardiol** 1997 Mar 1;79(5):581-6
Baseline clinical and angiographic data in the Quinapril Ischemic Event (QUIET) Trial. Lees RS, et al. **Am J Cardiol** 1996 Nov 1;78(9):1011-6
Response of symptomatic myocardial ischemia in ischemic cardiomyopathy to intensive vasodilator therapy. Levine TB, et al. **Am J Cardiol** 1997 Jul 15;80(2):212-4
Study design and baseline characteristics of the study to

evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE. Lonn EM, et al. **Am J Cardiol** 1996 Oct 15;78(8):914–9

Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Nguyen KN, et al. **Am J Cardiol** 1997 Jan 15;79(2):115–9

Improved endothelial function with angiotensin–converting enzyme inhibitors. Pepine CJ. **Am J Cardiol** 1997 Mar 6; 79(5A):29–32

The potential use of angiotensin–converting enzyme inhibitors in patients with hyperlipidemia. Pitt B. **Am J Cardiol** 1997 Mar 6;79(5A):24–8 (37 ref.)

ASHP therapeutic guidelines on angiotensin–converting–enzyme inhibitors in patients with left ventricular dysfunction. This official ASHP practice standard was developed through the ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 16, 1996 [see comments] **Am J Health Syst Pharm** 1997 Feb 1;54(3):299–313 (109 ref.). Comment in: Am J Health Syst Pharm 1997 Feb 1;54(3):264.

Trandolapril approved for marketing [news] **Am J Health Syst Pharm** 1996 Jul 15;53(14):1649

Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients. Briscoe TA, et al. **Am J Health Syst Pharm** 1996 Sep 15;53(18):2191–3

Promoting use of angiotensin–converting–enzyme inhibitors [editorial; comment] Cooke–Ariel H. **Am J Health Syst Pharm** 1997 Feb 1;54(3):264. Comment on: Am J Health Syst Pharm 1997 Feb 1;54(3):299–313.

Rationale and safety of angiotensin converting enzyme inhibitor combination with calcium channel blockers. Applegate WB. **Am J Hypertens** 1996 Dec;9(12 Pt 2):192S

Questions regarding Kostis' article on SOLVD [letter; comment] Borhani NO. **Am J Hypertens** 1996 Jun; 9(6):615–9. Comment on: Am J Hypertens 1995 Sep;8(9):909–14.

Additive effects of diltiazem and lisinopril in the treatment of elderly patients with mild–to–moderate hypertension. Chan P, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 1):743–9

Home self blood pressure measurement in general practice. The SMART study. Self–measurement for the Assessment of the Response to Trandolapril [see comments] Chatellier G, et al. **Am J Hypertens** 1996 Jul;9(7):644–52. Comment in: Am J Hypertens 1997 Jan;10(1):141–2.

Missing explanation on enalapril monotherapy [letter; comment] Cheng TO. **Am J Hypertens** 1997 Mar;10(3):366 . Comment on: Am J Hypertens 1996 Sep;9(9):909–14.

The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Dahlöf B, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 1):705–13

Fixed–dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group. DeQuattro V, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 2):138S–145S

Angiotensin converting enzyme inhibition corrects Na+/H+ exchanger overactivity in essential hypertension. Fortuño A, et al. **Am J Hypertens** 1997 Jan; 10(1):84–93

Commentary on Kostis' report from SOLVD [letter; comment] Gavras I, et al. **Am J Hypertens** 1996 Jun; 9(6):615, 616–9. Comment on: Am J Hypertens 1995 Sep;8(9):909–14.

Has the use of angiotensin converting enzyme inhibitors and calcium channel blockers improved the outcome for hypertensive patients? Gifford RW Jr. **Am J Hypertens** 1997 Mar;10(3):9S–12S (19 ref.)

The alterations in insulin sensitivity during angiotensin converting enzyme inhibitor treatment are related to changes in the calcium/magnesium balance. Haenni A, et al. **Am J Hypertens** 1997 Feb;10(2):145–51

Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. Multicenter Study Group. Larochelle P. **Am J Hypertens** 1996 Jun; 9(6):551–9

Salt sensitivity of hypertension and responses to angiotensin converting enzyme inhibition with benazepril. Moore TJ, et al. **Am J Hypertens** 1996 Jan;9(1):54–60

The effects of replacing beta–blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. Paran E, et al. **Am J Hypertens** 1996 Dec;9(12 Pt 1):1206–13

Effects of UP269–6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy. Villa E, et al. **Am J Hypertens** 1997 Mar; 10(3):275–81

Albuminuria in diabetes mellitus: relation to ambulatory versus office blood pressure and effects of cilazapril. Waeber B, et al. **Am J Hypertens** 1996 Dec;9(12 Pt 1):1220–7

Effect of enalapril therapy on glomerular accumulation of immune complexes and mesangial matrix in experimental glomerulonephritis in the nonhuman primate. Hebert LA, et al. **Am J Kidney Dis** 1997 Aug;30(2):243–52

The influence of angiotensin–converting enzyme inhibition on renal tubular function in progressive chronic nephropathy. Kamper AL, et al. **Am J Kidney Dis** 1996 Dec;28(6):822–31

Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria. Toto RD, et al. **Am J Kidney Dis** 1996 Dec;28(6):832–40

The renoprotective properties of angiotensin–converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. Zoja C, et al. **Am J Kidney Dis** 1997 Feb; 29(2):254–64

ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats. Kaneko K, et al. **Am J Med Sci** 1997 Jul;314(1):21–7

Effects of long–term treatment with enalapril or hydralazine on the renin–angiotensin–aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. Häggström J, et al. **Am J Vet Res** 1996 Nov; 57(11):1645–52

Hemodynamic effects of anesthesia in patients with ischemic heart failure chronically treated with angiotensin–converting enzyme inhibitors. Ryckwaert F, et al. **Anesth Analg** 1997 May;84(5):945–9

Effect of angiotensin–converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta–analysis of randomized trials. Angiotensin–Converting–Enzyme Inhibition and Progressive Renal Disease Study Group. Giatras I, et al. **Ann Intern Med** 1997 Sep 1;127(5):337–45

Effect of the ACE inhibitor ceronapril on cerebral blood flow in hypertensive patients. Cutler NR, et al. **Ann Pharmacother** 1996 Jun;30(6):578–82

Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy. Cziraky MJ, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):791–801 (81 ref.)

What is the role of angiotensin–converting enzyme inhibitors in congestive heart failure and after myocardial infarction? Nelson KM, et al. **Ann Pharmacother** 1996 Sep;30(9):986–93 (44 ref.)

Captopril in cardioplegia and reperfusion: protective effects on the ischemic heart. Gurevitch J, et al. **Ann Thorac Surg** 1997 Mar;63(3):627–33

Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin–converting enzyme inhibitor. Sigler C, et al. **Arch Dermatol** 1997 Aug;133(8):972–5

Heart failure treatment with angiotensin–converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium. **Arch Intern Med** 1997 May 26;157(10):1103–8

Effects of efonidipine, nicardipine and captopril on proteinuria in aged spontaneously hypertensive rats. Shudo C, et al. **Arzneimittelforschung** 1996 Sep;46(9):852–4

A cost–effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Butler JR, et al. **Aust N Z J Med** 1996 Feb;26(1):89–95

Nitritoid reaction in a patient on ACE inhibitor and Myocrisin treatments [letter] Ching DW, et al. **Aust N Z J Med** 1997 Jun;27(3):343

Remodeling after myocardial infarction: an opportunity for early intervention. Amos DJ, et al. **Basic Res Cardiol** 1997 Apr;92(2):69–71 (10 ref.)

Angiotensin II type 1 receptor induced signal–transduction pathways as new targets for pharmacological treatment of the renin–angiotensin system. Schorb W, et al. **Basic Res Cardiol** 1996;91 Suppl 2:91–6 (35 ref.)

Tissue repair and angiotensin II generated at sites of healing. Weber KT, et al. **Basic Res Cardiol** 1997 Apr;92(2):75–8 (10 ref.)

Protein synthesis during regression of left ventricular hypertrophy with lisinopril in abdominal aortic constriction model of hypertension. Siddiq T, et al. **Biochem Mol Med** 1996 Feb;57(1):19–24

Low dose of ACE–inhibitor enhances sodium excretion in volume expanded patients with borderline hypertension. Borghi C, et al. **Blood Press** 1996 Mar;5(2):105–12

Effect of angiotensin converting enzyme inhibition [Cilazapril] on blood pressure recording in hypertensive obstructive sleep apneic patients. Grote L, et al. **Blood Press** 1997 Jul;6(4):235–41

The Swedish Trial in old patients with hypertension–2 (STOP–hypertension–2): a progress report. Lindholm LH, et al. **Blood Press** 1996 Sep;5(5):300–4

Inhibitor index: a novel method for measuring pharmacological inhibition of angiotensin–converting enzyme. Reneland R, et al. **Blood Press** 1997 Mar; 6(2):103–8

Comparison of temocapril and atenolol in the long–term treatment of mild to moderate essential hypertension. Sierakowski B, et al. **Blood Press** 1997 Jul;6(4):229–34

ACE inhibitors and renal protection [letter; comment] Colson P. **Br J Anaesth** 1997 Apr;78(4):477–8. Comment on: Br J Anaesth 1996 May;76(5):632–9.

Further evidence that chronic perindopril treatment maintains neurohormonal suppression but does not lower blood pressure in chronic cardiac failure. MacFadyen RJ, et al. **Br J Clin Pharmacol** 1997 Jul;44(1):69–76

Influence of ACE inhibition on left ventricular hypertrophy. Agabiti–Rosei E, et al. **Br J Clin Pract Symp Suppl** 1996 Jul;84:17–22 (25 ref.)

How ACE inhibitors reduce death from myocardial infarction: hypotheses from the AIRE study. Acute Infarction Ramipril Efficacy study. Ball SG, et al. **Br J Clin Pract Symp Suppl** 1996 Jul;84:31–5

Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study. Gohlke P, et al. **Br J Clin Pract Symp Suppl** 1996 Jul; 84:1–10

ACE inhibitor use in elderly patients with systolic left ventricular dysfunction: problems and opportunities. Pitt B. **Br J Clin Pract Symp Suppl** 1996 Jul;84:11–6 (36 ref.)

Cardioprotective potential of angiotensin converting enzyme inhibitors. Gavras I, et al. **Braz J Med Biol Res** 1996 Jun; 29(6):701–5

Angiotensin–converting enzyme inhibition in myocardial infarction—Part 2: Clinical issues and controversies. Huckell VF, et al. **Can J Cardiol** 1997 Feb;13(2):173–82 (25 ref.)

Angiotensin–converting enzyme inhibition in myocardial infarction—Part 1: Clinical data. Huckell VF, et al. **Can J Cardiol** 1997 Feb;13(2):161–9 (7 ref.)

Effect of angiotensin–converting enzyme inhibition on infarct collagen deposition and remodelling during healing after transmural canine myocardial infarction. Jugdutt BI, et al. **Can J Cardiol** 1997 Jul;13(7):657–68

Is there a role for bradykinin in the therapeutic and side effects of angiotensin–converting enzyme inhibitors? Marceau F. **Can J Cardiol** 1997 Feb;13(2):187–94 (71 ref.)

Effect of angiotensin–converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function. Marcotte F, et al. **Can J Cardiol** 1997 May; 13(5):479–85

Effect of angiotensin–converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function [letter] Ray JG. **Can J Cardiol** 1997 Aug;13(8):780–1, 783

Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin–converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators. Teo KK, et al. **Can J Cardiol** 1997 Jun;13(6):591–9

A pragmatic approach to the use of angiotensin–converting enzyme inhibitors in acute myocardial infarction. Vantrimpont P, et al. **Can J Cardiol** 1996 Oct;12(10):924–9 (37 ref.)

What can angiotensin antagonists do that converting–enzyme inhibition can't: the case of post–angioplastic restenosis. Pham D, et al. **Can J Physiol Pharmacol** 1996 Jul; 74(7):867–77

Drugs that delay the progression of coronary atherosclerosis. Ferraro–Borgida M, et al. **Cardiologia** 1997 Feb; 42(2):149–61 (67 ref.)

Clinical aspects of ACE inhibition in patients with acute myocardial infarction. Borghi C, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):519–25 (44 ref.)

An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. Byyny RL, et al. **Cardiovasc Drugs Ther** 1996 Jul;10(3):313–9

Combination drug therapy in chronic heart failure: is treatment part of the problem in heart failure? Cleland JG. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:297–303 (47 ref.)

Left ventricular diastolic function during adrenergic stress in essential hypertension: acute and chronic effects of ACE inhibition. Covi G, et al. **Cardiovasc Drugs Ther** 1996 Jul; 10(3):321–9

Cardioprotective effect of angiotensin–converting enzyme inhibitors in patients with coronary artery disease. Ferrari R, et al. **Cardiovasc Drugs Ther** 1996 Nov;10 Suppl 2:639–47 (132 ref.)

Captopril does not acutely modulate plasma endothelin–1 concentration in human congestive heart failure. Grenier O, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):561–5

Emerging concepts: angiotensin–converting enzyme inhibition in coronary artery disease. Mancini GB. **Cardiovasc Drugs Ther** 1996 Nov;10 Suppl 2:609–12 (22 ref.)

Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril. Morisco C, et al. **Cardiovasc Drugs Ther** 1997 Mar;11(1):63–9

Regression of chronic hypoxia–induced pulmonary hypertension, right ventricular hypertrophy, and fibrosis: effect of enalapril. Pelouch V, et al. **Cardiovasc Drugs Ther** 1997 Apr;11(2):177–85

ACE inhibitors in heart failure: prospects and limitations. Pitt B. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:285–90 (42 ref.)

Angiotensin–converting enzyme inhibitors and coronary artery disease. Sayer JW, et al. **Cardiovasc Drugs Ther** 1996 Nov;10 Suppl 2:631–7 (42 ref.)

Both a calcium antagonist and ACE inhibitor reverse hypertrophy in hypertension but a calcium antagonist also depresses contractility. Sumimoto T, et al. **Cardiovasc Drugs Ther** 1997 Mar;11(1):27–32

Renin inhibitors: cardiovascular drugs of the future? Wood JM, et al. **Cardiovasc Drugs Ther** 1996 Jul;10(3):309–12 (31 ref.)

Wall stress–induced arrhythmias in the working rat heart as left ventricular hypertrophy regresses during captopril treatment. Dalton GR, et al. **Cardiovasc Res** 1997 Mar; 33(3):561–72

Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Galatius–Jensen S, et al. **Cardiovasc Res** 1996 Dec;32(6):1148–54

Ramipril therapy improves arterial dilation in experimental hypertension. Hutri-Kähönen N, et al. **Cardiovasc Res** 1997 Jan;33(1):188–95

A three year clinical review of the impact of angiotensin converting enzyme inhibitors on the intra hospital mortality of congestive heart failure in Nigerians. Adewole AD, et al. **Cent Afr J Med** 1996 Aug;42(8):253–5

Beneficial effects of captopril on prognosis in patients with acute myocardial infarction. Shanghai Secondary Prevention of Acute Myocardial Infarction Study Group. Shen W, et al. **Chin Med J (Engl)** 1996 Aug;109(8):588–91

Abnormal left ventricular systolic and diastolic functional response to isometric exercise in idiopathic dilated cardiomyopathy: beneficial effect of captopril. Shen W, et al. **Chin Med Sci J** 1995 Dec;10(4):232–6

Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Cohn JN, et al. **Circulation** 1997 Aug 5;96(3):856–63

ACE inhibitors in myocardial infarction [letter; comment] Di Pasquale P. **Circulation** 1996 Nov 1;94(9):2314–5. Comment on: Circulation 1995 Nov 15;92(10):3132–7.

Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Donckier JE, et al. **Circulation** 1997 Aug 19;96(4):1250–6

Enalapril does not enhance exercise capacity in patients after Fontan procedure. Kouatli AA, et al. **Circulation** 1997 Sep 2;96(5):1507–12

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study [see comments] [published erratum appears in Circulation 1996 Sep 15;94(6):1490] Mancini GB, et al. **Circulation** 1996 Aug 1; 94(3):258–65. Comment in: Circulation 1996 Aug 1;94(3):240–3.

Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure. Effects on survival, hemodynamics, and cardiovascular remodeling. Mulder P, et al. **Circulation** 1997 Mar 4;95(5):1314–9

Images in cardiovascular medicine. An 'ACE' of a test. Narula J, et al. **Circulation** 1997 May 20;95(10):2456–7

Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Nong Z, et al. **Circulation** 1996 Oct 15;94(8):1941–7

Reversing endothelial dysfunction with ACE inhibitors. A new trend [editorial; comment] Rajagopalan S, et al. **Circulation** 1996 Aug 1;94(3):240–3. Comment on: Circulation 1996 Aug 1;94(3):258–65.

Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Steimle AE, et al. **Circulation** 1997 Aug 19; 96(4):1165–72

Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Soejima H, et al. **Clin Cardiol** 1997 May;20(5):441–5

Efficacy of combination therapy with trandolapril and verapamil sr in primary hypertension: a 4 x 4 trial design. The Trandolapril Study Group. DeQuattro V, et al. **Clin Exp Hypertens** 1997 Apr;19(3):373–87

Cardioprotective effect of enalapril in renovascular and angiotensin II hypertension. Herizi A, et al. **Clin Exp Hypertens** 1997 Jul-Aug;19(5-6):953–64

Does combined therapy of Ca-channel blocker and angiotensin converting enzyme inhibitor exceed monotherapy in renal protection against hypertensive injury in rats? Kanno Y, et al. **Clin Exp Hypertens** 1996 Feb;18(2):243–56

Effects of quinapril hydrochloride in patients with essential hypertension and impaired renal function. Owada A, et al. **Clin Exp Hypertens** 1997 May;19(4):495–502

Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Wing LM, et al. **Clin Exp Hypertens** 1997 Jul-Aug;19(5-6):779–91

Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Management Committee on behalf of the High Blood Pressure Research Council of Australia. **Clin Exp Pharmacol Physiol** 1997 Feb; 24(2):188–92

Cardiac growth during high and low dose perindopril treatment in spontaneously hypertensive rats. Black MJ, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul; 23(6-7):605–7

Differential efficacy of perindopril and enalapril in experimental diabetic nephropathy. Duggan KA, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):608–10

Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist. Ledingham JM, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):576–8

Transgenic rats: tools to study the function of the renin-angiotensin system. Bader M, et al. **Clin Exp Pharmacol Physiol Suppl** 1996;3:S81–7 (80 ref.)

Do kinins mediate cardioprotective and renoprotective effects of cilazapril in spontaneously hypertensive rats with renal ablation? Kohzuki M, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S357–9

Long-term effects of treatment with enalapril on the structure of mesenteric resistance arteries in New Zealand genetically hypertensive rats. Ledingham JM, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S350–2

Long-term therapeutic effects of ace inhibitor and calcium antagonists on hypertensive vascular lesions in M-SHRSP. Ohta Y, et al. **Clin Exp Pharmacol Physiol Suppl** 1995; 1:S321–2

Enalapril improves glucose tolerance in two rat models: a new hypertensive diabetic strain and a fructose-induced hyperinsulinaemic rat. Rosenthal T, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S353–4

Changes of lipid peroxides and antioxidative factors levels in blood of patients treated with ACE inhibitors. Djordjević VB, et al. **Clin Nephrol** 1997 Apr;47(4):243–7

Angiotensin converting enzyme inhibitor improves nephrotic syndrome associated with cyanotic congenital heart disease [letter] Watanabe Y, et al. **Clin Nephrol** 1996 May; 45(5):362–3

Tissue expression of components of the renin-angiotensin system in experimental post-infarction heart failure in rats: effects of heart failure and angiotensin-converting enzyme inhibitor treatment. Kelly MP, et al. **Clin Sci (Colch)** 1997 May;92(5):455–65

Effects of cilazapril on ventricular arrhythmia in patients with congestive heart failure. Hattori Y, et al. **Clin Ther** 1997 May-Jun;19(3):481–6

Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Kuschnir E, et al. **Clin Ther** 1996 Nov-Dec;18(6):1213–24

An open-label, noncomparative, multicenter study of ramipril in the treatment of patients with mild-to-moderate hypertension. Sadick A, et al. **Clin Ther** 1996 Nov-Dec; 18(6):1161–8

Efficacy and tolerability of doxazosin versus enalapril in the treatment of patients with mild-to-moderate hypertension. Tan KW, et al. **Clin Ther** 1997 May-Jun;19(3):459–70

Sudden cardiac death in ischemic heart disease. Chang D, et al. **Compr Ther** 1997 Feb;23(2):95–103 (38 ref.)

Effect of antiproteinuric treatment on the lipid profile in nondiabetic renal disease. Navis G, et al. **Contrib Nephrol** 1997;120:88–96 (50 ref.)

Effects of BIBR-277, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs. Izumi H, et al. **Coron Artery Dis** 1996 Oct;7(10):775–9

Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction. Pedersen OD, et al. **Coron Artery Dis** 1997 May;8(5):283–91

The effect of an angiotensin converting enzyme inhibitor on skin microvascular hyperaemia in microalbuminuric insulin-dependent diabetes mellitus. Yosipovitch G, et al. **Diabet Med** 1997 Mar;14(3):235–41

Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Nielsen FS, et al. **Diabetes** 1997 Jul; 46(7):1182–8

Reversible hyperkalemia at the initiation of ACE inhibitors in a young diabetic patient with latent hyporeninemic hypoaldosteronism [letter] Bonnet F, et al. **Diabetes Care** 1996 Jul;19(7):781

Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. Gerstein HC, et al. **Diabetes Care** 1996 Nov;19(11):1225–8

Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Kontopoulos AG, et al. **Diabetes Care** 1997 Mar; 20(3):355–61

An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Rodby RA, et al. **Diabetes Care** 1996 Oct;19(10):1051–61

The DIAB-HYCAR Study. Passa P, et al. **Diabetologia** 1996 Dec;39(12):1662–7

Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Schnack C, et al. **Diabetologia** 1996 Dec;39(12):1611–6

Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Yokoyama H, et al. **Diabetologia** 1997 Apr;40(4):405–11

A risk-benefit assessment of ACE inhibitor therapy post-myocardial infarction. Borghi C, et al. **Drug Saf** 1996 May;14(5):277–87 (42 ref.)

Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure. Davis R, et al. **Drugs** 1997 Jul;54(1):103–16 (53 ref.)

Current drug treatment and treatment patterns with antihypertensive drugs. Freis ED, et al. **Drugs** 1996 Jul; 52(1):1–16 (136 ref.)

Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Goa KL, et al. **Drugs** 1996 Oct;52(4):564–88 (154 ref.)

Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Wagstaff AJ, et al. **Drugs** 1996 May;51(5):777–91 (75 ref.)

Chemoprophylaxis of diabetic nephropathy in the elderly. Jungmann E. **Drugs Aging** 1996 Dec;9(6):449–57 (53 ref.)

Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction. Randomized, placebo-controlled substudy of ISIS-4. Budaj A, et al. **Eur Heart J** 1996 Oct;17(10):1506–10

Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators [see comments] Cleland JG, et al. **Eur Heart J** 1997 Jan;18(1):41–51. Comment in: Eur Heart J 1997 Jan;18(1):3–4.

Slowing the progression of heart failure [editorial] Cohn JN. **Eur Heart J** 1996 Nov;17(11):1609–11

Can qualitative echocardiography be used to select patients for angiotensin-converting enzyme inhibitors following acute myocardial infarction? Darbar D, et al. **Eur Heart J** 1996 Dec;17(12):1783–6 (29 ref.)

Angina and left ventricular dysfunction. Dargie HJ. **Eur Heart J** 1996 Dec;17 Suppl G:2–7 (25 ref.)

Treatment effects on the total ischaemic burden and prognostic implications. Deanfield J. **Eur Heart J** 1996 Dec;17 Suppl G:64–8 (30 ref.)

The role of ACE inhibitors in preventing myocardial infarction: potential mechanisms and clinical implications. Francis GS. **Eur Heart J** 1995 Nov;16 Suppl K:1–3 (16 ref.)

More favourable haemodynamic effects from metoprolol than from captopril in patients with dilated cardiomyopathy. Jansson K, et al. **Eur Heart J** 1997 Jul;18(7):1115–21

Role of angiotensin converting enzyme inhibitors in preventing left ventricular remodelling following myocardial infarction. Konstam MA. **Eur Heart J** 1995 Nov;16 Suppl K:42–8 (57 ref.)

ACE inhibitors in heart failure: effect on mode of death [editorial; comment] Kübler W. **Eur Heart J** 1997 Jan; 18(1):3–4. Comment on: Eur Heart J 1997 Jan;18(1):41–51.

Captopril adjuvant therapy to beta-blockers and nitrates improves post-myocardial infarction left ventricular performance. Kyriakidis M, et al. **Eur Heart J** 1996 Jun; 17(6):864–73

Potential role of angiotensin converting enzyme inhibitors in treatment of atherosclerosis. Pitt B. **Eur Heart J** 1995 Nov;16 Suppl K:49–54 (37 ref.)

The value of angiotensin converting enzyme inhibitors for the treatment of patients with left ventricular dysfunction, heart failure or after acute myocardial infarction. Swedberg K, et al. **Eur Heart J** 1996 Sep;17(9):1306–11 (31 ref.)

Combined heart failure treatment with ACE inhibition and AT1-receptor blockade [letter] Willenheimer R, et al. **Eur Heart J** 1996 Nov;17(11):1768–9

Oral therapy with combined enalapril, prazosin and hydrochlorothiazide in the acute treatment of severe hypertension in Nigerians. Ajayi AA, et al. **Eur J Clin Pharmacol** 1996;51(1):45–8

ACE inhibitors before or after heart failure? Erhardt L. **Eur J Clin Pharmacol** 1996;49 Suppl 1:S19–28 (73 ref.)

Efficacy and safety of spirapril, a new ace-inhibitor, in elderly hypertensive patients. Kantola I, et al. **Eur J Clin Pharmacol** 1996;50(3):155–9

Adaptive changes in the acute haemodynamic effects of cilazapril during chronic treatment. Comparison with long-term clinical effect. Larsen J, et al. **Eur J Clin Pharmacol** 1996;50(6):433–41

Mega-trials: is meta-analysis an alternative? Lubsen J. **Eur J Clin Pharmacol** 1996;49 Suppl 1:S29–33

Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Persson B, et al. **Eur J Clin Pharmacol** 1996;50(4):259–64

Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension. Rangemark C, et al. **Eur J Clin Pharmacol** 1996;49(4):267–71

What have the ACE-inhibitor trials in postmyocardial patients with left ventricular dysfunction taught us? Reynolds G, et al. **Eur J Clin Pharmacol** 1996;49 Suppl 1:S35–9 (19 ref.)

Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. Zoja C, et al. **Exp Nephrol** 1996 Jul-Aug;4(4):213–21

Systemic, pulmonary, brachial, renal and hepato-splanchnic hemodynamic effects of spirapril in severe congestive heart failure. Bellissant E, et al. **Fundam Clin Pharmacol** 1996; 10(2):127–35

Effects of enalapril in rats with pressure overload cardiac hypertrophy. Di Paola Eugenio D, et al. **Gen Pharmacol** 1997 Apr;28(4):531–3

Can clonidine, enoximone, and enalaprilat help to protect the myocardium against ischaemia in cardiac surgery? [see comments] Boldt J, et al. **Heart** 1996 Sep;76(3):207–13. Comment in: Heart 1996 Sep;76(3):189–90.

ACE inhibitors and arrhythmias. Campbell RW. **Heart** 1996 Nov;76(3 Suppl 3):79–82 (36 ref.)

Inhibitors of the renin-angiotensin system in established cardiac failure. Chatterjee K. **Heart** 1996 Nov;76(3 Suppl 3):83–91 (38 ref.)

Inhibition of the renin-angiotensin system after acute myocardial infarction--treat first, select later? Hall AS, et al. **Heart** 1996 Nov;76(3 Suppl 3):73–8 (31 ref.)

ACE inhibitors unmask incoordinate diastolic wall motion

in restrictive left ventricular disease. Henein MY, et al. **Heart** 1996 Oct;76(4):326–31

Changing patterns of investigation and treatment of cardiac failure in hospital. Hillis GS, et al. **Heart** 1996 Nov; 76(5):427–9

The renin–angiotensin system and the heart. Introduction [editorial] Ikram H. **Heart** 1996 Nov;76(3 Suppl 3):3–6

Increased myocardial [123I]–metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Somsen GA, et al. **Heart** 1996 Sep; 76(3):218–22

Heart failure and atrial fibrillation: current concepts and controversies. Van den Berg MP, et al. **Heart** 1997 Apr; 77(4):309–13 (38 ref.)

Improvement of left ventricular diastolic dysfunction in hypertensive patients 1 month after ACE inhibition therapy: evaluation by ultrasonic automated boundary detection. Angomachalelis N, et al. **Heart Vessels** 1996; 11(6):303–9

Effects of enalapril and nitrendipine on exercise albuminuria in normotensive type I diabetic patients with incipient nephropathy. Heinemann L, et al. **Horm Metab Res** 1996 Oct;28(10):549–52

Prevention of diabetic nephropathy. Materson BJ, et al. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):129–34, 139–40 (12 ref.)

Effects of ACE inhibitors versus calcium antagonists on left ventricular morphology and function in patients with essential hypertension. Matsuzaki K, et al. **Hypertens Res** 1997 Mar;20(1):7–10

Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Benetos A, et al. **Hypertension** 1996 Dec;28(6):1081–4

Contribution of nitric oxide to the beneficial effects of enalapril in the fructose-induced hyperinsulinemic rat. Erlich Y, et al. **Hypertension** 1996 Nov;28(5):754–7

Cardiac transplantation, perindopril, and left ventricular hypertrophy in spontaneously hypertensive rats. Harrap SB, et al. **Hypertension** 1996 Oct;28(4):622–6

Combined sympathetic suppression and angiotensin–converting enzyme inhibition in congestive heart failure. Manolis AJ, et al. **Hypertension** 1997 Jan;29(1 Pt 2):525–30

Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo–controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Reisin E, et al. **Hypertension** 1997 Jul;30(1 Pt 1):140–5

Erythrocyte sodium–lithium countertransport in non–modulating offspring and essential hypertensive individuals: response to enalapril. Sánchez RA, et al. **Hypertension** 1997 Jul;30(1 Pt 1):99–105

Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries. Thürmann PA, et al. **Hypertension** 1996 Sep;28(3):450–6

Intrarenal determinants of sodium retention in mild heart failure: effects of angiotensin–converting enzyme inhibition. Volpe M, et al. **Hypertension** 1997 Aug;30(2 Pt 1):168–76

Angiotensin converting enzyme inhibitors: present status and future perspectives. Sharma S, et al. **Indian Heart J** 1995 Sep–Oct;47(5):509–16 (45 ref.)

Study on the effectiveness of enalapril as a monotherapy in mild to moderate hypertension. Poulose M, et al. **Indian J Med Sci** 1996 Jan;50(1):1–3

Effects of enalapril on lipid profile in diabetic and non–diabetic essential hypertensive patients. Satia MC, et al. **Indian J Physiol Pharmacol** 1996 Jan;40(1):83–6

Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. Novo S, et al. **Int Angiol** 1996 Jun;15(2):169–74

Effects of enalapril on left ventricular function and exercise performance after a first acute myocardial infarction. The EDEN Study Investigators. **Int J Cardiol** 1997 May 23; 59(3):257–65

Concurrent alpha 1 adrenergic blockade and angiotensin converting enzyme inhibition in the treatment of congestive heart failure. Ajayi AA, et al. **Int J Cardiol** 1996 Dec 6; 57(2):173–6

Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Houghton AR, et al. **Int J Cardiol** 1997 Mar; 59(1):7–10

ACE inhibitors and unilateral renal artery stenosis—what price? Kothari SS. **Int J Cardiol** 1996 Mar;53(3):199–201 (22 ref.)

Antihypertensive efficacy of a once a day verapamil SR/trandolapril combination. Oren S, et al. **Int J Cardiol** 1996 Jul 5;55(1):97–102

Randomized controlled trial of ACE–inhibitors and beta–blockers with and without vasodilating activity in chronic glomerulonephritis. Erley CM, et al. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):504–9

Metabolic effects of spirapril and atenolol: results from a randomized, long–term study. Hakamäki T, et al. **Int J Clin Pharmacol Ther** 1997 Jun;35(6):227–30

Changes in plasma cardiac natriuretic peptides concentrations during 1 year treatment with angiotensin–converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy. Kohno M, et al. **Int J Clin Pharmacol Ther** 1997 Jan;35(1):38–42

Comparison of captopril–thiazide and enalapril–thiazide combinations in the management of mild to moderate black hypertensive patients: how important is diuretic dose and duration of action of the ACE–inhibitor? Skoularigis J, et al. **Int J Clin Pharmacol Ther** 1996 Jun;34(6):263–8

Efficacy of enalapril after ineffective theophylline treatment on erythrocytosis after renal transplantation. Yagisawa T, et al. **Int Urol Nephrol** 1997;29(3):363–7

The diagnosis of renovascular hypertension with technetium–99m–ethylenedicysteine captopril scintigraphy. Ugur O, et al. **Invest Radiol** 1996 Aug;31(8):497–501

Progression of renal disease—can it be reversed? The role of calcium channel blockers and angiotensin–converting enzyme inhibitors. Boner G. **Isr J Med Sci** 1996 Dec; 32(12):1217–21 (42 ref.)

An adverse reaction to angiotensin–converting enzyme inhibitors in a patient with neglected C1 esterase inhibitor deficiency. Ebo DG, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):425–6

Angiotensin–converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction > 40% after acute myocardial infarction. Johnson DB, et al. **J Am Coll Cardiol** 1997 Jan;29(1):49–54

Angiotensin–converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. Moser M. **J Am Coll Cardiol** 1997 Jun; 29(7):1414–21 (46 ref.)

Beta–adrenergic blocking agents or angiotensin–converting enzyme inhibitors, or both, for postinfarction patients with left ventricular dysfunction [editorial] O'Rourke RA. **J Am Coll Cardiol** 1997 Feb;29(2):237–9

Do angiotensin–converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? [editorial] Packer M. **J Am Coll Cardiol** 1996 Nov 1; 28(5):1323–7 (25 ref.)

Long–term anti–ischemic effects of angiotensin–converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators. van den Heuvel AF, et al. **J Am Coll Cardiol** 1997 Aug;30(2):400–5

Additive beneficial effects of beta–blockers to angiotensin–converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. Vantrimpont P, et al. **J Am Coll Cardiol** 1997 Feb;29(2):229–36

Effect of angiotensin–converting enzyme inhibition in HIV–associated nephropathy. Burns GC, et al. **J Am Soc Nephrol** 1997 Jul;8(7):1140–6

Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non–insulin–dependent diabetes mellitus and nephropathy. Guasch A, et al. **J Am Soc Nephrol** 1997 May;8(5):793–8

Renal interstitial sclerosis in aging: effects of enalapril and nifedipine. Inserra F, et al. **J Am Soc Nephrol** 1996 May; 7(5):676–80

Association of angiotensin I–converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I–converting enzyme inhibitors in patients with proteinuria. Moriyama T, et al. **J Am Soc Nephrol** 1995 Dec;6(6):1676–8

Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke–prone rat. Münter K, et al. **J Am Soc Nephrol** 1996 May;7(5):681–6

Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine. Törnig J, et al. **J Am Soc Nephrol** 1996 May;7(5):667–75

Hypotensive mechanisms of captopril—a counter–view [letter] Lazar AI. **J Assoc Physicians India** 1996 Oct; 44(10):753

Effect of enalapril on renal profile and right ventricular dimensions in chronic cor pulmonale. Mahajan SK, et al. **J Assoc Physicians India** 1996 May;44(5):323–4

Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin–converting enzyme inhibitors is not beneficial: results of a placebo–controlled, double–blind study. Dorszewski A, et al. **J Card Fail** 1997 Jun;3(2):91–6

Effects of long–term treatment with trandolapril on augmented vasoconstriction in rats with chronic heart failure. Okumura Y, et al. **J Card Fail** 1996 Dec;2(4):301–10

The use of ACE inhibitors after myocardial infarction. Swedberg K, et al. **J Card Fail** 1996 Dec;2(4 Suppl):S231–7 (29 ref.)

Clinical and autonomic effects of ibopamine as adjunct to angiotensin–converting enzyme inhibitors in chronic heart failure [see comments] Szabó BM, et al. **J Card Fail** 1996 Sep;2(3):185–92. Comment in: J Card Fail 1996 Sep;2(3):193–6. Comment in: J Card Fail 1996 Sep;2(3):197–202.

Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension. Böhlen L, et al. **J Cardiovasc Pharmacol** 1996 Jun;27(6):770–6

Relative contribution of angiotensin II, bradykinin, and prostaglandins to the renal effects of converting enzyme inhibition in rats after chronic myocardial infarction. Deck CC, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):167–74

Effects of angiotensin–converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. Duncan AM, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):746–54

Fixed combination of benazepril and low–dose amlodipine in the treatment of mild to moderate essential hypertension: evaluation by 24–hour noninvasive ambulatory blood pressure monitoring. Fogari R, et al. **J Cardiovasc Pharmacol** 1997 Aug;30(2):176–81

Circadian variation in blood pressure and heart rate in nonhypertensive congestive heart failure. Giles TD, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):733–40

Fosinopril versus enalapril in the treatment of hypertension: a double–blind study in 195 patients. Hansson L, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):1–5

Indapamide is as effective as captopril in the control of microalbuminuria in diabetes. Molyneaux LM, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):424–7

Fosinopril improves regulation of vascular tone in mesenteric bed of diabetic rats. Olbrich A, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):187–94

Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin–converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin? Shimada Y, et al. **J Cardiovasc Pharmacol** 1996 Mar; 27(3):428–38

Moexipril versus captopril in patients with mild to moderate hypertension. Stimpel M, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):769–73

Autoregulation of total and zonal glomerular filtration rate in spontaneously hypertensive rats during antihypertensive therapy. Wang X, et al. **J Cardiovasc Pharmacol** 1996 Dec; 28(6):833–41

Comparison of enalapril to captopril by 24–hour ambulatory blood pressure monitoring. Bental T, et al. **J Clin Pharmacol** 1997 Jun;37(6):514–9

Effects of angiotensin–converting enzyme inhibition on left ventricular geometric patterns in patients with essential hypertension. De Castro S, et al. **J Clin Pharmacol** 1996 Dec;36(12):1141–8

Meeting on diabetic complications and early treatment using ACE inhibitors. Barnett AH, et al. **J Diabetes Complications** 1996 May–Jun;10(3):124–4

When to treat the hypertensive diabetic patient. Fuller JH. **J Diabetes Complications** 1996 May–Jun;10(3):144–5 (13 ref.)

Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study. Hasslacher C. **J Diabetes Complications** 1996 May–Jun;10(3):136–8

Diabetic complications and early treatment using ACE inhibitors: concluding remarks. Mogensen CE. **J Diabetes Complications** 1996 May–Jun;10(3):151–3

Practical problems in the management of hypertension in the diabetic patient. O'Hare JP. **J Diabetes Complications** 1996 May–Jun;10(3):146–8 (11 ref.)

Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. Parving HH. **J Diabetes Complications** 1996 May–Jun;10(3):133–5 (23 ref.)

The emerging role of ACE inhibitors in diabetes: from theory to therapeutic management. Yudkin JS. **J Diabetes Complications** 1996 May–Jun;10(3):129–32 (40 ref.)

Prognosis of diabetic patients post–MI: the role of ACE inhibitor treatment. GISSI–3 Investigators. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Zuanetti G. **J Diabetes Complications** 1996 May–Jun;10(3):139–40

Pharmacologic management of heart failure among older adults by office–based physicians in the United States. Croft JB, et al. **J Fam Pract** 1997 Apr;44(4):382–90

Premedication with cyclosporine and perindopril modifies the ischaemia–reperfusion injury during liver resection in rats. Hardy KJ, et al. **J Gastroenterol Hepatol** 1996 Jul; 11(7):652–7

Differences in generalist and specialist physicians' knowledge and use of angiotensin–converting enzyme inhibitors for congestive heart failure [see comments] Chin MH, et al. **J Gen Intern Med** 1997 Sep;12(9):523–30. Comment in: J Gen Intern Med 1997 Sep;12(9):581–2.

Utilization and dosing of angiotensin–converting enzyme inhibitors for heart failure. Effect of physician specialty and patient characteristics [see comments] Chin MH, et al. **J Gen Intern Med** 1997 Sep;12(9):563–6. Comment in: J Gen Intern Med 1997 Sep;12(9):581–2.

Heart failure and angiotensin–converting enzyme inhibitors. Is there a need for specialty care? [editorial; comment] Scheiner MA, et al. **J Gen Intern Med** 1997 Sep;12(9):581–2 . Comment on: J Gen Intern Med 1997 Sep;12(9):523–30. Comment on: J Gen Intern Med 1997 Sep;12(9):563–6.

Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. Bakris G, et al. **J Hum Hypertens** 1997 Jan;11(1):35–8 (35 ref.)

Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. Bénétos A, et al. **J Hum Hypertens** 1996 Feb;10(2):77–82

High–altitude pulmonary hypertension: effects of captopril on pulmonary and systemic arterial pressures. Niazova ZA, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S141–2

Impact of lipid and ACE inhibitor therapy on cardiovascular disease and metabolic abnormalities in the diabetic and hypertensive patient. Sowers JR. **J Hum Hypertens** 1997

Jan;11(1):9–16 (93 ref.)
Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study. Yodfat Y, et al. **J Hum Hypertens** 1996 Feb; 10(2):117–22
Assessment of drug efficacy using home self-blood pressure measurement: the SMART study. Self Measurement for the Assessment of the Response to Trandolapril. Zannad F, et al. **J Hum Hypertens** 1996 Jun;10(6):341–7
Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event. Gustafsson F, et al. **J Hypertens** 1997 Jul;15(7):793–8
Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors. Kohzuki M, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1785–90
Long-term inhibition of the renin-angiotensin system in genetic hypertension: analysis of the impact on blood pressure and cardiovascular structural changes. Lundie MJ, et al. **J Hypertens** 1997 Apr;15(4):339–48 (104 ref.)
Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension [see comments] Luque M, et al. **J Hypertens** 1996 Jun; 14(6):799–805. Comment in: J Hypertens 1996 Nov;14(11):1380–1.
PROGRESS (perindopril protection against recurrent stroke study): rationale and design. PROGRESS Management Committee [corrected] [published erratum appears in J Hypertens 1996 Apr;14(4):535] Neal B, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1869–73
Effects of antihypertensive therapy with angiotensin converting enzyme inhibitors or calcium antagonists on spontaneous cyclic vasomotor activity in small resistance arteries of spontaneously hypertensive rats. Rizzoni D, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1827–32
Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. Sasaki M, et al. **J Hypertens** 1996 Dec;14(12):1403–8
Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the angiotensin converting enzyme inhibitor moexipril, 17beta-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats. Stimpel M, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1852–6
Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. Tikkanen I, et al. **J Hypertens** 1995 Nov;13(11):1343–51
From vascular protection to secondary prevention in cardiovascular diseases. Proceedings of satellite symposium to the 16th Scientific Meeting of the International Society of Hypertension. Glasgow, United Kingdom, 23 June 1996. **J Hypertens Suppl** 1996 Dec;14(6):S1–53
PROGRESS--perindopril protection against recurrent stroke study: status in July 1996. PROGRESS Management Committee. **J Hypertens Suppl** 1996 Dec;14(6):S47–51
Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study. **J Hypertens Suppl** 1996 Sep; 14(2):S41–5; discussion S45–6 (20 ref.)
Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients. Cooper ME. **J Hypertens Suppl** 1996 Dec; 14(6):S11–4 (47 ref.)
Angiotensin converting enzyme inhibitor-calcium antagonist combination: an alliance for cardioprotection? Ferrari R. **J Hypertens Suppl** 1997 Mar;15(2):S109–17 (87 ref.)
Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). Hansen JF, et al. **J Hypertens Suppl** 1997 Mar; 15(2):S119–22 (32 ref.)
Perindopril treatment in the prevention of stroke in experimental animals. Lee RM, et al. **J Hypertens Suppl** 1996 Dec;14(6):S29–33
Blood pressure control after acute stroke. Lees KR, et al. **J Hypertens Suppl** 1996 Dec;14(6):S35–8 (22 ref.)
Endothelial function as an end-point in interventional trials: concepts, methods and current data. Lüscher TF, et al. **J Hypertens Suppl** 1996 Sep;14(2):S111–9; discussion S119–21 (82 ref.)
Complementary actions and risk reduction: the rationale for combination of an angiotensin converting enzyme inhibitor with a non-dihydropyridine calcium antagonist. Messerli FH. **J Hypertens Suppl** 1997 Mar;15(2):S35–8 (17 ref.)
Effects of angiotensin converting enzyme inhibition on vascular remodelling of resistance vessels in hypertensive patients. Mulvany MJ. **J Hypertens Suppl** 1996 Dec; 14(6):S21–4 (38 ref.)
Clinical benefit of angiotensin converting enzyme inhibition after acute myocardial infarction: myocardial reperfusion revisited. Renkin J. **J Hypertens Suppl** 1996 Dec; 14(6):S15–9 (40 ref.)
Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. Ritz E, et al. **J Hypertens Suppl** 1997 Mar;15(2):S21–6 (44 ref.)
Successful brief captopril treatment in experimental radiation nephropathy. Cohen EP, et al. **J Lab Clin Med** 1997 May; 129(5):536–47
Cardiovascular protection and repair and angiotensin converting enzyme (ACE) inhibitors [editorial] Birbari AE. **J Med Liban** 1995;43(4):182 (5 ref.)
HCQIP Project Report--findings released in Use of Ace Inhibitors in Heart Failure Project. McIlwain JS. **J Miss State Med Assoc** 1997 Jul;38(7):282
Beneficial effects of angiotensin I converting enzyme inhibitor on post-ischemic contractile function of perfused rat heart. Tanonaka K, et al. **J Mol Cell Cardiol** 1996 Aug; 28(8):1659–70
Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. Robson R, et al. **J Nephrol** 1997 Jan-Feb;10(1):33–40
Pharmacokinetics and pharmacodynamics of a sustained-release biodegradable pellet containing imidapril, a new angiotensin-converting enzyme inhibitor in spontaneously hypertensive rats. Yamanaka K, et al. **J Pharm Biomed Anal** 1997 Aug;15(12):1861–6
The influence of temocapril, an angiotensin converting enzyme inhibitor, on the cyclosporine-induced nephrotoxicity. Ishikawa A, et al. **J Urol** 1997 Feb; 157(2):739–42
The effect of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism on obstructed rat bladder. Palmer LS, et al. **J Urol** 1997 Sep;158(3 Pt 2):1100–4
Efficacy of monotherapy with benazepril, an angiotensin converting enzyme inhibitor, in dogs with naturally acquired chronic mitral insufficiency. Kitagawa H, et al. **J Vet Med Sci** 1997 Jul;59(7):513–20
Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis [see comments] Psaty BM, et al. **JAMA** 1997 Mar 5;277(9):739–45. Comment in: JAMA 1997 Jun 11;277(22):1759–60. Comment in: ACP J Club 1997 Sep-Oct;127(2):36.
Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction. Moriyama Y, et al. **Jpn Circ J** 1997 Apr;61(4):308–14
A case report of angioedema during long-term (66 months) angiotensin converting enzyme inhibition therapy with enalapril. Shionoiri H, et al. **Jpn Circ J** 1996 Mar; 60(3):166–70
Protective effect of captopril on ischemic myocardium. Yanagishita T, et al. **Jpn Circ J** 1997 Feb;61(2):161–9
Enalapril and pressure-diuresis in hypertensive rats transgenic for mouse renin gene. Springate J, et al. **Kidney Blood Press Res** 1997;20(1):1–5
Loin pain-hematuria syndrome associated with thin glomerular basement membrane disease and hemorrhage into renal tubules. Hebert LA, et al. **Kidney Int** 1996 Jan; 49(1):168–73
Renal hemodynamics in hypertensive renal allograft recipients: effects of calcium antagonists and ACE inhibitors. Grekas D, et al. **Kidney Int Suppl** 1996 Jun; 55:S97–100
Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Mosconi L, et al. **Kidney Int Suppl** 1996 Jun;55:S91–3
Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. Omata K, et al. **Kidney Int Suppl** 1996 Jun;55:S57–62
Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria. Piñol C, et al. **Kidney Int Suppl** 1996 Jun;55:S85–7
Antihypertensive activity and renal effects of benazepril in humans. Tramonti G, et al. **Kidney Int Suppl** 1996 Jun; 55:S107–8
Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension. Vallès Prats M, et al. **Kidney Int Suppl** 1996 Jun;55:S104–6
Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group [see comments] **Lancet** 1997 Jun 21; 349(9068):1787–92. Comment in: Lancet 1997 Jun 21;349(9068):1782–3.
Losartan versus captopril in elderly patients with heart failure [letter; comment] Ball SG. **Lancet** 1997 May 17; 349(9063):1474; discussion 1475. Comment on: Lancet 1997 Mar 15;349(9054):747–52.
Losartan versus captopril in elderly patients with heart failure [letter; comment] Fournier A, et al. **Lancet** 1997 May 17; 349(9063):1473–4; discussion 1475. Comment on: Lancet 1997 Mar 15;349(9054):747–52.
Angiotensin receptor antagonists [letter; comment] Goldsmith DJ. **Lancet** 1997 Apr 26;349(9060):1255. Comment on: Lancet 1997 Mar 1;349(9052):620.
Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Hall AS, et al. **Lancet** 1997 May 24; 349(9064):1493–7
Losartan versus captopril in elderly patients with heart failure [letter; comment] Jensen BV, et al. **Lancet** 1997 May 17; 349(9063):1473; discussion 1475. Comment on: Lancet 1997 Mar 15;349(9054):747–52.
Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study [letter] Krämer BK, et al. **Lancet** 1997 Sep 6;350(9079):736; discussion 736–7
ACE-inhibitors: panacea for progressive renal disease [comment] Navis G, et al. **Lancet** 1997 Jun 28; 349(9069):1852–3. Comment on: Lancet 1997 Jun 28;349(9069):1857–63.
Lisinopril and albumin excretion in diabetes [letter] Pintavorn P, et al. **Lancet** 1997 Aug 30;350(9078):663; discussion 663–4
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) [see comments] Pitt B, et al. **Lancet** 1997 Mar 15;349(9054):747–52. Comment in: Lancet 1997 May 17;349(9063):1473; discussion 1475. Comment in: Lancet 1997 May 17;349(9063):1473–4; discussion 1475. Comment in: Lancet 1997 May 17;349(9063):1474; discussion 1475. Comment in: ACP J Club 1997 Sep-Oct;127(2):29.
Lisinopril and albumin excretion in diabetes [letter] Sawicki PT. **Lancet** 1997 Aug 30;350(9078):662; discussion 663–4
Losartan versus captopril in elderly patients with heart failure [letter; comment] Sechi LA, et al. **Lancet** 1997 May 17; 349(9063):1474; discussion 1475. Comment on: Lancet 1997 Mar 15;349(9054):747–52.
Lisinopril and albumin excretion in diabetes [letter] van Guldener C, et al. **Lancet** 1997 Aug 30;350(9078):662–3; discussion 663–4
When should ACE inhibitors be given to normotensive patients with IDDM [comment] Wang PH. **Lancet** 1997 Jun 21;349(9068):1782–3. Comment on: Lancet 1997 Jun 21;349(9068):1787–92.
Lisinopril and albumin excretion in diabetes [letter] Williams B. **Lancet** 1997 Aug 30;350(9078):662–3
Inhibitors of the renin-angiotensin system. Krum H. **Med J Aust** 1997 Jul 7;167(1):38–40 (19 ref.)
Trandolapril: an ACE inhibitor for treatment of hypertension. **Med Lett Drugs Ther** 1996 Nov 22;38(988):104–5
Effects of perindopril treatment on plasma and urine of kallikrein activity and the stable metabolite of prostaglandin E2 in patients with essential hypertension. Zacharieva S, et al. **Methods Find Exp Clin Pharmacol** 1996 Apr; 18(3):205–9
Amlodipine in chronic heart failure [letter; comment] Allan JJ. **N Engl J Med** 1997 Apr 3;336(14):1023–4; discussion 1024. Comment on: N Engl J Med 1996 Oct 10;335(15):1107–14.
Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery [letter; comment] Ho T, et al. **N Engl J Med** 1997 May 15;336(20):1452; discussion 1453–4 . Comment on: N Engl J Med 1996 Dec 5;335(23):1713–20.
Quinapril for coronary artery disease. Seth S, et al. **Natl Med J India** 1997 Mar-Apr;10(2):73–4
The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Barnas U, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1822–4
Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night? Buter H, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:53–6
ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Dyadyk AI, et al. **Nephrol Dial Transplant** 1997 May;12(5):945–51
Treatment of post-transplant erythrocytosis by angiotensin II type I receptor antagonists [letter] Eustace JA, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2373–4
Diabetic nephropathy and pregnancy: the effect of ACE inhibitors prior to pregnancy on fetomaternal outcome. Hod M, et al. **Nephrol Dial Transplant** 1995 Dec; 10(12):2328–33
ACE inhibitors, AT1 receptor blockers, and the kidney [editorial] Hollenberg NK. **Nephrol Dial Transplant** 1997 Mar;12(3):381–3
The long-term tolerability of enalapril in hypertensive patients with renal impairment. Keane WF, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:75–81
Ace inhibition in chronic renal failure: a step forward [editorial] [see comments] Mann JF. **Nephrol Dial Transplant** 1996 Jun;11(6):932–3 (15 ref.). Comment in: Nephrol Dial Transplant 1997 Jan;12(1):234–5.
Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nielsen S, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:19–23
Antihypertensive treatment in nephropathy of type II diabetes: role of the pharmacological blockade of the renin-angiotensin system [editorial] Rodby RA. **Nephrol Dial Transplant** 1997 Jun;12(6):1095–6
ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients. van der Kleij FG, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:42–6
Reduction of renal function by angiotensin-converting enzyme inhibitors: effect of verapamil [letter] Bitar R, et al. **Nephron** 1997;75(4):486–7
Effects of weight reduction and angiotensin-converting enzyme inhibition on IgA nephropathy-associated proteinuria [letter] Kuiper JJ. **Nephron** 1996;74(2):462–3

Over 11 years of stable renal function after remission of nephrotic-range proteinuria in type I diabetics treated with an ACE inhibitor. McGregor D, et al. **Nephron** 1997; 76(3):270–5

Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors. MacGregor MS, et al. **Nephron** 1996; 74(3):517–21

Proteinuria and albumin homeostasis in the nephrotic syndrome: effect of dietary protein intake. Rodrigo R, et al. **Nutr Rev** 1996 Nov;54(11 Pt 1):337–47 (107 ref.)

Long-term therapy with enalapril in patients with nephrotic-range proteinuria. Proesmans W, et al. **Pediatr Nephrol** 1996 Oct;10(5):587–9

ACE inhibitors and proteinuria. Gansevoort RT, et al. **Pharm World Sci** 1996 Dec;18(6):204–10 (81 ref.)

Long-term effectiveness of enalapril plus extended-release diltiazem in essential hypertension. Applegate W, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):107–12

Absence of association between angiotensin I-converting enzyme (ACE) DD genotype and the frequency of ACE inhibitor therapy. Sigusch HH, et al. **Pharmazie** 1997 Jul; 52(7):565–6

Effects of thiorphan, bestatin and captopril on the Lewis lung carcinoma metastases in mice. Kowalski J, et al. **Pol J Pharmacol** 1995 Sep–Oct;47(5):423–7

Captopril augments antitumor activity of cyclophosphamide in mice. Kowalski J, et al. **Pol J Pharmacol** 1996 May–Jun; 48(3):281–5

Effects of captopril on renal functions, renal and portal hemodynamics in patients with cirrhosis. Tsai YT, et al. **Proc Natl Sci Counc Repub China B** 1996 Apr;20(2):44–50

Angiotensin-converting enzyme inhibition after acute myocardial infarction with special reference to the Fourth International Study of Infarct Survival (ISIS-4). Syed M, et al. **Prog Cardiovasc Dis** 1996 Sep–Oct;39(2):201–6

Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. Hendry BM, et al. **QJM** 1997 Apr; 90(4):277–82

Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence? Hillis GS, et al. **QJM** 1996 Feb;89(2):145–50

Diabetic nephropathy: an observational study on patients attending a joint diabetes renal clinic. Liew BS, et al. **QJM** 1997 May;90(5):353–8

The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy. Epstein M. **Ren Fail** 1996 Nov;18(6):813–32 (101 ref.)

Effects of the AT1-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs. Strohmenger HU, et al. **Resuscitation** 1997 Aug;35(1):61–8

New treatment approach for high blood pressure patients defined as cardioprotective by physicians. **S Afr Med J** 1997 Feb;87 Suppl 1:C60

Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Nielsen FS, et al. **Scand J Clin Lab Invest** 1997 Aug;57(5):427–34

Effect of perindopril therapy on fluidity and potential of erythrocyte membrane from individuals with coronary heart disease. Piasecka A, et al. **Scand J Clin Lab Invest** 1997 Feb;57(1):65–71

Treatment of hypertension. Fogo A, et al. **Semin Nephrol** 1996 Nov;16(6):555–66 (114 ref.)

Angiotensin converting enzyme inhibitors in pregnancy. Mastrobattista JM. **Semin Perinatol** 1997 Apr;21(2):124–34 (46 ref.)

Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Dyker AG, et al. **Stroke** 1997 Mar;28(3):580–3

The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertensive rats. MacLeod AB, et al. **Stroke** 1997 Sep;28(9):1821–8; discussion 1829

The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters. Zehetgruber M, et al. **Thromb Res** 1996 Jul 15;83(2):143–52

Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy [see comments] Fried MR, et al. **Transfusion** 1996 Oct;36(10):900–3. Comment in: Transfusion 1996 Oct;36(10):852–3.

Captopril (an inhibitor of angiotensin converting enzyme) inhibits obstructive changes in the neonatal rabbit bladder. Cheng EY, et al. **Urology** 1997 Sep;50(3):465–71

Improving use of ACE inhibitors in diabetic nephropathy. Gold JA. **Wis Med J** 1996 Aug;95(8):588–9

[The significance of trandelapril for mortality after AMI in patients with reduced left ventricular function. TRACE Study Group] Køber L, et al. **Ugeskr Laeger** 1997 Mar 10;159(11):1616–22 (Eng. Abstr.) **(Dan)**

[Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril] Pedersen EB. **Ugeskr Laeger** 1996 Oct 7;158(41):5798–9 **(Dan)**

[Angiotensin-converting enzyme inhibitors following a myocardial infarct: clinical abd echographic indications] de Waard DE, et al. **Ned Tijdschr Geneeskd** 1997 Jan 11; 141(2):84–8 (36 ref.) (Eng. Abstr.) **(Dut)**

[Trandolapril in patients with left ventricular insufficiency after myocardial infarction] Aliot E. **Arch Mal Coeur Vaiss** 1996 Aug;89 Spec No 3:23–31 (Eng. Abstr.) **(Fre)**

[Angiotensin converting enzyme inhibitors and ischemic heart diseases] Bounhoure JP. **Arch Mal Coeur Vaiss** 1996 Aug;89 Spec No 3:19–22 (Eng. Abstr.) **(Fre)**

[Treatment by angiotensin converting enzyme inhibitors after myocardial infarction. What did the clinical trials teach us?] Guéret P, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89 Spec No 3:33–8 (Eng. Abstr.) **(Fre)**

[Conversion enzyme inhibitors in myocardial infarct: who, when, how?] Pierard L. **Rev Med Liege** 1996 May; 51(5):336–40 (25 ref.) **(Fre)**

[Drug treatment of cardiac insufficiency with systolic dysfunction] Follath F. **Schweiz Rundsch Med Prax** 1997 Feb 11;86(7):254–7 (17 ref.) (Eng. Abstr.) **(Fre)**

[The effectiveness and tolerance of ramipril in comparison to captopril for heart failure in dogs] Hofmann S, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 May;103(5):159–63 (Eng. Abstr.) **(Ger)**

[Progress in new cardiovascular treatment. Background discussion and interview in the Basel Roche Research Center (interview)] Keil U. **Fortschr Med** 1996 Feb 10; 114(4):39–40 **(Ger)**

[Why does ACE inhibitor also reduce risk of myocardial infarct? Increased expression of endothelial nitric oxide synthase in atrial myocardium] Rohrbach S. **Fortschr Med** 1997 Mar 30;115(9):49 **(Ger)**

[ACE-inhibitors: the indication spectrum grows wider] **Fortschr Med Suppl** 1996;178:1–10 **(Ger)**

[Fosinopril in the cardiovascular management of elderly patients] **Fortschr Med Suppl** 1996;175:1–8 **(Ger)**

[Prevention of coronary heart disease with ACE-inhibitors] **Internist (Berl)** 1997 Aug;38(8 Suppl Khk):1–8 **(Ger)**

[Insulin resistance, hypertension and diabetes--value of Metformin and ACE-inhibitors] **Internist (Berl)** 1994 Jun; 35(6 Suppl):1–8 **(Ger)**

[Hope for infarct patients. The ACE inhibitor Trandolapril is effective even in high risk patients] **Internist (Berl)** 1994 Dec;35(12 Suppl):1–4 **(Ger)**

[Angiotensin II receptor antagonists] Chung O, et al. **Internist (Berl)** 1996 May;37(5):534–8; discussion 538 (34 ref.) **(Ger)**

[Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors] Tschudi MR, et al. **Schweiz Med Wochenschr** 1997 Apr 12;127(15):636–49 (99 ref.) (Eng. Abstr.) **(Ger)**

[ACE inhibitors and the kidney] Hörl WH. **Wien Med Wochenschr** 1996;146(11):231–4; discussion 234–5 (27 ref.) (Eng. Abstr.) **(Ger)**

[Current aspects of ACE inhibitor therapy from the cardiologic viewpoint] Klein W, et al. **Wien Med Wochenschr** 1996;146(11):221–4 (24 ref.) (Eng. Abstr.) **(Ger)**

[Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers] Pichler M, et al. **Wien Med Wochenschr** 1996;146(11):228–31 (35 ref.) (Eng. Abstr.) **(Ger)**

[Angiotensin II antagonist for heart insufficiency] **Z Kardiol** 1997 Jun;86(6 Suppl):1–8 **(Ger)**

[ACE inhibitors in cardiac insufficiency and myocardial infarct. What happens after myocardial infarct?] **Z Kardiol** 1994 Nov;83(11 Suppl):1–4 **(Ger)**

[New aspects of ACE inhibitor treatment of heart failure] Dietz R, et al. **Z Kardiol** 1996;85 Suppl 6:241–6 (46 ref.) (Eng. Abstr.) **(Ger)**

[Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases] Huber K, et al. **Z Kardiol** 1997 Apr;86(4):239–50 (124 ref.) (Eng. Abstr.) **(Ger)**

[Angiotensin-2 receptor blockade--new therapeutic approach to treatment of hypertension] Zimlichman R. **Harefuah** 1996 Jul;131(1–2):43–5 (27 ref.) **(Heb)**

[Use of captopril in therapeutic combinations] Alföldi S. **Acta Pharm Hung** 1997 Jul;67(4):149–53 (18 ref.) (Eng. Abstr.) **(Hun)**

[Captopril in the treatment of heart failure] Kékes E. **Acta Pharm Hung** 1997 Jul;67(4):155–63 (21 ref.) (Eng. Abstr.) **(Hun)**

[ACE inhibitor therapy of hemodialyzed patients] Pató E, et al. **Orv Hetil** 1997 Jul 27;138(30):1903–7 (26 ref.) (Eng. Abstr.) **(Hun)**

[Experience with benazepril, a long-acting ACE inhibitor, in the management of diabetic hypertension] Winkler G, et al. **Orv Hetil** 1997 Jul 6;138(27):1737–42 (27 ref.) (Eng. Abstr.) **(Hun)**

[The antagonistic effect of aspirin on the expression of prostaglandin participation in the antihypertensive activity of ACE inhibitors] Alimento M, et al. **Cardiologia** 1997 Jun;42(6):605–10 (Eng. Abstr.) **(Ita)**

[ACE inhibitors and renal insufficiency] Marcantoni C, et al. **Cardiologia** 1997 Aug;42(8):783–7 **(Ita)**

[The therapy of arterial hypertension: a comparison between ACE inhibitors and angiotensin-II-receptor antagonists] Rossi F, et al. **Clin Ter** 1996 Oct;147(10):475–88 (54 ref.) (Eng. Abstr.) **(Ita)**

[Is the reduction of the plasma levels of endothelin in the acute and sub-acute stage of myocardial infarct one of the beneficial effects of early treatment with ace inhibitors?] Di Pasquale P, et al. **G Ital Cardiol** 1996 Jun;26(6):673–80 (Eng. Abstr.) **(Ita)**

[Successful treatment for pulmonary hypertension with angiotensin 1 converting enzyme inhibitor in a patient with mixed connective tissue disease] Maekawa K, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Feb;20(1):79–85 (Eng. Abstr.) **(Jpn)**

[Ace inhibitors: treatment of congestive heart failure] Sekiguchi H, et al. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):70–4 (5 ref.) **(Jpn)**

[The effect of ACE inhibitors, beta blockers and calcium antagonists on the responses to pressor stress tests in the elderly hypertensive patients] Suzuki Y, et al. **Nippon Ronen Igakkai Zasshi** 1996 Jan;33(1):27–32 (Eng. Abstr.) **(Jpn)**

[Treatment of elderly patients with hypertension--complications and current drug therapy] Takagawa Y, et al. **Nippon Ronen Igakkai Zasshi** 1997 Jan; 34(1):30–7 (Eng. Abstr.) **(Jpn)**

[Patients with diabetes mellitus--secodary prophylaxis after myocardial infarction] Gundersen T. **Tidsskr Nor Laegeforen** 1997 Jun 20;117(16):2335–6 (Eng. Abstr.) **(Nor)**

[Influence of angiotensin I converting enzyme inhibitors on selected parameters of zinc metabolism] Pęczkowska M. **Pol Arch Med Wewn** 1996 Jul;96(1):32–8 (Eng. Abstr.) **(Pol)**

[Angiotensin converting enzyme inhibitors in secondary prevention of myocardial infarction (editorial)] Stajszczyk M, et al. **Pol Arch Med Wewn** 1996 Sep;96(3):199–207 **(Pol)**

[Angiotensin converting enzyme inhibitors for hypertension] Kobusiak-Prokopowicz M. **Pol Merkuriusz Lek** 1997 Jan; 2(7):66–70 (40 ref.) (Eng. Abstr.) **(Pol)**

[Use of converting enzyme inhibitors in children. I. General remarks] Rokicki W, et al. **Wiad Lek** 1997;50(1–3):28–31 (20 ref.) (Eng. Abstr.) **(Pol)**

[When does the treatment with captopril show a better improvement in physical performance in patients with heart failure?] Canesin MF, et al. **Arq Bras Cardiol** 1996 Aug; 67(2):77–80 (Eng. Abstr.) **(Por)**

[Effect of enalaprilat on cardiotoxicity induced by doxorubicin] Santos JM, et al. **Arq Bras Cardiol** 1996 Oct; 67(4):237–41 (Eng. Abstr.) **(Por)**

[Pharmacologic treatment of acute myocardial infarction: 2 large clinical trials at a central hospital] Fernando PB, et al. **Rev Port Cardiol** 1996 Sep;15(9):617–30, 611 (Eng. Abstr.) **(Por)**

[Left ventricular hypertrophy--its reversion speeded up by enalaprilat] Póvoa R, et al. **Rev Port Cardiol** 1997 Jan; 16(1):57–60 **(Por)**

[The efficacy of Capoten in different clinical courses of acute myocardial infarct] Mikashinovich ZI, et al. **Anesteziol Reanimatol** 1996 Sep–Oct;(5):39–44 **(Rus)**

[Angiotensin-II receptor blockers in the treatment of arterial hypertension] Ol'binskaia LI, et al. **Eksp Klin Farmakol** 1996 Sep–Oct;59(5):76–80 **(Rus)**

[Changes in the central hemodynamics during the treatment of hypertension with Renitec and its combination with hydrochlorothiazide] Malaia LT, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):57–60 (Eng. Abstr.) **(Rus)**

[The use of angiotensin-converting enzyme inhibitors and the function of the renin-angiotensin-aldosterone system in chronic glomerulonephritis (a review of the literature and the author's own data)] Ospanova TS. **Lik Sprava** 1996 Jul–Sep;(7–9):22–6 (29 ref.) **(Rus)**

[The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with chronic glomerulonephritis and pronounced kidney failure] Diadyk AI, et al. **Ter Arkh** 1997;69(6):24–7 (Eng. Abstr.) **(Rus)**

[The efficacy of treatment with the angiotensin-converting enzyme inhibitor ramipril in patients with congestive heart failure of rheumatic etiology] Karakin AA, et al. **Ter Arkh** 1996;68(2):43–6 **(Rus)**

[The anti-ischemic effect of angiotensin-converting enzyme inhibitors in treating stable stenocardia of effort in middle-aged and elderly patients] Lazebnik LB, et al. **Ter Arkh** 1996;68(4):40–2 **(Rus)**

[The activity of the neurohumoral regulatory systems, the status of the electrolyte balance and the clinical efficacy of Renitec in hypertension patients] Ol'binskaia LI, et al. **Ter Arkh** 1996;68(4):54–7 (Eng. Abstr.) **(Rus)**

[The effect of the new angiotensin-converting enzyme inhibitor moexipril on the circadian rhythms of arterial pressure in hypertension patients] Ol'binskaia LI, et al. **Ter Arkh** 1997;69(3):58–61 (Eng. Abstr.) **(Rus)**

[A decrease in left ventricular hypertrophy and the dynamics of the parameters of circadian BP monitoring under the influence of ramipril in patients with essential arterial hypertension] Pekarskiĭ SE, et al. **Ter Arkh** 1997; 69(4):18–20 (Eng. Abstr.) **(Rus)**

[ACE-inhibitors in the treatment of chronic heart failure: pathophysiologic principles of protective effects] Simko F, et al. **Bratisl Lek Listy** 1996 Oct;97(10):583–6 (Eng. Abstr.) **(Slo)**

[Ambulatory monitoring of arterial pressure in the treatment of mild-moderate arterial hypertension with lisinopril vs. enalapril] Motero Carrasco J. **Arch Inst Cardiol Mex** 1997 Jan–Feb;67(1):29–37 (Eng. Abstr.) **(Spa)**

[Oral enalapril in patients with symptomatic ventricular septal defects] Vázquez-Antona CA, et al. **Arch Inst Cardiol Mex** 1996 Nov–Dec;66(6):496–504 (Eng. Abstr.) **(Spa)**

[Cost-effectiveness analysis of the treatment with enalapril

of chronic heart failure in Spain] Antoñanzas Villar F, et al. **Gac Sanit** 1996 May-Jun;10(54):135-42 (Eng. Abstr.) **(Spa)**

[Effect of enalapril on microalbuminuria and lipid profile of normotensive type I diabetes mellitus patients] Hernández Mijares A, et al. **Rev Clin Esp** 1996 Jun;196(6):354-8 (Eng. Abstr.) **(Spa)**

[Current indications for the treatment with angiotensin-converting enzyme inhibitors (editorial)] Orte Martínez LM. **Rev Clin Esp** 1996 Jun;196(6):345-6 **(Spa)**

[The anti-ischemic effects of ACE inhibitors after an acute myocardial infarct] Rutherford JD. **Rev Clin Esp** 1996 Dec; 196(4 Monografico):41-2 (23 ref.) **(Spa)**

[Reperfusion arrhythmias in valvular patients undergoing extracorporeal surgery and pretreated with captopril] Ruiz-Ros JA, et al. **Rev Esp Cardiol** 1997 Jul;50(7):491-7 (Eng. Abstr.) **(Spa)**

[Urinary albumin excretion in non-insulin-dependent diabetic patients. Effects of an angiotensin-converting enzyme inhibitor] Durruty P, et al. **Rev Med Chil** 1996 Sep; 124(9):1036-44 (Eng. Abstr.) **(Spa)**

[A comparative study of the hemodynamic and antioxidant effects of Capoten and prazosin in patients with refractory heart failure] Sabadyshyn RO, et al. **Lik Sprava** 1997 Mar-Apr;(2):72-6 (Eng. Abstr.) **(Ukr)**

[The effect of the angiotensin-converting enzyme inhibitor Capoten on the volume-regulation indices of patients with stage-II hypertension] Vladkovs'kyĭ IK, et al. **Lik Sprava** 1996 Mar-Apr;(3-4):113-7 (Eng. Abstr.) **(Ukr)**

TOXICITY

Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Friehe H, et al. **Arzneimittelforschung** 1997 Feb;47(2):132-44

Preclinical toxicology studies with the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril). McGuire EJ, et al. **J Toxicol Sci** 1996 Nov;21(4):207-14 (21 ref.)

Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats. Shinosaki T, et al. **Jpn J Pharmacol** 1997 Apr;73(4):337-45

Angiotensin converting enzyme inhibition and protein restriction in progression of experimental chronic renal failure. Liu DT, et al. **Pathology** 1996 May;28(2):156-60

ANGIOTENSIN-FORMING ENZYME see **RENIN**

ANGIOTENSIN RECEPTORS see **RECEPTORS, ANGIOTENSIN**

ANGIOTENSINOGEN

ANALYSIS

Quantitation of five forms of high molecular weight angiotensinogen from human placenta. Tewksbury DA. **Am J Hypertens** 1996 Oct;9(10 Pt 1):1029-34

Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Danser AH, et al. **Circulation** 1997 Jul 1; 96(1):220-6

ANTAGONISTS & INHIBITORS

Antisense inhibition of angiotensinogen in hepatoma cell culture is enhanced by cationic liposome delivery. Wielbo D, et al. **Biochem Biophys Res Commun** 1997 Mar 27; 232(3):794-9

Angiotensinogen antisense oligonucleotides and fluid intake. Sinnayah P, et al. **Clin Exp Hypertens** 1997 Jul-Aug; 19(5-6):993-1007

BIOSYNTHESIS

Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Jones BH, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R236-42

Expression of angiotensinogen mRNA and localization of angiotensin II and renin in peripheral adrenergic neurons in primary culture. Wang JM, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):876-81

ATF-like element contributes to hepatic activation of human angiotensinogen promoter. Yanai K, et al. **Biochem Biophys Res Commun** 1997 Aug 8;237(1):158-62

Induction of cardiac angiotensinogen mRNA and angiotensin converting enzyme (ACE) activity in isoproterenol-induced heart injury. Ogiku N, et al. **Hypertens Res** 1996 Sep;19(3):179-87

Valvular interstitial cells express angiotensinogen and cathepsin D, and generate angiotensin peptides. Katwa LC, et al. **Int J Biochem Cell Biol** 1996 Jul;28(7):807-21

Angiotensinogen mRNA is synthesized locally in rat ocular tissues. Murata M, et al. **Ophthalmologica** 1997;211(5):301-4

BLOOD

Plasma angiotensinogen concentrations in obese patients. Umemura S, et al. **Am J Hypertens** 1997 Jun;10(6):629-33

Hypertension, serum angiotensinogen, and molecular variants of the angiotensinogen gene among Nigerians. Rotimi C, et al. **Circulation** 1997 May 20;95(10):2348-50

Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Schunkert H, et al. **Circulation** 1997 Jan 7;95(1):39-45

Elevated des-AngI-angiotensinogen levels by nephrectomy and adrenalectomy. Hilgenfeldt U, et al. **Clin Exp Hypertens** 1996 Jul;18(5):675-89

High human renin hypertension in transgenic rats. Bohlender J, et al. **Hypertension** 1997 Jan;29(1 Pt 2):428-34

Angiotensin-converting enzyme and angiotensinogen gene polymorphisms, plasma levels, cardiac dimensions. A twin study. Busjahn A, et al. **Hypertension** 1997 Jan;29(1 Pt 2):165-70

Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium. Katz SA, et al. **Hypertension** 1997 Aug;30(2 Pt 1):259-66

Selective recognition of M235T angiotensinogen variants and their determination in human plasma by monoclonal antibody-based immunoanalysis. Cohen P, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3505-12

Effect of angiotensinogen on blood pressure regulation in normotensive rats: application of a loss of function approach. Tomita N, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1767-74

Relationship between hepatic angiotensinogen mRNA expression and plasma angiotensinogen in patients with chronic hepatitis. Takahashi D, et al. **Life Sci** 1997; 60(18):1623-33

CHEMISTRY

Angiotensinogen: molecular biology, biochemistry and physiology. Morgan L, et al. **Int J Biochem Cell Biol** 1996 Nov;28(11):1211-22 (87 ref.)

DEFICIENCY

Nephrogenesis and renovascular development in angiotensinogen-deficient mice. Nagata M, et al. **Lab Invest** 1996 Nov;75(5):745-53

GENETICS

Analysis of Met235 to Thr variant of the angiotensinogen gene in relation to the blood pressure and family history of essential hypertension in Japanese children. Kataoka S, et al. **Acta Paediatr Jpn** 1996 Aug;38(4):312-6

Lack of association between variants of the angiotensinogen gene and the risk of coronary artery disease in middle-aged Japanese men. Ichihara S, et al. **Am Heart J** 1997 Aug;134(2 Pt 1):260-5

Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Ishanov A, et al. **Am Heart J** 1997 Feb;133(2):184-9

Haplotypes of angiotensinogen in essential hypertension. Jeunemaitre X, et al. **Am J Hum Genet** 1997 Jun; 60(6):1448-60

No effect of genetic variation at the angiotensinogen locus on ambulatory blood pressure level in normotensive subjects. Bigda J, et al. **Am J Hypertens** 1997 Jun; 10(6):692-5

Ambulatory blood pressure monitoring for detecting the relation between angiotensinogen gene polymorphism and hypertension. Gharavi AG, et al. **Am J Hypertens** 1997 Jun;10(6):687-91

Dietary sodium effects on renin and angiotensinogen gene expression in preweanling WKY and SHR. Kirby RF, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1439-46

Temporal and spatial expression pattern of the angiotensinogen gene in mice and rats. Niimura F, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R142-7

Modulation of tissue angiotensinogen gene expression in genetically obese hypertensive rats. Tamura K, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1704-11

Dopaminergic receptors and angiotensinogen gene expression in opossum kidney cells. Wang TT, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R519-27

Associations of candidate loci angiotensinogen and angiotensin-converting enzyme with severe hypertension: The NHLBI Family Heart Study. Borecki IB, et al. **Ann Epidemiol** 1997 Jan;7(1):13-21

Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI Family Heart Study. Ludwig EH, et al. **Ann Epidemiol** 1997 Jan;7(1):3-12

Antisense inhibition of angiotensinogen in hepatoma cell culture is enhanced by cationic liposome delivery. Wielbo D, et al. **Biochem Biophys Res Commun** 1997 Mar 27; 232(3):794-9

ATF-like element contributes to hepatic activation of human angiotensinogen promoter. Yanai K, et al. **Biochem Biophys Res Commun** 1997 Aug 8;237(1):158-62

Regulation by fatty acids of angiotensinogen gene expression in preadipose cells. Safonova I, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):235-9

Association between an angiotensinogen microsatellite marker in children and coronary events in their grandparents. Badenhop RF, et al. **Circulation** 1996 Jun 15;93(12):2092-6

Hypertension, serum angiotensinogen, and molecular variants of the angiotensinogen gene among Nigerians. Rotimi C, et al. **Circulation** 1997 May 20;95(10):2348-50

Regulation of hepatic angiotensinogen gene expression in nephrotic rats. Medina-Campos ON, et al. **Clin Exp Hypertens** 1997 Apr;19(3):343-62

Angiotensinogen antisense oligonucleotides and fluid intake. Sinnayah P, et al. **Clin Exp Hypertens** 1997 Jul-Aug; 19(5-6):993-1007

Development of polyuria in Tsukuba hypertensive mice carrying human renin and angiotensinogen genes. Uehara S, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S12-4

Nested PCR for detection of the Met235-->Thr variant of the human angiotensinogen gene from small volumes of serum. Davis DR, et al. **Clin Genet** 1996 Nov;50(5):435-6

Genetics of the renin-angiotensin system and renal disease: a progress report. Schmidt S, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):146-51 (57 ref.)

Examination of two genetic polymorphisms within the renin-angiotensin system: no evidence for an association with nephropathy in IDDM. Chowdhury TA, et al. **Diabetologia** 1996 Sep;39(9):1108-14

The role of genetic variants in angiotensin I converting enzyme, angiotensinogen and the angiotensin II type-1 receptor in the pathophysiology of heart muscle disease. Raynolds MV, et al. **Eur Heart J** 1995 Nov;16 Suppl K:23-30 (85 ref.)

Chromosomal mapping of human angiotensinogen gene and human renin gene by fluorescence in situ hybridization (FISH) in transgenic mice. Watanabe Y, et al. **Exp Anim** 1996 Jul;45(3):265-9

Evidence for a novel regulatory pathway activated by (carba)prostacyclin in preadipose and adipose cells. Aubert J, et al. **FEBS Lett** 1996 Nov 11;397(1):117-21

Differential action of AGCF2 upon cell type-dependent expression of human angiotensinogen gene. Yanai K, et al. **FEBS Lett** 1997 Jul 28;412(2):285-9

Genetic polymorphisms of the renin-angiotensin system and angiographic extent and severity of coronary artery disease: the CORGENE study. Jeunemaitre X, et al. **Hum Genet** 1997 Jan;99(1):66-73

Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese. Ko YL, et al. **Hum Genet** 1997 Aug;100(2):210-4

Association of the angiotensinogen gene to serum angiotensinogen in blacks and whites. Bloem LJ, et al. **Hypertension** 1997 May;29(5):1078-82

Dose effects of human renin in rats transgenic for human angiotensinogen. Bohlender J, et al. **Hypertension** 1997 Apr;29(4):1031-8

Angiotensin-converting enzyme and angiotensinogen gene polymorphisms, plasma levels, cardiac dimensions. A twin study. Busjahn A, et al. **Hypertension** 1997 Jan;29(1 Pt 2):165-70

Angiotensinogen in human essential hypertension. Caulfield M, et al. **Hypertension** 1996 Dec;28(6):1123-5 (16 ref.)

Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians. Hegele RA, et al. **Hypertension** 1997 May;29(5):1073-7

Blood pressure and the M235T polymorphism of the angiotensinogen gene. Hingorani AD, et al. **Hypertension** 1996 Nov;28(5):907-11

Variation at the angiotensin-converting enzyme gene and angiotensinogen gene loci in relation to blood pressure. Kiema TR, et al. **Hypertension** 1996 Dec;28(6):1070-5

Differential regulation of angiotensinogen transcripts after renin infusion. Milsted A, et al. **Hypertension** 1996 Oct; 28(4):678-81

The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Schunkert H, et al. **Hypertension** 1997 Feb;29(2):628-33

Angiotensinogen: molecular biology, biochemistry and physiology. Morgan L, et al. **Int J Biochem Cell Biol** 1996 Nov;28(11):1211-22 (87 ref.)

Genetic basis of left ventricular remodeling after myocardial infarction. Ohmichi N, et al. **Int J Cardiol** 1996 Mar; 53(3):265-72

Angiotensinogen gene expression is stimulated by the cAMP-responsive element binding protein in opossum kidney cells. Qian JF, et al. **J Am Soc Nephrol** 1997 Jul; 8(7):1072-9

Selective recognition of M235T angiotensinogen variants and their determination in human plasma by monoclonal antibody-based immunoanalysis. Cohen P, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3505-12

Complementation of reduced survival, hypotension, and renal abnormalities in angiotensinogen-deficient mice by the human renin and human angiotensinogen genes. Davisson RL, et al. **J Clin Invest** 1997 Mar 15;99(6):1258-64

A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. Inoue I, et al. **J Clin Invest** 1997 Apr 1;99(7):1786-97

Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. Okubo S, et al. **J Clin Invest** 1997 Mar 1; 99(5):855-60

Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. Pei Y, et al. **J Clin Invest** 1997 Aug 15; 100(4):814-20

ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. Cooper R, et al. **J Hum Hypertens** 1997 Feb;11(2):107-11

Molecular variant M235T of the angiotensinogen gene is associated with essential hypertension in Taiwanese.

ANGIOTENSINOGEN

Chiang FT, et al. **J Hypertens** 1997 Jun;15(6):607–11

M235—>T polymorphism of the angiotensinogen gene predicts hypertension in the elderly. Johnson AG, et al. **J Hypertens** 1996 Sep;14(9):1061–5

Angiotensinogen messenger RNA stabilization by angiotensin II. Klett CP, et al. **J Hypertens Suppl** 1996 Dec; 14(5):S25–36

beta-Adrenoceptors and dexamethasone synergistically stimulate the expression of the angiotensinogen gene in opossum kidney cells. Ming M, et al. **Kidney Int** 1996 Jul; 50(1):94–101

Relationship between hepatic angiotensinogen mRNA expression and plasma angiotensinogen in patients with chronic hepatitis. Takahashi D, et al. **Life Sci** 1997; 60(18):1623–33

Angiotensin I-converting enzyme and angiotensinogen gene polymorphisms in non-insulin-dependent diabetes mellitus. Lack of relationship with diabetic nephropathy and retinopathy in a Caucasian Mediterranean population. Gutiérrez C, et al. **Metabolism** 1997 Aug;46(8):976–80

Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-kappaB p65) transcription factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Li J, et al. **Mol Endocrinol** 1996 Mar;10(3):252–64

Angiotensinogen-M235T genotype and post-transplant hypertension. Beige J, et al. **Nephrol Dial Transplant** 1996 Aug;11(8):1538–41

Angiotensinogen gene M235T polymorphism is not associated with diabetic nephropathy. The Diabetic Nephropathy Study Group. Schmidt S, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1755–61

Angiotensinogen and natriuretic peptide mRNAs in rat brain: localization and differential regulation by adrenal steroids in hypothalamus. Ryan MC, et al. **Peptides** 1997; 18(4):495–504

Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome. Ibarra-Rubio ME, et al. **Ren Fail** 1997 May;19(3):389–99

Polymorphisms for angiotensin converting enzyme, angiotensinogen, nitric oxide synthase, and endothelin and their association with cardiac allograft vasculopathy in the first year posttransplant. Elstein E, et al. **Transplant Proc** 1997 Sep;29(6):2575

Polymorphisms in genes of angiotensin converting enzyme, angiotensinogen, nitric oxide synthase, and endothelin and their association with cardiac allograft rejection. Elstein E, et al. **Transplant Proc** 1997 Sep;29(6):2576

METABOLISM

Expression and localization of renin and angiotensinogen in rat heart after myocardial infarction. Passier RC, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1040–8

Characterization of renin activity in brown adipose tissue. Shenoy U, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C989–99

Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium. Katz SA, et al. **Hypertension** 1997 Aug;30(2 Pt 1):259–66

Mouse glomerular epithelial cells in culture with features of podocytes in vivo express aminopeptidase A and angiotensinogen but not other components of the renin-angiotensin system. Mentzel S, et al. **J Am Soc Nephrol** 1997 May;8(5):706–19

Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. Okubo S, et al. **J Clin Invest** 1997 Mar 1; 99(5):855–60

Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen [see comments] Takimoto E, et al. **Science** 1996 Nov 8;274(5289):995–8. Comment in: Science 1996 Nov 8;274(5289):922.

PHYSIOLOGY

Stretch-induced MAP kinase activation in cardiomyocytes of angiotensinogen-deficient mice. Nyui N, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):36–41

Novel perspectives on pituitary and brain angiotensinogen. Sernia C, et al. **Front Neuroendocrinol** 1997 Apr; 18(2):174–208 (179 ref.)

ANGIOTENSINOGENASE see **RENIN**

ANGIOTENSINS

see related
RECEPTORS, ANGIOTENSIN
RENIN-ANGIOTENSIN SYSTEM

ANALYSIS

TLC characterization of liposomes containing angiotensinogen, angiotensine I, angiotensine II and saralazin. Brailoiu E, et al. **Biomed Chromatogr** 1997 May-Jun;11(3):160–3

BLOOD

Differential regulation of angiotensin peptides in plasma and kidney: effects of adrenalectomy and estrogen treatment. Campbell DJ. **Clin Exp Hypertens** 1997 Jul-Aug; 19(5–6):687–98

Effect of acute volume expansion associated with salt load on the profile of plasma angiotensins in rats. Carvalho AC, et al. **Immunopharmacology** 1996 Jun;33(1–3):143–5

The practical assessment of compliance with ACE-inhibitor therapy--a novel approach. MacFadyen RJ, et al. **J Cardiovasc Pharmacol** 1997 Jan;29(1):119–24

Acute and long-term dose-response study of quinapril on hormonal profile and tissue angiotensin-converting enzyme in Wistar rats. Schaison FH, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):11–8

GENETICS

Relationship of polymorphisms in the renin-angiotensin system and in E-selectin of patients with early severe coronary heart disease. Wenzel K, et al. **J Mol Med** 1997 Jan;75(1):57–61

METABOLISM

Research on polychaete annelid osmoregulatory peptide(s) by immunocytochemical and physiological approaches. Computer reconstruction of the brain and evidence for a role of angiotensin-like molecules in Nereis (Hediste) diversicolor OF Müller. Fewou J, et al. **Biol Cell** 1995; 85(1):21–33

Differential regulation of angiotensin peptides in plasma and kidney: effects of adrenalectomy and estrogen treatment. Campbell DJ. **Clin Exp Hypertens** 1997 Jul-Aug; 19(5–6):687–98

Renal tissue angiotensins during converting enzyme inhibition in the spontaneously hypertensive rat. Grima M, et al. **Clin Exp Hypertens** 1997 Jul-Aug;19(5–6):671–85

Nitric oxide and delta-opioid receptors in the tissue interactions among enkephalins, angiotensins and kinins. Carmignani M, et al. **Immunopharmacology** 1996 May; 32(1–3):172–5

PHYSIOLOGY

Renin-angiotensin system in stretch-induced hypertrophy of cultured neonatal rat heart cells. Miyata S, et al. **Eur J Pharmacol** 1996 Jun 20;307(1):81–8

Chimeric mice carrying 'regional' targeted deletion of the angiotensin type 1A receptor gene. Evidence against the role for local angiotensin in the in vivo feedback regulation of renin synthesis in juxtaglomerular cells. Matsusaka T, et al. **J Clin Invest** 1996 Oct 15;98(8):1867–77

Role of angiotensin in the dipsogenic effect of bradykinin in rats. Rowland NE, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):699–705

ANGLE CLASS I see **MALOCCLUSION, ANGLE CLASS I**

ANGLE CLASS II see **MALOCCLUSION, ANGLE CLASS II**

ANGLE CLASS III see **MALOCCLUSION, ANGLE CLASS III**

ANGOR PECTORIS see **ANGINA PECTORIS**

ANGUILLA

A telephone survey of eel fishermen regarding external lesions and mortalities of American eels (Anguilla rostrata) from Lake Ontario and the St. Lawrence River basin, Canada. Dutil L, et al. **Prev Vet Med** 1997 Jul;31(1–2):33–49

A processing plant survey of external lesions of American eels (Anguilla rostrata) from Lake Ontario and the St. Lawrence River, Canada. Dutil LT, et al. **Prev Vet Med** 1997 Jul;31(1–2):19–32

BLOOD

Isolation of low density lipoprotein subfraction containing apolipoprotein B-like protein from Japanese eel Anguilla japonica plasma using dextran sulfate cellulose. Ando S, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Feb;116(2):191–6

Changes in plasma atrial and ventricular natriuretic peptide concentrations after transfer of eels from freshwater to seawater or vice versa. Kaiya H, et al. **Gen Comp Endocrinol** 1996 Dec;104(3):337–45

Oxygen equilibria of cathodic eel hemoglobin analysed in terms of the MWC model and Adair's successive oxygenation theory. Feuerlein RJ, et al. **J Comp Physiol [B]** 1996;165(8):597–606

CLASSIFICATION

Evolution of the freshwater eels. Aoyama J, et al. **Naturwissenschaften** 1997 Jan;84(1):17–21

GENETICS

Four polymorphic microsatellite markers in the European eel anguilla Anguilla (L.). Daemen E, et al. **Anim Genet** 1997 Feb;28(1):68

Genome size and AT content in Anguilliformes. Ronchetti E, et al. **Eur J Histochem** 1995;39(4):259–64

Molecular cloning of the cDNAs encoding pituitary glycoprotein hormone alpha- and gonadotropin II beta-subunits of the Japanese eel, Anguilla japonica, and increase in their mRNAs during ovarian development induced by injection of chum salmon pituitary homogenate. Nagae M, et al. **J Mol Endocrinol** 1996 Apr;16(2):171–81

Evolution of the freshwater eels. Aoyama J, et al. **Naturwissenschaften** 1997 Jan;84(1):17–21

GROWTH & DEVELOPMENT

Morphogenesis of the brain in larval and juvenile Japanese eels, Anguilla japonica. Tomoda H, et al. **Brain Behav Evol** 1996;47(1):33–41

METABOLISM

Control of acid secretion in cultured gas gland cells of the European eel Anguilla anguilla. Pelster B, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):R578–84

Kinetics of oxygen metabolism during respiratory burst in Japanese eel neutrophils. Itou T, et al. **Dev Comp Immunol** 1996 Sep-Oct;20(5):323–30

Residue study of mebendazole and its metabolites hydroxy-mebendazole and amino-mebendazole in eel (Anguilla anguilla) after bath treatment. Iosifidou EG, et al. **Drug Metab Dispos** 1997 Mar;25(3):317–20

Sublethal effects of an organophosphate insecticide on the European eel, Anguilla anguilla. Sancho E, et al. **Ecotoxicol Environ Saf** 1997 Feb;36(1):57–65

Primary cultures of dispersed pituitary cells from estradiol-pretreated female silver eels (Anguilla anguilla L.): immunocytochemical characterization of gonadotropic cells and stimulation of gonadotropin release. Montero M, et al. **Gen Comp Endocrinol** 1996 Oct;104(1):103–15

Potentiating effect of growth hormone on vitellogenin synthesis induced by 17 beta-estradiol in primary culture of female silver eel (Anguilla anguilla L.) hepatocytes. Peyon P, et al. **Gen Comp Endocrinol** 1996 May; 102(2):263–73

Androgens stimulate gonadotropin-II beta-subunit in eel pituitary cells in vitro. Huang YS, et al. **Mol Cell Endocrinol** 1997 Aug 8;131(2):157–66

PARASITOLOGY

Composition and structure of helminth communities in eels Anguilla anguilla from Italian coastal lagoons. Kennedy CR, et al. **J Helminthol** 1997 Mar;71(1):35–40

Colonization and establishment of Pomphorhynchus laevis (Acanthocephala) in an isolated English river. Kennedy CR. **J Helminthol** 1996 Mar;70(1):27–31

On the distribution and abundance of eel parasites in Nova Scotia: local versus regional patterns. Barker DE, et al. **J Parasitol** 1996 Oct;82(5):697–701

Changes in gas composition in the swimbladder of the European eel (Anguilla anguilla) infected with Anguillicola crassus (Nematoda). Würtz J, et al. **Parasitology** 1996 Feb; 112 (Pt 2):233–8

Influence of flumequine and oxytetracycline on the resistance of the European eel against the parasitic swimbladder nematode Anguillicola crassus. van der Heijden MH, et al. **Vet Immunol Immunopathol** 1996 Jun 15;52(1–2):127–34

PHYSIOLOGY

Changes in the electrophysiological parameters of the posterior intestine of Anguilla anguilla (Pisces) induced by oxytocin, urotensin II and aldosterone. Baldisserotto B, et al. **Braz J Med Biol Res** 1997 Jan;30(1):35–9

A lipoprotein secreted by cultured hepatocytes of silver or yellow eel: comparison with their plasma lipoproteins. Ndiaye D, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Feb; 116(2):209–16

Similarities and differences between the massive eel (Anguilla anguilla L.) devastations that occurred in Lake Balaton in 1991 and 1995. Bálint T, et al. **Ecotoxicol Environ Saf** 1997 Jun;37(1):17–23

Interaction of osmotic and volemic mechanisms in secretion of atrial and ventricular natriuretic peptides in eels. Kaiya H, et al. **Gen Comp Endocrinol** 1997 Sep;107(3):322–6

Mediation of serotonin-induced hyperventilation via 5-HT3-receptor in European eel Anguilla anguilla. Janvier JJ, et al. **J Comp Physiol [B]** 1996;165(8):640–6

The possible role of intracellular lipid in determining oxygen delivery to fish skeletal muscle. Hoofd L, et al. **Respir Physiol** 1997 Feb;107(2):191–202

ANGUILLULIASIS see **STRONGYLOIDIASIS**

ANHIDROSIS see **HYPOHIDROSIS**

ANHIDROTIC ECTODERMAL DYSPLASIA see **ECTODERMAL DYSPLASIA**

ANHYDRIDES

Treatment of experimental osteomyelitis by surgical debridement and the implantation of bioerodable, polyanhydride-gentamicin beads. Nelson CL, et al. **J Orthop Res** 1997 Mar;15(2):249–55

Urethane-protected N-carboxyanhydrides (UNCAs) as unique reactants for the study of intrinsic racemization tendencies in peptide synthesis. Romoff TT, et al. **J Pept Res** 1997 Apr;49(4):281–92

ANALYSIS

A spectrophotometric method for the quantitative determination of purity of diethylenetriaminepentaacetic anhydride. Hekman C. **Anal Biochem** 1996 Mar 1; 235(1):57–60

CHEMISTRY

Isolation and chemistry of the mixed anhydride intermediate in the reaction catalyzed by dethiobiotin synthetase. Gibson KJ. **Biochemistry** 1997 Jul 15;36(28):8474–8

Controlled protein delivery from biodegradable tyrosine-containing poly(anhydride-co-imide) microspheres. Chiba M, et al. **Biomaterials** 1997 Jul; 18(13):893–901

Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy. Dang W, et al. **Pharm Res** 1996 May;13(5):683–91

IMMUNOLOGY

Antibody specificity to the chemical structures of organic acid anhydrides studied by in-vitro and in-vivo methods. Zhang XD, et al. **Toxicology** 1997 Mar 28;118(2–3):223–32

ANHYDRO-ARA-C see **ANCITABINE**

ANHYDROGLUCOCHLORAL see **CHLORALOSE**

ANILIDES

ADMINISTRATION & DOSAGE

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Iversen P, et al. **Scand J Urol Nephrol** 1996 Apr;30(2):93–8

ADVERSE EFFECTS

Fulminant hepatic failure associated with bicalutamide. Dawson LA, et al. **Urology** 1997 Feb;49(2):283–4

ANALYSIS

Improved analysis of fatty acid anilides: application to toxic and to aniline and citric acid-containing oils. Guitart R, et al. **Bull Environ Contam Toxicol** 1996 Mar;56(3):351–8

CHEMICAL SYNTHESIS

Solid-phase synthesis of peptide-4-nitroanilides. Kaspari A, et al. **Int J Pept Protein Res** 1996 Nov;48(5):486–94

Synthesis of peptide p-nitroanilides mimicking fibrinogen- and hirudin-binding to thrombin. Design of slow reacting thrombin substrates. Rijkers DT, et al. **Int J Pept Protein Res** 1996 Aug;48(2):182–93

The solid-phase synthesis of side-chain-phosphorylated peptide-4-nitroanilides. Bernhardt A, et al. **J Pept Res** 1997 Aug;50(2):143–52

CHEMISTRY

Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. Esnouf RM, et al. **Biochem Biophys Res Commun** 1997 May 19; 234(2):458–64

The reaction of 2-(methylseleno)benzanilide with peroxynitrite. Masumoto H, et al. **Chem Res Toxicol** 1996 Oct-Nov;9(7):1057–62

Products of aniline and triglycerides in oil samples associated with the toxic oil syndrome. Schurz HH, et al. **Chem Res Toxicol** 1996 Sep;9(6):1001–6

METABOLISM

Enantioselective binding of Casodex to the androgen receptor. Mukherjee A, et al. **Xenobiotica** 1996 Feb; 26(2):117–22

PHARMACOKINETICS

Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. Buckheit RW Jr, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10; 13(9):789–96

The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. Cockshott ID, et al. **Biopharm Drug Dispos** 1997 Aug;18(6):499–507

In vitro and in vivo disposition of 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide (CI-976). Identification of a novel five-carbon cleavage metabolite in rats. Sinz MW, et al. **Drug Metab Dispos** 1997 Jan;25(1):123–30

PHARMACOLOGY

Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. Buckheit RW Jr, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10; 13(9):789–96

Absence of hepatic enzyme induction in prostate cancer patients receiving 'Casodex' (bicalutamide). Kaisary A, et al. **Anticancer Drugs** 1996 Jan;7(1):54–9

Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Balzarini J, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1454–66

Ornithine decarboxylase activity and polyamine levels in the epididymis of prepubertal rat after antiandrogen administration. Rulli SB, et al. **Arch Androl** 1997 Mar-Apr; 38(2):163–71

Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. Esnouf RM, et al. **Biochem Biophys Res Commun** 1997 May 19; 234(2):458–64

The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Barnard J, et al. **Biochemistry** 1997 Jun 24;36(25):7786–92

Effect of antiandrogens casodex and epitestosterone on bone composition in mice. Broulik PD, et al. **Bone** 1997 May; 20(5):473–5

Casodex (a nonsteroidal antiandrogen) reduces cancellous, endosteal, and periosteal bone formation in estrogen-replete female rats. Lea C, et al. **Calcif Tissue Int** 1996 Apr;58(4):268–72

NS-49, an alpha 1A-adrenoceptor agonist, selectively increases intraurethral pressure in dogs. Taniguchi N, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):117–22

Palmitic acid anilide-induced respiratory burst in human polymorphonuclear leukocytes is inhibited by a protein kinase C inhibitor, Ro 31-8220. Heiskanen KM, et al. **Free Radic Biol Med** 1997;22(7):1175–82

Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. Borkow G, et al. **J Virol** 1997 Apr; 71(4):3023–30

Immunological and biological activities of pituitary FSH isoforms in prepubertal male rats: effect of antiandrogens. Rulli SB, et al. **Neuroendocrinology** 1996 Jun;63(6):514–21

The suppressive effects of testosterone on growth in young chickens appears to be mediated via a peripheral androgen receptor; studies of the anti-androgen ICI 176,334. Fennell MJ, et al. **Poult Sci** 1996 Jun;75(6):763–6

Protection of rat lung from elastase-induced elastic fiber degradation in vitro and from emphysema in vivo by a trifluoroacetylpeptide anilide inhibitor. Amour A, et al. **Respiration** 1996;63(5):277–82

Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. Simard J, et al. **Urology** 1997 Apr;49(4):580–6; discussion 586–9

THERAPEUTIC USE

Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. Blackledge G, et al. **Anticancer Drugs** 1996 Jan;7(1):27–34 (38 ref.)

Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment. Palmberg C, et al. **Br J Urol** 1997 May;79(5):808–9

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Schellhammer PF, et al. **Cancer** 1996 Nov 15;78(10):2164–9

Bicalutamide ('Casodex') development: from theory to therapy [see comments] Kolvenbag GJ, et al. **Cancer J Sci Am** 1997 Jul-Aug;3(4):192–203 (86 ref.). Comment in: Cancer J Sci Am 1997 Jul-Aug;3(4):204–8.

'Casodex': defining the role of antiandrogens [comment] McCaffrey JA, et al. **Cancer J Sci Am** 1997 Jul-Aug; 3(4):204–8 (47 ref.). Comment on: Cancer J Sci Am 1997 Jul-Aug;3(4):192–203.

Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Blackledge GR, et al. **Eur Urol** 1997;31 Suppl 2:30–9 (44 ref.)

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Palmberg C, et al. **Eur Urol** 1997;31(2):216–9

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Scher HI, et al. **J Clin Oncol** 1997 Aug;15(8):2928–38

Estimated potency of Casodex: a problematic design [letter; comment] Labrie F, et al. **Urology** 1997 Aug;50(2):309–13 . Comment on: Urology 1995 May;45(5):745–52.

[The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer] Sivko AV, et al. **Urol Nefrol (Mosk)** 1997 May-Jun;(3):49–52 (83 ref.) **(Rus)**

TOXICITY

An overview of animal toxicology studies with bicalutamide (ICI 176,334). Iswaran TJ, et al. **J Toxicol Sci** 1997 May; 22(2):75–88 (38 ref.)

Oleoylanilide, a possible causative agent of toxic oil syndrome, interferes with the cytoskeleton in a neuronal cell line. Martínez JL, et al. **Neurotoxicol Teratol** 1997 Mar-Apr;19(2):147–50

ANILINE COMPOUNDS

New approaches to the simulation of heat-capacity curves and phase diagrams of pseudobinary phospholipid mixtures. Johann C, et al. **Biophys J** 1996 Dec;71(6):3215–28

Comparison of daunorubicin and Fluo-3 for detection of multidrug resistance in human tumor cells. Gheuens EE, et al. **Cancer Detect Prev** 1997;21(1):78–82

Monitoring of aromatic amine exposures in workers at a chemical plant with known bladder cancer excess [letter; comment] Freudenthal RI, et al. **J Natl Cancer Inst** 1997 May 21;89(10):734; discussion 735–6. Comment on: J Natl Cancer Inst 1996 Aug 7;88(15):1046–52.

Clinical application of a novel DNA fluorescence intercalator, pyrylium dye, for the quantification of PCR products. Ichikawa Y, et al. **Scand J Clin Lab Invest** 1996 Nov;56(7):641–7

[Development of calcium fluorescent probes and their application in life sciences] Zhang CL, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):37–42 (19 ref.) (Eng. Abstr.) **(Chi)**

[A new high definition histologic coloration method based on formic nigrosin] Novelli A. **Pathologica** 1996 Jun; 88(3):188–91 (Eng. Abstr.) **(Ita)**

ADMINISTRATION & DOSAGE

In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. Xu X, et al. **J Immunol** 1997 Jul 1;159(1):167–74

ADVERSE EFFECTS

Toxicologists versus toxicological disasters: toxic oil syndrome, clinical aspects. Gómez de la Cámara A, et al. **Arch Toxicol Suppl** 1997;19:31–40 (40 ref.)

Immunological aspects of the toxic oil syndrome. Lahoz C, et al. **Arch Toxicol Suppl** 1997;19:65–73 (35 ref.)

Epidemiology of the toxic oil syndrome. Philen RM, et al. **Arch Toxicol Suppl** 1997;19:41–52 (25 ref.)

ANALYSIS

Analytical measurements of products of aniline and triglycerides in oil samples associated with the toxic oil syndrome. Schurz HH, et al. **Arch Toxicol Suppl** 1997; 19:53–64

Rapid method for analysis of chloroacetanilide and chloronitrophenoxyaniline herbicides by gas chromatography. Dhouib M, et al. **Cent Eur J Public Health** 1996;4 Suppl:51–2

Analysis of nitramine and nitroaromatic explosives in pink water by capillary electrophoresis. Oehrle SA. **Electrophoresis** 1997 Feb;18(2):300–2

Simultaneous determination of malachite green, gentian violet and their leuco metabolites in catfish or trout tissue by high-performance liquid chromatography with visible detection. Rushing LG, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):325–30

BLOOD

MDA in plasma as a biomarker of exposure to pyrolysed MDI-based polyurethane: correlations with estimated cumulative dose and genotype for N-acetylation. Dalene M, et al. **Int Arch Occup Environ Health** 1996;68(3):165–9

CHEMICAL SYNTHESIS

N-[2-(1-azabicyclo[3.3.0]octan-5-yl)ethyl]-2-nitroaniline, a potent muscarinic agonist. Suzuki T, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1218–20

Synthesis and cytotoxic activities of the amine-exchange products of 2-dimethylaminomethyl-5-(E)-substituted arylidene cyclopentanones with anilines: 2-arylaminomethyl-5-(E)-arylidene cyclopentanones. Chen H, et al. **Drug Des Discov** 1996 Mar;14(1):43–52

Novel TcVO(III) N2S2 complexes: interconversion by redox reaction. Oya S, et al. **Nucl Med Biol** 1996 Jul;23(5):589–93

CHEMISTRY

Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Gazit A, et al. **Bioorg Med Chem** 1996 Aug;4(8):1203–7

Synthesis, characterization, and conformational analysis of DNA adducts from methylated anilines present in tobacco smoke. Marques MM, et al. **Chem Res Toxicol** 1996 Jan-Feb;9(1):99–108

Comparison of the QSAR models for toxicity and biodegradability of anilines and phenols. Damborsky J, et al. **Chemosphere** 1997 Feb;34(2):429–46

Species differences in the stereoselectivity of N-oxygenation of N-ethyl-N-methylaniline in vitro. Hadley MR, et al. **Chirality** 1996;8(6):430–40

Simultaneous measurement of Ca2+ and pH by laser cytometry using fluo-3 and SNARF-1. Atsumi T, et al. **Cytometry** 1996 Jun 1;24(2):99–105

Detection of plasma membrane Ca(2+)-ATPase activity in mouse T lymphocytes by flow cytometry using fluo-3-loaded vesicles. Telford WG, et al. **Cytometry** 1996 Jul 1;24(3):243–50

ANILINE COMPOUNDS

Differentiation of N-from C-protonated aniline by neutralization-reionization. Nold MJ, et al. **J Mass Spectrom** 1996 Oct;31(10):1169-72

Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. Chen C, et al. **J Med Chem** 1996 Oct 25;39(22):4358-60

Synthesis and biological evaluation of 3-(prop-2-enyl)- and 3-(prop-2-ynyl)pyrrolidine-2,5-dione derivatives as potential aromatase inhibitors. Barrell KJ, et al. **J Pharm Pharmacol** 1996 Feb;48(2):154-9

Arylamine-DNA adduct conformation in relation to mutagenesis. Beland FA, et al. **Mutat Res** 1997 May 12; 376(1-2):13-9

DIAGNOSTIC USE

Synthesis and tissue distribution of substituted [125I]iodophenylamine derivatives: possible brain imaging agents. Ghaffari MA, et al. **Nucl Med Biol** 1997 Feb; 24(2):151-64

METABOLISM

Influence of long-term ethanol treatment on rat liver aniline and p-nitrophenol hydroxylation. Wirkner K, et al. **Alcohol** 1996 Jan-Feb;13(1):69-74

Workers exposed to thermal degradation products of TDI- and MDI-based polyurethane: biomonitoring of 2,4-TDA, 2,6-TDA, and 4,4'-MDA in hydrolyzed urine and plasma. Dalene M, et al. **Am Ind Hyg Assoc J** 1997 Aug; 58(8):587-91

In vitro selection of DNA to chloroaromatics using magnetic microbead-based affinity separation and fluorescence detection. Bruno JG. **Biochem Biophys Res Commun** 1997 May 8;234(1):117-20

The iron(II)/reductant (DH2)-induced activation of dioxygen for the demethylation of N-methylanilines: reaction mimic for the cytochrome P-450/reductase system. Hage JP, et al. **Bioorg Med Chem** 1996 Jun; 4(6):821-4

Improved analysis of fatty acid anilides: application to toxic and to aniline and citric acid-containing oils. Guitart R, et al. **Bull Environ Contam Toxicol** 1996 Mar;56(3):351-8

A study of microbial transformations of trichloroaniline and p-cresol using size-fractionation technique. Hwang HM, et al. **Bull Environ Contam Toxicol** 1996 Mar;56(3):343-50

Metabolism of carcinogenic N-nitroso-N-methylaniline by purified cytochromes P450 2B1 and P450 2B2. Stiborová M, et al. **Cancer Lett** 1996 Dec 20;110(1-2):11-7

Nucleoplasmic and cytoplasmic differences in the fluorescence properties of the calcium indicator Fluo-3. Perez-Terzic C, et al. **Cell Calcium** 1997 Apr;21(4):275-82

Synthesis, characterization, and conformational analysis of DNA adducts from methylated anilines present in tobacco smoke. Marques MM, et al. **Chem Res Toxicol** 1996 Jan-Feb;9(1):99-108

Synthesis and quantification of DNA adducts of 4,4'-methylenedianiline. Schütze D, et al. **Chem Res Toxicol** 1996 Oct-Nov;9(7):1103-12

Identification of 2,6-xylidine as a major lidocaine metabolite in human liver slices. Parker RJ, et al. **Drug Metab Dispos** 1996 Nov;24(11):1167-73

Measurement and validation of kinetic parameter values for prediction of biodegradation rates in sewage treatment. Blok J, et al. **Ecotoxicol Environ Saf** 1996 Apr;33(3):217-27

Activation of aniline by extracts from plants and induction of chromosomal damages in Chinese hamster ovary cells. Kanaya N. **Genes Genet Syst** 1996 Oct;71(5):319-22

Influence of organic acid excretion on cuticle pH and drug absorption by Haemonchus contortus. Sims SM, et al. **Int J Parasitol** 1996 Jan;26(1):25-35

Nucleotide sequences and regulational analysis of genes involved in conversion of aniline to catechol in Pseudomonas putida UCC22(pTDN1). Fukumori F, et al. **J Bacteriol** 1997 Jan;179(2):399-408

Determination of the affinity constants of pea lectin for neutral sugars by capillary affinophoresis with a monoligand affinophore. Shimura K, et al. **J Biochem (Tokyo)** 1996 Dec;120(6):1146-52

Evidence for a 1-electron oxidation mechanism in N-dealkylation of N,N-dialkylanilines by cytochrome P450 2B1. Kinetic hydrogen isotope effects, linear free energy relationships, comparisons with horseradish peroxidase, and studies with oxygen surrogates. Guengerich FP, et al. **J Biol Chem** 1996 Nov 1;271(44):27321-9

Ca2+ binding to troponin C in skinned skeletal muscle fibers assessed with caged Ca2+ and a Ca2+ fluorophore. Invariance of Ca2+ binding as a function of sarcomere length. Patel JR, et al. **J Biol Chem** 1997 Feb 28; 272(9):6018-27

A high level of accumulation of 2-hydroxymuconic 6-semialdehyde from aniline by the transpositional mutant Y-2 of Pseudomonas species AW-2. Aoki K, et al. **Microbiol Res** 1997 Jul;152(2):129-35

Plasmid-encoded genes specifying aniline oxidation from Acinetobacter sp. strain YAA. Fujii T, et al. **Microbiology** 1997 Jan;143 (Pt 1):93-9

Aniline and its metabolites generate free radicals in yeast. Brennan RJ, et al. **Mutagenesis** 1997 Jul;12(4):215-20

PHARMACOKINETICS

Loading and localization of Fluo-3 and Fluo-3/AM calcium indicators in sinapis alba root tissue. Tretyn A, et al. **Folia Histochem Cytobiol** 1997;35(1):41-51

Synthesis and tissue distribution of substituted [125I]iodophenylamine derivatives: possible brain imaging agents. Ghaffari MA, et al. **Nucl Med Biol** 1997 Feb; 24(2):151-64

Novel TcVO(III) N2S2 complexes: interconversion by redox reaction. Oya S, et al. **Nucl Med Biol** 1996 Jul;23(5):589-93

Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats. Silva HT, et al. **Transplant Proc** 1996 Dec;28(6):3092-4

PHARMACOLOGY

RSR-13, an allosteric effector of hemoglobin, increases systemic and iliac vascular resistance in rats. Kunert MP, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H602-13

Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide. Kettle AJ, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):503-8

N-[2-(1-azabicyclo[3.3.0]octan-5-yl)ethyl]-2-nitroaniline, a potent muscarinic agonist. Suzuki T, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1218-20

Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro. Denny WA, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):424-7

Improved four-color flow cytometry method using fluo-3 and triple immunofluorescence for analysis of intracellular calcium ion ([Ca2+]i) fluxes among mouse lymph node B- and T-lymphocyte subsets. Greimers R, et al. **Cytometry** 1996 Mar 1;23(3):205-17

Stimulation of cell proliferation by calcium and a calcimimetic compound. Mailland M, et al. **Endocrinology** 1997 Sep;138(9):3601-5

In vitro anticryptosporidial activity of dinitroaniline herbicides. Arrowood MJ, et al. **FEMS Microbiol Lett** 1996 Mar 1;136(3):245-9

Immunosuppressant HR-325 attenuates progression of malignant arteritis in the kidney of Dahl salt-sensitive rats. Uehara Y, et al. **Hypertens Res** 1997 Jun;20(2):91-7

Esterase inhibitors diminish the modulation of gene expression by butyric acid derivative, pivaloyloxymethyl butyrate (AN-9). Rabizadeh E, et al. **Isr J Med Sci** 1996 Dec;32(12):1186-91

Studies on the pharmacological properties of novel arylene bis(methylketone) compounds using solid-phase extraction and high-performance liquid chromatography. Berger BJ, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11; 691(2):433-40

The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. Elder RT, et al. **J Immunol** 1997 Jul 1; 159(1):22-7

Inhibition of acyl-CoA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. Musanti R, et al. **J Lipid Res** 1996 Jan; 37(1):1-14

Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs. Curnock AP, et al. **J Pharmacol Exp Ther** 1997 Jul; 282(1):339-47

Non-steroidal L-245,976 acts as a classical antiandrogen in vitro. Toney JH, et al. **J Steroid Biochem Mol Biol** 1997 Jan;60(1-2):131-6

Low-affinity hemoglobin increases tissue PO2 and decreases arteriolar diameter and flow in the rat cremaster muscle. Kunert MP, et al. **Microvasc Res** 1996 Jul;52(1):58-68

Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines. Johnson BD, et al. **Mol Pharmacol** 1996 Nov;50(5):1388-400

FCE 27677: a novel inhibitor of acyl-CoA: cholesterol acyltransferase with potent oral hypolipidemic activity. Chiari A, et al. **Pharmacol Res** 1995 Oct;32(4):189-99

Correction of dyslipoproteinaemia of casein-fed rabbit by FCE 27677, a potent novel ACAT inhibitor. Chiari A, et al. **Pharmacol Res** 1996 Mar;33(3):181-9

Malononitrilamides inhibit T- and B-cell responsiveness in different species. Kurrle R, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1302-3

POISONING

Cytokine mRNA expression in lung tissue from toxic oil syndrome patients: a TH2 immunological mechanism. del Pozo V, et al. **Toxicology** 1997 Mar 14;118(1):61-70

THERAPEUTIC USE

Leflunomide and malononitrilamides. Silva Júnior HT, et al. **Am J Med Sci** 1997 May;313(5):289-301 (101 ref.)

Determination of an effective dose of eltenac and its comparison with that of flunixin meglumine in horses after experimentally induced carpitis. Hamm D, et al. **Am J Vet Res** 1997 Mar;58(3):298-302

Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. Sandelin J, et al. **Scand J Rheumatol** 1997;26(4):287-92

TOXICITY

Toxicity of 4-chloroaniline in early life-stages of zebrafish (Brachydanio rerio): I. cytopathology of liver and kidney after microinjection. Oulmi Y, et al. **Arch Environ Contam Toxicol** 1996 Mar;30(3):390-402

Analysis and prediction of structure-reactive toxicity relationships of substituted aromatic compounds. Liu ZT, et al. **Bull Environ Contam Toxicol** 1996 Sep;57(3):421-5

Synthesis and quantification of DNA adducts of 4,4'-methylenedianiline. Schütze D, et al. **Chem Res Toxicol** 1996 Oct-Nov;9(7):1103-12

Comparison of the QSAR models for toxicity and biodegradability of anilines and phenols. Damborsky J, et al. **Chemosphere** 1997 Feb;34(2):429-46

A scanning electron microscope investigation of the effects of pollutants on the hepatopancreatic ceca of Gammarus pulex (L.). Blockwell SJ, et al. **Ecotoxicol Environ Saf** 1996 Dec;35(3):209-21

Oxidative stress in the splenotoxicity of aniline. Khan MF, et al. **Fundam Appl Toxicol** 1997 Jan;35(1):22-30

Activation of aniline by extracts from plants and induction of chromosomal damages in Chinese hamster ovary cells. Kanaya N. **Genes Genet Syst** 1996 Oct;71(5):319-22

Accidental intoxication with methylene dianiline p,p'-diaminodiphenylmethane: acute liver damage after presumed ecstasy consumption. Tillmann HL, et al. **J Toxicol Clin Toxicol** 1997;35(1):35-40

Aniline and its metabolites generate free radicals in yeast. Brennan RJ, et al. **Mutagenesis** 1997 Jul;12(4):215-20

Comparative QSAR: radical toxicity and scavenging. Two different sides of the same coin. Hansch C, et al. **SAR QSAR Environ Res** 1995;4(2-3):73-82

Relationships between the regioselectivity of the hydroxylation of C4-substituted 2-fluoroaniline derivatives and their toxic endpoints. Cnubben NH, et al. **Toxicol Appl Pharmacol** 1996 Dec;141(2):403-15

Acute hematopoietic toxicity of aniline in rats. Khan MF, et al. **Toxicol Lett** 1997 Jun 16;92(1):31-7

Study of apoptosis in human lymphocytes by toxic substances implicated in toxic oil syndrome. Gallardo S, et al. **Toxicology** 1997 Mar 14;118(1):71-82

Modulation of taurine levels in the rat liver alters methylene dianiline hepatotoxicity. Seabra V, et al. **Toxicology** 1997 Oct 19;122(3):193-204

Characterization of methemoglobin formation induced by 3,5-dichloroaniline, 4-amino-2,6-dichlorophenol and 3,5-dichlorophenylhydroxylamine. Valentovic MA, et al. **Toxicology** 1997 Mar 14;118(1):23-36

Effect of malononitrilamides on human bone marrow. Czech J, et al. **Transplant Proc** 1996 Dec;28(6):3051-2

URINE

Application of a sequential analytical procedure for the detection of the beta-agonist brombuterol in bovine urine samples. Sangiorgi E, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):468-78

ANILINE HYDROXYLASE

METABOLISM

Effect of divalent metal ions on the microsomal aniline hydroxylase system of rainbow trout. Güner S, et al. **J Biochem Toxicol** 1996;11(5):257-62

ANILINE MUSTARD

ANALOGS & DERIVATIVES

Aniline mustard analogues of the DNA-intercalating agent amsacrine: DNA interaction and biological activity. Fan JY, et al. **Anticancer Drug Des** 1997 Apr;12(3):181-203

CHEMICAL SYNTHESIS

Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Rink SM, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24; 93(26):15063-8

METABOLISM

Kinetics of the conjugation of aniline mustards with glutathione and thiosulfate. Gamcsik MP, et al. **Chem Biol Interact** 1997 Jun 6;105(1):35-52

TOXICITY

Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Rink SM, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24; 93(26):15063-8

ANILINESULFONIC ACIDS see **SULFANILIC ACIDS**

ANILINO NAPHTHALENESULFONATES

CHEMISTRY

A simple assay for intracellular lipid-binding proteins using displacement of 1-anilinonaphthalene 8-sulfonic acid. Kane CD, et al. **Anal Biochem** 1996 Jan 15;233(2):197-204

Binding of 1-anilinonaphthalene-8-sulfonic acid to alpha-crystallin. Stevens A, et al. **Eur J Biochem** 1997 Feb 1;243(3):792-7

Hydroperoxide-mediated cytochrome P450-dependent 8-anilino-1-naphthalenesulfonic acid destruction, product formation and P450 modification. Yu XC, et al. **Mol Cell Biochem** 1997 Feb;167(1-2):159-68

METABOLISM

Detection of an unfolding intermediate in alpha-urease with enhanced affinity for ANSA. Peters CD, et al. **Biochem Cell Biol** 1997;75(1):55-61

The interaction of 8-anilinonaphthalene-1-sulfonate with His-47 of Taiwan cobra phospholipase A2 perturbing by the binding of calcium ion. Chang LS, et al. **Biochem Mol Biol Int** 1996 May;39(2):335-42

The hydrophobic probe 4,4'-bis(1-anilino-8-naphthalene sulfonic acid) is specifically photoincorporated into the N-terminal domain of alpha B-crystallin. Smulders RH, et al. **FEBS Lett** 1997 Jun 2;409(1):101-4

Interactions of 8-anilino-1-naphthalenesulfonic acid (ANS) and cytochrome P450 2B1: role of ANS as an effector as well as a reporter group. Yu XC, et al. **Mol Cell Biochem** 1996 Sep 20;162(2):89-95

PHARMACOLOGY

Stimulation of haemolytic activity of sea anemone cytolysins by 8-anilino-1-naphthalenesulphonate. Khoo HE, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):422-6

ANIMAL CARE COMMITTEES see **ANIMAL WELFARE**

ANIMAL COMMUNICATION

see related
PHEROMONES
VOCALIZATION, ANIMAL

Innateness of communicative behaviors. Ginsburg BE, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:484-5

Competition and chemical communication in wild groups of common marmosets (Callithrix jacchus). Lazaro-Perea C, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:534-7

Specialization in multi-agent systems through learning. Murciano A, et al. **Biol Cybern** 1997 May;76(5):375-82

Role of the central amygdala in social communication in Syrian hamsters (Mesocricetus auratus). Bamshad M, et al. **Brain Res** 1997 Jan 2;744(1):15-22

Hormonal modulation of communication signals in electric fish. Zakon HH. **Dev Neurosci** 1996;18(1-2):115-23 (42 ref.)

Acoustic communication underground: vocalization characteristics in subterranean social mole-rats (Cryptomys sp., Bathyergidae). Credner S, et al. **J Comp Physiol [A]** 1997 Mar;180(3):245-55

Perceptual salience of acoustic features of Japanese monkey coo calls. Le Prell CG, et al. **J Comp Psychol** 1997 Sep; 111(3):261-74

Vasopressin and developmental onset of flank marking behavior in golden hamsters. Ferris CF, et al. **J Neurobiol** 1996 Jun;30(2):192-204

Facilitative responses to species-specific calls in cortical FM-FM neurons of the mustached bat. Ohlemiller KK, et al. **Neuroreport** 1996 Jul 29;7(11):1749-55

Influence of various types of species-specific acoustic signals on the heart rate of mammals. Movchan VN. **Neurosci Behav Physiol** 1996 Jul-Aug;26(4):295-300

Transmission of information regarding the quantitative characteristics of an object in ants. Reznikova ZI, et al. **Neurosci Behav Physiol** 1996 Sep-Dec;26(5):397-405

Chemical communication in scarab beetles: reciprocal behavioral agonist-antagonist activities of chiral pheromones. Leal WS. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12112-5

The evolution of begging: signaling and sibling competition. Rodríguez-Gironés MA, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14637-41

Canine communication. Simpson BS. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):445-64 (49 ref.)

[The recognition by European lynxes (Lynx lynx, Felidae, Carnivora) through urinary odor signals of the species, sex and age of conspecific, familiar and unfamiliar individuals] Sokolov VE, et al. **Izv Akad Nauk Ser Biol** 1996 Sep-Oct; (5):571-7 (Eng. Abstr.) **(Rus)**

[The reaction of adult Roborovskii dwarf hamsters (Phodopus roborovskii) to the odor signals of individuals of their own and the opposite sex at different seasons of the year] Sokolov VE, et al. **Izv Akad Nauk Ser Biol** 1996 Sep-Oct;(5):578-82 (Eng. Abstr.) **(Rus)**

[The chemical interaction of tadpoles of the common frog Rana temporaria L. with conspecific and heterospecific anuran tadpoles] Kiseleva EI. **Zh Obshch Biol** 1996 Nov-Dec;57(6):740-6 (Eng. Abstr.) **(Rus)**

ANIMAL DISEASES

Testing the limits: a model of human dysfunction [letter] Rovee-Collier C. **Dev Psychobiol** 1996 Jul;29(5):397-8

Emerging diseases--what veterinarians need to know. Brown C. **J Vet Diagn Invest** 1997 Apr;9(2):113-7 (58 ref.)

Wildlife husbandry and diseases. **Rev Sci Tech** 1996 Mar; 15(1):1-342

Cumulative indexes-volumes 26-50, 1990-1996. **Vet Immunol Immunopathol** 1996 Apr;50(3-4):185-359

Voorjaarsdagen Congress 1997. Amsterdam, The Netherlands. April 25-27, 1997. Proceedings. **Vet Q** 1997; 19 Suppl 1:S1-67

CHEMICALLY INDUCED

Failure of loop diuretics to induce nursing sickness in mink at weaning. Hansen O, et al. **Can J Vet Res** 1996 Oct; 60(4):277-80

Taking a lead from wildlife. Colborn T, et al. **Neurotoxicol Teratol** 1996 May-Jun;18(3):235-7; discussion 271-6 (21 ref.)

Fumonisins, mycotoxins of increasing importance: their nature and their effects. Dutton MF. **Pharmacol Ther** 1996; 70(2):137-61 (400 ref.)

CLASSIFICATION

Dubbing animal diseases with color. Hadlow WJ. **Vet Pathol** 1997 Jan;34(1):74-8 (0 ref.)

DIAGNOSIS

Polioencephalomalacia in two alpacas. Beck C, et al. **Aust Vet J** 1996 Nov;74(5):350-2

Thymic lymphosarcoma of T cell lineage in a koala (Phascolarctos cinereus). Canfield PJ, et al. **Aust Vet J** 1996 Aug;74(2):151-4

Proctitis associated with chlamydial infection in a koala. Hemsley S, et al. **Aust Vet J** 1996 Aug;74(2):148-50

Providencia rettgeri meningitis in hatchling saltwater crocodiles (Crocodylus porosus). Ladds PW, et al. **Aust Vet J** 1996 Nov;74(5):397-8

Use of veterinary clinic records for evaluating possible risk factors for disease. Morton JM. **Aust Vet J** 1996 Nov; 74(5):365-6 (9 ref.)

Task force investigates disease [news] Murray G. **Aust Vet J** 1996 Sep;74(3):251

Interdigital subcutaneous emphysema ("bubble foot") in Crocodylus porosus hatchlings. Turton JA, et al. **Aust Vet J** 1996 Nov;74(5):395-7

DxMONITOR: compiling veterinary diagnostic laboratory results [news] Hueston W. **Emerg Infect Dis** 1995 Jan-Mar; 1(1):36

Medical diagnosis, diagnostic spaces, and fuzzy systems. Bellamy JE. **J Am Vet Med Assoc** 1997 Feb 1;210(3):390-6

Detection of animal pathogens by using the polymerase chain reaction (PCR). Rodriguez JM. **Vet J** 1997 May; 153(3):287-305 (232 ref.)

Fatal cytauxzoonosis in a captive-reared white tiger (Panthera tigris). Garner MM, et al. **Vet Pathol** 1996 Jan; 33(1):82-6

Rabies diagnosis and the Central Veterinary Laboratory. Whitby J. **Vet Rec** 1996 Nov 2;139(18):433

Pneumonic pasteurellosis associated with Pasteurella haemolytica in chipmunks (Tamias sibiricus). Astorga RJ, et al. **Zentralbl Veterinarmed [B]** 1996 Mar;43(1):59-62

[Blood parameters as an aid in the diagnosis of reptile diseases] Kölle P, et al. **Tierarztl Prax** 1996 Aug;24(4):402-5 (Eng. Abstr.) **(Ger)**

DIET THERAPY

Diet selection and special considerations in the management of hepatic diseases. Bauer JE. **J Am Vet Med Assoc** 1997 Mar 1;210(5):625-9 (38 ref.)

DRUG THERAPY

The role of omega-3 fatty acids in renal disorders. Plotnick AN. **J Am Vet Med Assoc** 1996 Sep 1;209(5):906-10 (55 ref.)

Proceedings of the 7th European Association for Veterinary pharmacology and Toxicology (EAVPT) International Congress. Madrid, Spain, 6-10 July 1997. **J Vet Pharmacol Ther** 1997 Aug;20 Suppl 1:1-340

Avoparcin ban [letter] Howarth F, et al. **Vet Rec** 1997 Jan 25;140(4):103-4

EPIDEMIOLOGY

Sero-surveying wildlife: a needle in a haystack? **Aust Vet J** 1996 Sep;74(3):257-8

Incidence of nursing sickness and biochemical observations in lactating mink with and without dietary salt supplementation. Clausen TN, et al. **Can J Vet Res** 1996 Oct;60(4):271-6

The Canadian Cooperative Wildlife Health Centre and surveillance of wild animal diseases in Canada. Leighton FA, et al. **Can Vet J** 1997 May;38(5):279-84

Rabid black bears in Ontario. Walroth R, et al. **Can Vet J** 1996 Aug;37(8):492

Disease and mortality in captive wild dogs (Lycaon pictus). van Heerden J, et al. **J S Afr Vet Assoc** 1996 Sep; 67(3):141-5

Cross-sectional serosurvey for Japanese encephalitis specific antibody from animal sera in Malaysia 1993. Oda K, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):463-70

The growth and use of veterinary epidemiology [editorial; comment] Wilesmith JW. **Vet J** 1997 Jan;153(1):7-8. Comment on: Vet J 1997 Jan;153(1):41-7.

Wildlife diseases in The Netherlands [editorial] van Dijk JE, et al. **Vet Q** 1996;18 Suppl 3:S123

International disease surveillance: September to December 1996. **Vet Rec** 1997 Feb 22;140(8):192

International disease surveillance: January to March 1996. **Vet Rec** 1996 Jun 29;138(26):633-4

International disease surveillance: summary for 1995. **Vet Rec** 1996 May 25;138(21):509-10

Descriptive epidemiology of captive cervid herds in Michigan, USA. Bruning-Fann CS, et al. **Vet Res** 1997 May-Jun;28(3):295-302

Molecular epidemiology of animal virus diseases. Haas L. **Zentralbl Veterinarmed [B]** 1997 Jul;44(5):257-72 (78 ref.)

ETIOLOGY

Proctitis associated with chlamydial infection in a koala. Hemsley S, et al. **Aust Vet J** 1996 Aug;74(2):148-50

Non-specific hyperreactivity related to the use of Freund's complete adjuvant [letter; comment] Andersen KE, et al. **Contact Dermatitis** 1996 Aug;35(2):127. Comment on: Contact Dermatitis 1996 Feb;34(2):111-4.

Reproductive toxicology in animals with induced and spontaneous diabetes. Kalter H. **Reprod Toxicol** 1996 Nov-Dec;10(6):417-38 (144 ref.)

Wildlife diseases in The Netherlands [editorial] van Dijk JE, et al. **Vet Q** 1996;18 Suppl 3:S123

GENETICS

Molecular epidemiology of animal virus diseases. Haas L. **Zentralbl Veterinarmed [B]** 1997 Jul;44(5):257-72 (78 ref.)

IMMUNOLOGY

Studies on coproantigen detection for diagnosis of Echinococcus infection in definitive hosts. Sakai H. **Jpn J Vet Res** 1996 Aug;44(2):125-7

Cytokines: communication molecules that influence the process of disease. Splitter G. **Jpn J Vet Res** 1997 May; 45(1):3-12 (64 ref.)

Inflammatory cytokines in animal health and disease. Murtaugh MP, et al. **Vet Immunol Immunopathol** 1996 Nov; 54(1-4):45-55 (65 ref.)

T cell cytokines and disease prevention. Wood PR, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):33-44 (83 ref.)

MICROBIOLOGY

AF/R2 adhesin and cytopathic effect as virulence traits of diarrhea-inducing Escherichia coli O103 in European rabbit. Chalareng C, et al. **Adv Exp Med Biol** 1997; 412:269-71

The expanding genus of Helicobacter: pathogenic and zoonotic potential. Fox JG. **Semin Gastrointest Dis** 1997 Jul;8(3):124-41 (165 ref.)

A review of Listeria monocytogenes and listeriosis [see comments] Low JC, et al. **Vet J** 1997 Jan;153(1):9-29 (272 ref.). Comment in: Vet J 1997 Jan;153(1):3-5.

Cumulative indexes, volumes 26-50. **Vet Microbiol** 1996 Jun; 50(3-4):167-333

Molecular identification and epidemiology of animal mycoplasmas. Frey J, et al. **Wien Klin Wochenschr** 1997 Aug 8;109(14-15):600-3

MORTALITY

Unraveling the manatee mystery [news] Suzik HA. **J Am Vet Med Assoc** 1997 Mar 15;210(6):740

Fatal cytauxzoonosis in a captive-reared white tiger (Panthera tigris). Garner MM, et al. **Vet Pathol** 1996 Jan; 33(1):82-6

PATHOLOGY

A German-Swedish collection of histopathological slides from 1893. Hansen HJ, et al. **Acta Vet Scand** 1997; 38(1):97-107

Spontaneous pathology of the gray short-tailed opossum (Monodelphis domestica). Hubbard GB, et al. **Lab Anim Sci** 1997 Feb;47(1):19-26

Inflammatory cytokines in animal health and disease. Murtaugh MP, et al. **Vet Immunol Immunopathol** 1996 Nov; 54(1-4):45-55 (65 ref.)

PHYSIOPATHOLOGY

Incidence of nursing sickness and biochemical observations in lactating mink with and without dietary salt supplementation. Clausen TN, et al. **Can J Vet Res** 1996 Oct;60(4):271-6

Failure of loop diuretics to induce nursing sickness in mink at weaning. Hansen O, et al. **Can J Vet Res** 1996 Oct; 60(4):277-80

The pathophysiology of spinal cord injury and its clinical implications. Kraus KH. **Semin Vet Med Surg (Small Anim)** 1996 Nov;11(4):201-7 (42 ref.)

PREVENTION & CONTROL

National considerations in the Nordic countries regarding vaccine licensing. Gunnarsson E, et al. **Acta Vet Scand Suppl** 1996;90:85-7

The tradition of animal disease control in the Nordic countries compared to the rest of Europe. Pedersen KB. **Acta Vet Scand Suppl** 1996;90:9-16

ANIMAL DISEASES

Experience with veterinary vaccines in warm climates. Tulasne JJ, et al. **Dev Biol Stand** 1996;87:33–42 (20 ref.)

DxMONITOR: compiling veterinary diagnostic laboratory results [news] Hueston W. **Emerg Infect Dis** 1995 Jan–Mar; 1(1):36

Geographic information systems for animal health management and disease control. McGinn TJ 3rd, et al. **J Am Vet Med Assoc** 1996 Dec 1;209(11):1917–21

World trade increases American interest in OIE [news] Reichard RE. **J Am Vet Med Assoc** 1997 Apr 1; 210(7):882–4

NAFTA and GATT: the future of animal health and trade. Sheesley D, et al. **J Am Vet Med Assoc** 1996 Dec 15; 209(12):1998–2000

Health status of experimental pigs. Hansen AK. **Pharmacol Toxicol** 1997;80 Suppl 2:10–5 (19 ref.)

The effect of a combined approach to schistosomiasis control on the transmission of Schistosoma japonicum in Xingzi of Poyang Lake area, China. Jiang Q, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):535–41

T cell cytokines and disease prevention. Wood PR, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):33–44 (83 ref.)

Potency of veterinary rabies vaccines in The Netherlands: a case for continued vigilance. Rooijakkers EJ, et al. **Vet Q** 1996 Dec;18(4):146–50

Rabies and quarantine: report of the BVA working group. **Vet Rec** 1997 Jul 19;141(3):79–81

Rabies and quarantine [letter] Carwardine P. **Vet Rec** 1996 Dec 14;139(24):604

Rabies and quarantine [letter] [see comments] Dean S. **Vet Rec** 1996 Nov 30;139(22):551. Comment in: Vet Rec 1996 Dec 7;139(23):574–5.

Rabies and quarantine [letter] Heathcote V. **Vet Rec** 1996 Dec 14;139(24):604

Use of gloves in veterinary practice [letter] [see comments] Thomas D. **Vet Rec** 1996 Nov 30;139(22):551. Comment in: Vet Rec 1996 Dec 7;139(23):574. Comment in: Vet Rec 1996 Dec 7;139(23):574–5.

SURGERY

Surgical correction of anorectal atresia and rectovaginal fistula in an alpaca cria. Carraro DB, et al. **Aust Vet J** 1996 Nov;74(5):352–4

Reduction and repair of colonic intussusception in a wapiti/red hybrid hind (Cervus elaphus). Jonsson NN. **Aust Vet J** 1995 Dec;72(12):471–2

THERAPY

Modes of treatment. Rijnberk A. **Aust Vet J** 1997 Apr; 75(4):260–1 (6 ref.)

An ethicist's commentary on the case of the infected research animal. Rollin BE. **Can Vet J** 1997 Mar;38(3):136

The effects of hypertonic saline in healthy and diseased animals. Cambier C, et al. **Vet Res Commun** 1997 Jul; 21(5):303–16 (52 ref.)

[Quackery or not, that is the question (letter)] Boerekamp RE. **Tijdschr Diergeneeskd** 1997 Apr 1;122(7):195–6 **(Dut)**

[How the Similia principle of homeopathy resolved an emergency (letter; comment)] Lumeij JT. **Tijdschr Diergeneeskd** 1997 Mar 1;122(5):134. Comment on: Tijdschr Diergeneeskd 1997 Jan 15;122(2):36–9; discussion 40. **(Dut)**

[How the Similia principle of homeopathy resolved an emergency (letter; comment)] Poll PH. **Tijdschr Diergeneeskd** 1997 Mar 1;122(5):133; discussion 134. Comment on: Tijdschr Diergeneeskd 1997 Jan 15;122(2):36–9; discussion 40. **(Dut)**

[How the Similia principle of homeopathy resolved an emergency (letter; comment)] Slappendel RJ. **Tijdschr Diergeneeskd** 1997 Mar 1;122(5):133; discussion 134. Comment on: Tijdschr Diergeneeskd 1997 Jan 15;122(2):36–9; discussion 40. **(Dut)**

TRANSMISSION

Use of gloves in veterinary practice [letter] [see comments] Thomas D. **Vet Rec** 1996 Nov 30;139(22):551. Comment in: Vet Rec 1996 Dec 7;139(23):574. Comment in: Vet Rec 1996 Dec 7;139(23):574–5.

ANIMAL FEED

The role of feed protein quality in reducing environmental pollution by lowering nitrogen excretion. III. Strategies of feeding: a review. Hegedüs M. **Acta Vet Hung** 1996; 44(2):153–63 (67 ref.)

Olive by-products in pig fattening. Rupić V, et al. **Acta Vet Hung** 1997;45(1):53–66

Sole haemorrhages in tied heifers in early gestation as an indicator of laminitis: effects of diet and flooring. Bergsten C, et al. **Acta Vet Scand** 1996;37(4):375–81

Sole haemorrhages in tied primiparous cows as an indicator of periparturient laminitis: effects of diet, flooring and season. Bergsten C, et al. **Acta Vet Scand** 1996;37(4):383–94

A long-term study on the health status and performance of sows on different feed allowances during late pregnancy. II. The total cell content and its percentage of polymorphonuclear leucocytes in pathogen-free colostrum and milk collected from clinically healthy sows. Persson A, et al. **Acta Vet Scand** 1996;37(3):279–91

A long-term study on the health status and performance of sows on different feed allowances during late pregnancy. III. Escherichia coli and other bacteria, total cell content, polymorphonuclear leucocytes and pH in colostrum and milk during the first 3 weeks of lactation. Persson A, et al. **Acta Vet Scand** 1996;37(3):293–313

Biological fate of fumonisin B1 in food-producing animals. Prelusky DB, et al. **Adv Exp Med Biol** 1996;392:265–78

Occurrence and fate of fumonisins in beef. Smith JS, et al. **Adv Exp Med Biol** 1996;392:39–55

Food hoarding is increased by pregnancy, lactation, and food deprivation in Siberian hamsters. Bartness TJ. **Am J Physiol** 1997 Jan;272(1 Pt 2):R118–25

Orally administered IGF-I increases intestinal mucosal growth in formula-fed neonatal pigs. Burrin DG, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R1085–91

Effects of refeeding of undernourished and insulin treatment of diabetic neonatal rats on IGF and IGFBP. Goya L, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):E223–31

Effects of exercise and feeding on the hexosamine biosynthetic pathway in rat skeletal muscle. Nelson BA, et al. **Am J Physiol** 1997 May;272(5 Pt 1):E848–55

Effect of amount and type of dietary fiber on food intake in energy-restricted dogs. Butterwick RF, et al. **Am J Vet Res** 1997 Mar;58(3):272–6

Dietary modulation of methotrexate-induced enteritis in cats. Marks SL, et al. **Am J Vet Res** 1997 Sep;58(9):989–96

Prediction of folding stability and degradability of the de novo designed protein MB-1 in cow rumen. MacCallum JD, et al. **Appl Biochem Biotechnol** 1997 Apr;66(1):83–93

Arsenic residues in eggs from laying hens fed with a diet containing arsenic (III) oxide. Holcman A, et al. **Arch Environ Contam Toxicol** 1997 May;32(4):407–10

The use of feed restriction for mortality control of chickens in broiler farms. Tottori J, et al. **Avian Dis** 1997 Apr–Jun; 41(2):433–7

The use of enzyme-digested soybean residue for feeding common carp. Wong MH, et al. **Biomed Environ Sci** 1996 Dec;9(4):418–23

Effect of dietary calcium intake and meal calcium content on calcium absorption in the rat. Cashman KD, et al. **Br J Nutr** 1996 Sep;76(3):463–70

Aversion-preference patterns in amino acid- or protein-deficient rats: a comparison with previously reported responses to thiamin-deficient diets. Fromentin G, et al. **Br J Nutr** 1997 Feb;77(2):299–314

Net flux of nutrients across splanchnic tissues in wethers consuming grasses of different sources and physical forms ad libitum. Goetsch AL, et al. **Br J Nutr** 1997 May; 77(5):769–81

Energy balance and liver respiratory activity in rats fed on an energy-dense diet. Iossa S, et al. **Br J Nutr** 1997 Jan; 77(1):99–105

Food intake and diet selection in sheep: the effect of manipulating the rates of digestion of carbohydrates and protein of the foods offered as a choice. Kyriazakis I, et al. **Br J Nutr** 1997 Feb;77(2):243–54

Apparent ileal dry matter and crude protein digestibility of rations fed to pigs and determined with the use of chromic oxide (Cr_2O_3) and acid-insoluble ash as digestive markers. van Leeuwen P, et al. **Br J Nutr** 1996 Oct;76(4):551–62

Digestion of feed amino acids in the rumen and small intestine of dairy cows measured with nylon-bag techniques. van Straalen WM, et al. **Br J Nutr** 1997 Jan;77(1):83–97

Preference for wheat straw by lambs conditioned with intraruminal infusions of starch. Villalba JJ, et al. **Br J Nutr** 1997 Feb;77(2):287–97

Effects of enzyme supplementation on the nutritive value of dehulled lupins. Annison G, et al. **Br Poult Sci** 1996 Mar;37(1):157–72

Increased small intestinal fermentation is partly responsible for the anti-nutritive activity of non-starch polysaccharides in chickens. Choct M, et al. **Br Poult Sci** 1996 Jul; 37(3):609–21

A comparative study between mature ostriches (Struthio camelus) and adult cockerels with respect to true and apparent metabolisable energy values for maize, barley, oats and triticale. Cilliers SC, et al. **Br Poult Sci** 1997 Mar; 38(1):96–100

Optimal diets for egg production. Curnow RN, et al. **Br Poult Sci** 1996 May;37(2):373–82

Incorporation of selenium into egg proteins from dietary selenite. Davis RH, et al. **Br Poult Sci** 1996 Mar; 37(1):197–211

Short-term effects of food protein content on subsequent diet selection by chickens and the consequences of alternate feeding of high- and low-protein foods. Forbes JM, et al. **Br Poult Sci** 1996 Jul;37(3):597–607

Relationships between the degree of food restriction and welfare indices in broiler breeder females. Hocking PM, et al. **Br Poult Sci** 1996 May;37(2):263–78

Effects of dietary protein content, addition of nonessential amino acids and dietary methionine to cysteine balance on responses to dietary sulphur-containing amino acids in broilers. Huyghebaert G, et al. **Br Poult Sci** 1996 Jul; 37(3):623–39

Ileal amino acid digestibility assay for the growing meat chicken--effect of the imposition of a fasting period and the nature of the test diet. Kadim IT, et al. **Br Poult Sci** 1997 Jul;38(3):285–90

Predicted response in food conversion ratio for growth by selection on the ratio or on linear component traits, in a (sequential) selection programme. Koerhuis AN, et al. **Br Poult Sci** 1996 May;37(2):317–27

Effect of probiotic supplementation on growth, nitrogen utilisation and serum cholesterol in broilers. Mohan B, et al. **Br Poult Sci** 1996 May;37(2):395–401

Effect of added soyabean oil and dietary energy on metabolisable and net energy of broiler diets. Nitsan Z, et al. **Br Poult Sci** 1997 Mar;38(1):101–6

Effect of sweet lupins on duckling growth. Olver MD. **Br Poult Sci** 1997 Mar;38(1):115–7

Effects of oven-drying tubers of two high-protein sweet potato varieties at different temperatures on their feeding value in broilers. Panigrahi S, et al. **Br Poult Sci** 1996 Mar; 37(1):173–88

Replacement of maize with sweet potato (Ipomoea batatas L.) tuber meal in broiler diets. Ravindran V, et al. **Br Poult Sci** 1996 Mar;37(1):95–103

Utilisation of squilla meal (a novel animal protein source) by broilers. Reddy VR, et al. **Br Poult Sci** 1997 Jul; 38(3):263–9

A comparison of the energy availability for chickens of ground and whole grain samples of two wheat varieties. Salah Uddin M, et al. **Br Poult Sci** 1996 May;37(2):347–57

Antibacterial activity of formic and propionic acids in the diet of hens on Salmonellas in the crop. Thompson JL, et al. **Br Poult Sci** 1997 Mar;38(1):59–65

Studies on acid oils and fatty acids for chickens. I. Influence of age, rate of inclusion and degree of saturation on fat digestibility and metabolisable energy of acid oils. Vila B, et al. **Br Poult Sci** 1996 Mar;37(1):105–17

Studies on acid oils and fatty acids for chickens. II. Effect of free fatty acid content and degree of saturation of free fatty acids and neutral fat on fatty acid digestibility. Vila B, et al. **Br Poult Sci** 1996 Mar;37(1):119–30

Studies on acid oils and fatty acids for chickens III. Effect of chemical composition on metabolisable energy of by-products of vegetable oil refining. Vila B, et al. **Br Poult Sci** 1996 Mar;37(1):131–44

NMDA-induced lesions of the nucleus accumbens or the ventral pallidum increase the rewarding efficacy of food to deprived rats. Johnson PI, et al. **Brain Res** 1996 May 25;722(1–2):109–17

Mycotoxins in fungal contaminated samples of animal feed from western Canada, 1982–1994. Abramson D, et al. **Can J Vet Res** 1997 Jan;61(1):49–52

Plasma concentration of thyroid hormones in lambs fed poultry offal meal in replacement of soybean meal at two energy levels. Alshaikh MA, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Jun;104(6):213–5

Residues of some veterinary drugs in animals and foods. Joint FAO/WHO Expert Committee on Food Additives [published erratum appears in FAO Food Nutr Pap 1997;41(9):141, 127–34] **FAO Food Nutr Pap** 1996; 41(8):1–166

Residues of some veterinary drugs in animals and foods. Monographs prepared by the Forty-Seventh meeting of the Joint FAO/WHO Expert Committee on Food Additives. Rome, 4–13 June 1996. **FAO Food Nutr Pap** 1997;41(9):1–139

Reduced intestinal colonisation with F18-positive enterotoxigenic Escherichia coli in weaned pigs fed chicken egg antibody against the fimbriae. Zúñiga A, et al. **FEMS Immunol Med Microbiol** 1997 Jul;18(3):153–61

New diet (NTP-2000) for rats in the National Toxicology Program toxicity and carcinogenicity studies. Rao GN. **Fundam Appl Toxicol** 1996 Jul;32(1):102–8

How to make the gut grow. Carey HV. **Gastroenterology** 1997 Apr;112(4):1420–2

Historical dose reconstruction project: estimating the population at risk. Rogers JF, et al. **Health Phys** 1997 Feb; 72(2):186–94

Lack of carcinogenesis superfluous by the back mushroom Agaricus bisporus in mice: different feeding regimen. Toth B, et al. **In Vivo** 1997 May–Jun;11(3):227–31

VFD simplified [news] **J Am Vet Med Assoc** 1997 May 1; 210(9):1252–3

Whole cottonseeds or a combination of soybeans and soybeans hulls in the diets of lactating dairy cows. Abel-Caines SF, et al. **J Dairy Sci** 1997 Jul;80(7):1353–7

Measuring the effectiveness of fiber by animal response trials. Armentano L, et al. **J Dairy Sci** 1997 Jul;80(7):1416–25 (36 ref.)

Characteristics of milk and reduced fat cheddar cheese from cows fed extruded soybeans and niacin. Baer RJ, et al. **J Dairy Sci** 1996 Jul;79(7):1127–36

Chewing activities and milk production of dairy cows fed alfalfa as hay, silage, or dried cubes of hay or silage. Beauchemin KA, et al. **J Dairy Sci** 1997 Feb;80(2):324–33

Milk production and composition responses to the source of protein supplements in diets containing wheat middlings. Bernard JK. **J Dairy Sci** 1997 May;80(5):938–42

Intake, site, and extent of nutrient digestion of lactating cows grazing pasture. Berzaghi P, et al. **J Dairy Sci** 1996 Sep; 79(9):1581–9

Effects of a supplemental liquid yeast product on feed intake, ruminal profiles, and yield, composition, and organoleptic characteristics of milk from lactating Holstein cows. Besong S, et al. **J Dairy Sci** 1996 Sep;79(9):1654–8

Comparison of milk and blood lipids in Jersey and Holstein cows fed total mixed rations with or without whole cottonseed. Bitman J, et al. **J Dairy Sci** 1996 Sep;

79(9):1596–602
Performance and profiles of milk fatty acids of cows fed full fat, heat–treated soybeans using various processing methods. Chouinard PY, et al. **J Dairy Sci** 1997 Feb; 80(2):334–42
Effects of tempered barley on milk yield, intake, and digestion kinetics of lactating Holstein cows. Christen SD, et al. **J Dairy Sci** 1996 Aug;79(8):1394–9
Effect of whole cottonseed on serum constituents, fragility of erythrocyte cells, and reproduction of growing Holstein heifers. Colin–Negrete J, et al. **J Dairy Sci** 1996 Nov; 79(11):2016–23
Nutrient fluxes in splanchnic tissue of dairy cows: influence of grass quality. De Visser H, et al. **J Dairy Sci** 1997 Aug; 80(8):1666–73
Particle size of roasted soybeans and the effect on milk production of dairy cows. Dhiman TR, et al. **J Dairy Sci** 1997 Aug;80(8):1722–7
Interactions among forages and nonforage fiber sources. Grant RJ. **J Dairy Sci** 1997 Jul;80(7):1438–46 (61 ref.)
Effect of percentage of dietary forage neutral detergent fiber and source of starch on performance of lactating Jersey cows. Harmison B, et al. **J Dairy Sci** 1997 May;80(5):905–11
Predicting ad libitum dry matter intake and yields of Jersey cows. Holter JB, et al. **J Dairy Sci** 1996 May;79(5):912–21
Forage source alters nutrient supply to the intestine without influencing milk yield. Khorasani GR, et al. **J Dairy Sci** 1996 May;79(5):862–72
A simple method for the analysis of particle sizes of forage and total mixed rations. Lammers BP, et al. **J Dairy Sci** 1996 May;79(5):922–8
Use of nitrogen from ammoniated alfalfa hay, urea, soybean meal, and animal protein meal by lactating cows. Lines LW, et al. **J Dairy Sci** 1996 Nov;79(11):1992–9
Effect of concentrate source and amount in diets on plasma hormone concentrations of prepubertal heifers. Nosbush BB, et al. **J Dairy Sci** 1996 Aug;79(8):1400–9
Roasted soybeans, blood meal, and tallow as sources of fat and ruminally undegradable protein in the diets of lactating cows. Pires AV, et al. **J Dairy Sci** 1996 Sep;79(9):1603–10
Lactational responses of dairy cows fed unsaturated fat from extruded soybeans or sunflower seeds. Schingoethe DJ, et al. **J Dairy Sci** 1996 Jul;79(7):1244–9
Utilization of supplemental triglycerides or free fatty acids by calves from 4 to 10 weeks of age. Spanski NA, et al. **J Dairy Sci** 1997 Mar;80(3):573–85
Digestion and passage kinetics of forage fiber in dairy cows as affected by fiber–free concentrate in the diet. Stensig T, et al. **J Dairy Sci** 1997 Jul;80(7):1339–52
Evaluation of wheat gluten in milk replacers and calf starters. Terui H, et al. **J Dairy Sci** 1996 Jul;79(7):1261–6
Effects of supplementation of energy or ruminally undegraded protein to lactating cows fed alfalfa hay or silage. Vagnoni DB, et al. **J Dairy Sci** 1997 Aug; 80(8):1703–12
Effects of dietary forage source and amount of forage addition on intake, milk yield, and digestion for lactating dairy cows. West JW, et al. **J Dairy Sci** 1997 Aug; 80(8):1656–65
The effect of diet on palatal prosthetic coverage in rats. Barclay SC, et al. **J Dent** 1997 Jan;25(1):71–8
A new model of acute liver steatosis induced in rats by fasting followed by refeeding a high carbohydrate–fat free diet. Biochemical and morphological analysis. Delzenne NM, et al. **J Hepatol** 1997 Apr;26(4):880–5
The speciation of lysine–complexed copper as a bovine nutritional supplement. Attaelmannan MA, et al. **J Inorg Biochem** 1996 Nov 15;64(3):215–24
A hidden paradox in carcinogenesis bioassays [letter] Paolini M, et al. **J Natl Cancer Inst** 1997 May 21;89(10):736–7
Behavior–relevant changes in nucleus accumbens dopamine transmission elicited by food reinforcement: an electrochemical study in rat. Richardson NR, et al. **J Neurosci** 1996 Dec 15;16(24):8160–9
Evaluation of solid–phase labels for gastric emptying studies in cats. Hoskinson JJ, et al. **J Nucl Med** 1997 Mar; 38(3):495–9
Plant limitations to fiber digestion and utilization. Buxton DR, et al. **J Nutr** 1997 May;127(5 Suppl):814S–818S (22 ref.)
Importance of sphingolipids and inhibitors of sphingolipid metabolism as components of animal diets. Merrill AH Jr, et al. **J Nutr** 1997 May;127(5 Suppl):830S–833S (22 ref.)
New nonpurified diet (NTP–2000) for rodents in the National Toxicology Program's toxicology and carcinogenesis studies. Rao GN. **J Nutr** 1997 May;127(5 Suppl):842S–846S (22 ref.)
Microbial and animal limitations to fiber digestion and utilization. Varga GA, et al. **J Nutr** 1997 May;127(5 Suppl):819S–823S (34 ref.)
Effects of different types of dietary fiber preparations isolated from bamboo shoots, edible burdock, apple and corn on fecal steroid profiles of rats. Shimizu J, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Dec;42(6):527–39
In vivo indicators of pathologic ruminal sulfide production in steers with diet–induced polioencephalomalacia. Gould DH, et al. **J Vet Diagn Invest** 1997 Jan;9(1):72–6
Chronic consumption of fumonisins derived from Fusarium moniliforme culture material: clinical and pathologic effects in swine. Guzman RE, et al. **J Vet Diagn Invest** 1997 Apr; 9(2):216–8
Effect of feeding deoxynivalenol (vomitoxin)–contaminated barley to horses. Johnson PJ, et al. **J Vet Diagn Invest** 1997 Apr;9(2):219–21
An improved method for monensin in feeds. Stahr HM, et al. **J Vet Diagn Invest** 1996 Jan;8(1):140–2
Mineral metabolism in plasma, urine and bone of periparturient cows fed anionic diets with different calcium and phosphorous contents. Won JH, et al. **J Vet Med Sci** 1996 Dec;58(12):1187–92
Fatal spongiform encephalopathy in a patient who had handled animal feed [letter] Weis J, et al. **Lancet** 1996 Nov 2;348(9036):1240
Growth of Anopheles mosquito larvae on dietary microbiota in aquatic surface microlayers. Wotton RS, et al. **Med Vet Entomol** 1997 Jan;11(1):65–70
Effect of storage duration on the nutritional value of corn kernels for broiler chicks. Bartov I. **Poult Sci** 1996 Dec; 75(12):1524–7
Microbial phytase improves amino acid utilization in young chicks fed diets based on soybean meal but not diets based on peanut meal. Biehl RR, et al. **Poult Sci** 1997 Feb; 76(2):355–60
Effect of high ambient temperature on feed digestibility in broilers. Bonnet S, et al. **Poult Sci** 1997 Jun;76(6):857–63
Pearl millet in layer diets enhances egg yolk n–3 fatty acids. Collins VP, et al. **Poult Sci** 1997 Feb;76(2):326–30
The influence of micronization, dehulling, and enzyme supplementation on the nutritional value of peas for laying hens. Igbasan FA, et al. **Poult Sci** 1997 Feb;76(2):331–7
Individual and combined effects of fumonisin B1 present in Fusarium moniliforme culture material and diacetoxyscirpenol or ochratoxin A in turkey poults. Kubena LF, et al. **Poult Sci** 1997 Feb;76(2):256–64
Individual and combined effects of moniliformin present in Fusarium fujikuroi culture material and aflatoxin in broiler chicks. Kubena LF, et al. **Poult Sci** 1997 Feb;76(2):265–70
Replacement value of betaine for DL–methionine in male broiler chicks. Schutte JB, et al. **Poult Sci** 1997 Feb; 76(2):321–5
The effect of nutrient intake during rearing of broiler breeder females on subsequent fertility. Walsh TJ, et al. **Poult Sci** 1997 Feb;76(2):297–305
Effect of feeding diets containing an antibiotic, a probiotic, or yucca extract on growth and intestinal urease activity in broiler chicks. Yeo J, et al. **Poult Sci** 1997 Feb; 76(2):381–5
The use of dietary calcium intake of dairy ruminants to predict the transfer coefficient of radiostrontium to milk. Howard BJ, et al. **Radiat Environ Biophys** 1997 Feb; 36(1):39–43
Quantitative review of ruminal and total tract digestion of mixed diet organic matter and carbohydrates. Archimède H, et al. **Reprod Nutr Dev** 1997;37(2):173–89 (31 ref.)
Effect of dietary protein on the regulation of populations of Nematodirus battus by lambs. Israf DA, et al. **Res Vet Sci** 1996 May;60(3):276–7
Responses to supplementation in white Fulani cattle under agro–pastoral management in northern Nigeria. II. Fodder. Campbell DA, et al. **Trop Anim Health Prod** 1996 Aug; 28(3):230–6
Serum immunoglobulin responses among broiler chickens fed Ugandan commercial poultry feeds and vaccinated against Newcastle disease. Opuda–Asibo J, et al. **Trop Anim Health Prod** 1996 May;28(2):163–73
Efficacy of an in–feed formulation of ivermectin against adult worms and somatic larvae of Strongyloides ransomi. Barth D, et al. **Vet Parasitol** 1996 Oct 15;65(1–2):89–97
A possible influence of diet composition on the establishment of nematodes in the pig. Bjørn H, et al. **Vet Parasitol** 1996 May;63(1–2):167–71
Acute maduramicin toxicity in calves. Shlosberg A, et al. **Vet Rec** 1997 Jun 21;140(25):643–6
Chemical euthanasia of horses [letter] Woodward KN, et al. **Vet Rec** 1996 Jun 15;138(24):600
Recent acute and subacute mycotoxicoses recognized in France. Le Bars J, et al. **Vet Res** 1996;27(4–5):383–94 (36 ref.)
[Medicated feed with or without A, D, and K additives (news)] **Tijdschr Diergeneeskd** 1996 Sep 15;121(18):524–5 **(Dut)**
[Feed intake and performance of dairy cows during feeding of fodder beets supplementing grass silage] Birkenmaier F, et al. **Arch Tierernahr** 1996;49(4):335–47 (Eng. Abstr.) **(Ger)**
[Sociocultural reasons for the pigeon problem] Haag–Wackernagel D. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):52–7 (Eng. Abstr.) **(Ger)**
[Effects of orally administered substances on rumen fermentation patterns in cattle (in vitro). 7. Effect of dried yeast in chronic ruminal acidosis] Höltershinken M, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug;104(8):317–20 (Eng. Abstr.) **(Ger)**
[Risks due to the medication of feed and water in animal facilities] Kamphues J. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):250–6 (37 ref.) (Eng. Abstr.) **(Ger)**
[Animal nutrition in veterinary medicine––actual case reports. Nutritionally related disturbences in bone development in emus and rheas] Wolf P, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Dec;103(12):519–22 (Eng. Abstr.) **(Ger)**
[Animal nutrition in veterinary medicine: actual situations: decreased feed intake in swine] Zentek J, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Jan;104(1):36–7 (Eng. Abstr.) **(Ger)**
[Antibiotics in animal husbandry (editorial)] Heinzl S. **Med Monatsschr Pharm** 1997 Jun;20(6):145 **(Ger)**
[Improving the human iodine supply by iodination of swine feed] Rambeck WA, et al. **Tierarztl Prax** 1997 Jul; 25(4):312–5 (Eng. Abstr.) **(Ger)**
[Bioavailability of cadmium: effect of vitamin C and phytase in broiler chickens] Rambeck WA, et al. **Tierarztl Prax** 1996 Oct;24(5):467–70 (Eng. Abstr.) **(Ger)**
[Hygienic evaluation of work conditions in the combined production of fodder using Biotrin protein additives] Rakhmatullin NR, et al. **Med Tr Prom Ekol** 1996;(11):36–8 **(Rus)**
[Toxicological and hygienic evaluation of a new fodder additive: liquid mash concentrate] Sorokina Elu, et al. **Vopr Pitan** 1997;(2):18–21 (Eng. Abstr.) **(Rus)**
[The anti–immunodepressive action of kumiss made from cow's milk] Fedechko IM, et al. **Lik Sprava** 1995 Sep–Dec; (9–12):104–6 (Eng. Abstr.) **(Ukr)**

ADVERSE EFFECTS

Hypersensitivity pneumonitis induced by exposure to the legume algarroba. Franco–Vicario R, et al. **Allergy** 1997 Apr;52(4):478–9
Allergy to pine nuts in a bird fancier. Jansen A, et al. **Allergy** 1996 Oct;51(10):741–4
In vitro effects of an acidic by–product feed on bovine teeth. Rogers GM, et al. **Am J Vet Res** 1997 May;58(5):498–503
Omeprazole, a specific gastric secretion inhibitor on oxynticopeptic cells, reduces gizzard erosion in broiler chicks fed with toxic fish meals. Hinrichsen JP, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jul;117(3):267–73
Photoallergic contact dermatitis in a pig farmer caused by olaquindox. Kumar A, et al. **Contact Dermatitis** 1996 Oct; 35(4):249–50
Contact dermatitis in agricultural workers: rôle of common crops, fodder and weeds. Mahajan VK, et al. **Contact Dermatitis** 1996 Dec;35(6):373–4
Olaquindox–induced airborne photoallergic contact dermatitis followed by transient or persistent light reactions in 15 pig breeders. Schauder S, et al. **Contact Dermatitis** 1996 Dec;35(6):344–54
Grounds for recovery and defenses in feed liability cases. Hannah HW. **J Am Vet Med Assoc** 1997 Jun 1; 210(11):1604–5
Correlation between heart muscle damage and high–nutrient feed in broiler chickens. Itoh N, et al. **J Vet Med Sci** 1997 Mar;59(3):209–11
Lung morphometric changes after exposure to hypobaria and/or hypoxia and undernutrition. Sekhon HS, et al. **Respir Physiol** 1996 Oct;106(1):99–107
FDA points–to–consider documents: the need for dietary control for the reduction of experimental variability within animal assays and the use of dietary restriction to achieve dietary control. Allaben WT, et al. **Toxicol Pathol** 1996 Nov–Dec;24(6):776–81
The effects of diet, ad libitum overfeeding, and moderate dietary restriction on the rodent bioassay: the uncontrolled variable in safety assessment. Keenan KP, et al. **Toxicol Pathol** 1996 Nov–Dec;24(6):757–68 (49 ref.)
Diet: the neglected variable in chemical safety evaluations. Newberne PM, et al. **Toxicol Pathol** 1996 Nov–Dec; 24(6):746–56 (32 ref.)
Oral squamous cell carcinoma in ad libitum–fed and food–restricted Brown–Norway rats. Thurman JD, et al. **Toxicol Pathol** 1997 Mar–Apr;25(2):217–24
Botulism outbreak associated with poultry litter consumption in three Brazilian cattle herds. Ortolani EL, et al. **Vet Hum Toxicol** 1997 Apr;39(2):89–92
Association of interleukin–6 in the cerebrospinal fluid during crisis of calf with ammoniated feed syndrome. Nakajima Y, et al. **Vet Immunol Immunopathol** 1997 Jun;57(1–2):79–85
Mutagenicity of feeds and bovine milk in districts with different levels of environmental pollution. Pokorná Z, et al. **Vet Med (Praha)** 1996 Nov;41(11):351–8
Effect of forage supplements on the incidence of bloat in dairy cows grazing high clover pastures. Phillips CJ, et al. **Vet Rec** 1996 Aug 17;139(7):162–5
Health status of dairy herds converting from conventional to organic dairy farming [see comments] Weller RF, et al. **Vet Rec** 1996 Aug 10;139(6):141–2. Comment in: Vet Rec 1996 Sep 14;139(11):267.
Influence of diet on the occurrence of intraepithelial microabscesses and foreign bodies in the ruminal mucosa of reindeer calves (Rangifer tarandus tarandus). Josefsen TD, et al. **Zentralbl Veterinarmed A** 1997 Jul;44(5):249–57

ANALYSIS

Fumonisins Veratox. A new rapid quantitative ELISA for determination of fumonisin in food and feed. Abouzied MM, et al. **Adv Exp Med Biol** 1996;392:135–44
Distribution of fumonisins in food and feed products prepared from contaminated corn. Bennett GA, et al. **Adv Exp Med Biol** 1996;392:317–22
Biological effects of feed and forage saponins and their impacts on animal production. Cheeke PR. **Adv Exp Med Biol** 1996;405:377–85 (57 ref.)
Tryptophan content of foods and feeds. Conditions for a

reliable quantitation. Landry J, et al. **Adv Exp Med Biol** 1996;398:703–9

Regulatory aspects of fumonisins with respect to animal feed. Animal derived residues in foods. Miller MA, et al. **Adv Exp Med Biol** 1996;392:363–8 (4 ref.)

Slurry preparation by high–pressure homogenization for the determination of heavy metals in zoological and botanical certified reference materials and animal feeds by electrothermal atomic absorption spectrometry. Tan Y, et al. **Analyst** 1996 Oct;121(10):1419–24

Insecticide residues in baby food, animal feed, and vegetables by gas liquid chromatography. Mukherjee I, et al. **Bull Environ Contam Toxicol** 1996 Mar;56(3):381–8

Exposure of laboratory animals to polychlorinated dibenzodioxins and polychlorinated dibenzofurans from commerical rodent chow. Schecter AJ, et al. **Chemosphere** 1996 Feb;32(3):501–8

Beta–agonists in animal feed. II: Optimization of the extraction. Courtheyn D, et al. **Food Addit Contam** 1996 Jul;13(5):493–509

Beta–agonists in animal feed. IV: Intercomparison study of a candidate reference confirmatory method. Leyssens L, et al. **Food Addit Contam** 1996 Nov–Dec;13(8):883–95

beta–agonists in animal feed. III: Optimization of the clean–up and the end–determination step. Leyssens L, et al. **Food Addit Contam** 1996 Oct;13(7):795–810

Mycotoxins in ingredients of animal feeding stuffs: I. Determination of Alternaria mycotoxins in oilseed rape meal and sunflower seed meal. Nawaz S, et al. **Food Addit Contam** 1997 Apr;14(3):249–62

Beta–agonists in animal feed. I: First intercomparison of methods of analysis for clenbuterol in animal feed materials. Schilt R, et al. **Food Addit Contam** 1996 Jul;13(5):477–92

Ochratoxin A in animal feed––effects of processing. Scudamore KA. **Food Addit Contam** 1996;13 Suppl:39–42 (14 ref.)

Occurrence of mycotoxins in raw ingredients used for animal feeding stuffs in the United Kingdom in 1992. Scudamore KA, et al. **Food Addit Contam** 1997 Feb–Mar;14(2):157–73

Determination of mycotoxins in pet foods sold for domestic pets and wild birds using linked–column immunoassay clean–up and HPLC. Scudamore KA, et al. **Food Addit Contam** 1997 Feb–Mar;14(2):175–86

European intercomparison study for the determination of the fumonisins content in two maize materials. Visconti A, et al. **Food Addit Contam** 1996 Nov–Dec;13(8):909–27

In vivo and in situ measurements of forage protein degradation in beef cattle. Vanzant ES, et al. **J Anim Sci** 1996 Nov;74(11):2773–84

Liquid chromatographic determination of monensin in premix and animal feeds: collaborative study. Coleman MR, et al. **J AOAC Int** 1997 Jul–Aug;80(4):693–702

Extension of dry ash atomic absorption and spectrophotometric methods to determination of minerals and phosphorus in soy–based, whey–based, and enteral formulae (modification of AOAC Official Methods 985.35 and 986.24): collaborative study. Cook KK. **J AOAC Int** 1997 Jul–Aug;80(4):834–44

Liquid chromatographic assay of tylosin in animal feeds. Houglum JE, et al. **J AOAC Int** 1996 Mar–Apr; 79(2):369–74

Colorimetric determination of selenium in mineral premixes. Hurlbut JA, et al. **J AOAC Int** 1997 Jul–Aug;80(4):709–16

International proficiency testing of analytical laboratories for foods and feeds from 1990 to 1996: the experiences of the United Kingdom Food Analysis Performance Assessment Scheme. Key PE, et al. **J AOAC Int** 1997 Jul–Aug; 80(4):895–9

Organohalogen and organophosphorus pesticides in mixed feed rations: findings from FDA's domestic surveillance during fiscal years 1989–1994. Lovell RA, et al. **J AOAC Int** 1996 Mar–Apr;79(2):544–8

Determination of tetracyclines in animal feeds in the presence of other drugs by thin–layer chromatography and microbiological method. Markakis PK. **J AOAC Int** 1996 Mar–Apr;79(2):375–9

Microbiological method for determining macrolides in animal feeds in the presence of other drugs by thin–layer chromatography detection. Markakis PK. **J AOAC Int** 1996 Nov–Dec;79(6):1263–8

Determination of selenium in feeds and premixes: collaborative study. Palmer IS, et al. **J AOAC Int** 1997 May–Jun;80(3):469–80

Determination of ethoxyquin in feeds by liquid chromatography: collaborative study. Schreier CJ, et al. **J AOAC Int** 1997 Jul–Aug;80(4):725–31

Liquid chromatographic analysis of bacitracin methylene disalicylate in feed. Webster GK. **J AOAC Int** 1997 Jul–Aug;80(4):732–5

Liquid chromatography and mass spectrometry for the speciation of arsenic animal feed additives. Pergantis SA, et al. **J Chromatogr A** 1997 Mar 14;764(2):211–22

Malate content of forage varieties commonly fed to cattle. Callaway TR, et al. **J Dairy Sci** 1997 Aug;80(8):1651–5

Effect of selenium fertilization on selenium in feedstuffs and selenium, vitamin E, and beta–carotene concentrations in blood of cattle. Jukola E, et al. **J Dairy Sci** 1996 May; 79(5):831–7

Detection of ergot (Claviceps purpurea) in a dairy feed component by gas chromatography and mass spectrometry. Mantle PG. **J Dairy Sci** 1996 Nov;79(11):1988–91

Analysis of forage fiber and cell walls in ruminant nutrition. Jung HJ. **J Nutr** 1997 May;127(5 Suppl):810S–813S (25 ref.)

Diet–induced changes in liver and bile but not brain fatty acids can be predicted from differences in plasma phospholipid fatty acids in formula– and milk–fed piglets. Rioux FM, et al. **J Nutr** 1997 Feb;127(2):370–7

A comparison between solid phase extraction and supercritical fluid extraction for the determination of fluconazole from animal feed. Khundker S, et al. **J Pharm Biomed Anal** 1995 Nov;13(12):1441–7

Supercritical fluid extraction method development for extraction of an experimental HIV protease inhibitor drug from animal feed. Roston DA, et al. **J Pharm Biomed Anal** 1997 Jan;15(4):461–8

High performance liquid chromatographic assay of amprolium and ethopabate in chicken feed using solid–phase extraction. Tan HS, et al. **J Pharm Biomed Anal** 1996 Nov;15(2):259–65

Monitoring program for mycotoxin contamination in Uruguayan food and feeds. Piñeiro M, et al. **Nat Toxins** 1996;4(5):242–5

Occurrence of nitrate, nitrite and volatile nitrosamines in certain feedstuffs and animal products. Ologhobo AD, et al. **Nutr Health** 1996;11(2):109–14

Utilization of fermented flocculated poultry sludge as a feed constituent for pigs. Fransen NG, et al. **Poult Sci** 1995 Dec; 74(12):1948–60

Protein and amino acid quality of meat and bone meal. Parsons CM, et al. **Poult Sci** 1997 Feb;76(2):361–8

Artificial neural network prediction of amino acid levels in feed ingredients. Roush WB, et al. **Poult Sci** 1997 May; 76(5):721–7

The concentration of creatine in meat, offal and commercial dog food. Harris RC, et al. **Res Vet Sci** 1997 Jan–Feb; 62(1):58–62

The trophodynamics of PCBs, including mono– and non–ortho congeners, in the food web of North–Central Lake Ontario. Metcalfe TL, et al. **Sci Total Environ** 1997 Aug 18;201(3):245–72

The effects of diet, ad libitum overfeeding, and moderate dietary restriction on the rodent bioassay: the uncontrolled variable in safety assessment. Keenan KP, et al. **Toxicol Pathol** 1996 Nov–Dec;24(6):757–68 (49 ref.)

Calcium deficiency, diet and dental disease in pet rabbits [see comments] Harcourt–Brown FM. **Vet Rec** 1996 Dec 7; 139(23):567–71. Comment in: Vet Rec 1997 Jan 11;140(2):52.

[Investigations in central Hessia on the occurrence of estrogenic activity content of cattle feed] Khodabandehlou H, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug; 104(8):291–4 (Eng. Abstr.) **(Ger)**

[Examination of commercial hedgehog feed for its quality (acceptance, digestibility, and nutritional composition)] Landes E, et al. **Tierarztl Prax** 1997 Apr;25(2):178–84 (Eng. Abstr.) **(Ger)**

[Studies on the stability of ferrous ion in the feeds added iron lactate during storage] Takeda Y, et al. **Eisei Shikenjo Hokoku** 1994;(112):128–30 (Eng. Abstr.) **(Jpn)**

[Bioassay of rainbow trout (Oncorhynchus mykiss) pigmentation using ancho chili (Capsicum annuum) extracts] Carter JV, et al. **Arch Latinoam Nutr** 1994 Dec; 44(4):252–5 (Eng. Abstr.) **(Spa)**

ECONOMICS

Economics of feeding pasteurized colostrum and pasteurized waste milk to dairy calves. Jamaluddin AA, et al. **J Am Vet Med Assoc** 1996 Aug 15;209(4):751–6

MICROBIOLOGY

Effects of pH on distribution of Listeria ribotypes in corn, hay, and grass silage. Ryser ET, et al. **Appl Environ Microbiol** 1997 Sep;63(9):3695–7

Destruction of Salmonella enteritidis in poultry feed by combination of heat and propionic acid. Matlho G, et al. **Avian Dis** 1997 Jan–Mar;41(1):58–61

Persistence of Salmonella enteritidis in poultry units and poultry food. Davies RH, et al. **Br Poult Sci** 1996 Jul; 37(3):589–96

The effect of white–rot basidiomycetes on chemical composition and in vitro digestibility of wheat straw. Jalč D, et al. **Folia Microbiol (Praha)** 1996;41(1):73–5

Fungal flora and aflatoxin contamination of feedstuff samples in Beida Governorate, Libya. el–Maraghy SS. **Folia Microbiol (Praha)** 1996;41(1):53–60

Dietary Spirulina platensis enhances humoral and cell–mediated immune functions in chickens. Qureshi MA, et al. **Immunopharmacol Immunotoxicol** 1996 Aug; 18(3):465–76

Assay of Salmonella in enrichment cultures of foods, feeds and environmental samples by the polymyxin–cloth enzyme immunoassay. Blais BW, et al. **Int J Food Microbiol** 1997 Jul 22;37(2–3):183–8

Screening of Salmonella in naturally contaminated feeds with rapid methods. Fierens H, et al. **Int J Food Microbiol** 1996 Aug;31(1–3):301–9

Prevalence of Salmonella organisms in swine feed. Harris IT, et al. **J Am Vet Med Assoc** 1997 Feb 1;210(3):382–5

Viability of Cryptosporidium parvum during ensilage of perennial ryegrass. Merry RJ, et al. **J Appl Microbiol** 1997 Jan;82(1):115–20

Effect of fungal biomass in moldy alfalfa hay on preference by dairy calves with no previous exposure to moldy feeds. Undi M, et al. **J Dairy Sci** 1996 Jul;79(7):1250–4

Effects of environmental heat and intake of tall fescue seed infested with Acremonium coenophialum on the acid–base status of young bulls. Wallace LL, et al. **J Vet Diagn Invest** 1996 Apr;8(2):233–7

Mycoflora and fumonisin–producing strains of Fusarium moniliforme in mixed poultry feeds and component raw material. Castellá G, et al. **Mycopathologia** 1996; 133(3):181–4

Toxic and antibiotic properties of red thread, Laetisaria fuciformis. di Menna ME, et al. **Mycopathologia** 1996; 135(3):187–90

Effect of medicating ingredients and other additives on microflora present on swine and chicken feeds from a Manitoba mill. Mills JT, et al. **Mycopathologia** 1996; 135(1):21–7

POISONING

Poisoning of feedlot cattle by seeds of Heliotropium europaeum. Hill BD, et al. **Aust Vet J** 1997 May;75(5):360–1

Disease signs reported in south–eastern Australian dairy cattle while grazing Brassica species. Morton JM, et al. **Aust Vet J** 1997 Feb;75(2):109–13

A probabilistic model for deriving soil quality criteria based on secondary poisoning of top predators. II. Calculations for dichlorodiphenyltrichloroethane (DDT) and cadmium. Jongbloed RH, et al. **Ecotoxicol Environ Saf** 1996 Aug; 34(3):279–306

A probabilistic model for deriving soil quality criteria based on secondary poisoning of top predators. I. Model description and uncertainty analysis. Traas TP, et al. **Ecotoxicol Environ Saf** 1996 Aug;34(3):264–78

Presumptive intoxication of cattle by corn cockle, Agrostemma githago (L) Scop. Smith RA, et al. **Vet Hum Toxicol** 1997 Aug;39(4):250

RADIATION EFFECTS

[The mutagenic action of radioactive contaminants of feed and food products on strains TA98 and TA100 of Salmonella typhimurium] Matseliukh BP, et al. **Mikrobiol Z** 1996 May–Jun;58(3):49–53 (Eng. Abstr.) **(Ukr)**

STANDARDS

Grazing and anthelmintic treatments to increase growth of Cashmere and Angora weaner goats [published erratum appears in Aust Vet J 1996 Nov;74(5):400] Robertson JA, et al. **Aust Vet J** 1996 Sep;74(3):246–8

Effects of two pasture systems on faecal nematode egg counts in breeding ewes. Saul GR. **Aust Vet J** 1996 Aug; 74(2):154–5

Good production practices in the feedlot. Van Donkersgoed J, et al. **Can Vet J** 1996 Sep;37(9):535–8

FDA proposes ruminant–to–ruminant feeding ban [news] **J Am Vet Med Assoc** 1997 Mar 1;210(5):595

TSE control approaches scrutinized at symposium [news] Dunham B. **J Am Vet Med Assoc** 1996 Jul 1;209(1):21–2, 25

Cottonseed meal or feather meal supplementation of ammoniated tropical grass hay for yearling cattle. Brown WF, et al. **J Anim Sci** 1997 Jun;75(6):1666–73

The utilization of multidimensional scaling to identify forage characteristics associated with preference in sheep. Buntinx SE, et al. **J Anim Sci** 1997 Jun;75(6):1641–50

Changes in forage quality, ingestive mastication, and digesta kinetics resulting from switchgrass maturity. Burns JC, et al. **J Anim Sci** 1997 May;75(5):1368–79

Influence of dietary forage level and forage coarseness of grind on growth performance and digestive function in feedlot steers. Calderon–Cortes JF, et al. **J Anim Sci** 1996 Oct;74(10):2310–6

The effects of physical form of feed, carbohydrate source, and inclusion of sodium bicarbonate on the diet selections of sheep. Cooper SD, et al. **J Anim Sci** 1996 Jun; 74(6):1240–51

Effect of enzyme preparations on in situ and in vitro degradation and in vivo digestive characteristics of mature cool–season grass forage in beef steers. Feng P, et al. **J Anim Sci** 1996 Jun;74(6):1349–57

Efficiency of production in cattle of two growth potentials on northern great plains rangelands during spring–summer grazing. Grings EE, et al. **J Anim Sci** 1996 Oct; 74(10):2317–26

Comparison of Marshall and Surrey ryegrass for continuous and rotational grazing. Hafley JL. **J Anim Sci** 1996 Sep; 74(9):2269–75

Effect of rotational vs continuous intensive stocking of bahiagrass on performance of Angus cows and calves and interaction with sire type on gastrointestinal nematode burden. Hammond AC, et al. **J Anim Sci** 1997 Sep; 75(9):2291–9

Ruminally degradable protein requirement of gestating beef cows grazing native winter sandhills range. Hollingsworth–Jenkins KJ, et al. **J Anim Sci** 1996 Jun; 74(6):1343–8

Early–vegetative tall fescue hay vs alfalfa hay as a supplement for cattle consuming low–quality roughages. Horney MR, et al. **J Anim Sci** 1996 Aug;74(8):1959–66

Raw and rendered animal by–products as ingredients in dog

diets. Murray SM, et al. **J Anim Sci** 1997 Sep; 75(9):2497–505

Acquired aversions as the basis for varied diets of ruminants foraging on rangelands. Provenza FD. **J Anim Sci** 1996 Aug;74(8):2010–20 (167 ref.)

Effect of forage:concentrate ratio on digestion and reproduction in primiparous beef heifers. Reed BK, et al. **J Anim Sci** 1997 Jul;75(7):1708–14

Performance of Angus and Brangus cow–calf pairs grazing Alicia bermudagrass and common bermudagrass–dallisgrass pastures. Wyatt WE, et al. **J Anim Sci** 1997 Jul; 75(7):1926–33

Effects of forage level on the comparative feeding value of supplemental fat in growing–finishing diets for feedlot cattle. Zinn RA, et al. **J Anim Sci** 1996 Jun;74(6):1194–201

Comparative feeding value of hulless vs covered barley for feedlot cattle. Zinn RA, et al. **J Anim Sci** 1996 Jun; 74(6):1187–93

Relative effectiveness of selenite cystine broth, tetrathionate broth, and rappaport–vassiliadis medium for recovery of Salmonella spp. from raw flesh, highly contaminated foods, and poultry feed: collaborative study. June GA, et al. **J AOAC Int** 1996 Nov–Dec;79(6):1307–23

Physicochemical data for some selected Fusarium toxins. Sydenham EW, et al. **J AOAC Int** 1996 Nov–Dec; 79(6):1365–79

Replacement of alfalfa neutral detergent fiber with a combination of nonforage fiber sources. Clark PW, et al. **J Dairy Sci** 1997 Apr;80(4):675–80

Influence of level of concentrate allocation and fermentability of forage fiber on chewing behavior and production of dairy cows. Robinson PH, et al. **J Dairy Sci** 1997 Apr; 80(4):681–91

Effect of processed grain sorghum and expeller soybean meal on performance of lactating cows. Titgemeyer EC, et al. **J Dairy Sci** 1997 Apr;80(4):714–21

Effect of two dietary regimens on gingivitis in the dog. Rawlings JM, et al. **J Small Anim Pract** 1997 Apr; 38(4):147–51

From the Food and Drug Administration. Nightingale SL. **JAMA** 1997 Feb 5;277(5):370

Supplementation of broiler diets with all–rac–alpha– or a mixture of natural source RRR–alpha–,gamma–,delta–tocopheryl acetate. 2. Effect on the oxidative stability of raw and precooked broiler meat products. Jensen C, et al. **Poult Sci** 1995 Dec; 74(12):2048–56

Protein quality and calcium availability from extruded and autoclaved turkey hatchery residue. Lilburn MS, et al. **Poult Sci** 1997 Jun;76(6):841–8

The response of broiler chickens and turkey poults to steam–pelleted diets supplemented with fat or carbohydrates. Plavnik I, et al. **Poult Sci** 1997 Jul; 76(7):1006–13

The combined influence of dietary flaxseed variety, level, form, and storage conditions on egg production and composition among vitamin E–supplemented hens. Scheideler SE, et al. **Poult Sci** 1996 Oct;75(10):1221–6

Associations between off–label feed additives and farm size, veterinary consultant use, and animal age. Dewey CE, et al. **Prev Vet Med** 1997 Jul;31(1–2):133–46

Design and implementation of the United States National Animal Health Monitoring System 1994–95 Cattle on Feed Evaluation, and an evaluation of the impact of response biases. Losinger WC, et al. **Prev Vet Med** 1997 Jul; 31(1–2):1–14

Issues concerning Mexican cattle on feedlots in the United States as reported in the United States National Animal Health Monitoring System 1994–1995 Cattle on Feed Evaluation. Losinger WC. **Prev Vet Med** 1997 Jul; 31(1–2):15–8

Safety assessment of a nematode–resistant tomato by a simple, short–term rat feeding study. Stoewsand GS, et al. **Regul Toxicol Pharmacol** 1996 Aug;24(1 Pt 1):6–8

Effect of feeding tagernut (Cyperus rotundus, L) meal on the performance of rabbits. Bamgbose AM, et al. **Trop Anim Health Prod** 1997 Feb;29(1):60–2

Improving feeding management and work performance of Mashona oxen through strategic supplementation with cobsheath–groundnut stover. Francis J, et al. **Trop Anim Health Prod** 1995 Nov;27(4):249–57

Nutritional and economic benefits of Leucaena and Gliricidia as feed supplements for small ruminants in humid West Africa. Jabbar MA, et al. **Trop Anim Health Prod** 1997 Feb;29(1):35–47 (44 ref.)

Effects of feeding cattle manure on growth performance and carcass characteristics of large white pigs. Manjeli Y, et al. **Trop Anim Health Prod** 1996 Nov;28(4):307–11

Performance of draught cattle in communal farming areas in Zimbabwe after dry season supplementation. Ndlovu LR, et al. **Trop Anim Health Prod** 1996 Nov;28(4):298–306

The toxic and abortifacient effects of ponderosa pine. Stegelmeier BL, et al. **Vet Pathol** 1996 Jan;33(1):22–8

Movement on by–products ban as Britain sets out its proposals on BSE [news] **Vet Rec** 1996 Jun 8;138(23):554

Effects of different energy levels, concentrate/forage ratios and lipid supplementation to the diet on the adaptation of the energy metabolism at calving in dairy cows. Holtenius P, et al. **Zentralbl Veterinarmed A** 1996 Sep;43(7):427–35

Sprayed medicated feed with sulfadimidine for piglets. Wanner M, et al. **Zentralbl Veterinarmed A** 1996 Oct; 43(8):473–81

[Medicated fodder with or without A, D and K additives (news)] **Tijdschr Diergeneeskd** 1997 May 1;122(9):256–7 **(Dut)**

[Examination of commercial hedgehog feed for its quality (acceptance, digestibility, and nutritional composition)] Landes E, et al. **Tierarztl Prax** 1997 Apr;25(2):178–84 (Eng. Abstr.) **(Ger)**

[Prohibition of use of beta agonists in the feed of market animals] Ungemach FR. **Tierarztl Prax** 1997 May; 25(3):9–10 **(Ger)**

STATISTICS & NUMERICAL DATA

[The use of feed medications in swine and poultry facilities in the Weser–Ems region] Rassow D, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):244–9 (Eng. Abstr.) **(Ger)**

TOXICITY

Mitochondrial myopathy in Senna occidentalis–seed–fed chicken. Cavaliere MJ, et al. **Ecotoxicol Environ Saf** 1997 Jul;37(2):181–5

Disposition of 14C–derived residues in tissues of pigs fed radiolabelled fumonisin B1. Prelusky DB, et al. **Food Addit Contam** 1996 Feb–Mar;13(2):155–62

Effects induced by feeding organochlorine–contaminated carp from Saginaw Bay, Lake Huron, to laying White Leghorn hens. I. Effects on health of adult hens, egg production, and fertility. Summer CL, et al. **J Toxicol Environ Health** 1996 Nov;49(4):389–407

Acute encephalopathy in a horse: toxic differentials [letter; comment] Villar D. **Vet Rec** 1996 Aug 24;139(8):195–6. Comment on: Vet Rec 1995 Dec 16;137(25):642–3.

VIROLOGY

Host resistance to rat cytomegalovirus (RCMV) and immune function in adult PVG rats fed herring from the contaminated Baltic Sea. Ross PS, et al. **Arch Toxicol** 1996; 70(10):661–71

Zoonotic agent consideration in xenotransplants. Introductory comments for breakout session F: adventitious agents from animal–derived raw materials and production systems. Honstead JP. **Dev Biol Stand** 1996;88:235–6

ANIMAL HOSPITALS see **HOSPITALS, ANIMAL**

ANIMAL–HUMAN BONDING see **BONDING, HUMAN–PET**

ANIMAL HUSBANDRY

see related
VETERINARY MEDICINE

A comparison of the lipolytic and anticoagulative properties of heparin and pentosan polysulphate in the thoroughbred horse. Orme CE, et al. **Acta Physiol Scand** 1997 Feb; 159(2):179–85

The effect of beta–carotene and vitamins A, D3 and E on some reproductive parameters in cows. Iwańska S, et al. **Acta Vet Hung** 1997;45(1):95–107

Role of the Danish pig production system in the success of infectious disease control: a review. Medveczky I. **Acta Vet Hung** 1997;45(1):45–51 (10 ref.)

Olive by–products in pig fattening. Rupić V, et al. **Acta Vet Hung** 1997;45(1):53–66

Sole haemorrhages in tied primiparous cows as an indicator of periparturient laminitis: effects of diet, flooring and season. Bergsten C, et al. **Acta Vet Scand** 1996;37(4):383–94

Sole haemorrhages in tied heifers in early gestation as an indicator of laminitis: effects of diet and flooring. Bergsten C, et al. **Acta Vet Scand** 1996;37(4):375–81

Sole haemorrhages and heel horn erosion in dairy cows: the influence of housing system on their prevalence and severity. Bergsten C, et al. **Acta Vet Scand** 1996; 37(4):395–408

Endocrine changes during group housing of primiparous sows in early pregnancy. Tsuma VT, et al. **Acta Vet Scand** 1996;37(4):481–9

Selective breeding for diet–induced obesity and resistance in Sprague–Dawley rats. Levin BE, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R725–30

Positive human health effects of dust suppression with canola oil in swine barns. Senthilselvan A, et al. **Am J Respir Crit Care Med** 1997 Aug;156(2 Pt 1):410–7

Effect of breed of cattle on innate resistance to infection with Babesia bovis, B bigemina and Anaplasma marginale. Bock RE, et al. **Aust Vet J** 1997 May;75(5):337–40

Rusa deer (Cervus timorensis russa) farming in New Caledonia: impact of different feed levels on herd breeding rate and performance of newborn fawns. Le Bel S, et al. **Aust Vet J** 1997 Mar;75(3):199–203

Impact of stocking density, breed, and feathering on the prevalence of abdominal skin scratches in broiler chickens. Elfadil AA, et al. **Avian Dis** 1996 Jul–Sep;40(3):546–52

Farm management risk factors associated with cellulitis in broiler chickens in southern Ontario. Elfadil AA, et al. **Avian Dis** 1996 Jul–Sep;40(3):699–706

The use of feed restriction for mortality control of chickens in broiler farms. Tottori J, et al. **Avian Dis** 1997 Apr–Jun; 41(2):433–7

Spring meeting of the UK branch of the World's Poultry Science Association. Scarborough, UK, 21–22 March 1996. Abstracts. **Br Poult Sci** 1996;37 Suppl:S7–95

Effect of isolation–rearing on noradrenaline release in rat hypothalamus and hippocampus in vitro. Fulford AJ, et al. **Brain Res** 1997 Feb 14;748(1–2):93–9

Hand–arm vibration and terrain vehicles. Anttonen H, et al. **Cent Eur J Public Health** 1995;3 Suppl:123–5

Accelerated lung function decline in swine confinement workers. Senthilselvan A, et al. **Chest** 1997 Jun; 111(6):1733–41

Solitary caging protects mice from ankylosing enthesopathy. Weinreich S, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:32–3

Cryptosporidiosis outbreak associated with an educational farm holiday [published erratum appears in Commun Dis Rep CDR Rev 1996 Mar 29;6(4):R67] Evans MR, et al. **Commun Dis Rep CDR Rev** 1996 Mar 1;6(3):R50–1

Photoallergic contact dermatitis in a pig farmer caused by olaquindox. Kumar A, et al. **Contact Dermatitis** 1996 Oct; 35(4):249–50

Experimental design and husbandry. Festing MF. **Exp Gerontol** 1997 Jan–Apr;32(1–2):39–47 (19 ref.)

Acute calcification of the peroneal tendons in a sheep shearer. Williams CR. **Foot Ankle Int** 1996 Jan;17(1):49–50

Identification and quantification of risk factors in animal management and transport regarding Salmonella spp. in pigs. Berends BR, et al. **Int J Food Microbiol** 1996 Jun; 30(1–2):37–53

Transmission dynamics of helminth parasites of pigs on continuous pasture: Oesophagostomum dentatum and Hyostrongylus rubidus. Roepstorff A, et al. **Int J Parasitol** 1997 May;27(5):553–62

Transmission dynamics of helminth parasites of pigs on continuous pasture: Ascaris suum and Trichuris suis. Roepstorff A, et al. **Int J Parasitol** 1997 May;27(5):563–72

Selecting, raising, and caring for dogs to avoid problem aggression. Hart BL, et al. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1129–34 (17 ref.)

The role of food animal practitioners with grazing beef cattle. Leverett G. **J Am Vet Med Assoc** 1996 Dec 15; 209(12):2006–9

Management variables associated with high mortality rates attributable to respiratory tract problems in female calves prior to weaning. Losinger WC, et al. **J Am Vet Med Assoc** 1996 Nov 15;209(10):1756–9

Responsible extra–label use of drugs [letter; comment] Reece TR. **J Am Vet Med Assoc** 1996 Nov 1;209(9):1545–6. Comment on: J Am Vet Med Assoc 1996 Sep 1;209(5):897–8.

American Society of Animal Science regional meetings. 1996. **J Anim Sci** 1996;74 Suppl 1:1–318

Sources of animal science research information: usefulness and reliability. Owens FN. **J Anim Sci** 1997 Feb;75(2):331–8

The role of industry in international animal agriculture. Peel CJ. **J Anim Sci** 1996 Jun;74(6):1382–5 (4 ref.)

Preference of laboratory rats for potentially enriching stimulus objects. Chmiel DJ Jr, et al. **Lab Anim** 1996 Apr; 30(2):97–101

Preparation and maintenance of SCID–hu mice for HIV research. Bristol GC, et al. **Methods** 1997 Aug;12(4):343–7

Chronic lymphocytic leukaemias and non–Hodgkin's lymphomas by histological type in farming–animal breeding workers: a population case–control study based on a priori exposure matrices. Nanni O, et al. **Occup Environ Med** 1996 Oct;53(10):652–7

Management and nutritional factors associated with the detection of Salmonella sp. from cattle fecal specimens from feedlot operations in the United States. Losinger WC, et al. **Prev Vet Med** 1997 Aug;31(3–4):231–44

Quality assurance initiative at the U.S. Department of Agriculture National Veterinary Services Laboratories. Hill RE Jr, et al. **Qual Assur** 1995 Dec;4(4):319–22

Wildlife husbandry and diseases. **Rev Sci Tech** 1996 Mar; 15(1):1–342

Special challenges of maintaining wild animals in captivity in North America. Cambre RC, et al. **Rev Sci Tech** 1996 Mar;15(1):251–66 (24 ref.)

Special challenges of maintaining wild animals in captivity: a southern African perspective. Colly LP, et al. **Rev Sci Tech** 1996 Mar;15(1):237–49 (14 ref.)

Special challenges of maintaining wild animals in captivity in South America. Cubas ZS. **Rev Sci Tech** 1996 Mar; 15(1):267–87 (26 ref.)

Development and challenges of wildlife husbandry: concluding remarks. Fowler ME. **Rev Sci Tech** 1996 Mar; 15(1):337–42

Husbandry and diseases of captive wild swine and peccaries. Fowler ME. **Rev Sci Tech** 1996 Mar;15(1):141–54 (14 ref.)

An overview of wildlife husbandry and diseases in captivity. Fowler ME. **Rev Sci Tech** 1996 Mar;15(1):15–42 **(Eng, Fre, Spa)**

Husbandry and diseases of camelids. Fowler ME. **Rev Sci Tech** 1996 Mar;15(1):155–69 (18 ref.)

Management practices to minimise infectious and parasitic diseases of farmed and ranched cervids and bison. Haigh JC. **Rev Sci Tech** 1996 Mar;15(1):209–26 (48 ref.)

Infectious and parasitic disease of captive reptiles and amphibians, with special emphasis on husbandry practices which prevent or promote diseases. Ippen R, et al. **Rev Sci Tech** 1996 Mar;15(1):43–54 (1 ref.)

Special challenges of maintaining wildlife in captivity in Europe and Asia. Kirkwood JK. **Rev Sci Tech** 1996 Mar; 15(1):309–21 (57 ref.)

Management protocols for animals in captive propagation

and reintroduction programmes. Mikota SK, et al. **Rev Sci Tech** 1996 Mar;15(1):191–208 (35 ref.)

Husbandry practices as related to infectious and parasitic diseases of farmed ratites. Tully TN, et al. **Rev Sci Tech** 1996 Mar;15(1):73–89 (33 ref.)

Husbandry practices employed by private aviculturists, bird markets and zoo collections, which may be conducive to fostering infectious diseases. Wolff PL. **Rev Sci Tech** 1996 Mar;15(1):55–71 (60 ref.)

Evaluation of shading of fish farming ponds as a larval control measure against Anopheles sundaicus Rodenwaldt (Diptera:Culicidae). Takagi M, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):748–53

Responses to supplementation in white Fulani cattle under agro–pastoral management in northern Nigeria. 1. Phosphorus. Campbell DA, et al. **Trop Anim Health Prod** 1996 May;28(2):183–90

Genetic and environmental trends in a large commercial Jersey herd in the Central Rift Valley, Kenya. Musani SK, et al. **Trop Anim Health Prod** 1997 May;29(2):108–16

Dairy cattle crossbreeding in the tropics: choice of crossbreeding strategy. Syrstad O. **Trop Anim Health Prod** 1996 Aug;28(3):223–9

Sustainable tick and tickborne disease control in livestock improvement in developing countries. de Castro JJ. **Vet Parasitol** 1997 Jul 31;71(2–3):77–97 (102 ref.)

Nematode control practices and anthelmintic resistance on British sheep farms. Coles GC. **Vet Rec** 1997 Jul 26; 141(4):91–3

Effects of feeding, watering and resting intervals on lambs transported by road and ferry to France. Knowles TG, et al. **Vet Rec** 1996 Oct 5;139(14):335–9

Clean livestock at slaughter [letter] Longstreeth JR, et al. **Vet Rec** 1997 Mar 1;140(9):239

Hypophosphataemic rickets and nephrocalcinosis in ostrich chicks brooded and reared on limestone sand. Morrow CJ, et al. **Vet Rec** 1997 May 17;140(20):531–2

[Pig farmer and veterinarian: a pair apart] Clerx V. **Tijdschr Diergeneeskd** 1997 May 1;122(9):255–6 **(Dut)**

[Performing of vaccination by 'either the veterinarian' or the stockbreeder (letter)] de Kruif A. **Tijdschr Diergeneeskd** 1997 Feb 15;122(4):110 **(Dut)**

[Do you vaccinate or do I vaccinate? (letter)] de Maar RE. **Tijdschr Diergeneeskd** 1997 Jan 15;122(2):42 **(Dut)**

[Utilization of serum banks for veterinary seroepidemiological research serving the Dutch livestock industry] Elbers AR. **Tijdschr Diergeneeskd** 1996 Dec 1; 121(23):676–8 (Eng. Abstr.) **(Dut)**

[Cattle farmers vaccinate (letter)] Kriele CP. **Tijdschr Diergeneeskd** 1997 Jan 1;122(1):20 **(Dut)**

[Cattle breeders vaccinate (letter)] Niehof J. **Tijdschr Diergeneeskd** 1997 Jan 1;122(1):20 **(Dut)**

[Dust concentration in deep litter with special reference to activity of growing pits and to the use aerosol application] Bönsch S, et al. **Berl Munch Tierarztl Wochenschr** 1996 Oct;109(10):388–91 (Eng. Abstr.) **(Ger)**

[The optimization of group size for fattening rabbits in group housing on grids made of artificial material] Drescher B, et al. **Berl Munch Tierarztl Wochenschr** 1996 Aug; 109(8):304–8 (Eng. Abstr.) **(Ger)**

[On calving in the pasture during the fall (veterinary expert)] Hoedemaker M, et al. **Berl Munch Tierarztl Wochenschr** 1996 Feb;109(2):51–4 (Eng. Abstr.) **(Ger)**

[Sanitation of biowaste compost by using Salmonella enteritidis as a pathogen indicator and survival of Salmonella in seepage water] Knop M, et al. **Berl Munch Tierarztl Wochenschr** 1996 Nov–Dec; 109(11–12):451–6 (Eng. Abstr.) **(Ger)**

[Health and environmental risks after the use of anti–infective agents and antiparasitic agents in domestic animal husbandry—avoidance strategies and ways out] Blaha T. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):278–80 (Eng. Abstr.) **(Ger)**

[Stress response of slaughter pigs in two different access systems to electrical stunning] Hartung VJ, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):66–8 (Eng. Abstr.) **(Ger)**

[Antibiotics in animal husbandry (editorial)] Heinzl S. **Med Monatsschr Pharm** 1997 Jun;20(6):145 **(Ger)**

[Systems for monitoring animal health in Switzerland] Stärk KD, et al. **Schweiz Arch Tierheilkd** 1996;138(8):392–8 (Eng. Abstr.) **(Ger)**

[Animal husbandry and hunting in the neolithic age as an example of animal remains Pestenacker (Lkr. Landsberg am Lech) settlement] Sorge G. **Tierarztl Prax** 1996 Oct; 24(5):432–5 (Eng. Abstr.) **(Ger)**

[Increase in the effectiveness of using inbreeding in pedigree stocks of dairy cattle] Kalmykov AN. **Genetika** 1997 Jun; 33(6):810–6 (Eng. Abstr.) **(Rus)**

[The effect of the multiyear agricultural use of animal husbandry wastes on the infectious morbidity of the local population] Prokopov VA, et al. **Lik Sprava** 1995 Mar–Apr; (3–4):127–32 (Eng. Abstr.) **(Rus)**

[Biotransformation of nitrogen–containing compounds in the process of the continuous final purification of effluents from swine–breeding farms by immobilized cells] Arkhipenko IA, et al. **Mikrobiologiia** 1996 Sep–Oct;65(5):621–6 (Eng. Abstr.) **(Rus)**

[The use of a live Salmonella bivalent vaccine for decreasing the circulation of salmonellae in a poultry plant] Efremov VE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct;(5):36–9 (Eng. Abstr.) **(Rus)**

[Survival of Salmonella typhimurium in the solid fraction from a farm waste water treatment plant] Plachá I, et al. **Vet Med (Praha)** 1997 May;42(5):133–7 (Eng. Abstr.) **(Slo)**

[Necrotic chin lesion in a patient with a meningeal syndrome] González A, et al. **Enferm Infecc Microbiol Clin** 1997 Mar; 15(3):163–4 **(Spa)**

ECONOMICS

Impact of exporting dependence on livestock production systems, industry structure, and research. Macmillan KL, et al. **J Anim Sci** 1997 Feb;75(2):522–32 (25 ref.)

Efficiency gains in broiler production through contract parameter fine tuning. Vukina T, et al. **Poult Sci** 1996 Nov; 75(11):1351–8

Economic impact of paratuberculosis. Hutchinson LJ. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):373–81 (21 ref.)

Evaluation of the effects of nursery depopulation of the profitability of 34 pig farms. Dee SA, et al. **Vet Rec** 1997 May 10;140(19):498–500

Reproductive and financial impact of a do–it–yourself artificial insemination programme compared with keeping a bull. Shaw C, et al. **Vet Rec** 1996 Dec 14;139(24):594–7

EDUCATION

Wage pressure a reality [letter] Fisher EM. **Aust Vet J** 1996 Oct;74(4):335

Continued BVDV education needed [letter; comment] Bezek D. **J Am Vet Med Assoc** 1997 Jan 15;210(2):167. Comment on: J Am Vet Med Assoc 1996 Nov 1;209(9):1618–22.

Evaluation of a practice–based ambulatory program in food animal medicine, surgery, and herd health management. Dartt BA, et al. **J Am Vet Med Assoc** 1997 Jun 1; 210(11):1590–4

Effect of participation by veterinarians in a dairy production medicine continuing education course on management practices and performance of client herds [see comments] Moore DA, et al. **J Am Vet Med Assoc** 1996 Sep 15; 209(6):1086–9. Comment in: J Am Vet Med Assoc 1996 Nov 15;209(10):1688–9.

Writing across the curriculum: putting theory into practice in animal science courses. Aaron DK. **J Anim Sci** 1996 Nov;74(11):2810–27 (18 ref.)

How to incorporate and evaluate writing skills in animal science and dairy science courses. Haug M. **J Anim Sci** 1996 Nov;74(11):2835–42 (7 ref.)

Global linkages in animal agriculture: new opportunities for United States agricultural universities. Johnson WL. **J Anim Sci** 1996 Jun;74(6):1386–94 (13 ref.)

introducing undergraduate students to animal science: a discovery course for non–majors. Kesler DJ. **J Anim Sci** 1997 Jan;75(1):273–6

Communication across the curriculum in animal science. Orr CL. **J Anim Sci** 1996 Nov;74(11):2828–34 (5 ref.)

Educational opportunities and challenges in poultry science: impact of resource allocation and industry needs. Pardue SL. **Poult Sci** 1997 Jul;76(7):938–43

INSTRUMENTATION

Effects of plastic anti–pecking devices on food intake and behaviour of laying hens fed on pellets or mash. Savory CJ, et al. **Br Poult Sci** 1997 May;38(2):125–31

Omasal sampling technique for assessing fermentative digestion in the forestomach of dairy cows. Huhtanen P, et al. **J Anim Sci** 1997 May;75(5):1380–92

Effects of the use of filtered microisolator tops on cage microenvironment and growth rate of mice. Baer LA, et al. **Lab Anim Sci** 1997 Jun;47(3):327–9

Water consumption by broilers in high cyclic temperatures: bell versus nipple waterers. May JD, et al. **Poult Sci** 1997 Jul;76(7):944–7

LEGISLATION & JURISPRUDENCE

Regulatory and legal aspects of supplementing grazing ruminants. Sellers R. **J Anim Sci** 1997 Feb;75(2):551–5 (5 ref.)

MANPOWER

Psychodemographic profile of stockpeople working on independent and integrated swine breeding farms in Quebec. Ravel A, et al. **Can J Vet Res** 1996 Oct;60(4):241–8

The role of mentors for women in animal science: perspectives from government. Glenn BP. **J Anim Sci** 1996 Nov;74(11):2855–9 (15 ref.)

METHODS

Pair–rearing infant monkeys (Macaca nemestrina) using a "rotating–peer" strategy. Novak MF, et al. **Am J Primatol** 1997;41(2):141–9

Effects of two pasture systems on faecal nematode egg counts in breeding ewes. Saul GR. **Aust Vet J** 1996 Aug; 74(2):154–5

A case–control study to identify farm factors affecting fertility of dairy herds: multivariate description of factors. Webster FB, et al. **Aust Vet J** 1997 Apr;75(4):262–5

A case–control study to identify farm factors affecting fertility of dairy herds: univariate description of factors. Webster FB, et al. **Aust Vet J** 1997 Apr;75(4):266–73

Evaluation of diagnostic procedures to detect Mycoplasma synoviae in commercial multiplier–breeder farms and commercial hatcheries in Florida. Ewing ML, et al. **Avian Dis** 1996 Oct–Dec;40(4):798–806

Use of four types of litter for rearing broilers. Anisuzzaman M, et al. **Br Poult Sci** 1996 Jul;37(3):541–5

Influence of different handling methods and crating periods on plasma corticosterone concentrations in broilers. Kannan G, et al. **Br Poult Sci** 1996 Mar;37(1):21–31

Bone characteristics and body weight of broilers in different husbandry systems. Tolon B, et al. **Br Poult Sci** 1997 May; 38(2):132–5

Use of a clinical sepsis score for predicting bacteremia in neonatal dairy calves on a calf rearing farm. Fecteau G, et al. **Can Vet J** 1997 Feb;38(2):101–4

Good production practices in the feedlot. Van Donkersgoed J, et al. **Can Vet J** 1996 Sep;37(9):535–8

Controlling internal parasites in grazing ruminants without recourse to anthelmintics: approaches, experiences and prospects. Niezen JH, et al. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):983–92 (35 ref.)

Delivery method and supplement consumption by grazing ruminants: a review. Bowman JG, et al. **J Anim Sci** 1997 Feb;75(2):543–50 (44 ref.)

Comment on the paper "Effects of space allocation and temperature on periparturient maternal behaviors, steroid concentrations, and piglet growth rates" [letter] Cronin GM, et al. **J Anim Sci** 1997 Jul;75(7):1985–7

Protein levels in beef cattle finishing diets: industry application, university research, and systems results. Galyean ML. **J Anim Sci** 1996 Nov;74(11):2860–70 (33 ref.)

Ewe fertility in the STAR accelerated lambing system. Lewis RM, et al. **J Anim Sci** 1996 Jul;74(7):1511–22

Maximizing the response of selection with a predefined rate of inbreeding. Meuwissen TH. **J Anim Sci** 1997 Apr; 75(4):934–40

Impact of environmental regulations on cattle production. Morse D. **J Anim Sci** 1996 Dec;74(12):3103–11 (43 ref.)

Hair sheep genetic resources and their contribution to diversified small ruminant production in the United States. Wildeus S. **J Anim Sci** 1997 Mar;75(3):630–40 (49 ref.)

Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic–resistant bacteria that infect man and compromise antimicrobial chemotherapy? [see comments] Piddock LJ. **J Antimicrob Chemother** 1996 Jul;38(1):1–3 (23 ref.). Comment in: J Antimicrob Chemother 1997 Feb;39(2):285–6. Comment in: J Antimicrob Chemother 1997 Mar;39(3):435.

Empirical Bayes prediction of 305–day milk production. Jones T. **J Dairy Sci** 1997 Jun;80(6):1060–75

Discrimination of people by dairy cows based on handling. Munksgaard L, et al. **J Dairy Sci** 1997 Jun;80(6):1106–12

Happy animals make good science. Poole T. **Lab Anim** 1997 Apr;31(2):116–24 (54 ref.)

Improved procedures for maintaining and breeding the short–tailed fruit bat (Carollia perspicillata) in a laboratory setting. Rasweiler JJ 4th, et al. **Lab Anim** 1996 Apr; 30(2):171–81

Preferences for nesting material as environmental enrichment for laboratory mice. Van de Weerd HA, et al. **Lab Anim** 1997 Apr;31(2):133–43

Health status of experimental pigs. Hansen AK. **Pharmacol Toxicol** 1997;80 Suppl 2:10–5 (19 ref.)

Effect of intermittent activity on broiler production parameters. Balog JM, et al. **Poult Sci** 1997 Jan;76(1):6–12

The applicability of particleboard residue as a litter material for male turkeys. Hester PY, et al. **Poult Sci** 1997 Feb; 76(2):248–55

Layer performance of four strains of Leghorn pullets subjected to various rearing programs. Leeson S, et al. **Poult Sci** 1997 Jan;76(1):1–5

Beak trimming of turkeys. 1. Effects of three methods of beak trimming on body weight and mortality of six genetic lines. Noble DO, et al. **Poult Sci** 1996 Jun;75(6):702–4

Effects of delayed housing of broiler chicks and three different types of waterers on broiler performance. Stamps LK, et al. **Poult Sci** 1995 Dec;74(12):1935–41

The association of serum nonesterified fatty acids and cholesterol, management and feeding practices with peripartum disease in dairy cows. Kaneene JB, et al. **Prev Vet Med** 1997 Jul;31(1–2):59–72

Survivorship approaches to measuring and comparing cull rates for dairies. Karuppanan P, et al. **Prev Vet Med** 1997 May;30(2):171–9

Validation of a poultry biosecurity survey. Nespeca R, et al. **Prev Vet Med** 1997 Jul;31(1–2):73–86

Economic evaluation of national identification and recording systems for pigs in Belgium. Saatkamp HW, et al. **Prev Vet Med** 1997 May;30(2):121–35

Associations between farm management practices, productivity, and bovine leukemia virus infection in Ontario dairy herds. Sargeant JM, et al. **Prev Vet Med** 1997 Aug;31(3–4):211–21

Role and management of donkeys in Samburu and Turkana pastoralist societies in northern Kenya. Twerda M, et al. **Trop Anim Health Prod** 1997 Feb;29(1):48–54

Herd monitoring in traditional cattle husbandry as a tool for productivity research and livestock development. van Klink EG, et al. **Trop Anim Health Prod** 1996 Nov; 28(4):273–9

Culling in 50 dairy herds in England. Esslemont RJ, et al. **Vet Rec** 1997 Jan 11;140(2):36–9

Use of rabbits in ostrich rearing [letter] Madeiros CA. **Vet Rec** 1997 Jun 28;140(26):688

Repeated oestrus synchrony and fixed–time artificial insemination in beef cows. Penny CD, et al. **Vet Rec** 1997 May 10;140(19):496–8

[Evaluation of methods for preparing chicken feces from the veterinary hygienic aspect] Dorn W, et al. **Zentralbl Veterinarmed [B]** 1997 Apr;44(2):105–18 (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Survey of management and housing in farrowing quarters among independent and integrated swine farms in Québec. Ravel A, et al. **Can J Vet Res** 1996 Jan;60(1):21–8

STANDARDS

Rearing conditions and foot–pad dermatitis in Swedish turkey poults. Ekstrand C, et al. **Acta Vet Scand** 1997;38(2):167–74

Comparison of ketosis, clinical mastitis, somatic cell count, and reproductive performance between free stall and tie stall barns in Norwegian dairy herds with automatic feeding. Valde JP, et al. **Acta Vet Scand** 1997;38(2):181–92

The isolation of Salmonellas from piggery waste water after orthodox pondage treatment. Henry DP, et al. **Aust Vet J** 1995 Dec;72(12):478–9

Questions results of Dairy Production Medicine Certificate Program [letter; comment] Ivancic J. **J Am Vet Med Assoc** 1996 Nov 15;209(10):1688–9. Comment on: J Am Vet Med Assoc 1996 Sep 15;209(6):1086–9.

Believes women are better at raising calves [letter; comment] Jessup RV. **J Am Vet Med Assoc** 1996 Aug 15;209(4):721 . Comment on: J Am Vet Med Assoc 1996 Jun 15;208(12):2035–42. Comment on: J Am Vet Med Assoc 1996 Jun 15;208(12):2043–6.

Association between management practices, dairy herd characteristics, and somatic cell count of bulk tank milk. Wilson DJ, et al. **J Am Vet Med Assoc** 1997 May 15; 210(10):1499–502

Ewe fertility in the STAR accelerated lambing system. Lewis RM, et al. **J Anim Sci** 1996 Jul;74(7):1511–22

Regulatory and legal aspects of supplementing grazing ruminants. Sellers R. **J Anim Sci** 1997 Feb;75(2):551–5 (5 ref.)

Effects of individual housing design and size on special–fed Holstein veal calf growth performance, hematology, and carcass characteristics. Terosky TL, et al. **J Anim Sci** 1997 Jul;75(7):1697–703

Soil and solid poultry waste nutrient management and water quality. Chapman SL. **Poult Sci** 1996 Jul;75(7):862–6 (26 ref.)

Impacts of water and air quality legislation on the poultry industry. Morse D. **Poult Sci** 1996 Jul;75(7):857–61 (6 ref.)

Relationship between feed withdrawal and viscera condition of broilers. Northcutt JK, et al. **Poult Sci** 1997 Feb; 76(2):410–4

Calf health in cow–calf herds in Switzerland. Busato A, et al. **Prev Vet Med** 1997 Apr;30(1):9–22

Rearing conditions and foot–pad dermatitis in Swedish broiler chickens. Ekstrand C, et al. **Prev Vet Med** 1997 Aug;31(3–4):167–74

Application of composite estimation in studies of animal population production with two–stage repeated sample designs. Farver TB, et al. **Prev Vet Med** 1997 May; 30(2):109–19

FAWC considers the needs of outdoor pigs and calls for a welfare code [editorial] **Vet Rec** 1996 Jun 1;138(22):532–3

Biosecurity systems and animal health [letter] Blackwell M. **Vet Rec** 1997 Jun 14;140(24):634–5

Elimination of Salmonella typhimurium infection by the strategic movement of pigs. Dahl J, et al. **Vet Rec** 1997 Jun 28;140(26):679–81

Reducing perinatal mortality in lambs [letter; comment] [see comments] Lester WA. **Vet Rec** 1997 Feb 1;140(5):136. Comment on: Vet Rec 1996 Nov 9;139(19):455–6. Comment in: Vet Rec 1997 Mar 15;140(11):292.

Reproductive and financial impact of a do–it–yourself artificial insemination programme compared with keeping a bull. Shaw C, et al. **Vet Rec** 1996 Dec 14;139(24):594–7

[Dairy cattle veterinary medicine up to 2010. Group BOVISIE 2010 [corrected] (published erratum appears in Tijdschr Diergeneeskd 1996 Dec 1;121(23):707)] Wentink GH. **Tijdschr Diergeneeskd** 1996 Oct 1;121(19):547–50 **(Dut)**

[Determination of concentration and emission of gases relevant to animal and environmental hygiene in different systems for fattening of pigs with the aid of multigas monitoring] Hoy S, et al. **Berl Munch Tierarztl Wochenschr** 1996 Feb;109(2):46–50 (Eng. Abstr.) **(Ger)**

[Prophylactic measures against infection in dairy cattle—necessity of hygiene management] Fehlings K, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug; 104(8):306–12 (Eng. Abstr.) **(Ger)**

[Chemical–physical risks originating from dead animals or animal products for the health of humans and animals and for the environment] Klein W. **DTW Dtsch Tierarztl Wochenschr** 1997 Jul;104(7):254–6 (Eng. Abstr.) **(Ger)**

[Animal Welfare Service of Lower Saxony—first report of experiences] Petermann S. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):76–8 (Eng. Abstr.) **(Ger)**

[Case report: decreased laying performance as a contributing problem] Zentek J, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Mar;104(3):120–2 (Eng. Abstr.) **(Ger)**

[Veterinary medical offer for udder health and milking hygiene: results in Rheinland–Pfalz] Luhofer G, et al. **Tierarztl Prax** 1996 Oct;24(5):459–66 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Associations between off–label feed additives and farm size, veterinary consultant use, and animal age. Dewey CE, et al. **Prev Vet Med** 1997 Jul;31(1–2):133–46

The Michigan equine monitoring system. I. Design, implementation and population estimates. Kaneene JB, et al. **Prev Vet Med** 1997 Feb;29(4):263–75

TRENDS

Poultry science: the next 20 years? [see comments] Morris TR. **Br Poult Sci** 1996 Mar;37(1):5–14. Comment in: Br Poult Sci 1996 Sep;37(4):869–72.

Drugs and biologics are not a substitute for effective management by food animal veterinarians. Herrick JB. **J Am Vet Med Assoc** 1997 May 15;210(10):1419–20

Ecosystems, sustainability, and animal agriculture. Heitschmidt RK, et al. **J Anim Sci** 1996 Jun;74(6):1395–405

Sustainability issues of U.S. swine production. Honeyman MS. **J Anim Sci** 1996 Jun;74(6):1410–7 (36 ref.)

Role of ruminant livestock in sustainable agricultural systems. Oltjen JW, et al. **J Anim Sci** 1996 Jun;74(6):1406–9 (13 ref.)

Sustainability of animal production systems: an ecological perspective. Vavra M. **J Anim Sci** 1996 Jun;74(6):1418–23 (38 ref.)

Educational opportunities and challenges in poultry science: impact of resource allocation and industry needs. Pardue SL. **Poult Sci** 1997 Jul;76(7):938–43

Hereditary diseases in dogs: working towards a common goal [news] **Vet Rec** 1997 May 10;140(19):490–1

[Problems and outlook for production of land animals] Coleou J. **Bull Acad Natl Med** 1996 Nov;180(8):1915–30; discussion 1930–2 (11 ref.) (Eng. Abstr.) **(Fre)**

ANIMAL IDENTIFICATION SYSTEMS

Everything you ever wanted to know about microchips. Ingwersen W. **Can Vet J** 1996 Nov;37(11):667–71 **(Eng, Fre)**

An ethicist's commentary on the case of the stray tattooed beagle. Rollin BE. **Can Vet J** 1996 Nov;37(11):648–9

Problems with microchipped strays [letter; comment] [see comments] Bower JM. **Vet Rec** 1996 Nov 9;139(19):476. Comment on: Vet Rec 1996 Oct 12;139(15):376. Comment on: Vet Rec 1996 Oct 26;139(17):427. Comment in: Vet Rec 1996 Nov 16;139(20):502–3.

Problems with microchipped strays [letter; comment] Hutchinson T. **Vet Rec** 1996 Nov 16;139(20):502–3. Comment on: Vet Rec 1996 Oct 12;139(15):376. Comment on: Vet Rec 1996 Oct 26;139(17):427. Comment on: Vet Rec 1996 Nov 9;139(19):476.

[I&R (identification and registration) system cattle: an analysis of its use during a foot–and–mouth–disease outbreak in The Netherlands] Nielen M, et al. **Tijdschr Diergeneeskd** 1996 Oct 15;121(20):576–81 (Eng. Abstr.) **(Dut)**

ECONOMICS

Economic evaluation of national identification and recording systems for pigs in Belgium. Saatkamp HW, et al. **Prev Vet Med** 1997 May;30(2):121–35

METHODS

Identification of nude mice in tumorigenicity assays [letter] van Meir EG. **Int J Cancer** 1997 Apr 10;71(2):310

Problems with the use of ear tags in cattle [letter] Wardrope DD. **Vet Rec** 1995 Dec 23–30;137(26):675

STANDARDS

Ethicist's second commentary on the case of the stray tattooed beagle. Rollin BE. **Can Vet J** 1997 Aug; 38(8):472–3

Economic evaluation of national identification and recording systems for pigs in Belgium. Saatkamp HW, et al. **Prev Vet Med** 1997 May;30(2):121–35

Certified herds scheme. British Veterinary Association. **Vet Rec** 1997 Feb 1;140(5):131–2

Problems with microchipped strays [letter; comment] [see comments] Price HJ. **Vet Rec** 1996 Oct 26;139(17):427. Comment on: Vet Rec 1996 Oct 12;139(15):376. Comment in: Vet Rec 1996 Nov 9;139(19):476. Comment in: Vet Rec 1996 Nov 16;139(2):502–3.

VETERINARY

Skin tumours in cattle and sheep after freeze– or heat–branding. Yeruham I, et al. **J Comp Pathol** 1996 Jan; 114(1):101–6

Welfare implications of identification of cattle by ear tags. Johnston AM, et al. **Vet Rec** 1996 Jun 22;138(25):612–4

ANIMAL NUTRITION

Altered nutrition and assimilation of the snail host (Biomphalaria glabrata) as a consequence of the parasitic spatial constraint (Schistosoma mansoni). Gerard C, et al. **Acta Trop** 1996 Mar;61(1):51–5

Orthocephalization in the postweaning squirrel monkey. Pucciarelli HM, et al. **Am J Phys Anthropol** 1996 Oct; 101(2):173–81

Adaptations of intestinal nutrient transport to chronic caloric restriction in mice. Casirola DM, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):G192–200

The somatotropic axis in neonatal calves can be modulated by nutrition, growth hormone, and Long–R3–IGF–I. Hammon H, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E130–8

Capsaicin attenuates feeding suppression but not reinforcement by intestinal nutrients. Lucas F, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R1059–64

Effect of nutritional state on substrate metabolism and contractile function in postischemic rat myocardium. Montessuit C, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H2060–70

Gastric volume rather than nutrient content inhibits food intake. Phillips RJ, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R766–9

Stimulation of fluid intake by nutrients: oil is less effective than carbohydrate. Ramirez I. **Am J Physiol** 1997 Jan;272(1 Pt 2):R289–93

Carbohydrate versus fat intake: differing patterns of macronutrient selection in two inbred mouse strains. Smith BK, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R357–62

Changes in nutrient and protein composition of cat milk during lactation. Adkins Y, et al. **Am J Vet Res** 1997 Apr; 58(4):370–5

Physical, hematologic, biochemical, and immunologic effects of supranutritional supplementation with dietary selenium in Holstein cows. Ellis RG, et al. **Am J Vet Res** 1997 Jul; 58(7):760–4

Level of nutrition modulates the dynamics of oestradiol feedback on plasma FSH in ovariectomized ewes. Adams NR, et al. **Anim Reprod Sci** 1997 May;47(1–2):59–70

Effect of nutrition on the balance of production of ovarian and pituitary hormones in ewes. Boukhliq R, et al. **Anim Reprod Sci** 1996 Dec 2;45(1–2):59–70

The nutritional effect of a–linolenic acid–rich emulsion with total parenteral nutrition in a rat model with inflammatory bowel disease. Inui K, et al. **Ann Nutr Metab** 1996; 40(4):227–33

Brewery waste as a substitute for soy protein in soy–brewer's yeast mixtures to feed broiler chickens. Carias D, et al. **Arch Latinoam Nutr** 1996 Mar;46(1):67–70

Effect of the type of dietary fat on cholesterolemia in rabbits fed brewer's yeast. Millán N, et al. **Arch Latinoam Nutr** 1996 Mar;46(1):71–4

Omega–3 fatty acids in pig nutrition: implications for zootechnical performances, carcass and fat quality. Van Oeckel MJ, et al. **Arch Tierernahr** 1997;50(1):31–42

Nutrition of grazing brood mares and growing horses. McMeniman NP. **Aust Vet J** 1996 Jul;74(1):64–70 (75 ref.)

The effect of photoperiod and nutrition on ascites incidence in broilers. Lott BD, et al. **Avian Dis** 1996 Oct–Dec; 40(4):788–91

Influence of maternal nutrition and stress on gut permeability to immunoglobulin in newborn lambs. Hodgson JC, et al. **Biochem Soc Trans** 1997 May;25(2):339S

Relationships between hypothalamic neuropeptide Y and food intake in the lactating rat. Pickavance L, et al. **Biochem Soc Trans** 1996 May;24(2):236S

Effect of plane of nutrition and growth hormone treatment on insulin receptor gene expression and kinase activity of sheep muscle and adipose tissue. Wilson LA, et al. **Biochem Soc Trans** 1996 May;24(2):222S

The mutual sparing effects of selenium and vitamin E in animal nutrition may be further explained by the discovery that mammalian thioredoxin reductase is a selenoenzyme. Tamura T, et al. **Biofactors** 1995–96;5(2):99–102 (42 ref.)

Early–life polysensorial stimulation and nutrition: topographic levels of susceptibility in the rat visual cortex. Fernández V, et al. **Biol Neonate** 1997;71(4):265–76

Growth and development of the exocrine pancreas in newborn pigs: the effect of colostrum feeding. Mubiru JN, et al. **Biol Neonate** 1997;71(5):317–26

Negative feedback potency of estradiol is increased in orchidectomized sheep during chronic nutrient restriction. Beckett JL, et al. **Biol Reprod** 1997 Aug;57(2):408–14

Moderate and severe nutrient restriction has divergent effects on gonadotroph function in orchidectomized sheep. Beckett JL, et al. **Biol Reprod** 1997 Aug;57(2):415–9

Changes in ovarian function and gonadotropin secretion preceding the onset of nutritionally induced anestrus in Bos indicus heifers. Rhodes FM, et al. **Biol Reprod** 1996 Dec; 55(6):1437–43

Kinetics of dodecanedioic acid and effect of its administration on glucose kinetics in rats. Bertuzzi A, et al. **Br J Nutr** 1997 Jul;78(1):143–53

Maintenance threonine requirement and efficiency of its use for accretion of whole–body threonine and protein in young chicks. Edwards HM 3rd, et al. **Br J Nutr** 1997 Jul;78(1):111–9

The energy costs of walking on the level and on negative and positive slopes in the Granadina goat (Capra hircus). Lachica M, et al. **Br J Nutr** 1997 Jan;77(1):73–81

The effects of acute and chronic protein depletion and accretion on plasma concentrations of insulin-like growth factor-1, fibronectin and total protein for ruminants nourished by intragastric infusion of nutrients. Liu SM, et al. **Br J Nutr** 1997 Sep;78(3):411–26

Nutrition in pregnant or lactating rats programs lipid metabolism in the offspring. Lucas A, et al. **Br J Nutr** 1996 Oct;76(4):605–12

Idiorrhythmic dose-rate variability in dietary zinc intake generates a different response pattern of zinc metabolism than conventional dose-response feeding. Momčilović B, et al. **Br J Nutr** 1997 Jul;78(1):173–91

Metabolic adaptation to fat-supplemented diet by the thoroughbred horse. Orme CE, et al. **Br J Nutr** 1997 Sep; 78(3):443–58

Novel dietary strategy for overcoming the antinutritional effects of soyabean whey of high agglutinin content. Pusztai A, et al. **Br J Nutr** 1997 Jun;77(6):933–45

Influence of dietary protein and fat on serum lipids and metabolism of essential fatty acids in rats. Ratnayake WM, et al. **Br J Nutr** 1997 Sep;78(3):459–67

Altered adipocyte properties in the offspring of protein malnourished rats. Shepherd PR, et al. **Br J Nutr** 1997 Jul;78(1):121–9

Immunocompetence in relation to a heat-processed diet (Maillard reaction) in weanling rats. Varela P, et al. **Br J Nutr** 1997 Jun;77(6):947–56

Maximum nutritional response to poor-quality protein and amino acid utilisation. Boorman KN, et al. **Br Poult Sci** 1996 Mar;37(1):145–56

Impact of antibiotic use in animal feeding on resistance of bacterial pathogens in humans. Witte W. **Ciba Found Symp** 1997;207:61–71; discussion 71–5 (36 ref.)

Effects of nutritional factors on reproduction, growth, preweaning reflex development and postweaning learning performance in SHRSP. Matsuo T, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S294–6

Nutritional modulation of somatotropic axis-cytokine relationships in cattle: a brief review. Elsasser TH, et al. **Comp Biochem Physiol A Physiol** 1997 Mar;116(3):209–21 (88 ref.)

Intrauterine programming of hypertension in the rat: nutrient interactions. Langley-Evans SC. **Comp Biochem Physiol A Physiol** 1996 Aug;114(4):327–33

Water turnover evaluated by the tritiated water method and by the nutritional method in European hedgehog (Erinaceus europaeus L.). Vignault MP, et al. **Comp Biochem Physiol A Physiol** 1996 Nov;115(3):187–94

Energy expenditure and quantitative oxidation of nutrients in rats (Rattus norvegicus) kept in different thermal environments and given two levels of dietary fiber. Zhao XQ, et al. **Comp Biochem Physiol A Physiol** 1997 Apr; 116(4):351–9

Adaptation of intestinal nutrient transport in health and disease. Part I. Thomson AB, et al. **Dig Dis Sci** 1997 Mar; 42(3):453–69 (254 ref.)

Adaptation of intestinal nutrient transport in health and disease. Part II. Thomson AB, et al. **Dig Dis Sci** 1997 Mar; 42(3):470–88 (271 ref.)

Plasma concentrations of hormones and metabolic substrates in growing pigs after bovine growth hormone injections under various nutritional conditions. Ozawa A, et al. **Endocr J** 1996 Aug;43(4):357–62

Nutrient requirements of the critically ill neonate. Borum PR. **Equine Vet J Suppl** 1988 Sep;(5):14–6 (24 ref.)

Effects of nutrition on uterine and umbilical venous plasma lipids in chronically catheterised mares in late gestation. Stammers JP, et al. **Equine Vet J Suppl** 1988 Sep;(5):37–40

New diet (NTP-2000) for rats in the National Toxicology Program toxicity and carcinogenicity studies. Rao GN. **Fundam Appl Toxicol** 1996 Jul;32(1):102–8

Behavioural effects of prenatal and postnatal undernutrition in rats. Jaiswal AK, et al. **Indian J Exp Biol** 1996 Dec; 34(12):1216–9

Nutrition and parasite interaction. Coop RL, et al. **Int J Parasitol** 1996 Aug-Sep;26(8–9):951–62 (89 ref.)

Nutritional enhancement of parasite control in small ruminant production systems in developing countries of South-East Asia and the Pacific. Knox M, et al. **Int J Parasitol** 1996 Aug-Sep;26(8–9):963–70 (44 ref.)

Evaluation of differential effects of carbohydrate and fat intake on weight gain, serum IGF-1 and erythrocyte Na+K+ATPase activity in suboptimal nutrition in rats. Tarim O, et al. **J Am Coll Nutr** 1997 Apr;16(2):159–65

Diet selection and special considerations in the management of hepatic diseases. Bauer JE. **J Am Vet Med Assoc** 1997 Mar 1;210(5):625–9 (38 ref.)

Hepatic disease, nutritional therapy, and the metabolic environment. Bauer JE. **J Am Vet Med Assoc** 1996 Dec 1;209(11):1850–4 (40 ref.)

Response of pigs to space allocation and diets varying in nutrient density. Brumm MC, et al. **J Anim Sci** 1996 Nov; 74(11):2730–7

Patterns of nutrient interchange and oxygen use among portal-drained viscera, liver, and hindquarters of beef steers from 235 to 525 kg body weight. Eisemann JH, et al. **J Anim Sci** 1996 Aug;74(8):1812–31

The recruitment of ovarian follicles is enhanced by increased dietary intake in heifers. Gutiérrez CG, et al. **J Anim Sci** 1997 Jul;75(7):1876–84

Progesterone mediates nutritionally induced effects on embryonic survival in gilts. Jindal R, et al. **J Anim Sci** 1997 Apr;75(4):1063–70

Relationships between nutrition and foraging behavior of free-ranging sheep and goats. Kronberg SL, et al. **J Anim Sci** 1997 Jul;75(7):1756–63

Influence of nutritional weaning on porcine adipocyte beta-adrenergic and adenosine A1 receptors. Mersmann HJ, et al. **J Anim Sci** 1997 Sep;75(9):2368–77

The relationship among dietary undetermined anion, acid-base balance, and nutrient metabolism in swine. Patience JF, et al. **J Anim Sci** 1997 Sep;75(9):2445–52

Riboflavin nutrition of sows. Pettigrew JE, et al. **J Anim Sci** 1996 Sep;74(9):2226–30

Preference of sheep for foods varying in flavors and nutrients. Provenza FD, et al. **J Anim Sci** 1996 Oct;74(10):2355–61

A review on environmental impacts of nutritional strategies in ruminants. Tamminga S. **J Anim Sci** 1996 Dec; 74(12):3112–24 (60 ref.)

Effects of immune challenge, dietary energy density, and source of energy on performance and immunity in weanling pigs. van Heugten E, et al. **J Anim Sci** 1996 Oct; 74(10):2431–40

Ruminant nutrition from an environmental perspective: factors affecting whole-farm nutrient balance. Van Horn HH, et al. **J Anim Sci** 1996 Dec;74(12):3082–102 (81 ref.)

Plasma flow and net nutrient flux across gut and liver of cattle fed twice daily. Whitt J, et al. **J Anim Sci** 1996 Oct; 74(10):2450–61

Nitrogen metabolism of sheep and goats consuming Acacia brevispica and Sesbania sesban. Woodward A, et al. **J Anim Sci** 1997 Apr;75(4):1130–9

Acute and chronic effects of temperature, and of nutritional state, on ion homeostasis and energy metabolism in teleost hepatocytes. Krumschnabel G, et al. **J Comp Physiol [B]** 1997 May;167(4):280–6

Measuring the effectiveness of fiber by animal response trials. Armentano L, et al. **J Dairy Sci** 1997 Jul;80(7):1416–25 (36 ref.)

Minimum versus optimum concentrations of fiber in dairy cow diets based on barley silage and concentrates of barley or corn. Beauchemin KA, et al. **J Dairy Sci** 1997 Aug; 80(8):1629–39

Effects of nonstructural carbohydrates and source of cereal grain in high concentrate diets of dairy cows. Beauchemin KA, et al. **J Dairy Sci** 1997 Aug;80(8):1640–50

Intake, site, and extent of nutrient digestion of lactating cows grazing pasture. Berzaghi P, et al. **J Dairy Sci** 1996 Sep; 79(9):1581–9

Effects of a supplemental liquid yeast product on feed intake, ruminal profiles, and yield, composition, and organoleptic characteristics of milk from lactating Holstein cows. Besong S, et al. **J Dairy Sci** 1996 Sep;79(9):1654–8

Effects of dietary fat with or without nicotinic acid on nutrient flow to the duodenum of dairy cows. Christensen RA, et al. **J Dairy Sci** 1996 Aug;79(8):1410–24

Influence of particle size on the effectiveness of beet pulp fiber. Clark PW, et al. **J Dairy Sci** 1997 May;80(5):898–904

Nutrient fluxes in splanchnic tissue of dairy cows: influence of grass quality. De Visser H, et al. **J Dairy Sci** 1997 Aug; 80(8):1666–73

Evaluation of equations based on animal factors to predict intake of lactating Holstein cows. Fuentes-Pila J, et al. **J Dairy Sci** 1996 Sep;79(9):1562–71

Nutrition during the dry period and hepatic lipid metabolism of periparturient dairy cows. Grum DE, et al. **J Dairy Sci** 1996 Oct;79(10):1850–64

Soybeans versus animal sources of rumen-undergradable protein and fat for early lactation dairy cows. Grummer RR, et al. **J Dairy Sci** 1996 Oct;79(10):1809–16

Correlation of acid detergent lignin and Klason lignin with digestibility of forage dry matter and neutral detergent fiber. Jung HG, et al. **J Dairy Sci** 1997 Aug;80(8):1622–8

Forage source alters nutrient supply to the intestine without influencing milk yield. Khorasani GR, et al. **J Dairy Sci** 1996 May;79(5):862–72

Effects on nutrient and hormonal profile of long-term infusions of glucose or insulin plus glucose in cows treated with recombinant bovine somatotropin before peak milk yield. Léonard M, et al. **J Dairy Sci** 1997 Jan;80(1):127–43

Use of nitrogen from ammoniated alfalfa hay, urea, soybean meal, and animal protein meal by lactating cows. Lines LW, et al. **J Dairy Sci** 1996 Nov;79(11):1992–9

Effect of plane of nutrition before and after 200 kilograms of body weight on mammary development of prepubertal Holstein heifers. Niezen JH, et al. **J Dairy Sci** 1996 Jul; 79(7):1255–60

The effect of replacing dietary beet pulp with wheat treated with sodium hydroxide, ground wheat, or ground corn in lactating cows. O'Mara FP, et al. **J Dairy Sci** 1997 Mar; 80(3):530–40

Body weight gain, feed efficiency, and fecal scores of dairy calves in response to galactosyl-lactose or antibiotics in milk replacers. Quigley JD 3rd, et al. **J Dairy Sci** 1997 Aug;80(8):1751–4

Milk replacers with or without animal plasma for dairy calves. Quigley JD 3rd, et al. **J Dairy Sci** 1996 Oct; 79(10):1881–84

Evaluation of alternative equations for prediction of intake for Holstein dairy cows. Roseler DK, et al. **J Dairy Sci** 1997 May;80(5):864–77

Development and evaluation of equations for prediction of feed intake for lactating Holstein dairy cows. Roseler DK, et al. **J Dairy Sci** 1997 May;80(5):878–93

An enzyme additive for corn silage: effects on silage composition and animal performance. Sheperd AC, et al. **J Dairy Sci** 1996 Oct;79(10):1760–66

Effects of tallow and escape protein on lactational and reproductive performance of dairy cows. Son J, et al. **J Dairy Sci** 1996 May;79(5):822–30

Influence of undergradability of protein in the diet on intake, daily gain, feed efficiency, and body composition of Holstein heifers. Tomlinson DL, et al. **J Dairy Sci** 1997 May;80(5):943–8

Components of growth in Holstein heifers fed either alfalfa or corn silage diets to produce two daily gains. Waldo DR, et al. **J Dairy Sci** 1997 Aug;80(8):1674–84

Effects of amount and ruminal degradability of protein on nutrient digestibility and production by cows fed tallow. Weigel DJ, et al. **J Dairy Sci** 1997 Jun;80(6):1150–9

Effect of vitamin E supplementation in diets with a low concentration of selenium on mammary gland health of dairy cows. Weiss WP, et al. **J Dairy Sci** 1997 Aug; 80(8):1728–37

Adequacy of amino acids in diets fed to lactating dairy cows. Wu Z, et al. **J Dairy Sci** 1997 Aug;80(8):1713–21

Effects of season, protein and nutritional state on glucose tolerance during an annual cycle of growth in young red deer stags. McMahon CD, et al. **J Endocrinol** 1997 Aug; 154(2):275–83

Regulation by nutrition and age of insulin-like growth factor binding sites in ovine kidney. Martyn JA, et al. **J Exp Zool** 1997 Apr 1;277(5):382–9

Effects of larval nutrition on the postembryonic development of Ctenocephalides felis felis (Siphonaptera:Pulicidae). Linardi PM, et al. **J Med Entomol** 1997 Jul;34(4):494–7

Preparation and characterization of a complex microencapsulated diet for striped bass Morone saxatilis larvae. Ozkizilcik S, et al. **J Microencapsul** 1996 May-Jun; 13(3):331–43

The domestic pig as a model for evaluating olestra's nutritional effects. Cooper DA, et al. **J Nutr** 1997 Aug; 127(8 Suppl):1555S–1565S

Analysis of forage fiber and cell walls in ruminant nutrition. Jung HJ. **J Nutr** 1997 May;127(5 Suppl):810S–813S (25 ref.)

Some considerations for the development of diets for mature rodents used in long-term investigations. McDonald RB. **J Nutr** 1997 May;127(5 Suppl):847S–850S (33 ref.)

Minimum thiamin requirement of weanling Sprague-Dawley outbred rats. Rains TM, et al. **J Nutr** 1997 Jan; 127(1):167–70

Nutritional factors required for alcoholic liver disease in rats. Rao GA, et al. **J Nutr** 1997 May;127(5 Suppl):896S–898S (29 ref.)

Components of the AIN-93 diets as improvements in the AIN-76A diet. Reeves PG. **J Nutr** 1997 May;127(5 Suppl):838S–841S (28 ref.)

To live longer, eat less! (McCay, 1934–1939). Swan PB. **J Nutr** 1997 May;127(5 Suppl):1039S–1041S

The minimum sodium requirement of growing kittens defined on the basis of plasma aldosterone concentration. Yu S, et al. **J Nutr** 1997 Mar;127(3):494–501

Effect of protein nutrition on insulin-like growth factor-I (IGF-I) receptor in various tissues of rats. Takenaka A, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Aug;42(4):347–57

Comparative study of pyridoxine-alpha, beta-glucosides, and phosphopyridoxyl-lysine as a vitamin B6 nutrient. Tsuge H, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Oct; 42(5):377–86

Effects of nutrition on testicular growth in mature Merino rams actively immunized against GnRH. Hötzel MJ, et al. **J Reprod Fertil** 1997 Jul;110(2):307–13

Pregnancy-specific protein B and progesterone concentrations in relation to nutritional regimen, placental mass and pregnancy outcome in growing adolescent ewes carrying singleton fetuses. Wallace JM, et al. **J Reprod Fertil** 1997 Jan;109(1):53–8

Nutrient partitioning and fetal growth in rapidly growing adolescent ewes. Wallace JM, et al. **J Reprod Fertil** 1996 Jul;107(2):183–90

Effects of luminal nutrients and small bowel transplants on congenital indirect hyperbilirubinemia. Burgos AA, et al. **J Surg Res** 1997 Apr;69(1):87–93

Correlation between heart muscle damage and high-nutrient feed in broiler chickens. Itoh N, et al. **J Vet Med Sci** 1997 Mar;59(3):209–11

The effect of host nutrition on itch mite, Psorergates ovis, populations and fleece derangement in sheep. Johnson PW. **Med Vet Entomol** 1996 Apr;10(2):121–8

Nutritional and metabolic effects and significance of mild orotic aciduria during dietary supplementation with arginine or its organic salts after trauma injury in rats. Jeevanandam M, et al. **Metabolism** 1997 Jul;46(7):785–92

Relationship between membrane potential and respiration rate in isolated liver mitochondria from rats fed an energy dense diet. Lionetti L, et al. **Mol Cell Biochem** 1996 May 24;158(2):133–8

Potential of the monoglyceride and triglyceride of DL-3-hydroxybutyrate for parenteral nutrition: synthesis and preliminary biological testing in the rat [see comments] Birkhahn RH, et al. **Nutrition** 1997 Mar;13(3):213–9. Comment in: Nutrition 1997 Mar;13(3):233–5.

Zinc and intestinal anaphylaxis to cow's milk proteins in malnourished guinea pigs. Darmon N, et al. **Pediatr Res** 1997 Aug;42(2):208–13

Nutritional factors modify the inhibition of CNS development by combined exposure to methadone and ethanol in neonatal rats. Kane CM, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):399–407

Nutrition of (Göttingen) minipigs: facts, assumptions and mysteries. Ritskes-Hoitinga J, et al. **Pharmacol Toxicol** 1997;80 Suppl 2:5–9 (19 ref.)

Nutritional effects on operant visual learning in Drosophila melanogaster. Xia SZ, et al. **Physiol Behav** 1997 Aug; 62(2):263–71

Late effects of early nutritional manipulations. Koldovský O, et al. **Physiol Res** 1995;44(6):357–60 (27 ref.)

Is diet shifting facilitated by modulation of intestinal nutrient uptake? Test of an adaptational hypothesis in yellow-rumped warblers. Afik D, et al. **Physiol Zool** 1997 Mar–Apr;70(2):213–21

Digestible sulfur amino acid requirement of starting turkeys. Boling SD, et al. **Poult Sci** 1997 Jun;76(6):873–7

Inclusion of oxidized vegetable oil in broiler diets. Its influence on nutrient balance and on the antioxidative status of broilers. Engberg RM, et al. **Poult Sci** 1996 Aug; 75(8):1003–11

Nutritional implications of pectins in chicks in relation to esterification and origin of pectins. Langhout DJ, et al. **Poult Sci** 1996 Oct;75(10):1236–42

Nutrition of the broiler chicken around the period of compensatory growth. Leeson S, et al. **Poult Sci** 1997 Jul; 76(7):992–9

25-hydroxycholecalciferol in poultry nutrition. Soares JH Jr, et al. **Poult Sci** 1995 Dec;74(12):1919–34 (102 ref.)

Evaluation of National Research Council amino acid recommendations for large white turkeys. Waldroup PW, et al. **Poult Sci** 1997 May;76(5):711–20

Effects of maternal nutrition on hatchability. Wilson HR. **Poult Sci** 1997 Jan;76(1):134–43 (134 ref.)

Management and nutritional factors associated with the detection of Salmonella sp. from cattle fecal specimens from feedlot operations in the United States. Losinger WC, et al. **Prev Vet Med** 1997 Aug;31(3–4):231–44

Molecular mechanisms involved in the nutritional and hormonal regulation of growth in pigs. Brameld JM. **Proc Nutr Soc** 1997 Jul;56(2):607–19 (71 ref.)

Nutrition Society Medal Lecture. A solution to the problem of predicting the response of an animal to its diet. Kyriazakis I. **Proc Nutr Soc** 1996 Mar;55(1B):155–66 (47 ref.)

Limits and limitations to nitrogen use in farm animals. Oldham JD, et al. **Proc Nutr Soc** 1997 Jul;56(2):525–34 (40 ref.)

Mathematical modelling of nitrogen flow in growing pigs and lactating sows. Pettigrew JE. **Proc Nutr Soc** 1997 Jul; 56(2):645–56 (27 ref.)

Intestinal adaptation to nutritional stress. Raul F, et al. **Proc Nutr Soc** 1996 Mar;55(1B):279–89 (74 ref.)

Nutrient-hormone signals regulating muscle protein turnover in pigs. Sève B, et al. **Proc Nutr Soc** 1997 Jul;56(2):565–80 (62 ref.)

Nutritional control of amino acid supply to the mammary gland during lactation in the pig. Trottier NL. **Proc Nutr Soc** 1997 Jul;56(2):581–91 (39 ref.)

Interactions between nutrition, testosterone and inhibin in the control of gonadotrophin secretion in mature rams. Tjondronegoro S, et al. **Reprod Fertil Dev** 1996;8(5):855–62

Morphological changes in the oesophagus of newborn pigs: effects of age, diet and oral insulin-like growth factor I (IGF-I) or IGF-II. Xu RJ, et al. **Reprod Fertil Dev** 1996; 8(5):903–9

Annual symposium on animal and human nutrition. Nantes, 9–11 October 1996. Proceedings and abstracts. **Reprod Nutr Dev** 1997 May–Jun;37(3):233–377

Nutrition and liver disease. Biourge VC. **Semin Vet Med Surg (Small Anim)** 1997 Feb;12(1):34–44 (61 ref.)

Nutritional modification of inflammatory diseases. Schoenherr WD, et al. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):212–22 (72 ref.)

Energy metabolism of the grafted liver and influence of preretrieval feeding process on swine orthotopic liver transplantation. Ishikawa T, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):397–9

Nutritional and economic benefits of Leucaena and Gliricidia as feed supplements for small ruminants in humid West Africa. Jabbar MA, et al. **Trop Anim Health Prod** 1997 Feb;29(1):35–47 (44 ref.)

Nutritional management of osteoarthritis. Richardson DC, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul; 27(4):883–911 (118 ref.)

The influence of supplementation with cotton seed cake on the resistance of Ugandan goats to primary and secondary challenges with Trypanosoma congolense and on their response to treatment. Katunguka-Rwakishaya E, et al. **Vet Parasitol** 1997 Jun;70(1–3):67–76

The pathophysiology and development of immunity during long-term subclinical infection with Trichostrongylus colubriformis of sheep receiving different nutritional treatments. Kyriazakis I, et al. **Vet Parasitol** 1996 Oct 15; 65(1–2):41–54

Animal welfare: reducing mortality in lambs [news] [see comments] **Vet Rec** 1996 Nov 9;139(19):455–6. Comment in: Vet Rec 1997 Feb 1;140(5):136.

Vitamin E content of different animal products: influence of animal nutrition. Leonhardt M, et al. **Z Ernahrungswiss** 1997 Mar;36(1):23–7

[Current views on the importance of iodine for animals] Herzig I, et al. **Vet Med (Praha)** 1996 Dec;41(12):379–86 (83 ref.) (Eng. Abstr.) **(Cze)**

[Hepatic retinol as a nutritional marker of the bovine diet] Raoul Y. **Bull Acad Natl Med** 1996 Oct;180(7):1575–81; discussion 1582–3 (Eng. Abstr.) **(Fre)**

[Nutritional biochemical aspects of the significance, of the utilization, of metabolism and of the administration of vitamin E and of selenium in sheep (review)] Kolb E, et al. **Berl Munch Tierarztl Wochenschr** 1997 May; 110(5):178–84 (48 ref.) (Eng. Abstr.) **(Ger)**

[Development of nutrition science in veterinary medicine as an example of the School of Veterinary Medicine Hannover] Meyer H. **DTW Dtsch Tierarztl Wochenschr** 1997 Jun;104(6):203–7 (Eng. Abstr.) **(Ger)**

ANIMAL RIGHTS

Reports of severe physical punishment and exposure to animal cruelty by inmates convicted of felonies and by university students. Miller KS, et al. **Child Abuse Negl** 1997 Jan;21(1):59–82

Additional opinions on the mortality of animal research [letter] Bonacquisti JP. **J Am Vet Med Assoc** 1997 May 1;210(9):1267–8

Morally relevant differences between animals and human beings justifying the use of animals in biomedical research [see comments] Dennis JU. **J Am Vet Med Assoc** 1997 Mar 1;210(5):612–8. Comment in: J Am Vet Med Assoc 1997 Apr 15;210(8):1100; discussion 1100–1. Comment in: J Am Vet Med Assoc 1997 Apr 15;210(8):1100–1.

Additional opinions on the morality of animal research [letter] Feldmann BM. **J Am Vet Med Assoc** 1997 May 1;210(9):1267; discussion 1268

Animal rights, or simply, compassion? [letter] Fox MW. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1726

Who is right about animal rights? [letter; comment] Greek R. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1100; discussion 1100–1. Comment on: J Am Vet Med Assoc 1997 Mar 1;210(5):612–8.

Additional opinions on the mortality of animal research [letter] Griffiths AO. **J Am Vet Med Assoc** 1997 May 1; 210(9):1264–5; discussion 1268

Dialogue on use of animals in research continues [letter; comment] Klinger MM. **J Am Vet Med Assoc** 1996 Sep 15;209(6):1060. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

More letters on article about nonhuman animal research [letter; comment] Kraus AL. **J Am Vet Med Assoc** 1996 Aug 15;209(4):715–6; discussion 716–7. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

In support of animal rights dialogue [letter] Kraus AL. **J Am Vet Med Assoc** 1997 May 15;210(10):1412–3

Animal rights, or simply, compassion? [letter] Mulvihill WJ. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1726

Who is right about animal rights? [letter; comment] Rowan AN. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1100–1. Comment on: J Am Vet Med Assoc 1997 Mar 1;210(5):612–8.

More letters on article about nonhuman animal research [letter; comment] Silverman J. **J Am Vet Med Assoc** 1996 Aug 15;209(4):713–4; discussion 716–7. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

The myth of stolen-animal trafficking [letter] Strandberg J. **J Am Vet Med Assoc** 1997 Jul 1;211(1):27

Additional opinions on the mortality of animal research [letter] Sutor S. **J Am Vet Med Assoc** 1997 May 1; 210(9):1266–7; discussion 1268

Animal rights groups target NASA's Bion projects [news] Walker E. **J Am Vet Med Assoc** 1996 Dec 15; 209(12):1988–9

Who is looking out for dogs' rights? [letter] Yanoff S. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1098–9

Animal rights v animal research: a modest proposal [see comments] Bernstein J. **J Med Ethics** 1996 Oct;22(5):300–1; discussion 302–3. Comment in: J Med Ethics 1997 Apr;23(2):119.

Animal research [letter; comment] Bernstein J. **J Med Ethics** 1997 Apr;23(2):119. Comment on: J Med Ethics 1996 Oct;22(5):300–1; discussion 302–3.

Should a doctor prescribe hormone replacement therapy which has been manufactured from mare's urine? Cox D. **J Med Ethics** 1996 Aug;22(4):199–203

Animals have no choice [letter] Siegel SY. **N Y State Dent J** 1997 May;63(5):14

Animal rights and human life [editorial] Schwartz JB. **PDA J Pharm Sci Technol** 1996 Jul–Aug;50(4):197

Development of an attitude scale to measure attitudes toward humans' use of nonhuman animals. Armstrong JB, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):1003–10

Medical research on dogs [letter] Campbell G. **Plast Reconstr Surg** 1997 Sep;100(4):1075–6

An animal rights attitude survey of undergraduate psychology students. Vigorito M. **Psychol Rep** 1996 Aug; 79(1):131–42

Animal rights: teaching or deceiving kids [editorial] Runkle D, et al. **Science** 1997 Sep 5;277(5331):1419

Conservation of British wildlife [news] **Vet Rec** 1996 Aug 3;139(5):103–4

[Scientific ethics and animal experiments (editorial)] Thorn NA. **Ugeskr Laeger** 1997 Jan 6;159(2):151 **(Dan)**

[Animal experimentation--is it defensible?] Christoffersen SA. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1068–9 **(Nor)**

LEGISLATION & JURISPRUDENCE

Working with laboratory animals: general principles and practical considerations. Wright KC. **J Vasc Interv Radiol** 1997 May–Jun;8(3):363–73 (48 ref.)

[Legal principles in criminal and regulatory infringements--proceedings of the view of the public prosecutor] Schulze P. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):58–60 (Eng. Abstr.) **(Ger)**

[Doping in animal rights law: the responsibility of the veterinary surgeon] Hirt A. **Tierarztl Prax** 1997 May; 25(3):244–8 (Eng. Abstr.) **(Ger)**

TRENDS

Animal extremists: a cause for concern? Landry VL. **J Burn Care Rehabil** 1996 May–Jun;17(3):260–2

ANIMAL TECHNICIANS

Respiratory allergy to rats: exposure-response relationships in laboratory animal workers. Hollander A, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):562–7

Reduction of exposure to laboratory animal allergens in the workplace. Gordon S, et al. **Clin Exp Allergy** 1997 Jul; 27(7):744–51

Occupational respiratory diseases in laboratory animal workers: initial results. Krakowiak A, et al. **Int J Occup Med Environ Health** 1997;10(1):31–6

Commentary and recommendations on control of waste anesthetic gases in the workplace. American College of Veterinary Anesthesiologists. **J Am Vet Med Assoc** 1996 Jul 1;209(1):75–7

Possible transmission of Blastomycosis dermatitidis via culture specimen [letter; comment] Côté E, et al. **J Am Vet Med Assoc** 1997 Feb 15;210(4):479–80. Comment on: J Am Vet Med Assoc 1997 Feb 15;210(4):502–4.

Survey of veterinary professionals and other veterinary conference attendees for antibodies to Bartonella henselae and B quintana. Noah DL, et al. **J Am Vet Med Assoc** 1997 Feb 1;210(3):342–4

HISTORY

[Prof. Dr. Richard Völker and the School for Veterinary Medicine Technical Assistants in Hannover] Hohmann M, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 May; 103(5):178–80 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Survey explores technician issues [news] Decker CA. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1362–3

ANIMAL TESTING ALTERNATIVES

Validation of alternative tests in the European Union. Balls M. **Curr Probl Dermatol** 1995;23:265–74 (15 ref.)

Transcutaneous electrical resistance: application in predicting skin corrosives. Lewis RW, et al. **Curr Probl Dermatol** 1995; 23:243–55 (15 ref.)

EEC/COLIPA in vitro photoirritancy program: results of the first stage of validation. Spielmann H, et al. **Curr Probl Dermatol** 1995;23:256–64 (9 ref.)

Alternatives in animal testing. **Environ Health Perspect** 1996 Mar;104(3):250–2

Tracking toxicants. Potera C. **Environ Health Perspect** 1997 Jan;105(1):48–50

A synthetic model for microsurgical training: a surgical contribution to reduce the number of animal experiments. Weber D, et al. **Eur J Pediatr Surg** 1997 Aug;7(4):204–6

Comparison of low-volume, Draize and in vitro eye irritation test data. I. Hydroalcoholic formulations. Gettings SD, et al. **Food Chem Toxicol** 1996 Aug;34(8):737–49

IRAG working group 6. Guidelines for the evaluation of eye irritation alternative tests: criteria for data submission. Interagency Regulatory Alternatives Group. Scala RA, et al. **Food Chem Toxicol** 1997 Jan;35(1):13–22

IRAG working group 2. CAM-based assays. Interagency Regulatory Alternatives Group. Spielmann H, et al. **Food Chem Toxicol** 1997 Jan;35(1):39–66

Development of an in vitro method for skin corrosion testing. Perkins MA, et al. **Fundam Appl Toxicol** 1996 May; 31(1):9–18

Additional opinions on the mortality of animal research [letter] Apostolou A. **J Am Vet Med Assoc** 1997 May 1; 210(9):1265; discussion 1268

Reduced use of laboratory animals in research institute [letter] Guaitani A, et al. **Lancet** 1997 May 24; 349(9064):1557–8

New model for microsurgical training and skills maintenance. Yen DM, et al. **Microsurgery** 1995;16(11):760–2

Delays in alternative tests defer animal ban [news] Abbott A. **Nature** 1996 Oct 31;383(6603):748

Laboratory animal science, welfare and ethics in pharmacology and toxicology. Svendsen O, et al. **Pharmacol Toxicol** 1997 Jan;80(1):3–5 (14 ref.)

ANIMAL TESTING ALTERNATIVES

An alternative approach to the analysis of animal carcinogenicity studies. Stallard N, et al. **Regul Toxicol Pharmacol** 1996 Jun;23(3):244–8

Animal research is wasteful and misleading. Barnard ND, et al. **Sci Am** 1997 Feb;276(2):80–2

Hunting for animal alternatives [news] [see comments] Roush W. **Science** 1996 Oct 11;274(5285):168–71. Comment in: Science 1997 Apr 4;276(5309):19.

Animal alternatives in Germany [letter; comment] Spielmann H. **Science** 1997 Apr 4;276(5309):19. Comment on: Science 1996 Oct 11;274(5285):168–71.

A skin equivalent model for cosmetological trials: an in vitro efficacy study of a new biopeptide. Augustin C, et al. **Skin Pharmacol** 1997;10(2):63–70

Validation of in vitro methods: societies' expectations require the involvement of toxicological pathologists [editorial; comment] Bertram TA. **Toxicol Pathol** 1996 Jul–Aug; 24(4):509–10. Comment on: Toxicol Pathol 1996 Jul–Aug;24(4):403–11. Comment on: Toxicol Pathol 1996 Jul–Aug;24(4):412–8.

Alternatives to animal experimentation in parasitology. Eckert J. **Vet Parasitol** 1997 Jul 31;71(2–3):99–120 (142 ref.)

[Science needs experimental animals] Kunstyr I. **Tierarztl Prax** 1996 Dec;24(6):532–6 (7 ref.) (Eng. Abstr.) **(Ger)**

[Living tissue surrogate for testing of surgical lasers] Nevorotin AI, et al. **Biull Eksp Biol Med** 1996 Nov; 122(11):597–600 **(Rus)**

[In vitro methods and their use in toxicology] Hurná E. **Vet Med (Praha)** 1997 Jul;42(7):213–5 (Eng. Abstr.) **(Slo)**

EDUCATION

The three Rs: the way forward. Zurlo J, et al. **Environ Health Perspect** 1996 Aug;104(8):878–80

LEGISLATION & JURISPRUDENCE

Global agreement on alternative testing. Clay R. **Environ Health Perspect** 1996 Jun;104(6):612–4

METHODS

Validation of in vitro methods to single out photoirritants using mechanistically based tests. Pape WJ. **Arch Toxicol Suppl** 1997;19:239–47 (13 ref.)

The impact of atopic status on a predictive human test of skin irritation potential. Basketter D, et al. **Contact Dermatitis** 1996 Jul;35(1):33–9

Microbial models of mammalian metabolism. Biotransformations of HP 749 (besipirdine) using Cunninghamella elegans. Rao GP, et al. **Drug Metab Dispos** 1997 Jun;25(6):709–15

Practical application of non-whole animal alternatives: summary of IRAG workshop on eye irritation testing. Interagency Regulatory Alternatives Group. Bradlaw J, et al. **Food Chem Toxicol** 1997 Jan;35(1):175–8 (0 ref.)

Perspectives on alternatives to the eye irritation test: industry, public interest, government. Bruner LH, et al. **Food Chem Toxicol** 1997 Jan;35(1):165–6

IRAG working group 5. Other assays. Interagency Regulatory Alternatives Group. Curren RD, et al. **Food Chem Toxicol** 1997 Jan;35(1):127–58

Evaluation of eye irritation potential: statistical analysis and tier testing strategies. de Silva O, et al. **Food Chem Toxicol** 1997 Jan;35(1):159–64

Statistical planning and analysis considerations in the evaluation of in vitro alternatives to whole animal use for eye irritation testing. Feder P, et al. **Food Chem Toxicol** 1997 Jan;35(1):167–74 (6 ref.)

IRAG working group 4. Cell cytotoxicity assays. Interagency Regulatory Alternatives Group. Harbell JW, et al. **Food Chem Toxicol** 1997 Jan;35(1):79–126

Millimeter wave-induced vibrational modes in DNA as a possible alternative to animal tests to probe for carcinogenic mutations. Woolard DL, et al. **J Appl Toxicol** 1997 Jul–Aug;17(4):243–6

In vitro toxicological methods for environmental health testing. Hasspieler BM, et al. **Rev Environ Health** 1996 Oct–Dec;11(4):213–27 (51 ref.)

ANIMAL VIRUSES see **VIRUSES**

ANIMAL VOCALIZATION see **VOCALIZATION, ANIMAL**

ANIMAL WELFARE

see related
ANIMAL TESTING ALTERNATIVES

Rearing conditions and foot-pad dermatitis in Swedish turkey poults. Ekstrand C, et al. **Acta Vet Scand** 1997;38(2):167–74

Sensitivity of reproducing sows and suckling pigs to stray voltage. Robert S, et al. **Am J Vet Res** 1996 Aug; 57(8):1245–9

Use of neuromuscular blocking drugs in scientific investigations involving animal subjects. The benefit of the doubt goes to the animal [editorial] Drummond JC, et al. **Anesthesiology** 1996 Oct;85(4):697–9

The use of pound dogs in teaching and research. Bellenger CR. **Aust Vet J** 1996 Dec;74(6):473–5

Pain is real [letter] Kelf I. **Aust Vet J** 1996 Oct;74(4):334

The role of veterinarians on animal experimentation ethics committees. Australian Veterinarians Associated with Scientific Establishments. Scott LR, et al. **Aust Vet J** 1996 Oct;74(4):309–11

Who are we treating? [letter] Snelling S. **Aust Vet J** 1997 May;75(5):376

The comeback trail: Africa's bid to save its endangered animals. Tribe A. **Aust Vet J** 1996 Jul;74(1):76–7

Relationships between the degree of food restriction and welfare indices in broiler breeder females. Hocking PM, et al. **Br Poult Sci** 1996 May;37(2):263–78

Comments on the 1995 Gordon Memorial Lecture [letter; comment] Hughes BO, et al. **Br Poult Sci** 1996 Sep; 37(4):869–72. Comment on: Br Poult Sci 1996 Mar;37(1):5–14.

Hormonal and physiological effects of a 15 hour road journey in sheep: comparison with the responses to loading, handling and penning in the absence of transport. Broom DM, et al. **Br Vet J** 1996 Sep;152(5):593–604

The language of animal welfare [editorial] Hare D. **Can Vet J** 1996 Aug;37(8):453–4 **(Eng, Fre)**

An ethicist's commentary on the case of the anorexic client who does not feed her dog. Rollin BE. **Can Vet J** 1997 May;38(5):263

An ethicist's commentary on the case of the infected research animal. Rollin BE. **Can Vet J** 1997 Mar;38(3):136

Animal health week--are you out of touch? [letter] Walliser R. **Can Vet J** 1996 Jul;37(7):389

The use of animals in research and ethical considerations [editorial; comment] Lore W. **East Afr Med J** 1996 Nov; 73(11):697–8. Comment on: East Afr Med J 1996 Nov;73(11):699–702.

Animal handling [letter; comment] Aguirre GD. **Invest Ophthalmol Vis Sci** 1997 May;38(6):1053. Comment on: Invest Ophthalmol Vis Sci 1996 Oct;37(11):2219–27.

More letters on article about nonhuman animal research [letter; comment] Harvey SB. **J Am Vet Med Assoc** 1996 Aug 15;209(4):714–5. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

Effects of aggressive behavior on canine welfare. Hunthausen W. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1134–6 (8 ref.)

Additional opinions on the morality of animal research [letter] Koltveit AJ. **J Am Vet Med Assoc** 1997 May 1; 210(9):1265–6; discussion 1268

More letters on article about nonhuman animal research [letter; comment] McPherson C. **J Am Vet Med Assoc** 1996 Aug 15;209(4):714; discussion 716–7. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

Current issues in the control of stray and feral cats. Mahlow JC, et al. **J Am Vet Med Assoc** 1996 Dec 15;209(12):2016–20

Overcoming domestic violence: Purdue's PetSafe program propels people and pets to protection [news] Spencer LM. **J Am Vet Med Assoc** 1996 Sep 15;209(6):1054

The issue of safe testing for brucellosis in Yellowstone bison [letter] Toigo J. **J Am Vet Med Assoc** 1997 Jul 1;211(1):25–7

More letters on article about nonhuman animal research [letter; comment] Ward GM. **J Am Vet Med Assoc** 1996 Aug 15;209(4):713; discussion 716–7. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

Veterinarians serving US animal care and control facilities. Yoffe-Sharp B, et al. **J Am Vet Med Assoc** 1996 Nov 15; 209(10):1692–6 (20 ref.)

Health, welfare, and productivity of pigs housed under Specific-Stress-Free conditions in comparison with two-site systems. Ekkel ED, et al. **J Anim Sci** 1996 Sep; 74(9):2081–7

Assessment of stress during handling and transport. Grandin T. **J Anim Sci** 1997 Jan;75(1):249–57 (93 ref.)

The use of electrolyte solutions for reducing transport stress. Schaefer AL, et al. **J Anim Sci** 1997 Jan;75(1):258–65 (97 ref.)

Statement letter in regard to use of animals in research [letter] Traber DL. **J Burn Care Rehabil** 1997 Jul–Aug;18(4):15A

Companion animal health education programmes in schools [letter; comment] McCrindle CM. **J S Afr Vet Assoc** 1996 Sep;67(3):102. Comment on: J S Afr Vet Assoc 1996 Mar;67(1):31–5.

Humane dentistry [letter] Gorrel C. **J Small Anim Pract** 1997 Jan;38(1):31

Emerging diseases--what veterinarians need to know. Brown C. **J Vet Diagn Invest** 1997 Apr;9(2):113–7 (58 ref.)

Happy animals make good science. Poole T. **Lab Anim** 1997 Apr;31(2):116–24 (54 ref.)

Preferences for nesting material as environmental enrichment for laboratory mice. Van de Weerd HA, et al. **Lab Anim** 1997 Apr;31(2):133–43

Referendum's challenge to transgenic research [editorial] **Nature** 1997 Sep 11;389(6647):103

NIH urged to address chimp care 'crisis' [news] Macilwain C. **Nature** 1997 Jul 17;388(6639):218

Pressure grows for inquiry into welfare of transgenic animals [news] Masood E. **Nature** 1997 Jul 24;388(6640):311–2

Animal researchers should 'start talking' to anti-vivisectionists [news] Masood E. **Nature** 1997 Sep 4; 389(6646):5

Laboratory animal science, welfare and ethics in pharmacology and toxicology. Svendsen O, et al. **Pharmacol Toxicol** 1997 Jan;80(1):3–5 (14 ref.)

Physiological responses of red deer (Cervus elaphus) to conditions experienced during road transport. Waas JR, et al. **Physiol Behav** 1997 Jun;61(6):931–8

Ethical aspects and dilemmas of fertility control of unwanted wildlife: an animal welfarist's perspective. Oogjes G. **Reprod Fertil Dev** 1997;9(1):163–7 (8 ref.)

Academy seeks government help to fight openness law [news] Lawler A. **Science** 1997 Jul 25;277(5325):473

Chimp retirement plan proposed [news] Roush W. **Science** 1997 Jul 25;277(5325):471

Welfare implications of gas stunning pigs: 3. The time to loss of somatosensory evoked potentials and spontaneous electrocorticogram of pigs during exposure to gases. Raj AB, et al. **Vet J** 1997 May;153(3):329–39

Required thermal thresholds during transport of animals. Schrama JW, et al. **Vet Q** 1996 Sep;18(3):90–5

Animal welfare: reducing mortality in lambs [news] [see comments] **Vet Rec** 1996 Nov 9;139(19):455–6. Comment in: Vet Rec 1997 Feb 1;140(5):136.

Greyhound welfare [letter] Graham-Jones O. **Vet Rec** 1996 Jun 22;138(25):627

Research on the welfare of pigs [letter] Hancock R. **Vet Rec** 1996 Sep 28;139(13):324

FAWC's 'five freedoms' [letter; comment] Hughes BO. **Vet Rec** 1996 Jun 29;138(26):651. Comment on: Vet Rec 1996 Jun 8;138(23):576.

Reducing perinatal mortality in lambs [letter; comment] [see comments] Lester WA. **Vet Rec** 1997 Feb 1;140(5):136. Comment on: Vet Rec 1996 Nov 9;139(19):455–6. Comment in: Vet Rec 1997 Mar 15;140(11):292.

Welfare and market forces [letter] Lewis W. **Vet Rec** 1996 Sep 14;139(11):267–8

Qualifications in animal welfare science, ethics and law [letter] Morton DB. **Vet Rec** 1997 Apr 19;140(16):435

'Battered pets' [letter] Munro HM. **Vet Rec** 1996 Jun 8; 138(23):576

Greyhound welfare [letter] Poulter D. **Vet Rec** 1996 Jun 8; 138(23):576

Aversive reactions of turkeys to argon, carbon dioxide and a mixture of carbon dioxide and argon. Raj AB. **Vet Rec** 1996 Jun 15;138(24):592–3

Freedom from boredom [letter] [see comments] Ryder RD. **Vet Rec** 1996 Jun 8;138(23):576. Comment in: Vet Rec 1996 Jun 29;138(26):651.

The BSE crisis [letter] Watkins J. **Vet Rec** 1996 Jul 6; 139(1):22

An immunological approach to the evaluation of welfare in Holstein Frisian cattle. Amadori M, et al. **Zentralbl Veterinarmed [B]** 1997 Aug;44(6):321–7

[The forgotten animal and the one-man associate] Deleu S. **Tijdschr Diergeneeskd** 1997 Feb 15;122(4):115–7 **(Dut)**

[New Professor human-animal relation. 'You can try to make the pain bearable'(interview by Sophie Deleu)] Noordhuizen-Stassen EN. **Tijdschr Diergeneeskd** 1996 Sep 15;121(18):522–3 **(Dut)**

[The optimization of group size for fattening rabbits in group housing on grids made of artificial material] Drescher B, et al. **Berl Munch Tierarztl Wochenschr** 1996 Aug; 109(8):304–8 (Eng. Abstr.) **(Ger)**

[Animal welfare aspects of the production of veal] Völker H, et al. **Berl Munch Tierarztl Wochenschr** 1996 Feb; 109(2):55–62 (Eng. Abstr.) **(Ger)**

[Space required for sheep during transport] Buchenauer D. **DTW Dtsch Tierarztl Wochenschr** 1997 Apr;104(4):135–9 (Eng. Abstr.) **(Ger)**

[The Animal Welfare Center of the Veterinary School of Hanover] Hackbarth H. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):75–6 (Eng. Abstr.) **(Ger)**

[Science needs experimental animals] Kunstyr I. **Tierarztl Prax** 1996 Dec;24(6):532–6 (7 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Eastern barred bandicoot recovery; the role of the veterinarian in the management of endangered species [letter; comment] Wright GR. **Aust Vet J** 1997 Jan;75(1):66 . Comment on: Aust Vet J 1996 Mar;73(3):81–3.

The Göttingen minipig in pharmacology and toxicology. Bollen P, et al. **Pharmacol Toxicol** 1997;80 Suppl 2:3–4 (14 ref.)

Jan Moor-Jankowski. A whistle-blower's wars [news] Mukerjee M. **Sci Am** 1997 Sep;277(3):32–3

Willingness-to-pay measures of public support for farm animal welfare legislation. Bennett RM. **Vet Rec** 1996 Sep 28;139(13):320–1

HISTORY

Trends in animal research. Mukerjee M. **Sci Am** 1997 Feb; 276(2):86–93

LEGISLATION & JURISPRUDENCE

Taking a position [letter] Grenn HH. **Can Vet J** 1994 Dec; 35(12):743

Canine legislation: can dogs get a fair shake in court? Burt MR. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1139–42 (19 ref.)

How should the practice of veterinary medicine be defined? Hannah HW. **J Am Vet Med Assoc** 1996 Jul 1;209(1):73–4

The statutory offense of cruelty to animals. Hannah HW. **J Am Vet Med Assoc** 1997 Jul 1;211(1):47–8

Working with laboratory animals: general principles and practical considerations. Wright KC. **J Vasc Interv Radiol** 1997 May–Jun;8(3):363–73 (48 ref.)

Germany may relax animal experiment rules [news] Abbott

A. **Nature** 1997 Feb 27;385(6619):760

Dealing with infectious and parasitic diseases in safari parks, roadside menageries, exotic animal auctions and rehabilitation centres. Porter SL. **Rev Sci Tech** 1996 Mar; 15(1):227–36 (20 ref.)

Jan Moor-Jankowski. A whistle-blower's wars [news] Mukerjee M. **Sci Am** 1997 Sep;277(3):32–3

Health and welfare issues related to using (domestic) ungulates for the management of nature parks in The Netherlands. Oosterbaan J, et al. **Vet Q** 1996;18 Suppl 3:S153–5 (15 ref.)

FAWC considers the needs of outdoor pigs and calls for a welfare code [editorial] **Vet Rec** 1996 Jun 1;138(22):532–3

Government issues draft legislation on welfare during transport [news] **Vet Rec** 1997 Jan 18;140(3):54

[Number of allowable interventions is limited as of 1 September] van Egmond S. **Tijdschr Diergeneeskd** 1996 Sep 1;121(17):487–93 **(Dut)**

[Investigation, securing of evidence and judgment in violations of animal welfare regulations] Fikuart K. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):60–1 (Eng. Abstr.) **(Ger)**

[Pain caused by breeding: definition, judgment, pathogenesis] Herzog A. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb; 104(2):71–4 (Eng. Abstr.) **(Ger)**

[Animal Welfare Service of Lower Saxony--first report of experiences] Petermann S. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):76–8 (Eng. Abstr.) **(Ger)**

[Pain caused by breeding in dogs] Reetz IC. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):68–70 (Eng. Abstr.) **(Ger)**

[Effect of hot-air balloon crossings on animals in the open air] Stephan E. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb; 104(2):79–82 (Eng. Abstr.) **(Ger)**

[Adequate animal housing and existence regulations of cats] Unshelm J, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):62–5 (Eng. Abstr.) **(Ger)**

[Suffering and misfortune--the beginning of comprehension] Winckler C, et al. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb;104(2):43–6 (25 ref.) (Eng. Abstr.) **(Ger)**

[Ethological approaches concerning forensic animal welfare] Zeeb K. **DTW Dtsch Tierarztl Wochenschr** 1996 Nov; 103(11):474–7 (Eng. Abstr.) **(Ger)**

[Animal welfare aspects relevant to the design of the spectacled bear facility in the Zürich Zoo] Rübel A. **Schweiz Arch Tierheilkd** 1996;138(12):586–90 (Eng. Abstr.) **(Ger)**

STANDARDS

Traumatic head injury in ruminant livestock. Finnie IW. **Aust Vet J** 1997 Mar;75(3):204–8 (29 ref.)

Poultry in transit--a cause for concern? [editorial] Metheringham J, et al. **Br Vet J** 1995 May;152(3):247–50

An ethicist's commentary on the case of the veterinarian who wishes to improve rural euthanasia. Rollin BE. **Can Vet J** 1997 Jun;38(6):334–5

Using aversion learning techniques to assess the mental state, suffering, and welfare of farm animals. Rushen J. **J Anim Sci** 1996 Aug;74(8):1990–5 (35 ref.)

Credentialing of research surgeons: can computers help in the process? [editorial] Othersen HB Jr, et al. **J Invest Surg** 1996 May-Jun;9(3):159–60

Sustainable improvement of animal health care by systematic quality risk management according to the HACCP concept. Noordhuizen JP, et al. **Vet Q** 1996 Dec;18(4):121–6 (32 ref.)

Farm assurance schemes [letter] Main D. **Vet Rec** 1996 Nov 30;139(22):551–2

Problems with microchipped strays [letter; comment] [see comments] Price HJ. **Vet Rec** 1996 Oct 26;139(17):427. Comment on: Vet Rec 1996 Oct 12;139(15):376. Comment in: Vet Rec 1996 Nov 9;139(19):476. Comment in: Vet Rec 1996 Nov 16;139(2):502–3.

[Is human embryo research necessary? What are the limits of animal experimentation?] Plachot M. **Contracept Fertil Sex** 1996 Nov;24(11):802–4 **(Fre)**

TRENDS

Report of the meeting on 'animal welfare in regulatory toxicology' under the auspices of the British Toxicology Society, 27 April 1995. Farningham DA, et al. **Hum Exp Toxicol** 1996 May;15(5):452–4

Revised proposals on the welfare of animals during transport [news] **Vet Rec** 1996 Sep 14;139(11):246–7

ANIMALS

Young children's recognition of commonalities between animals and plants. Inagaki K, et al. **Child Dev** 1996 Dec; 67(6):2823–40

Why dogs have puppies and cats have kittens: the role of birth in young children's understanding of biological origins. Johnson SC, et al. **Child Dev** 1997 Jun;68(3):404–19

ANATOMY & HISTOLOGY

[The morphological principles of the systematization of biodiversity] Mamkaev IuV. **Zh Obshch Biol** 1996 Mar-Apr;57(2):40–51 (44 ref.) **(Rus)**

[2 phases of form development realized during microevolution] Proniaev AV, et al. **Zh Obshch Biol** 1996 May-Jun;57(3):346–59 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

A novel classification of planar four-bar linkages and its application to the mechanical analysis of animal systems. Muller M. **Philos Trans R Soc Lond B Biol Sci** 1996 May 29;351(1340):689–720

[Problems in researching the diversity of the animal world in Russia] Alimov AF, et al. **Zh Obshch Biol** 1996 Mar-Apr;57(2):5–13 **(Rus)**

[The morphological principles of the systematization of biodiversity] Mamkaev IuV. **Zh Obshch Biol** 1996 Mar-Apr;57(2):40–51 (44 ref.) **(Rus)**

EMBRYOLOGY

[Integral behavior of animals based on genetic and ontogenetic mechanisms] Chailakhian LM. **Dokl Akad Nauk** 1996 Jun;348(6):838–41 **(Rus)**

GENETICS

Transposable elements as sources of variation in animals and plants. Kidwell MG, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):7704–11

[Integral behavior of animals based on genetic and ontogenetic mechanisms] Chailakhian LM. **Dokl Akad Nauk** 1996 Jun;348(6):838–41 **(Rus)**

[The ideas of G. A. Levitskiĭ and current data on chromosomal transformations in plant and animal evolution] Goroshchenko IuL, et al. **Tsitologiia** 1996; 38(11):1217–27 **(Rus)**

PHYSIOLOGY

Cardiovascular measurements in animals in the milligram range. Burggren W, et al. **Braz J Med Biol Res** 1995 Nov-Dec;28(11-12):1291–305

Signalling pathways: a common theme in plants and animals? Wilson I, et al. **Curr Biol** 1997 Mar 1;7(3):R175–8 (10 ref.)

Comments on Anand and Craig, PAIN, 67 (1996) 3–6 [letter; comment] Molony V. **Pain** 1997 Apr;70(2-3):293. Comment on: Pain 1996 Sep;67(1):3–6; discussion 209–11.

PSYCHOLOGY

The science of animal cognition: past, present, and future. Wasserman EA. **J Exp Psychol Anim Behav Process** 1997 Apr;23(2):123–35 (90 ref.)

ANIMALS, DOMESTIC

Comparison of hemisphere size in wild and domestic geese. Kalisińska E. **Anat Histol Embryol** 1997 Mar;26(1):3–9

In vivo imaging of fatty acid incorporation into brain to examine signal transduction and neuroplasticity involving phospholipids. Rapoport SI, et al. **Ann N Y Acad Sci** 1997 May 30;820:56–73; discussion 73–4 (35 ref.)

Salmonella meningitis acquired from pet snakes [letter] Paton JH, et al. **Arch Dis Child** 1997 Jul;77(1):93

Action on preservatives in fresh pet food. **Aust Vet J** 1997 May;75(5):379

Future trends for the veterinary profession in Australia: an occasional article on the 75th anniversary of the Australian Veterinary Association [editorial] Banyard MR, et al. **Aust Vet J** 1996 Jul;74(1):33–5

Wage pressure a reality [letter] Fisher EM. **Aust Vet J** 1996 Oct;74(4):335

Avian exposure and risk of lung cancer in women in Missouri: population based case-control study [see comments] Alavanja MC, et al. **BMJ** 1996 Nov 16;313(7067):1233–5 . Comment in: BMJ 1996 Nov 16;313(7067):1218–9.

Pet birds and lung cancer [editorial; comment] Britton J, et al. **BMJ** 1996 Nov 16;313(7067):1218–9. Comment on: BMJ 1996 Nov 16;313(7067):1233–5. Comment on: BMJ 1996 Nov 16;313(7067):1236–8.

Allergic patients do not comply with doctors' advice to stop owning pets [letter] Coren S. **BMJ** 1997 Feb 15; 314(7079):517

Risk of lung cancer needs to be studied in younger patients who keep pet birds [letter] Holst P. **BMJ** 1997 May 3; 314(7090):1353

Pet birds and risk of lung cancer in Sweden: a case-control study [see comments] Modigh C, et al. **BMJ** 1996 Nov 16;313(7067):1236–8. Comment in: BMJ 1996 Nov 16;313(7067):1218–9.

Prophylaxis should be considered even for trivial animal bites [letter] Morgan MS. **BMJ** 1997 May 10;314(7091):1413

Pets and diseases. Riordan A, et al. **Br J Hosp Med** 1996 Oct 2-15;56(7):321–4

Everything you ever wanted to know about microchips. Ingwersen W. **Can Vet J** 1996 Nov;37(11):667–71 **(Eng, Fre)**

Competing with pet superstores. Matthew B. **Can Vet J** 1996 Aug;37(8):502–5 **(Eng, Fre)**

An ethicist's commentary on the case of the veterinarian who euthanized an animal thinking that he had received owner permission. Rollin BE. **Can Vet J** 1996 Sep;37(9):519–20

An ethicist's commentary on the case of the stray tattooed beagle. Rollin BE. **Can Vet J** 1996 Nov;37(11):648–9

Cattle, pets, and Paget's disease of bone. López-Abente G, et al. **Epidemiology** 1997 May;8(3):247–51

Capnocytophaga canimorsus infections in human: review of the literature and cases report. Lion C, et al. **Eur J Epidemiol** 1996 Oct;12(5):521–33 (83 ref.)

Environmental control: an idea whose time has come [editorial; comment] Becker AB, et al. **Eur Respir J** 1997 Jun;10(6):1203–4. Comment on: Eur Respir J 1997 Jun;10(6):1217–23.

Determination of mycotoxins in pet foods sold for domestic pets and wild birds using linked-column immunoassay clean-up and HPLC. Scudamore KA, et al. **Food Addit Contam** 1997 Feb-Mar;14(2):175–86

The middle ear of a lion: comparison of structure and function to domestic cat. Huang GT, et al. **J Acoust Soc Am** 1997 Mar;101(3):1532–49

Cocaine addiction: hypothesis derived from imaging studies with PET. Volkow ND, et al. **J Addict Dis** 1996; 15(4):55–71 (49 ref.)

Marketing strategies to enhance the value of food animal veterinarians. Clevenger J. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1386–7

Composting alternative for animal carcass disposal. Glanville TD, et al. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1116–20 (23 ref.)

Grounds for recovery and defenses in feed liability cases. Hannah HW. **J Am Vet Med Assoc** 1997 Jun 1; 210(11):1604–5

Who owns the animal? Hannah HW. **J Am Vet Med Assoc** 1997 Apr 1;210(7):909–10

Integrating use of psychotropic drugs with environmental management and behavioral modification for treatment of problem behavior in animals [see comments] Hart BL, et al. **J Am Vet Med Assoc** 1996 Nov 1;209(9):1549–51 (6 ref.). Comment in: J Am Vet Med Assoc 1997 Jan 1;210(1):18–9.

An overview of disaster preparedness for veterinarians [comment] Heath SE, et al. **J Am Vet Med Assoc** 1997 Feb 1;210(3):345–8 (19 ref.). Comment on: J Am Vet Med Assoc 1997 Feb 1;210(3):325–8.

Integration of veterinarians into the official response to disasters. Heath SE, et al. **J Am Vet Med Assoc** 1997 Feb 1;210(3):349–52 (17 ref.)

The world's food supply and the role of food animal veterinarians [letter] Herrick JB. **J Am Vet Med Assoc** 1997 Mar 15;210(6):751–2

Drugs and biologics are not a substitute for effective management by food animal veterinarians. Herrick JB. **J Am Vet Med Assoc** 1997 May 15;210(10):1419–20

Food animal veterinarians and the use of a yellow legal pad. Humble JA. **J Am Vet Med Assoc** 1997 Feb 15;210(4):484–5

Challenges for food animal veterinarians in food animal production in the 21st century. Humble JA. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1106–8

Facilitating pet ownership through improved housing design. Jackson VS. **J Am Vet Med Assoc** 1996 Sep 15; 209(6):1076–9

Compendium of animal rabies control, 1997. National Association of State Public Health Veterinarians [published erratum appears in J Am Vet Med Assoc 1997 Feb 1;210(3):344] Jenkins R, et al. **J Am Vet Med Assoc** 1997 Jan 1;210(1):33–7

Rabies surveillance in the United States during 1995. Krebs JW, et al. **J Am Vet Med Assoc** 1996 Dec 15; 209(12):2031–44

"Pet friendly" stores: are they consumer friendly? [news] Lopez T. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1088–9

Raging wildfire in Alaska forces evacuation of homes, displaces companion animals [news] Meehan SK. **J Am Vet Med Assoc** 1996 Aug 15;209(4):707, 710

Factors associated with the decision to surrender a pet to an animal shelter. Miller DD, et al. **J Am Vet Med Assoc** 1996 Aug 15;209(4):738–42

The law of veterinary liability and the human-animal bond [see comments] Perron J. **J Am Vet Med Assoc** 1997 Jan 15;210(2):184–6. Comment in: J Am Vet Med Assoc 1997 Mar 15;210(6):748–9. Comment in: J Am Vet Med Assoc 1997 Mar 15;210(6):749.

Overcoming domestic violence: Purdue's PetSafe program propels people and pets to protection [news] Spencer LM. **J Am Vet Med Assoc** 1996 Sep 15;209(6):1054

Psychological elements of attachment to pets and responses to pet loss. Stern M. **J Am Vet Med Assoc** 1996 Nov 15; 209(10):1707–11

The myth of stolen-animal trafficking [letter] Strandberg J. **J Am Vet Med Assoc** 1997 Jul 1;211(1):27

Endorses concept of pet insurance [letter] Villalobos A. **J Am Vet Med Assoc** 1996 Aug 15;209(4):721–2

Tuberculosis persists in US livestock [news] [see comments] Walker E. **J Am Vet Med Assoc** 1996 Nov 1;209(9):1529–30 . Comment in: J Am Vet Med Assoc 1996 Dec 15;209(12):1996.

Who is looking out for dogs' rights? [letter] Yanoff S. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1098–9

Failure of dietary bentonite clay, Silent Herder mineral supplement, or parenteral Banamine to alleviate locoweed toxicosis in rats. Dugarte-Stavanja M, et al. **J Anim Sci** 1997 Jul;75(7):1867–75

Comparative longevity of pet dogs and humans: implications for gerontology research. Patronek GJ, et al. **J Gerontol A Biol Sci Med Sci** 1997 May;52(3):B171–8

Framing animal disease: housecats with feline urological syndrome, their owners, and their doctors. Jones SD. **J Hist Med Allied Sci** 1997 Apr;52(2):202–35

3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a

comparative study using SPECT and PET. Langen KJ, et al. **J Nucl Med** 1997 Apr;38(4):517–22

ACE–inhibitor cough in the Australian pink galah. Watts RW. **Med J Aust** 1996 Dec 2–16;165(11–12):682

Pets helping to heal the elderly. Propsner N. **N J Med** 1997 Sep;94(9):32

A new lease on life for transgenic livestock [news] Wall RJ. **Nat Biotechnol** 1997 May;15(5):416–7

Pet cat hair implicates murder suspect [letter] Menotti–Raymond MA, et al. **Nature** 1997 Apr 24; 386(6627):774

Culicoides (Diptera:Ceratopogonidae) associated with livestock in the Onderstepoort area, Gauteng, South Africa as determined by light–trap collections. Venter GJ, et al. **Onderstepoort J Vet Res** 1996 Dec;63(4):315–25

A study of animal companionship in a day hospice. Phear DN. **Palliat Med** 1996 Oct;10(4):336–8

Overview of the current international trade in ornamental fish, with special reference to Singapore. Cheong L. **Rev Sci Tech** 1996 Jun;15(2):445–81 (4 ref.)

Special challenges of maintaining wild animals in captivity: a southern African perspective. Colly LP, et al. **Rev Sci Tech** 1996 Mar;15(1):237–49 (14 ref.)

Characteristics of the current international trade in ornamental fish, with special reference to the European Union. Davenport KE. **Rev Sci Tech** 1996 Jun;15(2):435–43 (6 ref.)

Management practices to minimise infectious and parasitic diseases of farmed and ranched cervids and bison. Haigh JC. **Rev Sci Tech** 1996 Mar;15(1):209–26 (48 ref.)

Tuberculosis in free–ranging, semi free–ranging and captive cervids. Hunter DL. **Rev Sci Tech** 1996 Mar;15(1):171–81 (17 ref.)

Special challenges of maintaining wildlife in captivity in Europe and Asia. Kirkwood JK. **Rev Sci Tech** 1996 Mar; 15(1):309–21 (57 ref.)

Husbandry practices as related to infectious and parasitic diseases of farmed ratites. Tully TN, et al. **Rev Sci Tech** 1996 Mar;15(1):73–89 (33 ref.)

Husbandry practices employed by private aviculturists, bird markets and zoo collections, which may be conducive to fostering infectious diseases. Wolff PL. **Rev Sci Tech** 1996 Mar;15(1):55–71 (60 ref.)

The pregnancy that doesn't stay—lessons from 25 years of observation [editorial; comment] Allen GP. **Vet J** 1997 May;153(3):239–44 (28 ref.). Comment on: Vet J 1997 May;153(3):253–68.

Herpesviral abortion in domestic animals [see comments] Smith KC. **Vet J** 1997 May;153(3):253–68 (191 ref.). Comment in: Vet J 1997 May;153(3):239–44.

Mechanisms of transmission of Aujeszky's disease virus originating from feral swine in the USA. Hahn EC, et al. **Vet Microbiol** 1997 Apr;55(1–4):123–30

Sustainable tick and tickborne disease control in livestock improvement in developing countries. de Castro JJ. **Vet Parasitol** 1997 Jul 31;71(2–3):77–97 (102 ref.)

Pet fish radiography: technique and case history reports. Love NE, et al. **Vet Radiol Ultrasound** 1997 Jan–Feb; 38(1):24–9

Application of the pin–hole collimator in small animal nuclear scintigraphy: a review. Young K, et al. **Vet Radiol Ultrasound** 1997 Mar–Apr;38(2):83–93 (5 ref.)

Rabies and quarantine [letter] Carwardine P. **Vet Rec** 1996 Dec 14;139(24):604

Rabies and quarantine [letter] Heathcote V. **Vet Rec** 1996 Dec 14;139(24):604

Farm assurance schemes [letter] Main D. **Vet Rec** 1996 Nov 30;139(22):551–2

'Battered pets' [letter] Munro HM. **Vet Rec** 1996 Jun 8; 138(23):576

Outbreak of Chrysomyia bezziana in Khoozestan province, Iran. Navidpour S, et al. **Vet Rec** 1996 Aug 31;139(9):217

Problems with microchipped strays [letter; comment] [see comments] Price HJ. **Vet Rec** 1996 Oct 26;139(17):427. Comment on: Vet Rec 1996 Oct 12;139(15):376. Comment in: Vet Rec 1996 Nov 9;139(19):476. Comment in: Vet Rec 1996 Nov 16;139(2):502–3.

Generating biological models through gene transfer to domestic animals. Houdebine LM. **Vet Res** 1997 May–Jun; 28(3):201–5 (29 ref.)

Diagnostic results in animal dermatophytoses. Schmidt A. **Zentralbl Veterinarmed [B]** 1996 Nov;43(9):539–43

[Current views on the importance of iodine for animals] Herzig I, et al. **Vet Med (Praha)** 1996 Dec;41(12):379–86 (83 ref.) (Eng. Abstr.) **(Cze)**

[SPECT and PET in neurobiology] Paulson OB, et al. **Ugeskr Laeger** 1997 Apr 14;159(16):2351–5 **(Dan)**

[Wound care in companion animals (news)] **Tijdschr Diergeneeskd** 1997 Apr 15;122(8):234–5 **(Dut)**

[Workshop Vaccinology Rhône Mérieux. Annual revaccination under discussion] Deleu S. **Tijdschr Diergeneeskd** 1996 Nov 15;121(22):654–6 **(Dut)**

[Asbestos risk for companion animals] Misdorp W. **Tijdschr Diergeneeskd** 1997 Jan 15;122(2):50–1 **(Dut)**

[Chemotherapy in animals: ethical or unethical? (letter)] Rutteman GR, et al. **Tijdschr Diergeneeskd** 1997 Feb 1; 122(3):77–9 **(Dut)**

[Euthanasia or therapy? (letter)] Wijsmuller JM. **Tijdschr Diergeneeskd** 1997 Mar 15;122(6):171 **(Dut)**

[Supervision of distribution and use of veterinary drugs in Schleswig–Holstein] Bettin U. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):240–3 (Eng. Abstr.) **(Ger)**

[Health and environmental risks after the use of anti–infective agents and antiparasitic agents in domestic animal husbandry—avoidance strategies and ways out] Blaha T. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):278–80 (Eng. Abstr.) **(Ger)**

[Risks due to the medication of feed and water in animal facilities] Kamphues J. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):250–6 (37 ref.) (Eng. Abstr.) **(Ger)**

[Development of nutrition science in veterinary medicine as an example of the School of Veterinary Medicine Hannover] Meyer H. **DTW Dtsch Tierarztl Wochenschr** 1997 Jun;104(6):203–7 (Eng. Abstr.) **(Ger)**

[Cemeteries and crematoriums for animals? Social and emotional aspects of the changed human–animal relationship and the resulting needs and risks] Ratsch H. **DTW Dtsch Tierarztl Wochenschr** 1997 Jul;104(7):261–4 (Eng. Abstr.) **(Ger)**

[Effect of hot–air balloon crossings on animals in the open air] Stephan E. **DTW Dtsch Tierarztl Wochenschr** 1997 Feb; 104(2):79–82 (Eng. Abstr.) **(Ger)**

[Development of resistance in infectious agents of agricultural animals in Germany (1990–1994)—a review] Trolldenier H. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul; 103(7):256–60 (9 ref.) (Eng. Abstr.) **(Ger)**

[Monitoring of emergency and intensive care patients: simple diagnostic aids] Spreng DE, et al. **Schweiz Arch Tierheilkd** 1996;138(11):537–45 (18 ref.) (Eng. Abstr.) **(Ger)**

[Systems for monitoring animal health in Switzerland] Stärk KD, et al. **Schweiz Arch Tierheilkd** 1996;138(8):392–8 (Eng. Abstr.) **(Ger)**

[Prehistoric fauna in Bulgaria] Manhart H. **Tierarztl Prax** 1997 Jan;25(1):15–7 (Eng. Abstr.) **(Ger)**

[Animal husbandry and hunting in the neolithic age as an example of animal remains Pestenacker (Lkr. Landsberg am Lech) settlement] Sorge G. **Tierarztl Prax** 1996 Oct; 24(5):432–5 (Eng. Abstr.) **(Ger)**

[Positron emission tomography: foundations and applications] Gulyás B, et al. **Orv Hetil** 1996 Apr 7;137(14):731–8 (50 ref.) (Eng. Abstr.) **(Hun)**

[First Hungarian experiences with positron emission tomography (PET) studies. Members of the PET working group] Trón L, et al. **Orv Hetil** 1997 Feb 2;138(5):259–69 (50 ref.) (Eng. Abstr.) **(Hun)**

[Ecology and prion diseases in domestic animals] Naess K. **Tidsskr Nor Laegeforen** 1997 Feb 20;117(5):716 **(Nor)**

[Neuroimaging and fundamental symptoms in schizophrenia] Lopez–Ibor MI, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jan–Feb;24(1):25–8 (30 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Basket and basal–duct cells in domestic animals: different cytokeratin expression and shape. Zedda M, et al. **Anat Histol Embryol** 1996 Dec;25(4):257–62

Comparative morphology of the pectinate ligaments of domestic mammals, as observed under the dissecting microscope and the scanning electron microscope. Simones P, et al. **J Vet Med Sci** 1996 Oct;58(10):977–82

BLOOD

Rapid analysis of four bilirubins in domestic animal sera using high–performance liquid chromatography. Mizobe M, et al. **J Vet Med Sci** 1996 Jun;58(6):495–9

GENETICS

12th European Colloquium on Cytogenetics of Domestic Animals. Zaragoza, Spain, June 25–28, 1996. Abstracts. **Cytogenet Cell Genet** 1996;74(3):227–44

Gender preselection in mammals: an overview. Johnson LA. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep; 103(8–9):288–91 (19 ref.)

Modern genome research and DNA diagnostics in domestic animals in the light of classical breeding techniques. Buitkamp J, et al. **Electrophoresis** 1996 Jan;17(1):1–11 (111 ref.)

MHC studies in domestic animals. Ellis SA. **Eur J Immunogenet** 1994 Jun;21(3):209–15 (46 ref.)

Livestock genomics comes of age. Georges M, et al. **Genome Res** 1996 Oct;6(10):907–21 (89 ref.)

Primed in situ labeling (PRINS) detection of the telomeric (CCCTAA) sequences in chromosomes of domestic animals. Gu F, et al. **Mamm Genome** 1996 Mar;7(3):231–2

[Studies on theory and models of systemic conservation of animal and poultry genetic resources. I. Theory analysis of systemic conservation of animal and poultry genetic resources] Du L, et al. **I Chuan Hsueh Pao** 1995;22(2):91–6 (Eng. Abstr.) **(Chi)**

[Methods of production and perspectives for use of transgenic domestic animals] Espanion G, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep; 103(8–9):320–8 (147 ref.) (Eng. Abstr.) **(Ger)**

[Preservation of genetic variation in domestic animals using biotechnical methods] Falge R, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep; 103(8–9):336–40 (42 ref.) (Eng. Abstr.) **(Ger)**

[Analysis of gene effects on performance characteristics] Geldermann H. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):378–83 (16 ref.) (Eng. Abstr.) **(Ger)**

[Recent perceptions about chromosome pairing in meiosis] Nett P, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct; 103(10):375–7 (Eng. Abstr.) **(Ger)**

[Comparative analysis of morphologic traits in Mediterranean and Chinese chicken breeds. The problem of the origin of the domestic chicken] Moiseeva IG, et al. **Genetika** 1996 Nov;32(11):1553–61 (Eng. Abstr.) **(Rus)**

[Effect of domestication of the silver fox on the main enzymes of serotonin metabolism and serotonin receptors] Popova NK, et al. **Genetika** 1997 Mar;33(3):370–4 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Plasma thyroxine concentrations in farmed ostriches in relation to age, body weight, and growth hormone. Dawson A, et al. **Gen Comp Endocrinol** 1996 Sep; 103(3):308–15

IMMUNOLOGY

Dog allergy: understanding our 'best friend'? Tubiolo VC, et al. **Clin Exp Allergy** 1997 Apr;27(4):354–7 (44 ref.)

Serological examination of human and animal sera from six countries of three continents for the presence of rickettsial antibodies. Kováčová E, et al. **Eur J Epidemiol** 1996 Feb; 12(1):85–9

Regulation of metabolism and growth during immune challenge: an overview of cytokine function. Spurlock ME. **J Anim Sci** 1997 Jul;75(7):1773–83 (90 ref.)

The immunology of domestic animals: its present and future. Charley B. **Vet Immunol Immunopathol** 1996 Nov; 54(1–4):3–6

METABOLISM

Basket and basal–duct cells in domestic animals: different cytokeratin expression and shape. Zedda M, et al. **Anat Histol Embryol** 1996 Dec;25(4):257–62

Residue avoidance after topical application of veterinary drugs and parasiticides. Baynes RE, et al. **J Am Vet Med Assoc** 1997 May 1;210(9):1288–9 (2 ref.)

Limits and limitations to nitrogen use in farm animals. Oldham JD, et al. **Proc Nutr Soc** 1997 Jul;56(2):525–34 (40 ref.)

Use of fresh and cryopreserved hepatocytes to study the metabolism of pesticides in food–producing animals and rats. Salmon F, et al. **Xenobiotica** 1996 Aug;26(8):803–11

MICROBIOLOGY

Vancomycin–resistant enterococci from nosocomial, community, and animal sources in the United States. Coque TM, et al. **Antimicrob Agents Chemother** 1996 Nov; 40(11):2605–9

Presence of vancomycin–resistant enterococci in farm and pet animals. Devriese LA, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2285–7

Clostridial enteric diseases of domestic animals. Songer JG. **Clin Microbiol Rev** 1996 Apr;9(2):216–34 (450 ref.)

Prevalence and varieties of Helicobacter species in dogs from random sources and pet dogs: animal and public health implications. Eaton KA, et al. **J Clin Microbiol** 1996 Dec; 34(12):3165–70

Mycobacterium genavense infections in pet animals. Kiehn TE, et al. **J Clin Microbiol** 1996 Jul;34(7):1840–2

Vancomycin–resistant enterococci in cats and dogs [letter] van Belkun A, et al. **Lancet** 1996 Oct 12;348(9033):1038–9

PARASITOLOGY

Novel approaches to the control of helminth parasites of livestock. Proceedings of an international conference. Armidale, New South Wales, 18–21 April 1995. **Int J Parasitol** 1996 Aug–Sep;26(8–9):797–1007

Prospects for integration of novel parasite control options into grazing systems. Barger IA. **Int J Parasitol** 1996 Aug–Sep;26(8–9):1001–7 (23 ref.)

Vaccination against cestode parasites. Lightowlers MW. **Int J Parasitol** 1996 Aug–Sep;26(8–9):819–24 (27 ref.)

The prospects for biological control of the free–living stages of nematode parasites of livestock. Waller PJ, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):915–25 (81 ref.)

Fasciola infection in guinea–pigs in the Peruvian highlands. Gamarra RG. **Trop Anim Health Prod** 1996 May; 28(2):143–4

Survey on the distribution of ticks of domestic animals in the eastern zone of Ethiopia. Tafesse B. **Trop Anim Health Prod** 1996 May;28(2):145–6

Integrated control of tropical animal parasitoses. Uilenberg G. **Trop Anim Health Prod** 1996 Nov;28(4):257–65 (17 ref.)

Wildlife parasites: lessons for parasite control in livestock. Malan FS, et al. **Vet Parasitol** 1997 Jul 31;71(2–3):137–53 (69 ref.)

Giardia and Cryptosporidium in Canadian farm animals. Olson ME, et al. **Vet Parasitol** 1997 Mar;68(4):375–81

Ticks of domestic animals in the Macedonia region of Greece. Papadopoulos B, et al. **Vet Parasitol** 1996 May; 63(1–2):25–40

Prevalence of sarcocysts in livestock of northwest Ethiopia. Woldemeskel M, et al. **Zentralbl Veterinarmed [B]** 1996 Mar;43(1):55–8

[Presence in Cuba of screw worms (Cochliomyia hominivorax) in the livestock] Rodriguez Diego JG, et al. **Rev Elev Med Vet Pays Trop** 1996;49(3):223–5 (Eng. Abstr.)

(Fre)

[Integrated control of tropical parasitic diseases in animals] Uilenberg G. **Rev Elev Med Vet Pays Trop** 1996;49(2):124–9 (17 ref.) (Eng. Abstr.) **(Fre)**

[Development of resistance to antiparasitic agents in parasites pathogenic to animals] Daugschies A. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):260–3 (52 ref.) (Eng. Abstr.) **(Ger)**

[Parasite control and its effect on the environment] Liebisch A. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul; 103(7):268–73 (20 ref.) (Eng. Abstr.) **(Ger)**

[Vaccines against parasitic diseases of domestic animals] Eckert J, et al. **Tierarztl Prax** 1996 Aug;24(4):322–9 (50 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Behavioral problems of farmed ostriches in Canada. Samson J. **Can Vet J** 1996 Jul;37(7):412–4 (6 ref.)

Skeptical thinking for food animal veterinarians. Humble JA. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1730–2

Objectively measured boar sperm motility parameters correlate with the outcomes of on-farm inseminations: results of two fertility trials. Holt C, et al. **J Androl** 1997 May–Jun;18(3):312–23

Assessing sensory capacity of animals using operant technology. Arave CW. **J Anim Sci** 1996 Aug; 74(8):1996–2009 (65 ref.)

Enantioselective behaviour of drugs used in domestic animals: a review. Landoni MF, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):1–16 (114 ref.)

In-village studies of the use of work oxen in central Mali. Bartholomew PW, et al. **Trop Anim Health Prod** 1995 Nov; 27(4):241–8

Improving feeding management and work performance of Mashona oxen through strategic supplementation with cobsheath-groundnut stover. Francis J, et al. **Trop Anim Health Prod** 1995 Nov;27(4):249–57

Use of donkeys and their draught performance in smallholder farming in Zimbabwe. Hagmann J, et al. **Trop Anim Health Prod** 1995 Nov;27(4):231–9

[Analysis of gene effects on performance characteristics] Geldermann H. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):378–83 (16 ref.) (Eng. Abstr.) **(Ger)**

[The use of biotechnology in animal breeding] Groeneveld E, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep; 103(8–9):298–302 (9 ref.) (Eng. Abstr.) **(Ger)**

[The problem of breeding for fertility] Jansen S, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Oct;103(10):414–6 (14 ref.) (Eng. Abstr.) **(Ger)**

[Production of monozygotic multiple offspring in agricultural domestic animals] Reichelt B, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep; 103(8–9):340–8 (72 ref.) (Eng. Abstr.) **(Ger)**

[Anesthesia in domestic animals (small mammals, psittacines and reptiles)] Kuntze A. **Tierarztl Prax** 1996 Dec; 24(6):600–3 (24 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

On the temporal onset of postmortem animal scavenging. "Motivation" of the animal. Rothschild MA, et al. **Forensic Sci Int** 1997 Sep 19;89(1–2):57–64

Using aversion learning techniques to assess the mental state, suffering, and welfare of farm animals. Rushen J. **J Anim Sci** 1996 Aug;74(8):1990–5 (35 ref.)

Social dynamics and behavior problems in multiple-dog households. Juarbe-Díaz SV. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):497–514 (11 ref.)

Behavior problems of pet pigs. Tynes VV. **Vet Clin North Am Small Anim Pract** 1997 May; 27(3):667–90 (35 ref.)

Freedom from boredom [letter] [see comments] Ryder RD. **Vet Rec** 1996 Jun 8;138(23):576. Comment in: Vet Rec 1996 Jun 29;138(26):651.

VIROLOGY

Paget's disease of bone and unvaccinated dogs. Khan SA, et al. **Bone** 1996 Jul;19(1):47–50

Sero-positivity of domestic animals against Japanese encephalitis in Bareilly area, U.P. Mall MP, et al. **J Commun Dis** 1995 Dec;27(4):242–6

ANIMALS, LABORATORY

see related
ANIMAL TESTING ALTERNATIVES
LABORATORY ANIMAL SCIENCE

Human leukocyte antigens in occupational allergy: a possible protective effect of HLA-B16 in laboratory animal allergy. Sjöstedt L, et al. **Am J Ind Med** 1996 Oct;30(4):415–20

The role of veterinarians on animal experimentation ethics committees. Australian Veterinarians Associated with Scientific Establishments. Scott LR, et al. **Aust Vet J** 1996 Oct;74(4):309–11

Territorial aggression, body weight, carbohydrate metabolism and testosterone levels of wild rats maintained in laboratory colonies. Lucion AB, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1657–62

Reduction of exposure to laboratory animal allergens in the workplace. Gordon S, et al. **Clin Exp Allergy** 1997 Jul; 27(7):744–51

Exposure of laboratory animal workers to airborne rat and mouse urinary allergens. Hollander A, et al. **Clin Exp Allergy** 1997 Jun;27(6):617–26

A comparative study of whole-blood platelet aggregation in laboratory animals: its species differences and comparison with turbidimetric method. Kurata M, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1995 Nov;112(3):359–65

The use of animals in research and ethical considerations [editorial; comment] Lore W. **East Afr Med J** 1996 Nov; 73(11):697–8. Comment on: East Afr Med J 1996 Nov;73(11):699–702.

Alternatives in animal testing. **Environ Health Perspect** 1996 Mar;104(3):250–2

How to organize animal research in radiology. Hamm B, et al. **Eur Radiol** 1996;6 Suppl 1:S19–22

The ethics of animal research. A special lecture to the Japanese Association of Laboratory Animal Science 6th June 1995. Matfield M. **Exp Anim** 1996 Jul;45(3):209–15

Health care for research animals is essential and affordable. Jacoby RO, et al. **FASEB J** 1997 Jul;11(8):609–14 (6 ref.)

From teachers to toxicologists: answering the tough questions about animal research. Olson HM, et al. **Fundam Appl Toxicol** 1996 Nov;34(1):5–14

Laboratory animals for artificial organ evaluation. Giardino R, et al. **Int J Artif Organs** 1997 Feb;20(2):76–80 (12 ref.)

Animal handling [letter; comment] Aguirre GD. **Invest Ophthalmol Vis Sci** 1997 May;38(6):1053. Comment on: Invest Ophthalmol Vis Sci 1996 Oct;37(11):2219–27.

Morally relevant differences between animals and human beings justifying the use of animals in biomedical research [see comments] Dennis JU. **J Am Vet Med Assoc** 1997 Mar 1;210(5):612–8. Comment in: J Am Vet Med Assoc 1997 Apr 15;210(8):1100; discussion 1100–1. Comment in: J Am Vet Med Assoc 1997 Apr 15;210(8):1100–1.

More letters on article about nonhuman animal research [letter; comment] Harvey SB. **J Am Vet Med Assoc** 1996 Aug 15;209(4):714–5. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

Dialogue on use of animals in research continues [letter; comment] Klinger MM. **J Am Vet Med Assoc** 1996 Sep 15;209(6):1060. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

More letters on article about nonhuman animal research [letter; comment] Kraus AL. **J Am Vet Med Assoc** 1996 Aug 15;209(4):715–6; discussion 716–7. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

More letters on article about nonhuman animal research [letter; comment] McPherson C. **J Am Vet Med Assoc** 1996 Aug 15;209(4):714; discussion 716–7. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

More letters on article about nonhuman animal research [letter; comment] Silverman J. **J Am Vet Med Assoc** 1996 Aug 15;209(4):713–4; discussion 716–7. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

More letters on article about nonhuman animal research [letter; comment] Ward GM. **J Am Vet Med Assoc** 1996 Aug 15;209(4):713; discussion 716–7. Comment on: J Am Vet Med Assoc 1996 Jun 1;208(11):1798–801.

The contributions of animal research to care of the burn victim: the development of topical antimicrobials. Peck MD, et al. **J Burn Care Rehabil** 1996 Jan–Feb; 17(1):27A–8A

Use of mice in studies of brain microcirculation [letter] Rosenblum WI. **J Cereb Blood Flow Metab** 1996 Jul; 16(4):752–3

An investigation of leptospirosis in a laboratory animal house. Natrajaseenivasan K, et al. **J Commun Dis** 1996 Sep; 28(3):153–7

Some considerations for the development of diets for mature rodents used in long-term investigations. McDonald RB. **J Nutr** 1997 May;127(5 Suppl):847S–850S (33 ref.)

Working with laboratory animals: general principles and practical considerations. Wright KC. **J Vasc Interv Radiol** 1997 May–Jun;8(3):363–73 (48 ref.)

Preferences of mice and rats for types of bedding material. Blom HJ, et al. **Lab Anim** 1996 Jul;30(3):234–44

Recommendations for euthanasia of experimental animals: Part 1. DGXI of the European Commission. Close B, et al. **Lab Anim** 1996 Oct;30(4):293–316

Recommendations for euthanasia of experimental animals: Part 2. DGXT of the European Commission. Close B, et al. **Lab Anim** 1997 Jan;31(1):1–32

Preferences of individually housed TO strain laboratory mice for loose substrate or tubes for sleeping. Sherwin CM. **Lab Anim** 1996 Jul;30(3):245–51

Mousepox outbreak in a laboratory mouse colony. Dick EJ Jr, et al. **Lab Anim Sci** 1996 Dec;46(6):602–11

High prevalence of gastric trichobezoars (hair balls) in Wistar-Kyoto rats fed a semi-purified diet. Krugner-Higby L, et al. **Lab Anim Sci** 1996 Dec;46(6):635–9

Reduced use of laboratory animals in research institute [letter] Guaitani A, et al. **Lancet** 1997 May 24; 349(9064):1557–8

Fat rats and carcinogenesis screening. Festing MF. **Nature** 1997 Jul 24;388(6640):321–2

NIH urged to address chimp care 'crisis' [news] Macilwain C. **Nature** 1997 Jul 17;388(6639):218

Fat (and thin) rats distort results [letter] Turturro A, et al. **Nature** 1997 Sep 25;389(6649):326

Laboratory animal science, welfare and ethics in pharmacology and toxicology. Svendsen O, et al. **Pharmacol Toxicol** 1997 Jan;80(1):3–5 (14 ref.)

Revised Guide for the Care and Use of Laboratory Animals available. American Physiological Society. Bayne K. **Physiologist** 1996 Aug;39(4):199, 208–11

Animal research is wasteful and misleading. Barnard ND, et al. **Sci Am** 1997 Feb;276(2):80–2

Animal research is vital to medicine. Botting JH, et al. **Sci Am** 1997 Feb;276(2):83–5

Trends in animal research. Mukerjee M. **Sci Am** 1997 Feb; 276(2):86–93

The benefits and ethics of animal research. Rowan AN. **Sci Am** 1997 Feb;276(2):79

The costs of animal research: origins and options. Cork LC, et al. **Science** 1997 May 2;276(5313):758–9

Chimp retirement plan proposed [news] Roush W. **Science** 1997 Jul 25;277(5325):471

[Science needs experimental animals] Kunstyr I. **Tierarztl Prax** 1996 Dec;24(6):532–6 (7 ref.) (Eng. Abstr.) **(Ger)**

[Animal experimentation—is it defensible?] Christoffersen SA. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1068–9 **(Nor)**

[Laboratory animals as a cause of occupational allergy] Krakowiak A, et al. **Med Pr** 1996;47(5):523–31 (55 ref.) (Eng. Abstr.) **(Pol)**

[Quantitative patterns in the clinical manifestations of radiation sickness in large laboratory animals exposed to radiation at superlethal doses. The quantitative patterns in the manifestations of radiation sickness in monkeys] Darenskaia NG, et al. **Radiats Biol Radioecol** 1997 May–Jun;37(3):413–22 (Eng. Abstr.) **(Rus)**

[Quantitative patterns in the clinical manifestations of radiation sickness in large laboratory animals exposed to radiation at superlethal doses. The quantitative patterns in the manifestations of radiation sickness in dogs] Darenskaia NG, et al. **Radiats Biol Radioecol** 1997 May–Jun; 37(3):423–30 (Eng. Abstr.) **(Rus)**

ABNORMALITIES

Terminology of developmental abnormalities in common laboratory mammals (version 1). Wise LD, et al. **Teratology** 1997 Apr;55(4):249–92

ANATOMY & HISTOLOGY

Fluoride-induced lesions in the teeth of the short-tailed field vole (Microtus agrestis): a description of the dental pathology. Boulton IC, et al. **J Morphol** 1997 May; 232(2):155–67

Comparative anatomy of the cranial vena cava in laboratory animals. O'Farrell L, et al. **Lab Anim Sci** 1996 Aug; 46(4):448–9

Laboratory animal pathology—emphasis on an area of relevance to the toxicologic pathologist [editorial; comment] Maronpot RR. **Toxicol Pathol** 1996 Jul–Aug; 24(4):506. Comment on: Toxicol Pathol 1996 Jul–Aug;24(4):502–4.

[Dynamometric equipment for the study of mechanical properties of hollow organs of small laboratory animals] Tsibulevskii AIu, et al. **Biull Eksp Biol Med** 1997 Apr; 123(4):473–5 **(Rus)**

BLOOD

Blood sampled in rats from right ventricle may not always be truly representative of a mixed venous sample. Guitart R, et al. **Lab Anim** 1996 Jul;30(3):273–8

GENETICS

Gender preselection in mammals: an overview. Johnson LA. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep; 103(8–9):288–91 (19 ref.)

GROWTH & DEVELOPMENT

Effects of the use of filtered microisolator tops on cage microenvironment and growth rate of mice. Baer LA, et al. **Lab Anim Sci** 1997 Jun;47(3):327–9

[Conditions for the laboratory survival of Haemagogus janthinomys dyar, 1921 (Diptera:Culicidae)] Mondet B. **Rev Soc Bras Med Trop** 1996 Jan–Feb;30(1):11–4 (Eng. Abstr.) **(Por)**

IMMUNOLOGY

Respiratory allergy to rats: exposure-response relationships in laboratory animal workers. Hollander A, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):562–7

Occupational sensitization to laboratory animals [editorial] Gordon S. **Clin Exp Allergy** 1997 Jun;27(6):603–5

Cat and dog allergy and total IgE as risk factors of laboratory animal allergy. Hollander A, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):545–54

METABOLISM

Assessment of the accuracy of quantitative urine collection in mink (Mustela vison) using osmotic pumps for continuous release of p-amino-hippuric acid and inulin. Wamberg S, et al. **Lab Anim** 1996 Jul;30(3):267–72

MICROBIOLOGY

Survey for Pneumocystis carinii infection of wild-born and laboratory-bred monkeys by indirect immunofluorescence

ANIMALS, LABORATORY

and cyst-staining methods. Fujita M, et al. **Jpn J Med Sci Biol** 1996 Jun;49(3):113–20

Fungus Paecilomyces: a new agent in laboratory animals. Kunstýř I, et al. **Lab Anim** 1997 Jan;31(1):45–51

Comparison of the proportions of oral bacterial species in BALB/c mice from different suppliers. Rodrigue L, et al. **Lab Anim** 1996 Apr;30(2):108–13

Survey of dermatophytes isolated from the coats of laboratory animals in Italy. Papini R, et al. **Lab Anim Sci** 1997 Feb;47(1):75–7

PARASITOLOGY

Cryptosporidiosis in mice in Argentina. Fernández PE, et al. **Lab Anim Sci** 1996 Dec;46(6):685–6 (22 ref.)

Infectivity of Cryptosporidium muris directly isolated from the murine stomach for various laboratory animals. Aydin Y, et al. **Vet Parasitol** 1996 Nov 15;66(3–4):257–62

PHYSIOLOGY

FELASA recommendations for the health monitoring of mouse, rat, hamster, gerbil, guinea pig and rabbit experimental units. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Animal Health accepted by the FELASA Board of Management, November 1995. Rehbinder C, et al. **Lab Anim** 1996 Jul;30(3):193–208

Training a large number of laboratory mice using running wheels and analyzing running behavior by use of a computer-assisted system. Lapveteläinen T, et al. **Lab Anim Sci** 1997 Apr;47(2):172–9

The Göttingen minipig in pharmacology and toxicology. Bollen P, et al. **Pharmacol Toxicol** 1997;80 Suppl 2:3–4 (14 ref.)

[Devices for measuring the temperature of laboratory animals] Molodavkin GM. **Eksp Klin Farmakol** 1996 Sep–Oct;59(5):65–7 (Eng. Abstr.) **(Rus)**

[Quantitative patterns in the clinical manifestations of radiation sickness in large laboratory animals exposed to radiation at superlethal doses. Changes in the regulation of cardiovascular system function] Darenskaia NG, et al. **Radiats Biol Radioecol** 1997 May–Jun;37(3):431–7 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Happy animals make good science. Poole T. **Lab Anim** 1997 Apr;31(2):116–24 (54 ref.)

Observations on the prevalence of nest-building in non-breeding TO strain mice and their use of two nesting materials. Sherwin CM. **Lab Anim** 1997 Apr;31(2):125–32

Preferences for nesting material as environmental enrichment for laboratory mice. Van de Weerd HA, et al. **Lab Anim** 1997 Apr;31(2):133–43

VIROLOGY

Ebola bar creates monkey shortage [news] Nathan R. **Nature** 1996 Aug 29;382(6594):744

ANIMALS, NEWBORN

Effect of neonatal thyroid hormone alterations in CNS ethanol sensitivity in adult LS and SS mice. Segall MA, et al. **Alcohol** 1996 Nov–Dec;13(6):559–67

Lenten cell: ultrastructure, absorptive properties, and enzyme expression of a novel type of cell in the newborn and suckling pig intestinal epithelium. Heath JP, et al. **Anat Rec** 1996 Jan;244(1):95–104

Providencia rettgeri meningitis in hatchling saltwater crocodiles (Crocodylus porosus). Ladds PW, et al. **Aust Vet J** 1996 Nov;74(5):397–8

Interdigital subcutaneous emphysema ("bubble foot") in Crocodylus porosus hatchlings. Turton JA, et al. **Aust Vet J** 1996 Nov;74(5):395–7

Neonatal multifocal encephalomalacia and other lesions in the brains of Georgia chicks: 1991–95. Goodwin MA, et al. **Avian Dis** 1996 Oct–Dec;40(4):894–9

Enhancement of central noradrenaline release during development alters the packing density of neurons in the rat occipital cortex. Ruiz S, et al. **Biol Neonate** 1997; 71(2):119–25

A rat model for hypoxic-ischemic brain damage in very premature infants. Sheldon RA, et al. **Biol Neonate** 1996; 69(5):327–41

Whole body lean mass is altered by dexamethasone treatment through reductions in protein and energy utilization in piglets. Weiler HA, et al. **Biol Neonate** 1997;71(1):53–9

Novel expression of functional luteinizing hormone/chorionic gonadotropin receptors in cultured glial cells from neonatal rat brains. AL-Hader AA, et al. **Biol Reprod** 1997 Feb;56(2):501–7

Development in vitro of mouse oocytes from primordial follicles. Eppig JJ, et al. **Biol Reprod** 1996 Jan;54(1):197–207

Neonatal exposure of rats to recombinant follicle stimulating hormone increases adult Sertoli and spermatogenic cell numbers. Meachem SJ, et al. **Biol Reprod** 1996 Jan; 54(1):36–44

Ontogeny of gene expression in the gonadotroph of the developing female rat. Wilson ME, et al. **Biol Reprod** 1997 Feb;56(2):563–8

Neonatal hypothyroidism alters the pattern of prostatic growth and differentiation, as well as plasminogen activator and metalloprotease expression, in the rat. Wilson MJ, et al. **Biol Reprod** 1997 Feb;56(2):475–82

Experimental hepatitis in neonatally thymectomized mice: transfer of disease and the role of T cells. Kamiyasu M, et al. **Clin Immunol Immunopathol** 1997 Jun;83(3):302–9

Comparative effects of age and chronic low-level lead exposure on calcium mobilization from intracellular calcium stores in brain samples obtained from the neonatal and the adult rats. Singh AK, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 May;117(1):89–98

Developmental plasticity in the D1- and D2-mediation of motor behavior in rats depleted of dopamine as neonates. Byrnes EM, et al. **Dev Psychobiol** 1996 Dec;29(8):653–66

Evidence that endogenous corticotropin-releasing factor suppresses behavioral responses of guinea pig pups to brief isolation in novel surroundings. Hennessy MB, et al. **Dev Psychobiol** 1997 Jul;31(1):39–47

Animal models for the study of perinatal hypoxic-ischemic encephalopathy: a critical analysis. Roohey T, et al. **Early Hum Dev** 1997 Jan 20;47(2):115–46

Thyroid hormones regulate the onset of osmotic activity of rat liver mitochondria after birth. Almeida A, et al. **Endocrinology** 1997 Feb;138(2):764–70

Pre- and postnatal low protein diet affect pancreatic islet blood flow and insulin release in adult rats. Iglésias-Barreira V, et al. **Endocrinology** 1996 Sep; 137(9):3797–801

Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes. Prins GS, et al. **Endocrinology** 1997 May;138(5):1801–9

Neuronal mitochondrial morphology and transmembrane potential are severely altered by hypothyroidism during rat brain development. Vega-Núñez E, et al. **Endocrinology** 1997 Sep;138(9):3771–8

Foal diarrhoea between 1991 and 1994 in the United Kingdom associated with Clostridium perfringens, rotavirus, Strongyloides westeri and Cryptosporidium spp. Netherwood T, et al. **Epidemiol Infect** 1996 Oct; 117(2):375–83

Equine viral arteritis in newborn foals: clinical, pathological, serological, microbiological and immunohistochemical observations. Del Piero F, et al. **Equine Vet J** 1997 May; 29(3):178–85

Proceedings of the 1st International Conference on Veterinary Perinatology. Orlando, Florida, 17–18 January 1988. **Equine Vet J Suppl** 1988 Sep;(5):1–65

Equine clinical neonatology in the USA: past, present and future. Koterba AM, et al. **Equine Vet J Suppl** 1988 Sep; (5):6–10 (22 ref.)

Inhaled nitric oxide increases survival rates in newborn rats with congenital diaphragmatic hernia. Kluth D, et al. **Eur J Pediatr Surg** 1997 Apr;7(2):90–2

Sequential treatment with rmIL-3 or simultaneous treatment with rmIL-3 or rhIL-11 with thrombopoietin (TPO) fails to enhance in vivo neonatal rat thrombocytopoiesis. van de Ven C, et al. **Exp Hematol** 1997 Aug;25(9):1005–12

Effects of insulin-like growth factor I (IGF-I) on the porto-arterial concentration differences of amino acids and glucose: a comparison between oral and intraperitoneal administration in the newborn piglet. Fhölenhog K, et al. **Horm Metab Res** 1996 Nov;28(11):582–7

Intracarotid histamine administration results in dose-dependent vasogenic brain oedema formation in new-born pigs. Németh L, et al. **Inflamm Res** 1997 Mar; 46 Suppl 1:S45–6

Milk replacers with or without animal plasma for dairy calves. Quigley JD 3rd, et al. **J Dairy Sci** 1996 Oct; 79(10):1881–84

Saturated but not mono-unsaturated fatty acids induce apoptotic cell death in neonatal rat ventricular myocytes. de Vries JE, et al. **J Lipid Res** 1997 Jul;38(7):1384–94

The relationship between developing oligodendrocyte units and maturing axons during myelinogenesis in the anterior medullary velum of neonatal rats. Butt AM, et al. **J Neurocytol** 1997 May;26(5):327–38

Melatonin inhibits GnRH-induced increase of cFOS immunoreactivity in neonatal rat pituitary. Sumova A, et al. **J Neuroendocrinol** 1997 Feb;9(2):135–9

Toxicity of sucrose and fructose for neonatal pigs (Becker et al. 1954). Baker DH. **J Nutr** 1997 May;127(5 Suppl):1049S–1050S

The platelet-activating factor receptor antagonist WEB 2170 prevents neonatal necrotizing enterocolitis in rats. Caplan MS, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar; 24(3):296–301

Effect of thyroxine on pancreatic digestive enzymes and ornithine decarboxylase gene expression in neonatal rats. Lin CH, et al. **J Pediatr Gastroenterol Nutr** 1997 Jan; 24(1):18–24

Prognosis for neonatal foals in an intensive care unit. Furr M, et al. **J Vet Intern Med** 1997 May–Jun;11(3):183–8

Developmental alterations in 5-hydroxytryptamine concentration and turnover after treatment of neonatal rats with 5,7-dihydroxytryptamine. Mercugliano M, et al. **Neurobiol Learn Mem** 1996 Mar;65(2):163–76

Olfactory conditioning impairment following posttraining NMDA receptor blockade in neonatal rats. Weldon DA, et al. **Neurobiol Learn Mem** 1997 Jan;67(1):34–42

Inhibition of intermediate-term memory following passive avoidance training in neonate chicks by a presynaptic cholinergic blocker. Zhao WQ, et al. **Neurobiol Learn Mem** 1997 May;67(3):207–13

Alterations in the turnover rate of dopamine D1 but not D2 receptors in the adult rat neostriatum after a neonatal dopamine denervation. Dewar KM, et al. **Neurochem Int** 1997 Jun;30(6):613–21

GABAA receptor-mediated responses in the ventromedial nucleus of the hypothalamus of female and male neonatal rats. Smith ST, et al. **Neuroendocrinology** 1996 Aug; 64(2):103–13

Effect of acetyl-L-carnitine on hyperactivity and spatial memory deficits of rats exposed to neonatal anoxia. Dell'Anna E, et al. **Neurosci Lett** 1997 Feb 28;223(3):201–5

The effects of treatment with indomethacin on the cerebral vasculature of newborn piglets before and during hemorrhagic hypotension. Hayden JE, et al. **Pediatr Res** 1997 Jan;41(1):78–82

Sulfur amino acid requirement and cystine replacement value of broiler chicks during the period three to six weeks posthatching. Baker DH, et al. **Poult Sci** 1996 Jun; 75(6):737–42

Influence of male broiler breeder dietary energy intake on reproduction and progeny growth. Bramwell RK, et al. **Poult Sci** 1996 Jun;75(6):767–75

Long-term effects of fatty acids on cell viability and gene expression of neonatal cardiac myocytes. Van Bilsen M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):39–45 (37 ref.)

Insulin receptors: the binding capacity and localization in the digestive tract during the rabbits neonatal period. Nowak JW, et al. **Reprod Nutr Dev** 1996;36(5):513–21

Perinatal nutrition enriched with omega-3 polyunsaturated fatty acids attenuates endotoxic shock in newborn rats. Farolan LR, et al. **Shock** 1996 Oct;6(4):263–6

Carcinogenicity study of outdoor airborne particulate matter in newborn male NMRI mice. Heussen GA, et al. **Toxicol Lett** 1996 Nov;88(1–3):23–8

Role of neonatal and maternal risk factors in the faecal soiling of lambs. French NP, et al. **Vet Rec** 1996 Nov 9; 139(19):460–5

Stillbirth/perinatal weak calf syndrome: radiographic examination for growth retardation lines. Smyth JA, et al. **Vet Rec** 1996 Dec 14;139(24):599–600

Diffuser contact lenses retard axial elongation in infant rhesus monkeys. Bradley DV, et al. **Vision Res** 1996 Feb; 36(4):509–14

[Preparation of a realistic calf model for obstetrical instruction] Frey R, et al. **Tierarztl Prax** 1996 Dec; 24(6):542–8 (Eng. Abstr.) **(Ger)**

[Extracorporeal membrane oxygenation (ECMO). II. The development of an experimental model in newborn lambs] Valls i Soler A, et al. **An Esp Pediatr** 1997 Mar;46(3):266–71 (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Rectovesical fistula: a possible cause of postnatal lethality in F1 Dh/+ male mice between DDD female and DH (Dh/+) male. Suto J, et al. **Exp Anim** 1996 Oct; 45(4):399–402

ANATOMY & HISTOLOGY

Neuroepithelial bodies in relatively mature lungs: an investigation in prenatal and newborn lambs. van Lommel A, et al. **Acta Anat (Basel)** 1995;153(3):203–9

Hyperplasia and hypertrophy of chicken cardiac myocytes during posthatching development. Li F, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R518–26

Ultrastructure of pre- and postcolostral enterocytes of the newborn calf. Kaup FJ, et al. **Anat Histol Embryol** 1996 Dec;25(4):249–55

Anatomy of the ductus venosus in neonatal dogs (Canis familiaris). Tisdall PI, et al. **Anat Histol Embryol** 1997 Mar; 26(1):35–8

Dissociated spatial patterning of gap junctions and cell adhesion junctions during postnatal differentiation of ventricular myocardium. Angst BD, et al. **Circ Res** 1997 Jan;80(1):88–94

Newborn organ weight and spontaneous hypertension: recombinant inbred strain study. Dobešová Z, et al. **Clin Exp Hypertens** 1997 May;19(4):403–15

Field emission SEM, conventional TEM and HVTEM study of submandibular gland in prenatal and postnatal aging mouse. Watanabe I, et al. **Histol Histopathol** 1997 Apr; 12(2):447–57

Anatomy of medullary and peripheral autonomic neurons innervating the neonatal porcine heart. Hopkins DA, et al. **J Auton Nerv Syst** 1997 Jun 6;64(2–3):74–84

Primary sensory and forebrain motor systems in the newborn brain are preferentially damaged by hypoxia-ischemia. Martin LJ, et al. **J Comp Neurol** 1997 Jan 13;377(2):262–85

Contractile properties and myosin heavy chain composition of newborn rat soleus muscles at different stages of postnatal development. Picquet F, et al. **J Muscle Res Cell Motil** 1997 Feb;18(1):71–9

Neuronal progenitor cells derived from the anterior subventricular zone of the neonatal rat forebrain continue to proliferate in vitro and express a neuronal phenotype. Luskin MB, et al. **Mol Cell Neurosci** 1997;8(5):351–66

Magnetic resonance imaging of the brain of normal neonatal foals. Chaffin MK, et al. **Vet Radiol Ultrasound** 1997 Mar-Apr;38(2):102–11

Laparoscopic abdominal anatomy of foals positioned in dorsal

recumbency. Bouré L, et al. **Vet Surg** 1997 Jan–Feb; 26(1):1–6

[Intraepithelial nerve endings in the lingual marginal papillae of newborn piglets] Sommer U, et al. **Anat Histol Embryol** 1997 Jun;26(2):121–6 (Eng. Abstr.) **(Ger)**

BLOOD

Alteration of plasma folates in gestating sows and newborn piglets. Natsuhori M, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):R99–104

Increased spillover and reduced clearance both contribute to rise in plasma catecholamines after birth in lambs. Smolich JJ, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):H668–77

Insulin–stimulated amino acid utilization during glucose and amino acid clamps decreases with development. Wray–Cahen D, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):E305–14

Effects of diet enrichment with glucose and casein on blood cortisol concentration of calves in early postnatal period. Friedrich M. **Arch Vet Pol** 1995;35(1–2):117–25

Effect of chronic erythropoietin administration on plasma iron in newborn lambs. Peters C, et al. **Biol Neonate** 1996; 70(4):218–28

A murine model for human cord blood transplantation: near–term fetal and neonatal peripheral blood cells can achieve long–term bone marrow engraftment in sublethally irradiated adult recipients. Scaradavou A, et al. **Blood** 1997 Feb 1;89(3):1089–99

Influence of exogenous and endogenous acth on adrenal cortex activity in calves during the early postnatal period. Friedrich M. **Br Vet J** 1995 May;152(3):315–20

Use of a clinical sepsis score for predicting bacteremia in neonatal dairy calves on a calf rearing farm. Fecteau G, et al. **Can Vet J** 1997 Feb;38(2):101–4

Bacteriological culture of blood from critically ill neonatal calves. Fecteau G, et al. **Can Vet J** 1997 Feb;38(2):95–100

Effect of dexamethasone on rat plasma platelet activating factor acetylhydrolase during the perinatal period. Contador M, et al. **Early Hum Dev** 1997 Jan 20;47(2):167–76

Regulation of aldosterone in the 7–day–old rat. Feuillan PP, et al. **Endocrinology** 1996 Sep;137(9):3992–8

Circulating immunoreactive beta endorphin concentrations in the perinatal foal. Dudan FE, et al. **Equine Vet J Suppl** 1988 Sep;(5):46–9

Parathyroid hormone–related protein in neonatal and reproductive goats determined by a sensitive time–resolved immunofluorometric assay [see comments] Rong H, et al. **Eur J Endocrinol** 1997 May;136(5):546–51. Comment in: Eur J Endocrinol 1997 May;136(5):465–6.

Endotoxin–challenges precocial neonates and iron changes. Tęgowska E, et al. **J Comp Physiol [B]** 1997 Apr; 167(3):193–6

Effect of exogenous somatotropin on hematological variables of lactating cows and their offspring. Eppard PJ, et al. **J Dairy Sci** 1997 Aug;80(8):1582–91

Blockade of the neonatal increase in testosterone by a GnRH antagonist: the free androgen index, reproductive capacity and postmortem findings in the male marmoset monkey. Lunn SF, et al. **J Endocrinol** 1997 Jul;154(1):125–31

Effects of breeder hen age and dietary fat on embryonic and neonatal broiler serum lipids and glucose. Latour MA, et al. **Poult Sci** 1996 Jun;75(6):695–701

Watery mouth disease in lambs: biochemical parameters before and after treatment. Scott PR, et al. **Vet Rec** 1996 Aug 3;139(5):117–8

Changes in the profile of liver enzymes in newborn calves induced by experimental, subclinical acidosis in pregnant cows and osmotic diarrhoea. Lechowski R. **Vet Res Commun** 1996;20(4):351–65

CEREBROSPINAL FLUID

Cerebrospinal fluid concentrations of glutamate and GABA during perinatal cerebral hypoxia–ischemia and seizures. Cataltepe O, et al. **Brain Res** 1996 Feb 19;709(2):326–30

GENETICS

Genetic and developmental influences on infant mouse ultrasonic calling. I. A diallel analysis of the calls of 3–day olds. Hahn ME, et al. **Behav Genet** 1997 Mar;27(2):133–43

Cloning of a cDNA encoding a novel sugar transporter expressed in the neonatal mouse hippocampus. Matsuo N, et al. **Biochem Biophys Res Commun** 1997 Sep 8; 238(1):126–9

GROWTH & DEVELOPMENT

The connective tissue compartment in the terminal region of the developing rat lung. An ultrastructural study. Wasowicz M, et al. **Acta Anat (Basel)** 1996;156(4):268–82

Orally administered IGF–I increases intestinal mucosal growth in formula–fed neonatal pigs. Burrin DG, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R1085–91

Development of REM and slow wave sleep in the rat. Frank MG, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1792–9

Ontogeny of apical membrane ion conductances and channel expression in cortical collecting duct cells. Huber SM, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F698–708

Role of apoptosis in development of the ascending thin limb of the loop of Henle in rat kidney. Kim J, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):F831–45

An analogue of cAMP mimics developmental change in neonatal rat ventricular myocyte sodium current kinetics. Lipka LJ, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H194–9

Enhanced reproductive responses to melatonin in juvenile Siberian hamsters. Prendergast BJ, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R1041–6

Regulation of alveolar formation by retinoic acid [editorial] Rannels DE. **Am J Physiol** 1996 Feb;270(2 Pt 1):L171

Cardiovascular, renal, and endocrine responses to graded volume expansion in lambs during maturation. Smith FG, et al. **Am J Physiol** 1996 May;270(5 Pt 2):H1718–25

Insulin–stimulated amino acid utilization during glucose and amino acid clamps decreases with development. Wray–Cahen D, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):E305–14

Dorsal root ganglion neuron development in chick and rat. Matsuda S, et al. **Anat Embryol (Berl)** 1996 May; 193(5):475–80

Distribution of the neural cell adhesion molecule (NCAM) during pre– and postnatal development of mouse incisors. Obara N, et al. **Anat Embryol (Berl)** 1997 Feb; 195(2):193–202

The vestibular primary afferents and the vestibulospinal projections in the developing and adult opossum, Monodelphis domestica. Pflieger JF, et al. **Anat Embryol (Berl)** 1996 Jul;194(1):75–88

Effects of caffeine on bone cells and bone development in fast–growing rats. Wink CS, et al. **Anat Rec** 1996 Sep; 246(1):30–8

Postnatal development of the blood vasculature in the rat adrenal gland: a scanning electron microscope study of microcorrosion casts. Tokunaga H. **Arch Histol Cytol** 1996 Oct;59(4):305–15

Influences of gender, development, pregnancy and ethanol consumption on the hematotoxicity of inhaled 10 ppm benzene. Corti M, et al. **Arch Toxicol** 1996;70(3–4):209–17

The effect of feeding piglets up to the 100th day of their life with peat preparation on their growth and physiological and biochemical indices. Fuchs B, et al. **Arch Vet Pol** 1995; 35(1–2):97–107

Rusa deer (Cervus timorensis russa) farming in New Caledonia: impact of different feed levels on herd breeding rate and performance of newborn fawns. Le Bel S, et al. **Aust Vet J** 1997 Mar;75(3):199–203

The effect of delays in feeding colostrum and the relationship between immunoglobulin concentration in the serum of neonatal calves and their rates of growth. Todd AG, et al. **Aust Vet J** 1995 Nov;72(11):415–7

Leukotriene synthesis by isolated perinatal ovine intrapulmonary vessels correlates with age–related changes in 5–lipoxygenase protein. Ibe BO, et al. **Biochem Mol Med** 1997 Jun;61(1):63–71

Effects of colostrum feeding on intestinal development in newborn pigs. Wang T, et al. **Biol Neonate** 1996; 70(6):339–48

Engraftment of embryonic hematopoietic cells in conditioned newborn recipients. Yoder MC, et al. **Blood** 1997 Mar 15; 89(6):2176–83

Organ–selective growth in the offspring of protein–restricted mothers. Desai M, et al. **Br J Nutr** 1996 Oct;76(4):591–603

Development of cholinergic and inhibitory non–adrenergic non–cholinergic responses in the rat gastric funds. Smits GJ, et al. **Br J Pharmacol** 1996 Aug;118(8):1987–94

Nimodipine's protection against corticosterone–induced morphological changes in the hippocampus of young rats. Dachir S, et al. **Brain Res** 1997 Feb 14;748(1–2):175–83

The role of apoptosis in sexual differentiation of the rat sexually dimorphic nucleus of the preoptic area. Davis EC, et al. **Brain Res** 1996 Sep 23;734(1–2):10–8

Simultaneous determination of binding of a variety of radioligands related to ionotropic excitatory amino acid receptors in fetal and neonatal rat brains. Enomoto R, et al. **Brain Res** 1996 Jun 3;723(1–2):100–9

Stereological estimates of postnatal structural differentiation in a sexually dimorphic hypothalamic nucleus involved in vocal control. Holman SD, et al. **Brain Res** 1995 Oct 2; 694(1–2):167–76

Differential expression of FGF–2 isoforms in the rat adrenal medulla during postnatal development in vivo. Meisinger C, et al. **Brain Res** 1997 May 23;757(2):291–4

SC1, a SPARC–related glycoprotein, exhibits features of an ECM component in the developing and adult brain. Mendis DB, et al. **Brain Res** 1996 Mar 25;713(1–2):53–63

Electrocorticographic activity during repeated vs continuous hypoxia in piglets. Waters KA, et al. **Brain Res Bull** 1996; 41(3):185–92

Postnatal phencyclidine treatment differentially regulates N–methyl–D–aspartate receptor subunit mRNA expression in developing rat cerebral cortex. Sircar R, et al. **Brain Res Mol Brain Res** 1996 Sep 1;40(2):214–20

Two synaptotagmin genes, Syt1 and Syt4, are differentially regulated in adult brain and during postnatal development following kainic acid–induced seizures. Tocco G, et al. **Brain Res Mol Brain Res** 1996 Sep 1;40(2):229–39

Mechanical responses of chromium–deficient developing rat heart. Penefsky ZJ, et al. **Comp Biochem Physiol A Physiol** 1996 Jun;114(2):175–87

Polarizing activity, Sonic hedgehog, and tooth development in embryonic and postnatal mouse. Koyama E, et al. **Dev Dyn** 1996 May;206(1):59–72

Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Scaglia L, et al. **Endocrinology** 1997 Apr;138(4):1736–41

Immunohistochemical demonstration of adenohypophyseal hormones during postnatal ontogenesis in the Gray Short–tailed Opossum, Monodelphis domestica (marsupialia). Gasse H, et al. **Eur J Morphol** 1995 Nov; 33(4):373–80

Transience of astrocytes in the newborn macaque monkey retina. Distler C, et al. **Eur J Neurosci** 1996 Apr;8(4):847–51

Effect of hyperphenylalaninemia chemically induced on in vitro incorporation of 32P into cytoskeletal proteins from cerebral cortex of developing rats. de Freitas MS, et al. **Exp Neurol** 1997 Feb;143(2):188–95

Effect of rearing temperature on perirenal adipose tissue development and thermoregulation following methimazole treatment of postnatal lambs. Symonds ME, et al. **Exp Physiol** 1996 Nov;81(6):995–1006

Influence of rearing temperature on lung development following methimazole treatment of postnatal lambs. Symonds ME, et al. **Exp Physiol** 1996 Jul;81(4):673–83

Enhanced GABA release in cell–damaging conditions in the adult and developing mouse hippocampus. Saransaari P, et al. **Int J Dev Neurosci** 1997 Apr;15(2):163–74

Behavioral symptoms in adult rats after postnatal L–nitro–arginine. Wörtwein G, et al. **Int J Dev Neurosci** 1997 Apr;15(2):147–54

Myocardial microvasculature in fetuses and neonates of rat. Stereological study. Villar VC, et al. **Ital J Anat Embryol** 1995 Oct–Dec;100(4):211–8

Role of bradykinin B2 receptors in neonatal kidney growth. Yosipiv IV, et al. **J Am Soc Nephrol** 1997 Jun;8(6):920–8

Effects of space allocation and temperature on periparturient maternal behaviors, steroid concentrations, and piglet growth rates. Biensen NJ, et al. **J Anim Sci** 1996 Nov; 74(11):2641–8

Effects of the level of asphyxia during delivery on viability at birth and early postnatal vitality of newborn pigs. Herpin P, et al. **J Anim Sci** 1996 Sep;74(9):2067–75

The effect of dietary active dry yeast supplement on performance of sows during gestation–lactation and their pigs. Jurgens MH, et al. **J Anim Sci** 1997 Mar;75(3):593–7

Intestinal effects of milkborne growth factors in neonates of agricultural importance. Odle J, et al. **J Anim Sci** 1996 Oct;74(10):2509–22 (120 ref.)

Compensatory growth in runt pigs is not mediated by insulin–like growth factor I. Ritacco G, et al. **J Anim Sci** 1997 May;75(5):1237–43

Development of hypoglossal motoneurons. Berger AJ, et al. **J Appl Physiol** 1996 Sep;81(3):1039–48 (45 ref.)

Postnatal maturation of peripheral chemoreceptor ventilatory response to O2 and CO2 in newborn lambs [published errata appear in J Appl Physiol 1996 Nov;81(5):1861 and 1996 Dec;81(6):2766] Canet E, et al. **J Appl Physiol** 1996 Jun;80(6):1928–33

Greater airway narrowing in immature than in mature rabbits during methacholine challenge. Shen X, et al. **J Appl Physiol** 1996 Dec;81(6):2637–43

Ontogenic profile of brain lipids following perinatal exposure to cadmium. Gupta A, et al. **J Appl Toxicol** 1996 May–Jun; 16(3):227–33

Development and segmental organization of rostrocaudal dendrites of rat sympathetic preganglionic neurons. Ezerman EB, et al. **J Auton Nerv Syst** 1996 Feb 5; 57(1–2):29–35

Ocular growth in newborn rabbit eyes implanted with a poly(methyl methacrylate) or silicone intraocular lens. Kugelberg U, et al. **J Cataract Refract Surg** 1997;23 Suppl 1:629–34

After–cataract and ocular growth in newborn rabbit eyes implanted with a capsule tension ring. Kugelberg U, et al. **J Cataract Refract Surg** 1997;23 Suppl 1:635–40

Localized deposition of M–cadherin in the glomeruli of the granular layer during the postnatal development of mouse cerebellum [published erratum appears in J Comp Neurol 1997 May 26;382(1):139] Bahjaoui–Bouhaddi M, et al. **J Comp Neurol** 1997 Feb 10;378(2):180–95

Development of connections within and between areas V1 and V2 of macaque monkeys. Coogan TA, et al. **J Comp Neurol** 1996 Aug 26;372(3):327–42

Attempts to facilitate dorsal column axonal regeneration in a neonatal spinal environment. Dent LJ, et al. **J Comp Neurol** 1996 Aug 26;372(3):435–56

c–neu oncoprotein in developing rostral cerebral cortex: relationship to epidermal growth factor receptor. Kuhn PE, et al. **J Comp Neurol** 1996 Aug 19;372(2):189–203

Distribution of a reeler gene–related antigen in the developing cerebellum: an immunohistochemical study with an allogeneic antibody CR–50 on normal and reeler mice. Miyata T, et al. **J Comp Neurol** 1996 Aug 19; 372(2):215–28

Transient features of tachykinin peptide innervation of the dorsal lateral geniculate nucleus of the rabbit during postnatal development. Parnavelas JG, et al. **J Comp Neurol** 1997 Apr 14;380(3):310–8

Postnatal changes in NMDAR1 subunit expression in the rat trigeminal pathway to barrel field cortex. Rema V, et al. **J Comp Neurol** 1996 Apr 29;368(2):165–84

Olivocochlear innervation of inner and outer hair cells during postnatal maturation: evidence for a waiting period. Simmons DD, et al. **J Comp Neurol** 1996 Jul 8; 370(4):551–62

Supporting cells as phagocytes in the olfactory epithelium

after bulbectomy. Suzuki Y, et al. **J Comp Neurol** 1996 Dec 23;376(4):509–17

Neurogenesis in neonatal rat brain is regulated by peripheral injection of basic fibroblast growth factor (bFGF). Tao Y, et al. **J Comp Neurol** 1996 Dec 23;376(4):653–63

Susceptibility of developing cochlear nucleus neurons to deafferentation–induced death abruptly ends just before the onset of hearing. Tierney TS, et al. **J Comp Neurol** 1997 Feb 10;378(2):295–306

Postnatal development of amygdaloid projections to the prefrontal cortex in the rat studied with retrograde and anterograde tracers. Verwer RW, et al. **J Comp Neurol** 1996 Dec 2;376(1):75–96

Developmental fates and migratory pathways of dividing progenitors in the postnatal rat cerebellum. Zhang L, et al. **J Comp Neurol** 1996 Jul 8;370(4):536–50

Effect of volatile fatty acid infusion on development of the rumen epithelium in neonatal sheep. Lane MA, et al. **J Dairy Sci** 1997 Apr;80(4):740–6

A model of intrauterine growth retardation caused by chronic maternal undernutrition in the rat: effects on the somatotrophic axis and postnatal growth. Woodall SM, et al. **J Endocrinol** 1996 Aug;150(2):231–42

Maturation of tympanic membrane layers and collagen in the embryonic and post–hatch chick (Gallus domesticus). Chin K, et al. **J Morphol** 1997 Sep;233(3):257–66

Stimulation at 1–5 Hz does not produce long–term depression or depotentiation in the hippocampus of the adult rat in vivo. Errington ML, et al. **J Neurophysiol** 1995 Oct; 74(4):1793–9

Synaptically evoked prolonged depolarizations in the developing auditory system. Kotak VC, et al. **J Neurophysiol** 1995 Oct;74(4):1611–20

Postnatal development of corticospinal projections from motor cortex to the cervical enlargement in the macaque monkey. Armand J, et al. **J Neurosci** 1997 Jan 1; 17(1):251–66

Postnatal development of binocular disparity sensitivity in neurons of the primate visual cortex. Chino YM, et al. **J Neurosci** 1997 Jan 1;17(1):296–307

A role for nitric oxide in the development of the ferret retinogeniculate projection. Cramer KS, et al. **J Neurosci** 1996 Dec 15;16(24):7995–8004

Mice lacking brain–derived neurotrophic factor exhibit visceral sensory neuron losses distinct from mice lacking NT4 and display a severe developmental deficit in control of breathing. Erickson JT, et al. **J Neurosci** 1996 Sep 1; 16(17):5361–71

Developmental adaptation of rat nociceptive withdrawal reflexes after neonatal tendon transfer. Holmberg H, et al. **J Neurosci** 1997 Mar 15;17(6):2071–8

Developmental influence of glycinergic transmission: regulation of NMDA receptor–mediated EPSPs. Kotak VC, et al. **J Neurosci** 1996 Mar 1;16(5):1836–43

Pattern deformities and cell loss in Engrailed–2 mutant mice suggest two separate patterning events during cerebellar development. Kuemerle B, et al. **J Neurosci** 1997 Oct 15; 17(20):7881–9

An electrophysiological study of the postnatal development of the corticospinal system in the macaque monkey. Olivier E, et al. **J Neurosci** 1997 Jan 1;17(1):267–76

Maturation of neuronal form and function in a mouse thalamo–cortical circuit. Warren RA, et al. **J Neurosci** 1997 Jan 1;17(1):277–95

Bone growth after osteotomy and internal fixation in young rabbits. Albanese SA, et al. **J Orthop Res** 1996 Nov; 14(6):921–6

The role of the aryl hydrocarbon receptor in animal development, physiological homeostasis and toxicity of TCDD. Gonzalez FJ, et al. **J Toxicol Sci** 1996 Dec; 21(5):273–7 (9 ref.)

Pyelonephritis provokes growth retardation and apoptosis in infant rat renal cortex. Serlachius E, et al. **Kidney Int** 1997 Jun;51(6):1855–62

A problem of optimal harvesting policy in two–stage age–dependent populations. Busoni G, et al. **Math Biosci** 1997 Jul 1;143(1):1–33

Inactivation of bcl–2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development. Michaelidis TM, et al. **Neuron** 1996 Jul;17(1):75–89

Developmental changes in the distribution of oestrogen receptor mRNA expressing cells in the forebrain of female, male and masculinized female zebra finches. Gahr M. **Neuroreport** 1996 Nov 4;7(15–17):2469–73

Postsynaptic induction of mossy fibre long term depression in developing rat hippocampus. Györi J, et al. **Neuroreport** 1996 Jul 8;7(10):1660–4

Developmental changes in arachidonic acid potentiation of NMDA currents in cortical neurones. Horimoto N, et al. **Neuroreport** 1996 Nov 4;7(15–17):2463–7

Expression of SKP1 mRNA and protein in rat brain during postnatal development. Uro–Coste E, et al. **Neuroreport** 1997 May 6;8(7):1675–8

Decrease and disappearance of intramural neurons in the rat bladder during post–natal development. Alian M, et al. **Neurosci Lett** 1996 Nov 1;218(2):103–6

Postnatal development of spontaneous tonic activity in mouse medial vestibular nucleus neurones. Johnston AR, et al. **Neurosci Lett** 1996 Nov 15;219(1):17–20

Murine steroid sulfatase gene expression in the brain during postnatal development and adulthood. Mortaud S, et al. **Neurosci Lett** 1996 Sep 13;215(3):145–8

Freeze–etched neuronal growth cones from rat cerebral cortex at birth: plasma membrane morphology in relation to synapse formation. Surchev L. **Neurosci Lett** 1996 Aug 30;215(1):41–4

Movements of mouse fetuses in early stages of neural development studied in vitro. Suzue T. **Neurosci Lett** 1996 Nov 1;218(2):131–4

Developmental age–dependent upregulation of choline acetyltransferase and vesicular acetylcholine transporter mRNA expression in neonatal rat septum by nerve growth factor. Tian X, et al. **Neurosci Lett** 1996 May 10; 209(2):134–6

The organization of visual corticocortical connections in early postnatal kittens. Carić D, et al. **Neuroscience** 1996 Aug;73(3):817–29

Changes in baroreceptor vagal reflex performance in the developing rat. Kasparov S, et al. **Pflugers Arch** 1997 Aug; 434(4):438–44

Developmental change in the voltage–dependence of the pacemaker current, if, in rat ventricle cells. Robinson RB, et al. **Pflugers Arch** 1997 Feb;433(4):533–5

Ritanserin blocks DOI–altered embryonic motility and posthatch learning in the developing chicken. Bollweg G, et al. **Pharmacol Biochem Behav** 1996 Nov;55(3):397–403

Excessive stimulation of serotonin2 (5–HT2) receptors during late development of chicken embryos causes decreased embryonic motility, interferes with hatching, and induces herniated umbilici. Sparber SB, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):603–11

Influence of maternal stress on the effects of prenatal exposure to methylmercury and arsenic on postnatal development and behavior in mice: a preliminary evaluation. Colomina MT, et al. **Physiol Behav** 1997 Mar; 61(3):455–9

Ever higher: constant rise of body weight set–point in growing zucker rats. Gosselin C, et al. **Physiol Behav** 1996 Sep;60(3):817–21

Energetics, growth, and body composition of Adélie penguin chicks, Pygoscelis adeliae. Janes DN. **Physiol Zool** 1997 Mar–Apr;70(2):237–43

Effect of maternal glucose infusion on brown adipose tissue and liver development in the neonatal lamb. Clarke L, et al. **Reprod Fertil Dev** 1996;8(7):1045–54

Changes in lymphocyte subsets with age in perinatal cats: late gestation through eight weeks. Sellon RK, et al. **Vet Immunol Immunopathol** 1996 Sep;53(1–2):105–13

[Reproductive and developmental toxicity study of a new antineoplastic agent, S–1 (IV)—Perinatal and postnatal study in rats by oral administration] Furuhashi T, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:643–59 (Eng. Abstr.) **(Jpn)**

[The effect of leu–enkephalin analog dalargin on DNA synthesis in the myocardium and tongue epithelium of albino rats at early stages of postnatal ontogenesis] Goncharova EN, et al. **Biull Eksp Biol Med** 1997 Jan; 123(1):43–5 **(Rus)**

[Experimental study of the effect of formaldehyde during embryogenesis on the activity of rat liver enzyme systems in ontogenesis] Astakhova LF, et al. **Vopr Med Khim** 1996 Jul–Sep;42(3):217–22 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

The effect of delays in feeding colostrum and the relationship between immunoglobulin concentration in the serum of neonatal calves and their rates of growth. Todd AG, et al. **Aust Vet J** 1995 Nov;72(11):415–7

The timing of immunization affects the development of diabetes in rodents. Classen JB. **Autoimmunity** 1996; 24(3):137–45

Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects. Barrios C, et al. **Eur J Immunol** 1996 Nov; 26(11):2666–70

Maternal IgG stimulates B lineage cell development in the progeny. Malanchère E, et al. **Eur J Immunol** 1997 Mar; 27(3):788–93

Prevention of endotoxin–induced lethality in neonatal mice by interleukin–13. Nicoletti F, et al. **Eur J Immunol** 1997 Jun;27(6):1580–3

Targeted disruption of TRAF3 leads to postnatal lethality and defective T–dependent immune responses. Xu Y, et al. **Immunity** 1996 Nov;5(5):407–15

Effects of neonatal immunization and repeated allergen exposure on airway responsiveness in the rabbit. Minshall E, et al. **J Appl Physiol** 1996 Jun;80(6):2108–19

Effects of method of colostrum feeding and colostrum supplementation on concentrations of immunoglobulin G in the serum of neonatal calves. Hopkins BA, et al. **J Dairy Sci** 1997 May;80(5):979–83

Influence of injectable immunoglobulin on serum immunoglobulin concentrations in dairy calves. Quigley JD 3rd, et al. **J Dairy Sci** 1996 Nov;79(11):2032–7

Restoration of T cell–independent type 2 induction of Ig secretion by neonatal B cells in vitro. Snapper CM, et al. **J Immunol** 1997 Mar 15;158(6):2731–5

Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus [see comments] Wyand MS, et al. **Nat Med** 1997 Jan;3(1):32–6. Comment in: Nat Med 1997 Jan;3(1):17–8. Comment in: Nat Med 1997 Aug;3(8):816.

Induction of major histocompatibility class II antigen on microglial cells in postnatal and adult rats following intraperitoneal injections of lipopolysaccharide. Ng YK, et al. **Neurosci Res** 1997 Jun;28(2):111–8

Effect of beta–carotene, canthaxanthin, lutein, and vitamin E on neonatal immunity of chicks when supplemented in the broiler breeder diets. Haq AU, et al. **Poult Sci** 1996 Sep;75(9):1092–7

Postnatal development of lymphocyte subpopulations in the intestinal mucosa in goat. Navarro JA, et al. **Vet Immunol Immunopathol** 1997 Mar;55(4):303–11

Maturation of the mitogen responsiveness, and IL2 and IL6 production by neonatal swine leukocytes. Schwager J, et al. **Vet Immunol Immunopathol** 1997 Jun;57(1–2):105–19

Changes in lymphocyte subsets with age in perinatal cats: late gestation through eight weeks. Sellon RK, et al. **Vet Immunol Immunopathol** 1996 Sep;53(1–2):105–13

Cellular components of mammary secretions and neonatal immunity: a review. Le Jan C. **Vet Res** 1996;27(4–5):403–17 (82 ref.)

METABOLISM

D2–dopamine receptor–mediated stimulation of inositol trisphosphate formation in chick retina. Zawilska JB, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(4):961

Phenylalanine requirements determined by using L–[1–14C]phenylalanine in neonatal piglets receiving total parenteral nutrition supplemented with tyrosine. House JD, et al. **Am J Clin Nutr** 1997 Apr;65(4):984–93

Ontogeny of K+ transport in rat distal colon. Aizman RI, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G268–74

Monoclonal antibodies for high–resolution localization of NHE3 in adult and neonatal rat kidney. Biemesderfer D, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F289–99

Perinatal expression of adenylyl cyclase subtypes in rat brown adipose tissue. Chaudhry A, et al. **Am J Physiol** 1996 Apr; 270(4 Pt 2):R755–60

Regulation of AE2 Cl–/HCO3– exchanger during intestinal development. Chow A, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G330–7

Comparative analysis of the ontogeny of a sodium–dependent bile acid transporter in rat kidney and ileum. Christie DM, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G377–85

H–K–ATPase activity in PNA–binding intercalated cells of newborn rabbit cortical collecting duct. Constantinescu A, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):F167–77

Protein synthesis in skeletal muscle and jejunum is more responsive to feeding in 7–than in 26–day–old pigs. Davis TA, et al. **Am J Physiol** 1996 May;270(5 Pt 1):E802–9

Programming of hepatic insulin–sensitive enzymes in offspring of rat dams fed a protein–restricted diet. Desai M, et al. **Am J Physiol** 1997 May;272(5 Pt 1):G1083–90

An important role for endogenous synthesis of arginine in maintaining arginine homeostasis in neonatal pigs. Flynn NE, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1149–55

Adenylate cyclase–coupled ATP receptor and surfactant secretion in type II pneumocytes from newborn rats. Gobran LI, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):L187–96

Lipoprotein and apolipoprotein secretion by a newborn piglet intestinal cell line (IPEC–1). Gonzalez–Vallina R, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G249–59

Posttranscriptional upregulation of Na(+)-K(+)-ATPase activity in newborn guinea pig renal cortex. Guillery EN, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F254–63

IGF–I regulates K(+)-channel expression of cultured neonatal rat ventricular myocytes. Guo W, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2599–606

Coordinate regulation of SR Ca(2+)–ATPase and phospholamban expression in developing murine heart. Harrer JM, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H57–66

Impaired phosphoinositide metabolism in glucose–incompetent islets of neonatally streptozotocin–diabetic rats. Morin L, et al. **Am J Physiol** 1997 May;272(5 Pt 1):E737–45

Influence of hypoxia on endothelin–1 binding sites in neonatal porcine pulmonary vasculature. Noguchi Y, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H669–78

Differential expression of angiotensin II receptors during early renal morphogenesis. Norwood VF, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R662–8

Developmental changes in rabbit juxtamedullary proximal convoluted tubule water permeability. Quigley R, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):F871–6

Ontogeny of blood–brain barrier function in ovine fetuses, lambs, and adults. Stonestreet BS, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1594–601

Higher lung antioxidant enzyme activity persists after single dose of corticosteroids in preterm lambs. Walther FJ, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):L187–91

Apolipoprotein secretion and lipid synthesis: regulation by fatty acids in newborn swine intestinal epithelial cells. Wang H, et al. **Am J Physiol** 1997 May;272(5 Pt 1):G935–42

Expression of AQP family in rat kidneys during development and maturation. Yamamoto T, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):F198–204

Opioid growth factor–dependent DNA synthesis in the neonatal rat aorta. Zagon IS, et al. **Am J Physiol** 1996 Jan; 270(1 Pt 2):R22–32

Localization of proliferating cell nuclear antigen in the developing and mature rat heart cell. Marino TA, et al. **Anat Rec** 1996 Aug;245(4):677–84

Liver biopsy techniques for adult horses and neonatal foals

to assess copper status. Pearce SG, et al. **Aust Vet J** 1997 Mar;75(3):194–8

Expression and function of the cardiac Na+/Ca2+ exchanger in postnatal development of the rat, in experimental-induced cardiac hypertrophy and in the failing human heart. Studer R, et al. **Basic Res Cardiol** 1997; 92 Suppl 1:53–8 (34 ref.)

Transcription of hepatic cytosolic phosphoenolpyruvate carboxykinase gene in newborn dogs. Feng BC, et al. **Biochem Mol Med** 1996 Oct;59(1):13–9

Effects of dehydroepiandrosterone in rats injected with streptozotocin during the neonatal period. Giroix MH, et al. **Biochem Mol Med** 1997 Jun;61(1):72–81

Leukotriene synthesis by isolated perinatal ovine intrapulmonary vessels correlates with age-related changes in 5-lipoxygenase protein. Ibe BO, et al. **Biochem Mol Med** 1997 Jun;61(1):63–71

Plasma and cerebrospinal fluid hyperinsulinism in asphyxiated piglets. Abrahám CS, et al. **Biol Neonate** 1996;70(5):296–303

Penile absorption of EMLA cream in piglets: implications for use of EMLA in neonatal circumcision. Gazarian M, et al. **Biol Neonate** 1995;68(5):334–41

Reticuloendothelial system uptake of infused 125I-trypsin in newborn and adult rats. Levine JJ, et al. **Biol Neonate** 1997; 71(2):111–8

Changes in myocardial A1 adenosine receptor and message levels during fetal development and postnatal maturation. Matherne GP, et al. **Biol Neonate** 1996;70(4):199–205

Insulin-like growth factor I absorption in the jejunum of neonatal calves. Vacher PY, et al. **Biol Neonate** 1995; 68(5):354–67

Development of luteinizing hormone action in the perinatal rat ovary. Sokka TA, et al. **Biol Reprod** 1996 Sep; 55(3):663–70

Nutrition in pregnant or lactating rats programs lipid metabolism in the offspring. Lucas A, et al. **Br J Nutr** 1996 Oct;76(4):605–12

Altered adipocyte properties in the offspring of protein malnourished rats. Shepherd PR, et al. **Br J Nutr** 1997 Jul;78(1):121–9

Post-natal changes in biliary lipids in suckling goat kids. Fernández JI, et al. **Br Vet J** 1996 Nov;152(6):673–82

Identification of brainstem neurons responding to hypoxia in fetal and newborn sheep. Breen S, et al. **Brain Res** 1997 Feb 14;748(1-2):107–21

The c-Fos transcription factor in the auditory pathway of the juvenile rat: effects of acoustic deprivation and repetitive stimulation. Keilmann A, et al. **Brain Res** 1997 Apr 11;753(2):291–8

Corticosterone promotes increased heme oxygenase-2 protein and transcript expression in the newborn rat brain. Maines MD, et al. **Brain Res** 1996 May 25;722(1-2):83–94

Distinct cellular compartment of cyclin-dependent kinase 5 (Cdk5) and neuron-specific Cdk5 activator protein (p35nck5a) in the developing rat cerebellum. Matsushita M, et al. **Brain Res** 1996 Sep 23;734(1-2):319–22

SC1, a brain extracellular matrix glycoprotein related to SPARC and follistatin, is expressed by rat cerebellar astrocytes following injury and during development. Mendis DB, et al. **Brain Res** 1996 Aug 19;730(1-2):95–106

The maturation of GABA(A) receptor-mediated control of luteinizing hormone secretion in immature male rats. Mitsushima D, et al. **Brain Res** 1997 Feb 14;748(1-2):258–62

Effect of anoxia on striatal monoamine metabolism in immature rat brain compared with that of hypoxia: an in vivo microdialysis study. Nakajima W, et al. **Brain Res** 1996 Nov 18;740(1-2):316–22

Brain cell membrane Na+,K(+)-ATPase activity following severe hypoxic injury in the newborn piglet. Rosenkrantz TS, et al. **Brain Res** 1996 Aug 19;730(1-2):52–7

The effects of induced apneic episodes on cerebral cortical oxygenation in newborn piglets. Tammela OK, et al. **Brain Res** 1996 Nov 25;741(1-2):160–5

Synaptophysin-like immunoreactivity in the rat olfactory bulb during postnatal development and after restricted early olfactory experience. Johnson BA, et al. **Brain Res Dev Brain Res** 1996 Mar 29;92(1):24–30

GABA and GABA-A receptors are maximally expressed in association with cone synaptogenesis in neonatal rabbit retina. Mitchell CK, et al. **Brain Res Dev Brain Res** 1996 Aug 20;95(1):63–71

Distribution of muscarinic receptor subtypes in rat brain from postnatal to old age. Tice MA, et al. **Brain Res Dev Brain Res** 1996 Mar 29;92(1):70–6

Transient expression of FGF-5 mRNA in the rat cerebellar cortex during post-natal development. Hattori Y, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1-2):262–6

Changes in cerebrospinal fluid and cerebrovascular endothelin concentrations during hypotension and hypertension in newborn piglets with induced sterile meningitis. Modanlou HD, et al. **Can J Physiol Pharmacol** 1996 Apr;74(4):368–75

Organ-specific oxidative DNA damage associated with normal birth in rats [corrected and republished in Carcinogenesis 1997 Apr;18(4):859–66] Randerath E, et al. **Carcinogenesis** 1996 Dec;17(12):2563–70

Organ-specific oxidative DNA damage associated with normal birth in rats [corrected and republished article originally printed in Carcinogenesis 1996 Dec;17(12):2563–70] Randerath E, et al. **Carcinogenesis** 1997 Apr;18(4):859–66

Effects of cGMP on L-type calcium current of adult and newborn rabbit ventricular cells. Kumar R, et al. **Cardiovasc Res** 1997 Mar;33(3):573–82

Neonatal diethylstilbestrol treatment alters the estrogen-regulated expression of both cell proliferation and apoptosis-related proto-oncogenes (c-jun, c-fos, c-myc, bax, bcl-2, and bcl-x) in the hamster uterus. Zheng X, et al. **Cell Growth Differ** 1997 Apr;8(4):425–34

Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Kudoh S, et al. **Circ Res** 1997 Jan;80(1):139–46

Metabolic changes associated with sustained 48-hr shivering thermogenesis in the newborn pig. Berthon D, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Aug; 114(4):327–35

Polarizing activity, Sonic hedgehog, and tooth development in embryonic and postnatal mouse. Koyama E, et al. **Dev Dyn** 1996 May;206(1):59–72

Expression of neurotrophin receptors during rat tooth development is developmentally regulated, independent of innervation, and suggests functions in the regulation of morphogenesis and innervation. Luukko K, et al. **Dev Dyn** 1996 May;206(1):87–99

Uptake of thyroid hormones in neonatal rat cardiac myocytes. Everts ME, et al. **Endocrinology** 1996 Oct; 137(10):4235–42

Testicular expression of inhibin and activin subunits and follistatin in the rat and human fetus and neonate and during postnatal development in the rat. Majdic G, et al. **Endocrinology** 1997 May;138(5):2136–47

Developmental changes and differential regulation by testosterone and estradiol of growth hormone receptor expression in the rabbit. Yu YM, et al. **Eur J Endocrinol** 1996 Nov;135(5):583–90

Expression and coupling to polyphosphoinositide hydrolysis of group I metabotropic glutamate receptors in early postnatal and adult rat brain. Casabona G, et al. **Eur J Neurosci** 1997 Jan;9(1):12–7

NMDA receptor properties in rat supraoptic magnocellular neurons: characterization and postnatal development. Hussy N, et al. **Eur J Neurosci** 1997 Jul;9(7):1439–49

Neutral endopeptidase activity in newborn and adult rabbit tracheas. Haver K, et al. **Eur Respir J** 1997 Aug; 10(8):1844–9

Effects of perinatal asphyxia on the mesostriatal/mesolimbic dopamine system of neonatal and 4-week-old male rats. Ungethüm U, et al. **Exp Brain Res** 1996 Dec;112(3):403–10

In vivo steroid metabolism in embryonic and newly hatched steelhead trout (Oncorhynchus mykiss). Yeoh CG, et al. **Gen Comp Endocrinol** 1996 May;102(2):197–209

Valproic acid differs in its in vitro effect on glutamic acid decarboxylase activity in neonatal and adult rat brain. Wikinski SI, et al. **Gen Pharmacol** 1996 Jun;27(4):635–8

Sex differences in glutamic acid decarboxylase mRNA in neonatal rat brain: implications for sexual differentiation. Davis AM, et al. **Horm Behav** 1996 Dec;30(4):538–52

Study of oxidative-stress in rotavirus infected infant mice. Sodhi CP, et al. **Indian J Med Res** 1996 Oct;104:245–9

Postnatal changes of brain monoamine levels in prenatally malnourished and control rats. Chen JC, et al. **Int J Dev Neurosci** 1997 Apr;15(2):257–63

Dietary thiamin supply during gestation effects thiamin status of lactating rats and their suckling offspring. Kirchgessner M, et al. **Int J Vitam Nutr Res** 1997;67(4):248–54

Effects of maternal vitamin E and selenium status during the perinatal period on age-related changes in tissue concentration of vitamin E in rat pups. Pazak HE, et al. **Int J Vitam Nutr Res** 1996;66(2):126–33

Effects of maternal vitamin E and selenium status during the perinatal period on age-related changes in heart, lung and liver microsomal lipid peroxidation in rat pups. Pazak HE, et al. **Int J Vitam Nutr Res** 1996;66(2):134–40

Genotypic effects on norepinephrine-induced changes in thermogenesis, metabolic hormones, and metabolites in newborn calves. Carstens GE, et al. **J Anim Sci** 1997 Jul; 75(7):1746–55

Effect of fat content of colostrum on voluntary colostrum intake and fat utilization in newborn pigs. Le Dividich J, et al. **J Anim Sci** 1997 Mar;75(3):707–13

Ontogeny and dietary modulation of 3-hydroxy-3-methylglutaryl-CoA reductase activities in neonatal pigs. McWhinney VJ, et al. **J Anim Sci** 1996 Sep; 74(9):2203–10

Effect of inorganic or organic selenium at two dietary levels on reproductive performance and tissue selenium concentrations in first-parity gilts and their progeny. Mahan DC, et al. **J Anim Sci** 1996 Nov;74(11):2711–8

The effect of microbial phytase in a pearl millet-soybean meal diet on apparent digestibility and retention of nutrients, serum mineral concentration, and bone mineral density of nursery pigs. Murry AC, et al. **J Anim Sci** 1997 May;75(5):1284–91

Pancreatic exocrine secretion during the first days after weaning in pigs. Rantzer D, et al. **J Anim Sci** 1997 May; 75(5):1324–31

Influence of age and breed on the binding of oxygen to red blood cells of bovine calves. Gustin P, et al. **J Appl Physiol** 1997 Mar;82(3):784–90

Postnatal lung function and protein permeability after fetal or maternal corticosteroids in preterm lambs. Rebello CM, et al. **J Appl Physiol** 1997 Jul;83(1):213–8

Hypoxic-ischemic injury induces monocyte chemoattractant protein-1 expression in neonatal rat brain. Ivacko J, et al. **J Cereb Blood Flow Metab** 1997 Jul;17(7):759–70

Localized deposition of M-cadherin in the glomeruli of the granular layer during the postnatal development of mouse cerebellum [published erratum appears in J Comp Neurol 1997 May 26;382(1):139] Bahjaoui-Bouhaddi M, et al. **J Comp Neurol** 1997 Feb 10;378(2):180–95

Localisation of amino acid neurotransmitters during postnatal development of the rat retina. Fletcher EL, et al. **J Comp Neurol** 1997 Apr 21;380(4):449–71

Expression of neuronal acetylcholine nicotinic receptor alpha 4 and beta 2 subunits during postnatal development of the rat brain. Cimino M, et al. **J Neural Transm Gen Sect** 1995; 100(2):77–92

Influence of maternal melatonin on melatonin receptors in rat offspring. Zitouni M, et al. **J Neural Transm Gen Sect** 1995;100(2):111–22

(1 S,3 R)-1-aminocyclopentane-1,3-dicarboxylic acid-induced increases in cyclic AMP formation in the neonatal rat hippocampus are mediated by a synergistic interaction between phosphoinositide- and inhibitory cyclic AMP-coupled mGluRs. Schoepp DD, et al. **J Neurochem** 1996 May;66(5):1981–5

Developmental expression of platelet-derived growth factor alpha-receptor in neurons and glial cells of the mouse CNS. Oumesmar BN, et al. **J Neurosci** 1997 Jan 1;17(1):125–39

Emergence of activity-dependent, bidirectional control of microtubule-associated protein MAP2 phosphorylation during postnatal development. Quinlan EM, et al. **J Neurosci** 1996 Dec 1;16(23):7627–37

CaM I mRNA is localized to apical dendrites during postnatal development of neurons in the rat brain. Berry FB, et al. **J Neurosci Res** 1996 Mar 1;43(5):565–75

Cultured neonatal Schwann cells contain and secrete neuregulins. Raabe TD, et al. **J Neurosci Res** 1996 Oct 15;46(2):263–70

Arachidonate and docosahexaenoate added to infant formula influence fatty acid composition and subsequent eicosanoid production in neonatal pigs. Huang MC, et al. **J Nutr** 1996 Sep;126(9):2199–208

Gastrointestinal absorption of insulinlike growth factor-I in neonatal pigs. Xu RJ, et al. **J Pediatr Gastroenterol Nutr** 1996 Nov;23(4):430–7

Adrenomedullin is inactivated in the lungs of neonatal piglets. Sabates B, et al. **J Pharm Pharmacol** 1996 Jun;48(6):578–80

The newborn rabbit sino-atrial node expresses a neuronal type I-like Na+ channel. Baruscotti M, et al. **J Physiol (Lond)** 1997 Feb 1;498 (Pt 3):641–8

Interstitial PCO2 and pH, and their role as chemostimulants in the isolated respiratory network of neonatal rats. Voipio J, et al. **J Physiol (Lond)** 1997 Mar 1;499 (Pt 2):527–42

Effects of age on the pharmacokinetics of single dose ceftiofur sodium administered intramuscularly or intravenously to cattle. Brown SA, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):32–8

Selected pharmacokinetics of theophylline ethylenediamine in pre-term and term goat kids. Lidl GM, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):69–72

Expression of uKATP-1 (Kir6.1) in neonatal rat kidney proximal tubule. Anzai N, et al. **Jpn J Physiol** 1997;47 Suppl 1:S10–1

Ontogeny of angiotensin II receptors, types 1 and 2, in ovine mesonephros and metanephros. Butkus A, et al. **Kidney Int** 1997 Sep;52(3):628–36

Cold stress related alteration of RNA biosynthesis in brain cortex of mother-deprived newborn rats. Ibarra GR, et al. **Life Sci** 1997;60(24):2165–71

Cerebral hypoxia-ischemia increases microsomal iron in newborn piglets. Adcock LM, et al. **Metab Brain Dis** 1996 Dec;11(4):359–67

Role of bradykinin in the antihypertrophic effects of enalapril in the newborn pig heart. Beinlich CJ, et al. **Mol Cell Biochem** 1996 Oct-Nov;163-164:77–83

Calcium channels and cation transport ATPases in cardiac hypertrophy induced by aortic constriction in newborn rats. Zheng L, et al. **Mol Cell Biochem** 1996 Oct-Nov; 163-164:23–9

PDGF-alpha receptor and myelin basic protein mRNAs are not coexpressed by oligodendrocytes in vivo: a double in situ hybridization study in the anterior medullary velum of the neonatal rat. Butt AM, et al. **Mol Cell Neurosci** 1997; 8(5):311–22

Chick muscle expresses various ARIA isoforms: regulation during development, denervation, and regeneration. Ng YP, et al. **Mol Cell Neurosci** 1997;9(2):132–43

Amino acid distribution in immature rat brain. Banay-Schwartz M, et al. **Neurobiology (Bp)** 1996; 4(4):393–403

Hypophysiotropic somatostatin expression during postnatal development in growth hormone-deficient Ames dwarf mice: mRNA in situ hybridization. Hurley DL, et al. **Neuroendocrinology** 1997 Feb;65(2):98–106

Control of growth hormone secretion from porcine fetal and neonatal pituitary tissue in vitro by growth hormone-releasing hormone, somatostatin, and insulin-like growth factor. Torronteras R, et al. **Neuroendocrinology** 1997 Feb;65(2):117–28

Hexarelin stimulation of growth hormone release and mRNA levels in an infant and adult rat model of impaired GHRH function. Torsello A, et al. **Neuroendocrinology** 1997 Feb; 65(2):91–7

Shift from anti- to proinflammatory cytokine profiles in microglia through LPS- or IFN-gamma-mediated

pathways. Xiao BG, et al. **Neuroreport** 1996 Aug 12; 7(12):1893–8

Effects of glutamate receptor agonists on presumed presynaptic Ca(2+)-signals in juvenile rat hippocampal area CA1. Alici K, et al. **Neurosci Lett** 1996 Aug 16; 214(1):17–20

Modification of the N-methyl-D-aspartate (NMDA) receptor in the brain of newborn piglets following hyperventilation induced ischemia. Graham EM, et al. **Neurosci Lett** 1996 Oct 25;218(1):29–32

In vivo expression of inducible nitric oxide synthase in supraventricular amoeboid microglial cells in neonatal BALB/c and athymic mice. Htain WW, et al. **Neurosci Lett** 1997 Feb 14;223(1):53–6

Transient appearance of tyrosine hydroxylase–immunoreactive non–catecholaminergic neurons in the medial geniculate nucleus of postnatal mice. Nagatsu I, et al. **Neurosci Lett** 1996 Jun 28;211(3):183–6

Ontogeny of dopamine D3 receptors in the nucleus accumbens of the rat. Stanwood GD, et al. **Neurosci Lett** 1997 Feb 14;223(1):13–6

Changes in the expression of novel Cdk5 activator messenger RNA (p39nck5ai mRNA) during rat brain development. Cai XH, et al. **Neurosci Res** 1997 Aug;28(4):355–60

Prominent expression of nuclear hormone receptor ROR alpha in Purkinje cells from early development. Nakagawa S, et al. **Neurosci Res** 1997 Jun;28(2):177–84

Neonatal inhibition of brain estrogen synthesis alters adult neural Fos responses to mating and pheromonal stimulation in the male rat. Bakker J, et al. **Neuroscience** 1996 Sep; 74(1):251–60

Different rates of horseradish peroxidase transport in the optic nerve of neonatal and adult rats. Caleo M. **Neuroscience** 1996 Jun;72(3):725–30

Expression of alpha–, beta–, and gamma–subspecies of protein kinase C in the motor neurons in the embryonic and postnatal rat spinal cord. Miki A. **Neuroscience** 1996 Jun; 72(3):805–14

Galanin messenger RNA during postnatal development of the rat brain: expression patterns in Purkinje cells differentiate anterior and posterior lobes of cerebellum. Ryan MC, et al. **Neuroscience** 1997 Jun;78(4):1113–27

Expression of alpha 2 adrenoceptors during rat brain development—II. Alpha 2C messenger RNA expression and [3H]rauwolscine binding. Winzer-Serhan UH, et al. **Neuroscience** 1997 Jan;76(1):261–72

Assessment of evidence for K+–H+ exchange in isolated type–1 cells of neonatal rat carotid body. Richmond PH, et al. **Pflugers Arch** 1997 Aug;434(4):429–37

Influence of early postnatal gonadal hormones on anxiety in adult male rats. Lucion AB, et al. **Physiol Behav** 1996 Dec;60(6):1419–23

Effects of dexamethasone on pancreatic growth and thyroliberin (TRH) content in neonatal rat pancreas. Benický J, et al. **Physiol Res** 1995;44(3):165–72

Dynamics of brown fat thermogenesis in week–old rats: evidence of relative stability during moderate cold exposure. Blumberg MS, et al. **Physiol Zool** 1997 May–Jun; 70(3):324–30

Polyunsaturated fatty acids status in blood, heart, liver, intestine, retina and brain of newborn piglets fed either sow milk or a milk replacer diet. Alessandri JM, et al. **Reprod Nutr Dev** 1996;36(1):95–109

Pulmonary interstitial pressure in premature rabbits. Miserocchi G, et al. **Respir Physiol** 1995 Dec; 102(2–3):239–49

Calcitonin gene–related peptide induces the formation of second messengers in primary cultures of neonatal rat spinal cord. Parsons AM, et al. **Synapse** 1997 Jul;26(3):235–42

Postnatal effect of arecoline on chlorophyllin–modulated hepatic biotransformation system enzymes in suckling neonate and lactating mice. Singh A, et al. **Teratog Carcinog Mutagen** 1996;16(2):89–96

Developmental expression of protein kinase C immunoreactivity in rod bipolar cells of the rabbit retina. Casini G, et al. **Vis Neurosci** 1996 Sep–Oct;13(5):817–31

GABA–induced increases in [Ca2+]i in retinal neurons of postnatal rabbits. Huang BO, et al. **Vis Neurosci** 1996 May–Jun;13(3):441–7

Metabolic, endocrine and haematological responses to intravenous E. coli endotoxin administration in 1–week–old calves. Kinsbergen M, et al. **Zentralbl Veterinarmed A** 1994 Sep;41(7):530–47

[Thyroid hormones in dairy calves after birth and in the first days of life. Amplitude of variation, maternal–fetal relationships and reaction patterns specific to the individual] Steinhardt M, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Apr;103(4):136–41 (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Comparison of efficacy of sulbactam: ampicillin to ampicillin and saline for treatment of experimentally induced Escherichia coli diarrhea in neonatal calves. Lofstedt J, et al. **Can J Vet Res** 1996 Jul;60(3):210–5

Bacteriological culture of blood from critically ill neonatal calves. Fecteau G, et al. **Can Vet J** 1997 Feb;38(2):95–100

Use of a clinical sepsis score for predicting bacteremia in neonatal dairy calves on a calf rearing farm. Fecteau G, et al. **Can Vet J** 1997 Feb;38(2):101–4

Extra–pulmonary Rhodococcus equi in a thoroughbred foal. Nay TS. **Can Vet J** 1996 Oct;37(10):623–4

PARASITOLOGY

Trypanosomosis in intensively reared Muturu calves in Nigeria. Anene BM, et al. **Trop Anim Health Prod** 1995 Nov;27(4):229–30

Experimental neosporosis in pregnant ewes and their offspring. McAllister MM, et al. **Vet Pathol** 1996 Nov; 33(6):647–55

Investigations into the prevention of neonatal Toxocara canis infections in puppies by application of doramectin to the bitch. Schnieder T, et al. **Zentralbl Veterinarmed [B]** 1996 Mar;43(1):35–43

PHYSIOLOGY

The different responses of the female mouse thymus to estrogen after treatment of neonatal, prepubertal, and adult animals. Forsberg JG. **Acta Anat (Basel)** 1996;157(4):275–90

Neuropathology of normothermic circulatory arrest in newborn dogs. Towfighi J, et al. **Acta Neuropathol (Berl)** 1997 May;93(5):485–93

Effect of perinatal triiodothyronine (T3) treatment on thymic glucocorticoid and estrogen receptors and uterus estrogen receptors. Receptor selectivity during hormonal imprinting. Csaba G, et al. **Acta Physiol Hung** 1996; 84(1):19–23

Effect of neonatal treatment with monoclonal antibody to thyrotropin (TSH) receptor on the thyroxin (T4) level and certain parameters of the internal genital organs of adult rats. Karabélyos C, et al. **Acta Physiol Hung** 1996; 84(1):25–32

Alpha–adrenoceptor activation induces rhythmic contractile activity in carotid arteries from young, not adult, rats. Eddinger TJ, et al. **Acta Physiol Scand** 1997 Feb; 159(2):123–9

Neonatal pre–ganglionic sympathectomy affects morphometrically defined architecture in rat cerebral arteries. Kåhrström J, et al. **Acta Physiol Scand** 1996 Jun; 157(2):225–31

Neonatal chronic sympathectomy in normotensive rats affects pial arteries: enhanced stiffness and reduced capacity to dilate. Kåhrström J, et al. **Acta Physiol Scand** 1996 Jun; 157(2):217–24

Effects of treadmill training on the arteriolar and venular portions of capillary in soleus muscle of young and middle–aged rats. Suzuki J, et al. **Acta Physiol Scand** 1997 Feb;159(2):113–21

Adrenalectomy reduces the ability of newborn rats to gasp and survive anoxia. Yuan SZ, et al. **Acta Physiol Scand** 1997 Apr;159(4):285–92

Mechanisms of carotid chemoreceptor resetting after birth. In vitro studies. Carroll JL, et al. **Adv Exp Med Biol** 1996; 410:73–7 (19 ref.)

Embryonic spinal cord transplants enhance locomotor performance in spinalized newborn rats. Tessler A, et al. **Adv Neurol** 1997;72:291–303 (52 ref.)

Minimum interval from fetal betamethasone treatment to postnatal lung responses in preterm lambs. Ikegami M, et al. **Am J Obstet Gynecol** 1996 May;174(5):1408–13

Hormonal and neurogenic control of Na–K–ATPase and myosin isoforms in neonatal rat cardiac myocytes. Arystarkhova E, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C489–99

Preterm newborn lamb renal and cardiovascular responses after fetal or maternal antenatal betamethasone. Berry LM, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1972–9

On increasing the number of pulmonary alveoli in rats by postnatal treatment with retinoic acid [letter; comment] Blanco LN. **Am J Physiol** 1997 Apr;272(4 Pt 1):L792–4. Comment on: Am J Physiol 1996 Feb;270(2 Pt 1):L305–10.

Role of adrenoceptors in the hypertensive response to feeding in the conscious calf. Bowman EC, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R607–14

Role of nitric oxide in hypoxia–induced colonic dysfunction in the neonatal rat. Brown JF, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):G760–9

Near–infrared monitoring of cerebral tissue oxygen saturation and blood volume in newborn piglets. Brun NC, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H682–6

Influence of route of delivery and ambient temperature on thermoregulation in newborn lambs. Clarke L, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1931–9

Effect of neonatal sympathectomy on development of angiotensin II–induced hypertension. Csiky B, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H648–56

Intrauterine growth restriction does not alter response of protein synthesis to feeding in newborn pigs. Davis TA, et al. **Am J Physiol** 1997 May;272(5 Pt 1):E877–84

Development of diurnal organization of EEG slow–wave activity and slow–wave sleep in the rat. Frank MG, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R472–8

Effects of refeeding of undernourished and insulin treatment of diabetic neonatal rats on IGF and IGFBP. Goya L, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):E223–31

Thyrotropin–releasing hormone stimulates perinatal rat respiration in vitro. Greer JJ, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1160–4

Changes in action potentials and ion currents in long–term cultured neonatal rat ventricular cells. Guo W, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C93–102

Short– and long–term effects of neonatal hypo– and hyperthyroidism on coronary arterioles in rat. Heron MI, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1746–54

Age–dependent neutrophil and blood flow responsiveness in acute pulmonary inflammation in rabbits. Hyde DM, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):L471–8

Magnesium is a cerebrovasodilator in newborn piglets. Kim CR, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H511–6

Effect of substance P on C1 and other bulbospinal cells of the RVLM in neonatal rats. Li YW, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R805–13

Endogenous retinoids increase perinatal elastin gene expression in rat lung fibroblasts and fetal explants. McGowan SE, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):L410–6

Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats [see comments] Massaro GD, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):L305–10. Comment in: Am J Physiol 1997 Apr;272(4 Pt 1):L792–4.

Inhaled nitric oxide injures the pulmonary surfactant system of lambs in vivo. Matalon S, et al. **Am J Physiol** 1996 Feb; 270(2 Pt 1):L273–80

Regulation of renal sympathetic nerve activity at birth. Mazursky JE, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):R86–93

Arginine vasopressin modulation of arterial baroreflex responses in fetal and newborn sheep. Nuyt AM, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1643–53

Reduced vasodilator response to ANF in hypoxia–induced pulmonary hypertension in the newborn piglet. Perreault T, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):L289–95

Myosin heavy chain gene expression in neonatal rat heart cells: effects of [Ca2+]i and contractile activity. Qi M, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C394–403

Enteral glutamate is the preferential source for mucosal glutathione synthesis in fed piglets. Reeds PJ, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):E408–15

Ontogeny of the arterial and cardiopulmonary baroreflex during fetal and postnatal life. Segar JL. **Am J Physiol** 1997 Aug;273(2 Pt 2):R457–71 (148 ref.)

Role of endogenous ANG II and AT1 receptors in regulating arterial baroreflex responses in newborn lambs. Segar JL, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1862–73

Interrelation between ventricular function, myocardial blood flow, and O2 consumption changes at birth in lambs. Smolich JJ, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):H741–9

Cardiomyocyte DNA synthesis and binucleation during murine development. Soonpaa MH, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H2183–9

Retinol is specifically required during midgestation for neonatal survival. Wellik DM, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E25–9

Regulation of angiotensin II AT1 and AT2 receptors in neonatal ureteral obstruction. Yoo KH, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R503–9

Endothelin–activated calcium signaling in enteric glia derived from neonatal guinea pig. Zhang W, et al. **Am J Physiol** 1997 May;272(5 Pt 1):G1175–85

Effects of thermal environment on response to acute peripheral lipopolysaccharide challenge exposure in neonatal pigs. Klir JJ, et al. **Am J Vet Res** 1997 Apr; 58(4):364–9

Intracranial pressure and cerebral perfusion pressure in clinically normal equine neonates. Kortz GD, et al. **Am J Vet Res** 1995 Oct;56(10):1351–5

Prophylaxis of respiratory distress syndrome in premature calves by administration of dexamethasone or a prostaglandin F2 alpha analogue to their dams before parturition. Zaremba W, et al. **Am J Vet Res** 1997 Apr; 58(4):404–7

Seasonal effects on gestation length and birth weight in alpacas. Davis GH, et al. **Anim Reprod Sci** 1997 Apr; 46(3–4):297–303

Determination and correlation of in vitro viability for hairless mouse and human neonatal whole skin and stratum corneum/epidermis. Bhatt RH, et al. **Arch Dermatol Res** 1997 Feb;289(3):170–3

The effect of feeding piglets up to the 100th day of their life with peat preparation on their growth and physiological and biochemical indices. Fuchs B, et al. **Arch Vet Pol** 1995; 35(1–2):97–107

Neonatal cocaine exposure and activity rhythms in rats. Barron S, et al. **Behav Brain Res** 1996 Jan;74(1–2):167–74

Systemic administration of anti–NGF antibodies to neonatal mice impairs 24–h retention of an inhibitory avoidance task while increasing ChAT immunoreactivity in the medial septum. Calamandrei G, et al. **Behav Brain Res** 1996 Aug; 78(2):81–91

Long–term effects of neonatal ischemic–hypoxic brain injury on sensorimotor and locomotor tasks in rats. Jansen EM, et al. **Behav Brain Res** 1996 Aug;78(2):189–94

Functional changes induced by neonatal cerebral 6–hydroxydopamine treatment: effects of dose levels on behavioral parameters. Luthman J, et al. **Behav Brain Res** 1997 Jan;82(2):213–21

Active and passive avoidance learning in rats neonatally treated with intraventricular 6–hydroxydopamine. Takasuna M, et al. **Behav Brain Res** 1996 Jan; 74(1–2):119–26

Recovery of function after neonatal ablation of the auditory cortex in rats (Rattus norvegicus). Wakita M. **Behav Brain Res** 1996 Aug;78(2):201–9

Neonatal hippocampal lesions induced hyperresponsiveness to amphetamine: behavioral and in vivo microdialysis

studies. Wan RQ, et al. **Behav Brain Res** 1996 Aug; 78(2):211–23

Nitric oxide modulates glomerular filtration and renal blood flow of the newborn rabbit. Ballèvre L, et al. **Biol Neonate** 1996;69(6):389–98

Early–life polysensorial stimulation and nutrition: topographic levels of susceptibility in the rat visual cortex. Fernández V, et al. **Biol Neonate** 1997;71(4):265–76

Evaluation of potentially injurious effects of exogenous surfactant lysophospholipids on the alveolar epithelium and pulmonary mechanics. Fornasier M, et al. **Biol Neonate** 1997;71(5):337–44

Haemoglobin is inversely related to plasma lactate and heart rate in the newborn piglet. Haaland K, et al. **Biol Neonate** 1996;69(5):350–6

Effect of dopamine antagonism on the behavioral and hemodynamic responses to cocaine in piglets. Monitto CL, et al. **Biol Neonate** 1996;70(1):52–9

Growth and development of the exocrine pancreas in newborn pigs: the effect of colostrum feeding. Mubiru JN, et al. **Biol Neonate** 1997;71(5):317–26

Cardiopulmonary effects of tumor necrosis factor–alpha in the piglet: influence of cyclooxygenase inhibition. Osiovich H, et al. **Biol Neonate** 1995;68(5):342–353

Effects of combined carotid sinus and aortic depressor nerve denervations in neonatal rat pups. Shair HN, et al. **Biol Neonate** 1997;71(4):251–64

Engraftment of embryonic hematopoietic cells in conditioned newborn recipients. Yoder MC, et al. **Blood** 1997 Mar 15; 89(6):2176–83

Ontogeny of suckling mechanisms in opossums (Didelphis virginiana). German RZ, et al. **Brain Behav Evol** 1996; 48(3):157–64

Alterations in the pituitary–adrenal axis of adult mice following neonatal exposure to interleukin–1. del Rey A, et al. **Brain Behav Immun** 1996 Sep;10(3):235–48

Neonatal endotoxin exposure alters the development of social behavior and the hypothalamic–pituitary–adrenal axis in selectively bred mice. Granger DA, et al. **Brain Behav Immun** 1996 Sep;10(3):249–59

Cyclosporin A, an inhibitor of calcineurin, impairs memory formation in day–old chicks. Bennett PC, et al. **Brain Res** 1996 Aug 19;730(1–2):107–17

Dexamethasone prevents apoptosis in a neonatal rat model of hypoxic–ischemic encephalopathy (HIE) by a reactive oxygen species–independent mechanism. Ekert P, et al. **Brain Res** 1997 Jan 30;747(1):9–17

Influence of fasting and neuropeptide Y on the suppressive food intake induced by intracerebroventricular injection of glucagon–like peptide–1 in the neonatal chick. Furuse M, et al. **Brain Res** 1997 Aug 1;764(1–2):289–92

Effect of phosphatidylserine on the binding properties of glutamate receptors in brain sections from adult and neonatal rats. Gagné J, et al. **Brain Res** 1996 Nov 18; 740(1–2):337–45

Reduction in numerical synapse density in chick (Gallus domesticus) dorsal hippocampus following transient cerebral ischaemia [corrected and republished article originally printed in Brain Res 1995 Dec 12;703(1–2):245–50] Horner CH, et al. **Brain Res** 1996 Oct 7;735(2):354–9

Hypothyroidism coordinately and transiently affects myelin protein gene expression in most rat brain regions during postnatal development. Ibarrola N, et al. **Brain Res** 1997 Mar 28;752(1–2):285–93

Decreased dorsal raphe nucleus neuronal activity in adult chloral hydrate anesthetized rats following neonatal clomipramine treatment: implications for endogenous depression. Kinney GG, et al. **Brain Res** 1997 May 9; 756(1–2):68–75

Repeated postnatal phencyclidine administration in female juvenile rat delays onset of puberty but has no effect on pentylenetetrazol–induced seizure–susceptibility. Sircar R. **Brain Res** 1995 Oct 2;694(1–2):318–21

Ontogeny of beta–adrenoceptor/adenylyl cyclase desensitization mechanisms: the role of neonatal innervation. Slotkin TA, et al. **Brain Res** 1996 Dec 2; 742(1–2):317–28

Fructose–1,6–bisphosphate after hypoxic ischemic injury is protective to the neonatal rat brain. Sola A, et al. **Brain Res** 1996 Nov 25;741(1–2):294–9

Paired pulse facilitation of GABAergic IPSCs in ventral horn neurons in neonatal rat spinal cord. Tanabe M, et al. **Brain Res** 1996 Apr 15;716(1–2):101–6

Role of endothelin–1 in cerebral hematoma–induced modification of cerebral vascular reactivity in piglets. Yakubu MA, et al. **Brain Res** 1996 Sep 23;734(1–2):149–56

Neonatal isolation alters LTP in freely moving juvenile rats: sex differences. Bronzino JD, et al. **Brain Res Bull** 1996; 41(3):175–83

Spectral features of central pattern generation in the in vitro brain stem spinal cord preparation of the newborn rat. Tarasiuk A, et al. **Brain Res Bull** 1997;42(2):105–10

Administration of lanthanum chloride following a reminder induces a transient loss of memory retrieval in day–old chicks. Summers MJ, et al. **Brain Res Cogn Brain Res** 1996 Sep;4(2):109–19

Perinatal developmental changes in respiratory activity of medullary and spinal neurons: an in vitro study on fetal and newborn rats. Di Pasquale E, et al. **Brain Res Dev Brain Res** 1996 Jan 22;91(1):121–30

Myelin basic protein immunoreactivity in the internal capsule of neonates from rats on a low iodine intake or on methylmercaptoimidazole (MMI). Martinez–Galan JR, et al. **Brain Res Dev Brain Res** 1997 Jul 18;101(1–2):249–56

Sexually dimorphic effects of anti–NGF treatment in neonatal rats. Ricceri L, et al. **Brain Res Dev Brain Res** 1997 Jul 18;101(1–2):273–6

Long–term effects of neonatal maternal deprivation and ACTH on hippocampal mineralocorticoid and glucocorticoid receptors. Sutanto W, et al. **Brain Res Dev Brain Res** 1996 Apr 30;92(2):156–63

Effect of neural blockades, gastrointestinal regulatory peptides, and diversion of gastroduodenal contents on periodic pancreatic secretion in the preruminant calf. Zabielski R, et al. **Can J Physiol Pharmacol** 1995 Nov; 73(11):1616–24

Angiotensin converting enzyme inhibition in the postnatal rat results in decreased cell proliferation in the renal outer medulla. McCausland JE, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul;23(6–7):552–4

Transfection of cardiac muscle: effects of overexpression of c–myc and c–fos proto–oncogene proteins in primary cultures of neonatal rat cardiac myocytes. Green NK, et al. **Clin Sci (Colch)** 1997 Feb;92(2):181–8

Dopaminergic receptor–mediated effects in the mesenteric vasculature and renal vasculature of the chronically instrumented newborn piglet. Pearson RJ, et al. **Crit Care Med** 1996 Oct;24(10):1706–12

Fate determination and migration of progenitors in the postnatal mammalian CNS. Goldman JE, et al. **Dev Neurosci** 1997;19(1):42–8 (68 ref.)

The neonatal neurotoxicity of monosodium L–glutamate on the sexually dimorphic nucleus of the preoptic area in rats. Hsieh YL, et al. **Dev Neurosci** 1997;19(4):342–7

Excitatory and trophic action of GABA and related substances in newborn mice and organotypic cerebellar culture. Obata K. **Dev Neurosci** 1997;19(1):117–9

Alterations in the postnatal development of striatal preprotachykinin but not preproenkephalin mRNA expression in the serotonin–depleted rat. Walker PD, et al. **Dev Neurosci** 1997;19(2):135–42

Suppression of somatotroph function induced by growth hormone treatment in neonatal pigs. Matteri RL, et al. **Domest Anim Endocrinol** 1997 Mar;14(2):109–18

Somatotroph function in the neonatal pig. Matteri RL, et al. **Domest Anim Endocrinol** 1997 Jul;14(4):241–9

Neurobehavioral development of neonatal rats after in–utero hypothyroxinemia: efficacy of prenatal thyroxine treatment. Weller A, et al. **Early Hum Dev** 1996 Sep 20; 46(1–2):63–76

Photoperiodic history and hypothalamic control of prolactin secretion before birth. Houghton DC, et al. **Endocrinology** 1997 Apr;138(4):1506–11

Thyroid hormone controls the expression of insulin–like growth factor I receptor gene at different levels in lung and heart of developing and adult rats. Moreno B, et al. **Endocrinology** 1997 Mar;138(3):1194–203

Increased susceptibility to tetanus toxin–induced seizures in immature rats. Anderson AE, et al. **Epilepsy Res** 1997 Mar; 26(3):433–42

Acute effects of MK801 on kainic acid–induced seizures in neonatal rats. Stafstrom CE, et al. **Epilepsy Res** 1997 Jan; 26(2):335–44

Nutrient requirements of the critically ill neonate. Borum PR. **Equine Vet J Suppl** 1988 Sep;(5):14–6 (24 ref.)

Maturation of the cardiopulmonary system. Cottrill CM. **Equine Vet J Suppl** 1993 Apr;(14):26–30 (74 ref.)

Development of gastrointestinal functions in the foal: what can we learn from studies on man and experimental animals? Koldovsky O. **Equine Vet J Suppl** 1993 Apr; (14):23–5 (33 ref.)

Neurological and neuropathological observations on the equine neonate. Mayhew IG. **Equine Vet J Suppl** 1988 Sep; (5):28–33 (38 ref.)

Some aspects of perinatal maturation and adaptation. Mellor DJ. **Equine Vet J Suppl** 1993 Apr;(14):17–22 (110 ref.)

Regional gastric pH measurement in horses and foals. Murray MJ, et al. **Equine Vet J Suppl** 1989 Jun;(7):73–6

Cardiorespiratory adaptations in neonatal foals. Rose RJ. **Equine Vet J Suppl** 1988 Sep;(5):11–3 (24 ref.)

Perinatology: an end and a beginning. Rossdale PD. **Equine Vet J Suppl** 1988 Sep;(5):19–24 (61 ref.)

Clinical view of disturbances in equine foetal maturation. Rossdale PD. **Equine Vet J Suppl** 1993 Apr;(14):3–7 (75 ref.)

Newborn intensive care—success, failure and opportunities. Stahlman MT. **Equine Vet J Suppl** 1988 Sep;(5):1–4; discussion 5 (39 ref.)

Developmental aspects of prolactin receptor gene expression in fetal and neonatal mice. Brown–Borg HM, et al. **Eur J Endocrinol** 1996 Jun;134(6):751–7

Developmental study of N–methyl–D–aspartate–induced firing activity and whole–cell currents in nucleus tractus solitarii neurons. Vincent A, et al. **Eur J Neurosci** 1996 Dec;8(12):2748–52

MK–801 blocks the expression but not the development of tolerance to morphine in the isolated spinal cord of the neonatal rat. Bell JA, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):289–96

Co–treatment with MK–801 potentiates naloxone–precipitated morphine withdrawal in the isolated spinal cord of the neonatal rat. Bell JA, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):297–301

Protective effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes. Kang JX, et al. **Eur J Pharmacol** 1996 Feb 15;297(1–2):97–106

Interactions between medullary and spinal respiratory rhythm generators in the in vitro brainstem spinal cord preparation from newborn rats. Dubayle D, et al. **Exp Brain Res** 1996 Apr;109(1):1–8

Electrophysiological properties of neurones in cultures from postnatal rat dentate gyrus. Glimm H, et al. **Exp Brain Res** 1996;107(3):367–81

Development of contrast sensitivity and temporal–frequency selectivity in primate lateral geniculate nucleus. Hawken MJ, et al. **Exp Brain Res** 1997 Mar;114(1):86–98

Transgeniculate signal transmission to middle suprasylvian cortex in intact cats and following early removal of areas 17 and 18: a morphological study. MacNeil MA, et al. **Exp Brain Res** 1997 Mar;114(1):11–23

The effect of inherited hydrocephalus and shunt treatment on cortical pyramidal cell dendrites in the infant H–Tx rat. Harris NG, et al. **Exp Neurol** 1996 Oct;141(2):269–79

Glial cell reaction to cis–dichlorodiammine platinum treatment in the immature rat cerebellum. Necchi D, et al. **Exp Neurol** 1997 Mar;144(1):219–26

Unilateral neonatal hippocampal lesion alters septal innervation and trophism of the entorhinal cortex. van Praag H, et al. **Exp Neurol** 1996 Sep;141(1):130–40

Nutrition, temperature and homeostasis during perinatal development. Symonds ME, et al. **Exp Physiol** 1995 Nov; 80(6):907–40 (155 ref.)

Influence of skin and muscle lesions on the hepatic cytochrome P450 function in 10 and 60 day–old male Wistar rats. Klinger W, et al. **Exp Toxicol Pathol** 1995 Sep; 47(4):309–12

Leptin gene is expressed in rat brown adipose tissue at birth. Dessolin S, et al. **FASEB J** 1997 Apr;11(5):382–7

Perinatal methanol exposure in the rat. II. Behavioral effects in neonates and adults. Stern S, et al. **Fundam Appl Toxicol** 1997 Apr;36(2):163–76

Signal transduction pathways associated with contraction during development of the feline gastric antrum. Hillemeier AC, et al. **Gastroenterology** 1997 Aug;113(2):507–13

Astrocyte reactivity in neonatal mice: apparent dependence on the presence of reactive microglia/macrophages. Balasingam V, et al. **Glia** 1996 Sep;18(1):11–26

Transfer of horseradish peroxidase from oligodendrocyte to axon in the myelinating neonatal rat optic nerve: artefact or transcellular exchange? Duncan A, et al. **Glia** 1996 Aug; 17(4):349–55

Manipulation of adult body composition by treatment of the neonatal rat with growth hormone and prolactin. Kadim IT, et al. **Growth Regul** 1996 Dec;6(4):201–5

Parental care and the prolactin secretion pattern in the King penguin: an endogenously timed mechanism? Garcia V, et al. **Horm Behav** 1996 Sep;30(3):259–65

Hormonal responses to parental and nonparental conditions in male cotton–top tamarins, Saguinus oedipus, a New World primate. Ziegler TE, et al. **Horm Behav** 1996 Sep; 30(3):287–97

Transfection of neonatal rat cochlear cells in vitro with an adenovirus vector. Dazert S, et al. **Int J Dev Neurosci** 1997 Jul;15(4–5):595–600

Up–regulation of a keratan sulfate proteoglycan following cortical injury in neonatal rats. Geisert EE Jr, et al. **Int J Dev Neurosci** 1996 Jun;14(3):257–67

Properties of developing lateral geniculate neurones in the mouse. MacLeod N, et al. **Int J Dev Neurosci** 1997 Apr; 15(2):205–24

Plastic responses of neonatal 5–hydroxytryptamine1B receptors to 5,7–dihydroxytryptamine lesions mapped by quantitative autoradiography. Pranzatelli MR, et al. **Int J Dev Neurosci** 1996 Aug;14(5):621–9

Study of neurons and glial cells of basolateral amygdala in male and female rats neonatally treated with estrogen. Dmitar D, et al. **Int J Neurosci** 1995 Dec;83(3–4):145–51

Visual deprivation at the critical period modulates photic evoked responses. Yan HQ, et al. **Int J Neurosci** 1995 Dec; 83(3–4):241–52

Middle–ear development VII: umbo velocity in the neonatal rat. Doan DE, et al. **J Acoust Soc Am** 1996 Mar; 99(3):1566–72

Induction of parturition in alpacas and subsequent survival of neonates. Bravo PW, et al. **J Am Vet Med Assoc** 1996 Nov 15;209(10):1760–2

Three methods of oxytocin–induced parturition and their effects of foals. Macpherson ML, et al. **J Am Vet Med Assoc** 1997 Mar 15;210(6):799–803

Effect of supplemental pig milk replacer on litter performance: seasonal variation in response. Azain MJ, et al. **J Anim Sci** 1996 Sep;74(9):2195–202

Effects of sire, dam traits, calf traits, and environment on dystocia and subsequent reproduction of two–year–old heifers. Colburn DJ, et al. **J Anim Sci** 1997 Jun; 75(6):1452–60

Effects of twinning on dystocia, calf survival, calf growth, carcass traits, and cow productivity. Gregory KE, et al. **J Anim Sci** 1996 Jun;74(6):1223–33

Effects of the level of asphyxia during delivery on viability at birth and early postnatal vitality of newborn pigs. Herpin P, et al. **J Anim Sci** 1996 Sep;74(9):2067–75

The effect of dietary active dry yeast supplement on performance of sows during gestation–lactation and their

pigs. Jurgens MH, et al. **J Anim Sci** 1997 Mar;75(3):593–7

Effect of inorganic or organic selenium at two dietary levels on reproductive performance and tissue selenium concentrations in first-parity gilts and their progeny. Mahan DC, et al. **J Anim Sci** 1996 Nov;74(11):2711–8

The effect of microbial phytase in a pearl millet–soybean meal diet on apparent digestibility and retention of nutrients, serum mineral concentration, and bone mineral density of nursery pigs. Murry AC, et al. **J Anim Sci** 1997 May;75(5):1284–91

The effect of dietary lysine and valine fed during lactation on sow and litter performance. Richert BT, et al. **J Anim Sci** 1997 Jul;75(7):1853–60

Effect of feeding a milk replacer to early-weaned pigs on growth, body composition, and small intestinal morphology, compared with suckled littermates. Zijlstra RT, et al. **J Anim Sci** 1996 Dec;74(12):2948–59

Periodic breathing induced on demand in awake newborn lamb. Canet E, et al. **J Appl Physiol** 1997 Feb;82(2):607–12

Autonomic and behavioral thermoregulation in guinea pigs during postnatal maturation. Fewell JE, et al. **J Appl Physiol** 1997 Sep;83(3):830–6

Chronic hypoxia alters nitric oxide–dependent pulmonary vascular responses in lungs of newborn pigs. Fike CD, et al. **J Appl Physiol** 1996 Nov;81(5):2078–87

Prostaglandins E2 and I2 cause greater relaxations in pulmonary veins than in arteries of newborn lambs. Gao Y, et al. **J Appl Physiol** 1996 Dec;81(6):2534–9

Contribution of LFA-1 and Mac-1 to CD18-dependent neutrophil emigration in a neonatal rabbit model. Graf JM, et al. **J Appl Physiol** 1996 Jun;80(6):1984–92

Pathophysiology of neonatal lung injury induced by monoclonal antibody to surfactant protein B. Grossmann G, et al. **J Appl Physiol** 1997 Jun;82(6):2003–10

Effect of interval from fetal corticosteriod treatment to delivery on postnatal lung function of preterm lambs. Ikegami M, et al. **J Appl Physiol** 1996 Feb;80(2):591–7

Technique for repetitive recording from fetal respiratory neurons. Ioffe S, et al. **J Appl Physiol** 1996 Mar; 80(3):1057–60

Exogenous infusion of adenosine depresses whole body O2 use in fetal/neonatal sheep. Karimi A, et al. **J Appl Physiol** 1996 Aug;81(2):541–7

Effect on breathing of ventral medullary surface cooling in neonatal goats. Lowry TF, et al. **J Appl Physiol** 1996 Jun; 80(6):1949–57

Effects of renal denervation on cardiovascular and renal responses to ACE inhibition in conscious lambs. Smith FG, et al. **J Appl Physiol** 1997 Aug;83(2):414–9

Curtailed respiration by repeated vs. isolated hypoxia in maturing piglets is unrelated to NTS ME or SP levels. Waters KA, et al. **J Appl Physiol** 1997 Aug;83(2):522–9

Preliminary evidence for the evolution in complexity of heart rate dynamics during autonomic maturation in neonatal swine. Lipsitz LA, et al. **J Auton Nerv Syst** 1997 Jul 14; 65(1):1–9

Nitrergic neurons in the pancreas of newborn guinea pig: their distribution and colocalization with various neuropeptides and dopamine-beta-hydroxylase. Liu HP, et al. **J Auton Nerv Syst** 1996 Dec 14;61(3):248–56

Temperature dependency of the vagal chronotropic response in the young puppy: an 'environmental-autonomic interaction'. Pickoff AS, et al. **J Auton Nerv Syst** 1997 Jun 6;64(2–3):107–14

Effects of cardiac autonomic imbalance on postnatal changes in the electrocardiographic Q-T interval in conscious swine. Tong S, et al. **J Auton Nerv Syst** 1997 Jun 6; 64(2–3):162–5

Inhibin-B in the male rhesus monkey: impact of neonatal gonadotropin-releasing hormone antagonist treatment and sexual development. Mann DR, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1928–33

Development of spinal cord projections from neocortical transplants heterotopically placed in the neocortex of newborn hosts is highly dependent on the embryonic locus of origin of the graft. Ebrahimi-Gaillard A, et al. **J Comp Neurol** 1996 Jan 29;365(1):129–40

Organization of the dopaminergic innervation of forebrain areas relevant to learning: a combined immunohistochemical/retrograde tracing study in the domestic chick. Metzger M, et al. **J Comp Neurol** 1996 Dec 2;376(1):1–27

Excitotoxic neuronal death in the immature brain is an apoptosis–necrosis morphological continuum. Portera-Cailliau C, et al. **J Comp Neurol** 1997 Feb 3; 378(1):70–87

Cellular and subcellular distribution of alpha 2A-adrenergic receptors in the visual cortex of neonatal and adult rats. Venkatesan C, et al. **J Comp Neurol** 1996 Jan 29; 365(1):79–95

Young chickens learn to localize the centre of a spatial environment. Tommasi L, et al. **J Comp Physiol [A]** 1997 May;180(5):567–72

Effects of maternal iodine deficiency and thyroidectomy on basal neuroendocrine function in rat pups. Kondo K, et al. **J Endocrinol** 1997 Mar;152(3):423–30

Effects of GH and IGF-I administration on GHRH and somatostatin mRNA levels: II. A study in the infant rat. Grilli R, et al. **J Endocrinol Invest** 1997 Mar;20(3):151–4

Determinants of rhythm and rate in suckling. German RZ, et al. **J Exp Zool** 1997 May 1;278(1):1–8

Ontogeny of PFC-related behaviours is sensitive to a single non-invasive dose of methamphetamine in neonatal gerbils (Meriones unguiculatus). Dawirs RR, et al. **J Neural Transm** 1996;103(11):1235–45

Effects of neonatal clomipramine on cholinergic receptor sensitivity and passive avoidance behavior in adult rats. Prathiba J, et al. **J Neural Transm Gen Sect** 1995; 100(2):93–9

Ependymal/subependymal zone cells of postnatal and adult songbird brain generate both neurons and nonneuronal siblings in vitro and in vivo. Goldman SA, et al. **J Neurobiol** 1996 Aug;30(4):505–20

Long-term selective down-regulation of brain glucocorticoid receptors after neonatal dexamethasone treatment in rats. Felszeghy K, et al. **J Neuroendocrinol** 1996 Jul;8(7):493–9

Neonatal maternally deprived rats have as adults elevated basal pituitary-adrenal activity and enhanced susceptibility to apomorphine. Rots NY, et al. **J Neuroendocrinol** 1996 Jul;8(7):501–6

Effects of neonatal dexamethasone treatment on hypothalamo-pituitary adrenal axis and immune system of the rat. Bakker JM, et al. **J Neuroimmunol** 1997 Apr; 74(1–2):69–76

Myelination delay in the cerebral white matter of immature rats with kaolin-induced hydrocephalus is reversible. Del Bigio MR, et al. **J Neuropathol Exp Neurol** 1997 Sep; 56(9):1053–66

Pharmacological block of the electrogenic sodium pump disrupts rhythmic bursting induced by strychnine and bicuculline in the neonatal rat spinal cord. Ballerini L, et al. **J Neurophysiol** 1997 Jan;77(1):17–23

Regional distribution of the locomotor pattern-generating network in the neonatal rat spinal cord. Cowley KC, et al. **J Neurophysiol** 1997 Jan;77(1):247–59

Physiological and theoretical analysis of K+ currents controlling discharge in neonatal rat mesencephalic trigeminal neurons. Del Negro CA, et al. **J Neurophysiol** 1997 Feb;77(2):537–53

Localization of the spinal network associated with generation of hindlimb locomotion in the neonatal rat and organization of its transverse coupling system. Kremer E, et al. **J Neurophysiol** 1997 Mar;77(3):1155–70

Locomotor rhythm evoked by ventrolateral funiculus stimulation in the neonatal rat spinal cord in vitro. Magnuson DS, et al. **J Neurophysiol** 1997 Jan;77(1):200–6

Glutamate-mediated slow synaptic currents in neonatal rat deep dorsal horn neurons in vitro. Miller BA, et al. **J Neurophysiol** 1996 Sep;76(3):1465–76

Development of orientation preference maps in ferret primary visual cortex. Chapman B, et al. **J Neurosci** 1996 Oct 15;16(20):6443–53

Slow kinetics of miniature IPSCs during early postnatal development in granule cells of the dentate gyrus. Hollrigel GS, et al. **J Neurosci** 1997 Jul 1;17(13):5119–28

An adult-like pattern of ocular dominance columns in striate cortex of newborn monkeys prior to visual experience. Horton JC, et al. **J Neurosci** 1996 Mar 1;16(5):1791–807

Distribution of networks generating and coordinating locomotor activity in the neonatal rat spinal cord in vitro: a lesion study. Kjaerulff O, et al. **J Neurosci** 1996 Sep 15; 16(18):5777–94

Developing neonatal rat sympathetic and sensory neurons differ in their regulation of 5-HT3 receptor expression. Rosenberg M, et al. **J Neurosci** 1997 Sep 1;17(17):6629–38

A pacemaker current in dye-coupled hilar interneurons contributes to the generation of giant GABAergic potentials in developing hippocampus. Strata F, et al. **J Neurosci** 1997 Feb 15;17(4):1435–46

Thyroid hormone-responsive genes in developing cerebellum include a novel synaptotagmin and a hairless homolog. Thompson CC. **J Neurosci** 1996 Dec 15;16(24):7832–40

Insensitivity of the hippocampus to environmental stimulation during postnatal development. Waters NS, et al. **J Neurosci** 1997 Oct 15;17(20):7967–73

'Real time' measurement of dopamine release in an in vitro model of neostriatal ischaemia. Toner CC, et al. **J Neurosci Methods** 1996 Aug;67(2):133–40

Gene localization and developmental expression of light chain 3: a common subunit of microtubule-associated protein 1A(MAP1A) and MAP1B. Mann SS, et al. **J Neurosci Res** 1996 Mar 1;43(5):535–44

Effects of retinal pigment epithelial cell-secreted factors on neonatal rat retinal explant progenitor cells. Sheedlo HJ, et al. **J Neurosci Res** 1996 Jun 15;44(6):519–31

Characterization of alpha-adrenoceptor activity in term-newborn piglet mesentery. Ferrara JJ, et al. **J Pharm Pharmacol** 1996 Dec;48(12):1298–301

Postnatal development of the pattern of respiratory and cardiovascular response to systemic hypoxia in the piglet: the roles of adenosine. Elnazir B, et al. **J Physiol (Lond)** 1996 Apr 15;492 (Pt 2):573–85

PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade. England S, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):429–40

Chemosensory and cholinergic stimulation of fictive respiration in isolated CNS of neonatal opossum. Eugenín J, et al. **J Physiol (Lond)** 1997 Jun 1;501 (Pt 2):425–37

Growth and differentiation of fast and slow muscles in fetal sheep, and the effects of hypophysectomy. Javen I, et al. **J Physiol (Lond)** 1996 Aug 1;494 (Pt 3):839–49

Central effects of 5-HT on activity of respiratory and hypoglossally innervated muscles in newborn kittens. Khater-Boidin J, et al. **J Physiol (Lond)** 1996 Aug 15;495 (Pt 1):255–65

Synchronization of GABAergic interneuronal network in CA3 subfield of neonatal rat hippocampal slices. Khazipov R, et al. **J Physiol (Lond)** 1997 Feb 1;498 (Pt 3):763–72

Integrated phrenic responses to carotid afferent stimulation in adult rats following perinatal hyperoxia. Ling L, et al. **J Physiol (Lond)** 1997 May 1;500 (Pt 3):787–96

Effect of CO2 on the metabolic and ventilatory responses to ambient temperature in conscious adult and newborn rats. Saiki C, et al. **J Physiol (Lond)** 1996 Feb 15;491 (Pt 1):261–9

Long-term influence of neonatal hypoxia on catecholamine activity in carotid bodies and brainstem cell groups of the rat. Soulier V, et al. **J Physiol (Lond)** 1997 Jan 15;498 (Pt 2):523–30

Electrophysiological properties of neurones in the internal and external submucous plexuses of newborn pig small intestine. Thomsen L, et al. **J Physiol (Lond)** 1997 Feb 1; 498 (Pt 3):773–85

Twenty-four hour rhythms of serum prolactin, growth hormone and luteinizing hormone levels, and of medial basal hypothalamic corticotropin-releasing hormone levels and dopamine and serotonin metabolism in rats neonatally administered melatonin. Esquifino AI, et al. **J Pineal Res** 1997 Jan;22(1):52–8

Alteration of testicular response to long photoperiod by transient exposure to short photoperiod in collared lemmings (Dicrostonyx groenlandicus). Gower BA, et al. **J Reprod Fertil** 1997 Mar;109(2):257–62

The role of the aryl hydrocarbon receptor in animal development, physiological homeostasis and toxicity of TCDD. Gonzalez FJ, et al. **J Toxicol Sci** 1996 Dec; 21(5):273–7 (9 ref.)

Evaluation of five agents/methods for anesthesia of neonatal rats. Danneman PJ, et al. **Lab Anim Sci** 1997 Aug; 47(4):386–95

Postnatal variations of serum protein fractions in cynomolgus macaques (Macaca fascicularis): evaluation from birth to 20 months of age. D'Ovidio MC, et al. **Lab Anim Sci** 1996 Jun;46(3):347–9

Developmental changes of calcium transients and contractility during the cultivation of rat neonatal cardiomyocytes. Husse B, et al. **Mol Cell Biochem** 1996 Oct-Nov;163-164:13–21

Alcohol-mediated tactile conditioned aversions in infant rats: devaluation of conditioning through alcohol-sucrose associations. Molina JC, et al. **Neurobiol Learn Mem** 1996 Sep;66(2):121–32

Effects of neonatal administration of octreotide, a long-lasting somatostatin analogue, on growth hormone regulation in the adult rat. Slama A, et al. **Neuroendocrinology** 1996 Feb;63(2):173–80

Effects of hyperosmolar mannitol on regional oxygen supply and consumption in the newborn pig. Anwar M, et al. **Neurol Res** 1997 Apr;19(2):204–10

Deprenyl and pergolide rescue spinal motor neurons from axotomy-induced neuronal death in the neonatal rat. Iwasaki Y, et al. **Neurol Res** 1996 Apr;18(2):168–70

Developmental spectrum of the excitotoxic cascade induced by ibotenate: a model of hypoxic insults in fetuses and neonates. Gressens P, et al. **Neuropathol Appl Neurobiol** 1996 Dec;22(6):498–502 (22 ref.)

Apoptosis and necrosis in the newborn piglet brain following transient cerebral hypoxia-ischaemia. Yue X, et al. **Neuropathol Appl Neurobiol** 1997 Feb;23(1):16–25

Role of the 5-HT1A receptor in development of the neonatal rat brain: preliminary behavioral studies. Borella A, et al. **Neuropharmacology** 1997 Apr-May;36(4–5):445–50

Enhancement of postsynaptic sensitivity to dopaminergic agonists induced by neonatal hippocampal lesions. Wan RQ, et al. **Neuropsychopharmacology** 1997 Apr;16(4):259–68

Is MK-801 neuroprotection mediated by systemic hypothermia in the immature rat? Gilland E, et al. **Neuroreport** 1997 May 6;8(7):1603–5

The metabotropic glutamate agonist 2-amino-4-phosphonobutyric acid (APB) does not activate currents in postnatal retinal ganglion cells. Liets LC, et al. **Neuroreport** 1996 Nov 25;7(18):2873–7

Neonatal serotonin depletion modifies development but not plasticity in rat barrel cortex. Turlejski K, et al. **Neuroreport** 1997 May 27;8(8):1823–8

Differential effects of bilateral dopamine depletion in neonatal and adult rats. Moy SS, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):425–35 (124 ref.)

Perinatal asphyxia-induced changes in rat brain tyrosine hydroxylase-immunoreactive cell body number: effects of nicotine treatment. Chen Y, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):77–80

Development of GABA and calcium binding proteins immunoreactivity in the rat hippocampus following neonatal anoxia. Dell'Anna E, et al. **Neurosci Lett** 1996 Jun 21;211(2):93–6

Reduced hippocampal in vitro CA1 long-term potentiation in rat offsprings with increased circulating corticosterone during neonatal life. Domenici MR, et al. **Neurosci Lett** 1996 Oct 25;218(1):72–4

Neuropathic pain in neonatal rats. Lee DH, et al. **Neurosci Lett** 1996 May 10;209(2):140–2

The central neural pathways involved in micturition in the neonatal rat as revealed by the injection of pseudorabies

virus into the urinary bladder. Sugaya K, et al. **Neurosci Lett** 1997 Feb 28;223(3):197–200

Quantitative changes of dendrites in rat dentate gyrus and basal nucleus of Meynert after passive avoidance training in the neonatal period. Vozeh F, et al. **Neurosci Lett** 1996 Feb 2;204(1–2):21–4

Exogenous estrogen acts differently on production of estrogen receptor in the preoptic area and the mediobasal hypothalamic nuclei in the newborn rat. Orikasa C, et al. **Neurosci Res** 1996 Jul;25(3):247–54

Inhibition of spinal monosynaptic reflex in newborn rats by aurintricarboxylic acid. Sun X, et al. **Neurosci Res** 1997 Apr;27(4):371–6

Enzymatic inactivation of enkephalin neurotransmitters in the spinal cord of the neonatal rat. Suzuki H, et al. **Neurosci Res** 1997 Jul;28(3):261–7

Response of amoeboid and ramified microglial cells to lipopolysaccharide injections in postnatal rats--a lectin and ultrastructural study. Wu CH, et al. **Neurosci Res** 1997 Feb; 27(2):133–41

Changes in striatal immediate early gene expression following neonatal dopaminergic lesion and effects of intrastriatal dopaminergic transplants. Abrous DN, et al. **Neuroscience** 1996 Jul;73(1):145–59

gp120, a human immunodeficiency virus–1 coat protein, augments excitotoxic hippocampal injury in perinatal rats. Barks JD, et al. **Neuroscience** 1997 Jan;76(2):397–409

Prevention by lamotrigine, MK–801 and N omega–nitro–L–arginine methyl ester of motoneuron cell death after neonatal axotomy. Casanovas A, et al. **Neuroscience** 1996 Mar;71(2):313–25

Induction of transmitter release at the neuromuscular junction prevents motoneuron death after axotomy in neonatal rats. Greensmith L, et al. **Neuroscience** 1996 Mar; 71(1):213–20

Region–specific developmental patterns of atrial natriuretic factor– and nitric oxide–activated guanylyl cyclases in the postnatal frontal rat brain. Markerink–Van Ittersum M, et al. **Neuroscience** 1997 May;78(2):571–87

Early postnatal muscle contractile activity regulates the carbonic anhydrase phenotype of proprioceptive neurons in young and mature mice: evidence for a critical period in development. Mayeux V, et al. **Neuroscience** 1996 Apr; 71(3):787–95

Inhibitory learning and memory in newborn rats influenced by nitric oxide. Mysliveček J, et al. **Neuroscience** 1996 Mar; 71(2):299–312

Enhanced taurine release in cell–damaging conditions in the developing and ageing mouse hippocampus. Saransaari P, et al. **Neuroscience** 1997 Aug;79(3):847–54

Prostaglandin E2 increases the proportion of neonatal rat dorsal root ganglion neurons that respond to bradykinin. Stucky CL, et al. **Neuroscience** 1996 Oct;74(4):1111–23

Lithium enhances synaptic transmission in neonatal rat hippocampus. Valentín A, et al. **Neuroscience** 1997 May; 78(2):385–91

Functional renal maturation in rat neonates after prenatal exposure to furosemide. Mallie JP, et al. **Pediatr Nephrol** 1996 Aug;10(4):458–60

Glomerular basement membrane outpockets and glomerular growth in the postnatal development of the rat kidney. Watanabe H, et al. **Pediatr Nephrol** 1996 Aug;10(4):461–6

Early developmental profiles of plasma corticosterone are altered by birth condition in the rat: a comparison of vaginal birth, cesarean section, and cesarean section with added anoxia. Boksa P. **Pediatr Res** 1997 Jan;41(1):34–43

Absence of acetylcholine– and ionomycin–activated Cl– currents in submandibular cells of early postnatal rats. Fatherazi S, et al. **Pflugers Arch** 1996 Nov–Dec; 433(1–2):116–22

Roles of the voltage–gated K+ channel subunits, Kv 1.5 and Kv 1.4, in the developmental changes of K+ currents in cultured neonatal rat ventricular cells. Guo W, et al. **Pflugers Arch** 1997 Jun;434(2):206–8

Decreased hypothalamic serotonin levels in adult rats treated neonatally with clomipramine. Feenstra MG, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):647–52

Neuroanatomical and functional alterations resulting from early postnatal cerebellar insults in rodents. Ferguson SA. **Pharmacol Biochem Behav** 1996 Dec;55(4):663–71 (120 ref.)

Temporal determinants of neonatal alcohol–induced cerebellar damage and motor performance deficits. Goodlett CR, et al. **Pharmacol Biochem Behav** 1996 Dec; 55(4):531–40

Growth and behavioral effects of early postnatal chromium and manganese exposure in herring gull (larus argentatus) chicks [letter; comment] Symms KG. **Pharmacol Biochem Behav** 1997 Jan;56(1):155–9. Comment on: Pharmacol Biochem Behav 1995 Apr;50(4):607–12.

Effects of neonatally administered iprindole on adult behaviors of rats. Vogel G, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):157–61

Differential effects of prenatal protein malnutrition and prenatal cocaine on a test of homing behavior in rat pups. Tonkiss J, et al. **Physiol Behav** 1996 Sep;60(3):1013–8

Late effects of early nutritional manipulations. Koldovský O, et al. **Physiol Res** 1995;44(6):357–60 (27 ref.)

Calf health in cow–calf herds in Switzerland. Busato A, et al. **Prev Vet Med** 1997 Apr;30(1):9–22

The relationship of calfhood morbidity with survival after calving in 25 New York Holstein herds. Warnick LD, et al. **Prev Vet Med** 1997 Aug;31(3–4):263–73

Effect of ewe and lamb genotype on gestation length, lambing ease and neonatal behaviour of lambs. Dwyer CM, et al. **Reprod Fertil Dev** 1996;8(8):1123–9

Prenatal cocaine: effect on hypoxic ventilatory responsiveness in neonatal rats. Lipton JW, et al. **Respir Physiol** 1996 Nov;106(2):161–9

Laryngeal and diaphragmatic activities with a single expiratory load in newborn lambs. Watts TL, et al. **Respir Physiol** 1997 Jan;107(1):27–35

Phrenic response to hypercapnia in the unanesthetized, decerbrate, newborn rat. Zhou D, et al. **Respir Physiol** 1996 Apr–May;104(1):11–22

Bone marrow transplantation in newborn rats with mucopolysaccharidosis type VI: biochemical, pathological, and clinical findings. Simonaro CM, et al. **Transplantation** 1997 May 27;63(10):1386–93

Color flow Doppler imaging and Doppler spectral analysis of the brain of neonatal dogs. Hudson JA, et al. **Vet Radiol Ultrasound** 1997 Jul–Aug;38(4):313–22

Effects on calves less than one month old of feeding or not feeding them during road transport of up to 24 hours. Knowles TG, et al. **Vet Rec** 1997 Feb 1;140(5):116–24

Reducing perinatal mortality in lambs [letter; comment] [see comments] Lester WA. **Vet Rec** 1997 Feb 1;140(5):136. Comment on: Vet Rec 1996 Nov 9;139(19):455–6. Comment in: Vet Rec 1997 Mar 15;140(11):292.

Risk factors for perinatal and postnatal mortality in lambs. Nash ML, et al. **Vet Rec** 1996 Jul 20;139(3):64–7

Neonatal monocular enucleation and the geniculo–cortical system in the golden hamster: shrinkage in dorsal lateral geniculate nucleus and area 17 and the effects on relay cell size and number. Trevelyan AJ, et al. **Vis Neurosci** 1995 Sep–Oct;12(5):971–83

Collagen dysplasia in a litter of Garafiano shepherd dogs. Rodriguez F, et al. **Zentralbl Veterinarmed A** 1996 Oct; 43(8):509–12

[Physiological variables in calves and their significance for vitality and growth] Steinhardt M, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Aug–Sep; 103(8–9):354–63 (Eng. Abstr.) **(Ger)**

[Sucking and drinking behavior as criteria of vitality in newborn calves] Schulz J, et al. **Tierarztl Prax** 1997 Apr; 25(2):116–22 (Eng. Abstr.) **(Ger)**

[Permeability of blood–brain barrier in newborn rats during hyperthermia–induced seizures] Gurina OI, et al. **Biull Eksp Biol Med** 1997 Feb;123(2):146–9 **(Rus)**

[Characteristics of morphological differentiation of hepatocytes in ontogenesis of different animals depending on the type of nutrition] Kalashnikova MM. **Biull Eksp Biol Med** 1997 Jan;123(1):4–10 (31 ref.) **(Rus)**

PSYCHOLOGY

Perinatal stimulation and adaptation of the neonate. Ronca AE, et al. **Acta Paediatr Suppl** 1996 Oct;416:8–15

Social attachment, brain function, and aggression. Kraemer GW, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:121–35

Impairment of schedule–controlled behavior by pre– and postnatal exposure to hexachlorobenzene in rats. Lilienthal H, et al. **Arch Toxicol** 1996;70(3–4):174–81

Maternal handling during pregnancy reduces DMBA–induced mammary tumorigenesis among female offspring. Hilakivi–Clarke L. **Br J Cancer** 1997;76(2):150–5

Neonatal endotoxin exposure alters the development of social behavior and the hypothalamic–pituitary–adrenal axis in selectively bred mice. Granger DA, et al. **Brain Behav Immun** 1996 Sep;10(3):249–59

Administration of DL–2–amino–5–phosphonovaleric acid (AP5) induces transient inhibition of reminder–activated memory retrieval in day–old chicks. Summers MJ, et al. **Brain Res Cogn Brain Res** 1997 Jun;5(4):311–21

Instrumental learning for a thermal reinforcer in 1–day–old rats. Flory GS, et al. **Dev Psychobiol** 1997 Jan;30(1):41–7

The influence of natural preference for tactile stimuli on appetitive learning in rat pups. Rakover–Atar S, et al. **Dev Psychobiol** 1997 Jan;30(1):29–39

Oral grasping of a surrogate nipple by the newborn rat. Smotherman WP, et al. **Dev Psychobiol** 1997 Jul;31(1):3–17

Offspring–induced nurturance: animal–human parallels. Stern JM. **Dev Psychobiol** 1997 Jul;31(1):19–37 (114 ref.)

Early and later adoptions have different long–term effects on male rat offspring. Barbazanges A, et al. **J Neurosci** 1996 Dec 1;16(23):7783–90

Astrocyte–neuron interaction during one–trial aversive learning in the neonate chick. Hertz L, et al. **Neurosci Biobehav Rev** 1996 Autumn;20(3):537–51 (96 ref.)

Behavioral components of milk–induced activation in neonatal rat pups. Specht SM, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):903–11

URINE

Endogenous angiotensin II inhibits natriuresis after acute volume expansion in the neonatal rat. Chevalier RL, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):R393–7

VIROLOGY

Disordered migration and loss of virus–infected neuronal cells in developing mouse brains infected with murine cytomegalovirus. Shinmura Y, et al. **Acta Neuropathol (Berl)** 1997 Jun;93(6):551–7

Field evaluation of chicken egg yolk immunoglobulins specific for bovine rotavirus in neonatal calves. Kuroki M, et al. **Arch Virol** 1997;142(4):843–51

Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus [see comments] Wyand MS, et al. **Nat Med** 1997 Jan;3(1):32–6. Comment in: Nat Med 1997 Jan;3(1):17–8. Comment in: Nat Med 1997 Aug;3(8):816.

Characterization of upper respiratory disease in rats following neonatal inoculation with a rat–adapted influenza virus. Dye JA, et al. **Vet Pathol** 1996 Jan;33(1):43–54

ANIMALS, NONDOMESTIC see **ANIMALS, WILD**

ANIMALS, POISONOUS

Giant millipede 'burns' and the eye. Hudson BJ, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):183–5

METABOLISM

Occurrence of paralytic shellfish poison in the starfish, Asterias amurensis in Kure Bay, Hiroshima Prefecture, Japan. Asakawa M, et al. **Toxicon** 1997 Jul;35(7):1081–7

ANIMALS, SUCKLING

Lenten cell: ultrastructure, absorptive properties, and enzyme expression of a novel type of cell in the newborn and suckling pig intestinal epithelium. Heath JP, et al. **Anat Rec** 1996 Jan;244(1):95–104

Growth and development of the exocrine pancreas in newborn pigs: the effect of colostrum feeding. Mubiru JN, et al. **Biol Neonate** 1997;71(5):317–26

Sucrase–isomaltase gene expression in suckling rat intestine: hormonal, dietary, and growth factor control. Emvo EN, et al. **J Pediatr Gastroenterol Nutr** 1996 Oct;23(3):262–9

Effects of exogenous neurotensin on intestinal postresectional growth in the suckling rat. López JM, et al. **J Pediatr Gastroenterol Nutr** 1997 Apr;24(4):393–8

The absence of esophageal lesions in maternal progeny of silicone–injected rats [letter] Rasco DS, et al. **Plast Reconstr Surg** 1997 May;99(6):1784–5

Effect of supplementary feeding during the sucking period on net absorption from the small intestine of weaned pigs. Nabuurs MJ, et al. **Res Vet Sci** 1996 Jul;61(1):72–7

[Nursing and suckling behavior and mother–child contacts in domestic rabbits] Schulte I, et al. **Berl Munch Tierarztl Wochenschr** 1997 Apr;110(4):134–8 (Eng. Abstr.) **(Ger)**

GROWTH & DEVELOPMENT

Growth of artificially fed infant rats: effect of supplementation with insulin–like growth factor I. Philipps AF, et al. **Am J Physiol** 1997 May;272(5 Pt 2):R1532–9

Thyroid function in post–weaning rats whose dams were fed a low–protein diet during suckling. Ramos CF, et al. **Braz J Med Biol Res** 1997 Jan;30(1):133–7

Transforming growth factor–alpha in vivo stimulates epithelial cell proliferation in digestive tissues of suckling rats. Hormi K, et al. **Gut** 1996 Oct;39(4):532–8

Maternal lipid intake during pregnancy and lactation alters milk composition and production and litter growth in rats. Del Prado M, et al. **J Nutr** 1997 Mar;127(3):458–62

IMMUNOLOGY

The occurrence of macrophage–like cholera toxin uptake cells in the intestinal villi of suckling rats. Shimodori S, et al. **Pathology** 1996 Jan;28(1):58–64

METABOLISM

Food intake alters muscle protein gain with little effect on Na(+)–K(+)–ATPase and myosin isoforms in suckled rats. Fiorotto ML, et al. **Am J Physiol** 1997 May;272(5 Pt 2):R1461–71

Premature expression of sucrase–isomaltase triggered by corticoid–dependent changes in polyamine metabolism. Nsi–Emvo E, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):G54–9

Organ distribution and biliary excretion of intravenously injected insulin–like growth factor–I in suckling rats. Kong W, et al. **Biol Neonate** 1997;71(4):239–50

Respective roles of glucose and ketone bodies as substrates for cerebral energy metabolism in the suckling rat. Nehlig A. **Dev Neurosci** 1996;18(5–6):426–33

Effect of 3,5,3'–triiodothyronine on maturation of rat renal phosphate transport: kinetic characteristics and phosphate transporter messenger ribonucleic acid and protein abundance. Euzet S, et al. **Endocrinology** 1996 Aug; 137(8):3522–30

Effect of fat content of colostrum on voluntary colostrum intake and fat utilization in newborn pigs. Le Dividich J, et al. **J Anim Sci** 1997 Mar;75(3):707–13

Hexachlorobenzene accumulated by dams during pregnancy is transferred to suckling rats during early lactation. Nakashima Y, et al. **J Nutr** 1997 Apr;127(4):648–54

Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. Gips M, et al. **J Vet Pharmacol Ther** 1996 Apr;19(2):130–4

Apical endocytosis of lectins by the absorptive cells of the suckling rat jejunum in vivo. Oshikawa T, et al. **Okajimas Folia Anat Jpn** 1996 Dec;73(5):229–45

Transport of lanthanides in milk into suckling rats. Marciniak

ANIMALS, SUCKLING

M, et al. **Q J Nucl Med** 1996 Dec;40(4):351–8
Postnatal effect of arecoline on chlorophyllin–modulated hepatic biotransformation system enzymes in suckling neonate and lactating mice. Singh A, et al.
Teratog Carcinog Mutagen 1996;16(2):89–96
[Interaction of vitamin A and zinc in lactating rats. Experimental deficiency model] Yuyama LK, et al.
Arch Latinoam Nutr 1995 Dec;45(4):305–9 (Eng. Abstr.) **(Por)**

MICROBIOLOGY

Dual infection with attaching and effacing Escherichia coli and enterotoxigenic Escherichia coli in post–weaning pigs. Wada Y, et al. **J Comp Pathol** 1996 Jan;114(1):93–9

PHYSIOLOGY

Is the onset of obesity in suckling fa/fa rats linked to a potentially larger milk intake? Buchberger P, et al.
Am J Physiol 1996 Aug;271(2 Pt 2):R472–6
Dietary sodium effects on renin and angiotensinogen gene expression in preweanling WKY and SHR. Kirby RF, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1439–46
Insulin secretion in adult rats that had experienced different underfeeding patterns during their development. Martín MA, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):E634–40
The effect of fasting/refeeding and insulin treatment on the expression of the regulatory genes of ketogenesis in intestine and liver of suckling rats. Arias G, et al.
Arch Biochem Biophys 1997 Apr 15;340(2):287–98
Effect of milk–borne epidermal growth factor on the hepatic microcirculation and Kupffer cell function in suckling rats. McCuskey RS, et al. **Biol Neonate** 1997;71(3):202–6
A modification to the isotope–dilution technique for estimating milk intake of pigs using pig serum. Pluske JR, et al. **J Anim Sci** 1997 May;75(5):1279–83
The role of nursing frequency in milk production in domestic pigs. Spinka M, et al. **J Anim Sci** 1997 May;75(5):1223–8
Effect of feeding a milk replacer to early–weaned pigs on growth, body composition, and small intestinal morphology, compared with suckled littermates. Zijlstra RT, et al. **J Anim Sci** 1996 Dec;74(12):2948–59
Energetics during nursing and early postweaning fasting in hooded seal (Cystophora cristata) pups from the Gulf of St Lawrence, Canada. Lydersen C, et al.
J Comp Physiol [B] 1997 Feb;167(2):81–8
Determinants of rhythm and rate in suckling. German RZ, et al. **J Exp Zool** 1997 May 1;278(1):1–8
Effects of subchronic inhalation of vaporized plastic cement on exploratory behavior and Purkinje cell differentiation in the rat. Pascual R, et al. **J Toxicol Environ Health** 1996 Dec 6;49(5):525–32
Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor epsilon 2 subunit mutant mice. Kutsuwada T, et al.
Neuron 1996 Feb;16(2):333–44
The use of poly R–478 as a marker to determine gastric emptying and intestinal propulsive motility in suckling rats. Shinohara H, et al. **Physiol Res** 1995;44(5):281–6
Mothers and their infants: peptide–mediated physiological, behavioral and affective changes during suckling. Blass EM. **Regul Pept** 1996 Oct 8;66(1–2):109–12 (28 ref.)
[Physiological variables in calves and their significance for vitality and growth] Steinhardt M, et al.
DTW Dtsch Tierarztl Wochenschr 1996 Aug–Sep; 103(8–9):354–63 (Eng. Abstr.) **(Ger)**
[The role of oxytocin in the regulation of feeding behavior of mammalian pups during lactotrophic period] Shcherbakova VI, et al. **Biull Eksp Biol Med** 1994 Apr; 117(4):425–9 **(Rus)**

ANIMALS, TRANSGENIC

see related

CHIMERA

Transgenic rabbit models for the study of atherosclerosis. Taylor JM. **Ann N Y Acad Sci** 1997 Apr 15;811:146–52; discussion 152–4 (23 ref.)
Transgenic animals as new approaches in pharmacological studies. Wei LN. **Annu Rev Pharmacol Toxicol** 1997; 37:119–41 (110 ref.)
Electromechanical microinjection of pink bollworm Pectinophora gossypiella embryos increases survival. Peloquin JJ, et al. **Biotechniques** 1997 Mar;22(3):496–9
Developmental expression of Fos–lacZ in the brains of postnatal transgenic rats. Kasof GM, et al.
Brain Res Dev Brain Res 1996 May 31;93(1–2):191–7
Potential effect of cytokines on transgene expression in primary fibroblasts implanted into the rat brain. Schinstine M, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1–2):195–201
Enhanced cardiac preconditioning in the isolated heart of the transgenic ((mREN–2) 27) hypertensive rat. Randall MD, et al. **Cardiovasc Res** 1997 Feb;33(2):400–9
hGH transgenic rats expressing severe obesity and effect of treatment with hGH in a pulsatile manner. Ikeda A, et al. **Endocr J** 1996 Oct;43 Suppl:S99–101
Sentinel school [news] Manuel J. **Environ Health Perspect** 1996 Sep;104(9):934–6
Transgenic animals in mutation research. Satellite conference to the 1996 meeting of the Environmental Mutagen Society. Sidney, British Columbia, Canada, March 20–23, 1996.
Environ Mol Mutagen 1996;28(4):295–489
Transgenic animal models in reproductive endocrine research. Reventós J, et al. **Eur J Endocrinol** 1997 Jun; 136(6):566–80 (128 ref.)
Viability of transgenic rat embryos after freezing and thawing. Hirabayashi M, et al. **Exp Anim** 1997 Apr; 46(2):111–5
Food biotechnology's challenge to cultural integrity and individual consent. Thompson PB. **Hastings Cent Rep** 1997 Jul–Aug;27(4):34–8 (5 ref.)
High human renin hypertension in transgenic rats. Bohlender J, et al. **Hypertension** 1997 Jan;29(1 Pt 2):428–34
Transgenic rodents in toxicology. Dayan AD.
Int J Exp Pathol 1996 Dec;77(6):251–6 (17 ref.)
Transgenic technology: an introduction. Rülicke T.
Int J Exp Pathol 1996 Dec;77(6):243–5 (0 ref.)
Transgenic animal technology. Wall RJ, et al. **J Androl** 1997 May–Jun;18(3):236–9 (17 ref.)
Assessment of carcinogenicity using transgenic animals. Mitsumori K, et al. **J Toxicol Sci** 1996 Dec;21(5):479–82 (6 ref.)
Activated and inactivated renin–angiotensin system in transgenic animals: from genes to blood pressure. Fukamizu A, et al. **Lab Anim Sci** 1997 Apr;47(2):127–31 (36 ref.)
Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Böhm M, et al.
Mol Cell Biochem 1996 Oct–Nov;163–164:217–21
Transgene expression in mammary glands of newborn rats. Hirabayashi M, et al. **Mol Reprod Dev** 1996 Feb;43(2):145–9
Detection of microinjected genes in bovine preimplantation embryos with combined DNA digestion and polymerase chain reaction. Hyttinen JM, et al. **Mol Reprod Dev** 1996 Feb;43(2):150–7
A new lease on life for transgenic livestock [news] Wall RJ.
Nat Biotechnol 1997 May;15(5):416–7
Referendum's challenge to transgenic research [editorial]
Nature 1997 Sep 11;389(6647):103
Pressure grows for inquiry into welfare of transgenic animals [news] Masood E. **Nature** 1997 Jul 24;388(6640):311–2
Efficient Cre–lox linearisation of BACs: applications to physical mapping and generation of transgenic animals. Mullins LJ, et al. **Nucleic Acids Res** 1997 Jun 15; 25(12):2539–40
Transgenic animals. Docherty K. **Proc Nutr Soc** 1996 Mar; 55(1B):613–8 (17 ref.)
Transgenic and null mutant animals for psychosomatic research. Crnic LS. **Psychosom Med** 1996 Nov–Dec; 58(6):622–32 (57 ref.)
Failure to produce transgenic offspring by intra–tubal insemination of gilts with DNA–treated sperm. Gandolfi F, et al. **Reprod Fertil Dev** 1996;8(7):1055–60
The deleterious effects of human erythropoietin gene driven by the rabbit whey acidic protein gene promoter in transgenic rabbits. Massoud M, et al. **Reprod Nutr Dev** 1996; 36(5):555–63
Biologists mobilize against anti–genetics referendum [news] Koenig R. **Science** 1997 Jan 31;275(5300):607–8
Transgenic lambs from cloning lab [news] Pennisi E.
Science 1997 Aug 1;277(5326):631
Antisense and ribozyme constructs in transgenic animals. Sokol DL, et al. **Transgenic Res** 1996 Nov;5(6):363–71 (89 ref.)
Transgenic frogs and FGF signalling in early development. Smith JC. **Trends Genet** 1996 Nov;12(11):439–40 (35 ref.)
Antisense gene knockdown in the nervous system revisited: optimism for the future. Leslie R, et al.
Trends Neurosci 1997 Aug;20(8):321–2
Generating biological models through gene transfer to domestic animals. Houdebine LM. **Vet Res** 1997 May–Jun; 28(3):201–5 (29 ref.)
[Transgenic models of human thyroid pathologies: hyperfunctional adenoma, anaplastic cancer, differentiated cancer, hypothyroidism] Ledent C.
Bull Mem Acad R Med Belg 1996;151(2):195–201 (Eng. Abstr.) **(Fre)**
[Transgenic foods—advantages and risks] Mannhalter C.
Wien Klin Wochenschr 1997 Jan 31;109(2):33–9 (20 ref.) **(Ger)**
[Essays on modern molecular genetics from a lecture course for students of the biology department of Moscow State University. Essay 5. Transgenosis and new molecular genetics] Sverdlov ED. **Mol Gen Mikrobiol Virusol** 1996 Oct–Dec;(4):3–32 (65 ref.) **(Rus)**

EMBRYOLOGY

Nuclear transplantation from stably transfected cultured cells of Xenopus. Chan AP, et al. **Int J Dev Biol** 1996 Apr; 40(2):441–51

GENETICS

Proximal tubular fluid, kidney, and plasma levels of angiotensin II in hypertensive ren–2 transgenic rats. Mitchell KD, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F246–53
Circadian rhythms in renal function in hypertensive TGR(mRen–2)27 rats and their normotensive controls. Pons M, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R1002–8
Effects of heredity on response to drugs and environmental chemicals: construction of rodent models. Levy GN, et al. **Chem Res Toxicol** 1996 Dec;9(8):1215–24 (83 ref.)
Recombinant protein production in transgenic animals. Echelard Y. **Curr Opin Biotechnol** 1996 Oct;7(5):536–40 (60 ref.)
Database and software for the analysis of mutations at the lacI gene in both transgenic rodents and bacteria. Cariello NF, et al. **Environ Mol Mutagen** 1996;28(4):397–404
Mutational spectra in transgenic animal research: data analysis and study design based upon the mutant or mutation frequency. Carr GJ, et al.
Environ Mol Mutagen 1996;28(4):405–13
Mutational spectra of tamoxifen–induced mutations in the livers of lacI transgenic rats. Davies R, et al.
Environ Mol Mutagen 1996;28(4):430–3
An efficient laboratory protocol for the sequencing of large numbers of lacI mutants recovered from Big Blue transgenic animals. Erfle HL, et al.
Environ Mol Mutagen 1996;28(4):393–6
State of the art in transgenic animals in mutation research. Gorelick NJ, et al. **Environ Mol Mutagen** 1996;28(4):295–8
A strategy for the application of transgenic rodent mutagenesis assays. Gorelick NJ, et al.
Environ Mol Mutagen 1996;28(4):434–42 (83 ref.)
Initial consideration for use of transgenic mutation assays in a regulatory submission. Sofuni T, et al.
Environ Mol Mutagen 1996;28(4):443–6
Transgenic pigs—breakthrough in xenotransplantation. Braidley P, et al. **Isr J Med Sci** 1996 Oct;32(10):795–8; discussion 1052
Lifelong angiotensin–converting enzyme inhibition, pressure natriuresis, and renin–angiotensin system gene expression in transgenic (mRen–2)27 rats. Lippoldt A, et al.
J Am Soc Nephrol 1996 Oct;7(10):2119–29
Genomes of two water frog species resist germ line exclusion in interspecies hybrids. Guerrini F, et al. **J Exp Zool** 1997 Oct 1;279(2):163–76
Transgenics and essential hypertension. Mullins LJ, et al.
J Hum Hypertens 1996 Oct;10(10):627–31 (48 ref.)
Transgenic animal models: new avenues in cardiovascular physiology. Franz WM, et al. **J Mol Med** 1997 Feb; 75(2):115–29
Developmental biology. High hops of transgenic frogs [news] Slack JM. **Nature** 1996 Oct 31;383(6603):765–6
Do transgene arrays form heterochromatin in vertebrates? Dorer DR. **Transgenic Res** 1997 Jan;6(1):3–10 (60 ref.)
Phenotypic and genotypic stability of multiple lines of transgenic pigs expressing recombinant human protein C. Van Cott KE, et al. **Transgenic Res** 1997 May;6(3):203–12
Rapid identification of transgenic zebrafish. Kawakami K, et al. **Trends Genet** 1996 Jan;12(1):9–10
[Methods of production and perspectives for use of transgenic domestic animals] Espanion G, et al.
DTW Dtsch Tierarztl Wochenschr 1996 Aug–Sep; 103(8–9):320–8 (147 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Transgenic rabbits expressing human apolipoprotein A–I in the liver. Duverger N, et al.
Arterioscler Thromb Vasc Biol 1996 Dec;16(12):1424–9
Recombinant protein productio· in transgenic animals. Echelard Y. **Curr Opin Biotechnol** 1996 Oct;7(5):536–40 (60 ref.)
Transgenic livestock as drug factories. Velander WH, et al. **Sci Am** 1997 Jan;276(1):70–4
Blood proteins from transgenic animal bioreactors. Luboń H, et al. **Transfus Med Rev** 1996 Apr;10(2):131–43 (86 ref.)
Do transgene arrays form heterochromatin in vertebrates? Dorer DR. **Transgenic Res** 1997 Jan;6(1):3–10 (60 ref.)

PHYSIOLOGY

Genotype and cardiovascular phenotype: lessons from genetically manipulated animals and diseased humans. Sharp MG, et al. **Curr Opin Nephrol Hypertens** 1997 Jan; 6(1):51–7 (59 ref.)
Incorporation of cultured embryonic cells into transgenic and chimeric, porcine fetuses. Notarianni E, et al.
Int J Dev Biol 1997 Jun;41(3):537–40
Transgenic human decay accelerating factor makes normal pigs function as a concordant species. Schmoeckel M, et al. **J Heart Lung Transplant** 1997 Jul;16(7):758–64
Transgenic animal models: new avenues in cardiovascular physiology. Franz WM, et al. **J Mol Med** 1997 Feb; 75(2):115–29
Transgenic modeling of neuropsychiatric disorders. Campbell IL, et al. **Mol Psychiatry** 1996 May;1(2):105–20 (148 ref.)
Transgenic animal models as tools for studying renal developmental physiology. Davisson RL, et al.
Pediatr Nephrol 1996 Dec;10(6):798–803 (58 ref.)

VIROLOGY

Licensing of protein products from the milk of transgenic animals. Validation for pathogen removal—a strategy. Wright G, et al. **Dev Biol Stand** 1996;88:269–76

ANIMALS, WILD

Comparison of hemisphere size in wild and domestic geese. Kalisińska E. **Anat Histol Embryol** 1997 Mar;26(1):3–9
Simondsia paradoxa: newly recorded nematode parasite from feral pigs in Australia. Spratt DM, et al. **Aust Vet J** 1996 Nov;74(5):394–5
The comeback trail: Africa's bid to save its endangered animals. Tribe A. **Aust Vet J** 1996 Jul;74(1):76–7
The Canadian Cooperative Wildlife Health Centre and

surveillance of wild animal diseases in Canada. Leighton FA, et al. **Can Vet J** 1997 May;38(5):279–84

The relationship between the Canadian Wildlife Service Specimen Bank and the Wildlife Toxicology Program: the effect on specimen collection. Wakeford BJ, et al. **Chemosphere** 1997 May;34(9–10):1933–8

Disrupted patterns of behavior in natural populations as an index of ecotoxicity. Peakall DB. **Environ Health Perspect** 1996 Apr;104 Suppl 2:331–5 (33 ref.)

Cooperation key to handling feral cat population [news] Inserro JC. **J Am Vet Med Assoc** 1997 May 15; 210(10):1399–400

Compendium of animal rabies control, 1997. National Association of State Public Health Veterinarians [published erratum appears in J Am Vet Med Assoc 1997 Feb 1;210(3):344] Jenkins R, et al. **J Am Vet Med Assoc** 1997 Jan 1;210(1):33–7

Rabies surveillance in the United States during 1995. Krebs JW, et al. **J Am Vet Med Assoc** 1996 Dec 15; 209(12):2031–44

Another viewpoint on trap–sterilize–release programs [letter; comment] Patronek GJ. **J Am Vet Med Assoc** 1996 Sep 15;209(6):1061–3. Comment on: J Am Vet Med Assoc 1996 Jul 1;209(1):34–5.

Different viewpoints on trap–sterilize–release programs [letter; comment] [see comments] Stone EG, et al. **J Am Vet Med Assoc** 1996 Jul 1;209(1):34–5. Comment on: J Am Vet Med Assoc 1996 Feb 15;208(4):520–3. Comment in: J Am Vet Med Assoc 1996 Sep 15;209(6):1061–3.

Identification of pesticide poisoning in wildlife. Brown P, et al. **J Chromatogr A** 1996 Nov 22;754(1–2):463–78 (43 ref.)

Poisoning of wildlife in South Africa. Fourie N, et al. **J S Afr Vet Assoc** 1996 Jun;67(2):74–6

Disease and mortality in captive wild dogs (Lycaon pictus). van Heerden J, et al. **J S Afr Vet Assoc** 1996 Sep; 67(3):141–5

Statutory controls on viral haemorrhagic disease of rabbits to be removed [news] Elliott J. **J Small Anim Pract** 1996 Nov;37(11):564

Forensic (medico–legal) necropsy of wildlife. Wobeser G. **J Wildl Dis** 1996 Apr;32(2):240–9 (9 ref.)

Lead poisoning and intestinal perforations in a snapping turtle (Chelydra serpentina) due to fishing gear ingestion. Borkowski R. **J Zoo Wildl Med** 1997 Mar;28(1):109–13

Mercury distribution in American alligators (Alligator mississippiensis) in Florida. Heaton–Jones TG, et al. **J Zoo Wildl Med** 1997 Mar;28(1):62–70

Think link: critically evaluating linkages between conservation projects and development [editorial] Osofsky SA. **J Zoo Wildl Med** 1997 Jun;28(2):141–3

Organochlorine pesticides associated with ocular, nasal, or otic infection in the eastern box turtle (Terrapene carolina carolina). Tangredi BP, et al. **J Zoo Wildl Med** 1997 Mar; 28(1):97–100

Taking a lead from wildlife. Colborn T, et al. **Neurotoxicol Teratol** 1996 May–Jun;18(3):235–7; discussion 271–6 (21 ref.)

A comparison of fertility control and lethal control of bovine tuberculosis in badgers: the impact of perturbation induced transmission. Swinton J, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 May 29; 352(1353):619–31

Characteristics and motives of adolescent volunteers in wildlife education. Kidd AH, et al. **Psychol Rep** 1997 Jun; 80(3 Pt 1):747–53

Characteristics and motives of volunteers in wildlife rehabilitation. Kidd AH, et al. **Psychol Rep** 1996 Aug; 79(1):227–34

Current issues in rabies prevention in the United States health dilemmas. Public coffers, private interests. Rupprecht CE, et al. **Public Health Rep** 1996 Sep–Oct;111(5):400–7

Proceedings from the 4th International Conference on Fertility Control for Wildlife Management. Great Keppel Island, Queensland, 8–11 July 1996. **Reprod Fertil Dev** 1997; 9(1):1–186

Managing problem wildlife in the 'Old World': a veterinary perspective. Artois M. **Reprod Fertil Dev** 1997;9(1):17–25 (98 ref.)

Potential consequences and problems with wildlife contraceptives. Nettles VF. **Reprod Fertil Dev** 1997; 9(1):137–43 (75 ref.)

Ethical aspects and dilemmas of fertility control of unwanted wildlife: an animal welfarist's perspective. Oogjes G. **Reprod Fertil Dev** 1997;9(1):163–7 (8 ref.)

Neither human nor natural: ethics and feral animals. Singer P. **Reprod Fertil Dev** 1997;9(1):157–62 (7 ref.)

Zoonoses and fertility control in wildlife—requirements for vaccines. Stöhr K, et al. **Reprod Fertil Dev** 1997;9(1):149–55 (59 ref.)

Rubber tire leachates in the aquatic environment. Evans JJ. **Rev Environ Contam Toxicol** 1997;151:67–115 (125 ref.)

Organochlorine insecticide residues in African Fauna: 1971–1995. Wiktelius S, et al. **Rev Environ Contam Toxicol** 1997;151:1–37 (100 ref.)

Wildlife husbandry and diseases. **Rev Sci Tech** 1996 Mar; 15(1):1–342

Special challenges of maintaining wild animals in captivity: a southern African perspective. Colly LP, et al. **Rev Sci Tech** 1996 Mar;15(1):237–49 (14 ref.)

An overview of wildlife husbandry and diseases in captivity. Fowler ME. **Rev Sci Tech** 1996 Mar;15(1):15–42 **(Eng, Fre, Spa)**

Validity of using serological tests for diagnosis of diseases in wild animals. Gardner IA, et al. **Rev Sci Tech** 1996 Mar; 15(1):323–35 (20 ref.)

A perspective on the risk assessment process for endocrine–disruptive effects on wildlife and human health. Kavlock RJ, et al. **Risk Anal** 1996 Dec;16(6):731–9 (65 ref.)

Mechanisms of transmission of Aujeszky's disease virus originating from feral swine in the USA. Hahn EC, et al. **Vet Microbiol** 1997 Apr;55(1–4):123–30

Genital infection and transmission of pseudorabies virus in feral swine in Florida, USA. Romero CH, et al. **Vet Microbiol** 1997 Apr;55(1–4):131–9

Monitoring of porcine reproductive and respiratory syndrome virus infection in boars. Shin J, et al. **Vet Microbiol** 1997 Apr;55(1–4):337–46

Diseases in wild animals in relation to nature management. Broekhuizen S. **Vet Q** 1996;18 Suppl 3:S143–5 (8 ref.)

Leptospirosis in wild animals. Hartskeerl RA, et al. **Vet Q** 1996;18 Suppl 3:S149–50 (12 ref.)

Emerging diseases with a worldwide impact and the consequences for veterinary curricula. Osburn BI. **Vet Q** 1996;18 Suppl 3:S124–6 (0 ref.)

Veterinary science and nature management. Over HJ. **Vet Q** 1996;18 Suppl 3:S158

Wildlife diseases in The Netherlands [editorial] van Dijk JE, et al. **Vet Q** 1996;18 Suppl 3:S123

Parasitic zoonoses in wildlife. van Knapen F. **Vet Q** 1996; 18 Suppl 3:S141–2 (0 ref.)

Paratuberculosis in wild rabbits (Oryctolagus cuniculus) [see comments] Greig A, et al. **Vet Rec** 1997 Feb 8;140(6):141–3 . Comment in: Vet Rec 1997 Mar 15;140(11):292.

Pathological study of visceral leishmaniasis in a jackal (Canis aureus). Hervás J, et al. **Vet Rec** 1996 Sep 21;139(12):293–5

Adrenal cortical carcinoma in a free–ranging mouflon (Ovis musimon). Marco–Sánchez I, et al. **Vet Rec** 1996 Sep 7; 139(10):236–7

Hard decisions on TB [letter] Watson CL, et al. **Vet Rec** 1997 May 3;140(18):487

[Differential diagnosis of resorptive tooth diseases and caries] Berger M, et al. **Schweiz Arch Tierheilkd** 1996; 138(11):546–51 (Eng. Abstr.) **(Ger)**

[Liberation into the wild of wild felines—danger of the release of virus infections] Lutz H, et al. **Schweiz Arch Tierheilkd** 1996;138(12):579–85 (Eng. Abstr.) **(Ger)**

[Prehistoric fauna in Bulgaria] Manhart H. **Tierarztl Prax** 1997 Jan;25(1):15–7 (Eng. Abstr.) **(Ger)**

[Diversity of life—and the seventh great mass extinction] Hauge A. **Tidsskr Nor Laegeforen** 1997 Jan 10;117(1):76–81 **(Nor)**

[Forestry Law and the conservation of natural areas and wildlife] Villacrés V, et al. **J Ethnopharmacol** 1996 Apr; 51(1–3):167–72 (9 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Fluoride–induced lesions in the teeth of the short–tailed field vole (Microtus agrestis): a description of the dental pathology. Boulton IC, et al. **J Morphol** 1997 May; 232(2):155–67

BLOOD

Plasma alpha–tocopherol, beta–carotene, and lipid levels in semi–free–ranging Przewalski horses (Equus przewalskii). Dierenfeld ES, et al. **J Zoo Wildl Med** 1997 Jun;28(2):144–7

EMBRYOLOGY

[The creation of genetic cryobanks and the use of the methods of developmental biology as a means for preserving rare animal species. II. The obtaining and cryopreservation of the embryos of wild mammals] Rott NN. **Ontogenez** 1996 Jul–Aug;27(4):245–55 (84 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Conservation of British wildlife [news] **Vet Rec** 1996 Aug 3;139(5):103–4

IMMUNOLOGY

Use of enzyme–labelled protein G assay for the detection of anti Borrelia burgdorferi antibodies in wild animal sera. Deruaz D, et al. **Eur J Epidemiol** 1996 Oct;12(5):515–9

Amebicidal activity of wild animal serum. John DT, et al. **J Parasitol** 1997 Aug;83(4):757–9

Applications of pig zona pellucida immunocontraception to wildlife fertility control. Kirkpatrick JF, et al. **J Reprod Fertil Suppl** 1996;50:183–9

METABOLISM

The use of a tympanic membrane thermometer for assessing hyperthermia in bighorn sheep. Drew ML. **J Wildl Dis** 1996 Jul;32(3):512–6

Accumulation of cadmium and lead in red deer and wild boar at the Veluwe, The Netherlands. Kuiters AT. **Vet Q** 1996;18 Suppl 3:S134–5

MICROBIOLOGY

Isolation of Yersinia from wild animals living in suburbs of Tokyo and Yokohama. Suzuki A, et al. **Contrib Microbiol Immunol** 1995;13:43–5

Ecology study of Yersiniae isolated from small terrestrial mammals captured in the territory of the Barrage System Gabcikovo 1990–1994. Urgeová E, et al. **Contrib Microbiol Immunol** 1995;13:46–7

Tularemia: association with hunting and farming. Stewart SJ. **FEMS Immunol Med Microbiol** 1996 Mar;13(3):197–99

Location and ultrastructure of Borrelia japonica in naturally infected Ixodes ovatus and small mammals. Yano Y, et al. **Microbiol Immunol** 1997;41(1):13–9

New records of Histoplasma capsulatum from wild animals in the Brazilian Amazon. Naiff RD, et al. **Rev Inst Med Trop Sao Paulo** 1996 Jul–Aug;38(4):273–7

PARASITOLOGY

Environmental and human influence on the ecology of Trichinella spiralis and Trichinella britovi in Western Europe. Pozio E, et al. **Parasitology** 1996 Dec;113 (Pt 6):527–33

Contribution to the knowledge of Ixodidae ticks of wild mammals of Somalia. Iori A, et al. **Parassitologia** 1996 Dec; 38(3):571–3

Contribution to the knowledge of helminthofauna of wild mammals of Somalia. Iori A, et al. **Parassitologia** 1996 Dec; 38(3):511–5

Prevalence of Cryptosporidium spp. oocysts in cattle and wildlife in Morogoro region, Tanzania. Mtambo MM, et al. **Prev Vet Med** 1997 Aug;31(3–4):185–90

Evidences against a significant role of Mus musculus as natural host for Angiostrongylus costaricensis. dos Santos FT, et al. **Rev Inst Med Trop Sao Paulo** 1996 May–Jun; 38(3):171–5

Hepatozoon canis infection of wild carnivores in Brazil. Alencar NX, et al. **Vet Parasitol** 1997 Jul 1;70(4):279–82

Wildlife parasites: lessons for parasite control in livestock. Malan FS, et al. **Vet Parasitol** 1997 Jul 31;71(2–3):137–53 (69 ref.)

The effect of parasites on wildlife. Borgsteede FH. **Vet Q** 1996;18 Suppl 3:S138–40 (18 ref.)

[Effect of flubendazole on Muellerius capillaris in mouflon] Lamka J, et al. **Vet Med (Praha)** 1996 Nov;41(11):347–50 (Eng. Abstr.) **(Cze)**

[Anti–toxoplasma antibody levels in the main–land raccoon dog, Nyctereutes procyonoides viverrinus, in southeastern Kanagawa prefecture] Murasugi E, et al. **Kansenshogaku Zasshi** 1996 Oct;70(10):1068–71 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Lead and behavioral development: parental compensation for behaviorally impaired chicks. Burger J, et al. **Pharmacol Biochem Behav** 1996 Nov;55(3):339–49

Comparing different forms of male and female aggression in wild and laboratory mice: an ethopharmacological study. Ferrari PF, et al. **Physiol Behav** 1996 Aug;60(2):549–53

Corticosterone and the stress response in young western screech–owls: effects of captivity, gender, and activity period. Dufty AM Jr, et al. **Physiol Zool** 1997 Mar–Apr; 70(2):143–9

The effect of parasites on wildlife. Borgsteede FH. **Vet Q** 1996;18 Suppl 3:S138–40 (18 ref.)

Health and welfare issues related to using (domestic) ungulates for the management of nature parks in The Netherlands. Oosterbaan J, et al. **Vet Q** 1996;18 Suppl 3:S153–5 (15 ref.)

Effects of environmental contaminants in wildlife species. Seinen W. **Vet Q** 1996;18 Suppl 3:S129

PSYCHOLOGY

"Stepping–sticks" and "seat–sticks": new types of tools used by wild chimpanzees (Pan troglodytes) in Sierra Leone. Alp R. **Am J Primatol** 1997;41(1):45–52

URINE

Solid–phase extraction method for the quantitative analysis of organochlorine pesticides in wildlife urine. Petty EE, et al. **J Chromatogr Sci** 1997 Sep;35(9):430–4

Molecular heterogeneity of urinary proteins in wild house mouse populations. Robertson DH, et al. **Rapid Commun Mass Spectrom** 1997;11(7):786–90

VIROLOGY

Sero–surveying wildlife: a needle in a haystack? **Aust Vet J** 1996 Sep;74(3):257–8

Evidence of hantavirus in wild rodents in Northern Ireland. McCaughey C, et al. **Epidemiol Infect** 1996 Oct; 117(2):361–5

Mouse mammary tumor virus and mammary tumorigenesis in wild mice. Imai S. **Pathol Int** 1996 Dec;46(12):919–32 (136 ref.)

Isolation and characterisation of an Aujeszky's disease virus naturally infecting a wild boar (Sus scrofa). Capua I, et al. **Vet Microbiol** 1997 Apr;55(1–4):141–6

[Virus transmission in the tropical environment, the socio–ecology of primates and the balance of ecosystems] Galat G, et al. **Sante** 1997 Mar–Apr;7(2):81–7 (Eng. Abstr.)

(Fre)

ANIMALS, ZOO

Clinical challenge. Osteomyelitis of the distal half of the metacarpus with associated involucrum and bone sequestrum formation. Clippinger TL, et al. **J Zoo Wildl Med** 1997 Mar;28(1):115–9

Mercury distribution in American alligators (Alligator mississippiensis) in Florida. Heaton-Jones TG, et al. **J Zoo Wildl Med** 1997 Mar;28(1):62–70

Chlamydiosis in a fishing cat (Felis viverrina). Kik MJ, et al. **J Zoo Wildl Med** 1997 Jun;28(2):212–4

Lead and zinc intoxication in zoological medicine: a review. Mautino M. **J Zoo Wildl Med** 1997 Mar;28(1):28–35 (73 ref.)

Zinc toxicosis in a Celebes ape (Macaca nigra) following ingestion of pennies. Murray S, et al. **J Zoo Wildl Med** 1997 Mar;28(1):101–4

Think link: critically evaluating linkages between conservation projects and development [editorial] Osofsky SA. **J Zoo Wildl Med** 1997 Jun;28(2):141–3

Toxicant use in the zoo environment. Plumlee KH. **J Zoo Wildl Med** 1997 Mar;28(1):20–7 (22 ref.)

Encephalomyocarditis virus infections in an Australian zoo. Reddacliff LA, et al. **J Zoo Wildl Med** 1997 Jun;28(2):153–7

Cryptococcosis in tree shrews (Tupaia tana and Tupaia minor) and elephant shrews (Macroscelides proboscides). Tell LA, et al. **J Zoo Wildl Med** 1997 Jun;28(2):175–81

Presumptive red maple (Acer rubrum) toxicosis in Grevy's zebra (Equus grevyi). Weber M, et al. **J Zoo Wildl Med** 1997 Mar;28(1):105–8

Special challenges of maintaining wild animals in captivity in North America. Cambre RC, et al. **Rev Sci Tech** 1996 Mar;15(1):251–66 (24 ref.)

Special challenges of maintaining wild animals in captivity in South America. Cubas ZS. **Rev Sci Tech** 1996 Mar; 15(1):267–87 (26 ref.)

Development and challenges of wildlife husbandry: concluding remarks. Fowler ME. **Rev Sci Tech** 1996 Mar; 15(1):337–42

An overview of wildlife husbandry and diseases in captivity. Fowler ME. **Rev Sci Tech** 1996 Mar;15(1):15–42 (Eng, Fre, Spa)

Husbandry and diseases of captive wild swine and peccaries. Fowler ME. **Rev Sci Tech** 1996 Mar;15(1):141–54 (14 ref.)

Tuberculosis in free-ranging, semi free-ranging and captive cervids. Hunter DL. **Rev Sci Tech** 1996 Mar;15(1):171–81 (17 ref.)

Infectious and parasitic disease of captive reptiles and amphibians, with special emphasis on husbandry practices which prevent or promote diseases. Ippen R, et al. **Rev Sci Tech** 1996 Mar;15(1):43–54 (1 ref.)

Special challenges of maintaining wildlife in captivity in Europe and Asia. Kirkwood JK. **Rev Sci Tech** 1996 Mar; 15(1):309–21 (57 ref.)

Management protocols for animals in captive propagation and reintroduction programmes. Mikota SK, et al. **Rev Sci Tech** 1996 Mar;15(1):191–208 (35 ref.)

Quarantine protocols and preventive medicine procedures for reptiles, birds and mammals in zoos. Miller RE. **Rev Sci Tech** 1996 Mar;15(1):183–9 (1 ref.)

Dealing with infectious and parasitic diseases in safari parks, roadside menageries, exotic animal auctions and rehabilitation centres. Porter SL. **Rev Sci Tech** 1996 Mar; 15(1):227–36 (20 ref.)

Special challenges of maintaining wild animals in captivity in Australia and New Zealand: prevention of infectious and parasitic diseases. Schultz DJ, et al. **Rev Sci Tech** 1996 Mar;15(1):289–308 (53 ref.)

Infectious and parasitic diseases of captive carnivores, with special emphasis on the black-footed ferret (Mustela nigripes). Williams ES, et al. **Rev Sci Tech** 1996 Mar; 15(1):91–114 (154 ref.)

Husbandry practices employed by private aviculturists, bird markets and zoo collections, which may be conducive to fostering infectious diseases. Wolff PL. **Rev Sci Tech** 1996 Mar;15(1):55–71 (60 ref.)

Acute Chagas' cardiopathy in a polar bear (Ursus maritimus) in Guadalajara, Mexico. Jaime-Andrade J, et al. **Rev Soc Bras Med Trop** 1997 Jul-Aug;30(4):337–40 (13 ref.)

Epizootic disseminated toxoplasmosis in captive slender-tailed meerkats (Suricata suricatta). Juan-Sallés C, et al. **Vet Pathol** 1997 Jan;34(1):1–7

[Infectious pathology of Canidae and Felidae in zoological parks] Artois M, et al. **Rev Sci Tech** 1996 Mar;15(1):115–40 (50 ref.) (Eng. Abstr.) (Fre)

[Zoo and animal medicine] Schulze W. **DTW Dtsch Tierarztl Wochenschr** 1996 May;103(5):157–9 (Eng. Abstr.) (Ger)

[Differential diagnosis of resorptive tooth diseases and caries] Berger M, et al. **Schweiz Arch Tierheilkd** 1996; 138(11):546–51 (Eng. Abstr.) (Ger)

[The zoo veterinarian in changing times] Hatt JM, et al. **Schweiz Arch Tierheilkd** 1996;138(12):573–8 (21 ref.) (Eng. Abstr.) (Ger)

[Liberation into the wild of wild felines—danger of the release of virus infections] Lutz H, et al. **Schweiz Arch Tierheilkd** 1996;138(12):579–85 (Eng. Abstr.) (Ger)

[Animal welfare aspects relevant to the design of the spectacled bear facility in the Zürich Zoo] Rübel A. **Schweiz Arch Tierheilkd** 1996;138(12):586–90 (Eng. Abstr.) (Ger)

MICROBIOLOGY

Presence of vancomycin-resistant enterococci in farm and pet animals. Devriese LA, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2285–7

Demonstration of Helicobacter pylori-like organisms in the gastric mucosa of captive exotic carnivores. Jakob W, et al. **J Comp Pathol** 1997 Jan;116(1):21–33

Fecal shedding of Salmonella in exotic felids. Clyde VL, et al. **J Zoo Wildl Med** 1997 Jun;28(2):148–52

PARASITOLOGY

A survey for Cryptosporidium spp. in mammals at the Barcelona Zoo. Gómez MS, et al. **Int J Parasitol** 1996 Nov; 26(11):1331–3

Fatal hepatic sarcocystosis in two polar bears (Ursus maritimus). Garner HM, et al. **J Parasitol** 1997 Jun; 83(3):523–6

Antelopes (Bovidae) kept in European zoological gardens as intermediate hosts of Sarcocystis species. Stolte M, et al. **Parassitologia** 1996 Dec;38(3):565–70

[Detection of intestinal parasites from main-land raccoon dogs, Nyctereutes procyonoides viverrinus, in southeastern Kanagawa Prefecture] Asano R, et al. **Kansenshogaku Zasshi** 1997 Jul;71(7):664–7 (Eng. Abstr.) (Jpn)

PHYSIOLOGY

Chemical immobilisation of giraffe to facilitate short procedures. Vogelnest L, et al. **Aust Vet J** 1997 Mar; 75(3):180–2

PSYCHOLOGY

Use of fluoxetine for the treatment of stereotypical pacing behavior in a captive polar bear [see comments] Poulsen EM, et al. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1470–4 . Comment in: J Am Vet Med Assoc 1996 Dec 15;209(12):1995–6.

Viewing of self and nonself images in a group of captive orangutans (Pongo pygmaeus Abellii). Tobach E, et al. **Percept Mot Skills** 1997 Apr;84(2):355–70

VIROLOGY

Prevalence of Epstein-Barr virus (EBV) antibodies in primate stocks of zoological gardens. Fellinger J, et al. **J Med Primatol** 1996 Oct;25(5):327–32

ANION EXCHANGE RESINS

CHEMISTRY

Effect of mobile phase composition on selectivity in preparative hydrophobic interaction chromatographic purification of glucagon. Angelova M, et al. **Biomed Chromatogr** 1996 Sep-Oct;10(5):251–5

Comparison of anion-exchange and hydroxyapatite displacement chromatography for the isolation of whey proteins. Vogt S, et al. **J Chromatogr A** 1997 Jan 24; 760(1):125–37

Influence of column type and chromatographic conditions on the ion-exchange chromatography of immunoglobulins. Yang YB, et al. **J Chromatogr A** 1996 Aug 30;743(1):171–80

Differential behavior of (25R)-5,6-epoxyspirostan-22 alpha-O-3 beta-ol and (25R)-5,6-epoxyspirostan-22 alpha-O-3 beta, 4 beta-diol toward Dowex. Korde SS, et al. **Steroids** 1996 May;61(5):290–5

PHARMACOLOGY

Effect of cholestyramine resin on single dose valproate pharmacokinetics. Malloy MJ, et al. **Int J Clin Pharmacol Ther** 1996 May;34(5):208–11

Effects of cholestyramine and parenteral nutrition on hepatic metabolism of lidocaine: a study using isolated rat liver perfusion. Zaman N, et al. **JPEN J Parenter Enteral Nutr** 1996 Sep-Oct;20(5):349–56

ANION EXCHANGERS see **ANTIPORTERS**

ANION GAP see **ACID-BASE EQUILIBRIUM**

ANION PUMPS see **ION PUMPS**

ANION TRANSPORT PROTEIN, ERYTHROCYTE see **BAND 3 PROTEIN**

ANIONS

Charge density-dependent strength of hydration and biological structure. Collins KD. **Biophys J** 1997 Jan; 72(1):65–76

Effects of catholytes on the mobilization of proteins after capillary isoelectric focusing. Manabe T, et al. **Electrophoresis** 1997 Jan;18(1):92–7

The relationship among dietary undetermined anion, acid-base balance, and nutrient metabolism in swine. Patience JF, et al. **J Anim Sci** 1997 Sep;75(9):2445–52

Mineral status in beef cows fed broiler litter diets with cation-anion differences or supplemented with hay. Rude BJ, et al. **J Anim Sci** 1997 Mar;75(3):727–35

Carbonate interferences by ion chromatographic determination of anions in mineral waters. Novič M, et al. **J Chromatogr A** 1997 Mar 14;764(2):249–56

Influence of the inorganic counterion on the chiral micellar electrokinetic separation of basic drugs using the surfactant N-dodecoxycarbonylvaline. Peterson AG, et al. **J Chromatogr B Biomed Appl** 1997 Jul 18;695(1):131–45

Multinuclear MR frequency shifts of hydrated ions as a function of applied pressure and temperature. Sarkar SN, et al. **J Magn Reson B** 1996 Aug;112(2):197–9 (12 ref.)

ANALYSIS

Utilization of lipophilic ionic additives in liquid polymer film optodes for selective anion activity measurements. Barker SL, et al. **Anal Chem** 1997 Mar 15;69(6):990–5

Capillary zone electrophoresis of inorganic anions with conductivity detection. Kaniansky D, et al. **Electrophoresis** 1996 Dec;17(12):1890–7

Acid anion profiles in dental plaque following consumption of cereal-based foods and fruits. Pollard MA, et al. **Eur J Oral Sci** 1996 Oct-Dec;104(5–6):535–9

Electrolytes in the cornea: a therapeutic challenge [published erratum appears in Graefes Arch Clin Exp Ophthalmol 1997 Apr;235(4):262] Schrage NF, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Dec;234(12):761–4

Ion chromatographic characterization of toxic solutions: analysis and ion chemistry of biological liquids. Singh RP, et al. **J Chromatogr A** 1997 Jul 11;774(1–2):21–35 (83 ref.)

Validation of ion chromatographic methods for the trace analysis of ions in pharmacopoeial grades of water. Waterworth JP. **J Chromatogr A** 1997 May 16; 770(1–2):99–104

Endothelial-derived superoxide anions in pig coronary arteries: evidence from lucigenin chemiluminescence and histochemical techniques. Brandes RP, et al. **J Physiol (Lond)** 1997 Apr 15;500 (Pt 2):331–42

ANTAGONISTS & INHIBITORS

Effect of anion transport inhibition on mucus secretion by airway submucosal glands. Inglis SK, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):L372–7

CHEMISTRY

Superoxide anion scavenging effect of coumarins. Chang WS, et al. **Am J Chin Med** 1996;24(1):11–7

Anion binding to cytochrome c2: implications on protein-Ion interactions in class I cytochromes c. Battistuzzi G, et al. **Arch Biochem Biophys** 1997 Mar 15;339(2):283–90

Determination of thiocyanate anion by high-performance liquid chromatography with fluorimetric detection. Chen SH, et al. **J Anal Toxicol** 1996 Jan-Feb;20(1):38–42

Ion-pair chromatography of methotrexate in a column-switching system using an alkyl-diol silica precolumn for direct injection of plasma. Yu Z, et al. **J Chromatogr A** 1996 Aug 23;742(1–2):113–20

Anion gap: may the anions restricted to the intravascular space undergo modification in their valence? Kamel KS, et al. **Nephron** 1996;73(3):382–9

IMMUNOLOGY

beta 2-Glycoprotein-I is a cofactor for antibodies reacting with 5 anionic phospholipids [letter] Verrier Jones J, et al. **J Rheumatol** 1995 Oct;22(10):2009

Alterations in glomerular anionic sites in the autologous phase of canine anti-glomerular basement membrane nephritis. Sugimoto J, et al. **Toxicol Pathol** 1996 Sep-Oct; 24(5):627–35

ISOLATION & PURIFICATION

Depletion of glomerular anionic sites and proteineuria in nephrotic syndrome of children. Ramjee G, et al. **J Trop Pediatr** 1997 Jun;43(3):149–52

METABOLISM

Influence of changed blood pH on anionic sites in the labyrinth. Suzuki M, et al. **Acta Otolaryngol (Stockh)** 1995 Nov;115(6):747–53

Changes in the biliary excretion of exogenous organic anions by streptozotocin-induced diabetes. Bojcsev S, et al. **Acta Physiol Hung** 1996;84(3):263–4

Immunologic distribution of an organic anion transport protein in rat liver and kidney. Bergwerk AJ, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G231–8

Taurine permeation through swelling-activated anion conductance in rat IMCD cells in primary culture. Boese SH, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F498–507

Purinergic regulation of anion secretion by cystic fibrosis pancreatic duct cells. Chan HC, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C469–77

Halide transport patterns of apical anion exchange in rabbit cortical collecting duct intercalated cells. Emmons C. **Am J Physiol** 1996 Oct;271(4 Pt 2):F799–805

Anion channel blockers inhibit swelling-activated anion, cation, and nonelectrolyte transport in HeLa cells. Hall JA, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C579–88

Renal organic anion secretion: evidence for dopaminergic and adrenergic regulation. Halpin PA, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1372–9

Separate regulation of Na+ and anion transport by IMCD: location, aldosterone, hypertonicity, TGF-beta 1, and cAMP. Husted RF, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F433-9

Swelling-activated anion conductance in skate hepatocytes: regulation by cell Cl- and ATP. Jackson PS, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C57-66

Adhesion of calcium oxalate monohydrate crystals to anionic sites on the surface of renal epithelial cells. Lieske JC, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):F192-9

Adhesion of hydroxyapatite crystals to anionic sites on the surface of renal epithelial cells. Lieske JC, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F224-33

Flickery block of single CFTR chloride channels by intracellular anions and osmolytes. Linsdell P, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C628-34

Multiple pathways of organic anion secretion in renal proximal tubule revealed by confocal microscopy. Masereeuw R, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):F1173-82

Altered organic anion and osmolyte content and excretion in rat polycystic kidney disease: an NMR study. Ogbron MR, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):F63-9

Volume regulation in NIH/3T3 cells not expressing P-glycoprotein. I. Regulatory volume decrease. Pasantes-Morales H, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):C1798-803

Effects of anion exchange on intracellular pH and tension in basilar artery of dogs. Yu J, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1912-7

Effect of cAMP agonists on cell pH and anion transport by cultured rat inner medullary collecting duct cells. Zhang C, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):F131-40

Mutation of arginine 121 in lactoferrin destabilizes iron binding by disruption of anion binding: crystal structures of R121S and R121E mutants. Faber HR, et al. **Biochemistry** 1996 Nov 19;35(46):14473-9

A one-site, two-state model for the binding of anions in photosystem II. Lindberg K, et al. **Biochemistry** 1996 Nov 12;35(45):14259-67

Temperature dependence of the exchange of monovalent anions in human red blood cells. Baker GF, et al. **Biochim Biophys Acta** 1996 Dec 4;1285(2):192-202

Paracrine/autocrine regulation of anion secretion in the epididymis: role of angiotensin II. Chan HC, et al. **Biol Signals** 1996 Nov-Dec;5(6):309-16 (34 ref.)

Enantioselective fluorination of organic molecules. I. Synthetic studies of the agents for electrophilic, enantioselective fluorination of carbanions. Takeuchi Y, et al. **Chem Pharm Bull (Tokyo)** 1997 Jun;45(6):1085-8

Specific arginine and threonine residues control anion binding and transport in the light-driven chloride pump halorhodopsin. Rüdiger M, et al. **EMBO J** 1997 Jul 1; 16(13):3813-21

Anion binding to mitochondrial cytochromes c studied through electrochemistry. Effects of the neutralization of surface charges on the redox potential. Battistuzzi G, et al. **Eur J Biochem** 1996 Oct 1;241(1):208-14

Development of organic anion transport in the liver. Barth A, et al. **Exp Toxicol Pathol** 1996 Jul;48(5):421-32 (188 ref.)

Role for anions in pulmonary endothelial permeability. Griffin MP. **J Appl Physiol** 1997 Aug;83(2):615-22

Locating the anion-selectivity filter of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. Cheung M, et al. **J Gen Physiol** 1997 Mar; 109(3):289-99

Magnesium transport across the basolateral plasma membrane of the fish enterocyte. Bijvelds MJC, et al. **J Membr Biol** 1996 Dec;154(3):217-25

Two different conductances contribute to the anion currents in Coffea arabica protoplasts. Dieudonné S, et al. **J Membr Biol** 1997 Sep 1;159(1):83-94

Molecular recognition by natural macrocycles. I. d-tubocurarine as a host molecule for organic anions. Alcántar CG, et al. **J Mol Recognit** 1996 Mar-Apr; 9(2):54-64

Three distinct chloride channels control anion movements in rat parotid acinar cells. Arreola J, et al. **J Physiol (Lond)** 1996 Jan 15;490 (Pt 2):351-62

Anion secretion induced by capacitative Ca2+ entry through apical and basolateral membranes of cultured equine sweat gland epithelium. Ko WH, et al. **J Physiol (Lond)** 1996 Nov 15;497 (Pt 1):19-29

Measurement of the distribution of anion exchange function in normal human red cells. Raftos JE, et al. **J Physiol (Lond)** 1997 Feb 15;499 (Pt 1):17-25

Single channel properties of a volume sensitive anion channel: lessons from noise analysis. Jackson PS, et al. **Kidney Int** 1996 Jun;49(6):1695-9 (26 ref.)

Renal secretion of organic anions and cations. Pritchard JB, et al. **Kidney Int** 1996 Jun;49(6):1649-54 (29 ref.)

Temporal changes in charge content of cultured chondrocytes from bovine cartilaginous tissues. Van Damme MP, et al. **Matrix Biol** 1997 Mar;15(7):495-502

Hypotonicity-induced anion fluxes in cells expressing the multidrug-resistance-associated protein, MRP. Hainsworth AH, et al. **Pflugers Arch** 1996 Jun;432(2):234-40

PHARMACOKINETICS

Molecular aspects of organic anion uptake in liver. Sottocasa GL, et al. **J Hepatol** 1996;24 Suppl 1:36-41 (24 ref.)

PHARMACOLOGY

Interactions between organic anions, micelles and vesicles in model bile systems. Verkade HJ, et al. **Biochem J** 1996 Dec 15;320 (Pt 3):917-23

Anionic phospholipids modulate peptide insertion into membranes. Liu LP, et al. **Biochemistry** 1997 May 6; 36(18):5476-82

Anions modulate cation-induced responses of single units of the frog glossopharyngeal nerve. Kitada Y. **Brain Res** 1995 Oct 2;694(1-2):253-63

Effect of monovalent anions on type I collagen fibrillogenesis in vitro. Delorenzi NJ, et al. **Int J Biol Macromol** 1996 Jul;19(1):15-20

Protective effect of dextran sulfate and heparin on adult rat cardiomyocytes damaged by free radicals. Hiebert L, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):229-35

Effects of anions on ATP-activated nonselective cation current in NG108-15 cells. Kaiho H, et al. **J Neurophysiol** 1997 May;77(5):2717-22

External-anion-dependent anionic current in blastoderm cells of early medaka fish embryos. Shigemoto T, et al. **J Physiol (Lond)** 1996 Aug 15;495 (Pt 1):51-63

Anion exchange proteins and regulation of intracellular pH in cultured rat astrocytes and neurones. Bosman GJ, et al. **Neuroreport** 1997 Jan 20;8(2):427-30

Channel-specific effects of n-alkyl sulphate anions on three shaker-related potassium channels expressed in Xenopus oocytes. Elliott AA, et al. **Pflugers Arch** 1997 May; 434(1):132-6

URINE

What is the impact of potassium excretion on the intracellular fluid volume: importance of urine anions. Gowrishankar M, et al. **Kidney Int** 1996 Nov;50(5):1490-5

ANIRIDIA

[WAGR syndrome] Teraoka M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):227-8 (14 ref.) **(Jpn)**

COMPLICATIONS

[Aniridia and Wilms tumor: 2 cases of fetal rhabdomyomatous nephroblastoma] Schneider P, et al. **Arch Pediatr** 1996 Dec; 3(12):1243-7 (Eng. Abstr.) **(Fre)**

GENETICS

Gillespie syndrome: a report of two further cases. Nelson J, et al. **Am J Med Genet** 1997 Aug 8;71(2):134-8

Functional analysis of paired box missense mutations in the PAX6 gene. Tang HK, et al. **Hum Mol Genet** 1997 Mar; 6(3):381-6

The incidence of PAX6 mutation in patients with simple aniridia: an evaluation of mutation detection in 12 cases. Axton R, et al. **J Med Genet** 1997 Apr;34(4):279-86

FISH studies in a patient with sporadic aniridia and t(7;11)(q31.2;p13). Crolla JA, et al. **J Med Genet** 1996 Jan; 33(1):66-8

METABOLISM

[An immunohistochemical study on glycosaminoglycans distribution in the trabeculum of congenital aniridia] Asakawa M, et al. **Nippon Ganka Gakkai Zasshi** 1997 Jan; 101(1):87-91 (Eng. Abstr.) **(Jpn)**

SURGERY

Recurrent keratopathy after penetrating keratoplasty for aniridia. Gomes JA, et al. **Cornea** 1996 Sep;15(5):457-62

Iris diaphragm implantation in post-traumatic aniridia and tractional retinal detachment. Marullo M, et al. **Eur J Ophthalmol** 1997 Apr-Jun;7(2):171-3

Transscleral ciliary sulcus fixation of a posterior chamber lens in an eye with congenital aniridia. Segal EI, et al. **J Cataract Refract Surg** 1997 May;23(4):595-7

VETERINARY

Iridial hypoplasia (aniridia) accompanied by limbic dermoids and cataracts in a group of related quarterhorses. Joyce JR, et al. **Equine Vet J Suppl** 1990 Sep;(10):26-8

Aniridia in a thoroughbred horse. Ueda Y. **Equine Vet J Suppl** 1990 Sep;(10):29

ANISAKIASIS

Acute gastric anisakiasis: 28 cases during the last 10 years. Muraoka A, et al. **Dig Dis Sci** 1996 Dec;41(12):2362-5 (20 ref.)

COMPLICATIONS

Lack of an association of anisakiasis and inflammatory fibroid polyps [letter] Matsushita M, et al. **Gastrointest Endosc** 1997 Jul;46(1):92-4

Severe chest pain due to gastric anisakiasis. Machi T, et al. **Intern Med** 1997 Jan;36(1):28-30

[Urticariform reaction: endoscopic diagnosis (letter)] Durán FG, et al. **Rev Esp Enferm Dig** 1996 Oct;88(10):713-4 **(Spa)**

[Anisakidosis of the colon as a cause of acute abdomen] Louredo Méndez A, et al. **Rev Esp Enferm Dig** 1997 May; 89(5):403-6 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Benefit of immediate endoscopy after radiography for anisakiasis [letter] Kanematsu M, et al. **AJR Am J Roentgenol** 1997 Apr;168(4):1114-5

The use of IgE immunoblotting as a diagnostic tool in Anisakis simplex allergy. García M, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):497-501

[A case of asymptomatic colonic anisakiasis revealed by chance and treated by colonoscopy] Yoshikawa I, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Nov;93(11):837-40 (22 ref.) **(Jpn)**

[Endoscopic discovery of a worm larva at the base of a gastric ulcer] Cruchaga S, et al. **Enferm Infecc Microbiol Clin** 1995 Dec;13(10):631-2 **(Spa)**

[Gastric anisakiasis diagnosed by endoscopy] Romeo Ramírez JA, et al. **Gastroenterol Hepatol** 1997 Jun-Jul;20(6):306-8 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Enzyme-linked immunosorbent assay, immunoblot analysis and RAST fluoroimmunoassay analysis of serum responses against crude larval antigens of Anisakis simplex in a Spanish random population. García-Palacios L, et al. **J Helminthol** 1996 Dec;70(4):281-9

ETIOLOGY

Anisakis simplex induces not only anisakiasis: report on 28 cases of allergy caused by this nematode. Fernández de Corres L, et al. **J Investig Allergol Clin Immunol** 1996 Sep-Oct;6(5):315-9

IMMUNOLOGY

Anaphylaxis with Anisakis simplex in the gastric mucosa [letter] Alonso A, et al. **N Engl J Med** 1997 Jul 31; 337(5):350-1

Leukocyte parameters in the course of pig infection with III larval stage of Anisakis simplex. Podolska M, et al. **Wiad Parazytol** 1996;42(2):197-204

PARASITOLOGY

Anisakis, anisakidosis, and allergy to Anisakis [editorial] Buendia E. **Allergy** 1997 May;52(5):481-2

A case of extragastrointestinal anisakiasis involving a mesocolic lymph node. Kim HJ, et al. **Korean J Parasitol** 1997 Mar;35(1):63-6

THERAPY

[A case of asymptomatic colonic anisakiasis revealed by chance and treated by colonoscopy] Yoshikawa I, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Nov;93(11):837-40 (22 ref.) **(Jpn)**

VETERINARY

The infection status of anisakid larvae in marine fish and cephalopods from the Bohai Sea, China and their taxonomical consideration. Ma HW, et al. **Korean J Parasitol** 1997 Mar;35(1):19-24

ANISAKIS

CHEMISTRY

In vitro study on the effect of larval excretory/secretory products and crude extracts from Anisakis simplex on blood coagulation. Perteguer MJ, et al. **Int J Parasitol** 1996 Jan; 26(1):105-8

CLASSIFICATION

The infection status of anisakid larvae in marine fish and cephalopods from the Bohai Sea, China and their taxonomical consideration. Ma HW, et al. **Korean J Parasitol** 1997 Mar;35(1):19-24

ENZYMOLOGY

Evidence for arylamine N-acetyltransferase in the nematode Anisakis simplex. Chung JG, et al. **Cancer Lett** 1996 Aug 23;106(1):1-8

GENETICS

Genomic identification of Anisakis simplex isolates. Siles M, et al. **J Helminthol** 1997 Mar;71(1):73-5

Genetic and ecological data on the Anisakis simplex complex, with evidence for a new species (Nematoda, Ascaridoidea, Anisakidae). Mattiucci S, et al. **J Parasitol** 1997 Jun; 83(3):401-16

IMMUNOLOGY

Sensitization to Anisakis simplex: an unusual presentation. Estrada Rodríguez JL, et al. **Allergol Immunopathol (Madr)** 1997 Mar-Apr;25(2):95-7

Anisakis, anisakidosis, and allergy to Anisakis [editorial] Buendia E. **Allergy** 1997 May;52(5):481-2

Anisakis simplex, a relevant etiologic factor in acute urticaria. Del Pozo MD, et al. **Allergy** 1997 May;52(5):576-9

ANISAKIS

Periodate treatment of Anisakis simplex allergens. Moneo I, et al. **Allergy** 1997 May;52(5):565–9

Cross-reactivity between IgE-binding proteins from Anisakis, German cockroach, and chironomids. Pascual CY, et al. **Allergy** 1997 May;52(5):514–20

Allergic reactions to anisakis simplex parasitizing seafood. Moreno-Ancillo A, et al. **Ann Allergy Asthma Immunol** 1997 Sep;79(3):246–50

The use of IgE immunoblotting as a diagnostic tool in Anisakis simplex allergy. García M, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):497–501

Enzyme-linked immunosorbent assay, immunoblot analysis and RAST fluoroimmunoassay analysis of serum responses against crude larval antigens of Anisakis simplex in a Spanish random population. García-Palacios L, et al. **J Helminthol** 1996 Dec;70(4):281–9

Cooking and freezing may not protect against allergenic reactions to ingested Anisakis simplex antigens in humans. Audicana L, et al. **Vet Rec** 1997 Mar 1;140(9):235

ISOLATION & PURIFICATION

A case of extragastrointestinal anisakiasis involving a mesocolic lymph node. Kim HJ, et al. **Korean J Parasitol** 1997 Mar;35(1):63–6

[Endoscopic discovery of a worm larva at the base of a gastric ulcer] Cruchaga S, et al. **Enferm Infecc Microbiol Clin** 1995 Dec;13(10):631–2 **(Spa)**

PATHOGENICITY

Anisakis simplex induces not only anisakiasis: report on 28 cases of allergy caused by this nematode. Fernández de Corres L, et al. **J Investig Allergol Clin Immunol** 1996 Sep-Oct;6(5):315–9

ANISEIKONIA

COMPLICATIONS

Refractive aniseikonia: a source of binocular vision stress and asthenopia [letter] Enoch J. **J Refract Surg** 1996 Jul-Aug; 12(5):565–6

THERAPY

Management of aniseikonia after intraocular lens implantation or refractive surgery. Enoch JM. **J Refract Surg** 1997 Jan-Feb;13(1):79–82

Contemporary management of aniseikonia. Achiron LR, et al. **Surv Ophthalmol** 1997 Jan-Feb;41(4):321–30 (29 ref.)

ANISOCORIA

CHEMICALLY INDUCED

Anisocoria during isoflurane anaesthesia in a six-year-old girl. Kuhn I, et al. **Paediatr Anaesth** 1996;6(5):411–3

DIAGNOSIS

Pilocarpine should not be used to diagnose postoperative anisocoria [letter; comment] Sternberg TL, et al. **Anesth Analg** 1997 Apr;84(4):939. Comment on: Anesth Analg 1996 Sep;83(3):633–5.

ETIOLOGY

[Idiopathic hypertrophic cranial pachymeningitis associated with Horner's syndrome. A case report] Shindo K, et al. **Rinsho Shinkeigaku** 1997 Apr;37(4):300–3 (22 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Anisocoria--a pupillary sign of hippocampal lesions: an experimental study in the cat by using neurotoxins. Hashida N, et al. **J Hirnforsch** 1997;38(1):9–26

ANISOLES

2-Nitroanisole. **IARC Monogr Eval Carcinog Risks Hum** 1996;65:369–80 (28 ref.)

ADVERSE EFFECTS

Occupational contact dermatitis from anethole in food handlers. García-Bravo B, et al. **Contact Dermatitis** 1997 Jul;37(1):38

CHEMISTRY

Kinetic study of the oxidation of 4-hydroxyanisole catalyzed by tyrosinase. Espín JC, et al. **Biochem Mol Biol Int** 1997 May;41(6):1265–76

Covalent binding to DNA in vitro of 2',3'-oxides derived from allylbenzene analogs. Luo G, et al. **Drug Metab Dispos** 1996 Sep;24(9):1020–7

Chemical synthesis of 15 beta-hydroxytestosterone and its derivatives using a (4-methoxyphenyl)methyl protecting group. Cerný I, et al. **Steroids** 1996 Feb;61(2):58–64

ISOLATION & PURIFICATION

Isolation and structure elucidation of ardisenone: a new, cytotoxic alkenylphenol from Ardisia iwahigensis. Horgen FD, et al. **J Nat Prod** 1997 May;60(5):533–5

METABOLISM

Isolation of O-demethylase, an ether-cleaving enzyme system of the homoacetogenic strain MC. Kaufmann F, et al. **Arch Microbiol** 1997 Aug;168(2):136–42

Sex differences in biotransformation of the xenobiotic p-nitroanisole in isolated rat hepatocyte under the influence of phenobarbital. Mazur SP, et al. **Biochemistry (Mosc)** 1997 Apr;62(4):362–3

Solubilization and characterization of binding sites for [3H]NE-100, a novel and potent sigma 1 ligand, from guinea pig brain. Chaki S, et al. **Life Sci** 1996; 59(16):1331–40

PHARMACOKINETICS

Pathways of metabolism of [1'-14C]-trans-anethole in the rat and mouse. Bounds SV, et al. **Drug Metab Dispos** 1996 Jul;24(7):717–24

PHARMACOLOGY

Use of human skin reconstructs in the study of pigment modifiers. Bessou S, et al. **Arch Dermatol** 1997 Mar; 133(3):331–6

Mechanism of action of sarcoplasmic reticulum calcium-uptake activators--discrimination between sarco(endo)plasmic reticulum Ca2+ ATPase and phospholamban interaction. Berrebi-Bertrand I, et al. **Eur J Biochem** 1997 Aug 1;247(3):801–9

In vivo regulation of serotonin 5-HT2A receptors in rat brain by subchronic administration of sigma receptor ligand NE-100. Hashimoto K, et al. **Life Sci** 1997;60(24):2245–54

THERAPEUTIC USE

Hypolipidaemic activity of alpha-asarone in mice. Garduño L, et al. **J Ethnopharmacol** 1997 Jan;55(2):161–3

TOXICITY

Tumors of the bladder, kidney, and intestine of F344 rats and liver of B6C3F1 mice administered o-nitroanisole in feed. Irwin RD, et al. **Fundam Appl Toxicol** 1996 Mar; 30(1):1–12

ANISOMETROPIA

COMPLICATIONS

Anisometropia and amblyopia--chicken or egg? [editorial; comment] Fielder AR, et al. **Br J Ophthalmol** 1996 Oct; 80(10):857–8. Comment on: Br J Ophthalmol 1996 Oct;80(10):860–3.

ENZYMOLOGY

Pattern of ocular dominance columns and cytochrome oxidase activity in a macaque monkey with naturally occurring anisometropic amblyopia. Horton JC, et al. **Vis Neurosci** 1997 Jul-Aug;14(4):681–9

EPIDEMIOLOGY

Natural history of infantile anisometropia [see comments] Abrahamsson M, et al. **Br J Ophthalmol** 1996 Oct; 80(10):860–3. Comment in: Br J Ophthalmol 1996 Oct;80(10)857–8.

Anisometropia and amblyopia--chicken or egg? [editorial; comment] Fielder AR, et al. **Br J Ophthalmol** 1996 Oct; 80(10):857–8. Comment on: Br J Ophthalmol 1996 Oct;80(10):860–3.

ETIOLOGY

Traumatic cycloplegia and myopic anisometropia. Lin LL, et al. **J Ocul Pharmacol Ther** 1996 Spring;12(1):45–50

GENETICS

Mirror-image optic nerve dysplasia with associated anisometropia in identical twins. Cidis MB, et al. **J Am Optom Assoc** 1997 May;68(5):325–9

METABOLISM

Distribution and localization of NMDA receptor subunit 1 in the visual cortex of strabismic and anisometropic amblyopic cats. Yin ZQ, et al. **Neuroreport** 1996 Nov 25; 7(18):2997–3003

PHYSIOPATHOLOGY

The blood-aqueous barrier in anisometropia and high myopia. Shih YF, et al. **Ophthalmic Res** 1996;28(2):137–40

[Binocular problems caused by aniseikonia and anisophoria after cataract operation] Krzizok T, et al. **Klin Monatsbl Augenheilkd** 1996 Jun;208(6):477–80 (Eng. Abstr.) **(Ger)**

THERAPY

Compensation procedures for the anisometropic presbyope. Kozol F. **Surv Ophthalmol** 1996 Sep-Oct;41(2):171–4

ANISOMYCIN

ANALOGS & DERIVATIVES

Identification of preussin as a selective inhibitor for cell growth of the fission yeast ts mutants defective in Cdc2-regulatory genes. Kasahara K, et al. **Jpn J Antibiot** 1997 Mar;50(3):267–9

PHARMACOLOGY

Protein synthesis inhibitors cycloheximide and anisomycin induce interleukin-6 gene expression and activate transcription factor NF-kappaB. Faggioli L, et al. **Biochem Biophys Res Commun** 1997 Apr 17;233(2):507–13

Inhibition of male sexual behavior by intracranial implants of the protein synthesis inhibitor anisomycin into the medial preoptic area of the rat. McGinnis MY, et al. **Horm Behav** 1997 Feb;31(1):15–23

Selective activation of caspases during apoptotic induction in HL-60 cells. Effects Of a tetrapeptide inhibitor. Polverino AJ, et al. **J Biol Chem** 1997 Mar 14; 272(11):7013–21

Protein synthesis inhibitors delay transneuronal death in the piriform cortex of young adult rats. López-Mascaraque L, et al. **Neuroscience** 1997 Jul;79(2):463–75

Peptidyl-transferase inhibitors have antiviral properties by altering programmed -1 ribosomal frameshifting efficiencies: development of model systems. Dinman JD, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6606–11

ANISOTROPY

Anisotropy in cellular automata. Schönfisch B. **Biosystems** 1997;41(1):29–41

The effects of inhomogeneities and anisotropies on electrocardiographic fields: a 3-D finite-element study. Klepfer RN, et al. **IEEE Trans Biomed Eng** 1997 Aug; 44(8):706–19

Anisotropy of the apparent frequency dependence of backscatter in formalin fixed human myocardium. Hall CS, et al. **J Acoust Soc Am** 1997 Jan;101(1):563–8

Ultrasonic determination of the anisotropy of Young's modulus of fixed tendon and fixed myocardium. Hoffmeister BK, et al. **J Acoust Soc Am** 1996 Dec; 100(6):3933–40

A finite element solution for the anisotropic biphasic theory of tissue-equivalent mechanics: the effect of contact guidance on isometric cell traction measurement. Barocas VH, et al. **J Biomech Eng** 1997 Aug;119(3):261–8

A study of dielectric anisotropy in dehydrated cortical bone. García Sánchez FJ, et al. **Med Prog Technol** 1995-96; 21(3):165–70

Diffusion tensor MR imaging of the human brain. Pierpaoli C, et al. **Radiology** 1996 Dec;201(3):637–48

ANISOTROPY, FLUORESCENCE see **FLUORESCENCE POLARIZATION**

ANISOYLATED PLASMINOGEN-STREPTOKINASE ACTIVATOR COMPLEX see **ANISTREPLASE**

ANISTREPLASE

PHARMACOLOGY

Platelet aggregation by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex: heterogenous responses in platelet-rich plasma but not in washed platelets. Abdelouahed M, et al. **Thromb Res** 1997 May 1;86(3):255–62

THERAPEUTIC USE

TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. Barbagelata NA, et al. **Am Heart J** 1997 Mar;133(3):273–82

Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. Gibson CM, et al. **Am J Cardiol** 1997 Jul 1;80(1):21–6

A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. Julian DG, et al. **BMJ** 1996 Dec 7;313(7070):1429–31

An economic evaluation of thrombolysis in a remote rural community [see comments] Vale L, et al. **BMJ** 1997 Feb 22;314(7080):570–2. Comment in: BMJ 1997 May 10;314(7091):1417. Comment in: ACP J Club 1997 Sep-Oct;127(2):53.

Aspirin after thrombolysis for MI. Seaton TL. **J Fam Pract** 1997 Mar;44(3):249–50

[Thrombolytic therapy in acute myocardial infarct--is it being used to the fullest?] Carôla B, et al. **Rev Port Cardiol** 1996 Dec;15(12):867–76, 863 (Eng. Abstr.) **(Por)**

ANKLE

Peroneal tenosynovitis following acute gonococcal infection. Brown JT, et al. **Am J Orthop** 1996 Jun;25(6):445–7

Shoehorn-type ankle-foot orthoses: prediction of flexibility. Nagaya M. **Arch Phys Med Rehabil** 1997 Jan;78(1):82–4

Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal

atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Zheng ZJ, et al. **Atherosclerosis** 1997 May; 131(1):115–25

Aggressive hydatid disease of the foot and ankle. Akyar GS, et al. **Australas Radiol** 1997 Feb;41(1):41–3

Extraosseous manifestations of rheumatoid arthritis in the foot and ankle. O'Brien TS, et al. **Clin Orthop** 1997 Jul; (340):26–33 (46 ref.)

A preliminary evaluation of ankle orthoses in the management of children with cerebral palsy. Hainsworth F, et al. **Dev Med Child Neurol** 1997 Apr;39(4):243–7

Ultrasonographic examination of the posterior tibial tendon. Hsu TC, et al. **Foot Ankle Int** 1997 Jan;18(1):34–8

Effect of the posterior tibial tendon on the arch of the foot during simulated weightbearing: biomechanical analysis. Kitaoka HB, et al. **Foot Ankle Int** 1997 Jan;18(1):43–6

Analysis of clinical grading scales for the foot and ankle. Kitaoka HB, et al. **Foot Ankle Int** 1997 Jul;18(7):443–6

Centrocentral anastomosis with autologous nerve graft treatment of foot and ankle neuromas. Lidor C, et al. **Foot Ankle Int** 1996 Feb;17(2):85–8

Glomangioma of the ankle simulating injury to the flexor hallucis longus: a case report. Miyano JA, et al. **Foot Ankle Int** 1996 Dec;17(12):768–70

Functional bracing with a half-cast. Porter DA, et al. **Foot Ankle Int** 1996 Oct;17(10):644–5

Foot and ankle research priority: report from the Research Council of the American Orthopaedic Foot and Ankle Society. Saltzman CL, et al. **Foot Ankle Int** 1997 Jul; 18(7):447–8

Chronic ankle pain caused by osteoid osteoma of the neck of the talus. Snow SW, et al. **Foot Ankle Int** 1997 Feb; 18(2):98–101

Salvage of the septic ankle with concomitant tibial osteomyelitis. Thordarson DB, et al. **Foot Ankle Int** 1997 Mar;18(3):151–6

Ankle blood pressure measurement, an acceptable alternative to arm measurements. Block FE, et al. **Int J Clin Monit Comput** 1996 Aug;13(3):167–71

Long latency ankle responses to dynamic perturbation in older fallers and non-fallers. Smith BN, et al. **J Am Geriatr Soc** 1996 Dec;44(12):1447–54

Bilateral large ankle lipomas [letter] Davis E, et al. **J Am Podiatr Med Assoc** 1997 May;87(5):242–4

Nonossifying fibroma. Four cases and review of the literature. Glockenberg A, et al. **J Am Podiatr Med Assoc** 1997 Feb;87(2):66–9 (8 ref.)

Angioleiomyoma of the lower extremity. Hanft JR, et al. **J Am Podiatr Med Assoc** 1997 Aug;87(8):388–91

Piriformis syndrome mimics sural nerve entrapment [letter] Murphy BP. **J Am Podiatr Med Assoc** 1997 Apr;87(4):183–4

Nineteen-year-old female with unilateral ankle pain. What is your diagnosis? Sobel E, et al. **J Am Podiatr Med Assoc** 1997 Feb;87(2):74–9

Cutaneous rhinosporidiosis. Mitra K, et al. **J Indian Med Assoc** 1996 Feb;94(2):84

Certified athletic trainers discuss best type of ankle support [news] **J Okla State Med Assoc** 1996 Jan;89(1):28

Ankle-foot orthoses for preambulatory children with spastic diplegia. Wilson H, et al. **J Pediatr Orthop** 1997 May–Jun; 17(3):370–6

Tenosynovitis of the flexor hallucis longus in a long-distance runner. Theodore GH, et al. **Med Sci Sports Exerc** 1996 Mar;28(3):277–9

Occupational disorders of the foot and ankle. Trepman E, et al. **Orthop Clin North Am** 1996 Oct;27(4):815–29 (37 ref.)

The effect of ankle oedema on bone ultrasound assessment at the heel. Johansen A, et al. **Osteoporos Int** 1997;7(1):44–7

The effect of casting combined with stretching on passive ankle dorsiflexion in adults with traumatic head injuries. Moseley AM. **Phys Ther** 1997 Mar;77(3):240–7; discussion 248–59

AFOs and KFOs and surgery in cerebral palsy—what to use when? [see comments] Murphy W. **Physiother Res Int** 1996;1(4):213–20. Comment in: Physiother Res Int 1997;2(1):57–8.

Effects of foot and ankle MR imaging [letter; comment] Ehara S, et al. **Radiology** 1997 May;203(2):578–9. Comment on: Radiology 1996 Nov;201(2):515–7.

Open synovectomy for the prevention of recurrent hemarthrosis of the ankle in patients with hemophilia. A report of five cases with magnetic resonance imaging documentation. Plazanet F, et al. **Rev Rhum Engl Ed** 1997 Mar;64(3):166–71

Enlarged peroneal process with peroneus longus tendon entrapment. Boles MA, et al. **Skeletal Radiol** 1997 May; 26(5):313–5

[35-year-old patient with eyelid and ankle edema after foreign travel] Encke J, et al. **Internist (Berl)** 1997 May; 38(5):474–8 **(Ger)**

[Lasting disease-free course of synovial sarcoma] Shukin VV, et al. **Vopr Onkol** 1997;43(2):228–9 **(Rus)**

ABNORMALITIES

Anatomic considerations of the foot and leg in tibial hemimelia. Turker R, et al. **J Pediatr Orthop** 1996 Jul–Aug; 16(4):445–9

ANATOMY & HISTOLOGY

Alterations in the distal extension of the musculus peroneus brevis with foot movement. Rademaker J, et al. **AJR Am J Roentgenol** 1997 Mar;168(3):787–9

Study of ten anatomical variants of the foot and ankle. Chaney DM, et al. **J Am Podiatr Med Assoc** 1996 Nov; 86(11):532–7

Flexor digitorum accessorius longus muscle. VanCourt RB, et al. **J Am Podiatr Med Assoc** 1996 Nov;86(11):559–60 (5 ref.)

BLOOD SUPPLY

Factors influencing the outcome of paramalleolar bypass grafts. Plecha EJ, et al. **Ann Vasc Surg** 1996 Jul; 10(4):356–60

Ankle to arm index response to exercise and heat stress in healthy subjects. Desvaux B, et al. **Clin Physiol** 1996 Jan; 16(1):1–7

The relationship between the delayed improvement in ankle-brachial pressure index and changes in limb volume following balloon angioplasty for leg ischaemia. Ray SA, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):114–7

Completion arteriography in paramalleolar bypasses: effect of configurational changes, with special reference to spasm, on long-term outcome. Sato O, et al. **Int Angiol** 1996 Sep; 15(3):219–24

The diagnostic value of the measurement of the ankle-brachial systolic pressure index in primary health care. Stoffers HE, et al. **J Clin Epidemiol** 1996 Dec; 49(12):1401–5

False aneurysm—a complication following an inversion ankle sprain: a case report. Bandy WD, et al. **J Orthop Sports Phys Ther** 1996 Apr;23(4):272–9

The ankle-brachial index in normal neonates and infants is significantly lower than in older children and adults. Katz S, et al. **J Pediatr Surg** 1997 Feb;32(2):269–71

Delay in improvement of ankle-arm index and ankle waveforms after lower-extremity revascularization. Tripathi S, et al. **Mil Med** 1997 Apr;162(4):301–3

Changes in angiographic features and the ankle/brachial pressure index of femorodistal arterial bypass grafts during knee flexion. Akiyama N, et al. **Surg Today** 1996; 26(2):115–8

[Systolic pressure measurement of the big toe (and of the ankle) as the first line od complete angiologic investigation comprising TcPO2, echography, and doppler ultrasonography] Rommer P. **J Mal Vasc** 1997;22(1):64–6 **(Fre)**

INJURIES see ANKLE INJURIES

INNERVATION

Segmental near nerve sensory conduction studies of the medical and lateral plantar nerve. David WS, et al. **Electromyogr Clin Neurophysiol** 1996 Oct–Nov;36(7):411–7

Nerve injury and repair in the foot and ankle. Santi MD, et al. **Foot Ankle Int** 1996 Jul;17(7):425–39 (108 ref.)

PATHOLOGY

Magnetic resonance imaging of the musculoskeletal system: part 7. The ankle. Haygood TM. **Clin Orthop** 1997 Mar; (336):318–36 (41 ref.)

Multiple hereditary osteochondromatosis. Two cases with ankle and knee deformities. Glockenberg A, et al. **J Am Podiatr Med Assoc** 1997 Feb;87(2):70–3

Can running cause the appearance of marrow edema on MR images of the foot and ankle? Lazzarini KM, et al. **Radiology** 1997 Feb;202(2):540–2

Xanthomatous infiltration of ankle tendons. Kelman CG, et al. **Skeletal Radiol** 1997 Apr;26(4):256–9

[Magnetic resonance contribution in a case of multiple tenosynovitis of the ankle caused by orthopedic shoe] Bianchi D, et al. **Radiol Med (Torino)** 1997 Mar;93(3):292–3 **(Ita)**

PHYSIOLOGY

Influence of electrically stimulated ankle plantar flexors on the swinging leg. Bajd T, et al. **Artif Organs** 1997 Mar; 21(3):176–9

Ankle taping improves proprioception before and after exercise in young men. Robbins S, et al. **Br J Sports Med** 1995 Dec;29(4):242–7

The ankle strategy for postural control—a comparison between a model-based and a marker-based method. Karlsson A, et al. **Comput Methods Programs Biomed** 1997 Mar;52(3):165–73

Measurement of patellar and ankle tendon reflexes in normal subjects. Struys MA, et al. **Electromyogr Clin Neurophysiol** 1997 Jan–Feb;37(1):13–8

Standing strength training of the ankle plantar and dorsiflexors in older women, using concentric and eccentric contractions. Porter MM, et al. **Eur J Appl Physiol** 1997; 76(1):62–8

Foot orientation and lower limb kinematics during running. Viale F, et al. **Foot Ankle Int** 1997 Mar;18(3):157–62

Step length reductions in advanced age: the role of ankle and hip kinetics. Judge JO, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov;51(6):M303–12

Evidence of facilitation of soleus-coupled Renshaw cells during voluntary co-contraction of antagonistic ankle muscles in man. Nielsen J, et al. **J Physiol (Lond)** 1996 Jun 1;493 (Pt 2):603–11

Peripheral nerve dysfunction is reflected by loss of ankle reflexes but not by autonomic neuropathy in diabetic patients. Sundkvist G, et al. **Muscle Nerve** 1997 Jun; 20(6):740–3

Improving ankle dorsiflexion [letter] Bohannon RW, et al. **Phys Ther** 1997 Sep;77(9):982–3

Stiffness control in posterior-type plastic ankle-foot orthoses: effect of ankle trimline. Part 1: A device for measuring ankle moment. Sumiya T, et al. **Prosthet Orthot Int** 1996 Aug;20(2):129–31

Stiffness control in posterior-type plastic ankle-foot orthoses: effect of ankle trimline. Part 2: Orthosis characteristics and orthosis/patient matching. Sumiya T, et al. **Prosthet Orthot Int** 1996 Aug;20(2):132–7

PHYSIOPATHOLOGY

Effectiveness of external orthotic support on passive soft tissue resistance of the chronically unstable ankle. Hartsell HD, et al. **Foot Ankle Int** 1997 Mar;18(3):144–50

Mechanical behavior of the foot and ankle after plantar fascia release in the unstable foot. Kitaoka HB, et al. **Foot Ankle Int** 1997 Jan;18(1):8–15

Effect of persistent toe walking on ankle equinus. Analysis of 60 idiopathic toe walkers. Sobel E, et al. **J Am Podiatr Med Assoc** 1997 Jan;87(1):17–22 (33 ref.)

Three-dimensional finite element stress analysis of the polypropylene ankle-foot orthoses: static analysis by Chu et al [letter; comment] Paul JP. **Med Eng Phys** 1996 Oct; 18(7):607–8. Comment on: Med Eng Phys 1995 Jul;17(5):372–9.

Osteoarthritis in ankle and knee joints. Huch K, et al. **Semin Arthritis Rheum** 1997 Feb;26(4):667–74 (67 ref.)

RADIOGRAPHY

Ankle radiograph utilization after learning a decision rule: a 12-month follow-up. Verbeek PR, et al. **Acad Emerg Med** 1997 Aug;4(8):776–9

The impact of ankle radiographs on the diagnosis and management of acute ankle injuries. Omary RA, et al. **Acad Radiol** 1996 Sep;3(9):758–65

Observer reliability in ankle radiographic measurements. Brage ME, et al. **Foot Ankle Int** 1997 Jun;18(6):324–9

Clinical and radiographic outcome of revision surgery for failed triple arthrodesis. Haddad SL, et al. **Foot Ankle Int** 1997 Aug;18(8):489–99

[Radiological case of the month. Subacute osteomyelitis of the ankle] Cottalorda J, et al. **Arch Pediatr** 1996 Dec; 3(12):1276–7 **(Fre)**

SURGERY

Musculofascial flaps based on the dorsalis pedis vascular pedicle for coverage of the foot and ankle. Gibstein LA, et al. **Ann Plast Surg** 1996 Aug;37(2):152–7

Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Tan JS, et al. **Clin Infect Dis** 1996 Aug;23(2):286–91

Distally based flaps for skin coverage of the foot and ankle. Hallock GG. **Foot Ankle Int** 1996 Jun;17(6):343–8 (25 ref.)

Trochanteric bone grafts in foot and ankle surgery. Hayes WR Jr, et al. **Foot Ankle Int** 1996 Jul;17(7):402–5

Clinical safety and efficacy of calf tourniquets. Michelson JD, et al. **Foot Ankle Int** 1996 Sep;17(9):573–5

Popliteal sciatic nerve block for postoperative analgesia. Rongstad K, et al. **Foot Ankle Int** 1996 Jul;17(7):378–82

Introduction to bone grafting. Blitch EL, et al. **J Foot Ankle Surg** 1996 Sep–Oct;35(5):458–62 (20 ref.)

Different forms of bone grafts. Bollo A, et al. **J Foot Ankle Surg** 1996 Sep–Oct;35(5):400–5

The application of allograft bone in foot and ankle surgery. Catanzariti A, et al. **J Foot Ankle Surg** 1996 Sep–Oct; 35(5):440–51 (87 ref.)

Autogenous bone grafting. Hofbauer MH, et al. **J Foot Ankle Surg** 1996 Sep–Oct;35(5):386–90

Techniques for harvesting autogenous bone graft of the lower extremity. Mendicino RW, et al. **J Foot Ankle Surg** 1996 Sep–Oct;35(5):428–35

Utilization of autogenous corticocancellous bone graft from the distal tibia for reconstructive surgery of the foot and ankle. Saltrick KR, et al. **J Foot Ankle Surg** 1996 Sep–Oct; 35(5):406–12

Iliac crest donor site morbidity in foot and ankle surgery. Schulhofer SD, et al. **J Foot Ankle Surg** 1997 Mar–Apr; 36(2):155–8; discussion 161

Amputations of the foot and ankle: review of techniques and results. Choudhury SN, et al. **Orthopedics** 1997 May; 20(5):446–57; quiz 458–9 (70 ref.)

Regional anesthesia in foot and ankle surgery. Lee TH, et al. **Orthopedics** 1996 Jul;19(7):577–80

Suction lipectomy of the ankle area. Chamosa M. **Plast Reconstr Surg** 1997 Sep;100(4):1047–52; discussion 1053

Circumferential liposuction of knees, calves, and ankles. Ersek RA, et al. **Plast Reconstr Surg** 1996 Oct;98(5):880–3

ANKLE INJURIES

Ankle ligament injuries. Renström PA, et al. **Br J Sports Med** 1997 Mar;31(1):11–20 (134 ref.)

Lower leg, foot, and ankle injuries in young athletes. Stanish WD. **Clin Podiatr Med Surg** 1997 Jul;14(3):559–78 (71 ref.)

The triplane fracture: four years of follow-up of 21 cases and review of the literature. Kärrholm J.

ANKLE INJURIES

J Pediatr Orthop B 1997 Apr;6(2):91–102

CLASSIFICATION

Foot and ankle severity scale (FASS). Manoli A 2nd, et al. **Foot Ankle Int** 1997 Sep;18(9):598–602

COMPLICATIONS

Spontaneous fusion of the midfoot following reflex sympathetic dystrophy. A case report and review of the literature. Stratton NJ, et al. **Am J Orthop** 1996 Jul; 25(7):497–9 (16 ref.)

Chronic, painful ankle instability in skeletally immature athletes. Ununited osteochondral fractures of the distal fibula. Busconi BD, et al. **Am J Sports Med** 1996 Sep–Oct; 24(5):647–51

Impingement syndrome of the ankle caused by a medial meniscoid lesion. Egol KA, et al. **Arthroscopy** 1997 Aug; 13(4):522–5 (10 ref.)

Acute compartment syndrome due to closed muscle rupture. Gwynne Jones DP, et al. **Aust N Z J Surg** 1997 Apr; 67(4):227–8

Nonunion of a fracture of the lateral malleolus: a case report and review of literature [letter; comment] Lynn MD. **Foot Ankle Int** 1997 Jul;18(7):457. Comment on: Foot Ankle Int 1997 Jan;18(1):50–2.

Results of ankle arthrodesis for treatment of supramalleolar nonunion and ankle arthrosis. Marsh JL, et al. **Foot Ankle Int** 1997 Mar;18(3):138–43

Nonunion of a fracture of the lateral malleolus: a case report and review of the literature [see comments] Rand N, et al. **Foot Ankle Int** 1997 Jan;18(1):50–2 (15 ref.). Comment in: Foot Ankle Int 1997 Jul;18(7):457.

Intermittent pneumatic pedal compression and edema resolution after acute ankle fracture: a prospective, randomized study. Thordarson DB, et al. **Foot Ankle Int** 1997 Jun;18(6):347–50

Haemarthrosis following thrombolytic therapy for acute myocardial infarction. Finlayson J, et al. **Injury** 1997 Mar; 28(2):146–7

False aneurysm--a complication following an inversion ankle sprain: a case report. Bandy WD, et al. **J Orthop Sports Phys Ther** 1996 Apr;23(4):272–9

Bone bruises detected by magnetic resonance imaging following lateral ankle sprains. Pinar H, et al. **Knee Surg Sports Traumatol Arthrosc** 1997;5(2):113–7

A meningeal cyst of the thoracic spine presenting as prolonged paresis after ankle injury: case report. Adelson PD, et al. **Neuropediatrics** 1996 Aug;27(4):207–10

[Pseudarthrosis of the proximal ankle joint] Zwipp H, et al. **Orthopade** 1996 Sep;25(5):463–9 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Diagnosis of lateral ankle ligament injuries. Comparison between talar tilt, MRI and operative findings in 112 athletes. Gaebler C, et al. **Acta Orthop Scand** 1997 Jun; 68(3):286–90

Diagnosis of ligament rupture of the ankle joint. Physical examination, arthrography, stress radiography and sonography compared in 160 patients after inversion trauma. van Dijk CN, et al. **Acta Orthop Scand** 1996 Dec; 67(6):566–70

MR imaging of dislocation of the posterior tibial tendon. Bencardino J, et al. **AJR Am J Roentgenol** 1997 Oct; 169(4):1109–12

MR features of longitudinal tears of the peroneus brevis tendon. Rosenberg ZS, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):141–7

Using MR imaging to differentiate peroneal splits from other peroneal disorders. Schweitzer ME, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):129–33

MR imaging of peroneal tendon disorders. Tjin A Ton ER, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):135–40

Evaluation and diagnosis of ankle injuries [published erratum appears in Am Fam Physician 1997 Feb 15;55(3):788] Rubin A, et al. **Am Fam Physician** 1996 Oct;54(5):1609–18

Diagnosis of anterolateral ankle impingement. Comparison between magnetic resonance imaging and clinical examination. Liu SH, et al. **Am J Sports Med** 1997 May–Jun;25(3):389–93

Ankle arthroscopy: outcome in 79 consecutive patients. Amendola A, et al. **Arthroscopy** 1996 Oct;12(5):565–73

Magnetic resonance imaging of the musculoskeletal system: part 7. The ankle. Haygood TM. **Clin Orthop** 1997 Mar; (336):318–36 (41 ref.)

Fracture-dislocation of the ankle with posterior tibial tendon entrapment within the tibiofibular interosseous space: a case report of a late diagnosis. Anderson JG, et al. **Foot Ankle Int** 1996 Feb;17(2):114–8

Clinical examination and magnetic resonance imaging in the assessment of ankle sprains treated with an orthosis. De Simoni C, et al. **Foot Ankle Int** 1996 Mar;17(3):177–82

A comparison of MRI and clinical examination of acute lateral ankle sprains. Frey C, et al. **Foot Ankle Int** 1996 Sep;17(9):533–7

Fractures of the ankle and the distal part of the tibia. Vander Griend R, et al. **Instr Course Lect** 1997;46:311–21 (66 ref.)

The prognosis of ankle sprains. de Bie RA, et al. **Int J Sports Med** 1997 May;18(4):285–9

Magnetic resonance imaging in the diagnosis of acute injured distal tibiofibular syndesmosis. Vogl TJ, et al. **Invest Radiol** 1997 Jul;32(7):401–9

A pilot study to assess the sensitivity and specificity of an intrasound device in the diagnosis of ankle fractures. Dancocks A, et al. **J Accid Emerg Med** 1997 Jul;14(4):230–2

The relevance of hearing a crack in ankle injuries. Reid PM, et al. **J Accid Emerg Med** 1996 Jul;13(4):278–9

Physical examination is sufficient for the diagnosis of sprained ankles. van Dijk CN, et al. **J Bone Joint Surg Br** 1996 Nov;78(6):958–62

MRI versus lateral stress radiography in acute lateral ankle ligament injuries. Breitenseher MJ, et al. **J Comput Assist Tomogr** 1997 Mar–Apr;21(2):280–5

MRI of the sinus tarsi in acute ankle sprain injuries. Breitenseher MJ, et al. **J Comput Assist Tomogr** 1997 Mar–Apr;21(2):274–9

Peroneal tendons: use of kinematic MR imaging of the ankle to determine subluxation. Shellock FG, et al. **J Magn Reson Imaging** 1997 Mar–Apr;7(2):451–4

Extra-articular triplane fracture of the distal tibial epiphysis [letter; comment] Peterson HA. **J Pediatr Orthop** 1996 Sep–Oct;16(5):679. Comment on: J Pediatr Orthop 1995 Jul–Aug;15(4):479–81.

Arthroscopic assessment of the chronic unstable ankle joint. Schäfer D, et al. **Knee Surg Sports Traumatol Arthrosc** 1996; 4(1):48–52

Imaging of tendon injuries about the ankle. Clarke HD, et al. **Orthopedics** 1997 Jul;20(7):639–43; quiz 644–5 (39 ref.)

Fluoroscopically guided injections into the foot and ankle: localization of the source of pain as a guide to treatment--prospective study. Lucas PE, et al. **Radiology** 1997 Aug;204(2):411–5

Trabecular trauma of the talus and medial malleolus concurrent with lateral collateral ligamentous injuries of the ankle: evaluation with MR imaging. Nishimura G, et al. **Skeletal Radiol** 1996 Jan;25(1):49–54

Magnetic resonance imaging of injuries to the ankle joint: can it predict clinical outcome? Zanetti M, et al. **Skeletal Radiol** 1997 Feb;26(2):82–8

[Longitudinal splitting syndrome of the short fibular tendon. . Imaging and classification by MRI] Tavernier T, et al. **J Radiol** 1997 May;78(5):353–7 (Eng. Abstr.) **(Fre)**

[Diagnostic value of magnetic resonance tomography of the upper ankle joint--imaging of ligaments and tendons in standard slice orientation] Schröder RI, et al. **Aktuelle Radiol** 1996 Jan;6(1):19–24 (Eng. Abstr.) **(Ger)**

[Concomitant injuries after upper ankle joint dislocations] Dann K, et al. **Sportverletz Sportschaden** 1996 Sep; 10(3):67–9 (Eng. Abstr.) **(Ger)**

[Ligament injury of the ankle joint (I) (editorial)] Hintermann B. **Sportverletz Sportschaden** 1996 Sep;10(3):47 **(Ger)**

[Diagnostic imaging of ankle joint instability] Schäfer D, et al. **Sportverletz Sportschaden** 1996 Sep;10(3):55–7 (30 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic findings in the unstable upper ankle joint] Schäfer D, et al. **Sportverletz Sportschaden** 1996 Sep; 10(3):63–6 (Eng. Abstr.) **(Ger)**

[Magnetic resonance tomography (MRI) of ligament injuries of the upper ankle joint] Zanetti M, et al. **Sportverletz Sportschaden** 1996 Sep;10(3):58–62 (23 ref.) (Eng. Abstr.) **(Ger)**

[Dynamic pedography for assessing functional ankle joint instability] Becker HP, et al. **Unfallchirurg** 1997 Feb; 100(2):133–9 (Eng. Abstr.) **(Ger)**

[Magnetic resonance tomography study of ankle joint fractures. A prospective pathologic-anatomic study] Elsner KS, et al. **Unfallchirurg** 1996 Aug;99(8):581–6 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits. The Kapooka Ankle Sprain Study. Slatyer MA, et al. **Am J Sports Med** 1997 Jul–Aug;25(4):544–53

ECONOMICS

Comparison of costs in ankle fractures treated with absorbable or metallic fixation devices. Juutilainen T, et al. **Arch Orthop Trauma Surg** 1997;116(4):204–8

EPIDEMIOLOGY

Foot-ankle injuries: influence of crash location, seating position and age. Parenteau CS, et al. **Accid Anal Prev** 1996 Sep;28(5):607–17

Epidemiology of osteoporotic ankle fractures in elderly persons in Finland. Kannus P, et al. **Ann Intern Med** 1996 Dec 15;125(12):975–8

Predictors of ankle and foot fractures in older women. The Study of Osteoporotic Fractures Research Group. Seeley DG, et al. **J Bone Miner Res** 1996 Sep;11(9):1347–55

Incidence of acute volleyball injuries: a prospective cohort study of injury mechanisms and risk factors. Bahr R, et al. **Scand J Med Sci Sports** 1997 Jun;7(3):166–71

ETIOLOGY

Prediction of injury in female netball players. Macera C. **Clin J Sport Med** 1996 Jan;6(1):67

Overuse foot and ankle injuries in ballet. Denton J. **Clin Podiatr Med Surg** 1997 Jul;14(3):525–32 (7 ref.)

Bicycle-spoke injuries: a prospective study. Segers MJ, et al. **Injury** 1997 May;28(4):267–9

Comparison of two conservative methods of treating an isolated fracture of the lateral malleolus [letter; comment] Williams RL, et al. **J Bone Joint Surg Br** 1997 Mar; 79(2):339–40. Comment on: J Bone Joint Surg Br 1996 Jul;78(4):568–72.

Intramedullary nailing of unstable diaphyseal fractures of the tibia with distal intraarticular involvement. Konrath G, et al. **J Orthop Trauma** 1997 Apr;11(3):200–5

Jump distance of dance landings influencing internal joint forces: I. Axial forces. Simpson KJ, et al. **Med Sci Sports Exerc** 1997 Jul;29(7):916–27

Jump distance of dance landings influencing internal joint forces: II. Shear forces. Simpson KJ, et al. **Med Sci Sports Exerc** 1997 Jul;29(7):928–36

Ankle injury risk factors in sports. Barker HB, et al. **Sports Med** 1997 Feb;23(2):69–74 (33 ref.)

PATHOLOGY

Ankle fractures involving the fibula proximal to the distal tibiofibular syndesmosis. Ebraheim NA, et al. **Foot Ankle Int** 1997 Aug;18(8):513–21 (58 ref.)

The fate of the syndesmosis in type C ankle fractures: a cadaveric study. Harris IA, et al. **Injury** 1997 May; 28(4):275–7

'The bigger they come ...': the relationship between body mass index and severity of ankle fractures. Spaine LA, et al. **Injury** 1996 Dec;27(10):687–9

Reimplantation of the totally extruded talus. Brewster NT, et al. **J Orthop Trauma** 1997 Jan;11(1):42–5

PHYSIOPATHOLOGY

Delayed union following stress fracture of the distal fibula secondary to rotational malunion of lateral malleolar fracture. Guille JT, et al. **Am J Orthop** 1997 Jun;26(6):442–5

What best protects the inverted weightbearing ankle against further inversion? Evertor muscle strength compares favorably with shoe height, athletic tape, and three orthoses. Ashton-Miller JA, et al. **Am J Sports Med** 1996 Nov–Dec;24(6):800–9

Ankle inversion injuries. The role of the dynamic defense mechanism. Konradsen L, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):54–8

Ankle disk training influences reaction times of selected muscles in a simulated ankle sprain. Sheth P, et al. **Am J Sports Med** 1997 Jul–Aug;25(4):538–43

Is balance impaired by recurrent sprained ankle? Isakov E, et al. **Br J Sports Med** 1997 Mar;31(1):65–7

Postural corrections after standardised perturbations of single limb stance: effect of training and orthotic devices in patients with ankle instability. Pintsaar A, et al. **Br J Sports Med** 1996 Jun;30(2):151–5

Foot and ankle considerations in golf. Pietrocarlo TA. **Clin Sports Med** 1996 Jan;15(1):129–46 (18 ref.)

The stabilizing effect of orthotic devices on plantar flexion/dorsal extension and horizontal rotation of the ankle joint. An experimental cadaveric investigation. Bruns J, et al. **Int J Sports Med** 1996 Nov;17(8):614–8

Ankle trauma significantly impairs posture control--a study in basketball players and controls. Perrin PP, et al. **Int J Sports Med** 1997 Jul;18(5):387–92

Spontaneous regeneration of the lateral malleolus after traumatic loss in a three-year-old boy: a case report with seven-year follow-up. Park HW, et al. **J Bone Joint Surg Br** 1997 Jan;79(1):66–7

Changes in the flexibility characteristics of the ankle complex due to damage to the lateral collateral ligaments: an in vitro and in vivo study. Lapointe SJ, et al. **J Orthop Res** 1997 May;15(3):331–41

Peak passive resistive torque at maximum inversion range of motion in subjects with recurrent ankle inversion sprains. Birmingham TB, et al. **J Orthop Sports Phys Ther** 1997 May;25(5):342–8

The effect of sudden inversion stress on EMG activity of the peroneal and tibialis anterior muscles in the chronically unstable ankle. Ebig M, et al. **J Orthop Sports Phys Ther** 1997 Aug;26(2):73–7

Evaluation of kinesthetic deficits indicative of balance control in gymnasts with unilateral chronic ankle sprains. Forkin DM, et al. **J Orthop Sports Phys Ther** 1996 Apr; 23(4):245–50

Effect of ankle orthoses on functional performance for individuals with recurrent lateral ankle sprains. Gross MT, et al. **J Orthop Sports Phys Ther** 1997 Apr;25(4):245–52

Invertor vs. evertor peak torque and power deficiencies associated with lateral ankle ligament injury. Wilkerson GB, et al. **J Orthop Sports Phys Ther** 1997 Aug;26(2):78–86

Taping of the ankle--the effect on postural sway during perturbation, before and after a training session. Leanderson J, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(1):53–6

Isokinetic eccentric strength of the ankle evertors after injury. Heitman RJ, et al. **Percept Mot Skills** 1997 Feb; 84(1):258

[Biomechanics of the ligaments of the unstable ankle joint] Hintermann B. **Sportverletz Sportschaden** 1996 Sep; 10(3):48–54 (64 ref.) (Eng. Abstr.) **(Ger)**

[Proprioceptive reaction in the healthy and chronically unstable ankle joint] Löfvenberg R, et al. **Sportverletz Sportschaden** 1996 Dec;10(4):79–83 (Eng. Abstr.) **(Ger)**

[Effectiveness of outer stability aids on rotational stability of the ankle joints] Müller CC, et al. **Sportverletz Sportschaden** 1996 Dec;10(4):84–7 (Eng.

Abstr.) **(Ger)**

PREVENTION & CONTROL

What best protects the inverted weightbearing ankle against further inversion? Evertor muscle strength compares favorably with shoe height, athletic tape, and three orthoses. Ashton-Miller JA, et al. **Am J Sports Med** 1996 Nov-Dec;24(6):800-9

The effect of exercise, prewrap, and athletic tape on the maximal active and passive ankle resistance of ankle inversion. Manfroy PP, et al. **Am J Sports Med** 1997 Mar-Apr;25(2):156-63

Ankle taping improves proprioception before and after exercise in young men. Robbins S, et al. **Br J Sports Med** 1995 Dec;29(4):242-7

The bicycle spoke injury: an avoidable accident? D'Souza LG, et al. **Foot Ankle Int** 1996 Mar;17(3):170-3

A twofold reduction in the incidence of acute ankle sprains in volleyball after the introduction of an injury prevention program: a prospective cohort study. Bahr R, et al. **Scand J Med Sci Sports** 1997 Jun;7(3):172-7

RADIOGRAPHY

Ankle radiograph utilization after learning a decision rule: a 12-month follow-up. Verbeek PR, et al. **Acad Emerg Med** 1997 Aug;4(8):776-9

The impact of ankle radiographs on the diagnosis and management of acute ankle injuries. Omary RA, et al. **Acad Radiol** 1996 Sep;3(9):758-65

Isolated fracture of the posterolateral tibial lip (Volkmann's triangle). Neumaier Probst E, et al. **Acta Radiol** 1997 May; 38(3):359-62

Clinical application of the Ottawa ankle rules for the use of radiography in acute ankle injuries: an independent site assessment. Verma S, et al. **AJR Am J Roentgenol** 1997 Sep;169(3):825-7

Acute ankle injuries: clinical decision rules for radiographs. Tandeter HB, et al. **Am Fam Physician** 1997 Jun; 55(8):2721-8 (21 ref.)

Using the Ottawa Ankle Rules [letter; comment] Laupacis A, et al. **Ann Emerg Med** 1996 Dec;28(6):730-1. Comment on: Ann Emerg Med 1996 May;27(5):676.

Validation of the Ottawa ankle rules. Experience at a community hospital. McBride KL. **Can Fam Physician** 1997 Mar;43:459-65

Observer reliability in ankle radiographic measurements. Brage ME, et al. **Foot Ankle Int** 1997 Jun;18(6):324-9

Occult ankle fracture detected by an ankle effusion on plain radiography: a case report. Ho K, et al. **J Emerg Med** 1996 Jul-Aug;14(4):455-9

Distal tibia and proximal fibula fracture in an elderly woman. Jones TL. **J Emerg Med** 1996 Jul-Aug;14(4):497

Concomitant medial facet and dome fractures of the talus. Storm M, et al. **J Foot Ankle Surg** 1996 Jul-Aug; 35(4):331-4 (12 ref.)

Implementation of the Ottawa ankle rules in France. A multicenter randomized controlled trial [see comments] Auleley GR, et al. **JAMA** 1997 Jun 25;277(24):1935-9. Comment in: JAMA 1997 Jun 25;277(24):1977-8.

Radiology Quiz #12. Lisfranc fracture-dislocation. Francis RA. **Mo Med** 1997 May;94(5):213-4

Challenging fractures of the foot and ankle. Prokuski LJ, et al. **Radiol Clin North Am** 1997 May;35(3):655-70 (33 ref.)

[Astragalocalcanean subluxation in children] Chapelle S, et al. **Acta Orthop Belg** 1996 Dec;62(4):236-7 (Eng. Abstr.) **(Fre)**

REHABILITATION

Rehabilitation of foot and ankle injuries. Losito JM, et al. **Clin Podiatr Med Surg** 1997 Jul;14(3):533-57 (39 ref.)

Clinical examination and magnetic resonance imaging in the assessment of ankle sprains treated with an orthosis. De Simoni C, et al. **Foot Ankle Int** 1996 Mar;17(3):177-82

Gait analysis and bivalved serial casting of an athlete with shortened gastrocnemius muscles: a single case design. Selby-Silverstein L, et al. **J Orthop Sports Phys Ther** 1997 Apr;25(4):282-8

Management of ankle sprains. Chorley JN, et al. **Pediatr Ann** 1997 Jan;26(1):56-64 (21 ref.)

[Is functional conservative treatment of stable lateral ankle fractures justified?] Richter J, et al. **Chirurg** 1996 Dec; 67(12):1255-60 (Eng. Abstr.) **(Ger)**

[Effect of external stabilizing agents of the ankle joint on sports motor capacities in one legged jumping] Jerosch J, et al. **Sportverletz Sportschaden** 1997 Mar;11(1):27-32 (Eng. Abstr.) **(Ger)**

SURGERY

Ankle stability without the lateral malleolus--a report of 2 cases. Mostert AK, et al. **Acta Orthop Scand** 1996 Dec; 67(6):622-3

External rotation views in the diagnosis of posterior colliculus fracture of the medial malleolus. Ebraheim NA, et al. **Am J Orthop** 1996 May;25(5):380-2

Long-term functional outcome after primary repair of the lateral ligaments of the ankle. Kaikkonen A, et al. **Am J Sports Med** 1997 Mar-Apr;25(2):150-5

Fibular grooving for recurrent peroneal tendon subluxation. Kollias SL, et al. **Am J Sports Med** 1997 May-Jun; 25(3):329-35

Traumatic peroneal tendon instability [see comments] Mason RB, et al. **Am J Sports Med** 1996 Sep-Oct;24(5):652-8 (30 ref.). Comment in: Am J Sports Med 1997 Jul-Aug;25(4):587.

A retrospective evaluation of operative treatment of ankle fractures. Low CK, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):172-4

Bone mineral density in fractures treated with absorbable or metallic implants. Juutilainen T, et al. **Ann Chir Gynaecol** 1997;86(1):51-5

Arthroscopic treatment of soft-tissue impingement of the ankle in athletes. DeBerardino TM, et al. **Arthroscopy** 1997 Aug;13(4):492-8

Arthroscopically assisted reduction and fixation of an adult Tillaux fracture of the ankle. Miller MD. **Arthroscopy** 1997 Feb;13(1):117-9

Angioplasty balloon catheters used for distraction of the ankle joint. Sartoretti C, et al. **Arthroscopy** 1996 Feb; 12(1):82-6

Results of surgical treatment of tibial plafond fractures. Babis GC, et al. **Clin Orthop** 1997 Aug;(341):99-105

Surgical treatment of malleolar fractures. A review of 144 patients. Beris AE, et al. **Clin Orthop** 1997 Aug;(341):90-8

Reamed femoral nailing in patients with multiple injuries. Adverse effects of tourniquet use. Pollak AN, et al. **Clin Orthop** 1997 Jun;(339):41-6

Arthroscopy of the foot and ankle in the athlete. Cooper PS, et al. **Clin Sports Med** 1996 Oct;15(4):805-24 (68 ref.)

Anatomic structures at risk: combined subtalar and ankle arthrodesis with a retrograde intramedullary rod [letter; comment] Carr JB. **Foot Ankle Int** 1996 Mar;17(3):189-90 . Comment on: Foot Ankle Int 1995 Sep;16(9):542-7. Comment on: Foot Ankle Int 1995 Sep;16(9):572-6.

Tibial plafond fractures: limited internal fixation and a hybrid external fixator. Griffiths GP, et al. **Foot Ankle Int** 1996 Aug;17(8):444-8

Polyglycolide bioabsorbable screws in the treatment of ankle fractures. Hovis WD, et al. **Foot Ankle Int** 1997 Mar; 18(3):128-31

Displaced intra-articular calcaneus fractures treated with the Galveston plate. Laughlin RT, et al. **Foot Ankle Int** 1996 Feb;17(2):71-8

Spontaneous rupture of extensor hallucis longus tendon. Mulcahy DM, et al. **Foot Ankle Int** 1996 Mar;17(3):162-3 (10 ref.)

Ankle diastasis without fracture: an uncommon injury with an unusual complication. Burgert S, et al. **Injury** 1996 Nov; 27(9):666-7

Technical factors in hindfoot arthrodesis. Manoli A 2nd, et al. **Instr Course Lect** 1997;46:347-56 (23 ref.)

Reconstruction of the lateral ligaments of the ankle using a regional periosteal flap. Rudert M, et al. **J Bone Joint Surg Br** 1997 May;79(3):446-51

Arthroscopy for problems after ankle fracture. van Duk CN, et al. **J Bone Joint Surg Br** 1997 Mar;79(2):280-4

Retrospective analysis of operative ankle fractures. Calderone DR, et al. **J Foot Ankle Surg** 1996 May-Jun;35(3):230-6

Ankle arthroscopy: follow-up study of 33 ankles--effect of physical therapy and obesity. Japour C, et al. **J Foot Ankle Surg** 1996 May-Jun;35(3):199-209

Comparison of tension band wire and cancellous bone screw fixation for medial malleolar fractures. Johnson BA, et al. **J Foot Ankle Surg** 1997 Jul-Aug;36(4):284-9

Intraarticular calcaneus fractures: a biomechanical comparison or two fixation methods. Bailey EJ, et al. **J Orthop Trauma** 1997 Jan;11(1):34-7

Reimplantation of the totally extruded talus. Brewster NT, et al. **J Orthop Trauma** 1997 Jan;11(1):42-5

Local-advancement soft-tissue coverage in a child with ipsilateral grade IIIB open tibial and ankle fractures. Klein DM, et al. **J Orthop Trauma** 1996;10(8):577-80

Avulsion fracture of the calcaneus: report of a case using a new tension band technique. Levi N, et al. **J Orthop Trauma** 1997 Jan;11(1):61-2

Open total talus dislocation: case report and review of the literature. Palomo-Traver JM, et al. **J Orthop Trauma** 1997 Jan;11(1):45-9 (19 ref.)

Fragment of entire posterior talar process as an obstacle to reduction of an anterior talar subluxation: case report. Chen YJ, et al. **J Trauma** 1997 Feb;42(2):314-7

Early range of motion training after ligament reconstruction of the ankle joint. Karlsson J, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(3):173-7

Distally based sural island flap for foot and ankle reconstruction. Jeng SF, et al. **Plast Reconstr Surg** 1997 Mar;99(3):744-50

Reconstruction of the peroneal retinaculum using the plantaris tendon: a case report. Hansen BH. **Scand J Med Sci Sports** 1996 Dec;6(6):355-8

Management of unstable ankle fractures with Kirschner wires. Oosterhuis JW, et al. **Trop Doct** 1997 Oct;27(4):230-1

[Surgery in the region of the ankle joint--5 years' experience] Jirka Z. **Rozhl Chir** 1997 May;76(5):228-30 (Eng. Abstr.) **(Cze)**

[Fracture dislocation of the ankle with retro-tibial luxation of the fibula (Bosworth fracture) . Apropos of a case] Pidet O, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(7):631-4 (11 ref.) (Eng. Abstr.) **(Fre)**

[Osteosynthesis of internal malleolar fracture by staplers] Schiedts D, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1997;83(1):70-3 (Eng. Abstr.) **(Fre)**

[Anesthesiologic management of ankle joint osteosynthesis in the 35th week of pregnancy in a patient with Charcot-Marie-Tooth syndrome] Kirmayer UJ, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Nov; 31(9):582-4 (Eng. Abstr.) **(Ger)**

[Revision operations after failed arthrodeses of the upper ankle joint] Eingartner C, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:941-4 (Eng. Abstr.) **(Ger)**

[New developments in the application of resorbable implants] Rehm KE, et al. **Orthopade** 1997 May;26(5):489-97 (Eng. Abstr.) **(Ger)**

[Functional disorders of the foot after tenodeses: is the method still currently acceptable?] Becker HP, et al. **Sportverletz Sportschaden** 1996 Dec;10(4):94-9 (47 ref.) (Eng. Abstr.) **(Ger)**

[Dwyer osteotomy with or without lateral stabilization in calcaneus varus with lateral ligament insufficiency of the upper ankle joint] Csizy M, et al. **Sportverletz Sportschaden** 1996 Dec;10(4):100-2 (Eng. Abstr.) **(Ger)**

[Ligament injury of the ankle joint (2) (editorial)] Hintermann B. **Sportverletz Sportschaden** 1996 Dec;10(4):75 **(Ger)**

[Surgical treatment of chronic ankle joint instability--many variations in German clinics. Analysis of a 1994 German survey] Schmidt R, et al. **Sportverletz Sportschaden** 1997 Mar;11(1):21-6 (Eng. Abstr.) **(Ger)**

[Weber fibular ligament-plasty with plantar tendon with Segesser modification] Segesser B, et al. **Sportverletz Sportschaden** 1996 Dec;10(4):88-93 (Eng. Abstr.) **(Ger)**

[The unstable upper ankle joint. Treatment of acute ligament rupture--a review of the literature] Sommer CJ. **Sportverletz Sportschaden** 1996 Dec;10(4):76-8 (34 ref.) (Eng. Abstr.) **(Ger)**

[Injuries of the talus and calcaneus] Brunner U, et al. **Unfallchirurg** 1996 Feb;99(2):136-51 (10 ref.) **(Ger)**

[Primary closed, stabilization of type C 3 pilon fractures with external fixator without bridging the ankle joint] Vrabl M. **Unfallchirurg** 1997 May;100(5):406-8 (Eng. Abstr.) **(Ger)**

[Bases and results of revascularization of the talus in fracture-dislocation] Radomskiĭ OA. **Klin Khir** 1996; (6):19-22 **(Ukr)**

THERAPY

Strengthening exercises and support devices for ankle sprains [letter; comment] Thibault GF. **Am Fam Physician** 1997 Mar;55(4):1086, 1088. Comment on: Am Fam Physician 1996 Jun;53(8):2491-8, 2501-3.

Role of ankle taping and bracing in the athlete. Callaghan MJ. **Br J Sports Med** 1997 Jun;31(2):102-8 (64 ref.)

Primary care of foot and ankle injuries in the athlete. Clanton TO, et al. **Clin Sports Med** 1997 Jul;16(3):435-66 (71 ref.)

Stable lateral malleolar fractures treated with aircast ankle brace and DonJoy R.O.M.-Walker brace: a prospective randomized study. Brink O, et al. **Foot Ankle Int** 1996 Nov; 17(11):679-84

Fractures of the ankle and the distal part of the tibia. Vander Griend R, et al. **Instr Course Lect** 1997;46:311-21 (66 ref.)

Extra-articular triplane fracture of the distal tibial epiphysis [letter; comment] Peterson HA. **J Pediatr Orthop** 1996 Sep-Oct;16(5):679. Comment on: J Pediatr Orthop 1995 Jul-Aug;15(4):479-81.

Taping of the ankle--the effect on postural sway during perturbation, before and after a training session. Leanderson J, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(1):53-6

The treatment of acute soft tissue trauma in Danish emergency rooms. Johannsen F, et al. **Scand J Med Sci Sports** 1997 Jun;7(3):178-81

Early functional treatment for acute ligament injuries of the ankle joint. Karlsson J, et al. **Scand J Med Sci Sports** 1996 Dec;6(6):341-5

[Conservative or surgical treatment of ankle fractures? (comment)] Klasen HJ. **Ned Tijdschr Geneeskd** 1996 Nov 23;140(47):2320-1. Comment on: Ned Tijdschr Geneeskd 1996 Nov 23;140(47):2337-41. Comment on: Ned Tijdschr Geneeskd 1996 Nov 23;140(47):2342-9. **(Dut)**

[Differentiated protocol for the conservative/surgical treatment of ankle fractures in children (see comments)] Van Laarhoven CJ, et al. **Ned Tijdschr Geneeskd** 1996 Nov 23;140(47):2337-41 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1996 Nov 23;140(47):2320-1. **(Dut)**

[Differentiated protocol for the conservative/surgical treatment of ankle fractures in adults (see comments)] Van Laarhoven CJ, et al. **Ned Tijdschr Geneeskd** 1996 Nov 23; 140(47):2342-9 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1996 Nov 23;140(47):2320-1. **(Dut)**

[Functional therapy using a laced ankle brace in supination trauma of the ankle joint with lesions of the capsule-ligament apparatus] Els M, et al. **Swiss Surg** 1996; 2(6):280-3 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Sonographic diagnosis of anterior syndesmosis rupture] Krappel F, et al. **Z Orthop Ihre Grenzgeb** 1997 Mar-Apr; 135(2):116-9 (Eng. Abstr.) **(Ger)**

ANKLE JOINT

Ankle flexibility and injury patterns in dancers. Wiesler ER,

et al. **Am J Sports Med** 1996 Nov-Dec;24(6):754-7
Unusual but memorable. Wright GD, et al.
Ann Rheum Dis 1997 Apr;56(4):261
Foot and ankle issues in rheumatoid arthritis. Marks RM, et al. **Bull Rheum Dis** 1997 Aug;46(5):1-3
Clear cell sarcoma of tendons and aponeuroses with t(12;22)(q13;q12) diagnosed initially as malignant melanoma. Nedoszytko B, et al. **Cancer Genet Cytogenet** 1996 Oct 1; 91(1):37-9
Brucellar oligoarthritis involving the left temporomandibular, left sternoclavicular and left ankle joints [letter] Adak B, et al. **Clin Exp Rheumatol** 1997 Jan-Feb;15(1):122-3
Tenodesis versus carbon fiber repair of ankle ligaments: a clinical comparison. Becker HP, et al. **Clin Orthop** 1996 Apr;(325):194-202
Modification of the Van Nes rotationplasty: report of a case. Merkel KD, et al. **Clin Orthop** 1997 Mar;(336):195-8
Fracture-dislocation of the ankle with posterior tibial tendon entrapment within the tibiofibular interosseous space: a case report of a late diagnosis. Anderson JG, et al.
Foot Ankle Int 1996 Feb;17(2):114-8
A simple way to establish the posterolateral portal in ankle arthroscopy. Katchis SD, et al. **Foot Ankle Int** 1997 Mar; 18(3):178-9
Metastatic lung cancer to ankle synovium: a case report. Koss SD, et al. **Foot Ankle Int** 1996 Jan;17(1):51-3
Pseudoaneurysm formation after ankle arthroscopy. O'Farrell D, et al. **Foot Ankle Int** 1997 Sep;18(9):578-9
Split peroneus longus tenodesis for chronic lateral ligamentous instability of ankle. Srinivasan VB, et al.
Injury 1996 Sep;27(7):467-9
Degenerative changes at the knee and ankle related to malunion of tibial fractures [letter; comment] Milner S, et al. **J Bone Joint Surg Br** 1997 Jul;79(4):698. Comment on: J Bone Joint Surg Br 1996 Sep;78(5):722-5.
Degenerative changes at the knee and ankle related to malunion of tibial fractures. 15-year follow-up of 88 patients [see comments] van der Schoot DK, et al.
J Bone Joint Surg Br 1996 Sep;78(5):722-5. Comment in: J Bone Joint Surg Br 1997 Jul;79(4):698.
Lateral ankle instability and the Brostrom-Gould procedure. Keller M, et al. **J Foot Ankle Surg** 1996 Nov-Dec; 35(6):513-20
Congenital ball-and-socket anomaly of the ankle. Bettin D, et al. **J Pediatr Orthop** 1996 Jul-Aug;16(4):492-6
Screw epiphysiodesis for ankle valgus. Stevens PM, et al.
J Pediatr Orthop 1997 Jan-Feb;17(1):9-12
Instantaneous centers of rotation in dorsi/plantar flexion movements of posterior-type plastic ankle-foot orthoses. Sumiya T, et al. **J Rehabil Res Dev** 1997 Jul;34(3):279-85
Periarticular ankle sarcoidosis: a variant of Löfgren's syndrome [letter; comment] Molina JF, et al.
J Rheumatol 1997 Jan;24(1):239. Comment on: J Rheumatol 1996 May;23(5):874-7.
Influence of external stabilizing devices of the ankle on sport-specific capabilities. Jerosch J, et al.
Knee Surg Sports Traumatol Arthrosc 1997;5(1):50-7
Development of a home ankle exerciser. Petrosenko RD, et al. **Med Eng Phys** 1996 Jun;18(4):314-9
Ischemic contracture of the foot and ankle: principles of management and prevention. Botte MJ, et al.
Orthopedics 1996 Mar;19(3):235-44 (72 ref.)
Solving the problem of contractures--throw out the recipe book? Macfarlane A, et al. **Physiother Res Int** 1997;2(1):1-6
Synthesis of a cycloidal mechanism of the prosthetic ankle. Pitkin MR. **Prosthet Orthot Int** 1996 Dec;20(3):159-71
Management of the foot and ankle in rheumatoid arthritis. Mann RA, et al. **Rheum Dis Clin North Am** 1996 Aug; 22(3):457-76 (23 ref.)
[Value of intramedullary locked nailing in distal fractures of the tibia] Bonnevialle P, et al.
Rev Chir Orthop Reparatrice Appar Mot 1996;82(5):428-36 (Eng. Abstr.) **(Fre)**
[Fractures of the anterior rim of the distal part of the tibia. Apropos of a series of 38 cases] Cesari B, et al.
Rev Chir Orthop Reparatrice Appar Mot 1996;82(5):417-27 (20 ref.) (Eng. Abstr.) **(Fre)**
[Pure dislocations of the tibio-talar joint. Apropos of 9 cases] Garbuio P, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(7):601-08 (Eng. Abstr.) **(Fre)**
[Tenography in tenosynoviopathies of the posterior tibial tendon] Jardé O, et al.
Rev Chir Orthop Reparatrice Appar Mot 1996;82(8):700-4 (Eng. Abstr.) **(Fre)**
[Post-traumatic epiphysiodesis of the distal end of the tibia in children] Toupin JM, et al.
Rev Chir Orthop Reparatrice Appar Mot 1997;83(2):112-22 (Eng. Abstr.) **(Fre)**
[Pigmented villonodular synovitis of the lower limb. MR-tomography and histology in 3 cases] Leutloff UC, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Dec;165(6):605-8 **(Ger)**
[Determination of cartilage thickness in the ankle joint. an MRT (1.5)-anatomical comparative study] Trattnig S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Apr;166(4):303-6 (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Surgical management of ankle valgus in children: use of a transphyseal medial malleolar screw. Davids JR, et al.
J Pediatr Orthop 1997 Jan-Feb;17(1):3-8

ANATOMY & HISTOLOGY

Gastrocnemius muscle length in relation to knee and ankle joint angles: verification of a geometric model and some applications. Ettema GJ. **Anat Rec** 1997 Jan;247(1):1-8
An anatomical study of a new portal for ankle arthroscopy. Buckingham RA, et al. **J Bone Joint Surg Br** 1997 Jul; 79(4):650-2
In vivo human gastrocnemius architecture with changing joint angle at rest and during graded isometric contraction. Narici MV, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):287-97
MR imaging of the ankle and foot. Erickson SJ, et al.
Radiol Clin North Am 1997 Jan;35(1):163-92 (78 ref.)
Peroneus quartus muscle: MR imaging features. Cheung YY, et al. **Radiology** 1997 Mar;202(3):745-50
Pseudodefect of the talar dome: an anatomic pitfall of ankle MR imaging. Miller TT, et al. **Radiology** 1997 Jun; 203(3):857-8
MR imaging of articular cartilage in the ankle: comparison of available imaging sequences and methods of measurement in cadavers. Tan TC, et al.
Skeletal Radiol 1996 Nov;25(8):749-55

BLOOD SUPPLY

[Biomechanical stimulation therapy as physical treatment of arthrogenic venous insufficiency] Klyscz T, et al.
Hautarzt 1997 May;48(5):318-22 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Acute arthritis during isotretinoin treatment for acne conglobata [letter] De Francesco V, et al. **Dermatology** 1997;194(2):195

INJURIES see ANKLE INJURIES

INNERVATION

Noninvasive ankle distraction: relationship between force, magnitude of distraction, and nerve conduction abnormalities. Dowdy PA, et al. **Arthroscopy** 1996 Feb; 12(1):64-9
Sodium urate arthritis: effects on the sensory properties of articular afferents in the chicken. Gentle MJ. **Pain** 1997 Apr;70(2-3):245-51

MICROBIOLOGY

Pasteurella multocida infectious arthritis with acute gout after a cat bite. Butt TS, et al. **J Rheumatol** 1997 Aug; 24(8):1649-52 (56 ref.)

PATHOLOGY

Anterolateral soft-tissue impingement in the ankle: diagnosis using MR imaging. Rubin DA, et al.
AJR Am J Roentgenol 1997 Sep;169(3):829-35
Bloody arthritis. Annesley-Williams DJ, et al.
Ann Rheum Dis 1997 Jan;56(1):12-4
Ankle arthroscopy: outcome in 79 consecutive patients. Amendola A, et al. **Arthroscopy** 1996 Oct;12(5):565-73
Development and clinical application of a flexible arthroscopy system. Takahashi T, et al. **Arthroscopy** 1997 Feb;13(1):42-50
Case of the month: painful ankle swelling--diagnosis by MRI. Peh WC, et al. **Br J Radiol** 1996 Sep;69(825):881-2
Primary leiomyosarcoma affecting the ankle joint. Delsmann BM, et al. **Foot Ankle Int** 1996 Jul;17(7):420-4 (31 ref.)
Technique tips. Skeletal traction for ankle arthroscopy. Wright G. **Foot Ankle Int** 1996 Feb;17(2):119
The fate of the syndesmosis in type C ankle fractures: a cadaveric study. Harris IA, et al. **Injury** 1997 May; 28(4):275-7
MRI of the sinus tarsi in acute ankle sprain injuries. Breitenseher MJ, et al. **J Comput Assist Tomogr** 1997 Mar-Apr;21(2):274-9
Effect of foot and ankle MR imaging on clinical decision making [see comments] Anzilotti K Jr, et al. **Radiology** 1996 Nov;201(2):515-7. Comment in: Radiology 1997 May;203(2):578-9.
Ankle arthroscopy under local and general anaesthesia for diagnostic evaluation and treatment. Rolf C, et al.
Scand J Med Sci Sports 1996 Aug;6(4):255-8
Magnetic resonance imaging of injuries to the ankle joint: can it predict clinical outcome? Zanetti M, et al.
Skeletal Radiol 1997 Feb;26(2):82-8

PHYSIOLOGY

Three-dimensional analysis of normal ankle and foot mobility. Kitaoka HB, et al. **Am J Sports Med** 1997 Mar-Apr;25(2):238-42
Ankle disk training influences reaction times of selected muscles in a simulated ankle sprain. Sheth P, et al.
Am J Sports Med 1997 Jul-Aug;25(4):538-43
Ankle flexibility and injury patterns in dancers. Wiesler ER, et al. **Am J Sports Med** 1996 Nov-Dec;24(6):754-7
Effect of passive stretching and jogging on the series elastic muscle stiffness and range of motion of the ankle joint. McNair PJ, et al. **Br J Sports Med** 1996 Dec;30(4):313-7, discussion 318
Hip and ankle range of motion in elite classical ballet dancers and controls. Khan K, et al. **Clin J Sport Med** 1997 Jul; 7(3):174-9
Contribution of the anterolateral joint capsule to the mechanical stability of the ankle. Boardman DL, et al.
Clin Orthop 1997 Aug;(341):224-32
Critical evaluation of anterior drawer measurement methods in the ankle. Ray RG, et al. **Clin Orthop** 1997 Jan; (334):215-24
Soleus muscle length, stretch reflex excitability, and the contractile properties of muscle in children and adults: a study of the functional joint angle. Lin JP, et al.
Dev Med Child Neurol 1997 Jul;39(7):469-80
Influence of plyometric training on the mechanical impedance of the human ankle joint. Cornu C, et al.
Eur J Appl Physiol 1997;76(3):282-8
Changes in the mechanical properties of human and amphibian muscle after eccentric exercise. Jones C, et al.
Eur J Appl Physiol 1997;76(1):21-31
Identification of time-varying stiffness dynamics of the human ankle joint during an imposed movement. Kirsch RF, et al. **Exp Brain Res** 1997 Mar;114(1):71-85
Contribution of the deltoid ligament to ankle joint contact characteristics: a cadaver study. Earll M, et al.
Foot Ankle Int 1996 Jun;17(6):317-24
A reliability study of the universal goniometer, fluid goniometer, and electrogoniometer for the measurement of ankle dorsiflexion. Rome K, et al. **Foot Ankle Int** 1996 Jan;17(1):28-32
Influence of ankle ligaments on tibial rotation: an in vitro study. Sommer C, et al. **Foot Ankle Int** 1996 Feb; 17(2):79-84
The influence of antagonist muscle control strategies on the isometric frequency response of the cat's ankle joint. Goodwin A, et al. **IEEE Trans Biomed Eng** 1997 Jul; 44(7):634-9
Identification of intrinsic and reflex contributions to human ankle stiffness dynamics. Kearney RE, et al.
IEEE Trans Biomed Eng 1997 Jun;44(6):493-504
Effect of forward lean on postural ankle dynamics. Sinha T, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):348-59 (45 ref.)
The stabilizing effect of orthotic devices on plantar flexion/dorsal extension and horizontal rotation of the ankle joint. An experimental cadaveric investigation. Bruns J, et al. **Int J Sports Med** 1996 Nov;17(8):614-8
Isokinetic evaluation of calf muscle performance after Achilles rupture repair. Leppilahti J, et al.
Int J Sports Med 1996 Nov;17(8):619-23
Ankle joint dorsiflexion measurement studies. A review of the literature. Rome K. **J Am Podiatr Med Assoc** 1996 May; 86(5):205-11 (28 ref.)
Stepping over an obstacle increases the motions and moments of the joints of the trailing limb in young adults. Chou LS, et al. **J Biomech** 1997 Apr;30(4):331-7
Minimum energy trajectories of the swing ankle when stepping over obstacles of different heights. Chou LS, et al. **J Biomech** 1997 Feb;30(2):115-20
A controlled-release ergometer for the human ankle. Hof AL. **J Biomech** 1997 Feb;30(2):203-6
Moment arm length variations of selected muscles acting on talocrural and subtalar joints during movement: an in vitro study. Klein P, et al. **J Biomech** 1996 Jan;29(1):21-30
Transfer of mechanical energy between ankle and knee joints by gastrocnemius and plantaris muscles during cat locomotion. Prilutsky BI, et al. **J Biomech** 1996 Apr; 29(4):391-403
A six-degrees-of-freedom instrumented linkage for measuring the flexibility characteristics of the ankle joint complex. Siegler S, et al. **J Biomech** 1996 Jul;29(7):943-7
A method to determine bone movement in the ankle joint complex in vitro. Stähelin T, et al. **J Biomech** 1997 May; 30(5):513-6
Effects of joint motion constraints on the gait of normal subjects and their implications on the further development of hybrid FES orthosis for paraplegic persons. Yang L, et al. **J Biomech** 1996 Feb;29(2):217-26
The ankle clonus test for assessment of the integrity of the spinal cord during operations for scoliosis. Hoppenfeld S, et al. **J Bone Joint Surg Am** 1997 Feb;79(2):208-12
Spontaneous regeneration of the lateral malleolus after traumatic loss in a three-year-old boy: a case report with seven-year follow-up. Park HW, et al.
J Bone Joint Surg Br 1997 Jan;79(1):66-7
Reproducibility of the kinematics and kinetics of the lower extremity during normal stair-climbing. Yu B, et al.
J Orthop Res 1997 May;15(3):348-52
The effect of quadriceps femoris, hamstring, and placebo eccentric fatigue on knee and ankle dynamics during crossover cutting. Nyland JA, et al.
J Orthop Sports Phys Ther 1997 Mar;25(3):171-84
An evaluation of the posterior leaf spring orthosis using joint kinematics and kinetics. Ounpuu S, et al.
J Pediatr Orthop 1996 May-Jun;16(3):378-84
Vulpius and Z-lengthening. Yngve DA, et al.
J Pediatr Orthop 1996 Nov-Dec;16(6):759-64
In vivo human gastrocnemius architecture with changing joint angle at rest and during graded isometric contraction. Narici MV, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):287-97
A new method for quantifying pronation in overpronating and normal runners. Engsberg JR.
Med Sci Sports Exerc 1996 Mar;28(3):299-304

Lateral stability in sideward cutting movements. Stacoff A, et al. **Med Sci Sports Exerc** 1996 Mar;28(3):350–8
Mechanically evoked cerebral potentials to sudden ankle dorsiflexion in human subjects during standing. Dimitrov B, et al. **Neurosci Lett** 1996 Apr 26;208(3):199–202
Age-related muscle stiffness: predominance of non-reflex factors. Wolfarth S, et al. **Neuroscience** 1997 Jul; 79(2):617–28
Effects of speed and different types of treadmill on the range of motion of the lower extremities. Shih J, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 2):1399–402
The effect of strapping on the motor performance of the ankle and wrist joints. Kauranen K, et al. **Scand J Med Sci Sports** 1997 Aug;7(4):238–43

PHYSIOPATHOLOGY

What best protects the inverted weightbearing ankle against further inversion? Evertor muscle strength compares favorably with shoe height, athletic tape, and three orthoses. Ashton-Miller JA, et al. **Am J Sports Med** 1996 Nov-Dec;24(6):800–9
Chronic, painful ankle instability in skeletally immature athletes. Ununited osteochondral fractures of the distal fibula. Busconi BD, et al. **Am J Sports Med** 1996 Sep-Oct; 24(5):647–51
Prognosis of infants with ankle clonus within the first year of life. Futagi Y, et al. **Brain Dev** 1997 Jan;19(1):50–4
Disordered mobility of large joints in association with neuropathy in patients with long-standing insulin-dependent diabetes mellitus. Andersen H, et al. **Diabet Med** 1997 Mar;14(3):221–7
Limited joint mobility of the ankle in diabetic patients with cutaneous sensory deficit. Simmons RW, et al. **Diabetes Res Clin Pract** 1997 Aug;37(2):137–43
Effectiveness of external orthotic support on passive soft tissue resistance of the chronically unstable ankle. Hartsell HD, et al. **Foot Ankle Int** 1997 Mar;18(3):144–50
Kinematic and neuromuscular changes of the gait pattern after Achilles tendon rupture. Neumann D, et al. **Foot Ankle Int** 1997 Jun;18(6):339–41
Varus tilt of the tibial plafond as a factor in chronic ligament instability of the ankle. Sugimoto K, et al. **Foot Ankle Int** 1997 Jul;18(7):402–5
Kinematics and dynamic stability of the locomotion of post-polio patients. Hurmuzlu Y, et al. **J Biomech Eng** 1996 Aug;118(3):405–11
Varus malalignment of the talar neck. Its effect on the position of the foot and on subtalar motion. Daniels TR, et al. **J Bone Joint Surg Am** 1996 Oct;78(10):1559–67
Effects of medial and lateral displacement calcaneal osteotomies on tibiotalar joint contact stresses. Steffensmeier SJ, et al. **J Orthop Res** 1996 Nov;14(6):980–5
Evaluation of kinesthetic deficits indicative of balance control in gymnasts with unilateral chronic ankle sprains. Forkin DM, et al. **J Orthop Sports Phys Ther** 1996 Apr; 23(4):245–50
Functional outcome analysis of operatively treated malleolar fractures. Belcher GL, et al. **J Orthop Trauma** 1997 Feb-Mar;11(2):106–9
Effect of ankle-foot orthosis on active ankle moment in patients with hemiparesis. Miyazaki S, et al. **Med Biol Eng Comput** 1997 Jul;35(4):381–5
Identification of physiological systems: a robust method for non-parametric impulse response estimation. Westwick DT, et al. **Med Biol Eng Comput** 1997 Mar;35(2):83–90
[Effectiveness of outer stability aids on rotational stability of the ankle joints] Müller CC, et al. **Sportverletz Sportschaden** 1996 Dec;10(4):84–7 **(Ger)** (Eng. Abstr.)
[Modification of the flexibility of the upper and lower ankle joint by medical compression stockings] Lentner A, et al. **Vasa** 1996;25(1):60–4 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

The impact of ankle radiographs on the diagnosis and management of acute ankle injuries. Omary RA, et al. **Acad Radiol** 1996 Sep;3(9):758–65
Width of the medial tibiotalar joint. Fiirgaard B, et al. **Acta Radiol** 1997 Jul;38(4 Pt 1):520–2
Tuberculosis of the ankle in childhood: clinical, roentgenographic and computed tomography findings. Ruggieri M, et al. **Clin Pediatr (Phila)** 1997 Sep; 36(9):529–34
MRI of the foot and ankle. Lucas P, et al. **Curr Probl Diagn Radiol** 1997 Sep-Oct;26(5):209–66
MRI versus lateral stress radiography in acute lateral ankle ligament injuries. Breitenseher MJ, et al. **J Comput Assist Tomogr** 1997 Mar-Apr;21(2):280–5
Juvenile chronic arthritis: radiologic manifestations in the foot and ankle. Tong G, et al. **J Foot Ankle Surg** 1996 May-Jun;35(3):260–2
Osteochondritis dissecans of the talus presenting as an ankle ganglion. Iannacone WM, et al. **Orthopedics** 1997 Apr; 20(4):348–52

SURGERY

Ankle arthrodesis with cross screw fixation. Good results in 36/40 cases followed 3–7 years. Chen YJ, et al. **Acta Orthop Scand** 1996 Oct;67(5):473–8
Soft tissue contractures of the knee or ankle treated by the Ilizarov technique. High recurrence rate in 26 patients followed for 3–6 years. Huang SC. **Acta Orthop Scand** 1996 Oct;67(5):443–9
Biomechanics of ankle ligament reconstruction. An in vitro comparison of the Broström repair, Watson-Jones reconstruction, and a new anatomic reconstruction technique. Bahr R, et al. **Am J Sports Med** 1997 Jul-Aug; 25(4):424–32
Outcomes of the Chrisman-Snook and modified-Broström procedures for chronic lateral ankle instability. A prospective, randomized comparison. Hennrikus WL, et al. **Am J Sports Med** 1996 Jul-Aug;24(4):400–4
Comparison of two anatomic reconstructions for chronic lateral instability of the ankle joint. Karlsson J, et al. **Am J Sports Med** 1997 Jan-Feb;25(1):48–53
Arthroscopically assisted arthrodesis of the ankle joint. Jerosch J, et al. **Arch Orthop Trauma Surg** 1996; 115(3-4):182–9 (87 ref.)
Role of internal and external fixation in ankle fusion. Pfahler M, et al. **Arch Orthop Trauma Surg** 1996;115(3-4):146–8
Ankle arthroscopy: outcome in 79 consecutive patients. Amendola A, et al. **Arthroscopy** 1996 Oct;12(5):565–73
Noninvasive distraction for ankle arthroscopy. Cameron SE. **Arthroscopy** 1997 Jun;13(3):366–9
Ankle arthrodesis using an arthroscopic method: long-term follow-up of 34 cases. Glick JM, et al. **Arthroscopy** 1996 Aug;12(4):428–34
Angioplasty balloon catheters used for distraction of the ankle joint. Sartoretti C, et al. **Arthroscopy** 1996 Feb; 12(1):82–6
Arthroscopy of the ankle joint. van Dijk CN, et al. **Arthroscopy** 1997 Feb;13(1):90–6
Local anesthesia for arthroscopic surgery of the ankle using pethidine or prilocaine. Westman L, et al. **Arthroscopy** 1997 Jun;13(3):307–12
Arthroscopic stabilization of the ankle. Kashuk KB, et al. **Clin Podiatr Med Surg** 1997 Jul;14(3):459–78 (38 ref.)
Subtalar arthrorisis and associated procedures. Smith SD, et al. **Clin Podiatr Med Surg** 1997 Jan;14(1):87–98 (14 ref.)
The long-term results of ankle joint synovectomy for rheumatoid arthritis. Akagi S, et al. **Clin Rheumatol** 1997 May;16(3):284–90
Arthroscopic findings in ankle ligament reconstruction. Kibler WB. **Clin Sports Med** 1996 Oct;15(4):799–804
Revision ankle fusion using internal compression arthrodesis with screw fixation [published erratum appears in Foot Ankle Int 1997 Jun;18(6):379] Anderson JG, et al. **Foot Ankle Int** 1997 May;18(5):300–9
Intraoperative peroneus brevis tendon rupture: a technique to salvage the graft during ankle ligament reconstruction. Berg EE. **Foot Ankle Int** 1996 Jun;17(6):349–51
Arthroscopic treatment of anterior ankle impingement. Branca A, et al. **Foot Ankle Int** 1997 Jul;18(7):418–23
Complications following arthroscopic ankle arthrodesis. Crosby LA, et al. **Foot Ankle Int** 1996 Jun;17(6):340–2
A method to facilitate compression of intramedullary ankle arthrodesis. Donatto KC. **Foot Ankle Int** 1997 Apr; 18(4):247–8
Replacement of the lateral malleolus of the ankle joint with a reversed proximal fibular bone graft. Herring CL Jr, et al. **Foot Ankle Int** 1997 Jun;18(6):317–23
Salvage of pseudoarthrosis after tibiotalar arthrodesis. Levine SE, et al. **Foot Ankle Int** 1997 Sep;18(9):580–5
Results of ankle arthrodesis for treatment of supramalleolar nonunion and ankle arthrosis. Marsh JL, et al. **Foot Ankle Int** 1997 Mar;18(3):138–43
Treatment algorithm of chronic ankle and subtalar instability. Thermann H, et al. **Foot Ankle Int** 1997 Mar;18(3):163–9
Podiatry Institute ankle fusion technique. Mahan KT, et al. **J Am Podiatr Med Assoc** 1997 Mar;87(3):101–16 (63 ref.)
Pain in the posterior aspect of the ankle in dancers. Differential diagnosis and operative treatment. Hamilton WG, et al. **J Bone Joint Surg Am** 1996 Oct;78(10):1491–500
Clinical results of the Mayo total ankle arthroplasty. Kitaoka HB, et al. **J Bone Joint Surg Am** 1996 Nov;78(11):1658–64
Stress fracture of the tibia after arthrodesis of the ankle or the hindfoot. Lidor C, et al. **J Bone Joint Surg Am** 1997 Apr;79(4):558–64
Graft-enhanced arthrodesis. Catanzariti AR. **J Foot Ankle Surg** 1996 Sep-Oct;35(5):463–73 (31 ref.)
The use of the Synthes 7.3-mm. cannulated screw in rearfoot and ankle surgery: a preliminary prospective study. Rockett MS, et al. **J Foot Ankle Surg** 1997 Mar-Apr;36(2):87–94; discussion 159
Chronic ankle pain in soldiers: the role of ankle arthroscopy and soft tissue excision. Clasper JC, et al. **J R Army Med Corps** 1996 Oct;142(3):107–9
Ankle replacement: true dawn at last. Loxdale PH. **J R Nav Med Serv** 1996 Spring;82(1):25–6
Comment: long-term follow-up of joint stabilization procedures in the treatment of fixed deformities of feet in leprosy [letter; comment] Schreuder PA. **Lepr Rev** 1997 Mar;68(1):94. Comment on: Lepr Rev 1996 Jun;67(2):126–34.
Reconstruction of the lateral malleolus using a reverse-flow vascularized fibular head: a case report. Rajacic N, et al. **Microsurgery** 1996;17(3):158–61
[Long-term results following fibulo-tarsal ligament reconstruction. Comparison of the Watson-Jones and the (modified) Chrisman-Snook techniques Bernhard JA, et al. **Swiss Surg** 1996;2(6):274–9 (Eng. Abstr.) **(Ger)**
[Postoperative evaluation of osteochondrosis dissecans of the talus with special reference to medial malleolar osteotomy] Gaulrapp H, et al. **Z Orthop Ihre Grenzgeb** 1996 Jul-Aug; 134(4):346–53 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Sonography of tendons: patterns of disease. van Holsbeeck M, et al. **Instr Course Lect** 1994;43:475–81 (20 ref.)

ANKLE LATERAL LIGAMENT see **LATERAL LIGAMENT, ANKLE**

ANKYLOSIS

Solitary caging protects mice from ankylosing enthesopathy. Weinreich S, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:32–3

COMPLICATIONS

Management of unilateral temporomandibular ankylosis associated with facial asymmetry. el-Sheikh MM, et al. **J Craniomaxillofac Surg** 1997 Jun;25(3):109–15
[Simultaneous surgical correction of temporomandibular ankylosis and facial symmetry. Presentation of a case] De Ponte FS, et al. **Minerva Stomatol** 1995 Nov;44(11):551–8 (Eng. Abstr.) **(Ita)**

CONGENITAL

Congenital temporomandibular joint ankylosis—a case report. Komorowska A. **Eur J Orthod** 1997 Jun;19(3):243–8

ETIOLOGY

Multifocal heterotopic ossification in a patient with sickle cell disease: a case report. Fye MA, et al. **Am J Orthop** 1997 Mar;26(3):216–9
Pseudoankylosis of the mandible after supratentorial craniotomy. Kawaguchi M, et al. **Anesth Analg** 1996 Oct; 83(4):731–4
Condylar torque as a possible cause of hypomobility after sagittal split osteotomy: report of three cases. Van Sickels JE, et al. **J Oral Maxillofac Surg** 1997 Apr;55(4):398–402; discussion 402–3

GENETICS

Murine progressive ankylosis is not immunologically mediated. Krug HE, et al. **J Rheumatol** 1997 Jan; 24(1):115–22

HISTORY

Etiopathogenesis of skeletal hyperostosis. A study of a European population that lived 7700 years ago. Crubézy E. **Rev Rhum Engl Ed** 1996 Jul-Sep;63(7-8):481–4

IMMUNOLOGY

The role of MHC class I heterodimer expression in mouse ankylosing enthesopathy. Weinreich SS, et al. **Immunogenetics** 1997;46(1):35–40
Murine progressive ankylosis is not immunologically mediated. Krug HE, et al. **J Rheumatol** 1997 Jan; 24(1):115–22

PATHOLOGY

Ultrastructure of the ankylotic area in the osteopetrotic op/op mouse. Okada H, et al. **J Nihon Univ Sch Dent** 1996 Jul;38(2):87–93
Bilateral ankylosis of temporomandibular joint secondary to ankylosing spondylitis in a male Chinese. Chow TK, et al. **Scand J Rheumatol** 1997;26(2):133–4

PHYSIOPATHOLOGY

The absence of human beta 2-microglobulin increases the occurrence of ankylosing enthesopathy in HLA-B27 transgenic mice. Chopin M, et al. **Clin Rheumatol** 1996 Jan; 15 Suppl 1:28–31

SURGERY

An analytic study of surgical management of the temporomandibular joint ankylosis: an experience in Bangladesh. Molla MR, et al. **Bangladesh Med Res Counc Bull** 1996 Apr;22(1):43–50
Comparison of different materials for interposition arthroplasty in treatment of temporomandibular joint ankylosis surgery: long-term follow-up in 25 cases. Chossegros C, et al. **Br J Oral Maxillofac Surg** 1997 Jun; 35(3):157–60
Surgical management of bilateral complete bony ankylosis of the temporomandibular joint: a case report [letter] Omura S, et al. **Br J Oral Maxillofac Surg** 1997 Aug; 35(4):297–9
Total knee arthroplasty in a previously ankylosed or arthrodesed knee. Naranja RJ Jr, et al. **Clin Orthop** 1996 Oct;(331):234–7
New surgical technique for treatment of extraarticular knee ankylosis. Wang Y, et al. **Clin Orthop** 1997 Apr;(337):172–9
Total knee replacement with minimally constrained prostheses in spontaneous bony ankylosis. Huang CH, et al. **Int Orthop** 1996;20(2):100–2
Management of unilateral temporomandibular ankylosis associated with facial asymmetry. el-Sheikh MM, et al. **J Craniomaxillofac Surg** 1997 Jun;25(3):109–15
Articulated radial head replacement and elbow release for

ANKYLOSIS

post head-injury heterotopic ossification. Charnley G, et al. **J Orthop Trauma** 1996;10(1):68-71

Talocalcaneal coalition resection: a 10-year follow-up. McCormack TJ, et al. **J Pediatr Orthop** 1997 Jan-Feb; 17(1):13-5

THERAPY

Management of the completely stiff pediatric knee. Cole PA, et al. **J Pediatr Orthop** 1997 Jan-Feb;17(1):67-73

VETERINARY

What is your diagnosis? Ankylosis of the left temporomandibular joint. Anderson A. **J Small Anim Pract** 1997 Jul;38(7):279, 295

ANKYRIN REPEAT

The Arabidopsis NPR1 gene that controls systemic acquired resistance encodes a novel protein containing ankyrin repeats. Cao H, et al. **Cell** 1997 Jan 10;88(1):57-63

The ankyrin repeat-containing protein Akr1p is required for the endocytosis of yeast pheromone receptors. Givan SA, et al. **Mol Biol Cell** 1997 Jul;8(7):1317-27

Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Serebriiskii I, et al. **Oncogene** 1997 Aug 28; 15(9):1043-9

ANKYRINS

ANALYSIS

Cytoskeletal markers allowing discrimination between brush cells and other epithelial cells of the gut including enteroendocrine cells. Höfer D, et al. **Histochem Cell Biol** 1996 May;105(5):405-12

Molecular composition of the node of Ranvier: identification of ankyrin-binding cell adhesion molecules neurofascin (mucin+/third FNIII domain-) and NrCAM at nodal axon segments. Davis JQ, et al. **J Cell Biol** 1996 Dec; 135(5):1355-67

Isoforms of ankyrin-3 that lack the NH2-terminal repeats associate with mouse macrophage lysosomes. Hoock TC, et al. **J Cell Biol** 1997 Mar 10;136(5):1059-70

Distribution of ankyrin isoforms and their proteolysis after ischemia and reperfusion in rat brain. Harada K, et al. **J Neurochem** 1997 Jul;69(1):371-6

BLOOD

Apparently normal ankyrin content in unsplenectomized hereditary spherocytosis patients with the inactivation of one ankyrin (ANK1) allele. Miraglia del Giudice E, et al. **Haematologica** 1997 May-Jun;82(3):332-3

CHEMISTRY

Restriction by ankyrin of band 3 rotational mobility in human erythrocyte membranes and reconstituted lipid vesicles. Che A, et al. **Biochemistry** 1997 Aug 5;36(31):9588-95

Structural characterization of the tumor suppressor p16, an ankyrin-like repeat protein. Boice JA, et al. **Protein Sci** 1996 Sep;5(9):1776-84

Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2 [see comments] Gorina S, et al. **Science** 1996 Nov 8;274(5289):1001-5. Comment in: Science 1996 Nov 8;274(5289):921-2.

[Molecular defects of erythrocyte membrane proteins] Storozhok SA, et al. **Vopr Med Khim** 1996 Apr-Jun; 42(2):103-10 (73 ref.) **(Rus)**

DEFICIENCY

Red cell membranes of ankyrin-deficient nb/nb mice lack band 3 tetramers but contain normal membrane skeletons. Yi SJ, et al. **Biochemistry** 1997 Aug 5;36(31):9596-604

Ankyrin deficiency is the most common defect in dominant and non dominant hereditary spherocytosis. Lanciotti M, et al. **Haematologica** 1997 Jul-Aug;82(4):460-2

GENETICS

Ankyrin Bugey: a de novo deletional frameshift variant in exon 6 of the ankyrin gene associated with spherocytosis. Morlé L, et al. **Am J Hematol** 1997 Mar;54(3):242-8

Frequent de novo mutations of the ANK1 gene mimic a recessive mode of transmission in hereditary spherocytosis: three new ANK1 variants: ankyrins Bari, Napoli II and Anzio. Randon J, et al. **Br J Haematol** 1997 Mar; 96(3):500-6

Growth of Escherichia coli in acetate as a sole carbon source is inhibited by ankyrin-like repeats present in the 2',5'-linked oligoadenylate-dependent human RNase L enzyme. Díaz-Guerra M, et al. **FEMS Microbiol Lett** 1997 Apr 1;149(1):107-13

Fine genetic map of mouse chromosome 10 around the polycystic kidney disease gene, jcpk, and ankyrin 3. Bryda EC, et al. **Genomics** 1996 Aug 1;35(3):425-30

Structure and organization of the human ankyrin-1 gene. Basis for complexity of pre-mRNA processing. Gallagher PG, et al. **J Biol Chem** 1997 Aug 1;272(31):19220-8

Small, membrane-bound, alternatively spliced forms of ankyrin 1 associated with the sarcoplasmic reticulum of mammalian skeletal muscle. Zhou D, et al. **J Cell Biol** 1997 Feb 10;136(3):621-31

Tissue-specific regulation by vitamin D3 of a novel protein containing ankyrin-like repeats. Xu J, et al. **Mol Cell Endocrinol** 1997 Jan 3;126(1):101-7

NUC-2, a component of the phosphate-regulated signal transduction pathway in Neurospora crassa, is an ankyrin repeat protein. Poleg Y, et al. **Mol Gen Genet** 1996 Oct 28;252(6):709-16

METABOLISM

Analysis of the three-dimensional distributions of alpha-actinin, ankyrin, and filamin in developing hearts of normal and cardiac mutant axolotls (Ambystoma mexicanum). Lemanski SF, et al. **Anat Embryol (Berl)** 1997 Feb;195(2):155-63

Proteolysis of ankyrin and Na+/K(+)-ATPase in postmortem rat brain: is calpain involved? Harada K, et al. **Forensic Sci Int** 1997 Apr 18;86(1-2):77-85

Modulation of band 3-ankyrin interaction by protein 4.1. Functional implications in regulation of erythrocyte membrane mechanical properties. An XL, et al. **J Biol Chem** 1996 Dec 27;271(52):33187-91

Mapping of ankyrin binding determinants on the erythroid anion exchanger, AE1. Ding Y, et al. **J Biol Chem** 1996 Sep 13;271(37):22494-8

A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs. Tang J, et al. **J Biol Chem** 1997 Mar 28;272(13):8567-75

Identification of O-linked N-acetylglucosamine modification of ankyrinG isoforms targeted to nodes of Ranvier. Zhang X, et al. **J Biol Chem** 1996 Dec 6;271(49):31391-8

Tyrosine phosphorylation at a site highly conserved in the L1 family of cell adhesion molecules abolishes ankyrin binding and increases lateral mobility of neurofascin. Garver TD, et al. **J Cell Biol** 1997 May 5;137(3):703-14

Golgi membrane skeleton: identification, localization and oligomerization of a 195 kDa ankyrin isoform associated with the Golgi complex. Beck KA, et al. **J Cell Sci** 1997 May;110 (Pt 10):1239-49

Distribution of ankyrin isoforms and their proteolysis after ischemia and reperfusion in rat brain. Harada K, et al. **J Neurochem** 1997 Jul;69(1):371-6

Morphogenesis of the node of Ranvier: co-clusters of ankyrin and ankyrin-binding integral proteins define early developmental intermediates. Lambert S, et al. **J Neurosci** 1997 Sep 15;17(18):7025-36

ANLL see **LEUKEMIA, NONLYMPHOCYTIC, ACUTE**

ANNELIDA

Identification of the subunit loci in the extracellular multisubunit hemoglobin from annelid Perinereis aibuhitensis. Yamaki M, et al. **Arch Biochem Biophys** 1996 Nov 1;335(1):23-31

CHEMISTRY

Bioactive peptides of annelids are closely related to those of molluscs. Ukena K, et al. **Acta Biol Hung** 1995; 46(2-4):453-6

Lack of size and shape alteration of oxygenated and deoxygenated Lumbricus terrestris hemoglobin? Krebs A, et al. **Biochim Biophys Acta** 1996 Oct 17;1297(2):115-8

In situ localization of two fibrillar collagens in two compact connective tissues by immunoelectron microscopy after cryotechnical processing. Nicolas G, et al. **J Histochem Cytochem** 1997 Jan;45(1):119-28

Structural features of Glycera dibranchiata monomer hemoglobins. Primary sequences of monomer hemoglobin components II and III. Teske JG, et al. **J Protein Chem** 1997 Feb;16(2):139-50

EMBRYOLOGY

Dorsal or ventral: similarities in fate maps and gastrulation patterns in annelids, arthropods and chordates. Arendt D, et al. **Mech Dev** 1997 Jan;61(1-2):7-21 (97 ref.)

GENETICS

Cloning of an annelid fibrillar-collagen gene and phylogenetic analysis of vertebrate and invertebrate collagens. Sicot FX, et al. **Eur J Biochem** 1997 May 15; 246(1):50-8

Phylogenetic relationships of annelids, molluscs, and arthropods evidenced from molecules and morphology. Kim CB, et al. **J Mol Evol** 1996 Sep;43(3):207-15

Molecular evidence that echiurans and pogonophorans are derived annelids. McHugh D. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8006-9

METABOLISM

Research on polychaete annelid osmoregulatory peptide(s) by immunocytochemical and physiological approaches. Computer reconstruction of the brain and evidence for a role of angiotensin-like molecules in Nereis (Hediste) diversicolor OF Müller. Fewou J, et al. **Biol Cell** 1995; 85(1):21-33

PHYSIOLOGY

Parthenogenesis in Urechis caupo (Echiura). II. Role of intracellular pH in parthenogenesis induction. Stephano JL, et al. **Dev Growth Differ** 1997 Feb;39(1):99-104

Water lung and body wall contributions to respiration in an echiuran worm. Julian D, et al. **Respir Physiol** 1996 Nov; 106(2):187-98

ANNEXIN I

ANALYSIS

Annexins I and II show differences in subcellular localization and differentiation-related changes in human epidermal keratinocytes. Ma AS, et al. **Arch Dermatol Res** 1996 Sep; 288(10):596-603

Measurement of lipocortin 1 levels in murine peripheral blood leukocytes by flow cytometry: modulation by glucocorticoids and inflammation. Perretti M, et al. **Br J Pharmacol** 1996 Jun;118(3):605-10

S100A11, S100A10, annexin I, desmosomal proteins, small proline-rich proteins, plasminogen activator inhibitor-2, and involucrin are components of the cornified envelope of cultured human epidermal keratinocytes. Robinson NA, et al. **J Biol Chem** 1997 May 2;272(18):12035-46

ANTAGONISTS & INHIBITORS

Dexamethasone inhibition of acute opioid physical dependence in vitro is reverted by anti-lipocortin-1 and mimicked by anti-type II extracellular PLA2 antibodies. Capasso A, et al. **Life Sci** 1997;61(10):PL 127-34

BIOSYNTHESIS

Immunocytochemical appearance of cytokines, prostaglandin E2 and lipocortin-1 in the CNS during the incubation period of murine scrapie correlates with progressive PrP accumulations. Williams A, et al. **Brain Res** 1997 Apr 18; 754(1-2):171-80

TNF alpha alters mitochondrial membrane potential in L929 but not in TNF alpha-resistant L929.12 cells: relationship with the expression of stress proteins, annexin 1 and superoxide dismutase activity. Polla BS, et al. **Free Radic Res** 1996 Aug;25(2):125-31

Possible mechanisms of glucocorticoid--unresponsive pyrexia. Defect in lipocortin 1? Akama H, et al. **Mater Med Pol** 1995 Apr-Jun;27(2):75-8

CHEMISTRY

Binding to phosphatidyl serine membranes causes a conformational change in the concave face of annexin I. de la Fuente M, et al. **Biophys J** 1997 Jan;72(1):383-7

Antiflammins: endogenous nonapeptides with regulatory effect on inflammation. Moreno JJ. **Gen Pharmacol** 1997 Jan;28(1):23-6 (41 ref.)

GENETICS

Localization of annexin I (lipocortin I, p35) mRNA in normal and diseased human skin by in situ hybridization. Sato-Matsumura KC, et al. **Arch Dermatol Res** 1996 Sep; 288(10):565-9

Glucocorticoid induced the expression of mRNA and the secretion of lipocortin 1 in rat astrocytoma cells. Mizuno H, et al. **Brain Res** 1997 Jan 23;746(1-2):256-64

An antisense oligodeoxynucleotide to lipocortin 1 reverses the inhibitory actions of dexamethasone on the release of adrenocorticotropin from rat pituitary tissue in vitro. Taylor AD, et al. **Endocrinology** 1997 Jul;138(7):2909-18

In vivo modulation of annexins I, II and V expression by thyroxine and methylthiouracil. el Btaouri H, et al. **Eur J Biochem** 1996 Dec 15;242(3):506-11

The association of annexin I with early endosomes is regulated by Ca2+ and requires an intact N-terminal domain. Seemann J, et al. **Mol Biol Cell** 1996 Sep; 7(9):1359-74

IMMUNOLOGY

Inhibition of neutrophil and monocyte recruitment by endogenous and exogenous lipocortin 1. Getting SJ, et al. **Br J Pharmacol** 1997 Mar;120(6):1075-82

Annexin-immunoreactive proteins in the nervous system and eye of the gastropods, Aplysia and Helix. Kerschbaum HH, et al. **Brain Res** 1997 Jan 23;746(1-2):133-40

Lipocortin-1 (annexin-1) suppresses activation of autoimmune T cell lines in the Lewis rat. Gold R, et al. **J Neuroimmunol** 1996 Sep;69(1-2):157-64

METABOLISM

Annexins in the gastropod nervous system. Kerschbaum HH, et al. **Acta Biol Hung** 1995;46(2-4):413-6

Cellular and subcellular localizations of annexins I, IV, and VI in lung epithelia. Mayran N, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L863-71

Expression and secretion of lipocortin 1 in gut inflammation are not regulated by pituitary-adrenal axis. Vergnolle N, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R623-9

Presence and comparison of Ca2+ transport activity of annexins I, II, V, and VI in large unilamellar vesicles. Matsuda R, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):499-503

Structural requirements for annexin I-S100C complex-formation. Seemann J, et al. **Biochem J** 1996 Oct 1;319 (Pt 1):123-9

Lipocortin 1 binding sites on human T-cells: the population

of cells with the binding sites is larger in CD8+ T-lymphocytes than in CD4+ T-lymphocytes. Kim HW, et al. **Biochem Mol Biol Int** 1996 Dec;40(6):1167-73

Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes. Alvarez-Martinez MT, et al. **Biochim Biophys Acta** 1997 May 23;1339(2):331-40

Gliogenesis in postnatal rat optic nerve: LC1 + microglia and S100-beta + astrocytes. Zhang MZ, et al. **Brain Res Dev Brain Res** 1997 Jul 18;101(1-2):27-36

Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Ahn SH, et al. **Clin Exp Metastasis** 1997 Mar;15(2):151-6

Growth hormone induces tyrosine phosphorylation of annexin I in rat osteosarcoma cells. Salles JP, et al. **Endocrinology** 1996 Oct;137(10):4358-62

Eicosanoids and lipocortin-1 in BAL fluid in asthma: effects of smoking and inhaled glucocorticoids. Van Hal PT, et al. **J Appl Physiol** 1996 Aug;81(2):548-55

The hepatocyte growth factor receptor kinase-mediated phosphorylation of lipocortin-1 transduces the proliferating signal of the hepatocyte growth factor. Skouteris GG, et al. **J Biol Chem** 1996 Nov 1;271(44):27266-73

Transfer of phagocytosed particles to the parasitophorous vacuole of Leishmania mexicana is a transient phenomenon preceding the acquisition of annexin I by the phagosome. Collins HL, et al. **J Cell Sci** 1997 Jan;110 (Pt 2):191-200

Immunohistochemical localization of lipocortin 1 in rat brain is sensitive to pH, freezing, and dehydration. McKanna JA, et al. **J Histochem Cytochem** 1997 Apr;45(4):527-38

Exacerbation of adjuvant arthritis by adrenalectomy is associated with reduced leukocyte lipocortin 1. Yang YH, et al. **J Rheumatol** 1997 Sep;24(9):1758-64

Enhancement by ganglioside GT1b of annexin I phosphorylation in bovine mammary gland in the presence of phosphatidylserine and Ca2+. Katoh N, et al. **Lipids** 1996 Sep;31(9):983-7

The association of annexin I with early endosomes is regulated by Ca2+ and requires an intact N-terminal domain. Seemann J, et al. **Mol Biol Cell** 1996 Sep; 7(9):1359-74

Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration. Perretti M, et al. **Nat Med** 1996 Nov;2(11):1259-62

Glucocorticoids modulate the cellular disposition of lipocortin 1 in the rat brain in vivo and in vitro. Philip JG, et al. **Neuroreport** 1997 May 27;8(8):1871-6

Annexin I concentration and prostacyclin production in rat lung and alveolar macrophages following irradiation. Ts'ao C, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Feb;56(2):99-104

Enhanced expression of lipocortin-1 as a new immunosuppressive protein in cancer patients and its influence on reduced in vitro peripheral blood lymphocyte response to mitogens. Koseki H, et al. **Surg Today** 1997; 27(1):30-9

Lipocortin 1: glucocorticoids caught in the act? Smith SF. **Thorax** 1996 Oct;51(10):1057-9 (12 ref.)

PHARMACOLOGY

Lipocortin-1 inhibits CRH stimulation of plasma ACTH and IL-1 beta-stimulated hypothalamic CRH release in rats. Sudlow AW, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):R54-60

Inhibition of neutrophil and monocyte recruitment by endogenous and exogenous lipocortin 1. Getting SJ, et al. **Br J Pharmacol** 1997 Mar;120(6):1075-82

Lipocortin-1 inhibits proliferation of cultured human mesangial cells. Kim SB, et al. **Nephron** 1996;74(1):39-44

PHYSIOLOGY

Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Ferreira SH, et al. **Br J Pharmacol** 1997 Jul;121(5):883-8

Acute inflammatory response in the mouse: exacerbation by immunoneutralization of lipocortin 1. Perretti M, et al. **Br J Pharmacol** 1996 Mar;117(6):1145-54

Lipocortin 1: a second messenger of glucocorticoid action in the hypothalamo-pituitary-adrenocortical axis. Buckingham JC, et al. **Mol Med Today** 1997 Jul; 3(7):296-302 (39 ref.)

RADIATION EFFECTS

Annexin I in fibrotic rat lung and cultured lung fibroblasts following irradiation. Ts'ao C, et al. **Int J Radiat Biol** 1997 Aug;72(2):227-34

SECRETION

Translocation of lipocortin (annexin) 1 to the membrane of U937 cells induced by phorbol ester, but not by dexamethasone. Kang SA, et al. **Br J Pharmacol** 1996 Apr; 117(8):1780-4

Glucocorticoid induced the expression of mRNA and the secretion of lipocortin 1 in rat astrocytoma cells. Mizuno H, et al. **Brain Res** 1997 Jan 23;746(1-2):256-64

ANNEXIN II

ANALYSIS

Surface annexin II on placental membranes of the fetomaternal interface. Kristoffersen EK, et al. **Am J Reprod Immunol** 1996 Sep;36(3):141-9

Annexins I and II show differences in subcellular localization and differentiation-related changes in human epidermal keratinocytes. Ma AS, et al. **Arch Dermatol Res** 1996 Sep; 288(10):596-603

Altered expression of annexin II in human B-cell lymphoma cell lines. Chiang Y, et al. **Biochim Biophys Acta** 1996 Oct 11;1313(3):295-301

BIOSYNTHESIS

Overexpression of plasma membrane annexin II in NO2-exposed pulmonary artery endothelial cells. Li YD, et al. **Free Radic Biol Med** 1997;23(1):120-6

Modification of annexin II expression in PC12 cell lines does not affect Ca(2+)-dependent exocytosis. Graham ME, et al. **Mol Biol Cell** 1997 Mar;8(3):431-42

GENETICS

Differential expression of the calpactin I subunits annexin II and p11 in cultured keratinocytes and during wound repair. Munz B, et al. **J Invest Dermatol** 1997 Mar; 108(3):307-12

IMMUNOLOGY

Surface annexin II on placental membranes of the fetomaternal interface. Kristoffersen EK, et al. **Am J Reprod Immunol** 1996 Sep;36(3):141-9

METABOLISM

Annexin II: a novel mediator of cell surface plasmin generation. Hajjar KA, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:337-49 (30 ref.)

Presence and comparison of Ca2+ transport activity of annexins I, II, V, and VI in large unilamellar vesicles. Matsuda R, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):499-503

Characterization of human recombinant annexin II tetramer purified from bacteria: role of N-terminal acetylation. Kang HM, et al. **Biochemistry** 1997 Feb 25;36(8):2041-50

Characterization of type III intermediate filament regulatory protein target epitopes: S-100 (beta and/or alpha) binds the N-terminal head domain; annexin II2-p11(2) binds the rod domain. Garbuglia M, et al. **Biochim Biophys Acta** 1996 Oct 11;1313(3):268-76

Mapping of a regulatory important site for protein kinase C phosphorylation in the N-terminal domain of annexin II. Jost M, et al. **Biochim Biophys Acta** 1996 Oct 11; 1313(3):283-9

Annexin II binds to the membrane of A549 cells in a calcium-dependent and calcium-independent manner. Liu L, et al. **Cell Signal** 1997 May-Jun;9(3-4):299-304

In vivo modulation of annexins I, II and V expression by thyroxine and methylthiouracil. el Btaouri H, et al. **Eur J Biochem** 1996 Dec 15;242(3):506-11

Translocation of cytosolic annexin 2 to a Triton-insoluble membrane subdomain upon nicotine stimulation of chromaffin cultured cells. Sagot I, et al. **FEBS Lett** 1997 Jun 30;410(2-3):229-34

Tyrosine phosphorylation of annexin II tetramer is stimulated by membrane binding. Bellagamba C, et al. **J Biol Chem** 1997 Feb 7;272(6):3195-9

Annexin II is a novel player in insulin signal transduction. Possible association between annexin II phosphorylation and insulin receptor internalization. Biener Y, et al. **J Biol Chem** 1996 Nov 15;271(46):29489-96

Characterization of the heparin binding properties of annexin II tetramer. Kassam G, et al. **J Biol Chem** 1997 Jun 13; 272(24):15093-100

Identification and characterization of a novel type of annexin-membrane interaction: Ca2+ is not required for the association of annexin II with early endosomes. Jost M, et al. **J Cell Sci** 1997 Jan;110 (Pt 2):221-8

Phosphorylation by protein kinase C of annexin 2 in chromaffin cells stimulated by nicotine. Delouche B, et al. **J Neurochem** 1997 Apr;68(4):1720-7

Specific release of membrane-bound annexin II and cortical cytoskeletal elements by sequestration of membrane cholesterol. Harder T, et al. **Mol Biol Cell** 1997 Mar; 8(3):533-45

The Cdk-like protein PCTAIRE-1 from mouse brain associates with p11 and 14-3-3 proteins. Sladeczek F, et al. **Mol Gen Genet** 1997 May 20;254(5):571-7

Increased content of annexin II (p36) and p11 in human placenta brush-border membrane vesicles during syncytiotrophoblast maturation and differentiation. Kaczan-Bourgois D, et al. **Placenta** 1996 Nov;17(8):669-76

[The DNA-binding activity of the membrane protein annexin II and its interaction with antibodies to the chromatin nuclear ribonucleoprotein (alpha-RNP)] Krutilina RI, et al. **Tsitologiia** 1996;38(10):1106-14 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Annexin II inhibition of G protein-regulated inositol trisphosphate formation in rat aortic smooth muscle. Schelling JR, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):F682-90

Inhibition of lung surfactant secretion from alveolar type II cells and annexin II tetramer-mediated membrane fusion by phenothiazines. Liu L, et al. **Arch Biochem Biophys** 1997 Jun 15;342(2):322-8

PHYSIOLOGY

Involvement of annexin II in exocytosis of lamellar bodies from alveolar epithelial type II cells. Liu L, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L668-76

Annexin II modulates volume-activated chloride currents in vascular endothelial cells. Nilius B, et al. **J Biol Chem** 1996 Nov 29;271(48):30631-6

ANNEXIN III

CHEMISTRY

Can enzymatic activity, or otherwise, be inferred from structural studies of annexin III? Perron B, et al. **J Biol Chem** 1997 Apr 25;272(17):11321-6

METABOLISM

Decreased cyclic inositol phosphohydrolase activity in hamster renal tumors and human renal cell carcinomas. Sekar MC, et al. **Biochem Mol Med** 1995 Dec;56(2):104-7

ANNEXIN IV

ANALYSIS

Characterization of human p33/41 (annexin IV), a Ca2+ dependent carbohydrate-binding protein with monoclonal anti-annexin IV antibodies, AS11 and AS17. Satoh A, et al. **Biol Pharm Bull** 1997 Mar;20(3):224-9

Annexin IV is a marker of roof and floor plate development in the murine CNS. Hemre KM, et al. **J Comp Neurol** 1996 May 13;368(4):527-37

CHEMISTRY

Interaction of annexins IV and VI with phosphatidylserine in the presence of Ca2+: monolayer and proteolytic study. Bandorowicz-Pikula J, et al. **Mol Membr Biol** 1996 Oct-Dec;13(4):241-50

METABOLISM

Cellular and subcellular localizations of annexins I, IV, and VI in lung epithelia. Mayran N, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L863-71

Interaction of annexins IV and VI with ATP. An alternative mechanism by which a cellular function of these calcium- and membrane-binding proteins is regulated. Bandorowicz-Pikuła J, et al. **FEBS Lett** 1997 Jun 9; 409(2):300-6

Modulation of cell surface lectin receptors on K562 human erythroleukemia cells induced by transfection with annexin IV cDNA. Satoh A, et al. **FEBS Lett** 1997 Mar 17; 405(1):107-10

ANNEXIN V

ANALYSIS

The nuclear location of annexin V in the human osteosarcoma cell line MG-63 depends on serum factors and tyrosine kinase signaling pathways. Mohiti J, et al. **Exp Cell Res** 1997 Jul 10;234(1):98-104

Subcellular localization of annexin V in human foreskin fibroblasts: nuclear localization depends on growth state. Barwise JL, et al. **FEBS Lett** 1996 Sep 30;394(2):213-6

Absence of cell-surface annexin V is accompanied by defective collagen matrix binding in the Swarm rat chondrosarcoma. King KB, et al. **J Cell Biochem** 1997 May; 65(2):131-44

Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism [see comments] Rand JH, et al. **N Engl J Med** 1997 Jul 17; 337(3):154-60. Comment in: N Engl J Med 1997 Jul 17;337(3):197-8.

BIOSYNTHESIS

Expression and localization of annexin V and annexin VI during limb bud formation in the rat fetus. Rahman MM, et al. **Anat Embryol (Berl)** 1997 Jan;195(1):31-9

BLOOD

Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction. Kaneko N, et al. **Clin Chim Acta** 1996 Jul 15;251(1):65-80

CHEMISTRY

Conformational adaptation of annexin V upon binding to liposomes: a time-resolved fluorescence study. Follenius-Wund A, et al. **Biochem Biophys Res Commun** 1997 May 8;234(1):111-6

Annexin V interaction with phosphatidylserine-containing vesicles at low and neutral pH. Köhler G, et al. **Biochemistry** 1997 Jul 1;36(26):8189-94

ANNEXIN V

Thermodynamic stability of annexin V E17G: equilibrium parameters from an irreversible unfolding reaction. Vogl T, et al. **Biochemistry** 1997 Feb 18;36(7):1657–68

Bioincorporation of telluromethionine into proteins: a promising new approach for X-ray structure analysis of proteins. Budisa N, et al. **J Mol Biol** 1997 Jul 25; 270(4):616–23

GENETICS

Thermodynamic stability of annexin V E17G: equilibrium parameters from an irreversible unfolding reaction. Vogl T, et al. **Biochemistry** 1997 Feb 18;36(7):1657–68

Secretory production of recombinant urokinase-type plasminogen activator-annexin V chimeras in Pichia pastoris. Okabayashi K, et al. **Gene** 1996 Oct 24; 177(1–2):69–76

Mouse annexin V chromosomal localization, cDNA sequence conservation, and molecular evolution. Rodriguez-Garcia MI, et al. **Genomics** 1996 Jan 15;31(2):151–7

IMMUNOLOGY

Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Kaburaki J, et al. **Am J Hematol** 1997 Mar;54(3):209–13

Annexin V autoantibodies in rheumatoid arthritis. Rodríguez-García MI, et al. **Ann Rheum Dis** 1996 Dec; 55(12):895–900

Annexin-immunoreactive proteins in the nervous system and eye of the gastropods, Aplysia and Helix. Kerschbaum HH, et al. **Brain Res** 1997 Jan 23;746(1–2):133–40

METABOLISM

Annexins in the gastropod nervous system. Kerschbaum HH, et al. **Acta Biol Hung** 1995;46(2–4):413–6

Localization of annexin V in the adult and neonatal heart. Luckcuck T, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):622–8

Presence and comparison of Ca2+ transport activity of annexins I, II, V, and VI in large unilamellar vesicles. Matsuda R, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):499–503

Effects of lanthanide ions on the binding ability of annexin V to phospholipid vesicle. Funakoshi T, et al. **Biochem Mol Biol Int** 1996 Apr;38(5):965–72

Annexin V-mediated calcium flux across membranes is dependent on the lipid composition: implications for cartilage mineralization. Kirsch T, et al. **Biochemistry** 1997 Mar 18;36(11):3359–67

In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Ruf A, et al. **Br J Haematol** 1997 Jul;98(1):51–6

Annexin V interactions with collagen. von der Mark K, et al. **Cell Mol Life Sci** 1997 Jun;53(6):539–45 (54 ref.)

Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in chinese hamster ovary cell cultures treated with cisplatin. Boersma AW, et al. **Cytometry** 1996 Jun 1;24(2):123–30

Annexin-V and TUNEL use in monitoring the progression of apoptosis in plants. O'Brien IE, et al. **Cytometry** 1997 Sep 1;29(1):28–33

A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. van Engeland M, et al. **Cytometry** 1996 Jun 1;24(2):131–9

In vivo modulation of annexins I, II and V expression by thyroxine and methylthiouracil. el Btaouri H, et al. **Eur J Biochem** 1996 Dec 15;242(3):506–11

Annexin V-coated intraocular lenses. Chollet P, et al. **J Cataract Refract Surg** 1996;22 Suppl 1:818–24

Hepatitis B virus: specific binding and internalization of small HBsAg by human hepatocytes. de Bruin WC, et al. **J Gen Virol** 1995 Apr;76 (Pt 4):1047–50

Phospholipid degradation in energy-deprived cardiac myocytes: does annexin V play a role? Jans SW, et al. **J Mol Cell Cardiol** 1997 May;29(5):1401–10

Preferential localization of annexin V to the axon terminal. Gotow T, et al. **Neuroscience** 1996 Nov;75(2):507–21

PHARMACOLOGY

Annexin V inhibition of factor IXa-catalyzed factor X activation on human platelets and on negatively-charged phospholipid vesicles. London F, et al. **Biochemistry** 1996 Dec 24;35(51):16886–97

Partial coverage of phospholipid model membranes with annexin V may completely inhibit their degradation by phospholipase A2. Speijer H, et al. **FEBS Lett** 1997 Feb 3;402(2–3):193–7

Inhibition of cytosolic phospholipase A2 by annexin V in differentiated permeabilized HL-60 cells. Evidence of crucial importance of domain I type II Ca2+-binding site in the mechanism of inhibition. Mira JP, et al. **J Biol Chem** 1997 Apr 18;272(16):10474–82

Studies on the interaction of placental anticoagulant protein I, beta 2 glycoprotein 1, and antiphospholipid antibodies in the prothrombinase reaction and in the solid phase anticardiolipin assays. Pierangeli SS, et al. **J Lab Clin Med** 1996 Aug;128(2):194–201

PHYSIOLOGY

Similarity in calcium channel activity of annexin V and matrix vesicles in planar lipid bilayers. Arispe N, et al. **Biophys J** 1996 Oct;71(4):1764–75

Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Reutelingsperger CP, et al. **Cell Mol Life Sci** 1997 Jun; 53(6):527–32 (58 ref.)

Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line. Shibata S, et al. **Gynecol Oncol** 1997 Aug;66(2):217–21

ANNEXIN VI

BIOSYNTHESIS

Expression and localization of annexin V and annexin VI during limb bud formation in the rat fetus. Rahman MM, et al. **Anat Embryol (Berl)** 1997 Jan;195(1):31–9

CHEMISTRY

The crystal structure of annexin VI indicates relative rotation of the two lobes upon membrane binding. Kawasaki H, et al. **Biochim Biophys Acta** 1996 Oct 11;1313(3):277–82

Fluorescence spectroscopic studies on interactions between liver annexin VI and nucleotides—a possible role for a tryptophan residue. Bandorowicz-Pikula J, et al. **Eur J Biochem** 1997 Aug 15;248(1):238–44

Interaction of annexins IV and VI with phosphatidylserine in the presence of Ca2+: monolayer and proteolytic study. Bandorowicz-Pikula J, et al. **Mol Membr Biol** 1996 Oct-Dec;13(4):241–50

METABOLISM

Cellular and subcellular localizations of annexins I, IV, and VI in lung epithelia. Mayran N, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L863–71

Annexin VI modulates Ca2+ and K+ conductances of spinal cord and dorsal root ganglion neurons. Naciff JM, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):C2004–15

Presence and comparison of Ca2+ transport activity of annexins I, II, V, and VI in large unilamellar vesicles. Matsuda R, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):499–503

Fluorescence spectroscopic studies on interactions between liver annexin VI and nucleotides—a possible role for a tryptophan residue. Bandorowicz-Pikula J, et al. **Eur J Biochem** 1997 Aug 15;248(1):238–44

Interaction of annexins IV and VI with ATP. An alternative mechanism by which a cellular function of these calcium- and membrane-binding proteins is regulated. Bandorowicz-Pikula J, et al. **FEBS Lett** 1997 Jun 9; 409(2):300–6

The Ca2+-dependent lipid binding domain of P120GAP mediates protein-protein interactions with Ca2+-dependent membrane-binding proteins. Evidence for a direct interaction between annexin VI and P120GAP. Davis AJ, et al. **J Biol Chem** 1996 Oct 4;271(40):24333–6

Hydroperoxide-induced increases in intracellular calcium due to annexin VI translocation and inactivation of plasma membrane Ca2+-ATPase. Hoyal CR, et al. **J Biol Chem** 1996 Nov 15;271(46):29205–10

Lipid-depleted diet perturbs membrane composition and intracellular transport in lactating mammary cells. Ollivier-Bousquet M, et al. **J Lipid Res** 1997 May; 38(5):913–25

PHYSIOLOGY

Annexin VI overexpression targeted to heart alters cardiomyocyte function in transgenic mice. Gunteski-Hamblin AM, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):H1091–100

ANNEXIN VII

BIOSYNTHESIS

Detection and localization of synexin (Annexin VII) in Xenopus adult and embryonic tissues using an antibody to the Xenopus N-terminal PGQM repeat domain. Srivastava M, et al. **Exp Cell Res** 1996 Nov 25;229(1):14–9

CHEMISTRY

Crystal structure of the C-terminal tetrad repeat from synexin (annexin VII) of Dictyostelium discoideum. Liemann S, et al. **J Mol Biol** 1997 Jul 4;270(1):79–88

GENETICS

Antisense-mediated regulation of Annexin VII gene expression during the transition from growth to differentiation in Dictyostelium discoideum. Okafuji T, et al. **Gene** 1997 Apr 11;189(1):49–56

METABOLISM

Calcium-dependence of synexin binding may determine aggregation and fusion of lamellar bodies. Sen N, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):103–9

Calcium-dependent binding of sorcin to the N-terminal domain of synexin (annexin VII). Brownawell AM, et al. **J Biol Chem** 1997 Aug 29;272(35):22182–90

Crystal structure of the C-terminal tetrad repeat from synexin (annexin VII) of Dictyostelium discoideum. Liemann S, et al. **J Mol Biol** 1997 Jul 4;270(1):79–88

Membrane fusion protein synexin (annexin VII) as a Ca2+/GTP sensor in exocytotic secretion. Caohuy H, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10797–802

PHYSIOLOGY

Membrane fusion protein synexin (annexin VII) as a Ca2+/GTP sensor in exocytotic secretion. Caohuy H, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10797–802

ANNEXIN VIII see **ANNEXINS**

ANNEXIN IX see **ANNEXINS**

ANNEXIN X see **ANNEXINS**

ANNEXIN XI see **ANNEXINS**

ANNEXINS

Annexins and protein kinases C. Dubois T, et al. **Biochim Biophys Acta** 1996 Oct 11;1313(3):290–4 (32 ref.)

Annexins and membrane dynamics. Gerke V, et al. **Biochim Biophys Acta** 1997 Jun 27;1357(2):129–54 (223 ref.)

ANALYSIS

Isolation and characterization of two distinct low-density, Triton-insoluble, complexes from porcine lung membranes. Parkin ET, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):887–96

Immunoreactivities of p11 and calcyclin in baker's yeast, wheat germ and lobster. Kuo WN, et al. **Biochem Mol Biol Int** 1997 Jan;41(1):209–15

S100A11, S100A10, annexin I, desmosomal proteins, small proline-rich proteins, plasminogen activator inhibitor-2, and involucrin are components of the cornified envelope of cultured human epidermal keratinocytes. Robinson NA, et al. **J Biol Chem** 1997 May 2;272(18):12035–46

BIOSYNTHESIS

Cell cycle and post-transcriptional regulation of annexin expression in IMR-90 human fibroblasts. Raynal P, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):365–71

Characterization and gene expression of an annexin during fruit development in Capsicum annuum. Proust J, et al. **FEBS Lett** 1996 Apr 1;383(3):208–12

cDNA isolation and gene expression of the maize annexins p33 and p35. Battey NH, et al. **Plant Physiol** 1996 Nov; 112(3):1391–6

Effects of a mechanical stimulation of localization of annexin-like proteins in Bryonia dioica internodes. Thonat C, et al. **Plant Physiol** 1997 Jul;114(3):981–8

CHEMISTRY

Annexins: from structure to function. Benz J, et al. **Biol Chem** 1997 Mar-Apr;378(3–4):177–83 (66 ref.)

Characterization and gene expression of an annexin during fruit development in Capsicum annuum. Proust J, et al. **FEBS Lett** 1996 Apr 1;383(3):208–12

Differential expression of the calpactin I subunits annexin II and p11 in cultured keratinocytes and during wound repair. Munz B, et al. **J Invest Dermatol** 1997 Mar; 108(3):307–12

GENETICS

Annexin gene structures and molecular evolutionary genetics. Morgan RO, et al. **Cell Mol Life Sci** 1997 Jun;53(6):508–15 (55 ref.)

Sequence and chromosomal localization of mouse annexin XI. Fernandez MP, et al. **Genomics** 1996 Nov 1; 37(3):366–74

Distinct annexin subfamilies in plants and protists diverged prior to animal annexins and from a common ancestor. Morgan RO, et al. **J Mol Evol** 1997 Feb;44(2):178–88

Annexin-like protein from Arabidopsis thaliana rescues delta oxyR mutant of Escherichia coli from H2O2 stress. Gidrol X, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1; 93(20):11268–73

ISOLATION & PURIFICATION

Annexins in Paramecium cells. Involvement in site-specific positioning of secretory organelles. Knochel M, et al. **Histochem Cell Biol** 1996 Apr;105(4):269–81

METABOLISM

A role for calcium and annexins in the formation of caveolae. Parkin ET, et al. **Biochem Soc Trans** 1996 Aug;24(3):444S

Annexin XII forms calcium-dependent multimers in solution and on phospholipid bilayers: a chemical cross-linking study. Mailliard WS, et al. **Biochemistry** 1997 Jul 22; 36(29):9045–50

Translocation of annexin XI to neutrophil subcellular organelles. Sjölin C, et al. **Biochim Biophys Acta** 1997 May 22;1326(1):149–56

Annexins II, IV, V and VI relocate in response to rises in intracellular calcium in human foreskin fibroblasts. Barwise JL, et al. **J Cell Sci** 1996 Jan;109 (Pt 1):247–55

Localization of five annexins in J774 macrophages and on isolated phagosomes. Diakonova M, et al. **J Cell Sci** 1997 May;110 (Pt 10):1199–213

Structural analysis of junctions formed between lipid membranes and several annexins by cryo-electron microscopy. Lambert O, et al. **J Mol Biol** 1997 Sep 12; 272(1):42–55

Sperm protein (sp50) binds to acrosome and plasma membranes in a Ca(2+)-dependent manner: possible role in acrosome reaction. Othón Hernández E, et al. **Mol Reprod Dev** 1996 Mar;43(3):366–75

PHARMACOLOGY

Annexins from Ehrlich ascites cells inhibit the calcium-activated chloride current in Xenopus laevis oocytes. Jorgensen AJ, et al. **Pflugers Arch** 1997 Jul; 434(3):261–6

PHYSIOLOGY

Annexins: from structure to function. Benz J, et al. **Biol Chem** 1997 Mar–Apr;378(3–4):177–83 (66 ref.)

Annexins in cancer and autoimmune diseases. Bastian BC. **Cell Mol Life Sci** 1997 Jun;53(6):554–6 (44 ref.)

Structures and functions of annexins in plants. Delmer DP, et al. **Cell Mol Life Sci** 1997 Jun;53(6):546–53 (39 ref.)

Annexins in the secretory pathway. Donnelly SR, et al. **Cell Mol Life Sci** 1997 Jun;53(6):533–8 (30 ref.)

Annexins: what are they good for? Mollenhauer J. **Cell Mol Life Sci** 1997 Jun;53(6):506–7 (1 ref.)

Participation of annexins in protein phosphorylation. Rothhut B. **Cell Mol Life Sci** 1997 Jun;53(6):522–6 (51 ref.)

Partial mediation of glucocorticoid antiproliferative effects by lipocortins. Almawi WY, et al. **J Immunol** 1996 Dec 15;157(12):5231–9

ULTRASTRUCTURE

Three-dimensional structure of annexins. Liemann S, et al. **Cell Mol Life Sci** 1997 Jun;53(6):516–21 (51 ref.)

ANNIVERSARIES AND SPECIAL EVENTS

NIAAA 25th anniversary: advances in the neuroscience of alcohol. Gordis E. **Alcohol Clin Exp Res** 1996 Nov;20(8 Suppl):38A–44A

Anniversaries [editorial] Taylor CM. **Arch Psychiatr Nurs** 1996 Oct;10(5):263–4

From National Negro Health Week to National Public Health Week. Pollitt PA. **J Community Health** 1996 Dec; 21(6):401–7

Anti quackery day [letter] De S. **J Indian Med Assoc** 1996 Nov;94(11):428

ANNIVERSARY REACTION see **ADJUSTMENT DISORDERS**

ANNUAL IMPLEMENTATION PLANS see **REGIONAL HEALTH PLANNING**

ANNUAL REPORTS

What impact do annual public health reports have? Fulop N, et al. **Public Health** 1996 Sep;110(5):307–11

ANNULAR GROOVES see **AMNIOTIC BAND SYNDROME**

ANODE see **ELECTRODES**

ANODONTIA

GAPO syndrome (Radiographic clues to early diagnosis). Baxova A, et al. **Radiol Med (Torino)** 1997 Mar; 93(3):289–91

COMPLICATIONS

An adult malocclusion requiring a combination of orthodontic and prosthodontic treatment. Chan MD. **Am J Orthod Dentofacial Orthop** 1997 Jan;111(1):100–5

Site-specificity of tooth agenesis in subjects with maxillary canine malpositions. Peck S, et al. **Angle Orthod** 1996; 66(6):473–6

The effect of tooth agenesis on dentofacial structures. Yüksel S, et al. **Eur J Orthod** 1997 Feb;19(1):71–8

ETHNOLOGY

Congenitally absent third molars in 12 to 16 year old Singaporean Chinese patients: a retrospective radiographic study. Mok YY, et al. **Ann Acad Med Singapore** 1996 Nov; 25(6):828–30

ETIOLOGY

Growth retardation, alopecia, pseudoanodontia, and optic atrophy (GAPO syndrome) with congenital glaucoma. Mullaney PB, et al. **Arch Ophthalmol** 1997 Jul;115(7):940–1

[Ectodermal dysplasia: multiple manifestations of a hereditary disease] Ouellet B, et al. **J Can Dent Assoc** 1997 May; 63(5):377–81 (Eng. Abstr.) **(Fre)**

GENETICS

Schöpf-Schulz-Passarge syndrome with an unusual pattern of inheritance. Craigen WJ, et al. **Am J Med Genet** 1997 Aug 8;71(2):186–8

Tooth size in relatives of individuals with oligodontia. Schalk-van der Weide Y, et al. **Arch Oral Biol** 1996 May; 41(5):469–72

Palatal displacement of canine is genetic and related to congenital absence of teeth [letter] Becker A. **J Dent Res** 1997 Sep;76(9):1526

Palatal displacement of canine is genetic and related to congenital absence of teeth [letter; comment] Peck S, et al. **J Dent Res** 1997 Mar;76(3):728–9. Comment on: J Dent Res 1996 Jun;75(6):1346–52.

Palatal displacement of canine is genetic and related to congenital absence of teeth. Pirinen S, et al. **J Dent Res** 1996 Oct;75(10):1742–6

PATHOLOGY

Can the location of tooth agenesis and the location of initial bone loss seen in juvenile periodontitis be explained by neural developmental fields in the jaws? Kjaer I. **Acta Odontol Scand** 1997 Jan;55(1):70–2

Oral manifestations seen in association with a case of trisomy for the short arm of chromosome 9. Cobourne MT, et al. **Pediatr Dent** 1996 Nov–Dec;18(7):465–8

RADIOGRAPHY

Congenitally absent third molars in 12 to 16 year old Singaporean Chinese patients: a retrospective radiographic study. Mok YY, et al. **Ann Acad Med Singapore** 1996 Nov; 25(6):828–30

GAPO syndrome: first Egyptian case with ultrastructural changes in the gingiva. Meguid NA, et al. **Clin Genet** 1997 Aug;52(2):110–5

REHABILITATION

Dental implants in the oral rehabilitation of a teenager with hypohidrotic ectodermal dysplasia: report of a case. Davarpanah M, et al. **Int J Oral Maxillofac Implants** 1997 Mar–Apr;12(2):252–8

Prosthodontic management of ectodermal dysplasia: a review of the literature. Pigno MA, et al. **J Prosthet Dent** 1996 Nov;76(5):541–5 (73 ref.)

[The functional and esthetic aspects in the orthodontic treatment of partial anodontia (anodontia 2/2)] Persin LS, et al. **Stomatologiia (Mosk)** 1996;75(4):36–9 (Eng. Abstr.) **(Rus)**

SURGERY

Autotransplantation of premolars and molars in patients with tooth aplasia. Marcusson KA, et al. **J Dent** 1996 Sep; 24(5):355–8

THERAPY

Agenesis of mandibular second premolars. Spontaneous space closure after extraction therapy: a 4-year follow-up. Mamopoulou A, et al. **Eur J Orthod** 1996 Dec; 18(6):589–600

ANODYNES see **ANALGESICS**

ANOMIA

DIAGNOSIS

Naming deficit in herpes simplex encephalitis. Barbarotto R, et al. **Acta Neurol Scand** 1996 Apr;93(4):272–80 (28 ref.)

Activation of the phonological lexicon for reading and object naming in deep dyslexia. Katz RB, et al. **Brain Lang** 1997 Jun 1;58(1):46–60

The continuum of deep/surface dyslexia. Nolan KA, et al. **J Psycholinguist Res** 1997 Jul;26(4):413–24

Breakdown of cross-modal function in dementia. Freedman M, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr;10(2):102–6

Memory dysfunction in mild aphasics. Rönnberg J, et al. **Scand J Psychol** 1996 Mar;37(1):46–61

DRUG THERAPY

Effects of increased cholinergic activity on naming in aphasia [letter] Tanaka Y, et al. **Lancet** 1997 Jul 12;350(9071):116–7

PHYSIOPATHOLOGY

On the status of object concepts in aphasia. Chertkow H, et al. **Brain Lang** 1997 Jun 15;58(2):203–32

Cognitive neuropsychological analysis and neuroanatomic correlates in a case of acute anomia. Raymer AM, et al. **Brain Lang** 1997 Jun 1;58(1):137–56

Verb retrieval and sentence processing: dissociation of an established symptom association. Berndt RS, et al. **Cortex** 1997 Mar;33(1):99–114

A dissociation in naming digits and colors following commissurotomy. Corballis MC. **Cortex** 1996 Sep; 32(3):515–25

Differential impairments in recalling people's names: a case study in search of neuroanatomical correlates. Reinkemeier M, et al. **Neuropsychologia** 1997 May;35(5):677–84

The grammatical properties of mass nouns: an aphasia case study. Semenza C, et al. **Neuropsychologia** 1997 May; 35(5):669–75

Naming deficit for non-living items: neuropsychological and PET study. Silveri MC, et al. **Neuropsychologia** 1997 Mar; 35(3):359–67

Category-specific anomia: implication of different neural networks in naming. Ferreira CT, et al. **Neuroreport** 1997 May 6;8(7):1595–602

PSYCHOLOGY

Encoding-retrieval interactions in mild Alzheimer's disease: the role of access to categorical information. Lipinska B, et al. **Brain Cogn** 1997 Jul;34(2):274–86

The importance of word-initial phonology: error patterns in prolonged naming efforts by aphasic patients. Goodglass H, et al. **J Int Neuropsychol Soc** 1997 Mar;3(2):128–38

REHABILITATION

The treatment of anomia resulting from output lexical damage: analysis of two cases. Miceli G, et al. **Brain Lang** 1996 Jan;52(1):150–74

ANOMIE

see related
PERSONALITY DISORDERS
SOCIAL BEHAVIOR DISORDERS

Suicide and anomie. Spencer DJ. **J R Soc Med** 1997 Feb; 90(2):86–7 (6 ref.)

The impact of anomia as a factor in a demand resource model of health. Freidl W. **Soc Sci Med** 1997 May;44(9):1357–65

The hierarchical diffusion of AIDS and violent crime among U.S. metropolitan regions: inner-city decay, stochastic resonance and reversal of the mortality transition. Wallace R, et al. **Soc Sci Med** 1997 Apr;44(7):935–47

ANONYMS AND PSEUDONYMS

Anonymous submission to scientific meetings and journals [letter] Froehlich P. **Int J Pediatr Otorhinolaryngol** 1996 Feb;34(3):279

Pseudonyms for cancer registries. Pommerening K, et al. **Methods Inf Med** 1996 Jun;35(2):112–21

ANOPHELES

The contribution of repellent soap to malaria control. Kroeger A, et al. **Am J Trop Med Hyg** 1997 May; 56(5):580–4

A survey of larval and adult mosquitoes on the flood plains of Bangladesh, in relation to flood-control activities. Renshaw M, et al. **Ann Trop Med Parasitol** 1996 Dec; 90(6):621–34

Field trial of permethrin impregnated sisal curtains in malaria control in western Kenya. Oloo A, et al. **East Afr Med J** 1996 Nov;73(11):735–40

Field trial of bacticide on larval populations of two species of vector mosquitoes in Calcutta. Biswas D, et al. **Indian J Malariol** 1997 Mar;34(1):37–41

Domestic breeding sources and their contribution in Anopheles stephensi breeding in Dindigul, Tamil Nadu. Kar I, et al. **Indian J Malariol** 1996 Dec;33(4):191–9

Anophelines of Siliguri-Naxalbari block, Darjeeling, West Bengal. Malakar P, et al. **Indian J Malariol** 1995 Dec; 32(4):133–9

Bionomics of vector anophelines in District Naini Tal, Uttar Pradesh. Shukla RP, et al. **Indian J Malariol** 1995 Dec; 32(4):153–63

Field trials of combined use of two species of mermithid nematodes to control Anopheles and Culex breeding in China. Song J, et al. **Indian J Malariol** 1996 Dec; 33(4):161–5

Biological control of malaria vectors. Das PK, et al. **Indian J Med Res** 1997 Aug;106:174–97 (225 ref.)

Vector incrimination in Tamulpur primary health centre, district Nalbari, lower Assam during malaria outbreak 1995. Prakash A, et al. **Indian J Med Res** 1996 Mar;103:146–9

Insecticidal susceptibility status of Anopheles stephensi (Liston) in selected areas of Calcutta (West Bengal). Mukhopadhyay AK, et al. **Indian J Public Health** 1996 Oct–Dec;40(4):130–3

Pesticide avoidance behavior in Anopheles albimanus, a malaria vector in the Americas. Chareonviriyaphap T, et al. **J Am Mosq Control Assoc** 1997 Jun;13(2):171–83

Distribution of anopheline mosquitoes in northern Australia. Cooper RD, et al. **J Am Mosq Control Assoc** 1996 Dec; 12(4):656–63

Anopheline mosquitoes of the western province of Papua New Guinea. Cooper RD, et al. **J Am Mosq Control Assoc** 1997 Mar;13(1):5–12

Response of wild Anopheles funestus to repellent-protected volunteers is unaffected by malaria infection of the vector. Copeland RS, et al. **J Am Mosq Control Assoc** 1995 Dec; 11(4):438–40

Response of Anopheles farauti to permethrin-treated net and cloth fabrics in the laboratory. Frances SP, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):321–4

Effectiveness of repellent formulations containing deet against mosquitoes in northeastern Thailand. Frances SP, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):331–3

Importance of Hydrilla verticillata (hydrocharitaceae) as habitat for immature mosquitoes at the Ross River reservoir, Australia. Hearnden MN, et al. **J Am Mosq Control Assoc** 1997 Jun;13(2):164–70

Establishment of a free-mating colony of Anopheles albitarsis from Brazil. Horosko S 3rd, et al.
J Am Mosq Control Assoc 1997 Mar;13(1):95–6

Biological and physicochemical properties of fenitrothion microcapsules as a residual spraying formulation for mosquito control. Kawada H, et al.
J Am Mosq Control Assoc 1995 Dec;11(4):441–7

A nestable fiber pot for sampling resting mosquitoes. Komar N, et al. **J Am Mosq Control Assoc** 1995 Dec;11(4):463–7

Raising activity of Bacillus thuringiensis var. israelensis against Anopheles stephensi larvae by encapsulation in Tetrahymena pyriformis (Hymenostomatida:Tetrahymenidae). Manasherob R, et al.
J Am Mosq Control Assoc 1996 Dec;12(4):627–31

Characterization of Anopheles pseudopunctipennis larval habitats. Manguin S, et al. **J Am Mosq Control Assoc** 1996 Dec;12(4):619–26

Unusual features of pupal exuviae noted in the Anopheles quadrimaculatus complex (Diptera:Culicidae). Reinert JF, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):310–1

Acute and sublethal effects of (S)-methoprene on some Australian mosquitoes. Ritchie SA, et al.
J Am Mosq Control Assoc 1997 Jun;13(2):153–5

Differential attraction of Venezuelan Anophelines to human collectors. Rubio-Palis Y. **J Am Mosq Control Assoc** 1995 Dec;11(4):482–4

Factors affecting membrane feeding of Anopheles stephensi. Samish M, et al. **J Am Mosq Control Assoc** 1995 Dec; 11(4):408–15

A new serovar of Bacillus thuringiensis possessing 28a28c flagellar antigenic structure: Bacillus thuringiensis serovar jegathesan, selectively toxic against mosquito larvae. Seleena P, et al. **J Am Mosq Control Assoc** 1995 Dec; 11(4):471–3

Dynamics of malaria transmission in forested and deforested regions of Mandla District, central India (Madhya Pradesh). Singh N, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):225–34

Effects of sublethal dosages of methoprene on Anopheles dirus species A and B. Sithiprasasna R, et al.
J Am Mosq Control Assoc 1996 Sep;12(3 Pt 1):483–6

Seasonal occurrence and abundance of Aedes triseriatus and other mosquitoes in a La Crosse virus-endemic area in western North Carolina. Szumlas DE, et al.
J Am Mosq Control Assoc 1996 Jun;12(2 Pt 1):184–93

Evaluation of a eucalyptus-based repellent against Anopheles spp. in Tanzania. Trigg JK. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):243–6

Field evaluation of arthropod repellents, deet and a piperidine compound, AI3-37220, against Anopheles funestus and Anopheles arabiensis in western Kenya. Walker TW, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):172–6

Ecological observations on the anopheline mosquitoes of Jalpaiguri Duars, West Bengal. Nandi J, et al.
J Commun Dis 1996 Dec;28(4):279–86

Current insecticide susceptibility status of Anopheles minimus Theobald in Assam. Prakash A, et al.
J Commun Dis 1996 Jun;28(2):143–5

Field trial of cyfluthrin as an effective and safe insecticide for control of malaria vectors in triple insecticide resistant areas. Yadava RL, et al. **J Commun Dis** 1996 Dec; 28(4):287–98

Larvicidal activity of the naphthylisoquinoline alkaloid dioncophylline A against the malaria vector Anopheles stephensi. François G, et al. **J Ethnopharmacol** 1996 Nov; 54(2–3):125–30

Anopheline (Diptera:Culicidae) breeding in a traditional tank-based village ecosystem in north central Sri Lanka. Amerasinghe FP, et al. **J Med Entomol** 1997 May; 34(3):290–7

Effect of volatiles from neem and other natural products on gonotrophic cycle and oviposition of Anopheles stephensi and An. culicifacies (Diptera: Culicidae). Dhar R, et al.
J Med Entomol 1996 Mar;33(2):195–201

Indoor resting by outdoor biting females of Anopheles gambiae complex (Diptera:Culicidae) in the Sahel of northern Senegal. Faye O, et al. **J Med Entomol** 1997 May; 34(3):285–9

Spatial and temporal variation in abundance of Anopheles (Diptera:Culicidae) in a malaria endemic area in Papua New Guinea. Hii JL, et al. **J Med Entomol** 1997 Mar; 34(2):193–205

Comparative egg morphology of six species of the Albimanus section of Anopheles (Nyssorhynchus) (Diptera:Culicidae). Lounibos LP, et al. **J Med Entomol** 1997 Mar;34(2):136–55

Characterization of Anopheles darlingi (Diptera: Culicidae) larval habitats in Belize, Central America. Manguin S, et al. **J Med Entomol** 1996 Mar;33(2):205–11

Landscape surrounding human settlements and Anopheles albimanus (Diptera: Culicidae) abundance in Southern Chiapas, Mexico. Rodriguez AD, et al. **J Med Entomol** 1996 Jan;33(1):39–48

Status of malaria vectors in Italy. Romi R, et al.
J Med Entomol 1997 May;34(3):263–71

Efficacy of a granular formulation of Bacillus sphaericus against Culex quinquefasciatus and Anopheles gambiae in West African countries. Skovmand O, et al.
J Vector Ecol 1997 Jun;22(1):43–51

On human odour, malaria mosquitoes, and limburger cheese [letter; comment] Knols BG. **Lancet** 1996 Nov 9; 348(9037):1322. Comment on: Lancet 1996 May 25;347(9013):1423.

Drought and malaria retreat in the Sahel, west Africa [letter] Mouchet J, et al. **Lancet** 1996 Dec 21–28;348(9043):1735–6

Plasmodium vivax malaria acquired in far north Queensland. Brookes DL, et al. **Med J Aust** 1997 Jan 20;166(2):82–3

The relationship between female body size and survival rate of the malaria vector Anopheles arabiensis in Ethiopia. Ameneshewa B, et al. **Med Vet Entomol** 1996 Apr; 10(2):170–2

Behaviour of Anopheles albimanus in relation to pyrethroid-treated bednets. Arredondo-Jiménez JI, et al.
Med Vet Entomol 1997 Jan;11(1):87–94

Density, survival and dispersal of Anopheles gambiae complex mosquitoes in a west African Sudan savanna village. Costantini C, et al. **Med Vet Entomol** 1996 Jul; 10(3):203–19

Comparison of different insecticides and fabrics for anti-mosquito bednets and curtains. Curtis CF, et al.
Med Vet Entomol 1996 Jan;10(1):1–11

Permethrin-impregnated bednets are more effective than DDT house-spraying to control malaria in Solomon Islands. Kere NK, et al. **Med Vet Entomol** 1996 Apr; 10(2):145–8

Effects of community-wide use of lambdacyhalothrin-impregnated bednets on malaria vectors in rural Sierra Leone. Magbity EB, et al.
Med Vet Entomol 1997 Jan;11(1):79–86

Anopheles gambiae gonotrophic cycle duration, biting and exiting behaviour unaffected by permethrin-impregnated bednets in The Gambia. Quiñones ML, et al.
Med Vet Entomol 1997 Jan;11(1):71–8

Responses of mosquitoes of the Anopheles farauti complex to 1-octen-3-ol and light in combination with carbon dioxide in northern Queensland, Australia. van den Hurk AF, et al. **Med Vet Entomol** 1997 Apr;11(2):177–80

Long-term use of permethrin-impregnated nets does not increase Anopheles gambiae permethrin tolerance. Vulule JM, et al. **Med Vet Entomol** 1996 Jan;10(1):71–9

Biological variation in Anopheles darlingi Root. Charlwood JD. **Mem Inst Oswaldo Cruz** 1996 Jul-Aug;91(4):391–8 (80 ref.)

Bionomics of anopheles aquasalis Curry 1932, in Guaraí, State of Rio de Janeiro, southeastern Brazil--I. Seasonal distribution and parity rates. Flores-Mendoza C, et al.
Mem Inst Oswaldo Cruz 1996 May-Jun;91(3):265–70

Comparison of three sampling methods of man-biting anophelines in order to estimate the malaria transmission in a village of south Cameroon. Le Goff G, et al.
Parasite 1997 Mar;4(1):75–80

Studies on mosquitoes (Diptera:Culicidae) and anthropic environment. 12-host-seeking behaviour of Anopheles albitarsis s.l. in south-eastern Brazil. Forattini OP, et al.
Rev Saude Publica 1996 Aug;30(4):299–303

Toxicity of insecticides to Toxorhynchites splendens and three vector mosquitos and their sublethal effect on biocontrol potential of the predator. Amalraj DD, et al.
Southeast Asian J Trop Med Public Health 1996 Mar; 27(1):154–9

Malaria in Honiara, Solomon Islands: vector studies. Bell D, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):372–7

Microdroplet application of mosquitocidal Bacillus thuringiensis using ultra-low-volume generator for the control of mosquitos. Seleena P, et al.
Southeast Asian J Trop Med Public Health 1996 Sep; 27(3):628–32

Anopheles donaldi incriminated as a vector of periodic Brugia malayi in Grik, Perak, Malaysia. Vythilingam I, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):637–41

The biology and predatory potential of notonectid bug, Enithares indica (Fabr) against mosquito larvae. Wattal S, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):633–6

Application of deltamethrin-impregnated bednets for mosquito and malaria control in Yunnan, China. Zhang Z, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun;27(2):367–71 (14 ref.)

Effect of gametocyte sex ratio on infectivity of Plasmodium falciparum to Anopheles gambiae. Robert V, et al.
Trans R Soc Trop Med Hyg 1996 Nov-Dec;90(6):621–4

Compliance with malaria chemoprophylaxis and preventative measures against mosquito bites among Dutch travellers. Cobelens FG, et al. **Trop Med Int Health** 1997 Jul; 2(7):705–13

Malaria in Côte d'Ivoire wet savannah region: the entomological input. Dossou-yovo J, et al.
Trop Med Parasitol 1995 Dec;46(4):263–9

[The impact of curtains impregnated with deltamethrin on the vectors and morbidity of malaria: results in Ankazobe, on the plateaus of Madagascar] Rabarison P, et al.
Sante 1997 Jan-Feb;7(1):39–45 (Eng. Abstr.) **(Fre)**

[Identification of food sources of Anopheles aquasalis (Diptera: Culicidae) by precipitin test in the State of Rio de Janeiro, Brazil] Flores-Mendoza C, et al.
Rev Saude Publica 1996 Apr;30(2):129–34 (Eng. Abstr.) **(Por)**

[The season of possible malaria transmission by Anopheles claviger and Anophlese messeae mosquitoes in the Chu River valley of the Kyrgyz Republic] Bublikova LI, et al. **Med Parazitol (Mosk)** 1997 Apr-Jun;(2):30–2 (Eng. Abstr.) **(Rus)**

[Transmission of urban malaria in Buenaventrua, Colombia: entomological features] Olano V, et al.
Rev Panam Salud Publica 1997 Apr;1(4):287–94 (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Fine structure of the eggs of Anopheles (Anopheles) apicimacula (Diptera:Culicidae). Rodriguez MH, et al.
J Am Mosq Control Assoc 1996 Sep;12(3 Pt 1):454–9

Life history correlates of adult size in the malaria vector Anopheles darlingi. Lounibos LP, et al.
Mem Inst Oswaldo Cruz 1995 Nov-Dec;90(6):769–74

CHEMISTRY

The roles of temperature, pH and mosquito factors as triggers of male and female gametogenesis of Plasmodium berghei in vitro. Billker O, et al. **Parasitology** 1997 Jul;115 (Pt 1):1–7

CLASSIFICATION

Malaria transmission by Anopheles punctulatus in the highlands of Irian Jaya, Indonesia. Bangs MJ, et al.
Ann Trop Med Parasitol 1996 Feb;90(1):29–38

Rule-based system for the fast identification of species of Indian Anopheline mosquitoes. Murty US, et al.
Comput Appl Biosci 1996 Dec;12(6):491–5

A larval mosquito survey in northeastern Arkansas including a new record for Aedes albopictus. Jamieson DH, et al.
J Am Mosq Control Assoc 1994 Jun;10(2 Pt 1):236–9

Larval habitats of malaria vectors and other Anopheles mosquitoes around a transmission focus in northwestern Thailand. Rattanarithikul R, et al.
J Am Mosq Control Assoc 1995 Dec;11(4):428–33

The polymerase chain reaction method as a tool for identifying members of the Anopheles gambiae complex (Diptera:Culicidae) in northeastern Tanzania. Van Rensburg AJ, et al. **J Am Mosq Control Assoc** 1996 Jun; 12(2 Pt 1):271–4

Polymerase chain reaction used to describe larval habitat use by Anopheles gambiae complex (Diptera: Culicidae) in the environs of Ifakara, Tanzania. Charlwood JD, et al.
J Med Entomol 1996 Mar;33(2):202–4

Polymerase chain reaction species diagnostic assay for Anopheles quadrimaculatus cryptic species (Diptera: Culicidae) based on ribosomal DNA ITS2 sequences. Cornel AJ, et al. **J Med Entomol** 1996 Jan;33(1):109–16

Rapid isolation of anopheline mosquito eye-colour mutants, based on larval colour change. Benedict MQ, et al.
Med Vet Entomol 1996 Jan;10(1):93–6

Identification of species related to Anopheles (Nyssorhynchus) albitarsis by random amplified polymorphic DNA-polymerase chain reaction (Diptera: Culicidae). Wilkerson RC, et al.
Mem Inst Oswaldo Cruz 1995 Nov-Dec;90(6):721–32

Phylogeny of nearctic members of the Anopheles maculipennis species group derived from the D2 variable region of 28S ribosomal RNA. Porter CH, et al.
Mol Phylogenet Evol 1996 Oct;6(2):178–88

[Anopheles species and the transmission of malaria in the forest/savannah transition zone in central Cameroon] Manga L, et al. **Bull Soc Pathol Exot** 1997;90(2):128–30 (Eng. Abstr.) **(Fre)**

[Anopheles (Culicidae, Anophelinae) and Malaria in Buriticupu-Santa Luzia, pre-Amazonic Maranhao] Rebêlo JM, et al. **Rev Soc Bras Med Trop** 1997 Mar-Apr; 30(2):107–11 (Eng. Abstr.) **(Por)**

DRUG EFFECTS

Evaluation of Methoprene (Altosid) and Diflubenzuron (Dimilin) for control of mosquito breeding in Tezpur (Assam). Baruah I, et al. **Indian J Malariol** 1996 Jun; 33(2):61–6

Use of neem oil as a mosquito repellent in tribal villages of mandla district, madhya pradesh. Mishra AK, et al.
Indian J Malariol 1995 Sep;32(3):99–103

EMBRYOLOGY

Characterization of intraembryonic freezing in Anopheles gambiae embryos. Schreuders PD, et al. **Cryobiology** 1996 Oct;33(5):487–501

Binding kinetics of Bacillus sphaericus binary toxin to midgut brush-border membranes of Anopheles and Culex sp. mosquito larvae. Silva-Filha MH, et al. **Eur J Biochem** 1997 Aug 1;247(3):754–61

ENZYMOLOGY

Inhibition of mosquito salivary gland apyrase activity by antibodies produced in mice immunized by bites of Anopheles stephensi mosquitoes. Mathews GV, et al.
Am J Trop Med Hyg 1996 Oct;55(4):417–23

Cloning and characterization of two glutathione S-transferases from a DDT-resistant strain of Anopheles gambiae. Ranson H, et al. **Biochem J** 1997 May 15;324 (Pt 1):97–102

Trypsin and aminopeptidase gene expression is affected by age and food composition in Anopheles gambiae. Lemos FJ, et al. **Insect Biochem Mol Biol** 1996 Jul;26(7):651–8

The Tryptophan oxygenase gene of Anopheles gambiae. Mukabayire O, et al. **Insect Biochem Mol Biol** 1996 Jun; 26(6):525–8

Purification and characterization of a major glutathione S-transferase from the mosquito Anopheles dirus (species B). Prapanthadara LA, et al. **Insect Biochem Mol Biol** 1996 Mar;26(3):277–85

A glutathione S-transferase gene of the vector mosquito, Anopheles gambiae. Reiss RA, et al. **Insect Mol Biol** 1993; 2(1):25–32

Different effects of modulation of mosquito (Diptera:Culicidae) trypsin activity on the infectivity of two human malaria (Hemosporidia:Plasmodidae) parasites. Ramasamy MS, et al. **J Med Entomol** 1996 Sep;33(5):777–82

Electrophoretic separation and identification of phenoloxidases in hemolymph and midgut of adult Anopheles stephensi mosquitoes. Sidjanski S, et al. **J Parasitol** 1997 Aug;83(4):686–91

GENETICS

A genetic study of a melanization response to Sephadex beads in Plasmodium-refractory and -susceptible strains of Anopheles gambiae. Gorman MJ, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):446–51

Microsatellite polymorphism in Anopheles maculatus, a malaria vector in Thailand. Rongnoparut P, et al. **Am J Trop Med Hyg** 1996 Dec;55(6):589–94

Inheritance and linkage of aspartate aminotransferase in Anopheles stephensi. Adak T, et al. **Biochem Genet** 1996 Oct;34(9–10):363–6

Rescue of Drosophila engrailed mutants with a highly divergent mosquito engrailed cDNA using a homing, enhancer-trapping transposon. Whiteley M, et al. **Development** 1997 Apr;124(8):1531–41

Molecular cloning and expression of a hexamerin cDNA from the malaria mosquito, Anopheles gambiae. Zakharkin SO, et al. **Eur J Biochem** 1997 Jun 15;246(3):719–26

A shared genetic mechanism for melanotic encapsulation of CM-Sephadex beads and a malaria parasite, Plasmodium cynomolgi B, in the mosquito, Anopheles gambiae. Gorman MJ, et al. **Exp Parasitol** 1996 Dec;84(3):380–6

Analysis of a lysozyme gene from the malaria vector mosquito, Anopheles gambiae. Kang D, et al. **Gene** 1996 Oct 3;174(2):239–44

Heterochromatin variation in chromosome X in a natural population of Anopheles willmori (Diptera: Culicidae) of Thailand. Baimai V, et al. **Genetica** 1996 Mar;97(2):235–9

Pegasus, a small terminal inverted repeat transposable element found in the white gene of Anopheles gambiae. Besansky NJ, et al. **Genetica** 1996 Oct;98(2):119–29

Quetzal: a transposon of the Tc1 family in the mosquito Anopheles albimanus. Ke Z, et al. **Genetica** 1996 Oct; 98(2):141–7

Physical map of the malaria vector Anopheles gambiae. della Torre A, et al. **Genetics** 1996 Jul;143(3):1307–11

Selective introgression of paracentric inversions between two sibling species of the Anopheles gambiae complex. della Torre A, et al. **Genetics** 1997 May;146(1):239–44

Integrated genetic map of Anopheles gambiae: use of RAPD polymorphisms for genetic, cytogenetic and STS landmarks. Dimopoulos G, et al. **Genetics** 1996 Jun; 143(2):953–60

Inversion monophyly in African anopheline malaria vectors. García BA, et al. **Genetics** 1996 Jul;143(3):1313–20

Mapping a quantitative trait locus involved in melanotic encapsulation of foreign bodies in the malaria vector, Anopheles gambiae. Gorman MJ, et al. **Genetics** 1997 Jul; 146(3):965–71

An evaluation of evolutionary constraints on microsatellite loci using null alleles. Lehmann T, et al. **Genetics** 1996 Nov;144(3):1155–63

An integrated genetic map of the African human malaria vector mosquito, Anopheles gambiae. Zheng L, et al. **Genetics** 1996 Jun;143(2):941–52

Anopheles subpictus complex: distribution of sibling species in Sri Lanka. Abhayawardana TA, et al. **Indian J Malariol** 1996 Jun;33(2):53–60

Cytotaxonomical examination for sibling species in the taxon Anopheles culicifacies Giles in Sri Lanka. Abhayawardana TA, et al. **Indian J Malariol** 1996 Jun;33(2):74–80

First report on intraspecific morphological variations in some anophelines from District South 24-Parganas, West Bengal, India. Tandon N, et al. **Indian J Malariol** 1996 Jun; 33(2):88–98

The mitochondrial genome of the mosquito Anopheles gambiae: DNA sequence, genome organization, and comparisons with mitochondrial sequences of other insects. Beard CB, et al. **Insect Mol Biol** 1993;2(2):103–24

The Hsp70 heat-shock gene family of the mosquito Anopheles albimanus. Benedict MQ, et al. **Insect Mol Biol** 1993;2(2):93–102

Cloning and characterization of the white gene from Anopheles gambiae. Besansky NJ, et al. **Insect Mol Biol** 1995 Nov;4(4):217–31

The internal transcribed spacers of ribosomal DNA in five members of the Anopheles gambiae species complex. Paskewitz SM, et al. **Insect Mol Biol** 1993;2(4):247–57

Inducible immune factors of the vector mosquito Anopheles gambiae: biochemical purification of a defensin antibacterial peptide and molecular cloning of preprodefensin cDNA. Richman AM, et al. **Insect Mol Biol** 1996 Aug;5(3):203–10

Cloning and characterization of cDNAs preferentially expressed in the ovary of the mosquito, Anopheles gambiae. Zurita M, et al. **Insect Mol Biol** 1997 Feb;6(1):55–62

Genetic differences among Anopheles vestitipennis subpopulations collected using different methods in Chiapas state, southern México. Arredondo-Jiménez JI, et al. **J Am Mosq Control Assoc** 1996 Sep;12(3 Pt 1):396–401

Metaphase karyotypes of Anopheles of Thailand and Southeast Asia. VI. The Pyretophorus and the Neomyzomyia series, subgenus Cellia (Diptera:Culicidae). Baimai V, et al. **J Am Mosq Control Assoc** 1996 Dec; 12(4):669–75

Genetic analysis of a larval color mutant, yellow larva, in Anopheles sundaicus. Das MK, et al. **J Am Mosq Control Assoc** 1997 Jun;13(2):203–4

Cloning and localization of a glutathione S-transferase class I gene from Anopheles gambiae. Ranson H, et al. **J Biol Chem** 1997 Feb 28;272(9):5464–8

Mitochondrial DNA variation within and between two species of neotropical anopheline mosquitoes (Diptera:Culicidae). Conn JE, et al. **J Hered** 1997 Mar-Apr;88(2):98–107

Polymerase chain reaction species diagnostic assay for Anopheles quadrimaculatus cryptic species (Diptera: Culicidae) based on ribosomal DNA ITS2 sequences. Cornel AJ, et al. **J Med Entomol** 1996 Jan;33(1):109–16

Anopheles gambiae complex (Diptera:Culicidae) near Bissau City, Guinea Bissau, West Africa. Fonseca LF, et al. **J Med Entomol** 1996 Nov;33(6):939–45

Validation of a ribosomal DNA-polymerase chain reaction species diagnostic assay for the common malaria mosquito (Diptera:Culicidae) sibling species complex. Rutledge CR, et al. **J Med Entomol** 1996 Nov;33(6):952–4

Ribosomal DNA difference between species A and D of the Anopheles dirus complex of mosquitoes from China. Xu JN, et al. **Med Vet Entomol** 1997 Apr;11(2):134–8

Chromosome end elongation by recombination in the mosquito Anopheles gambiae. Roth CW, et al. **Mol Cell Biol** 1997 Sep;17(9):5176–83

Microgeographic structure of Anopheles gambiae in western Kenya based on mtDNA and microsatellite loci. Lehmann T, et al. **Mol Ecol** 1997 Mar;6(3):243–53

Identification and characterization of differentially expressed cDNAs of the vector mosquito, Anopheles gambiae. Dimopoulos G, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13066–71

Biology of Amazonian anopheline. XX. Ontogeny of esterases, leucine aminopeptidase and alpha-glycerophosphate dehydrogenase in Anopheles (Nyssorhynchus) darlingi Root, 1926 (Diptera, Culicidae). Dos Santos JM, et al. **Rev Bras Biol** 1996 Aug;56(3):591–8

Malaria fighters gather at site of early victory [news] Bagla P. **Science** 1997 Sep 5;277(5331):1437–8

Quantitative trait loci for refractoriness of Anopheles gambiae to Plasmodium cynomolgi B. Zheng L, et al. **Science** 1997 Apr 18;276(5311):425–8

Rapid, nonradioactive differential display using Tth polymerase. Favia G, et al. **Trends Genet** 1996 Oct; 12(10):396–7

[Cytogenetic and phenotypic variation in central and peripheral populations of the malaria mosquito, Anopheles messeae Fall. (Diptera, Culicidae)] Gordeev MI, et al. **Genetika** 1996 Sep;32(9):1199–205 (Eng. Abstr.) **(Rus)**

[Polymorphism of pericentromere heterochromatin of polytene chromosomes of ovarian trophocytes in natural populations of the malaria mosquito Anopheles messeae Fall.] Sharakhova MV, et al. **Genetika** 1997 Feb;33(2):281–3 (Eng. Abstr.) **(Rus)**

[Chromocenter organization in salivary glands of the malaria mosquito Anopheles messeae Fall.] Sharakhova MV, et al. **Genetika** 1997 Feb;33(2):196–201 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Assessment of a remote sensing-based model for predicting malaria transmission risk in villages of Chiapas, Mexico. Beck LR, et al. **Am J Trop Med Hyg** 1997 Jan;56(1):99–106

Larval habitat of Anopheles philippinensis: a vector of malaria in Bangladesh. Elias M. **Bull World Health Organ** 1996;74(4):447–50

Seasonal prevalence of common anophelines in Sagar Island. Sarkar S, et al. **Indian J Malariol** 1996 Sep;33(3):154–8

Age-related changes in development of the accessory glands of male Anopheles albimanus. Mahmood F. **J Am Mosq Control Assoc** 1997 Mar;13(1):35–9

Packed red blood cells and bovine serum albumin as a blood meal source for Anopheles farauti. Sianturi LJ, et al. **J Am Mosq Control Assoc** 1996 Dec;12(4):730–1

Growth of Anopheles mosquito larvae on dietary microbiota in aquatic surface microlayers. Wotton RS, et al. **Med Vet Entomol** 1997 Jan;11(1):65–70

Age structure of Anopheles subpictus (Diptera:Culicidae) collected by a light trap in Halmahela, Indonesia. Mogi M, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec;26(4):760–6

Evaluation of shading of fish farming ponds as a larval control measure against Anopheles sundaicus Rodenwaldt (Diptera:Culicidae). Takagi M, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):748–53

IMMUNOLOGY

Hemagglutinins in Anopheles quadrimaculatus, strains susceptible and refractory to Brugia malayi, and their role in the immune response to filarial parasites. Nayar JK, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Jan; 116(1):109–17

Characterization of Aedes communis, Aedes aegypti and Anopheles stephensi mosquito saliva antigens by immunoblotting. Brummer-Korvenkontio H, et al. **Int Arch Allergy Immunol** 1997 Feb;112(2):169–74

Antimidgut antibodies inhibit peritrophic membrane formation in the posterior midgut of Anopheles tessellatus (Diptera: Culicidae). Ramasamy MS, et al. **J Med Entomol** 1996 Jan;33(1):162–4

METABOLISM

Feeding behaviour of Anopheles stephensi in Calcutta. Chandra G, et al. **Indian J Malariol** 1996 Jun;33(2):103–5

A study on insecticide resistance in Anopheles fluviatilis and anopheles culicifacies to HCH and DDT in the Malkangiri district of Orissa. Sahu SS, et al. **Indian J Malariol** 1995 Sep;32(3):112–8

NAD(P)H-dependent production of oxygen reactive species by the salivary glands of the mosquito Anopheles albimanus. Ribeiro JM. **Insect Biochem Mol Biol** 1996 Jul; 26(7):715–20

Peritrophic matrix proteins of Anopheles gambiae and Aedes aegypti. Moskalyk LA, et al. **Insect Mol Biol** 1996 Nov; 5(4):261–8

PARASITOLOGY

Detection of Plasmodium falciparum sporozoites in naturally infected anopheline species using a fluorescein-labelled DNA probe. Lulu M, et al. **Acta Trop** 1997 Jan;63(1):33–42

Dose- and time-dependent relations between infective Anopheles inoculation and outcomes of Plasmodium falciparum parasitemia among children in western Kenya. McElroy PD, et al. **Am J Epidemiol** 1997 May 15; 145(10):945–56

Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus. Hurtado S, et al. **Ann Trop Med Parasitol** 1997 Jan;91(1):49–60

The effects of infection with Plasmodium yoelii nigeriensis on the reproductive fitness of Anopheles stephensi. Jahan N, et al. **Ann Trop Med Parasitol** 1997 Jun;91(4):365–9

Simplified methodology for PCR investigation of midguts from mosquitoes of the Anopheles gambiae complex, in which the vector and Plasmodium species can both be identified. Pinto J, et al. **Ann Trop Med Parasitol** 1997 Mar; 91(2):217–9

Hemagglutinins in Anopheles quadrimaculatus, strains susceptible and refractory to Brugia malayi, and their role in the immune response to filarial parasites. Nayar JK, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Jan; 116(1):109–17

Plasmodium berghei: infectivity of mice to Anopheles stephensi mosquitoes. Butcher GA, et al. **Exp Parasitol** 1996 Dec;84(3):371–9

Incrimination of Anopheles minimus as a vector of malaria in Karbi Anglong district of Assam. Dutta P, et al. **Indian J Malariol** 1995 Sep;32(3):129–31

Dynamics of malaria transmission near two permanent breeding sites in Baringo district, Kenya. Aniedu I. **Indian J Med Res** 1997 May;105:206–11

Urban malaria vector biology. Hati AK. **Indian J Med Res** 1997 Aug;106:149–63 (111 ref.)

Anopheline species complexes & malaria control. Subbarao SK, et al. **Indian J Med Res** 1997 Aug;106:164–73 (41 ref.)

Leukocytes in a Plasmodium falciparum-infected blood meal reduce transmission of malaria to Anopheles mosquitoes. Lensen AH, et al. **Infect Immun** 1997 Sep;65(9):3834–7

Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission-blocking immunity. Tsuboi T, et al. **Infect Immun** 1997 Jun;65(6):2260–4

Identification of endemic foci of filariasis by examination of mosquitoes for microfilariae. Gad AM, et al. **J Am Mosq Control Assoc** 1995 Dec;11(4):434–7

Two-site immunoradiometric assay (IRMA): detection, efficiency, and procedural modifications. Nanda N, et al. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 1):225–7

Lactate dehydrogenase as a marker of Plasmodium infection in malaria vector Anopheles. Riandey MF, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):194–8

Hyperendemic malaria in a forested, hilly Myanmar village. Tun-Lin W, et al. **J Am Mosq Control Assoc** 1995 Dec; 11(4):401–7

Endoparasitic hymenostome ciliate a potential biocontrol agent, naturally infecting anopheline larvae in Assam--a preliminary report. Narain K, et al. **J Commun Dis** 1996 Jun;28(2):139–42

Filariasis transmission potential of mosquitoes to humans of different age groups. Farid HA, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):355–64

Opportunistic properties of Nosema algerae (Microspora), a mosquito parasite, in immunocompromised mice. Trammer T, et al. **J Eukaryot Microbiol** 1997 May-Jun; 44(3):258–62

Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. Church LW, et al. **J Infect Dis** 1997 Apr;175(4):915–20

Plasmodium falciparum and P. vivax circumsporozoite proteins in anophelines (Diptera: Culicidae) collected in eastern Thailand. Frances SP, et al. **J Med Entomol** 1996 Nov;33(6):990–1

ANOPHELES

Comparison of behavior and vector efficiency of Anopheles gambiae and An. arabiensis (Diptera:Culicidae) in Barkedji, a Sahelian area of Senegal. Lemasson JJ, et al. **J Med Entomol** 1997 Jul;34(4):396–403

Mixed–species Plasmodium infections of Anopheles (Diptera:Culicidae). McKenzie FE, et al. **J Med Entomol** 1997 Jul;34(4):417–25

Enhanced gametocyte formation by Plasmodium chabaudi in immature erythrocytes: pattern of production, sequestration, and infectivity to mosquitoes. Gautret P, et al. **J Parasitol** 1996 Dec;82(6):900–6

Plasmodium yoelii sporozoite infectivity varies as a function of sporozoite loads in Anopheles stephensi mosquitoes. Pumpuni CB, et al. **J Parasitol** 1997 Aug;83(4):652–5

A land filled with mosquitoes: Fred L. Soper, the Rockefeller Foundation, and the anopheles gambiae invasion of Brazil. Packard RM, et al. **Med Anthropol** 1997 May;17(3):215–38

Perennial transmission of malaria by the Anopheles gambiae complex in a north Sudan Savanna area of Mali. Toure YT, et al. **Med Vet Entomol** 1996 Apr;10(2):197–9

Anopheles rivulorum, a vector of human malaria in Africa. Wilkes TJ, et al. **Med Vet Entomol** 1996 Jan;10(1):108–10

Isolation of a substance from the mosquito that activates Plasmodium fertilization. Garcia GE, et al. **Mol Biochem Parasitol** 1997 Sep;88(1–2):127–35

The effect of Plasmodium yoelii nigeriensis infection on ovarian protein accumulation by Anopheles stephensi. Hogg JC, et al. **Parasitol Res** 1997;83(4):374–9

Absence of relationships between selected human factors and natural infectivity of Plasmodium falciparum to mosquitoes in an area of high transmission. Haji H, et al. **Parasitology** 1996 Nov;113 (Pt 5):425–31

The effects of natural Plasmodium falciparum infection on the fecundity and mortality of Anopheles gambiae s. l. in north east Tanzania. Hogg JC, et al. **Parasitology** 1997 Apr; 114 (Pt 4):325–31

How the malaria parasite manipulates its hosts [news] Morell V. **Science** 1997 Oct 10;278(5336):223

Quantitative trait loci for refractoriness of Anopheles gambiae to Plasmodium cynomolgi B. Zheng L, et al. **Science** 1997 Apr 18;276(5311):425–8

Effects of Brugia malayi infection on the survival of Anopheles sinensis. Jin LZ, et al. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):149–53

Altitude and the risk of bites from mosquitoes infected with malaria and filariasis among the Mianmin people of Papua New Guinea. Attenborough RD, et al. **Trans R Soc Trop Med Hyg** 1997 Jan–Feb;91(1):8–10

Anopheles oswaldoi a potential malaria vector in Acre, Brazil. Branquinho MS, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):233

Measurement by membrane feeding of reduction in Plasmodium falciparum transmission induced by endemic sera. Lensen A, et al. **Trans R Soc Trop Med Hyg** 1996 Jan–Feb;90(1):20–2

[Distribution of natural parasites—fungi and microsporidia—in the population of malaria mosquito (Diptera: Culicidae) larva before and after infection by the entomopathogenic bacteria Bacillus thuringiensis Israelensis. Burlak VA, et al. **Parazitologiia** 1997 Jan–Feb; 31(1):45–52 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

High annual and seasonal variations in malaria transmission by anophelines and vector species composition in Dielmo, a holoendemic area in Senegal. Fontenille D, et al. **Am J Trop Med Hyg** 1997 Mar;56(3):247–53

Resting habits of Anopheles arabiensis in the Awash river valley of Ethiopia. Ameneshewa B, et al. **Ann Trop Med Parasitol** 1996 Oct;90(5):515–21

Genetics, ecology and behaviour of anophelines. Gibson G. **Ciba Found Symp** 1996;200:22–37; discussion 37–47 (43 ref.)

Biting rhythms of some anophelines in central Gujarat. Bhatt RM, et al. **Indian J Malariol** 1996 Dec;33(4):180–90

Diel oviposition and fecundity of Anopheles oswaldoi in Trinidad, West Indies. Chadee DD, et al. **J Am Mosq Control Assoc** 1996 Sep;12(3 Pt 1):402–5

Use of generalized regression tree models to characterize vegetation favoring Anopheles albimanus breeding. Hernandez JE, et al. **J Am Mosq Control Assoc** 1997 Mar; 13(1):28–34

A description and morphometric comparison of eggs from eight geographic populations of the South American malaria vector Anopheles (Nyssorhynchus) nuneztovari (Diptera:Culicidae). Linley JR, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):275–92

Sensory bases of attractancy: morphology of mosquito olfactory sensilla— a review. Sutcliffe JF. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 2):309–15 (54 ref.)

Variability in the relationship between weight and wing length of Anopheles gambiae (Diptera: Culicidae). Koella JC, et al. **J Med Entomol** 1996 Mar;33(2):261–4

Multiple blood feeding by Anopheles freeborni and Culex tarsalis (Diptera:Culicidae): spatial and temporal variation. Wekesa JW, et al. **J Med Entomol** 1997 Mar;34(2):219–25

Energetics and sugar–feeding of field–collected anopheline females. Holliday–Hanson ML, et al. **J Vector Ecol** 1997 Jun;22(1):83–9

Identification of electrophysiologically–active compounds for the malaria mosquito, Anopheles gambiae, in human sweat extracts. Cork A, et al. **Med Vet Entomol** 1996 Jul; 10(3):269–76

Effects of variations in a formulated protein meal on the fecundity and fertility of female mosquitoes. Cosgrove JB, et al. **Med Vet Entomol** 1996 Jul;10(3):260–4

Comparative fecundity and associated factors for two sibling species of the Anopheles gambiae complex occurring sympatrically in The Gambia. Hogg JC, et al. **Med Vet Entomol** 1996 Oct;10(4):385–91

Adaptive larval thermotolerance and induced cross–tolerance to propoxur insecticide in mosquitoes Anopheles stephensi and Aedes aegypti. Patil NS, et al. **Med Vet Entomol** 1996 Jul;10(3):277–82

Man–biting activity of Anopheles (Nyssorhynchus) albimanus and An. (Kerteszia) neivai (Diptera: Culicidae) in the Pacific lowlands of Colombia. Solarte Y, et al. **Mem Inst Oswaldo Cruz** 1996 Mar–Apr;91(2):141–6

Isolation of a substance from the mosquito that activates Plasmodium fertilization. Garcia GE, et al. **Mol Biochem Parasitol** 1997 Sep;88(1–2):127–35

Resting behaviour, ecology and genetics of malaria vectors in large scale agricultural areas of Western Kenya. Githeko AK, et al. **Parassitologia** 1996 Dec;38(3):481–9

Studies on mosquitoes (Diptera: Culicidae) and anthropic environment. 11—Biting activity and blood–seeking parity of Anopheles (Kerteszia) in south–eastern Brazil. Forattini OP, et al. **Rev Saude Publica** 1996 Apr;30(2):107–14

Feeding patterns of Anopheles dirus, the major vector of forest malaria in north east India. Dutta P, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):378–81

The late biting habit of parous Anopheles mosquitoes and pre–bedtime exposure of humans to infective female mosquitoes. Bockarie MJ, et al. **Trans R Soc Trop Med Hyg** 1996 Jan–Feb;90(1):23–5

[Biology of the vectors and transmission of Plasmodium falciparum, P. malariae and P. ovale in a village in the savanna of west Africa (Dielmo, Senegal)] Konate L, et al. **Parasite** 1994 Dec;1(4):325–33 (Eng. Abstr.) **(Fre)**

[Resistance to hunger as an element of the adaptive strategy of malaria mosquito larva] Gordeev MI. **Genetika** 1997 Jun; 33(6):844–51 (Eng. Abstr.) **(Rus)**

[The relation of the degree of water salinity to oviposition by female blood–sucking mosquitoes] Iasiukevich VV. **Med Parazitol (Mosk)** 1997 Apr–Jun;(2):32–5 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Larval rearing temperature affects morphology of Anopheles albimanus (Diptera:Culicidae) male genitalia. Hribar LJ. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):295–7

VIROLOGY

Facilitation of Rift Valley fever virus transmission by Plasmodium berghei sporozoites in Anopheles stephensi mosquitoes. Vaughan JA, et al. **Am J Trop Med Hyg** 1996 Oct;55(4):407–9

ANOPHTHALMOS

Bilateral clinical anophthalmos. Young A, et al. **Acta Ophthalmol Scand** 1997 Jun;75(3):308–10

Anophthalmia–Waardenburg syndrome or ophthalmo–acromelic syndrome: what is in a name? [letter; comment] Quarrell OW. **Am J Med Genet** 1997 Apr 14; 69(4):432. Comment on: Am J Med Genet 1996 Apr 24;62(4):391–7.

Bilateral microphthalmia, esophageal atresia, and cryptorchidism: the anophthalmia–esophageal–genital syndrome. Shah D, et al. **Am J Med Genet** 1997 May 16; 70(2):171–3 (9 ref.)

[Clinical, diagnostic and therapeutic aspects of congenital anophthalmos] Gundorova RA, et al. **Vestn Oftalmol** 1996 Sep–Oct;112(5):31–3 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Two sibs with anophthalmia and pulmonary hypoplasia (the Matthew–Wood syndrome). Seller MJ, et al. **Am J Med Genet** 1996 Mar 29;62(3):227–29

Oculocerebrocutaneous syndrome: a case report, a follow–up, and differential diagnostic considerations. Moog U, et al. **Genet Couns** 1996;7(4):257–65

DIAGNOSIS

Imaging findings in patients with clinical anophthalmos. Albernaz VS, et al. **AJNR Am J Neuroradiol** 1997 Mar; 18(3):555–61

EPIDEMIOLOGY

The descriptive epidemiology of anophthalmia and microphthalmia. Källén B, et al. **Int J Epidemiol** 1996 Oct; 25(5):1009–16

[Anophthalmia/micro–ophthalmia in syndromes: epidemiology study of newborns in Spain] Bermejo Sánchez E, et al. **An Esp Pediatr** 1996 Sep;45(3):269–75 (Eng. Abstr.) **(Spa)**

GENETICS

Hypothalamic–hypophyseal dysgenesis as a neuroimaging correlate of pituitary hormone deficiency in anophthalmia. Brodsky MC, et al. **Am J Ophthalmol** 1996 Nov; 122(5):747–8

Agenesis of corpus callosum and anophthalmia in the asplenia syndrome. A recognisable association? Devriendt K, et al. **Ann Genet** 1997;40(1):14–7

PATHOLOGY

Anophthalmia, intracerebral cysts, and cleft lip/palate: expansion of the phenotype in oculocerebrocutaneous syndrome? Angle B, et al. **Am J Med Genet** 1997 Jan 10; 68(1):39–42

Anterior encephalocele and anophthalmia. Al–Gazali LI, et al. **Clin Dysmorphol** 1996 Jan;5(1):81–3

SURGERY

Intraorbital tissue expansion in the management of congenital anophthalmos. Dunaway DJ, et al. **Br J Plast Surg** 1996 Dec;49(8):529–35

The effect of maturation on the ability to stimulate orbital growth using tissue expanders in the anophthalmic cat orbit. Heinz GW, et al. **Ophthal Plast Reconstr Surg** 1997 Jun;13(2):115–28

Human dura mater as a wrapping material for hydroxyapatite implantation in the anophthalmic socket. Lee SY, et al. **Ophthalmic Surg Lasers** 1997 May;28(5):428–31

ANOPLURA

Sucking lice (Anoplura) of mammals of Tennessee. Durden LA, et al. **J Vector Ecol** 1997 Jun;22(1):71–6

ANATOMY & HISTOLOGY

[Description of pre–imaginal and imaginal stages of Haematopinus apri (Anoplura)] Kadulski S, et al. **Wiad Parazytol** 1996;42(4):461–71 (Eng. Abstr.) **(Pol)**

ANORECTICS see **APPETITE DEPRESSANTS**

ANOREXIA

Cytokine action in the nervous system at pathophysiological versus pharmacological concentrations. Plata–Salamán CR. **Adv Exp Med Biol** 1996;402:191–7 (30 ref.)

Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. Sarraf P, et al. **J Exp Med** 1997 Jan 6;185(1):171–5

BLOOD

Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Mantovani G, et al. **Biochem Soc Trans** 1997 May; 25(2):296S

Plasma tryptophan levels and anorexia in liver cirrhosis. Laviano A, et al. **Int J Eat Disord** 1997 Mar;21(2):181–6

CHEMICALLY INDUCED

Chronic infusion of islet amyloid polypeptide causes anorexia in rats. Arnelo U, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1654–9

Involvement of the medial preoptic area in the anorectic action of estrogens. Dagnault A, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R311–7

LPS–induced anorexia in leptin–deficient (ob/ob) and leptin receptor–deficient (db/db) mice. Faggioni R, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R181–6

Delayed chronic diarrhea and weight loss possibly due to ticlopidine therapy. Mansoor GA, et al. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):870–2

Anorexia, weight loss and increased plasma interleukin–6 caused by chronic intracerebroventricular infusion of interleukin–1beta in the rat. Finck BN, et al. **Brain Res** 1997 Jul 4;761(2):333–7

Paroxetine–induced anorexia in a patient with bulimia nervosa [letter; comment] Sagduyu K. **J Clin Psychiatry** 1997 May;58(5):220–1. Comment on: J Clin Psychiatry 1994 Mar;55(3):118–9.

An approach to study molecular mechanisms involved in cytokine–induced anorexia. Ilyin SE, et al. **J Neurosci Methods** 1996 Dec;70(1):33–8

Selective serotonin reuptake inhibitors dissociate fenfluramine's anorectic and neurotoxic effects: importance of dose, species and drug. McCann UD, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1487–98

Differential responsiveness of obese (fa/fa) and lean (Fa/Fa) Zucker rats to cytokine–induced anorexia. Plata–Salamán CR, et al. **Obes Res** 1997 Jan;5(1):36–42

Attenuation of the anorectic effects of glucagon, cholecystokinin, and bombesin by the amylin receptor antagonist CGRP(8–37). Lutz TA, et al. **Peptides** 1996; 17(1):119–24

Different influence of CGRP (8–37), an amylin and CGRP antagonist, on the anorectic effects of cholecystokinin and bombesin in diabetic and normal rats. Lutz TA, et al. **Peptides** 1997;18(5):643–9

Neuropeptide Y blocks and reverses interleukin–1 beta–induced anorexia in rats. Sonti G, et al. **Peptides** 1996; 17(3):517–20

d–fenfluramine anorexia: dissociation of ingestion rate, meal duration, and meal size effects. Kaplan JM, et al.

Pharmacol Biochem Behav 1997 May-Jun;57(1-2):223-9

Effects of the alpha 1a-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats. Wellman PJ, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):281-4

COMPLICATIONS

Eating disorders [letter; comment] Bishop K, et al. **Br Dent J** 1996 Mar 23;180(6):207. Comment on: Br Dent J 1995 Mar 11;178(5):171-5.

Obsessive compulsive comorbidity in the dieting disorders. Thornton C, et al. **Int J Eat Disord** 1997 Jan;21(1):83-7

Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Beal JE, et al. **J Pain Symptom Manage** 1997 Jul;14(1):7-14

Anorexia during acute and chronic disease: relevance of neurotransmitter-peptide-cytokine interactions [letter; comment] Plata-Salamán CR. **Nutrition** 1997 Feb; 13(2):159-60. Comment on: Nutrition 1997 Jan;13(1):56-7.

DRUG THERAPY

Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumours. Azcona C, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):577-86

The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Strang P. **Anticancer Res** 1997 Jan-Feb;17(1B):657-62 (36 ref.)

Megestrol for appetite stimulation and as a progestin in hormone replacement therapy [letter] Rance LB, et al. **Arch Intern Med** 1996 Nov 25;156(21):2498

Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Beal JE, et al. **J Pain Symptom Manage** 1997 Jul;14(1):7-14

Neurobiological and psychopharmacological basis in the therapy of bulimia and anorexia. Mauri MC, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Feb; 20(2):207-40 (119 ref.)

[Anorexia associated with bronchial cancer] Jeanfaivre T, et al. **Rev Mal Respir** 1997 Apr;14(2):113-7 (38 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Tryptophan and secondary anorexia. Fanelli FR, et al. **Adv Exp Med Biol** 1996;398:545-9 (19 ref.)

Evidence for the anorexia of aging: gastrointestinal transit and hunger in healthy elderly vs. young adults. Clarkston WK, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R243-8

Role of cholecystokinin in the anorexia produced by duodenal delivery of glucose in rats. Woltman T, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1521-8

Lack of evidence for an association between Helicobacter pylori infection and the anorexia of aging [letter; comment] Howden CW. **Arch Intern Med** 1997 Aug 11-25; 157(15):1771-3. Comment on: Arch Intern Med 1997 Feb 10;157(3):269-72.

Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Wigmore SJ, et al. **Br J Surg** 1997 Feb;84(2):196-7

Anorexia and cachexia, asthenia, and lethargy. Watanabe S, et al. **Hematol Oncol Clin North Am** 1996 Feb;10(1):189-206 (100 ref.)

Fever and anorexia 10 years after major trauma. Ruiz W, et al. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):32, 34

Dietary induced anorexia: a review of involvement of the histaminergic system. Mercer LP, et al. **J Am Coll Nutr** 1996 Jun;15(3):223-30 (78 ref.)

Cancer anorexia: new pathogenic and therapeutic insights. Cangiano C, et al. **Nutrition** 1996 Jan;12(1 Suppl):S48-51 (26 ref.)

Some basic observations concerning experimental cancer anorexia [editorial] [see comments] Chance WT, et al. **Nutrition** 1996 Jul-Aug;12(7-8):556-7. Comment in: Nutrition 1997 Jan;13(1):56-7.

Cracking the riddle of cancer anorexia. Laviano A, et al. **Nutrition** 1996 Oct;12(10):706-10 (54 ref.)

Pathogenesis of cancer anorexia: personal perspective [letter; comment] [see comments] Laviano A, et al. **Nutrition** 1997 Jan;13(1):56-7. Comment on: Nutrition 1996 Feb;12(2):69-78. Comment on: Nutrition 1996 Jul-Aug;12(7-8):556-7. Comment in: Nutrition 1997 Feb;13(2):159-60.

Anorexia/cachexia in patients with HIV: lessons for the oncologist. Von Roenn JH, et al. **Oncology (Huntingt)** 1996 Jul;10(7):1049-56; discussion 1062-4, 1067-8 (52 ref.)

Influenza virus infection of mice induces anorexia: comparison with endotoxin and interleukin-1 and the effects of indomethacin. Swiergiel AH, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):389-96

Disorders of smell, taste, and food intake in a patient with a dorsomedial thalamic infarct. Rousseaux M, et al. **Stroke** 1996 Dec;27(12):2328-30

[Anorexia associated with bronchial cancer] Jeanfaivre T, et al. **Rev Mal Respir** 1997 Apr;14(2):113-7 (38 ref.) (Eng. Abstr.) **(Fre)**

[The female athletes' triad: eating disorders, amenorrhea, osteoporosis] Resch M. **Orv Hetil** 1997 Jun 1; 138(22):1393-7 (Eng. Abstr.) **(Hun)**

IMMUNOLOGY

Interactions between nutrition and immunity in anorexia nervosa: a 1-y follow-up study. Marcos A, et al. **Am J Clin Nutr** 1997 Aug;66(2):485S-490S

The anorectic effect of bacterial cell wall compounds - mechanisms and clinical implications. Langhans W. **Appetite** 1997 Aug;29(1):105

METABOLISM

Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype. Vickers SP, et al. **Psychopharmacology (Berl)** 1996 May; 125(2):168-75

MICROBIOLOGY

Helicobacter pylori infection and anorexia of aging [see comments] Portnoi VA. **Arch Intern Med** 1997 Feb 10; 157(3):269-72. Comment in: Arch Intern Med 1997 Aug 11-25;157(15):1771-3.

PATHOLOGY

Severe, chronic anorexia and extensive leg ulcerations as presenting signs of primary Sjögren's syndrome. Guggisberg D, et al. **Dermatology** 1997;195(1):93-5

PHYSIOPATHOLOGY

Tryptophan and secondary anorexia. Fanelli FR, et al. **Adv Exp Med Biol** 1996;398:545-9 (19 ref.)

Serotoninergic block in the ventromedial nucleus of hypothalamus improves food intake in anorectic tumor bearing rats. Laviano A, et al. **Adv Exp Med Biol** 1996; 398:551-3

Dissociation of temperature changes and anorexia after experimental colitis and LPS administration in rats. Larson SJ, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R967-72

Adaptation of cardiac myosin and creatine kinase to chronic hypoxia: role of anorexia and hypertension. Pissarek M, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1690-5

The anorectic effect of bacterial cell wall compounds - mechanisms and clinical implications. Langhans W. **Appetite** 1997 Aug;29(1):105

Coincidental changes in behavior and plasma cortisol in unrestrained pigs after intracerebroventricular injection of tumor necrosis factor-alpha. Warren EJ, et al. **Endocrinology** 1997 Jun;138(6):2365-71

Cachexia and anorexia in malignancy. Albrecht JT, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):791-800 (87 ref.)

Dietary induced anorexia: a review of involvement of the histaminergic system. Mercer LP, et al. **J Am Coll Nutr** 1996 Jun;15(3):223-30 (78 ref.)

Fasted and finicky without fight or flight: selective anorexic actions of a novel stress-related neuropeptide [news] Heinrichs SC. **Mol Psychiatry** 1996 Dec;1(6):427-8

Cancer anorexia: new pathogenic and therapeutic insights. Cangiano C, et al. **Nutrition** 1996 Jan;12(1 Suppl):S48-51 (26 ref.)

The gut-brain brain-gut axis in anorexia: toward an understanding of food intake regulation. Meguid MM, et al. **Nutrition** 1996 Jan;12(1 Suppl):S57-62 (44 ref.)

Assessment of the role of oxytocin receptors in phenylpropanolamine-induced anorexia in rats. McMahon LR, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):767-70

Anorexia induced by chronic central administration of cytokines at estimated pathophysiological concentrations. Plata-Salamán CR, et al. **Physiol Behav** 1996 Sep; 60(3):867-75

Neurobiological and psychopharmacological basis in the therapy of bulimia and anorexia. Mauri MC, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Feb; 20(2):207-40 (119 ref.)

Contribution of caudal brainstem to d-fenfluramine anorexia. Grill HJ, et al. **Psychopharmacology (Berl)** 1997 Apr; 130(4):375-81

PSYCHOLOGY

[Eating behavior abnormalities of psychosomatic origin in medical practice] Krylov VI, et al. **Klin Med (Mosk)** 1997; 75(3):44-6 (5 ref.) **(Rus)**

THERAPY

An alternating treatments comparison of two intensive interventions for food refusal. Ahearn WH, et al. **J Appl Behav Anal** 1996 Fall;29(3):321-32

Countertransference in the treatment of patients with eating disorders. Franko DL, et al. **Psychiatry** 1996 Spring; 59(1):108-16

ULTRASONOGRAPHY

Changes in ultrasound appearance of the internal female genital organs during treatment for eating disorders. Andolf E, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 May; 73(1):49-53

VETERINARY

Clinical evaluation of tube esophagostomy in small animals. Devitt CM, et al. **J Am Anim Hosp Assoc** 1997 Jan-Feb; 33(1):55-60

Nutritional support for rabbits using the percutaneously placed gastrostomy tube: a preliminary study. Smith DA, et al. **J Am Anim Hosp Assoc** 1997 Jan-Feb;33(1):48-54

Correlation between serum creatine kinase activities and anorexia in cats. Fascetti AJ, et al. **J Vet Intern Med** 1997 Jan-Feb;11(1):9-13

ANOREXIA NERVOSA

Childhood-onset anorexia nervosa is a serious illness. Lask B, et al. **Ann N Y Acad Sci** 1997 May 28;817:120-6 (27 ref.)

Chronic fatigue syndrome and dieting disorders: diagnosis and management problems. Griffiths RA, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):834-8

A comparative analysis of Minnesota Multiphasic Personality Inventory profiles of anorexia nervosa at hospital admission, discharge, and 10-year follow-up. Dancyger IF, et al. **Compr Psychiatry** 1997 May-Jun;38(3):185-91

Delayed detection of pregnancy in patients with anorexia nervosa: two case reports. Bonne OB, et al. **Int J Eat Disord** 1996 Dec;20(4):423-25

Anorexia nervosa and bulimia nervosa: sibling sex ratio and birth rank--a catchment area study. Britto DJ, et al. **Int J Eat Disord** 1997 May;21(4):335-40

Death due to alcoholic complications in a young woman with a severe eating disorder: a case report. Catterson ML, et al. **Int J Eat Disord** 1997 Apr;21(3):303-5

Hyperintense subcortical brain alterations in anorexia nervosa. Sieg KG, et al. **Int J Eat Disord** 1997 May; 21(4):391-4

Intriguing links between animal behavior and anorexia nervosa. Treasure JL, et al. **Int J Eat Disord** 1997 May; 21(4):307-11 (43 ref.)

Case study: an infection-triggered, autoimmune subtype of anorexia nervosa. Sokol MS, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Aug; 36(8):1128-33

Assessment and treatment of binge-eating disorder. Devlin MJ. **Psychiatr Clin North Am** 1996 Dec;19(4):761-72 (53 ref.)

Special issue. Anorexia Nervosa: Basic Mechanisms, Clinical Approaches and Treatment. Proceedings of a conference. Geneva, Switzerland, September 27-29, 1993. **Psychiatry Res** 1996 Apr 16;62(1):1-110

[Anorexia nervosa] Ishibashi H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):440-2 (12 ref.) **(Jpn)**

BLOOD

Resumption of menses in anorexia nervosa. New research findings and their clinical implications [editorial; comment] Silber TJ. **Arch Pediatr Adolesc Med** 1997 Jan;151(1):14-5 . Comment on: Arch Pediatr Adolesc Med 1997 Jan;151(1):16-21.

Serum immunoreactive leptin concentrations in patients with anorexia nervosa before and after partial weight recovery. Casanueva FF, et al. **Biochem Mol Med** 1997 Apr; 60(2):116-20

Increased cholecystokinin and pancreatic polypeptide responses to a fat-rich meal in patients with restrictive but not bulimic anorexia nervosa. Fujimoto S, et al. **Biol Psychiatry** 1997 May 15;41(10):1068-70

Factors related to sex hormone binding globulin concentrations in women with anorexia nervosa. Tomova A, et al. **Horm Metab Res** 1995 Nov;27(11):508-10

Hematological changes in anorexia nervosa are correlated with total body fat mass depletion. Lambert M, et al. **Int J Eat Disord** 1997 May;21(4):329-34

Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: effect of short- and long-term weight recuperation. Argente J, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2084-92

Serum leptin levels in women with anorexia nervosa. Grinspoon S, et al. **J Clin Endocrinol Metab** 1996 Nov; 81(11):3861-3

Endogenous codeine and morphine in anorexia and bulimia nervosa. Marrazzi MA, et al. **Life Sci** 1997;60(20):1741-7

Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration [see comments] Hebebrand J, et al. **Mol Psychiatry** 1997 Jul;2(4):330-4. Comment in: Mol Psychiatry 1997 Jul;2(4):267-9.

Low leptin levels predict amenorrhea in underweight and eating disordered females [see comments] Köpp W, et al. **Mol Psychiatry** 1997 Jul;2(4):335-40. Comment in: Mol Psychiatry 1997 Jul;2(4):267-9.

On serum albumin in anorexia nervosa [editorial; comment] Waterlow JC. **Nutrition** 1996 Oct;12(10):720-1. Comment on: Nutrition 1996 Oct;12(10):677-84.

Defective in vitro granulopoiesis in patients with anorexia nervosa. Vaisman N, et al. **Pediatr Res** 1996 Jul; 40(1):108-11

Modifications of erythrocyte membrane fluidity from patients with anorexia nervosa before and after refeeding. Lejoyeux M, et al. **Psychiatry Res** 1996 Jan 31;59(3):255-8

CEREBROSPINAL FLUID

Significant reduction of post-lumbar puncture headaches by the use of a 29-gauge spinal needle. McConaha C, et al. **Biol Psychiatry** 1996 Jun 15;39(12):1058-60

Cerebrospinal fluid leptin in anorexia nervosa: correlation with nutritional status and potential role in resistance to

weight gain. Mantzoros C, et al.
J Clin Endocrinol Metab 1997 Jun;82(6):1845–51

CHEMICALLY INDUCED

Anorexia nervosa and steroid withdrawal. Morgan J, et al. **Int J Eat Disord** 1996 Mar;19(2):213–5

CLASSIFICATION

Clinical correlates of anorexia nervosa subtypes. Pryor T, et al. **Int J Eat Disord** 1996 May;19(4):371–9

COMPLICATIONS

Hypercholesterolaemia in children and adolescents with pathological thinness and its dietetic treatment [letter] Zoppi G, et al. **Acta Paediatr** 1996 Jun;85(6):763–4

Alexithymia in anorexia nervosa: a controlled study using the 20-item Toronto Alexithymia Scale. Råstam M, et al. **Acta Psychiatr Scand** 1997 May;95(5):385–8

Mitral valve prolapse in patients with anorexia nervosa [letter; comment] Cheng TO. **Am Fam Physician** 1997 Jul; 56(1):52, 55. Comment on: Am Fam Physician 1996 Sep 15;54(4):1273–9, 1284–6.

Late-onset anorexia nervosa in schizophrenia: a case report. Muñoz CE, et al. **Ann Clin Psychiatry** 1997 Jun;9(2):109–11

Adolescents with anorexia nervosa: the impact of the disorder on bones and brains. Katzman DK, et al.
Ann N Y Acad Sci 1997 May 28;817:127–37 (76 ref.)

Resumption of menses in anorexia nervosa [letter; comment] Needles CF. **Arch Pediatr Adolesc Med** 1997 Jun; 151(6):634–5. Comment on: Arch Pediatr Adolesc Med 1997 Jan;151(1);16–21.

Experiences of physical and sexual abuse in Australian general practice attenders and an eating disordered population. Brown L, et al. **Aust N Z J Psychiatry** 1997 Jun;31(3):398–404

Acquired pili torti—a structural hair shaft defect in anorexia nervosa. Lurie R, et al. **Cutis** 1996 Mar;57(3):151–6

Anorexia nervosa: refeeding and hypophosphatemia. Birmingham CL, et al. **Int J Eat Disord** 1996 Sep; 20(2):211–3

A case of comorbid anorexia nervosa, bulimia nervosa, and Munchausen's syndrome. Bulik CM, et al.
Int J Eat Disord 1996 Sep;20(2):215–8

Bilateral foot-drop in a patient with anorexia nervosa. Kershenbaum A, et al. **Int J Eat Disord** 1997 Nov; 22(3):335–7

Dental erosion, oral hygiene, and nutrition in eating disorders. Milosevic A, et al. **Int J Eat Disord** 1997 Mar; 21(2):195–9

The significance of a prior history of anorexia in bulimia nervosa. Sullivan PF, et al. **Int J Eat Disord** 1996 Nov; 20(3):253–61

Prevalence of eating disorders among Norwegian women and men in a psychiatric outpatient unit. Taraldsen KW, et al. **Int J Eat Disord** 1996 Sep;20(2):185–90

Substance use among women with eating disorders. Wiederman MW, et al. **Int J Eat Disord** 1996 Sep; 20(2):163–8

A case of non-insulin-dependent diabetes mellitus associated with anorexia nervosa [letter] Aizawa M, et al.
Intern Med 1997 May;36(5):380

Anorexia nervosa with recurrent hypoglycemic coma and cerebral hemorrhage. Yamada Y, et al. **Intern Med** 1996 Jul;35(7):560–3

Transdermal versus oral administration of estrogen in the management of lumbar spine osteopenia in an adolescent with anorexia nervosa. Harel Z, et al. **J Adolesc Health** 1997 Sep;21(3):179–82

Trichotillomania and anorexia nervosa in an adolescent female: a case study of comorbidity [see comments] Pinhas L, et al. **J Adolesc Health** 1996 Aug;19(2):141–4 (27 ref.) . Comment in: J Adolesc Health 1997 May;20(5):336.

The association between secondary amenorrhea and common eating disordered weight control practices in an adolescent population. Selzer R, et al. **J Adolesc Health** 1996 Jul; 19(1):56–61

Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. Grinspoon S, et al.
J Clin Endocrinol Metab 1996 Nov;81(11):3864–70

Obsessive compulsiveness and physical activity in anorexia nervosa and high-level exercising. Davis C, et al.
J Psychosom Res 1995 Nov;39(8):967–76

Vulnerability to substance abuse in eating disorders. Kaye WH, et al. **NIDA Res Monogr** 1996;159:269–311; discussion 312–21

Comorbidity and outcome in eating disorders. Herzog DB, et al. **Psychiatr Clin North Am** 1996 Dec;19(4):843–59 (90 ref.)

Medical findings and predictors of long-term physical outcome in anorexia nervosa: a prospective, 12-year follow-up study. Herzog W, et al. **Psychol Med** 1997 Mar; 27(2):269–79

Movement behaviour of patients with eating disorders and inflammatory bowel disease: a controlled study. Lausberg H, et al. **Psychother Psychosom** 1996;65(5):272–6

Osteoporotic fractures revealing anorexia nervosa in five females. Maugars Y, et al. **Rev Rhum Engl Ed** 1996 Mar; 63(3):201–6

[Severe recurrent hypoglycemia disclosing anorexia nervosa (letter)] Paris JF, et al. **Presse Med** 1997 Apr 19;26(13):610 **(Fre)**

[Osteopenia: a consequence of anorexia nervosa] Jornod P, et al. **Rev Med Suisse Romande** 1997 Jun;117(6):485–94 (Eng. Abstr.) **(Fre)**

[Psychosomatic consequences of sexual abuse: a case of Bartter pseudo-syndrome in an anorexic patient] Martin-Du Pan RC, et al. **Rev Med Suisse Romande** 1997 Jun;117(6):495–500 (43 ref.) **(Fre)**

[Decompensated acute gastric dilatation caused by a bulimic attack in anorexia nervosa] Willeke F, et al.
Dtsch Med Wochenschr 1996 Oct 4;121(40):1220–5 (Eng. Abstr.) **(Ger)**

[Convulsions secondary to water intoxication in anorexia nervosa (letter)] Iglesias P, et al. **Med Clin (Barc)** 1996 Sep 7;107(7):275–6 **(Spa)**

DIAGNOSIS

Prediction of low body weight at long-term follow-up in acute anorexia nervosa by low body weight at referral. Hebebrand J, et al. **Am J Psychiatry** 1997 Apr;154(4):566–9

Cerebral gray matter volume deficits after weight recovery from anorexia nervosa. Lambe EK, et al.
Arch Gen Psychiatry 1997 Jun;54(6):537–42

The superior mesenteric artery syndrome and acute gastric dilatation in eating disorders: a report of two cases and a review of the literature. Adson DE, et al.
Int J Eat Disord 1997 Mar;21(2):103–14 (59 ref.)

The augmented platelet intracellular calcium response to serotonin in anorexia nervosa but not bulimia may be due to subsyndromal depression. Berk M, et al.
Int J Eat Disord 1997 Jul;22(1):57–63

The use of the eating disorder examination with children: a pilot study. Bryant-Waugh RJ, et al.
Int J Eat Disord 1996 May;19(4):391–7

Body weight in acute anorexia nervosa and at follow-up assessed with percentiles for the body mass index: implications of a low body weight at referral. Hebebrand J, et al. **Int J Eat Disord** 1996 May;19(4):347–57

Use of percentiles for the body mass index in anorexia nervosa: diagnostic, epidemiological, and therapeutic considerations. Hebebrand J, et al. **Int J Eat Disord** 1996 May;19(4):359–69

Course and outcome in adolescent anorexia nervosa. Herpertz-Dahlmann BM, et al. **Int J Eat Disord** 1996 May; 19(4):335–45

A mother's complaints of overeating by her 25-month-old daughter: a proposal of anorexia nervosa by proxy. Honjo S. **Int J Eat Disord** 1996 Dec;20(4):433–37

A comparison of subgroups of inpatients with anorexia nervosa. Nagata T, et al. **Int J Eat Disord** 1997 Nov; 22(3):309–14

Age of onset for binge eating: are there different pathways to binge eating? Spurrell EB, et al. **Int J Eat Disord** 1997 Jan;21(1):55–65

The sexual experience of women diagnosed with anorexia nervosa or bulimia nervosa. Wiederman MW, et al.
Int J Eat Disord 1996 Mar;19(2):109–18

Adolescent dieting: healthy weight control or borderline eating disorder? Patton GC, et al.
J Child Psychol Psychiatry 1997 Mar;38(3):299–306

A two-factor model of dietary restraint. Ricciardelli LA, et al. **J Clin Psychol** 1997 Feb;53(2):123–31

Attachment processes in eating disorder and depression. Cole-Detke H, et al. **J Consult Clin Psychol** 1996 Apr; 64(2):282–90

First recovery in anorexia nervosa patients in the long-term course: a discrete-time survival analysis. Herzog W, et al.
J Consult Clin Psychol 1997 Feb;65(1):169–77

Anorexia nervosa. Pal S. **J Indian Med Assoc** 1996 Nov; 94(11):419–21, 425

Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa [see comments] Katzman DK, et al. **J Pediatr** 1996 Dec;129(6):794–803. Comment in: J Pediatr 1996 Dec;129(6):779–81.

Use of the MMPI-2 in the outpatient assessment of women with Anorexia Nervosa or Bulimia Nervosa. Pryor T, et al. **J Pers Assess** 1996 Apr;66(2):363–73

Self-reports on the Eating Disorder Inventory by female aerobic instructors. Olson MS, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):1051–8

A schoolgirl with possible anorexia. Wynne-Jones M, et al.
Practitioner 1996 Oct;240(1567):567–71, 573 (2 ref.)

Initial assessment and early treatment options for anorexia nervosa and bulimia nervosa. Powers PS.
Psychiatr Clin North Am 1996 Dec;19(4):639–55 (78 ref.)

Nutritional management of eating disorders. Rock CL, et al. **Psychiatr Clin North Am** 1996 Dec;19(4):701–13 (75 ref.)

Neuroimaging in anorexia nervosa. Herholz K.
Psychiatry Res 1996 Apr 16;62(1):105–10 (28 ref.)

Clinical characteristics and course of anorexia nervosa in Latin America, a Brazilian sample. Negrão AB, et al.
Psychiatry Res 1996 Apr 16;62(1):17–21

Subclassifications in eating disorders and obesity: a comparative study of an Italian sample. Favaro A, et al.
Psychopathology 1996;29(2):77–84

Three cases of severe early-onset eating disorder: are they cases of anorexia nervosa? Nielsen GB, et al.
Psychopathology 1997;30(1):49–52

[Anorexia and bulimia nervosa] Csef H. **Internist (Berl)** 1997 Jul;38(7):721–31 (10 ref.) **(Ger)**

[Anorexia nervosa and bulimia nervosa in adolescence. Diagnosis, clinical findings, therapy] Lehmkuhl G. **Med Monatsschr Pharm** 1996 Sep;19(9):261–9 (39 ref.) **(Ger)**

[Comorbidity of schizophrenia and bulimic anorexia. A case with forensic implications] Joos A, et al. **Nervenarzt** 1997 May;68(5):417–20 (Eng. Abstr.) **(Ger)**

[Disorders of eating behavior—early detection and treatment possibilities in general practice] Buddeberg-Fischer B.
Schweiz Rundsch Med Prax 1997 Jul 30;86(31–32):1209–12 (5 ref.) (Eng. Abstr.) **(Ger)**

[Intelligence quotient levels, aspiration and self-acceptance in patients with restricting and binge-eating type of anorexia nervosa] Rajewski A, et al. **Psychiatr Pol** 1996 Sep-Oct;30(5):811–20 (Eng. Abstr.) **(Pol)**

[Vomiting as a symptom of a developing psychological eating disorder in a 15-year old girl] Zajadacz B, et al.
Wiad Lek 1996;49(1–6):72–5 (Eng. Abstr.) **(Pol)**

[Obsessive-phobic disorders in anorexia and bulimia nervosa] Tsivil'ko MA, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1997;97(3):16–9 (Eng. Abstr.) **(Rus)**

[Clinical, psychological and biological variables in a group of 108 adolescent patients with anorexia nervosa] Lázaro L, et al. **Med Clin (Barc)** 1996 Jun 29;107(5):169–74 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

High-dose naltrexone and liver function safety. Marrazzi MA, et al. **Am J Addict** 1997 Winter;6(1):21–9

Medications in the treatment of eating disorders. Jimerson DC, et al. **Psychiatr Clin North Am** 1996 Dec;19(4):739–54 (112 ref.)

EPIDEMIOLOGY

Confronting a rising tide of eating disorders and obesity: treatment vs. prevention and policy. Battle EK, et al.
Addict Behav 1996 Nov-Dec;21(6):755–65 (45 ref.)

Assessing the prevalence of eating disorders in an Australian twin population. Wade T, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):845–51

Anorexia nervosa rates--conclusions for the wrong reasons [letter; comment] Råstam M, et al. **Br J Psychiatry** 1996 Feb;168(2):251–2. Comment on: Br J Psychiatry 1995 Apr;166(4):462–71.

The demand for eating disorder care. An epidemiological study using the general practice research database. Turnbull S, et al. **Br J Psychiatry** 1996 Dec;169(6):705–12

The branched eating disorders test: validity in a nonclinical population. Selzer R, et al. **Int J Eat Disord** 1996 Jul; 20(1):57–64

Eating disorders in adolescence in a Swiss epidemiological study. Steinhausen HC, et al. **Int J Eat Disord** 1997 Sep; 22(2):147–51

Epidemiological data on anorexia nervosa in Japan [published erratum appears in Psychiatry Res 1996 Jun 1;62(3):285–6] Kuboki T, et al. **Psychiatry Res** 1996 Apr 16;62(1):11–6

Epidemiology of anorexia nervosa. Wakeling A.
Psychiatry Res 1996 Apr 16;62(1):3–9 (36 ref.)

ETHNOLOGY

A comparison of psychopathology in eating disorder patients from France and the United States. Hurt SW, et al.
Int J Eat Disord 1997 Sep;22(2):153–8

How lay is lay? Chinese students' perceptions of anorexia nervosa in Hong Kong. Lee S. **Soc Sci Med** 1997 Feb; 44(4):491–502

Reconsidering the status of anorexia nervosa as a western culture-bound syndrome. Lee S. **Soc Sci Med** 1996 Jan; 42(1):21–34

ETIOLOGY

Childhood-onset anorexia nervosa: towards identifying a biological substrate. Gordon I, et al. **Int J Eat Disord** 1997 Sep;22(2):159–65

The role of tumor necrosis factor-alpha in the pathogenesis of anorexia and bulimia nervosa, cancer cachexia and obesity. Holden RJ, et al. **Med Hypotheses** 1996 Dec; 47(6):423–38 (148 ref.)

Is there a specific trauma precipitating anorexia nervosa? Schmidt U, et al. **Psychol Med** 1997 May;27(3):523–30

[Anorexia nervosa and its clinical variations--a hormonal and behavioral paradigm] Rybakowa M. **Przegl Lek** 1996; 53(9):697–9 (18 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Anorexia nervosa: two cases of male-female dizygotic adolescent twins [letter] Roberts N, et al.
Can J Psychiatry 1996 Jun;41(5):316–7

Beta 3-adrenergic-receptor allele distributions in children, adolescents and young adults with obesity, underweight or anorexia nervosa. Hinney A, et al.
Int J Obes Relat Metab Disord 1997 Mar;21(3):224–30

Association between 5-HT2A gene promoter polymorphism and anorexia nervosa [letter] Collier DA, et al. **Lancet** 1997 Aug 9;350(9075):412

Two hearts beat as one. Eating disorder in a twin pair with hypertrophic cardiomyopathy. Hartman DC, et al.
Psychother Psychosom 1997;66(4):222–6

HISTORY

Anorexia nervosa in eighteenth century [letter] Gordon AG. **Am J Psychiatry** 1997 Jul;154(7):1041

The early Canadian history of anorexia nervosa. Goldbloom DS. **Can J Psychiatry** 1997 Mar;42(2):163–7

Charcot's comments on the therapeutic role of isolation in the treatment of anorexia nervosa. Silverman JA. **Int J Eat Disord** 1997 Apr;21(3):295–8

[The anorectic life of Empress Elisabeth of Austria (1837–1898). Slenderness cult of the Habsburg family] Vandereycken W, et al. **Nervenarzt** 1996 Jul;67(7):608–13 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity. Pomeroy C, et al. **Clin Exp Immunol** 1997 Jun;108(3):507–15

T lymphocyte subpopulations in anorexia nervosa and refeeding. Mustafa A, et al. **Clin Immunol Immunopathol** 1997 Mar;82(3):282–9

T-lymphocyte subsets in patients with abnormal body weight: longitudinal studies. in anorexia nervosa and obesity. Fink S, et al. **Int J Eat Disord** 1996 Nov; 20(3):295–305

Immunologic cytofluorometric studies in adolescents with anorexia nervosa. Silber TJ, et al. **Int J Eat Disord** 1996 May;19(4):415–8

Immunoendocrine aspects of anorexia nervosa. Brambilla F, et al. **Psychiatry Res** 1996 Apr 16;62(1):97–104

[Immunological system activity in anorexia nervosa] Komorowska-Pietrzykowska R, et al. **Psychiatr Pol** 1996 Sep–Oct;30(5):801–10 (Eng. Abstr.) **(Pol)**

METABOLISM

Increase in diet-induced thermogenesis at the start of refeeding in severely malnourished anorexia nervosa patients. Moukaddem M, et al. **Am J Clin Nutr** 1997 Jul; 66(1):133–40

The metabolic responses to starvation and refeeding in adolescents with anorexia nervosa. Schebendach JE, et al. **Ann N Y Acad Sci** 1997 May 28;817:110–9

The prediction of total body water from bioelectrical impedance in patients with anorexia nervosa. Scalfi L, et al. **Br J Nutr** 1997 Sep;78(3):357–65

Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa. Popovic V, et al. **Clin Endocrinol (Oxf)** 1997 May;46(5):539–43

Lack of effect of desmopressin on ACTH and cortisol responses to ovine corticotropin-releasing hormone in anorexia nervosa. Foppiani L, et al. **Eur J Clin Invest** 1996 Oct;26(10):879–83

Follow-up of bone mineral density in 27 cases of anorexia nervosa. Maugars YM, et al. **Eur J Endocrinol** 1996 Nov; 135(5):591–7

Food restriction decreases serotonin and its synthesis rate in the hypothalamus. Haleem DJ, et al. **Neuroreport** 1996 Apr 26;7(6):1153–6

Serum albumin distribution in early treated anorexia nervosa [see comments] Smith G, et al. **Nutrition** 1996 Oct; 12(10):677–84. Comment in: Nutrition 1996 Oct;12(10):720–1.

[Neuroendocrine disorders in anorexia nervosa--primary or secondary?] Støving RK, et al. **Ugeskr Laeger** 1996 Dec 2;158(49):7052–6 (40 ref.) (Eng. Abstr.) **(Dan)**

MORTALITY

Mortality in anorexia nervosa in Denmark during the period 1970–1987. Møller-Madsen S, et al. **Acta Psychiatr Scand** 1996 Dec;94(6):454–9

Mortality and sudden death in anorexia nervosa. Neumärker KJ. **Int J Eat Disord** 1997 Apr;21(3):205–12 (44 ref.)

PATHOLOGY

Structural brain changes and malnutrition in anorexia nervosa. Kohn MR, et al. **Ann N Y Acad Sci** 1997 May 28;817:398–9

A longitudinal magnetic resonance imaging study of brain changes in adolescents with anorexia nervosa. Katzman DK, et al. **Arch Pediatr Adolesc Med** 1997 Aug; 151(8):793–7

Bone mass and soft tissue composition in adolescents with anorexia nervosa. Kooh SW, et al. **Bone** 1996 Aug; 19(2):181–8

Case of the month. June 1996--anorexia nervosa. Lacomis D. **Brain Pathol** 1996 Oct;6(4):535–6

T lymphocyte subpopulations in anorexia nervosa and refeeding. Mustafa A, et al. **Clin Immunol Immunopathol** 1997 Mar;82(3):282–9

Anorexia nervosa and sudden death in childhood: clinical data and results obtained from quantitative neurohistological investigations of cortical neurons. Neumärker KJ, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(1):16–22

Morphometrical investigations on lamina-V-pyramidal-neurons in the frontal cortex of a case with anorexia nervosa. Schönheit B, et al. **J Hirnforsch** 1996;37(2):269–80

PHYSIOPATHOLOGY

Common biological pathways in eating disorders and obesity. Ericsson M, et al. **Addict Behav** 1996 Nov–Dec; 21(6):733–43 (65 ref.)

Changes in body composition and fat distribution after short-term weight gain in patients with anorexia nervosa. Orphanidou CI, et al. **Am J Clin Nutr** 1997 Apr; 65(4):1034–41

Refeeding improves muscle performance without normalization of muscle mass and oxygen consumption in anorexia nervosa patients. Rigaud D, et al. **Am J Clin Nutr** 1997 Jun;65(6):1845–51

Persistent alterations in behavior and serotonin activity after recovery from anorexia and bulimia nervosa. Kaye WH. **Ann N Y Acad Sci** 1997 May 28;817:162–78 (139 ref.)

Resumption of menses in anorexia nervosa [see comments] Golden NH, et al. **Arch Pediatr Adolesc Med** 1997 Jan; 151(1):16–21. Comment in: Arch Pediatr Adolesc Med 1997 Jan;151(1):14–5. Comment in: Arch Pediatr Adolesc Med 1997 Jun;151(6):634–5.

Body composition in female anorexia nervosa patients. Probst M, et al. **Br J Nutr** 1996 Nov;76(5):639–47

Eating disorders and hyperactivity: a psychobiological perspective. Davis C. **Can J Psychiatry** 1997 Mar; 42(2):168–75 (78 ref.)

Heart rate variability as a measure of autonomic nervous system function in anorexia nervosa. Petretta M, et al. **Clin Cardiol** 1997 Mar;20(3):219–24

A hitherto unknown pattern of pathologic gastrointestinal motility--a cause of repeated vomiting? Steinbrueckner BE, et al. **Hepatogastroenterology** 1996 May–Jun; 43(9):764–8

Bone density patterns in women with anorexia nervosa. Siemers B, et al. **Int J Eat Disord** 1996 Mar;19(2):179–86

Body fat distribution before and after weight gain in anorexia nervosa. Zamboni M, et al. **Int J Obes Relat Metab Disord** 1997 Jan;21(1):33–6

Cerebrospinal fluid leptin in anorexia nervosa: correlation with nutritional status and potential role in resistance to weight gain. Mantzoros C, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1845–51

Assessment of brain function in adolescent anorexia nervosa before and after weight gain. Bradley SJ, et al. **J Clin Exp Neuropsychol** 1997 Feb;19(1):20–33

Does right parietal cortex and vestibular dysfunction underlie body image distortion? [letter; comment] Tomasino SJ. **J Nerv Ment Dis** 1996 Dec;184(12):758. Comment on: J Nerv Ment Dis 1996 Apr;184(4):213–9.

Bone density in amenorrheic athletes and in anorexia nervosa [letter; comment] Mehler PS. **JAMA** 1996 Nov 6; 276(17):1384–5. Comment on: JAMA 1996 Jul 17;276(3):238–40.

Body mass index and daily physical activity in anorexia nervosa. Bouten CV, et al. **Med Sci Sports Exerc** 1996 Aug; 28(8):967–73

Leptin in anorexia nervosa and amenorrhea [editorial; comment] Licinio J. **Mol Psychiatry** 1997 Jul;2(4):267–9 (23 ref.). Comment on: Mol Psychiatry 1997 Jul;2(4):330–4. Comment on: Mol Psychiatry 1997 Jul;2(4):335–40.

Creutzfeldt-Jakob disease with features of obsessive-compulsive disorder and anorexia nervosa: the role of cortical-subcortical systems. Lopez OL, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr; 10(2):120–4

Relationship between thresholds to thermally and to mechanically induced pain in patients with eating disorders and healthy subjects. de Zwaan M, et al. **Pain** 1996 Oct; 67(2–3):511–2

Phosphorus-31 magnetic resonance spectroscopic observations in 4 cases with anorexia nervosa. Kato T, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 May; 21(4):719–24

Studies of serotonin function in anorexia nervosa. Brewerton TD, et al. **Psychiatry Res** 1996 Apr 16;62(1):31–42

Carbohydrate metabolism and its regulatory hormones in anorexia nervosa. Casper RC. **Psychiatry Res** 1996 Apr 16;62(1):85–96 (85 ref.)

The psychobiology of eating behavior in anorexia nervosa. Halmi KA. **Psychiatry Res** 1996 Apr 16;62(1):23–9 (21 ref.)

Neuropeptide abnormalities in anorexia nervosa. Kaye WH. **Psychiatry Res** 1996 Apr 16;62(1):65–74 (75 ref.)

The hypothalamic-pituitary-adrenal axis in anorexia nervosa. Licinio J, et al. **Psychiatry Res** 1996 Apr 16;62(1):75–83 (50 ref.)

Aspects of the neuroendocrine control of somatotropic function in calorically restricted dogs and patients with eating disorders: studies with cholinergic drugs. Müller EE, et al. **Psychiatry Res** 1996 Apr 16;62(1):51–63

Central and peripheral noradrenalin regulation in eating disorders. Pirke KM. **Psychiatry Res** 1996 Apr 16; 62(1):43–9 (35 ref.)

Pre- and postprandial pyridostigmine and oxiracetam effects on growth hormone secretion in anorexia nervosa. Mancini A, et al. **Psychoneuroendocrinology** 1996 Oct;21(7):621–9

Some nutritional parameters in adolescent females suffering from obesity or anorexia nervosa: a comparative study. Varela P, et al. **World Rev Nutr Diet** 1997;82:168–74

[Circadian blood serotonin and melatonin level in anorexia nervosa patients in comparison with normally menstruating women] Hoffmann G, et al. **Geburtshilfe Frauenheilkd** 1996 Sep;56(9):485–90 (Eng. Abstr.) **(Ger)**

[Anorexia nervosa beginning after the menopause] Hirschmann S, et al. **Harefuah** 1996 Jul;131(1-2):10–2, 71 (Eng. Abstr.) **(Heb)**

[Enlargement of the parotid glands in bulimia nervosa and anorexia nervosa] Rzeczycki P, et al. **Otolaryngol Pol** 1996; 50(3):318–20 (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Testing the hypothesis of the multidimensional model of anorexia nervosa in adolescents. Lyon M, et al. **Adolescence** 1997 Spring;32(125):101–11

Are two interventions worse than none? Joint primary and secondary prevention of eating disorders in college females. Mann T, et al. **Health Psychol** 1997 May;16(3):215–25

PSYCHOLOGY

Dissociative and hypnotic experiences in eating disorder patients: an exploratory study. Vanderlinden J, et al. **Am J Clin Hypn** 1995 Oct;38(2):97–108

Perfectionism in anorexia nervosa [letter; comment] Szabò CP, et al. **Am J Psychiatry** 1997 Jan;154(1):132. Comment on: Am J Psychiatry 1995 Nov;152(11):1630–4.

Kobe earthquake and patients with anorexia nervosa [letter] Inui A, et al. **Arch Intern Med** 1997 Feb 24;157(4):464–5

Resumption of menses in anorexia nervosa [see comments] Golden NH, et al. **Arch Pediatr Adolesc Med** 1997 Jan; 151(1):16–21. Comment in: Arch Pediatr Adolesc Med 1997 Jan;151(1):14–5. Comment in: Arch Pediatr Adolesc Med 1997 Jun;151(6):634–5.

The self-schema model: a theoretical approach to the self-concept in eating disorders. Stein KF. **Arch Psychiatr Nurs** 1996 Apr;10(2):96–109 (114 ref.)

Body image disturbances and their change with videofeedback in anorexia nervosa. Rushford N, et al. **Behav Res Ther** 1997 May;35(5):389–98

Comparison of obsessions and compulsions in patients with anorexia nervosa and obsessive compulsive disorder. Bastiani AM, et al. **Biol Psychiatry** 1996 Jun 1;39(11):966–9

Selective processing of three types of stimuli in eating disorders. Cooper M, et al. **Br J Clin Psychol** 1997 May; 36 (Pt 2):279–81

The influence of methodological differences on the outcome of body size estimation studies in anorexia nervosa. Smeets MA, et al. **Br J Clin Psychol** 1997 May;36 (Pt 2):263–77

Delusion, the overvalued idea and religious beliefs: a comparative analysis of their characteristics. Jones E, et al. **Br J Psychiatry** 1997 Apr;170:381–6

The role of socialization in male anorexia nervosa: two cases. Halperin EN. **Child Psychiatry Hum Dev** 1996 Spring; 26(3):159–68

Follow-up investigation of family relations in patients with anorexia nervosa. Wewetzer C, et al. **Eur Child Adolesc Psychiatry** 1996 Apr;5(1):18–24

Truly late onset of eating disorders: a study of 11 cases averaging 60 years of age at presentation. Beck D, et al. **Int J Eat Disord** 1996 Dec;20(4):389–95

The nature and extent of body-image disturbances in anorexia nervosa and bulimia nervosa: a meta-analysis. Cash TF, et al. **Int J Eat Disord** 1997 Sep;22(2):107–25

In defense of weight phobia as the central organizing motive in anorexia nervosa: historical and cultural arguments for a culture-sensitive psychological conception. Habermas T. **Int J Eat Disord** 1996 May;19(4):317–34 (73 ref.)

A mother's complaints of overeating by her 25-month-old daughter: a proposal of anorexia nervosa by proxy. Honjo S. **Int J Eat Disord** 1996 Dec;20(4):433–37

A comparison of psychopathology in eating disorder patients from France and the United States. Hurt SW, et al. **Int J Eat Disord** 1997 Sep;22(2):153–8

Disordered eating and its psychosocial correlates among Chinese adolescent females in Hong Kong. Lee AM, et al. **Int J Eat Disord** 1996 Sep;20(2):177–83

Attachment disruption in anorexia nervosa and bulimia nervosa: a review of theory and empirical research. O'Kearney R. **Int J Eat Disord** 1996 Sep;20(2):115–27 (74 ref.)

Perfectionism in weight-concerned and -unconcerned women: an experimental approach. Pliner P, et al. **Int J Eat Disord** 1996 May;19(4):381–9

Relationship of depression, anxiety, and obsessionality to state of illness in anorexia nervosa. Pollice C, et al. **Int J Eat Disord** 1997 May;21(4):367–76

Laxative abuse among women with eating disorders: an indication of psychopathology? Pryor T, et al. **Int J Eat Disord** 1996 Jul;20(1):13–8

A controlled study of trait narcissism in anorexia and bulimia nervosa. Steiger H, et al. **Int J Eat Disord** 1997 Sep; 22(2):173–8

Familial eating concerns and psychopathological traits: causal implications of transgenerational effects. Steiger H, et al. **Int J Eat Disord** 1996 Mar;19(2):147–57

Social support in patients with anorexia nervosa and bulimia nervosa. Tiller JM, et al. **Int J Eat Disord** 1997 Jan; 21(1):31–8

Coping, sexual abuse, and compensatory behavior. Tobin DL, et al. **Int J Eat Disord** 1996 Sep;20(2):143–8

Death themes in anorexia nervosa: dimensions for a reply to Jackson et al. Warren B. **Int J Eat Disord** 1997 Nov; 22(3):223–9 (22 ref.)

The relationship between sexual abuse and eating pathology. Zlotnick C, et al. **Int J Eat Disord** 1996 Sep;20(2):129–34

Trichotillomania and anorexia nervosa [letter; comment]

Tonkin RS. **J Adolesc Health** 1997 May;20(5):336. Comment on: J Adolesc Health 1996 Aug;19(2):141–4.

Brain hypometabolism of glucose in low-weight depressed patients and in anorectic patients: a consequence of starvation? Delvenne V, et al. **J Affect Disord** 1997 Jun; 44(1):69–77

Anorexia nervosa presenting as a somatic delusional disorder responsive to pharmacotherapy. Wenokur B, et al. **J Am Osteopath Assoc** 1997 Apr;97(4):231–2

Life event precipitants of adolescent anorexia nervosa. Gowers SG, et al. **J Child Psychol Psychiatry** 1996 May; 37(4):469–77

Perception of body shapes by anorexics and mature and teenage females. Baluch B, et al. **J Clin Psychol** 1997 Feb; 53(2):167–75

Attachment processes in eating disorder and depression. Cole-Detke H, et al. **J Consult Clin Psychol** 1996 Apr; 64(2):282–90

Measurement of nonclinical personality characteristics of women with anorexia nervosa or bulimia nervosa. Pryor T, et al. **J Pers Assess** 1996 Oct;67(2):414–21

Cognitive functioning, weight change and therapy in anorexia nervosa. Green MW, et al. **J Psychiatr Res** 1996 Sep–Oct;30(5):401–10

Pain sensitivity, alexithymia, and depression in patients with eating disorders: are they related? de Zwaan M, et al. **J Psychosom Res** 1996 Jul;41(1):65–70

Eating disorders associated with hyperemesis gravidarum [editorial] Lingam R, et al. **J Psychosom Res** 1996 Mar; 40(3):231–4 (21 ref.)

Perception of body size and body satisfaction in recovered anorexic women: comparison with restrained and unrestrained eaters. Lautenbacher S, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 2):1331–42

Alexithymia in patients with eating disorders: an investigation using a new projective technique. Smith GJ, et al. **Percept Mot Skills** 1997 Aug;85(1):247–56

Male/female comparison of morphine effect on food intake--relation to anorexia nervosa. Marrazzi MA, et al. **Pharmacol Biochem Behav** 1996 Feb;53(2):433–5

The imaginative use of religious symbols in subjective experiences of anorexia nervosa. Banks CG. **Psychoanal Rev** 1997 Apr;84(2):227–36

Characteristics of eating disorders among young ballet dancers. Abraham S. **Psychopathology** 1996;29(4):223–9

Temperament in juvenile eating disorders. Shaw RJ, et al. **Psychosomatics** 1997 Mar–Apr;38(2):126–31

The (dis)embodied self in anorexia nervosa. Lester RJ. **Soc Sci Med** 1997 Feb;44(4):479–89 (56 ref.)

[Childhood masturbation--a genetic viewpoint, especially in anorexia and bulimia nervosa] Binswanger R. **Psyche (Stuttg)** 1996 Jul;50(7):644–70 (Eng. Abstr.) **(Ger)**

[Body image disturbances in patients with anorexia nervosa 12 years after clinical consultation] Deter HC, et al. **Psychother Psychosom Med Psychol** 1997 Jan;47(1):1–11 (Eng. Abstr.) **(Ger)**

["Body psychosis": an interpretative hypothesis about some psychiatric disorders] Lorenzi P, et al. **Minerva Psichiatr** 1996 Mar;37(1):21–8 (38 ref.) (Eng. Abstr.) **(Ita)**

[Anorexia nervosa in monozygotic twins: case report] Kasperowicz-Dąbrowiecka A, et al. **Psychiatr Pol** 1996 Nov–Dec;30(6):939–52 (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Orbital fat edema in anorexia nervosa: a reversible finding. Demaerel P, et al. **AJNR Am J Neuroradiol** 1996 Oct; 17(9):1782–4

RADIONUCLIDE IMAGING

Brain hypometabolism of glucose in anorexia nervosa: normalization after weight gain. Delvenne V, et al. **Biol Psychiatry** 1996 Oct 15;40(8):761–8

Childhood-onset anorexia nervosa: towards identifying a biological substrate. Gordon I, et al. **Int J Eat Disord** 1997 Sep;22(2):159–65

Brain glucose metabolism in anorexia nervosa and affective disorders: influence of weight loss or depressive symptomatology. Delvenne V, et al. **Psychiatry Res** 1997 May 16;74(2):83–92

REHABILITATION

The use of guardianship legislation for anorexia nervosa: a report of 15 cases. Griffiths RA, et al. **Aust N Z J Psychiatry** 1997 Aug;31(4):525–31

Recovery from anorexia nervosa: a sociological perspective. Garrett CJ. **Int J Eat Disord** 1997 Apr;21(3):261–72

Long-term follow-up of patient-reported family functioning in eating disorders after intensive day hospital treatment. Woodside DB, et al. **J Psychosom Res** 1996 Sep; 41(3):269–77

Treating eating-disorder patients in a managed care environment. Contemporary American issues and Canadian response. Kaye WH, et al. **Psychiatr Clin North Am** 1996 Dec;19(4):793–810 (18 ref.)

Treatment for inpatients with anorexia nervosa: comparison of liquid formula with regular meals for improvement from emaciation. Arii I, et al. **Psychiatry Clin Neurosci** 1996 Apr; 50(2):55–9

Recovery from anorexia nervosa: a Durkheimian interpretation. Garrett CJ. **Soc Sci Med** 1996 Nov; 43(10):1489–506

THERAPY

Future directions in obesity and eating disorders. Foreyt JP, et al. **Addict Behav** 1996 Nov–Dec;21(6):767–78 (105 ref.)

Perfectionism in anorexia nervosa [letter; comment] Szabò CP, et al. **Am J Psychiatry** 1997 Jan;154(1):132. Comment on: Am J Psychiatry 1995 Nov;152(11):1630–4.

Computerised psychoeducation for patients with eating disorders. Andrewes DG, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):492–7

Body image disturbances and their change with videofeedback in anorexia nervosa. Rushford N, et al. **Behav Res Ther** 1997 May;35(5):389–98

To change or not to change--'how' is the question? Ward A, et al. **Br J Med Psychol** 1996 Jun;69 (Pt 2):139–46

Anorexia nervosa and bulimia: psychiatric approach. Walsh BT. **Curr Ther Endocrinol Metab** 1997;6:18–21 (3 ref.)

Anorexia, bulimia, and exercise-induced amenorrhea: medical approach. Warren MP. **Curr Ther Endocrinol Metab** 1997;6:13–7 (9 ref.)

Low levels of interrater reliability in a standard measure of outcome in eating disorders (the modified Morgan-Russell Assessment Schedule). Freeman RK, et al. **Int J Eat Disord** 1996 Jul;20(1):51–6

Does early intervention improve the prognosis in anorexia nervosa? A systematic review of the treatment-outcome literature. Schoemaker C. **Int J Eat Disord** 1997 Jan; 21(1):1–15 (90 ref.)

Expressed emotion and the prediction of outcome in adolescent eating disorders. van Furth EF, et al. **Int J Eat Disord** 1996 Jul;20(1):19–31

Persistent osteopenia after recovery from anorexia nervosa. Ward A, et al. **Int J Eat Disord** 1997 Jul;22(1):71–5

Outcome of anorexia nervosa in the younger patient. Steinhausen HC. **J Child Psychol Psychiatry** 1997 Mar; 38(3):271–6 (40 ref.)

Cognitive functioning, weight change and therapy in anorexia nervosa. Green MW, et al. **J Psychiatr Res** 1996 Sep–Oct;30(5):401–10

Selective serotonin reuptake inhibitors in anorexia [letter; comment] Bergh C, et al. **Lancet** 1996 Nov 23; 348(9039):1459–60. Comment on: Lancet 1996 Aug 3;348(9023):339–40.

Cognitive-behavioral treatment of anorexia nervosa. Kleifield EI, et al. **Psychiatr Clin North Am** 1996 Dec; 19(4):715–37

Initial assessment and early treatment options for anorexia nervosa and bulimia nervosa. Powers PS. **Psychiatr Clin North Am** 1996 Dec;19(4):639–55 (78 ref.)

[Presenting the treatment of an anorexia patient] Eckert C. **Psychiatr Prax** 1997 Jan;24(1):44–5 **(Ger)**

[Structured day care therapy program for eating disorders] Gerlinghoff M, et al. **Psychother Psychosom Med Psychol** 1997 Jan;47(1):12–20 (Eng. Abstr.) **(Ger)**

[Total symptom-oriented and psychodynamic concept in inpatient treatment of anorexia nervosa. A quasi-experimental comparative study of 40 admission episodes] Herzog T, et al. **Psychother Psychosom Med Psychol** 1996 Jan;46(1):11–22 (Eng. Abstr.) **(Ger)**

[Therapeutic effects of the Feldenkrais method "awareness through movement" in patients with eating disorders] Laumer U, et al. **Psychother Psychosom Med Psychol** 1997 May;47(5):170–80 (Eng. Abstr.) **(Ger)**

[Eating disorders] Isenschmid Gerster B, et al. **Ther Umsch** 1997 Jul;54(7):410–2 (Eng. Abstr.) **(Ger)**

[Does cognitive performance of adolescents with anorexia nervosa change with treatment?] Schmidt MH, et al. **Z Kinder Jugenpsychiatr** 1997 Mar;25(1):17–26 (Eng. Abstr.) **(Ger)**

[Determination of body feat in treatment of anorexia nervosa] Schmidt MH, et al. **Z Kinder Jugenpsychiatr** 1997 Mar; 25(1):27–34 (Eng. Abstr.) **(Ger)**

[Follow-up and treatment outcome of early anorexia nervosa] Schulze U, et al. **Z Kinder Jugenpsychiatr** 1997 Mar;25(1):5–16 (Eng. Abstr.) **(Ger)**

[Treatment of anorexia nervosa] Suematsu H. **Nippon Naika Gakkai Zasshi** 1997 May 10;86(5):856–61 (10 ref.) **(Jpn)**

[Clinical study of severe anorexia nervosa: the role of intravenous hyperalimentation therapy] Denda K, et al. **Seishin Shinkeigaku Zasshi** 1997;99(4):198–214 (Eng. Abstr.) **(Jpn)**

[Body-related psychotherapy for anorexia nervosa--treatment at the psychosomatic hospital in Germany] Noma S. **Seishin Shinkeigaku Zasshi** 1997; 99(2):68–78 (22 ref.) **(Jpn)**

ANOSMIA

CHEMICALLY INDUCED

Characterization of olfactory deficits in the rat following administration of 2,6-dichlorobenzonitrile (dichlobenil), 3,3'-iminodipropionitrile, or methimazole. Genter MB, et al. **Fundam Appl Toxicol** 1996 Jan;29(1):71–7

Design and evaluation of an olfactometer for the assessment of 3-methylindole-induced hyposmia. Owens JG, et al. **Fundam Appl Toxicol** 1996 Sep;33(1):60–70

Disturbances of taste and smell induced by drugs. Ackerman BH, et al. **Pharmacotherapy** 1997 May–Jun;17(3):482–96 (126 ref.)

Chloroform-induced olfactory mucosal degeneration and osseous ethmoid hyperplasia are not associated with olfactory deficits in Fischer 344 rats. Dorman DC, et al. **Toxicology** 1997 Sep 26;122(1–2):39–50

[Damage to sense of smell and taste following xylocaine administration? Process before the expert evaluation committee for medical malpractice of the North Rhine Physicians Organization in 1995 (Az. 91/588)] Wienke A. **Laryngorhinootologie** 1996 Feb;75(2):109–10 **(Ger)**

COMPLICATIONS

Neuropsychological, olfactory, and hygiene deficits in men with negative symptom schizophrenia. Brewer WJ, et al. **Biol Psychiatry** 1996 Nov 15;40(10):1021–31

CONGENITAL

Olfactory event-related potentials to amyl acetate in congenital anosmia. Cui L, et al. **Electroencephalogr Clin Neurophysiol** 1997 Apr; 102(4):303–6

Congenital anosmia. Vowles RH, et al. **Int J Pediatr Otorhinolaryngol** 1997 Aug 20;41(2):207–14 (24 ref.)

DIAGNOSIS

Posttraumatic olfactory dysfunction: MR and clinical evaluation. Yousem DM, et al. **AJNR Am J Neuroradiol** 1996 Jun–Jul;17(6):1171–9

Rapid clinical evaluation of anosmia. The alcohol sniff test. Davidson TM, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jun;123(6):591–4

Validation of the combined olfactory test. Robson AK, et al. **Clin Otolaryngol** 1996 Dec;21(6):512–8

Design and evaluation of an olfactometer for the assessment of 3-methylindole-induced hyposmia. Owens JG, et al. **Fundam Appl Toxicol** 1996 Sep;33(1):60–70

[Testing smell and taste] Jahnke V. **HNO** 1996 Oct;44(10):595 **(Ger)**

DRUG THERAPY

Topical corticosteroid treatment of anosmia associated with nasal and sinus disease. Mott AE, et al. **Arch Otolaryngol Head Neck Surg** 1997 Apr;123(4):367–72

Anosmia following head trauma: preliminary study of steroid treatment. Ikeda K, et al. **Tohoku J Exp Med** 1995 Dec; 177(4):343–51

ENZYMOLOGY

Development of 5'-nucleotidase staining in the olfactory bulbs of normal and naris-occluded rats. Clemow DB, et al. **Int J Dev Neurosci** 1996 Nov;14(7–8):901–11

EPIDEMIOLOGY

[Postoperative complications of anterior and middle skull base surgery] Tokutomi T, et al. **No Shinkei Geka** 1997 Jan;25(1):29–34 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Permanent postoperative anosmia: a hitherto undescribed complication following surgery of the posterior cranial fossa in the sitting position. Ramsbacher J, et al. **Acta Neurochir (Wien)** 1997;139(5):482–3

Postoperative anosmia after anterior communicating artery aneurysms surgery by the pterional approach. Aydin IH, et al. **Minim Invasive Neurosurg** 1996 Sep;39(3):71–3

Anosmia after anterior communicating artery aneurysm surgery: comparison between the anterior interhemispheric and basal interhemispheric approaches. Fujiwara H, et al. **Neurosurgery** 1996 Feb;38(2):325–8

Anosmia following head trauma: preliminary study of steroid treatment. Ikeda K, et al. **Tohoku J Exp Med** 1995 Dec; 177(4):343–51

[Disorders of smell and taste sensations] Schilling V. **Internist (Berl)** 1997 Jan;38(1):95–104 (13 ref.) **(Ger)**

[Postoperative olfactory dysfunction in interhemispheric approach for ruptured anterior communicating artery aneurysms] Ito S, et al. **No Shinkei Geka** 1996 Jul; 24(7):625–8 (Eng. Abstr.) **(Jpn)**

GENETICS

Genetic approaches to mammalian olfaction. Reed RR. **Cold Spring Harb Symp Quant Biol** 1996;61:165–72 (53 ref.)

Regulation of c-Fos mRNA and fos protein expression in olfactory bulbs from unilaterally odor-deprived adult mice. Jin BK, et al. **Int J Dev Neurosci** 1996 Nov;14(7–8):971–82

General anosmia caused by a targeted disruption of the mouse olfactory cyclic nucleotide-gated cation channel. Brunet LJ, et al. **Neuron** 1996 Oct;17(4):681–93

IMMUNOLOGY

Allergic rhinitis, olfactory disorders and secretory IgA. Paparo BS, et al. **Riv Eur Sci Med Farmacol** 1996 Jul–Aug; 18(4):157–61

PHYSIOPATHOLOGY

The aging olfactory epithelium: neurogenesis, response to damage, and odorant-induced activity. Loo AT, et al. **Int J Dev Neurosci** 1996 Nov;14(7-8):881-900

[Investigation of "anosmic zones" associated with nasal allergy] Higo R, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Nov;99(11):1648-52 (Eng. Abstr.) **(Jpn)**

[Objective assessment of .he olfactory analyzer function based on recording of olfacto-vegetative and olfacto-vestibular reactions] Ovchinnikov IuM, et al. **Vestn Otorinolaringol** 1996 May-Jun;(3):19-20 (Eng. Abstr.) **(Rus)**

THERAPY

[Reflex therapy in the treatment of cochleo-vestibular and olfactory disorders] Shibina LM, et al. **Vestn Otorinolaringol** 1996 May-Jun;(3):48-50 (Eng. Abstr.) **(Rus)**

ANOVA see **ANALYSIS OF VARIANCE**

ANOVULATION

BLOOD

Women with functional hypothalamic amenorrhea but not other forms of anovulation display amplified cortisol concentrations. Berga SL, et al. **Fertil Steril** 1997 Jun; 67(6):1024-30

Low levels of follicle-stimulating hormone receptor-activation inhibitors in serum and follicular fluid from normal controls and anovulatory patients with or without polycystic ovary syndrome. Schipper I, et al. **J Clin Endocrinol Metab** 1997 May;82(5):1325-31

DRUG THERAPY

An extended 10-day course of clomiphene citrate (CC) in women with CC-resistant ovulatory disorders. Fluker MR, et al. **Fertil Steril** 1996 Nov;66(5):761-4

Extended clomiphene citrate (CC) and prednisone for the treatment of chronic anovulation resistant to CC alone. Isaacs JD Jr, et al. **Fertil Steril** 1997 Apr;67(4):641-3

The safety and effectiveness of stepwise and low-dose administration of follicle stimulating hormone in WHO group II anovulatory infertile women: evidence from a large multicenter study in Spain. Balasch J, et al. **J Assist Reprod Genet** 1996 Aug;13(7):551-6

Dexamethasone as an adjuvant therapy for anovulatory, normoandrogenic patients during ovulation induction with exogenous gonadotropins. Bider D, et al. **J Assist Reprod Genet** 1996 Sep;13(8):613-6

[Ovulation induction with pure FSH in anovulatory patients resistant to clomifene citrate] Kably-Ambe A, et al. **Ginecol Obstet Mex** 1996 Jul;64:293-6 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Morning rounds and the search for evidence-based answers to clinical questions. Schneeweiss R. **J Am Board Fam Pract** 1997 Jul-Aug;10(4):298-300

[Ovulation induction with adjuvant antiandrogen treatment in Stein-Leventhal syndrome] Koloszár S, et al. **Orv Hetil** 1996 Nov 17;137(46):2569-71 (Eng. Abstr.) **(Hun)**

IMMUNOLOGY

The anovulation in female mice resulting from postnatal injections of estrogen is correlated with altered levels of CD8+ lymphocytes. Deshpande RR, et al. **Am J Reprod Immunol** 1997 Aug;38(2):114-20

METABOLISM

Low levels of follicle-stimulating hormone receptor-activation inhibitors in serum and follicular fluid from normal controls and anovulatory patients with or without polycystic ovary syndrome. Schipper I, et al. **J Clin Endocrinol Metab** 1997 May;82(5):1325-31

PHYSIOPATHOLOGY

Anovulation and monophasic cycles. Spence JE. **Ann N Y Acad Sci** 1997 Jun 17;816:173-6 (07 ref.)

Endocrine defects in mice carrying a null mutation for the progesterone receptor gene. Chappell PE, et al. **Endocrinology** 1997 Oct;138(10):4147-52

Endometrial cathepsin D immunostaining throughout ovulatory and anovulatory menstrual cycles. Camier B, et al. **Hum Reprod** 1996 Feb;11(2):392-7

Ovulation induction in the estrogenized anovulatory patient. Kettel LM, et al. **Semin Reprod Endocrinol** 1996 Nov; 14(4):309-15 (57 ref.)

[The neuroendocrine mechanisms of the development of the anovulatory hyperandrogenic syndrome in rats] Reznikov OH, et al. **Fiziol Zh** 1995 Sep-Dec;41(5-6):33-7 (Eng. Abstr.) **(Ukr)**

SURGERY

Surgical ovulation induction: the role of ovarian diathermy in polycystic ovary syndrome. Donesky BW, et al. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):293-309 (83 ref.)

Transvaginal interstitial laser treatment of the ovary: a feasibility study in cows. Kaaijk EM, et al. **Hum Reprod** 1996 Apr;11(4):808-13

THERAPY

Polycystic ovary syndrome: induction of ovulation. Homburg R. **Baillieres Clin Endocrinol Metab** 1996 Apr;10(2):281-92 (50 ref.)

Hypermenorrhea and anovulatory cycles in the adolescent. Flamigni C, et al. **Curr Ther Endocrinol Metab** 1997;6:243-5 (6 ref.)

Treatment of anovulatory infertility: the problem of multiple pregnancy. Farhi J, et al. **Hum Reprod** 1996 Feb; 11(2):429-34

Ovulation induction in the estrogenized anovulatory patient. Kettel LM, et al. **Semin Reprod Endocrinol** 1996 Nov; 14(4):309-15 (57 ref.)

ANOXEMIA

BLOOD

Delayed elevation of plasma endothelin-1 during unilateral alveolar hypoxia without systemic hypoxemia in humans. Takeda S, et al. **Acta Anaesthesiol Scand** 1997 Feb; 41(2):274-80

Cytokine control of PMN phagocytosis: regulatory effects of hypoxemia and hypoxemia-reoxygenation. Knowles R, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1352-64

Human erythrocyte CAI and CAII isoenzymes in hypoxemic and anemic fetuses. Akbar SA, et al. **Clin Biochem** 1996 Feb;29(1):57-62

Standardizing oxygen measurements [letter; comment] Petty TL. **Crit Care Med** 1997 Aug;25(8):1437. Comment on: Crit Care Med 1997 Jan;25(1):6-8. Comment on: Crit Care Med 1997 Jan;25(1):41-5.

Intra-operative gas exchange and post-operative hypoxaemia. Roe PG, et al. **Eur J Anaesthesiol** 1997 Mar; 14(2):203-10

Acute neurohormonal responses to hypoxaemia in man. Cargill RI, et al. **Eur J Appl Physiol** 1996;72(3):256-60

Nocturnal hypoxemia and oxygen desaturation events in neutropenic patients with sepsis or pneumonia [letter] von Eiff M, et al. **Intensive Care Med** 1996 Feb;22(2):174

Plasma catecholamine and met-enkephalin-Arg6-Phe7 responses to hypoxaemia after adrenalectomy in the fetal sheep. Simonetta G, et al. **J Auton Nerv Syst** 1996 Sep 12;60(3):108-14

Pulse oximeter performance during desaturation and resaturation: a comparison of seven models. Trivedi NS, et al. **J Clin Anesth** 1997 May;9(3):184-8

Vasopressin and catecholamine responses to 24-hour, steady-state hypoxemia in fetal goats. Sameshima H, et al. **J Matern Fetal Med** 1996 Sep-Oct;5(5):262-7

Cocaine does not compromise cerebral or myocardial oxygen delivery in fetal sheep. Burchfield DJ, et al. **Reprod Fertil Dev** 1996;8(3):383-9

Changes in arterial and transcutaneous oxygen and carbon dioxide tensions during and after voluntary hyperventilation. Steurer J, et al. **Respiration** 1997; 64(3):200-5

CHEMICALLY INDUCED

Hypoxemia associated with cimetidine therapy in a newborn infant. Kuint J, et al. **Am J Perinatol** 1996 Jul;13(5):301-3

The effect of epidural opioids on maternal oxygenation during labour and delivery [see comments] Porter JS, et al. **Anaesthesia** 1996 Oct;51(10):899-903. Comment in: Anaesthesia 1997 Mar;52(3):276-8.

COMPLICATIONS

Chronic fetal placental embolization and hypoxemia cause hypertension and myocardial hypertrophy in fetal sheep. Murotsuki J, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R201-7

Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Dawson A, et al. **Ann Intern Med** 1996 Dec 1;125(11):901-4

Sleep-related O2 desaturation and daytime pulmonary haemodynamics in COPD patients with mild hypoxaemia. Chaouat A, et al. **Eur Respir J** 1997 Aug;10(8):1730-5

Fetal rat brain injury: effect of transient maternal hypoxemia. Hallak M, et al. **Fetal Diagn Ther** 1997 Mar-Apr; 12(2):68-71

The pathophysiology of tension pneumothorax in ventilated swine. Barton ED, et al. **J Emerg Med** 1997 Mar-Apr; 15(2):147-53

Platypnea and orthodeoxia: shunting associated with an aortic aneurysm. Laybourn KA, et al. **J Thorac Cardiovasc Surg** 1997 May;113(5):955-6

Sleep-related hypoxaemia in chronic obstructive pulmonary disease: causes, consequences and treatment. Weitzenblum E, et al. **Respiration** 1997;64(3):187-93 (42 ref.)

Pseudohypoxaemia in a patient with acute leukaemia [see comments] Charoenratanakul S, et al. **Thorax** 1997 Apr; 52(4):394-5. Comment in: Thorax 1997 Apr;52(4):390-1.

DIAGNOSIS

Comparison of the Nellcor N-200 and N-3000 pulse oximeters during simulated postoperative activities. Lie C, et al. **Anaesthesia** 1997 May;52(5):450-2

The effects of motion on the performance of pulse oximeters in volunteers (revised publication). Barker SJ, et al. **Anesthesiology** 1997 Jan;86(1):101-8

Validation of pulse oximetry for monitoring of hypoxaemic episodes in the late postoperative period. Stausholm K, et al. **Br J Anaesth** 1997 Jan;78(1):86-7

Sleep-disordered breathing: a novel predictor of atrial fibrillation after coronary artery bypass surgery. Mooe T, et al. **Coron Artery Dis** 1996 Jun;7(6):475-8

Middle cerebral artery velocimetry as a predictor of hypoxemia in fetuses with increased resistance to blood flow in the umbilical artery. Dubiel M, et al. **Early Hum Dev** 1997 Jan 20;47(2):177-84

Hypoxemia and recurrent epistaxis in an 81-year-old woman. Parenti DJ, et al. **Hosp Pract (Off Ed)** 1997 Aug 15; 32(8):107-8, 115-6, 121

Principles & guidelines for respiratory monitoring on the general care floor. The Consortium on Respiratory Monitoring on the General Care Floor. **J Clin Monit** 1996 Sep;12(5):411-6

[Evaluation of postoperative hypoxemia with a pulse oximeter] Kobayashi Y, et al. **Masui** 1996 Feb;45(2):183-8 (Eng. Abstr.) **(Jpn)**

[Evaluation of postoperative hypoxemia after spinal anesthesia with a pulse oximeter] Kobayashi Y, et al. **Masui** 1997 Jun;46(6):818-22 (Eng. Abstr.) **(Jpn)**

[False hypoxemia in a patient with chronic myeloid leukemia (letter)] Sanchís Cervera J, et al. **Rev Clin Esp** 1996 Sep; 196(9):665 **(Spa)**

DRUG THERAPY

ECMO and inhaled nitric oxide for cardiopulmonary failure after heart retransplantation. Barzaghi N, et al. **Ann Thorac Surg** 1997 Feb;63(2):533-5

Helium/oxygen breathing improves hypoxemia after cardiac surgery. Yahagi N, et al. **Artif Organs** 1997 Jan;21(1):24-7

Effects of almitrine bismesylate in a microswine model of hypoxemic hypothermia. Gentile BJ, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):824-8

Early response to inhaled nitric oxide and its relationship to outcome in children with severe hypoxemic respiratory failure. Goldman AP, et al. **Chest** 1997 Sep;112(3):752-8

Adverse events with continuous doxapram infusion against late postoperative hypoxaemia. Rosenberg J, et al. **Eur J Clin Pharmacol** 1996;50(3):191-4

Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. Roberts JD Jr, et al. **N Engl J Med** 1997 Feb 27; 336(9):605-10

A double blind cross over trial of theophylline prophylaxis for sleep hypoxaemia in Duchenne muscular dystrophy. Khan Y, et al. **Neuromuscul Disord** 1997 Mar;7(2):75-80

[Nitric oxide via inhalation in the newborn infant and the child with acute hypoxemic respiratory failure] Biban P, et al. **Pediatr Med Chir** 1996 May-Jun;18(3):245-51 (44 ref.) (Eng. Abstr.) **(Ita)**

[The effect of clomipramine to nocturnal periodic hypoxemia in Duchenne muscular dystrophy] Ogata K, et al. **Rinsho Shinkeigaku** 1996 Apr;36(4):602-4 (Eng. Abstr.) **(Jpn)**

[Utilization of inhaled nitric oxide in a case of respiratory insufficiency following lung transplantation] Planas A, et al. **Rev Esp Anestesiol Reanim** 1996 Feb;43(2):70-3 (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Fetal sheep endocrine responses to sustained hypoxemic stress after chronic fetal placental embolization. Gagnon R, et al. **Am J Physiol** 1997 May;272(5 Pt 1):E817-23

ENZYMOLOGY

Effect of hypoxemia on tissue glycogen content and glycolytic enzyme activities in fetal sheep. Stratford LL, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R103-10

[Isoniazid acetylation, its relation to genetic and environmental altitude factors] Taboada Lopez G, et al. **Arch Biol Med Exp (Santiago)** 1987;20(1):13-9 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

[Early postoperative hypoxemia in infants, children and adults undergoing elective plastic surgery] Xue F, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 May;12(3):208-11 (Eng. Abstr.) **(Chi)**

ETIOLOGY

Influence of anesthetic technique on early postoperative hypoxemia. Georgiou LG, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):75-80

Effects of bottle feeding and two different methods of gavage feeding on oxygenation and breathing patterns in preterm infants. Poets CF, et al. **Acta Paediatr** 1997 Apr; 86(4):419-23

Transfusion-induced hypoxemia in beta-thalassaemia [letter] Tassiopoulos T, et al. **Am J Hematol** 1996 Nov;53(3):206

Inhibition of cytochrome P-450 attenuates hypoxemia of acute lung injury in dogs. Stephenson AH, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):H1355-62

A comparative study of early postoperative hypoxemia in infants, children, and adults undergoing elective plastic surgery. Xue FS, et al. **Anesth Analg** 1996 Oct;83(4):709-15

Postoperative hypoxaemia during transport and in the recovery area. George JM, et al. **Ann Acad Med Singapore** 1995 Nov;24(6):807-11

Predictors of hypoxaemia in hospital admissions with acute lower respiratory tract infection in a developing country. Weber MW, et al. **Arch Dis Child** 1997 Apr;76(4):310-4

Obstructive sleep apnoea syndrome: is this an overlooked cause of desaturation in the immediate postoperative period? Vidhani K, et al. **Br J Anaesth** 1997 Apr; 78(4):442-3

Airway closure and intraoperative hypoxaemia: twenty-five years later. Wahba RM. **Can J Anaesth** 1996 Nov; 43(11):1144-9 (32 ref.)

Postoperative hypoxaemia in children undergoing elective palatoplasty [letter] Xue FS, et al. **Can J Anaesth** 1997 Feb; 44(2):229

Hepatopulmonary syndrome associated with schistosomal liver disease. al-Moamary M, et al. **Can J Gastroenterol** 1997 Jul-Aug;11(5):449-50

Hypoxaemia and bronchopneumonia in infants less than six months of age. Brady JP, et al. **Cent Afr J Med** 1996 Jun; 42(6):163-5

Hypoxemia in a cirrhotic patient caused by hepatopulmonary syndrome: a case report. Jan JS, et al. **Chang Keng I Hsueh** 1996 Jun;19(2):160-5

Refractory hypoxemia due to intrapulmonary shunting associated with bronchioloalveolar carcinoma. Chetty KG, et al. **Chest** 1997 Apr;111(4):1120-1

Hypoxic ventilatory response and breathlessness following hypocapnic and isocapnic hyperventilation. Chin K, et al. **Chest** 1997 Jul;112(1):154-63

Arterial hypoxemia during pregnancy caused by pulmonary arteriovenous microfistulas. Wilmshurst P, et al. **Chest** 1996 Nov;110(5):1368-9

Percutaneous balloon catheter closure of a patent foramen ovale in a patient with pulmonary disease, profound hypoxemia, and normal right heart pressures. Allan JJ, et al. **Clin Cardiol** 1997 Mar;20(3):307-9

Refractory postoperative hypoxemia associated with regional cardiac tamponade and patent foramen ovale. Sandifer DP, et al. **Crit Care Med** 1997 Sep;25(9):1608-11

Oxygen saturation during daily activities in chronic obstructive pulmonary disease. Soguel Schenkel N, et al. **Eur Respir J** 1996 Dec;9(12):2584-9

The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome [see comments] Fallon MB, et al. **Gastroenterology** 1997 Aug;113(2):606-14. Comment in: Gastroenterology 1997 Aug;113(2):682-4.

Hepatopulmonary syndrome: is NO the right answer? [editorial; comment] Rodriguez-Roisin R, et al. **Gastroenterology** 1997 Aug;113(2):682-4. Comment on: Gastroenterology 1997 Aug;113(2):606-15.

Hypoxemia during diagnostic laparoscopy: a prospective study. Haydon GH, et al. **Gastrointest Endosc** 1996 Aug; 44(2):124-8

Hypoxemia and hypocapnia in a female drug abuser. Kalaria VG, et al. **Hosp Pract (Off Ed)** 1997 Apr 15;32(4):201-2, 205

A prospective study evaluating the usefulness of continuous supplemental oxygen in various endoscopic procedures. Reshef R, et al. **Isr J Med Sci** 1996 Sep;32(9):736-40

Severe hypoxemia after suction of the nonventilated lung via the bronchial blocker lumen of the univent tube [letter] Baraka A, et al. **J Cardiothorac Vasc Anesth** 1996 Aug; 10(5):694-5

Left, but not right, one-lung ventilation causes hypoxemia during endoscopic transthoracic sympathectomy. Katz Y, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):207-9

Hypoxic hepatitis caused by severe hypoxemia from obstructive sleep apnea. Henrion J, et al. **J Clin Gastroenterol** 1997 Jun;24(4):245-9

Primary biliary cirrhosis complicated by severe hypoxemia. Shiomi S, et al. **J Gastroenterol** 1995 Dec;30(6):790-4

Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Krowka MJ, et al. **Mayo Clin Proc** 1997 Jan;72(1):44-53 (41 ref.)

Inhibition of histamine release by nedocromil sodium reduces exercise-induced hypoxemia in master athletes. Préfaut C, et al. **Med Sci Sports Exerc** 1997 Jan;29(1):10-6

Hypoxaemia during direct laryngoscopy [letter] Saxena A, et al. **Natl Med J India** 1997 Jan-Feb;10(1):46

Orthostatic hypoxaemia in dialysed adult polycystic kidney disease patients. Korzets Z, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):733-5

Observation of early postoperative hypoxaemia in children undergoing elective plastic surgery. Xue FS, et al. **Paediatr Anaesth** 1996;6(1):21-8

Hypoxaemia in patients with hyperventilation syndrome. Chin K, et al. **QJM** 1997 Jul;90(7):477-85

Late resolution of hepatopulmonary syndrome after liver transplantation. Philit F, et al. **Respiration** 1997;64(2):173-5

[A study on the mechanism of severe hypoxemia associated with acute unilateral atelectasis in dogs] Deng X, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1996 Feb; 19(1):22-5 (Eng. Abstr.) **(Chi)**

[Retentional jaundice and hypoxemic pneumopathy] Schmitz N, et al. **Rev Pneumol Clin** 1997;53(3):159-61 (Eng. Abstr.) **(Fre)**

[Hypoxemia and pulmonary atelectasis after laparoscopic cholecystectomy] Di Vita G, et al. **G Chir** 1997 Jan-Feb; 18(1-2):19-22 (Eng. Abstr.) **(Ita)**

[Rigid spine syndrome associated with marked hypoxemia and hypercapnia] Toh Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 May; 34(5):605-9 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Is it possible to predict nocturnal hypoxemia in snorers?] Grebstad JA, et al. **Tidsskr Nor Laegeforen** 1997 Mar 10; 117(7):923-6 (Eng. Abstr.) **(Nor)**

METABOLISM

Effect of hypoxemia on tissue glycogen content and glycolytic enzyme activities in fetal sheep. Stratford LL, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R103-10

Use of an adjustable tourniquet to reverse cyanosis in the newborn pig. Warner KG, et al. **Ann Thorac Surg** 1997 Feb;63(2):456-8

On constructing graphs [letter] Boba A. **Crit Care Med** 1997 Sep;25(9):1612

Effects of hypoxemia and reoxygenation with 21% or 100% oxygen in newborn piglets: extracellular hypoxanthine in cerebral cortex and femoral muscle [see comments] Feet BA, et al. **Crit Care Med** 1997 Aug;25(8):1384-91. Comment in: Crit Care Med 1997 Aug;25(8):1269.

Biosynthesis of prostacyclin and thromboxane A2 during chronic hypoxaemia in children with cyanotic congenital heart disease. Leonhardt A, et al. **Eur J Clin Invest** 1996 Dec;26(12):1057-61

Effects of hypoxemia on 11 beta-hydroxysteroid dehydrogenase types 1 and 2 gene expression in preterm fetal sheep. Yang K, et al. **J Soc Gynecol Investig** 1997 May-Jun;4(3):124-9

Hormonal modifications in patients admitted to an internal intensive care unit for acute hypoxaemic respiratory failure. Kullmer T, et al. **Respir Med** 1996 Nov;90(10):601-8

PATHOLOGY

Enhancement of hypoxemia by right-to-left atrial shunting in severe asthma [letter; comment] Boon ES. **Intensive Care Med** 1996 Feb;22(2):176. Comment on: Intensive Care Med 1994 Nov;20(8):585-7.

Early neuropathologic effects of mild or moderate hypoxemia after controlled cortical impact injury in rats. Clark RS, et al. **J Neurotrauma** 1997 Apr;14(4):179-89

PHYSIOPATHOLOGY

Oxygen desaturation on swallowing in patients with stroke: what it mean? [letter; comment] Teramoto S, et al. **Age Ageing** 1996 Jul;25(4):333-4. Comment on: Age Ageing 1995 Jul;24(4):267-70.

Effects of prolonged hypoxemia on fetal renal function and amniotic fluid volume in sheep. Cock ML, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):320-6

Dynamics of myocardial adaptation to low-flow ischemia and hypoxemia. Merati G, et al. **Am J Physiol** 1996 Dec; 271(6 Pt 2):H2300-5

Inhibition of cytochrome P-450 attenuates hypoxemia of acute lung injury in dogs. Stephenson AH, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):H1355-62

Role of hypoxemia and pulmonary mechanics in exercise limitation in interstitial lung disease. Harris-Eze AO, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):994-1001

Body position and late postoperative nocturnal hypoxaemia. Rosenberg-Adamsen S, et al. **Anaesthesia** 1997 Jun; 52(6):589-92

Acute hypoxemia depresses the cardiorespiratory response during phase I constant load exercise and unloaded cycling. Zattara-Hartmann MC, et al. **Arch Physiol Biochem** 1996; 104(2):212-9

Prolonged repolarization during hypoxemia in epicardial electrogram: difference from ischemia and a competitive action of cyclic AMP. Ikeno E, et al. **Basic Res Cardiol** 1995 Nov-Dec;90(6):451-8

Severe hypoxemia in the absence of blood loss depresses hepatocellular function and up-regulates IL-6 and PGE2. Wang P, et al. **Biochim Biophys Acta** 1997 Jul 10; 1361(1):42-8

Cerebral oxygen delivery is reduced during the acidaemia associated with prolonged hypoxaemia in the immature ovine fetus. McCrabb GJ, et al. **Biol Neonate** 1997; 71(6):385-94

Decreased body-core temperature during acute hypoxemia in guinea pigs during postnatal maturation: a regulated thermoregulatory response. Clark DJ, et al. **Can J Physiol Pharmacol** 1996 Mar;74(3):331-6

Influence of carotid denervation on the body-core temperature and metabolic responses to changes in ambient temperature during normoxemia and acute hypoxemia in guinea pigs during postnatal maturation. Fewell JE, et al. **Can J Physiol Pharmacol** 1997 Feb;75(2):104-11

Fetal breathing is not inhibited by ethanol exposure during prolonged reduced uterine blood flow. Watson CS, et al. **Can J Physiol Pharmacol** 1996 Sep;74(9):1016-24

Heart rate during obstructive sleep apnea depends on individual hypoxic chemosensitivity of the carotid body. Sato F, et al. **Circulation** 1997 Jul 1;96(1):274-81

Alterations in fetal urine production during prolonged hypoxaemia induced by reduced uterine blood flow in sheep: mechanisms. Cock ML, et al. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):57-63

Indices of hypoxemia in patients with acute respiratory distress syndrome: reliability, validity, and clinical usefulness [editorial; comment] [see comments] Gould MK, et al. **Crit Care Med** 1997 Jan;25(1):6-8. Comment on: Crit Care Med 1997 Jan;25(1):41-45. Comment in: Crit Care Med 1997 Aug;25(8):1437.

Variability of indices of hypoxemia in adult respiratory distress syndrome [see comments] Gowda MS, et al. **Crit Care Med** 1997 Jan;25(1):41-5. Comment in: Crit Care Med 1997 Jan;25(1):6-8. Comment in: Crit Care Med 1997 Aug;25(8):1437.

Effects of hypoxemia on the electroretinogram in diabetics. Rimmer TJ, et al. **Doc Ophthalmol** 1995-96;91(4):311-21

The relationship between test protocol and the development of exercise-induced hypoxemia (EIH) in highly trained athletes. Lama IL, et al. **Eur J Appl Physiol** 1996; 74(4):330-5

Relief of hypoxemia contributes to a reduction in cardiac index related to the use of positive end-expiratory pressure. Borelli M, et al. **Intensive Care Med** 1996 May;22(5):382-6

Changes in cardiac autonomic control during nocturnal repetitive oxygen desaturation episodes in patients with coronary artery disease. Keyl C, et al. **J Cardiovasc Risk** 1996 Apr;3(2):221-7

Cognitive function in patients with sleep apnea after acute nocturnal nasal continuous positive airway pressure (CPAP) treatment: sleepiness and hypoxemia effects. Valencia-Flores M, et al. **J Clin Exp Neuropsychol** 1996 Apr;18(2):197-210

Characteristics of hypoxemic episodes in very low birth weight infants on ventilatory support. Dimaguila MA, et al. **J Pediatr** 1997 Apr;130(4):577-83

Regional blood flow during severe hypoxemia and resuscitation with 21% or 100% O2 in newborn pigs. Rootwelt T, et al. **J Perinat Med** 1996;24(3):227-36

A comparison of the ventilatory response of sleeping newborn lambs to step and progressive hypoxaemia. Cohen G, et al. **J Physiol (Lond)** 1997 Aug 15;503 (Pt 1):203-13

Activation of the fetal hypothalamic-pituitary-adrenal axis with prolonged and graded hypoxemia. Carmichael L, et al. **J Soc Gynecol Investig** 1997 Jan-Feb;4(1):8-14

Sleep state, cardiorespiratory and electrocortical activity in infants with transposition of great vessels. Sahni R, et al. **Neuropediatrics** 1997 Jun;28(3):162-7

The influence of extracorporeal membrane oxygenation on cerebral oxygenation and hemodynamics in normoxemic and hypoxemic piglets. Liem KD, et al. **Pediatr Res** 1996 Feb;39(2):209-15

Hemodynamics and tissue blood flow after porcine surfactant replacement in surfactant-depleted newborn piglets. Moen A, et al. **Pediatr Res** 1996 Aug;40(2):215-24

Regional blood flow and the endocrine response to sustained hypoxemia in the preterm ovine fetus. Richardson B, et al. **Pediatr Res** 1996 Aug;40(2):337-43

Circulatory Doppler parameters in fetal hypoxaemia. Gonser M, et al. **Prenat Diagn** 1996 Aug;16(8):755-9

VA/Q abnormalities during gram negative sepsis. Huang YC, et al. **Respir Physiol** 1996 Aug;105(1-2):109-21

Prevalence of severity of hypoxemia following clinical voluntary hyperventilation. Chin K, et al. **Respiration** 1996; 63(4):223-9

Living related liver transplantation in children with hypoxemia related to intrapulmonary shunting. Uemoto S, et al. **Transpl Int** 1996;9 Suppl 1:S157-9

Effects of hypoxemia on early postoperative course of liver transplantation in pediatric patients with intrapulmonary shunting. Uemoto S, et al. **Transplantation** 1997 Feb 15; 63(3):407-14

Absence of significant hemodynamic changes in the fetus following maternal betamethasone administration. Cohlen BJ, et al. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):252-5

Effects of adaptation level and hypoglycemia on function of the cat retina during hypoxemia. McRipley MA, et al. **Vis Neurosci** 1997 Mar-Apr;14(2):339-50

[Spectroscopic measurement of the intracerebral cytochrome system] Krauskopf KH, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):374-8 **(Ger)**

[Request for pathophysiologic explanation of hypoxemic disorders (e.g. heart defect with right-left shunt, diseases with respiratory insufficiency) leading to clubbed fingers and toes and hour-glass nail manifestations] Horstkotte. **Internist (Berl)** 1996 Nov;37(11):1170-1 **(Ger)**

[Hepatopulmonary syndrome] Lotterer E, et al. **Schweiz Rundsch Med Prax** 1997 Jan 21;86(4):104-8 (30 ref.) (Eng. Abstr.) **(Ger)**

[Signs of right heart stress in diurnal normoxemic patients with chronic obstructive lung disease and nocturnal hypoxemia] Rasche K, et al. **Wien Med Wochenschr** 1996; 146(13-14):350-2 (Eng. Abstr.) **(Ger)**

[Alteration of myocardial contractility during progressive hypoxemia in pigs] Matsuda Y. **Masui** 1997 Mar; 46(3):344-50 (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

The effect of supplemental oxygen on the incidence of hypoxaemia after premedication in patients undergoing

cardiac surgery. Royse CF, et al. **Anaesth Intensive Care** 1997 Aug;25(4):347–9

Pre–oxygenation, hyperoxygenation and lung aeration [letter; comment] Scott PV. **Anaesthesia** 1996 Dec;51(12):1186. Comment on: Anaesthesia 1996 Aug;51(8):733–7.

Effect of upright and supine posture on hypoxemia during air transport. Knutson SW, et al. **Aviat Space Environ Med** 1996 Jan;67(1):14–8

Influence of motivation of care providers on the incidence of postoperative hypoxaemia in the recovery room. Rheineck–Leyssius AT, et al. **Br J Anaesth** 1996 Oct; 77(4):453–7

Augmented hyperventilation via normoxic helium breathing does not prevent exercise–induced hypoxemia. Buono MJ, et al. **Can J Appl Physiol** 1996 Aug;21(4):264–70

Routine use of pulse oximetry and supplemental oxygen during endoscopic procedures under conscious sedation: British beef or common sense? [editorial; comment] Bell GD, et al. **Endoscopy** 1996 Oct;28(8):718–21. Comment on: Endoscopy 1996 Oct;28(8):703–11.

Pulse oximetry and supplemental oxygen during gastrointestinal endoscopy: a critical review [see comments] Holm C, et al. **Endoscopy** 1996 Oct;28(8):703–11 (85 ref.) . Comment in: Endoscopy 1996 Oct;28(8):718–21.

Prone positioning decreases episodes of hypoxemia in extremely low birth weight infants (1000 grams or less) with chronic lung disease. McEvoy C, et al. **J Pediatr** 1997 Feb;130(2):305–9

Inhibition of histamine release by nedocromil sodium reduces exercise–induced hypoxemia in master athletes. Préfaut C, et al. **Med Sci Sports Exerc** 1997 Jan;29(1):10–6

Effect of nursing in the head elevated tilt position (15 degrees) on the incidence of bradycardic and hypoxemic episodes in preterm infants. Jenni OG, et al. **Pediatrics** 1997 Oct;100(4):622–5

[Effect of L–carnitine on lipid peroxidation and lipid composition in blood serum in hemic hypoxia] Sidoriak NG, et al. **Ukr Biokhim Zh** 1996 Sep–Oct;68(5):54–8 (Eng. Abstr.) **(Rus)**

SURGERY

Lack of efficacy of TIPS for hepatopulmonary syndrome [letter; comment] Corley DA, et al. **Gastroenterology** 1997 Aug;113(2):728–30. Comment on: Gastroenterology 1995 Sep;109(3):978–83.

THERAPY

Extracorporeal membrane oxygenation for transport of hypoxaemic patients with severe ARDS. Rossaint R, et al. **Br J Anaesth** 1997 Mar;78(3):241–6

Effects of hypoxemia and reoxygenation with 21% or 100% oxygen in newborn piglets: extracellular hypoxanthine in cerebral cortex and femoral muscle [see comments] Feet BA, et al. **Crit Care Med** 1997 Aug;25(8):1384–91. Comment in: Crit Care Med 1997 Aug;25(8):1269.

Effect of blood transfusion on apnoea, bradycardia and hypoxaemia in preterm infants. Poets CF, et al. **Eur J Pediatr** 1997 Apr;156(4):311–6

Does long–term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia? Okubadejo AA, et al. **Eur Respir J** 1996 Nov;9(11):2335–9

Hemodynamic and gas exchange responses to inhalation of nitric oxide in patients with the acute respiratory distress syndrome and in hypoxemic patients with chronic obstructive pulmonary disease. Blanch L, et al. **Intensive Care Med** 1997 Jan;23(1):51–7

Relief of hypoxemia contributes to a reduction in cardiac index related to the use of positive end–expiratory pressure. Borelli M, et al. **Intensive Care Med** 1996 May;22(5):382–6

A prospective study evaluating the usefulness of continuous supplemental oxygen in various endoscopic procedures. Reshef R, et al. **Isr J Med Sci** 1996 Sep;32(9):736–40

Oxygen delivery: nasopharyngeal catheter or nasal prongs? [letter; comment] Shann F. **J Pediatr** 1996 Jul;129(1):185; discussion 186. Comment on: J Pediatr 1995 Sep;127(3):378–83.

Purine metabolism and inhibition of xanthine oxidase in severely hypoxic neonates going onto extracorporeal membrane oxygenation. Marro PJ, et al. **Pediatr Res** 1997 Apr;41(4 Pt 1):513–20

Eliminating sleep–associated hypoxemia improves growth in infants with bronchopulmonary dysplasia. Moyer–Mileur LJ, et al. **Pediatrics** 1996 Oct;98(4 Pt 1):779–83

[Nitric oxide treatment of children with impairment of oxygenation] Kristensen BB, et al. **Ugeskr Laeger** 1997 May 5;159(19):2878–80 (Eng. Abstr.) **(Dan)**

[Eight years of experience in Warsaw with domiciliary long term oxygen therapy] Tobiasz M, et al. **Pneumonol Alergol Pol** 1996;64(9–10):568–76 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Diagnostic and therapeutic implications of transesophageal echocardiography in medical ICU patients with unexplained shock, hypoxemia, or suspected endocarditis. Slama MA, et al. **Intensive Care Med** 1996 Sep;22(9):916–22 (24 ref.)

VETERINARY

Effects of training on the development of exercise–induced arterial hypoxemia in horses. Christley RM, et al. **Am J Vet Res** 1997 Jun;58(6):653–7

Maternal and fetal catecholamine responses to acute hypoxemia in Japanese Saanen goats. Sakamoto H, et al. **J Vet Med Sci** 1996 Jun;58(6):489–93

ANOXIA

Phosphate and cyclic AMP excretion decreases during less than 12 hours of hypoxia in conscious rats. Mimura Y. **Acta Physiol Scand** 1996 Dec;158(4):317–23

Role of activation of calcium–sensitive K+ channels in NO– and hypoxia–induced pial artery vasodilation. Armstead WM. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1785–90

Activator calcium and myocardial contractility in fetal sheep exposed to long–term high–altitude hypoxia. Browne VA, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1196–204

Cobalt but not hypoxia stimulates PDGF gene expression in rats. Bucher M, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E451–7

Electroencephalogram activity in the anoxic turtle brain. Fernandes JA, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R911–9

Hypoxia inhibits nitric oxide synthesis in isolated rabbit lung. Kantrow SP, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):L1167–73

Induction of cardiac natriuretic peptide gene expression in rats trained in hypobaric hypoxic conditions. Perhonen M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R344–52

Acute hypoxia stimulates renin secretion and renin gene expression in vivo but not in vitro. Ritthaler T, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1105–11

Glutathione systems and anoxia tolerance in turtles. Willmore WG, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R219–25

Third European Consensus Conference in Intensive Care Medicine. Tissue hypoxia: How to detect, how to correct, how to prevent. Société de Réanimation de Langue Française. The American Thoracic Society. European Society of Intensive Care Medicine. **Am J Respir Crit Care Med** 1996 Nov;154(5):1573–8 (34 ref.)

Nitric–oxide–induced reoxygenation injury in the cyanotic immature heart is prevented by controlling oxygen content during initial reoxygenation. Ihnken K, et al. **Angiology** 1997 Mar;48(3):189–202

Hypoxia–induced ABR change and heat shock protein expression in the pontine auditory pathway of young rabbits. Inagaki M, et al. **Brain Res** 1997 May 16; 757(1):111–8

An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis–associated genes in murine tumor cells. Jang A, et al. **Clin Exp Metastasis** 1997 Sep;15(5):469–83

Neonatal hemodynamic responses to extreme ranges of controlled graded hypoxia. Torrance SM, et al. **Crit Care Med** 1996 Nov;24(11):1886–92

Accuracy of pulse oximetry during intense exercise under severe hypoxic conditions. Benoit H, et al. **Eur J Appl Physiol** 1997;76(3):260–3

Low–dose carbon monoxide does not reduce vasoconstriction in isolated rat lungs. Cantrell JM, et al. **Exp Lung Res** 1996 Jan–Feb;22(1):21–32

Morphofunctional effects of moderate forebrain ischemia combined with short–term hypoxia in rats—protective effects of Cerebrolysin. Schwab M, et al. **Exp Toxicol Pathol** 1997 Feb;49(1–2):29–37

Endoscopy and hypoxia: not so uncomfortable [letter; comment] Bafna S. **Indian J Gastroenterol** 1996 Jul; 15(3):114. Comment on: Indian J Gastroenterol 1996 Apr;15(2):37–9. Comment on: Indian J Gastroenterol 1996 Apr;15(2):40–2.

Tissue hypoxia. How to detect, how to correct, how to prevent? Richard C. **Intensive Care Med** 1996 Nov; 22(11):1250–7 (34 ref.)

Effects of acute hypoxia and hyperoxia on ventilation in spontaneously hypertensive and normotensive rat. Grisk O, et al. **J Auton Nerv Syst** 1996 Mar 7;57(3):177–80

Effect of exposure time on the survival of immature pigs in a confined atmosphere. Arieli R, et al. **J Basic Clin Physiol Pharmacol** 1996;7(2):83–96

Lactate accumulation during moderate hypoxic hypoxia in neocortical rat brain. Payen JF, et al. **J Cereb Blood Flow Metab** 1996 Nov;16(6):1345–52

Isolated pelvic perfusion for inoperable advanced tumors: hyperthermic or hypoxic perfusion? De Simone M, et al. **J Chemother** 1997 Apr;9(2):138–9

Balancing hypoxia and hypothermia in cold–submerged frogs. Tattersall GJ, et al. **J Exp Biol** 1997 Mar;200 (Pt 6):1031–8

Nonpeptide endothelin receptor antagonists. VIII: attentuation of acute hypoxia–induced pulmonary hypertension in the dog. Willette RN, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):695–701

Myocardial protection of the hypoxic heart [letter; comment] Baker JE, et al. **J Thorac Cardiovasc Surg** 1997 Jun; 113(6):1123–4. Comment on: J Thorac Cardiovasc Surg 1996 Nov;112(5):1193–200; discussion 1200–1.

Myocardial protection in normal and hypoxically stressed neonatal hearts: the superiority of hypocalcemic versus normocalcemic blood cardioplegia [see comments] Bolling K, et al. **J Thorac Cardiovasc Surg** 1996 Nov; 112(5):1193–200; discussion 1200–1. Comment in: J Thorac Cardiovasc Surg 1997 Jun;113(6):1123–4.

Hyperoxic cardiopulmonary bypass causes reoxygenation injury and lipid peroxidation [letter] Ihnken K. **J Thorac Cardiovasc Surg** 1997 Aug;114(2):304–6

Exploitation of hypoxia for radiation therapy: a lesson from phenothiazines. Kale RK. **Med Hypotheses** 1996 Aug; 47(2):107–10

Antioxidant systems and anoxia tolerance in a freshwater turtle Trachemys scripta elegans. Willmore WG, et al. **Mol Cell Biochem** 1997 May;170(1–2):177–85

Both 5' and 3' sequences of maize adh1 mRNA are required for enhanced translation under low–oxygen conditions. Bailey–Serres J, et al. **Plant Physiol** 1996 Oct;112(2):685–95

Prevention of hypoxic liver injury by in vivo transfection of the human bcl–2 gene. Yamabe K, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):384–5

[Regression of Yoshida sarcoma during normoxia and hypoxia after fractionated irradiation] Strnad V, et al. **Strahlenther Onkol** 1997 Mar;173(3):141–5 (Eng. Abstr.) **(Ger)**

[Regression of Yoshida sarcoma during normoxia and hypoxia after fractionated irradiation. Commentary on the article by Strnad et al in this issue] Trott KR. **Strahlenther Onkol** 1997 Mar;173(3):146–7 **(Ger)**

[Methodological aspects and clinicophysiological substantiation of applying the hypoxic therapy] Novikov VS, et al. **Aviakosm Ekolog Med** 1996;30(6):42–6 (34 ref.) (Eng. Abstr.) **(Rus)**

[Hypoxic training stimulates the insulin apparatus of the pancreas in intact and diabetic rats] Kolesnik IuM, et al. **Biull Eksp Biol Med** 1995 Dec;120(12):565–7 **(Rus)**

[Experience in treating patients with cardiovascular diseases by means of adaptation to periodic barochamber hypoxia] Aleshin IA, et al. **Ter Arkh** 1997;69(1):54–8 (Eng. Abstr.) **(Rus)**

[Possibilities of normobaric hypoxic training in rehabilitation of patients with chronic bronchitis] Aleksandrov OV, et al. **Vestn Ross Akad Med Nauk** 1997;(5):27–30 (Eng. Abstr.) **(Rus)**

[Analysis of the effectiveness of interval hypoxic training in rehabilitation of apparently healthy persons: an individual approach] Glazachev OS, et al. **Vestn Ross Akad Med Nauk** 1997;(5):50–5 **(Rus)**

[Adaptation to hypoxia as a factor enhancing work capacity] Kozlov SA. **Vestn Ross Akad Med Nauk** 1997;(5):46–50 (Eng. Abstr.) **(Rus)**

[Use of hypoxic training in sports medicine] Radzievskii PA. **Vestn Ross Akad Med Nauk** 1997;(5):41–6 (Eng. Abstr.) **(Rus)**

[Use of normobaric hypoxic training in obstetrics] Tsyganova TN. **Vestn Ross Akad Med Nauk** 1997;(5):30–3 (Eng. Abstr.) **(Rus)**

[Possibility of correction of the hormonal state of girls by hypoxic training] Zakusilo MP. **Vestn Ross Akad Med Nauk** 1997;(5):38–41 (Eng. Abstr.) **(Rus)**

BLOOD

Delayed elevation of plasma endothelin–1 during unilateral alveolar hypoxia without systemic hypoxemia in humans. Takeda S, et al. **Acta Anaesthesiol Scand** 1997 Feb; 41(2):274–80

Norepinephrine–mediated hypoxic stimulation of embryonic red cell carbonic anhydrase and 2,3–DPG synthesis. Dragon S, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R982–9

Serum succinate by capillary zone electrophoresis: marker candidate for hypoxia. Komaromy–Hiller G, et al. **Ann Clin Lab Sci** 1997 Mar–Apr;27(2):163–8

Human erythropoietin response to hypocapnic hypoxia, normocapnic hypoxia, and hypocapnic normoxia. Klausen T, et al. **Eur J Appl Physiol** 1996;74(5):475–80

Effect of acute normobaric hypoxia on quadriceps integrated electromyogram and blood metabolites during incremental exercise to exhaustion. Taylor AD, et al. **Eur J Appl Physiol** 1996;73(1–2):121–9

Effects of high–altitude chronic hypoxia on platelet alpha 2–receptors in man. Zaccaria M, et al. **Eur J Clin Invest** 1997 Apr;27(4):316–21

Prostanoid production in the presence of platelet activation in hypoxic cocaine–treated rats. Togna G, et al. **Haemostasis** 1996 Nov–Dec;26(6):311–8

Retinal large vessel oxygen saturations correlate with early blood loss and hypoxia in anesthetized swine. Denninghoff KR, et al. **J Trauma** 1997 Jul;43(1):29–34

Effects of exposure to hypobaric–hypoxia on body weight, muscular and hematological characteristics, and work performance in rats. Tanaka M, et al. **Jpn J Physiol** 1997 Feb;47(1):51–7

[Hypoxia induced increase of MDA and echinocytes from erythrocytes in rabbit's blood with special reference to inhibition of the increase by MPEG–SOD] Han ZY, et al. **Sheng Li Hsueh Pao** 1995 Dec;47(6):565–72 (Eng. Abstr.) **(Chi)**

[Effect of a three month training period on the maximal oxygen deficiency in high level performance sprinters] Heugas AM, et al. **Can J Appl Physiol** 1997 Apr; 22(2):171–81 (Eng. Abstr.) **(Fre)**

[Predictive information of basic indices of biochemical status of a man in evaluating the tolerance to acute hypoxia] Nagornev SN, et al. **Aviakosm Ekolog Med** 1996;30(5):13–9

(Eng. Abstr.) **(Rus)**

[Effect of carotid glomectomy on red blood cells parameters of rats depending on individual resistance to acute hypoxia] Shevchenko LV, et al. **Biull Eksp Biol Med** 1996 Jul; 122(7):12–3 **(Rus)**

CEREBROSPINAL FLUID

Relationship between vasopressin and opioids in hypoxia induced pial artery vasodilation. Rossberg MI, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H521–7

Cerebrospinal fluid concentrations of glutamate and GABA during perinatal cerebral hypoxia–ischemia and seizures. Cataltepe O, et al. **Brain Res** 1996 Feb 19;709(2):326–30

CHEMICALLY INDUCED

Severe hypoxia and hypothermia following barbiturate poisoning [letter] Hantson P, et al. **Intensive Care Med** 1996 Sep;22(9):998–9

Characterization of a chemical anoxia model in cerebellar granule neurons using sodium azide: protection by nifedipine and MK–801. Varming T, et al. **J Neurosci Res** 1996 Apr 1;44(1):40–6

CLASSIFICATION

The value of a scoring system for hypoxic ischaemic encephalopathy in predicting neurodevelopmental outcome. Thompson CM, et al. **Acta Paediatr** 1997 Jul; 86(7):757–61

COMPLICATIONS

Endothelin receptor A antagonism prevents hypoxia–induced intrauterine growth restriction in the rat. Thaete LG, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):73–6

Reduced vasodilator response to ANF in hypoxia–induced pulmonary hypertension in the newborn piglet. Perreault T, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):L289–95

Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. O'Donnell DE, et al. **Am J Respir Crit Care Med** 1997 Feb; 155(2):530–5

Clinical trial of induced hypothermia in comatose survivors of out–of–hospital cardiac arrest. Bernard SA, et al. **Ann Emerg Med** 1997 Aug;30(2):146–53

Hypoxia–ischemia causes abnormalities in glutamate transporters and death of astroglia and neurons in newborn striatum. Martin LJ, et al. **Ann Neurol** 1997 Sep; 42(3):335–48

Arrhythmia and electrical heterogeneity during prolonged hypoxia in guinea pig papillary muscles. Hayashi H, et al. **Can J Physiol Pharmacol** 1997 Jan;75(1):44–51

Regression of chronic hypoxia–induced pulmonary hypertension, right ventricular hypertrophy, and fibrosis: effect of enalapril. Pelouch V, et al. **Cardiovasc Drugs Ther** 1997 Apr;11(2):177–85

Changes of distribution of platelet activating factor in the lung of rats with hypoxic pulmonary hypertension. Chen D, et al. **Chin Med J (Engl)** 1996 Oct;109(10):776–9

Inhibition of tissue angiotensin–converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Nong Z, et al. **Circulation** 1996 Oct 15;94(8):1941–7

Comparison of the effect of inhaled nitric oxide and intravenous nitroglycerine on hypoxia–induced pulmonary hypertension in pigs. Troncy E, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):521–9

Trandolapril plus verapamil inhibits the coronary vasospasm induced by hypoxia following ischemia–reperfusion injury in dogs. Lee JJ, et al. **Gen Pharmacol** 1996 Sep;27(6):1057–9

High altitude and spontaneous preterm birth. Ali KZ, et al. **Int J Gynaecol Obstet** 1996 Jul;54(1):11–5

Methylprednisolone attenuates hypoxic pulmonary vasoconstriction in man [letter] Bjertnaes LJ, et al. **Intensive Care Med** 1996 Jul;22(7):715–7

Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. Lawson CA, et al. **J Clin Invest** 1997 Apr 1;99(7):1729–38

Obstructive sleep apnea–induced supraventricular tachycardia. Randazzo DN, et al. **J Electrocardiol** 1996 Jan;29(1):65–7

Lack of major hypoxia and significant brain damage in rats despite dramatic hyponatremic encephalopathy. Soupart A, et al. **J Lab Clin Med** 1997 Aug;130(2):226–31

Endotoxin and transient hypoxia cause severe acidosis in the piglet. Groner JI. **J Pediatr Surg** 1997 Jul;32(7):1123–5; discussion 1126

Echo–Doppler sonographic diagnosis of hypoxic hepatitis in patients with cardiac failure. Gorka W, et al. **J Ultrasound Med** 1997 Apr;16(4):293–5

Congenital syphilis associated with persistent pulmonary hypertension of the neonate––a clinico–pathological case study. Smith J, et al. **S Afr Med J** 1995 Nov;85(11 Suppl):1232–5

Perinatal asphyxia, hypoxia, ischemia and hearing loss. An overview. Borg E. **Scand Audiol** 1997;26(2):77–91 (53 ref.)

The effect of hypoxia on baroreflexes and pressor sensitivity in sleep apnea and hypertension. Ziegler MG, et al. **Sleep** 1995 Dec;18(10):859–65

Impaired cardiac function during postnatal hypoxia in rats exposed to nicotine prenatally: implications for perinatal morbidity and mortality, and for sudden infant death syndrome. Slotkin TA, et al. **Teratology** 1997 Mar; 55(3):177–84

[The inhibitory effects of Radix Astragali on hypoxic pulmonary hypertension of rats] Xi S, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Aug;25(4):236–8 (Eng. Abstr.) **(Chi)**

[A pathological survey of the therapeutic effect on experimental hypoxic–ischemic encephalopathy] Zhang L, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1996 Apr; 25(2):102–4 (Eng. Abstr.) **(Chi)**

[Experimental studies on inhibitory effects of radix Peucedani on hypoxic pulmonary hypertension in rats] Xi SC, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Apr; 16(4):218–20 (Eng. Abstr.) **(Chi)**

[Protective and treated effects of L–arginine on hypoxia–induced pulmonary hypertension in rats] Cheng D, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1996 Mar; 27(1):68–70 (Eng. Abstr.) **(Chi)**

[Role of hypoxia in the development of epileptiform seizures] Agadzhanian NA, et al. **Aviakosm Ekolog Med** 1996; 30(4):40–4 (Eng. Abstr.) **(Rus)**

[The role of detrusor hypoxia in the pathogenesis of urination disorders in patients with benign prostatic hyperplasia] Loran OB, et al. **Urol Nefrol (Mosk)** 1996 Nov–Dec; (6):33–7 (Eng. Abstr.) **(Rus)**

[Pathology and pathogenesis of secondary epilepsy to hypoxic–ischemic encephalopathies] Marín–Padilla M. **Rev Neurol** 1997 May;25(141):673–82 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Tissue hypoxia: how to detect, how to correct, how to prevent? Third European Consensus Conference in Intensive Care Medicine. Organized by the Société de Réanimation de Langue Française, Cosponsored by the American Thoracic Society and the European Society of Intensive Care Medicine. **J Crit Care** 1997 Mar;12(1):39–47 (34 ref.)

The prognostic value of the Glasgow Coma Scale, hypoxia and computerised tomography in outcome prediction of pediatric head injury. Ong L, et al. **Pediatr Neurosurg** 1996 Jun;24(6):285–91

Measurement of cytochrome oxidase and mitochondrial energetics by near–infrared spectroscopy. Cooper CE, et al. **Philos Trans R Soc Lond B Biol Sci** 1997 Jun 29; 352(1354):669–76 (62 ref.)

Improved monitoring of preterm infants by Fuzzy Logic. Wolf M, et al. **Technol Health Care** 1996 Aug;4(2):193–201

[Immunohistochemical detection of myocardial hypoxia] Toupalík P. **Soud Lek** 1997 May;42(2):23–5 (Eng. Abstr.) **(Cze)**

[Non–invasive measurement of average cerebral O2 saturation of hemoglobin] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):378–80 **(Ger)**

[Assessing the probability of hypoxic complications in cardiosurgery patients using statistical simulation of hypoxia] Mikhailov IuM, et al. **Anesteziol Reanimatol** 1997 Jan–Feb;(1):15–7 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Alkali therapy extends the period of survival during hypoxia: studies in rats. Halperin FA, et al. **Am J Physiol** 1996 Aug; 271(2 Pt 2):R381–7

Inhaled prostacyclin (PGI2) versus nitric oxide (NO) [letter; comment] Tibballs J. **Anaesth Intensive Care** 1996 Aug; 24(4):515–6. Comment on: Anaesth Intensive Care 1996 Feb;24(1):87–90.

Nitric oxide involvement in hypoxic dilation of pial arteries in the cat. Ishimura N, et al. **Anesthesiology** 1996 Dec; 85(6):1350–6

Additional insights into combined surfactant and nitric oxide therapy [letter; comment] Kapur P, et al. **Ann Thorac Surg** 1997 Jan;63(1):299–300. Comment on: Ann Thorac Surg 1996 May;61(5):1543–5.

Chemistry of indoles carrying a basic function, Part 3. Synthesis of spiro[cyclopropane–1,3'[3H]indol]–2'(1'H)–ones with antihypoxic effects. Moldvai I, et al. **Arch Pharm (Weinheim)** 1996 Dec;329(12):541–9

Mepacrine protects the isolated rat heart during hypoxia and reoxygenation––but not by inhibition of phospholipase A2. Bugge E, et al. **Basic Res Cardiol** 1997 Feb;92(1):17–24

Resuscitating effect of melanocortin peptides after prolonged respiratory arrest. Guarini S, et al. **Br J Pharmacol** 1997 Aug;121(7):1454–60

Pyridoxalated hemoglobin polyoxyethylene conjugate does not restore hypoxic pulmonary vasoconstriction in ovine sepsis. Fischer SR, et al. **Crit Care Med** 1997 Sep; 25(9):1551–9

The endothelin ETB receptor antagonist BQ–788 reduces the pulmonary vasodilator effect of endothelin–1 during acute hypoxia in pigs. Holm P, et al. **Eur J Pharmacol** 1997 Mar 26;323(1):83–7

Myocardium–protective effects of Ginkgo biloba extract (EGb 761) in old rats against acute isobaric hypoxia. An electron microscopic morphometric study. II. Protection of microvascular endothelium. Welt K, et al. **Exp Toxicol Pathol** 1996 Jan;48(1):81–6

Effects of tetramethylpyrazine on the release of PGI2 and TXA2 in the hypoxic isolated rat heart. Feng J, et al. **Mol Cell Biochem** 1997 Feb;167(1–2):153–8

Nitric oxide in the pulmonary circulation. Adnot S, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):519–27 (30 ref.)

Mechanisms of hippocampal reoxygenation injury. Treatment with antioxidants. Horáková L, et al. **Neuropharmacology** 1997 Feb;36(2):177–84

The action of pramiracetam on consequences of hypobaric hypoxia is only moderate. Marešová D, et al. **Physiol Res** 1996;45(3):245–8

The somatostatin analog angiopeptin does not reduce chronic hypoxic pulmonary hypertension in rats. Sidney EJ, et al. **Proc Soc Exp Biol Med** 1996 Oct;213(1):43–9

[Hypoxia and its pharmacological correction: a key problem of anesthesiology and intensive care] Smirnov AV, et al. **Anesteziol Reanimatol** 1997 May–Jun;(3):97–8 **(Rus)**

[Energizing and antihypoxic effects of energostime] Luk'ianova LD, et al. **Biull Eksp Biol Med** 1997 Jun; 123(6):659–62 **(Rus)**

[The protective action of ethomersol in acute hypobaric hypoxia and during the recovery after it] Kosolapov VA, et al. **Eksp Klin Farmakol** 1996 Nov–Dec;59(6):51–3 (Eng. Abstr.) **(Rus)**

[A biochemiluminescent analysis of the pharmacotherapeutic activity of acetylsalicylic acid in combination with quercetin in a hypoxic syndrome] Luk'ianchuk VD, et al. **Eksp Klin Farmakol** 1997 Jan–Feb;60(1):62–4 (Eng. Abstr.) **(Rus)**

[The possible mechanisms of the antioxidant action of calcium channel blockers in the hypoxic syndrome] Savchenko LV, et al. **Eksp Klin Farmakol** 1996 Mar–Apr;59(2):53–5 (Eng. Abstr.) **(Rus)**

[The effect of amtizol on energy metabolism and lipid peroxidation processes in acute hypoxia] Smirnov AV, et al. **Eksp Klin Farmakol** 1996 Sep–Oct;59(5):56–8 (Eng. Abstr.) **(Rus)**

[The combined pharmacological correction of oxidative homeostasis in a hypoxic syndrome] Savchenkova LV. **Lik Sprava** 1996 Mar–Apr;(3–4):117–20 (Eng. Abstr.) **(Rus)**

[Role of glutathione containing amino acids in the correction of body's dysadaptation states] Pavlov VA. **Probl Tuberk** 1997;(3):51–3 (10 ref.) (Eng. Abstr.) **(Rus)**

[Pharmacological correction of lipid peroxidation during hypoxia and possibility to enhance human resistance to high altitude by using preparations of the metabolic type of action] Nagornev SN, et al. **Vestn Ross Akad Med Nauk** 1996;(7):53–60 (Eng. Abstr.) **(Rus)**

[Bio–antioxidant activity of 3,5–di–tert–butylpyrocatechol and its influence on hypoxia, inflammation, pain and burns] Shadyro OI, et al. **Vopr Med Khim** 1997 May–Jun; 43(3):153–7 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Regulation of human endothelial nitric oxide synthase by hypoxia and inflammation in human pulmonary arteries––implications for the therapy of pulmonary hypertension in COPD patients. Ziesche R, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:97–8

Effects of angiotensin II on brain monoamine oxidase activity in non–hypoxic and hypoxic mice. Stancheva S, et al. **Acta Physiol Pharmacol Bulg** 1996;22(1):27–30

Chronic hypoxia enhances expression of catecholamine biosynthesizing enzymes in rat carotid body. Hannhart B, et al. **Adv Exp Med Biol** 1996;410:275–7

A phospholipase C inhibitor impedes the hypoxic ventilatory response in the cat. Pokorski M, et al. **Adv Exp Med Biol** 1996;410:397–403

A cascade of degradative hydrolase activity contributes to hepatocyte necrosis during anoxia. Arora AS, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G238–45

Effects of acute and chronic hypoxia on rat lung cyclooxygenase. Chida M, et al. **Am J Physiol** 1996 May; 270(5 Pt 1):L872–8

Acute hypoxia upregulates NOS gene expression in rats. Gess B, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R905–10

Regulation of ornithine decarboxylase by hypoxia in pulmonary artery smooth muscle cells. Harrod KS, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):L31–7

Regulation of ATP synthase subunit e gene expression by hypoxia: cell differentiation stage–specific control. Levy FH, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C457–65

Inhibition of Na–K–ATPase activity after prolonged hypoxia in an alveolar epithelial cell line. Planès C, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):L70–8

Chronic hypoxia induces LLC–PK1 cell proliferation and dedifferentiation by the activation of protein kinase C. Sahai A, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):F809–15

Hypoxia inhibits the induction of argininosuccinate synthetase by endotoxin in lung endothelial cells. Su Y, et al. **Am J Physiol** 1997 May;272(5 Pt 1):L934–8

Alpha 1–adrenergic stimulation induces cardiac tolerance to hypoxia via induction and activation of Mn–SOD. Yamashita N, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1356–62

Pulmonary artery NADPH–oxidase is activated in hypoxic pulmonary vasoconstriction. Marshall C, et al. **Am J Respir Cell Mol Biol** 1996 Nov;15(5):633–44

Endothelial nitric oxide synthase in hypoxic newborn porcine pulmonary vessels. Hislop AA, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Jul;77(1):F16–22

Role of ICE–like proteases in endothelial cell hypoxic and

reperfusion injury. Harrison-Shostak DC, et al.
Biochem Biophys Res Commun 1997 Feb 24;231(3):844-7
Decreased rat brain cytochrome oxidase activity after prolonged hypoxia. LaManna JC, et al. **Brain Res** 1996 May 13;720(1-2):1-6
Brain cell membrane Na+,K(+)-ATPase activity following severe hypoxic injury in the newborn piglet. Rosenkrantz TS, et al. **Brain Res** 1996 Aug 19;730(1-2):52-7
Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension. Morrell NW, et al. **Cardiovasc Res** 1997 May; 34(2):393-403
Murine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of the brain most susceptible to hypoxic and ischemic injury. Ichimiya S, et al.
DNA Cell Biol 1997 Mar;16(3):311-21
Induction of nitric oxide synthase activity in pulmonary arteries from normoxic and chronically hypoxic rats. Carville C, et al. **Eur Respir J** 1997 Feb;10(2):437-45
Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. Lee PJ, et al. **J Biol Chem** 1997 Feb 28; 272(9):5375-81
Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. Schmedtje JF Jr, et al. **J Biol Chem** 1997 Jan 3;272(1):601-8
Hypoxia-ischemia, but not hypoxia alone, induces the expression of heme oxygenase-1 (HSP32) in newborn rat brain. Bergeron M, et al. **J Cereb Blood Flow Metab** 1997 Jun;17(6):647-58
Hypoxia alters the subcellular distribution of protein kinase C isoforms in neonatal rat ventricular myocytes. Goldberg M, et al. **J Clin Invest** 1997 Jan 1;99(1):55-61
Regulation of inducible nitric oxide synthase expression in IFN-gamma-treated murine macrophages cultured under hypoxic conditions. Melillo G, et al. **J Immunol** 1996 Sep 15;157(6):2638-44
Expression of neuronal nitric oxide synthase corresponds to regions of selective vulnerability to hypoxia-ischaemia in the developing rat brain. Black SM, et al.
Neurobiol Dis 1995 Jun;2(3):145-55
Effects of hypoxia on enzyme activities in skeletal muscle of rats of different ages. An attempt at pharmacological treatment. Pastoris O, et al. **Pharmacol Res** 1995 Dec; 32(6):375-81
[Activity of liver monooxygenase system in rats with low and high resistance to hypoxia] Sharapov VI, et al.
Biull Eksp Biol Med 1996 Sep;122(9):291-4 **(Rus)**

ETIOLOGY

Nonobstetric conditions causing hypoxia during pregnancy: asthma and epilepsy. Coleman MT, et al.
Am J Obstet Gynecol 1997 Jul;177(1):1-7 (34 ref.)
Ins(1,4,5)P3 receptors in cerebral arteries: changes with development and high-altitude hypoxia. Zhou L, et al.
Am J Physiol 1997 Jun;272(6 Pt 2):R1954-9
Passive smoking and airway complications in children [letter; comment] Cole PV, et al. **Anaesthesia** 1997 Apr;52(4):386-7 . Comment on: Anaesthesia 1996 Apr;51(4):324-6.
Intraoperative hypoxia from nitrogen tanks with oxygen fittings. Bernstein DB, et al. **Anesth Analg** 1997 Jan; 84(1):225-7
Hypoxic syncope. Westendorp RG, et al.
Aviat Space Environ Med 1997 May;68(5):410-4
Blocking the endogenous increase in HSP 72 increases susceptibility to hypoxia and reoxygenation in isolated adult feline cardiocytes. Nakano M, et al. **Circulation** 1997 Mar 18;95(6):1523-31
Debunking myths of chronic obstructive lung disease [editorial; comment] Hoyt JW. **Crit Care Med** 1997 Sep; 25(9):1450-1. Comment on: Crit Care Med 1997 Sep;25(9):1522-6.
Endoscopy and hypoxia: an uncomfortable association [editorial] [see comments] Bhatia S.
Indian J Gastroenterol 1996 Apr;15(2):37-9. Comment in: Indian J Gastroenterol 1996 Jul;15(3):114.
Hemodialysis associated hypoxia extends into the post-dialysis period. Dhakal MP, et al.
Int J Artif Organs 1997 Apr;20(4):204-7
Hyperglycemic cytosolic reductive stress 'pseudohypoxia': implications for diabetic retinopathy [letter; comment] Ido Y, et al. **Invest Ophthalmol Vis Sci** 1997 Jul;38(8):1467-70 . Comment on: Invest Ophthalmol Vis Sci 1995 Jul;36(8):1675-85. Comment on: Invest Ophthalmol Vis Sci 1997 Jan;38(1):62-71.
A case of unexplained oxygen desaturation during laparoscopic cholecystectomy. Amayem A, et al.
J Okla State Med Assoc 1996 Apr;89(4):129-30
Right ventricular infundibular beta-adrenoceptor complex in tetralogy of Fallot patients. Sun LS, et al.
Pediatr Res 1997 Jul;42(1):12-6
Automatic garage door openers: hazard for children. Kriel RL, et al. **Pediatrics** 1996 Oct;98(4 Pt 1):770-3
Effect of nicotine exposure on postnatal ventilatory responses to hypoxia and hypercapnia. Bamford OS, et al.
Respir Physiol 1996 Oct;106(1):1-11
An almitrine analog acts as hypoxia in isolated rat lungs. Robineau P, et al. **Respir Physiol** 1996 Sep;105(3):225-33
The rat as a model of chronic recurrent episodic hypoxia and effect upon systemic blood pressure. Fletcher EC, et al. **Sleep** 1996 Dec;19(10 Suppl):S210-2
Carcinoid heart disease with severe hypoxia due to interatrial shunt through patent foramen ovale. Boglioli LR, et al. **Tex Heart Inst J** 1997;24(2):125-8
[Fulminant or sub-fulminant hepatocellular failure caused by metastatic invasiveness of the liver: an other cause of hypoxic hepatitis?] Henrion J, et al.
Gastroenterol Clin Biol 1996;20(6-7):535-43 (38 ref.) (Eng. Abstr.) **(Fre)**
[Pneumological aspects of environmental medicine. Medical relevance of environmental pollution of outdoor air (1)] Hüttemann U. **Z Arztl Fortbild Qualitatssich** 1997 Feb; 91(1):27-30 (Eng. Abstr.) **(Ger)**
[Delayed hypoxia after the surgical correction of femoral neck fracture] Goh R, et al. **Masui** 1996 Nov;45(11):1323-9 (Eng. Abstr.) **(Jpn)**

GENETICS

Evaluation of gene expression in the rat carotid body using the differential display technique. Chen J, et al.
Adv Exp Med Biol 1996;410:119-25
Induction of immediate early response genes by hypoxia. Possible molecular bases for systems adaptation to low pO2. Cherniack NS, et al. **Adv Exp Med Biol** 1996;410:127-34
Regulation of neuronal nitric oxide synthase gene expression by hypoxia. Role of nitric oxide in respiratory adaptation to low pO2. Prabhakar NR, et al. **Adv Exp Med Biol** 1996; 410:345-8
Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Le Cras TD, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):L164-70
Regulation of ATP synthase subunit e gene expression by hypoxia: cell differentiation stage-specific control. Levy FH, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C457-65
Brief hypoxic stress downregulates E. coli-induced IL-1 alpha and IL-1 beta gene expression in perfused liver. Matuschak GM, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1311-8
Determination of xanthine dehydrogenase mRNA by a reverse transcription-coupled competitive quantitative polymerase chain reaction assay: regulation in rat endothelial cells by hypoxia and hyperoxia. Lanzillo JJ, et al. **Arch Biochem Biophys** 1996 Nov 15;335(2):377-80
Inheritance of hypoxic exercise tolerance in mice. McCall RD, et al. **Behav Genet** 1997 May;27(3):181-90
Anoxia regulates gene expression in the central nervous system of Drosophila melanogaster. Ma E, et al.
Brain Res Mol Brain Res 1997 Jun;46(1-2):325-8
Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. Semenza GL, et al. **J Biol Chem** 1996 Dec 20;271(51):32529-37
Nuclear factor interleukin 6 motifs mediate tissue-specific gene transcription in hypoxia. Yan SF, et al.
J Biol Chem 1997 Feb 14;272(7):4287-94
Tyrosine phosphorylation in DNA damage and cell death in hypoxic injury to LLC-PK1 cells. Hagar H, et al.
Kidney Int 1997 Jun;51(6):1747-53
Effects of hypoxia on growth factor expression in the rat kidney in vivo. Krämer BK, et al. **Kidney Int** 1997 Feb; 51(2):444-7
Induction of VEGF and VEGF receptor gene expression by hypoxia: divergent regulation in vivo and in vitro. Sandner P, et al. **Kidney Int** 1997 Feb;51(2):448-53
In vivo carbon monoxide exposure and hypoxic hypoxia stimulate immediate early gene expression. Gess B, et al.
Pflugers Arch 1997 Sep;434(5):568-74

IMMUNOLOGY

Regulation of inducible nitric oxide synthase expression in IFN-gamma-treated murine macrophages cultured under hypoxic conditions. Melillo G, et al. **J Immunol** 1996 Sep 15;157(6):2638-44
The interval between a septic stimulus and hypoxia/reoxygenation affects cytokine elaboration by murine peritoneal macrophages. Arya G, et al.
J Pediatr Surg 1996 Nov;31(11):1469-74

METABOLISM

Endogenous nitric oxide attenuates hypoxic vasoconstriction of small pulmonary arteries and veins in anaesthetized cats. Shirai M, et al. **Acta Physiol Scand** 1997 Mar;159(3):263-4
Ca2+ channel currents in type I carotid body cells from normoxic and chronically hypoxic rats. Carpenter E, et al. **Adv Exp Med Biol** 1996;410:105-8
Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status. Evans SM, et al.
Adv Exp Med Biol 1997;411:215-25
Is cytochrome P-450 involved in hypoxic inhibition of K+ currents in rat type I carotid body cells? Hatton CJ, et al. **Adv Exp Med Biol** 1996;410:89-92
Cyclic nucleotide analogs do not interfere with hypoxic inhibition of K+ currents in isolated rat type I carotid body cells. Hatton CJ, et al. **Adv Exp Med Biol** 1996; 410:93-6
Effect of hypoxic hypoxia on transmural gut and subcutaneous tissue oxygen tension. Suski MD, et al.
Adv Exp Med Biol 1997;411:319-22
Carbon monoxide excretion, not oxygen secretion? Torrance RW. **Adv Exp Med Biol** 1996;410:335-9 (11 ref.)
Ions, channels, and transporters involved in anoxic injury of central nervous system white matter. Stys PK.
Adv Neurol 1996;71:153-63; discussion 163-6
Effects of hypoxia and hyperoxia on lung prostaglandin E1 metabolism. Pisarello JB, et al. **Am J Med Sci** 1997 Mar; 313(3):147-52
Effect of three hours of hypoxia on atrial natriuretic factor gene expression in the ovine fetal heart. Johnson DD, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):42-8
GSH transport and GSH-dependent detoxication in small intestine of rats exposed in vivo to hypoxia. Bai C, et al.
Am J Physiol 1996 Oct;271(4 Pt 1):G701-6
Decreased total ventricular and mitochondrial protein synthesis during extended anoxia in turtle heart. Bailey JR, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1660-7
Cellular energy utilization and supply during hypoxia in embryonic cardiac myocytes. Budinger GR, et al.
Am J Physiol 1996 Jan;270(1 Pt 1):L44-53
Oxygen dependence of mitochondrial function measured by high-resolution respirometry in long-term hypoxic rats. Costa LE, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C852-8
Transport and metabolism of L-glutamate during oxygenation, anoxia, and reoxygenation of rat cardiac myocytes. Dinkelborg LM, et al. **Am J Physiol** 1996 May; 270(5 Pt 2):H1825-32
Hypoxia-induced expression of VEGF is reversible in myocardial vascular smooth muscle cells. Gu JW, et al.
Am J Physiol 1997 Aug;273(2 Pt 2):H628-33
Relationship between anoxia exposure and antioxidant status in the frog Rana pipiens. Hermes-Lima M, et al.
Am J Physiol 1996 Oct;271(4 Pt 2):R918-25
Lactate distribution and metabolism during and after anoxia in the turtle, Chrysemys picta bellii. Jackson DC, et al.
Am J Physiol 1996 Aug;271(2 Pt 2):R409-16
Hypoxia induces PECAM-1 phosphorylation and transendothelial migration of monocytes. Kalra VK, et al.
Am J Physiol 1996 Nov;271(5 Pt 2):H2025-34
Chronic hypoxia and glutathione-dependent detoxication in rat small intestine. LeGrand TS, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):G725-9
Chronic hypoxia, glutathione-dependent detoxication, and metabolic instability in rat small intestine. LeGrand TS, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):G328-34
Influence of hypoxia on endothelin-1 binding sites in neonatal porcine pulmonary vasculature. Noguchi Y, et al.
Am J Physiol 1997 Feb;272(2 Pt 2):H669-78
Effect of chronic hypoxia on K+ channels: regulation in human pulmonary vascular smooth muscle cells. Peng W, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1271-8
Developmental changes in ATP utilization during graded hypoxia and reoxygenation in the heart in vivo. Portman MA, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H216-23
Cytosolic [Ca2+], [Na+], and pH in guinea pig ventricular myocytes exposed to anoxia and reoxygenation. Ralenkotter L, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2679-85
Mechanisms of pHi recovery from NH4Cl-induced acidosis in anoxic isolated turtle heart: a 31P-NMR study. Shi H, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R6-15
Tissue-specific changes in protein synthesis rates in vivo during anoxia in crucian carp. Smith RW, et al.
Am J Physiol 1996 Oct;271(4 Pt 2):R897-904
Neurochemical mechanisms behind gill microcirculatory responses to hypoxia in trout: in vivo microscopy study. Sundin L, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R576-85
Regulation of oxygen diffusion in hypoxic isolated cardiac myocytes. Takahashi E, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1734-8
Hypoxia-reoxygenation increases O2-. efflux which injures endothelial cells by an extracellular mechanism. Terada LS.
Am J Physiol 1996 Mar;270(3 Pt 2):H945-50
Synergistic effect of acidification and hypoxia: in vivo 31P-NMR and respirometric study in fishes. van Ginneken V, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1746-52
Adrenomedullin activity in chronically hypoxic rat lungs. Zhao L, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H622-9
Role of membrane potential in hypoxic inhibition of L-arginine uptake by lung endothelial cells. Zharikov SI, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):L78-84
Ins(1,4,5)P3 receptors in cerebral arteries: changes with development and high-altitude hypoxia. Zhou L, et al.
Am J Physiol 1997 Jun;272(6 Pt 2):R1954-9
Intracellular generation of reactive oxygen species in endothelial cells exposed to anoxia-reoxygenation. Zulueta JJ, et al. **Am J Physiol** 1997 May;272(5 Pt 1):L897-902
Hypoxia increases bromodeoxyuridine labeling indices in bovine neonatal pulmonary arteries. Belknap JK, et al.
Am J Respir Cell Mol Biol 1997 Apr;16(4):366-71
Effect of hypoxia and carbon monoxide on muscle oxygenation during exercise. Maehara K, et al.
Am J Respir Crit Care Med 1997 Jan;155(1):229-35
Michaelis-Menten kinetics model of oxygen consumption by rat brain slices following hypoxia. McGoron AJ, et al.
Ann Biomed Eng 1997 May-Jun;25(3):565-72
Carotid body dopamine content and release by short-term hypoxia: effect of haloperidol and alpha methyl paratyrosine. Basson H, et al. **Arch Physiol Biochem** 1997 Feb;105(1):3-9
Wound hypoxia and acidosis limit neutrophil bacterial killing mechanisms. Allen DB, et al. **Arch Surg** 1997 Sep; 132(9):991-6
Relation of sympathetic activation to ventilation in man at 4300 m altitude. Asano K, et al.
Aviat Space Environ Med 1997 Feb;68(2):104-10
Renal function of substance P in rats chronically exposed

to hypoxia. Chen CF, et al. **Aviat Space Environ Med** 1997 Aug;68(8):705–9

Effect of acute exposure to hypoxia on electrolytes and water metabolism regulatory hormones. De Angelis C, et al. **Aviat Space Environ Med** 1996 Aug;67(8):746–50

Erythropoietin production in healthy volunteers subjected to controlled hypobaric hypoxia: further evidence against a role for adenosine. Gleiter CH, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):203–5

Pharmacological evidence that the activation of the Na(+)–Ca2+ exchanger protects C6 glioma cells during chemical hypoxia. Amoroso S, et al. **Br J Pharmacol** 1997 May;121(2):303–9

Differential presynaptic modulation of noradrenaline release in human atrial tissue in normoxia and anoxia. Münch G, et al. **Br J Pharmacol** 1996 Aug;118(7):1855–61

Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung. Zhao L, et al. **Br J Pharmacol** 1996 Nov;119(6):1217–22

Identification of brainstem neurons responding to hypoxia in fetal and newborn sheep. Breen S, et al. **Brain Res** 1997 Feb 14;748(1–2):107–21

Effects of barbiturates on hypoxic cultures of brain derived microvascular endothelial cells. Fischer S, et al. **Brain Res** 1996 Jan 22;707(1):47–53

The effect of MK–801 on extracellular neuroactive amino acids in hippocampus after closed head injury followed by hypoxia in rats. Katoh H, et al. **Brain Res** 1997 May 30;758(1–2):153–62

Glutamate, glutamine and glutamine synthetase in the neonatal rat brain following hypoxia. Krajnc D, et al. **Brain Res** 1996 Jan 22;707(1):134–7

Alteration in central and peripheral substance P– and neuropeptide Y–like immunoreactivity after chronic hypoxia in the rat. Poncet L, et al. **Brain Res** 1996 Sep 9;733(1):64–72

Identification of calcium channels involved in neuronal injury in rat hippocampal slices subjected to oxygen and glucose deprivation. Small DL, et al. **Brain Res** 1997 Apr 11; 753(2):209–18

Activation of ATP–sensitive potassium channels decreases neuronal injury caused by chemical hypoxia. Wind T, et al. **Brain Res** 1997 Mar 21;751(2):295–9

Distribution of substance P and calcitonin gene–related peptide immunoreactive nerve fibers in the trachea of chronically hypoxic rats. Kusakabe T, et al. **Brain Res Bull** 1996;39(6):335–9

Activation of nitric oxide synthase gene expression by hypoxia in central and peripheral neurons. Prabhakar NR, et al. **Brain Res Mol Brain Res** 1996 Dec 31;43(1–2):341–6

The role of the cyclic AMP–responsive element binding protein (CREB) in hypoxic–ischemic brain damage and repair. Walton M, et al. **Brain Res Mol Brain Res** 1996 Dec 31;43(1–2):21–9

Biochemical adjustments to hypoxia by Amazon cichlids. Almeida–Val VM, et al. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1257–63 (27 ref.)

Oxygen transfer in fish: morphological and molecular adjustments. Val AL. **Braz J Med Biol Res** 1995 Nov–Dec; 28(11–12):1119–27 (53 ref.)

Anoxia and ischemia tolerance in turtle hearts. Wasser JS. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1233–40 (23 ref.)

Oxygen deficit: a measure of the anaerobic energy production during intense exercise? [see comments] Bangsbo J. **Can J Appl Physiol** 1996 Oct;21(5):350–63; discussion 364–9 (26 ref.). Comment in: Can J Appl Physiol 1996 Oct;21(5):347–9.

Oxygen deficit: introduction to the assumptions and the skepticism [comment] Graham TE. **Can J Appl Physiol** 1996 Oct;21(5):347–9 (3 ref.). Comment on: Can J Appl Physiol 1996 Oct;21(5):350–63; discussion 364–9. Comment on: Can J Appl Physiol 1996 Oct;21(5):370–83; discussion 384–8.

Creatine ingestion increases anaerobic capacity and maximum accumulated oxygen deficit. Jacobs I, et al. **Can J Appl Physiol** 1997 Jun;22(3):231–43

Is the maximal accumulated oxygen deficit an adequate measure of the anaerobic capacity? [see comments] Medbø JI. **Can J Appl Physiol** 1996 Oct;21(5):370–83; discussion 384–8 (37 ref.). Comment in: Can J Appl Physiol 1996 Oct;21(5):347–9.

Maximal accumulated oxygen deficit of resistance–trained men. Pizza FX, et al. **Can J Appl Physiol** 1996 Oct; 21(5):391–402

Hypoxia–induced release of prostaglandins: mechanisms and sources of production in coronary resistance vessels of the isolated rabbit heart. Nakhostine N, et al. **Can J Physiol Pharmacol** 1995 Dec;73(12):1742–9

Endogenous adenosine increases O2 utilisation efficiency in isoprenaline–stimulated canine myocardium. Mallet RT, et al. **Cardiovasc Res** 1996 Jan;31(1):102–16

Effect of brief hypoxia on reperfusion arrhythmias and release of Ca2+ by rat heart homogenate blocked by ryanodine. Tani M, et al. **Cardiovasc Res** 1996 Feb;31(2):263–9

The effects of hypoxia on pHi in porcine coronary artery endothelium and smooth muscle. A novel method for measurements in endothelial cells in situ. Foy RA, et al. **Circ Res** 1997 Jan;80(1):21–7

Chronic hypoxia modulates the interleukin–1beta–stimulated inducible nitric oxide synthase pathway in cardiac myocytes. Kacimi R, et al. **Circulation** 1997 Sep 16; 96(6):1937–43

Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia [see comments] Waltenberger J, et al. **Circulation** 1996 Oct 1;94(7):1647–54 . Comment in: Circulation 1996 Oct 1;94(7):1496–8.

Role of nitric oxide and its interaction with superoxide in the suppression of cardiac muscle mitochondrial respiration. Involvement in response to hypoxia/reoxygenation. Xie YW, et al. **Circulation** 1996 Nov 15;94(10):2580–6

The effect of high and low Dk/L soft contact lenses on the glycocalyx layer of the corneal epithelium and on the membrane associated receptors for lectins [see comments] Latkovic S, et al. **CLAO J** 1997 Jul;23(3):185–91. Comment in: CLAO J 1997 Jul;23(3):148.

Energy turnover in the normoxic and anoxic turtle heart. Arthur PG, et al. **Comp Biochem Physiol A Physiol** 1997 May;117(1):121–6

Peripheral chemosensitivity and central integration: neuroplasticity of catecholaminergic cells under hypoxia. Soulier V, et al. **Comp Biochem Physiol A Physiol** 1997 Sep;118(1):1–7

Effects of anoxia on intracellular free Ca2+ in isolated cardiomyocytes from turtles. Wasser JS, et al. **Comp Biochem Physiol A Physiol** 1997 Apr;116(4):305–12

Metabolic adaptations supporting anoxia tolerance in reptiles: recent advances. Storey KB. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):23–35 (92 ref.)

Brain parenchyma PO2, PCO2, and pH during and after hypoxic, ischemic brain insult in dogs. McKinley BA, et al. **Crit Care Med** 1996 Nov;24(11):1858–68

Extracellular acidosis delays cell death against glucose–oxygen deprivation in neuroblastoma x glioma hybrid cells. Morimoto Y, et al. **Crit Care Med** 1997 May; 25(5):841–7

Energy metabolism in liver of anoxia–tolerant turtle species (Pseudemys scripta): a model for studying hepatic tolerance to cold hypoxia. Churchill TA, et al. **Cryobiology** 1997 Aug;35(1):14–9

New aspects of lactate metabolism: IGF–I and insulin regulate mitochondrial function in cultured brain cells during normoxia and hypoxia. Sonnewald U, et al. **Dev Neurosci** 1996;18(5–6):443–8

Astrocyte glucose metabolism under normal and pathological conditions in vitro. Swanson RA, et al. **Dev Neurosci** 1996; 18(5–6):515–21

Atrial natriuretic factor (ANF) and ANF receptor C gene expression and localization in the respiratory system: effects induced by hypoxia and hemodynamic overload. Di Nardo P, et al. **Endocrinology** 1996 Oct;137(10):4339–50

Anoxia–induced gene expression in turtle heart. Upregulation of mitochondrial genes for NADH–ubiquinone oxidoreductase subunit 5 and cytochrome c oxidase subunit 1. Cai Q, et al. **Eur J Biochem** 1996 Oct 1;241(1):83–92

Tissue hypoxia in ipsilateral and contralateral testes undergoing surgically induced maldescent. Karnak I, et al. **Eur J Pediatr Surg** 1996 Oct;6(5):281–4

Effect of aescine on hypoxia–induced activation of human endothelial cells. Arnould T, et al. **Eur J Pharmacol** 1996 Nov 14;315(2):227–33

The vein utilizes different sources of energy than the artery during pulmonary hypoxic vasoconstriction. Zhao Y, et al. **Exp Lung Res** 1996 Jan–Feb;22(1):51–63

Production of hydroxyl radical in the hippocampus after CO hypoxia or hypoxic hypoxia in the rat. Piantadosi CA, et al. **Free Radic Biol Med** 1997;22(4):725–32

A novel RNA species from the turtle mitochondrial genome: induction and regulation of transcription and processing under anoxic and freezing stresses. Cai Q, et al. **Genome** 1997 Aug;40(4):534–43

VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF–overexpressing human tumor cell lines. White FC, et al. **Growth Factors** 1995; 12(4):289–301

Behavioral strategy and the physiological stress response in rainbow trout exposed to severe hypoxia. van Raaij MT, et al. **Horm Behav** 1996 Mar;30(1):85–92

Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodeling in the hypoxic rat. Xue C, et al. **Hypertension** 1996 Nov; 28(5):743–53

Biochemical and biomolecular aspects of oxidative stress due to acute and severe hypoxia in human muscle tissue. Corbucci GG, et al. **Int J Tissue React** 1995;17(3):125–7

Metabolic aspects of cardiac and skeletal muscle tissues in the condition of hypoxia, ischaemia and reperfusion induced by extracorporeal circulation. Corbucci GG, et al. **Int J Tissue React** 1995;17(5–6):219–25

Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Takagi H, et al. **Invest Ophthalmol Vis Sci** 1996 Oct;37(11):2165–76

Rise in cytosolic Ca2+ and collapse of mitochondrial potential in anoxic, but not hypoxic, rat proximal tubules. Peters SM, et al. **J Am Soc Nephrol** 1996 Nov;7(11):2348–56

Atrial natriuretic peptide levels and plasma volume contraction in acute alveolar hypoxia. Albert TS, et al. **J Appl Physiol** 1997 Jan;82(1):102–10

Acute alveolar hypoxia increases blood–to–tissue albumin transport: role of atrial natriuretic peptide. Albert TS, et al. **J Appl Physiol** 1997 Jan;82(1):111–7

Hormonal and metabolic adjustments during exercise in hypoxia or normoxia in highland natives. Favier R, et al. **J Appl Physiol** 1996 Feb;80(2):632–7

Ventilatory and metabolic responses to ambient hypoxia or hypercapnia in rats exposed to CO hypoxia. Gautier H, et al. **J Appl Physiol** 1997 Jul;83(1):253–61

Sherpa brain glucose metabolism and defense adaptations against chronic hypoxia. Hochachka PW, et al. **J Appl Physiol** 1996 Sep;81(3):1355–61

Decreased energy metabolism in brain stem during central respiratory depression in response to hypoxia. LaManna JC, et al. **J Appl Physiol** 1996 Oct;81(4):1772–7

Hypoxia in vivo inhibits aldosterone synthesis and aldosterone synthase mRNA in rats. Raff H, et al. **J Appl Physiol** 1996 Aug;81(2):604–10

Effect of 2,4–dinitrophenol on the hypometabolic response to hypoxia of conscious adult rats. Saiki C, et al. **J Appl Physiol** 1997 Aug;83(2):537–42

Activation of hypoxia–inducible factor–1; definition of regulatory domains within the alpha subunit. Pugh CW, et al. **J Biol Chem** 1997 Apr 25;272(17):11205–14

ATP–sensitive potassium channels in isolated rat aorta during physiologic, hypoxic, and low–glucose conditions. Hüsken BC, et al. **J Cardiovasc Pharmacol** 1997 Jan;29(1):130–5

Hypoxia primes endotoxin–induced tissue factor expression in human monocytes and endothelial cells by a PAF–dependent mechanism. Herbert JM, et al. **J Cell Physiol** 1996 Nov;169(2):290–9

Hypoxic–ischemic injury induces monocyte chemoattractant protein–1 expression in neonatal rat brain. Ivacko J, et al. **J Cereb Blood Flow Metab** 1997 Jul;17(7):759–70

Protein synthesis under conditions of anoxia and changing workload in ventricle strips from turtle heart. Bailey JR, et al. **J Exp Zool** 1997 Aug 1;278(5):273–82

Relationship between cellular ATP content and cellular functions of primary cultured rat hepatocytes in hypoxia. Hayashi K, et al. **J Gastroenterol Hepatol** 1997 Mar; 12(3):249–56

Hypoxia attenuates metabolism of platelet activating factor by fetal and newborn lamb lungs. Salva AM, et al. **J Lipid Res** 1996 Apr;37(4):783–9

KATP channel activation in a rabbit model of chronic myocardial hypoxia. Baker JE, et al. **J Mol Cell Cardiol** 1997 Feb;29(2):845–8

Beneficial effects of a nitric oxide donor on recovery of contractile function following brief hypoxia in isolated rat heart. Draper NJ, et al. **J Mol Cell Cardiol** 1997 Apr; 29(4):1195–205

The role of Na+–H+ exchange occurring during hypoxia in the genesis of reoxygenation–induced myocardial oedema. Inserte J, et al. **J Mol Cell Cardiol** 1997 Apr; 29(4):1167–75

Hypoxia–induced alterations in cytoskeleton coincide with collagenase expression in cultured neonatal rat cardiomyocytes. VanWinkle WB, et al. **J Mol Cell Cardiol** 1995 Dec;27(12):2531–42

Exposure of astrocytes to hypoxia/reoxygenation enhances expression of glucose–regulated protein 78 facilitating astrocyte release of the neuroprotective cytokine interleukin 6. Hori O, et al. **J Neurochem** 1996 Mar; 66(3):973–9

Increased calcium current in carotid body glomus cells following in vivo acclimatization to chronic hypoxia. Hempleman SC. **J Neurophysiol** 1996 Sep;76(3):1880–6

The effect of isoflurane on biochemical changes during and electrophysiological recovery after anoxia in rat hippocampal slices. Kass IS, et al. **J Neurosurg Anesthesiol** 1997 Jul;9(3):280–6

Acute alterations in [Ca2+]i in NG108–15 cells subjected to high strain rate deformation and chemical hypoxia: an in vitro model for neural trauma. Cargill RS 2nd, et al. **J Neurotrauma** 1996 Jul;13(7):395–407

Effect of nifedipine on the elimination of theophylline in the rabbit subjected to hypoxia or to an inflammatory reaction. Barakat M, et al. **J Pharm Pharmacol** 1996 Sep;48(9):906–10

Detection of platinum in the brain of mice treated with cisplatin and subjected to short–term hypoxia. Minami T, et al. **J Pharm Pharmacol** 1996 May;48(5):505–9

Substance P receptors in brain stem respiratory centers of the rat: regulation of NK1 receptors by hypoxia. Mazzone SB, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1547–56

Neurones in the ventrolateral pons are required for post–hypoxic frequency decline in rats. Coles SK, et al. **J Physiol (Lond)** 1996 Nov 15;497 (Pt 1):79–94

The role of nitric oxide synthesis in cardiovascular responses to acute hypoxia in the late gestation sheep fetus. Green LR, et al. **J Physiol (Lond)** 1996 Nov 15;497 (Pt 1):271–7

Evaluation of purine nucleotide loss, lipid peroxidation and ultrastructural alterations in post–hypoxic hepatocytes. Grune T, et al. **J Physiol (Lond)** 1997 Jan 15;498 (Pt 2):511–22

Hypoxia increases persistent sodium current in rat ventricular myocytes. Ju YK, et al. **J Physiol (Lond)** 1996 Dec 1;497 (Pt 2):337–47

Contrasting effects of hypoxia on cytosolic Ca2+ spikes in conduit and resistance myocytes of the rabbit pulmonary artery. Ureña J, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):103–9

Hypoxia induces intercellular adhesion molecule–1 on cultured human tubular cells. Combe C, et al. **Kidney Int** 1997 Jun;51(6):1703–9

Modulation of hypoxia–induced calpain activity in rat renal

proximal tubules. Edelstein CL, et al. **Kidney Int** 1996 Oct; 50(4):1150–7

Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism. Orphanides C, et al. **Kidney Int** 1997 Sep;52(3):637–47

Purine nucleotide cycle in rat renal cortex and medulla under conditions that mimic normal and low oxygen supply. Stepinski J, et al. **Kidney Int** 1996 Oct;50(4):1195–201

The effects of propofol on cerebral high energy metabolites, lactate, and glucose in normoxic and severely hypoxic rats. Ori C, et al. **Life Sci** 1997;60(16):1349–57

Evolution of dopamine receptors in the rat after neonatal hypoxia-ischemia: autoradiographic studies. Zouakia A, et al. **Life Sci** 1997;60(2):151–62

The effects of lidocaine and hypoxia on phospholipid biosynthesis in the isolated hamster heart. Wong JT, et al. **Lipids** 1996 Oct;31(10):1059–67

Cerebral hypoxia-ischemia increases microsomal iron in newborn piglets. Adcock LM, et al. **Metab Brain Dis** 1996 Dec;11(4):359–67

Nonexocytotic noradrenaline release induced by pharmacological agents or anoxia in human cardiac tissue. Kurz T, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jun;354(1):7–16

Neuropeptide Y and somatostatin immunoreactivity in the rat hippocampus after moderate hypoxia. Schwarzer C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jun; 354(1):67–71

Role of nitric oxide and superoxide balance in hypoxia-reoxygenation proximal tubular injury. Yaqoob M, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1738–42 (34 ref.)

Role of nitric oxide and superoxide balance in hypoxia-reoxygenation proximal tubular injury. Yaqoob M, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1743–6 (34 ref.)

Cytokine contribution to the repair processes and homeostasis recovery following anoxic insult: a possible IFN-gamma-regulating role in IL-1beta neurotoxic action in physiological or damaged CNS. Pellegrini P, et al. **Neuroimmunomodulation** 1996 Jul–Aug;3(4):213–8

Alpha 2-adrenergic agonists reduce glutamate release and glutamate receptor-mediated calcium changes in hippocampal slices during hypoxia. Bickler PE, et al. **Neuropharmacology** 1996 Jun;35(6):679–87

Cell culture studies of the role of elevated extracellular glutamate and K+ in neuronal cell death during and after anoxia/ischemia. Huang R, et al. **Neurosci Biobehav Rev** 1997 Mar;21(2):129–34 (26 ref.)

Development of GABA and calcium binding proteins immunoreactivity in the rat hippocampus following neonatal anoxia. Dell'Anna E, et al. **Neurosci Lett** 1996 Jun 21;211(2):93–6

Nitric oxide modulates synaptic glutamate release during anoxia. Katchman AN, et al. **Neurosci Lett** 1997 May 30; 228(1):50–4

Chronic hypoxia induces modification of the N-methyl-D-aspartate receptor in rat brain. Pichiule P, et al. **Neurosci Lett** 1996 Nov 1;218(2):83–6

Hypoxia decreases opioid delta receptor expression in mouse brain. Mayfield KP, et al. **Neuroscience** 1996 Jun; 72(3):785–9

Elemental composition and water content of rat optic nerve myelinated axons during in vitro post-anoxia reoxygenation. Stys PK, et al. **Neuroscience** 1996 Aug; 73(4):1081–90

Prenatal cocaine exposure and postnatal hypoxia independently decrease carotid body dopamine in neonatal rats. Lipton JW, et al. **Neurotoxicol Teratol** 1996 May–Jun; 18(3):283–7

Effects of hypoxia and hypercapnia on contact lens-induced corneal acidosis. Rivera RK, et al. **Optom Vis Sci** 1996 Mar;73(3):178–83

Age dependence of tolerance to anoxia and changes in cytosolic calcium in rabbit renal proximal tubules. Constantinescu AR, et al. **Pediatr Nephrol** 1996 Oct; 10(5):606–12

The biphasic ventilatory response to hypoxia in preterm infants is not due to a decrease in metabolism. Rehan V, et al. **Pediatr Pulmonol** 1996 Nov;22(5):287–94

Increased levels of lipid peroxidation products malondialdehyde and 4-hydroxynonenal after perinatal hypoxia. Schmidt H, et al. **Pediatr Res** 1996 Jul;40(1):15–20

Long-term impairment in the neurochemical activity of the sympathoadrenal system after neonatal hypoxia in the rat. Soulier V, et al. **Pediatr Res** 1997 Jul;42(1):30–8

Right ventricular infundibular beta-adrenoceptor complex in tetralogy of Fallot patients. Sun LS, et al. **Pediatr Res** 1997 Jul;42(1):12–6

ANP gene expression in rat hearts during hypoxia. Pfeifer M, et al. **Pflugers Arch** 1997 May;434(1):63–9

Hypoxia and cobalt stimulate vascular endothelial growth factor receptor gene expression in rats. Sandner P, et al. **Pflugers Arch** 1997 Apr;433(6):803–8

Gluconeogenesis during hypoxia in vascular smooth muscle studied by 13C-NMR. Hardin CD, et al. **Physiol Res** 1995; 44(4):257–60

Molecular aspects of regulation of cardiac contraction. Pelouch V. **Physiol Res** 1995;44(1):53–60 (63 ref.)

Production of hydrogen peroxide by alveolar macrophages from rats exposed to subacute and chronic hypoxia. Wilhelm J, et al. **Physiol Res** 1996;45(3):185–91

Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery. Lyall F, et al. **Placenta** 1997 May;18(4):269–76

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Iliopoulos O, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10595–9

The influence of nicardipine and ifenprodil on the brain free arachidonic acid level and behavior in hypoxia-exposed rats. Erakovic V, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 May; 21(4):633–47

Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime. Azuma C, et al. **Radiat Res** 1997 Jul;148(1):35–42

Susceptibility of human proximal tubular cells to hypoxia: effect of hypoxic preconditioning and comparison to glomerular cells. Turman MA, et al. **Ren Fail** 1997 Jan; 19(1):47–60

Prematurity alters hypoxic and hypercapnic ventilatory responses in developing lambs. Davey MG, et al. **Respir Physiol** 1996 Aug;105(1–2):57–67

Hypoxic constrictor response in the isolated pulmonary artery from chronically hypoxic rats. Karamsetty VS, et al. **Respir Physiol** 1996 Aug;105(1–2):85–93

In vitro responses of VLM neurons to hypoxia after normobaric hypoxic acclimatization. Nolan PC, et al. **Respir Physiol** 1996 Aug;105(1–2):23–33

Hypoxia depletes ascorbate in the cat carotid body. Pokorski M, et al. **Respir Physiol** 1997 Mar;107(3):213–8

Respiratory responses to rapid-onset, repetitive vs. continuous hypoxia in piglets. Waters KA, et al. **Respir Physiol** 1996 Aug;105(1–2):135–42

Potentiation of oxygen-glucose deprivation-induced neuronal death after induction of iNOS. Hewett SJ, et al. **Stroke** 1996 Sep;27(9):1586–91

Vasopressin and oxytocin release during prolonged environmental hypoxia in the rat. Kelestimur H, et al. **Thorax** 1997 Jan;52(1):84–8

Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. Closse C, et al. **Thromb Res** 1997 Jan 15;85(2):159–64

Hypoxic effects on cholesterol metabolism of cultured rat aortic and brain microvascular endothelial cells, and aortic vascular smooth muscle cells. Arai Y, et al. **Tohoku J Exp Med** 1996 Sep;180(1):17–25

Hypoxia, but not reoxygenation, induces interleukin 6 gene expression through NF-kappa B activation. Muraoka K, et al. **Transplantation** 1997 Feb 15;63(3):466–70

[Oxygen pressure distribution in lymph node metastases and the changes during acute respiratory hypoxia] Strnad V, et al. **Strahlenther Onkol** 1997 May;173(5):267–71 (Eng. Abstr.) **(Ger)**

[Neural activity and energy metabolism of brain slices--survival period of neurons during deprivation of oxygen and/or glucose] Okada Y. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):65–71 (7 ref.) **(Jpn)**

[Hypoxic changes in metabolism and effectiveness of therapy of surgical sepsis in children] Mironov PI, et al. **Anesteziol Reanimatol** 1996 Nov–Dec;(6):59–60 (Eng. Abstr.) **(Rus)**

[The intensity of respiration in pea and corn seedlings under high-altitude hypoxia] Astafurova TP, et al. **Aviakosm Ekolog Med** 1996;30(3):35–9 (Eng. Abstr.) **(Rus)**

[Effects of a hypoxic stimulus on the dependence of tissue respiration on oxygen pressure in vitro] Ibraimova GI. **Aviakosm Ekolog Med** 1997;31(2):32–7 (Eng. Abstr.) **(Rus)**

[Biochemical evaluation of various respiration conditions during simulation of extended flight] Nagornev SN, et al. **Aviakosm Ekolog Med** 1996;30(2):20–6 (Eng. Abstr.) **(Rus)**

[Comparative study of lipid peroxidation indicators in the heart, liver and brain of rats with varying resistance to hypoxia] Khachatur'ian ML, et al. **Biull Eksp Biol Med** 1996 Feb;121(2):138–43 **(Rus)**

[Interaction between lipid peroxides, the antioxidant system, and levels of cyclic AMP and cyclic GMP in hypoxic and hyperthermic animals] Savchenkova LV. **Ukr Biokhim Zh** 1995 Nov–Dec;67(6):102–5 (Eng. Abstr.) **(Rus)**

[Pharmacological correction of lipid peroxidation during hypoxia and possibility to enhance human resistance to high altitude by using preparations of the metabolic type of action] Nagornev SN, et al. **Vestn Ross Akad Med Nauk** 1996;(7):53–60 (Eng. Abstr.) **(Rus)**

[Changes in glycolipid level in the brain of rats with different resistance to hypoxia during acclimation to cold] Kozulina LE, et al. **Vopr Med Khim** 1996 Apr–Jun;42(2):141–3 (Eng. Abstr.) **(Rus)**

[The critical pressure of oxygen] Rosenmann M. **Arch Biol Med Exp (Santiago)** 1987;20(1):75–8 (Eng. Abstr.) **(Spa)**

[The effect of hypoxic hypoxia on energy metabolism in the liver mitochondria and the acetylcholine content of different tissues] Doliba MM, et al. **Fiziol Zh** 1996; 42(5–6):45–50 (Eng. Abstr.) **(Ukr)**

PATHOLOGY

Transient cerebral ischaemia in Mongolian gerbils pre-exposed to hypoxia. Kobayashi H, et al. **Acta Neurochir (Wien)** 1997;139(7):678–83

Early ultrastructural changes after brief histotoxic hypoxia in cultured cortical and hippocampal CA1 neurons. Dux E, et al. **Acta Neuropathol (Berl)** 1996 Dec;92(6):541–4

Ultrastructural concomitants of hypoxia-induced angiogenesis. Stewart PA, et al. **Acta Neuropathol (Berl)** 1997 Jun;93(6):579–84

Adequacy of cerebral vascular remodeling following three weeks of hypobaric hypoxia. Examined by an integrated composite analytical model. Lauro KL, et al. **Adv Exp Med Biol** 1997;411:369–76

A cascade of degradative hydrolase activity contributes to hepatocyte necrosis during anoxia. Arora AS, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G238–45

Cellular energy utilization and supply during hypoxia in embryonic cardiac myocytes. Budinger GR, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):L44–53

Loss of cytoskeletal support is not sufficient for anoxic plasma membrane disruption in renal cells. Chen J, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1319–28

Unopposed phosphatase action initiates ezrin dysfunction: a potential mechanism for anoxic injury. Chen J, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C710–6

Chronic hypoxia induces LLC-PK1 cell proliferation and dedifferentiation by the activation of protein kinase C. Sahai A, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):F809–15

Distinct effect of hypoxia on endothelial cell proliferation and cycling. Tucci M, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1700–8

Pulmonary artery smooth muscle cells from chronically hypoxic neonatal calves retain fetal-like and acquire new growth properties. Xu Y, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):L234–45

Hypoxic-ischaemic encephalopathy: MRI findings [letter; comment] Pilling D, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 Jul;77(1):F78–9. Comment on: Arch Dis Child Fetal Neonatal Ed 1996 Nov;75(3):F145–51.

Hypoxic pretreatment protects against neuronal damage of the rat hippocampus induced by severe hypoxia. Gorgias N, et al. **Brain Res** 1996 Apr 1;714(1–2):215–25

Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia, and excitatory amino acids in murine cortical cultures. Regan RF, et al. **Brain Res** 1997 Aug 1;764(1–2):133–40

Activation of ATP-sensitive potassium channels decreases neuronal injury caused by chemical hypoxia. Wind T, et al. **Brain Res** 1997 Mar 21;751(2):295–9

Cardiorespiratory and renal responses to arterial chemoreceptor stimulation by hypoxia or almitrine in men. Brauer H, et al. **Clin Exp Pharmacol Physiol** 1996 Dec; 23(12):1021–7

Hypoxic and excitotoxic damage to cultured rat retinal ganglion cells. Kitano S, et al. **Exp Eye Res** 1996 Jul; 63(1):105–12

Anoxia-induced neuronal injury: role of Na+ entry and Na+-dependent transport. Chidekel AS, et al. **Exp Neurol** 1997 Aug;146(2):403–13

Myocardium-protective effects of Ginkgo biloba extract (EGb 761) in old rats against acute isobaric hypoxia. An electron microscopic morphometric study. I. Protection of cardiomyocytes. Fitzl G, et al. **Exp Toxicol Pathol** 1996 Jan;48(1):33–9

Myocardium-protective effects of Ginkgo biloba extract (EGb 761) in old rats against acute isobaric hypoxia. An electron microscopic morphometric study. II. Protection of microvascular endothelium. Welt K, et al. **Exp Toxicol Pathol** 1996 Jan;48(1):81–6

A histopathological study of anoxic-resuscitated liver allografts. Jurado F, et al. **Histol Histopathol** 1997 Jan; 12(1):123–33

Development of vulnerability to hypoxic damage in in vitro hippocampal neurons. Di Loreto S, et al. **Int J Dev Neurosci** 1997 Apr;15(2):225–30

Sensitivity of murine haemopoietic stem cell populations to X-rays and 1 MeV fission neutrons in vitro and in vivo under hypoxic conditions. Meijne EI, et al. **Int J Radiat Biol** 1996 Nov;70(5):571–7

Alterations in structure of elastic laminae of rat pulmonary arteries in hypoxic hypertension. Liu SQ. **J Appl Physiol** 1996 Nov;81(5):2147–55

Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line. Shen Y, et al. **J Biol Chem** 1997 Feb 7;272(6):3550–3

Preservation of phosphagen kinase function during transient hypoxia via enzyme abundance or resistance to oxidative inactivation. Dykens JA, et al. **J Comp Physiol [B]** 1996; 166(6):359–68

Ultrastructural changes in cerebral cortical blood vessels of immature and adult rats after a single episode of neonatal hypoxia. Zhang HF, et al. **J Hirnforsch** 1997;38(1):81–97

Carotid artery and jugular vein ligation with and without hypoxia in the rat. Klein MD, et al. **J Pediatr Surg** 1997 Apr;32(4):565–70

Effects of exposure to hypobaric-hypoxia on body weight, muscular and hematological characteristics, and work performance in rats. Tanaka M, et al. **Jpn J Physiol** 1997 Feb;47(1):51–7

Tyrosine phosphorylation in DNA damage and cell death in hypoxic injury to LLC-PK1 cells. Hagar H, et al. **Kidney Int** 1997 Jun;51(6):1747-53

Involvement of nitric oxide in the deregulation of cytosolic calcium in cerebellar neurons during combined glucose-oxygen deprivation. Mei JM, et al. **Mol Chem Neuropathol** 1996 Feb;27(2):155-66

Rapid alterations in dendrite morphology during sublethal hypoxia or glutamate receptor activation. Park JS, et al. **Neurobiol Dis** 1996;3(3):215-27

Apoptosis and necrosis in the newborn piglet brain following transient cerebral hypoxia-ischaemia. Yue X, et al. **Neuropathol Appl Neurobiol** 1997 Feb;23(1):16-25

Nuclear condensation and fragmentation following cerebral hypoxia-ischemia occurs more frequently in immature than older rats. Sidhu RS, et al. **Neurosci Lett** 1997 Feb 21; 223(2):129-32

Pulmonary, vascular responses in rats exposed to chronic hypobaric hypoxia at two different altitude levels. Nakanishi K, et al. **Pathol Res Pract** 1996 Oct; 192(10):1057-67

Brain injury after perinatal hypoxia-ischemia is exacerbated in copper/zinc superoxide dismutase transgenic mice. Ditelberg JS, et al. **Pediatr Res** 1996 Feb;39(2):204-8

Time course of lung growth following exposure to hypobaria and/or hypoxia in rats. Sekhon HS, et al. **Respir Physiol** 1996 Sep;105(3):241-52

Lung morphometric changes after exposure to hypobaria and/or hypoxia and undernutrition. Sekhon HS, et al. **Respir Physiol** 1996 Oct;106(1):99-107

Potentiation of oxygen-glucose deprivation-induced neuronal death after induction of iNOS. Hewett SJ, et al. **Stroke** 1996 Sep;27(9):1586-91

Selective N-type calcium channel antagonist omega conotoxin MVIIA is neuroprotective against hypoxic neurodegeneration in organotypic hippocampal-slice cultures. Pringle AK, et al. **Stroke** 1996 Nov;27(11):2124-30

[Ultrastructure of the sympathetic ganglia in hypoxia] Chairkin IN, et al. **Arkh Patol** 1997 Jan-Feb;59(1):46-50 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Metabolic, ventilatory and circulatory effects of doxapram in anaesthetized pigs during normoxia and hypoxia. Björk L, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):919-26

Reduced hypoxic chemosensitivity in partially paralysed man. A new property of muscle relaxants? Eriksson LI. **Acta Anaesthesiol Scand** 1996 May;40(5):520-3

Impact of reoxygenation with oxygen and air on the extent of the brain damage after hypoxia-ischaemia in neonatal rats. Bågenholm R, et al. **Acta Paediatr** 1996 Oct; 85(10):1228-31

Hypoxia-ischaemia model in the 7-day-old rat: possibilities and shortcomings. Hagberg H, et al. **Acta Paediatr Suppl** 1997 Jul;422:85-8 (48 ref.)

Long-lasting treatment with adenosine receptor antagonists: effects on hypoxic tolerance and vascular responsiveness. Cseppentö A, et al. **Acta Physiol Hung** 1996;84(3):275-6

Different reactivity of two rabbit vessels under hypoxia. Kriška M, et al. **Acta Physiol Hung** 1995;83(3):249-57

The effect of chronic diazepam treatment on hypoxia-induced alterations in functional activity of guinea pig myocardium. Ujfalusi A, et al. **Acta Physiol Hung** 1996; 84(3):345-6

The energetics of the quiescent heart muscle: high potassium cardioplegic solution and the influence of calcium and hypoxia on the rat heart. Marquez MT, et al. **Acta Physiol Scand** 1997 Jul;160(3):229-33

Maximal muscle activation is not limited by pulmonary ventilation in chronic hypoxia. Savard GK, et al. **Acta Physiol Scand** 1996 Jun;157(2):187-90

Adrenalectomy reduces the ability of newborn rats to gasp and survive anoxia. Yuan SZ, et al. **Acta Physiol Scand** 1997 Apr;159(4):285-92

PO2 affinities, heme proteins, and reactive oxygen intermediates involved in intracellular signal cascades for sensing oxygen. Acker H. **Adv Exp Med Biol** 1996; 410:59-64 (36 ref.)

Role of potassium channels in hypoxic chemoreception in rat carotid body type-I cells. Buckler KJ. **Adv Exp Med Biol** 1996;410:83-7

Role of carotid bodies in the guinea-pig. Cragg PA, et al. **Adv Exp Med Biol** 1996;410:377-81

The changes of skin and mesenteric microvascular permeability in adaptation to hypoxia in rats. Dubina MV, et al. **Adv Exp Med Biol** 1996;388:363-6

The role of carotid body CO2 during ventilatory acclimatization to hypoxia in the goat. Dwinell MR, et al. **Adv Exp Med Biol** 1996;410:387-90

The presynaptic component of a cholinergic mechanism in the carotid body chemotransduction of hypoxia in the cat. Fitzgerald RS, et al. **Adv Exp Med Biol** 1996;410:245-52

Modulation of voltage-gated Ca2+ channels by O2 tension. Significance for arterial oxygen chemoreception. Franco-Obregón A, et al. **Adv Exp Med Biol** 1996; 410:97-103 (283 ref.)

Chemoreceptors in autonomic responses to hypoxia in conscious rats. Hayashida Y, et al. **Adv Exp Med Biol** 1996; 410:439-42

Augmented ventilatory response to sustained normocapnic hypoxia following 100% O2 breathing in humans. Honda Y, et al. **Adv Exp Med Biol** 1996;410:371-5

Effects of continuous intracarotid infusion of dopamine during long-term hypoxia in awake goats. Janssen PL, et al. **Adv Exp Med Biol** 1996;410:383-6

Afferent input from peripheral chemoreceptors in response to hypoxia and amino acid neurotransmitter generation in the medulla. Kazemi H, et al. **Adv Exp Med Biol** 1996; 410:365-9

Mitochondrial division, blood vessel dilation, and large intercellular space expansion of goat carotid body during hypoxia. Xue D, et al. **Adv Exp Med Biol** 1996;410:55-8

Significance of endothelium-derived relaxing factor (EDRF) on pulmonary vasoconstriction induced by hypoxia and hypercapnia. Yamaguchi K, et al. **Adv Exp Med Biol** 1996; 388:473-81

Domperidone as a tool to assess the role of dopamine within carotid body chemoreception. Zapata P, et al. **Adv Exp Med Biol** 1996;410:291-7 (36 ref.)

Augmentation of hypoxic pulmonary vasoconstriction by N(G)-L-methyl-arginine in a rabbit model of thermal injury. Mayers I, et al. **Am J Emerg Med** 1996 Nov; 14(7):629-34

Fetal heart rate patterns in growth-restricted fetal sheep induced by chronic fetal placental embolization. Murotsuki J, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):282-90

Endothelium-derived nitric oxide mediates hypoxic vasodilation of resistance vessels in humans. Blitzer ML, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1182-5

Role of the nitric oxide pathway in hypoxia-induced hypothermia of rats. Branco LG, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R967-71

Role of nitric oxide in hypoxia-induced colonic dysfunction in the neonatal rat. Brown JF, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):G760-9

Unopposed phosphatase action initiates ezrin dysfunction: a potential mechanism for anoxic injury. Chen J, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C710-6

Time course of the human pulmonary vascular response to 8 hours of isocapnic hypoxia. Dorrington KL, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1126-34

Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Eddahibi S, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1173-81

Development of cardiovascular responses to hypoxia in larvae of the frog Xenopus laevis. Fritsche R, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R912-7

Endothelin receptor changes in hypoxia-induced pulmonary hypertension in the newborn piglet. Gosselin R, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):L72-9

Effect of carbon dioxide on autonomic cardiovascular responses to systemic hypoxia in conscious rats. Hirakawa H, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R747-54

Hypoxia compared with normoxia alters the effects of nitric oxide in ischemia-reperfusion lung injury. Huang YC, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):L504-12

Atrial natriuretic peptide expression in rats with different pulmonary hypertensive responses to hypoxia. Klinger JR, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H411-7

Hypoxia and the cardiovascular response to dynamic knee-extensor exercise. Koskolou MD, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2655-63

Action potentials in right and left ventricles from chronic hypoxic rats: effect of almitrine. Kreher P, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1856-63

Cerebral arteriolar dilation to hypoxia: role of prostanoids. Leffler CW, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H418-24

Autoregulation of myocardial glycogen concentration during intermittent hypoxia. McNulty PH, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):R311-9

Functional response to graded increases in renal nerve activity during hypoxia in conscious rabbits. Malpas SC, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1489-99

Frequency and amplitude of sympathetic discharges by baroreflexes during hypoxia in conscious rabbits. Malpas SC, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2563-74

Integration of vascular, contractile and metabolic responses to hypoxia: effects of maturation and adenosine. Matherne GP, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):R895-905

Microheterogeneity of myocardial blood flow in rabbit hearts during normoxic and hypoxic states. Matsumoto T, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):H435-41

Effects of hypoxia and hypercapnia on patterns of sleep-associated apnea in elephant seal pups. Milsom W, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R1017-24

Effects of charybdotoxin on responses to nitrosovasodilators and hypoxia in the rat lung. Nossaman BD, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):L787-91

Adaptation of cardiac myosin and creatine kinase to chronic hypoxia: role of anorexia and hypertension. Pissarek M, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1690-5

Hypoxic pHi and function modulation by Na+/H+ exchange and alpha-adrenoreceptor inhibition in heart in vivo. Portman MA, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2664-70

Effect of exposure to hypoxia from birth on aldosterone in rabbits: role of unesterified fatty acids. Raff H, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1084-7

Endothelial-borne platelet-activating factor and interleukin-8 rapidly immobilize rolling neutrophils. Rainger GE, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H114-22

Role of K+ in regulating hypoxic cerebral blood flow in the rat: effect of glibenclamide and ouabain. Reid JM, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H45-52

Relationship between vasopressin and opioids in hypoxia induced pial artery vasodilation. Rossberg MI, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H521-7

Adenine nucleotides via activation of ATP-sensitive K+ channels modulate hypoxic response in rat pulmonary artery. Shigemori K, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L803-9

Medullary vasomotor activity and hypoxic sympathoexcitation in pentobarbital-anesthetized rats. Sun MK, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):R348-55

Neurochemical mechanisms behind gill microcirculatory responses to hypoxia in trout: in vivo microscopy study. Sundin L, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R576-85

Hypoxia impairs nitrovasodilator-induced pulmonary vasodilation: role of Na-K-ATPase activity. Tamaoki J, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):L172-7

Pulmonary vascular pressure effects by endothelin-1 in normoxia and chronic hypoxia: a longitudinal study. Tjen-A-Looi S, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2246-53

Chronic hypoxia inhibits postnatal maturation of porcine intrapulmonary artery relaxation. Tulloh RM, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2436-45

Hypoxia-reoxygenation impairs endothelium-dependent relaxation in isolated rat aorta. Yokoyama S, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R1126-31

Membrane depolarization in PC-12 cells during hypoxia is regulated by an O2-sensitive K+ current. Zhu WH, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C658-65

Nitric oxide modulates ventilatory responses to hypoxia in the developing rat. Gozal D, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1755-62

Pulmonary artery pressure response to hypoxia in sleep apnea. Laks L, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):193-8

Role of chemosensitivity in intrathoracic pressure changes during obstructive sleep apnea. Sforza E, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1741-7

Time course of hypoxic pulmonary vasoconstriction: a rabbit model of regional hypoxia. Vejlstrup NG, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):216-21

Acute, arterial hypoxia. Overview. Mertzlufft F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):370-2

Thresholds for hypoxic cerebral vasodilation in volunteers. Gupta AK, et al. **Anesth Analg** 1997 Oct;85(4):817-20

Intraventricular dexmedetomidine decreases cerebral blood flow during normoxia and hypoxia in dogs. McPherson RW, et al. **Anesth Analg** 1997 Jan;84(1):139-47

Hypoxic pulmonary vasoconstriction in nonventilated lung areas contributes to differences in hemodynamic and gas exchange responses to inhalation of nitric oxide [see comments] Benzing A, et al. **Anesthesiology** 1997 Jun; 86(6):1254-61. Comment in: Anesthesiology 1997 Jun;86(6):1228-30.

Influences of morphine on the ventilatory response to isocapnic hypoxia. Berkenbosch A, et al. **Anesthesiology** 1997 Jun;86(6):1342-9

Hypoxic pulmonary vasoconstriction in human lungs. A stimulus-response study. Hambraeus-Jonzon K, et al. **Anesthesiology** 1997 Feb;86(2):308-15

Michaelis-Menten kinetics model of oxygen consumption by rat brain slices following hypoxia. McGoron AJ, et al. **Ann Biomed Eng** 1997 May-Jun;25(3):565-72

Acute and chronic effects of hypoxia on the developing hippocampus. Owens J Jr, et al. **Ann Neurol** 1997 Feb; 41(2):187-99

Cardioplegia preserves hypoxic response in isolated coronary arteries but not in isolated hearts. Barbé CC, et al. **Ann Thorac Surg** 1997 May;63(5):1303-8

Nitric oxide dose response during moderate and severe hypoxia in swine. Emil SG, et al. **Ann Thorac Surg** 1997 Feb;63(2):414-8

Relation of sympathetic activation to ventilation in man at 4300 m altitude. Asano K, et al. **Aviat Space Environ Med** 1997 Feb;68(2):104-10

Effects of altitude hypoxia on middle latency auditory evoked potentials in humans. Bouchet P, et al. **Aviat Space Environ Med** 1997 Aug;68(8):699-704

Ventilatory capacities at sea level and high altitude. Forte VA Jr, et al. **Aviat Space Environ Med** 1997 Jun; 68(6):488-93

Acute ventilatory response to simulated altitude, normobaric hypoxia, and hypobaria. Loeppky JA, et al. **Aviat Space Environ Med** 1996 Nov;67(11):1019-22

Effects of hypobaric-hypoxia on the salivary cortisol levels of aircraft pilots. Obmiński Z, et al. **Aviat Space Environ Med** 1997 Mar;68(3):183-6

Hypoxic syncope. Westendorp RG, et al. **Aviat Space Environ Med** 1997 May;68(5):410-4

Comparisons of altitude tolerance and hypoxia symptoms between nonsmokers and habitual smokers. Yoneda I, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):807-11

ACTH and growth hormone in myocardial LDH adaptation to hypoxia in rats. Kaaja R, et al. **Basic Res Cardiol** 1996 Jul-Aug;91(4):269-74

Characterization and developmental aspects of anoxia-induced gasping in the rat. Gozal D, et al. **Biol Neonate** 1996;70(5):280-8

Role of the autonomic nervous system in the acute blood

pressure elevation during repetitive hypoxic and hypercapnic breathing in rats. Bakehe M, et al. **Blood Press** 1996 Nov;5(6):371–5

Inhalation of a nitric oxide synthase inhibitor to a hypoxic or collapsed lung lobe in anaesthetized pigs: effects on pulmonary blood flow distribution. Fredén F, et al. **Br J Anaesth** 1996 Sep;77(3):413–8

Influence of 0.2 minimum alveolar concentration of enflurane on the ventilatory response to sustained hypoxia in humans. Nagyova B, et al. **Br J Anaesth** 1997 Jun;78(6):707–13

Effects of frusemide and hypoxia on the pulmonary vascular bed in man. Kiely DG, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):309–13

On the cerebro-protective effects of caroverine, a calcium-channel blocker and antiglutamatergic drug: double-blind, placebo-controlled, EEG mapping and psychometric studies under hypoxia. Saletu B, et al. **Br J Clin Pharmacol** 1996 Feb;41(2):89–99

The effect of carotid sinus denervation on fetal heart rate variation in normoxia, hypoxia and post-hypoxia in fetal sheep. Kozuma S, et al. **Br J Obstet Gynaecol** 1997 Apr; 104(4):460–5

Depressant effects of hypoxia and hypoglycaemia on neuro-effector transmission of guinea-pig intestine studied in vitro with a pharmacological model. Corbett AD, et al. **Br J Pharmacol** 1997 Jan;120(1):107–15

Role of potassium channels and nitric oxide in the effects of iloprost and prostaglandin E1 on hypoxic vasoconstriction in the isolated perfused lung of the rat. Dumas M, et al. **Br J Pharmacol** 1997 Feb;120(3):405–10

Effects of hydroxyethylrutosides on hypoxia-induced activation of human endothelial cells in vitro. Janssens D, et al. **Br J Pharmacol** 1996 Jun;118(3):599–604

The in vivo and in vitro effects of hypoxia on pig urethral smooth muscle. Greenland JE, et al. **Br J Urol** 1997 Apr; 79(4):525–31

Hypoxic and ischemic disorders of infants and children. Lecture for 38th meeting of Japanese Society of Child Neurology, Tokyo, Japan, July 1996. Johnston MV. **Brain Dev** 1997 Jun;19(4):235–9 (50 ref.)

Endogenous adenosine mediates the sustained inhibition of excitatory synaptic transmission during moderate hypoxia. Arlinghaus L, et al. **Brain Res** 1996 Jun 17;724(2):265–8

Is activation of metabotropic glutamate receptors responsible for acute hyposic changes in hippocampal neurons? Erdemli G, et al. **Brain Res** 1996 Jun 3;723(1–2):1–7

Cerebral blood flow regulation in neonatal rabbits is altered by chronic cocaine administration. Feuer P, et al. **Brain Res** 1997 Apr 25;755(1):142–5

Time-course and reversibility of the hypoxia-induced alterations in cerebral vascularity and cerebral capillary glucose transporter density. Harik N, et al. **Brain Res** 1996 Oct 21;737(1–2):335–8

High metabolic rates of 4-hydroxynonenal in brain capillary endothelial cells during hypoxia/reoxygenation. Kunstmann S, et al. **Brain Res** 1996 Nov 18;740(1–2):353–5

Thapsigargin enhances carotid body chemosensory discharge in response to hypoxia in zero [Ca2+]e: evidence for intracellular Ca2+ release. Lahiri S, et al. **Brain Res** 1996 Feb 12;709(1):141–4

Effect of anoxia on striatal monoamine metabolism in immature rat brain compared with that of hypoxia: an in vivo microdialysis study. Nakajima W, et al. **Brain Res** 1996 Nov 18;740(1–2):316–22

Cell swelling exacerbates hypoxic neuronal damage in rat hippocampal slices. Payne RS, et al. **Brain Res** 1996 Jun 3;723(1–2):210–3

Effects of long-term hypoxia on tyrosine hydroxylase protein content in catecholaminergic rat brainstem areas: a quantitative autoradiographic study. Pépin JL, et al. **Brain Res** 1996 Sep 9;733(1):1–8

Seasonal- and temperature-dependent variation in CNS ascorbate and glutathione levels in anoxia-tolerant turtles. Pérez-Pinzón MA, et al. **Brain Res** 1995 Dec 24; 705(1–2):45–52

Brain lactate, not glucose, fuels the recovery of synaptic function from hypoxia upon reoxygenation: an in vitro study. Schurr A, et al. **Brain Res** 1997 Jan 2;744(1):105–11

Electrocorticographic activity during repeated vs continuous hypoxia in piglets. Waters KA, et al. **Brain Res Bull** 1996; 41(3):185–92

Ventrolateral medullary neurons show age-dependent depolarizations to hypoxia in vitro. Nolan PC, et al. **Brain Res Dev Brain Res** 1996 Jan 22;91(1):111–20

Plasticity of tyrosine hydroxylase gene expression in the rat nucleus tractus solitarius after ventilatory acclimatization to hypoxia. Dumas S, et al. **Brain Res Mol Brain Res** 1996 Sep 1;40(2):188–94

Electrocardiographic characterization of myocardial function in normoxic and hypoxic teleosts. Rantin FT, et al. **Braz J Med Biol Res** 1995 Nov-Dec;28(11–12):1277–89 (47 ref.)

Cardiovascular, respiratory and metabolic responses to temperature and hypoxia of the winter frog Rana catesbeiana. Rocha PL, et al. **Braz J Med Biol Res** 1997 Jan;30(1):125–31

Oxygen as a modulator of body temperature. Wood SC. **Braz J Med Biol Res** 1995 Nov-Dec;28(11–12):1249–56 (62 ref.)

Locomotory, ventilatory and metabolic responses of the subterranean Stenasellus virei (Crustacea, Isopoda) to severe hypoxia and subsequent recovery. Hervant F, et al. **C R Acad Sci III** 1997 Feb;320(2):139–48

Somatosensory evoked potentials during hypoxia and hypocapnia in conscious humans. Ledsome JR, et al. **Can J Anaesth** 1996 Oct;43(10):1025–9

The ventilatory response to hypoxia below the carbon dioxide threshold. Rapanos T, et al. **Can J Appl Physiol** 1997 Feb;22(1):23–36

Arrhythmia and electrical heterogeneity during prolonged hypoxia in guinea pig papillary muscles. Hayashi H, et al. **Can J Physiol Pharmacol** 1997 Jan;75(1):44–51

Hypoxia-induced release of prostaglandins: mechanisms and sources of production in coronary resistance vessels of the isolated rabbit heart. Nakhostine N, et al. **Can J Physiol Pharmacol** 1995 Dec;73(12):1742–9

Sympathetic modulation of hypoxic pulmonary vasoconstriction in intact dogs. Brimioulle S, et al. **Cardiovasc Res** 1997 May;34(2):384–92

The hypoxic response: huffing and HIFing. Guillemin K, et al. **Cell** 1997 Apr 4;89(1):9–12 (21 ref.)

Hypoxic ventilatory response and breathlessness following hypocapnic and isocapnic hyperventilation. Chin K, et al. **Chest** 1997 Jul;112(1):154–63

Relaxant effects of vasoactive intestinal peptide on pulmonary artery in chronically hypoxic rats. Chen Y, et al. **Chin Med Sci J** 1996 Mar;11(1):21–4

Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: role of adenosine A1/A3 and bradykinin B2 receptor activation. Giannella E, et al. **Circ Res** 1997 Sep; 81(3):415–22

Myocyte adaptation to chronic hypoxia and development of tolerance to subsequent acute severe hypoxia. Silverman HS, et al. **Circ Res** 1997 May;80(5):699–707

Increased tolerance of the chronically hypoxic immature heart to ischemia. Contribution of the KATP channel. Baker JE, et al. **Circulation** 1997 Mar 4;95(5):1278–85

Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. Collard CD, et al. **Circulation** 1997 Jul 1;96(1):326–33

Effect of central endogenous angiotensin II on sympathetic activation induced by hypoxia. Gaudet EA, et al. **Clin Exp Hypertens** 1997 Jul-Aug;19(5–6):913–23

Renal kallikrein in chronic hypoxic rats. Chen CF, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):819–24

Baroreflex control of heart rate during hypoxia and hypercapnia in chronically hypertensive rabbits. Groom AS, et al. **Clin Exp Pharmacol Physiol** 1997 Mar-Apr; 24(3–4):229–34

Oxygen sensing and signal transduction in metabolic defense against hypoxia: lessons from vertebrate facultative anaerobes. Hochachka PW, et al. **Comp Biochem Physiol A Physiol** 1997 Sep;118(1):23–9 (40 ref.)

Functional consequences of acute and chronic hypoxia on respiratory and skeletal muscles in mammals. Jammes Y, et al. **Comp Biochem Physiol A Physiol** 1997 Sep; 118(1):15–22 (54 ref.)

Oxygen sensors in the organism: examples of regulation under altitude hypoxia in mammals. Richalet JP. **Comp Biochem Physiol A Physiol** 1997 Sep;118(1):9–14 (16 ref.)

Hypothermia in hypoxic animals: mechanisms, mediators, and functional significance. Wood SC, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):37–43 (86 ref.)

Antioxidant enzymatic activity in embryos and placenta of rats chronically exposed to hypoxia and hyperoxia. Mover H, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jun;117(2):151–7

Contractile activity of the uterus prior to labor alters the temporal organization of spontaneous motor activity in the fetal sheep. Robertson SS, et al. **Dev Psychobiol** 1996 Dec; 29(8):667–83

Animal models for the study of perinatal hypoxic-ischemic encephalopathy: a critical analysis. Roohey T, et al. **Early Hum Dev** 1997 Jan 20;47(2):115–46

Hypoxia-induced hyperexcitability in vivo and in vitro in the immature hippocampus. Jensen FE, et al. **Epilepsy Res** 1996 Dec;26(1):131–40 (72 ref.)

An AFM investigation of the effects of acute hypoxia on mental rotation. Lindeis AE, et al. **Ergonomics** 1996 Feb; 39(2):278–84

Susceptibility of isolated rat facial nerve to anaerobic stress. Jund R, et al. **Eur Arch Otorhinolaryngol Suppl** 1997; 1:S64–7

Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Leyva F, et al. **Eur Heart J** 1997 May;18(5):858–65

Training-induced increases in sea level VO2max and endurance are not enhanced by acute hypobaric exposure. Emonson DL, et al. **Eur J Appl Physiol** 1997;76(1):8–12

Volume changes in the forearm and lower limbs during 2 h of acute hypobaric hypoxia in nonacclimatized subjects. Schirlo C, et al. **Eur J Appl Physiol** 1997;75(2):124–31

Hypoxic ventilatory response during rest and exercise after a Himalayan expedition. Steinacker JM, et al. **Eur J Appl Physiol** 1996;73(3–4):202–9

Effect of acute mild hypoxia during exercise on plasma free and sulphoconjugated catecholamines. Strobel G, et al. **Eur J Appl Physiol** 1996;73(1–2):82–7

Effect of acute normobaric hypoxia on quadriceps integrated electromyogram and blood metabolites during incremental exercise to exhaustion. Taylor AD, et al. **Eur J Appl Physiol** 1996;73(1–2):121–9

Myoelectric evidence of peripheral muscle fatigue during exercise in severe hypoxia: some references to m. vastus lateralis myosin heavy chain composition. Taylor AD, et al. **Eur J Appl Physiol** 1997;75(2):151–9

Pain perception under chronic high-altitude hypoxia. Noël-Jorand MC, et al. **Eur J Neurosci** 1996 Oct; 8(10):2075–9

In vitro hypoxia on rat pulmonary artery: effects on contractions to spasmogens and role of KATP channels. Wanstall JC, et al. **Eur J Pharmacol** 1996 May 6; 303(1–2):71–8

Relationship between breathlessness and hypoxic and hypercapnic ventilatory response in patients with COPD. Kobayashi S, et al. **Eur Respir J** 1996 Nov;9(11):2340–5

Patterns of inspiratory muscle shortening during hypoxia and hypercapnia in dogs. Suzuki M, et al. **Eur Respir J** 1997 Feb;10(2):430–6

The capacity to accumulate cyclic AMP in the preoptic-anterior hypothalamic area of the rat is affected by the exposition to low ambient temperature and the subsequent recovery. Zamboni G, et al. **Exp Brain Res** 1996 Apr;109(1):164–8

Cardiovascular and renal effects of systemic hypoxia in chronically instrumented conscious WKY and SHR rats. Habermann G, et al. **Exp Clin Endocrinol Diabetes** 1997; 105 Suppl 2:26–8

Effects of 8h of eucapnic and poikilocapnic hypoxia on middle cerebral artery velocity and heart rate in humans. Clar C, et al. **Exp Physiol** 1997 Jul;82(4):791–802

The role of carotid chemoreceptors in the effects of hypoxia on renal blood flow in the late gestation sheep fetus. Green LR, et al. **Exp Physiol** 1997 Jan;82(1):183–92

Unilateral cooling in the region of locus coeruleus blocks the fall in respiratory output during hypoxia in anaesthetized neonatal sheep. Moore PJ, et al. **Exp Physiol** 1996 Nov;81(6):983–94

Intracellular signalling pathways that regulate vascular cell proliferation: effect of hypoxia. Scott PH, et al. **Exp Physiol** 1997 Mar;82(2):317–26 (29 ref.)

A new index for assessing arterial oxygen profile in patients with respiratory failure. Iluchev D. **Folia Med (Plovdiv)** 1996;38(1):39–43

Effects of hypoxia/reoxygenation on aortic vasoconstrictor responsiveness. Gao H, et al. **Free Radic Biol Med** 1996; 21(5):591–600

Comparison between acute hypoxia-induced and mechanically-induced pulmonary artery hypertension on the hemodynamics, myocardial contractility and regional blood flow in dogs. Girard C, et al. **Fundam Clin Pharmacol** 1995;9(6):554–61

Effect of asphyxia on the composition of cationic elements in the perilymph. Hara A, et al. **Hear Res** 1995 Oct; 90(1–2):228–31

Behavioral strategy and the physiological stress response in rainbow trout exposed to severe hypoxia. van Raaij MT, et al. **Horm Behav** 1996 Mar;30(1):85–92

Hypoxia, obstructive sleep apnea syndrome, and pulmonary hypertension [editorial; comment] Kay JM. **Hum Pathol** 1997 Mar;28(3):261–3. Comment on: Hum Pathol 1997 Mar;28(3):264–9.

Evaluation of indicators of tissue hypoxia during progressive hemorrhage and blood retransfusion. Hossain MA, et al. **In Vivo** 1997 Jan-Feb;11(1):39–44

Effect of blood gas derangement on QTc dispersion in severe chronic obstructive pulmonary disease: evidence of an electropathy? Sarubbi B, et al. **Int J Cardiol** 1997 Feb; 58(3):287–92

Isolation and characterization of the products of anoxic irradiation of d(CpGpTpA). Budzinski EE, et al. **Int J Radiat Biol** 1997 Mar;71(3):327–36

Influence of oxygen on radiation-induced DNA damage in testicular cells of C3H mice. Zheng H, et al. **Int J Radiat Biol** 1997 Mar;71(3):275–82

Oxygen uptake during submaximal incremental and constant work load exercises in hypoxia. Benoit H, et al. **Int J Sports Med** 1997 Feb;18(2):101–5

Acute hypoxic pulmonary vascular response does not accompany plasma endothelin-1 elevation in subjects susceptible to high altitude pulmonary edema. Droma Y, et al. **Intern Med** 1996 Apr;35(4):257–60

Hyperthermia and hypoxia increase tolerance of retinal ganglion cells to anoxia and excitotoxicity. Caprioli J, et al. **Invest Ophthalmol Vis Sci** 1996 Nov;37(12):2376–81

Tissue oxygen during a critical developmental period controls the death and survival of photoreceptors. Maslim J, et al. **Invest Ophthalmol Vis Sci** 1997 Aug;38(9):1667–77

Hypercapnic and hypoxic ventilatory responses [letter; comment] Abraham K, et al. **J Appl Physiol** 1996 Aug; 81(2):1033–4. Comment on: J Appl Physiol 1994 Jan;76(1):314–20.

Autoregressive spectral analysis of phrenic neurogram during eupnea and gasping. Akay M, et al. **J Appl Physiol** 1996 Aug;81(2):530–40; discussion 528–9

Pulmonary entrapment of sickle cells: the role of regional alveolar hypoxia. Aldrich TK, et al. **J Appl Physiol** 1996 Feb;80(2):531–9

Acute blood pressure elevation during repetitive hypocapnic and eucapnic hypoxia in rats. Bao G, et al. **J Appl Physiol** 1997 Apr;82(4):1071–8

Blood pressure response to chronic episodic hypoxia: role of the sympathetic nervous system. Bao G, et al. **J Appl Physiol** 1997 Jul;83(1):95–101

Pulmonary vasoreactivity to serotonin during hypoxia is modulated by ATP-sensitive potassium channels. Barman SA. **J Appl Physiol** 1997 Aug;83(2):569–74

Effect of altitude and socioeconomic status on VO2max and anaerobic power in prepubertal Bolivian girls. Blonc S, et al. **J Appl Physiol** 1996 Jun;80(6):2002–8

Role of vagal fibers in the hypoxia-induced increases in end-expiratory lung volume and diaphragmatic activity. Bonora M, et al. **J Appl Physiol** 1997 Sep;83(3):700–6

Effects of hypoxic pulmonary vasoconstriction on pulmonary gas exchange. Brimioulle S, et al. **J Appl Physiol** 1996 Oct; 81(4):1535–43

Influence of reduced carotid body drive during sustained hypoxia on hypoxic depression of ventilation in humans. Dahan A, et al. **J Appl Physiol** 1996 Aug;81(2):565–72

Use of a hypoxic lung as a deoxygenator to provide extended assessment of pulmonary function in rats. DeCampos KN, et al. **J Appl Physiol** 1996 May;80(5):1835–40

Hypoxic pulmonary vasoconstriction and gas exchange in acute canine pulmonary embolism. Delcroix M, et al. **J Appl Physiol** 1996 Apr;80(4):1240–8

Muscle tissue adaptations of high-altitude natives to training in chronic hypoxia or acute normoxia. Desplanches D, et al. **J Appl Physiol** 1996 Nov;81(5):1946–51

Effects of carotid body hypocapnia during ventilatory acclimatization to hypoxia. Dwinell MR, et al. **J Appl Physiol** 1997 Jan;82(1):118–24

Effects of hypoxic hypoxia on O2 uptake and heart rate kinetics during heavy exercise. Engelen M, et al. **J Appl Physiol** 1996 Dec;81(6):2500–8

Hormonal and metabolic adjustments during exercise in hypoxia or normoxia in highland natives. Favier R, et al. **J Appl Physiol** 1996 Feb;80(2):632–7

Chronic hypoxia alters nitric oxide-dependent pulmonary vascular responses in lungs of newborn pigs. Fike CD, et al. **J Appl Physiol** 1996 Nov;81(5):2078–87

Further cholinergic aspects of carotid body chemotransduction of hypoxia in cats. Fitzgerald RS, et al. **J Appl Physiol** 1997 Mar;82(3):819–27

Effect of episodic eucapnic and hypocapnic hypoxia on systemic blood pressure in hypertension-prone rats. Fletcher EC, et al. **J Appl Physiol** 1996 Nov;81(5):2088–94

Muscle fatigue and exhaustion during dynamic leg exercise in normoxia and hypobaric hypoxia. Fulco CS, et al. **J Appl Physiol** 1996 Nov;81(5):1891–900

Ventilatory and metabolic responses to ambient hypoxia or hypercapnia in rats exposed to CO hypoxia. Gautier H, et al. **J Appl Physiol** 1997 Jul;83(1):253–61

Interactions among metabolic rate, hypoxia, and control of breathing. Gautier H. **J Appl Physiol** 1996 Aug;81(2):521–7 (67 ref.)

Effect of chronic resistive loading on hypoxic ventilatory responsiveness. Greenberg HE, et al. **J Appl Physiol** 1997 Feb;82(2):500–7

Hypoxic vasoconstriction in pulmonary arterioles and venules. Hillier SC, et al. **J Appl Physiol** 1997 Apr; 82(4):1084–90

Effect of prior O2 breathing on ventilatory response to sustained isocapnic hypoxia in adult humans. Honda Y, et al. **J Appl Physiol** 1996 Oct;81(4):1627–32

Role of carotid body activity responsible for hypoxic ventilatory decline in awake humans [letter; comment] Honda Y, et al. **J Appl Physiol** 1997 Jan;82(1):371. Comment on: J Appl Physiol 1995 Aug;79(2):373–4.

Cardiovascular and ventilatory response to isocapnic hypoxia at sea level and at 5,050 m. Insalaco G, et al. **J Appl Physiol** 1996 May;80(5):1724–30

Augmented hypoxic cerebral vasodilation in men during 5 days at 3,810 m altitude. Jensen JB, et al. **J Appl Physiol** 1996 Apr;80(4):1214–8

Eucapnic hypoxia lowers human cold thermoregulatory response thresholds and accelerates core cooling. Johnston CE, et al. **J Appl Physiol** 1996 Feb;80(2):422–9

Effects of upper airway stimulation on swallowing, gasping, and autoresuscitation in hypoxic mice. Khurana A, et al. **J Appl Physiol** 1996 Feb;80(2):472–7

Alterations in autonomic adjustments to acute hypoxia in conscious rats with aging. Kregel KC. **J Appl Physiol** 1996 Feb;80(2):540–6

Decreased energy metabolism in brain stem during central respiratory depression in response to hypoxia. LaManna JC, et al. **J Appl Physiol** 1996 Oct;81(4):1772–7

Hypoxia- and normoxia-induced reversibility of autonomic control in Andean guinea pig heart. León-Velarde F, et al. **J Appl Physiol** 1996 Nov;81(5):2229–34

Extended models of the ventilatory response to sustained isocapnic hypoxia in humans. Liang PJ, et al. **J Appl Physiol** 1997 Feb;82(2):667–77

Effect of N-methyl-D-aspartate-receptor blockade on hypoxic ventilatory response in unanesthetized piglets. Lin J, et al. **J Appl Physiol** 1996 May;80(5):1759–63

Regression of hypoxic hypertension-induced changes in the elastic laminae of rat pulmonary arteries. Liu SQ. **J Appl Physiol** 1997 May;82(5):1677–84

Effects of sustained and repetitive isocapnic hypoxia on ventilation and genioglossal and diaphragmatic EMGs. McEvoy RD, et al. **J Appl Physiol** 1996 Aug;81(2):866–75

Effect of hypoxia on abdominal motor unit activities in spontaneously breathing cats. Mateika JH, et al. **J Appl Physiol** 1996 Dec;81(6):2428–35

Respiratory and sympathetic activity during recovery from hypoxic depression and gasping in cats. Melton JE, et al. **J Appl Physiol** 1996 Jun;80(6):1940–8

Development of ventilatory responsiveness to progressive hypoxia and hypercapnia in low-birth-weight lambs. Moss TJ, et al. **J Appl Physiol** 1996 Oct;81(4):1555–61

Thapsigargin stimulates increased NO activity in hypoxic hypertensive rat lungs and pulmonary arteries. Muramatsu M, et al. **J Appl Physiol** 1996 Apr;80(4):1336–44

Respiration during acute hypoxia: angiotensin- and vasopressin-receptor blocks. Overgaard CB, et al. **J Appl Physiol** 1996 Mar;80(3):810–7

Dynamics of the cerebral blood flow response to step changes in end-tidal PCO2 and PO2 in humans. Poulin MJ, et al. **J Appl Physiol** 1996 Sep;81(3):1084–95

Acute mountain sickness: increased severity during simulated altitude compared with normobaric hypoxia. Roach RC, et al. **J Appl Physiol** 1996 Nov;81(5):1908–10

Comparison of effects of sustained isocapnic hypoxia on ventilation in men and women. Sajkov D, et al. **J Appl Physiol** 1997 Aug;83(2):599–607

Effect of hypoxia on respiratory system impedance in dogs. Simon BA, et al. **J Appl Physiol** 1997 Aug;83(2):451–8

Effect of high-altitude hypoxia on feeding responses and hedonic matrix in rats. Singh SB, et al. **J Appl Physiol** 1996 Apr;80(4):1133–7

Ventilatory effects of specific carotid body hypocapnia and hypoxia in awake dogs. Smith CA, et al. **J Appl Physiol** 1997 Mar;82(3):791–8

Human ventilatory response to acute hyperoxia during and after 8 h of both isocapnic and poikilocapnic hypoxia. Tansley JG, et al. **J Appl Physiol** 1997 Feb;82(2):513–9

Effects of hypoxia on diaphragm relaxation rate during fatigue. Van Lunteren E, et al. **J Appl Physiol** 1997 May; 82(5):1472–8

Interaction between hypoxia and hypercapnia in regulating canine diaphragm arteriolar diameter. Ward ME. **J Appl Physiol** 1996 Mar;80(3):802–9

Effect of inhibition of nitric oxide synthesis on the diaphragmatic microvascular response to hypoxia. Ward ME. **J Appl Physiol** 1996 Oct;81(4):1633–41

Curtailed respiration by repeated vs. isolated hypoxia in maturing piglets is unrelated to NTS ME or SP levels. Waters KA, et al. **J Appl Physiol** 1997 Aug;83(2):522–9

The autonomic nervous system and hypoxia: mountain medicine. Appenzeller O, et al. **J Auton Nerv Syst** 1996 Feb 5;57(1–2):1–12 (70 ref.)

Activation of hepatic sympathetic nerves during hypoxic, hypotensive and glucopenic stress. Mundinger TO, et al. **J Auton Nerv Syst** 1997 Apr 14;63(3):153–60

P1-purinoceptor-mediated vasodilatation and vasoconstriction in hypoxia. Broadley KJ, et al. **J Auton Pharmacol** 1996 Dec;16(6):363–6

Dual effect of aminophylline on the ventilatory response to hypoxia in the rat. Maskrey M, et al. **J Basic Clin Physiol Pharmacol** 1994 Jul–Dec;5(3–4):227–38

Multiparameter monitoring and analysis of in vivo ischemic and hypoxic heart. Osbakken M, et al. **J Basic Clin Physiol Pharmacol** 1996;7(2):97–113

The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. Chen SJ, et al. **J Cardiovasc Pharmacol** 1997 Jun;29(6):713–25

Role of nitric oxide, cyclic nucleotides, and the activation of ATP-sensitive K+ channels in the contribution of adenosine to hypoxia-induced pial artery dilation. Armstead WM. **J Cereb Blood Flow Metab** 1997 Jan; 17(1):100–8

Hypoxia-induced inhibition of the response to nitroxidergic nerve stimulation in canine cerebral arteries. Okamura T, et al. **J Cereb Blood Flow Metab** 1997 Jul;17(7):807–13

Cerebral angiogenesis triggered by severe chronic hypoxia displays regional differences. Patt S, et al. **J Cereb Blood Flow Metab** 1997 Jul;17(7):801–6

Hepatic leukostasis and hypoxic stress in adhesion molecule-deficient mice after gut ischemia/reperfusion. Horie Y, et al. **J Clin Invest** 1997 Feb 15;99(4):781–8

Conformational changes of smooth endoplasmic reticulum induced by brief anoxia in rat Purkinje cells. Banno T, et al. **J Comp Neurol** 1996 Jun 3;369(3):462–71

Relationship between cellular ATP content and cellular functions of primary cultured rat hepatocytes in hypoxia. Hayashi K, et al. **J Gastroenterol Hepatol** 1997 Mar; 12(3):249–56

Absence of bradycardic response to apnea and hypoxia in heart transplant recipients with obstructive sleep apnea. Madden BP, et al. **J Heart Lung Transplant** 1997 Apr; 16(4):394–7

Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. Detmar M, et al. **J Invest Dermatol** 1997 Mar;108(3):263–8

Effect of slow versus fast desaturation on the ventilatory response to hypoxia. Sugimori K, et al. **J Med** 1996; 27(5–6):277–92

Mitochondrial function is not decreased in stunned papillary muscle at 20 degrees C. Zuurbier CJ, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):347–55

Hypoxia dramatically increases the nonspecific transport of blood-borne proteins to the brain. Plateel M, et al. **J Neurochem** 1997 Feb;68(2):874–7

Histopathologic clues to the pathways of neuronal death following ischemia/hypoxia. Rosenblum WI. **J Neurotrauma** 1997 May;14(5):313–26 (47 ref.)

Decreased ventilatory response to hypoxia in sedated newborn piglets prenatally exposed to cocaine. Suguihara C, et al. **J Pediatr** 1996 Mar;128(3):389–95

Respiratory mechanics during exhaustive submaximal exercise at high altitude in healthy humans. Cibella F, et al. **J Physiol (Lond)** 1996 Aug 1;494 (Pt 3):881–90

Postnatal development of the pattern of respiratory and cardiovascular response to systemic hypoxia in the piglet: the roles of adenosine. Elnazir B, et al. **J Physiol (Lond)** 1996 Apr 15;492 (Pt 2):573–85

The effects of breathing He-O2 mixtures on maximal oxygen consumption in normoxic and hypoxic men. Esposito F, et al. **J Physiol (Lond)** 1997 Aug 15;503 (Pt 1):215–22

Hypoxia inhibits the recombinant alpha 1C subunit of the human cardiac L-type Ca2+ channel. Fearon IM, et al. **J Physiol (Lond)** 1997 May 1;500 (Pt 3):551–6

The decrease of maximal oxygen consumption during hypoxia in man: a mirror image of the oxygen equilibrium curve. Ferretti G, et al. **J Physiol (Lond)** 1997 Jan 1;498 (Pt 1):231–7

Contribution of oxygen-sensitive neurons of the rostral ventrolateral medulla to hypoxic cerebral vasodilatation in the rat. Golanov EV, et al. **J Physiol (Lond)** 1996 Aug 15;495 (Pt 1):201–16

Chronic hypoxia suppresses pharmacomechanical coupling of the uterine artery in near-term pregnant sheep. Hu XQ, et al. **J Physiol (Lond)** 1997 Mar 1;499 (Pt 2):551–9

Dissociation of hypoxia-induced chemosensory responses and catecholamine efflux in cat carotid body superfused in vitro. Iturriaga R, et al. **J Physiol (Lond)** 1996 Dec 1; 497 (Pt 2):551–64

Hypoxia increases persistent sodium current in rat ventricular myocytes. Ju YK, et al. **J Physiol (Lond)** 1996 Dec 1;497 (Pt 2):337–47

Attenuation of the hypoxic ventilatory response in adult rats following one month of perinatal hyperoxia. Ling L, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):561–71

The behaviour of muscle microcirculation in chronically hypoxic rats: the role of adenosine. Mian R, et al. **J Physiol (Lond)** 1996 Mar 1;491 (Pt 2):489–98

The role of the renin-angiotensin system in the renal response to moderate hypoxia in the rat. Neylon M, et al. **J Physiol (Lond)** 1996 Mar 1;491 (Pt 2):479–88

The effects of chronic hypoxia on renal function in the rat. Neylon M, et al. **J Physiol (Lond)** 1997 May 15;501 (Pt 1):243–50

Mechanisms involved in increased iron uptake across rat duodenal brush-border membrane during hypoxia. O'Riordan DK, et al. **J Physiol (Lond)** 1997 Apr 15;500 (Pt 2):379–84

Studies on the roles of ATP, adenosine and nitric oxide in mediating muscle vasodilatation induced in the rat by acute systemic hypoxia. Skinner MR, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):553–60

Long-term influence of neonatal hypoxia on catecholamine activity in carotid bodies and brainstem cell groups of the rat. Soulier V, et al. **J Physiol (Lond)** 1997 Jan 15;498 (Pt 2):523–30

The roles of adenosine in regulating the respiratory and cardiovascular systems in chronically hypoxic, adult rats. Thomas T, et al. **J Physiol (Lond)** 1997 Jun 1;501 (Pt 2):439–47

Developmental loss of hypoxic chemosensitivity in rat adrenomedullary chromaffin cells. Thompson RJ, et al. **J Physiol (Lond)** 1997 Jan 15;498 (Pt 2):503–10

Long-term facilitation of ventilation following repeated hypoxic episodes in awake goats. Turner DL, et al. **J Physiol (Lond)** 1997 Mar 1;499 (Pt 2):543–50

Red nucleus lesions abolish the biphasic respiratory response to isocapnic hypoxia in decerebrate young rabbits. Waites BA, et al. **J Physiol (Lond)** 1996 Aug 15;495 (Pt 1):217–25

Inhaled nitric oxide, right ventricular efficiency, and pulmonary vascular mechanics: selective vasodilation of small pulmonary vessels during hypoxic pulmonary vasoconstriction. Hillman ND, et al. **J Thorac Cardiovasc Surg** 1997 Jun;113(6):1006–13

Continuous antegrade warm blood cardioplegia attenuates augmented coronary endothelium-dependent contraction after cardiac global ischemia and reperfusion. Lin PJ, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):100–8

Maturation alters the pulmonary arterial response to hypoxia and inhaled nitric oxide in the presence of endothelial dysfunction. Myers JL, et al. **J Thorac Cardiovasc Surg** 1997 Feb;113(2):270–7

Factors accounting for different responses of pulmonary and cerebral vessels to hypoxia. Wang D, et al. **J Tongji Med Univ** 1996;16(2):65–9

Hypoxia and proliferation are primarily responsible for induction of lactate dehydrogenase activity in cultured cells. Nowak G, et al. **J Toxicol Environ Health** 1996 Nov; 49(4):439–52

The effect of anoxia and glucose-free solutions on the contractile response of guinea-pig detrusor strips to intrinsic nerve stimulation and the application of excitatory agonists. Pessina F, et al. **J Urol** 1997 Jun;157(6):2375–80

Influence of hypoxia/ischemia on cerebrovascular responses to oxytocin in piglets. Bari F, et al. **J Vasc Res** 1997 Jul–Aug;34(4):312–20

Initial transient phase of salivary secretion by the submandibular glands of rats under anoxic conditions. Nakamura A, et al. **Jpn J Physiol** 1996 Apr;46(2):155–61

Unexpected hypoxia–dependent erythropoietin secretion during experimental conditions not affecting tissue oxygen supply/demand ratio. Bozzini CE, et al. **Kidney Int** 1997 Feb;51(2):413–5

Diversity of response in vascular smooth muscle cells to changes in oxygen tension. Weir EK, et al. **Kidney Int** 1997 Feb;51(2):462–6 (41 ref.)

Hypoxia–induced modulation of endothelial cell properties: regulation of barrier function and expression of interleukin–6. Yan SF, et al. **Kidney Int** 1997 Feb; 51(2):419–25 (26 ref.)

Could diuretics in hypoxic states be bad for the pulmonary circulation? Shale DJ. **Lancet** 1997 Jun 28;349(9069):1856

Physiologic basis for BOLD MR signal changes due to hypoxia/hyperoxia: separation of blood volume and magnetic susceptibility effects. Kennan RP, et al. **Magn Reson Med** 1997 Jun;37(6):953–6

Breathing pattern in tetraplegics during exposure to hypoxia and hypercapnia. Pokorski M, et al. **Mater Med Pol** 1995 Jul–Sep;27(3):97–100

Aging and detoxifying enzymes responses to hypoxic or hyperoxic treatment. Amicarelli F, et al. **Mech Ageing Dev** 1997 Sep;97(3):215–26

Skeletal muscle adaptations to training under normobaric hypoxic versus normoxic conditions. Melissa L, et al. **Med Sci Sports Exerc** 1997 Feb;29(2):238–43

Correction of hypoxia and hypercapnia in COPD patients: effects on cerebrovascular flow. Cannizzaro G, et al. **Monaldi Arch Chest Dis** 1997 Feb;52(1):9–12

Hippocampal and hypothalamic type I corticosteroid receptor affinities are reduced in adult rats born by a caesarean procedure with or without an added period of anoxia. Boksa P, et al. **Neuroendocrinology** 1996 Jul; 64(1):25–34

Developmental spectrum of the excitotoxic cascade induced by ibotenate: a model of hypoxic insults in fetuses and neonates. Gressens P, et al. **Neuropathol Appl Neurobiol** 1996 Dec;22(6):498–502 (22 ref.)

Mechanisms of hippocampal reoxygenation injury. Treatment with antioxidants. Horáková L, et al. **Neuropharmacology** 1997 Feb;36(2):177–84

Endogenous adenosine on membrane properties of CA1 neurons in rat hippocampal slices during normoxia and hypoxia. Zhu PJ, et al. **Neuropharmacology** 1997 Feb; 36(2):169–76

Hypoxia potentiates traumatic brain injury–induced expression of c–fos in rats. Dave JR, et al. **Neuroreport** 1997 Jan 20;8(2):395–8

Sulphonylureas reverse hypoxia induced K(+)–conductance increase in substantia nigra pars reticulata neurones. Wu CW, et al. **Neuroreport** 1996 Nov 4;7(15–17):2513–7

Use of phenylthiocarbamide for assessing cAMP–dependent resistance to anoxia in animals. Bolekhan EA, et al. **Neurosci Behav Physiol** 1997 May–Jun;27(3):268–71

Glucocorticoids and the prevention of hypoxic–ischemic brain damage. Tuor UI. **Neurosci Biobehav Rev** 1997 Mar; 21(2):175–9 (33 ref.)

The effect of age on susceptibility to hypoxic–ischemic brain damage. Yager JY, et al. **Neurosci Biobehav Rev** 1997 Mar; 21(2):167–74 (91 ref.)

Effect of acetyl–L–carnitine on hyperactivity and spatial memory deficits of rats exposed to neonatal anoxia. Dell'Anna E, et al. **Neurosci Lett** 1997 Feb 28;223(3):201–5

Increased macromolecular resonances in the rat cerebral cortex during severe energy failure as detected by 1H nuclear magnetic resonance spectroscopy. Hakumäki JM, et al. **Neurosci Lett** 1996 Jul 19;212(3):151–4

Systemic hypoxia facilitates somato–cardiac sympathetic A– and C–reflexes in anesthetized rats. Li WM, et al. **Neurosci Lett** 1996 Oct 4;216(3):175–8

Hypoxia–induced Fos expression in neurons projecting to the pressor region in the rostral ventrolateral medulla. Hirooka Y, et al. **Neuroscience** 1997 Oct;80(4):1209–24

Anoxic preconditioning in hippocampal slices: role of adenosine. Pérez–Pinzón MA, et al. **Neuroscience** 1996 Dec; 75(3):687–94

Leukocyte responses to hypoxic/ischemic conditions. Scannell G. **New Horiz** 1996 May;4(2):179–83 (27 ref.)

Pulmonary, vascular responses in rats exposed to chronic hypobaric hypoxia at two different altitude levels. Nakanishi K, et al. **Pathol Res Pract** 1996 Oct; 192(10):1057–67

Modification of the open circuit N2 washout technique for measurement of functional residual capacity in premature infants. Hentschel R, et al. **Pediatr Pulmonol** 1997 Jun; 23(6):434–41

Early developmental profiles of plasma corticosterone are altered by birth condition in the rat: a comparison of vaginal birth, cesarean section, and cesarean section with added anoxia. Boksa P. **Pediatr Res** 1997 Jan;41(1):34–43

Effect of hypoxia on blood glucose, hormones, and insulin receptor functions in newborn calves. Cheng N, et al. **Pediatr Res** 1997 Jun;41(6):852–6

Effect of hypoxia on glucose–modulated cerebral lactic acidosis, agonal glycolytic rates, and energy utilization. Corbett RJ, et al. **Pediatr Res** 1996 Mar;39(3):477–86

Glycolysis is not responsible for the tolerance of immature renal tubules to anoxia. Gaudio KM, et al. **Pediatr Res** 1996 Sep;40(3):457–61

The role of neutrophils in the production of hypoxic–ischemic brain injury in the neonatal rat. Hudome S, et al. **Pediatr Res** 1997 May;41(5):607–16

Cardiovascular and respiratory consequences of body warming during hypoxia in conscious newborn cats. Rohlicek CV, et al. **Pediatr Res** 1996 Jul;40(1):1–5

Postganglionic sympathetic discharge in neonatal swine. Sica AL, et al. **Pediatr Res** 1996 Jan;39(1):85–9

A piglet survival model of posthypoxic encephalopathy. Thoresen M, et al. **Pediatr Res** 1996 Nov;40(5):738–48

Hypoxic inhibition of K+ currents in isolated rat type I carotid body cells: evidence against the involvement of cyclic nucleotides. Hatton CJ, et al. **Pflugers Arch** 1996 Nov–Dec;433(1–2):129–35

Influence of gender and endogenous sex steroids on catecholaminergic structures involved in physiological adaptation to hypoxia. Pequignot JM, et al. **Pflugers Arch** 1997 Mar;433(5):580–6

Simultaneous recording of ATP–sensitive K+ current and intracellular Ca2+ in anoxic rat ventricular myocytes. Effects of glibenclamide. Russ U, et al. **Pflugers Arch** 1996 May;432(1):75–80

Effect of nimodipine on systemic, renal, and cerebral haemodynamics after a mild hypoxic–ischaemic insult in newborn piglets. Raju TN, et al. **Pharmacol Res** 1996 Jan; 33(1):5–12

Effects of chronic episodic hypoxia on monoamine metabolism and motor activity. Li R, et al. **Physiol Behav** 1996 Oct;60(4):1071–6

Vasodilator action of the S–nitrosothiol, SNAP, in rat isolated perfused lung. Emery CJ. **Physiol Res** 1995; 44(1):19–24

Perinatal lung injury extends in adults the site of hypoxic pulmonary vasoconstriction upstream. Herget J, et al. **Physiol Res** 1995;44(1):25–30

The inhibition of angiotensin converting enzyme attenuates the effects of chronic hypoxia on pulmonary blood vessels in the rat. Herget J, et al. **Physiol Res** 1996;45(3):221–6

Acute hypoxic pulmonary vasoconstriction: a model of oxygen sensing. Michelakis ED, et al. **Physiol Res** 1995; 44(6):361–7 (45 ref.)

Ontogenetic differences in cardiopulmonary adaptation to chronic hypoxia. Oštádal B, et al. **Physiol Res** 1995; 44(1):45–51 (37 ref.)

Vasorelaxation by pinacidil in isolated perfused lungs is enhanced in rats with hypoxic pulmonary hypertension but is dependent on the constrictor. Wanstall JC. **Physiol Res** 1995;44(1):1–6

Acute hypoxic vasoconstriction in isolated rat small and large pulmonary arteries. Zhang F, et al. **Physiol Res** 1995; 44(1):7–18

Differential effects of platelet–derived growth factor BB in accelerating wound healing in aged versus young animals: the impact of tissue hypoxia. Wu L, et al. **Plast Reconstr Surg** 1997 Mar;99(3):815–22; discussion 823–4

Hypoxia and brain development. Nyakas C, et al. **Prog Neurobiol** 1996 May;49(1):1–51 (345 ref.)

The influence of nimodipine and MK–801 on the brain free arachidonic acid level and the learning ability in hypoxia–exposed rats. Mršić J, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Feb; 21(2):345–58

Long–lasting changes in synaptic excitability induced by anoxia in the rat hippocampus. Tancredi V. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):211–32

Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Wouters BG, et al. **Radiat Res** 1997 May;147(5):541–50

Effects of lidocaine on pulmonary circulation during hyperoxia and hypoxia in the dog. Yukioka H, et al. **Reg Anesth** 1996 Jul–Aug;21(4):327–37

Hypoxia–induced long–term facilitation of respiratory activity is serotonin dependent. Bach KB, et al. **Respir Physiol** 1996 Jul;104(2–3):251–60

Role of beta–adrenergic and cholinergic systems in acclimatization to hypoxia in the rat. Clancy RL, et al. **Respir Physiol** 1997 Jan;107(1):75–84

Lack of long–term facilitation of ventilation after exposure to hypoxia in goats. Dwinell MR, et al. **Respir Physiol** 1997 Apr;108(1):1–9

Blood viscosity in chronically hypoxic rats: an effect independent of packed cell volume. Fedde MR, et al. **Respir Physiol** 1996 Apr–May;104(1):45–52

Ventral medullary surface activity during hypoxia in awake and anesthetized goats. Forster HV, et al. **Respir Physiol** 1996 Jan;103(1):45–56

Characterization of ventilatory responses to hypoxia in neonatal rats. Fung ML, et al. **Respir Physiol** 1996 Jan; 103(1):57–66

Effect of theophylline on ventilatory roll–off during hypoxia in goats. Gershan WM, et al. **Respir Physiol** 1996 Feb; 103(2):157–64

Chronic hypoxia decreases heterogeneity of pulmonary blood flow distribution in rats. Kuwahira I, et al. **Respir Physiol** 1996 Jul;104(2–3):205–12

Prenatal cocaine: effect on hypoxic ventilatory responsiveness in neonatal rats. Lipton JW, et al. **Respir Physiol** 1996 Nov;106(2):161–9

Cardioventilatory responses to hypoxia and NaCN in the neotenous axolotl. McKenzie DJ, et al. **Respir Physiol** 1996 Dec;106(3):255–62

Respiratory training, hypoxic ventilatory response and acute mountain sickness. Markov G, et al. **Respir Physiol** 1996 Sep;105(3):179–86

Chronic hypoxia affects capillary density and geometry in pigeon pectoralis muscle. Mathieu–Costello O, et al. **Respir Physiol** 1997 Jul;109(1):39–52

The effect of hypoxia on the ventilatory response to carbon dioxide in man. Mohan R, et al. **Respir Physiol** 1997 May; 108(2):101–15

Ventilatory response to hypoxia in rats: gender differences. Mortola JP, et al. **Respir Physiol** 1996 Oct;106(1):21–34

An almitrine analog acts as hypoxia in isolated rat lungs. Robineau P, et al. **Respir Physiol** 1996 Sep;105(3):225–33

Development of respiratory chemoreflexes to hypoxia and CO2 in unanaesthetized kittens. Watanabe T, et al. **Respir Physiol** 1996 Dec;106(3):247–54

Effect of heart failure and physical training on the acute ventilatory response to hypoxia at rest and during exercise. Barlow CW, et al. **Respiration** 1997;64(2):131–7

The effect of exercise on the development of respiratory depression during sustained isocapnic hypoxia in humans. Pandit JJ, et al. **Respiration** 1997;64(1):86–95

A comparison of pathophysiological changes during hypobaric and normobaric hypoxia in rats. Sheedy W, et al. **Respiration** 1996;63(4):217–22

Influence of hypoxia and pulmonary air embolism on lung injury in perfused rat lungs. Takeoka M, et al. **Respiration** 1996;63(6):346–51

Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction. Holm P. **Scand Cardiovasc J Suppl** 1997;46:1–40 (231 ref.)

Effect of modulators of hypoxic pulmonary vasoconstriction on the response to inhaled nitric oxide in a neonatal model of severe pulmonary atelectasis. Eyal FG, et al. **Semin Perinatol** 1996 Jun;20(3):186–93

Effects of hypoxia on the ventral root motor–evoked potential in the in vitro spinal cord preparation. Ataka H, et al. **Spine** 1996 Sep 15;21(18):2095–100

Differential effects of short–term hypoxia and hypercapnia on N–methyl–D–aspartate–induced cerebral vasodilatation in piglets. Bari F, et al. **Stroke** 1996 Sep;27(9):1634–9; discussion 1639–40

Effects of fenoterol on ventilatory response to hypercapnia and hypoxia in patients with chronic obstructive pulmonary disease. Suzuki S, et al. **Thorax** 1997 Feb;52(2):125–9

[Acute, arterial hypoxia: a new method in diagnosis and O2 administration (editorial)] Mertzlufft F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):368–70 **(Ger)**

[Pulmonary causes of hypoxia in premature infants and its therapeutic possibilities] Schachinger H. **Pneumologie** 1997 Apr;51 Suppl 2:406–10 (Eng. Abstr.) **(Ger)**

[A reply to the comment by K. R. Trott in Strahlenther. Onkol. 173 (1997), 146–147 on the article by Strnad et al.: "The regression of Yoshida sarcoma during normoxia and hypoxia after fractionated irradiation" in Strahlenther. Onkol. 173 (1997), 141–145 (letter)] Kamprad F. **Strahlenther Onkol** 1997 May;173(5):287 **(Ger)**

[Hemorheologic assessment in hypoxic and hypoxic–hypercapnic states] Cortinovis A, et al. **Minerva Med** 1996 Dec;87(12):553–63 (Eng. Abstr.) **(Ita)**

[Ventilatory response to hypoxia and hypercapnia] Saito H, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:65–9 (12 ref.) **(Jpn)**

[Effects of hypoxemia and umbilical cord occlusion on fetal circulation in sheep] Kozuma S. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug;48(8):654–9 (0 ref.) **(Jpn)**

[Hypoxia and vascular–platelet hemostasis in patients with acute coronary insufficiency] Shvarts IuG, et al. **Anesteziol Reanimatol** 1997 Jan–Feb;(1):18–20 (Eng. Abstr.) **(Rus)**

[Cortical and thalamic regulating mechanisms of the pulse neuron activity of oblongata medulla respiration center of the rats in normal condition and during hypoxia] Akopian NS, et al. **Aviakosm Ekolog Med** 1996;30(1):36–42 (Eng. Abstr.) **(Rus)**

[Compensatory reactions of the rabbit respiratory system to hypoxic stimulation in hyperbaric conditions] Donina ZhA, et al. **Aviakosm Ekolog Med** 1996;30(4):34–8 (Eng. Abstr.) **(Rus)**

[Adaptational disorders of the cardiovascular regulation during brief exposure to hypobaric hypoxia] Karlov VN, et al. **Aviakosm Ekolog Med** 1996;30(5):19–22 (Eng. Abstr.) **(Rus)**

[The effect of adaptation of hypoxia on cytochrome levels in rat brain and liver] Dudchenko AM, et al. **Biull Eksp Biol Med** 1995 Dec;120(12):576–9 **(Rus)**

[Differences in blood supply of the brain and liver during acute blood loss in rats with different resistance to circulatory hypoxia] Kovalenko NIa, et al. **Biull Eksp Biol Med** 1997 Mar;123(3):253–7 **(Rus)**

[Effect of periodic adaptation to hypoxia on oxidative phosphorylation in brain mitochondria from rats with varying tolerance to oxygen insufficiency] Lukianova LD, et al. **Biull Eksp Biol Med** 1995 Dec;120(12):572–5 **(Rus)**

[Antihypoxic effect of succinate–containing derivative of oxypyridine on the EEG spectrum in rats with different

resistance to oxygen deficiency] Luk'ianova LD, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):57–62 **(Rus)**

[The effect of hypoxia of progressive severity on the dynamics of cerebral cortex EEG in rats with different resistance to acute oxygen deficiency] Malyshev AIu, et al. **Biull Eksp Biol Med** 1996 Sep;122(9):262–7 **(Rus)**

[Features of hormonal status in aborigines of Northeast Russia as a function of the level of hypoxic resistance] Batosh TP, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):5–9 **(Rus)**

[Normalizing effect of normobaric hypoxic hypoxia] Chizhov AIa, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):108–12 **(Rus)**

[Character of the changes in bioelectrical activity of the brain in persons performing operator work under conditions of high-altitude hypoxia] Dzhunusova GS, et al. **Fiziol Cheloveka** 1997 Jul–Aug;23(4):52–7 **(Rus)**

[Effect of hypoxic training on the health of school children residing in ecologically unfavorable regions] Glazachev OS, et al. **Fiziol Cheloveka** 1996 Jan–Feb;22(1):88–92 **(Rus)**

[Adaptation of the circulatory system to medium- and high-altitude hypoxia in heterozygous and homozygous adolescent twins] Zaslavskaia RM, et al. **Fiziol Cheloveka** 1997 Jan–Feb;23(1):29–32 **(Rus)**

[The influence of the limbic cortex and hypothalamus on the impulse activity of the bulbar respiratory neurons and on respiration under hypoxia] Akopian NS, et al. **Fiziol Zh** 1997;43(1–2):50–6 (Eng. Abstr.) **(Rus)**

[The distribution of cardiac output in waking rats with a decrease in body temperature to 2.3 degrees C through cooling or hypoxia] Turganbaeva AS, et al. **Fiziol Zh Im I M Sechenova** 1996 Dec;82(12):65–71 (Eng. Abstr.) **(Rus)**

[Experience in treating patients with cardiovascular diseases by means of adaptation to periodic barochamber hypoxia] Aleshin IA, et al. **Ter Arkh** 1997;69(1):54–8 (Eng. Abstr.) **(Rus)**

[The characteristics of the adaptation to the hypoxic conditions at a low-altitude health resort in IHD patients after an aortocoronary bypass] Amiiants VIu. **Ter Arkh** 1996;68(9):52–4 (Eng. Abstr.) **(Rus)**

[Medical use of stepwise adaptation to hypoxia] Kolchinskaia AZ. **Vestn Ross Akad Med Nauk** 1997;(5):12–9 (Eng. Abstr.) **(Rus)**

[Effects of hypoxia on the activity of the sympathetic-adrenal system] Nagnibeda NN. **Vestn Ross Akad Med Nauk** 1997; (5):19–23 (Eng. Abstr.) **(Rus)**

[Hypoxic training at intervals in the treatment of hypothyroidism] Kolchinskaia AZ, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 May–Jun; (3):42–4 **(Rus)**

[Intersensory correlations in diabetic neuropathy during adaptation to intervalic normobaric hypoxia] Starkova NT, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997; 97(3):40–4 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Fire hazard in oxygen-enriched atmospheres at low barometric pressures. West JB. **Aviat Space Environ Med** 1997 Feb;68(2):159–62 (6 ref.)

A model of anoxic preconditioning in the isolated rat cardiac myocyte. Importance of adenosine and insulin. Cave AC, et al. **Basic Res Cardiol** 1996 May–Jun;91(3):210–8

Beneficial effect of cold dialysate for the prevention of hemodialysis-induced hypoxia. Hegbrant J, et al. **Blood Purif** 1997;15(1):15–24

Post-operative nocturnal hypoxia in septoplasty: the value of nasal packing with airway tubes. Kristensen S, et al. **Clin Otolaryngol** 1996 Aug;21(4):331–4

Use of a modified non-rebreathing mask during upper intestinal endoscopy. Kelly MC, et al. **Endoscopy** 1996 Oct; 28(8):689–93

Myocardium-protective effects of Ginkgo biloba extract (EGb 761) in old rats against acute isobaric hypoxia. An electron microscopic morphometric study. I. Protection of cardiomyocytes. Fitzl G, et al. **Exp Toxicol Pathol** 1996 Jan;48(1):33–9

Splanchnic hypoxia after cardiac surgery [editorial; comment] Gutierrez G. **Intensive Care Med** 1996 Jan; 22(1):1–2. Comment on: Intensive Care Med 1996 Jan;22(1):26–33.

Phospholipase A2-induced cytoprotection of proximal tubules: potential determinants and specificity for ATP depletion-mediated injury. Zager RA, et al. **J Am Soc Nephrol** 1996 Jan;7(1):64–72

Possible mechanisms for the protective action of alpha-tocopherol in vascular hypoxia. Kelly MJ, et al. **J Auton Pharmacol** 1996 Apr;16(2):87–95

Tissue oxygenation and routine nursing procedures in critically ill patients. Jesurum J. **J Cardiovasc Nurs** 1997 Jul;11(4):12–30 (72 ref.)

Prevention of the hypoxic reoxygenation injury with the use of a leukocyte-depleting filter. Bolling KS, et al. **J Thorac Cardiovasc Surg** 1997 Jun;113(6):1081–9; discussion 1089–90

Is tubuloglomerular feedback a tool to prevent nephron oxygen deficiency? Schurek HJ, et al. **Kidney Int** 1997 Feb; 51(2):386–92

Characteristics of the protective action of alpha-Tocopherol in vascular hypoxia. Kelly MJ, et al. **Pharmacol Toxicol** 1996 Apr;78(4):209–13

Selective N-type calcium channel antagonist omega conotoxin MVIIA is neuroprotective against hypoxic neurodegeneration in organotypic hippocampal-slice cultures. Pringle AK, et al. **Stroke** 1996 Nov;27(11):2124–30

[New possibilities for metabolic protection from hypoxia in pregnant rats and their progeny] Korneev AA, et al. **Eksp Klin Farmakol** 1996 Sep–Oct;59(5):31–5 (Eng. Abstr.) **(Rus)**

[Treatment of medical complications: hypertension/hypotension, hyperglycemia, hyperthermia, hypoxia, cardiac complications and pulmonary embolism] Trejo Gabriel y Galán JM. **Neurologia** 1995 Dec;10 Suppl 2:16–22 (54 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Specific semantic memory loss after hypoxic-ischemic injury. Alexander MP. **Neurology** 1997 Jan;48(1):165–73

Effect of acetyl-L-carnitine on hyperactivity and spatial memory deficits of rats exposed to neonatal anoxia. Dell'Anna E, et al. **Neurosci Lett** 1997 Feb 28;223(3):201–5

THERAPY

Comparison of three oxygen delivery systems during exercise in hypoxemic patients with chronic obstructive pulmonary disease. Hagarty EM, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):893–8

Permanent cardiac pacing for reflex anoxic seizure [letter] Sreeram N, et al. **Arch Dis Child** 1996 Nov;75(5):462

Effective cross-circulation technique of venoarterial bypass for differential hypoxia condition. Kitamura M, et al. **Artif Organs** 1997 Jul;21(7):786–8

Inhalation injury treated with extracorporeal CO2 elimination. Kornberger E, et al. **Burns** 1997 Jun; 23(4):354–9

The LMA for the application of postoperative CPAP [letter] Glaisyer HR, et al. **Can J Anaesth** 1997 Jul;44(7):784–5

Heat shock protein 70 messenger RNA reflects the severity of ischemia/hypoxia-reperfusion injury in the perfused rat liver. Aoe T, et al. **Crit Care Med** 1997 Feb;25(2):324–9

Response to nitric oxide in term and preterm infants. Laubscher B, et al. **Eur J Pediatr** 1997 Aug;156(8):639–42

Tissue hypoxia: how to detect, how to correct, how to prevent? Third European Consensus Conference in Intensive Care Medicine. Organized by the Société de Réanimation de Langue Française, Cosponsored by the American Thoracic Society and the European Society of Intensive Care Medicine. **J Crit Care** 1997 Mar;12(1):39–47 (34 ref.)

Magnesium sulfate solution dramatically improves immediate recovery of rats from hypoxia. Siemkowicz E. **Resuscitation** 1997 Aug;35(1):53–9

Intermittent negative pressure ventilation in the treatment of hypoxic hypercapnic coma in chronic respiratory insufficiency [see comments] Corrado A, et al. **Thorax** 1996 Nov;51(11):1077–82. Comment in: Thorax 1996 Nov;51(11):1069–70.

[Improving pulmonary gas exchange using kinetic therapy] Bein T, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):391–4 **(Ger)**

[O2 administration and O2 monitoring in jet ventilation] Klein U, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):385–9 **(Ger)**

[Acute, arterial hypoxia and the laryngeal mask] Krier C. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):389–91 **(Ger)**

[Optimal O2 administration via the naso-oral method] Mertzlufft F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):381–5 **(Ger)**

[Therapeutic limit values of acute, arterial hypoxia] Zander R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):372–4 **(Ger)**

[Medical use of stepwise adaptation to hypoxia] Kolchinskaia AZ. **Vestn Ross Akad Med Nauk** 1997;(5):12–9 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Vascular reactivity in middle cerebral artery and basilar artery by transcranial Doppler in normals subjects during hypoxia. Garbin L, et al. **Ital J Neurol Sci** 1997 Jun; 18(3):135–7

Indexes of flow and cross-sectional area of the middle cerebral artery using doppler ultrasound during hypoxia and hypercapnia in humans. Poulin MJ, et al. **Stroke** 1996 Dec;27(12):2244–50

URINE

Urinary leukotriene E4 levels increase upon exposure to hypobaric hypoxia. Roach JM, et al. **Chest** 1996 Oct; 110(4):946–51

Effects of hypoxia on urinary organic acid and hypoxanthine excretion in fetal sheep. Walker V, et al. **Pediatr Res** 1996 Aug;40(2):309–18

VETERINARY

Effect of dietary flax oil and hypobaric hypoxia on right ventricular hypertrophy and ascites in broiler chickens. Bond JM, et al. **Br Poult Sci** 1996 Sep;37(4):731–41

Second messenger and cAMP-dependent protein kinase responses to dehydration and anoxia stresses in frogs. Holden CP, et al. **J Comp Physiol [B]** 1997 May; 167(4):305–12

The comparative role of haemoglobinaemia and hypoxia in the development of canine babesial nephropathy. Lobetti RG, et al. **J S Afr Vet Assoc** 1996 Dec;67(4):188–98

The effects of mechanical compression and hypoxia on nerve root and dorsal root ganglia. An analysis of ectopic firing using an in vitro model. Sugawara O, et al. **Spine** 1996 Sep 15;21(18):2089–94

Welfare implications of gas stunning pigs: 3. The time to loss of somatosensory evoked potentials and spontaneous electrocorticogram of pigs during exposure to gases. Raj AB, et al. **Vet J** 1997 May;153(3):329–39

Pulmonary function values in Friesian and double-muscled calves during acute poikilocapnic hypoxia. Rollin F, et al. **Zentralbl Veterinarmed A** 1997 Apr;44(2):79–90

ANOXIA, CELLULAR see **CELL HYPOXIA**

ANOXIA, FETAL see **FETAL ANOXIA**

ANP see **ATRIAL NATRIURETIC FACTOR**

ANP RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ANT VENOMS

ADVERSE EFFECTS

Anaphylaxis due to a red harvest ant bite. Schmid-Grendelmeier P, et al. **Allergy** 1997 Feb; 52(2):230–1

CHEMISTRY

Expression of jumper ant (Myrmecia pilosula) venom allergens: post-translational processing of allergen gene products. Donovan GR, et al. **Biochem Mol Biol Int** 1996 Aug;39(5):877–85

GENETICS

Expression of jumper ant (Myrmecia pilosula) venom allergens: post-translational processing of allergen gene products. Donovan GR, et al. **Biochem Mol Biol Int** 1996 Aug;39(5):877–85

IMMUNOLOGY

Immunotherapy for allergy to fire ant venom [letter; comment] Freeman TM. **Ann Allergy Asthma Immunol** 1997 Jun;78(6):602. Comment on: Ann Allergy Asthma Immunol 1996 Aug;77(2):87–95; quiz 96–9.

Management of imported fire ant allergy: results of a survey. Moffitt JE, et al. **Ann Allergy Asthma Immunol** 1997 Aug; 79(2):125–30

ANTACIDS

An esophageal foreign body impaction from a Tums E-X tablet. Wisniewski RM, et al. **Gastrointest Endosc** 1997 Jun; 45(6):518–21

[Determination of formulation quantities for three kinds of antacid using triangle coordinates] Sofue M, et al. **Yakugaku Zasshi** 1997 Mar;117(3):185–92 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Effervescent and standard formulations of ranitidine--a comparison of their pharmacokinetics and pharmacology. Watson RG, et al. **Aliment Pharmacol Ther** 1996 Dec; 10(6):913–8

Formulation of aspirin–magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats. al Gohary OM, et al. **Boll Chim Farm** 1996 Jul–Aug; 135(7):421–8

A pilot study of a randomized controlled trial of pragmatic eradication of Helicobactor pylori in primary care. Hippisley-Cox J, et al. **Br J Gen Pract** 1997 Jun; 47(419):375–7

[Antacids for postoperative prevention of stress ulcer in infants: a dose finding study] Kentrup H, et al. **Klin Padiatr** 1996 Jan–Feb;208(1):14–6 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Aluminium in antacids and cooking pots and the risk of hip fractures in elderly people. Cumming RG, et al. **Age Ageing** 1994 Nov;23(6):468–72

Safety of bismuth [letter; comment] Playford RJ, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):1035–6. Comment on: Aliment Pharmacol Ther 1996 Aug;10(4):459–67.

Antacid-induced osteomalacia. Boutsen Y, et al. **Clin Rheumatol** 1996 Jan;15(1):75–80 (29 ref.)

Prolonged gastric acid suppression therapy: a significant risk factor for Listeria monocytogenes infection? [comment] Glupczynski Y. **Eur J Gastroenterol Hepatol** 1996 Nov; 8(11):1063–6 (19 ref.). Comment on: Eur J Gastroenterol Hepatol 1996 Nov;8(11):1071–4.

Metabolic alkalosis and myoclonus from antacid ingestion. Okada K, et al. **Intern Med** 1996 Jun;35(6):515–6

Metachronous transitional cell carcinoma and tubulointerstitial nephritis after chronic ingestion of antacids: a novel disease association [letter] Vella JP, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2367–8

[Pseudo-esophagitis in antacid abuse] Bokemeyer B, et al. **Leber Magen Darm** 1996 Nov;26(6):320, 323–4 (Eng. Abstr.) **(Ger)**

CHEMICAL SYNTHESIS

Nicotinamide derivatives as a new class of gastric (H+/K+)-ATPase inhibitors. III. Synthesis and gastric antisecretory activity of 2-[(2- and 4-aminobenzyl, and alpha-methylbenzyl)sulfinyl]-N-(4-pyridinyl) -3-pyridinecarboxamides. Terauchi H, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1177–82

CHEMISTRY

Absence of gastrointestinal absorption or urinary excretion of aluminium from an allantoinate complex contained in two antacid formulations in patients with normal renal function. Guillard O, et al. **Eur J Clin Chem Clin Biochem** 1996 Aug;34(8):609–12

Determination of norfloxacin by fluorescence in the presence of different antacids: quantification of analytical interferences. Córdoba-Borrego M, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):977–82

The effect of pH on the in-vitro dissolution of three second-generation sulphonylurea preparations: mechanism of antacid-sulphonylurea interaction. Lehto P, et al. **J Pharm Pharmacol** 1996 Sep;48(9):899–901

[Evaluation of the liberation of aluminum and magnesium ions from preparations made up of antacid] Pawlaczyk J, et al. **Acta Pol Pharm** 1992;49(1-2):11-5 (Eng. Abstr.) **(Pol)**

[Formulation of calcium carbonate tablets with various binding substances] Gazikalović E, et al. **Vojnosanit Pregl** 1996 Mar-Apr;53(2):117-20 (Eng. Abstr.) **(Scr)**

METABOLISM

Absence of gastrointestinal absorption or urinary excretion of aluminium from an allantoinate complex contained in two antacid formulations in patients with normal renal function. Guillard O, et al. **Eur J Clin Chem Clin Biochem** 1996 Aug;34(8):609–12

PHARMACOKINETICS

Effervescent and standard formulations of ranitidine--a comparison of their pharmacokinetics and pharmacology. Watson RG, et al. **Aliment Pharmacol Ther** 1996 Dec; 10(6):913–8

Regional differences in gastric acidity and antacid distribution: is a single pH electrode sufficient? Fisher RS, et al. **Am J Gastroenterol** 1997 Feb;92(2):263–70

Comparative absorption of bismuth in Sprague-Dawley rats following oral administration of preparations containing bismuth sucrose octasulfate, bismuth subsalicylate, and bismuth subcitrate. Rao N, et al. **Biopharm Drug Dispos** 1997 Jan;18(1):1–8

Interaction between sotalol and an antacid preparation. Läer S, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):269–72

In vivo absorption of calcium carbonate and magnesium oxide from the large intestine in rats. Ohta A, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Feb;43(1):35–46

The kinetics of initial gastrointestinal absorption of an aluminium-containing antacid (Tisacid) in patients with various stages of chronic renal insufficiency [letter] Sárszegi Z, et al. **Nephrol Dial Transplant** 1997 Feb; 12(2):372–3

PHARMACOLOGY

Effects of ranitidine bismuth citrate on gastric acid secretion and gastrin release in subjects with and without Helicobacter pylori infection. Ciociola AA, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):905–12

Interaction of an aluminum-magnesium containing antacid and gastric mucus: possible contribution to the cytoprotective function of antacids. Grübel P, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):139–45

Optimizing the pharmacology of acid control in acid-related disorders. Howden CW. **Am J Gastroenterol** 1997 Apr;92(4 Suppl):17S–19S; discussion 19S–21S (27 ref.)

Enhancement of bismuth antibacterial activity with lipophilic thiol chelators. Domenico P, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1697–703

Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. Wong SL, et al. **Biopharm Drug Dispos** 1997 Aug;18(6):533–41

In vitro evaluation of magaldrate antacid efficacy in the presence of some drugs and its effect on their dissolution rates: Part I. al Gohary OM. **Boll Chim Farm** 1996 Dec; 135(11):621–37

An oral sodium citrate-citric acid non-particulate buffer in humans. Hauptfleisch JJ, et al. **Br J Anaesth** 1996 Nov; 77(5):642–4

Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Bullingham R, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):513–6

Nicotinamide derivatives as a new class of gastric (H+/K+)-ATPase inhibitors. III. Synthesis and gastric antisecretory activity of 2-[(2- and 4-aminobenzyl, and alpha-methylbenzyl)sulfinyl]-N-(4-pyridinyl) -3-pyridinecarboxamides. Terauchi H, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1177–82

The effects of famotidine, ranitidine and magnesium hydroxide/aluminium hydroxide on gastric fluid pH in adult horses. Murray MJ, et al. **Equine Vet J Suppl** 1992 Feb;(11):52–5

A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. Maya MT, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct-Dec; 20(4):275–9

Absence of rebound effect with calcium carbonate. Simoneau G. **Eur J Drug Metab Pharmacokinet** 1996 Oct-Dec; 21(4):351–7

Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Mück W, et al. **Int J Clin Pharmacol Ther** 1997 Jun;35(6):261–4

Sodium citrate ingestion enhances 30 km cycling performance. Potteiger JA, et al. **Int J Sports Med** 1996 Jan;17(1):7–11

Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. Teng R, et al. **J Antimicrob Chemother** 1997 Jun;39 Suppl B:93–7

Activity of amoxicillin, metronidazole, bismuth salicylate and six aminoglycosides against Helicobacter pylori. Brenciaglia MI, et al. **J Chemother** 1996 Feb;8(1):52–4

Interaction of meloxicam with cimetidine, Maalox, or aspirin. Busch U, et al. **J Clin Pharmacol** 1996 Jan;36(1):79–84

Effect of antacid magaldrate oral suspension on in-vitro and in-vivo availability of indomethacin in dogs. al-Gohary OM, et al. **Pharm Acta Helv** 1997 Apr;72(2):81–6

[Gastroprotective effect of an antacid coating agent in rats. Role of endogenous prostaglandins, capsaicin-sensitive afferents neurons and nitric oxide] Ramaholimihaso F, et al. **Gastroenterol Clin Biol** 1997;21(5):370–6 (Eng. Abstr.) **(Fre)**

[in vitro comparison of liquid antacids of commercial use] Dominguez A, et al. **Rev Gastroenterol Peru** 1996 May-Aug;16(2):138–41 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. De Boer WA, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):633–8

Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy. Goddard AF, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):1009–13

Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Freston JW. **Am J Gastroenterol** 1997 Apr;92(4 Suppl):51S–55S; discussion 55S–57S (28 ref.)

A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study. Lerang F, et al. **Am J Gastroenterol** 1997 Apr;92(4):653–8

Is the incidence of hemorrhagic stress ulceration in surgical critically ill patients affected by modern antacid prophylaxis? Zeltsman D, et al. **Am Surg** 1996 Dec; 62(12):1010–3

Antimicrobial management of Helicobacter pylori-associated gastrointestinal tract disease. Guay DR, et al. **Arch Fam Med** 1997 Mar-Apr;6(2):173–80 (00 ref.)

Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats. al Gohary OM, et al. **Boll Chim Farm** 1996 Jul-Aug; 135(7):421–8

Triple therapy as a cure for Helicobacter pylori infection. Bardhan KD. **Eur J Gastroenterol Hepatol** 1996 Oct;8 Suppl 1:S27–30 (36 ref.)

Follow-up on 242 patients with peptic ulcer disease one year after eradication of Helicobacter pylori infection. Berstad A, et al. **Hepatogastroenterology** 1995 Sep-Oct;42(5):655–9

Comparative study of antacid and sucralfate suspension for acute upper gastro-intestinal hemorrhage in Chaiyaphum Hospital, Thailand. Charoenwat S. **J Med Assoc Thai** 1996 Nov;79(11):727–31

Is antacid treatment necessary in obstetric anesthesia? Al Mazrooa AA, et al. **Middle East J Anesthesiol** 1995 Oct; 13(3):335–40

Pooled analysis of anti-Helicobacter pylori treatment regimens. Unge P, et al. **Scand J Gastroenterol Suppl** 1996; 220:27–40 (307 ref.)

Pure silicate fragment in a recurrent stone former of calcium oxalate. Ichiyanagi O, et al. **Urol Int** 1997;58(3):192–6

Current Perspectives in Acid Inhibitory Therapy. New Haven, Connecticut, November 17-19, 1995. Proceedings of a conference. **Yale J Biol Med** 1996 Jan-Feb;69(1):1–104

[New proton pump inhibitors. Advances in the therapy of acid-induced diseases] **Internist (Berl)** 1994 Sep;35(9 Suppl):1–8 **(Ger)**

[A clinical trial on the effect of aluminum containing antacids on the course of duodenal ulcer healing and morphology of the gastric mucosa] Mach T. **Folia Med Cracov** 1995; 36(1-4):3–20 (Eng. Abstr.) **(Pol)**

ANTAZOLINE

ADMINISTRATION & DOSAGE

[Antazoline/tetryzoline eyedrops in comparison with levocabastine eyedrops in acute allergic conjunctivitis] Wertheimer R, et al. **Klin Monatsbl Augenheilkd** 1997 Feb; 210(2):93–6 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Antazoline increases insulin secretion and improves glucose tolerance in rats and dogs. Berdeu D, et al. **Eur J Pharmacol** 1997 Apr 18;324(2-3):233–9

ANTELOPES

Control of energy balance by a wild ungulate, the kudu (Tragelaphus strepsiceros) through adaptive foraging behaviour. Owen-Smith N. **Proc Nutr Soc** 1997 Mar; 56(1A):15–24

Magnesium deficiency in captive antelope. Váhala J. **Vet Rec** 1997 Feb 22;140(8):207–8

ANATOMY & HISTOLOGY

Infraorbital glands of a male Formosan serow (Capricornis crispus swinhoei). Atoji Y, et al. **Eur J Morphol** 1996; 34(2):87–94

CLASSIFICATION

[The Mongolian saiga: its present status and preservation outlook] Lushchekina AA, et al. **Izv Akad Nauk Ser Biol** 1997 Mar-Apr;(2):177–85 (44 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Chromosomes of Damaliscus (Artiodactyla, Bovidae): simple and complex centric fusion rearrangements. Kumamoto AT, et al. **Chromosome Res** 1996 Dec;4(8):614–21

X chromosome evolution in the suni and eland antelope: detection of homologous regions by fluorescence in situ hybridization and G-banding. Robinson TJ, et al. **Cytogenet Cell Genet** 1997;77(3-4):218–22

The karyotype of the addax and its comparison with karyotypes of other species of Hippotraginae antelopes. Claro F, et al. **Hereditas** 1996;124(3):223–7

Genetic and behavioural evidence of monogamy in a mammal, Kirk's dik-dik (Madoqua kirkii). Brotherton PN, et al. **Proc R Soc Lond B Biol Sci** 1997 May 22; 264(1382):675–81

METABOLISM

Swayback in a blesbok (Damaliscus dorcas phillipsi) and a black wildebeest (Connochaetes gnou). Penrith ML, et al. **J S Afr Vet Assoc** 1996 Jun;67(2):93–6

Pharmacokinetics of a single intravenous enrofloxacin dose in scimitar-horned oryx (Oryx dammah). Gamble KC, et al. **J Zoo Wildl Med** 1997 Mar;28(1):36–42

The mineralization of crystalline inorganic components in Japanese serow horn. Hashiguchi K, et al. **Okajimas Folia Anat Jpn** 1995 Dec;72(5):235–43

PARASITOLOGY

Sites of attachment and density assessment of ixodid ticks (Acari:Ixodidae) on impala (Aepyceros melampus). Matthee S, et al. **Exp Appl Acarol** 1997 Mar;21(3):179–92

Neurologic disease attributable to infection with Parelaphostrongylus tenuis in blackbuck antelope. Oliver JL 3rd, et al. **J Am Vet Med Assoc** 1996 Jul 1;209(1):140–2

A pilot trial on the experimental infection of springbok (Antidorcas marsupialis) and eland (Taurotragus oryx) with a goat strain of Strongyloides papillosus [editorial] Norval AG, et al. **J S Afr Vet Assoc** 1996 Jun;67(2):72–3

Clinical challenge. Parelaphostrongylus tenuis (meningeal worm) infection of the cranial spinal cord and brain stem. Ferrell ST, et al. **J Zoo Wildl Med** 1997 Jun;28(2):221–3

Parasites of South African wildlife. XIV. Helminths of nyalas (Tragelaphus angasii) in the Mkuzi Game Reserve, KwaZulu-Natal. Boomker J, et al. **Onderstepoort J Vet Res** 1996 Dec;63(4):265–71

Onchocerca suzukii n. sp. and O. skrjabini (= O. tarsicola) from a relict bovid, Capricornis crispus, in Japan. Yagi K, et al. **Parasite** 1994 Dec;1(4):349–56

Antelopes (Bovidae) kept in European zoological gardens as intermediate hosts of Sarcocystis species. Stolte M, et al. **Parassitologia** 1996 Dec;38(3):565–70

PHYSIOLOGY

Effects of a carfentanil-xylazine combination on cardiopulmonary function and plasma catecholamine concentrations in female bongo antelopes. Schumacher J, et al. **Am J Vet Res** 1997 Feb;58(2):157–61

How muscle mass is part of the fabric of behavioral ecology in East African bovids (Madoqua, Gazella, Damaliscus, Hippotragus). Grand TI. **Anat Embryol (Berl)** 1997 Apr; 195(4):375–86

Activity, blood temperature and brain temperature of free-ranging springbok. Mitchell D, et al. **J Comp Physiol [B]** 1997 Jul;167(5):335–43

Cardiopulmonary effects of carfentanil in dama gazelles

ANTELOPES

(Gazella dama). Schumacher J, et al. **J Zoo Wildl Med** 1997 Jun;28(2):166–70

Oestrous synchronization, semen preservation and artificial insemination in the Mohor gazelle (Gazella dama mhorr) for the establishment of a genome resource bank programme. Holt WV, et al. **Reprod Fertil Dev** 1996; 8(8):1215–22

Impala, Aepyceros melampus, platelets: count, morphology, and morphometric observations. du Plessis L, et al. **Tissue Cell** 1997 Apr;29(2):217–20

PSYCHOLOGY

Genetic and behavioural evidence of monogamy in a mammal, Kirk's dik-dik (Madoqua kirkii). Brotherton PN, et al. **Proc R Soc Lond B Biol Sci** 1997 May 22; 264(1382):675–81

VIROLOGY

The 1992 foot-and-mouth disease epizootic in the Kruger National Park. Keet DF, et al. **J S Afr Vet Assoc** 1996 Jun;67(2):83–7

Gazelle herpesvirus 1: a new neurotropic herpesvirus immunologically related to equine herpesvirus 1. Fukushi H, et al. **Virology** 1997 Jan 6;227(1):34–44

ANTELOPINES see **ANTELOPES**

ANTERIOR CHAMBER

Metastatic anterior chamber non-Hodgkin lymphoma in a patient with acquired immunodeficiency syndrome. España-Gregori E, et al. **Am J Ophthalmol** 1997 Aug; 124(2):243–5

Pupillary block, angle-closure glaucoma produced by an anterior chamber air bubble in a nanophthalmic [corrected] eye [letter; comment] [published erratum appears in Arch Ophthalmol 1997 Sep;115(9):1112] Shugar JK. **Arch Ophthalmol** 1997 Mar;115(3):432. Comment on: Arch Ophthalmol 1996 Sep;114(9):1145–6.

Preventing expulsive hemorrhage using an anterior chamber maintainer to eliminate hypotony. Blumenthal M, et al. **J Cataract Refract Surg** 1997 May;23(4):476–9

Anterior chamber irrigation with unpreserved lidocaine 1% for anesthesia during cataract surgery. Koch PS. **J Cataract Refract Surg** 1997 May;23(4):551–4

Efficacy of anterior chamber paracentesis and Carbogen in treating acute nonarteritic central retinal artery occlusion. Atebara NH, et al. **Ophthalmology** 1995 Dec; 102(12):2029–34; discussion 2034–5

ABNORMALITIES

Autosomal recessive nanophthalmos. Altintaş AK, et al. **Acta Ophthalmol Scand** 1997 Jun;75(3):325–8

CHARGE association with congenital glaucoma due to maldevelopment of the anterior chamber angle. Katai N, et al. **Acta Ophthalmol Scand** 1997 Jun;75(3):322–4

Rieger syndrome: a case report. Dimitrakopoulos J, et al. **J Oral Maxillofac Surg** 1997 May;55(5):517–21

[Goniodysplasia in the Bouvier des Flandres] Rühli MB, et al. **Schweiz Arch Tierheilkd** 1996;138(6):307–11 (Eng. Abstr.) **(Ger)**

ANATOMY & HISTOLOGY

Anterior chamber depth in Mongolians: variation with age, sex, and method of measurement. Foster PJ, et al. **Am J Ophthalmol** 1997 Jul;124(1):53–60

Ultrasound biomicroscopy of globes from young adult pigs. Bartholomew LR, et al. **Am J Vet Res** 1997 Sep;58(9):942–8

Submicrometer precision biometry of the anterior segment of the human eye. Drexler W, et al. **Invest Ophthalmol Vis Sci** 1997 Jun;38(7):1304–13

Tangential penlight angle estimation. Sparks BI 3rd. **J Am Optom Assoc** 1997 Jul;68(7):432–4

Gonioscopy: evaluation of the anterior chamber angle. Part II. Prokopich CL, et al. **Ophthalmic Physiol Opt** 1997 Mar; 17 Suppl 1:S9–13 (5 ref.)

Anterior chamber maintenance during drainage of a suprachoroidal hemorrhage in two phakic eyes. Birt CM, et al. **Ophthalmic Surg Lasers** 1996 Sep;27(9):739–45

Anterior chamber depth measurement in clinical practice. Barrett BT, et al. **Optom Vis Sci** 1996 Jul;73(7):482–6

Comparison of carboxymethylcellulose vs. hydroxypropyl methylcellulose as a gonioscopic fluid. Nguyen TP, et al. **Optom Vis Sci** 1996 Jul;73(7):466–72

[A study on method of measurement and analysis of anterior chamber configuration by computerized image processing] Wang N, et al. **Chung Hua Yen Ko Tsa Chih** 1995 Nov; 31(6):412–6 (Eng. Abstr.) **(Chi)**

[Calculation of the assumed postoperative anterior chamber depth as an important factor in the calculation of optic power of the intraocular lens] Pontúchová E, et al. **Cesk Slov Oftalmol** 1996 Sep;52(4):215–9 (Eng. Abstr.) **(Slo)**

CYTOLOGY

Effect of commercial dilating agents on laser flare-cell measurements. Chin PK, et al. **Can J Ophthalmol** 1996 Dec; 31(7):362–5

DRUG EFFECTS

Interaction between head-down tilt and anterior chamber infusions on intraocular pressure of anesthetized rats. Searles RV, et al. **Exp Eye Res** 1996 Jun;62(6):621–6

Ultrasound biomicroscopic analysis of the effect of pilocarpine on the anterior chamber angle. Kobayashi H, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Jul; 235(7):425–30

Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery. Wedrich A, et al. **J Cataract Refract Surg** 1997 Jul-Aug;23(6):873–7

Anterior chamber angles shallowing and intraocular pressure after topical pilocarpine. Yang CC, et al. **J Ocul Pharmacol Ther** 1997 Jun;13(3):219–24

Effect of suleparoide on fibrinolysis in the anterior chamber of rabbits. Lepri A, et al. **Ophthalmic Res** 1996;28(3):176–83

[Band-like keratopathy after treatment of postoperative fibrin reaction with tissue plasminogen activator] Wollensak G, et al. **Klin Monatsbl Augenheilkd** 1996 Jul;209(1):43–6 (Eng. Abstr.) **(Ger)**

[Anterior chamber inflammation after the injection of endothelin-1 into the vitreous and the effect of an anti-prostaglandin agent] Shoji N, et al. **Nippon Ganka Gakkai Zasshi** 1997 Mar;101(3):209–14 (Eng. Abstr.) **(Jpn)**

[Anterior chamber inflammation after the injection of endothelin-1 into the vitreous and the effect of ETA receptor antagonist] Shoji N, et al. **Nippon Ganka Gakkai Zasshi** 1997 Apr;101(4):305–11 (Eng. Abstr.) **(Jpn)**

[Studies of changes in filtration angle after experimental administration of ethacrynic acid into the anterior chamber] Toczołowski J, et al. **Klin Oczna** 1996 Feb;98(2):89–91 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

The effect of IL-12 on immune privilege of the eye. Uno T, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:426–8

Differential immune responses to fetal intracameral spinal cord and cortex cerebri grafts. Shinoda M, et al. **Exp Brain Res** 1996 Jul;110(2):223–34

Role of Th1 and Th2 cells in anterior chamber-associated immune deviation. Li XY, et al. **Immunology** 1996 Sep; 89(1):34–40

Serum TABM produced during anterior chamber-associated immune deviation passively transfers suppression of delayed-type hypersensitivity to primed mice. Wang Y, et al. **Int Immunol** 1997 Feb;9(2):211–8

Loss and restoration of immune privilege in eyes with corneal neovascularization. Dana MR, et al. **Invest Ophthalmol Vis Sci** 1996 Nov;37(12):2485–94

Effect of cyclosporine on anterior chamber-associated immune deviation with retinal transplantation. Ishioka M, et al. **Invest Ophthalmol Vis Sci** 1997 Sep;38(10):2152–60

Anterior chamber-associated immune deviation promotes corneal allograft survival. Niederkorn JY, et al. **Invest Ophthalmol Vis Sci** 1996 Dec;37(13):2700–7

The antigen-bearing eye and the spleen are indispensable in maintaining anterior chamber-associated immune deviation. Yao YF, et al. **Invest Ophthalmol Vis Sci** 1997 Feb;38(2):534–9

Correlation of anterior chamber-associated immune deviation with suppression of corneal epithelial rejection in mice. Yao YF, et al. **Invest Ophthalmol Vis Sci** 1997 Feb; 38(2):292–300

Intraocular injection of class II-restricted peptide induces an unexpected population of CD8 regulatory cells. Kosiewicz MM, et al. **J Immunol** 1996 Sep 1;157(5):1905–12

Direct thymic involvement in anterior chamber-associated immune deviation: evidence for a nondeletional mechanism of centrally induced tolerance to extrathymic antigens in adult mice. Wang Y, et al. **J Immunol** 1997 Mar 1; 158(5):2150–5

Relationship of the strain and the intraocular amount of herpes simplex virus types 1 and 2 in the induction of anterior-chamber-associated immune deviation. Akiba M, et al. **Ophthalmic Res** 1996;28(5):289–95

INJURIES

Erosion and migration of a Watzke sleeve into the anterior chamber. Ahn CS, et al. **Retina** 1997;17(1):71–3

METABOLISM

The kinetics of anterior chamber ofloxacin penetration. Bouchard CS, et al. **Cornea** 1996 Jan;15(1):72–5

Corneal endothelial hyaluronidase: a role in anterior chamber hyaluronic acid catabolism. Schwartz DM, et al. **Cornea** 1997 Mar;16(2):188–91

Cyclosporin-A and its metabolites in the anterior chamber after topical and systemic application as determined with high-performance liquid chromatography-electrospray mass spectrometry. Althaus C, et al. **Ger J Ophthalmol** 1996 Jul;5(4):189–94

Anterior chamber concentrations of vancomycin in the irrigating solution at the end of cataract surgery. Adenis JP, et al. **J Cataract Refract Surg** 1997 Jan-Feb;23(1):111–4

Half-life of intracameral gentamicin after phacoemulsification. Lehmann OJ, et al. **J Cataract Refract Surg** 1997 Jul-Aug;23(6):883–8

Penetration into the anterior chamber via the conjunctival/scleral pathway. Schoenwald RD, et al. **J Ocul Pharmacol Ther** 1997 Feb;13(1):41–59

Ocular pharmacokinetics and convectional flow: evidence from spatio-temporal analysis of mydriasis. Wyatt HJ. **J Ocul Pharmacol Ther** 1996 Winter;12(4):441–59

Endothelin-1 and intraocular inflammation in pigmented rabbit eyes. Shoji N, et al. **Jpn J Ophthalmol** 1997 May-Jun; 41(3):150–3

Growth factors and their receptors in the anterior chamber. Absence of epidermal growth factor and transforming growth factor alpha in human aqueous humor. van Setten GB, et al. **Ophthalmic Res** 1996;28(6):361–4

Facility changes mediated by cAMP in the bovine anterior segment in vitro. Gilabert R, et al. **Vision Res** 1997 Jan; 37(1):9–15

MICROBIOLOGY

The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study. A comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Bannerman TL, et al. **Arch Ophthalmol** 1997 Mar;115(3):357–61

Bacterial anterior chamber contamination with foldable silicone lens implantation using a forceps and an injector. Weindler J, et al. **J Cataract Refract Surg** 1996;22 Suppl 2:1263–6

Anterior chamber contamination following uncomplicated cataract surgery: comparative results using intravenous imipenem. Duch-Samper AM, et al. **Ophthalmic Surg Lasers** 1996 Dec;27(12):1005–11

Changes in bacterial strains before and after cataract surgery. Hara T, et al. **Ophthalmology** 1996 Nov;103(11):1876–9

Chronic postoperative gram-negative endophthalmitis. Aaberg TM Jr, et al. **Retina** 1997;17(3):260–2

PARASITOLOGY

Freely mobile cysticercus in the anterior chamber. Sachdeva RS, et al. **Indian J Ophthalmol** 1995 Sep;43(3):135–6

PATHOLOGY

Complications of retained nuclear fragments in the anterior chamber after phacoemulsification with posterior chamber lens implant. Bohigian GM, et al. **Am J Ophthalmol** 1997 Apr;123(4):546–7

Acanthamoeba keratitis with granulomatous reaction involving the stroma and anterior chamber. Mietz H, et al. **Arch Ophthalmol** 1997 Feb;115(2):259–63

The pathogenesis of polychromatic cholesterol crystals in the anterior chamber. Kennedy CJ. **Aust N Z J Ophthalmol** 1996 Aug;24(3):267–73

The flashlight test and van Herick's test are poor predictors for occludable angles. Thomas R, et al. **Aust N Z J Ophthalmol** 1996 Aug;24(3):251–6

Pseudohypopyon due to synchisis scintillans [letter] Eke T, et al. **Eye** 1996;10 (Pt 4):527–8

Flare-cell meter measurement of inflammation after uneventful cataract surgery with intraocular lens implantation. Alió JL, et al. **J Cataract Refract Surg** 1997 Jul-Aug;23(6):935–9

Postoperative inflammatory response to phacoemulsification and extracapsular cataract surgery: aqueous flare and cells. Pande MV, et al. **J Cataract Refract Surg** 1996;22 Suppl 1:770–4

Corneal epithelial defect may affect anterior chamber flare [letter; comment] Sun R, et al. **J Refract Surg** 1996 Nov-Dec;12(7):755. Comment on: J Refract Surg 1996 Jan-Feb;12(1):103–7.

Anterior chamber flare after photorefractive keratectomy [see comments] Tomas-Barberan S, et al. **J Refract Surg** 1996 Jan-Feb;12(1):103–7. Comment in: J Refract Surg 1996 Nov-Dec;12(7):755.

Surgical reconstruction for angle-closure glaucoma due to a flat anterior chamber following trabeculectomy. Tanihara H, et al. **Ophthalmic Surg Lasers** 1997 Jun;28(6):510–2

[The study of grading standard photos of oblique flashlight test] Yu Q, et al. **Yen Ko Hsueh Pao** 1995 Jun;11(2):80–5 (Eng. Abstr.) **(Chi)**

[The postoperative change of depth of anterior chamber, refraction and anterior capsulorhexis size after intraocular lens implantation] Nishigaki S, et al. **Nippon Ganka Gakkai Zasshi** 1996 Feb;100(2):156–8 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Diurnal change of anterior chamber depth in rabbits. Larsson LI, et al. **Acta Ophthalmol Scand** 1995 Dec;73(6):534–6

Re-forming the flat anterior chamber with Healon [letter] Schipper I. **J Cataract Refract Surg** 1996 Oct;22(8):1002–3

Comparative analysis of the fluidics of the AMO Prestige, Alcon Legacy, and Storz Premiere phacoemulsification systems. Wilbrandt HR. **J Cataract Refract Surg** 1997 Jun; 23(5):766–80

Development of grafts of the neocortex of human embryos in the anterior chamber of the rat eye. Smirnov EB, et al. **Neurosci Behav Physiol** 1996 May-Jun;26(3):220–4

SURGERY

Long-term graft survival in patients with flexible open-loop anterior-chamber intraocular lenses. Lois N, et al. **Cornea** 1997 Jul;16(4):387–92

Corneal endothelial permeability after implantation of angle-fitted anterior chamber lenses in myopic phakic eyes. Preliminary results. Benitez del Castillo JM, et al. **Doc Ophthalmol** 1995-96;91(3):201-6

Long-term evaluation of primary anterior chamber intraocular lens implantation in complicated cataract surgery. Bergman M, et al. **Int Ophthalmol** 1996-97; 20(6):295-9

Endothelial changes in phakic eyes after anterior chamber lens implantation [letter] Eifrig DE, et al. **J Cataract Refract Surg** 1996 Dec;22(10):1392

Secondary implantation of open-loop, flexible, anterior chamber intraocular lenses. Ellerton CR, et al. **J Cataract Refract Surg** 1996 Sep;22(7):951-4

Magnification and visual acuity in highly myopic phakic eyes corrected with an anterior chamber intraocular lens versus by other methods. García M, et al. **J Cataract Refract Surg** 1996 Dec;22(10):1416-22

In defense of phakic anterior chamber lenses [letter] Kaufman HE, et al. **J Cataract Refract Surg** 1997 Jul-Aug; 23(6):815-7

Opaque iris claw lens in a phakic eye to correct acquired diplopia. Landesz M, et al. **J Cataract Refract Surg** 1997 Jan-Feb;23(1):137-8

Endothelial changes in phakic eyes with anterior chamber intraocular lenses to correct high myopia. Pérez-Santonja JJ, et al. **J Cataract Refract Surg** 1996 Oct;22(8):1017-22

Uses of the Sheets lens glide in contemporary cataract [letter] Piccone MR, et al. **J Cataract Refract Surg** 1997 Jan-Feb; 23(1):9-10

Neovascular glaucoma [letter] Frenkel RE, et al. **J Glaucoma** 1996 Apr;5(2):150

Surgical correction of high myopia in phakic eyes with Worst-Fechner myopia intraocular lenses. Pérez-Santonja JJ, et al. **J Refract Surg** 1997 May-Jun;13(3):268-81; discussion 281-4

Correction of high myopia by implantation of minus-power intraocular lenses in phakic eyes [letter] Wichmann W. **J Refract Surg** 1996 Sep-Oct;12(6):672-3

Phacoemulsification for cataract following pars plana vitrectomy. McDermott ML, et al. **Ophthalmic Surg Lasers** 1997 Jul;28(7):558-64

An unusual complication of a postcataract filtering bleb. Rao SK, et al. **Ophthalmic Surg Lasers** 1997 Jul;28(7):601-2

Block excision of tumors of the anterior uvea. Report on 68 consecutive patients. Naumann GO, et al. **Ophthalmology** 1996 Dec;103(12):2017-27; discussion 2027-8

Acceptable AC IOLs in the 1990s [letter; comment] Spencer M. **Ophthalmology** 1995 Jul;102(7):1001-2. Comment on: Ophthalmology 1994 Dec;101(12):1913-22.

Experimental vitreous and aqueous replacement with perfluorophenanthrene. Clinical, histologic, and electrophysiologic results. Stolba U, et al. **Retina** 1997; 17(2):146-53

ULTRASONOGRAPHY

Ultrasound biomicroscopic measurement of anterior chamber angle in premature infants. Kobayashi H, et al. **Br J Ophthalmol** 1997 Jun;81(6):460-4

Preoperative ultrasound biomicroscopy to assess ease of haptic removal before penetrating keratoplasty combined with lens exchange. Rutnin SS, et al. **J Cataract Refract Surg** 1997 Mar;23(2):239-43

Intraobserver and interobserver agreement in evaluating the anterior chamber angle configuration by ultrasound biomicroscopy. Spaeth GL, et al. **J Glaucoma** 1997 Feb; 6(1):13-7

Ultrasound biomicroscopy of Baikoff anterior chamber phakic intraocular lenses. Saragoussi JJ, et al. **J Refract Surg** 1997 Mar-Apr;13(2):135-41

ULTRASTRUCTURE

Corrosion casts of the suprachoroidal space and uveoscleral drainage routes in the pig eye. Krohn J, et al. **Acta Ophthalmol Scand** 1997 Feb;75(1):28-31

Corrosion casts of the suprachoroidal space and uveoscleral drainage routes in the human eye. Krohn J, et al. **Acta Ophthalmol Scand** 1997 Feb;75(1):32-5

ANTERIOR CHAMBER EPITHELIUM see **ENDOTHELIUM, CORNEAL**

ANTERIOR COMPARTMENT SYNDROME

COMPLICATIONS

Exercise induced leg pain-chronic compartment syndrome. Is the increase in intra-compartment pressure exercise specific? Padhiar N, et al. **Br J Sports Med** 1996 Dec; 30(4):360-2

DIAGNOSIS

An aviator with an unusual gait: a rare disease teaches some everyday lessons. Brooks KE, et al. **Aviat Space Environ Med** 1997 Feb;68(2):147-50

Compartment monitoring in tibial fractures. The pressure threshold for decompression. McQueen MM, et al. **J Bone Joint Surg Br** 1996 Jan;78(1):99-104

Anterior tibial dystrophy (late onset foot drop muscular dystrophy with rimmed vacuoles). Partanen J. **Neurol Neurochir Pol** 1996;30 Suppl 3:77-80

ETIOLOGY

Acute compartment syndrome in tibial diaphyseal fractures [see comments] McQueen MM, et al. **J Bone Joint Surg Br** 1996 Jan;78(1):95-8. Comment in: J Bone Joint Surg Br 1996 Jan;78(1):95-8.

Anterior compartment syndrome after revision hip arthroplasty. Nicholl JE, et al. **J Bone Joint Surg Br** 1996 Sep;78(5):812-3

Acute tibial compartment syndrome secondary to psychosomatic disorder. Eskander MB, et al. **J R Army Med Corps** 1994 Jun;140(2):97-8 (5 ref.)

[Acute compartment syndrome of the tibia—complication of popliteal artery aneurysm] Dellanna M, et al. **Zentralbl Chir** 1997;122(3):193-6 (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Pyomyositis of the anterior tibial compartment. Cone LA, et al. **Clin Infect Dis** 1997 Jul;25(1):146-8

PHYSIOPATHOLOGY

[Good results of fasciotomy in chronic compartment syndrome of the lower leg (letter; comment)] Fontijne WP, et al. **Ned Tijdschr Geneeskd** 1997 Mar 8;141(10):494-5. Comment on: Ned Tijdschr Geneeskd 1996 Dec 14;140(50):2513-7. **(Dut)**

[Good results of fasciotomy in chronic compartment syndrome of the lower leg (letter; comment)] van Vugt AB. **Ned Tijdschr Geneeskd** 1997 Mar 8;141(10):494. Comment on: Ned Tijdschr Geneeskd 1996 Dec 14;140(50):2513-7. **(Dut)**

[How relevant are calculations of mean intracompartmental pressure in functional compartment syndrome?] Jerosch J, et al. **Biomed Tech (Berl)** 1997 Mar;42(3):42-7 (12 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Prevention of compartment syndrome associated with dorsal lithotomy position. Scott JR, et al. **Am Surg** 1997 Sep; 63(9):801-6

RADIONUCLIDE IMAGING

Chronic exertional compartment syndrome in lower legs: localization and follow-up with thallium-201 SPECT imaging. Takebayashi S, et al. **J Nucl Med** 1997 Jun; 38(6):972-6

SURGERY

[Good results of fasciotomy in chronic compartment syndrome of the lower leg (see comments)] Verleisdonk EJ, et al. **Ned Tijdschr Geneeskd** 1996 Dec 14; 140(50):2513-7 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1997 Mar 8;141(10):494. **(Dut)**

[Corrective soft tissue interventions for equinovarus deformity. Foot deformities after tibial compartment syndrome] Dávid A, et al. **Unfallchirurg** 1997 May; 100(5):371-4 (Eng. Abstr.) **(Ger)**

[Traumatically-induced compartment syndrome of the tibia. Ultrasound diagnosis for qualitative assessment of late sequelae for musculature after dermatofasciotomy] Küllmer K, et al. **Unfallchirurgie** 1997 Jun;23(3):87-91 (Eng. Abstr.) **(Ger)**

ANTERIOR CRUCIATE LIGAMENT

see related
MEDIAL COLLATERAL LIGAMENT, KNEE
POSTERIOR CRUCIATE LIGAMENT

Knee dislocation without anterior cruciate ligament disruption. A report of three cases. Bellabarba C, et al. **Am J Knee Surg** 1996 Fall;9(4):167-70

Ganglion of the anterior cruciate ligament presented as a knee mass [letter; comment] Kaempffe FA. **Am J Orthop** 1996 Aug;25(8):521. Comment on: Am J Orthop 1996 Jan;25(1):46-8.

The effect of functional knee bracing on the anterior cruciate ligament in the weightbearing and nonweightbearing knee. Beynnon BD, et al. **Am J Sports Med** 1997 May-Jun; 25(3):353-9

Isometry measurements in the knee with the anterior cruciate ligament intact, sectioned, and reconstructed. Furia JP, et al. **Am J Sports Med** 1997 May-Jun;25(3):346-52

The Insall Award. Total knee replacement with posterior cruciate ligament retention in patients with a fixed varus deformity. Laskin RS. **Clin Orthop** 1996 Oct;(331):29-34

Anterior cruciate ligament injuries in skeletally immature patients. Janarv PM, et al. **J Pediatr Orthop** 1996 Sep-Oct; 16(5):673-7

Gait adaptations before and after anterior cruciate ligament reconstruction surgery. Devita P, et al. **Med Sci Sports Exerc** 1997 Jul;29(7):853-9

ABNORMALITIES

Abnormal femoral origin of the anterior cruciate ligament combined with a discoid lateral meniscus. Hoffmann FF. **Arthroscopy** 1997 Apr;13(2):254-6

Bilateral complete discoid medial menisci combined with anomalous insertion and cyst formation. Kim SJ, et al. **Arthroscopy** 1996 Feb;12(1):112-5

Fascia lata autograft for treatment of congenital cranial cruciate ligament deficiency in a llama. Anderson DE, et al. **J Am Vet Med Assoc** 1997 Mar 15;210(6):811-3

ANATOMY & HISTOLOGY

Intercondylar notch width and its relation to the configuration and cross-sectional area of the anterior cruciate ligament. A cadaveric knee study. Muneta T, et al. **Am J Sports Med** 1997 Jan-Feb;25(1):69-72

Cruciate ligament graft intra-articular distances. Miller MD, et al. **Arthroscopy** 1997 Jun;13(3):291-5

MRI of normal anterior cruciate ligament (ACL) and reconstructed ACL: comparison of when the knee is extended with when the knee is flexed. Nakanishi K, et al. **Eur Radiol** 1997;7(7):1020-4

BLOOD SUPPLY

Vascular anatomy of the ovine anterior cruciate ligament. A macroscopic, histological and radiographic study. Seitz H, et al. **Arch Orthop Trauma Surg** 1997;116(1-2):19-21

Vascular anatomy of the human cruciate ligaments and surrounding structures. Scapinelli R. **Clin Anat** 1997; 10(3):151-62

CHEMISTRY

Decrease in fibronectin occurs coincident with the increased expression of its integrin receptor alpha5beta1 in stress-deprived ligaments. AbiEzzi SS, et al. **Iowa Orthop J** 1997;17:102-9

CYTOLOGY

Signal pathways and ligament cell adhesiveness. Sung KL, et al. **J Orthop Res** 1996 Sep;14(5):729-35

INJURIES

Neural and muscular electric activity in the cat's knee. Changes when the anterior cruciate ligament is transected. Gómez-Barrena E, et al. **Acta Orthop Scand** 1997 Apr; 68(2):149-55

Medial collateral knee ligament healing. Combined medial collateral and anterior cruciate ligament injuries studied in rabbits. Woo SL, et al. **Acta Orthop Scand** 1997 Apr; 68(2):142-8

Using MR imaging to diagnose partial tears of the anterior cruciate ligament: value of axial images. Roychowdhury S, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1487-91

Endoscopic anterior cruciate ligament reconstruction: complication of graft rupture and a method of salvage. Arciero RA. **Am J Knee Surg** 1996 Winter;9(1):27-31

Clinical and functional outcome of anterior cruciate ligament reconstruction in the recreational athlete over the age of 35. Novak PJ, et al. **Am J Knee Surg** 1996 Summer; 9(3):111-6

Meniscal and nonosseous ACL injuries in children and adolescents. Williams JS Jr, et al. **Am J Knee Surg** 1996 Winter;9(1):22-6

C-reactive protein levels determine the severity of soft-tissue injuries. Pritchett JW. **Am J Orthop** 1996 Nov; 25(11):759-61

Arthroscopically assisted semitendinosus and gracilis tendon graft in reconstruction for acute anterior cruciate ligament injuries in athletes. Aglietti P, et al. **Am J Sports Med** 1996 Nov-Dec;24(6):726-31

The effect of tourniquet use in anterior cruciate ligament reconstruction. A prospective, randomized study [see comments] Arciero RA, et al. **Am J Sports Med** 1996 Nov-Dec;24(6):758-64. Comment in: Am J Sports Med 1997 Mar-Apr;25(2):275-6.

Quadriceps muscle contraction protects the anterior cruciate ligament during anterior tibial translation. Aune AK, et al. **Am J Sports Med** 1997 Mar-Apr;25(2):187-90

Evidence of reinnervation of free patellar tendon autograft used for anterior cruciate ligament reconstruction. Barrack RL, et al. **Am J Sports Med** 1997 Mar-Apr;25(2):196-202

Evaluation of knee joint laxity and the structural properties of the anterior cruciate ligament graft in the human. A case report. Beynnon BD, et al. **Am J Sports Med** 1997 Mar-Apr;25(2):203-6

Epidemiology of anterior cruciate ligament injuries in soccer. Bjordal JM, et al. **Am J Sports Med** 1997 May-Jun; 25(3):341-5

The effects of joint position and direction of joint motion on proprioceptive sensibility in anterior cruciate ligament-deficient athletes. Borsa PA, et al. **Am J Sports Med** 1997 May-Jun;25(3):336-40

Evaluation of pain after arthroscopically assisted anterior cruciate ligament reconstruction. Brown DW, et al. **Am J Sports Med** 1997 Mar-Apr;25(2):182-6

The use of cold therapy in the postoperative management of patients undergoing arthroscopic anterior cruciate ligament reconstruction. Edwards DJ, et al. **Am J Sports Med** 1996 Mar-Apr;24(2):193-5

The scientific basis of rehabilitation. Eriksson E. **Am J Sports Med** 1996;24(6 Suppl):S25-7

Football cleat design and its effect on anterior cruciate ligament injuries [letter; comment] Garrick JG, et al. **Am J Sports Med** 1996 Sep-Oct;24(5):705-6. Comment on:

Am J Sports Med 1996 Mar–Apr;24(2):155–9.

Central quadriceps tendon for anterior cruciate ligament reconstruction. Part I: Morphometric and biomechanical evaluation. Harris NL, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):23–8

Increased tibial translation after partial sectioning of the anterior cruciate ligament. The posterolateral bundle. Hole RL, et al. **Am J Sports Med** 1996 Jul–Aug;24(4):556–60

Analysis of skiing accidents involving combined injuries to the medial collateral and anterior cruciate ligaments. Hull ML. **Am J Sports Med** 1997 Jan–Feb;25(1):35–40

Neuromuscular performance characteristics in elite female athletes. Huston LJ, et al. **Am J Sports Med** 1996 Jul–Aug; 24(4):427–36

Biologic remodeling after anterior cruciate ligament reconstruction using a collagen matrix derived from demineralized bone. An experimental study in the goat model. Jackson DW, et al. **Am J Sports Med** 1996 Jul–Aug; 24(4):405–14

Herniation of the patellar fat pad through the patellar tendon defect after autologous bone–patellar tendon–bone anterior cruciate ligament reconstruction. A case report. Johnson DL, et al. **Am J Sports Med** 1996 Mar–Apr;24(2):201–4

Football cleat design and its effect on anterior cruciate ligament injuries. A three–year prospective study [see comments] Lambson RB, et al. **Am J Sports Med** 1996 Mar–Apr;24(2):155–9. Comment in: Am J Sports Med 1996 Sep–Oct;24(5):705–6.

Simultaneous rupture of the anterior cruciate ligament and the patellar tendon. Six case reports. Levakos Y, et al. **Am J Sports Med** 1996 Jul–Aug;24(4):498–503

Proprioception in anterior cruciate ligament–deficient and reconstructed knees. MacDonald PB, et al. **Am J Sports Med** 1996 Nov–Dec;24(6):774–8

Anterior cruciate ligament reconstruction with multistranded autogenous semitendinosus tendon. Maeda A, et al. **Am J Sports Med** 1996 Jul–Aug;24(4):504–9

Anterior knee laxity and loss of extension after anterior cruciate ligament injury. Muneta T, et al. **Am J Sports Med** 1996 Sep–Oct;24(5):603–7

Quantitative analysis of synovial fibrosis in the infrapatellar fat pad before and after anterior cruciate ligament reconstruction. Murakami S, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):29–34

A comparison of results in acute and chronic anterior cruciate ligament ruptures of arthroscopically assisted autogenous patellar tendon reconstruction. Noyes FR, et al. **Am J Sports Med** 1997 Jul–Aug;25(4):460–71

The diagnostic accuracy of history, physical examination, and radiographs in the evaluation of traumatic knee disorders. O'Shea KJ, et al. **Am J Sports Med** 1996 Mar–Apr;24(2):164–7

The effects of knee reconstruction on combined anterior cruciate ligament and anterolateral capsular deficiencies. Samuelson M, et al. **Am J Sports Med** 1996 Jul–Aug; 24(4):492–7

The use of a generic, patient–based health assessment (SF–36) for evaluation of patients with anterior cruciate ligament injuries. Shapiro ET, et al. **Am J Sports Med** 1996 Mar–Apr;24(2):196–200

Classification and management of arthrofibrosis of the knee after anterior cruciate ligament reconstruction. Shelbourne KD, et al. **Am J Sports Med** 1996 Nov–Dec;24(6):857–62

Preventing anterior knee pain after anterior cruciate ligament reconstruction. Shelbourne KD, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):41–7

Intraarticular migration of a femoral interference fit screw. A complication of anterior cruciate ligament reconstruction. Sidhu DS, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):268–71

The relationship between passive joint laxity and functional outcome after anterior cruciate ligament injury. Snyder–Mackler L, et al. **Am J Sports Med** 1997 Mar–Apr; 25(2):191–5

Distal femoral shaft fracture: a complication of endoscopic anterior cruciate ligament reconstruction. A case report. Wiener DF, et al. **Am J Sports Med** 1996 Mar–Apr; 24(2):244–7

Anterior cruciate ligament functional brace use in sports. Wojtys EM, et al. **Am J Sports Med** 1996 Jul–Aug; 24(4):539–46

Effects of initial graft tension on clinical outcome after anterior cruciate ligament reconstruction. Autogenous doubled hamstring tendons connected in series with polyester tapes. Yasuda K, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):99–106

Increased concentrations of bone sialoprotein in joint fluid after knee injury. Lohmander LS, et al. **Ann Rheum Dis** 1996 Sep;55(9):622–6

Knee joint proprioception in normal volunteers and patients with anterior cruciate ligament tears, taking special account of the effect of a knee bandage. Jerosch J, et al. **Arch Orthop Trauma Surg** 1996;115(3–4):162–6

To compare and contrast the various evaluation scoring systems after anterior cruciate ligament reconstruction. Labs K, et al. **Arch Orthop Trauma Surg** 1997;116(1–2):92–6

Instrumented measurement of anterior–posterior translation in knees with chronic anterior cruciate ligament tear. Mononen T, et al. **Arch Orthop Trauma Surg** 1997; 116(5):283–6

Primary repair plus intra–articular iliotibial band augmentation in the treatment of an acute anterior cruciate ligament rupture. A follow–up study of 70 patients. Natri A, et al. **Arch Orthop Trauma Surg** 1996;115(1):22–7

Five–year results of conservatively treated tears of the anterior cruciate ligament. Neusel E, et al. **Arch Orthop Trauma Surg** 1996;115(6):332–6

Single versus two–incision arthroscopic anterior cruciate ligament reconstruction. Arciero RA, et al. **Arthroscopy** 1996 Aug;12(4):462–9

Effects of knee flexion angle at graft fixation on the outcome of anterior cruciate ligament reconstruction. Asahina S, et al. **Arthroscopy** 1996 Feb;12(1):70–5

Arthroscopic anterior cruciate ligament reconstruction using a patellar tendon graft in press–fit technique: surgical technique and follow–up. Boszotta H. **Arthroscopy** 1997 Jun;13(3):332–9

Femoral interference screw placement through the tibial tunnel: a radiographic evaluation of interference screw divergence angles after endoscopic anterior cruciate ligament reconstruction. Brodie JT, et al. **Arthroscopy** 1996 Aug;12(4):435–40

Regional anesthesia in knee arthroscopy: a new technique involving femoral and sciatic nerve blocks in knee arthroscopy. Cappellino A, et al. **Arthroscopy** 1996 Feb; 12(1):120–3

The dimpling phenomenon: articular cartilage injury overlying an occult osteochondral lesion at the time of anterior cruciate ligament reconstruction. Coen MJ, et al. **Arthroscopy** 1996 Aug;12(4):502–5

Avulsion of the femoral attachment of the anterior cruciate ligament in a 3–year–old boy. Corso SJ, et al. **Arthroscopy** 1996 Feb;12(1):95–8

Interference screw divergence in endoscopic anterior cruciate ligament reconstruction. Dworsky BD, et al. **Arthroscopy** 1996 Feb;12(1):45–9

Arthroscopically assisted combined anterior and posterior cruciate ligament reconstruction. Fanelli GC, et al. **Arthroscopy** 1996 Feb;12(1):5–14

"Subcutaneous pretibial cyst formation associated with anterior cruciate ligament allografts" [letter; comment] Fleiss DJ. **Arthroscopy** 1996 Feb;12(1):134. Comment on: Arthroscopy 1995 Aug;11(4):486–94.

A comparison of accuracy between clinical examination and magnetic resonance imaging in the diagnosis of meniscal and anterior cruciate ligament tears [letter; comment] Friedman RL. **Arthroscopy** 1997 Apr;13(2):271–5; discussion 276–7, 279–80. Comment on: Arthroscopy 1996 Aug;12(4):398–405. Comment on: Arthroscopy 1996 Aug;12(4):406–13.

Bone–patellar tendon–bone grafts for anterior cruciate ligament reconstruction: the effects of graft pretensioning. Howard ME, et al. **Arthroscopy** 1996 Jun;12(3):287–92

A comparison of accuracy between clinical examination and magnetic resonance imaging in the diagnosis of meniscal and anterior cruciate ligament tears [letter; comment] Kirkley S. **Arthroscopy** 1997 Apr;13(2):271; discussion 279–80. Comment on: Arthroscopy 1996 Aug;12(4):398–405.

The 'N + 7 rule' for tibial tunnel placement in endoscopic anterior cruciate ligament reconstruction [letter; comment] Kurzweil PR. **Arthroscopy** 1996 Jun;12(3):392–4. Comment on: Arthroscopy 1996 Feb;12(1):124–6.

Use of an endoscopic aimer for femoral tunnel placement in anterior cruciate ligament reconstruction. McGuire DA, et al. **Arthroscopy** 1996 Feb;12(1):26–31

The relationship between anterior cruciate ligament reconstruction tibial tunnel location and the anterior aspect of the posterior cruciate ligament insertion. McGuire DA, et al. **Arthroscopy** 1997 Aug;13(4):465–73

The "N + 7 rule" for tibial tunnel placement in endoscopic anterior cruciate ligament reconstruction [see comments] Miller MD, et al. **Arthroscopy** 1996 Feb;12(1):124–6. Comment in: Arthroscopy 1996 Jun;12(3):392–4.

Comparison of screw post fixation and free bone block interference fixation for anterior cruciate ligament soft tissue grafts: biomechanical considerations. Novak PJ, et al. **Arthroscopy** 1996 Aug;12(4):470–3

A comparison of results of arthroscopic–assisted anterior cruciate ligament reconstruction between workers' compensation and noncompensation patients. Noyes FR, et al. **Arthroscopy** 1997 Aug;13(4):474–84

Arthroscopic–assisted allograft anterior cruciate ligament reconstruction in patients with symptomatic arthrosis. Noyes FR, et al. **Arthroscopy** 1997 Feb;13(1):24–32

What would you do? Acute extension block caused by anterior cruciate ligament tear: a case report. Pedowitz RA, et al. **Arthroscopy** 1996 Aug;12(4):489–91; discussion 492–5

"A complication of ACL reconstruction" [letter; comment] Prager BI. **Arthroscopy** 1996 Feb;12(1):133. Comment on: Arthroscopy 1995 Apr;11(2):225–8.

A comparison of accuracy between clinical examination and magnetic resonance imaging in the diagnosis of meniscal and anterior cruciate ligament tears [see comments] Rose NE, et al. **Arthroscopy** 1996 Aug;12(4):398–405. Comment in: Arthroscopy 1997 Apr;13(2):271; discussion 279–80. Comment in: Arthroscopy 1996 Apr;13(2):271–5; discussion 276–7, 279–80. Comment in: Arthroscopy 1997 Apr;13(2):275–6; discussion 277–80.

A prospective outcome study of rehabilitation programs and anterior cruciate ligament reconstruction. Schenck RC Jr, et al. **Arthroscopy** 1997 Jun;13(3):285–90

Comparison of anterior cruciate ligament reconstructions using patellar tendon autograft or allograft. Stringham DR, et al. **Arthroscopy** 1996 Aug;12(4):414–21

Femoral bone plug recession in endoscopic anterior cruciate ligament reconstruction. Taylor DE, et al. **Arthroscopy** 1996 Aug;12(4):513–5

A comparison of accuracy between clinical examination and magnetic resonance imaging in the diagnosis of meniscal and anterior cruciate ligament tears [letter; comment] Trieshmann HW Jr, et al. **Arthroscopy** 1997 Apr; 13(2):275–6; discussion 277–80. Comment on: Arthroscopy 1996 Aug;12(4):398–405. Comment on: Arthroscopy 1996 Aug;12(4):406–13.

Diagnostic equivalence of conventional and fast spin echo magnetic resonance imaging of the anterior cruciate ligament of the knee. Munk PL, et al. **Australas Radiol** 1997 Aug;41(3):238–42

Joint position sense and rehabilitation in the anterior cruciate ligament deficient knee. Carter ND, et al. **Br J Sports Med** 1997 Sep;31(3):209–12

Spontaneous rupture of the anterior cruciate ligament after anabolic steroids. Freeman BJ, et al. **Br J Sports Med** 1995 Dec;29(4):274–5 (8 ref.)

Isokinetic strength of the quadriceps and hamstrings and functional ability of anterior cruciate deficient knees in recreational athletes. Li RC, et al. **Br J Sports Med** 1996 Jun;30(2):161–4

Central nervous system modifications in patients with lesion of the anterior cruciate ligament of the knee. Valeriani M, et al. **Brain** 1996 Oct;119 (Pt 5):1751–62

Anterior cruciate ligament replacement using part of the patellar tendon as a free graft. Papadopoulos D, et al. **Bull Hosp Jt Dis** 1996;55(1):33–5

Closed kinetic chain exercises after anterior cruciate ligament reconstruction. Kirkley A. **Clin J Sport Med** 1996 Jan; 6(1):66

Stabilometric assessment in the anterior cruciate ligament–reconstructed knee. Shiraishi M, et al. **Clin J Sport Med** 1996 Jan;6(1):32–9

Failure of anterior cruciate ligament reconstruction: the biologic basis. Corsetti JR, et al. **Clin Orthop** 1996 Apr; (325):42–9 (39 ref.)

The future of anterior cruciate ligament restoration. Dye SF. **Clin Orthop** 1996 Apr;(325):130–9 (46 ref.)

Isolated tear of the anterior cruciate ligament: 5–year followup study [classical article] Feagin JA Jr, et al. **Clin Orthop** 1996 Apr;(325):4–9

Anterior cruciate ligament reconstruction. Bone–patella tendon–bone versus semitendinosus anatomic reconstruction. Feagin JA Jr, et al. **Clin Orthop** 1997 Aug; (341):69–72

Anterior cruciate ligament surgery 1996. State of the art? Fu FH, et al. **Clin Orthop** 1996 Apr;(325):19–24 (45 ref.)

Revision of failed prosthetic anterior cruciate ligament reconstruction. Greis PE, et al. **Clin Orthop** 1996 Apr; (325):78–90 (34 ref.)

Editorial comment [editorial] Harner CD. **Clin Orthop** 1996 Apr;(325):2–3

Why grafts fail. Jaureguito JW, et al. **Clin Orthop** 1996 Apr; (325):25–41 (102 ref.)

Revision anterior cruciate ligament surgery: experience from Pittsburgh. Johnson DL, et al. **Clin Orthop** 1996 Apr; (325):100–9

Revision anterior cruciate ligament surgery: experience from Cincinnati. Noyes FR, et al. **Clin Orthop** 1996 Apr; (325):116–29

Graft selection in anterior cruciate ligament revision surgery. Ritchie JR, et al. **Clin Orthop** 1996 Apr;(325):65–77 (58 ref.)

Technical considerations of revision anterior cruciate ligament surgery. Safran MR, et al. **Clin Orthop** 1996 Apr; (325):50–64 (24 ref.)

Electromyographic analysis of muscle fatigue in anterior cruciate ligament deficient knees. Tho KS, et al. **Clin Orthop** 1997 Jul;(340):142–51

Revision anterior cruciate ligament surgery: experience from Miami. Uribe JW, et al. **Clin Orthop** 1996 Apr;(325):91–9

Revision anterior cruciate ligament surgery: experience from Germany. Wirth CJ, et al. **Clin Orthop** 1996 Apr; (325):110–5

The management of meniscal tears in the ACL–deficient knee. Schmitz MA, et al. **Clin Sports Med** 1996 Jul; 15(3):573–93 (142 ref.)

Arthroscopic anterior cruciate ligament reconstruction. Veltri DM. **Clin Sports Med** 1997 Jan;16(1):123–44 (56 ref.)

Avulsion of the cranial cruciate ligament insertion in a horse. Edwards RB 3rd, et al. **Equine Vet J** 1996 Jul;28(4):334–6

Functional adaptations in patients with ACL–deficient knees. Hurwitz DE, et al. **Exerc Sport Sci Rev** 1997;25:1–20 (43 ref.)

Rupture of the anterior cruciate ligament—a quiet epidemic? Bollen SR, et al. **Injury** 1996 Jul;27(6):407–9

Semitendinosus and gracilis tendon graft fixation for ACL reconstructions. Beynnon BD, et al. **Iowa Orthop J** 1996; 16:118–21

Cranial cruciate ligament rupture [letter] Chauvet A. **J Am Anim Hosp Assoc** 1997 Jan–Feb;33(1):9

Computer simulation of landing movement in downhill skiing: anterior cruciate ligament injuries. Gerritsen KG, et al. **J Biomech** 1996 Jul;29(7):845–54

Biomechanics of knee ligament healing, repair and reconstruction. Woo SL, et al. **J Biomech** 1997 May; 30(5):431–9 (68 ref.)

Knee pain: a clue to internal derangement on lateral plain

radiograph of the knee. Neitzschman HR, et al. **J La State Med Soc** 1996 Dec;148(12):515–6

Expression of collagen and matrix metalloproteinases in ruptured human anterior cruciate ligament: an in situ hybridization study. Spindler KP, et al. **J Orthop Res** 1996 Nov;14(6):857–61

The relationship between static posture and ACL injury in female athletes. Loudon JK, et al. **J Orthop Sports Phys Ther** 1996 Aug;24(2):91–7

Injury to a soccer player. Monu JU, et al. **J South Orthop Assoc** 1994 Winter;3(4):303–5

Lower extremity injuries in in-line skaters: a report of two cases. Malanga GA, et al. **J Sports Med Phys Fitness** 1996 Jun;36(2):139–42

Morphogenesis of degenerative changes predisposing dogs to rupture of the cranial cruciate ligament. Narama I, et al. **J Vet Med Sci** 1996 Nov;58(11):1091–7

Isolated partial rupture of the anterior cruciate ligament. Long-term follow-up of 56 cases. Bak K, et al. **Knee Surg Sports Traumatol Arthrosc** 1997;5(2):66–71

Prevention of anterior cruciate ligament injuries in soccer. A prospective controlled study of proprioceptive training. Caraffa A, et al. **Knee Surg Sports Traumatol Arthrosc** 1996; 4(1):19–21

Different patterns of meniscal tears in acute anterior cruciate ligament (ACL) ruptures and in chronic ACL-deficient knees. Classification, staging and timing of treatment. Cipolla M, et al. **Knee Surg Sports Traumatol Arthrosc** 1995; 3(3):130–4 (15 ref.)

Isolated partial rupture of the anterior cruciate ligament [editorial] Eriksson E. **Knee Surg Sports Traumatol Arthrosc** 1997;5(2):65

Compression or distraction of the anterior cruciate injured knee. Variations in injury pattern in contact sports and downhill skiing. Fridén T, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(3):144–7

Proprioception in the nearly extended knee. Measurements of position and movement in healthy individuals and in symptomatic anterior cruciate ligament injured patients. Fridén T, et al. **Knee Surg Sports Traumatol Arthrosc** 1996; 4(4):217–24

Can we predict the outcome of a partial rupture of the anterior cruciate ligament? A prospective study of 43 cases. Fritschy D, et al. **Knee Surg Sports Traumatol Arthrosc** 1997;5(1):2–5

High tibial osteotomy alone or combined with ligament reconstruction in anterior cruciate ligament-deficient knees. Lattermann C, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(1):32–8

Reconstruction of the anterior cruciate ligament with carbon fibres: unsatisfactory results after 8 years. Mäkisalo SE, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(3):132–6

Arthroscopic reconstruction of the anterior cruciate ligament with Leeds-Keio ligament in non-professional athletes. Results after a minimum 5 years' follow-up. Marcacci M, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(1):9–13

Anterior cruciate ligament reconstruction with fresh-frozen patellar tendon allografts: sixty cases with 2 years' minimum follow-up. Nin JR, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(3):137–42

Tibial tunnel enlargement after anterior cruciate ligament reconstruction by autogenous bone-patellar tendon-bone graft. Peyrache MD, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(1):2–8

Timing of surgery in anterior cruciate ligament-injured knees. Shelbourne KD, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(3):148–56 (22 ref.)

Management of anterior cruciate ligament injuries in skeletally immature adolescents. Shelbourne KD, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(2):68–74

Comparison of augmented and non-augmented anterior cruciate ligament reconstruction combined with high tibial osteotomy. Stutz G, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(3):143–8

Histological and ultrastructural evaluation of Leeds-Keio ligament six years after implant. A case report. Zaffagnini S, et al. **Knee Surg Sports Traumatol Arthrosc** 1997; 5(2):89–94

Anatomic endoscopic ACL reconstruction with autogenous patellar tendon graft. Clancy WG Jr. **Orthopedics** 1997 May;20(5):397, 399–400 (5 ref.)

Magnetic resonance imaging of the anterior cruciate ligament: current concepts. Friedman RL, et al. **Orthopedics** 1996 Jun;19(6):525–32

The role of MRI in evaluation of the cruciate ligaments in knee dislocations [see comments] Reddy PK, et al. **Orthopedics** 1996 Feb;19(2):166–70. Comment in: Orthopedics 1997 Jan;20(1):10.

ACL reconstruction: semitendinosus tendon is the graft of choice. Rosenberg TD, et al. **Orthopedics** 1997 May; 20(5):396, 398 (14 ref.)

Fifty-two year follow up of an anterior cruciate ligament reconstruction [see comments] Severud EL, et al. **Orthopedics** 1996 Jun;19(6):541–5. Comment in: Orthopedics 1996 Oct;19(10):845.

ACL injury patterns in women. Traina SM, et al. **Orthopedics** 1997 Jun;20(6):545–9; quiz 550–1 (28 ref.)

MRI in patients with traumatic knee dislocations [letter; comment] Yu JS. **Orthopedics** 1997 Jan;20(1):10. Comment on: Orthopedics 1996 Feb;19(2):166–70.

Comparison between two techniques for surgical repair of the acutely torn anterior cruciate ligament. A prospective, randomized follow-up study of 48 patients. Grøntvedt T, et al. **Scand J Med Sci Sports** 1995 Dec;5(6):358–63

Isokinetic muscle performance in healthy female handball players and players with a unilateral anterior cruciate ligament reconstruction. Lund-Hanssen H, et al. **Scand J Med Sci Sports** 1996 Jun;6(3):172–5

Popliteus function in ACL-deficient patients. Weresh MJ, et al. **Scand J Med Sci Sports** 1997 Feb;7(1):14–9

Anterior cruciate ligament injury rehabilitation in athletes. Biomechanical considerations. Beynnon BD, et al. **Sports Med** 1996 Jul;22(1):54–64 (45 ref.)

Postoperative analgesia for stifle surgery: a comparison of intra-articular bupivacaine, morphine, or saline. Sammarco JL, et al. **Vet Surg** 1996 Jan-Feb;25(1):59–69

[Postoperative MRI morphology of the anterior cruciate ligament after primary ligament suture or ligament-plasty. A prospective study of 50 patients] Uhl M, et al. **Aktuelle Radiol** 1996 Jan;6(1):13–8 (Eng. Abstr.) **(Ger)**

[Interventions on the anterior cruciate ligament: consider the innervation!] Haus J. **Fortschr Med** 1997 Feb 20;115(5):35 **(Ger)**

[Conservative treatment of cruciate ligament rupture. Magnetic resonance tomography provides prognostic information for conservative healing] Schittich I, et al. **Fortschr Med** 1997 Feb 20;115(5):32–5 (Eng. Abstr.) **(Ger)**

[Alloplastic augmented femoral reinserted anterior cruciate liganent. Value of 2 channel augmentation for postoperative rehabilitation] Seitz H, et al. **Langenbecks Arch Chir** 1996; 381(1):10–17 (Eng. Abstr.) **(Ger)**

[Systemic genotoxic effect caused by ischemia-/reperfusion-/surgical trauma of the lower extremity--detection of DNA chain breaks in leukocytes with the Comet Assay] Dahouk S, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:601–5 (Eng. Abstr.) **(Ger)**

[Rupture of the anterior cruciate ligament] Romero J. **Schweiz Rundsch Med Prax** 1996 Sep 10;85(37):1136–45 (76 ref.) (Eng. Abstr.) **(Ger)**

[Resorbable reinforcement-plasty] **Sportverletz Sportschaden** 1996 Sep;10(3):XI **(Ger)**

[Are complications in cruciate ligament replacement operations with patellar tendon transplantation dependent on surgical technique and surgical timing?] Schippinger G, et al. **Swiss Surg** 1997;3(4):154–9 (Eng. Abstr.) **(Ger)**

[Maintenance of the cranial cruciate ligament rupture in the dog using an intra-articular ("over-the-top") and an extra-articular ("fascia-doubling") method] Timmermann C, et al. **Tierarztl Prax** 1996 Dec;24(6):590–5 (Eng. Abstr.) **(Ger)**

[Ultrasound diagnosis of acute rupture of the anterior cruciate ligament. An experimental and clinical study] Chylarecki C, et al. **Unfallchirurg** 1996 Jan;99(1):24–30 (Eng. Abstr.) **(Ger)**

[Long-term outcome of conservative or surgical therapy of anterior cruciate ligament rupture] Fink C, et al. **Unfallchirurg** 1996 Dec;99(12):964–9 (Eng. Abstr.) **(Ger)**

[Proprioceptive capacity of the knee joint area in patients after rupture of the anterior cruciate ligament] Jerosch J, et al. **Unfallchirurg** 1996 Nov;99(11):861–8 (Eng. Abstr.) **(Ger)**

[Ultrasound imaging of the anterior cruciate ligament. Possibilities and limits] Kelsch G, et al. **Unfallchirurg** 1996 Feb;99(2):119–23 (Eng. Abstr.) **(Ger)**

[Mid-term outcome after surgically managed re-rupture of the anterior cruciate ligament] Krüger-Franke M, et al. **Unfallchirurg** 1997 Apr;100(4):274–9 (Eng. Abstr.) **(Ger)**

[Diagnosis of acute rupture of the anterior cruciate ligament. Value of ultrasonic in addition to clinical examination] Richter J, et al. **Unfallchirurg** 1996 Feb;99(2):124–9 (Eng. Abstr.) **(Ger)**

[Manual ultrasound of the knee joint. A general practice method for diagnosis of fresh rupture of the anterior cruciate ligament] Schwarz W, et al. **Unfallchirurg** 1997 Apr;100(4):280–5 (Eng. Abstr.) **(Ger)**

[Arthroscopic replacement of the anterior cruciate ligament with a double semitendinosus tendon] Sperner G, et al. **Unfallchirurg** 1996 Nov;99(11):869–74 (Eng. Abstr.) **(Ger)**

[Value of MRI in assessment of cruciate ligament replacement] Stöckle U, et al. **Unfallchirurg** 1997 Mar; 100(3):212–8 (Eng. Abstr.) **(Ger)**

[Meniscus lesions after isolated anterior cruciate ligament rupture] Seitz H, et al. **Wien Klin Wochenschr** 1996 Nov 29;108(22):727–30 (Eng. Abstr.) **(Ger)**

[Cruciate ligament injuries with knee joint effusion--why can the Lachman sign not be elicited?] Hopf T, et al. **Z Orthop Ihre Grenzgeb** 1996 Sep-Oct;134(5):418–21 (Eng. Abstr.) **(Ger)**

[Lesions of the popliteus system and their significance for the stability of the knee joint] Scherer MA, et al. **Zentralbl Chir** 1996;121(7):591–8 (Eng. Abstr.) **(Ger)**

[Knee instability in sportsmen due to anterior cruciate ligament tear] Soudry M, et al. **Harefuah** 1996 Jun 16; 130(12):863–7 (42 ref.) **(Heb)**

[Levels of chondroitin 4-sulfate, chondroitin 6-sulfate and carboxy-terminal type II procollagen peptide in knee synovial fluid after injury to the anterior cruciate ligament] Yoshihara Y, et al. **Ryumachi** 1996 Oct;36(5):734–40 (Eng. Abstr.) **(Jpn)**

[The physical diagnosis and treatment of insufficiency of the anterior cruciate ligament] Biushko VM, et al. **Vestn Khir Im I I Grek** 1996;155(2):54–6 (Eng. Abstr.) **(Rus)**

INNERVATION

Segmental sensory innervation of the anterior cruciate ligament and the patellar tendon of the cat's knee [see comments] Gómez-Barrena E, et al. **Acta Orthop Scand** 1996 Dec;67(6):545–52. Comment in: Acta Orthop Scand 1996 Dec;67(6):533–5. Comment in: Acta Orthop Scand 1997 Apr;68(2):183–5.

The sensitivity of joint afferents to knee translation. Cole KJ, et al. **Sportverletz Sportschaden** 1996 Jun;10(2):27–31

[Interventions on the anterior cruciate ligament: consider the innervation!] Haus J. **Fortschr Med** 1997 Feb 20;115(5):35 **(Ger)**

[Projections and fiber characteristics of sensory afferents of the anterior cruciate ligament in an animal experiment] Parsch D, et al. **Unfallchirurgie** 1996 Oct;22(5):193–201 (Eng. Abstr.) **(Ger)**

METABOLISM

Permeation from the synovial fluid as nutritional pathway for the anterior cruciate ligament in rabbits. Murakami Y, et al. **Acta Physiol Scand** 1996 Oct;158(2):181–7

Changes in the distribution of fibrillar collagens in the collateral and cruciate ligaments of the rabbit knee joint during fetal and postnatal development. Bland YS, et al. **Histochem J** 1996 May;28(5):325–34

Effect of growth factors on matrix synthesis by ligament fibroblasts. Marui T, et al. **J Orthop Res** 1997 Jan; 15(1):18–23

Expression of collagen and matrix metalloproteinases in ruptured human anterior cruciate ligament: an in situ hybridization study. Spindler KP, et al. **J Orthop Res** 1996 Nov;14(6):857–61

PATHOLOGY

Intraarticular ganglia of the knee: prevalence, presentation, etiology, and management. Bui-Mansfield LT, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):123–7

MR imaging of anterior cruciate ligament reconstruction. Schatz JA, et al. **AJR Am J Roentgenol** 1997 Jul; 169(1):223–8

Scarring of the anterior cruciate ligament to the posterior cruciate ligament does not decrease anterior translation. Wright RW, et al. **Am J Knee Surg** 1997 Summer; 10(3):125–8

The adverse effects of sectioning the posterior cruciate ligament in rabbits. Changes in the structural and morphological properties of the femur-anterior cruciate ligament-tibia complex. Murao T, et al. **Arch Orthop Trauma Surg** 1997;116(1-2):1–5

Tenosynovial giant-cell tumor arising from the anterior cruciate ligament of the knee. Otsuka Y, et al. **Arthroscopy** 1996 Aug;12(4):496–9

Diagnostic equivalence of conventional and fast spin echo magnetic resonance imaging of the anterior cruciate ligament of the knee. Munk PL, et al. **Australas Radiol** 1997 Aug;41(3):238–42

Electron and immunoelectron microscopy on healing process of the rat anterior cruciate ligament after partial transection: the roles of multipotent fibroblasts in the synovial tissue. Maekawa K, et al. **Histol Histopathol** 1996 Jul;11(3):607–19

Migration and healing of ligament cells under inflammatory conditions. Witkowski J, et al. **J Orthop Res** 1997 Mar; 15(2):269–77

Morphogenesis of degenerative changes predisposing dogs to rupture of the cranial cruciate ligament. Narama I, et al. **J Vet Med Sci** 1996 Nov;58(11):1091–7

Magnetic resonance imaging of the anterior cruciate ligament: current concepts. Friedman RL, et al. **Orthopedics** 1996 Jun;19(6):525–32

[Synovial cyst of the cruciate ligament. Findings with magnetic resonance in 8 symptomatic cases] Bellelli A, et al. **Radiol Med (Torino)** 1996 Oct;92(4):346–50 (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Age-related changes in human anterior cruciate ligament (ACL) collagen fibrils. Strocchi R, et al. **Ital J Anat Embryol** 1996 Oct-Dec;101(4):213–20

Sensory innervation of the cat knee articular capsule and cruciate ligament visualised using anterogradely transported wheat germ agglutinin-horseradish peroxidase. Madey SM, et al. **J Anat** 1997 Feb;190 (Pt 2):289–97

Structural capacity of the knee to anterior cruciate ligament failure during quadriceps contraction. An in vivo study in the rat. Aune AK, et al. **J Biomech** 1996 Jul;29(7):891–7

Direct measurement of strain in the posterolateral bundle of the anterior cruciate ligament. Bach JM, et al. **J Biomech** 1997 Mar;30(3):281–3

An inverse dynamics modeling approach to determine the restraining function of human knee ligament bundles. Mommersteeg TJ, et al. **J Biomech** 1997 Feb;30(2):139–46

A musculoskeletal model of the knee for evaluating ligament forces during isometric contractions. Shelburne KB, et al. **J Biomech** 1997 Feb;30(2):163–76

Evaluation of the effect of joint constraints on the in situ

force distribution in the anterior cruciate ligament. Livesay GA, et al. **J Orthop Res** 1997 Mar;15(2):278–84

In situ forces in the anterior cruciate ligament and its bundles in response to anterior tibial loads. Sakane M, et al. **J Orthop Res** 1997 Mar;15(2):285–93

Parameter sensitivity of a mathematical model of the anterior cruciate ligament. Toutoungi DE, et al. **Proc Inst Mech Eng [H]** 1997;211(3):235–46

The differential adhesion forces of anterior cruciate and medial collateral ligament fibroblasts: effects of tropomodulin, talin, vinculin, and alpha-actinin. Sung KL, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9182–7

Anterior cruciate ligament strength. Can it be estimated by non-destructive testing? Nordsletten L, et al. **Scand J Med Sci Sports** 1997 Aug;7(4):203–5

PHYSIOPATHOLOGY

Scarring of the anterior cruciate ligament to the posterior cruciate ligament does not decrease anterior translation. Wright RW, et al. **Am J Knee Surg** 1997 Summer; 10(3):125–8

Patterns of meniscal injury in the anterior cruciate-deficient knee: a review of the literature. Bellabarba C, et al. **Am J Orthop** 1997 Jan;26(1):18–23 (90 ref.)

Evaluation of knee joint laxity and the structural properties of the anterior cruciate ligament graft in the human. A case report. Beynnon BD, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):203–6

Long-term study of the biochemistry and biomechanics of anterior cruciate ligament–patellar tendon autografts in goats. Ng GY, et al. **J Orthop Res** 1996 Nov;14(6):851–6

Migration and healing of ligament cells under inflammatory conditions. Witkowski J, et al. **J Orthop Res** 1997 Mar; 15(2):269–77

Laxity of knee cruciate ligaments during pregnancy. Dumas GA, et al. **J Orthop Sports Phys Ther** 1997 Jul;26(1):2–6

Good muscle performance does not compensate instability symptoms in chronic anterior cruciate ligament deficiency. Harilainen A, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(3):135–7

RADIOGRAPHY

Femoral insertion of the ACL. Radiographic quadrant method. Bernard M, et al. **Am J Knee Surg** 1997 Winter; 10(1):14–21; discussion 21–2

Radiological method for preoperative determination of isometric attachment points of an anterior cruciate ligament graft. Collette M, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(2):75–83

SURGERY

MR imaging findings in anterior cruciate ligament reconstruction: evaluation of notchplasty. May DA, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):217–22

Femoral insertion of the ACL. Radiographic quadrant method. Bernard M, et al. **Am J Knee Surg** 1997 Winter; 10(1):14–21; discussion 21–2

The fat pad. Clinical observations [see comments] Duri ZA, et al. **Am J Knee Surg** 1996 Spring;9(2):55–66. Comment in: Am J Knee Surg 1996 Spring;9(2):43.

Patellar tendon length after anterior cruciate ligament reconstruction.A prospective study. Krosser BI, et al. **Am J Knee Surg** 1996 Fall;9(4):158–60

Geometrical relationships between bone plug configuration and patellar tendon graft width. Matava MJ, et al. **Am J Knee Surg** 1996 Spring;9(2):67–72

Arthroscopic reconstruction of the ACL with semitendinosus–gracilis autograft in skeletally immature adolescent patients. Matava MJ, et al. **Am J Knee Surg** 1997 Spring;10(2):60–9

Clinical and functional outcome of anterior cruciate ligament reconstruction in the recreational athlete over the age of 35. Novak PJ, et al. **Am J Knee Surg** 1996 Summer; 9(3):111–6

Assessment of morbidity of semitendinosus and gracilis tendon harvest for ACL reconstruction. Simonian PT, et al. **Am J Knee Surg** 1997 Spring;10(2):54–9

Assessing the need for extensive supervised rehabilitation following arthroscopic ACL reconstruction. Treacy SH, et al. **Am J Orthop** 1997 Jan;26(1):25–9

Arthroscopically assisted semitendinosus and gracilis tendon graft in reconstruction for acute anterior cruciate ligament injuries in athletes. Aglietti P, et al. **Am J Sports Med** 1996 Nov–Dec;24(6):726–31

The effect of tourniquet use in anterior cruciate ligament reconstruction. A prospective, randomized study [see comments] Arciero RA, et al. **Am J Sports Med** 1996 Nov–Dec;24(6):758–64. Comment in: Am J Sports Med 1997 Mar–Apr;25(2):275–6.

A rigorous comparison between the sexes of results and complications after anterior cruciate ligament reconstruction. Barber–Westin SD, et al. **Am J Sports Med** 1997 Jul–Aug;25(4):514–26

Evidence of reinnervation of free patellar tendon autograft used for anterior cruciate ligament reconstruction. Barrack RL, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):196–202

Analysis of a semitendinosus autograft in a rabbit model. Blickenstaff KR, et al. **Am J Sports Med** 1997 Jul–Aug; 25(4):554–9

The effect of tourniquet use in anterior cruciate ligament reconstruction--a prospective randomised study [letter; comment] Bollen S. **Am J Sports Med** 1997 Mar–Apr; 25(2):275–6. Comment on: Am J Sports Med 1996 Nov–Dec;24(6):758–64.

Evaluation of pain after arthroscopically assisted anterior cruciate ligament reconstruction. Brown DW, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):182–6

Clinical failure of tibial interference screw fixation after anterior cruciate ligament reconstruction. A report of two cases [see comments] Cooper DE, et al. **Am J Sports Med** 1996 Sep–Oct;24(5):693–7. Comment in: Am J Sports Med 1997 May–Jun;25(3):417–8.

The use of cold therapy in the postoperative management of patients undergoing arthroscopic anterior cruciate ligament reconstruction. Edwards DJ, et al. **Am J Sports Med** 1996 Mar–Apr;24(2):193–5

Central quadriceps tendon for anterior cruciate ligament reconstruction. Part I: Morphometric and biomechanical evaluation. Harris NL, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):23–8

An analysis of anterior cruciate ligament reconstruction in middle-aged patients. Heier KA, et al. **Am J Sports Med** 1997 Jul–Aug;25(4):527–32

Biologic remodeling after anterior cruciate ligament reconstruction using a collagen matrix derived from demineralized bone. An experimental study in the goat model. Jackson DW, et al. **Am J Sports Med** 1996 Jul–Aug; 24(4):405–14

Herniation of the patellar fat pad through the patellar tendon defect after autologous bone–patellar tendon–bone anterior cruciate ligament reconstruction. A case report. Johnson DL, et al. **Am J Sports Med** 1996 Mar–Apr;24(2):201–4

The use of cold therapy after anterior cruciate ligament reconstruction. A prospective, randomized study and literature review. Konrath GA, et al. **Am J Sports Med** 1996 Sep–Oct;24(5):629–33 (25 ref.)

Proprioception in anterior cruciate ligament-deficient and reconstructed knees. MacDonald PB, et al. **Am J Sports Med** 1996 Nov–Dec;24(6):774–8

Anterior cruciate ligament reconstruction with multistranded autogenous semitendinosus tendon. Maeda A, et al. **Am J Sports Med** 1996 Jul–Aug;24(4):504–9

Long-term results of anterior cruciate ligament reconstruction with a Dacron prosthesis. The frequency of osteoarthritis after seven to eleven years. Maletius W, et al. **Am J Sports Med** 1997 May–Jun;25(3):288–93

Late patellar tendon ruptures after removal of the central third for anterior cruciate ligament reconstruction. A report of two cases. Marumoto JM, et al. **Am J Sports Med** 1996 Sep–Oct;24(5):698–701 (31 ref.)

Quantitative analysis of synovial fibrosis in the infrapatellar fat pad before and after anterior cruciate ligament reconstruction. Murakami S, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):29–34

Anterior cruciate ligament graft fixation. Initial comparison of patellar tendon and semitendinosus autografts in young fresh cadavers. Rowden NJ, et al. **Am J Sports Med** 1997 Jul–Aug;25(4):472–8

The effects of knee reconstruction on combined anterior cruciate ligament and anterolateral capsular deficiencies. Samuelson M, et al. **Am J Sports Med** 1996 Jul–Aug; 24(4):492–7

Classification and management of arthrofibrosis of the knee after anterior cruciate ligament reconstruction. Shelbourne KD, et al. **Am J Sports Med** 1996 Nov–Dec;24(6):857–62

Preventing anterior knee pain after anterior cruciate ligament reconstruction. Shelbourne KD, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):41–7

The effect of anterior cruciate ligament graft elongation at the time of implantation on the biomechanical behavior of the graft and knee. Tohyama H, et al. **Am J Sports Med** 1996 Sep–Oct;24(5):608–14

Distal femoral shaft fracture: a complication of endoscopic anterior cruciate ligament reconstruction. A case report. Wiener DF, et al. **Am J Sports Med** 1996 Mar–Apr; 24(2):244–7

Quality of tibial fixation in ACL reconstructions [letter; comment] Williams A, et al. **Am J Sports Med** 1997 May–Jun;25(3):417–8. Comment on: Am J Sports Med 1996 Sep–Oct;24(5):693–7.

Septic arthritis after arthroscopic anterior cruciate ligament reconstruction. Diagnosis and management. Williams RJ 3rd, et al. **Am J Sports Med** 1997 Mar–Apr;25(2):261–7

Effects of initial graft tension on clinical outcome after anterior cruciate ligament reconstruction. Autogenous doubled hamstring tendons connected in series with polyester tapes. Yasuda K, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):99–106

To compare and contrast the various evaluation scoring systems after anterior cruciate ligament reconstruction. Labs K, et al. **Arch Orthop Trauma Surg** 1997;116(1–2):92–6

Primary repair plus intra-articular iliotibial band augmentation in the treatment of an acute anterior cruciate ligament rupture. A follow-up study of 70 patients. Natri A, et al. **Arch Orthop Trauma Surg** 1996;115(1):22–7

Single versus two-incision arthroscopic anterior cruciate ligament reconstruction. Arciero RA, et al. **Arthroscopy** 1996 Aug;12(4):462–9

Arthroscopic meniscal repair in conjunction with anterior cruciate ligament reconstruction: factors affecting the healing rate. Asahina S, et al. **Arthroscopy** 1996 Oct; 12(5):541–5

Is an anterior cruciate ligament reconstruction outcome age dependent? Barber FA, et al. **Arthroscopy** 1996 Dec; 12(6):720–5

Meniscus repair rehabilitation with concurrent anterior cruciate reconstruction. Barber FA, et al. **Arthroscopy** 1997 Aug;13(4):433–7

Preliminary results of the T-fix endoscopic meniscus repair technique in an anterior cruciate ligament reconstruction population. Barrett GR, et al. **Arthroscopy** 1997 Apr; 13(2):218–23

The effect of intraoperative isometric measurement on the outcome of anterior cruciate ligament reconstruction: a clinical analysis. Barrett GR, et al. **Arthroscopy** 1996 Dec; 12(6):645–51

Management of patella fractures associated with central third bone–patella tendon–bone autograft ACL reconstructions. Berg EE. **Arthroscopy** 1996 Dec;12(6):756–9

Arthroscopic anterior cruciate ligament reconstruction using a patellar tendon graft in press-fit technique: surgical technique and follow-up. Boszotta H. **Arthroscopy** 1997 Jun;13(3):332–9

Femoral interference screw placement through the tibial tunnel: a radiographic evaluation of interference screw divergence angles after endoscopic anterior cruciate ligament reconstruction. Brodie JT, et al. **Arthroscopy** 1996 Aug;12(4):435–40

Comparison of "inside-out" and "outside-in" interference screw fixation for anterior cruciate ligament surgery in a bovine knee. Bryan JM, et al. **Arthroscopy** 1996 Feb; 12(1):76–81

Biomechanical comparison between BioScrew and titanium alloy interference screws for bone-patellar tendon-bone graft fixation in anterior cruciate ligament reconstruction. Caborn DN, et al. **Arthroscopy** 1997 Apr;13(2):229–32

The dimpling phenomenon: articular cartilage injury overlying an occult osteochondral lesion at the time of anterior cruciate ligament reconstruction. Coen MJ, et al. **Arthroscopy** 1996 Aug;12(4):502–5

The incidence of deep venous thrombosis in anterior cruciate ligament reconstruction. Cullison TR, et al. **Arthroscopy** 1996 Dec;12(6):657–9

The predictive value of intraoperative KT-1000 arthrometer measurements in single incision anterior cruciate ligament reconstruction. Giannotti BF, et al. **Arthroscopy** 1996 Dec; 12(6):660–6

Local and intra-articular infiltration of bupivacaine before surgery: effect on postoperative pain after anterior cruciate ligament reconstruction. Höher J, et al. **Arthroscopy** 1997 Apr;13(2):210–7

The impact of surgical timing on postoperative motion and stability following anterior cruciate ligament reconstruction. Hunter RE, et al. **Arthroscopy** 1996 Dec; 12(6):667–74

The effect of anterior cruciate ligament graft fixation site at the tibia on knee stability: evaluation using a robotic testing system. Ishibashi Y, et al. **Arthroscopy** 1997 Apr; 13(2):177–82

Anterior cruciate ligament reconstruction in athletes with an ossicle associated with Osgood-Schlatter's disease. McCarroll JR, et al. **Arthroscopy** 1996 Oct;12(5):556–60

The relationship between anterior cruciate ligament reconstruction tibial tunnel location and the anterior aspect of the posterior cruciate ligament insertion. McGuire DA, et al. **Arthroscopy** 1997 Aug;13(4):465–73

Consistent and accurate graft passage and interference screw guide wire placement during single incision anterior cruciate ligament reconstruction. McGuire DA, et al. **Arthroscopy** 1997 Aug;13(4):526–9

Comparison of screw post fixation and free bone block interference fixation for anterior cruciate ligament soft tissue grafts: biomechanical considerations. Novak PJ, et al. **Arthroscopy** 1996 Aug;12(4):470–3

A comparison of results of arthroscopic-assisted anterior cruciate ligament reconstruction between workers' compensation and noncompensation patients. Noyes FR, et al. **Arthroscopy** 1997 Aug;13(4):474–84

Arthroscopic-assisted allograft anterior cruciate ligament reconstruction in patients with symptomatic arthrosis. Noyes FR, et al. **Arthroscopy** 1997 Feb;13(1):24–32

Fixation strength of a biodegradable interference screw and a press-fit technique in anterior cruciate ligament reconstruction with a BPTB graft. Rupp S, et al. **Arthroscopy** 1997 Feb;13(1):61–5

A prospective outcome study of rehabilitation programs and anterior cruciate ligament reconstruction. Schenck RC Jr, et al. **Arthroscopy** 1997 Jun;13(3):285–90

Arthroscopically assisted reconstruction of the anterior cruciate ligament: initial clinical experience and minimal 2-year follow-up comparing endoscopic transtibial and two-incision techniques. Sgaglione NA, et al. **Arthroscopy** 1997 Apr;13(2):156–65

Autograft versus allograft anterior cruciate ligament reconstruction. Shelton WR, et al. **Arthroscopy** 1997 Aug; 13(4):446–9

Clinical degradation and biocompatibility of different bioabsorbable interference screws: a report of six cases. Stähelin AC, et al. **Arthroscopy** 1997 Apr;13(2):238–44

Comparison of anterior cruciate ligament reconstructions using patellar tendon autograft or allograft. Stringham DR, et al. **Arthroscopy** 1996 Aug;12(4):414–21

Femoral bone plug recession in endoscopic anterior cruciate ligament reconstruction. Taylor DE, et al. **Arthroscopy** 1996 Aug;12(4):513–5

Anterior cruciate ligament replacement using part of the patellar tendon as a free graft. Papadopoulos D, et al. **Bull Hosp Jt Dis** 1996;55(1):33–5

X-ray evaluation of interferential femoral screw positioning in ACL reconstruction. Cassisa G, et al. **Chir Organi Mov** 1996 Jul–Sep;81(3):257–61 **(Eng, Ita)**

Failure of anterior cruciate ligament reconstruction: the biologic basis. Corsetti JR, et al. **Clin Orthop** 1996 Apr; (325):42–9 (39 ref.)

The future of anterior cruciate ligament restoration. Dye SF. **Clin Orthop** 1996 Apr;(325):130–9 (46 ref.)

Isolated tear of the anterior cruciate ligament: 5-year followup study [classical article] Feagin JA Jr, et al. **Clin Orthop** 1996 Apr;(325):4–9

Anterior cruciate ligament reconstruction. Bone–patella tendon–bone versus semitendinosus anatomic reconstruction. Feagin JA Jr, et al. **Clin Orthop** 1997 Aug; (341):69–72

Anterior cruciate ligament surgery 1996. State of the art? Fu FH, et al. **Clin Orthop** 1996 Apr;(325):19–24 (45 ref.)

Revision of failed prosthetic anterior cruciate ligament reconstruction. Greis PE, et al. **Clin Orthop** 1996 Apr; (325):78–90 (34 ref.)

Editorial comment [editorial] Harner CD. **Clin Orthop** 1996 Apr;(325):2–3

Why grafts fail. Jaureguito JW, et al. **Clin Orthop** 1996 Apr; (325):25–41 (102 ref.)

Revision anterior cruciate ligament surgery: experience from Pittsburgh. Johnson DL, et al. **Clin Orthop** 1996 Apr; (325):100–9

Revision anterior cruciate ligament surgery: experience from Cincinnati. Noyes FR, et al. **Clin Orthop** 1996 Apr; (325):116–29

Graft selection in anterior cruciate ligament revision surgery. Ritchie JR, et al. **Clin Orthop** 1996 Apr;(325):65–77 (58 ref.)

Technical considerations of revision anterior cruciate ligament surgery. Safran MR, et al. **Clin Orthop** 1996 Apr; (325):50–64 (24 ref.)

Revision anterior cruciate ligament surgery: experience from Miami. Uribe JW, et al. **Clin Orthop** 1996 Apr;(325):91–9

Revision anterior cruciate ligament surgery: experience from Germany. Wirth CJ, et al. **Clin Orthop** 1996 Apr; (325):110–5

Arthroscopic anterior cruciate ligament reconstruction. Veltri DM. **Clin Sports Med** 1997 Jan;16(1):123–44 (56 ref.)

MRI of normal anterior cruciate ligament (ACL) and reconstructed ACL: comparison of when the knee is extended with when the knee is flexed. Nakanishi K, et al. **Eur Radiol** 1997;7(7):1020–4

Group II phospholipase A2 in serum after knee surgery and intramedullary nailing of tibial shaft fracture. Lindström T, et al. **Injury** 1997 Apr;28(3):169–71

Reflex sympathetic dystrophy, patella infera contracture syndrome, and loss of motion following anterior cruciate ligament surgery. Bach BR Jr, et al. **Instr Course Lect** 1997; 46:251–60 (25 ref.)

Bioresorbable implants: applications in orthopaedic surgery. Blasier RD, et al. **Instr Course Lect** 1997;46:531–46 (64 ref.)

Reconstruction of the anterior cruciate ligament using a patellar tendon autograft. A long term follow up. Mitsou A, et al. **Int Orthop** 1996;20(5):285–9

Reconstruction of the chronically insufficient anterior cruciate ligament: long term results of the Eriksson procedure. Natri A, et al. **Int Orthop** 1996;20(1):28–31

Graft selection in anterior cruciate ligament reconstruction—prospective analysis of patellar tendon autografts compared with allografts. Victor J, et al. **Int Orthop** 1997;21(2):93–7

Anterior cruciate ligament reconstruction by mini-arthrotomy. al-Zarahini S, et al. **Int Orthop** 1997; 21(3):161–3

Semitendinosus and gracilis tendon graft fixation for ACL reconstructions. Beynnon BD, et al. **Iowa Orthop J** 1996; 16:118–21

Biomechanics of knee ligament healing, repair and reconstruction. Woo SL, et al. **J Biomech** 1997 May; 30(5):431–9 (68 ref.)

Biomechanical consequences of replacement of the anterior cruciate ligament with a patellar ligament allograft. Part I: insertion of the graft and anterior–posterior testing. Markolf KL, et al. **J Bone Joint Surg Am** 1996 Nov; 78(11):1720–7

Biomechanical consequences of replacement of the anterior cruciate ligament with a patellar ligament allograft. Part II: forces in the graft compared with forces in the intact ligament. Markolf KL, et al. **J Bone Joint Surg Am** 1996 Nov;78(11):1728–34

Arthroscopic reconstruction of the anterior cruciate ligament using bone–patellar tendon–bone grafts with and without augmentation. A prospective randomised study. Grøntvedt T, et al. **J Bone Joint Surg Br** 1996 Sep;78(5):817–22

MRI and morphology of the insertion of the patellar tendon after graft harvesting. Liu SH, et al. **J Bone Joint Surg Br** 1996 Sep;78(5):823–6

Popliteal artery compression: a complication of Gore-Tex anterior cruciate ligament reconstruction. Spalding TJ, et al. **J Bone Joint Surg Br** 1996 Jan;78(1):151–2

Computer-assisted knee anterior cruciate ligament reconstruction: first clinical tests. Dessenne V, et al. **J Image Guid Surg** 1995;1(1):59–64

Contact pressure and tension in anterior cruciate ligament grafts subjected to roof impingement during passive extension. Goss BC, et al. **J Orthop Res** 1997 Mar; 15(2):263–8

Braided polypropylene augmentation device in reconstructive surgery of the anterior cruciate ligament: long-term clinical performance of 594 patients and short-term arthroscopic results, failure analysis by scanning electron microscopy, and synovial histomorphology. Kdolsky RK, et al. **J Orthop Res** 1997 Jan;15(1):1–10

Long-term study of the biochemistry and biomechanics of anterior cruciate ligament–patellar tendon autografts in goats. Ng GY, et al. **J Orthop Res** 1996 Nov;14(6):851–6

Physical properties of rabbit articular cartilage after transection of the anterior cruciate ligament. Sah RL, et al. **J Orthop Res** 1997 Mar;15(2):197–203

Patella fractures associated with accelerated ACL rehabilitation in patients with autogenous patella tendon reconstructions. Brownstein B, et al. **J Orthop Sports Phys Ther** 1997 Sep;26(3):168–72

The effects of "decelerated" rehabilitation following anterior cruciate ligament reconstruction on a hyperelastic female adolescent: a case study. Hardin JA, et al. **J Orthop Sports Phys Ther** 1997 Jul;26(1):29–34

Follow-up to the clinical and cost-effectiveness of two different programs for rehabilitation following ACL reconstruction [letter; comment] Irrgang JJ. **J Orthop Sports Phys Ther** 1997 Jul;26(1):39–40; discussion 40–6. Comment on: J Orthop Sports Phys Ther 1997 Jan;25(1):43–8.

A measurement of anterior tibial displacement in the closed and open kinetic chain. Jenkins WL, et al. **J Orthop Sports Phys Ther** 1997 Jan;25(1):49–56

Follow-up to the clinical and cost-effectiveness of two different programs for rehabilitation following ACL reconstruction [letter; comment] Snyder-Mackler L. **J Orthop Sports Phys Ther** 1997 Jul;26(1):39; discussion 40–6. Comment on: J Orthop Sports Phys Ther 1997 Jan;25(1):43–8.

The clinical and cost-effectiveness of two different programs for rehabilitation following ACL reconstruction [see comments] Timm KE. **J Orthop Sports Phys Ther** 1997 Jan;25(1):43–8. Comment in: J Orthop Sports Phys Ther 1997 Jul;26(1):39; discussion 40–6. Comment in: J Orthop Sports Phys Ther 1997 Jul;26(1):39–40; discussion 40–6.

Arthroscopic anterior cruciate ligament transection induces canine osteoarthritis. Marshall KW, et al. **J Rheumatol** 1996 Feb;23(2):338–43

Comparison of rear-entry (two-incision) and endoscopic techniques for reconstruction of the anterior cruciate ligament. Barrett GR, et al. **J South Orthop Assoc** 1996 Summer;5(2):87–95

Serial ultrasonographic imaging evaluation of the patellar tendon after harvesting its central one third for anterior cruciate ligament reconstruction. Wiley JP, et al. **J Ultrasound Med** 1997 Apr;16(4):251–5

Healing of the patellar tendon after harvesting of its mid-third for anterior cruciate ligament reconstruction and evolution of the unclosed donor site defect. Adriani E, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(3):138–43

Anterior cruciate ligament reconstruction combined with valgus tibial osteotomy (combined procedure). Boss A, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(3):187–91

Postoperative analgesic effects of an external cooling system and intra-articular bupivacaine/morphine after arthroscopic cruciate ligament surgery. Brandsson S, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(4):200–5

Gait patterns after anterior cruciate ligament reconstruction. Bulgheroni P, et al. **Knee Surg Sports Traumatol Arthrosc** 1997;5(1):14–21

Different patterns of meniscal tears in acute anterior cruciate ligament (ACL) ruptures and in chronic ACL-deficient knees. Classification, staging and timing of treatment. Cipolla M, et al. **Knee Surg Sports Traumatol Arthrosc** 1995; 3(3):130–4 (15 ref.)

Radiological method for preoperative determination of isometric attachment points of an anterior cruciate ligament graft. Collette M, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(2):75–83

Light and scan electron microscopic analysis of cyclops syndrome: etiopathogenic hypothesis and technical solutions. Delcogliano A, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(4):194–9

Use of an extension-assisting brace following anterior cruciate ligament reconstruction. Feller J, et al. **Knee Surg Sports Traumatol Arthrosc** 1997;5(1):6–9

Pullout strength of tibial graft fixation in anterior cruciate ligament replacement with a patellar tendon graft: interference screw versus staple fixation in human knees. Gerich TG, et al. **Knee Surg Sports Traumatol Arthrosc** 1997;5(2):84–8

Knee brace after bone–tendon–bone anterior cruciate ligament reconstruction. Randomized, prospective study with 2-year follow-up. Harilainen A, et al. **Knee Surg Sports Traumatol Arthrosc** 1997;5(1):10–3

Reconstruction of the anterior cruciate ligament with carbon fibres: unsatisfactory results after 8 years. Mäkisalo SE, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(3):132–6

Arthroscopic reconstruction of the anterior cruciate ligament with Leeds-Keio ligament in non-professional athletes. Results after a minimum 5 years' follow-up. Marcacci M, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(1):9–13

Anterior cruciate ligament reconstruction with fresh-frozen patellar tendon allografts: sixty cases with 2 years' minimum follow-up. Nin JR, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(3):137–42

Timing of surgery in anterior cruciate ligament-injured knees. Shelbourne KD, et al. **Knee Surg Sports Traumatol Arthrosc** 1995;3(3):148–56 (22 ref.)

Behavior of sutures used in anterior cruciate ligament reconstructive surgery. Spencer EE, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(2):84–8

Comparison of augmented and non-augmented anterior cruciate ligament reconstruction combined with high tibial osteotomy. Stutz G, et al. **Knee Surg Sports Traumatol Arthrosc** 1996;4(3):143–8

Histological and ultrastructural evaluation of Leeds-Keio ligament six years after implant. A case report. Zaffagnini S, et al. **Knee Surg Sports Traumatol Arthrosc** 1997; 5(2):89–94

Eccentric knee flexor torque following anterior cruciate ligament surgery. Osternig LR, et al. **Med Sci Sports Exerc** 1996 Oct;28(10):1229–34

Assessment of metabolic response and functional changes after anterior cruciate ligament surgery. Petschnig R, et al. **Med Sci Sports Exerc** 1997 Jan;29(1):3–9

A prospective, clinical study evaluating arthroscopic ACL reconstruction using the semitendinosus and iliotibial band: 2- to 5-year follow up. Billotti JD, et al. **Orthopedics** 1997 Feb;20(2):125–31

Anatomic endoscopic ACL reconstruction with autogenous patellar tendon graft. Clancy WG Jr. **Orthopedics** 1997 May;20(5):397, 399–400 (5 ref.)

ACL reconstruction: semitendinosus tendon is the graft of choice. Rosenberg TD, et al. **Orthopedics** 1997 May; 20(5):396, 398 (14 ref.)

Fifty-two year follow up of an anterior cruciate ligament reconstruction [see comments] Severud EL, et al. **Orthopedics** 1996 Jun;19(6):541–5. Comment in: Orthopedics 1996 Oct;19(10):845.

52-year follow up of ACL reconstruction [letter; comment] Wertzberger KL. **Orthopedics** 1996 Oct;19(10):845. Comment on: Orthopedics 1996 Jun;19(6):541–5.

Serial kinematic analysis of the canine hindlimb joints after deafferentation and anterior cruciate ligament transection. Vilensky JA, et al. **Osteoarthritis Cartilage** 1997 May; 5(3):173–82

Reliability of lower extremity girth measurements after anterior cruciate ligament reconstruction. Soderberg GL, et al. **Physiother Res Int** 1996;1(1):7–16

Comparison between two techniques for surgical repair of the acutely torn anterior cruciate ligament. A prospective, randomized follow-up study of 48 patients. Grøntvedt T, et al. **Scand J Med Sci Sports** 1995 Dec;5(6):358–63

Anterior cruciate ligament reconstruction with the patellar tendon—augmentation or not? A 2-year follow-up of 82 patients. Thuresson P, et al. **Scand J Med Sci Sports** 1996 Aug;6(4):247–54

Tunnel placement in anterior cruciate ligament reconstruction: MRI analysis as an important factor in the radiological report. Tomczak RJ, et al. **Skeletal Radiol** 1997 Jul;26(7):409–13

[Arthroscopic reconstruction using the Leeds-Keio ligament following anterior cruciate ligament lesions in 200 patients (letter; comment)] Bakens JA. **Ned Tijdschr Geneeskd** 1997 Apr 26;141(17):845–6. Comment on: Ned Tijdschr Geneeskd 1996 Nov 9;140(45):2231–4. **(Dut)**

[Arthroscopic reconstruction using the Leeds-Keio ligament following anterior cruciate ligament lesions in 200 patients (see comments)] Meins GA, et al. **Ned Tijdschr Geneeskd** 1996 Nov 9;140(45):2231–4 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1997 Apr 26;141(17):845–6. **(Dut)**

[Arthroscopic reconstruction using the Leeds-Keio ligament in anterior cruciate ligament lesions (comment)] van Kampen A. **Ned Tijdschr Geneeskd** 1996 Nov 9; 140(45):2225–6. Comment on: Ned Tijdschr Geneeskd 1996 Nov 9;140(45):2231–4. **(Dut)**

[Isometric reconstruction of the anterior cruciate ligament. Determination of the femoral and tibial tunnels] Laboureau JP, et al. **Acta Orthop Belg** 1996;62 Suppl 1:166–77 **(Fre)**

[Systemic granulomatosis caused by a Dacron prosthetic ligament] Aziza R, et al. **J Radiol** 1997 Jul;78(7):507–9 (Eng. Abstr.) **(Fre)**

[A prospective study of the outcome of anterior laxity of the knee after anterior cruciate ligament reconstruction with procedures using two different patellar tendon grafting methods] Lerat JL, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1997;83(3):217–28 (Eng. Abstr.) **(Fre)**

[Knee joint ligament reconstruction—indications, results] Friederich NF, et al. **Ther Umsch** 1996 Oct;53(10):780–6 (Eng. Abstr.) **(Ger)**

[Maintenance of the cranial cruciate ligament rupture in the dog using an intra-articular ("over-the-top") and an extra-articular ("fascia-doubling") method] Timmermann C, et al. **Tierarztl Prax** 1996 Dec;24(6):590–5 (Eng. Abstr.) **(Ger)**

[Cruciate reconstruction using an 8-fold plantaris tendon] Henche HR. **Z Orthop Ihre Grenzgeb** 1997 Mar–Apr; 135(2):Oa6 **(Ger)**

[Control of muscle reinforcement with the isokinetic

ANTERIOR CRUCIATE LIGAMENT

endurance test in patients undergoing reconstruction of the anterior cruciate ligament of the knee] Felicetti G, et al. **G Ital Med Lav Ergon** 1996 Jan–May;18(1–3):73–6 (Eng. Abstr.) **(Ita)**

[Cyclops type changes––a specific complication after anterior cruciate reconstruction––a clinical and histopathologic study] Latosiewicz R, et al. **Chir Narzadow Ruchu Ortop Pol** 1996;61(4):397–401 (Eng. Abstr.) **(Pol)**

[Texture of cruciate ligaments as a modifying factors of grafts] Urban J. **Polim Med** 1996;26(3–4):7–19 (Eng. Abstr.) **(Pol)**

TRANSPLANTATION

Reconstruction of the anterior cruciate ligament with a cyropreserved ACL allograft. A microangiographic and immunohistochemical study in rabbits. Fromm B, et al. **Int Orthop** 1996;20(6):378–82

ANTERIOR EYE SEGMENT

Anterior segment prosthesis development: evaluation of expanded polytetrafluoroethylene as a sclera-attached prosthetic material. Guo A, et al. **Cornea** 1996 Mar; 15(2):210–4

Resolution of pigmentary dispersion syndrome following radial keratotomy [letter] Smith JP. **J Refract Surg** 1996 May–Jun;12(4):456

[Commission for prophylaxis of infections in the anterior eye segment in newborn infants] **Klin Oczna** 1995 Sep–Oct; 97(9–10):314 **(Pol)**

ABNORMALITIES

Ciliary body band width as an indicator of goniodysgenesis. Tawara A, et al. **Am J Ophthalmol** 1996 Dec; 122(6):790–800

Anterior segment pathology associated with hypermetropia. Spierer A, et al. **Ophthalmic Genet** 1996 Jun;17(2):79–83

Corneal coloboma, aphakia and retinal neovascularization with anterior segment dysgenesis (Peters' anomaly). Gunderson CA, et al. **Ophthalmologica** 1996;210(6):361–6

Autosomal–dominant iridogoniodysgenesis and Axenfeld–Rieger syndrome are genetically distinct. Walter MA, et al. **Ophthalmology** 1996 Nov;103(11):1907–15

ANATOMY & HISTOLOGY

The morphology of the equine iridocorneal angle: a light and scanning electron microscopic study. De Geest JP, et al. **Equine Vet J Suppl** 1990 Sep;(10):30–5

Rotating slit image camera TOPCON SL 45. New developments for simultaneous image acquisition by photographic and CCD–assisted on–line documentation. Dragomirescu V, et al. **Ophthalmic Res** 1996;28 Suppl 2:102–8

Axial length as a risk factor to branch retinal vein occlusion. Timmerman EA, et al. **Retina** 1997;17(3):196–9

BLOOD SUPPLY

Disorders of perfusion of the anterior segment of the eye. Gillies WE, et al. **Aust N Z J Ophthalmol** 1996 Aug; 24(3):169–87

Anterior segment ischaemia after excision of conjunctival squamous cell carcinoma [letter] al–Hemidan AI, et al. **Br J Ophthalmol** 1997 Jun;81(6):516–7

Microvascular change of the anterior eye segment after tenotomy in the rabbit. Ohtsuki H, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Jun;235(6):393–8

Anterior segment ischemia following pterygium surgery. Gündüz K, et al. **Jpn J Ophthalmol** 1997 May–Jun; 41(3):192–5

CHEMISTRY

[An immunohistochemical study on glycosaminoglycans distribution in the trabeculum of congenital aniridia] Asakawa M, et al. **Nippon Ganka Gakkai Zasshi** 1997 Jan; 101(1):87–91 (Eng. Abstr.) **(Jpn)**

CYTOLOGY

Cytoskeleton and tissue origin in the anterior cynomolgus monkey eye. Hamanaka T, et al. **Jpn J Ophthalmol** 1997 May–Jun;41(3):138–49

DRUG EFFECTS

Ocular toxicity following topical application of anesthetic cream to the eyelid skin [published erratum appears in Ophthalmic Surg Lasers 1996 Jul;27(7):594] Cohen RG, et al. **Ophthalmic Surg Lasers** 1996 May;27(5):374–7

[Successes and complications of rTPA treatment of the anterior eye segment. Comment on the contribution by K.U. Löffler et al. (letter; comment)] Hesse L, et al. **Ophthalmologe** 1997 Jun;94(6):446–7. Comment on: Ophthalmologe 1997 Jan;94(1):50–2. **(Ger)**

[Success and complications of rTPA treatment of the anterior eye segment (see comments)] Löffler KU, et al. **Ophthalmologe** 1997 Jan;94(1):50–2 (Eng. Abstr.). Comment in: Ophthalmologe 1997 Jun;94(6):446–7. **(Ger)**

EMBRYOLOGY

[Histochemical studies on the separation of the lens vesicle] Mizuno S, et al. **Nippon Ganka Gakkai Zasshi** 1997 Jan; 101(1):46–51 (Eng. Abstr.) **(Jpn)**

GROWTH & DEVELOPMENT

Morphometric analysis of pars plana development in humans. Hairston RJ, et al. **Retina** 1997;17(2):135–8

INJURIES

Topical aminocaproic acid in the treatment of traumatic hyphema [see comments] Crouch ER Jr, et al. **Arch Ophthalmol** 1997 Sep;115(9):1106–12. Comment in: Arch Ophthalmol 1997 Sep;115(9):1189–90.

The treatment of traumatic hyphema with topical epsilon–aminocaproic acid [editorial; comment] Goldberg MF. **Arch Ophthalmol** 1997 Sep;115(9):1189–90. Comment on: Arch Ophthalmol 1997 Sep;115(9):1106–12.

Ultrasound biomicroscopy in anterior ocular trauma. Berinstein DM, et al. **Ophthalmic Surg Lasers** 1997 Mar; 28(3):201–7

Severe ocular trauma managed with primary pars plana vitrectomy and silicone oil. Spiegel D, et al. **Retina** 1997; 17(4):275–85

[Fluorescence angiography of the anterior eye segment in severe eye chemical burns] Kuckelkorn R, et al. **Klin Monatsbl Augenheilkd** 1996 Aug–Sep;209(2–3):109–13 (Eng. Abstr.) **(Ger)**

METABOLISM

Calponin distribution in human ciliary muscle and other anterior segment tissues. Kashiwagi K, et al. **Invest Ophthalmol Vis Sci** 1997 Feb;38(2):349–56

Glycosaminoglycan stratification of the juxtacanalicular tissue in normal and primary open–angle glaucoma. Knepper PA, et al. **Invest Ophthalmol Vis Sci** 1996 Nov; 37(12):2414–25

Accommodation and presbyopia in the human eye. Changes in the anterior segment and crystalline lens with focus. Koretz JF, et al. **Invest Ophthalmol Vis Sci** 1997 Mar; 38(3):569–78

Increased extracellular deposition of fibrillin–containing fibrils in pseudoexfoliation syndrome. Schlötzer–Schrehardt U, et al. **Invest Ophthalmol Vis Sci** 1997 Apr;38(5):970–84

MICROBIOLOGY

Posttraumatic fungal endophthalmitis resulting from Scopulariopsis brevicaulis. Gariano RF, et al. **Retina** 1997; 17(3):256–8

PARASITOLOGY

Parasitic infections of the anterior segment. Young JA, et al. **Int Ophthalmol Clin** 1996 Summer;36(3):49–71 (86 ref.)

PATHOLOGY

Simple choristoma of the anterior segment containing brain tissue. Marshman WE, et al. **Arch Ophthalmol** 1997 Sep; 115(9):1198–200

Ring melanoma of the anterior uvea presenting as unilateral neovascular glaucoma. Allaire GS, et al. **Can J Ophthalmol** 1997 Aug;32(5):338–41 (14 ref.)

Anterior segment recurrence of acute myelogenous leukemia: treatment with subconjunctival injections of methotrexate and triamcinolone acetonide. Katz SE, et al. **Can J Ophthalmol** 1997 Jun;32(4):265–7

Centration and fixation of silicone intraocular lenses: clinicopathological findings in human autopsy eyes. Auffarth GU, et al. **J Cataract Refract Surg** 1996;22 Suppl 2:1281–5

Clinicopathological findings in human autopsy eyes with an Anis circular lens. Auffarth GU, et al. **J Cataract Refract Surg** 1996 Dec;22(10):1471–5

Intraocular metallic–appearing foreign bodies after phacoemulsification. Braunstein RE, et al. **J Cataract Refract Surg** 1996 Nov;22(9):1247–50

Bilateral diffuse uveal melanocytic proliferation simulating an arteriovenous fistula. Murphy MA, et al. **J Neuroophthalmol** 1997 Sep;17(3):166–9

Free–floating cyst in the anterior chamber of the eye. Shields JA, et al. **J Pediatr Ophthalmol Strabismus** 1996 Nov–Dec; 33(6):330–1

Should patients with anatomically narrow angles have prophylactic iridectomy? Wilensky JT, et al. **Surv Ophthalmol** 1996 Jul–Aug;41(1):31–6 (35 ref.)

[Optical coherence tomography of the cornea and the anterior eye segment] Koop N, et al. **Ophthalmologe** 1997 Jul;94(7):481–6 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Aqueous humor dynamics in rats. Mermoud A, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234 Suppl 1:S198–203

Anterior segment physiology after bumetanide inhibition of Na–K–Cl cotransport. Gabelt BT, et al. **Invest Ophthalmol Vis Sci** 1997 Aug;38(9):1700–7

Effects of time of storage, albumin, and osmolality changes on outflow facility (C) of bovine anterior segment in vitro. Gual A, et al. **Invest Ophthalmol Vis Sci** 1997 Sep; 38(10):2165–71

Morphometric analysis of hippocampal pyramidal neurons in situ and in grafts developing in the anterior eye chambers of young and aged Wistar rats. Zhuravleva ZN, et al. **J Neural Transplant Plast** 1997 Jan–Mar;6(1):49–57

RADIOGRAPHY

[Incidental CT finding: calcinosis of the anterior eye segment. Senile scleral plaques] Windmann R, et al. **Radiologe** 1996 Sep;36(9):759–61 **(Ger)**

SURGERY

Anterior segment prosthesis development: retinal function following anterior segment removal. Guo A, et al. **Cornea** 1997 Jan;16(1):88–93

One quadrant sub–Tenon's capsule anesthesia in anterior segment surgery. Kapran Z, et al. **Eur J Ophthalmol** 1996 Apr–Jun;6(2):131–6

Poly (triethylenglycol monomethacrylate) and poly (glycerol monomethacrylate) cross–linked gel as potential viscoelastics for intraoperative use. Karel I, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Mar;235(3):186–9

Ultrasound biomicroscopy following the intraocular use of silicone oil. Azzolini C, et al. **Int Ophthalmol** 1995–96; 19(3):191–5

Do standard procedures in squint surgery influence the blood–aqueous barrier? Neugebauer A, et al. **Ophthalmic Surg Lasers** 1997 Jul;28(7):570–3

Noninvasive closure of a persistent cyclodialysis cleft [see comments] Brooks AM, et al. **Ophthalmology** 1996 Nov; 103(11):1943–5. Comment in: Ophthalmology 1997 Aug;104(8):1207.

Apraclonidine and anterior segment laser surgery. Comparison of 0.5% versus 1.0% apraclonidine for prevention of postoperative intraocular pressure rise. Rosenberg LF, et al. **Ophthalmology** 1995 Sep; 102(9):1312–8

ULTRASONOGRAPHY

Ultrasound biomicroscopic imaging of the anterior aspect of peripheral choroidal melanomas. Maberly DA, et al. **Am J Ophthalmol** 1997 Apr;123(4):506–14

Ultrasound biomicroscopy following the intraocular use of silicone oil. Azzolini C, et al. **Int Ophthalmol** 1995–96; 19(3):191–5

Ultrasound biomicroscopic morphometry of the anterior eye segment before and after one drop of pilocarpine. Németh J, et al. **Int Ophthalmol** 1996–97;20(1–3):39–42

Ultrasound biomicroscopy of the anterior segment. Liebmann JM, et al. **J Am Optom Assoc** 1996 Aug;67(8):469–79 (42 ref.)

Appositional angle closure in eyes with narrow angles: an ultrasound biomicroscopic study. Sakuma T, et al. **J Glaucoma** 1997 Jun;6(3):165–9

An ultrasound biomicroscopic study of filtering blebs after mitomycin C trabeculectomy. Yamamoto T, et al. **Ophthalmology** 1995 Dec;102(12):1770–6

[Ultrasound biomicroscopic observation of the anterior eye segment in a sclerocornea and a microcornea] Park M, et al. **Nippon Ganka Gakkai Zasshi** 1997 Jan;101(1):69–73 (Eng. Abstr.) **(Jpn)**

VIROLOGY

The spectrum of herpes simplex virus disease of the anterior segment in the 1990s. Claoué C, et al. **Acta Ophthalmol Scand** 1996 Aug;74(4):407–10

Herpesvirus infections of the anterior segment. Chang EJ, et al. **Int Ophthalmol Clin** 1996 Summer;36(3):17–28 (31 ref.)

ANTERIOR HORN CELLS

CYTOLOGY

Age–related changes in human spinal ventral horn cells with special reference to the loss of small neurons in the intermediate zone: a quantitative analysis. Terao S, et al. **Acta Neuropathol (Berl)** 1996 Aug;92(2):109–14

DRUG EFFECTS

Preferential enhancement of inhibitory synaptic transmission by CS–722 in the ventral horn neurons of neonatal rat spinal cord. Tanabe M, et al. **Eur J Pharmacol** 1996 Oct 17; 313(3):187–9

Effects of NMDA and its antagonists on ventral horn cholinergic neurons in organotypic roller tube spinal cord cultures. Delfs JR, et al. **J Neural Transm** 1997;104(1):31–51

ENZYMOLOGY

Influence of spaceflight on succinate dehydrogenase activity and soma size of rat ventral horn neurons. Ishihara A, et al. **Acta Anat (Basel)** 1996;157(4):303–8

METABOLISM

Age–related changes in human spinal ventral horn cells with special reference to the loss of small neurons in the intermediate zone: a quantitative analysis. Terao S, et al. **Acta Neuropathol (Berl)** 1996 Aug;92(2):109–14

PATHOLOGY

Golgi apparatus and intraneuronal inclusions of anterior horn

cells in amyotrophic lateral sclerosis: an immunohistochemical study. Matsumoto S, et al. **Acta Neuropathol (Berl)** 1996;91(6):603–7

Disaggregation of polyribosomes in the spinal anterior horn cells in a patient with X-linked spinal and bulbar muscular atrophy. Oyanagi K, et al. **Acta Neuropathol (Berl)** 1996; 91(4):444–7

The lateral corticospinal tract and spinal ventral horn in X-linked recessive spinal and bulbar muscular atrophy: a quantitative study. Terao S, et al. **Acta Neuropathol (Berl)** 1997 Jan;93(1):1–6

Neurotrophic effects of Schwann cells in culture on spinal anterior horn neurons. Wu B, et al. **Chin Med J (Engl)** 1996 Jul;109(7):547–50

Synaptic alterations of anterior horn cells in Werdnig–Hoffmann disease. Yamanouchi Y, et al. **Pediatr Neurol** 1996 Jul;15(1):32–5

[A clinicopathological study of the Guillain–Barré syndrome—fifteen Japanese postmortem cases] Sobue G. **Rinsho Shinkeigaku** 1995 Dec;35(12):1362–4 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Giant repeater F-wave in patients with anterior horn cell disorders. Role of motor unit size. Ibrahim IK, et al. **Am J Phys Med Rehabil** 1997 Jul–Aug;76(4):281–7

Preferential enhancement of inhibitory synaptic transmission by CS-722 in the ventral horn neurons of neonatal rat spinal cord. Tanabe M, et al. **Eur J Pharmacol** 1996 Oct 17; 313(3):187–9

ULTRASTRUCTURE

Dendritic synapses of anterior horn neurons in amyotrophic lateral sclerosis: an ultrastructural study. Sasaki S, et al. **Acta Neuropathol (Berl)** 1996;91(3):278–83

Ultrastructural study of synapses in the anterior horn neurons of patients with amyotrophic lateral sclerosis. Sasaki S, et al. **Neurosci Lett** 1996 Feb 2;204(1–2):53–6

ANTERIOR HYPOTHALAMIC AREA see **HYPOTHALAMIC AREA, ANTERIOR**

ANTERIOR HYPOTHALAMIC NUCLEUS see **HYPOTHALAMIC AREA, ANTERIOR**

ANTERIOR LONGITUDINAL LIGAMENT see **LONGITUDINAL LIGAMENTS**

ANTERIOR PERFORATED SUBSTANCE see **OLFACTORY PATHWAYS**

ANTERIOR TIBIAL MUSCLE see **MUSCLE, SKELETAL**

ANTERIOR TIBIAL SYNDROME see **ANTERIOR COMPARTMENT SYNDROME**

ANTHELMINTICS

The effect of cooking on veterinary drug residues in food; 5. Oxfendazole. Rose MD, et al. **Food Addit Contam** 1997 Jan;14(1):15–26

Novel sources of anthelmintics. Bennet-Jenkins E, et al. **Int J Parasitol** 1996 Aug–Sep;26(8–9):937–47 (33 ref.)

Workshop summary: anthelmintic resistance. Borgsteede FH, et al. **Vet Parasitol** 1996 Aug;64(1–2):129–32

Workshop summary: biological control of nematode parasites of livestock. Waller PJ, et al. **Vet Parasitol** 1996 Aug; 64(1–2):135–7

ADMINISTRATION & DOSAGE

Cutaneous larva migrans: the case for routine oral treatment [letter] Loughrey MB, et al. **Br J Dermatol** 1997 Jul; 137(1):155–6

Safety of milbemycin as an oral or bath treatment for the tropical freshwater angelfish Pterophyllum scalare. Killino TJ, et al. **J Zoo Wildl Med** 1997 Mar;28(1):94–6

An oral ivermectin regimen that eradicates pinworms (Syphacia spp.) in laboratory rats and mice. Klement P, et al. **Lab Anim Sci** 1996 Jun;46(3):286–90

Comparison of moxidectin oral gel and ivermectin oral paste against a spectrum of internal parasites of ponies with special attention to encysted cyathostome larvae. Monahan CM, et al. **Vet Parasitol** 1996 Jun;63(3–4):225–35

Oesophageal injury associated with the administration of an anthelmintic bolus to calves. Mannion PA, et al. **Vet Rec** 1997 Mar 29;140(13):331–4

Anthelmintic coils in cattle causing pharyngeal and oesophageal perforation. West HJ, et al. **Vet Rec** 1996 Jul 13;139(2):44–5

[E. Multilocularis infection under treatment with albendazole for very long durations (letter)] Ilias I, et al. **Presse Med** 1997 Apr 26;26(14):667 **(Fre)**

[The technology for manufacturing antiparasitic preparations. 8. The preparation rilanid and its use for treating fascioliasis and intestinal nematodiases] Mikhailitsyn FS, et al. **Med Parazitol (Mosk)** 1997 Jan–Mar;(1):28–30 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Aplastic anemia during treatment with albendazole [letter] Fernández FJ, et al. **Am J Hematol** 1996 Sep;53(1):53–4

Development of bone marrow toxicosis after albendazole administration in a dog and cat. Stokol T, et al. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1753–6

IgG4 and IgE responses to Schistosoma mansoni adult worms after treatment [letter; comment] Webster M, et al. **J Infect Dis** 1997 Feb;175(2):493–4. Comment on: J Infect Dis 1996 May;173(5):1242–7.

Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection [see comments] Gardon J, et al. **Lancet** 1997 Jul 5; 350(9070):18–22. Comment in: Lancet 1997 Jul 5;350(9070):2–3.

[Polyradiculoneuritis and neurocysticercosis: report of a case] Agapejev S, et al. **Arq Neuropsiquiatr** 1996 Mar; 54(1):107–13 (Eng. Abstr.) **(Por)**

ANALYSIS

Determination of concentration of albendazole sulfoxide in plasma and uterine fluid of heifers. Piscopo SE, et al. **Am J Vet Res** 1997 Jan;58(1):62–5

Effects of drug residues in the faeces of cattle treated with injectable formulations of ivermectin and moxidectin on larvae of the bush fly, Musca vetustissima and the house fly, Musca domestica. Wardhaugh KG, et al. **Aust Vet J** 1996 Nov;74(5):370–4

Rapid quantitative screening assay of trace benzimidazole residues in milk by liquid chromatography. Fletouris D, et al. **J AOAC Int** 1996 Nov–Dec;79(6):1281–7

Determination of avermectin B1 in biological samples by immunoaffinity column cleanup and liquid chromatography with UV detection. Li J, et al. **J AOAC Int** 1996 Sep–Oct; 79(5):1062–7

Simultaneous determination of five fasciolicides in milk by liquid chromatography with electrochemical detection. Takeba K, et al. **J AOAC Int** 1996 Jul–Aug;79(4):848–52

BLOOD

Determination of concentration of albendazole sulfoxide in plasma and uterine fluid of heifers. Piscopo SE, et al. **Am J Vet Res** 1997 Jan;58(1):62–5

Immunoaffinity column cleanup and liquid chromatographic method for determining ivermectin in sheep serum. Li J, et al. **J AOAC Int** 1996 Nov–Dec;79(6):1300–2

Determination of moxidectin in plasma by high-performance liquid chromatography with automated solid-phase extraction and fluorescence detection. Alvinerie M, et al. **J Chromatogr B Biomed Appl** 1995 Dec 1;674(1):119–24

Enhanced plasma availability of the metabolites of albendazole in fasted adult sheep. Lifschitz A, et al. **Vet Res Commun** 1997 Apr;21(3):201–11

CHEMICAL SYNTHESIS

Synthesis of catecholamide spiroarsoranes and their in vitro anthelmintic properties against Molinema dessetae and Nippostrongylus brasiliensis infective larvae. Loiseau PM, et al. **Arzneimittelforschung** 1996 Nov;46(11):1095–8

[The technology for manufacturing antiparasitic preparations. 8. The preparation rilanid and its use for treating fascioliasis and intestinal nematodiases] Mikhailitsyn FS, et al. **Med Parazitol (Mosk)** 1997 Jan–Mar;(1):28–30 (Eng. Abstr.) **(Rus)**

ECONOMICS

Overberg Research Projects. VII. Anthelmintic sales in the Swellendam area of the southern Cape. Louw JP. **J S Afr Vet Assoc** 1990 Dec;61(4):159–62

ISOLATION & PURIFICATION

Novel anthelmintic compounds and molluscicides from medicinal plants. Whitfield PJ. **Trans R Soc Trop Med Hyg** 1996 Nov–Dec;90(6):596–600 (46 ref.)

METABOLISM

Cytochrome P450 3A4 mediated metabolism of 2,4-dichlorophenol. Mehmood Z, et al. **Chemosphere** 1997 Jun;34(11):2281–91

Fate of 4"-epiacetylamino-4"-deoxyavermectin B1 in rats. Zeng Z, et al. **Drug Metab Dispos** 1996 May;24(5):572–8

Haemonchus contortus: the uptake and metabolism of closantel. Rothwell J, et al. **Int J Parasitol** 1997 Mar; 27(3):313–9

Avermectin B1a binds to high- and low-affinity sites with dual effects on the gamma-aminobutyric acid-gated chloride channel of cultured cerebellar granule neurons. Huang J, et al. **J Pharmacol Exp Ther** 1997 Apr; 281(1):261–6

Study of the distribution of albendazole-sulphoxide (ABZ-SO) in fertilized egg compartments. Navarro M, et al. **J Pharmacol Toxicol Methods** 1997 Jun;37(4):191–6

Stability of ivermectin in rumen fluids. Andrew NW, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):295–9

Characterization of calcineurin from Hymenolepis microstoma and H. diminuta and its interaction with cyclosporin A. Roberts HC, et al. **Parasitology** 1997 Mar; 114 (Pt 3):279–83

Evaluation of certain veterinary drug residues in food. Forty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives. **World Health Organ Tech Rep Ser** 1996;864:1–62 (118 ref.)

PHARMACOKINETICS

Persistence of ivermectin in plasma and faeces following treatment of cows with ivermectin sustained-release, pour-on or injectable formulations. Herd RP, et al. **Int J Parasitol** 1996 Oct;26(10):1087–93

Haemonchus contortus: the uptake and metabolism of closantel. Rothwell J, et al. **Int J Parasitol** 1997 Mar; 27(3):313–9

Efficacy in sheep and pharmacokinetics in cattle that led to the selection of eprinomectin as a topical endectocide for cattle. Shoop WL, et al. **Int J Parasitol** 1996 Nov; 26(11):1227–35

Distribution of the anthelmintic drug albendazole and its major metabolites in ovine milk and milk products after a single oral dose. De Liguoro M, et al. **J Dairy Res** 1996 Nov;63(4):533–42

The effect of level of feed intake on the pharmacokinetic disposition and efficacy of ivermectin in sheep. Ali DN, et al. **J Vet Pharmacol Ther** 1996 Apr;19(2):89–94

The bioavailability of febantel in dehydrated camels. Ben-Zvi Z, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):288–94

Metabolism and pharmacokinetics of albendazole after oral administration to chickens. Csikó GY, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):322–5

Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle. Lanusse C, et al. **J Vet Pharmacol Ther** 1997 Apr;20(2):91–9

Fasting-induced changes to the pharmacokinetic behaviour of albendazole and its metabolites in calves. Sánchez SF, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):38–47

Disposition kinetics of albendazole in buffalo and cattle. Sanyal PK. **J Vet Pharmacol Ther** 1997 Jun;20(3):240–2

Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Takayanagui OM, et al. **Ther Drug Monit** 1997 Feb;19(1):51–5

Disposition of netobimin, albendazole, and its metabolites in the pregnant rat: developmental toxicity. Cristòfol C, et al. **Toxicol Appl Pharmacol** 1997 May;144(1):56–61

Depletion and bioavailability of 14C-oxibendazole residues in swine tissues. Gottschall DW, et al. **Vet Parasitol** 1996 Aug;64(1–2):83–93

Efficacy and pharmacokinetics of triclabendazole in buffalo with induced fasciolosis. Sanyal PK, et al. **Vet Parasitol** 1996 May;63(1–2):75–82

Influence of drench volume on the disposition of oxfendazole in sheep. Hennessy DR, et al. **Vet Rec** 1997 Apr 19; 140(16):429–30

Pharmacokinetics of ivermectin in the camel (Camelus dromedarius). Oukessou M, et al. **Vet Rec** 1996 Oct 26; 139(17):424–5

The efficacy and pharmacokinetics of long-term low-level intraruminal administration of triclabendazole in buffalo with induced fasciolosis. Sanyal PK, et al. **Vet Res Commun** 1996;20(5):461–8

Some pharmacokinetic parameters of oxfendazole in sheep. Soraci AL, et al. **Vet Res Commun** 1997 May;21(4):283–7

PHARMACOLOGY

Increases in the effects of albendazole on Echinococcus multilocularis metacestodes by the dipeptide methyl ester (Phe-Phe-OMe). Sarciron ME, et al. **Am J Trop Med Hyg** 1997 Feb;56(2):226–30

Comparison of effects of albendazole sulfoxide on in vitro produced bovine embryos and rat embryos. Piscopo SE, et al. **Am J Vet Res** 1997 Sep;58(9):1038–42

In vitro effects of anthelmintics on the histochemistry of Haemonchus contortus and Trichuris globulosa. Kaur M, et al. **Appl Parasitol** 1996 Dec;37(4):302–11

Effects of drug residues in the faeces of cattle treated with injectable formulations of ivermectin and moxidectin on larvae of the bush fly, Musca vetustissima and the house fly, Musca domestica. Wardhaugh KG, et al. **Aust Vet J** 1996 Nov;74(5):370–4

Activation and cooperative multi-ion block of single nicotinic-acetylcholine channel currents of Ascaris muscle by the tetrahydropyrimidine anthelmintic, morantel. Evans AM, et al. **Br J Pharmacol** 1996 Jul;118(5):1127–40

Effects of acetylcholine on a slow voltage-activated non-selective cation current mediated by non-nicotinic receptors on isolated Ascaris muscle bags. Martin RJ, et al. **Exp Physiol** 1996 Nov;81(6):909–25

Developmental differences determine larval susceptibility to nitric oxide-mediated killing in a murine model of vaccination against Schistosoma mansoni. Ahmed SF, et al. **Infect Immun** 1997 Jan;65(1):219–26

Evaluation of a larval development assay for the detection of anthelmintic resistance in Ostertagia circumcincta. Amarante AF, et al. **Int J Parasitol** 1997 Mar;27(3):305–11

Development of chemotherapeutic model for the in vitro screening of drugs against Echinoccus granulosus cysts: the effects of an albendazole-albendazole sulphoxide combination. Casado N, et al. **Int J Parasitol** 1996 Jan; 26(1):59–65

Management of anthelmintic resistance: inheritance of resistance and selection with persistent drugs [published erratum appears in Int J Parasitol 1997 Jan;27(1):141] Dobson RJ, et al. **Int J Parasitol** 1996 Aug–Sep; 26(8–9):993–1000 (27 ref.)

ANTHELMINTICS

Beta-tubulin gene polymorphism and benzimidazole resistance in trichostrongylus colubriformis. Grant WN, et al. **Int J Parasitol** 1996 Jan;26(1):71–7

The death rate of Ostertagia circumcincta and Trichostrongylus colubriformis in lactating ewes: implications for anthelmintic resistance. Leathwick DM, et al. **Int J Parasitol** 1997 Apr;27(4):411–6

In vitro characterization of lines of Oesophagostomum dentatum selected or not selected for resistance to pyrantel, levamisole and ivermectin. Várady M, et al. **Int J Parasitol** 1997 Jan;27(1):77–81

Sequences of beta-tubulin cDNA from benzimidazole-susceptible and -resistant strains of Teladorsagia circumcincta, a nematode parasite of small ruminants. Elard L, et al. **Mol Biochem Parasitol** 1996 Aug; 79(2):249–53

Characterization of subtypes of gamma-aminobutyric acid receptors in an Ascaris muscle preparation by binding assay and binding of PF1022A, a new anthelmintic, on the receptors. Chen W, et al. **Parasitol Res** 1996;82(2):97–101

In vivo inhibition of the regenerative capacity of hydatid material after treatment with netobimin. García-Llamazares JL, et al. **Parasitol Res** 1997;83(2):105–8

Influence of PF1022A on the motility of Angiostrongylus cantonensis in vitro. Kachi S, et al. **Parasitol Res** 1997; 83(6):578–82

In vitro anthelmintic activity of root-tuber extract of Flemingia vestita, an indigenous plant in Shillong, India. Tandon V, et al. **Parasitol Res** 1997;83(5):492–8

An electrophysiological preparation of Ascaris suum pharyngeal muscle reveals a glutamate-gated chloride channel sensitive to the avermectin analogue, milbemycin D. Martin RJ. **Parasitology** 1996 Feb;112 (Pt 2):247–52

Pharmacology of anthelmintic resistance. Sangster N. **Parasitology** 1996;113 Suppl:S201–16 (88 ref.)

Susceptibility of Brugia malayi and Onchocerca lienalis microfilariae to nitric oxide and hydrogen peroxide in cell-free culture and from IFN gamma-activated macrophages. Taylor MJ, et al. **Parasitology** 1996 Mar;112 (Pt 3):315–22

Prospects for rational approaches to anthelmintic discovery. Thompson DP, et al. **Parasitology** 1996;113 Suppl:S217–38 (173 ref.)

Inhibition of superoxide dismutase from Ascaris suum by benzimidazoles and synthesized pyrimidine and glycine derivatives. Sanchez-Moreno M, et al. **Pharmacology** 1996 Jan;52(1):61–8

Effect of sub-lethal doses of albendazole on the fecundity of Dictyocaulus viviparus. Osman AM, et al. **Res Vet Sci** 1996 Jul;61(1):92–3

Choline esters and biogenic amines in the hypobranchial gland of 55 molluscan species of the neogastropod Muricoidea superfamily. Roseghini M, et al. **Toxicon** 1996 Jan;34(1):33–55

Modes of action of anthelmintic drugs [see comments] Martin RJ. **Vet J** 1997 Jul;154(1):11–34 (80 ref.). Comment in: Vet J 1997 Jul;154(1):5–7.

How do anthelmintic drugs work? [editorial; comment] Prichard R. **Vet J** 1997 Jul;154(1):5–7. Comment on: Vet J 1997 Jul;154(1):11–34.

A questionnaire investigation on factors of importance for the development of anthelmintic resistance of nematodes in sow herds in Denmark. Dangolla A, et al. **Vet Parasitol** 1996 Jun;63(3–4):257–71

The value of bulk milk ELISA Ostertagia antibody titres as indicators of milk production response to anthelmintic treatment in the dry period. Kloosterman A, et al. **Vet Parasitol** 1996 Sep 2;64(3):197–205

Critical test evaluation (1977–1992) of drug efficacy against endoparasites featuring benzimidazole-resistant small strongyles (population S) in Shetland ponies. Lyons ET, et al. **Vet Parasitol** 1996 Nov 1;66(1–2):67–73

A study (1977–1992) of population dynamics of endoparasites featuring benzimidazole-resistant small strongyles (population S) in Shetland ponies. Lyons ET, et al. **Vet Parasitol** 1996 Nov 1;66(1–2):75–86

A survey of anthelmintic resistance in nematode parasites of goats in Denmark. Maingi N, et al. **Vet Parasitol** 1996 Nov 1;66(1–2):53–66

A survey of anthelmintic resistance by nematodes on three sheep and two goat farms in Hisar (India). Singh S, et al. **Vet Res Commun** 1997 Aug;21(6):447–51

[Helminth nervous system as a field for anthelmintic action] Boczoń K. **Wiad Parazytol** 1996;42(4):373–9 (26 ref.) (Eng. Abstr.) **(Pol)**

[The effect of cydectin on the survival of second stage larvae and mature Ascaris suum cultured in vitro] Zóltowska K, et al. **Wiad Parazytol** 1996;42(3):319–26 (Eng. Abstr.) **(Pol)**

[The development of Ascaris suum eggs in the presence of moxidectin] Zóltowska K, et al. **Wiad Parazytol** 1996; 42(2):205–12 (Eng. Abstr.) **(Pol)**

[Structural changes in the genital system of nematodes of the suborder Strongylata after exposure to anthelmintics] Bogoiavlenskiĭ IuK. **Med Parazitol (Mosk)** 1997 Jan–Mar; (1):58–61 (4 ref.) **(Rus)**

[The results of micromorphological and histochemical studies of the musculocutaneous sac of nematodes in the suborder Oxyurata after anthelmintic exposure] Bogoiavlenskiĭ IuK, et al. **Med Parazitol (Mosk)** 1996 Jul–Sep;(3):57–62 (15 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Field trials of a formulation containing moxidectin and 6 in 1 vaccines for sheep. Schwartzkoff CL, et al. **Aust Vet J** 1996 Sep;74(3):225–7

Availability of medicines for sheep and goats [letter] Coles GC. **Vet Rec** 1996 Nov 2;139(18):452

SUPPLY & DISTRIBUTION

Ivermectin where Loa loa is endemic [comment] Burnham GM. **Lancet** 1997 Jul 5;350(9070):2–3. Comment on: Lancet 1997 Jul 5;350(9070):18–22.

River blindness (onchocerciasis). Progress in ivermectin distribution. **Wkly Epidemiol Rec** 1997 Jul 25;72(30):221–3 **(Eng, Fre)**

THERAPEUTIC USE

Cure by ivermectin of a chronic, persistent, intestinal strongyloidosis. Adenusi AA. **Acta Trop** 1997 Sep 10; 66(3):163–7

Reduction of abdominal hydatid disease with prolonged treatment. Jover R, et al. **Am J Gastroenterol** 1997 Jul; 92(7):1231–2

Intraductal administration of albendazole for biliary ascariasis. van den Bogaerde JB, et al. **Am J Gastroenterol** 1997 Sep;92(9):1531–3

Albendazole monitoring [letter] Smith AL, et al. **Am J Health Syst Pharm** 1997 Feb 1;54(3):319–20

Ocular and sinus microsporidial infection cured with systemic albendazole. Gritz DC, et al. **Am J Ophthalmol** 1997 Aug; 124(2):241–3

Clinical improvement of asthma after anthelminthic treatment in a tropical situation. Lynch NR, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):50–4

Short report: long-term serum antibody isotype responses to Strongyloides stercoralis filariform antigens in eight patients treated with ivermectin. Lindo JF, et al. **Am J Trop Med Hyg** 1996 Nov;55(5):474–6

A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Marti H, et al. **Am J Trop Med Hyg** 1996 Nov; 55(5):477–81

Evaluation of ivermectin and milbemycin oxime efficacy against Dirofilaria immitis infections of three and four months' duration in dogs. McCall JW, et al. **Am J Vet Res** 1996 Aug;57(8):1189–92

Field evaluation of doramectin for treatment of gastrointestinal nematode infections and louse infestations of cattle. Phillips FE, et al. **Am J Vet Res** 1996 Oct; 57(10):1468–71

Efficacy of a pour-on formulation of eprinomectin (MK-397) against nematode parasites of cattle, with emphasis on inhibited early fourth-stage larvae of Ostertagia spp. Williams JC, et al. **Am J Vet Res** 1997 Apr;58(4):379–83

The safety and efficacy of amocarzine in African onchocerciasis and the influence of ivermectin on the clinical and parasitological response to treatment. Awadzi K, et al. **Ann Trop Med Parasitol** 1997 Apr;91(3):281–96

Ivermectin treatment of mansonellosis in Blanchisseuse, Trinidad, West Indies. Chadee DD, et al. **Ann Trop Med Parasitol** 1996 Dec;90(6):645–9

Onchocerca volvulus and O. lienalis: the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo. Tagboto SK, et al. **Ann Trop Med Parasitol** 1996 Oct;90(5):497–505

Is the course of neurocysticercosis modified by treatment with anthelmintic agents? [letter; comment] Del Brutto OH. **Arch Intern Med** 1997 Jan 13;157(1):128–30. Comment on: Arch Intern Med 1995 Oct 9;155(18):1982–8.

Severe forms of neurocysticercosis: treatment with albendazole. Agapejev S, et al. **Arq Neuropsiquiatr** 1996 Mar;54(1):82–93

Effect of early treatment with praziquantel on serum connective tissue metabolite markers in children and adolescents with intestinal schistosomiasis mansoni. Hassanein HI, et al. **Arzneimittelforschung** 1997 Jan; 47(1):84–7

Duration of the persistent activity of moxidectin against Haemonchus contortus in sheep. Abbott KA, et al. **Aust Vet J** 1995 Nov;72(11):408–10

Naphthalophos combinations with benzimidazoles or levamisole as effective anthelmintics for sheep. Cooper NA, et al. **Aust Vet J** 1996 Sep;74(3):221–4

Influence of alternative treatment strategies on the output of strongyle eggs in the faeces of horses. Hunt ER, et al. **Aust Vet J** 1996 Aug;74(2):159–61

Grazing and anthelmintic treatments to increase growth of Cashmere and Angora weaner goats [published erratum appears in Aust Vet J 1996 Nov;74(5):400] Robertson JA, et al. **Aust Vet J** 1996 Sep;74(3):246–8

Persistent efficacy of abamectin and doramectin against gastrointestinal nematodes of cattle. Rolfe PF, et al. **Aust Vet J** 1997 Jan;75(1):33–5

Responses in milk production to control of gastrointestinal nematode and paramphistome parasites in dairy cattle. Spence SA, et al. **Aust Vet J** 1996 Dec;74(6):456–9

Albendazole versus thiabendazole as therapy for trichinosis: a retrospective study. Cabié A, et al. **Clin Infect Dis** 1996 Jun;22(6):1033–5

Primary hydatidosis of the peripheral muscles: treatment with albendazole. Carpintero P, et al. **Clin Infect Dis** 1997 Jan; 24(1):85–6

Anthelmintics. A comparative review of their clinical pharmacology. de Silva N, et al. **Drugs** 1997 May; 53(5):769–88 (241 ref.)

Preoperative albendazole treatment for liver hydatid disease decreases the viability of the cyst. Aktan AO, et al. **Eur J Gastroenterol Hepatol** 1996 Sep;8(9):877–9

Medical treatment of cerebral cysticercosis. Estanol B. **Eur Neurol** 1997;37(2):125–6

The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Frayha GJ, et al. **Gen Pharmacol** 1997 Feb; 28(2):273–99 (132 ref.)

Complete heart block caused by cardiac echinococcosis and successfully treated with albendazole. Ozdemir M, et al. **Heart** 1997 Jan;77(1):84–5

Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery. Ishizu H, et al. **Hepatology** 1997 Mar;25(3):528–31

Albendazole therapy in orbital cysticercosis. Srivastava VK, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):265–6

Childhood neurocysticercosis: issues in diagnosis and management. Garg RK. **Indian Pediatr** 1995 Sep; 32(9):1023–9 (40 ref.)

Albendazole therapy in liver hydatidosis. Singh H, et al. **Indian Pediatr** 1995 Oct;32(10):1105–6

Albendazole versus ricobendazole (albendazole-sulphoxide) against enteral and parenteral stages of Trichinella spiralis in mice. Lopez-Garcia ML, et al. **Int J Parasitol** 1997 Jul; 27(7):781–5

The response of breeding doses to nematodiasis: segregation into "responders" and "non-responders". Patterson DM, et al. **Int J Parasitol** 1996 Nov;26(11):1295–303

The effects of closantel treatment on the ultrastructure of Haemonchus contortus. Rothwell JT, et al. **Int J Parasitol** 1996 Jan;26(1):49–57

Eprinomectin: a novel avermectin for use as a topical endectocide for cattle. Shoop WL, et al. **Int J Parasitol** 1996 Nov;26(11):1237–42

Albendazole treatment and serological follow-up in hydatid disease of bone. Bonifacino R, et al. **Int Orthop** 1997; 21(2):127–32

The use of ivermectin in the treatment of scabies [editorial] [see comments] Coleman R. **Ir Med J** 1996 Sep–Oct; 89(5):167. Comment in: Ir Med J 1997 Jan–Feb;90(1):38.

Abdominal cystic hydatid disease (CHD): classification of sonographic appearance and response to treatment. Caremani M, et al. **J Clin Ultrasound** 1996 Nov–Dec; 24(9):491–500

Comparative studies on the effect of bithionol, praziquantel and triclabendazole in rabbit's fascioliasis [letter] el-Bahy MM. **J Egypt Soc Parasitol** 1997 Aug;27(2):615–6

Detection of circulating antigens in blood to evaluate treatment of fascioliasis. Hammouda NA, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):365–71

Effects of the anthelmintics clorsulon, rafoxanide, mebendazole and arprinocid on Echinostoma caproni in ICR mice [corrected and republished article originally printed in J Helminthol 1995 Dec;69(4):373–4] Maurer K, et al. **J Helminthol** 1996 Mar;70(1):95–6

Serologic evolution of neurocysticercosis patients after antiparasitic therapy. Cysticercosis Working Group in Peru. Garcia HH, et al. **J Infect Dis** 1997 Feb;175(2):486–9

IgG4 and IgE responses to Schistosoma mansoni adult worms after treatment [letter; comment] Webster M, et al. **J Infect Dis** 1997 Feb;175(2):493–4. Comment on: J Infect Dis 1996 May;173(5):1242–7.

Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients. Del Brutto OH. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):659–61

Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle. Proaño JV, et al. **J Neurosurg** 1997 Jul;87(1):29–33

Hypovolaemic shock after anthelmintic treatment of canine angiostrongylosis. Søland J, et al. **J Small Anim Pract** 1996 Dec;37(12):594–6

Effects of albendazole on growth of primary school children and the prevalence and intensity of soil-transmitted helminths in Sierra Leone [letter] Koroma MM, et al. **J Trop Pediatr** 1996 Dec;42(6):371–2

Efficacy of doramectin against intestinal nematodes and sarcoptic manage mites in naturally infected swine. Saeki H, et al. **J Vet Med Sci** 1997 Feb;59(2):129–32

Avermectins and milbemycins. McKellar QA, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):331–51 (223 ref.)

Biliary ascariasis--a letter to the editor [letter; comment] Shuaib IL, et al. **Med J Malaysia** 1995 Sep;50(3):284. Comment on: Med J Malaysia 1995 Mar;50(1):118–9.

Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru. Garcia HH, et al. **Neurology** 1997 May;48(5):1421–7

Between goat-farm biological variability of the nematode Muellerius capillaris first-stage larvea. Influence of anthelmintic treatment. Kulo A, et al. **Parasite** 1994 Mar; 1(1):65–70

Therapeutic and prophylactic efficacy of the Ivomec SR Bolus against nematodes and Psoroptes ovis in cattle weighing more than 300 kg at the time of treatment. Rehbein S, et al. **Parasitol Res** 1997;83(7):722–6

Hepatic fascioliasis: case report and review. Abdul-Hadi S, et al. **Rev Inst Med Trop Sao Paulo** 1996 Jan–Feb; 38(1):69–73 (35 ref.)

Ascariasis in the subdistrict of Cavacos, municipality of alterosa (MG), Brazil: effect of mass treatment with albendazole on the intensity of infection. Machado MT, et al. **Rev Inst Med Trop Sao Paulo** 1996 Jul-Aug; 38(4):265-71

Intramedullary cysticercosis cured with drug treatment. A case report. Corral I, et al. **Spine** 1996 Oct 1;21(19):2284-7

Medical decompression of vertebral hydatidosis. Lam KS, et al. **Spine** 1997 Sep 1;22(17):2050-5

Modelling the dynamic effects of community chemotherapy on patterns of morbidity due to Schistosoma mansoni. Chan MS, et al. **Trans R Soc Trop Med Hyg** 1997 Mar-Apr; 91(2):216-20

Comparative efficacy of three anthelmintics against mixed gastrointestinal nematode infections in camels. Mukhwana EJ, et al. **Trop Anim Health Prod** 1997 May;29(2):99-101

Acute and subacute Fasciolosis of alpacas (Lama pacos) and treatment with triclabendazole. Puente GL. **Trop Anim Health Prod** 1997 Feb;29(1):31-2

Comparative efficacies of closantel, ivermectin, oxfendazole, thiophanate and levamisole against thiabendazole resistant Haemonchus contortus in sheep. Waruiru RM, et al. **Trop Anim Health Prod** 1996 Aug;28(3):216-20

The management of hydatid disease of the liver: Part 2. Fenton-Lee D, et al. **Trop Doct** 1997 Apr;27(2):87-8

Immunohistological studies on an Onchocerca volvulus ankyrin (EI). Erttmann KD, et al. **Trop Med Int Health** 1996 Oct;1(5):558-74

Anthelmintic efficacy of ivermectin against Syngamus trachea and Capillaria spp. in pheasant. Lamka J, et al. **Vet Med (Praha)** 1997 Jun;42(6):157-60

Efficacy of an in-feed formulation of ivermectin against adult worms and somatic larvae of Strongyloides ransomi. Barth D, et al. **Vet Parasitol** 1996 Oct 15;65(1-2):89-97

Anthelmintic resistance of trichostrongylids in sheep in the highveld of Zimbabwe. Boersema JH, et al. **Vet Parasitol** 1997 Mar;68(4):383-8

Anthelmintic resistant nematodes in goats in The Netherlands. Borgsteede FH, et al. **Vet Parasitol** 1996 Oct 15;65(1-2):83-7

A survey of dairy cattle worm control practices in southeast Brazil. Charles TP, et al. **Vet Parasitol** 1996 Oct 15; 65(1-2):65-73

Efficacy of an albendazole slow-release capsule for the control of susceptible or resistant nematode parasites of dairy goats. Chartier C, et al. **Vet Parasitol** 1996 Dec 31; 67(3-4):197-206

The effect of truncated infections with Ostertagia ostertagi on the development of acquired resistance in calves. Claerebout E, et al. **Vet Parasitol** 1996 Nov 15; 66(3-4):225-39

Faecal egg count reduction percentage calculations to detect anthelmintic resistance in Oesophagostomum spp. in pigs. Dangolla A, et al. **Vet Parasitol** 1997 Jan;68(1-2):127-42

Efficacy of moxidectin as a 1% injectable solution and a 0.1% oral drench against nasal bots, pulmonary and gastrointestinal nematodes in sheep. Dorchies P, et al. **Vet Parasitol** 1996 Oct 15;65(1-2):163-8

Anthelmintic resistance in India. Gill BS. **Vet Parasitol** 1996 May;63(1-2):173-6

Persistent efficacy of topical moxidectin against Dictyocaulus viviparus and Ostertagia ostertagi. Hubert J, et al. **Vet Parasitol** 1997 Jan;68(1-2):187-90

Use of two in vitro methods for the detection of benzimidazole resistance in equine small strongyles (Cyathostoma spp.). Ihler CF, et al. **Vet Parasitol** 1996 Oct 15;65(1-2):117-25

Efficacy of closantel against Fasciola hepatica in Korean native goats. Lee CG, et al. **Vet Parasitol** 1996 Oct 25; 65(3-4):307-11

Activity of doramectin against nematode and arthropod parasites of swine. Logan NB, et al. **Vet Parasitol** 1996 Nov 1;66(1-2):87-94

A questionnaire survey of nematode parasite control practices on goat farms in Denmark. Maingi N, et al. **Vet Parasitol** 1996 Nov 1;66(1-2):25-37

Worm control practices on sheep farms in Denmark and implications for the development of anthelmintic resistance. Maingi N, et al. **Vet Parasitol** 1996 Nov 1;66(1-2):39-52

Triclabendazole treatment in experimental goat fasciolosis: anthelmintic efficacy and influence in antibody response and pathophysiology of the disease. Martinez-Moreno A, et al. **Vet Parasitol** 1997 Jan;68(1-2):57-67

Efficacy of moxidectin 0.5% pour-on against naturally acquired nematode infections in cattle. Morin D, et al. **Vet Parasitol** 1996 Oct 15;65(1-2):75-81

Efficacies of different doses of ivermectin against male, female and L4 Oesophagostomum dentatum in pigs. Petersen MB, et al. **Vet Parasitol** 1996 Oct 15;65(1-2):55-63

Efficacy and pharmacokinetics of triclabendazole in buffalo with induced fasciolosis. Sanyal PK, et al. **Vet Parasitol** 1996 May;63(1-2):75-82

The effects of first-season strategic and tactical ivermectin treatments on trichostrongylosis in the first- and second-season grazing. Satrija F, et al. **Vet Parasitol** 1996 Sep 2;64(3):219-37

The development of protective immunity against gastrointestinal nematode and lungworm infections after use of an ivermectin bolus in first-year grazing calves. Schnieder T, et al. **Vet Parasitol** 1996 Sep 2;64(3):239-50

Doramectin efficacy against gastrointestinal nematodes in pigs. Stewart TB, et al. **Vet Parasitol** 1996 Nov 1; 66(1-2):101-8

Doramectin efficacy against the kidney worm, Stephanurus dentatus in sows. Stewart TB, et al. **Vet Parasitol** 1996 Nov 1;66(1-2):95-9

Comments on the paper 'World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) Second Edition of Guidelines for Evaluating the Efficacy of Anthelmintics in Ruminants (Bovine, Ovine, Caprine)' [letter; comment] van Wyk JA, et al. **Vet Parasitol** 1997 Jul 1;70(4):283-8. Comment on: Vet Parasitol 1995 Jun;58(3):181-213.

Sustainable helminth control of ruminants in developing countries. Waller PJ. **Vet Parasitol** 1997 Jul 31; 71(2-3):195-207 (33 ref.)

Efficacy of moxidectin pour-on against gastrointestinal nematodes and Dictyocaulus viviparus in cattle. Williams JC, et al. **Vet Parasitol** 1996 Sep 16;64(4):277-83

Effect of strategic gastrointestinal nematode control on growth of N'Dama cattle in Gambia. Zinsstag J, et al. **Vet Parasitol** 1997 Jan;68(1-2):143-53

Evaluation of the persistence of the effect of ivermectin and abamectin against gastrointestinal and pulmonary nematodes in cattle. Barth D, et al. **Vet Rec** 1997 Mar 15; 140(11):278-9

Management of anthelmintic resistance [letter] Coles GC. **Vet Rec** 1997 Jul 12;141(2):56

Hypobiosis in the ostertagids of red deer and the efficacy of ivermectin and fenbendazole against them. Connan RM. **Vet Rec** 1997 Feb 22;140(8):203-5

Occurrence of anthelmintic resistant nematodes on sheep farms in England and goat farms in England and Wales. Hong C, et al. **Vet Rec** 1996 Jul 27;139(4):83-6

Compatibility of the programmed use of doramectin with lungworm vaccination in calves. Jacobs DE, et al. **Vet Rec** 1996 Aug 24;139(8):191-2

Occurrence of resistance to anthelmintics in sheep in Paraná State, Brazil. Soccol VT, et al. **Vet Rec** 1996 Oct 26; 139(17):421-2

Efficacy of triclabendazole against Fasciola hepatica in the donkey (Equus asinus). Trawford AF, et al. **Vet Rec** 1996 Aug 10;139(6):142-3

Persistence of the efficacy of pour-on and injectable moxidectin against Ostertagia ostertagi and Dictyocaulus viviparus in experimentally infected cattle. Vercruysse J, et al. **Vet Rec** 1997 Jan 18;140(3):64-6

Control of gastrointestinal nematodes in calves by prophylactic treatments with doramectin and ivermectin. Vercruysse J, et al. **Vet Rec** 1996 Nov 30;139(22):547-8

Comparative therapeutic efficacy of doramectin and ivermectin against naturally acquired nematode infections in cattle. Yazwinski TA, et al. **Vet Rec** 1997 Mar 29; 140(13):343-4

Prospects for plant anthelmintics in tropical veterinary medicine. Hammond JA, et al. **Vet Res Commun** 1997 Apr; 21(3):213-28 (40 ref.)

The effects of a controlled-release albendazole capsule (Proftril-Captec) on parasitism in grazing Corriedale ewes in the Nyandarua district of Kenya [published erratum appears in Vet Res Commun 1997 Jul;21(5):324] Munyua WK, et al. **Vet Res Commun** 1997 Feb;21(2):85-99

The efficacy and pharmacokinetics of long-term low-level intraruminal administration of triclabendazole in buffalo with induced fasciolosis. Sanyal PK, et al. **Vet Res Commun** 1996;20(5):461-8

The efficacy of an albendazole-medicated block in controlling sheep nematodes in Xinjiang province, north-west China. Tan LX, et al. **Vet Res Commun** 1996; 20(5):427-35

The efficacy of doramectin on arrested larvae of Ancylostoma caninum in early pregnancy of bitches. Schnieder T, et al. **Zentralbl Veterinarmed [B]** 1996 Aug; 43(6):351-6

Investigations into the prevention of neonatal Toxocara canis infections in puppies by application of doramectin to the bitch. Schnieder T, et al. **Zentralbl Veterinarmed [B]** 1996 Mar;43(1):35-43

[Results of sequential prolonged courses of albendazole and praziquantel in recurrent neurocysticercosis (letter)] Alla P, et al. **Med Trop (Mars)** 1996;56(3):308 **(Fre)**

[Value of an antiparasitic treatment against Strongyloidea and Coccidia in Djallonke ewes at lambing] Hounzangbe-Adote MS, et al. **Rev Elev Med Vet Pays Trop** 1996;49(2):150-6 (Eng. Abstr.) **(Fre)**

[Spectrum of species and incidence of endoparasites in foals and their mother mares from breeding farms with and without anthelmintic prophylaxis in upper Bavaria] Beelitz P, et al. **Tierarztl Prax** 1996 Feb;24(1):48-54 (Eng. Abstr.) **(Ger)**

[The influence of treatment on the course of experimental Fasciola hepatica infection and weight gains in sheep] Ramisz G, et al. **Wiad Parazytol** 1997;43(1):69-77 (Eng. Abstr.) **(Pol)**

[Treatment of intra-abdominal hydatidosis with albendazole (letter)] Martinez G, et al. **Gastroenterol Hepatol** 1996 Dec; 19(10):542-3 **(Spa)**

TOXICITY

Endoparasite control strategies: implications for biodiversity of native fauna. Spratt DM. **Int J Parasitol** 1997 Feb; 27(2):173-80

P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Lankas GR, et al. **Toxicol Appl Pharmacol** 1997 Apr;143(2):357-65

Anthelmintic resistance of trichostrongylids in sheep in the highveld of Zimbabwe. Boersema JH, et al. **Vet Parasitol** 1997 Mar;68(4):383-8

[Intensity of liver tumor promotion effects in rats given repeated oral administrations of benzimidazole compounds] Onodera H, et al. **Eisei Shikenjo Hokoku** 1996;(114):21-6 (Eng. Abstr.) **(Jpn)**

ANTHOCYANINS

ADMINISTRATION & DOSAGE

The effect of condensed tannins in Lotus pedunculatus on the solubilization and degradation of ribulose-1,5-bisphosphate carboxylase (EC 4.1.1.39; Rubisco) protein in the rumen and the sites of Rubisco digestion. McNabb WC, et al. **Br J Nutr** 1996 Oct; 76(4):535-49

The effects of condensed tannins from Desmodium intortum and Calliandra calothyrsus on protein and carbohydrate digestion in sheep and goats. Perez-Maldonado RA, et al. **Br J Nutr** 1996 Oct;76(4):515-33

[Effect of anthocyanins on human connective tissue metabolism in the human] Boniface R, et al. **Klin Monatsbl Augenheilkd** 1996 Dec;209(6):368-72 (Eng. Abstr.) **(Ger)**

ANALYSIS

HPTLC and reflectance mode densitometry of anthocyanins in Malva silvestris L.: a comparison with gradient-elution reversed-phase HPLC. Farina A, et al. **J Pharm Biomed Anal** 1995 Dec;14(1-2):203-11

BIOSYNTHESIS

The an11 locus controlling flower pigmentation in petunia encodes a novel WD-repeat protein conserved in yeast, plants, and animals. de Vetten N, et al. **Genes Dev** 1997 Jun 1;11(11):1422-34

Evolution of anthocyanin biosynthesis in maize kernels: the role of regulatory and enzymatic loci. Hanson MA, et al. **Genetics** 1996 Jul;143(3):1395-407

Molecular and biochemical characterization of three anthocyanin synthetic enzymes from Gentiana triflora. Tanaka Y, et al. **Plant Cell Physiol** 1996 Jul;37(5):711-6

Functional analysis of yeast-derived phytochrome A and B phycocyanobilin adducts. Kunkel T, et al. **Plant J** 1996 Oct;10(4):625-36

Mutants of Arabidopsis thaliana with pleiotropic effects on the expression of the gene for beta-amylase and on the accumulation of anthocyanin that are inducible by sugars. Mita S, et al. **Plant J** 1997 Apr;11(4):841-51

Expression of anthocyanin biosynthesis pathway genes in red and white grapes. Boss PK, et al. **Plant Mol Biol** 1996 Nov;32(3):565-9

GENETICS

Evidence for direct activation of an anthocyanin promoter by the maize C1 protein and comparison of DNA binding by related Myb domain proteins. Sainz MB, et al. **Plant Cell** 1997 Apr;9(4):611-25

ISOLATION & PURIFICATION

Five new anthocyanins, ternatins A3, B4, B3, B2, and D2, from Clitoria ternatea flowers. Terahara N, et al. **J Nat Prod** 1996 Feb;59(2):139-44

METABOLISM

Digestion of 14C-labelled condensed tannins from Desmodium intortum in sheep and goats. Perez-Maldonado RA, et al. **Br J Nutr** 1996 Oct;76(4):501-13

PHARMACOLOGY

Inhibition of lipid peroxidation and the active oxygen radical scavenging effect of anthocyanin pigments isolated from Phaseolus vulgaris L. Tsuda T, et al. **Biochem Pharmacol** 1996 Oct 11;52(7):1033-9

Antioxidant action of Vaccinium myrtillus extract on human low density lipoproteins in vitro: initial observations. Laplaud PM, et al. **Fundam Clin Pharmacol** 1997; 11(1):35-40

Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract in vitro. Bagchi D, et al. **Res Commun Mol Pathol Pharmacol** 1997 Feb;95(2):179-89

THERAPEUTIC USE

Novel lipid-lowering properties of Vaccinium myrtillus L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate. Cignarella A, et al. **Thromb Res** 1996 Dec 1;84(5):311-22

ANTHRACENEDIONES see **ANTHRAQUINONES**

ANTHRACENES

Separation of carnitine enantiomers as the 9-anthroylnitrile

ANTHRACENES

derivatives and high-performance liquid chromatographic analysis on an ovomucoid-conjugated column. Takahashi M, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1579–84

CHEMISTRY

1,8-bis(hydroxymethyl)anthracene. Aumiller WD, et al. **Acta Crystallogr C** 1997 Jun 15;53 (Pt 6):769–71

Anthracene-9-carboxylic acid. Fitzgerald LJ, et al. **Acta Crystallogr C** 1997 Jan 15;53 (Pt 1):71–3

Anthracene-1-carboxylic acid. Fitzgerald LJ, et al. **Acta Crystallogr C** 1997 Aug 15;53 (Pt 8):1080–2

A diiodo-substituted 9-anthracenone. Thalji RK, et al. **Acta Crystallogr C** 1997 Aug 15;53 (Pt 8):1138–9

Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene. Longo A, et al. **J Chromatogr B Biomed Appl** 1996 Nov 15;686(2):129–39

Chelation-enhanced fluorescence chemosensing of Pb(II), an inherently quenching metal ion. Chae MY, et al. **J Mol Recognit** 1996 Jul-Aug;9(4):297–303

METABOLISM

Expression of lip genes during growth in soil and oxidation of anthracene by Phanerochaete chrysosporium. Bogan BW, et al. **Appl Environ Microbiol** 1996 Oct; 62(10):3697–703

Evidence for the role of 2-hydroxychromene-2-carboxylate isomerase in the degradation of anthracene by Sphingomonas yanoikuyae B1. Kim E, et al. **FEMS Microbiol Lett** 1997 Aug 15;153(2):479–84

PHARMACOKINETICS

Natural anthracenone subcellular distribution and effects on NADPH-cytochrome P450 reductase microsomal activity. Guerrero-Olazarán M, et al. **Drug Chem Toxicol** 1996 Nov; 19(4):301–12

PHARMACOLOGY

A purgative action of barbaloin is induced by Eubacterium sp. strain BAR, a human intestinal anaerobe, capable of transforming barbaloin to aloe-emodin anthrone. Akao T, et al. **Biol Pharm Bull** 1996 Jan;19(1):136–8

Phosphatase-mediated enhancement of cardiac cAMP-activated Cl-conductance by a Cl- channel blocker, anthracene-9-carboxylate. Zhou SS, et al. **Circ Res** 1997 Aug;81(2):219–28

Effects of aloin and some structure-related anthracene, anthracenone, and anthraquinone derivatives on lipid peroxidation in rat brain cortex homogenates. Scheibler P. **Pharmazie** 1997 May;52(5):411–2

TOXICITY

Genotoxic effects of Karwinskia humboldtiana toxin T-514 in peripheral blood lymphocytes. Velazco MR, et al. **Anticancer Drugs** 1996 Aug;7(6):710–5

The effects of anthracene and methylated anthracenes on gap junctional intercellular communication in rat liver epithelial cells. Upham BL, et al. **Fundam Appl Toxicol** 1996 Dec;34(2):260–4

Experimental evidence for toxic damage induced by a dimeric anthracenone: diast T-514 (peroxisomicine A2). Martínez FJ, et al. **Toxicol Lett** 1997 Feb 7;90(2-3):155–62

Studies on the effect of peroxisomicine on catalase activity in albino mice. Moreno-Sepúlveda M, et al. **Toxicon** 1997 May;35(5):777–83

ANTHRACOSILICOSIS

DIAGNOSIS

[Information on the new 4111 occupational disease: "chronic obstructive bronchitis or emphysema in miners of bituminous coal mines with evidence of the exposure to a cumulative fine dust dose around 100 ([mg/m3] x years)] Nowak D. **Pneumologie** 1996 Sep;50(9):652–4 **(Ger)**

PATHOLOGY

Pulmonary endocrine cells in anthracosilicotic lungs. Gosney JR, et al. **Eur Respir J** 1997 Feb;10(2):388–91

ANTHRACYCLINE ANTIBIOTICS see **ANTIBIOTICS, ANTHRACYCLINE**

ANTHRACYCLINES

ADMINISTRATION & DOSAGE

Liposomal drug delivery. Ranson M, et al. **Cancer Treat Rev** 1996 Sep;22(5):365–79 (137 ref.)

Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Greenberg RE, et al. **Urology** 1997 Mar;49(3):471–5

ADVERSE EFFECTS

Anthracycline-induced cardiotoxicity [letter; comment] Klein HO. **Ann Intern Med** 1997 May 15;126(10):827; discussion 827–8. Comment on: Ann Intern Med 1996 Jul 1;125(1):47–58.

Anthracycline-induced cardiotoxicity [letter; comment] Steinherz LJ. **Ann Intern Med** 1997 May 15;126(10):827; discussion 827–8. Comment on: Ann Intern Med 1996 Jul 1;125(1):47–58.

Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients. Kakadekar AP, et al. **Med Pediatr Oncol** 1997 Jan;28(1):22–6

ICRF-187 as a cardioprotectant in children treated with anthracyclines [editorial; comment] Blatt J. **Pediatr Hematol Oncol** 1997 May-Jun;14(3):iii-vi (13 ref.) . Comment on: Pediatr Hematol Oncol 1997 May-Jun;14(3):213–22.

Safety of dexrazoxane in children with all undergoing anthracycline therapy: preliminary results of a prospective pilot study [letter] Schuler D, et al. **Pediatr Hematol Oncol** 1997 Jan-Feb;14(1):93–4

CHEMISTRY

Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Lampidis TJ, et al. **Biochemistry** 1997 Mar 4;36(9):2679–85

Liquid-crystalline structure of nucleic acids: effect of antracycline drugs and copper ions. Yevdokimov YM, et al. **J Biomol Struct Dyn** 1997 Aug;15(1):97–105

Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation. Animati F, et al. **Mol Pharmacol** 1996 Sep; 50(3):603–9

PHARMACOKINETICS

Flow cytometric study of the epirubicine accumulation modulation in the human erythrocytes by a Nocardia opaca fraction. Dumitrescu M, et al. **Roum Arch Microbiol Immunol** 1995 Jan-Jun;54(1-2):43–51

PHARMACOLOGY

Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Heijn M, et al. **Biochim Biophys Acta** 1997 May 22;1326(1):12–22

Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Morceau F, et al. **Cell Growth Differ** 1996 Aug;7(8):1023–9

Anthracyclines enhance tension development in cardiac muscle by direct interaction with the contractile system. Bottone AE, et al. **J Mol Cell Cardiol** 1997 Mar; 29(3):1001–8

Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. De Wolf D, et al. **Pediatr Res** 1996 Mar;39(3):504–12

POISONING

Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. Link G, et al. **J Lab Clin Med** 1996 Mar;127(3):272–8

THERAPEUTIC USE

Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study. Michelotti A, et al. **Ann Oncol** 1996 Oct;7(8):857–60

Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. Gabizon A, et al. **J Drug Target** 1996;3(5):391–8

Screening for multidrug resistance in leukemia: cell reactivity to MRK-16 correlates with anthracycline retention and sensitivity of leukemic cells. Michieli M, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):99–105

Anthracycline resistance: the problem and its current definition. Gianni L. **Semin Oncol** 1997 Aug;24(4 Suppl 10):S10-11–S10-17 (36 ref.)

Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer. Ravdin PM. **Semin Oncol** 1997 Aug;24(4 Suppl 10):S10-18–S10-21 (26 ref.)

TOXICITY

Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation. Animati F, et al. **Mol Pharmacol** 1996 Sep; 50(3):603–9

ANTHRALIN

ADMINISTRATION & DOSAGE

A novel dithranol formulation (Micanol): the effects of monotherapy and UVB combination therapy on epidermal differentiation, proliferation and cutaneous inflammation in psoriasis vulgaris. Van der Vleuten CJ, et al. **Acta Derm Venereol** 1996 Sep;76(5):387–91

ANALOGS & DERIVATIVES

Reduction of nitroxides by anthralin and some of its derivatives. Pečar S, et al. **Free Radic Biol Med** 1995 Mar; 18(3):459–65

ANALYSIS

Direct determination of drug content in semisolid formulations using step-scan FT-IR photoacoustic spectroscopy. Neubert R, et al. **Pharm Res** 1997 Jul; 14(7):946–8

METABOLISM

Reduction of nitroxides by anthralin and some of its derivatives. Pečar S, et al. **Free Radic Biol Med** 1995 Mar; 18(3):459–65

PHARMACOLOGY

Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. Mrowietz U, et al. **Br J Dermatol** 1997 Apr;136(4):542–7

THERAPEUTIC USE

The effect of fumaric acid esters and dithranol on acanthosis and hyperproliferation in psoriasis vulgaris. Bacharach-Buhles M, et al. **Acta Derm Venereol** 1996 May; 76(3):190–3

Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals. Müller K. **Biochem Pharmacol** 1997 May 9;53(9):1215–21 (69 ref.)

Epidermal differentiation characteristics of the psoriatic plaque during short contact treatment with dithranol cream. van der Vleuten CJ, et al. **Clin Exp Dermatol** 1996 Nov;21(6):409–14

ANTHRANILATE PHOSPHORIBOSYLTRANSFERASE

BIOSYNTHESIS

Introns act post-transcriptionally to increase expression of the Arabidopsis thaliana tryptophan pathway gene PAT1. Rose AB, et al. **Plant J** 1997 Mar;11(3):455–64

GENETICS

An allelic series of blue fluorescent trp1 mutants of Arabidopsis thaliana. Rose AB, et al. **Genetics** 1997 Jan; 145(1):197–205

Introns act post-transcriptionally to increase expression of the Arabidopsis thaliana tryptophan pathway gene PAT1. Rose AB, et al. **Plant J** 1997 Mar;11(3):455–64

ANTHRANILATE SYNTHASE

BIOSYNTHESIS

Expression of Sulfolobus solfataricus trpE and trpG genes in E. coli. Tutino ML, et al. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):306–10

ANTHRANILATE SYNTHETASE see **ANTHRANILATE SYNTHASE**

ANTHRANILIC ACIDS

ADMINISTRATION & DOSAGE

Successful treatment of pemphigus vulgaris with prednisolone and tranilast [letter] Miyamoto H, et al. **Acta Derm Venereol** 1997 Jan;77(1):87–8

Treatment of keloid and hypertrophic scars by iontophoretic transdermal delivery of tranilast. Shigeki S, et al. **Scand J Plast Reconstr Surg Hand Surg** 1997 Jun; 31(2):151–8

CHEMICAL SYNTHESIS

Synthesis and spectral characterization of sulfhydryl-reactive fluorescent probes. Pouchnik DJ, et al. **Anal Biochem** 1996 Mar 1;235(1):26–35

Synthesis, local anaesthetic and antiarrhythmic activity of methyl N-(2-substituted aminopropanoyl)-3-cyanoanthranilates. al-Obaid AR. **Boll Chim Farm** 1996 Jul-Aug;135(7):415–20

Synthesis of a fluorescent 7-methylguanosine analog and a fluorescence spectroscopic study of its reaction with wheatgerm cap binding proteins. Ren J, et al. **Nucleic Acids Res** 1996 Sep 15;24(18):3629–34

CHEMISTRY

C-terminal incorporation of fluorogenic and affinity labels using wild-type and mutagenized carboxypeptidase Y. Stennicke HR, et al. **Anal Biochem** 1997 May 15; 248(1):141–8

A QSAR study of anti-inflammatory N-arylanthranilic acids. Duffy JC, et al. **J Pharm Pharmacol** 1996 Sep;48(9):883–6

METABOLISM

Purification and 1H NMR spectroscopic characterization of phase II metabolites of tolfenamic acid. Sidelmann UG, et al. **Drug Metab Dispos** 1997 Jun;25(6):725–31

Phosphoribosyl anthranilate isomerase from Thermotoga maritima is an extremely stable and active homodimer. Sterner R, et al. **Protein Sci** 1996 Oct;5(10):2000–8

PHARMACOKINETICS

The effect of experimental renal failure on tolfenamic acid disposition in the dog. Lefebvre HP, et al. **Biopharm Drug Dispos** 1997 Jan;18(1):79–91

Pharmacokinetics of tolfenamic acid in the horse. Jaussaud P, et al. **Equine Vet J Suppl** 1992 Feb;(11):69–72

Pharmacokinetics of tolfenamic acid in pediatric patients after single oral dose. Niopas I, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct–Dec; 20(4):293–6

Tolfenamic acid in the control of ocular inflammation in the dog: pharmacokinetics and clinical results obtained in an experimental model. Roze M, et al. **J Small Anim Pract** 1996 Aug;37(8):371–5

Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. Landoni MF, et al. **Res Vet Sci** 1996 Jul; 61(1):26–32

PHARMACOLOGY

Tranilast (N–(3,4–dimethoxycinnamoyl) anthranilic acid) down–regulates the growth of scirrhous gastric cancer. Yashiro M, et al. **Anticancer Res** 1997 Mar–Apr; 17(2A):895–900

Tranilast inhibits contraction and Ca2+ movement of porcine coronary arteries. Ishibashi S, et al. **Atherosclerosis** 1997 Apr;130(1–2):113–9

Tranilast antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells. Miyazawa K, et al. **Atherosclerosis** 1996 Apr 5;121(2):167–73

Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. Ikeda H, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):322–7

Suppressive effects of tranilast on the expression of inducible cyclooxygenase (COX2) in interleukin–1beta–stimulated fibroblasts. Inoue H, et al. **Biochem Pharmacol** 1997 Jun 15;53(12):1941–4

Inhibition of glucose–induced insulin secretion by the diacylglycerol lipase inhibitor RHC 80267 and the phospholipase A2 inhibitor ACA through stimulation of K+ permeability without diminution by exogenous arachidonic acid. Thams P, et al. **Biochem Pharmacol** 1997 Apr 25;53(8):1077–86

Inhibition by fenamates of calcium influx and proliferation of human lymphocytes. Kankaanranta H, et al. **Br J Pharmacol** 1996 Oct;119(3):487–94

Antiproliferative and c–myc mRNA suppressive effect of tranilast on newborn human vascular smooth muscle cells in culture. Miyazawa K, et al. **Br J Pharmacol** 1996 Jun; 118(4):915–22

Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells. Fukuyama J, et al. **Can J Physiol Pharmacol** 1996 Jan; 74(1):80–4

Effects of flunixin, tolfenamic acid, R(–) and S(+) ketoprofen on the response of equine synoviocytes to lipopolysaccharide stimulation. Landoni MF, et al. **Equine Vet J** 1996 Nov;28(6):468–75

Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high–cholesterol diet. Fukuyama J, et al. **Eur J Pharmacol** 1996 Dec 30; 318(2–3):327–32

Tranilast inhibits contraction of rat aortic smooth muscle. Ihara T, et al. **Eur J Pharmacol** 1997 Jun 18;329(1):43–8

Tranilast inhibits the growth of rat mesangial cells. Ikeda M, et al. **Eur J Pharmacol** 1997 Apr 18;324(2–3):283–7

Tranilast restores cytokine–induced nitric oxide production against platelet–derived growth factor in vascular smooth muscle cells. Hishikawa K, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):200–7

Current views on the pharmacological properties of the immunomodulator, lobenzarit disodium. González R, et al. **J Investig Allergol Clin Immunol** 1997 Mar–Apr;7(2):77–82 (49 ref.)

Effect of topical tranilast and corticosteroids on subepithelial haze after photorefractive keratectomy in rabbits. Furukawa H, et al. **J Refract Surg** 1997 Aug;13(5 Suppl):S457–8

Fenamates potentiate the alpha 1–adrenoceptor–activated nonselective cation channels in rabbit portal vein smooth muscle. Yamada K, et al. **Jpn J Pharmacol** 1996 Jan; 70(1):81–4

Effects of chloride channel blockers on hypoxic injury in rat proximal tubules. Reeves WB. **Kidney Int** 1997 May; 51(5):1529–34

Blockade of DNA synthesis induced by platelet–derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells. Nie L, et al. **Mol Pharmacol** 1996 Oct;50(4):763–9

Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. Landoni MF, et al. **Res Vet Sci** 1996 Jul; 61(1):26–32

THERAPEUTIC USE

A case of atypical localized scleroderma presenting with pseudoainhum: treatment with tranilast, an anti–fibrotic agent [letter] Tajima S, et al. **Acta Derm Venereol** 1996 Mar;76(2):162

Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti–inflammatory drugs. Giuseppe P, et al. **Ann Allergy Asthma Immunol** 1997 Jan; 78(1):74–8

Use of tolfenamic acid in febrile children with and without glucose–6–phosphate dehydrogenase deficiency. Haliotis FA, et al. **Int J Clin Pharmacol Ther** 1997 Mar;35(3):103–6

Factors affecting hypertrophic scar development in median sternotomy incisions for congenital cardiac surgery. Nakamura K, et al. **J Am Coll Surg** 1997 Sep;185(3):218–23

Effects of pemirolast and tranilast on intimal thickening after arterial injury in the rat. Miyazawa N, et al. **J Cardiovasc Pharmacol** 1997 Aug;30(2):157–62

Tolfenamic acid in the control of ocular inflammation in the dog: pharmacokinetics and clinical results obtained in an experimental model. Roze M, et al. **J Small Anim Pract** 1996 Aug;37(8):371–5

Floctafenin versus acetaminophen for pain control in patients with osteoarthritis in the lower limbs. Franco–Belgian Task Force. Lequesne M, et al. **Rev Rhum Engl Ed** 1997 May; 64(5):327–33

[Inhibitor of chemical mediator release] Fujimura M. **Nippon Rinsho** 1996 Nov;54(11):3029–33 (8 ref.) (Eng. Abstr.) **(Jpn)**

[A case of colonic Crohn's disease possibly managed with tranilast] Kikuchi T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Mar;94(3):195–9 **(Jpn)**

TOXICITY

Cinnamyl anthranilate causes coinduction of hepatic microsomal and peroxisomal enzymes in mouse but not rat. Viswalingam A, et al. **Toxicol Appl Pharmacol** 1997 Feb; 142(2):338–47

ANTHRAQUINONES

Incorporation of two anthraquinonylmethyl groups into the 2'–O–positions of oligonucleotides: increased affinity and sequence specificity of anthraquinone–modified oligonucleotides in hybrid formation with DNA and RNA. Yamana K, et al. **Bioconjug Chem** 1996 Nov–Dec; 7(6):715–20

The use of poly R–478 as a marker to determine gastric emptying and intestinal propulsive motility in suckling rats. Shinohara H, et al. **Physiol Res** 1995;44(5):281–6

[A study on the viability of corneal endothelium in rabbit by dual staining with trypan blue and alizanin red S] Liu H, et al. **Yen Ko Hsueh Pao** 1995 Jun;11(2):65–6, 69 (Eng. Abstr.) **(Chi)**

[Preparing for colonoscopy: a reliable and easily implemented regimen (letter)] Albrecbt U. **Z Gastroenterol** 1997 Apr; 35(4):XXXII–XXXIV **(Ger)**

[Protein kinase inhibitors—screening of new molecular target therapeutics] Uehara Y. **Gan To Kagaku Ryoho** 1997 Jan; 24(2):136–44 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

[Preparation for colonoscopy: a reliable and easily implemented regimen] Krakamp B, et al. **Z Gastroenterol** 1996 Oct;34(10):686–91 (Eng. Abstr.) **(Ger)**

[Use of sennosides A + B in the preparation of the colon for endoscopy (letter)] Nisa ME, et al. **Rev Esp Enferm Dig** 1996 Apr;88(4):303–4 **(Spa)**

ADVERSE EFFECTS

The pigment of melanosis coli: a lectin histochemical study. Benavides SH, et al. **Gastrointest Endosc** 1997 Aug; 46(2):131–8

ANALYSIS

Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high–performance liquid chromatography. Cummings J, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):159–64

CHEMICAL SYNTHESIS

Synthesis, DNA–binding and cytotoxic properties of a bis(netropsin)–anthracenedione conjugate. Boitte N, et al. **Anticancer Drug Des** 1997 Sep;12(6):481–501

Inhibition of human telomerase by a G–quadruplex–interactive compound. Sun D, et al. **J Med Chem** 1997 Jul 4;40(14):2113–6

CHEMISTRY

Molecular modeling of singlet–oxygen binding to anthraquinones in relation to the peroxidating activity of antitumor anthraquinone drugs. Liwo A, et al. **Acta Biochim Pol** 1995;42(4):445–56 (47 ref.)

DNA minor groove cleaving agents: synthesis, binding and strand cleaving properties of anthraquinone–oligopyrrolecarboxamide hybrids. Helissey P, et al. **Anticancer Drug Des** 1996 Oct;11(7):527–51

Molecular modeling of the interaction of anthracenyl–amino acid topoisomerase inhibitors with the DNA sequence d(CGTACG). Cummings J, et al. **Anticancer Drugs** 1996 Aug;7(6):636–41

Selective stabilization of triplex DNA by anthraquinone sulfonamide derivatives. Kan Y, et al. **Biochemistry** 1997 Feb 11;36(6):1461–6

Salen–anthraquinone conjugates. Synthesis, DNA–binding and cleaving properties, effects on topoisomerases and cytotoxicity. Routier S, et al. **Bioorg Med Chem** 1996 Aug; 4(8):1185–96

Inhibitory effects on Epstein–Barr virus activation of anthraquinones: correlation with redox potentials. Koyama J, et al. **Cancer Lett** 1997 May 19;115(2):179–83

Construction of a dimeric DNA–binding peptide model by peptide–anthraquinone conjugation. Takenaka S, et al. **Int J Pept Protein Res** 1996 Oct;48(4):397–400

A novel neuronal cell protecting substance, espicufolin, produced by Streptomyces sp. cu39 [letter] Kim JS, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):947–8

Interaction of oligonucleotides containing anthraquinone at the 2'–sugar position with complementary nucleic acids. Mitsui T, et al. **Nucleic Acids Symp Ser** 1995;(34):35–6

ISOLATION & PURIFICATION

SNA–8073–B, a new isotetracenone antibiotic inhibits prolyl endopeptidase. I. Fermentation, isolation and biological properties. Kimura K, et al. **J Antibiot (Tokyo)** 1997 Apr; 50(4):291–6

METABOLISM

avnA, a gene encoding a cytochrome P–450 monooxygenase, is involved in the conversion of averantin to averufin in aflatoxin biosynthesis in Aspergillus parasiticus. Yu J, et al. **Appl Environ Microbiol** 1997 Apr;63(4):1349–56

Structural modification changes the DNA binding mode of cation–substituted anthraquinone photonucleases: association by intercalation or minor groove binding determines the DNA cleavage efficiency. Breslin DT, et al. **Biochemistry** 1997 Aug 26;36(34):10463–73

A sennoside–hydrolyzing beta–glucosidase from Bifidobacterium sp. strain SEN is inducible. Yang L, et al. **Biol Pharm Bull** 1996 May;19(5):701–4

Purification and characterization of a novel sennoside–hydrolyzing beta–glucosidase from Bifidobacterium sp. strain SEN, a human intestinal anaerobe. Yang L, et al. **Biol Pharm Bull** 1996 May; 19(5):705–9

A pathway for biodegradation of an anthraquinone dye, C.I. disperse red 15, by a yeast strain Pichia anomala. Itoh K, et al. **Bull Environ Contam Toxicol** 1996 Mar;56(3):413–8

Purification and characterization of the esterases involved in aflatoxin biosynthesis in Aspergillus parasiticus. Kusumoto K, et al. **Can J Microbiol** 1996 Aug;42(8):804–10

Elucidation of phase I and phase II metabolic pathways of rhein: species differences and their potential relevance. Dahms M, et al. **Drug Metab Dispos** 1997 Apr;25(4):442–52

A novel neuronal cell protecting substance, espicufolin, produced by Streptomyces sp. cu39 [letter] Kim JS, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):947–8

Minimal Streptomyces sp. strain C5 daunorubicin polyketide biosynthesis genes required for aklanonic acid biosynthesis. Rajgarhia VB, et al. **J Bacteriol** 1997 Apr;179(8):2690–6

Aza–bioisosteres of 9, 10–anthracenedione: a modulation of DNA sequence specificity. Sissi C, et al. **Mol Pharmacol** 1996 Oct;50(4):838–45

Site–specific and photo–induced alkylation of DNA by a dimethylanthraquinone–oligodeoxynucleotide conjugate. Kang H, et al. **Nucleic Acids Res** 1996 Oct 15; 24(20):3896–902

Cytotoxicity and DNA–binding property of non–diynene class of dynemicins and aza–anthraquinones. Shirai R, et al. **Nucleic Acids Symp Ser** 1995;(34):151–2

PHARMACOLOGY

Potentiation of the antimalarial agent rufigallol. Winter RW, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1408–11

Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3–diaza–anthracenediones. de Isabella P, et al. **Biochem Pharmacol** 1997 Jan 24; 53(2):161–9

Impairment of phosphatidylinositol signaling in acetylshikonin–treated neutrophils. Wang JP, et al. **Biochem Pharmacol** 1997 Apr 25;53(8):1173–7

Inhibitory effect of acetylshikonin on the activation of NADPH oxidase in polymorphonuclear leukocytes in both whole cell and cell–free systems. Kawakami N, et al. **Biol Pharm Bull** 1996 Oct;19(10):1266–70

Investigation of the inhibition by acetylshikonin of the respiratory burst in rat neutrophils. Wang JP, et al. **Br J Pharmacol** 1997 Jun;121(3):409–16

Effect of a cytotoxic analog of LH–RH (T–98) on the growth of estrogen–dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors. Szepeshazi K, et al. **Breast Cancer Res Treat** 1996;40(2):129–39

Inhibitory effects on Epstein–Barr virus activation of anthraquinones: correlation with redox potentials. Koyama J, et al. **Cancer Lett** 1997 May 19;115(2):179–83

Enhancement of cell proliferation and prostaglandin biosynthesis by 1,8–dihydroxyanthraquinone in the rat large intestine. Nishikawa A, et al. **Carcinogenesis** 1997 Jun; 18(6):1259–63

Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N–oxides in intact human cells using 647–nm krypton laser excitation. Smith PJ, et al. **Cytometry** 1997 Jan 1;27(1):43–53

Cell cycle effects of the novel topoisomerase I inhibitor NU/ICRF 505 in a panel of Chinese hamster ovary cell

ANTHRAQUINONES

lines. Macpherson JS, et al. **Eur J Cancer** 1997 Feb; 33(2):280–3

In vitro inhibition of microbial methane production by 9,10–anthraquinone. Garcia–Lopez PM, et al. **J Anim Sci** 1996 Sep;74(9):2276–84

The synergistic purgative action of aloe–emodin anthrone and rhein anthrone in mice: synergism in large intestinal propulsion and water secretion. Yagi T, et al. **J Pharm Pharmacol** 1997 Jan;49(1):22–5

Aza–bioisosteres of 9, 10–anthracenedione: a modulation of DNA sequence specificity. Sissi C, et al. **Mol Pharmacol** 1996 Oct;50(4):838–45

Site–specific hydrolysis of yeast tRNAPhe by anthraquinone–glycine and anthraquinone–iminodiacetate conjugates. Endo M, et al. **Nucleic Acids Symp Ser** 1995; (34):109–10

Cytotoxicity and DNA–binding property of non–diynene class of dynemicins and aza–anthraquinones. Shirai R, et al. **Nucleic Acids Symp Ser** 1995;(34):151–2

Effects of aloin and some structure–related anthracene, anthracenone, and anthraquinone derivatives on lipid peroxidation in rat brain cortex homogenates. Scheibler P. **Pharmazie** 1997 May;52(5):411–2

In vitro antimutagenic effects of anthraquinone aglycones and naphthopyrone glycosides from Cassia tora. Choi JS, et al. **Planta Med** 1997 Feb;63(1):11–4

STANDARDS

[Sennosides Reference Standard (Control 951) of the National Institute of Health Sciences] Okada S, et al. **Eisei Shikenjo Hokoku** 1996;(114):106–12 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Phase II trial of piroxantrone in advanced squamous cell carcinoma of the cervix: a Gynecological Oncology Group study. Lincoln S, et al. **Am J Clin Oncol** 1997 Feb; 20(1):84–5

A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group study 8918. Malviya VK, et al. **Anticancer Drugs** 1996 Jul;7(5):527–30

Diacerein. Spencer CM, et al. **Drugs** 1997 Jan;53(1):98–106; discussion 107–8 (45 ref.)

Correction of outflow obstruction with the use of sennosides in CAPD patients [letter] Garcia Ramon R, et al. **Perit Dial Int** 1996 Nov–Dec;16(6):642–3

TOXICITY

Lysosomal storage of sulfated glycosaminoglycans induced by two bis–aminomethyl anthrachinones. Fischer J, et al. **Arch Toxicol** 1996;70(6):373–9

DNA topoisomerase II–dependent cytotoxicity of alkylaminoanthraquinones and their N–oxides. Smith PJ, et al. **Cancer Chemother Pharmacol** 1997;39(5):455–61

Biomarkers of effect in evaluating dithianon cocarcinogenesis: selective induction and suppression of murine CYP3A isoform. Paolini M, et al. **Cancer Lett** 1997 Feb 26;113(1–2):221–8

The hepatotoxicity of rhein involves impairment of mitochondrial functions. Bironaite D, et al. **Chem Biol Interact** 1997 Jan 24;103(1):35–50

Genotoxicity of the laxative drug components emodin, aloe–emodin and danthron in mammalian cells: topoisomerase II mediated? Müller SO, et al. **Mutat Res** 1996 Dec 20;371(3–4):165–73

Acute and subacute toxicity tests of madder root, natural colorant extracted from madder (Rubia tinctorum), in (C57BL/6 X C3H)F1 mice. Ino N, et al. **Toxicol Ind Health** 1995 Jul–Aug;11(4):449–58

URINE

Chromatographic identification of phenolic compounds in human urine following oral administration of the herbal medicines Daisaiko–to and Shosaiko–to. Li C, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):191–8

ANTHRAX

A case of human anthrax in Victoria. Lester R, et al. **Commun Dis Intell** 1997 Feb 20;21(4):47–8

Anthrax toxin–mediated delivery of a cytotoxic T–cell epitope in vivo. Ballard JD, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12531–4

Anthrax pneumonia. Penn CC, et al. **Semin Respir Infect** 1997 Mar;12(1):28–30

COMPLICATIONS

Acute abdomen due to anthrax. Tekin A, et al. **Br J Surg** 1997 Jun;84(6):813

DIAGNOSIS

Evaluation of the anthraxin skin test for diagnosis of acute and past human anthrax. Shlyakhov E, et al. **Eur J Clin Microbiol Infect Dis** 1996 Mar;15(3):242–5

Isolation of a specific chromosomic DNA sequence of Bacillus anthracis and its possible use in diagnosis. Patra G, et al. **FEMS Immunol Med Microbiol** 1996 Oct; 15(4):223–31

[Necrotic chin lesion in a patient with a meningeal syndrome] González A, et al. **Enferm Infecc Microbiol Clin** 1997 Mar; 15(3):163–4 **(Spa)**

ECONOMICS

The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Kaufmann AF, et al. **Emerg Infect Dis** 1997 Apr–Jun;3(2):83–94 (22 ref.)

ETIOLOGY

Factors associated with human anthrax outbreak in the Chikupo and Ngandu villages of Murewa district in Mashonaland East Province, Zimbabwe. Mwenye KS, et al. **Cent Afr J Med** 1996 Nov;42(11):312–5

HISTORY

[Anthracosis in members of the aristocracy and mummies in Hungary (letter; comment)] Petrányi G. **Orv Hetil** 1997 Mar 30;138(13):826. Comment on: Orv Hetil 1996 Jul 14;137(28):1542–3. **(Hun)**

IMMUNOLOGY

Protective immunity induced by Bacillus anthracis toxin mutant strains. Pezard C, et al. **Adv Exp Med Biol** 1996; 397:69–72 (13 ref.)

[Molecular mechanisms underlying bacillus anthracis infection at early stages and search for novel vaccines] Stepanov AV, et al. **Vestn Ross Akad Med Nauk** 1997; (6):16–20 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Extraordinary case report: cutaneous anthrax. Mallon E, et al. **Am J Dermatopathol** 1997 Feb;19(1):79–82

PREVENTION & CONTROL

Protective immunity induced by Bacillus anthracis toxin mutant strains. Pezard C, et al. **Adv Exp Med Biol** 1996; 397:69–72 (13 ref.)

Anthrax: memorandum from a WHO meeting. **Bull World Health Organ** 1996;74(5):465–70

Preparation for emergency relief after biological warfare. Steffen R, et al. **J Infect** 1997 Mar;34(2):127–32

RADIOGRAPHY

Anthrax meningoencephalitis: radiologic findings [letter] Domínguez E, et al. **AJR Am J Roentgenol** 1997 Jul; 169(1):317

VETERINARY

Drainage a factor in anthrax outbreak [news] **Aust Vet J** 1997 May;75(5):319

Anthrax in cattle in southern Western Australia. Forshaw D, et al. **Aust Vet J** 1996 Nov;74(5):391–3

Anthrax in northern Alberta [news] Coupland R, et al. **Can Vet J** 1996 Dec;37(12):748

Bovine anthrax in eastern Ontario [news] Lusis P, et al. **Can Vet J** 1996 Dec;37(12):747

Anthraxin skin testing: an alternative method for anthrax vaccine and post–vaccinal immunity assessment. Shlyakhov E, et al. **Zentralbl Veterinarmed [B]** 1996 Oct;43(8):483–8

ANTHROPOIDEA see **HAPLORHINI**

ANTHROPOLOGY

see related

HOMINIDAE

66th Annual meeting of the American Association of Physical Anthropologists (AAPA). St. Louis, Missouri, April 1–5, 1997. Abstracts. **Am J Phys Anthropol** 1997;Suppl 24:1–249

Scientometric analysis of anthropology in the Republic of Croatia for the period of 1980–1996. Bencetic Klaić Z, et al. **Coll Antropol** 1997 Jun;21(1):301–18

Obituary: Arthur Mourant (1904–1994). Roberts DF. **Hum Biol** 1997 Apr;69(2):277–9

Amplification of human short tandem repeats from medieval teeth and bone samples. Zierdt H, et al. **Hum Biol** 1996 Apr;68(2):185–99

Anthropology, nursing and midwifery: a natural alliance? Mulhall A. **Int J Nurs Stud** 1996 Dec;33(6):629–37

Chronological changes in stone tool assemblages from Krapina (Croatia). Simek JF, et al. **J Hum Evol** 1997 Jun; 32(6):561–75

Bringing political ecology into critical medical anthropology: a challenge to biocultural approaches. Baer HA. **Med Anthropol** 1996 Dec;17(2):129–41 (59 ref.)

Toward a political ecology of health in medical anthropology [comment] Baer HA. **Med Anthropol Q** 1996 Dec; 10(4):451–4 (15 ref.). Comment on: Med Anthropol Q 1996 Dec;10(4):455–75. Comment on: Med Anthropol Q 1996 Dec;10(4):476–95. Comment on: Med Anthropol Q 1996 Dec;10(4):496–515.

Introduction to symposium: on–going studies in critical medical anthropology. Baer HA. **Soc Sci Med** 1997 May; 44(10):1563

The misconstruction of critical medical anthropology: a response to a cultural constructivist critique. Baer HA. **Soc Sci Med** 1997 May;44(10):1565–73

HISTORY

In memoriam: Mary Douglas Leakey (1913–1996). Tobias PV. **Am J Phys Anthropol** 1997 May;103(1):1–5

Frederic Wood Jones: his major books and how they were reviewed. Christophers BE. **Aust N Z J Surg** 1997 Sep; 67(9):645–59

Identity, ideology and inequality: methodologies in medical anthropology, Guatemala 1950–1995. Barrett B. **Soc Sci Med** 1997 Mar;44(5):579–87

METHODS

The human genome project and molecular anthropology. Stoneking M. **Genome Res** 1997 Feb;7(2):87–91 (36 ref.)

An anthropological perspective on optimizing calcium consumption for the prevention of osteoporosis. Nelson DA. **Osteoporos Int** 1996;6(4):325–8 (47 ref.)

Schistosomiasis in two Nile delta villages: an anthropological perspective. el Katsha S, et al. **Trop Med Int Health** 1997 Sep;2(9):846–54

TRENDS

[Prospects in prehistoric anthropology?] Herrmann B. **Anthropol Anz** 1997 Jun;55(2):97–100 (Eng. Abstr.) **(Ger)**

ANTHROPOLOGY, CULTURAL

see related

ETHNOPSYCHOLOGY

Expanding the biocultural synthesis toward a biology of poverty. Leatherman TL, et al. **Am J Phys Anthropol** 1997 Jan;102(1):1–3

Awarding of the Herder Award to Dunja Rihtman–Auguštin. Muraj A. **Coll Antropol** 1997 Jun;21(1):335–7

An universal model of health and work output: theoretical structure and testing strategy. Steegmann AT Jr, et al. **Coll Antropol** 1997 Jun;21(1):47–65

Alcoholism, a contagious disease. A contribution towards an anthropological definition of contagion. Fainzang S. **Cult Med Psychiatry** 1996 Dec;20(4):473–87

Mapping and/or discovering meaning in family therapy: an e–mail conversation [comment] Beels CC, et al. **Fam Process** 1997 Jun;36(2):127–32. Comment on: Fam Process 1997 Jun;36(2):101–26.

Reinventing the tale [letter] Coope C. **Hastings Cent Rep** 1997 Jan–Feb;27(1):2

Ethnography: studying the fate of health promotion in coronary families. Preston RM. **J Adv Nurs** 1997 Mar; 25(3):554–61

Ethical theory, ethnography, doctors and nurses [letter; comment] Jefferys M. **J Med Ethics** 1997 Feb;23(1):55. Comment on: J Med Ethics 1996 Oct;22(5):259–60. Comment on: J Med Ethics 1996 Oct;22(5):292–9.

At work in the fields of public health: the abuse of rationality. Bibeau G. **Med Anthropol Q** 1997 Jun;11(2):246–51

Reconfiguring nature and culture: intersections of medical anthropology and technoscience studies. Casper MJ, et al. **Med Anthropol Q** 1996 Dec;10(4):523–36 (64 ref.)

Reflections on Amazonian anthropologies of the body [comment] Conklin BA. **Med Anthropol Q** 1996 Sep; 10(3):373–5; discussion 378–80. Comment on: Med Anthropol Q 1996 Sep;10(3):319–41. Comment on: Med Anthropol Q 1996 Sep;10(3):347–72.

More thoughts on negotiating relevance [comment] Coreil J. **Med Anthropol Q** 1997 Jun;11(2):252–5. Comment on: Med Anthropol Q 1997 Jun;11(2):131–46. Comment on: Med Anthropol Q 1997 Jun;11(2):147–63.

An excellent prognosis. Franklin S. **Med Anthropol Q** 1996 Dec;10(4):683–6

The cultural debate over female circumcision: the Sudanese are arguing this one out for themselves [see comments] Gruenbaum E. **Med Anthropol Q** 1996 Dec;10(4):455–75. Comment in: Med Anthropol Q 1996 Dec;10(4):451–4. Comment in: Med Anthropol Q 1996 Dec;10(4):516–9. Comment in: Med Anthropol Q 1996 Dec;10(4):519–22.

Technology and alternative cancer therapies: an analysis of heterodoxy and constructivism. Hess DJ. **Med Anthropol Q** 1996 Dec;10(4):657–74 (62 ref.)

Transforming "body parts" into therapeutic tools: a report from Germany. Hogle LF. **Med Anthropol Q** 1996 Dec; 10(4):675–82

Anthropology and technoscience studies: prospects for synthesis and ambiguity. Kaufert PA, et al. **Med Anthropol Q** 1996 Dec;10(4):686–90

"How's the baby doing?" Struggling with narratives of progress in a neonatal intensive care unit. Layne LL. **Med Anthropol Q** 1996 Dec;10(4):624–56

A biocultural perspective on health and household economy in southern Peru [see comments] Leatherman TL. **Med Anthropol Q** 1996 Dec;10(4):476–95. Comment in: Med Anthropol Q 1996 Dec;10(4):451–4. Comment in: Med Anthropol Q 1996 Dec;10(4):516–9. Comment in: Med Anthropol Q 1996 Dec;10(4):519–22.

Death in technological time: locating the end of meaningful life. Lock M. **Med Anthropol Q** 1996 Dec;10(4):575–600 (63 ref.)

The body that knows: from Cashinahua epistemology to a medical anthropology of lowland South America [see comments] McCallum C. **Med Anthropol Q** 1996 Sep; 10(3):347–72. Comment in: Med Anthropol Q 1996 Sep;10(3):373–5; discussion 378–80.

Should medical ecology be political? [comment] McElroy A. **Med Anthropol Q** 1996 Dec;10(4):519–22. Comment on: Med Anthropol Q 1996 Dec;10(4):455–75. Comment on: Med Anthropol Q 1996 Dec;10(4):476–95. Comment on: Med Anthropol Q 1996 Dec;10(4):496–515.

More than dialogue: contributions to the recapturing of anthropology [comment] Morsy SA. **Med Anthropol Q** 1996 Dec;10(4):516–9. Comment on: Med Anthropol Q 1996 Dec;10(4):455–75. Comment on: Med Anthropol Q 1996 Dec;10(4):476–95. Comment on: Med Anthropol Q 1996 Dec;10(4):496–515.

Farewell to adaptationism: unnatural selection and the politics of biology [see comments] Singer M. **Med Anthropol Q** 1996 Dec;10(4):496–515 (74 ref.). Comment in: Med Anthropol Q 1996 Dec;10(4):451–4. Comment in: Med Anthropol Q 1996 Dec;10(4):516–9. Comment in: Med Anthropol Q 1996 Dec;10(4):519–22.

Negotiating relevance: belief, knowledge, and practice in international health projects [see comments] Yoder PS. **Med Anthropol Q** 1997 Jun;11(2):131–46 (54 ref.). Comment in: Med Anthropol Q 1997 Jun;11(2):252–5.

The misconstruction of critical medical anthropology: a response to a cultural constructivist critique. Baer HA. **Soc Sci Med** 1997 May;44(10):1565–73

Anthropology, clinical pathology and the electronic fetal monitor: lessons from the heart. Bassett K. **Soc Sci Med** 1996 Jan;42(2):281–92

AIDS as a paradox of manhood and development in Kilimanjaro, Tanzania. Setel P. **Soc Sci Med** 1996 Oct; 43(8):1169–78

The social organization of nutritional inequities. Travers KD. **Soc Sci Med** 1996 Aug;43(4):543–53

Ethnography: an overview. Agar MH. **Subst Use Misuse** 1997 Jul;32(9):1155–73 (19 ref.)

[Academic medical versus unconventional cancer therapy: anthropological viewpoints of an endless history] Kappauf H, et al. **Geburtshilfe Frauenheilkd** 1996 Aug;56(8):M116–9 **(Ger)**

[Ethnography of acute respiratory infections in a rural zone of Mexican highlands] Martínez H, et al. **Salud Publica Mex** 1997 May–Jun;39(3):207–16 (Eng. Abstr.) **(Spa)**

METHODS

Methods for successful follow-up of elusive urban populations: an ethnographic approach with homeless men. Conover S, et al. **Bull N Y Acad Med** 1997 Summer; 74(1):90–108

The application of anthropological methods in general practice research. Helman C. **Fam Pract** 1996 Dec;13 Suppl 1:S13–6

Qualitative methods in general practice research: experience from the Oceanpoint Study. Whittaker A. **Fam Pract** 1996 Jun;13(3):310–6

Studying knowledge, culture, and behavior in applied medical anthropology [see comments] Pelto PJ, et al. **Med Anthropol Q** 1997 Jun;11(2):147–63 (29 ref.). Comment in: Med Anthropol Q 1997 Jun;11(2):252–5.

A selected bibliography on the drug use(r) "career". Hunt DE. **Subst Use Misuse** 1997 Feb;32(3):283–91

ANTHROPOLOGY, FORENSIC see **FORENSIC ANTHROPOLOGY**

ANTHROPOLOGY, PHYSICAL

see related
ANTHROPOMETRY
BIOMETRY
GENETICS, MEDICAL

Sixty-fifth Annual Meeting of the American Association of Physical Anthropologists. Research Triangle Park, North Carolina, April 9–13, 1996. Abstracts. **Am J Phys Anthropol** 1996;Suppl 22:1–251

Morphometric variation in Plio-Pleistocene hominid distal humeri. Lague MR, et al. **Am J Phys Anthropol** 1996 Nov; 101(3):401–27

Size and location of the human temporomandibular joint. Wish-Baratz S, et al. **Am J Phys Anthropol** 1996 Nov; 101(3):387–400 (39 ref.)

Anthropology and orthodontics. Crutcher FF. **Angle Orthod** 1997;67(1):73–8

Nuragic bone collagen retains its molecular structure. Tedde G, et al. **Ital J Anat Embryol** 1995 Oct–Dec;100(4):195–202

HISTORY

Early anthropological contributions to "geometric morphometrics". Cole TM 3rd. **Am J Phys Anthropol** 1996 Oct;101(2):291–6

The anatomy lesson of Professor Barge. Hendriksen J, et al. **J R Soc Med** 1996 Nov;89(11):649–50

The legacy of serological studies in American physical anthropology. Marks J. **Pubbl Stn Zool Napoli II** 1996; 18(3):345–62

The Hyrtl skull collection. Worden G. **Trans Stud Coll Physicians Phila** 1995 Dec;17:94–113

MANPOWER

Brief communication: the 1996 American Association of Physical Anthropology membership survey. Turner TR. **Am J Phys Anthropol** 1997 Aug;103(4):565–9

METHODS

Technical note: CT determination of the mineral density of dry bone specimens using the dipotassium phosphate phantom. Chen X, et al. **Am J Phys Anthropol** 1997 Aug; 103(4):557–60

A Monte Carlo study of the inferential properties of three methods of shape comparison. Coward WM, et al. **Am J Phys Anthropol** 1996 Mar;99(3):369–77

Estimating sexual dimorphism by method-of-moments. Josephson SC, et al. **Am J Phys Anthropol** 1996 Jun; 100(2):191–206

Comparative degenerative joint disease of the vertebral column in the medieval monastic cemetery of the Gilbertine priory of St. Andrew, Fishergate, York, England. Knüsel CJ, et al. **Am J Phys Anthropol** 1997 Aug;103(4):481–95

A new, three-dimensional method for determining tooth wear. Mayhall JT, et al. **Am J Phys Anthropol** 1997 Aug; 103(4):463–9

[aDNA--a new approach to old questions] Hummel S, et al. **Z Morphol Anthropol** 1995 Dec;81(1):41–65 (Eng. Abstr.) **(Ger)**

ANTHROPOMETRY

Ocular axial length in children with unilateral congenital cataract. Kugelberg U, et al. **Acta Ophthalmol Scand** 1996 Jun;74(3):220–3

Short-term measurements of linear growth in early life: infant knemometry. Michaelsen KF. **Acta Paediatr** 1997 Jun; 86(6):551–3 (27 ref.)

The anterior dimensions of the pelvis in male and female Nigerians. Nwoha PU. **Afr J Med Med Sci** 1995 Dec; 24(4):329–35

Anthropometric reference data for international use: recommendations from a World Health Organization Expert Committee. de Onis M, et al. **Am J Clin Nutr** 1996 Oct;64(4):650–8

Body composition of a young, multiethnic female population. Ellis KJ, et al. **Am J Clin Nutr** 1997 Mar;65(3):724–31

Maternal anthropometry and infant feeding practices in Israel in relation to growth in infancy: the North African Infant Feeding Study. Fawzi WW, et al. **Am J Clin Nutr** 1997 Jun;65(6):1731–7

New method for assessing bone mineral mass [letter] Fukunaga M, et al. **Am J Clin Nutr** 1996 Oct;64(4):664

Clinical characteristics influencing bioelectrical impedance analysis measurements. Kushner RF, et al. **Am J Clin Nutr** 1996 Sep;64(3 Suppl):423S–427S (38 ref.)

Prediction of percentage body fat from anthropometric measurements: comparison of New Zealand European and Polynesian young women [comment] Rush EC, et al. **Am J Clin Nutr** 1997 Jul;66(1):2–7. Comment on: Am J Clin Nutr 1997 Jul;66(1):26–32.

The fatness-specific bioelectrical impedance analysis equations of Segal et al: are they generalizable and practical? Stolarczyk LM, et al. **Am J Clin Nutr** 1997 Jul; 66(1):8–17

Human immunodeficiency virus infection and nutritional status in female drug addicts undergoing detoxification: anthropometric and immunologic assessments. Varela P, et al. **Am J Clin Nutr** 1997 Aug;66(2):504S–508S

Effects of human immunodeficiency virus infection and detoxification time on anthropometric measurements and dietary intake of male drug addicts. Varela P, et al. **Am J Clin Nutr** 1997 Aug;66(2):509S–514S

Regional fat distribution in women and risk of cardiovascular disease [see comments] Williams MJ, et al. **Am J Clin Nutr** 1997 Mar;65(3):855–60. Comment in: Am J Clin Nutr 1997 Sep;66(3):712–3.

Craniofacial anthropometric analysis in several types of chondrodysplasia. Hunter AG. **Am J Med Genet** 1996 Oct 2;65(1):5–12

Relative growth, ontogeny, and sexual dimorphism in gorilla (Gorilla gorilla gorilla and G. g. beringei): evolutionary and ecological considerations. Taylor AB. **Am J Primatol** 1997;43(1):1–31

Anthropometric variables as predictors for duration of action of atracurium-induced neuromuscular block. Kirkegaard-Nielsen H, et al. **Anesth Analg** 1996 Nov; 83(5):1076–80

Bichat's fat-pad: correlations with some anthropometric parameters. Gravante G, et al. **Ann Hum Biol** 1997 Mar–Apr;24(2):181–5

The relationship between anthropometric indices derived from the CDC/WHO international reference. Macfarlane SB. **Ann Hum Biol** 1996 Nov–Dec;23(6):421–30

Similarities in anthropometrical traits of children and their parents in a Bulgarian population. Nikolova M. **Ann Hum Genet** 1996 Nov;60 (Pt 6):517–25

Evaluation of methodology for nutritional assessment in children: anthropometry, body composition, and energy expenditure. Zemel BS, et al. **Annu Rev Nutr** 1997; 17:211–35 (126 ref.)

An examination of the relationship between foot length, foot breath, ball girth, height and weight of Turkish university students aged between 17 and 25. Anil A, et al. **Anthropol Anz** 1997 Mar;55(1):79–87

Anthropometric analysis of the female Latino nose. Revised aesthetic concepts and their surgical implications. Milgrim LM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Oct; 122(10):1079–86

Anthropometrical measurements and androgen levels in males, females, and hormonally untreated female-to-male transsexuals. Bosinski HA, et al. **Arch Sex Behav** 1997 Apr; 26(2):143–57

Effect of age, race, body surface area, heart weight and atherosclerosis on coronary artery dimensions in young males. Litovsky SH, et al. **Atherosclerosis** 1996 Jun; 123(1–2):243–50

Stability of human proportions through adolescent growth. Ackland TR, et al. **Aust J Sci Med Sport** 1996 Jun; 28(2):57–60

Technical note: anthropometric normative data for female international basketball players. Ackland TR, et al. **Aust J Sci Med Sport** 1997 Mar;29(1):22–4

Anthropometric measurements and ejection injuries. Edwards M. **Aviat Space Environ Med** 1996 Dec; 67(12):1144–7

Evaluation of validity of British anthropometric reference data for assessing nutritional state of elderly people in Edinburgh: cross sectional study. Bannerman E, et al. **BMJ** 1997 Aug 9;315(7104):338–41

Energy intakes, anthropometry and body composition of Nigerian adolescent girls: a case study of an institutionalized secondary school in Ibadan. Cole AH, et al. **Br J Nutr** 1997 Apr;77(4):497–509

Anthropometric characteristics of healthy Italian nonagenarians and centenarians. Ravaglia G, et al. **Br J Nutr** 1997 Jan;77(1):9–17

Comparison of second trimester biometry in singleton and twin pregnancies conceived with assisted reproductive techniques. Gardosi J, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):737–40

The relation between fetal abdominal circumference and birthweight: findings in 3512 pregnancies. Smith GC, et al. **Br J Obstet Gynaecol** 1997 Feb;104(2):186–90

The New Zealand rugby injury and performance project. III. Anthropometric and physical performance characteristics of players [published erratum appears in Br J Sports Med 1996 Sep;30(3):273] Quarrie KL, et al. **Br J Sports Med** 1995 Dec;29(4):263–70

The role of anthropometry in the assessment of vectorcardiographic norms. Regecová V, et al. **Bratisl Lek Listy** 1996 Sep;97(9):553–7

Relationship of spinal fracture to bone density, textural, and anthropometric parameters. Ito M, et al. **Calcif Tissue Int** 1997 Mar;60(3):240–4

Height, weight weight change, and postmenopausal breast cancer risk: The Netherlands Cohort Study. van den Brandt PA, et al. **Cancer Causes Control** 1997 Jan;8(1):39–47

Anthropometric and motor characteristics of Senegalese children with different nutritional histories. Bénéfice E, et al. **Child Care Health Dev** 1996 May;22(3):151–65

Accuracy of anthropometric measurements: past, present, and future. Farkas LG. **Cleft Palate Craniofac J** 1996 Jan; 33(1):10–8; discussion 19–22 (98 ref.)

The aging process--an analysis of the latent structure of body morphology (in males). Živičnjak M, et al. **Coll Antropol** 1997 Jun;21(1):117–26

Waist circumference and waist-to-hip ratio are related to gestational glucose tolerance. Branchtein L, et al. **Diabetes Care** 1997 Apr;20(4):509–11

Transvaginal fetal biometry in early pregnancy. Rosati P, et al. **Early Hum Dev** 1997 Sep 19;49(2):91–6

Isometric muscle strength of Chinese young males in Taiwan. Chuang MC, et al. **Ergonomics** 1997 May;40(5):576–90

Longitudinal changes in anthropometric characteristics of elderly Europeans. SENECA Investigators. de Groot CP, et al. **Eur J Clin Nutr** 1996 Jul;50 Suppl 2:S9–15

Anthropometric measurements from a cross-sectional survey of community dwelling subjects aged over 90 years of age. Rea IM, et al. **Eur J Clin Nutr** 1997 Feb;51(2):102–6

Relationship between maternal nutritional status and infant's weight and body proportions at birth. Thame M, et al. **Eur J Clin Nutr** 1997 Mar;51(3):134–8

Predictive value of conditional centile charts for weight and fundal height in pregnancy in detecting light for gestational age births. Thompson ML, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72(1):3–8

Sonographic measurement of the thymus in infants. Hasselbalch H, et al. **Eur Radiol** 1996;6(5):700–3

Visceral obesity, insulin resistance, and dyslipidemia: contribution of endurance exercise training to the treatment of the plurimetabolic syndrome. Després JP. **Exerc Sport Sci Rev** 1997;25:271–300 (125 ref.)

Geometric data of hallux valgus feet. Lamur KS, et al. **Foot Ankle Int** 1996 Sep;17(9):548–54

The measurement of neonates. Wales JK, et al. **Horm Res** 1997;48 Suppl 1:2–10 (20 ref.)

Timing of menopause in relation to body size and weight change. Leidy LE. **Hum Biol** 1996 Dec;68(6):967–82

Offspring sex ratio in women with android body fat distribution. Singh D, et al. **Hum Biol** 1997 Aug; 69(4):545–56

Calf circumference as a predictor of low birth weight babies. Gupta V, et al. **Indian Pediatr** 1996 Feb;33(2):119–21

Interviewer variability in anthropometric measurements and estimates of body composition. Klipstein-Grobusch K, et al. **Int J Epidemiol** 1997;26 Suppl 1:S174–80

Intra-household correlations of nutritional status in rural Ethiopia. Lindtjørn B, et al. **Int J Epidemiol** 1997 Feb; 26(1):160–5

Factors related to plasma folate and vitamin B12. The SENECA study. Weggemans RM, et al.

ANTHROPOMETRY

Int J Food Sci Nutr 1997 Mar;48(2):141–50

A WHO collaborative study of maternal anthropometry and pregnancy outcomes. **Int J Gynaecol Obstet** 1997 Apr; 57(1):1–15

Growth patterns of the humeral and femur length in a multiethnic population. Raman S, et al. **Int J Gynaecol Obstet** 1996 Aug;54(2):143–7

New age–adjusted measure of body fat distribution in children and adolescents: standardization of waist–hip ratio using multivariate analysis. Asayama K, et al. **Int J Obes Relat Metab Disord** 1997 Jul;21(7):594–9

Predicting intra–abdominal fatness from anthropometric measures: the influence of stature. Han TS, et al. **Int J Obes Relat Metab Disord** 1997 Jul;21(7):587–93

Anthropometric equations for estimating abdominal adipose tissue distribution in women. Kekes–Szabo T, et al. **Int J Obes Relat Metab Disord** 1996 Aug;20(8):753–8

The reliability of upper limb anthropometry in older Chinese people. Kwok T, et al. **Int J Obes Relat Metab Disord** 1997 Jul;21(7):542–7

Anthropometric correlates to changes in visceral adipose tissue over 7 years in women. Lemieux S, et al. **Int J Obes Relat Metab Disord** 1996 Jul;20(7):618–24

Familial resemblance for anthropometric measurements and relative fat distribution among African Americans. Rotimi C, et al. **Int J Obes Relat Metab Disord** 1995 Dec; 19(12):875–80

Body build—is it a factor in acute subglottic laryngitis? Chmielik M, et al. **Int J Pediatr Otorhinolaryngol** 1997 Jun 20;40(2–3):147–53

Physical characteristics as risk factors for sports injuries: a four year prospective study. Twellaar M, et al. **Int J Sports Med** 1997 Jan;18(1):66–71

Dietary intake and anthropometric measures in a Spanish students group. Quiles JL, et al. **Int J Vitam Nutr Res** 1996; 66(4):371–7

A study of errors that can occur when weighing infants. Alsop–Shields L, et al. **J Adv Nurs** 1997 Mar;25(3):587–94

Dietary, anthropometric, hematological and biochemical assessment of the nutritional status of centenarians and elderly people in Okinawa, Japan. Chan YC, et al. **J Am Coll Nutr** 1997 Jun;16(3):229–35

Cross–validation of anthropometric and bioelectrical resistance prediction equations for body composition in older people using the 4–compartment model as a criterion method. Goran MI, et al. **J Am Geriatr Soc** 1997 Jul; 45(7):837–43

Joint center longitudinal positions computed from a selected subset of Chandler's data. de Leva P. **J Biomech** 1996 Sep; 29(9):1231–3

Racial differences in bone density between young adult black and white subjects persist after adjustment for anthropometric, lifestyle, and biochemical differences. Ettinger B, et al. **J Clin Endocrinol Metab** 1997 Feb; 82(2):429–34

Blood pressure and anthropometry in parents and children of a southern Italian village. Buonomo E, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S77–9

Anthropometrical and mechanical considerations in determining normal parameters for the sagittal lumbar spine. Dulhunty JA. **J Manipulative Physiol Ther** 1997 Feb; 20(2):92–102 (34 ref.)

Perspectives on integrating experimental and epidemiologic research on diet, anthropometry and breast cancer. Ballard–Barbash R, et al. **J Nutr** 1997 May;127(5 Suppl):936S–939S (22 ref.)

Diet, anthropometry and breast cancer: integration of experimental and epidemiologic approaches. Clinton SK. **J Nutr** 1997 May;127(5 Suppl):916S–920S (25 ref.)

Anthropometry and breast cancer. Ziegler RG. **J Nutr** 1997 May;127(5 Suppl):924S–928S (26 ref.)

Anthropometric and nutritional evaluation of short statured children from low socio–economic class. Büyükgebiz B, et al. **J Pediatr Endocrinol Metab** 1996 Mar–Apr; 9(2):189–92

Intra– and interexaminer reliability of anthropometric measurements of term infants. Johnson TS, et al. **J Pediatr Gastroenterol Nutr** 1997 May;24(5):497–505

The relationship of ponderal index and other measurements to birthweight in preterm neonates. Chard T, et al. **J Perinat Med** 1997;25(1):111–4

Anthropometric characteristics of full–term infants: effects of varying degrees of "normal" glucose metabolism. Mello G, et al. **J Perinat Med** 1997;25(2):197–204

3–D imaging of residual limbs using ultrasound. He P, et al. **J Rehabil Res Dev** 1997 Jul;34(3):269–78

Assessment of stature in spinal cord injury. Garshick E, et al. **J Spinal Cord Med** 1997 Jan;20(1):36–42

Anthropometric, strength, endurance and flexibility characteristics of elite and recreational climbers. Grant S, et al. **J Sports Sci** 1996 Aug;14(4):301–9

Physique as a risk factor for ulnar variance in elite female gymnasts. Claessens A L, et al. **Med Sci Sports Exerc** 1996 May;28(5):560–9

Risk factors predicting exertional heat illness in male Marine Corps recruits. Gardner JW, et al. **Med Sci Sports Exerc** 1996 Aug;28(8):939–44

Gravitational moment correction in isokinetic dynamometry using anthropometric data. Kellis E, et al. **Med Sci Sports Exerc** 1996 Jul;28(7):900–7

Alterations in total and regional body composition in patients with moderate to severe obstructive lung disease. ZuWallack RL, et al. **Monaldi Arch Chest Dis** 1996 Dec; 51(6):507–9

The use of upper extremity anthropometrics in the clinical assessment of patients with amyotrophic lateral sclerosis. Kasarskis EJ, et al. **Muscle Nerve** 1997 Mar;20(3):330–5

Biparietal diameter: a useful measure for determining gestational age of human abortuses. Sailaja K, et al. **Natl Med J India** 1996 Jul–Aug;9(4):165–7

Anthropometric measures and risk of cancers of the upper digestive and respiratory tract. D'Avanzo B, et al. **Nutr Cancer** 1996;26(2):219–27

Why do we weigh infants and children? Morley D. **Nutr Health** 1996;11(2):105–8

A comparison of body fat estimates using anthropometry and bioelectrical impedance analysis with distinct prediction equations in elderly persons in the Republic of Guatemala. Mazariegos M, et al. **Nutrition** 1996 Mar;12(3):168–75

Anthropometrics do not influence dual X–ray absorptiometry (DXA) measurement of fat in normal to obese adults: a comparison with in vivo neutron activation analysis (IVNA). Marcus MA, et al. **Obes Res** 1997 Mar;5(2):122–30

Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans--a 7–year prospective study. Wei M, et al. **Obes Res** 1997 Jan; 5(1):16–23

Enucleation volume measurement. Thaller VT. **Ophthal Plast Reconstr Surg** 1997 Mar;13(1):18–20

Fractional urea clearance estimates using two anthropometric formulas in continuous peritoneal dialysis: sex, height, and body composition differences. Tzamaloukas AH, et al. **Perit Dial Int** 1996 Mar–Apr;16(2):135–41

Influence of environmental factors on development of Bialystok newborns born in 1987. Litwiejko–Pietryńczak E. **Rocz Akad Med Bialymst** 1996;41(2):457–62

Body composition in patients on home parenteral nutrition. Tjellesen L, et al. **Scand J Clin Lab Invest** 1996 Jul; 56(4):295–303

The Q angle and sport. Hahn T, et al. **Scand J Med Sci Sports** 1997 Feb;7(1):43–8

Accuracy of CPAP predicted from anthropometric and polysomnographic indices [letter] [see comments] Gokcebay N, et al. **Sleep** 1996 Sep;19(7):600–1. Comment in: Sleep 1997 Mar;20(3):237–8.

The quantitative anatomy of the thoracic facet and the posterior projection of its inferior facet. Ebraheim NA, et al. **Spine** 1997 Aug 15;22(16):1811–7; discussion 1818

Radiographic standing cervical segmental alignment in adult volunteers without neck symptoms. Hardacker JW, et al. **Spine** 1997 Jul 1;22(13):1472–80; discussion 1480

Axial rotation measurement of scoliotic vertebrae by means of computed tomography scans. Krismer M, et al. **Spine** 1996 Mar 1;21(5):576–81

Anthropometric and physiological characteristics of rugby union football players. Nicholas CW. **Sports Med** 1997 Jun; 23(6):375–96 (75 ref.)

Vertebral level of the ending of the spinal cord and its relationship to the length of the vertebral column in northern Turkish neonates. Içten N, et al. **Surg Radiol Anat** 1995;17(4):315–8

Is there any difference in coronary heart disease risk factors and prevalence of fatty liver in subjects with normal body mass index having different physiques? Hsieh SD, et al. **Tohoku J Exp Med** 1995 Nov;177(3):223–31

[Measure of abdominal cavity volumes by gynecologic laparoscopy] Jambon AC, et al. **Contracept Fertil Sex** 1997 May;25(5):VI–XII **(Fre)**

[Improved organ survival in transplantation of pediatric kidneys by optimizing donor–recipient size relation] Banafsche R, et al. **Urologe A** 1996 Jan;35(1):18–25 (Eng. Abstr.) **(Ger)**

[Comment on neonatal growth standards. Letter] Morabito D, et al. **Minerva Pediatr** 1997 Apr;49(4):171–2 **(Ita)**

[Cephalometric measurements of nasopharyngeal and palatal flow in cleft palate children by comparison with hearing impairment] Kubik P, et al. **Otolaryngol Pol** 1996; 50(1):81–90 (Eng. Abstr.) **(Pol)**

[Adult stature prediction in boys according to the Khamis–Roche method and proposed regression equations] Zarów R. **Pediatr Pol** 1996 Sep;71(9):801–6 (Eng. Abstr.) **(Pol)**

[Relationship between the iron status of the pregnant woman and her body size and body composition before and during pregnancy] Zimna–Walendzik E, et al. **Przegl Lek** 1997; 54(2):92–5 (Eng. Abstr.) **(Pol)**

[Relation between the abdominal sagittal diameter, fat tissue distribution and metabolic complications] Stokić E, et al. **Med Pregl** 1996;49(9–10):365–8 (Eng. Abstr.) **(Scr)**

[Anthropometric assessment of the nutritional status of the adolescent population of Cádiz (Spain)] Ruiz Jiménez MA, et al. **An Esp Pediatr** 1996 Oct;45(4):369–76 (Eng. Abstr.) **(Spa)**

[Waist/hip ratio and vascular risk factors in obese and not obese individuals (see comments)] de Portugal Alvarez J, et al. **An Med Interna** 1997 Jan;14(1):3–8 (Eng. Abstr.). Comment in: An Med Interna 1997 Jan;14(1):1–2. **(Spa)**

[Waist/hip ratio. Obesity and cardiovascular risk (editorial; comment)] Jover Sanz E. **An Med Interna** 1997 Jan; 14(1):1–2. Comment on: An Med Interna 1997 Jan;14(1):3–8. **(Spa)**

[Comparison between nutritional status of school children of low socioeconomic level from Santiago, Chile and Sao Paulo, Brazil] Amigo H, et al. **Arch Latinoam Nutr** 1995 Mar;45(1):31–5 (Eng. Abstr.) **(Spa)**

[An anthropometric equation for the determination of the percentage of body fat in young men from the Canarian population] López Calbet JA, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):207–13 (Eng. Abstr.) **(Spa)**

[Anthropometric evolution of height, weight and total body water pre and post menarche] Zurlo de Mirotti SM, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53 Suppl:17–22 (Eng. Abstr.) **(Spa)**

[Nutritional status of school children from different socioeconomic levels] Amigo H, et al. **Rev Med Chil** 1995 Sep;123(9):1063–70 (Eng. Abstr.) **(Spa)**

[Body fat distribution: anthropometric indicators] Yáñez M, et al. **Rev Med Chil** 1995 Dec;123(12):1520–4 (35 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

Contribution to the origin of progeny in middle European Habsburgs: skeletal roentgencephalometric analysis of the Habsburgs buried in Prague. Víček E, et al. **Acta Chir Plast** 1997;39(2):39–47

The history of the Army weight standards. Johnson NA. **Mil Med** 1997 Aug;162(8):564–70

INSTRUMENTATION

The measurement of knee–heel length in newborn infants using a simple vernier calipers. Skinner AM, et al. **Acta Paediatr** 1997 May;86(5):512–7

Construction and use of an inexpensive "anthropometer". Clarke GS. **Am J Phys Anthropol** 1996 Aug;100(4):605–8

Infrared optoelectronic volumetry, the ideal way to measure limb volume. Tierney S, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):412–7

Assessing the accuracy of a prototype drill guide for fibular graft placement in femoral head necrosis. Schnieders MJ, et al. **Iowa Orthop J** 1997;17:58–63

Development and evaluation of a precision forearm and hand volumeter and measuring cylinder. Boland R, et al. **J Hand Ther** 1996 Oct–Dec;9(4):349–58

Validation of an optoelectronic limb volumeter (Perometer). Stanton AW, et al. **Lymphology** 1997 Jun;30(2):77–97

Evaluation of the reliability of reflective marker placements. Marks R, et al. **Physiother Res Int** 1996;1(1):50–61

Reliability of lower extremity girth measurements after anterior cruciate ligament reconstruction. Soderberg GL, et al. **Physiother Res Int** 1996;1(1):7–16

METHODS

The straight line graph in limb length inequality. A new design based on 182 Dutch children. Beumer A, et al. **Acta Orthop Scand** 1997 Aug;68(4):355–60

Intrauterine growth curves based on ultrasonically estimated foetal weights. Maršál K, et al. **Acta Paediatr** 1996 Jul; 85(7):843–8

Estimating urea volume in amputees on peritoneal dialysis by modified anthropometric formulas. Tzamaloukas AH, et al. **Adv Perit Dial** 1996;12:143–6

Anthropometric determination of craniofacial morphology [editorial] Farkas LG, et al. **Am J Med Genet** 1996 Oct 2;65(1):1–4

Anterior chamber depth in Mongolians: variation with age, sex, and method of measurement. Foster PJ, et al. **Am J Ophthalmol** 1997 Jul;124(1):53–60

Femoral sulcus angle measurements. Mulligan ME, et al. **Am J Orthop** 1997 Aug;26(8):541–3

Underestimation of daily energy expenditure with the factorial method: implications for anthropological research. Leonard WR, et al. **Am J Phys Anthropol** 1997 Aug; 103(4):443–54

Measuring the human pelvis: a comparison of direct and radiographic techniques using a modern United States--based sample. Schroeder CF, et al. **Am J Phys Anthropol** 1997 Aug;103(4):471–9

Prediction of total body water in Indian men from anthropometry and bioelectrical impedance using deuterium dilution as reference. Borgonha S, et al. **Ann Hum Biol** 1997 Jul–Aug;24(4):355–61

Mini–knemometry: an accurate technique for lower leg length measurements in early childhood. Hermanussen M, et al. **Ann Hum Biol** 1997 Jul–Aug;24(4):307–13

A predictive morphometric model for the obstructive sleep apnea syndrome. Kushida CA, et al. **Ann Intern Med** 1997 Oct 15;127(8 (Pt 1)):581–7

Computer–aided video analysis of vertebrofemoral motion during toe touching in healthy subjects. Tully EA, et al. **Arch Phys Med Rehabil** 1997 Jul;78(7):759–66

Customised fetal growth assessment. Leeson S, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):648–51 (38 ref.)

Laser scanning for the identification of repeatable landmarks of the ears and face. Coward TJ, et al. **Br J Plast Surg** 1997 Jul;50(5):308–14

The development of MUAC–for–age reference data recommended by a WHO Expert Committee. de Onis M, et al. **Bull World Health Organ** 1997;75(1):11–8

Photoanthropometric study of craniofacial traits in individuals with Williams syndrome. Hovis CL, et al. **Clin Genet** 1997 Jun;51(6):379–87

The Ranawat Award. Sulcus morphology of the distal femur.

Eckhoff DG, et al. **Clin Orthop** 1996 Oct;(331):23–8

What's the baby like? [editorial; comment] Bar MC. **Dev Med Child Neurol** 1997 May;39(5):285. Comment on: Dev Med Child Neurol 1997 May;39(5):343–6.

Use of biometric embryonic growth parameters as indicator of exposure to a teratogen. Amwayi PJ, et al. **East Afr Med J** 1997 Jan;74(1):6–11

Automatic calculation of the medial axis of foot outline and its flexion angles. Mochimaru M, et al. **Ergonomics** 1997 Apr;40(4):450–64

Comparison between estimates of hand volume and hand strengths with sex and age with and without anthropometric data in healthy working people. Chau N, et al. **Eur J Epidemiol** 1997 Apr;13(3):309–16

Estimation of stature from stride length while walking fast. Jasuja OP, et al. **Forensic Sci Int** 1997 May 5;86(3):181–6

Bevelling in exit gunshot wounds in bones. Quatrehomme G, et al. **Forensic Sci Int** 1997 Sep 19;89(1–2):93–101

Anthropometry and body composition in children. Van den Broeck J, et al. **Horm Res** 1997;48 Suppl 1:33–42 (130 ref.)

Validation study of self-reported measures of fat distribution. Weaver TW, et al. **Int J Obes Relat Metab Disord** 1996 Jul;20(7):644–50

Assessment of body composition in youths and relationship to sport. Houtkooper LB. **Int J Sport Nutr** 1996 Jun; 6(2):146–64 (48 ref.)

Submicrometer precision biometry of the anterior segment of the human eye. Drexler W, et al. **Invest Ophthalmol Vis Sci** 1997 Jun;38(7):1304–13

Precise determination of anthropometric dimensions by means of image processing methods for estimating human body segment parameter values. Baca A. **J Biomech** 1996 Apr;29(4):563–7

Comparative follow-up of patients with acute and obtuse infundibulum-pelvic angle submitted to extracorporeal shockwave lithotripsy for lower caliceal stones: preliminary report and proposed study design. Sampaio FJ, et al. **J Endourol** 1997 Jun;11(3):157–61

The anthropometry of contemporary commercial cremation. Warren MW, et al. **J Forensic Sci** 1997 May;42(3):417–23

Measurement of body fat and fat distribution. Keller C, et al. **J Nurs Meas** 1995 Winter;3(2):159–74 (47 ref.)

Intraexaminer reliability, interexaminer reliability, and mean values for nine lower extremity skeletal measures in healthy naval midshipmen. Jonson SR, et al. **J Orthop Sports Phys Ther** 1997 Apr;25(4):253–63

Use of vertebral levels to measure presumed internal rotation at the shoulder: a radiographic analysis. Mallon WJ, et al. **J Shoulder Elbow Surg** 1996 Jul–Aug;5(4):299–306

Direct spinal curvature digitization in scoliosis screening—a comparative study with Moiré contourgraphy. Wong HK, et al. **J Spinal Disord** 1997 Jun;10(3):185–92

Absolute values or Z scores of mid-upper arm circumference to identify wasting? Evaluation in a community as well as a clinical sample of under fives from Nchelenge, Zambia. Gernaat HB, et al. **J Trop Pediatr** 1996 Feb;42(1):27–33

Fat mass, fat mass percentage, body mass index, and mid-upper arm circumference in a healthy population of Nigerian children. Owa JA, et al. **J Trop Pediatr** 1997 Feb; 43(1):13–9

An easy way for estimation of low birth weight in newborn babies in Baghdad, Iraq. Tawfeek HI. **J Trop Pediatr** 1996 Oct;42(5):302–4

Growth-monitoring teaching aid to improve mothers' understanding [letter] Sohal H, et al. **Lancet** 1997 Aug 23; 350(9077):562–3

Iliac wing angle as a marker for trisomy 21 in the second trimester. Bork MD, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):734–7

Three-dimensional ultrasound-assessed fetal thigh volumetry in predicting birth weight. Chang FM, et al. **Obstet Gynecol** 1997 Sep;90(3):331–9

Ophthalmoscopic measurement of the optic disc. Jonas JB, et al. **Ophthalmology** 1995 Jul;102(7):1102–6

Evaluation of the nasal cavity by acoustic rhinometry in normal and allergic subjects. Corey JP, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):22–8

Calibration of a total body potassium monitor with an anthropomorphic phantom. Hansen RD, et al. **Phys Med Biol** 1996 Nov;41(11):2447–62

On the McKenzie approach [letter; comment] Bybee R, et al. **Phys Ther** 1996 Nov;76(11):1258, 1260; discussion 1260–1. Comment on: Phys Ther 1996 Jul;76(7):706–16; discussion 717–26.

On the McKenzie approach [letter; comment] Pearson N, et al. **Phys Ther** 1996 Nov;76(11):1256, 1258; discussion 1260–1. Comment on: Phys Ther 1996 Jul;76(7):706–16; discussion 717–26.

The reliability of measuring quadriceps cross-sectional area with compound B ultrasound scanning. Howe TE, et al. **Physiother Res Int** 1996;1(2):112–26

Reliability of lower extremity girth measurements after anterior cruciate ligament reconstruction. Soderberg GL, et al. **Physiother Res Int** 1996;1(1):7–16

Measurements of scapular position and rotation: a reliability study. T'Jonck L, et al. **Physiother Res Int** 1996;1(3):148–58

Clinical evaluation of facial morphology in cleft lip palate patients [letter; comment] Farkas LG. **Plast Reconstr Surg** 1997 Jan;99(1):262–3. Comment on: Plast Reconstr Surg 1995 Jul;96(1):9–23; discussion 24–6.

Fetal biometric ratios by transvaginal sonography as a marker for aneuploidies in early pregnancy. Guariglia L, et al. **Prenat Diagn** 1997 May;17(5):415–22

A comparison of trial shoe and shell shoe fitting techniques. Chen RC, et al. **Prosthet Orthot Int** 1995 Dec;19(3):181–7

Prediction of scoliotic cobb angle with the use of the scoliometer [see comments] [published erratum appears in Spine 1997 Apr 15;22(8):926] Korovessis PG, et al. **Spine** 1996 Jul 15;21(14):1661–6. Comment in: Spine 1997 Apr 15;22(8):926.

Diurnal changes in lumbar intervertebral distance, measured using ultrasound. Ledsome JR, et al. **Spine** 1996 Jul 15; 21(14):1671–5

Estimating the surface area of the human body. Bailey BJ, et al. **Stat Med** 1996 Jul 15;15(13):1325–32

Anthropometric measures as a predictor of cephalopelvic disproportion. Burgess HA. **Trop Doct** 1997 Jul;27(3):135–8

Cephalic vein cutdown: a new approach [letter] Chitkara N, et al. **Trop Doct** 1997 Jul;27(3):192

Cephalopelvic disproportion [editorial] Payne PR. **Trop Doct** 1997 Jul;27(3):129–30

[3-D evaluation of posture in normal and scoliotic adolescents] Le Blanc R, et al. **Ann Chir** 1996;50(8):631–6 (Eng. Abstr.) **(Fre)**

[Normal fetal growth profile—a uniform model for calculating normal curves for current head and abdomen parameters and long limb bones] Merz E, et al. **Ultraschall Med** 1996 Aug;17(4):153–62 (Eng. Abstr.) **(Ger)**

[Techniques for the measurement of body composition and body fat distribution] Katsukawa F, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:282–6 (7 ref.) **(Jpn)**

[Validity of self-notified measures of weight and height in the estimation of obesity prevalence (letter; comment)] Ramalle-Gómara E, et al. **Med Clin (Barc)** 1997 May 10; 108(18):716. Comment on: Med Clin (Barc) 1996 May 18;106(19):725–9. **(Spa)**

ANTI-D-IMMUNOGLOBULIN see **RHO(D) IMMUNE GLOBULIN**

ANTIADRENERGIC AGENTS see **ADRENERGIC ANTAGONISTS**

ANTIAGGREGANTS, PLATELET see **PLATELET AGGREGATION INHIBITORS**

ANTI-AIDS AGENTS see **ANTI-HIV AGENTS**

ANTI-ALLERGIC AGENTS

see related
HISTAMINE H1 ANTAGONISTS

Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Burkhart GA, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):93–6

Anti-allergic properties of the natural PAF antagonist yangambin. Serra MF, et al. **Planta Med** 1997 Jun; 63(3):207–12

[Physicochemical properties of suplatast tosilate racemate and enantiomers] Ushio T, et al. **Yakugaku Zasshi** 1996 Nov;116(11):866–75 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Holmberg K, et al. **Ann Allergy Asthma Immunol** 1997 Mar;78(3):270–6

Efficacy of intranasally applied dimethindene maleate solution as spray in adult volunteers with symptoms of seasonal allergic rhinitis in the Vienna challenge chamber. Kyrein HJ, et al. **Arzneimittelforschung** 1996 Aug; 46(8):794–9

Preparation of controlled release granules of TA-5707F using enteric polymers and ethylcellulose, and their in vivo evaluation. Yamakita H, et al. **Biol Pharm Bull** 1996 Jan; 19(1):106–13

First-line treatment of hay fever: what is the best option? [editorial; comment] Freedman SO. **Can Med Assoc J** 1997 Apr 15;156(8):1141–3. Comment on: Can Med Assoc J 1997 Apr 15;156(8):1123–31.

First-line treatment of seasonal (ragweed) rhinoconjunctivitis. A randomized management trial comparing a nasal steroid spray and a nonsedating antihistamine [see comments] Juniper EF, et al. **Can Med Assoc J** 1997 Apr 15;156(8):1123–31. Comment in: Can Med Assoc J 1997 Apr 15;156(8):1141–3.

A double-blind, placebo-controlled trial of decongestant-antihistamine for the treatment of sinusitis in children. McCormick DP, et al. **Clin Pediatr (Phila)** 1996 Sep;35(9):457–60

The effect of fluticasone propionate aqueous nasal spray on eosinophils and cytokines in nasal secretions of patients with ragweed allergic rhinitis. Alvarado-Valdés CA, et al. **Clin Ther** 1997 Mar–Apr;19(2):273–81

A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Newson-Smith G, et al. **Eur Arch Otorhinolaryngol** 1997;254(5):236–41

Soy allergy and DSCG in atopic eczema: "much ado about nothing"? Ventura A, et al. **Pediatr Med Chir** 1996 May–Jun;18(3):283–8

Design and evaluation of transdermal chlorpheniramine maleate drug delivery system. Andronis V, et al. **Pharm Acta Helv** 1995 Dec;70(4):301–6

The effect of intranasal fluticasone propionate on the diving reflex in patients with non-eosinophilic non-allergic rhinitis. Cook JA, et al. **Rhinology** 1996 Sep;34(3):144–6

[Treatment of hay fever] Mygind N, et al. **Ugeskr Laeger** 1997 Sep 1;159(36):5358–61 **(Dan)**

[Antazoline/tetryzoline eyedrops in comparison with levocabastine eyedrops in acute allergic conjunctivitis] Wertheimer R, et al. **Klin Monatsbl Augenheilkd** 1997 Feb; 210(2):93–6 (Eng. Abstr.) **(Ger)**

[The effect of initial treatment by FP aqueous nasal spray in patients with Japanese cedar pollinosis] Nakabayashi S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Sep; 99(9):1162–71 (Eng. Abstr.) **(Jpn)**

[Anti-inflammatory drugs for the treatment of bronchial hyperresponsiveness] Sano Y. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:48–53 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Allergic conjunctivitis from eyedrops. Blanco R, et al. **Allergy** 1997 Jun;52(6):686–7

Learning impairment and allergic rhinitis. Simons FE. **Allergy Asthma Proc** 1996 Jul–Aug;17(4):185–9. (35 ref.)

Safety profiles of tramadol, lindane, and astemizole updated [news] **Am J Health Syst Pharm** 1996 May 15;53(10):1116, 1122

Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Einarson A, et al. **Ann Allergy Asthma Immunol** 1997 Feb;78(2):183–6

Hay fever drug to be banned by the FDA [news] Josefson D. **BMJ** 1997 Jan 25;314(7076):248

Nonsedating antihistamines in pregnancy. Mazzotta P, et al. **Can Fam Physician** 1997 Sep;43:1509–11

A case of iatrogenic growth retardation induced by a corticosteroid containing anti-allergic drug [letter] Singh SK. **Horm Metab Res** 1996 Mar;28(3):156–7

Hypoglycemic effect of terfenadine in patients of allergic rhinitis [letter] Chakravarti A, et al. **Indian J Physiol Pharmacol** 1996 Apr;40(2):191–2

Coprescription of terfenadine and erythromycin or ketaconazole: an assessment of potential harm. Carlson AM, et al. **J Am Pharm Assoc (Wash)** 1996 Apr;NS36(4):263–9

[Syncopes during simultaneous use of terfenadine and itraconazole] Romkes JH, et al. **Ned Tijdschr Geneeskd** 1997 May 10;141(19):950–3 (Eng. Abstr.) **(Dut)**

BLOOD

Analysis of terfenadine in human plasma using microbore high-performace liquid chromatography-electrospray ionisation mass spectrometry. Adams DA, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):345–51

CHEMICAL SYNTHESIS

Development of bioactive functions in hydrangeae dulcis folium. VI. Syntheses of thunberginols A and F and their 3'-deoxy-derivatives using regiospecific lactonization of stilbene carboxylic acid: structures and inhibitory activity on histamine release of hydramacrophyllols A and B. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Oct; 44(10):1890–8

ECONOMICS

A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis. Kozma CM, et al. **Clin Ther** 1996 Mar–Apr; 18(2):334–46; discussion 302

IMMUNOLOGY

Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats. Seiffge D. **J Rheumatol** 1996 Dec; 23(12):2086–91

ISOLATION & PURIFICATION

Development of bioactive functions in hydrangeae dulcis folium. V. On the antiallergic and antimicrobial principles of hydrangeae dulcis folium. (2). Thunberginols C, D, and E, thunberginol G 3'-O-glucoside, (-)-hydrangenol 4'-o-glucoside, and (+)-hydrangenol 4'-O-glucoside. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Aug; 44(8):1440–7

Bioactive constituents of Chinese natural medicines. II. Rhodiolae radix. (1). Chemical structures and antiallergic activity of rhodiocyanosides A and B from the underground part of Rhodiola quadrifida (Pall.) Fisch. et Mey. (Crassulaceae). Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2086–91

METABOLISM

Propolypeptide of von Willebrand factor is a novel ligand for very late antigen-4 integrin. Isobe T, et al. **J Biol Chem** 1997 Mar 28;272(13):8447–53

Integrin cross talk: activation of lymphocyte function-associated antigen-1 on human T cells alters alpha4beta1- and alpha5beta1-mediated function. Porter JC, et al. **J Cell Biol** 1997 Sep 22;138(6):1437–47

Investigation of the stereoselective in vitro metabolism of the chiral antiasthmatic/antiallergic drug flezelastine by

high-performance liquid chromatography and capillary zone electrophoresis. Paris S, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):463-71

Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. Sharif NA, et al. **J Ocul Pharmacol Ther** 1996 Winter;12(4):401-7

Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor. Kakiuchi M, et al. **Jpn J Pharmacol** 1997 Apr; 73(4):291-8

PHARMACOKINETICS

Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Thorsson L, et al. **Br J Clin Pharmacol** 1997 Feb;43(2):155-61

Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. Rau SE, et al. **Clin Pharmacol Ther** 1997 Apr;61(4):401-9

Ketotifen pharmacokinetics in children with atopic perennial asthma. McFadyen ML, et al. **Eur J Clin Pharmacol** 1997; 52(5):383-6

Design of a suitable formulation of FK613, a novel antiallergic agent, based on its pharmacokinetic and pharmacodynamic properties in healthy subjects. Uematsu T, et al. **Eur J Clin Pharmacol** 1996;49(4):279-84

PHARMACOLOGY

Late phase response during nasal challenge: effect of astemizole on leukotriene B4 levels. Kumar NS, et al. **Allergy Asthma Proc** 1996 Mar-Apr;17(2):93-9

Effect of cetirizine on antigen-induced tracheal contraction of passively sensitized guinea pigs. Dobashi K, et al. **Ann Allergy Asthma Immunol** 1996 Oct;77(4):310-8

Efficacy and tolerability of astemizole-D and Loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber. Horak F, et al. **Arzneimittelforschung** 1996 Nov;46(11):1077-81

Effect of the new antiallergic agent olopatadine on EEG spectral powers in conscious rats. Kamei C, et al. **Arzneimittelforschung** 1996 Aug;46(8):789-93

Effect of an active metabolite of the antiallergic agent tazanolast on histamine release from rat mast cells. Kamei C, et al. **Arzneimittelforschung** 1997 Apr;47(4):390-4

Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice. Sakai A, et al. **Arzneimittelforschung** 1997 Aug;47(8):954-8

Ketotifen inhibits allergen-specific T lymphocytes' responses by suppressing antigen presentation with concomitant decrease of HLA-DQ antigen on macrophages. Kawano Y, et al. **Asian Pac J Allergy Immunol** 1996 Dec;14(2):69-79

Suppressive effects of tranilast on the expression of inducible cyclooxygenase (COX2) in interleukin-1beta-stimulated fibroblasts. Inoue H, et al. **Biochem Pharmacol** 1997 Jun 15;53(12):1941-4

Anti-allergic effect of tea-leaf saponin (TLS) from tea leaves (Camellia sinensis var. sinensis). Akagi M, et al. **Biol Pharm Bull** 1997 May;20(5):565-7

Studies on Alismatis rhizoma. I. Anti-allergic effects of methanol extract and six terpene components from Alismatis rhizoma (dried rhizome of Alisma orientale). Kubo M, et al. **Biol Pharm Bull** 1997 May;20(5):511-6

Inhibitory effects of dehydrocorydaline isolated from Corydalis Tuber against type I-IV allergic models. Matsuda H, et al. **Biol Pharm Bull** 1997 Apr;20(4):431-4

KW-4679-induced inhibition of tachykininergic contraction in the guinea-pig bronchi by prejunctional inhibition of peripheral sensory nerves [published erratum appears in Br J Pharmacol 1996 Jul;118(6):1565] Ikemura T, et al. **Br J Pharmacol** 1996 Mar;117(5):967-73

Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells. Fukuyama J, et al. **Can J Physiol Pharmacol** 1996 Jan; 74(1):80-4

Bioactive constituents of Chinese natural medicines. II. Rhodiolae radix. (1). Chemical structures and antiallergic activity of rhodiocyanosides A and B from the underground part of Rhodiola quadrifida (Pall.) Fisch. et Mey. (Crassulaceae). Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2086-91

Development of bioactive functions in hydrangeae dulcis folium. V. On the antiallergic and antimicrobial principles of hydrangeae dulcis folium. (2). Thunberginols C, D, and E, thunberginol G 3'-O-glucoside, (-)-hydrangenol 4'-o-glucoside, and (+)-hydrangenol 4'-O-glucoside. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Aug; 44(8):1440-7

Effect of terfenadine on TNF alpha release from peripheral blood mononuclear cells during cow's milk allergy. Benlounes N, et al. **Clin Exp Allergy** 1997 Aug;27(8):942-8

Fluticasone propionate: topical or systemic effects? Howland WC 3rd. **Clin Exp Allergy** 1996 May;26 Suppl 3:18-22

The inhibitory effect of TMK688, a novel anti-allergic drug having both 5-lipoxygenase inhibitory activity and anti-histamine activity, against bronchoconstriction, leukotriene production and inflammatory cell infiltration in sensitized guinea pigs. Tohda Y, et al. **Clin Exp Allergy** 1997 Jan;27(1):110-8

Effects of the anti-allergics astemizole and norastemizole on Fc epsilon RI receptor-mediated signal transduction processes. Fischer MJ, et al. **Eur J Pharmacol** 1997 Mar 12;322(1):97-105

Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet. Fukuyama J, et al. **Eur J Pharmacol** 1996 Dec 30; 318(2-3):327-32

Tranilast inhibits the growth of rat mesangial cells. Ikeda M, et al. **Eur J Pharmacol** 1997 Apr 18;324(2-3):283-7

Influence of the anti-allergic drug oxatomide on the signal transduction mechanism in a mast cell model. Paulussen JJ, et al. **Eur J Pharmacol** 1996 Sep 19;312(1):121-30

Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs [published erratum appears in Eur J Pharmacol 1997 Mar 5;321(3):397] Taniguchi H, et al. **Eur J Pharmacol** 1996 Dec 30;318(2-3):447-54

Inhibitory effects of terfenadine on the rising phase of action potentials and sinus rates in isolated guinea-pig myocardium. Tanaka H, et al. **Gen Pharmacol** 1996 Mar; 27(2):337-40

Effect of TYB-2285 on antigen-induced accumulation of eosinophils into the peritoneal cavity of rats sensitized with Ascaris suum extract. Tominaga T, et al. **Gen Pharmacol** 1997 Mar;28(3):411-4

Inhibition of human eosinophil chemotaxis in vitro by the anti-allergic agent emedastine difumarate. el-Shazly AE, et al. **Immunopharmacol Immunotoxicol** 1996 Nov; 18(4):587-95

Antiallergic activity of alkyl substituted pyrazolo[3, 4-d]pyrimidine (compound 88-765). Gupta PP, et al. **Indian J Exp Biol** 1995 Jan;33(1):38-40

Relation between effects of a set of anti-allergic drugs on calcium pathways and membrane structure in Fc epsilon RI activated signal transduction. Fischer MJ, et al. **Inflamm Res** 1996 Nov;45(11):564-73

Characterization of a primate model of asthma using anti-allergy/anti-asthma agents. Turner CR, et al. **Inflamm Res** 1996 May;45(5):239-45

G proteins as biological targets for anti-allergic drugs? Rihoux JP, et al. **Int Arch Allergy Immunol** 1997 May-Jul; 113(1-3):339-41

Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. Ezeamuzie CI. **Int J Immunopharmacol** 1996 Apr; 18(4):263-70

Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: effects of cetirizine. Zweiman B, et al. **J Allergy Clin Immunol** 1997 Sep;100(3):341-7

Suppression of TNF-alpha secretion by azelastine in a rat mast (RBL-2H3) cell line: evidence for differential regulation of TNF-alpha release, transcription, and degranulation. Hide I, et al. **J Immunol** 1997 Sep 15; 159(6):2932-40

The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. Yanni JM, et al. **J Ocul Pharmacol Ther** 1996 Winter; 12(4):389-400

Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. Sharif NA, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1252-61

Stimulation of airway mucociliary transport and epithelial ciliary motility by the triazolopyridazin derivative TAK-225. Tamaoki J, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1186-90

Inhibitory effect of KW-4679, an anti-allergic drug, on tachykinin-mediated airway response induced by electrical vagal stimulation in guinea pigs. Ikemura T, et al. **Jpn J Pharmacol** 1996 Jun;71(2):179-82

Effect of terfenadine and KW-4679, a novel antiallergic compound, on action potential of guinea pig ventricular myocytes. Kato Y, et al. **Jpn J Pharmacol** 1996 Feb; 70(2):199-202

Effects of E-4716, a new antihistaminic with antiallergic properties, on chemical mediators induction of immunologic reactions. Gutiérrez B, et al. **Methods Find Exp Clin Pharmacol** 1996 Jul-Aug; 18(6):397-406

Effects of non-steroidal antiallergic eyedrops on the complement-mediated histamine release from human cells. Goldschmidt P, et al. **Ocul Immunol Inflamm** 1997 Mar; 5(1):11-7

Azelastine suppresses the release of arachidonic acid metabolites from cultured human umbilical vein endothelial cells. Watanabe K, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Mar; 56(3):209-11

[Antagonistic effect of oleanolic acid on anaphylactic shock] Zhang LR, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Nov; 16(6):527-30 (Eng. Abstr.) **(Chi)**

[Skin reactions to bradykinin] Rihoux JP, et al. **Allerg Immunol (Paris)** 1995 Oct;27(8):279-83 (33 ref.) (Eng. Abstr.) **(Fre)**

[Anti-allergic effects of beta-adrenoceptor agonists in the clinical pharmacological studies] Horikoshi S, et al. **Nippon Rinsho** 1996 Nov;54(11):3068-72 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Antiallergic effects of a novel compound, SWR-00151] Tanaka Y, et al. **Nippon Yakurigaku Zasshi** 1997 Apr; 109(4):193-206 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Clinical use of recombinant allergens and epitopes. Bousquet J, et al. **Adv Exp Med Biol** 1996;409:463-9 (48 ref.)

Clinical experience with treatment of allergies with T cell epitope containing peptides. Norman PS. **Adv Exp Med Biol** 1996;409:457-61 (13 ref.)

Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Géhanno P, et al. **Allergy** 1997 Apr;52(4):445-50

Effects of ketotifen on symptoms and on bronchial mucosa in patients with atopic asthma. Hoshino M, et al. **Allergy** 1997 Aug;52(8):814-20

The effect of cetirizine on sulfidoleukotriene production by blood leukocytes in children with allergic rhinitis. Kalayci O, et al. **Allergy** 1995 Dec;50(12):964-9

Cetirizine: effective treatment for food (egg) allergy. Shaikh WA. **Allergy** 1996 Apr;51(4):275-6

Is there a role for immunotherapy in the treatment of asthma? Yes [editorial] Norman PS. **Am J Respir Crit Care Med** 1996 Nov;154(5):1225-6

Effects of anti-allergic drugs on substance P (SP) and vasoactive intestinal peptide (VIP) in nasal secretions. Shinoda M, et al. **Am J Rhinol** 1997 May-Jun;11(3):237-41

Effects of a single dose of loratadine on flying ability under conditions of simulated cabin pressure. Valk PJ, et al. **Am J Rhinol** 1997 Jan-Feb;11(1):27-33

Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Day JH, et al. **Ann Allergy Asthma Immunol** 1997 Aug;79(2):163-72

Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Einarson A, et al. **Ann Allergy Asthma Immunol** 1997 Feb;78(2):183-6

Study protocol on azelastine [letter; comment] Kelso JM. **Ann Allergy Asthma Immunol** 1997 Feb;78(2):244. Comment on: Ann Allergy Asthma Immunol 1996 Feb;76(2):181-8.

Fluticasone propionate aqueous nasal spray treatment for perennial allergic rhinitis in children. Ngamphaiboon J, et al. **Ann Allergy Asthma Immunol** 1997 May;78(5):479-84

Urinary N-methylhistamine in asthmatic children receiving azelastine hydrochloride. Takei S, et al. **Ann Allergy Asthma Immunol** 1997 May;78(5):492-6

Anti-inflammatory effect of suplatast tosilate on mild asthma [letter] Sano Y, et al. **Chest** 1997 Sep;112(3):862-3

Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Ciprandi G, et al. **Clin Exp Allergy** 1997 Feb;27(2):182-91

Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Zuberbier T, et al. **Dermatology** 1996; 193(4):324-7

Comparison of the efficacy of ebastine 10mg and 20mg once daily with that of cetirizine 10mg once daily in adults with seasonal allergic rhinitis. A multicentre double-blind study. Cohen B, et al. **Drugs** 1996;52 Suppl 1:26-9

Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Kalis B. **Drugs** 1996;52 Suppl 1:30-4

New directions in therapy for ocular allergy. el-Defrawy S, et al. **Int Ophthalmol Clin** 1996 Spring;36(2):25-44 (121 ref.)

The safety of astemizole in pregnancy. Pastuszak A, et al. **J Allergy Clin Immunol** 1996 Oct;98(4):748-50

Treatment of aquagenic urticaria with PUVA and astemizole. Martínez-Escribano JA, et al. **J Am Acad Dermatol** 1997 Jan;36(1):118-9

Treatment of hay fever. Pabian C, et al. **J Fam Pract** 1997 Sep;45(3):201

Effect of M-711 on experimental skin reactions induced by chemical mediators in rats. Shichinohe K, et al. **J Vet Med Sci** 1996 May;58(5):419-23

Effect of KW-4679, an orally active anti-allergic drug, on antigen-induced airway hyperresponsiveness in actively sensitized guinea pigs. Kawasaki H, et al. **Jpn J Pharmacol** 1996 Mar;70(3):277-80

Management of allergic conjunctivitis [letter; comment] Bartlett JD. **Ophthalmology** 1997 Mar;104(3):345-6. Comment on: Ophthalmology 1996 Sep;103(9):1335-6.

Fluticasone propionate aqueous nasal spray: a well-tolerated and effective treatment for children with perennial rhinitis. Richards DH, et al. **Pediatr Allergy Immunol** 1996 Feb; 7(1):35-43

Cetirizine: a new antihistamine with minimal sedation [editorial] Hendeles L. **Pharmacotherapy** 1996 Sep-Oct; 16(5):967-8

Clinical trials of Astemizol in children with cow's milk hypersensitivity. Cudowska B, et al. **Rocz Akad Med Bialymst** 1995;40(3):613-8

Ketotifen in the treatment of changes of the upper part of digestive tract in allergic children. Szczepanowska A, et al. **Rocz Akad Med Bialymst** 1995;40(3):607-12

Clinical effects of specific immunotheraphy in children with atopic dermatitis. Trofimowicz A, et al. **Rocz Akad Med Bialymst** 1995;40(2):414-22

Prophylaxis for anaphylactoid reactions in high risk patients receiving radiopaque contrast media. Robertson PS, et al. **Surg Neurol** 1997 Sep;48(3):292-3

[Clinical observation of treatment of tooth hypersensitiveness with silver ammonia fluoride and potassium nitrate

solution] Liu Y, et al.
Chung Hua Kou Chiang Hsueh Tsa Chih 1995 Nov; 30(6):352–4 (Eng. Abstr.) **(Chi)**
[An animal model for screening of antiallergic and antipruritic drugs] Xu JH, et al. **Yao Hsueh Hsueh Pao** 1996;31(6):420–4 (Eng. Abstr.) **(Chi)**
[International study of prevention. Use of loratadine in the management of children at risk for recurrent respiratory tract infections. Proceedings of a conference. London, 26–28 October 1995] **Allerg Immunol (Paris)** 1997 Mar; 29(3):69–82 **(Fre)**
[Strategy for preventing upper respiratory tract infections. Consensus of the Consulting Committee]
Allerg Immunol (Paris) 1997 Mar;29(3):80–2 (Eng. Abstr.) **(Fre)**
[Rhinoconjunctivitis. Highly selective therapy using topical H1-blockers] **HNO** 1996 Mar;44(3 Suppl):1–4 **(Ger)**
[New drugs in the treatment of respiratory allergic diseases] Gani F, et al. **Recenti Prog Med** 1997 Jul–Aug; 88(7–8):333–41 (38 ref.) (Eng. Abstr.) **(Ita)**
[Nedocromil sodium 1% nasal spray in the treatment of allergic rhinitis caused by Dermatophagoides pteronyssinus] Pacor ML, et al. **Recenti Prog Med** 1997 Jul–Aug;88(7–8):309–11 (Eng. Abstr.) **(Ita)**
[Classification of asthma according to etiology, pathophysiology, and treatment: effects of antiallergic drugs] Fujimura M.
Nippon Kyobu Shikkan Gakkai Zasshi 1995 Dec;33 Suppl:125–33 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Successful treatment of chronic eosinophilic pneumonia with suplatast tosilate] Kusumoto H, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1997 May; 35(5):550–4 (Eng. Abstr.) **(Jpn)**
[Fluticasone propionate—a new name common in asthma and rhinitis] Ulmeanu R, et al. **Pneumoftiziologia** 1997 Jan–Mar; 46(1):63–4 (8 ref.) **(Rum)**
[Anti-allergic agents] Red'kin IuV. **Eksp Klin Farmakol** 1996 Mar–Apr;59(2):62–8 **(Rus)**
[Airway hyperreactivity and respiratory allergy in children] **Rev Alerg Mex** 1996;43 Spec No:22–37 (73 ref.) **(Spa)**

ANTIANDROGENS see **ANDROGEN ANTAGONISTS**

ANTI-ANTIBODIES see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTI-ANXIETY AGENTS

see related
ADRENERGIC BETA-ANTAGONISTS

Noise stress and the development of benzodiazepine dependence in the rat. File SE, et al. **Anxiety** 1994;1(1):8–12
Concomitant use of anxiolytics and hypnotics with selective serotonin reuptake inhibitors. Gregor KJ, et al.
Clin Ther 1996 May–Jun;18(3):521–7; discussion 520
Management of the prescription-drug-dependent adult: case of meprobamate abuse and its treatment. Gonzales JJ, et al. **J Geriatr Psychiatry Neurol** 1996 Apr;9(2):91–6
[Biological study of anxiety and depression and the application for the pharmacological study] Yamamoto T, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):147–9 (6 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics. Sheehan DV, et al. **Anxiety** 1996;2(1):40–6
Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety. Sramek JJ, et al. **Clin Ther** 1997 May–Jun;19(3):498–506
Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. Van Ameringen M, et al. **J Affect Disord** 1996 Jul 8;39(2):115–21
Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study. Sramek JJ, et al. **J Clin Psychopharmacol** 1996 Dec; 16(6):454–8
Central and peripheral administration of atriopeptin is anxiolytic in rats. Ströhle A, et al. **Neuroendocrinology** 1997 Mar;65(3):210–5

ADVERSE EFFECTS

Coma from the health food store: interaction between kava and alprazolam [letter] Almeida JC, et al.
Ann Intern Med 1996 Dec 1;125(11):940–1
Fixed drug eruption of the penis due to hydroxyzine hydrochloride. Cohen HA, et al. **Ann Pharmacother** 1997 Mar;31(3):327–9
Fixed drug eruption of the scrotum due to hydroxyzine hydrochloride (Atarax). Cohen HA, et al. **Cutis** 1996 Jun; 57(6):431–2
Managing dementia-related behavior in the community. Mort JR, et al. **J Am Pharm Assoc (Wash)** 1996 Apr; NS36(4):249–56
Ritanserin facilitates anxiety in a simulated public-speaking paradigm. Guimarães FS, et al.
J Psychopharmacol (Oxf) 1997;11(3):225–31
The stock market is a source of information on the efficacy and side effects of drugs. Sénard JM.
Methods Find Exp Clin Pharmacol 1996;18 Suppl B:59–60

ANALYSIS

Measurement and pharmacokinetic analysis of buspirone by means of brain microdialysis coupled to high-performance liquid chromatography with electrochemical detection. Tsai TH, et al. **J Chromatogr A** 1997 Feb 21; 762(1–2):269–73

ANTAGONISTS & INHIBITORS

A nifedipine-induced inhibition of lithium clearance [letter] Pinkofsky HB, et al. **Psychosomatics** 1997 Jul–Aug; 38(4):400–1

BLOOD

Determination of the terfenadine metabolite azacyclonol in human serum using gas chromatography-mass spectrometry. Martens J. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):349–53
Simultaneous determination of nerisopam, a novel anxiolytic agent showing polymorphic metabolism, and its N-acetyl metabolite from human plasma by a validated high performance liquid chromatographic method. Rona K, et al. **J Chromatogr B Biomed Appl** 1996 Mar 29;678(1):63–72
Detection of alprazolam in three cases of methadone/benzodiazepine overdose. Rogers WO, et al. **J Forensic Sci** 1997 Jan;42(1):155–6
Labelling of haptenic drug with digoxigenin for competitive immunoassay: its application to lesopitron, a new anxiolytic agent. Adam A, et al. **J Pharm Biomed Anal** 1996 Oct; 15(1):13–9

CHEMICAL SYNTHESIS

Synthesis and anxiolytic activity of N-substituted cyclic imides N-[4-[(4-aryl)-1-piperazinyl]alkyl]-5,7-dioxabicyclo[2.2.2]octane-2, 3-dicarboximide.
Zawadowski T, et al. **Acta Pol Pharm** 1995 Jan–Feb; 52(1):43–6
Synthesis and pharmacological profile of bicyclo[2.2.2]octane derivatives: N-(1-aryl-4-piperazinyl-butyl) derivatives of 7-isopropyl-6-methyl- and 1-isopropyl-4-methylbicyclo[2.2.2]oct-5-ene-2,3-dicarboxyimide. Zawadowski T, et al. **Acta Pol Pharm** 1995 Mar–Apr;52(2):129–32
Synthesis of N,N'-bis-aminoalkyl-substituted derivatives of bicyclo[2.2.2]oct-7-ene-2,3,5,6-tetracarboxydiimide with potential anxiolytic activity. Turło J, et al. **Farmaco** 1996 Dec;51(12):815–8
Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. Monn JA, et al. **J Med Chem** 1997 Feb 14;40(4):528–37
Novel and selective partial agonists of 5-HT3 receptors. 2. Synthesis and biological evaluation of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines. Prunier H, et al.
J Med Chem 1997 Jun 6;40(12):1808–19

CHEMISTRY

Molecular basis of peripheral vs central benzodiazepine receptor selectivity in a new class of peripheral benzodiazepine receptor ligands related to alpidem. Anzini M, et al. **J Med Chem** 1996 Oct 11;39(21):4275–84
Synthesis and in vitro activity of 3 beta-substituted-3 alpha-hydroxypregnan-20-ones: allosteric modulators of the GABAA receptor. Hogenkamp DJ, et al.
J Med Chem 1997 Jan 3;40(1):61–72

ECONOMICS

Combination analgesics with meprobamate as constituent [letter] Truter I. **S Afr Med J** 1996 Aug;86(8):973

HISTORY

From "happiness pills" to "national nightmare": changing cultural assessment of minor tranquilizers in America, 1955–1980. Speaker SL. **J Hist Med Allied Sci** 1997 Jul; 52(3):338–76

IMMUNOLOGY

Production and characterization of polyclonal anti-S 20499 antibodies: influence of the hapten structure on stereospecificity. Got PA, et al. **J Pharm Sci** 1997 Jun; 86(6):654–9

ISOLATION & PURIFICATION

Pharmacologically active components of a Peruvian medicinal plant, huanarpo (Jatropha cilliata). Okuyama E, et al. **Chem Pharm Bull (Tokyo)** 1996 Feb;44(2):333–6

METABOLISM

3-amino-3,4-dihydro-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 2. Synthesis and quantitative structure-activity relationship studies of spiro[pyrrolidine- and piperidine-2,3'(2'H)-benzopyrans] Comoy C, et al.
J Med Chem 1996 Oct 11;39(21):4285–98
Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Briggs CA, et al. **Pharmacol Biochem Behav** 1997 May-Jun; 57(1–2):231–41

PHARMACOKINETICS

Absorption of the anxiolytic pazinaclone in animals as a criterion for species selection for toxicity studies. Kondo T, et al. **Arzneimittelforschung** 1996 Sep;46(9):839–43
Enantiomeric toxicokinetics of the new isoindoline anxiolytic pazinaclone in rats and dogs. Kondo T, et al.
Arzneimittelforschung 1996 Jan;46(1):11–14
Pharmacokinetics and toxicokinetics of an orally active tripeptide, IRI-695, in animals. Adusumalli V, et al.
Biopharm Drug Dispos 1996 Jan;17(1):25–41
Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Barel S, et al. **Clin Pharmacol Ther** 1997 Apr;61(4):442–9
Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. Huang HF, et al. **J Clin Pharmacol** 1996 Oct;36(10):963–9
Absorption, distribution and excretion of [14C]-Lesopitron after single and repeated administration in rats and dogs [published erratum appears in Methods Find Exp Clin Pharmacol 1997 Apr;19(3):212] Serafini MT, et al.
Methods Find Exp Clin Pharmacol 1997 Jan-Feb; 19(1):61–72
Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Andrée B, et al. **Psychopharmacology (Berl)** 1997 Jun; 131(4):339–45

PHARMACOLOGY

The pharmacology of (-)-nicotine and novel cholinergic channel modulators. Brioni JD, et al. **Adv Pharmacol** 1997; 37:153–214 (298 ref.)
Buspirone as an inhibitor of voluntary ethanol intake in male rats. Hedlund L, et al. **Alcohol Alcohol** 1996 Mar; 31(2):149–56
Effects of maternal ethanol consumption and buspirone treatment on dopamine and norepinephrine reuptake sites and D1 receptors in offspring. Gillespie RA, et al.
Alcohol Clin Exp Res 1997 May;21(3):452–9
Does estrogen facilitate social behavior by reducing anxiety? McCarthy MM, et al. **Ann N Y Acad Sci** 1997 Jan 15; 807:541–2
Primate displacement activities as an ethopharmacological model of anxiety. Schino G, et al. **Anxiety** 1996;2(4):186–91
The anxiolytic serotonin 5-HT1A receptor agonists buspirone, ipsapirone and gepirone are inhibitors of tyrosine hydroxylation in rat striatum. Johnson EA, et al.
Behav Brain Res 1996;73(1–2):331–5
Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models. Ballaz S, et al.
Br J Pharmacol 1997 Jun;121(4):759–67
In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Kennett GA, et al. **Br J Pharmacol** 1996 Feb; 117(3):427–434
R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Kuroki T, et al. **Brain Res** 1996 Dec 16;743(1–2):357–61
The neuroanatomical specificity of the anxiolytic effects of intra-septal infusions of midazolam. Pesold C, et al.
Brain Res 1996 Feb 26;710(1–2):161–8
Differential anxiolytic effects of neurosteroids in the mirrored chamber behavior test in mice. Reddy DS, et al.
Brain Res 1997 Mar 28;752(1–2):61–71
Synergism of 5-HT 1B/D antagonists with paroxetine on serotonin efflux in rat ventral lateral geniculate nucleus slices. Davidson C, et al. **Brain Res Bull** 1997;43(4):405–9
Comparison of lorazepam alone vs lorazepam, morphine, and perphenazine for cardiac premedication. Saccomanno PM, et al. **Can J Anaesth** 1997 Feb;44(2):146–53
A cholecystokinin-B receptor antagonist potentiates GABAergic and glycinergic inhibition in the nucleus of the solitary tract of the rat. McLean HA, et al.
Eur J Neurosci 1996 Jun;8(6):1078–84
The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors. Brot MD, et al. **Eur J Pharmacol** 1997 Apr 23;325(1):1–7
The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. Chojnacka-Wójcik E, et al. **Eur J Pharmacol** 1997 Jan 29; 319(2–3):153–6
Pretreatment with 5-HT1A receptor agonist flesinoxan attenuates Fos protein in rat hypothalamus. Compaan JC, et al. **Eur J Pharmacol** 1997 Apr 18;324(2–3):161–8
The anxiolytics CI-988 and chlordiazepoxide fail to reduce immediate early gene mRNA stimulation following exposure to the rat elevated X-maze. Hinks GL, et al.
Eur J Pharmacol 1996 Sep 26;312(2):153–61
5-HT1A receptor agonist effects of BMY-14802 on serotonin release in dorsal raphe and hippocampus. Matos FF, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):49–54
Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Teixeira RM, et al. **Eur J Pharmacol** 1996 Sep 5;311(1):7–14
Barakol, a natural anxiolytic, inhibits striatal dopamine release but off uptake in vitro. Thongsaard W, et al.

Eur J Pharmacol 1997 Jan 29;319(2-3):157-64

Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Wiley JL, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):101-7

Anxioselective properties of 6,3'-dinitroflavone, a high-affinity benzodiazepine receptor ligand. Wolfman C, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):23-30

Effect of repeated ipsapirone treatment on hippocampal excitatory synaptic transmission in the freely behaving rat: role of 5-HT1A receptors and relationship to anxiolytic effect. Xu L, et al. **Eur J Pharmacol** 1997 Mar 26; 323(1):59-68

Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats. Jenck F, et al. **Eur Neuropsychopharmacol** 1996 Nov;6(4):291-8

Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Rush CR, et al. **Exp Clin Psychopharmacol** 1997 Feb;5(1):28-38

Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events. Patchev VK, et al. **J Clin Invest** 1997 Mar 1;99(5):962-6

Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link. Stahl SM. **J Clin Psychiatry** 1997;58 Suppl 8:20-6 (64 ref.)

Screening 'white-coat' hypertension with an anxiolytic agent [letter; comment] de la Torre J. **J Hypertens** 1996 Aug; 14(8):1047. Comment on: J Hypertens 1995 Mar;13(3):373-4.

Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. Lin NH, et al. **J Med Chem** 1997 Jan 31; 40(3):385-90

TJS-010, a new prescription of oriental medicine, enhances 8-OH-DPAT-induced effects in rats. Kagaya A, et al. **J Neural Transm** 1996;103(1-2):69-75

Neurosteroid prolongs GABAA channel deactivation by altering kinetics of desensitized states. Zhu WJ, et al. **J Neurosci** 1997 Jun 1;17(11):4022-31

Selectivity in the generalization profile in baboons trained to discriminate lorazepam: benzodiazepines, barbiturates and other sedative/anxiolytics. Ator NA, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1442-57

Genetic differences in behavioral sensitivity to a neuroactive steroid. Finn DA, et al. **J Pharmacol Exp Ther** 1997 Feb; 280(2):820-8

Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats. Kleven MS, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):747-59

S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. Millan MJ, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):148-61

Partial agonism by 3alpha,21-dihydroxy-5beta-pregnan-20-one at the gamma-aminobutyric acidA receptor neurosteroid site. Xue BG, et al. **J Pharmacol Exp Ther** 1997 Jun; 281(3):1095-101

Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice. Da-Rocha MA Jr, et al. **J Psychopharmacol (Oxf)** 1997;11(3):211-8

Effects of buspirone on dopaminergic supersensitivity. Queiroz CM, et al. **Life Sci** 1997;61(4):371-82

Effects of theophylline in p-chlorophenylalanine-treated mice in a light/dark test. Imaizumi M, et al. **Methods Find Exp Clin Pharmacol** 1996 Oct;18(8):513-20

Animal behavioral models for testing antianxiety agents. Kulkarni SK, et al. **Methods Find Exp Clin Pharmacol** 1996 Apr;18(3):219-30 (72 ref.)

Anxiolytic effects of dotarizine, a possible antimigraine drug. Petkov VD, et al. **Methods Find Exp Clin Pharmacol** 1995 Dec;17(10):659-68

Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model. Roychoudhury M, et al. **Methods Find Exp Clin Pharmacol** 1997 Mar; 19(2):107-11

Gender differences in psychotropic medications. Lewis-Hall F. **Mt Sinai J Med** 1996 Oct-Nov;63(5-6):326-9 (36 ref.)

Experimental anxiety and antidepressant drugs: the effects of moclobemide, a selective reversible MAO-A inhibitor, fluoxetine and imipramine in mice. de Angelis L. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug-Sep; 354(3):379-83

(+/-)-1-(2,5-Dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2), a novel putative anxiolytic agent lacking affinity for benzodiazepine sites and serotonin-1A receptors. Reyes-Parada M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):579-85

Some doubts about the basic concept of hole-board test. Bilkei-Gorzó A, et al. **Neurobiology (Bp)** 1996;4(4):405-15

Neurosteroid modulation of the benzodiazepine receptor in developing chick optic lobe. Pignataro L, et al. **Neurochem Int** 1996 Oct;29(4):405-10

Effect of receptor blockers on brain natriuretic peptide and C-type natriuretic peptide caused anxiolytic state in rats. Bíró E, et al. **Neuropeptides** 1996 Feb;30(1):59-65

(+/-)-kavain inhibits the veratridine- and KCl-induced increase in intracellular Ca2+ and glutamate-release of rat cerebrocortical synaptosomes. Gleitz J, et al. **Neuropharmacology** 1996 Feb;35(2):179-86

Anxiolytic-like actions of the selective 5-HT4 receptor antagonists SB 204070A and SB 207266A in rats. Kennett GA, et al. **Neuropharmacology** 1997 Apr-May; 36(4-5):707-12

Chronic administration of antipanic drugs alters rat brainstem GABAA receptor subunit mRNA levels. Tanay VA, et al. **Neuropharmacology** 1996;35(9-10):1475-82

Electrophysiological actions of neuropeptide Y and its analogs: new measures for anxiolytic therapy? Ehlers CL, et al. **Neuropsychopharmacology** 1997 Jul;17(1):34-43

The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Patchev VK, et al. **Neuropsychopharmacology** 1996 Dec;15(6):533-40

PD-135158, a CCKB receptor antagonist, microinjected into the nucleus accumbens and the expression of conditioned rewarded behavior. Josselyn SA, et al. **Neurosci Lett** 1996 May 10;209(2):85-8

Interactions of Ginkgo biloba extract (EGb 761), diazepam and ethyl beta-carboline-3-carboxylate on social behavior of the rat. Chermat R, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):333-9

Multiple within-day conflict testing to define the time course of anxiolytic drug effects. Commissaris RL, et al. **Pharmacol Biochem Behav** 1996 Feb;53(2):369-77

Rewarding effect of the neuroactive steroid 3 alpha-hydroxy-5 alpha-pregnan-20-one in mice. Finn DA, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):261-4

Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Griebel G, et al. **Pharmacol Biochem Behav** 1997 Aug; 57(4):817-27

Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S 21,357. Griebel G, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):509-16

Anticonflict effect of alpidem as compared with the benzodiazepine alprazolam in rats. Hascoët M, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):317-24

Anxiolytic-like effect of combined extracts of Zingiber officinale and ginkgo biloba in the elevated plus-maze. Hasenöhrl RU, et al. **Pharmacol Biochem Behav** 1996 Feb; 53(2):271-5

Buspirone enhances immobility in the forced swim test in mice. Kitamura Y, et al. **Pharmacol Biochem Behav** 1996 Nov;55(3):445-51

Discriminative stimulus effects and antipunishment effects of drugs measured during the same session. McMillan DE, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):161-6

Behavioral effects of the putative anxiolytic (+/-)-1-(2,5-dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2) in rats and mice. Scorza MC, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):355-61

Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Stevens KE, et al. **Pharmacol Biochem Behav** 1997 Aug; 57(4):869-74

Barakol: a potential anxiolytic extracted from Cassia siamea. Thongsaard W, et al. **Pharmacol Biochem Behav** 1996 Mar; 53(3):753-8

Daily rhythms in spontaneous and diazepam-induced anxiolysis in Syrian hamsters. Yannielli PC, et al. **Pharmacol Biochem Behav** 1996 Aug;54(4):651-6

An anxiolytic action of oxytocin is enhanced by estrogen in the mouse. McCarthy MM, et al. **Physiol Behav** 1996 Nov;60(5):1209-15

Anxiolytic-like effects of metabotropic glutamate antagonist (RS)-alpha-methylserine-O-phosphate in rats. Chojnacka-Wójcik E, et al. **Pol J Pharmacol** 1996 Sep-Oct; 48(5):507-9

The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Hutchinson MA, et al. **Prog Neurobiol** 1996 May; 49(1):73-97 (146 ref.)

A nonbenzodiazepine partial agonist, S-(+)-DN-2327, has minimal physical dependence-producing liability, but shows cross-dependence on barbital in rats. Inui Y, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Oct; 20(7):1197-211

Anxiolytic activity of NPY receptor agonists in the conflict test. Britton KT, et al. **Psychopharmacology (Berl)** 1997 Jul; 132(1):6-13

Anxiolytic properties of endogenously occurring pregnanediols in two rodent models of anxiety. Carboni E, et al. **Psychopharmacology (Berl)** 1996 Jul;126(2):173-8

Increased levels of extracellular noradrenaline in the frontal cortex of rats exposed to naturalistic environmental stimuli: modulation by acute systemic administration of diazepam or buspirone. Dalley JW, et al. **Psychopharmacology (Berl)** 1996 Sep;127(1):47-54

Ethanol-like discriminative stimulus effects of the neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one in female Macaca fascicularis monkeys. Grant KA, et al. **Psychopharmacology (Berl)** 1996 Apr;124(4):340-6

Psychomotor effects of the anxiolytic abecarnil: a comparison with lorazepam. Hege SG, et al. **Psychopharmacology (Berl)** 1997 May;131(2):101-7

Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Molewijk HE, et al. **Psychopharmacology (Berl)** 1996 Nov;128(1):31-8

Effect of the neuroactive steroid alpha-THDOC on staircase test behavior in mice. Pick CG, et al. **Psychopharmacology (Berl)** 1996 Nov;128(1):61-6

Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418. Prendergast MA, et al. **Psychopharmacology (Berl)** 1997 Apr;130(3):276-84

The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Singh L, et al. **Psychopharmacology (Berl)** 1996 Sep;127(1):1-9

Anxiolytic-like effects of PNU-101017, a partial agonist at the benzodiazepine receptor. Tang AH, et al. **Psychopharmacology (Berl)** 1997 Jun;131(3):255-63

[Effects of co-administration of an antidepressant and an anxiolytic drug in the "learned helplessness" paradigm: importance of hydroxyzine] Martin P, et al. **Encephale** 1996 Jul-Aug;22(4):270-9 (Eng. Abstr.) **(Fre)**

[A new approach to innovating selective anxiolytics: pharmacological profile of a novel 5-HT1A agonist (tandospirone)] Sasa M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):53-9 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of the tranquilizer mebicar on lipid metabolism and lipid peroxidation in a rat hypokinesic model] Zamakova IE, et al. **Biull Eksp Biol Med** 1996 May;121(5):535-7 **(Rus)**

[Buspirone--a wide-spectrum preparation] Molodavkin GM, et al. **Eksp Klin Farmakol** 1997 Mar-Apr;60(2):3-6 (Eng. Abstr.) **(Rus)**

[Experimental bases of the use of pharmacologic agents aimed at higher heat resistance of humans as means of individual protection] Makarov VI, et al. **Med Tr Prom Ekol** 1997; (5):35-8 (Eng. Abstr.) **(Rus)**

POISONING

Detection of alprazolam in three cases of methadone/benzodiazepine overdose. Rogers WO, et al. **J Forensic Sci** 1997 Jan;42(1):155-6

THERAPEUTIC USE

Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder. Klein E, et al. **Acta Psychiatr Scand** 1995 Dec;92(6):399-408

Efficacy of buspirone in alcohol dependence: a review. Malec TS, et al. **Alcohol Clin Exp Res** 1996 Aug;20(5):853-8 (39 ref.)

Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Nair NP, et al. **Anxiety** 1996;2(4):192-8

Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder [letter] Sramek JJ, et al. **Anxiety** 1994-95;1(5):242-3

Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings. Sramek JJ, et al. **Anxiety** 1994-95;1(3):141-3

Personality dimensions in panic disorder before and after effective treatment. Starcevic V, et al. **Anxiety** 1996; 2(2):95-8

Treatment with buspirone in a patient with autism. McCormick LH. **Arch Fam Med** 1997 Jul-Aug;6(4):368-70

A management approach to anxiety. Lampe LA. **Aust Fam Physician** 1996 Oct;25(10):1561-3, 1566-7 (17 ref.)

Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic. Cowley DS, et al. **Biol Psychiatry** 1996 Sep 15;40(6):550-2

ABC of mental health. Psychotropic drug treatment. Pathare SR, et al. **BMJ** 1997 Sep 13;315(7109):661-4 (0 ref.)

Treatment of anxiety disorders in late life. Sadavoy J, et al. **Can J Psychiatry** 1997 Jun;42 Suppl 1:28S-34S (78 ref.)

Efficacy of buspirone in smoking cessation: a placebo-controlled trial. Schneider NG, et al. **Clin Pharmacol Ther** 1996 Nov;60(5):568-75

Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety. Sramek JJ, et al. **Clin Ther** 1997 May-Jun;19(3):498-506

A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Pecknold JC. **Drug Saf** 1997 Feb; 16(2):118-32 (241 ref.)

The therapeutic potential of neuropeptide Y. Analgesic, anxiolytic and antihypertensive. Munglani R, et al. **Drugs** 1996 Sep;52(3):371-89 (213 ref.)

Optimal management of anxiety in older patients. Weiss KJ. **Drugs Aging** 1996 Sep;9(3):191-201 (76 ref.)

A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Lundkvist J, et al. **Eur J Pharmacol** 1996 Aug 8;309(2):195-200

Panic attack syndrome [see comments] Prabhu SS, et al. **Indian Pediatr** 1996 May;33(5):409-11 (9 ref.). Comment in: Indian Pediatr 1996 Oct;33(10):869-70.

The use of buspirone with aggressive behavior [letter]

Hillbrand M, et al. **J Autism Dev Disord** 1995 Dec; 25(6):663–4

Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. Fairbanks JM, et al. **J Child Adolesc Psychopharmacol** 1997 Spring;7(1):17–29

Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. Steingard RJ, et al. **J Child Adolesc Psychopharmacol** 1997 Spring; 7(1):9–15

Clinical issues in the long-term treatment of panic disorder. Rosenbaum JF, et al. **J Clin Psychiatry** 1996;57 Suppl 10:44–8; discussion 49–50 (22 ref.)

Buspirone for the treatment of anxiety in patients with chronic obstructive airways disease [letter] Alderman CP, et al. **J Clin Psychopharmacol** 1996 Oct;16(5):410–1

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Blin O, et al. **J Clin Psychopharmacol** 1996 Feb; 16(1):38–44

Patient with progressive dementia and choreaothetoid movements treated with buspirone [letter] Hamner M, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):261–2

Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder. Pourmotabbed T, et al. **J Clin Psychopharmacol** 1996 Jun; 16(3):202–7

Zalospirone in major depression: a placebo-controlled multicenter study. Rickels K, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):212–7

Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. Rickels K, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):272–7

Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study. Sramek JJ, et al. **J Clin Psychopharmacol** 1996 Dec; 16(6):454–8

A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. van Vliet IM, et al. **J Clin Psychopharmacol** 1996 Aug;16(4):299–306

Description of antipanic therapy in a prospective longitudinal study. Yonkers KA, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):223–32 (59 ref.)

Recent developments in the pharmacotherapy of alcohol dependence. Schuckit MA. **J Consult Clin Psychol** 1996 Aug;64(4):669–76 (82 ref.)

Efficacy of a brief psychosocial treatment for panic disorder in an active duty sample: implications for military readiness. Schmidt NB, et al. **Mil Med** 1997 Feb;162(2):123–9

MCPP-induced anxiety--a potential new method for screening anxiolytic activity. Bilkei-Gorzó A, et al. **Neurobiology (Bp)** 1996;4(3):253–5

Single-subject experiments to determine individually differential effects of anxiolytics in generalized anxiety disorder. Wurthmann C, et al. **Neuropsychobiology** 1996; 33(4):196–201

Anxiety and depression. Diagnosis and treatment during pregnancy. Diket AL, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):535–58 (50 ref.)

Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. Volz HP, et al. **Pharmacopsychiatry** 1997 Jan;30(1):1–5

Improvement of hemichorea with ondansetron [letter] Erdinç OO, et al. **Postgrad Med J** 1997 Feb;73(856):127

A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal. Anton RF, et al. **Psychopharmacology (Berl)** 1997 May; 131(2):123–9

Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. van Vliet IM, et al. **Psychopharmacology (Berl)** 1996 Sep;127(2):174–80

A nifedipine-induced inhibition of lithium clearance [letter] Pinkofsky HB, et al. **Psychosomatics** 1997 Jul-Aug; 38(4):400–1

Aggressive lithium treatment for mania in a hemodialysis patient with end-stage renal disease [letter] Quentzel SJ, et al. **Psychosomatics** 1997 Jul-Aug;38(4):398–9

Study and course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone. Bouvard M, et al. **Psychother Psychosom** 1997;66(1):27–32

[Pharmacotherapy of panic disorder] Bougerol T, et al. **Encephale** 1996 Dec;22 Spec No 5:46–53 (53 ref.) (Eng. Abstr.) **(Fre)**

[Range of activity of anxiolytic and antidepressant drugs] Linkowski P. **Rev Med Brux** 1996 Sep;17(4):220–3 (Eng. Abstr.) **(Fre)**

[Anxiety and depression. Highlights from the 149th Session of the American Psychiatric Association, New York 4–9 May 1996] **Fortschr Neurol Psychiatr** 1997 Apr;65(4 Suppl Angst Und):1–4 **(Ger)**

[The 5-HT1A receptor: a new effective principle in psychopharmacologic therapy?] Davids E, et al. **Fortschr Neurol Psychiatr** 1996 Nov;64(11):460–72 (135 ref.) (Eng. Abstr.) **(Ger)**

[Panic disorder] Heinzl S. **Med Monatsschr Pharm** 1996 Mar; 19(3):79–80 (2 ref.) **(Ger)**

[Drug therapy of panic disorders. Kava-specific extract WS 1490 compared to benzodiazepines] **Nervenarzt** 1994 Jan; 65(1 Suppl):1–4 **(Ger)**

[Effects of buspirone on the development of an experimental depressive syndrome in rats, caused by systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)] Krupina NA, et al. **Biull Eksp Biol Med** 1996 May; 121(5):489–94 **(Rus)**

[The comparative effect of melatonin and diazepam on shifts in the anxiety-phobia status of rats evoked by damage to the amygdala] Arushanian EB, et al. **Eksp Klin Farmakol** 1997 Jan-Feb;60(1):7–9 (Eng. Abstr.) **(Rus)**

[The effect of calcium channel blockers on anxiety evoked by amputation of the vibrissae in rats] Kozlovskiĭ VL, et al. **Eksp Klin Farmakol** 1997 Jan-Feb;60(1):10–2 (Eng. Abstr.) **(Rus)**

TOXICITY

Enantiomeric toxicokinetics of the new isoindoline anxiolytic pazinaclone in rats and dogs. Kondo T, et al. **Arzneimittelforschung** 1996 Jan;46(1):11–14

Pharmacokinetics and toxicokinetics of an orally active tripeptide, IRI-695, in animals. Adusumalli V, et al. **Biopharm Drug Dispos** 1996 Jan;17(1):25–41

Effect of glycine on antidepressant- and anxiolytic-like action of 1-aminocyclopropanecarboxylic acid (ACPC) in rats. Chojnacka-Wójcik E, et al. **Pol J Pharmacol** 1996 Nov-Dec;48(6):627–9

Effects found in a one-year oral toxicity study in Sprague-Dawley rats of a novel 5-HT1A receptor partial agonist for the treatment of anxiety in humans. Zwicker GM, et al. **Toxicol Pathol** 1996 Mar-Apr;24(2):207–13

[The anxiolytic effect of the new 2-mercaptobenzimidazole derivative in MR and MNRA rats] Seredinin SB, et al. **Eksp Klin Farmakol** 1997 May-Jun;60(3):3–5 (Eng. Abstr.) **(Rus)**

ANTI-ANXIETY AGENTS, BENZODIAZEPINE

Flunitrazepam and its involvement in date or acquaintance rape. Anglin D, et al. **Acad Emerg Med** 1997 Apr;4(4):323–6

Alcohol consumption and regular benzodiazepine use in 55-year-old female Malmö residents: results of a health screening. Osterling A, et al. **Acta Psychiatr Scand** 1996 Sep;94(3):141–8

Benzodiazepine types in high versus therapeutic dose dependence. Martinez-Cano H, et al. **Addiction** 1996 Aug; 91(8):1179–86

Combining analgesia with sedation on the unit. Pasero CL. **Am J Nurs** 1996 Nov;96(11):17–9

A method to produce sedation in critically ill patients [see comments] Watling SM, et al. **Ann Pharmacother** 1996 Nov; 30(11):1227–31. Comment in: Ann Pharmacother 1997 May;31(5):647–8.

Noise stress and the development of benzodiazepine dependence in the rat. File SE, et al. **Anxiety** 1994;1(1):8–12

The role of coping strategies in protecting individuals against long-term tranquillizer use. Bish A, et al. **Br J Med Psychol** 1996 Jun;69 (Pt 2):101–15

The benzodiazepine dependence questionnaire: development, reliability and validity. Baillie AJ, et al. **Br J Psychiatry** 1996 Sep;169(3):276–81

An epidemiological survey on use and abuse of antianxiety drugs among Beijing residents. Jiang Z, et al. **Chin Med J (Engl)** 1996 Oct;109(10):801–6

Antagonism of AND and AND-OR drug mixture discriminations in rats. Mariathasan EA, et al. **Drug Alcohol Depend** 1997 Jan 10;44(1):31–4

Conscious sedation for endoscopy. McCloy R, et al. **Eur J Gastroenterol Hepatol** 1996 Dec;8(12):1233–40

Estazolam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:105–14 (26 ref.)

Oxazepam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:115–42 (102 ref.)

Prazepam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:143–55 (44 ref.)

Temazepam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:161–73 (53 ref.)

Diazepam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:37–96 (255 ref.)

Doxefazepam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:97–104 (12 ref.)

Multiple drug use and psychiatric comorbidity in patients admitted to the hospital with severe benzodiazepine dependence. Busto UE, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):51–7

Abuse liability of flunitrazepam. Woods JH, et al. **J Clin Psychopharmacol** 1997 Jun;17(3 Suppl 2):1S–57S (232 ref.)

Abuse of flunitrazepam (Rohypnol) and other benzodiazepines in Austin and south Texas. Calhoun SR, et al. **J Psychoactive Drugs** 1996 Apr-Jun;28(2):183–9

An acutely painful leg. Wedderburn A, et al. **Postgrad Med J** 1997 Jun;73(860):359–60

Rohypnol misuse in the United States. Saum CA, et al. **Subst Use Misuse** 1997 May;32(6):723–31

[Benzodiazepines and falls in the elderly] Shats V, et al. **Harefuah** 1996 Oct;131(7–8):279–82 **(Heb)**

[Clinical dose dependence of anti-anxiety agents] Murasaki M. **Seishin Shinkeigaku Zasshi** 1996;98(9):612–21 (38 ref.) **(Jpn)**

[Make flunitrazepam an A-preparation (letter)] Buer OA. **Tidsskr Nor Laegeforen** 1997 Jan 20;117(2):263 **(Nor)**

[Rohypnol, drug addicts and family physicians (letter; comment)] Vázquez Torguet A, et al. **Aten Primaria** 1997 Jun 15;20(1):57–8. Comment on: Aten Primaria 1996 Dec;18(10):539–45. **(Spa)**

ADMINISTRATION & DOSAGE

Transitions between routes of benzodiazepine administration among heroin users in Sydney. Ross J, et al. **Addiction** 1997 Jun;92(6):697–705

Assessment of diazepam loading dose therapy of delirium tremens. Wasilewski D, et al. **Alcohol Alcohol** 1996 May; 31(3):273–8

Patient Stage of Change predicts outcome in a panic disorder medication trial. Beitman BD, et al. **Anxiety** 1994;1(2):64–9

Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients. Pols H, et al. **Biol Psychiatry** 1996 Nov 1;40(9):913–7

Prediction of the therapeutic dose for benzodiazepine anxiolytics based on receptor occupancy theory. Ito K, et al. **Biopharm Drug Dispos** 1997 May;18(4):293–303 (37 ref.)

Nasal rather than rectal benzodiazepines in the management of acute childhood seizures? [see comments] O'Regan ME, et al. **Dev Med Child Neurol** 1996 Nov;38(11):1037–45. Comment in: Dev Med Child Neurol 1997 Feb;39(2):137–8.

Benzodiazepine consumption in Spain [letter] Rayón P, et al. **Eur J Clin Pharmacol** 1997;52(4):321–3

Oral low-dose midazolam as premedication for intraocular surgery in retrobulbar anesthesia: cardiovascular effects and relief of perioperative anxiety. Kiefer RT, et al. **Eur J Ophthalmol** 1997 Apr-Jun;7(2):185–92

Preparation and properties of a stable intravenous lorazepam emulsion. Yalin M, et al. **J Clin Pharm Ther** 1997 Feb; 22(1):39–44

The treatment of panic disorder in a clinical setting: a 12-month naturalistic study. Marchesi C, et al. **Neuropsychobiology** 1997;36(1):25–31

Multidrug intravenous sedation: determinants of the sedative dose of midazolam. Moore PA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):5–10

Effects of midazolam on pain sensations in the face. Nakanishi O, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):11–5

Oral midazolam compared with diazepam-droperidol and trimeprazine as premedicants in children. Patel D, et al. **Paediatr Anaesth** 1997;7(4):287–93

A comparison of two oral ketamine-diazepam regimens for sedating anxious pediatric dental patients. Reinemer HC, et al. **Pediatr Dent** 1996 Jul-Aug;18(4):294–300

A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Chamberlain JM, et al. **Pediatr Emerg Care** 1997 Apr;13(2):92–4

Pharmacokinetic aspects of rectal formulations of temazepam. Hanff LM, et al. **Pharm World Sci** 1996 Jun;18(3):114–9

[Premedication with midazolam in adults with special reference to anxiety treatment] Röse VW. **Anaesthesiol Reanim** 1996;21(1):14–23 (Eng. Abstr.) **(Ger)**

[The use of low dose midazolam for the management of spinal anesthesia] Nagahama H, et al. **Masui** 1997 Jun;46(6):803–8 (Eng. Abstr.) **(Jpn)**

[The efficiency of alprazolam for seasonal affective disorder (SAD, autumn/winter type)] Yamadera H, et al. **Nippon Ika Daigaku Zasshi** 1997 Feb;64(1):53–6 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Effect of pharmacotherapy on serum cholesterol levels in patients with panic disorder. Shioiri T, et al. **Acta Psychiatr Scand** 1996 Mar;93(3):164–7

New evidence on benzodiazepine use and falls: the time factor. Neutel CI, et al. **Age Ageing** 1996 Jul;25(4):273–8

Dysphagia induced by chronic ingestion of benzodiazepine. Dantas RO, et al. **Am J Gastroenterol** 1997 Jul;92(7):1194–6

Treatment of a paradoxical reaction to midazolam with haloperidol. Khan LC, et al. **Anesth Analg** 1997 Jul; 85(1):213–5

Does midazolam cause retrograde amnesia, and can flumazenil reverse that amnesia? Koht A, et al. **Anesth Analg** 1997 Jul;85(1):211–2

Coma from the health food store: interaction between kava and alprazolam [letter] Almeida JC, et al. **Ann Intern Med** 1996 Dec 1;125(11):940–1

Medications and fractures [letter; comment] Byrne A. **Aust Fam Physician** 1997 Apr;26(4):475. Comment on: Aust Fam Physician 1997 Feb;26(2):115–21.

Acutely shifting the sleep-wake cycle: nighttime sleepiness after diurnal administration of temazepam or placebo. Porcù S, et al. **Aviat Space Environ Med** 1997 Aug; 68(8):688–94

Photo-induced toxic epidermal necrolysis caused by clobazam. Redondo P, et al. **Br J Dermatol** 1996 Dec; 135(6):999–1002

Benzodiazepine use by students: risky business [letter] McSherry J. **Can Fam Physician** 1996 Feb;42:234, 236

Withdrawal strategies for outpatients. Alcohol, benzodiazepine, barbiturate, and opiate addictions.

Mezciems PE. **Can Fam Physician** 1996 Sep;42:1745–52 (27 ref.)

Very long sleep after one dose of clorazepate [letter] Calenda E, et al. **Eur J Anaesthesiol** 1997 Jul;14(4):477–8

Cardiovascular and metabolic responses to clonidine and midazolam premedication. Taittonen M, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):190–6

Increased risk of ischaemic heart disease mortality in elderly men using anxiolytics–hypnotics and analgesics. Results of the 10–year follow–up of the prospective population study "Men born in 1914", Malmo, Sweden. Merlo J, et al. **Eur J Clin Pharmacol** 1996;49(4):261–5

Carbamazepine normalizes the altered behavioral and neurochemical response to stress in benzodiazepine–withdrawn rats. Martijena ID, et al. **Eur J Pharmacol** 1997 Jul 9;330(2–3):101–8

Intravenous flumazenil following prolonged exposure to lormetazepam in humans: lack of precipitated withdrawal. Gerra G, et al. **Int Clin Psychopharmacol** 1996 Jun; 11(2):81–8

Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients. Ramaekers JG, et al. **Int Clin Psychopharmacol** 1997 May; 12(3):159–69

Two cases of alprazolam–induced hyperprolactinemia in patients with panic disorder. Shioiri T, et al. **Int Clin Psychopharmacol** 1996 Jun;11(2):149–52

Catatonia after benzodiazepine withdrawal. Rosebush PI, et al. **J Clin Psychopharmacol** 1996 Aug;16(4):315–9

Visual hallucinations [letter; comment] Ashton H. **J R Coll Physicians Lond** 1997 Mar–Apr;31(2):221–2. Comment on: J R Coll Physicians Lond 1997 Jan–Feb;31(1):42–8.

Use of benzodiazepines in elderly patients [letter; comment] Maletta GJ. **Mayo Clin Proc** 1996 Nov;71(11):1124. Comment on: Mayo Clin Proc 1995 Jul;70(7):685–93.

Progesterone modulation of diazepam withdrawal syndrome in mice. Pesce ME, et al. **Pharmacol Toxicol** 1996 Dec; 79(6):331–3

Hallucinations after a therapeutic dose of benzodiazepine hypnotics with co–administration of erythromycin. Tokinaga N, et al. **Psychiatry Clin Neurosci** 1996 Dec; 50(6):337–9

Lorazepam impairs perceptual integration of visual forms: a central effect. Giersch A, et al. **Psychopharmacology (Berl)** 1996 Aug;126(3):260–70

Changes in "withdrawal symptoms" following discontinuation of low–dose diazepam. Hayward P, et al. **Psychopharmacology (Berl)** 1996 Jun;125(4):392–7

Catatonia associated with lorazepam withdrawal. Glover SG, et al. **Psychosomatics** 1997 Mar–Apr;38(2):148–50

Protracted benzodiazepine withdrawal syndrome mimicking psychotic depression [letter] Modell JG. **Psychosomatics** 1997 Mar–Apr;38(2):160–1

Galactorrhoea induced by a pharmacodynamic interaction between citalopram, alprazolam and tramadol: a case report [letter] Bondolfi G, et al. **Therapie** 1997 Jan–Feb;52(1):76–7

[Hypertestosteronemia after treatment with benzodiazepines (letter)] Duquenne M, et al. **Presse Med** 1997 Mar 8; 26(7):321 **(Fre)**

[Benzodiazepines in geriatrics--a case report on prolonged action] Dressler C, et al. **Anaesthesiol Reanim** 1996; 21(5):136–8 (Eng. Abstr.) **(Ger)**

[Benzodiazepine withdrawal with carbamazepine] Kaendler SH, et al. **Nervenarzt** 1996 May;67(5):381–6 (Eng. Abstr.) **(Ger)**

[Complications after benzodiazepine dependence] Künstler U. **Psychiatr Prax** 1996 Sep;23(5):248 **(Ger)**

[Benzodiazepine withdrawal syndrome in low dose dependency] Thomas H, et al. **Psychiatr Prax** 1996 Sep; 23(5):249–50 **(Ger)**

[Benzodiazepine administration increases accidental fall–induced femoral fractures!] Klipstein A. **Schweiz Rundsch Med Prax** 1997 Jul 2;86(27–28):1120–1 **(Ger)**

[Effect of withdrawal of phenazepam and nicotinamide on the status of the system of reception of benzodiazepines and NAD] Fomenko AI, et al. **Ukr Biokhim Zh** 1996 Sep–Oct;68(5):20–5 (Eng. Abstr.) **(Rus)**

ANALYSIS

Determination of chronic flunitrazepam abuse by hair analysis using GC–MS–NCI. Cirimele V, et al. **J Anal Toxicol** 1996 Nov–Dec;20(7):596–8

Sensitive determination of bromazepam in human tissues using capillary gas chromatography–mass spectrometry. Zhang XX, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23;677(1):111–6

[The analysis of grandaksin in cadaveric material] Bodrina DE, et al. **Sud Med Ekspert** 1996 Oct–Dec;39(4):45–7 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Evaluation of sedation in quail induced by use of midazolam and reversed by use of flumazenil [see comments] Day TK, et al. **J Am Vet Med Assoc** 1996 Sep 1;209(5):969–71. Comment in: J Am Vet Med Assoc 1996 Dec 15;209(12):1992–3.

Discriminative stimulus effects of flumazenil in rhesus monkeys treated chronically with chlordiazepoxide. France CP, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):447–55

Naloxone blocks anxiolytic–like effects of benzodiazepines in Swiss but not in Balb/c mice. Belzung C, et al. **Psychopharmacology (Berl)** 1997 Jul;132(2):195–201

BLOOD

Determination of benzodiazepin–1,4 derivatives in biological material. Part I. An attempt to apply high–performance liquid chromatography (HPLC) in the determination of diazepam and nitrazepam in human serum. Welk B. **Acta Pol Pharm** 1996 Jan–Feb;53(1):3–6

The effect of ondansetron on the pharmacokinetics and pharmacodynamics of temazepam. Preston GC, et al. **Anaesthesia** 1996 Sep;51(9):827–30

High–performance liquid chromatography of alprazolam in postmortem blood using solid–phase extraction. Hall MA, et al. **J Anal Toxicol** 1995 Oct;19(6):511–3

Simultaneous high–performance liquid chromatographic analysis of flunitrazepam and four metabolites in serum. Berthault F, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25;685(2):383–7

Determination of midazolam and its metabolites in serum microsamples by high–performance liquid chromatography and its application to pharmacokinetics in rats. Ma F, et al. **J Chromatogr B Biomed Appl** 1996 Jun 28;682(1):109–13

Simultaneous determination of twelve benzodiazepines in human serum using a new reversed–phase chromatographic column on a 2–microns porous microspherical silica gel. Tanaka E, et al. **J Chromatogr B Biomed Appl** 1996 Jun 28;682(1):173–8

Determination of alprazolam and alpha–hydroxyalprazolam in human plasma by gas chromatography/negative–ion chemical ionization mass spectrometry. Höld KM, et al. **J Mass Spectrom** 1996 Sep;31(9):1033–8

Gas chromatographic assay for estazolam in human plasma and results of a bioequivalence study. Dal Bo L, et al. **Pharmacol Res** 1997 Apr;35(4):329–33

Analysis of clobazam and its active metabolite norclobazam in plasma and serum using HPLC/DAD. Akerman KK. **Scand J Clin Lab Invest** 1996 Nov;56(7):609–14

[RP–HPLC retention characteristics of benzodiazepines during ion–pair chromatography] Kastner P, et al. **Ceska Slov Farm** 1997 Apr;46(2):84–7 (Eng. Abstr.) **(Cze)**

CHEMISTRY

More on usability of lorazepam admixtures for continuous infusion [letter; comment] Boullata JI, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2754–5. Comment on: Am J Health Syst Pharm 1996 Aug 1;53(15):1850.

Precipitation of lorazepam during infusion by volumetric pump [letter] [see comments] Grillo JA, et al. **Am J Health Syst Pharm** 1996 Aug 1;53(15):1850. Comment in: Am J Health Syst Pharm 1996 Nov 15;53(22):2754–5.

Stability of midazolam hydrochloride in syringes and i.v. fluids. Pramar YV, et al. **Am J Health Syst Pharm** 1997 Apr 15;54(8):913–5

More on usability of lorazepam admixtures for continuous infusion [letter] Volles DF. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2753–4

Precipitation of lorazepam infusion [letter] Boullata JI, et al. **Ann Pharmacother** 1996 Sep;30(9):1037–8

Highly stereoselective acid–catalyzed homonucleophilic substitution reactions. Yang SK. **Chirality** 1996;8(7):525–30

Stereoselective nucleophilic substitution of oxazepam and racemization in acidic methanol and ethanol. Yang SK, et al. **Chirality** 1996;8(2):214–23

Physical stability of solid dispersions containing triamterene or temazepam in polyethylene glycols. Dordunoo SK, et al. **J Pharm Pharmacol** 1997 Apr;49(4):390–6

DIAGNOSTIC USE

New diagnostic tests for Cushing's syndrome: uses of naloxone, vasopressin and alprazolam. Jackson RV, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul;23(6–7):579–81

Chlordiazepoxide discriminates between the neural circuits mediating neuroendocrine responses to fear– and anxiety–producing stimuli in the rat. Yagi K, et al. **Neurosci Res** 1996 Jan;24(2):151–8

ISOLATION & PURIFICATION

Highly stereoselective acid–catalyzed homonucleophilic substitution reactions. Yang SK. **Chirality** 1996;8(7):525–30

Supercritical fluid extraction of selected pharmaceuticals from water and serum. Simmons BR, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):291–302

METABOLISM

Alprazolam hydroxylation by mouse liver microsomes in vitro: the effect of age and phenobarbital induction. Charpentier KP, et al. **Biopharm Drug Dispos** 1997 Mar; 18(2):139–49

Prediction of the therapeutic dose for benzodiazepine anxiolytics based on receptor occupancy theory. Ito K, et al. **Biopharm Drug Dispos** 1997 May;18(4):293–303 (37 ref.)

Diazepam–omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. Zomorodi K, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):157–62

Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna–expressed human cytochrome P450. Ghosal A, et al. **Drug Metab Dispos** 1996 Sep;24(9):940–7

Diazepam metabolism by cDNA–expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N–demethylases. Jung F, et al. **Drug Metab Dispos** 1997 Feb;25(2):133–9

N3–phenacyluridine, a novel hypnotic compound, interacts with the benzodiazepine receptor. Kimura T, et al. **Eur J Pharmacol** 1996 Sep 12;311(2–3):265–9

Simultaneous high–performance liquid chromatographic analysis of flunitrazepam and four metabolites in serum. Berthault F, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25;685(2):383–7

Determination of midazolam and its metabolites in serum microsamples by high–performance liquid chromatography and its application to pharmacokinetics in rats. Ma F, et al. **J Chromatogr B Biomed Appl** 1996 Jun 28;682(1):109–13

Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. von Moltke LL, et al. **J Clin Pharmacol** 1996 Sep;36(9):783–91

Acid–catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions. Yang SK. **J Pharm Sci** 1994 Jun;83(6):898–902

Concentration–dependent metabolism of diazepam in mouse liver. St–Pierre MV, et al. **J Pharmacokinet Biopharm** 1995 Jun;23(3):243–66

PHARMACOKINETICS

Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Gugler R, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):249–52

Disposition of diazepam in young and elderly subjects after acute and chronic dosing. Herman RJ, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):147–55

Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Gardner MJ, et al. **Clin Pharmacokinet** 1997;32 Suppl 1:43–9

Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Ahonen J, et al. **Eur J Clin Pharmacol** 1997;51(5):415–9

The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Ahonen J, et al. **Fundam Clin Pharmacol** 1996;10(3):314–8

Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. Otani K, et al. **Int Clin Psychopharmacol** 1997 May;12(3):153–7

Interaction between midazolam and clarithromycin: comparison with azithromycin. Yeates RA, et al. **Int J Clin Pharmacol Ther** 1996 Sep;34(9):400–5

High–performance liquid chromatographic determination of midazolam in rat brain. Jiang Q, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30;683(2):276–80

Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. Ciraulo DA, et al. **J Clin Pharmacol** 1997 Jan;37(1):64–73

Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. Samara EE, et al. **J Clin Pharmacol** 1997 May;37(5):442–50

Pharmacokinetics and psychomotor performance of alprazolam: concentration–effect relationship. Wright CE, et al. **J Clin Pharmacol** 1997 Apr;37(4):321–9

Can you provide a table of equivalences for benzodiazepines and other marketed benzodiazepine receptor agonists? Shader RI, et al. **J Clin Psychopharmacol** 1997 Aug; 17(4):331

Pharmacokinetics of midazolam in Vietnamese subjects. Balson KR, et al. **J Gastroenterol Hepatol** 1996 Dec; 11(12):1177–80

Concentration–dependent metabolism of diazepam in mouse liver. St–Pierre MV, et al. **J Pharmacokinet Biopharm** 1995 Jun;23(3):243–66

Use of benzodiazepines in elderly patients [letter; comment] Maletta GJ. **Mayo Clin Proc** 1996 Nov;71(11):1124. Comment on: Mayo Clin Proc 1995 Jul;70(7):685–93.

Effects of genetically determined S–mephenytoin 4–hydroxylation status and cigarette smoking on the single–dose pharmacokinetics of oral alprazolam. Otani K, et al. **Neuropsychopharmacology** 1997 Jan;16(1):8–14

Pharmacokinetic aspects of rectal formulations of temazepam. Hanff LM, et al. **Pharm World Sci** 1996 Jun;18(3):114–9

A pilot pharmacokinetic–pharmacodynamic study of benzodiazepine antagonism by flumazenil and aminophylline. Bonfiglio MF, et al. **Pharmacotherapy** 1996 Nov–Dec;16(6):1166–72

Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food–limited regimen: relating DRL performance to pharmacokinetics. Lau CE, et al. **Psychopharmacology (Berl)** 1996 Aug;126(3):241–8

Human liver microsomal diazepam metabolism using cDNA–expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Ono S, et al. **Xenobiotica** 1996 Nov;26(11):1155–66

[The relationship between single–oral dose kinetics of alprazolam and cytochrome P4503A and cytochrome P4502C19] Yasui N. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun;

16(3):109–12 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Dexmedetomidine, diazepam, and propranolol in the treatment of ethanol withdrawal symptoms in the rat. Riihioja P, et al. **Alcohol Clin Exp Res** 1997 Aug; 21(5):804–8

Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Roy-Byrne P, et al. **Am J Psychiatry** 1996 Nov; 153(11):1444–9

Potential morphine sparing effect of midazolam [letter] Mirakhur RK. **Anaesthesia** 1997 Aug;52(8):803–4

Interaction of midazolam with the nicotinic acetylcholine receptor of mouse myotubes. Hertle I, et al. **Anesth Analg** 1997 Jul;85(1):174–81

The direct effects of diazepam and midazolam on myocardial depression in cultured rat ventricular myocytes. Nakae Y, et al. **Anesth Analg** 1997 Oct;85(4):729–33

Alteration of the cardiac effects of midazolam by hypothermia in rat isolated atria. Melnikov AL, et al. **Arch Int Pharmacodyn Ther** 1996 May–Jun;331(3):263–72

Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light/dark and dark/light tests. Chaouloff F, et al. **Behav Brain Res** 1997 Apr;85(1):27–35

The effects of extended training and acute administration of an anxiolytic on avoidance learning and intertrial responding in the Syracuse strains of rats. Gendron CM, et al. **Behav Genet** 1996 Nov;26(6):575–80

I.m. midazolam as premedication produces a concentration-dependent decrease in core temperature in male volunteers. Matsukawa T, et al. **Br J Anaesth** 1997 Apr;78(4):396–9

Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. Rammes G, et al. **Br J Pharmacol** 1996 Mar;117(6):1209–21

Bicuculline administered into the amygdala after training blocks benzodiazepine-induced amnesia. Dickinson-Anson H, et al. **Brain Res** 1997 Mar 28;752(1–2):197–202

Chlordiazepoxide improves the performance of septal lesioned but not hippocampal lesioned animals in a Morris maze. Farber HT. **Brain Res** 1996 Jul 1;725(2):257–62

Brainstem mediates diazepam enhancement of palatability and feeding: microinjections into fourth ventricle versus lateral ventricle. Peciña S, et al. **Brain Res** 1996 Jul 15; 727(1–2):22–30

Pupillometric assessment of compensatory effort in a memory search task under physical and pharmacologically-induced suboptimal states. Deijen JB, et al. **Can J Exp Psychol** 1995 Sep;49(3):387–96

Effects of benzodiazepines on potassium-induced increase in free cytosolic calcium concentration in astrocytes: interactions with nifedipine and the peripheral-type benzodiazepine antagonist PK 11195. Zhao Z, et al. **Can J Physiol Pharmacol** 1996 Mar;74(3):273–7

The effects of midazolam and ephedrine on post-exercise autonomic chronotropic control of the heart in normal subjects. Lindqvist A, et al. **Clin Auton Res** 1996 Dec; 6(6):343–9

Significant inhibition of spontaneous IgA secretion by selective peripheral-type benzodiazepine receptor ligands. Bessler H, et al. **Clin Neuropharmacol** 1997 Jun;20(3):215–23

Effects of acute daily administration of diazepam on spatial learning and working memory. Nakamura-Palacios EM, et al. **Drug Alcohol Depend** 1997 Jul 4;46(3):181–90

Mechanism of the negative inotropic effect of midazolam and diazepam in cultured foetal mouse cardiac myocytes. Nonaka A, et al. **Eur J Anaesthesiol** 1997 Sep;14(5):481–7

Moxonidine and cognitive function: interactions with moclobemide and lorazepam. Wesnes K, et al. **Eur J Clin Pharmacol** 1997;52(5):351–8

Naloxone potentiates the effects of subeffective doses of anxiolytic agents in mice. Belzung C, et al. **Eur J Pharmacol** 1997 Apr 4;323(2–3):133–6

Time course of discriminative stimulus effects of bretazenil and chlordiazepoxide in rats. Bronson M, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):7–12

Effect of alprazolam on opiate withdrawal: a combined behavioural and microdialysis study. Gray AM. **Eur J Pharmacol** 1996 Oct 10;313(1–2):73–7

Effects of chronic diazepam treatment on pre- and postsynaptic 5-HT1A receptors in the rat brain. Lanfumey L, et al. **Eur J Pharmacol** 1997 Apr 4;323(2–3):137–48

PK 11195 antagonizes the positive inotropic response of the isolated rat heart to diazepam but not the negative inotropic response. Leeuwin RS, et al. **Eur J Pharmacol** 1996 Mar 28;299(1–3):149–52

Conditional control by midazolam and amphetamine in a rapid appetitive discrimination procedure. Maes JH, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):5–11

Anxiolytic homophthalazines increase Fos-like immunoreactivity in selected brain areas of the rat. Palkovits M, et al. **Eur J Pharmacol** 1997 Jul 16; 331(1):53–63

Involvement of the opioid system in the anxiolytic effect of diazepam in mice. Tsuda M, et al. **Eur J Pharmacol** 1996 Jun 20;307(1):7–14

Hormonal modulation of benzodiazepines' actions on rat isolated uterus. Yiu MK, et al. **Eur J Pharmacol** 1996 Apr 29;302(1–3):99–108

Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjects. Hajak G, et al. **Eur Neuropsychopharmacol** 1996 May;6(2):149–53

Chlordiazepoxide counteracts activity-induced suppression of eating in rats. Lett BT, et al. **Exp Clin Psychopharmacol** 1997 Feb;5(1):24–7

Effects of lorazepam on the distribution of spatial attention. Post RB, et al. **Exp Clin Psychopharmacol** 1997 May; 5(2):143–9

Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Rush CR, et al. **Exp Clin Psychopharmacol** 1997 Feb;5(1):28–38

Punishment alters the discriminative stimulus effects of midazolam. Tatham TA, et al. **Exp Clin Psychopharmacol** 1997 Aug;5(3):171–82

Effect of a single dose of diazepam on balance measures in older people. Cutson TM, et al. **J Am Geriatr Soc** 1997 Apr;45(4):435–40

Evaluation of sedation in quail induced by use of midazolam and reversed by use of flumazenil [see comments] Day TK, et al. **J Am Vet Med Assoc** 1996 Sep 1;209(5):969–71. Comment in: J Am Vet Med Assoc 1996 Dec 15;209(12):1992–3.

Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. Samara EE, et al. **J Clin Pharmacol** 1997 May;37(5):442–50

A novel tool to quantify physical activities: ambulatory accelerometry in psychopharmacology. Tulen JH, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):202–7

Lorazepam reduces cardiac vagal modulation in normal subjects. Vogel LR, et al. **J Clin Psychopharmacol** 1996 Dec;16(6):449–53

Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. Barrington SF, et al. **J Nucl Med** 1996 Jul; 37(7):1127–9

Reproducibility of regional brain metabolic responses to lorazepam. Wang GJ, et al. **J Nucl Med** 1996 Oct; 37(10):1609–13

Selectivity in the generalization profile in baboons trained to discriminate lorazepam: benzodiazepines, barbiturates and other sedative/anxiolytics. Ator NA, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1442–57

Tolerance to the anxiolytic effects of the triazolobenzodiazepines triazolam and alprazolam, as measured by the ingestion of a hypertonic sodium chloride solution in rats. Barbarito EJ, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1201–8

Alertness and memory after sleep deprivation and diazepam intake. Gorissen M, et al. **J Psychopharmacol (Oxf)** 1997; 11(3):233–9

Early diazepam treatment following unilateral labyrinthectomy does not impair vestibular compensation of spontaneous nystagmus in guinea pig. Martin J, et al. **J Vestib Res** 1996 Mar–Apr;6(2):135–9

The behaviour of healthy awake cats following intravenous and intramuscular administration of midazolam. Ilkiw JE, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):205–16

The effect of intravenous administration of variable-dose midazolam after fixed-dose ketamine in healthy awake cats. Ilkiw JE, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):217–24

Analysis of sleep EEGs by the interval histogram method--validity of the baseline night as a control and the effect of ethyl loflazepate (CM6912). Kuwahara H, et al. **Kurume Med J** 1996;43(4):305–12

Abecarnil, a beta-carboline derivative, does not exhibit anticonvulsant tolerance or withdrawal effects in mice. Natolino F, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):612–7

Effects of diazepam on conflict behaviour and on plasma corticosterone levels in male and female rats. Perićić D, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Mar; 353(4):369–76

The role of the hypothalamic-pituitary-adrenocortical axis in memory-related effects of anxiolytics. Korneyev AY. **Neurobiol Learn Mem** 1997 Jan;67(1):1–13 (162 ref.)

Hypoglycemia-induced inhibition of LH and stimulation of ACTH secretion in the rhesus monkey is blocked by alprazolam. Van Vugt DA, et al. **Neuroendocrinology** 1997 May;65(5):344–52

Effects of the tranquillizer diazepam and the stimulant methylphenidate on alertness and memory. Unrug A, et al. **Neuropsychobiology** 1997;36(1):42–8

Assessment of the anxiolytic and amnesic effects of three benzodiazepines, diazepam, alprazolam and triazolam, by conflict and non-matching to sample tests in mice. Kuribara H, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Feb;17(1):1–6

Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline, and fluvoxamine. I. Social interactions. Cutler MG, et al. **Pharmacol Biochem Behav** 1997 May–Jun; 57(1–2):119–25

Diazepam enhances conditioned defeat in hamsters (Mesocricetus auratus). Hebert MA, et al. **Pharmacol Biochem Behav** 1996 Nov;55(3):405–13

Increased food intake following injection of the benzodiazepine receptor agonist midazolam into the IVth ventricle. Higgs S, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):81–6

Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze. Rodgers RJ, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):127–36

Tolerance to the anticonflict effects of diazepam: importance of methodological considerations. Smith RL, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):61–6

Midazolam does not influence intravenous fentanyl-induced analgesia in healthy volunteers. Zacny JP, et al. **Pharmacol Biochem Behav** 1996 Oct;55(2):275–80

Flumazenil, diazepam, nordiazepam and oxazepam interactions on plasma protein binding. Wala EP, et al. **Pharmacol Res** 1995 Nov;32(5):299–304

The influence of lorazepam upon pre- and poststimulus EEG during sleep in man. Wagner P, et al. **Pharmacopsychiatry** 1997 Jan;30(1):16–22

A pilot pharmacokinetic-pharmacodynamic study of benzodiazepine antagonism by flumazenil and aminophylline. Bonfiglio MF, et al. **Pharmacotherapy** 1996 Nov–Dec;16(6):1166–72

Effect of chlordiazepoxide on the response to repeated reductions in sucrose concentration in free-fed rats. Flaherty CF, et al. **Physiol Behav** 1996 Nov;60(5):1291–8

Lack of tolerance to contrast-reducing actions of chlordiazepoxide with repeated reward reductions. Flaherty CF, et al. **Physiol Behav** 1996 Aug;60(2):645–52

Effects of opioid antagonists on anticonvulsant and hypnotic activity of benzodiazepines. Fidecka S, et al. **Pol J Pharmacol** 1996 Jul–Aug;48(4):409–14

Effect of aging on the spatial learning deficit produced by diazepam in rats. McNamara RK, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jul; 20(5):873–81

Diazepam attenuation of restraint stress-induced corticosterone levels is enhanced by prior exposure to repeated restraint. Kalman BA, et al. **Psychoneuroendocrinology** 1997 Jul;22(5):349–60

Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Sundström I, et al. **Psychoneuroendocrinology** 1997 Jan;22(1):25–38

Pharmacological manipulation of ultrasound induced defence behaviour in the rat. Beckett SR, et al. **Psychopharmacology (Berl)** 1996 Oct;127(4):384–90

Prior non-spatial pretraining eliminates sensorimotor disturbances and impairments in water maze learning caused by diazepam. Cain DP. **Psychopharmacology (Berl)** 1997 Apr;130(4):313–9

Increased levels of extracellular noradrenaline in the frontal cortex of rats exposed to naturalistic environmental stimuli: modulation by acute systemic administration of diazepam or buspirone. Dalley JW, et al. **Psychopharmacology (Berl)** 1996 Sep;127(1):47–54

The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands. Griebel G, et al. **Psychopharmacology (Berl)** 1996 Apr;124(3):245–54

Alprazolam increases food intake in humans. Haney M, et al. **Psychopharmacology (Berl)** 1997 Aug;132(3):311–4

Differences in enhancing effects of zolpidem and benzodiazepine drugs on recurrent inhibition in rat hippocampal slices. Higashima M, et al. **Psychopharmacology (Berl)** 1997 Jun;131(4):394–8

Symmetrical effects of amphetamine and alpha-flupenthixol on conditioned punishment and conditioned reinforcement: contrasts with midazolam. Killcross AS, et al. **Psychopharmacology (Berl)** 1997 Jan;129(2):141–52

Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug. Kondo T, et al. **Psychopharmacology (Berl)** 1996 Oct;127(4):311–4

Flumazenil blockade of anxiety following ethanol withdrawal in rats. Moy SS, et al. **Psychopharmacology (Berl)** 1997 Jun; 131(4):354–60

Behavioral reactivity to aversive stimuli in a transgenic mouse model of impaired glucocorticoid (type II) receptor function: effects of diazepam and FG-7142. Rochford J, et al. **Psychopharmacology (Berl)** 1997 Jul;132(2):145–52

Assessment of benzodiazepine receptor heterogeneity in vivo: apparent pA2 and pKB analyses from behavioral studies. Rowlett JK, et al. **Psychopharmacology (Berl)** 1996 Nov; 128(1):1–16

Effects of oxazepam and lorazepam on implicit and explicit memory: evidence for possible influences of time course. Stewart SH, et al. **Psychopharmacology (Berl)** 1996 Nov; 128(2):139–49

Effects of alprazolam and lorazepam on catecholaminergic and cardiovascular activity during supine rest, mental load and orthostatic challenge. van den Berg F, et al. **Psychopharmacology (Berl)** 1996 Nov;128(1):21–30

Effects of lorazepam and diazepam on conscious and automatic memory processes. Vidailhet P, et al. **Psychopharmacology (Berl)** 1996 Sep;127(1):63–72

Primate vocalizations during social separation and aggression: effects of alcohol and benzodiazepines. Weerts EM, et al. **Psychopharmacology (Berl)** 1996 Oct;127(3):255–64

The effects of early postnatal stimulation on Morris water-maze acquisition in adult mice: genetic and maternal factors. Zaharia MD, et al. **Psychopharmacology (Berl)** 1996 Dec;128(3):227–39

Evidence that conditioned stress enhances outflow of dopamine in rat prefrontal cortex: a search for the influence of diazepam and 5-HT1A agonists. Wędzony K, et al. **Synapse** 1996 Nov;24(3):240–7

[Effects of co-administration of an antidepressant and an anxiolytic drug in the "learned helplessness" paradigm:

importance of hydroxyzine] Martin P, et al. **Encephale** 1996 Jul-Aug;22(4):270-9 (Eng. Abstr.) **(Fre)**

[Chronic prenatal exposure to diazepam, brain metabolism and behavior: long-term consequences in the adult rat] Schroeder H, et al. **Encephale** 1997 Mar-Apr;23(2):131-41 (Eng. Abstr.) **(Fre)**

[Functional MRI employing diazepam; a proposal of neuropharmacological fMRI] Yoshizawa T, et al. **Nippon Rinsho** 1997 Jul;55(7):1712-8 (Eng. Abstr.) **(Jpn)**

[Pharmacologic analysis of phenazepam and flunitrazepam activity when administered in extremely low doses] Molodavkin GM, et al. **Biull Eksp Biol Med** 1996 Feb; 121(2):164-6 **(Rus)**

[A reversible functional disorder of the escape reaction as a model for studying the effect of tranquilizers] Inozemtsev AN, et al. **Eksp Klin Farmakol** 1996 Mar-Apr;59(2):3-5 (Eng. Abstr.) **(Rus)**

POISONING

Clinical and toxicological findings in two young siblings and autopsy findings in one sibling with multiple hospital admissions resulting in death. Evidence suggesting Munchausen syndrome by proxy. Valentine JL, et al. **Am J Forensic Med Pathol** 1997 Sep;18(3):276-81

[Kinetocardiotocography--follow-up of diazepam poisoning] Heinrich J. **Zentralbl Gynakol** 1996; 118(12):689-92 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

A naturalistic 6-year follow-up study of patients with panic disorder. Lepola U, et al. **Acta Psychiatr Scand** 1996 Mar; 93(3):181-3

Influence of acupuncture and pharmacotherapy on sensitivity of sensory systems to alcohol irritants in patients with alcoholism. Timofeev MF. **Am J Chin Med** 1996; 24(2):177-84

Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Battaglia J, et al. **Am J Emerg Med** 1997 Jul;15(4):335-40

Physician rationale for benzodiazepine prescriptions to elderly hospitalized patients. Zisselman MH, et al. **Am J Geriatr Psychiatry** 1997 Spring;5(2):167-71

Change from zolpidem to clorazepate won't solve the patient's problem [letter; comment] Davis NH. **Am J Health Syst Pharm** 1997 Mar 1;54(5):588. Comment on: Am J Health Syst Pharm 1996 Nov 1;53(21):2638.

Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Roy-Byrne P, et al. **Am J Psychiatry** 1996 Nov; 153(11):1444-9

An investigation of the potential morphine sparing effect of midazolam [see comments] Gilliland HE, et al. **Anaesthesia** 1996 Sep;51(9):808-11. Comment in: Anaesthesia 1997 Apr;52(4):389.

Lactate-induced anxiety after imipramine and diazepam treatment. Pohl R, et al. **Anxiety** 1994;1(2):54-63

Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Curtis GC, et al. **Biol Psychiatry** 1997 Jan 1;41(1):76-85

Another perspective on management of withdrawal [letter; comment] [see comments] Bates D. **Can Fam Physician** 1997 Mar;43:421-4. Comment on: Can Fam Physician 1996 Nov;42:2186-90. Comment in: Can Fam Physician 1997 Jul;43:1209, 1211-2.

Combination midazolam and droperidol for severe post-ECT agitation [letter] Hines AH, et al. **Convuls Ther** 1997 Jun; 13(2):113-4

Alprazolam-reinforced medication use in outpatients with anxiety. Roache JD, et al. **Drug Alcohol Depend** 1997 May 2;45(3):143-55

Optimal management of behavioural disorders associated with dementia. Class CA, et al. **Drugs Aging** 1997 Feb; 10(2):95-106 (70 ref.)

Oral low-dose midazolam as premedication for intraocular surgery in retrobulbar anesthesia: cardiovascular effects and relief of perioperative anxiety. Kiefer RT, et al. **Eur J Ophthalmol** 1997 Apr-Jun;7(2):185-92

The long-term use of benzodiazepines: patients' views, accounts and experiences. Barter G, et al. **Fam Pract** 1996 Dec;13(6):491-7

Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Foster S, et al. **Int Clin Psychopharmacol** 1997 May; 12(3):175-9

Comparative study of oral clonidine and diazepam as premedicants in children. Ramesh VJ, et al. **Int J Clin Pharmacol Ther** 1997 May;35(5):218-21

Somatic treatment of catatonia. Hawkins JM, et al. **Int J Psychiatry Med** 1995;25(4):345-69 (109 ref.)

Application of the Stages of Change Scale in a clinical drug trial. Wilson M, et al. **J Anxiety Disord** 1997 Jul-Aug; 11(4):395-408

Addition of d-fenfluramine to benzodiazepines produces a marked improvement in refractory panic disorder--a case report [letter] Hetem LA. **J Clin Psychopharmacol** 1996 Feb;16(1):77-8

Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. Rickels K, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):272-7

Reevaluation of "Alprazolam and suicidal ideation: a meta-analysis of controlled trials in the treatment of depression" [letter; comment] Yoo K, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):328; discussion 329. Comment on: J Clin Psychopharmacol 1996 Jun;16(3):208-11.

Physicians' decisions to prescribe benzodiazepines for nervousness and insomnia. Brown RL, et al. **J Gen Intern Med** 1997 Jan;12(1):44-52

Alcohol withdrawal treatment practices [letter; comment] Wartenberg AA. **J Gen Intern Med** 1996 May;11(5):315-6. Comment on: J Gen Intern Med 1995 Sep;10(9):479-87.

Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect. Srisurapanont M, et al. **J Med Assoc Thai** 1997 Mar; 80(3):183-8

Hypothalamic-pituitary-adrenal axis activity in panic disorder: effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. Abelson JL, et al. **J Psychiatr Res** 1996 Mar-Apr;30(2):79-93

The impact on community benzodiazepine prescribing of hospitalization. Millar HL, et al. **J Psychosom Res** 1997 Jan;42(1):61-9

Palliative care: an update on "terminal restlessness". Burke AL. **Med J Aust** 1997 Jan 6;166(1):39-42 (37 ref.)

Benzodiazepine prescribing in a Sydney teaching hospital [see comments] Howes JB, et al. **Med J Aust** 1996 Sep 16; 165(6):305-8. Comment in: Med J Aust 1996 Sep 16;165(6):299-300.

Drug use in nursing homes: some new evidence [letter; comment] Walsh RA. **Med J Aust** 1997 Apr 21;166(8):447. Comment on: Med J Aust 1996 Sep 2;165(5):295-6.

MCPP-induced anxiety--a potential new method for screening anxiolytic activity. Bilkei-Gorzó A, et al. **Neurobiology (Bp)** 1996;4(3):253-5

Comparison of effectiveness of maneuvers and medication in the treatment of benign paroxysmal positional vertigo. Itaya T, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 May-Jun;59(3):155-8

Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a ramdomized, double-blind, placebo-controlled trial. Quijada-Carrera J, et al. **Pain** 1996 May-Jun;65(2-3):221-5

Effect of chronic diazepam treatment on footshock-induced ultrasonic vocalization in adult male rats. Nielsen CK, et al. **Pharmacol Toxicol** 1995 Sep;77(3):177-81

A new design of trial for hypnotics comparison: a double-blind cross-over trial with patient's preference assessment and continuation of the preferred treatment. Bourin M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Apr; 20(3):373-85

Polysomnographic effects of hypnotic drugs. A review. Parrino L, et al. **Psychopharmacology (Berl)** 1996 Jul; 126(1):1-16 (131 ref.)

Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment. Kiliç C, et al. **Psychother Psychosom** 1997;66(4):175-8

The course of alcohol withdrawal in a general hospital [letter] Green J, et al. **QJM** 1997 Aug;90(8):552

Long-term benzodiazepine use: factors of importance and the development of individual use patterns over time--a 13-year follow-up in a Swedish community. Isacson D. **Soc Sci Med** 1997 Jun;44(12):1871-80

Tranquillizers are good for you. Hallström C. **Trans Med Soc Lond** 1994-95;111:59-62

[Treatment of sleep disorders] Holsboer-Trachsler E. **Internist (Berl)** 1997 Jul;38(7):704 **(Ger)**

[Sedation with flunitarazepam at magnetic resonance imaging in the elderly patients with dementia] Mori S, et al. **Nippon Ronen Igakkai Zasshi** 1996 Jan;33(1):7-11 (Eng. Abstr.) **(Jpn)**

[The comparative effect of melatonin and diazepam on shifts in the anxiety-phobia status of rats evoked by damage to the amygdala] Arushanian EB, et al. **Eksp Klin Farmakol** 1997 Jan-Feb;60(1):7-9 (Eng. Abstr.) **(Rus)**

[Differences in the effects of piracetam and fenazepam in emotional stress caused by the spatial reversal of a habit] Inozemtsev AN, et al. **Eksp Klin Farmakol** 1996 Nov-Dec; 59(6):3-5 (Eng. Abstr.) **(Rus)**

[The effect of benzodiazepine derivatives on the formation of brain edema-swelling in the dynamics of the posttraumatic period] Novikov VE. **Eksp Klin Farmakol** 1996 May-Jun;59(3):61-3 (Eng. Abstr.) **(Rus)**

TOXICITY

Behavioural effects of prenatal diazepam administration on anxiety patterns in rats. Singh Y, et al. **Indian J Exp Biol** 1996 Nov;34(11):1095-9

URINE

Urine screening for flunitrazepam: applicability of Emit immunoassay [letter] Mørland H, et al. **Clin Chem** 1997 Jul;43(7):1245-6

Automated on-line hydrolysis of benzodiazepines improves sensitivity of urine screening by a homogeneous enzyme immunoassay. Ropero-Miller JD, et al. **Clin Chem** 1997 Sep;43(9):1659-60

Identification of urinary benzodiazepines and their metabolites: comparison of automated HPLC and GC-MS after immunoassay screening of clinical specimens. Valentine JL, et al. **J Anal Toxicol** 1996 Oct;20(6):416-24

Use of direct-probe mass spectrometry as a toxicology confirmation method for demoxepam in urine following high-performance liquid chromatography. Essien H, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30;683(2):199-208

ANTI-ARRHYTHMIA AGENTS

see related
ADRENERGIC BETA-ANTAGONISTS
CALCIUM CHANNEL BLOCKERS

Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Foster RH, et al. **Drugs** 1997 Aug; 54(2):312-30 (58 ref.)

Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro. Leeder RG, et al. **J Biochem Toxicol** 1996;11(3):147-60

[Class III antiarrhythmic drugs] Aiba T, et al. **Nippon Rinsho** 1996 Aug;54(8):2125-31 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Vaughan Williams class IV antiarrhythmic drugs] Horie M, et al. **Nippon Rinsho** 1996 Aug;54(8):2132-7 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical use of beta-blocker an as antiarrhythmic agent] Okazaki O, et al. **Nippon Rinsho** 1996 Aug;54(8):2117-24 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Other antiarrhythmic agents] Sato T. **Nippon Rinsho** 1996 Aug;54(8):2138-43 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Drug refractory arrhythmia] Igawa O, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):535-7 (6 ref.) **(Jpn)**

[Zocor and Sotacor (letter)] Tonstad S. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1187 **(Nor)**

ADMINISTRATION & DOSAGE

Neonatal supraventricular tachycardia: predictors of successful treatment withdrawal. Lemler MS, et al. **Am Heart J** 1997 Jan;133(1):130-1

Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators. Atarashi H, et al. **Am J Cardiol** 1996 Sep 15;78(6):694-7

Usefulness of self-administration of intramuscular lidocaine in the prehospital setting for ventricular tachyarrhythmias unassociated with acute myocardial infarction (the "Shahal" experience in Israel). Roth A, et al. **Am J Cardiol** 1997 Mar 1;79(5):611-4

Influence of beta-adrenergic and vagal activity on the effect of exogenous adenosine on supraventricular tachycardia termination. Tai CT, et al. **Am J Cardiol** 1997 Jun 15; 79(12):1628-31

Use of flecainide for refractory atrial tachycardia of pregnancy. Ahmed K, et al. **Am J Crit Care** 1996 Jul; 5(4):306-8

Fetal supraventricular tachycardia complicated by hydrops fetalis: a role for direct fetal intramuscular therapy. Parilla BV, et al. **Am J Perinatol** 1996 Nov;13(8):483-6

Intramuscular atropine sulfate in children: comparison of injection sites. Sullivan KJ, et al. **Anesth Analg** 1997 Jan; 84(1):54-8

The rational use of intravenous amiodarone in the perioperative period. Balser JR. **Anesthesiology** 1997 Apr; 86(4):974-87 (83 ref.)

Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. Crijns HJ, et al. **Cardiovasc Drugs Ther** 1996 May;10(2):145-52

Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: efficacy and safety. Lee KL, et al. **Clin Cardiol** 1997 Apr; 20(4):372-7

Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. **Eur Heart J** 1997 Apr;18(4):649-54

Facilitating influence of procainamide on conversion of atrial flutter by rapid atrial pacing. Heisel A, et al. **Eur Heart J** 1997 May;18(5):866-9

Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo [see comments] Jordaens L, et al. **Eur Heart J** 1997 Apr; 18(4):643-8. Comment in: Eur Heart J 1997 Apr;18(4):546-7.

Magnesium sulphate in the treatment of ventricular fibrillation in amitriptyline poisoning [letter] Knudsen K, et al. **Eur Heart J** 1997 May;18(5):881-2

Intravenous digoxin: still the drug of choice for acute termination of atrial fibrillation? [editorial; comment] Lévy S. **Eur Heart J** 1997 Apr;18(4):546-7. Comment on: Eur Heart J 1997 Apr;18(4):643-8.

Efficacy and safety of low-dose propranolol versus diltiazem in the prophylaxis of supraventricular tachyarrhythmia after coronary artery bypass grafting. Babin-Ebell J, et al. **Eur J Cardiothorac Surg** 1996;10(6):412-6

Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy. James PR, et al. **Heart** 1997 Jun;77(6):583-4

Verapamil responsive incessant ventricular tachycardia

resulting in severe ventricular dysfunction in a young child: successful management with oral verapamil. **Ma JS, et al. Heart** 1997 Mar;77(3):286–7

Low-dose amiodarone in severe chronic heart failure. Biswas A, et al. **Indian Heart J** 1996 Jul–Aug;48(4):361–4

Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Botto GL, et al. **Int J Cardiol** 1997 Jan 3;58(1):55–61

Effects of digoxin on time domain measures of heart rate variability in patients with stable chronic cardiac failure: withdrawal and comparison group studies. Flapan AD, et al. **Int J Cardiol** 1997 Mar;59(1):29–36

Intravenous amiodarone. Kowey PR, et al. **J Am Coll Cardiol** 1997 May;29(6):1190–8 (110 ref.)

Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence. Lee SD, et al. **J Am Coll Cardiol** 1997 Jan;29(1):100–5

Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. Ayers GM, et al. **J Cardiovasc Electrophysiol** 1996 Aug;7(8):713–21

Sinus node recovery time assessment revisited: role of pharmacologic blockade of the autonomic nervous system. Bergfeldt L, et al. **J Cardiovasc Electrophysiol** 1996 Feb; 7(2):95–101

Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. Buchanan LV, et al. **J Cardiovasc Electrophysiol** 1996 Feb; 7(2):113–9

Alteration of human placental vascular tone by antiarrhythmic medications in vitro. Omar HA, et al. **J Cardiovasc Electrophysiol** 1996 Dec;7(12):1197–203

Mechanisms underlying different surface ECG morphologies of recurrent monomorphic ventricular tachycardia and their modification by procainamide. Osswald S, et al. **J Cardiovasc Electrophysiol** 1997 Jan;8(1):11–23

Adenosine-sensitive bundle branch reentry. Rubenstein DS, et al. **J Cardiovasc Electrophysiol** 1997 Jan;8(1):80–8

Frequency-dependent electrophysiologic effects of d,l-sotalol and quinidine and modulation by beta-adrenergic stimulation. Sager PT, et al. **J Cardiovasc Electrophysiol** 1996 Feb;7(2):102–12

Atrial flutter in the human fetus: diagnosis, hemodynamic consequences, and therapy. Soyeur DJ. **J Cardiovasc Electrophysiol** 1996 Oct;7(10):989–98 (33 ref.)

Antifibrillatory effect of esmolol alone and in combination with lidocaine. Tisdale JE, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):376–82

Effects of magnesium and potassium on Wolff-Parkinson-White syndrome. Sideris AM, et al. **J Electrocardiol** 1996 Jan;29(1):11–5

Low-dose amiodarone-related complications after cardiac operations. Dimopoulou I, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):31–7

Loading dose of digoxin. Barbey JT, et al. **JAMA** 1997 Feb 19;277(7):518

Effects of long-term oral administration of amiodarone on the ventricular repolarization of rabbit hearts. Iwata H, et al. **Jpn Circ J** 1996 Sep;60(9):662–72

Adenosine mediates the antiarrhythmic effect of ischemic preconditioning in isolated rat hearts. Miyatake Y, et al. **Jpn Circ J** 1996 Jun;60(6):341–8

Safety and efficacy of oral flecainide acetate in patients with cardiac arrhythmias. Nakazato Y, et al. **Jpn Heart J** 1997 May;38(3):379–85

Amiodarone in a newborn with ventricular tachycardia and an intracardiac tumor: adjusting the dose according to an individualized dosing regimen. Bouillon T, et al. **Pediatr Cardiol** 1996 Mar–Apr;17(2):112–4

Radiofrequency catheter ablation of a verapamil-sensitive ventricular tachycardia. Mangru NN, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):235–6

Evaluation of an open-loop, computer-based infusion system designed to achieve a series of constant, targeted plasma procainamide concentrations in patients undergoing electrophysiologic testing. Coyle JD, et al. **Pharmacotherapy** 1997 May–Jun;17(3):445–56

Is it safe to inject adenosine through a central line? Drew BJ, et al. **Prog Cardiovasc Nurs** 1997 Winter;12(1):47–8

The effect of low-dose amiodarone in prevention of paroxysmal atrial fibrillation. Zdrenghea D, et al. **Rom J Intern Med** 1996 Jul–Dec;34(3–4):199–204

[n-3 polyunsaturated fatty acids, heart rate variability and ventricular arrhythmias in post-AMI-patients. A clinical controlled trial] Christensen JH, et al. **Ugeskr Laeger** 1997 Sep 8;159(37):5525–9 (Eng. Abstr.) **(Dan)**

[Metoprolol prevents myocardial ischemia during endoscopic retrograde cholangiopancreatography] Rosenberg J, et al. **Ugeskr Laeger** 1997 Sep 8;159(37):5514–8 (Eng. Abstr.) **(Dan)**

[Development of a practical guide for utilization of injectable drugs in neonatology and in pediatrics] Veillet B, et al. **Therapie** 1996 Jul–Aug;51(4):403–9 (Eng. Abstr.) **(Fre)**

[Anti-arrhythmia therapy in general practice only for patients with healthy hearts (interview by Dr. rer. nat. Anita Scheiger)] Dotzer F. **Fortschr Med** 1997 Jan 20; 115(1–2):42, 44 **(Ger)**

[Medicamentous anti-arrhythmia therapy. Is oral adjuvant therapy with electrolytes of value?] Haberl R. **Herz** 1997 Jun;22 Suppl 1:77–80 (20 ref.) (Eng. Abstr.) **(Ger)**

[Value of K+ and Mg2+ in treatment of acute myocardial infarct] Kunert M, et al. **Herz** 1997 Jun;22 Suppl 1:63–72 (24 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium deficiency and magnesium substitution. Effect on ventricular cardiac arrhythmias of various etiology] Zehender M, et al. **Herz** 1997 Jun;22 Suppl 1:56–62 (54 ref.) (Eng. Abstr.) **(Ger)**

[Experiences in therapy of bradycardic cardiac arrhythmias in childhood with ipratropium bromide] Krienke L, et al. **Klin Padiatr** 1997 Jan–Feb;209(1):21–5 (Eng. Abstr.) **(Ger)**

[Conversion rate and prevention of recurrence of paroxysmal and sustained atrial fibrillation or atrial flutter with verapamil/quinidine] Trappe HJ, et al. **Med Klin** 1996 Oct 15;91(10):617–25 (Eng. Abstr.) **(Ger)**

[Magnesium: current studies—critical evaluation—consequences] Meinertz T. **Z Kardiol** 1996;85 Suppl 6:147–51 (13 ref.) (Eng. Abstr.) **(Ger)**

[Exogenous adenosine as an anti-arrhythmia agent] Tebbenjohanns J, et al. **Z Kardiol** 1996;85 Suppl 6:191–9 (47 ref.) (Eng. Abstr.) **(Ger)**

[Successful treatment of fetal supraventricular tachycardia with a combination of digoxin and amiodarone] Hajdú J, et al. **Orv Hetil** 1996 Oct 6;137(40):2209–11 (Eng. Abstr.) **(Hun)**

[The effect of intravenously given amiodarone on maintenance of ventricular signal averaged electrocardiogram in patients with ischemic heart disease] Banasiak W, et al. **Przegl Lek** 1996;53(6):463–7 (Eng. Abstr.) **(Pol)**

[Digoxin. The drug of choice for the in-utero treatment of paroxysmal supraventricular tachycardia] Silva IS, et al. **Acta Med Port** 1997 Jan;10(1):95–8 (7 ref.) (Eng. Abstr.) **(Por)**

[Pharmacological correction of impaired tolerance to strophanthin in a model of cardiac decompensation] Galenko-Iaroshevskiĭ PA, et al. **Biull Eksp Biol Med** 1994 May;117(5):487–90 **(Rus)**

[Effect of intravenous verapamil in experimental ventricular arrhythmia] de Micheli A, et al. **Arch Inst Cardiol Mex** 1995 Nov–Dec;65(6):484–95 (Eng. Abstr.) **(Spa)**

[Intravenous diltiazem in the reversion to sinus rhythm in supraventricular tachyarrhythmias] Luciardi H, et al. **Arch Inst Cardiol Mex** 1996 Nov–Dec;66(6):505–9 (Eng. Abstr.) **(Spa)**

[How risky is chemical conversion of atrial fibrillation (letter)] Sandvik CJ. **Lakartidningen** 1997 Jan 8; 94(1–2):18–9 **(Swe)**

ADVERSE EFFECTS

Unusual atrial pro-arrhythmic effect of flecainide: a contemporary review. De Meester A, et al. **Acta Cardiol** 1996;51(6):529–34

Enlargement of extraocular muscles during treatment with amiodarone. Sundelin K, et al. **Acta Ophthalmol Scand** 1997 Jun;75(3):333–4

Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Kowey PR, et al. **Am J Cardiol** 1996 Oct 17;78(8A):46–52 (15 ref.)

Does subclinical hypothyroidism explain the increased susceptibility of women to torsades de pointes? Lehmann MH, et al. **Am J Cardiol** 1997 Apr 1;79(7):963–5

Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death. Prystowsky EN. **Am J Cardiol** 1996 Oct 17; 78(8A):35–41 (87 ref.)

Lithium treatment in amiodarone-induced thyrotoxicosis. Dickstein G, et al. **Am J Med** 1997 May;102(5):454–8

Amiodarone-induced thyrotoxicosis. Tavackoli S, et al. **Am J Med Sci** 1997 Aug;314(2):97–100 (29 ref.)

Torsade de pointes [letter; comment] Campens D. **Anesth Analg** 1996 Oct;83(4):887. Comment on: Anesth Analg 1995 Nov;81(5):1119.

Regional anesthesia for thyroidectomy in two patients with amiodarone-induced hyperthyroidism. Klein SM, et al. **Anesth Analg** 1997 Jul;85(1):222–4

Preoperative therapy with amiodarone and the incidence of acute organ dysfunction after cardiac surgery. Rady MY, et al. **Anesth Analg** 1997 Sep;85(3):489–97

Cholestyramine therapy for quinidine-induced diarrhea. Case reports. RuDusky BM. **Angiology** 1997 Feb;48(2):173–6

Adenosine-induced atrial arrhythmia: a prospective analysis. Strickberger SA, et al. **Ann Intern Med** 1997 Sep 15; 127(6):417–22

Digoxin toxicity secondary to clarithromycin therapy. Nawarskas JJ, et al. **Ann Pharmacother** 1997 Jul–Aug; 31(7–8):864–6

A case of a naval aviator on quinidine for lone atrial fibrillation. Wingard DM, et al. **Aviat Space Environ Med** 1996 Apr;67(4):341–3

Amiodarone pulmonary toxicity. Amiodarone should be used with caution in patients in intensive care [letter; comment] Donaldson L, et al. **BMJ** 1997 Jun 21;314(7097):1832. Comment on: BMJ 1997 Mar 1;314(7081):619–20.

Amiodarone pulmonary toxicity [editorial] [see comments] Jessurun GA, et al. **BMJ** 1997 Mar 1;314(7081):619–20. Comment in: BMJ 1997 Jun 21;314(7097):1831–2. Comment in: BMJ 1997 Jun 21;314(7097):1832.

Amiodarone pulmonary toxicity. Authors did not emphasise typical radiological and histological features sufficiently [letter; comment] Leonard A, et al. **BMJ** 1997 Jun 21; 314(7097):1831–2. Comment on: BMJ 1997 Mar 1;314(7081):619–20.

Amiodarone and dysthyroid eye disease [letter] Banerjee S, et al. **Br J Ophthalmol** 1996 Sep;80(9):851–2

Sotalol-induced torsades de pointes in patients with renal failure. Dancey D, et al. **Can J Cardiol** 1997 Jan;13(1):55–8

Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade. Skanes AC, et al. **Can J Cardiol** 1997 Apr;13(4):383–6 (36 ref.)

Sudden hypothyroidism and amiodarone-lithium combination: an interaction. Ahmad S. **Cardiovasc Drugs Ther** 1995 Dec;9(6):827–8

Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia. Fujiki A, et al. **Cardiovasc Drugs Ther** 1996 May;10(2):159–66

Angle closure glaucoma complicating systemic atropine use in the cardiac catheterization laboratory. Mandak JS, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):262–4

Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis. Goldstein I, et al. **Chest** 1997 May;111(5):1446–7

Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. Winters SL, et al. **Chest** 1997 May; 111(5):1454–7 (6 ref.)

Sex difference in risk of torsade de pointes with d,l-sotalol. Lehmann MH, et al. **Circulation** 1996 Nov 15; 94(10):2535–41

Bronchiolitis obliterans organizing pneumonia during low-dose amiodarone therapy. Jessurun GA, et al. **Clin Cardiol** 1997 Mar;20(3):300–2

Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation. Kounis NG, et al. **Clin Cardiol** 1996 Jul;19(7):592–4

Propafenone-induced drug fever in the absence of agranulocytosis. O'Rourke DJ, et al. **Clin Cardiol** 1997 Jul; 20(7):662–4

Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone-induced thyroiditis. Samaras K, et al. **Clin Endocrinol (Oxf)** 1996 Sep;45(3):365–8

Quinidine-induced pigmentation. Conroy EA, et al. **Cutis** 1996 Jun;57(6):425–7

Adverse effects of class I antiarrhythmic drugs. Caron J, et al. **Drug Saf** 1997 Jul;17(1):8–36 (366 ref.)

Primary ventricular fibrillation: a reason to be cautious [editorial; comment] Jordaens LJ, et al. **Eur Heart J** 1997 Jun;18(6):890–2. Comment on: Eur Heart J 1997 Jun;18(6):919–24.

Avoiding drug problems. The safety of drugs for supraventricular tachycardia. Reimold SC. **Eur Heart J** 1997 May;18 Suppl C:C40–4 (8 ref.)

Towards an animal model of amiodarone-induced thyroid dysfunction [comment] Wiersinga WM. **Eur J Endocrinol** 1997 Jul;137(1):15–7. Comment on: Eur J Endocrinol 1997 Jul;137(1):89–98.

Amiodarone-induced epididymitis. Report of 2 cases. Hamoud K, et al. **Eur Urol** 1996;29(4):497–8

Torsades de pointes induced by transesophageal atrial stimulation after administration of almokalant. Darpö B, et al. **Int J Cardiol** 1996 Mar;53(3):311–3

Torsade de pointes occurring early during oral amiodarone treatment [letter] Faggiano P, et al. **Int J Cardiol** 1996 Jul 26;55(2):205–8

Akinesia and amiodarone therapy [letter] Malaterre HR, et al. **Int J Cardiol** 1997 Mar;59(1):107–8

Myasthenia-like syndrome induced by overdosage of cibenzoline. Kasuga A, et al. **Intern Med** 1996 Jun; 35(6):512–4

Adverse effects of amiodarone at low dose: plus ça change [editorial; comment] Sopher SM, et al. **J Am Coll Cardiol** 1997 Sep;30(3):799–801. Comment on: J Am Coll Cardiol 1997 Sep;30(3):791–8.

Adverse effects of low dose amiodarone: a meta-analysis [see comments] Vorperian VR, et al. **J Am Coll Cardiol** 1997 Sep;30(3):791–8. Comment in: J Am Coll Cardiol 1997 Sep;30(3):799–801.

Lidocaine-induced cardiac asystole. Sadikot R, et al. **J Ark Med Soc** 1997 Jan;93(8):410–1

Lidocaine and nisoldipine attenuate almokalant-induced dispersion of repolarization and early afterdepolarizations in vitro. Abrahamsson C, et al. **J Cardiovasc Electrophysiol** 1996 Nov;7(11):1074–81

Iodine accumulation in the liver during long-term treatment with amiodarone. Beuers U, et al. **J Hepatol** 1997 Feb; 26(2):439

Amiodarone-induced dysthyroidism. Pitfalls and management. Leenhardt L. **J Med Liban** 1995;43(3):148–9 (14 ref.)

Low-dose amiodarone-related complications after cardiac operations. Dimopoulou I, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):31–7

A case of amiodarone-induced thyrotoxicosis successfully treated with prednisolone. Hayashi K, et al. **Jpn Circ J** 1997 Apr;61(4):361–6

SWORD trial of d-sotalol [letter; comment] Ghali JK. **Lancet** 1996 Sep 21;348(9030):827. Comment on: Lancet 1996 Jul 6;348(9019):7–12.

Amiodarone after myocardial infarction: EMIAT and CAMIAT trials [letter; comment] Incalzi RA, et al.

Lancet 1997 Jun 14;349(9067):1768; discussion 1769-70. Comment on: Lancet 1997 Mar 8;349(9053):667-74.

SWORD trial of d-sotalol [letter; comment] Tan LB. **Lancet** 1996 Sep 21;348(9030):827-8. Comment on: Lancet 1996 Jul 6;348(9019):2-3. Comment on: Lancet 1996 Jul 6;348(9019):7-12.

Adverse reactions to digoxin in four patients with normal or low serum digoxin levels [letters] Mitchell G. **Med J Aust** 1997 Jul 21;167(2):111

Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: clinical, radiological and histological pattern. Conte SC, et al. **Monaldi Arch Chest Dis** 1997 Feb; 52(1):24-6

Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy. Nakayama Y, et al. **Pacing Clin Electrophysiol** 1997 Jul;20(7):1881-2

Adenosine induced polymorphic ventricular tachycardia in adults without structural heart disease. Smith JR, et al. **Pacing Clin Electrophysiol** 1997 Mar;20(3 Pt 1):743-5

Severe hypoglycaemia associated with preoperative fasting and intraoperative propranolol. A case report and discussion. Bush GH, et al. **Paediatr Anaesth** 1996; 6(5):415-7

Paranoid psychosis due to flecainide toxicity in malignant neuropathic pain. Bennett MI. **Pain** 1997 Mar;70(1):93-4

Relationship of amiodarone to postoperative complications of transthoracic implantation of automatic implantable cardioverter defibrillators. Calkins H, et al. **Panminerva Med** 1996 Jun;38(2):89-97

Sotalol-induced Torsade de pointes in a CAPD patient--successful treatment with intermittent peritoneal dialysis [letter] Tang S, et al. **Perit Dial Int** 1997 Mar-Apr; 17(2):207-8

Torsades de pointes with administration of high-dose intravenous d-sotalol to a patient with congestive heart failure. Gottlieb SS, et al. **Pharmacotherapy** 1997 Jul-Aug; 17(4):830-1

QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. Lin JC, et al. **Pharmacotherapy** 1997 May-Jun;17(3):626-30

Prolonged quinidine half-life with associated toxicity in a patient with hepatic failure. Stanek EJ, et al. **Pharmacotherapy** 1997 May-Jun;17(3):622-5

Environmental hazard assessment of pharmaceuticals. Henschel KP, et al. **Regul Toxicol Pharmacol** 1997 Jun; 25(3):220-5

Neuromuscular blockade with acute respiratory failure in a patient receiving cibenzoline. Similowski T, et al. **Thorax** 1997 Jun;52(6):582-4

[Amiodarone neuropathy of the optic nerve from the viewpoint of the neuro-ophthalmologist] Jirásková N, et al. **Cesk Slov Oftalmol** 1996 Oct;52(5):308-18 (Eng. Abstr.) **(Cze)**

[Cozaar (Losartan, MSD) and depression (letter)] Christensen KB. **Ugeskr Laeger** 1997 Mar 31;159(14):2106 **(Dan)**

[Losartan (Cozaar) and depression] Jensen JB. **Ugeskr Laeger** 1997 Mar 31;159(14):2108 **(Dan)**

[Amiodarone-induced thyrotoxicosis cured by thyroidectomy] Le Cosquer P, et al. **Ann Fr Anesth Reanim** 1996;15(7):1092-4 (Eng. Abstr.) **(Fre)**

[Amiodarone-induced hypothyroidism followed by hyperthyroidism. Apropos of 2 new cases] Wilhelm JM, et al. **Ann Med Interne (Paris)** 1996;147(5):369-72 (20 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of amiodarone-induced hyperthyroidism by carbimazole with maintenance of amiodarone] Talard P, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89(10):1301-3 (Eng. Abstr.) **(Fre)**

[Clarithromycin-digoxin: an unrecognized interaction in some patients (letter)] Guillemet C, et al. **Presse Med** 1997 Apr 5;26(11):512 **(Fre)**

[Non-thyroidal side effects of amiodarone] Creplet J. **Rev Med Brux** 1996 Sep;17(4):198-202 (15 ref.) (Eng. Abstr.) **(Fre)**

[Early pulmonary changes caused by amiodarone] Leipner N, et al. **Aktuelle Radiol** 1996 Sep;6(5):235-8 (Eng. Abstr.) **(Ger)**

[Amiodarone pigmentation] Ammann R, et al. **Hautarzt** 1996 Dec;47(12):930-1 (Eng. Abstr.) **(Ger)**

[Torsade de pointes tachycardia during administration of quinidine and verapamil in atrial fibrillation] Karch M, et al. **Herz** 1997 Feb;22(1):51-6 (Eng. Abstr.) **(Ger)**

[Cardiac side effects of anti-arrhythmia agents] Pfeiffer D, et al. **Internist (Berl)** 1996 Jan;37(1):53-9 (44 ref.) **(Ger)**

[Increased liver density in computed tomography as a result of anti-arrhythmia therapy with amiodarone] Heuck A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jan;166(1):14-7 (Eng. Abstr.) **(Ger)**

[Amiodarone and the thyroid] Martino E, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):173-8 **(Ita)**

[Extracardiovascular toxic effects of drugs used in cardiology] Zennaro RG. **Cardiologia** 1995 Dec;40(12 Suppl 1):99-104 **(Ita)**

[Thoracic radiography and high resolution computerized tomography in the diagnosis of pulmonary disorders caused by amiodarone] Polverosi R, et al. **Radiol Med (Torino)** 1996 Jul-Aug;92(1-2):58-62 (Eng. Abstr.) **(Ita)**

[Therapeutic drug monitoring in perioperative period--management of atrial fibrillation in a patient with bradycardia due to relative overdose of digitalis] Murakawa T, et al. **Masui** 1997 Apr;46(4):521-4 (Eng. Abstr.) **(Jpn)**

[Benefit of monitoring the level of blood flecainide acetate in an elderly patient with ventricular premature contractions] Nagashima J, et al. **Nippon Ronen Igakkai Zasshi** 1997 Jan;34(1):54-9 (Eng. Abstr.) **(Jpn)**

[Drug-induced pericarditis] Ohnishi A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):612-4 (22 ref.) **(Jpn)**

[Drug induced arrhythmias] Usuda K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):538-41 (12 ref.) **(Jpn)**

[Amiodarone and the lung] Mendonça C, et al. **Rev Port Cardiol** 1996 Oct;15(10):745-51 (48 ref.) (Eng. Abstr.) **(Por)**

[The treatment of paroxysmal supraventricular arrhythmias in IHD patients with a high risk of developing complications from the anti-arrhythmic therapy] Andriushchenko OM, et al. **Ter Arkh** 1996;68(5):57-60 (Eng. Abstr.) **(Rus)**

[Possibilities of correcting adverse effects of anti-arrhythmia agents] Skibitskiĭ VV, et al. **Vestn Ross Akad Med Nauk** 1996;(5):9-12 (Eng. Abstr.) **(Rus)**

[Subtotal thyroidectomy. A treatment to keep in mind in amiodarone-induced thyrotoxicosis] López Mínguez JR, et al. **Rev Esp Cardiol** 1996 Jun;49(6):474-6 (Eng. Abstr.) **(Spa)**

[News on side effects. 59 reports on losartan. Even cough is reported] **Lakartidningen** 1996 Oct 9;93(41):3601 **(Swe)**

ANALYSIS

Identification of flecainide and lorcainide in blood by means of TLC. Paw B, et al. **Acta Pol Pharm** 1995 Jan-Feb; 52(1):5-7

Determination of sotalol in human cardiac tissue by high-performance liquid chromatography. Läer S, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):291-8

Unusual interference from primary collection tube in a high-performance liquid chromatography assay of amiodarone. Murthy VV. **J Clin Lab Anal** 1997;11(4):232-4

BLOOD

The serum digoxin concentration: ten questions to ask. Cauffield JS, et al. **Am Fam Physician** 1997 Aug; 56(2):495-503, 509-10 (22 ref.)

Lidocaine pharmacokinetics after cardiac arrest and external cardiopulmonary resuscitation. Hendrie J, et al. **Am J Cardiol** 1996 Dec 1;78(11):1322-3

Digoxin-itraconazole interaction: possible mechanisms. Alderman CP, et al. **Ann Pharmacother** 1997 Apr; 31(4):438-40

Antiarrhythmic drug plasma concentrations in ambulatory patients [letter] Latini R, et al. **Ann Pharmacother** 1996 Mar; 30(3):298-300

A new interference in some digoxin assays: anti-murine heterophilic antibodies. Liendo C, et al. **Clin Pharmacol Ther** 1996 Nov;60(5):593-8

High-performance liquid chromatographic determination of mexiletine enantiomers in plasma using direct and indirect enantioselective separations. Lanchote VL, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25;685(2):281-9

Evaluation of an on-line solid-phase extraction method for determination of almokalant, an antiarrhythmic drug, by liquid chromatography. Svennberg H, et al. **J Chromatogr B Biomed Appl** 1997 Feb 21;689(2):371-7

Quantitation of pentisomide and its metabolite by high-pressure liquid chromatography in human serum. Mewis C, et al. **J Chromatogr Sci** 1996 Apr;34(4):161-5

A tandem solid phase extraction, reversed-phase HPLC method for determining SDZ WAG 994 in dog, monkey and rat blood. Cramer JA, et al. **J Pharm Biomed Anal** 1997 Mar;15(6):749-58

Adverse reactions to digoxin in four patients with normal or low serum digoxin levels [letters] Mitchell G. **Med J Aust** 1997 Jul 21;167(2):111

Internally standardized simultaneous assay of gallopamil enantiomers in human plasma by means of high performance liquid chromatography. Kern R. **Methods Find Exp Clin Pharmacol** 1996 May;18(4):279-85

Evaluation of an open-loop, computer-based infusion system designed to achieve a series of constant, targeted plasma procainamide concentrations in patients undergoing electrophysiologic testing. Coyle JD, et al. **Pharmacotherapy** 1997 May-Jun;17(3):445-56

Altered protein binding of quinidine in patients with atrial fibrillation and flutter. McCollam PL, et al. **Pharmacotherapy** 1997 Jul-Aug;17(4):753-9

Direct comparison of three methods for predicting digoxin concentrations. Williams PJ, et al. **Pharmacotherapy** 1996 Nov-Dec;16(6):1085-92

Enantioselective determination of diprafenone in human plasma. Zhong D, et al. **Pharmazie** 1997 Feb;52(2):106-9

Interference of oleandrin and oleandrigenin in digitoxin immunoassays: minimal cross reactivity with a new monoclonal chemiluminescent assay and high cross reactivity with the fluorescence polarization assay. Datta P, et al. **Ther Drug Monit** 1997 Aug;19(4):465-9

Enzyme-multiplied immunoassay (EMIT 2000) digoxin assay compared with fluorescence polarization immunoassay and amerlex 125I-radioimmunoassay at two Australian centers. Saccoia NC, et al. **Ther Drug Monit** 1996 Dec;18(6):672-7

[Benefit of monitoring the level of blood flecainide acetate in an elderly patient with ventricular premature contractions] Nagashima J, et al. **Nippon Ronen Igakkai Zasshi** 1997 Jan;34(1):54-9 (Eng. Abstr.) **(Jpn)**

CHEMICAL SYNTHESIS

Synthesis and properties of some aryloxyaminoalkanes. Marona H, et al. **Acta Pol Pharm** 1996 Jan-Feb;53(1):47-52

Search for new antiarrhythmic and hypotensive compounds. Synthesis, antiarrhythmic, antihypertensive, and alpha-adrenoceptor blocking activity of novel 1-[(2-hydroxy-3-amino)]-propylpyrrolidin-2-one derivatives. Filipek B, et al. **Arch Pharm (Weinheim)** 1997 Jul;330(7):225-31

Synthesis, local anaesthetic and antiarrhythmic activity of methyl N-(2-substituted aminopropanoyl)-3-cyanoanthranilates. al-Obaid AR. **Boll Chim Farm** 1996 Jul-Aug;135(7):415-20

Synthesis and pharmacological profile of novel N-substituted N-[5H-[1]benzopyrano[4,3-d]pyrimidin-2-YL]-N-methylglycinamides. Bruno O, et al. **Farmaco** 1996 Feb; 51(2):137-40

CHEMISTRY

Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Allen LV Jr, et al. **Am J Health Syst Pharm** 1996 Sep 1;53(17):2073-8

Stability of propafenone hydrochloride in i.v. solutions. Dupuis LL, et al. **Am J Health Syst Pharm** 1997 Jun 1; 54(11):1293-5

Stability of amiodarone in an oral suspension stored under refrigeration and at room temperature. Nahata MC. **Ann Pharmacother** 1997 Jul-Aug;31(7-8):851-2

CLASSIFICATION

Antiarrhythmic drug therapy--Part II: Specific drugs. Kayser SR. **Prog Cardiovasc Nurs** 1996 Summer;11(3):33-8 (6 ref.)

[The classification of antiarrhythmic drugs] Iinuma H. **Nippon Rinsho** 1996 Aug;54(8):2104-9 (6 ref.) **(Jpn)**

[Class-I antiarrhythmic drugs] Kuga K, et al. **Nippon Rinsho** 1996 Aug;54(8):2110-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSTIC USE

Dipyridamole and dobutamine-atropine stress echocardiography in the diagnosis of coronary artery disease. Comparison with exercise stress test, analysis of agreement, and impact of antianginal treatment. San Román JA, et al. **Chest** 1996 Nov;110(5):1248-54

HISTORY

[When the heart loses its rhythm... On the history of cardiac arrhythmias and their therapy with anti-arrhythmia substances] Lüderitz B. **Z Kardiol** 1996;85 Suppl 6:11-23 **(Ger)**

ISOLATION & PURIFICATION

Chromatographic (TLC) analysis of diltiazem in pharmaceutical form in presence of other antiarrhythmics. Witek A, et al. **Acta Pol Pharm** 1996 Jan-Feb;53(1):9-12

METABOLISM

Determination of the new MDR-modifier PFP 6 and its metabolites in human liver microsomes by high-performance liquid chromatography. Spatzenegger M, et al. **Biomed Chromatogr** 1996 May-Jun;10(3):127-30

Stereoselective metabolism of rac-mexiletine by the fungus Cunninghamella echinulata yields the major human metabolites hydroxymethylmexiletine and p-hydroxymexiletine. Freitag DG, et al. **Drug Metab Dispos** 1997 Jun;25(6):685-92

[3H]dofetilide binding to cardiac myocytes: modulation by extracellular potassium. Duff HJ, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):183-91

[3H]dofetilide binding: biological models that manifest solely the high or the low affinity binding site. Fiset C, et al. **J Mol Cell Cardiol** 1996 May;28(5):1085-96

In vitro assessment of various cytochromes P450 and glucuronosyltransferases using the antiarrhythmic propafenone as a probe drug. Kroemer HK, et al. **Methods Enzymol** 1996;272:99-105

Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination. Grant AO. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):432-44 (65 ref.)

Awareness of potential drug interactions may aid avoidance [letter] DeVane CL, et al. **Ther Drug Monit** 1997 Jun; 19(3):366-7

Heat treatment of human serum to inactivate HIV does not alter protein binding of selected drugs. Mosley AK, et al. **Ther Drug Monit** 1997 Aug;19(4):477-9

Diffusion characteristics of placental preparations affect the digoxin passage across the isolated placental lobule. Schmolling J, et al. **Ther Drug Monit** 1997 Feb;19(1):11–6

Human moricizine metabolism. I. Isolation and identification of metabolites in human urine. Richards LE, et al. **Xenobiotica** 1997 Feb;27(2):217–29

PHARMACOKINETICS

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part IV. Lidocaine. Orszulak-Michalak D. **Acta Pol Pharm** 1995 Jul–Aug;52(4):315–9

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part III. Propranolol. Orszulak-Michalak D. **Acta Pol Pharm** 1995 Jul–Aug;52(4):309–13

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part I. Procainamide and its active metabolite-N-acetylprocainamide. Orszulak-Michalak D. **Acta Pol Pharm** 1995 Mar–Apr;52(2):141–6

The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part II. N-acetylprocainamide. Orszulak-Michalak D. **Acta Pol Pharm** 1995 Mar–Apr; 52(2):147–51

Electrophysiology and pharmacology of ibutilide. Naccarelli GV, et al. **Am J Cardiol** 1996 Oct 17;78(8A):12–6 (16 ref.)

Pharmacokinetic evaluation of a case of massive sotalol intoxication. Gustavsson CG, et al. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):856–9

Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: a critical view. Mahmood I. **Biopharm Drug Dispos** 1997 Aug;18(6):465–73

Intestinal absorption kinetics of amiodarone in rat small intestine. Martín-Algarra RV, et al. **Biopharm Drug Dispos** 1997 Aug;18(6):523–32

Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. Harder S, et al. **Br J Clin Pharmacol** 1997 May; 43(5):475–80

Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers. Kimura M, et al. **Br J Clin Pharmacol** 1996 Nov;42(5):583–8

Interaction between sotalol and an antacid preparation. Läer S, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):269–72

Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Martin DE, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):661–4

A computer model for the measurement of compliance using a dual tracer technique. Shine D, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):283–90

Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods. Mehvar R, et al. **Clin Pharmacokinet** 1997 Aug;33(2):122–41 (88 ref.)

Effect of physical activity on serum concentrations of digoxin and digitoxin. Grille W, et al. **Eur J Clin Pharmacol** 1996; 50(3):237–9

Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone--a novel antiarrhythmic agent. Koytchev R, et al. **Eur J Clin Pharmacol** 1996;50(4):315–9

Disopyramide concentrations in human plasma and saliva: comparison of disopyramide concentrations in saliva and plasma unbound concentrations. Sagawa K, et al. **Eur J Clin Pharmacol** 1997;52(1):65–9

Determination of an arylacetamide antiarrhythmic in rat blood and tissues using reversed-phase high-performance liquid chromatography. Walker ML, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26;675(2):257–63

Pharmacokinetics of pirmenol enantiomers and pharmacodynamics of pirmenol racemate in patients with premature ventricular contractions. Janiczek N, et al. **J Clin Pharmacol** 1997 Jun;37(6):502–13

Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. Korth-Bradley JM, et al. **J Clin Pharmacol** 1996 Aug;36(8):715–9

Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide. Martin DE, et al. **J Clin Pharmacol** 1996 Jan;36(1):85–91

Pharmacokinetics of sematilide in renal failure. Shi J, et al. **J Clin Pharmacol** 1996 Feb;36(2):131–43

Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers. Shum L, et al. **J Clin Pharmacol** 1996 Dec;36(12):1161–8

Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy. Tisdale JE, et al. **J Clin Pharmacol** 1996 Jan;36(1):35–41

Disposition of intravenous amiodarone in subjects with normal and impaired renal function. Ujhelyi MR, et al. **J Clin Pharmacol** 1996 Feb;36(2):122–30

Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function [published erratum appears in J Clin Pharmacol 1997 Jan;37(1):73–5] Vadiei K, et al. **J Clin Pharmacol** 1996 Aug;36(8):720–7

Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. Vadiei K, et al. **J Clin Pharmacol** 1997 Jul;37(7):610–7

Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization. Yang BB, et al. **J Clin Pharmacol** 1996 Jul;36(7):623–33

Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. Yukawa E, et al. **J Clin Pharmacol** 1997 Feb;37(2):92–100

Redistribution of amiodarone in heart transplant recipients treated with the drug before operation. Nanas JN, et al. **J Heart Lung Transplant** 1997 Apr;16(4):387–9

Pharmacokinetics and pharmacodynamics of pirmenol enantiomers in coronary artery ligated dogs. Janiczek N, et al. **J Pharm Sci** 1997 Apr;86(4):443–9

Mechanisms of food effects of structurally related antiarrhythmic drugs, disopyramide and bidisomide in the rat. Lee KH, et al. **Pharm Res** 1997 Aug;14(8):1030–8

Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. Cheng JW, et al. **Pharmacotherapy** 1997 May–Jun;17(3):584–90

Altered protein binding of quinidine in patients with atrial fibrillation and flutter. McCollam PL, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):753–9

Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias. Nolan PE Jr. **Pharmacotherapy** 1997 Mar–Apr;17(2 Pt 2):65S–75S; discussion 89S–91S (107 ref.)

Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers. Tarral A, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):791–5

PHARMACOLOGY

Magnesium--a profibrillatory or antifibrillatory drug depending on plasma concentration, heart rate and myocardial perfusion. Aupetit JF, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):516–23

Application of mapping of cardiac electrical activity to the pharmacology. D'Alché EP. **Acta Cardiol** 1996; 51(5):381–94

Effect of almokalant a specific inhibitor of IKr on myocardial ischaemia-reperfusion induced arrhythmias in rabbits. Farkas A, et al. **Acta Physiol Hung** 1996;84(3):281–2

Antiarrhythmic activity of oximethers. Hegedüs M, et al. **Acta Physiol Hung** 1995;83(3):223–6

Effect of restacorin on the early and delayed after depolarization in dog Purkinje fibres. Krassói I, et al. **Acta Physiol Hung** 1996;84(3):299–300

Comparison of the effects of restacorin and flecainide on various cardiac transmembrane potassium currents. Németh M, et al. **Acta Physiol Hung** 1996;84(3):317–8

Derivatives of 2-mercaptobenzenesulphonamide. XVIII. Syntheses and cardiovascular effects of some S- and S,N-substituted 4-chloro-2-mercapto-5-methyl-N-(5-amino-1,2,4-triazol-3-yl) benzenesulphonamide derivatives. Brzozowski Z, et al. **Acta Pol Pharm** 1995 May–Jun; 52(3):223–30

Effects of verapamil, propranolol, and procainamide on adenosine-induced negative dromotropism in human beings. Lai WT, et al. **Am Heart J** 1996 Oct;132(4):768–75

Reduction of myocardial infarct size in rabbits and inhibition of activation of rabbit and human neutrophils by lidocaine. Vitola JV, et al. **Am Heart J** 1997 Mar;133(3):315–22

Hemodynamic effects of the class III antiarrhythmic drug, d-sotalol, in patients with congestive heart failure. Gottlieb SS, et al. **Am J Cardiol** 1996 Dec 15;78(12):1411–5

Effects of adenosine on wavelength of premature atrial complexes in patients without structural heart disease. Kabell G, et al. **Am J Cardiol** 1996 Dec 15;78(12):1443–6

Electrophysiology and pharmacology of ibutilide. Naccarelli GV, et al. **Am J Cardiol** 1996 Oct 17;78(8A):12–6 (16 ref.)

Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Stambler BS, et al. **Am J Cardiol** 1997 Aug 15;80(4):458–63

Central hemodynamic effects of oxytocin and interaction with magnesium and pregnancy in the isolated perfused rat heart. Coulson CC, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):91–3

Preconditioning is not abolished by the delayed rectifier K+ blocker dofetilide. Grover GJ, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1207–14

Actions of lidocaine on reentrant ventricular rhythms in the subacute myocardial infarction period in dogs. Yin H, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H299–309

Intracellular pH regulation in cultured human pleural mesothelial cells. Liaw YS, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):597–602

Effects of amiodarone on thyroid function. Harjai KJ, et al. **Ann Intern Med** 1997 Jan 1;126(1):63–73 (109 ref.)

Effects of cromakalim and glibenclamide in ischemic and reperfused hearts. Tosaki A, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:460–5

Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Chow MS. **Ann Pharmacother** 1996 Jun; 30(6):637–43 (38 ref.)

Effects of lidocaine on cerebral lipid peroxidation and neutrophil activation following complete compression ischemia. Lantos J, et al. **Arch Int Pharmacodyn Ther** 1996 Mar–Apr;331(2):179–88

Arrhythmogenic effect of beta-adrenoceptor-blocking drugs in Purkinje fibres of guinea-pig hearts. Lemmens-Gruber R, et al. **Arch Int Pharmacodyn Ther** 1996 Jan–Feb; 331(1):46–58

Drug profile of new benzofurane derivatives in guinea-pig isolated heart muscle preparations. Lemmens Gruber R, et al. **Arch Int Pharmacodyn Ther** 1995 Sep–Oct; 330(2):165–76

Action of adenine derivatives on experimental atrial flutter in the canine heart. Alvarado JL, et al. **Arch Med Res** 1997 Autumn;28(3):329–35

Search for new antiarrhythmic and hypotensive compounds. Synthesis, antiarrhythmic, antihypertensive, and alpha-adrenoceptor blocking activity of novel 1-[(2-hydroxy-3-amino)]-propylpyrrolidin-2-one derivatives. Filipek B, et al. **Arch Pharm (Weinheim)** 1997 Jul;330(7):225–31

New benzothiophene compounds related to propafenone. Unterhalt B, et al. **Arch Pharm (Weinheim)** 1997 Apr; 330(4):107–8

Effects of acute cardioselective and non-selective beta-adrenergic blockade on plasma ammonia levels in exercising dogs. Matthys D, et al. **Arch Physiol Biochem** 1996;104(1):14–9

Antiarrhythmic action of the new calcium antagonist [1,2,5-trimethyl-4-phenyl-4-beta-(N-cyanoethyl-N-4'-methoxybenzyl) -ethylamino]piperidine dihydrochloride. Alexanian AR, et al. **Arzneimittelforschung** 1996 Dec; 46(12):1110–3

Cardiovascular and antiarrhythmic effects of the azulene-1-carboxamidine derivative N1,N1-dimethyl-N2-(2-pyridylmethyl)-5-isopropyl-3, 8-dimethylazulene-1-carboxamidine. Saitoh M, et al. **Arzneimittelforschung** 1997 Jul;47(7):810–5

Electromechanical effects of newly synthetized propafenone derivatives on isolated guinea-pig heart muscle preparations. Studenik C, et al. **Arzneimittelforschung** 1996 Feb;46(2):134–8

Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Koley AP, et al. **Biochem Pharmacol** 1997 Feb 21;53(4):455–60

Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats. Ohtani H, et al. **Biol Pharm Bull** 1996 Sep; 19(9):1189–96

Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. Harder S, et al. **Br J Clin Pharmacol** 1997 May; 43(5):475–80

Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation. Aupetit JF, et al. **Br J Pharmacol** 1997 Feb;120(3):523–9

Electrophysiological mechanisms for antiarrhythmic efficacy and positive inotropy of liriodenine, a natural aporphine alkaloid from Fissistigma glaucescens. Chang GJ, et al. **Br J Pharmacol** 1996 Aug;118(7):1571–83

IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats. Chen J, et al. **Br J Pharmacol** 1996 Nov; 119(5):937–42

Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Chi L, et al. **Br J Pharmacol** 1996 Mar;117(6):1261–9

Inhibition of L-type calcium current by propafenone in single myocytes isolated from the rabbit atrioventricular node. Hancox JC, et al. **Br J Pharmacol** 1997 May;121(1):7–14

Block of pancreatic ATP-sensitive K+ channels and insulinotrophic action by the antiarrhythmic agent, cibenzoline. Ishida-Takahashi A, et al. **Br J Pharmacol** 1996 Apr;117(8):1749–55

Effects of class III antiarrhythmic drugs on the Na(+)-activated K+ channels in guinea-pig ventricular cells. Mori K, et al. **Br J Pharmacol** 1996 Sep;119(1):133–41

Electrophysiological effects of CI-980, a tubulin binding agent, on guinea-pig papillary muscles. Pérez O, et al. **Br J Pharmacol** 1997 Jan;120(2):187–92

Effect of lignocaine in myocardial contusion: an experiment on rabbit isolated heart. Pu Q, et al. **Br J Pharmacol** 1996 Jun;118(4):1072–8

Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Varró A, et al. **Br J Pharmacol** 1996 Mar;117(6):1181–6

Potent block of volume-activated chloride currents in endothelial cells by the uncharged form of quinine and quinidine. Voets T, et al. **Br J Pharmacol** 1996 Aug; 118(7):1869–71

Cardiac effects of quinidine on guinea-pig isolated perfused hearts after in vivo quinidine pretreatment. Yang Q, et al. **Br J Pharmacol** 1997 Sep;122(1):7–12

The effect of clofilium, a K-channel blocker, on the electrogenic K secretion and the sensory discharge at the frog semicircular canal. Rossi ML, et al. **Brain Res** 1996 May 20;721(1-2):174–80

Class III antiarrhythmic effects of ceruloplasmin on rat heart. Atanasiu R, et al. **Can J Physiol Pharmacol** 1996 Jun; 74(6):652–6

Effects of procainamide on the excitable gap composition in a canine model of atrial flutter. Jalil E, et al. **Can J Physiol Pharmacol** 1997 Jan;75(1):1–8

Verapamil blockade of the paradoxic bradycardia in rats induced by inferior vena cava occlusion during the administration of isoproterenol or calcium: the role of Ca2+. Waxman MB, et al. **Can J Physiol Pharmacol** 1996

Oct;74(10):1132–40
Neurohumoral effects of digoxin: a target for further investigation. Gheorghiade M. **Cardiologia** 1996 Oct; 41(10):967–72 (49 ref.)
Assessment of frequency dependency of the class III effects of almokalant: a study using programmed stimulation and recording of monophasic action potentials and ventricular paced QT intervals. Darpö B, et al.
Cardiovasc Drugs Ther 1996 Nov;10(5):539–47
Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential. Nair LA, et al.
Cardiovasc Drugs Ther 1997 Apr;11(2):149–67 (140 ref.)
Effects of AWD 23–111, a new antiarrhythmic substance, on cardiac conduction and refractoriness. Stark U, et al.
Cardiovasc Drugs Ther 1996 Nov;10(5):531–8
Hypotonic–induced stretch counteracts the efficacy of the class III antiarrhythmic agent E–4031 in guinea pig myocytes. Groh WJ, et al. **Cardiovasc Res** 1996 Feb; 31(2):237–45
Insulin secretion and its modulation by antiarrhythmic and sulfonylurea drugs. Horie M, et al. **Cardiovasc Res** 1997 Apr;34(1):69–72 (42 ref.)
Cellular electropharmacology of amiodarone. Kodama I, et al. **Cardiovasc Res** 1997 Jul;35(1):13–29 (188 ref.)
Role of nitric oxide, cyclic GMP and superoxide in inhibition by adenosine of calcium current in rabbit atrioventricular nodal cells. Martynyuk AE, et al. **Cardiovasc Res** 1997 May; 34(2):360–7
The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers. Németh M, et al.
Cardiovasc Res 1996 Feb;31(2):246–8
Short–term inhibition of the Na–H exchanger limits acidosis and reduces ischemic injury in the rat heart. Schaefer S, et al. **Cardiovasc Res** 1997 May;34(2):329–36
Magnesium abolishes inadequate kinetics of frequency adaptation of the Q–aT interval in the presence of sotalol. Stark G, et al. **Cardiovasc Res** 1997 Jul;35(1):43–51
Effect of brief hypoxia on reperfusion arrhythmias and release of Ca2+ by rat heart homogenate blocked by ryanodine. Tani M, et al. **Cardiovasc Res** 1996 Feb;31(2):263–9
Reversal of doxorubicin resistance by the amiloride analogue EIPA in multidrug resistant human colon carcinoma cells. Pannocchia A, et al. **Cell Biochem Funct** 1996 Mar; 14(1):11–8
Oxygen uptake kinetics and cardiopulmonary performance in lone atrial fibrillation and the effects of sotalol. Lok NS, et al. **Chest** 1997 Apr;111(4):934–40
Lidocaine block of LQT–3 mutant human Na+ channels. An RH, et al. **Circ Res** 1996 Jul;79(1):103–8
Termination of reentry by lidocaine in the tricuspid ring in vitro. Role of cycle–length oscillation, fast use–dependent kinetics, and fixed block. Fei H, et al. **Circ Res** 1997 Feb; 80(2):242–52
Relative role of alkalosis and sodium ions in reversal of class I antiarrhythmic drug–induced sodium channel blockade by sodium bicarbonate. Bou–Abboud E, et al.
Circulation 1996 Oct 15;94(8):1954–61
Postischemic antiarrhythmic effects of angiotensin–converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion. Brunner F, et al. **Circulation** 1996 Oct 1;94(7):1752–61
Mechanism of action potential prolongation by RP 58866 and its active enantiomer, terikalant. Block of the rapidly activating delayed rectifier K+ current, IKr. Jurkiewicz NK, et al. **Circulation** 1996 Dec 1;94(11):2938–46
Molecular physiology and pharmacology of HERG. Single–channel currents and block by dofetilide. Kiehn J, et al. **Circulation** 1996 Nov 15;94(10):2572–9
Amiodarone inhibits production of tumor necrosis factor–alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. Matsumori A, et al. **Circulation** 1997 Sep 2,96(5):1386–9
More on amiodarone and torsade de pointes [letter; comment] Ostermaier R, et al. **Circulation** 1996 Nov 1;94(9):2316–8 . Comment on: Circulation 1995 Dec 1;92(11):3255–63. Comment on: Circulation 1995 Dec 1;92(11):3264–72.
Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long–QT syndrome. Shimizu W, et al. **Circulation** 1997 Sep 16; 96(6):2038–47
Class III antiarrhythmic effects of zatebradine. Time–, state–, use–, and voltage–dependent block of hKv1.5 channels. Valenzuela C, et al. **Circulation** 1996 Aug 1;94(3):562–70
The effects of lidocaine on cardiac parasympathetic control in normal subjects and in subjects after myocardial infarction. Abramovich–Sivan S, et al. **Clin Auton Res** 1996 Dec;6(6):313–9
Differential effects of antiarrhythmic agents on pos'–pause repolarization in cardiac Purkinje fibres. Wyse KR, et al.
Clin Exp Pharmacol Physiol 1996 Sep;23(9):825–9
Pharmacokinetic–pharmacodynamic profile of angiotensin II receptor antagonists. Csajka C, et al.
Clin Pharmacokinet 1997 Jan;32(1):1–29 (112 ref.)
The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Capon DA, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):295–307
Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Laganière S, et al.
Clin Pharmacol Ther 1996 Sep;60(3):255–64
Quinidine administration increases steady state serum digoxin concentration in horses [see comments] Parraga ME, et al. **Equine Vet J Suppl** 1995 Sep;(19):114–9. Comment in: Equine Vet J Suppl 1995 Sep;(19):97–100.
The differentiation of propafenone from other class Ic agents, focusing on the effect on ventricular response rate attributable to its beta–blocking action. Faber TS, et al.
Eur J Clin Pharmacol 1996;51(3–4):199–208 (103 ref.)
Cardiac electrophysiological effects of propafenone and its 5–hydroxylated metabolite in the conscious dog. Boucher M, et al. **Eur J Pharmacol** 1996 Nov 14;315(2):171–7
A comparison between the effects of BMS–180448, a novel K+ channel opener, and cromakalim in rat and dog. D'Alonzo AJ, et al. **Eur J Pharmacol** 1995 Dec 27; 294(1):271–80
5–hydroxydecanoate fails to attenuate ventricular fibrillation in a conscious canine model of sudden cardiac death. Friedrichs GS, et al. **Eur J Pharmacol** 1996 Jun 13; 306(1–3):99–106
Increase in gap junction conductance by an antiarrhythmic peptide. Müller A, et al. **Eur J Pharmacol** 1997 May 26; 327(1):65–72
The cardiac electrophysiological effects of sparteine and its analogue BRB–I–28 in the rat. Pugsley MK, et al.
Eur J Pharmacol 1995 Dec 27;294(1):319–27
Rate–dependent effects of ajmaline and propafenone on atrioventricular conduction. Stark G, et al.
Eur J Pharmacol 1996 Aug 22;310(1):29–35
Blockade of cardiac Na+ channels by a charged class I antiarrhythmic agent, bisaramil: possible interaction of the drug with a pre–open closed state. Sunami A, et al.
Eur J Pharmacol 1996 Sep 26;312(2):245–55
Antiarrhythmic effects of HOE642, a novel Na(+)–H+ exchange inhibitor, on ventricular arrhythmias in animal hearts. Xue YX, et al. **Eur J Pharmacol** 1996 Dec 19; 317(2–3):309–16
Synthesis and pharmacological activity of some N,N–disubstituted 1–amino–2–phenyl–3H,12H–naphtho[1,2–b]pyrano[2,3–d]pyran–3–ones. Longobardi M, et al. **Farmaco** 1996 Oct; 51(10):665–8
Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241. Suessbrich H, et al.
FEBS Lett 1997 Sep 8;414(2):435–8
Direct evidence for in vivo nitroxide free radical production from a new antiarrhythmic drug by EPR spectroscopy. Twomey P, et al. **Free Radic Biol Med** 1997;22(5):909–16
Effect of a prenylamine analog (MG8926) on spontaneous action potentials in isolated rabbit sinoatrial node. Nakanishi H, et al. **Fukushima J Med Sci** 1996 Dec; 42(1–2):1–10
Clinical electrophysiologic effects of a single high oral dose of amiodarone. Deharo JC, et al.
Fundam Clin Pharmacol 1997;11(3):275–80
Triiodothyronine and amiodarone effects on beta 3–adrenoceptor density and lipolytic response to the beta 3–adrenergic agonist BRL 37344 in rat white adipocytes. Germack R, et al. **Fundam Clin Pharmacol** 1996; 10(3):289–97
Chronotropic and inotropic effects of terikalant on isolated, blood–perfused atrial and ventricular preparations of dogs. Lakhe M, et al. **Fundam Clin Pharmacol** 1997;11(4):331–8
Electropharmacology of Ro 22–9194, a new antiarrhythmic agent. Kodama I, et al. **Gen Pharmacol** 1996 Jul; 27(5):755–60 (19 ref.)
Electrophysiological effects of EGIS–7229, a new antiarrhythmic agent, in isolated guinea pig papillary muscle. Pankucsi C, et al. **Gen Pharmacol** 1997 Aug; 29(2):275–80
Antiarrhythmic and electrophysiological effects of the novel KATP channel opener, rilmakalim, in rabbit cardiac cells. Riccioppo Neto F, et al. **Gen Pharmacol** 1997 Aug; 29(2):201–5
Sematilide blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. Takai H, et al.
Gen Pharmacol 1997 May;28(5):665–70
Effect of long–term administration of stobadine to rats on selective variables of spontaneous behaviour of their offspring. Dubovický M, et al. **Gen Physiol Biophys** 1996 Apr;15(2):181–6
The protective effect of D–sotalol against hypoxia–induced myocardial uncoupling. Manoach M, et al.
Heart Vessels 1996;11(6):281–8
Cardiomyocytes in culture––a model to study the cellular actions of amiodarone. Kessler–Icekson G, et al.
Isr J Med Sci 1996 Dec;32(12):1212–6
Preferential action of mexiletine on central common pathway of reentrant ventricular tachycardia. Aizawa Y, et al.
J Am Coll Cardiol 1996 Dec;28(7):1759–64
Optical mapping of drug–induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart [see comments] Asano Y, et al. **J Am Coll Cardiol** 1997 Mar 15;29(4):831–42. Comment in: J Am Coll Cardiol 1997 Mar 15;29(4):843–5.
Propafenone during acute myocardial ischemia in patients: a double–blind, randomized, placebo–controlled study. Faber TS, et al. **J Am Coll Cardiol** 1997 Mar 1;29(3):561–7
Electrophysiologic effects of sodium channel blockade on anisotropic conduction and conduction block in canine myocardium: preferential slowing of longitudinal conduction by flecainide versus disopyramide or lidocaine. Kondo T, et al. **J Am Coll Cardiol** 1997 Jun;29(7):1639–44
Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? Murakawa Y, et al. **J Am Coll Cardiol** 1997 Mar 1; 29(3):688–92
Effect of long–term administration of stobadine on exploratory behaviour and on striatal levels of dopamine and serotonin in rats and their offspring. Dubovický M, et al. **J Appl Toxicol** 1997 Jan–Feb;17(1):63–70
The effect of quinidine and myocardial ischemia on the isolated rat heart with fat–free diet. Merkin MS, et al.
J Basic Clin Physiol Pharmacol 1994 Apr–Jun;5(2):133–49
Effects of levosimendan on left ventricular function: correlation with plasma concentrations in conscious dogs. McGough MF, et al. **J Cardiothorac Vasc Anesth** 1997 Feb; 11(1):49–53
Flecainide and the electrophysiologic matrix: the effects of flecainide acetate on the determinants of cardiac excitability in sheep Purkinje fibers. Arnsdorf MF, et al.
J Cardiovasc Electrophysiol 1996 Dec;7(12):1172–82
Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy [see comments] Cha Y, et al.
J Cardiovasc Electrophysiol 1996 Sep;7(9):809–27. Comment in: J Cardiovasc Electrophysiol 1996 Sep;7(9):828–32.
Comparison of the rate–dependent properties of the class III antiarrhythmic agents azimilide (NE–10064) and E–4031: considerations on the mechanism of reverse rate–dependent action potential prolongation. Groh WJ, et al.
J Cardiovasc Electrophysiol 1997 May;8(5):529–36
Effects of a class III antiarrhythmic drug and biphasic shocks on the postdefibrillation refractory period of relatively refractory myocardium. Murakawa Y, et al.
J Cardiovasc Electrophysiol 1996 Jul;7(7):603–11
Dofetilide versus quinidine for atrial flutter: viva la difference!? [editorial; comment] Olshansky B.
J Cardiovasc Electrophysiol 1996 Sep;7(9):828–32 (18 ref.) . Comment on: J Cardiovasc Electrophysiol 1996 Sep;7(9):809–27.
Early afterdepolarizations produced by d,l–sotalol and clofilium. Patterson E, et al. **J Cardiovasc Electrophysiol** 1997 Jun;8(6):667–78
Effects of azimilide dihydrochloride on circus movement atrial flutter in the canine sterile pericarditis model. Restivo M, et al. **J Cardiovasc Electrophysiol** 1996 Jul;7(7):612–24
Modulation of procainamide's effect on conduction by cellular uncoupling in perfused rabbit hearts. Spear JF, et al. **J Cardiovasc Electrophysiol** 1997 Feb;8(2):199–214
Azimilide (NE–10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca, and Na channels. Yao JA, et al. **J Cardiovasc Electrophysiol** 1997 Feb;8(2):184–98
Class III antiarrhythmic effects of LY–190147 on defibrillation threshold. Beatch GN, et al.
J Cardiovasc Pharmacol 1996 Feb;27(2):218–25
Rate–dependent effects of sematilide on ventricular monophasic action potential duration and delayed rectifier K+ current in rabbits. Beatch GN, et al.
J Cardiovasc Pharmacol 1996 Nov;28(5):618–30
Electrophysiological mechanisms for the antiarrhythmic action of (–)–caryachine in rat heart. Chen L, et al.
J Cardiovasc Pharmacol 1996 May;27(5):740–8
Electrophysiologic effects of a class I antiarrhythmic agent, cibenzoline, on the refractoriness and conduction of the human atrium in vivo. Esato M, et al.
J Cardiovasc Pharmacol 1996 Aug;28(2):321–7
Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG–V–13, in the mammalian heart. Fazekas T, et al.
J Cardiovasc Pharmacol 1996 Aug;28(2):182–91
Electrophysiologic effects of SD–3212, a new class I antiarrhythmic drug, on canine atrial flutter and atrial action–potential characteristics. Fujiki A, et al.
J Cardiovasc Pharmacol 1997 Apr;29(4):471–5
Quinidine pharmacodynamics in normal and isoproterenol–induced hypertrophied blood–perfused working rabbit hearts. Gillis AM, et al.
J Cardiovasc Pharmacol 1996 Jun;27(6):916–26
Differential class III antiarrhythmic effects of ambasilide and dofetilide at different extracellular potassium and pacing frequencies. Gjini V, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):314–20
Interaction between amiodarone and lidocaine. Ha HR, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):533–9
Changes in atrioventricular conduction properties with refractory–period modulation. Hewett KW, et al.
J Cardiovasc Pharmacol 1996 Dec;28(6):824–32
Atrioventricular junctional rhythm induced by sympathetic stimulation in E–4031–treated dog hearts. Imamura H, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):507–12
Possible involvement of altered Na+ –Ca2+ exchange in negative inotropic effects of class I antiarrhythmic drugs on rabbit and rat ventricles. Ito K, et al.
J Cardiovasc Pharmacol 1996 Mar;27(3):355–61
Protective effect of the sodium/hydrogen exchange inhibitors during global low–flow ischemia. Khandoudi N, et al.
J Cardiovasc Pharmacol 1996 Oct;28(4):540–6
Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias. Kobayashi Y, et al. **J Cardiovasc Pharmacol** 1997 Sep;30(3):367–73
Zatebradine slows ectopic ventricular rhythms in canine

heart 24 hours after coronary artery ligation. Lasker SM, et al. **J Cardiovasc Pharmacol** 1997 May;29(5):662–9

Selectivity of class–III antiarrhythmic action of clofilium in guinea pig ventricular myocytes. Li Q, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):401–10

Pharmacological studies on a new antihypertensive agent, S–2150, a benzothiazepine derivative: 1. Antinecrotic and antiarrhythmic effects in reperfused rat hearts. Masui M, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):526–32

Antiarrhythmic effects of optical isomers of disopyramide on canine ventricular arrhythmias. Nakamura M, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):368–75

Amiodarone–induced lymphocyte toxicity and mitochondrial function. Yasuda SU, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):94–100

Pharmacological targeting of long QT mutant sodium channels. Wang DW, et al. **J Clin Invest** 1997 Apr 1; 99(7):1714–20

Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers. Shum L, et al. **J Clin Pharmacol** 1996 Dec;36(12):1161–8

Modifications in the evolution of the dominant frequency in ventricular fibrillation induced by amiodarone, diltiazem, and flecainide. An experimental study. Chorro FJ, et al. **J Electrocardiol** 1996 Oct;29(4):319–26

Arrhythmogenic and antiarrhythmic actions of substances of abuse: effects on triggered activity. Gallardo–Carpentier A, et al. **J Electrocardiol** 1997 Apr;30(2):137–42

Effects of lidocaine and diltiazem on recovery of electrophysiologic activity during partial reperfusion following severe myocardial ischemia in canine hearts. Murasato Y, et al. **J Electrocardiol** 1997 Apr;30(2):113–25

Facilitation of epinephrine–induced afterdepolarizations by class III antiarrhythmic drugs. Patterson E, et al. **J Electrocardiol** 1997 Jul;30(3):217–24

Tri–iodothyronine prevents the amiodarone–induced decrease in the expression of the liver low–density lipoprotein receptor gene. Hudig F, et al. **J Endocrinol** 1997 Mar;152(3):413–21

Mechanisms of amiodarone–induced inhibition of Ca2+ current in isolated neonatal rabbit ventricular myocytes. Chen F, et al. **J Investig Med** 1996 Dec;44(9):583–9

Clofilium–induced block of delayed rectifier type K+ current in atrial tumor cells (AT–1 cells). Bhattacharyya ML, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):301–7

Effects of caffeine and cyclopiazonic acid on contractile proteins of adult and newborn ferret cardiac fibres. Bonnet V, et al. **J Mol Cell Cardiol** 1996 Jun;28(6):1287–95

Further investigations into the mechanism of antifibrillatory action of the specific IK1 blocker, RP58866, assessed using the rat dual coronary perfusion model. Rees SA, et al. **J Mol Cell Cardiol** 1995 Dec;27(12):2595–606

Epinephrine facilitates cardiac fibrillation by shortening action potential refractoriness. Tovar OH, et al. **J Mol Cell Cardiol** 1997 May;29(5):1447–55

Comparison of the effects of class I anti–arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K+ current of guinea–pig ventricular myocytes. Wang DW, et al. **J Mol Cell Cardiol** 1996 May; 28(5):893–903

The in–vivo cardiovascular effects of a putative class III anti–arrhythmic drug, AM 92016. Hagerty MJ, et al. **J Pharm Pharmacol** 1996 Apr;48(4):417–21

Electrophysiologic effects of nibentan (HE–11) on canine cardiac tissue. Anyukhovsky EP, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1137–46

Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse. De Luca A, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):93–100

Mechanisms of the atrium–specific positive inotropic activities of quinidine– and atropine–like agents in rats. Deng XF, et al. **J Pharmacol Exp Ther** 1997 Apr; 281(1):322–9

Effects of class III antiarrhythmic drugs on transient outward and ultra–rapid delayed rectifier currents in human atrial myocytes. Feng J, et al. **J Pharmacol Exp Ther** 1997 Apr; 281(1):384–92

Effects of the new class I antiarrhythmic agent Ro 22–9194, (2R)–2–amino–N–(2,6–dimethylphenyl)–N–[3–(3–pyridyl) propyl]propionamide D–tartrate, on ischemia– and reperfusion–induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. Murakami M, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):877–83

Class III electrophysiologic actions of imidazole–substituted diheterabicyclononanes in canine myocardium. Patterson E, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):155–62

Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. Thomas GP, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1090–7

Quinidine enhances and suppresses Kv1.2 from outside and inside the cell, respectively. Tseng GN, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):844–55

Inhibitory effect of amiodarone on the muscarinic acetylcholine receptor–operated potassium current in guinea pig atrial cells. Watanabe Y, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):617–24

Quinidine preferentially blocks the slow delayed rectifier potassium channel in the rested state. Yao JA, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):856–64

Gating charge and ionic currents associated with quinidine block of human Kv1.5 delayed rectifier channels. Fedida D. **J Physiol (Lond)** 1997 Mar 15;499 (Pt 3):661–75

The effects of class I drugs on the cycle length of sustained ventricular tachycardia and the signal–averaged electrocardiogram. Doi T, et al. **Jpn Circ J** 1997 Jun; 61(6):495–502

Action of antiarrhythmic agents on the area of slow conduction in ventricular tachycardia. Aizawa Y, et al. **Jpn Heart J** 1996 Sep;37(5):773–84 (24 ref.)

Acute and chronic effects of amiodarone on mammalian ventricular cells. Kodama I, et al. **Jpn Heart J** 1996 Sep; 37(5):719–30 (25 ref.)

The heart sodium channel phenotype for inactivation and lidocaine block. Makielski JC. **Jpn Heart J** 1996 Sep; 37(5):733–9

Effects of antiarrhythmic agents and Mg2+ on aconitine–induced arrhythmias. Sawanobori T, et al. **Jpn Heart J** 1996 Sep;37(5):709–18 (26 ref.)

Effects of sematilide, a novel class III antiarrhythmic agent, on delayed rectifier K+ current in guinea pig atrial myocytes. Ishii Y, et al. **Jpn J Pharmacol** 1996 Aug; 71(4):361–5

Effects of aprindine on ischemia/reperfusion–induced cardiac contractile dysfunction of perfused rat heart. Kamiyama T, et al. **Jpn J Pharmacol** 1996 Mar;70(3):227–34

Antiarrhythmic and proarrhythmic effects of sematilide in canine ventricular arrhythmia models. Xue YX, et al. **Jpn J Pharmacol** 1996 Feb;70(2):129–38

Cholinergic autoantibodies in sinus–node dysfunction [letter] Ferrari I, et al. **Lancet** 1997 Jul 26;350(9073):262–3

Life–threatening interaction between clarithromycin and disopyramide [letter] Paar D, et al. **Lancet** 1997 Feb 1; 349(9048):326–7

Screening for novel drug effects with a microphysiometer: a potent effect of clofilium unrelated to potassium channel blockade. Rabinowitz JD, et al. **Life Sci** 1997; 61(7):PL87–94

Polyunsaturated fatty acids exert antiarrhythmic actions as free acids rather than in phospholipids. Weylandt KH, et al. **Lipids** 1996 Sep;31(9):977–82

Stobadine pretreatment enhances glutathione peroxidase activity in the heart of irradiated mice. Kovácková Z, et al. **Methods Find Exp Clin Pharmacol** 1997 May;19(4):241–3

Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Dixon IM, et al. **Mol Cell Biochem** 1996 Dec 6;165(1):31–45

Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers. De Luca A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec; 352(6):653–61

Electrophysiological properties of the propafenone–analogue GE 68 (1–[3–(phenylethyl)–2–benzofuryl]–2–(propylamino)–ethanol) in isolated preparations and ventricular myocytes of guinea–pig hearts. Lemmens–Gruber R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):230–8

Actions of the antiarrhythmic peptide AAP10 on intercellular coupling. Müller A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jul; 356(1):76–82

Electrophysiological effects of EGIS–7229, a new antiarrhythmic agent, in isolated mammalian and human cardiac tissues. Pankucsi C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Mar; 355(3):398–405

Interaction of class III antiarrhythmic drugs with muscarinic M2 and M3 receptors: radioligand binding and functional studies. Uemura H, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec; 353(1):73–9

Inhibition of potassium currents by the antiarrhythmic drug E4031 in rat taste receptor cells. Sun XD, et al. **Neurosci Lett** 1996 Feb 9;204(3):149–52

Correlation between electrophysiological effects of mexiletine and ischemic protection in central nervous system white matter. Stys PK, et al. **Neuroscience** 1996 Mar;71(1):27–36

Steroid–eluting electrodes prevent chronic pacing threshold rise in the atrial chamber after oral propafenone administration. Cornacchia D, et al. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 1):240–4

Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination. Grant AO. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):432–44 (65 ref.)

Electrophysiological effects of E 4031, a drug with selective class III properties, in man. Katritsis D, et al. **Pacing Clin Electrophysiol** 1997 Apr;20(4 Pt 1):930–7

The influence of sodium channel blockade on the defibrillation energy requirements of biphasic versus monophasic shocks. Nelson SD, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 1):1568–73

How to measure AV nodal refractoriness in the presence of verapamil, amiodarone, digoxin, and diltiazem. Stark G, et al. **Pacing Clin Electrophysiol** 1996 Feb;19(2):157–64

Influence of duration of rapid ventricular pacing on ventricular refractoriness in the presence of propafenone and lidocaine. Stark U, et al. **Pacing Clin Electrophysiol** 1997 Jan;20(1 Pt 1):43–50

The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Jett MF, et al. **Pain** 1997 Jan;69(1–2):161–9

The class III antiarrhythmic agent E–4031 selectively blocks the inactivating inward–rectifying potassium current in rat anterior pituitary tumor cells (GH3/B6 cells). Weinsberg F, et al. **Pflugers Arch** 1997 May;434(1):1–10

Indirect parasympathomimetic activity of the class III antiarrhythmic substance D/L–sotalol in vitro: reversible inhibition of cholinesterase isoenzymes from blood and the human central nervous system. Chemnitius JM, et al. **Pharmacol Res** 1996 Nov–Dec;34(5–6):193–200

Flecainide alters the cardiac microscopic activation pattern. An in–vitro study using voltage sensitive dyes. Dhein S, et al. **Pharmacol Res** 1996 Sep–Oct;34(3–4):125–30

Thimerosal attenuates ischaemia–reperfusion arrhythmias in rats: no modification by anti–ischaemic agent trimetazidine or endothelin receptor antagonist bosentan. Iskit AB, et al. **Pharmacol Res** 1996 Jul–Aug;34(1–2):17–23

Bisaramil and antiarrhythmics as inhibitors of free radical generation. Paróczai M, et al. **Pharmacol Res** 1997 Apr; 35(4):279–85

Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias? Rees S, et al. **Pharmacol Ther** 1996;69(3):199–217 (272 ref.)

Effect of the class III antiarrhythmic agent E–4031 on the ATP–sensitive potassium channel in rabbit ventricular myocytes. West PD, et al. **Pharmacol Toxicol** 1996 Feb; 78(2):89–93

Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias. Nolan PE Jr. **Pharmacotherapy** 1997 Mar–Apr;17(2 Pt 2):65S–75S; discussion 89S–91S (107 ref.)

Myocardial protective effect of honokiol: an active component in Magnolia officinalis. Tsai SK, et al. **Planta Med** 1996 Dec;62(6):503–6

Effect of butobendin on dopamine beta–hydroxylase in vitro. Grabowska M, et al. **Pol J Pharmacol** 1996 Jan–Feb; 48(1):39–45

Influence of selected antiarrhythmic drugs on the hemodynamic parameters in rabbits during anesthesia. Part III. Ketamine anesthesia. Orszulak–Michalak D. **Pol J Pharmacol** 1995 Sep–Oct;47(5):407–16

Regulation of sodium channel gene expression by class I antiarrhythmic drugs and n – 3 polyunsaturated fatty acids in cultured neonatal rat cardiac myocytes. Kang JX, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2724–8

Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage–gated Na+ channels. Ragsdale DS, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9270–5

Antiarrhythmic effects of LR–A/113 a new calcium antagonistic drug. Stella L, et al. **Res Commun Mol Pathol Pharmacol** 1996 Aug;93(2):235–48

Excitatory actions of adenosine on ventricular automaticity. Hernández J, et al. **Trends Pharmacol Sci** 1996 Apr; 17(4):141–4 (39 ref.)

Targeting ischaemia––cell swelling and drug efficacy. Wright AR, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):224–8 (45 ref.)

Cardiopulmonary effects of combinations of medetomidine hydrochloride and atropine sulphate in dogs. Alibhai HI, et al. **Vet Rec** 1996 Jan 6;138(1):11–3

[Influence of anti–arrhythmia agents on heart rate variability] Brembilla–Perrot B, et al. **Ann Cardiol Angeiol (Paris)** 1997 Mar;46(3):129–34 (Eng. Abstr.) **(Fre)**

[Quinidine and high–amplification ECG] Brembilla–Perrot B, et al. **Ann Cardiol Angeiol (Paris)** 1997 Jan;46(1):15–20 (20 ref.) (Eng. Abstr.) **(Fre)**

[Class III antiarrhythmic drugs] Aiba T, et al. **Nippon Rinsho** 1996 Aug;54(8):2125–31 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Protective effects of mexiletine on reperfused ischemic myocardium] Tanaka T, et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):155–9 (Eng. Abstr.) **(Jpn)**

[Brazilian multicenter study of sotalol effectiveness in ventricular arrhythmias] Maia IG, et al. **Arq Bras Cardiol** 1996 Mar;66(3):173–8 (Eng. Abstr.) **(Por)**

[Effect of befol on the threshold of electric fibrillation of heart ventricles] Galenko–Iaroshevskiĭ PA, et al. **Biull Eksp Biol Med** 1997 Mar;123(3):305–7 **(Rus)**

[Comparative anti–arrhythmia activity of rinocaine and lidocaine] Galenko–Iaroshevskiĭ PA, et al. **Biull Eksp Biol Med** 1996 Nov;122(11):517–20 **(Rus)**

[Correction with cordarone of changes in cathepsin D induced by simulated circulatory insufficiency and toxic effect of strophanthin] Galenko–Iarpsjevskii' PA, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):407–9 **(Rus)**

[A study of the mechanism of lidocaine and befol effects on Na–exchange in normal cardiomyocytes and in the experimental model of hypoxia in vitro] Khankoeva AI, et al. **Biull Eksp Biol Med** 1996 Jul;122(7):45–7 **(Rus)**

[Comparative characteristic of sodium blocking properties of anti–arrhythmia agents on isolated rats cardiomyocytes] Khankoeva AI, et al. **Biull Eksp Biol Med** 1997 Jun; 123(6):666–8 **(Rus)**

[The anti–arrhythmic effect of the mu–opiate receptor agonists in adrenal arrhythmia: the role of the autonomic nervous system] Maslov LN, et al. **Biull Eksp Biol Med** 1996 Jul;122(7):25–7 **(Rus)**

[Differences in the anti–arrhythmia effect of dalargin and

beta-endorphin in severe myocardial ischemia during stimulation of the sensorimotor cortex] Mikhallova SD, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):28-31 **(Rus)**

[Mechanism of the protective effect of dalargin on development of ischemic heart arrhythmias] Mikhallova SD, et al. **Biull Eksp Biol Med** 1996 Aug;122(8):176-8 **(Rus)**

[The interaction of dialkylaminoacyl derivatives of phenothiazine, dibenzazepine and dibenzdiazepine with opiate receptors] Brusova EG, et al. **Eksp Klin Farmakol** 1996 Mar-Apr;59(2):20-3 (Eng. Abstr.) **(Rus)**

[The effect of thymogen on the heart in ischemia and reperfusion] Filippova OV, et al. **Eksp Klin Farmakol** 1997 May-Jun;60(3):27-9 (Eng. Abstr.) **(Rus)**

[The effect of naloxone on rhythm disorders and on the conduction system of the heart] Shliakhto EV, et al. **Eksp Klin Farmakol** 1996 May-Jun;59(3):34-6 (Eng. Abstr.) **(Rus)**

POISONING

Flecainide overdose: is cardiopulmonary support the treatment? Yasui RK, et al. **Ann Emerg Med** 1997 May; 29(5):680-2

Pharmacokinetic evaluation of a case of massive sotalol intoxication. Gustavsson CG, et al. **Ann Pharmacother** 1997 Jul-Aug;31(7-8):856-9

Clarithromycin-induced digoxin intoxication. Laberge P, et al. **Ann Pharmacother** 1997 Sep;31(9):999-1002

Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis. Link MS, et al. **Chest** 1997 Aug;112(2):556-7

Lethal suicidal intoxication with propafenone, after a history of self-inflicted injuries. Maxeiner H, et al. **Forensic Sci Int** 1997 Sep 19;89(1-2):27-32 (12 ref.)

An overdose fatality in a child involving disopyramide and sulindac. Singer P, et al. **J Anal Toxicol** 1995 Oct; 19(6):529-30

Sodium bicarbonate to correct widened QRS in a case of flecainide overdose. Goldman MJ, et al. **J Emerg Med** 1997 Mar-Apr;15(2):183-6

Pediatric ECMO for severe quinidine cardiotoxicity. Tecklenburg FW, et al. **Pediatr Emerg Care** 1997 Apr; 13(2):111-3

Fatality due to intravenous diltiazem for acute ventricular rate control. Moser LR, et al. **Pharmacotherapy** 1996 Mar-Apr;16(2):306-10

[Isolated neuropsychiatric manifestations related to a digoxin overdose. Apropos of a case (letter)] Moreau D, et al. **Ann Med Interne (Paris)** 1997;148(1):108-9 **(Fre)**

[A case of fatal poisoning with the anti-arrhythmia agents Katen and Neo-Gilurytmal] Petovský P, et al. **Soud Lek** 1997 May;42(2):18-20 (Eng. Abstr.) **(Slo)**

THERAPEUTIC USE

Treatment of out-of-hospital supraventricular tachycardia: adenosine vs verapamil [see comments] Brady WJ Jr, et al. **Acad Emerg Med** 1996 Jun;3(6):574-85. Comment in: Acad Emerg Med 1996 Jun;3(6):564-6.

To treat or not to treat (out-of-hospital) paroxysmal supraventricular tachycardia, that is the question [editorial; comment] Gausche M. **Acad Emerg Med** 1996 Jun; 3(6):564-6. Comment on: Acad Emerg Med 1996 Jun;3(6):574-85.

Contrast-medium-induced ventricular fibrillation: arrhythmogenic mechanisms and the role of antiarrhythmic drugs in dogs [letter] Idée JM, et al. **Acad Radiol** 1996 Sep;3(9):781-5

Effects of verapamil in ventricular tachycardias. An experimental and clinical study. De Micheli A, et al. **Acta Cardiol** 1997;52(1):1-15

The complications of thoracic surgery: prophylaxis and treatment of arrhythmias. Van Mieghem W. **Acta Cardiol** 1995;50(5):381-6 (11 ref.)

Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias. Lee RJ, et al. **Am Heart J** 1996 Nov;132(5):973-8

Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Wanless RS, et al. **Am Heart J** 1997 Apr;133(4):441-6

Atrial fibrillation follow-up investigation of rhythm management -- the AFFIRM study design. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. **Am J Cardiol** 1997 May 1;79(9):1198-202

Are implantable cardioverter-defibrillators or drugs more effective in prolonging life? The Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial Executive Committee [editorial] [see comments] **Am J Cardiol** 1997 Mar 1;79(5):661-3. Comment in: Am J Cardiol 1997 Jul 15;80(2):194-7.

Impact of the Food and Drug Administration approval of flecainide and encainide on coronary artery disease mortality: putting "Deadly Medicine" to the test. Anderson JL, et al. **Am J Cardiol** 1997 Jan 1;79(1):43-7

Acute treatment of atrial fibrillation and flutter. Anderson JL. **Am J Cardiol** 1996 Oct 17;78(8A):17-21 (23 ref.)

Effectiveness of sotalol for atrial flutter in children after surgery for congenital heart disease. Beaufort-Krol GC, et al. **Am J Cardiol** 1997 Jan 1;79(1):92-4

Effects of amiodarone on the circadian pattern of sudden cardiac death (Department of Veterans Affairs Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy). Behrens S, et al. **Am J Cardiol** 1997 Jul 1;80(1):45-8

Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function? Block M, et al. **Am J Cardiol** 1996 Sep 12;78(5A):62-8 (67 ref.)

Intravenous clofilium for conversion of atrial fibrillation. Borzak S, et al. **Am J Cardiol** 1997 Jan 1;79(1):94-7

Efficacy of intravenous propafenone in termination of atrial flutter by overdrive transesophageal pacing previously ineffective. D'Este D, et al. **Am J Cardiol** 1997 Feb 15; 79(4):500-2

Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm. Di Benedetto S. **Am J Cardiol** 1997 Aug 15;80(4):518-9

Efficacy of ibutilide for termination of atrial fibrillation and flutter. Ellenbogen KA, et al. **Am J Cardiol** 1996 Oct 17; 78(8A):42-5 (18 ref.)

Characteristics and management of chaotic atrial tachycardia of infancy [see comments] Fish FA, et al. **Am J Cardiol** 1996 Nov 1;78(9):1052-5. Comment in: Am J Cardiol 1997 Aug 1;80(3):395-6.

Why the antiarrhythmics versus implantable defibrillator (AVID) trial sets the wrong precedent [editorial] Fogoros RN. **Am J Cardiol** 1997 Sep 15;80(6):762-5

Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study [see comments] Giorgberidze I, et al. **Am J Cardiol** 1997 Sep 11;80(5B):3F-9F. Comment in: Am J Cardiol 1997 Sep 11;80(5B):1F-2F.

Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Gold MR, et al. **Am J Cardiol** 1996 Nov 1;78(9):975-9

The AVID trial: evidence based or randomized control trials--is the AVID study too late? Antiarrhythmics Versus Implantable Defibrillators [editorial; comment] Josephson ME, et al. **Am J Cardiol** 1997 Jul 15;80(2):194-7. Comment on: Am J Cardiol 1997 Mar 1;79(5):661-3.

Transthoracic cardioversion of atrial fibrillation and flutter: standard techniques and new advances. Kerber RE. **Am J Cardiol** 1996 Oct 17;78(8A):22-6 (33 ref.)

Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease. Khalighi K, et al. **Am J Cardiol** 1997 Sep 1;80(5):591-4

Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the Antiarrhythmics Vs Implantable Defibrillators (AVID) trial and nonrandomized registry patients. Kim SG, et al. **Am J Cardiol** 1997 Aug 15;80(4):454-7

Effectiveness of digitalis with or without acebutolol in preventing atrial arrhythmias after coronary artery surgery. Kowey PR, et al. **Am J Cardiol** 1997 Apr 15;79(8):1114-7

Direct-current cardioversion of atrial tachyarrhythmias under oral flecainide therapy. Leclercq JF, et al. **Am J Cardiol** 1997 Sep 1;80(5):645-8

Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Lee SH, et al. **Am J Cardiol** 1997 Apr 1; 79(7):905-8

Management of atrial fibrillation after coronary artery bypass graft. Olshansky B. **Am J Cardiol** 1996 Oct 17;78(8A):27-34 (57 ref.)

Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring. Reiffel JA, et al. **Am J Cardiol** 1997 Apr 15; 79(8):1048-53

Reproducibility of drug efficacy predictions by Holter monitoring in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. ESVEM Investigators. Reiter MJ, et al. **Am J Cardiol** 1997 Feb 1; 79(3):315-22

Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). Roy D, et al. **Am J Cardiol** 1997 Aug 15;80(4):464-8

There should never be another antiarrhythmics versus implantable defibrillator (AVID) trial [editorial] Singer I, et al. **Am J Cardiol** 1997 Sep 15;80(6):766-8

Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Stroobandt R, et al. **Am J Cardiol** 1997 Feb 15;79(4):418-23

Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Tieleman RG, et al. **Am J Cardiol** 1997 Jan 1;79(1):53-7

Introduction: acute treatment of atrial fibrillation and flutter--ibutilide in perspective. Waldo AL, et al. **Am J Cardiol** 1996 Oct 17;78(8A):1-2

What can we expect from prophylactic implantable defibrillators? [see comments] Wilber DJ, et al. **Am J Cardiol** 1997 Sep 11;80(5B):20F-27F (54 ref.). Comment in: Am J Cardiol 1997 Sep 11;80(5B):1F-2F.

Adenosine as an antiarrhythmic agent. Wilbur SL, et al. **Am J Cardiol** 1997 Jun 19;79(12A):30-7 (69 ref.)

Amiodarone: a late comer. Futterman LG, et al. **Am J Crit Care** 1997 May;6(3):233-9 (23 ref.)

Dilemmas in the acute pharmacologic treatment of uncontrolled atrial fibrillation. Elam K, et al. **Am J Emerg Med** 1997 Jul;15(4):418-9 (11 ref.)

Adenosine for the treatment of paroxysmal supraventricular tachycardia in full-term and preterm newborn infants. Paret G, et al. **Am J Perinatol** 1996 Aug;13(6):343-6

Beta blockade to prevent atrial dysrhythmias following coronary bypass surgery. Paull DL, et al. **Am J Surg** 1997 May;173(5):419-21

Lidocaine-related increase in defibrillation threshold. Peters RW, et al. **Anesth Analg** 1997 Aug;85(2):299-300

Adenosine in wide-complex tachycardia. Herbert ME, et al. **Ann Emerg Med** 1997 Jan;29(1):172-4 (15 ref.)

Effectiveness of verapamil-quinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation. Innes GD, et al. **Ann Emerg Med** 1997 Jan;29(1):126-34

Glucagon therapy in the treatment of symptomatic bradycardia. Love JN, et al. **Ann Emerg Med** 1997 Jan; 29(1):181-3

Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Schreck DM, et al. **Ann Emerg Med** 1997 Jan;29(1):135-40

Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Boriani G, et al. **Ann Intern Med** 1997 Apr 15;126(8):621-5

The role of intravenous amiodarone in the management of cardiac arrhythmias. Desai AD, et al. **Ann Intern Med** 1997 Aug 15;127(4):294-303 (71 ref.)

Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Maisel WH, et al. **Ann Intern Med** 1997 Aug 15; 127(4):281-4

Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death [see comments] Owens DK, et al. **Ann Intern Med** 1997 Jan 1;126(1):1-12. Comment in: ACP J Club 1997 May-Jun;126(3):61.

Responses to acute myocardial stress and prior drug therapy on plasma levels of antioxidants and oxidants and the proposed role of interventions on molecular adaptations. Singh RB, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:517-20

Is there an expanded role for digoxin in patients with heart failure and sinus rhythm? An antagonist viewpoint. Munger MA, et al. **Ann Pharmacother** 1997 Jul-Aug;31(7-8):893-6 (36 ref.)

Is there an expanded role for digoxin in patients with heart failure and sinus rhythm? A protagonist viewpoint. Williamson KM, et al. **Ann Pharmacother** 1997 Jul-Aug; 31(7-8):888-92 (51 ref.)

Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy [see comments] Wright JM, et al. **Ann Pharmacother** 1997 Jan;31(1):29-34. Comment in: Ann Pharmacother 1997 Jan;31(1):116-7.

Effects of diltiazem versus digoxin on dysrhythmias and cardiac function after pneumonectomy. Amar D, et al. **Ann Thorac Surg** 1997 May;63(5):1374-81; discussion 1381-2

Disappearance with ischaemic depolarization of the antifibrillatory activity in a sodium channel blocker and appearance in calcium channel blocker. Bui-Xuan B, et al. **Arch Int Pharmacodyn Ther** 1996 May-Jun; 331(3):246-62

Beta-blockers for ventricular arrhythmias: have we underestimated their value? Campbell TJ. **Aust N Z J Med** 1996 Oct;26(5):689-96 (59 ref.)

Reduced infarct size in the rabbit heart in vivo by ethylisopropyl-amiloride. A role for Na+/H+ exchange. Bugge E, et al. **Basic Res Cardiol** 1996 May-Jun; 91(3):203-9

An overview of the management of electrical storm. Dorian P, et al. **Can J Cardiol** 1997 Mar;13 Suppl A:13A-17A (19 ref.)

Use of the newer antiarrhythmic drugs in patients with supraventricular tachyarrhythmias: let's not throw out the baby with the bath water. Mitchell LB. **Can J Cardiol** 1996 Oct;12(10):972-82 (60 ref.)

Pharmacologic control of heart rate in atrial fibrillation. Falk RH. **Cardiol Clin** 1996 Nov;14(4):521-36 (71 ref.)

Antiarrhythmic drug therapy in the treatment of atrial fibrillation. Jung F, et al. **Cardiol Clin** 1996 Nov; 14(4):507-20 (101 ref.)

Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation--a single-blind placebo-controlled study. Bellandi F, et al. **Cardiovasc Drugs Ther** 1996 May; 10(2):153-7

Programmed ventricular stimulation after myocardial infarction does not help reduce the risk of ventricular events. Brembilla-Perrot B, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):549-56

Activity of Procanbid, procainamide twice-daily formulation, to suppress ventricular premature depolarizations. The Study Group Investigators. Kerin NZ, et al. **Cardiovasc Drugs Ther** 1997 Apr;11(2):169-75

Effects of hypothyroidism on the vulnerability to ventricular fibrillation in dogs: a comparative study with amiodarone. Liu P, et al. **Cardiovasc Drugs Ther** 1996 Jul;10(3):369-78

Tedisamil increases coherence during ventricular fibrillation and decreases defibrillation energy requirements. Dorian P, et al. **Cardiovasc Res** 1997 Feb;33(2):485-94

Differential effects of d-sotalol on normal and infarcted myocardium: an experimental study using epicardial

mapping. Freigang KD, et al. **Cardiovasc Res** 1997 Jul; 35(1):52–9

Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium. Verduyn SC, et al. **Cardiovasc Res** 1997 Jun; 34(3):453–63

A man with a prolonged episode of palpitations. Irwin RS, et al. **Chest** 1996 Nov;110(5):1351–2

Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Daoud EG, et al. **Circulation** 1997 Sep 2;96(5):1542–50

Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. Doval HC, et al. **Circulation** 1996 Dec 15;94(12):3198–203

Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Hamada M, et al. **Circulation** 1997 Sep 2;96(5):1520–4

Antiarrhythmic effects of polyunsaturated fatty acids. Recent studies. Kang JX, et al. **Circulation** 1996 Oct 1; 94(7):1774–80 (52 ref.)

Patients with valvular heart disease presenting with sustained ventricular tachyarrhythmias or syncope: results of programmed ventricular stimulation and long-term follow-up [see comments] Martínez-Rubio A, et al. **Circulation** 1997 Jul 15;96(2):500–8. Comment in: Circulation 1997 Jul 15;96(2):386–7.

Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Massie BM, et al. **Circulation** 1996 Jun 15;93(12):2128–34

Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. Oltrona L, et al. **Circulation** 1997 Apr 15; 95(8):2003–6

Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators [see comments] Stambler BS, et al. **Circulation** 1996 Oct 1;94(7):1613–21. Comment in: Circulation 1996 Oct 1;94(7):1499–502.

Mexiletine in the treatment of resistant ventricular arrhythmias [letter; comment] Weissenburger J, et al. **Circulation** 1996 Dec 1;94(11):2986–7. Comment on: Circulation 1995 Dec 15;92(12):3381–6.

Cardioversion or rate control for atrial fibrillation: balancing risks and benefits. Ellenbogen KA, et al. **Cleve Clin J Med** 1997 Jan;64(1):31–6

Strategies for managing atrial fibrillation. Katcher MS, et al. **Cleve Clin J Med** 1996 Sep;63(5):282–94 (54 ref.)

Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality ON Dofetilide. **Clin Cardiol** 1997 Aug; 20(8):704–10

Atrial fibrillation/flutter: rapid conversion to sinus rhythm with ibutilide [editorial] Conti CR. **Clin Cardiol** 1997 Sep; 20(9):745–6

Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias. Cybulski J, et al. **Clin Cardiol** 1996 Jul; 19(7):563–6

Effect of amiodarone on QT dispersion in the 12-lead standard electrocardiogram and its significance for subsequent arrhythmic events. Grimm W, et al. **Clin Cardiol** 1997 Feb;20(2):107–10

Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. Opolski G, et al. **Clin Cardiol** 1997 Apr;20(4):337–40

Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Singh BN. **Clin Cardiol** 1997 Jul;20(7):608–18 (33 ref.)

Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction. Underwood RD, et al. **Clin Cardiol** 1997 Sep;20(9):753–8 (60 ref.)

Clarithromycin-associated digoxin toxicity in the elderly. Brown BA, et al. **Clin Infect Dis** 1997 Jan;24(1):92–3

Post-myocardial infarction trials: beta blockers, antiarrhythmics, thrombolytics. Anderson JL. **Control Clin Trials** 1996 Jun;17(3 Suppl):17S–27S (35 ref.)

Ongoing risk stratification trials: the primary prevention of sudden death. Buxton AE. **Control Clin Trials** 1996 Jun; 17(3 Suppl):47S–51S (3 ref.)

Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias. Fogoros RN. **Control Clin Trials** 1996 Jun;17(3 Suppl):37S–46S (18 ref.)

Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM): a critical appraisal. Prystowsky EN. **Control Clin Trials** 1996 Jun;17(3 Suppl):28S–36S

Management of paroxysmal atrioventricular nodal reentrant tachycardia in the critically ill surgical patient. Kirton OC, et al. **Crit Care Med** 1997 May;25(5):761–6

Successful treatment of severe dysrhythmias in infants with respiratory syncytial virus infections: two cases and a literature review. Thomas JA, et al. **Crit Care Med** 1997 May;25(5):880–6 (44 ref.)

Pharmacologic and nonpharmacologic treatment of ventricular arrhythmias in heart failure. Stevenson WG, et al. **Curr Opin Cardiol** 1997 May;12(3):242–50 (80 ref.)

The treatment of atrial fibrillation: pharmacologic and nonpharmacologic strategies. Viskin S, et al. **Curr Probl Cardiol** 1997 Feb;22(2):37–108 (229 ref.)

Influence of oral antidiabetic treatment on electrocardiac alterations induced by myocardial infarction. Lomuscio A, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S21–6

Novel drugs and current therapeutic approaches in the treatment of heart failure. Bonarjee VV, et al. **Drugs** 1996 Mar;51(3):347–58 (122 ref.)

Antiarrhythmic therapies for the prevention of sudden cardiac death. McAlister FA, et al. **Drugs** 1997 Aug; 54(2):235–52 (115 ref.)

Depression and myocardial infarction. Implications for medical prognosis and options for treatment. Cleophas TJ. **Drugs Aging** 1997 Aug;11(2):111–8 (64 ref.)

When, and when not, to use digoxin in the elderly. Gosselink AT, et al. **Drugs Aging** 1997 Jun;10(6):411–20 (54 ref.)

Pharmacological management of arrhythmias in the elderly. Van Gelder IC, et al. **Drugs Aging** 1997 Aug;11(2):96–110 (65 ref.)

Defibrillators are superior to antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias. Böcker D, et al. **Eur Heart J** 1997 Jan;18(1):26–30 (28 ref.)

Supraventricular tachycardia. Doing the right things. Campbell RW. **Eur Heart J** 1997 May;18 Suppl C:C50–3 (12 ref.)

Using the right drug. A treatment algorithm for atrial fibrillation. Cobbe SM. **Eur Heart J** 1997 May;18 Suppl C:C33–9 (59 ref.)

Management of atrial fibrillation in the setting of heart failure. Crijns HJ, et al. **Eur Heart J** 1997 May;18 Suppl C:C45–9 (35 ref.)

Survival analysis and clinical medicine. An observational comparison of the implantable cardioverter defibrillator, amiodarone treatment, and heart transplantation. Ector H, et al. **Eur Heart J** 1996 Sep;17(9):1444–7

Clinical challenge. II. Management of recent onset atrial fibrillation. PAFIT-2 Investigators. Fresco C, et al. **Eur Heart J** 1996 Jul;17 Suppl C:41–7 (38 ref.)

Follow-up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation. Kerr C, et al. **Eur Heart J** 1996 Jul;17 Suppl C:48–51 (12 ref.)

Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs. Kühlkamp V, et al. **Eur Heart J** 1995 Nov; 16(11):1625–31

Using the right drug: a treatment algorithm for regular supraventricular tachycardias. Lévy S, et al. **Eur Heart J** 1997 May;18 Suppl C:C27–32 (19 ref.)

Sleep suppression of ventricular arrhythmias: a predictor of beta-blocker efficacy [see comments] Pitzalis MV, et al. **Eur Heart J** 1996 Jun;17(6):917–25. Comment in: Eur Heart J 1997 Feb;18(2):349–50.

Clinical challenge. I: Control of recurrent symptomatic atrial fibrillation. Reimold SC. **Eur Heart J** 1996 Jul;17 Suppl C:35–40 (23 ref.)

Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris. Sedgwick ML, et al. **Eur Heart J** 1995 Nov;16(11):1641–6

Normalization of peripheral thyroid hormone metabolism induced by successful chronic amiodarone treatment in patients with ventricular arrhythmias. Iervasi G, et al. **Eur J Clin Invest** 1996 May;26(5):382–90

Antiarrhythmic effects of an aconitine-like compound, TJN-505, on canine arrhythmia models. Arita J, et al. **Eur J Pharmacol** 1996 Dec 30;318(2–3):333–40

KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats. Baczkó I, et al. **Eur J Pharmacol** 1997 Apr 11;324(1):77–83

Nicorandil suppressed ventricular arrhythmias in a canine model of myocardial ischaemia. Vegh A, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):163–8

Recovery of atrial systolic function after pharmacological conversion of chronic atrial fibrillation to sinus rhythm: a Doppler echocardiographic study. Jović A, et al. **Heart** 1997 Jan;77(1):46–9

Studies on the efficacy and prognostic significance of drug therapy of ventricular tachyarrhythmias [editorial] Borchard U, et al. **Herz** 1997 Jun;22 Suppl 1:1–2 **(Eng, Ger)**

Therapeutic options in atrial flutter and fibrillation. Wilber DJ, et al. **Hosp Pract (Off Ed)** 1997 May 15;32(5):143–4, 149–50, 153–9 passim

Amiodarone in high-risk post-infarction patients, Lessons from EMIAT and CAMIAT. European Myocardial Infarct Amiodarone Trial and Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Gambhir DS. **Indian Heart J** 1996 Jul–Aug;48(4):339–41 (14 ref.)

Novel monohydroxamate drugs attenuate myocardial reperfusion-induced arrhythmias. Collis CS, et al. **Int J Biochem Cell Biol** 1996 Apr;28(4):405–13

The antiarrhythmic effect of verapamil on atrioventricular re-entry in the Wolff-Parkinson-White syndrome: a computer model study. Fleischmann PH, et al. **Int J Biomed Comput** 1996 Apr;41(2):125–36

Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group. Frost L, et al. **Int J Cardiol** 1997 Jan 31;58(2):135–40

Experience with moricizine HCl in children with supraventricular tachycardia. Mehta AV, et al. **Int J Cardiol** 1996 Nov 15;57(1):31–5

Influence of amiodarone on QT dispersion in patients with life-threatening ventricular arrhythmias and clinical outcome. Meierhenrich R, et al. **Int J Cardiol** 1997 Aug 8;60(3):289–94

Reversal of heart failure with sotalol in a case of incessant supraventricular tachycardia. Passaretti B, et al. **Int J Cardiol** 1996 Apr 19;54(1):1–4

The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. Wolk R, et al. **Int J Cardiol** 1996 Jun;54(3):207–11

Management of atrial fibrillation. Coumel P. **Isr J Med Sci** 1996 Oct;32(10):871–2 (0 ref.)

Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators [see comments] Falk RH, et al. **J Am Coll Cardiol** 1997 Feb;29(2):385–90. Comment in: J Am Coll Cardiol 1997 Feb;29(2):391–3.

Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. Haverkamp W, et al. **J Am Coll Cardiol** 1997 Aug;30(2):487–95

Intravenous amiodarone in treatment of recent-onset atrial fibrillation [letter; comment] Lip GY. **J Am Coll Cardiol** 1996 Oct;28(4):1080–2. Comment on: J Am Coll Cardiol 1996 Apr;27(5):1079–82.

Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicéntricos en Argentina. Nul DR, et al. **J Am Coll Cardiol** 1997 May;29(6):1199–205

Acute conversion of atrial fibrillation and flutter: direct current cardioversion versus intravenously administered pure class III agents [editorial; comment] Singh BN. **J Am Coll Cardiol** 1997 Feb;29(2):391–3. Comment on: J Am Coll Cardiol 1997 Feb;29(2):385–90.

Value of digoxin in heart failure and sinus rhythm: new features of an old drug? van Veldhuisen DJ, et al. **J Am Coll Cardiol** 1996 Oct;28(4):813–9 (99 ref.)

Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. Magnesium in Cardiac Arrhythmias (MAGICA) Investigators. Zehender M, et al. **J Am Coll Cardiol** 1997 Apr;29(5):1028–34

Long-term prevention of atrial fibrillation after coronary artery bypass surgery: comparison of quinidine, verapamil, and amiodarone in maintaining sinus rhythm. Yilmaz AT, et al. **J Card Surg** 1996 Jan–Feb;11(1):61–4

The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. Larbuisson R, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):229–34

ICD-antiarrhythmic drug and ICD-pacemaker interactions. Brode SE, et al. **J Cardiovasc Electrophysiol** 1997 Jul; 8(7):830–42 (100 ref.)

Pharmacologic therapy of atrial flutter. Campbell RW. **J Cardiovasc Electrophysiol** 1996 Oct;7(10):1008–12 (32 ref.)

Antiarrhythmic drug therapy for ventricular arrhythmias: current perspectives. Link MS, et al. **J Cardiovasc Electrophysiol** 1996 Jul;7(7):653–70 (156 ref.)

Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation. Nattel S, et al. **J Cardiovasc Electrophysiol** 1997 Apr;8(4):469–80 (53 ref.)

Congestive heart failure and arrhythmias: therapeutic modalities. Singh SN. **J Cardiovasc Electrophysiol** 1997 Jan; 8(1):89–97 (61 ref.)

Antiischemic and antiarrhythmic activities of some novel alinidine analogs in the rat heart. Challinor-Rogers JL, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):499–507

Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs. Chen J, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):576–84

Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. Drexler AP, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):848–55

Prevention of reoxygenation-induced arrhythmias in guinea pig papillary muscles. Hayashi H, et al. **J Cardiovasc Pharmacol** 1996 Jun;27(6):816–23

Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias. Kühlkamp V, et al. **J Cardiovasc Pharmacol** 1997 Mar;29(3):373–81

Potent antifibrillatory effect of combined blockade of calcium channels and 5-HT2 receptors with nexopamil during myocardial ischemia and reperfusion in dogs: comparison to diltiazem. Nearing BD, et al. **J Cardiovasc Pharmacol** 1996 Jun;27(6):777–87

Long-term cost-effectiveness of alternative management strategies for patients with life-threatening ventricular arrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) Investigators. Hlatky MA, et al. **J Clin Epidemiol** 1997 Feb;50(2):185–93

Discrepant drug action of disopyramide on ECG abnormalities and induction of ventricular arrhythmias in a patient with Brugada syndrome. Chinushi M, et al. **J Electrocardiol** 1997 Apr;30(2):133–6

Effect of adenosine on ventricular parasystole. Tomcsányi J, et al. **J Electrocardiol** 1996 Jan;29(1):61–3

Sustained ventricular tachycardia in cardiac hemochromatosis treated with amiodarone. Yalçinkaya S, et al. **J Electrocardiol** 1997 Apr;30(2):147–9

ANTI-ARRHYTHMIA AGENTS

Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. Lee SH, et al. **J Intern Med** 1996 Mar;239(3):253–60

The role of the Na+ channel in the accumulation of intracellular Na+ during myocardial ischemia: consequences for post-ischemic recovery. van Emous JG, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):85–96

Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. Galer BS, et al. **J Pain Symptom Manage** 1996 Sep; 12(3):161–7

High prevalence of antiphospholipid antibodies in patients taking procainamide. Merrill JT, et al. **J Rheumatol** 1997 Jun;24(6):1083–8

Efficacy and toxicity of tocainide for the treatment of ventricular tachyarrhythmias in Doberman pinschers with occult cardiomyopathy. Calvert CA, et al. **J Vet Intern Med** 1996 Jul–Aug;10(4):235–40

Effect of intravenous magnesium sulfate on cardiac arrhythmias in critically ill patients with low serum ionized magnesium. Kasaoka S, et al. **Jpn Circ J** 1996 Nov; 60(11):871–5

Effects of class IA antiarrhythmic drugs on the reentrant circuit in common human atrial flutter. Ohga N, et al. **Jpn Circ J** 1995 Dec;59(12):799–807

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators [published erratum appears in Lancet 1997 Jun 14;349(9067):1776] [see comments] Cairns JA, et al. **Lancet** 1997 Mar 8;349(9053):675–82. Comment in: Lancet 1997 Mar 8;349(9053):662–3. Comment in: Lancet 1997 Jun 14;349(9067):1767. Comment in: ACP J Club 1997 Sep–Oct;127(2):30–1.

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators [published errata appear in Lancet 1997 Apr 19;349(9059):1180 and 1997 Jun 14;349(9067):1776] [see comments] Julian DG, et al. **Lancet** 1997 Mar 8;349(9053):667–74. Comment in: Lancet 1997 Mar 8;349(9053):662–3. Comment in: Lancet 1997 Jun 14;349(9067):1767. Comment in: Lancet 1997 Jun 14;349(9067):1768; discussion 1769–70. Comment in: Lancet 1997 Jun 14;349(9067):1768–9; discussion 1769–70. Comment in: ACP J Club 1997 Sep–Oct;127(2):31.

Amiodarone after myocardial infarction: EMIAT and CAMIAT trials [letter; comment] Malik M, et al. **Lancet** 1997 Jun 14;349(9067):1767–8. Comment on: Lancet 1997 Mar 8;349(9053):662–3.

DIAMOND antiarrhythmic trials. Danish Investigations of Arrhythmia and Mortality on Dofetilide [letter; comment] Møller M. **Lancet** 1996 Dec 7;348(9041):1597–8. Comment on: Lancet 1996 Jul 6;348(9019):7–12.

Amiodarone after myocardial infarction: EMIAT and CAMIAT trials [letter; comment] Norris RM. **Lancet** 1997 Jun 14;349(9067):1767. Comment on: Lancet 1997 Mar 8;349(9053):662–3. Comment on: Lancet 1997 Mar 8;349(9053):667–74. Comment on: Lancet 1997 Mar 8;349(9053):675–82.

Amiodarone after myocardial infarction: EMIAT and CAMIAT trials [letter; comment] Pinski SL. **Lancet** 1997 Jun 14;349(9067):1768–9; discussion 1769–70. Comment on: Lancet 1997 Mar 8;349(9053):667–74.

KC8851, a tedisamil analogue with mixed channel blockade, exhibits antiarrhythmic properties against ischemia- and electrically-induced arrhythmias. Xu R, et al. **Life Sci** 1997; 61(3):237–48

Antiarrhythmic action of pharmacological administration of magnesium in heart failure: a critical review of new data. Sueta CA, et al. **Magnes Res** 1995 Dec;8(4):389–401 (78 ref.)

Antiarrhythmic agents: current status and perspectives. Mátyus P, et al. **Med Res Rev** 1997 Sep;17(5):427–51 (165 ref.)

Arrhythmias and antiarrhythmic drugs. Hoffman BF. **Mt Sinai J Med** 1997 Mar;64(2):136–41 (22 ref.)

Unsustained ventricular tachycardia—to treat or not to treat? [editorial; comment] Friedman PL, et al. **N Engl J Med** 1996 Dec 26;335(26):1984–5. Comment on: N Engl J Med 1996 Dec 26;335(26):1933–40.

Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators [see comments] Moss AJ, et al. **N Engl J Med** 1996 Dec 26;335(26):1933–40. Comment in: N Engl J Med 1996 Dec 26;335(26):1984–5. Comment in: ACP J Club 1997 May–Jun;126(3):60–1. Comment in: N Engl J Med 1997 Jun 5;336(23):1676; discussion 1677. Comment in: N Engl J Med 1997 Jun 5;336(23):1677.

Atrial arrhythmias after cardiothoracic surgery [published erratum appears in N Engl J Med 1997 Jul 17;337(3):209] Ommen SR, et al. **N Engl J Med** 1997 May 15; 336(20):1429–34 (58 ref.)

Implantable defibrillators in patients with coronary artery disease at high risk for ventricular arrhythmia [letter; comment] Uretsky BF. **N Engl J Med** 1997 Jun 5; 336(23):1677. Comment on: N Engl J Med 1996 Dec 26;335(26):1933–40.

Torsade de pointes in haemodialysis patients [editorial] [see comments] Bahrle S, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):944–6 (7 ref.). Comment in: Nephrol Dial Transplant 1997 Feb;12(2):365.

201Tl scintigraphy does not allow visualization of the thyroid in euthyroid and hyperthyroid patients treated with amiodarone. van de Wiele C, et al. **Nucl Med Commun** 1997 Jun;18(6):513–6

Electrophysiological findings in idiopathic recurrent ventricular fibrillation: special reference to mode of induction, drug testing, and long-term outcomes. Aizawa Y, et al. **Pacing Clin Electrophysiol** 1996 Jun;19(6):929–39

Sotalol for atrial tachycardias after surgery for congenital heart disease. Beaufort-Krol GC, et al. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2125–9

Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? Botto GL, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1939–43

Verapamil sensitive incessant ventricular tachycardia in the newborn. Dhala A, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 1):1652–4

Type II atrial flutter interruption with transesophageal pacing: use of propafenone and possible change of the substrate. Doni F, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1958–61

Effect of digoxin on the ventricular rate variability during paroxysmal atrial fibrillation. Hnatkova K, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1968–71

Combined transesophageal left atrial pacing and antiarrhythmic therapy in the treatment of atrial flutter. Matiouchine GV, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1947–50

Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs. Matsuo K, et al. **Pacing Clin Electrophysiol** 1997 Apr;20(4 Pt 1):938–45

Amiodarone as treatment for atrial tachycardias after surgery. Villain E. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2130–2

Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation. Wiesfeld AC, et al. **Pacing Clin Electrophysiol** 1996 Jul;19(7):1026–35 (77 ref.)

Long-term prevention of atrial fibrillation after coronary artery surgery. Yilmaz AT, et al. **Panminerva Med** 1997 Jun;39(2):103–5

Adenosine: an effective and safe antiarrhythmic drug in pediatrics. Paul T, et al. **Pediatr Cardiol** 1997 Mar–Apr; 18(2):118–26 (82 ref.)

New antiarrhythmic drug in pediatric use: sotalol. Pfammatter JP, et al. **Pediatr Cardiol** 1997 Jan–Feb; 18(1):28–34 (62 ref.)

Effects of bisaramil on coronary-occlusion-reperfusion injury and free-radical-induced reactions. Paróczai M, et al. **Pharmacol Res** 1996 Jun;33(6):327–36

Potassium channel activation: a potential therapeutic approach? Lawson K. **Pharmacol Ther** 1996;70(1):39–63 (301 ref.)

Class III antiarrhythmic agents: the next wave. Bauman JL. **Pharmacotherapy** 1997 Mar–Apr;17(2 Pt 2):76S–83S; discussion 89S–91S (28 ref.)

Advanced cardiac life support controversy: where do antiarrhythmic agents fit in? [published erratum appears in Pharmacotherapy 1997 May–Jun;17(3):634] Chow MS. **Pharmacotherapy** 1997 Mar–Apr;17(2 Pt 2):84S–88S; discussion 89S–91S (36 ref.)

Ibutilide: a new class III antiarrhythmic agent. Cropp JS, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):1–9 (45 ref.)

Pharmacologic prophylaxis of supraventricular tachyarrhythmias after coronary artery bypass. Dorovenis SA, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):615–8 (24 ref.)

Pharmacologic conversion of atrial fibrillation and atrial flutter to normal sinus rhythm: the role of ibutilide [editorial] Katcher MS, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):177–80

Acute management of ventricular arrhythmias: role of antiarrhythmic agents. Singh BN. **Pharmacotherapy** 1997 Mar–Apr;17(2 Pt 2):56S–64S; discussion 89S–91S (32 ref.)

Antiarrhythmic drug therapy—Part IV: Ventricular arrhythmias [news] Banerji S, et al. **Prog Cardiovasc Nurs** 1997 Summer;12(3):32–6

"Relative" sinus bradycardia. Drew BJ, et al. **Prog Cardiovasc Nurs** 1996 Summer;11(3):47–8

Antiarrhythmic drug therapy—Part II: Specific drugs. Kayser SR. **Prog Cardiovasc Nurs** 1996 Summer;11(3):33–8 (6 ref.)

Ibutilide—a new drug for the rapid termination of atrial fibrillation and atrial flutter [news] Kayser SR. **Prog Cardiovasc Nurs** 1997 Winter;12(1):39–43 (10 ref.)

Antiarrhythmic drug therapy—Part I: General principles of drug selection. Kayser SR. **Prog Cardiovasc Nurs** 1996 Spring;11(2):33–7 (11 ref.)

Antiarrhythmic drug therapy—part III: atrial fibrillation. Kayser SR. **Prog Cardiovasc Nurs** 1996 Fall;11(4):35–43,45 (19 ref.)

Lidocaine in out-of-hospital ventricular fibrillation. Does it improve survival? Herlitz J, et al. **Resuscitation** 1997 Jan; 33(3):199–205

Lidocaine: work still in progress [editorial; comment] Koster RW. **Resuscitation** 1997 Jan;33(3):197–8. Comment on: Resuscitation 1997 Jan;33(3):223–31.

Is hospitalisation necessary for recent-onset atrial fibrillation? **S Afr Med J** 1997 Jun;87 Suppl 3:C183

Short- and intermediate-term efficacy of amiodarone in infants and children with cardiac arrhythmia. Celiker A, et al. **Turk J Pediatr** 1997 Apr–Jun;39(2):219–25

[Digoxin in chronic heart failure and sinus rhythm: is the end of the controversy in sight?] van Veldhuisen DJ, et al. **Ned Tijdschr Geneeskd** 1997 Mar 8;141(10):460–4 (39 ref.) (Eng. Abstr.) **(Dut)**

[Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study] Lardoux H, et al. **Ann Cardiol Angeiol (Paris)** 1996 Oct;45(8):469–79 (Eng. Abstr.) **(Fre)**

[Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias] Maison-Blanche P, et al. **Ann Cardiol Angeiol (Paris)** 1997 Feb;46(2):109–16 (Eng. Abstr.) **(Fre)**

[European protocol for the management of fetal supraventricular tachycardia. European Association of Pediatric Cardiology] Azancot-Benisty A, et al. **Arch Mal Coeur Vaiss** 1997 May;90(5):735–43 **(Fre)**

[Predictive factors of induction of ventricular arrhythmia under amiodarone] Bourret N, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89(10):1277–81 (Eng. Abstr.) **(Fre)**

[Etiologies of electric storm] Dorian P. **Arch Mal Coeur Vaiss** 1997 Apr;90 Spec No 1:27–31 (Eng. Abstr.) **(Fre)**

[Fetal supraventricular tachycardia with anasarca complicating benign extrasystole: treatment with flecainide. Apropos of a case] Hamel P, et al. **Arch Mal Coeur Vaiss** 1997 Mar;90(3):407–10 (Eng. Abstr.) **(Fre)**

[Pharmacological treatment of atrial fibrillation] Leenhardt A, et al. **Arch Mal Coeur Vaiss** 1997 Apr;90 Spec No 1:41–6 (28 ref.) (Eng. Abstr.) **(Fre)**

[Flecaine: drug of choice for supraventricular tachycardias with anasarca. A case report] Hamel P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(1):37–9 (Eng. Abstr.) **(Fre)**

[Paroxysmal atrial fibrillation: which patients need anti-arrhythmia drugs? (interview by Dr. med. Ulrike Hennemann)] Meinertz T. **Fortschr Med** 1996 Aug 30; 114(24):42–3 **(Ger)**

[Heart frequency control in chronic and paroxysmal atrial fibrillation. Critical evaluation of traditional therapy concepts] Ostermaier R, et al. **Fortschr Med** 1997 Jan 20; 115(1–2):26–8, 30, 32, passim (23 ref.) (Eng. Abstr.) **(Ger)**

[Clinico-electrophysiologic effects of magnesium, especially in supraventricular tachycardia] Vester EG. **Herz** 1997 Jun; 22 Suppl 1:40–50 (33 ref.) (Eng. Abstr.) **(Ger)**

[Modern therapy of tachycardiac heart arrhythmias] **Internist (Berl)** 1995 Sep;36(9 Suppl Moderne):1–8 **(Ger)**

[Successful treatment of cardiac arrhythmias. Current and future therapeutic possibilities] **Internist (Berl)** 1994 Nov; 35(11 Suppl):1–12 **(Ger)**

[Arrhythmia as risk factor] **Internist (Berl)** 1997 Feb;38(2 Suppl Risikofakt):1–8 **(Ger)**

[Drug therapy of supraventricular and ventricular tachyarrhythmias] Hohnloser SH. **Internist (Berl)** 1996 Jan; 37(1):45–52 (31 ref.) **(Ger)**

[Drug therapy of ventricular arrhythmias] Hohnloser SH. **Med Klin** 1997 Apr 15;92(4):208–10 (11 ref.) (Eng. Abstr.) **(Ger)**

[Change in therapy of cardiac arrhythmias. Current studies--initial results] Meinertz T. **Med Klin** 1997 Apr 15; 92(4):211–4 (16 ref.) (Eng. Abstr.) **(Ger)**

[Drug therapy of tachycardic atrial arrhythmias] Wietholt D, et al. **Med Klin** 1997 Apr 15;92(4):197–201 (12 ref.) (Eng. Abstr.) **(Ger)**

[Drug therapy of atrial fibrillation] Gloor HO. **Schweiz Med Wochenschr** 1996 Oct 12;126(41):1739–47 (43 ref.) (Eng. Abstr.) **(Ger)**

[Adenosin: an anti-arrhythmia agent with therapeutic and diagnostic potential] **Z Kardiol** 1995 Mar;84(3 Suppl):1–8 **(Ger)**

[Angiotensin II antagonist for heart insufficiency] **Z Kardiol** 1997 Jun;86(6 Suppl):1–8 **(Ger)**

[Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs] Haverkamp W, et al. **Z Kardiol** 1996;85 Suppl 6:97–106 (66 ref.) (Eng. Abstr.) **(Ger)**

[Ventricular cardiac arrhythmias. New anti-arrhythmia agents] Scholz H. **Z Kardiol** 1996;85 Suppl 6:91–6 (27 ref.) (Eng. Abstr.) **(Ger)**

[Drug therapy of atrial fibrillation: control of heart rate versus establishing sinus rhythm] Steinbeck G. **Z Kardiol** 1996;85 Suppl 6:69–74 (32 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium as an anti-arrhythmic therapy principle in supraventricular and ventricular cardiac arrhythmias] Zehender M. **Z Kardiol** 1996;85 Suppl 6:135–45 (120 ref.) (Eng. Abstr.) **(Ger)**

[Adenosine-sensitive atrial tachycardia] Tomcsányi J, et al. **Orv Hetil** 1996 Jul 14;137(28):1535–7 (Eng. Abstr.) **(Hun)**

[Vasovagal syncope and increased baroreceptor activity: evidence for increased sensibility of the baroreflex and its rapid reversal with acute administration of metoprolol]

Pucciarelli G, et al. **Cardiologia** 1997 Jul;42(7):721–7 (Eng. Abstr.) **(Ita)**

[Sotalol, propafenone, and flecainide: compared multiparametric analysis of ventricular repolarization in subjects without organic cardiopathy] Sarubbi B, et al. **Cardiologia** 1996 Jul;41(7):645–51 (Eng. Abstr.) **(Ita)**

[Prevention of sudden death in myocardial infarct: do experimental results help to understand the clinical reality? The case of the clinical trial SWORD (Survival With ORal D-sotalol)] Schwartz PJ. **Cardiologia** 1996 Aug; 41(8):739–45 **(Ita)**

[Comparison of anti-arrhythmic therapy guided by the transesophageal electropharmacologic test and emperic therapy in the prophylaxis of atrial fibrillation recurrence] Fera MS, et al. **G Ital Cardiol** 1997 Feb;27(2):152–63 (Eng. Abstr.) **(Ita)**

[What information is given by controlled clinical trials (pharmacological and nonpharmacological) for anti-arrhythmia therapy in the prevention of sudden death?] Naccarella F, et al. **G Ital Cardiol** 1996 Nov; 26(11):1345–64 (154 ref.) **(Ita)**

[Propafenone and flecainide in the therapy of ventricular arrhythmias] Paperini L, et al. **Minerva Cardioangiol** 1995 Oct;43(10):449–57 (32 ref.) (Eng. Abstr.) **(Ita)**

[Prediction of long-term efficacy of amiodarone for refractory ventricular tachycardia: clinical significance of electrophysiologic study and Holter monitoring] Tsuchiya M, et al. **J Cardiol** 1996 Nov;28(5):267–76 (Eng. Abstr.) **(Jpn)**

[Treatment of ventricular arrhythmia associated with heart failure] Kasakinu H. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):80–7 (5 ref.) **(Jpn)**

[The effect of sotalol hydrochloride therapy on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation] Telichowski A, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):303–9 (Eng. Abstr.) **(Pol)**

[Effect of intravenous propafenone on maintenance of atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation] Banasiak W, et al. **Pol Tyg Lek** 1996 Mar; 51(10–13):141–4 (Eng. Abstr.) **(Pol)**

[Treatment of arrhythmia in pregnant women (editorial)] Halawa B. **Pol Tyg Lek** 1996 Mar;51(10–13):131–4 **(Pol)**

[Antiarrhythmic effects of prajmaline (Neo-Gilurythmal) in stable angina pectoris in light of Holter electrocardiographic monitoring] Janicki K, et al. **Przegl Lek** 1995;52(10):485–491 (Eng. Abstr.) **(Pol)**

[Propafenone, flecainide, procainamide in the treatment of a fresh attack of atrial fibrillation] Kosmala W, et al. **Wiad Lek** 1994 Nov–Dec;47(21–24):801–7 (Eng. Abstr.) **(Pol)**

[Brazilian multicenter study of sotalol effectiveness in ventricular arrhythmias] Maia IG, et al. **Arq Bras Cardiol** 1996 Mar;66(3):173–8 (Eng. Abstr.) **(Por)**

[Experience with dl-sotalol in the treatment of supraventricular arrhythmia] Trabulo M, et al. **Rev Port Cardiol** 1996 Oct;15(10):725–9, 696 (Eng. Abstr.) **(Por)**

[Comparative anti-arrhythmia activity of befol, lidocaine, and bonnecor] Galenko-Iaroshevskiĭ PA, et al. **Biull Eksp Biol Med** 1996 Dec;122(12):665–8 **(Rus)**

[Comparative evaluation of the effect of dimebon, obzidan, finoptin, and cordarone on the functional state of the ischemic focus and the size of necrosis zone during experimental myocardial infarction] Galenko-Iaroshevskiĭ PA, et al. **Biull Eksp Biol Med** 1996 Dec;122(12):642–4 **(Rus)**

[Comparative evaluation of the anti-arrhythmia efficacy of fencarol and dimebon during neurogenic atrial fibrillation] Galenko Iaroshevskiĭ PA, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):81–5 **(Rus)**

[Comparative evaluation of the anti-arrhythmia effect of KLN-93, dicaine, and lidocaine during neurogenic atrial fibrillation] Leonidov NB, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):77–80 **(Rus)**

[The anti-arrhythmia activity of energy-providing and electron-acceptor compounds] Balashov VP, et al. **Eksp Klin Farmakol** 1996 Mar–Apr;59(2):17–9 (Eng. Abstr.) **(Rus)**

[A preclinical evaluation of the pharmacological activity of a mixed potassium and magnesium glutamate] Berliand AS, et al. **Eksp Klin Farmakol** 1997 Mar–Apr;60(2):16–9 (Eng. Abstr.) **(Rus)**

[The cardiohemodynamic characteristics of the action of obzidan in patients with an artificial pacemaker and ischemic heart disease with different types of blood circulation] Iskenderov BG, et al. **Eksp Klin Farmakol** 1996 Jul–Aug;59(4):21–4 (Eng. Abstr.) **(Rus)**

[The participation of the mu-, delta- and kappa-opioid receptors in the realization of the anti-arrhythmia effect of Rhodiola rosea] Maimeskulova LA, et al. **Eksp Klin Farmakol** 1997 Jan–Feb;60(1):38–9 (Eng. Abstr.) **(Rus)**

[The mechanism of the anti-arrhythmia action of mu-opioid-receptor agonists in a model of CaCl2-induced arrhythmias: the role of the autonomic nervous system] Maslov LN, et al. **Eksp Klin Farmakol** 1997 Jan–Feb; 60(1):35–7 (Eng. Abstr.) **(Rus)**

[The anti-arrhythmic effect of the selective sigma-receptor antagonist DuP 734 [1-(cyclopropylmethyl)-4-(2'-(4''-fluorophenyl)-2'-oxoethyl)piper idine HBr]] Maslov LN, et al. **Eksp Klin Farmakol** 1997 Mar–Apr;60(2):24–6 (Eng. Abstr.) **(Rus)**

[The participation of the central and peripheral kappa-opiate receptors in the mechanism of the anti-arrhythmia action of benzeneacetamide derivatives] Maslov LN, et al. **Eksp Klin Farmakol** 1996 Nov–Dec;59(6):20–2 (Eng. Abstr.) **(Rus)**

[The effect of naloxone on rhythm disorders and on the conduction system of the heart] Shliakhto EV, et al. **Eksp Klin Farmakol** 1996 May–Jun;59(3):34–6 (Eng. Abstr.) **(Rus)**

[Clinical trial of propafenone (rytmonorm) in arrhythmia of patients with ischemic heart disease)] Dobrotvorskaia TE, et al. **Klin Med (Mosk)** 1996;74(3):51–3 **(Rus)**

[The efficacy of anti-arrhythmia therapy with bonnecor in middle-aged and elderly patients] Zaslavskaia RM, et al. **Klin Med (Mosk)** 1996;74(2):30–2 (Eng. Abstr.) **(Rus)**

[Peptide correction of arrhythmias induced by stimulation of the vagal sympathetic trunk in cats] Osadchiĭ OE, et al. **Patol Fiziol Eksp Ter** 1997 Jul–Sep;(3):10–3 (Eng. Abstr.) **(Rus)**

[The treatment of paroxysmal supraventricular arrhythmias in IHD patients with a high risk of developing complications from the anti-arrhythmic therapy] Andriushchenko OM, et al. **Ter Arkh** 1996;68(5):57–60 (Eng. Abstr.) **(Rus)**

[Surgical treatment of an anomaly of the conduction system in a case of supraventricular paroxysmal tachycardia with WPW syndrome resistant to four conventional antiarrhythmic agents] Mesihović H, et al. **Med Arh** 1996; 50(1–2):35–7 (Eng. Abstr.) **(Scr)**

[The effect of piperazine analogs of aryloxyaminopropanol (IIIq and IIIb) on the occurrence of reperfusion dysrhythmias in an in vivo experiment on rats] Jadroňová O, et al. **Ceska Slov Farm** 1996 Nov;45(6):292–5 (Eng. Abstr.) **(Slo)**

[Treatment with adenosine for supraventricular paroxysmal tachycardia during pregnancy (letter; comment)] Varela Aguilar JM, et al. **Med Clin (Barc)** 1997 Jun 21;109(4):159 . Comment on: Med Clin (Barc) 1996 Jun 1;107(1):29–36. **(Spa)**

[Implantable automatic defibrillator after MADIT and EMIAT (editorial) Farré J. **Rev Esp Cardiol** 1996 Oct; 49(10):709–13 **(Spa)**

[Pharmacologic maintenance of sinusal rhythm and/or control of the ventricular response in patients with atrial fibrillation or flutter] López Gil M, et al. **Rev Esp Cardiol** 1996;49 Suppl 2:32–41 (Eng. Abstr.) **(Spa)**

TOXICITY

Chronic amiodarone ingestion induces pulmonary toxicity in rats. Carvalho CR, et al. **Braz J Med Biol Res** 1996 Jun;29(6):779–91

Cytotoxicity of amiodarone in cultured human endothelial cells. Baudin B, et al. **Cardiovasc Drugs Ther** 1996 Nov; 10(5):557–60

Clarithromycin-associated digoxin toxicity in the elderly. Brown BA, et al. **Clin Infect Dis** 1997 Jan;24(1):92–3

Amiodarone induces a different pattern of ultrastructural change in the thyroid to iodine excess alone in both the BB/W rat and the Wistar rat [see comments] Pitsiavas V, et al. **Eur J Endocrinol** 1997 Jul;137(1):89–98. Comment in: Eur J Endocrinol 1997 Jul;137(1):15–7.

Effects of lidocaine, ajmaline, and diltiazem on ventricular defibrillation energy requirements in isolated rabbit heart. Anvari A, et al. **J Cardiovasc Pharmacol** 1997 Apr; 29(4):429–35

Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion. Heisler BE, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):317–24

Toxicity of amiodarone on mouse pulmonary endothelial cells cultured with or without alveolar macrophages. Futamura Y. **J Toxicol Sci** 1996 Nov;21(4):253–67

Amiodarone induces two different types of disorders in mouse alveolar macrophages. Futamura Y. **Jpn J Pharmacol** 1997 May;74(1):21–8

Prevention by calcium antagonists of profibrillatory effects of class I antiarrhythmic drugs in acute myocardial ischemia: study in pig heart in situ. Bui-Xuan B, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):737–45

Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II). Esposito M, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):370–7

[The cardiotoxic properties of anti-arrhythmia agents] Spasov AA, et al. **Eksp Klin Farmakol** 1997 Mar–Apr; 60(2):20–3 (Eng. Abstr.) **(Rus)**

URINE

Comparison of fluorescence polarization immunoassay with liquid chromatography for quantification of procainamide and N-acetylprocainamide in urine. Tisdale JE, et al. **Ther Drug Monit** 1996 Dec;18(6):693–7

ANTI-ASTHMATIC AGENTS

Safety of treatment. Bisgaard H, et al. **Eur Respir J Suppl** 1996 Apr;21:28s–34s (57 ref.)

ADMINISTRATION & DOSAGE

The effects of combined intravenous and inhaled steroids (beclomethasone dipropionate) for the emergency treatment of acute asthma. The Asthma ED Study Group. Guttman A, et al. **Acad Emerg Med** 1997 Feb;4(2):100–6

Inhalational therapy in asthma. Oppenheimer J. **Allergy Asthma Proc** 1996 Nov–Dec;17(6):351–3 (21 ref.)

Fluticasone propionate in children with moderate asthma. Hoekstra MO, et al. **Am J Respir Crit Care Med** 1996 Oct; 154(4 Pt 1):1039–44

Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Olivieri D, et al. **Am J Respir Crit Care Med** 1997 Jun; 155(6):1864–71

Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Weersink EJ, et al. **Am J Respir Crit Care Med** 1997 Apr; 155(4):1241–6

Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Pearlman DS, et al. **Ann Allergy Asthma Immunol** 1997 Apr;78(4):356–62

Refractory asthma, Part 1: Epidemiology, pathophysiology, pharmacologic interventions. Jagoda A, et al. **Ann Emerg Med** 1997 Feb;29(2):262–74 (159 ref.)

Comparison of bronchodilating effects of two salbutamol dry powder inhalers in asthmatic patients. Laurikainen K, et al. **Arzneimittelforschung** 1997 Jan;47(1):44–6

Options in asthma management. Adams R, et al. **Aust Fam Physician** 1996 Mar;25(3):309–15 (8 ref.)

Asthma medication and caries [letter] Ginty J. **Br Dent J** 1997 Feb 8;182(3):88

Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus inhaler compared with the Turbohaler inhaler in paediatric patients. UK Study Group. Williams J, et al. **Br J Clin Pract** 1997 Apr–May; 51(3):147–53

Inhaled drug delivery in asthma patients [letter; comment] Lenney W. **Br J Gen Pract** 1996 Dec;46(413):757. Comment on: Br J Gen Pract 1995 Dec;45(401):683–7.

Respiratory drug delivery devices [letter; comment] Lenney W. **Br J Gen Pract** 1996 Aug;46(409):492–3. Comment on: Br J Gen Pract 1995 Dec;45(401):683–7.

Practical aspects of aerosol therapy in asthma (1) [published erratum appears in Ceylon Med J 1997 Mar;42(1):29] Ariyananda PL, et al. **Ceylon Med J** 1996 Dec;41(4):162–5

Practical aspects of aerosol therapy in asthma (3): Dry powder inhalers (DPI). Ariyananda PL, et al. **Ceylon Med J** 1997 Jun;42(2):96–7

Practical aspects of aerosol therapy in asthma (2): Metered dose inhalers and spacers. Ariyananda PL, et al. **Ceylon Med J** 1997 Mar;42(1):26–9

Asthma therapy: what's new and is it necessarily better? [editorial; comment] Georgitis JW. **Chest** 1997 Jul; 112(1):3–5. Comment on: Chest 1997 Jul;112(1):34–9.

A comparison of double-strength beclomethasone dipropionate (84 microg) MDI with beclomethasone dipropionate (42 microg) MDI in the treatment of asthma [see comments] Nathan RA, et al. **Chest** 1997 Jul; 112(1):34–9. Comment in: Chest 1997 Jul;112(1):3–5.

Challenge studies of a leukotriene receptor antagonist. Okudaira H. **Chest** 1997 Feb;111(2 Suppl):46S–51S (22 ref.)

Allergic rhinitis in children: effects of flunisolide and disodium cromoglycate on nasal eosinophil cationic protein. Sensi LG, et al. **Clin Exp Allergy** 1997 Mar; 27(3):270–6

Oral vs inhaled asthma therapy. Pros, cons and combinations. Fabbri LM, et al. **Drugs** 1996;52 Suppl 6:20–8 (82 ref.)

A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Grahnén A, et al. **Eur J Clin Pharmacol** 1997;52(4):261–7

Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 microg x day(-1). Hoekx JC, et al. **Eur Respir J** 1996 Nov;9(11):2263–72

The effect of inhaled sodium cromoglycate on cellular infiltration into the bronchial mucosa and the expression of adhesion molecules in asthmatics. Hoshino M, et al. **Eur Respir J** 1997 Apr;10(4):858–65

Accuracy of asthma treatment in schoolchildren in NSW, Australia. Paterson NA, et al. **Eur Respir J** 1997 Mar; 10(3):658–64

Effect of inhaled beclomethasone dipropionate on isocapnic hyperventilation with cold air in asthmatics, measured with forced oscillation technique. Pennings HJ, et al. **Eur Respir J** 1997 Mar;10(3):665–71

Compliance with inhaled medication and self-treatment guidelines following a self-management programme in adult asthmatics. van der Palen J, et al. **Eur Respir J** 1997 Mar;10(3):652–7

Overcoming the problem of poor inhaler technique. Bhadoria DP, et al. **J Assoc Physicians India** 1995 Jan;43(1):68–9

Aerosol systems in asthma: selection and practice [see comments] Jayakrishnan B. **J Assoc Physicians India** 1996 Mar;44(3):186–8 (20 ref.). Comment in: J Assoc Physicians India 1996 Mar;44(3):165.

Dum spiro, spero—while I breathe, I hope [editorial; comment] Joshi JM. **J Assoc Physicians India** 1996 Mar; 44(3):165. Comment on: J Assoc Physicians India 1996 Mar;44(3):186–8.

ANTI-ASTHMATIC AGENTS

Health beliefs of adults with asthma: toward an understanding of the difference between symptomatic and preventive use of inhaler treatment. Hand CH, et al. **J Asthma** 1996; 33(5):331–8

Intravenous magnesium therapy for moderate to severe pediatric asthma: results of a randomized, placebo-controlled trial [see comments] Ciarallo L, et al. **J Pediatr** 1996 Dec;129(6):809–14. Comment in: J Pediatr 1996 Dec;129(6):783–5.

Humoral immunity in steroid-dependent children with asthma and hypogammaglobulinemia. Lack G, et al. **J Pediatr** 1996 Dec;129(6):898–903

Treatment of mild asthma. O'Byrne PM. **Lancet** 1997 Mar 22;349(9055):818

Intravenous glucocorticoids in adult acute severe asthma [see comments] Harper JP, et al. **N Z Med J** 1997 May 9; 110(1043):159–61 (26 ref.). Comment in: N Z Med J 1997 Jun 27;110(1046):238.

Oral delivery of sodium cromolyn: preliminary studies in vivo and in vitro. Leone-Bay A, et al. **Pharm Res** 1996 Feb; 13(2):222–6

Nebulization of NanoCrystals: production of a respirable solid-in-liquid-in-air colloidal dispersion. Wiedmann TS, et al. **Pharm Res** 1997 Jan;14(1):112–6

Effects of Y-24180, a long-acting and potent antagonist to platelet-activating factor, on immediate asthmatic response in guinea pigs. Kagoshima M, et al. **Pharmacology** 1997 Jan;54(1):1–7

Hospitalization of adults for asthma and inhaled corticosteroid use in an island population. Cacciottolo JM, et al. **Respir Med** 1997 Aug;91(7):411–6

Medication, chronic illness and identity: the perspective of people with asthma. Adams S, et al. **Soc Sci Med** 1997 Jul;45(2):189–201

Steroids in exacerbations of asthma: tablets or inhalers? [editorial] Griffiths C. **Thorax** 1996 Nov;51(11):1071–2

Asthma guidelines [letter; comment] Todd G. **Thorax** 1997 Jul;52(7):665; discussion 665–6. Comment on: Thorax 1997 Feb;52 Suppl 1:S2–8, S11–5, S20–1.

[Budesonide and beclamethasone dipropionate inhalation powders. The effect on bone and collagen turnover in children] Birkebaek NH, et al. **Ugeskr Laeger** 1997 Apr 21;159(17):2559–62 (Eng. Abstr.) **(Dan)**

[The most rapid steroid (letter)] Heebøll-Nielsen N. **Ugeskr Laeger** 1996 Nov 25;158(48):6928 **(Dan)**

[The most fastest-acting steroid—again (letter)] Heebøll-Nielsen NC. **Ugeskr Laeger** 1997 Feb 3;159(6):775 **(Dan)**

[Generic substitution—unfortunate consequences (letter)] Lund J. **Ugeskr Laeger** 1997 Sep 8;159(37):5545–6 **(Dan)**

[Guidelines for treatment of bronchial asthma in children. Dansk Paediatrisk Selkabs Astma- og Allergiudvalg] Pedersen S. **Ugeskr Laeger** 1997;159 Suppl 4:1–10 **(Dan)**

[Can inhaled corticosteroid used for asthma cure allergic rhinitis? (letter)] Säynävälammi P. **Duodecim** 1995; 111(18):1805 **(Fin)**

[Problems raised by the reformulation of inhalations after the removing of propulsors "chlorofluorocarbons" (CFC)] Aiache JM. **Ann Pharm Fr** 1997;55(2):62–8 (Eng. Abstr.) **(Fre)**

[Pharma Clinics. Metallic inhalation chamber for the young asthmatic child: the Kidspacer] Leclercq-Foucart J. **Rev Med Liege** 1997 Feb;52(2):123–5 **(Fre)**

[Aerosols. Administration systems for pulmonary administration of drugs] Holzner P. **Med Monatsschr Pharm** 1997 Jul;20(7):177–90 (68 ref.) **(Ger)**

[Controlled clinical comparative evaluation of fluticasone powder inhalation versus flunisolide dose aerosol in patients with mild to moderate asthma] Bergmann KC. **Pneumologie** 1997 Jan;51(1):27–32 (Eng. Abstr.) **(Ger)**

[Effect of long-term treatment with an inhaled corticosteroid on bronchial hyper-responsiveness and clinical asthma in asthmatic subjects] Ikuta N, et al. **Arerugi** 1996 Dec; 45(12):1231–6 (Eng. Abstr.) **(Jpn)**

[The efficacy of Turbuhaler dry powder inhaler in Japanese asthma—measurement of peak inspiratory flow when using Turbuhaler] Kaneko N, et al. **Arerugi** 1996 Jul;45(7):649–54 (Eng. Abstr.) **(Jpn)**

[Evaluations of a specified number of inhalations and how to assess the contents in metered-dose inhalers] Obata T, et al. **Arerugi** 1996 Oct;45(10):1089–97 (Eng. Abstr.) **(Jpn)**

[The efficacy of the magnesium sulfate aerosol treatment of bronchial asthma patients] Emel'ianov AV, et al. **Ter Arkh** 1997;69(3):35–9 (Eng. Abstr.) **(Rus)**

[The effect of the liposomal form of hydrocortisone on the status of cellular and humoral immunity in patients with steroid-dependent bronchial asthma] Prishchepa IV, et al. **Ter Arkh** 1997;69(3):39–42 (Eng. Abstr.) **(Rus)**

[The efficacy of inhaled glucocorticosteroids in different dosage regimens and in combination with theophylline preparations in bronchial asthma patients] Tsoĭ AN, et al. **Ter Arkh** 1997;69(3):27–30 (Eng. Abstr.) **(Rus)**

[Treatment of asthma using aerosols] Negro JM, et al. **Allergol Immunopathol (Madr)** 1996 Jul-Aug;24(4):139–45 (42 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Asthma drug linked with Churg-Strauss syndrome [news] Josefson D. **BMJ** 1997 Aug 9;315(7104):330

Asthma in the elderly [letter; comment] Jolobe OM. **Br J Hosp Med** 1996 Nov 6-19;56(9):488. Comment on: Br J Hosp Med 1996 Feb 7-20;55(3):118–20.

The association between asthma drugs and severe life-threatening attacks. Rea HH, et al. **Chest** 1996 Dec; 110(6):1446–51

Contact dermatitis from sodium-cromoglycate-containing eyedrops. Camarasa JG, et al. **Contact Dermatitis** 1997 Mar; 36(3):160–1

Successful treatment of salbutamol-induced panic disorder with citalopram. Rihmer Z. **Eur Neuropsychopharmacol** 1997 Aug;7(3):241–2

Near-death asthmatic reaction induced by disodium cromoglycate [see comments] Katayama H, et al. **Intern Med** 1996 Dec;35(12):976–8 (14 ref.). Comment in: Intern Med 1996 Dec;35(12):922–3.

Attained adult height after childhood asthma: effect of glucocorticoid therapy. Silverstein MD, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):466–74

Medication-induced psychotic reaction [letter] Türktaş L, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Aug; 36(8):1017–8

Secrets about drugs are not healthy [editorial] **Lancet** 1996 Sep 21;348(9030):765

High-dose inhaled steroids in asthmatic children [letter; comment] Cade A, et al. **Lancet** 1996 Sep 21;348(9030):819 . Comment on: Lancet 1996 Jul 6;348(9019):27–9.

High-dose inhaled steroids in asthmatic children [letter; comment] Lenney W. **Lancet** 1996 Sep 21;348(9030):819–20 . Comment on: Lancet 1996 Jul 6;348(9019):27–9.

Knemometry, urine cortisol excretion, and measures of the insulin-like growth factor axis and collagen turnover in children treated with inhaled glucocorticosteroids. Wolthers OD, et al. **Pediatr Res** 1997 Jan;41(1):44–50

An assessment of steroid hypersensitivity in asthma. Wilkinson SM, et al. **Respir Med** 1997 Apr;91(4):231–3

Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Clark DJ, et al. **Thorax** 1997 Jan;52(1):55–8

BLOOD

Analysis of terfenadine in human plasma using microbore high-performace liquid chromatography-electrospray ionisation mass spectrometry. Adams DA, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):345–51

CHEMICAL SYNTHESIS

Structure optimization of a leukotriene D4 antagonist by combinatorial chemistry in solution. Maehr H, et al. **Bioorg Med Chem** 1997 Mar;5(3):493–6

Synthesis and dual antagonistic activity against thromboxane A2 and leukotriene D4 of [4-[1-(benzenesulfonamido)alkyl]phenyl]alkanoic acid derivatives. Sakurai S, et al. **Chem Pharm Bull (Tokyo)** 1997 May;45(5):849–62

[Synthesis and dual antagonistic activity against thromboxane A2 and leukotriene D4 of benzenesulfonamide derivatives] Sakurai S, et al. **Yakugaku Zasshi** 1997 May;117(5):298–318 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Compatibility of nebulizer solution admixtures. Joseph JC. **Ann Pharmacother** 1997 Apr;31(4):487–9 (17 ref.)

ECONOMICS

Treating asthma in developing countries: a problem of inaccessible unavailable essential medication [editorial; comment] Parry E. **Thorax** 1997 Jul;52(7):589. Comment on: Thorax 1997 Jul;52(7):605–7.

Is asthma treatment affordable in developing countries?[see comments] Watson JP, et al. **Thorax** 1997 Jul;52(7):605–7 . Comment in: Thorax 1997 Jul;52(7):589.

[Cost of asthma therapy in relation to severity. An empirical study] Graf von der Schulenburg JM, et al. **Med Klin** 1996 Oct 15;91(10):670–6 (Eng. Abstr.) **(Ger)**

METABOLISM

Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Kumar GN, et al. **Drug Metab Dispos** 1997 Jan;25(1):110–5

Investigation of the stereoselective in vitro metabolism of the chiral antiasthmatic/antiallergic drug flezelastine by high-performance liquid chromatography and capillary zone electrophoresis. Paris S, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):463–71

PHARMACOKINETICS

Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Mackie AE, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):539–42

Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Thorsson L, et al. **Br J Clin Pharmacol** 1997 Feb;43(2):155–61

Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. Rau SE, et al. **Clin Pharmacol Ther** 1997 Apr;61(4):401–9

Food interaction study of a new theophylline (Egifilin) 200 and 400 mg retard tablet in healthy volunteers. Urmös I, et al. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):65–70

Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. Rohatagi S, et al. **J Clin Pharmacol** 1996 Oct;36(10):938–41

PHARMACOLOGY

Leukotrienes: pathophysiologic role and therapeutic potentials in asthma. Sanico AM, et al. **Allergy Asthma Proc** 1996 Nov-Dec;17(6):331–4 (41 ref.)

Attenuation of aspirin-induced bronchoconstriction by sodium cromoglycate and nedocromil sodium. Robuschi M, et al. **Am J Respir Crit Care Med** 1997 Apr; 155(4):1461–4

Adrenal function and high dose inhaled corticosteroids for asthma. Yiallouros PK, et al. **Arch Dis Child** 1997 May; 76(5):405–10

Antipyretic effect of Lumbricus spencer in acetylsalicylic acid-induced asthma. Kurosawa M, et al. **Arzneimittelforschung** 1996 Feb;46(2):172–4

Anti-allergic effect of tea-leaf saponin (TLS) from tea leaves (Camellia sinensis var. sinensis). Akagi M, et al. **Biol Pharm Bull** 1997 May;20(5):565–7

The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. Banner KH, et al. **Br J Pharmacol** 1996 Nov;119(6):1255–61

Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction. Hay DW. **Chest** 1997 Feb;111(2 Suppl):35S–45S (131 ref.)

Anti-asthma effect of an antiviral drug, acyclovir: a clinical case and experimental study. Okada H, et al. **Clin Exp Allergy** 1997 Apr;27(4):431–7

Effects of nedocromil sodium on the oxidative burst of polymorphonuclear leukocytes: comparison with salbutamol. Braga PC, et al. **Drugs Exp Clin Res** 1997; 23(1):33–8

The effect of nedocromil sodium on human airway epithelial cell-induced eosinophil chemotaxis and adherence to human endothelial cell in vitro. Abdelaziz MM, et al. **Eur Respir J** 1997 Apr;10(4):851–7

Effect of frusemide on Cl- channel in rat peritoneal mast cells. Meyer G, et al. **Eur Respir J** 1996 Dec;9(12):2461–7

Ozone-induced mediator release from human bronchial epithelial cells in vitro and the influence of nedocromil sodium. Rusznak C, et al. **Eur Respir J** 1996 Nov; 9(11):2298–305

A comparison of the inhibitory effect of cromoline and nedocromil Na on histamine release from airway metachromatic cells and from peripheral basophils. Kivity S, et al. **Immunol Lett** 1996 Nov;53(2-3):147–51

Effects of a cysteinyl leukotriene antagonist, ONO-1078 (pranlukast), on total airway resistance after antigen challenge in sensitized guinea pigs. Narita S, et al. **Inflamm Res** 1997 Apr;46(4):143–6

Influence of high dose inhaled steroids on hypothalamo-pituitary-adrenal axis function in Japanese patients with asthma: a comparison over the course of time [published erratum appears in Intern Med 1996 Aug;35(8):674] Hasegawa T, et al. **Intern Med** 1996 May; 35(5):362–6

Novel approaches to the inhibition of cytokine responses in asthma. Higgs OA. **J Pharm Pharmacol** 1997 May;49 Suppl 3:25–31 (92 ref.)

Phosphodiesterase inhibitors: knockout drops? Raeburn D, et al. **J Pharm Pharmacol** 1997 May;49 Suppl 3:19–24 (22 ref.)

High-dose inhaled steroids in asthmatic children [letter; comment] Brus RH, et al. **Lancet** 1996 Sep 21; 348(9030):820–1; discussion 821. Comment on: Lancet 1996 Jul 6;348(9019):27–9.

New asthma drugs target inflammatory cascade [news] Larkin M. **Lancet** 1997 Apr 5;349(9057):1004

High-dose inhaled steroids in asthmatic children [letter; comment] Lipworth BJ, et al. **Lancet** 1996 Sep 21; 348(9030):820; discussion 821. Comment on: Lancet 1996 Jul 6;348(9019):27–9.

Effect of YM934, a KATP channel opener, on airway hyperresponsiveness induced by platelet activating factor in guinea-pigs. Saitoh C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):203–9

The effects of nedocromil sodium and sodium cromoglycate on airway nerves and neurogenic responses in asthma. Norris AA. **Pulm Pharmacol** 1995 Aug-Oct;8(4–5):227–30 (31 ref.)

Sodium cromoglycate and nedocromil sodium in the therapy of asthma, a critical comparison. Parnham MJ. **Pulm Pharmacol** 1996 Apr;9(2):95–105 (81 ref.)

Airway sensory nerves in asthma—targets for therapy? Spina D, et al. **Pulm Pharmacol** 1996 Feb;9(1):1–18 (257 ref.)

Impact of the global on patient perceivable change in an asthma specific QOL questionnaire. Barber BL, et al. **Qual Life Res** 1996 Feb;5(1):117–22

E .-2-agonists have antioxidant function in vitro. 1. Inhibition of superoxide anion, hydrogen peroxide, hypochlorous acid and hydroxyl radical. Gillissen A, et al. **Respiration** 1997;64(1):16–22

Beta-2-agonists have antioxidant function in vitro. 2. The effect of beta-2-agonists on oxidant-mediated cytotoxicity and on superoxide anion generated by human polymorphonuclear leukocytes. Gillissen A, et al. **Respiration** 1997;64(1):23–8

Measuring systemic effects of inhaled beclomethasone [letter;

comment] Jolobe O. **Thorax** 1996 Sep;51(9):968. Comment on: Thorax 1995 Dec;50(12):1280–4.

Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers. O'Shaughnessy TC, et al. **Thorax** 1997 Jun;52(6):519–22

Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1 ra) expression in asthmatic bronchial epithelium. Sousa AR, et al. **Thorax** 1997 May; 52(5):407–10

Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. Giembycz MA.
Trends Pharmacol Sci 1996 Sep;17(9):331–6 (62 ref.)

[Effect of inhaled corticosteroids on serum eosinophil cationic protein and sIL-2R levels in asthmatics pulmonary hypertension] Wang H, et al.
Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih 1995 Oct; 18(5):306–8, 319 (Eng. Abstr.) **(Chi)**

[Leukotrienes and antagonists of leukotriene receptors]
J Pharm Belg 1997 May–Jun;52(3):131–2 (0 ref.) **(Fre)**

[Clinical pharmacology of leucotriene inhibitors] Paggiaro PL, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:85S–89S (39 ref.) (Eng. Abstr.) **(Ita)**

[Effect of sodium cromoglycate on airway vascular leakage caused by hypertonic saline in the rat trachea] Yamawaki I, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Sep; 34(9):973–7 (Eng. Abstr.) **(Jpn)**

[Synthesis and dual antagonistic activity against thromboxane A2 and leukotriene D4 of benzenesulfonamide derivatives] Sakurai S, et al. **Yakugaku Zasshi** 1997 May;117(5):298–318 (Eng. Abstr.) **(Jpn)**

[Chemotactic activity of neutrophils from atopic and non-atopic subjects—effect of sodium cromoglycate (DSCG)] Szkudlińska B, et al. **Pneumonol Alergol Pol** 1996; 64(7–8):379–85 (Eng. Abstr.) **(Pol)**

[New drugs in the treatment of asthma] de Diego Damiá A. **Arch Bronconeumol** 1996 Aug–Sep;32(7):357–65 (73 ref.) **(Spa)**

STANDARDS

Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Pearlman DS, et al.
Ann Allergy Asthma Immunol 1997 Apr;78(4):356–62

THERAPEUTIC USE

Changes in bone markers in children with asthma during inhaled budesonide and nedocromil treatments. Sorva R, et al. **Acta Paediatr** 1996 Oct;85(10):1176–80

Effect of a potent platelet-activating factor antagonist, WEB-2086, on asthma. A multicenter, double-blind placebo-controlled study in Japan. Tamura G, et al.
Adv Exp Med Biol 1996;416:371–80

Comparative study of inhaled amiloride and inhaled furosemide in exercise-induced asthma. Larramendi CH, et al. **Allergol Immunopathol (Madr)** 1997 Mar–Apr; 25(2):85–90

Biosynthesis inhibitors for leukotrienes in bronchial asthma. Negro JM, et al. **Allergol Immunopathol (Madr)** 1997 Jul–Aug;25(4):209–16 (48 ref.)

Exercise-induced asthma prophylaxis in athletes using inhaled nedocromil sodium. Valero A, et al.
Allergol Immunopathol (Madr) 1996 Mar–Apr;24(2):81–6

Anti-inflammatory drugs do not alleviate bronchial hyperreactivity in Sjögren's syndrome. Stålenheim G, et al. **Allergy** 1997 Apr;52(4):423–7

Serum eosinophil cationic protein (ECP) as a marker of disease activity and treatment efficacy in seasonal asthma. Vatrella A, et al. **Allergy** 1996 Aug;51(8):547–55

FDA approves zafirlukast, first of new type of asthma drug [news] **Am J Health Syst Pharm** 1996 Dec 1;53(23):2778

Enhanced expression of neutral endopeptidase (NEP) in airway epithelium in biopsies from steroid- versus nonsteroid-treated patients with atopic asthma. Sont JK, et al. **Am J Respir Cell Mol Biol** 1997 May;16(5):549–56

Changes in peak flow, symptom score, and the use of medications during acute exacerbations of asthma. Chan-Yeung M, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):889–93

Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Tamaoki J, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1235–40

Steroid-resistant asthma: evaluation and management. Nimmagadda SR, et al. **Ann Allergy Asthma Immunol** 1996 Nov;77(5):345–55; quiz 355–6 (76 ref.)

Effect of inhaled furosemide and cromolyn on bronchoconstriction induced by ultrasonically nebulized distilled water in asthmatic subjects. Siffredi M, et al.
Ann Allergy Asthma Immunol 1997 Feb;78(2):238–43

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Suissa S, et al.
Ann Intern Med 1997 Feb 1;126(3):177–83

Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions [letter] Westermann AM, et al.
Ann Oncol 1996 Jan;7(1):104

Cromolyn sodium for ACE inhibitor-induced cough. Allen TL, et al. **Ann Pharmacother** 1997 Jun;31(6):773–5 (31 ref.)

Zafirlukast for chronic asthma: convenient and generally safe, but is it effective? [comment] Hendeles L, et al.
Ann Pharmacother 1997 Sep;31(9):1084–6 (21 ref.). Comment on: Ann Pharmacother 1997 Sep;31(9):1012–21.

Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma [see comments] Kelloway JS. **Ann Pharmacother** 1997 Sep;31(9):1012–21 (43 ref.). Comment in: Ann Pharmacother 1997 Sep;31(9):1084–6.

Guidelines and realities of asthma management. The Philadelphia story. Lang DM, et al. **Arch Intern Med** 1997 Jun 9;157(11):1193–200

Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents. Smith LJ. **Arch Intern Med** 1996 Oct 28;156(19):2181–9 (95 ref.)

Comparison of bronchodilating effects of two salbutamol dry powder inhalers in asthmatic patients. Laurikainen K, et al. **Arzneimittelforschung** 1997 Jan;47(1):44–6

Effectiveness of the anticholinergic agent oxitropium bromide in elderly patients with bronchial asthma. Shioya T, et al. **Arzneimittelforschung** 1996 Dec;46(12):1130–3

Do patients with asthma fill their prescriptions? A primary compliance study. Watts RW, et al.
Aust Fam Physician 1997 Jan;26 Suppl 1:S4–6

Near-fatal asthma in South Australia: descriptive features and medication use [see comments] Campbell DA, et al. **Aust N Z J Med** 1996 Jun;26(3):356–62. Comment in: Aust N Z J Med 1996 Aug;26(4):487–9.

Study in London confirms influence of ethnic group on treatment for asthma [letter] Sturdy P, et al. **BMJ** 1996 Nov 16;313(7067):1260

Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate [published erratum appears in Br J Clin Pract 1997 Mar;51(2):124] Dahl R, et al. **Br J Clin Pract** 1997 Jan–Feb;51(1):11–5

Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Barnes NC, et al. **Chest** 1997 Feb;111(2 Suppl):52S–60S (20 ref.)

Current therapies for asthma. Promise and limitations. Barnes PJ. **Chest** 1997 Feb;111(2 Suppl):17S–26S (95 ref.)

Partial beta 2-agonists and their impartial assessment [editorial] Dickey BF, et al. **Chest** 1996 Nov;110(5):1131–2

Future directions in asthma therapy. Is a cure possible? Leff AR. **Chest** 1997 Feb;111(2 Suppl):61S–68S (18 ref.)

Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis [see comments] Marin MG. **Chest** 1997 Jul;112(1):29–33. Comment in: Chest 1997 Jul;112(1):1–3.

Utilization of anti-asthma medications in two Quebec populations of anti-asthma medication users: a prescription database analysis. Laurier C, et al. **Chronic Dis Can** 1997; 18(1):20–6

Double-blind placebo-controlled study of oxatomide in the treatment of childhood asthma. Chiu CP, et al.
Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1997 Jan–Feb;38(1):14–20

Disturbing asthma statistics reflect suboptimal management. Grum CM. **Cleve Clin J Med** 1997 Mar;64(3):123–5

The effect of inhaled and intranasal sodium cromoglycate on symptoms of upper respiratory tract infections [see comments] Aberg N, et al. **Clin Exp Allergy** 1996 Sep; 26(9):1045–50. Comment in: Clin Exp Allergy 1996 Sep;26(9):989–94.

Cromolyns: treatment for the common cold [editorial; comment] Johnston SL. **Clin Exp Allergy** 1996 Sep; 26(9):989–94 (49 ref.). Comment on: Clin Exp Allergy 1996 Sep;26(9):1045–50.

A retrospective assessment of cost avoidance associated with the use of nedocromil sodium metered-dose inhaler in the treatment of patients with asthma. Thomas P, et al.
Clin Ther 1996 Sep–Oct;18(5):939–52

Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Wolfe JD, et al. **Clin Ther** 1996 Jul–Aug;18(4):635–46

Three steps toward better management of asthma. Li JT. **Compr Ther** 1996 Jun;22(6):345–52 (30 ref.)

Antileukotriene agents. Tan RA, et al.
Curr Opin Pulm Med 1997 May;3(3):215–20 (46 ref.)

Compliance and outcomes in patients with asthma. Cochrane GM. **Drugs** 1996;52 Suppl 6:12–9 (44 ref.)

The patient perspective. What should a new anti-asthma agent provide? Osman L. **Drugs** 1996;52 Suppl 6:29–35 (40 ref.)

Management of asthma with zafirlukast. Clinical experience and tolerability profile. Spector SL. **Drugs** 1996;52 Suppl 6:36–46 (46 ref.)

Medication use modifies the health effects of particulate sulfate air pollution in children with asthma. Peters A, et al. **Environ Health Perspect** 1997 Apr;105(4):430–5

Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group. Faurschou P, et al. **Eur Respir J** 1996 Sep;9(9):1885–90

Users of antiasthma drugs in Iceland: a drug utilization study. Gislason T, et al. **Eur Respir J** 1997 Jun;10(6):1230–4

Anti-inflammatory effects of inhaled beclomethasone dipropionate in nonatopic asthmatics. Hoshino M, et al. **Eur Respir J** 1996 Apr;9(4):696–702

Change in osmolarity of disodium cromoglycate solution and protection against exercise-induced bronchospasm in children with asthma. Kano S, et al. **Eur Respir J** 1996 Sep;9(9):1891–5

Effects of fluticasone propionate on methacholine dose-response curves in nonsmoking atopic asthmatics. Overbeek SE, et al. **Eur Respir J** 1996 Nov;9(11):2256–62

Glucocorticoid-resistant asthma: pathogenesis and clinical implications for management. Szefler SJ, et al.
Eur Respir J 1997 Jul;10(7):1640–7 (45 ref.)

Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs. Kagoshima M, et al.
Inflamm Res 1997 Apr;46(4):147–53

Disodium cromoglycate as a controller for asthma [editorial; comment] Nakagawa T. **Intern Med** 1996 Dec;35(12):922–3 . Comment on: Intern Med 1996 Dec;35(12):976–8.

Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. Adelroth E, et al.
J Allergy Clin Immunol 1997 Feb;99(2):210–5

Retention of asthmatic patients in a longitudinal clinical trial. Bender BG, et al. **J Allergy Clin Immunol** 1997 Feb; 99(2):197–203

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. Liu MC, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):859–71

Inhaled beclomethasone dipropionate downregulates CD4 and CD8 T-lymphocyte activation in peripheral blood of patients with asthma. Majori M, et al.
J Allergy Clin Immunol 1997 Sep;100(3):379–82

Comparative efficacy of inhaled furosemide and disodium cromoglycate in the treatment of exercise-induced asthma in children. Melo RE, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):204–9

Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. Grossman J, et al.
J Asthma 1997;34(4):321–8

Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma. Mahajan P, et al. **J Asthma** 1997;34(3):227–34

Furosemide given by inhalation ameliorates acute exacerbation of asthma. Ono Y, et al. **J Asthma** 1997; 34(4):283–9

New insights into the pathogenesis and management of steroid-resistant asthma. Spahn JD, et al. **J Asthma** 1997; 34(3):177–94 (150 ref.)

Deaths from asthma in Italy (1974–1988): is there a relationship with changing pharmacological approaches? Mormile F, et al. **J Clin Epidemiol** 1996 Dec;49(12):1459–66

Prescribing trends for anti-asthma drugs in Tasmania following the National Asthma Campaign. Jacobson GA, et al. **J Clin Pharm Ther** 1996 Oct;21(5):317–24

Evaluation of Nigerian traditional medicine: effects of Gakani, a herbal anti-asthmatic drug. Akah PA, et al.
J Ethnopharmacol 1997 Jan;55(2):87–92

HELIOX in children with acute severe asthma [letter] Carter ER, et al. **J Pediatr** 1997 Aug;131(2):333–4

Current therapy for asthma: time for a change? Barnes NC.
J Pharm Pharmacol 1997 May;49 Suppl 3:13–6 (36 ref.)

Community care of asthma: the pharmacist as counsellor? Chrystyn H. **J Pharm Pharmacol** 1997 May;49 Suppl 3:51–4 (37 ref.)

Management of asthma in childhood. Everard ML.
J Pharm Pharmacol 1997 May;49 Suppl 3:45–50 (58 ref.)

Effect of YM934, a novel potassium-channel opener, in various experimental asthma models in guinea-pigs. Ishikawa J, et al. **J Pharm Pharmacol** 1996 Oct; 48(10):1034–40

Current drug treatment of asthma. Jack D.
J Pharm Pharmacol 1997 May;49 Suppl 3:17–8 (3 ref.)

Assessing equivalence of inhaled products. Snell NJ.
J Pharm Pharmacol 1997 May;49 Suppl 3:55–60 (52 ref.)

Leukotriene receptor antagonists: clinical effects. Barnes N.
J R Soc Med 1997 Apr;90(4):200–4 (63 ref.)

Inhaled steroids and the risk of hospitalization for asthma. Donahue JG, et al. **JAMA** 1997 Mar 19;277(11):887–91

Taking asthma seriously [news] Voelker R. **JAMA** 1997 Jul 2;278(1):11

Leukotriene receptor antagonists: the newest in asthma drugs. Stevenson AM. **MCN Am J Matern Child Nurs** 1997 May–Jun;22(3):170, 169

Zafirlukast for asthma. **Med Lett Drugs Ther** 1996 Dec 20; 38(990):111–2

Maintenance therapy: the compliance issue. Olivieri D, et al. **Monaldi Arch Chest Dis** 1996 Dec;51(6):557

Inhaled beclomethasone dipropionate (BDP) prevents seasonal changes in atopic asthmatics. Ponticiello A, et al.
Monaldi Arch Chest Dis 1997 Apr;52(2):112–7

Under the volcano: fire, ash and asthma? Bradshaw L, et al. **N Z Med J** 1997 Mar 28;110(1040):90–1

Zafirlukast: a new treatment for asthma [news] Kupecz D.
Nurse Pract 1997 May;22(5):182, 185–6, 189–90 (41 ref.)

Pharmacologic therapy of asthma during pregnancy. Dombrowski MP. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):559–74 (64 ref.)

The course of chickenpox in asthmatic children receiving inhaled budesonide. Nursoy MA, et al.
Pediatr Infect Dis J 1997 Jan;16(1):74–7

Effect of asthma treatment on urinary growth hormone excretion in children [letter; comment] Nikolaizik WH.
Pediatr Pulmonol 1997 Feb;23(2):126–7. Comment on: Pediatr Pulmonol 1996 Jun;21(6):361–6.

Effect of asthma treatment on urinary growth hormone excretion in children [see comments] O'Leary PC, et al.
Pediatr Pulmonol 1996 Jun;21(6):361–6. Comment in:

Pediatr Pulmonol 1997 Feb;23(2):126–7.

Asthma: too much diagnosis and too much medicine [letter; comment] Giannini AV. **Pediatrics** 1996 Oct;98(4 Pt 1):800–1. Comment on: Pediatrics 1993 Jul;92(1):144–6.

Use of allergen bronchoprovocation to screen drugs for anti-asthma activity. Hendeles L, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1 Pt 2):39S–49S (53 ref.)

Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Lipworth BJ. **Pulm Pharmacol** 1996 Feb;9(1):19–27 (48 ref.)

Sodium cromoglycate and nedocromil sodium in the therapy of asthma, a critical comparison. Parnham MJ. **Pulm Pharmacol** 1996 Apr;9(2):95–105 (81 ref.)

Nocturnal waking and morning dip of peak expiratory flow in clinically stable asthma patients during treatment. Occurrence and patient characteristics. Van Keimpema AR, et al. **Respiration** 1997;64(1):29–34

The treatment of allergic rhinitis improves the recovery from asthma and upper respiratory infections. Sarti W, et al. **Rev Paul Med** 1995 Sep–Oct;113(5):968–72

The changing face of asthma therapy. Marchiando RJ. **S D J Med** 1997 Mar;50(3):103–4

New clues to asthma therapies [news] Vogel G. **Science** 1997 Jun 13;276(5319):1643–6

A profile of acute asthma patients presenting to the emergency room. Abisheganaden J, et al. **Singapore Med J** 1996 Jun;37(3):252–4

Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Barnes NC, et al. **Thorax** 1997 Jun;52(6):523–7

Provision of asthma medications in developing countries: a view from the pharmaceutical industry [editorial] Fuller RW. **Thorax** 1997 Jul;52(7):590

Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Levy ML, et al. **Thorax** 1996 Nov;51(11):1087–92

Influenza vaccination in patients with asthma: effect on peak expiratory flow, asthma symptoms and use of medication. Ahmed AH, et al. **Vaccine** 1997 Jun;15(9):1008–9

[Study on effect of strengthening body resistance method on asthmatic attack] Xu DS, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Apr; 16(4):198–200 (Eng. Abstr.) **(Chi)**

[A new oral therapy for the preventive treatment of asthma. Accolate: clinical profile] Pauwels R. **J Pharm Belg** 1997 May–Jun;52(3):134 **(Fre)**

[Non-cancer uses of methotrexate] Brion N, et al. **Presse Med** 1996 Dec 14;25(39):1929–34 (37 ref.) (Eng. Abstr.) **(Fre)**

[Asthma and obstructive bronchopneumopathies: the consensus] Yernault JC. **Rev Med Brux** 1996 Sep; 17(4):263–5 (Eng. Abstr.) **(Fre)**

[Leukotriene-receptor antagonists: a new therapeutic principle in bronchial asthma? (editorial)] Pforte A. **Dtsch Med Wochenschr** 1996 Sep 13;121(37):1111–2 **(Ger)**

[Leukotriene receptor antagonists] Bornkessel B. **Med Monatsschr Pharm** 1996 Oct;19(10):284–6 (3 ref.) **(Ger)**

[Anti-leukotrienes--a new perspective in treatment of bronchial asthma. 1. Scientific Pneumology Symposium, Cannes, 14–16 February 1997] Steinkamp G. **Pneumologie** 1997 Jul;51(7):688–93 **(Ger)**

[Bronchial asthma in infants, children and youths: recommendations for therapy 1997. Work Group for Pediatric Pneumology. Swiss Pediatric Society. Swiss Pneumology Society] **Schweiz Med Wochenschr** 1997 Mar 8;127(10):406–10 **(Ger)**

[Update on treatment of asthma] Battistini A. **Pediatr Med Chir** 1996 Jul–Aug;18(4):333–40 (52 ref.) (Eng. Abstr.) **(Ita)**

[New drugs in the treatment of respiratory allergic diseases] Gani F, et al. **Recenti Prog Med** 1997 Jul–Aug; 88(7–8):333–41 (38 ref.) (Eng. Abstr.) **(Ita)**

[Cough-variant asthma successfully treated with a peptide leukotriene receptor antagonist] Nishi K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Jan; 35(1):117–23 (Eng. Abstr.) **(Jpn)**

[Leukotrienes and asthma. Clinical and experimental experiences with leukotriene receptor antagonists and leukotriene synthesis inhibitors] Henriksen AH, et al. **Tidsskr Nor Laegeforen** 1997 Feb 20;117(5):647–51 (27 ref.) (Eng. Abstr.) **(Nor)**

[Fluticasone propionate in treatment of seasonal allergic rhinitis--open multicenter study] Kokot M, et al. **Pol Merkuriusz Lek** 1996 Jul;1(1):38–40 (Eng. Abstr.) **(Pol)**

[Magnesium sulfate in management of bronchial asthma] Emel'ianova AV, et al. **Klin Med (Mosk)** 1996;74(8):55–8 (Eng. Abstr.) **(Rus)**

[The effect of polyunsaturated fatty acids of the omega-3 class on the late phase of the allergic reaction in bronchial asthma patients] Masuev KA. **Ter Arkh** 1997;69(3):31–3 (Eng. Abstr.) **(Rus)**

[The effect of polyunsaturated fatty acids on the biochemical indices of bronchial asthma patients] Masuev KA. **Ter Arkh** 1997;69(3):33–5 (Eng. Abstr.) **(Rus)**

[New developments in the treatment of bronchial asthma: leukotriene inhibitors] Tsoĭ AN, et al. **Ter Arkh** 1997; 69(2):83–8 (54 ref.) **(Rus)**

[Therapy of chronic allergic conjunctivitis with sodium cromoglycate (lecrolin)] Polunin GS, et al. **Vestn Oftalmol** 1997 Mar–Apr;113(2):21–2 (Eng. Abstr.) **(Rus)**

[Evaluation of inhalation treatment in asthmatic infants] Gracia Antequera M, et al. **An Esp Pediatr** 1997 Jan; 46(1):13–9 (Eng. Abstr.) **(Spa)**

[Beta-adrenergic agents in asthma (editorial)] Morales AM, et al. **Rev Alerg Mex** 1996 Jan–Feb;43(1):2–4 **(Spa)**

[New drugs in asthma treatment. Leukotriene receptor blockers and leukotriene synthesis inhibitors] Männistö J, et al. **Nord Med** 1997 Apr;112(4):122–5 (15 ref.) (Eng. Abstr.) **(Swe)**

URINE

Development and validation of an ion-pair liquid chromatographic method for the quantitation of sodium cromoglycate in urine following inhalation. Aswania OA, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7; 690(1-2):373–8

ANTI-AUSTRALIA ANTIGENS see **HEPATITIS B ANTIBODIES**

ANTIBIOSIS

The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo. Bernet-Camard MF, et al. **Appl Environ Microbiol** 1997 Jul;63(7):2747–53

Physiological and biochemical characterization of Trichoderma harzianum, a biological control agent against soilborne fungal plant pathogens. Grondona I, et al. **Appl Environ Microbiol** 1997 Aug;63(8):3189–98

Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium C5 infection. Hudault S, et al. **Appl Environ Microbiol** 1997 Feb;63(2):513–8

Nitrogen availability of grape juice limits killer yeast growth and fermentation activity during mixed-culture fermentation with sensitive commercial yeast strains. Medina K, et al. **Appl Environ Microbiol** 1997 Jul; 63(7):2821–5

A secretory protein involved in the antagonistic interactions between methanotrophic bacteria. Pashkova NI, et al. **Biochemistry (Mosc)** 1997 Apr;62(4):386–90

Virus set against virus [news] Josefson D. **BMJ** 1997 Sep 20;315(7110):700

Inhibition of Salmonella typhimurium by the products of tartrate metabolism by a Veillonella species. Hinton A Jr, et al. **J Appl Bacteriol** 1996 Aug;81(2):188–90

Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. Rodrigues AC, et al. **J Appl Bacteriol** 1996 Sep;81(3):251–6

Application of antimicrobial-producing lactic acid bacteria to control pathogens in ready-to-use vegetables. Vescovo M, et al. **J Appl Bacteriol** 1996 Aug;81(2):113–9

Effect of Lactobacillus reuteri on intestinal resistance to Cryptosporidium parvum infection in a murine model of acquired immunodeficiency syndrome. Alak JI, et al. **J Infect Dis** 1997 Jan;175(1):218–21

A microbiology investigation on probiotic pharmaceutical products used for human health. Canganella F, et al. **Microbiol Res** 1997 Jul;152(2):171–9

Strains of the genus Serratia as beneficial rhizobacteria of oilseed rape with antifungal properties. Kalbe C, et al. **Microbiol Res** 1996 Dec;151(4):433–9

Killer factor interference in mixed opportunistic yeast cultures. Conti S, et al. **Mycopathologia** 1996;135(1):1–8

Are biological antagonists an alternative to synthetic fungicides for preventing postharvest diseases of fruits and vegetables? Droby S, et al. **Rev Environ Health** 1996 Jan–Jun;11(1-2):71–7 (47 ref.)

Bacterial interference caused by autoinducing peptide variants. Ji G, et al. **Science** 1997 Jun 27;276(5321):2027–30

Predacious yeasts. Lachance MA, et al. **Yeast** 1997 Mar 15; 13(3):225–32

[The biological properties of Aerococcus antagonists, representatives of human microbiocenoses] Kremenchutskiĭ GN, et al. **Mikrobiol Z** 1994 Jul–Sep;56(4):36–42 (61 ref.) (Eng. Abstr.) **(Rus)**

[The antagonistic properties of microaerophilic bacteria isolated from the human and mink digestive tracts] Sudenko VI, et al. **Mikrobiol Z** 1996 Sep–Oct;58(5):58–66 (Eng. Abstr.) **(Rus)**

[The antagonistic action of lactobacilli on Helicobacter pylori] Bazhenov LG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 May–Jun; (3):89–91 (Eng. Abstr.) **(Rus)**

[The action of bacterial antagonists on the aerobic microflora of human skin] Klymniuk SI, et al. **Mikrobiol Z** 1997 Jan–Feb;59(1):53–60 (Eng. Abstr.) **(Ukr)**

GENETICS

Improved biocontrol activity of Trichoderma harzianum by over-expression of the proteinase-encoding gene prb1. Flores A, et al. **Curr Genet** 1997 Jan;31(1):30–7

PHYSIOLOGY

The nasopharyngeal bacterial flora in children with otitis media with effusion [see comments] Fujimori I, et al. **Eur Arch Otorhinolaryngol** 1996;253(4–5):260–3. Comment in: Eur Arch Otorhinolaryngol 1997;254(1):19. Comment in: Eur Arch Otorhinolaryngol 1997;254(2):113.

Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Kabir AM, et al. **Gut** 1997 Jul;41(1):49–55

[Antagonistic properties of bacterial flora in the mouth and throat of children] Krzemiński Z, et al. **Med Dosw Mikrobiol** 1996;48(3–4):117–21 (Eng. Abstr.) **(Pol)**

RADIATION EFFECTS

[The antagonistic properties of bacteria isolated from the digestive tract of female mink housed in the area of the Chernobyl Atomic Electric Power Station] Sudenko VI, et al. **Mikrobiol Z** 1996 Nov–Dec;58(6):38–44 (Eng. Abstr.) **(Rus)**

ANTIBIOTIC-ASSOCIATED COLITIS see **ENTEROCOLITIS, PSEUDOMEMBRANOUS**

ANTIBIOTIC PROPHYLAXIS

Antibiotic prophylaxis in vascular and interventional radiology. McDermott VG, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):31–8 (66 ref.)

Antibiotic prophylaxis for orthopedic prostheses and GI procedures: report of a survey. Meyer GW, et al. **Am J Gastroenterol** 1997 Jun;92(6):989–91

Antibiotic prophylaxis in percutaneous endoscopic gastrostomy. Sturgis TM, et al. **Am J Gastroenterol** 1996 Nov;91(11):2301–4

Antibiotic prophylaxis for spontaneous bacterial peritonitis [letter; comment] Yarze JC, et al. **Am J Gastroenterol** 1997 Jan;92(1):180. Comment on: Am J Gastroenterol 1996 May;91(5):1050–1.

Improving the timing of antimicrobial prophylaxis [letter] Matuschka PR. **Am J Health Syst Pharm** 1996 Aug 1; 53(15):1846, 1849

Antibiotic prophylaxis for hemodialysis access placement [editorial; comment] Kovalik EC, et al. **Am J Kidney Dis** 1997 Sep;30(3):448. Comment on: Am J Kidney Dis 1997 Sep;30(3):343–8.

Preoperative vancomycin prophylaxis decreases incidence of postoperative hemodialysis vascular access infections [see comments] Zibari GB, et al. **Am J Kidney Dis** 1997 Sep; 30(3):343–8. Comment in: Am J Kidney Dis 1997 Sep;30(3):448.

The clinical impact of echocardiography on antibiotic prophylaxis use in patients with suspected mitral valve prolapse. Heidenreich PA, et al. **Am J Med** 1997 Apr; 102(4):337–43

Use of a subcutaneous closed drainage system and antibiotics in obese gynecologic patients. Gallup DC, et al. **Am J Obstet Gynecol** 1996 Aug;175(2):358–61; discussion 362

A prospective, double-blind, randomized, controlled clinical trial of ampicillin-sulbactam for preterm premature rupture of membranes in women receiving antenatal corticosteroid therapy. Lovett SM, et al. **Am J Obstet Gynecol** 1997 May; 176(5):1030–8

The efficacy of prophylactic erythromycin in preventing vertical transmission of Ureaplasma urealyticum. Ogasawara KK, et al. **Am J Perinatol** 1997 Apr;14(4):233–7

Protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma. Sirvent JM, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1729–34

Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Villarino ME, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1735–8

The status of anti-infectives in surgery in 1996: a roundtable discussion. **Am J Surg** 1996 Dec;172(6A):49S–61S

A critical review of antibiotic prophylaxis in severe acute pancreatitis. Barie PS. **Am J Surg** 1996 Dec; 172(6A):38S–43S (31 ref.)

Let us shorten antibiotic prophylaxis and therapy in surgery. Wittmann DH, et al. **Am J Surg** 1996 Dec;172(6A):26S–32S (46 ref.)

Oral administration of tylosin phosphate for treatment and prevention of proliferative enteropathy in pigs. McOrist S, et al. **Am J Vet Res** 1997 Feb;58(2):136–9

Absorbable, delayed-release antibiotic beads reduce surgical wound infection. Galandiuk S, et al. **Am Surg** 1997 Sep; 63(9):831–5

How many antibiotics are necessary to treat abdominal trauma victims? Sims EH, et al. **Am Surg** 1997 Jun; 63(6):525–35

Antibiotic prophylaxis before endoscopic retrograde cholangiopancreatography [letter; comment] Byl B, et al. **Ann Intern Med** 1997 Jun 15;126(12):1001–2. Comment on: Ann Intern Med 1996 Sep 15;125(6):442–7.

Prevention of group B Streptococcus infection in neonates. Logsdon BA, et al. **Ann Pharmacother** 1997 Jul–Aug; 31(7–8):897–906 (68 ref.)

The prevention of anastomotic leakage after total gastrectomy with local decontamination. A prospective, randomized, double-blind, placebo-controlled multicenter trial. Schardey HM, et al. **Ann Surg** 1997 Feb;225(2):172–80

Double-blind comparison of cefazolin and ceftizoxime for prophylaxis against infections following elective biliary

tract surgery. Jewesson PJ, et al.
Antimicrob Agents Chemother 1996 Jan;40(1):70–4

Concentrations of ceftriaxone (1,000 milligrams intravenously) in abdominal tissues during open prostatectomy. Martin C, et al.
Antimicrob Agents Chemother 1996 May;40(5):1311–3

Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. Rouse MS, et al. **Antimicrob Agents Chemother** 1997 Aug; 41(8):1673–6

Antibiotic–impregnated cement and beads for orthopedic infections. Wininger DA, et al.
Antimicrob Agents Chemother 1996 Dec;40(12):2675–9 (49 ref.)

Antibiotic administration [letter; comment] Dunn D.
AORN J 1997 May;65(5):888. Comment on: AORN J 1997 Jan;65(1):109–15.

Prophylactic antibiotics for posttraumatic cerebrospinal fluid fistulae. A meta–analysis. Brodie HA.
Arch Otolaryngol Head Neck Surg 1997 Jul;123(7):749–52

Management of intra–abdominal infections. The case for intraoperative cultures and comprehensive broad–spectrum antibiotic coverage. The Canadian Intra–abdominal Infection Study Group. Christou NV, et al. **Arch Surg** 1996 Nov;131(11):1193–201

Influence of hemodilution on cefuroxime levels and bacterial contamination of intra– and postoperative processed wound blood during hip replacement. Wollinsky KH, et al.
Beitr Infusionsther Transfusionsmed 1996;33:191–5

Prevention of prosthetic valve endocarditis by impregnation of gentamicin into surgical pledgets. Khor E, et al.
Biomaterials 1996 Aug;17(16):1631–7

Commentary: summary statistics of poor quality studies must be treated cautiously [comment] Berlin JA. **BMJ** 1997 Feb 1;314(7077):337. Comment on: BMJ 1997 Feb 1;314(7077):334–6.

Prophylaxis should be considered even for trivial animal bites [letter] Morgan MS. **BMJ** 1997 May 10;314(7091):1413

Meta–analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence [see comments] Shann F. **BMJ** 1997 Feb 1;314(7077):334–6. Comment in: BMJ 1997 Feb 1;314(7077):337.

Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide–doxorubicin–etoposide using granulocyte colony–stimulating factor with or without antimicrobial prophylaxis in patients with small–cell lung cancer. Ardizzoni A, et al. **Br J Cancer** 1996 Oct;74(7):1141–7

Comparative intraocular penetration of topical and injected cefuroxime [see comments] Jenkins CD, et al.
Br J Ophthalmol 1996 Aug;80(8):685–8. Comment in: Br J Ophthalmol 1996 Aug;80(8):681–2.

Randomized placebo–controlled trial of teicoplanin in the antibiotic prophylaxis of infection following manipulation of burn wounds. Steer JA, et al. **Br J Surg** 1997 Jun; 84(6):848–53

Morbidity of ultrasound–guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy. A prospective study in 415 cases. Enlund AL, et al.
Br J Urol 1997 May;79(5):777–80

Effect of probiotic supplementation on growth, nitrogen utilisation and serum cholesterol in broilers. Mohan B, et al. **Br Poult Sci** 1996 May;37(2):395–401

Breakthrough bacteraemic and fungaemic episodes during antimicrobial prophylaxis and therapy in cancer patients: analysis of risk factors, etiology, therapy and outcome in 123 episodes. Spánik S, et al. **Bratisl Lek Listy** 1996 Nov; 97(11):652–9

Incidence of deep sepsis in uncemented total hip arthroplasty using clean air facility as a function of antibiotic prophylaxis. Hauser R, et al. **Bull Hosp Jt Dis** 1996; 54(3):175–9

Prophylaxis against Staphylococcus epidermidis vascular graft infection with rifampicin–soaked, gelatin–sealed Dacron. Sardelic F, et al. **Cardiovasc Surg** 1996 Jun; 4(3):389–92

Antimicrobial prophylaxis with ceftriaxone in neurosurgical procedures. A prospective study of 100 patients undergoing shunt operations. Arnaboldi L. **Chemotherapy** 1996 Sep–Oct;42(5):384–90

Low–dose, single–shot perioperative antibiotic prophylaxis in colorectal surgery. Peiper C, et al. **Chemotherapy** 1997 Jan–Feb;43(1):54–9

Selective decontamination of the digestive tract. Consider cross–infection of Staphylococcus aureus? [letter; comment] Hurley J. **Chest** 1996 Dec;110(6):1625–6. Comment on: Chest 1996 Mar;109(3):765–72.

Short–course chemoprophylaxis for tuberculosis. Bishai WR, et al. **Clin Chest Med** 1997 Mar;18(1):115–22 (56 ref.)

Emergence of antibiotic–resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Montravers P, et al. **Clin Infect Dis** 1996 Sep;23(3):486–94

Prophylaxis in lower–extremity infectious diseases. Joseph WS, et al. **Clin Podiatr Med Surg** 1996 Oct;13(4):647–60 (41 ref.)

Antibiotic prophylaxis for patients at risk of infective endocarditis [letter; comment] O'Doherty AJ, et al.
Clin Radiol 1997 Apr;52(4):322. Comment on: Clin Radiol 1996 Sep;51(9):649–50.

Antibiotic prophylaxis during clean neurosurgery: a large, multicenter study using cefuroxime. Holloway KL, et al.
Clin Ther 1996 Jan–Feb;18(1):84–94

Pneumocystis carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case and review of the literature. Scott AM, et al.
Dis Colon Rectum 1997 Aug;40(8):973–6

Antibiotic prophylaxis in gastrointestinal endoscopy: a report by a working party for the British Society of Gastroenterology endoscopy committee. Mani V, et al.
Endoscopy 1997 Feb;29(2):114–9

Pharmacokinetics of cloxacillin in patients undergoing hip or knee replacement. Vinge E, et al.
Eur J Clin Pharmacol 1997;52(5):407–11

Prophylactic, empiric and therapeutic use of antibiotics. Do we need a guide: a universal edition or a local one? Peetermans WE. **Eur J Emerg Med** 1997 Mar;4(1):15–8 (12 ref.)

Antibiotic prophylaxis in umbilical and incisional hernia repair: a prospective randomised study. Abramov D, et al. **Eur J Surg** 1996 Dec;162(12):945–8; discussion 949

Comparative trial of four antibiotic combinations for perforated appendicitis in children. Ciftci AO, et al.
Eur J Surg 1997 Aug;163(8):591–6

Penetration of clindamycin and metronidazole into inflamed appendiceal tissue. Levy Y, et al. **Eur J Surg** 1996 Aug; 162(8):633–5

Pharmacotherapy—the facts and fantasies of prophylaxis and combined therapies. Scaglione F. **Eur J Surg Suppl** 1997; (578):11–5 (20 ref.)

The value of antibiotic prophylaxis during extracorporeal shock wave lithotripsy in the prevention of urinary tract infections in patients with urine proven sterile prior to treatment. Bierkens AF, et al. **Eur Urol** 1997;31(1):30–5

Early antibiotic treatment in acute necrotizing pancreatitis. Bartholomew M, et al. **Gastrointest Endosc** 1996 Dec; 44(6):763–4

Is rifabutin prophylaxis against Mycobacterium avium complex infection in HIV infection worthwhile? The net impact on patients suggests not. Stephenson JM, et al.
Genitourin Med 1996 Aug;72(4):272–6 (10 ref.)

Short–term versus long–term antimicrobial prophylaxis in oncologic head and neck surgery. Righi M, et al.
Head Neck 1996 Sep–Oct;18(5):399–404

Comparison of three prophylactic antibiotic regimens in clean–contaminated head and neck surgery. Rodrigo JP, et al. **Head Neck** 1997 May;19(3):188–93

Antibiotics for prophylaxis and treatment of intra–abdominal infections. Michalopoulos A, et al.
Hepatogastroenterology 1997 Jul–Aug;44(16):947–58 (76 ref.)

Antibiotic prophylaxis in gastroduodenal surgery. Schilling J, et al. **Hepatogastroenterology** 1997 Jan–Feb;44(13):116–20

Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Pauwels A, et al. **Hepatology** 1996 Oct; 24(4):802–6

Local antibiotic prophylaxis in surgery. Martin C, et al.
Infect Control Hosp Epidemiol 1996 Aug;17(8):539–44 (64 ref.)

Inhalatory pentamidine therapy and the duration of the QT interval in HIV–infected patients. Cardoso JS, et al.
Int J Cardiol 1997 May 23;59(3):285–9

Perioperative pharmacokinetics of piperacillin during liver transplantation. Bourget P, et al.
Int J Clin Pharmacol Ther 1996 Dec;34(12):550–4

ACOG educational bulletin. Antibiotics and gynecologic infections. American College of Obstetricians and Gynecologists. Number 237, June 1997 (Replaces No. 153, March 1991). **Int J Gynaecol Obstet** 1997 Sep;58(3):333–40

Low risk of perioperative infection without prophylactic antibiotics for transperineal prostate brachytherapy. Wallner K, et al. **Int J Radiat Oncol Biol Phys** 1996 Oct 1;36(3):681–3

Are prophylactic antibiotics required for elective laparoscopic cholecystectomy? Illig KA, et al.
J Am Coll Surg 1997 Apr;184(4):353–6

The impact of rufloxacin given as prophylaxis to patients with cancer on their oral and faecal microflora. D'Antonio D, et al. **J Antimicrob Chemother** 1996 Nov;38(5):839–47

Optimizing the timing of antimicrobial prophylaxis in surgery: an intervention study. Gyssens IC, et al.
J Antimicrob Chemother 1996 Aug;38(2):301–8

Antibiotic prophylaxis for transrectal prostate biopsy. Taylor HM, et al. **J Antimicrob Chemother** 1997 Feb;39(2):115–7

Prophylactic use of antibiotics for procedures after total joint replacement. Deacon JM, et al. **J Bone Joint Surg Am** 1996 Nov;78(11):1755–70

Antibiotic prophylaxis in total hip arthroplasty. Review of 10,905 primary cemented total hip replacements reported to the Norwegian arthroplasty register, 1987 to 1995. Espehaug B, et al. **J Bone Joint Surg Br** 1997 Jul; 79(4):590–5

Antibiotic prophylaxis, dental treatment and arthroplasty: time to explode a myth [editorial] Sandhu SS, et al.
J Bone Joint Surg Br 1997 Jul;79(4):521–2

Study of antibiotic prophylaxis during burn wound debridement in children. Rodgers GL, et al.
J Burn Care Rehabil 1997 Jul–Aug;18(4):342–6

Concentration of cefamandole in plasma and tissues of patients undergoing cardiac surgery: the influence of different cefamandole dosage. Menges T, et al.
J Cardiothorac Vasc Anesth 1997 Aug;11(5):565–70

Vancomycin prophylaxis and intraocular contamination during cataract surgery. Feys J, et al.
J Cataract Refract Surg 1997 Jul–Aug;23(6):894–7

Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor of the uninflamed human eye. Akkan AG, et al. **J Chemother** 1997 Aug; 9(4):257–62

Psoriasis and elective foot surgery [see comments] Cheleuitte E, et al. **J Foot Ankle Surg** 1996 Jul–Aug;35(4):297–302; discussion 371 (25 ref.). Comment in: J Foot Ankle Surg 1997 Jan–Feb;36(1):77–8.

Antibiotic prophylaxis and tourniquet application in podiatric surgery. Deacon JS, et al. **J Foot Ankle Surg** 1996 Jul–Aug; 35(4):344–9 (31 ref.)

Retrospective assessment of antibiotic and tourniquet use in an ambulatory surgery center. Reyes C, et al.
J Foot Ankle Surg 1997 Jan–Feb;36(1):55–62

Preventing endoscopic retrograde cholangiopancreatography related sepsis: a randomized controlled trial comparing two antibiotic regimes. Smith BC, et al.
J Gastroenterol Hepatol 1996 Oct;11(10):938–41

Efficacy of antibiotic prophylaxis for prevention of Lyme disease. Warshafsky S, et al. **J Gen Intern Med** 1996 Jun; 11(6):329–33

Management of an outbreak of methicillin–resistant Staphylococcus aureus in a risk area with empirical intranasal mupirocin [letter] Rodríguez G, et al.
J Hosp Infect 1997 Jun;36(2):155–7

Cephazolin and metronidazole prophylaxis in head and neck surgery. Strauss M, et al. **J Laryngol Otol** 1997 Jul; 111(7):631–4

The efficacy of a single dose antibiotic regimen in adults undergoing tonsillectomy. Cannon CR.
J Miss State Med Assoc 1996 Nov;37(11):817–21

Antibiotic prophylaxis: theory and reality in orthopaedics. Dougall TW, et al. **J R Coll Surg Edinb** 1996 Oct; 41(5):321–2

Prophylactic antibiotic project. Gunter N, et al.
J S C Med Assoc 1997 May;93(5):174–6

Cardiac surgery in a high–risk group of patients: is prolonged postoperative antibiotic prophylaxis effective? Niederhäuser U, et al. **J Thorac Cardiovasc Surg** 1997 Aug; 114(2):162–8

Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. Sieber PR, et al. **J Urol** 1997 Jun; 157(6):2199–200 (13 ref.)

Sepsis associated with hematological malignancies: prophylaxis of Pseudomonas aeruginosa sepsis. Sakamoto M, et al. **Kansenshogaku Zasshi** 1996 Feb;70(2):116–22

Prophylactic strategies to meet infectious complications in fludarabine–treated CLL. Südhoff T, et al. **Leukemia** 1997 Apr;11 Suppl 2:S38–41 (38 ref.)

Vascular infections: exceeding the threshold. Cox TR.
Mil Med 1995 Dec;160(12):609–11

Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Morb Mortal Wkly Rep 1997 Feb 14; 46(RR–5):1–10

Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Morb Mortal Wkly Rep 1997 Feb 14; 46(RR–5):13–21

Osteomyelitis [see comments] Lew DP, et al.
N Engl J Med 1997 Apr 3;336(14):999–1007 (62 ref.). Comment in: N Engl J Med 1997 Aug 7;337(6):428; discussion 429. Comment in: N Engl J Med 1997 Aug 7;337(6):428–9.

Prophylactic use of topical anti–infectives in ophthalmology. Kramer A, et al. **Ophthalmologica** 1997;211 Suppl 1:68–76 (43 ref.)

Efficacy of prophylactic antibiotics in arthroscopic surgery. Wieck JA, et al. **Orthopedics** 1997 Feb;20(2):133–4

The anaesthetist as determinant factor of quality of surgical antimicrobial prophylaxis. A survey in a university hospital. Gyssens IC, et al. **Pharm World Sci** 1997 Apr;19(2):89–92

Prophylactic use of antibiotics and vaccines in patients with rheumatologic disorders. Mounzer KC, et al.
Rheum Dis Clin North Am 1997 May;23(2):259–75 (83 ref.)

Another deadly disease we can prevent—perinatal GBS [editorial] Barlow JF. **S D J Med** 1996 Nov;49(11):399–400

Viridans streptococcal bacteraemia due to penicillin–resistant and penicillin–sensitive streptococci: analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis. Spanik S, et al. **Scand J Infect Dis** 1997;29(3):245–9

Use of prophylactic antibiotics in the prevention of infective endocarditis and prosthesis infection. Lam MS, et al.
Singapore Med J 1995 Aug;36(4):424–7 (22 ref.)

Ceftriaxone versus cefazolin in peripheral arterial operations: a randomized, prospective trial. Ross CB, et al.
South Med J 1997 Jan;90(1):16–22

Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high–dose chemotherapy and autologous stem cell rescue. Meisenberg B, et al.
Support Care Cancer 1996 Sep;4(5):364–9

Intraoperative antibiotic prophylaxis. Malis LI, et al.
Surg Neurol 1997 May;47(5):481–3

Intravenous administration of vancomycin is ineffective against bacteremia following tooth extraction. Kaneko A,

et al. **Tokai J Exp Clin Med** 1995 May;20(1):65–6

Prophylactic antibiotics in renal transplantation. Melchor JL, et al. **Transplant Proc** 1996 Dec;28(6):3305

Parenteral fluoroquinolones prevent translocation of enterobacteria following combined liver–small bowel transplantation in pigs. Privitera G, et al. **Transplant Proc** 1996 Oct;28(5):2669–70

Bacterial translocation is enhanced in pig intestinal transplantation when the colon is included in the graft. Spada M, et al. **Transplant Proc** 1996 Oct;28(5):2658–9

Recurrences and progression of superficial bladder cancer following long–term intravesical prophylactic therapy with mitomycin C: 48–month follow–up. Minervini R, et al. **Urol Int** 1996;56(4):234–7

Antimicrobial prophylaxis prior to shock wave lithotripsy in patients with sterile urine before treatment: a meta–analysis and cost–effectiveness analysis. Pearle MS, et al. **Urology** 1997 May;49(5):679–86

Antibiotic prophylaxis for pit viper envenomation: prospective, controlled trial. Kerrigan KR, et al. **World J Surg** 1997 May;21(4):369–72; discussion 372–3

[The use of cefotetan for the prevention of infectious postoperative complications in gynecology] Doganov N, et al. **Akush Ginekol (Sofiia)** 1997;36(1):11–3 (Eng. Abstr.) **(Bul)**

[Mitomycin C in glaucoma filtering surgery] Váša M, et al. **Cesk Slov Oftalmol** 1997 Jun;53(3):155–67 (Eng. Abstr.) **(Cze)**

[Intravenous administration of Augmentin in the prevention of infectious complications in abdominal hysterectomy] Kučera E, et al. **Ceska Gynekol** 1996 Jun;61(3):148–50 (Eng. Abstr.) **(Cze)**

[Preventive strategies against infections in autologous bone marrow transplantation] Olesen G, et al. **Ugeskr Laeger** 1997 Mar 3;159(10):1438–42 (Eng. Abstr.) **(Dan)**

[Antibiotic prophylaxis in cesarean section] Pedersen TK, et al. **Ugeskr Laeger** 1997 Feb 24;159(9):1265–7 (Eng. Abstr.) **(Dan)**

[Surgical antibiotic prophylaxis] Adenis JP, et al. **J Fr Ophtalmol** 1997;20(1):85–7 **(Fre)**

[The current status of vaccination and antibiotic prophylaxis in splenectomy. I: Adults] Funk EM, et al. **Chirurg** 1997 Jun;68(6):586–90 (25 ref.) (Eng. Abstr.) **(Ger)**

[Current status of vaccination and antibiotic prophylaxis in splenectomy. II: Children] Funk EM, et al. **Chirurg** 1997 Jun;68(6):591–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[Comment on the contribution by A. Pennekamp, P. Tschirky and R. Grossenbacher. Significance of Staphylococcus aureus in nose operations (letter; comment)] Damm M. **HNO** 1996 Aug;44(8):429–30. Comment on: HNO 1995 Nov;43(11):664–8. **(Ger)**

[Antibiotic prophylaxis in laterobasal fractures (see comments)] Steidtmann K, et al. **HNO** 1997 Jun;45(6):448–52 (Eng. Abstr.). Comment in: HNO 1997 Jun;45(6):421–3. **(Ger)**

[Antibiotic prophylaxis in the ENT specialty (comment)] Zimmerli W. **HNO** 1997 Jun;45(6):421–3. Comment on: HNO 1997 Jun;45(6):448–52. **(Ger)**

[Peritoneal and subcutaneous administration of cefazolin as perioperative antibiotic prophylaxis in colorectal operations. Prospective randomized comparative study of 200 patients] Quendt J, et al. **Langenbecks Arch Chir** 1996;381(6):318–22 (Eng. Abstr.) **(Ger)**

[When is antibiotic prophylaxis required?] Hansis M. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:708–12 (16 ref.) (Eng. Abstr.) **(Ger)**

[Nosocomial infections in Germany. Microbiological diagnosis, preventive antibiotics and antibiotic therapy] Hauer T, et al. **Med Klin** 1996 Nov 15;91(11):681–6 (Eng. Abstr.) **(Ger)**

[Results before and after introduction of perioperative antibiotic prophylaxis in hip joint prostheses treatment of geriatric patients] Kaiser W, et al. **Unfallchirurgie** 1996 Aug;22(4):153–9 (Eng. Abstr.) **(Ger)**

[Can the rate of infection of problem wounds after anus praeter reconstruction be decreased by implantation of gentamycin containing collagen sponge?] Fischer A. **Zentralbl Chir** 1996;121 Suppl:75 **(Ger)**

[Blind prophylactic antibiotic administration in premature rupture of fetal membranes] Ahr A, et al. **Zentralbl Gynakol** 1997;119(3):111–6 (Eng. Abstr.) **(Ger)**

[Incidence of inflammatory placental changes in threatened premature labor with and without additional antibiotic therapy] Winkler M, et al. **Zentralbl Gynakol** 1997;119(2):54–9 (Eng. Abstr.) **(Ger)**

[The use of prophylactic antibiotics in common infections in the community] Bisharat N, et al. **Harefuah** 1997 Jun 1;132(11):792–6 (40 ref.) **(Heb)**

[Significance of antibiotic prophylaxis in infection prevention in biliary surgery. Personal experience] Zuccarini F, et al. **Ann Ital Chir** 1995 Sep–Oct;66(5):665–9 (Eng. Abstr.) **(Ita)**

[Oral therapy with ciprofloxacin in the prophylaxis of urinary infections in surgical patients with permanent bladder catheter] Salvestrini F, et al. **Minerva Chir** 1996 Jul–Aug;51(7–8):625–8 (Eng. Abstr.) **(Ita)**

[The effects of preventive regimens for the prophylaxis of infection after bone marrow transplantation] Morishima Y, et al. **Rinsho Ketsueki** 1997 Feb;38(2):108–16 (Eng. Abstr.) **(Jpn)**

[Follow–up of a procedure of antibiotic prophylaxis in cesarean section] Larsen A, et al. **Tidsskr Nor Laegeforen** 1997 Aug 20;117(19):2762–4 (Eng. Abstr.) **(Nor)**

[Cefamandole for perioperative prophylaxis in total hip alloplasty] Jackowiak M, et al. **Chir Narzadow Ruchu Ortop Pol** 1997;62(1):55–8 (Eng. Abstr.) **(Pol)**

[A single dose of antibiotic––as a prophylaxis during cesarean section] Krasnodębski J, et al. **Ginekol Pol** 1997 Jan;68(1):30–5 (Eng. Abstr.) **(Pol)**

[Role of antibiotics in the prophylaxis of surgical infections. A comparative analysis of short–acting and long–acting antibiotics] Hell C. **Anesteziol Reanimatol** 1997 May–Jun;(3):8–10 **(Rus)**

[General and local antibiotic treatment with ceftriaxone of suppurative–septic diseases and complications] Mariutin PV, et al. **Anesteziol Reanimatol** 1997 May–Jun;(3):14–8 (Eng. Abstr.) **(Rus)**

[The use of endolymphatic antibacterial therapy to prevent suppurative complications after heart operations under artificial blood circulation] Spitsyn PI, et al. **Vestn Khir Im I I Grek** 1996;(1):75–6 (Eng. Abstr.) **(Rus)**

[Problems in drug prevention and treatment of endogenous infection and dysbacteriosis] Melńikova VM, et al. **Vestn Ross Akad Med Nauk** 1997;(3):26–9 (21 ref.) (Eng. Abstr.) **(Rus)**

[Antibiotic prophylaxis in thoracic surgery] Janík M, et al. **Rozhl Chir** 1997 Jun;76(6):281–3 (Eng. Abstr.) **(Slo)**

[Scheduled biliary surgery and antibiotic prophylaxis. Is its use always justified?] Blanco JR, et al. **An Med Interna** 1997 Mar;14(3):111–3 (Eng. Abstr.) **(Spa)**

[Antibiotic prophylaxis in biliary surgery (editorial)] Torres García AJ, et al. **An Med Interna** 1997 Mar;14(3):109–10 **(Spa)**

ADVERSE EFFECTS

Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis. Pozniak A, et al. **Genitourin Med** 1996 Aug;72(4):269–71 (14 ref.)

Cardiorespiratory disturbances following antibiotic prophylaxis in general surgery: reasons for a complex reappraisal of a common problem. Stinner B, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S71–2

Megaloblastic anaemia and pancytopenia secondary to prophylactic cotrimoxazole therapy. Tapp H, et al. **J Paediatr Child Health** 1997 Apr;33(2):166–7

ECONOMICS

Cost–analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Inadomi J, et al. **Gastroenterology** 1997 Oct;113(4):1289–94

Comparison of ceftriaxone with penicillin for antibiotic prophylaxis for compound mandible fractures. Heit JM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Apr;83(4):423–6

[Cost savings by disinfection for prevention of surgical wound dehiscence after gastrectomy] Schardey HM, et al. **Chirurg** 1997 Apr;68(4):416–24 (Eng. Abstr.) **(Ger)**

[Cost increase due to incorrect antibiotic prophylaxis in visceral, thoracic and vascular surgery] Zengaffinen R, et al. **Swiss Surg** 1997;3(3):125–8 (Eng. Abstr.) **(Ger)**

HISTORY

Leonard I. Malis and prophylactic antibiotics. Savitz SI. **Mt Sinai J Med** 1997 May;64(3):187–8

METHODS

Autotransfusion––bacterial contamination during hip arthroplasty and efficacy of cefuroxime prophylaxis. A randomized controlled study of 40 patients. Wollinsky KH, et al. **Acta Orthop Scand** 1997 Jun;68(3):225–30

Studies on the duration of antibiotic administration for surgical prophylaxis. Scher KS. **Am Surg** 1997 Jan;63(1):59–62

Local application of vancomycin for prophylaxis of graft infection: release of vancomycin from antibiotic–bonded Dacron grafts, toxicity in endothelial cell culture, and efficacy against graft infection in an animal model. Muhl E, et al. **Ann Vasc Surg** 1996 May;10(3):244–53

Calcium phosphate ceramic coatings as carriers of vancomycin. Radin S, et al. **Biomaterials** 1997 Jun;18(11):777–82

Selective decontamination of the digestive tract in intensive care patients. van Saene HK, et al. **Br J Hosp Med** 1995 Dec 13–1996 Jan 16;54(11):558–61 (21 ref.)

Outpatient antibiotic therapy for febrile episodes in low–risk neutropenic patients with cancer. Escalante CP, et al. **Cancer Invest** 1997;15(3):237–42 (25 ref.)

Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Arnow PM, et al. **Clin Infect Dis** 1996 Jun;22(6):997–1003

Applications of local antibiotic therapy. Rushton N. **Eur J Surg Suppl** 1997;(578):27–30 (19 ref.)

Local antimicrobial prophylaxis in cataract surgery: recent controversies and clinical guidelines. Adenis JP, et al. **Ophthalmologica** 1997;211 Suppl 1:77–80 (20 ref.)

Antibiotic supplementation of intraocular irrigating solutions [letter; comment] Teichmann KD. **Ophthalmology** 1997 Jun;104(6):900–1. Comment on: Ophthalmology 1996 Aug;103(8):1204–8; discussion 1208–9.

Influence of different protocols of antibiotic prophylaxis on endoluminal bacterial overgrowth and translocation following small–bowel or combined liver–small–bowel transplantation in a large–animal model. Privitera G, et al. **Transplant Proc** 1997 May;29(3):1826–8

[Antibiotic prophylaxis in cesarean section with cefoxitin (Mefoxin)] Stoĭkov S, et al. **Akush Ginekol (Sofiia)** 1997;36(1):9–11 (Eng. Abstr.) **(Bul)**

[Inguinal hernia: contribution of randomized studies over the last 10 years] Parc Y, et al. **Ann Chir** 1996;50(9):827–31 (18 ref.) (Eng. Abstr.) **(Fre)**

[How I treat...a patient at risk of infectious endocarditis] Kulbertus H, et al. **Rev Med Liege** 1997 May;52(5):316 **(Fre)**

[Antibiotic prophylaxis of postoperative infective complications in patients with rectal and colonic cancers] Dmitrieva NV, et al. **Khirurgiia (Mosk)** 1997;(6):56–61 (Eng. Abstr.) **(Rus)**

STANDARDS

The use of antibiotics to prevent serious sequelae in children at risk for occult bacteremia: a meta–analysis. Bulloch B, et al. **Acad Emerg Med** 1997 Jul;4(7):679–83

A new standard of care: administration of preoperative antibiotics in the operating room. Matuschka PR, et al. **Am Surg** 1997 Jun;63(6):500–3

Prevention of bacterial endocarditis: American Heart Association recommendations [letter] Cheng TO. **JAMA** 1997 Oct 15;278(15):1233

Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Dajani AS, et al. **JAMA** 1997 Jun 11;277(22):1794–801 (66 ref.)

Prevention of bacterial endocarditis: American Heart Association recommendations [letter] Park JY. **JAMA** 1997 Oct 15;278(15):1232; discussion 1233

Prevention of bacterial endocarditis: American Heart Association recommendations [letter] Singer AJ. **JAMA** 1997 Oct 15;278(15):1232; discussion 1233

Prophylactic antibiotics in cataract operations. Liesegang TJ. **Mayo Clin Proc** 1997 Feb;72(2):149–59 (99 ref.)

STATISTICS & NUMERICAL DATA

Surveillance of the use of antibiotic prophylaxis in surgery. Finkelstein R, et al. **Isr J Med Sci** 1996 Nov;32(11):1093–7

Antibiotic prophylaxis among commercial sex workers in Cebu City, Philippines. Patterns of use and perceptions of efficacy [see comments] Abellanosa I, et al. **Sex Transm Dis** 1996 Sep–Oct;23(5):407–12. Comment in: Sex Transm Dis 1996 Sep–Oct;23(5):353–6.

TRENDS

Vascular catheters impregnated with antimicrobial agents: present knowledge and future direction [editorial; comment] Raad II. **Infect Control Hosp Epidemiol** 1997 Apr;18(4):227–9. Comment on: Infect Control Hosp Epidemiol 1997 Apr;18(4):230–6.

UTILIZATION

Who decides on the need for antibiotic prophylaxis in patients with major arthroplasties requiring dental treatment: is it a joint responsibility? Sandhu SS, et al. **Ann R Coll Surg Engl** 1997 Mar;79(2):143–7

Timing of perioperative antibiotic administration [see comments] Butts JD, et al. **AORN J** 1997 Jan;65(1):109–15 (22 ref.). Comment in: AORN J 1997 May;65(5):888.

Rational and appropriate use of prophylactic antibiotics [letter; comment] Barie PS. **Arch Surg** 1997 Mar;132(3):320–1. Comment on: Arch Surg 1996 Jul;131(7):744–8.

Risk factors for surgical–wound infection in general surgery: a prospective study. Lizán–García M, et al. **Infect Control Hosp Epidemiol** 1997 May;18(5):310–5

Advisory statement. Antibiotic prophylaxis for dental patients with total joint replacements. American Dental Association; American Academy of Orthopaedic Surgeons. **J Am Dent Assoc** 1997 Jul;128(7):1004–8

Antimicrobials in dentistry: with knowledge comes responsibility [editorial] Loesche WJ. **J Dent Res** 1996 Jul;75(7):1432–3

VETERINARY

Depletion of dietary sulphamonomethoxine and sulphadimethoxine from various tissues of laying hens. Furusawa N, et al. **Br Poult Sci** 1996 May;37(2):435–42

Effect of feeding diets containing an antibiotic, a probiotic, or yucca extract on growth and intestinal urease activity in broiler chicks. Yeo J, et al. **Poult Sci** 1997 Feb;76(2):381–5

ANTIBIOTIC RESISTANCE see **DRUG RESISTANCE, MICROBIAL**

ANTIBIOTICS

Antibiotics and the host–parasite relationship (a short review). Gemmell CG. **Acta Microbiol Immunol Hung** 1996;43(2–3):107–14 (17 ref.)

Antibiotics: what's new? Choi C. **Compr Ther** 1997 Jun;

23(6):378–83 (21 ref.)
Antibiotics update. Southern PM Jr. **Compr Ther** 1997 Sep; 23(9):575–82 (29 ref.)
Antibiotic sale behaviour in Nairobi: a contributing factor to antimicrobial drug resistance [see comments] Indalo AA. **East Afr Med J** 1997 Mar;74(3):171–3. Comment in: East Afr Med J 1997 Mar;74(3):121–3.
Development of mupirocin resistance among methicillin–resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Miller MA, et al. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):811–3
Emergence of high–level mupirocin resistance in methicillin–resistant Staphylococcus aureus isolated from Brazilian university hospitals [see comments] Netto dos Santos KR, et al. **Infect Control Hosp Epidemiol** 1996 Dec; 17(12):813–6. Comment in: Infect Control Hosp Epidemiol 1996 Dec;17(12):775–9.
Pandora's pillbox [letter] MacKnight C, et al. **J Am Geriatr Soc** 1997 May;45(5):656–7
Physicians' perception of sources of education about antibiotics in Kuwait. Dobardzic AM, et al. **J Chemother** 1995 Nov;7 Suppl 4:208–10
New directions in antibacterial research. Chu DT, et al. **J Med Chem** 1996 Sep 27;39(20):3853–74 (199 ref.)
Pros and cons of foreign genes in crops [letter; comment] Bengtsson BO. **Nature** 1997 Jan 23;385(6614):290. Comment on: Nature 1996 Oct 17;383(6601):559. Comment on: Nature 1996 Nov 28;384(6607):304.
Antibiotics: what is the current position? Leanord A. **Practitioner** 1997 Feb;241(1571):91–4 (12 ref.)
Comparative in vitro activity of piperacillin/tazobactam against gram–negative bacilli. Liebowitz LD, et al. **S Afr Med J** 1996 Oct;86(10):1276–80
[Antibiotics on the Internet (editorial)] Kolmos HJ. **Ugeskr Laeger** 1997 Mar 17;159(12):1733 **(Dan)**
[Clinical and preclinical efficacy of antimicrobial catheters] Schierholz JM, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 May; 32(5):298–305 (102 ref.) (Eng. Abstr.) **(Ger)**
[Feature of antibiotics in the 21st century] Omura S. **Jpn J Antibiot** 1996 Aug;49(8):755–65 (23 ref.) **(Jpn)**
[Analysis of the program of control of the use of antimicrobials at the Hospital São Paulo--Escola Paulista de Medicina] Pereira CA, et al. **Rev Assoc Med Bras** 1995 Nov–Dec;41(6):379–85 (Eng. Abstr.) **(Por)**
[Strategies for rationing the use of antibiotics in hospitals (letter; comment)] Soto J. **Enferm Infecc Microbiol Clin** 1996 Nov;14(9):576–7. Comment on: Enferm Infecc Microbiol Clin 1995 Dec;13(10):577–80. **(Spa)**

ADMINISTRATION & DOSAGE

A study on prophylactic antibiotics in cesarean sections--is it worthwhile? Yip SK, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):547–9
Drug compliance of children and infants with oral antibiotics for pediatric use. Iwai N. **Acta Paediatr Jpn** 1997 Feb; 39(1):132–42
Effect of fever–management strategy on the progression of dementia of the Alzheimer type [see comments] Hurley AC, et al. **Alzheimer Dis Assoc Disord** 1996 Spring; 10(1):5–10. Comment in: Alzheimer Dis Assoc Disord 1996 Spring;10(1):3–4.
Cost analysis of three intravenous drug delivery systems in a neonatal intensive care unit. Yu YK, et al. **Am J Health Syst Pharm** 1996 Oct 1;53(19):2314–8
Let us shorten antibiotic prophylaxis and therapy in surgery. Wittmann DH, et al. **Am J Surg** 1996 Dec;172(6A):26S–32S (46 ref.)
Linkup of a fast protein liquid chromatography system with a stirred thermostated cell for sterile preparation of liposomes by the proliposome–liposome method: application to encapsulation of antibiotics, synthetic peptide immunomodulators, and a photosensitizer. Turánek J, et al. **Anal Biochem** 1997 Jul 1;249(2):131–9
Treatment guidelines in central nervous system Whipple's disease [letter; comment] Schnider PJ, et al. **Ann Neurol** 1997 Apr;41(4):561–2. Comment on: Ann Neurol 1996 Oct;40(4):561–8.
Pharmacoepidemiology of urinary tract infections in Iowa Medicaid patients in urban long–term–care facilities. Bjornson DC, et al. **Ann Pharmacother** 1997 Jul–Aug; 31(7–8):837–41
Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers. Matsui D, et al. **Ann Pharmacother** 1996 Jun;30(6):586–8
AUIC--the universal parameter within the constraint of a reasonable dosing interval [editorial; comment] Schentag JJ, et al. **Ann Pharmacother** 1996 Sep;30(9):1029–31. Comment on: Ann Pharmacother 1996 Sep;30(9):1024–8.
Treatment of chronic, nonhealing abdominal wound in a liquid environment. Eriksson E, et al. **Ann Plast Surg** 1996 Jan;36(1):80–3
Effect of gentamicin dosing interval on efficacy of penicillin or ceftriaxone treatment of experimental endocarditis due to penicillin–susceptible, ceftriaxone–tolerant viridans group streptococci. Brandt CM, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2901–3
Antibiotic–impregnated cement and beads for orthopedic infections. Wininger DA, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2675–9 (49 ref.)
Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV–1 infected patients. Borin MT, et al. **Antiviral Res** 1997 Jun;35(1):53–63
Decrease of intraocular pressure after subconjunctival injection of mitomycin in human glaucoma [letter; comment] Gebhardt DO. **Arch Ophthalmol** 1996 Oct; 114(10):1298. Comment on: Arch Ophthalmol 1995 May;113(5):582–5.
The role of antibiotic prophylaxis in severe acute pancreatitis. Ho HS, et al. **Arch Surg** 1997 May;132(5):487–92; discussion 492–3
Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis. Sakiniene E, et al. **Arthritis Rheum** 1996 Sep;39(9):1596–605
Controlled release of antibiotics from biomedical polyurethanes: morphological and structural features. Schierholz JM, et al. **Biomaterials** 1997 Jun;18(12):839–44
Comparative investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin. Wachol–Drewek Z, et al. **Biomaterials** 1996 Sep;17(17):1733–8
Intravenous antibiotic treatment at home can provide higher quality care [letter; comment] Conlon CP, et al. **BMJ** 1997 May 24;314(7093):1551. Comment on: BMJ 1996 Dec 14;313(7071):1541–3.
Community–acquired lower respiratory tract infection: implementation of an antibiotic protocol. Menown IB, et al. **Br J Clin Pract** 1997 Mar;51(2):74–7
Topical chloramphenicol: have GPs cried halt? [letter] Backhouse OC, et al. **Br J Gen Pract** 1997 Jul;47(420):461
Oral antibiotics for common infections in children: for and against. Payne D, et al. **Br J Hosp Med** 1996 Nov 6–19; 56(9):481–5
Influence of foliage from African multipurpose trees on activity of rumen protozoa and bacteria. Newbold CJ, et al. **Br J Nutr** 1997 Aug;78(2):237–49
An alternative approach to common bile duct stones [letter] Grabham J, et al. **Br J Surg** 1997 Apr;84(4):581
Prophylaxis of graft infection with rifampicin–bonded Gelseal graft: 2–year follow–up of a prospective clinical trial. Italian Investigators Group. D'Addato M, et al. **Cardiovasc Surg** 1996 Apr;4(2):200–4
Comparative study on vaginal or oral treatment of bacterial vaginosis. Mikamo H, et al. **Chemotherapy** 1997 Jan–Feb; 43(1):60–8
A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Dawson CR, et al. **Clin Infect Dis** 1997 Mar; 24(3):363–8
Oral administration of antibiotics: a rational alternative to the parenteral route. MacGregor RR, et al. **Clin Infect Dis** 1997 Mar;24(3):457–67 (139 ref.)
Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Santolaya ME, et al. **Clin Infect Dis** 1997 Jul;25(1):92–7
Treatment of osteomyelitis with a biodegradable antibiotic implant. Calhoun JH, et al. **Clin Orthop** 1997 Aug; (341):206–14
A double–blind taste comparison of pediatric antibiotic suspensions [see comments] Steele RW, et al. **Clin Pediatr (Phila)** 1997 Apr;36(4):193–9. Comment in: Clin Pediatr (Phila) 1997 Apr;36(4):207–8.
Bacterial translocation in the course of acute pancreatitis: beneficial role of nonabsorbable antibiotics and lactitol enemas. Marotta F, et al. **Digestion** 1996 Nov–Dec; 57(6):446–52
Ocular chloramphenicol and aplastic anaemia. Is there a link? Rayner SA, et al. **Drug Saf** 1996 May;14(5):273–6 (27 ref.)
Applications of local antibiotic therapy. Rushton N. **Eur J Surg Suppl** 1997;(578):27–30 (19 ref.)
Duration of antibiotic treatment in surgical infections of the abdomen. Forum statement: a plea for selective and controlled postoperative antibiotic administration. Schein M, et al. **Eur J Surg Suppl** 1996;(576):66–9
Duration of antibiotic treatment in surgical infections of the abdomen. Pharmacokinetic basis for short courses of antimicrobial therapy. Wittmann DH. **Eur J Surg Suppl** 1996;(576):19–23
Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Wolter JM, et al. **Eur Respir J** 1997 Apr; 10(4):896–900
Audit on the use of prophylactic parenteral antimicrobial agents and the use of co–amoxiclav and metronidazole. Redding PJ, et al. **Health Bull (Edinb)** 1996 Nov; 54(6):499–504
Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Rolston KV, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):223–37 (29 ref.)
New perspectives on the management of septic shock in the cancer patient. Toney JF, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):239–53 (95 ref.)
Do patients get the best deal when antibiotics are prescribed out of hours? Lark KA, et al. **J Accid Emerg Med** 1997 May;14(3):159–62
Oral contraceptive failure rates and oral antibiotics. Helms SE, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 1):705–10
PMMA bead versus parenteral treatment of Staphylococcus aureus osteomyelitis [published erratum appears in J Am Podiatr Med Assoc 1997 May;87(5):208] Heard GS, et al. **J Am Podiatr Med Assoc** 1997 Apr;87(4):153–64
Nasal mupirocin prevents Staphylococcus aureus exit–site infection during peritoneal dialysis. Mupirocin Study Group. **J Am Soc Nephrol** 1996 Nov;7(11):2403–8
Why do patients with infection remain in hospital once changed to oral antibiotics? [letter] Boyter AC, et al. **J Antimicrob Chemother** 1997 Feb;39(2):286–8
Safe intravenous antibiotic therapy at home: experience of a UK based programme. Kayley J, et al. **J Antimicrob Chemother** 1996 May;37(5):1023–9
Allograft is superior to topical antimicrobial therapy in the treatment of partial–thickness scald burns in children. Rose JK, et al. **J Burn Care Rehabil** 1997 Jul–Aug;18(4):338–41
Strategies to minimize the development of antibiotic resistance. Baquero F, et al. **J Chemother** 1997 May;9 Suppl 3:29–37 (13 ref.)
Short–term effects of the clindamycin–steroid regimen in the treatment of ocular toxoplasmosis. Djurkovic–Djakovic O, et al. **J Chemother** 1995 Nov;7 Suppl 4:199–201
Pharmacodynamics and the relationship between in vitro and in vivo activity of antimicrobial agents. Gould IM. **J Chemother** 1997 May;9 Suppl 1:74–83 (61 ref.)
Pharmacodynamics of antimicrobial agents and rationale for their dosing. MacGowan AP, et al. **J Chemother** 1997 May; 9 Suppl 1:64–73 (90 ref.)
How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. de Boer WA. **J Clin Gastroenterol** 1996 Jun;22(4):313–6 (28 ref.)
Influencing prescribing in primary care: a comparison of two different prescribing feedback methods. Braybrook S, et al. **J Clin Pharm Ther** 1996 Aug;21(4):247–54
Peripheral long lines in cystic fibrosis. Millar–Jones L, et al. **J Clin Pharm Ther** 1997 Feb;22(1):45–6
Guidelines for antimicrobial prophylaxis. Nahata MC. **J Clin Pharm Ther** 1996 Aug;21(4):255–60
Relationship between the prescriber's instructions and compliance with antibiotherapy in outpatients treated for an acute infectious disease. Favre O, et al. **J Clin Pharmacol** 1997 Mar;37(3):175–8
Body weight gain, feed efficiency, and fecal scores of dairy calves in response to galactosyl–lactose or antibiotics in milk replacers. Quigley JD 3rd, et al. **J Dairy Sci** 1997 Aug;80(8):1751–4
Antibiotic use in the emergency department. IV: Single–dose therapy and parenteral–loading dose therapy. Hoang KD, et al. **J Emerg Med** 1996 Sep–Oct;14(5):619–28 (130 ref.)
Reasons for delay in administration of antibiotics to patients with meningitis and meningococcaemia. Wilks D, et al. **J Infect** 1996 Jan;32(1):49–51
In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. Beaulac C, et al. **J Microencapsul** 1997 May–Jun;14(3):335–48
Microbiological response to mechanical treatment in combination with adjunctive therapy. A review of the literature. Bollen CM, et al. **J Periodontol** 1996 Nov; 67(11):1143–58 (118 ref.)
The effect of subgingival antimicrobial therapy on the levels of stromelysin and tissue inhibitor of metalloproteinases in gingival crevicular fluid. Pourtaghi N, et al. **J Periodontol** 1996 Sep;67(9):866–70
Comparison of 3 periodontal local antibiotic therapies in persistent periodontal pockets. Radvar M, et al. **J Periodontol** 1996 Sep;67(9):860–5
Home intravenous antibiotic therapy: practical aspects in children. Leaver J, et al. **J R Soc Med** 1997;90 Suppl 31:26–33 (5 ref.)
Home intravenous antibiotic therapy: practical aspects in adults. Phillips AM. **J R Soc Med** 1997;90 Suppl 31:34–6 (14 ref.)
Impregnation of sewing ring with antibiotics to avoid prosthetic valve endocarditis [letter; comment] Actis Dato GM, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):145–6 . Comment on: J Thorac Cardiovasc Surg 1996 Aug;112(2):248–52.
Evaluation of various oral antimicrobial formulations for eradication of Helicobacter hepaticus. Foltz CJ, et al. **Lab Anim Sci** 1996 Apr;46(2):193–7
Is it time to ban all antibiotics as animal growth–promoting agents? [letter; comment] Burch DG. **Lancet** 1996 Nov 23; 348(9039):1455; discussion 1455–6. Comment on: Lancet 1996 Aug 31;348(9027):619.
Tissue concentration of clindamycin and gentamicin near ischaemic ulcers with transvenous injection in Bier's arterial arrest. Burgmann H, et al. **Lancet** 1996 Sep 21; 348(9030):781–3
Is it time to ban all antibiotics as animal growth–promoting agents? [letter; comment] Mudd AJ. **Lancet** 1996 Nov 23; 348(9039):1454; discussion 1455–6. Comment on: Lancet 1996 Aug 31;348(9027):619.
Sustained release of antibiotic from a fibrin–gelatin–antibiotic mixture. Park MS, et al. **Laryngoscope** 1997 Oct; 107(10):1378–81
Antibiotic use in the Australian community, 1990–1995 [see comments] McManus P, et al. **Med J Aust** 1997 Aug 4; 167(3):124–7. Comment in: Med J Aust 1997 Aug 4;167(3):116–7.
Outpatient parenteral antimicrobial–drug therapy. Gilbert DN, et al. **N Engl J Med** 1997 Sep 18;337(12):829–38 (89 ref.)
Osteomyelitis [letter; comment] Glatt AE. **N Engl J Med** 1997 Aug 7;337(6):428; discussion 429. Comment on: N Engl J Med 1997 Apr 3;336(14):999–1007.
Osteomyelitis [letter; comment] Shea KW. **N Engl J Med**

1997 Aug 7;337(6):428–9. Comment on: N Engl J Med 1997 Apr 3;336(14):999–1007.

Combined peribulbar and retrobulbar block anesthesia and antibiotic–steroid injection: a simple method to prevent retrobulbar hemorrhage, globe perforation, or infection. Girard LJ, et al. **Ophthalmic Surg Lasers** 1997 Mar; 28(3):251–4

Therapeutic effects of continuous intraarterial antibiotic infusion in preventing pancreatic infection in experimental acute necrotizing pancreatitis. Hayashi J, et al. **Pancreas** 1996 Aug;13(2):184–92

Fever and neutropenia in children with malignant disease. Roguin A, et al. **Pediatr Hematol Oncol** 1996 Nov–Dec; 13(6):503–10

Timing therapy for meningococcal infection [letter; comment] Radetsky M. **Pediatr Infect Dis J** 1997 May; 16(5):540–2. Comment on: Pediatr Infect Dis J 1996 Nov;15(11):967–78; quiz 979.

Effect of nebulizer type and antibiotic concentration on device performance. Weber A, et al. **Pediatr Pulmonol** 1997 Apr;23(4):249–60

C-reactive protein is a useful marker for guiding duration of antibiotic therapy in suspected neonatal bacterial infection. Ehl S, et al. **Pediatrics** 1997 Feb;99(2):216–21

Toward simple but safe management of osteomyelitis [comment] Nelson JD. **Pediatrics** 1997 Jun;99(6):883–4. Comment on: Pediatrics 1997 Jun;99(6):846–50.

Intermittent versus continuous antibiotics for PD–related peritonitis [editorial; comment] Golper T. **Perit Dial Int** 1997 Jan–Feb;17(1):11–2. Comment on: Perit Dial Int 1997 Jan–Feb;17(1):87–9. Comment on: Perit Dial Int 1997 Jan–Feb;17(1):91–4.

Treatment in PD patients of peritonitis caused by gram–positive organisms with single daily dose of antibiotics [see comments] Vas S, et al. **Perit Dial Int** 1997 Jan–Feb;17(1):91–4. Comment in: Perit Dial Int 1997 Jan–Feb;17(1):11–2.

Feasibility of an antibiotic order form. First experience in the department of internal medicine of a university hospital. Blok WL, et al. **Pharm World Sci** 1996 Aug;18(4):137–41

Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6–month prospective study. Ahkee S, et al. **Pharmacotherapy** 1997 May–Jun; 17(3):569–75

Intravenous–to–oral antibiotic switch therapy. A cost–effective approach. Cunha BA. **Postgrad Med** 1997 Apr;101(4):111–2, 115–8, 122–3 passim (13 ref.)

Subtleties of antibiotic dosages—do doses and intervals make a difference in the critically ill? [editorial] Lipman J, et al. **S Afr J Surg** 1996 Nov;34(4):160–2

Chronic bacterial prostatitis treated with intraprostatic injection of antibiotics. Yamamoto M, et al. **Scand J Urol Nephrol** 1996 Jun;30(3):199–202

The addition of antibiotics to fibrin glue. Thompson DF, et al. **South Med J** 1997 Jul;90(7):681–4 (15 ref.)

Salvage of instrumental lumbar fusions complicated by surgical wound infection. Glassman SD, et al. **Spine** 1996 Sep 15;21(18):2163–9

Nebulisers for bronchiectasis. Currie DC. **Thorax** 1997 Apr; 52 Suppl 2:S72–4

Nebulised antipseudomonal antibiotic therapy in cystic fibrosis [letter; comment] Hoekstra MO, et al. **Thorax** 1997 Apr;52(4):398–9. Comment on: Thorax 1996 Apr;51(4):364–8.

Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis. Spencer DA. **Thorax** 1997 Apr;52 Suppl 2:S89–91 (27 ref.)

Nebulised antibiotics for adults with cystic fibrosis. Webb AK, et al. **Thorax** 1997 Apr;52 Suppl 2:S69–71

Home parenteral antibiotic therapy: benefits in the treatment of cellulitis. Swanston WH. **Trop Doct** 1997 Apr; 27(2):109–10

Treatment for Haemobartonella felis in cats [letter] Stevenson M. **Vet Rec** 1997 May 10;140(19):512

[Utilization of antibiotics in Denmark 1994–1995. A population–based study] Juul KV. **Ugeskr Laeger** 1996 Dec 16;158(51):7407–10 (Eng. Abstr.) **(Dan)**

[Antibiotic treatment of traveller's diarrhea] Petersen JA, et al. **Ugeskr Laeger** 1997 Sep 1;159(36):5355–8 **(Dan)**

[Utilization of antibiotics at the Arhus Municipal Hospital. A prevalence study] Tarp BD, et al. **Ugeskr Laeger** 1997 Feb 10;159(7):936–9 (Eng. Abstr.) **(Dan)**

[Risks due to the medication of feed and water in animal facilities] Kamphues J. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):250–6 (37 ref.) (Eng. Abstr.) **(Ger)**

[The use of feed medications in swine and poultry facilities in the Weser–Ems region] Rassow D, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):244–9 (Eng. Abstr.) **(Ger)**

[Anti–Helicobacter pylori therapy. Who should be treated, how, how long?] Lux G. **Fortschr Med** 1996 Aug 20; 114(22–23):273–5 **(Ger)**

[Therapy with antibiotics in renal failure] Anding K, et al. **Med Klin** 1996 Nov 15;91(11):698–702 (42 ref.) **(Ger)**

[Antibiotics in animal husbandry (editorial)] Heinzl S. **Med Monatsschr Pharm** 1997 Jun;20(6):145 **(Ger)**

[Frequent problems with antibiotic chemotherapy of bacterial CNS diseases. Case reports and recommendations for initial treatment] Bitsch A, et al. **Nervenarzt** 1997 Apr;68(4):331–5 (Eng. Abstr.) **(Ger)**

[Use of drugs in stomatology II. Use of antibiotics in dental practice] Gáspár L, et al. **Fogorv Sz** 1997 Jun;90(6):177–84 (Eng. Abstr.) **(Hun)**

[Analysis of antibiotic use based on case histories] Almási I, et al. **Orv Hetil** 1996 Jul 7;137(27):1473–7 (Eng. Abstr.) **(Hun)**

[Usage of antibiotics in hospitals] Ternák G, et al. **Orv Hetil** 1996 Dec 29;137(52):2917–21 (Eng. Abstr.) **(Hun)**

[Utilization of antibiotics according to most frequent indications at Hungarian hospitals and results of surveys] Ternák G, et al. **Orv Hetil** 1997 May 25;138(21):1333–9 (Eng. Abstr.) **(Hun)**

[Streptococcus group B and pregnancy: the therapeutic role of topical intravaginal clindamycin] Danti L, et al. **Minerva Ginecol** 1997 May;49(5):235–40 (Eng. Abstr.) **(Ita)**

[Antibacterial activities of combination uses of cefpirome with various antibiotics in vitro against clinically isolated glucose non–fermentative gram–negative rods: part 1. the results against Pseudomonas aeruginosa] Suzuki Y, et al. **Jpn J Antibiot** 1996 Jan;49(1):71–82 (Eng. Abstr.) **(Jpn)**

[The old and new problems of the antibiotics treatment in hemorrhagic enterocolitis and hemolytic uremic syndrome, according to Japanese epidemiological studies] Kohsaka T, et al. **Nippon Rinsho** 1997 Mar;55(3):706–14 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Is it possible to influence the utilization of antibiotics?] Berild D. **Tidsskr Nor Laegeforen** 1997 May 30;117(14):2056–9 (Eng. Abstr.) **(Nor)**

[Antibiotic treatment of newborn infants. Experiences from a neonatal department] Kolsrud E, et al. **Tidsskr Nor Laegeforen** 1997 Apr 20;117(10):1450–2 (Eng. Abstr.) **(Nor)**

[Role of antibiotics in the prophylaxis of surgical infections. A comparative analysis of short–acting and long–acting antibiotics] Hell C. **Anesteziol Reanimatol** 1997 May–Jun; (3):8–10 **(Rus)**

[Entrapment of antibiotics in liposomes containing phosphatidylethanol] Davydov VIu, et al. **Antibiot Khimioter** 1996 May;41(5):25–9 (Eng. Abstr.) **(Rus)**

[Clinical and immunological bases of effectiveness of the use of endolymphatic therapy in the treatment of patients with pleural empyema] Feshchenko IuI, et al. **Klin Khir** 1996; (4):24–6 **(Rus)**

[A comparative evaluation of the efficacy of endolymphatically administered antibiotics in the combined treatment of phlegmons of the maxillofacial area] Tereshchenko AE, et al. **Stomatologiia (Mosk)** 1996;Spec No:82–3 **(Rus)**

[Endolymphatic therapy and current detoxication methods in the treatment of peritonitis] Petrov SV, et al. **Vestn Khir Im I I Grek** 1996;155(5):30–2 (Eng. Abstr.) **(Rus)**

[Conservative treatment of chronic suppurative mesotympanitis by meato–tympanic administration of drugs] Mikina GM, et al. **Vestn Otorinolaringol** 1996 Jul–Aug;(4):47–8 **(Rus)**

[Inhalation antibiotherapy] Vendrell Relat M, et al. **Arch Bronconeumol** 1997 Jan;33(1):41–9 (94 ref.) **(Spa)**

[Short–term antibiotic therapy of post–cesarean–section endometritis] Rodríguez–Ballesteros R, et al. **Ginecol Obstet Mex** 1996 Aug;64:359–62 (Eng. Abstr.) **(Spa)**

[Meaningless with an expensive yeast preparation in diarrhea (letter)] Cronberg S. **Lakartidningen** 1996 Nov 27; 93(48):4389–90 **(Swe)**

[Epidemic C difficile–associated diarrhea is a reality. Fewer prescriptions and more soap] Karlström O, et al. **Lakartidningen** 1997 Jun 4;94(23):2187–92 **(Swe)**

[Misleading marketing of the use of antibiotics (letter)] Sörberg M, et al. **Lakartidningen** 1996 Oct 9;93(41):3553–4 **(Swe)**

[PC–resistant pneumococci are increasing in Skåne. Fewer and fewer children receive antibiotics—is there a cause?] Wilhelmson B. **Lakartidningen** 1997 Apr 16;94(16):1511–3 **(Swe)**

[Clinical effectiveness of the use of liposomes with antibiotics and ecterocide in purulent–inflammatory thoracic and abdominal complications] Bashtan VP. **Klin Khir** 1997; (1):14–6 (Eng. Abstr.) **(Ukr)**

[Use of liposomes and biologically active soluble antibiotics in the prevention and treatment of postoperative infectious–suppurative complications] Gilenko IO, et al. **Klin Khir** 1996;(10):53–4 **(Ukr)**

ADVERSE EFFECTS

Adverse effects of antibiotics. Iwata S, et al. **Acta Paediatr Jpn** 1997 Feb;39(1):143–54

Review article: antibiotic–induced Clostridium difficile infection. Settle CD, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):835–41 (64 ref.)

Are we prescribing too many antibiotics? [editorial; comment] Wellbery C. **Am Fam Physician** 1997 Apr; 55(5):1535–6. Comment on: Am Fam Physician 1997 Apr;55(5):1647–54, 1657–8.

Lymphadenitis associated with the administration of clindamycin. Southern PM Jr. **Am J Med** 1997 Aug; 103(2):164–5

Inflammatory opacities of the vitreous in rifabutin–associated uveitis. Chaknis MJ, et al. **Am J Ophthalmol** 1996 Oct; 122(4):580–2

Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Lynch JP 3rd, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):395–420 (353 ref.)

Fusarium keratitis following the use of topical antibiotic–corticosteroid therapy in traumatised eyes. Wong TY, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):862–5 (19 ref.)

Uveitis associated with rifabutin prophylaxis and itraconazole therapy [letter] Lefort A, et al. **Ann Intern Med** 1996 Dec 1;125(11):939–40

Antibiotic–associated hepatitis: update from 1990. Vial T, et al. **Ann Pharmacother** 1997 Feb;31(2):204–20 (162 ref.)

Generalized pustular rash and erythema. Toxic pustuloderma. Wollina U, et al. **Arch Dermatol** 1997 Apr;133(4):500–1, 503–4

Safety of chloramphenicol eyedrops [editorial] Firkin F, et al. **Aust N Z J Ophthalmol** 1997 Feb;25(1):3

It is time to stop using topical chloramphenicol. Smith JR, et al. **Aust N Z J Ophthalmol** 1997 Feb;25(1):83–8 (21 ref.)

Drug toxicity and surveillance in children. Choonara I, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):407–10 (47 ref.)

Chorioamnionitis due to Pseudomonas aeruginosa: a complication of prolonged antibiotic therapy for premature rupture of membranes [letter; comment] Cook SG. **Br J Obstet Gynaecol** 1996 Oct;103(10):1055; discussion 1055–6. Comment on: Br J Obstet Gynaecol 1996 Feb;103(2):181–3.

Chorioamnionitis due to Pseudomonas aeruginosa: a complication of prolonged antibiotic therapy for premature rupture of membranes [letter; comment] Ugwumadu AH, et al. **Br J Obstet Gynaecol** 1996 Oct;103(10):1054–5; discussion 1055–6. Comment on: Br J Obstet Gynaecol 1996 Feb;103(2):181–3.

Dental health of children taking antimicrobial and non–antimicrobial liquid oral medication long–term. Maguire A, et al. **Caries Res** 1996;30(1):16–21

The contribution of antibiotic use on the frequency of antibiotic resistance in hospitals. Gaynes R, et al. **Ciba Found Symp** 1997;207:47–56; discussion 56–60 (40 ref.)

Impact of antibiotic use in animal feeding on resistance of bacterial pathogens in humans. Witte W. **Ciba Found Symp** 1997;207:61–71; discussion 71–5 (36 ref.)

Increased incidence of Clostridium difficile–associated diarrhea following decreased restriction of antibiotic use. Ho M, et al. **Clin Infect Dis** 1996 Dec;23 Suppl 1:S102–6

Delayed allergic reactions to amoxycillin and clindamycin. García R, et al. **Contact Dermatitis** 1996 Aug;35(2):116–7

Erythema–multiforme–like eruption from antibiotics of 3 different groups. Munoz D, et al. **Contact Dermatitis** 1996 Mar;34(3):227–8

Antibiotics: more than just "bug" killers [editorial; comment] Casey LC. **Crit Care Med** 1997 Aug;25(8):1270–1. Comment on: Crit Care Med 1997 Aug;25(8):1392–5.

Antibacterial–induced hepatotoxicity. Incidence, prevention and management. George DK, et al. **Drug Saf** 1996 Jul; 15(1):79–85 (56 ref.)

Ocular chloramphenicol and aplastic anaemia. Is there a link? Rayner SA, et al. **Drug Saf** 1996 May;14(5):273–6 (27 ref.)

An outbreak of hemolytic uremic syndrome associated with antibiotic treatment of hospital inpatients for dysentery. Al–Qarawi S, et al. **Emerg Infect Dis** 1995 Oct–Dec; 1(4):138–40

Child–care practices: effects of social change on the epidemiology of infectious diseases and antibiotic resistance. Holmes SJ, et al. **Epidemiol Rev** 1996;18(1):10–28 (175 ref.)

Management of Clostridium difficile infection and other antibiotic–associated diarrhoeas. Bartlett JG. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1054–61 (86 ref.)

Epidemiology and typing of Clostridium difficile. Jumaa P, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1035–40 (53 ref.)

Duration of antibiotic treatment in surgical infections of the abdomen. Undesired effects of antibiotics and future studies. Dellinger EP. **Eur J Surg Suppl** 1996;(576):29–31; discussion 31–2

Cardiovascular adverse effects of antimicrobials in complex surgical cases. Kuenneke M, et al. **Eur J Surg Suppl** 1996; (576):24–8

Duration of antibiotic treatment in surgical infections of the abdomen. Antibiotics and the gut. Saadia R, et al. **Eur J Surg Suppl** 1996;(576):39–41

Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents. Reddy KR, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):923–36 (99 ref.)

Rifabutin–associated anterior uveitis in patients infected with human immunodeficiency virus. Schimkat M, et al. **Ger J Ophthalmol** 1996 Jul;5(4):195–201

Antibiotic–associated diarrhea in HIV–infected patients receiving clindamycin [letter] Slevogt H, et al. **Infection** 1997 May–Jun;25(3):189

Acute renal failure in association with fusidic acid [letter] Davies JP, et al. **Int J Clin Pract** 1997 Jun;51(4):264

Antibiotic–associated colitis in orthopaedic patients. Boehler M, et al. **Int Orthop** 1996;20(4):204–6

Allergic contact dermatitis from mupirocin ointment. Zappi EG, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):266

Ocular spherulocystosis. Kini U, et al. **J Clin Pathol** 1996 Oct;49(10):857–8

Incidence of diarrhea with antibiotics and the increase of

clostridia in rabbits. Hara-Kudo Y, et al. **J Vet Med Sci** 1996 Dec;58(12):1181-5

Rifamycin-induced lupus syndrome [letter] Berning SE, et al. **Lancet** 1997 May 24;349(9064):1521-2

Role of Candida in indirect pathogenesis of antibiotic associated diarrhoea in infants. Ponnuvel KM, et al. **Mycopathologia** 1996;135(3):145-7

Antibiotic-induced or Aspergillus infection related acute interstitial nephritis? [letter] Renoult E, et al. **Nephron** 1996; 72(3):493-4

Rifabutin ocular toxicity mimicking endophthalmitis. Le Saux N, et al. **Pediatr Infect Dis J** 1997 Jul;16(7):716-8

Evaluation of antibiotic-induced nephrotoxicity in preterm neonates by determining urinary alpha 1-microglobulin. Fanos V, et al. **Pediatr Nephrol** 1996 Oct;10(5):645-7

A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. García Rodríguez LA, et al. **Pharmacotherapy** 1997 Jul-Aug;17(4):721-8

Adverse reactions to antibiotics. Clues for recognizing, understanding, and avoiding them. Gleckman RA, et al. **Postgrad Med** 1997 Apr;101(4):97-8, 101-4, 107-8 (6 ref.)

Antibiotic-associated diarrhoea, Clostridium difficile, and short-chain fatty acids. Hove H, et al. **Scand J Gastroenterol** 1996 Jul;31(7):688-93

Ascites associated with antibiotic-associated pseudomembranous colitis [letter; comment] Parikh VA, et al. **South Med J** 1997 Apr;90(4):460. Comment on: South Med J 1996 Oct;89(10):1014-7.

[Gram negative folliculitis. A complication of antibiotic therapy of acne vulgaris. 2: Diagnosis and differential diagnosis--therapy] Jansen T, et al. **Fortschr Med** 1997 Feb 10;115(4):42-4 **(Ger)**

[Gram-negative folliculitis. Complication of antibiotic therapy of acne vulgaris, 1: Disease picture and classification--special form: whirlpool dermatitis] Jansen T, et al. **Fortschr Med** 1997 Jan 30;115(3):37-8 **(Ger)**

[Antimicrobial nephrotoxicity] Nakahama H. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):547-9 (7 ref.) **(Jpn)**

[Occurrence and clinical picture of Clostridium difficile infections after antibiotic therapy] Lapiński TW, et al. **Przegl Epidemiol** 1995;49(4):361-5 (Eng. Abstr.) **(Pol)**

[Allergic drug-dependent lesions of the lungs] Sinopal'nikov AI. **Klin Med (Mosk)** 1996;74(4):59-62 **(Rus)**

[Absolute diet therapy and antibiotic tolerance in bronchial asthma patients] Fedoseev GB, et al. **Ter Arkh** 1996; 68(8):28-31 (Eng. Abstr.) **(Rus)**

[Pseudomembranous colitis and "intestinal sepsis" as a consequence of dysbacteriosis due to antibiotics] Eriukhin IA, et al. **Vestn Khir Im I I Grek** 1997;156(2):108-11 (Eng. Abstr.) **(Rus)**

[Rifabutin as a cause of curable visual alterations in patients with human immunodeficiency virus infection (letter)] Fernández Peña CM, et al. **Med Clin (Barc)** 1997 Jul 5; 109(6):239 **(Spa)**

[Desensitization to antibiotics] Moreno Gardea HL, et al. **Rev Alerg Mex** 1997 Jan-Feb;44(1):8-12 (46 ref.) (Eng. Abstr.) **(Spa)**

[Do ecological risks stop registration? It is reasonable to discuss the impact of antibiotics on the environment] Wilhelmson B. **Lakartidningen** 1997 Apr 16;94(16):1514 **(Swe)**

ANALYSIS

Determination of hydrophobicity parameters of antibiotics by reversed-phase chromatography. The effect of support. Cserháti T, et al. **Biomed Chromatogr** 1996 May-Jun; 10(3):117-21

A comparative evaluation of three detectors in the HPLC analysis of sodium fusidate. Gatti R, et al. **Farmaco** 1996 Feb;51(2):115-9

Development of an ELISA for maduramicin and determination of the depletion kinetics of maduramicin residues in poultry. Kennedy DG, et al. **Food Addit Contam** 1997 Jan;14(1):27-33

Alternatives for validation of diagnostic assays used to detect antibiotic residues in milk. Gardner IA, et al. **J Am Vet Med Assoc** 1996 Jul 1;209(1):46-52

Targeted screening for elongation factor Tu binding antibiotics. Selva E, et al. **J Antibiot (Tokyo)** 1997 Jan; 50(1):22-6

Planar chromatography for the multiclass, multiresidue screening of chloramphenicol, nitrofuran, and sulfonamide residues in pork and beef. Abjean JP. **J AOAC Int** 1997 Jul-Aug;80(4):737-40

Determination of citrinin in barley by indirect and direct enzyme immunoassay. Abramson D. **J AOAC Int** 1996 Nov-Dec;79(6):1325-9

Analytical strategies for the screening of veterinary drugs and their residues in edible products (review), by Aerts et al.: an addendum [comment] Nicolas A. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1-2):210-1 . Comment on: J Chromatogr B Biomed Appl 1995 May 5;667(1):1-40.

Evaluation of selected antibiotic residue screening tests for milk from individual goats. Contreras A, et al. **J Dairy Sci** 1997 Jun;80(6):1113-8

Quality milk and tests for antibiotic residues. Sischo WM. **J Dairy Sci** 1996 Jun;79(6):1065-73 (20 ref.)

Liquid chromatographic analysis of a formulation containing polymyxin, gramicidin and neomycin. Adams E, et al. **J Pharm Biomed Anal** 1997 Jan;15(4):505-11

Conductimetric titrimetry for assay of selected antibiotics in non-aqueous media. Kiliç E, et al. **J Pharm Biomed Anal** 1995 Nov;13(12):1453-8

Assessment of the incidence of substandard drugs in developing countries. Shakoor O, et al. **Trop Med Int Health** 1997 Sep;2(9):839-45

Antibiotic residues and prevalence of mastitis pathogen isolation in heifers during early lactation following prepartum antibiotic therapy. Oliver SP, et al. **Zentralbl Veterinarmed [B]** 1997 Jun;44(4):213-20

[LAL test used for detection of undesirable biologically active substances in biopreparations] Aleksandrowicz J, et al. **Med Dosw Mikrobiol** 1996;48(3-4):215-21 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

[Tricuspid valvulectomy in antibiotic-refractory right-heart endocarditis] Hust MH, et al. **Dtsch Med Wochenschr** 1997 Jan 24;122(4):80-5 (36 ref.) (Eng. Abstr.) **(Ger)**

[The etiological structure of the causative agents of inflammatory nonspecific urological diseases and the dynamics of their resistance to the widely used antibiotics] Derevianko NI, et al. **Urol Nefrol (Mosk)** 1997 May-Jun; (3):13-8 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Detection of microcin production by pathogenic Escherichia coli isolates from children with acute diarrhoea. Cavazza ME, et al. **Acta Cient Venez** 1994;45(2):106-11

Applications of transposition mutagenesis in antibiotic producing streptomycetes. Baltz RH, et al. **Antonie Van Leeuwenhoek** 1997 Feb;71(1-2):179-87 (39 ref.)

Iterative type II polyketide synthases, cyclases and ketoreductases exhibit context-dependent behavior in the biosynthesis of linear and angular decapolyketides. Meurer G, et al. **Chem Biol** 1997 Jun;4(6):433-43

Engineering antibiotic producers to overcome the limitations of classical strain improvement programs. Lal R, et al. **Crit Rev Microbiol** 1996;22(4):201-55 (222 ref.)

The activity of microcin E492 from Klebsiella pneumoniae is regulated by a microcin antagonist. Orellana C, et al. **FEMS Microbiol Lett** 1996 Mar 1;136(3):297-303

Constitution of the metabolic type of streptomycetes during the first hours of cultivation. Janeček J, et al. **Folia Microbiol (Praha)** 1997;42(2):75-96 (120 ref.)

Some developments in the biosynthesis of antibiotics. Thomas R. **Folia Microbiol (Praha)** 1995;40(1):4-16 (26 ref.)

Cloning, sequencing, overexpression in Escherichia coli, and inactivation of the valine dehydrogenase gene in the polyether antibiotic producer Streptomyces cinnamonensis. Leiser A, et al. **Gene** 1996 Oct 24;177(1-2):217-22

Crop improvement and disease suppression by a Bacillus spp. SR2 from pea nut rhizosphere. Kumar BS. **Indian J Exp Biol** 1996 Aug;34(8):794-8

A novel method for improving Streptomyces coelicolor A3(2) for production of actinorhodin by introduction of rpsL (encoding ribosomal protein S12) mutations conferring resistance to streptomycin [letter] Hesketh A, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):532-5

Pyralomicins, novel antibiotics from Microtetraspora spiralis. III. Biosynthesis of pyralomicin 1a. Kawamura N, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):657-60

Pyralomicins, novel antibiotics from Microtetraspora spiralis. I. Taxonomy and production. Kawamura N, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):706-9

Kinetic isotope effect and reaction mechanism of 2-deoxy-scyllo-inosose synthase derived from butirosin-producing Bacillus circulans. Kudo F, et al. **J Antibiot (Tokyo)** 1997 May;50(5):424-8

Biosynthesis of bioactive microbial metabolites and its application to the structural studies and production of hybrid compounds. Nakagawa A, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):717-41 (135 ref.)

HP17, a new pigment-like antibiotic produced by a new strain of Spirillospora. Hacéne H, et al. **J Appl Bacteriol** 1996 May;80(5):565-9

Environmental signals triggering methylenomycin production by Streptomyces coelicolor A3(2). Hayes A, et al. **J Bacteriol** 1997 Sep;179(17):5511-5

bldA dependence of undecylprodigiosin production in Streptomyces coelicolor A3(2) involves a pathway-specific regulatory cascade. White J, et al. **J Bacteriol** 1997 Feb; 179(3):627-33

An NADPH:FAD oxidoreductase from the valanimycin producer, Streptomyces viridifaciens. Cloning, analysis, and overexpression. Parry RJ, et al. **J Biol Chem** 1997 Sep 12;272(37):23303-11

Antibiotic activity of polyketide products derived from combinatorial biosynthesis: implications for directed evolution. Fu H, et al. **Mol Divers** 1996 Feb;1(2):121-4

afsR is a pleiotropic but conditionally required regulatory gene for antibiotic production in Streptomyces coelicolor A3(2). Floriano B, et al. **Mol Microbiol** 1996 Jul; 21(2):385-96

Characterization of a genomic locus required for synthesis of the antibiotic 2,4-diacetylphloroglucinol by the biological control agent Pseudomonas fluorescens Q2-87. Bangera MG, et al. **Mol Plant Microbe Interact** 1996 Mar; 9(2):83-90

Production of lytic enzyme from Pseudomonas aeruginosa M-1001. Wang SL, et al. **Proc Natl Sci Counc Repub China B** 1995 Oct;19(4):216-24

From peptide precursors to oxazole and thiazole-containing peptide antibiotics: microcin B17 synthase [see comments] Li YM, et al. **Science** 1996 Nov 15;274(5290):1188-93. Comment in: Science 1996 Nov 15;274(5290):1152-3.

One of nature's macromolecular machines demystified [comment] Stubbe J. **Science** 1996 Nov 15;274(5290):1152-3 . Comment on: Science 1996 Nov 15;274(5290):1188-93.

Isolation and analysis of moenomycin and its biosynthetic intermediates from Streptomyces ghanaensis (ATCC 14672) wildtype and selected mutants. Subramaniam-Niehaus B, et al. **Z Naturforsch [C]** 1997 Mar-Apr;52(3-4):217-26

[Structure analysis of a DNA fragment containing strong promoter activity from Streptomyces mycarofaciens 1748] Gu H, et al. **I Chuan Hsueh Pao** 1996;23(6):469-76 (Eng. Abstr.) **(Chi)**

[Streptomycete genetics, basis for the production of new antibiotics] Bechtold A. **Pharm Unserer Zeit** 1997 Jan; 26(1):12-6 (22 ref.) **(Ger)**

[Controlled biosynthesis of polyketide antibiotics] Kuczek K, et al. **Postepy Biochem** 1996;42(3):276-83 (61 ref.) **(Pol)**

[Biosynthesis of avermectins: physiological and technological aspects] Mironov VA, et al. **Antibiot Khimioter** 1997; 42(3):31-6 (24 ref.) **(Rus)**

[Use of hydrogen peroxide in the treatment of sewage in antibiotic production] Polunina EE, et al. **Antibiot Khimioter** 1996 Mar;41(3):15-9 (Eng. Abstr.) **(Rus)**

[A genetic locus controlling biosynthesis of phenazine antibiotic in Pseudomonas fluorescens strain 2-79] Mavrodi DV, et al. **Dokl Akad Nauk** 1997 Jan;352(1):117-20 **(Rus)**

[Role of the rpoS gene in the regulation of expression of plasmid genes determining the synthesis of C51 microcin] Fomenko DE, et al. **Genetika** 1997 Feb;33(2):284-6 (Eng. Abstr.) **(Rus)**

[Identification and expression of plasmid genes participating in the synthesis of microcin C51] Fomenko DE, et al. **Genetika** 1996 Oct;32(10):1326-32 (Eng. Abstr.) **(Rus)**

BLOOD

Planar chromatographic and liquid chromatographic analysis of thiamphenicol in bovine and human plasma. Dreassi E, et al. **J AOAC Int** 1997 Jul-Aug;80(4):746-50

Easy enzyme-linked immunosorbent assay for spectinomycin in chicken plasma. Tanaka T, et al. **J AOAC Int** 1996 Mar-Apr;79(2):426-30

Therapeutic monitoring, the concentration-effect relationship and impact on the clinical efficacy of antibiotic agents. Dawson SJ, et al. **J Chemother** 1997 May;9 Suppl 1:84-92 (52 ref.)

Determination of rifabutin in human plasma by high-performance liquid chromatography with ultraviolet detection. Lau YY, et al. **J Chromatogr B Biomed Appl** 1996 Feb 9;676(1):125-30

Plasma disposition of clindamycin microbiological activity in cats after single oral doses of clindamycin hydrochloride as either capsules or aqueous solution. Boothe DM, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):491-4

Contribution of alpha 1-acid glycoprotein to plasma protein binding of some basic antimicrobials in pigs. Son DS, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):176-83

[Determination of serum aminoglycoside and vancomycin concentrations by the microbiological method in the presence of other antimicrobials] Corso A, et al. **Rev Argent Microbiol** 1996 Jul-Sep;28(3):123-31 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Estimation of steady state antibiotic concentration in cerebrospinal fluid from single-dose kinetics. Nau R, et al. **Eur J Clin Pharmacol** 1996;49(5):407-9 (17 ref.)

CHEMICAL SYNTHESIS

Synthesis and biological activities of some new 4,5-dihydro-1H-1,2,4-triazol-5-ones. Demirbas A, et al. **Acta Pol Pharm** 1996 Mar-Apr;53(2):117-21

Asymmetric synthesis and structure-activity relationship of the four stereoisomers of the antibiotic amidinomycin. Part 2: Microbiological testing. Sung SY, et al. **Arch Pharm (Weinheim)** 1997 Jan-Feb;330(1-2):21-4

Dynamic reaction design of enzymic biotransformations in organic media: equilibrium-controlled synthesis of antibiotics by penicillin G acylase. Fernandez-Lafuente R, et al. **Biotechnol Appl Biochem** 1996 Oct;24 (Pt 2):139-43

Synthesis and antimicrobial activities of 4-purpuromycin derivatives. Trani A, et al. **Farmaco** 1996 Jul;51(7):503-12

The synthesis and characterization of analogs of the antimicrobial compound squalamine: 6 beta-hydroxy-3-aminosterols synthesized from hyodeoxycholic acid. Jones SR, et al. **Steroids** 1996 Oct; 61(10):565-71

CHEMISTRY

A study of purified pyorubrin produced by local Pseudomonas aeruginosa. Kandela SA, et al.

Acta Microbiol Pol 1997;46(1):37–43
Stability of 14 drugs in the latex reservoir of an elastomeric infusion device. Allen LV Jr, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2740–3
Metal complexation reactions of quinolone antibiotics in a quadrupole ion trap. Alvarez EJ, et al. **Anal Chem** 1997 Mar 15;69(6):1147–55
Engineering of novel polyketides. Progress and Prospects. Kramer PJ, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:32–45
In vitro evaluation of antibiotic diffusion from antibiotic-impregnated biodegradable beads and polymethylmethacrylate beads. Mader JT, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):415–8
Theoretical aspects of antibiotic diffusion into microbial biofilms. Stewart PS. **Antimicrob Agents Chemother** 1996 Nov;40(11):2517–22
Determination of hydrophobicity parameters of antibiotics by reversed-phase chromatography. The effect of support. Cserháti T, et al. **Biomed Chromatogr** 1996 May–Jun; 10(3):117–21
Automated flow-injection fluorimetric determination of different penicillins in pharmaceutical dosage forms. Solich P, et al. **Biomed Chromatogr** 1997 Mar–Apr;11(2):65–6
Scutione, a new bioactive norquinonemethide triterpene from Maytenus scutioides (Celastraceae). González AG, et al. **Bioorg Med Chem** 1996 Jun;4(6):815–20
Fluviols, bicyclic nitrogen-rich antibiotics produced by Pseudomonas fluorescens. Smirnov VV, et al. **FEMS Microbiol Lett** 1997 Aug 15;153(2):357–61
Prevention of peroxynitrite-dependent tyrosine nitration and inactivation of alpha1-antiproteinase by antibiotics. Whiteman M, et al. **Free Radic Res** 1997 Jan;26(1):49–56
A new substance (Yoshixol) with an interesting antibiotic mechanism from wood oil of Japanese traditional tree (Kiso-Hinoki), Chamaecyparis obtusa. Koyama S, et al. **Gen Pharmacol** 1997 May;28(5):797–804
Structure-biological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. Kang JH, et al. **Int J Pept Protein Res** 1996 Oct;48(4):357–63
XR651, a novel naphthacene-5,12-dione. Bahl S, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):169–71
Heliquinomycin, a new inhibitor of DNA helicase, produced by Streptomyces sp. MJ929-SF2 II. Structure determination of heliquinomycin. Chino M, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):143–6
APHE-3 and APHE-4, two new pyrazoloisoquinolinone antibiotics produced by Streptoverticillium griseocarneum NCIMB 40447. Cruz R, et al. **J Antibiot (Tokyo)** 1996 Jul; 49(7):700–2
Pyralomicins, novel antibiotics from Microtetraspora spiralis. II. Structure determination. Kawamura N, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):651–6
Pyralomicins, novel antibiotics from Microtetraspora spiralis. IV. Absolute configuration. Kawamura N, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):147–9
New piericidin antibiotics, 7-demethylpiericidin A1 and 7-demethyl-3'-rhamnopiericidin A1. Kimura K, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):697–9
Lactonamycin, a new antimicrobial antibiotic produced by Streptomyces rishiriensis [letter] Matsumoto N, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):953–4
Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. II. Structure elucidation of chloropeptin I. Matsuzaki K, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):66–9
Chlovalicin, a new cytocidal antibiotic produced by Sporothrix sp. FO-4649. II. Physicochemical properties and structural elucidation. Takamatsu S, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):635–8
Structure determination of an immunopotentiator peptide, cinnamycin, complexed with lysophosphatidylethanolamine by 1H-NMR1. Hosoda K, et al. **J Biochem (Tokyo)** 1996 Feb;119(2):226–30
Compatibility of corticosteroids and antibiotics in combination. Mahlberg K, et al. **J Cataract Refract Surg** 1997 Jul–Aug;23(6):878–82
Separation of proteases: old and new approaches. Ibrahim-Granet O, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):239–63 (161 ref.)
Application of fast atom bombardment combined with tandem mass spectrometry to the structural elucidation of O-demethylabierixin and related polyether antibiotics. Kim YH, et al. **J Mass Spectrom** 1996 Aug;31(8):855–60
Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. Pereira ER, et al. **J Med Chem** 1996 Oct 25;39(22):4471–7
Charge-transfer chromatographic study of the interaction of antibiotics with sodium dodecylsulfate. Forgács E, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1295–302
Aggregation behavior of sodium fusidate in aqueous solution. Coello A, et al. **J Pharm Sci** 1994 Jun;83(6):828–32
Elution of six antibiotics bonded to polyethylene vascular grafts sealed with three proteins. Galdbart JO, et al. **J Surg Res** 1996 Dec;66(2):174–8
Hydrogen bond geometry in DNA-minor groove binding drug complexes. Tabernero L, et al. **Nucleic Acids Res** 1996 Sep 1;24(17):3458–66
Novel CCK-B receptor agonists: diketopiperazine analogues derived for CCK4 bioactive conformation. Weng JH, et al. **Regul Pept** 1996 Aug 27;65(1):3–9
An alpha to beta conformational switch in EF-Tu. Abel K, et al. **Structure** 1996 Oct 15;4(10):1153–9
[Antibiotic and electrochemical properties of some natural ionophoric compounds from streptomycetes] Sverdlova AN, et al. **Mol Gen Mikrobiol Virusol** 1997;(2):29–33 (Eng. Abstr.) **(Rus)**

CONTRAINDICATIONS

Oral antibiotics for common infections in children: for and against. Payne D, et al. **Br J Hosp Med** 1996 Nov 6–19; 56(9):481–5
[Antibiotics in otitis media with effusion (see comments)] Grote JJ. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):76–7 (15 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1997 Feb 22;141(8):401–2. Comment in: Ned Tijdschr Geneeskd 1997 Apr 5;141(14):702. **(Dut)**
[Antibiotics and bronchial asthma (letter)] Endre L. **Orv Hetil** 1997 Feb 16;138(7):448 **(Hun)**

ECONOMICS

Antimicrobial formulary control: is the glass half empty or half full? [comment] Rapp RP, et al. **Am J Health Syst Pharm** 1996 Sep 1;53(17):2091–2. Comment on: Am J Health Syst Pharm 1996 Sep 1;53(17):2054–62.
Benchmark analysis of strategies hospitals use to control antimicrobial expenditures [see comments] Rifenburg RP, et al. **Am J Health Syst Pharm** 1996 Sep 1;53(17):2054–62 . Comment in: Am J Health Syst Pharm 1996 Sep 1;53(17):2091–2.
Antibiotic optimization. An evaluation of patient safety and economic outcomes. Fraser GL, et al. **Arch Intern Med** 1997 Aug 11–25;157(15):1689–94
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori [see comments] Taylor JL, et al. **Arch Intern Med** 1997 Jan 13;157(1):87–97. Comment in: ACP J Club 1997 Jul–Aug;127(1):22.
Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. John JF Jr, et al. **Clin Infect Dis** 1997 Mar;24(3):471–85 (89 ref.)
The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost. Hotchkies L, et al. **Clin Ther** 1996 Jul–Aug;18(4):716–25; discussion 702
A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Oh PI, et al. **Clin Ther** 1996 Jan–Feb;18(1):160–82
Antibiotic usage: policy, clinical and pharmacoeconomic outcomes. Carbon C. **Drugs** 1996;52 Suppl 2:78–9
Antibiotic policies. Economics and effectiveness from a UK perspective. Davey P. **Drugs** 1996;52 Suppl 2:83–7
Antibiotic usage: pharmacoeconomic impact in a changing healthcare system. Milkovich G. **Drugs** 1996;52 Suppl 2:80–2
Much ado about nothing: methicillin-resistant Staphylococcus aureus. Shannon T, et al. **J Burn Care Rehabil** 1997 Jul–Aug;18(4):326–31
Cost-effectiveness analysis [letter; comment] Barry HC. **J Fam Pract** 1997 Jun;44(6):524; discussion 524–5. Comment on: J Fam Pract 1997 Mar;44(3):261–5.
Antibiotics: neither cost effective nor 'cough' effective [see comments] Hueston WJ. **J Fam Pract** 1997 Mar;44(3):261–5 . Comment in: J Fam Pract 1997 Jun;44(6):524; discussion 524–5. Comment in: J Fam Pract 1997 Jun;44(6):524–5.
Cost-effectiveness analysis [letter; comment] King DE. **J Fam Pract** 1997 Jun;44(6):524–5. Comment on: J Fam Pract 1997 Mar;44(3):261–5.
Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. Gleason PP, et al. **JAMA** 1997 Jul 2;278(1):32–9
Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis. Eckman MH, et al. **N Engl J Med** 1997 Jul 31;337(5):357–63
Cost and wastage of antibiotic suspensions: a comparative study for various weight groups. Detar E, et al. **Pediatr Infect Dis J** 1997 Jun;16(6):619–22
Overall cost in the treatment of otitis media. Kaplan B, et al. **Pediatr Infect Dis J** 1997 Feb;16(2 Suppl):S9–11
Pharmacoeconomic impact of factors affecting compliance with antibiotic regimens in the treatment of acute otitis media. Wandstrat TL, et al. **Pediatr Infect Dis J** 1997 Feb; 16(2 Suppl):S27–9
A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Bailey TC, et al. **Pharmacotherapy** 1997 Mar–Apr;17(2):277–81
Cost of oral antibiotic therapy. Nightingale CH, et al. **Pharmacotherapy** 1997 Mar–Apr;17(2):302–7
[How to estimate the cost of antibacterial therapy in the hospital. Methodological ways suggested by the literature] Ronchetto F. **Recenti Prog Med** 1996 Jun;87(6):259–61 (15 ref.) **(Ita)**
[Antimicrobial treatment: some considerations regarding its economic evaluation] Palau E, et al. **Enferm Infecc Microbiol Clin** 1996 Dec;14(10):614–9 (42 ref.) **(Spa)**

HISTORY

The naming of antibiotics. Aronson SM. **Med Health R I** 1997 Jun;80(6):180
Antibiotics: past, present, and future. Unearthing nature's magic bullets. Hoel D, et al. **Postgrad Med** 1997 Jan; 101(1):114–8, 121–2
[The 50th anniversary of the State Scientific Center on Antibiotics (pages from its history)] Kuznetsova SM. **Antibiot Khimioter** 1997;42(5):10–23 **(Rus)**
[The science of antibiotics: a retrospective and view to the future] Navashin SM. **Antibiot Khimioter** 1997;42(5):3–9 **(Rus)**
[Our journal is 40 years old. Antibiotiki i Khimioterapiia] Navashin SM, et al. **Antibiot Khimioter** 1997;42(1):3–6 **(Rus)**
[Contribution of military medical workers to development of technologies for the manufacture of the first Soviet antibiotics] Vasil'ev NT, et al. **Antibiot Khimioter** 1996 Apr; 41(4):3–6 **(Rus)**

IMMUNOLOGY

Antibiotics: more than just "bug" killers [editorial; comment] Casey LC. **Crit Care Med** 1997 Aug;25(8):1270–1. Comment on: Crit Care Med 1997 Aug;25(8):1392–5.
Immunomodulating effects of antibiotics: literature review. Van Vlem B, et al. **Infection** 1996 Jul–Aug;24(4):275–91 (187 ref.)

ISOLATION & PURIFICATION

Purification and characterization of enterocin 4, a bacteriocin produced by Enterococcus faecalis INIA 4. Joosten HM, et al. **Appl Environ Microbiol** 1996 Nov;62(11):4220–3
Antimicrobial activities of Streptomyces pulcher, S. canescens and S. citreofluorescens against fungal and bacterial pathogens of tomato in vitro. el-Abyad MS, et al. **Folia Microbiol (Praha)** 1996;41(4):321–8
Exophilin A, a new antibiotic from a marine microorganism Exophiala pisciphila. Doshida J, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1105–9
Chlovalicin, a new cytocidal antibiotic produced by Sporothrix sp. FO-4649. I. Taxonomy, fermentation, isolation and biological activities. Hayashi M, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):631–4
YM-30059, a novel quinolone antibiotic produced by Arthrobacter sp. Kamigiri K, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):823–5
A novel neuronal cell protecting substance, naphthomycinol, produced by Streptomyces sp. PF7. Kim JS, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1172–4
SNA-8073-B, a new isotetracenone antibiotic inhibits prolyl endopeptidase. I. Fermentation, isolation and biological properties. Kimura K, et al. **J Antibiot (Tokyo)** 1997 Apr; 50(4):291–6
Illudins C2 and C3, new illudin C derivatives from Coprinus atramentarius ASI20013. Lee IK, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):821–2
Brasiliquinones A, B and C, new benz[alpha]anthraquinone antibiotics from Nocardia brasiliensis. I. Producing strain, isolation and biological activities of the antibiotics [published erratum appears in J Antibiot (Tokyo) 1997 Apr;50(4):C-1] Nemoto A, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):18–21
(E)-4-oxonon-2-enoic acid, an antibiotically active fatty acid produced by Streptomyces olivaceus Tü 4018. Pfefferle C, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):826–8
Dihydrophencomycin methyl ester, a new phenazine derivative from a marine Streptomycete. Pusecker K, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):479–83
Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. I. Taxonomy, fermentation, isolation, and physico-chemical properties and biological activities. Tanaka H, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):58–65
Benesudon, a new antibiotic fungal metabolite from cultures of Mollisia benesuada (Tul.) Phill. Thines E, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):13–7
IT-143-A and B, novel piericidin-group antibiotics produced by Streptomyces sp. Urakawa A, et al. **J Antibiot (Tokyo)** 1996 Oct;49(10):1052–5
HP17, a new pigment-like antibiotic produced by a new strain of Spirillospora. Hacéne H, et al. **J Appl Bacteriol** 1996 May;80(5):565–9
Isolation and characterization of antibiotic-like substances produced by natural Escherichia coli isolates. Cavazza ME, et al. **J Chemother** 1995 Nov;7 Suppl 4:46–8
Illudinic acid, a novel illudane sesquiterpene antibiotic. Dufresne C, et al. **J Nat Prod** 1997 Feb;60(2):188–90
Metabolites from an Antarctic sponge-associated bacterium, Pseudomonas aeruginosa. Jayatilake GS, et al. **J Nat Prod** 1996 Mar;59(3):293–6
Chlorochimaphilin: a new antibiotic from Moneses uniflora. Saxena G, et al. **J Nat Prod** 1996 Jan;59(1):62–5
Isolation and analysis of moenomycin and its biosynthetic intermediates from Streptomyces ghanaensis (ATCC 14672) wildtype and selected mutants. Subramaniam-Niehaus B, et al. **Z Naturforsch [C]** 1997 Mar-Apr;52(3–4):217–26
[Structural analysis of defense molecules found in large and small granules in hemocytes of horseshoe crab] Kawabata S. **Seikagaku** 1996 Sep;68(9):1523–36 (63 ref.) **(Jpn)**
[Royleanones in the roots of Salvia officinalis L. of domestic provenance and their antimicrobial activity (published erratum appears in Ceska Slov Farm 1996 Nov;45(6):301)] Mašterová I, et al. **Ceska Slov Farm** 1996 Sep;45(5):242–5 (Eng. Abstr.) **(Slo)**

METABOLISM

Metabolism of a 5-nitroimidazole in susceptible and resistant isogenic strains of Bacteroides fragilis. Carlier JP, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1495–9

Species selectivity of new siderophore–drug conjugates that use specific iron uptake for entry into bacteria. Diarra MS, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2610–7

O-Acetyltransferases for chloramphenicol and other natural products. Murray IA, et al.
Antimicrob Agents Chemother 1997 Jan;41(1):1–6 (41 ref.)

Isolation of a gene encoding a novel spectinomycin phosphotransferase from Legionella pneumophila. Suter TM, et al. **Antimicrob Agents Chemother** 1997 Jun; 41(6):1385–8

Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Trapnell CB, et al.
Antimicrob Agents Chemother 1997 May;41(5):924–6

Cytochrome P-450 complex formation in rat liver by the antibiotic tiamulin. Witkamp RF, et al.
Antimicrob Agents Chemother 1996 Jan;40(1):50–4

The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo. Bernet-Camard MF, et al.
Appl Environ Microbiol 1997 Jul;63(7):2747–53

Antibiotic diffusion pathways in the outer membrane of Pseudomonas aeruginosa. Kitahara T, et al.
Biochem Biophys Res Commun 1997 Sep 18;238(2):457–61

The role of mex-gene products in antibiotic extrusion in Pseudomonas aeruginosa. Yoneyama H, et al.
Biochem Biophys Res Commun 1997 Apr 28;233(3):611–8

Recognition determinants for proteins and antibiotics within 23S rRNA. Douthwalte S, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11–12):1179–85 (56 ref.)

Structural and functional implications in the eubacterial ribosome as revealed by protein-rRNA and antibiotic contact sites. Wittmann-Liebold B, et al.
Biochem Cell Biol 1995 Nov-Dec;73(11–12):1187–97

Antibiotics MDL 62,879 and kirromycin bind to distinct and independent sites of elongation factor Tu (EF-Tu). Landini P, et al. **Biochemistry** 1996 Dec 3;35(48):15288–94

Aspartate aminotransferase complexed with erythro-beta-hydroxyaspartate: crystallographic and spectroscopic identification of the carbinolamine intermediate. von Stosch AG. **Biochemistry** 1996 Dec 3; 35(48):15260–8

The selection in vivo and characterization of an RNA recognition motif for spectinomycin. Thom G, et al.
Bioorg Med Chem 1997 Jun;5(6):1081–6

Dynamic reaction design of enzymic biotransformations in organic media: equilibrium-controlled synthesis of antibiotics by penicillin G acylase. Fernandez-Lafuente R, et al. **Biotechnol Appl Biochem** 1996 Oct;24 (Pt 2):139–43

Unusual behavior of ion transport mediated by polyene antibiotics. Activation energies for the exchange of Na+ ions through liposomal membranes studied by 23Na-NMR spectroscopy. Kimura A, et al.
Chem Pharm Bull (Tokyo) 1997 Mar;45(3):431–6

A comparative study of the redox-cycling of a quinone (rifamycin S) and a quinonimine (rifabutin) antibiotic by rat liver microsomes. Rao DN, et al.
Free Radic Biol Med 1997;22(3):439–46

Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis. Foitzik T, et al. **Gut** 1997 Apr;40(4):526–30

Determination of lincomycin residue in salmon tissues by ion-pair reversed-phase liquid chromatography with electrochemical detection. Luo W, et al. **J AOAC Int** 1996 Jul-Aug;79(4):839–43

Antimicrobial activity of food-related Penicillium sp. against pathogenic bacteria in laboratory media and a cheese model system. Larsen AG, et al. **J Appl Microbiol** 1997 Jul; 83(1):111–9

Identification of a monooxygenase from Streptomyces coelicolor A3(2) involved in biosynthesis of actinorhodin: purification and characterization of the recombinant enzyme. Kendrew SG, et al. **J Bacteriol** 1997 Jul; 179(13):4305–10

Induction of actinorhodin production by rpsL (encoding ribosomal protein S12) mutations that confer streptomycin resistance in Streptomyces lividans and Streptomyces coelicolor A3(2). Shima J, et al. **J Bacteriol** 1996 Dec; 178(24):7276–84

Study of the binding of antibiotics to human serum albumin by charge-transfer chromatography. Cserháti T, et al.
J Chromatogr A 1997 Jul 25;776(1):31–6

Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics. Terada T, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1415–21

Studies on the biosynthesis of bialaphos. Biochemical mechanism of C-P bond formation: discovery of phosphonopyruvate decarboxylase which catalyzes the formation of phosphonoacetaldehyde from phosphonopyruvate. Nakashita H, et al. **Jpn J Antibiot** 1997 Mar;50(3):212–9

The cutRS signal transduction system of Streptomyces lividans represses the biosynthesis of the polyketide antibiotic actinorhodin. Chang HM, et al.
Mol Microbiol 1996 Sep;21(5):1075–85

Azurocidin, a natural antibiotic from human neutrophils: expression, antimicrobial activity, and secretion. Almeida RP, et al. **Protein Expr Purif** 1996 Jun;7(4):355–66

New concepts in the pulmonary disposition of antibiotics [letter; comment] Lockhart A. **Pulm Pharmacol** 1996 Feb; 9(1):63, 65. Comment on: Pulm Pharmacol 1995 Apr-Jun;8(2-3):65–81.

Evaluation of certain veterinary drug residues in food. Forty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives.
World Health Organ Tech Rep Ser 1996;864:1–62 (118 ref.)

PHARMACOKINETICS

Intravitreal concentrations of some drugs administered with microdialysis. Waga J, et al. **Acta Ophthalmol Scand** 1997 Feb;75(1):36–40

Pharmacokinetics of antibiotics in neonates. Sato Y.
Acta Paediatr Jpn 1997 Feb;39(1):124–31

Pharmacokinetics of antibiotics in children. Toyonaga Y.
Acta Paediatr Jpn 1997 Feb;39(1):114–23

The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Burman WJ. **Am J Med Sci** 1997 Jun; 313(6):355–63 (100 ref.)

The importance of antibiotic pharmacokinetics in critical illness. Fry DE. **Am J Surg** 1996 Dec;172(6A):20S–25S (18 ref.)

AUIC--the universal parameter within the constraint of a reasonable dosing interval [editorial; comment] Schentag JJ, et al. **Ann Pharmacother** 1996 Sep;30(9):1029–31. Comment on: Ann Pharmacother 1996 Sep;30(9):1024–8.

In vitro assessment of gastric mucosal transfer of anti-Helicobacter therapeutic agents. Goddard AF, et al.
Antimicrob Agents Chemother 1997 Jun;41(6):1246–9

New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. Hultén K, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2727–31

Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Borin MT, et al. **Antiviral Res** 1997 Jun;35(1):53–63

Penetration of antibiotics in diseased antral mucosa. Westergren V, et al. **Arch Otolaryngol Head Neck Surg** 1996 Dec;122(12):1390–4

Selective compartments for resistant microorganisms in antibiotic gradients. Baquero F, et al. **Bioessays** 1997 Aug; 19(8):731–6 (21 ref.)

A model based assessment of redistribution dependent elimination and bioavailability of rifabutin. Li RC, et al.
Biopharm Drug Dispos 1996 Apr;17(3):223–36

Drug efflux as a mechanism of resistance. Williams JB.
Br J Biomed Sci 1996 Dec;53(4):290–3 (22 ref.)

Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis. Taylor CA 3rd, et al.
Clin Pharmacokinet 1996 Oct;31(4):293–308 (104 ref.)

Pharmacokinetic considerations in the camel (Camelus dromedarius): a review. Ali BH, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1996 Sep;115(1):1–9 (61 ref.)

Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Honeybourne D. **Curr Opin Pulm Med** 1997 Mar;3(2):170–4 (35 ref.)

Tissue concentrations and pharmacokinetics of florfenicol in broiler chickens. Afifi NA, et al.
DTW Dtsch Tierarztl Wochenschr 1997 May;104(5):178–80

Ocular penetration kinetics of fosfomycin administered as a one-hour infusion. Forestier F, et al. **Eur J Ophthalmol** 1996 Apr-Jun;6(2):137–42

Pharmacokinetic investigation of fusidic acid 1% viscous eye drops in healthy volunteers. Thorn P, et al.
Eur J Ophthalmol 1997 Jan-Mar;7(1):9–12

Penetration of clindamycin and metronidazole into inflamed appendiceal tissue. Levy Y, et al. **Eur J Surg** 1996 Aug; 162(8):633–5

Duration of antibiotic treatment in surgical infections of the abdomen. Pharmacokinetic basis for short courses of antimicrobial therapy. Wittmann DH. **Eur J Surg Suppl** 1996;(576):19–23

In vitro models for prediction of antimicrobial activity: a pharmacokinetic and pharmacodynamic perspective. Li RC, et al. **J Chemother** 1997 May;9 Suppl 1:55–63 (81 ref.)

Determination of monensin, salinomycin and narasin in muscle, liver and eggs from domestic fowl using liquid chromatography-electrospray mass spectrometry.
Blanchflower WJ, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26;675(2):225–33

In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. Beaulac C, et al.
J Microencapsul 1997 May-Jun;14(3):335–48

Tissue concentration of clindamycin and gentamicin near ischaemic ulcers with transvenous injection in Bier's arterial arrest. Burgmann H, et al. **Lancet** 1996 Sep 21; 348(9030):781–3

Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. Joos B, et al. **Nephrol Dial Transplant** 1996 Aug;11(8):1582–5

Use of generic antibiotics in children. Tam J.
Pediatr Ann 1996 Nov;25(11):614–7

Using antibiotic concentrations in middle ear fluid to predict potential clinical efficacy. Harrison CJ.
Pediatr Infect Dis J 1997 Feb;16(2 Suppl):S12–6

Predicting the clinical efficacy of antibiotics: toward definitive criteria. Scaglione F. **Pediatr Infect Dis J** 1997 Mar;16(3 Suppl):S56–9 (31 ref.)

New concepts in the pulmonary disposition of antibiotics [see comments] Bergogne-Berezin E. **Pulm Pharmacol** 1995 Apr-Jun;8(2-3):65–81 (92 ref.). Comment in: Pulm Pharmacol 1996 Feb;9(1):63, 65.

The bacterial outer membrane as a drug barrier. Hancock RE. **Trends Microbiol** 1997 Jan;5(1):37–42 (26 ref.)

[Kinetics of antibiotic distribution in the bronchopulmonary area] Fourtillan JB. **Rev Pneumol Clin** 1996;52 Suppl 2:S43–6 **(Fre)**

[Intracellular pharmacokinetics and pharmacodynamics of antibiotics] Tulkens PM. **Rev Pneumol Clin** 1996;52 Suppl 2:S51–5 **(Fre)**

[Acquisition of antibiotic-resistance in bacteria by alteration of molecular target, or by the decreased permeability] Hashimoto H. **Nippon Rinsho** 1997 May;55(5):1167–72 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Antibiotic extrusion and multidrug resistance] Nakae T.
Nippon Rinsho 1997 May;55(5):1173–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Mutagenesis and ultraviolet inactivation of transforming DNA of Haemophilus influenzae complexed with a Bacillus subtilis protein that alters DNA conformation. Setlow JK, et al. **Acta Biochim Pol** 1996;43(1):107–14

In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxycillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin, and azithromycin. Delmée M, et al. **Acta Clin Belg** 1996;51(4):237–43

Antibiotic resistance of Campylobacter jejuni with reference to plasmid profiles of clinical and chicken isolates. Lękowska-Kochaniak A, et al. **Acta Microbiol Pol** 1996; 45(3–4):249–59

Microbiology of chronic maxillary sinusitis in adults: isolated aerobic and anaerobic bacteria and their susceptibility to twenty antibiotics. Hartog B, et al.
Acta Otolaryngol (Stockh) 1995 Sep;115(5):672–7

Susceptibility of gram-positive bacteria isolated from a paediatric hospital environment to antibiotics.
Zembrzuska-Sadkowska E, et al. **Acta Pol Pharm** 1995 Mar-Apr;52(2):153–60

Susceptibility of gram-negative bacteria isolated from a paediatric hospital environment to antibiotics.
Zembrzuska-Sadkowska E, et al. **Acta Pol Pharm** 1995 Mar-Apr;52(2):161–71

Susceptibility of bacteria isolated from non-parenteral preparations applied in paediatric hospitals to antibiotics.
Zembrzuska-Sadkowska E, et al. **Acta Pol Pharm** 1995 Jan-Feb;52(1):77–85

The antimicrobial susceptibility of Streptococcus pyogenes isolates from the Philadelphia area. Ferraro AL, et al.
Adv Exp Med Biol 1995;390:119–21

Molecular epidemiologic analysis of antibiotic resistant microorganisms. John JF Jr. **Adv Exp Med Biol** 1995; 390:155–68 (56 ref.)

Antibiotic-resistance in Streptococcus pneumoniae. Krisher K. **Adv Exp Med Biol** 1995;390:123–40 (102 ref.)

Emerging trends in antimicrobial resistance: a laboratory perspective. Sahm DF. **Adv Exp Med Biol** 1995;390:141–54 (46 ref.)

Resistance to antibacterial agents. Sanders CC, et al.
Adv Exp Med Biol 1995;390:15–23 (16 ref.)

Patterns of resistance in organisms causing gynecologic infections. Tumah H, et al. **Adv Exp Med Biol** 1995; 390:169–75

Mechanisms of antibacterial resistance. Hickey SM, et al.
Adv Pediatr 1997;44:1–41 (86 ref.)

Measurement of antimicrobial susceptibility among invasive isolates of Streptococcus pneumoniae: comparison of the Etest with the standard agar dilution method. Fitzgerald MA, et al. **Alaska Med** 1997 Jan-Mar;39(1):3–7

Resistance of Helicobacter pylori to antibiotics. Mégraud F.
Aliment Pharmacol Ther 1997 Apr;11 Suppl 1:43–53 (39 ref.)

Resistant pneumococci: protecting patients through judicious use of antibiotics [see comments] Dowell SF, et al.
Am Fam Physician 1997 Apr;55(5):1647–54, 1657–8 (33 ref.) . Comment in: Am Fam Physician 1997 Apr;55(5):1535–6.

Studies on the antimicrobial activity of juglans regia. Alkhawajah AM. **Am J Chin Med** 1997;25(2):175–80

Minimum inhibitory concentration of various single agents and the effect of their combinations against Helicobacter pylori, as estimated by a fast and simple in vitro assay method. Bamba H, et al. **Am J Gastroenterol** 1997 Apr; 92(4):659–62

Microbial resistance to drug therapy: a review. Cohen FL, et al. **Am J Infect Control** 1997 Feb;25(1):51–64 (114 ref.)

Induction of creatininase activity in chronic renal failure: timing of creatinine degradation and effect of antibiotics. Dunn SR, et al. **Am J Kidney Dis** 1997 Jan;29(1):72–7

Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar pomona infection in hamsters and swine. Alt DP, et al. **Am J Vet Res** 1996 Jan;57(1):59–62

Changing trends in the antimicrobial susceptibility of clinical isolates of Acinetobacter baumannii. Sng LH, et al.
Ann Acad Med Singapore 1996 Mar;25(2):179–83

Serotypes and antimicrobial resistance in Haemophilus

influenzae in a hospital practice. Tee NW, et al. **Ann Acad Med Singapore** 1996 Mar;25(2):184–7

Rifampin resistance in Neisseria meningitidis due to alterations in membrane permeability. Abadi FJ, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):646–51

Modes of action of tunicamycin, liposidomycin B, and mureidomycin A: inhibition of phospho-N-acetylmuramyl-pentapeptide translocase from Escherichia coli. Brandish PE, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1640–4

Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin. Brouqui P, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1552–4

Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods. Chang JC, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1301–6

Antibiotic activity in microbiological media versus that in human urine: comparison of ampicillin, ciprofloxacin, and trimethoprim-sulfamethoxazole. Drobot GR, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):237–40

Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole. Ednie LM, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1037–41

Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Fasola EL, et al. **Antimicrob Agents Chemother** 1997 Jan; 41(1):129–34

Treatment of experimental endocarditis due to ampicillin-susceptible or ampicillin-resistant Salmonella enteritidis. Fernández Guerrero ML, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1589–93

Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Finlay JE, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1137–9

In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus. Frean JA, et al. **Antimicrob Agents Chemother** 1996 Nov; 40(11):2646–7

Differential induction of pro- and anti-inflammatory cytokines in whole blood by bacteria: effects of antibiotic treatment. Frieling JT, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1439–43

Postexposure factors influencing the duration of postantibiotic effect: significance of temperature, pH, cations, and oxygen tension. Fuursted K. **Antimicrob Agents Chemother** 1997 Aug;41(8):1693–6

Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Garrison MW, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2859–64

Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock. Genovese F, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1733–5

Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. Gillum JG, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1866–9

Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex after liposome encapsulation. Gomez-Flores R, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2545–9

Susceptibility testing of Mycobacterium avium complex isolates. Heifets L. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1759–67 (117 ref.)

Frequency of high-level mupirocin-resistant Staphylococcus aureus in a tertiary care facility [letter] Irizarry L, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1967–8

Change in prevalence and antibiotic resistance of Enterococcus species isolated from blood cultures over an 8-year period [letter] Iwen PC, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):494–5

Antimicrobial activities of squalamine mimics. Kikuchi K, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1433–8

Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis. Klepser ME, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):630–5

Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods. Klepser ME, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1941–4

Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa. Lamp KC, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):247–52

Postantibiotic effect assessments for antibiotics exhibiting a wide range of bactericidal activities by using a modified total-cell-counting method. Li RC, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1170–2

Novel method for assessing postantibiotic effect by using the Coulter counter. Li RC, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1751–3

Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Marques MB, et al. **Antimicrob Agents Chemother** 1997 May;41(5):881–5

Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Matsumoto T, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):308–13

Antimicrobial activity of human pancreatic juice and its interaction with antibiotics. Minelli EB, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2099–105

Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Palmer SM, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):701–5

MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. Pankuch GA, et al. **Antimicrob Agents Chemother** 1996 Sep; 40(9):2071–4

In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii. Romand S, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2015–20

Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Slayden RA, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2813–9

Pharmacodynamic effects of antibiotics and antibiotic combinations on growing and nongrowing Staphylococcus epidermidis cells. Svensson E, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):107–11

Conjugative transfer of high-level mupirocin resistance from Staphylococcus haemolyticus to other staphylococci. Udo EE, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):693–5

Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria [published erratum appears in Antimicrob Agents Chemother 1997 Feb;41(2):496] Vaara M, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1801–5

Bacterial biofilms and the bioelectric effect. Wellman N, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2012–4

Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis. Xue IB, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1403–7

The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo. Bernet-Camard MF, et al. **Appl Environ Microbiol** 1997 Jul;63(7):2747–53

Association of multiple-antibiotic-resistance profiles with point and nonpoint sources of Escherichia coli in Apalachicola Bay. Parveen S, et al. **Appl Environ Microbiol** 1997 Jul;63(7):2607–12

Inhibition of the trehalose-P synthase of mycobacteria by various antibiotics. Pan YT, et al. **Arch Biochem Biophys** 1996 Nov 15;335(2):258–66

Asymmetric synthesis and structure-activity relationship of the four stereoisomers of the antibiotic amidinomycin. Part 2: Microbiological testing. Sung SY, et al. **Arch Pharm (Weinheim)** 1997 Jan-Feb;330(1-2):21–4

Effect of maduramicin and monensin on survival of Lactobacillus salivarius 51R administered in the crop and caeca of young chickens. Rada V, et al. **Arch Tierernahr** 1997;50(1):25–9

In vitro activity of a new rifamycin derivative against Mycobacterium leprae. Dhople AM, et al. **Arzneimittelforschung** 1996 Feb;46(2):210–2

Antibacterial activity of benzydamine and antibiotic-benzydamine combinations against multifold resistant clinical isolates. Fanaki NH, et al. **Arzneimittelforschung** 1996 Mar;46(3):320–3

In vitro and in vivo effects of rifampin on Staphylococcus epidermidis graft infections. Garrison JR Jr, et al. **ASAIO J** 1997 Jan-Feb;43(1):8–12

Elongation factor Tu1 of the antibiotic GE2270A producer Planobispora rosea has an unexpected resistance profile against EF-Tu targeted antibiotics. Möhrle VG, et al. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):320–6

beta-Galactosidase reporter system in mycobacteria and its application in rapid antimycobacterial drug screening. Srivastava R, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):602–5

Antibiotic inhibition of the movement of tRNA substrates through a peptidyl transferase cavity. Porse BT, et al. **Biochem Cell Biol** 1995 Nov-Dec;73(11-12):877–85 (47 ref.)

In vitro susceptibility of Escherichia coli O157 to several antimicrobial agents. Oie S, et al. **Biol Pharm Bull** 1997 May;20(5):584–5

Scutione, a new bioactive norquinonemethide triterpene from Maytenus scutioides (Celastraceae). González AG, et al. **Bioorg Med Chem** 1996 Jun;4(6):815–20

Dentists, pills and pregnancies [see comments] Stephens IF, et al. **Br Dent J** 1996 Oct 5;181(7):236–9. Comment in: Br Dent J 1997 Feb 22;182(4):126.

Dentists, pills and pregnancies [letter; comment] Wheatcroft M, et al. **Br Dent J** 1997 Feb 22;182(4):126. Comment on: Br Dent J 1996 Oct 5;181(7):236–9.

Effects of immunosuppressive drugs and antibiotics on GM-CSF and G-CSF secretion in vitro by monocytes, T lymphocytes and endothelial cells. Lenhoff S, et al. **Br J Haematol** 1996 Oct;95(1):33–8

Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity. van 't Veen A, et al. **Br J Pharmacol** 1996 Jun;118(3):593–8

Effect of fusidic acid on pancreatic islet allograft rejection. Mendola JF, et al. **Cell Transplant** 1997 Jan-Feb;6(1):39–45

Susceptibilities of 55 strains of Neisseria meningitidis isolated in Spain in 1993 and 1994. Florez C, et al. **Chemotherapy** 1997 May-Jun;43(3):168–70

In vitro antimicrobial activity of the thiazolyl peptide antibiotic MDL 62,879 (GE2270 A). Kenny MT, et al. **Chemotherapy** 1997 Jul-Aug;43(4):254–63

In vitro and in vivo antibacterial activities of TOC-50, a new parenteral cephalosporin, against Enterococcus faecalis. Nomura S, et al. **Chemotherapy** 1996 Nov-Dec; 42(6):432–8

Anti-Salmonella activity of CP-99,219, a novel azabicyclo-naphthridone fluoroquinolone. Qadri SM, et al. **Chemotherapy** 1996 Nov-Dec;42(6):439–42

Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center. Rolston KV, et al. **Chemotherapy** 1996 Sep-Oct;42(5):348–53

Susceptibility of Moraxella catarrhalis to 21 antimicrobial drugs: validity of current NCCLS criteria for the interpretation of agar disk diffusion antibiograms. Traub WH, et al. **Chemotherapy** 1997 May-Jun;43(3):159–67

Antibiotic susceptibility of alpha- and nonhemolytic streptococci from patients and healthy adults to 24 antimicrobial drugs. Traub WH, et al. **Chemotherapy** 1997 Mar-Apr;43(2):123–31

Antibiotic susceptibility of clinical isolates of Streptococcus pneumoniae. Traub WH, et al. **Chemotherapy** 1996 Jul-Aug;42(4):240–7

In vitro antitumor and antimicrobial activities of N-substituents of maleimide by adamantane and diamantane. Wang JJ, et al. **Chemotherapy** 1997 May-Jun; 43(3):182–9

The antibiotic selective process: concentration-specific amplification of low-level resistant populations. Baquero F, et al. **Ciba Found Symp** 1997;207:93–105; discussion 105–11 (27 ref.)

Antibiotic resistance: a view from the pharmaceutical industry. Bax RP. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S151–3

Clindamycin resistance in the Bacteroides fragilis group: association with hospital-acquired infections. Dalmau D, et al. **Clin Infect Dis** 1997 May;24(5):874–7

Resistance of the normal human microflora to mercury and antimicrobials after exposure to mercury from dental amalgam fillings. Edlund C, et al. **Clin Infect Dis** 1996 Jun; 22(6):944–50

The role of fundamental research and biotechnology in finding solutions to the global problem of antibiotic resistance. Hancock RE. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S148–50

Perspectives on chemotherapeutic approaches to antibiotic-resistant bacteria. Kessler RE. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S146–7

Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers. Pitkin DH, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S238–48

Reports on surveillance of antimicrobial resistance in individual countries. Rahal K, et al. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S169–75

Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992–1994. Reinert RR, et al. **Clin Infect Dis** 1995 Dec;21(6):1398–401

Management of listeriosis. Hof H, et al. **Clin Microbiol Rev** 1997 Apr;10(2):345–57 (144 ref.)

The emerging role of multi-drug-resistant Streptococcus pneumoniae--a cause for concern [editorial] Koay B, et al. **Clin Otolaryngol** 1996 Aug;21(4):289–91 (36 ref.)

Antimicrobial susceptibility of pathogenic Yersinia enterocolitica isolated in Canada from 1972 to 1990. Preston M, et al. **Contrib Microbiol Immunol** 1995;13:175–9

Activity of 24 antimicrobials against Yersinia enterocolitica. Stolk-Engelaar V, et al. **Contrib Microbiol Immunol** 1995; 13:172–4

Streptococcus pneumoniae: impact of antibiotic resistance in pediatrics. Kaplan SL. **Curr Probl Pediatr** 1997 May-Jun; 27(5):187–95 (74 ref.)

Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Goldstein EJ, et al. **Diabetes Care** 1996 Jun;19(6):638–41

Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. Bonilla HF, et al. **Diagn Microbiol Infect Dis** 1996 Jul;25(3):127–31

Susceptibility of beta-hemolytic streptococci to nine antimicrobial agents among four medical centers in Salt Lake City, Utah, USA. Carroll KC, et al. **Diagn Microbiol Infect Dis** 1997 Apr;27(4):123–8

In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood. Chang SC, et al. **Diagn Microbiol Infect Dis** 1995 Nov;23(3):105–110

Phenotypic detection of mec A-positive staphylococcal blood stream isolates: high accuracy of simple disk diffusion tests. Cormican MG, et al. **Diagn Microbiol Infect Dis** 1996 Jul;25(3):107–12

Disk diffusion interpretive criteria for fusidic acid susceptibility testing of staphylococci by the National Committee for Clinical Laboratory Standards method.

Coutant C, et al. **Diagn Microbiol Infect Dis** 1996 May; 25(1):9–13

Antimicrobial resistance issues of the future. Craig WA. **Diagn Microbiol Infect Dis** 1996 Aug;25(4):213–7

The future—can we learn from the past? Craig WA. **Diagn Microbiol Infect Dis** 1997 Jan–Feb;27(1–2):49–53 (11 ref.)

Reproducibility of broth microdilution and disk diffusion susceptibility tests of nine antimicrobial agents against Streptococcus pneumoniae ATCC 49619. Fuchs PC, et al. **Diagn Microbiol Infect Dis** 1997 May;28(1):27–9

Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Grüneberg RN, et al. **Diagn Microbiol Infect Dis** 1996 Aug;25(4):169–81

The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. Jones RN. **Diagn Microbiol Infect Dis** 1996 Aug;25(4):153–61 (57 ref.)

A 1994–95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. Jones RN, et al. **Diagn Microbiol Infect Dis** 1997 Mar;27(3):75–83

Comparative evaluation of etest for susceptibility testing Neisseria meningitidis with eight antimicrobial agents. An investigation using U.S. Food and Drug Administration regulatory criteria. Marshall SA, et al. **Diagn Microbiol Infect Dis** 1997 Mar;27(3):93–7

Highlights of the French Antimicrobial Resistance Surveillance Project. French Study Group. Péan Y, et al. **Diagn Microbiol Infect Dis** 1996 Aug;25(4):191–4

Evaluation of CPS ID 2 chromogenic agar as a single medium for urine culture. Reisner BS, et al. **Diagn Microbiol Infect Dis** 1997 Jul;28(3):113–7

Alexander Project Symposium. The Hague, Netherlands. November 1–3, 1995. Introduction. Schito GC. **Diagn Microbiol Infect Dis** 1996 Aug;25(4):151–2

A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992–1994. The Alexander Project. Washington JA. **Diagn Microbiol Infect Dis** 1996 Aug; 25(4):183–90

Minimum inhibitory concentration (MIC) of some antibiotics against Vibrio cholerae O139 isolates from Pondicherry. Vijayalakshmi N, et al. **Epidemiol Infect** 1997 Aug; 119(1):25–8

The stimulating effect of fosfomycin, an antibiotic in common use in Japan, on the production/release of verotoxin-1 from enterohaemorrhagic Escherichia coli O157:H7 in vitro. Yoh M, et al. **Epidemiol Infect** 1997 Aug;119(1):101–3

Inhibition of human placenta glutathione transferase P1-1 by the antibiotic calvatic acid and its diazocyanide analogue—evidence for multiple catalytic intermediates. Antonini G, et al. **Eur J Biochem** 1997 May 1;245(3):663–7

Influence of the Gloeophyllum metabolite oosponol and some synthetic analogues on protein and RNA synthesis in target cells. Sonnenbichler J, et al. **Eur J Biochem** 1997 May 15; 246(1):45–9

Quinine in the treatment of Babesia divergens infections in humans [letter] Brasseur P, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):840–1

Is it important to identify extended-spectrum beta-lactamase-producing isolates? [editorial] Bush K. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):361–4 (38 ref.)

Antimicrobial susceptibility of Escherichia coli O157 and other enterohaemorrhagic Escherichia coli isolated in Italy [letter] Farina C, et al. **Eur J Clin Microbiol Infect Dis** 1996 Apr;15(4):351–3

Antibiotic resistance in Shigella and Salmonella in a region of Lithuania. Jensen G, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):872–6

Analysis of the prevaccine population of noncapsulate Haemophilus influenzae and identification of a putative epidemic clone. Leaves NI, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):410–4

First reported African case of Anaerobiospirillum succiniciproducens septicemia. Marcus L, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep;15(9):741–4 (12 ref.)

Invasive Haemophilus influenzae in the Republic of Ireland. Moloney AC, et al. **Eur J Clin Microbiol Infect Dis** 1997 May;16(5):377–80

In vitro activity of nonsteroidal anti-inflammatory agents, phenotiazines, and antidepressants against Brucella species. Muñoz-Criado S, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):418–20

Risk factors for sporadic salmonellosis in Switzerland. Schmid H, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep; 15(9):725–32

Tumor necrosis factor alpha and interleukin 6 release induced by antibiotic killing of Pseudomonas aeruginosa and Staphylococcus aureus. Schneider CM, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jun;16(6):467–71

Inoculum effect and bactericidal activity of cefditoren and other antibiotics against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis. Soriano F, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep; 15(9):761–3

Study of Pseudomonas aeruginosa serotype O12 isolates with a common antibiotic susceptibility pattern. Talarmin A, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jun;15(6):459–64

In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Tessier F, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb;16(2):159–62

Interactions between calvatic acid and related compounds with rat liver microsomes. Miglietta A, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct–Dec; 20(4):249–54

Tetranactin inhibits interleukin 1 beta and cAMP induction of group II phospholipase A2 in rat renal mesangial cells. Walker G, et al. **Eur J Pharmacol** 1996 Jun 13; 306(1–3):265–70

Effect of intraperitoneal antimicrobials on the concentration of bacteria, endotoxin, and tumor necrosis factor in abdominal fluid and plasma in rats. Rosman C, et al. **Eur Surg Res** 1996;28(5):351–60

Movement of the 3′-end of tRNA through the peptidyl transferase centre and its inhibition by antibiotics. Kirillov S, et al. **FEBS Lett** 1997 Apr 14;406(3):223–33 (165 ref.)

Rifampicin: an inhibitor of Xp12-specific protein phosphorylation in Xanthomonas oryzae pv. oryzae. Cheng CM, et al. **FEMS Microbiol Lett** 1996 Oct 1;143(2–3):141–9

Specific interaction of the protein-D2 porin of Pseudomonas aeruginosa with antibiotics. Ishii J, et al. **FEMS Microbiol Lett** 1996 Feb 1;136(1):85–90

Processing of semen in an antibiotic-rich culture medium to minimize microbial presence during in vitro fertilization. Cottell E, et al. **Fertil Steril** 1997 Jan;67(1):98–103

Antibiotics: effect on cryopreserved-thawed human sperm motility in vitro. King K, et al. **Fertil Steril** 1997 Jun; 67(6):1146–51

Changes in macrophage function during chemotherapy. Vučković D, et al. **Folia Biol (Praha)** 1997;43(1):33–8

New azidometalkojates and their biological activity. Hudecová D, et al. **Folia Microbiol (Praha)** 1996; 41(6):473–6

A new substance (Yoshixol) with an interesting antibiotic mechanism from wood oil of Japanese traditional tree (Kiso-Hinoki), Chamaecyparis obtusa. Koyama S, et al. **Gen Pharmacol** 1997 May;28(5):797–804

Cloning of a gene from Escherichia coli that confers resistance to fosmidomycin as a consequence of amplification. Fujisaki S, et al. **Gene** 1996 Oct 10; 175(1–2):83–7

Antibiotics and garlic clove extract—inhibitory agents of cell wall degrading enzymes. Alice D, et al. **Hindustan Antibiot Bull** 1995 Feb–Nov;37(1–4):44–7

Nonabsorbable antibiotics reduce bacterial and endotoxin translocation in hepatectomised rats. Kakkos SK, et al. **HPB Surg** 1997;10(5):283–9; discussion 289–91

The spectrum of antimicrobial resistance among methicillin resistant Staphylococcus aureus (MRSA) in a tertiary care centre in India. Pulimood TB, et al. **Indian J Med Res** 1996 Apr;103:212–5

Antibiogram study over bacterial isolates from cases of bacteraemias. Nema S, et al. **Indian J Med Sci** 1996 Sep; 50(9):325–9

Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units. Manian FA, et al. **Infect Control Hosp Epidemiol** 1996 Apr;17(4):222–6

Porphyromonas gingivalis lipopolysaccharide-stimulated bone resorption via CD14 is inhibited by broad-spectrum antibiotics. Miyata Y, et al. **Infect Immun** 1997 Sep; 65(9):3513–9

In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Baradaran-Dilmaghani R, et al. **Infection** 1996 Jan–Feb; 24(1):60–3

Staphylococcus aureus sensitivity to various antibiotics—a national survey in Ireland 1993. Moorhouse E, et al. **Ir J Med Sci** 1996 Jan–Mar;165(1):40–3

Swelling of collagen intracanalicular implants. Lowther GE, et al. **J Am Optom Assoc** 1997 Jan;68(1):38–42

Ardacin for steers grazing endophyte-free fescue pasture: effects on live weight gain, forage intake, nitrogen and fiber digestion, ruminal fluid kinetics, ruminal fermentation, and serum hormones and metabolites. Judkins MB, et al. **J Anim Sci** 1997 Apr;75(4):1100–11

XR651, a novel naphthacene-5,12-dione. Bahl S, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):169–71

APHE-3 and APHE-4, two new pyrazoloisoquinolinone antibiotics produced by Streptoverticillium griseocarneum NCIMB 40447. Cruz R, et al. **J Antibiot (Tokyo)** 1996 Jul; 49(7):700–2

Chlovalicin, a new cytocidal antibiotic produced by Sporothrix sp. FO-4649. I. Taxonomy, fermentation, isolation and biological activities. Hayashi M, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):631–4

41-Demethylhomooligomycin B, a new immunosuppresant antibiotic from Streptomyces ostreogriseus. Kim HS, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1275–7

New piericidin antibiotics, 7-demethylpiericidin A1 and 7-demethyl-3′-rhamnopiericidin A1. Kimura K, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):697–9

Antimicrobial activities of chemically modified thiazolyl peptide antibiotic MDL 62,879 (GE2270A). Lociuro S, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):344–9

Lactonamycin, a new antimicrobial antibiotic produced by Streptomyces rishiriensis [letter] Matsumoto N, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):953–4

Aflastatin A, a novel inhibitor of aflatoxin production by aflatoxigenic fungi. Ono M, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):111–8

Dihydrophencomycin methyl ester, a new phenazine derivative from a marine Streptomycete. Pusecker K, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):479–83

Inhibitors of type-I interleukin-1 receptor from microbial metabolites. Stefanelli S, et al. **J Antibiot (Tokyo)** 1997 Jun; 50(6):484–9

Synthesis and biological evaluation of new fragments from kirromycin antibiotic. Tavecchia P, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1249–57

Susceptibility of some strains of enterococci and streptococci to antibiotics and biocides [letter] Alqurashi AM, et al. **J Antimicrob Chemother** 1996 Oct;38(4):745

Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. Baquero F. **J Antimicrob Chemother** 1996 Jul;38 Suppl A:117–32

The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro. Barclay ML, et al. **J Antimicrob Chemother** 1996 Nov;38(5):853–8

Comparative in-vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin-and macrolide-resistant pneumococci by the Etest [letter] Biedenbach D, et al. **J Antimicrob Chemother** 1996 Sep; 38(3):553–5

The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria. Bowker KE, et al. **J Antimicrob Chemother** 1996 Aug;38(2):271–81

The pharmacokinetics and protein-binding of fusidic acid in patients with severe renal failure requiring either haemodialysis or continuous ambulatory peritoneal dialysis. Brown NM, et al. **J Antimicrob Chemother** 1997 Jun; 39(6):803–9

Decreased susceptibility to antibiotic killing of a stable small colony variant of Staphylococcus aureus in fluid phase and on fibronectin-coated surfaces. Chuard C, et al. **J Antimicrob Chemother** 1997 May;39(5):603–8

The Garrod Lecture. Evasion of antibiotic action by bacteria. Courvalin P. **J Antimicrob Chemother** 1996 May; 37(5):855–69 (79 ref.)

Anti-candidal activity of mupirocin-evidence for uptake via an amino acid transport system [letter] De Wet PM, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1107–8

Relevance of the Alexander Project: pharmacodynamic considerations. Drusano GL, et al. **J Antimicrob Chemother** 1996 Jul;38 Suppl A:141–54

Antimicrobial susceptibility of Haemophilus influenzae, Neisseria meningitidis and Streptococcus pneumoniae isolates causing meningitis in The Netherlands, 1993–1994. Enting RH, et al. **J Antimicrob Chemother** 1996 Nov; 38(5):777–86

Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter coli. Gaudreau C, et al. **J Antimicrob Chemother** 1997 Jun;39(6):707–12

Comparative in-vitro activity of cefoperazone/sulbactam and 11 other agents against multidrug resistant Bacteroides fragilis group species. Goldstein EJ, et al. **J Antimicrob Chemother** 1996 Oct;38(4):733–7

The Alexander Project: using in-vitro susceptibility data for choosing empirical therapy in LRTI. Grüneberg RN. **J Antimicrob Chemother** 1996 Jul;38 Suppl A:155–70

Synergy between aminoglycosides and penicillin, teicoplanin and cefpirome in enterococci [letter] Gutiérrez J, et al. **J Antimicrob Chemother** 1996 Oct;38(4):751–2

Construction and interpretation of isobolograms [letter] Hamilton-Miller JM. **J Antimicrob Chemother** 1995 Dec; 36(6):1104–5

Observations on the possible origin of Mycoplasma fermentans incognitus strain based on antibiotic sensitivity tests. Hannan PC. **J Antimicrob Chemother** 1997 Jan; 39(1):25–30

Comparison of the Etest with agar dilution for antimicrobial susceptibility testing of Haemophilus ducreyi. Lagergård T, et al. **J Antimicrob Chemother** 1996 Nov;38(5):849–52

Correlation between bactericidal activity and postantibiotic effect for five antibiotics with different mechanisms of action. Li RC, et al. **J Antimicrob Chemother** 1997 Jul; 40(1):39–45

Profile and trend of antimicrobial resistance of non-opportunistic bacterial pathogens isolated from patients with HIV infection [letter] Manfredi R, et al. **J Antimicrob Chemother** 1996 Nov;38(5):910–3

Distribution of Streptococcus pneumoniae resistant to penicillin in the USA and in-vitro susceptibility to selected oral antibiotics. Mason EO, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1043–8

Antibacterial activity of T-5575, a novel 2-carboxypenam, and its stability to beta-lactamase. Matsumura N, et al. **J Antimicrob Chemother** 1997 Jan;39(1):31–4

Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro. Midolo PD, et al. **J Antimicrob Chemother** 1997 Mar; 39(3):331–7

In-vitro activity of psychiatric drugs against Corynebacterium urealyticum (Corynebacterium group D2). Muñoz-Bellido JL, et al. **J Antimicrob Chemother** 1996 May;37(5):1005–9

Activity of fosfomycin in a rabbit model of experimental pneumococcal meningitis. Nau R, et al. **J Antimicrob Chemother** 1995 Dec;36(6):997-1004

Lack of resistance to erythromycin, rifampicin and ciprofloxacin in 98 clinical isolates of Legionella pneumophila. Onody C, et al. **J Antimicrob Chemother** 1997 Jun;39(6):815-6

Antibiotic susceptibilities of 38 non-toxigenic strains of Corynebacterium diphtheriae [letter] Patey O, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1108-10

Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae. Pikis A, et al. **J Antimicrob Chemother** 1997 Jul;40(1):105-8

No increase in endotoxin release during antibiotic killing of meningococci. Prins JM, et al. **J Antimicrob Chemother** 1997 Jan;39(1):13-8

A multinational European survey on the in-vitro activity of rufloxacin and other comparative antibiotics on respiratory and urinary bacterial pathogens. Schito GC, et al. **J Antimicrob Chemother** 1996 Oct;38(4):627-39

Postantibiotic effect and host-bacteria interactions. Shibl AM, et al. **J Antimicrob Chemother** 1995 Dec;36(6):885-7 (23 ref.)

A flow cytometric study of antibiotic-induced damage and evaluation as a rapid antibiotic susceptibility test for methicillin-resistant Staphylococcus aureus. Suller MT, et al. **J Antimicrob Chemother** 1997 Jul;40(1):77-83

In-vitro ranking of the efficacy of antimicrobial agents. Tajima Y. **J Antimicrob Chemother** 1997 Mar;39(3):401-4

In-vitro activity of a new quinolone, clinafloxacin, against clinical isolates of Corynebacterium species [letter] Yagüe G, et al. **J Antimicrob Chemother** 1996 Oct;38(4):740-2

A mechanism of rifamycin inhibition and resistance in Pseudomonas aeruginosa. Yee YC, et al. **J Antimicrob Chemother** 1996 Jul;38(1):133-7

Mechanisms of biocontrol by Pantoea dispersa of sugar cane leaf scald disease caused by Xanthomonas albilineans. Zhang L, et al. **J Appl Microbiol** 1997 Apr;82(4):448-54

Presence of UDP-N-acetylmuramyl-hexapeptides and -heptapeptides in enterococci and staphylococci after treatment with ramoplanin, tunicamycin, or vancomycin. Billot-Klein D, et al. **J Bacteriol** 1997 Aug;179(15):4684-8

Transcription termination factor Rho is essential for Micrococcus luteus. Nowatzke WL, et al. **J Bacteriol** 1997 Aug;179(16):5238-40

In vivo and in vitro effects of thiolactomycin on fatty acid biosynthesis in Streptomyces collinus. Wallace KK, et al. **J Bacteriol** 1997 Jun;179(12):3884-91

The antibiotic bicyclomycin affects the secondary RNA binding site of Escherichia coli transcription termination factor Rho. Magyar A, et al. **J Biol Chem** 1996 Oct 11; 271(41):25369-74

Antibiotics induce genome-wide hypermethylation in cultured Nicotiana tabacum plants. Schmitt F, et al. **J Biol Chem** 1997 Jan 17;272(3):1534-40

Bioluminescence measurements of the antilisterial activity of nisin: comparison with ampicillin and streptomycin. Ukuku DO, et al. **J Biolumin Chemilumin** 1996 May-Jun; 11(3):169-73

Interactions among antibiotics, bacteria and the human immune system: the clinical relevance of in vitro testing. Bergogne-Berezin E. **J Chemother** 1997 May;9 Suppl 1:109-15 (26 ref.)

Biological interactions between antibiotics and bacterial adhesivity. Braga PC. **J Chemother** 1995 Nov;7 Suppl 4:15-7

The susceptibility patterns of the most common Staphylococcus coagulase-negative species to 13 antimicrobials. Dobardzic R, et al. **J Chemother** 1995 Nov; 7 Suppl 4:63-5

Comparative susceptibility patterns of Acinetobacter isolated in different departments of a Kuwaiti hospital. Dobardzic R, et al. **J Chemother** 1995 Nov;7 Suppl 4:66-8

The minimum inhibitory concentration of seventeen antimicrobials for Salmonella isolates from septic patients. Dobardzic R, et al. **J Chemother** 1996 Oct;8(5):369-74

Antibiotic susceptibility of clinical isolates of Prevotella bivia in Lagos, Nigeria. Egwari LO, et al. **J Chemother** 1996 Feb;8(1):47-51

Type frequency and antimicrobial susceptibility of Mycobacterium avium-intracellulare complex strains isolated in Italy from AIDS and non-AIDS patients. Fattorini L, et al. **J Chemother** 1996 Feb;8(1):37-42

In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa. Garcia-Rodriguez JA, et al. **J Chemother** 1996 Oct; 8(5):358-64

Pharmacodynamics and the relationship between in vitro and in vivo activity of antimicrobial agents. Gould IM. **J Chemother** 1997 May;9 Suppl 1:74-83 (61 ref.)

In vitro antimicrobial activity of Pistacia lentiscus L. extracts: preliminary report. Iauk L, et al. **J Chemother** 1996 Jun; 8(3):207-9

Antibiotic susceptibility of hospital staphylococci in Egypt. Kamal El-Din W, et al. **J Chemother** 1995 Nov;7 Suppl 4:81-6

In vitro models for prediction of antimicrobial activity: a pharmacokinetic and pharmacodynamic perspective. Li RC, et al. **J Chemother** 1997 May;9 Suppl 1:55-63 (81 ref.)

Pharmacodynamics of antimicrobial agents and rationale for their dosing. MacGowan AP, et al. **J Chemother** 1997 May; 9 Suppl 1:64-73 (90 ref.)

Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method. Marone P, et al. **J Chemother** 1997 Aug;9(4):247-50

In vitro antibacterial activity of nine oral antibiotics against Branhamella catarrhalis clinical isolates. Paraskaki I, et al. **J Chemother** 1995 Nov;7 Suppl 4:69-70

A comparison of in vitro activity of ten oral antimicrobial agents against respiratory tract pathogens. Platsouka E, et al. **J Chemother** 1995 Nov;7 Suppl 4:58-60

Antimicrobial susceptibility pattern of clinical isolates of pneumococci in an Indian hospital. Revathi-Bhanuprakash G, et al. **J Chemother** 1995 Nov;7 Suppl 4:78-80

Comparison of the serum-supplemented Todd-Hewitt and the new Haemophilus test media for broth microdilution susceptibility testing of Streptococcus pneumoniae. Roger M, et al. **J Chemother** 1996 Jun;8(3):178-87

Outbreak of multi-drug resistant Staphylococcus aureus: a cluster analysis. Yoshida J, et al. **J Clin Epidemiol** 1996 Dec;49(12):1447-52

Species belonging to the "Streptococcus milleri" group: antimicrobial susceptibility and comparative prevalence in significant clinical specimens. Bantar C, et al. **J Clin Microbiol** 1996 Aug;34(8):2020-2

Multicenter laboratory evaluation of the bioMérieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa. Doern GV, et al. **J Clin Microbiol** 1997 Aug;35(8):2115-9

Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center. Emery CL, et al. **J Clin Microbiol** 1997 Aug;35(8):2061-7

Application of the Etest to the antimicrobial susceptibility testing of Mycobacterium marinum clinical isolates. Flynn CM, et al. **J Clin Microbiol** 1997 Aug;35(8):2083-6

Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae. Jorgensen JH, et al. **J Clin Microbiol** 1996 Nov;34(11):2679-84

Proposed MIC quality control guidelines for National Committee for Clinical Laboratory Standards susceptibility tests using seven veterinary antimicrobial agents: ceftiofur, enrofloxacin, florfenicol, penicillin G-novobiocin, pirlimycin, premafloxacin, and spectinomycin. Marshall SA, et al. **J Clin Microbiol** 1996 Aug;34(8):2027-9

Development of resistance to metronidazole and minocycline in vitro. Larsen T, et al. **J Clin Periodontol** 1997 Apr; 24(4):254-9

Antimicrobial susceptibility tests on anaerobic oral mixed cultures in periodontal diseases. Pacini N, et al. **J Clin Periodontol** 1997 Jun;24(6):401-9

The activity of a combination of penicillin and novobiocin against bovine mastitis pathogens: development of a disk diffusion test. Thornsberry C, et al. **J Dairy Sci** 1997 Feb; 80(2):413-21

Activity of selected antimicrobial agents against strains of Staphylococcus aureus isolated from bovine intramammary infections that produce beta-lactamase. Watts JL, et al. **J Dairy Sci** 1997 Apr;80(4):788-91

Changing patterns of the prevalence of different Shigella species and their antibiotic susceptibilities in Ankara, Turkey. Ceyhan M, et al. **J Diarrhoeal Dis Res** 1996 Sep; 14(3):187-9

Multiple drug-resistant Shigella dysenteriae type 1 in Rajbari district, Bangladesh. Jahan Y, et al. **J Diarrhoeal Dis Res** 1997 Mar;15(1):17-20

An ethnobotanical study of the traditional medicine of the Mestizo people of Suni Miraño, Loreto, Peru. Jovel EM, et al. **J Ethnopharmacol** 1996 Sep;53(3):149-56

Differential antibiotic-induced endotoxin release and interleukin-6 production by human umbilical vein endothelial cells (HUVECs): amplification of the response by coincubation of HUVECs and blood cells. Arditi M, et al. **J Infect Dis** 1997 May;175(5):1255-8

Semisynthetic derivatives of purpuromycin as potential topical agents for vaginal infections. Trani A, et al. **J Med Chem** 1997 Mar 14;40(6):967-71

In-vitro effects of penicillin and clindamycin on the expression of Streptococcus pneumoniae capsule. Brook I, et al. **J Med Microbiol** 1996 Dec;45(6):505-6

Throwing a spanner in the works: antibiotics and the translation apparatus. Spahn CM, et al. **J Mol Med** 1996 Aug;74(8):423-39 (150 ref.)

Koningic acid (a potent glyceraldehyde-3-phosphate dehydrogenase inhibitor)-induced fragmentation and condensation of DNA in NG108-15 cells. Nakazawa M, et al. **J Neurochem** 1997 Jun;68(6):2493-9

Effect of tunicamycin on the uptake and incorporation of galactose in Hymenolepis diminuta. Hildreth MB, et al. **J Parasitol** 1997 Aug;83(4):555-8

Re: Antibiotics and periodontal disease [letter] Gillette W. **J Periodontol** 1996 Jul;67(7):726

Effects of antibiotics on epithelial ion transport in the rabbit distal colon in-vitro. Goldhill JM, et al. **J Pharm Pharmacol** 1996 Jun;48(6):651-6

Treatment of multidrug-resistant typhoid fever [letter] Mishra OP, et al. **J Trop Pediatr** 1996 Oct;42(5):310-1

Minimum inhibitory concentrations of selected antimicrobial agents against bacteria isolated from 1-14-day-old broiler chicks. Klein LK, et al. **J Vet Diagn Invest** 1996 Oct; 8(4):494-5

The fractional inhibitory concentration index of antimicrobial agents for bacteria and Mycoplasma isolated from the nasal swabs of cattle with respiratory diseases. Katoh T, et al. **J Vet Med Sci** 1996 Aug;58(8):781-2

Influence of calcium concentration on the antimicrobial activity of lasalocid against Selenomonas ruminantium. Nakamura I, et al. **J Vet Med Sci** 1996 Aug;58(8):755-9

In vitro susceptibility of Escherichia coli strains isolated from diarrhoeic lambs and goat kids to 14 antimicrobial agents. Cid D, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):397-401

Biological activity and mechanistic studies of andrimid. Singh MP, et al. **Jpn J Antibiot** 1997 Mar;50(3):270-3

Model of Streptococcus pneumoniae meningitis in adult rats. Strake JG, et al. **Lab Anim Sci** 1996 Oct;46(5):524-9

Widespread occurrence of integrons causing multiple antibiotic resistance in bacteria [letter] Jones ME, et al. **Lancet** 1997 Jun 14;349(9067):1742-3

Persistence of vancomycin-resistant Enterococcus faecium gastrointestinal tract colonization in antibiotic-treated mice. Dever LL, et al. **Microb Drug Resist** 1996 Winter; 2(4):415-21

Cellular signals regulating antibiotic sensitivities of bacteria. Matsuhashi M, et al. **Microb Drug Resist** 1996 Spring; 2(1):91-3

Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. Gotoh A, et al. **Microbiol Immunol** 1997;41(1):7-12

Antibiotic-induced endotoxin release from bacteria and its clinical significance. Kirikae T, et al. **Microbiol Immunol** 1997;41(4):285-94 (81 ref.)

Natural kirromycin resistance of elongation factor Tu from the kirrothricin producer Streptomyces cinnamoneus. Cappellano C, et al. **Microbiology** 1997 Feb;143 (Pt 2):617-24

SYR2, a gene necessary for syringomycin growth inhibition of Saccharomyces cerevisiae. Cliften P, et al. **Microbiology** 1996 Mar;142 (Pt 3):477-84

The lipid A biosynthesis deficiency of the Escherichia coli antibiotic-supersensitive mutant LH530 is suppressed by a novel locus, ORF195. Hirvas L, et al. **Microbiology** 1997 Jan;143 (Pt 1):73-81

A 32 kb nucleotide sequence from the region of the lincomycin-resistance gene (22 degrees-25 degrees) of the Bacillus subtilis chromosome and identification of the site of the lin-2 mutation. Kumano M, et al. **Microbiology** 1997 Aug;143 (Pt 8):2775-82

A novel fusidic acid resistance gene from Streptomyces lividans 66 encodes a highly specific esterase. von der Haar B, et al. **Microbiology** 1997 Mar;143 (Pt 3):867-74

Drug resistance in Detroit River gram-negative bacilli. Campeau RC, et al. **Microbios** 1996;88(357):205-12

Influence of the culture medium on the inhibitory activity of Arthrinium strains. Larrondo J, et al. **Microbios** 1996; 87(350):39-42

Antibiotic activity of strains of the genus Arthrinium on bacteria and yeasts. Larrondo J, et al. **Microbios** 1997; 89(360-361):163-70

An antibiotic, ascofuranone, specifically inhibits respiration and in vitro growth of long slender bloodstream forms of Trypanosoma brucei brucei [corrected and republished in Mol Biochem Parasitol 1997 Feb;84(2):271-80] Minagawa N, et al. **Mol Biochem Parasitol** 1996 Oct 30;81(2):127-36

An antibiotic, ascofuranone, specifically inhibits respiration and in vitro growth of long slender bloodstream forms of Trypanosoma brucei brucei [corrected and republished article originally printed in Mol Biochem Parasitol 1996 Oct 30;81(2):127-36] Minagawa N, et al. **Mol Biochem Parasitol** 1997 Feb;84(2):271-80

Site-directed mutagenesis using positive antibiotic selection. Bohnsack RN. **Mol Biotechnol** 1997 Apr;7(2):181-8

Antibiotic activity of polyketide products derived from combinatorial biosynthesis: implications for directed evolution. Fu H, et al. **Mol Divers** 1996 Feb;1(2):121-4

An elongation factor Tu (EF-Tu) resistant to the EF-Tu inhibitor GE2270 in the producing organism Planobispora rosea. Soslo M, et al. **Mol Microbiol** 1996 Oct;22(1):43-51

Antibiotics and RNA [editorial; comment] **Nat Struct Biol** 1997 Jun;4(6):421-2. Comment on: Nat Struct Biol 1997 Jun;4(6):483-9.

Effects of intraperitoneal antibiotics on human peritoneal mesothelial cell growth. Yen CJ, et al. **Nephron** 1996; 74(4):694-700

Evaluation of the in vitro activity of seven selected antimicrobial agents to be used for the isolation of human intestinal spirochaetes. Calderaro A, et al. **New Microbiol** 1997 Jan;20(1):35-45

Ocular infections: antibiotics and bacterial adhesion on biomaterials used in ocular surgery. Marone P, et al. **Ophthalmologica** 1995;209(6):315-8

Antibiotic sensitivity of recent clinical isolates from patients with ocular infections. Ooishi M, et al. **Ophthalmologica** 1997;211 Suppl 1:15-24

In vitro susceptibility patterns of nonserotypable Haemophilus influenzae from patients with chronic bronchitis. Butt HL, et al. **Pathology** 1997 Feb;29(1):72-5

Disc susceptibility testing for thermomphilic campylobacters. Huysmans MB, et al. **Pathology** 1997 May;29(2):209-16

In vitro activity of meropenem compared to nine other antimicrobial agents: importance of its stability when used in agar dilution systems. Mudaliar UA, et al. **Pathology** 1996 Nov;28(4):352-5

A pediatrician's view. More rifle, less shotgun [editorial] Altemeier WA 3rd. **Pediatr Ann** 1996 Sep;25(9):474, 487,

500
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Craig WA, et al. **Pediatr Infect Dis J** 1996 Mar;15(3):255–9 (30 ref.)
Prevalence of antimicrobial resistance among pneumococcal isolates from children with otitis media in southern Israel. Goldbart A, et al. **Pediatr Infect Dis J** 1997 May; 16(5):521–3
Bilateral empyema and pneumonia due to chloramphenicol–resistant Haemophilus influenzae type b. Chang AB, et al. **Pediatr Pulmonol** 1996 Sep;22(3):207–9
In vitro testing of antibiotics. Ackerman BH, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2):201–17 (161 ref.)
The influence of postantibiotic effects and postantibiotic effects of sub–inhibitory concentrations of quinolones and aminoglycosides on phospholipase C of Pseudomonas aeruginosa. Hybenová D, et al. **Pharmazie** 1997 Feb; 52(2):157–9
In vitro activity of synthetic bromo analogs of pyrrolmycins against clinical Staphylococcus aureus strains. Schillaci D, et al. **Pharmazie** 1996 Jan;51(1):64
Virginiamycin and caloric density effects on live performance, blood serum metabolite concentration, and carcass composition of broilers reared in thermoneutral and cycling ambient temperatures. Belay T, et al. **Poult Sci** 1996 Nov;75(11):1383–92
Additional information of antimicrobial susceptibility of enterococci in Mexico [letter] Solórzano Santos F, et al. **Rev Invest Clin** 1996 Sep–Oct;48(5):407–8
Incidence of bacterial colonization in the throat and in urines at paediatric age with evaluation of sensitivity to common antibiotics. Catania S, et al. **Riv Eur Sci Med Farmacol** 1996 Jul–Aug;18(4):169–72
Salmonella infections: a retrospective 10–year analysis of 134 cases in a regional hospital in Taiwan. Yang CH, et al. **Scand J Infect Dis** 1996;28(2):171–5
Susceptibility testing of bacteria and fungi. Report from "the Norwegian Working Group on Antibiotics". Bergan T, et al. **Scand J Infect Dis Suppl** 1997;103:1–36
Assay of antibiotic susceptibility of Chlamydia pneumoniae. Hjelm E, et al. **Scand J Infect Dis Suppl** 1997;104:13–4
Pharmacological therapy of Helicobacter pylori infection. Hoffman JS. **Semin Gastrointest Dis** 1997 Jul;8(3):156–63
Antimicrobial susceptibilities of strains of Neisseria gonorrhoeae in Bangkok, Thailand: 1994–1995. Knapp JS, et al. **Sex Transm Dis** 1997 Mar;24(3):142–8
Atracurium and persistent paralysis [letter; comment] Marinella MA. **South Med J** 1997 Jan;90(1):95. Comment on: South Med J 1996 Jun;89(6):624–6.
The synthesis and characterization of analogs of the antimicrobial compound squalamine: 6 beta–hydroxy–3–aminosterols synthesized from hyodeoxycholic acid. Jones SR, et al. **Steroids** 1996 Oct; 61(10):565–71
Influence of antibiotics on posttransfusion platelet increment. Böck M, et al. **Transfusion** 1996 Nov–Dec;36(11–12):952–4 (12 ref.)
Effect of antibiotic luminal flushing on bacterial translocation: experimental study in small bowel autotransplantation in dogs. López F, et al. **Transplant Proc** 1996 Oct;28(5):2642–3
Probing the dynamics of prion diseases with amphotericin B. Adjou KT, et al. **Trends Microbiol** 1997 Jan;5(1):27–31 (31 ref.)
Antibiotic sensitivity of Staphylococcus aureus and Escherichia coli strains isolated in Gondar, Ethiopia [letter] Aseffa A, et al. **Trop Doct** 1997 Apr;27(2):121–2
Influence of antimicrobial agents on bactericidal activity of bovine milk polymorphonuclear leukocytes. Hoeben D, et al. **Vet Immunol Immunopathol** 1997 May;56(3–4):271–82
Application of a modified disc diffusion technique to antimicrobial susceptibility testing of Vibrio anguillarum and Aeromonas salmonicida clinical isolates. Guérin–Faublée V, et al. **Vet Microbiol** 1996 Jul; 51(1–2):137–49
Antimicrobial susceptibility of Bordetella bronchiseptica isolates from cats and a comparison of the agar dilution and E–test methods. Speakman AJ, et al. **Vet Microbiol** 1997 Jan;54(1):63–72
In–vitro antimicrobial susceptibility of Clostridium perfringens from commercial turkey and broiler chicken origin. Watkins KL, et al. **Vet Microbiol** 1997 Feb; 54(2):195–200
Clonal spread of tetracycline–resistant Salmonella typhimurium in Danish dairy herds. Aarestrup FM, et al. **Vet Rec** 1997 Mar 22;140(12):313–4
Characterization of Salmonella dublin and Salmonella typhimurium (Copenhagen) isolates from cattle. Brackelsberg CA, et al. **Vet Res Commun** 1997 Aug; 21(6):409–20
Lachnellins A, B, C, D, and naphthalene–1,3,8–triol, biologically active compounds from a Lachnellula species (ascomycetes). Semar M, et al. **Z Naturforsch [C]** 1996 Jul–Aug;51(7–8):500–12
Lactarane type sesquiterpenoids as inhibitors of leukotriene biosynthesis and other, new metabolites from submerged cultures of Lentinellus cochleatus (Pers. ex Fr.) Karst. Wunder A, et al. **Z Naturforsch [C]** 1996 Jul–Aug; 51(7–8):493–9
Susceptibility to antimicrobial agents of Streptococcus suis capsular type 2 strains isolated from pigs. Seol B, et al. **Zentralbl Bakteriol** 1996 Mar;283(3):328–31
Therapeutic and prophylactic effect of prepartum antibiotic infusion in heifers. Owens WE, et al. **Zentralbl Veterinarmed [B]** 1996 Oct;43(8):455–9
[The status of antibiotic sensitivity of Vibrio cholerae 0:1 in Ecuador (letter)] Aldighieri S, et al. **Med Trop (Mars)** 1997;57(1):98 **(Fre)**
[Sensitivity to fosfomycin of multiresistant serotype 012 Pseudomonas aeruginosa. Multicenter study] Dubrous P, et al. **Pathol Biol (Paris)** 1997 Jun;45(6):472–8 (Eng. Abstr.) **(Fre)**
[Antibiotic sensitivity of aerobic gram–negative bacilli isolated from severe infections in 1992: results of a French multicenter study. Groupe d'Etude d'Infections à bacilles à Gram Négatif (GEIGN)] Koeck JL, et al. **Presse Med** 1996 Oct 12;25(30):1363–6 (Eng. Abstr.) **(Fre)**
[Development of resistance in infectious agents of agricultural animals in Germany (1990–1994)—a review] Trolldenier H. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul; 103(7):256–60 (9 ref.) (Eng. Abstr.) **(Ger)**
[Growth inhibition of human pancreatic cancer by farnesyl transferase inhibitor] Kainuma O, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1657–9 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Screening of phosphatidylinositol turnover inhibitors and regulation of cell cycle progression] Umezawa K, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1578–84 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1995)] Ikemoto H, et al. **Jpn J Antibiot** 1997 May;50(5):421–59 (Eng. Abstr.) **(Jpn)**
[Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)] Ikemoto H, et al. **Jpn J Antibiot** 1996 Jan;49(1):34–70 (Eng. Abstr.) **(Jpn)**
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). III. Differences in susceptibilities from previous years] Kumamoto Y, et al. **Jpn J Antibiot** 1997 Apr;50(4):306–410 (Eng. Abstr.) **(Jpn)**
[Mechanism of fosfomycin–resistance in clinical isolates] O'Hara K, et al. **Jpn J Antibiot** 1996 Jun;49(6):533–43 (61 ref.) **(Jpn)**
[Isolation rate of Pseudomonas aeruginosa from surgical infections and their susceptibilities] Shinagawa N, et al. **Jpn J Antibiot** 1996 Jun;49(6):544–54 (Eng. Abstr.) **(Jpn)**
[Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents. Special references to bacteria isolated between July 1994 and June 1995] Shinagawa N, et al. **Jpn J Antibiot** 1996 Sep;49(9):849–91 (Eng. Abstr.) **(Jpn)**
[Evaluation of antibiotics used for enterohemorrhagic Escherichia coli O157 enteritis—effect of various antibiotics on extracellular release of verotoxin] Ito T, et al. **Kansenshogaku Zasshi** 1997 Feb;71(2):130–5 (Eng. Abstr.) **(Jpn)**
[The taxonomic distribution, characteristic and susceptibility against antimicrobial agents of methicillin–resistant staphylococci isolated from blood] Kawaguchi E, et al. **Kansenshogaku Zasshi** 1996 Nov;70(11):1147–53 (Eng. Abstr.) **(Jpn)**
[Antimicrobial susceptibility of coagulase negative staphylococci isolated from urine] Uesugi A, et al. **Kansenshogaku Zasshi** 1996 Feb;70(2):187–97 (Eng. Abstr.) **(Jpn)**
[Kinds of antimicrobial agents and their mode of actions] Yokota T. **Nippon Rinsho** 1997 May;55(5):1155–60 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Novel utilization of antibiotics—a finding method of damaged parts in bacteria] Sawai J, et al. **Nippon Saikingaku Zasshi** 1996 Feb;51(2):589–99 (15 ref.) **(Jpn)**
[How antibiotics gain and lose their activities] Hashimoto H. **Nippon Seikeigeka Gakkai Zasshi** 1996 Nov; 70(11):727–39 (0 ref.) **(Jpn)**
[Determination of in vitro synergy when amphotericin B is combined with various antimicrobial agents against yeasts by using a colorimetric microdilution checkerboard] Yamane N, et al. **Rinsho Byori** 1997 Jul;45(7):689–95 (Eng. Abstr.) **(Jpn)**
[Synthesis and antibacterial properties of pyrido[2,3–b]pyrazine derivatives] Miyazawa T, et al. **Yakugaku Zasshi** 1997 Feb;117(2):126–32 (Eng. Abstr.) **(Jpn)**
[The influence of selected antibiotics on the central action of aminophyllines—experimental studies] Szmygin K. **Pneumonol Alergol Pol** 1996;64 Suppl 1:63–9 (Eng. Abstr.) **(Pol)**
[Multicenter study of isolated micro–organisms resistant to antimicrobials in 10 Portuguese hospitals in 1994] Cristino JM, et al. **Acta Med Port** 1996 Apr–Jun;9(4–6):141–50 (Eng. Abstr.) **(Por)**
[An estimation of the degree of antibiotic sensitivity of microbial strains isolated in pediatric and neonatal wards] Coşniţă M, et al. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan–Jun;42(1–2):15–20 **(Rum)**
[The sensitivity of Salmonella strains in diarrheal disease to new quinolones compared with other antimicrobial substances] David E, et al. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jan–Jun; 41(1–2):43–6 (Eng. Abstr.) **(Rum)**
[An antibiotic sensitivity study of Klebsiella sp. strains isolated between the years 1994 and 1996] Ionescu G, et al. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan–Jun; 42(1–2):45–9 **(Rum)**
[The comparative aspects of the behavior of antimicrobial agents against 1299 Shigella strains isolated in the years 1977, 1986 and 1995] Lucinescu S, et al. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan–Jun; 42(1–2):39–44 **(Rum)**
[The antibiotic susceptibility of Campylobacter strains isolated in Moldova. The possibilities for estimation and the results] Sicinschi L. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jul–Dec; 41(3–4):123–9 (Eng. Abstr.) **(Rum)**
[The comparative results of the antibiograms for Mycobacterium tuberculosis performed in 2 different laboratories] Homorodean D, et al. **Pneumoftiziologia** 1997 Jan–Mar;46(1):21–2 (Eng. Abstr.) **(Rum)**
[Effect of medium temperature and pH on the sensitivity of pathogenic pseudomonads to chemotherapeutic agents] Iliukhin VI, et al. **Antibiot Khimioter** 1997;42(4):21–3 (Eng. Abstr.) **(Rus)**
[Antibiotic sensitivity of Vibrio cholerae 01, isolated in the Ukraine in 1994] Khaitovich AB, et al. **Antibiot Khimioter** 1996 Jun;41(6):25–8 (Eng. Abstr.) **(Rus)**
[Comparison of the results of determining antibiotic sensitivity on AGV medium and on Mueller–Hinton and isosensitest agars] Kozlov RS, et al. **Antibiot Khimioter** 1996;41(10):22–7 (Eng. Abstr.) **(Rus)**
[The sensitivity of Pseudomonas mallei strains to antibacterial preparations in in–vitro experiments on a cell culture model] Manzeniuk IN, et al. **Antibiot Khimioter** 1996; 41(11):14–7 (Eng. Abstr.) **(Rus)**
[A new metabolite with fungistatic and bacteriostatic activity, produced by strain L–30 of Flavobacterium sp.] Shenin IuD, et al. **Antibiot Khimioter** 1996 May;41(5):6–12 (Eng. Abstr.) **(Rus)**
[Comparative characterization of the sensitivity of regional strains of various microorganisms to cefuroxime and other antibiotics] Veselov AIa, et al. **Antibiot Khimioter** 1996; 41(10):32–4 **(Rus)**
[Specificity and time of the appearance of His+ reversions induced by histidine starvation in Salmonella typhimurium] Gizatullin FSh, et al. **Genetika** 1996 Oct;32(10):1333–40 (Eng. Abstr.) **(Rus)**
[Sensitivity of dissociation variants of Micrococcus luteus to the action of delta–endotoxins of Bacillus thuringiensis] Iudina TG, et al. **Mikrobiologiia** 1996 May–Jun;65(3):365–9 (Eng. Abstr.) **(Rus)**
[Antibiotic and electrochemical properties of some natural ionophoric compounds from streptomycetes] Sverdlova AN, et al. **Mol Gen Mikrobiol Virusol** 1997;(2):29–33 (Eng. Abstr.) **(Rus)**
[The effect of the prodigiozan stimulation of Kupffer cells on the development of perisinusoidal fibrosis in experimental hypervitaminosis A] Vishnevskaia EK. **Morfologiia** 1996;110(5):91–5 (Eng. Abstr.) **(Rus)**
[Antimicrobial and immunomodulatory activities of Lactobacillus acidophilus Ke–10] Zalashko MV, et al. **Prikl Biokhim Mikrobiol** 1997 May–Jun;33(3):305–9 (Eng. Abstr.) **(Rus)**
[Stimulation of regenerative processes and correction of the functional activity of the liver in its partial resection and toxic lesions] Abakumova OIu, et al. **Vestn Ross Akad Med Nauk** 1996;(5):36–41 (Eng. Abstr.) **(Rus)**
[The effect of drug preparations on the expression of the persistence properties of uropathogenic strains of enterobacteria] Chelpachenko OE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May–Jun; (3):84–6 (Eng. Abstr.) **(Rus)**
[The use of a method of estimating the count of viable Rickettsia prowazekii for the screening of efficacious antibiotics] Predtechenskiĭ AB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Mar–Apr;(2):3–5 (Eng. Abstr.) **(Rus)**
[Antimicrobial agents and adhesion of coagulase–negative staphylococci] Gómez–García AC, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):261–6 (55 ref.) **(Spa)**
[Antimicrobial activity in Staphylococcus epidermidis biofilms on polyvinyl chloride catheters] Ramírez de Arellano E, et al. **Enferm Infecc Microbiol Clin** 1995 Dec; 13(10):581–6 (Eng. Abstr.) **(Spa)**
[Bactericide activity of sulbactam before bacteria belonging to the Acinetobacter calcoaceticus–Acinetobacter baumannii complex] Villar HE, et al. **Enferm Infecc Microbiol Clin** 1996 Nov;14(9):524–7 (Eng. Abstr.) **(Spa)**
[Antimicrobial activity and interaction with DNA of medicinal plants from the Peruvian Amazon region] Mongelli E, et al. **Rev Argent Microbiol** 1995 Oct–Dec; 27(4):199–203 (Eng. Abstr.) **(Spa)**
[Pharmacology and drug interactions in antimicrobial treatment in transplantation recipients] Azanza Perea JR, et al. **Rev Clin Esp** 1995 Oct;195 Spec No:44–51 **(Spa)**
[Identification of Enterococcus species from clinical samples and their antimicrobial susceptibility] Giglio MS, et al. **Rev Med Chil** 1996 Jan;124(1):70–6 (Eng. Abstr.) **(Spa)**

[In vitro comparative activity (E test) of sparfloxacin and other 8 antimicrobial agents against bacteria isolated from patients with respiratory infections acquired in the community] Prado V, et al. **Rev Med Chil** 1995 Nov; 123(11):1394–1401 (Eng. Abstr.) **(Spa)**

[Antimicrobial susceptibility of Streptococcus pneumoniae colonizing the nasopharynx of Colombian children with pneumonia] Leal AL, et al. **Rev Panam Salud Publica** 1997 Apr;1(4):266–72 **(Spa)**

POISONING

Using MTT viability assay to test the cytotoxicity of antibiotics and steroid to cultured porcine corneal endothelial cells. Wang HZ, et al.
J Ocul Pharmacol Ther 1996 Spring;12(1):35–43

Acute maduramicin toxicity in calves. Shlosberg A, et al. **Vet Rec** 1997 Jun 21;140(25):643–6

STANDARDS

Clinical trials of new antibiotics in children in Japan. Fujii R. **Acta Paediatr Jpn** 1997 Feb;39(1):98–104

THERAPEUTIC USE

Topical lomefloxacin twice daily compared with fucidic acid in acute bacterial conjunctivitis. Malminiemi K, et al.
Acta Ophthalmol Scand 1996 Jun;74(3):280–4

The effect of antibiotic treatment on the release of endotoxin during nontypable Haemophilus influenzae–induced otitis media in the chinchilla. Jauris–Heipke S, et al.
Acta Otolaryngol (Stockh) 1997 Jan;117(1):109–12

Transitional concentration of antibacterial agent to the maxillary sinus via a nebuliser. Kondo H, et al.
Acta Otolaryngol Suppl (Stockh) 1996;525:64–7

Antimicrobial ear drop medication therapy. Suzuki K, et al.
Acta Otolaryngol Suppl (Stockh) 1996;525:68–72

Antibiotic–resistance in Streptococcus pneumoniae. Krisher K. **Adv Exp Med Biol** 1995;390:123–40 (102 ref.)

Infection surveillance and antibiotic utilization in a community–based skilled nursing facility. Lee YL, et al.
Aging (Milano) 1996 Apr;8(2):113–22

Rhodococcus equi infections: antibiotic therapy and relapses [letter; comment] Giacometti A, et al. **AIDS** 1997 Jan; 11(1):120–1. Comment on: AIDS 1996 Apr;10(4):359–62.

HIV–associated lymphoma. Kaplan LD. **AIDS Clin Rev** 1997–98;:349–73 (80 ref.)

Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Penston JG.
Aliment Pharmacol Ther 1996 Aug;10(4):469–86 (200 ref.)

The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Peterson WL.
Aliment Pharmacol Ther 1997 Apr;11 Suppl 1:21–5 (36 ref.)

The treatment of Helicobacter pylori infection. Pounder RE, et al. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:35–41 (35 ref.)

Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. Spinzi G, et al.
Aliment Pharmacol Ther 1997 Apr;11(2):317–22

The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori. Wyeth JW, et al.
Aliment Pharmacol Ther 1996 Aug;10(4):623–30

Community–acquired pneumonia in adults: initial antibiotic therapy. King DE, et al. **Am Fam Physician** 1997 Aug; 56(2):544–50 (27 ref.)

A new stable pluronic F68 gel carrier for antibiotics in contaminated wound treatment. Faulkner DM, et al.
Am J Emerg Med 1997 Jan;15(1):20–4

Testing for Helicobacter pylori infection after antibiotic treatment [editorial; comment] Katelaris PH, et al.
Am J Gastroenterol 1997 Aug;92(8):1245–7. Comment on: Am J Gastroenterol 1997 Aug;92(8):1268–74.

Two products released for H. pylori treatment [news]
Am J Health Syst Pharm 1996 Nov 1;53(21):2556

New trends in the drug therapy of localized and disseminated Mycobacterium avium complex infection [see comments] Sesin GP, et al. **Am J Health Syst Pharm** 1996 Nov 1; 53(21):2585–90 (29 ref.). Comment in: Am J Health Syst Pharm 1997 May 15;54(10):1208–9.

Antimicrobials prescribed for otitis media in a pediatric Medicaid population. White LL, et al.
Am J Health Syst Pharm 1996 Dec 15;53(24):2963–9

Measuring antibiotic use in a long–term care facility. Mylotte JM. **Am J Infect Control** 1996 Jun;24(3):174–9

Experience with a hospital–wide outbreak of vancomycin–resistant enterococci. Quale J, et al.
Am J Infect Control 1996 Oct;24(5):372–9

The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Burman WJ. **Am J Med Sci** 1997 Jun; 313(6):355–63 (100 ref.)

Use of antibiotics to prevent preterm birth. Gibbs RS, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):375–80 (35 ref.)

Consistent definition of outcomes—a prerequisite for metaanalysis [letter; comment] Lacy JB, et al.
Am J Obstet Gynecol 1996 Nov;175(5):1394–5. Comment on: Am J Obstet Gynecol 1996 Feb;174(2):589–97.

Antibiotic treatment for preterm premature rupture of membranes [letter; comment] Mercer BM.
Am J Obstet Gynecol 1996 Sep;175(3 Pt 1):755–6. Comment on: Am J Obstet Gynecol 1996 Feb;174(2):589–97.

Intravenous antibiotics for endophthalmitis [editorial; comment] Davis JL. **Am J Ophthalmol** 1996 Nov; 122(5):724–6 (18 ref.). Comment on: Am J Ophthalmol 1996 Nov;122(5):678–83. Comment on: Am J Ophthalmol 1996 Nov;122(5):684–9.

Increased intrapartum antibiotic administration associated with epidural analgesia in labor. Mayer DC, et al.
Am J Perinatol 1997 Feb;14(2):83–6

Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Lynch JP 3rd, et al.
Am J Respir Crit Care Med 1997 Feb;155(2):395–420 (353 ref.)

The value of routine microbial investigation in ventilator–associated pneumonia. Rello J, et al.
Am J Respir Crit Care Med 1997 Jul;156(1):196–200

Antimicrobial therapy for intraabdominal infection. Nathens AB, et al. **Am J Surg** 1996 Dec;172(6A):1S–6S (27 ref.)

Experimentally induced Bartonella henselae infections followed by challenge exposure and antimicrobial therapy in cats. Regnery RL, et al. **Am J Vet Res** 1996 Dec; 57(12):1714–9

Varicella pneumonia in adults—clinical spectrum. Oh HM, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):816–9

Corneal ulcers in two institutions in Singapore: analysis of causative factors, organisms and antibiotic resistance. Tan DT, et al. **Ann Acad Med Singapore** 1995 Nov;24(6):823–9

Treatment of erythema migrans [letter; comment] Collins JJ. **Ann Intern Med** 1997 Mar 1;126(5):408; discussion 408–9 . Comment on: Ann Intern Med 1996 May 1;124(9):785–91.

Treatment of erythema migrans [letter; comment] Patmas MA. **Ann Intern Med** 1997 Mar 1;126(5):408; discussion 408–9. Comment on: Ann Intern Med 1996 May 1;124(9):785–91.

Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic–resistant bacteria. Tzianabos AO, et al.
Ann N Y Acad Sci 1996 Oct 25;797:285–7

Oral antibiotic therapy in infective endocarditis. Fuller RE, et al. **Ann Pharmacother** 1996 Jun;30(6):676–8

Antibiotic use in children with febrile seizures [letter] [corrected and republished letter originally printed in Ann Pharmacother 1996 Jan;30(1):85] James C, et al.
Ann Pharmacother 1996 Mar;30(3):301–2

Management of otitis media with effusion in young children. Paap CM. **Ann Pharmacother** 1996 Nov;30(11):1291–7 (19 ref.)

Undertreatment and overtreatment of patients with infected antiarrhythmic implantable devices. Molina JE.
Ann Thorac Surg 1997 Feb;63(2):504–9

Therapeutic aspects of typhoidal salmonellosis in childhood: the Karachi experience. Bhutta ZA. **Ann Trop Paediatr** 1996 Dec;16(4):299–306

Dexamethasone adjunctive therapy for bacterial meningitis in children: a retrospective study in Brazil. Macaluso A, et al. **Ann Trop Paediatr** 1996 Sep;16(3):193–8

Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis. Araujo FG, et al.
Antimicrob Agents Chemother 1997 Jan;41(1):188–90

Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients. Dautzenberg B, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1722–5

Protein binding of clindamycin in sera of patients with AIDS. Flaherty JF Jr, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1134–8

Treatment of experimental pneumonia due to penicillin–resistant Streptococcus pneumoniae in immunocompetent rats. Gavaldà J, et al.
Antimicrob Agents Chemother 1997 Apr;41(4):795–801

Clindamycin therapy of experimental meningitis caused by penicillin– and cephalosporin–resistant Streptococcus pneumoniae. París MM, et al.
Antimicrob Agents Chemother 1996 Jan;40(1):122–6

Noncompromised penicillin–resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Tateda K, et al.
Antimicrob Agents Chemother 1996 Jun;40(6):1520–5

Efficacy of clarithromycin versus that of clindamycin for single–dose prophylaxis of experimental streptococcal endocarditis. Vermot D, et al.
Antimicrob Agents Chemother 1996 Mar;40(3):809–11

Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott–Aldrich syndrome. Litzman J, et al. **Arch Dis Child** 1996 Nov;75(5):436–9

Secondary cases of meningococcal disease [letter] Pollard AJ, et al. **Arch Dis Child** 1996 Dec;75(6):546–7

Antibiotic use during the first 200 days of life. Bergus GR, et al. **Arch Fam Med** 1996 Oct;5(9):523–6

Antibiotic optimization. An evaluation of patient safety and economic outcomes. Fraser GL, et al. **Arch Intern Med** 1997 Aug 11–25;157(15):1689–94

Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori [see comments] Taylor JL, et al. **Arch Intern Med** 1997 Jan 13;157(1):87–97. Comment in: ACP J Club 1997 Jul–Aug;127(1):22.

Antibiotic prophylaxis for bacterial endocarditis: an evolving story with new paradigms [letter] Zuccaro G Jr, et al.
Arch Intern Med 1997 Jan 13;157(1):130, 132–3

Strategies for managing group A streptococcal pharyngitis. A survey of board–certified pediatricians. Hofer C, et al.
Arch Pediatr Adolesc Med 1997 Aug;151(8):824–9

A randomized controlled trial of penicillin vs clindamycin for the treatment of aspiration pneumonia in children. Jacobson SJ, et al. **Arch Pediatr Adolesc Med** 1997 Jul; 151(7):701–4

Home and hospital intravenous therapy for two acute infections: an early study. Montalto M, et al.
Aust N Z J Med 1997 Feb;27(1):19–23

Factors associated with the effectiveness of antibiotic treatment for ovine virulent footrot. Jordan D, et al.
Aust Vet J 1996 Jun;73(6):211–5

Cerebral gliomas. Growth factors and angiogenesis. Weingart JD, et al. **Baillieres Clin Neurol** 1996 Jun;5(2):307–18 (56 ref.)

Prevalence of antibiotic resistance in pneumococci .... and Merseyside... [letter; comment] Allen KD, et al. **BMJ** 1996 Sep 28;313(7060):820. Comment on: BMJ 1996 Jun 8;312(7044):1454–6.

Are antibiotics indicated as initial treatment for children with acute otitis media? A meta–analysis. Del Mar C, et al.
BMJ 1997 May 24;314(7093):1526–9

Antimicrobials for acute otitis media? A review from the International Primary Care Network. Froom J, et al.
BMJ 1997 Jul 12;315(7100):98–102 (58 ref.)

Prevalence of antibiotic resistance in pneumococci ... and Northern Ireland [letter; comment] Goldsmith CE, et al. **BMJ** 1996 Sep 28;313(7060):820. Comment on: BMJ 1996 Jun 8;312(7044):1454–6.

Treating diarrhoea [editorial] Gorbach SL. **BMJ** 1997 Jun 21;314(7097):1776–7

Relation between general practitioners' prescribing of antibacterial drugs and their use of laboratory tests. Kelsey MC, et al. **BMJ** 1996 Oct 12;313(7062):922

Open randomised trial of prescribing strategies in managing sore throat [see comments] Little P, et al. **BMJ** 1997 Mar 8;314(7082):722–7. Comment in: BMJ 1997 Jun 28;314(7098):1904–5. Comment in: BMJ 1997 Jun 28;314(7098):1905.

Trial of prescribing strategies in managing sore throat. Failure to show antibiotic effectiveness was due to inclusion of cases of sore throat of viral origin [letter; comment] McIsaac WJ. **BMJ** 1997 Jun 28;314(7098):1905 . Comment on: BMJ 1997 Mar 8;314(7082):722–7.

Acute otitis media in children [editorial; comment] Majeed A, et al. **BMJ** 1997 Aug 9;315(7104):321–2. Comment on: BMJ 1997 Aug 9;315(7104):350–2.

Intravenous antimicrobial therapy in the community: underused, inadequately resourced, or irrelevant to health care in Britain? [see comments] Nathwani D, et al.
BMJ 1996 Dec 14;313(7071):1541–3. Comment in: BMJ 1997 May 24;314(7093):1551.

Prevalence of antibiotic resistance in pneumococci. Prevalence of resistance to penicillin is higher in east London ... [letter; comment] Wilson P, et al. **BMJ** 1996 Sep 28;313(7060):819–20. Comment on: BMJ 1996 Jun 8;312(7044):1454–6.

Prophylaxis and pre–emptive therapy of bacterial infections following allogeneic bone marrow transplantation in children. Vossen JM, et al. **Bone Marrow Transplant** 1996 Nov;18 Suppl 2:93–6

Acute dentoalveolar infections: an investigation of the duration of antibiotic therapy. Martin MV, et al.
Br Dent J 1997 Aug 23;183(4):135–7

Antibiotic prescription for acute dental conditions in the primary care setting [see comments] Thomas DW, et al. **Br Dent J** 1996 Dec 7–21;181(11–12):401–4. Comment in: Br Dent J 1997 Feb 22;182(4):126.

Hospital antibiotic prescribing successfully modified by 'immediate concurrent feedback' [see comments] Seto WH, et al. **Br J Clin Pharmacol** 1996 Mar;41(3):229–34. Comment in: Br J Clin Pharmacol 1997 Apr;43(4):449–50.

Bacterial vaginosis. Priestley CJ, et al. **Br J Clin Pract** 1996 Sep;50(6):331–4 (26 ref.)

A randomized controlled trial of antibiotics on symptom resolution in patients presenting to their general practitioner with a sore throat. Howe RW, et al.
Br J Gen Pract 1997 May;47(418):280–4

Antimicrobial therapy: toward the future [published erratum appears in Br J Hosp Med 1997 Feb 19–Mar 4;57(4):172] Ellis R, et al. **Br J Hosp Med** 1996 Aug 21–Sep 3; 56(4):145–50 (13 ref.)

Traumatic cerebrospinal fluid leakage: risk factors and the use of prophylactic antibiotics. Choi D, et al.
Br J Neurosurg 1996 Dec;10(6):571–5

An audit of antibiotic prescribing in third molar surgery. Thomas DW, et al. **Br J Oral Maxillofac Surg** 1997 Apr; 35(2):126–8

Conservative management of infective mastitis and breast abscesses after ultrasonographic assessment. O'Hara RJ, et al. **Br J Surg** 1996 Oct;83(10):1413–4

Acute epididymitis in boys: are antibiotics indicated? Lau P, et al. **Br J Urol** 1997 May;79(5):797–800

Standard management of acute respiratory infections in a children's hospital in Pakistan: impact on antibiotic use and case fatality. Qazi SA, et al. **Bull World Health Organ** 1996; 74(5):501–7

Using antibiotics for acute bronchitis. Evans MF, et al.
Can Fam Physician 1997 Sep;43:1525–6 (4 ref.)

Physicians to break habit [letter; comment] Riley GT.
Can Fam Physician 1996 Dec;42:2344. Comment on: Can Fam Physician 1996 Oct;42:1903–4.

Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer.

O'Brien B, et al. **Can J Gastroenterol** 1997 May-Jun; 11(4):323-31

Evaluation of florfenicol for the treatment of undifferentiated fever in feedlot calves in western Canada. Booker CW, et al. **Can Vet J** 1997 Sep;38(9):555-60

Antimicrobial therapy of urinary tract infections. Dowling PM. **Can Vet J** 1996 Jul;37(7):438-41 (6 ref.)

Controversies in the antibacterial treatment of patients with neutropenia: a matter of comprehension or apprehension? De Pauw BE, et al. **Cancer Invest** 1997;15(1):37-46 (52 ref.)

Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Escalante CP, et al. **Cancer Invest** 1997;15(3):237-42 (25 ref.)

Advances in medical and antibiotic management of infective endocarditis. Kubak BM, et al. **Cardiol Clin** 1996 Aug; 14(3):405-36 (205 ref.)

Serum concentrations and ex vivo inhibitory/bactericidal activity of clindamycin after administration of two oral dosages. Dan M, et al. **Chemotherapy** 1997 Jul-Aug; 43(4):227-31

Rifabutin for experimental pneumococcal meningitis. Schmidt H, et al. **Chemotherapy** 1997 Jul-Aug;43(4):264-71

Role of bacterial biofilms in the chemotherapy of cholangitis with brown pigment stones. Uetera Y, et al. **Chemotherapy** 1996 Sep-Oct;42(5):363-73

Antibiotics in acute bronchitis and exacerbations of chronic bronchitis: what is general practitioners' habit? [letter] Trevisani L, et al. **Chest** 1997 Jun;111(6):1788-9

Specific antibiotic therapy by needle-aspiration for the treatment of osteomyelitis of the pubis. A description of two clinical cases. Corezzola R, et al. **Chir Organi Mov** 1996 Jul-Sep;81(3):311-6 **(Eng, Ita)**

Epidemiological factors influencing the emergence of antimicrobial resistance. Cohen ML. **Ciba Found Symp** 1997;207:223-31; discussion 231-7 (38 ref.)

The effect of monitoring of antibiotic use on decreasing antibiotic resistance in the hospital. Giamarellou H, et al. **Ciba Found Symp** 1997;207:76-86; discussion 86-92 (15 ref.)

Prophylaxis post-transplant. The role of monitoring surveillance bronchoscopy and antimicrobials. Corris PA. **Clin Chest Med** 1997 Jun;18(2):311-8 (38 ref.)

Correlation of seroreactivity with response to antibiotics in pediatric Lyme borreliosis. Fawcett PT, et al. **Clin Diagn Lab Immunol** 1997 Jan;4(1):85-8

Monitoring and management of bacterial resistance to antimicrobial agents: a World Health Organization symposium. Geneva, Switzerland, 29 November-2 December, 1995. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S1-176

Consequences of bacterial resistance to antibiotics in medical practice. Acar JF. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S17-8

Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Arnow PM, et al. **Clin Infect Dis** 1996 Jun;22(6):997-1003

Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia. Barber BA, et al. **Clin Infect Dis** 1996 Oct;23(4):718-22

Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home [letter; comment] Benoit JL, et al. **Clin Infect Dis** 1997 Apr;24(4):743-4. Comment on: Clin Infect Dis 1996 Aug;23(2):418-9.

Therapy for severe community-acquired pneumonia [letter] Berk SL. **Clin Infect Dis** 1997 Jul;25(1):168-9

The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Bradley JS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S213-21 (58 ref.)

Strategies for the rational use of antimicrobials. Couper MR. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S154-6

Clinical significance of extraintestinal Hafnia alvei isolates from 61 patients and review of the literature. Günthard H, et al. **Clin Infect Dis** 1996 Jun;22(6):1040-5 (26 ref.)

How to modify conditions limiting resistance in bacteria in animals and other reservoirs. Helmuth R, et al. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S136-8

A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. Hemsell DL, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S222-30

Antibiotic-lock technique for the treatment of central venous catheter infections [letter; comment] [see comments] Kentos A, et al. **Clin Infect Dis** 1996 Aug;23(2):418-9. Comment on: Clin Infect Dis 1995 Nov;21(5):1286-8. Comment in: Clin Infect Dis 1997 Apr;24(4):743-4.

Bacteriology of dentoalveolar abscesses in patients who have received empirical antibiotic therapy. Külekçi G, et al. **Clin Infect Dis** 1996 Dec;23 Suppl 1:S51-3

Clinical and bacteriologic impact of rifabutin prophylaxis for Mycobacterium avium complex infection in patients with human immunodeficiency virus infection. Maslo C, et al. **Clin Infect Dis** 1997 Mar;24(3):344-9

Disseminated and cerebral infection due to Nocardia farcinica: diagnosis by blood culture and cure with antibiotics alone. Peters BR, et al. **Clin Infect Dis** 1996 Nov;23(5):1165-7

Failure to clear a Roseomonas line infection with antibiotic therapy. Richardson JD. **Clin Infect Dis** 1997 Jul;25(1):155

Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. Wilson SE. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S197-206

Management of listeriosis. Hof H, et al. **Clin Microbiol Rev** 1997 Apr;10(2):345-57 (144 ref.)

Efficacy of antibiotics alone for orthopaedic device related infections. Isiklar ZU, et al. **Clin Orthop** 1996 Nov; (332):184-9

Parental issues in selection of antimicrobial agents for infants and children [see comments] Bauchner H, et al. **Clin Pediatr (Phila)** 1997 Apr;36(4):201-5. Comment in: Clin Pediatr (Phila) 1997 Apr;36(4):207-8.

Risk factors for penicillin-resistant systemic pneumococcal infections in children [see comments] Doone JL, et al. **Clin Pediatr (Phila)** 1997 Apr;36(4):187-91. Comment in: Clin Pediatr (Phila) 1997 Apr;36(4):207-8.

Appropriate principles in the use of antibiotics in children [editorial; comment] Green M. **Clin Pediatr (Phila)** 1997 Apr;36(4):207-8. Comment on: Clin Pediatr (Phila) 1997 Apr;36(4):187-91. Comment on: Clin Pediatr (Phila) 1997 Apr;36(4):193-9. Comment on: Clin Pediatr (Phila) 1997 Apr;36(4):201-5.

Antibacterial therapy in pregnancy and neonates. Edwards MS. **Clin Perinatol** 1997 Mar;24(1):251-66 (78 ref.)

Pharmacokinetic optimisation of the treatment of septic arthritis. Hamed KA, et al. **Clin Pharmacokinet** 1996 Aug; 31(2):156-63 (32 ref.)

Streptococcal pharyngitis: is penicillin still the right choice? Pichichero ME. **Compr Ther** 1996 Dec;22(12):782-7 (37 ref.)

Current concepts in the management of pharyngitis. Smith DS. **Compr Ther** 1996 Dec;22(12):806-9 (3 ref.)

A case-based consiliarius for therapy recommendation (ICONS): computer-based advice for calculated antibiotic therapy in intensive care medicine. Heindl B, et al. **Comput Methods Programs Biomed** 1997 Feb;52(2):117-27

Update on management of patients with Nocardia infection. Threlkeld SC, et al. **Curr Clin Top Infect Dis** 1997;17:1-23 (120 ref.)

Medical management of sinusitis in pediatric patients. Hopp R, et al. **Curr Probl Pediatr** 1997 May-Jun;27(5):178-86 (43 ref.)

Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii. Gross U, et al. **Curr Top Microbiol Immunol** 1996;219:235-45 (39 ref.)

Lasers and allergic contact dermatitis to topical antibiotics, with particular reference to bacitracin [news] Fisher AA. **Cutis** 1996 Oct;58(4):252-4

Eikenella corrodens infections. Case report in two adolescent females with IDDM. Newfield RS, et al. **Diabetes Care** 1996 Sep;19(9):1011-3

Clinical perspectives on the management of community-acquired pneumonia. Garau J. **Diagn Microbiol Infect Dis** 1996 Aug;25(4):205-11

Role of oral antibiotics in treatment of community-acquired lower respiratory tract infections. Legnani D. **Diagn Microbiol Infect Dis** 1997 Jan-Feb;27(1-2):41-7 (33 ref.)

Defining resistance: breakpoints and beyond implications for pediatric respiratory infection. Pelton SI. **Diagn Microbiol Infect Dis** 1996 Aug;25(4):195-9

Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations. de Lalla F. **Drugs** 1997 May;53(5):789-804 (103 ref.)

Common ocular infections. A prescriber's guide. Donahue SP, et al. **Drugs** 1996 Oct;52(4):526-40 (66 ref.)

Use of antimicrobials in Swiss hospitals. Swiss Committee of Anti-Infective Agents. Lew DP, et al. **Drugs** 1996;52 Suppl 2:88-91

Optimum treatment of intracellular infection. Maurin M, et al. **Drugs** 1996 Jul;52(1):45-59 (127 ref.)

Epidemiology, control and treatment of multiresistant gram-negative rods. Wiedemann B. **Drugs** 1996;52 Suppl 2:95-100; discussion 100-2 (9 ref.)

Principles of antibiotic prescribing in the elderly. Borrego F, et al. **Drugs Aging** 1997 Jul;11(1):7-18 (47 ref.)

Use of antibiotics for expansion of the Merocel packing following endoscopic sinus surgery. Shikani AH. **Ear Nose Throat J** 1996 Aug;75(8):524-6, 528

Survey of antibiotic prescribing pattern in government health facilities of the Wassa west district of Ghana. Bosu WK, et al. **East Afr Med J** 1997 Mar;74(3):138-42

Childhood nephrotic syndrome in Africa: the steroid question [editorial; comment] Luta M. **East Afr Med J** 1997 Apr; 74(4):205-6 (9 ref.). Comment on: East Afr Med J 1997 Apr;74(4):207-9.

Rational use of antibiotics in neonatal infections. Musoke RN. **East Afr Med J** 1997 Mar;74(3):147-50 (23 ref.)

Action plan for drug-resistant Streptococcus pneumoniae. The DRSP Working Group [editorial] Cetron MS, et al. **Emerg Infect Dis** 1995 Apr-Jun;1(2):64-5

Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. The Italian Surveillance Group for Antimicrobial Resistance. Cornaglia G, et al. **Emerg Infect Dis** 1996 Oct-Dec; 2(4):339-42

An outbreak of hemolytic uremic syndrome associated with antibiotic treatment of hospital inpatients for dysentery. Al-Qarawi S, et al. **Emerg Infect Dis** 1995 Oct-Dec; 1(4):138-40

WHO Scientific Working Group on monitoring and management of bacterial resistance to antimicrobial agents. Tenover FC, et al. **Emerg Infect Dis** 1995 Jan-Mar;1(1):37

TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Teicher BA, et al. **Eur J Cancer** 1996 Dec;32A(14):2461-6 (52 ref.)

Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. Araujo FG, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):394-7

Quinine in the treatment of Babesia divergens infections in humans [letter] Brasseur P, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):840-1

Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. Gendrel D, et al. **Eur J Clin Microbiol Infect Dis** 1997 May;16(5):388-91

Prophylactic, empiric and therapeutic use of antibiotics. Do we need a guide: a universal edition or a local one? Peetermans WE. **Eur J Emerg Med** 1997 Mar;4(1):15-8 (12 ref.)

Helicobacter pylori infection status in relation to antibiotic and non-steroidal prescribing in patients on maintenance treatment for chronic duodenal ulcer. Prach AT, et al. **Eur J Gastroenterol Hepatol** 1997 Mar;9(3):251-6

Selective intrapartum anti-bioprophylaxy of group B streptococci infection of neonates: a prospective study in 2454 subsequent deliveries. Poulain P, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Apr;72(2):137-40

Ciprofloxacin ophthalmic solution in the treatment of conjunctivitis and blepharitis: a comparison with fusidic acid. Adenis JP, et al. **Eur J Ophthalmol** 1996 Oct-Dec; 6(4):368-74

Comparative evaluation of the short-term bactericidal potential of a steroid-antibiotic combination versus steroid in the treatment of chronic bacterial blepharitis and conjunctivitis. Shulman DG, et al. **Eur J Ophthalmol** 1996 Oct-Dec;6(4):361-7

Factors associated with increased risk in inappropriate empiric antibiotic treatment of childhood bacteraemia. Ashkenazi S, et al. **Eur J Pediatr** 1996 Jul;155(7):545-50

Duration of Antibiotic Treatment in Surgical Infections of the Abdomen. Discussion forum for attaining consensus. **Eur J Surg Suppl** 1996;(576):1-75 (184 ref.)

Duration of antibiotic treatment in surgical infections of the abdomen. Choice of antibiotics in two French hospitals. Fingerhut A, et al. **Eur J Surg Suppl** 1996;(576):63-4; discussion 64-5

Duration of antibiotic treatment in surgical infections of the abdomen. Minimal antibiotic therapy: technology assessment instead of clinical trials. Lechleuthner A, et al. **Eur J Surg Suppl** 1996;(576):36-7; discussion 37-8

Duration of antibiotic treatment in surgical infections of the abdomen. Introduction--the different ways to reach consensus. Lorenz W, et al. **Eur J Surg Suppl** 1996;(576):5-8

Duration of antibiotic treatment in surgical infections of the abdomen. The future: randomised prospective studies. Solomkin JS. **Eur J Surg Suppl** 1996;(576):33-5

Lower respiratory tract infections in the community: towards a more rational approach [editorial; comment] Dorca J, et al. **Eur Respir J** 1996 Aug;9(8):1588-9 (17 ref.). Comment on: Eur Respir J 1996 Aug;9(8):1596-600.

Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Huchon GJ, et al. **Eur Respir J** 1996 Aug;9(8):1590-5

Use of investigations in lower respiratory tract infection in the community: a European survey [see comments] Woodhead M, et al. **Eur Respir J** 1996 Aug;9(8):1596-600 . Comment in: Eur Respir J 1996 Aug;9(8):1588.

Sore throat management practices of Canadian family physicians. McIsaac WJ, et al. **Fam Pract** 1997 Feb; 14(1):34-9

Maxillary sinusitis in adults: an evaluation of placebo-controlled double-blind trials. Stalman W, et al. **Fam Pract** 1997 Apr;14(2):124-9

Are antibiotics over-prescribed in Poland? Management of upper respiratory tract infections in primary health care region of Warszawa, Wola. Windak A, et al. **Fam Pract** 1996 Oct;13(5):445-9

Antibiotics and pancreatitis. Foxx-Orenstein A, et al. **Gastroenterologist** 1997 Jun;5(2):157-64 (63 ref.)

Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Labenz J, et al. **Gastroenterology** 1997 May;112(5):1442-7

Antibiotic treatment for gonorrhoea in the UK [letter; comment] Fitzgerald M. **Genitourin Med** 1997 Apr; 73(2):149. Comment on: Genitourin Med 1996 Aug;72(4):253-7. Comment on: Genitourin Med 1996 Aug;72(4):302.

Antimicrobial agents and gonorrhoea: therapeutic choice, resistance and susceptibility testing [see comments] Ison CA. **Genitourin Med** 1996 Aug;72(4):253-7 (46 ref.). Comment in: Genitourin Med 1997 Apr;73(2):149.

Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis. Pozniak A, et al. **Genitourin Med** 1996 Aug;72(4):269-71 (14 ref.)

Is rifabutin prophylaxis against Mycobacterium avium complex infection in HIV infection worthwhile? The net impact on patients suggests not. Stephenson JM, et al. **Genitourin Med** 1996 Aug;72(4):272-6 (10 ref.)

Treating respiratory infections in the elderly: current strategies and considerations. Norman DC, et al. **Geriatrics** 1997 Jan;52 Suppl 1:S1-28 (18 ref.)

Listeria endocarditis: current management and patient

outcome—world literature review. Spyrou N, et al. **Heart** 1997 Apr;77(4):380–3 (51 ref.)

Antibiotics for prophylaxis and treatment of intra-abdominal infections. Michalopoulos A, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):947–58 (76 ref.)

Pharmaceuticals ... too much of a good thing [news] **Hosp Health Netw** 1996 Oct 5;70(19):12

Rosacea: beyond first blush. Zuber TJ. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):188–9

Is there a rationale for fixed-dose antibiotic-antiamebic drug combinations in diarrhea? [letter] Nanivadekar S, et al. Indian J **Gastroenterol** 1997 Apr;16(2):76–7

Multidrug resistance in Vibrio cholerae. Anand VK, et al. **Indian Pediatr** 1996 Sep;33(9):774–7

Current antibiotic choice for enteric fever. Bhatnagar S, et al. **Indian Pediatr** 1997 Feb;34(2):173–4

ARI Control Programme: standard case management guidelines vs conventional treatment—an open study. Gupta D, et al. **Indian Pediatr** 1996 Jan;33(1):41–3

Control of methicillin-resistant Staphylococcus aureus in a neonatal intensive-care unit: use of intensive microbiologic surveillance and mupirocin. Back NA, et al. **Infect Control Hosp Epidemiol** 1996 Apr;17(4):227–31

Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients: the effect of nasal mupirocin. Boelaert JR, et al. **Infect Control Hosp Epidemiol** 1996 Dec; 17(12):809–11

Changing the infection control paradigm from off-line to real time: the experience at Millard Fillmore Health System. Carr JR, et al. **Infect Control Hosp Epidemiol** 1997 Apr;18(4):255–9

Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Kluytmans JA, et al. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):793–7

Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus [see comments] Kluytmans JA, et al. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):780–5. Comment in: Infect Control Hosp Epidemiol 1996 Dec;17(12):775–9.

Antimicrobial use in long-term-care facilities. Nicolle LE, et al. **Infect Control Hosp Epidemiol** 1996 Feb;17(2):119–28 (56 ref.)

Antimicrobial use in patients with positive intravascular catheter cultures: a six-month prospective survey in a teaching hospital. Rello J, et al. **Infect Control Hosp Epidemiol** 1996 Oct;17(10):668–9

Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery [see comments] VandenBergh MF, et al. **Infect Control Hosp Epidemiol** 1996 Dec; 17(12):786–92. Comment in: Infect Control Hosp Epidemiol 1996 Dec;17(12):775–9.

Antibiotic selection in obstetric patients. Duff P. **Infect Dis Clin North Am** 1997 Mar;11(1):1–12 (42 ref.)

Treatment of urinary tract infections in Dutch hospitals. Stobberingh E, et al. **Infection** 1996 May–Jun;24(3):234–7

Controversies in the use of antimicrobials for the prevention and treatment of Lyme disease. Wormser GP. **Infection** 1996 Mar–Apr;24(2):178–81 (38 ref.)

Physician preferences in the diagnosis and treatment of Lyme disease in the United States. Ziska MH, et al. **Infection** 1996 Mar–Apr;24(2):182–6 (29 ref.)

Phagocyte chemiluminescence in pre-term infants. Pierce LA, et al. **Int J Clin Lab Res** 1996;26(2):112–8

The homoeopathic treatment of otitis media in children—comparisons with conventional therapy. Friese KH, et al. **Int J Clin Pharmacol Ther** 1997 Jul;35(7):296–301

Analysis of amount, expenditures and indications of drug and blood product prescriptions at surgical intensive care units. Tepper J, et al. **Int J Clin Pharmacol Ther** 1995 Dec; 33(12):658–63

Protective effects of topical antimicrobials against neonatal tetanus. Bennett J, et al. **Int J Epidemiol** 1997 Aug; 26(4):897–903

ACOG educational bulletin. Antibiotics and gynecologic infections. American College of Obstetricians and Gynecologists. Number 237, June 1997 (Replaces No. 153, March 1991). **Int J Gynaecol Obstet** 1997 Sep;58(3):333–40

ACOG committee opinion. Prevention of early-onset group B streptococcal disease in newborns. Number 173—June 1996. Committee on Obstetric Practice. American College of Obstetrics and Gynecologists. **Int J Gynaecol Obstet** 1996 Aug;54(2):197–205 (47 ref.)

Significance and treatment of asymptomatic bacteriuria during pregnancy. Hall DR, et al. **Int J Gynaecol Obstet** 1997 May;57(2):179–80

Antibiotic prophylaxis in prosthetic penile surgery: critical assessment of results in 75 consecutive patients. Maffezzini M, et al. **Int J Impot Res** 1996 Jun;8(2):87–9

Evaluation of antimicrobial drugs for acute otitis media [editorial] Shurin PA. **Int J Pediatr Otorhinolaryngol** 1996 Feb;34(3):219–23

Antimicrobial self medication in patients attending a sexually transmitted diseases clinic. Adu-Sarkodie YA. **Int J STD AIDS** 1997 Jul;8(7):456–8

Use of microbiological diagnostics and antibiotics in Danish general practice. Sørensen HT, et al. **Int J Technol Assess Health Care** 1996 Fall;12(4):745–51

New horizons in antibacterial therapy. Gritz DC, et al. **Int Ophthalmol Clin** 1996 Spring;36(2):153–70 (109 ref.)

Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination (SOD). Abele-Horn M, et al. **Intensive Care Med** 1997 Feb; 23(2):187–95

Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Alvarez-Lerma F. **Intensive Care Med** 1996 May;22(5):387–94

Short-term impact of the European Consensus Conference on the use of selective decontamination of the digestive tract with antibiotics in ICU patients. Misset B, et al. **Intensive Care Med** 1996 Sep;22(9):981–4

Serious Clostridium difficile sepsis [letter; comment] Mohammedi I, et al. **Intensive Care Med** 1997 May; 23(5):601. Comment on: Intensive Care Med 1996 Sep;22(9):990–4.

Effect of combined antibacterial and antifungal treatment in severe atopic dermatitis [see comments] Kolmer HL, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):702–7. Comment in: J Allergy Clin Immunol 1997 Jun;99(6 Pt 1):861.

Antimicrobial agents for the dermatologist. I. Beta-lactam antibiotics and related compounds. Epstein ME, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 1):149–65; quiz 166–8 (143 ref.)

Treatments and outcomes of nursing-home-acquired pneumonia [see comments] Thompson RS, et al. **J Am Board Fam Pract** 1997 Mar–Apr;10(2):82–7. Comment in: J Am Board Fam Pract 1997 Mar–Apr;10(2):168–70.

Antibiotic use in dentistry. ADA Council on Scientific Affairs. **J Am Dent Assoc** 1997 May;128(5):648

Treatment of ocular bacterial infections: an update. Hammond RW, et al. **J Am Optom Assoc** 1997 Mar; 68(3):178–87 (59 ref.)

Cardiovascular manifestations of Lyme disease. Paparone PW. **J Am Osteopath Assoc** 1997 Mar;97(3):156–61 (31 ref.)

Extemporaneous preparation of antibiotic ophthalmic solutions. Hammond RW, et al. **J Am Pharm Assoc (Wash)** 1996 Mar;NS36(3):206–9

A community-pharmacy-based callback program for antibiotic therapy. Westfall GR, et al. **J Am Pharm Assoc (Wash)** 1997 May–Jun;NS37(3):330–4

Extra-label drug use: with rights come responsibilities [see comments] Cleland JL. **J Am Vet Med Assoc** 1996 Sep 1;209(5):897–8. Comment in: J Am Vet Med Assoc 1996 Nov 1;209(9):1545. Comment in: J Am Vet Med Assoc 1996 Nov 1;209(9):1545–6.

Use of yohimbine to reverse prolonged effects of xylazine hydrochloride in a horse being treated with chloramphenicol. Grubb TL, et al. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1771–3

Eosinophilic keratoconjunctivitis in seven horses. Yamagata M, et al. **J Am Vet Med Assoc** 1996 Oct 1;209(7):1283–6

Indications for antibiotic use in ICU patients: a one-year prospective surveillance. Bergmans DC, et al. **J Antimicrob Chemother** 1997 Apr;39(4):527–35

Outpatient intravenous antibiotic therapy. Conlon CP. **J Antimicrob Chemother** 1996 Oct;38(4):557–9

Antimicrobial resistance—use in veterinary and human medicine [letter; comment] Cook RR. **J Antimicrob Chemother** 1997 Mar;39(3):435. Comment on: J Antimicrob Chemother 1996 Jul;38(1):1–3.

Analysis of oral antibiotic treatment that failed to prevent the development of Haemophilus influenzae meningitis: consequences on mortality. Dabernat H, et al. **J Antimicrob Chemother** 1996 Oct;38(4):679–89

Relevance of the Alexander Project: pharmacodynamic considerations. Drusano GL, et al. **J Antimicrob Chemother** 1996 Jul;38 Suppl A:141–54

The influence of the opinion of an infectious disease consultant on the appropriateness of antibiotic treatment in a general hospital. Gómez J, et al. **J Antimicrob Chemother** 1996 Aug;38(2):309–14

Over-the-counter availability of antibiotics [letter] Gould IM, et al. **J Antimicrob Chemother** 1996 Mar;37(3):635–6

Trends in hospital antibiotic prescribing after introduction of an antibiotic policy. Gould IM, et al. **J Antimicrob Chemother** 1996 Nov;38(5):895–904

Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. Gui GP, et al. **J Antimicrob Chemother** 1997 Mar;39(3):393–400

Clinical features of patients with beta-lactamase producing Haemophilus influenzae isolated from sputum. Johnson SR, et al. **J Antimicrob Chemother** 1996 Nov;38(5):881–4

Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyelonephritis. Meulbroek JA, et al. **J Antimicrob Chemother** 1996 Oct;38(4):641–53

Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. Miller YW, et al. **J Antimicrob Chemother** 1996 Nov;38(5):829–37

Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic-resistant bacteria that infect man and compromise antimicrobial chemotherapy? [see comments] Piddock LJ. **J Antimicrob Chemother** 1996 Jul;38(1):1–3 (23 ref.). Comment in: J Antimicrob Chemother 1997 Feb;39(2):285–6. Comment in: J Antimicrob Chemother 1997 Mar;39(3):435.

Accelerated bacteriological evaluation in the management of lower respiratory tract infection in general practice. Shackley P, et al. **J Antimicrob Chemother** 1997 May; 39(5):663–6

Self learning/self assessment [letter] Mader ME. **J Can Dent Assoc** 1997 May;63(5):320

Pseudomonas spp. and antibiotics in exacerbation of chronic obstructive pulmonary disease (COPD). Beghi G, et al. **J Chemother** 1995 Nov;7 Suppl 4:163–4

Therapeutic monitoring, the concentration–effect relationship and impact on the clinical efficacy of antibiotic agents. Dawson SJ, et al. **J Chemother** 1997 May;9 Suppl 1:84–92 (52 ref.)

Antimicrobial agents rationale and monitoring in an Italian hospital. De Lalla F. **J Chemother** 1996 Oct;8(5):342–50

Antibiotic prescriptions in surgical and medical departments and urine culture susceptibility reports. Dobardzic AM, et al. **J Chemother** 1995 Nov;7 Suppl 4:170–2

Antimicrobial treatment of periodontal diseases disturbs the human ecology: a review. Edlund C, et al. **J Chemother** 1996 Oct;8(5):331–41 (65 ref.)

Etiology and therapy of community-acquired pneumonia. Ginesu F, et al. **J Chemother** 1997 Aug;9(4):285–92

What's the use of susceptibility testing? Greenwood D. **J Chemother** 1997 May;9 Suppl 1:7–12 (25 ref.)

Respiratory tract infection: epidemiology and surveillance. Jacobs MR. **J Chemother** 1997 May;9 Suppl 3:10–7 (25 ref.)

In vitro antibiotics testing and its relationship to clinical activity. Mouton Y, et al. **J Chemother** 1997 May;9 Suppl 1:93–9 (24 ref.)

Five years of experience in the treatment of chronic obstructive pulmonary diseases (COPD) caused by penicillin-resistant Streptococcus pneumoniae. Music E, et al. **J Chemother** 1995 Nov;7 Suppl 4:160–2

Greek physicians' and dentists' compliance with the British society for antimicrobial chemotherapy (BSAC) guidelines for preventing bacterial endocarditis. Panos G, et al. **J Chemother** 1996 Aug;8(4):270–7

The chemotherapeutic formula revisited. Periti P. **J Chemother** 1997 May;9 Suppl 1:123–33 (19 ref.)

The importance of in-vitro susceptibility testing in the management of compromised hosts. Venditti M, et al. **J Chemother** 1997 May;9 Suppl 1:116–22 (23 ref.)

Effect of antimicrobial agents on the piliation of Pseudomonas aeruginosa and adherence to mouse tracheal epithelium. Yamasaki T, et al. **J Chemother** 1997 Feb; 9(1):32–7

Managing acid peptic disease in the Helicobacter pylori era. Marshall BJ. **J Clin Gastroenterol** 1995;21 Suppl 1:S155–9 (14 ref.)

Helicobacter pylori eradication helps resolve pyloric and duodenal stenosis. Tursi A, et al. **J Clin Gastroenterol** 1996 Sep;23(2):157–8

Detection of Borrelia burgdorferi-specific DNA in urine specimens from patients with erythema migrans before and after antibiotic therapy. Schmidt B, et al. **J Clin Microbiol** 1996 Jun;34(6):1359–63

Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Mitchell PL, et al. **J Clin Oncol** 1997 Mar;15(3):1163–70

Systemic antimicrobial treatment and guided tissue regeneration. Clinical and microbiological effects in furcation defects. Mombelli A, et al. **J Clin Periodontol** 1996 Apr;23(4):386–96

The effects of early antibiotic treatment following diagnosis of mastitis detected by a change in the electrical conductivity of milk. Milner P, et al. **J Dairy Sci** 1997 May;80(5):859–63

Comparison of success of antibiotic therapy during lactation and results of antimicrobial susceptibility tests for bovine mastitis. Owens WE, et al. **J Dairy Sci** 1997 Feb;80(2):313–7

Efficacy of cefquinome for treatment of cows with mastitis experimentally induced using Escherichia coli. Shpigel NY, et al. **J Dairy Sci** 1997 Feb;80(2):318–23

Antibiotic use in the emergency department. II The aminoglycosides, macrolides, tetracyclines, sulfa drugs, and urinary antiseptics. Graeme KA, et al. **J Emerg Med** 1996 May–Jun;14(3):361–71 (90 ref.)

Antibiotic use in the emergency department. III. The quinolones, new beta lactams, beta lactam combination agents, and miscellaneous antibiotics. Schmidt J, et al. **J Emerg Med** 1996 Jul–Aug;14(4):483–96 (101 ref.)

Serious bacterial infection in children. Bergus G. **J Fam Pract** 1997 Jun;44(6):531–2

Evaluation and treatment of respiratory infections: does managed care make a difference? Hueston WJ, et al. **J Fam Pract** 1997 Jun;44(6):572–7

Antibiotics: neither cost effective nor 'cough' effective [see comments] Hueston WJ. **J Fam Pract** 1997 Mar;44(3):261–5 . Comment in: J Fam Pract 1997 Jun;44(6):524; discussion 524–5. Comment in: J Fam Pract 1997 Jun;44(6):524–5.

Appropriateness of antibiotics [letter; comment] Keegan JM. **J Fam Pract** 1996 Oct;43(4):330–1. Comment on: J Fam Pract 1996 Apr;42(4):357–61.

Antibiotic treatment for AOM. Lagace E. **J Fam Pract** 1997 Sep;45(3):202–3

Patient knowledge of upper respiratory infections: implications for antibiotic expectations and unnecessary utilization. Mainous AG 3rd, et al. **J Fam Pract** 1997 Jul; 45(1):75–83

Patient satisfaction with antibiotic use. Rao G. **J Fam Pract** 1996 Nov;43(5):436–7

Treatment of acute bronchitis in adults without underlying lung disease [see comments] MacKay DN. **J Gen Intern Med** 1996 Sep;11(9):557–62 (48 ref.). Comment in: ACP J Club 1997 Mar–Apr;126(2):39.

Do antibiotic policies have an effect? **J Hosp Infect** 1997 Jun;36(2):85–93

Mupirocin–resistant methicillin–resistant Staphylococcus aureus [letter; comment] Ambler JE, et al. **J Hosp Infect** 1996 Jan;32(1):71–82. Comment on: J Hosp Infect 1994 Sep;28(1):75–8.

Mupirocin resistance and methicillin–resistant Staphylococcus aureus (MRSA). Eltringham I. **J Hosp Infect** 1997 Jan;35(1):1–8 (44 ref.)

Hepatic abscess due to Eikenella corrodens and Streptococcus milleri: implications for antibiotic therapy. Quinlivan D, et al. **J Infect** 1996 Jul;33(1):47–8

Pan–European survey of patients' attitudes to antibiotics and antibiotic use. Branthwaite A, et al. **J Int Med Res** 1996 May–Jun;24(3):229–38

An open study of mupirocin in Libyan patients with skin infections. El Ferghani N. **J Int Med Res** 1995 Nov–Dec; 23(6):508–17

Sensitivity to antibacterials of Staphylococcus aureus isolated from different types of skin infections. Nishijima S, et al. **J Int Med Res** 1997 Jan–Feb;25(1):1–7

Sensitivity to antibacterials of Staphylococcus aureus isolated from skin infections: a comparison of two hospitals. Nishijima S, et al. **J Int Med Res** 1997 Jan–Feb;25(1):8–13

Initial antibiotic management of community acquired pneumonia. Astin GT, et al. **J Med Assoc Ga** 1997 Apr; 86(2):105–8

Antibiotics and respiratory infections: do antibiotic prescriptions improve outcomes? Hamm RM, et al. **J Okla State Med Assoc** 1996 Aug;89(8):267–74

Risk–stratified nosocomial infection surveillance in a neonatal intensive care unit: report on 24 months of surveillance. Ferguson JK, et al. **J Paediatr Child Health** 1996 Dec; 32(6):525–31

Spectrum of pediatric dacryocystitis: medical and surgical management of 54 cases. Campolattaro BN, et al. **J Pediatr Ophthalmol Strabismus** 1997 May–Jun; 34(3):143–53; quiz 186–7

Is interval appendectomy necessary after rupture of an appendiceal mass? Ein SH, et al. **J Pediatr Surg** 1996 Jun; 31(6):849–50

Systemic antibiotics in periodontics. **J Periodontol** 1996 Aug; 67(8):831–8 (63 ref.)

Pneumonia I and Pneumonia II Projects. Gunter N, et al. **J S C Med Assoc** 1997 May;93(5):180–2

Potentiating effect of EDTA–Tris on the activity of antibiotics against resistant bacteria associated with otitis, dermatitis and cystitis. Farca AM, et al. **J Small Anim Pract** 1997 Jun;38(6):243–5

New combination for the therapy of canine otitis externa. I. Microbiology of otitis externa. Kiss G, et al. **J Small Anim Pract** 1997 Feb;38(2):51–6

New combination for the therapy of canine otitis externa. II. Efficacy in vitro and in vivo. Kiss G, et al. **J Small Anim Pract** 1997 Feb;38(2):57–60

Influence of selective decontamination of the digestive tract on cell–mediated immune function and bacteria/endotoxin translocation in thermally injured rats. Yao YM, et al. **J Trauma** 1997 Jun;42(6):1073–9

Spectrum of Haemophilus influenzae type b disease in children at a university hospital in Riyadh, Saudi Arabia. Abdullah AM, et al. **J Trop Pediatr** 1997 Feb;43(1):10–2

Evaluation of antibiotics for the elimination of the tonsillar carrier state of Streptococcus suis in pigs. Amass SF, et al. **J Vet Diagn Invest** 1996 Jan;8(1):64–7

Comparison in prescribing patterns of antibacterial drugs in salmonid farming in Norway during the periods 1980–1988 and 1989–1994. Grave K, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):184–91

Diagnosing streptococcal pharyngitis in patients taking antibiotics. Brunell P. **JAMA** 1997 Apr 16;277(15):1197

Practice guidelines for treatment of peptic ulcer disease [letter; comment] Fennerty MB. **JAMA** 1996 Oct 9; 276(14):1135; discussion 1136–7. Comment on: JAMA 1996 Feb 28;275(8):622–9.

Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians [see comments] Gonzales R, et al. **JAMA** 1997 Sep 17;278(11):901–4. Comment in: JAMA 1997 Sep 17;278(11):944–5.

Practice guidelines for treatment of peptic ulcer disease [letter; comment] Olson CA. **JAMA** 1996 Oct 9; 276(14):1135–6; discussion 1136–7. Comment on: JAMA 1996 Feb 28;275(8):622–9.

Preventing the emergence of antimicrobial resistance. A call for action by clinicians, public health officials, and patients [editorial;comment] Schwartz B, et al. **JAMA** 1997 Sep 17;278(11):944–5. Comment on: JAMA 1997 Sep 17;278(11):901–4.

Antibiotic treatment in acute bacterial sinusitis [letter; comment] Lindbaek M, et al. **Lancet** 1997 May 17; 349(9063):1476; discussion 1476–7. Comment on: Lancet 1997 Mar 8;349(9053):683–7.

Can we treat coronary artery disease with antibiotics? [comment] Lip GY, et al. **Lancet** 1997 Aug 9; 350(9075):378–9. Comment on: Lancet 1997 Aug 9;350(9075):404–7. Comment on: Lancet 1997 Aug 9;350(9075):430–6.

Treatment of pig bites [letter; comment] Morgan MS. **Lancet** 1996 Nov 2;348(9036):1246. Comment on: Lancet 1996 Sep 28;348(9031):888.

Abandoning empirical antibiotics for febrile children [letter] Pollard AJ, et al. **Lancet** 1997 Sep 13;350(9080):811–2

Rational antibiotic therapy for intra–abdominal infections. Quinn JP. **Lancet** 1997 Feb 22;349(9051):517–8

Incidental eradication of Helicobacter pylori by antibiotics given for unrelated conditions and declining incidence of gastric carcinoma [letter; comment] Simini B. **Lancet** 1996 Nov 16;348(9038):1390–1. Comment on: Lancet 1997 Jan 4;349(9044):59.

Randomised controlled trial of treatment of chronic suppurative otitis media in Kenyan schoolchildren [see comments] Smith AW, et al. **Lancet** 1996 Oct 26; 348(9035):1128–33. Comment in: Lancet 1996 Oct 26;348(9035):1113–4.

Abandoning empirical antibiotics for febrile children. Stamos JK, et al. **Lancet** 1997 Jul 12;350(9071):84

Effectiveness of clinical guidelines for the presumptive treatment of streptococcal pharyngitis in Egyptian children [see comments] Steinhoff MC, et al. **Lancet** 1997 Sep 27; 350(9082):918–21. Comment in: Lancet 1997 Sep 27;350(9082):899–900.

Prophylactic antibiotics in cataract operations. Liesegang TJ. **Mayo Clin Proc** 1997 Feb;72(2):149–59 (99 ref.)

Specialist and generalist physicians' adoption of antibiotic therapy to eradicate Helicobacter pylori infection. Hirth RA, et al. **Med Care** 1996 Dec;34(12):1199–204

Neurologic manifestations of HIV infection. Simpson DM, et al. **Med Clin North Am** 1996 Nov;80(6):1363–94 (253 ref.)

Antibiotic use or misuse? [editorial; comment] Turnidge J. **Med J Aust** 1997 Aug 4;167(3):116–7. Comment on: Med J Aust 1997 Aug 4;167(3):124–7.

Meropenem––a new parenteral broad–spectrum antibiotic. **Med Lett Drugs Ther** 1996 Sep 27;38(984):88–90 (0 ref.)

Fosfomycin for urinary tract infections. **Med Lett Drugs Ther** 1997 Jul 18;39(1005):66–8

Antibiotic–resistant pneumococci in pediatric disease. Klugman KP, et al. **Microb Drug Resist** 1995 Spring; 1(1):5–8 (31 ref.)

Lower respiratory tract infections in the intensive care unit: consequences of antibiotic resistance for choice of antibiotic. Lode H, et al. **Microb Drug Resist** 1995 Summer; 1(2):163–7 (33 ref.)

Treatment of gunshot wounds [letter; comment] Baker MS. **Mil Med** 1997 Jul;162(7):ii. Comment on: Mil Med 1997 Apr;162(4):266–7.

Outpatient antibiotic treatment of uncomplicated gunshot wounds: ramifications for military use [see comments] Brouker ME. **Mil Med** 1997 Apr;162(4):266–7 (6 ref.). Comment in: Mil Med 1997 Jul;162(7):ii.

Drug–resistant bacteria: responding to the infectious disease crisis. Jack DB. **Mol Med Today** 1996 Dec;2(12):499–502 (0 ref.)

Empirical antibiotic therapy and lower respiratory tract infections: European guidelines and current practices. Woodhead M. **Monaldi Arch Chest Dis** 1995 Dec; 50(6):472–6 (20 ref.)

Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis. Eckman MH, et al. **N Engl J Med** 1997 Jul 31;337(5):357–63

Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group [see comments] Gerber MA, et al. **N Engl J Med** 1996 Oct 24; 335(17):1270–4. Comment in: N Engl J Med 1997 Apr 10;336(15):1107; discusssion 1107–8.

Treatment of bacterial meningitis. Quagliarello VJ, et al. **N Engl J Med** 1997 Mar 6;336(10):708–16 (96 ref.)

Antibiotics with an attitude: are they working? [see comments] Berlin B. **N J Med** 1996 Nov;93(11):25–31. Comment in: N J Med 1996 Nov;93(11):17–8.

Don't fool with Mother Nature [editorial; comment] Slobodien HD. **N J Med** 1996 Nov;93(11):17–8. Comment on: N J Med 1996 Nov;93(11):25–31.

An ounce of protection [letter] Kessler J. **N Y State Dent J** 1997 Jun–Jul;63(6):10

Otitis media treatment in New Zealand general practice. Tilyard MW, et al. **N Z Med J** 1997 Apr 25;110(1042):143–5

Antibiotic therapy in tuberculin–positive children with lung lesions [letter] Deivanayagam CN. **Natl Med J India** 1996 Mar–Apr;9(2):99

Salmonella enteritidis: phage types and drug resistance among the strains isolated in India and Zimbabwe [letter] Sharma NC, et al. **Natl Med J India** 1996 Jul–Aug;9(4):199–200

Sequential antibiotic therapy. Mandell LA. **Neth J Med** 1997 Mar;50(3):93–6 (31 ref.)

Spinal epidural abscess: evaluation of factors influencing outcome. Khanna RK, et al. **Neurosurgery** 1996 Nov; 39(5):958–64

Could invasive diagnostic techniques for ventilator–associated pneumonia be associated with reduced antibiotic usage in the ICU? Brun–Buisson C. **New Horiz** 1996 Aug;4(3):345–52 (58 ref.)

Does antibiotic restriction prevent resistance? McGowan JE Jr, et al. **New Horiz** 1996 Aug;4(3):370–6 (43 ref.)

Antibiotic use in pregnancy. Dashe JS, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):617–29 (57 ref.)

Impact of cultures on management decisions following surgical repair of penetrating ocular trauma. Rubsamen PE, et al. **Ophthalmic Surg Lasers** 1997 Jan;28(1):43–9

Local antimicrobial prophylaxis in cataract surgery: recent controversies and clinical guidelines. Adenis JP, et al. **Ophthalmologica** 1997;211 Suppl 1:77–80 (20 ref.)

Treatment of chlamydial conjunctivitis. Nakagawa H. **Ophthalmologica** 1997;211 Suppl 1:25–8 (17 ref.)

The importance of initial management in the treatment of severe infectious corneal ulcers. McLeod SD, et al. **Ophthalmology** 1995 Dec;102(12):1943–8

Chronic sinusitis: a medical or surgical disease? Parsons DS. **Otolaryngol Clin North Am** 1996 Feb;29(1):1–9 (19 ref.)

Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. Delcenserie R, et al. **Pancreas** 1996 Aug; 13(2):198–201

Successful non operative management of late infrainguinal polytetrafluoroethylene vascular graft infection with antibiotics alone: a report of two cases. Wilkinson JM, et al. **Panminerva Med** 1997 Jun;39(2):128–31

Continuation of antibiotic therapy for serious bacterial infections outside of the hospital. Gutierrez K. **Pediatr Ann** 1996 Nov;25(11):639–45

Presumptive antibiotic therapy for hospitalized children with sepsis and meningitis: cost–effective analysis and antibiotic restriction guidelines. Jacobs RF, et al. **Pediatr Ann** 1996 Nov;25(11):631–8

The management of common infections in ambulatory children. Mason WH. **Pediatr Ann** 1996 Nov;25(11):620–9 (56 ref.)

Antibiotic update: overview. Prober CG. **Pediatr Ann** 1996 Nov;25(11):604, 606–7

Antibiotic choices: the critical first hour. Sotiropoulos SV. **Pediatr Ann** 1996 Jun;25(6):345–50 (18 ref.)

An evidence–based approach to treating otitis media. Rosenfeld RM. **Pediatr Clin North Am** 1996 Dec; 43(6):1165–81 (86 ref.)

Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Bass JW, et al. **Pediatr Infect Dis J** 1997 Jul;16(7):708–10

Treatment of Helicobacter pylori infection: a review. Blecker U, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):391–9 (105 ref.)

Acute otitis media in pediatrics: are there rational issues for empiric therapy? Boccazzi A, et al. **Pediatr Infect Dis J** 1997 Mar;16(3 Suppl):S65–9 (19 ref.)

Change in nasopharyngeal carriage of Streptococcus pneumoniae resulting from antibiotic therapy for acute otitis media in children. Cohen R, et al. **Pediatr Infect Dis J** 1997 Jun;16(6):555–60

Oral antibiotic therapy for uncomplicated bacterial skin infections in children. Darmstadt GL. **Pediatr Infect Dis J** 1997 Feb;16(2):227–40 (182 ref.)

Contemporary issues in the management of pediatric infections. Helwig H. **Pediatr Infect Dis J** 1997 Mar;16(3 Suppl):S39–42 (19 ref.)

Patterns and determinants of use of antibiotics for acute respiratory tract infection in children in China. Hui L, et al. **Pediatr Infect Dis J** 1997 Jun;16(6):560–4

Streptococcal diagnostic testing and antibiotics prescribed for pediatric tonsillopharyngitis. Mainous AG 3d, et al. **Pediatr Infect Dis J** 1996 Sep;15(9):806–10

Variations in the treatment of common infections [letter] Miles VH, et al. **Pediatr Infect Dis J** 1997 Aug;16(8):826–7

Purulent rhinitis:antibiotic prescribing survey [letter] Murray DL. **Pediatr Infect Dis J** 1997 Aug;16(8):825–6

Empiric antibiotic selection criteria for respiratory infections in pediatric practice. Pichichero ME. **Pediatr Infect Dis J** 1997 Mar;16(3 Suppl):S60–4 (38 ref.)

Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pichichero ME, et al. **Pediatr Infect Dis J** 1997 Jul;16(7):680–95 (144 ref.)

Predicting the clinical efficacy of antibiotics: toward definitive criteria. Scaglione F. **Pediatr Infect Dis J** 1997 Mar;16(3 Suppl):S56–9 (31 ref.)

Antimicrobial prescribing for acute purulent rhinitis in children: a survey of pediatricians and family practitioners. Schwartz RH, et al. **Pediatr Infect Dis J** 1997 Feb; 16(2):185–90

The preservation of function: treatment of new acquisition of a pathogen [editorial; comment] Rabin HR, et al. **Pediatr Pulmonol** 1997 May;23(5):323–4 (3 ref.). Comment on: Pediatr Pulmonol 1997 May;23(5):330–5.

Something is (not) rotten in Denmark [Hamlet (not) W. Shakespeare] [editorial; comment] Schidlow DV. **Pediatr Pulmonol** 1997 May;23(5):325–6 (4 ref.). Comment on: Pediatr Pulmonol 1997 May;23(5):330–5.

Adrenobronchial fistula complicating a neonatal adrenal abscess: treatment by percutaneous aspiration and antibiotics. Pointe HD, et al. **Pediatr Radiol** 1997 Feb; 27(2):184–5

Clindamycin. Rosenberg MG. **Pediatr Rev** 1996 Oct; 17(10):373–4

Therapy for children with invasive pneumococcal infections. American Academy of Pediatrics Committee on Infectious Diseases. **Pediatrics** 1997 Feb;99(2):289–99

Otitis media–related antibiotic prescribing patterns, outcomes, and expenditures in a pediatric medicaid population. Berman S, et al. **Pediatrics** 1997 Oct; 100(4):585–92

Parents can dose liquid medication accurately. McMahon SR, et al. **Pediatrics** 1997 Sep;100(3 Pt 1):330–3

Simplified treatment of acute staphylococcal osteomyelitis of childhood. The Finnish Study Group [see comments] Peltola H, et al. **Pediatrics** 1997 Jun;99(6):846–50. Comment in: Pediatrics 1997 Jun;99(6):883–4.

Do oral antibiotics prevent meningitis and serious bacterial

infections in children with Streptococcus pneumoniae occult bacteremia? A meta-analysis. Rothrock SG, et al. **Pediatrics** 1997 Mar;99(3):438-44

Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update [see comments] Keane WF, et al. **Perit Dial Int** 1996 Nov-Dec;16(6):557-73. Comment in: Perit Dial Int 1996 Nov-Dec;16(6):548-9.

The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic and pharmacoeconomic considerations. Janknegt R. **Pharm World Sci** 1997 Jun;19(3):133-41 (45 ref.)

Selective decontamination of the digestive tract: effect of cessation of routine application at an ICU. Tissot van Patot HA, et al. **Pharm World Sci** 1996 Oct;18(5):171-7

Efficacy of semduramicin and salinomycin against Eimeria maxima in a laboratory test using two levels of oocyst inocula. Conway DP, et al. **Poult Sci** 1995 Dec; 74(12):1942-7

Diarrhoeal disease morbidity and home treatment practices in Egypt. Jousilahti P, et al. **Public Health** 1997 Jan; 111(1):5-10

Contemporary use of antibiotics in 1089 adults presenting with acute lower respiratory tract illness in general practice in the U.K.: implications for developing management guidelines. Macfarlane J, et al. **Respir Med** 1997 Aug; 91(7):427-34

Experimental posttraumatic Bacillus cereus endophthalmitis in a swine model. Efficacy of intravitreal ciprofloxacin, vancomycin, and imipenem. Alfaro DV 3rd, et al. **Retina** 1996;16(4):317-23

Experimental pseudomonal posttraumatic endophthalmitis in a swine model. Treatment with ceftazidime, amikacin, and imipenem. Alfaro DV 3rd, et al. **Retina** 1997;17(2):139-45

Management of community-acquired pneumonia in adults. Working groups of the South African Pulmonology Society and the Antibiotic Study Group of South Africa [published erratum appears in S Afr Med J 1996 Oct;86(10):1302-3] **S Afr Med J** 1996 Sep;86(9 Pt 2):1152-63

Impact of antimicrobial resistance and antibiotic choice on the outcome of pneumococcal meningitis [letter; comment] Klugman KP. **S Afr Med J** 1997 Jul;87(7):912. Comment on: S Afr Med J 1997 Jan;87(1):51-6.

Drug treatment of otitis media. Jensen W. **S D J Med** 1997 Apr;50(4):137-8

Eradication of Helicobacter pylori: omeprazole in combination with antibiotics. Axon AT, et al. **Scand J Gastroenterol Suppl** 1996;215:82-9 (58 ref.)

Helicobacter pylori reinfection after apparent eradication—the Ipswich experience. Bell GD, et al. **Scand J Gastroenterol Suppl** 1996;215:96-104

Dual and triple therapy regimens of antisecretory agents and antibiotics for the eradication of Helicobacter pylori: an overview. Ciociola AA, et al. **Scand J Gastroenterol Suppl** 1996;218:3-9 (119 ref.)

Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Jönsson B. **Scand J Gastroenterol Suppl** 1996;215:90-5

Management of Helicobacter pylori-positive peptic ulcer disease. Malfertheiner P. **Scand J Gastroenterol Suppl** 1996; 215:69

Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics. Solcia E, et al. **Scand J Gastroenterol Suppl** 1996;215:105-10

Pooled analysis of anti-Helicobacter pylori treatment regimens. Unge P, et al. **Scand J Gastroenterol Suppl** 1996; 220:27-40 (307 ref.)

Two patients with recurrent melioidosis after prolonged antibiotic therapy. Silbermann MH, et al. **Scand J Infect Dis** 1997;29(2):199-201

Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in gram-negative sepsis. Horn DL, et al. **Scand J Infect Dis Suppl** 1996;101:9-13 (48 ref.)

Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental gram-negative sepsis. Morrison DC, et al. **Scand J Infect Dis Suppl** 1996;101:3-8 (25 ref.)

Prescriptions of antibiotics for children. Prescribing habits of district, hospital, and private physicians. Cars H, et al. **Scand J Prim Health Care** 1997 Mar;15(1):22-5

What determines a family doctor's prescribing habits for antibiotics? A comparative study on a doctor's own behaviour in two different settings. Pétursson P. **Scand J Prim Health Care** 1996 Dec;14(4):196-202

Antibiotic therapy for preterm premature rupture of the membranes. Mercer BM, et al. **Semin Perinatol** 1996 Oct; 20(5):426-38 (83 ref.)

Antimicrobial therapy of pneumonia in infants and children. Harris JA. **Semin Respir Infect** 1996 Sep;11(3):139-47

Inflammatory liver disease. Weiss DJ, et al. **Semin Vet Med Surg (Small Anim)** 1997 Feb;12(1):22-7 (28 ref.)

Approaches to screening and antibiotic use for syphilis prevention [editorial; comment] Farley TA. **Sex Transm Dis** 1997 Apr;24(4):227-8 (13 ref.). Comment on: Sex Transm Dis 1997 Apr;24(4):218-26.

Self-medication and STD prevention [editorial; comment] Nichter M. **Sex Transm Dis** 1996 Sep-Oct;23(5):353-6 (2 ref.). Comment on: Sex Transm Dis 1996 Sep-Oct;23(5):407-12.

Treatment regimens of STD patients in Cameroon: a need for intervention. Trebucq A, et al. **Sex Transm Dis** 1994 Mar-Apr;21(2):124-6

In vitro activities of oral antimicrobial agents against penicillin-resistant Streptococcus pneumoniae: implications for outpatient treatment. Waites K, et al. **South Med J** 1997 Jun;90(6):621-6

Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant falciparum malaria. Na-Bangchang K, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):522-5

Use of serum bactericidal activity in assessing previous antibiotic therapy in acute lower respiratory tract infection in children. Vasudevan G, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):639-41

Prevention of urinary tract infection in patients with spinal cord injury--a microbiological review. Galloway A. **Spinal Cord** 1997 Apr;35(4):198-204 (87 ref.)

A comparative study of several antibiotic formulations using a design based on a combination of balanced incomplete blocks and Latin squares. Prescott P, et al. **Stat Med** 1994 Jan 15;13(1):11-21

Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients. Escalante CP, et al. **Support Care Cancer** 1996 Sep;4(5):358-63 (18 ref.)

2nd International Symposium on Febrile Neutropenia, Brussels, 14-16 December 1995. Hess U. **Support Care Cancer** 1996 Jul;4(4):320-1

Prophylactic antibiotics in ophthalmic surgery [letter; comment] Kownacki JJ. **Surv Ophthalmol** 1997 May-Jun; 41(6):503-5. Comment on: Surv Ophthalmol 1995 May-Jun;39(6):485-501.

Antibiotic selection in the treatment of endophthalmitis: the significance of drug combinations and synergy. Roth DB, et al. **Surv Ophthalmol** 1997 Mar-Apr;41(5):395-401 (70 ref.)

First case of Lagochilascaris minor infection in Bolivia. Ollé-Goig JE, et al. **Trop Med Int Health** 1996 Dec; 1(6):851-3

Therapeutic efficacy of clindamycin in combination with quinine for treating uncomplicated malaria in a village dispensary in Gabon. Vaillant M, et al. **Trop Med Int Health** 1997 Sep;2(9):917-9

Randomised controlled trial of ranitidine versus omeprazole in combination with antibiotics for eradication of Helicobacter pylori. Tham TC, et al. **Ulster Med J** 1996 Nov;65(2):131-6

The new antibiotics, 1997. Townsend GC, et al. **Va Med Q** 1997 Spring;124(2):108-11

Management of nonobstructive idiopathic feline lower urinary tract disease. Kruger JM, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):571-88 (65 ref.)

Treatment and prevention of porcine proliferative enteropathy with oral tiamulin. McOrist S, et al. **Vet Rec** 1996 Dec 21-28;139(25):615-8

Helicobacter pylori and stomach ulcers [letter] [see comments] Maloney A. **Vet Rec** 1996 Aug 17;139(7):172. Comment in: Vet Rec 1996 Aug 24;139(8):196.

Antibiotic resistance [letter] Reilly WJ, et al. **Vet Rec** 1997 Jul 5;141(1):26

In vivo studies on lysosubtilin. I. Efficacy for prophylaxis and treatment of gastrointestinal disorders in newborn calves. Biziulevichius GA, et al. **Vet Res** 1997;28(1):19-35

The cost effective medical treatment of suppurative otitis media in a Nigerian environment. Amadasun JE. **West Afr J Med** 1997 May-Jun;16(2):85-7

Red eye unresponsive to treatment. Michelson PE. **West J Med** 1997 Feb;166(2):145-7

Bacterial resistance and the dilemma of antibiotic usage. Prober CG. **West J Med** 1997 May;166(5):337-8

Initial management of sepsis. Etsinger C, et al. **Wis Med J** 1997 Feb;96(2):49-50

Evaluation of therapeutic regimens for the treatment of Helicobacter pylori infection. Lee DH, et al. **Yonsei Med J** 1996 Aug;37(4):270-7

Effects of selective dry-cow therapy on culling rate, clinical mastitis, milk yield and cow somatic cell count. A randomized clinical field study in cows. Osterås O, et al. **Zentralbl Veterinarmed [B]** 1996 Nov;43(9):555-75

[Antibiotic treatment of coronary disease—towards a change of paradigm?] Kolmos HJ. **Ugeskr Laeger** 1997 Sep 8; 159(37):5539-41 **(Dan)**

[Clinical judgment and decision making in clinical practice. A patient with the 'flu' (letter; comment)] Bohte R, et al. **Ned Tijdschr Geneeskd** 1997 Feb 15;141(7):352-3. Comment on: Ned Tijdschr Geneeskd 1996 Dec 7;140(49):2451-5. **(Dut)**

[Antibiotics in otitis media with effusion (letter; comment)] Ponsioen BP. **Ned Tijdschr Geneeskd** 1997 Apr 5; 141(14):702. Comment on: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):76-7. **(Dut)**

[No routine antibiotic prophylaxis necessary in endoscopic retrograde cholangiopancreatography] van de Meeberg PC, et al. **Ned Tijdschr Geneeskd** 1997 Mar 1;141(9):412-3 (Eng. Abstr.) **(Dut)**

[Direct antibiotic sensitivity testing in the treatment of urinary tract infections in a nursing home] Achterberg WP, et al. **Tijdschr Gerontol Geriatr** 1997 Feb;28(1):7-10 (Eng. Abstr.) **(Dut)**

[Methods in surgical antibacterial prophylaxis in Belgium, 1992-1995] Ronveaux O, et al. **Acta Clin Belg** 1996; 51(6):386-94 (Eng. Abstr.) **(Fre)**

[Current status in the prevention of Mycobacterium avium complex infections in patients with HIV infection] Doco-Lecompte T, et al. **Ann Med Interne (Paris)** 1997; 148(2):167-71 (21 ref.) (Eng. Abstr.) **(Fre)**

[Use of antibiotics in pediatric surgery at the University Hospital Center at Yopougon, Abidjan (Ivory Coast)] Aguehounde C, et al. **Bull Soc Pathol Exot** 1996;89(5):350-2 (Eng. Abstr.) **(Fre)**

[Antibiotics in obstetrics] Fernandez H, et al. **Contracept Fertil Sex** 1997 Jun;25(6):429-33 (13 ref.) **(Fre)**

[Value of clindamycin in the treatment of ocular toxoplasmosis] Jeddi A, et al. **J Fr Ophtalmol** 1997; 20(6):418-22 (Eng. Abstr.) **(Fre)**

[Use of an experimental Chlamydia trachomatis salpingitis model for evaluating the effectiveness of antibiotics and anti-inflammatory agents on fertility] Verhoest P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(3):309-14 (Eng. Abstr.) **(Fre)**

[Infections in pediatrics] Aujard Y, et al. **Presse Med** 1997 Jan 18-25;26(1):39-44 (23 ref.) (Eng. Abstr.) **(Fre)**

[From epidemiology to therapeutic choices. Infections in patients with neutropenia] Cordonnier C, et al. **Presse Med** 1997 Jan 18-25;26(1):45-50 (26 ref.) (Eng. Abstr.) **(Fre)**

[Mucoviscidosis. Antibiotic management] Le Bourgeois M, et al. **Presse Med** 1997 May 3-10;26(15):727-32 (29 ref.) **(Fre)**

[Probability-based choice of antibiotherapy] Portier H. **Presse Med** 1997 Jan 18-25;26(1):18-9 **(Fre)**

[Infections in the elderly] Veyssier P. **Presse Med** 1997 Jan 18-25;26(1):32-8 (22 ref.) (Eng. Abstr.) **(Fre)**

[Management of bronchial infectious episodes in general medicine] Chauvin P, et al. **Rev Mal Respir** 1996; 13(4):397-404 (Eng. Abstr.) **(Fre)**

[Conservative treatment of gastroduodenal peptic ulcer perforations: indications and results] Alizadeh N, et al. **Schweiz Med Wochenschr Suppl** 1997;89:17S-19S (Eng. Abstr.) **(Fre)**

[Mycobacterium avium complex infections: the point on the treatments] Brandissou S, et al. **Therapie** 1997 Jan-Feb; 52(1):65-71 (47 ref.) (Eng. Abstr.) **(Fre)**

[Antibacterial action of clindamycin in chronic, recurrent tonsillitis] Müller R, et al. **Arzneimittelforschung** 1996 May; 46(5):534-8 (Eng. Abstr.) **(Ger)**

[Antibiotic resistance of important infection sources in 1996 in Weser-Ems] Klarmann D. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug;104(8):325-35 (Eng. Abstr.) **(Ger)**

[Bacterial endocarditis and endocarditis prevention. 2: Endocarditis prevention] Markreiter M, et al. **Fortschr Med** 1997 May 20;115(14):49-50 **(Ger)**

[Infectiology of the urogenital tract. 5. Therapy of complicated and nosocomial urinary tract infections and of unusual pathogens--selection of antibiotics] Naber KG. **Fortschr Med** 1997 Jun 10;115(16):48-50 **(Ger)**

[Infectiology of the urogenital tract. 4: Quality assurance--antibiotic selection in uncomplicated urinary tract infections] Naber KG. **Fortschr Med** 1997 May 30; 115(15):38-42 **(Ger)**

[Pathogen spectrum and antibiotic resistance in peritonsillar abscess] Fischer M, et al. **HNO** 1996 Feb;44(2):68-72 (Eng. Abstr.) **(Ger)**

[Differentiated use of quinolones and cephalosporins] **Internist (Berl)** 1995 Nov;36(11 Suppl):1-8 **(Ger)**

[Eradication of Helicobacter pylori infection. A new therapy standard for duodenal ulcer] Caspary WF, et al. **Internist (Berl)** 1996 Dec;37(12):1204-11 (41 ref.) **(Ger)**

[Prevention, diagnosis and therapy of infections in patients with malignant diseases] Hiddemann W, et al. **Internist (Berl)** 1996 Dec;37(12):1212-24 (56 ref.) **(Ger)**

[Diagnosis and antimicrobial therapy of bacterial meningitis. Recommendations of the "CNS Diseases" Study Group of the Paul Ehrlich Society of Chemotherapy e.V. and the German Society of Pediatric Infectiology] Helwig H, et al. **Klin Padiatr** 1997 Mar-Apr;209(2):91-3 **(Ger)**

[Current developments in Helicobacter pylori therapy] Labenz J. **Leber Magen Darm** 1996 Jul;26(4):223-6 (0 ref.) **(Ger)**

[Nosocomial infections in Germany. Microbiological diagnosis, preventive antibiotics and antibiotic therapy] Hauer T, et al. **Med Klin** 1996 Nov 15;91(11):681-6 (Eng. Abstr.) **(Ger)**

[Classical and current aspects of purulent meningitis] Ring A, et al. **Nervenarzt** 1996 Aug;67(8):630-8 (30 ref.) (Eng. Abstr.) **(Ger)**

[Antibiotic treatment strategies in cystic fibrosis] Smaczny C. **Pneumologie** 1996 Dec;50 Suppl 3:831-3 **(Ger)**

[Modifiability of antibiotic use in a medical clinic] Bögli F, et al. **Schweiz Med Wochenschr** 1996 Nov 30; 126(48):2078-81 (Eng. Abstr.) **(Ger)**

[When and why are antibiotics indicated in airway infections (except pneumonia)?] Brändli O, et al. **Schweiz Rundsch Med Prax** 1997 Apr 30;86(18):737-40 (14 ref.) (Eng. Abstr.) **(Ger)**

[Helicobacter pylori: pretherapeutic resistance status in Germany (Ruhr area)] Tillenburg B, et al. **Z Gastroenterol** 1997 Mar;35(3):165-9 (Eng. Abstr.) **(Ger)**

[Calculated and controlled pharmacotherapy of problem infections in intensive care patients] Breithaupt H.

Zentralbl Chir 1996;121 Suppl:37–8 **(Ger)**
[Development of resistance—a problem?] Rodloff AC.
Zentralbl Chir 1996;121 Suppl:41–3 **(Ger)**
[The use of prophylactic antibiotics in common infections in the community] Bisharat N, et al. **Harefuah** 1997 Jun 1;132(11):792–6 (40 ref.) **(Heb)**
[Simple parameters of antibiotic utilization and diagnostic background of antimicrobial therapy in Hungarian hospitals in 1995] Almási I, et al. **Orv Hetil** 1997 Feb 23;138(8):473–8 (Eng. Abstr.) **(Hun)**
[Chemoantibiotic therapy in otorhinolaryngology] Turano A. **Acta Otorhinolaryngol Ital** 1996 Aug;16(4):380–91 **(Ita)**
[Conservative treatment of post-traumatic hepatic hematoma. Case reports] Brunero M, et al. **Minerva Pediatr** 1996 Sep; 48(9):387–91 (Eng. Abstr.) **(Ita)**
[Pericarditis caused by Gemella morbillorum. Description of a case] Condoluci C, et al. **Minerva Pediatr** 1995 Dec; 47(12):545–7 (Eng. Abstr.) **(Ita)**
[International guidelines for the clinical evaluation of anti-infective drugs] Sagawa K. **Jpn J Antibiot** 1997 Jan; 50(1):87–106 (7 ref.) **(Jpn)**
[Guideline for the clinical evaluation fo anti-infective agents] Sagawa K, et al. **Jpn J Antibiot** 1997 Jan;50(1):107–142 **(Jpn)**
[Recent clinical circumstance causing by antibiotics-resistant bacterial strains] Kaku M. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1843–7 (8 ref.) **(Jpn)**
[An assessment of infant morbidity and antibiotic therapy according to the type and course of delivery between 1983 and 1993] Kozielec T, et al. **Pediatr Pol** 1996 Jun; 71(6):529–35 (Eng. Abstr.) **(Pol)**
[Intensive antibacterial therapy of multiple trauma] Kamalov EKh, et al. **Anesteziol Reanimatol** 1996 May–Jun;(3):71–3 (Eng. Abstr.) **(Rus)**
[Antibiotics in emergency medicine] Zaĭtsev AA, et al. **Anesteziol Reanimatol** 1997 May–Jun;(3):10–4 (0 ref.) **(Rus)**
[The treatment of pneumonia: the choice of the initial preparation] Dvoretskiĭ LI. **Antibiot Khimioter** 1997; 42(1):30–6 **(Rus)**
[Antibiotics in the prevention of rheumatic fever (lecture)] Kuznetsova SM, et al. **Antibiot Khimioter** 1996 Feb; 41(2):43–51 **(Rus)**
[Effect of contemporary chemotherapeutic drugs on phagocyte activity and the immune response] Nikitin AV, et al. **Antibiot Khimioter** 1996;41(7–8):49–56 (14 ref.) **(Rus)**
[Antioxidants and immunomodulating action of antibiotics and antibiotic-treated erythrocytes in staphylococcal infections] Prokopenko LG, et al. **Antibiot Khimioter** 1997; 42(3):15–9 (Eng. Abstr.) **(Rus)**
[Comparative evaluation of the effectiveness of ofloxacin in comprehensive treatment of acute inflammatory diseases of the uterus and uterine appendages] Savel'eva GM, et al. **Antibiot Khimioter** 1996;41(9):81–3 (Eng. Abstr.) **(Rus)**
[Medical microbial ecology: current status and outlook] Shenderov BA. **Antibiot Khimioter** 1996;41(10):10–2 **(Rus)**
[Treatment of AIDS and associated diseases] Rytik PG. **Klin Med (Mosk)** 1997;75(1):5–10 (22 ref.) **(Rus)**
[The problem of the antibacterial therapy of inflammatory diseases of the maxillofacial area] Ushakov RV, et al. **Stomatologiia (Mosk)** 1996;Spec No:84 **(Rus)**
[The rapid microbiological control of the efficacy of the antibacterial therapy of bacteremia and septicemia] Kotliarova GA, et al. **Urol Nefrol (Mosk)** 1997 May–Jun; (3):8–13 (Eng. Abstr.) **(Rus)**
[Possibilities of using bioparox in the treatment of patients with diseases of the upper airways] Ovchinnikov IuM, et al. **Vestn Otorinolaringol** 1996 May–Jun;(3):56–7 **(Rus)**
[Current problems of antibacterial therapy in rheumatology] Sidorenko SV. **Vestn Ross Akad Med Nauk** 1996;(12):10–2 (Eng. Abstr.) **(Rus)**
[Strategy for choosing antibiotics for treating bacterial infections associated with chronic tick-borne encephalitis] Malenko GV, et al. **Vopr Virusol** 1996 May–Jun; 41(3):138–41 (Eng. Abstr.) **(Rus)**
[The possibility of colonizing the intestines of white mice with Lactobacillus acidophilus during bacterial therapy] Kruglikov VD, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb;(1):67–9 (Eng. Abstr.) **(Rus)**
[Old and new antibiotics in pneumology (editorial)] Rodríguez de Castro F, et al. **Arch Bronconeumol** 1997 Mar; 33(3):109–12 **(Spa)**
[The quality of antibacterial prescription in a primary care district. Its evolution in 1994–1995] García Lirola MA, et al. **Aten Primaria** 1997 May 31;19(9):487–92 (Eng. Abstr.) **(Spa)**
[Changes in the use of antibacterial agents in Catalonia, Impact of new marketed drugs] Llop JC. **Aten Primaria** 1997 Mar 31;19(5):230–6 (Eng. Abstr.) **(Spa)**
[Treatment of acute otitis media in children. Some questions] del Castillo Martín F. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):212–7 (95 ref.) **(Spa)**
[Is it possible to rationalize antibiotic usage in hospitals? (editorial) (see comments)] Ribas J, et al. **Enferm Infecc Microbiol Clin** 1995 Dec;13(10):577–80. Comment in: Enferm Infecc Microbiol Clin 1996 Nov;14(9):576–7. **(Spa)**
[Antibiotic use and bacterial resistance to antibiotics: "something that concerns you"] Alós JI, et al. **Med Clin (Barc)** 1997 Sep 6;109(7):264–70 **(Spa)**
[Prevalence of susceptibility to quinolones and other antibiotics in microorganisms isolated from community bacteriuria in Madrid in 1995. Study Group of Infections in Primary Care] Alós Cortés JI, et al. **Rev Clin Esp** 1997 Mar;197(3):167–71 (Eng. Abstr.) **(Spa)**
[Use of antibiotics as preventive or curative measure in acute pancreatitis] Fernández-del Castillo C. **Rev Gastroenterol Mex** 1996 Oct–Dec;61(4 Suppl 2):S56–7 **(Spa)**
[Antibiotics in acute otitis a touchstone in the debate on resistance] Karlsson Y. **Lakartidningen** 1997 Sep 3; 94(36):3021 **(Swe)**
[The validation of empirical emergency antibacterial therapy in acute pyelonephritis] Mitchenko MV. **Lik Sprava** 1996 Oct–Dec;(10–12):94–7 (Eng. Abstr.) **(Ukr)**

TOXICITY

Membrane action of chloramphenicol measured by protozoan motility inhibition. Wu C, et al. **Arch Toxicol** 1996; 70(12):850–3
Cytotoxicity tests for antimicrobial agents using cultured skin substitutes fixed at interface of air and culture medium. Kuroyanagi Y, et al. **J Biomater Sci Polym Ed** 1996; 7(11):1005–15
Bax accelerates staurosporine-induced but suppresses nigericin-induced neuronal cell death. Oh JH, et al. **Neuroreport** 1997 May 27;8(8):1851–6
Cytotoxic effects of four antibiotics on endothelial cells. Lanbeck P, et al. **Pharmacol Toxicol** 1995 Dec;77(6):365–70
The gene for albicidin detoxification from Pantoea dispersa encodes an esterase and attenuates pathogenicity of Xanthomonas albilineans to sugarcane. Zhang L, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9984–9
Permanent testicular damage induced in rats by a single dose of tunicamycin. Peterson JE, et al. **Reprod Toxicol** 1996 Jan–Feb;10(1):61–9
Safety of lysosubtilin per os in mice, rabbits and calves. Biziulevichius GA, et al. **Vet Res** 1997 Jul–Aug; 28(4):385–95

URINE

Antibiotic activity in microbiological media versus that in human urine: comparison of ampicillin, ciprofloxacin, and trimethoprim-sulfamethoxazole. Drobot GR, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):237–40

ANTIBIOTICS, AMINOGLYCOSIDE

Immersion in antibiotic solution prevents bacterial adhesion onto biodegradable prostatic stents. Cormio L, et al. **Br J Urol** 1997 Mar;79(3):409–13
Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases. Hon WC, et al. **Cell** 1997 Jun 13;89(6):887–95
The most frequent aminoglycoside resistance mechanisms—changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Miller GH, et al. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S46–62
Antimicrobial resistance of Salmonella enterica typhimurium DT104 isolates and investigation of strains with transferable apramycin resistance. Low JC, et al. **Epidemiol Infect** 1997 Apr;118(2):97–103
Threshold changes in auditory brainstem response (ABR) due to the administration of kanamycin in dogs. Uzuka Y, et al. **Exp Anim** 1996 Oct;45(4):325–31
Selective chemical vestibulectomy. Preliminary results. Ecke U, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 Jul–Aug; 59(4):209–14
Incidence of high-level gentamicin resistance in enterococci at Johannesburg Hospital. Keddy KH, et al. **S Afr Med J** 1996 Oct;86(10):1273–6

ADMINISTRATION & DOSAGE

Streptomycin/lignocaine local infiltration in the treatment of hypertrophic scar pain. A preliminary report [letter] Kumar A, et al. **Acta Anaesthesiol Scand** 1997 Apr;41(4):546
Persistent osteomyelitis of the femur—2 cases of exchange intramedullary nailing with gentamicin beads in the nail. Tandon SC, et al. **Acta Orthop Scand** 1996 Dec;67(6):620–2
Once-daily aminoglycoside dosing [letter; comment] Daniels AJ. **Am Fam Physician** 1997 Jul;56(1):49–50. Comment on: Am Fam Physician 1996 Apr;53(5):1782–6.
Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Ferriols-Lisart R, et al. **Am J Health Syst Pharm** 1996 May 15;53(10):1141–50
Estimating aminoglycoside dosage requirements in patients with low serum creatinine concentrations [letter] Hailemeskel B, et al. **Am J Health Syst Pharm** 1997 Apr 15;54(8):986–7
Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Lin HC, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):2024–9
Single intravenous and multiple dose pharmacokinetics of gentamicin in healthy llamas. Lackey MN, et al. **Am J Vet Res** 1996 Aug;57(8):1193–9
Absorbable, delayed-release antibiotic beads reduce surgical wound infection. Galandiuk S, et al. **Am Surg** 1997 Sep; 63(9):831–5
Once-daily aminoglycoside dosing [letter; comment] Baxter R. **Ann Intern Med** 1997 Feb 15;126(4):330. Comment on: Ann Intern Med 1996 Apr 15;124(8):717–25.
Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Prins JM, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2494–9
Postoperative contamination after using vancomycin and gentamicin during phacoemulsification. Ferro JF, et al. **Arch Ophthalmol** 1997 Feb;115(2):165–70
Limitations in the 'area under the curve' method for predicting daily doses of gentamicin [letter] Millar JA. **Aust N Z J Med** 1996 Feb;26(1):116–8
Prevention of prosthetic valve endocarditis by impregnation of gentamicin into surgical pledgets. Khor E, et al. **Biomaterials** 1996 Aug;17(16):1631–7
Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Duffull SB, et al. **Br J Clin Pharmacol** 1997 Feb; 43(2):125–35
Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. van't Veen A, et al. **Br J Pharmacol** 1996 Nov; 119(6):1145–8
The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Coates AL, et al. **Chest** 1997 May;111(5):1206–12
A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides [see comments] Ali MZ, et al. **Clin Infect Dis** 1997 May;24(5):796–809. Comment in: Clin Infect Dis 1997 May;24(5):816–9. Comment in: Clin Infect Dis 1997 May;24(5):820–3.
A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides [see comments] Bailey TC, et al. **Clin Infect Dis** 1997 May;24(5):786–95. Comment in: Clin Infect Dis 1997 May;24(5):816–9. Comment in: Clin Infect Dis 1997 May;24(5):820–3.
Single daily dose of aminoglycosides—a concept whose time has not yet come [editorial; comment] Bertino JS Jr, et al. **Clin Infect Dis** 1997 May;24(5):820–3. Comment on: Clin Infect Dis 1997 May;24(5):786–95. Comment on: Clin Infect Dis 1997 May;24(5):796–809. Comment on: Clin Infect Dis 1997 May;24(5):810–5.
Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides [editorial; comment] Gilbert DN. **Clin Infect Dis** 1997 May; 24(5):816–9. Comment on: Clin Infect Dis 1997 May;24(5):786–95. Comment on: Clin Infect Dis 1997 May;24(5):796–809. Comment on: Clin Infect Dis 1997 May;24(5):810–5.
Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review [see comments] Hatala R, et al. **Clin Infect Dis** 1997 May; 24(5):810–5 (37 ref.). Comment in: Clin Infect Dis 1997 May;24(5):816–9. Comment in: Clin Infect Dis 1997 May;24(5):820–3.
Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. Bailey RR, et al. **Clin Nephrol** 1996 Sep;46(3):183–6
Successful treatment of Aeromonas hydrophila peritoneal dialysis-associated peritonitis using intermittent intraperitoneal gentamicin. Eisele G, et al. **Clin Nephrol** 1995 Dec;44(6):402
Daily dosage of aminoglycosides. Urban AW, et al. **Curr Clin Top Infect Dis** 1997;17:236–55 (100 ref.)
Aminoglycosides once daily? **Drug Ther Bull** 1997 May; 35(5):36–7 (24 ref.)
Aminoglycoside administration as a single daily dose. An improvement to current practice or a repeat of previous errors? Marra F, et al. **Drugs** 1996 Sep;52(3):344–70 (130 ref.)
Once-daily gentamicin: translating theory into practice. Cunningham R, et al. **Eur J Clin Pharmacol** 1996; 50(3):151–4 (28 ref.)
A comparison of intratracheal and intravenous administration of gentamicin during liquid ventilation. Zelinka MA, et al. **Eur J Pediatr** 1997 May;156(5):401–4
Prevention of wound infection in elective colorectal surgery by local application of a gentamicin-containing collagen sponge. Rutten HJ, et al. **Eur J Surg Suppl** 1997;(578):31–5
Local treatment of bone and soft tissue infections with the collagen-gentamicin sponge. Stemberger A, et al. **Eur J Surg Suppl** 1997;(578):17–26 (80 ref.)
Once-daily dosing of aminoglycosides. A consensus document. Anaizi N. **Int J Clin Pharmacol Ther** 1997 Jun; 35(6):223–6 (21 ref.)
Audit of once-daily dosing gentamicin therapy in neutropenic fever. Cooke RP, et al. **Int J Clin Pract** 1997 Jun;51(4):229–31
Blastomycosis-like pyoderma (Pyoderma vegetans) responding to antibiotics and topical disodium chromoglycate. Rongioletti F, et al. **Int J Dermatol** 1996 Nov;35(11):828–30
Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient [see comments] Botha FJ, et al. **Intensive Care Med** 1996 May;22(5):443–6. Comment in: Intensive Care Med 1997 Feb;23(2):236–7.
Antibiotic and cholestyramine treatment of chronic diarrhea

in HIV-infected children [see comments] Fontana M, et al. **Ital J Gastroenterol Hepatol** 1997 Feb;29(1):22-4. Comment in: Ital J Gastroenterol Hepatol 1997 Feb;29(1):10-2.

PMMA bead versus parenteral treatment of Staphylococcus aureus osteomyelitis [published erratum appears in J Am Podiatr Med Assoc 1997 May;87(5):208] Heard GS, et al. **J Am Podiatr Med Assoc** 1997 Apr;87(4):153-64

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. Freeman CD, et al. **J Antimicrob Chemother** 1997 Jun;39(6):677-86 (75 ref.)

Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model. Petersen EA, et al. **J Antimicrob Chemother** 1996 Nov; 38(5):819-28

Antimicrobial practice. Development of guidelines for gentamicin dosing. Thomson AH, et al. **J Antimicrob Chemother** 1996 Nov;38(5):885-93

Elution characteristics of vancomycin and tobramycin combined in acrylic bone-cement. Penner MJ, et al. **J Arthroplasty** 1996 Dec;11(8):939-44

Tissue reactions to bacteria-inoculated rat lead samples. I. Effect of local gentamicin release through vicinal sponge or solution-dipping. van Wachem PB, et al. **J Biomed Mater Res** 1997 May;35(2):217-32

Tissue reactions to bacteria-inoculated rat lead samples. II. Effect of local gentamicin release through surface-modified polyurethane tubing. van Wachem PB, et al. **J Biomed Mater Res** 1997 May;35(2):233-47

Does once-daily dosing of aminoglycosides affect neuromuscular function? Wong J, et al. **J Clin Pharm Ther** 1996 Dec;21(6):407-11

Encapsulation of vancomycin and gentamicin within cationic liposomes for inhibition of growth of Staphylococcus epidermidis. Sanderson NM, et al. **J Drug Target** 1996; 4(3):181-9

Antibiotic-loaded hydroxyapatite blocks in the treatment of experimental osteomyelitis in rats. Itokazu M, et al. **J Med Microbiol** 1997 Sep;46(9):779-83

Treatment of experimental osteomyelitis by surgical debridement and the implantation of bioerodable, polyanhydride-gentamicin beads. Nelson CL, et al. **J Orthop Res** 1997 Mar;15(2):249-55

Reamed nailing of open tibial fractures: does the antibiotic bead pouch reduce the deep infection rate? Keating JF, et al. **J Orthop Trauma** 1996;10(5):298-303

Gentamicin-loaded hydraulic calcium phosphate bone cement as antibiotic delivery system. Bohner M, et al. **J Pharm Sci** 1997 May;86(5):565-72

Use of an antibiotic-impregnated bone cement block in the revision of an infected shoulder arthroplasty. Ramsey ML, et al. **J Shoulder Elbow Surg** 1996 Nov-Dec;5(6):479-82

Intraotic administration of gentamicin: a new method to study ototoxicity in the crista ampullaris of the bullfrog. Carranza A, et al. **Laryngoscope** 1997 Jan;107(1):137-43

Low-dose intratympanic gentamicin and the treatment of Meniere's disease: preliminary results. Driscoll CL, et al. **Laryngoscope** 1997 Jan;107(1):83-9

Intratympanic gentamicin for treatment of intractable Meniere's disease: a preliminary report. Rauch SD, et al. **Laryngoscope** 1997 Jan;107(1):49-55

Outpatient antimicrobial protocol for febrile neutropenia: a nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents. Sahu S, et al. **Pediatr Hematol Oncol** 1997 May-Jun;14(3):205-11

Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Charnas R, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):346-53

Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Freeman CD, et al. **Pharmacotherapy** 1996 Nov-Dec;16(6):1093-102

Exploration of once-daily dosing of aminoglycosides through Bayesian simulation. Garrelts JC. **Pharmacotherapy** 1996 Mar-Apr;16(2):286-94

Subtleties of antibiotic dosages--do doses and intervals make a difference in the critically ill? [editorial] Lipman J, et al. **S Afr J Surg** 1996 Nov;34(4):160-2

Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring. Isemann BT, et al. **Ther Drug Monit** 1996 Oct;18(5):549-55

Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Nicolau DP, et al. **Ther Drug Monit** 1996 Jun;18(3):263-6

Clinical mastitis in dairy cows after 'blitz' therapy [letter] Biggs AM. **Vet Rec** 1997 Jul 19;141(3):84

[Experience with daily single dose administration of gentamicin] Christensen SB, et al. **Ugeskr Laeger** 1997 May 19;159(21):3167-71 (Eng. Abstr.) **(Dan)**

[Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection] Mordasini C, et al. **Schweiz Med Wochenschr** 1997 May 24;127(21):905-10 (46 ref.) (Eng. Abstr.) **(Ger)**

[Lymph dilution as a method of treatment in endotoxicosis] Iarema IV, et al. **Anesteziol Reanimatol** 1997 May-Jun; (3):57-9 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Unusual hypokalaemia. Selvais PL, et al. **Acta Clin Belg** 1996; 51(5):357-9

Gentamicin-free bone cement does not alter proteinuria after hip arthroplasty [letter] Nergelius G, et al. **Acta Orthop Scand** 1997 Aug;68(4):410-1

Induction of free radicals in the cochlea by an aminoglycoside antibiotic. Takayama M, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;528:19-24

Effect of gentamycin on the melanosomes in the stria vascularis of the pigmented guinea pig: an ultrastructural study. Yoshihara T, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;528:25-9

Contact sensitivity to gentamicin with tolerance of systemic exposure. Muñoz Bellido FJ, et al. **Allergy** 1996 Oct; 51(10):758-9

Acute massive gentamicin intoxication in a patient with end-stage renal disease. Lu CM, et al. **Am J Kidney Dis** 1996 Nov;28(5):767-71

Topical gentamicin-induced hearing loss: a mitochondrial ribosomal RNA study of genetic susceptibility. Chen JM, et al. **Am J Otol** 1996 Nov;17(6):850-2

Estimation of arcuate artery resistive index as a diagnostic tool for aminoglycoside-induced acute renal failure in dogs. Rivers BJ, et al. **Am J Vet Res** 1996 Nov;57(11):1536-44

Acute renal failure in cardiac surgical patients, potentiated by gentamicin and calcium. Schneider M, et al. **Anaesth Intensive Care** 1996 Dec;24(6):647-50

Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta-lactam antibiotics. Nix DE, et al. **Ann Pharmacother** 1997 Jun; 31(6):696-703

Once-daily aminoglycoside therapy: potential ototoxicity [letter; comment] Kirkpatrick CM, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):879-80. Comment on: Antimicrob Agents Chemother 1996 Sep;40(9):2209-11.

Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Prins JM, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2494-9

Once-daily aminoglycoside therapy: potential ototoxicity [see comments] Singer C, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2209-11. Comment in: Antimicrob Agents Chemother 1997 Apr;41(4):879-80.

Macula toxicity after intravitreal amikacin. Seawright AA, et al. **Aust N Z J Ophthalmol** 1996 May;24(2):143-6

Antibiotic resistance and neurotoxicity: a molecular link to neurotrophins [letter] Vieira AV, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):575-6

Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. Mulheran M, et al. **Br J Audiol** 1997 Feb; 31(1):5-9

Measurement of total phospholipids in urine of patients treated with gentamicin. Saunders DA, et al. **Br J Clin Pharmacol** 1997 Apr;43(4):435-40

Failure of neuromuscular blockade reversal after rocuronium in a patient who received oral neomycin. Hasfurther DL, et al. **Can J Anaesth** 1996 Jun;43(6):617-20

A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides [see comments] Ali MZ, et al. **Clin Infect Dis** 1997 May;24(5):796-809. Comment in: Clin Infect Dis 1997 May;24(5):816-9. Comment in: Clin Infect Dis 1997 May;24(5):820-3.

A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides [see comments] Bailey TC, et al. **Clin Infect Dis** 1997 May;24(5):786-95. Comment in: Clin Infect Dis 1997 May;24(5):816-9. Comment in: Clin Infect Dis 1997 May;24(5):820-3.

Single daily dose of aminoglycosides--a concept whose time has not yet come [editorial; comment] Bertino JS Jr, et al. **Clin Infect Dis** 1997 May;24(5):820-3. Comment on: Clin Infect Dis 1997 May;24(5):786-95. Comment on: Clin Infect Dis 1997 May;24(5):796-809. Comment on: Clin Infect Dis 1997 May;24(5):810-5.

Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Prins JM, et al. **Clin Pharmacol Ther** 1997 Jul;62(1):106-11

Allergic contact dermatitis from streptomycin in a cattle breede. Gauchía R, et al. **Contact Dermatitis** 1996 Dec; 35(6):374-5

Cross-reactions with 4 aminoglycoside antibiotics at various concentrations. Rudzki E, et al. **Contact Dermatitis** 1996 Jul;35(1):62

Cell biology of aminoglycoside nephrotoxicity: newer aspects. Molitoris BA. **Curr Opin Nephrol Hypertens** 1997 Jul;6(4):384-8 (22 ref.)

Neonatal orbital irritant contact dermatitis caused by gentamicin ointment. Merlob P, et al. **Cutis** 1996 Jun; 57(6):429-30

Mechanism and prevention of aminoglycoside ototoxicity: outer hair cells as targets and tools. Priuska EM, et al. **Ear Nose Throat J** 1997 Mar;76(3):164-6, 168, 170-1 (52 ref.)

Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. Nikolaizik WH, et al. **Eur J Pediatr** 1996 Jul;155(7):608-11

Generalized exanthematous pustulosis induced by medications. Sawhney RA, et al. **Int J Dermatol** 1996 Nov; 35(11):826-7

Gray-scale sonographic characterization of aminoglycoside-induced nephrotoxicosis in a canine model. Rivers BJ, et al. **Invest Radiol** 1996 Oct;31(10):639-51

Evaluation of urine gamma-glutamyl transpeptidase-to-creatinine ratio as a diagnostic tool in an experimental model of aminoglycoside-induced acute renal failure in the dog. Rivers BJ, et al. **J Am Anim Hosp Assoc** 1996 Jul-Aug;32(4):323-36

Ototoxicity from ototopical aminoglycosides. Hui Y, et al. **J Otolaryngol** 1997 Feb;26(1):53-6

Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy. Sasaki T, et al. **Kidney Int** 1997 Jan; 51(1):301-9

Ototoxicity resulting from combined administration of cisplatin and gentamicin [letter; comment] Kohn S, et al. **Laryngoscope** 1997 Mar;107(3):407-8. Comment on: Laryngoscope 1996 Apr;106(4):401-6.

N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss [see comments] Basile AS, et al. **Nat Med** 1996 Dec;2(12):1338-43. Comment in: Nat Med 1996 Dec;2(12):1313-4.

Aminoglycoside excitement silences hearing [news; comment] Ernfors P, et al. **Nat Med** 1996 Dec;2(12):1313-4 . Comment on: Nat Med 1996 Dec;2(12):1338-43.

Gentamicin retinal toxicity after cataract surgery in an eye that underwent vitrectomy. Rosenbaum JD, et al. **Ophthalmic Surg Lasers** 1997 Mar;28(3):236-8

Do aminoglycoside otic preparations cause ototoxicity in the presence of tympanic membrane perforations? Wong DL, et al. **Otolaryngol Head Neck Surg** 1997 Mar;116(3):404-10

Effect of aminoglycoside therapy on renal function in full-term infants. Andronikou S, et al. **Pediatr Nephrol** 1996 Dec;10(6):766-8

Recording of brainstem evoked potentials and their association with gentamicin in neonates. Chayasirisobhon S, et al. **Pediatr Neurol** 1996 May;14(4):277-80

Drug nephrotoxicity: an overview. Bennett WM. **Ren Fail** 1997 Mar;19(2):221-4 (28 ref.)

Ototoxicity of aminoglycoside drugs in tuberculosis treatment. Voogt GR, et al. **S Afr J Commun Disord** 1996; 43:3-6

Tetany in a child with AIDS receiving intravenous tobramycin. Slayton W, et al. **South Med J** 1996 Nov; 89(11):1108-10

[Effect of streptomycin placing in the fenestra of semicircular canals on the function and morphology of the normal and hydropic ears in guinea pigs] Peng A, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995;30(6):329-31 (Eng. Abstr.) **(Chi)**

[Is it still possible to reduce the incidence of nephrotoxicity of aminoglycosides?] Beauchamp D, et al. **Pathol Biol (Paris)** 1995 Nov;43(9):779-87 (89 ref.) (Eng. Abstr.) **(Fre)**

[Post-antibiotic effect and the principle of once-a-day aminoglycoside administration] Bitzur R, et al. **Harefuah** 1997 Jun 15;132(12):890-3 (14 ref.) **(Heb)**

[Aminoglycosides, risk factors and neonatal kidney] Khoory BJ, et al. **Pediatr Med Chir** 1996 Sep-Oct;18(5):495-9 (38 ref.) (Eng. Abstr.) **(Ita)**

[Side effects of drug on the central part of the vestibule] Kosztyla-Hojna B, et al. **Otolaryngol Pol** 1995;49(6):583-5 (Eng. Abstr.) **(Pol)**

[Rational use of antibiotics--basis for prevention of their side effects] Gurin NG, et al. **Antibiot Khimioter** 1996 Mar; 41(3):40-3 (Eng. Abstr.) **(Rus)**

[Pathophysiological basis of aminoglycoside-induced ototoxicity] Alamo C, et al. **Acta Otorrinolaringol Esp** 1996 May-Jun;47(3):181-6 (64 ref.) (Eng. Abstr.) **(Spa)**

ANALYSIS

Development of a high-performance liquid chromatographic assay for G418 sulfate (Geneticin). Bethune C, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):661-4

Does intraoperative blood loss affect antibiotic serum and tissue concentrations? Swoboda SM, et al. **Arch Surg** 1996 Nov;131(11):1165-71; discussion 1171-2

Measurement of tobramycin in bronchoalveolar lavage fluid by a modified fluorescence polarization immunoassay [letter] Govantes C, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1111-3

Rapid determination of neomycin by a microbiological agar diffusion assay using triphenyltetrazolium chloride. Yamamoto CH, et al. **J AOAC Int** 1996 Mar-Apr; 79(2):434-440

Sensitive high-performance liquid chromatographic assay for aminoglycosides in biological matrices enables the direct estimation of bacterial drug uptake. Stead DA, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):415-21

Analysis of gentamicin sulfate and a study of its degradation in dextrose solution. Graham AE, et al. **J Pharm Biomed Anal** 1997 Jan;15(4):537-43

A chemical assessment and HPLC assay validation of bulk paromomycin sulfate. Olson LL, et al. **J Pharm Biomed Anal** 1997 Mar;15(6):783-93

ANTAGONISTS & INHIBITORS

The aminonucleoside antibiotic A201A is inactivated by a phosphotransferase activity from Streptomyces capreolus NRRL 3817, the producing organism. Isolation and molecular characterization of the relevant encoding gene and its DNA flanking regions. Barrasa MI, et al.

Eur J Biochem 1997 Apr 1;245(1):54–63

Glucose transporter 2 expression: prevention of streptozotocin-induced reduction in beta-cells with 5-thio-D-glucose. Wang Z, et al.
Exp Clin Endocrinol Diabetes 1995;103 Suppl 2:83–97

Transforming growth factor alpha treatment alters intracellular calcium levels in hair cells and protects them from ototoxic damage in vitro. Staecker H, et al.
Int J Dev Neurosci 1997 Jul;15(4–5):553–62

Attenuation of aminoglycoside ototoxicity by glutathione. Nishida I, et al. **ORL J Otorhinolaryngol Relat Spec** 1996 Mar–Apr;58(2):68–73

[New immortalized cell lines from transgenic rat embryos. I. The isolation and characteristics of cell lines from rat embryos with an injected v-mos oncogene coupled with or without the gene for genecitin resistance] Pugovkina NA, et al. **Tsitologiia** 1996;38(4–5):530–41 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Identification of stsC, the gene encoding the L-glutamine:scyllo-inosose aminotransferase from streptomycin-producing Streptomycetes. Ahlert J, et al. **Arch Microbiol** 1997 Aug;168(2):102–13

Mechanism of multiple aminoglycoside resistance of kasugamycin-producing Streptomyces kasugaensis MB273: involvement of two types of acetyltransferases in resistance to astromicin group antibiotics. Hotta K, et al.
J Antibiot (Tokyo) 1996 Jul;49(7):682–8

[Metabolites produced by Streptomyces kanamyceticus mutants with impaired biosynthesis of kanamycin] Golets LM, et al. **Antibiot Khimioter** 1997;42(4):8–11 (Eng. Abstr.) **(Rus)**

[Kanamycin biosynthesis and aminoglycoside resistance in mutants of Streptomyces kanamyceticus resistant to 2-deoxyglucose] Golets LM, et al. **Antibiot Khimioter** 1996 Jun;41(6):10–4 (Eng. Abstr.) **(Rus)**

BLOOD

Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Prins JM, et al.
Clin Pharmacol Ther 1997 Jul;62(1):106–11

Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin.lesassays@uknequsaa.win-uk.net. White LO, et al. **J Antimicrob Chemother** 1997 Mar;39(3):355–61

Fluorodensitometric evaluation of gentamicin from plasma and urine by high-performance thin-layer chromatography. Bhogte CP, et al.
J Chromatogr B Biomed Appl 1997 Jul 4;694(2):443–7

Determination of amikacin in human plasma by high-performance capillary electrophoresis with fluorescence detection. Oguri S, et al.
J Chromatogr B Biomed Appl 1996 Nov 15;686(2):205–10

Determination of paromomycin in human plasma and urine by reversed-phase high-performance liquid chromatography using 2,4-dinitrofluorobenzene derivatization. Lu J, et al.
J Chromatogr B Biomed Sci Appl 1997 Aug 1;695(2):329–35

Effect of time and temperature on inactivation of aminoglycosides by ampicillin at neonatal dosages. Daly JS, et al. **J Perinatol** 1997 Jan–Feb;17(1):42–5

Statistical approach to neural network model building for gentamicin peak predictions. Smith BP, et al.
J Pharm Sci 1996 Jan;85(1):65–9

Aminoglycoside levels in critically ill surgical patients: the implications of physiologic criteria of sepsis. Cornwell EE 3rd, et al. **South Med J** 1997 Jan;90(1):33–6

Application of a neural network for gentamicin concentration prediction in a general hospital population. Corrigan BW, et al. **Ther Drug Monit** 1997 Feb;19(1):25–8

[Monitoring of gentamycin serum concentration in neonates. Usefulness in adjustment of dosage] García-Delgado R, et al. **An Esp Pediatr** 1997 Jan;46(1):47–52 (Eng. Abstr.) **(Spa)**

[Determination of serum aminoglycoside and vancomycin concentrations by the microbiological method in the presence of other antimicrobials] Corso A, et al.
Rev Argent Microbiol 1996 Jul–Sep;28(3):123–31 (Eng. Abstr.) **(Spa)**

CHEMICAL SYNTHESIS

Synthesis of dibekacin analogs containing 3-oxa- and 3-aza-2,3,4-trideoxy-D-glycero-hexopyranose. Kuwahara R, et al. **Carbohydr Res** 1996 Oct 23;293(1):15–20

Synthesis of kanamycin A analogs containing 6-amino-3-oxa-2,3,4,6-tetradeoxy-D- and -L-glycero-hexopyranose. Kuwahara R, et al.
Carbohydr Res 1996 Jun 5;286:107–22

CHEMISTRY

Stability and antimicrobial activity of gentamicin sulfate, tobramycin sulfate and amikacin sulfate in polypropylene syringes for use in once-daily aminoglycoside therapy. Mitrzyk B, et al. **Am J Health Syst Pharm** 1996 Dec 1; 53(23):2855–9

Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium, and tobramycin sulfate in polyvinyl chloride drug reservoirs. Stiles ML, et al.
Am J Health Syst Pharm 1997 May 1;54(9):1068–70

Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry. Siegel MM, et al.
Anal Chem 1997 Jul 15;69(14):2716–26

Structure-based discovery of ligands targeted to the RNA double helix. Chen Q, et al. **Biochemistry** 1997 Sep 23; 36(38):11402–7

Biologically important conformations of aminoglycoside antibiotics bound to an aminoglycoside 3'-phosphotransferase as determined by transferred nuclear Overhauser effect spectroscopy. Cox JR, et al.
Biochemistry 1997 Mar 4;36(9):2353–9

Saccharide-RNA recognition in an aminoglycoside antibiotic-RNA aptamer complex. Jiang L, et al.
Chem Biol 1997 Jan;4(1):35–50

Solution structure of the esperamicin A1-DNA complex. Kumar RA, et al. **J Mol Biol** 1997 Jan 17;265(2):173–86

Solution structure of the calicheamicin gamma 1I-DNA complex. Kumar RA, et al. **J Mol Biol** 1997 Jan 17; 265(2):187–201

ECONOMICS

Pharmacoeconomic impact of once-daily aminoglycoside administration. Hitt CM, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):810–4

ISOLATION & PURIFICATION

Development of a chromatographic method for the isolation and detection of hygromycin B in biological fluids. Campbell NF, et al. **J Chromatogr B Biomed Appl** 1997 May 9;692(2):367–74

METABOLISM

Enzymatic method for inactivation of aminoglycosides during measurement of postantibiotic effect. den Hollander JG, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):488–90

Recognition of aminoglycoside antibiotics by enterococcal-staphylococcal aminoglycoside 3'-phosphotransferase type IIIa: role of substrate amino groups. McKay GA, et al.
Antimicrob Agents Chemother 1996 Nov;40(11):2648–50

Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region. Wang Y, et al.
Biochemistry 1997 Jan 28;36(4):768–79

RNA molecules that specifically and stoichiometrically bind aminoglycoside antibiotics with high affinities. Wang Y, et al. **Biochemistry** 1996 Sep 24;35(38):12338–46

The binding of Violamycin BI to poly-C. Oncescu T, et al. **Biophys Chem** 1996 Dec 10;63(1):55–65

Binding of aminoglycoside antibiotics by degranulating mast cells. Decorti G, et al. **Chemotherapy** 1997 Jan–Feb; 43(1):36–42

A new immunohistochemical method for the detection of gentamicin in inner ear fluid compartments. Mihelic-Rapp M, et al. **Eur Arch Otorhinolaryngol** 1996;253(7):411–6

Effect of temperature on aminoglycoside binding sites in Stenotrophomonas maltophilia. Rahmati-Bahram A, et al.
J Antimicrob Chemother 1997 Jan;39(1):19–24

Specific targeting of protein-DNA complexes by DNA-reactive drugs (+)-CC-1065 and pluramycins. Henderson D, et al. **J Mol Recognit** 1996 Mar–Apr; 9(2):75–87 (59 ref.)

An antibiotic-binding motif of an RNA fragment derived from the A-site-related region of Escherichia coli 16S rRNA. Miyaguchi H, et al. **Nucleic Acids Res** 1996 Oct 1;24(19):3700–6

Photophysical properties of gilvocarcins V and M and their binding constant to calf thymus DNA. Oyola R, et al.
Photochem Photobiol 1997 May;65(5):802–10

Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Fourmy D, et al. **Science** 1996 Nov 22;274(5291):1367–71

PHARMACOKINETICS

Gentamicin pharmacokinetics in Native Americans of Apache ancestry. Murphy JE, et al.
Am J Health Syst Pharm 1996 Sep 15;53(18):2189–91

Aminoglycoside levels in the rabbit vitreous cavity after intravenous administration [see comments] el-Massry A, et al. **Am J Ophthalmol** 1996 Nov;122(5):684–9. Comment in: Am J Ophthalmol 1996 Nov;122(5):724–6.

Single intravenous and multiple dose pharmacokinetics of gentamicin in healthy llamas. Lackey MN, et al.
Am J Vet Res 1996 Aug;57(8):1193–9

Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: application of optimal sampling theory. Burstein AH, et al. **Ann Pharmacother** 1997 Sep;31(9):980–3

AUIC--a general target for the optimization of dosing regimens of antibiotics? [see comments] Dalla Costa T, et al. **Ann Pharmacother** 1996 Sep;30(9):1024–8. Comment in: Ann Pharmacother 1996 Sep;30(9):1029–31.

Population pharmacokinetics of amikacin in critically ill patients. Bressolle F, et al.
Antimicrob Agents Chemother 1996 Jul;40(7):1682–9

Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Demczar DJ, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1115–9

Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model. den Hollander JG, et al.
Antimicrob Agents Chemother 1996 Mar;40(3):784–6

Once-daily aminoglycoside therapy: potential ototoxicity [letter; comment] Kirkpatrick CM, et al.
Antimicrob Agents Chemother 1997 Apr;41(4):879–80. Comment on: Antimicrob Agents Chemother 1996 Sep;40(9):2209–11.

Gentamicin concentrations in human subcutaneous tissue. Lorentzen H, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1785–9

Influence of experimental rat model of multiple organ dysfunction on cefepime and amikacin pharmacokinetics. Mimoz O, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):819–21

Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections. Radwanski E, et al.
Antimicrob Agents Chemother 1997 Aug;41(8):1794–6

Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Touw DJ, et al.
Antimicrob Agents Chemother 1997 Jan;41(1):184–7

Effect of polyaspartic acid on pharmacokinetics of gentamicin after single intravenous dose in the dog. Whittem T, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1237–41

Aqueous humor penetration of topically applied ciprofloxacin, ofloxacin and tobramycin. Durmaz B, et al.
Arzneimittelforschung 1997 Apr;47(4):413–5

Enhanced gentamicin clearance associated with ileostomy fluid loss [letter] Gaskin TL, et al. **Aust N Z J Med** 1997 Apr;27(2):196–7

Kinetics of nikkomycin Z degradation in aqueous solution and in plasma. Tokumura T, et al. **Biol Pharm Bull** 1997 May;20(5):577–80

Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers. Champoux N, et al.
Br J Clin Pharmacol 1996 Sep;42(3):325–31

Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides [editorial; comment] Gilbert DN. **Clin Infect Dis** 1997 May; 24(5):816–9. Comment on: Clin Infect Dis 1997 May;24(5):786–95. Comment on: Clin Infect Dis 1997 May;24(5):796–809. Comment on: Clin Infect Dis 1997 May;24(5):810–5.

Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Lugo G, et al.
Crit Care Med 1997 May;25(5):806–11

Gentamicin pharmacokinetics in neonates with patent ductus arteriosus. Williams BS, et al. **Crit Care Med** 1997 Feb; 25(2):273–5

Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations. Mörike K, et al.
Drugs Aging 1997 Apr;10(4):259–77 (192 ref.)

A relationship between serum gentamicin concentrations and minimal inhibitory concentration. Bezirtzoglou E, et al.
Drugs Exp Clin Res 1996;22(2):57–60

Efficacy of iontophoresis in the rat cornea. Frucht-Pery J, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Dec; 234(12):765–9

Penetration of gentamicin and ofloxacin in human vitreous after systemic administration. Verbraeken H, et al.
Graefes Arch Clin Exp Ophthalmol 1996 Aug;234 Suppl 1:S59–65

Pharmacokinetics of kanamycin in the developing rat. Henley CM, et al. **Hear Res** 1996 Sep 15;99(1–2):85–90

Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient [see comments] Botha FJ, et al.
Intensive Care Med 1996 May;22(5):443–6. Comment in: Intensive Care Med 1997 Feb;23(2):236–7.

Volume distribution of amikacin [letter; comment] Sleigh JW.
Intensive Care Med 1997 Feb;23(2):236–7. Comment on: Intensive Care Med 1996 May;22(5):443–6.

Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. Hoey LL, et al. **J Burn Care Rehabil** 1997 Mar–Apr;18(2):116–24

Half-life of intracameral gentamicin after phacoemulsification. Lehmann OJ, et al.
J Cataract Refract Surg 1997 Jul–Aug;23(6):883–8

Pharmacokinetics of amikacin in intensive care unit patients. Fernández de Gatta MM, et al. **J Clin Pharm Ther** 1996 Dec;21(6):417–21

Pharmacokinetics of once-daily dosing of gentamicin in neonates. Hayani KC, et al. **J Pediatr** 1997 Jul;131(1 Pt 1):76–80

Application of neural networks to population pharmacokinetic data analysis. Chow HH, et al.
J Pharm Sci 1997 Jul;86(7):840–5

Estimation of population pharmacokinetics using the Gibbs sampler. Best NG, et al. **J Pharmacokinet Biopharm** 1995 Aug;23(4):407–35

The disposition of five therapeutically important antimicrobial agents in llamas. Christensen JM, et al.
J Vet Pharmacol Ther 1996 Dec;19(6):431–8

Pharmacokinetics of gentamicin in llamas. Dowling PM, et al. **J Vet Pharmacol Ther** 1996 Apr;19(2):161–3

Bioavailability in the rabbit of penicillin and dihydrostreptomycin from three commercial penicillin/aminoglycoside fixed combination products for intramuscular injection. Groen K, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):364–9

Bioequivalence study in calves of three commercial penicillin/dihydrostreptomycin fixed combination products for intramuscular injection. Groen K, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):370–5

Pharmacokinetics of gentamicin in donkeys. Welfare RE, et al. **J Vet Pharmacol Ther** 1996 Apr;19(2):167–9

Pharmacokinetic interactions between repeated dose phenylbutazone and gentamicin in the horse. Whittem T, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):454–9

The pharmacokinetics of a single intramuscular dose of amikacin in red-tailed hawks (Buteo jamaicensis). Bloomfield RB, et al. **J Zoo Wildl Med** 1997 Mar; 28(1):55–61

Disposition of single-dose intravenously administered amikacin in emus (Dromaius novaehollandiae). Helmick KE, et al. **J Zoo Wildl Med** 1997 Mar;28(1):49–54

Amikacin pharmacokinetics and the effects of ambient temperature on the dosage regimen in ball pythons (Python regius). Johnson JH, et al. **J Zoo Wildl Med** 1997 Mar; 28(1):80–8

Effect of endotoxin on gentamicin pharmacokinetics in old and young adult rats. Tanira MO, et al. **Life Sci** 1997; 60(6):413–24

Quantitation of tobramycin concentration by laser microscopy in an epithelial cell of renal tubule. Kimura H, et al. **Nippon Hoigaku Zasshi** 1996 Aug;50(4):241–7

Absorption of topically administered ciprofloxacin, ofloxacin and gentamicin in the inflamed rabbit eye. Behrens-Baumann W. **Ophthalmologica** 1996;210(2):119–22

Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm. Touw DJ, et al. **Pharm World Sci** 1997 Jun; 19(3):142–51

Exploration of once-daily dosing of aminoglycosides through Bayesian simulation. Garrelts JC. **Pharmacotherapy** 1996 Mar-Apr;16(2):286–94

Clinical pharmacokinetic pearls: bolus versus infusion equations. Murphy JE, et al. **Pharmacotherapy** 1996 Jul-Aug;16(4):698–700

Intravenous gentamicin and ceftazidime in penetrating ocular trauma: a swine model. Schech JM, et al. **Retina** 1997; 17(1):28–32

Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring. Isemann BT, et al. **Ther Drug Monit** 1996 Oct;18(5):549–55

Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Lugo G, et al. **Ther Drug Monit** 1997 Jun;19(3):271–6

Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Nicolau DP, et al. **Ther Drug Monit** 1996 Jun;18(3):263–6

Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis. Town DJ, et al. **Ther Drug Monit** 1996 Oct;18(5):562–9

Systemic absorption of gentamicin in penile prosthesis operations. Ulker V, et al. **Urol Int** 1996;57(4):218–20

Pharmacokinetics and dosing regimen of aminosidine in the dog. Belloli C, et al. **Vet Res Commun** 1996;20(6):533–41

[Accumulation sites of kanamycin in cochlear basal membrane cells] Ding D, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1995;30(6):323–5 (Eng. Abstr.) **(Chi)**

[Clinical, pharmacokinetic and therapeutic study of amikacin with single daily dose and in combination in neutropenic children with fever] Bertrand Y, et al. **Arch Pediatr** 1996 Sep;3(9):854–60 (Eng. Abstr.) **(Fre)**

[Antibiotic release by tricalcic phosphate bone implantation. In vitro and in vivo pharmacokinetics of different galenic forms] Thomazeau H, et al. **Chirurgie** 1997 Jan; 121(9–10):663–6 (Eng. Abstr.) **(Fre)**

[In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model] Elkhaïli H, et al. **Pathol Biol (Paris)** 1997 May; 45(5):347–56 (Eng. Abstr.) **(Fre)**

[Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology] Pivot-Dumarest C, et al. **Pathol Biol (Paris)** 1996 Apr; 44(4):299–305 (Eng. Abstr.) **(Fre)**

[Individual variability of pharmacokinetic parameters of amikacin in the elderly: retrospective studies] Vincent S, et al. **Pathol Biol (Paris)** 1996 Sep;44(7):667–74 (Eng. Abstr.) **(Fre)**

[The plasma level of kanamycin after intravenous and intramuscular injections in horses] Klee S, et al. **Tierarztl Prax** 1996 Aug;24(4):368–72 (Eng. Abstr.) **(Ger)**

[Post-antibiotic effect and the principle of once-a-day aminoglycoside administration] Bitzur R, et al. **Harefuah** 1997 Jun 15;132(12):890–3 (14 ref.) **(Heb)**

[Individualized monitoring of the therapy with gentamycin using pharmacokinetic methods. Which method to choose?] Carvalho A, et al. **Acta Med Port** 1996 Jul-Sep; 9(7–9):187–95 (Eng. Abstr.) **(Por)**

PHARMACOLOGY

A study on temperature dependent vestibular potential: effect of long lasting thermal stimulus and aminoglycoside agent. Suzuki M, et al. **Acta Otolaryngol (Stockh)** 1997 Mar; 117(2):219–21

Incorporation of tetracycline into otoconia of the guinea-pig following streptomycin intoxication. Zhang DM, et al. **Acta Otolaryngol (Stockh)** 1996 Nov;116(6):812–6

Topical gentamicin-induced hearing loss: a mitochondrial ribosomal RNA study of genetic susceptibility. Chen JM, et al. **Am J Otol** 1996 Nov;17(6):850–2

Cellular mechanism of aminoglycoside tolerance in long-term gentamicin treatment. Sundin DP, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1309–18

Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs. Martinez EA, et al. **Am J Vet Res** 1996 Nov;57(11):1623–6

Multiple antibiotic resistance in Stenotrophomonas maltophilia. Alonso A, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1140–2

Modes of action of tunicamycin, liposidomycin B, and mureidomycin A: inhibition of phospho-N-acetylmuramyl-pentapeptide translocase from Escherichia coli. Brandish PE, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1640–4

Resistance to amikacin and isepamicin in rabbits with experimental endocarditis of an aac(6')-Ib-bearing strain of Klebsiella pneumoniae susceptible in vitro. Caulin E, et al. **Antimicrob Agents Chemother** 1996 Dec; 40(12):2848–53

A novel gentamicin resistance gene in Enterococcus. Chow JW, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):511–4

Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. den Hollander JG, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):95–100

Characterization of the 6'-N-aminoglycoside acetyltransferase gene aac(6')-Il associated with a sulI-type integron. Hannecart-Pokorni E, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):314–8

Chromosomal gentamicin resistance transposon Tn3706 in Streptococcus agalactiae B128. Horaud T, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1085–90

In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa. Karlowsky JA, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1387–93

Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa. Li RC, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1808–11

High-level plasmid-mediated gentamicin resistance and pheromone response of plasmids present in clinical isolates of Enterococcus faecalis. Shiojima M, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):702–5

Combination of flucloxacillin and gentamicin inhibits toxic shock syndrome toxin 1 production by Staphylococcus aureus in both logarithmic and stationary phases of growth. van Langevelde P, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1682–5

Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing. Wood PJ, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1321–4

Overexpression and characterization of the chromosomal aminoglycoside 6'-N-acetyltransferase from Enterococcus faecium. Wright GD, et al. **Antimicrob Agents Chemother** 1997 May;41(5):956–60

Influence of pH on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides and their postantibiotic effects. Xiong YQ, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):35–9

Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Xiong YQ, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):823–6

Aminoglycoside resistance mechanisms in Enterobacteriaceae and Pseudomonas spp. from two Danish hospitals: correlation with type of aminoglycoside used. Busch-Sørensen C, et al. **APMIS** 1996 Oct; 104(10):763–8

Aminoglycoside resistance among Danish blood culture isolates of coagulase-negative staphylococci. Busch-Sørensen C, et al. **APMIS** 1996 Dec;104(12):873–80

Neomycin resistance as a selectable marker in Methanococcus maripaludis. Argyle JL, et al. **Appl Environ Microbiol** 1996 Nov;62(11):4233–7

Evidence that neomycin inhibits human cytomegalovirus infection of fibroblasts. Lobert PE, et al. **Arch Virol** 1996; 141(8):1453–62

Comparison of the effects of amikacin and kanamycins A and B on dimyristoylphosphatidylglycerol bilayers. An infrared spectroscopic investigation. Carrier D, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):401–8

DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Bailly C, et al. **Biochemistry** 1997 Apr 1;36(13):3917–29

Block of P/Q-type calcium channels by therapeutic concentrations of aminoglycoside antibiotics. Pichler M, et al. **Biochemistry** 1996 Nov 19;35(46):14659–64

Mutations in yeast ribosomal proteins S28 and S4 affect the accuracy of translation and alter the sensitivity of the ribosomes to paromomycin. Synetos D, et al. **Biochim Biophys Acta** 1996 Nov 11;1309(1–2):156–66

Design and analysis of molecular motifs for specific recognition of RNA. Li K, et al. **Bioorg Med Chem** 1997 Jun;5(6):1157–72

Clonal variability in beta-globin mRNA content in an interleukin-3-dependent bone marrow cell line transfected with the erythropoietin receptor before and after stimulation with erythropoietin. Ishiguro K, et al. **Blood** 1997 Sep 15;90(6):2273–81

The in vitro synergistic inhibitory effect of human amniotic fluid and gentamicin on growth of Escherichia coli. Miglioli PA, et al. **Chemotherapy** 1996 May-Jun; 42(3):206–9

Protective effect of liposomal gentamicin against systemic acute murine brucellosis. Vitas AI, et al. **Chemotherapy** 1997 May-Jun;43(3):204–10

Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers. Pitkin DH, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S238–48

Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices. Biedenbach DJ, et al. **Diagn Microbiol Infect Dis** 1997 Jan-Feb;27(1–2):1–5

Investigation of nosocomial infection caused by arbekacin-resistant, methicillin-resistant Staphylococcus aureus. Obayashi Y, et al. **Diagn Microbiol Infect Dis** 1997 Jun;28(2):53–9

In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Tessier F, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb;16(2):159–62

Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. Van Bambeke F, et al. **Eur J Pharmacol** 1996 Oct 24;314(1–2):203–14

Gentamicin treatment increases mesangial cell nitric oxide production. Rivas-Cabañero L, et al. **Exp Nephrol** 1997 Jan-Feb;5(1):23–30

Addition of G418 and other aminoglycoside antibiotics to mammalian cells results in the release of GPI-anchored proteins. Küng M, et al. **FEBS Lett** 1997 Jun 16; 409(3):333–8

Stability and modulated expression of a hygromycin resistance gene integrated in Botrytis cinerea transformants. Hamada W, et al. **FEMS Microbiol Lett** 1997 Sep 15; 154(2):187–93

Acridine orange as an indicator of bacterial susceptibility to gentamicin. Mason DJ, et al. **FEMS Microbiol Lett** 1997 Aug 1;153(1):199–204

Pharmacodynamic parameters of aminoglycosides and their effect on exoenzymes of Pseudomonas aeruginosa. Hoštacká A. **Folia Microbiol (Praha)** 1996;41(2):149–53

Postantibiotic effects of subinhibitory concentrations of some antibiotics and their influence on Pseudomonas aeruginosa enzymic activity. Hoštacká A. **Folia Microbiol (Praha)** 1996;41(1):39–42

Inhibition of Pseudomonas aeruginosa alginate expression by subinhibitory concentrations of antibiotics. Majtán V, et al. **Folia Microbiol (Praha)** 1996;41(1):61–4

A simple and rapid method for the determination of recombinant retrovirus titer by G418 selection. Byun J, et al. **Gene Ther** 1996 Nov;3(11):1018–20

Hygromycin-resistant calli generated by activation and excision of maize Ac/Ds transposable elements in diploid and hexaploid wheat cultured cell lines. Takumi S. **Genome** 1996 Dec;39(6):1169–75

Biochemical evidence for nuclear gene involvement in phenotype of non-syndromic deafness associated with mitochondrial 12S rRNA mutation. Guan MX, et al. **Hum Mol Genet** 1996 Jul;5(7):963–71

High level aminoglycoside resistance in enterococci isolated from hospitalized patients. Bhat KG, et al. **Indian J Med Res** 1997 May;105:198–9

Postantibiotic effect of ceftriaxone and gentamicin alone and in combination on Klebsiella pneumoniae, Pseudomonas aeruginosa and Streptococcus viridans. Buxbaum A, et al. **Infection** 1996 Nov-Dec;24(6):459–64

Ardacin for steers grazing endophyte-free fescue pasture: effects on live weight gain, forage intake, nitrogen and fiber digestion, ruminal fluid kinetics, ruminal fermentation, and serum hormones and metabolites. Judkins MB, et al. **J Anim Sci** 1997 Apr;75(4):1100–11

Structure-activity relationships of hygromycin A and its analogs: protein synthesis inhibition activity in a cell free system. Hayashi SF, et al. **J Antibiot (Tokyo)** 1997 Jun; 50(6):514–21

Mechanism of multiple aminoglycoside resistance of kasugamycin-producing Streptomyces kasugaensis MB273: involvement of two types of acetyltransferases in resistance to astromicin group antibiotics. Hotta K, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):682–8

Liposidomycin B inhibits in vitro formation of polyprenyl (pyro)phosphate N-acetylglucosamine, an intermediate in glycoconjugate biosynthesis [letter] Muroi M, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):103–4

The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro. Barclay ML, et al. **J Antimicrob Chemother** 1996 Nov;38(5):853–8

In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa. Giamarellos-Bourboulis EJ, et al. **J Antimicrob Chemother** 1996 Aug;38(2):287–91

In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria. Ho YI, et al. **J Antimicrob Chemother** 1997 Jul;40(1):27–32

Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo. Mimoz O, et al. **J Antimicrob Chemother** 1997 Mar;39(3):363–9

Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages. Pellegrin I, et al. **J Antimicrob Chemother** 1996 Mar;37(3):501–10

The absence of genetic markers for streptomycin and rifampicin resistance in Mycobacterium avium complex strains. Portillo-Gomez L, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1049–53

Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. Watanabe T, et al. **J Antimicrob Chemother** 1997 Apr;39(4):471–6

Antimicrobial susceptibility and plasmid-mediated streptomycin resistance of Plesiomonas shigelloides isolated from blue crab. Marshall DL, et al. **J Appl Bacteriol** 1996 Aug;81(2):195–200

Apramycin resistance as a selective marker for gene transfer in mycobacteria. Paget E, et al. **J Bacteriol** 1996 Nov; 178(21):6357–60

Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors. Daigle DM, et al. **J Biol Chem** 1997 Oct 3;272(40):24755–8

Activity of amoxicillin, metronidazole, bismuth salicylate and six aminoglycosides against Helicobacter pylori. Brenciaglia MI, et al. **J Chemother** 1996 Feb;8(1):52–4

In vivo bacterial regrowth-inhibition effect of cefbuperazone and amikacin in puerperal uterine cavity. Izumi K, et al. **J Chemother** 1995 Nov;7 Suppl 4:173–6

Aminoglycoside resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates in a Greek tertiary-care hospital. Platsouka E, et al. **J Chemother** 1995 Nov;7 Suppl 4:73–5

In vitro bactericidal effect of a beta-lactam + aminoglycoside combination against multiresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Roussel-Delvallez M, et al. **J Chemother** 1996 Oct;8(5):365–8

Recognition of a Nocardia transvalensis complex by resistance to aminoglycosides, including amikacin, and PCR-restriction fragment length polymorphism analysis. Wilson RW, et al. **J Clin Microbiol** 1997 Sep;35(9):2235–42

Block of single L-type Ca2+ channels in skeletal muscle fibers by aminoglycoside antibiotics. Haws CM, et al. **J Gen Physiol** 1996 Mar;107(3):421–32

Subconductance block of single mechanosensitive ion channels in skeletal muscle fibers by aminoglycoside antibiotics. Winegar BD, et al. **J Gen Physiol** 1996 Mar; 107(3):433–43

Gene transfer, gentamicin resistance and enterococci. Simjee S, et al. **J Hosp Infect** 1997 Aug;36(4):249–59 (36 ref.)

Sequential emergence of multi-resistant Klebsiella pneumoniae in Bahrain. Wallace MR, et al. **J Hosp Infect** 1995 Dec;31(4):247–52

Neomycin inhibits secretion of apolipoprotein[a] by increasing retention on the hepatocyte cell surface. Lanford RE, et al. **J Lipid Res** 1996 Oct;37(10):2055–64

Structures and biological activities of tobramycin-ticarcillin adducts. Huh K, et al. **J Pharm Sci** 1994 Jun;83(6):763–7

A simple in vitro model to test the efficacy of antimicrobial agents released from dressings. Grzybowski J, et al. **J Pharmacol Toxicol Methods** 1996 Oct;36(2):73–6

Biphasic glomerular hypertrophy in rats administered puromycin aminonucleoside. Cahill MM, et al. **Kidney Int** 1996 Sep;50(3):768–75

Effect of cortisporin otic suspension on cochlear function and efferent activity in the guinea pig. Perry BP, et al. **Laryngoscope** 1996 Dec;106(12 Pt 1):1557–61

In vitro susceptibility of Streptococcus pneumoniae strains to nine beta-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin. Marton A, et al. **Microb Drug Resist** 1996 Fall;2(3):361–9

Molecular epidemiology of enterococci with high-level resistance to aminoglycosides. Privitera O, et al. **Microb Drug Resist** 1995 Winter;1(4):293–7

Characterization of HEp-2 cell projection formation induced by diffusely adherent Escherichia coli. Cookson ST, et al. **Microb Pathog** 1996 Dec;21(6):421–34

Effect of neomycin on glycosyl-phosphatidylinositol and phosphatidylinositol system of Tetrahymena. Kovács P, et al. **Microbios** 1996;85(342):7–18

Stable coexpression of a drug-resistance gene and a heterologous gene in an ancient parasitic protozoan Giardia lamblia. Yu DC, et al. **Mol Biochem Parasitol** 1996 Dec 2;83(1):81–91

Complexes between nascent polypeptides and their molecular chaperones in the cytosol of mammalian cells. Eggers DK, et al. **Mol Biol Cell** 1997 Aug;8(8):1559–73

Dissemination of the strA-strB streptomycin-resistance genes among commensal and pathogenic bacteria from humans, animals, and plants. Sundin GW, et al. **Mol Ecol** 1996 Feb; 5(1):133–43 (100 ref.)

Adhesion of Candida albicans to epithelial cells--effect of nikkomycin. Segal E, et al. **Mycoses** 1997 Jan-Feb; 40(1–2):33–9

Neomycin and gadolinium applied to an L5 spinal nerve lesion prevent mechanical allodynia-like behaviour in rats. Blenk KH, et al. **Pain** 1997 Apr;70(2–3):155–65

Vancomycin and amikacin in cell cultures for virus isolation. Lo JY, et al. **Pathology** 1996 Nov;28(4):366–9

Aminoglycoside adaptive resistance. Karlowsky JA, et al. **Pharmacotherapy** 1997 May-Jun;17(3):549–55 (37 ref.)

The influence of postantibiotic effects and postantibiotic effects of sub-inhibitory concentrations of quinolones and aminoglycosides on phospholipase C of Pseudomonas aeruginosa. Hybenová D, et al. **Pharmazie** 1997 Feb; 52(2):157–9

Neuromuscular blocking actions of the aminoglycoside antibiotics sisomicin and micronomicin in the rabbit. Matsukawa S, et al. **Tohoku J Exp Med** 1997 Apr; 181(4):471–3

Bacterial resistance to aminoglycoside antibiotics. Davies J, et al. **Trends Microbiol** 1997 Jun;5(6):234–40 (47 ref.)

Postantibiotic effect and virulence factors depression induced by ciprofloxacin and by aminoglycosides in a clinical isolate of Pseudomonas aeruginosa. Hostacka A. **Zentralbl Bakteriol** 1996 Mar;283(3):322–7

Selection of subpopulations resistnat to amikacin and netilmicin of gentamicin-resistant clinical strains of Staphylococcus aureus and Staphylococcus epidermidis. Torres García M, et al. **Zentralbl Bakteriol** 1996 Jun; 284(1):58–66

The effect of neomycin on the kidney function of the horse. Fuentes VO, et al. **Zentralbl Veterinarmed A** 1997 Jun; 44(4):201–5

[Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance] Canis F, et al. **Pathol Biol (Paris)** 1997 May;45(5):420–3 (Eng. Abstr.) **(Fre)**

[In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model] Elkhaïli H, et al. **Pathol Biol (Paris)** 1997 May; 45(5):347–56 (Eng. Abstr.) **(Fre)**

[Tricentric study of the sensitivity of Pseudomonas aeruginosa serotyping to beta-lactams and aminoglycosides] Vachée A, et al. **Pathol Biol (Paris)** 1997 May;45(5):357–62 (Eng. Abstr.) **(Fre)**

["Killing" of pseudomonas aeruginosa isolated from patients with critical post-operative complications. Effect of various antibiotics] Delogu G, et al. **Ann Ital Chir** 1997 Mar-Apr;68(2):219–24 (Eng. Abstr.) **(Ita)**

[Tobramycin--clinical pharmacology and chemotherapy] Periti P. **J Chemother** 1996 Jan;8 Suppl 1:3–30 (171 ref.) (Eng. Abstr.) **(Ita)**

[Antimicrobial activities of arbekacin against methicillin-resistant Staphylococcus aureus] Deguchi K, et al. **Jpn J Antibiot** 1997 Jan;50(1):1–11 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). III. Secular changes in susceptibility] Kumamoto Y, et al. **Jpn J Antibiot** 1996 Jun; 49(6):555–657 (Eng. Abstr.) **(Jpn)**

[Gentamicin-induced alteration in drug susceptibility and lipopolysaccharide-composition of Pseudomonas aeruginosa isolates] Hasegawa M, et al. **Kansenshogaku Zasshi** 1997 Mar;71(3):199–206 (Eng. Abstr.) **(Jpn)**

[The taxonomic distribution, characteristic and susceptibility against antimicrobial agents of methicillin-resistant staphylococci isolated from blood] Kawaguchi E, et al. **Kansenshogaku Zasshi** 1996 Nov;70(11):1147–53 (Eng. Abstr.) **(Jpn)**

[Biochemical and genetic mechanisms for bacteria to acquire aminoglycoside antibiotic resistance] Hotta K. **Nippon Rinsho** 1997 May;55(5):1231–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Characteristics of Streptomyces kanamyceticus mutants resistant to aminoglycoside antibiotics] Demidchuk IuA, et al. **Antibiot Khimioter** 1996 Jun;41(6):15–20 (Eng. Abstr.) **(Rus)**

[Ultrastructural study of the organ of Corti in animals given kanamycin and ceruloplasmin] Il'inskaya EV, et al. **Vestn Otorinolaringol** 1997;(4):24–6 (Eng. Abstr.) **(Rus)**

[Pathophysiological basis of aminoglycoside-induced ototoxicity] Alamo C, et al. **Acta Otorrinolaringol Esp** 1996 May-Jun;47(3):181–6 (64 ref.) (Eng. Abstr.) **(Spa)**

[Synergic effect of a teicoplanin and cefpirome combination with aminoglucosides on enterococci. Therapeutic importance] Hoyos López A, et al. **An Med Interna** 1995 Aug;12(8):374–6 (Eng. Abstr.) **(Spa)**

[Fluoroquinolone and aminoglycoside resistance in chromosomal cephalosporinase-overproducing gram-negative bacilli strains with inducible beta-lactamase] López-Yeste M, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):211–4 (Eng. Abstr.) **(Spa)**

POISONING

Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Fischel-Ghodsian N, et al. **Am J Otolaryngol** 1997 May-Jun;18(3):173–8

Mutation in the mitochondrial 12S rRNA gene in two families from Mongolia with matrilineal aminoglycoside ototoxicity. Pandya A, et al. **J Med Genet** 1997 Feb; 34(2):169–72

THERAPEUTIC USE

Disseminated tuberculosis treated with amikacin in a patient with acute myelocytic leukemia. Engervall P, et al. **Acta Oncol** 1997;36(4):444–6

Intramedullary, antibiotic-loaded cemented, massive allografts for skeletal reconstruction. 26 cases compared with 19 uncemented allografts. Ozaki T, et al. **Acta Orthop Scand** 1997 Aug;68(4):387–91

When and how to use gentamicin in the treatment of Menière's disease. Odkvist LM, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;526:54–7

Bacterial killing by use of once daily gentamicin dosage in guinea pigs with Escherichia coli infection. Campbell BG, et al. **Am J Vet Res** 1996 Nov;57(11):1627–30

Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ribera E, et al. **Ann Intern Med** 1996 Dec 15;125(12):969–74

Inhaled antibiotics in cystic fibrosis: a review. Toso C, et al. **Ann Pharmacother** 1996 Jul-Aug;30(7–8):840–50 (61 ref.)

Once-daily gentamicin therapy for experimental Escherichia coli meningitis. Ahmed A, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):49–53

Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Beaulac C, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):665–9

In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model. Bugnon D, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1164–9

Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Gavaldà J, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):173–8

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Leibovici L, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1127–33

Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. Lounis N, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1168–9

Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Lounis N, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):607–10

Treatment of human brucellosis with doxycycline and gentamicin [see comments] Solera J, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):80–4. Comment in: Antimicrob Agents Chemother 1997 Jul;41(7):1621–2.

Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Xiong YQ, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):823–6

Efficacy of a single dose of erythromycin or penicillin/streptomycin for the treatment of ovine dermatophilosis. Scrivener CJ, et al. **Aust Vet J** 1995 Dec; 72(12):475–6

Amikacin may be drug of choice in Nocardia keratitis [letter] Denk PO, et al. **Br J Ophthalmol** 1996 Oct;80(10):928–9

Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Cordonnier C, et al. **Clin Infect Dis** 1997 Jan;24(1):41–51

A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. Hemsell DL, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S222–30

Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. Wilson SE. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S197–206

Necrotizing external otitis: aminoglycoside and beta-lactam antibiotic treatment combined with surgical treatment. Pedersen HB, et al. **Clin Otolaryngol** 1997 Jun;22(3):271–4

A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children [see comments] Gross RD, et al. **Clin Pediatr (Phila)** 1997 Aug;36(8):435–44. Comment in: Clin Pediatr (Phila) 1997 Aug;36(8):445–8.

Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Lugo G, et al. **Crit Care Med** 1997 May;25(5):806–11

Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Denton M, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):402–5

ANTIBIOTICS, AMINOGLYCOSIDE

A comparison of two ophthalmic steroid-antibiotic combinations after cataract surgery. van Endt JJ, et al. **Eur J Ophthalmol** 1997 Apr-Jun;7(2):144-8

Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Vic P, et al. **Eur J Pediatr** 1996 Nov;155(11):948-53

Comparative trial of four antibiotic combinations for perforated appendicitis in children. Ciftci AO, et al. **Eur J Surg** 1997 Aug;163(8):591-6

Temperature-dependent resistance to gentamicin in graft keratitis by stenotrophomonas (Xanthamonas) maltophilia [letter] Richardson PR, et al. **Eye** 1997;11 (Pt 1):124-6

Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines [see comments] Evans ME, et al. **Infect Control Hosp Epidemiol** 1996 Jun;17(6):356-9. Comment in: Infect Control Hosp Epidemiol 1996 Jun;17(6):353-5. Comment in: Infect Control Hosp Epidemiol 1996 Dec;17(12):773-4.

Prevention and control of vancomycin resistance in gram-positive coccal microorganisms: fire prevention and fire fighting [editorial; comment] Mayhall CG. **Infect Control Hosp Epidemiol** 1996 Jun;17(6):353-5. Comment on: Infect Control Hosp Epidemiol 1996 Jun;17(6):356-9.

Dosage adjustment of antiinfective therapy in patients with renal impairment. Eckhardt A, et al. **Int J Clin Pharmacol Ther** 1997 Mar;35(3):99-102

Aseptic loosening of BonelocR cemented hip prostheses. Wedderkopp N, et al. **Int Orthop** 1997;21(2):87-90

Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma. Allen SL, et al. **Invest New Drugs** 1996; 14(2):213-7

Responsible extra-label use of drugs [letter; comment] Reece TR. **J Am Vet Med Assoc** 1996 Nov 1;209(9):1545-6. Comment on: J Am Vet Med Assoc 1996 Sep 1;209(5):897-8.

Topical treatment of Pseudomonas sp-infected corneal ulcers in horses: 70 cases (1977-1994). Sweeney CR, et al. **J Am Vet Med Assoc** 1996 Sep 1;209(5):954-7

Veterinary use of antimicrobial agents and problems of resistance in human bacterial infections [letter; comment] Johnson AP. **J Antimicrob Chemother** 1997 Feb;39(2):285-6 . Comment on: J Antimicrob Chemother 1996 Jul;38(1):1-3.

Tissue reactions to bacteria-inoculated rat lead samples. II. Effect of local gentamicin release through surface-modified polyurethane tubing. van Wachem PB, et al. **J Biomed Mater Res** 1997 May;35(2):233-47

Tissue reactions to bacteria-inoculated rat lead samples. I. Effect of local gentamicin release through vicinal sponge or solution-dipping. van Wachem PB, et al. **J Biomed Mater Res** 1997 May;35(2):217-32

Efficacy and safety of combined diclofenac 0.1% and gentamicin 0.3% eyedrops after phacoemulsification. Rossetti L, et al. **J Cataract Refract Surg** 1997 Jun; 23(5):745-9

Aminoglycoside prescription, therapeutic monitoring and nephrotoxicity at a university hospital in Saudi Arabia. Eltahawy AT, et al. **J Chemother** 1996 Aug;8(4):278-83

Amikacin as first-choice aminoglycoside in a medical intensive care unit: a one-year bacteriological surveillance study. Peetermans WE, et al. **J Chemother** 1996 Feb; 8(1):17-24

Therapeutic drug monitoring of gentamicin: a 6-year follow-up audit. Ismail R, et al. **J Clin Pharm Ther** 1997 Feb;22(1):21-5

Safety of topical ear drops containing ototoxic antibiotics. Rakover Y, et al. **J Otolaryngol** 1997 Jun;26(3):194-6

Ampicillin/sulbactam vs. clindamycin/gentamicin in the treatment of postpartum endometritis. Gall S, et al. **J Reprod Med** 1996 Aug;41(8):575-80

Selective intestinal decontamination in multiple trauma patients: prospective, controlled trial. Lingnau W, et al. **J Trauma** 1997 Apr;42(4):687-94

Antimicrobial effects of amikacin therapy on experimentally induced Salmonella typhimurium infection in fowls. Itoh N, et al. **J Vet Med Sci** 1996 May;58(5):425-9

Systemic absorption of gentamicin following intramammary administration to cows with mastitis [correction of mastititis]. Sweeney RW, et al. **J Vet Pharmacol Ther** 1996 Apr;19(2):155-7

Ophthalmic fluorometholone-gentamicin versus ophthalmic betamethasone-gentamicin following cataract surgery. Steinbach PD, et al. **Ocul Immunol Inflamm** 1997 Mar; 5(1):51-4

A prospective randomized study of medications after silicone intubation. Liu D. **Ophthalmic Surg Lasers** 1996 Jun; 27(6):434-7

Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Hyndiuk RA, et al. **Ophthalmology** 1996 Nov; 103(11):1854-62; discussion 1862-3

Free versus liposome-entrapped streptomycin sulfate in treatment of infections caused by Salmonella enteritidis. Khalil RM, et al. **Pharmazie** 1996 Mar;51(3):182-4

Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever. Engervall P, et al. **Scand J Infect Dis** 1996;28(3):297-303

Aminoglycosides do not improve the efficacy of cephalosporins for treatment of acute pyelonephritis in women. Sandberg T, et al. **Scand J Infect Dis** 1997; 29(2):175-9

MRSA meningitis and intrathecal injection of arbekacin. Fujita T, et al. **Surg Neurol** 1997 Jul;48(1):69

Nebulised antipseudomonal therapy in cystic fibrosis [letter; comment] Touw DJ, et al. **Thorax** 1996 Dec;51(12):1283 . Comment on: Thorax 1996 Apr;51(4):364-8.

A survey of horses with acute diarrhoea: diagnosis, assessment of the prognosis, and comparison of two antibiotic therapies. van Duijkeren E, et al. **Vet Q** 1996 Dec;18(4):153-6

[Toxic shock-like syndrome caused by streptococci--treated with clindamycin] Nørgaard M. **Ugeskr Laeger** 1997 Apr 14;159(16):2396-7 (Eng. Abstr.) **(Dan)**

[Clinical, pharmacokinetic and therapeutic study of amikacin with single daily dose and in combination in neutropenic children with fever] Bertrand Y, et al. **Arch Pediatr** 1996 Sep;3(9):854-60 (Eng. Abstr.) **(Fre)**

[Efficacy and tolerability of a combination of indomethacin and gentamicin for preventing inflammation after cataract surgery] Renard G, et al. **J Fr Ophtalmol** 1996; 19(11):689-95 (Eng. Abstr.) **(Fre)**

[Tobramycin--clinical pharmacology and chemotherapy] Periti P. **J Chemother** 1996 Jan;8 Suppl 1:3-30 (171 ref.) (Eng. Abstr.) **(Ita)**

[Effects of hyperbaric oxygenation in skin and pulmonary infections caused by Pseudomonas aeruginosa] Marmo M, et al. **Minerva Anestesiol** 1996 Sep;62(9):281-7 (Eng. Abstr.) **(Ita)**

[Current problems in the treatment of bacterial meningitis] Principi N. **Minerva Pediatr** 1996 Dec;48(12):551-69 (Eng. Abstr.) **(Ita)**

[Effect of 2-methyl-4-amino-6-hydroxypyrimidine on the effectiveness of antibiotic therapy in experimental staphylococcal infection in the context of immunosuppression] Ismagilova AF, et al. **Antibiot Khimioter** 1996 Mar;41(3):29-31 (Eng. Abstr.) **(Rus)**

[Treatment of purulent postoperative wounds with collagen and immobilised gentamycin] Khanin AG, et al. **Khirurgiia (Mosk)** 1997;(6):44-6 (Eng. Abstr.) **(Rus)**

[Effectiveness of medical treatment of endocarditis due to Candida in premature newborns] García Cantó E, et al. **An Esp Pediatr** 1997 Mar;46(3):277-9 **(Spa)**

[Monitoring of gentamycin serum concentration in neonates. Usefulness in adjustment of dosage] García-Delgado R, et al. **An Esp Pediatr** 1997 Jan;46(1):47-52 (Eng. Abstr.) **(Spa)**

[Comparison of the therapeutic efficacy of the piperacillin/tazobactame combination vs. ampicillin and gentamycin in in the management of post-cesarean endometritis] Figueroa-Damian R, et al. **Ginecol Obstet Mex** 1996 May;64:214-8 (Eng. Abstr.) **(Spa)**

TOXICITY

Effect of streptomycin intoxication on vestibular nerve regeneration and posture recovery. Kadir A, et al. **Acta Otolaryngol (Stockh)** 1997 May;117(3):376-81

Effects of fasting on temporal variations in nephrotoxicity of gentamicin in rats. Beauchamp D, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):670-6

Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin. Beauchamp D, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1237-45

Time-restricted feeding schedules modify temporal variation of gentamicin experimental nephrotoxicity. Beauchamp D, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1468-74

Temporal variation in nephrotoxicity of low doses of isepamicin in rats. Yoshiyama Y, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):802-6

Changes in polyurethane calcification due to antibiotics. Chandy T, et al. **Artif Organs** 1996 Jul;20(7):752-60

Kidney and urine enzyme activity in experimental gentamicin nephrotoxicity in the Sprague-Dawley rat. Brown D, et al. **Biochem Soc Trans** 1996 May;24(2):317S

Regenerated hair cells exhibit a transient resistance to aminoglycoside toxicity. Hashino E, et al. **Brain Res** 1996 May 13;720(1-2):172-82

Cell death caused by the acute effects of aminoglycoside and zinc in the ampullary cristae of guinea pigs. Nakagawa T, et al. **Eur Arch Otorhinolaryngol** 1997;254(3):153-7

Involvement of platelet-activating factor in gentamicin nephrotoxicity in rats. Rodriguez-Barbero A, et al. **Exp Nephrol** 1997 Jan-Feb;5(1):47-54

Sex dependent electrocardiogram (ECG) changes in anthracycline-treated mice. Nachbar A, et al. **Exp Toxicol Pathol** 1997 Feb;49(1-2):75-7

Secretion of a new basal layer of tectorial membrane following gentamicin-induced hair cell loss. Epstein JE, et al. **Hear Res** 1995 Oct;90(1-2):31-43

The binding site on cochlear stereocilia for antisera raised against renal Na+ channels is blocked by amiloride and dihydrostreptomycin. Furness DN, et al. **Hear Res** 1996 Apr;93(1-2):136-46

Sensitive developmental periods for kanamycin ototoxic effects on distortion-product otoacoustic emissions. Henley CM, et al. **Hear Res** 1996 Sep 1;98(1-2):93-103

Reactive oxygen species in chick hair cells after gentamicin exposure in vitro. Hirose K, et al. **Hear Res** 1997 Feb; 104(1-2):1-14

Variable efficacy of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo. Song BB, et al. **Hear Res** 1996 May;94(1-2):87-93

Influence of chronic kanamycin administration on basement membrane anionic sites in the labyrinth. Yamasoba T, et al. **Hear Res** 1996 Dec 1;102(1-2):116-24

Does the organ of Corti attempt to differentiate new hair cells after antibiotic intoxication in rat pups? Lenoir M, et al. **Int J Dev Neurosci** 1997 Jul;15(4-5):487-95

Quantification of the process of hair cell loss and recovery in the chinchilla crista ampullaris after gentamicin treatment. Lopez I, et al. **Int J Dev Neurosci** 1997 Jul; 15(4-5):447-61

Transforming growth factor alpha treatment alters intracellular calcium levels in hair cells and protects them from ototoxic damage in vitro. Staecker H, et al. **Int J Dev Neurosci** 1997 Jul;15(4-5):553-62

Evaluation of gentamicin-induced nephrotoxicosis in toadfish. Reimschuessel R, et al. **J Am Vet Med Assoc** 1996 Jul 1;209(1):137-9

Interaction of tobramycin and pH in cultured chick tibiae. Murakami T, et al. **J Orthop Res** 1996 Sep;14(5):742-8

Expression of hygR in transgenic mice causes resistance to toxic effects of hygromycin B in vivo. Aubrecht J, et al. **J Pharmacol Exp Ther** 1997 May;281(2):992-7

Protection from gentamicin ototoxicity by iron chelators in guinea pig in vivo. Song BB, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):369-77

Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats. Shinosaki T, et al. **Jpn J Pharmacol** 1997 Apr;73(4):337-45

Synergestic effects of noise and aminoglycoside antibiotic (gentamicin) on auditory function in the gerbil. Chen TJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Jul; 13(7):407-16

Identification of an overexpressed yeast gene which prevents aminoglycoside toxicity. Prezant TR, et al. **Microbiology** 1996 Dec;142 (Pt 12):3407-14

Aminoglycoside-induced viability in cultured PtK1 proximal tubular cell lines. Shibasaki T, et al. **Miner Electrolyte Metab** 1997;23(1):1-6

The spontaneous appearance of hair cell-like cells in the mammalian cochlea following aminoglycoside ototoxicity. Romand R, et al. **Neuroreport** 1996 Dec 20;8(1):133-7

Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats. Fauconneau B, et al. **Ren Fail** 1997 Jan;19(1):15-22

The relationship between enzymuria and kidney enzyme activities in experimental gentamicin nephrotoxicity. Whiting PH, et al. **Ren Fail** 1996 Nov;18(6):899-909

Gentamicin-induced nephrotoxicosis in lambs. Fadel AA, et al. **Res Vet Sci** 1996 Nov;61(3):187-92

Poly-l-aspartic acid protects cultured human proximal tubule cells against aminoglycoside-induced electrophysiological alterations. Todd JH, et al. **Toxicol Lett** 1997 Feb 7; 90(2-3):217-21

URINE

Fluorodensitometric evaluation of gentamicin from plasma and urine by high-performance thin-layer chromatography. Bhogte CP, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):443-7

Determination of paromomycin in human plasma and urine by reversed-phase high-performance liquid chromatography using 2,4-dinitrofluorobenzene derivatization. Lu J, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1;695(2):329-35

ANTIBIOTICS, ANTHRACYCLINE

Sex difference in progression of adriamycin-induced nephropathy in rats. Sakemi T, et al. **Am J Nephrol** 1996; 16(6):540-7

Stability study of epirubicin in NaCl 0.9% injection. Pujol M, et al. **Ann Pharmacother** 1997 Sep;31(9):992-5

The anthracycline resistance-associated (ara) gene, a novel gene associated with multidrug resistance in a human leukaemia cell line. Longhurst TJ, et al. **Br J Cancer** 1996 Nov;74(9):1331-5

Comparison of daunorubicin and Fluo-3 for detection of multidrug resistance in human tumor cells. Gheuens EE, et al. **Cancer Detect Prev** 1997;21(1):78-82

Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy. Barker IK, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):323-9

The influence of cyclosporin on lipid peroxidation and superoxide dismutase in adriamycin nephropathy in rats. Zima T, et al. **Nephron** 1997;75(4):464-8

Epirubicin cardiotoxicity: a study comparing low- with high-dose-intensity weekly schedules. Berchem GJ, et al. **Support Care Cancer** 1996 Jul;4(4):308-12

[A human cell line panel for screening anti-cancer drugs] Yamori T. **Gan To Kagaku Ryoho** 1997 Jan;24(2):129-35 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Phase II study of liposomal encapsulated daunorubicin in the

treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. Girard PM, et al. **AIDS** 1996 Jun;10(7):753-7

Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer. Gridelli C, et al. **Am J Clin Oncol** 1996 Dec;19(6):589-91

Gonadal function following ABVD therapy for Hodgkin's disease. Kulkarni SS, et al. **Am J Clin Oncol** 1997 Aug; 20(4):354-7

Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer. Michael M, et al. **Am J Clin Oncol** 1997 Jun;20(3):259-62

Liposomal daunorubicin marketed for HIV-related Kaposi's sarcoma [news] **Am J Health Syst Pharm** 1996 Jul 1; 53(13):1500, 1505

Isolated lung perfusion with doxorubicin prolongs survival in a rodent model of pulmonary metastases. Abolhoda A, et al. **Ann Thorac Surg** 1997 Jul;64(1):181-4

Release of daunorubicin from polymethylmethacrylate for the improvement of the local growth control of bone metastasis animal experiments. Fröschle GW, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):995-1002

Prediction of the optimum clinical dosing schedule for menogaril from results with tumor-bearing mice. Yoshida M, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2869-73

Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection [letter] Fournier S, et al. **Arch Dermatol** 1997 Jul; 133(7):918-9

Use of adriamycin-impregnated methylmethacrylate in the treatment of tumor metastases in the long bones. Katagiri H, et al. **Arch Orthop Trauma Surg** 1997;116(6-7):329-33

Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Batrakova EV, et al. **Br J Cancer** 1996 Nov;74(10):1545-52

Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Ali-el-Dein B, et al. **Br J Urol** 1997 May;79(5):731-5

Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Vail DM, et al. **Cancer Chemother Pharmacol** 1997;39(5):410-6

A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res., 56: 4686-4693, 1996 [letter; comment] Gallo JM, et al. **Cancer Res** 1997 Jul 15;57(14):3063-5. Comment on: Cancer Res 1996 Oct 15;56(20):4686-93. Comment on: Cancer Res 1996 Oct 15;56(20):4694-701.

Preclinical experiences with magnetic drug targeting: tolerance and efficacy [see comments] Lübbe AS, et al. **Cancer Res** 1996 Oct 15;56(20):4694-701. Comment in: Cancer Res 1997 Jul 15;57(14):3063-5.

Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors [see comments] Lübbe AS, et al. **Cancer Res** 1996 Oct 15;56(20):4686-93. Comment in: Cancer Res 1997 Jul 15;57(14):3063-5.

Early postoperative intraperitoneal Adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma. Sugarbaker PH. **Cancer Treat Res** 1996;81:7-14 (12 ref.)

Objective response to epirubicin and lonidamine. A case of advanced thymoma previously treated with the ADOC scheme and unresponsive to paclitaxel plus cyclophosphamide [letter] Berruti A, et al. **Chest** 1997 May; 111(5):1473-4

The efficacy of doxorubicin microspheres for hepatic micrometastases in a rat tumour model. Esdale WJ, et al. **Clin Exp Metastasis** 1997 May;15(3):239-45

Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Coukell AJ, et al. **Drugs** 1997 Mar; 53(3):520-38 (68 ref.)

Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Bielack SS, et al. **Eur J Cancer** 1996 Sep;32A(10):1652-60 (129 ref.)

Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy? Schwaibold H, et al. **Eur Urol** 1997;31(2):153-9

A case of hepatocellular carcinoma effectively treated with epirubicin aqueous vesicles in monodispersed iodized poppy-seed oil microdroplets. Higashi S, et al. **Hepatogastroenterology** 1996 Nov-Dec;43(12):1427-30

Tumour eradication with high-dose idarubicin-anti-Ly-2.1 with murine tumour necrosis factor-alpha in mice. Pietersz GA, et al. **Immunol Cell Biol** 1997 Jun;75(3):253-8

Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group. Naito S, et al. **Int J Urol** 1997 Jul; 4(4):352-7

Inhibition of posterior capsule opacification by an intraocular-lens-bound sustained drug delivery system: an experimental animal study and literature review. Tetz MR, et al. **J Cataract Refract Surg** 1996 Oct;22(8):1070-8 (49 ref.)

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. Northfelt DW, et al. **J Clin Oncol** 1997 Feb; 15(2):653-9

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. Northfelt DW, et al. **J Clin Pharmacol** 1996 Jan;36(1):55-63

Liposomal doxorubicin. Tardi PG, et al. **J Drug Target** 1996; 4(3):129-40 (58 ref.)

Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion. Synold TW, et al. **J Infus Chemother** 1996 Spring;6(2):69-73 (31 ref.)

The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. Mayer LD, et al. **J Pharmacol Exp Ther** 1997 Mar; 280(3):1406-14

Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). Parr MJ, et al. **J Pharmacol Exp Ther** 1997 Mar; 280(3):1319-27

Targeting of different ethiodized oil-doxorubicin mixtures to hypovascular hepatic metastases with intraarterial and intraportal injections. Cay O, et al. **J Vasc Interv Radiol** 1996 May-Jun;7(3):409-17

Intrapleural pirarubicin (4'-O-tetrahydropyranyladriamycin) for treatment of malignant pleural effusion. Gotoh T, et al. **Jpn J Clin Oncol** 1996 Oct;26(5):328-34

Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group. Feig SA, et al. **Med Pediatr Oncol** 1996 Dec;27(6):505-14

DaunoXome shows promise as breast cancer treatment [news] **Oncology (Huntingt)** 1996 Mar;10(3):425

Liver metastases from colorectal cancer: drug delivery with liposome-encapsulated doxorubicin. Cay O, et al. **Radiology** 1997 Oct;205(1):95-101

A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Amadori D, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):16-22

A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer. Conte PF, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):28-31

Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Dombernowsky P, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):23-7

Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Kawai S, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6-38-S6-45

Combination of transcatheter arterial embolization and percutaneous ethanol injection for hepatocellular carcinoma: comparison of efficacies of doxorubicin and epirubicin in transcatheter arterial embolization. Nakamura S, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6-46-S6-49

Combined therapy with external beam irradiation and hepatic arterial epirubicin infusion through an implanted port for advanced hepatocellular carcinoma. Takizawa K, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6-116-S6-121

Liposomal formulations of cytotoxic drugs. Janknegt R. **Support Care Cancer** 1996 Jul;4(4):298-304 (31 ref.)

Effectiveness of an adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines. Jinno H, et al. **Surg Today** 1996;26(7):501-7

[The clinical and pharmacokinetic results of intrapleural epirubicin application] Schilcher RB, et al. **Strahlenther Onkol** 1997 Apr;173(4):236-7 **(Ger)**

[Performance and complications of totally implantable port device in bolus hepatic intra-arterial chemotherapy] Civalleri D, et al. **G Chir** 1997 Mar;18(3):127-30 (Eng. Abstr.) **(Ita)**

[Neoadjuvant intra-arterial infusion chemotherapy in over stage III and inflammatory carcinoma of the breast] Higuchi K, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1533-6 (Eng. Abstr.) **(Jpn)**

[Characteristic and effective usage of adriamycin] Horiuchi K, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1916-9 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Evaluation of a single catheter technique for percutaneous isolated liver perfusion] Ku Y, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1502-5 (Eng. Abstr.) **(Jpn)**

[Evaluation of concomitant use of cyclosporin and percutaneous isolated liver perfusion under complete venous isolation and charcoal hemoperfusion] Kusunoki N, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1408-11 (Eng. Abstr.) **(Jpn)**

[TUT-7 phase I clinical study. TUT-7 Study Group] Taguchi T, et al. **Gan To Kagaku Ryoho** 1997 Jul; 24(9):1125-33 (Eng. Abstr.) **(Jpn)**

[Menogaril (TUT-7) late phase II study for malignant lymphoma, adult T-cell leukemia and lymphoma (ATLL)] Taguchi T, et al. **Gan To Kagaku Ryoho** 1997 Aug; 24(10):1263-71 (Eng. Abstr.) **(Jpn)**

[A clinical trial of neoadjuvant intraarterial chemotherapy for the treatment of locally advanced breast cancer] Takatsuka Y, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1523-5 (Eng. Abstr.) **(Jpn)**

[Long-term survival cases of hepatocellular carcinoma with portal tumor thrombus by repeated arterial infusion chemotherapy using implantable port system] Endo T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jun;94(6):413-8 **(Jpn)**

[Randomized controlled study of very low-dose Ara-C versus low-dose aclarubicin for the treatment of myelodysplastic syndrome] Shibuya T, et al. **Rinsho Ketsueki** 1996 Sep;37(9):782-4 **(Jpn)**

[Malignant mesothelioma--therapeutic response to various combinations of anthracyclines] Popov I, et al. **Srp Arh Celok Lek** 1996 Mar-Apr;124(3-4):77-81 (Eng. Abstr.) **(Scc)**

ADVERSE EFFECTS

Anthracycline-induced cardiotoxicity in children with malignancies. Godoy LY, et al. **Acta Paediatr Jpn** 1997 Apr;39(2):188-93

Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma [letter] White RM. **AIDS** 1997 Sep;11(11):1412-3

Cardiovascular responses to dynamic submaximal exercise in children previously treated with anthracycline. Johnson D, et al. **Am Heart J** 1997 Feb;133(2):169-73

The role of radionuclide angiocardiography in the treatment of patients receiving doxorubicin-based chemotherapy: a reassessment. Dreicer R, et al. **Am J Clin Oncol** 1997 Apr; 20(2):132-7

Early detection of the anthracycline-induced cardiotoxicity. A non-invasive haemodynamic study. Massidda B, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):663-8

An increase of serum lipids after cumulative doses of doxorubicin and epirubicin in experimental animals. Stathopoulos GP, et al. **Anticancer Res** 1996 Nov-Dec; 16(6B):3429-33

Early identification of anthracycline cardiomyopathy: possibilities and implications. Bu'Lock FA, et al. **Arch Dis Child** 1996 Nov;75(5):416-22

Influence of selenium deficiency on the acute cardiotoxicity of adriamycin in rats. Matsuda A, et al. **Biol Trace Elem Res** 1997 May;57(2):157-67

A report on pathological changes of the dipole moment in children suffering from anthracycline cardiomyopathy. Diez U, et al. **Bratisl Lek Listy** 1996 Sep;97(9):521-5

Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Herman EH, et al. **Cancer Chemother Pharmacol** 1997;40(5):400-8

A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. Bates M, et al. **Clin Ther** 1997 Jan-Feb;19(1):167-84

Idarubicin-induced pigmentary changes of the nails. Borecky DJ, et al. **Cutis** 1997 Apr;59(4):203-4

A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy. Abraham R, et al. **Drug Saf** 1996 Dec;15(6):406-29 (208 ref.)

Feasibility of paclitaxel in a patient with anthracycline-induced congestive heart failure [letter] Colleoni M, et al. **Eur J Cancer** 1997 Feb;33(2):321-2

Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it? [corrected and republished in Eur J Cancer 1996 Dec;32A(13):2374-7] HjiYiannakis P, et al. **Eur J Cancer** 1996 Oct;32A(11):1845-8 (41 ref.)

Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it? [corrected and republished article originally printed in Eur J Cancer 1996 Oct;32A(11):1845-8] HjiYiannakis P, et al. **Eur J Cancer** 1996 Dec;32A(13):2374-7 (41 ref.)

Cardiac transplantation in childhood cancer survivors in Great Britain. Levitt G, et al. **Eur J Cancer** 1996 May; 32A(5):826-30

5-Hydroxymethyluracil excretion, plasma TBARS and plasma antioxidant vitamins in adriamycin-treated patients. Faure H, et al. **Free Radic Biol Med** 1996;20(7):979-83

Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Sung RY, et al. **Int J Cardiol** 1997 Aug 8; 60(3):239-48

A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. Jeyaseelan R, et al. **J Biol Chem** 1997 Sep 5;272(36):22800-8

Myocardial sympathetic dysinnervation in doxorubicin cardiomyopathy. Takano H, et al. **J Cardiol** 1996 Feb; 27(2):49-55

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. Krischer JP, et al. **J Clin Oncol** 1997 Apr; 15(4):1544-52

Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. Sorensen K, et al. **J Clin Oncol** 1997 Jan;15(1):61-8

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. Swain SM,

et al. **J Clin Oncol** 1997 Apr;15(4):1333–40

Cardioprotection with dexrazoxane for doxorubicin–containing therapy in advanced breast cancer. Swain SM, et al. **J Clin Oncol** 1997 Apr;15(4):1318–32

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. Venturini M, et al. **J Clin Oncol** 1996 Dec; 14(12):3112–20

Serum troponin T levels in adults undergoing anthracycline therapy [letter] Raderer M, et al. **J Natl Cancer Inst** 1997 Jan 15;89(2):171

Dexrazoxane (ICRF–187): a cardioprotective agent during anthracycline chemotherapy. O'Marcaigh AS, et al. **J Pediatr Oncol Nurs** 1997 Apr;14(2):96–8 (11 ref.)

Evaluation of cardiac function by echocardiography in dogs treated with doxorubicin. Hanai K, et al. **J Toxicol Sci** 1996 Feb;21(1):1–10

Review of tests for monitoring doxorubicin–induced cardiomyopathy. Ganz WI, et al. **Oncology** 1996 Nov–Dec; 53(6):461–70 (62 ref.)

Transverse leukonychia (Mees' lines) due to daunorubicin chemotherapy. Shelley WB, et al. **Pediatr Dermatol** 1997 Mar–Apr;14(2):144–5

TRAM flap breast reconstruction and adriamycin therapy [letter] Gargan TJ. **Plast Reconstr Surg** 1997 Jan;99(1):256

Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care. Hellmann K. **Support Care Cancer** 1996 Jul;4(4):305–7 (5 ref.)

Heart transplantation for doxorubicin–induced congestive heart failure in children and adolescents. Musci M, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):578–9

[Angiotensin–converting enzyme inhibitor in the treatment of epirubicin–induced dilated cardiomyopathy] Jensen BV, et al. **Ugeskr Laeger** 1997 Mar 24;159(13):1945–9 (Eng. Abstr.) **(Dan)**

[The prevention of anthracycline–induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF–187)] Sauer H. **Strahlenther Onkol** 1997 Jan;173(1):51–2 **(Ger)**

[Evaluation of left ventricular function in patients with mammary carcinoma after treatment with epidoxorubicin using a high–dose, short–term protocol] D'Alto M, et al. **Cardiologia** 1997 Jun;42(6):611–8 (Eng. Abstr.) **(Ita)**

[Clinical usefulness of 123I–BMIPP (beta–methyl iodophenyl pentadecanoic (acid) myocardial SPECT in patients with hematological malignancies with adriamycin–induced cardiomyopathy] Niitsu N, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1793–7 (Eng. Abstr.) **(Jpn)**

[Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy] Okada Y, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):585–9 (Eng. Abstr.) **(Jpn)**

[The cardiotoxicity of anticancer agents] Wakasugi S. **Ryoikibetsu Shokogun Shirizu** 1996;(14):83–7 (14 ref.) **(Jpn)**

[Cardioxan as a cardioprotector in antineoplastic chemotherapy] Lichinitser MP, et al. **Klin Med (Mosk)** 1996;74(5):65–7 **(Rus)**

ANALYSIS

Simultaneous determination of cytotoxic (adriamycin, vincristine) and modulator of resistance (verapamil, S 9788) drugs in human cells by high–performance liquid chromatography and ultraviolet detection. Tassin JP, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):449–56

HPLC methods for the determination of bound and free doxorubicin, and of bound and free galactosamine, in methacrylamide polymer–drug conjugates. Configliacchi E, et al. **J Pharm Biomed Anal** 1996 Oct;15(1):123–9

[Rubomycin Q1—an anthracycline metabolite from Streptomyces coeruleorubidus 2679, a strain producing rubomycin C] Fedorova GB, et al. **Antibiot Khimioter** 1996 Mar;41(3):3–8 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR–1065, in vitro. Dorr RT, et al. **Eur J Cancer** 1996;32A Suppl 4:S21–5

Dexrazoxane for protection against cardiotoxic effects of anthracyclines [letter; comment] Sehested M, et al. **J Clin Oncol** 1996 Oct;14(10):2884. Comment on: J Clin Oncol 1996 Feb;14(2):328–31.

Protective effect of butylated hydroxyanisole on adriamycin–induced cardiotoxicity. Vora J, et al. **J Pharm Pharmacol** 1996 Sep;48(9):940–4

Protective effects of cardioxane against anthracycline–induced cardiotoxicity in relapsed acute myeloid leukemias. Lemež P, et al. **Neoplasma** 1996; 43(6):417–9

BIOSYNTHESIS

Isolation of new anthracyclines 10–O–rhodosaminyl beta–rhodomycinone and beta–isorhodomycinone from mild–acid treated culture of obelmycin–producing Streptomyces violaceus. Johdo O, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):522–5

BLOOD

Effect of SDZ PSC 833 ([3'–keto–Bmt1]–[Val2]–cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide in vitro. Watanabe T, et al. **Anticancer Drugs** 1997 Apr;8(4):400–4

Reversible binding of anthracycline antibiotics to erythrocytes treated with glutaraldehyde. Ataullakhanov FI, et al. **Biotechnol Appl Biochem** 1996 Dec;24 (Pt 3):241–4

[Binding of epirubicin to human plasma protein and erythrocytes: interaction with the cytoprotective amifostine] Pernkopf I, et al. **Pharmazie** 1996 Nov; 51(11):897–901 (Eng. Abstr.) **(Ger)**

CHEMICAL SYNTHESIS

Structure–based design of a new bisintercalating anthracycline antibiotic. Chaires JB, et al. **J Med Chem** 1997 Jan 31;40(3):261–6

[Enantioselective synthesis of anthracyclines] Monneret C. **Ann Pharm Fr** 1997;55(1):5–11 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Stability of doxorubicin hydrochloride and vincristine sulfate in two portable infusion–pump reservoirs. Nyhammar EK, et al. **Am J Health Syst Pharm** 1996 May 15;53(10):1171–3

Structure of a DNA–bisdaunomycin complex. Hu GG, et al. **Biochemistry** 1997 May 20;36(20):5940–6

Transport of the anti–cancer drug doxorubicin across cytoplasmic membranes and membranes composed of phospholipids derived from Escherichia coli occurs via a similar mechanism. Speelmans G, et al. **Biochim Biophys Acta** 1996 Oct 23;1284(2):240–6

The overall partitioning of anthracyclines into phosphatidyl–containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids. Gallois L, et al. **Eur J Biochem** 1996 Nov 1;241(3):879–87

Inhibition of anthracycline semiquinone formation by ICRF–187 (dexrazoxane) in cells. Malisza KL, et al. **Free Radic Biol Med** 1996;20(7):905–14

New betaclamycin and aclarubicin analogs obtained by prolonged microbial conversion with an aclarubicin–negative mutant. Johdo O, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):669–75

Biochemical and pharmacological activity of novel 8–fluoroanthracyclines: influence of stereochemistry and conformation. Animati F, et al. **Mol Pharmacol** 1996 Sep; 50(3):603–9

[Chemical stability of pirarubicin in its use for continuous infusion] Leca F, et al. **Bull Cancer** 1996 Nov;83(11):923–8 (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Isolation of new anthracyclines 10–O–rhodosaminyl beta–rhodomycinone and beta–isorhodomycinone from mild–acid treated culture of obelmycin–producing Streptomyces violaceus. Johdo O, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):522–5

A new anthracycline antibiotic, IT–62–B, converts the morphology of ras–transformed cells back to normal: taxonomy, fermentation, isolation, structure elucidation and biological characterization. Kawauchi T, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):297–303

Isolation and characterization of 8–demethoxy steffimycins and generation of 2,8–demethoxy steffimycins in Streptomyces steffisburgensis by the nogalamycin biosynthesis genes. Kunnari T, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):496–501

METABOLISM

Pharmacokinetic analysis of protein–conjugated doxorubicin (DXR) and its degraded adducts in DXR–sensitive and –resistant rat hepatoma cells. Takahashi N, et al. **Anticancer Drugs** 1996 Aug;7(6):687–96

The multidrug–resistant human lung tumour cell line, DLKP–A10, expresses novel drug accumulation and sequestration systems. Cleary I, et al. **Biochem Pharmacol** 1997 May 15;53(10):1493–502

Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy. Robinson H, et al. **Biochemistry** 1997 Jul 22;36(29):8663–70

The anionic phospholipid–mediated membrane interaction of the anti–cancer drug doxorubicin is enhanced by phosphatidylethanolamine compared to other zwitterionic phospholipids. Speelmans G, et al. **Biochemistry** 1997 Jul 15;36(28):8657–62

Transport of the anti–cancer drug doxorubicin across cytoplasmic membranes and membranes composed of phospholipids derived from Escherichia coli occurs via a similar mechanism. Speelmans G, et al. **Biochim Biophys Acta** 1996 Oct 23;1284(2):240–6

Transport mechanism of pirarubicin in human mononuclear cells. Nagasawa K, et al. **Biol Pharm Bull** 1996 Sep; 19(9):1203–9

Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin. Nagasawa K, et al. **Biol Pharm Bull** 1996 Jan;19(1):100–5

Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug–resistant K562/ADM cells. Nagasawa K, et al. **Biol Pharm Bull** 1996 Jul; 19(7):971–6

Adriamycin binds to the matrix of secretory granules during mast cell exocytosis. Crivellato E, et al. **Biotech Histochem** 1997 Mar;72(2):111–6

Vesicular anthracycline accumulation in doxorubicin–selected U–937 cells: participation of lysosomes. Hurwitz SJ, et al. **Blood** 1997 May 15; 89(10):3745–54

Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. de Verdière AC, et al. **Br J Cancer** 1997;76(2):198–205

Targeting of stealth liposomes to erbB–2 (Her/2) receptor: in vitro and in vivo studies. Goren D, et al. **Br J Cancer** 1996 Dec;74(11):1749–56

Direct measurement of doxorubicin concentration in the intact, living single cancer cell during hyperthermia. Kawai H, et al. **Cancer** 1997 Jan 15;79(2):214–9

Comparative serum protein binding of anthracycline derivatives. Chassany O, et al. **Cancer Chemother Pharmacol** 1996;38(6):571–3

Relationship between the inhibition of azidopine binding to P–glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Hu YP, et al. **Cancer Lett** 1996 Dec 3;109(1–2):203–9

Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells. Wood DJ, et al. **Cancer Lett** 1996 Nov 12;108(1):41–7

Reductive activation of doxorubicin by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. Yee SB, et al. **Chem Biol Interact** 1997 May 2; 104(2–3):87–101

Altered intracellular distribution of daunorubicin in immature acute myeloid leukemia cells. Lautier D, et al. **Int J Cancer** 1997 Apr 10;71(2):292–9

New betaclamycin and aclarubicin analogs obtained by prolonged microbial conversion with an aclarubicin–negative mutant. Johdo O, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):669–75

Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. Taatjes DJ, et al. **J Med Chem** 1997 Apr 11; 40(8):1276–86

Comparison of drug accumulation in P–glycoprotein–expressing and MRP–expressing human leukaemia cells. Davey MW, et al. **Leuk Res** 1996 Aug; 20(8):657–64

A novel energy dependent mechanism reducing daunorubicin accumulation in acute myeloid leukemia. Hedley DW, et al. **Leukemia** 1997 Jan;11(1):48–53

Synthesis and binding properties of conjugates between oligodeoxynucleotides and daunorubicin derivatives. Garbesi A, et al. **Nucleic Acids Res** 1997 Jun 1; 25(11):2121–8

Carbonyl reduction of daunorubicin in rabbit liver and heart. Pröpper D, et al. **Pharmacol Toxicol** 1997 May;80(5):240–5

PHARMACOKINETICS

Paclitaxel induces significant changes in epidoxorubicin distribution in mice [published erratum appears in Ann Oncol 1997 Feb;8(2):207] Colombo T, et al. **Ann Oncol** 1996 Oct;7(8):801–5

Plasma pharmacokinetics of idarubicin and its 13–dihydro metabolite—a comparison of bolus versus 2 h infusion during a 3 day course. Eksborg S, et al. **Anticancer Drugs** 1997 Jan;8(1):42–7

Effects of intra–abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Jacquet P, et al. **Anticancer Drugs** 1996 Jul; 7(5):596–603

MDR–related properties of K 562 cells grown in two different culture media. Ferrand VL, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3653–8

Nanoerythrosomes, a new derivative of erythrocyte ghost II: identification of the mechanism of action. Moorjani M, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2831–6

Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP). Slapak CA, et al. **Biochem Pharmacol** 1996 Nov 22;52(10):1569–76

Relationship between expression level of P–glycoprotein and daunorubicin transport in LLC–PK1 cells transfected with human MDR1 gene. Tanaka K, et al. **Biochem Pharmacol** 1997 Mar 7;53(5):741–6

Confocal microscopy of idarubicin localisation in sensitive and multidrug–resistant bladder cancer cell lines [see comments] Duffy PM, et al. **Br J Cancer** 1996 Sep; 74(6):906–9. Comment in: Br J Cancer 1997;76(1):136.

Tumour uptake of doxorubicin in polyethylene glycol–coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Vaage J, et al. **Br J Cancer** 1997;75(4):482–6

Pharmacological evaluation of portal venous isolation and charcoal haemoperfusion for high–dose intra–arterial chemotherapy of the pancreas. Tominaga M, et al. **Br J Surg** 1997 Aug;84(8):1072–6

Age–related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat. Cusack BJ, et al. **Cancer Chemother Pharmacol** 1997;39(6):505–12

Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg

phosphatidylcholine/cholesterol liposomes. Harasym TO, et al. **Cancer Chemother Pharmacol** 1997;40(4):309–17

Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit. Looby M, et al. **Cancer Chemother Pharmacol** 1997;39(6):554–6

Pharmacokinetics of doxorubicin and epirubicin in mice during chlorpromazine-induced hypothermia. Lundgren-Eriksson L, et al. **Cancer Chemother Pharmacol** 1997;40(5):419–24

Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Mosure KW, et al. **Cancer Chemother Pharmacol** 1997; 40(3):251–8

Localization of anthracycline accumulation in sensitive and resistant urothelial tumor cell lines. Davies CL, et al. **Cancer Detect Prev** 1996;20(6):625–33

Flow cytometry evaluation of the multidrug-resistant phenotype with functional tests involving uptake of daunorubicin, Hoechst 33342, or rhodamine 123: a comparative study. Lizard G, et al. **Cancer Detect Prev** 1995;19(6):527–34

Effects of administered route on tissue distribution and antitumor activity of polyethyleneglycol-coated liposomes containing adriamycin. Sadzuka Y, et al. **Cancer Lett** 1997 Jan 1;111(1–2):77–86

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Amantea MA, et al. **Clin Pharmacol Ther** 1997 Mar;61(3):301–11

Flow cytometric analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas. Kunikane H, et al. **Cytometry** 1997 Aug 15;30(4):197–203

Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. Yoon EJ, et al. **Drug Metab Dispos** 1997 Jan;25(1):66–74

Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. Boven E, et al. **Eur J Cancer** 1996 Jul; 32A(8):1382–7

Modulation of doxorubicin cytotoxicity by ethacrynic acid. Awasthi S, et al. **Int J Cancer** 1996 Nov 4;68(3):333–9

Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Gaber MH, et al. **Int J Radiat Oncol Biol Phys** 1996 Dec 1;36(5):1177–87

Noninvasive monitoring of intraocular pharmacokinetics of daunorubicin using fluorophotometry. Kizhakkethara I, et al. **Int Ophthalmol** 1995–96;19(6):363–7

Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. Lee SD, et al. **J Clin Pharm Ther** 1996 Aug;21(4):201–13

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. Northfelt DW, et al. **J Clin Pharmacol** 1996 Jan;36(1):55–63

Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles. Kwon Y, et al. **J Pharm Sci** 1996 Sep;85(9):935–9

Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. Huwyler J, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1541–6

Anthracycline subcellular distribution in human leukemic cells by microspectrofluorometry: factors contributing to drug-induced cell death and reversal of multidrug resistance. Morjani H, et al. **Leukemia** 1997 Jul;11(7):1170–9

Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole. Desai PB, et al. **Methods Find Exp Clin Pharmacol** 1997 May; 19(4):231–9

Blood and plasma lipoprotein distribution and gender differences in the plasma pharmacokinetics of lipid-associated annamycin. Wasan KM, et al. **Pharmacol Toxicol** 1997 Jun;80(6):301–7

Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. Choi YJ, et al. **Res Commun Mol Pathol Pharmacol** 1996 Nov; 94(2):181–92

Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to uranyl nitrate-induced acute renal failure rats. Lee HJ, et al. **Res Commun Mol Pathol Pharmacol** 1996 Feb; 91(2):195–204

Disposition of epirubicin after intraarterial administration in Lipiodol to patients with hepatocellular carcinoma. Dodds HM, et al. **Ther Drug Monit** 1996 Oct;18(5):537–43

Pharmacokinetics of intravenous adriamycin for anhepatic chemotherapy during liver transplantation. Kitagawa T, et al. **Transpl Int** 1996;9 Suppl 1:S105–8

Uptake and intracellular distribution of idarubicin in secondary cultures of normal and neoplastic urothelium. De Angeli S, et al. **Urol Res** 1997;25(2):125–30

[Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients] Wihlm J, et al. **Bull Cancer** 1997 Jun; 84(6):603–8 (Eng. Abstr.) **(Fre)**

[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats] Fuse E, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):975–9 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetic analyses of intra-arterial and intra-portal chemotherapeutic agent infusion] Terashima M, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1499–501 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin. Bennis S, et al. **Anticancer Drugs** 1997 Jul;8(6):610–7

Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Strumberg D, et al. **Anticancer Drugs** 1996 Jun;7(4):415–21

Partial synergism between dextran-conjugated doxorubicin and cancer drugs on the killing of multidrug resistant KB-V1 cells. Fong WF, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3773–8

Effect of antineoplastic agents on non proliferating yeast cells: a possible membrane effect of doxorubicin. Karavokyros I, et al. **Anticancer Res** 1997 Mar-Apr; 17(2A):1079–82

L-histidinol selectively modulates daunomycin toxicity in normal and tumorigenic kidney epithelial cells. Warrington RC, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3629–33

Mimetics of L-histidinol which selectively modulate daunomycin toxicity in normal and tumorigenic epithelial cells. Warrington RC, et al. **Anticancer Res** 1996 Nov-Dec; 16(6B):3635–9

In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp. Wardle HM, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2229–31

Transfection of a 4-hydroxynonenal metabolizing glutathione S-transferase isozyme, mouse GSTA4-4, confers doxorubicin resistance to Chinese hamster ovary cells. He NG, et al. **Arch Biochem Biophys** 1996 Sep 1;333(1):214–20

Decreased sensitivity to adriamycin in cadmium-resistant human lung carcinoma A549 cells. Hatcher EL, et al. **Biochem Pharmacol** 1997 Mar 7;53(5):747–54

Enhanced functional capacity of the peritoneal macrophages as antigen presenting cells after aclacinomycin treatment in mice. Bravo-Cuellar A, et al. **Biomed Pharmacother** 1997;51(4):181–4

Endogenous tumor necrosis factor as a predictor of doxorubicin sensitivity in leukemic patients. Kobayashi D, et al. **Blood** 1997 Apr 1;89(7):2472–9

Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines. Lehne G, et al. **Br J Cancer** 1996 Dec;74(11):1719–29

Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay. Kurbacher CM, et al. **Breast Cancer Res Treat** 1996; 41(2):161–70

Effects of doxorubicin, 4'-epirubicin, and antioxidant enzymes on the contractility of isolated cardiomyocytes. Chan EM, et al. **Can J Physiol Pharmacol** 1996 Aug; 74(8):904–10

Adriamycin-induced histamine release from heart tissue in vitro. Decorti G, et al. **Cancer Chemother Pharmacol** 1997; 40(4):363–6

Mechanism of action and spectrum of cell types susceptible to doxorubicin photochemotherapy. Gao JP, et al. **Cancer Chemother Pharmacol** 1997;40(2):138–42

Cellular uptake and antitumor activity of the new anthracycline analog DA-125 in human cancer cell lines. Lim KH, et al. **Cancer Chemother Pharmacol** 1997; 40(1):23–30

Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells. Tolomeo M, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):157–61

Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Yamazaki K, et al. **Cancer Chemother Pharmacol** 1997; 39(3):192–8

Adriamycin induces apoptosis in rat thymocytes. Azmi S, et al. **Cancer Lett** 1997 Jan 1;111(1–2):225–31

Micronuclei-induction and its correlation to cell survival in HeLa cells treated with different doses of adriamycin. Jagetia GC, et al. **Cancer Lett** 1996 Dec 20;110(1–2):123–8

Adriamycin activates c-jun N-terminal kinase in human leukemia cells: a relevance to apoptosis. Yu R, et al. **Cancer Lett** 1996 Oct 1;107(1):73–81

p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc. Han JW, et al. **Cancer Res** 1997 Jan 1;57(1):176–82

Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. McConkey DJ, et al. **Cancer Res** 1996 Dec 15;56(24):5594–9

Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Trail PA, et al. **Cancer Res** 1997 Jan 1;57(1):100–5

Reversal of doxorubicin resistance by the amiloride analogue EIPA in multidrug resistant human colon carcinoma cells. Pannocchia A, et al. **Cell Biochem Funct** 1996 Mar; 14(1):11–8

The amplification and expression of MDR1 gene in adriamycin resistant cell line of colon cancer cell HR8348. Zhou Z, et al. **Chin Med Sci J** 1996 Mar;11(1):17–20

Doxorubicin chemomyectomy in orbicularis oculi: increasing drug infiltration at the injection site. McLoon LK, et al. **Curr Eye Res** 1996 Aug;15(8):883–9

Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Coukell AJ, et al. **Drugs** 1997 Mar;53(3):453–82 (146 ref.)

Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Buckley MM, et al. **Drugs Aging** 1997 Jul;11(1):61–86 (125 ref.)

Verapamil increases the bacteriostatic and bactericidal effects of adriamycin on Escherichia coli. Abramov Y, et al. **Drugs Exp Clin Res** 1996;22(6):295–300

Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells. Montaudon D, et al. **Eur J Biochem** 1997 Apr 15;245(2):307–15

Pradimicins: a novel class of broad-spectrum antifungal compounds. Walsh TJ, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):93–7 (27 ref.)

Recovery of drug sensitivity by MS-209, a new multidrug resistance-reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line. Wang YH, et al. **Eur J Haematol** 1997 Mar; 58(3):186–94

Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Siegsmund MJ, et al. **Eur Urol** 1997;31(3):365–70

Development of a bacterial model for studying anthracycline-membrane interactions. Burrow SM, et al. **FEMS Microbiol Lett** 1996 Dec 1;145(2):281–6

Cellular resistance to anthracyclines. Nielsen D, et al. **Gen Pharmacol** 1996 Mar;27(2):251–5 (30 ref.)

Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin. Michieli M, et al. **Haematologica** 1996 Jul-Aug;81(4):295–301

Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Working PK, et al. **Hum Exp Toxicol** 1996 Sep;15(9):751–85 (68 ref.)

Modulation of doxorubicin cytotoxicity by ethacrynic acid. Awasthi S, et al. **Int J Cancer** 1996 Nov 4;68(3):333–9

Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Cai Z, et al. **Int J Cancer** 1996 Nov 15;68(4):535–46

Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. De Vincenzo R, et al. **Int J Cancer** 1996 Nov 4;68(3):340–8

Decreased sensitivity of carcinoembryonic antigen cDNA-transfected cells to adriamycin. Kawaharata H, et al. **Int J Cancer** 1997 Jul 17;72(2):377–82

Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. Perez-Soler R, et al. **Int J Cancer** 1997 Mar 28;71(1):35–41

Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives. Ripamonti M, et al. **Invest New Drugs** 1996;14(2):139–46

Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines. Takagi T, et al. **Invest New Drugs** 1996;14(4):357–63

A new anthracycline antibiotic, IT-62-B, converts the morphology of ras-transformed cells back to normal: taxonomy, fermentation, isolation, structure elucidation and biological characterization. Kawauchi T, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):297–303

Antifungal antibiotic benanomicin A increases susceptibility of Candida albicans to phagocytosis by murine macrophages. Watabe H, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1221–5

The in-vitro activity of an antifungal antibiotic benanomicin A in comparison with amphotericin B. Watanabe M, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1073–7

Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. Boland MP, et al. **J Biol Chem** 1997 May 16;272(20):12952–60

Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. Osborn MT, et al. **J Biol Chem** 1996 Nov 29;271(48):30950–5

Application of an in vitro system in the study of chemotherapeutic drug effects on DNA replication. Diaz-Perez MJ, et al. **J Cell Biochem** 1996 Jun 1; 61(3):444–51

Daunomycin disrupts nuclear assembly and the coordinate initiation of DNA replication in Xenopus egg extracts. Leng F, et al. **J Cell Biochem** 1997 Mar 1;64(3):476–91

Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes. Puri PL, et al. **J Cell Biochem** 1997 Jul 1;66(1):27–36

Effect of epirubicin on 3H-thymidine labelling index in cultured L-strain cells. Ozcan FG, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):23–7

ANTIBIOTICS, ANTHRACYCLINE

Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. Taatjes DJ, et al. **J Med Chem** 1996 Oct 11;39(21):4135–8

Anthracyclines enhance tension development in cardiac muscle by direct interaction with the contractile system. Bottone AE, et al. **J Mol Cell Cardiol** 1997 Mar; 29(3):1001–8

Bicinchoninic acid protein assay in the determination of adriamycin cytotoxicity modulated by the MDR glycoprotein. Hall AM, et al. **J Nat Prod** 1996 Jan; 59(1):35–40

Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies. Watanabe T, et al. **J Natl Cancer Inst** 1997 Apr 2;89(7):512–8

Mechanisms in inhibitory action of aclarubicin on contractility of rat aorta. Wakabayashi I, et al. **J Pharm Pharmacol** 1995 Dec;47(12A):1025–8

Nitric oxide contributes to adriamycin's antitumor effect. Lind DS, et al. **J Surg Res** 1997 May;69(2):283–7

Inhibition of nucleolar function and morphological change by adriamycin associated with heat shock protein 70 accumulation. Abe T, et al. **Jpn J Cancer Res** 1996 Sep; 87(9):945–51

Apoptosis and resistance to daunorubicin in human leukemic cells. Efferth T, et al. **Leukemia** 1997 Jul;11(7):1180–6

Reversal of multidrug resistance by tacrolimus hydrate. Wu J, et al. **Methods Find Exp Clin Pharmacol** 1996 Dec; 18(10):651–8

Effect of anthracycline antitumor antibiotics (adriamycin and nogalamycin) and cycloheximide on the biosynthesis and processing of major UsnRNAs. Ray R, et al. **Mol Cell Biochem** 1996 Sep 6;162(1):75–82

Isolation and characterization of daunorubicin-resistant AML-2 sublines. Choi CH, et al. **Mol Cells** 1997 Apr 30; 7(2):170–7

Comparison of the in vitro effect of adriblastina on induction of SCEs in V79 cells and human peripheral blood lymphocytes. Szabová E. **Neoplasma** 1996;43(6):407–9

Daunomycin induces elongation for a compacted single DNA molecule. Yoshikawa Y, et al. **Nucleic Acids Symp Ser** 1995; (34):173–4

Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Allouche M, et al. **Oncogene** 1997 Apr 17;14(15):1837–45

Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin. Kawanami K, et al. **Oncol Res** 1996;8(5):197–206

The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251. Killion JJ, et al. **Oncol Res** 1995;7(9):453–9

Cytotoxic effects of four antibiotics on endothelial cells. Lanbeck P, et al. **Pharmacol Toxicol** 1995 Dec;77(6):365–70

Tumour blood flow influences combined radiation and doxorubicin treatments. Durand RE, et al. **Radiother Oncol** 1997 Feb;42(2):171–9

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB [see comments] Wang CY, et al. **Science** 1996 Nov 1;274(5288):784–7. Comment in: Science 1996 Nov 1;274(5288):724. Comment in: Science 1997 Apr 11;276(5310):185.

Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer? Seckin B, et al. **World J Urol** 1996;14 Suppl 1:S26–9

[The internalization of immunotargeting drugs for hepatocellar carcinoma and its significance] Sui Y, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Nov;76(11):845–7 (Eng. Abstr.) **(Chi)**

[Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry] Belhoussine R, et al. **Bull Cancer** 1997 Apr;84(4):343–9 (39 ref.) (Eng. Abstr.) **(Fre)**

[Effect of adjuvant cytostasis after organ transplantation: an experimental study with a combined transplantation-tumor model] Zimmermann T, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:551–4 (Eng. Abstr.) **(Ger)**

[A comparative study on in vitro chemosensitivity of urotherial cancers to three anthracyclines] Yamada S, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1339–41 **(Jpn)**

[The genetic activity of superlow doses of antitumor antibiotics and 2-nitrofluorene: the ecological aspects of the problem] Vasil'eva SV, et al. **Izv Akad Nauk Ser Biol** 1996 Nov–Dec;(6):676–80 (Eng. Abstr.) **(Rus)**

[The nuclease activity of the cell nuclei in 2 lines of murine myeloma sp2/0 differing in their resistance to cytostatics in adriamycin-induced apoptosis] Meliksetian MB, et al. **Tsitologiia** 1996;38(6):611–5 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Aas T, et al. **Acta Oncol** 1996;35 Suppl 5:5–8

Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. Girard PM, et al. **AIDS** 1996 Jun;10(7):753–7

Activity of standard-dose carboplatin, cyclophosphamide, and etoposide in patients with metastatic breast cancer with previous exposure to anthracyclines. Recchia F, et al. **Am J Clin Oncol** 1997 Apr;20(2):166–8

Continuous infusion, intravesical doxorubicin for the treatment of regionally advanced bladder cancer: a phase I–II trial. See WA, et al. **Am J Clin Oncol** 1997 Aug; 20(4):331–7

Misprint of dosage interval for liposomal doxorubicin hydrochloride [letter] Subach RA, et al. **Am J Health Syst Pharm** 1996 Jul 15;53(14):1727

Oral idarubicin and prednisone for advanced, previously untreated, multiple myeloma: a pilot study. Cooperative Group of Study and Treatment of Multiple Myeloma [letter] Brugnatelli S, et al. **Ann Oncol** 1996 Jul;7(5):537–8

Treatment of patients resistant to anthracycline therapy. Ravdin PM. **Anticancer Drugs** 1996 Aug;7 Suppl 2:13–6

Thermosensitivity and thermotolerance in the adriamycin-resistant strain of Ehrlich ascites tumor cells. Asaumi J, et al. **Anticancer Res** 1996 Sep–Oct; 16(5A):2569–73

Multidisciplinary treatment with anthracyclines in inflammatory breast cancer. Iino Y, et al. **Anticancer Res** 1996 Sep–Oct;16(5B):3111–5

Activity of menogaril against various malignant lymphoma cell lines and a human lymphoma xenograft in mice. Yoshida M, et al. **Anticancer Res** 1996 Sep–Oct; 16(5A):2875–9

Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Vingerhoeds MH, et al. **Br J Cancer** 1996 Oct;74(7):1023–9

Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin. The Medical Research Council's Working Party on Childhood Leukaemia. Lilleyman JS, et al. **Br J Haematol** 1997 Jun;97(3):603–6

Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. Wyler B, et al. **Br J Haematol** 1997 Apr;97(1):65–75

Changes of biological features in breast cancer cells determined by primary chemotherapy. Frassoldati A, et al. **Breast Cancer Res Treat** 1997 Jul;44(3):185–92

Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors. Brun B, et al. **Cancer** 1997 Jun 1;79(11):2137–46

Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Mizutani Y, et al. **Cancer** 1997 Mar 15;79(6):1180–9

A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland. Schmid HP, et al. **Cancer** 1997 May 1; 79(9):1703–9

Activity of anthracyclines in refractory ovarian cancer: recent experience and review. Garcia A, et al. **Cancer Invest** 1997;15(4):329–34

Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice. Itokazu M, et al. **Cancer Lett** 1996 Oct 1;107(1):11–8

Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Buckley MM, et al. **Drugs Aging** 1997 Jul;11(1):61–86 (125 ref.)

Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. Boven E, et al. **Eur J Cancer** 1996 Jul; 32A(8):1382–7

Phase II trial of epirubicin at standard dose in relapsed ovarian cancer [letter] Peláez I, et al. **Eur J Cancer** 1996 May;32A(5):899–900

Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line. Toffoli G, et al. **Eur J Cancer** 1996 Aug;32A(9):1591–7

Effects of anthracyclin-based chemotherapy on total plasma antioxidant capacity in small cell lung cancer patients. Erhola M, et al. **Free Radic Biol Med** 1996;21(3):383–90

Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer. Fleming GF, et al. **Gynecol Oncol** 1997 Apr;65(1):42–5

A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer. Havsteen H, et al. **Gynecol Oncol** 1996 Nov;63(2):210–5

Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Kohno H, et al. **Hepatogastroenterology** 1996 Nov–Dec;43(12):1405–9

Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer [letter] Paulsen T, et al. **Int J Cancer** 1997 Feb 20;74(1):138–40

Thermal enhancement of pirarubicin (THP-adriamycin) by mild hyperthermia in vitro. Takahashi T, et al. **Int J Hyperthermia** 1997 May–Jun;13(3):317–24

BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes. Melekos MD, et al. **Int Urol Nephrol** 1996;28(4):499–509

Intravesical epirubicin in the prophylaxis of superficial bladder cancer. Sengör F, et al. **Int Urol Nephrol** 1996; 28(2):201–6

Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987–1995). Valerius KD, et al. **J Am Vet Med Assoc** 1997 Feb 15;210(4):512–6

The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole. Ohtsuka K, et al. **J Antimicrob Chemother** 1997 Jan; 39(1):71–7

The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma. Erkisi M, et al. **J Chemother** 1996 Jun;8(3):224–8

Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. Casper ES, et al. **J Clin Oncol** 1997 May;15(5):2111–7

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Muggia FM, et al. **J Clin Oncol** 1997 Mar;15(3):987–93

Gamma scintigraphy of the biodistribution of 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. Pimm MV, et al. **J Drug Target** 1996;3(5):375–83

Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. Pimm MV, et al. **J Drug Target** 1996;3(5):385–90

The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models. Uchegbu IF, et al. **J Drug Target** 1996;3(5):399–409

Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Escudier SM, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):435–9

Successful medical treatment of an epithelioid hemangioendothelioma of liver. Idilman R, et al. **Oncology** 1997 Mar–Apr;54(2):171–5

Epiretinal membrane formation [letter] Oh KT, et al. **Retina** 1996;16(4):346–7

A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. Tamura K. **Semin Hematol** 1996 Oct;33(4 Suppl 3):2–11 (21 ref.)

An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer. Piccart-Gebhart MJ, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):11–5

High-dose epirubicin in locally advanced operable noninflammatory breast cancer: a feasibility trial. Crivellari D, et al. **Tumori** 1997 May–Jun;83(3):656–60

Weekly low dose epirubicin in elderly cancer patients. Nicolella D, et al. **Tumori** 1996 Jul–Aug;82(4):369–71

Paclitaxel activity in anthracycline refractory breast cancer patients. Vici P, et al. **Tumori** 1997 May–Jun;83(3):661–4

Canine osteosarcoma: amputation and chemotherapy. Berg J. **Vet Clin North Am Small Anim Pract** 1996 Jan; 26(1):111–21 (29 ref.)

[New data: daunoxome against Kaposi sarcoma. Fifth European Conference on clinical aspects and treatment of HIV infection (news)] **Pharm Unserer Zeit** 1996 Jan; 25(1):42–3 **(Ger)**

[Evaluation of left ventricular function in patients with mammary carcinoma after treatment with epidoxorubicin using a high-dose, short-term protocol] D'Alto M, et al. **Cardiologia** 1997 Jun;42(6):611–8 (Eng. Abstr.) **(Ita)**

[TUT-7 early phase II clinical study for various solid tumors and hematologic malignancies] Taguchi T, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1253–61 (Eng. Abstr.) **(Jpn)**

[Proliferative vitreoretinopathy treated with daunorubicin] Inoue M, et al. **Nippon Ganka Gakkai Zasshi** 1997 Aug; 101(8):656–61 (Eng. Abstr.) **(Jpn)**

[Chemotherapy schedules and bacteremia in adult patients with acute leukemia] Brodsky AL, et al. **Medicina (B Aires)** 1996;56(4):327–32 (Eng. Abstr.) **(Spa)**

TOXICITY

Toxicity of daunorubicin and naphthoquinones to HL-60 cells: an involvement of oxidative stress. Dičkancaitė E, et al. **Biochem Mol Biol Int** 1997 Apr;41(5):987–94

Inhibition of calcium accumulation by the sarcoplasmic reticulum: a putative mechanism for the cardiotoxicity of adriamycin. Halili-Rutman I, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):211–4

Toxicity and antiproliferative effect of aclacinomycin A on RPE cells in vitro. Schmidt JF, et al. **Curr Eye Res** 1996 Nov;15(11):1112–6

Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. Mansat V, et al. **FASEB J** 1997 Jul; 11(8):695–702

Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Gille L, et al. **Free Radic Biol Med** 1997; 23(5):775–82

Changes in cholinesterase activities after daunorubicin administration to rabbits. Geršl V, et al. **Hum Exp Toxicol** 1996 Oct;15(10):834–8

Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. Solem LE, et al. **J Mol Cell Cardiol** 1996 May;28(5):1023–32

Pharmacokinetic-toxicodynamic relationships of adriamycin in rat: prediction of butylated hydroxyanisole-mediated reduction in anthracycline cardiotoxicity. Vora J, et al. **J Pharm Pharmacol** 1996 Dec;48(12):1264–9

Oxidation of erythrocyte protein and lipid, and hemolysis in rabbit red blood cells treated with benzo[a]pyrene or adriamycin. Lee SK, et al. **J Toxicol Environ Health** 1997 Aug 29;51(6):557–69

The ovaries attenuate the aggravating effect of testosterone on glomerular injury in Adriamycin-induced nephropathy of female rats. Sakemi T, et al. **Kidney Blood Press Res** 1997;20(1):44–50

A new antithrombotic agent, aspalatone, attenuated cardiotoxicity induced by doxorubicin in the mouse; possible involvement of antioxidant mechanism. Kim C, et al. **Life Sci** 1997;60(4–5):PL75–82

Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation. Animati F, et al. **Mol Pharmacol** 1996 Sep; 50(3):603–9

Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity. Binaschi M, et al. **Mol Pharmacol** 1997 Jun;51(6):1053–9

Pefloxacin in adriamycin induced nephrotic syndrome in the rat. Korzets Z, et al. **Nephrol Dial Transplant** 1997 Feb; 12(2):286–8

Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results [see comments] Schiavetti A, et al. **Pediatr Hematol Oncol** 1997 May–Jun;14(3):213–22. Comment in: Pediatr Hematol Oncol 1997 May–Jun;14(3):iii–vi.

Ultrastructural and spectroscopic methods in the study of anthracycline-membrane interaction. Arancia G, et al. **Pharmacol Res** 1995 Nov;32(5):255–72 (103 ref.)

Effects of eicosapentaenoic acid and docosahexaenoic acid diet supplement on tolerance to the cardiotoxicity of epirubicin and to ischaemia reperfusion in the isolated rat heart. Schjøtt J, et al. **Pharmacol Toxicol** 1996 Aug; 79(2):65–72

Pretreatment with ischaemia attenuates acute epirubicin-induced cardiotoxicity in isolated rat hearts. Schjøtt J, et al. **Pharmacol Toxicol** 1996 Jun;78(6):381–6

Lipid peroxidation and antioxidant defense mechanisms in rat renal tissue after daunorubicin administration. Dioudis C, et al. **Ren Fail** 1996 Jul;18(4):537–43

Flow cytometric evaluation of the effects of doxorubicin on rat spermatogenesis. Suter L, et al. **Reprod Toxicol** 1997 Jul–Aug;11(4):521–31

Transgenic mice overexpressing metallothionein are not resistant to adriamycin cardiotoxicity. DiSilvestro RA, et al. **Res Commun Mol Pathol Pharmacol** 1996 Aug; 93(2):163–70

Effect of probucol on the cytological and biochemical changes induced by adriamycin in Swiss albino mice. al-Gharably NM. **Res Commun Mol Pathol Pharmacol** 1996 Dec;94(3):289–303

Long-lasting effect of dexrazoxane against anthracycline cardiotoxicity in rats. Della Torre P, et al. **Toxicol Pathol** 1996 Jul–Aug;24(4):398–402

Doxorubicin- and daunorubicin-induced energy deprivation and nucleotide degradation in isolated cardiomyocytes. Vidal RF, et al. **Toxicology** 1996 Nov 15;114(1):1–10

[The effect of calcium gluconate on the acute and chronic toxicity of doxorubicin in mice] Bogush TA, et al. **Antibiot Khimioter** 1997;42(1):17–22 (Eng. Abstr.) **(Rus)**

[Glutathione and enzymes associated with glutathione metabolism in adriamycin nephropathy] Simić T, et al. **Srp Arh Celok Lek** 1996;124 Suppl 1:45–7 (Eng. Abstr.) **(Scc)**

ANTIBIOTICS, ANTIFUNGAL

Amphotericin B is incompatible with lipid emulsions [letter] Ericsson O, et al. **Ann Pharmacother** 1996 Mar;30(3):298

Antibiotics update. Southern PM Jr. **Compr Ther** 1997 Sep; 23(9):575–82 (29 ref.)

ADMINISTRATION & DOSAGE

Orally administered amphotericin B in the treatment of oral candidiasis in HIV-infected patients caused by azole-resistant Candida albicans [letter] Nguyen MT, et al. **AIDS** 1996 Dec;10(14):1745–7

Amphotericin B in fat emulsion [editorial; comment] Kintzel PE. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2701. Comment on: Am J Health Syst Pharm 1996 Nov 15;53(22):2724–7.

A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. Lo WK, et al. **Am J Kidney Dis** 1996 Oct;28(4):549–52

Nutritional impact of lipid-associated amphotericin B formulations [letter] Sacks GS, et al. **Ann Pharmacother** 1997 Jan;31(1):121–2

Controlled pilot study of rapid amphotericin B infusions. Dele Davies H, et al. **Arch Dis Child** 1997 Feb;76(2):165–6

Liposomal amphotericin (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency. Pasic S, et al. **Bone Marrow Transplant** 1997 Jun;19(12):1229–32

Successful program to prevent aspergillus infections in children undergoing marrow transplantation: use of nasal amphotericin. Trigg ME, et al. **Bone Marrow Transplant** 1997 Jan;19(1):43–7

Nystatin pastilles and suspension in the treatment of oral candidosis. Millns B, et al. **Br Dent J** 1996 Sep 21; 181(6):209–11

Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Evdoridou J, et al. **Infection** 1997 Mar–Apr;25(2):112–6 (29 ref.)

Treatment of onychomycosis: a randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. Friedman-Birnbaum R, et al. **Int J Dermatol** 1997 Jan;36(1):67–9

The value of a single amphotericin B bladder washout in candiduria. Fong IW. **J Antimicrob Chemother** 1995 Dec; 36(6):1067–71

Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. Joly V, et al. **J Antimicrob Chemother** 1996 Jul;38(1):117–26

Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans. van Etten EW, et al. **J Antimicrob Chemother** 1995 Dec;36(6):961–74

Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. Legrand P, et al. **J Drug Target** 1997;4(5):311–9

Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and flucytosine in the treatment of cryptococcal meningitis in AIDS. Chotmongkol V, et al. **J Med Assoc Thai** 1997 Jul;80(7):416–25

Local application of antimycotics in mucormycosis cerebri: a case report. Mohsenipour I, et al. **J Neurol Neurosurg Psychiatry** 1996 Nov;61(5):521–2

Disposition of aerosolized liposomal amphotericin B. Lambros MP, et al. **J Pharm Sci** 1997 Sep;86(9):1066–9

Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation. Krüger W, et al. **Leuk Lymphoma** 1997 Feb;24(5–6):491–9

Use of intralipid as a vehicle for amphotericin B in the treatment of cryptococcal meningitis in a renal transplant recipient [letter] Nicol AJ, et al. **Nephron** 1996;73(2):312–3

FDA clears new treatment for invasive aspergillosis. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):107

Candida peritonitis treated with liposomal amphotericin B [letter] Ng SY, et al. **Postgrad Med J** 1996 Oct; 72(852):636–7

A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Alak A, et al. **Ther Drug Monit** 1996 Oct; 18(5):604–9

[Amphotericin B deoxycholate (Fungizone): old drug, new versions] Chavanet P. **Rev Med Interne** 1996;17 Suppl 3:349s–353s (86 ref.) **(Fre)**

[Drug treatment of invasive aspergillosis of the paranasal sinuses] Streppel M, et al. **Laryngorhinootologie** 1997 Jan; 76(1):19–22 (Eng. Abstr.) **(Ger)**

[The antifungal and immunomodulating lymphotropic therapy of candidiasis of the oral mucosa] Shumskiĭ AV, et al. **Stomatologiia (Mosk)** 1996;75(4):17–9 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Acute renal failure with amphotericin B in lipid emulsion [letter] Gales MA, et al. **Ann Pharmacother** 1996 Sep; 30(9):1036

Amphotericin B–associated hypertension. Le Y, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):765–7

Anaphylactic reaction to liposomal amphotericin B in children [letter] Torre I, et al. **Ann Pharmacother** 1996 Sep; 30(9):1036–7

Efficacy of nefopam for the prevention and treatment of amphotericin B–induced shivering. Rosa G, et al. **Arch Intern Med** 1997 Jul 28;157(14):1589–92

Safety of amphotericin B colloidal dispersion. Herbrecht R. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):74–80

Urinary adenosine excretion in patients receiving amphotericin B. Carlson MA, et al. **Surgery** 1997 Feb; 121(2):190–3

[Amphotericin B–intralipid 20% combination. In vivo evaluation of its tolerability (letter)] Débat Zoguéreh D, et al. **Ann Med Interne (Paris)** 1997;148(1):100–2 **(Fre)**

[Thrombopenia induced by amphotericin B in an extremely premature infant with congenital candidiasis (letter)] Baud O, et al. **Arch Pediatr** 1996 Aug;3(8):831–2 **(Fre)**

[Cyanotic Raynaud phenomenon as a side effect of Amphotericin B] Zernikow B, et al. **Klin Padiatr** 1996 Mar–Apr;208(2):53–5 (Eng. Abstr.) **(Ger)**

ANALYSIS

Amphotericin B enzyme-linked immunosorbent assay. Cleary JD, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):637–41

Practical capillary electrophoresis method for the quantitation of the acetate counter-ion in a novel antifungal lipopeptide. Zhou L, et al. **J Chromatogr A** 1997 Feb 28; 763(1–2):279–84

New high-performance liquid chromatographic method for amphotericin B analysis using an internal standard. Lambros MP, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):135–40

BIOSYNTHESIS

Four genes from Pseudomonas fluorescens that encode the biosynthesis of pyrrolnitrin. Hammer PE, et al. **Appl Environ Microbiol** 1997 Jun;63(6):2147–54

Cyclosporin C is the main antifungal compound produced by Acremonium luzulae. Moussaïf M, et al. **Appl Environ Microbiol** 1997 May;63(5):1739–43

Characterization of iturin synthetase in the wild-type Bacillus subtilis strain producing iturin and in an iturin deficient mutant. Feignier C, et al. **FEMS Microbiol Lett** 1996 Feb 15;136(2):117–22

Effect of ferrous ion on mildiomycin production by Streptoverticillium rimofaciens. Kishimoto K, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):770–4

Effect of phosphate ion on mildiomycin production by Streptoverticillium rimofaciens. Kishimoto K, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):775–80

Precursor directed biosynthesis of aureobasidins. Takesako K, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):676–81

Effect of ferrous ion on amino acid metabolism in mildiomycin production by Streptoverticillium rimofaciens. Kishimoto K, et al. **Jpn J Antibiot** 1997 Mar;50(3):206–11

Genotypic and phenotypic analysis of zwittermicin A-producing strains of Bacillus cereus. Raffel SJ, et al. **Microbiology** 1996 Dec;142 (Pt 12):3425–36

BLOOD

Rapid high performance liquid chromatographic assay for antifungal agents in human sera. Ng TK, et al. **J Antimicrob Chemother** 1996 Mar;37(3):465–72

Determination of amphotericin B in human serum by liquid chromatography. Lopez-Galera R, et al. **J Chromatogr B Biomed Appl** 1995 Dec 15;674(2):298–300

Development of a plasma high-performance liquid chromatographic assay for LY303366, a lipopeptide antifungal agent, and its application in a dog pharmacokinetic study. Zornes LL, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1;695(2):381–7

A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Alak A, et al. **Ther Drug Monit** 1996 Oct; 18(5):604–9

CHEMICAL SYNTHESIS

Synthesis and antimicrobial activities of 4-purpuromycin derivatives. Trani A, et al. **Farmaco** 1996 Jul;51(7):503–12

[The possibility of using the mycelial wastes from the production of antifungal antibiotics as additives to lubricating oils] Belakhov VV, et al. **Antibiot Khimioter** 1997;42(5):35–7 (Eng. Abstr.) **(Rus)**

[Synthesis and biological activity of hydrophosphoryl derivatives of amphotericin B] Belakhov VV, et al. **Antibiot Khimioter** 1996;41(7–8):4–8 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Precipitation of amphotericin B from i.v. fat emulsion [letter] Heide PE. **Am J Health Syst Pharm** 1997 Jun 15; 54(12):1449

Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion [see comments] Lopez RM, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2724–7. Comment in: Am J Health Syst Pharm 1996 Nov 15;53(22):2701.

Comment: compatibility of amphotericin B with lipid emulsions [letter] Montoro JB, et al. **Ann Pharmacother** 1996 Dec;30(12):1501

Pterulinic acid and pterulone, two novel inhibitors of NADH:ubiquinone oxidoreductase (complex I) produced by a Pterula species. II. Physico-chemical properties and structure elucidation. Engler M, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):330–3

UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517-02. II. Structural elucidation. Hanafi M, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1226–31

NP-101A, antifungal antibiotic from Streptomyces aurantiogriseus NPO-101. Phay N, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):703–5

Stereostructure of amphotericin A. Sowiński P, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1232–5

Precursor directed biosynthesis of aureobasidins. Takesako K, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):676–81

Lipid complexes of amphotericin B: the competitive picture [editorial] Richardson MD. **J Med Microbiol** 1997 Mar; 46(3):185–7 (10 ref.)

Conformational analysis of amphotericin B molecule. Silberstein AYa, et al. **Membr Cell Biol** 1997;10(5):553–63

Evidence for the formation of amphotericin B–phospholipid complexes in Langmuir monolayers. Lance MR, et al.

Pharm Res 1996 Jul;13(7):1008–14

Stability of nystatin in mouthrinses; effect of pH temperature, concentration and colloidal silver addition, studied using an in vitro antifungal activity. Vermerie N, et al. **Pharm World Sci** 1997 Aug;19(4):197–201

[Photostability of antifungal agents. 2.Photostability of polyene antibiotics] Thoma K, et al. **Pharmazie** 1997 Apr; 52(4):294–302 (Eng. Abstr.) **(Ger)**

[Sumiki–Umezawa Memorial Award '95, award lecture] Obukata M. **Jpn J Antibiot** 1996 Mar;49(3):301 **(Jpn)**

[Stabilization of roseofungin by antioxidants] Shenin IuD, et al. **Antibiot Khimioter** 1996 Apr;41(4):7–15 (Eng. Abstr.) **(Rus)**

CONTRAINDICATIONS

Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet. Zaman MM, et al. **Clin Infect Dis** 1996 Feb; 22(2):378

ECONOMICS

Comment: expense of amphotericin B product [letter; comment] Andersen JM. **Ann Pharmacother** 1996 Nov; 30(11):1342. Comment on: Ann Pharmacother 1996 Apr;30(4):409–12.

Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Marchetti A, et al. **Clin Ther** 1996 Jul–Aug;18(4):757–77; discussion 702

ISOLATION & PURIFICATION

Cyclosporin C is the main antifungal compound produced by Acremonium luzulae. Moussaïf M, et al. **Appl Environ Microbiol** 1997 May;63(5):1739–43

Isolation and structure of bergofungin, a new antifungal peptaibol from Emericellopsis donezkii HKI 0059. Berg A, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):817–20

Pterulinic acid and pterulone, two novel inhibitors of NADH:ubiquinone oxidoreductase (complex I) produced by a Pterula species. I. Production, isolation and biological activities. Engler M, et al. **J Antibiot (Tokyo)** 1997 Apr; 50(4):325–9

UK–2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517–02. I. Fermentation, isolation, and biological properties. Ueki M, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):639–43

METABOLISM

Aureobasidin A, an antifungal cyclic depsipeptide antibiotic, is a substrate for both human MDR1 and MDR2/P-glycoproteins. Kino K, et al. **FEBS Lett** 1996 Dec 9;399(1–2):29–32

PHARMACOKINETICS

Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Ayestarán A, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):609–12

Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Heinemann V, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1275–80

Serum pharmacology of amphotericin B applied in lipid emulsions. Heinemann V, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):728–32

Kinetics of nikkomycin Z degradation in aqueous solution and in plasma. Tokumura T, et al. **Biol Pharm Bull** 1997 May;20(5):577–80

Biopharmaceutical aspects of lipid formulations of amphotericin B. Storm G, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):64–73 (63 ref.)

Diversity of lipid-based polyene formulations and their behavior in biological systems. Wasan KM, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):81–92 (87 ref.)

Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. Legrand P, et al. **J Antimicrob Chemother** 1996 Mar; 37(3):519–33

Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. Hutchaleelaha A, et al. **J Pharm Pharmacol** 1997 Feb; 49(2):178–83

Disposition of aerosolized liposomal amphotericin B. Lambros MP, et al. **J Pharm Sci** 1997 Sep;86(9):1066–9

PHARMACOLOGY

Cryptococcosis. Aberg JA, et al. **Adv Pharmacol** 1997; 37:215–51 (117 ref.)

Antagonistic effect of amphotericin B on carboplatin antitumor activity in human osteosarcoma xenografts. Crnalic S, et al. **Anticancer Drugs** 1996 Jun;7(4):489–92

Antifungal azoxybacilin exhibits activity by inhibiting gene expression of sulfite reductase. Aoki Y, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):127–32

Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Bartlett MS, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1811–6

Fungicidal action of aureobasidin A, a cyclic depsipeptide antifungal antibiotic, against Saccharomyces cerevisiae. Endo M, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):672–6

New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents. Flattery AM, et al. **Antimicrob Agents Chemother** 1996 Jul; 40(7):1604–9

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Klepser ME, et al. **Antimicrob Agents Chemother** 1997 Jun; 41(6):1392–5

In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates. Martinez-Suarez JV, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1277–9

Evaluation of a flow cytofluorometric method for rapid determination of amphotericin B susceptibility of yeast isolates. Peyron F, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1537–40

In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Pfaller MA, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):763–6

Effects of incubation temperature, inoculum size, and time of reading on broth microdilution susceptibility test results for amphotericin B fgainst Fusarium. Pujol I, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):808–11

Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Sanati H, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1345–8

In vitro antifungal and fungicidal activities and erythrocyte toxicities of cyclic lipodepsinonapeptides produced by Pseudomonas syringae pv. syringae. Sorensen KN, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2710–3

Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide. Tohyama M, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1919–23

In vitro interaction between amphotericin B and azoles in Candida albicans. Vazquez JA, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2511–6

In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp. Wardle HM, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2229–31

Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis. Wasan KM, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1806–10

In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Zhanel GG, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):863–5

The effect of sterols on the sensitivity of membranes to the channel-forming antifungal antibiotic, syringomycin E. Feigin AM, et al. **Biochim Biophys Acta** 1997 Feb 21; 1324(1):102–10

Activation of the sphingomyelin cycle by brefeldin A: effects of brefeldin A on differentiation and implications for a role for ceramide in regulation of protein trafficking. Linardic CM, et al. **Cell Growth Differ** 1996 Jun;7(6):765–74

Experimental evidences for a role of subinhibitory concentrations of rilopirox, nystatin and fluconazole on adherence of Candida spp. to vaginal epithelial cells. Braga PC, et al. **Chemotherapy** 1996 Jul–Aug;42(4):259–65

Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Sterling TR, et al. **Clin Infect Dis** 1996 Jul;23(1):187–8

Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Ernst ME, et al. **Diagn Microbiol Infect Dis** 1996 Nov–Dec; 26(3–4):125–31

Comparison of the leishmanicidal activity of fungizone, liposomal AmB and amphotericin B incorporated into egg lecithin–bile salt mixed micelles. Ramos H, et al. **Drugs Exp Clin Res** 1995;21(6):211–6

Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. Kelly SL, et al. **FEBS Lett** 1997 Jan 2;400(1):80–2

Griseofulvin-induced hepatopathy due to abnormalities in heme pathway. Polo CF, et al. **Gen Pharmacol** 1997 Aug; 29(2):207–10

In vivo and in vitro antifungal activity of the polyene derivative SPA-S-753 against encapsulated form of Cryptococcus neoformans. Strippoli V, et al. **Infection** 1997 Jan–Feb;25(1):27–31

Dansyl N-acetyl glucosamine as a precursor of fluorescent chitin: a method to detect fungal cell wall inhibitors. Carrano L, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):177–9

Pterulinic acid and pterulone, two novel inhibitors of NADH:ubiquinone oxidoreductase (complex I) produced by a Pterula species. I. Production, isolation and biological activities. Engler M, et al. **J Antibiot (Tokyo)** 1997 Apr; 50(4):325–9

NP-101A, antifungal antibiotic from Streptomyces aurantiogriseus NPO-101. Phay N, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):703–5

Inhibitors of type-I interleukin-1 receptor from microbial metabolites. Stefanelli S, et al. **J Antibiot (Tokyo)** 1997 Jun; 50(6):484–9

UK-2A, B, C and D, novel antifungal antibiotics from Streptomyces sp. 517–02. I. Fermentation, isolation, and biological properties. Ueki M, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):639–43

Antifungal antibiotic benanomicin A increases susceptibility of Candida albicans to phagocytosis by murine macrophages. Watabe H, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1221–5

Anti-candidal activity of mupirocin–evidence for uptake via an amino acid transport system [letter] De Wet PM, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1107–8

In-vitro activity of purpuromycin and MDL 63,604 against microorganisms that cause vaginitis and vaginosis. Goldstein BP, et al. **J Antimicrob Chemother** 1995 Dec; 36(6):1061–5

Treatment of experimental systemic mycoses with BRL 49594A. Najvar LK, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1005–1011

The in-vitro activity of an antifungal antibiotic benanomicin A in comparison with amphotericin B. Watanabe M, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1073–7

Sphingolipid synthesis as a target for antifungal drugs. Complementation of the inositol phosphorylceramide synthase defect in a mutant strain of Saccharomyces cerevisiae by the AUR1 gene. Nagiec MM, et al. **J Biol Chem** 1997 Apr 11;272(15):9809–17

Bafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling. Presley JF, et al. **J Biol Chem** 1997 May 23;272(21):13929–36

Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar blue tests. Jahn B, et al. **J Clin Microbiol** 1996 Aug;34(8):2039–41

Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B. Lozano-Chiu M, et al. **J Clin Microbiol** 1997 Jan; 35(1):270–2

Rapid flow cytometric susceptibility testing of Candida albicans. Ramani R, et al. **J Clin Microbiol** 1997 Sep; 35(9):2320–4

Identification of an amphotericin B resistant strain of Candida albicans using a rapid 3H-glucose incorporation microassay. Sweeney JF, et al. **J Infect** 1996 Nov; 33(3):221–6

Role of macrophages in the candidacidal activity of liposomal amphotericin B. Mehta RT, et al. **J Infect Dis** 1997 Jan; 175(1):214–7

Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. Joseph-Horne T, et al. **J Med Vet Mycol** 1996 Jun–Jul; 34(3):223–5

Lipopeptide inhibitors of fungal glucan synthase. Kurtz MB, et al. **J Med Vet Mycol** 1997 Mar–Apr;35(2):79–86 (52 ref.)

Sch 54445: a new polycyclic xanthone with highly potent antifungal activity produced by Actinoplanes sp. Chu M, et al. **J Nat Prod** 1997 May;60(5):525–8

The in vitro adhesion of Candida albicans to buccal epithelial cells (BEC) from diabetic and non-diabetic individuals after in vivo and in vitro application of nystatin. Darwazeh AM, et al. **J Oral Pathol Med** 1997 May;26(5):233–6

Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients [letter] Kelly SL, et al. **Lancet** 1996 Nov 30;348(9040):1523–4

Nystatin-rhodamine B assay for estimating activity of killer toxin from Kluyveromyces lactis. Palková Z, et al. **Methods Mol Biol** 1996;53:325–9 (5 ref.)

Functional reconstitution of a purified proline permease from Candida albicans: interaction with the antifungal cispentacin. Jethwaney D, et al. **Microbiology** 1997 Feb;143 (Pt 2):397–404

A disc plate assay for characterization of the effect of interaction between polyenes and azoles on growth of Candida albicans CA12. Cao B, et al. **Microbios** 1996; 87(352):161–7

Effect of amphotericin B on the lipids of yeast cells of Sporothrix schenckii. Hamdan JS, et al. **Mycopathologia** 1996–97;136(3):125–31

Adhesion of Candida albicans to epithelial cells--effect of nikkomycin. Segal E, et al. **Mycoses** 1997 Jan–Feb; 40(1–2):33–9

Inhibition by nystatin of Kv1.3 channels expressed in Chinese hamster ovary cells. Hahn SJ, et al. **Neuropharmacology** 1996;35(7):895–901

Evaluation of the in vitro activity of seven selected antimicrobial agents to be used for the isolation of human intestinal spirochaetes. Calderaro A, et al. **New Microbiol** 1997 Jan;20(1):35–45

Stability of nystatin in mouthrinses; effect of pH temperature, concentration and colloidal silver addition, studied using an in vitro antifungal activity. Vermerie N, et al. **Pharm World Sci** 1997 Aug;19(4):197–201

Postantifungal effect and effects of low concentrations of amphotericin B and fluconazole on previously treated Candida albicans. Mínguez F, et al. **Scand J Infect Dis** 1996; 28(5):503–6

Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. Rasmussen BB, et al. **Ther Drug Monit** 1997 Feb;19(1):56–62

Inhibition of hormone-stimulated inositol phosphate

production and disruption of cytoskeletal structure. Effects of okadaic acid, microcystin, chlorpromazine, W7 and nystatin. Macías-Silva M, et al. **Toxicon** 1994 Jan; 32(1):105-12

[Preparation of beta-1,3-glucan synthase and its application to the screening of antifungal antibiotics] Zheng D, et al. **Wei Sheng Wu Hsueh Pao** 1996 Feb;36(1):73-5 (Eng. Abstr.) **(Chi)**

[Determination of in vitro synergy when amphotericin B is combined with various antimicrobial agents against yeasts by using a colorimetric microdilution checkerboard] Yamane N, et al. **Rinsho Byori** 1997 Jul;45(7):689-95 (Eng. Abstr.) **(Jpn)**

[Molecular targets of cell cycle inhibitors and their mode of action] Yoshida M. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1751-60 (65 ref.) **(Jpn)**

[Effect of cyclosporin A and amphotericin B on protoplasts of Tolypocladium inflatum] Sazukin IuO, et al. **Antibiot Khimioter** 1997;42(3):3-5 (Eng. Abstr.) **(Rus)**

[Amphotericin B: properties, chemical structure, screening of derivatives] Shenin IuD, et al. **Antibiot Khimioter** 1997; 42(4):34-46 (102 ref.) **(Rus)**

RADIATION EFFECTS

[The effect of solar ultraviolet on the system of microorganisms-higher plant antibiotics, a natural phenomenon and a new approach to enhancing the efficacy of antibiotics] Smirnov VV, et al. **Antibiot Khimioter** 1996; 41(11):7-13 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Renal tolerance with the use of intralipid-amphotericin B in low-birth-weight neonates. Friedlich PS, et al. **Am J Perinatol** 1997 Aug;14(7):377-83

Response to initial griseofulvin therapy in pediatric patients with tinea capitis. Abdel-Rahman SM, et al. **Ann Pharmacother** 1997 Apr;31(4):406-10

Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections? Nagata MP, et al. **Ann Pharmacother** 1996 Jul-Aug; 30(7-8):811-8 (58 ref.)

Comparison of fluconazole and amphotericin B in prophylaxis of experimental Candida endocarditis caused by non-C. albicans strains. Bayer AS, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):494-6

Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits. Chemlal K, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):263-6

Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Cicogna CE, et al. **Antimicrob Agents Chemother** 1997 Feb; 41(2):259-61

Potent antifungal effects of a new derivative of partricin A in a murine model of cerebral cryptococcosis. Luna T, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):706-8

Effects of pentoxifylline or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: evidence of neuroexcitatory pathogenic mechanisms. Ostrosky-Zeichner L, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1194-7

Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Yardley V, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):752-6

Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis. Kretschmar M, et al. **Arzneimittelforschung** 1996 Jul; 46(7):711-5

Onychomycosis. Going for cure. Gupta AK, et al. **Can Fam Physician** 1997 Feb;43:299-305 (49 ref.)

Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Lake DE, et al. **Chemotherapy** 1996 Jul-Aug;42(4):308-14

The role of azole antifungal agents for systemic antifungal therapy. Lee YP, et al. **Cleve Clin J Med** 1997 Feb; 64(2):99-106 (67 ref.)

Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Joly V, et al. **Clin Infect Dis** 1996 Sep;23(3):556-62

Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS [see comments] Sharkey PK, et al. **Clin Infect Dis** 1996 Feb;22(2):315-21. Comment in: Clin Infect Dis 1996 Feb;22(2):329-30.

Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. White MH, et al. **Clin Infect Dis** 1997 Apr;24(4):635-42

Ultra-long amphotericin B therapy for hepatosplenic candidiasis complicating acute promyelocytic leukaemia [letter] Lai ST, et al. **Clin Lab Haematol** 1996 Mar; 18(1):62-3

Nystatin prophylaxis [letter; comment] Dubé MP, et al. **Clin Microbiol Rev** 1997 Apr;10(2):368. Comment on: Clin Microbiol Rev 1996 Oct;9(4):499-511.

Musculoskeletal coccidioidomycosis. A review of 25 cases. Kushwaha VP, et al. **Clin Orthop** 1996 Nov;(332):190-9

Home intravenous anti-infective therapy (HIVAT): do the benefits outweigh the risks? Williams DN. **Drug Saf** 1996 Jan;14(1):1-7

Nonsurgical cure of isolated cerebral mucormycosis in an intravenous drug user. Blázquez R, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jul;15(7):598-9

Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Erjavec Z, et al. **Eur J Clin Microbiol Infect Dis** 1997 May;16(5):364-8

Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Phillips P, et al. **Eur J Clin Microbiol Infect Dis** 1997 May;16(5):337-45

A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Abele-Horn M, et al. **Infection** 1996 Nov-Dec;24(6):426-32

Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Evdoridou J, et al. **Infection** 1997 Mar-Apr;25(2):112-6 (29 ref.)

Liposomal amphotericin B and recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in the treatment of paediatric AIDS-related cryptococcosis. Manfredi R, et al. **Int J STD AIDS** 1997 Jun;8(6):406-8

New antifungal drugs in ophthalmology. O'Day DM. **Int Ophthalmol Clin** 1996 Spring;36(2):45-51 (27 ref.)

Changes in the natural history of invasive pulmonary aspergillosis in neutropenic leukemic patients. Ruchlemer R, et al. **Isr J Med Sci** 1996 Nov;32(11):1089-92

Ocular blastomycosis in dogs: 73 cases, 108 eyes (1985-1993). Bloom JD, et al. **J Am Vet Med Assoc** 1996 Oct 1; 209(7):1271-4

The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole. Ohtsuka K, et al. **J Antimicrob Chemother** 1997 Jan; 39(1):71-7

Breakthrough fungemia due to Hansenula anomala in a leukemia patient successfully treated with amphotericin B [letter] Kunovà A, et al. **J Chemother** 1996 Feb;8(1):85-6

Histoplasmosis--a ten year follow-up. Johnston AW, et al. **J Infect** 1996 Sep;33(2):111-3

Reversal of encephalopathy during treatment with amphotericin-B. Antonini G, et al. **J Neurol Sci** 1996 Dec; 144(1-2):212-3

Dark ring sign: finding in patients with fungal liver lesions and transfusional hemosiderosis undergoing treatment with antifungal antibiotics. Kelekis NL, et al. **Magn Reson Imaging** 1996;14(6):615-8

Tinea of the skin, hair and nails [letter; comment] Quinn DI. **Med J Aust** 1996 Sep 16;165(6):350-1. Comment on: Med J Aust 1996 May 6;164(9):552-6.

Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Andström EE, et al. **Mycoses** 1996 May-Jun;39(5-6):185-93

Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients. Böhme A, et al. **Mycoses** 1996 Nov-Dec;39(11-12):419-26

Use of intralipid as a vehicle for amphotericin B in the treatment of cryptococcal meningitis in a renal transplant recipient [letter] Nicol AJ, et al. **Nephron** 1996;73(2):312-3

Intraconal amphotericin B for the treatment of rhino-orbital mucormycosis. Luna JD, et al. **Ophthalmic Surg Lasers** 1996 Aug;27(8):706-8

Successful therapy of Candida albicans arthritis with a sequential intravenous amphotericin B and oral fluconazole regimen. Barson WJ, et al. **Pediatr Infect Dis J** 1996 Dec; 15(12):1119-22 (42 ref.)

Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Driessen M, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1107-12

Successful combination of amphotericin therapy and surgical resection for fungal necrotizing pneumoniae in a child receiving chemotherapy for leukemia. Suc A, et al. **Pediatr Pulmonol** 1997 May;23(5):386-8

Nosocomial cerebral aspergillosis: a report of 3 cases. Darras-Joly C, et al. **Scand J Infect Dis** 1996;28(3):317-9 (28 ref.)

Fatal outcome of disseminated candidosis after allogeneic bone marrow transplantation under treatment with liposomal and conventional amphotericin-B. A report of 4 cases with determination of the Mic values. Krüger W, et al. **Scand J Infect Dis** 1996;28(3):313-6

[Palliative percutaneous treatment under ultrasonographic control of inoperable pulmonary aspergilloma: Galenic analysis (letter)] Meges B, et al. **Rev Mal Respir** 1996 Dec; 13(6):614-5 **(Fre)**

[Otorhinolaryngological manifestations of mucormycosis. Study of 6 cases] Duque Fisher CS, et al. **Acta Otorrinolaringol Esp** 1996 Jul-Aug;47(4):291-4 (Eng. Abstr.) **(Spa)**

[Liposomal amphotericin B in the treatment of systemic fungal infection in the neonate. The results of one case] Baquero Artigao F, et al. **An Esp Pediatr** 1996 Aug; 45(2):209-12 **(Spa)**

[Resolution of a disseminated infection by Fusarium solani in a patient with acute promyelocytic leukemia and granulocytopenia secondary to chemotherapy by the combined use of G-CSF and liposomal amphotericin B (letter)] Sancho JM, et al. **Med Clin (Barc)** 1997 Jun 21; 109(4):156-7 **(Spa)**

[Oral amphotericin B inefficacy in the treatment of fluconazole++ resistant oropharyngeal candidiasis in HIV-positive patients (letter)] Laguna F, et al. **Rev Clin Esp** 1996 Dec;196(12):878-9 **(Spa)**

TOXICITY

Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B. Walev I, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1116-20

Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Wasan KM, et al. **Clin Infect Dis** 1997 Jan; 24(1):78-80

Effect of amphotericin B associated with a lipid emulsion on the oxidative burst of human polymorphonuclear leukocytes. Marzzullo L, et al. **Gen Pharmacol** 1997 Feb; 28(2):203-7

Cytogenetic effect of griseofulvin in mouse spermatocytes. Fahmy MA, et al. **J Appl Toxicol** 1996 Mar-Apr; 16(2):177-83

Differential killer toxin sensitivity patterns of varieties of Cryptococcus neoformans. Boekhout T, et al. **J Med Vet Mycol** 1997 Mar-Apr;35(2):147-9

ANTIBIOTICS, ANTINEOPLASTIC

Implementing a formal cytotoxic agent program at an overseas medical treatment facility. Huntzinger PE. **Mil Med** 1997 Jan;162(1):71-3

Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Cragg GM, et al. **Semin Oncol** 1997 Apr;24(2):156-63 (22 ref.)

ADMINISTRATION & DOSAGE

Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Loggie BW, et al. **Acta Cytol** 1996 Nov-Dec;40(6):1154-8

Gonadal function following ABVD therapy for Hodgkin's disease. Kulkarni SS, et al. **Am J Clin Oncol** 1997 Aug; 20(4):354-7

A long-term dose-response study of mitomycin in glaucoma filtration surgery [see comments] Robin AL, et al. **Arch Ophthalmol** 1997 Aug;115(8):969-74. Comment in: Arch Ophthalmol 1997 Aug;115(8):1068-9.

Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor-bearing rats. Kitazawa H, et al. **Biol Pharm Bull** 1997 Mar; 20(3):278-81

Preparation and drug release characteristics of the conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan. Sato M, et al. **Biol Pharm Bull** 1996 Feb;19(2):241-5

The effect of adriamycin against a liver metastatic model by encapsulation in liposomes. Yachi K, et al. **Biopharm Drug Dispos** 1996 Nov;17(8):699-715

Postoperative instillation of 0.04% mitomycin C in the treatment of primary pterygium in Zaire. Kaimbo Wa Kaimbo D. **Bull Soc Belge Ophtalmol** 1996;261:107-10

Histology of conjunctival vascular endothelium after filtering surgery with mitomycin C in rabbits. Assalian A, et al. **Can J Ophthalmol** 1996 Oct;31(6):289-95

Pharmacokinetic, angiographic, and histologic comparison of catheter-directed chemoembolization versus systemic chemotherapy in a canine model. Zhan X, et al. **Can J Physiol Pharmacol** 1996 Oct;74(10):1117-25

Enhancement of therapeutic efficacy of bleomycin by incorporation into biodegradable poly-d,l-lactic acid. Kumanohoso T, et al. **Cancer Chemother Pharmacol** 1997; 40(2):112-6

Advantages and safety of local treatment with MMC/Beriplast P for cancer tumors. Matsuoka H, et al. **Cancer Chemother Pharmacol** 1996;38(6):508-12

Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C. Fernández-Trigo V, et al. **Cancer Treat Res** 1996;81:51-61

Survival time and prevention of side effects of intraperitoneal hyperthermic perfusion with mitomycin C combined with surgery for patients with advanced gastric cancer. Fujimoto S, et al. **Cancer Treat Res** 1996;81:169-76

Heated intraperitoneal mitomycin C infusion treatment for patients with gastric cancer and peritoneal metastasis. Fujimoto S, et al. **Cancer Treat Res** 1996;81:239-45

Complications of heated intraperitoneal chemotherapy and strategies for prevention. Loggie BW, et al. **Cancer Treat Res** 1996;82:221-33

Peritoneal carcinomatosis and radioimmunoguided surgery. Schneebaum S, et al. **Cancer Treat Res** 1996;82:193-209

Mechanism and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to carbon particles. Takahashi T, et al. **Cancer Treat Res** 1996; 81:185-92

Prospective randomized trial of talc slurry vs bleomycin in pleurodesis for symptomatic malignant pleural effusions. Zimmer PW, et al. **Chest** 1997 Aug;112(2):430-4

Quantification of the dosage of mitomycin in trabculectomy by the 'mito-pill' [letter] Blanksma LJ, et al. **Doc Ophthalmol** 1996-97;92(1):77-8

A comparative study of undifferentiated nasopharyngeal carcinoma treated with radiotherapy or combined treatment with zorubicin-cisplatin and radiotherapy. Pendjer I, et al. **Eur Arch Otorhinolaryngol Suppl** 1997; 1:S127-9

Clinical evaluation of the effect of mitomycin-C in

re-operation for primary open angle glaucoma. Andreanos D, et al. **Eur J Ophthalmol** 1997 Jan-Mar;7(1):49-54

Low-dosage mitomycin C as an adjunct to trabeculectomy. A prospective controlled study. Martini E, et al. **Eur J Ophthalmol** 1997 Jan-Mar;7(1):40-8

A new treatment with bleomycin for complicated cutaneous hemangioma in children. Sarihan H, et al. **Eur J Pediatr Surg** 1997 Jun;7(3):158-62

Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. Bono AV, et al. **Eur Urol** 1996;29(4):385-90

Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy? Schwaibold H, et al. **Eur Urol** 1997;31(2):153-9

Cytophotometry in the monitoring of bladder cancer under intravesical chemotherapy. Simak R, et al. **Eur Urol** 1996; 29(4):391-8

Treatment of cancer using pulsed electric field in combination with chemotherapeutic agents or genes. Nishi T, et al. **Hum Cell** 1997 Mar;10(1):81-6

Toxicity and antitumor activity of niosomal bleomycin in tumor bearing mice. Naresh RA, et al. **Indian J Exp Biol** 1996 Aug;34(8):764-72

Subconjunctival injection of low-dose Mitomycin-C for treatment of failing human trabeculectomies. Apostolov VI, et al. **Int Ophthalmol** 1996-97;20(1-3):101-5

Semiconductor diode laser transscleral cyclophotocoagulation versus filtering surgery with Mitomycin-C. Pablo LE, et al. **Int Ophthalmol** 1996-97; 20(1-3):11-4

Scleral free auto-implant plug with mitomycin as limitation of trepanosclerectomy flow in glaucoma filtering surgery. Szymanski A. **Int Ophthalmol** 1996-97;20(1-3):89-94

A fluorophotometric study of corneal endothelium after trabeculectomy using different concentrations of Mitomycin-C. Szymanski A, et al. **Int Ophthalmol** 1996-97; 20(1-3):95-9

Trabeculectomy with mitomycin C: an electron microscopic and clinical study. Turáçli ME, et al. **Int Ophthalmol** 1995-96;19(6):337-46

A novel MMC-loaded pHEMA drainage device for the treatment of glaucoma: in vitro and in vivo studies. Kiremitçi-Gümüşderelioglu M, et al. **J Biomater Sci Polym Ed** 1996;7(10):857-69

Safe anesthetic management of patients undergoing a novel method of treating human hepatocellular cancer. Dougherty TB, et al. **J Clin Anesth** 1997 May;9(3):220-7

Midterm follow-up results of combined phacoemulsification, lens implantation, and mitomycin-C trabeculectomy procedure. Belyea DA, et al. **J Glaucoma** 1997 Apr; 6(2):90-8

Results of intraoperative 5-fluorouracil or lower dose mitomycin-C administration on initial trabeculectomy surgery. Smith MF, et al. **J Glaucoma** 1997 Apr;6(2):104-10

Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. Chen MY, et al. **J Surg Oncol** 1997 Sep;66(1):19-23

Superselective intra-arterial chemotherapy with mitomycin C in hepatic metastases from colorectal cancer. Mäkelä J, et al. **J Surg Oncol** 1997 Jun;65(2):127-31

Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. Ali-el-Dein B, et al. **J Urol** 1997 Jul; 158(1):68-73; discussion 73-4

Surgical results and complications of trabeculectomy with intraoperative application of mitomycin C. Matsuda T, et al. **Jpn J Ophthalmol** 1996;40(4):526-32

Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy. Heller R, et al. **Melanoma Res** 1997 Feb;7(1):10-8

Nanophthalmic uveal effusion managed with scleral windows and topical mitomycin-C. Akduman L, et al. **Ophthalmic Surg Lasers** 1997 Apr;28(4):325-7

Use of a scleral shield for the application of mitomycin-C during trabeculectomy: preliminary clinical results. Mietz H, et al. **Ophthalmic Surg Lasers** 1996 Dec;27(12):989-94

Mitomycin-C in laser sclerostomy: benefit and complications. Schmidt-Erfurth U, et al. **Ophthalmic Surg Lasers** 1997 Jan;28(1):14-20

Histopathologic effects of mitomycin-C on endoscopic transnasal dacryocystorhinostomy. Ugurbas SH, et al. **Ophthalmic Surg Lasers** 1997 Apr;28(4):300-4

Intraoperative mitomycin-C for glaucoma associated with ocular inflammation. Wright MM, et al. **Ophthalmic Surg Lasers** 1997 May;28(5):370-6

Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. Cardillo JA, et al. **Ophthalmology** 1995 Dec;102(12):1949-52

Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Katz GJ, et al. **Ophthalmology** 1995 Sep;102(9):1263-9

Adjunctive subconjunctival mitomycin C in glaucoma triple procedure [see comments] Shin DH, et al. **Ophthalmology** 1995 Oct;102(10):1550-8. Comment in: Ophthalmology 1996 Mar;103(3)347-8.

An ultrasound biomicroscopic study of filtering blebs after mitomycin C trabeculectomy. Yamamoto T, et al. **Ophthalmology** 1995 Dec;102(12):1770-6

Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice. Emanuel N, et al. **Pharm Res** 1996 Jun;13(6):861-8

Zinostatin stimalamer-transcatheter arterial embolization for hepatocellular carcinoma: a comparison with lipiodol-transcatheter arterial embolization. Hirashima N, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6-91-S6-96

[A pilot study of high-dose zorubicin in advanced stages of soft tissue sarcoma in adults] Jelić S, et al. **Bull Cancer** 1996 Dec;83(12):1002-7 (Eng. Abstr.) **(Fre)**

[Mitomycin as local therapeutic drug in ocular neoplasms] Löffler KU. **Ophthalmologe** 1997 Jul;94(7):529-31 **(Ger)**

[Antitumor effect of TNP-470 against tongue carcinoma model by intratumor administration] Ninomiya Y, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1993-6 **(Jpn)**

ADVERSE EFFECTS

Mitomycin lung toxicity. Acute and chronic phases. Okuno SH, et al. **Am J Clin Oncol** 1997 Jun;20(3):282-4

Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Groff JA, et al. **Am J Kidney Dis** 1997 Feb;29(2):280-4

Late onset of sequential multifocal bleb leaks after glaucoma filtration surgery with 5-fluorouracil and mitomycin C. Belyea DA, et al. **Am J Ophthalmol** 1997 Jul;124(1):40-5

Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470. Hori K, et al. **Br J Cancer** 1997;75(12):1730-4

Transgenic mice expressing the Sh ble bleomycin resistance gene are protected against bleomycin-induced pulmonary fibrosis. Weinbach J, et al. **Cancer Res** 1996 Dec 15; 56(24):5659-65

Reduction of bleomycin-induced acute DNA injury in the rat lung by the 21-aminosteroid, U-74389G. Dallessio JJ, et al. **Crit Care Med** 1997 Apr;25(4):652-6

Effects of actinomycin D on developing hamster molar tooth germs in vitro. Lyaruu DM, et al. **Eur J Oral Sci** 1997 Feb;105(1):52-8

Hepatic veno-occlusive disease in Wilms' tumor. Kullendorff CM, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):338-40

Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix. Rakovitch E, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15;38(5):979-87

Mitomycin-C induced hemolytic uremic syndrome: a case report and literature review. Wu DC, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):115-8 (27 ref.)

Management of chronic hypotony following trabeculectomy with mitomycin C. Hyung SM, et al. **Korean J Ophthalmol** 1997 Jun;11(1):15-24

Cutaneous toxicity following the administration of dactinomycin. Coppes MJ, et al. **Med Pediatr Oncol** 1997 Sep;29(3):226-7

Indications for and complications of mitomycin-C in pterygium surgery. Anduze AL, et al. **Ophthalmic Surg Lasers** 1996 Aug;27(8):667-73

Scleritis after glaucoma filtering surgery with mitomycin C. Fourman S. **Ophthalmology** 1995 Oct;102(10):1569-71

[Bleomycin-induced pneumonia] Berger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Nov; 31(9):577-81 (Eng. Abstr.) **(Ger)**

[The effect of herbal medicines on the immunodeficient animals by injecting cancer chemotherapeutic agent-special reference to age related recovery of the function] Li AL, et al. **Kansenshogaku Zasshi** 1996 Jul;70(7):717-26 (Eng. Abstr.) **(Jpn)**

[Doxorubicin-induced myocardial damage in elderly patients with hematologic malignancies] Niitsu N, et al. **Nippon Ronen Igakkai Zasshi** 1997 Jan;34(1):38-42 (Eng. Abstr.) **(Jpn)**

[Nephrotoxicity of antineoplastic agents (antibiotics)] Nakahama H. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):539-41 (9 ref.) **(Jpn)**

ANALYSIS

Determination of gentamicin in bovine milk using liquid chromatography with post-column derivatization and fluorescence detection. Kijak PJ, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):377-82

ANTAGONISTS & INHIBITORS

[Pentoxifylline inhibits experimental bleomycin-induced fibrosing alveolitis] Entzian P, et al. **Pneumologie** 1997 Apr; 51(4):375-80 (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

UCE6, a new antitumor antibiotic with topoisomerase I-mediated DNA cleavage activity produced by actinomycetes: producing organism, fermentation, isolation and biological activity. Fujii N, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):490-5

Studies on new antitumor antibiotics, leptofuranins A, B, C and D.I. Taxonomy, fermentation, isolation and biological activities. Hayakawa Y, et al. **J Antibiot (Tokyo)** 1996 Oct; 49(10):974-9

Cloning and insertional inactivation of Streptomyces argillaceus genes involved in the earliest steps of biosynthesis of the sugar moieties of the antitumor polyketide mithramycin. Lombó F, et al. **J Bacteriol** 1997 May;179(10):3354-7

Purification and preliminary characterization of (E)-3-(2,4-dioxo-6-methyl-5-pyrimidinyl)acrylic acid synthase, an enzyme involved in biosynthesis of the antitumor agent sparsomycin. Parry RJ, et al. **J Bacteriol** 1997 Feb;179(4):1385-92

Two multifunctional peptide synthetases and an O-methyltransferase are involved in the biosynthesis of the DNA-binding antibiotic and antitumour agent saframycin Mx1 from Myxococcus xanthus. Pospiech A, et al. **Microbiology** 1996 Apr;142 (Pt 4):741-6

BLOOD

Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction. Paroni R, et al. **Clin Chem** 1997 Apr;43(4):615-8

Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Fernández de Gatta MD, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):332-40

Is bleomycin-detectable iron present in the plasma of patients with sepsis syndrome? [editorial; comment] Weinberg ED. **Intensive Care Med** 1997 Jun;23(6):613-4. Comment on: Intensive Care Med 1997 Jun;23(6):635-9.

Quantitation of beta-lapachone and 3-hydroxy-beta-lapachone in human plasma samples by reversed-phase high-performance liquid chromatography. Glen VL, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):181-6

Direct injection isocratic high-performance liquid chromatographic analysis of mitomycin C in plasma. Song D, et al. **J Chromatogr B Biomed Appl** 1996 Feb 9; 676(1):165-8

Manual and automatic extraction and high-performance liquid chromatographic determination of a spicamycin derivative, KRN5500, in rat plasma. Yoshioka E, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):371-5

Modifications in high-density lipoprotein lipid composition and structure alter the plasma distribution of free and liposomal annamycin. Wasan KM, et al. **J Pharm Sci** 1997 Jul;86(7):872-5

CHEMICAL SYNTHESIS

Synthesis, chemical solvolytic stability and preliminary biological evaluation of (+/-)-N-Boc-CPzI: a pyrazole analog of the left-hand segment of the antitumor agent CC-1065. Baraldi PG, et al. **Anticancer Drug Des** 1997 Jan; 12(1):67-74

Synthesis and antitumor activity of water-soluble enediyne compounds related to dynemicin A. Unno R, et al. **Bioorg Med Chem** 1997 May;5(5):987-99

Structure-activity relationships of cyclic enediynes related to dynemicin A. I. Synthesis and antitumor activity of 9-acetoxy enediynes equipped with aryl carbamate moieties. Unno R, et al. **Bioorg Med Chem** 1997 May; 5(5):883-901

Structure-activity relationships of cyclic enediynes related to dynemicin A. II. Synthesis and antitumor activity of 9- and 12-substituted enediynes equipped with aryl carbamate moieties. Unno R, et al. **Bioorg Med Chem** 1997 May;5(5):903-19

Synthesis and biological evaluation of novel cyclic enediyne compounds related to dynemicin A as antitumor agents. Unno R, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan; 45(1):125-33

Synthesis and antitumor activity of duocarmycin derivatives: A-ring pyrrole compounds bearing cinnamoyl groups. Nagamura S, et al. **J Med Chem** 1997 Mar 14;40(6):972-9

Efficient chemical conversion of louisianin A to C and D, the inhibitor of angiogenesis. Sunazuka T, et al. **Jpn J Antibiot** 1997 Mar;50(3):274-5

Synthetic analogues of netropsin and distamycin. III. Synthesis of a pyridine analogue of the pyrrolecarboxamide antitumour antibiotics. Bielawski K, et al. **Rocz Akad Med Bialymst** 1996;41(2):293-304

[Enantioselective synthesis of anthracyclines] Monneret C. **Ann Pharm Fr** 1997;55(1):5-11 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Structural studies of mitomycins. VIII. Mitomycin D hydrate, C15H18N4O5.1.5H2O. Hirayama N, et al. **Acta Crystallogr C** 1996 Sep 15;52 (Pt 9):2365-7

Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry. Siegel MM, et al. **Anal Chem** 1997 Jul 15;69(14):2716-26

Enediyne-lexitropsin DNA-targeted anticancer agents. Physicochemical and cytotoxic properties in human neoplastic cells in vitro, and intracellular distribution. Xie Y, et al. **Anticancer Drug Des** 1997 Apr;12(3):169-79

Interactions of deglycosylated cobalt(III)-pepleomycin (green form) with DNA based on NMR structural studies,. Caceres-Cortes J, et al. **Biochemistry** 1997 Aug 19; 36(33):9995-10005

Chromatographic and spectroscopic assignment of thiol induced cycloaromatizations of enediyne in neocarzinostatin. Chin DH, et al. **Biochim Biophys Acta** 1997 Jul 19;1336(1):43-50

The structure of streptonigrin semiquinone in solution. Soedjak H, et al. **Biochim Biophys Acta** 1997 Apr 17; 1335(1-2):73-90

Synthesis and antitumor activity of duocarmycin derivatives: A-ring pyrrole analogues of duocarmycin B2. Nagamura S, et al. **Bioorg Med Chem** 1996 Aug;4(8):1379-91

Studies on duocarmycin SA and its derivatives. Nagamura S, et al. **Bioorg Med Chem** 1997 Mar;5(3):623-30

Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: effect of surfactant on liposome formation, stability and size. Zou Y, et al. **Cancer Chemother Pharmacol** 1996;39(1-2):103-8

Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Stebbins CE, et al. **Cell** 1997 Apr 18;89(2):239-50

Deciphering the biosynthetic origin of the aglycone of the aureolic acid group of anti-tumor agents. Blanco G, et al. **Chem Biol** 1996 Mar;3(3):193-6

Michael-type addition of illudin S, a toxic substance from Lampteromyces japonicus, with cysteine and cysteine-containing peptides in vitro. Tanaka K, et al. **Chem Pharm Bull (Tokyo)** 1996 Feb;44(2):273-9

Fluviols, bicyclic nitrogen-rich antibiotics produced by Pseudomonas fluorescens. Smirnov VV, et al. **FEMS Microbiol Lett** 1997 Aug 15;153(2):357-61

PM-94128, a new isocoumarin antitumor agent produced by a marine bacterium. Cañedo LM, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):175-6

Studies on new antitumor antibiotics, leptofuranins A, B, C and D II. Physiocochemical properties and structure elucidation. Hayakawa Y, et al. **J Antibiot (Tokyo)** 1996 Oct;49(10):980-4

Cytotrienin A, a novel apoptosis inducer in human leukemia HL-60 cells [letter] Kakeya H, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):370-2

TMC-1 A, B, C and D, new antibiotics of the manumycin group produced by Streptomyces sp. Taxonomy, production, isolation, physico-chemical properties, structure elucidation and biological properties. Kohno J, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1212-20

Structures of two remarkable dimerization products of sarkomycin. Kondo S, et al. **J Antibiot (Tokyo)** 1997 Apr; 50(4):363-5

New antitumor substances, FR901463, FR901464 and FR901465. III. Structures of FR901463, FR901464 and FR901465. Nakajima H, et al. **J Antibiot (Tokyo)** 1997 Jan; 50(1):96-9

Pyrrolosporin A, a new antitumor antibiotic from Micromonospora sp. C39217-R109-7. II. Isolation, physico-chemical properties, spectroscopic study and X-ray analysis. Schroeder DR, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):865-72

NF00659A1, A2, A3, B1 and B2, novel antitumor antibiotics produced by Aspergillus sp. NF 00659. II. Structural elucidation. Suzuki K, et al. **J Antibiot (Tokyo)** 1997 Apr; 50(4):318-24

NK154183A and B, antitumor substances produced by Streptomyces sp. Tsuchiya K, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1281-3

Enzyme-linked immunosorbent assay of neocarzinostatin chromophore (NCS-chr) by use of a monoclonal antibody against NCS-chr analog. Mizugaki M, et al. **J Immunoassay** 1996 May;17(2):133-44

Solution structure of the calicheamicin gamma 1I-DNA complex. Kumar RA, et al. **J Mol Biol** 1997 Jan 17; 265(2):187-201

Solution structure of the esperamicin A1-DNA complex. Kumar RA, et al. **J Mol Biol** 1997 Jan 17;265(2):173-86

Stability and compatibility studies of zorubicin in intravenous fluids and PVC infusion bags. Benaji B, et al. **J Pharm Biomed Anal** 1996 Apr;14(6):695-705

DIAGNOSTIC USE

Imaging and staging of head and neck cancer using a low pH In-111-bleomycin complex. Kairemo KJ, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):311-21

IMMUNOLOGY

Screening of immunological properties of vermiculine in selected model situations. Rovenský J, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:369-71

Enzyme-linked immunosorbent assay of neocarzinostatin chromophore (NCS-chr) by use of a monoclonal antibody against NCS-chr analog. Mizugaki M, et al. **J Immunoassay** 1996 May;17(2):133-44

ISOLATION & PURIFICATION

New anticancer antibiotics pelagiomicins, produced by a new marine bacterium Pelagiobacter variabilis. Imamura N, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):8-12

A new isopatulin derivative pintulin produced by Penicillium vulpinum F-4148 taxonomy, isolation, physico-chemical properties, structure and biological properties. Mikami A, et al. **J Antibiot (Tokyo)** 1996 Oct;49(10):985-9

NF00659A1, A2, A3, B1 and B2, novel antitumor antibiotics produced by Aspergillus sp. NF 00659. I. Taxonomy, fermentation, isolation and biological activities. Suzuki K, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):314-7

Sparoxomycins A1 and A2, new inducers of the flat reversion of NRK cells transformed by temperature sensitive Rous sarcoma virus. I. Taxonomy of the producing organism, fermentation and biological activity. Ubukata M, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1096-100

A new cytotoxic phenylthiazoline, 4-methylaeruginoic acid, from Streptomyces sp. KCTC 9303 [published erratum appears in Jpn J Antibiot 1997 Apr;50(4):C-2] Ryoo IJ, et al. **Jpn J Antibiot** 1997 Mar;50(3):256-8

Epopromycins, novel cell wall synthesis inhibitors of plant protoplast produced by Streptomyces sp. NK04000. Tsuchiya K, et al. **Jpn J Antibiot** 1997 Mar;50(3):261-3

METABOLISM

Thiol-independent DNA cleavage by a leinamycin degradation product. Asai A, et al. **Bioorg Med Chem** 1997 Apr;5(4):723-9

CC-1065/duocarmycin and bleomycin A2 hybrid agents: lack of enhancement of DNA alkylation by attachment to noncomplementary DNA binding subunits. Boger DL, et al. **Bioorg Med Chem** 1997 Feb;5(2):233-43

Catalysis of the CC-1065 and duocarmycin DNA alkylation reaction: DNA binding induced conformational change in the agent results in activation. Boger DL, et al. **Bioorg Med Chem** 1997 Feb;5(2):263-76

Demonstration and definition of the noncovalent binding selectivity of agents related to CC-1065 by an affinity cleavage agent: noncovalent binding coincidental with alkylation. Boger DL, et al. **Bioorg Med Chem** 1996 Jun; 4(6):859-67

FR900482, a close cousin of mitomycin C that exploits mitosene-based DNA cross-linking. Williams RM, et al. **Chem Biol** 1997 Feb;4(2):127-37

Human colorectal carcinoma cells in vitro as a means to assess the metabolism of analogs of mycophenolic acid. Franklin TJ, et al. **Drug Metab Dispos** 1997 Mar;25(3):367-70

Interspecies variability of TNP-470 metabolism, using primary monkey, rat, and dog cultured hepatocytes. Placidi L, et al. **Drug Metab Dispos** 1997 Jan;25(1):94-9

Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42. Moran E, et al. **Eur J Cancer** 1997 Apr;33(4):652-60

In vitro and in vivo binding of a CC-1065 analogue to human gene sequences: a polymerase-chain reaction study. Passadore M, et al. **Eur J Pharmacol** 1997 Jan 29; 319(2-3):317-25

Pyrrolosporin A, a new antitumor antibiotic from Micromonospora sp. C39217-R109-7. I. Taxonomy of producing organism, fermentation and biological activity. Lam KS, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):860-4

Cloning of the enomycin structural gene from Streptomyces mauvecolor and production of recombinant enomycin in Escherichia coli. Takeuchi S, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):27-31

The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. Stancato LF, et al. **J Biol Chem** 1997 Feb 14;272(7):4013-20

Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. Akima K, et al. **J Drug Target** 1996;4(1):1-8

Binding specificity of post-activated neocarzinostatin chromophore drug-bulged DNA complex studied using electrospray ionization mass spectrometry. Gao Q, et al. **J Mass Spectrom** 1996 Jan;31(1):31-6

Decreased renal accumulation of biotinylated chimeric monoclonal antibody-neocarzinostatin conjugate after administration of avidin. Otsuji E, et al. **Jpn J Cancer Res** 1997 Feb;88(2):205-12

Rapamycin destabilizes interleukin-3 mRNA in autocrine tumor cells by a mechanism requiring an intact 3' untranslated region. Banholzer R, et al. **Mol Cell Biol** 1997 Jun;17(6):3254-60

Cytotoxicity and DNA-binding property of non-diynene class of dynemicins and aza-anthraquinones. Shirai R, et al. **Nucleic Acids Symp Ser** 1995;(34):151-2

Photophysical properties of gilvocarcins V and M and their binding constant to calf thymus DNA. Oyola R, et al. **Photochem Photobiol** 1997 May;65(5):802-10

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Sin N, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6099-103

PHARMACOKINETICS

Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor-bearing rats. Kitazawa H, et al. **Biol Pharm Bull** 1997 Mar; 20(3):278-81

Pharmacokinetics of highly lipophilic antitumor agent palmitoyl rhizoxin incorporated in lipid emulsions in rats. Kurihara A, et al. **Biol Pharm Bull** 1996 Feb;19(2):252-8

Pharmacokinetic, angiographic, and histologic comparison of catheter-directed chemoembolization versus systemic chemotherapy in a canine model. Zhan X, et al. **Can J Physiol Pharmacol** 1996 Oct;74(10):1117-25

Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells. Kelner MJ, et al. **Cancer Chemother Pharmacol** 1997;40(1):65-71

Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. Morgan DJ, et al. **Cancer Chemother Pharmacol** 1997; 40(3):202-8

Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration. Sugarbaker PH, et al. **Cancer Treat Res** 1996;82:41-52

Disposition of DX-52-1, a novel anticancer agent, after intravenous administration to mice and dogs. Fuse E, et al. **Eur J Drug Metab Pharmacokinet** 1997 Jan-Mar; 22(1):53-63

Pharmacokinetics of intraarterial mitomycin C in the chemoembolisation treatment of liver metastases. Rump AF, et al. **Gen Pharmacol** 1996 Jun;27(4):669-71

Disposition of mitomycin C after local intraarterial application. Theisohn M, et al. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):72-6

Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice. Fujita T, et al. **J Drug Target** 1997;4(5):289-96

Uptake and release of [3H]formycin B via sodium-dependent nucleoside transporters in mouse leukemic L1210/MA27.1 cells. Borgland SL, et al. **J Pharmacol Exp Ther** 1997 Apr; 281(1):347-53

Blood and plasma lipoprotein distribution and gender differences in the plasma pharmacokinetics of lipid-associated annamycin. Wasan KM, et al. **Pharmacol Toxicol** 1997 Jun;80(6):301-7

The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Figg WD, et al. **Pharmacotherapy** 1997 Jan-Feb; 17(1):91-7

[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats] Fuse E, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):975-9 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Characteristics of mutagenesis by bleomycin and adriamycin in salmonella typhimurium: action of superoxide dismutase. Ejchart A, et al. **Acta Pol Pharm** 1996 Jan-Feb;53(1):13-7

Mizoribine reduces urinary protein excretion in rats given puromycin aminonucleoside. Shibasaki T, et al. **Am J Nephrol** 1996;16(2):167-72

Structural and functional relationships of toyocamycin on NPM-translocation. Finch RA, et al. **Anticancer Drug Des** 1997 Apr;12(3):205-15

Interaction of the antitumour antibiotic streptonigrin with DNA and oligonucleotides. Long GV, et al. **Anticancer Drug Des** 1997 Sep;12(6):453-72

Enediyne-lexitropsin DNA-targeted anticancer agents. Physicochemical and cytotoxic properties in human neoplastic cells in vitro, and intracellular distribution. Xie Y, et al. **Anticancer Drug Des** 1997 Apr;12(3):169-79

In vitro detection of the MDR phenotype in rat myocardium: use of PCR, [3H]daunomycin and MDR reversing agents. Cayre A, et al. **Anticancer Drugs** 1996 Nov;7(8):833-7

Fostriecin: a review of the preclinical data. de Jong RS, et al. **Anticancer Drugs** 1997 Jun;8(5):413-8 (45 ref.)

In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Maier JA, et al. **Anticancer Drugs** 1997 Mar;8(3):238-44

Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug-resistant cell lines. Stammler G, et al. **Anticancer Drugs** 1997 Mar; 8(3):265-8

Angiogenesis inhibitor TNP-470 augments the effect of repeated arterial ischemia on growth but does not affect take in a rat liver tumor model. Möller PH, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2401-6

Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo. Oikawa T, et al. **Anticancer Res** 1997 May-Jun; 17(3C):1881-6

Induction of differentiation of human myeloid leukemia cells by 2'-deoxycoformycin in combination with 2'-deoxyadenosine. Niitsu N, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):100-6

Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus. Czar MJ, et al. **Biochemistry** 1997 Jun 24;36(25):7776-85

DNA-damaging enediyne C-1027 inhibits initiation of intracellular SV40 DNA replication in trans. McHugh MM, et al. **Biochemistry** 1997 Feb 4;36(5):1003-9

Physical and biological characteristics of the antitumor drug actinomycin D analogues derivatized at N-methyl-L-valine residues. Takusagawa F, et al. **Biochemistry** 1996 Oct 8;35(40):13240-9

Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells. Chen HM, et al. **Biochim Biophys Acta** 1997 Aug 29;1336(2):171-9

Synergetic cytotoxicity of bleomycin and polyhydric alcohols: DNA strand breakage evaluated by "comet assay". Kasamatsu T, et al. **Biol Pharm Bull** 1996 Apr;19(4):632-5

In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan. Sato M, et al. **Biol Pharm Bull** 1996 Sep;19(9):1170-7

Induction of apoptosis by ubenimex (Bestatin) in human non-small-cell lung cancer cell lines. Ezawa K, et al. **Biomed Pharmacother** 1996;50(6-7):283-9

On the chemistry of RNA degradation by Fe.bleomycin. Holmes CE, et al. **Bioorg Med Chem** 1997 Jun;5(6):1235-48

Effect of ribonucleotide substitution on nucleic acid bulge

recognition by neocarzinostatin. Kappen LS, et al. **Bioorg Med Chem** 1997 Jun;5(6):1221–7

Selective cleavages of tRNAPhe with secondary and tertiary structures by enediyne antitumor antibiotics. Sugiura Y, et al. **Bioorg Med Chem** 1997 Jun;5(6):1229–34

Structure–activity relationships of cyclic enediynes related to dynemicin A. I. Synthesis and antitumor activity of 9–acetoxy enediynes equipped with aryl carbamate moieties. Unno R, et al. **Bioorg Med Chem** 1997 May; 5(5):883–901

Synthesis and antitumor activity of water–soluble enediyne compounds related to dynemicin A. Unno R, et al. **Bioorg Med Chem** 1997 May;5(5):987–99

Structure–activity relationships of cyclic enediynes related to dynemicin A. II. Synthesis and antitumor activity of 9– and 12–substituted enediynes equipped with aryl carbamate moieties. Unno R, et al. **Bioorg Med Chem** 1997 May;5(5):903–19

Kinetics of cleavage of intra– and extracellular simian virus 40 DNA with the enediyne anticancer drug C–1027. Kirk CA, et al. **Biophys Chem** 1997 Jan 31;63(2–3):201–9

Daunomycin unfolds compactly packed DNA. Yoshikawa Y, et al. **Biophys Chem** 1996 Oct 30;61(2–3):93–100

Inhibition of lymph node metastasis by an anti–angiogenic agent, TNP–470. Ohta Y, et al. **Br J Cancer** 1997; 75(4):512–5

Effect of mitomycin C on the optic nerve in rabbits. Mietz H, et al. **Br J Ophthalmol** 1997 Jul;81(7):584–9

A Saccharomyces cerevisiae phleomycin–sensitive mutant, ph140, is defective in the RAD6 DNA repair gene. He CH, et al. **Can J Microbiol** 1996 Dec;42(12):1263–6

A Saccharomyces cerevisiae mutant defines a new locus essential for resistance to the antitumour drug bleomycin. Ramotar D, et al. **Can J Microbiol** 1996 Aug;42(8):835–43

Depletion of p185erbB2, Raf–1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. An WG, et al. **Cancer Chemother Pharmacol** 1997; 40(1):60–4

Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. Morgan DJ, et al. **Cancer Chemother Pharmacol** 1997; 40(3):202–8

Cytotoxicity of bleomycin and external radiation in squamous cell cancer cell lines of head and neck. Jääskelä–Saari HA, et al. **Cancer Detect Prev** 1996;20(4):279–84

Mutagen sensitivity exhibits a dose–response relationship in case–control studies. Wu X, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jul;5(7):577–8

Survival of cells with bleomycin–induced chromosomal lesions in the cultured lymphocytes of lung cancer patients. Wu XF, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jul; 5(7):527–32

Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O–(chloroacetyl–carbamoyl) fumagillol (TNP–470; AGM–1470). Fujimoto J, et al. **Cancer Lett** 1997 Feb 26;113(1–2):187–94

Hyaluronidase induces murine L929 fibrosarcoma cells resistant to tumor necrosis factor and Fas cytotoxicity in the presence of actinomycin D. Chang NS. **Cell Biochem Biophys** 1995–96;27(2):109–32

Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo–cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV–1) Rev protein and Rev–dependent mRNA. Wolff B, et al. **Chem Biol** 1997 Feb;4(2):139–47

Synthesis and antitumor activity of duocarmycin derivatives: modification of segment A of duocarmycin B2. Nagamura S, et al. **Chem Pharm Bull (Tokyo)** 1996 Sep;44(9):1723–30

Synthesis and biological evaluation of novel cyclic enediyne compounds related to dynemicin A as antitumor agents. Unno R, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan; 45(1):125–33

The fumagillin analogue TNP–470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet–derived growth factor and insulin–like growth factor–I. Possible involvement of cyclin–dependent kinase 2. Koyama H, et al. **Circ Res** 1996 Oct;79(4):757–64

Effects of TNP–470, a potent angiogenesis inhibitor, on growth of hematopoietic progenitors [letter] Hasuike T, et al. **Eur J Haematol** 1997 Apr;58(4):293–4

Spontaneous and pharmacologically–modulated wound healing after Nd:YAG laser sclerostomy ab interno in rabbits. Iliev ME, et al. **Eur J Ophthalmol** 1997 Jan–Mar; 7(1):24–8

Effects of cytotoxic drugs on translocation of nucleolar RNA helicase RH–II/Gu. Perlaky L, et al. **Exp Cell Res** 1997 Sep 15;235(2):413–20

Induction of apoptosis in megakaryocytic leukemia cell lines by MX2, a morpholino anthracycline. Katsurada T, et al. **Exp Hematol** 1997 Sep;25(10):1077–83

Changes of hydroxyproline levels in myocardium after chronic administration of bleomycin. Anasiewicz A, et al. **Folia Morphol (Warsz)** 1996;55(4):206–7

Measurement of hydroxyl radicals catalyzed in the immediate vicinity of DNA by metal–bleomycin complexes. Chakrabarti S, et al. **Free Radic Biol Med** 1996;20(6):777–83

Bleomycin: revival of an old drug. Mir LM, et al. **Gen Pharmacol** 1996 Jul;27(5):745–8 (30 ref.)

Inducible synthesis of the mitomycin C resistance gene product (MCRA) from Streptomyces lavendulae. August PR, et al. **Gene** 1996 Oct 10;175(1–2):261–7

Effects of mitomycin C on the expression of proliferating cell nuclear antigen after filtering surgery in rabbits. Watanabe J, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Apr;235(4):234–40

Enhancement of chemotherapeutic effects with focused shock waves: extracorporeal shock wave chemotherapy (ESWC). Kambe M, et al. **Hum Cell** 1997 Mar;10(1):87–94

Application of surfactin for mycoplasma inactivation in virus stocks [letter] Nissen E, et al. **In Vitro Cell Dev Biol Anim** 1997 Jun;33(6):414–5

Specific regulation of HSPs in human tumor cell lines by PSK. Morino M, et al. **In Vivo** 1997 May–Jun;11(3):261–4

In vitro effects of mitomycin C on human Tenon's capsule fibroblasts & correlation with surgical outcome in glaucoma patients. Vijaya L, et al. **Indian J Med Res** 1997 Mar; 105:125–30

Mechanisms of target selection by DNA–damaging chemicals: studies with enediyne anticancer drugs. Dedon PC. **Int Arch Occup Environ Health** 1996;68(6):408–14 (59 ref.)

Oral administration of PSK can improve the impaired anti–tumor CD4+ T–cell response in gut–associated lymphoid tissue (GALT) of specific–pathogen–free mice. Harada M, et al. **Int J Cancer** 1997 Jan 27;70(3):362–72

Molecular targeting of mitomycin C chemotherapy. Nishiyama M, et al. **Int J Cancer** 1997 Aug 7;72(4):649–56

Differential effects of polyunsaturated fatty acids on chemosensitivity of NIH3T3 cells and its transformants. Tsai WS, et al. **Int J Cancer** 1997 Jan 27;70(3):357–61

Idarubicin: a brief overview on pharmacology and clinical use. Borchmann P, et al. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):80–3 (30 ref.)

Herbimycin A down–regulates messages of cyclin D1 and c–myc during erythroid differentiation of K562 cells. Yamada H, et al. **Int J Hematol** 1996 Dec;65(1):31–40

An antiangiogenic agent (TNP–470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Murata R, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 15;37(5):1107–13

Antimetastatic effect of PSK, a protein–bound polysaccharide, against the B16–BL6 mouse melanoma. Matsunaga K, et al. **Invasion Metastasis** 1996;16(1):27–38

PM–94128, a new isocoumarin antitumor agent produced by a marine bacterium. Cañedo LM, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):175–6

UCE6, a new antitumor antibiotic with topoisomerase I–mediated DNA cleavage activity produced by actinomycetes: producing organism, fermentation, isolation and biological activity. Fujii N, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):490–5

TMC–1 A, B, C and D, new antibiotics of the manumycin group produced by Streptomyces sp. Taxonomy, production, isolation, physico–chemical properties, structure elucidation and biological properties. Kohno J, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1212–20

Pyrrolosporin A, a new antitumor antibiotic from Micromonospora sp. C39217–R109–7. I. Taxonomy of producing organism, fermentation and biological activity. Lam KS, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):860–4

Novel blockade of cell surface expression of virus glycoproteins by leucinostatin A. Muroi M, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1119–26

New antitumor substances, FR901463, FR901464 and FR901465. I. Taxonomy, fermentation, isolation, physico–chemical properties and biological activities. Nakajima H, et al. **J Antibiot (Tokyo)** 1996 Dec; 49(12):1196–203

NK154183A and B, antitumor substances produced by Streptomyces sp. Tsuchiya K, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1281–3

Sparoxomycins A1 and A2, new inducers of the flat reversion of NRK cells transformed by temperature sensitive Rous sarcoma virus. I. Taxonomy of the producing organism, fermentation and biological activity. Ubukata M, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1096–100

Role of the stress–activated/c–Jun NH2–terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. Osborn MT, et al. **J Biol Chem** 1996 Nov 29;271(48):30950–5

The function of steroid hormone receptors is inhibited by the hsp90–specific compound geldanamycin. Segnitz B, et al. **J Biol Chem** 1997 Jul 25;272(30):18694–701

In vitro and in vivo modulation by rhizoxin of non–P–glycoprotein–mediated vindesine resistance. Arioka H, et al. **J Cancer Res Clin Oncol** 1997;123(4):195–200

Inhibitory effect of the angiogenesis inhibitor TNP–470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma. Xia JL, et al. **J Cancer Res Clin Oncol** 1997;123(7):383–7

The effects of combined treatments with low hyperthermia and bleomycin on survivals of murine L cells. Shioura H, et al. **J Exp Clin Cancer Res** 1997 Jun;16(2):147–52

Actinomycin D treatment leads to differentiation and inhibits proliferation in rhabdomyosarcoma cells. Marchal JA, et al. **J Lab Clin Med** 1997 Jul;130(1):42–50

Neuritogenic effect of epolactaene derivatives on human neuroblastoma cells which lack high–affinity nerve growth factor receptors. Kakeya H, et al. **J Med Chem** 1997 Feb 14;40(4):391–4

Synthesis and antitumor activity of duocarmycin derivatives: A–ring pyrrole compounds bearing cinnamoyl groups. Nagamura S, et al. **J Med Chem** 1997 Mar 14;40(6):972–9

Cross–sensitivity of X–ray–hypersensitive cells derived from LEC strain rats to DNA–damaging agents. Okui T, et al. **J Vet Med Sci** 1996 Nov;58(11):1067–71

Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inhibitor TNP–470. Shishido T, et al. **Jpn J Cancer Res** 1996 Sep;87(9):958–62

Rapamycin resistance tied to defective regulation of p27Kip1. Luo Y, et al. **Mol Cell Biol** 1996 Dec;16(12):6744–51

Correlation between the formation of cleavable complex with topoisomerase I and growth–inhibitory activity for saintopin–type antibiotics. Fujii N, et al. **Mol Pharmacol** 1997 Feb;51(2):269–76

Targeted base substitutions and small deletions induced by neocarzinostatin at the APRT locus in plateau–phase CHO cells. Wang P, et al. **Mutat Res** 1997 Jan 3;373(1):17–29

Experimental studies of the antitumor effect of TNP–470 on malignant brain tumors. Antitumor effect of TNP–470 on a human medulloblastoma xenograft line. Isobe N, et al. **Neuropediatrics** 1996 Jun;27(3):136–42

Cytotoxicity and DNA–binding property of non–diynene class of dynemicins and aza–anthraquinones. Shirai R, et al. **Nucleic Acids Symp Ser** 1995;(34):151–2

Inhibitory action of reveromycin A on TGF–alpha–dependent growth of ovarian carcinoma BG–1 in vitro and in vivo. Takahashi H, et al. **Oncol Res** 1997; 9(1):7–11

Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice. Kurihara A, et al. **Pharm Res** 1996 Feb;13(2):305–10

Different pH dependency of mitomycin C activity in monolayer and three–dimensional cultures. Yen WC, et al. **Pharm Res** 1996 Dec;13(12):1887–91

The anti–angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP–2. Sin N, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6099–103

Binding of tacrolimus (FK506) with human plasma proteins re–evaluation and effect of mycophenolic acid. Iwasaki K, et al. **Res Commun Mol Pathol Pharmacol** 1996 Dec; 94(3):251–7

[Antitumor activity of yungumycin] Xue YC, et al. **Yao Hsueh Hsueh Pao** 1996;31(3):171–5 (Eng. Abstr.) **(Chi)**

[Mechanism of regression of metastatic liver tumors in rats treated with angiogenesis inhibitor with special reference to apoptosis] Arai T, et al. **Gan To Kagaku Ryoho** 1997 Jul;24 Suppl 2:296–300 (Eng. Abstr.) **(Jpn)**

[Protein synthesis inhibitor—antitumor activity and mode of action of KRN 5500] Kawai H. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1571–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

[DT–diaphorase] Mikami K, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1606–10 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of action of azatyrosine: recent process] Monden Y, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1563–70 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Biochemical mechanisms of NCS–chromophore–induced DNA cleavage and inhibition of protein kinase activity] Ohtsuki K, et al. **Gan To Kagaku Ryoho** 1997 Feb; 24(4):443–53 (35 ref.) (Eng. Abstr.) **(Jpn)**

[A comparative study on in vitro chemosensitivity of urotherial cancers to three anthracyclines] Yamada S, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1339–41 **(Jpn)**

[Growth inhibitory effects of ubenimex on leukemic cell lines resistant to chemotherapeutic agents] Fujii H, et al. **Jpn J Antibiot** 1996 Dec;49(12):1109–15 (Eng. Abstr.) **(Jpn)**

[Biochemical mechanisms of the DNA cleavage induced by NCS–chromophore] Ohtsuki K. **Seikagaku** 1996 Dec; 68(12):1817–24 (21 ref.) **(Jpn)**

[The genetic activity of superlow doses of antitumor antibiotics and 2–nitrofluorene: the ecological aspects of the problem] Vasil'eva SV, et al. **Izv Akad Nauk Ser Biol** 1996 Nov–Dec;(6):676–80 (Eng. Abstr.) **(Rus)**

[The effect of actinomycin D on electroencephalographic activity in the rabbit brain] Naumović N, et al. **Med Pregl** 1996;49(9–10):361–4 (Eng. Abstr.) **(Scr)**

THERAPEUTIC USE

Squamous cell cancer cell lines: sensitivity to bleomycin and suitability for animal xenograft studies. Jääskelä–Saari HA, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;529:241–4

Comparison of intratumoral administration of cisplatin versus bleomycin for treatment of periocular squamous cell carcinomas in horses. Théon AP, et al. **Am J Vet Res** 1997 Apr;58(4):431–6

Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined–modality therapy. Loggie BW, et al. **Am Surg** 1997 Feb;63(2):137–43

Treatment of patients resistant to anthracycline therapy. Ravdin PM. **Anticancer Drugs** 1996 Aug;7 Suppl 2:13–6

Bleomycin therapy of experimental disseminated candidiasis in mice. Graybill JR, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):816–8

Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia. Frucht–Pery J, et al. **Arch Ophthalmol** 1996 Oct;114(10):1261–4

Adjunctive use of mitomycin in filtration surgery. Is it worth the risk? [editorial; comment] Higginbotham EJ. **Arch Ophthalmol** 1997 Aug;115(8):1068–9. Comment on: Arch Ophthalmol 1997 Aug;115(8):969–74.

A new method for permeabilization of the plasma membrane of cultured mammalian cells. VI. Enhanced cytotoxicity of bleomycin toward leukemia P388 cells inoculated into the tail vein of mice together with high molecular weight polyacrylic acid—similarity of blood stream to vortex-stirring. Ikeda Y, et al. **Biol Pharm Bull** 1997 Jan; 20(1):25–7

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups. McLeod HL, et al. **Br J Cancer** 1996 Dec;74(12):1944–8

The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study. Matutes E, et al. **Br J Haematol** 1997 Aug;98(2):375–83

Treatment of malignant pleural effusions with a combination of bleomycin and tetracycline. A comparison of bleomycin or tetracycline alone versus a combination of bleomycin and tetracycline. Emad A, et al. **Cancer** 1996 Dec 15; 78(12):2498–501

Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen. Kamishohara M, et al. **Cancer Chemother Pharmacol** 1996;38(6):495–8

Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Hayakawa K, et al. **Cancer Detect Prev** 1997;21(1):71–7

Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. MacDonald JR, et al. **Cancer Res** 1997 Jan 15;57(2):279–83

Successful treatment of recurrent corneal intraepithelial neoplasia with topical mitomycin C. Tseng SH, et al. **Cornea** 1997 Sep;16(5):595–7

TNP-470 (AGM-1470): mechanisms of action and early clinical development. Castronovo V, et al. **Eur J Cancer** 1996 Dec;32A(14):2520–7 (55 ref.)

Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer—dosimetric and biokinetic aspects [published erratum appears in Eur J Nucl Med 1997 Feb;24(2):235] Kairemo KJ, et al. **Eur J Nucl Med** 1996 Jun;23(6):631–8

Clinical experience with 2'-deoxycoformycin. Catovsky D. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S103–7 (25 ref.)

Tumor-specific synergistic therapy of mitomycin C: modulation of bioreductive activation. Sakamoto N, et al. **Hiroshima J Med Sci** 1997 Jun;46(2):67–73

Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470. Kalebic T, et al. **Int J Cancer** 1996 Nov 27;68(5):596–9

Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into nude mice. Kanai T, et al. **Int J Cancer** 1997 May 29;71(5):838–41

Idarubicin: a brief overview on pharmacology and clinical use. Borchmann P, et al. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):80–3 (30 ref.)

Inhibition of lymphatic metastasis in a syngeneic rat fibrosarcoma model by an angiogenesis inhibitor, AGM-1470. Futami H, et al. **Invasion Metastasis** 1996; 16(2):73–82

Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma. Allen SL, et al. **Invest New Drugs** 1996; 14(2):213–7

Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. Greiner D, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):950–5

Cytotrienin A, a novel apoptosis inducer in human leukemia HL-60 cells [letter] Kakeya H, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):370–2

New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. Nakajima H, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1204–11

NF00659A1, A2, A3, B1 and B2, novel antitumor antibiotics produced by Aspergillus sp. NF 00659. I. Taxonomy, fermentation, isolation and biological activities. Suzuki K, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):314–7

Herbimycin A, a tyrosine kinase inhibitor, impairs hypercalcemia associated with a human squamous cancer producing interleukin-6 in nude mice. Moriyama K, et al. **J Bone Miner Res** 1996 Jul;11(7):905–11

Combined phacoemulsification and trabeculectomy with mitomycin-C. Ruderman JM, et al. **J Cataract Refract Surg** 1996 Oct;22(8):1085–90

Safe anesthetic management of patients undergoing a novel method of treating human hepatocellular cancer. Dougherty TB, et al. **J Clin Anesth** 1997 May;9(3):220–7

Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. Haffty BG, et al. **J Clin Oncol** 1997 Jan;15(1):268–76

Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. Liu G, et al. **J Clin Oncol** 1996 Dec;14(12):3141–7

Bleomycin sulfate in the treatment of mosaic plantar verrucae [letter; comment] McAloon C. **J Foot Ankle Surg** 1997 Jan-Feb;36(1):70–1. Comment on: J Foot Ankle Surg 1996 Mar-Apr;35(2):169–72.

Radiofrequency capacitive hyperthermia for unresectable hepatic cancers. Yamamoto K, et al. **J Gastroenterol** 1997 Jun;32(3):361–6

The role of mitomycin treatment duration and previous intraocular surgery on the success of trabeculectomy surgery. Cohen JS, et al. **J Glaucoma** 1997 Feb;6(1):3–9

Epithelial barrier function of the filtering bleb conjunctiva and the cornea after trabeculectomy with mitomycin C. Taniguchi T, et al. **J Glaucoma** 1996 Aug;5(4):233–6

Targeting immunotherapy using the avidin-biotin system for a human colon adenocarcinoma in vitro. Nakaki M, et al. **J Int Med Res** 1997 Jan-Feb;25(1):14–23

TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. Nagabuchi E, et al. **J Pediatr Surg** 1997 Feb;32(2):287–93

Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. Tanaka Y, et al. **J Urol** 1997 Feb; 157(2):683–8

Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Marinelli A, et al. **Jpn J Clin Oncol** 1996 Oct;26(5):341–50

A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Dutcher JP, et al. **Leuk Res** 1997 May;21(5):375–80

Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Cortes J, et al. **Leukemia** 1997 Jun;11(6):788–91

Regression of rubeosis iridis after trabeculectomy combined with mitomycin-C. Gaspar AZ, et al. **Ophthalmic Surg Lasers** 1996 Aug;27(8):709–12

Bleb rupture following filtering surgery with mitomycin-C: clinicopathologic correlations. Greenfield DS, et al. **Ophthalmic Surg Lasers** 1996 Oct;27(10):876–7

Intraoperative mitomycin-C versus postoperative topical mitomycin-C drops for the treatment of pterygium. Helal M, et al. **Ophthalmic Surg Lasers** 1996 Aug;27(8):674–8

Topical mitomycin-C for pterygia: is single application appropriate? Rubinfeld RS, et al. **Ophthalmic Surg Lasers** 1997 Aug;28(8):662–9

Mitomycin C-augmented trabeculectomy in refractory congenital glaucoma. Mandal AK, et al. **Ophthalmology** 1997 Jun;104(6):996–1001; discussion 1002–3

Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial. Manning CA, et al. **Ophthalmology** 1997 May;104(5):844–8

Long-term results using adjunctive mitomycin C in optic nerve sheath decompression for pseudotumor cerebri. Spoor TC, et al. **Ophthalmology** 1995 Dec;102(12):2024–8

The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Wassberg E, et al. **Pediatr Res** 1997 Mar;41(3):327–33

Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Witjes WP, et al. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):10–6

Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up. Minervini R, et al. **Urol Int** 1996;56(4):234–7

[Phase I clinical study of a new anticancer drug boanmycin] Feng F, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Apr; 18(2):143–6 (Eng. Abstr.) **(Chi)**

[Pleurodesis in malignant pleural effusion: bleomycin vs. mitoxantrone] Schmidt M, et al. **Pneumologie** 1997 Apr; 51(4):367–72 (Eng. Abstr.) **(Ger)**

[Mitomycin-C 30 mg for 12 months versus Mitomycin-C 40 mg for 6 months in the prevention of superficial bladder carcinoma G1-G2] Vecchioli Scaldazza C. **Minerva Urol Nefrol** 1996 Dec;48(4):203–6 (Eng. Abstr.) **(Ita)**

[Cytotoxic properties of the complex of the antineoplastic antibiotic bleomycetin and Bacillus intermedius ribonuclease] Kalacheva NV, et al. **Antibiot Khimioter** 1997;42(4):16–20 (Eng. Abstr.) **(Rus)**

[Results of a prospective study of chemoprophylaxis with alternating mitomycin-C and BCG: complete response and recurrence and progression index] Nohales Taurines G, et al. **Arch Esp Urol** 1996 Sep;49(7):689–92 (Eng. Abstr.) **(Spa)**

[The antitumor action of antibiotics produced by Streptomyces globisporus 1912 studied in a model of Guérin's carcinoma in rats] Polishchuk LV, et al. **Mikrobiol Z** 1996 Mar-Apr;58(2):55–8 (Eng. Abstr.) **(Ukr)**

TOXICITY

A new method for permeabilization of the plasma membrane of cultured mammalian cells. IV. Structural requirement for high molecular weight polymers for potentiation of bleomycin cytotoxicity toward mammalian cells under conditions of vortex-stirring. Shimizu N, et al. **Biol Pharm Bull** 1996 Sep;19(9):1126–9

Protective effect of liposomal alpha-tocopherol against bleomycin-induced lung injury. Suntres ZE, et al. **Biomed Environ Sci** 1997 Mar;10(1):47–59

Effects of dietary consumption of black tea infusion alone and in combination with known clastogens on mouse bone marrow chromosomes in vivo. Mukherjee P, et al. **Food Chem Toxicol** 1997 Jul;35(7):657–61

Effect of a vegan diet on biomarkers of chemoprevention in females. Verhagen H, et al. **Hum Exp Toxicol** 1996 Oct; 15(10):821–5

Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant. Magil A. **J Am Soc Nephrol** 1996 Nov;7(11):2340–7

Long-term intraocular toxic effects of topical mitomycin C in rabbits. Mietz H, et al. **J Glaucoma** 1996 Oct;5(5):325–33

Curcumin protects bleomycin-induced lung injury in rats. Venkatesan N, et al. **Life Sci** 1997;61(6):PL51–8

gamma-Linolenic acid-containing diet attenuates bleomycin-induced lung fibrosis in hamsters. Ziboh VA, et al. **Lipids** 1997 Jul;32(7):759–67

Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. Gustafson DL, et al. **Mol Pharmacol** 1996 Oct;50(4):728–35

Comparison of the lethal effects of different actinomycins on a repair-deficient strain of Escherichia coli. Holmalahti J, et al. **Mutat Res** 1997 Jun 13;391(1-2):33–8

Assessment of the flexed-tail mouse as a possible model for Fanconi anemia: analysis of mitomycin C-induced micronuclei. Urlando C, et al. **Mutat Res** 1996 Sep 13; 370(2):99–106

Antiapoptotic effect of ras in the apoptosis induced by serum deprivation and exposure to actinomycin D. Chou CC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):177–82

Augmentation of epirubicin cytotoxicity by cycloheximide. Furusawa S, et al. **Res Commun Mol Pathol Pharmacol** 1996 Feb;91(2):245–8

Bleomycin induces strain-dependent alterations in the pattern of epithelial cell-specific marker expression in mouse lung. Daly HE, et al. **Toxicol Appl Pharmacol** 1997 Feb; 142(2):303–10

ANTIBIOTICS, ANTITUBERCULAR

New antimycobacterial agents. Yew WW, et al. **Monaldi Arch Chest Dis** 1996 Oct;51(5):394–404 (143 ref.)

Rifampin. Glatman-Freedman A. **Pediatr Rev** 1996 Aug; 17(8):294–5

[Rifabutin] **Enferm Infecc Microbiol Clin** 1996 May; 14(5):329–30 **(Spa)**

ADMINISTRATION & DOSAGE

Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Villarino ME, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1735–8

Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Deol P, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1211–4

Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Klemens SP, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):298–301

Esophagomediastinal fistula as a complication of tuberculous mediastinal lymphadenitis. Ohtake M, et al. **Intern Med** 1996 Dec;35(12):984–6

Treatment of nontuberculous mycobacterial lymphadenitis with clarithromycin plus rifabutin. Berger C, et al. **J Pediatr** 1996 Mar;128(3):383–6

Targeting of multiple emulsions to the lungs. Khopade AJ, et al. **Pharmazie** 1996 Aug;51(8):558–62

Multiple emulsion based systems for prolonged delivery of rifampicin: in vitro and in vivo characterization. Nakhare S, et al. **Pharmazie** 1997 Mar;52(3):224–6

[Anti-Mycobacterium avium complex activities of KRM-1648, clarithromycin and levofloxacin in 7HSF medium at peak or average blood concentrations after their oral administration of clinical dosages] Sato K, et al. **Kekkaku** 1997 Jul;72(7):449–53 (Eng. Abstr.) **(Jpn)**

[Pilot studies on the treatment of Mycobacterium avium complex lung disease—new macrolides and new quinolones. (2) Multi-drug chemotherapy for initial cases on trial] Tanaka E. **Kekkaku** 1996 Sep;71(9):547–9 **(Jpn)**

ADVERSE EFFECTS

Methemoglobinemia after rifampin therapy [letter] Luzio JL, et al. **Ann Pharmacother** 1996 Nov;30(11):1339–40

Uveitis associated with rifabutin and macrolide therapy for Mycobacterium avium intracellulare infection in AIDS patients. Kelleher P, et al. **Genitourin Med** 1996 Dec; 72(6):419–21

Paradoxical worsening in tuberculosis during therapy in an HIV-infected patient [letter] Mofredj A, et al. **Infection** 1996 Sep-Oct;24(5):390–1

Uveitis associated with rifabutin therapy: a clinical alert. Petrowski JT 3rd. **J Am Optom Assoc** 1996 Nov; 67(11):693–6 (17 ref.)

Thrombocytopenia—a rare but serious side effect of rifampicin [letter] Shah NM, et al. **J Assoc Physicians India** 1996 May;44(5):359–60

Severe neutropenia and prophylactic doses of rifabutin [letter; comment] Tansey MJ, et al. **Lancet** 1996 Dec 7; 348(9041):1592–3. Comment on: Lancet 1996 Sep 7;348(9028):685.

New ophthalmic manifestations of presumed rifabutin-related uveitis. Arevalo JF, et al. **Ophthalmic Surg Lasers** 1997 Apr;28(4):321–4

Adverse drug reaction to rifampin: a case with long lasting

antiplatelet antibodies. Tricerri A, et al. **Panminerva Med** 1997 Mar;39(1):64–6

Recurrent bilateral anterior uveitis with hypopyon and rifabutin therapy. Zenone T, et al. **Scand J Infect Dis** 1996; 28(3):325–6

Delayed onset of pseudomembranous colitis after rifampin therapy. Byrd RP Jr, et al. **South Med J** 1997 Jun; 90(6):644–6 (18 ref.)

Rifampicin-induced immune thrombocytopenia. Mehta YS, et al. **Tuber Lung Dis** 1996 Dec;77(6):558–62

[Four cases of similar Hexheimer's reaction during the initial chemotherapy for tuberculosis bacillus] Lu H, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Dec; 18(6):348–50, 382–3 (10 ref.) (Eng. Abstr.) **(Chi)**

[Rifabutin-induced hypopyon iritis in HIV infection] Diemer PR, et al. **Klin Monatsbl Augenheilkd** 1996 Jul;209(1):40–2 (Eng. Abstr.) **(Ger)**

[Fulminant hepatitis during the therapy for tuberculous meningitis] Garavelli PL. **Recenti Prog Med** 1996 Dec; 87(12):597 (8 ref.) **(Ita)**

[Pseudojaundice caused by rifabutine (letter)] Martínez Rivera C, et al. **Med Clin (Barc)** 1997 May 31;109(1):38 **(Spa)**

ANALYSIS

Discrepancy among dissolution rates of commercial tablets as a function of dissolution method. part 6: rifampicin. Ammar HO, et al. **Pharmazie** 1996 Mar;51(3):165–8

BLOOD

Determination of rifampin in human plasma by high-performance liquid chromatography with ultraviolet detection. Lau YY, et al. **J Chromatogr B Biomed Appl** 1996 Feb 9;676(1):147–52

Effect of Mycobacterium avium infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages. Bermudez LE, et al. **Microb Drug Resist** 1997 Fall;3(3):277–82

HISTORY

[Streptomycin and alkalinization in the therapy of tuberculous empyema] Quijano-Pitman F. **Gac Med Mex** 1996 Mar-Apr;132(2):217 **(Spa)**

ISOLATION & PURIFICATION

The elution and binding characteristics of rifampicin for three commercially available protein-sealed vascular grafts. Lovering AM, et al. **J Antimicrob Chemother** 1996 Oct; 38(4):599–604

PHARMACOKINETICS

Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Hosoe K, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2749–55

Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. Kaltenbach G, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2043–6

Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. Li RC, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1566–70

Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol. Schall R, et al. **Arzneimittelforschung** 1995 Nov;45(11):1236–9

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Borin MT, et al. **Clin Pharmacol Ther** 1997 May;61(5):544–53

Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Iatsimirskaia E, et al. **Clin Pharmacol Ther** 1997 May;61(5):554–62

Bioequivalence study of two pharmaceutical forms of rifampicin capsules in man. Chouchane N, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct–Dec; 20(4):315–20

Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients. Jaruratanasirikul S, et al. **J Antimicrob Chemother** 1996 Nov;38(5):877–80

Targeting of multiple emulsions to the lungs. Khopade AJ, et al. **Pharmazie** 1996 Aug;51(8):558–62

[Correlation between pharmacokinetic parameters of rifampicin and its biologically active metabolite as related to estimation of the relative bioavailability of the antibiotic] Firsov AA, et al. **Antibiot Khimioter** 1996 Apr;41(4):36–43 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Monooxygenase-like sequence of a Rhodococcus equi gene conferring increased resistance to rifampin by inactivating this antibiotic. Andersen SJ, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):218–21

In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Bahl D, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1293–7

Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City. Cooksey RC, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1186–8

Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Kelly BP, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2809–12

Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Meier A, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2452–4

Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Moghazeh SL, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2655–7

Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Mor N, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1482–5

Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice. Tomioka H, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):357–62

Insufficient evidence of synergistic effect of levofloxacin and rifampin against Legionella pneumophila [letter; comment] van Ogtrop ML. **Antimicrob Agents Chemother** 1996 Feb; 40(2):524–5. Comment on: Antimicrob Agents Chemother 1995 Aug;39(8):1661–6.

Concentrations and effects of zopiclone are greatly reduced by rifampicin. Villikka K, et al. **Br J Clin Pharmacol** 1997 May;43(5):471–4

Detection of resistance to isoniazid, rifampin, and streptomycin in clinical isolates of Mycobacterium tuberculosis by molecular methods. Nachamkin I, et al. **Clin Infect Dis** 1997 May;24(5):894–900

Triazolam is ineffective in patients taking rifampin. Villikka K, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):8–14

Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. Taniguchi H, et al. **FEMS Microbiol Lett** 1996 Oct 15;144(1):103–8

The effects of therapy with rifampicin and isoniazid on basic investigations for Cushing's syndrome. Zawawi TH, et al. **Ir J Med Sci** 1996 Oct–Dec;165(4):300–2

Determination of the in vivo post-antibiotic effects of ciprofloxacin and rifampicin. Meng X, et al. **J Antimicrob Chemother** 1995 Dec;36(6):987–96

Rifampicin resistance in Neisseria meningitidis: evidence from a study of sibling strains, description of new mutations and notes on population genetics. Nolte O. **J Antimicrob Chemother** 1997 Jun;39(6):747–55

The absence of genetic markers for streptomycin and rifampicin resistance in Mycobacterium avium complex strains. Portillo-Gomez L, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1049–53

Factors affecting development of rifampicin resistance in biofilm-producing Staphylococcus epidermidis. Svensson E, et al. **J Antimicrob Chemother** 1997 Jun;39(6):817–20

Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. Cáceres NE, et al. **J Bacteriol** 1997 Aug;179(16):5046–55

Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City. Cooksey RC, et al. **J Clin Microbiol** 1997 May;35(5):1281–3

Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis. Garza-González E, et al. **J Clin Microbiol** 1997 May; 35(5):1287–9

Emergence of rifampin-resistant Rhodococcus equi in an infected foal. Takai S, et al. **J Clin Microbiol** 1997 Jul; 35(7):1904–8

Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients. Kim YH, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):247–52

Stimulation of bile acid 6 alpha-hydroxylation by rifampin. Wietholtz H, et al. **J Hepatol** 1996 Jun;24(6):713–8

Detection of rifampin resistance in Mycobacterium tuberculosis by use of a rapid, simple, and specific RNA/RNA mismatch assay. Nash KA, et al. **J Infect Dis** 1997 Aug;176(2):533–6

The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. Ndanusa BU, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1571–5

Detection of rifampin resistance among isolates of Mycobacterium tuberculosis from Mozambique. Caugant DA, et al. **Microb Drug Resist** 1995 Winter;1(4):321–6

Geographic variation of the predictive values of genomic mutations associated with streptomycin resistance in Mycobacterium tuberculosis. Dobner P, et al. **Mol Cell Probes** 1997 Apr;11(2):123–6

Drug interaction: rifampicin and glibenclamide. Surekha V, et al. **Natl Med J India** 1997 Jan–Feb;10(1):11–2

Evaluation of the in vitro activity of seven selected antimicrobial agents to be used for the isolation of human intestinal spirochaetes. Calderaro A, et al. **New Microbiol** 1997 Jan;20(1):35–45

Antimycobacterial synergism of clarithromycin and rifabutin. Ghebremichael S, et al. **Scand J Infect Dis** 1996; 28(4):387–90

Inability to attain oral anticoagulation: warfarin-rifampin interaction revisited. Casner PR. **South Med J** 1996 Dec; 89(12):1200–3 (21 ref.)

[Genetic evaluation for rifampicin-susceptibility of Mycobacterium tuberculosis] Ohno H, et al. **Kansenshogaku Zasshi** 1997 Apr;71(4):323–8 (Eng. Abstr.) **(Jpn)**

[In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis] Sato K, et al. **Kekkaku** 1996 Aug;71(8):459–64 (Eng. Abstr.) **(Jpn)**

[Preclinical study of therapeutic agents used against Mycobacterium avium complex infections--with special reference to new macrolides and new quinolones] Tomioka H, et al. **Kekkaku** 1996 Sep;71(9):531–5 **(Jpn)**

[Detection of rifampicin-resistant strains of Mycobacterium tuberculosis by a non-radioactive PCR-SSCP method] Yamazaki T, et al. **Kekkaku** 1996 Aug;71(8):465–71 (Eng. Abstr.) **(Jpn)**

[Influence of rifampicin on antihypertensive effects of dihydropiridine calcium-channel blockers in four elderly patients] Yoshimoto H, et al. **Nippon Ronen Igakkai Zasshi** 1996 Sep;33(9):692–6 (Eng. Abstr.) **(Jpn)**

[Regulatory properties of RNA polymerase from rifampicin-resistant E. coli strain rpoB403] Kamzolova SG. **Biokhimiia** 1996 Aug;61(8):1483–8 (Eng. Abstr.) **(Rus)**

[Experience with classical methods for serodiagnosis of tuberculosis in detecting drug resistance of mycobacterium] Evdokimov VN, et al. **Probl Tuberk** 1996;(5):19–20 **(Rus)**

THERAPEUTIC USE

Disseminated Mycobacterium avium complex infection: implications of recent clinical trials on prophylaxis and treatment. Benson CA. **AIDS Clin Rev** 1997–98;:271–87 (37 ref.)

Current issues in the pathogenesis and management of HIV-related tuberculosis. Daley CL. **AIDS Clin Rev** 1997–98;:289–321 (96 ref.)

CDC lists options for managing rifampin, protease inhibitor therapy [news] **Am J Health Syst Pharm** 1996 Dec 15; 53(24):2940; 2943

Criteria for use of rifabutin in adult patients with human immunodeficiency virus (HIV)-associated disease. Fish N, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1598–9

Mycobacterium avium disease: progress at last [letter] Campbell IA. **Am J Respir Crit Care Med** 1996 Nov; 154(5):1580

Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. McGregor MM, et al. **Am J Respir Crit Care Med** 1996 Nov; 154(5):1462–7

Selective malabsorption and the origin of mono-rifampin-resistant Mycobacterium tuberculosis [letter; comment] Perlman DC, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):1213. Comment on: Am J Respir Crit Care Med 1996 Feb;153(2):837–40.

Rifampin preventive therapy for tuberculosis in Boston's homeless. Polesky A, et al. **Am J Respir Crit Care Med** 1996 Nov;154(5):1473–7

Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group [see comments] Raad I, et al. **Ann Intern Med** 1997 Aug 15;127(4):267–74. Comment in: Ann Intern Med 1997 Aug 15;127(4):304–6.

Efficacies of ofloxacin, rifampin, and clindamycin in treatment of Staphylococcus aureus abscesses and correlation with results of an in vitro assay of intracellular bacterial killing. Bamberger DM, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1178–81

How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? Ji B, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):437–42

In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Yamamoto T, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):426–8

Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. Yamamoto T, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):429–32

Early diagnosis of childhood tuberculosis. Failing regimens should be modified with multiple drugs instituted simultaneously [letter; comment] Greig JR, et al. **BMJ** 1996 Oct 26;313(7064):1084. Comment on: BMJ 1996 Jul 27;313(7051):221–2.

Methadone maintenance and tuberculosis treatment [see comments] Raistrick D, et al. **BMJ** 1996 Oct 12; 313(7062):925–6. Comment in: BMJ 1997 Jan 25;314(7076):303.

Concurrent mucosal leishmaniasis and pulmonary tuberculosis. Escobar MA, et al. **Clin Infect Dis** 1996 Oct; 23(4):836–7

Rifampin-resistant Mycobacterium kansasii infection in a patient with AIDS who was receiving rifabutin. Meynard JL, et al. **Clin Infect Dis** 1997 Jun;24(6):1262–3

Disseminated infection due to multidrug-resistant Mycobacterium bovis in a patient who was seropositive

for human immunodeficiency virus. Schultsz C, et al. **Clin Infect Dis** 1996 Oct;23(4):841–3

Changes in the size of adrenal glands in acute pulmonary tuberculosis with therapy. Gülmez I, et al. **Endocr J** 1996 Oct;43(5):573–6

The use of rifabutin in Europe for the treatment of mycobacterial infection in AIDS patients. Dautzenberg B. **Infection** 1997 Jan–Feb;25(1):63–6 (16 ref.)

Paradoxical worsening in tuberculosis during therapy in an HIV–infected patient [letter] Mofredj A, et al. **Infection** 1996 Sep–Oct;24(5):390–1

Drug interaction between cyclosporine and two antimicrobial agents, josamycin and rifampicin, in organ–transplanted patients. Capone D, et al. **Int J Clin Pharmacol Res** 1996; 16(2–3):73–6

Human immunodeficiency virus infection in children with tuberculosis in Santo Domingo, Dominican Republic: prevalence, clinical findings, and response to antituberculosis treatment. Espinal MA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Oct 1;13(2):155–9

Impact of Mycobacterium avium complex prophylaxis on the incidence of mycobacterial infections and transfusion–requiring anemia in an HIV–positive population. Kravcik S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):27–32

Antimicrobial treatment of fish tank granuloma. Laing RB, et al. **J Hand Surg [Br]** 1997 Feb;22(1):135–7

From the Centers for Disease Control and Prevention. Clinical update: impact of HIV protease inhibitors on the treatment of HIV–infected tuberculosis patients with rifampin. **JAMA** 1996 Nov 20;276(19):1546

Clinical update: impact of HIV protease inhibitors on the treatment of HIV–infected tuberculosis patients with rifampin. **MMWR Morb Mortal Wkly Rep** 1996 Oct 25; 45(42):921–5

Prospective randomized study of thrice weekly six–month and nine–month chemotherapy for cervical tuberculous lymphadenopathy. Yuen AP, et al. **Otolaryngol Head Neck Surg** 1997 Feb;116(2):189–92

Loss of analgesic effect of morphine due to coadministration of rifampin. Fromm MF, et al. **Pain** 1997 Aug;72(1–2):261–7

Evaluation of the use of mass chemoprophylaxis during a school outbreak of enzyme type 5 serogroup B meningococcal disease. Jackson LA, et al. **Pediatr Infect Dis J** 1996 Nov;15(11):992–8

Clinical experience with rifabutin in the treatment of mycobacterial infections. De Cian W, et al. **Scand J Infect Dis Suppl** 1995;98:22–6 (28 ref.)

Treatment of mycobacterial infections in HIV–negative immunocompromised patients. Heurlin N. **Scand J Infect Dis Suppl** 1995;98:21

Experience of tacrolimus–based immunosuppression in living–related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. Kiuchi T, et al. **Transplant Proc** 1996 Dec;28(6):3171–2

Treatment of clinical paratuberculosis in cattle. St Jean G. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):417–30 (51 ref.)

[Pilot studies on the treatment of Mycobacterium avium complex lung disease—new macrolides and new quinolones. (1) Continuous positive cases (failure of the initial chemotherapy)] Sakatani M. **Kekkaku** 1996 Sep; 71(9):544–7 **(Jpn)**

[Preclinical study of therapeutic agents used against Mycobacterium avium complex infections—with special reference to new macrolides and new quinolones] Tomioka H, et al. **Kekkaku** 1996 Sep;71(9):531–5 **(Jpn)**

[Rifabutin—a new antituberculous antibiotic] **Antibiot Khimioter** 1997;42(5):47–8 (13 ref.) **(Rus)**

[Effectiveness of complex treatment in combination with short–wave therapy and protease inhibitors in first detected patients with pulmonary tuberculosis] Lomachenkov VD, et al. **Probl Tuberk** 1997;(1):42–4 (Eng. Abstr.) **(Rus)**

URINE

Isolation and identification of major urinary metabolites of rifabutin in rats and humans. Utkin I, et al. **Drug Metab Dispos** 1997 Aug;25(8):963–9

ANTIBIOTICS, BETA–LACTAM see **ANTIBIOTICS, LACTAM**

ANTIBIOTICS, CARBAPENEM see **CARBAPENEMS**

ANTIBIOTICS, CEPHALOSPORIN see **CEPHALOSPORINS**

ANTIBIOTICS, CEPHAMYCIN see **CEPHAMYCINS**

ANTIBIOTICS, COMBINATION see **ANTIBIOTICS, COMBINED**

ANTIBIOTICS, COMBINED

Treatment of human brucellosis with netilmicin and doxycycline. Solera J, et al. **Clin Infect Dis** 1996 Mar; 22(3):441–5

Multidrug–resistant Pneumococcus causing vertebral osteomyelitis. Antony SJ. **J Natl Med Assoc** 1997 Sep; 89(9):634–5

Piperacillin–Tazobactam: a new beta–lactam–beta–lactamase inhibitor combination. Daniel KP, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2):149–62

[Development of beta–lactamase inhibitors] Hyodo A, et al. **Nippon Rinsho** 1997 May;55(5):1272–80 (20 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Prolonged continuous i.v. "desensitization" in Tienam hypersensitivity. Confino–Cohen R, et al. **Allergy** 1997 Jun; 52(6):683–4

Once–daily aminoglycoside dosing [letter; comment] Baxter R. **Ann Intern Med** 1997 Feb 15;126(4):330. Comment on: Ann Intern Med 1996 Apr 15;124(8):717–25.

Topical antimicrobial prophylaxis in minor wounds. Langford JH, et al. **Ann Pharmacother** 1997 May; 31(5):559–63

Effect of gentamicin dosing interval on efficacy of penicillin or ceftriaxone treatment of experimental endocarditis due to penicillin–susceptible, ceftriaxone–tolerant viridans group streptococci. Brandt CM, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2901–3

A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation–induced mucositis. Okuno SH, et al. **Cancer** 1997 Jun 1;79(11):2193–9

Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Uemura N, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Aug;6(8):639–42

Multicenter randomized study of two once daily regimens in the initial management of community–acquired respiratory tract infections in 163 children: azithromycin versus ceftibuten. Galova K, et al. **Chemotherapy** 1996 May–Jun;42(3):231–4

Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. Lo WC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Mar;59(3):171–6

A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Dawson CR, et al. **Clin Infect Dis** 1997 Mar; 24(3):363–8

Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. Bailey RR, et al. **Clin Nephrol** 1996 Sep;46(3):183–6

Silastic catheters for home antibiotic therapy in patients with cystic fibrosis. Buck C, et al. **Eur J Pediatr** 1997 Mar; 156(3):209–11

Prevention of wound infection in elective colorectal surgery by local application of a gentamicin–containing collagen sponge. Rutten HJ, et al. **Eur J Surg Suppl** 1997;(578):31–5

Pharmacotherapy—the facts and fantasies of prophylaxis and combined therapies. Scaglione F. **Eur J Surg Suppl** 1997; (578):11–5 (20 ref.)

A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. McCormick PA, et al. **Hepatology** 1997 Apr;25(4):833–6

Spinal epidural abscess associated with epidural anesthesia: gadolinium–enhanced magnetic resonance imaging and its usefulness in diagnosis and treatment. Higuchi T, et al. **Intern Med** 1996 Nov;35(11):902–4

"Mediterranean lymphoma" treated with antibiotics [see comments] Matsumoto S, et al. **Intern Med** 1996 Dec; 35(12):961–5. Comment in: Intern Med 1996 Dec;35(12):917–8.

Borrelia burgdorferi–associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa–2a. Kütting B, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 2):311–4

Aerosolization of imipenem/cilastatin prevents pseudomonas–induced acute lung injury. Hashimoto S, et al. **J Antimicrob Chemother** 1996 Nov;38(5):809–18

Sustained–release microcapsules of nitrofurantoin and amoxicillin; preparation, in–vitro release rate, kinetic and micromeritic studies. Ertan G, et al. **J Microencapsul** 1997 May–Jun;14(3):379–88

Effect of recombinant human granulocyte colony–stimulating factor on combination therapy with aztreonam and clindamycin for infections in neutropenic patients with hematologic diseases. Toyama K, et al. **Kansenshogaku Zasshi** 1996 Dec;70(12):1242–53

Intraperitoneal once–daily dose of cefazolin and gentamicin for treating CAPD peritonitis [see comments] Lai MN, et al. **Perit Dial Int** 1997 Jan–Feb;17(1):87–9. Comment in: Perit Dial Int 1997 Jan–Feb;17(1):11–2.

Galenic formulations and Helicobacter pylori eradication [letter; comment] Boixeda D, et al. **Scand J Gastroenterol** 1996 Jul;31(7):736. Comment on: Scand J Gastroenterol 1996 Jan;31(1):49–53.

Clinical mastitis in dairy cows after 'blitz' therapy [letter] Biggs AM. **Vet Rec** 1997 Jul 19;141(3):84

Development of a new CSF–shunt with sustained release of an antimicrobial broad–spectrum combination. Schierholz JM, et al. **Zentralbl Bakteriol** 1997 Jun;286(1):107–23

[Intravenous administration of Augmentin in the prevention of infectious complications in abdominal hysterectomy] Kučera E, et al. **Ceska Gynekol** 1996 Jun;61(3):148–50 (Eng. Abstr.) **(Cze)**

[Clinical study of tazobactam/piperacillin in obstetrics and gynecological infections] Chimura T, et al. **Jpn J Antibiot** 1996 Aug;49(8):808–12 (Eng. Abstr.) **(Jpn)**

[Measurement of antibody titers to chlamydial infection and effects of levofloxacin in cystic cervicitis and chlamydial infection] Chimura T. **Jpn J Antibiot** 1997 May; 50(5):479–84 (Eng. Abstr.) **(Jpn)**

[Effect of imipenem/cilastatin combined with vancomycin for MRSA infection] Fukabori T, et al. **Jpn J Antibiot** 1997 Apr;50(4):299–305 (Eng. Abstr.) **(Jpn)**

[Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders] Sawae Y, et al. **Jpn J Antibiot** 1996 Dec;49(12):1049–61 (Eng. Abstr.) **(Jpn)**

[Clinical efficacy of imipenem/cilastatin sodium for respiratory infections in patients with lung cancer] Yoshida M, et al. **Jpn J Antibiot** 1997 Jan;50(1):22–38 (Eng. Abstr.) **(Jpn)**

[The combination of amoxicillin–clavulanic acid and ofloxacin in the treatment of multidrug–resistant Mycobacterium tuberculosis] Iwanaga T, et al. **Kekkaku** 1997 Jan;72(1):9–13 (Eng. Abstr.) **(Jpn)**

[A case of ovarian abscess aspirated under transvaginal ultrasonography followed by local administration of antibiotics] Serikawa T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Sep;48(9):841–4 **(Jpn)**

[A case of gastric MALT lymphoma regressed endoscopically and pathologically after eradication of Helicobacter pylori] Seko A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):21–6 **(Jpn)**

[A single dose of antibiotic—as a prophylaxis during cesarean section] Krasnodębski J, et al. **Ginekol Pol** 1997 Jan; 68(1):30–5 (Eng. Abstr.) **(Pol)**

[Enhancement of treatment efficacy in experimental plague by the sequential administration of antibiotics] Makarovskaia LN, et al. **Antibiot Khimioter** 1996; 41(11):25–7 (Eng. Abstr.) **(Rus)**

[Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes] Figuera A, et al. **Rev Clin Esp** 1996 Aug; 196(8):515–22 (Eng. Abstr.) **(Spa)**

[The efficacy of using a short course of 6–day duration (OCA–6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin (letter)] Rodrigo Sáez L, et al. **Rev Esp Enferm Dig** 1997 Feb; 89(2):146–7 **(Spa)**

ADVERSE EFFECTS

Antibiotic–induced iatrogenic hemobilia. Huilgol VR, et al. **Am J Gastroenterol** 1997 Apr;92(4):706–7 (11 ref.)

Impact of dosage–monitoring system on frequency of seizures associated with imipenem–cilastatin [letter] Guglielmo BJ, et al. **Am J Health Syst Pharm** 1996 Sep 1;53(17):2097–8

Seizures related to use of imipenem–cilastatin [letter] Lane M, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1605–6

Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta–lactam antibiotics. Nix DE, et al. **Ann Pharmacother** 1997 Jun; 31(6):696–703

Reversible bone marrow depression by high–dose piperacillin/tazobactam. Ruiz–Irastorza G, et al. **Br J Haematol** 1996 Dec;95(4):611–2

Treatment of HIV infection. Tolerability of commonly used antiretroviral agents. Notermans DW, et al. **Drug Saf** 1996 Sep;15(3):176–87 (118 ref.)

Drug reactions in patients with acute HIV infection [letter] Dingen ME, et al. **Int J Dermatol** 1996 Sep;35(9):678–9

Imipenem–cilastatin–induced leukocytoclastic vasculitis [letter] Reiner MR, et al. **J Am Podiatr Med Assoc** 1997 May;87(5):245–7

Intrahepatic cholestasis without hepatitis induced by amoxycillin/clavulanic acid. Pedro–Botet J, et al. **J Clin Gastroenterol** 1996 Sep;23(2):137–8

Severe neutropenia and prophylactic doses of rifabutin [letter; comment] Tansey MJ, et al. **Lancet** 1996 Dec 7; 348(9041):1592–3. Comment on: Lancet 1996 Sep 7;348(9028):685.

Adverse hepatic events associated with drug therapy [letter] Hewitt J, et al. **Med J Aust** 1996 Sep 16;165(6):347, 350

Severe penicillin allergy precipitated by inhalation and topical exposure to co–amoxiclav (Augmentin) [letter] Jarrett P, et al. **N Z Med J** 1996 Sep 27;109(1030):366

Suspected acute interstitial nephritis induced by piperacillin–tazobactam. Pill MW, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):166–9

[Hepatitis caused by the amoxicillin–clavulanic acid combination. An example of drug–induced biliary hepatotoxicity] Bralet MP, et al. **Ann Pathol** 1996 Dec; 16(6):425–9 (Eng. Abstr.) **(Fre)**

[Sulfamethoxazole–trimethoprim–induced pneumonitis in a patient with hemophilia B who was infected with the human immunodeficiency virus] Yamagishi T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul;34(7):822–8 (Eng. Abstr.) **(Jpn)**

[Hepatotoxicity caused by amoxicillin, clavulanic acid or both? (letter) (see comments)] Caballero Plasencia AM, et al. **Gastroenterol Hepatol** 1997 Jan;20(1):45–6. Comment in: Gastroenterol Hepatol 1997 Jun–Jul;20(6):337–8. **(Spa)**

ANTIBIOTICS, COMBINED

[Hepatotoxicity caused by amoxicillin–clavulanic acid (letter; comment)] Reñe JM, et al. **Gastroenterol Hepatol** 1997 Jun–Jul;20(6):337–8. Comment on: Gastroenterol Hepatol 1997 Jan;20(1):45–6. **(Spa)**

ANALYSIS

Quantitative estimation of sultamicillin p–toluenesulfonate in pharmaceutical preparations by reverse–phase high performance liquid chromatography. Argekar AP, et al. **J Pharm Biomed Anal** 1996 Dec;15(3):423–7

Analysis of binary mixtures of cephalothin and cefoxitin by using first–derivative spectrophotometry. Murillo JA, et al. **J Pharm Biomed Anal** 1996 Jan;14(3):257–66

Simultaneous determination of amoxycillin and clavulanic acid in pharmaceutical products by HPLC with beta–cyclodextrin stationary phase. Tsou TL, et al. **J Pharm Biomed Anal** 1997 May;15(8):1197–205

CHEMISTRY

Disastrous reflavorig of antibiotics [letter] Perrin JH. **Pediatrics** 1997 Sep;100(3 Pt 1):420

ECONOMICS

An investigation of the hospital charges related to the treatment of endophthalmitis in the Endophthalmitis Vitrectomy Study [see comments] Wisniewski SR, et al. **Ophthalmology** 1997 May;104(5):739–45. Comment in: Ophthalmology 1997 May;104(5):737–8.

Pharmacoeconomics of aztreonam–clindamycin versus gentamicin–clindamycin in the treatment of penetrating abdominal injury. Fabian TC, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):951–7

[Ophthalmic preparations Polyspectran (combination of neomycin, polymyxin B and bacitracin/gramicidin) and Terramycin (oxytetracycline with polymyxin B) mistakenly no longer reimbursed] Brandenburg HC, et al. **Ned Tijdschr Geneeskd** 1997 Jan 25;141(4):204–5 (Eng. Abstr.) **(Dut)**

PHARMACOKINETICS

Efficacy of ampicillin–sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions. Alexov M, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2468–77

Clinical pharmacokinetics of piperacillin–tazobactam combination in patients with major burns and signs of infection. Bourget P, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):139–45

Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem–cilastatin. Dreetz M, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):105–9

Importance of beta–lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor–drug combinations: studies with piperacillin–tazobactam and piperacillin–sulbactam. Lister PD, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):721–7

Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Lortholary O, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1242–7

A comparative study of the distribution of ofloxacin and ciprofloxacin in prostatic tissues after simultaneous oral ingestion. Png JC, et al. **Br J Urol** 1997 May;79(5):781–4

Pharmacokinetics of amoxicillin/clavulanic acid combination and of both drugs alone after intravenous administration to goats. Escudero E, et al. **Br Vet J** 1996 Sep;152(5):551–9

Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment. Derendorf H, et al. **Int J Clin Pharmacol Ther** 1996 Nov;34(11):482–8

Clinical pharmacokinetics of amoxicillin and clavulanate. Reed MD. **Pediatr Infect Dis J** 1996 Oct;15(10):949–54

PHARMACOLOGY

In vitro assessment of the effect of clavulanic acid at concentrations achieved in human serum on the bactericidal activity of amoxicillin at physiological concentrations against Staphylococcus aureus: implications for dosage regimens. Aguilar L, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1403–5

Efficacy of ampicillin–sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions. Alexov M, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2468–77

Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time–kill methods. Bajaksouzian S, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):1973–6

In vivo activity and pharmacodynamics of amoxicillin in combination with fosfomycin in fibrin clots infected with highly penicillin–resistant Streptococcus pneumoniae. Chavanet P, et al. **Antimicrob Agents Chemother** 1996 Sep; 40(9):2062–66

Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. den Hollander JG, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):95–100

Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta–lactamase–positive strains resistant to amoxicillin–clavulanate: results of a national multicenter surveillance study. Doern GV, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):292–7

Net effect of inoculum size on antimicrobial action of ampicillin–sulbactam: studies using an in vitro dynamic model. Firsov AA, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):7–12

Predictors of effect of ampicillin–sulbactam against TEM–1 beta–lactamase–producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Firsov AA, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):734–8

Molecular aspects of high–level resistance to sulbactam–cefoperazone in Klebsiella oxytoca clinical isolates. Kimura K, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):1988–94

Comparison of the bactericidal activities of piperacillin–tazobactam, ticarcillin–clavulanate, and ampicillin–sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Klepser ME, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):435–9

In vitro susceptibility of penicillin–resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time–kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. Klugman KP, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2802–4

In vitro synergy testing of macrolide–quinolone combinations against 41 clinical isolates of Legionella. Martin SJ, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1419–21

In vitro synergy testing of clarithromycin and 14–hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. Meyer JM, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1607–8

The macrolide–lincosamide–streptogramin B resistance phenotypes characterized by using a specifically deleted, antibiotic–sensitive strain of Streptomyces lividans. Pernodet JL, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):581–5

Pharmacodynamic effects of antibiotics and antibiotic combinations on growing and nongrowing Staphylococcus epidermidis cells. Svensson E, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):107–11

Postantibiotic and post–beta–lactamase inhibitor effects of amoxicillin plus clavulanate. Thorburn CE, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2796–801

Lack of correlation between in vitro and in vivo studies of combinations of rifampin plus vancomycin or beta–lactam antibiotics against Streptococcus pneumoniae [letter; comment] Tuban F, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1573–4. Comment on: Antimicrob Agents Chemother 1995 Dec;39(12):2798–800.

Combination of flucloxacillin and gentamicin inhibits toxic shock syndrome toxin 1 production by Staphylococcus aureus in both logarithmic and stationary phases of growth. van Langevelde P, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1682–5

Comparative activity of trovafloxacin, alone and in combination with other agents, against gram–negative nonfermentative rods. Visalli MA, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1475–81

Comparison of three different in vitro methods of detecting synergy: time–kill, checkerboard, and E test. White RL, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1914–8

In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium. Yajko DM, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):743–9

Comparison of postantibiotic effects of imipenem and netilmicin alone and in combination against Pseudomonas aeruginosa. Hoštacká A. **Arzneimittelforschung** 1997 Aug; 47(8):965–7

In vitro time–kill curves of cefepime and cefpirome combined with amikacin, gentamicin or ciprofloxacin against Klebsiella pneumoniae producing extended–spectrum beta–lactamase. Elkhaïli H, et al. **Chemotherapy** 1997 Jul–Aug;43(4):245–53

Superior effect of tazobactam/piperacillin compared to piperacillin on beta–lactamase–producing Pseudomonas aeruginosa. Nishida K, et al. **Chemotherapy** 1997 May–Jun; 43(3):171–8

Endocarditis caused by Stenotrophomonas maltophilia: case report and review. Gutiérrez Rodero F, et al. **Clin Infect Dis** 1996 Dec;23(6):1261–5 (26 ref.)

beta–Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. Williams JD. **Clin Infect Dis** 1997 Mar;24(3):494–7 (7 ref.)

In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood. Chang SC, et al. **Diagn Microbiol Infect Dis** 1995 Nov;23(3):105–110

Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: analysis of the correlations between in vitro test results and clinical response. Jones RN, et al. **Diagn Microbiol Infect Dis** 1997 May;28(1):5–18

In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. Milatovic D, et al. **Eur J Clin Microbiol Infect Dis** 1996 Aug;15(8):688–93

In vitro activity of trimethoprim against Borrelia burgdorferi. Reisinger EC, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jun;16(6):458–60

In vitro & in vivo experimental susceptibility of Mycobacterium marinum to augmentin. Chakrabarti A, et al. **Indian J Med Res** 1996 Nov;104:281–3

Postantibiotic effect of ceftriaxone and gentamicin alone and in combination on Klebsiella pneumoniae, Pseudomonas aeruginosa and Streptococcus viridans. Buxbaum A, et al. **Infection** 1996 Nov–Dec;24(6):459–64

Effect of ticarcillin and ticarcillin/clavulanic acid on the in–vitro activity of human granulocytes against beta–lactamase–producing Klebsiella pneumoniae. Cuffini AM, et al. **Int J Tissue React** 1995;17(5–6):199–203

Modification of natural immunity in mice by imipenem/cilastatin. Ortega E, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):502–8

Anaerobic activity of levofloxacin and metronidazole separately and in combination [letter] Barry AL, et al. **J Antimicrob Chemother** 1996 Jun;37(6):1178–9

Potential effects of amoxycillin/clavulanic acid and ticarcillin/clavulanic acid on human granulocyte activity: a comparative study. Cuffini AM, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1013–22

Effect of NCCLS, SFM, and DIN breakpoints upon the incidence of co–amoxiclav resistance in Escherichia coli [letter] Durodia J, et al. **J Antimicrob Chemother** 1995 Dec; 36(6):1105–6

Reduced susceptibility to co–amoxiclav in Escherichia coli, Salmonella typhimurium and Klebsiella pneumoniae isolated in Romania between 1985 and 1993. Espinasse F, et al. **J Antimicrob Chemother** 1997 Jan;39(1):103–6

In–vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin. Gould IM, et al. **J Antimicrob Chemother** 1997 Jan; 39(1):53–61

Multicentre in–vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co–amoxiclav and sparfloxacin. Hoogkamp–Korstanje JA, et al. **J Antimicrob Chemother** 1997 Mar;39(3):411–4

Effect of combination therapy of rifampicin and azithromycin on TNF levels during a rat model of chronic osteomyelitis. Littlewood–Evans AJ, et al. **J Antimicrob Chemother** 1997 Apr;39(4):493–8

A new time–kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative beta–lactam, aminoglycoside and fluoroquinolone. MacGowan AP, et al. **J Antimicrob Chemother** 1996 Aug;38(2):193–203

In–vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii [letter] Martinez–Martinez L, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1107–8

Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron [letter] Nagai K, et al. **J Antimicrob Chemother** 1997 Feb; 39(2):295–6

The synergic effects of quinolones and oral cephem antibiotics on Serratia marcescens. Otsuki M, et al. **J Antimicrob Chemother** 1996 Nov;38(5):771–6

Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages. Pellegrin I, et al. **J Antimicrob Chemother** 1996 Mar;37(3):501–10

In–vitro activity of a new oral streptogramin, RPR 106972, alone and in combination with rifampicin or ciprofloxacin against Legionella spp. Pendland SL, et al. **J Antimicrob Chemother** 1997 May;39(5):651–3

In–vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase–negative staphylococci. Raymond J, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1067–71

In–vitro killing activity of combinations of beta–lactam agents with aminoglycosides against penicillin–resistant pneumococci. Schlegel L, et al. **J Antimicrob Chemother** 1997 Jan;39(1):95–8

Evaluation of the resistance induction in enteric flora in children caused by oral ampicillin plus sulbactam. Soylu A, et al. **J Antimicrob Chemother** 1997 Jun;39(6):833–5

Exacerbation of COPD: amoxicillin + clavulanic acid in vitro activity vs S. pneumoniae, H. influenzae and M. catarrhalis. Beghi G, et al. **J Chemother** 1995 Nov;7 Suppl 4:61–2

In vitro activity of ampicillin–sulbactam against clinical multiresistant Acinetobacter baumannii isolates. Gales AC, et al. **J Chemother** 1996 Dec;8(6):416–9

Tazobactam–piperacillin compared with sulbactam–ampicillin, clavulanic acid–ticarcillin, sulbactam–cefoperazone, and piperacillin for activity against beta–lactamase–producing bacteria isolated from patients with complicated urinary tract infections. Nomura S, et al. **J Chemother** 1997 Apr;9(2):89–94

Effect of vancomycin and teicoplanin alone or in combination with fusidic acid or amikacin against methicillin–resistant staphylococci. Roussel–Delvallez M, et al. **J Chemother** 1997 Feb;9(1):5–8

Response of enteric gram–negative bacteria to disks containing 20 micrograms each of ampicillin and sulbactam. Isenberg HD, et al. **J Clin Microbiol** 1997 Feb;35(2):523–4

Effect of time and temperature on inactivation of

aminoglycosides by ampicillin at neonatal dosages. Daly JS, et al. **J Perinatol** 1997 Jan-Feb;17(1):42-5

The fractional inhibitory concentration index of antimicrobial agents for bacteria and Mycoplasma isolated from the nasal swabs of cattle with respiratory diseases. Katoh T, et al. **J Vet Med Sci** 1996 Aug;58(8):781-2

Effects of combination of benzylpenicillin and fosfomycin on penicillin-resistant Streptococcus pneumoniae. Kikuchi K, et al. **Microb Drug Resist** 1995 Summer;1(2):185-9

In vitro susceptibility of Streptococcus pneumoniae strains to nine beta-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin. Marton A, et al. **Microb Drug Resist** 1996 Fall;2(3):361-9

The antibacterial activity of amoxycillin/clavulanic acid against Staphylococcus aureus ingested by human granulocytes. Cuffini AM, et al. **Microbios** 1996; 87(350):31-8

Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin. Fuller RE, et al. **Pharmacotherapy** 1996 Jul-Aug;16(4):584-92 (87 ref.)

In vitro postantibiotic effect of imipenem and enoxacin alone and in combination against Pseudomonas aeruginosa. Hoštacká A. **Pharmazie** 1997 Jul;52(7):544-6

Pharmacological therapy of Helicobacter pylori infection. Hoffman JS. **Semin Gastrointest Dis** 1997 Jul;8(3):156-63

[Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance] Canis F, et al. **Pathol Biol (Paris)** 1997 May;45(5):420-3 (Eng. Abstr.) **(Fre)**

[Study of in vitro activity of 3 cephalosporins and their combination with 2 beta-lactamase inhibitors against 4 enterobacteria strains producing extended spectrum beta-lactamase] Cattoen C, et al. **Pathol Biol (Paris)** 1997 May;45(5):425-9 (Eng. Abstr.) **(Fre)**

[Pseudomonas aeruginosa: bactericidal activity on various beta-lactam resistance phenotypes of 8 antibiotics and 7 combinations] Dubrous P, et al. **Pathol Biol (Paris)** 1997 May;45(5):433-7 (Eng. Abstr.) **(Fre)**

[Bactericidal activity of quinolones (including sparfloxacin) against Enterococcus; in vitro antagonisms with gentamicin] Watine J, et al. **Pathol Biol (Paris)** 1997 May; 45(5):430-2 (Eng. Abstr.) **(Fre)**

[A conjugate of ristomycin A ristosaminylaglycon-polymyxin B: the spectrum of its antimicrobial action and its membranolytic activity] Polin AN, et al. **Antibiot Khimioter** 1997;42(5):24-8 (Eng. Abstr.) **(Rus)**

[Synergic effect of a teicoplanin and cefpirome combination with aminoglucosides on enterococci. Therapeutic importance] Hoyos López A, et al. **An Med Interna** 1995 Aug;12(8):374-6 (Eng. Abstr.) **(Spa)**

[In vitro bactericide activity of different antibiotic combinations to Streptococcus pneumoniae resistant to penicillin and cefotaxime] Tubau F, et al. **Enferm Infecc Microbiol Clin** 1996 Dec;14(10):590-5 (Eng. Abstr.) **(Spa)**

[Eradication of Helicobacter pylori and chronic abdominal pain (editorial)] Madrazo de la Garza JA. **Rev Gastroenterol Mex** 1996 Oct-Dec;61(4):398-9 **(Spa)**

THERAPEUTIC USE

"Modern therapies for Helicobacter pylori infection". Go MF. **Acta Gastroenterol Latinoam** 1996;26(2):119-23

Oral treatment of late Lyme borreliosis with a combination of roxithromycin and co-trimoxazole--a pilot study on 18 patients. Gasser R, et al. **Acta Med Austriaca** 1996; 23(3):99-101

Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. Delchier JC, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):263-8

Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection. Jaup BH, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):275-7

Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. Lim AG, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):537-40

The future of Helicobacter pylori eradication: a personal perspective. Marshall BJ. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:109-15 (30 ref.)

Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. Tursi A, et al. **Aliment Pharmacol Ther** 1996 Jun; 10(3):285-8

Three new studies expand understanding of MAC therapy [news] **Am J Health Syst Pharm** 1996 Oct 15;53(20):2376, 2380

Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen. Benator DA, et al. **Am J Med Sci** 1997 Jun;313(6):346-51 (25 ref.)

A prospective, double-blind, randomized, controlled clinical trial of ampicillin-sulbactam for preterm premature rupture of membranes in women receiving antenatal corticosteroid therapy. Lovett SM, et al. **Am J Obstet Gynecol** 1997 May; 176(5):1030-8

Effect of antibiotic therapy on nasal nitric oxide concentration in children with acute sinusitis. Baraldi E, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1680-3

Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Chang DC, et al. **Am J Surg** 1997 Sep;174(3):284-90

How many antibiotics are necessary to treat abdominal trauma victims? Sims EH, et al. **Am Surg** 1997 Jun; 63(6):525-35

Comparison of oral agents for treatment of Pneumocystis carinii pneumonia [letter; comment] Perazella MA. **Ann Intern Med** 1997 Mar 1;126(5):407-8. Comment on: Ann Intern Med 1996 May 1;124(9):792-802.

Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma: follow-up together with sequential molecular studies. Montalban C, et al. **Ann Oncol** 1997;8 Suppl 2:37-9

Fluconazole and amphotericin B for cryptococcal meningitis. Clark AB, et al. **Ann Pharmacother** 1996 Dec; 30(12):1408-10

Topical antimicrobial prophylaxis in minor wounds. Langford JH, et al. **Ann Pharmacother** 1997 May; 31(5):559-63

Failure of short antimicrobial treatments for human brucellosis [letter; comment] Abramson O, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1621-2. Comment on: Antimicrob Agents Chemother 1997 Jan;41(1):80-4.

Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. Brun-Pascaud M, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2067-70

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Cometta A, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1108-15

Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model. Darras-Joly C, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2147-51

Importance of penicillinase production for activity of penicillin alone or in combination with sulbactam in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Fantin B, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1219-24

Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections [published erratum appears in Antimicrob Agents Chemother 1996 Oct;40(10):2441] Fournier JL, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):325-30

Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Gavaldà J, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):173-8

Regimens to treat lepromatous leprosy [letter] Gelber RH. **Antimicrob Agents Chemother** 1997 Jul;41(7):1618-20

Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group. Gwaltney JM Jr, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1517-20

Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. Hidalgo M, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1175-7

Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Ji B, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):393-9

How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? Ji B, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):437-42

Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Ji B, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2137-41

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Leibovici L, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1127-33

Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis. Nicolau DP, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):55-60

Use of PCR and culture to detect Helicobacter pylori in naturally infected cats following triple antimicrobial therapy. Perkins SE, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1486-90

Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Plouffe JF, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1175-9

Ampicillin-sulbactam is effective in prevention and therapy of experimental endocarditis caused by beta-lactamase-producing coagulase-negative staphylococci. Ramos MC, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):97-101

Once-versus thrice-daily netilmicin combined with amoxicillin, penicillin, or vancomycin against Enterococcus faecalis in a pharmacodynamic in vitro model. Schwank S, et al. **Antimicrob Agents Chemother** 1996 Oct; 40(10):2258-61

Treatment of human brucellosis with doxycycline and gentamicin [see comments] Solera J, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):80-4. Comment in: Antimicrob Agents Chemother 1997 Jul;41(7):1621-2.

Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Thauvin-Eliopoulos C, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1053-7

Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. Yamamoto T, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):429-32

Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Yamamura D, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1704-8

Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis. Vic P, et al. **Arch Dis Child** 1997 May;76(5):437-40

Treatment of vancomycin-resistant Enterococcus faecium infections. Lai KK. **Arch Intern Med** 1996 Dec 9-23; 156(22):2579-84

Outpatient treatment of bleb infection. Chen PP, et al. **Arch Ophthalmol** 1997 Sep;115(9):1124-8

Antibiotic treatment of children with secretory otitis media. Amoxicillin-clavulanate is superior to penicillin V in a double-blind randomized study. Thomsen J, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jul;123(7):695-9

Therapy for acute otitis media [letter; comment] Ozsoylu S. **Arch Pediatr Adolesc Med** 1996 Dec;150(12):1315. Comment on: Arch Pediatr Adolesc Med 1996 Apr;150(4):396-9.

Perinatal infection with Listeria monocytogenes. Craig S, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):286-90

Owner compliance with short term antimicrobial medication in dogs. Barter LS, et al. **Aust Vet J** 1996 Oct;74(4):277-80

Early diagnosis of childhood tuberculosis. Failing regimens should be modified with multiple drugs instituted simultaneously [letter; comment] Greig JR, et al. **BMJ** 1996 Oct 26;313(7064):1084. Comment on: BMJ 1996 Jul 27;313(7051):221-2.

Hospital antibiotic prescribing and feedback [letter; comment] Hemeryck L, et al. **Br J Clin Pharmacol** 1997 Apr;43(4):449-50. Comment on: Br J Clin Pharmacol 1996 Mar;41(3):229-34.

Eradication of Helicobacter pylori: an objective assessment of current therapies. Penston JG, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):223-43 (376 ref.)

Bioactive substance accumulation and septic complications in a burn trauma patient: effect of perioperative blood transfusion? Nielsen HJ, et al. **Burns** 1997 Feb;23(1):59-63

A thermal burn to a prolapsed uterus. Sagi A, et al. **Burns** 1997 Mar;23(2):174-5

Comparison of ceftibuten versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Aubier MA. **Chemotherapy** 1997 Jul-Aug;43(4):297-302

Effects of selective digestive decontamination on lung injury and outcome: the verdict is not yet in [editorial; comment] Dematte JE, et al. **Chest** 1997 Aug;112(2):304-6. Comment on: Chest 1997 Aug;112(2):491-5.

Gut decontamination reduces bowel ischemia-induced lung injury in rats [see comments] Sorkine P, et al. **Chest** 1997 Aug;112(2):491-5. Comment in: Chest 1997 Aug;112(2):304-6.

Conservative treatment for Brucella endocarditis. Cohen N, et al. **Clin Cardiol** 1997 Mar;20(3):291-4 (24 ref.)

Retroperitoneal fibrosis and infection of an aortic graft prosthesis: diagnosis and therapeutic problems. Cuny C, et al. **Clin Cardiol** 1997 Sep;20(9):810-2

Effect of antibiotic treatment on vegetation size and complication rate in infective endocarditis. Rohmann S, et al. **Clin Cardiol** 1997 Feb;20(2):132-40

Failure to cure Mycobacterium gordonae peritonitis associated with continuous ambulatory peritoneal dialysis. Harro C, et al. **Clin Infect Dis** 1997 May;24(5):955-7

Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Jiménez-Mejías ME, et al. **Clin Infect Dis** 1997 May;24(5):932-5

Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine. Plemmons RM, et al. **Clin Infect Dis** 1997 May;24(5):995-7

Failure to clear a Roseomonas line infection with antibiotic therapy. Richardson JD. **Clin Infect Dis** 1997 Jul;25(1):155

Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Saiman L, et al. **Clin Infect Dis** 1996 Sep;23(3):532-7

Necrotizing external otitis: aminoglycoside and beta-lactam

antibiotic treatment combined with surgical treatment. Pedersen HB, et al. **Clin Otolaryngol** 1997 Jun;22(3):271–4

Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. Steele RW. **Clin Pediatr (Phila)** 1996 Jul;35(7):378–9 (0 ref.)

Infection of a total knee joint prosthesis by peptostreptococcus micros and propionibacterium acnes in an elderly RA patient: implant salvage with longterm antibiotics and needle aspiration/irrigation. Stoll T, et al. **Clin Rheumatol** 1996 Jul;15(4):399–402

Recent advances in antibiotic regimens for the treatment of obstetric–gynecologic infections. Zambrano D. **Clin Ther** 1996 Mar–Apr;18(2):214–27; discussion 213 (72 ref.)

Helicobacter pylori and peptic ulcer disease: issues for primary care providers. Taniguchi DK, et al. **Compr Ther** 1996 Jul;22(7):434–9 (20 ref.)

Major advances in the treatment of HIV–1 infection. **Drug Ther Bull** 1997 Apr;35(4):25–9 (36 ref.)

Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Balfour JA, et al. **Drugs** 1996 Jan; 51(1):99–136 (281 ref.)

Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician. Rybak MJ, et al. **Drugs** 1996 Sep;52(3):390–405 (110 ref.)

Imipenem or cefoperazone–sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Bodey G, et al. **Eur J Clin Microbiol Infect Dis** 1996 Aug;15(8):625–34

One bolus dose of gentamicin and early oral therapy versus cefotaxime and subsequent oral therapy in the treatment of febrile urinary tract infection. Sundman K, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jun;16(6):455–8

Triple therapy as a cure for Helicobacter pylori infection. Bardhan KD. **Eur J Gastroenterol Hepatol** 1996 Oct;8 Suppl 1:S27–30 (36 ref.)

Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single–centre study [see comments] de Boer WA, et al. **Eur J Gastroenterol Hepatol** 1995 Dec;7(12):1189–94. Comment in: ACP J Club 1996 May–Jun;124(3):64–5.

Update on Helicobacter pylori research. Eradication. Graham DY, et al. **Eur J Gastroenterol Hepatol** 1997 Jun; 9(6):626–8

Experience with imipenem in internal medicine—a postmarketing surveillance study. Schaumann R, et al. **Eur J Med Res** 1997 Mar 24;2(3):93–6

Comparative trial of four antibiotic combinations for perforated appendicitis in children. Ciftci AO, et al. **Eur J Surg** 1997 Aug;163(8):591–6

Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. **Gut** 1997 Jul;41(1):8–13 (50 ref.)

Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study [seecomments] Lam SK, et al. **Gut** 1997 Jul;41(1):43–8

Treating Helicobacter pylori induced ulcers with antibiotics alone [comment] Lambert J. **Gut** 1997 Jul;41(1):129–30. Comment on: Gut 1997 Jul;41(1):43–8.

Comparison of ampicillin/sulbactam versus clindamycin in the prevention of infection in patients undergoing head and neck surgery. Johnson JT, et al. **Head Neck** 1997 Aug; 19(5):367–71

Comparison of three prophylactic antibiotic regimens in clean–contaminated head and neck surgery. Rodrigo JP, et al. **Head Neck** 1997 May;19(3):188–93

Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra–abdominal infections. Kempf P, et al. **Infection** 1996 Nov–Dec;24(6):473–9

Therapy of Lyme borreliosis in children. Krbkova L, et al. **Infection** 1996 Mar–Apr;24(2):170–3

Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Shah PM, et al. **Infection** 1996 Nov–Dec; 24(6):480–4

Antibiotic therapy in men with leukocytospermia. Erel CT, et al. **Int J Fertil Womens Med** 1997 May–Jun;42(3):206–10

Importance of mastoid pneumatization on secretory otitis media. Bayramoğlu I, et al. **Int J Pediatr Otorhinolaryngol** 1997 May 4;40(1):61–6

Vancouver: optimism, but at a cost [editorial] Churchill D, et al. **Int J STD AIDS** 1996 Oct;7(6):385–7

Antibiotic–resistant endocarditis in a hemodialysis patient. Vijayvargiya R, et al. **J Am Soc Nephrol** 1996 Apr; 7(4):536–42

In–vivo activity and pharmacodynamics of cefotaxime in combination with vancomycin in fibrin clots infected with highly penicillin–resistant Streptococcus pneumoniae. Chavanet P, et al. **J Antimicrob Chemother** 1996 Oct; 38(4):655–70

Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. Drancourt M, et al. **J Antimicrob Chemother** 1997 Feb;39(2):235–40

Carbapenems in febrile neutropenic patients [letter; comment] Gaya H. **J Antimicrob Chemother** 1997 May;39(5):667–8. Comment on: J Antimicrob Chemother 1996 May;37(5):975–86.

Once–daily, 3–day azithromycin versus a three–times–daily, 10–day course of co–amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double–blind comparative study. Gris P. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:93–101

Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community–acquired pneumonia. Higuera F, et al. **J Antimicrob Chemother** 1996 Mar;37(3):555–64

In–vitro activity of teicoplanin and ceftriaxone in combination against pathogens involved in paediatric bone and joint infections. Lhopital S, et al. **J Antimicrob Chemother** 1996 Oct;38(4):713–8

Correlation of in–vitro activity and pharmacokinetic parameters with in–vivo effect of amoxycillin, co–amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. Soriano F, et al. **J Antimicrob Chemother** 1996 Aug;38(2):227–36

A randomized, comparative study to evaluate the efficacy and tolerability of a 3–day course of azithromycin versus a 10–day course of co–amoxiclav as treatment of adult patients with lower respiratory tract infections. Zachariah J. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:103–13

Efficacy of sulbactam–ampicillin for the treatment of severe diabetic foot infections. Akova M, et al. **J Chemother** 1996 Aug;8(4):284–9

Amoxycillin clavulanate: an assessment after 15 years of clinical application. Ball P, et al. **J Chemother** 1997 Jun; 9(3):167–98 (251 ref.)

Imipenem/cilastatin monotherapy as salvage treatment in febrile neutropenic patients. Engervall P, et al. **J Chemother** 1996 Oct;8(5):382–6

Efficacy and safety of once–daily amikacin in combination with ceftazidime in critically ill adults with severe gram–negative infections. Fayed DF, et al. **J Chemother** 1996 Dec;8(6):457–64

Inhibition of intracellular growth of Staphylococcus aureus by exposure of infected human monocytes to clarithromycin and azithromycin. Fietta A, et al. **J Chemother** 1997 Feb;9(1):17–22

Aztreonam/clavulanic acid in the treatment of serious infections caused by Stenotrophomonas maltophilia in neutropenic patients: case reports. García Sánchez JE, et al. **J Chemother** 1997 Jun;9(3):238–40

Piperacillin–tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies. Hazel DL, et al. **J Chemother** 1997 Aug;9(4):267–72

Randomized trial comparing netilmicin plus imipenem–cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients. Laszlo D, et al. **J Chemother** 1997 Apr;9(2):95–101

Prophylactic administration of amoxicillin and clavulanic acid in pregnant women with premature rupture of the membranes. Tampakoudis P, et al. **J Chemother** 1996 Aug; 8(4):290–4

Microbiological and immunohistological findings in a patient with Papillon–Lefèvre syndrome. Kleinfelder JW, et al. **J Clin Periodontol** 1996 Nov;23(11):1032–8

Preventing endoscopic retrograde cholangiopancreatography related sepsis: a randomized controlled trial comparing two antibiotic regimes. Smith BC, et al. **J Gastroenterol Hepatol** 1996 Oct;11(10):938–41

Is amoxicillin–cotrimoxazole the most appropriate antibiotic regimen for listeria meningoencephalitis? Review of 22 cases and the literature. Merle–Melet M, et al. **J Infect** 1996 Sep;33(2):79–85

Importance of using relapse studies or tests for detection of antibiotic resistance before considering that a treatment for multidrug–resistant enterococcal experimental endocarditis is effective [letter; comment] Caron F. **J Infect Dis** 1997 Jan;175(1):232–3. Comment on: J Infect Dis 1996 Apr;173(4):909–13.

Comparison of azithromycin and co–amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group. Biebuyck XA. **J Int Med Res** 1996 Sep–Oct; 24(5):407–18

Dirithromycin versus amoxiclav in the treatment of acute exacerbations of chronic bronchitis. Van Royen P, et al. **J Int Med Res** 1997 Jan–Feb;25(1):33–40

Cephazolin and metronidazole prophylaxis in head and neck surgery. Strauss M, et al. **J Laryngol Otol** 1997 Jul; 111(7):631–4

Early otorrhea following ear tube insertion. Cannon CR. **J Miss State Med Assoc** 1997 Feb;38(2):39–43

Outpatient treatment with ceftriaxone alone or in combination with teicoplanin in febrile neutropenic children and adolescents with cancer [letter; comment] Preis S, et al. **J Pediatr** 1997 Mar;130(3):500–1. Comment on: J Pediatr 1996 Jun;128(6):847–9.

Ampicillin/sulbactam vs. clindamycin/gentamicin in the treatment of postpartum endometritis. Gall S, et al. **J Reprod Med** 1996 Aug;41(8):575–80

Selective intestinal decontamination in multiple trauma patients: prospective, controlled trial. Lingnau W, et al. **J Trauma** 1997 Apr;42(4):687–94

Management of port infections. Simpson KR. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):591–3 (8 ref.)

Post–therapy antibody titers in dogs with ehrlichiosis: follow–up study on 68 patients treated primarily with tetracycline and/or doxycycline. Bartsch RC, et al. **J Vet Intern Med** 1996 Jul–Aug;10(4):271–4

Effect of a combination of antimicrobial agents for the treatment of respiratory disease in cattle. Katoh T, et al. **J Vet Med Sci** 1996 Aug;58(8):783–5

Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. Mercer BM, et al. **JAMA** 1997 Sep 24; 278(12):989–95

Typhoid perforation treated with and without metronidazole along with chloramphenicol, gentamycin. Javaid K, et al. **JPMA J Pak Med Assoc** 1996 Mar;46(3):49–50

Treatment of glue ear in general practice [letter; comment] Cantekin EI. **Lancet** 1997 Jan 11;349(9045):133–4. Comment on: Lancet 1996 Sep 14;348(9029):713–6.

Incidental eradication of Helicobacter pylori [letter; comment] Harris A, et al. **Lancet** 1997 Jan 4;349(9044):59 . Comment on: Lancet 1996 Nov 16;348(9038):1390–1.

Treatment of persistent otitis media [letter; comment] van den Broek P, et al. **Lancet** 1996 Nov 30;348(9040):1517–8 . Comment on: Lancet 1996 Sep 14;348(9029):713–6.

Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation. Mehta J, et al. **Leuk Lymphoma** 1997 Jun;26(1–2):83–8

Cases of Lyme borreliosis resistant to conventional treatment: improved symptoms with cephalosporin plus specific beta–lactamase inhibition. Gasser R, et al. **Microb Drug Resist** 1995 Winter;1(4):341–4

A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. Rolfs RT, et al. **N Engl J Med** 1997 Jul 31;337(5):307–14

Preterm premature ruptured membranes: a randomized trial of steroids after treatment with antibiotics. Lewis DF, et al. **Obstet Gynecol** 1996 Nov;88(5):801–5

A new perspective in ocular infection and the role of antibiotics. Miyanaga Y. **Ophthalmologica** 1997;211 Suppl 1:9–14 (7 ref.)

Antibiotic supplementation of intraocular irrigating solutions [letter; comment] Teichmann KD. **Ophthalmology** 1997 Jun;104(6):900–1. Comment on: Ophthalmology 1996 Aug;103(8):1204–8; discussion 1208–9.

A multicenter, open label trial of azithromycin vs. amoxicillin/ clavulanate for the management of acute otitis media in children. Aronovitz G. **Pediatr Infect Dis J** 1996 Sep;15(9 Suppl):S15–9

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Church DA, et al. **Pediatr Infect Dis J** 1997 Jan;16(1):97–105; discussion 123–6

Comparison of the efficacy, safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. Gooch WM 3rd, et al. **Pediatr Infect Dis J** 1997 Feb;16(2 Suppl):S21–4

Effectiveness of five days of therapy with cefuroxime axetil suspension for treatment of acute otitis media. Gooch WM 3rd, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):157–64

Efficacy of amoxicillin/clavulanate for acute otitis media: relation to Streptococcus pneumoniae susceptibility. Hoberman A, et al. **Pediatr Infect Dis J** 1996 Oct; 15(10):955–62

Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Hoberman A, et al. **Pediatr Infect Dis J** 1997 May; 16(5):463–70

A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. Khurana CM. **Pediatr Infect Dis J** 1996 Sep;15(9 Suppl):S24–9

A multicenter, double blind comparison of azithromycin and amoxicillin/ clavulanate for the treatment of acute otitis media in children. McLinn S. **Pediatr Infect Dis J** 1996 Sep;15(9 Suppl):S20–3

Malignant external otitis as the presentation of childhood acute lymphocytic leukemia. Pacini DL, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1132–4 (21 ref.)

Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Richard DA, et al. **Pediatr Infect Dis J** 1997 Jun;16(6):572–8

Failure of short–term antimicrobial therapy in childhood brucellosis. Sánchez–Tamayo T, et al. **Pediatr Infect Dis J** 1997 Mar;16(3):323–4

Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Schaad UB, et al. **Pediatr Infect Dis J** 1997 Jan;16(1):106–11; discussion 123–6

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis [see comments] Frederiksen B, et al. **Pediatr Pulmonol** 1997 May;23(5):330–5. Comment in: Pediatr Pulmonol 1997 May;23(5):323–4. Comment in: Pediatr Pulmonol 1997 May;23(5):325–1.

Multiple brain abscesses in a 25–year–old patient with cystic

fibrosis, successfully treated with an anti-Pseudomonas plus anti-mycobacterial antibiotic regimen [letter] Wiersbitzky SK, et al. **Pediatr Pulmonol** 1997 May;23(5):389-91

Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury. Fabian TC, et al. **Pharmacotherapy** 1996 Sep-Oct;16(5):951-7

Mixed pulmonary infection with Nocardia, Candida, methicillin-resistant Staphylococcus aureus, and group D Streptococcus species. Vassallo J, et al. **Postgrad Med J** 1996 Nov;72(853):680-1

Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime. Ho A, et al. **Respiration** 1997;64(3):224-8

Efficacy of combined clarithromycin and sparfloxacin therapy in a patient with discitis: due to Mycobacterium xenopi [letter] Roche B, et al. **Rev Rhum Engl Ed** 1997 Jan;64(1):64-5

Helicobacter pylori eradication: therapy other than with bismuth or proton-pump inhibitors. Korman MG. **Scand J Gastroenterol Suppl** 1996;220:41-3 (25 ref.)

A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. Angerås MH, et al. **Scand J Infect Dis** 1996;28(5):513-8

Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group. Brismar B, et al. **Scand J Infect Dis** 1996;28(5):507-12

New developments in the treatment of nontuberculous mycobacterial (NTM) disease. Griffith DE, et al. **Semin Respir Infect** 1996 Dec;11(4):301-10 (54 ref.)

Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia [letter; comment] Lim TK. **Singapore Med J** 1997 Mar;38(3):139 . Comment on: Singapore Med J 1996 Jun;37(3):255-7.

Efficacy of twice weekly treatment for tuberculosis given under direct observation in Africa. Wilkinson D, et al. **Trans R Soc Trop Med Hyg** 1997 Jan-Feb;91(1):87-9

Influence of different protocols of antibiotic prophylaxis on endoluminal bacterial overgrowth and translocation following small-bowel or combined liver-small-bowel transplantation in a large-animal model. Privitera G, et al. **Transplant Proc** 1997 May;29(3):1826-8

Penicillin G and penicillin G-tinidazole treatment of experimentally induced summer mastitis--effect on elimination rates of bacteria and outcome of the disease. Hirvonen J, et al. **Vet Microbiol** 1994 Dec;42(4):307-15

Watery mouth disease in lambs: biochemical parameters before and after treatment. Scott PR, et al. **Vet Rec** 1996 Aug 3;139(5):117-8

[Mycobacterium avium infection in HIV-infected patients: epidemiology, diagnosis, prevention and treatment (letter; comment)] Blaauwwiekel EE, et al. **Ned Tijdschr Geneeskd** 1997 Mar 22;141(12):602-3. Comment on: Ned Tijdschr Geneeskd 1997 Jan 11;141(2):80-3. **(Dut)**

[Microscopic colitis: benefit of antibiotic treatment (letter)] Chapoutot C, et al. **Ann Med Interne (Paris)** 1996; 147(7):527-8 **(Fre)**

[Helicobacter pylori eradication: finally clarity (editorial)] Labenz J. **Leber Magen Darm** 1996 Nov;26(6):282-3 **(Ger)**

[Therapy of infections in patients with acute leukemia] Hiddemann W, et al. **Med Klin** 1997 Jul 15;92(7):406-9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of spontaneous bacterial peritonitis] Gräter H. **Schweiz Rundsch Med Prax** 1997 Jan 21;86(4):98-101 (Eng. Abstr.) **(Ger)**

[Clinical evaluation of sulbactam/cefoperazone for lower respiratory tract infections. Correlation between the efficacy of sulbactam/cefoperazone and beta-lactamase] Koga H, et al. **Jpn J Antibiot** 1996 Aug;49(8):800-7 (Eng. Abstr.) **(Jpn)**

[Optimal antibacterial chemotherapy for infectious diseases associated with hematological malignancies] Sakamoto M. **Kansenshogaku Zasshi** 1997 Jan;71(1):72-82 (Eng. Abstr.) **(Jpn)**

[The effects of preventive regimens for the prophylaxis of infection after bone marrow transplantation] Morishima Y, et al. **Rinsho Ketsueki** 1997 Feb;38(2):108-16 (Eng. Abstr.) **(Jpn)**

[Recovery rate in chemotherapy of glanders] Batmanov VP, et al. **Antibiot Khimioter** 1996 May;41(5):30-4 (Eng. Abstr.) **(Rus)**

[Piperacillin/tazobactam in the treatment of abdominal sepsis in patients with peritonitis] Gel'fand BR, et al. **Antibiot Khimioter** 1997;42(2):17-20 (Eng. Abstr.) **(Rus)**

[Use of piperacillin/tazobactam as empirical monotherapy in the treatment of bacterial infections in a resuscitation department] Iakovlev SV, et al. **Antibiot Khimioter** 1997; 42(2):33-7 (Eng. Abstr.) **(Rus)**

[A combined dosage form of piperacillin and tazobactam--tazocin] Iakovlev SV. **Antibiot Khimioter** 1997;42(2):5-16 (81 ref.) **(Rus)**

[Clinico-laboratory study of piperacillin/tazobactam in the treatment of patients with would infection] Iakovlev VP, et al. **Antibiot Khimioter** 1997;42(2):21-5 (Eng. Abstr.) **(Rus)**

[Effectiveness of piperacillin/tazobactam in the treatment of fever of unknown etiology in patients with granulocytopenia] Maschan AA, et al. **Antibiot Khimioter** 1997;42(2):38-40 (Eng. Abstr.) **(Rus)**

[Effect of piperacillin/tazobactam on the anti-infection resistance in patients with infections in the peritoneal cavity] Savitskaia KI, et al. **Antibiot Khimioter** 1997; 42(2):41-8 (Eng. Abstr.) **(Rus)**

[Use of piperacillin-tazobactam in abdominal surgery] Savov AM, et al. **Antibiot Khimioter** 1997;42(2):26-32 (Eng. Abstr.) **(Rus)**

[Antibiotic prophylaxis of postoperative infective complications in patients with rectal and colonic cancers] Dmitrieva NV, et al. **Khirurgiia (Mosk)** 1997;(6):56-61 (Eng. Abstr.) **(Rus)**

[Local treatment in anaerobic infections of soft tissues] Tamm TI. **Klin Khir** 1996;(5):5-7 **(Rus)**

[A trial of the clinical use of thienam in treating severe and life-threatening suppurative-septic complications] Grinev MV, et al. **Vestn Khir Im I I Grek** 1996;155(4):54-6 (Eng. Abstr.) **(Rus)**

[Our protocol in the treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis] Kostić S, et al. **Srp Arh Celok Lek** 1996;124 Suppl 1:149-51 (Eng. Abstr.) **(Scc)**

[Antibiotic therapy in the treatment of inflammatory diseases in the minor pelvis] Vasiljević M, et al. **Srp Arh Celok Lek** 1996 Jul-Aug;124(7-8):193-6 (Eng. Abstr.) **(Scc)**

[Severe orbital cellulitis: therapeutic results in 9 patients and review of the literature] Asensi V, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):250-4 (24 ref.) (Eng. Abstr.) **(Spa)**

[Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis] Colmenero JD, et al. **Enferm Infecc Microbiol Clin** 1997 Mar;15(3):129-33 (Eng. Abstr.) **(Spa)**

[Cotrimoxazole plus rifampicin in the treatment of staphylococcal osteoarticular infection] Sánchez C, et al. **Enferm Infecc Microbiol Clin** 1997 Jan;15(1):10-3 (Eng. Abstr.) **(Spa)**

[Serum bactericidal rate. Methodological proposal to predict the efficacy of antimicrobial therapy] Riera EB, et al. **Medicina (B Aires)** 1996;56(2):115-8 (Eng. Abstr.) **(Spa)**

[The use of thienam for the emergency antibacterial therapy of acute suppurative pyelonephritis] Pasiechnikov SP, et al. **Lik Sprava** 1997 Jan-Feb;(1):84-7 (Eng. Abstr.) **(Ukr)**

ANTIBIOTICS, GLYCOPEPTIDE

Control of vancomycin-resistant enterococcus [letter; comment] Lai KK. **Ann Intern Med** 1997 Jun 15; 126(12):1000-1. Comment on: Ann Intern Med 1996 Sep 15;125(6):448-56.

Colonization with vancomycin-resistant Enterococcus faecium: comparison of a long-term-care unit with an acute-care hospital. Bonilla HF, et al. **Infect Control Hosp Epidemiol** 1997 May;18(5):333-9

Bloodstream infection from a Port-A-Cath: successful treatment with the antibiotic lock technique [letter] Bregenzer T, et al. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):772

Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Rafferty ME, et al. **Infect Control Hosp Epidemiol** 1997 May; 18(5):342-4

Activity of disinfectants against vancomycin-resistant Enterococcus faecium [see comments] Saurina G, et al. **Infect Control Hosp Epidemiol** 1997 May;18(5):345-7. Comment in: Infect Control Hosp Epidemiol 1997 May;18(5):306-9.

Role of environmental contamination in the transmission of vancomycin-resistant enterococci [editorial; comment] Weber DJ, et al. **Infect Control Hosp Epidemiol** 1997 May; 18(5):306-9 (33 ref.). Comment on: Infect Control Hosp Epidemiol 1997 May;18(5):345-7.

Retention of the antibiotic teicoplanin on a hydromer-coated central venous catheter to prevent bacterial colonization in postoperative surgical patients. Bach A, et al. **Intensive Care Med** 1996 Oct;22(10):1066-9

Screening patients for glycopeptide-resistant enterococci [letter; comment] Chadwick PR, et al. **J Hosp Infect** 1996 Jul;33(3):226-8. Comment on: J Hosp Infect 1995 Jun;30 Suppl:483-93.

Report of a meeting on the epidemiology and control of glycopeptide-resistant enterococci. Chadwick PR, et al. **J Hosp Infect** 1996 Jun;33(2):83-92

Investigation of an outbreak of vancomycin-resistant Enterococcus faecium by random amplified polymorphic DNA (RAPD) assay. Issack MI, et al. **J Hosp Infect** 1996 Jul;33(3):191-200

Vancomycin-resistant gram-positive cocci: risk factors for faecal carriage. Rao GG, et al. **J Hosp Infect** 1997 Jan; 35(1):63-9

Vancomycin-resistant enterococci in vegetarians [letter; comment] van den Braak N, et al. **Lancet** 1997 Jul 12; 350(9071):146-7. Comment on: Lancet 1997 Apr 26;349(9060):1258.

Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases. Dever LL, et al. **Microb Drug Resist** 1996 Winter;2(4):407-13

[Effect of the kinetic selectivity of eremomycin adsorption on the concentration of components in chromatographic bands] Pisarev OA, et al. **Prikl Biokhim Mikrobiol** 1997 May-Jun;33(3):257-61 (Eng. Abstr.) **(Rus)**

[Vancomycin and teicoplanin: differential aspects] Cobo J. **Enferm Infecc Microbiol Clin** 1995 Dec;13(10):600-10 (112 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Preoperative vancomycin prophylaxis decreases incidence of postoperative hemodialysis vascular access infections [see comments] Zibari GB, et al. **Am J Kidney Dis** 1997 Sep; 30(3):343-8. Comment in: Am J Kidney Dis 1997 Sep;30(3):448.

Central venous line sepsis in the intensive care unit. A study comparing antibiotic coated catheters with plain catheters [published erratum appears in Anaesthesia 1997 Feb;52(2):192] Thornton J, et al. **Anaesthesia** 1996 Nov; 51(11):1018-20

Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. James JK, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):696-700

Postoperative contamination after using vancomycin and gentamicin during phacoemulsification. Ferro JF, et al. **Arch Ophthalmol** 1997 Feb;115(2):165-70

A simple method for administering vancomycin in the spinal cord injured population. Griver AR, et al. **Arch Phys Med Rehabil** 1997 May;78(5):459-62

Successful treatment of Stomatococcus mucilaginosus meningitis with intravenous vancomycin and intravenous ceftriaxone. Park MK, et al. **Clin Infect Dis** 1997 Feb; 24(2):278

Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Rodvold KA, et al. **Clin Pharmacokinet** 1997 Jul;33(1):32-51 (89 ref.)

Bolus or infusion teicoplanin for intravascular catheter associated infections in immunocompromised patients? Ley BE, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1091-5

Elution characteristics of vancomycin and tobramycin combined in acrylic bone-cement. Penner MJ, et al. **J Arthroplasty** 1996 Dec;11(8):939-44

A self-setting TTCP-DCPD apatite cement for release of vancomycin. Hamanishi C, et al. **J Biomed Mater Res** 1996 Fall;33(3):139-43

Encapsulation of vancomycin and gentamicin within cationic liposomes for inhibition of growth of Staphylococcus epidermidis. Sanderson NM, et al. **J Drug Target** 1996; 4(3):181-9

Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Barth RH, et al. **Kidney Int** 1996 Sep;50(3):929-36

Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Barriga FJ, et al. **Med Pediatr Oncol** 1997 Mar;28(3):196-200

Parameter estimation and dosage adjustment in the treatment with vancomycin of methicillin-resistant Staphylococcus aureus ocular infections. Saitoh A, et al. **Ophthalmologica** 1997;211(4):232-5

Teicoplanin pharmacokinetics in pediatric patients. Dufort G, et al. **Pediatr Infect Dis J** 1996 Jun;15(6):494-8

IV vancomycin-oral ciprofloxacin: a safe and efficient therapeutic protocol for CAPD peritonitis (preliminary report). Goffin E, et al. **Perit Dial Int** 1996 Mar-Apr; 16(2):174-7

Comparison of intraperitoneal administration of two preparations of vancomycin in causing chemical peritonitis [see comments] Wang AY, et al. **Perit Dial Int** 1996 Mar-Apr;16(2):172-4. Comment in: Perit Dial Int 1996 Mar-Apr;16(2):116-7.

Intravenous administration of vancomycin is ineffective against bacteremia following tooth extraction. Kaneko A, et al. **Tokai J Exp Clin Med** 1995 May;20(1):65-6

Ban on avoparcin [letter] Taylor DJ. **Vet Rec** 1997 Mar 29; 140(13):347

[Effect of imipenem/cilastatin combined with vancomycin for MRSA infection] Fukabori T, et al. **Jpn J Antibiot** 1997 Apr;50(4):299-305 (Eng. Abstr.) **(Jpn)**

[MRSA-induced prosthetic valve endocarditis complicated by synthetic graft infection that did not respond to repeated vancomycin administration but improved after surgery] Tanaka K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep;44(9):1767-71 (Eng. Abstr.) **(Jpn)**

[Treatment of peritonitis in patients on chronic peritoneal dialysis with a single dose of vancomycin] Radovanović Lj. **Srp Arh Celok Lek** 1996;124 Suppl 1:151-3 (Eng. Abstr.) **(Scc)**

[Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes] Figuera A, et al. **Rev Clin Esp** 1996 Aug; 196(8):515-22 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Vancomycin-induced Stevens-Johnson syndrome. Alexander II, et al. **Allergy Asthma Proc** 1996 Mar-Apr; 17(2):75-8

Minimizing the occurrence of red-man syndrome [letter] Szymusiak-Mutnick BA, et al.

Am J Health Syst Pharm 1996 Sep 1;53(17):2098

Diphenhydramine/vancomycin admixture for infusion phlebitis [letter] Fisher CH, et al. **Ann Pharmacother** 1996 Dec;30(12):1495

Vancomycin-induced thrombocytopenia: a challenge and rechallenge. Howard CE, et al. **Ann Pharmacother** 1997 Mar;31(3):315–8

Bullous drug eruption treated with amputation. A challenging case of vancomycin-induced linear IgA disease. Bitman LM, et al. **Arch Dermatol** 1996 Nov;132(11):1289–90

Suppression of progenitor cell growth by vancomycin following autologous stem cell transplantation. Meehan KR, et al. **Bone Marrow Transplant** 1997 May; 19(10):1029–32

Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Papanicolaou GA, et al. **Clin Infect Dis** 1996 Oct;23(4):760–6

Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Tornieporth NG, et al. **Clin Infect Dis** 1996 Oct;23(4):767–72

The comparative efficacy and safety of teicoplanin and vancomycin [letter; comment] Cobo J, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1113–4. Comment on: J Antimicrob Chemother 1996 Feb;37(2):209–22.

Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. Korman TM, et al. **J Antimicrob Chemother** 1997 Mar;39(3):371–81

Teicoplanin-induced thrombocytopenia [letter] Veldman RG, et al. **Nephron** 1996;73(4):721–2

Vancomycin revisited [editorial; comment] Golper TA, et al. **Perit Dial Int** 1996 Mar–Apr;16(2):116–7. Comment on: Perit Dial Int 1996 Mar–Apr;16(2):172–3.

A prospective study of vancomycin-(Vancoled-)induced chemical peritonitis in CAPD patients. Wong PN, et al. **Perit Dial Int** 1997 Mar–Apr;17(2):202–4

Thrombocytopenia induced by vancomycin-dependent platelet antibody. Mizon P, et al. **Vox Sang** 1997;73(1):49–51

[Risk of heavy precipitation of vancomycin in the presence of fluid gelatin in infusion tubes (letter)] Narbonne H, et al. **Therapie** 1996 Sep–Oct;51(5):599 **(Fre)**

ANTAGONISTS & INHIBITORS

Vancomycin-resistant enterococci. Murray BE. **Am J Med** 1997 Mar;102(3):284–93 (37 ref.)

BIOSYNTHESIS

Production of hybrid glycopeptide antibiotics in vitro and in Streptomyces toyocaensis. Solenberg PJ, et al. **Chem Biol** 1997 Mar;4(3):195–202

Novel teicoplanins by directed biosynthesis. Lazzarini A, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):180–3

BLOOD

Vancomycin removal by plasmapheresis [letter] Brophy DF, et al. **Ann Pharmacother** 1996 Sep;30(9):1038

Do low vancomycine serum levels predict failures of vancomycine therapy in neutropenic cancer patients? Netriová J, et al. **Bratisl Lek Listy** 1996 Nov;97(11):680–3

Topical application of eosin to burns produces interference in measurement of serum vancomycin by fluorescence polarization immunoassay. Leal T, et al. **Clin Chem** 1997 Jul;43(7):1238–40

Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Fernández de Gatta MD, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):332–40

Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin.lesassays@ukneqasaa.win-uk.net. White LO, et al. **J Antimicrob Chemother** 1997 Mar;39(3):355–61

The quality of clinical serum teicoplanin assays: an experimental European EQA distribution. White LO, et al. **J Antimicrob Chemother** 1996 Oct;38(4):701–6

Monitoring vancomycin serum concentrations in cancer patients undergoing cytotoxic chemotherapy [letter] Kremery V Jr, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):184

Effects of dialysis membrane on intradialytic vancomycin administration. Scott MK, et al. **Pharmacotherapy** 1997 Mar–Apr;17(2):256–62

Interference with vancomycin fluorescence polarisation immunoassay in a nonuraemic patient. Bowhay S, et al. **Ther Drug Monit** 1997 Feb;19(1):117–9

CHEMICAL SYNTHESIS

Semisynthetic glycopeptides: chemistry, structure-activity relationships and prospects. Ciabatti R, et al. **Farmaco** 1997 May;52(5):313–21

Synthesis and antibacterial activity of derivatives of the glycopeptide antibiotic A-40926 and its aglycone. Hermann R, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1236–48

Substitution of amino acids 1 and 3 in teicoplanin aglycon: synthesis and antibacterial activity of three first non-natural dalbaheptides. Malabarba A, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):70–81

A new type of chemical modification of glycopeptides antibiotics: aminomethylated derivatives of eremomycin and their antibacterial activity. Pavlov AY, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):509–13

Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance. Nicas TI, et al. **Trends Microbiol** 1997 Jun;5(6):240–9 (74 ref.)

[Non-natural aglycones of glycopeptide antibiotics of the vancomycin group. Synthesis and antibacterial activity.] Pavlov AIu, et al. **Bioorg Khim** 1997 May;23(5):410–21 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Stability of ceftazidime sodium and teicoplanin sodium in a peritoneal dialysis solution. Manduru M, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2731–4

Use of capillary electrophoresis to measure dimerization of glycopeptide antibiotics. LeTourneau DL, et al. **Anal Biochem** 1997 Mar 1;246(1):62–6

3D structure of ramoplanin: a potent inhibitor of bacterial cell wall synthesis. Kurz M, et al. **Biochemistry** 1996 Sep 24;35(38):12570–5

A modification of the N-terminal amino acid in the eremomycin aglycone. Miroshnikova OV, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1157–61

Isolation and structure determination of a novel complex of the teicoplanin family. Quarta C, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):644–50

Structural modifications of glycopeptide antibiotics. Malabarba A, et al. **Med Res Rev** 1997 Jan;17(1):69–137 (90 ref.)

The glycopeptide story--how to kill the deadly 'superbugs'. Williams DH. **Nat Prod Rep** 1996 Dec;13(6):469–77 (32 ref.)

Crystal structure of vancomycin. Schäfer M, et al. **Structure** 1996 Dec 15;4(12):1509–15

[Non-natural aglycones of glycopeptide antibiotics of the vancomycin group. Synthesis and antibacterial activity.] Pavlov AIu, et al. **Bioorg Khim** 1997 May;23(5):410–21 (Eng. Abstr.) **(Rus)**

ECONOMICS

Impact of glycopeptide therapy after hospital discharge on inpatient costs: a comparison of teicoplanin and vancomycin. Davey PG, et al. **J Antimicrob Chemother** 1996 Mar;37(3):623–33

ISOLATION & PURIFICATION

Purification of glycopeptide antibiotics by isoelectric focusing in multicompartment electrolyzers with immobiline membranes. Bossi A, et al. **Electrophoresis** 1996 Jul;17(7):1234–41

METABOLISM

Vancomycin-dependent Enterococci: a clinical and laboratory assessment. Fraimow HS, et al. **Adv Exp Med Biol** 1995;390:97–107

Production of bleomycin N-acetyltransferase in Escherichia coli and Streptomyces verticillus. Matsuo H, et al. **FEMS Microbiol Lett** 1997 Aug 1;153(1):83–8

High-performance liquid chromatographic determination of vancomycin in rabbit serum, vitreous and aqueous humour after intravitreal injection of the drug. Del Nozal MJ, et al. **J Chromatogr A** 1996 Mar 15;727(2):231–8

Renal excretion of vancomycin in rats with acute renal failure. Nakamura T, et al. **J Pharm Pharmacol** 1997 Feb; 49(2):154–7

Vancomycin-binding characteristics in patients with serious infections. Li L, et al. **Pharmacotherapy** 1996 Nov-Dec; 16(6):1024–9

PHARMACOKINETICS

Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Amaker RD, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1139–42

Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. James JK, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):696–700

Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues. Martin C, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1150–5

Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Pleasants RA, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):186–90

Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Rodvold KA, et al. **Clin Pharmacokinet** 1997 Jul;33(1):32–51 (89 ref.)

Pulmonary disposition of vancomycin in critically ill patients. Georges H, et al. **Eur J Clin Microbiol Infect Dis** 1997 May;16(5):385–8

Pharmacokinetics of vancomycin in patients with severely impaired renal function. Gonzalez-Martin G, et al. **Int J Clin Pharmacol Ther** 1996 Feb;34(2):71–5

Penetration of vancomycin into human lung tissue. Cruciani M, et al. **J Antimicrob Chemother** 1996 Nov;38(5):865–9

Teicoplanin concentrations in serum, pericardium, pericardial fluid and thoracic wall fat in patients undergoing cardio-pulmonary bypass surgery. Miglioli PA, et al. **J Antimicrob Chemother** 1997 Feb;39(2):229–33

The pharmacokinetics of teicoplanin in infants and children. Reed MD, et al. **J Antimicrob Chemother** 1997 Jun; 39(6):789–96

Pharmacokinetics of a single dose of teicoplanin in burn patients. Steer JA, et al. **J Antimicrob Chemother** 1996 Mar; 37(3):545–53

Anterior chamber concentrations of vancomycin in the irrigating solution at the end of cataract surgery. Adenis JP, et al. **J Cataract Refract Surg** 1997 Jan-Feb;23(1):111–4

Vancomycin cerebrospinal fluid concentrations after intravenous administration in premature infants. Reiter PD, et al. **J Perinatol** 1996 Sep-Oct;16(5):331–5 (14 ref.)

In-vivo clearance study of vancomycin in rats. Nakamura T, et al. **J Pharm Pharmacol** 1996 Nov;48(11):1197–200

Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Barth RH, et al. **Kidney Int** 1996 Sep;50(3):929–36

Teicoplanin pharmacokinetics in pediatric patients. Dufort G, et al. **Pediatr Infect Dis J** 1996 Jun;15(6):494–8

Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes. Zoer J, et al. **Pharm World Sci** 1997 Aug;19(4):191–6

Influence of biochemical parameters of liver function on vancomycin pharmacokinetics. Martí R, et al. **Pharmacol Toxicol** 1996 Aug;79(2):55–9

Clinical pharmacokinetic pearls: bolus versus infusion equations. Murphy JE, et al. **Pharmacotherapy** 1996 Jul-Aug;16(4):698–700

Special considerations for monitoring vancomycin concentrations in pediatric patients. Miles MV, et al. **Ther Drug Monit** 1997 Jun;19(3):265–70

Vancomycin serum concentrations in patients with renal dysfunction: a comparison of fluorescence polarization immunoassay and the enzyme-multiplied immunoassay technique. Peckman HJ, et al. **Ther Drug Monit** 1996 Dec; 18(6):647–53

Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes. Thalhammer F, et al. **Wien Klin Wochenschr** 1997 May 23;109(10):362–5

[Antibiotic release by tricalcic phosphate bone implantation. In vitro and in vivo pharmacokinetics of different galenic forms] Thomazeau H, et al. **Chirurgie** 1997 Jan; 121(9-10):663–6 (Eng. Abstr.) **(Fre)**

[Bayesian forecasting of plasma vancomycin concentration using time-dependent pharmacokinetics] Nakamura T, et al. **Yakugaku Zasshi** 1996 Nov;116(11):876–83 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetics of vancomycin in neonates of postconceptional age less than or equal to 32 weeks] Ginovart Galiana G, et al. **An Esp Pediatr** 1996 Aug; 45(2):167–71 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Glycopeptide resistance in gram-positive pathogens. Fraimow HS, et al. **Adv Exp Med Biol** 1995;390:81–95 (51 ref.)

Vancomycin-resistant Staphylococcus aureus [letter; comment] Lai KK. **Ann Intern Med** 1996 Nov 15; 125(10):859; discussion 859–60. Comment on: Ann Intern Med 1996 Feb 1;124(3):329–34.

Vancomycin-resistant Staphylococcus aureus [letter; comment] Lundstrom T, et al. **Ann Intern Med** 1996 Nov 15;125(10):858–9; discussion 859–60. Comment on: Ann Intern Med 1996 Feb 1;124(3):329–34.

Vancomycin-resistant Staphylococcus aureus [letter; comment] Olmsted RN, et al. **Ann Intern Med** 1996 Nov 15;125(10):858; discussion 859–60. Comment on: Ann Intern Med 1996 Feb 1;124(3):329–34.

Vancomycin-resistant Staphylococcus aureus [letter; comment] Vandenbroucke-Grauls CM. **Ann Intern Med** 1996 Nov 15;125(10):859; discussion 859–60. Comment on: Ann Intern Med 1996 Feb 1;124(3):329–34.

Treatment of vancomycin-resistant staphylococcal infections. Christensen KJ, et al. **Ann Pharmacother** 1996 Mar;30(3):288–90

Vancomycin-resistant enterococci [see comments] Gin AS, et al. **Ann Pharmacother** 1996 Jun;30(6):615–24 (82 ref.). Comment in: Ann Pharmacother 1996 Dec;30(12):1500.

Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin and PCR identification of genes within the VanA cluster. Aarestrup FM, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1938–40

Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic. Allen NE, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2356–62

Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues. Allen NE, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):66–71

Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis. Baptista M, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2291–5

Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Coque TM, et al. **Antimicrob Agents Chemother** 1996 Nov; 40(11):2605–9

Some repair-deficient mutants of Dictyostelium discoideum display enhanced susceptibilities to bleomycin. Deering RA, et al. **Antimicrob Agents Chemother** 1996 Feb;

40(2):464–7
Presence of vancomycin-resistant enterococci in farm and pet animals. Devriese LA, et al.
Antimicrob Agents Chemother 1996 Oct;40(10):2285–7
In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci [letter] Evans PA, et al.
Antimicrob Agents Chemother 1997 Jun;41(6):1406
Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci. Fasola E, et al. **Antimicrob Agents Chemother** 1996 Nov; 40(11):2661–3
Pharmacokinetic behavior of intraperitoneal teicoplanin during treatment of peritonitis complicating continuous ambulatory peritoneal dialysis [letter] Finch RC, et al.
Antimicrob Agents Chemother 1996 Aug;40(8):1971–2
Antimicrobial susceptibility patterns of some recently established coryneform bacteria. Funke G, et al.
Antimicrob Agents Chemother 1996 Dec;40(12):2874–8
Penicillin tolerance and modification of lipoteichoic acid associated with expression of vancomycin resistance in VanB-type Enterococcus faecium D366. Gutmann L, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):257–9
Heterogeneous expression of glycopeptide resistance in enterococci associated with transfer of vanB. Hayden MK, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):872–4
In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Jones RN, et al.
Antimicrob Agents Chemother 1997 Feb;41(2):488–93
The effect of vancomycin on the structure of vancomycin-susceptible and -resistant Enterococcus faecium strains [letter] Lorian V, et al.
Antimicrob Agents Chemother 1997 Jun;41(6):1410–1
Identification and characterization of IS1476, an insertion sequence-like element that disrupts VanY function in a vancomycin-resistant Enterococcus faecium strain. MacKinnon MG, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1805–7
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Mercier RC, et al.
Antimicrob Agents Chemother 1997 Jun;41(6):1307–12
Overproduction of a 37-kilodalton cytoplasmic protein homologous to NAD+-linked D-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus. Milewski WM, et al.
Antimicrob Agents Chemother 1996 Jan;40(1):166–72
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Nicas TI, et al. **Antimicrob Agents Chemother** 1996 Sep; 40(9):2194–9
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Palmer SM, et al.
Antimicrob Agents Chemother 1996 Mar;40(3):701–5
Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis. Poyart C, et al.
Antimicrob Agents Chemother 1997 Jan;41(1):24–9
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci [see comments] Schwalbe RS, et al.
Antimicrob Agents Chemother 1996 Oct;40(10):2416–9. Comment in: Antimicrob Agents Chemother 1997 Jun;41(6):1407–8.
Vancomycin dependence in a vanA-producing Enterococcus avium strain with a nonsense mutation in the natural D-Ala-D-Ala ligase gene [letter] Sifaoui F, et al.
Antimicrob Agents Chemother 1997 Jun;41(6):1409
MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Visalli MA, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):362–6
Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model. Whitman MS, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1526–30
Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains [letter; comment] Zelenitsky SA, et al.
Antimicrob Agents Chemother 1997 Jun;41(6):1407–8. Comment on: Antimicrob Agents Chemother 1996 Oct;40(10):2416–9.
Treatment of vancomycin-resistant Enterococcus faecium infections. Lai KK. **Arch Intern Med** 1996 Dec 9–23; 156(22):2579–84
Surgical Infection Society position on vancomycin-resistant Enterococcus. Davis JM, et al. **Arch Surg** 1996 Oct; 131(10):1061–8
Is it time to stop searching for MRSA? Constant vigilance is needed to halt the emergence of resistance to vancomycin [letter; comment] Loudon K, et al. **BMJ** 1997 Jul 5; 315(7099):59. Comment on: BMJ 1997 Mar 1;314(7081):665–6.
Vancomycin-resistant enterococci on a renal ward in an Ontario hospital. Lior L, et al. **Can Commun Dis Rep** 1996 Aug 1;22(15):125–8 **(Eng, Fre)**
Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Walsh CT, et al. **Chem Biol** 1996 Jan;3(1):21–8 (32 ref.)
The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci. Itokazu GS, et al.
Chemotherapy 1996 Jul–Aug;42(4):235–9
Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. Beezhold DW, et al. **Clin Infect Dis** 1997 Apr;24(4):704–6
Resistance to glycopeptides in enterococci. Leclercq R, et al. **Clin Infect Dis** 1997 Apr;24(4):545–54; quiz 555–6 (92 ref.)
Recurrent vancomycin-resistant Enterococcus faecium bacteremia in a leukemia patient who was persistently colonized with vancomycin-resistant enterococci for two years. Roghmann MC, et al. **Clin Infect Dis** 1997 Mar; 24(3):514–5
Effect of cefazolin and vancomycin on osteoblasts in vitro. Edin ML, et al. **Clin Orthop** 1996 Dec;(333):245–51
Vancomycin-resistant enterococci. Thakor K, et al.
Clin Podiatr Med Surg 1996 Oct;13(4):661–9 (43 ref.)
Vancomycin resistant enterococci in hospitals in the United Kingdom--1995. **Commun Dis Rep CDR Wkly** 1996 Aug 2;6(31):267
In vivo effect of teicoplanin and vancomycin upon haemolytic and bactericidal activity of serum against Staphylococcus aureus. Rodriguez AB, et al.
Comp Immunol Microbiol Infect Dis 1996 Sep;19(4):283–8
Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee [news] **Emerg Infect Dis** 1995 Apr–Jun;1(2):66
Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications. McDonald LC, et al. **Emerg Infect Dis** 1997 Jul–Sep; 3(3):311–7 (52 ref.)
Vancomycin-resistant Bacillus circulans carrying the vanA gene responsible for vancomycin resistance in enterococci [letter] Fontana R, et al.
Eur J Clin Microbiol Infect Dis 1997 Jun;16(6):473–4
A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus. Sieradzki K, et al.
FEMS Microbiol Lett 1996 Sep 1;142(2–3):161–6
Vancomycin down-regulates lipopolysaccharide-induced tumour necrosis factor alpha (TNF alpha) production and TNF alpha-mRNA accumulation in human blood monocytes. Siedlar M, et al. **Immunopharmacology** 1997 Jan;35(3):265–71
Susceptibility of vancomycin-resistant enterococci to environmental disinfectants. Anderson RL, et al.
Infect Control Hosp Epidemiol 1997 Mar;18(3):195–9
Synthesis and antibacterial activity of derivatives of the glycopeptide antibiotic A-40926 and its aglycone. Hermann R, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1236–48
A new type of chemical modification of glycopeptides antibiotics: aminomethylated derivatives of eremomycin and their antibacterial activity. Pavlov AY, et al.
J Antibiot (Tokyo) 1997 Jun;50(6):509–13
Glycopeptide-resistant enterococci isolated from uncooked meat [letter] Chadwick PR, et al.
J Antimicrob Chemother 1996 Nov;38(5):908–9
The treatment and control of vancomycin resistant enterococci. Fraise AP. **J Antimicrob Chemother** 1996 Nov; 38(5):753–6
The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. Larsson AJ, et al.
J Antimicrob Chemother 1996 Oct;38(4):589–97
Susceptibility of staphylococci to teicoplanin and vancomycin [letter] Murphy OM, et al.
J Antimicrob Chemother 1996 Aug;38(2):316–7
In-vitro study of the synergy between beta-lactam antibiotics and glycopeptides against enterococci. Ravizzola G, et al.
J Antimicrob Chemother 1997 Apr;39(4):461–70
In-vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative staphylococci. Raymond J, et al.
J Antimicrob Chemother 1996 Dec;38(6):1067–71
In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients. Rolston KV, et al.
J Antimicrob Chemother 1996 Aug;38(2):265–9
The effect of ramoplanin coating on colonization by Staphylococcus aureus of catheter segments implanted subcutaneously in mice. Romanò G, et al.
J Antimicrob Chemother 1997 May;39(5):659–61
Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. Shonekan D, et al.
J Antimicrob Chemother 1997 Mar;39(3):405–9
The VanS sensor negatively controls VanR-mediated transcriptional activation of glycopeptide resistance genes of Tn1546 and related elements in the absence of induction. Arthur M, et al. **J Bacteriol** 1997 Jan;179(1):97–106
Peptidoglycan structure of Lactobacillus casei, a species highly resistant to glycopeptide antibiotics. Billot-Klein D, et al. **J Bacteriol** 1997 Oct;179(19):6208–12
Knockout of the two ldh genes has a major impact on peptidoglycan precursor synthesis in Lactobacillus plantarum. Ferain T, et al. **J Bacteriol** 1996 Sep; 178(18):5431–7
Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. Sieradzki K, et al. **J Bacteriol** 1997 Apr; 179(8):2557–66
A vancomycin-inducible lacZ reporter system in Bacillus subtilis: induction by antibiotics that inhibit cell wall synthesis and by lysozyme. Ulijasz AT, et al.
J Bacteriol 1996 Nov;178(21):6305–9
Microfibrillar collagen (Avitene) and antibiotic-containing fibrin-glue after median sternotomy. Watanabe G, et al.
J Card Surg 1997 Mar–Apr;12(2):110–1
Effect of vancomycin and teicoplanin alone or in combination with fusidic acid or amikacin against methicillin-resistant staphylococci. Roussel-Delvallez M, et al. **J Chemother** 1997 Feb;9(1):5–8
Vancomycin susceptibility in enterococcal blood isolates in Italy: a multicenter retrospective analysis. Venditti M, et al. **J Chemother** 1996 Feb;8(1):33–6
Use of in-house studies of molecular epidemiology and full species identification for controlling spread of vancomycin-resistant Enterococcus faecalis isolates. Bodnar UR, et al. **J Clin Microbiol** 1996 Sep;34(9):2129–32
Emergence of teicoplanin-resistant coagulase-negative staphylococci. Cercenado E, et al. **J Clin Microbiol** 1996 Jul;34(7):1765–8
Clonal dissemination and colony morphotype variation of vancomycin-resistant Enterococcus faecium isolates in metropolitan Detroit, Michigan. Dunne WM Jr, et al.
J Clin Microbiol 1997 Feb;35(2):388–92
Discrepancies between results by E-test and standard microbroth dilution testing of Streptococcus pneumoniae for susceptibility to vancomycin. Hashemi FB, et al.
J Clin Microbiol 1996 Jun;34(6):1546–7
Revised approach for identification and detection of ampicillin and vancomycin resistance in Enterococcus species by using MicroScan panels. Iwen PC, et al.
J Clin Microbiol 1996 Jul;34(7):1779–83
Factors influencing the vitek gram-positive susceptibility system's detection of vanB-encoded vancomycin resistance among enterococci. Jett B, et al. **J Clin Microbiol** 1996 Mar;34(3):701–6
Comparison of inoculation methods for testing enterococci by using vancomycin screening agar. Jorgensen JH, et al.
J Clin Microbiol 1996 Nov;34(11):2841–2
Comparison of five selective media for identifying fecal carriage of vancomycin-resistant enterococci. Landman D, et al. **J Clin Microbiol** 1996 Mar;34(3):751–2
Vancomycin-resistant Aureobacterium species cellulitis and bacteremia in a patient with acute myelogenous leukemia. Nolte FS, et al. **J Clin Microbiol** 1996 Aug;34(8):1992–4
Emergence and dissemination of a highly vancomycin-resistant vanA strain of Enterococcus faecium at a large teaching hospital. Pegues DA, et al.
J Clin Microbiol 1997 Jun;35(6):1565–70
Molecular epidemiology and antibiotic susceptibility of enterococci in Cincinnati, Ohio: a prospective citywide survey. Perlada DE, et al. **J Clin Microbiol** 1997 Sep; 35(9):2342–7
Detection of vancomycin-resistant enterococci in fecal samples by PCR. Satake S, et al. **J Clin Microbiol** 1997 Sep;35(9):2325–30
Evaluation of commercial vancomycin agar screen plates for detection of vancomycin-resistant enterococci. Van Horn KG, et al. **J Clin Microbiol** 1996 Aug;34(8):2042–4
Epidemiology of an outbreak due to glycopeptide-resistant Enterococcus faecium on a leukaemia unit. Chadwick PR, et al. **J Hosp Infect** 1996 Nov;34(3):171–82
Mechanisms of glycopeptide resistance in enterococci. Arthur M, et al. **J Infect** 1996 Jan;32(1):11–6 (20 ref.)
Selection of glycopeptide-resistant mutants of VanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis. Aslangul E, et al. **J Infect Dis** 1997 Mar; 175(3):598–605
Vancomycin-resistant enterococci: clinical, microbiologic, and epidemiologic features. Noskin GA.
J Lab Clin Med 1997 Jul;130(1):14–20 (40 ref.)
From the Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. **JAMA** 1997 Aug 13; 278(6):461–2
From the Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. **JAMA** 1997 Sep 17; 278(11):891–2
From the Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. **JAMA** 1997 Oct 8; 278(14):1145–6
Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Bonten MJ, et al. **Lancet** 1996 Dec 14;348(9042):1615–9
Vancomycin-dependent Enterococcus faecalis [letter] [see comments] Farrag N, et al. **Lancet** 1996 Dec 7; 348(9041):1581–2. Comment in: Lancet 1997 Feb 8;349(9049):429. Comment in: Lancet 1997 Feb 8;349(9049):429–30. Comment in: Lancet 1997 Feb 8;349(9049):430.
Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci [letter] Jumaa PA, et al.
Lancet 1997 Sep 6;350(9079):738–9
Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Michel M, et al. **Lancet** 1997 Jun 28;

349(9069):1901–6 (63 ref.)
Vancomycin-dependent enterococcus [letter; comment] Rossney AS, et al. **Lancet** 1997 Feb 8;349(9049):430. Comment on: Lancet 1996 Dec 7;348(9041):1581–2.
VRE and meat [letter; comment] Schouten MA, et al. **Lancet** 1997 Apr 26;349(9060):1258. Comment on: Lancet 1997 Jul 12;350(9071):146–7.
Vancomycin-resistant enterococci in cats and dogs [letter] van Belkun A, et al. **Lancet** 1996 Oct 12;348(9033):1038–9
Vancomycin-dependent enterococcus [letter; comment] Wilks M. **Lancet** 1997 Feb 8;349(9049):429. Comment on: Lancet 1996 Dec 7;348(9041):1581–2.
Occurrence of glycopeptide resistance among Enterococcus faecium isolates from conventional and ecological poultry farms. Aarestrup FM. **Microb Drug Resist** 1995 Fall; 1(3):255–7
Genotypic characterization of a nosocomial outbreak of VanA Enterococcus faecalis. Biavasco F, et al. **Microb Drug Resist** 1996 Summer;2(2):231–7
Peptidoglycan composition of vancomycin-resistant Enterococcus faecium. de Jonge BL, et al. **Microb Drug Resist** 1996 Summer;2(2):225–9
Persistence of vancomycin-resistant Enterococcus faecium gastrointestinal tract colonization in antibiotic-treated mice. Dever LL, et al. **Microb Drug Resist** 1996 Winter; 2(4):415–21
Genetics of glycopeptide resistance in enterococci. Evers S, et al. **Microb Drug Resist** 1996 Summer;2(2):219–23 (40 ref.)
An electron microscopic study of clinical and laboratory-derived strains of teicoplanin-resistant Staphylococcus haemolyticus. Giovanetti E, et al. **Microb Drug Resist** 1996 Summer;2(2):239–43
Induction of VanA vancomycin resistance genes in Enterococcus faecalis: use of a promoter fusion to evaluate glycopeptide and nonglycopeptide induction signals. Grissom-Arnold J, et al. **Microb Drug Resist** 1997 Spring; 3(1):53–64
Conjugative mobilization of a vancomycin resistance plasmid by a putative Enterococcus faecium sex pheromone response plasmid. Heaton MP, et al. **Microb Drug Resist** 1995 Summer;1(2):177–83
Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community. Klare I, et al. **Microb Drug Resist** 1995 Fall;1(3):265–72
In vitro susceptibility of Streptococcus pneumoniae strains to nine beta-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin. Marton A, et al. **Microb Drug Resist** 1996 Fall;2(3):361–9
Multiplicity of genetic backgrounds among vancomycin-resistant Enterococcus faecium isolates recovered from an outbreak in a New York City hospital. Mato R, et al. **Microb Drug Resist** 1996 Fall;2(3):309–17
Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Mekonen ET, et al. **Microb Drug Resist** 1995 Fall; 1(3):249–53
In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium. Ristow TA, et al. **Microb Drug Resist** 1995 Winter; 1(4):335–9
Glycopeptide-resistant Enterococcus faecium outside Hospitals: a commentary. Witte W, et al. **Microb Drug Resist** 1995 Fall;1(3):259–63
Plasmid-mediated vanB glycopeptide resistance in enterococci. Woodford N, et al. **Microb Drug Resist** 1995 Fall;1(3):235–40
Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996. **MMWR Morb Mortal Wkly Rep** 1997 Jul 11;46(27):624–6
Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. **MMWR Morb Mortal Wkly Rep** 1997 Jul 11;46(27):626–8, 635
Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. **MMWR Morb Mortal Wkly Rep** 1997 Aug 22;46(33):765–6
Update: Staphylococcus aureus with reduced susceptibility to vancomycin — United States, 1997. **MMWR Morb Mortal Wkly Rep** 1997 Sep 5;46(35):813–5
Vancomycin resistant enterococci--a threat to the nephrologist on the horizon? Glycopeptide-resistant enterococci and ICDC-recommendations for a limited use of glycopeptides. Lameire N, et al. **Nephrol Dial Transplant** 1996 Dec;11(12):2402–6 (32 ref.)
Evaluation of the in vitro activity of seven selected antimicrobial agents to be used for the isolation of human intestinal spirochaetes. Calderaro A, et al. **New Microbiol** 1997 Jan;20(1):35–45
Vancomycin and amikacin in cell cultures for virus isolation. Lo JY, et al. **Pathology** 1996 Nov;28(4):366–9
When normal flora turn nasty [comment] Goldmann DA. **Pediatr Infect Dis J** 1996 Oct;15(10):845–7. Comment on: Pediatr Infect Dis J 1996 Oct;15(10):848–54.
Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection [see comments] Henning KJ, et al. **Pediatr Infect Dis J** 1996 Oct;15(10):848–54. Comment in: Pediatr Infect Dis J 1996 Oct;15(10):845–7.
Vancomycin-resistant enterococci. Palmer SM, et al. **Pharmacotherapy** 1996 Sep-Oct;16(5):819–29 (72 ref.)
Effects of feed antibiotic avoparcine on organ morphology in broiler chickens. Krinke AL, et al. **Poult Sci** 1996 Jun; 75(6):705–10
Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms. Bager F, et al. **Prev Vet Med** 1997 Jul;31(1-2):95–112
Intrahospital spread of vancomycin-resistant Enterococcus faecium in Sweden. Torell E, et al. **Scand J Infect Dis** 1997;29(3):259–63
Antibacterial activity of teicoplanin against Clostridium difficile. Wongwanich S, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):606–9
Glycopeptide resistance in enterococci. Arthur M, et al. **Trends Microbiol** 1996 Oct;4(10):401–7 (41 ref.)
[Vancomycin-resistant enterococci . Work Group Hospital Infection Epidemiology] Endtz HP, et al. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):108–9 (Eng. Abstr.) **(Dut)**
[Molecular and epidemiologic aspects of the resistance to antibiotics: example of glycopeptides on enterococci] Courvalin P. **C R Seances Soc Biol Fil** 1996;190(4):467–9 (6 ref.) (Eng. Abstr.) **(Fre)**
[Combination effect between panipenem and vancomycin on highly methicillin-resistant Staphylococcus aureus] Fukuoka T, et al. **Jpn J Antibiot** 1997 Apr;50(4):411–9 (Eng. Abstr.) **(Jpn)**
[Isolation rate of Enterococcus spp. from surgical infections and their susceptibilities] Shinagawa N, et al. **Jpn J Antibiot** 1997 May;50(5):460–73 (Eng. Abstr.) **(Jpn)**
[Combination effect of vancomycin and cefpirome against methicillin-resistant Staphylococcus aureus in vitro—antimicrobial activities in postantibiotic phase] Hasegawa H, et al. **Kansenshogaku Zasshi** 1996 Feb; 70(2):151–60 (Eng. Abstr.) **(Jpn)**
[Regulation mechanism of glycopeptide resistance expression] Ohno A, et al. **Nippon Rinsho** 1997 May; 55(5):1206–12 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Laboratory-evaluation of antimicrobial susceptibility testings to detect vancomycin-resistant enterococci] Yamane N, et al. **Rinsho Byori** 1997 Apr;45(4):381–90 (Eng. Abstr.) **(Jpn)**
[Evaluation of susceptibility of methicillin resistant Staphylococcus aureus strains to vancomycin] Młynarczyk G, et al. **Med Dosw Mikrobiol** 1995;47(3-4):133–9 (Eng. Abstr.) **(Pol)**
[Study of the susceptibility of Staphylococcus sp. and Enterococcus sp. to teicoplanin and vancomycin] Mimica I, et al. **Rev Assoc Med Bras** 1996 Jul-Sep;42(3):147–50 (Eng. Abstr.) **(Por)**
[Resistance to glycopeptide antibiotics] Trenin AS. **Antibiot Khimioter** 1996 May;41(5):49–60 (78 ref.) **(Rus)**
[Non-natural aglycones of glycopeptide antibiotics of the vancomycin group. Synthesis and antibacterial activity.] Pavlov AIu, et al. **Bioorg Khim** 1997 May;23(5):410–21 (Eng. Abstr.) **(Rus)**
[Synergic effect of a teicoplanin and cefpirome combination with aminoglucosides on enterococci. Therapeutic importance] Hoyos López A, et al. **An Med Interna** 1995 Aug;12(8):374–6 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Intramedullary, antibiotic-loaded cemented, massive allografts for skeletal reconstruction. 26 cases compared with 19 uncemented allografts. Ozaki T, et al. **Acta Orthop Scand** 1997 Aug;68(4):387–91
Teicoplanin pharmacology in prophylaxis for coagulase-negative staphylococcal sepsis of very low birthweight infants [letter] Möller JC, et al. **Acta Paediatr** 1996 May;85(5):638–9
Managing methicillin-resistant Staphylococcus aureus in hospital: the balance of risk. Stone SP. **Age Ageing** 1997 May;26(3):165–8 (45 ref.)
Treatment recommendations for invasive pneumococcal infections updated; resistance is behind change [news] **Am J Health Syst Pharm** 1997 Apr 1;54(7):747–8
Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium. Belliveau PP, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1570–5
Order form for restricting vancomycin prescribing [letter] Burke CE, et al. **Am J Health Syst Pharm** 1997 Aug 15; 54(16):1893, 1897
Vancomycin resistance: when failure becomes an opportunity for leadership. Edmiston CE Jr. **Ann Pharmacother** 1996 Jun;30(6):680–2
Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Morgan AS, et al. **Ann Pharmacother** 1997 Sep;31(9):970–3
Comment: Vancomycin-resistant enterococci [letter; comment] Rapp RP. **Ann Pharmacother** 1996 Dec; 30(12):1500. Comment on: Ann Pharmacother 1996 Jun;30(6):615–24.
Local application of vancomycin for prophylaxis of graft infection: release of vancomycin from antibiotic-bonded Dacron grafts, toxicity in endothelial cell culture, and efficacy against graft infection in an animal model. Muhl E, et al. **Ann Vasc Surg** 1996 May;10(3):244–53
Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae [letter] Bhattacharya S. **Antimicrob Agents Chemother** 1996 Mar;40(3):827–8
In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Kazragis RJ, et al. **Antimicrob Agents Chemother** 1996 Nov; 40(11):2632–6
Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. Anglim AM, et al. **Arch Intern Med** 1997 May 26;157(10):1132–6
Enterococcal bacteremia in the surgical intensive care unit. Does vancomycin resistance affect mortality? The Johns Hopkins SICU Study Group. Mainous MR, et al. **Arch Surg** 1997 Jan;132(1):76–81
Vancomycin resistant Staphylococcus aureus reported [news] Josefson D. **BMJ** 1997 Sep 20;315(7110):700
Randomized placebo-controlled trial of teicoplanin in the antibiotic prophylaxis of infection following manipulation of burn wounds. Steer JA, et al. **Br J Surg** 1997 Jun; 84(6):848–53
Vancomycin resistance and mortality associated with enterococcal bacteremia [letter; comment] Lautenbach E, et al. **Clin Infect Dis** 1997 Mar;24(3):530–1. Comment on: Clin Infect Dis 1996 Apr;22(4):663–70.
Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Papanicolaou GA, et al. **Clin Infect Dis** 1996 Oct;23(4):760–6
Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Tornieporth NG, et al. **Clin Infect Dis** 1996 Oct;23(4):767–72
Use of vancomycin in dialysis patients [letter] Saghafi D. **Clin Nephrol** 1996 May;45(5):366
Leuconostoc bacteremia after liver transplantation: another cause of vancomycin resistant gram-positive infection. Espinoza R, et al. **Clin Transplant** 1997 Aug;11(4):322–4
Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin. Dompeling EC, et al. **Eur J Cancer** 1996 Jul;32A(8):1332–9
A review of teicoplanin in the treatment of serious neonatal infections. Fanos V, et al. **Eur J Pediatr** 1997 Jun; 156(6):423–7 (33 ref.)
Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines [letter; comment] Beidas S, et al. **Infect Control Hosp Epidemiol** 1996 Dec;17(12):773–4. Comment on: Infect Control Hosp Epidemiol 1996 Jun;17(6):356–9.
Vancomycin-resistant enterococcus. Detection, epidemiology, and control measures. Boyce JM. **Infect Dis Clin North Am** 1997 Jun;11(2):367–84 (95 ref.)
Dosage adjustment of antiinfective therapy in patients with renal impairment. Eckhardt A, et al. **Int J Clin Pharmacol Ther** 1997 Mar;35(3):99–102
Corynebacterium minutissimum endophthalmitis: management with antibiotic irrigation of the capsular bag. Arsan AK, et al. **Int Ophthalmol** 1995–96;19(5):313–6
Experimental lobar pneumonia due to penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in immunocompetent and neutropenic rats: efficacy of penicillin and teicoplanin treatment. Candiani G, et al. **J Antimicrob Chemother** 1997 Feb;39(2):199–207
The comparative efficacy and safety of teicoplanin and vancomycin [letter; comment] Cobo J, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1113–4. Comment on: J Antimicrob Chemother 1996 Feb;37(2):209–22.
Impact of glycopeptide therapy after hospital discharge on inpatient costs: a comparison of teicoplanin and vancomycin. Davey PG, et al. **J Antimicrob Chemother** 1996 Mar;37(3):623–33
Teicoplanin versus flucloxacillin in the treatment of infection following burns. Steer JA, et al. **J Antimicrob Chemother** 1997 Mar;39(3):383–92
Vancomycin prophylaxis and intraocular contamination during cataract surgery. Feys J, et al. **J Cataract Refract Surg** 1997 Jul-Aug;23(6):894–7
Retrospective assessment of antibiotic and tourniquet use in an ambulatory surgery center. Reyes C, et al. **J Foot Ankle Surg** 1997 Jan-Feb;36(1):55–62
Breakthrough nosocomial bacteraemia due to teicoplanin-resistant Staphylococcus haemolyticus in five patients with acute leukaemia [letter] Spanik S, et al. **J Hosp Infect** 1997 Feb;35(2):155–9
Importance of using relapse studies or tests for detection of antibiotic resistance before considering that a treatment for multidrug-resistant enterococcal experimental endocarditis is effective [letter; comment] Caron F. **J Infect Dis** 1997 Jan;175(1):232–3. Comment on: J Infect Dis 1996 Apr;173(4):909–13.
Treatment of experimental methicillin-resistant Staphylococcus epidermidis endophthalmitis with intravitreal vancomycin and intravitreal dexamethasone. Smith MA, et al. **J Infect Dis** 1997 Feb;175(2):462–6
Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. Nachman SA, et al. **Microb Drug Resist** 1995 Spring;1(1):95–6
Vascular infections: exceeding the threshold. Cox TR. **Mil Med** 1995 Dec;160(12):609–11
Development of listeriosis during vancomycin therapy in a neutropenic patient. Arsene O, et al. **Scand J Infect Dis**

1996;28(4):415–6
First documented isolation of vancomycin–resistant Enterococcus faecium in Sweden. Melhus A, et al. **Scand J Infect Dis** 1996;28(2):191–3 (23 ref.)
Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance. Nicas TI, et al. **Trends Microbiol** 1997 Jun;5(6):240–9 (74 ref.)
Avoparcin ban [letter] Howarth F, et al. **Vet Rec** 1997 Jan 25;140(4):103–4
[Clinical pilot study on repeated use of heparin, vancomycin, colimycine locked flush solution for central intravenous implanted catheter in oncology] Guillet P, et al. **Pathol Biol (Paris)** 1997 Jun;45(6):506–13 (Eng. Abstr.) **(Fre)**
[Severe methicillin–resistant Staphylococcus aureus infections. Emergence of resistance to fusidic acid or fosfomycin during treatment with continuous infusion of vancomycin] Georges B, et al. **Presse Med** 1997 Apr 5; 26(11):502–6 (Eng. Abstr.) **(Fre)**
[Vancomycin resistant enterococci in Austria (see comments)] Allerberger F, et al. **Wien Klin Wochenschr** 1997 May 9;109(9):312–20 (Eng. Abstr.). Comment in: Wien Klin Wochenschr 1997 May 9;109(9):293–300. **(Ger)**
[Glycopeptide resistant enterococci. Occurrence, distribution, resistance transmission, significance (editorial; comment)] Klare I, et al. **Wien Klin Wochenschr** 1997 May 9;109(9):293–300 (58 ref.). Comment on: Wien Klin Wochenschr 1997 May 9;109(9):312–20. **(Ger)**
[The use of teicoplanin for Gram–positive infections in patients with kidney transplantation] Jákics J, et al. **Orv Hetil** 1996 Jun 23;137(25):1355–8 (Eng. Abstr.) **(Hun)**
[Teichoplanin: a clinical study of treatment of serious infections in hospitalized patients] Di Rosa R, et al. **Riv Eur Sci Med Farmacol** 1995 Nov–Dec;17(6):231–5 (Eng. Abstr.) **(Ita)**
[Clinical studies on vancomycin in the treatment of MRSA infection] Shimizu K, et al. **Jpn J Antibiot** 1996 Aug; 49(8):782–99 (Eng. Abstr.) **(Jpn)**

TOXICITY

Enhanced production of an EGF–like growth factor by parenchymal macrophages following bleomycin–induced pulmonary injury. Temelkovski J, et al. **Exp Lung Res** 1997 Sep–Oct;23(5):377–91
Prevention of bleomycin–induced lung injury in rats by keratinocyte growth factor. Deterding RR, et al. **Proc Assoc Am Physicians** 1997 May;109(3):254–68
Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats. Fauconneau B, et al. **Ren Fail** 1997 Jan;19(1):15–22

ANTIBIOTICS, GLYCOSIDE see **ANTIBIOTICS, AMINOGLYCOSIDE**

ANTIBIOTICS, LACTAM

Assessment of the palatability of beta–lactamase–resistant antibiotics in children. Matsui D, et al. **Arch Pediatr Adolesc Med** 1997 Jun;151(6):599–602
Evolution and dissemination of beta–lactamases accelerated by generations of beta–lactam antibiotics. Medeiros AA. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S19–45 (243 ref.)

ADMINISTRATION & DOSAGE

A study on prophylactic antibiotics in cesarean sections––is it worthwhile? Yip SK, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):547–9
Assessment of two penicillins plus beta–lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections [published erratum appears in Antimicrob Agents Chemother 1996 Oct;40(10):2441] Fournier JL, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):325–30
Efficacy of twice–daily dosing of amoxycillin/clavulanate in acute otitis media in children. Behre U, et al. **Infection** 1997 May–Jun;25(3):163–6
Is continuous infusion of beta–lactam antibiotics worthwhile?––efficacy and pharmacokinetic considerations. Mouton JW, et al. **J Antimicrob Chemother** 1996 Jul;38(1):5–15 (44 ref.)
Subtleties of antibiotic dosages––do doses and intervals make a difference in the critically ill? [editorial] Lipman J, et al. **S Afr J Surg** 1996 Nov;34(4):160–2
Galenic formulations and Helicobacter pylori eradication [letter; comment] Boixeda D, et al. **Scand J Gastroenterol** 1996 Jul;31(7):736. Comment on: Scand J Gastroenterol 1996 Jan;31(1):49–53.
[In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model] Elkhaïli H, et al. **Pathol Biol (Paris)** 1997 May; 45(5):347–56 (Eng. Abstr.) **(Fre)**
[Clinical study of tazobactam/piperacillin in obstetrics and gynecological infections] Chimura T, et al. **Jpn J Antibiot** 1996 Aug;49(8):808–12 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Hypoprothrombinemia associated with cefmetazole. Breen GA, et al. **Ann Pharmacother** 1997 Feb;31(2):180–4
Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta–lactam antibiotics. Nix DE, et al. **Ann Pharmacother** 1997 Jun; 31(6):696–703
Acute liver injury associated with amoxicillin–clavulanic acid [letter; comment] Fletcher AP, et al. **Arch Intern Med** 1997 Feb 10;157(3):358. Comment on: Arch Intern Med 1996 Jun 24;156(12):1327–32.
Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Carmeli Y, et al. **Clin Infect Dis** 1997 Jun;24(6):1131–4
Penicillin allergy. **Drug Ther Bull** 1996 Nov;34(11):87–8 (17 ref.)
Intrahepatic cholestasis without hepatitis induced by amoxycillin/clavulanic acid. Pedro–Botet J, et al. **J Clin Gastroenterol** 1996 Sep;23(2):137–8
Booster responses in the study of allergic reactions to beta–lactam antibiotics. Lopez–Serrano MC, et al. **J Investig Allergol Clin Immunol** 1996 Jan–Feb;6(1):30–5
Adverse hepatic events associated with drug therapy [letter] Hewitt J, et al. **Med J Aust** 1996 Sep 16;165(6):347, 350
Prospective study of toxigenic Clostridium difficile in children given amoxicillin/clavulanate for otitis media. Mitchell DK, et al. **Pediatr Infect Dis J** 1996 Jun; 15(6):514–9
[Lyell syndrome after amoxicillin administration in a 2 year old child] Surbled M, et al. **Ann Fr Anesth Reanim** 1996; 15(7):1095–8 (Eng. Abstr.) **(Fre)**
[A case of severe odontogenic infection with allergic skin reaction for beta–lactam antibiotics] Kuriyama T, et al. **Kansenshogaku Zasshi** 1997 May;71(5):459–63 (Eng. Abstr.) **(Jpn)**
[Cholestatic hepatitis caused by amoxycillin–clavulanic acid. Report of a new case] Bustamante Balén M, et al. **Gastroenterol Hepatol** 1997 Apr;20(4):187–9 (14 ref.) (Eng. Abstr.) **(Spa)**
[Hepatotoxicity caused by amoxicillin, clavulanic acid or both? (letter) (see comments)] Caballero Plasencia AM, et al. **Gastroenterol Hepatol** 1997 Jan;20(1):45–6. Comment in: Gastroenterol Hepatol 1997 Jun–Jul;20(6):337–8. **(Spa)**
[Hepatotoxicity caused by amoxicillin–clavulanic acid (letter; comment)] Reñe JM, et al. **Gastroenterol Hepatol** 1997 Jun–Jul;20(6):337–8. Comment on: Gastroenterol Hepatol 1997 Jan;20(1):45–6. **(Spa)**

ANALYSIS

Beta–lactam stability in frozen microdilution PASCO MIC panels using strains with known resistance mechanisms as biosensors. Valdezate S, et al. **Diagn Microbiol Infect Dis** 1996 Oct;26(2):53–61
Development of indicators for cephamycin bioassay. Rani S, et al. **Indian J Exp Biol** 1996 Aug;34(8):816–7
Determination of amoxicillin in catfish and salmon tissues by liquid chromatography with precolumn formaldehyde derivatization. Ang CYW, et al. **J AOAC Int** 1996 Mar–Apr;79(2):389–96
Rapid method for the determination of ampicillin residues in animal muscle tissues by high–performance liquid chromatography with fluorescence detection. Luo W, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):401–7
[Determination of moxalactam, aztreonam and imipenem by the perchloric hydroxylamine method] Pajchel G, et al. **Acta Pol Pharm** 1992;49(1–2):7–10 (Eng. Abstr.) **(Pol)**

BIOSYNTHESIS

Characterisation and identification of broad spectrum antibiotic producing Streptomyces hygroscopicus D 1.5. Chakraborty D, et al. **Hindustan Antibiot Bull** 1995 Feb–Nov;37(1–4):37–43
Effect of water activity on production of beta–lactam antibiotics by Streptomyces clavuligerus in submerged culture. Cochet N, et al. **J Appl Bacteriol** 1996 Mar; 80(3):333–7
Chemistry and biosynthesis of clavulanic acid and other clavams. Baggaley KH, et al. **Nat Prod Rep** 1997 Aug; 14(4):309–33 (229 ref.)

CHEMICAL SYNTHESIS

Synthesis and biological properties of a new series of anti–MRSA beta–lactams; 2–(thiazol–2–ylthio)carbapenems. Shinagawa H, et al. **Bioorg Med Chem** 1997 Mar;5(3):601–21
5,6–Cis–penems: broad–spectrum anti–methicillin–resistant Staphylococcus aureus beta–lactam antibiotics. Ishiguro M, et al. **J Med Chem** 1997 Jul 4;40(14):2126–32

CHEMISTRY

Mass spectrometric studies on the inhibition of TEM–2 beta–lactamase by clavulanic acid derivatives. Brown RP, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):184–5
Thiomarinols D, E, F and G, new hybrid antimicrobial antibiotics produced by a marine bacterium; isolation, structure, and antimicrobial activity [letter] Shiozawa H, et al. **J Antibiot (Tokyo)** 1997 May;50(5):449–52
GT32–B new 20–membered macrocyclic lactam antibiotic [letter] [published erratum appears in J Antibiot (Tokyo) 1997 Apr;50(4):C–1] Takahashi I, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):186–8
Chemistry and biosynthesis of clavulanic acid and other clavams. Baggaley KH, et al. **Nat Prod Rep** 1997 Aug; 14(4):309–33 (229 ref.)
Disastrous reflavorig of antibiotics [letter] Perrin JH. **Pediatrics** 1997 Sep;100(3 Pt 1):420
[The effect of the chemical character of some penicillins on the stability of beta–lactams and their molecules] Płotkowiak ZM. **Acta Pol Pharm** 1992;49(1–2):25–7 **(Pol)**

ECONOMICS

Cost–effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb–threatening foot infections in diabetic patients. McKinnon PS, et al. **Clin Infect Dis** 1997 Jan;24(1):57–63

IMMUNOLOGY

Drug allergy to the beta–lactam antibiotics clavulanic acid and amoxicillin. Cahen YD, et al. **Allergy** 1997 Jan; 52(1):117–8
Specific IgE determination in the diagnosis of beta–lactam allergy. Sanz ML, et al. **J Investig Allergol Clin Immunol** 1996 Mar–Apr;6(2):89–93

ISOLATION & PURIFICATION

Maltophilin: a new antifungal compound produced by Stenotrophomonas maltophilia R3089. Jakobi M, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1101–4
Thiomarinols D, E, F and G, new hybrid antimicrobial antibiotics produced by a marine bacterium; isolation, structure, and antimicrobial activity [letter] Shiozawa H, et al. **J Antibiot (Tokyo)** 1997 May;50(5):449–52

METABOLISM

Specific interaction between beta–lactams and soluble penicillin–binding protein 2a from methicillin–resistant Staphylococcus aureus: development of a chromogenic assay. Roychoudhury S, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2075–9
Mathematical model of beta–lactam penetration into a biofilm of Pseudomonas aeruginosa while undergoing simultaneous inactivation by released beta–lactamases. Dibdin GH, et al. **J Antimicrob Chemother** 1996 Nov;38(5):757–69
Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase–I [letter] Mori M, et al. **J Antimicrob Chemother** 1996 May;37(5):1034–6
Advances in determination of antibiotic residues. Moats WA. **J AOAC Int** 1997 Jan–Feb;80(1):1–4
Liquid chromatographic analysis of penem antibiotic FCE22101 in biological fluids with a liquid–liquid extraction procedure. Matsuoka M, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25;685(2):273–9
Detection of extended–spectrum beta–lactamase (ESBL)–producing strains by the Etest ESBL screen. Cormican MG, et al. **J Clin Microbiol** 1996 Aug; 34(8):1880–4

PHARMACOKINETICS

Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori–positive healthy subjects. Pommerien W, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):295–301
Efficacy of ampicillin–sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions. Alexov M, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2468–77
Effects of nifedipine and diltiazem on pharmacokinetics of cefpodoxime following its oral administration. Deslandes A, et al. **Antimicrob Agents Chemother** 1996 Dec; 40(12):2879–81
Altered permeability and beta–lactam resistance in a mutant of Mycobacterium smegmatis. Mukhopadhyay S, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1721–4
Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin–resistant Staphylococcus aureus. Sundelof JG, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):795–8
A study to determine the pharmacokinetics and inflammatory fluid penetration of two doses of a solid formulation of the hexetil prodrug of a trinem, sanfetrinem (GV 104326). Wise R, et al. **Antimicrob Agents Chemother** 1997 Aug; 41(8):1761–4
Pharmacokinetics of amoxicillin/clavulanic acid combination and of both drugs alone after intravenous administration to goats. Escudero E, et al. **Br Vet J** 1996 Sep;152(5):551–9
Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery. Condon RE, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S181–3
Tissue penetration of Meropenem in patients undergoing gynecologic surgery. Gall S, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S178–80
Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Moon YS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S249–55 (44 ref.)
Pharmacokinetics of meropenem in patients with liver disease. Thyrum PT, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S184–90
Efficacy of beta–lactam antibiotics: integration of

pharmacokinetics and pharmacodynamics. Cars O. **Diagn Microbiol Infect Dis** 1997 Jan–Feb;27(1–2):29–33 (16 ref.)

Pharmacokinetics of ceftriaxone in healthy horses. Ringger NC, et al. **Equine Vet J** 1996 Nov;28(6):476–9

Cephaloridine in vitro toxicity and accumulation in renal slices from normoglycemic and diabetic rats. Valentovic M, et al. **Fundam Appl Toxicol** 1997 Aug;38(2):184–90

Penetration of ampicillin and sulbactam into human epididymis and testis. Klotz T, et al. **Infection** 1996 Sep–Oct;24(5):372–4

Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Drusano GL, et al. **J Chemother** 1997 May;9 Suppl 3:38–44 (11 ref.)

Restricted intestinal absorption of some beta-lactam antibiotics by an energy-dependent efflux system in rat intestine. Saitoh H, et al. **Pharm Res** 1997 May;14(5):645–9

Single-dose pharmacokinetics of ampicillin/sulbactam (2:1) combination after intravenous administration to sheep and goats. Carceles CM, et al. **Res Vet Sci** 1996 Sep;61(2):143–6

Bioavailability of pivampicillin and ampicillin trihydrate administered as an oral paste in horses. Ensink JM, et al. **Vet Q** 1996;18 Suppl 2:S117–20

Some pharmacokinetic parameters of ampicillin/sulbactam combination after intravenous and intramuscular administration to goats. Espuny A, et al. **Vet Q** 1996 Dec; 18(4):136–40

Sanfetrinem and sanfetrinem-cilexetil: disposition in rat and dog. Iavarone L, et al. **Xenobiotica** 1997 Jul;27(7):693–709

PHARMACOLOGY

Evolution and resistance expression of MRSA. Evaluation of beta-lactam antibiotics against a set of isogenic strains with different types of phenotypic expression. Asada K, et al. **Acta Biochim Pol** 1995;42(4):517–24

In vitro susceptibilities of 176 clinical isolates of Streptococcus pneumoniae to 11 beta-lactams, erythromycin, and tetracycline. Vanhoof R, et al. **Acta Clin Belg** 1996;51(6):377–85

Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects. Pommerien W, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):295–301

Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Pitout JD, et al. **Am J Med** 1997 Jul;103(1):51–9 (27 ref.)

In vitro assessment of the effect of clavulanic acid at concentrations achieved in human serum on the bactericidal activity of amoxicillin at physiological concentrations against Staphylococcus aureus: implications for dosage regimens. Aguilar L, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1403–5

Multiple antibiotic resistance in Stenotrophomonas maltophilia. Alonso A, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1140–2

In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim–sulfamethoxazole against nonfermentative gram-negative bacilli. Fass RJ, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1412–8

Simultaneous pharmacodynamic analysis of the lag and bactericidal phases exhibited by beta-lactams against Escherichia coli. Li RC. **Antimicrob Agents Chemother** 1996 Oct;40(10):2306–10

Susceptibility to beta-lactam antibiotics of Pseudomonas aeruginosa overproducing penicillin-binding protein 3. Liao X, et al. **Antimicrob Agents Chemother** 1997 May; 41(5):1158–61

Survey and molecular genetics of SHV beta-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12. Nüesch-Inderbinen MT, et al. **Antimicrob Agents Chemother** 1997 May;41(5):943–9

Beta-lactamases and detection of beta-lactam resistance in Enterobacter spp. Pitout JD, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):35–9

Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Rasheed JK, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):647–53

Abnormal physiological properties and altered cell wall composition in Streptococcus pneumoniae grown in the presence of clavulanic acid. Severin A, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):504–10

In vitro selection of one-step mutants of Streptococcus pneumoniae resistant to different oral beta-lactam antibiotics is associated with alterations of PBP2x. Sifaoui F, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):152–6

In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms. Singh KV, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2142–6

Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model. Soriano F, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2686–90

MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents. Spangler SK, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):148–55

Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors. Tajada P, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1924–5

Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate. Thorburn CE, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2796–801

Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods. Visalli MA, et al. **Antimicrob Agents Chemother** 1997 Apr; 41(4):767–70

In vitro activity of the tricyclic beta-lactam GV104326. Wise R, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1248–53

Cell elongation and septation are two mutually exclusive processes in Escherichia coli. Canepari P, et al. **Arch Microbiol** 1997 Aug;168(2):152–9

Bacterial filamentation of Yersinia pestis by beta-lactam antibiotics in experimentally infected mice. Davis KJ, et al. **Arch Pathol Lab Med** 1997 Aug;121(8):865–8

Synergistic effect of polyoxotungstates in combination with beta-lactam antibiotics on antibacterial activity against methicillin-resistant Staphylococcus aureus. Yamase T, et al. **Biol Pharm Bull** 1996 Mar;19(3):459–65

Molecular evolution of bacterial beta-lactam resistance. Knox JR, et al. **Chem Biol** 1996 Nov;3(11):937–47

Activities of piperacillin, ceftazidime, cefepime and cefpirome against Pseudomonas aeruginosa strains with intrinsic ticarcillin resistance. Bert F, et al. **Chemotherapy** 1996 Nov–Dec;42(6):426–31

In vitro activity of BAY 12–8039, a new 8-methoxyquinolone. Dalhoff A, et al. **Chemotherapy** 1996 Nov–Dec;42(6):410–25

Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors. Qadri SM, et al. **Chemotherapy** 1996 Sep–Oct; 42(5):334–42

The pharmacology of meropenem, a new carbapenem antibiotic. Craig WA. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S266–75 (62 ref.)

Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Iaconis JP, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S191–6

Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Lipsky BA, et al. **Clin Infect Dis** 1997 Apr;24(4):643–8

Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers. Pitkin DH, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S238–48

Effect of pre-operative antibiotic treatment on the bacterial content of the tonsil. Cafferkey MT, et al. **Clin Otolaryngol** 1993 Dec;18(6):512–6

Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Cars O. **Diagn Microbiol Infect Dis** 1997 Jan–Feb;27(1–2):29–33 (16 ref.)

In vitro activity of sanfetrinem (GV104326), a new trinem antimicrobial agent, versus Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Doern GV, et al. **Diagn Microbiol Infect Dis** 1996 Sep;26(1):39–42

Nontypeable Haemophilus influenzae susceptibility: effect of inoculum size and beta-lactamase production. Gould JM, et al. **Diagn Microbiol Infect Dis** 1996 Oct;26(2):95–8

Evaluation of Haemophilus influenzae isolates with elevated MICs to amoxicillin/clavulanic acid. Jacobs MR, et al. **Diagn Microbiol Infect Dis** 1997 Jul;28(3):105–12

Comparative activity of twelve beta-lactam drugs tested against penicillin-resistant Streptococcus pneumoniae from five medical centers: effects of serum protein and capsular material on potency and spectrum as measured by reference tests. Johnson DM, et al. **Diagn Microbiol Infect Dis** 1996 Jul;25(3):137–41

Imipenem and meropenem activity against mecA-positive homogeneously and heterogeneously oxacillin-resistant and mecA-negative oxacillin-borderline-susceptible staphylococci. Knapp CC, et al. **Diagn Microbiol Infect Dis** 1997 Jun;28(2):81–6

Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli. Pohlman JK, et al. **Diagn Microbiol Infect Dis** 1996 Sep;26(1):29–33

Potentiation of human polymorphonuclear leukocyte phagocytosis and intracellular bactericidal activity by amoxycillin/clavulanic acid. Cuffini AM, et al. **Drugs Exp Clin Res** 1996;22(1):9–15

Urinary tract infections caused by beta-lactam-sensitive Corynebacterium urealyticum strains [letter] Zapardiel J, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb;16(2):174–6

Contribution of beta-lactamase production to the resistance of mycobacteria to beta-lactam antibiotics. Quinting B, et al. **FEBS Lett** 1997 Apr 14;406(3):275–8

Inhibition of Pseudomonas aeruginosa alginate expression by subinhibitory concentrations of antibiotics. Majtán V, et al. **Folia Microbiol (Praha)** 1996;41(1):61–4

Evidence of interhospital transmission of extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in the United States, 1986 to 1993. The National Nosocomial Infections Surveillance System. Monnet DL, et al. **Infect Control Hosp Epidemiol** 1997 Jul;18(7):492–8

Supernatants from Staphylococcus epidermidis grown in the presence of different antibiotics induce differential release of tumor necrosis factor alpha from human monocytes. Mattsson E, et al. **Infect Immun** 1996 Oct;64(10):4351–5

Mass spectrometric studies on the inhibition of TEM-2 beta-lactamase by clavulanic acid derivatives. Brown RP, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):184–5

Modification of natural immunity in mice by imipenem/cilastatin. Ortega E, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):502–8

SYN-1012: a new beta-lactamase inhibitor of penem skeleton. Phillips OA, et al. **J Antibiot (Tokyo)** 1997 Apr; 50(4):350–6

GT32-B new 20-membered macrocyclic lactam antibiotic [letter] [published erratum appears in J Antibiot (Tokyo) 1997 Apr;50(4):C-1] Takahashi I, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):186–8

Susceptibility testing of fastidious organisms [letter] Andrews JM, et al. **J Antimicrob Chemother** 1997 Mar;39(3):436–7

Pharmacodynamic properties of faropenem demonstrated by studies of time-kill kinetics and postantibiotic effect. Boswell FJ, et al. **J Antimicrob Chemother** 1997 Mar; 39(3):415–8

Acidic pH and beta-lactam activity [letter; comment] Corkill JE, et al. **J Antimicrob Chemother** 1996 Jul;38(1):151. Comment on: J Antimicrob Chemother 1995 Sep;36(3):513–9.

Potential effects of amoxycillin/clavulanic acid and ticarcillin/clavulanic acid on human granulocyte activity: a comparative study. Cuffini AM, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1013–22

Mechanisms responsible for reduced susceptibility to imipenem in Bacteroides fragilis. Edwards R, et al. **J Antimicrob Chemother** 1996 Dec;38(6):941–51

Changes in beta-lactam antibiotic susceptibility and beta-lactamase production of clinical isolates of Bacteroides and Prevotella species over a 9 year period [letter] Edwards R, et al. **J Antimicrob Chemother** 1996 Mar;37(3):636–8

Changes in the surface carbohydrate composition and exposure of anionic groups caused by beta-lactam antibiotics in streptococci. Figueiredo AM, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1031–6

Novel transferable beta-lactam resistance with cephalosporinase characteristics in Salmonella enteritidis. Gaillot O, et al. **J Antimicrob Chemother** 1997 Jan; 39(1):85–7

In-vitro microbiological assessment of a new penem, Men 10700. Hamilton-Miller JM, et al. **J Antimicrob Chemother** 1997 May;39(5):575–84

Resistance to imipenem in Pseudomonas aeruginosa. King A, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1037–41

In-vitro pharmacodynamic simulation of clavulanic acid concentrations: effect on Staphylococcus aureus and Haemophilus influenzae beta-lactamase activity [letter] Martin M, et al. **J Antimicrob Chemother** 1997 Feb; 39(2):290–2

In-vitro study of the synergy between beta-lactam antibiotics and glycopeptides against enterococci. Ravizzola G, et al. **J Antimicrob Chemother** 1997 Apr;39(4):461–70

Evaluation of the resistance induction in enteric flora in children caused by oral ampicillin plus sulbactam. Soylu A, et al. **J Antimicrob Chemother** 1997 Jun;39(6):833–5

Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other beta-lactams. Spangler SK, et al. **J Antimicrob Chemother** 1997 Feb; 39(2):141–8

Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. Craiu A, et al. **J Biol Chem** 1997 May 16;272(20):13437–45

Susceptibility of macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy. Cellesi C, et al. **J Chemother** 1996 Jun;8(3):188–92

Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Drusano GL, et al. **J Chemother** 1997 May;9 Suppl 3:38–44 (11 ref.)

Carbapenem-induced resistance to beta-lactams in Pseudomonas aeruginosa. Giacometti A, et al. **J Chemother** 1995 Nov;7 Suppl 4:76–7

Beta-lactam resistance in anaerobic bacteria: a review. Hedberg M, et al. **J Chemother** 1996 Feb;8(1):3–16 (109 ref.)

The influence of cefuroxime and ampicillin on uterus contractility. Kouvelas D, et al. **J Chemother** 1995 Nov; 7 Suppl 4:99–100

In vitro bactericidal effect of a beta-lactam+aminoglycoside combination against multiresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Roussel-Delvallez M, et al. **J Chemother** 1996 Oct;8(5):365–8

Trends in the activity of macrolide and beta-lactam antibiotics and resistance development. Alexander Project Group. Schito GC, et al. **J Chemother** 1997 May;9 Suppl 3:18–28

Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks. Zerva L, et al. **J Clin Microbiol** 1996 Aug; 34(8):1970–4

Molecular diversity and evolution of blaTEM genes encoding beta-lactamases resistant to clavulanic acid in clinical E.

coli. Caniça MM, et al. **J Mol Evol** 1997 Jan;44(1):57–65

Spread of beta–lactam–resistant Pseudomonas aeruginosa in a cystic fibrosis unit [letter; comment] Denton M, et al. **Lancet** 1996 Dec 7;348(9041):1596–7. Comment on: Lancet 1996 Sep 7;348(9028):639–42.

Effects of beta–lactam antibiotics on intestinal microflora and bile acid metabolism in rats. Hashimoto S, et al. **Lipids** 1996 Jun;31(6):601–9

Emergence of resistance to beta–lactam agents in enterobacteriaceae species with group I beta–lactamases in Spain. Colom K, et al. **Microb Drug Resist** 1996 Fall; 2(3):353–9

In vitro susceptibility of Streptococcus pneumoniae strains to nine beta–lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin. Marton A, et al. **Microb Drug Resist** 1996 Fall;2(3):361–9

Resistance determinants for beta–lactam antibiotics in laboratory mutants of Streptococcus pneumoniae that are involved in genetic competence. Zähner D, et al. **Microb Drug Resist** 1996 Summer;2(2):187–91

Comparative susceptibility of clinical isolates producing extended spectrum beta–lactamases to ceftibuten: effect of large inocula. Medeiros AA, et al. **Pediatr Infect Dis J** 1997 Mar;16(3 Suppl):S49–55

Are all beta–lactams created equal? Livermore DM. **Scand J Infect Dis Suppl** 1996;101:33–43 (46 ref.)

[In vitro antibacterial activity of cefoperazone–sulbactam] Zhang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct; 34(10):676–9 (Eng. Abstr.) **(Chi)**

[Resistance to amoxicillin and amoxicillin–clavulanic acid combination of 231 clinical strains of Escherichia coli, isolated in 1992 at the Cochin Hospital] Bémer–Melchior P, et al. **Pathol Biol (Paris)** 1995 Nov;43(9):760–5 (Eng. Abstr.) **(Fre)**

[Pseudomonas aeruginosa: bactericidal activity on various beta–lactam resistance phenotypes of 8 antibiotics and 7 combinations] Dubrous P, et al. **Pathol Biol (Paris)** 1997 May;45(5):433–7 (Eng. Abstr.) **(Fre)**

[Routine detection of beta–lactamases TEM resistant to inhibitors (IRT) and oxacillinases (OXA) in Escherichia coli.] Libert JM, et al. **Pathol Biol (Paris)** 1997 Jan; 45(1):34–40 (Eng. Abstr.) **(Fre)**

[Comparative in vitro activity of cefepime: multicenter study in Aquitaine] Quentin C, et al. **Pathol Biol (Paris)** 1997 May;45(5):363–70 (Eng. Abstr.) **(Fre)**

[Tricentric study of the sensitivity of Pseudomonas aeruginosa serotyping to beta–lactams and aminoglycosides] Vachée A, et al. **Pathol Biol (Paris)** 1997 May;45(5):357–62 (Eng. Abstr.) **(Fre)**

[Penicillin––binding protein: the target for beta–lactam antibiotics, beta–lactamases and their inhibitors] Lessel J. **Pharm Unserer Zeit** 1996 Jan;25(1):17–27 (24 ref.) **(Ger)**

[Antibacterial activities of combination uses of isepamicin and beta–lactams in vitro against clinically isolated strains. Part 2. The results against enterobacteriaceae] Deguchi K, et al. **Jpn J Antibiot** 1996 Mar;49(3):279–88 (Eng. Abstr.) **(Jpn)**

[Possibility of drug design of beta–lactam antibiotics effective for multiresistant gram–positive pathogens] Okonogi K, et al. **Nippon Rinsho** 1997 May;55(5):1261–5 (11 ref.) (Eng. Abstr.) **(Jpn)**

[beta–Lactam antibiotics––mechanisms of action and resistance in Enterobacteriaceae] Laušová A, et al. **Epidemiol Mikrobiol Imunol** 1997 May;46(2):73–80 (70 ref.) (Eng. Abstr.) **(Slo)**

[Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin–sulbactam and amoxicillin–clavulanic acid] Villar HE, et al. **Enferm Infecc Microbiol Clin** 1996 May;14(5):308–10 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

The use of antibiotics to prevent serious sequelae in children at risk for occult bacteremia: a meta–analysis. Bulloch B, et al. **Acad Emerg Med** 1997 Jul;4(7):679–83

Role of newer broad–spectrum beta–lactam and fluoroquinolone antibiotics in children. Bonafede ME, et al. **Adv Pediatr Infect Dis** 1996;12:71–108 (124 ref.)

Dose–response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. Pommerien W, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):303–8

PCR–based detection of bacterial DNA after antimicrobial treatment is indicative of persistent, viable bacteria in the chinchilla model of otitis media. Post JC, et al. **Am J Otolaryngol** 1996 Mar–Apr;17(2):106–11

Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Barlan IB, et al. **Ann Allergy Asthma Immunol** 1997 Jun;78(6):598–601

Single dose of betamethasone in combined medical treatment of secretory otitis media. Hemlin C, et al. **Ann Otol Rhinol Laryngol** 1997 May;106(5):359–63

A practical look at the clinical usefulness of the beta–lactam/beta–lactamase inhibitor combinations. Hart SM, et al. **Ann Pharmacother** 1996 Oct;30(10):1130–40 (79 ref.)

Monotherapy versus beta–lactam–aminoglycoside combination treatment for gram–negative bacteremia: a prospective, observational study. Leibovici L, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1127–33

Comparison of efficacy of sulbactam: ampicillin to ampicillin and saline for treatment of experimentally induced Escherichia coli diarrhea in neonatal calves. Lofstedt J, et al. **Can J Vet Res** 1996 Jul;60(3):210–5

Use of meropenem in the treatment of serious infections in children: review of the current literature. Arrieta A. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S207–12 (51 ref.)

The challenge of penicillin–resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Bradley JS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S213–21 (58 ref.)

Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group. Calver AD, et al. **Clin Infect Dis** 1997 Apr;24(4):570–4

Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches. Hathorn JW, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S256–65 (72 ref.)

A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. Hemsell DL, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S222–30

Cost–effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb–threatening foot infections in diabetic patients. McKinnon PS, et al. **Clin Infect Dis** 1997 Jan;24(1):57–63

Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra–abdominal infections. Wilson SE. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S197–206

Effect of pre–operative antibiotic treatment on the bacterial content of the tonsil. Cafferkey MT, et al. **Clin Otolaryngol** 1993 Dec;18(6):512–6

Necrotizing external otitis: aminoglycoside and beta–lactam antibiotic treatment combined with surgical treatment. Pedersen HB, et al. **Clin Otolaryngol** 1997 Jun;22(3):271–4

The antibiotic treatment of acute otitis media and sinusitis in children. Cohen R. **Diagn Microbiol Infect Dis** 1997 Jan–Feb;27(1–2):35–9 (19 ref.)

Cefdinir versus amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children. Adler M, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):214–9

Risk factors leading to clinical failure in the treatment of intra–abdominal or skin/soft tissue infections. Falagas ME, et al. **Eur J Clin Microbiol Infect Dis** 1996 Dec; 15(12):913–21

Leprosy resistant to multi–drug–therapy (MDT) successfully treated with ampicillin–sulbactam combination––(a case report). Mehta VR. **Indian J Med Sci** 1996 Nov; 50(11):305–7

A multi–centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. Mehtar S, et al. **J Antimicrob Chemother** 1997 May;39(5):631–8

Importance of using relapse studies or tests for detection of antibiotic resistance before considering that a treatment for multidrug–resistant enterococcal experimental endocarditis is effective [letter; comment] Caron F. **J Infect Dis** 1997 Jan;175(1):232–3. Comment on: J Infect Dis 1996 Apr;173(4):909–13.

Ampicillin/sulbactam vs. clindamycin/gentamicin in the treatment of postpartum endometritis. Gall S, et al. **J Reprod Med** 1996 Aug;41(8):575–80

Antimicrobial therapy for sinusitis. Poole MD. **Otolaryngol Clin North Am** 1997 Jun;30(3):331–9 (25 ref.)

Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Block SL. **Pediatr Infect Dis J** 1997 Apr;16(4):449–56 (39 ref.)

Monthly changes in the rate of recovery of penicillin–resistant organisms from children. Brook I, et al. **Pediatr Infect Dis J** 1997 Feb;16(2):255–7

Prospective study of toxigenic Clostridium difficile in children given amoxicillin/clavulanate for otitis media. Mitchell DK, et al. **Pediatr Infect Dis J** 1996 Jun; 15(6):514–9

Comparison of ceftriaxone and trimethoprim–sulfamethoxazole for acute otitis media. Greater Boston Otitis Media Study Group. Barnett ED, et al. **Pediatrics** 1997 Jan;99(1):23–8

A hospital outbreak of high–level beta–lactam–resistant Enterobacter spp.: association more with ampicillin and cephalosporin therapy than with nosocomial transmission. Walder M, et al. **Scand J Infect Dis** 1996;28(3):293–6

Cefuroxime compared to amoxicillin–clavulanic acid in the treatment of community–acquired pneumonia [see comments] Oh HM, et al. **Singapore Med J** 1996 Jun; 37(3):255–7. Comment in: Singapore Med J 1997 Mar;38(3):139.

A survey of horses with acute diarrhoea: diagnosis, assessment of the prognosis, and comparison of two antibiotic therapies. van Duijkeren E, et al. **Vet Q** 1996 Dec;18(4):153–6

[A randomized controlled clinical trial of sulperazone as compared with cefotaxime in the treatment of bacterial infections] Li J, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):680–2 (Eng. Abstr.) **(Chi)**

[Current problems in the treatment of bacterial meningitis] Principi N. **Minerva Pediatr** 1996 Dec;48(12):551–69 (Eng. Abstr.) **(Ita)**

[Streptococcus pneumoniae and beta–lactam antibiotic agents] Ranin L, et al. **Srp Arh Celok Lek** 1996 Jan–Feb; 124(1–2):18–23 (Eng. Abstr.) **(Scc)**

[Meningitis due to beta–lactase resistant pneumococcus: presentation of two cases] Beltrán de Heredia Balsategui P, et al. **An Esp Pediatr** 1997 Feb;46(2):199–201 **(Spa)**

TOXICITY

Cephaloridine in vitro toxicity and accumulation in renal slices from normoglycemic and diabetic rats. Valentovic M, et al. **Fundam Appl Toxicol** 1997 Aug;38(2):184–90

Spasmogenic action of beta–lactam antibiotics on the gastrointestinal tract of experimental animals. Janković SM, et al. **Indian J Med Res** 1996 Sep;104:216–22

[Neurotoxicity of carbapenem compounds and other beta–lactam antibiotics] Sunagawa M, et al. **Jpn J Antibiot** 1996 Jan;49(1):1–16 (54 ref.) (Eng. Abstr.) **(Jpn)**

ANTIBIOTICS, MACROLIDE

Dirithromycin: a new macrolide. Wintermeyer SM, et al. **Ann Pharmacother** 1996 Oct;30(10):1141–9 (68 ref.)

Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Burkhart GA, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):93–6

Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Powers JL. **Pediatr Infect Dis J** 1996 Sep;15(9 Suppl):S30–7

A clinical isolate of Neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin. Ehret JM, et al. **Sex Transm Dis** 1996 Jul–Aug;23(4):270–2

[History and renewal of macrolides] Bryskier A. **Presse Med** 1997 Jun 28;26(22):1063–9 (20 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Axon AT, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):81–7

One–week low–dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. Labenz J, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):89–93

Efficacy and tolerability of a one–week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. Labenz J, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):95–100

H. pylori treatment recognized by FDA [news] **Am J Health Syst Pharm** 1996 Jun 1;53(11):1229

Short–course, low–dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Sundar S, et al. **Ann Intern Med** 1997 Jul 15; 127(2):133–7

Toleration of intravenous azithromycin. Luke DR, et al. **Ann Pharmacother** 1997 Sep;31(9):965–9

Comparative study of once–weekly azithromycin and once–daily amoxicillin treatments in prevention of recurrent acute otitis media in children. Marchisio P, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2732–6

Controlled pilot study of rapid amphotericin B infusions. Dele Davies H, et al. **Arch Dis Child** 1997 Feb;76(2):165–6

Helicobacter pylori: new developments and treatments. Veldhuyzen van Zanten SJ, et al. **Can Med Assoc J** 1997 Jun 1;156(11):1565–74 (112 ref.)

Multicenter randomized study of two once daily regimens in the initial management of community–acquired respiratory tract infections in 163 children: azithromycin versus ceftibuten. Galova K, et al. **Chemotherapy** 1996 May–Jun;42(3):231–4

Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. Lo WC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Mar;59(3):171–6

Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Gupta S, et al. **Circulation** 1997 Jul 15; 96(2):404–7

Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori–associated gastric disorders. Markham A, et al. **Drugs** 1996 Jan; 51(1):161–78 (67 ref.)

Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Heath CH, et al. **Eur J Clin Microbiol Infect Dis** 1996 Apr;15(4):286–90

Regression of duodenal mucosa–associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. Nagashima R, et al. **Gastroenterology** 1996 Dec; 111(6):1674–8

Azithromycin in gonorrhoea [letter] Handsfield HH. **Int J STD AIDS** 1997 Jul;8(7):472–3

Azithromycin in non–gonococcal urethritis. Charoenwatanachokchai A, et al. **J Med Assoc Thai** 1997 Jul;80(7):440–5

Treatment of nontuberculous mycobacterial lymphadenitis with clarithromycin plus rifabutin. Berger C, et al. **J Pediatr** 1996 Mar;128(3):383–6

Treatment of visceral leishmaniasis in children with liposomal amphotericin B. di Martino L, et al. **J Pediatr** 1997 Aug; 131(2):271–7

ANTIBIOTICS, MACROLIDE

Topical delivery of erythromycin from various formulations: an in vivo hairless mouse study. Jayaraman SC, et al. **J Pharm Sci** 1996 Oct;85(10):1082–4

Azithromycin: only once a day. Burke SM. **MCN Am J Matern Child Nurs** 1996 May–Jun;21(3):162

Efficacy of three–day azithromycin vs. ten–day penicillin V in the treatment of streptococcal pharyngitis [letter; comment] Pacifico L, et al. **Pediatr Infect Dis J** 1997 May; 16(5):542. Comment on: Pediatr Infect Dis J 1996 Sep;15(9):791–5.

Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections. Halperin SA, et al. **Pediatrics** 1997 Jul;100(1):65–71

Liposomal formulations of cytotoxic drugs. Janknegt R. **Support Care Cancer** 1996 Jul;4(4):298–304 (31 ref.)

Effects of long–term low–dose macrolide administration on neutrophil recruitment and IL–8 in the nasal discharge of chronic sinusitis patients. Suzuki H, et al. **Tohoku J Exp Med** 1997 Jun;182(2):115–24

Treatment of gingival hyperplasia secondary to cyclosporine by the new macrolide azithromycin. Puig JM, et al. **Transplant Proc** 1997 Aug;29(5):2379–80

Outbreak of clinical mastitis in dairy cows following 'blitz' therapy [letter] Boyer PJ. **Vet Rec** 1997 Jul 12;141(2):55

[Antibiotics—how do I administer them to my child? (news)] Schweiger A. **Fortschr Med** 1997 Feb 28;115(6):20, 22–3 **(Ger)**

[Effectiveness of short–term triple therapy for healing Helicobacter pylori infection in ulcer disease] Kobler E, et al. **Schweiz Med Wochenschr Suppl** 1997;89:14S–16S (Eng. Abstr.) **(Ger)**

[Prophylactic use of roxithromycin in dental procedures] Gáspár L, et al. **Fogorv Sz** 1997 Aug;90(8):241–5 (Eng. Abstr.) **(Hun)**

[Anti–Mycobacterium avium complex activities of KRM–1648, clarithromycin and levofloxacin in 7HSF medium at peak or average blood concentrations after their oral administration of clinical dosages] Sato K, et al. **Kekkaku** 1997 Jul;72(7):449–53 (Eng. Abstr.) **(Jpn)**

[Pilot studies on the treatment of Mycobacterium avium complex lung disease—new macrolides and new quinolones. (2) Multi–drug chemotherapy for initial cases on trial] Tanaka E. **Kekkaku** 1996 Sep;71(9):547–9 **(Jpn)**

[A clinical study on combination therapy of antimicrobial agents for complicated urinary tract infection—with special reference to combination with clarithromycin] Sano M, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 Jun;88(6):596–604 (Eng. Abstr.) **(Jpn)**

[One–week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer] Gisbert JP, et al. **Med Clin (Barc)** 1997 Apr 12;108(14):524–9 (Eng. Abstr.) **(Spa)**

[The efficacy of using a short course of 6–day duration (OCA–6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin (letter)] Rodrigo Sáez L, et al. **Rev Esp Enferm Dig** 1997 Feb; 89(2):146–7 **(Spa)**

ADVERSE EFFECTS

QT interval prolongation and risk of life–threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Stramba–Badiale M, et al. **Am Heart J** 1997 Jan;133(1):108–11

Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Sekkarie MA. **Am J Kidney Dis** 1997 Sep;30(3):437–9

Azithromycin–induced intrahepatic cholestasis. Longo G, et al. **Am J Med** 1997 Feb;102(2):217–8

Cisapride, erythromycin and arrhythmia [letter] [see comments] Jenkins IR, et al. **Anaesth Intensive Care** 1996 Dec;24(6):728. Comment in: Anaesth Intensive Care 1997 Jun;25(3):318–9.

Erythromycin—a pro–kinetic and pro–arrhythmogenic agent [letter; comment] Kluger MT. **Anaesth Intensive Care** 1997 Jun;25(3):318–9. Comment on: Anaesth Intensive Care 1996 Dec;24(6):728.

Ototoxic effect of erythromycin on cochlear potentials in the guinea pig. Kobayashi T, et al. **Ann Otol Rhinol Laryngol** 1997 Jul;106(7 Pt 1):599–603

Interaction between clarithromycin and oral anticoagulants [letter] Grau E, et al. **Ann Pharmacother** 1996 Dec; 30(12):1495–6

Clarithromycin–induced fever in a patient with Helicobacter pylori gastritis [letter] Kadayifçi A, et al. **Ann Pharmacother** 1997 Jun;31(6):788

Clarithromycin–induced digoxin intoxication. Laberge P, et al. **Ann Pharmacother** 1997 Sep;31(9):999–1002

Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin [letter] Lane G. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):884–5

Toleration of intravenous azithromycin. Luke DR, et al. **Ann Pharmacother** 1997 Sep;31(9):965–9

Hypersensitivity reaction to clarithromycin [letter] Vangala R, et al. **Ann Pharmacother** 1996 Mar;30(3):300

Safety, toleration, and pharmacokinetics of intravenous azithromycin. Luke DR, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2577–81

The mechanism of cyclosporine toxicity induced by clarithromycin. Spicer ST, et al. **Br J Clin Pharmacol** 1997 Feb;43(2):194–6

Spiramycin–associated acute dystonia during neuroleptic treatment [letter] Benazzi F. **Can J Psychiatry** 1997 Aug; 42(6):665–6

Clarithromycin–associated digoxin toxicity in the elderly. Brown BA, et al. **Clin Infect Dis** 1997 Jan;24(1):92–3

Relationship of adverse events to serum drug levels in patients receiving high–dose azithromycin for mycobacterial lung disease. Brown BA, et al. **Clin Infect Dis** 1997 May;24(5):958–64 (25 ref.)

Contact allergy to erythromycin. Valsecchi R, et al. **Contact Dermatitis** 1996 Jun;34(6):428

Baboon syndrome. Goossens C, et al. **Dermatology** 1997; 194(4):421–2

Hypomagnesaemia–associated tetany due to intravenous administration of amphotericin B [letter] Narita M, et al. **Eur J Pediatr** 1997 May;156(5):421–2

Uveitis associated with rifabutin and macrolide therapy for Mycobacterium avium intracellulare infection in AIDS patients. Kelleher P, et al. **Genitourin Med** 1996 Dec; 72(6):419–21

Drug–induced torsades de pointes in one patient with congenital long QT syndrome. Hsieh MH, et al. **Int J Cardiol** 1996 Apr 19;54(1):85–8

Coprescription of terfenadine and erythromycin or ketaconazole: an assessment of potential harm. Carlson AM, et al. **J Am Pharm Assoc (Wash)** 1996 Apr;NS36(4):263–9

Drug interactions with azithromycin and the macrolides: an overview. Nahata M. **J Antimicrob Chemother** 1996 Jun; 37 Suppl C:133–42 (43 ref.)

Paediatric safety of azithromycin: worldwide experience. Treadway G, et al. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:143–9

Hypothermia from azithromycin? [letter; comment] Walson PD. **J Toxicol Clin Toxicol** 1997;35(5):459. Comment on: J Toxicol Clin Toxicol 1997;35(2):225–6.

Macrolide–induced Churg–Strauss syndrome in a patient with atopy [letter] Hübner C, et al. **Lancet** 1997 Aug 23; 350(9077):563

Severe neutropenia and prophylactic doses of rifabutin [letter; comment] Tansey MJ, et al. **Lancet** 1996 Dec 7; 348(9041):1592–3. Comment on: Lancet 1996 Sep 7;348(9028):685.

Roxithromycin–induced digoxin toxicity. Corallo CE, et al. **Med J Aust** 1996 Oct 21;165(8):433–4

Interaction between azithromycin and cyclosporin? [letter; comment] Gómez E, et al. **Nephron** 1996;73(4):724. Comment on: Nephron 1995;70(1):130.

QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. Lin JC, et al. **Pharmacotherapy** 1997 May–Jun;17(3):626–30

QTc–interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Tschida SJ, et al. **Pharmacotherapy** 1996 Jul–Aug; 16(4):663–74 (52 ref.)

Economic analysis of treatment with roxithromycin in comparison with erythromycin in patients with lower respiratory tract infections. Norinder A, et al. **Scand J Infect Dis** 1997;29(1):83–6

Interaction between tacrolimus and erythromycin. Padhi ID, et al. **Ther Drug Monit** 1997 Feb;19(1):120–2

Clinical mastitis in dairy cows after 'blitz' therapy [letter] Bradley AJ, et al. **Vet Rec** 1997 Aug 16;141(7):179–80

[Torsades de pointe with spiramycine and metiquazine therapy. Apropos of a case] Verdun F, et al. **Arch Mal Coeur Vaiss** 1997 Jan;90(1):103–6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Acute symptomatic cytolytic hepatitis probably related to clarithromycin (letter)] Cadranel JF, et al. **Gastroenterol Clin Biol** 1996;20(11):1034–5 **(Fre)**

[Clarithromycin–digoxin: an unrecognized interaction in some patients (letter)] Guillemet C, et al. **Presse Med** 1997 Apr 5;26(11):512 **(Fre)**

[Vascular purpura and cryoglobulinémia: the difficulties of pharmacovigilance (letter)] Sentenac L, et al. **Presse Med** 1996 Sep 21;25(27):1259 **(Fre)**

[Rokitamycin tolerance in patients with adverse reactions to chemotherapeutic agents] Cenci L, et al. **Clin Ter** 1996 Dec; 147(12):621–6 (Eng. Abstr.) **(Ita)**

[Erythromycin–induced hearing loss in a patient with Listeria monocytogenes meningo–ventriculitis] Moriyasu H, et al. **Rinsho Shinkeigaku** 1996 Sep;36(9):1107–9 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Matrix solid–phase dispersion technique for the determination of moxidectin in bovine tissues. Alvinerie M, et al. **Analyst** 1996 Oct;121(10):1469–72

Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease. Matera MG, et al. **Eur Respir J** 1997 Jan;10(1):98–103

Multiresidue method for confirmation of macrolide antibiotics in bovine muscle by liquid chromatography/mass spectrometry. Delépine B, et al. **J AOAC Int** 1996 Mar–Apr;79(2):397–404

Liquid chromatographic assay of tylosin in animal feeds. Houglum JE, et al. **J AOAC Int** 1996 Mar–Apr; 79(2):369–74

Microbiological method for determining macrolides in animal feeds in the presence of other drugs by thin–layer chromatography detection. Markakis PK. **J AOAC Int** 1996 Nov–Dec;79(6):1263–8

Selective spectrophotometric method for the determination of erythromycin and its esters in pharmaceutical formulations using gentiana violet. Amin AS, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1625–9

BIOSYNTHESIS

Essential role of endogenously synthesized tylosin for induction of ermSF in Streptomyces fradiae. Memili E, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1203–5

Molecular analysis of tlrD, an MLS resistance determinant from the tylosin producer, Streptomyces fradiae. Gandecha AR, et al. **Gene** 1996 Nov 21;180(1–2):173–6

Analysis of four tylosin biosynthetic genes from the tylLM region of the Streptomyces fradiae genome. Gandecha AR, et al. **Gene** 1997 Jan 15;184(2):197–203

Biosynthesis of albocycline: origin of the carbon skeleton. Taddei A, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):526–8

Production of brominated tiacumicin derivatives. Hochlowski JE, et al. **Jpn J Antibiot** 1997 Mar;50(3):201–5

[Effect of Ca2+ ions on biosynthesis and component composition of tylosin in Streptomyces fradiae] Mironov VA, et al. **Antibiot Khimioter** 1997;42(4):3–7 (Eng. Abstr.) **(Rus)**

[Biosynthesis of nactinic compounds by population variants of macrotetrolide–producing streptomycetes] Sverdlova AN, et al. **Antibiot Khimioter** 1996 Jun;41(6):3–9 (Eng. Abstr.) **(Rus)**

[Genetic recombination during protoplast fusion in Streptomyces antibioticus, the producer of oleandomycin] Luk'ianchuk VV, et al. **Mikrobiol Z** 1996 Jul–Aug; 58(4):38–42 (Eng. Abstr.) **(Ukr)**

BLOOD

Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Wildfeuer A, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):75–9

Relationship of adverse events to serum drug levels in patients receiving high–dose azithromycin for mycobacterial lung disease. Brown BA, et al. **Clin Infect Dis** 1997 May;24(5):958–64 (25 ref.)

Determination of erythromycin in urine and plasma using microbore liquid chromatography with tris(2,2'–bipyridyl)ruthenium(II) electrogenerated chemiluminescence detection. Ridlen JS, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):393–400

Plasma profile study of moxidectin in a cow and its suckling calf. Alvinerie M, et al. **Vet Res** 1996;27(4–5):545–9

CHEMICAL SYNTHESIS

Preparation and in vitro antibacterial activity of 9–O–glycosyloxime derivatives of erythromycin A, a new class of macrolide antibiotics. Grandjean C, et al. **J Antibiot (Tokyo)** 1996 Oct;49(10):1036–43

Cladinose analogues of sixteen–membered macrolide antibiotics. III. Efficient synthesis of 4–O–alkyl–L–cladinose analogues: improved antibacterial activities compatible with pharmacokinetics. Kurihara K, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):32–44

[Synthesis and biological activity of hydrophosphoryl derivatives of amphotericin B] Belakhov VV, et al. **Antibiot Khimioter** 1996;41(7–8):4–8 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Amphotericin B protects cis–parinaric acid against peroxyl radical–induced oxidation: amphotericin B as an antioxidant. Osaka K, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):743–7

Association of polyene antibiotics with sterol–free lipid membranes. II. Hydrophobic binding of nystatin to dilauroylphosphatidylcholine bilayers. Milhaud J, et al. **Biochim Biophys Acta** 1997 May 22;1326(1):54–66

Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer–aided conformational studies. Montenez JP, et al. **Eur J Pharmacol** 1996 Oct 24;314(1–2):215–27

Cladinose analogues of sixteen–membered macrolide antibiotics. V. Preparation of unsubstituted L–cladinose analogues: effect of methylation of a 3"–hydroxyl group on the bioactivity. Ajito K, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):366–9

Cladinose analogues of sixteen–membered macrolide antibiotics. IV. Improved therapeutic effects of 4–O–acyl–L–cladinose analogues of sixteen–membered macrolide antibiotics. Ajito K, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):150–61

Structure–activity studies of tylosin–related macrolides. Fish SA, et al. **J Antibiot (Tokyo)** 1996 Oct;49(10):1044–8

A family of novel macrocyclic lactones, the saccharocarcins produced by Saccharothrix aerocolonigenes subsp. antibiotica. II. Physico–chemical properties and structure determination. Hegde VR, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):126–34

GERI–155, a new macrolide antibiotic related to chalcomycin [letter] Kim SD, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):955–7

Pyrrolosporin A, a new antitumor antibiotic from Micromonospora sp. C39217–R109–7. II. Isolation, physico–chemical properties, spectroscopic study and X–ray analysis. Schroeder DR, et al. **J Antibiot (Tokyo)**

1996 Sep;49(9):865–72
Stereostructure of amphotericin A. Sowiński P, et al. **J Antibiot (Tokyo)** 1996 Dec;49(12):1232–5
Kanchanamycins, new polyol macrolide antibiotics produced by Streptomyces olivaceus Tii 4018. II. Structure elucidation. Stephan H, et al. **J Antibiot (Tokyo)** 1996 Aug; 49(8):765–9
Cytovaricin B, a new inhibitor of JAK–STAT signal transduction produced by Streptomyces torulosus. Yamashita N, et al. **J Antibiot (Tokyo)** 1997 May; 50(5):440–2
Ion-pair high-performance liquid chromatographic assay method for the assessment of clarithromycin stability in aqueous solution and in gastric juice. Erah PO, et al. **J Chromatogr B Biomed Appl** 1996 Jun 28;682(1):73–8
Conformational analysis of amphotericin B molecule. Silberstein AYa, et al. **Membr Cell Biol** 1997;10(5):553–63
Investigation on the chemical stability of erythromycin in solutions using an optimization system. Brisaert M, et al. **Pharm World Sci** 1996 Oct;18(5):182–6
[A laboratory method for sensitized isomerization of polyene macrolides] Shenin IuD, et al. **Antibiot Khimioter** 1996 Feb; 41(2):16–21 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Candidin in immediate hypersensitivity. Comparison of two antigens. Netto CF, et al. **J Investig Allergol Clin Immunol** 1996 Nov–Dec;6(6):392–4

ECONOMICS

Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin. Carbon C, et al. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:151–61
Economic analysis of treatment with roxithromycin in comparison with erythromycin in patients with lower respiratory tract infections. Norinder A, et al. **Scand J Infect Dis** 1997;29(1):83–6
Azithromycin as a cost–effective treatment for nongonococcal urethritis in men [letter; comment] Carlin EM, et al. **Sex Transm Dis** 1997 Jan;24(1):57. Comment on: Sex Transm Dis 1995 Sep–Oct;22(5):274–80.

IMMUNOLOGY

Candidin in immediate hypersensitivity. Comparison of two antigens. Netto CF, et al. **J Investig Allergol Clin Immunol** 1996 Nov–Dec;6(6):392–4

ISOLATION & PURIFICATION

Kanchanamycins, new polyol macrolide antibiotics produced by Streptomyces olivaceus Tü 4018. I. Taxonomy, fermentation, isolation and biological activities. Fiedler HP, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):758–64
A new 16–membered chalcomycin type macrolide antibiotic, 250–144C. Goo YM, et al. **J Antibiot (Tokyo)** 1997 Jan; 50(1):85–8
A family of novel macrocyclic lactones, the saccharocarcins produced by Saccharothrix aerocolonigenes subsp. antibiotica. I. Taxonomy, fermentation, isolation and biological properties. Horan AC, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):119–25
Separation and detection of macrolide antibiotics by HPLC using macrolide–imprinted synthetic polymers as stationary phases. Siemann M, et al. **J Antibiot (Tokyo)** 1997 Jan; 50(1):89–91
Cytovaricin B, a new inhibitor of JAK–STAT signal transduction produced by Streptomyces torulosus. Yamashita N, et al. **J Antibiot (Tokyo)** 1997 May; 50(5):440–2
Malolactomycins C and D, new 40–membered macrolides active against Botrytis. Tanaka Y, et al. **Jpn J Antibiot** 1997 Mar;50(3):194–200
New macrolactone of the desertomycin family from Streptomyces spectabilis. Ivanova V. **Prep Biochem Biotechnol** 1997 Feb;27(1):19–38

METABOLISM

Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Rodrigues AD, et al. **Drug Metab Dispos** 1997 May;25(5):623–30
Pyrrolosporin A, a new antitumor antibiotic from Micromonospora sp. C39217–R109–7. I. Taxonomy of producing organism, fermentation and biological activity. Lam KS, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):860–4
Microbial glycosylation of macrolide antibiotics by Streptomyces hygroscopicus ATCC 31080 and distribution of a macrolide glycosyl transferase in several Streptomyces strains. Sasaki J, et al. **J Antibiot (Tokyo)** 1996 Nov; 49(11):1110–8
Mechanism of inhibition of protein synthesis by macrolide and lincosamide antibiotics. Menninger JR. **J Basic Clin Physiol Pharmacol** 1995;6(3–4):229–50
Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. Fietta A, et al. **J Chemother** 1997 Feb;9(1):23–31
Determination of the alpha1–acid glycoprotein binding of azithromycin in vitro by equilibrium dialysis. Gastearena I, et al. **J Chemother** 1995 Nov;7 Suppl 4:26–8
Tonsillar tissue penetration of dirithromycin after multiple doses. Benson JM, et al. **J Clin Pharmacol** 1996 Sep; 36(9):832–7
[Protein binding of clarithromycin in patients with chronic renal failure] Yago K, et al. **Jpn J Antibiot** 1996 Mar; 49(3):256–63 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Transdermal delivery of erythromycin lactobionate—implications for the therapy of gastroparesis. Brand RM, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):589–92
Single–dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Conte JE Jr, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1617–22
Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Jaruratanasirikul S, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):825–6
Safety, toleration, and pharmacokinetics of intravenous azithromycin. Luke DR, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2577–81
Characterization of peripheral–compartment kinetics of antibiotics by in vivo microdialysis in humans. Müller M, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2703–9
Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Olsen KM, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2582–5
Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Patel KB, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2375–9
Intrapulmonary steady–state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Rodvold KA, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1399–402
Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Wildfeuer A, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):75–9
Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Iatsimirskaia E, et al. **Clin Pharmacol Ther** 1997 May;61(5):554–62
Disposition of oral azithromycin in humans. Luke DR, et al. **Clin Pharmacol Ther** 1997 Jun;61(6):641–8
Diversity of lipid–based polyene formulations and their behavior in biological systems. Wasan KM, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):81–92 (87 ref.)
Multiple dose bioequivalence study with josamycin propionate, a drug with highly variable kinetics, in healthy volunteers. Van Hoogdalem EJ, et al. **Int J Clin Pharmacol Ther** 1996 May;34(5):202–7
Cladinose analogues of sixteen–membered macrolide antibiotics. II. Preparation of pharmacokinetically improved analogues via biotransformation. Ajito K, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):92–5
The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. Foulds G, et al. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:37–44
Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. Girard AE, et al. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:9–19
Influence of immunosuppression on the pharmacokinetics and pharmacodynamics of azithromycin in infected mouse tissues. Girard D, et al. **J Antimicrob Chemother** 1996 Jun; 37 Suppl C:21–35
Azithromycin uptake by tissue cultured epithelial cells [letter] Pascual A, et al. **J Antimicrob Chemother** 1997 Feb; 39(2):293–5
Delivery of azithromycin to Chlamydia trachomatis–infected polarized human endometrial epithelial cells by polymorphonuclear leucocytes. Paul TR, et al. **J Antimicrob Chemother** 1997 May;39(5):623–30
Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. Pukander J, et al. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:53–61
Concentrations of azithromycin in tonsilar and/or adenoid tissue from paediatric patients. Vaudaux BP, et al. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:45–51
Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Drusano GL, et al. **J Chemother** 1997 May;9 Suppl 3:38–44 (11 ref.)
Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. Hutchaleelaha A, et al. **J Pharm Pharmacol** 1997 Feb; 49(2):178–83
Clarithromycin pharmacokinetics after oral administration with or without fasting in crossbred beagles. Vilmányi E, et al. **J Small Anim Pract** 1996 Nov;37(11):535–9
Penetration of clarithromycin into middle ear fluid of children with acute otitis media. Gan VN, et al. **Pediatr Infect Dis J** 1997 Jan;16(1):39–43
Pharmacokinetics and pharmacodynamics of newer macrolides. Nightingale CH. **Pediatr Infect Dis J** 1997 Apr; 16(4):438–43 (29 ref.)
Possible role of the intestinal P–450 enzyme system in a cyclosporine–clarithromycin interaction. Sketris IS, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2):301–5
Choline esters and biogenic amines in the hypobranchial gland of 55 molluscan species of the neogastropod Muricoidea superfamily. Roseghini M, et al. **Toxicon** 1996 Jan;34(1):33–55
Plasma profile study of moxidectin in a cow and its suckling calf. Alvinerie M, et al. **Vet Res** 1996;27(4–5):545–9
The use of an experimental metritis model to study antibiotic distribution in genital tract secretions in the ewe. Cester CC, et al. **Vet Res** 1996;27(4–5):479–89
[New pharmacologic approaches to macrolides: example of roxithromycin] Bergogne–Bérézin E. **Presse Med** 1996 Dec 14;25(39):1982–8 (29 ref.) (Eng. Abstr.) **(Fre)**
[Intracellular penetration of macrolides] Labro MT. **Presse Med** 1997 Mar;26 Suppl 2:11–5 (23 ref.) **(Fre)**
[Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field] Akita H, et al. **Jpn J Antibiot** 1996 Oct;49(10):899–916 (Eng. Abstr.) **(Jpn)**
[Pharmacokinetic and clinical evaluation of azithromycin in pediatric infections] Ishida Y, et al. **Jpn J Antibiot** 1996 Nov;49(11):1030–8 (Eng. Abstr.) **(Jpn)**
[Pharmacokinetic and clinical evaluation of azithromycin in the pediatric field] Kitamura K, et al. **Jpn J Antibiot** 1997 Feb;50(2):206–14 (Eng. Abstr.) **(Jpn)**
[Clinical study of a macrolide antibiotic, azithromycin, in pediatric patients] Kobayashi Y, et al. **Jpn J Antibiot** 1996 Nov;49(11):1004–12 (Eng. Abstr.) **(Jpn)**
[Pharmacokinetic and clinical studies on azithromycin in children] Ohtsuka Y, et al. **Jpn J Antibiot** 1996 Nov; 49(11):1039–48 (Eng. Abstr.) **(Jpn)**
[Pharmacokinetic and clinical evaluations of azithromycin in the pediatric field] Okada T, et al. **Jpn J Antibiot** 1996 Nov;49(11):1024–9 (Eng. Abstr.) **(Jpn)**
[Pharmacokinetic and clinical evaluation of azithromycin in pediatrics] Okumura A, et al. **Jpn J Antibiot** 1996 Nov; 49(11):994–1003 (Eng. Abstr.) **(Jpn)**
[Pharmacokinetic, bacteriological and clinical studies on azithromycin in children] Tajima T, et al. **Jpn J Antibiot** 1997 Feb;50(2):200–5 (Eng. Abstr.) **(Jpn)**
[Pharmacokinetic and clinical evaluation of azithromycin using fine granules or capsules in the pediatric patients] Toyonaga Y, et al. **Jpn J Antibiot** 1996 Nov;49(11):981–93 (Eng. Abstr.) **(Jpn)**
[Pharmacokinetic profile of azithromycin. Role in the treatment of genital Chlamydia infections] Chulig I. **Antibiot Khimioter** 1996 Feb;41(2):14–5 **(Rus)**

PHARMACOLOGY

In vitro susceptibilities of 176 clinical isolates of Streptococcus pneumoniae to 11 beta–lactams, erythromycin, and tetracycline. Vanhoof R, et al. **Acta Clin Belg** 1996;51(6):377–85
Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa. Kondoh K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:56–60
Inhibitory effect of roxithromycin on biofilm formation of Pseudomonas aeruginosa. Ozeki M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:61–3
Effect of erythromycin on human biliary motility. Wehrmann T, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):421–6
Lipopolysaccharide–induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Tamaoki J, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):L15–9
Erythromycin modulates IL–8 expression in normal and inflamed human bronchial epithelial cells. Takizawa H, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):266–71
Effect of treatment with erythromycin on bronchoalveolar lavage fluid cell populations in foals. Lakritz J, et al. **Am J Vet Res** 1997 Jan;58(1):56–61
Effects of indomethacin, dexamethasone, and erythromycin on endotoxin–induced intraepithelial mucus production of rat nasal epithelium. Takahashi Y, et al. **Ann Otol Rhinol Laryngol** 1997 Aug;106(8):683–7
Digoxin–macrolide drug interaction. Bizjak ED, et al. **Ann Pharmacother** 1997 Sep;31(9):1077–9 (29 ref.)
Drug interactions of macrolides: emphasis on dirithromycin. Watkins VS, et al. **Ann Pharmacother** 1997 Mar; 31(3):349–56 (63 ref.)
In vitro activities of eight macrolide antibiotics and RP–59500 (quinupristin–dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Alcaide F, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2117–20
Effects of two oral erythromycin ethylsuccinate formulations on the motility of the small intestine in human beings. Caron F, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1796–800
Bafilomycin A1 and intracellular multiplication of Legionella pneumophila. Cattani L, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):212–4
50S ribosomal subunit synthesis and translation are equivalent targets for erythromycin inhibition in Staphylococcus aureus. Champney WS, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1301–3
Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin–susceptible and penicillin–resistant pneumococci. Ednie LM, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1950–2
Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta–lactams, clindamycin, and metronidazole. Ednie LM, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1037–41
Susceptibilities of 228 penicillin– and

erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents. Ednie LM, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1033–6

Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha,25-dihydroxyvitamin D3-stimulated THP-1 cells. Fujii T, et al. **Antimicrob Agents Chemother** 1996 Jun; 40(6):1548–51

Comparative study of bactericidal activities, postantibiotic effects, and effects of bacterial virulence of penicillin G and six macrolides against Streptococcus pneumoniae. Fuursted K, et al. **Antimicrob Agents Chemother** 1997 Apr; 41(4):781–4

Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. Gerardo SH, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2413–5

Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. Gillum JG, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1715–6

In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. Gnarpe J, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1843–5

In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers. Ives TJ, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):578–82

In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. Jamjian C, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):454–9

Induction of ermSV by 16-membered-ring macrolide antibiotics. Kamimiya S, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):530–4

In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. Kuo CC, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2669–70

Tandem duplication in ermC translational attenuator of the macrolide-lincosamide-streptogramin B resistance plasmid pSES6 from Staphylococcus equorum. Lodder G, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):215–7

In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella. Martin SJ, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1419–21

Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Morikawa K, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1366–70

Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Mozaffarian N, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1825–9

Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex [published erratum appears in Antimicrob Agents Chemother 1996 Oct;40(10):2442] Nash KA, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1748–50

Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies. Pankuch GA, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1653–6

Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Paul M, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1731–4

Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Polis MA, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1709–14

Clarithromycin does not affect phosphorylation of zidovudine in vitro. Rana KZ, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1945–7

Characterization of tetracycline and erythromycin resistance determinants in Treponema denticola [published erratum appears in Antimicrob Agents Chemother 1996 Sep;40(9):2236] Roberts MC, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1690–4

Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associated with mutations in 23S rRNA. Ross JI, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1162–5

In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Schülin T, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1196–202

A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Stone GG, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):712–4

Detection of erythromycin-resistant determinants by PCR. Sutcliffe J, et al. **Antimicrob Agents Chemother** 1996 Nov; 40(11):2562–6

Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Sutcliffe J, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1817–24

Effects of roxithromycin and erythromycin on interleukin 8-induced neutrophil recruitment and goblet cell secretion in guinea pig tracheas. Tamaoki J, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1726–8

Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Tateda K, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2271–5

Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Versalovic J, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):477–80

Effects of topical erythromycin on ecology of aerobic cutaneous bacterial flora. Vowels BR, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2598–604

In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. Welsh L, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):212–4

Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear leukocyte function assessed ex vivo by flow cytometry. Wenisch C, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2039–42

Macrolide-lincosamide-streptogramin B resistance in Staphylococcus lentus results from the integration of part of a transposon into a small plasmid. Werckenthin C, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2224–5

High incidence of erythromycin-resistant streptococci in Taiwan. Wu JJ, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):844–6

Suppression of cytokine production of human memory T cells by roxithromycin. Hirohata S, et al. **Arerugi** 1995 Nov; 44(11):1322–30

Intracellular activity of azithromycin against Mycobacterium avium complex in human macrophages. Wildfeuer A, et al. **Arzneimittelforschung** 1997 Jul;47(7):866–8

Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Zimmermann T, et al. **Arzneimittelforschung** 1996 Feb;46(2):213–7

In vitro activity of tylosin and its derivatives against Ureaplasma urealyticum. Zuzulova M, et al. **Arzneimittelforschung** 1995 Nov;45(11):1222–4

Effect of clarithromycin on the bioavailability of cyclosporin in rats. Ohba M, et al. **Biol Pharm Bull** 1996 May; 19(5):733–7

Effects of erythromycin, clarithromycin and rokitamycin on nifedipine metabolism in rats. Tsuruta S, et al. **Biol Pharm Bull** 1997 Apr;20(4):411–6

The macrolide antibiotic, roxithromycin suppresses IFN-gamma-mediated immunological functions of cultured normal human keratinocytes. Wakita H, et al. **Biol Pharm Bull** 1996 Feb;19(2):224–7

Concanamycin B, a vacuolar H(+)-ATPase specific inhibitor suppresses bone resorption in vitro. Woo JT, et al. **Biol Pharm Bull** 1996 Feb;19(2):297–9

Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. Wang JS, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):195–8

Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia. Best LM, et al. **Can J Gastroenterol** 1997 May-Jun;11(4):298–300

Activation of the sphingomyelin cycle by brefeldin A: effects of brefeldin A on differentiation and implications for a role for ceramide in regulation of protein trafficking. Linardic CM, et al. **Cell Growth Differ** 1996 Jun;7(6):765–74

Experimental evidences for a role of subinhibitory concentrations of rilopirox, nystatin and fluconazole on adherence of Candida spp. to vaginal epithelial cells. Braga PC, et al. **Chemotherapy** 1996 Jul-Aug;42(4):259–65

In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Dalhoff A, et al. **Chemotherapy** 1996 Nov-Dec;42(6):410–25

The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Ichimiya T, et al. **Chemotherapy** 1996 May-Jun;42(3):186–91

In vitro and in vivo antibacterial activities of clarithromycin. Ono T, et al. **Chemotherapy** 1996 May-Jun;42(3):159–69

Effect of subinhibitory concentrations of ceftazidime, ciprofloxacin, and azithromycin on the hemagglutination and adherence of uropathogenic Escherichia coli strains. Vranes J. **Chemotherapy** 1996 May-Jun;42(3):177–85

Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Matsuoka N, et al. **Clin Exp Immunol** 1996 Jun;104(3):501–8

Effects of oral erythromycin on fasting and postprandial antroduodenal motility in patients with type I diabetes, measured with an ambulatory manometric technique. Samsom M, et al. **Diabetes Care** 1997 Feb;20(2):129–34

Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates. Barrett MS, et al. **Diagn Microbiol Infect Dis** 1996 Feb;24(2):113–6

Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Hachem CY, et al. **Diagn Microbiol Infect Dis** 1996 Jan; 24(1):37–41

Comparison of Etest and agar dilution for testing the activity of three macrolides against Bordetella parapertussis. Hoppe JE, et al. **Diagn Microbiol Infect Dis** 1997 May;28(1):49–51

Antimicrobial activity of RU-66647, a new ketolide. Jones RN, et al. **Diagn Microbiol Infect Dis** 1997 Jan-Feb; 27(1-2):7–12

In vitro activity of macrolides against intracellular Legionella pneumophila. Segreti J, et al. **Diagn Microbiol Infect Dis** 1996 Jul;25(3):123–6

Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Shortridge VD, et al. **Diagn Microbiol Infect Dis** 1996 Oct;26(2):73–8

Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. Visalli MA, et al. **Diagn Microbiol Infect Dis** 1997 Jul;28(3):131–7

Mechanism of action of streptogramins and macrolides. Vannuffel P, et al. **Drugs** 1996;51 Suppl 1:20–30

Microtubules are involved in bafilomycin A1-induced tubulation and Rab5-dependent vacuolation of early endosomes. D'Arrigo A, et al. **Eur J Cell Biol** 1997 Feb; 72(2):95–103

In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori. Alarcón T, et al. **Eur J Clin Microbiol Infect Dis** 1996 Dec;15(12):937–40

Synergistic effect of azithromycin on the phagocytic killing of Staphylococcus aureus by human polymorphonuclear leukocytes. Herrera-Insúa I, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):13–6

Antibiotic susceptibility of pneumococci isolated in Austria over a four-year period. Mittermayer H, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):817–20

Evaluation of rapid molecular methods for detection of clarithromycin resistance in Helicobacter pylori. Szczebara F, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb; 16(2):162–4

Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. van Zwet AA, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov; 15(11):861–4

Serotyping and susceptibility to macrolides and other antimicrobial drugs of Streptococcus pyogenes isolated from patients with invasive diseases in southern Israel. Weiss I, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan; 16(1):20–3

The frequency of resistance to erythromycin in group A streptococci in Ankara. Kürekçi AE, et al. **Eur J Pediatr** 1996 Sep;155(9):780–2

Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. Van Bambeke F, et al. **Eur J Pharmacol** 1996 Oct 24;314(1-2):203–14

Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation. Gerbaux C, et al. **FEBS Lett** 1996 Oct 7;394(3):307–10

Bafilomycin A1 induces apoptosis in PC12 cells independently of intracellular pH [published erratum appears in FEBS Lett 1997 Feb 10;403(1):112] Kinoshita K, et al. **FEBS Lett** 1996 Nov 25;398(1):61–6

Molecular analysis of naturally occuring ermC-encoding plasmids in staphylococci isolated from animals with and without previous contact with macrolide/lincosamide antibiotics. Lodder G, et al. **FEMS Immunol Med Microbiol** 1997 May;18(1):7–15

Inhibition of Pseudomonas aeruginosa alginate expression by subinhibitory concentrations of antibiotics. Majtán V, et al. **Folia Microbiol (Praha)** 1996;41(1):61–4

In vitro and in vivo ultrastructural changes induced by macrolide antibiotic LY281389. Horn JW, et al. **Fundam Appl Toxicol** 1996 Aug;32(2):205–16

Minimal functional system required for expression of erythromycin resistance by msrA in Staphylococcus aureus RN4220. Ross JI, et al. **Gene** 1996 Dec 12;183(1-2):143–8

Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Anderson R, et al. **Inflammation** 1996 Dec;20(6):693–705

Interaction between midazolam and clarithromycin: comparison with azithromycin. Yeates RA, et al. **Int J Clin Pharmacol Ther** 1996 Sep;34(9):400–5

Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Young H, et al. **Int J STD AIDS** 1997 May;8(5):299–302

Structure-activity studies of tylosin-related macrolides. Fish SA, et al. **J Antibiot (Tokyo)** 1996 Oct;49(10):1044–8

GERI-155, a new macrolide antibiotic related to chalcomycin [letter] Kim SD, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):955–7

Pyrrolosporin A, a new antitumor antibiotic from Micromonospora sp. C39217-R109-7. I. Taxonomy of producing organism, fermentation and biological activity. Lam KS, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):860–4

In vitro interaction between dirithromycin or its metabolite, erythromycylamine, and oxidative polymorphonuclear metabolism. Moutard I, et al. **J Antibiot (Tokyo)** 1997 Jan; 50(1):53–7

Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA [letter] Barry AL, et al. **J Antimicrob Chemother** 1997 Jul;40(1):139–40

In-vitro activity of ketolides against mycoplasmas [letter] Bébéar CM, et al. **J Antimicrob Chemother** 1997 May; 39(5):669–70

Ketolides lack inducibility properties of MLS(B) resistance phenotype. Bonnefoy A, et al. **J Antimicrob Chemother** 1997 Jul;40(1):85–90

In-vitro activities of clarithromycin and other antimicrobial agents against Helicobacter pylori isolated from children

[letter] Dhaenens L, et al. **J Antimicrob Chemother** 1996 Aug;38(2):318–9

Effect of minor pH changes on the in-vitro activity of azithromycin and clarithromycin [letter] Fuchs PC, et al. **J Antimicrob Chemother** 1997 Jan;39(1):109–10

In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. Giacometti A, et al. **J Antimicrob Chemother** 1996 Sep; 38(3):399–408

Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. Girard AE, et al. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:9–19

Influence of immunosuppression on the pharmacokinetics and pharmacodynamics of azithromycin in infected mouse tissues. Girard D, et al. **J Antimicrob Chemother** 1996 Jun; 37 Suppl C:21–35

Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin. Hoogkamp-Korstanje JA, et al. **J Antimicrob Chemother** 1997 Mar;39(3):411–4

In-vitro activity of azithromycin in against intracellular Helicobacter pylori. Hulten K, et al. **J Antimicrob Chemother** 1996 Mar;37(3):483–9

The in-vitro anti-rickettsial activity of macrolides. Keysary A, et al. **J Antimicrob Chemother** 1996 Oct;38(4):727–31

Azithromycin--review of key chemical, pharmacokinetic and microbiological features. Lode H, et al. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:1–8 (41 ref.)

The activity of azithromycin on the infectivity of Chlamydia trachomatis in human amniotic cells. Patton DL, et al. **J Antimicrob Chemother** 1995 Dec;36(6):951–9

Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages. Pellegrin I, et al. **J Antimicrob Chemother** 1996 Mar;37(3):501–10

In-vitro activity of dirithromycin against Chlamydia pneumoniae. Roblin PM, et al. **J Antimicrob Chemother** 1997 May;39(5):647–9

Mobile rRNA methylase genes coding for erythromycin resistance in Actinobacillus actinomycetemcomitans. Roe DE, et al. **J Antimicrob Chemother** 1996 Mar;37(3):457–64

Azithromycin induces in vitro a time-dependent increase in the intracellular killing of Staphylococcus aureus by human polymorphonuclear leucocytes without damaging phagocytes. Silvestri M, et al. **J Antimicrob Chemother** 1995 Dec;36(6):941–50

The in-vitro activity of an antifungal antibiotic benanomicin A in comparison with amphotericin B. Watanabe M, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1073–7

Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. Xia HX, et al. **J Antimicrob Chemother** 1996 Mar;37(3):473–81

Uncoupling mechanism of glycoside antibiotic aculeximycin in isolated rat-liver mitochondria. Miyoshi H, et al. **J Biochem (Tokyo)** 1996 Feb;119(2):274–80

Mutations of pma-1, the gene encoding the plasma membrane H+-ATPase of Neurospora crassa, suppress inhibition of growth by concanamycin A, a specific inhibitor of vacuolar ATPases. Bowman EJ, et al. **J Biol Chem** 1997 Jun 6; 272(23):14776–86

Bafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling. Presley JF, et al. **J Biol Chem** 1997 May 23;272(21):13929–36

Megalomicin disrupts lysosomal functions. Bonay P, et al. **J Cell Sci** 1997 Aug;110 (Pt 16):1839–49

Inhibitory and bactericidal activity of rokitamycin against Helicobacter pylori and morphological alterations. Brenciaglia MI, et al. **J Chemother** 1996 Dec;8(6):425–31

Susceptibility of macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy. Cellesi C, et al. **J Chemother** 1996 Jun;8(3):188–92

Significance of environmental conditions (pH and serum) on the in vitro potency of azithromycin against Brucella melitensis. Domingo S, et al. **J Chemother** 1995 Nov;7 Suppl 4:29–31

Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Drusano GL, et al. **J Chemother** 1997 May;9 Suppl 3:38–44 (11 ref.)

Effect of sub-inhibitory concentrations of clarithromycin and erythromycin on the production of Staphylococcus aureus capsules. Ohtomo T, et al. **J Chemother** 1995 Nov;7 Suppl 4:9–11

Incidence of erythromycin resistance and penicillin resistance in clinical isolates of Streptococcus pneumoniae from a Spanish university hospital. Perez-Ramos S, et al. **J Chemother** 1995 Nov;7 Suppl 4:71–2

Trends in the activity of macrolide and beta-lactam antibiotics and resistance development. Alexander Project Group. Schito GC, et al. **J Chemother** 1997 May;9 Suppl 3:18–28

Effects of macrolide antibiotics on bacteria-platelet interactions. Usui Y, et al. **J Chemother** 1995 Nov;7 Suppl 4:40–2

Erythromycin and clomipramine: noncompetitive inhibition of demethylation [letter] Oesterheld JR. **J Child Adolesc Psychopharmacol** 1996 Fall;6(3):211–3

Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae. Jorgensen JH, et al. **J Clin Microbiol** 1996 Nov;34(11):2679–84

Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH. Nilius AM, et al. **J Clin Microbiol** 1997 Jun;35(6):1311–5

Azithromycin in the treatment of periodontal disease. Effect on microbial flora. Sefton AM, et al. **J Clin Periodontol** 1996 Nov;23(11):998–1003

Effect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and pharmacodynamics of terfenadine in vivo. Goldberg MJ, et al. **J Clin Pharmacol** 1996 Dec; 36(12):1154–60

Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. Dröse S, et al. **J Exp Biol** 1997 Jan;200 (Pt 1):1–8 (69 ref.)

Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPases, inhibits the receptor-mediated endocytosis of asialoglycoproteins in isolated rat hepatocytes. Harada M, et al. **J Hepatol** 1996 May; 24(5):594–603

Laboratory and field studies on the effects of the antibiotic tylosin on honey bee Apis mellifera L. (Hymenoptera: Apidae) development and prevention of American foulbrood disease. Peng CYS, et al. **J Invertebr Pathol** 1996 Jan;67(1):65–71

Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. McFarland JW, et al. **J Med Chem** 1997 Apr 25;40(9):1340–6

Repromicin derivatives with potent antibacterial activity against Pasteurella multocida. McFarland JW, et al. **J Med Chem** 1997 Mar 14;40(6):1041–5

Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes. Yamazaki H, et al. **J Toxicol Sci** 1996 Nov;21(4):215–26

Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella spp. associated with bovine respiratory disease. Shryock TR, et al. **J Vet Diagn Invest** 1996 Jul;8(3):337–44

In vitro susceptibility of Mycoplasma hyosynoviae and M. hyorhinis to antimicrobial agents. Kobayashi H, et al. **J Vet Med Sci** 1996 Nov;58(11):1107–11

Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogs. Main BW, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):225–32

Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori. Shibata K, et al. **Jpn J Antibiot** 1997 Jun; 50(6):525–31

Effect of macrolide antibiotics on neutrophil function in human peripheral blood. Sugihara E. **Kansenshogaku Zasshi** 1997 Apr;71(4):329–36

Macrolides reduce the expression of surface Mac-1 molecule on neutrophil. Okubo Y. **Kurume Med J** 1997;44(2):115–23

Life-threatening interaction between clarithromycin and disopyramide [letter] Paar D, et al. **Lancet** 1997 Feb 1; 349(9048):326–7

Japanese encephalitis virus infection in Vero cells: the involvement of intracellular acidic vesicles in the early phase of viral infection was observed with the treatment of a specific vacuolar type H+-ATPase inhibitor, bafilomycin A1. Nawa M. **Microbiol Immunol** 1997; 41(7):537–43

Effect of macrolide antibiotics on macrophage functions. Xu G, et al. **Microbiol Immunol** 1996;40(7):473–9

Solution structure of an rRNA methyltransferase (ErmAM) that confers macrolide-lincosamide-streptogramin antibiotic resistance [see comments] Yu L, et al. **Nat Struct Biol** 1997 Jun;4(6):483–9. Comment in: Nat Struct Biol 1997 Jun;4(6):421–2.

Release of noradrenaline from isolated rat tail artery induced by bafilomycin A1. Palatý V. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Mar; 353(4):431–7

Evaluation of the in vitro activity of seven selected antimicrobial agents to be used for the isolation of human intestinal spirochaetes. Calderaro A, et al. **New Microbiol** 1997 Jan;20(1):35–45

Microbiologic activity of the newer macrolide antibiotics. McCracken GH Jr. **Pediatr Infect Dis J** 1997 Apr; 16(4):432–7 (21 ref.)

Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media. McLinn S, et al. **Pediatr Infect Dis J** 1996 Sep;15(9 Suppl):S3–9

In vivo characterization of the colonic prokinetic effect of erythromycin in the rabbit. Costa A, et al. **Pharmacology** 1997 Feb;54(2):64–75

Molecular properties of the erythromycin resistance plasmid pPV141 from Staphylococcus chromogenes. Somkuti GA, et al. **Plasmid** 1997;37(2):119–27

Modulatory effect of roxithromycin on human neutrophil function. Mitsuyama T, et al. **Res Exp Med (Berl)** 1996; 196(5):301–7

Inhibition by erythromycin of human pulmonary artery endothelial cell injury induced by human neutrophils. Mitsuyama T, et al. **Respiration** 1997;64(3):206–10

Antimycobacterial synergism of clarithromycin and rifabutin. Ghebremichael S, et al. **Scand J Infect Dis** 1996; 28(4):387–90

Comparison of E-test with agar dilution methods in testing susceptibility of N. gonorrhoeae to azithromycin. Yasin RM, et al. **Sex Transm Dis** 1997 May;24(5):257–60

In vitro drug susceptibility of Acanthamoeba castellani to chloroquine, ivermectin and fungizon. Rain AN, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):319–24

Studies of reproductive competence in male Dirofilaria immitis treated with milbemycin oxime. Lok JB, et al. **Trop Med Parasitol** 1995 Dec;46(4):235–40

Entry of Semliki forest virus into cells: effects of concanamycin A and nigericin on viral membrane fusion and infection. Irurzun A, et al. **Virology** 1997 Jan 20; 227(2):488–92

Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes. Yamazaki H, et al. **Xenobiotica** 1996 Nov; 26(11):1143–53

Sequential development of resistance to fluoroquinolones and erythromycin in an isolate of Campylobacter jejuni. Burnens AP, et al. **Zentralbl Bakteriol** 1996 Mar; 283(3):314–21

[New pharmacologic approaches to macrolides: example of roxithromycin] Bergogne-Bérézin E. **Presse Med** 1996 Dec 14;25(39):1982–8 (29 ref.) (Eng. Abstr.) **(Fre)**

[New pharmacological approaches of macrolides. Example of roxithromycin] Bergogne-Bérézin E. **Presse Med** 1997 Mar;26 Suppl 2:4–10 (29 ref.) **(Fre)**

[A new strategy for the therapy of pancreatic cancer by proton pump inhibitor] Ohta T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1660–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field] Akita H, et al. **Jpn J Antibiot** 1996 Oct;49(10):899–916 (Eng. Abstr.) **(Jpn)**

[Antimicrobial activities of clarithromycin against clinical isolates] Koguchi M, et al. **Jpn J Antibiot** 1996 Mar; 49(3):289–300 (Eng. Abstr.) **(Jpn)**

[Effect of macrolides on cytokine mRNA expression in human whole blood model] Arikawa K, et al. **Kansenshogaku Zasshi** 1996 Jul;70(7):696–701 (Eng. Abstr.) **(Jpn)**

[Suppressive effect of clarithromycin on the production of verotoxin by E. coli O157] Nakata K, et al. **Kansenshogaku Zasshi** 1997 May;71(5):437–42 (Eng. Abstr.) **(Jpn)**

[Preclinical study of therapeutic agents used against Mycobacterium avium complex infections--with special reference to new macrolides and new quinolones] Tomioka H, et al. **Kekkaku** 1996 Sep;71(9):531–5 **(Jpn)**

[Evaluation of the effect of erythromycin on otitis media with effusion in experimental rat models] Enomoto F, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Aug; 99(8):1126–35 (Eng. Abstr.) **(Jpn)**

[Effect of erythromycin and clarithromycin on ion transport across dissected canine tracheal epithelium] Kato A. **Nippon Jibiinkoka Gakkai Kaiho** 1997 Mar;100(3):351–6 (Eng. Abstr.) **(Jpn)**

[Cell surface antigens on inflammatory cells in the paranasal mucosa of patients after macrolide therapy] Miyazawa T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1997 Jun; 100(6):671–7 (Eng. Abstr.) **(Jpn)**

[Effects of erythromycin on H2O2 generation by neutrophils] Matsumoto K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Jan;35(1):3–8 (Eng. Abstr.) **(Jpn)**

[Effects of erythromycin on surfactant synthesis, secretion, and recycling by rat alveolar type II cells] Suwabe A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Oct; 34(10):1104–8 (Eng. Abstr.) **(Jpn)**

[Resistance to macrolides] Endou K, et al. **Nippon Rinsho** 1997 May;55(5):1238–44 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The effect of new quinolone antimicrobial agents and macrolide antibiotics on the clearance of theophylline] Honma M. **Nippon Rinsho** 1996 Nov;54(11):3125–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Roxithromycin--a new macrolide antibiotic] Iakovlev SV, et al. **Ter Arkh** 1995;67(12):61–6 (72 ref.) **(Rus)**

[Macrolide antibiotics: Streptococcus pneumoniae and Haemophilus influenzae] Soriano F, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):503–4 (7 ref.) **(Spa)**

POISONING

Tacrolimus (FK 506) overdose: a report of five cases. Mrvos R, et al. **J Toxicol Clin Toxicol** 1997;35(4):395–9

THERAPEUTIC USE

Incidence of Chlamydia trachomatis in women with PID: effectiveness of therapy. De Punzio C, et al. **Acta Eur Fertil** 1995 Jul-Aug;26(4):149–51

Clinical effect of low-dose, long-term roxithromycin chemotherapy in patients with chronic sinusitis. Kimura N, et al. **Acta Med Okayama** 1997 Feb;51(1):33–7

Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Hashiba M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:73–8

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. Chaisson RE, et al. **AIDS** 1997 Mar;11(3):311–7

Azithromycin for relapsing cerebral toxoplasmosis in AIDS [letter] Nasta P, et al. **AIDS** 1997 Jul 15;11(9):1188

Helicobacter pylori eradication using one–week low–dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. Cammarota G, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):997–1000

Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Harris AW, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):1005–8

The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post–vagotomy–antrectomy gastroparesis. Kendall BJ, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):381–5

Randomized comparison of differing periods of twice–a–day triple therapy for the eradication of Helicobacter pylori. Laine L, et al. **Aliment Pharmacol Ther** 1996 Dec; 10(6):1029–33

Prospective evaluation of the macrolide antibiotic dirithromycin for the treatment of Helicobacter pylori. Laine L, et al. **Aliment Pharmacol Ther** 1996 Jun; 10(3):269–73

One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. Moshkowitz M, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):1015–9

Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group [see comments] Peterson WL, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):251–61. Comment in: Aliment Pharmacol Ther 1996 Dec;10(6):1035.

A seven–day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate. Weldon MJ, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):279–83

One–week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. Yousfi MM, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):617–21

Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). Yousfi MM, et al. **Aliment Pharmacol Ther** 1996 Feb;10(1):119–22

Treating acute bronchitis with azithromycin [letter] Mosby JA. **Am Fam Physician** 1997 Feb 1;55(2):444, 447–8

Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. Chey WD, et al. **Am J Gastroenterol** 1997 Sep;92(9):1483–6

Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. Chiba N. **Am J Gastroenterol** 1996 Oct;91(10):2139–43

The efficacy of prophylactic erythromycin in preventing vertical transmission of Ureaplasma urealyticum. Ogasawara KK, et al. **Am J Perinatol** 1997 Apr;14(4):233–7

Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Rubin BK, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):2018–23

Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Yanagihara K, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):337–42

Evaluation of ivermectin and milbemycin oxime efficacy against Dirofilaria immitis infections of three and four months' duration in dogs. McCall JW, et al. **Am J Vet Res** 1996 Aug;57(8):1189–92

Use of tilmicosin for treatment of pasteurellosis in rabbits. McKay SG, et al. **Am J Vet Res** 1996 Aug;57(8):1180–4

Oral administration of tylosin phosphate for treatment and prevention of proliferative enteropathy in pigs. McOrist S, et al. **Am J Vet Res** 1997 Feb;58(2):136–9

Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double–blind, randomized, controlled trial. Khan WA, et al. **Ann Intern Med** 1997 May 1; 126(9):697–703

Lovastatin–induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Grunden JW, et al. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):859–63

Digoxin toxicity secondary to clarithromycin therapy. Nawarskas JJ, et al. **Ann Pharmacother** 1997 Jul–Aug; 31(7–8):864–6

Potential interaction between clarithromycin and warfarin. Recker MW, et al. **Ann Pharmacother** 1997 Sep;31(9):996–8

Efficacy of clarithromycin treatment of acute otitis media caused by infection with penicillin–susceptible, –intermediate, and –resistant Streptococcus pneumoniae in the chinchilla. Alper CM, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1889–92

Clarithromycin in treatment of early Lyme disease: a pilot study. Dattwyler RJ, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):468–9

Influence of inducible cross–resistance to macrolides, lincosamides, and streptogramin B–type antibiotics in Enterococcus faecium on activity of quinupristin–dalfopristin in vitro and in rabbits with experimental endocarditis. Fantin B, et al. **Antimicrob Agents Chemother** 1997 May;41(5):931–5

Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Ji B, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):393–9

Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. Lounis N, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1168–9

Prospective open randomized study comparing efficacies and safeties of a 3–day course of azithromycin and a 10–day course of erythromycin in children with community–acquired acute lower respiratory tract infections. Roord JJ, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2765–8

Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. Rouse MS, et al. **Antimicrob Agents Chemother** 1997 Aug; 41(8):1673–6

Efficacy of clarithromycin versus that of clindamycin for single–dose prophylaxis of experimental streptococcal endocarditis. Vermot D, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):809–11

Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis. Watkins VS, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):72–5

Comparison of erythromycin and oxytetracycline for the treatment of virulent footrot in grazing sheep. Rendell DK, et al. **Aust Vet J** 1997 May;75(5):354

Efficacy of a single dose of erythromycin or penicillin/streptomycin for the treatment of ovine dermatophilosis. Scrivener CJ, et al. **Aust Vet J** 1995 Dec; 72(12):475–6

The minimum inhibitory concentration of tilmicosin and tylosin for mycoplasma gallisepticum and Mycoplasma synoviae and a comparison of their efficacy in the control of Mycoplasma gallisepticum infection in broiler chicks. Jordan FT, et al. **Avian Dis** 1996 Apr–Jun;40(2):326–34

Eradication of Helicobacter pylori: an objective assessment of current therapies. Penston JG, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):223–43 (376 ref.)

Comparison of clarithromycin suspension and amoxycillin syrup for the treatment of children with pharyngitis and/or tonsillitis. Kearsley NL, et al. **Br J Clin Pract** 1997 Apr–May;51(3):133–7

Lansoprazole plus clarithromycin: evaluation of a new dual therapy for Helicobacter pylori eradication. Phull PS, et al. **Br J Clin Pract** 1996 Oct–Nov;50(7):360–2

The comparative efficacy of benzoyl peroxide 5%/erythromycin 3% gel and erythromycin 4%/zinc 1.2% solution in the treatment of acne vulgaris. Chu A, et al. **Br J Dermatol** 1997 Feb;136(2):235–8

Comparison of amoxycillin and clarithromycin as initial treatment of community–acquired lower respiratory tract infections. MacFarlane JT, et al. **Br J Gen Pract** 1996 Jun; 46(407):357–60

Further studies on the efficacy of tylosin tablets for the treatment of pyoderma due to Staphylococcus intermedius infection in dogs. Scott DW, et al. **Can Vet J** 1996 Oct; 37(10):617–8

Significant survival benefit to patients with advanced non–small–cell lung cancer from treatment with clarithromycin. Mikasa K, et al. **Chemotherapy** 1997 Jul–Aug;43(4):288–96

Legionella species community–acquired pneumonia [letter; comment] Kane GC. **Chest** 1997 Jan;111(1):254. Comment on: Chest 1996 May;109(5):1243–9.

Oral empiric treatment of community–acquired pneumonia. A multicenter, double–blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Ortqvist A, et al. **Chest** 1996 Dec;110(6):1499–506

The relationship between erythromycin consumption and resistance in Finland. Finnish Study Group for Antimicrobial Resistance. Huovinen P, et al. **Ciba Found Symp** 1997;207:36–41; discussion 41–6 (12 ref.)

Chronic sinusitis refractory to standard management in patients with humoral immunodeficiencies. Buehring I, et al. **Clin Exp Immunol** 1997 Sep;109(3):468–72

Clarithromycin–associated digoxin toxicity in the elderly. Brown BA, et al. **Clin Infect Dis** 1997 Jan;24(1):92–3

Streamlining antimicrobial therapy for lower respiratory tract infections. Hitt CM, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S231–7 (58 ref.)

A prospective study of the impact of community–based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Leach AJ, et al. **Clin Infect Dis** 1997 Mar;24(3):356–62

Outpatient use of erythromycin: link to increased erythromycin resistance in group A streptococci. Seppälä H, et al. **Clin Infect Dis** 1995 Dec;21(6):1378–85

Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction. Villanueva A, et al. **Clin Infect Dis** 1997 Jun;24(6):1147–53

Erythromycin, clarithromycin, and azithromycin: are the differences real? Amsden GW. **Clin Ther** 1996 Jan–Feb; 18(1):56–72; discussion 55 (63 ref.)

Clinical efficacy of dirithromycin in patients with bacteremic pneumonia. Hernández JM, et al. **Clin Ther** 1996 Nov–Dec; 18(6):1128–38

Alternative treatments in the patient with intractable asthma. Spector SL. **Curr Opin Pulm Med** 1997 Jan;3(1):23–9 (64 ref.)

A surgical wound infection due to Mycobacterium chelonae successfully treated with clarithromycin. Saluja A, et al. **Dermatol Surg** 1997 Jul;23(7):539–43

The antibiotic treatment of acute otitis media and sinusitis in children. Cohen R. **Diagn Microbiol Infect Dis** 1997 Jan–Feb;27(1–2):35–9 (19 ref.)

Effect of erythromycin on postprandial gastroesophageal reflux in reflux esophagitis. Pehl C, et al. **Dis Esophagus** 1997 Jan;10(1):34–7

The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections. Amsden GW, et al. **Drugs** 1997 Jul;54(1):69–80 (63 ref.)

Choosing the right macrolide antibiotic. A guide to selection. Charles L, et al. **Drugs** 1997 Mar;53(3):349–57 (107 ref.)

Azithromycin. A review of its pharmacological properties and use as 3–day therapy in respiratory tract infections. Dunn CJ, et al. **Drugs** 1996 Mar;51(3):483–505 (120 ref.)

Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Langtry HD, et al. **Drugs** 1997 Jun;53(6):973–1004 (205 ref.)

Low dose erythromycin regimen for the treatment of chancroid. Kimani J, et al. **East Afr Med J** 1995 Oct; 72(10):645–8

Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993–1995. The Italian Surveillance Group for Antimicrobial Resistance. Cornaglia G, et al. **Emerg Infect Dis** 1996 Oct–Dec; 2(4):339–42

PCR–RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin. Stone GG, et al. **Epidemiol Infect** 1997 Apr;118(2):119–24

Five days of erythromycin estolate versus ten days of penicillin V in the treatment of group A streptococcal tonsillopharyngitis in children. Pharyngitis Study Group. Adam D, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep; 15(9):712–7

Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis. Hayle R, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):849–53

Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. O'Doherty B. **Eur J Clin Microbiol Infect Dis** 1996 Sep;15(9):718–24

Helicobacter pylori eradication with short–term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy [see comments] Goh KL, et al. **Eur J Gastroenterol Hepatol** 1996 May;8(5):421–3 . Comment in: Eur J Gastroenterol Hepatol 1996 May;8(5):415–6.

Clarithromycin or amoxycillin plus high–dose ranitidine in the treatment of Helicobacter pylori–positive functional dyspepsia. Schütze K, et al. **Eur J Gastroenterol Hepatol** 1996 Jan;8(1):41–6

Anti–inflammatory effects of macrolide antibiotics [editorial; comment] Black PN. **Eur Respir J** 1997 May;10(5):971–2 . Comment on: Eur Respir J 1997 May;10(5):994–9.

Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double–blind, placebo–controlled study [see comments] Koh YY, et al. **Eur Respir J** 1997 May;10(5):994–9. Comment in: Eur Respir J 1997 May;10(5):971–2.

Erythromycin treatment for subclinical Ureaplasma urealyticum infection in preterm labor. Antsaklis A, et al. **Fetal Diagn Ther** 1997 Mar–Apr;12(2):89–92

Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. Bardhan KD, et al. **Gut** 1997 Aug;41(2):181–6

Evaluation of safety and efficacy of azithromycin in lower respiratory tract infections (LRTI) [published erratum appears in Indian J Med Sci 1996 Oct;50(10):367] Adhikari P, et al. **Indian J Med Sci** 1996 Sep;50(9):313–7

Amphotericin B in visceral leishmaniasis [letter; comment] Jha BB. **Indian Pediatr** 1996 Nov;33(11):971. Comment on: Indian Pediatr 1996 Jun;33(6):499–501.

Amphotericin B in resistant visceral leishmaniasis [see comments] Sahay AS, et al. **Indian Pediatr** 1996 Jun; 33(6):499–501. Comment in: Indian Pediatr 1996 Nov;33(11):971.

A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections. Dautzenberg B, et al. **Infection** 1997 Jan–Feb;25(1):16–21

Drug interaction between cyclosporine and two antimicrobial agents, josamycin and rifampicin, in organ–transplanted patients. Capone D, et al. **Int J Clin Pharmacol Res** 1996; 16(2–3):73–6

Azithromycin in the treatment of pneumonias caused by Chlamydia spp: a retrospective study. Kuzman I, et al. **Int J Clin Pharmacol Res** 1996;16(4–5):103–7

Use of flurythromycin ethylsuccinate in infections of lower airways due to sensitive germs: multicenter comparative study with clarithromycin. Vagliasindi M. **Int J Clin Pharmacol Ther** 1997 Jun;35(6):245–9

Isolated cutaneous Mycobacterium avium complex infection in AIDS. Alfandari S, et al. **Int J Dermatol** 1997 Apr; 36(4):294–5

Azithromycin for the treatment of acne [letter] Fernandez–Obregon AC. **Int J Dermatol** 1997 Mar; 36(3):239–40

Donovanosis: treatment with azithromycin. Arévalo Morles C, et al. **Int J STD AIDS** 1997 Jan;8(1):54–6

Azithromycin as the first–line treatment of non–gonococcal urethritis (NGU): a study of follow–up rates, contact attendance and patients' treatment preference. Carlin EM, et al. **Int J STD AIDS** 1996 May–Jun;7(3):185–9

Donovanosis: sequelae of severe disease and successful azithromycin treatment. Mein J, et al. **Int J STD AIDS** 1996 Oct;7(6):448–51

Efficacy of anti–chlamydial therapy with oxytetracycline and erythromycin. Ross JD, et al. **Int J STD AIDS** 1996 Aug–Sep;7(5):373–4

Development of resistance to clarithromycin after treatment of cutaneous Mycobacterium chelonae infection. Driscoll MS, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 1):495–6

Cladinose analogues of sixteen–membered macrolide antibiotics. IV. Improved therapeutic effects of 4–O–acyl–L–cladinose analogues of sixteen–membered macrolide antibiotics. Ajito K, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):150–61

Comparison of various macrolides on stimulation of human neutrophil degranulation in vitro. Abdelghaffar H, et al. **J Antimicrob Chemother** 1996 Jul;38(1):81–93

Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin. Carbon C, et al. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:151–61

Once–daily, 3–day azithromycin versus a three–times–daily, 10–day course of co–amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double–blind comparative study. Gris P. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:93–101

Two–year–outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. Gui GP, et al. **J Antimicrob Chemother** 1997 Mar;39(3):393–400

Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. Laurent K. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:115–24

A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. Montero L. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:125–31

An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. O'Doherty B. **J Antimicrob Chemother** 1996 Jun; 37 Suppl C:71–81

An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. Rodriguez AF. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:63–9

The role of macrolides in Streptococcus pyogenes pharyngitis. Schito GC, et al. **J Antimicrob Chemother** 1997 May;39(5):562–5 (34 ref.)

What is the best azithromycin–based therapy for Helicobacter pylori infection? [letter; comment] Tursi A, et al. **J Antimicrob Chemother** 1997 Jan;39(1):111. Comment on: J Antimicrob Chemother 1996 Apr;37(4):849–50.

A randomized, comparative study to evaluate the efficacy and tolerability of a 3–day course of azithromycin versus a 10–day course of co–amoxiclav as treatment of adult patients with lower respiratory tract infections. Zachariah J. **J Antimicrob Chemother** 1996 Jun;37 Suppl C:103–13

Experience with roxithromycin in visceral leishmaniasis in north Bihar. Lal SK, et al. **J Assoc Physicians India** 1996 Sep;44(9):615–7

Roxithromycin attenuates acid–induced cough and water–induced bronchoconstriction in children with asthma. Shimizu T, et al. **J Asthma** 1997;34(3):211–7

Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. Arguedas A, et al. **J Chemother** 1997 Feb;9(1):44–50

Chlamydia pneumoniae pneumonia: role of new macrolides. Blasi F, et al. **J Chemother** 1995 Nov;7 Suppl 4:117–8

A five–day course of dirithromycin in the treatment of acute exacerbation of severe chronic obstructive pulmonary disease. Cazzola M, et al. **J Chemother** 1997 Aug; 9(4):279–84

Inadequate azithromycin activity against Brucella melitensis in mice with acute or chronic infections. Domingo S, et al. **J Chemother** 1996 Feb;8(1):55–8

Azithromycin: 3–day versus 5–day course in the treatment of respiratory tract infections in children. Croatian Azithromycin Study Group. Ficnar B, et al. **J Chemother** 1997 Feb;9(1):38–43

Comparative trial of azithromycin and ciprofloxacin in the treatment of gonorrhea. Gruber F, et al. **J Chemother** 1997 Aug;9(4):263–6

Evaluation of the efficacy of josamycin in the treatment of impetigo in children and its in vitro activity on erythromycin resistant Staphylococcus aureus strains. Mosca A, et al. **J Chemother** 1995 Nov;7 Suppl 4:158–9

Randomized controlled study of clarithromycin versus cefaclor suspensions in the treatment of acute otitis media in children. Pavlopoulou J, et al. **J Chemother** 1995 Nov; 7 Suppl 4:150–3

Erythromycin and trimethoprim–sulphamethoxazole in the treatment of cholera in children. Kabir I, et al. **J Diarrhoeal Dis Res** 1996 Dec;14(4):243–7

Erythromycin for treatment of acute bronchitis [comment] Franko JP. **J Fam Pract** 1996 Sep;43(3):230–1. Comment on: J Fam Pract 1996 Jun;42(6):601–5.

Treating acute bronchitis [letter; comment] Kaufman D. **J Fam Pract** 1996 Dec;43(6):527; discussion 528–9. Comment on: J Fam Pract 1996 Jun;42(6):601–5.

Treating acute bronchitis [letter; comment] Kimber RG. **J Fam Pract** 1996 Dec;43(6):527; discussion 528–9. Comment on: J Fam Pract 1996 Jun;42(6):601–5.

Effects of erythromycin in chronic idiopathic intestinal pseudo–obstruction. Minami T, et al. **J Gastroenterol** 1996 Dec;31(6):855–9

Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. Moayyedi P, et al. **J Gastroenterol** 1997 Feb; 32(1):24–7

Significant increase in eradication rates of Helicobacter pylori infection with two consecutive dual therapies (omeprazole and amoxycillin or omeprazole and clarithromycin). A randomized study in 450 Spanish patients. Moreno JA, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:48–52

Efficacy of clarithromycin in eradicating Helicobacter pylori. Satoh K, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:53–5 (34 ref.)

The effect of erythromycin on resolution of symptoms among adults with pharyngitis not caused by group A streptococcus. Petersen K, et al. **J Gen Intern Med** 1997 Feb;12(2):95–101

Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS. Wiselka MJ, et al. **J Infect** 1996 Nov;33(3):227–9

Effect of ethambutol on emergence of clarithromycin–resistant Mycobacterium avium complex in the beige mouse model. Bermudez LE, et al. **J Infect Dis** 1996 Dec;174(6):1218–22

Comparison of azithromycin and co–amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group. Biebuyck XA. **J Int Med Res** 1996 Sep–Oct; 24(5):407–18

Azithromycin compared with clarithromycin in the treatment of adult patients with acute purulent tracheobronchitis: a cost of illness study. Sternon J, et al. **J Int Med Res** 1995 Nov–Dec;23(6):413–22

Dirithromycin versus amoxiclav in the treatment of acute exacerbations of chronic bronchitis. Van Royen P, et al. **J Int Med Res** 1997 Jan–Feb;25(1):33–40

Azithromycin in the treatment of chlamydial cervicitis and eradication of Ureaplasma urealyticum in female lower genital tract. Charoenwatanachokchai A, et al. **J Med Assoc Thai** 1997 Jun;80(6):343–7

Efficacy of short–term treatment of pertussis with clarithromycin and azithromycin. Aoyama T, et al. **J Pediatr** 1996 Nov;129(5):761–4

Cryptosporidium in patients infected with human immunodeficiency virus: azithromycin revisited [letter; comment] Ramos JT, et al. **J Pediatr** 1997 Jun; 130(6):1009–10. Comment on: J Pediatr 1996 Aug;129(2):297–300.

Selective intestinal decontamination in multiple trauma patients: prospective, controlled trial. Lingnau W, et al. **J Trauma** 1997 Apr;42(4):687–94

Avermectins and milbemycins. McKellar QA, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):331–51 (223 ref.)

Pharmacokinetic–pharmacodynamic model for spiramycin in staphylococcal mastitis. Renard L, et al. **J Vet Pharmacol Ther** 1996 Apr;19(2):95–103

Practice guidelines for treatment of peptic ulcer disease [letter; comment] Webb DD. **JAMA** 1996 Oct 9; 276(14):1136; discussion 1136–7. Comment on: JAMA 1996 Feb 28;275(8):622–9.

Neutrophil chemotactic activity in cryptogenic organizing pneumonia and the response to erythromycin. Hotta M. **Kurume Med J** 1996;43(3):207–217

Randomised trial of roxithromycin in non–Q–wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group [see comments] Gurfinkel E, et al. **Lancet** 1997 Aug 9; 350(9075):404–7. Comment in: Lancet 1997 Aug 9;350(9075):378–9.

Regression of mucosa–associated lymphoid–tissue lymphoma after eradication of Helicobacter pylori [letter] Wright DH. **Lancet** 1997 Sep 27;350(9082):960–1

Pneumonia during remission induction chemotherapy in patients with AML or MDS. Wilhelm M, et al. **Leukemia** 1996 Dec;10(12):1870–3

Antibiotic treatment in mice infected with Japanese Borrelia garinii: efficacy of ceftriaxone for eradicating the infection induced by Ixodes persulcatus tick bites. Konishi T, et al. **Microbiol Immunol** 1997;41(2):165–8

The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance [see comments] Seppälä H, et al. **N Engl J Med** 1997 Aug 14;337(7):441–6. Comment in: N Engl J Med 1997 Aug 14;337(7):491–2.

Rhodococcus equi in CAPD–associated peritonitis treated with azithromycin [see comments] Hoque S, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2340–1. Comment in: Nephrol Dial Transplant 1997 May;12(5):1080–1.

A multicenter, open label trial of azithromycin vs. amoxicillin/ clavulanate for the management of acute otitis media in children. Aronovitz G. **Pediatr Infect Dis J** 1996 Sep;15(9 Suppl):S15–9

Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Block SL. **Pediatr Infect Dis J** 1997 Apr;16(4):449–56 (39 ref.)

Successful treatment of chronic Mycobacterium abscessus otitis media with clarithromycin. Ferguson PJ, et al. **Pediatr Infect Dis J** 1996 Apr;15(4):384–5

Breakthrough sepsis in macrolide–resistant pneumococcal infection. Jackson MA, et al. **Pediatr Infect Dis J** 1996 Nov;15(11):1049–51

A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. Khurana CM. **Pediatr Infect Dis J** 1996 Sep;15(9 Suppl):S24–9

History of macrolide use in pediatrics. Klein JO. **Pediatr Infect Dis J** 1997 Apr;16(4):427–31 (30 ref.)

A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media. McCarty J. **Pediatr Infect Dis J** 1996 Sep;15(9 Suppl):S10–4

A multicenter, double blind comparison of azithromycin and amoxicillin/ clavulanate for the treatment of acute otitis media in children. McLinn S. **Pediatr Infect Dis J** 1996 Sep;15(9 Suppl):S20–3

Azithromycin vs. doxycycline for Mediterranean spotted fever. Meloni G, et al. **Pediatr Infect Dis J** 1996 Nov; 15(11):1042–4

Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. The Swiss Tonsillopharyngitis Study Group [see comments] Schaad UB, et al. **Pediatr Infect Dis J** 1996 Sep;15(9):791–5. Comment in: Pediatr Infect Dis J 1997 May;16(5):542.

Future indications for macrolides. Tarlow MJ, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):457–62 (27 ref.)

Macrolides in the management of streptococcal pharyngitis/tonsillitis. Tarlow MJ. **Pediatr Infect Dis J** 1997 Apr;16(4):444–8 (24 ref.)

Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction. Pollak PT, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):827–9

Efficacy of combined clarithromycin and sparfloxacin therapy in a patient with discitis: due to Mycobacterium xenopi [letter] Roche B, et al. **Rev Rhum Engl Ed** 1997 Jan;64(1):64–5

Efficacy and safety of azithromycin versus lymecyline in the treatment of genital chlamydial infections in women. Brihmer C, et al. **Scand J Infect Dis** 1996;28(5):451–4

New developments in the treatment of nontuberculous mycobacterial (NTM) disease. Griffith DE, et al. **Semin Respir Infect** 1996 Dec;11(4):301–10 (54 ref.)

Multicenter trial of single–dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Handsfield HH, et al. **Sex Transm Dis** 1994 Mar–Apr;21(2):107–11

Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. Nonata R, et al. **Trans R Soc Trop Med Hyg** 1997 Jan–Feb;91(1):77

Response of babesiosis to a combined regimen of quinine and azithromycin. Shaio MF, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):214–5

Azithromycin prophylaxis prevents epidemic dysentery. Shanks GD, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):316

Erythromycin resistance of Campylobacter isolates from pigs [letter; comment] Davies P, et al. **Vet Rec** 1996 Sep 7; 139(10):244. Comment on: Vet Rec 1996 Mar 30;138(13):306–7.

An open evaluation of the efficacy and safety of the new macrolide roxithromycin in the treatment of lower respiratory tract infections and pneumonia in Nigerian patients. Isah AO, et al. **West Afr J Med** 1996 Apr–Jun; 15(2):111–6

[Clarithromycin versus amoxicillin–clavulanic acid in the treatment of acute maxillary sinusitis in adults] Géhanno P, et al. **Pathol Biol (Paris)** 1996 Apr;44(4):293–7 (Eng. Abstr.) **(Fre)**

[Macrolides: indications in 1997] Bouhour D, et al. **Presse Med** 1997 Mar;26 Suppl 2:22–6 (31 ref.) **(Fre)**

[Antibiotic strategy in bronchial infections. Role of roxithromycin] Gaillat J. **Presse Med** 1997 Mar;26 Suppl 2:16–21 (26 ref.) **(Fre)**

[Asthma and Chlamydia pneumoniae. A future prospect for macrolides in general and roxithromycin in particular?] Mayaud C. **Presse Med** 1997 Mar;26 Suppl 2:27–9 (21 ref.) **(Fre)**

[Lower respiratory infections: predictive factors of therapeutic response] Bedos JP, et al. **Rev Pneumol Clin** 1996;52 Suppl 2:S47–50 **(Fre)**

[Community–acquired pneumonia of atypical presentation, role of macrolides (letter)] Roblot F, et al. **Rev Pneumol Clin** 1997;53(2):111–2 **(Fre)**

[Efficacy of a 5–day treatment with an azalide (azithromycin) in superinfections of chronic bronchitis] Zuck P. **Rev Pneumol Clin** 1996;52 Suppl 2:S56–9 **(Fre)**

[Prevention of congenital toxoplasmosis with spiramycin; value and limits of levels in amniotic fluid (letter)] Bourget P, et al. **Therapie** 1996 Nov–Dec;51(6):685–7 **(Fre)**

[Current antibiotics for clinical practice] Zimmerli W. **Schweiz Rundsch Med Prax** 1996 Oct 1;85(40):1240–4 (20 ref.) (Eng. Abstr.) **(Ger)**

[Azithromycin combined with pyrimethamine in the treatment of neurotoxoplasmosis, in an AIDS patient]

Trotta M, et al. **Minerva Med** 1997 Mar;88(3):117–9 (Eng. Abstr.) **(Ita)**

[Double-blind evaluation of mepartricin 150.000 U (40 mg) compared with placebo in benign prostatic hypertrophy] Prezioso D, et al. **Minerva Urol Nefrol** 1996 Dec; 48(4):207–11 (Eng. Abstr.) **(Ita)**

[Immunoglobulin positive cells in paranasal mucosa treated with macrolides] Iino Y, et al. **Arerugi** 1996 Jan;45(1):62–9 (Eng. Abstr.) **(Jpn)**

[A clinical evaluation of azithromycin in the treatment of pediatric infection] Furukawa S, et al. **Jpn J Antibiot** 1996 Nov;49(11):1013–23 (Eng. Abstr.) **(Jpn)**

[Therapeutic efficacy of azithromycin in pediatrics] Haruta T, et al. **Jpn J Antibiot** 1996 Oct;49(10):926–31 (Eng. Abstr.) **(Jpn)**

[Clinical study of a macrolide antibiotic, azithromycin, in pediatric patients] Kobayashi Y, et al. **Jpn J Antibiot** 1996 Nov;49(11):1004–12 (Eng. Abstr.) **(Jpn)**

[Therapy with azithromycin in pediatric infections] Kuroda Y, et al. **Jpn J Antibiot** 1996 Oct;49(10):932–8 (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of azithromycin in pediatric infections] Nishimura T, et al. **Jpn J Antibiot** 1996 Oct;49(10):917–25 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetic and clinical studies on azithromycin in children] Ohtsuka Y, et al. **Jpn J Antibiot** 1996 Nov; 49(11):1039–48 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetic and clinical evaluations of azithromycin in the pediatric field] Okada T, et al. **Jpn J Antibiot** 1996 Nov;49(11):1024–9 (Eng. Abstr.) **(Jpn)**

[Clinical studies on azithromycin in pediatrics] Okamoto T, et al. **Jpn J Antibiot** 1996 Oct;49(10):939–46 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetic and clinical evaluation of azithromycin in pediatrics] Okumura A, et al. **Jpn J Antibiot** 1996 Nov; 49(11):994–1003 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetic, bacteriological and clinical studies on azithromycin in children] Tajima T, et al **Jpn J Antibiot** 1997 Feb;50(2):200–5 (Eng. Abstr.) **(Jpn)**

[Pharmacokinetic and clinical evaluation of azithromycin using fine granules or capsules in the pediatric patients] Toyonaga Y, et al. **Jpn J Antibiot** 1996 Nov;49(11):981–93 (Eng. Abstr.) **(Jpn)**

[Pilot studies on the treatment of Mycobacterium avium complex lung disease—new macrolides and new quinolones. (1) Continuous positive cases (failure of the initial chemotherapy)] Sakatani M. **Kekkaku** 1996 Sep; 71(9):544–7 **(Jpn)**

[Preclinical study of therapeutic agents used against Mycobacterium avium complex infections—with special reference to new macrolides and new quinolones] Tomioka H, et al. **Kekkaku** 1996 Sep;71(9):531–5 **(Jpn)**

[The clinical study of clarithromycin for pulmonary Mycobacterium avium-intracellulare complex infection] Yamamoto M, et al. **Kekkaku** 1997 Jan;72(1):1–7 (Eng. Abstr.) **(Jpn)**

[Bronchiolitis obliterans preceding rheumatoid arthritis: effect of clarithromycin] Iwata M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Nov; 34(11):1271–6 (Eng. Abstr.) **(Jpn)**

[Two cases of pulmonary disease caused by Mycobacterium chelonae subsp. abscessus] Naoki K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Nov; 34(11):1264–70 (Eng. Abstr.) **(Jpn)**

[Effect of clarithromycin on symptoms and mucociliary transport in patients with sino-bronchial syndrome] Nishi K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec; 33(12):1392–1400 (Eng. Abstr.) **(Jpn)**

[Lung cancer: progress in diagnosis and treatment. IV. Related topics: 2. Macrolides as biological response modifiers for the treatment of lung cancer] Mikasa K, et al. **Nippon Naika Gakkai Zasshi** 1997 Jan 10;86(1):100–7 **(Jpn)**

[Effect of erythromycin on early delayed gastric emptying after pylorus preserving pancreatoduodenectomy—case report] Ogawa T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb;93(2):149–54 **(Jpn)**

[Secondary prophylaxis in rheumatic fever. Oral antibiotic therapy versus benzathine penicillin] Herdy GV, et al. **Arq Bras Cardiol** 1996 Nov;67(5):331–3 (Eng. Abstr.) **(Por)**

[Azithromycin (sumamed)—in the treatment of respiratory tract infections] Fomina IP, et al. **Antibiot Khimioter** 1996 Feb;41(2):52–61 (36 ref.) **(Rus)**

["Sumamed in the treatment of urogenital infections"] Kuznetsova SM. **Antibiot Khimioter** 1996 Feb;41(2):3–4 **(Rus)**

[Clinico-laboratory evaluation of the effectiveness of azithromycin in the treatment of patients with Chlamydia and mixed Chlamydia-gonorrhea infections] Vasil'ev MM, et al. **Antibiot Khimioter** 1996 Feb;41(2):9–13 (Eng. Abstr.) **(Rus)**

[Comparative study of the antimicrobial activity of pefloxacin, ciprofloxacin, norfloxacin and azithromycin with respect to Strains of Yersinia pseudotuberculosis] Zaitseva EA, et al. **Antibiot Khimioter** 1996 Jan;41(1):19–21 (Eng. Abstr.) **(Rus)**

[Role of macrolides in the treatment of outpatient pneumonia] Sinopal'nikov AI, et al. **Klin Med (Mosk)** 1997;75(6):46–50 **(Rus)**

[The efficacy of the macrolide antibiotic rovamycin in treating acute pneumonia] Aleksanian LA, et al. **Ter Arkh** 1997;69(1):60–1 **(Rus)**

[The macrolide antibiotic rovamycin in the treatment of pneumonias] Gel'tser BI, et al. **Ter Arkh** 1996;68(12):22–5 (Eng. Abstr.) **(Rus)**

[What is the current role of clarithromycin in the eradication of Helicobacter pylori?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1997 Apr;89(4):305–12 (108 ref.) **(Spa)**

TOXICITY

Nephrotoxicity of amphotericin B administered to dogs in a fat emulsion versus five percent dextrose solution. Randall SR, et al. **Am J Vet Res** 1996 Jul;57(7):1054–8

Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. Tseng AL, et al. **Clin Infect Dis** 1997 Jan;24(1):76–7

Effect of amphotericin B associated with a lipid emulsion on the oxidative burst of human polymorphonuclear leukocytes. Marzzullo L, et al. **Gen Pharmacol** 1997 Feb; 28(2):203–7

Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. Antzelevitch C, et al. **J Am Coll Cardiol** 1996 Dec; 28(7):1836–48

Cytotoxicity of macrolide antibiotics in a cultured human liver cell line. Viluksela M, et al. **J Antimicrob Chemother** 1996 Sep;38(3):465–73

Protection from amphotericin B-induced lipid peroxidation in rats by fructose-1,6-diphosphate. Rao MR, et al. **Res Commun Mol Pathol Pharmacol** 1997 Feb;95(2):217–20

URINE

Determination of erythromycin in urine and plasma using microbore liquid chromatography with tris(2,2'-bipyridyl)ruthenium(II) electrogenerated chemiluminescence detection. Ridlen JS, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):393–400

ANTIBIOTICS, MONOBACTAM see **MONOBACTAMS**

ANTIBIOTICS, PENICILLIN see **PENICILLINS**

ANTIBIOTICS, PEPTIDE

Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination. Griswold MW, et al. **Am J Health Syst Pharm** 1996 Sep 1;53(17):2045–53

Proceedings of the 2nd International Workshop on Lantibiotics. Arnhem, The Netherlands, 20–23 November 1994. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):87–202

Novel lantibiotics and their pre-peptides. Nes IF, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):89–97 (57 ref.)

Peptide antibiotics [see comments] Hancock RE. **Lancet** 1997 Feb 8;349(9049):418–22 (23 ref.). Comment in: Lancet 1997 Apr 5;349(9057):1026–7.

ADMINISTRATION & DOSAGE

[Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection] Mordasini C, et al. **Schweiz Med Wochenschr** 1997 May 24;127(21):905–10 (46 ref.) (Eng. Abstr.) **(Ger)**

[Bacterial translocation induces remnant liver injury after subtotal (90%) hepatectomy in rats—the effect of decontamination of gram-negative rods in digestive tract by oral polymyxin B treatment] Iso A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):544–52 (Eng. Abstr.) **(Jpn)**

[Enhancement of treatment efficacy in experimental plague by the sequential administration of antibiotics] Makarovskaia LN, et al. **Antibiot Khimioter** 1996; 41(11):25–7 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Interaction between quinupristin/dalfopristin and cyclosporine. Stamatakis MK, et al. **Ann Pharmacother** 1997 May;31(5):576–8

Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Chow JW, et al. **Clin Infect Dis** 1997 Jan;24(1):91–2

Severe reversible reticulocytopenic anemia associated with quinupristin/dalfopristin RP59500 therapy. Launay O, et al. **Clin Infect Dis** 1997 Jul;25(1):156

ANALYSIS

Liquid chromatographic analysis of bacitracin methylene disalicylate in feed. Webster GK. **J AOAC Int** 1997 Jul-Aug;80(4):732–5

Improved method for quantification of the bacteriocin nisin. Wolf CE, et al. **J Appl Bacteriol** 1996 Apr;80(4):453–7

Determination of the Fusarium mycotoxin beauvericin at micrograms/kg levels in corn by high-performance liquid chromatography with diode-array detection. Krska R, et al. **J Chromatogr A** 1996 Oct 11;746(2):233–8

Practical capillary electrophoresis method for the quantitation of the acetate counter-ion in a novel antifungal lipopeptide. Zhou L, et al. **J Chromatogr A** 1997 Feb 28; 763(1-2):279–84

New caerin antibacterial peptides from the skin glands of the Australian tree frog Litoria xanthomera. Part 2. Sequence determination using mass spectrometry and associated techniques. Steinborner ST, et al. **Rapid Commun Mass Spectrom** 1997;11(9):997–1000

ANTAGONISTS & INHIBITORS

[The isolation and characteristics of mutants of the Saccharopolyspora erythraea strain resistant to thiostrepton] Nastasiak IN, et al. **Antibiot Khimioter** 1997; 42(1):7–11 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

The biosynthesis of the lantibiotics epidermin, gallidermin, Pep5 and epilancin K7. Bierbaum G, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):119–127 (42 ref.)

Genetics of subtilin and nisin biosyntheses: biosynthesis of lantibiotics. Entian KD, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):109–17 (74 ref.)

Ribosomally synthesized antimicrobial peptides: their function, structure, biogenesis, and mechanism of action. Nissen-Meyer J, et al. **Arch Microbiol** 1997 Feb-Mar; 167(2-3):67–77 (90 ref.)

Protein templates for the biosynthesis of peptide antibiotics. Marahiel MA. **Chem Biol** 1997 Aug;4(8):561–7 (31 ref.)

Biosynthesis of acylpeptidolactones of the daptomycin type. A comparative analysis of peptide synthetases forming A21978C and A54145. Wessels P, et al. **Eur J Biochem** 1996 Dec 15;242(3):665–73

Characterization of iturin synthetase in the wild-type Bacillus subtilis strain producing iturin and in an iturin deficient mutant. Feignier C, et al. **FEMS Microbiol Lett** 1996 Feb 15;136(2):117–22

Effect of leader peptide mutations on biosynthesis of the lantibiotic Pep5. Neis S, et al. **FEMS Microbiol Lett** 1997 Apr 15;149(2):249–55

Inducible production and cellular location of the epidermin biosynthetic enzyme EpiB using an improved staphylococcal expression system. Peschel A, et al. **FEMS Microbiol Lett** 1996 Apr 1;137(2-3):279–84

Pristinamycin I biosynthesis in Streptomyces pristinaespiralis: molecular characterization of the first two structural peptide synthetase genes. de Crécy-Lagard V, et al. **J Bacteriol** 1997 Feb;179(3):705–13

Evidence for a multimeric subtilin synthetase complex. Kiesau P, et al. **J Bacteriol** 1997 Mar;179(5):1475–81

Purification of peptide synthetases involved in pristinamycin I biosynthesis. Thibaut D, et al. **J Bacteriol** 1997 Feb; 179(3):697–704

Cloning and expression in Escherichia coli of genetic determinants for production of and immunity to microcin E492 from Klebsiella pneumoniae. Wilkens M, et al. **J Bacteriol** 1997 Aug;179(15):4789–94

Production of nisin-like bacteriocins by Lactococcus lactis strains isolated from vegetables. Franz CM, et al. **J Basic Microbiol** 1997;37(3):187–96

Genotypic and phenotypic analysis of zwittermicin A-producing strains of Bacillus cereus. Raffel SJ, et al. **Microbiology** 1996 Dec;142 (Pt 12):3425–36

Organization and expression of a gene cluster involved in the biosynthesis of the lantibiotic lactocin S. Skaugen M, et al. **Mol Gen Genet** 1997 Feb 27;253(6):674–86

Finetuning pristinamycin synthesis in streptomycetes [news] Hopwood D. **Nat Biotechnol** 1997 Apr;15(4):321

[Nisin: conditions for production and isolation of the drug] Baranova IP, et al. **Antibiot Khimioter** 1997;42(3):37–44 (69 ref.) **(Rus)**

[Pool of free amino acids in mycelium and culture fluid of Streptomyces galbus (F) subsp. achromogenes 695, a strain producing actinomycin complex and its variants] Iocheva LD, et al. **Antibiot Khimioter** 1996 Mar;41(3):9–14 (Eng. Abstr.) **(Rus)**

[Molecular genetic study of the strain Streptomyces virginiae—the producer of virginiamycin] Kudriavtseva EA, et al. **Genetika** 1996 Apr;32(4):510–6 (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Synthesis and antibacterial action of cecropin and proline-arginine-rich peptides from pig intestine. Vunnam S, et al. **J Pept Res** 1997 Jan;49(1):59–66

Hydrophobic effects on antibacterial and channel-forming properties of cecropin A-melittin hybrids. Juvvadi P, et al. **J Pept Sci** 1996 Jul-Aug;2(4):223–32

CHEMISTRY

Three dimensional structure of the antibiotic bacitracin A complexed to two different subtilisin proteases: novel mode of enzyme inhibition. Pfeffer-Hennig S, et al. **Adv Exp Med Biol** 1996;379:29–41

Genetics of subtilin and nisin biosyntheses: biosynthesis of lantibiotics. Entian KD, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):109–17 (74 ref.)

Enterococcus faecalis cytolysin and lactocin S of Lactobacillus sake. Gilmore MS, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):129–38 (35 ref.)

Protein engineering of lantibiotics. Kuipers OP, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):161–69 (28 ref.)

Comparison of lantibiotic gene clusters and encoded proteins. Siezen RJ, et al. **Antonie Van Leeuwenhoek** 1996 Feb; 69(2):171–84 (73 ref.)

Structures of lantibiotics studied by NMR. van De Ven FJ,

et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):99–107 (37 ref.)

Structural elucidation of XR586, a peptaibol–like antibiotic from Acremonium persicinum. Sharman GJ, et al. **Biochem J** 1996 Dec 15;320 (Pt 3):723–8

The C–terminal region of nisin is responsible for the initial interaction of nisin with the target membrane. Breukink E, et al. **Biochemistry** 1997 Jun 10;36(23):6968–76

Self–assembly of designed antimicrobial peptides in solution and micelles. Javadpour MM, et al. **Biochemistry** 1997 Aug 5;36(31):9540–9

Interaction of the 14–residue peptaibols, harzianins HC, with lipid bilayers: permeability modifications and conductance properties. Lucaciu M, et al. **Biochim Biophys Acta** 1997 Jan 14;1323(1):85–96

Helix bending in alamethicin: molecular dynamics simulations and amide hydrogen exchange in methanol. Gibbs N, et al. **Biophys J** 1997 Jun;72(6):2490–5

Streptogramins. A unique class of antibiotics. Pechère JC. **Drugs** 1996;51 Suppl 1:13–9 (21 ref.)

Constitution and solution conformation of the antibiotic mersacidin determined by NMR and molecular dynamics. Prasch T, et al. **Eur J Biochem** 1997 Mar 1;244(2):501–12

Structure and biological activity of chemically modified nisin A species. Rollema HS, et al. **Eur J Biochem** 1996 Nov 1;241(3):716–22

The three–dimensional solution structure of the lantibiotic murein–biosynthesis–inhibitor actagardine determined by NMR. Zimmermann N, et al. **Eur J Biochem** 1997 Jun 15; 246(3):809–19

cDNA cloning of three cecropin–like antimicrobial peptides (Styelins) from the tunicate, Styela clava. Zhao C, et al. **FEBS Lett** 1997 Jul 21;412(1):144–8

The structures of sulfomycins II and III. Kohno J, et al. **J Antibiot (Tokyo)** 1996 Oct;49(10):1063–5

YM–24074, a new peptide antibiotic. II. Structural elucidation. Sato T, et al. **J Antibiot (Tokyo)** 1996 Aug; 49(8):811–4

Characterization of novel cysteine–rich antimicrobial peptides from scorpion blood. Ehret–Sabatier L, et al. **J Biol Chem** 1996 Nov 22;271(47):29537–44

Structure–affinity relationships for the binding of actinomycin D to DNA. Gallego J, et al. **J Comput Aided Mol Des** 1997 Mar;11(2):114–28

Crystal structure of the gramicidin/potassium thiocyanate complex. Doyle DA, et al. **J Mol Biol** 1997 Mar 14; 266(5):963–77

Monoclonal antibody against bovine Lactoferricin and its epitopic site. Shimazaki K, et al. **J Vet Med Sci** 1996 Dec; 58(12):1227–9

Observation of non–covalent interactions between beauvericin and oligonucleotides using electrospray ionization mass spectrometry. Pócsfalvi G, et al. **Rapid Commun Mass Spectrom** 1997;11(3):265–72

PR–39, a proline–rich peptide antibiotic from pig, and FALL–39, a tentative human counterpart. Agerberth B, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):127–31 (19 ref.)

Isolation of a new epidermin variant from two strains of Staphylococcus epidermidis--frequency of lantibiotic production in coagulase–negative staphylococci. Israil AM, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):285–96

IMMUNOLOGY

Immunity to lantibiotics. Saris PE, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):151–9 (49 ref.)

ISOLATION & PURIFICATION

Cloning and sequence analysis of zooA, a Streptococcus zooepidemicus gene encoding a bacteriocin–like inhibitory substance having a domain structure similar to that of lysostaphin. Simmonds RS, et al. **Gene** 1997 Apr 21; 189(2):255–61

Isolation and structure of bergofungin, a new antifungal peptaibol from Emericellopsis donezkii HKI 0059. Berg A, et al. **J Antibiot (Tokyo)** 1996 Aug;49(8):817–20

Lipohexin, a new inhibitor of prolyl endopeptidase from Moeszia lindtneri (HKI–0054) and Paecilomyces sp. (HKI–0055; HKI–0096). I. Screening, isolation and structure elucidation. Heinze S, et al. **J Antibiot (Tokyo)** 1997 May;50(5):379–83

Propeptin, a new inhibitor of prolyl endopeptidase produced by Microbispora. I. Fermentation, isolation and biological properties. Kimura K, et al. **J Antibiot (Tokyo)** 1997 May; 50(5):373–8

Identification of CRAMP, a cathelin–related antimicrobial peptide expressed in the embryonic and adult mouse. Gallo RL, et al. **J Biol Chem** 1997 May 16;272(20):13088–93

Fusaricidins B, C and D, new depsipeptide antibiotics produced by Bacillus polymyxa KT–8: isolation, structure elucidation and biological activity. Kajimura Y, et al. **Jpn J Antibiot** 1997 Mar;50(3):220–8

METABOLISM

Stereospecific reduction of virginiamycin M1 as the virginiamycin resistance pathway in Streptomyces virginiae. Lee CK, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):595–601

Post–translational modifications of lantibiotics. Kupke T, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):139–50 (72 ref.)

cDNA cloning and characterization of buforin I, an antimicrobial peptide: a cleavage product of histone H2A. Kim HS, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):381–7

Crystal structure of the DNA decamer d(CGCAATTGCG) complexed with the minor groove binding drug netropsin. Nunn CM, et al. **Biochemistry** 1997 Apr 22;36(16):4792–9

Glucosylation of the peptide leucinostatin A, produced by an endophytic fungus of European yew, may protect the host from leucinostatin toxicity. Strobel GA, et al. **Chem Biol** 1997 Jul;4(7):529–36

In vitro selection of a viomycin–binding RNA pseudoknot. Wallis MG, et al. **Chem Biol** 1997 May;4(5):357–66

Gravity dependency of the gramicidin A channel conductivity. A model for gravity perception on the cellular level. Schatz A, et al. **Eur Biophys J** 1996; 25(1):37–41

Aureobasidin A, an antifungal cyclic depsipeptide antibiotic, is a substrate for both human MDR1 and MDR2/P–glycoproteins. Kino K, et al. **FEBS Lett** 1996 Dec 9;399(1–2):29–32

In vivo reaction of affinity–tag–labelled epidermin precursor peptide with flavoenzyme EpiD. Kupke T, et al. **FEMS Microbiol Lett** 1997 Aug 1;153(1):25–32

Evidence for a role of NisT in transport of the lantibiotic nisin produced by Lactococcus lactis N8. Qiao M, et al. **FEMS Microbiol Lett** 1996 Oct 15;144(1):89–93

Cloning of the enomycin structural gene from Streptomyces mauvecolor and production of recombinant enomycin in Escherichia coli. Takeuchi S, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):27–31

The enethiolate anion reaction products of EpiD. Pka value of the enethiol side chain is lower than that of the thiol side chain of peptides. Kupke T, et al. **J Biol Chem** 1997 Feb 21;272(8):4759–62

Structure–affinity relationships for the binding of actinomycin D to DNA. Gallego J, et al. **J Comput Aided Mol Des** 1997 Mar;11(2):114–28

Preparation of site–specific isotopically labelled zervamicins, the antibiotic peptaibols produced by Emericellopsis salmosynnemata. Egorova–Zachernyuk TA, et al. **J Pept Sci** 1996 Nov–Dec;2(6):341–50

Secretion of the lantibiotics epidermin and gallidermin: sequence analysis of the genes gdmT and gdmH, their influence on epidermin production and their regulation by EpiQ. Peschel A, et al. **Mol Gen Genet** 1997 Apr 16; 254(3):312–8

Redistribution of phosphatidylethanolamine at the cleavage furrow of dividing cells during cytokinesis. Emoto K, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):12867–72

PHARMACOLOGY

Studies of antibiotic resistance of rough and smooth Proteus mirabilis strains and influence of polymyxin E on their lipopolysaccharide composition. Kaca W, et al. **Acta Microbiol Pol** 1996;45(2):161–8

Antibiotic resistance in Streptomyces lividans: fluorescence assay for streptogramin B lyase. Bateman KP, et al. **Anal Biochem** 1997 Jun 1;248(2):297–9

Inhibition assay for the binding of biotinylated von Willebrand factor to platelet–bound microtiter wells in the presence of ristocetin or botrocetin. Miura S, et al. **Anal Biochem** 1996 May 1;236(2):215–20

Clinical investigation of topical antimicrobials in healthy volunteers. Langford JH, et al. **Ann Pharmacother** 1997 Jan;31(1):34–8

Distribution of genes encoding resistance to streptogramin A and related compounds among staphylococci resistant to these antibiotics. Allignet J, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2523–8

In vitro antifungal activity of pneumocandin L–743,872 against a variety of clinically important molds. Del Poeta M, et al. **Antimicrob Agents Chemother** 1997 Aug; 41(8):1835–6

In vitro susceptibilities of clinical isolates of vancomycin–resistant enterococci [letter] Evans PA, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1406

Improved activity of a synthetic indolicidin analog. Falla TJ, et al. **Antimicrob Agents Chemother** 1997 Apr; 41(4):771–5

Pneumocandin L–743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Franzot SP, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):331–6

Antibacterial activity in bovine lactoferrin–derived peptides. Hoek KS, et al. **Antimicrob Agents Chemother** 1997 Jan; 41(1):54–9

Indole and (E)–2–hexenal, phytochemical potentiators of polymyxins against Pseudomonas aeruginosa and Escherichia coli. Kubo A, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1438–41

Stereospecific reduction of virginiamycin M1 as the virginiamycin resistance pathway in Streptomyces virginiae. Lee CK, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):595–601

Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor. Lin PF, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):133–8

Tandem duplication in ermC translational attenuator of the macrolide–lincosamide–streptogramin B resistance plasmid pSES6 from Staphylococcus equorum. Lodder G, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):215–7

In vitro activities of semisynthetic pneumocandin L–733,560 against fluconazole–resistant and –susceptible Candida albicans isolates. Martinez–Suarez JV, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1277–9

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (ravefloxacin), and dalfopristin–quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Mulazimoglu L, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2428–30

Pharmacodynamics of RP 59500 (quinupristin–dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus–infected fibrin–platelet clots in an in vitro infection model. Rybak MJ, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1359–63

In vitro antifungal and fungicidal activities and erythrocyte toxicities of cyclic lipodepsinonapeptides produced by Pseudomonas syringae pv. syringae. Sorensen KN, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2710–3

Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U–100592 and U–100766), and other oral and parenteral agents against 203 penicillin–susceptible and –resistant pneumococci. Spangler SK, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):481–4

In vitro activity of a new pneumocandin antifungal, L–743,872, against azole–susceptible and –resistant Candida species. Vazquez JA, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1612–4

Macrolide–lincosamide–streptogramin B resistance in Staphylococcus lentus results from the integration of part of a transposon into a small plasmid. Werckenthin C, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2224–5

Mechanism of lantibiotic–induced pore–formation. Moll GN, et al. **Antonie Van Leeuwenhoek** 1996 Feb;69(2):185–91 (36 ref.)

Mode of action of a lysostaphin–like bacteriolytic agent produced by Streptococcus zooepidemicus 4881. Simmonds RS, et al. **Appl Environ Microbiol** 1996 Dec;62(12):4536–41

Antimycoplasma properties and application in cell culture of surfactin, a lipopeptide antibiotic from Bacillus subtilis. Vollenbroich D, et al. **Appl Environ Microbiol** 1997 Jan; 63(1):44–9

Efrapeptins block exocytic but not endocytic trafficking of proteins. Muroi M, et al. **Biochem Biophys Res Commun** 1996 Oct 23;227(3):800–9

DNA–damaging enediyne C–1027 inhibits initiation of intracellular SV40 DNA replication in trans. McHugh MM, et al. **Biochemistry** 1997 Feb 4;36(5):1003–9

Ion–channels formed by hypelcins, antibiotic peptides, in planar bilayer lipid membranes. Koide N, et al. **Biochim Biophys Acta** 1997 May 22;1326(1):47–53

Interaction of the 14–residue peptaibols, harzianins HC, with lipid bilayers: permeability modifications and conductance properties. Lucaciu M, et al. **Biochim Biophys Acta** 1997 Jan 14;1323(1):85–96

Role of the Gln/Glu residues of trichocellins A–II/B–II in ion–channel formation in lipid membranes and catecholamine secretion from chromaffin cells. Wada S, et al. **Biochim Biophys Acta** 1997 Apr 26;1325(2):209–14

Kinetics of cleavage of intra– and extracellular simian virus 40 DNA with the enediyne anticancer drug C–1027. Kirk CA, et al. **Biophys Chem** 1997 Jan 31;63(2–3):201–9

The influence of Lactobacillus acidophilus and bacitracin on layer performance of chickens and cholesterol content of plasma and egg yolk. Abdulrahim SM, et al. **Br Poult Sci** 1996 May;37(2):341–6

Stevastelins, a novel group of immunosuppressants, inhibit dual–specificity protein phosphatases. Hamaguchi T, et al. **Chem Biol** 1997 Apr;4(4):279–86

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing. Jamjian C, et al. **Diagn Microbiol Infect Dis** 1997 Apr;27(4):129–38

Medium and supplement effects on the antimicrobial activity of quinupristin/dalfopristin tested by agar dilution and Etest methods. Jones RN. **Diagn Microbiol Infect Dis** 1996 Oct;26(2):99–102

Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using stepwise in vitro exposure. Millichap J, et al. **Diagn Microbiol Infect Dis** 1996 May;25(1):15–20

In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group. Putnam SD, et al. **Diagn Microbiol Infect Dis** 1997 Jul;28(3):139–47

Antimicrobial activity of quinupristin–dalfopristin [letter; comment] Bouanchaud DH. **Drugs** 1996 Nov;52(5):795. Comment on: Drugs 1996 Sep;52(3):406–15.

The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Brötz H, et al. **Eur J Biochem** 1997 May 15;246(1):193–9

Influence of charge differences in the C–terminal part of nisin on antimicrobial activity and signaling capacity. Van Kraaij C, et al. **Eur J Biochem** 1997 Jul 1;247(1):114–20

In vitro activity of an orally administered streptogramin (RPR 106,972) compared to quinupristin/dalfopristin and erythromycin. Barry AL, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb;16(2):155–8

In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter–related staphylococcal infections. Garcia R, et al.

ANTIBIOTICS, PEPTIDE

Eur J Clin Microbiol Infect Dis 1996 Dec;15(12):933–6

Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia. Muñoz JL, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):879–82

Antibacterial and hemolytic activities of linenscin OC2, a hydrophobic substance produced by Brevibacterium linens OC2. Boucabeille C, et al. **FEMS Microbiol Lett** 1997 Aug 15;153(2):295–301

Fabatins: new antimicrobial plant peptides. Zhang Y, et al. **FEMS Microbiol Lett** 1997 Apr 1;149(1):59–64

Intracellular delivery of lipopolysaccharide during DNA transfection activates a lipid A–dependent cell death response that can be prevented by polymyxin B. Cotten M, et al. **Hum Gene Ther** 1997 Mar 20;8(5):555–61

Cytokine production by human peripheral blood mononuclear cells stimulated by a Pseudomonas aeruginosa culture filtrate: role of plasma and polymyxin B. Sundaram S, et al. **Int J Artif Organs** 1996 May;19(5):276–83

Efficacy of the antimicrobial compound U–82,127 as a growth promoter for growing–finishing pigs. Cromwell GL, et al. **J Anim Sci** 1996 Jun;74(6):1284–7

Clonostachin, a novel peptaibol that inhibits platelet aggregation. Chikanishi T, et al. **J Antibiot (Tokyo)** 1997 Feb;50(2):105–10

Lipohexin, a new inhibitor of prolyl endopeptidase from Moeszia lindtneri (HKI–0054) and Paecilomyces sp. (HKI–0055; HKI–0096). II. Inhibitory activities and specificity. Christner C, et al. **J Antibiot (Tokyo)** 1997 May; 50(5):384–9

Lipohexin, a new inhibitor of prolyl endopeptidase from Moeszia lindtneri (HKI–0054) and Paecilomyces sp. (HKI–0055; HKI–0096). I. Screening, isolation and structure elucidation. Heinze S, et al. **J Antibiot (Tokyo)** 1997 May;50(5):379–83

Propeptin, a new inhibitor of prolyl endopeptidase produced by Microbispora. I. Fermentation, isolation and biological properties. Kimura K, et al. **J Antibiot (Tokyo)** 1997 May; 50(5):373–8

Novel blockade of cell surface expression of virus glycoproteins by leucinostatin A. Muroi M, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1119–26

A reassessment of the in–vitro activity of colistin sulphomethate sodium. Catchpole CR, et al. **J Antimicrob Chemother** 1997 Feb;39(2):255–60

The efficacy of antibiotics enhanced by electrical currents against Pseudomonas aeruginosa biofilms. Jass J, et al. **J Antimicrob Chemother** 1996 Dec;38(6):987–1000

Antimicrobial activity of cecropins. Moore AJ, et al. **J Antimicrob Chemother** 1996 Jun;37(6):1077–89

Comparative in–vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram–positive bacteria. Shonekan D, et al. **J Antimicrob Chemother** 1997 Mar;39(3):405–9

Involvement of the cell envelope of Listeria monocytogenes in the acquisition of nisin resistance. Davies EA, et al. **J Appl Bacteriol** 1996 Aug;81(2):139–46

Nisin induces changes in membrane fatty acid composition of Listeria monocytogenes nisin–resistant strains at 10 degrees C and 30 degrees C. Mazzotta AS, et al. **J Appl Microbiol** 1997 Jan;82(1):32–8

Brucella–Salmonella lipopolysaccharide chimeras are less permeable to hydrophobic probes and more sensitive to cationic peptides and EDTA than are their native Brucella sp. counterparts. Freer E, et al. **J Bacteriol** 1996 Oct; 178(20):5867–76

Cell wall synthesis is a major target of mycoparasitic antagonism by Trichoderma harzianum. Lorito M, et al. **J Bacteriol** 1996 Nov;178(21):6382–5

Role of transmembrane pH gradient and membrane binding in nisin pore formation. Moll GN, et al. **J Bacteriol** 1997 Jan;179(1):135–40

epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus. Sugai M, et al. **J Bacteriol** 1997 Jul;179(13):4311–8

Modulation of structure and antibacterial and hemolytic activity by ring size in cyclic gramicidin S analogs. Kondejewski LH, et al. **J Biol Chem** 1996 Oct 11; 271(41):25261–8

Inhibition of Plasmodium falciparum protein synthesis. Targeting the plastid–like organelle with thiostrepton. McConkey GA, et al. **J Biol Chem** 1997 Jan 24; 272(4):2046–9

Bioluminescence measurements of the antilisterial activity of nisin: comparison with ampicillin and streptomycin. Ukuku DO, et al. **J Biolumin Chemilumin** 1996 May–Jun; 11(3):169–73

Home–use nebulizers: a potential primary source of Burkholderia cepacia and other colistin–resistant, gram–negative bacteria in patients with cystic fibrosis [published erratum appears in J Clin Microbiol 1996 Jun;34(6):1601] Hutchinson GR, et al. **J Clin Microbiol** 1996 Mar;34(3):584–7

Electrodiffusion, barrier, and gating analysis of DIDS–insensitive chloride conductance in human red blood cells treated with valinomycin or gramicidin. Freedman JC, et al. **J Gen Physiol** 1997 Feb;109(2):201–16

Chemoattractant properties of PR–39, a neutrophil antibacterial peptide. Huang HJ, et al. **J Leukoc Biol** 1997 May;61(5):624–9

Pharmacological characterisation of a new model of antigen–induced pulmonary late–phase reaction in the conscious guinea pig which uses additional polymyxin B inhalation. Heuer HO, et al. **J Lipid Mediat Cell Signal** 1996 Dec;15(1):17–28

Antibacterial peptides and the outer membranes of gram–negative bacilli [editorial] Hancock RE. **J Med Microbiol** 1997 Jan;46(1):1–3

In vitro growth–inhibitory activity of pneumocandins L–733,560 and L–743,872 against putatively amphotericin B– and fluconazole–resistant Candida isolates: influence of assay conditions. Nelson PW, et al. **J Med Vet Mycol** 1997 Jul–Aug;35(4):285–7

Effects of polymyxin B on mammalian urinary bladder. Berg JR, et al. **J Membr Biol** 1996 Nov;154(2):119–30

Properties of voltage–gated ion channels formed by syringomycin E in planar lipid bilayers. Feigin AM, et al. **J Membr Biol** 1996 Jan;149(1):41–7

Kawaguchipeptin B, an antibacterial cyclic undecapeptide from the cyanobacterium Microcystis aeruginosa. Ishida K, et al. **J Nat Prod** 1997 Jul;60(7):724–6

Alternatamides A–D: new bromotryptamine peptide antibiotics from the Atlantic marine bryozoan Amathia alternata. Lee NK, et al. **J Nat Prod** 1997 Jul;60(7):697–9

The antistaphylococcal effect of nisin in a suitable vehicle: a potential therapy for atopic dermatitis in man. Valenta C, et al. **J Pharm Pharmacol** 1996 Sep;48(9):988–91

Almost complete protection from [Met5]–enkephalin–Arg6–Gly7–Leu8 (Met–enk–RGL) hydrolysis in membrane preparations by the combination of amastatin, captopril and phosphoramidon. Hiranuma T, et al. **J Pharmacol Exp Ther** 1997 May;281(2):769–74

Effects of pentoxifylline and polymyxin B on the acute–phase–response to Escherichia coli endotoxin in dwarf goats. van Miert AS, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):61–8

Vancomycin–dependent enterococcus. Sensitivity plate of Pseudomonas aeruginosa isolated from urine [letter; comment] Hayek L. **Lancet** 1997 Feb 8;349(9049):429–30 . Comment on: Lancet 1996 Dec 7;348(9041):1581–2.

Activity of nisin against Clostridium difficile [letter; comment] Kerr KG, et al. **Lancet** 1997 Apr 5; 349(9057):1026–7. Comment on: Lancet 1997 Feb 8;349(9049):418–22.

Effect of cortisporin otic suspension on cochlear function and efferent activity in the guinea pig. Perry BP, et al. **Laryngoscope** 1996 Dec;106(12 Pt 1):1557–61

Lipoteichoic acid as a target for antimicrobial action. Canepari P, et al. **Microb Drug Resist** 1996 Spring;2(1):85–9 (20 ref.)

Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Low DE. **Microb Drug Resist** 1995 Fall;1(3):223–34 (74 ref.)

In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin–resistant Enterococcus faecium. Ristow TA, et al. **Microb Drug Resist** 1995 Winter; 1(4):335–9

Isolation and partial characterization of polymyxin B–resistant isolates of Vibrio parahaemolyticus. Koga T, et al. **Microbiol Res** 1996 Mar;151(1):43–8

Evaluation of the in vitro activity of seven selected antimicrobial agents to be used for the isolation of human intestinal spirochaetes. Calderaro A, et al. **New Microbiol** 1997 Jan;20(1):35–45

Killing kinetics of RP 59500 and pristinamycin against penicillin–resistant pneumococci. Barakett V, et al. **Pathol Biol (Paris)** 1997 May;45(5):438–40

Anti–pseudomonal activity of collagen sponge with liposomal polymyxin B. Trafny EA, et al. **Pharmacol Res** 1996 Jan; 33(1):63–5

The bioefficacy of zinc bacitracin in practical diets for broilers and laying hens. Huyghebaert G, et al. **Poult Sci** 1997 Jun;76(6):849–56

Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Dodd ME, et al. **Thorax** 1997 Jul;52(7):656–8

Bacterial translocation from gut to portal blood in the recipient as a factor of hypercoagulopathy in hepatic sinusoids after orthotopic liver transplantation in rats. Mochida S, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):874–5

Effects of the lantibiotic mersacidin on the morphology of staphylococci. Molitor E, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):318–28

[Molecular targets of cell cycle inhibitors and their mode of action] Yoshida M. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1751–60 (65 ref.) **(Jpn)**

[Absorption of various actinomycins by Staphylococcus aureus cells] Polin AN, et al. **Antibiot Khimioter** 1996 May; 41(5):13–8 (Eng. Abstr.) **(Rus)**

[Actinomycin D resistance of gramicidin–resistant strains of Staphylococcus] Polin AN, et al. **Antibiot Khimioter** 1996; 41(7–8):13–7 (Eng. Abstr.) **(Rus)**

[A conjugate of ristomycin A ristosaminylaglycon–polymyxin B: the spectrum of its antimicrobial action and its membranolytic activity] Polin AN, et al. **Antibiot Khimioter** 1997;42(5):24–8 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Topical antimicrobial prophylaxis in minor wounds. Langford JH, et al. **Ann Pharmacother** 1997 May; 31(5):559–63

Influence of inducible cross–resistance to macrolides, lincosamides, and streptogramin B–type antibiotics in Enterococcus faecium on activity of quinupristin–dalfopristin in vitro and in rabbits with experimental endocarditis. Fantin B, et al. **Antimicrob Agents Chemother** 1997 May;41(5):931–5

Treatment of murine disseminated candidiasis with L–743,872. Graybill JR, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1775–7

Effect of tryptophan–N–formylated gramicidin on growth of Plasmodium berghei in mice. Otten–Kuipers MA, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1778–82

Treatment of vancomycin–resistant Enterococcus faecium infections. Lai KK. **Arch Intern Med** 1996 Dec 9–23; 156(22):2579–84

Use of bacitracin therapy for infection due to vancomycin–resistant Enterococcus faecium. Chia JK, et al. **Clin Infect Dis** 1995 Dec;21(6):1520

Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Chow JW, et al. **Clin Infect Dis** 1997 Jan;24(1):91–2

Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Chow JW, et al. **Clin Infect Dis** 1997 Jan;24(1):90–1

Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns. Furlong WB, et al. **Clin Infect Dis** 1997 Jul;25(1):163–4

Prolonged efficiency of secondary prophylaxis with colistin aerosols for respiratory infection due to Pseudomonas aeruginosa in patients infected with human immunodeficiency virus. Zylberberg H, et al. **Clin Infect Dis** 1996 Sep;23(3):641–3

Activity of the quinupristin–dalfopristin combination (RP–59500; Synercid) tested against vancomycin–resistant Enterococcus species [letter; comment] Cormican MG, et al. **Diagn Microbiol Infect Dis** 1996 Jan;24(1):59–60. Comment on: Diagn Microbiol Infect Dis 1995 Jan;21(1):47–50.

Quinupristin–dalfopristin [see comments] Bryson HM, et al. **Drugs** 1996 Sep;52(3):406–15 (62 ref.). Comment in: Drugs 1996 Nov;52(5):795.

Future prospects and therapeutic potential of streptogramins. Rubinstein E, et al. **Drugs** 1996;51 Suppl 1:38–42 (30 ref.)

Safety of topical ear drops containing ototoxic antibiotics. Rakover Y, et al. **J Otolaryngol** 1997 Jun;26(3):194–6

The post–antibiotic era beckons [editorial] Fox R. **J R Soc Med** 1996 Nov;89(11):602–3

Selective intestinal decontamination in multiple trauma patients: prospective, controlled trial. Lingnau W, et al. **J Trauma** 1997 Apr;42(4):687–94

Methicillin–resistant Staphylococcus aureus and vancomycin–resistant enterococci [letter] Woodford N, et al. **Lancet** 1997 Sep 6;350(9079):738

Treatment of vancomycin–resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases. Dever LL, et al. **Microb Drug Resist** 1996 Winter;2(4):407–13

Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Low DE. **Microb Drug Resist** 1995 Fall;1(3):223–34 (74 ref.)

Quinupristin/dalfopristin (RP 59500) therapy for vancomycin–resistant Enterococcus faecium aortic graft infection: case report. Sahgal VS, et al. **Microb Drug Resist** 1995 Fall;1(3):245–7

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis [see comments] Frederiksen B, et al. **Pediatr Pulmonol** 1997 May;23(5):330–5. Comment in: Pediatr Pulmonol 1997 May;23(5):323–4. Comment in: Pediatr Pulmonol 1997 May;23(5):325–1.

[Clinical pilot study on repeated use of heparin, vancomycin, colimycine locked flush solution for central intravenous implanted catheter in oncology] Guillet P, et al. **Pathol Biol (Paris)** 1997 Jun;45(6):506–13 (Eng. Abstr.) **(Fre)**

ANTIBIOTICS, TETRACYCLINE

Doxycycline revisited. Joshi N, et al. **Arch Intern Med** 1997 Jul 14;157(13):1421–8 (139 ref.)

[Characterization of isolates of Paenibacillus larvae with biochemical type and oxytetracycline resistance] Alippi AM. **Rev Argent Microbiol** 1996 Oct–Dec;28(4):197–203 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

One–day intensified lansoprazole–quadruple therapy for cure of Helicobacter pylori infection. de Boer WA, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):109–12

A one–week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. Vautier G, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):107–8

Absorbable, delayed–release antibiotic beads reduce surgical wound infection. Galandiuk S, et al. **Am Surg** 1997 Sep; 63(9):831–5

A Lyme disease controversy: duration of treatment [letter; comment] Nadelman RB, et al. **Arch Intern Med** 1997 Mar

24;157(6):697, 700. Comment on: Arch Intern Med 1996 Jul 22;156(14):1493–500.

Residues from long–acting antimicrobial preparations in injection sites in cattle. Mawhinney H, et al. **Aust Vet J** 1996 Aug;74(2):140–2

Five–year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience. Akbulut H, et al. **Cancer** 1997 Jul 1;80(1):8–14 (19 ref.)

Intraarticular minocycline injection in experimental synovitis. Weinberger A, et al. **Clin Rheumatol** 1996 May;15(3):290–4

A modified placement technique to improve retention. Of tetracycline–impregnated fibers. Donley TG. **J Am Dent Assoc** 1997 Apr;128(4):465–8

A randomized controlled trial of a 2% minocycline gel as an adjunct to non–surgical periodontal treatment, using a design with multiple matching criteria. Graça MA, et al. **J Clin Periodontol** 1997 Apr;24(4):249–53

Gingival fluid tetracycline release from bioerodible gels. Maze GI, et al. **J Clin Periodontol** 1996 Dec;23(12):1133–6

Clinical response to local delivery of tetracycline in relation to overall and local periodontal conditions. Mombelli A, et al. **J Clin Periodontol** 1997 Jul;24(7):470–7

Evaluation of the long–term efficacy and safety of locally–applied minocycline in adult periodontitis patients. Timmerman MF, et al. **J Clin Periodontol** 1996 Aug; 23(8):707–16

Sustained–release of oxytetracycline from chitosan microspheres prepared by interfacial acylation and spray hardening methods. Mi FL, et al. **J Microencapsul** 1997 Sep–Oct;14(5):577–91

Multi–center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. I. Study design, procedures, and management. Polson AM, et al. **J Periodontol** 1997 Feb; 68(2):110–8

Multi–center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results. Polson AM, et al. **J Periodontol** 1997 Feb;68(2):119–26

Periodontal pocket treatment in beagle dogs using subgingival doxycycline from a biodegradable system. I. Initial clinical responses. Polson AM, et al. **J Periodontol** 1996 Nov;67(11):1176–84

Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial. Bluhm GB, et al. **J Rheumatol** 1997 Jul;24(7):1295–302

Doxymycine–cyanoacrylate treatment of recurrent aphthous ulcers. Ylikontiola L, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Mar;83(3):329–33

Development and mechanical characterization of bioadhesive semi–solid, polymeric systems containing tetracycline for the treatment of periodontal diseases. Jones DS, et al. **Pharm Res** 1996 Nov;13(11):1734–8

Chemical pleurodesis with doxycycline 1 g. Herrington JD, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2):280–5

Murine typhus: a forgotten cause of febrile illness in Singapore. Loh KC, et al. **Singapore Med J** 1996 Feb; 37(1):39–43

New approaches to the management and treatment of malignant pericardial effusion. Tomkowski W, et al. **Support Care Cancer** 1997 Jan;5(1):64–6

Treatment for Haemobartonella felis in cats [letter] Stevenson M. **Vet Rec** 1997 May 10;140(19):512

[Low–dose doxycycline therapy: effect on crevicular fluid collagenase elastase and beta–glucuronidase activity in humans] Sha Y, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Sep; 30(5):289–91 **(Chi)**

[Antibacterial therapy as a means of preventing ixodid tick–borne borreliosis] Korenberg EI, et al. **Med Parazitol (Mosk)** 1996 Apr–Jun;(2):3–8 (Eng. Abstr.) **(Rus)**

[The clinical aspects of the results of antibiotic prophylaxis in ixodid tick–borne borreliosis] Vorob'eva NN, et al. **Med Parazitol (Mosk)** 1996 Apr–Jun;(2):8–10 **(Rus)**

ADVERSE EFFECTS

Pseudotumor cerebri induced by minocycline treatment for acne vulgaris [letter] Lewis PA, et al. **Acta Derm Venereol** 1997 Jan;77(1):83

Anaphylactoid symptoms due to oral minocycline [letter] Okano M, et al. **Acta Derm Venereol** 1996 Mar;76(2):164 (6 ref.)

Minocycline–induced acute generalized exanthematous pustulosis in a patient with generalized pustular psoriasis showing elevated level of sELAM–1 [letter] Yamamoto T, et al. **Acta Derm Venereol** 1997 Mar;77(2):168–9

Minocycline–induced serum sickness. Levenson T, et al. **Allergy Asthma Proc** 1996 Mar–Apr;17(2):79–81

Acute hepatitis and drug–related lupus induced by minocycline treatment. Golstein PE, et al. **Am J Gastroenterol** 1997 Jan;92(1):143–6

Intracranial hypertension and minocycline [letter] Shiri J, et al. **Ann Intern Med** 1997 Jul 15;127(2):168

Severe minocycline–induced eosinophilic pneumonia: extrapulmonary manifestations and the use of in vitro immunoassays. Bentur L, et al. **Ann Pharmacother** 1997 Jun;31(6):733–5

Peritoneal adhesions produced by oral tetracycline [letter] Bishara J, et al. **Ann Pharmacother** 1997 Feb;31(2):255

Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA. Elkayam O, et al. **Ann Rheum Dis** 1996 Oct;55(10):769–71

Q–switched ruby laser treatment of minocycline–induced cutaneous hyperpigmentation [letter] Knoell KA, et al. **Arch Dermatol** 1996 Oct;132(10):1251–3

Treatment of minocycline–induced hyperpigmentation with the Q–switched ruby laser [letter] Tsao H, et al. **Arch Dermatol** 1996 Oct;132(10):1250–1

Minocycline–induced pigmentation resolves after treatment with the Q–switched ruby laser. Collins P, et al. **Br J Dermatol** 1996 Aug;135(2):317–9

Minocycline–induced discolouration of the sclerae. Sabroe RA, et al. **Br J Dermatol** 1996 Aug;135(2):314–6

Antineutrophil cytoplasmic antibody–positive polyarthritis associated with minocycline therapy [letter] Gaffney K, et al. **Br J Rheumatol** 1996 Dec;35(12):1327

Minocycline and hepatitis [letter] Hardman CM, et al. **Clin Exp Dermatol** 1996 May;21(3):244–5

Psoriatic arthritis and minocycline induced autoantibodies. Leitch DN, et al. **Clin Rheumatol** 1997 May;16(3):317–8

Study of immune reactivity of minocycline–induced chronic active hepatitis. Herzog D, et al. **Dig Dis Sci** 1997 May; 42(5):1100–3

Drug–induced oesophageal ulceration in a patient with acquired immunodeficiency syndrome. Craig JM, et al. **Int J STD AIDS** 1996 Aug–Sep;7(5):370–1

Minocycline–related lupus erythematosus with associated liver disease. Crosson J, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 2):867–8

Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline. MacNeil M, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 2):347–50

Doxycycline–induced lithium toxicity [letter] Miller SC. **J Clin Psychopharmacol** 1997 Feb;17(1):54–5

OC failure rates and oral antibiotics. King VJ. **J Fam Pract** 1997 Aug;45(2):104–5

Progressive cervical root resorption related to tetracycline root conditioning. Ben–Yehouda A. **J Periodontol** 1997 May;68(5):432–5

Minocycline–induced intraoral pharmacogenic pigmentation: case reports and review of the literature. Westbury LW, et al. **J Periodontol** 1997 Jan;68(1):84–91 (78 ref.)

Minocycline related lupus [letter] Emery P, et al. **J Rheumatol** 1997 Sep;24(9):1850; discussion 1851–2

Minocycline related lupus. Masson C, et al. **J Rheumatol** 1996 Dec;23(12):2160–1 (7 ref.)

Minocycline related lupus [letter] Pointud P. **J Rheumatol** 1997 Sep;24(9):1851; discussion 1851–2

Lupuslike reaction associated with minocycline [letter] Singer SJ, et al. **JAMA** 1997 Jan 22–29;277(4):295–6

Benefit–risk assessment of acne therapies [letter; comment] Bénéton N, et al. **Lancet** 1997 Apr 26;349(9060):1252. Comment on: Lancet 1997 Feb 8;349(9049):374.

Minocycline–induced oral hyperpigmentation [letter] [see comments] Eisen D. **Lancet** 1997 Feb 8;349(9049):400. Comment in: Lancet 1997 Feb 8;349(9049):379.

Safety of minocycline for acne [comment] [see comments] Gottlieb A. **Lancet** 1997 Feb 8;349(9049):374. Comment on: Lancet 1997 Feb 8;349(9049):400. Comment in: Lancet 1997 Apr 26;349(9060):1251–2. Comment in: Lancet 1997 Apr 26;349(9060):1252.

Helicobacter pylori infection [letter; comment] Larson JT, et al. **Lancet** 1997 Mar 22;349(9055):878–9. Comment on: Lancet 1997 Jan 25;349(9047):265–9.

Response to doxycycline vs. mefloquine [letter; comment] Conrad KA, et al. **Mil Med** 1997 Jun;162(6):iii. Comment on: Mil Med 1997 Apr;162(4):i, iv.

Teratogenic study of doxycycline. Czeizel AE, et al. **Obstet Gynecol** 1997 Apr;89(4):524–8

Minocycline–induced scleral pigmentation. Fraunfelder FT, et al. **Ophthalmology** 1997 Jun;104(6):936–8 (11 ref.)

Phrenic nerve paralysis after doxycycline sclerotherapy for chylous fistula. Kirse DJ, et al. **Otolaryngol Head Neck Surg** 1997 Jun;116(6 Pt 1):680–3

Liver reactions to oral low–dose tetracyclines. Björnsson E, et al. **Scand J Gastroenterol** 1997 Apr;32(4):390–5 (20 ref.)

[Malaria prophylaxis (letter; comment)] Leutscher PD. **Ugeskr Laeger** 1997 Aug 4;159(32):4866–8. Comment on: Ugeskr Laeger 1997 Apr 28;159(18):2723–30. **(Dan)**

[Doxycycline induced photoonycholysis] Leutscher PD, et al. **Ugeskr Laeger** 1997 Jun 16;159(25):3965–7 (Eng. Abstr.) **(Dan)**

[Stevens–Johnson syndrome caused by doxycycline (letter)] Gallais V, et al. **Presse Med** 1997 May 31;26(18):855 **(Fre)**

[Acute eosinophilic lung during minocycline therapy (letter)] Marlier S, et al. **Presse Med** 1996 Nov 23;25(36):1801 **(Fre)**

[A cause of respiratory distress: eosinophilic pneumopathy due to minocycline] Liegeon MN, et al. **Rev Mal Respir** 1996 Oct;13(5):517–9 (Eng. Abstr.) **(Fre)**

[Minocycline in Acne—an autoimmune disease–like syndrome as a side effect] Jagusch W, et al. **Hautarzt** 1996 Dec;47(12):936 **(Ger)**

[Acute hepatitis associated with treatment with minocycline (letter)] Bruguera M, et al. **Med Clin (Barc)** 1997 Apr 19; 108(15):596 (10 ref.) **(Spa)**

[Esophageal injury in treatment with Doryx] **Lakartidningen** 1997 Jul 23;94(30–31):2665 **(Swe)**

ANALYSIS

Residues from long–acting antimicrobial preparations in injection sites in cattle. Mawhinney H, et al. **Aust Vet J** 1996 Aug;74(2):140–2

Liquid chromatographic determination of oxytetracycline in swine tissues. Kawata S, et al. **J AOAC Int** 1996 Nov–Dec; 79(6):1463–5

Chlortetracycline, oxytetracycline, and tetracycline in edible animal tissues, liquid chromatographic method: collaborative study. MacNeil JD, et al. **J AOAC Int** 1996 Mar–Apr;79(2):405–17

Determination of tetracyclines in animal feeds in the presence of other drugs by thin–layer chromatography and microbiological method. Markakis PK. **J AOAC Int** 1996 Mar–Apr;79(2):375–9

Improvement of chemical analysis of antibiotics. XXIII. Identification of residual tetracyclines in bovine tissues by electrospray high–performance liquid chromatography–tandem mass spectrometry. Oka H, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):337–44

On–line metal chelate affinity chromatography clean–up for the high–performance liquid chromatographic determination of tetracycline antibiotics in animal tissues. Stubbings G, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1–2):137–45

Capillary zone electrophoresis of minocycline. Li YM, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1095–9

Validation of a simple method for the determination of oxytetracycline in ointment by non–aqueous capillary electrophoresis. Tjørnelund J, et al. **J Pharm Biomed Anal** 1997 May;15(8):1077–82

[Oxytetracycline in the milk of dairy cows with clinical signs of mastitis during the lactation period] Dudriková E, et al. **Vet Med (Praha)** 1996 Nov;41(11):329–33 (Eng. Abstr.) **(Slo)**

ANTAGONISTS & INHIBITORS

In vitro studies of the loss of antibacterial activity of oxytetracycline in presence of Ca(II) or Mg(II) ions. Naz S, et al. **Arzneimittelforschung** 1996 Jul;46(7):701–4

BIOSYNTHESIS

[Effect of redox potential of culture broth on oxytetracycline biosynthesis] Vlasov VI. **Antibiot Khimioter** 1996 Apr; 41(4):23–9 (Eng. Abstr.) **(Rus)**

BLOOD

Validation of a high–performance liquid chromatographic method for the determination of doxycycline in turkey plasma. Santos MD, et al. **J Chromatogr B Biomed Appl** 1996 Jul 12;682(2):301–8

CHEMISTRY

Equilibrium studies on tetracycline–metal ion systems. Novák–Pékli M, et al. **J Pharm Biomed Anal** 1996 Jun; 14(8–10):1025–9

HISTORY

New therapeutic uses for an old family of drugs: travels of a dental researcher from the lab to the university's office of technology transfer and beyond. Golub LM, et al. **Technol Health Care** 1996 Sep;4(3):311–6

METABOLISM

Glycylcyclines bind to the high–affinity tetracycline ribosomal binding site and evade Tet(M)– and Tet(O)–mediated ribosomal protection. Bergeron J, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2226–8

Mechanism for the anti–thyroid action of minocycline. Doerge DR, et al. **Chem Res Toxicol** 1997 Jan;10(1):49–58

Otoconial formation in the chick: changing patterns of tetracycline incorporation during embryonic development and after hatching. Kido T. **Hear Res** 1997 Mar; 105(1–2):191–201

alpha 1–Proteinase inhibitor in gingival crevicular fluid of humans with adult periodontitis: serpinolytic inhibition by doxycycline. Lee HM, et al. **J Periodontal Res** 1997 Jan; 32(1 Pt 1):9–19

Chlortetracycline analysis of boar spermatozoa after incubation, flow cytometric sorting, cooling, or cryopreservation. Maxwell WM, et al. **Mol Reprod Dev** 1997 Mar;46(3):408–18

PHARMACOKINETICS

The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. Jung H, et al. **Biopharm Drug Dispos** 1997 Jul;18(5):459–63

Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. Tod M, et al. **Comput Methods Programs Biomed** 1996 Jun;50(1):13–22

Oxytetracycline residues in milk after intrauterine treatment of cows with retained fetal membranes. Dinsmore RP, et al. **J Am Vet Med Assoc** 1996 Nov 15;209(10):1753–5

Comparison of the pharmacokinetics and local tolerance of three injectable oxytetracycline formulations in pigs. Banting AL, et al. **J Vet Pharmacol Ther** 1996 Feb; 19(1):50–5

The pharmacokinetics of a long–acting formulation of

oxytetracycline in sheep and goats. Escudero E, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):75–7
Pharmacokinetics of long–acting oxytetracycline in fallow deer (Dama dama). Haigh JC, et al. **J Vet Pharmacol Ther** 1997 Jun;20(3):243–5
Pharmacokinetics of oxytetracycline after intravenous administration at two dose levels to hens. Moreno L, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):495–7
Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. Nielsen P, et al. **J Vet Pharmacol Ther** 1996 Aug; 19(4):305–11
Pharmacokinetics and bioavailability of doxycycline in turkeys. Santos MD, et al. **J Vet Pharmacol Ther** 1996 Aug; 19(4):274–80
Oxytetracycline residues in channel catfish: a feeding trail. O'Hara TM, et al. **Vet Hum Toxicol** 1997 Apr;39(2):65–70
Concentration–time profiles of oxytetracycline in blood, kidney and liver of tench (Tinca tinca L) after intramuscular administration. Reja A, et al. **Vet Hum Toxicol** 1996 Oct;38(5):344–7
The effects of the method of calculation on the evaluation of the pharmacokinetic parameters of oxytetracycline after intravenous administration to calves. Errecalde JO, et al. **Vet Res Commun** 1997 May;21(4):273–81
Aspects of the pharmacokinetics of doxycycline given to healthy and pneumonic East African dwarf goats by intramuscular injection. Ole–Mapenay IM, et al. **Vet Res Commun** 1997 Aug;21(6):453–62

PHARMACOLOGY

In vitro susceptibilities of 176 clinical isolates of Streptococcus pneumoniae to 11 beta–lactams, erythromycin, and tetracycline. Vanhoof R, et al. **Acta Clin Belg** 1996;51(6):377–85
Incorporation of tetracycline into otoconia of the guinea–pig following streptomycin intoxication. Zhang DM, et al. **Acta Otolaryngol (Stockh)** 1996 Nov;116(6):812–6
Characteristics of mutagenesis by bleomycin and adriamycin in salmonella typhimurium: action of superoxide dismutase. Ejchart A, et al. **Acta Pol Pharm** 1996 Jan–Feb;53(1):13–7
In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. Gnarpe J, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1843–5
Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood. Milano S, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):117–21
In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. Welsh L, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):212–4
In vitro modulation of epidermal inflammatory cytokines (IL–1 alpha, IL–6, TNF alpha) by minocycline. Célérier P, et al. **Arch Dermatol Res** 1996 Jun;288(7):411–4
Tetracyclines induce changes in accessibility of ribosomal proteins to proteases. Kolesnikov IV, et al. **Biochimie** 1996; 78(10):868–73
Tetracycline prevents cancellous bone loss and maintains near–normal rates of bone formation in streptozotocin diabetic rats. Bain S, et al. **Bone** 1997 Aug;21(2):147–53
Potential of tetracyclines to modify cartilage breakdown in osteoarthritis [see comments] Ryan ME, et al. **Curr Opin Rheumatol** 1996 May;8(3):238–47 (76 ref.). Comment in: Curr Opin Rheumatol 1996 May;8(3):235–7.
Occurrence of high ratio of males after introduction of minocycline in a colony of Leptotrombidium fletcheri infected with Orientia tsutsugamushi. Takahashi M, et al. **Eur J Epidemiol** 1997 Jan;13(1):79–86
In vitro activities of tetracycline & ciprofloxacin against Chlamydia trachomatis isolates from conjunctivitis patients. Madhavan HN, et al. **Indian J Med Res** 1996 Mar; 103:138–41
The role of the variable region in Tet repressor for inducibility by tetracycline. Berens C, et al. **J Biol Chem** 1997 Mar 14;272(11):6936–42
Tetracycline demineralization of dentin: the effects of concentration and application time. Sterrett JD, et al. **J Clin Periodontol** 1997 Jul;24(7):457–63
Tetracycline inhibits Porphyromonas gingivalis lipopolysaccharide–induced lesions in vivo and TNF alpha processing in vitro. Shapira L, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):183–8
A simple in vitro model to test the efficacy of antimicrobial agents released from dressings. Grzybowski J, et al. **J Pharmacol Toxicol Methods** 1996 Oct;36(2):73–6
Inhibition of recombinant human neutrophil collagenase by doxycycline is pH dependent. Smith GN Jr, et al. **J Rheumatol** 1997 Sep;24(9):1769–73
Long–term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts [see comments] Bohl D, et al. **Nat Med** 1997 Mar;3(3):299–305. Comment in: Nat Med 1997 Mar;3(3):278–9.
Effect of feeding diets containing an antibiotic, a probiotic, or yucca extract on growth and intestinal urease activity in broiler chicks. Yeo J, et al. **Poult Sci** 1997 Feb; 76(2):381–5
Minocycline and the thyroid: antithyroid effects of the drug, and the role of thyroid peroxidase in minocycline–induced black pigmentation of the gland. Taurog A, et al. **Thyroid** 1996 Jun;6(3):211–9
Influence of flumequine and oxytetracycline on the resistance of the European eel against the parasitic swimbladder nematode Anguillicola crassus. van der Heijden MH, et al. **Vet Immunol Immunopathol** 1996 Jun 15;52(1–2):127–34
Comparative in vitro activity of doxycycline and oxytetracycline against porcine respiratory pathogens. Bousquet E, et al. **Vet Rec** 1997 Jul 12;141(2):37–40
Breath hydrogen excretion by healthy cats after oral administration of oxytetracycline and metronidazole. Muir P, et al. **Vet Rec** 1996 Jun 29;138(26):635–9
Chemosensitizing effect of verapamil on Swiss–3T3 cells transfected with human MDR1 gene. Wang N, et al. **Yao Hsueh Hsueh Pao** 1996;31(5):346–51
[Protective effect of a tetracycline–sensitive strain of Escherichia coli on the growth of a tetracyclic–resistant strain in the presence of tetracycline in a coculture] Nikolaev IuA. **Mikrobiologiia** 1996 Nov–Dec;65(6):745–8 (Eng. Abstr.) **(Rus)**
[Multiple protective effect of an exometabolite (exometabolites) released by Escherichia coli during treatment with tetracycline] Nikolaev IuA. **Mikrobiologiia** 1996 Nov–Dec;65(6):749–52 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Minocycline induces an increase in the number of excreting pilosebaceous follicles in acne vulgaris. A randomised study. Bodokh I, et al. **Acta Derm Venereol** 1997 Jul; 77(4):255–9
Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. De Boer WA, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):633–8
Central venous catheters coated with minocycline and rifampin for the prevention of catheter–related colonization and bloodstream infections. A randomized, double–blind trial. The Texas Medical Center Catheter Study Group [see comments] Raad I, et al. **Ann Intern Med** 1997 Aug 15;127(4):267–74. Comment in: Ann Intern Med 1997 Aug 15;127(4):304–6.
Prednisolone at anti–inflammatory or immunosuppressive dosages in conjunction with doxycycline does not potentiate the severity of Rickettsia rickettsii infection in dogs. Breitschwerdt EB, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):141–7
Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Ji B, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):393–9
Treatment of human brucellosis with doxycycline and gentamicin [see comments] Solera J, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):80–4. Comment in: Antimicrob Agents Chemother 1997 Jul;41(7):1621–2.
Confluent and reticulate papillomatosis: successful treatment with minocycline [letter] [published erratum appears in Arch Dermatol 1997 Mar;133(3):293] Fung MA, et al. **Arch Dermatol** 1996 Nov;132(11):1400–1
Minocycline treatment for leukocytoclastic vasculitis associated with rheumatoid arthritis. Houck HE, et al. **Arch Dermatol** 1997 Jan;133(1):15–6
Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline [see comments] Quarterman MJ, et al. **Arch Dermatol** 1997 Jan;133(1):49–54 . Comment in: Arch Dermatol 1997 Jan;133(1):89–90.
Minocycline in rheumatoid arthritis [editorial; comment] Breedveld FC. **Arthritis Rheum** 1997 May;40(5):794–6. Comment on: Arthritis Rheum 1997 May;40(5):842–8.
Comparison of erythromycin and oxytetracycline for the treatment of virulent footrot in grazing sheep. Rendell DK, et al. **Aust Vet J** 1997 May;75(5):354
Mefloquine versus doxycycline for malaria prophylaxis in intermittent exposure of Israeli Air Force aircrew in Rwanda. Shamiss A, et al. **Aviat Space Environ Med** 1996 Sep;67(9):872–3
Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. Williams S, et al. **Bone** 1996 Dec;19(6):637–44
Comparative effectiveness of co–trimoxazole and tetracycline in the treatment of Cholera. Grados P, et al. **Bull Pan Am Health Organ** 1996 Mar;30(1):36–42
Another look at minocycline [letter; comment] Alarcón GS, et al. **Bull Rheum Dis** 1996 Dec;45(8):6–7. Comment on: Bull Rheum Dis 1996 Apr;45(2):2–5.
Should minocycline be used to treat rheumatoid arthritis? [see comments] Panush RS, et al. **Bull Rheum Dis** 1996 Apr;45(2):2–5 (33 ref.). Comment in: Bull Rheum Dis 1996 Dec;45(8):6–7.
Tetracycline therapy for chronic Lyme disease. Donta ST. **Clin Infect Dis** 1997 Jul;25 Suppl 1:S52–6
Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections. Raad I, et al. **Clin Infect Dis** 1997 Jul;25(1):149–51
Tetracycline derivatives, alternative treatment for nocardiosis in transplanted patients. Leitersdorf I, et al. **Clin Nephrol** 1997 Jul;48(1):48–51
Minocycline treatment for confluent and reticulated papillomatosis. Chang SN, et al. **Cutis** 1996 Jun;57(6):454–7
Confluent and reticulated papillomatosis responsive to minocycline. Shimizu S, et al. **Dermatology** 1997; 194(1):59–61
A case of pyoderma gangrenosum stabilized with lymecycline, topical benzoyl peroxide and treated by autograft. Vereecken P, et al. **Dermatology** 1997;195(1):50–1
Gastritis and Helicobacter pylori: forty years of antibiotic therapy. Lieber CS. **Digestion** 1997;58(3):203–10 (62 ref.)
Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. Avsar E, et al. **Eur J Gastroenterol Hepatol** 1996 May;8(5):449–52
Follow–up on 242 patients with peptic ulcer disease one year after eradication of Helicobacter pylori infection. Berstad A, et al. **Hepatogastroenterology** 1995 Sep–Oct;42(5):655–9
Triple–drug therapy of Helicobacter pylori infection in duodenal ulcer disease. Dayal VM, et al. **Indian J Gastroenterol** 1997 Apr;16(2):46–8
A case of Q fever endocarditis treated medically: 9 years of follow–up [letter] Dalmau D, et al. **Infection** 1997 Mar–Apr;25(2):131–2
Azithromycin in the treatment of pneumonias caused by Chlamydia spp: a retrospective study. Kuzman I, et al. **Int J Clin Pharmacol Res** 1996;16(4–5):103–7
Antibiotic therapy in men with leukocytospermia. Erel CT, et al. **Int J Fertil Womens Med** 1997 May–Jun;42(3):206–10
Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. Mane I, et al. **Int J Lepr Other Mycobact Dis** 1997 Jun;65(2):224–9
Efficacy of anti–chlamydial therapy with oxytetracycline and erythromycin. Ross JD, et al. **Int J STD AIDS** 1996 Aug–Sep;7(5):373–4
Eradication of Helicobacter pylori: the results of a pilot study of 3, 5 & 7 day triple antibiotic regime with bismuth for one month. O'Connor HJ, et al. **Ir J Med Sci** 1997 Jan–Mar; 166(1):32–4
Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. Hornschuh B, et al. **J Am Acad Dermatol** 1997 Jan; 36(1):101–3
New uses for tetracyclines [news] **J Am Dent Assoc** 1997 Jul;128(7):822, 826
Treatment of Pemphigus senilis with tetracycline plus nicotinamide: long term follow–up [letter] Fimiani M, et al. **J Am Geriatr Soc** 1997 Feb;45(2):256–8
Comparison of topical application of three products for treatment of papillomatous digital dermatitis in dairy cattle. Britt JS, et al. **J Am Vet Med Assoc** 1996 Sep 15; 209(6):1134–6
Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection. Dutta D, et al. **J Antimicrob Chemother** 1996 Mar;37(3):575–81
One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy. Phull PS, et al. **J Antimicrob Chemother** 1995 Dec; 36(6):1085–8
Comparison of nested PCR with immunofluorescent–antibody assay for detection of Ehrlichia canis infection in dogs treated with doxycycline. Wen B, et al. **J Clin Microbiol** 1997 Jul;35(7):1852–5
Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. Liu G, et al. **J Clin Oncol** 1996 Dec;14(12):3141–7
Adjunctive controlled topical application of tetracycline HCl in the treatment of localized persistent or recurrent periodontitis. Effects on clinical parameters and elastase–alpha1–proteinase inhibitor in gingival crevicular fluid. Flemmig TF, et al. **J Clin Periodontol** 1996 Oct; 23(10):914–21
The effect of tetracycline fiber therapy on beta–glucuronidase and interleukin–1 beta in crevicular fluid. Lamster IB, et al. **J Clin Periodontol** 1996 Sep;23(9):816–22
Topographic distribution of black–pigmenting anaerobes before and after periodontal treatment by local delivery of tetracycline. Mombelli A, et al. **J Clin Periodontol** 1996 Oct;23(10):906–13
A double–blind trial of tetracycline in the management of early onset periodontitis. Palmer RM, et al. **J Clin Periodontol** 1996 Jul;23(7):670–4
Fibrin glue application in conjunction with tetracycline root conditioning and coronally positioned flap procedure in the treatment of human gingival recession defects. Trombelli L, et al. **J Clin Periodontol** 1996 Sep;23(9):861–7
Use of the polymeric matrix as internal standard for quantitation of in vivo delivery of tetracycline HCl from Actisite tetracycline fiber during periodontal treatment. Litch JM, et al. **J Periodontal Res** 1996 Nov;31(8):540–4
Clinical evaluation of tetracycline HCl conditioning in the treatment of gingival recessions. A comparative study. Bouchard P, et al. **J Periodontol** 1997 Mar;68(3):262–9
The effects of different tetracyclines on the dentin root surface of instrumented, periodontally involved human teeth: a comparative scanning electron microscope study. Madison JG 3rd, et al. **J Periodontol** 1997 Aug;68(8):739–45
A clinical evaluation of demineralized freeze–dried bone allograft in combination with tetracycline in the treatment of periodontal osseous defects. Masters LB, et al. **J Periodontol** 1996 Aug;67(8):770–81
The use of tetracycline–containing controlled–release fibers in the treatment of refractory periodontitis. Vandekerckhove BN, et al. **J Periodontol** 1997 Apr; 68(4):353–61
Post–therapy antibody titers in dogs with ehrlichiosis: follow–up study on 68 patients treated primarily with tetracycline and/or doxycycline. Bartsch RC, et al. **J Vet Intern Med** 1996 Jul–Aug;10(4):271–4

Benefit-risk assessment of acne therapies [letter; comment] Seukeran DC, et al. **Lancet** 1997 Apr 26;349(9060):1251-2 . Comment on: Lancet 1997 Feb 8;349(9049):374.
Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. Dattwyler RJ, et al. **N Engl J Med** 1997 Jul 31;337(5):289-94
Azithromycin vs. doxycycline for Mediterranean spotted fever. Meloni G, et al. **Pediatr Infect Dis J** 1996 Nov; 15(11):1042-4
New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials. Cunha BA. **Postgrad Med** 1997 Apr;101(4):68-70, 73-4, 79-80 passim (19 ref.)
Health education and antibiotic therapy in trachoma control. Resnikoff S, et al. **Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique** 1995;72:89-98, 101-10 **(Eng, Fre)**
Efficacy and safety of azithromycin versus lymecyline in the treatment of genital chlamydial infections in women. Brihmer C, et al. **Scand J Infect Dis** 1996;28(5):451-4
Identifying malaria control issues: a district hospital-based evaluation. Kimerling ME, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):611-9
Chemotherapy of dermatophilosis--a preliminary study. Aning KG, et al. **Trop Anim Health Prod** 1996 May;28(2 Suppl):38S-43S; discussion 74S-86S
Immunisation of cattle in Zimbabwe using Theileria parva (Boleni) without concurrent tetracycline therapy. Kanhai GK, et al. **Trop Anim Health Prod** 1997 May;29(2):92-8
Effect of four therapeutic agents on Trichomonas phasiani carriage in pheasants [see comments] Pennycott TW. **Vet Rec** 1996 Aug 31;139(9):214-5. Comment in: Vet Rec 1996 Oct 19;139(16):399.
[Antibiotic treatment in rheumatoid arthritis? (editorial)] Leirisalo-Repo M. **Duodecim** 1995;111(13):1181-2 **(Fin)**
[A case of Tsutsugamushi disease as an imported infection] Ueda S, et al. **Kansenshogaku Zasshi** 1997 May;71(5):464-7 (Eng. Abstr.) **(Jpn)**
[Effects of a synthetic carbon-mineral sorbent and antibiotics on the development of combined radiation and thermal injury] Nesterenko VS, et al. **Radiats Biol Radioecol** 1996 Sep-Oct;36(5):727-30 (Eng. Abstr.) **(Rus)**

TOXICITY

Effects of sanguinarium, chlorhexidine and tetracycline on neutrophil viability and functions in vitro. Agarwal S, et al. **J Periodontal Res** 1997 Apr;32(3):335-44
Oxytetracycline-induced nephrotoxicosis in dogs after intravenous administration for experimental bone labeling. Moalli MR, et al. **Lab Anim Sci** 1996 Oct;46(5):497-502

URINE

Renal excretion of tetracycline is transiently decreased during short-term heat exposure. Vanakoski J, et al. **Int J Clin Pharmacol Ther** 1997 May;35(5):204-7

ANTIBIOTICS, THIENAMYCIN see **THIENAMYCINS**

ANTIBODIES

see related
ANTIGEN-ANTIBODY REACTIONS

Specific antigens of Chlamydia pecorum and their homologues in C psittaci and C trachomatis. Baghian A, et al. **Am J Vet Res** 1996 Dec;57(12):1720-5
Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood. Hutchison RE, et al. **Ann Oncol** 1997;8 Suppl 1:37-42
Molecular imprinting: synthesis of polymer particles with antibody-like binding characteristics for glucose oxidase. Burow M, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):419-22
Expression of recombinant rat interleukin-13 (IL-13) and generation of a neutralizing rat IL-13 antiserum. Lakkis FG, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):529-32
Phosphorylation of 558T of moesin detected by site-specific antibodies in RAW264.7 macrophages. Nakamura F, et al. **Biochem Biophys Res Commun** 1996 Sep 24;226(3):650-6
Antipeptide antibodies as probes of subunit-dependent structural changes in the regulatory domain of the gamma-subunit of phosphorylase kinase. Wangsgard WP, et al. **Biochem Biophys Res Commun** 1997 Jan 3; 230(1):179-83
Hybrid antibodies monitoring receptor profiles on lymphocyte subsets. Bell CG. **Biochem Soc Trans** 1996 Aug;24(3):496S
Designing immunogens for the generation of antibodies that catalyse the hydrolysis of cocaine. Hagi-Pavli E, et al. **Biochem Soc Trans** 1997 Feb;25(1):83S
Use of morpholinonucleosides to conjugate oxidized DNA bases to proteins. Girault I, et al. **Bioconjug Chem** 1996 Jul-Aug;7(4):445-50
Antenatal depression and thyroid antibodies. Oretti RG, et al. **Biol Psychiatry** 1997 Jun 1;41(11):1143-6
Preparation, production and functional characterization of anti cAMP and cGMP antibodies. Defagot C, et al. **Biol Res** 1994;27(3-4):193-7
Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Grynspan F, et al. **Brain Res** 1997 Jul 25;763(2):145-58
The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies. Matthews DC, et al. **Cancer Treat Res** 1997;77:121-39 (42 ref.)
Platelet antibodies. Pulkrabek SM. **Clin Lab Med** 1996 Dec; 16(4):817-35 (51 ref.)
Probing human beta 1- and beta 2-adrenoceptors with domain-specific fusion protein antibodies. Jahns R, et al. **Eur J Pharmacol** 1996 Nov 28;316(1):111-21
Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Kircheis R, et al. **Gene Ther** 1997 May;4(5):409-18
Intrabodies: turning the humoral immune system outside in for intracellular immunization. Marasco WA. **Gene Ther** 1997 Jan;4(1):11-5 (61 ref.)
Determination of anti-AGE antibodies in human serum. Baydanoff S, et al. **Glycoconj J** 1996 Jun;13(3):335-9
Antibody-mediated clean-up of blood for simultaneous HPLC determination of morphine and morphine glucuronides. Beike J, et al. **Int J Legal Med** 1997; 110(4):226-9
Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. Smith GK, et al. **J Biol Chem** 1997 Jun 20;272(25):15804-16
Preparation of purified atactic polypropylene and polyvinyl methyl ether surfaces for thrombogenicity studies. Aziz CA, et al. **J Biomed Mater Res** 1996 Oct;32(2):193-202
Increased ALZ-50 immunoreactivity in sudden infant death syndrome. Sparks DL, et al. **J Child Neurol** 1996 Mar; 11(2):101-7
Evaluation of anti-human antibodies for immunohistochemistry on archival nonhuman primate tissues. Wykrzykowska JJ, et al. **J Med Primatol** 1996 Apr; 25(2):71-7
Biorecognition of antibodies in vivo: potential in drug targeting. Fritzberg AR. **J Mol Recognit** 1996 Sep-Dec; 9(5-6):309-15 (47 ref.)
Neutralizing antibodies to poliovirus types 1 and 3 in cord blood of Nigerian children [letter] Odemuyiwa SO, et al. **J Trop Pediatr** 1997 Jun;43(3):187
Mel-5: a novel antibody for differential diagnosis of epidermal pigmented lesions of the skin in paraffin-embedded sections. Bhawan J. **Melanoma Res** 1997 Feb;7(1):43-8
Polyclonal antibodies against human gamma-tubulin stain centrioles in mammalian cells from different tissues. Komarova YuA, et al. **Membr Cell Biol** 1997;10(5):503-13
Immunoprecipitation of human mitochondrial translation products with peptide-specific antibodies. Bentlage HA, et al. **Methods Enzymol** 1996;264:218-28
Microinjection of antibodies into mammalian cells. Lamb NJ, et al. **Methods Enzymol** 1997;283:72-83
Immunological screening of lambda-phage cDNA expression libraries. Hurst HC. **Methods Mol Biol** 1997;69:155-9
Real-time measurements of corticosteroids in conscious animals using an antibody-based electrode [see comments] Cook CJ. **Nat Biotechnol** 1997 May;15(5):467-71. Comment in: Nat Biotechnol 1997 May;15(5):421.
Catalytic antibodies--reaching adolescence? Thomas NR. **Nat Prod Rep** 1996 Dec;13(6):479-511 (212 ref.)
New polyclonal antiserum against microtubule-associated protein 2 (MAP2); preparation and preliminary characterization. Jancsik V, et al. **Neurobiology (Bp)** 1996; 4(3):241-5
Acetylcholine receptor antibodies and single-fiber EMG in first-degree relatives of children with myasthenia gravis [letter] Anlar B, et al. **Neuropediatrics** 1995 Dec;26(6):335-6
The epitopes for natural polyreactive antibodies are rich in proline. Tchernychev B, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6335-9
Immunological manipulation of growth. Pell JM. **Proc Nutr Soc** 1997 Jul;56(2):621-30 (39 ref.)
Immunohistochemical localization of type-II (AT2) angiotensin receptors with a polyclonal antibody against a peptide from the C-terminal tail. Yiu AK, et al. **Regul Pept** 1997 May 14;70(1):15-21
Antibodies' problem in invertebrate immunology [letter] Leclerc M. **Thymus** 1997;24(3):201-2
[Catalytic antibodies: generation of a new class of protein catalysts exploiting the immune system] Fujii I. **Yakugaku Zasshi** 1996 Aug;116(8):606-21 (26 ref.) (Eng. Abstr.) **(Jpn)**
[Anti-Tr antibodies and cerebellar paraneoplastic degeneration associated with Hodgkin's disease] Graus F, et al. **Neurologia** 1996 Aug-Sep;11(7):261 **(Spa)**

ADMINISTRATION & DOSAGE

Treatment of endotoxemic mice with anti-interleukin-6 antibody paradoxically increases interleukin-6 levels and stimulates mucosal protein synthesis. Wang Q, et al. **Arch Surg** 1997 Jan;132(1):82-8
Oral delivery of antibodies. Future pharmacokinetic trends. Reilly RM, et al. **Clin Pharmacokinet** 1997 Apr; 32(4):313-23 (53 ref.)
An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Wright M, ct al. **Gene Ther** 1997 Apr;4(4):317-22
Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Fujita J, et al. **Int J Cancer** 1996 Nov 27;68(5):637-43
Prolongation of murine cardiac allograft survival by microspheres containing TNF alpha and IL1-beta neutralizing antibodies. Gerber DA, et al. **J Drug Target** 1995;3(4):311-5
CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. Wang R, et al. **J Immunol** 1997 Mar 15;158(6):2856-61
Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. Balthasar JP, et al. **J Pharm Sci** 1996 Oct;85(10):1035-43
Formation of abdominal adhesions is inhibited by antibodies to transforming growth factor-beta1. Lucas PA, et al. **J Surg Res** 1996 Oct;65(2):135-8
Early induction of the NGFI-B/Nur77 family genes in nephritis induced by anti-glomerular basement membrane antibody. Hayashi K, et al. **Mol Cell Endocrinol** 1996 Oct 30;123(2):205-9
Protective effects of combined adhesion molecule blockade in models of acute lung injury. Mulligan MS, et al. **Proc Assoc Am Physicians** 1996 May;108(3):198-208
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. DeNardo SJ, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):4000-4
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Yuan F, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14765-70
Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis. Wong AG, et al. **Thromb Haemost** 1997 Jun;77(6):1143-7

ADVERSE EFFECTS

Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo. Davis-Daneshfar A, et al. **J Immunother** 1997 May;20(3):208-13

ANALYSIS

Expression of microglial markers in the human CNS after closed head injury. Engel S, et al. **Acta Neurochir Suppl (Wien)** 1996;66:89-95
The use of paraffin-embedded tissue for detection of antineuronal antibodies [letter] Dalmau J. **Acta Neuropathol (Berl)** 1997 Sep;94(3):300-1
Immune response to food antigens: kinetics of food-specific antibodies in the normal population. Ahmed T, et al. **Acta Paediatr Jpn** 1997 Jun;39(3):322-8
Identification of human sperm antigen recognized by serum of an immunoinfertile woman: a candidate for immunocontraception. Suri A, et al. **Am J Reprod Immunol** 1996 Dec;36(6):317-26
Anti-Ro (SSA) and anti-La (SSB) antibodies and complete congenital heart block. Finkelstein Y, et al. **Ann Med Interne (Paris)** 1997;148(3):205-8 (60 ref.)
Serum antibodies to gangliosides in systemic lupus erythematosus. Neisser A, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:300-2
Association of Campylobacter jejuni serotype with antiganglioside antibody in Guillain-Barré syndrome and Fisher's syndrome. Yuki N, et al. **Ann Neurol** 1997 Jul; 42(1):28-33
Characteristics of men and women with circulating antisperm antibodies in a combined infertility clinic in Kuwait. Omu AE, et al. **Arch Androl** 1997 Jul-Aug;39(1):55-64
Antibodies released from immunoadsorbents: effect of support, activation and elution conditions. Ubrich N, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1996 Jan; 24(1):65-75
Characterization of a 34 kDa immunoreactive peptide with the anti protein kinase C antibody which can recognize part of the C4 region. Ayaki M, et al. **Biochem Mol Biol Int** 1997 Apr;41(5):969-77
Expression and purification of recombinant human N-formyl-L-leucyl-L-phenylalanine (FMLP) receptor: generation of polyclonal antibody against FMLP receptor. Lala A, et al. **Biochem Pharmacol** 1997 Aug 1;54(3):381-90
Sensitive ELISA method for quantitating antibodies to specific protein epitopes. Picard MD, et al. **Biotechniques** 1996 Oct;21(4):628-30
Detection of drug-dependent, platelet-reactive antibodies by solid-phase red cell adherence assays. Leach MF, et al. **Br J Haematol** 1997 Jun;97(4):755-61
Lupus anticoagulants: strong association with the major histocompatibility complex class II and platelet antibodies. Panzer S, et al. **Br J Haematol** 1997 Aug;98(2):342-5
Prevalence of anti-FVIII antibodies in severe haemophilia A patients with inversion of intron 22. Vianello F, et al. **Br J Haematol** 1997 Jun;97(4):807-9
Six cases positive for anti-centromere antibodies with ulcer and gangrene in the extremities. Takahashi M, et al. **Br J Rheumatol** 1997 Aug;36(8):889-93
Anti-endothelial cell antibodies in Takayasu arteritis. Eichhorn J, et al. **Circulation** 1996 Nov 15;94(10):2396-401
Antibodies to Tamm-Horsfall protein in patients treated with extracorporeal shock wave lithotripsy (ESWL). Jelaković

B, et al. **Clin Chim Acta** 1996 Dec 30;256(2):95–102

Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN–alpha2 therapy. Antonelli G, et al. **Clin Exp Immunol** 1996 Jun; 104(3):384–7

Anti–endothelial cell antibodies in patients with various forms of vasculitis. Salojin KV, et al. **Clin Exp Rheumatol** 1996 Mar–Apr;14(2):163–9

Detection of circulating anti–p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. Shibata Y, et al. **Dis Colon Rectum** 1996 Nov; 39(11):1269–74

Immunologic evaluation of the child with recurrent otitis media [letter] Neustrom MR. **Ear Nose Throat J** 1997 Aug; 76(8):584

Detection of equine antisperm antibodies by indirect immunofluorescence and the tube–slide agglutination test. Day MJ. **Equine Vet J** 1996 Nov;28(6):494–6

Relationships between plasma thyrotropin receptor antibodies and lipid or lipoprotein parameters in Graves' disease. Rieu M, et al. **Eur J Endocrinol** 1996 Jul; 135(1):77–81

Antimitochondrial antibody detection by indirect immunofluorescence on mouse sperms. Martínez S, et al. **Eur J Histochem** 1996;40(4):315–22

Anti–endomysium antibody on human umbilical cord vein tissue: an inexpensive and sensitive diagnostic tool for the screening of coeliac disease. Not T, et al. **Eur J Pediatr** 1997 Aug;156(8):616–8

Antibodies to bovine serum albumin (BSA) in type 1 diabetes and other autoimmune disorders [see comments] Füchtenbusch M, et al. **Exp Clin Endocrinol Diabetes** 1997; 105(2):86–91. Comment in: Exp Clin Endocrinol Diabetes 1997 ;105(2):83–5.

Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies—therapeutic consequences. Göschel H, et al. **Exp Neurol** 1997 Sep;147(1):96–102

Antibodies to beta 2–glycoprotein I and prothrombin in habitual abortion. Ailus K, et al. **Fertil Steril** 1996 Dec; 66(6):937–41

Prospective study showing that antisperm antibodies are not associated with pregnancy losses. Simpson JL, et al. **Fertil Steril** 1996 Jul;66(1):36–42

Classification of male factor infertility relevant to in–vitro fertilization insemination strategies using mannose ligands, acrosome status and anti–cytoskeletal antibodies. Benoff S, et al. **Hum Reprod** 1996 Sep;11(9):1905–18

Decreased amounts of antibodies to 22 and 18 kDa antigens in the peritoneal fluid of patients with endometriosis. LE Group d'Investigation en Gynecologie. Berkova N, et al. **Hum Reprod** 1996 Apr;11(4):861–7

Circulating antibodies to Chlamydia trachomatis in women: relationship to antisperm and antichlamydial antibodies in semen of male partners. Witkin SS. **Hum Reprod** 1996 Aug; 11(8):1635–7

Indirect enzyme–linked immunosorbent assay (ELISA) for monitoring antibodies in rainbow trout Oncorhynchus mykiss. Saifi AI, et al. **Indian J Exp Biol** 1996 Dec; 34(12):1274–5

Comparison of anti–GBM antibodies in sera with or without ANCA. Hellmark T, et al. **J Am Soc Nephrol** 1997 Mar; 8(3):376–85

Thyrotropin receptor antibodies and Graves' disease, a side–effect of 131I treatment in patients with nontoxic goiter. Nygaard B, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2926–30

A method for measuring specific antibodies in bovine lacteal secretions during the nonlactating period. Guidry AJ, et al. **J Dairy Sci** 1996 May;79(5):846–50

Evaluation of cross–reacting anti–human antibodies in the euthymic hairless guinea pig model (HGP) suggests that the HGP may be a model for the study of proliferative skin disease. Smith KJ, et al. **J Dermatol Sci** 1997 Mar; 14(3):240–50

Influence of anti–HLA antibodies and positive T–lymphocytotoxic crossmatch on survival and graft rejection in human liver transplantation. Charco R, et al. **J Hepatol** 1996 Apr;24(4):452–9

Frequency and significance of antibodies to P450IID6 protein in Japanese patients with chronic hepatitis C. Nishioka M, et al. **J Hepatol** 1997 May;26(5):992–1000

The quantitation of coupled bead antibody by enzyme–linked immunosorbent assay. Derango R, et al. **J Immunoassay** 1996 May;17(2):145–53

A quantitative cell–ELISA for alpha–galactose specific antibodies in human malaria. Satapathy AK, et al. **J Immunoassay** 1996 Aug;17(3):245–56

Analysis of antibody selection by phage display utilizing anti–phenobarbital antibodies. Malone J, et al. **J Mol Recognit** 1996 Sep–Dec;9(5–6):738–45

Purification and identification of ABA–binding proteins and antibody preparation. Wan Y, et al. **J Mol Recognit** 1996 Sep–Dec;9(5–6):722–7

Multiple antibodies to nerve glycoconjugates in a patient with neuropathy and monoclonal IgA gammopathy. Farrer RG, et al. **J Neuroimmunol** 1996 May;66(1–2):71–6

Close association of Guillain–Barré syndrome with antibodies to minor monosialogangliosides GM1b and GM1 alpha. Yuki N, et al. **J Neuroimmunol** 1997 Apr;74(1–2):30–4

Raised antibody titre against conjugated S–nitrosocysteine in IgM paraproteinaemic peripheral, neuropathy: possible role of nitric oxide in pathogenesis [letter] Boullerne AI, et al. **J Neurol Neurosurg Psychiatry** 1997 Feb;62(2):202–3

Post–infectious encephalitis with anti–galactocerebroside antibody subsequent to Mycoplasma pneumoniae infection. Nishimura M, et al. **J Neurol Sci** 1996 Sep 1;140(1–2):91–5

Patients with delayed–onset sulfonamide hypersensitivity reactions have antibodies recognizing endoplasmic reticulum luminal proteins. Cribb AE, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):1064–71

Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti–beta 2–glycoprotein–I than with antiphospholipid antibodies. Cabiedes J, et al. **J Rheumatol** 1995 Oct;22(10):1899–906

Antibodies to phospholipid–free beta 2–glycoprotein–I in patients with primary antiphospholipid syndrome. Cabral AR, et al. **J Rheumatol** 1995 Oct;22(10):1894–8

Anti–lipid A antibodies in childhood arthritis: methods of immobilization affect quantitation and crossreactivity measured by ELISA. Miller JJ 3rd, et al. **J Rheumatol** 1996 Dec;23(12):2125–31

Enzyme–linked immunosorbent assay for detection of feline serum amyloid A protein by use of immunological cross–reactivity of polyclonal anti–canine serum amyloid A protein antibody. Kajikawa T, et al. **J Vet Med Sci** 1996 Nov;58(11):1141–3

Antipolymer antibodies, silicone breast implants, and fibromyalgia [letter; comment] Angell M. **Lancet** 1997 Apr 19;349(9059):1171–2; discussion 1172–3. Comment on: Lancet 1997 Feb 15;349(9050):449–54.

Screening test for coeliac disease [letter; comment] Bürgin–Wolff A, et al. **Lancet** 1997 Jun 21;349(9068):1843–4 . Comment on: Lancet 1997 Feb 1;349(9048):325–6.

Antipolymer antibodies, silicone breast implants, and fibromyalgia [letter; comment] Edlavitch SA. **Lancet** 1997 Apr 19;349(9059):1170. Comment on: Lancet 1997 Feb 15;349(9050):449–54.

Antipolymer antibodies, silicone breast implants, and fibromyalgia [letter] Ellis TM, et al. **Lancet** 1997 Apr 19; 349(9059):1173

Antipolymer antibodies, silicone breast implants, and fibromyalgia [letter; comment] Everson MP, et al. **Lancet** 1997 Apr 19;349(9059):1171; discussion 1172–3. Comment on: Lancet 1997 Feb 15;349(9050):449–54.

Antipolymer antibodies, silicone breast implants, and fibromyalgia [letter; comment] Korn JH. **Lancet** 1997 Apr 19;349(9059):1171. Comment on: Lancet 1997 Feb 15;349(9050):449–54.

Antipolymer antibodies, silicone breast implants, and fibromyalgia [letter; comment] Lamm SH. **Lancet** 1997 Apr 19;349(9059):1170–1; discussion 1172–3. Comment on: Lancet 1997 Feb 15;349(9050):449–54.

Indirect quenching fluororeceptor assay of anti–AChR antibodies. Messripour M, et al. **Mol Chem Neuropathol** 1997 May;31(1):43–51

Antibodies to potassium channels of PC12 in serum of Isaacs' syndrome: Western blot and immunohistochemical studies. Arimura K, et al. **Muscle Nerve** 1997 Mar;20(3):299–305

Acetylcholine receptor antibodies as a marker of treatable fatigue in HIV–1 infected individuals. Cupler EJ, et al. **Muscle Nerve** 1996 Sep;19(9):1186–8

Cytokines and myelin antibodies in Crow–Fukase syndrome. Saida K, et al. **Muscle Nerve** 1996 Dec;19(12):1620–2

High–titer immunoglobulin M antibody to nerve–specific class III beta–tubulin in the serum of a patient with sensory demyelinating polyneuropathy [letter] Stubbs EB Jr, et al. **Muscle Nerve** 1996 Dec;19(12):1638–9

SLE; should a rise in dsDNA antibody be treated? [letter] Loo CS, et al. **Nephrol Dial Transplant** 1996 Aug;11(8):1668

The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn. Gardnerova M, et al. **Neurology** 1997 Jan;48(1):50–4

Anticytokine antibodies in beta interferon–treated MS patients and the need for testing: plight of the practicing neurologist. Pachner AR. **Neurology** 1997 Sep;49(3):647–50

Antibodies to synthetic peptides of the alpha1A subunit of the voltage–gated calcium channel in Lambert–Eaton myasthenic syndrome. Takamori M, et al. **Neurology** 1997 May;48(5):1261–5

Encephalomyelitis subsequent to mycoplasma infection with elevated serum anti–Gal C antibody. Kumada S, et al. **Pediatr Neurol** 1997 Apr;16(3):241–4

Determining the safety of the silicone envelope: in search of a silicone antibody [letter] Rohrich RJ, et al. **Plast Reconstr Surg** 1997 Apr;99(5):1472

Anti–vascular endothelial cell antibodies (AECA): comparison of two assay methods and clinical applications. Meyer O, et al. **Rev Rhum Engl Ed** 1995 Dec;62(11):737–47

Heat–shock–proteins–antibodies in patients with Helicobacter pylori associated chronic gastritis. Leri O, et al. **Riv Eur Sci Med Farmacol** 1996 Mar–Apr;18(2):45–7

Quantities and units for biological reference materials used with in vitro diagnostic measuring systems for antibodies. Dybkaer R. **Scand J Clin Lab Invest** 1996 Aug;56(5):385–91

The use of heparinase improves the specificity of crossreactivity testing in heparin–induced thrombocytopenia [letter] Pötzsch B, et al. **Thromb Haemost** 1996 Dec;76(6):1121

Immobilization of small molecules on solid matrices: a novel approach to enzyme–linked immunosorbent assay screening for saxitoxin and evaluation of anti–saxitoxin antibodies. Kralovec JA, et al. **Toxicon** 1996 Oct;34(10):1127–40

The use of pooled red cells and column techniques for routine red cell antibody detection [see comments] Eggington JA, et al. **Transfus Med** 1996 Dec;6(4):345–9. Comment in: Transfus Med 1996 Dec;6(4):307–9.

Challenges in the determination of clinically significant granulocyte antibodies and antigens. Bux J. **Transfus Med Rev** 1996 Jul;10(3):222–32 (58 ref.)

Detection of HLA class I– and class II–specific antibodies by flow cytometry and PRA–STAT screening in renal transplant recipients. Harmer AW, et al. **Transplantation** 1997 Jun 27;63(12):1828–32

Islet cell antibodies and glutamic acid decarboxylase antibodies in patients with insulin–dependent diabetes mellitus undergoing kidney and islet–after–kidney transplantation. Jaeger C, et al. **Transplantation** 1996 Aug 15;62(3):424–6

False–negative results in anti–HLA antibody detection by Sangstat ELISA: complement dependent cytotoxicity is not yet obsolete. Pierquin A, et al. **Transplantation** 1996 Nov 27;62(10):1533–4

Antibody screening by enzyme–linked immunosorbent assay using pooled soluble HLA in renal transplant candidates. Zaer F, et al. **Transplantation** 1997 Jan 15;63(1):48–51

Design, production and characterization of antibodies discriminating between the phenol– and monoamine–sulphating forms of human phenol sulphotransferase. Rubin GL, et al. **Xenobiotica** 1996 Nov; 26(11):1113–9

Detection of antibodies to melanocytes in vitiligo by western immunoblotting. Hann SK, et al. **Yonsei Med J** 1996 Dec; 37(6):365–70

[Monitoring immunity factors in serum and peritoneal fluid after laparoscopy in women. II. Sperm and zona pellucida antibodies] Ulčová–Gallová Z, et al. **Ceska Gynekol** 1996 Jun;61(3):139–41 (Eng. Abstr.) **(Cze)**

[Anti–endomysium and anti–reticulin antibodies in adults with celiac disease followed–up in the Paris area] Boige V, et al. **Gastroenterol Clin Biol** 1996;20(11):931–7 (Eng. Abstr.) **(Fre)**

[Clinical reliability of a new IgE detection system using chemiluminescent enzyme immunoassay named LUMIWARD immunoassay system] Nakagawa T, et al. **Arerugi** 1996 Jul;45(7):637–48 (Eng. Abstr.) **(Jpn)**

[The influence of anti–interferon–alpha 2a antibodies in initial daily four–week interferon–alpha 2a therapy for chronic hepatitis C] Habu D, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 May;94(5):319–27 (Eng. Abstr.) **(Jpn)**

[Immunologic response against spermatozoa in the human genital tract] Domagała A, et al. **Ginekol Pol** 1996 Jun; 67(6):304–8 (26 ref.) (Eng. Abstr.) **(Pol)**

[TSH–receptor antibodies in thyroid diseases] Hasse–Lazar K, et al. **Pol Arch Med Wewn** 1997 Mar;97(3):239–51 (Eng. Abstr.) **(Pol)**

[Prospects of etiological diagnosis of bronchitis] Afanas'ev IA, et al. **Klin Med (Mosk)** 1996;74(9):34–5 (Eng. Abstr.) **(Rus)**

[Assessment of the formation of antibodies to interferon in patients with juvenile respiratory papillomatosis on interferon therapy] Kol'tsov VD, et al. **Vestn Otorinolaringol** 1996 Jul–Aug;(4):25–7 (Eng. Abstr.) **(Rus)**

[Antibodies to brain galactocerebrosides in the serum and cerebrospinal fluid of patients with disseminated sclerosis] Totolian NA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(4):75–7 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS see ANTIBODY FORMATION

BLOOD

Clinical significance and time course of antibodies to glutamic acid decarboxylase in Japanese children with type I (insulin–dependent) diabetes mellitus. Sugihara S, et al. **Acta Paediatr** 1996 May;85(5):558–63

Serological screening (antigliadin and antiendomysium antibodies) for non–overt coeliac disease in children of short stature. de Lecea A, et al. **Acta Paediatr Suppl** 1996 May;412:54–5

Anti–low–density lipoprotein antibodies in alcoholics without and with liver disease and in social drinkers. Wehr H, et al. **Alcohol Alcohol** 1997 Jan–Feb;32(1):43–9

Studies on the usefulness of acetaldehyde–modified proteins and associated antibodies as markers of alcohol abuse. Worrall S, et al. **Alcohol Alcohol Suppl** 1994;2:503–7

Antibodies to cow's milk proteins in chronic urticaria. Paranos S, et al. **Allergy** 1996 Apr;51(4):273–5

Characterization of latex allergens and correlation of serum IgE/IgG antibody ratio with clinical symptoms. Chen HD, et al. **Allergy Asthma Proc** 1996 May–Jun;17(3):143–8

Regular measurement of anti–GBM antibodies in Goodpasture's disease? [letter; comment] Greenbaum LA. **Am J Kidney Dis** 1996 Nov;28(5):786. Comment on: Am J Kidney Dis 1996 Apr;27(4):573–8.

Comparison of the immunobead binding test (IBT) and immunospheres (IS) assay for detecting serum antisperm antibodies. Centola GM, et al. **Am J Reprod Immunol** 1997 Apr;37(4):300–3

Anti–seminal plasma antibodies associated with infertility: I. Serum antibodies against normozoospermic seminal plasma in patients with unexplained infertility. Fichorova RN, et al. **Am J Reprod Immunol** 1996 Oct;36(4):198–203

Identification of human sperm antigen recognized by serum of an immunoinfertile woman: a candidate for immunocontraception. Suri A, et al. **Am J Reprod Immunol** 1996 Dec;36(6):317-26

Tick avoidance behaviors associated with a decreased risk of anti-tick salivary gland protein antibody seropositivity in military personnel exposed to Amblyomma americanum in Arkansas. Schwartz BS, et al. **Am J Trop Med Hyg** 1996 Oct;55(4):410-6

Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA. Rajan GP, et al. **Arch Dermatol Res** 1996 Aug;288(9):543-8

Effect of a proline-rich polypeptide on IgG level in Chickens. Janusz M, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(1):23-6

Comparison of an enzyme-linked immunosorbent assay for antibodies to beta 2-glycoprotein I and a conventional anticardiolipin immunoassay [see comments] Roubey RA, et al. **Arthritis Rheum** 1996 Sep;39(9):1606-7. Comment in: Arthritis Rheum 1996 Sep;39(9):1441-3. Comment in: Arthritis Rheum 1997 Jul;40(7):1366-8.

Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus [see comments] Tsutsumi A, et al. **Arthritis Rheum** 1996 Sep;39(9):1466-74. Comment in: Arthritis Rheum 1996 Sep;39(9):1441-3. Comment in: Arthritis Rheum 1997 Jul;40(7):1366-8.

Correlation of serum IgG antibodies to recombinant P0 fusion protein with IgG antibodies to carboxyl-terminal 22 synthetic peptides and carboxyl-terminal 22 amino acid-deleted recombinant P0 fusion protein in patients with systemic lupus erythematosus. Yoshio T, et al. **Arthritis Rheum** 1997 Jul;40(7):1364-5

Cardiopulmonary bypass using lomoparan: monitoring of anticoagulation using anti-Xa levels and thromboelastography. Sharma S, et al. **Aust N Z J Surg** 1997 Jun;67(6):392-4

Antibodies to lactoferrin--a possible link between cow's milk intolerance and autoimmune disease. Brock JH, et al. **Biochem Soc Trans** 1997 May;25(2):317S

Immunoblot detection of decreased antibodies to haptoglobin-like protein in the serum of infertile women with or without endometriosis. Berkova N, et al. **Biol Reprod** 1997 Jul;57(1):178-85

Adsorption of immunoglobulin G and anti-factor VIII inhibitory antibody from haemophiliac plasma to derivatized polystyrenes. Cornelius RM, et al. **Biomaterials** 1997 Mar;18(5):429-36

Presence of antibodies to heat stress proteins and its possible significance in workers exposed to high temperature and carbon monoxide. Wu TC, et al. **Biomed Environ Sci** 1996 Dec;9(4):370-9

Interferon antibodies in patients with infectious diseases. Anti-interferon antibodies. Antonelli G, et al. **Biotherapy** 1997;10(1):7-14 (50 ref.)

Natural antibodies to IL-2. Balsari A, et al. **Biotherapy** 1997; 10(1):25-8 (12 ref.)

Natural antibodies to interferon-gamma. Caruso A, et al. **Biotherapy** 1997;10(1):29-37 (21 ref.)

The expression of potency of neutralizing antibodies for interferons and other cytokines. Grossberg SE, et al. **Biotherapy** 1997;10(1):93-8 (18 ref.)

The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors. Oberg K, et al. **Biotherapy** 1997;10(1):1-5 (21 ref.)

Treatment-induced antibodies to interleukin-2. Prümmer O. **Biotherapy** 1997;10(1):15-24 (66 ref.)

Measurement of cytokine antibodies. Test development. Svenson M, et al. **Biotherapy** 1997;10(1):87-92 (21 ref.)

Association between antibodies reactive with neutrophils, rate of neutrophil engraftment, and incidence of post-engraftment neutropenia following BMT. Klumpp TR, et al. **Bone Marrow Transplant** 1996 Sep;18(3):559-64

Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. von Brevern MC, et al. **Cancer Res** 1996 Nov 1;56(21):4917-21

Clinical evaluation of primary biliary cirrhosis in Chinese patients without serum anti-mitochondrial antibody. Li CP, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Jun; 59(6):334-40

Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Bauer TL, et al. **Circulation** 1997 Mar 4; 95(5):1242-6

Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Kobashigawa JA, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II294-7

Diagnostic value of various serum antibodies detected by diverse methods in childhood celiac disease. Sacchetti L, et al. **Clin Chem** 1996 Nov;42(11):1838-42

Rapid method for detection of anti-recombinant human erythropoietin antibodies as a new form of erythropoietin resistance. Urra JM, et al. **Clin Chem** 1997 May;43(5):848-9

Evidence of antibodies to erythromycin in serum of a patient following an episode of acute drug-induced hepatitis. Gómez-Lechón MJ, et al. **Clin Exp Allergy** 1996 May; 26(5):590-6

Screening for celiac disease [editorial; comment] Davidson AG, et al. **CMAJ** 1997 Sep 1;157(5):547-8. Comment on: CMAJ 1997 Sep 1;157(5):527-35.

Prevalence of antithyroid antibodies in mood disorders. Haggerty JJ Jr, et al. **Depress Anxiety** 1997;5(2):91-6

The prevalence of anti-bovine serum albumin antibodies in Japanese children with IDDM [letter] Sugihara S, et al. **Diabetes Care** 1996 Nov;19(11):1308-10

Insulin responses to intravenous glucose, intravenous arginine and a hyperglycaemic clamp in ICA-positive subjects with different degrees of glucose tolerance. Rakotoambinina B, et al. **Diabetes Metab** 1997 Feb;23(1):43-50

Effect of excessive GnRH-binding substance on circulating maternal hCG in human pregnancy. Siler-Khodr TM, et al. **Early Pregnancy** 1997 Mar;3(1):10-4

Circulating anti-(xanthine oxidoreductase) antibodies in healthy human adults. Benboubetra M, et al. **Eur J Clin Invest** 1997 Jul;27(7):611-9

Screening and characterization of specific anti-lipopolysaccharide antibodies in Belgian blood donors by enzyme-linked immunosorbent assays. Nys M, et al. **Eur J Clin Invest** 1996 Dec;26(12):1134-42

Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Faden D, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 May;73(1):37-42

Natural hidden antibodies reacting with DNA or cardiolipin bind to thymocytes and evoke their death. Zamulaeva IA, et al. **FEBS Lett** 1997 Aug 18;413(2):231-5

Factors associated with serum antibodies to reticulin, endomysium, and gliadin in an adult population. McMillan SA, et al. **Gut** 1996 Jul;39(1):43-7

Antibody levels against alpha-galactosyl epitopes in sera of patients with squamous intraepithelial lesions and early invasive cervical carcinoma. Tremont-Lukats IW, et al. **Gynecol Oncol** 1997 Feb;64(2):207-12

Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Frostegård J, et al. **Hypertension** 1997 Jan;29(1 Pt 1):40-4

Development of IgE antibody to gelatin in children with systemic immediate-type reactions to vaccines. Sakaguchi M, et al. **J Allergy Clin Immunol** 1997 May;99(5):720-1

High feline trypsin-like immunoreactivity in a cat with pancreatitis and hepatic lipidosis. Bruner JM, et al. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1757-60

Sperm immobilization antibodies in infertile male sera decrease the acrosome reaction: a possible mechanism for immunologic infertility. Taşdemir I, et al. **J Assist Reprod Genet** 1996 May;13(5):413-6

ACP Broadsheet No 149: September 1996. Serological diagnosis of gluten sensitive enteropathy. Unsworth DJ. **J Clin Pathol** 1996 Sep;49(9):704-11

Influence of panel-reactive antibody on survival and rejection after lung transplantation. Gammie JS, et al. **J Heart Lung Transplant** 1997 Apr;16(4):408-15

Redirecting circulating antibodies via ligand-hapten conjugates eliminates target cells in vivo. Lussow AR, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):257-65

High frequencies of human T-lymphotropic virus type I (HTLV-I) infection and presence of HTLV-II proviral DNA in blood donors with anti-thyroid antibodies. Mine H, et al. **J Mol Med** 1996 Aug;74(8):471-7

Antibodies to 125I-glutamic acid decarboxylase in patients with stiff man syndrome. Vincent A, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):395-7

Development of primary hypothyroidism with antithyroglobulin, antiperoxidase, and blocking-type thyrotropin receptor antibodies after radiation therapy for neuroblastoma. Kikawa Y, et al. **J Pediatr** 1996 Dec; 129(6):909-12 (19 ref.)

Antibodies to Klebsiella, Proteus, and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis. Tani Y, et al. **J Rheumatol** 1997 Jan; 24(1):109-14

Antenatal screening of thyroid antibodies [letter; comment] Lazarus JH, et al. **Lancet** 1996 Nov 30;348(9040):1516-7. Comment on: Lancet 1996 Oct 5;348(9032):906-7.

Silicone breast implants and antipolymer antibodies [letter] Miller SH. **Lancet** 1997 Sep 6;350(9079):740-1

Hairy cell leukemia in association with thrombotic thrombocytopenic purpura and factor VIII antibodies. Moses J, et al. **Leuk Lymphoma** 1996 Jul;22(3-4):351-4

Antimitochondrial antibodies in patients with chronic hepatitis C. Grimbert S, et al. **Liver** 1996 Jun;16(3):161-5

Phage-displayed peptides as tools for characterization of human sera. Felici F, et al. **Methods Enzymol** 1996; 267:116-29

The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A. Kessler KR, et al. **Mov Disord** 1997 Jan;12(1):95-9

Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency [letter] Brewer KW, et al. **N Engl J Med** 1997 Jul 17;337(3):202

The incidence of antisperm antibodies in patients with seminal tract obstructions. Yamamoto M, et al. **Nagoya J Med Sci** 1996 Mar;59(1-2):25-9

Determination of antibodies to Borrelia burgdorferi in the serum of patients living in Calabria, southern Italy. Santino I, et al. **Panminerva Med** 1996 Sep;38(3):167-72

The distribution of antibodies to streptokinase. Lynch M, et al. **Postgrad Med J** 1996 May;72(847):290-2

Demonstration of a novel circulating anti-prostacyclin receptor antibody. Kahn NN, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8779-82

GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia. Nardi MA, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8; 94(14):7589-94

Cytokine enhancement of immune responses important for immunocontraception. Ramsay AJ, et al. **Reprod Fertil Dev** 1997;9(1):91-7 (40 ref.)

Development of anti-OKT3 antibodies after OKT3 treatment. Jensen PB, et al. **Scand J Urol Nephrol** 1996 Jun;30(3):227-30

Seroprevalence of Sarcoptes scabiei var canis antibodies among aborigines in peninsular Malaysia. Normaznah Y, et al. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):53-6

Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis [letter] de Sancho M, et al. **Thromb Haemost** 1996 Apr;75(4):695-6

beta 2 glycoprotein-I inhibits factor XII activation on triglyceride rich lipoproteins: the effect of antibodies from plasma of patients with antiphospholipid syndrome. McNally T, et al. **Thromb Haemost** 1996 Aug;76(2):220-5

Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Peerlinck K, et al. **Thromb Haemost** 1997 Jan;77(1):80-6

T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Singer ST, et al. **Thromb Haemost** 1996 Jul; 76(1):17-22

Antibody-mediated thrombosis. Vermylen J, et al. **Thromb Haemost** 1997 Jul;78(1):420-6 (73 ref.)

Application of beryllium antibodies in risk assessment and health surveillance: two case studies. Clarke SM, et al. **Toxicol Ind Health** 1995 Jul-Aug;11(4):399-411

The humoral and cellular immune response to a lipid attenuated pore-forming toxin from the sea anemone Actinia equina L. Narat M, et al. **Toxicon** 1994 Jan; 32(1):65-71

From maximum surgical blood ordering schedule to unlimited computer crossmatching: evolution of blood transfusion for surgical patients at a tertiary hospital in Hong Kong. Chan AH, et al. **Transfus Med** 1996 Jun; 6(2):121-4

The effect of intravenous immunoglobulin on placental transfer of a platelet-specific antibody: anti-P1A1. Morgan CL, et al. **Transfus Med** 1991 Dec;1(4):209-16

Application of a computer program to exclude additional unexpected antibodies. Rondeel JM, et al. **Transfusion** 1997 Mar;37(3):298-303

Significance of preformed anti-donor antibodies in liver transplantation. Fujita S, et al. **Transplantation** 1997 Jan 15;63(1):84-8

Fluorescence videomicroscopic assessment of xenogeneic microcirculation and impact of antibody removal by immunoadsorption. Seehofer D, et al. **Transplantation** 1997 Feb 15;63(3):460-5

Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Coombes AG, et al. **Vaccine** 1996 Oct;14(15):1429-38

Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability. Scheifele D, et al. **Vaccine** 1996 Oct;14(15):1399-406

Sero-surveillance of hypodermosis in a herd under therapeutic control. Effect of a low level of infestation. Boulard C, et al. **Vet Parasitol** 1996 Nov 1;66(1-2):109-17

Serodiagnosis of sarcoptic mange in pigs. Bornstein S, et al. **Vet Rec** 1997 Jul 5;141(1):8-12

A new microplate red blood cell monolayer technique for screening and identifying red blood cell antibodies. Llopis F, et al. **Vox Sang** 1996;70(3):152-6

[PRA-STAT test and anti-HLA antibody detection (letter)] Montagnac R, et al. **Nephrologie** 1996;17(8):453-4 **(Fre)**

[A comparative study of MAST and CAP RAST with 90 patients with bronchial asthma] Mita S, et al. **Arerugi** 1995 Dec;44(12):1394-400 (Eng. Abstr.) **(Jpn)**

[Case of p-ANCA-positive rapidly progressing glomerulonephritis requiring hemodialysis: effectiveness of anti-MPO antibody determiantion in predicting pulmonary hemorrhage] Matsuda T, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):675-7 **(Jpn)**

[Elastin-derived peptides and anti-elastic antibodies in children with recurrent or obstructive bronchitis] Polańska B, et al. **Pediatr Pol** 1996 Sep;71(9):759-63 (Eng. Abstr.) **(Pol)**

[Detection of antisperm antibodies in the serum of women following the use of spermatozoa from different donors] Nikolaeva MA, et al. **Biull Eksp Biol Med** 1997 Jul; 124(7):89-91 **(Rus)**

[Natural antibodies to the ABO(H)-system antigens in the blood serum of chickens (a preliminary report)] Kolokolova GP, et al. **Sud Med Ekspert** 1996 Jul-Sep;39(3):32-4 (Eng. Abstr.) **(Rus)**

ANTIBODIES

CEREBROSPINAL FLUID

Probing for cerebrospinal fluid antibody specificities by a panel of random peptide libraries. Dybwad A, et al. **Autoimmunity** 1997;25(2):85–9

CHEMISTRY

The potential of catalytic antibodies. Kirby AJ. **Acta Chem Scand** 1996 Mar;50(3):203–10 (27 ref.)

Antibody binding sites. Huston JS, et al. **Adv Protein Chem** 1996;49:329–450 (326 ref.)

Insight into antibody combining sites using nuclear magnetic resonance and spin label haptens. McConnell HM, et al. **Adv Protein Chem** 1996;49:135–48 (27 ref.)

Computational biochemistry of antibodies and T-cell receptors. Novotny J, et al. **Adv Protein Chem** 1996; 49:149–260 (492 ref.)

X-ray crystallography of antibodies. Padlan EA. **Adv Protein Chem** 1996;49:57–133 (175 ref.)

Antibodies to presenilin proteins detect neurofibrillary tangles in Alzheimer's disease. Murphy GM Jr, et al. **Am J Pathol** 1996 Dec;149(6):1839–46

Antibodies as tools to study the structure of membrane proteins: the case of the nicotinic acetylcholine receptor. Conti-Fine BM, et al. **Annu Rev Biophys Biomol Struct** 1996;25:197–229 (112 ref.)

Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications. Arano Y, et al. **Bioconjug Chem** 1996 Nov-Dec;7(6):628–37

Adsorption of immunoglobulin G and anti-factor VIII inhibitory antibody from haemophiliac plasma to derivatized polystyrenes. Cornelius RM, et al. **Biomaterials** 1997 Mar;18(5):429–36

The measurement of affinity between ligand and antibody using ligand-induced antibody fluorescence change. Glaudemans CP, et al. **Carbohydr Res** 1997 May 12; 300(2):169–70

Ligand function of antigenized antibodies expressing the RGD motif. Billetta R, et al. **Chem Immunol** 1997;65:159–78 (53 ref.)

Development of polyclonal antibodies for detection of protein modification by 1,2-naphthoquinone. Zheng J, et al. **Chem Res Toxicol** 1996 Jul-Aug;9(5):904–9

Phage display of combinatorial antibody libraries. Rader C, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):503–8 (47 ref.)

A novel method for boronating antibodies without loss of immunoreactivity, for use in neutron capture therapy. Ferro VA, et al. **Drug Des Discov** 1995 Aug;13(1):13–25

Comparison of the amide proton exchange behavior of the rapidly formed folding intermediate and the native state of an antibody scFv fragment. Freund C, et al. **FEBS Lett** 1997 Apr 21;407(1):42–6

Structural classification of CDR-H3 in antibodies. Shirai H, et al. **FEBS Lett** 1996 Dec 9;399(1-2):1–8

Expression vectors for the introduction of highly diverged sequences into the six complementarity-determining regions of an antibody. Iba Y, et al. **Gene** 1997 Jul 18; 194(1):35–46

Phosphorylation-dependent control of structures of intermediate filaments: a novel approach using site- and phosphorylation state-specific antibodies. Inagaki M, et al. **J Biochem (Tokyo)** 1997 Mar;121(3):407–14 (113 ref.)

Electron spectroscopic imaging of antigens by reaction with boronated antibodies. Qualmann B, et al. **J Microsc** 1996 Jul;183 (Pt 1):69–77

Analysis of protein-protein interactions and the effects of amino acid mutations on their energetics. The importance of water molecules in the binding epitope. Covell DG, et al. **J Mol Biol** 1997 Jun 6;269(2):281–97

Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies. Martin AC, et al. **J Mol Biol** 1996 Nov 15; 263(5):800–15

Antibody-antigen recognition: a canonical structure paradigm. Lara-Ochoa F, et al. **J Mol Evol** 1996 Dec; 43(6):678–84

In vitro targeting of antibody-conjugated echogenic liposomes for site-specific ultrasonic image enhancement. Demos SM, et al. **J Pharm Sci** 1997 Feb;86(2):167–71

Production and characterization of polyclonal anti-S 20499 antibodies: influence of the hapten structure on stereospecificity. Got PA, et al. **J Pharm Sci** 1997 Jun; 86(6):654–9

Determination of loading values and distributions for drugs conjugated to proteins and antibodies by MALDI-MS and ESI-MS. Siegel MM. **Methods Mol Biol** 1996;61:211–26

Antibody characterization by isothermal titration calorimetry. Livingstone JR. **Nature** 1996 Dec 5; 384(6608):491–2 (11 ref.)

Can a cysteine challenge assay predict the in vivo behavior of 99mTc-labeled antibodies? Hnatowich DJ, et al. **Nucl Med Biol** 1994 Nov;21(8):1035–44

Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody. Flick MB, et al. **Oncogene** 1997 May 29;14(21):2553–61

The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. Pei XY, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9637–42

Accessing the Kabat antibody sequence database by computer. Martin AC. **Proteins** 1996 May;25(1):130–3

Structural model of the anti-snake-toxin antibody, M alpha 2,3. Tenette C, et al. **Proteins** 1996 Sep;26(1):9–31

Investigations of directly labeling antibodies with rhenium-188. Winnard P Jr, et al. **Q J Nucl Med** 1996 Jun;40(2):151–60

Probing the structure-function relationship of alpha-latrotoxin-formed channels with antibodies and pronase. Chanturiya AN, et al. **Toxicon** 1996 Oct; 34(10):1157–64

Detection of homocytotropic antibody in lambs infested with the louse, Bovicola ovis, using a basophil histamine-release assay. Pfeffer A, et al. **Vet Immunol Immunopathol** 1997 Jul;57(3-4):315–25

[Glycoconjugates on the basis of polyacrylamide--tools for studying lectins, antibodies, and glycosyltransferases in glycobiology, cytochemistry, and histochemistry] Bovin NV. **Bioorg Khim** 1996 Sep;22(9):643–63 (81 ref.) (Eng. Abstr.) **(Rus)**

[Study of the interaction of polyreactive antibodies with nucleic acids using alkylating oligonucleotide derivatives] Pautova LV, et al. **Mol Biol (Mosk)** 1996 Jul-Aug; 30(4):941–50 **(Rus)**

DEFICIENCY see IMMUNOLOGIC DEFICIENCY SYNDROMES

DIAGNOSTIC USE

Useful panel of antibodies for the classification of acute leukemia by immunohistochemical methods in bone marrow trephine biopsy specimens. Chuang SS, et al. **Am J Clin Pathol** 1997 Apr;107(4):410–8

Engineering antibodies for imaging and therapy. Carter P, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):449–54 (54 ref.)

Use of antibodies directed against blood group substances and lectins together with glycosidase digestion to study the composition and cellular distribution of glycoproteins in the large human airways. Bals R, et al. **J Anat** 1997 Jan;190 (Pt 1):73–84

A novel technique for producing antibody-coated microprobes using a thiol-terminal silane and a heterobifunctional crosslinker. Routh VH, et al. **J Neurosci Methods** 1997 Feb;71(2):163–8

Clinical aspects of coeliac disease in children with insulin-dependent diabetes mellitus. Lorini R, et al. **J Pediatr Endocrinol Metab** 1996 Mar;9 Suppl 1:101–11 (66 ref.)

Antibodies to 68 kd antigen--specific for inner ear disease? [letter; comment] Dhingra J, et al. **Laryngoscope** 1997 Mar; 107(3):405–6. Comment on: Laryngoscope 1995 Dec;105(12 Pt 1):1347–52.

GENETICS

Maturation of the immune response. Milstein C, et al. **Adv Protein Chem** 1996;49:451–85 (143 ref.)

Molecular cloning and primary characterization of a single-chain antibody against human sarcoma-associated antigen p200. Chen H, et al. **Anticancer Res** 1996 Nov-Dec; 16(6B):3551–6

An increased incidence of thyroid antibodies in patients with Turner's syndrome and their first degree relatives. Wilson R, et al. **Autoimmunity** 1996;25(1):47–52

Full-scale 'naïve' human antibody repertoires assembled from VH and VL variable regions. Sodoyer R, et al. **Hum Antibodies** 1997;8(1):37–42

In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Noël D, et al. **Hum Gene Ther** 1997 Jul 1;8(10):1219–29

Screening of phage antibody libraries. Harrison JL, et al. **Methods Enzymol** 1996;267:83–109

The primary antibody repertoire of normal, immunodeficient and autoimmune mice is characterized by differences in V gene expression. Kaushik A, et al. **Res Immunol** 1996 Jan;147(1):9–26 (48 ref.)

An improved phage display vector for antibody repertoire cloning by construction of combinatorial libraries. Burioni R, et al. **Res Virol** 1997 Mar-Apr;148(2):161–4

Profile: Thereza Imanishi-Kari. Beardsley T. **Sci Am** 1996 Nov;275(5):50, 52

Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(alpha1,3)Galactose epitope. McMorrow IM, et al. **Transplantation** 1997 Aug 15; 64(3):501–10

IMMUNOLOGY

Proliferative responses to PHA, anti-CD3 and antigens in patients with lymphoproliferative disease of granular lymphocytes. Mannoproteins of Candida albicans induce proliferation and cytotoxicity. Giovannetti A, et al. **Acta Haematol** 1997;98(2):65–71

Anti-glomerular basement membrane antibody-induced inflammation in rat cochlear plexus. Satoh H. **Acta Otolaryngol (Stockh)** 1997 Jan;117(1):80–6

Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Kaburaki J, et al. **Am J Hematol** 1997 Mar;54(3):209–13

Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha. Tefferi A, et al. **Am J Hematol** 1996 Jul;52(3):231–3

Polyarteritis nodosa and antiglomerular basement membrane disease without antineutrophil cytoplasm antibodies. Kirkland GS, et al. **Am J Nephrol** 1996;16(5):442–5

Prevention of postoperative adhesions by an antibody to vascular permeability factor/vascular endothelial growth factor in a murine model. Saltzman AK, et al. **Am J Obstet Gynecol** 1996 May;174(5):1502–6

Antibodies to glycosphingolipid antigens in patients with immune-mediated cochleovestibular disorders. Lake GM 3rd, et al. **Am J Otol** 1997 Mar;18(2):175–8

Inhibition of T cell recruitment and cutaneous delayed-type hypersensitivity-induced inflammation with antibodies to monocyte chemoattractant protein-1. Rand ML, et al. **Am J Pathol** 1996 Mar;148(3):855–64

Activation of human platelets by protein kinase C antibody: role for surface phosphorylation in homeostasis. Babinska A, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H2134–44

Quantitative determination of IgG and IgA on sperm from infertile patients with and without antisperm antibodies. Hjort T. **Am J Reprod Immunol** 1996 Oct;36(4):211–5

Inhibition of mosquito salivary gland apyrase activity by antibodies produced in mice immunized by bites of Anopheles stephensi mosquitoes. Mathews GV, et al. **Am J Trop Med Hyg** 1996 Oct;55(4):417–23

Analysis of 3',5'-cAMP and adenylyl cyclase activity in higher plants using polyclonal chicken egg yolk antibodies. Roef L, et al. **Anal Biochem** 1996 Jan 15;233(2):188–96

Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis. Sinha AA, et al. **Anat Rec** 1996 Aug;245(4):652–61

Generation of antisera against mouse and human synthetic ZP3 peptides. Hinsch E, et al. **Andrologia** 1996;28 Suppl 1:9–14

The association of antibodies to beta 2 glycoprotein I with the antiphospholipid syndrome: a meta-analysis. Najmey SS, et al. **Ann Clin Lab Sci** 1997 Jan-Feb;27(1):41–6

Characterization by molecular cloning an antigen reactive with antireticulin antibodies. Uibo R, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:509–11

Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts. Stein GM, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S57–9 (10 ref.)

Analysis of nonlinear properties of immune network reactions. Hirayama H, et al. **Artif Organs** 1996 Aug; 20(8):866–77

Immunological and virological study of sudden deafness. Yoshida Y, et al. **Auris Nasus Larynx** 1996;23:63–8

Probing for cerebrospinal fluid antibody specificities by a panel of random peptide libraries. Dybwad A, et al. **Autoimmunity** 1997;25(2):85–9

Association of circulating hepatitis G virus with lipoproteins for a lack of binding with antibodies. Sato K, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):719–25

Erythrocruorin of Glossoscolex paulistus (Oligochaeta, Glossoscolecidae): modulation of oxygen affinity by specific antibodies. Cardillo F, et al. **Biochem Mol Biol Int** 1997 Mar;41(3):497–509

Immunodetection of mitochondrial glycerophosphate dehydrogenase (mGDH) by a polyclonal antibody raised against a recombinant mGDH fragment product. Novials A, et al. **Biochem Mol Med** 1996 Dec;59(2):187–91

The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Balaban N, et al. **Biochim Biophys Acta** 1996 Nov 8;1314(1-2):147–56

Association of the anti-hen egg lysozyme antibody HyHEL-5 with avian species variant and mutant lysozymes. Shick KA, et al. **Biochim Biophys Acta** 1997 Jul 18;1340(2):205–14

Improved characteristics of a human beta-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy. Houba PH, et al. **Bioconjug Chem** 1996 Sep-Oct;7(5):606–11

Recombinant soluble human complement receptor type 1 inhibits antisperm antibody- and neutrophil-mediated injury to human sperm. Cruz OJ, et al. **Biol Reprod** 1996 Jun;54(6):1217–28

How do antibodies and lectins recognize histo-blood group antigens? A 3D-QSAR study by comparative molecular field analysis (CoMFA). Imberty a, et al. **Bioorg Med Chem** 1996 Nov;4(11):1979–88

Repeated probing of western blots obtained from coomassie brilliant blue-stained or unstained polyacrylamide gels. Suck RW, et al. **Biotechniques** 1996 Sep;21(3):418–22

Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Ponce E, et al. **Blood** 1997 Jul 1;90(1):43–8

Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in haemophiliacs. Hanley JP, et al. **Br J Haematol** 1996 Sep; 94(3):551–6

The epitope specificity of heparin-induced thrombocytopenia. Horsewood P, et al. **Br J Haematol** 1996 Oct;95(1):161–7

Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Macchi L, et al. **Br J Haematol** 1997

Aug;98(2):336–41

Antibodies to macrophage inflammatory protein–1beta in preoptic area of rats fail to suppress PGE2 hyperthermia. Armengol JA, et al. **Brain Res** 1997 Feb 14;748(1–2):245–9

Intracellularly applied anti–P70 antibody blocks the induction of abnormal membrane properties by pentylenetetrazole in identified Euhadra neurons. Onozuka M, et al. **Brain Res** 1996 Apr 15;716(1–2):187–91

New therapeutic possibility of blocking cytokine–induced neutrophil chemoattractant on transient ischemic brain damage in rats. Yamasaki Y, et al. **Brain Res** 1997 Jun 6; 759(1):103–11

An anti–chi–1 antibody recognizes a heavily glycosylated protein in rat brain. Ciabarra AM, et al. **Brain Res Mol Brain Res** 1997 Jun;46(1–2):85–90

Serotonin transporter antibodies: production, characterization, and localization in the brain. Zhou FC, et al. **Brain Res Mol Brain Res** 1996 Dec 31;43(1–2):267–78

Characterization and potential uses of rabbit polyclonal antibodies against human plasma lecithin–cholesterol acyltransferase. Lima VL, et al. **Braz J Med Biol Res** 1996 Aug;29(8):957–68

Effect of adjuvants on the antibody response of mice to Bothrops asper (Terciopelo) snake venom. Rucavado A, et al. **Braz J Med Biol Res** 1996 Oct;29(10):1337–40

Improved immunohistochemical staining of osteopontin (OPN) in paraffin–embedded archival bone specimens following antigen retrieval: anti–human OPN antibody recognizes multiple molecular forms. Devoll RE, et al. **Calcif Tissue Int** 1997 Apr;60(4):380–6

Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis. Krolick KA, et al. **Cell Immunol** 1996 Aug 25;172(1):10–20

Artificial antibodies to corticosteroids prepared by molecular imprinting. Ramström O, et al. **Chem Biol** 1996 Jun; 3(6):471–7

Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns. Collen D, et al. **Circulation** 1997 Jan 21; 95(2):455–62

Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency. Collen D, et al. **Circulation** 1997 Jan 21;95(2):463–72

Monoclonal and polyclonal antibodies against casein components of cow milk for evaluation of residual antigenic activity in 'hypoallergenic' infant formulas. Plebani A, et al. **Clin Exp Allergy** 1997 Aug;27(8):949–56

Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN–alpha2 therapy. Antonelli G, et al. **Clin Exp Immunol** 1996 Jun; 104(3):384–7

Preferential binding with Escherichia coli hsp60 of antibodies prevalent in sera from patients with rheumatoid arthritis. Hirata D, et al. **Clin Immunol Immunopathol** 1997 Feb; 82(2):141–8

Immunological studies of rabbit antibodies against hemorrhagic fractions of Crotalus viridis viridis venom: role of crossreacting antibodies in neutralization. Li Q, et al. **Comp Biochem Physiol A Physiol** 1996 Jun;114(2):167–73

Inhibitory anti–peptide antibody against human CYP3A4. Wang RW, et al. **Drug Metab Dispos** 1997 Jun;25(6):762–7

Thyrotropin (TSH) receptor antibodies (TSHrAb) can inhibit TSH–mediated cyclic adenosine 3',5'– monophosphate production in thyroid cells by either blocking TSH binding or affecting a step subsequent to TSH binding. Dallas JS, et al. **Endocrinology** 1996 Aug;137(8):3329–39

Characterization of a peptide antibody against a C–terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. He Q, et al. **Eur J Cell Biol** 1996 Jun;70(2):117–24

Antibodies targeting the calcium sensing receptor: acquired hypoparathyroidism—an autoimmune disease at last? Hofbauer LC, et al. **Eur J Endocrinol** 1996 Aug; 135(2):172–3 (8 ref.)

Haemolytic disease of the newborn due to anti–K antibodies. de Jonge N, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jul;67(1):69–72

Elongation factor–2 kinase: immunological evidence for the existence of tissue–specific isoforms. Hait WN, et al. **FEBS Lett** 1996 Nov 11;397(1):55–60

Anti–peptide antibodies sensitive to the 'active' state of the beta2–adrenergic receptor. Mijares A, et al. **FEBS Lett** 1996 Dec 9;399(1–2):188–91

Natural human antibodies to dietary lectins. Tchernychev B, et al. **FEBS Lett** 1996 Nov 18;397(2–3):139–42

Antibodies to rat soluble IL–6 receptor stimulate B9 hybridoma cell proliferation. Thibault V, et al. **FEBS Lett** 1997 May 19;408(2):182–6

Trying to make heads or tails out of antisperm antibody data [letter; comment] Katsoff D, et al. **Fertil Steril** 1996 Mar; 65(3):675–7. Comment on: Fertil Steril 1995 Jun;63(6):1287–92.

A human antibody binds to alpha–galactose receptors and mimics the effects of Clostridium difficile toxin A in rat colon. Pothoulakis C, et al. **Gastroenterology** 1996 Jun; 110(6):1704–12

An antibody–lectin sandwich assay for the determination of CA125 antigen in ovarian cancer patients. Madiyalakan R, et al. **Glycoconj J** 1996 Aug;13(4):513–7

Natural human anti–Gal alpha(1,3)Gal antibodies react with human mucin peptides. Sandrin MS, et al. **Glycoconj J** 1997 Jan;14(1):97–105

Serum IgA, IgG, and IgM antibodies directed against acetaldehyde–derived epitopes: relationship to liver disease severity and alcohol consumption. Viitala K, et al. **Hepatology** 1997 Jun;25(6):1418–24

Ex vivo spleen and kidney absorption of xenoreactive natural antibodies decreases severity of hyperacute rejection in pig–to–dog renal xenotransplantation. Nitta K. **Hiroshima J Med Sci** 1996 Dec;45(4):119–25

Evidence for restricted diversity of antigen–specific human antibodies in immunized hu–PBL–SCID mice. Bazin R, et al. **Hum Antibodies Hybridomas** 1996;7(3):129–34

Cross reactive anti–tetanus and anti–melittin Fab fragments by phage display after tetanus toxoid immunisation. Vogel M, et al. **Hum Antibodies Hybridomas** 1996;7(1):11–20

Recognition of tissue– and subtype–specific modulation of angiotensin II receptors using antibodies against AT1 and AT2 receptors. Rakugi H, et al. **Hypertens Res** 1997 Mar; 20(1):51–5

Comparison of strategies for the construction of libraries of artificial antibodies. Iba Y, et al. **Immunol Cell Biol** 1997 Apr;75(2):217–21

Native DNA fragments photocrosslinked to psoralen binds to anti–B and anti–Z DNA antibodies. Arjumand S, et al. **Immunol Lett** 1995 Dec;48(3):215–9

Unusual discrimination against carrier protein antibodies during partial purification of hapten–protein polyclonal antibodies to plant stress hormones. Manju RV, et al. **Indian J Exp Biol** 1995 Jan;33(1):1–5

A placebo–controlled flow cytometric study of the effect of low–dose prednisolone treatment on sperm–bound antibody levels. Räs anen M, et al. **Int J Androl** 1996 Jun; 19(3):150–4

Nonneutralizing antibody against the glycoprotein K of herpes simplex virus type–1 exacerbates herpes simplex virus type–1–induced corneal scarring in various virus–mouse strain combinations. Ghiasi H, et al. **Invest Ophthalmol Vis Sci** 1997 May;38(6):1213–21

Plasma membrane Ca2+ pump in rat brain. Patterns of alternative splices seen by isoform–specific antibodies. Filoteo AG, et al. **J Biol Chem** 1997 Sep 19;272(38):23741–7

Increased ALZ–50 immunoreactivity in sudden infant death syndrome. Sparks DL, et al. **J Child Neurol** 1996 Mar; 11(2):101–7

Incidence of transient congenital hypothyroidism due to maternal thyrotropin receptor–blocking antibodies in over one million babies. Brown RS, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1147–51

Flow cytometric analyses of antibody binding to Chinese hamster ovary cells expressing human thyrotropin receptor. Patibandla SA, et al. **J Clin Endocrinol Metab** 1997 Jun; 82(6):1885–93

Generation and characterization of an IGFBP–7 antibody: identification of 31kD IGFBP–7 in human biological fluids and Hs578T human breast cancer conditioned media. Wilson EM, et al. **J Clin Endocrinol Metab** 1997 Apr; 82(4):1301–3

Changes in isotype composition and antigen recognition of anti–Trypanosoma cruzi antibodies from acute to chronic Chagas disease. Umezawa ES, et al. **J Clin Lab Anal** 1996; 10(6):407–13

Humoral (antibody–mediated) rejection in lung transplantation. Saint Martin GA, et al. **J Heart Lung Transplant** 1996 Dec;15(12):1217–22

QBEnd10 (CD34) antibody is unsuitable for routine use in the ISHAGE CD34+ cell determination assay [letter] Weinberg DS, et al. **J Hematother** 1996 Dec;5(6):599–603

Specificity of antibodies against rodent transforming growth factor–alpha protein. Aoyama H, et al. **J Histochem Cytochem** 1997 May;45(5):695–701

The recognition of human 60–kDa Ro ribonucleoprotein particles by antibodies associated with cutaneous lupus and neonatal lupus. Lee LA, et al. **J Invest Dermatol** 1996 Aug; 107(2):225–8

An antibody to p53 recognizes soluble keratins in epidermal keratinocyte cultures under differentiating, but not proliferating, conditions [letter] Weinberg WC, et al. **J Invest Dermatol** 1997 Oct;109(4):611–2

IgA antibodies in chronic bullous disease of childhood react with 97 kDa basement membrane zone protein. Zone JJ, et al. **J Invest Dermatol** 1996 Jun;106(6):1277–80

Preparation of specific polyclonal antibodies to a C–C chemokine receptor, CCR1, and determination of CCR1 expression on various types of leukocytes. Su SB, et al. **J Leukoc Biol** 1996 Nov;60(5):658–66

Characterization of a specific polyclonal antibody against 13–hydroperoxyoctadecadienoic acid–modified protein: formation of lipid hydroperoxide–modified apoB–100 in oxidized LDL. Kato Y, et al. **J Lipid Res** 1997 Jul; 38(7):1334–46

Antimidgut antibodies inhibit peritrophic membrane formation in the posterior midgut of Anopheles tessellatus (Diptera: Culicidae). Ramasamy MS, et al. **J Med Entomol** 1996 Jan;33(1):162–4

Determination of binding constants of diabodies directed against prostate–specific antigen using electrochemiluminescence–based immunoassays. Abraham R, et al. **J Mol Recognit** 1996 Sep–Dec;9(5–6):456–61

Corticotrophin–releasing hormone receptor type 1: generation and characterization of polyclonal antipeptide antibodies and their localization in pituitary cells and cortical neurones in vitro. Castro MG, et al. **J Neuroendocrinol** 1996 Jul;8(7):521–31

Affinity of anti–GM1 antibodies in Guillain–Barré syndrome patients. Deisenhammer F, et al. **J Neuroimmunol** 1996 May;66(1–2):85–93

Immunological characterization of a neuronal antibody (anti–Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. Graus F, et al. **J Neuroimmunol** 1997 Apr;74(1–2):55–61

Reactivity of serum IgG anti–GM1 ganglioside antibodies with the lipopolysaccharide fractions of Campylobacter jejuni isolates from patients with Guillain–Barre syndrome (GBS). Gregson NA, et al. **J Neuroimmunol** 1997 Mar; 73(1–2):28–36

A novel ganglioside, 9–O–acetyl GD1b, is recognized by serum antibodies in Guillain–Barré syndrome. Hitoshi S, et al. **J Neuroimmunol** 1996 May;66(1–2):95–101

Aggravation of murine experimental allergic encephalomyelitis by administration of T–cell receptor gammadelta–specific antibody. Kobayashi Y, et al. **J Neuroimmunol** 1997 Mar;73(1–2):169–74

Cholinergic neuron–specific ganglioside GQ1b alpha a possible target molecule for serum IgM antibodies in some patients with sensory ataxia. Tagawa Y, et al. **J Neuroimmunol** 1997 May;75(1–2):196–9

Induction of anti–GM1 ganglioside antibodies by Campylobacter jejuni lipopolysaccharides. Wirguin I, et al. **J Neuroimmunol** 1997 Sep;78(1–2):138–42

Chronic sensory ataxic neuropathy and ophthalmoplegia with oculomotor nerve hypertrophy associated with IgM antibodies against gangliosides containing disialosyl groups [letter] Umehara F, et al. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):673–4

Paraneoplastic encephalomyelitis: an update of the effects of the anti–Hu immune response on the nervous system and tumour [editorial] Voltz RD, et al. **J Neurol Neurosurg Psychiatry** 1997 Aug;63(2):133–6 (49 ref.)

Antibodies to a synthetic peptide that react with flavin–containing monooxygenase (HLFMO3) in human hepatic microsomes. Myers CR, et al. **J Pharmacol Toxicol Methods** 1997 Mar;37(2):61–6

Mapping of the antibody–binding regions on botulinum neurotoxin H–chain domain 855–1296 with antitoxin antibodies from three host species. Atassi MZ, et al. **J Protein Chem** 1996 Oct;15(7):691–700

Detection of epitopes on follicle–stimulating hormone and FSH–antiserum–induced suppression of bioactivity of follicle–stimulating hormone and luteinizing hormone. Westhoff WE, et al. **J Reprod Immunol** 1996 May; 30(2–3):133–49

beta 2–Glycoprotein–I is a cofactor for antibodies reacting with 5 anionic phospholipids [letter] Verrier Jones J, et al. **J Rheumatol** 1995 Oct;22(10):2009

Enzyme–linked immunosorbent assay for detection of feline serum amyloid A protein by use of immunological cross–reactivity of polyclonal anti–canine serum amyloid A protein antibody. Kajikawa T, et al. **J Vet Med Sci** 1996 Nov;58(11):1141–3

Antibody cross–reactivity with CD46 and lack of cell surface expression suggest that moesin might not mediate measles virus binding [published erratum appears in J Virol 1997 May;71(5):4186] Devaux P, et al. **J Virol** 1997 Feb; 71(2):1679–82

Screening for colorectal cancer by immunochemical fecal occult blood testing. Saito H. **Jpn J Cancer Res** 1996 Oct; 87(10):1011–24 (89 ref.)

Dexamethasone inhibition of acute opioid physical dependence in vitro is reverted by anti–lipocortin–1 and mimicked by anti–type II extracellular PLA2 antibodies. Capasso A, et al. **Life Sci** 1997;61(10):PL 127–34

Immunodominant Entamoeba histolytica antigens recognized by serum and intestinal antibodies after local or systemic immunization of mice with glutaraldehyde fixed trophozoites. Moreno–Fierros L, et al. **Life Sci** 1996; 59(16):1283–95

Uniformity of protective antigens among isolates of the cattle tick, Boophilus microplus. Knowles AG, et al. **Med Vet Entomol** 1996 Oct;10(4):301–4

Immunogenic proteins in the body and faecal material of the human body louse, Pediculus humanus, and their homology to antigens of other lice species. Mumcuoglu KY, et al. **Med Vet Entomol** 1996 Jan;10(1):105–7

Human lipoprotein lipase: production in vitro, purification, and generation of polyclonal antibody. Potenz R, et al. **Methods Enzymol** 1996;263:319–26

Antibodies that recognize nitrotyrosine. Ye YZ, et al. **Methods Enzymol** 1996;269:201–9 (11 ref.)

Epitope mapping by antibody competition. Methodology and Evaluation of the validity of the technique. Tzartos SJ. **Methods Mol Biol** 1996;66:55–66

Sequence and structure specific antibodies from phage display libraries. Tanha J, et al. **Mol Immunol** 1997 Feb; 34(2):109–13

Nobel laureates face libel suits from 'water memory' researcher [news] Butler D. **Nature** 1997 Oct 2; 389(6650):427

A possible role for the alpha 1—>3 galactosyl epitope and the natural anti–gal antibody in oncogenesis. Gollogly L, et al. **Neoplasma** 1996;43(5):285–9 (27 ref.)

Additional anti–HLA antibody detection by using PRASTAT [letter] Montagnac R, et al.

Nephrol Dial Transplant 1996 Nov;11(11):2376–7

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta–1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group [see comments] **Neurology** 1996 Oct;47(4):889–94. Comment in: Neurology 1996 Oct;47(4):865–6. Comment in: Neurology 1997 Aug;49(2):641–2.

Guidelines for physicians with patients on IFN beta–1b: the use of an assay for neutralizing antibodies (NAB) [comment] Paty DW, et al. **Neurology** 1996 Oct;47(4):865–6 . Comment on: Neurology 1996 Oct;47(4):889–94.

The sensitivity and specificity of anti–GM1 antibody testing. Taylor BV, et al. **Neurology** 1996 Oct;47(4):951–5

Antibodies to diethylcarbamazine potentiate the antifilarial activity of the drug. Mukhopadhyay S, et al. **Parasite Immunol** 1997 Apr;19(4):191–5

Subtractive isolation of phage–displayed single–chain antibodies to thymic stromal cells by using intact thymic fragments. Van Ewijk W, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3903–8

Expression of a recombinant kringle V of human apolipoprotein(a): antibody characterization and species specificity. Chenivesse X, et al. **Protein Expr Purif** 1996 Sep;8(2):145–50

Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. Cugno M, et al. **Thromb Haemost** 1996 Aug;76(2):234–8

Different anticoagulant and immunological properties of anti–prothrombin antibodies in patients with antiphospholipid antibodies. Galli M, et al. **Thromb Haemost** 1997 Mar;77(3):486–91

Induction of human factor VIII inhibitors in rats 2: Fine mapping of rat anti–human rFVIII antibodies. Levin LG, et al. **Thromb Haemost** 1996 Dec;76(6):998–1003

A case of a non–insulin dependent diabetic patient with regular spontaneous hypoglycemic attacks, which were due to insulin–binding antibodies induced by human insulin therapy. Suzuki K, et al. **Tohoku J Exp Med** 1997 Jun; 182(2):163–73

Can pooled red cells be used for antibody screening of patients' specimens? [editorial; comment] Phillips P, et al. **Transfus Med** 1996 Dec;6(4):307–9. Comment on: Transfus Med 1996 Dec;6(4):345–9.

The incidence of anti–Wra and Wra antigen in blood donors and hospital patients. Wallis JP, et al. **Transfus Med** 1996 Dec;6(4):361–4

Hyperacute renal allograft rejection from anti–HLA class 1 antibody to B cells—antibody detection by two color FCXM was possible only after using pronase–digested donor lymphocytes. Lobo PI, et al. **Transpl Int** 1997; 10(1):69–73

Posttransplant antibody response and chronic rejection. Paul LC, et al. **Transplant Proc** 1997 Sep;29(6):2529–30

Recipient–reactive antibodies occur during development of acute graft–versus–host reaction after small bowel transplantation. Johnsson C, et al. **Transplantation** 1996 Aug 15;62(3):343–6

Glycans derived from porcine stomach mucin are effective inhibitors of natural anti–alpha–galactosyl antibodies in vitro and after intravenous infusion in baboons. Li SF, et al. **Transplantation** 1996 Nov 15;62(9):1324–31

Antibody–mediated rejection of human renal allografts: an electron microscopic study of peritubular capillaries. Lajoie G. **Ultrastruct Pathol** 1997 May–Jun;21(3):235–42

The antibody–neutralisation of PDGF, CSF–1, TGFb2,3, EGF and EGF–receptor in utero in pre–implantation mice. Holmes PV, et al. **Ups J Med Sci** 1997;102(1):41–8

Human anti–factor VIII antibodies: epitope localization and inhibitory function. Scandella D. **Vox Sang** 1996;70 Suppl 1:9–14

Reactivation of recipient antibody to blood cell antigens soon after allogeneic bone marrow transplantation. Wernet D, et al. **Vox Sang** 1996;71(4):212–5

[Evaluation of sensitivity and specificity of antigliadin antibodies for the diagnosis of celiac disease in childhood] Bottaro G, et al. **Minerva Pediatr** 1995 Dec;47(12):505–10 (Eng. Abstr.) **(Ita)**

[Effects of neutralizing antibodies on cytokine treatment for anti–GBM nephritis in mouse] Hattori T, et al. **Nippon Jinzo Gakkai Shi** 1996 Dec;38(12):563–70 (Eng. Abstr.) **(Jpn)**

[Antigenic structure of the Pro–rich region 536–566 of Bordetella pertussis pertactin (P.69). II. Analysis of peptide–specific antibodies] Kavun EM, et al. **Biokhimiia** 1996 Aug;61(8):1366–74 (Eng. Abstr.) **(Rus)**

[Effect of specific antibodies on morphological characteristics of murine oocytes] Verbitskiĭ MSh, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):115–9 **(Rus)**

[Antibodies against alpha–2 and gamma–interferons affect the course of juvenile respiratory papillomatosis in children treated with alpha–2 interferon preparations] Kol'tsov VD, et al. **Vestn Otorinolaringol** 1997;(4):13–5 (Eng. Abstr.) **(Rus)**

[Antiganglioside antibodies in neuropathies and motor neuronopathies] Gallardo E, et al. **Neurologia** 1996 Dec;11 Suppl 5:75–80 (44 ref.) (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

A simple solid–phase method for the identification of red cell–bound antibodies without elution. Nagamine K, et al. **Am J Clin Pathol** 1996 Sep;106(3):365–9

A method for isolation and purification of specific antibodies to a protein fused to the GST. Bar–Peled M, et al. **Anal Biochem** 1996 Oct 1;241(1):140–2

Preparation of biotinylated, affinity–purified antibodies for enzyme–linked immunoassays using blotting membrane as an antigen support [published erratum appears in Anal Biochem 1997 Mar 15;246(2):271] Rucklidge GJ, et al. **Anal Biochem** 1996 Dec 1;243(1):158–64

A new method for isolation of human antisperm antibodies. Shohat M, et al. **Andrologia** 1996 Sep–Oct;28(5):275–9

A novel method for purification of catalytic antibodies toward DNA from sera of patients with lymphoproliferative diseases. Kozyr AV. **Biochem Mol Biol Int** 1996 May;39(2):403–13

Multichannel flow electrophoresis and its applications in purification of proteins, enzymes, and antibodies. Liu Z, et al. **Chin J Biotechnol** 1996;12(4):241–8

Hen egg yolk antibodies purified by antigen affinity under highly alkaline conditions provide new tools for diagnostics. Human intact parathyrin as a model antigen. Kuronen I, et al. **Eur J Clin Chem Clin Biochem** 1997 Jun; 35(6):435–40

Affinity chromatography of human anti–dextran antibodies. Isolation of two distinct populations. Anastase S, et al. **J Chromatogr B Biomed Appl** 1996 Nov 15;686(2):141–50

Purification of anti–chymotrypsin antibodies for the preparation of a bioaffinity matrix with oriented chymotrypsin as immobilized ligand. Bílková Z, et al. **J Chromatogr B Biomed Appl** 1997 Feb 7;689(1):273–9

In vitro study on the removal of pemphigus antibody with immunoadsorption. Yamada H, et al. **J Clin Apheresis** 1996; 11(1):14–5

Protein A mimetic peptide ligand for affinity purification of antibodies. Fassina G, et al. **J Mol Recognit** 1996 Sep–Dec; 9(5–6):564–9

Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus [see comments] Bortolotti F, et al. **J Pediatr** 1997 Jun; 130(6):990–3. Comment in: J Pediatr 1997 Jun;130(6):859–61.

Antenatal screening of thyroid antibodies [see comments] Ball S. **Lancet** 1996 Oct 5;348(9032):906–7. Comment in: Lancet 1996 Nov 30;348(9040):1516–7.

Development of specific anti–thymosin beta 10 antipeptide antibodies for application in immunochemical techniques. Leondiadis L, et al. **Peptides** 1996;17(7):1091–6

Pig to monkey bone marrow and kidney xenotransplantation. Sablinski T, et al. **Surgery** 1997 Apr;121(4):381–91

Removing IgG antibodies from intact red cells: comparison of acid and EDTA, heat, and chloroquine elution methods. Burin des Roziers N, et al. **Transfusion** 1997 May; 37(5):497–501

Anticipation of highly sensitised renal patients' immunoadsorption requirements by prescreening using protein A minicolumns. Bevan DJ, et al. **Transpl Int** 1996; 9 Suppl 1:S20–4

Apheresis and column absorption for specific removal of Gal–alpha–1,3 Gal natural antibodies in a pig–to–baboon model. Kozlowski T, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):961

METABOLISM

Anti–seminal plasma antibodies associated with infertility: II. Comparative investigation of human antibody binding to normo–, astheno–, and azoospermic seminal plasma antigens. Fichorova R, et al. **Am J Reprod Immunol** 1996 Oct;36(4):204–10

Does in vitro fertilization (IVF) influence the levels of sperm and zona pellucida (ZP) antibodies in infertile women? Ulčová–Gallová Z, et al. **Am J Reprod Immunol** 1996 Oct; 36(4):216–9

Internalization and catabolism of radiolabelled antibodies to the MHC class–II invariant chain by B–cell lymphomas. Hansen HJ, et al. **Biochem J** 1996 Nov 15;320 (Pt 1):293–300

Heat–treated myosin does not bind ATPase—inhibiting antibodies. Grőschel–Stewart U, et al. **Biochem Mol Biol Int** 1997 Jul;42(3):611–9

Are polyclonal catalytic antibodies heterogeneous? Carter S, et al. **Biochem Soc Trans** 1997 Feb;25(1):86S

Energetic and kinetic contributions of contact residues of antibody D1.3 in the interaction with lysozyme. England P, et al. **Biochemistry** 1997 Jan 7;36(1):164–72

3–(2–pyridyldithio)propionic acid hydrazide as a cross–linker in the formation of liposome–antibody conjugates. Ansell SM, et al. **Bioconjug Chem** 1996 Jul–Aug;7(4):490–6

Influence of coupling method on the luminescence properties, coupling efficiency, and binding affinity of antibodies labeled with europium (III) chelates. Karşılayan H, et al. **Bioconjug Chem** 1997 Jan–Feb;8(1):71–5

The culture fluid of Isaira japonica yasuda augments anti–sheep red blood cell antibody response in mice. Takano F, et al. **Biol Pharm Bull** 1996 Apr;19(4):641–3

Influence of diffusion to fractal surfaces on the binding kinetics for antibody–antigen, analyte–receptor, and analyte–receptorless (protein) systems. Sadana A, et al. **Biophys Chem** 1997 Mar 27;65(1):29–44

Immunochemical analysis of the Kx protein from human red cells of different Kell phenotypes using antibodies raised against synthetic peptides. Carbonnet F, et al. **Br J Haematol** 1997 Mar;96(4):857–63

Anti–endothelial cell antibodies to the endothelial hybridoma cell line (EAhy926) in systemic lupus erythematosus patients with antiphospholipid antibodies. Matsuda J, et al. **Br J Haematol** 1997 Apr;97(1):227–32

Tumor cell targeting with antibody–avidin complexes and biotinylated tumor necrosis factor alpha. Moro M, et al. **Cancer Res** 1997 May 15;57(10):1922–8

Establishment and characterization of a human B cell line producing IgG type antibodies to DNA [letter] Maeda Y, et al. **Clin Rheumatol** 1997 Jun;16(4):430–1

The state of antibody catalysis. Smithrud DB, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):459–66 (46 ref.)

Detection of novel molecules recognized by anti–placental lactogen antibody in rat amniotic fluid. Imai A, et al. **Endocr J** 1997 Apr;44(2):265–74

Enzymes and antibodies in organic media: analytical applications. Stöcklein WF, et al. **EXS** 1997;80:83–96

Gal alpha 4Gal–binding antibodies: specificity and use for the mapping of glycolipids of Burkitt lymphoma and other human tumors. Lanne B, et al. **Glycobiology** 1996 Jun; 6(4):423–31

In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Noël D, et al. **Hum Gene Ther** 1997 Jul 1;8(10):1219–29

Effect of hemoglobin and immunization status on energy metabolism of weanling pigs. Gentry JL, et al. **J Anim Sci** 1997 Apr;75(4):1032–40

Immune response and growth of stressed weanling pigs fed diets supplemented with organic or inorganic forms of chromium. van Heugten EV, et al. **J Anim Sci** 1997 Feb; 75(2):409–16

Determination of dissociation constant and concentration of an anti–DNA antibody by using the light–addressable potentiometric sensor. Dill K, et al. **J Biochem Biophys Methods** 1996 Jan 11;31(1–2):17–21

Bound Tris confounds the identification of binding site residues in a paraquat single chain antibody. Bowles MR, et al. **J Biochem (Tokyo)** 1997 Jul;122(1):101–8

Immunization of male rabbits with sheep luteal receptor to LH results in production of antibodies exhibiting hormone–agonistic and –antagonistic activities. Jeyakumar M, et al. **J Endocrinol** 1996 Sep;150(3):431–43

The quantitation of coupled bead antibody by enzyme–linked immunosorbent assay. Derango R, et al. **J Immunoassay** 1996 May;17(2):145–53

Interaction of anti–cholesterol antibodies with human lipoproteins. Dijkstra J, et al. **J Immunol** 1996 Sep 1; 157(5):2006–13

Antibody penetration into the cells of mice and men [editorial; comment] McCauliffe DP. **J Invest Dermatol** 1996 Jul;107(1):3–4. Comment on: J Invest Dermatol 1996 Jul;107(1):95–100.

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. Atwell S, et al. **J Mol Biol** 1997 Jul 4;270(1):26–35

Paraneoplastic opsomyoclonus, cerebellar ataxia and encephalopathy associated with anti–Purkinje cell antibodies [letter] Honnorat J, et al. **J Neurol** 1997 May; 244(5):333–5

Comparison of the properties of concanavalin A and anti–alpha–D–glucose antibodies. Pazur JH, et al. **J Protein Chem** 1996 May;15(4):329–35

Passage of chicken egg yolk antibody treated with hydroxypropyl methylcellulose phthalate in the gastrointestinal tract of calves. Ikemori Y, et al. **J Vet Med Sci** 1996 Apr;58(4):365–7

CD40 and the effect of anti–CD40–binding on human multiple myeloma clonogenicity. Tong AW, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):1–8 (83 ref.)

Antibodies live long and prosper [news] Riechmann L, et al. **Nat Biotechnol** 1997 Jul;15(7):617

Influence of isoelectric point on glomerular deposition of antibodies and immune complexes. Woitas RP, et al. **Nephron** 1996;74(4):713–9

Immunoresponsiveness in chickens: association of antibody production and the B system of the major histocompatibility complex. Dunnington EA, et al. **Poult Sci** 1996 Oct;75(10):1156–60

Group selection for adaptation to multiple–hen cages: humoral immune response. Hester PY, et al. **Poult Sci** 1996 Nov;75(11):1315–20

Patterning of functional antibodies and other proteins by photolithography of silane monolayers. Mooney JF, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12287–91

'Knobs–into–holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Ridgway JB, et al. **Protein Eng** 1996 Jul;9(7):617–21

Studies on the uptake mechanisms of 99mTc–labeled antibodies by liver tissue. Xue LY, et al. **Q J Nucl Med** 1996 Jun;40(2):176–81

Receptor imaging: competitive or complementary to antibody imaging? Goldsmith SJ. **Semin Nucl Med** 1997 Apr;27(2):85–93 (20 ref.)

Cross–reactivities of polyclonal antibodies against lebetase, fibrinolytic enzyme of Levantine viper (Vipera lebetina) venom. Siigur J, et al. **Toxicon** 1996 May;34(5):608–13 (17 ref.)

In vivo immunoadsorption of antipig antibodies in baboons using a specific Gal(alpha)1–3Gal column. Taniguchi S, et al. **Transplantation** 1996 Nov 27;62(10):1379–84

[Equilibrium and kinetic parameters of interaction between peroxidase conjugates of strophanthin and anti–peroxidase

antibodies] Tarun EI, et al. **Prikl Biokhim Mikrobiol** 1997 Mar-Apr;33(2):172-9 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Regulation of expression of taurine transport in two continuous renal epithelial cell lines and inhibition of taurine transporter by a site-directed antibody. Han X, et al. **Adv Exp Med Biol** 1996;403:173-91

An antibody to leukocyte integrins attenuates coronary vascular injury due to ischemia and reperfusion in dogs. Horwitz LD, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H618-24

Effect of antibodies to staphylococcal alpha and beta toxins and Staphylococcus aureus on the cytotoxicity for and adherence of the organism to bovine mammary epithelial cells. Cifrian E, et al. **Am J Vet Res** 1996 Sep;57(9):1308-11

Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Liaw L, et al.
Arterioscler Thromb Vasc Biol 1997 Jan;17(1):188-93

Specific inhibition of human CYP1A2 using a targeted antibody. Adams DA, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):189-97

Characterization of anti-peptide antibodies directed towards the automodification domain and apoptotic fragment of poly (ADP-ribose) polymerase. Duriez PJ, et al.
Biochim Biophys Acta 1997 Feb 11;1334(1):65-72

Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. Szebeni J, et al.
Biochim Biophys Acta 1996 Dec 4;1285(2):127-30

Delay of radiation-induced decline and recovery of hematopoiesis following treatment with anti-HLA-DR antibody. Deeg HJ, et al.
Biol Blood Marrow Transplant 1996 May;2(2):105-11

Induction of apoptosis in equine chorionic gonadotropin (eCG)-primed rat ovaries by anti-eCG antibody. Boone DL, et al. **Biol Reprod** 1997 Aug;57(2):420-7

Agonistic effects of anti-peptide antibodies and autoantibodies directed against adrenergic and cholinergic receptors: absence of desensitization. Wallukat G, et al. **Blood Press Suppl** 1996;3:31-6

Effects of anti-peptide antibodies against human M2 muscarinic receptors on cardiac function in rats in vivo. Wang WZ, et al. **Blood Press Suppl** 1996;3:25-7

Effects of anti-peptide antibodies against human M2 muscarinic receptors on the cAMP generating system in guinea pig ventricles. Wang WZ, et al.
Blood Press Suppl 1996;3:22-4

Antibodies to macrophage inflammatory protein-1beta in preoptic area of rats fail to suppress PGE2 hyperthermia. Armengol JA, et al. **Brain Res** 1997 Feb 14;748(1-2):245-9

Antibodies to tumor necrosis factor alpha prevent increases in cell replication in liver due to the potent peroxisome proliferator, WY-14,643. Bojes HK, et al.
Carcinogenesis 1997 Apr;18(4):669-74

Introducing specific antibodies into electropermeabilized cells is a valuable tool for eliminating specific cell functions. Verspohl EJ, et al. **Cell Biochem Funct** 1997 Jun; 15(2):127-34

Inhibition of in vitro limb cartilage differentiation by syndecan-3 antibodies. Seghatoleslami MR, et al.
Dev Dyn 1996 Sep;207(1):114-9

Autocrine role of insulin-like growth factor II secretion by the rat choroid plexus. Nilsson C, et al. **Eur J Neurosci** 1996 Mar;8(3):629-35

Galanin inhibits ACTH release in vitro and can be demonstrated immunocytochemically in dispersed corticotrophs. Cimini V. **Exp Cell Res** 1996 Nov 1; 228(2):212-5

Activation of the p21-activated protein kinases from neutrophils with an antibody that reacts with the N-terminal region of Pak 1. Lian JP, et al. **FEBS Lett** 1997 Mar 10;404(2-3):211-5

Ob gene product (leptin) and antileptin antibodies [letter] Berstein LM. **Horm Metab Res** 1996 Aug;28(8):402

Diversity of the blocking effects of antisperm antibodies on fertilization in human and mouse. Shibahara H, et al.
Hum Reprod 1996 Dec;11(12):2595-9

Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines. Fellenberg J, et al.
Int J Cancer 1997 Jul 29;72(3):536-42

Decreased spermatogenesis as the result of an induced autoimmune reaction directed against the gonadotropin receptors in male rats. Graf KM, et al. **J Androl** 1997 Mar-Apr;18(2):174-85

Identification of amino acids in the glutamate receptor, GluR3, important for antibody-binding and receptor-specific activation. Carlson NG, et al.
J Biol Chem 1997 Apr 25;272(17):11295-301

Antibodies to interferon in patients undergoing IFN therapy: an update. Antonelli G. **J Biol Regul Homeost Agents** 1995 Oct-Dec;9(4):123-31 (84 ref.)

Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. Lane HA, et al. **J Cell Biol** 1996 Dec; 135(6 Pt 2):1701-13

The inhibition of vascular smooth muscle cell migration by peptide and antibody antagonists of the alphavbeta3 integrin complex is reversed by activated calcium/calmodulin- dependent protein kinase II. Bilato C, et al. **J Clin Invest** 1997 Aug 1;100(3):693-704

Albumin nitrosylated by activated macrophages possesses antiparasitic effects neutralized by anti-NO-acetylated-cysteine antibodies. Mnaimneh S, et al. **J Immunol** 1997 Jan 1;158(1):308-14

Effect of antipeptide antibodies directed against three domains of connexin43 on the gap junctional permeability of cultured heart cells. Bastide B, et al. **J Membr Biol** 1996 Apr;150(3):243-53

Effect of POMC(1-76), its C-terminal fragment gamma3-MSH and anti-POMC(1-76) antibodies on DNA replication in lactotrophs in aggregate cell cultures of immature rat pituitary. Tilemans D, et al.
J Neuroendocrinol 1997 Aug;9(8):627-37

Aggravation of murine experimental allergic encephalomyelitis by administration of T-cell receptor gammadelta-specific antibody. Kobayashi Y, et al.
J Neuroimmunol 1997 Mar;73(1-2):169-74

Angiogenic and inflammatory responses following skeletal muscle injury are altered by immune neutralization of endogenous basic fibroblast growth factor, insulin-like growth factor-1 and transforming growth factor-beta 1. Lefaucheur JP, et al. **J Neuroimmunol** 1996 Oct;70(1):37-44

Apoptosis of human glioma cells in vitro and in vivo induced by a neutralizing antibody against human basic fibroblast growth factor. Murai N, et al. **J Neurosurg** 1996 Dec; 85(6):1072-7

Nerve growth factor antibody stimulates reactivation of ocular herpes simplex virus type 1 in latently infected rabbits. Hill JM, et al. **J Neurovirol** 1997 Jun;3(3):206-11

Comparison of the pulmonary distribution and efficacy of antibodies given to mice by intratracheal instillation or aerosol inhalation. Vogel P, et al. **Lab Anim Sci** 1996 Oct; 46(5):516-23

Xenoreactive natural antibodies and induced antibodies--their effects of beating cardiomyocytes as a model of a xenograft. Müller-Werdan U, et al.
Mol Cell Biochem 1996 Jul-Aug;160-161:315-23

Effects of anti-peptide antibodies against the second extracellular loop of human M2 muscarinic acetylcholine receptors on transmembrane potentials and currents in guinea pig ventricular myocytes. Zhao R, et al.
Mol Cell Biochem 1996 Oct-Nov;163-164:185-93

Anti-CD38 prevents the development of the adaptive response induced by X-rays in human lymphocytes. Wojewódzka M, et al. **Mutagenesis** 1996 Nov;11(6):593-6

Monoclonal gammopathy associated with crescentic glomerulonephritis and antimyeloperoxidase antibodies. Martin JC, et al. **Nephron** 1996;72(1):79-81

Antibody against synthetic rat PTH peptide (1-34) blocks PTH-mediated cAMP formation and phosphate transport in opossum kidney cells. Zhang Z, et al. **Nephron** 1997; 75(2):245-8

Antibody to day-old chick brain glycoprotein produces amnesia in adult rats. Alexinsky T, et al.
Neurobiol Learn Mem 1997 Jan;67(1):14-20

Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Reiter Y, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4631-6

Efficacy of anti-tumor necrosis factor polyclonal antibody on phosphoenolpyruvate carboxykinase expression in septic and endotoxemic rats. Chang CK, et al. **Shock** 1996 Jul; 6(1):57-60

Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Marches R, et al. **Ther Immunol** 1995 Jun;2(3):125-36

Aerosolized specific antibody protects mice from lung injury associated with aerosolized ricin exposure. Poli MA, et al.
Toxicon 1996 Sep;34(9):1037-44

Opposing effects of cyclosporin A and anti-interferon-gamma antibodies on immune tolerance mechanisms. Kuschnaroff L, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1156-7

In vitro system for evaluation of the immunomodulatory capacity of CD45(R) reagents. Poppema S, et al.
Transplant Proc 1996 Dec;28(6):3263-4

Interleukin-13, in combination with anti-interleukin-12, increases graft prolongation after portal venous immunization with cultured allogeneic bone marrow-derived dendritic cells. Gorczynski RM, et al.
Transplantation 1996 Dec 15;62(11):1592-600

Removal of xenoreactive human anti-pig antibodies by absorption on recombinant mucin-containing glycoproteins carrying the Gal alpha1,3Gal epitope. Liu J, et al.
Transplantation 1997 Jun 15;63(11):1673-82

Prolongation of murine vascularized heart allograft survival by recipient-specific anti-major histocompatibility complex class II antibody. Smith RM, et al. **Transplantation** 1997 Aug 15;64(3):525-8

Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig. Yin DP, et al. **Transplantation** 1996 Dec 15; 62(11):1537-9

Microinjection of anti-alpha-tubulin antibody (DM1A) inhibits progesterone-induced meiotic maturation and deranges the microtubule array in follicle-enclosed oocytes of the frog, Rana pipiens. Lessman CA, et al. **Zygote** 1997 Feb;5(1):83-95

[The effect of the blockade of the serotonin-modulating protein SMP-69 by antibodies on rat exploratory behavior] Mekhtiev AA, et al.
Zh Vyssh Nerv Deiat Im I P Pavlova 1996 Mar-Apr; 46(2):386-8 **(Rus)**

[The effect of dopamine and noradrenaline antibodies on pain sensitivity in animals] Trekova NA, et al.
Zh Vyssh Nerv Deiat Im I P Pavlova 1996 May-Jun; 46(3):604-6 **(Rus)**

PHYSIOLOGY

Hypothyroidism due to thyrotropin-receptor blocking antibodies associated with sarcoidosis [letter] Heshmati HM, et al. **Ann Med Interne (Paris)** 1997;148(1):102-3

Antibodies to proteinase-3 mediate expression of intercellular adhesion molecule-1 (ICAM-1, CD 54). De Bandt M, et al. **Br J Rheumatol** 1997 Aug;36(8):839-46

Ligand function of antigenized antibodies expressing the RGD motif. Billetta R, et al. **Chem Immunol** 1997;65:159-78 (53 ref.)

The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. Vuist WM, et al.
J Clin Immunol 1997 Jul;17(4):301-10

Self assertion modeled as a network repertoire of multi-determinant antibodies. Takumi K, et al.
J Theor Biol 1996 Nov 7;183(1):55-66

Hyperacute lung rejection in a pig-to-human transplant model: the role of anti-pig antibody and complement. Pierson RN 3rd, et al. **Transplantation** 1997 Feb 27; 63(4):594-603

THERAPEUTIC USE

Modulation of anti-allergen immune responses by allergen-antibody complexes. Saint-Remy JM.
Adv Exp Med Biol 1996;409:417-24 (24 ref.)

A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo. Shimizu M, et al.
Biochem Biophys Res Commun 1996 Nov 12;228(2):375-9

Engineering antibodies for imaging and therapy. Carter P, et al. **Curr Opin Biotechnol** 1997 Aug;8(4):449-54 (54 ref.)

Myasthenia gravis. Somnier FE. **Dan Med Bull** 1996 Feb; 43(1):1-10 (126 ref.)

Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with antirat interferon-gamma antibody. Nicoletti F, et al.
Endocrinology 1997 Jan;138(1):281-8

Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. Ke-Lin, et al. **Eur J Cancer** 1996 Dec;32A(14):2467-73

Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). Wada T, et al. **FASEB J** 1996 Oct; 10(12):1418-25

A controlled trial of anti-tumor necrosis factor alpha antibody for Crohn's disease. Sandborn WJ.
Gastroenterology 1997 Sep;113(3):1042-3

Acceleration of wound healing in gastric ulcers by local injection of neutralising antibody to transforming growth factor beta 1. Ernst H, et al. **Gut** 1996 Aug;39(2):172-5

Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Galili U, et al.
Immunol Today 1997 Jun;18(6):281-5 (58 ref.)

In vivo alterations in cytokine production following interleukin-12 (IL-12) and anti-IL-4 antibody treatment of CB6F1 mice with chronic cutaneous leishmaniasis. Li J, et al. **Infect Immun** 1996 Dec;64(12):5248-54

Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Sartani G, et al.
Invest Ophthalmol Vis Sci 1996 Oct;37(11):2211-8

Researchers identify tooth decay antibody [news]
J Can Dent Assoc 1997 May;63(5):332

Antibodies against CD14 protect primates from endotoxin-induced shock. Leturcq DJ, et al.
J Clin Invest 1996 Oct 1;98(7):1533-8

Applications of molecular biology and biotechnology: antibody therapy of sepsis. Wheeler AP, et al.
J Crit Care 1996 Jun;11(2):77-94 (102 ref.)

Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases. Krause RM, et al.
J Infect Dis 1997 Sep;176(3):549-59 (72 ref.)

Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action. Feldmann M, et al. **J Inflamm** 1995-96;47(1-2):90-6 (32 ref.)

Dosage and timing of anti-TNF-alpha antibody treatment determine its effect of resistance to sepsis after injury. O'Riordain MG, et al. **J Surg Res** 1996 Jul 15;64(1):95-101

Inhibition of human immunodeficiency virus type 1 production in infected peripheral blood mononuclear cells by human leukocyte antigen class I-specific antibodies: evidence for a novel antiviral mechanism. Briant L, et al.
J Virol 1996 Aug;70(8):5213-20

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease [see comments] Stack WA, et al. **Lancet** 1997 Feb 22;349(9051):521-4. Comment in: Lancet 1997 May 3;349(9061):1328.

Antibodies live long and prosper [news] Riechmann L, et al. **Nat Biotechnol** 1997 Jul;15(7):617

Antibodies as pharmacokinetic and metabolic modifiers of neurotoxicity. Owens SM. **NIDA Res Monogr** 1997;

173:259–72 (34 ref.)
Parasitemia and parasitic loads in acute infection and after anti–gamma–interferon treatment in a toxoplasmic mouse model. Miédougé M, et al. **Parasitol Res** 1997;83(4):339–44
Quality assurance after process changes of the production of a therapeutic antibody. Brass JM, et al.
Pharm Acta Helv 1996 Dec;71(6):395–403
Differential effectiveness of anti–CD8 treatment on ongoing graft–versus–host reactions in mice. Noort WA, et al.
Transpl Immunol 1996 Sep;4(3):198–202
An investigation of "tolerance" induction following islet allotransplantation in the mouse. Asakura T, et al.
Transplant Proc 1997 Feb–Mar;29(1–2):1152
Effect of anti CD45 on different immunosuppressive regimes in renal transplantation. Talbot D, et al.
Transplant Proc 1996 Dec;28(6):3212–3
Anti–VLA–4 and cyclosporine synergistically prolong rat heterotopic small bowel allografts. Tice DG, et al.
Transplant Proc 1996 Oct;28(5):2496
Usage of antibacterial and antiparasitic drugs in animals in Sweden between 1988 and 1993 [published erratum appears in Vet Rec 1996 Oct 5;139(14):350] Björnerot L, et al.
Vet Rec 1996 Sep 21;139(12):282–6
[Clinical application of interleukin–6 receptor antibody] Nishimoto N, et al.
Nihon Rinsho Meneki Gakkai Kaishi 1997 Apr;20(2):87–94 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Chemokines and anti–chemokine therapy in kidney diseases] Yokoyama H. **Nippon Naika Gakkai Zasshi** 1997 Apr 10; 86(4):689–94 (10 ref.) **(Jpn)**
[Steroid therapy and immunotherapy of patients with collagen diseases] Yoshizaki K, et al.
Nippon Naika Gakkai Zasshi 1996 Nov 10;85(11):1895–901 (5 ref.) **(Jpn)**
[Effect of humanized anti–interleukin–6 receptor antibody on new xenograft model of multiple myeloma] Shimazaki C, et al. **Rinsho Ketsueki** 1997 Apr;38(4):281–4 **(Jpn)**
[Suppression of experimental autoimmune encephalomyelitis with antibodies against adhesion molecules] Kawai K, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1504 (4 ref.) **(Jpn)**
[Immunotherapy of experimental drug addiction with antibodies to serotonin and dopamine] Evseev VA, et al.
Biull Eksp Biol Med 1996 Aug;122(8):189–92 **(Rus)**
[New therapeutic methods against rheumatoid arthritisp6. Antibodies against TNFalpha significant for the progress] Bondeson J. **Lakartidningen** 1997 Jan 8;94(1–2):42–5 (30 ref.) (Eng. Abstr.) **(Swe)**

TOXICITY

Pharmacokinetics of teratogenic antibodies administered to rats. Fawcett LB, et al. **Teratology** 1995 Nov;52(5):260–6

ULTRASTRUCTURE

Antibody–antigen interactions: contact analysis and binding site topography. MacCallum RM, et al. **J Mol Biol** 1996 Oct 11;262(5):732–45

URINE

Development of a screening method for anti–6 beta–hydroxycortisol antibody using an enzyme–linked immunosorbent assay (ELISA) and its applications. Yeung JH, et al. **Methods Find Exp Clin Pharmacol** 1997 Mar; 19(2):79–86

ANTIBODIES, ALLOTYPIC see **IMMUNOGLOBULIN ALLOTYPES**

ANTIBODIES, ANTICARDIOLIPIN

Mondor's disease as first thrombotic event in hereditary protein C deficiency and anticardiolipin antibodies. Wester JP, et al. **Neth J Med** 1997 Feb;50(2):85–7

ADVERSE EFFECTS

Lipoprotein(a) and anticardiolipin antibodies as risk factors for thrombotic events in polymyalgia rheumatica and giant cell arteritis [letter] Seriolo B, et al. **J Rheumatol** 1996 Aug; 23(8):1478–80

ANALYSIS

Anticardiolipin antibodies and acute myocardial infarction in non–systemic lupus erythmatosus patients: a controlled prospective study. Zuckerman E, et al. **Am J Med** 1996 Oct;101(4):381–6
Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis. Seriolo B, et al.
Clin Exp Rheumatol 1996 Nov–Dec;14(6):593–9
Clinical features associated with a positive anticardiolipin antibody in Irish patients with systemic lupus erythematosus. Gourley IS, et al. **Clin Rheumatol** 1996 Sep; 15(5):457–60
Anticardiolipin antibodies are not associated with restenosis or endothelial activation after percutaneous transluminal angioplasty. Tsakiris DA, et al. **Int Angiol** 1997 Jun; 16(2):88–93
Anticardiolipin antibodies in Crohn's disease associated with diabetes mellitus. Kanda A, et al. **Intern Med** 1996 Nov; 35(11):866–70
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Grossman D, et al.
J Am Acad Dermatol 1997 Sep;37(3 Pt 1):409–13
HCV hepatitis associated with anticardiolipin antibody and a cerebrovascular accident. Response to interferon therapy. Malnick SD, et al. **J Clin Gastroenterol** 1997 Jan;24(1):40–2
Studies on the interaction of placental anticoagulant protein I, beta 2 glycoprotein 1, and antiphospholipid antibodies in the prothrombinase reaction and in the solid phase anticardiolipin assays. Pierangeli SS, et al.
J Lab Clin Med 1996 Aug;128(2):194–201
Prevalence and clinical significance of IgG isotype anti–beta 2–glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. Sanmarco M, et al. **J Lab Clin Med** 1997 May; 129(5):499–506
Anticardiolipin antibodies: do they reflect the severity of systemic lupus erythematosus? Piamphongsant T, et al.
J Med Assoc Thai 1996 Jun;79(6):370–3
Anticardiolipin antibodies in ischemic stroke in the young: Indian experience. Nagaraja D, et al. **J Neurol Sci** 1997 Sep 10;150(2):137–42
Placental pathologic conditions in anticardiolipin antibody positive women whose infants had congenital heart defects. Kowal–Vern A, et al. **J Perinatol** 1996 Jul–Aug; 16(4):268–71
Analytical and clinical relationships between human IgG autoantibodies to beta 2 glycoprotein I and anticardiolipin antibodies. El–Kadi HS, et al. **J Rheumatol** 1995 Dec; 22(12):2233–7
Antiphospholipid antibodies among anti–U1–70 kDa autoantibody positive patients with mixed connective tissue disease. Komatireddy GR, et al. **J Rheumatol** 1997 Feb; 24(2):319–22
Anticardiolipin antibody associated with renal carcinoma [letter; comment] Malnick SD, et al. **J Rheumatol** 1995 Oct; 22(10):2007–8. Comment on: J Rheumatol 1994 Nov;21(11):2162–3.
Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. Molina JF, et al. **J Rheumatol** 1997 Feb; 24(2):291–6
Anticardiolipin antibodies and the risk of recurrent thrombo–occlusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS). **Neurology** 1997 Jan;48(1):91–4
Anticardiolipin antibodies and retinal vascular complications in Behçet's disease. Ozdemir Y, et al.
Ophthalmic Surg Lasers 1997 Aug;28(8):653–6
Congenital rubella reinfection in a mother with anti–cardiolipin and anti–platelet antibodies. Barfield W, et al. **Pediatr Infect Dis J** 1997 Feb;16(2):249–51
Nodular regenerative hyperplasia of the liver in systemic lupus erythematosus. The relationship with anticardiolipin antibody and lupus anticoagulant. Sekiya M, et al.
Scand J Rheumatol 1997;26(3):215–7 (13 ref.)
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis [see comments] Deschiens MA, et al. **Stroke** 1996 Oct; 27(10):1724–30. Comment in: Stroke 1996 Oct;27(10):1719–20.
IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo–occlusive events and death. A prospective cohort study. Levine SR, et al. **Stroke** 1997 Sep;28(9):1660–5
The effect of different microtitre plates on the enzyme–linked immunosorbent assay (ELISA) for anticardiolipin antibodies (ACAs) [published erratum appears in Thromb Res 1996 Dec 15;84(6):481] Hughes JR, et al.
Thromb Res 1996 Nov 1;84(3):217–22
[Cerebral apoplexy—anticardiolipin antibody and factor V Leiden mutation] Kirkeby R, et al. **Ugeskr Laeger** 1997 Apr 7;159(15):2233–5 (Eng. Abstr.) **(Dan)**
[Value of the search for anticardiolipin antibodies during the course of systemic lupus erythematosus] Gorgi Y, et al.
Ann Med Interne (Paris) 1996;147(8):531–5 (Eng. Abstr.) **(Fre)**
[Serum cardiolipin antibodies in patients with alcoholic cirrhosis] Gervais A, et al. **Gastroenterol Clin Biol** 1996; 20(10):736–42 (Eng. Abstr.) **(Fre)**
[Hepatic granulomatosis associated with a circulating anticoagulant, disclosing Q fever (letter)] Devars du Mayne JF, et al. **Presse Med** 1997 Apr 26;26(14):666 **(Fre)**
[Distal gangrene and cryoglobulinemia related to hepatitis C virus infection with presence of anticardiolipin antibodies] Jacq F, et al. **Rev Med Interne** 1997;18(4):324–7 (Eng. Abstr.) **(Fre)**
[A 10–year–old girl with anticardiolipin antibody, who showed bleeding tendency] Kawashima H, et al.
Nihon Rinsho Meneki Gakkai Kaishi 1996 Jun;19(3):244–50 (Eng. Abstr.) **(Jpn)**
[Sudden sensorineural hearing loss associated with anticardiolipin antibody] Hisashi K, et al.
Nippon Jibiinkoka Gakkai Kaiho 1996 Sep;99(9):1157–61 (Eng. Abstr.) **(Jpn)**
[Antibodies to cardiolipin and tumor–associated antigens CA–125 and CA–19–9 in patients with ovarian tumors] Karpov NI, et al. **Klin Med (Mosk)** 1996;74(4):42–5 (Eng. Abstr.) **(Rus)**
[Arterial thrombosis associated with anticardiolipin antibodies in a patient with ulcerative colitis (letter)] Zambrana García JL, et al. **Gastroenterol Hepatol** 1997 Jun–Jul;20(6):337 **(Spa)**

BIOSYNTHESIS

The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Sebastiani GD, et al. **Semin Arthritis Rheum** 1996 Jun; 25(6):414–20 (38 ref.)

BLOOD

A study of coagulation and anti–endothelial antibodies in idiopathic livedo reticularis. Faclieru D, et al.
Acta Derm Venereol 1997 May;77(3):181–3
Prevalence and clinical significance of antiphospholipid antibodies in heart valve disease: a case–control study. Bouillanne O, et al. **Am Heart J** 1996 Oct;132(4):790–5
The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Merkel PA, et al. **Am J Med** 1996 Dec;101(6):576–83
Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Verrot D, et al. **Am J Med** 1997 Jul;103(1):33–7
Anticardiolipin antibodies and physical disability in the elderly [letter] Cesbron JY, et al. **Ann Intern Med** 1997 Jun 15;126(12):1003
Comparison of an enzyme–linked immunosorbent assay for antibodies to beta 2–glycoprotein I and a conventional anticardiolipin immunoassay [see comments] Roubey RA, et al. **Arthritis Rheum** 1996 Sep;39(9):1606–7. Comment in: Arthritis Rheum 1996 Sep;39(9):1441–3. Comment in: Arthritis Rheum 1997 Jul;40(7):1366–8.
Antibodies to beta 2–glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus [see comments] Tsutsumi A, et al.
Arthritis Rheum 1996 Sep;39(9):1466–74. Comment in: Arthritis Rheum 1996 Sep;39(9):1441–3. Comment in: Arthritis Rheum 1997 Jul;40(7):1366–8.
Increased levels of autoantibodies to cardiolipin and oxidised low density lipoprotein are inversely associated with plasma vitamin C status in cigarette smokers. Fickl H, et al. **Atherosclerosis** 1996 Jul;124(1):75–81
Anti–cardiolipin antibodies in blood donors. Panton JA, et al. **Biochem Soc Trans** 1997 May;25(2):320S
Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Nojima J, et al.
Br J Haematol 1997 Mar;96(3):447–50
Dietary fat affects lipids and anti–cardiolipin antibody levels in autoimmune–prone NZB/W F1 mice. Lin BF, et al.
Br J Nutr 1997 Apr;77(4):657–69
Enrichment of antibodies against phospholipids in circulating immune complexes (CIC) in the anti–phospholipid syndrome (APLS). Arfors L, et al. **Clin Exp Immunol** 1997 Apr;108(1):47–51
Measurement of anticardiolipin antibodies by ELISA using beta 2–glycoprotein I (beta 2–GPI) in systemic sclerosis. Ihn H, et al. **Clin Exp Immunol** 1996 Sep;105(3):475–9
Anticardiolipin antibodies in acute rheumatic fever and chronic rheumatic heart disease: is there a significant association? Narin N, et al. **Clin Exp Rheumatol** 1996 Sep–Oct;14(5):567–9
Anticardiolipin (aCL) antibodies in a patient with Behçet's syndrome with vena cava inferior thrombosis. Ebo DG, et al. **Clin Rheumatol** 1997 Jan;16(1):96–8 (15 ref.)
Nailfold capillary microscopy in patients with anticardiolipin antibodies: a case–control study. Vayssairat M, et al.
Dermatology 1997;194(1):36–40
Anti–beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti–beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia–eclampsia. Faden D, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 May;73(1):37–42
Anticardiolipin antibodies in pregnancy induced hypertension. Uncu G, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Dec;70(1):97–100
Midfollicular anticardiolipin and antiphosphatidylserine antibody titers do not correlate with in vitro fertilization outcome. Kowalik A, et al. **Fertil Steril** 1997 Aug; 68(2):298–304
Chromosome analysis of aborted conceptuses of recurrent aborters positive for anticardiolipin antibody. Takakuwa K, et al. **Fertil Steril** 1997 Jul;68(1):54–8
Anti–cardiolipin antibodies in sexual partners of recurrent aborters. Panton JA, et al. **Hum Reprod** 1997 Mar; 12(3):464–7
Anticardiolipin antibodies and lipoprotein (a) levels in patients with chronic renal failure treated with dialysis: associations with atherothrombotic disease. Petersen LJ, et al. **Int J Artif Organs** 1996 Jun;19(6):339–42
Pyoderma gangrenosum associated with anticardiolipin antibodies in a pregnant patient. Freedman AM, et al.
Int J Dermatol 1997 Mar;36(3):205–7
Prevalence of elevated anticardiolipin antibodies in pregnant women with unexplained elevations of alpha–fetoprotein. Yetman DL, et al. **J Reprod Immunol** 1997 Apr;33(1):71–81
Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus. Bengtsson A, et al.
Lupus 1996 Dec;5(6):598–601
Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Borba EF, et al. **Lupus** 1997;6(6):533–9
Flow cytometric detection of circulating activated platelets

in primary antiphospholipid syndrome. Correlation with thrombocytopenia and anticardiolipin antibodies. Fanelli A, et al. **Lupus** 1997;6(3):261–7

Epilepsy and antiphospholipid antibodies in systemic lupus erythematosus patients [letter; comment] Formiga F, et al. **Lupus** 1997;6(5):486. Comment on: Lupus 1996 Aug;5(4):307–12.

Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients [see comments] Liou HH, et al. **Lupus** 1996 Aug;5(4):307–12. Comment in: Lupus 1997;6(5):486.

Why do patients with antiphospholipid antibody clot? [editorial; comment] Lockshin MD. **Lupus** 1997;6(4):351–2 . Comment on: Lupus 1997 ;6(4):358–64.

Association between IgM anticardiolipin antibodies and deep venous thrombosis in patients without systemic lupus erythematosus. Oger E, et al. **Lupus** 1997;6(5):455–61

Autoimmune aberration in sudden sensorineural hearing loss: association with anti-cardiolipin antibodies. Toubi E, et al. **Lupus** 1997;6(6):540–2

Isolation and purification of anticardiolipin antibody from plasma of a patient with antiphospholipid syndrome: induced generation of platelet thromboxane A2 synthesis. Leung S, et al.
Prostaglandins Leukot Essent Fatty Acids 1996 Dec; 55(6):385–93

Anticardiolipin antibodies and HLA-DR antigens in a southern Italian family with multiple immunological disorders. Ferlazzo B, et al. **Recenti Prog Med** 1996 Jul–Aug;87(7–8):356–7

Antibodies to cardiolipin and beta 2 glycoprotein I in patients with polymyalgia rheumatica and giant cell arteritis. Meyer O, et al. **Rev Rhum Engl Ed** 1996 Apr;63(4):241–7

Trends in immunoglobulin G anticardiolipin antibodies in ten successful heparin-treated pregnancies. Ruffatti A, et al. **Rheumatol Int** 1996;16(1):15–8

Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Fijnheer R, et al.
Thromb Haemost 1996 Oct;76(4):514–7

Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Forastiero RR, et al. **Thromb Haemost** 1996 May;75(5):717–20

The relationship between plasma microparticles, protein S and anticardiolipin antibodies in patients with human immunodeficiency virus infection. Gris JC, et al.
Thromb Haemost 1996 Jul;76(1):38–45

Anticardiolipin antibodies and recurrent thromboembolism [letter; comment] Rance A, et al. **Thromb Haemost** 1997 Jan;77(1):221–2. Comment on: Thromb Haemost 1996 May;75(5):859.

Antiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes [published erratum appears in Thromb Res 1996 Nov 15;84(4):299] Boddi M, et al. **Thromb Res** 1996 May 1;82(3):207–16

Anticardiolipin antibody-associated stroke after liver transplantation. Bronster DJ, et al. **Transplantation** 1997 Mar 27;63(6):908–9

[Risk of thrombosis with increased anticardiolipin antibodies] Winckelmann G. **Dtsch Med Wochenschr** 1997 Apr 11; 122(15):492–3 **(Ger)**

[A case of Sjögren's syndrome with a high titer of anticardiolipin antibody that developed as parkinsonism] Mochizuki H, et al. **Rinsho Shinkeigaku** 1997 Jan;37(1):57–9 (Eng. Abstr.) **(Jpn)**

[Cardiolipin antibodies in patients with chronic parenchymatous parotitis, Sjögren's syndrome and disease and tumors of the parotid salivary glands] Varshavskaia AA. **Stomatologiia (Mosk)** 1996;Spec No:48–9 **(Rus)**

[Thrombophlebitis in a patient with acute Q fever and anticardiolipin antibodies (letter)] Gálvez J, et al.
Med Clin (Barc) 1997 Mar 15;108(10):396–7 (6 ref.) **(Spa)**

CHEMISTRY

Characterization of estrogen-induced autoantibodies to cardiolipin in non-autoimmune mice. Verthelyi D, et al. **J Autoimmun** 1997 Apr;10(2):115–25

GENETICS

Immunoglobulin gene sequence analysis of anti-cardiolipin and anti-cardiolipin idiotype (H3) human monoclonal antibodies. Hohmann A, et al. **Autoimmunity** 1995; 22(1):49–58

High familial anticardiolipin antibody titer and major histocompatibility complex [letter] Bridey F, et al.
Thromb Haemost 1996 Dec;76(6):1118–9

IMMUNOLOGY

Characterization of beta2-glycoprotein I-dependent and -independent "antiphospholipid" antibodies from lupus-prone NZW/BXSB F1 hybrid male mice. Thiagarajan P, et al. **Am J Hematol** 1997 Oct;56(2):86–92

Site-directed mutagenesis of recombinant human beta 2-glycoprotein I. Effect of phospholipid binding and anticardiolipin antibody activity. Sheng Y, et al.
Ann N Y Acad Sci 1997 Apr 5;815:331–3

Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Pierangeli SS, et al. **Circulation** 1996 Oct 1;94(7):1746–51

Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. López-Soto A, et al. **Clin Exp Rheumatol** 1997 Mar–Apr;15(2):143–9

Isolated tricuspid valve disease in a patient with elevated levels of anticardiolipin antibodies. Sastry BK.
Indian Heart J 1997 Jan–Feb;49(1):87–9

Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. Swadzba J, et al. **J Rheumatol** 1997 Sep;24(9):1710–5

High association between hyperprolactinemia and anticardiolipin antibodies [letter] Toubi E, et al.
J Rheumatol 1997 Jul;24(7):1451

Induction of anticardiolipin antibody and/or lupus anticoagulant in rabbits by immunization with lipoteichoic acid, lipopolysaccharide and lipid A. Gotoh M, et al.
Lupus 1996 Dec;5(6):593–7

Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in Mexican patients with systemic lupus erythematosus (SLE). Granados J, et al. **Lupus** 1997;6(1):57–62

Cerebral infarction in children with high levels of anticardiolipin antibody [letter] Watanabe M, et al.
Pediatr Radiol 1997 Jun;27(6):560

[Antiphospholipid syndrome in SLE males] Nasonov EL, et al. **Klin Med (Mosk)** 1996;74(4):18–22 **(Rus)**

[Antiphospholipid antibodies and neurological disorders. Types and mechanisms] Viñets C, et al. **Rev Neurol** 1996 Oct;24(134):1224–8 (42 ref.) (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Isolation and purification of anticardiolipin antibody from plasma of a patient with antiphospholipid syndrome: induced generation of platelet thromboxane A2 synthesis. Leung S, et al.
Prostaglandins Leukot Essent Fatty Acids 1996 Dec; 55(6):385–93

METABOLISM

Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Willems GM, et al. **Biochemistry** 1996 Oct 29;35(43):13833–42

Comparative assessment of phospholipid-binding antibodies indicates limited overlapping. de Maistre E, et al.
J Clin Lab Anal 1996;10(1):6–12

Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. Sheng Y, et al. **J Immunol** 1996 Oct 15; 157(8):3744–51

Beta 2-glycoprotein I and anticardiolipin antibody binding to resting and activated cultured human endothelial cells. Hanly JG, et al. **J Rheumatol** 1996 Sep;23(9):1543–9

[Anticardiolipin antibodies are released from the bound state during development of burn shock] Abakushin DN, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):425–6 **(Rus)**

PHARMACOLOGY

Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Hasunuma Y, et al.
Clin Exp Immunol 1997 Mar;107(3):569–73

Anticardiolipin, but not the 16/6 Id anti-DNA antibody induces pregnancy failure. Sthoeger ZM, et al.
Immunol Lett 1996 Jan;49(1–2):117–22

Effects of monoclonal anticardiolipin antibody on pregnant mice. Suzuki T, et al. **J Rheumatol** 1996 Jan;23(1):83–6

Effect of beta 2glycoprotein I and human monoclonal anticardiolipin antibody on the protein S/C4b-binding protein system [see comments] Atsumi T, et al. **Lupus** 1997; 6(4):358–64. Comment in: Lupus 1997 ;6(4):351–2.

PHYSIOLOGY

Antiphospholipid antibody: functional specificity for inhibition of prothrombin activation by the prothrombinase complex. Pierangeli SS, et al. **Br J Haematol** 1997 Jun; 97(4):768–74

Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Pierangeli SS, et al. **Circulation** 1996 Oct 1;94(7):1746–51

Functional effects of anticardiolipin antibodies. Harris EN, et al. **Lupus** 1996 Oct;5(5):372–7 (33 ref.)

[Prevalence and role of anticardiolipin antibodies in Crohn disease] Lonjon I, et al. **Gastroenterol Clin Biol** 1996; 20(8–9):633–7 (Eng. Abstr.) **(Fre)**

[Anticoagulating activity of natural cardiolipin antibodies] Ziablitskiĭ VM, et al. **Biull Eksp Biol Med** 1996 Aug; 122(8):197–9 **(Rus)**

ANTIBODIES, ANTI-DNA see **ANTIBODIES, ANTINUCLEAR**

ANTIBODIES, ANTI-IDIOTYPIC

see related
IMMUNOGLOBULIN IDIOTYPES
MOLECULAR MIMICRY

Anti-idiotypic antibody identifies a consensus recognition site for phosphatidylserine common to protein kinase C and other cellular phosphatidylserine-binding proteins. Igarashi K, et al. **Ann N Y Acad Sci** 1993 Dec 20;707:536–9

Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Polonelli L, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):142–6

Purification by affinity chromatography with anti-idiotypic monoclonal antibodies of immunoreactive monoclonal antibodies following labeling with 188Re. Hamby CV, et al. **Hybridoma** 1997 Feb;16(1):27–31

Manuscripts presented at the DNA Antibody Workshop. London, May 11–12, 1996. **Lupus** 1997;6(3):287–350

Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention? Yi Q, et al.
Med Oncol 1996 Mar;13(1):1–7 (70 ref.)

Reflections on internal images [news; comment] Greenspan NS. **Nat Biotechnol** 1997 Feb;15(2):123–4. Comment on: Nat Biotechnol 1997 Feb;15(2):155–8.

Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity [see comments] Magliani W, et al. **Nat Biotechnol** 1997 Feb;15(2):155–8. Comment in: Nat Biotechnol 1997 Feb;15(2):123–4.

Cross-reactive idiotypes on rabbit anti-SEA antibodies stimulate anti-idiotype spleen and lymph node cell responses of mice infected with Schistosoma mansoni. Amano T, et al. **Parasite Immunol** 1996 Jan;18(1):21–8

Normal human polyclonal immunoglobulins for intravenous use contain anti-idiotypes against natural xenophile antibodies and prolong discordant xenograft survival. Schussler O, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):959–60

ADVERSE EFFECTS

Anti-D testing in intravenous immunoglobulins: shouldn't it be considered [letter] Pisani G, et al. **Vox Sang** 1996; 71(2):132

ANALYSIS

Luminal antigliadin antibodies in small intestinal bacterial overgrowth. Riordan SM, et al. **Am J Gastroenterol** 1997 Aug;92(8):1335–8

Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. DeKeyser F, et al. **Clin Exp Rheumatol** 1996 Nov–Dec;14(6):587–91

Seroprevalence of Lyme borreliosis in forestry workers from Brandenburg, Germany. Rath PM, et al.
Eur J Clin Microbiol Infect Dis 1996 May;15(5):372–7

Evaluation of four commercial enzyme immunoassays for detection of immunoglobulin M antibodies to human parvovirus B19. Sloots T, et al.
Eur J Clin Microbiol Infect Dis 1996 Sep;15(9):758–61

Human umbilical vein endothelial cells: a new easily available source of endomysial antigens. Whelan A, et al.
Eur J Gastroenterol Hepatol 1996 Oct;8(10):961–6

Serum house dust mite antibodies: predictor of increased bronchial responsiveness in adults of a community. Omenaas E, et al. **Eur Respir J** 1996 May;9(5):919–25

High prevalence of mollusc shell hypersensitivity pneumonitis in nacre factory workers. Orriols R, et al.
Eur Respir J 1997 Apr;10(4):780–6

Immunological outcome measures. Björkstén B.
Eur Respir J Suppl 1996 Apr;21:22s–27s (26 ref.)

Non Hodgkin's lymphoma presenting as neutropenia related to an IgM monoclonal anti-i antibody. Cartron J, et al.
Hematol Cell Ther 1996 Apr;38(2):225–30

A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. Gazzano-Santoro H, et al. **J Immunol Methods** 1997 Mar 28;202(2):163–71

The role of antiperipheral nerve antibodies in nerve damage in leprosy. Desikan P, et al. **Lepr Rev** 1994 Sep;65(3):222–30

Sociodemographic, hygienic and nutritional correlates of Helicobacter pylori infection of young Bangladeshi children. Clemens J, et al. **Pediatr Infect Dis J** 1996 Dec; 15(12):1113–8

Polymerase chain reaction for diagnosis of varicella zoster virus central nervous system infections without skin manifestations. Bergström T. **Scand J Infect Dis Suppl** 1996; 100:41–5

Three-dimensional imaging of single molecules solvated in pores of poly(acrylamide) gels. Dickson RM, et al.
Science 1996 Nov 8;274(5289):966–9

The pH, conductivity and osmolality of low ionic strength solutions used within the U.K. for the antiglobulin test. Phillips PK, et al. **Transfus Med** 1991 Sep;1(3):155–8

Antiepithelial cell antibodies do not impair paediatric renal allograft survival but appear to be associated with acute viral infections. Spencer SE, et al. **Transpl Immunol** 1996 Mar;4(1):19–22

[Successful gamma globulin therapy in a patient with anti-IgA antibodies] Litzman J, et al. **Vnitr Lek** 1997 Feb; 43(2):102–4 (Eng. Abstr.) **(Cze)**

[Small-cell lung cancer and subacute sensory neuropathy in a patient positive for the anti-Hu antigen] Okishio K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul; 34(7):816–21 (Eng. Abstr.) **(Jpn)**

[Anti-idiotypic antibodies against antibodies to HBsAg and against antibodies to pre-S1 and pre-S2 fragments of HBV in patients with chronic HBs antigenemia] Jagielski P, et al. **Med Dosw Mikrobiol** 1996;48(1–2):79–85 (Eng. Abstr.)

ANTIBODIES, ANTI-IDIOTYPIC

(Pol)

[TSH anti-receptor antibodies in Graves' disease] Sérgio MR, et al. **Acta Med Port** 1996 Jul-Sep;9(7-9):229-31 (Eng. Abstr.) **(Por)**

[Clinical expression of systemic lupus erythematosus with anti-U1-RNP and anti-Sm antibodies] López-Longo FJ, et al. **Rev Clin Esp** 1997 May;197(5):329-35 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Clark JI, et al. **Cancer Immunol Immunother** 1997 Jul;44(5):265-72

Establishment of internal-image anti-idiotype monoclonal antibodies to a human antibody to lung cancer. Saito H, et al. **Cancer Immunol Immunother** 1997 Apr;44(2):83-7

Induction and suppression of anti-antibodies to syngeneic T cell-binding antibodies in mice. Kremmer E, et al. **Clin Exp Immunol** 1997 Jul;109(1):180-4

Inhibitory effect of thiophosphoric acid alkaloid derivatives from Chelidonium majus L. (Ukrain) on ovalbumin antigenicity and antiovalbumin IgE antibody response in mice. Wyczółkowska J, et al. **Drugs Exp Clin Res** 1996; 22(3-5):195-200

A comparison of the anti-idiotypic responses generated by antibodies to a protein and a hapten: a common interspecies idiotype on antibodies against human albumin induces an idiotypic network in rabbits. Comacchio RM, et al. **Immunol Cell Biol** 1996 Feb;74(1):72-80

Can active immunization redirect an anti-IgE immune response? Stadler BM, et al. **Int Arch Allergy Immunol** 1997 May-Jul;113(1-3):216-8

Induction of a non-oscillating, long-lasting humoral immune response to an internal network antigen. Lange H, et al. **Int Immunol** 1996 May;8(5):683-8

Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. Blanco I, et al. **J Clin Immunol** 1997 Jan;17(1):96-106

Role of repetitive antigen patterns for induction of antibodies against antibodies [see comments] Fehr T, et al. **J Exp Med** 1997 May 19;185(10):1785-92. Comment in: J Exp Med 1997 May 19;185(10):1721-3.

DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. Spellerberg MB, et al. **J Immunol** 1997 Aug 15;159(4):1885-92

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. Albertini MR, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):278-95

Production and characterisation of monoclonal antibodies recognising ovine IgE. Shaw RJ, et al. **Vet Immunol Immunopathol** 1996 Jun 1;51(3-4):235-51

BLOOD

Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus [published erratum appears in Arthritis Rheum 1997 May;40(5):977] Isshi K, et al. **Arthritis Rheum** 1996 Sep;39(9):1483-90

Common occurrence of an antiidiotypic antibody that recognizes T14+ anti-DNA antibodies in patients with systemic lupus erythematosus. Lim PL, et al. **Arthritis Rheum** 1996 Dec;39(12):1980-9

Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Higgins RM, et al. **Lancet** 1996 Nov 2;348(9036):1208-11

Function and expression of a human idiotypic network in Schistosomiasis japonica. Wisnewski AV, et al. **Parasite Immunol** 1996 Sep;18(9):439-47

Value of serologic markers for clinical diagnosis and population studies of coeliac disease. Ascher H, et al. **Scand J Gastroenterol** 1996 Jan;31(1):61-7

Characterization of anti-thymoglobulin, anti-Atgam and anti-OKT3 IgG antibodies in human serum with an 11-min ELISA. Regan J, et al. **Transpl Immunol** 1997 Mar; 5(1):49-56

Lymphocytotoxic antibody responses to one prospective HLA-DR typed blood transfusion in naive patients awaiting renal transplantation. The Groupe Coopératif de Transplantation de l'Ile de France. Busson M, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1415-6

Anti-HLA antibodies detected in posttransplant renal allograft recipient sera correlate with chronic rejection. Kerman RH, et al. **Transplant Proc** 1997 Feb-Mar; 29(1-2):1515-6

Association of pretransplant anti-heart antibodies against human heat shock protein 60 with clinical course following cardiac transplantation. Latif N, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1039-40

Role of idiotype-independent anti-IgG autoantibodies in human kidney transplantation: natural anti-F(ab')2 antibodies recognize an IgG1 hinge region epitope. Terness P, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1412-4

Anti-IgG autoantibodies and possible immune regulatory mechanisms in patients with pulmonary tuberculosis. Rajalingam R, et al. **Tuber Lung Dis** 1996 Dec;77(6):502-9

[Immunochemical correlates of the severity of Parkinson's disease] Morozov SG, et al. **Vopr Med Khim** 1997 Jan-Feb; 43(1):34-8 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Polyclonal catalytic anti-idiotypic antibodies with a beta-lactamase activity. Avalle B, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:172-5

Generation and characterization of a human monoclonal IgM antibody that recognizes a conserved epitope shared by lipopolysaccharides of different gram-negative bacteria. Seifert M, et al. **Hybridoma** 1996 Jun;15(3):191-8

Characterization of a T cell line specific to an anti-Id antibody related to the carbohydrate antigen, sialyl SSEA-1, and the immundominant T cell antigenic site of the antibody. Tsuyuoka K, et al. **J Immunol** 1996 Jul 15; 157(2):661-9

Crystal structure of an Fv-Fv idiotope-anti-idiotope complex at 1.9 A resolution. Braden BC, et al. **J Mol Biol** 1996 Nov 22;264(1):137-51

The antigen-binding domain of a human IgG-anti-F(ab')2 autoantibody. Welschof M, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1902-7

Monoclonal and polyclonal antibodies to chicken immunoglobulin isotypes specifically detect turkey immunoglobulin isotypes. Van Nerom A, et al. **Vet Immunol Immunopathol** 1997 Jul;57(3-4):305-14

GENETICS

Immunoglobulin gene sequence analysis of anti-cardiolipin and anti-cardiolipin idiotype (H3) human monoclonal antibodies. Hohmann A, et al. **Autoimmunity** 1995; 22(1):49-58

[High homology between antigen of HFRSV with anti-idiotype antibody against HFRSY] Gao L, et al. **Chung Hua I Hsueh Tsa Chih** 1996 May;76(5):349-51 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Anti-idiotypic antibodies in the treatment of allergies. Hébert J, et al. **Adv Exp Med Biol** 1996;409:431-7 (39 ref.)

Skin prick tests and specific IgE in adults from three different areas of Sweden. Plaschke P, et al. **Allergy** 1996 Jul; 51(7):461-72

In vitro synthesis of Alternaria allergens and their recognition by murine monoclonal and human IgE antibodies. Bush RK, et al. **Ann Allergy Asthma Immunol** 1997 Mar; 78(3):287-92

An anti-idiotypic (T14) antibody found commonly in patients with systemic lupus erythematosus that may be pathogenic. Lim PL, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:462-4

Identification of an idiotype on mouse monoclonal antibody directed to a 35 kDa glycoprotein from Entamoeba histolytica. Chávez-Rueda K, et al. **Arch Med Res** 1997; 28 Spec No:242-4

Incidence and disease associations of a proteinase 3-antineutrophil cytoplasmic antibody idiotype (5/7 Id) whose antiidiotype inhibits proteinase 3-antineutrophil cytoplasmic antibody antigen binding activity. Strunz HP, et al. **Arthritis Rheum** 1997 Jan;40(1):135-42

Active immunization with anti-DNA autoantibody idiopeptide 88H.64-80 is nephritogenic in (NZB x NZW)F1 and Balb/c mice. Howe CA, et al. **Biochem Soc Trans** 1997 May;25(2):316S

Protective activity of rabbit polyclonal anti-idiotype antibody against Leptospira interrogans infection in hamsters. Masuzawa T, et al. **Biol Pharm Bull** 1996 Apr; 19(4):613-5

Anti-idiotype cancer vaccines: past and future. Herlyn D, et al. **Cancer Immunol Immunother** 1996 Oct;43(2):65-76 (105 ref.)

Suppression of experimental lung colonization of mouse colon adenocarcinoma 26 in vivo by an anti-idiotype monoclonal antibody recognizing a platelet surface molecule. Kato Y, et al. **Cancer Res** 1997 Jul 15; 57(14):3040-5

Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Pervin S, et al. **Cancer Res** 1997 Feb 15;57(4):728-34

Quaternary structure-dependent idiotope and antigen binding of a monoclonal antibody specific for conformational epitope on type II collagen. Ito HO, et al. **Cell Mol Life Sci** 1997 Jan;53(1):51-60

Induction and suppression of anti-antibodies to syngeneic T cell-binding antibodies in mice. Kremmer E, et al. **Clin Exp Immunol** 1997 Jul;109(1):180-4

Polyclonal anti-idiotypic antibodies to idazoxan and their interaction with human brain imidazoline binding sites. Bennai F, et al. **Eur J Pharmacol** 1996 Jun 13; 306(1-3):211-8

Human lung mast cells release small amounts of interleukin-4 and tumour necrosis factor-alpha in response to stimulation by anti-IgE and stem cell factor. Gibbs BF, et al. **Eur J Pharmacol** 1997 May 26;327(1):73-8

Fibrous connective tissue of rat binds anti-immunoglobulin antibodies. Kozłowska H, et al. **Folia Histochem Cytobiol** 1997;35(2):123-4

Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy. Abe A, et al. **Gene Ther** 1996 Nov;3(11):988-93

Anti-idiotypic monoclonal antibodies to GM1 identify ganglioside binding proteins. Riggott MJ, et al. **Glycobiology** 1996 Sep;6(6):581-9

Incidence of anti-mouse antibodies in thrombocytopenic patients with autoimmune disorders. Clofent-Sanchez G, et al. **Hum Antibodies** 1997;8(2):50-9

Receptor analysis of idiotype antibodies derived from MALT type B-cell lymphoma hybridomas. Haedicke W, et al. **Hum Antibodies** 1997;8(1):33-6

Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity. Durrant LG, et al. **Hybridoma** 1997 Feb;16(1):23-6

Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43.13? Reinsberg J, et al. **Hybridoma** 1997 Feb;16(1):59-63

Production of a single-chain fragment of the murine anti-idiotypic antibody ACA125 as phage-displayed and soluble antibody by recombinant phage antibody technique. Schlebusch H, et al. **Hybridoma** 1997 Feb;16(1):47-52

Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Wagner U, et al. **Hybridoma** 1997 Feb;16(1):33-40

Prolongation of the responsiveness of newborn mice to syngeneic IgE by inhibition of IgE synthesis. Haba S, et al. **Immunol Lett** 1995 Sep;47(3):205-8

Moloney leukemia virus-induced cell surface antigen mimicry by monoclonal antibodies. Baskin JG, et al. **Immunol Res** 1995;14(4):292-316 (96 ref.)

Autologous anti-idiotypic antibody response is regulated by the level of circulating complementary idiotype. Borghesi C, et al. **Immunology** 1996 Oct;89(2):172-7

Chemotaxis of human B lymphocytes to anti-IgD. Komai-Koma M, et al. **Immunology** 1996 Aug;88(4):600-3

Role of c-myc and CD45 in spontaneous and anti-receptor-induced apoptosis in adult murine B cells. Scott DW, et al. **Int Immunol** 1996 Sep;8(9):1375-85

How to overcome the disturbing effects of human anti-mouse antibodies (HAMA) on in vitro assays. Oltrogge JB, et al. **Int J Biol Markers** 1997 Jan-Mar;12(1):15-7

Generation of human monoclonal anti-idiotypic antibodies with specificity to the murine monoclonal anti-CA 125 antibody B43.13. Oltrogge JB, et al. **Int J Biol Markers** 1996 Oct-Dec;11(4):211-5

Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens. Manetti C, et al. **Int J Cancer** 1997 Jun 11;71(6):1000-9

Common infections, idiotypic dysregulation, autoantibody spread and induction of autoimmune diseases. Shoenfeld Y. **J Autoimmun** 1996 Apr;9(2):235-9 (39 ref.)

Antisera directed against anti-histone H4 antibodies recognize linker histones. Novel immunological probes to detect histone interactions. Thiriet C, et al. **J Biol Chem** 1997 Jul 25;272(30):18740-5

Tissue IgA antibody against Helicobacter pylori in patients with gastroduodenal diseases: comparison with bacterial culture, serum IgG antibody, and [13C]Urea breath test. Matsukura N, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S146-50

Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. Miyajima I, et al. **J Clin Invest** 1997 Mar 1;99(5):901-14

In vitro decrease of rat-derived Pneumocystis carinii attachment induced by human natural yeast killer toxin-like antiidiotypic candidacidal antibodies. Séguy N, et al. **J Eukaryot Microbiol** 1996 Sep-Oct;43(5):27S

Immunoregulatory idiotypes stimulate T helper 1 cytokine responses in experimental Schistosoma mansoni infections. Montesano MA, et al. **J Immunol** 1997 Apr 15; 158(8):3800-4

A natural IgA-anti-F(ab')2gamma autoantibody occurring in healthy individuals and kidney graft recipients recognizes an IgG1 hinge region epitope. Terness P, et al. **J Immunol** 1996 Nov 1;157(9):4251-7

Experimental immunization with a monoclonal anti-idiotope antibody that mimics the Neisseria gonorrhoeae lipooligosaccharide epitope 2C7. Gulati S, et al. **J Infect Dis** 1996 Dec;174(6):1238-48

Immunization with antibodies that mimic LPS protects against gram negative bacterial sepsis. Klaerner HG, et al. **J Surg Res** 1997 May;69(2):249-54

Size and connectivity of the idiotypic network are independent of the discreteness of the affinity distribution. Detours V, et al. **J Theor Biol** 1996 Dec 21;183(4):409-16

Variable regions of two murine antibodies that bind the SLE associated 16/6 idiotype. Waisman A, et al. **Lupus** 1996 Aug;5(4):279-87

Biological mimicry of the bluetongue virus core protein VP7 by rabbit anti-idiotype. Lin M, et al. **Microbiol Immunol** 1996;40(6):435-41

Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Whittum-Hudson JA, et al. **Nat Med** 1996 Oct;2(10):1116-21

Influence of a syngeneic anti-idiotypic antibody response to a mouse anti-tumour monoclonal antibody on biodistribution of its radiolabelled Fc-intact monovalent Fab/c fragment. Pimm MV, et al. **Nucl Med Biol** 1994 Jan;21(1):125-7

Characterization of anti-anti-idiotypic antibodies that bind antigen and an anti-idiotype. Goldbaum FA, et al.

Proc Natl Acad Sci U S A 1997 Aug 5;94(16):8697-701
Internal image concept revisited. Bona CA.
Proc Soc Exp Biol Med 1996 Oct;213(1):32-42 (126 ref.)
Anti-idiotypic T cells in early stages of myasthenia gravis: increase in the number and prevalence correlated to clinical improvement in patients. Yi Q, et al. **Scand J Immunol** 1996 Dec;44(6):630-7
Anti-idiotypic monoclonal antibody cancer vaccines. Chapman PB. **Semin Cancer Biol** 1995 Dec;6(6):367-74 (53 ref.)
Successful management of hemolysis in ABO-nonidentical orthotopic liver transplantation by steroid therapy: a case report. Auwerda JJ, et al. **Transpl Int** 1996;9(5):509-12
Large scale production of rabbit-derived anti-idiotypic antibodies: a new tool in immunosuppressive therapy? Greger B, et al. **Transplant Proc** 1996 Dec;28(6):3205-7
Monoclonal antiidiotypic antibodies neutralize cytotoxic effects of anti-alphaGal antibodies. Koren E, et al. **Transplantation** 1996 Sep 27;62(6):837-43
Anti-idiotypic antibody to the V3 domain of gp120 binds to vimentin: a possible role of intermediate filaments in the early steps of HIV-1 infection cycle. Thomas EK, et al. **Viral Immunol** 1996;9(2):73-87
Haemolytic disease of the newborn due to anti-G. Hadley AG, et al. **Vox Sang** 1996;71(2):108-12
Transfusion support for a patient with severe common variable immunodeficiency with anti-IgA undergoing orthotopic liver transplantation [letter] Win N, et al. **Vox Sang** 1997;72(4):251
[Advances in the research of anti-idiotypic antibody against ovarian cancer] Zhang X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Sep;31(9):571-4 (26 ref.) **(Chi)**
[Attempt at preventing hyperacute xenogenic rejection by isotopic suppression of IgM in the recipient] Pitre J, et al. **Ann Chir** 1996;50(7):524-31 (37 ref.) (Eng. Abstr.) **(Fre)**
[Rheumatoid factor idiotypes in patients with Sjögren's syndrome] Chen X, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Oct;19(5):468-76 (Eng. Abstr.) **(Jpn)**
[The use of anti-idiotypic antibodies for correction of autoimmune response to brain protein S-100] Poletaev AB, et al. **Biull Eksp Biol Med** 1996 Nov;122(11):508-11 **(Rus)**
[Monoclonal anti-idiotypic antibodies, imitating the antigenic determinant of hemagglutination site of Venezuelan equine encephalomyelitis virus glycoprotein E2] Lifke VV, et al. **Vopr Virusol** 1997 Jan-Feb;42(1):19-23 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Immunoapheresis, an advanced technique for depleting human anti-porcine antibodies, delays hyperacute rejection of xenogeneic perfused pig livers. Pascher A, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):962-3

METABOLISM

Binding of anti-immunoglobulin antibodies to the fibrous connective tissue of skeletal muscle. Kozłowska H, et al. **Folia Histochem Cytobiol** 1996;34 Suppl 1:95-6
Application of antibody adsorbed polyester cloth for the rapid screening of elution conditions for antigen immunopurification. Boyd S, et al. **Immunol Invest** 1996 Sep-Nov;25(5-6):447-53
A new multivalent B cell activation model--anti-IgD bound to Fc gamma RI: properties and comparison with CD40L-mediated activation. Cho S, et al. **Int Immunol** 1997 Feb;9(2):239-48
Effect of anti-IgE antibodies on Fc epsilonRI-bound IgE. Rudolf MP, et al. **J Immunol** 1996 Dec 15;157(12):5646-52
Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. Fox JA, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):1000-8
Characterization of components of the murine B cell receptor complex and their role in anti-Ig stimulation. Vogel L, et al. **Scand J Immunol** 1997 Mar;45(3):287-93
[Anti-idiotypic monoclonal antibodies against latrotoxin interact with rat brain synaptosomes and modify latrotoxin-induced calcium entry into synaptosomes] Pashkov VN, et al. **Bioorg Khim** 1996 Jun;22(6):403-7 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Osorio LM, et al. **Blood** 1997 Apr 15;89(8):2833-41
Down-regulation of Listeria monocytogenes-specific Th1 cytokine response by treatment of mice with goat antibody to mouse IgD. Song F, et al. **Immunobiology** 1996; 196(4):449-62
Anti-alpha3 integrin antibody induces the activated form of matrix metalloprotease-2 (MMP-2) with concomitant stimulation of invasion through matrigel by human rhabdomyosarcoma cells. Kubota S, et al. **Int J Cancer** 1997 Jan 6;70(1):106-11
Anti-immunoglobulin-induced apoptosis in WEHI 231 cells involves the slow formation of ceramide from sphingomyelin and is blocked by bcl-XL. Wiesner DA, et al. **J Biol Chem** 1997 Apr 11;272(15):9868-76
CD40, but not lipopolysaccharide and anti-IgM stimulation of primary B lymphocytes, leads to a persistent nuclear accumulation of RelB. Neumann M, et al. **J Immunol** 1996 Dec 1;157(11):4862-9
Canine leucocyte histamine release: response to antigen and to anti-IgE. Jackson HA, et al. **Vet Immunol Immunopathol** 1996 Oct;53(3-4):195-206
Quantification of total sheep IgE concentration using anti-ovine IgE monoclonal antibodies in an enzyme immunoassay. Shaw RJ, et al. **Vet Immunol Immunopathol** 1997 Jul;57(3-4):253-65
[Anti-C5a suppresses post-traumatic permeability damage of the lung after severe burn trauma] Schmid E, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:631-4 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Naturally occurring anti-idiotypic antibodies to anti-phosphotyrosine in systemic lupus erythematosus interact with SRC-homology 2 domains. Stefanescu M, et al. **Autoimmunity** 1995;22(2):81-6
Production of macrophage inflammatory protein-1alpha by human mast cells: increased anti-IgE-dependent secretion after IgE-dependent enhancement of mast cell IgE-binding ability. Yano K, et al. **Lab Invest** 1997 Aug;77(2):185-93
Human polyreactive IgM monoclonal antibodies with blocking activity against self-reactive IgG. Melero J, et al. **Scand J Immunol** 1997 Apr;45(4):393-400
IgA red cell autoantibodies and autoimmune hemolysis. Sokol RJ, et al. **Transfusion** 1997 Feb;37(2):175-81
Dynamics of donor-reactive IgG, IgA and IgM antibodies against T and B lymphocytes early after clinical kidney transplantation using flow cytometry. Groth J, et al. **Transpl Immunol** 1996 Sep;4(3):215-9

THERAPEUTIC USE

Anti-CD4 monoclonal antibody (mAb) and anti-idiotypic mAb to anti-CD4 in the therapy of autoimmune diseases. Perosa F, et al. **Clin Exp Rheumatol** 1997 Mar-Apr; 15(2):201-10 (51 ref.)
Genetic control of anti-idiotypic vaccination against coronavirus infection. Yu MW, et al. **Eur J Immunol** 1996 Dec;26(12):3230-3
Demonstration of the therapeutic potential of non-anaphylactogenic anti-IgE antibodies in murine models of skin reaction, lung function and inflammation. Heusser CH, et al. **Int Arch Allergy Immunol** 1997 May-Jul; 113(1-3):231-5
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. Casale TB, et al. **J Allergy Clin Immunol** 1997 Jul;100(1):110-21
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. Corne J, et al. **J Clin Invest** 1997 Mar 1;99(5):879-87
Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. MacGlashan DW Jr, et al. **J Immunol** 1997 Feb 1;158(3):1438-45
Anti-idiotypic monoclonal antibodies as therapeutic vaccines [letter; comment] Ferrone S. **Melanoma Res** 1996 Apr; 6(2):179. Comment on: Melanoma Res 1996 Feb;6(1):5-10.
[The study of immunotherapy of ovarian carcinoma with anti-idiotypic antibody] Wang J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jun;31(6):353-6 (Eng. Abstr.) **(Chi)**

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC

Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis. Esteve M, et al. **Gut** 1996 Jun; 38(6):894-8
1996 International meeting on ANCA and ANCA-related diseases. The 7th International ANCA Workshop. Rochester, Minnesota, October 14-16, 1996. Proceedings and abstracts. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct; 13(3):207-84
[Antineutrophil cytoplasmic antibody (ANCA). Diagnostic tool in small vessel vasculitis] Skogh T, et al. **Lakartidningen** 1997 Mar 5;94(10):854-7 **(Swe)**

ANALYSIS

Cytoplasmic antineutrophil cytoplasmic antibody-positive vasculitis associated with ulcerative colitis. Weir A, et al. **Am J Gastroenterol** 1997 Mar;92(3):506-8
Scleroderma, D-penicillamine treatment, and progressive renal failure associated with positive antimyeloperoxidase antineutrophil cytoplasmic antibodies. Hillis GS, et al. **Am J Kidney Dis** 1997 Aug;30(2):279-81
Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Eberhard OK, et al. **Arthritis Rheum** 1997 Jul; 40(7):1250-6
Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis: a marker of severe disease with associated nephropathy. Mustila A, et al. **Arthritis Rheum** 1997 Apr;40(4):710-7
Specificity of cANCA for Wegener's granulomatosis [letter] Nolan P, et al. **Aust N Z J Med** 1996 Oct;26(5):720-1 (4 ref.)
Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group. Guillevin L, et al. **Br J Rheumatol** 1996 Oct;35(10):958-64
Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Spronk PE, et al. **Br J Rheumatol** 1996 Jul; 35(7):625-31
Are antineutrophil cytoplasmic antibodies associated with spondyloarthropathies? [letter; comment] Weinerth JD, et al. **Br J Rheumatol** 1996 Oct;35(10):1032-3. Comment on: Br J Rheumatol 1995 Jul;34(7):695-6.
Wegener's granulomatosis involving the urogenital tract. Davenport A, et al. **Br J Urol** 1996 Sep;78(3):354-7
Human mast cells expressing recombinant proteinase 3 (PR3) as substrate for clinical testing for anti-neutrophil cytoplasmic antibodies (ANCA). Specks U, et al. **Clin Exp Immunol** 1997 Aug;109(2):286-95
Prevalence of anti-neutrophil cytoplasmic antibodies (ANCA) in juvenile chronic arthritis. Speckmaier M, et al. **Clin Exp Rheumatol** 1996 Mar-Apr;14(2):211-6
Incidence and studies on antigenic specificities of antineutrophil-cytoplasmic autoantibodies (ANCA) in poststreptococcal glomerulonephritis. Ardiles LG, et al. **Clin Nephrol** 1997 Jan;47(1):1-5
Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature. Kitahara T, et al. **Clin Nephrol** 1997 May; 47(5):336-40 (20 ref.)
ANCA-associated diseases and silica exposure. Gregorini G, et al. **Clin Rev Allergy Immunol** 1997 Spring;15(1):21-40 (80 ref.)
von Willebrand factor antigen and adhesive molecules in Wegener's granulomatosis and microscopic polyangiitis [letter] Becvar R, et al. **Clin Rheumatol** 1997 May; 16(3):324-5
Antineutrophil cytoplasmic antibodies in systemic sclerosis [letter] Kiraz S, et al. **Clin Rheumatol** 1996 Sep;15(5):519-20
Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features. Nishiya K, et al. **Clin Rheumatol** 1997 Jan; 16(1):70-5
Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques. Bansi DS, et al. **Eur J Gastroenterol Hepatol** 1997 Jun;9(6):575-80
Genetic and immunological markers in pouchitis. Brett PM, et al. **Eur J Gastroenterol Hepatol** 1996 Oct;8(10):951-5
Distinct patterns of immunoglobulin classes and IgG subclasses of autoantibodies in patients with inflammatory bowel disease. Müller-Ladner U, et al. **Eur J Gastroenterol Hepatol** 1996 Jun;8(6):579-84
Neutrophil antibodies (pANCA) in chronic liver disease and inflammatory bowel disease: do they react with different antigens? Seibold F, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1095-100
Neutrophil-related cytokines and neutrophil products in bronchoalveolar lavage fluid of a patient with ANCA negative Wegener's granulomatosis. Mukae H, et al. **Eur Respir J** 1996 Sep;9(9):1950-4
Propylthiouracil-induced alveolar haemorrhage associated with antineutrophil cytoplasmic antibody. Ohtsuka M, et al. **Eur Respir J** 1997 Jun;10(6):1405-7
Do pANCA define a clinical subgroup in patients with Crohn's disease? [letter; comment] Jamar-Leclerc N, et al. **Gastroenterology** 1997 Jan;112(1):316-7. Comment on: Gastroenterology 1996 Jun;110(6):1810-9.
Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup [see comments] Vasiliauskas EA, et al. **Gastroenterology** 1996 Jun;110(6):1810-9. Comment in: Gastroenterology 1997 Jan;112(1):316-7.
Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease. Walmsley RS, et al. **Gut** 1997 Jan;40(1):105-9
Comparison of anti-GBM antibodies in sera with or without ANCA. Hellmark T, et al. **J Am Soc Nephrol** 1997 Mar; 8(3):376-85
Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. Abad E, et al. **J Autoimmun** 1997 Apr;10(2):175-80
Case report: anti-proteinase 3 antibody activity in a patient with primary sclerosing cholangitis: clinical remission following ursodeoxycholic acid therapy. Wong SS, et al. **J Gastroenterol Hepatol** 1996 Dec;11(12):1161-3
Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. Hagen EC, et al. **J Immunol Methods** 1996 Sep 13; 196(1):1-15
Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA. Schultz H, et al. **J Immunol Methods** 1997 Jul 14;205(2):127-33

Painful bilateral abducens nerve palsy associated with anti-neutrophil cytoplasmic autoantibodies [letter] Sanjo N, et al. **J Neurol** 1996 Aug;243(8):612–3

Antineutrophil cytoplasmic antibodies in leptospirosis. Constantin A, et al. **J Rheumatol** 1996 Feb;23(2):411

Do antineutrophil cytoplasmic antibodies correlate with disease activity in systemic lupus erythematosus? [letter] Konca K, et al. **J Rheumatol** 1996 Nov;23(11):2007–8

Are antineutrophil cytoplasmic antibodies of immunodiagnostic value in reactive arthritis? [letter; comment] Stoffel MP, et al. **J Rheumatol** 1996 Sep; 23(9):1670–2. Comment on: J Rheumatol 1995 Dec;22(12):2304–6.

Shared idiotypy among patients with myeloperoxidase-anti-neutrophil cytoplasmic autoantibody associated glomerulonephritis and vasculitis. Nachman PH, et al. **Lab Invest** 1996 Feb;74(2):519–27

ANCA-Tutor: a program that teaches interpretation of an immunofluorescence assay. Wener MH, et al. **MD Comput** 1996 May–Jun;13(3):216–20

ANCA-associated pauci-immune crescentic glomerulonephritis complicating Sjögren's syndrome. Hernández JL, et al. **Nephrol Dial Transplant** 1996 Nov; 11(11):2313–5

Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis associated with thiamazole therapy [letter] Hori Y, et al. **Nephron** 1996;74(4):734–5

An adolescent case of anti-neutrophil cytoplasmic autoantibodies-associated crescentic glomerulonephritis complicated with subclinical autoimmune thyroiditis. Tanaka H, et al. **Nippon Jinzo Gakkai Shi** 1996 Oct; 38(10):463–8

The diagnostic and prognostic significance of ANCA. Lesavre P. **Ren Fail** 1996 Sep;18(5):803–12 (30 ref.)

Isotretinoin-induced vasculitis imitating polyarteritis nodosa, with perinuclear antineutrophil cytoplasmic antibody in titers correlated with clinical symptoms. Chochrad D, et al. **Rev Rhum Engl Ed** 1997 Feb;64(2):129–31

Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Savige JA, et al. **Rheumatol Int** 1996;16(3):109–14

The association between human leukocyte antigens (HLA) and cytoplasmic-antineutrophil cytoplasmic antibody (cANCA)-positive Wegener's granulomatosis in a Japanese population. Nakamaru Y, et al. **Rhinology** 1996 Sep; 34(3):163–5

Absence of ANCA in Mexican patients with Takayasu's arteritis. García-Torres R, et al. **Scand J Rheumatol** 1997; 26(1):55–7 (17 ref.)

Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat. Waldhauser L, et al. **Toxicology** 1996 Dec 2;114(2):155–62

[Heighten the awareness of antineutrophil cytoplasmic autoantibody-related systemic small vessel angiitis (editorial)] Chen Y, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jun;76(6):405–6 **(Chi)**

[Antineutrophilic cytoplasmic antibodies (ANCA) in respiratory pathology] Lauque D. **Rev Mal Respir** 1996 Oct;13(5):534–6 (22 ref.) **(Fre)**

[Intra-alveolar hemorrhage of toxic origin and antineutrophil cytoplasmic antibodies (p-ANCA) (letter)] Corne PH, et al. **Rev Med Interne** 1996;17(12):1042–3 **(Fre)**

[ANCA-associated vasculitis. Wegener disease, microscopic poly-angiitis and Churg-Strauss syndrome] Schmitt WH, et al. **HNO** 1997 Jun;45(6):477–91 **(Ger)**

[ANCA-associated forms of vasculitis] Helmchen U, et al. **Verh Dtsch Ges Pathol** 1996;80:38–45 (30 ref.) (Eng. Abstr.) **(Ger)**

[Importance of ANCAs in the pathogenesis of chronic inflammatory bowel diseases] Müller-Ladner U, et al. **Verh Dtsch Ges Pathol** 1996;80:215 **(Ger)**

[Diagnostic aspects in the determination of antineutrophil cytoplasmic antibodies] Manes M, et al. **Recenti Prog Med** 1997 Jan;88(1):17–20 (Eng. Abstr.) **(Ita)**

[Clinical significance of anti-neutrophil cytoplasmic antibody and pathogenetic role of adhesion molecules for Wegener's granulomatosis] Takizawa M. **Hokkaido Igaku Zasshi** 1996 Jul;71(4):517–29 (Eng. Abstr.) **(Jpn)**

[A case of fluminant septic shock due to Streptococcus agalactiae in a patient with MPO-ANCA related glomerulonephritis] Tanaka A, et al. **Kansenshogaku Zasshi** 1996 Nov;70(11):1186–9 (Eng. Abstr.) **(Jpn)**

[An autopsy case of anti-neutrophil cytoplasmic antibodies associated vasculitis accompanied by autoimmune hepatitis and hepatocellular carcinoma] Suwa A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Apr;20(2):117–25 (Eng. Abstr.) **(Jpn)**

[A case of necrotizing crescentic glomerulonephritis in which myeloperoxidase antineutrophil cytoplasmic antibodies (ANCA) reflect the disease activity and recognize various neutrophil cytoplasmic constituents] Fujimoto T, et al. **Nippon Jinzo Gakkai Shi** 1997 Mar;39(2):172–7 (Eng. Abstr.) **(Jpn)**

[A case of Grave's disease with MPO-ANCA-associated glomerulonephritis during propylthiouracil (PTU) therapy following interstitial pneumonitis] Saeki T, et al. **Nippon Jinzo Gakkai Shi** 1997 Mar;39(2):167–71 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Alveolar hemorrhage, skin eruption, and gastrointestinal bleeding accompanied by crescentric glomerulonephritis in a patient with cytoplasmic anti-neutrophil cytoplasmic antibody] Kishimoto N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul;34(7):790–5 (Eng. Abstr.) **(Jpn)**

[Chronic interstitial pneumonia and crescentic glomerulonephritis associated with perinuclear antineutrophil cytoplasmic antibodies] Matsuyama W, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 May; 35(5):555–60 (Eng. Abstr.) **(Jpn)**

[Two patients with pulmonary hemorrhage associated with myeloperoxidase-antineutrophil cytoplasmic antibody] Niho S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Jan;35(1):111–6 (Eng. Abstr.) **(Jpn)**

[Case of p-ANCA-positive rapidly progressing glomerulonephritis requiring hemodialysis: effectiveness of anti-MPO antibody determiantion in predicting pulmonary hemorrhage] Matsuda T, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):675–7 **(Jpn)**

[A case of MPO-ANCA related vasculitis with transient leukoencephalopathy and multiple cerebral hemorrhage] Honda H, et al. **Rinsho Shinkeigaku** 1996 Sep;36(9):1089–94 (Eng. Abstr.) **(Jpn)**

[Case of MPO-ANCA positive interstitial pneumonitis and necrotizing, crescentic glomerulonephritis] Chikaraishi A, et al. **Ryumachi** 1996 Dec;36(6):869–73 (Eng. Abstr.) **(Jpn)**

[A case of MPO-ANCA positive progressive systemic sclerosis with status epilepticus] Uriuhara A, et al. **Ryumachi** 1997 Jun;37(3):483–6 (Eng. Abstr.) **(Jpn)**

[MPO-ANCA positive two cases associated with interstitial pneumonitis] Yoshida A, et al. **Ryumachi** 1996 Jun; 36(3):570–3 (Eng. Abstr.) **(Jpn)**

[Antineutrophil cytoplasmic antibody (ANCA) and vasculitis] Yoshida M. **Ryumachi** 1995 Dec;35(6):934–42 (30 ref.) **(Jpn)**

[Rapidly progressive glomerulonephritis associated with myeloperoxidase specific-antineutrophil cytoplasmic antibody in patients with rheumatoid arthritis : report of three cases] Yoshihara R, et al. **Ryumachi** 1996 Oct; 36(5):762–8 (Eng. Abstr.) **(Jpn)**

[Anti-neutrophil cytoplasmic antibodies (ANCA) in the glomerulonephritis] Kacprzyk F, et al. **Pol Arch Med Wewn** 1996 Jun;95(6):514–23 (Eng. Abstr.) **(Pol)**

[Churg-Strauss syndrome and antineutrophil cytoplasmic antibodies (letter)] Lafont A, et al. **Med Clin (Barc)** 1997 May 24;108(20):797 **(Spa)**

BIOSYNTHESIS

Raised anti-endothelial cell autoantibodies (AECA), but not anti-neutrophil cytoplasmic autoantibodies (ANCA), in recurrent oral ulceration: modulation of AECA binding by tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma). Healy CM, et al. **Clin Exp Immunol** 1996 Dec;106(3):523–8

Polyarthritis with perinuclear antineutrophil cytoplasmic antibody inaugurating microscopic polyangiitis. Report of a case. Pizzuti P, et al. **Rev Rhum Engl Ed** 1997 May; 64(5):342–4

BLOOD

Anti-neutrophil autoantibodies and systemic vasculitis: a report of five cases [letter] Laux-End R, et al. **Acta Paediatr** 1997 Apr;86(4):438–9

HLA association and occurrence of autoantibodies in Asian-Indian patients with ulcerative colitis [see comments] Habeeb MA, et al. **Am J Gastroenterol** 1997 May; 92(5):772–6. Comment in: Am J Gastroenterol 1997 May;92(5):733–4.

Esophageal carcinoma presenting with nephrotic syndrome: association with anti-neutrophil cytoplasmic antibody. Yedidag A, et al. **Am J Gastroenterol** 1997 Feb;92(2):326–8 (20 ref.)

Membranous lupus nephritis with antineutrophil cytoplasmic antibody-associated segmental necrotizing and crescentic glomerulonephritis. Marshall S, et al. **Am J Kidney Dis** 1997 Jan;29(1):119–24 (28 ref.)

Recurrence of immunoglobulin A nephropathy with immunoglobulin A antineutrophil cytoplasmic antibodies following renal transplantation. Martin SJ, et al. **Am J Kidney Dis** 1997 Jan;29(1):125–31 (29 ref.)

Outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis following cadaveric kidney transplantation. Rostaing L, et al. **Am J Kidney Dis** 1997 Jan;29(1):96–102

Distribution of antineutrophil cytoplasmic autoantibodies in SLE patients with and without renal involvement [letter] Nassberger L. **Am J Nephrol** 1996;16(6):548–9

Monitoring of endothelial leucocyte adhesion molecule-1 in anti-neutrophil-cytoplasmic-antibody-positive vasculitis. Yaqoob M, et al. **Am J Nephrol** 1996;16(2):106–13

Progressive obstructive lung disease associated with microscopic polyangiitis. Brugiere O, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):739–42

Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Merkel PA, et al. **Ann Intern Med** 1997 Jun 1; 126(11):866–73

Antineutrophil cytoplasmic antibodies in inflammatory bowel disease: diagnostic tool or research procedure?. Andreani ML, et al. **Ann Ital Med Int** 1996 Oct–Dec;11(4):254–7

Some anti-thyroperoxidase antibodies positive sera give a pANCA pattern on ethanol-fixed human neutrophils: cross-reactivity or false positives? Farsi A, et al. **Autoimmunity** 1997;25(2):117–22

Microscopic polyangiitis mimicking Henoch-Schönlein purpura followed by severe renal involvement: a diagnostic role for antineutrophil cytoplasmic autoantibody [letter] Akimoto S, et al. **Br J Dermatol** 1997 Feb;136(2):298–9

Antineutrophil cytoplasmic antibody-positive polyarthritis associated with minocycline therapy [letter] Gaffney K, et al. **Br J Rheumatol** 1996 Dec;35(12):1327

ANCA in RA patients [letter] Guang LS. **Br J Rheumatol** 1996 Dec;35(12):1328–9

Prospective evaluation of neutrophil autoantibodies in 500 consecutive patients with inflammatory bowel disease. Freeman H, et al. **Can J Gastroenterol** 1997 Apr;11(3):203–7

Perinuclear antineutrophil cytoplasmic antibodies in collagenous or lymphocytic colitis with or without celiac disease. Freeman HJ. **Can J Gastroenterol** 1997 Jul–Aug; 11(5):417–20

Atypical perinuclear antineutrophil cytoplasmic antibodies after colectomy in inflammatory bowel disease. Freeman HJ, et al. **Can J Gastroenterol** 1997 May–Jun;11(4):305–10

Anti-neutrophil cytoplasmic antibodies in patients with chromomycosis. Galperin C, et al. **Clin Exp Rheumatol** 1996 Sep–Oct;14(5):479–83

Anti-monocyte cytoplasmic antibodies in granulomatous disease. Forde AM, et al. **Clin Immunol Immunopathol** 1996 Oct;81(1):88–95

Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Bansi DS, et al. **Eur J Gastroenterol Hepatol** 1996 Sep;8(9):881–5

Granulomatous gastritis in Wegener's disease: differentiation from Crohn's disease supported by a positive test for antineutrophil antibodies. Temmesfeld-Wollbrueck B, et al. **Gut** 1997 Apr;40(4):550–3

Diffuse alveolar hemorrhage associated with proteinase 3-specific anti-neutrophil cytoplasmic antibodies. Kikawada M, et al. **Intern Med** 1997 Jun;36(6):430–4

Are HLA-DR or TAP genes genetic markers of severity in ulcerative colitis? Heresbach D, et al. **J Autoimmun** 1996 Dec;9(6):777–84

Comparative evaluation of unfixed and fixed human neutrophils for determination of antineutrophil cytoplasmic antibodies by indirect immunofluorescence. Yang P. **J Clin Pathol** 1997 Aug;50(8):677–80

A simple high yield procedure for purification of human proteinase 3, the main molecular target of cANCA. Stummann L, et al. **J Immunol Methods** 1997 Aug 7; 206(1-2):35–42

Antineutrophil cytoplasmic antibodies: a missing link in the pathogenesis of periodontal disease? Novo E, et al. **J Periodontal Res** 1996 Jul;31(5):365–8

Atypical antineutrophil cytoplasmic antibodies sera do not react with MRP8/14 neutrophil cytosolic proteins [letter] Ivanov GE, et al. **J Rheumatol** 1997 May;24(5):1019–20

The prevalence of serum antineutrophil cytoplasmic autoantibodies in preeclampsia and eclampsia. Shaarawy M, et al. **J Soc Gynecol Investig** 1997 Jan–Feb;4(1):34–9

Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases. Claise C, et al. **Liver** 1996 Feb;16(1):28–34

Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Jayne DR, et al. **Mayo Clin Proc** 1997 Aug;72(8):737–47 (63 ref.)

Crescentic glomerulonephritis with antineutrophil cytoplasmic antibodies associated with chronic lymphocytic leukaemia. Dussol B, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):785–6

A child with panniculitis and microhaematuria/proteinuria--an unusual presentation of p-ANCA-positive vasculitis. Korzets Z, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):787–9

ANCA-positive rapidly progressive glomerulonephritis: there may be more to the diagnosis than you think! Messiaen T, et al. **Nephrol Dial Transplant** 1997 Apr; 12(4):839–41

Does the presence of ANCA in patients with ulcerative colitis necessarily imply renal involvement? Rosa M, et al. **Nephrol Dial Transplant** 1996 Dec;11(12):2426–9

ANCA-positive Churg-Strauss syndrome with renal failure. Rychlík I, et al. **Nephrol Dial Transplant** 1997 Apr; 12(4):837–8

Crescentic glomerulonephritis associated with p-ANCA positivity in fludarabine-treated chronic lymphocytic leukaemia. Tisler A, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2306–8

Renal transplantation in patients with microscopic polyarteritis and antimyeloperoxidase antibodies: report of three cases. Frasca GM, et al. **Nephron** 1996;72(1):82–5

Antineutrophil cytoplasmic antibodies and acute pancreatitis [letter] Berney T, et al. **Pancreas** 1997 Jul;15(1):106–7

Antineutrophil cytoplasm antibodies in patients with silicosis. Cojocaru M, et al. **Rom J Intern Med** 1996 Jul–Dec; 34(3-4):233–7

Recurrence of ANCA-associated microscopic polyangiitis after cadaveric renal transplant. Le Mao G, et al. **Transplant Proc** 1996 Oct;28(5):2803–4

[Role of perinuclear antibodies against cytoplasm of neutrophilic granulocytes (p-ANCA) in the diagnosis of vasculitis and chronic inflammatory diseases (letter; comment)] Oudkerk Pool M. **Ned Tijdschr Geneeskd** 1997 Jan 4;141(1):63-4. Comment on: Ned Tijdschr Geneeskd 1996 Oct 19;140(42):2076-82. **(Dut)**

[Microscopic polyangiitis with eosinophilia--an overlap syndrome or separate disease entity? A case report and review of the literature] Weninger W, et al. **Hautarzt** 1997 May;48(5):332-8 (48 ref.) (Eng. Abstr.) **(Ger)**

[Bactericidal permeability increasing protein (BPI-ANCA marked chronic inflammatory bowel diseases and hepatobiliary diseases] Schnabel A, et al. **Med Klin** 1997 Jul 15;92(7):389-93 (Eng. Abstr.) **(Ger)**

[A case of myeloperoxidase-specific antineutrophil cytoplasmic antibody (MPO-ANCA)-related glomerulonephritis associated with Cogan's syndrome] Suzuki M, et al. **Nippon Jinzo Gakkai Shi** 1996 Sep; 38(9):423-7 (Eng. Abstr.) **(Jpn)**

[Alveolar hemorrhage and glomerulonephritis in two patients with anti-neutrophil cytoplasmic antibodies] Takiguchi Y. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Mar; 35(3):334-40 (Eng. Abstr.) **(Jpn)**

[Antineutrophil cytoplasmic antibodies (ANCA): study of their presence in diseases not associated with arteritis] Novo E, et al. **Invest Clin** 1996 Jun;37(2):83-94 (Eng. Abstr.) **(Spa)**

[Antineutrophil cytoplasmic antibodies and nonspecific ulcerative colitis] Rojas G, et al. **Rev Med Chil** 1996 Apr; 124(4):449-55 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Meningeal involvement in Wegener's granulomatosis confirmed and monitored by positive circulating antineutrophil cytoplasm in cerebrospinal fluid. Spranger M, et al. **Neurology** 1997 Jan;48(1):263-5

GENETICS

Searching for the ulcerative colitis genes [editorial; comment] Bevins CL, et al. **Am J Gastroenterol** 1997 May;92(5):733-4 . Comment on: Am J Gastroenterol 1997 May;92(5):772-6.

IMMUNOLOGY

Polyarteritis nodosa and antiglomerular basement membrane disease without antineutrophil cytoplasm antibodies. Kirkland GS, et al. **Am J Nephrol** 1996;16(5):442-5

Complexed plasma elastase as an in vivo marker for leukocyte activation in antineutrophil cytoplasmic antibody-associated vasculitis. Haubitz M, et al. **Arthritis Rheum** 1997 Sep;40(9):1680-4

Incidence and disease associations of a proteinase 3-antineutrophil cytoplasmic antibody idiotype (5/7 Id) whose antiidiotype inhibits proteinase 3-antineutrophil cytoplasmic antibody antigen binding activity. Strunz HP, et al. **Arthritis Rheum** 1997 Jan;40(1):135-42

Spontaneous splenic rupture in c-ANCA positive vasculitis [letter] Hawley PH, et al. **Aust N Z J Med** 1996 Jun; 26(3):431-2

Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Martin SJ, et al. **Bone Marrow Transplant** 1997 Jul;20(1):45-8

Autoantibodies to neutrophil granule proteins: pathogenic potential in vasculitis? Locke IC, et al. **Br J Biomed Sci** 1996 Dec;53(4):302-16 (133 ref.)

Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis: non-histone chromosomal proteins, HMG1 and HMG2. Sobajima J, et al. **Clin Exp Immunol** 1997 Jan;107(1):135-40

Propylthiouracil-induced rapidly progressive glomerulonephritis associated with antineutrophil cytoplasmic autoantibodies. Kudoh Y, et al. **Clin Nephrol** 1997 Jul;48(1):41-3

Characterization of target antigens from anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis type-I. Kellner R, et al. **Electrophoresis** 1997 Mar-Apr; 18(3-4):507-10

Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis. Jenne DE, et al. **FEBS Lett** 1997 May 19;408(2):187-90

Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Zauli D, et al. **Hepatology** 1997 May; 25(5):1105-7

Myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibodies -- related scleroderma renal crisis treated with double-filtration plasmapheresis. Omote A, et al. **Intern Med** 1997 Jul;36(7):508-13

Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. Hogan SL, et al. **J Am Soc Nephrol** 1996 Jan;7(1):23-32

Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. Kettritz R, et al. **J Am Soc Nephrol** 1997 Mar;8(3):386-94

Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. Nachman PH, et al. **J Am Soc Nephrol** 1996 Jan;7(1):33-9

Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. Gilligan HM, et al. **J Exp Med** 1996 Dec 1;184(6):2231-41

Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1. Orth T, et al. **J Hepatol** 1997 Jan;26(1):37-47

A comprehensive method to purify three major ANCA antigens: proteinase 3, myeloperoxidase and bactericidal/permeability-increasing protein from human neutrophil granule acid extract. Zhao MH, et al. **J Immunol Methods** 1996 Oct 16;197(1-2):121-30

Antineutrophil cytoplasmic autoantibodies (ANCA) and systemic sclerosis. Carvajal I, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):576-7

Systemic vasculitis with antineutrophil cytoplasmic autoantibodies (ANCA) in three dental technicians. Grateau G, et al. **Nephrol Dial Transplant** 1997 Mar; 12(3):578-81

Lack of evidence of antineutrophil cytoplasmic antibodies involvement in the acute phase of thrombotic thrombocytopenic purpura. Italian Cooperative Group for TTP [letter] Porta C, et al. **Nephron** 1996;73(2):352-3

ANCA defines the clinical disease manifestations of vasculitis. The "con" side of the issue. Colby TV. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):227-9 (22 ref.)

A lung biopsy is unnecessary in the management of ANCA-positive patients with chest-roentgenographic abnormalities. Cordier JF. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):235-7 (17 ref.)

A renal biopsy in essential for the management of ANCA-positive patients with glomerulonephritis. Falk RJ, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct; 13(3):230-1 (13 ref.)

Gene structure of ANCA target antigens: implications for the pathogenesis of vasculitis. Jenne DE. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):209-13 (49 ref.)

A lung biopsy is necessary in the management of ANCA-positive patients with chest roentgenographic abnormalities. King TE Jr. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):238-40 (10 ref.)

Serial ANCA testing has limited value during the follow-up of disease activity in patients with ANCA-associated vasculitis. Lesavre P, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):246-8 (11 ref.)

A renal biopsy is essential for the management of ANCA-positive patients with glomerulonephritis: the contra-view. Niles JL. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):232-4 (10 ref.)

Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides. Tervaert JW, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct; 13(3):241-5 (40 ref.)

ANCA defines the clinical disease manifestations of vasculitis. Zhao MH, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):221-6 (59 ref.)

Target antigen for anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease [letter; comment] Stoffel MP, et al. **Scand J Gastroenterol** 1996 Sep;31(9):943-4. Comment on: Scand J Gastroenterol 1995 Jul;30(7):693-8.

Perinuclear antineutrophil cytoplasmic antibody in pouchitis after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Yang P, et al. **Scand J Gastroenterol** 1996 Jun;31(6):594-8

Aortitis, aortic valve incompetence, and left coronary ostium stenosis in a patient with C-ANCA-associated necrotizing vasculitis. Morshuis WJ, et al. **Thorac Cardiovasc Surg** 1997 Apr;45(2):97-9

[Rapidly progressive glomerulonephritis and ANCA--anti-GBM antibody] Nagase M. **Nippon Naika Gakkai Zasshi** 1997 Mar 10;86(3):501-5 (9 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Rheumatic disease: choosing the most useful diagnostic tests. Shmerling RH. **Geriatrics** 1996 Nov;51(11):22-6, 29-30, 32

[The role of perinuclear antineutrophil granulocytes cytoplasmic antibodies in the diagnosis of vasculitis and chronic inflammatory diseases (see comments)] Franssen CF, et al. **Ned Tijdschr Geneeskd** 1996 Oct 19; 140(42):2076-82 (66 ref.). Comment in: Ned Tijdschr Geneeskd 1997 Jan 4;141(1):63-4. **(Dut)**

METABOLISM

Genetic markers may predict disease behavior in patients with ulcerative colitis. Roussomoustakaki M, et al. **Gastroenterology** 1997 Jun;112(6):1845-53

ANCA small-vessel vasculitis. Falk RJ, et al. **J Am Soc Nephrol** 1997 Feb;8(2):314-22 (31 ref.)

Human renal tubular epithelial cells as target cells for antibodies to proteinase 3 (c-ANCA). Schwarting A, et al. **Nephrol Dial Transplant** 1997 May;12(5):916-23

Antineutrophil cytoplasmic antibodies (ANCA)-associated crescentic glomerulonephritis and propylthiouracil therapy. Yuasa S, et al. **Nephron** 1996;73(4):701-3

[Antineutrophil cytoplasmic antibodies in patients with rheumatoid arthritis: prevalence and clinical correlation (letter)] Clerig U, et al. **Med Clin (Barc)** 1997 Jan 18; 108(2):79 **(Spa)**

PHARMACOLOGY

IL-1 beta production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic autoantibodies: relevance to systemic vasculitis. Brooks CJ, et al. **Clin Exp Immunol** 1996 Nov;106(2):273-9

Anti-neutrophil cytoplasmic antibody-enriched IgG induces adhesion of human T lymphocytes to extracellular matrix proteins. Tomer Y, et al. **Clin Immunol Immunopathol** 1997 Jun;83(3):245-53

Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils. Gionchetti P, et al. **Gut** 1997 Jan;40(1):102-4

PHYSIOLOGY

Finding a valid model for antineutrophil cytoplasmic antibody-related vasculitis [letter; comment] Béliveau A, et al. **Arthritis Rheum** 1997 May;40(5):986-7. Comment on: Arthritis Rheum 1995 Oct;38(10):1375-81. Comment on: Arthritis Rheum 1996 Jul;39(7):1262-3.

The pathophysiology of anti-neutrophil cytoplasmic antibodies (ANCA) and their clinical relevance. Mayet WJ, et al. **Crit Rev Oncol Hematol** 1996 Jun;23(2):151-65 (132 ref.)

ANCA-positive vasculitis and alpha 1-antitrypsin deficiency: could free ANCA antigens released by neutrophils mediate vasculitic lesions? [editorial] Esnault VL. **Nephrol Dial Transplant** 1997 Feb;12(2):249-51

ANTIBODIES, ANTINUCLEAR

see related

COLLAGEN DISEASES

Antinucleolar autoantibody induced by mercuric chloride in mice: does sodium selenite inhibit autoantibody production? Saegusa J, et al. **Ind Health** 1996;34(2):139-42

Genetic and environmental issues in assessing the role of DNA antibodies--a summary of research presented at the DNA antibody workshop. Schwartz RS. **Lupus** 1997; 6(3):344-5

[The pathogenesis of neonatal lupus erythematosus and Ro52] Itoh Y. **Ryumachi** 1996 Dec;36(6):884-90 (35 ref.) **(Jpn)**

ANALYSIS

New variants of enzyme immunoassay of antibodies to DNA. Babkina SS, et al. **Anal Chem** 1996 Nov 1;68(21):3827-31

Clinical significance of antinuclear antibodies in systemic rheumatic diseases. Hietarinta M, et al. **Ann Med** 1996 Aug; 28(4):283-91 (84 ref.)

Antiperinuclear factors are present in polyarthritis before ACR criteria for rheumatoid arthritis are fulfilled [see comments] Berthelot JM, et al. **Ann Rheum Dis** 1997 Feb; 56(2):123-5. Comment in: Ann Rheum Dis 1997 Jun;56(6):395.

Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Emlen W, et al. **Arthritis Rheum** 1997 Sep;40(9):1612-8

Range of antinuclear antibodies in "healthy" individuals. Tan EM, et al. **Arthritis Rheum** 1997 Sep;40(9):1601-11

Indirect immunoperoxidase staining of Crithidia luciliae for detecting anti-dsDNA: comparison with other serodiagnostic tests. Mahakittikun V, et al. **Asian Pac J Allergy Immunol** 1997 Mar;15(1):35-40

Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor [see comments] Cordonnier C, et al. **Br J Rheumatol** 1996 Jul;35(7):620-4. Comment in: Br J Rheumatol 1997 Jun;36(6):710-2.

Anti-RNP antibody in a child with undifferentiated carcinoma and no evidence of mixed connective tissue disease. Foster HE, et al. **Br J Rheumatol** 1997 Feb; 36(2):289-91

Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay. Gniewek RA, et al. **Clin Diagn Lab Immunol** 1997 Mar; 4(2):185-8

Precise quantitation of antinuclear antibodies on HEp-2 cells without the need for serial dilution. Hollingsworth PN, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):374-7

Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Rutjes SA, et al. **Clin Exp Immunol** 1997 Jul;109(1):32-40

Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE). Spronk PE, et al. **Clin Exp Immunol** 1996 Jun;104(3):446-53

Benign monoclonal gammopathy with IgG anti-DNA, anti-Sm and anti-F(ab')2 activity. Williams RC Jr, et al. **Clin Exp Rheumatol** 1997 Jan-Feb;15(1):33-8

Follow-up of 151 patients with high-titer U1RNP antibodies. Frandsen PB, et al. **Clin Rheumatol** 1996 May;15(3):254-60

Undiagnosed polyarthritis with positive anti-Ro/SSA antibodies following a biliopancreatic bypass for morbid

obesity [letter] Zoli A, et al. **Clin Rheumatol** 1996 Sep; 15(5):514–5

Soluble interleukin-2 receptors and serum autoantibodies in dry eye patients: correlation with lacrimal gland function. Tsubota K, et al. **Cornea** 1997 May;16(3):339–44

Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives. Folwaczny C, et al. **Dig Dis Sci** 1997 Aug;42(8):1593–7

Antinuclear antibodies in patients with lichen planus. Carrizosa AM, et al. **Exp Dermatol** 1997 Feb;6(1):54–6

Clinical significance of different antinuclear antibodies patterns in the course of primary biliary cirrhosis. Remmel T, et al. **Hepatogastroenterology** 1996 Sep–Oct; 43(11):1135–40

The comparative study of anti-double stranded DNA antibody levels measured by radioimmunoassay and enzyme-linked immunosorbent assay in systemic lupus erythematosus. Takeuchi Y, et al. **J Dermatol** 1997 May; 24(5):297–300

Anti-Ro/SSA associated recurrent annular erythema: autoimmune response to recombinant 60- and 52-kDa Ro/SSA proteins. Miyagawa S, et al. **J Dermatol Sci** 1996 Jun;12(2):127–31

Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. Strassburg CP, et al. **J Hepatol** 1996 Dec; 25(6):859–66

Counterimmunoelectrophoresis with serum prediffusion: an improved method for the detection and identification of antibodies against extractable nuclear and cytoplasmic antigens. Walravens MJ, et al. **J Immunol Methods** 1997 Feb 14;201(1):89–98

Neonatal lupus erythematosus: HLA-DR and -DQ distributions are different among the groups of anti-Ro/SSA-positive mothers with different neonatal outcomes. Miyagawa S, et al. **J Invest Dermatol** 1997 Jun; 108(6):881–5

Antineutrophil cytoplasmic antibodies in synovial fluid and in serum of patients with rheumatoid arthritis and other types of synovitis. Afeltra A, et al. **J Rheumatol** 1996 Jan; 23(1):10–5

Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. Amigues JM, et al. **J Rheumatol** 1996 Dec; 23(12):2055–62

Benign hypergammaglobulinemic purpura and anti-Ro(SSA) antibodies in undifferentiated connective tissue disease. Caporali R, et al. **J Rheumatol** 1996 Feb;23(2):410–1

Coexistence of serum anti-DNA topoisomerase I and anti-Sm antibodies: report of 3 cases. Kameda H, et al. **J Rheumatol** 1997 Feb;24(2):400–3

Studies on associations of antinuclear antibodies with antibodies to an uveitogenic peptide of retinal S antigen in children with uveitis. Rosenberg AM, et al. **J Rheumatol** 1996 Feb;23(2):370–3

Anti-(DNA-histone) antibodies in active lupus nephritis. Suenaga R, et al. **J Rheumatol** 1996 Feb;23(2):279–84

Frequency and significance of antinuclear antibodies in multiple sclerosis. Collard RC, et al. **Neurology** 1997 Sep; 49(3):857–61

Rapid and sensitive detection of anti-Ro (SS-A) antibodies by indirect immunofluorescence of 60kDa Ro HEp-2 transfectants. Keech CL, et al. **Pathology** 1996 Jan; 28(1):54–7

Antiperinuclear factor in the diagnosis of juvenile rheumatoid arthritis. el-Gamal Y, et al. **Pediatr Allergy Immunol** 1995 Aug;6(3):165–9

Adult seronegative arthritis with antinuclear antibodies: a distinct group of patients with a different immunogenetic pattern from seropositive rheumatoid arthritis and a good outcome. Saudan-Kister A, et al. **Rev Rhum Engl Ed** 1996 May;63(5):313–20

Antinuclear antibody in systemic sclerosis (scleroderma). Okano Y. **Rheum Dis Clin North Am** 1996 Nov; 22(4):709–35 (138 ref.)

Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat. Waldhauser L, et al. **Toxicology** 1996 Dec 2;114(2):155–62

[Autoantibodies in bronchial asthma] Fujimori K, et al. **Arerugi** 1996 Jul;45(7):655–9 (Eng. Abstr.) **(Jpn)**

[Present status of molecular immunological diagnosis--special reference to antinuclear antibodies] Hashimoto H. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):597–601 (8 ref.) **(Jpn)**

[Rapidly progressing BOOP in a patient with positive anti-Jo-1 antibody: response to corticosteroid pulse and immunosuppressant therapy] Ikuta N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Oct; 34(10):1156–62 (Eng. Abstr.) **(Jpn)**

[Differential diagnosis of mitochondrial myopathy from dermatomyositis with various autoantibodies] Tegoshi H, et al. **Nippon Naika Gakkai Zasshi** 1996 Jul 10;85(7):1154–6 **(Jpn)**

[Clinical evaluation of immuno-serological laboratory data] Kasukawa R, et al. **Rinsho Byori** 1996 Dec;44(12):1157–63 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Two cases of lupus nephritis having a high titer of anti-(histone-DNA) complex antibody without IgG anti-dsDNA antibody] Mizushima N, et al. **Rinsho Byori** 1996 Jun;44(6):585–9 (Eng. Abstr.) **(Jpn)**

[A case report of typical scleroderma accompanied with serum abnormalities characteristic of SLE during the course] Nishiyama S, et al. **Ryumachi** 1997 Feb;37(1):24–9 (Eng. Abstr.) **(Jpn)**

[Allotransplantation of pancreatic islet cells and antinuclear antibodies] Galibin OV, et al. **Klin Lab Diagn** 1996 May-Jun;(3):27–9 (Eng. Abstr.) **(Rus)**

[Study of antibodies to DNA in patients with bilateral and unilateral endogenous uveitis] Bykovskaia GN, et al. **Vestn Oftalmol** 1997 Mar-Apr;113(2):30–2 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Testosterone suppresses anti-DNA antibody production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Kanda N, et al. **Arthritis Rheum** 1997 Sep;40(9):1703–11

Active immunization with anti-DNA autoantibody idiopeptide 88H.64–80 is nephritogenic in (NZB x NZW)F1 and Balb/c mice. Howe CA, et al. **Biochem Soc Trans** 1997 May;25(2):316S

Antibody reactivity profiles following immunization with diverse peptides of the PERB11 (MIC) family. Leelayuwat C, et al. **Clin Exp Immunol** 1996 Dec;106(3):568–76

Superantigens and experimental SLE induced by idiotypic dysregulation. Baharav E, et al. **Clin Exp Rheumatol** 1996 Jul-Aug;14(4):359–66

Interaction between certain major histocompatibility complex class II and T-cell receptor V beta alleles promotes the antibody production to extractable nuclear antigen-related peptides. Youinou P, et al. **Hum Immunol** 1997 Jan;52(1):12–21

Experimental expression in mice and spontaneous expression in human SLE of polyomavirus T-antigen. A molecular basis for induction of antibodies to DNA and eukaryotic transcription factors. Rekvig OP, et al. **J Clin Invest** 1997 Apr 15;99(8):2045–54

Expression of an anti-DNA-associated VH gene in immunized and autoimmune mice. Ash-Lerner A, et al. **J Immunol** 1997 Aug 1;159(3):1508–19

Treatment with dsDNA-anti-dsDNA antibody complexes extends survival, decreases anti-dsDNA antibody production and reduces severity of nephritis in MRLlpr mice. Burny W, et al. **Lupus** 1997;6(1):4–17

T helper cells driving pathogenic anti-DNA autoantibody production in lupus: nucleosomal epitopes and CD40 ligand signals. Datta SK, et al. **Lupus** 1997;6(3):333–6 (4 ref.)

Role of environmental antigen in triggering anti-DNA antibody production. Diamond B. **Lupus** 1997;6(3):326

Enhanced expression of nucleobindin in lymphatic organs of lupus-prone mice. Iizuka H, et al. **Lupus** 1997; 6(4):365–70

Analysis of B/W-DNA 16 V(H) gene expression following DNA-peptide immunization. Lerner J, et al. **Lupus** 1997; 6(3):328–9

Polyoma induced autoimmunity to DNA; experimental systems and clinical observations in human SLE. Rekvig O. **Lupus** 1997;6(3):325–6

Late development of anti-La/SS-B antibodies in a patient with Sjogren's syndrome and high titer anti-Ro/SS-A antibodies. Satoh M, et al. **Lupus** 1996 Aug;5(4):337–9

Expression of anti-DNA antibodies. Stevenson FK, et al. **Lupus** 1997;6(3):321–3 (7 ref.)

Bacterial expression of anti-DNA antibody domains. Stollar BD. **Methods** 1997 Jan;11(1):12–9

Induction of anti-polycation antibodies in H-2s mice by immunization with nuclear antigens. Monestier M, et al. **Mol Immunol** 1997 Jan;34(1):39–51

Transplantation of systemic sclerosis (SSc) skin grafts into severe combined immunodeficient mice: increased presence of SSc leukocytes in SSc skin grafts and autoantibody production following autologous leukocyte transfer. Kräling BM, et al. **Pathobiology** 1996;64(2):99–114

Inheritance of serum autoantibody, reduced serum IgA and autoimmune disease in a canine breeding colony. Day MJ. **Vet Immunol Immunopathol** 1996 Oct;53(3-4):207–19

[The mechanism of autoantibody production in systemic autoimmune diseases] Misaki Y, et al. **Nippon Rinsho** 1997 Jun;55(6):1468–74 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Specific inhibition of anti-DNA antibody production by an anti-DH ribozyme] Suzuki Y, et al. **Nippon Rinsho** 1997 Jun;55(6):1557–61 (18 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Anti-single-stranded DNA antibody in the sera of patients with type 2 diabetes mellitus. Relation to vascular complications. Giardina E, et al. **Acta Diabetol** 1997 Mar; 34(1):39–41

Positivity for antinuclear antibody in patients with advanced rheumatoid arthritis. Nishimura S, et al. **Acta Med Okayama** 1996 Oct;50(5):261–5

Antibodies against retroviral proteins and nuclear antigens in a subset of idiopathic CD4+ T lymphocytopenia patients. Garry RF, et al. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):931–40

HLA association and occurrence of autoantibodies in Asian-Indian patients with ulcerative colitis [see comments] Habeeb MA, et al. **Am J Gastroenterol** 1997 May; 92(5):772–6. Comment in: Am J Gastroenterol 1997 May;92(5):733–4.

Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Spencer-Green G, et al. **Am J Med** 1997 Sep;103(3):242–8 (52 ref.)

Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Verrot D, et al. **Am J Med** 1997 Jul;103(1):33–7

Antiperinuclear factors are present in polyarthritis before ACR criteria for rheumatoid arthritis are fulfilled [letter; comment] Boerbooms AM. **Ann Rheum Dis** 1997 Jun; 56(6):395. Comment on: Ann Rheum Dis 1997 Feb;56(2):123–5.

Antinuclear antibody determination in a routine laboratory. Feltkamp TE. **Ann Rheum Dis** 1996 Oct;55(10):723–7

Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. Smolen JS, et al. **Arthritis Rheum** 1997 Mar;40(3):413–8

The prevalence of antinuclear, anti-dsDNA, anti-Sm and anti-RNP antibodies in a group of healthy blood donors. Azizah MR, et al. **Asian Pac J Allergy Immunol** 1996 Dec; 14(2):125–8

Childhood scleroderma-polymyositis: report of a case with the anti-PM/Scl antibody and mechanic's hands. García-Patos V, et al. **Br J Dermatol** 1996 Oct;135(4):613–6

Effective treatment of anti Jo-1 antibody-positive polymyositis with cyclosporin [letter; comment] Dawson JK, et al. **Br J Rheumatol** 1997 Jan;36(1):144–5. Comment on: Br J Rheumatol 1995 Dec;34(12):1187–8.

Antinuclear and antinucleolar antibodies in patients with scleroderma-polymyositis overlap syndrome [letter] Hietarinta M, et al. **Br J Rheumatol** 1996 Dec;35(12):1326–7

Antiperinuclear factor in early synovitis [letter; comment] Muñoz S, et al. **Br J Rheumatol** 1997 Jun;36(6):710–2. Comment on: Br J Rheumatol 1996 Jul;35(7):620–4.

Arthralgias, myalgias, facial erythema, and a positive ANA: not necessarily SLE. Alarcón GS. **Cleve Clin J Med** 1997 Jul-Aug;64(7):361–4

Anti-U5 small nuclear ribonucleoprotein (snRNP) antibodies: a rare anti-U snRNP specificity. Okano Y, et al. **Clin Immunol Immunopathol** 1996 Oct;81(1):41–7

Severe combined immunodeficiency with oligoclonal hypergammaglobulinemia and high positive ANA. Hostoffer R, et al. **Clin Pediatr (Phila)** 1996 Jan;35(1):43–6

Clinical setting of patients with systemic sclerosis by serum autoantibodies. Picillo U, et al. **Clin Rheumatol** 1997 Jun; 16(4):378–83

Gamma delta T cell help of B cells is induced by repeated parasitic infection, in the absence of other T cells. Pao W, et al. **Curr Biol** 1996 Oct 1;6(10):1317–25

Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Czaja AJ, et al. **Dig Dis Sci** 1997 Aug;42(8):1688–96

Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Czaja AJ, et al. **Hepatology** 1997 Sep;26(3):567–72

Immunoglobulin E and autoantibodies in mercury-exposed workers. Dantas DC, et al. **Immunopharmacol Immunotoxicol** 1997 Aug;19(3):383–92

High-affinity anti-DNA antibody parallels clinical course of immunoadsorption therapy for systemic lupus erythematosus. Funauchi M, et al. **Intern Med** 1996 May; 35(5):367–72

Anti-Hu antibody in a patient with Lambert-Eaton myasthenic syndrome and early detection of small cell lung cancer. Tomiyasu K, et al. **Intern Med** 1995 Nov; 34(11):1082–5

Photosensitivity and antinuclear antibodies in black patients with systemic lupus erythematosus. Smikle MF, et al. **J Assoc Acad Minor Phys** 1996;7(2):53–5

Production of anti-Ro/SS-A and anti-La/SS-B autoantibodies is closely coordinated in systemic lupus erythematosus and independent of anti-dsDNA production. Meilof JF, et al. **J Autoimmun** 1997 Feb; 10(1):67–75

Anti-dsDNA antibody kinetics during in vivo apheresis in systemic lupus erythematosus patients and in an in vitro apheresis model. Suzuki K, et al. **J Clin Apheresis** 1996; 11(4):211–6

Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. Konstantinov K, et al. **J Clin Invest** 1996 Oct 15;98(8):1888–96

SS-A/Ro antibodies in Chinese patients with systemic lupus erythematosus and Sjögren's syndrome. Tsay GJ, et al. **J Formos Med Assoc** 1996 Dec;95(12):905–10

Diversity of antinuclear antibody responses in hepatocellular carcinoma. Covini G, et al. **J Hepatol** 1997 Jun; 26(6):1255–65

Transient positivity of antinuclear and anti-smooth muscle antibodies in hepatitis A virus infection [letter] Gutiérrez A, et al. **J Hepatol** 1996 Jan;24(1):123

Clinical significance of the antinuclear antibody test in selected children with idiopathic thrombocytopenic purpura. Zimmerman SA, et al. **J Pediatr Hematol Oncol** 1997 Jul-Aug;19(4):297–303

Antineutrophil cytoplasmic antibodies in synovial fluid and in serum of patients with rheumatoid arthritis and other types of synovitis. Afeltra A, et al. **J Rheumatol** 1996 Jan; 23(1):10–5

Antinuclear antibody positivity in pediatric patients with autoimmune thyroid disease. Inamo Y, et al. **J Rheumatol** 1997 Mar;24(3):576–8

Anti-T cell receptor antibody treatment of mice with lupus-like graft versus host disease: suppression of

glomerulonephritis without reduction in anti-DNA antibody levels. Maeda T, et al. **J Rheumatol** 1995 Dec; 22(12):2259–65

Detection of antinuclear antibodies by indirect immunofluorescence in dog sera: comparison of rat liver tissue and human epithelial-2 cells as antigenic substrate. Hansson H, et al. **J Vet Intern Med** 1996 Jul–Aug; 10(4):199–203

Clinical connections: assays and assignment. Bell DA, et al. **Lupus** 1997;6(3):305–6 (15 ref.)

Immunologically restricted and inhibitory anti-Ro/SSA in monozygotic twins. Scofield RH, et al. **Lupus** 1997; 6(4):395–8

Stability of immunoblot profile of anti-SSA/Ro-SSB/La antibodies over time in mothers whose children have neonatal lupus. Tseng CE, et al. **Lupus** 1996 Jun;5(3):212–5

A cross-sectional study of anti-DNA antibodies in the serum and IgG and IgM fraction of healthy individuals, patients with systemic lupus erythematosus and their relatives. Williams WM, et al. **Lupus** 1996 Dec;5(6):576–86

Analysis and significance of anti-nuclear antibodies in dogs. Bell SC, et al. **Res Vet Sci** 1997 Jan–Feb;62(1):83–4

IgG subclasses of canine anti-erythrocyte, antinuclear and anti-thyroglobulin autoantibodies. Day MJ. **Res Vet Sci** 1996 Sep;61(2):129–35

The frequency of autoantibodies in Turkish patients with lupus nephritis. Düzgün N, et al. **Rheumatol Int** 1997; 17(1):1–4

Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Noda K, et al. **Scand J Gastroenterol** 1996 Jul;31(7):716–22

Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. Bootsma H, et al. **Scand J Rheumatol** 1996;25(6):352–9

Antineutrophil nuclear antibodies (ANNA) in primary biliary cirrhosis: their prevalence and antigen specificity. Orth T, et al. **Z Gastroenterol** 1997 Feb;35(2):113–21

[Detection of dsDNA antibodies in diagnosis of systemic lupus erythematosus--comparative studies of diagnostic effectiveness of 3 ELISA methods with different antigens and a Crithidia luciliae immunofluorescence test] Wigand R, et al. **Z Rheumatol** 1997 Mar–Apr;56(2):53–62 (Eng. Abstr.) **(Ger)**

[A comparative study of the ELISA and IF methods for antinuclear antibody test] Shiba N, et al. **Rinsho Byori** 1997 Feb;45(2):175–8 (Eng. Abstr.) **(Jpn)**

[Non-specific elevation of anti-dsDNA antibody measured by Farr method found in a patient with liver cirrhosis] Takamura T, et al. **Rinsho Byori** 1996 Sep;44(9):903–7 (Eng. Abstr.) **(Jpn)**

[Decreased incidence of peripheral nuclear staining pattern by indirect immunofluorescent antibody technique using HEp-2 cells] Miyawaki S, et al. **Ryumachi** 1996 Aug; 36(4):644–50 (Eng. Abstr.) **(Jpn)**

[Study of the interaction of DNA-hydrolyzing autoantibodies from serum of patients with lymphoproliferative disorders with oligodeoxyribonucleotides using an affinity sorption method] Aleksandrova ES. **Mol Biol (Mosk)** 1996 Jul–Aug; 30(4):921–6 **(Rus)**

[Antinuclear antibodies in multiple sclerosis] Antigüedad A, et al. **Neurologia** 1997 Jun–Jul;12(6):245–8 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Comparison of structural characteristics of antisubnucleosome and anti-DNA monoclonal antibodies derived from lupus mice. Koutouzov S, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:327–30

Restricted heterogeneity and changing spectrotypes in autoantibodies to La/SS-B. Satoh M, et al. **Autoimmunity** 1996;24(4):229–36

Framework and CDR structures of anti-DNA antibodies are implicated in antigen binding. Ward FJ, et al. **Biochem Soc Trans** 1997 May;25(2):310S

Cytoplasmic detection of a novel protein containing a nuclear localization sequence by human autoantibodies. Garcia-Lozano JR, et al. **Clin Exp Immunol** 1997 Mar; 107(3):501–6

Mimotopes of polyreactive anti-DNA antibodies identified using phage-display peptide libraries. Sibille P, et al. **Eur J Immunol** 1997 May;27(5):1221–8

Antigen specificity of anti-nuclear antibodies complexed to nucleosomes determines glomerular basement membrane binding in vivo. van Bruggen MC, et al. **Eur J Immunol** 1997 Jun;27(6):1564–9

Anti-DNA antibodies: from gene usage to crystal structures. Isenberg D, et al. **Immunol Today** 1997 Apr;18(4):149–53

Is structural flexibility of antigen-binding loops involved in the affinity maturation of anti-DNA antibodies? Miyazaki S, et al. **Int Immunol** 1997 May;9(5):771–7

Immuno-capillary electrophoresis for the characterization of a monoclonal antibody against DNA. Heegaard NH, et al. **J Chromatogr A** 1996 Sep 13;744(1-2):285–94

Structural analysis of anti-DNA antibodies. Kalsi JK, et al. **Lupus** 1997;6(3):317–20

An overview of the anti-DNA antibody workshop: expansion of molecular structural analysis. Stollar BD. **Lupus** 1997;6(3):346–8

Structural features of nephritogenic lupus autoantibodies. Vargas MT, et al. **Methods** 1997 Jan;11(1):62–9

The structure of human lupus anti-DNA antibodies. Zouali M. **Methods** 1997 Jan;11(1):27–35

CLASSIFICATION

Analysis of IgG subclasses of human antitopoisomerase I autoantibodies suggests chronic B cell stimulation. Vázquez-Abad D, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):65–72

DIAGNOSTIC USE

Antiperinuclear factor: a useful test for the diagnosis of rheumatoid arthritis. Muñoz-Fernández S, et al. **Rheumatol Int** 1995;15(4):145–9

GENETICS

Use of phage expression to analyze regions of a human V4-34(VH4-21)-encoded IgG autoantibody required for recognition of DNA. No involvement of the 9G4 idiotope. Mockridge I, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:338–41

Expression of a human fetal anti-DNA antibody idiotype BEG-2 beta in the families of patients with rheumatoid arthritis. Ravirajan CT, et al. **Autoimmunity** 1995; 21(4):269–75

Molecular cloning of anti-SS-A/Ro 60-kDa peptide Fab fragments from infiltrating salivary gland lymphocytes of a patient with Sjögren's syndrome. Suzuki H, et al. **Biochem Biophys Res Commun** 1997 Mar 6;232(1):101–6

A human monoclonal antiendothelial cell autoantibody uses a VH gene associated with an anti-DNA autoantibody. Yazici ZA, et al. **Biochem Soc Trans** 1997 May;25(2):321S

Editing disease-associated autoantibodies. Chen C, et al. **Immunity** 1997 Jan;6(1):97–105

Anti-DNA antibodies: from gene usage to crystal structures. Isenberg D, et al. **Immunol Today** 1997 Apr;18(4):149–53

Characterization of a germline Vk gene encoding cationic anti-DNA antibody and role of receptor editing for development of the autoantibody in patients with systemic lupus erythematosus. Suzuki N, et al. **J Clin Invest** 1996 Oct 15;98(8):1843–50

Expression of an anti-DNA-associated VH gene in immunized and autoimmune mice. Ash-Lerner A, et al. **J Immunol** 1997 Aug 1;159(3):1508–19

Use of phage surface expression to analyze regions of human V4-34(VH4-21)-encoded IgG autoantibody required for recognition of DNA: no involvement of the 9G4 idiotope. Mockridge CI, et al. **J Immunol** 1996 Sep 15;157(6):2449–54

Molecular properties of anti-DNA induced in preautoimmune NZB/W mice by immunization with bacterial DNA. Wloch MK, et al. **J Immunol** 1997 May 1;158(9):4500–6

Lack of linkage between anti-nuclear antibody or clinical features of systemic lupus erythematosus (SLE) and TCR-A/Vbeta loci in families of subjects with SLE. Huang Q, et al. **Lupus** 1997;6(6):527–32

Genetic control of DNA antibody production: focus on the heavy chain. Tsao B, et al. **Lupus** 1997;6(3):310–4 (21 ref.)

Sequences of monoclonal antiphospholipid antibodies: variations on an anti-DNA antibody theme. Rahman A, et al. **Semin Arthritis Rheum** 1996 Oct;26(2):515–25 (40 ref.)

Inheritance of serum autoantibody, reduced serum IgA and autoimmune disease in a canine breeding colony. Day MJ. **Vet Immunol Immunopathol** 1996 Oct;53(3–4):207–19

[V gene repertoire and pathogenic autoantibodies] Hirabayashi Y, et al. **Nippon Rinsho** 1997 Jun;55(6):1455–61 (20 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Antinucleosome antibodies and systemic lupus erythematosus. Amoura Z, et al. **Adv Nephrol Necker Hosp** 1997;26:303–16 (66 ref.)

Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease. Douvas A, et al. **AIDS Res Hum Retroviruses** 1996 Nov 1;12(16):1509–17

Sperm, nuclear, phospholipid, and red blood cell antibodies and isotype RF in infertile couples and patients with autoimmune rheumatic diseases. Fichorova R, et al. **Am J Reprod Immunol** 1996 Dec;36(6):309–16

Neutrophils and anti-Ro/SSA. Kurien BT, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:481–3

Common occurrence of an antiidiotypic antibody that recognizes T14+ anti-DNA antibodies in patients with systemic lupus erythematosus. Lim PL, et al. **Arthritis Rheum** 1996 Dec;39(12):1980–9

SLE autoantibodies recognize spermine induced Z-conformation of native calf thymus DNA. Ali M, et al. **Biochem Mol Biol Int** 1996 Nov;40(4):787–97

Antigen binding specificity of antibodies against 8-methoxypsoralen photoadducted DNA. Arif Z, et al. **Biochem Mol Biol Int** 1996 Apr;38(5):1067–77

Anti-DNA autoantibodies: the other DNA-binding proteins. Bill RM, et al. **Bioorg Med Chem** 1997 Mar;5(3):467–72 (58 ref.)

Extraction of DNA using monoclonal anti-DNA and magnetic beads. Gelsthorpe AR, et al. **Biotechniques** 1997 Jun;22(6):1080–2

Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor [see comments] Cordonnier C, et al. **Br J Rheumatol** 1996 Jul;35(7):620–4. Comment in: Br J Rheumatol 1997 Jun;36(6):710–2.

Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Spronk PE, et al. **Br J Rheumatol** 1996 Jul; 35(7):625–31

Anti-Ro fine specificity defined by multiple antigenic peptides identifies components of tertiary epitopes. Scofield RH, et al. **Clin Exp Immunol** 1997 Sep;109(3):480–7

Autoantibodies to double-stranded (ds)DNA immunoprecipitate 18S ribosomal RNA by virtue of their interaction with ribosomal protein S1 and suppress in vitro protein synthesis. Tsuzaka K, et al. **Clin Exp Immunol** 1996 Dec;106(3):504–8

Upregulation of adhesion molecule expression on endothelial cells by anti-DNA autoantibodies in systemic lupus erythematosus. Lai KN, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):229–38

Spontaneously produced anti-DNA/DNase I autoantibodies modulate nuclear apoptosis in living cells. Madaio MP, et al. **Eur J Immunol** 1996 Dec;26(12):3035–41

Autoantibody-associated sensory neuronopathy and intestinal pseudo-obstruction without detectable neoplasia. Briellmann RS, et al. **Eur Neurol** 1996;36(6):369–73 (26 ref.)

Immune activation by bacterial DNA: a new genetic code. Pisetsky DS. **Immunity** 1996 Oct;5(4):303–10 (70 ref.)

Reactive oxygen species modified thymine and poly(dT) present unique epitope for human anti-DNA autoantibodies. Ahmad J, et al. **Immunol Lett** 1997 Jul; 58(2):69–74

Immunoglobulin E and autoantibodies in mercury-exposed workers. Dantas DC, et al. **Immunopharmacol Immunotoxicol** 1997 Aug;19(3):383–92

Recent developments in the understanding of antinuclear autoantibodies. Casiano CA, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):308–13 (33 ref.)

Murine silver-induced autoimmunity: silver shares induction of antinucleolar antibodies with mercury, but causes less activation of the immune system. Johansson U, et al. **Int Arch Allergy Immunol** 1997 Aug;113(4):432–43

Presence and persistence of serum anti-benzo[a]pyrene diolepoxide-DNA adduct antibodies in smokers: effects of smoking reduction and cessation. Pulerà N, et al. **Int J Cancer** 1997 Jan 17;70(2):145–9

Murine genotype influences the specificity, magnitude and persistence of murine mercury-induced autoimmunity. Hultman P, et al. **J Autoimmun** 1996 Apr;9(2):139–49

Specificity of monoclonal anti-nucleosome auto-antibodies derived from lupus mice. Kramers K, et al. **J Autoimmun** 1996 Dec;9(6):723–9

Accessibility of epitopes on the 52-kD Ro/SSA protein (Ro52) and on the RoRNP associated Ro52 protein as determined by anti-peptide antibodies. Ricchiuti V, et al. **J Autoimmun** 1997 Apr;10(2):181–91

Repertoire cloning of lupus anti-DNA autoantibodies. Roben P, et al. **J Clin Invest** 1996 Dec 15;98(12):2827–37

Characterization of autoantibody activities in sera anti-DNA antibody and circulating immune complexes from 12 systemic lupus erythematosus patients. Adyel FZ, et al. **J Clin Lab Anal** 1996;10(6):451–7

Correlation between the amino acid position of arginine in VH-CDR3 and specificity for native DNA among autoimmune antibodies. Krishnan MR, et al. **J Immunol** 1996 Sep 15;157(6):2430–9

Characterization of anti-single-stranded DNA B cells in a non-autoimmune background. Nguyen KA, et al. **J Immunol** 1997 Sep 15;159(6):2633–44

DNA-binding antibodies from viable motheaten mutant mice: implications for B cell tolerance. Westhoff CM, et al. **J Immunol** 1997 Sep 15;159(6):3024–33

Anti-52 kDa Ro(SSA) autoantibodies in different autoimmune diseases preferentially recognize epitopes on the central region of the antigen. Dorner T, et al. **J Rheumatol** 1996 Mar;23(3):462–8

Antinuclear antibodies in children with localized scleroderma. Rosenberg AM, et al. **J Rheumatol** 1995 Dec; 22(12):2337–43

Treatment with dsDNA-anti-dsDNA antibody complexes extends survival, decreases anti-dsDNA antibody production and reduces severity of nephritis in MRLlpr mice. Burny W, et al. **Lupus** 1997;6(1):4–17

DNA antibodies focus on the light chain. Diamond B, et al. **Lupus** 1997;6(3):315–6 (2 ref.)

T and B cell recognition of idiotypes of anti-DNA autoantibodies. Gavalchin J, et al. **Lupus** 1997;6(3):337–43 (52 ref.)

Peptides from Vh regions of antibodies to DNA activate T cell help to upregulate autoantibody synthesis. Hahn BH, et al. **Lupus** 1997;6(3):330–2

Congenital heart block and subsequent connective tissue disorder in adolescence. Hubscher O, et al. **Lupus** 1997; 6(3):283–4

The role of antibodies to DNA in systemic lupus erythematosus--a review and introduction to an international workshop on DNA antibodies held in London, May 1996. Isenberg DA, et al. **Lupus** 1997; 6(3):290–304 (146 ref.)

Ethnic differences in the clinical expression of systemic lupus erythematosus: a comparative study between African-Americans and Latin Americans. Molina JF, et al. **Lupus** 1997;6(1):63–7

ANTIBODIES, ANTINUCLEAR

Are DNA antibodies actually pathogenic? Naparstek Y, et al. **Lupus** 1997;6(3):307–9 (8 ref.)
Why the difference between B–DNA and Z–DNA? Stollar BD. **Lupus** 1997;6(3):327–8
The existence of antibodies specific for DNA in systemic autoimmune diseases [editorial] Marion TN. **Methods** 1997 Jan;11(1):1–2
Monoclonal anti–DNA antibodies: structure, specificity, and biology. Marion TN, et al. **Methods** 1997 Jan;11(1):3–11
Specificity and immunochemical properties of antibodies to bacterial DNA. Pisetsky DS. **Methods** 1997 Jan;11(1):55–61
Selection of recurrent V genes and somatic mutations in autoantibodies to DNA. Radic MZ, et al. **Methods** 1997 Jan;11(1):20–6
Human polyomavirus BK and immunogenicity of mammalian DNA: a conceptual framework. Rekvig OP, et al. **Methods** 1997 Jan;11(1):44–54
Studies on the structure, regulation, and pathogenic potential of anti–dsDNA antibodies. Spatz L, et al. **Methods** 1997 Jan;11(1):70–8
Autoantibody to the nucleosome subunit (H2A–H2B)–DNA is an early and ubiquitous feature of lupus–like conditions. Burlingame RW, et al. **Mol Biol Rep** 1996;23(3–4):159–66 (46 ref.)
Antinuclear autoantibodies: probes for defining proteolytic events associated with apoptosis. Casiano CA, et al. **Mol Biol Rep** 1996;23(3–4):211–6 (44 ref.)
Clinical relevance of autoantibodies in systemic rheumatic diseases. Fritzler MJ. **Mol Biol Rep** 1996;23(3–4):133–45 (204 ref.)
What triggers anti–dsDNA antibodies? Herrmann M, et al. **Mol Biol Rep** 1996;23(3–4):265–7 (12 ref.)
Epitope analysis of chromo antigen and clinical features in a subset of patients with anti–centromere antibodies. Muro Y, et al. **Mol Biol Rep** 1996;23(3–4):147–51
Anterior ischemic optic neuropathy in a patient with positive antinuclear antibody and lupus anticoagulant findings. Togashi M, et al. **Ophthalmologica** 1996;210(2):132–5
The diverse pathogenic potential of anti–DNA antibodies from various sources to induce experimental systemic lupus erythematosus. Swissa M, et al. **Pathobiology** 1996; 64(1):32–9
Peptide inhibition of glomerular deposition of an anti–DNA antibody. Gaynor B, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1955–60
Cross–reactivity of anti–nDNA antibodies with nuclear envelope proteins. Isolation of a cDNA encoding the 70 kDa annular protein recognized by autoantibodies from patients with systemic lupus erythematosus. Herrera–Diosdado R, et al. **Rev Rhum Engl Ed** 1997 Feb; 64(2):82–8
[Augmentation of DNA breaks by anti–dsDNA antibody] Kubota T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):605–8 **(Jpn)**
[Analysis of B cell autoepitopes and mechanisms for autoantibody production in autoimmune diseases] Kato T. **Nippon Rinsho** 1997 Jun;55(6):1462–7 (17 ref.) (Eng. Abstr.) **(Jpn)**
[DNA–hydrolyzing antibodies in lymphoproliferative disorders] Kozyr' AV, et al. **Biull Eksp Biol Med** 1996 Feb;121(2):204–6 **(Rus)**
[Properties of free and hidden natural antibodies, reacting with DNA and cardiolipin] Lekakh IV, et al. **Mol Biol (Mosk)** 1997 Jan–Feb;31(1):176–9 **(Rus)**
[Clinico serological discordance in patients with systemic lupus (letter)] Cagnoli P, et al. **Medicina (B Aires)** 1996; 56(2):206–7 **(Spa)**

ISOLATION & PURIFICATION

[Coexistence of virus C and antinuclear antibodies in chronic active hepatitis: diagnostic and therapeutic implications] Pirotte J. **Rev Med Liege** 1996 Sep;51(9):586–9 **(Fre)**

METABOLISM

Affinity columns containing anti–DNA Id+ human myeloma proteins adsorb human epibodies from intravenous gamma globulin. Williams RC Jr, et al. **Arthritis Rheum** 1997 Apr; 40(4):683–93
Human anti–Ro autoantibodies bind multiple conformational epitopes of 60–kD Ro autoantigen. Huang SC, et al. **J Clin Immunol** 1997 May;17(3):212–9
Receptor–mediated cellular entry of nuclear localizing anti–DNA antibodies via myosin 1. Yanase K, et al. **J Clin Invest** 1997 Jul 1;100(1):25–31
Mechanisms of cellular penetration and nuclear localization of an anti–double strand DNA autoantibody. Zack DJ, et al. **J Immunol** 1996 Sep 1;157(5):2082–8
Reduction in circulating dsDNA antibody titer after administration of LJP 394. Weisman MH, et al. **J Rheumatol** 1997 Feb;24(2):314–8
The nuclear compartment of living cells is not an absolute immunologically sequestered site: evidence for spontaneous intranuclear entry of lupus autoantibodies to living cells. Golan TD. **Leukemia** 1997 Jan;11(1):6–9 (52 ref.)

PHARMACOLOGY

Autoantibodies to double–stranded (ds)DNA immunoprecipitate 18S ribosomal RNA by virtue of their interaction with ribosomal protein S1 and suppress in vitro protein synthesis. Tsuzaka K, et al. **Clin Exp Immunol** 1996 Dec;106(3):504–8
Upregulation of adhesion molecule expression on endothelial cells by anti–DNA autoantibodies in systemic lupus erythematosus. Lai KN, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):229–38
Spontaneously produced anti–DNA/DNase I autoantibodies modulate nuclear apoptosis in living cells. Madaio MP, et al. **Eur J Immunol** 1996 Dec;26(12):3035–41
Effect of nucleic acid reactive antibodies on tumor cells grown in vivo. Kala KC, et al. **Immunol Invest** 1996 Jul; 25(4):321–31
Anticardiolipin, but not the 16/6 Id anti–DNA antibody induces pregnancy failure. Sthoeger ZM, et al. **Immunol Lett** 1996 Jan;49(1–2):117–22

PHYSIOLOGY

Autoimmunity against nucleosomes and lupus nephritis. Van Bruggen MC, et al. **Ann Med Interne (Paris)** 1996; 147(7):485–9 (61 ref.)
The penetrating potential of autoantibodies into live cells in vitro coincides with the in vivo staining of epidermal nuclei. Golan TD, et al. **Lupus** 1997;6(1):18–26

TOXICITY

The diverse pathogenic potential of anti–DNA antibodies from various sources to induce experimental systemic lupus erythematosus. Swissa M, et al. **Pathobiology** 1996; 64(1):32–9

ANTIBODIES, ANTIPHOSPHOLIPID

see related
ANTIPHOSPHOLIPID SYNDROME

Recurrent identical rearrangement and repeated expression of identical heavy and light chains in single anti–phosphatidylcholine B cells. Seidl KJ, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:484–8
The Italian Registry of Antiphospholipid Antibodies. Finazzi G. **Haematologica** 1997 Jan–Feb;82(1):101–5 (25 ref.)
Intracardiac thrombi associated with antiphospholipid antibodies. Plein D, et al. **J Am Soc Echocardiogr** 1996 Nov–Dec;9(6):891–3
New Orleans 7th International Symposium on Antiphospholipid Antibodies. Proceedings and abstracts. **Lupus** 1996 Oct;5(5):343–558
Antiphospholipid antibody associated thrombosis: a consensus for treatment? McCrae KR. **Lupus** 1996 Dec; 5(6):560–70 (39 ref.)
Protein C resistance and antiphospholipid antibodies [letter; comment] Ruiz–Argüelles GJ. **Lupus** 1996 Dec;5(6):633. Comment on: Lupus 1996 Apr;5(2):163–6.
Nitrite and nitrate plasma levels, as markers of nitric oxide synthesis, in antiphospholipid antibodies–related conditions and in thrombotic thrombocytopenic purpura [letter] Porta C, et al. **Thromb Haemost** 1997 Aug;78(2):965–7
[Antiphospholipid antibodies and antiphospholipid syndrome and their relation with preqnancy–induced hypertension] Zhang X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Aug;31(8):506–7 (10 ref.) **(Chi)**
[Antiphospholipid syndrome: a syndrome with re–recognition (editorial)] Dong Y. **Chung Hua Nei Ko Tsa Chih** 1996 Jan;35(1):7–8 **(Chi)**

ADVERSE EFFECTS

Efficacy of low dose prednisone plus aspirin in preventing spontaneous abortions and/or fetal deaths due to antiphospholipid antibodies: results of a pilot study [letter] Mazzucconi MG, et al. **Autoimmunity** 1996;24(2):123–5
Stroke and pregnancy [letter] Brown AJ. **N Engl J Med** 1997 Feb 27;336(9):665

ANALYSIS

Antiphospholipid antibodies in children. Kontiainen S, et al. **Acta Paediatr** 1996 May;85(5):614–5
Patients with antiphospholipid antibodies: CT and MR findings of the brain. Provenzale JM, et al. **AJR Am J Roentgenol** 1996 Dec;167(6):1573–8
Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies. Laroche P, et al. **Am J Clin Pathol** 1996 Oct; 106(4):549–54
Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: a report of two cases. Trent K, et al. **Am J Hematol** 1997 Feb;54(2):155–9 (31 ref.)
Antiphospholipid antibodies in patients with preeclampsia. Allen JY, et al. **Am J Reprod Immunol** 1996 Aug;36(2):81–5
Phospholipid binding plasma proteins required for antiphospholipid antibody detection—an overview. McIntyre JA, et al. **Am J Reprod Immunol** 1997 Jan; 37(1):101–10 (86 ref.)
The clinical significance of antiphospholipid antibodies. Martini A, et al. **Ann Med** 1997 Apr;29(2):159–63
Different target specificities of phospholipid–dependent antibodies. Amiral J, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:18–21
Frequent difficulties encountered in the laboratory diagnosis of antiphospholipid–protein antibodies. Triplett DA. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:5–9 (29 ref.)
Antiphospholipid antibodies and the antiphospholipid syndrome. Clinical relevance in neuropsychiatric systemic lupus erythematosus. Alarcón–Segovia D, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:279–88
Antiphospholipid antibodies and cerebral lupus. Harris EN, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:270–8 (53 ref.)
Antiphospholipid antibodies: new complexities and new assays [editorial; comment] Emlen W. **Arthritis Rheum** 1996 Sep;39(9):1441–3. Comment on: Arthritis Rheum 1996 Sep;39(9):1466–74. Comment on: Arthritis Rheum 1996 Sep;39(9):1606–7.
Hereditary resistance to activated protein C: an uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies. Sasso EH, et al. **Arthritis Rheum** 1997 Sep;40(9):1720–1
Tests for heparin–induced thrombocytopenia in primary antiphospholipid syndrome [letter] Lasne D, et al. **Br J Haematol** 1997 Jun;97(4):939
Intravenous immunoglobulin contains detectable amounts of antiphospholipid antibodies [letter] Stratta P, et al. **Br J Haematol** 1997 Mar;96(4):872–3
Coexistence of anti–phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Ferro D, et al. **Circulation** 1997 Mar 18;95(6):1425–32
Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 80 patients. Cervera R, et al. **Clin Exp Rheumatol** 1997 Jul–Aug;15(4):361–5
Transient regional osteoporosis with antiphospholipid antibodies: a report of two cases. Paran D, et al. **Clin Exp Rheumatol** 1996 Nov–Dec;14(6):677–80
Transient disappearance of serum antiphospholipid antibodies can also be due to prednisone therapy [letter; comment] Silveira LH, et al. **Clin Exp Rheumatol** 1996 Mar–Apr; 14(2):217–9. Comment on: Clin Exp Rheumatol 1994 Jul–Aug;12(4):460–1.
Histological appearance of the intra–osseous vessels of the femoral head in aseptic osteonecrosis of the hip, with or without antiphospholipid antibodies. Laroche M, et al. **Clin Rheumatol** 1997 Jun;16(4):367–71
A decrease in antiphospholipid antibodies before a thrombotic event. Praprotnik S, et al. **Clin Rheumatol** 1996 May;15(3):298–300
Antiphospholipid antibodies in a child: an unusual presentation without thrombotic events [letter] Felici L, et al. **Eur J Pediatr** 1996 Nov;155(11):994
Antiphospholipid antibodies and human reproductive failure. Balasch J, et al. **Hum Reprod** 1996 Oct;11(10):2310–5
Antiphospholipid antibodies and the antiphospholipid antibody syndrome. Nahass GT. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):149–68; quiz 169–72 (302 ref.)
Anti–phospholipid antibodies in preeclampsia and their binding ability for placental villous lipid fractions. Yamamoto T, et al. **J Obstet Gynaecol Res** 1996 Jun; 22(3):275–83
Antiphospholipid antibodies and coagulation regulatory protein abnormalities in children with pulmonary emboli. Nuss R, et al. **J Pediatr Hematol Oncol** 1997 May–Jun; 19(3):202–7
The antiphospholipid/cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to beta 2–glycoprotein I but no antibodies detectable in standard antiphospholipid assays. Alarcon–Segovia D, et al. **J Rheumatol** 1997 Aug;24(8):1545–51
Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti–beta 2–glycoprotein–I than with antiphospholipid antibodies. Cabiedes J, et al. **J Rheumatol** 1995 Oct;22(10):1899–906
Presence of IgG antiphospholipid autoantibody in nude mice [letter; comment] Cheng HM, et al. **J Rheumatol** 1995 Oct; 22(10):2006–7. Comment on: J Rheumatol 1994 Dec;21(12):2242–5.
MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus. Goldstein R, et al. **J Rheumatol** 1996 Jul;23(7):1173–9
Prevalence of antiphospholipid antibodies in patients with ankylosing spondylitis. Juanola X, et al. **J Rheumatol** 1995 Oct;22(10):1891–3
High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. Karmochkine M, et al. **J Rheumatol** 1996 Feb;23(2):286–90
Cardiac valvular disease in scleroderma and systemic lupus erythematosus/scleroderma overlap associated with antiphospholipid antibodies. Penmetcha M, et al. **J Rheumatol** 1996 Dec;23(12):2171–4
Prospective comparison of infrainguinal bypass grafting in patients with and without antiphospholipid antibodies. Lee RW, et al. **J Vasc Surg** 1996 Oct;24(4):524–31; discussion 531–3
Antiphospholipid antibody. Babies, blood clots, biology [clinical conference] Lockshin MD. **JAMA** 1997 May 21; 277(19):1549–51
Antigenic specificities of antiphospholipid autoantibodies: implications for clinical laboratory testing and diagnosis of the antiphospholipid syndrome. Roubey RA. **Lupus** 1996 Oct;5(5):425–30 (33 ref.)
Antiphospholipid ELISA: the state of the art. Tincani A, et al. **Lupus** 1996 Oct;5(5):477–9
Lupus anticoagulants/antiphospholipid–protein antibodies: the great imposters. Triplett DA. **Lupus** 1996 Oct; 5(5):431–5 (36 ref.)
Valvular heart disease and systemic lupus erythematosus

[letter; comment] Piette JC, et al. **N Engl J Med** 1997 May 1;336(18):1324; discussion 1324–5. Comment on: N Engl J Med 1996 Nov 7;335(19):1424–30.

Antiphospholipid antibodies and movement disorders [letter] Jimenez MD, et al. **Rev Rhum Engl Ed** 1996 Mar; 63(3):227–8

Antiphospholipid antibodies: basic immunology and assays. Schultz DR. **Semin Arthritis Rheum** 1997 Apr;26(5):724–39 (122 ref.)

Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Crowther MA, et al. **Thromb Haemost** 1996 Nov;76(5):689–91

Influence of the phosphatidylethanolamine (PE) and bovine serum origins on anti-PE antibody detection by ELISA. Berard M, et al. **Thromb Res** 1997 Mar 1;85(5):439–42

Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies. Simantov R, et al. **Thromb Res** 1996 Dec 1;84(5):361–5

[Anti-phosphatidylserine antibodies in women with reproductive disorders] Fialová L, et al. **Ceska Gynekol** 1996 Jun;61(3):154–7 (Eng. Abstr.) **(Cze)**

[Appearance of antiphospholipid antibodies in patients with hepatitis C treated with interferon-alpha (letter)] Doutre MS, et al. **Ann Med Interne (Paris)** 1997;148(1):99–100 **(Fre)**

[Antiphospholipid antibody/cofactors. What are they? Why, when and how to search for them? Is treatment justified?] Piette JC, et al. **Ann Med Interne (Paris)** 1996;147(7):492–7 (36 ref.) (Eng. Abstr.) **(Fre)**

[Antiphospholipid antibodies: limitations and potential use in liver diseases (editorial)] Valla DC. **Gastroenterol Clin Biol** 1996;20(10):723–6 **(Fre)**

[Presence of antiphospholipid antibodies in Legionnaires' disease (letter)] Durupt S, et al. **Presse Med** 1996 Nov 9; 25(34):1649 **(Fre)**

[Lupic spinal cord diseases and antiphospholipid antibodies] Feki I, et al. **Rev Neurol (Paris)** 1997 Mar;153(2):138–40 (Eng. Abstr.) **(Fre)**

[Clinical significance and predictive value of laboratory tests in thrombosis associated with antiphospolipid antibodies] Barbui T, et al. **Ann Ital Med Int** 1997 Apr–Jun;12(2):76–83 (60 ref.) (Eng. Abstr.) **(Ita)**

[Acute cardiac failure due to dilated cardiomyopathy in systemic lupus erythematosus with antiphospholipid antibody] Takeda T, et al. **Ryumachi** 1996 Dec;36(6):856–61 (Eng. Abstr.) **(Jpn)**

[Evan's syndrome with antiphospholipid-protein antibodies] Frołow M, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):344–5 (Eng. Abstr.) **(Pol)**

[Changes in the spectrum of antibodies to membrane phospholipids in women with habitual abortion] Ponomareva IV, et al. **Biull Eksp Biol Med** 1997 Mar; 123(3):312–5 **(Rus)**

[Immunoenzyme analysis in the determination of antibodies to main classes of cell phospholipids in human blood] Ponomareva IV, et al. **Klin Lab Diagn** 1997 Jul;(7):35–7 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Cryz SJ, et al. **Vaccine** 1996 Oct;14(14):1381–3

BLOOD

Comparative study of antiphospholipid antibody detection in eleven Belgian laboratories. Capel P, et al. **Acta Clin Belg** 1997;52(2):84–91

Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin. Marzusch K, et al. **Acta Obstet Gynecol Scand** 1996 Nov;75(10):922–6

Antiphospholipid antibodies in pediatric lupus nephritis. Massengill SF, et al. **Am J Kidney Dis** 1997 Mar; 29(3):355–61

Antiphospholipid antibodies and thrombosis [letter; comment] Antivalle M. **Am J Med** 1997 Mar;102(3):318–9 . Comment on: Am J Med 1996 May;100(5):530–6.

Antiphospholipid antibodies and essential thrombocythemia [letter] Harrison CN, et al. **Am J Med** 1997 Mar; 102(3):317–8

Hughes syndrome: perspectives on thrombosis and antiphospholipid antibody [editorial] Wilson WA, et al. **Am J Med** 1996 Dec;101(6):574–5

Physiologic apoptosis, beta 2-glycoprotein I, and antiphospholipid autoantibodies [letter; comment] Cheng HM. **Am J Obstet Gynecol** 1996 Nov;175(5):1393. Comment on: Am J Obstet Gynecol 1995 Nov;173(5):1410–5.

Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Cowchock S, et al. **Am J Obstet Gynecol** 1997 May;176(5):1099–100

Pathogenic antibodies in women with obstetric features of antiphospholipid syndrome who have negative test results for lupus anticoagulant and anticardiolipin antibodies. Silver RM, et al. **Am J Obstet Gynecol** 1997 Mar; 176(3):628–33

Antiphospholipid antibody prevalence in patients with IVF failure. Kaider BD, et al. **Am J Reprod Immunol** 1996 Apr; 35(4):388–93

A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Kutteh WH, et al. **Am J Reprod Immunol** 1996 Apr;35(4):402–7

Antiphospholipid antibodies and recurrent pregnancy loss. Rote NS. **Am J Reprod Immunol** 1996 Apr;35(4):394–401 (63 ref.)

Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Girolami A, et al. **Blood Coagul Fibrinolysis** 1996 Jun;7(4):497–501

Anti-beta 2-glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome. Teixidó M, et al. **Br J Rheumatol** 1997 Jan;36(1):113–6

Clinical setting of patients with systemic sclerosis by serum autoantibodies. Picillo U, et al. **Clin Rheumatol** 1997 Jun; 16(4):378–83

Antiphospholipid antibodies and pregnancy rates and outcome in in vitro fertilization patients. Denis AL, et al. **Fertil Steril** 1997 Jun;67(6):1084–90

Antiphospholipid-protein antibodies: clinical use of laboratory test results (identification, predictive value, treatment). Triplett DA. **Haemostasis** 1996 Oct;26 Suppl 4:358–67 (44 ref.)

Effect of antiphospholipid antibodies in women undergoing in-vitro fertilization: role of heparin and aspirin. Kutteh WH, et al. **Hum Reprod** 1997 Jun;12(6):1171–5

Antiphospholipid antibodies in women undergoing in-vitro fertilization [letter; comment] Rai R, et al. **Hum Reprod** 1997 Jan;12(1):197–8. Comment on: Hum Reprod 1996 Jun;11(6):1185–9.

High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Rai RS, et al. **Hum Reprod** 1995 Dec; 10(12):3301–4

Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus with antiphospholipid antibody. Otsuka F, et al. **Intern Med** 1996 Apr;35(4):341–4

Alteration of the aPA ELISA by UV exposure of polystyrene microtiter plates. Goldberg JS, et al. **J Clin Lab Anal** 1996; 10(5):243–9

Hypoperfusion of brain single photon emission computerized tomography in patients with antiphospholipid antibodies. Kato T, et al. **J Dermatol Sci** 1997 Jan;14(1):20–8

Treatment for patients with recurrent abortion with positive antiphospholipid antibodies using a traditional Chinese herbal medicine. Takakuwa K, et al. **J Perinat Med** 1996; 24(5):489–94

Pregnancy outcome. Influence of antiphospholipid antibody titer, prior pregnancy losses and treatment. Reece EA, et al. **J Reprod Med** 1997 Jan;42(1):49–55

Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases [see comments] Berard M, et al. **J Rheumatol** 1996 Aug;23(8):1369–74. Comment in: J Rheumatol 1996 Aug;23(8):1319–22.

Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity [see comments] Boffa MC, et al. **J Rheumatol** 1996 Aug;23(8):1375–9. Comment in: J Rheumatol 1996 Aug;23(8):1319–22.

Antiphospholipid antibodies in patients with eosinophilia myalgia and toxic oil syndrome. Carreira PE, et al. **J Rheumatol** 1997 Jan;24(1):69–72

High prevalence of antiphospholipid antibodies in patients taking procainamide. Merrill JT, et al. **J Rheumatol** 1997 Jun;24(6):1083–8

A case of Budd-Chiari syndrome with high antiphospholipid antibody in a patient with systemic lupus erythematosus. Yun YY, et al. **Korean J Intern Med** 1996 Jan;11(1):82–6

Hepatic necrosis and haemorrhage in pregnant patients with antiphospholipid antibodies. Amant F, et al. **Lupus** 1997; 6(6):552–5

Thrombosis associated with antiphospholipid antibody in juvenile chronic arthritis. Andrews A, et al. **Lupus** 1997; 6(6):556–7

Antiphospholipid antibodies and retinal vascular disease. Dunn JP, et al. **Lupus** 1996 Aug;5(4):313–22

Why do patients with antiphospholipid antibody clot? [editorial; comment] Lockshin MD. **Lupus** 1997;6(4):351–2 . Comment on: Lupus 1997 ;6(4):358–64.

Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Martini F, et al. **Lupus** 1996 Jun; 5(3):206–11

Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis. Wahl DG, et al. **Lupus** 1997;6(5):467–73

Clinical implications of antiphospholipid antibodies in obstetrics. Danilenko-Dixon DR, et al. **Mayo Clin Proc** 1996 Nov;71(11):1118–20 (16 ref.)

Do not forget lupus anticoagulant in the era of antiphospholipid antibodies [letter] Stratta P, et al. **Nephron** 1997;76(2):233–4

Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Branch DW, et al. **Obstet Gynecol** 1997 Apr; 89(4):549–55

Antiphospholipid antibodies in healthy pregnant women. Lynch A, et al. **Rheum Dis Clin North Am** 1997 Feb; 23(1):55–70 (106 ref.)

Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Abuaf N, et al. **Thromb Haemost** 1997 May;77(5):856–61

Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies--a crucial role for acquired free protein S deficiency. Ames PR, et al. **Thromb Haemost** 1996 Aug;76(2):190–4

Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Fijnheer R, et al. **Thromb Haemost** 1996 Oct;76(4):514–7

Antiphospholipid antibodies: predictive value of laboratory tests. Galli M, et al. **Thromb Haemost** 1997 Jul;78(1):75–8 (28 ref.)

Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Horbach DA, et al. **Thromb Haemost** 1996 Dec;76(6):916–24

Pseudo factor XII deficiency and phospholipid antibodies [letter] Jones DW, et al. **Thromb Haemost** 1996 Apr; 75(4):696–7

High prevalence of antiphospholipid antibodies in disseminated intravascular coagulation [letter] Karmochkine M, et al. **Thromb Haemost** 1996 Jun;75(6):971

Increased plasma thrombomodulin in different subgroups of patients with antiphospholipid and anti beta(2) glycoprotein I antibodies [letter] Martinuzzo ME, et al. **Thromb Haemost** 1996 Jun;75(6):972–3

Inhibition of protein S by autoantibodies in patients with acquired protein S deficiency. Sorice M, et al. **Thromb Haemost** 1996 Apr;75(4):555–9

Antiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes [published erratum appears in Thromb Res 1996 Nov 15;84(4):299] Boddi M, et al. **Thromb Res** 1996 May 1;82(3):207–16

Hemostatic abnormalities in inflammatory bowel disease. Chiarantini E, et al. **Thromb Res** 1996 Apr 15;82(2):137–46

Antiphospholipid-protein antibodies are not an uncommon feature in retinal venous occlusions. Coniglio M, et al. **Thromb Res** 1996 Jul 15;83(2):183–8

A simple procedure that increases the specificity of the activated protein C resistance test in samples containing antiphospholipid antibodies. Jacobsen EM, et al. **Thromb Res** 1997 Jun 1;86(5):385–91

Antiphospholipid antibodies and disturbances of phospholipid dependent coagulation tests in patients with systemic sclerosis and severe peripheral ischaemia [letter] Lewandowski K, et al. **Thromb Res** 1996 Mar 15; 81(6):693–5

[Antiphospholipid antibodies in patients with neurologic diseases] Peterová V, et al. **Sb Lek** 1996;97(3):377–83 (Eng. Abstr.) **(Cze)**

[Antiphospholipid antibodies, lupus anticoagulant and thrombosis] Capel P. **Rev Med Brux** 1997 Jun;18(3):108–10 (18 ref.) (Eng. Abstr.) **(Fre)**

[Renovascular hypertension associated with antiphospholipid antibodies in a woman with systemic lupus erythematosus] Serino R, et al. **Nippon Jinzo Gakkai Shi** 1996 Sep; 38(9):417–22 (Eng. Abstr.) **(Jpn)**

[Analysis of immunoglobulin classes of five anti-phospholipid antibodies in sera from patients with SLE, ITP and recurrent fetal abortion by enzyme linked immunosorbent assay] Hayashi S, et al. **Rinsho Byori** 1996 Feb;44(2):169–75 (Eng. Abstr.) **(Jpn)**

[Paludism and antiphospholipid antibodies (letter)] Rodríguez Hernández MJ, et al. **An Med Interna** 1996 Dec; 13(12):614–5 **(Spa)**

[Antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus] Formiga F, et al. **Rev Clin Esp** 1996 Nov;196(11):734–6 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Immunologic characterization and functional properties of murine antibodies raised against deleted mutants of human beta 2-glycoprotein I. George J, et al. **Int Immunol** 1997 Jun;9(6):913–21

Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. Price BE, et al. **J Immunol** 1996 Sep 1; 157(5):2201–8

CLASSIFICATION

Significance of aPL IgG subclasses. Sammaritano LR. **Lupus** 1996 Oct;5(5):436–9 (19 ref.)

DIAGNOSTIC USE

Antiphospholipid and antiendothelial antibodies. Meroni PL, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):320–5 (46 ref.)

GENETICS

Deletion in HCDR3 rescues T15 antibody mutants from a secretion defect caused by mutations in HCDR2. Martin TM, et al. **J Immunol** 1996 Nov 15;157(10):4341–6

Sequences of monoclonal antiphospholipid antibodies: variations on an anti-DNA antibody theme. Rahman A, et al. **Semin Arthritis Rheum** 1996 Oct;26(2):515–25 (40 ref.)

ANTIBODIES, ANTIPHOSPHOLIPID

IMMUNOLOGY

Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies. Laroche P, et al. **Am J Clin Pathol** 1996 Oct; 106(4):549–54

Sperm, nuclear, phospholipid, and red blood cell antibodies and isotype RF in infertile couples and patients with autoimmune rheumatic diseases. Fichorova R, et al. **Am J Reprod Immunol** 1996 Dec;36(6):309–16

Antiphospholipid antibodies in patients with chronic hepatitis C virus infection or alcoholic liver disease. Preliminary results. Biron C, et al. **Ann Med Interne (Paris)** 1996 Sep; 147 Suppl 1:48–9

Questions–answers about antiphospholipid–protein antibodies and the "antiphospholipid antibody syndrome". Boffa MC, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:54–6

Do some antiphospholipid antibodies target endothelial cells? Dueymes M, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:22–3

The possible contribution of cell apoptosis and necrosis to the generation of phospholipid–binding antibodies. Eschwège V, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:33–5 (27 ref.)

The presence of anti–beta 2–glycoprotein I and anti–prothrombin antibodies and their correlations with venous and arterial thrombosis. Horbach DA, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:42–3

The role of oxidized LDL in atherogenesis: immunological response and anti–phospholipid antibodies. Witztum JL, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:88–96; discussion 96–9 (27 ref.)

Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance, and therapeutic options. Feldmann E, et al. **Ann Neurol** 1995 May;37 Suppl 1:S114–30 (172 ref.)

T cell help and antiphospholipid antibody immunogenesis [letter; comment] Cheng HM, et al. **Arthritis Rheum** 1997 Jan;40(1):196–7. Comment on: Arthritis Rheum 1995 Jan;38(1):115–22.

Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Loizou S, et al. **Arthritis Rheum** 1997 Jan;40(1):103–8

Do plasma anti phospholipid antibodies in patients with autoimmune haemolytic anaemia correlate with reduced levels of erythrocyte complement receptor 1? Jones DR, et al. **Autoimmunity** 1996;23(1):45–51

Apoptotic antigens, B2–glycoprotein I, and antiphospholipid autoantibodies [letter; comment] Cheng HM. **Blood** 1996 Dec 1;88(11):4396. Comment on: Blood 1996 Jun 15;87(12):5185–95.

Thrombogenic properties of murine anti–cardiolipin antibodies induced by beta 2 glycoprotein I and human immunoglobulin G antiphospholipid antibodies. Pierangeli SS, et al. **Circulation** 1996 Oct 1;94(7):1746–51

Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. López–Soto A, et al. **Clin Exp Rheumatol** 1997 Mar–Apr;15(2):143–9

Failure of the war to the knife against antiphospholipid antibodies by conventional immunosuppressive therapy in systemic lupus erythematosus [letter] Stratta P, et al. **Clin Nephrol** 1996 Nov;46(5):356

Pathogenic role of antiprotein–phospholipid antibodies. Carreras LO, et al. **Haemostasis** 1996 Oct;26 Suppl 4:340–57 (91 ref.)

Deletion in HCDR3 rescues T15 antibody mutants from a secretion defect caused by mutations in HCDR2. Martin TM, et al. **J Immunol** 1996 Nov 15;157(10):4341–6

The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. Denburg SD, et al. **J Int Neuropsychol Soc** 1997 Jul; 3(4):377–86

Immunology update: symposium on antiphospholipid antibodies. Silver RM. **J Reprod Immunol** 1997 Feb; 32(3):269–72

Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. Kent M, et al. **J Rheumatol** 1997 Sep;24(9):1725–33

On the antiphospholipid/cofactor syndromes [letter] Mercado U. **J Rheumatol** 1997 Aug;24(8):1658–9

Guidelines for looking at the antiphospholipid antibodies in systemic lupus erythematosus. Stratta P, et al. **Nephron** 1997;76(4):400–5 (70 ref.)

The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Hörkkö S, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10356–61

Antiphospholipid antibodies: basic immunology and assays. Schultz DR. **Semin Arthritis Rheum** 1997 Apr;26(5):724–39 (122 ref.)

Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis. Bokarewa MI, et al. **Semin Hematol** 1997 Jul;34(3):235–43 (74 ref.)

Thrombogenic mechanisms of antiphospholipid antibodies. Esmon NL, et al. **Thromb Haemost** 1997 Jul;78(1):79–82 (26 ref.)

Different anticoagulant and immunological properties of anti–prothrombin antibodies in patients with antiphospholipid antibodies. Galli M, et al. **Thromb Haemost** 1997 Mar;77(3):486–91

Autoantibodies to phospholipid–binding plasma proteins in patients with thrombosis and phospholipid–reactive antibodies. Pengo V, et al. **Thromb Haemost** 1996 May; 75(5):721–4

Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation [letter] [see comments] Prandoni P, et al. **Thromb Haemost** 1996 May; 75(5):859. Comment in: Thromb Haemost 1997 Jan;77(1):221–2.

Specific cross–reaction of IgG anti–phospholipid antibody with platelet glycoprotein IIIa. Tokita S, et al. **Thromb Haemost** 1996 Jan;75(1):168–74

Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Ducloux D, et al. **Transplant Proc** 1997 Aug;29(5):2400–1

Positive direct antiglobulin test due to antiphospholipid antibodies in normal healthy blood donors. Win N, et al. **Vox Sang** 1997;72(3):182–4

[New targets of antiphospholipid antibodies] Arvieux J, et al. **Rev Med Interne** 1997;18(4):292–302 (69 ref.) (Eng. Abstr.) **(Fre)**

[Primary antiphospholipid antibody syndrome with left atrial intracardiac thombosis] Amato S, et al. **G Ital Cardiol** 1997 Apr;27(4):380–6 (Eng. Abstr.) **(Ita)**

[Anti–endothelial antibodies and defects of heart valves in antiphospholipid syndrome: analysis of pathogenic mechanisms] Nasonov EL, et al. **Klin Med (Mosk)** 1997; 75(2):17–22 **(Rus)**

[Antiphospholipid antibodies and neurological disorders. Types and mechanisms] Viñets C, et al. **Rev Neurol** 1996 Oct;24(134):1224–8 (42 ref.) (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

[Antiphospholipid antibodies syndrome: follow–up of patients with a high antiphospholipid antibodies titer] Urfer C, et al. **Schweiz Med Wochenschr** 1996 Dec 7; 126(49):2136–40 (17 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Anti–endothelial cell antibodies to the endothelial hybridoma cell line (EAhy926) in systemic lupus erythematosus patients with antiphospholipid antibodies. Matsuda J, et al. **Br J Haematol** 1997 Apr;97(1):227–32

Antiphospholipid antibody–dependent C5b–9 formation. Stewart MW, et al. **Br J Haematol** 1997 Mar;96(3):451–7

Antiphospholipid antibodies and reproductive failure: what they do and what they do not do; how to, and how not to treat! Gleicher N. **Hum Reprod** 1997 Jan;12(1):13–6 (34 ref.)

Influence of degraded phosphatidylserine on binding of antiphospholipid antibodies. Božič B, et al. **Int Arch Allergy Immunol** 1997 Jan;112(1):19–26

Sequence changes at the V–D junction of the VH1 heavy chain of anti–phosphocholine antibodies alter binding to and protection against Streptococcus pneumoniae. Guo WX, et al. **Int Immunol** 1997 May;9(5):665–77

Discordant effects on eicosanoids and fibrin degradation products in two murine models of antiphospholipid antibody. Schorer AE. **Thromb Res** 1997 Feb 15; 85(4):295–304

PHARMACOLOGY

Variable effects on murine pregnancy of immunoglobulin G fractions from women with antiphospholipid antibodies. Silver RM, et al. **Am J Obstet Gynecol** 1997 Jul; 177(1):229–33

Studies on the interaction of placental anticoagulant protein I, beta 2 glycoprotein 1, and antiphospholipid antibodies in the prothrombinase reaction and in the solid phase anticardiolipin assays. Pierangeli SS, et al. **J Lab Clin Med** 1996 Aug;128(2):194–201

PHYSIOLOGY

Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti–beta 2–glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2–glycoprotein I and induce endothelial activation. Del Papa N, et al. **Arthritis Rheum** 1997 Mar;40(3):551–61

Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. Ziporen L, et al. **J Clin Invest** 1997 Aug 1; 100(3):613–9

Activated protein C resistance phenotype in patients with antiphospholipid antibodies. Aznar J, et al. **J Lab Clin Med** 1997 Aug;130(2):202–8

The catastrophic antiphospholipid syndrome 1996: acute multi–organ failure associated with antiphospholipid antibodies: a review of 31 patients. Asherson RA, et al. **Lupus** 1996 Oct;5(5):414–7

Antiphospholipid antibodies, eicosanoids and expression of endothelial cyclooxygenase–2. Carreras LO, et al. **Lupus** 1996 Oct;5(5):494–7 (46 ref.)

Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. de Groot PG, et al. **Lupus** 1996 Oct; 5(5):488–93 (52 ref.)

Non beta 2–glycoprotein I cofactors for antiphospholipid antibodies. Galli M. **Lupus** 1996 Oct;5(5):388–92 (42 ref.)

Platelets and antiphospholipid antibodies. Machin SJ. **Lupus** 1996 Oct;5(5):386–7 (6 ref.)

Modulation of endothelial cell function by antiphospholipid antibodies. Meroni PL, et al. **Lupus** 1996 Oct;5(5):448–50

Antibodies against phospholipids other than cardiolipin: potential roles for both phospholipid and protein. Rauch J, et al. **Lupus** 1996 Oct;5(5):498–502 (62 ref.)

Antiphospholipid antibodies activate vascular endothelial cells. Simantov R, et al. **Lupus** 1996 Oct;5(5):440–1

Antiphospholipid antibodies and atherosclerosis. Vaarala O. **Lupus** 1996 Oct;5(5):442–7 (48 ref.)

Autoantibodies and pregnancy loss [editorial; comment] Cowchock S. **N Engl J Med** 1997 Jul 17;337(3):197–8. Comment on: N Engl J Med 1997 Jul 17;337(3):148–50. Comment on: N Engl J Med 1997 Jul 17;337(3):154–60.

Pregnancy loss in the antiphospholipid–antibody syndrome—a possible thrombogenic mechanism [see comments] Rand JH, et al. **N Engl J Med** 1997 Jul 17; 337(3):154–60. Comment in: N Engl J Med 1997 Jul 17;337(3):197–8.

ANTIBODIES, BACTERIAL

Production and characterization of mouse monoclonal antibodies against Afipia felis. Engbaek K, et al. **APMIS** 1997 Mar;105(3):192–8

Identification of Afipia felis antigens in culture medium: reaction with human sera. Engbaek K, et al. **APMIS** 1997 Mar;105(3):199–206

Monoclonal antibodies for use in detection of Bacillus and Clostridium spores. Quinlan JJ, et al. **Appl Environ Microbiol** 1997 Feb;63(2):482–7

Identification of a functionally important population in phenol–digesting activated sludge with antisera raised against isolated bacterial strains. Watanabe K, et al. **Appl Environ Microbiol** 1996 Oct;62(10):3901–4

Monoclonal antibodies to P24 and P61 immunodominant antigens from Nocardia brasiliensis. Salinas–Carmona MC, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):133–7

Construction of CTB fusion proteins for screening of monoclonal antibodies against Salmonella typhi OmpC peptide loops. Paniagua–Solís J, et al. **FEMS Microbiol Lett** 1996 Jul 15;141(1):31–6

Localization of the regions on the C–terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Rosenberg JS, et al. **Immunol Invest** 1997 Jun;26(4):491–504

Molecular cloning, purification, and serological characterization of MPT63, a novel antigen secreted by Mycobacterium tuberculosis. Manca C, et al. **Infect Immun** 1997 Jan;65(1):16–23

Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme–linked immunosorbent spot assay for detection of mycobacteria. Glatman–Freedman A, et al. **J Clin Microbiol** 1996 Nov; 34(11):2795–802

Clinical comparison of borreliacidal–antibody test with indirect immunofluorescence and enzyme–linked immunosorbent assays for diagnosis of Lyme disease. Agger WA, et al. **Mayo Clin Proc** 1997 Jun;72(6):510–4

A high molecular weight protein from Staphylococcus intermedius cross–reacts with Staphylococcus aureus enterotoxin antibodies. Laffan JJ, et al. **Microbios** 1996; 88(357):237–51

ADMINISTRATION & DOSAGE

Passive immunization with monoclonal antibodies specific for lipopolysaccharide (LPS) O–side chain protects mice against intravenous Yersinia enterocolitica serotype O:3 infection. Skurnik M, et al. **APMIS** 1996 Jul–Aug; 104(7–8):598–602

Reduced intestinal colonisation with F18–positive enterotoxigenic Escherichia coli in weaned pigs fed chicken egg antibody against the fimbriae. Zúñiga A, et al. **FEMS Immunol Med Microbiol** 1997 Jul;18(3):153–61

Antibodies to the leucine–rich repeat region of internalin block entry of Listeria monocytogenes into cells expressing E–cadherin. Mengaud J, et al. **Infect Immun** 1996 Dec; 64(12):5430–3

ANALYSIS

High risk of Helicobacter pylori infection associated with cow's milk antibodies in young diabetics. Pococco M, et al. **Acta Paediatr** 1997 Jul;86(7):700–3

An evaluation of near–patient testing for Helicobacter pylori in general practice. Jones R, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):101–5

Immunologic response to Bartonella henselae as determined by enzyme immunoassay and Western blot analysis. Litwin CM, et al. **Am J Clin Pathol** 1997 Aug;108(2):202–9

Evaluation of whole blood antibody kit to detect active Helicobacter pylori infection. Borody TJ, et al. **Am J Gastroenterol** 1996 Dec;91(12):2509–12

Mycobacterium fortuitum glycolipids for the serodiagnosis of pulmonary tuberculosis. Escamilla L, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1864–7

Detection of antibodies to Salmonella lipopolysaccharide in muscle fluid from cattle. Hoorfar J, et al. **Am J Vet Res** 1997 Apr;58(4):334–7

Positive serology to Legionella longbeachae in patients with adult respiratory distress syndrome. Konecny P, et al. **Anaesth Intensive Care** 1996 Dec;24(6):678–81

Detection of immunoglobulins on bacterial surface by laser flow cytometry: analysis between Haemophilus influenzae type b and Vibrio cholerae O1 of healthy mother–full term newborn sera. Cano–Morales S, et al. **Arch Med Res** 1996 Spring;27(1):67–70

Detection and specificity of anti–Staphylococcus intermedius secretory IgA in human tears. Lan J, et al. **Aust N Z J Ophthalmol** 1997 May;25 Suppl 1:S17–9

Applying tests for specific yolk antibodies to predict contamination by Salmonella enteritidis in eggs from experimentally infected laying hens. Gast RK, et al. **Avian Dis** 1997 Jan–Mar;41(1):195–202

Antibody responses of chickens to inoculation with Mycoplasma gallisepticum membrane proteins in immunostimulating complexes. McLaren JM, et al. **Avian Dis** 1996 Oct–Dec;40(4):813–22

Characterisation of serum and mucosal antibodies against Helicobacter pylori. McBride PD, et al. **Biochem Soc Trans** 1997 May;25(2):334S

Evaluation of salivary antibodies to detect infection with Helicobacter pylori. Loeb MB, et al. **Can J Gastroenterol** 1997 Jul–Aug;11(5):437–40

Bovine IgG2a antibodies to Haemophilus somnus and allotype expression. Corbeil LB, et al. **Can J Vet Res** 1997 Jul;61(3):207–13

Measurement of antibodies against meningococcal capsular polysaccharides B and C in enzyme–linked immunosorbent assays: towards an improved surveillance of meningococcal disease. Andersen J, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):345–51

Collaborative study for the evaluation of enzyme–linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens. Lynn F, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):689–700

Antipolysaccharide antibodies in 450 children with otitis media. Misbah SA, et al. **Clin Exp Immunol** 1997 Jul; 109(1):67–72

Anti–bacterial antibodies in Behçet's disease [letter] Iannone F, et al. **Clin Exp Rheumatol** 1997 Jul–Aug;15(4):451–2

Antibodies to streptococcal cell wall in psoriatic arthritis and cutaneous psoriasis. Rantakokko K, et al. **Clin Exp Rheumatol** 1997 Jul–Aug;15(4):399–404

Immunopathology of Helicobacter pylori gastritis. Kirchner T, et al. **Digestion** 1997;58 Suppl 1:14–6 (5 ref.)

Helicobacter antibodies in 1973 and 1994 in the adult population of Vammala, Finland. Kosunen TU, et al. **Epidemiol Infect** 1997 Aug;119(1):29–34

The effect of measurement error on the determination of Helicobacter pylori prevalence. Cockburn M, et al. **Epidemiology** 1997 Mar;8(2):205–9

Comparison of immunofluorescence with enzyme immunoassay for detection of Q fever. D'Harcourt SC, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep;15(9):749–52

Seroprevalence of immunoglobulin G antibodies to Bartonella henselae in cat owners [letter] Rath PM, et al. **Eur J Clin Microbiol Infect Dis** 1997 Apr;16(4):326–7

Evaluation of a serological test for diagnosis of Helicobacter pylori infection in children. Raymond J, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):415–7

The Helicobacter pylori seroprevalence in blood donors related to Lewis (a,b) histo–blood group phenotype. Klaamas K, et al. **Eur J Gastroenterol Hepatol** 1997 Apr; 9(4):367–70

Anti–Borrelia burgdorferi immunoglobulin seroprevalence in pulmonary sarcoidosis: a negative report. Martens H, et al. **Eur Respir J** 1997 Jun;10(6):1356–8

Immunoglobulin G response against 10–kDa and 65–kDa heat–shock proteins in leprosy patients and their household contacts. Rojas RE, et al. **FEMS Immunol Med Microbiol** 1996 Oct;15(4):189–98

Evaluation of two nonculture antigen tests and three serotests for detection of anti–chlamydial antibodies in the diagnosis of ocular chlamydial infections. Haller EM, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234(8):510–4

Detection of antibodies to Borrelia species among patients with confirmed sarcoidosis in a region where Lyme disease is nonendemic. Ishihara M, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Dec;234(12):770–3

Is saliva serology useful for the diagnosis of Helicobacter pylori? Christie JM, et al. **Gut** 1996 Jul;39(1):27–30

The 60 kDa heat shock protein in human semen: relationship with antibodies to spermatozoa and Chlamydia trachomatis. Munoz MG, et al. **Hum Reprod** 1996 Dec;11(12):2600–3

Circulating antibodies to Chlamydia trachomatis in women: relationship to antisperm and antichlamydial antibodies in semen of male partners. Witkin SS. **Hum Reprod** 1996 Aug; 11(8):1635–7

Instantaneous cloth–based enzyme immunoassay for the semi–quantitative visual determination of antibodies. Boyd S, et al. **Immunol Invest** 1997 Apr;26(3):313–21

Comparative evaluation of two indigenously developed tests for rapid detection of group–A streptococci directly from throat swabs. Gupta R, et al. **Indian J Med Res** 1997 May; 105:200–5

Leptospiral antibodies in patients with recurrent ophthalmic involvement. Rathinamsivakumar, et al. **Indian J Med Res** 1996 Jan;103:66–8

Antigenicity of a synthetic peptide from glucosyltransferases of Streptococcus mutans in humans. Chia JS, et al. **Infect Immun** 1997 Mar;65(3):1126–30

Success and failure in the treatment of acrodermatitis chronica atrophicans. Aberer E, et al. **Infection** 1996 Jan–Feb;24(1):85–7

Boostering antitoxic diphtheria immunity in adults [letter] Hasselhorn HM, et al. **Infection** 1996 Mar–Apr;24(2):168–9

Takayasu's arteritis: role of Mycobacterium tuberculosis and its 65 kDa heat shock protein. Aggarwal A, et al. **Int J Cardiol** 1996 Jul 5;55(1):49–55

Effect of age, sex and smoking habits on pneumococcal antibodies in an elderly population. Sankilampi U, et al. **Int J Epidemiol** 1997 Apr;26(2):420–7

Investigation of anti–Mycobacterium leprae antibodies in leprosy patients' sera by an A60 antigen immunoassay [letter] Casal M, et al. **Int J Lepr Other Mycobact Dis** 1996 Sep;64(3):325–7

Helicobacter pylori infection in families of Helicobacter pylori–positive children. Bonamico M, et al. **Ital J Gastroenterol** 1996 Dec;28(9):512–7

Pneumococcal antibody assay standardization [letter; comment] Hamilton RG. **J Allergy Clin Immunol** 1997 Feb; 99(2):270. Comment on: J Allergy Clin Immunol 1996 Jul;98(1):205–15.

Comparison of milk with serum ELISA for the detection of paratuberculosis in dairy cows. Hardin LE, et al. **J Am Vet Med Assoc** 1996 Jul 1;209(1):120–2

Monoclonal antibody detection of Clostridium microcolonies directly on membrane used for milk filtration. Batina P, et al. **J Appl Microbiol** 1997 May;82(5):619–24

Enzyme immunoassay to detect antituberculous glycolipid antigen (anti–TBGL antigen) antibodies in serum for diagnosis of tuberculosis. Kawamura M, et al. **J Clin Lab Anal** 1997;11(3):140–5

Pitfalls and fallacies of cat scratch disease serology: evaluation of Bartonella henselae–based indirect fluorescence assay and enzyme–linked immunoassay. Bergmans AM, et al. **J Clin Microbiol** 1997 Aug; 35(8):1931–7

Serological diagnosis of bovine, caprine, and ovine mastitis caused by Listeria monocytogenes by using an enzyme–linked immunosorbent assay. Bourry A, et al. **J Clin Microbiol** 1997 Jun;35(6):1606–8

Sensitive assay for measurement of antibodies to Clostridium botulinum neurotoxins A, B, and E: use of hapten–labeled–antibody elution to isolate specific complexes. Doellgast GJ, et al. **J Clin Microbiol** 1997 Mar; 35(3):578–83

Immunoglobulin M immunoblot for diagnosis of Borrelia burgdorferi infection in patients with acute facial palsy. Jain VK, et al. **J Clin Microbiol** 1996 Aug;34(8):2033–5

Determination of anti–streptolysin O antibody titer by a new passive agglutination method using sensitized torayspheре particles. Kodama T, et al. **J Clin Microbiol** 1997 Apr; 35(4):839–42

Comparison of the western blot assay with the neutralizing–antibody and enzyme–linked immunosorbent assays for measuring antibody to verocytotoxin 1. Reymond D, et al. **J Clin Microbiol** 1997 Mar;35(3):609–13

Evaluation of enzyme immunoassay for detection of salivary antibody to Helicobacter pylori. Simor AE, et al. **J Clin Microbiol** 1996 Mar;34(3):550–3

Evaluation of a commercial enzyme–linked immunosorbent assay for detection of immunoglobulin M antibody in diagnosis of human leptospiral infection. Winslow WE, et al. **J Clin Microbiol** 1997 Aug;35(8):1938–42

Bovine mastitis caused by Listeria monocytogenes: kinetics of antibody responses in serum and milk after experimental infection. Bourry A, et al. **J Dairy Sci** 1996 Dec; 79(12):2189–95

Detection of Helicobacter pylori DNA in gastric juice by the polymerase chain reaction: comparison with findings in bacterial culture and the detection of tissue IgA and serum IgG antibodies against Helicobacter pylori. Matsukura N, et al. **J Gastroenterol** 1995 Dec;30(6):689–95

Serological response to Chlamydia pneumoniae in patients with sarcoidosis. Puolakkainen M, et al. **J Infect** 1996 Nov; 33(3):199–205

Cross–reactivity to Borrelia burgdorferi proteins in serum samples from residents of a tropical country nonendemic for Lyme disease. Burkot TR, et al. **J Infect Dis** 1997 Feb; 175(2):466–9

Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. Fairley CK, et al. **J Infect Dis** 1996 Dec; 174(6):1360–3

Elevated IgG titer against the C region of streptococcal M protein and its immunodeterminants in patients with poststreptococcal acute glomerulonephritis. Mori K, et al. **J Pediatr** 1997 Aug;131(2):293–9

Elevation in anti–Proteus antibodies in patients with rheumatoid arthritis from Bermuda and England. Subair H, et al. **J Rheumatol** 1995 Oct;22(10):1825–8

The effect of immunization against tetanus during pregnancy for protective antibody titres and specific antibody responses of infants. Kütükçüler N, et al. **J Trop Pediatr** 1996 Oct;42(5):308–9

Detection of toxigenic Pasteurella multocida infections in swine herds by assaying antibodies in sow colostrum. Levonen K, et al. **J Vet Diagn Invest** 1996 Oct;8(4):455–9

Detection of S–100 protein and anticeramide antibodies in leprosy patients by ELISA. Narayan R, et al. **Lepr Rev** 1997 Jun;68(2):117–24

Serological study of Bartonella henselae in cat scratch disease in Japan. Yoshida H, et al. **Microbiol Immunol** 1996; 40(9):671–3

Serological survey of leptospiral infections in sheep, goats and dogs in Cordillera province, Bolivia. Ciceroni L, et al. **New Microbiol** 1997 Jan;20(1):77–81

Detection of antichlamydial antibodies in tears: a diagnostic aid? Haller EM, et al. **Ophthalmology** 1997 Jan; 104(1):125–30

Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. Gibb D, et al. **Pediatr Infect Dis J** 1996 Dec; 15(12):1097–101

Antibodies to pneumococcal polysaccharides in human milk: lack of relationship to colonization and acute otitis media. Rosen IA, et al. **Pediatr Infect Dis J** 1996 Jun;15(6):498–507

Comparison of serum antibodies to pneumolysin with those to pneumococcal capsular polysaccharides in children with acute otitis media. Virolainen A, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):128–33

Post–immunization pneumococcal antibody titers and IgG subclasses. Sorensen RU, et al. **Pediatr Pulmonol** 1996 Sep; 22(3):167–73

Detecting infections of chickens with recent Salmonella pullorum isolates using standard serological methods. Gast RK. **Poult Sci** 1997 Jan;76(1):17–23

Assessing the sensitivity of egg yolk antibody testing for detecting Salmonella enteritidis infections in laying hens. Gast RK, et al. **Poult Sci** 1997 Jun;76(6):798–801

Correlation between anti–Proteus antibodies and isolation rates of P. mirabilis in rheumatoid arthritis. Wilson C, et al. **Rheumatol Int** 1997;16(5):187–9

Positive Lyme titers in a patient with active sarcoidosis [letter] Graber TA, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1997 Mar;14(1):86

Serum antibodies against haemophilus influenzae type b and tetanus at 2.5 years of age: a follow–up of 2 different regimens of infant vaccination. Carlsson RM, et al. **Scand J Infect Dis** 1996;28(5):519–23

Antibody response and reactions to completion of a four–dose series with a two– or three–component acellular pertussis vaccine compared to whole cell pertussis vaccine. Pichichero ME, et al. **Scand J Infect Dis** 1996;28(2):159–63

Antibody to Haemophilus ducreyi among trucking company workers in Kenya. Rakwar J, et al. **Sex Transm Dis** 1997 May;24(5):267–71

Field evaluation of an indirect ELISA for detection of brucellosis in lowland Bolivia. Kerby PJ, et al. **Trop Anim Health Prod** 1997 May;29(2):65–72

Association of Chlamydia trachomatis antibodies with genital contact disease in women in Benin City, Nigeria. Azenabor AA, et al. **Trop Med Int Health** 1997 Apr;2(4):389–92

Parenteral vaccination of mice and piglets with F4+ Escherichia coli suppresses the enteric anti–F4 response upon oral infection. Bianchi AT, et al. **Vaccine** 1996 Feb; 14(3):199–206

Mycoplasma pneumoniae reinfection and vaccination: protective oral vaccination and harmful immunoreactivity after re–infection and parenteral immunization. Cimolai N, et al. **Vaccine** 1996 Oct;14(15):1479–83

Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit–O1/O139 whole cell cholera vaccine. Jertborn M, et al. **Vaccine** 1996 Oct;14(15):1459–65

Modulation of antigen–specific T and B cell responses influence bacterial clearance of non–typeable Haemophilus influenzae from the lung in a rat model. Kyd JM, et al. **Vaccine** 1996 Oct;14(15):1471–8

Development and validation of an indirect enzyme immunoassay for detection of antibody to Brucella abortus in milk. Nielsen K, et al. **Vet Microbiol** 1996 Sep; 52(1–2):165–73

Development and validation of an indirect enzyme immunoassay for detection of ovine antibody to Brucella ovis. Vigliocco AM, et al. **Vet Microbiol** 1997 Mar; 54(3–4):357–68

Detection of Vibrio anguillarum by a sandwich enzyme–linked immunosorbent assay performed with monoclonal antibodies. Adone R, et al. **Zentralbl Veterinarmed [B]** 1996 Dec;43(10):579–84

[Diagnosis of Lyme borreliosis with western blotting] Hulínská D. **Epidemiol Mikrobiol Imunol** 1997 Mar; 46(1):3–8 (Eng. Abstr.) **(Cze)**

[Occurrence of antibodies to chlamydial group antigens in the population of the Czech Republic] Pospíšil L, et al. **Epidemiol Mikrobiol Imunol** 1997 Mar;46(1):13–7 (Eng. Abstr.) **(Cze)**

[Infection with Helicobacter pylori and its serologic detection] Havlasová J, et al. **Vnitr Lek** 1997 Feb; 43(2):111–4 (Eng. Abstr.) **(Cze)**

[Antibody titers against Borrelia in horses in serum and in eyes and occurrence of equine recurrent uveitis] Gerhards H, et al. **Berl Munch Tierarztl Wochenschr** 1996 Aug; 109(8):273–8 (Eng. Abstr.) **(Ger)**

[Clinical study of serum antibodies specific to Chlamydia trachomatis in patients with chronic nonbacterial prostatitis and prostatodynia] Miyata Y, et al. **Hinyokika Kiyo** 1996 Sep;42(9):651–3 (Eng. Abstr.) **(Jpn)**

[Measurement of antibody titers to chlamydial infection and effects of levofloxacin in cystic cervicitis and chlamydial infection] Chimura T. **Jpn J Antibiot** 1997 May;

50(5):479–84 (Eng. Abstr.) **(Jpn)**

[The prevalence of Helicobacter pylori positive serology in asymptomatic Japanese children] Kawakami S, et al. **Kansenshogaku Zasshi** 1996 Nov;70(11):1193–4 **(Jpn)**

[Assay of specific anti–Chlamydia pneumoniae antibodies by ELISA method. 1. Evaluation of ELISA kit using outer membrane complex] Kishimoto T, et al. **Kansenshogaku Zasshi** 1996 Aug;70(8):821–9 (Eng. Abstr.) **(Jpn)**

[Assay of specific anti–Chlamydia pneumoniae antibodies by ELISA method. 2. studies on clinical usefulness and serological diagnostic standards] Kishimoto T, et al. **Kansenshogaku Zasshi** 1996 Aug;70(8):830–9 (Eng. Abstr.) **(Jpn)**

[Evaluation of the assay technique for detection of anti–chlamydial IgA and IgG antibodies in PID patients] Yasuda J, et al. **Kansenshogaku Zasshi** 1997 Mar;71(3):241–7 (Eng. Abstr.) **(Jpn)**

[Evaluation of antibacterial and antitoxic activity of normal human immunoglobulin for intravenous use (IVIG)] Bucholc B, et al. **Med Dosw Mikrobiol** 1996;48(1–2):87–94 (Eng. Abstr.) **(Pol)**

[Results of determining antibodies against Borrelia burgdorferi in patients with limited scleroderma] Silny W, et al. **Pol Tyg Lek** 1996 Jun;51(23–26):329–30 **(Pol)**

[Comparative incidence of detection of specific antibodies to Yersinia pestis capsular antigen and lipopolysaccharide in humans immunized with pest vaccine] Devdariani ZL, et al. **Klin Lab Diagn** 1997 Apr;(4):39–41 (Eng. Abstr.) **(Rus)**

[Assessment of secretory and humoral immune response to group A polysaccharide in rheumatism] Miasoedova SE, et al. **Klin Lab Diagn** 1996 Jul–Aug;(4):43–5 **(Rus)**

[Diagnostic test kit for detection of antibodies to syphilis agent] Vikha IV, et al. **Klin Lab Diagn** 1997 Apr;(4):24, 33–6 (Eng. Abstr.) **(Rus)**

[Frequency of lyme borreliosis and diagnostic titers of antibodies to borrelia burgdorferi in patients with neurological diseases in endemic region of Russia] Il'ina NS, et al. **Klin Med (Mosk)** 1996;74(4):39–42 (Eng. Abstr.) **(Rus)**

[Mycobacterial antigens and antitubercular antibodies in patients with tuberculosis salpingo–oophoritis] Bazarova AB, et al. **Probl Tuberk** 1997;(4):26–8 (Eng. Abstr.) **(Rus)**

[Experience with classical methods for serodiagnosis of tuberculosis in detecting drug resistance of mycobacterium] Evdokimov VN, et al. **Probl Tuberk** 1996;(5):19–20 **(Rus)**

[Detection of antitubercular antibodies in children and adolescents at the health resort stage of management] Lozovskaia ME, et al. **Probl Tuberk** 1997;(4):28–30 (Eng. Abstr.) **(Rus)**

[Immunity to diphtheria in the Croatian population in 1994] Borčić B, et al. **Lijec Vjesn** 1996 Oct;118(10):227–9 (Eng. Abstr.) **(Scr)**

[Leptospira antibodies in small mammals in Eastern Slovakia] Stanko M, et al. **Vet Med (Praha)** 1996 Dec;41(12):373–7 (Eng. Abstr.) **(Slo)**

BIOSYNTHESIS

Structure and protective capacity of tetanus and diphtheria antibodies produced during human pregnancy and transferred to new–born. Pasetti MF, et al. **Am J Reprod Immunol** 1997 Mar;37(3):250–6

Antibody responses of rats and humans to flagella–less cells and OspA protein of Borrelia burgdorferi. Sadziene A, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:140–50

The clonal antibody response to Pseudomonas aeruginosa heat shock protein is highly diverse in cystic fibrosis patients. Ulanova M, et al. **APMIS** 1997 Jun;105(6):449–56

Effect of adjuvants on antibody responses of sheep immunised with recombinant pili from Dichelobacter nodosus. Walduck AK, et al. **Aust Vet J** 1996 Dec;74(6):451–5

Induction of humoral and cellular immune responses by vaccination with M. tuberculosis antigen 85 DNA. Montgomery DL, et al. **Cell Mol Biol (Noisy–le–grand)** 1997 May;43(3):285–92

Humoral immune response against lipopolysaccharide and cytoplasmic proteins of Brucella abortus in cattle vaccinated with B. abortus S19 or experimentally infected with Yersinia enterocolitica serotype 0:9. Baldi PC, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):472–6

Detection of anti–Borrelia burgdorferi antibody responses with the borreliacidal antibody test, indirect fluorescent–antibody assay performed by flow cytometry, and western immunoblotting. Creson JR, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):184–90

Human humoral responses to antigens of Mycobacterium tuberculosis: immunodominance of high–molecular–mass antigens. Laal S, et al. **Clin Diagn Lab Immunol** 1997 Jan; 4(1):49–56

Vibriocidal antibody responses in North American volunteers exposed to wild–type or vaccine Vibrio cholerae O139: specificity and relevance to immunity. Losonsky GA, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):264–9

Antibody response of monkeys to invasion plasmid antigen D after infection with Shigella spp. Oaks EV, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):242–5

Expression of Haemophilus influenzae type b idiotype 1 on naturally acquired antibodies. Ulanova M, et al. **Clin Exp Immunol** 1996 Sep;105(3):422–8

Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette–Guérin (BCG) in patients with superficial bladder cancer. Zlotta AR, et al. **Clin Exp Immunol** 1997 Jul;109(1):157–65

Vaccine–induced IgG antibodies to the linear epitope on the PorB outer membrane protein promote opsonophagocytosis of Neisseria meningitidis by human neutrophils. Delvig AA, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):27–35

Effect of inactivated poliovirus vaccine on the antibody response to Bordetella pertussis antigens when combined with diphtheria–pertussis–tetanus vaccine. Halperin SA, et al. **Clin Infect Dis** 1996 Jan;22(1):59–62

IgA antibodies against Klebsiella and other Gram–negative bacteria in ankylosing spondylitis and acute anterior uveitis. Sprenkels SH, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:48–51

IgA antibodies in HLA–B27 associated acute anterior uveitis and ankylosing spondylitis. Sprenkels SH, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:52–6

Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease? Granoff DM, et al. **Dev Biol Stand** 1997;89:379–89 (39 ref.)

Methods for estimating serological correlates of protection. Siber GR. **Dev Biol Stand** 1997;89:283–96 (16 ref.)

Factors influencing antibody responses to acellular pertussis vaccines. Trollfors B. **Dev Biol Stand** 1997;89:279–82 (14 ref.)

Differences by antigen in seroconversion: sensitivity, specificity and bias in the serological confirmation of pertussis. Wassilak SG, et al. **Dev Biol Stand** 1997;89:221–8 (10 ref.)

Rhodococcal pneumonia: humoral versus cell–mediated immunity [editorial; comment] Hines SA, et al. **Equine Vet J** 1996 Sep;28(5):339–40. Comment on: Equine Vet J 1996 Sep;28(5):344–9.

Field investigations of tularemia in Norway. Berdal BP, et al. **FEMS Immunol Med Microbiol** 1996 Mar;13(3):191–5

Molecular analysis of the modulatory factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. Bouige P, et al. **FEMS Immunol Med Microbiol** 1996 Jan;13(1):71–9

Prevalence of IgG reactivity in Lyme borreliosis patients versus Borrelia garinii and Borrelia afzelii in a restricted area of Northern Italy. Cinco M, et al. **FEMS Immunol Med Microbiol** 1995 Dec;12(3–4):217–22

A recombinant Escherichia coli heat–stable enterotoxin b (STb) fusion protein eliciting neutralizing antibodies. Dubreuil JD, et al. **FEMS Immunol Med Microbiol** 1996 Apr;13(4):317–23

Serum IgG response to an outer membrane porin protein of Burkholderia cepacia in patients with cystic fibrosis. Lacy DE, et al. **FEMS Immunol Med Microbiol** 1997 Feb; 17(2):87–94

Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine. Milagres LG, et al. **FEMS Immunol Med Microbiol** 1996 Jan;13(1):9–17

Immunogenicity of a new lot of Francisella tularensis live vaccine strain in human volunteers. Waag DM, et al. **FEMS Immunol Med Microbiol** 1996 Mar;13(3):205–9

Production and characterisation of a monoclonal antibody to Serpulina hyodysenteriae. Lee BJ, et al. **FEMS Microbiol Lett** 1996 Feb 15;136(2):193–7

Detection of two isotypically different antibodies produced by a murine hybridoma. Chen D, et al. **Hybridoma** 1997 Apr;16(2):195–9

Islet cell and glutamic acid decarboxylase antibodies and heat–shock protein 65 responses in children with newly diagnosed insulin–dependent diabetes mellitus. Scheinin T, et al. **Immunol Lett** 1996 Jan;49(1–2):123–6

Antibody– and cell–mediated immune responses of Actinobacillus pleuropneumoniae–infected and bacterin–vaccinated pigs. Furesz SE, et al. **Infect Immun** 1997 Feb;65(2):358–65

Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor–deficient mice despite a strong local immunoglobulin A response. Johansson M, et al. **Infect Immun** 1997 Mar;65(3):1032–44

Prolonged and preferential production of polymeric immunoglobulin A in response to Streptococcus pneumoniae capsular polysaccharides. Johnson S, et al. **Infect Immun** 1996 Oct;64(10):4339–44

Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Kotloff KL, et al. **Infect Immun** 1996 Nov;64(11):4542–8

Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome–toxoid vaccines. Lowell GH, et al. **Infect Immun** 1996 Nov;64(11):4686–93

Borrelia burgdorferi–pulsed dendritic cells induce a protective immune response against tick–transmitted spirochetes. Mbow ML, et al. **Infect Immun** 1997 Aug; 65(8):3386–90

Immune responses and resistance to brucellosis in mice vaccinated orally with Brucella abortus RB51. Stevens MG, et al. **Infect Immun** 1996 Nov;64(11):4534–41

Identification of D motif epitopes in Staphylococcus aureus fibronectin–binding protein for the production of antibody inhibitors of fibronectin binding. Sun Q, et al. **Infect Immun** 1997 Feb;65(2):537–43

Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Yamamoto M, et al. **Infect Immun** 1997 Feb;65(2):640–4

ELISPOT assay for Chlamydia–specific, antibody–producing cells correlated with conventional complement fixation and microimmunofluorescence. Daugharty H, et al. **J Clin Lab Anal** 1997;11(1):45–52

Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti–OspA IgG in mice. Bockenstedt LK, et al. **J Immunol** 1996 Dec 15;157(12):5496–502

Humoral immunity and regulation of intrapulmonary growth of Legionella pneumophila in the immunocompetent host. Brieland JK, et al. **J Immunol** 1996 Dec 1;157(11):5002–8

A novel role for B cells in early protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. Culkin SJ, et al. **J Immunol** 1997 Apr 1;158(7):3277–84

A model for induction of T cell–independent humoral immunity in response to polysaccharide antigens. Snapper CM, et al. **J Immunol** 1996 Sep 15;157(6):2229–33 (72 ref.)

Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse–human chimeric antibodies as standards. Naess LM, et al. **J Immunol Methods** 1996 Sep 13;196(1):41–9

Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn's disease. Griffin PM, et al. **J Infect Dis** 1997 Mar; 175(3):633–7

An OspA–based DNA vaccine protects mice against infection with Borrelia burgdorferi. Luke CJ, et al. **J Infect Dis** 1997 Jan;175(1):91–7

Primary human immune response to Neisseria meningitidis serogroup C in interleukin–12–treated severe combined immunodeficient mice engrafted with human peripheral blood lymphocytes. Westerink MA, et al. **J Infect Dis** 1997 Jan;175(1):84–90

Prevalence of Helicobacter pylori antibodies in normal children. Ader–Shotet F, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):172–4

Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well–tolerated and able to induce an antibody response in infants. Ahman H, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):134–9

Serum antibodies in six–year–old children vaccinated in infancy with a Haemophilus influenzae type b–tetanus toxoid conjugate vaccine. Claesson BA, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):170–2

Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Kristensen K, et al. **Pediatr Infect Dis J** 1996 Jun; 15(6):525–9

Passively acquired anti–tetanus and anti–Haemophilus antibodies and the response to Haemophilus influenzae type b–tetanus toxoid conjugate vaccine in infancy. Kurikka S, et al. **Pediatr Infect Dis J** 1996 Jun;15(6):530–5

Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Taranger J, et al. **Pediatr Infect Dis J** 1997 Feb;16(2):180–4

Immune responses in mice after gastric and subcutaneous immunization with BCG. Ibsen MW, et al. **Scand J Immunol** 1997 Sep;46(3):274–80

Cross–reactive immune responses against Mycobacterium bovis BCG in mice infected with non–tuberculous mycobacteria belonging to the MAIS–Group. Lozes E, et al. **Scand J Immunol** 1997 Jul;46(1):16–26

The meningococcal transferrin–binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Ala'Aldeen DA, et al. **Vaccine** 1996 Jan;14(1):49–53

Outer membrane vesicle vaccines made from short–chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response. Andersen SR, et al. **Vaccine** 1997 Aug;15(11):1225–34

A nasal whole–cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin. Berstad AK, et al. **Vaccine** 1997 Aug–Sep;15(12–13):1473–8

Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long–lasting humoral and cellular responses in adults. Di Tommaso A, et al. **Vaccine** 1997 Aug;15(11):1218–24

Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Halperin SA, et al. **Vaccine** 1996 Jun;14(8):767–72

Responses to primary and a booster dose of acellular, component, and whole–cell pertussis vaccines initiated at 2 months of age. Huang LM, et al. **Vaccine** 1996 Jun; 14(9):916–22

Factors associated with superior antibody responses to a single dose of Haemophilus influenzae type b–tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. Levine OS, et al. **Vaccine** 1997 Feb; 15(3):325–8

Commensal bacteria as vectors for mucosal vaccines against sexually transmitted diseases: vaginal colonization with recombinant streptococci induces local and systemic

antibodies in mice. Medaglini D, et al. **Vaccine** 1997 Aug–Sep;15(12–13):1330–7

Oral immunization with recombinant Salmonella typhimurium expressing surface protein antigen A (SpaA) of Streptococcus sobrinus: effects of the Salmonella virulence plasmid on the induction of protective and sustained humoral responses in rats. Redman TK, et al. **Vaccine** 1996 Jun;14(9):868–78

Humoral and cellular immune responses in the murine respiratory tract following oral immunization with cholera toxin or Escherichia coli heat–labile enterotoxin. Ruedl C, et al. **Vaccine** 1996 Jun;14(8):792–8

Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein. Thiesen B, et al. **Vaccine** 1997 Feb; 15(2):209–19

Protection, humoral and cell–mediated immune responses in calves immunized with multiple emulsion haemorrhagic septicaemia vaccine. Verma R, et al. **Vaccine** 1997 Aug; 15(11):1254–60

Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Weltzin R, et al. **Vaccine** 1997 Mar;15(4):370–6

The effect of temperature and water quality on antibody response to Aeromonas salmonicida in sunshine bass (Morone chrysops x Morone saxatilis). Hrubec TC, et al. **Vet Immunol Immunopathol** 1996 Mar;50(1–2):157–66

Evidence for genetic control of vaccine–induced antibody responses in cattle. Newman MJ, et al. **Vet Immunol Immunopathol** 1996 Mar;50(1–2):43–54

The immune response of foetal calves. Tierney TJ, et al. **Vet Immunol Immunopathol** 1997 Jul;57(3–4):229–38

Impaired specific immunoreactivity in cows with hepatic lipidosis. Wentink GH, et al. **Vet Immunol Immunopathol** 1997 May;56(1–2):77–83

Immunogenicity of outer membrane protein of Pasteurella multocida in buffalo calves. Pati US, et al. **Vet Microbiol** 1996 Oct;52(3–4):301–11

In vitro cellular responses from sheep draining lymph node cells after subcutaneous inoculation with Salmonella abortusovis. Doucet F, et al. **Vet Res** 1997;28(2):165–78

Production and characterization of monoclonal antibodies against Taylorella equigenitalis. Gradinaru DA, et al. **Vet Res** 1997;28(1):65–76

The serum neutralizing antibody response in cattle to Fusobacterium necrophorum leukotoxoid and possible protection against experimentally induced hepatic abscesses. Saginala S, et al. **Vet Res Commun** 1996; 20(6):493–504

[Anti–Chlamydia pneumoniae antibodies and production of interleukin 6 in acute myocardial infarct] Vergassola R, et al. **G Ital Cardiol** 1997 May;27(5):470–5 (Eng. Abstr.) **(Ita)**

BLOOD

Immune response to phospholipase–A fractions of Salmonella typhi on experimental typhoid infection in mice. Punj V, et al. **Acta Microbiol Pol** 1996;45(3–4):261–7

Stillbirths and maternal antibodies to Chlamydia trachomatis. A new EIA test for serology. Koskiniemi M, et al. **Acta Obstet Gynecol Scand** 1996 Aug;75(7):657–61

Preliminary comparative studies on complement fixation, dot enzyme immunoassay, and western blotting for the detection of antibodies to Mycoplasma mycoides subspecies mycoides SC in Nigerian camel (Camelus dromedarius). Egwu GO, et al. **Acta Vet Hung** 1997;45(2):111–8

Autoimmune component in individuals during immune response to inactivated combined vaccine against Q fever. Krutitskaya L, et al. **Acta Virol** 1996 Sep;40(4):173–7

Chlamydia pneumoniae seroprevalence among HIV–1–infected and uninfected people with known HIV risk factor. Viscott Comandini U, et al. **AIDS** 1996 Nov; 10(13):1543–7

Non–endoscopic tests in the diagnosis of Helicobacter pylori infection. Atherton JC. **Aliment Pharmacol Ther** 1997 Apr; 11 Suppl 1:11–20 (107 ref.)

Chronic cutaneous bacterial hypersensitivity. Backman KS, et al. **Allergy Asthma Proc** 1996 May–Jun;17(3):137–42

Low cord blood pneumococcal immunoglobulin G (IgG) antibodies predict early onset acute otitis media in infancy. Salazar JC, et al. **Am J Epidemiol** 1997 Jun 1; 145(11):1048–56

Detection of serum antibodies to Helicobacter pylori by an immunochromatographic method. Anderson JC, et al. **Am J Gastroenterol** 1997 Jul;92(7):1135–9

Prevalence of serum antibodies to Helicobacter pylori and to CagA protein in liver transplant recipients. Rudi J, et al. **Am J Gastroenterol** 1997 Sep;92(9):1492–5

Antibodies to the chlamydial 60 kd heat–shock protein are associated with laparoscopically confirmed perihepatitis. Money DM, et al. **Am J Obstet Gynecol** 1997 Apr; 176(4):870–7

Diagnostic value of an antibody enzyme–linked immunosorbent assay using affinity–purified antigen in an area endemic for melioidosis. Dharakul T, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):418–23

Seroepidemiologic evidence for murine and scrub typhus in Malang, Indonesia. Richards AL, et al. **Am J Trop Med Hyg** 1997 Jul;57(1):91–5

Evaluation of an enzyme–linked immunosorbent assay in Thai scrub typhus patients. Suwanabun N, et al. **Am J Trop Med Hyg** 1997 Jan;56(1):38–43

Comparison of whole–cell antigens of pressure– and formalin–killed Flexibacter columnaris from channel catfish (Ictalurus punctatus). Bader JA, et al. **Am J Vet Res** 1997 Sep;58(9):985–8

Antibody responses of cattle to outer membrane proteins of Pasteurella multocida A:3. Confer AW, et al. **Am J Vet Res** 1996 Oct;57(10):1453–7

Effects of oral or intravenous inoculation with Brucella abortus strain RB51 vaccine in beagles. Palmer MV, et al. **Am J Vet Res** 1997 Aug;58(8):851–6

Diagnosis of ovine enzootic abortion, using a competitive ELISA based on monoclonal antibodies against variable segments 1 and 2 of the major outer membrane protein of Chlamydia psittaci serotype 1. Salti–Montesanto V, et al. **Am J Vet Res** 1997 Mar;58(3):228–35

Association of gut inflammation with increased serum IgA class Klebsiella antibody concentrations in patients with axial ankylosing spondylitis (AS): implication for different aetiopathogenetic mechanisms for axial and peripheral AS? Mäki–Ikola O, et al. **Ann Rheum Dis** 1997 Mar;56(3):180–3

Human immunoglobulin isotype and IgG subclass response to different antigens of Moraxella catarrhalis. Rahman M, et al. **APMIS** 1997 Mar;105(3):213–20

The major 20–kDa polysaccharide of Staphylococcus epidermidis extracellular slime and its antibodies as powerful agents for detecting antibodies in blood serum and differentiating among slime–positive and –negative S. epidermidis and other staphylococci species. Karamanos NK, et al. **Arch Biochem Biophys** 1997 Jun 15;342(2):389–95

Antibodies to Bartonella species in inner–city intravenous drug users in Baltimore, Md. Comer JA, et al. **Arch Intern Med** 1996 Nov 25;156(21):2491–5

Detection of immunoglobulins on bacterial surface by laser flow cytometry: analysis between Haemophilus influenzae type b and Vibrio cholerae O1 of healthy mother–full term newborn sera. Cano–Morales S, et al. **Arch Med Res** 1996 Spring;27(1):67–70

Serological survey for antibodies to infectious agents in beef cattle in northern South Australia [published erratum appears in Aust Vet J 1997 Apr;75(4):273] Durham PJ, et al. **Aust Vet J** 1997 Feb;75(2):139–40

Serosurvey for Cowdria ruminantium, Coxiella burnetii, and Spotted fever group rickettsiae in ostriches (Struthio camelus) from Zimbabwe. Kelly PJ, et al. **Avian Dis** 1996 Apr–Jun;40(2):448–52

Comparison of procedures to detect Chlamydia psittaci antibodies in cockatiels (Nymphicus hollandicus). Tully TN Jr, et al. **Avian Dis** 1996 Apr–Jun;40(2):266–71

Chlamydia pneumoniae antibodies and serum lipids in Finnish men: cross sectional study. Laurila A, et al. **BMJ** 1997 May 17;314(7092):1456–7

Antibody responses to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT). Chan CY, et al. **Bone Marrow Transplant** 1997 Jul;20(1):33–8

Haemophilus influenzae type b (HIB)–conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Molrine DC, et al. **Bone Marrow Transplant** 1996 Jun;17(6):1149–55

IgG subclasses specific to Staphylococcus epidermidis and Propionibacterium acnes in patients with acne vulgaris. Ashbee HR, et al. **Br J Dermatol** 1997 May;136(5):730–3

Antibody levels to Clostridium perfringens and response to sulphasalazine [letter] Bradley SM, et al. **Br J Rheumatol** 1996 Dec;35(12):1327–8

Antibodies against bacterial lipopolysaccharides in Japanese patients with ankylosing spondylitis. Tani Y, et al. **Br J Rheumatol** 1997 Apr;36(4):491–3

High prevalence of serum immunoglobulin G antibody to Helicobacter pylori and raised serum gastrin and pepsinogen levels in enlarged fold gastritis. Yasunaga Y, et al. **Can J Gastroenterol** 1997 Jul–Aug;11(5):433–6

Detection of antibodies against Actinobacillus pleuropneumoniae serotype 5 using an inhibition enzyme immunoassay. Stenbaek EI, et al. **Can J Vet Res** 1997 Jan; 61(1):1–7

Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high–risk Chinese population. Zhang L, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug; 5(8):627–30

Chlamydial infection in a population of Ethiopian women attending obstetric, gynaecological and mother and child health clinics. Duncan ME, et al. **Cent Afr J Med** 1996 Jan;42(1):1–14

Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Gupta S, et al. **Circulation** 1997 Jul 15; 96(2):404–7

Evaluation of a rapid, new method for detecting serum IgG antibodies to Helicobacter pylori. Sharma TK, et al. **Clin Chem** 1997 May;43(5):832–6

Lipopolysaccharide–specific antibodies in plasma and stools of children with Shigella–associated leukemoid reaction and hemolytic–uremic syndrome. Azim T, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):701–5

Serum antibody response to outer membrane proteins of Moraxella (Branhamella) catarrhalis in patients with bronchopulmonary infection. Christensen JJ, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):717–21

Combined determination of Coxiella burnetii–specific immunoglobulin M (IgM) and IgA improves specificity in the diagnosis of acute Q fever. Devine P, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):384–6

Inhibition of Prevotella and Capnocytophaga immunoglobulin A1 proteases by human serum. Frandsen EV, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):458–64

Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection. Kutlin A, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):213–6

Modification of the Mycobacterium bovis extracellular protein MPB70 with fluorescein for rapid detection of specific serum antibodies by fluorescence polarization. Lin M, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):438–43

Characterization of specific immunoglobulin G (IgG) and its subclasses (IgG1 and IgG2) against the 23–valent pneumococcal vaccine in a healthy adult population: proposal for response criteria. Rodrigo MJ, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):168–72

Humoral antibody to Mobiluncus curtisii, a potential serological marker for bacterial vaginosis. Schwebke JR, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):567–9

Serological follow–up of human brucellosis by measuring IgG antibodies to lipopolysaccharide and cytoplasmic proteins of Brucella species. Baldi PC, et al. **Clin Infect Dis** 1996 Mar;22(3):446–55

Serum antibody concentrations of cytotoxin, exotoxin, A, lipopolysaccharide, protease, and elastase and survival of patients with Pseudomonas aeruginosa bacteremia. Baltch AL, et al. **Clin Infect Dis** 1996 Nov;23(5):1109–16

Association of antibodies to Chlamydia trachomatis heat–shock protein 60 kD with chronic nongonococcal urethritis. Horner PJ, et al. **Clin Infect Dis** 1997 Apr; 24(4):653–60

The lack of association between aging and postvaccination levels of IgG antibody to capsular polysaccharides of Streptococcus pneumoniae. Musher DM, et al. **Clin Infect Dis** 1996 Jan;22(1):165–7

Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization. Musher DM, et al. **Clin Infect Dis** 1997 Mar;24(3):441–6

Chronic subdural empyema: a new presentation of neurobrucellosis. Shoshan Y, et al. **Clin Infect Dis** 1996 Aug;23(2):400–1

Prevalence of Bartonella henselae antibodies among human immunodeficiency virus–infected patients from Bahrain. Yousif A, et al. **Clin Infect Dis** 1996 Aug;23(2):398–9

Ig A antibodies to klebsiella in ankylosing spondylitis. Ardiçoğlu O, et al. **Clin Rheumatol** 1996 Nov;15(6):573–6

Detection of Yersinia enterocolitica O:3 specific antibodies in experimentally infected pigs by an indirect LPS ELISA. Nielsen B, et al. **Contrib Microbiol Immunol** 1995;13:117–9

A comparison of enzyme immunoassays used to measure serum antibodies to components of Bordetella pertussis. Lynn F, et al. **Dev Biol Stand** 1997;89:197–204

Increased prevalence of IgA–Chlamydia antibodies in NIDDM patients. Toplak H, et al. **Diabetes Res Clin Pract** 1996 Apr;32(1–2):97–101

Detection of antibodies to Mycoplasma pneumoniae adhesion P1 in serum specimens from infected and non–infected subjects by immunoblotting. Rastawicki W, et al. **Diagn Microbiol Infect Dis** 1996 Nov–Dec;26(3–4):141–3

High seropositivity of anti–CagA antibody in Helicobacter pylori–infected patients irrelevant to peptic ulcers and normal mucosa in Japan. Maeda S, et al. **Dig Dis Sci** 1997 Sep;42(9):1841–7

Serum antibodies against Helicobacter pylori proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma. Rudi J, et al. **Dig Dis Sci** 1997 Aug; 42(8):1652–9

Serological evidence of Lyme borreliosis in Africa: results from studies in Dar es Salaam, Tanzania. Mhalu FS, et al. **East Afr Med J** 1996 Sep;73(9):583–5

Improved serodiagnostic testing for Lyme disease: results of a multicenter serologic evaluation. Craven RB, et al. **Emerg Infect Dis** 1996 Apr–Jun;2(2):136–40

Emergence of Bartonella quintana infection among homeless persons. Jackson LA, et al. **Emerg Infect Dis** 1996 Apr–Jun; 2(2):141–4

Implications of Helicobacter pylori serological titer for the histological severity of antral gastritis. Sheu BS, et al. **Endoscopy** 1997 Jan;29(1):27–30

Seroprevalence of brucella antibodies among persons in high–risk occupation in Lebanon. Araj GF, et al. **Epidemiol Infect** 1996 Oct;117(2):281–8

Use of a virulence–associated protein based enzyme–linked immunosorbent assay for Rhodococcus equi serology in horses [see comments] Prescott JF, et al. **Equine Vet J** 1996 Sep;28(5):344–9. Comment in: Equine Vet J 1996 Sep;28(5):339–40.

Serological response of experimental ponies orally infected with Ehrlichia risticii. Palmer JE, et al. **Equine Vet J Suppl** 1989 Jun;(7):19–20

Circulating immune complexes in human tuberculosis sera: demonstration of specific antibodies against Mycobacterium tuberculosis glycolipid (DAT, PGLTb1, LOS) antigens in isolated circulating immune complexes. Simonney N, et al. **Eur J Clin Invest** 1997 Feb;27(2):128–34

Use of enzyme–labelled protein G assay for the detection of anti Borrelia burgdorferi antibodies in wild animal sera. Deruaz D, et al. **Eur J Epidemiol** 1996 Oct;12(5):515–9

A seroepidemiological study of Mycoplasma pneumoniae

infections in Denmark over the 50-year period 1946-1995. Lind K, et al. **Eur J Epidemiol** 1997 Jul;13(5):581-6

Exposure of cats in southern Africa to Coxiella burnetii, the agent of Q fever. Matthewman L, et al. **Eur J Epidemiol** 1997 Jun;13(4):477-9

High incidence of Coxiella burnetii markers in a rural population in France. Thibon M, et al. **Eur J Epidemiol** 1996 Oct;12(5):509-13

Antibodies to CagA protein are associated with gastric atrophy in Helicobacter pylori infection. Beales IL, et al. **Eur J Gastroenterol Hepatol** 1996 Jul;8(7):645-9

Seroprevalence of Helicobacter pylori in a birth cohort of 21-year-old New Zealanders. Fawcett JP, et al. **Eur J Gastroenterol Hepatol** 1996 Apr;8(4):365-9

The significance of selected epidemiologico-clinical factors in the prevalence of the Helicobacter pylori infection in young males. Kopański Z, et al. **Eur J Med Res** 1997 Aug 28;2(8):358-60

Plasma concentrations of endotoxin and antiendotoxin antibodies in patients with multiple injuries: a prospective clinical study. Buttenschoen K, et al. **Eur J Surg** 1996 Nov; 162(11):853-60

IgM and IgG significant reactivity to Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii among Italian patients affected by Lyme arthritis or neuroborreliosis. Cinco M, et al. **FEMS Immunol Med Microbiol** 1996 Jun;14(2-3):159-66

Human immune response to epitopes on the meningococcal outer membrane class 5 protein following natural infection. Danelli MG, et al. **FEMS Immunol Med Microbiol** 1996 Sep;15(2-3):159-68

Detection of serum antibodies against Chlamydia pneumoniae by ELISA. Numazaki K, et al. **FEMS Immunol Med Microbiol** 1996 Jun;14(2-3):179-83

Electrophoretic mobility and immune response of outer membrane proteins of Vibrio cholerae O139. Pal S, et al. **FEMS Immunol Med Microbiol** 1996 Sep;15(2-3):143-8

Serum antibodies to commensal oral and gut bacteria vary with age. Percival RS, et al. **FEMS Immunol Med Microbiol** 1996 Aug;15(1):35-42

Francisella tularensis resistance to bactericidal action of normal human serum. Sorokin VM, et al. **FEMS Immunol Med Microbiol** 1996 Mar;13(3):249-52

Enhanced in vitro engulfment of Listeria monocytogenes by rabbit polymorphonuclear leukocytes in the presence of sera from immune rabbits. Vahidy R, et al. **FEMS Immunol Med Microbiol** 1996 Jun;14(2-3):103-7

Antibody response to MfGL-II, a phosphocholine-containing major lipid of Mycoplasma fermentans membranes. Ben-Menachem G, et al. **FEMS Microbiol Lett** 1997 Sep 15;154(2):363-9

Human serum antibody response against iron-repressible outer membrane proteins of Helicobacter pylori. Worst DJ, et al. **FEMS Microbiol Lett** 1996 Oct 15;144(1):29-32

The presence of serum antibody to the chlamydial heat shock protein (CHSP60) as a diagnostic test for tubal factor infertility. Claman P, et al. **Fertil Steril** 1997 Mar; 67(3):501-4

The accuracy of serum chlamydial antibodies in the diagnosis of tubal pathology: a meta-analysis. Mol BW, et al. **Fertil Steril** 1997 Jun;67(6):1031-7

Serological and clinical correlates of gonorrhoea and syphilis in fertile and infertile Nigerian women. Okonofua FE, et al. **Genitourin Med** 1997 Jun;73(3):194-7

Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection [see comments] Parsonnet J, et al. **Gut** 1997 Mar;40(3):297-301. Comment in: ACP J Club 1997 Sep-Oct;127(2):50.

Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Sakagami T, et al. **Gut** 1996 Nov;39(5):639-48

Lack of serologic evidence for Helicobacter pylori infection in head and neck cancer. Grandis JR, et al. **Head Neck** 1997 May;19(3):216-8

Involvement of bacterial antigens in immunoglobulin A nephropathy. Hirabayashi A, et al. **Hiroshima J Med Sci** 1996 Dec;45(4):113-7

Chlamydial serology in 1303 asymptomatic subfertile couples. Eggert-Kruse W, et al. **Hum Reprod** 1997 Jul;12(7):1464-75

Chlamydia trachomatis antibody titres by enzyme-linked immunosorbent assay are useful in predicting severity of adnexal adhesion. Tanikawa M, et al. **Hum Reprod** 1996 Nov;11(11):2418-21

Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Brandt ER, et al. **Immunology** 1996 Nov; 89(3):331-7

Elevated levels of anti-proteus antibodies in patients with active rheumatoid arthritis. Wanchu A, et al. **Indian J Med Res** 1997 Jan;105:39-42

Immunoglobulin profile in mycetoma. Singhvi A, et al. **Indian J Pathol Microbiol** 1996 Jul;39(3):203-6

Immunoglobulin allotypes and immunoglobulin G subclass responses to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in early-onset periodontitis. Choi JI, et al. **Infect Immun** 1996 Oct;64(10):4226-30

Genetic control of antibody responses induced by recombinant Mycobacterium bovis BCG expressing a foreign antigen. Lagranderie M, et al. **Infect Immun** 1997 Aug;65(8):3057-64

Chlamydia trachomatis major outer membrane protein variants escape neutralization by both monoclonal antibodies and human immune sera. Lampe MF, et al. **Infect Immun** 1997 Jan;65(1):317-9

Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice. Ryan ET, et al. **Infect Immun** 1997 Aug;65(8):3118-25

Assessment of the humoral immune response against Plasmodium falciparum rhoptry-associated proteins 1 and 2. Stowers A, et al. **Infect Immun** 1997 Jun;65(6):2329-38

Reinfection in Lyme borreliosis. Eiffert H, et al. **Infection** 1996 Nov-Dec;24(6):437-9

Neurologic manifestation and classification of borreliosis. Haass A, et al. **Infection** 1996 Nov-Dec;24(6):467-9 (12 ref.)

Lyme borreliosis--problems of serological diagnosis. Hofmann H. **Infection** 1996 Nov-Dec;24(6):470-2 (8 ref.)

Lyme borreliosis--an overdiagnosed disease? Svenungsson B, et al. **Infection** 1997 May-Jun;25(3):140-3

A seroepidemiologic survey on brucellosis antibodies in southern Italy. Torre I, et al. **Infection** 1997 May-Jun; 25(3):150-3

Seroprevalences of hepatitis B and C viruses and Helicobacter pylori infection in a small, isolated population at high risk of gastric and liver cancer. Chen SY, et al. **Int J Cancer** 1997 May 29;71(5):776-9

Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer. Laurila AL, et al. **Int J Cancer** 1997 Feb 20;74(1):31-4

Bangkok Workshop on Leprosy Research. Immunodiagnostics, including skin tests. Brennan PJ, et al. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S58-62

Enzyme-linked immunosorbent assay (ELISA) with mycobacterial crude antigens for the sero-epidemiological diagnosis of active tuberculosis. Escobar-Gutierrez A, et al. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4):417-27

The contribution of serological tests to leprosy control. Klatser PR, et al. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4 Suppl):S63-6; discussion S66-7 (21 ref.)

Chlamydia trachomatis infection during pregnancy: can it cause an intrauterine infection? Fejgin MD, et al. **Isr J Med Sci** 1997 Feb;33(2):98-102

The value of anti-Helicobacter pylori IgG antibodies in establishing eradication of infection in children. Fradkin A, et al. **Isr J Med Sci** 1997 Feb;33(2):87-92

Early fall of anti Helicobacter pylori IgG in eradicated patients with non-ulcer dyspepsia [letter; comment] Di Mario F, et al. **Ital J Gastroenterol** 1995 Dec;27(9):510. Comment on: Ital J Gastroenterol 1994 Apr;26(3):107-10.

Anecdotal association of endosalpingiosis with chlamydia trachomatis IgG titers and Fitz-Hugh-Curtis adhesions. Khare VK, et al. **J Am Assoc Gynecol Laparosc** 1995 Feb; 2(2):143-5

Suspected ehrlichial infection in five cats from a household. Peavy GM, et al. **J Am Vet Med Assoc** 1997 Jan 15; 210(2):231-4

Proficiency testing of selected antigen and antibody tests for use in dogs and cats. Troy GC, et al. **J Am Vet Med Assoc** 1996 Sep 1;209(5):914-7

Vaccination schedules to raise antibody concentrations against epsilon-toxin of Clostridium perfringens in ewes and their triplet lambs. de la Rosa C, et al. **J Anim Sci** 1997 Sep;75(9):2328-34

Clostridial vaccination efficacy on stimulating and maintaining an immune response in beef cows and calves. Troxel TR, et al. **J Anim Sci** 1997 Jan;75(1):19-25

Anti-smooth muscle antibody in clinical human and experimental animal Mycoplasma pneumoniae infection. Cimolai N, et al. **J Appl Microbiol** 1997 May;82(5):625-30

Serum anti-Helicobacter pylori antibodies and gastritis. Yamamoto I, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S164-8

Infrequent detection of lipoarabinomannan antibodies in human immunodeficiency virus-associated mycobacterial disease. Swiss HIV Cohort Study. Boggian K, et al. **J Clin Microbiol** 1996 Jul;34(7):1854-5

Performance of Meridian ImmunoCard Mycoplasma Test in a multicenter clinical trial [letter; comment] Dorigo-Zetsma JW, et al. **J Clin Microbiol** 1996 Dec; 34(12):3249-50. Comment on: J Clin Microbiol 1996 May;34(5):1180-3.

Serodiagnosis of listeriosis based upon detection of antibodies against recombinant truncated forms of listeriolysin O. Gholizadeh Y, et al. **J Clin Microbiol** 1996 Jun;34(6):1391-5

Seroepidemiology of Helicobacter pylori infection in a cohort of children monitored from 6 months to 11 years of age. Granström M, et al. **J Clin Microbiol** 1997 Feb;35(2):468-70

LEPTO dipstick, a dipstick assay for detection of Leptospira-specific immunoglobulin M antibodies in human sera. Gussenhoven GC, et al. **J Clin Microbiol** 1997 Jan;35(1):92-7

Interpretation criteria for standardized Western blots for three European species of Borrelia burgdorferi sensu lato. Hauser U, et al. **J Clin Microbiol** 1997 Jun;35(6):1433-44

Temporal study of immunoglobin M seroreactivity to Borrelia burgdorferi in patients treated for Lyme borreliosis. Hilton E, et al. **J Clin Microbiol** 1997 Mar; 35(3):774-6

Recommendation to include OspA and OspB in the new immunoblotting criteria for serodiagnosis of Lyme disease. Hilton E, et al. **J Clin Microbiol** 1996 Jun;34(6):1353-4

Dot-immunogold filtration assay as a screening test for syphilis. Huang Q, et al. **J Clin Microbiol** 1996 Aug; 34(8):2011-3

Evaluation of Pyloriset Dry, a new rapid agglutination test for Helicobacter pylori antibody detection. Lozniewski A, et al. **J Clin Microbiol** 1996 Jul;34(7):1773-5

Evaluation of eight enzyme immunoassays for detection of immunoglobulin G against Helicobacter pylori. Meijer BC, et al. **J Clin Microbiol** 1997 Jan;35(1):292-4

Rapid method for detection of Coxiella burnetii antibodies using high-density particle agglutination. Nguyen SV, et al. **J Clin Microbiol** 1996 Dec;34(12):2947-51

An indirect immunofluorescence assay using a cell culture-derived antigen for detection of antibodies to the agent of human granulocytic ehrlichiosis. Nicholson WL, et al. **J Clin Microbiol** 1997 Jun;35(6):1510-6

Immunoblot assay for serodiagnosis of Helicobacter pylori infections. Nilsson I, et al. **J Clin Microbiol** 1997 Feb; 35(2):427-32

Use of the Treponema pallidum-specific captia syphilis IgG assay in conjunction with the rapid plasma reagin to test for syphilis. Reisner BS, et al. **J Clin Microbiol** 1997 May; 35(5):1141-3

Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents. Reymond D, et al. **J Clin Microbiol** 1996 Sep;34(9):2053-7

Serum CagA antibodies in asymptomatic subjects and patients with peptic ulcer: lack of correlation of IgG antibody in patients with peptic ulcer or asymptomatic Helicobacter pylori gastritis. Graham DY, et al. **J Clin Pathol** 1996 Oct; 49(10):829-32

Helicobacter pylori antibody titres in serum, plasma and successively thawed specimens: implications for epidemiological and clinical studies. Pearce DC, et al. **J Clin Pathol** 1996 Dec;49(12):1017-9

Detection of IgM antibodies in pulmonary tuberculosis by ELISA using A60 antigen. Mahajan M, et al. **J Commun Dis** 1996 Sep;28(3):176-80

Serological tests for monitoring Helicobacter pylori eradication treatment. Hirschl AM, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:33-6

Helicobacter pylori infection in childhood: H. pylori isolation rate in gastric juice in relation to positive serum antibody rates. Okuda M, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:6-8

A homogeneous fluorescence polarization assay for detection of antibody to Brucella abortus. Nielsen K, et al. **J Immunol Methods** 1996 Sep 9;195(1-2):161-8

Capture-ELISA: a new assay for the detection of immunoglobulin M isotype antibodies using Chlamydia trachomatis antigen. Poussin M, et al. **J Immunol Methods** 1997 May 12;204(1):1-12

Sensitivity of EIA in the diagnosis of tuberculosis using 38-kDa antigen. Chander J, et al. **J Indian Med Assoc** 1996 Oct;94(10):376-8

Comparison of enzyme immunoassays for antibodies to Haemophilus ducreyi in a community outbreak of chancroid in the United States. Chen CY, et al. **J Infect Dis** 1997 Jun;175(6):1390-5

Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. Daum RS, et al. **J Infect Dis** 1997 Aug;176(2):445-55

Prevalence and correlates of antibody to chlamydial heat shock protein in women attending sexually transmitted disease clinics and women with confirmed pelvic inflammatory disease. Eckert LO, et al. **J Infect Dis** 1997 Jun;175(6):1453-8

Seroepidemiology of emerging tickborne infectious diseases in a Northern California community. Fritz CL, et al. **J Infect Dis** 1997 Jun;175(6):1432-9

The early humoral response in human granulocytic ehrlichiosis. IJdo JW, et al. **J Infect Dis** 1997 Sep; 176(3):687-92

Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. Janoff EN, et al. **J Infect Dis** 1997 Apr;175(4):975-8

Surrogate marker of preclinical tuberculosis in human immunodeficiency virus infection: antibodies to an 88-kDa secreted antigen of Mycobacterium tuberculosis. Laal S, et al. **J Infect Dis** 1997 Jul;176(1):133-43

Immune response to non-O157 Vero toxin-producing Escherichia coli in patients with hemolytic uremic syndrome [see comments] Ludwig K, et al. **J Infect Dis** 1996 Nov;174(5):1028-39. Comment in: J Infect Dis 1996 Nov;174(5):1136-9.

Antibody response to Arcanobacterium haemolyticum infection in humans. Nyman M, et al. **J Infect Dis** 1997 Jun;175(6):1515-8

Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine. Padilla ML, et al. **J Infect Dis** 1996 Oct;174(4):739-46

Seroprevalence of CagA-positive strains among Helicobacter pylori-infected, healthy young adults. Parsonnet J, et al. **J Infect Dis** 1997 May;175(5):1240-2

Antibody to chlamydial hsp60 predicts an increased risk for chlamydial pelvic inflammatory disease. Peeling RW, et

al. **J Infect Dis** 1997 May;175(5):1153–8

Relationship of immune response to heat-shock protein A and characteristics of Helicobacter pylori-infected patients. Pérez-Pérez GI, et al. **J Infect Dis** 1996 Nov; 174(5):1046–50

Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection. Robin G, et al. **J Infect Dis** 1997 May; 175(5):1128–33

A new multiantigen immunoassay for the quantification of IgG antibodies to capsular polysaccharides of Streptococcus pneumoniae. Roth F, et al. **J Infect Dis** 1997 Aug;176(2):526–9

A population-based serologic survey of Helicobacter pylori infection in children and adolescents in the United States. Staat MA, et al. **J Infect Dis** 1996 Nov;174(5):1120–3

Diagnostic potential of a serological assay for the diagnosis of ulcerans disease based on the putative Mycobacterium ulcerans toxin. Roberts B, et al. **J Med Microbiol** 1997 Apr; 46(4):333–9

Type-specific antibodies to purified streptococcal M proteins from potentially rheumatogenic M-types in patients with rheumatic fever and rheumatic heart disease. Thakur A, et al. **J Med Microbiol** 1996 Dec;45(6):483–9

Levels of serum IgG against Porphyromonas gingivalis in patients with rapidly progressive periodontitis, rheumatoid arthritis and adult periodontitis. Yusof Z, et al. **J Nihon Univ Sch Dent** 1995 Dec;37(4):197–200

Prevalence of Helicobacter pylori infection in asymptomatic children. Hardikar W, et al. **J Paediatr Child Health** 1995 Dec;31(6):537–41

Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis [see comments] Bjornson AB, et al. **J Pediatr** 1996 Dec;129(6):828–35. Comment in: J Pediatr 1996 Dec;129(6):788–9.

Immunity to Haemophilus influenzae type b polysaccharide capsule after vaccination with the complete series of oligosaccharide CRM197 conjugate vaccine in infants with human immunodeficiency virus infection. Peters VB, et al. **J Pediatr** 1996 Mar;128(3):363–5

A comparison of IgG antibody reactive with Bacteroides forsythus and Porphyromonas gingivalis in adult and early-onset periodontitis. Califano JV, et al. **J Periodontol** 1997 Aug;68(8):734–8

Relationship between serum antibody levels and subgingival colonization of Porphyromonas gingivalis in patients with various types of periodontitis. Kojima T, et al. **J Periodontol** 1997 Jul;68(7):618–25

The relationship between gingivitis and the serum antibodies to the microbiota associated with periodontal disease in children with Down's syndrome. Morinushi T, et al. **J Periodontol** 1997 Jul;68(7):626–31

Elevated serum Chlamydia trachomatis IgG antibodies. What do they mean for IVF pregnancy rates and loss? Sharara FI, et al. **J Reprod Med** 1997 May;42(5):281–6

The absence of antibodies against Borrelia burgdorferi in the sera of Japanese patients with localized scleroderma [letter] Akimoto S, et al. **J Rheumatol** 1996 Mar;23(3):573–4

Antibodies to Klebsiella, Proteus, and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis. Tani Y, et al. **J Rheumatol** 1997 Jan; 24(1):109–14

Serological survey for bovine leptospirosis in the Volksrust district. Myburgh JG, et al. **J S Afr Vet Assoc** 1990 Dec; 61(4):172–3

A dot immunobinding assay (dot-ELISA) for the rapid serodiagnosis of Salmonella enteritidis infection in chickens. Charles SD, et al. **J Vet Diagn Invest** 1996 Jul;8(3):310–4

Immunoblot analysis of the immunoglobulin G response to Ehrlichia canis in dogs: an international survey. Hegarty BC, et al. **J Vet Diagn Invest** 1997 Jan;9(1):32–8

Serologic responses of Brucella abortus strain 19 calfhood-vaccinated cattle following adult vaccination with strain RB51. Olsen SC, et al. **J Vet Diagn Invest** 1996 Oct;8(4):451–4

Comparison of polyclonal antibodies to three different preparations of Mycobacterium paratuberculosis in immunohistochemical diagnosis of Johne's disease in cattle. Stabel JR, et al. **J Vet Diagn Invest** 1996 Oct;8(4):469–73

Post-therapy antibody titers in dogs with ehrlichiosis: follow-up study on 68 patients treated primarily with tetracycline and/or doxycycline. Bartsch RC, et al. **J Vet Intern Med** 1996 Jul-Aug;10(4):271–4

An enzyme-linked immunosorbent assay (ELISA) for the detection of antibody against Streptococcus suis type 2 in infected pigs. Kataoka Y, et al. **J Vet Med Sci** 1996 Apr; 58(4):369–72

A recombinant antigen from the heartwater agent (Cowdria ruminatium) reactive with antibodies in some southeastern United States white-tailed deer (Odocoileus virginianus), but not cattle, sera. Katz JB, et al. **J Wildl Dis** 1996 Jul; 32(3):424–30

Exposure of wild waterfowl to Mycoplasma anatis. Samuel MD, et al. **J Wildl Dis** 1996 Apr;32(2):331–7

Epidemiological survey of small rodents for spotted fever rickettsial antibody in Hokkaido, Japan. Okabayashi T, et al. **Jpn J Med Sci Biol** 1996 Apr;49(2):63–8

Serological reactivity to a synthetic analog of phenolic glycolipid I and early detection of leprosy in an area of low endemicity. González-Abreu E, et al. **Lepr Rev** 1996 Mar;67(1):4–12

Detection of antibodies to Bartonella henselae in clinically diagnosed cat scratch disease. Flexman JP, et al. **Med J Aust** 1997 May 19;166(10):532–5

Analysis of the human antibody response to outer surface protein C (OspC) of Borrelia burgdorferi sensu stricto, B. garinii, and B. afzelii. Mathiesen MJ, et al. **Med Microbiol Immunol (Berl)** 1996 Nov;185(3):121–9

Impaired antigen specific responses and enhanced polyclonal stimulation in mice infected with Ehrlichia muris. Kawahara M, et al. **Microbiol Immunol** 1996;40(8):575–81

Isolation of Coxiella burnetii from children with influenza-like symptoms in Japan. Nagaoka H, et al. **Microbiol Immunol** 1996;40(2):147–51

Serological survey of spotted fever group rickettsia in wild rats in Thailand in the 1970s. Okabayashi T, et al. **Microbiol Immunol** 1996;40(12):895–8

Seroepidemiology of feline chlamydiosis by microimmunofluorescence assay with multiple strains as antigens. Pudjiatmoko, et al. **Microbiol Immunol** 1996; 40(10):755–9

Serological indicators of Helicobacter pylori infection in adult dyspeptic patients and healthy blood donors. Rechciński T, et al. **Microbiol Immunol** 1997;41(5):387–93

The Mycoplasma hominis P120 membrane protein contains a 216 amino acid hypervariable domain that is recognized by the human humoral immune response. Nyvold C, et al. **Microbiology** 1997 Feb;143 (Pt 2):675–88

Use of enzyme-linked-immunosorbent assay for detection of IgG and IgM antibodies to Fusobacterium necrophorum in cattle. Kanoe M, et al. **Microbios** 1996;87(353):257–62

Detection of Lyme disease after OspA vaccine [letter] Schutzer SE, et al. **N Engl J Med** 1997 Sep 11;337(11):794–5

Prevalence of Helicobacter pylori antibodies in CAPD patients [letter] Antoniou S, et al. **Nephron** 1997;75(3):358–9

Serum IgG antibodies to Helicobacter pylori in patients with recurrent aphthous stomatitis and other oral disorders. Porter SR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Mar;83(3):325–8

Endotoxin antibodies in African sleeping sickness. Pentreath VW, et al. **Parasitology** 1997 Apr;114 (Pt 4):361–5

Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. King JC Jr, et al. **Pediatr Infect Dis J** 1996 Mar;15(3):192–6

Differential antibody responses in 6.B major histocompatibility (B) complex congenic chickens. Dix MC, et al. **Poult Sci** 1996 Feb;75(2):203–7

Genetic differences and heritability of antibody response to Escherichia coli vaccination in young broiler chicks. Yonash N, et al. **Poult Sci** 1996 Jun;75(6):683–90

Leptospira interrogans serovar icterohaemorrhagiae seropositivity and the reproductive performance of sows. Ferreira Neto JS, et al. **Prev Vet Med** 1997 Jul; 31(1-2):87–93

The prevalence of serum antibodies to tick-borne infections in cattle in smallholder dairy farms in Murang'a District, Kenya; a cross-sectional study. Gitau GK, et al. **Prev Vet Med** 1997 May;30(2):95–107

Estimated prevalence of paratuberculosis in Missouri, USA cattle. Thorne JG, et al. **Prev Vet Med** 1997 Jul; 31(1-2):51–7

Seroprevalence of Borrelia burgdorferi in dogs in Alabama, USA. Wright JC, et al. **Prev Vet Med** 1997 Jul; 31(1-2):127–31

Deficient expression of antibodies specific for bacterial DNA by patients with systemic lupus erythematosus. Pisetsky DS, et al. **Proc Assoc Am Physicians** 1997 May; 109(3):237–44

Antibody response to Salmonella typhi in human schistosomiasis mansoni. Muniz-Junqueira MI, et al. **Rev Soc Bras Med Trop** 1996 Sep-Oct;29(5):441–5

High frequency of Yersinia antibodies in healthy populations in Finland and Germany. Mäki-Ikola O, et al. **Rheumatol Int** 1997;16(6):227–9

Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Tiwana H, et al. **Rheumatol Int** 1997;17(1):11–6

Low seroprevalence of Helicobacter pylori antibodies in historical sera of patients with Crohn's disease. Wagtmans MJ, et al. **Scand J Gastroenterol** 1997 Jul;32(7):712–8

Serology of chlamydia in relation to asthma and bronchial hyperresponsiveness. Bjornsson E, et al. **Scand J Infect Dis** 1996;28(1):63–9

A seroepidemiologic study of Chlamydia pneumoniae, Chlamydia trachomatis and Chlamydia psittaci in different populations on the mainland of China. Ni AP, et al. **Scand J Infect Dis** 1996;28(6):553–7

Circulating antibody secreting cells and humoral antibody response after parenteral immunization with a meningococcal polysaccharide vaccine. Nieminen T, et al. **Scand J Infect Dis** 1996;28(1):53–8

Respiratory Chlamydial infections in a Hong Kong teaching hospital and association with coronary heart disease. Thomas GN, et al. **Scand J Infect Dis Suppl** 1997;104:30–3

Evaluation of the Mycobacterium leprae particle agglutination (MLPA) test as a tool in the epidemiology of leprosy in high prevalence village in South Sulawesi, Indonesia. Hatta M, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):631–5

Retrospective review of dot enzyme immunoassay test for typhoid fever in an endemic area. Jackson AA, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):625–30

Indirect hemagglutination antibodies against Burkholderia pseudomallei in normal blood donors and suspected cases of melioidosis in Malaysia. Norazah A, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):263–6

Detection of Mycoplasma gallisepticum antibodiesin the sera of village chickens by the enzyme-linked immunosorbent assay. Shah-Majid M. **Trop Anim Health Prod** 1996 May; 28(2):181–2

Helicobacter pylori serology in childhood. Gürakan F, et al. **Turk J Pediatr** 1996 Jul-Sep;38(3):329–34

Diphtheria antitoxin titres six years after basic immunization of adults. Björkholm B, et al. **Vaccine** 1996 Dec; 14(17-18):1633–6

Serum antibody responses of cattle vaccinated with partially purified native Pasteurella haemolytica leukotoxin. Confer AW, et al. **Vaccine** 1997 Aug-Sep;15(12-13):1423–9

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Peeters CC, et al. **Vaccine** 1996 Jul;14(10):1009–15

Enhanced antibody response in cattle against Leptospira hardjo by intradermal vaccination. Samina I, et al. **Vaccine** 1997 Aug-Sep;15(12-13):1434–6

Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly. Sankilampi U, et al. **Vaccine** 1997 Jul;15(10):1133–7

The use of listeriolysin O in an ELISA, a skin test and a lymphocyte blastogenesis assay on sheep experimentally infected with Listeria monocytogenes, Listeria ivanovii or Listeria innocua. Baetz AL, et al. **Vet Microbiol** 1996 Jul; 51(1-2):151–9

Comparative seroreactivity to Bartonella henselae and Bartonella quintana among cats from Israel and North Carolina. Baneth G, et al. **Vet Microbiol** 1996 May; 50(1-2):95–103

Competitive enzyme-linked immunosorbent assay using monoclonal antibodies to the Brucella melitensis BP26 protein to evaluate antibody responses in infected and B. melitensis Rev.1 vaccinated sheep. Debbarh HS, et al. **Vet Microbiol** 1996 Dec;53(3-4):325–37

Antigenic analysis of Rhodococcus equi preparations using different horse sera. Fontanals AM, et al. **Vet Microbiol** 1997 Jun 16;56(3-4):247–55

Time course of the serological response to Yersinia enterocolitica O:3 in experimentally infected pigs. Nielsen B, et al. **Vet Microbiol** 1996 Feb;48(3-4):293–303

Assessment of the immunogenic potential of Rhodococcus equi virulence associated protein (VapA) in mice. Prescott JF, et al. **Vet Microbiol** 1997 Jun 16;56(3-4):213–25

An indirect ELISA using a monoclonal anti IgG1 enzyme conjugate for the diagnosis of bovine brucellosis. Uzal FA, et al. **Vet Microbiol** 1996 Sep;52(1-2):175–80

Enzyme-linked immunosorbent assay and immunoblot analysis for detection of antibodies to Borrelia burgdorferi in dogs. The impact of serum absorption with homologous and heterologous bacteriae. Wittenbrink MM, et al. **Vet Microbiol** 1996 Feb;48(3-4):257–68

Development and validation of an indirect enzyme immunoassay for detection of antibody to Anaplasma marginale in bovine sera. Nielsen K, et al. **Vet Parasitol** 1996 Dec 31;67(3-4):133–42

Use of the enzyme-linked immunosorbent assay for screening cattle for Brucella antibodies in Nigeria. Ocholi RA, et al. **Vet Q** 1996 Mar;18(1):22–4

Comparison of the absorbed ELISA and agar gel immunodiffusion test with clinicopathological findings in ovine clinical paratuberculosis. Clarke CJ, et al. **Vet Rec** 1996 Dec 21-28;139(25):618–21

Lyme disease serology in cattle [letter; comment] [see comments] Cranwell MP, et al. **Vet Rec** 1996 Jun 1; 138(22):551–2. Comment on: Vet Rec 1994 Dec 10;135(24):577–8. Comment in: Vet Rec 1996 Jun 15;138(24):600.

Comparison of five tests for the detection of antibodies against chlamydial (enzootic) abortion of ewes. Jones GE, et al. **Vet Rec** 1997 Aug 16;141(7):164–8

Detection of serum antibodies against Chlamydia pneumoniae by in vitro neutralization and microimmunofluorescence assays. Donati M, et al. **Zentralbl Bakteriol** 1996 Jun; 284(1):52–7

Serum antibody reactivity to recombinant mig and whole cell antigens in Mycobacterium avium infection. Plum G, et al. **Zentralbl Bakteriol** 1996 Jul;284(2-3):348–60

Prevalence of antibodies to Eperythrozoon ovis in Norwegian sheep. Brun-Hansen H, et al. **Zentralbl Veterinarmed [B]** 1997 Jul;44(5):307–8

Serologic survey for antibodies to Borrelia burgdorferi in sheep, goats and dogs in Cordillera Province, Bolivia. Ciceroni L, et al. **Zentralbl Veterinarmed [B]** 1997 May; 44(3):133–7

[A comparison of purified urease antigen and whole cell antigen of Helicobacter pylori by ELISA test—study on the application and serum diagnoses of Helicobacter pylori urease diagnostic reagent] Chen JJ, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Feb;

17(1):44–6 (Eng. Abstr.) **(Chi)**

[A serological study on the infection of Helicobacter pylori among children] Li M, et al.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1996 Feb; 17(1):33–5 (Eng. Abstr.) **(Chi)**

[Application of serology and 14C-urea breath test to monitoring of the effect of anti-Helicobacter pylori chemotherapy] Hu P, et al.
Chung Hua Nei Ko Tsa Chih 1995 Dec;34(12):819–22 (Eng. Abstr.) **(Chi)**

[Serodiagnosis of Helicobacter pylori infections by detection of immunoglobulin G antibodies with an immunoblot technique] Pan Z, et al. **Chung Hua Nei Ko Tsa Chih** 1996 Jan;35(1):9–11 (Eng. Abstr.) **(Chi)**

[Helicobacter pylori: antibodies in sera of pigs and calves] Seidel KE, et al. **Berl Munch Tierarztl Wochenschr** 1996 Nov–Dec;109(11–12):434–9 (Eng. Abstr.) **(Ger)**

[Diphtheria booster immunization for adults] Hasselhorn HM, et al. **Dtsch Med Wochenschr** 1997 Mar 7;122(10):281–6 (Eng. Abstr.) **(Ger)**

[Appearance of antibodies against Borrelia burgdorferi in different populations of pigeons (Columba livia var. domestica vel urbana] Thormählen B, et al.
Tierarztl Prax 1997 Apr;25(2):145–7 (Eng. Abstr.) **(Ger)**

[Determination of cutoff value of serum anti-Legionella antibody titer--microplate agglutination test (MPAT)] Yabuuchi E, et al. **Kansenshogaku Zasshi** 1997 Feb; 71(2):116–24 (Eng. Abstr.) **(Jpn)**

[Serodiagnosis of tuberculosis by detection of antituberculous glycolipid antigen (TBGL antigen) antibodies in serum using enzyme-linked immunosorbent assay: clinical evaluation of anti-TBGL antibodies assay kit] Toyoda T, et al. **Kekkaku** 1996 Dec;71(12):655–61 (Eng. Abstr.) **(Jpn)**

[Serological diagnosis of enterohaemorrhagic Escherichia coli(EHEC) infection by passive hemagglutination assay] Kai A, et al. **Nippon Rinsho** 1997 Mar;55(3):680–5 (Eng. Abstr.) **(Jpn)**

[Bacterial agglutination test for diagnosis of enterohemorrhagic Escherichia coli(EHEC) infection] Kobayashi K. **Nippon Rinsho** 1997 Mar;55(3):675–9 (Eng. Abstr.) **(Jpn)**

[Prevalence of serum anti-Helicobacter pylori IgG antibody in persons with severe motor and intellectual disabilities--comparison between institutionalized persons and persons living at home] Takano N, et al.
No To Hattatsu 1997 Jul;29(4):273–7 (Eng. Abstr.) **(Jpn)**

[Distribution of EIA reactive values and serum antibody titers of Chlamydia trachomatis urethritis and cervicitis at the first visit] Kojima H, et al. **Rinsho Byori** 1996 Feb; 44(2):153–8 (Eng. Abstr.) **(Jpn)**

[A case of neuroborreliosis with unilateral radiculoneuropathy and elevated serum antibodies for Borrelia garinii and Borrelia afzelii] Miyazaki K, et al.
Rinsho Shinkeigaku 1996 Oct;36(10):1155–60 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Usefulness of the cytotoxic test for testing levels of diphtheria antibodies in sera of immunized animals] Kudelski Z, et al. **Med Dosw Mikrobiol** 1996;48(1–2):95–8 (Eng. Abstr.) **(Pol)**

[An anti-Listeria seroepidemiological study in Uberaba, MG] Tavares-Neto J, et al. **Rev Soc Bras Med Trop** 1996 Jan–Feb;29(1):41–5 (Eng. Abstr.) **(Por)**

[The value of serological examination in detecting the etiological agents involved in causing reactive arthritis] Constantiniu S, et al.
Bacteriol Virusol Parazitol Epidemiol 1996 Jan–Jun; 41(1–2):75–9 **(Rum)**

[A standard immunoenzyme test system for detecting antibodies to the causative agent of tuberculosis: the means for its utilization in tuberculosis control work] Vasil'ev AV, et al. **Probl Tuberk** 1996;(1):13–5 (Eng. Abstr.) **(Rus)**

[The structure of the determinants of streptococcal group A polysaccharide common to epidermal antigens to which antibodies are formed at different stages of the rheumatic process] Bazanova EA, et al.
Zh Mikrobiol Epidemiol Immunobiol 1996 Sep–Oct;(5):16–9 (Eng. Abstr.) **(Rus)**

[Antibody titers to glycolipid chemotype Re and endotoxin binding by leukocytes in suppurative meningitis] Iushchuk ND, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov–Dec;(6):50–3 (Eng. Abstr.) **(Rus)**

[The evaluation of different agglutination and adhesion tests with erythrocytic reagents in determining antibodies to the O and H antigens of Salmonella typhimurium in comparison with immunoenzyme analysis (IEA)] Karal'nik BV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct;(5):76–80 (Eng. Abstr.) **(Rus)**

[The isotypic characteristics of antibodies in persons inoculated with a serogroup-A meningococcal polysaccharide vaccine] Skirda TA, et al.
Zh Mikrobiol Epidemiol Immunobiol 1996 Jan–Feb;(1):42–6 (Eng. Abstr.) **(Rus)**

[Detection of anti-Treponema pallidum antibodies with colloidal gold immunoprobes] Burgos JD, et al.
Enferm Infecc Microbiol Clin 1996 May;14(5):304–7 (Eng. Abstr.) **(Spa)**

[Serologic study in patients with streptococcal infective endocarditis] Planes AM, et al. **Med Clin (Barc)** 1996 Nov 23;107(18):693–7 (Eng. Abstr.) **(Spa)**

[Determination of bactericidal antibodies directed against vibrio cholerae in an adult population in Montevideo] Varela G, et al. **Rev Argent Microbiol** 1995 Oct–Dec; 27(4):185–90 (Eng. Abstr.) **(Spa)**

[Unjustified disposal of transfusion blood because of antibodies against brucella] Martínez-Canseco J, et al.
Rev Invest Clin 1996 Jul–Aug;48(4):297–300 (Eng. Abstr.) **(Spa)**

[immunization and immune response to pneumococcal vaccination] Hidalgo H, et al. **Rev Med Chil** 1996 Mar; 124(3):287–92 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Clinical value of specific intrathecal production of antibodies. Treib J, et al. **Acta Virol** 1997 Feb;41(1):27–30

Identification of antibody responses to Mycobacterium tuberculosis antigens in the CSF of tuberculous meningitis patients by Western blotting. Patil SA, et al.
Clin Immunol Immunopathol 1996 Oct;81(1):35–40

Diagnostic value of cerebrospinal fluid examination in children with peripheral facial palsy and suspected Lyme borreliosis. Albisetti M, et al. **Neurology** 1997 Sep; 49(3):817–24

Endotoxin antibodies in African sleeping sickness. Pentreath VW, et al. **Parasitology** 1997 Apr;114 (Pt 4):361–5

Application of anti-leptospira ELISA-IgM for the etiologic elucidation of meningitis. Silva MV, et al.
Rev Inst Med Trop Sao Paulo 1996 Mar–Apr;38(2):153–6

Comparison of intrathecal synthesis of Treponema pallidum-specific IgG antibodies and polymerase chain reaction for the diagnosis of neurosyphilis. Moskophidis M, et al. **Zentralbl Bakteriol** 1996 Mar;283(3):295–305

CHEMISTRY

Structure and protective capacity of tetanus and diphtheria antibodies produced during human pregnancy and transferred to new-born. Pasetti MF, et al.
Am J Reprod Immunol 1997 Mar;37(3):250–6

Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a. Hartman AB, et al. **Clin Diagn Lab Immunol** 1996 Sep; 3(5):584–9

Low affinity, antibody binding of an Escherichia coli-derived component. Ohlin M, et al.
FEMS Immunol Med Microbiol 1996 Feb;13(2):161–8

Analysis of culture filtrate and cell wall-associated antigens of Mycobacterium paratuberculosis with monoclonal antibodies. Mutharia LM, et al. **Infect Immun** 1997 Feb; 65(2):387–94

Epitope mapping of homologous and cross-reactive antigens by monoclonal antibodies to streptococcal cell membrane (mAb to SCM). Lange CF, et al. **Mol Immunol** 1996 Jun; 33(9):777–86

Bactericidal antibody recognition of a PorA epitope of Neisseria meningitidis: crystal structure of a Fab fragment in complex with a fluorescein-conjugated peptide. van den Elsen JM, et al. **Proteins** 1997 Sep;29(1):113–25

Screening for Salmonella with a murine monoclonal antibody M105 detects both Felix O1 bacteriophage sensitive and resistant Salmonella strains. Tsang RS, et al.
Zentralbl Bakteriol 1997 Jun;286(1):23–32

CLASSIFICATION

Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards. Naess LM, et al. **J Immunol Methods** 1996 Sep 13;196(1):41–9

DIAGNOSTIC USE

Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a "gold standard"? Callister SM, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):399–402

Monoclonal antibodies to the enterotoxin of Bacteroides fragilis: production, characterization, and immunodiagnostic application. Qadri F, et al.
Clin Diagn Lab Immunol 1996 Sep;3(5):608–10

Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Romero-Steiner S, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):415–22

Colonization by Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis and Prevotella intermedia in adult periodontitis patients as detected by the antibody-based Evalusite Test. Boyer BP, et al.
J Clin Periodontol 1996 May;23(5):477–84

[Immunoenzyme analysis for the identification of Mycobacterium bovis by using monoclonal antibodies] Androsova MV, et al. **Probl Tuberk** 1996;(1):40–3 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Activity of antibodies against Salmonella dublin, Toxoplasma gondii, or Actinobacillus pleuropneumoniae in sera after treatment with electron beam irradiation or binary ethylenimine. Kyvsgaard NC, et al.
Clin Diagn Lab Immunol 1996 Nov;3(6):628–34

GENETICS

Phage display and bacterial expression of a recombinant Fab specific for Pseudomonas aeruginosa serotype O6 lipopolysaccharide. Tout NL, et al.
Clin Diagn Lab Immunol 1997 Mar;4(2):147–55

Avidity maturation, repertoire shift, and strain differences in antibodies to bacterial levan, a type 2 thymus-independent polysaccharide antigen. Boswell CM, et al. **J Immunol** 1996 Sep 1;157(5):1996–2005

Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. Musher DM, et al. **J Investig Med** 1997 Feb;45(2):57–68

Of four murine, anti-Shigella dysenteriae type 1 O-polysaccharide antibodies, three employ V-genes that differ extensively from those of the fourth. Miller CE, et al. **Mol Immunol** 1996 Nov;33(16):1217–22

Antibody response to Actinobacillus pleuropneumoniae antigens after vaccination of pigs bred for high and low immune response. Magnusson U, et al. **Vaccine** 1997 Jun; 15(9):997–1000

IMMUNOLOGY

Monoclonal antibody based differentiation of Coxiella burnetii isolates. Sekeyová Z, et al. **Acta Virol** 1996 Jun; 40(3):127–32

Immunoglobulin response to Salmonella enteritidis outer membrane proteins. Use for evaluating infectious status. Maddox CW, et al. **Adv Exp Med Biol** 1997;412:89–92

Passive protection of calves with Pasteurella haemolytica antiserum. Mosier DA, et al. **Am J Vet Res** 1995 Oct; 56(10):1317–21

Role of passive humoral immunity in experimental mycetoma by Nocardia brasiliensis. Salinas-Carmona MC, et al.
Ann N Y Acad Sci 1996 Oct 25;797:263–5

Local and systemic antibody levels against protein D of Haemophilus influenzae following immunization and infection in rats. Akkoyunlu M, et al. **APMIS** 1996 Oct; 104(10):709–17

Semiquantitative estimation of Shigella antigen-specific antibodies: correlation with disease severity during shigellosis. Islam D, et al. **APMIS** 1996 Jul–Aug; 104(7–8):563–74

Immunomagnetic detection of Bacillus stearothermophilus spores in food and environmental samples. Blake MR, et al. **Appl Environ Microbiol** 1997 May;63(5):1643–6

Comparison of serological reactions of Rickettsiae-infected patients and rabbit anti-Proteus OX antibodies with Proteus OX2, OX19 and OXK lipopolysaccharides. Amano K, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(4):235–40

Serotyping of Actinobacillus pleuropneumoniae serotype 5 strains using a monoclonal-based polystyrene agglutination test. Dubreuil JD, et al. **Can J Vet Res** 1996 Jan;60(1):69–71

Effect of antibodies on the chain length and growth of Streptococcus sobrinus. van Raamsdonk M, et al.
Caries Res 1997;31(1):35–40

Humoral immune response against lipopolysaccharide and cytoplasmic proteins of Brucella abortus in cattle vaccinated with B. abortus S19 or experimentally infected with Yersinia enterocolitica serotype 0:9. Baldi PC, et al.
Clin Diagn Lab Immunol 1996 Jul;3(4):472–6

Immunoblot analysis of anti-Ureaplasma urealyticum antibody in pregnant women and newborn infants. Cunningham CK, et al. **Clin Diagn Lab Immunol** 1996 Sep; 3(5):487–92

Specific antibody reactivity against a 110-kilodalton Actinobacillus actinomycetemcomitans protein in subjects with periodontitis. Fleming TF, et al.
Clin Diagn Lab Immunol 1996 Nov;3(6):678–81

Rates of tetanus protection and transplacental tetanus antibody transfer in pregnant women from different socioeconomic groups in Peru. Madico G, et al.
Clin Diagn Lab Immunol 1996 Nov;3(6):753–5

Humoral antibody to Mobiluncus curtisii, a potential serological marker for bacterial vaginosis. Schwebke JR, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):567–9

Specificity and immunochemical properties of antibodies to bacterial DNA in sera of normal human subjects and patients with systemic lupus erythematosus (SLE). Wu ZQ, et al. **Clin Exp Immunol** 1997 Jul;109(1):27–31

Activity of sera from patients with Lyme disease against Borrelia burgdorferi. Pavia CS, et al. **Clin Infect Dis** 1997 Jul;25 Suppl 1:S25–30

Ehrlichia equi infection associated with rhabdomyolysis. Shea KW, et al. **Clin Infect Dis** 1996 Mar;22(3):605

Role of IgA, IgG, and IgM antibodies against Haemophilus parainfluenzae antigens in IgA nephropathy. Suzuki S, et al. **Clin Nephrol** 1996 Nov;46(5):287–95

Molecular mimicry: the geographical distribution of immune responses to Klebsiella in ankylosing spondylitis and its relevance to therapy. Ebringer A, et al. **Clin Rheumatol** 1996 Jan;15 Suppl 1:57–61 (24 ref.)

Antibodies to Listeria monocytogenes. Bhunia AK.
Crit Rev Microbiol 1997;23(2):77–107 (179 ref.)

Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Giuliano M, et al. **Dev Biol Stand** 1997;89:275–8

Human IgG binding ability of streptococcal M3 protein: its related complement activation-dependent M3 protein polymerization. Hong K.
FEMS Immunol Med Microbiol 1997 Jul;18(3):163–74

Serological characterisation of anti-endotoxin sera directed against the conjugates of oligosaccharide core of Escherichia coli type R1, R2, R3, J5 and Salmonella Ra with tetanus toxoid. Lugowski C, et al.

FEMS Immunol Med Microbiol 1996 Nov;16(1):21–30

Characterization of monoclonal antibodies that recognize common epitopes located on O antigen of lipopolysaccharide of serotypes 1, 9 and 11 of Actinobacillus pleuropneumoniae. Rodríguez Barbosa JI, et al. **FEMS Immunol Med Microbiol** 1996 Dec 31; 16(3–4):173–81

Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines. Rouppe van der Voort EM, et al. **FEMS Immunol Med Microbiol** 1997 Mar; 17(3):139–48

The major outer membrane protein, CD, extracted from Moraxella (Branhamella) catarrhalis is a potential vaccine antigen that induces bactericidal antibodies. Yang YP, et al. **FEMS Immunol Med Microbiol** 1997 Mar;17(3):187–99

Adaptive surface antigen variation in Mycoplasma bovis to the host immune response. Le Grand D, et al. **FEMS Microbiol Lett** 1996 Nov 1;144(2–3):267–75

Analysis of functional domains of Vibrio parahaemolyticus thermostable direct hemolysin using monoclonal antibodies. Tang G, et al. **FEMS Microbiol Lett** 1997 May 15; 150(2):289–96

Characterization of monoclonal antibodies for rapid identification of Actinomyces naeslundii in clinical samples. Thurnheer T, et al. **FEMS Microbiol Lett** 1997 May 15; 150(2):255–62

In vitro evaluation of the role of antibodies against Helicobacter pylori in inhibiting adherence of the organism to gastric cells. Clyne M, et al. **Gut** 1997 Jun;40(6):731–8

Characterization and application of a strain-specific monoclonal antibody against the rhizosphere bacterium Azospirillum brasilense Wa5. Schloter M, et al. **Hybridoma** 1997 Apr;16(2):183–7

A human monoclonal antibody which inhibits the coaggregation activity of Porphyromonas gingivalis. Abiko Y, et al. **Infect Immun** 1997 Sep;65(9):3966–9

Biological activity of serum antibodies to a nonacylated form of lipoprotein D of Haemophilus influenzae. Akkoyunlu M, et al. **Infect Immun** 1996 Nov;64(11):4586–92

Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Amersdorfer P, et al. **Infect Immun** 1997 Sep;65(9):3743–52

Immunization with outer membrane protein P6 from nontypeable Haemophilus influenzae induces bactericidal antibody and affords protection in the chinchilla model of otitis media. DeMaria TF, et al. **Infect Immun** 1996 Dec; 64(12):5187–92

OspA antibodies inhibit the acquisition of Borrelia burgdorferi by Ixodes ticks. de Silva AM, et al. **Infect Immun** 1997 Aug;65(8):3146–50

Listeriolysin and IrpA are major protein targets of the human humoral response against Listeria monocytogenes. Grenningloh R, et al. **Infect Immun** 1997 Sep;65(9):3976–80

Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Ho M, et al. **Infect Immun** 1997 Sep;65(9):3648–53

Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Kozlowski PA, et al. **Infect Immun** 1997 Apr;65(4):1387–94

Anti-Ehrlichia chaffeensis antibody complexed with E. chaffeensis induces potent proinflammatory cytokine mRNA expression in human monocytes through sustained reduction of IkappaB-alpha and activation of NF-kappaB. Lee EH, et al. **Infect Immun** 1997 Jul;65(7):2890–7

Heterogeneity of antibodies reactive with the dominant antigen of Actinobacillus actinomycetemcomitans. Nakashima K, et al. **Infect Immun** 1997 Sep;65(9):3794–8

Evidence for the presence of streptococcal-superantigen–neutralizing antibodies in normal polyspecific immunoglobulin G. Norrby-Teglund A, et al. **Infect Immun** 1996 Dec;64(12):5395–8

Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains. Rokbi B, et al. **Infect Immun** 1997 Jan;65(1):55–63

Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection. Rukavina T, et al. **Infect Immun** 1997 May;65(5):1754–60

A monoclonal antibody to Borrelia burgdorferi flagellin modifies neuroblastoma cell neuritogenesis in vitro: a possible role for autoimmunity in the neuropathy of Lyme disease. Sigal LH, et al. **Infect Immun** 1997 May; 65(5):1722–8

Low antigenicity of the polysaccharide region of Helicobacter pylori lipopolysaccharides derived from tumors of patients with gastric cancer. Yokota S, et al. **Infect Immun** 1997 Sep;65(9):3509–12

Effects of antibodies against cell surface protein antigen PAc-glucosyltransferase fusion proteins on glucan synthesis and cell adhesion of Streptococcus mutans. Yu H, et al. **Infect Immun** 1997 Jun;65(6):2292–8

Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Zollinger WD, et al. **Infect Immun** 1997 Mar;65(3):1053–60

A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity against Shiga-like toxins and EHEC-hemolysin of Escherichia coli O157:H7. Lissner R, et al. **Infection** 1996 Sep–Oct;24(5):378–83

Chlamydial antibodies in semen: search for "silent" chlamydial infections in asymptomatic andrological patients. Weidner W, et al. **Infection** 1996 Jul–Aug;24(4):309–13

Recognition of lipid antigens by sera of mice infected with Mycobacterium lepraemurium. Luna-Herrera J, et al. **Int J Lepr Other Mycobact Dis** 1996 Sep;64(3):299–305

Antibodies to phenolic glycolipid-I and sulfatide-I in leprosy and tuberculosis [letter] Luna-Herrera J, et al. **Int J Lepr Other Mycobact Dis** 1996 Sep;64(3):327–9

Evidence against colonic mucosa colonisation by Helicobacter pylori. Lack of a specific antibody response in homogenates of rectal endoscopic biopsies. Luzza F, et al. **Ital J Gastroenterol** 1996 Oct–Nov;28(8):447–51

Immune response to Fusobacterium nucleatum, Prevotella intermedia and other anaerobes in children with acute tonsillitis. Brook I, et al. **J Antimicrob Chemother** 1997 Jun; 39(6):763–9

Immunomagnetic separation of Erwinia carotovora subsp. atroseptica from potato peel extracts to improve detection sensitivity on a crystal violet pectate medium or by PCR. van der Wolf JM, et al. **J Appl Bacteriol** 1996 May; 80(5):487–95

Immunochemical characterization of O polysaccharides composing the alpha-D-rhamnose backbone of lipopolysaccharide of Pseudomonas syringae and classification of bacteria into serogroups O1 and O2 with monoclonal antibodies. Ovod V, et al. **J Bacteriol** 1996 Nov;178(22):6459–65

Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection. Thankavel K, et al. **J Clin Invest** 1997 Sep 1;100(5):1123–36

Isolation of catalase-negative Listeria monocytogenes strains from listeriosis patients and their rapid identification by anti-p60 antibodies and/or PCR. Bubert A, et al. **J Clin Microbiol** 1997 Jan;35(1):179–83

Detection and characterization of the coli surface antigen 6 of enterotoxigenic Escherichia coli strains by using monoclonal antibodies. Helander A, et al. **J Clin Microbiol** 1997 Apr;35(4):867–72

Serological cross-reactions between Bartonella quintana, Bartonella henselae, and Coxiella burnetii. La Scola B, et al. **J Clin Microbiol** 1996 Sep;34(9):2270–4

Use of monoclonal antibodies to facilitate identification, cloning, and purification of Chlamydia trachomatis hsp10. LaVerda D, et al. **J Clin Microbiol** 1997 May;35(5):1209–15

Detection of Antibodies to Pasteurella multocida by capture enzyme immunoassay using a monoclonal antibody against P37 antigen. Peterson RR, et al. **J Clin Microbiol** 1997 Jan;35(1):208–12

Typing of Helicobacter pylori with monoclonal antibodies against Lewis antigens in lipopolysaccharide. Simoons-Smit IM, et al. **J Clin Microbiol** 1996 Sep; 34(9):2196–200

Protein characterization of Australian spotted fever group rickettsiae and monoclonal antibody typing of Rickettsia honei. Stenos J, et al. **J Clin Microbiol** 1997 Jan;35(1):261–3

Detection of endocervical anti-Chlamydia trachomatis immunoglobulin A in pregnant women by a rapid, 6-minute enzyme-linked immunosorbent assay: comparison with PCR and chlamydial antigen detection methods. Witkin SS, et al. **J Clin Microbiol** 1997 Jul;35(7):1781–3

Production of monoclonal antibodies against Rickettsia massiliae and their use in antigenic and epidemiological studies. Xu W, et al. **J Clin Microbiol** 1997 Jul; 35(7):1715–21

Characterization of and application of monoclonal antibodies against Rickettsia africae, a newly recognized species of spotted fever group rickettsia. Xu W, et al. **J Clin Microbiol** 1997 Jan;35(1):64–70

Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. Brandwein SL, et al. **J Immunol** 1997 Jul 1;159(1):44–52

Differential binding avidities of human IgM for staphylococcal protein A derive from specific germ-line VH3 gene usage. Hakoda M, et al. **J Immunol** 1996 Oct 1;157(7):2976–81

Staphylococcal protein A simultaneously interacts with framework region 1, complementarity-determining region 2, and framework region 3 on human VH3-encoded Igs. Potter KN, et al. **J Immunol** 1996 Oct 1;157(7):2982–8

Characterization of murine monoclonal antibodies specific for the 45/47 kDa antigen complex (APA) of Mycobacterium tuberculosis, M. bovis and BCG. Horn C, et al. **J Immunol Methods** 1996 Oct 16;197(1–2):151–9

Cross-reactivity to Borrelia burgdorferi proteins in serum samples from residents of a tropical country nonendemic for Lyme disease. Burkot TR, et al. **J Infect Dis** 1997 Feb; 175(2):466–9

Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. Jacobs BC, et al. **J Infect Dis** 1997 Mar;175(3):729–33

Mechanism of antibody-mediated reduction of nasopharyngeal colonization by Haemophilus influenzae type b studied in an infant rat model. Kauppi-Korkeila M, et al. **J Infect Dis** 1996 Dec;174(6):1337–40

Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. Nahm MH, et al. **J Infect Dis** 1997 Sep;176(3):698–703

Anti-Staphylococcus aureus, anti-Streptococcus pneumoniae and anti-Moraxella catarrhalis specific IgE in asthmatic children. Brarda OA, et al. **J Investig Allergol Clin Immunol** 1996 Jul–Aug;6(4):266–9

Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. Musher DM, et al. **J Investig Med** 1997 Feb;45(2):57–68

Site-specific geographic association between Amblyomma americanum (Acari: Ixodidae) infestations and Ehrlichia chaffeensis-reactive (Rickettsiales: Ehrlichieae) antibodies in white-tailed deer. Lockhart JM, et al. **J Med Entomol** 1996 Jan;33(1):153–8

Identification by monoclonal antibodies of serotype D strains of Pasteurella multocida representing various geographic origins and host species. Vasfi Marandi M, et al. **J Med Microbiol** 1997 Jul;46(7):603–10

Epitope mapping by negative selection of randomized antigen libraries displayed on filamentous phage. Jespers L, et al. **J Mol Biol** 1997 Jun 27;269(5):704–18

Immunization with antibodies that mimic LPS protects against gram negative bacterial sepsis. Klaerner HG, et al. **J Surg Res** 1997 May;69(2):249–54

Anti-OspA antibody reduces reservoir competence of mice for Borrelia burgdorferi, the agent of Lyme disease. Brunet LR, et al. **Med Vet Entomol** 1997 Apr;11(2):198–200

Monoclonal antibodies against Haemophilus influenzae lipopolysaccharides: clone MAHI 4 binding to a pentasaccharide containing terminal beta-Gal residues and clone MAHI 10 recognizing terminal phosphorylated saccharide residues. Borrelli S, et al. **Microb Pathog** 1996 Nov;21(5):307–18

Heat shock response of Streptococcus pneumoniae: identification of immunoreactive stress proteins. Hamel J, et al. **Microb Pathog** 1997 Jul;23(1):11–21

Complement resistance of capsulated strains of Aeromonas salmonicida. Merino S, et al. **Microb Pathog** 1997 May; 22(5):315–20

Antibodies are generated during infection to Coxiella burnetii macrophage infectivity potentiator protein (Cb-Mip). Seshu J, et al. **Microbiol Immunol** 1997;41(4):371–6

Characterization of serotype II polysaccharide antigen of group E streptococci using a monoclonal antibody. Tomotake H, et al. **Microbiol Res** 1997 Jul;152(2):113–9

Monoclonal antibodies against Streptococcus pneumoniae detect epitopes on eubacterial ribosomal proteins L7/L12 and on streptococcal elongation factor Ts. Kolberg J, et al. **Microbiology** 1997 Jan;143 (Pt 1):55–61

Antibody mediated inhibition of adhesion of Shigella dysenteriae 1 to guinea pig colonic epithelial cells in vitro. Guhathakurta B, et al. **Microbios** 1996;87(353):249–56

Generation of antiserum to specific epitopes. Marchion DC, et al. **Mol Biotechnol** 1996 Dec;6(3):231–40

Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Whittum-Hudson JA, et al. **Nat Med** 1996 Oct;2(10):1116–21

Hepatitis C after immunoglobulin administration [letter; comment] Barton LL. **Pediatr Infect Dis J** 1996 Jun; 15(6):558. Comment on: Pediatr Infect Dis J 1995 Nov;14(11):982–92.

Persistent elevation of immunoglobulin G titer against the C region of recombinant group A streptococcal M protein in patients with rheumatic fever. Mori K, et al. **Pediatr Res** 1996 Feb;39(2):336–42

Serodiagnosis of tuberculous meningitis by enzyme-linked immunosorbent assay (ELISA). Niculescu D, et al. **Roum Arch Microbiol Immunol** 1996 Jul–Sep;55(3):205–14

Immunomodulation of LPS ability to induce the local Shwartzman reaction. Aguillón JC, et al. **Scand J Immunol** 1996 Dec;44(6):551–5

Significance of antibodies to streptococcal M protein in psoriatic arthritis and their association with HLA-A*0207. Muto M, et al. **Tissue Antigens** 1996 Dec;48(6):645–50

Antibody response to Actinobacillus pleuropneumoniae antigens after vaccination of pigs bred for high and low immune response. Magnusson U, et al. **Vaccine** 1997 Jun; 15(9):997–1000

Recombinant Opc meningococcal protein, folded in vitro, elicits bactericidal antibodies after immunization. Musacchio A, et al. **Vaccine** 1997 Apr–May;15(6–7):751–8

Antibodies to OspB prevent infection of C3H mice challenged with Borrelia burgdorferi isolates expressing truncated OspB antigens. Probert WS, et al. **Vaccine** 1997 Jan;15(1):15–9

Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection. Van De Verg LL, et al. **Vaccine** 1996 Aug;14(11):1062–8

Rapid identification of porcine Serpulina species by colony blot assay using a genus-specific monoclonal antibody [see comments] Achacha M, et al. **Vet Rec** 1996 Nov 30; 139(22):539–41. Comment in: Vet Rec 1997 Jan 11;140(2):51–2.

Antibodies against 12 serotypes of Actinobacillus pleuropneumoniae in finnish slaughter sows. Levonen K, et al. **Zentralbl Veterinarmed [B]** 1996 Oct;43(8):489–95

[Antibodies against Bacillus megaterium H glycoprotein in patients with oncological and nononcological pathology of gastro-intestinal tract] Autenshlius AI, et al. **Biull Eksp Biol Med** 1994 May;117(5):520–2 **(Rus)**

[An analysis of the specificity of anti-Mycobacterium

monoclonal antibodies and of the chemical nature of the antigenic determinants with which they react] Avdienko VG, et al. **Probl Tuberk** 1996;(1):6–8 (Eng. Abstr.) **(Rus)**

[Dependence of immunological reactivity on blood groups and microflora in patients with chronic purulent otitis media] Zemskov AM, et al. **Vestn Otorinolaringol** 1996 Sep–Oct;(5):39–42 (Eng. Abstr.) **(Rus)**

[New concepts of the mechanisms of immunopatholgies+ of Streptococcal etiology] Burova LA, et al. **Vestn Ross Akad Med Nauk** 1996;(11):28–34 (Eng. Abstr.) **(Rus)**

[The immunochemical and biological properties of monoclonal antibodies to Chlamydia trachomatis] Kutlin AV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jan–Feb;(1):3–6 (Eng. Abstr.) **(Rus)**

[Cross-reactivity between Chlamydia psittaci and Acinetobacter in indirect immunofluorescence assays] Espinosa M, et al. **Rev Argent Microbiol** 1996 Jul–Sep; 28(3):143–6 (Eng. Abstr.) **(Spa)**

[Immunologic response in Helicobacter pylori gastric infection] Terrés AM, et al. **Rev Esp Enferm Dig** 1996 Sep; 88(9):625–9 (43 ref.) **(Spa)**

ISOLATION & PURIFICATION

Immunopurification of polyclonal antibodies to recombinant proteins of the same gene family. Pompéia C, et al. **Biotechniques** 1996 Dec;21(6):986–8, 990

Culture-negative listeriosis of the central nervous system diagnosed by detection of antibodies to listeriolysin O [letter] Gholizadeh Y, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb;16(2):176–8

Serological examination of human and animal sera from six countries of three continents for the presence of rickettsial antibodies. Kováčová E, et al. **Eur J Epidemiol** 1996 Feb; 12(1):85–9

Prevalence of antibodies to rickettsiae in the north-western part of Bosnia and Herzegovina. Punda-Polic V, et al. **Eur J Epidemiol** 1995 Dec;11(6):697–9

Borrelia burgdorferi sensu lato in an endemic environment: wild sika deer (Cervus nippon yesoensis) with infected ticks and antibodies. Isogai E, et al. **Microbiol Immunol** 1996; 40(1):13–19

Evaluation of protein A and protein G as indicator system in an ELISA for detecting antibodies in mink to Pseudomonas aeruginosa. Rivera E, et al. **Vet Microbiol** 1994 Dec;42(4):265–71

[The isolation and characteristics of monoclonal antibodies to Mycobacterium smegmatis and M. kansasii] Kulikovskaia NV, et al. **Probl Tuberk** 1996;(1):43–6 (Eng. Abstr.) **(Rus)**

METABOLISM

Immunoresponsiveness of fast-growing chickens as influenced by feeding regimen. Praharaj NK, et al. **Br Poult Sci** 1996 Sep;37(4):779–86

Immunisation of chickens to reduce intestinal colonisation with Campylobacter jejuni. Widders PR, et al. **Br Poult Sci** 1996 Sep;37(4):765–78

Rates of tetanus protection and transplacental tetanus antibody transfer in pregnant women from different socioeconomic groups in Peru. Madico G, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):753–5

Antibodies to chlamydia trachomatis in semen and relationship with parameters of male fertility. Eggert-Kruse W, et al. **Hum Reprod** 1996 Jul;11(7):1408–17

Chicken anti-protein A prevents Staphylococcus aureus protein A from binding to human and rabbit IgG in immunoassays and eliminates most false positive results. Hoffman WL, et al. **J Immunol Methods** 1996 Oct 30; 198(1):67–77

Multi-well ELISA based on independent peptide antigens for antibody capture. Application to Lyme disease serodiagnosis. Yu Z, et al. **J Immunol Methods** 1996 Oct 30;198(1):25–33

Antibody response to Mycoplasma bovis of calves introduced to a farm contaminated with the organism. Nagatomo H, et al. **J Vet Med Sci** 1996 Sep;58(9):919–20

Mucosal immune responses to intestinal bacterial pathogens. Bloom PD, et al. **Semin Gastrointest Dis** 1996 Jul; 7(3):151–66 (125 ref.)

Association of placental transfer of anti-Haemophilus influenzae type b polysaccharide antibodies with their V regions. Park MK, et al. **Vaccine** 1996 Sep;14(13):1219–22

Effect of Pasteurella multocida toxin on in vivo immune responses in piglets. van Diemen PM, et al. **Vet Q** 1996 Dec;18(4):141–6

PHARMACOLOGY

An in vitro model to study the effect of antibodies and cell receptor analogues on meningococcal adherence to human oroepithelial cells. Carbonare SB, et al. **Braz J Med Biol Res** 1996 Feb;29(2):239–44

Inhibition of Prevotella and Capnocytophaga immunoglobulin A1 proteases by human serum. Frandsen EV, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):458–64

Molecular analysis of the modulatory factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. Bouige P, et al. **FEMS Immunol Med Microbiol** 1996 Jan;13(1):71–9

Francisella tularensis resistance to bactericidal action of normal human serum. Sorokin VM, et al. **FEMS Immunol Med Microbiol** 1996 Mar;13(3):249–52

Anti-receptor antibodies inhibit Pseudomonas aeruginosa binding to the cornea and prevent corneal perforation. Hobden JA, et al. **Immunol Cell Biol** 1996 Jun;74(3):258–64

Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection. Rukavina T, et al. **Infect Immun** 1997 May;65(5):1754–60

A monoclonal antibody to Borrelia burgdorferi flagellin modifies neuroblastoma cell neuritogenesis in vitro: a possible role for autoimmunity in the neuropathy of Lyme disease. Sigal LH, et al. **Infect Immun** 1997 May; 65(5):1722–8

Dual effects of LPS antibodies on cellular uptake of LPS and LPS-induced proinflammatory functions. Pollack M, et al. **J Immunol** 1997 Oct 1;159(7):3519–30

Enhancement of Streptococcus pneumoniae serotype 6B infection in mice after passive immunization with human serum. Aaberge IS, et al. **Microb Pathog** 1996 Aug; 21(2):125–37

Electron microscopic observation of the antibody-induced capsular swelling phenomenon in Klebsiella pneumoniae. Meno Y, et al. **Microbiol Immunol** 1996;40(5):339–44

The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Ala'Aldeen DA, et al. **Vaccine** 1996 Jan;14(1):49–53

PHYSIOLOGY

Antibody- and cell-mediated immune responses of Actinobacillus pleuropneumoniae-infected and bacterin-vaccinated pigs. Furesz SE, et al. **Infect Immun** 1997 Feb;65(2):358–65

Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice. Su H, et al. **Infect Immun** 1997 Jun;65(6):1993–9

RADIATION EFFECTS

Activity of antibodies against Salmonella dublin, Toxoplasma gondii, or Actinobacillus pleuropneumoniae in sera after treatment with electron beam irradiation or binary ethylenimine. Kyvsgaard NC, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):628–34

THERAPEUTIC USE

Towards anti-Pseudomonas aeruginosa adhesion therapy. Gilboa-Garber N. **Adv Exp Med Biol** 1996;408:39–50 (63 ref.)

Failure of hyperimmune plasma to prevent pneumonia caused by Rhodococcus equi in foals. Hurley JR, et al. **Aust Vet J** 1995 Nov;72(11):418–20

Passive immunization against dental plaque formation in humans: effect of a mouth rinse containing egg yolk antibodies (IgY) specific to Streptococcus mutans. Hatta H, et al. **Caries Res** 1997;31(4):268–74

Oral administration of antibodies as prophylaxis and therapy in Campylobacter jejuni-infected chickens. Tsubokura K, et al. **Clin Exp Immunol** 1997 Jun;108(3):451–5

Serum therapy for Cryptococcal meningitis [see comments] Gordon MA, et al. **Clin Infect Dis** 1995 Dec;21(6):1477–9 . Comment in: Clin Infect Dis 1996 Jul;23(1):209–10.

Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Preston MJ, et al. **Invest Ophthalmol Vis Sci** 1997 Jun;38(7):1418–25

Passive immune cross-protection in mice produced by rabbit antisera against different serotypes of Pasteurella multocida. Rimler RB. **J Comp Pathol** 1996 May;114(4):347–60

Immunoprotection by monoclonal antibodies to the porins and lipopolysaccharide of Salmonella typhimurium. Singh SP, et al. **Microb Pathog** 1996 Oct;21(4):249–63

Chicken egg yolk antibodies against F18ab fimbriae of Escherichia coli inhibit shedding of F18 positive E. coli by experimentally infected pigs. Imberechts H, et al. **Vet Microbiol** 1997 Mar;54(3–4):329–41

URINE

Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination. Cohen D, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):451–5

ANTIBODIES, BISPECIFIC

see related
IMMUNOTOXINS
RADIOIMMUNOTHERAPY

Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody. Hombach A, et al. **Anticancer Res** 1997 May-Jun; 17(3C):2025–32

Bispecific antibody mediated targeting of nido-carboranes to human colon carcinoma cells. Primus FJ, et al. **Bioconjug Chem** 1996 Sep–Oct;7(5):532–5

Agglutination-inhibition assay for the detection of recombinant proteins tagged with peptide epitopes. Dolezal O, et al. **Biotechniques** 1997 May;22(5):897–904

Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. Wickham TJ, et al. **J Virol** 1996 Oct;70(10):6831–8

Happy coupling: recruiting both antigen and effector function [news] Fearon D. **Nat Biotechnol** 1997 Jul;15(7):618–9

Mix and match: building manifold binding sites [news; comment] Hoogenboom HR. **Nat Biotechnol** 1997 Feb; 15(2):125–6. Comment on: Nat Biotechnol 1997 Feb;15(2):159–63.

Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Holliger P, et al. **Protein Eng** 1996 Mar;9(3):299–305

[Antithrombogenic effect of urokinase bound to the collagen surface with bifunctional antibodies] Stepanova IP, et al. **Biull Eksp Biol Med** 1994 May;117(5):504–7 **(Rus)**

BIOSYNTHESIS

Novel bispecific immunoprobe for rapid and sensitive detection of prostate-specific antigen. Kreutz FT, et al. **Clin Chem** 1997 Apr;43(4):649–56

Mono- and bispecific single-chain antibody fragments for cancer therapy. Thirion S, et al. **Eur J Cancer Prev** 1996 Dec;5(6):507–11

Construction and expression of bi-functional proteins of single-chain Fv with effector domains. Luo D, et al. **J Biochem (Tokyo)** 1996 Aug;120(2):229–32

Design and production of novel tetravalent bispecific antibodies [see comments] Coloma MJ, et al. **Nat Biotechnol** 1997 Feb;15(2):159–63. Comment in: Nat Biotechnol 1997 Feb;15(2):125–6.

CHEMISTRY

New protein engineering approaches to multivalent and bispecific antibody fragments. Plückthun A, et al. **Immunotechnology** 1997 Jun;3(2):83–105 (174 ref.)

Bispecific rabbit Fab'-bovine serum albumin conjugate used in hemagglutination immunoassay for beta-microseminoprotein. Yukawa N, et al. **J Immunoassay** 1997 Aug;18(3):215–33

Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase. Atwell JL, et al. **Mol Immunol** 1996 Dec;33(17–18):1301–12

Design and production of novel tetravalent bispecific antibodies [see comments] Coloma MJ, et al. **Nat Biotechnol** 1997 Feb;15(2):159–63. Comment in: Nat Biotechnol 1997 Feb;15(2):125–6.

Remodeling domain interfaces to enhance heterodimer formation. Zhu Z, et al. **Protein Sci** 1997 Apr;6(4):781–8

DIAGNOSTIC USE

Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens. Results and clinical perspectives. Rouvier E, et al. **Horm Res** 1997; 47(4–6):163–7

Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. Vuillez JP, et al. **J Nucl Med** 1997 Apr;38(4):507–11

Pre-clinical and clinical studies of two new bifunctional chelating agents for immunoscintigraphy with 111In-anti-CEA monoclonal antibody. Faivre-Chauvet A, et al. **Nucl Med Commun** 1996 Sep;17(9):781–9

GENETICS

Construction and expression of bi-functional proteins of single-chain Fv with effector domains. Luo D, et al. **J Biochem (Tokyo)** 1996 Aug;120(2):229–32

IMMUNOLOGY

A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. Kuwahara M, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2661–7

Therapy of streptozotocin induced diabetes with a bifunctional antibody that delivers vinca alkaloids to IL-2 receptor positive cells. Kuus-Reichel K, et al. **Autoimmunity** 1995;22(3):173–81

Study of antigen-binding properties of bispecific antibodies. Smirnova MB, et al. **Biochemistry (Mosc)** 1997 Jan; 62(1):41–8

Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models. Lindhofer H, et al. **Blood** 1996 Dec 15;88(12):4651–8

Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies. Haas C, et al. **Cancer Immunol Immunother** 1996 Nov; 43(3):190–4 (41 ref.)

Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Renner C, et al. **Cancer Immunol Immunother** 1997 Apr;44(2):70–6

Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens. Manetti C, et al. **Int J Cancer** 1997 Jun 11;71(6):1000–9

Idiotypic study of a bispecific thyroglobulin and thyroperoxidase monoclonal antibody. Villa M, et al. **J Autoimmun** 1996 Oct;9(5):653–60

Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein. Goldstein J, et al. **J Immunol** 1997 Jan 15; 158(2):872–9

Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. Mack M, et al. **J Immunol** 1997 Apr 15;158(8):3965-70
Antigen specificity of dual reactive T hybridomas determines the requirement for CD40 ligand-CD40 interactions. Ozaki ME, et al. **J Immunol** 1997 Jul 1;159(1):214-21
Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. Taylor RP, et al. **J Immunol** 1997 Jan 15;158(2):842-50

METABOLISM

Alteration of B-cell antigen receptor signaling by CD19 co-ligation. A study with bispecific antibodies. Lankester AC, et al. **J Biol Chem** 1996 Sep 13;271(37):22326-30
Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. Taylor RP, et al. **J Immunol** 1997 Jan 15;158(2):842-50

PHARMACOKINETICS

Effect of pre-irradiation on radiopharmaceutical localization in human colon tumor xenografts using mono- and bispecific monoclonal antibodies. Gridley DS, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3453-8
Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques. Devys A, et al. **Int J Cancer** 1996 Sep 17; 67(6):883-91

PHARMACOLOGY

Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells. Cho BK, et al. **Bioconjug Chem** 1997 May-Jun;8(3):338-46
Development of a bispecific F(ab')2 conjugate against the complement receptor CR3 of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage-mediated tumor cytotoxicity. Somasundaram C, et al. **Cancer Immunol Immunother** 1996 Jul;42(6):343-50
CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Mazzoni A, et al. **Cancer Res** 1996 Dec 1;56(23):5443-9
Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity. Hombach A, et al. **Clin Exp Immunol** 1997 May;108(2):352-7
Role of naive and memory T cells in tumor cell lysis mediated by bi-specific antibodies. Renner C, et al. **Immunobiology** 1997 Jun;197(1):122-32
Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein. Goldstein J, et al. **J Immunol** 1997 Jan 15; 158(2):872-9
Bispecific humanized anti-IL-2 receptor alpha beta antibodies inhibitory for both IL-2- and IL-15-mediated proliferation. Pilson RS, et al. **J Immunol** 1997 Aug 1; 159(3):1543-56
Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody. Csóka M, et al. **Leukemia** 1996 Nov;10(11):1765-72
Retargeting serum immunoglobulin with bispecific diabodies. Holliger P, et al. **Nat Biotechnol** 1997 Jul;15(7):632-6
Complement recruitment using bispecific diabodies. Kontermann RE, et al. **Nat Biotechnol** 1997 Jul; 15(7):629-31
The induction of cytotoxicity by a bispecific antibody against CEA positive cell line, in vitro. Hideshima T, et al. **Surg Today** 1996;26(2):83-8

THERAPEUTIC USE

Treatment of Hodgkin's disease with bispecific antibodies. Hartmann F, et al. **Ann Oncol** 1996;7 Suppl 4:143-6 (17 ref.)
Functional studies of bispecific antibodies directed against HIV-1 and the Fc gamma I receptor type I. Gorny MK, et al. **Antibiot Chemother** 1996;48:173-83
Critical evaluation of bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. Liu L, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2581-7
Therapy of streptozotocin induced diabetes with a bifunctional antibody that delivers vinca alkaloids to IL-2 receptor positive cells. Kuus-Reichel K, et al. **Autoimmunity** 1995;22(3):173-81
Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Hartmann F, et al. **Blood** 1997 Mar 15;89(6):2042-7
Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha. Schmidt M, et al. **Br J Cancer** 1996 Sep;74(6):853-62
Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Clark JI, et al. **Cancer Immunol Immunother** 1997 Jul;44(5):265-72
Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. Keler T, et al. **Cancer Res** 1997 Sep 15;57(18):4008-14
Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. Robert B, et al. **Cancer Res** 1996 Oct 15;56(20):4758-65
Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Stockmeyer B, et al. **Cancer Res** 1997 Feb 15;57(4):696-701
Bispecific antibodies overcome the opsonin-receptor mismatch of cystic fibrosis in vitro: restoration of neutrophil-mediated phagocytosis and killing of Pseudomonas aeruginosa. McCormick LL, et al. **J Immunol** 1997 Apr 1;158(7):3474-82
Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. Bardiès M, et al. **J Nucl Med** 1996 Nov; 37(11):1853-9

ANTIBODIES, BLOCKING

ADMINISTRATION & DOSAGE

Inhibition of corneal fibrosis by topical application of blocking antibodies to TGF beta in the rabbit. Jester JV, et al. **Cornea** 1997 Mar;16(2):177-87

ANALYSIS

Reverse transcriptase and corresponding activity-blocking antibody for monitoring SIVsm infection in macaques. Ekstrand DH, et al. **AIDS Res Hum Retroviruses** 1997 May 1;13(7):601-10
Identification of thyroid blocking antibodies and receptor epitopes in autoimmune hypothyroidism by affinity purification using synthetic TSH receptor peptides. Bryant WP, et al. **Autoimmunity** 1995;22(2):69-79

BIOSYNTHESIS

Identification of D motif epitopes in Staphylococcus aureus fibronectin-binding protein for the production of antibody inhibitors of fibronectin binding. Sun Q, et al. **Infect Immun** 1997 Feb;65(2):537-43

BLOOD

Subacute thyroiditis with thyroid-stimulation blocking antibodies: a case report. Nakamura S, et al. **Endocr J** 1996 Apr;43(2):185-9
Clinical courses and thyroid conditions in three infants born to a mother with thyroid stimulating-blocking antibodies. Notsu K, et al. **Endocr J** 1997 Apr;44(2):233-7
Responsiveness of human male volunteers to immunization with ovine follicle stimulating hormone vaccine: results of a pilot study. Moudgal NR, et al. **Hum Reprod** 1997 Mar; 12(3):457-63

CHEMISTRY

Structural diversity of monoclonal CD4 antibodies and their capacity to block the HIV gp120/CD4 interaction. Weissenhorn W, et al. **Hybridoma** 1996 Apr;15(2):117-24

IMMUNOLOGY

Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. Ahlers JD, et al. **AIDS Res Hum Retroviruses** 1996 Mar 1;12(4):259-72
Reverse transcriptase and corresponding activity-blocking antibody for monitoring SIVsm infection in macaques. Ekstrand DH, et al. **AIDS Res Hum Retroviruses** 1997 May 1;13(7):601-10
Monitoring of specific IgG4 antibodies in respiratory allergy due to the pollen of Parietaria judaica. Evidence for a protective role. Panzani RC, et al. **Allergol Immunopathol (Madr)** 1996 Nov-Dec;24(6):263-8
Characterization of fertilization-blocking monoclonal antibody 1G12 with human sperm-immobilizing activity. Komori S, et al. **Clin Exp Immunol** 1997 Sep;109(3):547-54
Characterization of a novel adhesion function blocking monoclonal antibody to rat/mouse P-selectin generated in the P-selectin-deficient mouse. Walter UM, et al. **Hybridoma** 1997 Jun;16(3):249-57
Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. Riemersma S, et al. **J Clin Invest** 1996 Nov 15; 98(10):2358-63
Blockade of CD86 ameliorates Leishmania major infection by down-regulating the Th2 response. Brown JA, et al. **J Infect Dis** 1996 Dec;174(6):1303-8
Blocking of iron uptake from transferrin by antibodies against the transferrin binding proteins in Neisseria meningitidis. Pintor M, et al. **Microb Pathog** 1996 Mar;20(3):127-39

PHARMACOLOGY

Human cytotrophoblastic cells absorb the NK blocking activity of monoclonal BA11. Cadavid AP, et al. **Am J Reprod Immunol** 1997 Jan;37(1):73-8
Effect of CD80 and CD86 blockade and anti-interleukin-12 treatment on mouse acute graft-versus-host disease. Saito K, et al. **Eur J Immunol** 1996 Dec;26(12):3098-106
Binding of human leukocytes to fibronectin is augmented by an anti-CD44 mAb (TL-1) and blocked by another anti-CD44 mAb (Hermes-3) but not by anti-VLA-4/VLA-5 mAbs. Cao L, et al. **Immunobiology** 1996-97;196(5):504-12
Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. Graus YF, et al. **J Immunol** 1997 Feb 15;158(4):1919-29
Dissociation of T cell anergy from apoptosis by blockade of Fas/Apo-1 (CD95) signaling. Hargreaves RG, et al. **J Immunol** 1997 Apr 1;158(7):3099-107
A novel monoclonal antibody mNI-58A against the alpha-chain of leukocyte function-associated antigen-1 (LFA-1) blocks the homotypic cell aggregation and actively regulates morphological changes in the phorbol myristate acetate (PMA)-activated human monocyte-like cell line, U937. Ikewaki N, et al. **Tissue Antigens** 1996 Sep; 48(3):161-73

PHYSIOLOGY

Further characterisation of an IGF-I enhancing antibody: actions on IGF-I-induced hypoglycaemia and interaction with the analogue LR3IGF-I. Pell JM, et al. **Prog Growth Factor Res** 1995;6(2-4):367-75 (23 ref.)
Human polyreactive IgM monoclonal antibodies with blocking activity against self-reactive IgG. Melero J, et al. **Scand J Immunol** 1997 Apr;45(4):393-400
Blocking antibodies inhibit complete African swine fever virus neutralization. Gómez-Puertas P, et al. **Virus Res** 1997 Jun;49(2):115-22

THERAPEUTIC USE

Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation. Danzig M, et al. **Allergy** 1997 Aug;52(8):787-94 (102 ref.)
Anti-somatostatin antisera, but neither a somatostatin agonist (octreotide) nor antagonist (CYCAM), attenuates hyperalgesia in the rat. Traub RJ, et al. **Peptides** 1996; 17(5):769-73
Inhibition of the monocyte chemiluminescent response to anti-D-sensitized red cells by Fc gamma RI-blocking antibodies which ameliorate the severity of haemolytic disease of the newborn. Shepard SL, et al. **Vox Sang** 1996; 70(3):157-63

ANTIBODIES, CATALYTIC

Characterization of polyclonal antibody-catalyzed hydrolysis. Liu D, et al. **Ann N Y Acad Sci** 1996 Oct 12; 799:46-9
Chemical selection for catalysis in combinatorial antibody libraries. Janda KD, et al. **Science** 1997 Feb 14; 275(5302):945-8

ANALYSIS

Anti-cocaine catalytic antibodies--a novel approach to the problem of addiction. Landry DW, et al. **J Addict Dis** 1997; 16(3):1-17 (53 ref.)
In vivo versus in vitro screening or selection for catalytic activity in enzymes and abzymes. Fastrez J. **Mol Biotechnol** 1997 Feb;7(1):37-55 (139 ref.)

BIOSYNTHESIS

Using the process of reactive immunization to induce catalytic antibodies with complex mechanisms: aldolases. Lerner RA, et al. **Acta Chem Scand** 1996 Aug;50(8):672-8

BLOOD

RNA-hydrolyzing antibodies from peripheral blood of patients with lupus erythematosus. Vlassov AV, et al. **Biochemistry (Mosc)** 1997 May;62(5):474-9

CHEMISTRY

Polyclonal catalytic anti-idiotypic antibodies with a beta-lactamase activity. Avalle B, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:172-5
Catalytic antibodies: the rerouting of chemical reactions. Towards electrophilic aromatic substitution by carbon dioxide. Yli-Kauhaluoma JT, et al. **Ann N Y Acad Sci** 1996 Oct 12;799:26-31
The structural and functional basis of antibody catalysis. Wade H, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:461-93 (113 ref.)
Expanding the 43C9 class of catalytic antibodies using a chain-shuffling approach. Miller GP, et al. **Bioorg Med Chem** 1997 Mar;5(3):581-90
The scope of antibody catalysis. Jacobsen JR, et al. **Curr Opin Struct Biol** 1995 Dec;5(6):818-24 (43 ref.)
Altered cleavage site preference of a proteolytic antibody light chain induced by denaturation. Sun M, et al. **FEBS Lett** 1997 May 5;407(3):289-90
Pyridoxal 5'-phosphate-dependent catalytic antibody. Gramatikova SI, et al. **J Biol Chem** 1996 Nov 29; 271(48):30583-6
The interplay between binding energy and catalysis in the evolution of a catalytic antibody. Ulrich HD, et al.

ANTIBODIES, CATALYTIC

Nature 1997 Sep 18;389(6648):271–5
X-ray structures of a hydrolytic antibody and of complexes elucidate catalytic pathway from substrate binding and transition state stabilization through water attack and product release. Gigant B, et al.
Proc Natl Acad Sci U S A 1997 Jul 22;94(15):7857–61
Structural convergence in the active sites of a family of catalytic antibodies. Charbonnier JB, et al. **Science** 1997 Feb 21;275(5303):1140–2
Evolutionary chemistry: getting there from here [comment] Joyce GF. **Science** 1997 Jun 13;276(5319):1658–9. Comment on: Science 1997 Jun 13;276(5319):1665–9.
Structural insights into the evolution of an antibody combining site [see comments] Wedemayer GJ, et al. **Science** 1997 Jun 13;276(5319):1665–9. Comment in: Science 1997 Jun 13;276(5319):1658–9.

DRUG EFFECTS

Mechanism of inactivation of a catalytic antibody by p–nitrophenyl esters. Gigant B, et al. **Eur J Biochem** 1997 Jun 1;246(2):471–6

GENETICS

Phage display of a catalytic antibody to optimize affinity for transition–state analog binding. Baca M, et al.
Proc Natl Acad Sci U S A 1997 Sep 16;94(19):10063–8

IMMUNOLOGY

Natural catalytic antibodies. Paul S. **Mol Biotechnol** 1996 Jun;5(3):197–207 (49 ref.)
[DNA–hydrolyzing antibodies in lymphoproliferative disorders] Kozyr' AV, et al. **Biull Eksp Biol Med** 1996 Feb;121(2):204–6 **(Rus)**

METABOLISM

Asymmetric organic synthesis with catalytic antibodies. Keinan E, et al. **Acta Chem Scand** 1996 Aug;50(8):679–87
Catalytic antibodies. Driggers EM, et al.
Adv Protein Chem 1996;49:261–87 (74 ref.)
The structural and functional basis of antibody catalysis. Wade H, et al. **Annu Rev Biophys Biomol Struct** 1997; 26:461–93 (113 ref.)
Phosphorylation of different human milk proteins by human catalytic secretory immunoglobulin A. Kit YYa, et al. **Biochem Mol Biol Int** 1996 Jun;39(3):521–7
Synthesis of five enantiomerically pure haptens designed for in vitro evolution of antibodies with peptidase activity. Wagner J, et al. **Bioorg Med Chem** 1996 Jun;4(6):901–16
Hydrolytic antibodies: variations on a theme. MacBeath G, et al. **Chem Biol** 1996 Jun;3(6):433–45 (58 ref.)
The scope of antibody catalysis. Jacobsen JR, et al.
Curr Opin Struct Biol 1995 Dec;5(6):818–24 (43 ref.)
Efficient and selective p–nitrophenyl–ester–hydrolyzing antibodies elicited by a p–nitrobenzyl phosphonate hapten. Tawfik DS, et al. **Eur J Biochem** 1997 Mar 1;244(2):619–26
Artificial peroxidase–like hemoproteins based on antibodies constructed from a specifically designed ortho–carboxy substituted tetraarylporphyrin hapten and exhibiting a high affinity for iron–porphyrins. Quilez R, et al. **FEBS Lett** 1996 Oct 14;395(1):73–6
Kinetic characterization of antibody–catalyzed insertion of a metal ion into porphyrin. Kawamura–Konishi Y, et al. **J Biochem (Tokyo)** 1996 May;119(5):857–62
Site–directed mutagenesis of active site contact residues in a hydrolytic abzyme: evidence for an essential histidine involved in transition state stabilization. Miyashita H, et al. **J Mol Biol** 1997 Apr 18;267(5):1247–57
Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain. Sun M, et al. **J Mol Biol** 1997 Aug 22;271(3):374–85
[Catalytic antibodies] Shchurov DV. **Mol Biol (Mosk)** 1997 Jan–Feb;31(1):5–15 (65 ref.) **(Rus)**

ULTRASTRUCTURE

Crystal structures of the free and liganded form of an esterolytic catalytic antibody. Wedemayer GJ, et al.
J Mol Biol 1997 May 2;268(2):390–400

ANTIBODIES, ENHANCING see **ANTIBODIES, BLOCKING**

ANTIBODIES, FUNGAL

Monoclonal yeast killer toxin–like candidacidal anti–idiotypic antibodies. Polonelli L, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):142–6

ANALYSIS

Detection of antibodies to Coccidioides immitis by enzyme immunoassay. Zartarian M, et al. **Am J Clin Pathol** 1997 Feb;107(2):148–53
IgE antibodies to protein and mannan antigens of pityrosporum ovale in atopic dermatitis patients. Lintu P, et al. **Clin Exp Allergy** 1997 Jan;27(1):87–95
Subcutaneous mucormycosis seen after gypsum fixation for bone fracture. Maeda M, et al. **Cutis** 1996 Mar;57(3):147–50
Detection of Pneumocystis carinii with direct fluorescence antibody and calcofluor white stain. Aslanzadeh J, et al. **Infection** 1996 May–Jun;24(3):248–50
A model for the prediction of relative titres of avian malaria and Aspergillus spp. IgG in Jackass penguin (Spheniscus demersus) females based on maternal IgG in egg–yolk. Graczyk TK, et al. **Int J Parasitol** 1996 Jul;26(7):749–54
Aspergillus fumigatus specific antibodies in multitransfused children with human immunodeficiency virus (HIV) infection in relation to serum levels of Interleukin–2, gamma Interferon and tumour necrosis factor. Bhatnagar PK, et al. **J Trop Pediatr** 1996 Apr;42(2):85–90
Transmission of Pneumocystis carinii from patients to hospital staff. Lundgren B, et al. **Thorax** 1997 May; 52(5):422–4
Investigations of pneumocystosis among humans and rodents in Lithuania. Bajorinienė DJ, et al. **Wiad Parazytol** 1997; 43(1):53–9
[Summer–type hypersensitivity pneumonitis in a patient with a positive skin test (15 minutes) for Trichosporon mucoides and a high serum IgE level] Nakajima M, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1996 Oct; 34(10):1168–73 (20 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Differential humoral response against alpha– and beta–linked mannose residues associated with tissue invasion by Candida albicans. Jouault T, et al.
Clin Diagn Lab Immunol 1997 May;4(3):328–33
Specific antibody response to oligomannosidic epitopes in Crohn's disease. Sendid B, et al.
Clin Diagn Lab Immunol 1996 Mar;3(2):219–26
Cellular requirements for immunomodulatory effects caused by cell wall components of Paracoccidioides brasiliensis on antibody production. Silva MF, et al.
Clin Exp Immunol 1997 Aug;109(2):261–71
Generation of biologically active anti–Cryptococcus neoformans IgG, IgE and IgA isotype switch variant antibodies by acridine orange mutagenesis. Spira G, et al.
Clin Exp Immunol 1996 Sep;105(3):436–42

BLOOD

Anti–Candida albicans IgE and IgG subclasses in sera of patients with allergic bronchopulmonary aspergillosis (ABPA). Roig E, et al. **Allergy** 1997 Apr;52(4):394–403
Evidence for the presence of immunoglobulin E antibodies specific to the cell wall phosphomannoproteins of Candida albicans in patients with allergies. Kanbe T, et al.
Clin Diagn Lab Immunol 1996 Nov;3(6):645–50
Recognition of cytoplasmic yeast antigens of Cryptococcus neoformans var. neoformans and Cryptococcus neoformans var. gattii by immune human sera. Hamilton AJ, et al.
FEMS Immunol Med Microbiol 1997 Feb;17(2):111–9
Immunoglobulin profile in mycetoma. Singhvi A, et al.
Indian J Pathol Microbiol 1996 Jul;39(3):203–6
Clinical and serologic evaluation of cats with cryptococcosis. Flatland B, et al. **J Am Vet Med Assoc** 1996 Sep 15; 209(6):1110–3
Enzyme immunoassays for specific IgG and IgE antibodies to Pichia pastoris components in normal humans. Ohtani W, et al. **J Clin Lab Anal** 1997;11(4):196–201
Allergic bronchopulmonary aspergillosis: serologic update for 1995. Krasnick J, et al. **J Clin Lab Immunol** 1995; 46(3):137–42
Antibody responses to Pneumocystis carinii in hospital personal with and without exposure to patients with P. carinii pneumonia. Lundgren B, et al.
J Eukaryot Microbiol 1996 Sep–Oct;43(5):10S
IgG, IgM and IgA antibody response for the diagnosis and follow–up of paracoccidioidomycosis: comparison of counterimmunoelectrophoresis and complement fixation. Bueno JP, et al. **J Med Vet Mycol** 1997 May–Jun; 35(3):213–7
Purification and characterization of a 93 kDa Aspergillus fumigatus antigen with diagnostic potential. Haynes KA, et al. **J Med Vet Mycol** 1996 Nov–Dec;34(6):421–6
Serum antibody response to active infection with Cryptococcus neoformans and its varieties in immunocompetent subjects. Speed BR, et al.
J Med Vet Mycol 1996 Jun–Jul;34(3):187–93
Skin and serum reactivity among humans to histoplasmin in the vicinity of a natural focus of Histoplasma capsulatum var. duboisii. Muotoe–Okafor FA, et al. **Mycopathologia** 1996;134(2):71–4
Characterization of specific anti–Candida IgM, IgA and IgE: diagnostic value in deep–seated infections. Aubert D, et al. **Mycoses** 1996 May–Jun;39(5–6):169–76
Specific antibody detection in human aspergillosis: a GEMO* multicentre evaluation of a rapid immunoelectrophoresis method (Paragon). Group d'Etude des Mycoses Opportunistes. Persat F, et al. **Mycoses** 1996 Nov–Dec; 39(11–12):427–32
[Clinical significant of malassezia furfur specific IgE antibody in atopic dermatitis] Mukai H, et al. **Arerugi** 1997 Jan; 46(1):26–33 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Fungal anti–A agglutinins with different affinities for subgroups A1 and A2 red cells. Ying R, et al.
Exp Clin Immunogenet 1995;12(4):232–7

CLASSIFICATION

A new method of antibiotyping yeasts for subspecies discrimination and distribution in human clinical specimens. Quindós G, et al. **Eur J Epidemiol** 1996 Feb;12(1):55–62

IMMUNOLOGY

Development of polyclonal antibodies for detection of aflatoxigenic molds involving culture filtrate and chimeric proteins expressed in Escherichia coli. Shapira R, et al. **Appl Environ Microbiol** 1997 Mar;63(3):990–5
Protective role of antimannan and anti–aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. De Bernardis F, et al. **Infect Immun** 1997 Aug;65(8):3399–405
A 77–kilodalton protein of Cryptococcus neoformans, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis. Kakeya H, et al. **Infect Immun** 1997 May; 65(5):1653–8
Peptide epitopes recognized by a human anti–cryptococcal glucuronoxylomannan antibody. Zhang H, et al.
Infect Immun 1997 Apr;65(4):1158–64
Western blot analysis of rat Pneumocystis carinii antigens using convalescent rat sera and rabbit anti–gp120. Pascale JM, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):30S
In vitro decrease of rat–derived Pneumocystis carinii attachment induced by human natural yeast killer toxin–like antiidiotypic candidacidal antibodies. Séguy N, et al.
J Eukaryot Microbiol 1996 Sep–Oct;43(5):27S
Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. Feldmesser M, et al. **J Immunol** 1997 Jan 15;158(2):790–9
Kinetics of anti–mannan antibodies useful in confirming invasive candidiasis in immunocompromised patients. van Deventer AJ, et al. **Microbiol Immunol** 1996;40(2):125–31
Monoclonal antibodies as probes for fungal wall structure during morphogenesis. Marshall M, et al. **Microbiology** 1997 Jul;143 (Pt 7):2255–65
Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi? Pirofski LA, et al.
Zentralbl Bakteriol 1996 Aug;284(4):475–95 (135 ref.)

METABOLISM

Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy. Goldman DL, et al. **J Med Vet Mycol** 1997 Jul–Aug; 35(4):271–8

PHARMACOLOGY

Monoclonal antibodies against the 43,000 Da glycoprotein from Paracoccidioides brasiliensis modulate laminin–mediated fungal adhesion to epithelial cells and pathogenesis. Gesztesi JL, et al. **Hybridoma** 1996 Dec; 15(6):415–22

THERAPEUTIC USE

Monoclonal antibodies against the 43,000 Da glycoprotein from Paracoccidioides brasiliensis modulate laminin–mediated fungal adhesion to epithelial cells and pathogenesis. Gesztesi JL, et al. **Hybridoma** 1996 Dec; 15(6):415–22
Antibodies against Candida: potential therapeutics? Matthews R, et al. **Trends Microbiol** 1996 Sep;4(9):354–8 (41 ref.)

ANTIBODIES, HELMINTH

ANALYSIS

Antibody responses of patients with cystic hydatid disease to recombinant myophilin of Echinococcus granulosus. Martin RM, et al. **Acta Trop** 1996 Aug;61(4):307–14
Short report: long–term serum antibody isotype responses to Strongyloides stercoralis filariform antigens in eight patients treated with ivermectin. Lindo JF, et al.
Am J Trop Med Hyg 1996 Nov;55(5):474–6
Evaluation of a stage–specific proteolytic enzyme of Schistosoma mansoni as a marker of exposure. Ramzy RM, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):668–73
Immunological parameters associated with susceptibility or resistance to alveolar hydatid disease in Yupiks/Inupiats. Gottstein B, et al. **Arctic Med Res** 1996 Jan;55(1):14–9
Specific immunoglobulin measurements related to exposure and resistance to Schistosoma mansoni infection in Sudanese canal cleaners. Satti MZ, et al.
Clin Exp Immunol 1996 Oct;106(1):45–54
Serologic recognition of hydatid cyst antigens using different purification methods. Sbihi Y, et al.
Diagn Microbiol Infect Dis 1996 Apr;24(4):205–11
Sequential cellular and humoral responses in the abomasal mucosa and blood of Romney sheep dosed with Trichostrongylus axei. Pfeffer A, et al. **Int J Parasitol** 1996 Jul;26(7):765–73
Specific recognition of hydatid cyst antigens by serum IgG, IgE, and IgA using western blot. Sbihi Y, et al.
J Clin Lab Anal 1997;11(3):154–7
Case report: eosinophilic colitis with high antibody titre against Ascaris suum. Takeyama Y, et al.
J Gastroenterol Hepatol 1997 Mar;12(3):204–6
Irradiated larval vaccination and antibody responses evaluated in relation to the expression of immunity to Heligmosomoides polygyrus. Pleass RJ, et al.

Parasitol Res 1996;82(5):445–53

Potential for diagnosis of intestinal nematode infections through antibody detection in saliva. Needham CS, et al. **Trans R Soc Trop Med Hyg** 1996 Sep–Oct;90(5):526–30

Subclass-specific serological reactivity and IgG4-specific antigen recognition in human echinococcosis. Dreweck CM, et al. **Trop Med Int Health** 1997 Aug;2(8):779–87

The value of bulk milk ELISA Ostertagia antibody titres as indicators of milk production response to anthelmintic treatment in the dry period. Kloosterman A, et al. **Vet Parasitol** 1996 Sep 2;64(3):197–205

[Clinical significance of serological diagnosis with ELISA and Western blotting in alveolar echinococcosis of the liver] Takahashi H. **Hokkaido Igaku Zasshi** 1996 Sep; 71(5):611–21 (Eng. Abstr.) **(Jpn)**

[Comparison of 2 serologic methods for the diagnosis of hydatidosis] Arienti HM, et al. **Bol Oficina Sanit Panam** 1996 Sep;121(3):221–7 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Schistosoma mansoni excretory circulating cathodic antigen shares Lewis-x epitopes with a human granulocyte surface antigen and evokes host antibodies mediating complement-dependent lysis of granulocytes. van Dam GJ, et al. **Blood** 1996 Dec 1;88(11):4246–51

Immune response and in vivo production of cytokines in patients with liver hydatidosis. Torcal J, et al. **Clin Exp Immunol** 1996 Nov;106(2):317–22

Correlation between degree of protection and humoral antibody response in hamsters immunized with somatic and excretory secretory antigens of Ancylostoma ceylanicum. Khan AM, et al. **Indian J Exp Biol** 1996 Oct;34(10):1015–8

Developmentally regulated expression of a Haemonchus contortus surface antigen. Raleigh JM, et al. **Int J Parasitol** 1996 Jun;26(6):673–5

Oral vaccination of mice with recombinant Schistosoma japonicum proteins induces specific anti-parasite antibodies and damage to adult worms after a challenge infection. Yang W, et al. **Int J Parasitol** 1997 Jul;27(7):843–53

Zinc deficiency and host response to helminth infection: Echinostoma caproni infections in CBA mice. Baek J, et al. **J Helminthol** 1996 Mar;70(1):7–12

Antibody responses against Echinococcus multilocularis antigens in naturally infected Rattus norvegicus. Ito A, et al. **J Helminthol** 1996 Dec;70(4):355–7

Larval somatic antigens effective in inducing an IgG response and protection against Strongyloides papillosus infection. Ooba C, et al. **J Helminthol** 1996 Sep;70(3):231–5

IL-12 enhances vaccine-induced immunity to schistosomes by augmenting both humoral and cell-mediated immune responses against the parasite. Wynn TA, et al. **J Immunol** 1996 Nov 1;157(9):4068–78

Production of monoclonal antibodies against excretory-secretory products of adult male Onchocerca gibsoni. Harnett W, et al. **J Parasitol** 1997 Apr;83(2):316–9

Schistosoma mansoni: the immune response against cercarial glycocalyx. Hussein AH, et al. **J Parasitol** 1997 Jun; 83(3):424–9

Immunological characteristics and localization of the Trichinella spiralis glutathione S-transferase. Rojas J, et al. **J Parasitol** 1997 Aug;83(4):630–5

Specific cellular and humoral immune responses induced by different antigen preparations of Echinococcus multilocularis metacestodes in patients with alveolar echinococcosis. Nicod L, et al. **Parasite** 1994 Sep; 1(3):261–70

Intranasal immunization of mice with Echinococcus granulosus surface antigens iscoms evokes a strong immune response, biased towards glucidic epitopes. Carol H, et al. **Parasite Immunol** 1997 May;19(5):197–205

Heterologous expression of the cuticular-glutathione peroxidase of lymphatic filariae in an attenuated vaccine strain of Salmonella typhimurium abrogates H-2 restriction of specific antibody responses. Chacón MR, et al. **Parasite Immunol** 1996 Jun;18(6):307–16

In vitro stimulation of naive mouse lymphocytes by Heligmosomoides polygyrus adult worm antigens induces the production of IgG1. Robinson M, et al. **Parasite Immunol** 1996 Feb;18(2):87–93

Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep. Rothel JS, et al. **Parasite Immunol** 1997 May;19(5):221–7

Humoral and cellular immune responses to experimental Fasciola hepatica infections in goats. Martínez-Moreno A, et al. **Parasitol Res** 1997;83(7):680–6

Induction of protective immunity and modulation of granulomatous hypersensitivity in mice using PIII, an anionic fraction of Schistosoma mansoni adult worm. Hirsch C, et al. **Parasitology** 1997 Jul;115 (Pt 1):21–8

Immunoepidemiology of the equine tapeworm Anoplocephala perfoliata: age-intensity profile and age-dependency of antibody subtype responses. Proudman CJ, et al. **Parasitology** 1997 Jan;114 (Pt 1):89–94

Urea/DTT solubilization of a recombinant Taenia ovis antigen, 45W, expressed as a GST fusion protein results in enhanced protective immune response to the 45W moiety. Rothel JS, et al. **Vaccine** 1997 Apr;15(5):469–72

DNA-based vaccination using Schistosoma japonicum (Asian blood-fluke) genes. Waine GJ, et al. **Vaccine** 1997 Jun;15(8):846–8

Long-term humoral antibody responses by various serologic tests in pigs orally inoculated with oocysts of four strains of Toxoplasma gondii. Dubey JP, et al. **Vet Parasitol** 1997 Jan;68(1–2):41–50

Serum and bile antibody responses (IgG and IgA) during subclinical Fasciola hepatica infection in sheep. Ferre I, et al. **Vet Parasitol** 1997 Feb;68(3):261–7

A Trichuris specific diagnostic antigen from culture fluids of Trichuris suis adult worms. Hill DE, et al. **Vet Parasitol** 1997 Jan;68(1–2):91–102

Immunological responses in the mouse host to a cloned antigen of Taenia crassiceps. Hill DE, et al. **Vet Parasitol** 1996 Oct 25;65(3–4):247–58

Triclabendazole treatment in experimental goat fasciolosis: anthelmintic efficacy and influence in antibody response and pathophysiology of the disease. Martínez-Moreno A, et al. **Vet Parasitol** 1997 Jan;68(1–2):57–67

Bovine humoral immune responses to Haemonchus placei excretory secretory antigens. Schallig HD, et al. **Vet Parasitol** 1996 Oct 25;65(3–4):289–96

BLOOD

Differential immune response to Onchocerca volvulus: IgG4 antibody responses differ in onchocerciasis patients from Guatemala and Ghana. Guzmán GE, et al. **Acta Trop** 1997 Jan;63(1):15–31

A comparative study on specific antibodies and circulating antigen (CAA) in serum and parasitological findings for diagnosis of schistosomiasis mansoni in an endemic area in Tanzania. Håkangård C, et al. **Acta Trop** 1996 May; 61(3):213–22

Expression and immunological characterisation of Echinococcus granulosus recombinant antigen B for IgG4 subclass detection in human cystic echinococcosis. McVie A, et al. **Acta Trop** 1997 Sep 15;67(1–2):19–35

IgG1 and IgG4 serum antibody responses in asymptomatic and clinically expressed cystic echinococcosis patients. Shambesh MK, et al. **Acta Trop** 1997 Apr 1;64(1–2):53–63

Effects of maternal ethanol consumption on the subsequent development of immunity to Trichinella spiralis in rat neonates. Seelig LL Jr, et al. **Alcohol Clin Exp Res** 1996 May;20(3):514–22

A serologic study of human toxocariasis in the Canary Islands (Spain): environmental influences. Jimenez JF, et al. **Am J Trop Med Hyg** 1997 Jan;56(1):113–5

Geographic clustering and seroprevalence of schistosomiasis in Puerto Rico (1995). Tsang VC, et al. **Am J Trop Med Hyg** 1997 Jan;56(1):107–12

Efficacy of an enzyme-linked immunosorbent assay in the diagnosis of and serologic distinction between acute and chronic Schistosoma mansoni infection. Valli LC, et al. **Am J Trop Med Hyg** 1997 Sep;57(3):358–62

Immunopathogenesis and immunoregulation in schistosomiasis. Distinct chronic pathologic syndromes in CBA/J mice. Freeman GL Jr, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:151–65

Humoral immune responses in patients with acute Schistosoma mansoni infection who were followed up for two years after treatment. Rabello AL, et al. **Clin Infect Dis** 1997 Mar;24(3):304–8

Seroprevalence of Toxocara infection in middle-class and disadvantaged children in northern Spain (Gipuzkoa, Basque Country). Cilla G, et al. **Eur J Epidemiol** 1996 Oct; 12(5):541–3

Relationship between allergic manifestations and Toxocara seropositivity: a cross-sectional study among elementary school children. Buijs J, et al. **Eur Respir J** 1997 Jul; 10(7):1467–75

Worm kinetics and serum IgE in hooded lister rats infected with the acanthocephalan Moniliformis moniliformis and the nematode Nippostrongylus brasiliensis. Hindsbo O, et al. **Int J Parasitol** 1996 Nov;26(11):1287–94

Dot-immunogold-silver staining in the diagnosis of cysticercosis. Liu YS, et al. **Int J Parasitol** 1996 Jan; 26(1):127–9

Drug-abbreviated infections and development of immunity against Trichostrongylus colubriformis in sheep. Stankiewicz M, et al. **Int J Parasitol** 1996 Jan;26(1):97–103

Low molecular weight Cooperia oncophora antigens. Potential to discriminate between susceptible and resistant calves after infection. van Diemen PM, et al. **Int J Parasitol** 1997 May;27(5):587–93

Immunological pattern in Syrian golden hamsters experimentally infected with Schistosoma mansoni and Leishmania d. infantum. Mangoud AM, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):497–504

Seroprevalence of toxocariasis in children and adults in Madrid and Tenerife, Spain. Fenoy S, et al. **J Helminthol** 1996 Jun;70(2):109–13

Enzyme-linked immunosorbent assay, immunoblot analysis and RAST fluoroimmunoassay analysis of serum responses against crude larval antigens of Anisakis simplex in a Spanish random population. García-Palacios L, et al. **J Helminthol** 1996 Dec;70(4):281–9

Toxocara titres in maternal and cord blood. Taylor MR, et al. **J Infect** 1996 May;32(3):231–3

High levels of parasite-specific IgG1 correlate with the amicrofilaremic state in Loa loa infection. Akue JP, et al. **J Infect Dis** 1997 Jan;175(1):158–63

A recombinant protein from Schistosoma mansoni useful for the detection of S. mansoni and Schistosoma haematobium antibodies. Hancock K, et al. **J Parasitol** 1997 Aug; 83(4):612–8

Exposure of swine to Trichinella spiralis antigen as determined by consecutive ELISAs and western blot. Shin SS, et al. **J Parasitol** 1997 Jun;83(3):430–3

Effects of anti-IgE mAb on serum IgE, Fc epsilon RII/CD23 expression on splenic B cells and worm burden in mice infected with Paragonimus westermani. Shin MH, et al. **Korean J Parasitol** 1997 Mar;35(1):47–54

Prevalence of anti-Taenia solium antibodies in sera from outpatients in an Andean region of Ecuador. Escalante L, et al. **Mem Inst Oswaldo Cruz** 1995 Nov–Dec;90(6):715–9

Glutathione-binding proteins of Setaria digitata: antibody responses in human infected with Wuchereria bancrofti. Bal M, et al. **Parasite Immunol** 1996 Sep;18(9):473–7

Serological reactivity to heat shock protein 70 in patients with hydatid disease. Colebrook AL, et al. **Parasite Immunol** 1997 Jan;19(1):41–6

Antibody response of Echinococcus granulosus infected mice: recognition of glucidic and peptidic epitopes and lack of avidity maturation. Ferragut G, et al. **Parasite Immunol** 1996 Aug;18(8):393–402

Age-related antibody profiles in Schistosoma haematobium infections in a rural community in Zimbabwe. Ndhlovu P, et al. **Parasite Immunol** 1996 Apr;18(4):181–91

Human isotype antibody responses to an Onchocerca volvulus glutathione S-transferase. Salinas G, et al. **Parasite Immunol** 1996 Aug;18(8):377–86

The immunodiagnostic potential of Echinococcus granulosus adult-worm antigens in human cystic echinococcosis. Ersfeld K, et al. **Parasitol Res** 1997;83(1):90–2

Neutral glycolipids of Schistosoma mansoni as feasible antigens in the detection of schistosomiasis. Dennis RD, et al. **Parasitology** 1996 Mar;112 (Pt 3):295–307

Experimental Schistosoma bovis infection in goats. Circulating antigen and antibody responses to egg and adult worm antigens during infection and following treatment with praziquantel. Johansen MV, et al. **Parasitology** 1996 Oct;113 (Pt 4):367–75

Production of a monoclonal antibody specific for ovine immunoglobulin E and its application to monitor serum IgE responses to Haemonchus contortus infection. Kooyman FN, et al. **Parasitology** 1997 Apr;114 (Pt 4):395–406

Dissociation of early and late protective immunity to the nematode Nippostrongylus brasiliensis in Brown Norway and Fischer-344 rats. Uchikawa R, et al. **Parasitology** 1996 Mar;112 (Pt 3):339–45

The influence of sex and age on antibody isotype responses to Schistosoma mansoni and Schistosoma japonicum in human populations in Kenya and the Philippines. Webster M, et al. **Parasitology** 1997 Apr;114 (Pt 4):383–93

The serum immune response of young lambs to a primary infection with Nematodirus battus. Winter MD, et al. **Parasitology** 1996 Nov;113 (Pt 5):491–6

Echinococcus granulosus antigen B and seroreactivity in natural ovine hydatidosis. Ibrahem MM, et al. **Res Vet Sci** 1996 Sep;61(2):102–6

Seroepidemiological study of Toxocara infection in Nepal. Rai SK, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):286–90

Parasite-specific serum IgG following successful treatment of endemic strongyloidiasis using ivermectin. Lindo JF, et al. **Trans R Soc Trop Med Hyg** 1996 Nov–Dec; 90(6):702–3

Correlations between specific antibody levels and urine egg counts for Schistosoma haematobium. Ndhlovu PD, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):324–5

Demonstration of immunoglobulin G antibodies against Onchocerca volvulus excretory-secretory antigens in different forms and stages of onchocerciasis. Wanni NO, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr; 91(2):226–30

Trichinella spiralis infection in pigs in eastern Bolivia. Brown DF, et al. **Trop Anim Health Prod** 1996 May;28(2):137–42

A longitudinal study of local and peripheral isotype/subclass antibodies in Dictyocaulus viviparus-infected calves. Scott CA, et al. **Vet Immunol Immunopathol** 1996 Oct; 53(3–4):235–47

The effect of truncated infections with Ostertagia ostertagi on the development of acquired resistance in calves. Claerebout E, et al. **Vet Parasitol** 1996 Nov 15; 66(3–4):225–39

Evaluation of an ELISA for the routine diagnosis of Dictyocaulus viviparus infections in cattle. Cornelissen JB, et al. **Vet Parasitol** 1997 Jun;70(1–3):153–64

Antibody and circulating antigen profiles before and after chemotherapy in goats infected with Fasciola gigantica. Mbuh JV, et al. **Vet Parasitol** 1996 Nov 15;66(3–4):171–9

Seroepidemiological survey of Taenia saginata cysticercosis in Kenya. Onyango-Abuje JA, et al. **Vet Parasitol** 1996 Sep 2;64(3):177–85

Variation in infection levels with gastrointestinal nematodes in first-year grazing calves in The Netherlands. Poot J, et al. **Vet Parasitol** 1997 Jan;68(1–2):103–11

Anti-fecundity immunity to Schistosoma japonicum induced in Chinese water buffaloes (Bos buffelus) after vaccination with recombinant 26 kDa glutathione-S-transferase (reSjc26GST). Shuxian L, et al. **Vet Parasitol** 1997 Apr; 69(1–2):39–47

[Diagnosis of bovine fascioliasis using serology of pools of sera. Interpretation in field conditions] Chauvin A, et al.

ANTIBODIES, HELMINTH

Vet Res 1997;28(1):37–43 (Eng. Abstr.) **(Fre)**
[Frequency of anti-Cysticercus cellulosae antibodies in individuals from five counties in the Northern region of Brazil] Lonardoni MV, et al. **Rev Saude Publica** 1996 Jun; 30(3):273–9 (Eng. Abstr.) **(Por)**

CEREBROSPINAL FLUID

Immunoblot with cerebrospinal fluid from patients with neurocysticercosis using antigen from cysticerci of Taenia solium and Taenia crassiceps. Vaz AJ, et al.
Am J Trop Med Hyg 1997 Sep;57(3):354–7
Immunoperoxidase for the detection of antibodies in cerebrospinal fluid in neurocysticercosis: use of Cysticercus cellulosae and Cysticercus longicollis particles fixed on microscopy slides. de Andrade AP, et al.
Rev Inst Med Trop Sao Paulo 1996 Jul–Aug;38(4):259–63

CHEMISTRY

Investigation of immunofluorescence cross–reactions against Trichinella spiralis by western blot (immunoblot) analysis. Robert F, et al. **Clin Diagn Lab Immunol** 1996 Sep; 3(5):575–7

CLASSIFICATION

A longitudinal study of local and peripheral isotype/subclass antibodies in Dictyocaulus viviparus–infected calves. Scott CA, et al. **Vet Immunol Immunopathol** 1996 Oct; 53(3–4):235–47

DIAGNOSTIC USE

Production of monoclonal antibodies for the identification of the eggs of Taenia solium. Montenegro TC, et al.
Ann Trop Med Parasitol 1996 Apr;90(2):145–55
Assessment of the diagnostic value of 99mTc–radiolabelled specific antibodies in experimental hydatidosis. Gonźalez S, et al. **Q J Nucl Med** 1996 Jun;40(2):161–9

GENETICS

The immunogenetics of resistance to Trichostrongylus colubriformis and Haemonchus contortus parasites in sheep [see comments] Hohenhaus MA, et al. **Br Vet J** 1995 Mar–Apr;151(2):119–40 (65 ref.). Comment in: Br Vet J 1995 Mar–Apr;151(2):111–3.

IMMUNOLOGY

Extraction of Schistosoma haematobium antigens from infected human urine and generation of potential diagnostic monoclonal antibodies to urinary antigens. Bosompem KM, et al. **Acta Trop** 1996 Oct;62(2):91–103
Specific monoclonal antibodies to Fasciola gigantica. Maleewong W, et al. **Asian Pac J Allergy Immunol** 1997 Mar;15(1):49–54
Immunopathology of onchocerciasis: a role for eosinophils in onchocercal dermatitis and keratitis. Pearlman E.
Chem Immunol 1997;66:26–40 (62 ref.)
Rodents infected with Schistosoma mansoni produce cytolytic IgG and IgM antibodies to the Lewis x antigen. Nyame AK, et al. **Glycobiology** 1997 Mar;7(2):207–15
IgE, allergies and helminth parasites: a new perspective on an old conundrum. Bell RG. **Immunol Cell Biol** 1996 Aug; 74(4):337–45 (81 ref.)
In utero exposure to Onchocerca volvulus: relationship to subsequent infection intensity and cellular immune responsiveness. Elson LH, et al. **Infect Immun** 1996 Dec; 64(12):5061–5
Immunological interactions between Trichinella spiralis and Heligmosomoides polygyrus: cross reactivity between muscle larvae and antibodies raised to unrelated antigens. Robinson M, et al. **Int J Parasitol** 1997 Jul;27(7):865–72
Wuchereria bancrofti recombinant antigen–derived poly– and monoclonal antibodies for the detection of circulating antigen(s) in the sera of lymphatic filarial patients. Theodore JG, et al. **J Helminthol** 1996 Mar;70(1):69–74
Immunoregulatory idiotypes stimulate T helper 1 cytokine responses in experimental Schistosoma mansoni infections. Montesano MA, et al. **J Immunol** 1997 Apr 15; 158(8):3800–4
Intestinal transport and catabolism of IgE: a major blood–independent pathway of IgE dissemination during a Trichinella spiralis infection of rats. Negrão–Corrêa D, et al. **J Immunol** 1996 Nov 1;157(9):4037–44
Role of adhesion molecules of the selectin–carbohydrate families in antibody–dependent cell–mediated cytoxicity to schistosome targets. Trottein F, et al. **J Immunol** 1997 Jul 15;159(2):804–11
Acquisition and expression of humoral reactivity to antigens of infective stages of filarial larvae. Bailey JW, et al.
Parasite Immunol 1995 Dec;17(12):617–23
Elimination of a primary schistosome infection from rats coincides with elevated IgE titres and mast cell degranulation. Cutts L, et al. **Parasite Immunol** 1997 Feb; 19(2):91–102
The isolation of a 22 kDa band after SDS–PAGE of Schistosoma mansoni adult worms and its use to demonstrate that IgE responses against the antigen(s) it contains are associated with human resistance to reinfection. Dunne DW, et al. **Parasite Immunol** 1997 Feb; 19(2):79–89
Immunoglobulin and cytokine profile in murine secondary hydatidosis. Haralabidis S, et al. **Parasite Immunol** 1995 Dec;17(12):625–30
Accelerated clearance of Onchocerca microfilariae and resistance to reinfection in interleukin–4 gene knockout mice. Hogarth PJ, et al. **Parasite Immunol** 1995 Dec; 17(12):653–7
Immunomodulation by hydatid cyst fluid toxin (Echinococcus granulosus). Janssen D, et al.
Parasite Immunol 1997 Apr;19(4):149–60
Heterogeneity in the recognition of Ostertagia circumcincta antigens by serum antibody from mature, infected sheep. McCririe L, et al. **Parasite Immunol** 1997 May;19(5):235–42
The specificity of the human IgE response to Necator americanus. Pritchard DI, et al. **Parasite Immunol** 1995 Nov;17(11):605–7
Antibodies against Echinococcus multilocularis alkaline phosphatase as markers for the specific diagnosis and the serological monitoring of alveolar echinococcosis. Sarciron EM, et al. **Parasite Immunol** 1997 Feb;19(2):61–8
Regulation of egg production, worm burden, worm length and worm fecundity by host responses in sheep infected with Ostertagia circumcincta. Stear MJ, et al.
Parasite Immunol 1995 Dec;17(12):643–52
Structural and molecular specificity of antibody responses in mice immune to third stage larvae of Onchocerca volvulus. Yutanawiboonchai W, et al. **Parasite Immunol** 1996 Feb;18(2):95–102
Differential responsiveness of humans with early–stage schistosomiasis haematobium to Schistosoma haematobium soluble adult–worm and egg antigens. El Ridi R, et al.
Parasitol Res 1997;83(5):471–7
Blocking anti–Trichinella spiralis antibodies in chronically infected rats. Venturiello SM, et al. **Parasitol Res** 1996; 82(1):77–81
Identification and partial characterization of a myosin–like protein from cysticerci and adults of Taenia solium using a monoclonal antibody. Ambrosio J, et al. **Parasitology** 1997 Jun;114 (Pt 6):545–53
Impaired antibody responses and loss of reactivity to Onchocerca volvulus antigens by HIV–seropositive onchocerciasis patients. Tawill SA, et al.
Trans R Soc Trop Med Hyg 1996 Jan–Feb;90(1):85–9
Use of a new glass microfibre histamine release method to study the modulation of the host response in human schistosomiasis mansoni. Individuals with different degrees of exposure to the disease show differing antibody biological function. Satti MZ, et al.
Trop Med Int Health 1996 Oct;1(5):655–66
Feline heartworm (Dirofilaria immitis) infection: detection of specific IgG for the diagnosis of occult infections. Prieto C, et al. **Vet Parasitol** 1997 Jul 1;70(4):209–17

ISOLATION & PURIFICATION

IgG4 responses to antigens of adult Necator americanus: potential for use in large–scale epidemiological studies. Palmer DR, et al. **Bull World Health Organ** 1996; 74(4):381–6
Seroprevalence of toxocariasis in children and a case of VLM. Guerra A, et al. **Eur J Epidemiol** 1995 Dec; 11(6):701–2
Immunoperoxidase for the detection of antibodies in cerebrospinal fluid in neurocysticercosis: use of Cysticercus cellulosae and Cysticercus longicollis particles fixed on microscopy slides. de Andrade AP, et al.
Rev Inst Med Trop Sao Paulo 1996 Jul–Aug;38(4):259–63

METABOLISM

Activities of different cysteine proteases of Paragonimus westermani in cleaving human IgG. Chung YB, et al.
Korean J Parasitol 1997 Jun;35(2):139–42

PHYSIOLOGY

Specificity and role of anti–Trypanosoma cruzi clearance antibodies. Umekita LF, et al. **Braz J Med Biol Res** 1996 Jan;29(1):25–31

THERAPEUTIC USE

Synergistic action of cyclosporin A and polyspecific rabbit anti–sera against murine Schistosoma mansoni. Millership JJ, et al. **Parasite Immunol** 1996 Feb;18(2):71–7

ANTIBODIES, HEPATITIS see **HEPATITIS ANTIBODIES**

ANTIBODIES, HETEROGENETIC see **ANTIBODIES, HETEROPHILE**

ANTIBODIES, HETEROPHILE

Normal human polyclonal immunoglobulins for intravenous use contain anti–idiotypes against natural xenophile antibodies and prolong discordant xenograft survival. Schussler O, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):959–60
Induction of accommodation prevents hyperacute rejection. Vriens PW, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):597–8

BIOSYNTHESIS

Development of antibodies to fetal calf serum with arthus–like reactions in human immunodeficiency virus–infected patients given syngeneic lymphocyte infusions. Selvaggi TA, et al. **Blood** 1997 Feb 1;89(3):776–9
Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver. Baquerizo A, et al.
Transplant Proc 1997 Feb–Mar;29(1–2):964–5
Successful down–regulation of natural and xenoreactive antibodies in pig–to–baboon xenotransplantation by high–dose cyclophosphamide. Morschheuser T, et al.
Transplant Proc 1997 Feb–Mar;29(1–2):970–2
Genetic evidence that the antibody response to xenografts is directed at a restricted number of target antigens. Wu GD, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):954
Offspring of xenogeneically–reconstituted scid/scid mice are capable of a primary xenogeneic immune response to DNP–KLH. Greenwood JD, et al.
Vet Immunol Immunopathol 1996 Mar;50(1–2):145–55

BLOOD

Diagnostic importance of heterophile antibodies and immunoglobulins IgA, IgE, IgM and low–avidity IgG against Epstein–Barr virus capsid antigen in children. Votava M, et al. **Acta Virol** 1996 Apr;40(2):99–101
On the correct determination of reference values for serum antibodies against pigeon serum antigen using a group of healthy blood donors. Bañales JL, et al. **Arch Med Res** 1997 Summer;28(2):289–91
Heterophile antibodies to chicken erythrocytes in sheep infected with Trypanosoma congolense. Joshua RA, et al.
Onderstepoort J Vet Res 1996 Sep;63(3):253–8

CHEMISTRY

Isohemagglutinins and xenoreactive antibodies: members of a distinct family of natural antibodies. Parker W, et al.
Hum Immunol 1996 Feb;45(2):94–104
Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B cell lineage and development. Parker W, et al. **J Clin Immunol** 1997 Jul; 17(4):311–21

IMMUNOLOGY

Structure and pathophysiology of the erythrocyte membrane–associated Paul–Bunnell heterophile antibody determinant in Epstein–Barr virus–associated disease. Patarca R, et al. **Crit Rev Oncog** 1995;6(3–6):305–26
Specificity of xenoreactive anti–Gal alpha 1–3Gal IgM for alpha–galactosyl ligands. Parker W, et al. **Glycobiology** 1996 Jul;6(5):499–506
Incidence of anti–mouse antibodies in thrombocytopenic patients with autoimmune disorders. Clofent–Sanchez G, et al. **Hum Antibodies** 1997;8(2):50–9
Preferential association of V lambda x light chains with gamma 2a heavy chains in naturally occurring human myelin basic protein reactive antibodies. Galin FS, et al.
J Neuroimmunol 1996 Oct;70(1):15–20
Neutralization of myonecrosis, hemorrhage, and edema induced by Bothrops asper snake venom by homologous and heterologous pre–existing antibodies in mice. Rucavado A, et al. **Toxicon** 1996 May;34(5):567–77
Human NK cell–mediated direct and IgG–dependent cytotoxicity against xenogeneic porcine endothelial cells. Watier H, et al. **Transpl Immunol** 1996 Dec;4(4):293–9
Removal of anti–Gal alpha (1,3)Gal antibodies diminishes the cytotoxic effect of primate xenoreactive antibodies on rat endothelial cells. Azimzadeh A, et al.
Transplant Proc 1997 Aug;29(5):2337
Rebound in complement–dependent cytotoxicity and antibody–dependent cell–mediated cytotoxic activity in primate serum after pig liver perfusion. Azimzadeh A, et al. **Transplant Proc** 1997 Aug;29(5):2385–6
Possible role of preformed natural antibodies in preventing bone marrow engraftment in a discordant xenogeneic species combination (human–to–mouse). Kong SS, et al.
Transplant Proc 1997 Jun;29(4):2069–70
Cell and extracellular matrix rejection in arterial concordant and discordant xenografts in the rat. Allaire E, et al.
Transplantation 1996 Sep 27;62(6):794–803
Comparison between aortic and sinusoidal liver endothelial cells as targets of hyperacute xenogeneic rejection in the pig to human combination. Cattan P, et al.
Transplantation 1996 Sep 27;62(6):803–10
Monoclonal antiidiotypic antibodies neutralize cytotoxic effects of anti–alphaGal antibodies. Koren E, et al.
Transplantation 1996 Sep 27;62(6):837–43
Tumor necrosis factor–induced expression of porcine glycoproteins gp65 and gp100 recognized by human xenoreactive natural antibodies. Vetr H, et al.
Transplantation 1996 Aug 15;62(3):396–402
[A patient showing increased T3 and T4 levels due to ALP–interfering substances and heterophilic antibody] Kawakita S. **Rinsho Byori** 1996 Sep;44(9):899–902 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Application of immunoapheresis for delaying hyperacute rejection during isolated xenogeneic pig liver perfusion. Pascher A, et al. **Transplantation** 1997 Mar 27;63(6):867–75

METABOLISM

Butein ameliorates experimental anti-glomerular basement membrane (GBM) antibody-associated glomerulonephritis in rats (1). Hayashi K, et al. **Jpn J Pharmacol** 1996 Jan; 70(1):55–64

PHYSIOLOGY

Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B cell lineage and development. Parker W, et al. **J Clin Immunol** 1997 Jul; 17(4):311–21

Human IgG xenoreactive antibodies mediate damage to porcine endothelial cells in vitro by both humoral and cellular mechanisms. Cooke SP, et al. **Transpl Immunol** 1997 Mar;5(1):39–44

Inhibition of human serum mediated lysis of porcine endothelial cells using a novel peptide which blocks C1Q binding to xenoantibody. Fryer JP, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):883

THERAPEUTIC USE

Heterophilic antibodies produce spuriously elevated concentrations of the MB isoenzyme of creatine kinase in a selected patient population. Sosolik RC, et al. **Am J Clin Pathol** 1997 May;107(5):506–10

ANTIBODIES, HETEROTYPIC see **ANTIBODIES, HETEROPHILE**

ANTIBODIES, INTERNAL IMAGE see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTIBODIES, MONOCLONAL

see related
HYBRIDOMAS

Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1. Bailey ME, et al. **Acta Cytol** 1996 Nov–Dec; 40(6):1212–6

Breast tumor diagnosis in cytologic aspirates using monoclonal antibodies to keratin 8 and 17. Kirjushkina MS, et al. **Acta Cytol** 1997 Mar–Apr;41(2):307–12

Antimacrophage monoclonal antibody D11 in the diagnosis of tumors of histiocytic origin. Petrovichev NN, et al. **Acta Cytol** 1997 Mar–Apr;41(2):357–63

Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome. Ziegler B, et al. **Acta Diabetol** 1996 Sep;33(3):225–31

A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. Reimann KA, et al. **AIDS Res Hum Retroviruses** 1997 Jul 20;13(11):933–43

Automated immunohistochemical assay for estrogen receptor status in breast cancer using monoclonal antibody CC4-5 on the Ventana ES. Nichols GE, et al. **Am J Clin Pathol** 1996 Sep;106(3):332–8

Specific antigens of Chlamydia pecorum and their homologues in C psittaci and C trachomatis. Baghian A, et al. **Am J Vet Res** 1996 Dec;57(12):1720–5

Development of monoclonal antibodies for measurement of immunoglobulin G antibody responses in blue and gold macaws (Ara ararauna). Lung NP, et al. **Am J Vet Res** 1996 Aug;57(8):1157–61

Screening panels of monoclonal antibodies using phage-displayed antigen. Lijnen HR, et al. **Anal Biochem** 1997 Jun 1;248(2):211–5

A comparison of immunohistochemical staining of human cultured mesothelial cells and ovarian tumour cells using epithelial and mesothelial cell markers. Radford H, et al. **Anal Cell Pathol** 1996 Aug;11(3):173–82

Identification of avian dendritic cells in the spleen using a monoclonal antibody specific for chicken follicular dendritic cells. Gallego M, et al. **Anat Rec** 1997 Sep; 249(1):81–5

Monoclonal antibody marker for olfactory sustentacular cell microvilli. Pixley SK, et al. **Anat Rec** 1997 Jul; 248(3):307–21

Immunophenotypic characterization of human primary and metastatic melanoma infiltrating leukocytes. Bodey B, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3439–46

Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody. Hombach A, et al. **Anticancer Res** 1997 May–Jun; 17(3C):2025–32

Production and characterization of mouse monoclonal antibodies against Afipia felis. Engbaek K, et al. **APMIS** 1997 Mar;105(3):192–8

Molecular cloning and expression of hepatitis C virus core protein and production of monoclonal antibodies to the recombinant protein. Songsivilai S, et al. **Asian Pac J Allergy Immunol** 1996 Jun;14(1):31–41

Production and characterization of monoclonal antibodies against avian reovirus strain S1133. Li L, et al. **Avian Dis** 1996 Apr–Jun;40(2):349–57

Detection of endothelial cells by MEC 13.3 monoclonal antibody in mice mammary tumors. Vanzulli S, et al. **Biocell** 1997 Apr;21(1):39–46

Antibodies to the HIV-1 p17 protein cross-react with human superoxide dismutase-2. Kato T, et al. **Biochem Biophys Res Commun** 1997 Jan 3;230(1):184–7

A monoclonal antibody against human lipoprotein lipase inhibiting heparin binding without affecting catalytic activity. Cadelis F, et al. **Biochem Cell Biol** 1996; 74(3):383–9

Purification of GnSAF from human follicular fluid for production of a monoclonal antibody. Bates RL, et al. **Biochem Soc Trans** 1996 May;24(2):269S

Construction of a single-chain Fv from an antibody which catalyses a Diels Alder cycloaddition. Brooks L, et al. **Biochem Soc Trans** 1996 May;24(2):313S

Characterisation of a monoclonal antibody which recognises the enzyme chitinase from Lepeophtheirus salmonis. Labus MB, et al. **Biochem Soc Trans** 1996 May;24(2):207S

Phage antibodies: new technology to obtain monoclonal antibodies to the multidrug-resistance gene product P-glycoprotein. McLaren S, et al. **Biochem Soc Trans** 1996 May;24(2):314S

Characterisation and expression of the novel lymphocyte activation antigen using the monoclonal antibody 6B2D. O'Shea U, et al. **Biochem Soc Trans** 1997 May;25(2):196S

Characterization of monoclonal antibodies against arginine vasopressin. Smith SC, et al. **Biochem Soc Trans** 1996 May; 24(2):270S

Monoclonal antibodies from three new regions of huntingtin, the Huntington's disease protein. Wilkinson F, et al. **Biochem Soc Trans** 1997 Feb;25(1):51S

Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Debrock S, et al. **Biochim Biophys Acta** 1997 Feb 8; 1337(2):257–66

Syntheses of functionalized indium porphyrins for monoclonal antibody labeling. Bedel-Cloutour CH, et al. **Bioconjug Chem** 1996 Nov–Dec;7(6):617–27

Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. Rogers BE, et al. **Bioconjug Chem** 1996 Jul–Aug;7(4):511–22

Use of antibodies against the human antigen of erythroblasts for the detection of nucleated erythrocytes in the maternal circulation. Savion S, et al. **Biol Neonate** 1997;71(2):126–30

Contraceptive effect of sperm-agglutinating monoclonal antibodies in rabbits. Castle PE, et al. **Biol Reprod** 1997 Jan;56(1):153–9

Extraction of DNA using monoclonal anti-DNA and magnetic beads. Gelsthorpe AR, et al. **Biotechniques** 1997 Jun;22(6):1080–2

Re-probing of immunoblots after storage for more than a decade. Gorr SU. **Biotechniques** 1997 Aug;23(2):250–2, 254

Specific detection of his-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions. Lindner P, et al. **Biotechniques** 1997 Jan;22(1):140–9

Restricted use of cationic germline V(H) gene segments in human Rh(D) red cell antibodies. Boucher G, et al. **Blood** 1997 May 1;89(9):3277–86

Drawbacks of the MAIPA technique in characterising human antiplatelet antibodies. Morel-Kopp MC, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):144–6

Evaluation of a new automated ELISA test for von Willebrand factor using two monoclonal antibodies. Pittet JL, et al. **Blood Coagul Fibrinolysis** 1997 Jun;8(4):209–15

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA. Nilsson O, et al. **Br J Cancer** 1997;75(6):789–97

B-B4 monoclonal antibody and identification of human bone marrow plasma cells [letter] Palacios MF, et al. **Br J Haematol** 1997 Mar;96(3):655–7

Monoclonal antibodies against low density lipoprotein with various degrees of oxidative modifications. Gidlund, et al. **Braz J Med Biol Res** 1996 Dec;29(12):1625–8

Differential reactivity of a monoclonal antibody directed to the membrane protein of porcine reproductive and respiratory syndrome virus. Magar R, et al. **Can J Vet Res** 1997 Jan;61(1):69–71

Breast carcinoma detection with a combination of radiolabeled monoclonal antibodies. Promising results from immunohistochemistry studies. Mangili F, et al. **Cancer** 1996 Dec 1;78(11):2334–9

Detection of breast tumor associated mucin epitope on CAMA cell line using monoclonal antibody G3F1 generated against HMFG membrane. Babu PB, et al. **Cancer Biochem Biophys** 1997 Jun;15(4):263–74

Correspondence re: C. Chen, K. E. Malone, J. Prunty, and J. R. Daling, Measurement of urinary estrogen metabolites using a monoclonal enzyme-linked immunoassay kit: assay performance and feasibility for epidemiological studies [letter; comment] Bradlow HL, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Feb;6(2):145–7. Comment on: Cancer Epidemiol Biomarkers Prev 1996 Sep;5(9):727–32.

Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Liu H, et al. **Cancer Res** 1997 Sep 1;57(17):3629–34

Monoclonal antibody raised against human mitotic cyclin B1, identifies cyclin B-like mitotic proteins in synchronized onion (Allium cepa L.) root meristem. Chaudhuri SK, et al. **Cell Biol Int** 1997 Mar;21(3):159–66

Interspecies cross-reactivity of a monoclonal antibody directed against wheat chloroplast fructose-1,6-bisphosphatase. Hagelin K, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Jul;42(5):673–82

Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the 'Ki-67' proteins. Heidebrecht HJ, et al. **Cell Prolif** 1996 Jul;29(7):413–25

Biochemical and histological analysis of two Müller cell antibodies in developing and adult cat and rat central nervous system. Distler C, et al. **Cell Tissue Res** 1997 Sep; 289(3):411–26

Sub-populations of haemocytes in the adult and developing marine mussel, Mytilus edulis, identified by use of monoclonal antibodies. Dyrynda EA, et al. **Cell Tissue Res** 1997 Sep;289(3):527–36

Bovine Reissner's fiber (RF) and the central canal of the spinal cord: an immunocytochemical study using a set of monoclonal antibodies against the RF-glycoproteins. Pérez J, et al. **Cell Tissue Res** 1996 Oct;286(1):33–42

Monoclonal antibody recognition of cholesterol monohydrate crystal faces. Perl-Treves D, et al. **Chem Biol** 1996 Jul;3(7):567–77

Use of enzyme immunoassay for measurement of skeletal troponin-I utilizing isoform-specific monoclonal antibodies. Takahashi M, et al. **Clin Biochem** 1996 Aug; 29(4):301–8

Epitope mapping of prostate-specific antigen with monoclonal antibodies. Jette DC, et al. **Clin Chem** 1996 Dec;42(12):1961–9

Competitive enzyme immunoassay with monoclonal antibody for homovanillic acid measurement in human urine samples. Taran F, et al. **Clin Chem** 1997 Feb;43(2):363–8

Production and characterization of monoclonal antibodies against L-carnitine: radioimmunologic assays for L-carnitine determination. Marini S, et al. **Clin Chim Acta** 1996 May 30;249(1–2):93–108

Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Polonelli L, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):142–6

Monoclonal antibodies to P24 and P61 immunodominant antigens from Nocardia brasiliensis. Salinas-Carmona MC, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):133–7

Flow cytometric platelet enumeration utilizing monoclonal antibody CD42a. Tanaka C, et al. **Clin Lab Haematol** 1996 Dec;18(4):265–9

Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994. Gosse ME, et al. **Clin Pharmacol Ther** 1996 Dec; 60(6):608–18

Monoclonal antibodies to a tumour-associated antigen isolated from circulating immune complexes of bovine leukemia virus-infected cattle. Alexandrov II, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jun;20(3):241–51

Antigenic epitope characterization of matrix protein of Newcastle disease virus using monoclonal antibody approach: contrasting variability amongst NDV strains. Panshin A, et al. **Comp Immunol Microbiol Infect Dis** 1997 Feb;20(2):177–89

Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. Bonsing BA, et al. **Cytometry** 1997 May 1;28(1):11–24

Proposed reference method for peripheral-blood monocyte counting using fluorescence-labelled monoclonal antibodies. Hübl W, et al. **Cytometry** 1996 Mar 15; 26(1):69–74

Flow cytometric detection of the Golgi apparatus using antibodies to glycosyltransferases. Mrkoci Felner K, et al. **Cytometry** 1997 May 1;28(1):50–7

Evaluation of four monoclonal antibodies against HLA-B27 for their reliability in HLA-B27 typing with flow cytometry (FC): comparison with the classic microlymphocytotoxic test (MLCT). Neumüller J, et al. **Cytometry** 1996 Sep 15;26(3):209–15

New monoclonal antibody diagnostic reagents for type I diabetes: differential lymphocyte surface antigen expression related to disease. Pinies JA, et al. **Diabetes** 1997 Mar; 46(3):363–71

Altered immunoreactivity of islet amyloid polypeptide (IAPP) may reflect major modifications of the IAPP molecule in amyloidogenesis. Ma Z, et al. **Diabetologia** 1997 Jul;40(7):793–801

CD2 related immunoregulation in oral cancer. Balaram P, et al. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):43–6

Characterization of MEC 14.7, a new monoclonal antibody recognizing mouse CD34: a useful reage for identifying and characterizing blood vessels and hematopoietic precursors. Garlanda C, et al. **Eur J Cell Biol** 1997 Aug; 73(4):368–77

Photoreceptor differentiation analyzed by the novel monoclonal antibody 1G1. Schlosshauer B, et al. **Eur J Cell Biol** 1997 Jun;73(2):150–7

The specificity of anti-HLA class II monoclonal antibodies in cattle. Nilsson PR, et al. **Eur J Immunogenet** 1997 Jun; 24(3):211–23

Comparison between two HNK-1-related antibodies immunoreactivity (HNK-1-anti-leu 7 and anti-HNK-1/N-CAM) during rat cephalogenesis. Louryan S, et al. **Eur J Morphol** 1996 Nov;34(4):295–300

Differential distribution of immunoreactivity in the adult rat spinal cord revealed by the monoclonal antibody, Py: a light and electron microscopic study. Brook GA, et al.

Exp Neurol 1997 Jul;146(1):265–76

Synaptic distribution of the AMPA–GluR2 subunit and its colocalization with calcium–binding proteins in rat cerebral cortex: an immunohistochemical study using a GluR2–specific monoclonal antibody. Vissavajjhala P, et al. **Exp Neurol** 1996 Dec;142(2):296–312

The use of recombinant vaccinia virus to generate monoclonal antibodies against the cell–surface glycoprotein endoglin. Luque A, et al. **FEBS Lett** 1997 Aug 18; 413(2):265–8

Detection of ERK activation by a novel monoclonal antibody. Yung Y, et al. **FEBS Lett** 1997 May 26; 408(3):292–6

Binding diversity of monoclonal antibodies to alpha(2–>8) polysialic acid conjugated to outer membrane vesicle via adipic acid dihydrazide. Devi SJ, et al. **FEMS Immunol Med Microbiol** 1996 Jul;14(4):211–20

Variable expression and geographic distribution of Mycoplasma agalactiae surface epitopes demonstrated with monoclonal antibodies. Bergonier D, et al. **FEMS Microbiol Lett** 1996 Oct 1;143(2–3):159–65

Construction of CTB fusion proteins for screening of monoclonal antibodies against Salmonella typhi OmpC peptide loops. Paniagua–Solís J, et al. **FEMS Microbiol Lett** 1996 Jul 15;141(1):31–6

Evaluation of three individual glucosyltransferases produced by Streptococcus mutans using monoclonal antibodies. Tomita Y, et al. **FEMS Microbiol Lett** 1996 Dec 15; 145(3):427–32

Monoclonal antibodies against the common polysaccharide of Streptococcus agalactiae. Rosocha J, et al. **Folia Microbiol (Praha)** 1996;41(5):436–40

Monoclonal antibodies for detection of 4–hydroxynonenal modified proteins. Waeg G, et al. **Free Radic Res** 1996 Aug; 25(2):149–59

Establishment of a monoclonal antibody directed against Gb3Cer/CD77: a useful immunochemical reagent for a differentiation marker in Burkitt's lymphoma and germinal centre B cells. Miyamoto D, et al. **Glycoconj J** 1997 Apr; 14(3):379–88

Non Hodgkin's lymphoma presenting as neutropenia related to an IgM monoclonal anti–i antibody. Cartron J, et al. **Hematol Cell Ther** 1996 Apr;38(2):225–30

A novel monoclonal antibody, RM–4, specifically recognizes rat macrophages and dendritic cells in formalin–fixed, paraffin–embedded tissues. Iyonaga K, et al. **Histochem J** 1997 Feb;29(2):105–16

MIB–1 immunoreactivity reveals different labelling in low–grade and in malignant epithelial neoplasms of the choroid plexus. Vajtai I, et al. **Histopathology** 1996 Aug; 29(2):147–51

Human glucagon receptor monoclonal antibodies: antagonism of glucagon action and use in receptor characterization. Buggy J, et al. **Horm Metab Res** 1996 May;28(5):215–9

5th International Conference on Human Antibodies and Hybridomas. Jerusalem, Israel, 14–16 October 1996. Abstracts. **Hum Antibodies Hybridomas** 1996;7(2):50–88

Detection of cytosine deaminase in genetically modified tumor cells by specific antibodies. Haack K, et al. **Hum Gene Ther** 1997 Jul 20;8(11):1395–401

Nondepleting anti–CD4 antibody treatment prolongs lung–directed E1–deleted adenovirus–mediated gene expression in rats. Lei D, et al. **Hum Gene Ther** 1996 Dec 1;7(18):2273–9

Introduction of a myc reporter tag to improve the quality of mutation detection using the protein truncation test. Rowan AJ, et al. **Hum Mutat** 1997;9(2):172–6

Recognition of normal, neoplastic, and fetal airway epithelial cell membranes by two monoclonal antibodies. Strayer DS, et al. **Hum Pathol** 1997 Jul;28(7):840–6

Production and characterization of a monoclonal antibody specific for the polyamine spermidine and its application in ELISA. Catcheside JA, et al. **Hybridoma** 1996 Jun; 15(3):199–204

Conformational changes in pH2–treated human interferon–alpha 2 detected with monoclonal antibodies. Kúdela O, et al. **Hybridoma** 1996 Jun;15(3):185–9

Tumor antigen expression in compound dysplastic nevi and superficial spreading melanoma defined by a panel of nevomelanoma monoclonal antibodies. Lazzaro B, et al. **Hybridoma** 1996 Apr;15(2):141–6

Structural characterization of immunodominant regions of streptokinase recognized by murine monoclonal antibodies. Parhami–Seren B, et al. **Hybridoma** 1996 Jun;15(3):169–76

Mapping of an autoreactive epitope within glutamate decarboxylase using a diabetes–associated human monoclonal autoantibody and an epitope cDNA library. Richter W, et al. **Hybridoma** 1996 Apr;15(2):103–8

VLA–beta 1 integrin subunit–specific monoclonal antibodies MB1.1 and MB1.2: binding to epitopes not dependent on thymocyte development or regulated by phorbol ester and divalent cations. Von Ballestrem CG, et al. **Hybridoma** 1996 Apr;15(2):125–32

Epitope mapping of new monoclonal antibodies recognizing distinct human FcRII (CD32) isoforms. Weinrich V, et al. **Hybridoma** 1996 Apr;15(2):109–16

Monoclonal antibody to VIP: production, characterization, immunoneutralizing activity, and usefulness in cytochemical staining. Wong HC, et al. **Hybridoma** 1996 Apr;15(2):133–9

Murine monoclonal IgG antibodies: differences in their IgG isotypes can affect the antibody effector activity when using human cells. Lobo PI, et al. **Immunol Cell Biol** 1997 Jun;75(3):267–74

Isolation of microvascular endothelial cells using magnetic beads coated with anti–PECAM–1 antibodies [letter; comment] Hewett PW, et al. **In Vitro Cell Dev Biol Anim** 1996 Sep;32(8):462. Comment on: In Vitro Cell Dev Biol Anim 1995 Jun;31(6):473–81.

Monoclonal antibodies against lactate dehydrogenase of Plasmodium knowlesi. Kaushal DC, et al. **Indian J Exp Biol** 1995 Jan;33(1):6–11

Purification of a tumoral marker recognized by monoclonal antibody Po66 and associated with human lung squamous cell carcinoma. Brichory F, et al. **Int J Biol Markers** 1996 Jul–Sep;11(3):148–52

Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK–8): identification as a mucin–type molecule. Lloyd KO, et al. **Int J Cancer** 1997 May 29;71(5):842–50

Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Menssen HD, et al. **Int J Cancer** 1997 Mar 4;70(5):518–23

Evaluation with MIB1 antibody of proliferative activity in ovarian clear cell adenocarcinoma. Morimura Y, et al. **Int J Gynecol Pathol** 1996 Oct;15(4):315–9

Trichinella spiralis: ultrastructural localization of a target antigen recognized by a monoclonal antibody. Niimura M, et al. **Int J Parasitol** 1996 May;26(5):553–5

Epitope mapping and functional characterization of monoclonal antibodies specific for herpes simplex virus type I DNA polymerase. Strick R, et al. **Intervirology** 1997; 40(1):41–9

Quantification of the major brown shrimp allergen Pen a 1 (tropomyosin) by a monoclonal antibody–based sandwich ELISA. Jeoung BJ, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):229–34

Molecular characterizations of an intraacrosomal antigen defined by HS–33 monoclonal antibody. Yoshiki T, et al. **J Androl** 1996 Nov–Dec;17(6):666–73

Metal binding properties of a monoclonal antibody directed toward metal–chelate complexes. Blake DA, et al. **J Biol Chem** 1996 Nov 1;271(44):27677–85

N–Acetylated domains in heparan sulfates revealed by a monoclonal antibody against the Escherichia coli K5 capsular polysaccharide. Distribution of the cognate epitope in normal human kidney and transplant kidney with chronic vascular rejection. Born J, et al. **J Biol Chem** 1996 Sep 13;271(37):22802–9

Characterization of a CD43/leukosialin–mediated pathway for inducing apoptosis in human T–lymphoblastoid cells. Brown TJ, et al. **J Biol Chem** 1996 Nov 1;271(44):27686–95

A novel activating anti–beta1 integrin monoclonal antibody binds to the cysteine–rich repeats in the beta1 chain. Faull RJ, et al. **J Biol Chem** 1996 Oct 11;271(41):25099–106

Monoclonal antibodies against Nalpha–(5'–phosphopyridoxyl)–L–lysine. Screening and spectrum of pyridoxal 5'–phosphate–dependent activities toward amino acids. Gramatikova SI, et al. **J Biol Chem** 1997 Apr 11;272(15):9779–84

Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein. Itabe H, et al. **J Biol Chem** 1996 Dec 27; 271(52):33208–17

Binding of the Brucella abortus lipopolysaccharide O–chain fragment to a monoclonal antibody. Quantitative analysis by fluorescence quenching and polarization. Lin M, et al. **J Biol Chem** 1997 Jan 31;272(5):2821–7

Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (II). Epitope mapping by monoclonal antibodies. Xuan JW, et al. **J Cell Biochem** 1997 May;65(2):186–97

Single particle tracking of cell–surface HLA–DR molecules using R–phycoerythrin labeled monoclonal antibodies and fluorescence digital imaging. Wilson KM, et al. **J Cell Sci** 1996 Aug;109 (Pt 8):2101–9

A monoclonal antibody shows discrete cellular and subcellular localizations of mGluR1 alpha metabotropic glutamate receptors. Petralia RS, et al. **J Chem Neuroanat** 1997 Jul;13(2):77–93

Selective recognition of M235T angiotensinogen variants and their determination in human plasma by monoclonal antibody–based immunoanalysis. Cohen P, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3505–12

Characterization of nonmotile variants of Escherichia coli O157 and other serotypes by using an antiflagellin monoclonal antibody. Feng P, et al. **J Clin Microbiol** 1996 Nov;34(11):2856–9

Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme–linked immunosorbent spot assay for detection of mycobacteria. Glatman–Freedman A, et al. **J Clin Microbiol** 1996 Nov; 34(11):2795–802

Detection of enteroviruses from clinical specimens by spin amplification shell vial culture and monoclonal antibody assay. Klespies SL, et al. **J Clin Microbiol** 1996 Jun; 34(6):1465–7

A novel quantitative immunoassay system for p53 using antibodies selected for optimum designation of p53 status. Thomas MD, et al. **J Clin Pathol** 1997 Feb;50(2):143–7

Differential titration of plasmin and plasminogen in milk using sandwich ELISA with monoclonal antibodies. Dupont D, et al. **J Dairy Res** 1997 Feb;64(1):77–86

Detection and localization of peptidases in Lactococcus lactis with monoclonal antibodies. Laan H, et al. **J Dairy Res** 1996 May;63(2):245–56

Expression of cutaneous lymphocyte–associated antigen defined by monoclonal antibody HECA–452 on human Langerhans cells. Yasaka N, et al. **J Dermatol Sci** 1996 Jan;11(1):19–27

Proliferative potentials of glioma cells and vascular components determined with monoclonal antibody MIB–1. Di X, et al. **J Exp Clin Cancer Res** 1997 Jun;16(2):153–7

Intermediates in the assembly and degradation of class I major histocompatibility complex (MHC) molecules probed with free heavy chain–specific monoclonal antibodies. Machold RP, et al. **J Exp Med** 1996 Dec 1; 184(6):2251–9

Characterization of monoclonal antibody–escape mutants of tick–borne encephalitis virus with reduced neuroinvasiveness in mice. Holzmann H, et al. **J Gen Virol** 1997 Jan;78 (Pt 1):31–7

Monoclonal antibodies to the ORF5 product of porcine reproductive and respiratory syndrome virus define linear neutralizing determinants. Pirzadeh B, et al. **J Gen Virol** 1997 Aug;78 (Pt 8):1867–73

Mapping of monoclonal antibody epitopes of the rabies virus P protein. Raux H, et al. **J Gen Virol** 1997 Jan;78 (Pt 1):119–24

A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. Wang Z, et al. **J Gen Virol** 1997 Sep;78 (Pt 9):2209–15

Detection of human topoisomerase II alpha in cell lines and tissues: characterization of five novel monoclonal antibodies. Kellner U, et al. **J Histochem Cytochem** 1997 Feb;45(2):251–63

Immunocytochemical localization of heparin in secretory granules of rat peritoneal mast cells using a monoclonal anti–heparin antibody (ST–1). Oliani SM, et al. **J Histochem Cytochem** 1997 Feb;45(2):231–5

PDGFR alpha expression during mouse embryogenesis: immunolocalization analyzed by whole–mount immunohistostaining using the monoclonal anti–mouse PDGFR alpha antibody APA5. Takakura N, et al. **J Histochem Cytochem** 1997 Jun;45(6):883–93

Direct determination of serum glycyrrhetic acid by a monoclonal antibody–based inhibition ELISA using ibuprofen for releasing serum albumin–bound glycyrrhetic acid. Itoh K, et al. **J Immunoassay** 1996 Nov;17(4):343–52

Monoclonal antibody based enzyme immunoassay for marihuana (cannabinoid) compounds. Tanaka H, et al. **J Immunoassay** 1996 Nov;17(4):321–42

Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse–human chimeric antibodies as standards. Naess LM, et al. **J Immunol Methods** 1996 Sep 13;196(1):41–9

Detection of blood group antigens utilising immobilised antibodies and surface plasmon resonance. Quinn JG, et al. **J Immunol Methods** 1997 Aug 7;206(1–2):87–96

Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research. **J Immunother** 1997 May; 20(3):214–43

Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. D'Souza MP, et al. **J Infect Dis** 1997 May;175(5):1056–62

Monoclonal antibodies against the human mannose receptor as a specific marker in flow cytometry and immunohistochemistry for macrophages. Noorman F, et al. **J Leukoc Biol** 1997 Jan;61(1):63–72

Selection of monoclonal antibodies for linear epitopes of an apolipoprotein yields antibodies with comparable affinity for lipid–free and lipid–associated apolipoprotein. Curtiss LK, et al. **J Lipid Res** 1996 Apr;37(4):884–92

Laminin–binding epitope on gp43 from Paracoccidioides brasiliensis is recognized by a monoclonal antibody raised against Staphylococcus aureus laminin receptor. Vicentini AP, et al. **J Med Vet Mycol** 1997 Jan–Feb;35(1):37–43

Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. Ditzel HJ, et al. **J Mol Biol** 1997 Apr 4;267(3):684–95

Monoclonal antibodies to the human TSH receptor: epitope mapping and binding to the native receptor on the basolateral plasma membrane of thyroid follicular cells. Nicholson LB, et al. **J Mol Endocrinol** 1996 Apr; 16(2):159–70

Characterization of HPC–1 antigen, an isoform of syntaxin–1, with the isoform–specific monoclonal antibody, 14D8. Kushima Y, et al. **J Mol Neurosci** 1997 Feb;8(1):19–27

Nonmuscle myosin heavy chain B is recognized by a monoclonal antibody that inhibits GM1–enhanced neuritogenesis. Mummert CM, et al. **J Neurochem** 1997 Feb;68(2):596–600

Ultrastructural localization of a synaptic ribbon protein recognized by antibody B16. Balkema GW, et al. **J Neurocytol** 1996 Oct;25(10):565–71

Ultrastructural study of perivascular nerve fibres and endothelial cells of the rat basilar artery immunolabelled

with monoclonal antibodies to neuronal and endothelial nitric oxide synthase. Loesch A, et al. **J Neurocytol** 1996 Sep;25(9):525–34

A novel monoclonal antibody which reacts with a high molecular weight neuronal cytoplasmic protein and myelin basic protein (MBP) in a patient with macroglobulinemia. Kira J, et al. **J Neurol Sci** 1997 May 1;148(1):47–52

Comparison of bromodeoxyuridine uptake and MIB 1 immunoreactivity in medulloblastomas determined with single and double immunohistochemical staining methods. Onda K, et al. **J Neurooncol** 1996 Aug;29(2):129–36

Bcl–xl–specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states. Drache B, et al. **J Neurosci Res** 1997 Jan 1;47(1):98–108

Alz–50 and MC–1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. Jicha GA, et al. **J Neurosci Res** 1997 Apr 15;48(2):128–32

Generation of a monoclonal antibody to the carboxy–terminal domain of tau by immunization with the amino–terminal domain of the amyloid precursor protein. Philippe B, et al. **J Neurosci Res** 1996 Dec 15;46(6):709–19

Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. Casalini P, et al. **J Nucl Med** 1997 Sep;38(9):1378–81

Comparative PET imaging of experimental tumors with bromine–76–labeled antibodies, fluorine–18–fluorodeoxyglucose and carbon–11–methionine. Lövqvist A, et al. **J Nucl Med** 1997 Jul;38(7):1029–35

Preclinical studies of indium–111–labeled IgM: a human monoclonal antibody for infection imaging. Subramanian R, et al. **J Nucl Med** 1997 Jul;38(7):1054–9

A monoclonal antibody pool for routine immunohistochemical detection of human respiratory syncytial virus antigens in formalin–fixed, paraffin–embedded tissue. Wright C, et al. **J Pathol** 1997 Jun;182(2):238–44

Induction of native protein reactive antibodies by immunization with peptides containing linear B–cell epitopes defined by anti–porcine ZP3 beta monoclonal antibodies. Afzalpurkar A, et al. **J Reprod Immunol** 1997 Jun;33(2):113–25

Monoclonal antibody to intercellular adhesion molecule–1 reduces cardiac contractile dysfunction after burn injury in rabbits. Horton JW, et al. **J Surg Res** 1996 Jul 15; 64(1):49–56

Evaluation of the cross–reactivity between human and feline or canine leucocyte antigens using commercially available antibodies. Darbès J, et al. **J Vet Diagn Invest** 1997 Jan; 9(1):94–7

Development of murine monoclonal antibodies for the immunohistochemical diagnosis of systemic bovine aspergillosis. Jensen HE, et al. **J Vet Diagn Invest** 1996 Jan;8(1):68–75

Production of monoclonal antibodies against classical swine fever virus and their use for antigenic characterization of Japanese isolates. Nishimori T, et al. **J Vet Med Sci** 1996 Jul;58(7):707–10

A monoclonal antibody, 169.1, against canine leukocyte surface antigen identifies cytoskeletal components in epithelial cells and peripheral neurons. Iwami Y, et al. **Jpn J Vet Res** 1997 Feb;44(4):193–206

Efficient induction of apoptosis in cultured rat glomerular mesangial cells by dimeric monoclonal IgA anti–Thy–1 antibodies. Sato T, et al. **Kidney Int** 1997 Jan;51(1):173–81

Antibody mediated ligation of platelet/endothelial cell adhesion molecule–1 (PECAM–1) on neutrophils enhances adhesion to cultured human dermal microvascular endothelial cells. Kuwabara H, et al. **Kobe J Med Sci** 1996 Aug;42(4):233–41

A carbohydrate antigen of Clonorchis sinensis recognized by a species–specific monoclonal antibody. Yong TS, et al. **Korean J Parasitol** 1996 Dec;34(4):279–81

Establishment of three monoclonal antibodies specific for prespermatogonia and intratubular malignant germ cells in humans. Hiraoka N, et al. **Lab Invest** 1997 Mar;76(3):427–38

Autologous transplantation with CD52 monoclonal antibody–purged marrow for acute lymphoblastic leukemia: long–term follow–up. Mehta J, et al. **Leuk Lymphoma** 1997 May;25(5–6):479–86

Expression of glycosyl–phosphatidylinositol–linked glycoproteins in blood cells from paroxysmal nocturnal haemoglobinuria patients: a flow cytometry study using CD55, CD58 and CD59 monoclonal antibodies. Navenot JM, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):143–51

Antibodies directed against a variable and neutralizable region of the HTLV–I envelope surface glycoprotein. Londos–Gagliardi D, et al. **Leukemia** 1997 Apr;11 Suppl 3:38–41

Expression of the immunoglobulin–associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Zomas AP, et al. **Leukemia** 1996 Dec; 10(12):1966–70

KM195 as an immunohistochemical marker of adenocarcinoma of the lung. Kawai T, et al. **Lung Cancer** 1996 Aug;15(1):41–50

Anti–melanoma monoclonal antibody HMB–45 on enhanced chemiluminescence–western blotting recognizes a 30–35 kDa melanosome–associated sialated glycoprotein. Chiamenti AM, et al. **Melanoma Res** 1996 Aug;6(4):291–8

Preparation and properties of anti–biotin antibodies. Kohen F, et al. **Methods Enzymol** 1997;279:451–63 (19 ref.)

Epitope mapping of monoclonal antibodies directed against subunits of RNA polymerase of Escherichia coli. Sharif KA, et al. **Methods Enzymol** 1996;274:503–13

Immunoaffinity purification of RNA polymerase II and transcription factors using polyol–responsive monoclonal antibodies. Thompson NE, et al. **Methods Enzymol** 1996; 274:513–26

Epitopes of Bordetella pertussis lipopolysaccharides as potential markers for typing of isolates with monoclonal antibodies. Le Blay K, et al. **Microbiology** 1996 Apr;142 (Pt 4):971–8

The use of monoclonal antibodies with colloidal gold–labeled probes in postembedding immunoelectron microscopy. Suarez CE, et al. **Mol Biotechnol** 1997 Apr;7(2):145–51 (29 ref.)

Separation of PP2A core enzyme and holoenzyme with monoclonal antibodies against the regulatory A subunit: abundant expression of both forms in cells. Kremmer E, et al. **Mol Cell Biol** 1997 Mar;17(3):1692–701

Monoclonal antibody affinities of structurally related modified nucleosides. Higginson–Clarke D, et al. **Mol Chem Neuropathol** 1996 May–Aug;28(1–3):269–77

Utilization of multiple phage display libraries for the identification of dissimilar peptide motifs that bind to a B7–1 monoclonal antibody. De Ciechi PA, et al. **Mol Divers** 1996 Feb;1(2):79–86

Mapping the detailed specificity of a calcium–dependent monoclonal antibody through the use of soluble positional scanning combinatorial libraries: identification of potent calcium–independent antigens. Pinilla C, et al. **Mol Divers** 1995 Sep;1(1):21–8

Identification of new tag sequences with differential and selective recognition properties for the anti–FLAG monoclonal antibodies M1, M2 and M5. Slootstra JW, et al. **Mol Divers** 1997 Mar;2(3):156–64

The 26 kD protein recognized on rat cauda epididymal sperm by monoclonal antibody 4E9 has internal peptide sequence that is identical to the secreted form of epididymal protein E. Xu W, et al. **Mol Reprod Dev** 1997 Mar;46(3):377–82

Happy coupling: recruiting both antigen and effector function [news] Fearon D. **Nat Biotechnol** 1997 Jul;15(7):618–9

Reflections on internal images [news; comment] Greenspan NS. **Nat Biotechnol** 1997 Feb;15(2):123–4. Comment on: Nat Biotechnol 1997 Feb;15(2):155–8.

Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity [see comments] Magliani W, et al. **Nat Biotechnol** 1997 Feb;15(2):155–8. Comment in: Nat Biotechnol 1997 Feb;15(2):123–4.

Epitope–defined monoclonal antibodies against type–IV collagen for diagnosis of Alport's syndrome. Kagawa M, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1238–41

Visualization of protein kinase activities in single cells by antibodies against phosphorylated vimentin and GFAP. Inagaki N, et al. **Neurochem Res** 1996 Jul;21(7):795–800 (30 ref.)

Detection of neuron–specific protein gene product (PGP) 9.5 in the rat and zebrafish using anti–human PGP9.5 antibodies. Trowern AR, et al. **Neurosci Lett** 1996 May 24;210(1):21–4

Monoclonal antibodies specific to the integral membrane protein P0 of bovine peripheral nerve myelin. Yoshimura K, et al. **Neurosci Res** 1996 May;25(1):41–9

Cell death induced by a 131I–labeled monoclonal antibody in ovarian cancer multicell spheroids. Filippovich IV, et al. **Nucl Med Biol** 1996 Jul;23(5):623–6

Thermodynamic analysis of monoclonal antibody binding to duplex DNA. Tanha J, et al. **Nucleic Acids Res** 1997 Apr 1;25(7):1442–9

A PAb240+ conformation of wild type p53 binds DNA. McLure KG, et al. **Oncogene** 1996 Sep 19;13(6):1297–303

Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer. Divgi CR. **Oncology (Huntingt)** 1996 Jun;10(6):939–53; discussion 954, 957–8 (76 ref.)

Reactivity of monoclonal antibodies 17.13 and 63.12 with oral epithelial dysplasia and hyperkeratosis. Merrell P, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Mar;83(3):367–72

Monoclonal antibody MAT–1 against human tyrosinase can detect melanogenic cells on formalin–fixed paraffin–embedded sections. Sato N, et al. **Pigment Cell Res** 1996 Apr;9(2):72–6

Immunohistochemical examination of trophoblast populations in human first trimester and term placentae and of first trimester spiral arteries with the monoclonal antibody GZ 112. Hartmann M, et al. **Placenta** 1997 Sep; 18(7):481–9

Highly specific monoclonal antibody demonstrates that pregnancy–specific glycoprotein (PSG) is limited to syncytiotrophoblast in human early and term placenta. Zhou GQ, et al. **Placenta** 1997 Sep;18(7):491–501

Exploring the basis of peptide–carbohydrate crossreactivity: evidence for discrimination by peptides between closely related anti–carbohydrate antibodies. Harris SL, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2454–9

Monoclonal antibodies reveal receptor specificity among G–protein–coupled receptor kinases. Oppermann M, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7649–54

Potentiation of glutamatergic EPSPs in rat CA1 hippocampal neurons after selective cholinergic denervation by 192 IgG–saporin. Jouvenceau A, et al. **Synapse** 1997 Jul; 26(3):292–300

Effect of monoclonal antibody on the adhesion of platelets to aortic segments. Chiang TM. **Thromb Res** 1996 Dec 1; 84(5):345–9

Proceedings of the 3rd International Workshop and Symposium on Monoclonal Antibodies against Red Blood Cells and Related Antigens. Nantes, 25–27 September 1996. **Transfus Clin Biol** 1996;3(6):329–541

3rd International Workshop and Symposium on Monoclonal Antibodies against Human Red Blood Cells and Related Antigens. **Transfus Clin Biol** 1996;3 Spec No:5s–68s

Rh serology––coordinator's report. Scott M. **Transfus Clin Biol** 1996;3(6):333–7

Monoclonal antibodies to the cell surface of a unique human lymphoid/myeloid cell line detect epitopes absent from peripheral blood mononuclear cells. Cusano G, et al. **Transplant Proc** 1997 Jun;29(4):2046

Epstein–Barr virus–encoded deoxyuridine triphosphate nucleotidohydrolase (dUTPase): a potential target for drug therapy. Kremmer E, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):812–4

The use of MAB 1977 monoclonal antibody for the immunohistochemical localization of beta 1 integrins in paraffin–embedded human kidney. Bernardini N, et al. **Tumori** 1997 May–Jun;83(3):673–8

Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD–1 Workshop. Nap M, et al. **Tumour Biol** 1996; 17(6):325–31

Proceedings of the 3rd workshop on ruminant leukocyte antigens. Davis, California, 16 July 1995. **Vet Immunol Immunopathol** 1996 Aug;52(4):213–468

Characterisation of monoclonal antibodies specific to SEF 21 fimbriae of Salmonella enteritidis and their reactivity with other Salmonellae and Enterobacteria. Sojka MG, et al. **Vet Microbiol** 1996 Feb;48(3–4):207–21

Monoclonal antibodies against Babesia caballi and Babesia equi and their application in serodiagnosis. Brüning A, et al. **Vet Parasitol** 1997 Jan;68(1–2):11–26

Production and characterization of murine IgA monoclonal antibodies to the surface antigens of rhesus rotavirus. Giammarioli AM, et al. **Virology** 1996 Nov 1;225(1):97–110

Antigenic variation of the Epstein–Barr virus nuclear antigen EBNA1 as revealed by monoclonal antibodies. Iwakiri D, et al. **Virus Res** 1997 Aug;50(2):139–49

Characterization of Tula virus antigenic determinants defined by monoclonal antibodies raised against baculovirus–expressed nucleocapsid protein. Lundkvist A, et al. **Virus Res** 1996 Nov;45(1):29–44

Selection of monoclonal antibodies for the identification of D variants: ability to detect weak D and to split epD2, epD5 and epD6/7. Jones J, et al. **Vox Sang** 1996;70(3):173–9

Definition of essential amino acid residues in the recognition of a peptide by a mouse monoclonal antibody. Rosanó L, et al. **Z Naturforsch [C]** 1997 Mar–Apr;52(3–4):274–8

[Comparison of proliferative activity in malignant lymphomas determined by immunohistologic methods with various antibodies] Campr V, et al. **Cesk Patol** 1997 May;33(2):43–5 (Eng. Abstr.) **(Cze)**

[Monoclonal immunoglobulins (editorial)] Brouet JC. **Ann Med Interne (Paris)** 1996;147(8):567–9 (Eng. Abstr.) **(Fre)**

[Study on the specificity of a monoclonal antibody against recombinant envelope proteins of a human endogenous retrovirus, ERV3] Shibata M. **Hokkaido Igaku Zasshi** 1996 Jul;71(4):463–73 (Eng. Abstr.) **(Jpn)**

[A basic and clinical evaluation of a new immunoradiometric assay kit for human serum tissue polypeptide antigen (TPA)] Shimojo K, et al. **Kaku Igaku** 1996 Jun;33(6):655–61 (Eng. Abstr.) **(Jpn)**

[Subserogrouping of 49 Legionella pneumophila serogroup 1 strains with monoclonal antibodies by slide latex agglutination method and its usefulness for epidemiologic study] Gondaira F, et al. **Kansenshogaku Zasshi** 1996 Jul; 70(7):673–80 (Eng. Abstr.) **(Jpn)**

[Analysis of T cell subsets with monoclonal antibodies] Homma T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:159–65 (15 ref.) **(Jpn)**

[Preparation of F(ab')2 mu fragments of IgM monoclonal antibodies] Morimoto K, et al. **Seikagaku** 1996 Jan; 68(1):42–5 **(Jpn)**

[An efficient, antigen–saving, labor–saving, and time–saving technique for making monoclonal antibodies with enlarged rat lymph nodes] Sado Y, et al. **Seikagaku** 1997 Feb; 69(2):128–31 (6 ref.) **(Jpn)**

[Monoclonal antibodies] Arai T. **Tanpakushitsu Kakusan Koso** 1997 May;42(7 Suppl):1128–33 (20 ref.) **(Jpn)**

[Enzyme immunoassay with monoclonal antibody for environmental contaminants] Nakata M, et al. **Tanpakushitsu Kakusan Koso** 1996 Nov;41(14):2132–8 (7 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Kleiman NS. **Am J Cardiol** 1997 Aug 18; 80(4A):29B–33B (17 ref.)

A streptococcal preparation (OK–432) enhances monoclonal antibody NCC–ST–421 cytotoxicity against human colon cancer. Kawano Y, et al. **Anticancer Res** 1997 Jul–Aug; 17(4A):2449–53

Passive immunization with monoclonal antibodies specific

for lipopolysaccharide (LPS) O-side chain protects mice against intravenous Yersinia enterocolitica serotype O:3 infection. Skurnik M, et al. **APMIS** 1996 Jul-Aug; 104(7-8):598-602

Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism. Taylor VC, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):919-25

Cytomedical therapy for IgG1 plasmacytosis in human interleukin-6 transgenic mice using hybridoma cells microencapsulated in alginate-poly(L)lysine-alginate membrane. Okada N, et al. **Biochim Biophys Acta** 1997 Feb 27;1360(1):53-63

7E3 F(ab')2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli. Taylor FB, et al. **Blood** 1997 Jun 1;89(11):4078-84

Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Takeuchi T, et al. **Cancer Immunol Immunother** 1997 Jan;43(6):375-81

Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Wersäll P, et al. **Cancer Immunol Immunother** 1997 May;44(3):157-64

Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Tschmelitsch J, et al. **Cancer Res** 1997 Jun 1;57(11):2181-6

Intrathecal administration of antibodies against LFA-1 and against ICAM-1 suppresses experimental allergic encephalomyelitis in rats. Kawai K, et al. **Cell Immunol** 1996 Aug 1;171(2):262-8

Monoclonal antibodies neutralizing the toxin II from Androctonus australis hector scorpion venom: usefulness of a synthetic, non-toxic analog. Devaux C, et al. **FEBS Lett** 1997 Aug 4;412(3):456-60

CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Stronkhorst A, et al. **Gut** 1997 Mar;40(3):320-7

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Alvarez RD, et al. **Gynecol Oncol** 1997 Apr;65(1):94-101

In vivo binding and hearing loss after intracochlear infusion of KHRI-3 antibody. Nair TS, et al. **Hear Res** 1997 May; 107(1-2):93-101

CD4 monoclonal antibody VIT4 in human alloimmune response in vitro and in vivo. Nachbaur D, et al. **Immunobiology** 1996 Jan;195(1):33-46

Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. Nagano H, et al. **J Clin Invest** 1997 Aug 1;100(3):550-7

Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. Willenborg DO, et al. **J Immunol** 1996 Sep 1;157(5):1973-80

Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature. Muzykantov VR, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):1026-34

Persistence of CD4+ T cells in the arthritic joint after CAMPATH-1H treatment [letter] Finnegan A, et al. **J Rheumatol** 1997 Jul;24(7):1448-9

Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Sykes M, et al. **Nat Med** 1997 Jul;3(7):783-7

CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Kirk AD, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8789-94

The effect of anti-L-selectin (EL-246) on remote lung injury after infrarenal ischemia/reperfusion. Seekamp A, et al. **Shock** 1997 Jun;7(6):447-54

Effectiveness of an adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines. Jinno H, et al. **Surg Today** 1996;26(7):501-7

Coexistence of Th1- and Th2-type cytokine profiles in anti-CD2 monoclonal antibody-induced tolerance. Krieger NR, et al. **Transplantation** 1996 Nov 15;62(9):1285-92

Topically applied human recombinant monoclonal IgG1 antibody and its Fab and F(ab')2 fragments protect mice from vaginal transmission of HSV-2. Zeitlin L, et al. **Virology** 1996 Nov 1;225(1):213-5

[Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor] Knöchel B, et al. **Pneumologie** 1996 Aug;50(8):569-70 **(Ger)**

ADVERSE EFFECTS

Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Kereiakes DJ, et al. **Am J Cardiol** 1996 Nov 15;78(10):1161-3

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. Lincoff AM, et al. **Am J Cardiol** 1997 Feb 1;79(3):286-91

Intravenous lidocaine: effects on controlling pain after anti-GD2 antibody therapy in children with neuroblastoma--a report of a series. Wallace MS, et al. **Anesth Analg** 1997 Oct;85(4):794-6

Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Kageyama S, et al. **Br J Pharmacol** 1997 Sep;122(1):165-71

De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Jonas S, et al. **Cancer** 1997 Sep 15;80(6):1141-50

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Berkowitz SD, et al. **Circulation** 1997 Feb 18;95(4):809-13

Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Tang SC, et al. **Leuk Lymphoma** 1996 Dec;24(1-2):93-101

Cytogenetic damage in marrow cells of mice after injections of yttrium-90-labeled monoclonal antibody. McFee AF, et al. **Nucl Med Biol** 1994 Nov;21(8):1109-14

Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). Tax WJ, et al. **Transplantation** 1997 Jan 15;63(1):106-12

ANALYSIS

Human decidua-associated protein (hDP) 200 identified as a monoclonal rheumatoid factor is not an acute phase reactant. Halperin R, et al. **Am J Reprod Immunol** 1997 Feb;37(2):195-8

Microchip-based capillary electrophoresis for immunoassays: analysis of monoclonal antibodies and theophylline. Chiem N, et al. **Anal Chem** 1997 Feb 1;69(3):373-8

pH-dependent isoform transitions of a monoclonal antibody monitored by micellar electrokinetic capillary chromatography. Kats M, et al. **Anal Chem** 1997 Feb 1; 69(3):338-43

A monoclonal antibody to astrocytes, subepithelial fibroblasts of small intestinal villi and interstitial cells of the myenteric plexus layer. Furuya S, et al. **Anat Embryol (Berl)** 1997 Feb;195(2):113-26

Further characterization of a monoclonal antibody recognizing apolipoprotein E peptides in amyloid deposits. Yamada T, et al. **Ann Clin Lab Sci** 1997 Jul-Aug; 27(4):276-81

Characterization of human p33/41 (annexin IV), a Ca2+ dependent carbohydrate-binding protein with monoclonal anti-annexin IV antibodies, AS11 and AS17. Satoh A, et al. **Biol Pharm Bull** 1997 Mar;20(3):224-9

Fluorescent microtiter screening assay for immunocytochemically reactive antibodies. Su JL, et al. **Biotechniques** 1997 Feb;22(2):320-4

Perivascular localization of TRPM1- and TRPM2-positive cells in the rat brain. Rodella L, et al. **Boll Soc Ital Biol Sper** 1996 Jul-Aug;72(7-8):223-6

Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Colwell NS, et al. **Br J Haematol** 1997 Apr;97(1):219-26

Identification of monoclonal antibodies for immunohistochemical staining of feline B lymphocytes in frozen and formalin-fixed paraffin-embedded tissues. Monteith CE, et al. **Can J Vet Res** 1996 Jul;60(3):193-8

Vascular adhesion molecules and immunogenicity in blood vessels used as coronary artery bypass grafts. Chester AH, et al. **Eur J Cardiothorac Surg** 1996;10(8):676-83

Phenotypic analysis of intestinal non-inflamed mucosa in Crohn's disease: evidence of mononuclear cell depletion in lamina propria. Souza HS, et al. **Eur J Gastroenterol Hepatol** 1996 Jun;8(6):563-8

Studies on tumor proliferation using monoclonal antibody, Ki 67 and expression of p53 in cancer of the uterine cervix. Bar JK, et al. **Eur J Gynaecol Oncol** 1996;17(5):378-80

The usefulness of anti-fucosylated antigen antibody YB-2 for diagnosis of hepatocellular carcinoma. Nakamura J, et al. **Glycoconj J** 1997 Jan;14(1):81-7

Comparison of several mouse and rat monoclonal antibodies against human fibrinogen. Mareček F, et al. **Hybridoma** 1996 Dec;15(6):423-7

Monoclonal antibody detection of Clostridium microcolonies directly on membrane used for milk filtration. Batina P, et al. **J Appl Microbiol** 1997 May;82(5):619-24

Influence of severe burn injury on the expression of RM 3/1 and HLA-DR antigens in human blood monocytes. Zwadlo-Klarwasser G, et al. **J Burn Care Rehabil** 1996 Jul-Aug;17(4):287-93

Capillary isoelectric focusing and sodium dodecyl sulfate-capillary gel electrophoresis of recombinant humanized monoclonal antibody HER2. Hunt G, et al. **J Chromatogr A** 1996 Sep 13;744(1-2):295-301

Determination of anti-HBsAg IgM monoclonal antibodies in cell culture media by perfusion immunoassay. Brackett JM, et al. **J Immunol Methods** 1997 Jan 15;200(1-2):39-46

HECA-452+ T cells migrate through superficial vascular plexus but not through deep vascular plexus endothelium. Kunstfeld R, et al. **J Invest Dermatol** 1997 Mar;108(3):343-8

Congenital monoblastic leukemia as a cause of third-trimester fetal loss: the role of monoclonal antibody testing. Greenbaum BH, et al. **J Perinatol** 1996 May-Jun;16(3 Pt 1):202-4 (20 ref.)

Epitope mapping of a monoclonal antibody specific to feline panleukopenia virus and mink enteritis virus. Horiuchi M, et al. **J Vet Med Sci** 1997 Feb;59(2):133-6

A monoclonal antibody to human placental lactogen hormone facilitates isolation of fetal cells from maternal blood in a model system. Latham SE, et al. **Prenat Diagn** 1996 Sep;16(9):813-21

Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Barren RJ 3rd, et al. **Prostate** 1997 Jan 1;30(1):65-8

Analysis of monoclonal antibodies reactive with molecules upregulated or expressed only on activated lymphocytes. Davis WC, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):301-11

Biochemical characterization of antigens detected with anti-platelet monoclonal antibodies. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):363-70

Analysis of bovine B cell reactive monoclonal antibodies. Mukwedeya DT, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):285-94

Reactivity of monoclonal antibodies with bovine blood mononuclear cells activated by mitogens and superantigens. Schuberth HJ, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):313-21

Detection of Vibrio anguillarum by a sandwich enzyme-linked immunosorbent assay performed with monoclonal antibodies. Adone R, et al. **Zentralbl Veterinarmed [B]** 1996 Dec;43(10):579-84

[Immunohistochemical detection of bcl-2 and MIB-1/Ki-67 in breast cancer: retrospective analysis of 238 cases] Sundlad AS, et al. **Medicina (B Aires)** 1996;56(3):252-8 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Large scale cultivation of an anti-D (IgM) antibody producing human/mouse heterohybridoma. Fizil A, et al. **Acta Microbiol Immunol Hung** 1996;43(4):345-57

Effect of medium composition on hybridoma growth and antibody production. Hencsey Z, et al. **Acta Microbiol Immunol Hung** 1996;43(4):359-70

Preparation of monoclonal antibody against plant extracellular glycoprotein with deglycosylated peptide as antigen. Kurosaki F. **Anal Biochem** 1997 Jan 1;244(1):170-2

Molecular cloning, expression, and characterization of a functional single-chain Fv antibody to the mycotoxin zearalenone. Yuan Q, et al. **Appl Environ Microbiol** 1997 Jan;63(1):263-9

Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies. Tinari N, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):367-72

Development of a human IgA antibody specific for the tumour antigen TAG-72. Ingram PE, et al. **Biochem Soc Trans** 1997 May;25(2):330S

Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Mansfield E, et al. **Biochem Soc Trans** 1997 May;25(2):709-14

Identification and enrichment of human osteoprogenitor cells by using differentiation stage-specific monoclonal antibodies. Joyner CJ, et al. **Bone** 1997 Jul;21(1):1-6

Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas. Denton G, et al. **Br J Cancer** 1997;76(5):614-21

Establishment of internal-image anti-idiotype monoclonal antibodies to a human antibody to lung cancer. Saito H, et al. **Cancer Immunol Immunother** 1997 Apr;44(2):83-7

A novel method for production of monoclonal antibodies. Evaluation and expectation of the rat lymph node method in cell and molecular biology. Sado Y, et al. **Cell Biol Int** 1996 Jan;20(1):7-14

Immunogenicity of viral epitopes expressed on genetically and enzymatically engineered immunoglobulins. Bona CA, et al. **Chem Immunol** 1997;65:179-206 (70 ref.)

Engineering minibody-like ligands by design and selection. Sollazzo M, et al. **Chem Immunol** 1997;65:1-17 (64 ref.)

Chemical engineering at the antibody hinge. Stevenson GT. **Chem Immunol** 1997;65:57-72 (25 ref.)

Development of monoclonal antibodies to the malondialdehyde-deoxyguanosine adduct, pyrimidopurinone. Sevilla CL, et al. **Chem Res Toxicol** 1997 Feb;10(2):172-80

Preparation and characterization of monoclonal antibodies against aflatoxin B1. Lu G, et al. **Chin J Biotechnol** 1995; 11(4):253-8

Preparation of monoclonal antibodies specific for methyl esters of gibberellins A7 and A4. Zheng Z, et al. **Chin J Biotechnol** 1995;11(4):221-6

Novel bispecific immunoprobe for rapid and sensitive detection of prostate-specific antigen. Kreutz FT, et al. **Clin Chem** 1997 Apr;43(4):649-56

Monoclonal antibodies to surface-exposes proteins of Mycoplasma mycoides subsp. mycoides (small-colony strain), which causes contagious bovine pleuropneumonia. Kiarie MN, et al. **Clin Diagn Lab Immunol** 1996 Nov; 3(6):746-52

Monoclonal antibodies to the enterotoxin of Bacteroides fragilis: production, characterization, and immunodiagnostic application. Qadri F, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):608-10

Characterization of monoclonal antibody B7, which neutralizes the cytotoxicity of Pseudomonas aeruginosa exotoxin A. Shang HF, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):727-32

Species-specific measurement of the second group of Dermatophagoides mite allergens, Der p 2 and Der f 2,

using a monoclonal antibody-based ELISA. Yasueda H, et al. **Clin Exp Allergy** 1996 Feb;26(2):171-7

Characterization of fertilization-blocking monoclonal antibody 1G12 with human sperm-immobilizing activity. Komori S, et al. **Clin Exp Immunol** 1997 Sep;109(3):547-54

Generation and characterisation of monoclonal antibodies against rainbow trout, Oncorhynchus mykiss, leucocytes. Bowden LA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jul;117(3):291-8

Immunotherapy for cancer: construction, expression and functional characterization of chimeric antibodies. Motmans K, et al. **Eur J Cancer Prev** 1996 Dec;5(6):512-9

Mono- and bispecific single-chain antibody fragments for cancer therapy. Thirion S, et al. **Eur J Cancer Prev** 1996 Dec;5(6):507-11

Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Bogen B. **Eur J Immunol** 1996 Nov;26(11):2671-9

The effect of space flight on monoclonal antibody synthesis in a hybridoma mouse cell line. Smiley SA, et al. **Exp Cell Res** 1997 Feb 1;230(2):411-4

A polyreactive human anti-lipid A monoclonal antibody having cross reactivity to polysaccharide portions of Pseudomonas aeruginosa lipopolysaccharides. Yokota S, et al. **FEMS Immunol Med Microbiol** 1996 May;14(1):31-8

Production and characterisation of a monoclonal antibody to Serpulina hyodysenteriae. Lee BJ, et al. **FEMS Microbiol Lett** 1996 Feb 15;136(2):193-7

Production and characterization of a new monoclonal antibody effective in recognizing the CD3 T-cell associated antigen in formalin-fixed embedded tissue. Steward M, et al. **Histopathology** 1997 Jan;30(1):16-22

Incorporation of T cell counterparts in the fusion partners for generation of human monoclonal antibodies from Staphylococcus aureus stimulated B lymphocytes. Gore MM, et al. **Hum Antibodies** 1997;8(1):26-32

Lung cancer-reacting human recombinant antibody AE6F4: potential usefulness in the sputum cytodiagnosis. Shoji M, et al. **Hum Antibodies Hybridomas** 1996;7(1):27-36

Production and characterization of the monoclonal antibody against SGP120, a novel serum protein. Basta M, et al. **Hybridoma** 1996 Feb;15(1):69-75

Generation of a monoclonal antibody directed against a human cell substrate adhesion molecule and the expression of the antigen in human tissues. Coene E, et al. **Hybridoma** 1997 Feb;16(1):77-83

Hapten-carrier interactions and their role in the production of monoclonal antibodies against hydrophobic haptens. Fasciglione GF, et al. **Hybridoma** 1996 Feb;15(1):1-9

Production and properties of monoclonal antibodies against human IgG isotypes. Hasnaoui M, et al. **Hybridoma** 1996 Oct;15(5):351-8

Monoclonal antibody to thyroid transcription factor-1: production, characterization, and usefulness in tumor diagnosis. Holzinger A, et al. **Hybridoma** 1996 Feb;15(1):49-53

Production and characterization of monoclonal antibodies against class theta glutathione S-transferase T1-1. Juronen E, et al. **Hybridoma** 1996 Feb;15(1):77-82

Production of monoclonal antibodies against quail Pax-1. Kaneko K, et al. **Hybridoma** 1996 Feb;15(1):83-6

Generation and characterization of a humanized antibody with specificity for preS2 surface antigen of hepatitis B virus. Park SS, et al. **Hybridoma** 1996 Dec;15(6):435-41

A monoclonal antibody to ruminant fibrinogen produced through immunization with ovine peripheral blood leukocytes. Pintado CO, et al. **Hybridoma** 1996 Feb;15(1):87-90

Production and characterization of monoclonal antibodies against human natriuretic peptide receptor-A or -B. Kitano K, et al. **Immunol Lett** 1995 Sep;47(3):215-22

Obtaining a functional recombinant anti-rhesus (D) antibody using the baculovirus-insect cell expression system. Edelman L, et al. **Immunology** 1997 May;91(1):13-9

Preparation of monoclonal anti-porcine CD3 antibodies and preliminary characterization of porcine T lymphocytes. Yang H, et al. **Immunology** 1996 Aug;88(4):577-85

Efficient production of IgG human monoclonal antibodies by lymphocytes stimulated by lipopolysaccharide, pokeweed mitogen, and interleukin 4. Yoshinari K, et al. **In Vitro Cell Dev Biol Anim** 1996 Jun;32(6):372-7

Production & evaluation of a monoclonal antibody against human myeloperoxidase. Badrinath Y, et al. **Indian J Med Res** 1997 Apr;105:176-9

Production of monoclonal antibodies to the non-membrane-damaging cytotoxin (NMDCY) purified from Vibrio cholerae O26 and distribution of NMDCY among strains of Vibrio cholerae and other enteric bacteria determined by monoclonal-polyclonal sandwich enzyme-linked immunosorbent assay. Saha PK, et al. **Infect Immun** 1997 Feb;65(2):801-5

Production of a novel monoclonal antibody against MUC4 mucin [letter] Botti C, et al. **Int J Biol Markers** 1997 Jan-Mar;12(1):42-3

Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1. Lebecque S, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):374-84

Antibody humanization using monovalent phage display. Baca M, et al. **J Biol Chem** 1997 Apr 18;272(16):10678-84

Synthesis of IGFBP-3 fragments in a baculovirus system and characterization of monoclonal anti-IGFBP-3 antibodies. Vorwerk P, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2368-70

Production and characterization of monoclonal antibodies specific for the lipopolysaccharide of Escherichia coli O157. Westerman RB, et al. **J Clin Microbiol** 1997 Mar;35(3):679-84

Production, characterization and immunodiagnostic application of a monoclonal antibody to Shiga toxin. Qadri F, et al. **J Diarrhoeal Dis Res** 1996 Jun;14(2):95-100

Modulation of the immune response in multiple sclerosis: production of monoclonal antibodies specific to HLA/myelin basic protein. Puri J, et al. **J Immunol** 1997 Mar 1;158(5):2471-6

Cell-cell adherence as a selection method for the generation of anti-melanoma monoclonal antibodies. Barral AM, et al. **J Immunol Methods** 1997 Apr 11;203(1):103-9

Production of murine monoclonal antibodies against sulcofuron and flucofuron by in vitro immunisation. Bonwick GA, et al. **J Immunol Methods** 1996 Sep 27;196(2):163-73

Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. Kawakami Y, et al. **J Immunol Methods** 1997 Mar 10;202(1):13-25

A novel method for the production of antibodies against ACTH: their characterization and use in epitope mapping. Kertesz G, et al. **J Immunol Methods** 1997 Jan 15;200(1-2):161-72

Production and characterization of monoclonal antibodies against the leukemia inhibitory factor low affinity receptor, gp190. Pitard V, et al. **J Immunol Methods** 1997 Jul 14;205(2):177-90

Production and characterisation of monoclonal antibodies to Brucella melitensis cytosoluble proteins that are able to differentiate antibody responses of infected sheep from Rev. 1 vaccinated sheep. Cloeckaert A, et al. **J Med Microbiol** 1996 Sep;45(3):206-13

Characterization of novel monoclonal antibodies raised against formalin-fixed, paraffin-embedded human ameloblastoma. Kumamoto H, et al. **J Oral Pathol Med** 1996 Oct;25(9):484-90

Production of monoclonal antibodies against excretory-secretory products of adult male Onchocerca gibsoni. Harnett W, et al. **J Parasitol** 1997 Apr;83(2):316-9

Retinoblastoma protein in human breast carcinoma: immunohistochemical study using a new monoclonal antibody effective on routinely processed tissues. Anderson JJ, et al. **J Pathol** 1996 Sep;180(1):65-70

Influence of mouse placental factors on in vitro antibody synthesis. Miranda S, et al. **J Reprod Immunol** 1996 May;30(2-3):151-71

Production of a monoclonal antibody (59.4) against canine lymphocyte surface antigen and its immunohistochemical application. Iwami Y, et al. **J Vet Med Sci** 1997 Apr;59(4):239-44

Generation of monoclonal antibodies against a feline CD antigen (CD4) expressed by a recombinant baculovirus. Shimojima M, et al. **J Vet Med Sci** 1997 Jun;59(6):467-9

Production of panels of monoclonal antibodies by the hybridoma method. Nguyen TM, et al. **Methods Mol Biol** 1996;66:377-89

Production of monoclonal antibody discriminating serological difference in Escherichia coli O9 and O9a polysaccharides. Kido N, et al. **Microbiol Immunol** 1997;41(7):519-25

IBC sixth annual meeting on antibody engineering Dec 4-6 1995, La Jolla, CA. Metz C. **Mol Med** 1996 Mar;2(2):169-70

A monoclonal antibody (1F3) to human glomerular epithelial cells: a new marker for renal epithelial cell injury. Kagami S, et al. **Nephron** 1997;75(1):65-71

Generation and characterization of subtype-specific monoclonal antibodies to K+ channel alpha- and beta-subunit polypeptides. Bekele-Arcuri Z, et al. **Neuropharmacology** 1996;35(7):851-65

Production of monoclonal anti-thymine-dimer antibody and its use for detection of STR alleles. Fukuda M, et al. **Nippon Hoigaku Zasshi** 1996 Oct;50(5):343-8

Immunologic advances in monoclonal antibody therapy: implications for oncology nursing. Karius D, et al. **Oncol Nurs Forum** 1997 Apr;24(3):483-94; QUIZ 495-6 (74 ref.)

Cultivation of mouse-mouse hybridomas producing IgM monoclonal antibodies. Knežević M, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R231-2

Development of monoclonal antibodies against a riboflavin-tryptophan photoinduced adduct: reactivity to eye lens proteins. Diaz M, et al. **Photochem Photobiol** 1996 Jun;63(6):762-7

A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Babcook JS, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7843-8

Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity. Zapata G, et al. **Protein Eng** 1995 Oct;8(10):1057-62

Retrovirally induced mouse anti-TCR monoclonals can synergize the in vitro proliferative T cell response to bacterial superantigens. Dehghanpisheh K, et al. **Scand J Immunol** 1997 Jun;45(6):645-54

Polyreactive binding of antibodies generated by polyclonal B cell activation. II. Crossreactive and monospecific antibodies can be generated from an identical Ig rearrangement by differential glycosylation. Fernández C, et al. **Scand J Immunol** 1997 Mar;45(3):240-7

Preparation of an antifibrin thrombus-specific murine/human chimeric monoclonal antibody Fab fragment in Escherichia coli. Xia L, et al. **Thromb Res** 1996 Feb 15;81(4):477-84

Construction and expression of single-chain Fv antibody against human bladder carcinoma. Yu LZ, et al. **Urol Res** 1996;24(5):273-7

Production and characterisation of monoclonal antibodies recognising ovine IgE. Shaw RJ, et al. **Vet Immunol Immunopathol** 1996 Jun 1;51(3-4):235-51

Production and characterization of monoclonal antibodies against Taylorella equigenitalis. Gradinaru DA, et al. **Vet Res** 1997;28(1):65-76

[Establishment of anti-HCV NS5 alpha McAb hybridoma cell lines and its application on clinical immunohistochemical diagnosis] Gao J, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Aug;76(8):585-7 (Eng. Abstr.) **(Chi)**

[Production and characterization of specific monoclonal antibody against Porphyromonas endodontalis] Xue Y, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Nov;30(6):343-5, 384 (Eng. Abstr.) **(Chi)**

[Species-specific monoclonal antibodies against the major outer membrane protein (MOMP) of Chlamydia trachomatis] Ni A, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Dec;17(6):428-33 (Eng. Abstr.) **(Chi)**

[Monoclonal antibodies to human progesterone receptors: production, indentification and clinical application] Huang W, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1996 Mar;27(1):40-5 (Eng. Abstr.) **(Chi)**

[Characterization of chick embryo fibroblast culture--overview of its effectiveness as a hybridoma cell] Hlinak A, et al. **Tierarztl Prax** 1996 Feb;24(1):96-101 (Eng. Abstr.) **(Ger)**

[Antibody engineering and gene therapy in cancer] Hinoda Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Oct;19(5):453-9 (17 ref.) **(Jpn)**

[Monoclonal antibody against an urinary protein secreted from the renal tubules--immunohistochemical analysis of renal cell carcinoma] Hamada H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Sep;87(9):1120-6 (Eng. Abstr.) **(Jpn)**

BLOOD

Autoantibodies and anti-mouse antibodies in thrombocytopenic patients as assessed by different MAIPA assays. Clofent-Sanchez G, et al. **Br J Haematol** 1996 Oct;95(1):153-60

Relationship between ZCE 025 blood clearance and liver accumulation in patients with colorectal cancer. Slater JB, et al. **Immunopharmacology** 1996 Nov;35(2):111-8

Use of a modified binding model for the investigation of affinity dependence on antibody concentration in immunoassay systems. Strohner P, et al. **J Immunol Methods** 1997 Apr 25;203(2):113-22

Screening with monoclonal anti-Fy3 to provide blood for phenotype-matched transfusions for patients with sickle cell disease. Sandler SG, et al. **Transfusion** 1997 Apr;37(4):393-7

Identification of monoclonal antibodies with specificity to alpha- or beta-chains of beta 2-integrins using peripheral blood leucocytes of normal and bovine leucocyte adhesion deficient (BLAD) cattle. Rutten VP, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):341-5

[Cryofibrinogenemia caused by monoclonal antifibrinogen antibodies. Pseudo-cryofibrinogenemia (letter; comment)] Baumgärtel MW, et al. **Dtsch Med Wochenschr** 1997 Apr 25;122(17):562. Comment on: Dtsch Med Wochenschr 1996 Sep 6;121(36):1084-9. **(Ger)**

[Cryofibrinogenemia caused by monoclonal antifibrinogen antibodies (letter)] Zeuner RA, et al. **Dtsch Med Wochenschr** 1997 Jun 6;122(23):769 **(Ger)**

CHEMISTRY

Immunocytochemical identification of immature rat peritoneal mast cells using a monoclonal antibody specific for rat mast cells. Faraco CD, et al. **Acta Histochem** 1997 Mar;99(1):23-7

The M22 antibody identifies highly activated reactive astrocytes responding to central nervous system disease. Eddleston M, et al. **Acta Neuropathol (Berl)** 1996;91(3):298-308

Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques? Dickson DW. **Am J Pathol** 1997 Jul;151(1):7-11 (33 ref.)

Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Luther T, et al. **Am J Pathol** 1997 Apr;150(4):1231-44

Monoclonal antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains. Schmidt ML, et al. **Am J Pathol** 1997 Jul;151(1):69-80

Monoclonal antibodies as direct probes for human sperm acrosome reaction. Dorjee S, et al.

Am J Reprod Immunol 1997 Apr;37(4):283–90
Multistep denaturation and hierarchy of disulfide bond cleavage of a monoclonal antibody. Brody T.
Anal Biochem 1997 May 1;247(2):247–56
Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose. Sheeley DM, et al.
Anal Biochem 1997 Apr 5;247(1):102–10
Assessment of heterogeneity in antibody-antigen displacement reactions. Rabbany SY, et al. **Anal Chem** 1997 Jan 15;69(2):175–82
Comparison of structural characteristics of antisubnucleosome and anti-DNA monoclonal antibodies derived from lupus mice. Koutouzov S, et al.
Ann N Y Acad Sci 1997 Apr 5;815:327–30
Phage-displayed Fab fragments against anti-human interleukin-2 receptor alpha. Detection of antigen-bound phages with anti-cpIII monoclonal antibodies. Raivio E, et al. **APMIS** 1997 Feb;105(2):108–14
Radiolabeling antibodies with holmium-166. Dadachova E, et al. **Appl Radiat Isot** 1997 Apr;48(4):477–81
The variable domain glycosylation in a monoclonal antibody specific to GnRH modulates antigen binding. Khurana S, et al. **Biochem Biophys Res Commun** 1997 May 19; 234(2):465–9
Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies. Tinari N, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):367–72
Identification of the epitope for a monoclonal antibody that blocks platelet aggregation induced by type III collagen. Glattauer V, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):45–9
Epitope mapping of a monoclonal antibody to human glutathione transferase P1-1 the binding of which is inhibited by glutathione. Takahata T, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):531–6
Characterisation of anti-IgG monoclonal antibody A57H by epitope mapping. Nelson PN, et al. **Biochem Soc Trans** 1997 May;25(2):373S
Binding of ligand or monoclonal antibody 4B1 induces discrete structural changes in the lactose permease of Escherichia coli. Frillingos S, et al. **Biochemistry** 1997 May 27;36(21):6408–14
Refined structure of an intact IgG2a monoclonal antibody. Harris LJ, et al. **Biochemistry** 1997 Feb 18;36(7):1581–97
Effects of secondary forces on the ligand binding and conformational state of antifluorescein monoclonal antibody 9–40. Mummert ME, et al. **Biochemistry** 1997 Sep 30;36(39):11918–22
Influence of heavy metal ions on antibodies and immune complexes investigated by dynamic light scattering and enzyme-linked immunosorbent assay. Bauer R, et al.
Biochim Biophys Acta 1997 Feb 11;1334(1):98–108
Characterization of monoclonal antibodies against (1R,2R)-cyclohexanediamine platinum(II)-DNA adduct. Hirose J, et al. **Biol Pharm Bull** 1996 Sep;19(9):1220–2
Characterization of immunochemical reaction for human growth hormone with its monoclonal antibody by perfusion protein G affinity chromatography and capillary zone electrophoresis. Zou H, et al. **Biomed Chromatogr** 1996 Mar-Apr;10(2):78–82
Regioselectivity and enantioselectivity in an antibody catalyzed hetero Diels-Alder reaction. Meekel AA, et al. **Bioorg Med Chem** 1996 Jul;4(7):1051–7
Kinetics and locus of failure of receptor-ligand-mediated adhesion between latex spheres. II. Protein-protein bond. Kwong D, et al. **Biophys J** 1996 Aug;71(2):1115–22
Kinetics and locus of failure of receptor-ligand-mediated adhesion between latex spheres. I. Protein-carbohydrate bond. Tees DF, et al. **Biophys J** 1996 Aug;71(2):1102–14
Use of conformationally constrained peptides for a topographical analysis of the combing site of a monoclonal anti-substance P antibody. Déry O, et al. **Biopolymers** 1996 Jul;39(1):67–74
Compared structures of the free nicotinic acetylcholine receptor main immunogenic region (MIR) decapeptide and the antibody-bound [A76]MIR analogue: a molecular dynamics simulation from two-dimensional NMR data. Orlewski P, et al. **Biopolymers** 1996;40(5):419–32
Patterning of immobilized antibody layers via photolithography and oxygen plasma exposure. Flounders AW, et al. **Biosens Bioelectron** 1997;12(6):447–56
Crystal structure of NMC-4 fab anti-von Willebrand factor A1 domain. Celikel R, et al. **Blood Cells Mol Dis** 1997; 23(1):123–34
Monoclonal antibodies against human tetranectin, epitope characterization and use in immunohistochemistry. Høgdall CK, et al. **Clin Chim Acta** 1997 Feb 17;258(2):159–77
Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a. Hartman AB, et al. **Clin Diagn Lab Immunol** 1996 Sep; 3(5):584–9
Comparison of commercially available antibody reagents for the cytomegalovirus pp65 antigenemia assay. St George K, et al. **Clin Diagn Virol** 1997 Feb;7(3):147–52
A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Anderson D, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):73–84
Ki-67 immunoreactivity in meningiomas--determination of the proliferative potential of meningiomas using the monoclonal antibody Ki-67. Madsen C, et al.
Clin Neuropathol 1997 May-Jun;16(3):137–42
Humoral immunoglobulins of the white sturgeon, Acipenser transmontanus: partial characterization of and recognition with monoclonal antibodies. Adkison MA, et al.
Dev Comp Immunol 1996 Jul-Aug;20(4):285–98
Characterization of five monoclonal antibodies specific for swine class II major histocompatibility antigens and crossreactivity studies with leukocytes of domestic animals. Bullido R, et al. **Dev Comp Immunol** 1997 May-Jun; 21(3):311–22
Profiling of oligosaccharide-mediated microheterogeneity of a monoclonal antibody by capillary electrophoresis. Hoffstetter-Kuhn S, et al. **Electrophoresis** 1996 Feb; 17(2):418–22
Structure of the complex of an Fab fragment of a neutralizing antibody with foot-and-mouth disease virus: positioning of a highly mobile antigenic loop. Hewat EA, et al.
EMBO J 1997 Apr 1;16(7):1492–500
Synthesis of different immunotoxins composed by ribosome inactivating proteins non-covalently bound to monoclonal antibody. Dosio F, et al. **Farmaco** 1996 Jul;51(7):477–82
Helical epitopes determined by low-stringency antibody screening of a combinatorial peptide library. Stern B, et al. **FASEB J** 1997 Feb;11(2):147–53
MPM-2 epitope sequence is not sufficient for recognition and phosphorylation by ME kinase-H. Che S, et al.
FEBS Lett 1997 Aug 25;413(3):417–23
Sequence analysis and bacterial production of the anti-c-myc antibody 9E10: the V(H) domain has an extended CDR-H3 and exhibits unusual solubility. Schiweck W, et al.
FEBS Lett 1997 Sep 1;414(1):33–8
Altered cleavage site preference of a proteolytic antibody light chain induced by denaturation. Sun M, et al.
FEBS Lett 1997 May 5;407(3):289–90
Low affinity, antibody binding of an Escherichia coli-derived component. Ohlin M, et al.
FEMS Immunol Med Microbiol 1996 Feb;13(2):161–8
Differences in phycoerythrin- or fluorescein-isothiocyanate conjugated 8G12 on CD34+ cell evaluation. Ortuño F, et al. **Haematologica** 1997 May-Jun;82(3):334–5
Follicular dendritic cells in bone marrow lymphoproliferative diseases: an immunohistochemical study including a new paraffin-resistant monoclonal antibody, DR53.
Meugé-Moraw C, et al. **Histopathology** 1996 Apr; 28(4):341–7
Production and characterization of a new monoclonal antibody effective in recognizing the CD3 T-cell associated antigen in formalin-fixed embedded tissue. Steward M, et al. **Histopathology** 1997 Jan;30(1):16–22
Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region. Sato K, et al. **Hum Antibodies Hybridomas** 1996;7(4):175–83
Production and characterization of the monoclonal antibody against SGP120, a novel serum protein. Basta M, et al.
Hybridoma 1996 Feb;15(1):69–75
Identification of functional domains on gC1Q-R, a cell surface protein that binds to the globular "heads" of C1Q, using monoclonal antibodies and synthetic peptides. Ghebrehiwet B, et al. **Hybridoma** 1996 Oct;15(5):333–42
Monoclonal antibody to thyroid transcription factor-1: production, characterization, and usefulness in tumor diagnosis. Holzinger A, et al. **Hybridoma** 1996 Feb; 15(1):49–53
Characterization of a series of isotype switch variants of a new CD20 monoclonal antibody. Hooijberg E, et al.
Hybridoma 1996 Feb;15(1):23–31
Production and characterization of monoclonal antibodies against class theta glutathione S-transferase T1-1. Juronen E, et al. **Hybridoma** 1996 Feb;15(1):77–82
Mapping of monoclonal antibody- and receptor-binding domains on human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) using a surface plasmon resonance-based biosensor. Laricchia-Robbio L, et al. **Hybridoma** 1996 Oct;15(5):343–50
Characterization of monoclonal antibodies recognizing human merosin and their use in affinity purification of native merosin. Mizuta T, et al. **Hybridoma** 1996 Oct; 15(5):373–8
Monoclonal antibody specific to bovine lens epithelial cell membrane: preparation of a lens epithelial cell-selective immunotoxin. Ozaki L, et al. **Hybridoma** 1996 Dec; 15(6):409–14
Characterization of rat HSA/CD24 protein bearing the B lineage-restricted epitope recognized by MAb HIS50. Pearce EI, et al. **Hybridoma** 1996 Feb;15(1):33–42
Development and characterization of monoclonal antibodies specific for amylin. Phelps JL, et al. **Hybridoma** 1996 Oct; 15(5):379–86
Monoclonal antibodies directed against the amino-terminal domain of human TBP cross-react with TBP from other species. Ruppert SM, et al. **Hybridoma** 1996 Feb; 15(1):55–68
Mouse monoclonal antipeptide antibodies specific for cholesteryl ester transfer protein (CETP). Thomas AP, et al. **Hybridoma** 1996 Oct;15(5):359–64
Structural diversity of monoclonal CD4 antibodies and their capacity to block the HIV gp120/CD4 interaction. Weissenhorn W, et al. **Hybridoma** 1996 Apr;15(2):117–24
Characterization of monoclonal antibodies to the 26-kDa glutathione S-transferase of Schistosoma japonicum. Yan BS, et al. **Hybridoma** 1996 Dec;15(6):429–33
Identification of a 35 kDa glycoprotein from Entamoeba histolytica by sera from patients with amoebic liver abscess and with mouse monoclonal antibody. Agundis-Mata C, et al. **Immunol Invest** 1996 Sep-Nov;25(5-6):519–29
Application of cloth-based enzyme immunoassay for the characterization of monoclonal antibodies to Salmonella lipopolysaccharide antigens. Brown JG, et al.
Immunol Invest 1996 Jul;25(4):369–81
Sequence, specificity and crystallization of an oestrone-3-glucuronide antibody (3910). He M, et al.
Immunology 1997 Apr;90(4):632–9
The in vivo and in vitro characterisation of an engineered human antibody to E-selectin. Owens R, et al.
Immunotechnology 1997 Jun;3(2):107–16
Similarities and disparities between core-specific and O-side-chain-specific antilipopolysaccharide monoclonal antibodies in models of endotoxemia and bacteremia in mice. Bailat S, et al. **Infect Immun** 1997 Feb;65(2):811–4
Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Belay T, et al. **Infect Immun** 1997 Feb;65(2):718–28
Analysis of culture filtrate and cell wall-associated antigens of Mycobacterium paratuberculosis with monoclonal antibodies. Mutharia LM, et al. **Infect Immun** 1997 Feb; 65(2):387–94
Characterization of rat CD80 and CD86 by molecular cloning and mAb. Maeda K, et al. **Int Immunol** 1997 Jul; 9(7):993–1000
Synthesis of a new class of isothiocyanatopeptide bifunctional chelating agents for coupling to monoclonal antibodies. Ram S, et al. **Int J Pept Protein Res** 1996 Jul;48(1):79–86
Mapping of SLE-specific Sm B cell epitopes using murine monoclonal antibodies. Pruijn GJ, et al. **J Autoimmun** 1997 Apr;10(2):127–36
Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. Arakawa F, et al.
J Biochem (Tokyo) 1996 Sep;120(3):657–62
Antibody humanization using monovalent phage display. Baca M, et al. **J Biol Chem** 1997 Apr 18;272(16):10678–84
Role of salt bridge formation in antigen-antibody interaction. Entropic contribution to the complex between hen egg white lysozyme and its monoclonal antibody HyHEL10. Tsumoto K, et al. **J Biol Chem** 1996 Dec 20;271(51):32612–6
Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic epithelial antigen by the use of an optical biosensor. A comparison of immobilisation strategies. Catimel B, et al. **J Chromatogr A** 1997 Jul 25; 776(1):15–30
Immuno-capillary electrophoresis for the characterization of a monoclonal antibody against DNA. Heegaard NH, et al. **J Chromatogr A** 1996 Sep 13;744(1-2):285–94
Intermediate- and low-molecular-weight keratin detection with the monoclonal antibody MNF116. An immunohistochemical study on 232 paraffin-embedded cutaneous lesions. Prieto VG, et al. **J Cutan Pathol** 1996 Jun;23(3):234–41
Characterization of a V3 domain-specific neutralizing human monoclonal antibody that preferentially recognizes non-syncytium-inducing human immunodeficiency virus type 1 strains. Schutten M, et al. **J Gen Virol** 1995 Jul;76 (Pt 7):1665–73
Enzyme-linked immunosorbent assay of neocarzinostatin chromophore (NCS-chr) by use of a monoclonal antibody against NCS-chr analog. Mizugaki M, et al.
J Immunoassay 1996 May;17(2):133–44
Alleles of highly homologous rat T cell receptor beta-chain variable segments 8.2 and 8.4: strain-specific expression, reactivity to superantigens, and binding of the mAb R78. Asmuss A, et al. **J Immunol** 1996 Nov 15;157(10):4436–41
High affinity antibodies against Lex and sialyl Lex from a phage display library. Dinh Q, et al. **J Immunol** 1996 Jul 15;157(2):732–8
Alloreactive monoclonal antibodies select Kd molecules with different peptide profiles. Noun G, et al. **J Immunol** 1996 Sep 15;157(6):2455–61
Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites. Riggs MW, et al. **J Immunol** 1997 Feb 15;158(4):1787–95
VHDJH gene sequences and antigen reactivity of monoclonal antibodies produced by human B-1 cells: evidence for somatic selection. Schettino EW, et al.
J Immunol 1997 Mar 1;158(5):2477–89
A model system for detection and isolation of a tumor cell surface antigen using antibody phage display. Pereira S, et al. **J Immunol Methods** 1997 Apr 11;203(1):11–24
Isolation of cell surface-specific human monoclonal antibodies using phage display and magnetically-activated cell sorting: applications in immunohematology. Siegel DL, et al. **J Immunol Methods** 1997 Aug 7;206(1-2):73–85
Characterization of anti-human interleukin-18 (IL-18)/interferon-gamma-inducing factor (IGIF) monoclonal antibodies and their application in the measurement of human IL-18 by ELISA. Taniguchi M, et al. **J Immunol Methods** 1997 Aug 7;206(1-2):107–13
Three-dimensional structure of an Fab-peptide complex: structural basis of HIV-1 protease inhibition by a monoclonal antibody. Lescar J, et al. **J Mol Biol** 1997 Apr 18;267(5):1207–22

Prediction of IgE(Lb4)-ligand complex structures by automated docking. Winger RH, et al. **J Mol Recognit** 1996 May-Jun;9(3):239-46

Monoclonal antibody PHF-9 recognizes phosphorylated serine 404 of tau protein and labels paired helical filaments. Zemlan FP, et al. **J Neurosci Res** 1996 Oct 1;46(1):90-7

The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody. Usami A, et al. **J Pharm Biomed Anal** 1996 Jun;14(8-10):1133-40

Characterization of anti-sperm antibodies and their coding cDNA sequences by Epstein-Barr virus transformed B cell lines from lymphocytes of infertile women possessing anti-sperm antibodies. Dimitrova-Dikanarova DK, et al. **J Reprod Immunol** 1996 Dec;32(2):171-91

The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside. Pichla SL, et al. **J Struct Biol** 1997 Jun;119(1):6-16

Epitope mapping of homologous and cross-reactive antigens by monoclonal antibodies to streptococcal cell membrane (mAb to SCM). Lange CF, et al. **Mol Immunol** 1996 Jun; 33(9):777-86

Effects of secondary forces on the ligand binding properties and variable domain conformations of a monoclonal anti-fluorescyl antibody. Mummert ME, et al. **Mol Immunol** 1996 Sep;33(13):1067-77

Characterization by serial deletion competition ELISAs of HIV-1 V3 loop epitopes recognized by monoclonal antibodies. Seligman SJ, et al. **Mol Immunol** 1996 Jun; 33(9):737-45

The interplay between binding energy and catalysis in the evolution of a catalytic antibody. Ulrich HD, et al. **Nature** 1997 Sep 18;389(6648):271-5

Orientation of myelin proteolipid protein in the oligodendrocyte cell membrane. Greer JM, et al. **Neurochem Res** 1996 Apr;21(4):431-40

Stability of a metabolizable ester bond in radioimmunoconjugates. Arano Y, et al. **Nucl Med Biol** 1996 Feb;23(2):129-36

A freeze dried kit formulation for the preparation of 99mTc-EHDP-MoAb-IOR CEA1 complex. Ferro-Flores G, et al. **Nucl Med Biol** 1994 Oct;21(7):1013-6

A computer program for quantification of SH groups generated after reduction of monoclonal antibodies. Iznaga Escobar N, et al. **Nucl Med Biol** 1996 Jul;23(5):635-9

Micromethod for quantification of SH groups generated after reduction of monoclonal antibodies. Iznaga Escobar N, et al. **Nucl Med Biol** 1996 Jul;23(5):641-4

In vitro and in vivo evaluation of structure-stability relationship of 111In- and 67Ga-labeled antibody via 1B4M or C-NOTA chelates. Lee J, et al. **Nucl Med Biol** 1997 Apr;24(3):225-30

Direct 99mTc-labeling of antibodies by sodium dithionite reduction, and role of ascorbate as a stabilizer in cysteine challenge. Qi P, et al. **Nucl Med Biol** 1996 Aug;23(6):827-35

Evaluation of a direct method for technetium labeling intact and F(ab')2 1A3, an anticolorectal monoclonal antibody. Schwarz SW, et al. **Nucl Med Biol** 1994 May;21(4):619-26

Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments. Vaidyanathan G, et al. **Nucl Med Biol** 1994 Jan; 21(1):105-10

Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. Zalutsky MR, et al. **Nucl Med Biol** 1997 Apr;24(3):255-61

Healing of polytetrafluoroethylene vascular grafts analyzed by anti-smooth muscle myosin heavy chain isoforms. Okahara K, et al. **Pathobiology** 1995;63(3):160-7

Comparison of two monoclonal antibodies for the detection of estrogen receptors in primary breast carcinomas. Nedergaard L, et al. **Pathol Res Pract** 1996 Oct; 192(10):983-8

Formulation development of an antifibrin monoclonal antibody radiopharmaceutical. Kamat MS, et al. **Pharm Biotechnol** 1996;9:343-64 (18 ref.)

Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody. Duddu SP, et al. **Pharm Res** 1997 May;14(5):591-5

The relationship between protein aggregation and molecular mobility below the glass transition temperature of lyophilized formulations containing a monoclonal antibody. Duddu SP, et al. **Pharm Res** 1997 May;14(5):596-600

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Ghetie MA, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7509-14

Molecular recognition of the Lewis Y antigen by monoclonal antibodies. Blaszczyk-Thurin M, et al. **Protein Eng** 1996 May;9(5):447-59

Structure and humanization of a rat monoclonal Fab to human interleukin-5. Cook WJ, et al. **Protein Eng** 1996 Jul;9(7):623-8

Preliminary crystallographic studies of an anti-HIV-1 protease antibody that inhibits enzyme activity. Lescar J, et al. **Protein Sci** 1996 May;5(5):966-8

Conformation of P22 tailspike folding and aggregation intermediates probed by monoclonal antibodies. Speed MA, et al. **Protein Sci** 1997 Jan;6(1):99-108

Comparison of an antibody model with an X-ray structure: the variable fragment of BR96. Bajorath J, et al. **Proteins** 1996 Feb;24(2):152-7

Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA. Fledelius C, et al. **Scand J Clin Lab Invest** 1997 Feb; 57(1):73-83

A new murine lymphocytotoxic monoclonal antibody recognizing HLA-A2, -A28 and -A9. Mizuno S, et al. **Tissue Antigens** 1996 Sep;48(3):224-7

Ruminant cluster CD14. Berthon P, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):245-8

Monoclonal antibodies to a high molecular weight isoform of porcine CD45: biochemical and tissue distribution analyses. Bullido R, et al. **Vet Immunol Immunopathol** 1997 May;56(1-2):151-62

Identification of three myeloid-specific differentiation antigens in sheep. Hopkins J, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):329-39

Ruminant cluster WC14. Howard CJ. **Vet Immunol Immunopathol** 1996 Aug;52(4):261-2

Immunohistochemical demonstration of cellular antigens of the cat defined by anti-human antibodies. Joling P, et al. **Vet Immunol Immunopathol** 1996 Sep;53(1-2):115-27

Ruminant cluster CD41/CD61. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):251-3

Biochemical analysis of preliminary clusters in the non-lineage panel. Naessens J, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):347-56

Characterisation of bovine transferrin receptor on normal activated and Theileria parva-transformed lymphocytes by a new monoclonal antibody. Naessens J, et al. **Vet Immunol Immunopathol** 1996 Jun 15;52(1-2):65-76

Identification of chicken Bu-1 alloantigens using the monoclonal antibody AV20. Rothwell CJ, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1-3):225-34

Cross-reactivity of monoclonal antibodies to defined human leucocyte differentiation antigens with bovine cells. Sopp P, et al. **Vet Immunol Immunopathol** 1997 May; 56(1-2):11-25

Monoclonal and polyclonal antibodies to chicken immunoglobulin isotypes specifically detect turkey immunoglobulin isotypes. Van Nerom A, et al. **Vet Immunol Immunopathol** 1997 Jul;57(3-4):305-14

Different affinity of monoclonal antibodies for conserved neutralizing epitopes on two strains of rubella virus. Cordoba P, et al. **Viral Immunol** 1997;10(2):103-10

Antigenic features of foot-and-mouth disease virus serotype Asia1 as revealed by monoclonal antibodies and neutralization-escape mutants. Sanyal A, et al. **Virus Res** 1997 Aug;50(2):107-17

Screening for Salmonella with a murine monoclonal antibody M105 detects both Felix O1 bacteriophage sensitive and resistant Salmonella strains. Tsang RS, et al. **Zentralbl Bakteriol** 1997 Jun;286(1):23-32

CLASSIFICATION

Flow cytometric analysis of the reactivity of workshop monoclonal antibodies on sheep lymph node cells, after infection with Salmonella abortusovis. Bernard S, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):403-9

Immunohistochemical study on the reactivity of workshop monoclonal antibodies with sheep lymph nodes. Berthon P, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):393-401

Reactivity of workshop antibodies with a non-ruminant species: crossreactivity with canine blood leukocytes. H-Joachim S, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):427-33

Two monoclonal antibodies from the platelet panel recognize sheep plasma fibrinogen. Pérez de la Lastra JM, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):371-5

Immunohistochemical reactivity of anti-platelet monoclonal antibodies. Simon M, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):377-82

Appendices. Sopp P. **Vet Immunol Immunopathol** 1996 Aug; 52(4):445-68

DIAGNOSTIC USE

Staging of cardiac rejection by simultaneous administration of 123I-antimyosin and 111In-anti MHC class II antibodies. Isobe M, et al. **Acta Cardiol** 1996;51(6):515-20

MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Mizoue T, et al. **Acta Neurochir (Wien)** 1997;139(5):426-31; discussion 431-2

Inner ear content of glycosaminoglycans as shown by monoclonal antibodies. Hultcrantz M, et al. **Acta Otolaryngol (Stockh)** 1996 Jan;116(1):25-32

Antigenic analysis of Cryptomeria japonica and Chamaecyparis obtusa using anti-Cry j 1 monoclonal antibodies. Suzuki M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:85-9

Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies. Nakao A, et al. **Am J Gastroenterol** 1997 Jun;92(6):1031-4

Biologic markers of arthritis [letter; comment] Slater R. **Am J Orthop** 1996 Aug;25(8):521, 570. Comment on: Am J Orthop 1996 Apr;25(4):263-72.

Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary. Rishi M, et al. **Am J Surg Pathol** 1997 May;21(5):583-9

Immunophenotyping of dermal spindle cell tumors: diagnostic value of monocyte marker Ki-M1p and histogenetic considerations. Rudolph P, et al. **Am J Surg Pathol** 1997 Jul;21(7):791-800

Detection of circulating antigen by monoclonal antibodies for immunodiagnosis of angiostrongyliasis. Chye SM, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):408-12

Monoclonal antibodies to Paragonimus heterotremus and their potential for diagnosis of paragonimiasis. Maleewong W, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):413-7

Use of monoclonal antibodies for immunohistochemical study of bovine spleen on frozen sections. Delverdier M, et al. **Anat Histol Embryol** 1996 Dec;25(4):243-7

Binding of a human monoclonal antithyroglobulin antibody to cultured human thyroid cancer cells. Misaki T, et al. **Ann Nucl Med** 1997 May;11(2):81-5

Diagnosing sternal wound infections with 99mTc-labeled monoclonal granulocyte antibody scintigraphy. Bitkover CY, et al. **Ann Thorac Surg** 1996 Nov;62(5):1412-6; discussion 1416-7

Production of monoclonal antibodies for the identification of the eggs of Taenia solium. Montenegro TC, et al. **Ann Trop Med Parasitol** 1996 Apr;90(2):145-55

Production of specific monoclonal antibodies to Burkholderia pseudomallei and their diagnostic application. Pongsunk S, et al. **Asian Pac J Allergy Immunol** 1996 Jun;14(1):43-7

The use of monoclonal antibody stains in Mohs micrographic surgery. Salmon RM. **Australas J Dermatol** 1997 Feb; 38(1):44-5

A comparison of cleavable and noncleavable hydrazinopyridine linkers for the 99mTc labeling of Fab' monoclonal antibody fragments. Bridger GJ, et al. **Bioconjug Chem** 1996 Mar-Apr;7(2):255-64

Preparation of a monoclonal antibody specific for 5-methyl-2'-deoxycytidine and its application for the detection of DNA methylation levels in human peripheral blood cells. Mizugaki M, et al. **Biol Pharm Bull** 1996 Dec; 19(12):1537-40

Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies. Mottolese M, et al. **Br J Cancer** 1997;75(4):572-8

A comparison between 111In-anti-E-selectin mAb and 99Tcm-labelled human non-specific immunoglobulin in radionuclide imaging of rheumatoid arthritis. Jamar F, et al. **Br J Radiol** 1997 May;70(833):473-81

Gelatinase B in chronic synovitis: immunolocalization with a monoclonal antibody. Grillet B, et al. **Br J Rheumatol** 1997 Jul;36(7):744-7

Investigation of rabies virus strains in Mexico with a panel of monoclonal antibodies used to classify Lyssavirus. Loza-Rubio E, et al. **Bull Pan Am Health Organ** 1996 Mar; 30(1):31-5

Effusion cytology of malignant melanoma. A morphologic and immunocytochemical analysis including application of the MART-1 antibody. Beaty MW, et al. **Cancer** 1997 Feb 25;81(1):57-63

Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer. Bonner RB, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Dec;5(12):971-8

Measurement of urinary estrogen metabolites using a monoclonal enzyme-linked immunoassay kit: assay performance and feasibility for epidemiological studies [see comments] Chen C, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Sep;5(9):727-32. Comment in: Cancer Epidemiol Biomarkers Prev 1997 Feb;6(2):145-7.

RIGS: surgery. Talking the talk and (just possibly) walking the walk [editorial; comment] Larson SM. **Cancer Invest** 1996;14(6):637-9. Comment on: Cancer Invest 1996;14(6):560-71.

The use of monoclonal antibodies (MAbs) and the development of an intraoperative hand-held probe for cancer detection [see comments] Martin EW Jr, et al. **Cancer Invest** 1996;14(6):560-71 (21 ref.). Comment in: Cancer Invest 1996;14(6):637-9.

Noninvasive detection of atherosclerotic lesions by 99mTc-based immunoscintigraphic targeting of proliferating smooth muscle cells. Narula J, et al. **Chest** 1997 Jun;111(6):1684-90

Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation [see comments] Müller-Bardorff M, et al. **Clin Chem** 1997 Mar;43(3):458-66. Comment in: Clin Chem 1997 Mar;43(3):421-3.

Immunoblot reactivity of polyclonal and monoclonal antibodies with periplasmic flagellar proteins FlaA1 and FlaB of porcine Serpulina species. Fisher LN, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):400-4

Preparation of a monoclonal antibody specific for Entamoeba dispar and its ability to distinguish E. dispar from E. histolytica. Tachibana H, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):409-14

Use of immunoblotting and monoclonal antibodies to evaluate the residual antigenic activity of milk protein hydrolysed formulae. Restani P, et al. **Clin Exp Allergy** 1996 Oct;26(10):1182-7

Use and evaluation of leucocyte monoclonal antibodies in the diagnostic laboratory: a review. Reilly JT. **Clin Lab Haematol** 1996 Mar;18(1):1-5 (19 ref.)

Intussusception secondary to Meckel's diverticulum detection

with Tc-99m monoclonal antibodies to granulocytes (Leukoscan). Barron BJ, et al. **Clin Nucl Med** 1996 Nov; 21(11):834–7

Site of mistletoe injection observed on In-111 OncoScint imaging. Choe W. **Clin Nucl Med** 1997 Feb;22(2):127

Quantitative analysis of In-111 satumomab pendetide immunoscintigraphy. An aid to visual interpretation of images in patients with suspected carcinomatosis. Neal CE, et al. **Clin Nucl Med** 1996 Aug;21(8):638–42

In-111 CYT-103 immunoscintigraphy of isolated splenic metastasis from ovarian carcinoma. Nguyen BD, et al. **Clin Nucl Med** 1997 Apr;22(4):256–7

Lipomas as a potential cause for uptake of In-111 MAb72.3 (Oncoscint CR). Sakow NK, et al. **Clin Nucl Med** 1996 Apr;21(4):332–3

Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. Sodee DB, et al. **Clin Nucl Med** 1996 Oct;21(10):759–67

Evaluation of HMFG2 and thyroglobulin in the diagnosis of thyroid fine needle aspiration (FNA). Veneti S, et al. **Cytopathology** 1997 Feb;8(1):13–9

A monoclonal antibody recognizing nestin and the phosphorylated form of neurofilament-M. Sakuma H, et al. **Dev Neurosci** 1997;19(4):348–56

Localization of p53 and proliferating cell nuclear antigen in fine-needle aspirates of benign and primary malignant tumors of the human breast: an immunocytochemical study using supersensitive monoclonal antibodies and the biotin-streptavidin-amplified method. Alexiev BA. **Diagn Cytopathol** 1996 Nov;15(4):277–81

Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki67. Kyzer S, et al. **Dis Colon Rectum** 1997 Mar;40(3):322–5

Three-step immunoscintigraphy with anti-chromogranin A monoclonal antibody in tumours of the pituitary region. Colombo P, et al. **Eur J Endocrinol** 1996 Aug;135(2):216–21

The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model. Davies Q, et al. **Eur J Nucl Med** 1997 Feb; 24(2):206–9

Site-specific conjugation and labelling of prostate antibody 7E11C5.3 (CYT-351) with technetium-99m. Stalteri MA, et al. **Eur J Nucl Med** 1997 Jun;24(6):651–4

Immunohistochemical demonstration of bleeding in decomposed bodies by using anti-glycophorin A monoclonal antibody. Tabata N, et al. **Forensic Sci Int** 1997 May 23;87(1):1–8

Limited value of the NKI/C3-antibody for the differential diagnosis of Paget's disease of the nipple and intra-epidermal malignant melanoma. Biesterfeld S, et al. **Histopathology** 1996 Mar;28(3):269–70

Immunohistochemical differentiation of metastases of renal carcinomas versus other carcinomas with anti-gamma GT monoclonal antibody 138H11. Kaufmann O, et al. **Histopathology** 1997 Jul;31(1):31–7

Search for the optimal fetal cell antibody: results of immunophenotyping studies using flow cytometry. Zheng YL, et al. **Hum Genet** 1997 Jul;100(1):35–42

Limited field evaluation of a rapid monoclonal antibody-based dipstick assay for urinary schistosomiasis. Bosompem KM, et al. **Hybridoma** 1996 Dec;15(6):443–7

Multiplicity of uses of monoclonal antibodies that define papillomavirus linear immunodominant epitopes. Jenson AB, et al. **Immunol Res** 1997 Feb;16(1):115–9 (22 ref.)

Myocardial indium-111 antimyosin uptake after uncomplicated coronary artery bypass surgery. Astorri E, et al. **Int J Cardiol** 1996 Aug;55(3):239–44

Antimyosin antibody imaging in clinical myocarditis and cardiomyopathy: principle and application. Matsumori A, et al. **Int J Cardiol** 1996 May;54(2):183–90 (33 ref.)

Combination of monoclonal antibodies for radioimmunoguided surgery. de Nardi P, et al. **Int J Colorectal Dis** 1997;12(1):24–8

Regulated expression of chondroitin sulfates at sites of epithelial-mesenchymal interaction: spatio-temporal patterning identified with anti-chondroitin sulfate monoclonal antibodies. Sorreli JM, et al. **Int J Dev Neurosci** 1996 Jun;14(3):233–48

Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. Rudolph P, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 1):169–78

Spectrum of alcohol-induced myocardial damage detected by indium-111-labeled monoclonal antimyosin antibodies. Ballester M, et al. **J Am Coll Cardiol** 1997 Jan;29(1):160–7

The neurofilament antibody RT97 recognises a developmentally regulated phosphorylation epitope on microtubule-associated protein 1B. Johnstone M, et al. **J Anat** 1997 Aug;191 (Pt 2):229–44

Cryptic antigenic determinants on the extracellular pyruvate dehydrogenase complex/mimeotope found in primary biliary cirrhosis. A probe by affinity mass spectrometry. Yip TT, et al. **J Biol Chem** 1996 Dec 20;271(51):32825–33

Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients. Uttenreuther-Fischer MM, et al. **J Clin Lab Anal** 1997; 11(2):94–103

Simple diagnosis of Encephalitozoon sp. microsporidial infections by using a panspecific antiexospore monoclonal antibody. Enriquez FJ, et al. **J Clin Microbiol** 1997 Mar; 35(3):724–9

Use of flow cytometry in the analysis of stage III squamous cell carcinoma of the oesophagus and its association with MIB-1. Lam KY, et al. **J Clin Pathol** 1996 Dec; 49(12):975–8

The role of MT2 and anti-bcl-2 protein antibodies in the differentiation of benign from malignant cutaneous infiltrates of B-lymphocytes with germinal center formation. Chimenti S, et al. **J Cutan Pathol** 1996 Aug; 23(4):319–22

Production, characterization and immunodiagnostic application of a monoclonal antibody to Shiga toxin. Qadri F, et al. **J Diarrhoeal Dis Res** 1996 Jun;14(2):95–100

A monoclonal antibody-based enzyme immunoassay for detecting parasite antigenaemia and antigenuria in Schistosomiasis mansoni. Kamel MA, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):789–95

Physical mapping of human insulin-like growth factor-I using specific monoclonal antibodies. Mañes S, et al. **J Endocrinol** 1997 Aug;154(2):293–302

Sensitive detection of Plasmodium vivax in blood by a cell-ELISA using a monoclonal antibody. Bracho C, et al. **J Immunoassay** 1996 May;17(2):155–74

Assessment of diagnostic utility of anti-CD34 in soft tissue tumors. Park HR, et al. **J Korean Med Sci** 1995 Dec; 10(6):436–41

Antimyosin antibody imaging in experimental aortic regurgitation [see comments] Lu P, et al. **J Nucl Cardiol** 1997 Jan-Feb;4(1 Pt 1):25–32. Comment in: J Nucl Cardiol 1997 Jan-Feb;4(1 Pt 1):79–82.

Maximizing radiotracer delivery to experimental atherosclerotic lesions with high-dose, negative charge-modified Z2D3 antibody for immunoscintigraphic targeting [see comments] Narula J, et al. **J Nucl Cardiol** 1997 May-Jun;4(3):226–33. Comment in: J Nucl Cardiol 1997 May-Jun;4(3):246–8.

Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351). Chengazi VU, et al. **J Nucl Med** 1997 May; 38(5):675–82

Photopenia in chronic vertebral osteomyelitis with technetium-99m-antigranulocyte antibody (BW 250/183). Gratz S, et al. **J Nucl Med** 1997 Feb;38(2):211–6

Antigranulocyte antibody uptake in bone marrow is age-dependent [letter; comment] Ivančević V, et al. **J Nucl Med** 1997 Jul;38(7):1172. Comment on: J Nucl Med 1996 Jun;37(6):978–82.

Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. Leichner PK, et al. **J Nucl Med** 1997 Apr;38(4):512–6

Diagnostic test comparisons in patients with deep venous thrombosis. Line BR, et al. **J Nucl Med** 1997 Jan; 38(1):89–92

Preclinical studies of indium-111-labeled IgM: a human monoclonal antibody for infection imaging. Subramanian R, et al. **J Nucl Med** 1997 Jul;38(7):1054–9

Transient neutropenia: neutrophil distribution and replacement. Thakur ML, et al. **J Nucl Med** 1996 Mar; 37(3):489–94

Imaging inflammatory diseases with neutrophil-specific technetium-99m-labeled monoclonal antibody anti-SSEA-1. Thakur ML, et al. **J Nucl Med** 1996 Nov; 37(11):1789–95

Tumor imaging with technetium-99m-labeled hydrazinonicotinamide-Fab' conjugates. Ultee ME, et al. **J Nucl Med** 1997 Jan;38(1):133–8

Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment. Yoo TM, et al. **J Nucl Med** 1997 Feb;38(2):294–300

Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. Zhu H, et al. **J Nucl Med** 1997 May;38(5):731–41

Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy. Goldenberg DM, et al. **J Nucl Med Technol** 1997 Mar; 25(1):18–23; quiz 34 (46 ref.)

The monoclonal antibody GZS-1 detects a maturation-associated antigen of human spermatozoa that is also present on the surface of human mononuclear blood cells. Hutter H, et al. **J Reprod Immunol** 1996 May; 30(2-3):115–32

Radioimmunodetection with 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer. Chung YS, et al. **Jpn J Cancer Res** 1997 Apr;88(4):427–34

Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Yiannakou JY, et al. **Lancet** 1997 Feb 8;349(9049):389–92

Parathyroid visualization with cibacron blue/BB5-G1. King RC, et al. **Laryngoscope** 1996 Nov;106(11):1365–71

Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. Nordgård S, et al. **Laryngoscope** 1997 Apr; 107(4):531–6

Heterogenous expression of CD15 in acute lymphoblastic leukemia: a study of ten anti-CD15 monoclonal antibodies in 158 patients. Maynadié M, et al. **Leuk Lymphoma** 1997 Mar;25(1-2):135–43

Simultaneous double immunoenzymatic labeling: a new procedure for the histopathologic routine. Chaubert P, et al. **Mod Pathol** 1997 Jun;10(6):585–91

Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Minervini MI, et al. **Mod Pathol** 1997 Jul;10(7):686–92

HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Sack MJ, et al. **Mod Pathol** 1997 Jul;10(7):668–74

Measurement of proliferation in renal biopsy specimens: evidence of subclinical tubular damage in the nephrotic syndrome. Howie AJ, et al. **Nephrol Dial Transplant** 1995 Dec;10(12):2212–18

Basal forebrain cholinergic immunolesion by 192IgG-saporin: evidence for a presynaptic location of subpopulations of alpha 2- and beta-adrenergic as well as 5-HT2A receptors on cortical cholinergic terminals. Heider M, et al. **Neurochem Res** 1997 Aug;22(8):957–66

Radioimaging of human glioma by indium-111 labeled G-22 anti-glioma monoclonal antibody. Wakabayashi T, et al. **Noshuyo Byori** 1995;12(2):105–10

Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and 111In-DTPA-biocytin. Alvarez-Diez TM, et al. **Nucl Med Biol** 1996 May;23(4):459–66

Radioimmunoscintigraphy using technetium-99m-labeled parental mouse and mouse-human chimeric antibodies to carcinoembryonic antigen in athymic nude mice bearing tumor. Karube Y, et al. **Nucl Med Biol** 1996 Aug; 23(6):753–9

Investigation of tumor invasion with [111In]antimyosin. Kubota K, et al. **Nucl Med Biol** 1994 Feb;21(2):239–44

Pre-clinical and clinical studies of two new bifunctional chelating agents for immunoscintigraphy with 111In-anti-CEA monoclonal antibody. Faivre-Chauvet A, et al. **Nucl Med Commun** 1996 Sep;17(9):781–9

Choice of imaging agent in inflammation [letter; comment] Perkins AC, et al. **Nucl Med Commun** 1996 Nov;17(11):999 . Comment on: Nucl Med Commun 1996 Jun;17(6):455–8.

99Tcm-IMMU4 imaging in recurrent colorectal cancer: efficacy and impact on surgical management. Sirisriro R, et al. **Nucl Med Commun** 1996 Jul;17(7):568–76

Falsely negative 99mTc-anti-granulocyte immunoscintigraphy and positive 99mTc-HMPAO labelled leukocyte scan in active Crohn's disease [letter; comment] [corrected and republished letter originally printed in Nuklearmedizin 1996 Aug;35(4):55] Aprile C, et al. **Nuklearmedizin** 1996 Oct;35(5):65–6. Comment on: Nuklearmedizin 1995 Dec;34(6):248–51.

Immunologic advances in monoclonal antibody therapy: implications for oncology nursing. Karius D, et al. **Oncol Nurs Forum** 1997 Apr;24(3):483–94; QUIZ 495–6 (74 ref.)

Radiolabelled monoclonal antibodies in clinical and surgical oncology: a review. Biassoni L, et al. **Panminerva Med** 1997 Mar;39(1):46–52 (17 ref.)

Growth fraction determination in pulmonary hypoplasia using Ki-67 (MIB-1) antibody. Thomas PA, et al. **Pediatr Pathol Lab Med** 1996 Sep-Oct;16(5):745–53

Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Schmider J, et al. **Pharmacology** 1996 Feb;52(2):125–34

Tumour cell proliferation rate as determined by MIB-1 antibody in Wilms' tumour. Juszkiewicz P, et al. **Pol J Pathol** 1997;48(2):113–9

Exploration of novel strategies to enhance monoclonal antibodies targeting. Khawli LA, et al. **Q J Nucl Med** 1997 Mar;41(1):25–35 (80 ref.)

Factors influencing the in vivo pharmacokinetics of peptides and antibody fragments: the pharmacokinetics of two PET-labeled low molecular weight proteins. Lang L, et al. **Q J Nucl Med** 1997 Jun;41(2):53–61

Distinction between pleural mesothelioma and pulmonary adenocarcinoma using MOC31 in an asbestos sprayer. Ryan PJ, et al. **Respir Med** 1997 Jan;91(1):57–60

Immunohistochemical localization of Gnathostoma spinigerum larval antigens by monoclonal antibodies: II. Electron microscopy. Rojekittikhun W, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):570–3

Application of local products R-phycoerythrin and monoclonal antibody as a fluorescent antibody probe to detect Entamoeba histolytica trophozoites. Thammapalerd N, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun;27(2):297–303

Axotomy-induced alterations in the red nucleus revealed by monoclonal antibody, Py, following a low thoracic spinal cord lesion in the adult rat. Brook GA, et al. **Spinal Cord** 1997 Jul;35(7):474–81

Characterizing kappa3 opioid receptors with a selective monoclonal antibody. Brooks AI, et al. **Synapse** 1996 Mar; 22(3):247–52

My secret life (in the gingival crevice). Rossomando EF. **Technol Health Care** 1996 Sep;4(3):359–63

A monoclonal antibody (SZ21) specific for platelet GPIIIa distinguishes P1A1 from P1A2. Weiss EJ, et al. **Tissue Antigens** 1995 Nov;46(5):374–81

Monoclonal antibody against an amniotic protein carrying ABH blood group epitopes and its forensic application. Nagae M, et al. **Tohoku J Exp Med** 1995 Dec;177(4):353–64

Localization and imaging of human plasmacytoma xenografts in severe combined immunodeficiency mice by a new murine monoclonal antibody, anti-HM1.24. Ozaki K, et al. **Tokushima J Exp Med** 1996 Jun;43(1-2):7–15

Advances in the use of monoclonal antibodies for blood group testing. Rouger P, et al. **Transfus Clin Biol** 1997 Jul; 4(4):345–9 (14 ref.)

A comparison of monoclonal antibody immobilization of

platelet antigen (MAIPA) and immunobead methods for detection of GPIIb/IIIa antiplatelet antibodies in immune thrombocytopenic purpura. Crossley A, et al. **Transfus Med** 1997 Jun;7(2):127–34

Evaluation of a monoclonal antibody–based sandwich–ELISA for detection of circulating Schistosoma japonicum antigen (Sj31/32) in an endemic area of China. Li YL, et al. **Trop Med Int Health** 1996 Dec;1(6):847–50

Radioimmunodetection and radioimmunotherapy of breast cancer. Riva P, et al. **Tumori** 1997 Mar–Apr;83(2):552–7

Expression of MIB–1, mitotic index and S–phase fraction as indicators of cell proliferation in superficial bladder cancer. Finnbladder Group. Liukkonen TJ, et al. **Urol Res** 1996;24(1):61–6

What type of chromogranin does PHE5 monoclonal antibody react with? [letter; comment] Declich P, et al. **Virchows Arch** 1997 Jun;430(6):509–10. Comment on: Virchows Arch 1996 Jul;428(4–5):237–41.

Microglia in the nerve fiber layer of the cat retina: detection of postnatal changes by a new monoclonal antibody. Tumosa N, et al. **Vis Neurosci** 1996 Jul–Aug;13(4):671–82

The monoclonal antibody H386F labels microglia in the retinal nerve fiber layer of several mammals. Tumosa N, et al. **Vis Neurosci** 1997 Jul–Aug;14(4):663–9

Use of monoclonal antibodies in colorectal cancer: a review. Schulte WJ. **World J Surg** 1996 Feb;20(2):238–40 (6 ref.)

[Expression of various monoclonal antibodies in nodules and band stage in Dupuytren's disease] Brenner P, et al. **Handchir Mikrochir Plast Chir** 1996 Nov;28(6):322–7 (Eng. Abstr.) **(Ger)**

[Suitability of monoclonal reagents in determination of ABO blood group of newborn infants] Strobel E. **Infusionsther Transfusionsmed** 1996 Jun;23(3):138–42 (Eng. Abstr.) **(Ger)**

[Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies] Schröder S, et al. **Pathologe** 1996 Nov; 17(6):425–32 (Eng. Abstr.) **(Ger)**

[Rate of proliferation as a prognostic criterion in endometrial carcinoma—an immunohistochemical analysis with the monoclonal antibody KI–S1] Backe J, et al. **Zentralbl Gynakol** 1997;119(7):334–42 (Eng. Abstr.) **(Ger)**

[Receptor function and monoclonal antibody] Ueno S. **Nippon Rinsho** 1997 Apr;55 Suppl 2:457–62 (15 ref.) **(Jpn)**

[Monoclonal antibodies against P–epitope of chordin in glial cultures detect astrocytes of the second type] Khalanskiĭ AS, et al. **Biull Eksp Biol Med** 1996 Aug;122(8):209–13 **(Rus)**

[Immunoenzyme analysis for the identification of Mycobacterium bovis by using monoclonal antibodies] Androsova MV, et al. **Probl Tuberk** 1996;(1):40–3 (Eng. Abstr.) **(Rus)**

[The use of monoclonal antibodies for the study of California serogroup viruses] Larichev VF, et al. **Vopr Virusol** 1996 Nov–Dec;41(6):242–4 (28 ref.) **(Rus)**

[Immunodiagnostic preparations based on monoclonal antibodies to Chlamydia trachomatis] Kutlin AV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Nov–Dec; (6):42–4 (Eng. Abstr.) **(Rus)**

ECONOMICS

Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands. van Hout BA, et al. **Eur Heart J** 1995 Nov;16 Suppl L:81–5

The influence of clinical study design on cost–effectiveness projections for the treatment of gram–negative sepsis with human anti–endotoxin antibody. Linden PK, et al. **J Crit Care** 1995 Dec;10(4):154–64

[Abciximab (c7E3)—a new monoclonal antibody—from the pharmaco–economic viewpoint. Initial reports from the literature] Sturm C. **Med Klin** 1996 Nov 15;91(11):735–8 **(Ger)**

GENETICS

Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha–linked galactose. Sheeley DM, et al. **Anal Biochem** 1997 Apr 5;247(1):102–10

Molecular cloning and primary characterization of a single–chain antibody against human sarcoma–associated antigen p200. Chen H, et al. **Anticancer Res** 1996 Nov–Dec; 16(6B):3551–6

Molecular cloning, expression, and characterization of a functional single–chain Fv antibody to the mycotoxin zearalenone. Yuan Q, et al. **Appl Environ Microbiol** 1997 Jan;63(1):263–9

Immunoglobulin gene sequence analysis of anti–cardiolipin and anti–cardiolipin idiotype (H3) human monoclonal antibodies. Hohmann A, et al. **Autoimmunity** 1995; 22(1):49–58

A human monoclonal antiendothelial cell autoantibody uses a VH gene associated with an anti–DNA autoantibody. Yazici ZA, et al. **Biochem Soc Trans** 1997 May;25(2):321S

Induction and suppression of anti–antibodies to syngeneic T cell–binding antibodies in mice. Kremmer E, et al. **Clin Exp Immunol** 1997 Jul;109(1):180–4

Cytotoxicity of murine B lymphocytes induced by human VH4–34 (VH4.21) gene–encoded monoclonal antibodies. Bhat NM, et al. **Clin Immunol Immunopathol** 1997 Sep; 84(3):283–9

Cloning and characterization of cDNAs coding for heavy and light chains of a monoclonal antibody (MabA34) specific for human plasma apolipoprotein A–I. Kwak JW, et al. **Gene** 1996 Sep 16;173(2):257–9

Cloning and expression of cDNAs encoding the variable domains of the antibreast carcinoma antibody Mc5. Christian RB, et al. **Hybridoma** 1996 Apr;15(2):155–8

Characterization of a series of isotype switch variants of a new CD20 monoclonal antibody. Hooijberg E, et al. **Hybridoma** 1996 Feb;15(1):23–31

Primary structure and functional expression of heavy– and light–chain variable region genes of a monoclonal antibody specific for human fibrin. Song Z, et al. **Hybridoma** 1997 Jun;16(3):235–41

RT–PCR cloning and characterization of mouse immunoglobulin variable domains with high affinity for HLA–DR antigens. Eswarakumar VP, et al. **Immunogenetics** 1997;46(3):249–50

Peptide epitope binding specificity and V K and V H gene usage in a monoclonal IgM natural autoantibody to T cell receptor CDR1 from a viable motheaten mouse. Dehghanpisheh K, et al. **Immunol Invest** 1996 May; 25(3):241–52

Strategies for expressing human antibody repertoires in transgenic mice. Brüggemann M, et al. **Immunol Today** 1996 Aug;17(8):391–7 (47 ref.)

Cloning and expression of human V–genes derived from phage display libraries as fully assembled human anti–TNF alpha monoclonal antibodies. Mahler SM, et al. **Immunotechnology** 1997 Mar;3(1):31–43

A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. Rosok MJ, et al. **J Biol Chem** 1996 Sep 13;271(37):22611–8

Molecular characterization of Bip I, a monoclonal antibody that modulates IgE binding to birch pollen allergen, Bet v 1. Laffer S, et al. **J Immunol** 1996 Dec 1;157(11):4953–62

Humanization of an anti–lymphocyte function–associated antigen (LFA)–1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA–1. Werther WA, et al. **J Immunol** 1996 Dec 1;157(11):4986–95

Somatic mutation in VH complementarity–determining region 2 and framework region 2: differential effects on antigen binding and Ig secretion. Wiens GD, et al. **J Immunol** 1997 Aug 1;159(3):1293–302

Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. Krebber A, et al. **J Immunol Methods** 1997 Feb 14;201(1):35–55

Characterization of anti–sperm antibodies and their coding cDNA sequences by Epstein–Barr virus transformed B cell lines from lymphocytes of infertile women possessing anti–sperm antibodies. Dimitrova–Dikanarova DK, et al. **J Reprod Immunol** 1996 Dec;32(2):171–91

Variable region gene segment utilization in rhesus monkey hybridomas producing human red blood cell–specific antibodies: predominance of the VH4 family but not VH4–21 (V4–34). Andris JS, et al. **Mol Immunol** 1997 Feb; 34(3):237–53

Human fertilin beta: identification, characterization, and chromosomal mapping of an ADAM gene family member. Vidaeus CM, et al. **Mol Reprod Dev** 1997 Mar;46(3):363–9

A new class of antigen–specific killer cells [see comments] Yang AG, et al. **Nat Biotechnol** 1997 Jan;15(1):46–51. Comment in: Nat Biotechnol 1997 Jan;15(1):18–9.

Monoclonal antibodies. Mice perform a human repertoire [news] Neuberger M, et al. **Nature** 1997 Mar 6; 386(6620):25–6

Redesigned anti–human placental alkaline phosphatase single–chain Fv: soluble expression, characterization and in vivo tumour targeting. Deonarain MP, et al. **Protein Eng** 1997 Jan;10(1):89–98

A comparison of two murine monoclonal antibodies humanized by CDR–grafting and variable domain resurfacing [published erratum appears in Protein Eng 1997 Feb;10(2):181] Roguska MA, et al. **Protein Eng** 1996 Oct; 9(10):895–904

Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity. Zapata G, et al. **Protein Eng** 1995 Oct;8(10):1057–62

Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells. Magnuson NS, et al. **Protein Expr Purif** 1996 Mar; 7(2):220–8

Human monoclonal recombinant Fabs specific for HCV antigens obtained by repertoire cloning in phage display combinatorial vectors. Plaisant P, et al. **Res Virol** 1997 Mar–Apr;148(2):165–9

Sequences of monoclonal antiphospholipid antibodies: variations on an anti–DNA antibody theme. Rahman A, et al. **Semin Arthritis Rheum** 1996 Oct;26(2):515–25 (40 ref.)

Construction and expression of single–chain Fv antibody against human bladder carcinoma. Yu LZ, et al. **Urol Res** 1996;24(5):273–7

Baculovirus expression of a human G2–specific, neutralizing IgG monoclonal antibody to Puumala virus. Liang M, et al. **Virology** 1997 Sep 1;235(2):252–60

[Amplification, cloning and sequence analysis of the variable region genes of monoclonal antibody against human bladder carcinoma] Xiao S, et al. **Chung Hua Wai Ko Tsa Chih** 1996 Jan;34(1):13–5 (Eng. Abstr.) **(Chi)**

HISTORY

The treatment of rheumatoid arthritis in this century: from spas to monoclonal antibodies. Pasero G. **Clin Exp Rheumatol** 1997 May–Jun;15 Suppl 17:S67–70

Summary of immunohistologic dissection of the human kidney using monoclonal antibodies (by Neil H. Bander, MD, Carlos Cordon–Cardo, MD, PhD, Connie L. Finstad, PhD, Willet F. Whitmore, Jr, MD, E. Darracott Vaughan, Jr, MD, Herbert F. Oettgen, MD, Myron Melamed, MD, and Lloyd J. Old, MD). 1985. Bander NH, et al. **Semin Urol Oncol** 1997 May;15(2):123–9

IMMUNOLOGY

Comparison of the islet cell antibody pattern of monoclonal glutamic acid decarboxylase antibodies recognizing linear and conformational epitopes. Augstein P, et al. **Acta Histochem** 1996 Apr;98(2):229–41

A new monoclonal antibody for specific immunocytochemical staining of nucleoli. Vissers CJ, et al. **Acta Histochem** 1996 Apr;98(2):113–21

Extraction of Schistosoma haematobium antigens from infected human urine and generation of potential diagnostic monoclonal antibodies to urinary antigens. Bosompem KM, et al. **Acta Trop** 1996 Oct;62(2):91–103

Monoclonal antibodies against potato virus A — immunoblot analysis. Subr Z, et al. **Acta Virol** 1996 Nov–Dec; 40(5–6):289–92

IgE and monoclonal antibody reactivities to the major shrimp allergen Pen a 1 (tropomyosin) and vertebrate tropomyosins. Reese G, et al. **Adv Exp Med Biol** 1996; 409:225–30

Characterization of the EaeA protein of attaching and effacing Escherichia coli O45 from pigs using monoclonal antibodies. Zhu C, et al. **Adv Exp Med Biol** 1997;412:105–7

Anti–tumor necrosis factor–alpha therapy of rheumatoid arthritis. Feldmann M, et al. **Adv Immunol** 1997;64:283–350 (271 ref.)

Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. Kessler JA 2nd, et al. **AIDS Res Hum Retroviruses** 1997 May 1;13(7):575–82

Altered CD4 interactions of HIV type 1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4. Klasse PJ, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20; 12(11):1015–21

Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti–HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. Li A, et al. **AIDS Res Hum Retroviruses** 1997 May 20; 13(8):647–56

MR of carcinoma–specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. Remsen LG, et al. **AJNR Am J Neuroradiol** 1996 Mar;17(3):411–8

Production and characterization of profilin monoclonal antibodies. Arilla MC, et al. **Allergol Immunopathol (Madr)** 1997 May–Jun;25(3):145–51

Latent membrane protein antibody reacts with normal hematopoietic precursor cells and leukemic blasts in tissues lacking Epstein–Barr virus genome by polymerase chain reaction. Hammer RD, et al. **Am J Clin Pathol** 1996 Oct; 106(4):469–74

Failure of anti–T–cell receptor V beta antibodies to consistently identify a malignant T–cell clone in Sézary syndrome. Bigler RD, et al. **Am J Pathol** 1996 Nov; 149(5):1477–83

P–glycoprotein–associated chloride currents revealed by specific block by an anti–P–glycoprotein antibody. Han ES, et al. **Am J Physiol** 1996 May;270(5 Pt 1):C1370–8

Endothelial cells internalize monoclonal antibody to angiotensin–converting enzyme. Muzykantov VR, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L704–13

Monoclonal antibody against conductive chloride transport in pig ileal apical membrane vesicles. Racette KJ, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C478–85

Blocking L–selectin function attenuates reperfusion injury following hemorrhagic shock in rabbits. Ramamoorthy C, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1871–7

Identification of epitopes of monoclonal antibodies to porcine zona pellucida 3 beta glycoprotein, a homologue of the mouse/human sperm receptor. Afzalpurkar A, et al. **Am J Reprod Immunol** 1997 Jul;38(1):26–32

Monoclonal antibodies reacting against capacitated but not with freshly ejaculated boar spermatozoa. Mollova MV, et al. **Am J Reprod Immunol** 1996 Dec;36(6):301–8

Use of monoclonal antibody against human inhibin as a marker for sex cord–stromal tumors of the ovary. Rishi M, et al. **Am J Surg Pathol** 1997 May;21(5):583–9

Isolation and characterization of the canine melanoma antigen recognized by the murine monoclonal antibody IBF9 and its distribution in cultured canine melanoma cell lines. Oliver JL, et al. **Am J Vet Res** 1997 Jan;58(1):46–52

Use of a resonant mirror biosensor to characterize the interaction of carboxypeptidase A with an elicited monoclonal antibody. Hall DR, et al. **Anal Biochem** 1997 Jan 1;244(1):152–60

Flow cytometric determination of binding of monoclonal antibodies to human spermatozoa. Schwarzinger F, et al.

Andrologia 1997 May-Jun;29(3):163-8
In vitro synthesis of Alternaria allergens and their recognition by murine monoclonal and human IgE antibodies. Bush RK, et al. **Ann Allergy Asthma Immunol** 1997 Mar; 78(3):287-92
Further characterization of a monoclonal antibody recognizing apolipoprotein E peptides in amyloid deposits. Yamada T, et al. **Ann Clin Lab Sci** 1997 Jul-Aug; 27(4):276-81
Inhibition of monocyte and polymorphonuclear granulocyte immune phagocytosis by monoclonal antibodies specific for Fc gamma RI, II and III. Flesch BK, et al.
Ann Hematol 1997 Jan;74(1):15-22
Characterization of monoclonal antibodies against human interleukin-12 and their use in an ELISA for the measurement of this cytokine. Fauchet F, et al.
Ann N Y Acad Sci 1996 Oct 31;795:334-6
A sulfatide-reactive monoclonal antibody derived from a patient with multiple sclerosis binds to myelin in situ. Kirschning E, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:455-8
Use of monoclonal antibodies to detect disease associated HLA-DRB1 alleles and the shared epitope in rheumatoid arthritis. Wicks I, et al. **Ann Rheum Dis** 1997 Feb; 56(2):135-9
Apoptosis induced in human colorectal carcinoma by anti-Fas antibody. Meterissian SH, et al.
Ann Surg Oncol 1997 Mar;4(2):169-75
Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Nakamura S, et al. **Anticancer Res** 1997 Jan-Feb; 17(1A):173-9
Characterization of a monoclonal antibody that specifically inhibits pullulanase activity of Bacillus circulans amylase-pullulanase enzyme. Kim CH, et al.
Appl Biochem Biotechnol 1997 Feb-Mar;62(2-3):191-200
Epitope specificity and application of Salmonella typhimurium O-antigen-specific monoclonal antibodies [letter; comment] Luk JM, et al.
Appl Environ Microbiol 1997 Mar;63(3):1192-4. Comment on: Appl Environ Microbiol 1996 Jan;62(1):1-5.
Parallel detection of Na,K-ATPase alpha subunit isoforms by pan-specific monoclonal mAb 9A7. Choi Y, et al.
Arch Biochem Biophys 1997 Aug 1;344(1):165-75
Generation and characterization of mouse monoclonal antibodies specific for N-linked neutral oligosaccharides of glycoproteins. Ozawa H, et al.
Arch Biochem Biophys 1997 Jun 1;342(1):48-57
A monoclonal antibody to avidin dissociates quaternary structure and curtails biotin binding to avidin and streptavidin. Subramanian N, et al.
Arch Biochem Biophys 1997 Aug 15;344(2):281-8
Characterization of monoclonal antibodies recognizing different fragments of cartilage oligomeric matrix protein in human body fluids. Vilim V, et al.
Arch Biochem Biophys 1997 May 1;341(1):8-16
Comparison of serological reactions of Rickettsiae-infected patients and rabbit anti-Proteus OX antibodies with Proteus OX2, OX19 and OXK lipopolysaccharides. Amano K, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(4):235-40
Monoclonal antibody analysis of glomerular and renal interstitial immune cells in steroid-resistant and steroid-responsive minimal change disease in children. Wągrowska-Danilewicz M, et al.
Arch Immunol Ther Exp (Warsz) 1996;44(2-3):165-70
Cross reactivity of mouse monoclonal antibodies to glycoprotein with two different antigens from the outer membrane of Entamoeba histolytica. Agundis-Mata C, et al. **Arch Med Res** 1997;28 Spec No:239-41
Identification of an idiotype on mouse monoclonal antibody directed to a 35 kDa glycoprotein from Entamoeba histolytica. Chávez-Rueda K, et al. **Arch Med Res** 1997; 28 Spec No:242-4
Urinary antigens as markers of papillary toxicity. I. Identification and characterization of rat kidney papillary antigens with monoclonal antibodies. Falkenberg FW, et al. **Arch Toxicol** 1996;71(1-2):80-92
Modified activity of a VP2-located neutralizing epitope on various vaccine, pathogenic and hypervirulent strains of infectious bursal disease virus. Eterradossi N, et al.
Arch Virol 1997;142(2):255-70
VP4 and VP7 typing using monoclonal antibodies. Coulson BS. **Arch Virol Suppl** 1996;12:113-8 (23 ref.)
Production of monoclonal antibodies to study the molecular biology of bovine viral diarrhea virus. Drèze F, et al.
Arch Virol Suppl 1991;3:239-44
Identification of cattle infected with bovine virus diarrhoea virus using a monoclonal antibody capture ELISA. Fenton A, et al. **Arch Virol Suppl** 1991;3:169-74
BVD monoclonal antibodies: relationship between viral protein specificity and viral strain specificity. Paton DJ, et al. **Arch Virol Suppl** 1991;3:47-54
7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Simon DI, et al.
Arterioscler Thromb Vasc Biol 1997 Mar;17(3):528-35
Immunohistochemical characterization of a new monoclonal antibody reactive with dengue virus-infected cells in frozen tissue using immunoperoxidase technique. Bhoopat L, et al. **Asian Pac J Allergy Immunol** 1996 Dec;14(2):107-13
Specific monoclonal antibodies to Fasciola gigantica. Maleewong W, et al. **Asian Pac J Allergy Immunol** 1997 Mar;15(1):49-54
Monoclonal antibodies specific to Mycoplasma iowae. Singh P, et al. **Avian Dis** 1996 Jul-Sep;40(3):613-9
Monoclonal antibodies: epitope specificity and typing of Dpartial cells. Sonneborn HH, et al.
Beitr Infusionsther Transfusionsmed 1996;33:13-6
Monoclonal antibodies against pupa-specific surface antigens of Sarcophaga peregrina (flesh fly) hemocytes. Hori S, et al. **Biochem Biophys Res Commun** 1997 Jul 18; 236(2):497-501
Subtype specific recognition of human alpha2C2 adrenergic receptor using monoclonal antibodies against the third intracellular loop. Liitti S, et al.
Biochem Biophys Res Commun 1997 Apr 7;233(1):166-72
The epitope recognized by a monoclonal antibody in the myelin-associated protein CNP. Stricker R, et al.
Biochem Biophys Res Commun 1997 Aug 18;237(2):266-70
Overexpression of a 40-kDa protein in human multidrug resistant cells. Wang Y, et al.
Biochem Biophys Res Commun 1997 Jul 18;236(2):483-8
Nucleic acid-8-methoxypsoralen crosslinks bind monoclonal anti-Z-DNA antibody. Arif Z, et al.
Biochem Mol Biol Int 1996 Nov;40(5):871-9
Epitope mapping of preS2 of the hepatitis B virus surface antigen against a conformation-dependent monoclonal antibody using synthetic peptides. Lee MK, et al.
Biochem Mol Biol Int 1996 Dec;40(6):1077-85
Inhibitory monoclonal antibodies to human cytochrome P450 2D6. Krausz KW, et al. **Biochem Pharmacol** 1997 Jul 1; 54(1):15-7
Isolation and characterization of neutralizing single-chain antibodies against Xenopus mitogen-activated protein kinase kinase from phage display libraries. Kosako H, et al. **Biochemistry** 1996 Oct 8;35(40):13212-21
The last two cytoplasmic loops in the lactose permease of Escherichia coli comprise a discontinuous epitope for a monoclonal antibody. Sun J, et al. **Biochemistry** 1997 Jan 7;36(1):274-80
Preparation and characterization of monoclonal antibodies to foot-and-mouth disease virus type Asia-1. Amineva SP, et al. **Biochemistry (Mosc)** 1997 May;62(5):469-73
Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Nishida M, et al.
Biol Pharm Bull 1996 Nov;19(11):1407-11
Epitope tag-antibody combination useful for the detection of protein expression in prokaryotic and eukaryotic cells. Rüdiger M, et al. **Biotechniques** 1997 Jul;23(1):96-7
Fluorescent microtiter screening assay for immunocytochemically reactive antibodies. Su JL, et al.
Biotechniques 1997 Feb;22(2):320-4
Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Carbone A, et al.
Blood 1997 May 15;89(10):3787-94
Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy. Fearnley DB, et al. **Blood** 1997 May 15;89(10):3708-16
Inhibition of binding of anti-PLA1 antibodies to platelets with monoclonal antibody LK-4. Evidence for multiple PLA1 receptor sites on platelet GPIIIa. Liu LX, et al.
Blood 1996 Nov 1;88(9):3601-7
Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Pulford K, et al. **Blood** 1997 Feb 15;89(4):1394-404
Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: characterization and diagnostic utility. Sang BC, et al.
Blood 1997 Apr 15;89(8):2909-14
Immunoreactivity of cross-linked fibrin derivatives (D-dimer) and monoclonal antibodies [letter; comment] Rylatt D, et al. **Blood Coagul Fibrinolysis** 1996 Apr;7(3):365 . Comment on: Blood Coagul Fibrinolysis 1995 Dec;6(8):738-42.
Diverse effects of anti-CD44 antibodies on the stromal cell-mediated support of normal but not leukaemic (CML) haemopoiesis in vitro. Ghaffari S, et al. **Br J Haematol** 1997 Apr;97(1):22-8
Inhibition of the acute-phase response in vivo by anti-gp130 monoclonal antibodies. Harrison P, et al.
Br J Haematol 1996 Dec;95(3):443-51
Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Elliott MJ, et al. **Br J Rheumatol** 1997 May;36(5):589-93
Serotyping of Actinobacillus pleuropneumoniae serotype 5 strains using a monoclonal-based polystyrene agglutination test. Dubreuil JD, et al. **Can J Vet Res** 1996 Jan;60(1):69-71
Suppression of experimental lung colonization of mouse colon adenocarcinoma 26 in vivo by an anti-idiotype monoclonal antibody recognizing a platelet surface molecule. Kato Y, et al. **Cancer Res** 1997 Jul 15; 57(14):3040-5
Development of a human monoclonal antibody to ganglioside G(M2) with potential for cancer treatment. Nishinaka Y, et al. **Cancer Res** 1996 Dec 15;56(24):5666-71
Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Pervin S, et al. **Cancer Res** 1997 Feb 15;57(4):728-34
Nuclear antigens, as DNA, of DSB389 MAb and some other anti-desmin monoclonal antibodies. Kamei H.
Cell Biol Int 1996 Nov;20(11):769-75
Anti-HLA class I antibody inhibits Staphylococcus enterotoxin A (SEA)-induced proliferation of human PBMC. Baskar P, et al. **Cell Immunol** 1996 Aug 25; 172(1):135-8
Quaternary structure-dependent idiotope and antigen binding of a monoclonal antibody specific for conformational epitope on type II collagen. Ito HO, et al.
Cell Mol Life Sci 1997 Jan;53(1):51-60
Immunogenicity of viral epitopes expressed on genetically and enzymatically engineered immunoglobulins. Bona CA, et al. **Chem Immunol** 1997;65:179-206 (70 ref.)
Engineering minibody-like ligands by design and selection. Sollazzo M, et al. **Chem Immunol** 1997;65:1-17 (64 ref.)
Chemical engineering at the antibody hinge. Stevenson GT.
Chem Immunol 1997;65:57-72 (25 ref.)
Production of a high-affinity monoclonal antibody specific for 7-(benzo[alpha]pyren-6-yl) guanine and its application in a competitive enzyme-linked immunosorbent assay. Casale GP, et al. **Chem Res Toxicol** 1996 Sep;9(6):1037-43
Inhibitory and noninhibitory monoclonal antibodies to human cytochrome P450 2E1. Gelboin HV, et al.
Chem Res Toxicol 1996 Sep;9(6):1023-30
Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Runge MS, et al. **Circulation** 1996 Sep 15;94(6):1412-22
Monoclonal antibodies to surface-exposes proteins of Mycoplasma mycoides subsp. mycoides (small-colony strain), which causes contagious bovine pleuropneumonia. Kiarie MN, et al. **Clin Diagn Lab Immunol** 1996 Nov; 3(6):746-52
Monoclonal antibodies to the enterotoxin of Bacteroides fragilis: production, characterization, and immunodiagnostic application. Qadri F, et al.
Clin Diagn Lab Immunol 1996 Sep;3(5):608-10
Characterization of monoclonal antibody B7, which neutralizes the cytotoxicity of Pseudomonas aeruginosa exotoxin A. Shang HF, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):727-32
Monoclonal and polyclonal antibodies against casein components of cow milk for evaluation of residual antigenic activity in 'hypoallergenic' infant formulas. Plebani A, et al. **Clin Exp Allergy** 1997 Aug;27(8):949-56
Characterization of the allergen Der f 7 from house dust mite extracts by species-specific and crossreactive monoclonal antibodies. Shen HD, et al.
Clin Exp Allergy 1997 Jul;27(7):824-32
IgE and monoclonal antibody binding by the mite allergen Der p 7. Shen HD, et al. **Clin Exp Allergy** 1996 Mar; 26(3):308-15
Characterization of the 33-kilodalton major allergen of Penicillium citrinum by using MoAbs and N-terminal amino acid sequencing. Shen HD, et al.
Clin Exp Allergy 1997 Jan;27(1):79-86
Anti-native and recombinant myeloperoxidase monoclonals and human autoantibodies. Audrain MA, et al.
Clin Exp Immunol 1997 Jan;107(1):127-34
Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies, II. Bhat NM, et al. **Clin Exp Immunol** 1997 Apr; 108(1):151-9
Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Harris CL, et al. **Clin Exp Immunol** 1997 Feb;107(2):364-71
Characterization of fertilization-blocking monoclonal antibody 1G12 with human sperm-immobilizing activity. Komori S, et al. **Clin Exp Immunol** 1997 Sep;109(3):547-54
Induction and suppression of anti-antibodies to syngeneic T cell-binding antibodies in mice. Kremmer E, et al.
Clin Exp Immunol 1997 Jul;109(1):180-4
Preparation of a monoclonal antibody against mouse brain natriuretic peptide (BNP) and tissue distribution of BNP in mice. Nakagawa M, et al.
Clin Exp Pharmacol Physiol Suppl 1995;1:S186-7
Recognition of complement factor H by a monoclonal antibody used for "specifically" measuring IgA-alpha 1 antitrypsin complexes [letter; comment] Mattey DL, et al. **Clin Exp Rheumatol** 1997 Jan-Feb;15(1):117-8. Comment on: Clin Exp Rheumatol 1996 Mar-Apr;14(2):119-23.
Cytotoxicity of murine B lymphocytes induced by human VH4-34 (VH4.21) gene-encoded monoclonal antibodies. Bhat NM, et al. **Clin Immunol Immunopathol** 1997 Sep; 84(3):283-9
A monoclonal antibody based elisa for quantitation of human leukaemia inhibitory factor. Taupin JL, et al. **Cytokine** 1997 Feb;9(2):112-8
Improved fetal nucleated erythrocyte sorting purity using intracellular antifetal hemoglobin and Hoechst 33342. DeMaria MA, et al. **Cytometry** 1996 Sep 1;25(1):37-45
Novel flow cytometric analysis of the progress and route of internalization of a monoclonal anti-carcinoembryonic antigen (CEA) antibody. Ford CH, et al. **Cytometry** 1996 Mar 1;23(3):228-40
Flow cytometric analysis of cell surface antigen recognized by monoclonal antibody (MSN-1) in normal, hyperplasia, and carcinoma of endometrial cells: its diagnostic value for endometrial carcinoma. Kobayashi Y, et al.
Cytometry 1997 Feb 15;30(1):23-7
Characterization of a T cell lineage marker in carp (Cyprinus

carpio L.). Rombout JH, et al. **Dev Comp Immunol** 1997 Jan-Feb;21(1):35-46
Monoclonal antimyogenin antibodies define epitopes outside the bHLH domain where binding interferes with protein-protein and protein-DNA interactions. Wright WE, et al. **Dev Genet** 1996;19(2):131-8
Molecular basis for species and ligand specificity of a monoclonal antibody raised against human IGF-I. Van Wyk JJ, et al. **Endocrinology** 1997 Oct;138(10):4521-2
Monoclonal antibodies to rat calcitonin: their use in antigenic mapping and immunohistochemistry. Zhang R, et al. **Endocrinology** 1997 Apr;138(4):1691-6
A monoclonal antibody against rat calcitonin inhibits the growth of a rat medullary thyroid carcinoma cell line in vitro. Zhang R, et al. **Endocrinology** 1997 Apr; 138(4):1697-703
Properties of chloride-conductive pathways in rat kidney cortical and outer-medulla brush-border membranes--inhibition by anti-(cystic fibrosis transmembrane regulator) mAbs. Benharouga M, et al. **Eur J Biochem** 1997 Jun 1;246(2):367-72
Characterization of two vaccinia CD36 recombinant-virus-generated monoclonal antibodies (10/5, 13/10): effects on malarial cytoadherence and platelet functions. Daviet L, et al. **Eur J Biochem** 1997 Jan 15; 243(1-2):344-9
Activation of the gp130 signaling pathway by monoclonal antibodies directed against the gp130 molecule. Autissier P, et al. **Eur J Immunol** 1997 Mar;27(3):794-7
Sensitivity of Epstein-Barr virus-induced B cell tumor to apoptosis mediated by anti-CD95/Apo-1/fas antibody. Durandy A, et al. **Eur J Immunol** 1997 Feb;27(2):538-43
Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection. Kalinke U, et al. **Eur J Immunol** 1996 Dec;26(12):2801-6
CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies. Sivori S, et al. **Eur J Immunol** 1996 Oct; 26(10):2487-92
The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy [letter] Paganelli G, et al. **Eur J Nucl Med** 1997 Mar;24(3):350-1
Epitope mapping of murine monoclonal antibodies against human immunodeficiency virus type 1 Nef. Otake K, et al. **Exp Anim** 1997 Jan;46(1):53-8
Partial characterization of the MPM-2 phosphoepitope. Ding M, et al. **Exp Cell Res** 1997 Feb 25;231(1):3-13
Plasmodium falciparum: gp195 tripeptide repeat-specific monoclonal antibody inhibits parasite growth in vitro. Locher CP, et al. **Exp Parasitol** 1996 Oct;84(1):74-83
Monoclonal antibodies that specifically recognize crystals of dinitrobenzene. Kessler N, et al. **FASEB J** 1996 Oct; 10(12):1435-42
The recognition of haemoglobin by antibodies raised for the immunoassay of beta-amyloid. Cutler P, et al. **FEBS Lett** 1997 Jul 28;412(2):341-5
Probing the structure of HIV-1 Rev by protein footprinting of multiple monoclonal antibody-binding sites. Jensen TH, et al. **FEBS Lett** 1997 Sep 1;414(1):50-4
A novel domain of fibronectin revealed by epitope mapping of a monoclonal antibody which inhibits fibroblasts-mediated collagen gel contraction. Obara M, et al. **FEBS Lett** 1997 Jul 21;412(1):48-52
Influence of antibody binding on oxygen binding behavior of Panulirus interruptus hemocyanin. Perton FG, et al. **FEBS Lett** 1997 May 19;408(2):124-6
Analysis of functional domains of Vibrio parahaemolyticus thermostable direct hemolysin using monoclonal antibodies. Tang G, et al. **FEMS Microbiol Lett** 1997 May 15; 150(2):289-96
Characterization of monoclonal antibodies for rapid identification of Actinomyces naeslundii in clinical samples. Thurnheer T, et al. **FEMS Microbiol Lett** 1997 May 15; 150(2):255-62
Detection using antisperm monoclonal antibodies of shared epitopes expressed by human spermatozoa and oocytes. Fusi FM, et al. **Fertil Steril** 1997 Jul;68(1):158-63
Inhibition of a Porphyromonas gingivalis colonizing factor between Actinomyces viscosus ATCC 19246 by monoclonal antibodies against recombinant 40-kDa outer-membrane protein. Saito S, et al. **Gen Pharmacol** 1997 May;28(5):675-80
In vitro targeting and specific transfection of human neuroblastoma cells by chCE7 antibody-mediated gene transfer. Coll JL, et al. **Gene Ther** 1997 Feb;4(2):156-61
Antibody expression from the core region of the human IgH locus reconstructed in transgenic mice using bacteriophage P1 clones. Wagner SD, et al. **Genomics** 1996 Aug 1; 35(3):405-14
A monoclonal antibody directed to terminal residue of beta-galactofuranose of a glycolipid antigen isolated from Paracoccidioides brasiliensis: cross-reactivity with Leishmania major and Trypanosoma cruzi. Suzuki E, et al. **Glycobiology** 1997 Jun;7(4):463-8
A monoclonal antibody directed against high M(r) salivary mucins recognizes the SO3-3Gal beta 1-3GlcNAc moiety of sulfo-Lewis(a): a histochemical survey of human and rat tissue. Veerman EC, et al. **Glycobiology** 1997 Feb; 7(1):37-43
The usefulness of anti-fucosylated antigen antibody YB-2 for diagnosis of hepatocellular carcinoma. Nakamura J, et al. **Glycoconj J** 1997 Jan;14(1):81-7
Neutralising antibodies to the granulocyte colony-stimulating factor receptor recognise both the immunoglobulin-like domain and the cytokine receptor homologous domain. Layton JE, et al. **Growth Factors** 1997;14(2-3):117-30
Specificity and functional effects of antibodies to human stem cell factor. Zannettino AC, et al. **Growth Factors** 1997; 14(1):67-79
Monoclonal antibody WGM1 directed against proteinase 3: an immunohistochemical marker for naphthol ASD chloroacetate. Braun MG, et al. **Hematol Oncol** 1996 Jun; 14(2):83-90
Cell-, tissue-, and position-specific monoclonal antibodies against the planarian Dugesia (Girardia) tigrina. Bueno D, et al. **Histochem Cell Biol** 1997 Feb;107(2):139-49
Monoclonal antibodies against glutaraldehyde-conjugated histamine: application to immunocytochemistry. Fujiwara K, et al. **Histochem Cell Biol** 1997 Jan;107(1):39-45
VS38 immunostaining in neuroendocrine tumours. Banerjee SS, et al. **Histopathology** 1997 Mar;30(3):256-9
Hepatocellular carcinoma arising in an adenoma: value of QBend 10 immunostaining in diagnosis of liver cell carcinoma [see comments] Scott FR, et al. **Histopathology** 1996 May;28(5):472-4. Comment in: Histopathology 1996 Dec;29(6):593-4.
Incidence of anti-mouse antibodies in thrombocytopenic patients with autoimmune disorders. Clofent-Sanchez G, et al. **Hum Antibodies** 1997;8(2):50-9
Human recombinant anti-Rh(D) monoclonal antibodies: improvement of biological properties by in vitro class-switch. Klein P, et al. **Hum Antibodies** 1997; 8(1):17-25
Human monoclonal antibodies to viral peptides. Sidorova E, et al. **Hum Antibodies** 1997;8(2):65-9
Synergy between anti-CD40 MAb and Epstein-Barr virus in activation and transformation of human B lymphocytes. Tsuchiyama L, et al. **Hum Antibodies** 1997;8(1):43-7
A humanized antibody with specificity for hepatitis B surface antigen. Ryu CJ, et al. **Hum Antibodies Hybridomas** 1996; 7(3):113-22
Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region. Sato K, et al. **Hum Antibodies Hybridomas** 1996;7(4):175-83
Short synthetic CDR-peptides forming the antibody combining site of the monoclonal antibody against RNA bacteriophage fr neutralize the phage activity. Steinbergs J, et al. **Hum Antibodies Hybridomas** 1996;7(3):106-12
Characterization of monoclonal antibodies reactive with Schistosoma haematobium-soluble egg and infected human urinary antigens. Amanor JD, et al. **Hybridoma** 1996 Jun; 15(3):219-24
Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain. Baron AT, et al. **Hybridoma** 1997 Jun;16(3):259-71
Limited field evaluation of a rapid monoclonal antibody-based dipstick assay for urinary schistosomiasis. Bosompem KM, et al. **Hybridoma** 1996 Dec;15(6):443-7
Monoclonal antibody NM11 recognizes a C-terminal epitope shared by p300 and CBP. Dallas PB, et al. **Hybridoma** 1997 Jun;16(3):273-5
Primary structure and functional scFv antibody expression of an antibody against the human protooncogen c-myc. Fuchs P, et al. **Hybridoma** 1997 Jun;16(3):227-33
Monoclonal antibodies against the 43,000 Da glycoprotein from Paracoccidioides brasiliensis modulate laminin-mediated fungal adhesion to epithelial cells and pathogenesis. Gesztesi JL, et al. **Hybridoma** 1996 Dec; 15(6):415-22
Production and properties of monoclonal antibodies against human IgG isotypes. Hasnaoui M, et al. **Hybridoma** 1996 Oct;15(5):351-8
Monoclonal antibodies against recombinant human growth hormone as probes to study immune function. Lattuada D, et al. **Hybridoma** 1996 Jun;15(3):211-7
Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-->6) T antigens. O'Boyle KP, et al. **Hybridoma** 1996 Dec; 15(6):401-8
Generation and characterization of a humanized antibody with specificity for preS2 surface antigen of hepatitis B virus. Park SS, et al. **Hybridoma** 1996 Dec;15(6):435-41
Functional characterization of monoclonal antibody inhibitors of alpha 2-antiplasmin that accelerate fibrinolysis in different animal plasmas. Reed GL. **Hybridoma** 1997 Jun; 16(3):281-6
Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43.13? Reinsberg J, et al. **Hybridoma** 1997 Feb;16(1):59-63
Production and characterization of strain-specific monoclonal antibodies against outer membrane components of Azospirillum brasilense Sp245. Schloter M, et al. **Hybridoma** 1996 Jun;15(3):225-32
Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies. Schwabe RF, et al. **Hybridoma** 1997 Jun;16(3):217-26
Characterization of a novel adhesion function blocking monoclonal antibody to rat/mouse P-selectin generated in the P-selectin-deficient mouse. Walter UM, et al. **Hybridoma** 1997 Jun;16(3):249-57
Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Dadaglio G, et al. **Immunity** 1997 Jun;6(6):727-38
Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Porgador A, et al. **Immunity** 1997 Jun;6(6):715-26
A comparison of the anti-idiotypic responses generated by antibodies to a protein and a hapten: a common interspecies idiotype on antibodies against human albumin induces an idiotypic network in rabbits. Comacchio RM, et al. **Immunol Cell Biol** 1996 Feb;74(1):72-80
The monoclonal antibody Mac 387 recognizes three S100 proteins in human neutrophils. Guignard F, et al. **Immunol Cell Biol** 1996 Feb;74(1):105-7
Inhibition of T cell mitogenesis by a novel anti-CD45R monoclonal antibody. Robson SC, et al. **Immunol Cell Biol** 1996 Feb;74(1):65-71
Molecular interaction of growth hormone with two monoclonal antibodies recognizing distinct epitopes. Wang BS, et al. **Immunol Cell Biol** 1997 Feb;75(1):29-34
Schistosoma mansoni-infected mice show augmented hepatic fibrosis and selective inhibition of liver cytokine production after treatment with anti-NK1.1 antibodies. Asseman C, et al. **Immunol Lett** 1996 Dec 1;54(1):11-20
Monoclonal antibodies against Dermatophagoides group I allergens as pseudo-cystatins blocking the catalytic site of cysteine proteinases. Cambra O, et al. **Immunol Lett** 1996 May;50(3):173-7
Monoclonal antibodies recognize 2300 years aged alkaline phosphatase. Etspüler H, et al. **Immunol Lett** 1995 Dec; 48(3):187-91
Moloney leukemia virus-induced cell surface antigen mimicry by monoclonal antibodies. Baskin JG, et al. **Immunol Res** 1995;14(4):292-316 (96 ref.)
Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Cobbold SP, et al. **Immunol Rev** 1996 Feb;149:5-33 (109 ref.)
New perspectives on recombinant human antibodies. de Kruif J, et al. **Immunol Today** 1996 Oct;17(10):453-5 (13 ref.)
Characterization of swine leukocyte differentiation antigens. Saalmüller A. **Immunol Today** 1996 Aug;17(8):352-4
Differential functional effects of a humanized anti-CD4 antibody on resting and activated human T cells. Brett SJ, et al. **Immunology** 1997 Jul;91(3):346-53
Enhancement in antigen binding by a combination of synergy and antibody capture. Klonisch T, et al. **Immunology** 1996 Oct;89(2):165-71
Peptides isolated from random peptide libraries on phage elicit a neutralizing anti-HIV-1 response: analysis of immunological mimicry. Lundin K, et al. **Immunology** 1996 Dec;89(4):579-86
Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Mateo C, et al. **Immunotechnology** 1997 Mar;3(1):71-81
Monoclonal antibodies against human chondrocytes. Bujia J, et al. **In Vitro Cell Dev Biol Anim** 1996 Jun;32(6):366-71
Production & evaluation of a monoclonal antibody against human myeloperoxidase. Badrinath Y, et al. **Indian J Med Res** 1997 Apr;105:176-9
A human monoclonal antibody which inhibits the coaggregation activity of Porphyromonas gingivalis. Abiko Y, et al. **Infect Immun** 1997 Sep;65(9):3966-9
Structurally defined epitopes of Haemophilus ducreyi lipooligosaccharides recognized by monoclonal antibodies. Ahmed HJ, et al. **Infect Immun** 1997 Aug;65(8):3151-8
B7-1 and B7-2 monoclonal antibodies modulate the severity of murine Lyme arthritis. Anguita J, et al. **Infect Immun** 1997 Aug;65(8):3037-41
A nonsubstituted primary hydroxyl group in position 6' of free lipid A is required for binding of lipid A monoclonal antibodies. Brade L, et al. **Infect Immun** 1997 Sep; 65(9):3961-5
Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes. Charoenvit Y, et al. **Infect Immun** 1997 Aug;65(8):3430-7
Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. De Bernardis F, et al. **Infect Immun** 1997 Aug;65(8):3399-405
In vitro inhibition of Cryptosporidium parvum infection by human monoclonal antibodies. Elliot BC, et al. **Infect Immun** 1997 Sep;65(9):3933-5
Passive transfer of a monoclonal antibody specific for a sialic acid-dependent epitope on the surface of Trypanosoma cruzi trypomastigotes reduces infection in mice. Franchin G, et al. **Infect Immun** 1997 Jul;65(7):2548-54
Repetitive elements of the Mycoplasma hominis adhesin p50 can be differentiated by monoclonal antibodies. Henrich B, et al. **Infect Immun** 1996 Oct;64(10):4027-34
Passive immunization of channel catfish (Ictalurus punctatus) against the ciliated protozoan parasite Ichthyophthirius multifiliis by use of murine monoclonal antibodies. Lin TL, et al. **Infect Immun** 1996 Oct;64(10):4085-90
Purification and identification of Haemophilus ducreyi cytotoxin by use of a neutralizing monoclonal antibody. Purvén M, et al. **Infect Immun** 1997 Aug;65(8):3496-9
Plasmodium falciparum gametocyte adhesion to C32 cells via CD36 is inhibited by antibodies to modified band 3. Rogers NJ, et al. **Infect Immun** 1996 Oct;64(10):4261-8
Protective effect of antilipopolysaccharide monoclonal

antibody in experimental Klebsiella infection. Rukavina T, et al. **Infect Immun** 1997 May;65(5):1754–60

Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Savoy AC, et al. **Infect Immun** 1997 May;65(5):1800–7

A monoclonal antibody to Borrelia burgdorferi flagellin modifies neuroblastoma cell neuritogenesis in vitro: a possible role for autoimmunity in the neuropathy of Lyme disease. Sigal LH, et al. **Infect Immun** 1997 May; 65(5):1722–8

Diminished T lymphocyte proliferative response to polyclonal mitogens in acute brucellosis patients. Rodriguez-Zapata M, et al. **Infection** 1996 Mar–Apr; 24(2):115–20

Kinetics of protein phosphorylation and mediator secretion following antigen challenge of mast cells sensitized with monoclonal IgE or with reaginic serum. Guérin-Marchand C, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S21–2

In vivo effects of monoclonal antibody against ICAM-1 and LFA-1 on antigen-induced nasal symptoms and eosinophilia in sensitized rats. Asakura K, et al. **Int Arch Allergy Immunol** 1996 Oct;111(2):156–60

Monoclonal antibody LR-1 recognizes murine heat-stable antigen, a marker of antigen-presenting cells and developing hematopoietic cells. Hunt DW, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):218–29

Bip 1, a monoclonal antibody with specificity for the major birch pollen allergen Bet v 1, modulates IgE binding to the allergen. Laffer S, et al. **Int Arch Allergy Immunol** 1997 May-Jul;113(1–3):260–1

Induction of Fas-dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis. Hasunuma T, et al. **Int Immunol** 1996 Oct;8(10):1595–602

Identification of the complete expressed human TCR V gamma repertoire by flow cytometry. Hinz T, et al. **Int Immunol** 1997 Aug;9(8):1065–72

IL-4 and anti-CD40 protect against Fas-mediated B cell apoptosis and induce B cell growth and differentiation. Nakanishi K, et al. **Int Immunol** 1996 May;8(5):791–8

Monoclonal IgG as antigens: reduction is an early intracellular event of their processing by antigen-presenting cells. Santoro L, et al. **Int Immunol** 1996 Feb;8(2):211–9

Production and characterization of monoclonal antibodies directed against the laminin receptor precursor. Butò S, et al. **Int J Biol Markers** 1997 Jan–Mar;12(1):1–5

How to overcome the disturbing effects of human anti-mouse antibodies (HAMA) on in vitro assays. Oltrogge JB, et al. **Int J Biol Markers** 1997 Jan–Mar;12(1):15–7

Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Avichezer D, et al. **Int J Cancer** 1997 Jul 3;72(1):119–27

Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. Brinkmann U, et al. **Int J Cancer** 1997 May 16;71(4):638–44

Characterization of 10 new monoclonal antibodies against prostate-specific antigen by analysis of affinity, specificity and function in sandwich assays. Corey E, et al. **Int J Cancer** 1997 Jun 11;71(6):1019–28

Human monoclonal antibodies specific for the tumour associated Thomsen-Friedenreich antigen. Dahlenborg K, et al. **Int J Cancer** 1997 Jan 6;70(1):63–71

Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. Hekele A, et al. **Int J Cancer** 1996 Oct 9;68(2):232–8

Reactivity of anti-macrophage monoclonal antibody D11 in human leukemia and malignant lymphoma. Tupitsyn NN, et al. **Int J Cancer** 1996 Oct 9;68(2):160–3

Characterization of monoclonal antibodies for the rapid detection of foodborne campylobacters. Lu P, et al. **Int J Food Microbiol** 1997 Jun 17;37(1):87–91

The use of antibodies to study the architecture and developmental regulation of plant cell walls. Knox JP. **Int Rev Cytol** 1997;171:79–120 (203 ref.)

Mouse monoclonal antibodies directed against the HTLV-I protease recognize epitopes internal to the dimer. Mamoun RZ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Feb 1;14(2):184–8

Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1. Lebecque S, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):374–84

Production of a mouse/human chimeric IgE monoclonal antibody to the house dust mite allergen Der p 2 and its use for the absolute quantification of allergen-specific IgE. Schuurman J, et al. **J Allergy Clin Immunol** 1997 Apr; 99(4):545–50

Anti-bull sperm monoclonal antibodies: I. Identification of major antigenic domains of bull sperm and manifestation of interspecies cross-reactivity. Ambrose JD, et al. **J Androl** 1996 Sep–Oct;17(5):567–78

Anti-bull sperm monoclonal antibodies: II. Binding changes during capacitation and influence on sperm-zona interactions in vitro. Ambrose JD, et al. **J Androl** 1996 Sep–Oct;17(5):579–86

An anti-adipocyte monoclonal antibody is cytotoxic to porcine preadipocytes in vitro and depresses the development of pig adipose tissue. De clercq L, et al. **J Anim Sci** 1997 Jul;75(7):1791–7

Inhibition of CD18 or CD11b attenuates acute lung injury after acid instillation in rabbits. Folkesson HG, et al. **J Appl Physiol** 1997 Jun;82(6):1743–50

Pathophysiology of neonatal lung injury induced by monoclonal antibody to surfactant protein B. Grossmann G, et al. **J Appl Physiol** 1997 Jun;82(6):2003–10

Specificity of monoclonal anti-nucleosome auto-antibodies derived from lupus mice. Kramers K, et al. **J Autoimmun** 1996 Dec;9(6):723–9

Idiotypic study of a bispecific thyroglobulin and thyroperoxidase monoclonal antibody. Villa M, et al. **J Autoimmun** 1996 Oct;9(5):653–60

Identification of a mannoprotein present in the inner layer of the cell wall of Saccharomyces cerevisiae. Moukadiri I, et al. **J Bacteriol** 1997 Apr;179(7):2154–62

Monoclonal anti-human aldolase C antibodies that react to the isozyme group-specific sequences and generally conserved sequences of human aldolase C1. Kaihara R, et al. **J Biochem (Tokyo)** 1996 Feb;119(2):281–90

A battery of monoclonal antibodies that induce unique conformations to evolve cryptic but constitutive functions of plasminogen. Madoiwa S, et al. **J Biochem (Tokyo)** 1997 Feb;121(2):278–87

The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. Carmel G, et al. **J Biol Chem** 1996 Dec 20;271(51):32789–95

Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging. Duperray A, et al. **J Biol Chem** 1997 Jan 3;272(1):435–41

Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies. Elliott S, et al. **J Biol Chem** 1996 Oct 4;271(40):24691–7

Characterization of a 50-kDa component of epithelial basement membranes using GDA-J/F3 monoclonal antibody. Gayraud B, et al. **J Biol Chem** 1997 Apr 4; 272(14):9531–8

The functional architecture of an acetylcholine receptor-mimicking antibody. Mérienne K, et al. **J Biol Chem** 1997 Sep 19;272(38):23775–83

Defining the topology of integrin alpha5beta1-fibronectin interactions using inhibitory anti-alpha5 and anti-beta1 monoclonal antibodies. Evidence that the synergy sequence of fibronectin is recognized by the amino-terminal repeats of the alpha5 subunit. Mould AP, et al. **J Biol Chem** 1997 Jul 11;272(28):17283–92

An antibody reactive with domain 4 of the platelet-derived growth factor beta receptor allows BB binding while inhibiting proliferation by impairing receptor dimerization. Shulman T, et al. **J Biol Chem** 1997 Jul 11;272(28):17400–4

Molecular and structural analysis of a continuous birch profilin epitope defined by a monoclonal antibody. Wiedemann P, et al. **J Biol Chem** 1996 Nov 22; 271(47):29915–21

Reconstruction and expression of chimeric anti-HBx antibody in Escherichia coli. Zhou G, et al. **J Cancer Res Clin Oncol** 1997;123(6):325–30

Capillary isoelectric focusing and sodium dodecyl sulfate-capillary gel electrophoresis of recombinant humanized monoclonal antibody HER2. Hunt G, et al. **J Chromatogr A** 1996 Sep 13;744(1–2):295–301

Use of monoclonal antibodies for weak affinity chromatography. Ohlson S, et al. **J Chromatogr A** 1997 Jan 17;758(2):199–208

Investigations on the specificity of thiophilic interaction for monoclonal antibodies of different subclasses. Finger UB, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26; 675(2):197–204

Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. Blanco I, et al. **J Clin Immunol** 1997 Jan;17(1):96–106

A novel human monoclonal antibody rapidly induces homotypic cell aggregation and promotes antibody-secreting activity by human B lymphoblastoid cell line IM-9. Ikewaki N. **J Clin Immunol** 1997 Mar; 17(2):127–39

Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. Takeya H, et al. **J Clin Invest** 1997 May 1;99(9):2260–8

Ultrasensitive and more specific enzyme immunoassay (immune complex transfer enzyme immunoassay) for p24 antigen of HIV-1 in serum using affinity-purified rabbit anti-p24 Fab' and monoclonal mouse anti-p24 Fab'. Hashida S, et al. **J Clin Lab Anal** 1996;10(5):302–7

Detection and characterization of the coli surface antigen 6 of enterotoxigenic Escherichia coli strains by using monoclonal antibodies. Helander A, et al. **J Clin Microbiol** 1997 Apr;35(4):867–72

Use of monoclonal antibodies to facilitate identification, cloning, and purification of Chlamydia trachomatis hsp10. LaVerda D, et al. **J Clin Microbiol** 1997 May;35(5):1209–15

Characterization of monoclonal antibodies to the hemagglutinin-esterase glycoprotein of a bovine coronavirus associated with winter dysentery and cross-reactivity to field isolates. Milane G, et al. **J Clin Microbiol** 1997 Jan;35(1):33–40

Monoclonal antibodies capable of distinguishing epizootic from enzootic varieties of subtype I Venezuelan equine encephalitis viruses in a rapid indirect immunofluorescence assay. Roehrig JT, et al. **J Clin Microbiol** 1997 Jul; 35(7):1887–90

Evaluation of monoclonal antibodies for subtyping of currently circulating human type A influenza viruses. Tkáčová M, et al. **J Clin Microbiol** 1997 May;35(5):1196–8

Production of monoclonal antibodies against Rickettsia massiliae and their use in antigenic and epidemiological studies. Xu W, et al. **J Clin Microbiol** 1997 Jul; 35(7):1715–21

Characterization of and application of monoclonal antibodies against Rickettsia africae, a newly recognized species of spotted fever group rickettsia. Xu W, et al. **J Clin Microbiol** 1997 Jan;35(1):64–70

Immunohistochemical demonstration of S-phase cells by anti-bromodeoxyuridine monoclonal antibody in cattle tissues. Yanai T, et al. **J Comp Pathol** 1996 Apr; 114(3):265–72

Protective immunity to nematode infection is induced by CTLA-4 blockade. McCoy K, et al. **J Exp Med** 1997 Jul 21;186(2):183–7

N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. Pon RA, et al. **J Exp Med** 1997 Jun 2;185(11):1929–38

Anti-peptide monoclonal antibodies to intestinal mucin 3. Apostolopoulos V, et al. **J Gastroenterol Hepatol** 1995 Sep-Oct;10(5):555–61

Characterization of virus-specific and cross-reactive monoclonal antibodies to Herpesvirus simiae (B virus). Blewett EL, et al. **J Gen Virol** 1996 Nov;77 (Pt 11):2787–93

Antibodies to a new linear site at the topographical or functional interface between the haemagglutinin and fusion proteins protect against measles encephalitis. Fournier P, et al. **J Gen Virol** 1997 Jun;78 (Pt 6):1295–302

Monoclonal antibodies specific for Semliki Forest virus replicase protein nsP2. Kujala P, et al. **J Gen Virol** 1997 Feb;78 (Pt 2):343–51

Human parainfluenza virus type 2 phosphoprotein: mapping of monoclonal antibody epitopes and location of the multimerization domain. Nishio M, et al. **J Gen Virol** 1997 Jun;78 (Pt 6):1303–8

Regulation of human immunodeficiency virus gp160-mediated cell fusion by antibodies against fusion regulatory protein 1. Ohgimoto S, et al. **J Gen Virol** 1996 Nov;77 (Pt 11):2747–56

Human herpesvirus 7 infection of CD4+(+) T cells does not require expression of the OKT4 epitope. Yasukawa M, et al. **J Gen Virol** 1996 Dec;77 (Pt 12):3103–6

Protection against measles virus encephalitis by monoclonal antibodies binding to a cystine loop domain of the H protein mimicked by peptides which are not recognized by maternal antibodies. Ziegler D, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2479–89

Wuchereria bancrofti recombinant antigen-derived poly- and monoclonal antibodies for the detection of circulating antigen(s) in the sera of lymphatic filarial patients. Theodore JG, et al. **J Helminthol** 1996 Mar;70(1):69–74

BIRMA-K3, a new monoclonal antibody for CD34 immunophenotyping and stem and progenitor cell assay. Höffkes HG, et al. **J Hematother** 1996 Jun;5(3):261–70

Multi-organ reactivity of a monoclonal natural autoantibody that promotes remyelination in a mouse model of multiple sclerosis. Miller DJ, et al. **J Histochem Cytochem** 1996 Sep; 44(9):1005–11

Determination of the localization of gangliosides using anti-ganglioside antibodies: comparison of fixation methods. Schwarz A, et al. **J Histochem Cytochem** 1997 Apr;45(4):611–8

B cell responses to a peptide epitope. I. The cellular basis for restricted recognition. Agarwal A, et al. **J Immunol** 1996 Oct 1;157(7):2779–88

Molecular analysis of stimulatory anti-thyrotropin receptor antibodies (TSAbs) involved in Graves' disease. Isolation and reconstruction of antibody genes, and production of monoclonal TSAbs. Akamizu T, et al. **J Immunol** 1996 Oct 1;157(7):3148–52

Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. Guex-Crosier Y, et al. **J Immunol** 1997 Jan 1;158(1):452–8

Triggering of motile behavior in T lymphocytes via cross-linking of alpha 4 beta 1 and alpha L beta 2. Hauzenberger D, et al. **J Immunol** 1997 Jan 1;158(1):76–84

Carbohydrate and peptide specificity of MHC class II-restricted T cell hybridomas raised against an O-glycosylated self peptide. Jensen T, et al. **J Immunol** 1997 Apr 15;158(8):3769–78

Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II. Lando PA, et al. **J Immunol** 1996 Oct 1;157(7):2857–63

Differential effects of a monoclonal antibody to cis-urocanic acid on the suppression of delayed and contact hypersensitivity following ultraviolet irradiation. Moodycliffe AM, et al. **J Immunol** 1996 Oct 1; 157(7):2891–9

Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. Pinckard JK, et al. **J Immunol** 1997 Apr 15;158(8):3869–73

Analysis of the promoter elements necessary for IL-4 and anti-CD40 antibody induction of murine Fc epsilon RII (CD23): comparison with the germline epsilon promoter. Richards ML, et al. **J Immunol** 1997 Jan 1;158(1):263–72

L-selectin (CD62L) blockade does not impair peritoneal neutrophil emigration or subcutaneous host defense to bacteria in rabbits. Sharar SR, et al. **J Immunol** 1996 Sep 15;157(6):2555–63

Immune reactivity of diabetes-associated human monoclonal autoantibodies defines multiple epitopes and detects two domain boundaries in glutamate decarboxylase. Syren K, et al. **J Immunol** 1996 Dec 1;157(11):5208–14

A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. Zhang C, et al. **J Immunol** 1996 Nov 1;157(9):3980–7

Generation of antibodies to human IL-12 and amphiregulin by immunization of Balb/c mice with diepitope multiple antigen peptides. Ahlborg N, et al. **J Immunol Methods** 1997 May 12;204(1):23–32

Interest of immunomodulation as a mean to improve the preparation of polyclonal and monoclonal antibody reagents. Bouige P, et al. **J Immunol Methods** 1997 Jan 15;200(1–2):27–37

Monoclonal antibody 2F4/11 recognizes the alpha chain of a porcine beta 2 integrin involved in adhesion and complement mediated phagocytosis. Bullido R, et al. **J Immunol Methods** 1996 Sep 9;195(1–2):125–34

A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. Gazzano-Santoro H, et al. **J Immunol Methods** 1997 Mar 28;202(2):163–71

Characterization of murine monoclonal antibodies specific for the 45/47 kDa antigen complex (APA) of Mycobacterium tuberculosis, M. bovis and BCG. Horn C, et al. **J Immunol Methods** 1996 Oct 16;197(1–2):151–9

A monoclonal antibody reacts with maltose-binding protein of Escherichia coli and related enteric bacteria. Hsu SC, et al. **J Immunol Methods** 1997 May 26;204(2):169–74

Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). McCloskey N, et al. **J Immunol Methods** 1997 Jun 23;205(1):67–72

Methodology for selection of human antibodies to membrane proteins from a phage-display library. Sawyer C, et al. **J Immunol Methods** 1997 May 26;204(2):193–203

Adoptive immunotherapy involving recombinant human M-CSF and R24 anti-melanoma antibody induces human T-cell infiltration into human melanoma xenografts. Conlon KC, et al. **J Immunother Emphasis Tumor Immunol** 1996 Sep; 19(5):317–23

Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients. Curti BD, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):296–308

Experimental immunization with a monoclonal anti-idiotope antibody that mimics the Neisseria gonorrhoeae lipooligosaccharide epitope 2C7. Gulati S, et al. **J Infect Dis** 1996 Dec;174(6):1238–48

Maternal monoclonal antibody to the V3 loop alters specificity of the response to a human immunodeficiency virus vaccine. Jelonek MT, et al. **J Infect Dis** 1996 Oct; 174(4):866–9

Mechanism of antibody-mediated reduction of nasopharyngeal colonization by Haemophilus influenzae type b studied in an infant rat model. Kauppi-Korkeila M, et al. **J Infect Dis** 1996 Dec;174(6):1337–40

Anti-interleukin-6 antibodies inhibit herpes simplex virus reactivation. Kriesel JD, et al. **J Infect Dis** 1997 Apr; 175(4):821–7

Identification of a new antibody population directed against a desmosomal plaque antigen in pemphigus vulgaris and pemphigus foliaceus. Joly P, et al. **J Invest Dermatol** 1997 Apr;108(4):469–75

Novel fibroblast-specific monoclonal antibodies: properties and specificities. Saalbach A, et al. **J Invest Dermatol** 1996 Jun;106(6):1314–9

Anti-IL-4 antibody inhibits antigen specific IgE response but fails to prevent chicken gamma globulin-induced active systemic anaphylaxis: evidence for the involvement of IgG antibodies. Lee HK, et al. **J Korean Med Sci** 1996 Apr; 11(2):111–7

Monoclonal antibody production and characterization for the measurement of plasma high density lipoprotein. Lee SH, et al. **J Korean Med Sci** 1996 Oct;11(5):390–6

Immunologically specific activation of a cephalosporin derivative of mitomycin C by monoclonal antibody beta-lactamase conjugates. Vrudhula VM, et al. **J Med Chem** 1997 Aug 15;40(17):2788–92

Isolation and characterization of mouse monoclonal antibodies reactive with soft tick (Acari: Argasidae) salivary antigens of high molecular weight. Wozniak EJ, et al. **J Med Entomol** 1996 Mar;33(2):216–9

Production and characterisation of monoclonal antibodies to Brucella melitensis cytosoluble proteins that are able to differentiate antibody responses of infected sheep from Rev. 1 vaccinated sheep. Cloeckaert A, et al. **J Med Microbiol** 1996 Sep;45(3):206–13

Differentiation of thermolysins and serralysins by monoclonal antibodies. Kooi C, et al. **J Med Microbiol** 1996 Sep; 45(3):219–25

Characterisation and protective capacity of monoclonal antibodies elicited in mice against protein epitopes of antibiotic-exposed Escherichia coli. Lun MT, et al. **J Med Microbiol** 1997 Feb;46(2):122–8

Biovar-specific epitopes of the urease enzyme of Ureaplasma urealyticum. MacKenzie CR, et al. **J Med Microbiol** 1996 Nov;45(5):366–71

Blocking of iron uptake by monoclonal antibodies specific for the Neisseria meningitidis transferrin-binding protein 2. Pintor M, et al. **J Med Microbiol** 1996 Oct;45(4):252–7

Identification by monoclonal antibodies of serotype D strains of Pasteurella multocida representing various geographic origins and host species. Vasfi Marandi M, et al. **J Med Microbiol** 1997 Jul;46(7):603–10

Characterisation of a panel of monoclonal antibodies raised against recombinant HCV core protein. Ferns RB, et al. **J Med Virol** 1996 Nov;50(3):221–9

In vitro neutralization of hepatitis B virus by monoclonal antibodies against the viral surface antigen. Ryu CJ, et al. **J Med Virol** 1997 Jun;52(2):226–33

Comparative interaction kinetics of two recombinant Fabs and of the corresponding antibodies directed to the coat protein of tobacco mosaic virus. Chatellier J, et al. **J Mol Recognit** 1996 Jan–Feb;9(1):39–51

The effect of water activity on the association constant and the enthalpy of reaction between lysozyme and the specific antibodies D1.3 and D44.1. Goldbaum FA, et al. **J Mol Recognit** 1996 Jan–Feb;9(1):6–12

Effect of antibody orientation on immunosorbent performance. Subramanian A, et al. **J Mol Recognit** 1996 Sep–Dec;9(5–6):528–35

Monoclonal antibodies against the human metalloprotease EC 3.4.24.15 label neurofibrillary tangles in Alzheimer's disease brain. Conn KJ, et al. **J Neurochem** 1996 May;66(5):2011–8

Preparation and characterization of monoclonal antibodies specific for lauroylated isoform of bovine transducin alpha-subunit: immunohistochemical analysis of bovine retinas. Shouno O, et al. **J Neurochem** 1996 May; 66(5):2188–96

Protection from experimental autoimmune encephalomyelitis (EAE): non-depleting anti-CD4 mAb treatment induces peripheral T-cell tolerance to MBP in PL/J mice. Biasi G, et al. **J Neuroimmunol** 1997 Mar;73(1–2):117–23

Antibodies to lymphotoxin alpha (LT alpha) and LT beta recognize different glial cell types in the central nervous system. Cannella B, et al. **J Neuroimmunol** 1997 Sep; 78(1–2):172–9

A monoclonal antibody to the ligand-binding domain of the neurokinin 1 receptor (NK1-R) for the neuropeptide substance P. Déry O, et al. **J Neuroimmunol** 1997 Jun; 76(1–2):1–9

Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. Hsu DW, et al. **J Neuropathol Exp Neurol** 1997 Aug;56(8):857–65

Reelin is a secreted glycoprotein recognized by the CR-50 monoclonal antibody. D'Arcangelo G, et al. **J Neurosci** 1997 Jan 1;17(1):23–31

Development and application of a modified monoclonal hybridoma technique for isolating monoclonal antibodies to human brain regions. Fukuyama R, et al. **J Neurosci Methods** 1996 Jan;64(1):135

OX-40 antibody enhances for autoantigen specific V beta 8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. Weinberg AD, et al. **J Neurosci Res** 1996 Jan 1;43(1):42–9

Generation and characterization of anti-sulfoglucuronosyl paragloboside monoclonal antibody NGR50 and its immunoreactivity with peripheral nerve. Yamawaki M, et al. **J Neurosci Res** 1996 Jun 15;44(6):586–93

Immunohistochemical characterization of monoclonal antibodies (PDs) as markers of the periderm in the developing chicken embryo. Isokawa K, et al. **J Nihon Univ Sch Dent** 1996 Dec;38(3–4):131–40

Immunohistochemical diagnosis of Toxoplasma gondii: potential for cross-reactivity with Neospora caninum. Sundermann CA, et al. **J Parasitol** 1997 Jun;83(3):440–3

Characterization of the Porphyromonas gingivalis antigen recognized by a monoclonal antibody which prevents colonization by the organism. Booth V, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 1):54–60

Interaction of thrombin-activated platelets with extracellular matrices (fibronectin and vitronectin): comparison of the activity of Arg-Gly-Asp-containing venom peptides and monoclonal antibodies against glycoprotein IIb/IIIa complex. Sheu JB, et al. **J Pharm Pharmacol** 1997 Jan; 49(1):78–84

Anti-interleukin 4 antibody and indomethacin synergistic effect on B16 melanoma tumor progression. Blaya C, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):472–7

Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. Huwyler J, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1541–6

Studies on the epitope of pig zona pellucida recognized by a fertilization-blocking monoclonal antibody. Koyama K, et al. **J Reprod Fertil Suppl** 1996;50:135–42

The monoclonal antibody GZS-1 detects a maturation-associated antigen of human spermatozoa that is also present on the surface of human mononuclear blood cells. Hutter H, et al. **J Reprod Immunol** 1996 May; 30(2–3):115–32

Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis. Moreland LW. **J Rheumatol Suppl** 1996 Mar;44:78–83 (74 ref.)

Immunization with antibodies that mimic LPS protects against gram negative bacterial sepsis. Klaerner HG, et al. **J Surg Res** 1997 May;69(2):249–54

Cytotoxicity of B72.3XOKT3 bispecific antibody recognizing human colon cancer. Shpitz B, et al. **J Surg Res** 1996 Feb 15;61(1):134–8

Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. Bergman PJ, et al. **J Vet Intern Med** 1996 Nov–Dec;10(6):354–9

Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodies. Castilla J, et al. **J Virol** 1997 Jul;71(7):5251–8

Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. Davison E, et al. **J Virol** 1997 Aug;71(8):6204–7

Blocking of feline immunodeficiency virus infection by a monoclonal antibody to CD9 is via inhibition of virus release rather than interference with receptor binding. de Parseval A, et al. **J Virol** 1997 Aug;71(8):5742–9

Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies. Fiore L, et al. **J Virol** 1997 Sep;71(9):6905–12

Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. Fouts TR, et al. **J Virol** 1997 Apr;71(4):2779–85

Monoclonal antibodies to a 55-kilodalton protein present in duck liver inhibit infection of primary duck hepatocytes with duck hepatitis B virus. Guo JT, et al. **J Virol** 1997 Jun;71(6):4829–31

Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. Hadlock KG, et al. **J Virol** 1997 Aug;71(8):5828–40

Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody. Lee S, et al. **J Virol** 1997 Aug;71(8):6037–43

Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. Mascola JR, et al. **J Virol** 1997 Oct;71(10):7198–206

Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off Mo H, et al. **J Virol** 1997 Sep;71(9):6869–74

Evaluation of monoclonal antibodies for generic detection of flaviviruses by ELISA. Brown JM, et al. **J Virol Methods** 1996 Dec;62(2):143–51

Neutralization titres of HIV-1-specific monoclonal antibodies vary according to the batch of primary human peripheral blood lymphocytes, but do not vary coordinately. McLain L, et al. **J Virol Methods** 1997 Aug; 67(1):69–76

Immunohistochemical demonstration with anti-bromodeoxyuridine monoclonal antibody in experimental meningeal carcinomatosis model. Huang TY, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Mar; 13(3):136–40

Induction of microhematuria by an IgA isotype switch variant of a monoclonal anti-Thy-1.1 antibody in the rat. van Dixhoorn MG, et al. **Kidney Int** 1996 Nov; 50(5):1612–23

Reactivity of anti-AraC-resistant cell monoclonal antibody, YU-311, in formalin-fixed paraffin-embedded specimens of various hematopoietic disorders. Fukuda T, et al. **Leuk Res** 1996 Nov–Dec;20(11–12):953–61

The value of the monoclonal antibody, DBA44, in the diagnosis of B-lymphoid disorders. Salomon-Nguyen F, et al. **Leuk Res** 1996 Nov–Dec;20(11–12):909–13

Monoclonal antibodies specific for P-glycoprotein. Okochi E, et al. **Leukemia** 1997 Jul;11(7):1119–23 (43 ref.)

Variable regions of two murine antibodies that bind the SLE associated 16/6 idiotype. Waisman A, et al. **Lupus** 1996 Aug;5(4):279–87

Resting cell neutralization assay for HIV-1 primary isolates. Hioe C, et al. **Methods** 1997 Aug;12(4):300–5

Monoclonal anti-DNA antibodies: structure, specificity, and biology. Marion TN, et al. **Methods** 1997 Jan;11(1):3–11

A simple solid-phase competition assay with labeled antigen. Kuroki M. **Methods Mol Biol** 1996;66:47–53

Reiterative screening of phage-display peptide libraries with antibodies. Pereboev A, et al. **Methods Mol Biol** 1996; 66:195–206

Monoclonal antibodies against Haemophilus influenzae lipopolysaccharides: clone MAHI 4 binding to a pentasaccharide containing terminal beta-Gal residues and clone MAHI 10 recognizing terminal phosphorylated saccharide residues. Borrelli S, et al. **Microb Pathog** 1996 Nov;21(5):307–18

Monoclonal antibodies against fimbrial subunits of colonization factor antigen I (CFA/I) inhibit binding to human enterocytes and protect against enterotoxigenic Escherichia coli expressing heterologous colonization factors. Rudin A, et al. **Microb Pathog** 1996 Jul;21(1):35–45

Neutralization of hemolytic and mouse lethal activities of C. perfringens alpha-toxin need simultaneous blockade of two epitopes by monoclonal antibodies. Schoepe H, et al. **Microb Pathog** 1997 Jul;23(1):1–10

Differential expression of a Mycobacterium tuberculosis protein recognized by a mouse monoclonal antibody. Cummings PJ, et al. **Microbiol Immunol** 1996;40(11):883–6

ANTIBODIES, MONOCLONAL

Monoclonal antibody #5-2-26 recognizes the phosphatase-sensitive epitope of rabies virus nucleoprotein. Kawai A, et al. **Microbiol Immunol** 1997;41(1):33-42

Production, binding characteristics and protective immunity of monoclonal antibody to pneumococcal type-9V conjugate. Lee CJ, et al. **Microbiol Immunol** 1996; 40(11):857-65

Monoclonal antibodies as probes for fungal wall structure during morphogenesis. Marshall M, et al. **Microbiology** 1997 Jul;143 (Pt 7):2255-65

Characterization of monoclonal antibodies to aflatoxin M1 and molecular modeling studies of related aflatoxins. Holtzapple CK, et al. **Mol Immunol** 1996 Aug; 33(11-12):939-46

Neutralizing murine monoclonal anti-interleukin-10 antibodies enhance binding of antibodies against a different epitope. Sabat R, et al. **Mol Immunol** 1996 Oct; 33(14):1103-11

Immunological effects of an arginine side chain contaminating synthetically prepared peptides. Schlagel LJ, et al. **Mol Immunol** 1997 Feb;34(2):185-94

Determination of the N- and C-terminal sequences required to bind human IgE of the major house dust mite allergen Der f 2 and epitope mapping for monoclonal antibodies. Takai T, et al. **Mol Immunol** 1997 Feb;34(3):255-61

Functional characterization of monoclonal antibodies specific to growth hormone receptor. Wang BS, et al. **Mol Immunol** 1996 Oct;33(15):1197-202

Identification of the Fy6 epitope recognized by two monoclonal antibodies in the N-terminal extracellular portion of the Duffy antigen receptor for chemokines. Waśniowska K, et al. **Mol Immunol** 1996 Aug; 33(11-12):917-23

Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice. Krasemann S, et al. **Mol Med** 1996 Nov;2(6):725-34

Characterization of monoclonal antibodies recognizing three distinct, phosphorylated carbohydrate epitopes in the lipopolysaccharide of the deep rough mutant I-69 Rd-/b+ of Haemophilus influenzae. Rozalski A, et al. **Mol Microbiol** 1997 Feb;23(3):569-77

Resolution of CNS lesions following treatment of experimental allergic encephalomyelitis in macaques with monoclonal antibody to the CD18 leukocyte integrin. Rose LM, et al. **Mult Scler** 1997 Jan;2(6):259-66

Synergistic inhibition of human cell-mediated cytotoxicity by complement component antisera indicates that target cell lysis may result from an enzymatic cascade involving granzymes and perforin. Brahmi Z, et al. **Nat Immun** 1995 Sep;14(5-6):271-85

Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Whittum-Hudson JA, et al. **Nat Med** 1996 Oct;2(10):1116-21

Monoclonal antibodies. Mice perform a human repertoire [news] Neuberger M, et al. **Nature** 1997 Mar 6; 386(6620):25-6

Adhesion molecules and the mechanisms of kidney rejection [editorial] de Bustillo EM, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):949-52 (34 ref.)

TG-1: a marker for neuronal nuclei in Alzheimer's disease. Vincent I, et al. **Neurobiol Dis** 1994 Dec;1(3):145-57

Monoclonal antibodies to proteins of the myelin-like sheath of earthworm giant axons show cross-reactivity to crayfish CNS glia: an immunogold electron microscopy study. Cardone B, et al. **Neurochem Res** 1996 Apr;21(4):505-10

Identification of monoclonal antibody At5 as a new member of HNK-1 antibody family: the reactivity with myelin-associated glycoprotein and with two brain-specific proteoglycans, phosphacan and neurocan. Preobrazhensky AA, et al. **Neurochem Res** 1997 Feb; 22(2):133-40

IB4, a monoclonal antibody against the CD18 leukocyte adhesion protein, reduces intracranial pressure following thromboembolic stroke in the rabbit. Bednar MM, et al. **Neurol Res** 1996 Apr;18(2):171-5

Serum IgM monoclonal autoantibody binding to the 301 to 314 amino acid epitope of beta-tubulin: clinical association with slowly progressive demyelinating polyneuropathy. Connolly AM, et al. **Neurology** 1997 Jan;48(1):243-8

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. van Oosten BW, et al. **Neurology** 1997 Aug; 49(2):351-7

Indefinite survival of neural xenografts induced with anti-CD4 monoclonal antibodies. Wood MJ, et al. **Neuroscience** 1996 Feb;70(3):775-89

Radioimmunoscintigraphy using technetium-99m-labeled parental mouse and mouse-human chimeric antibodies to carcinoembryonic antigen in athymic nude mice bearing tumor. Karube Y, et al. **Nucl Med Biol** 1996 Aug; 23(6):753-9

Influence of a syngeneic anti-idiotypic antibody response to a mouse anti-tumour monoclonal antibody on biodistribution of its radiolabelled Fc-intact monovalent Fab/c fragment. Pimm MV, et al. **Nucl Med Biol** 1994 Jan;21(1):125-7

Quantitation of radiolabeled antibody binding to cells by thin-layer chromatography. Zamora PO, et al. **Nucl Med Biol** 1994 Feb;21(2):205-10

A solid-phase assay to screen monoclonal antibodies against DNA-binding protein. Ishii N, et al. **Nucleic Acids Res** 1997 Sep 1;25(17):3550-1

Depletion of CD4+ or CD8+ T-cells prevents Plasmodium berghei induced cerebral malaria in end-stage disease. Hermsen C, et al. **Parasitology** 1997 Jan;114 (Pt 1):7-12

Epitope mapping on the ookinete surface antigen Pbs21 of Plasmodium berghei: identification of the site of binding of transmission-blocking monoclonal antibody 13.1. Spano F, et al. **Parassitologia** 1996 Dec;38(3):559-63

Immunohistochemical study with anti-advanced glycation end-products antibody in murine amyloidosis. Hoshii Y, et al. **Pathol Int** 1996 Oct;46(10):738-42

Highly specific, cross-reactive sequences recognized by an anti-HBsAg antibody identified from a positional scanning synthetic combinatorial library. Appel JR, et al. **Pept Res** 1996 Jul-Aug;9(4):174-82

A monoclonal antibody affects chromophore apoprotein interactions of phytochrome A. Nakazawa M, et al. **Photochem Photobiol** 1997 Apr;65(4):745-9

Detection of mouse tyrosinase with a monoclonal antibody MAT-1 against human tyrosinase. Suzuki S, et al. **Pigment Cell Res** 1996 Dec;9(6):298-303

Preparation of a monoclonal antibody against soybean nodule uricase (nod-35), and immunoblot analysis of the expression of nod-35 in tissues of various legumes. Tajima S, et al. **Plant Cell Physiol** 1996 Dec;37(8):1188-92

Monoclonal antibodies to barley aleurain and homologs from other plants. Rogers SW, et al. **Plant J** 1997 Jun; 11(6):1359-68

Random phage mimotopes recognized by monoclonal antibodies against the pyruvate dehydrogenase complex-E2 (PDC-E2). Cha S, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10949-54

Rolling and transient tethering of leukocytes on antibodies reveal specializations of selectins. Chen S, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3172-7

Modified cytokeratins expressed on the surface of carcinoma cells undergo endocytosis upon binding of human monoclonal antibody and its recombinant Fab fragment. Ditzel HJ, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22; 94(15):8110-5

Peptide inhibition of glomerular deposition of an anti-DNA antibody. Gaynor B, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1955-60

Ly-6C regulates endothelial adhesion and homing of CD8(+) T cells by activating integrin-dependent adhesion pathways. Hänninen A, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6898-903

Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Solomon B, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):4109-12

Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen. Eerola R, et al. **Prostate** 1997 May 1;31(2):84-90

Redesigned anti-human placental alkaline phosphatase single-chain Fv: soluble expression, characterization and in vivo tumour targeting. Deonarain MP, et al. **Protein Eng** 1997 Jan;10(1):89-98

Recognition of phage-expressed peptides containing Asx-Pro sequences by monoclonal antibodies produced against Plasmodium falciparum circumsporozoite protein. Wilson DR, et al. **Protein Eng** 1997 May;10(5):531-40

Complementarity determining region residues aspartic acid at H55, serine at H95 and tyrosines at H97 and L96 play important roles in the B72.3 antibody-TAG72 antigen interaction. Xiang J, et al. **Protein Eng** 1996 Jun;9(6):539-43

Effect of temperature on the reactivities of polyreactive and monospecific monoclonal IgG antibodies. Labrousse H, et al. **Res Immunol** 1997 May;148(4):267-76

Similar binding properties for a neutralizing anti-tetanus toxoid human monoclonal antibody and its bacterially expressed Fab. Lafaye P, et al. **Res Immunol** 1996 Jan; 147(1):61

Production and characterization of monoclonal antibodies to the EDTA extract of Leptospira interrogans, serovar icterohaemorrhagiae. Leite LT, et al. **Rev Soc Bras Med Trop** 1996 Sep-Oct;29(5):483-9

Binding specificities of a polyreactive and a monoreactive human monoclonal IgG rheumatoid factor: role of oligosaccharides. al-Balaghi S, et al. **Scand J Immunol** 1996 Nov;44(5):470-7

The MoAb-V kappa IIIb cross-reactive idiotope on A27a (Humkv325) encoded kappa chains maps to framework region 3. off Potter KN, et al. **Scand J Immunol** 1996 Oct; 44(4):305-13

Anti-idiotypic monoclonal antibody cancer vaccines. Chapman PB. **Semin Cancer Biol** 1995 Dec;6(6):367-74 (53 ref.)

Pyruvate: ferredoxin oxidoreductase from Entamoeba histolytica recognized by a monoclonal antibody. Thammapalerd N, et al. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):63-70

Production and characterization of monoclonal antibodies to dehydroepiandrosterone sulfate: application to direct enzyme-linked immunosorbent assays of dehydroepiandrosterone sulfate and androsterone/epiandrosterone sulfates in plasma. Lewis JG, et al. **Steroids** 1996 Dec;61(12):682-7

Effect of anti-intercellular adhesion molecule-1 and anti-leukocyte function associated antigen-1 monoclonal antibodies on rat-to-mouse cardiac xenograft rejection. Miwa S, et al. **Surgery** 1997 Jun;121(6):681-9

Monoclonal antibodies to human fibrin: interaction with other animal fibrins. Edgell T, et al. **Thromb Haemost** 1996 Apr;75(4):595-9

A novel regulatory epitope defined by a murine monoclonal antibody to the platelet GPIIb-IIIa complex (alpha IIb beta 3 integrin). Tokuhira M, et al. **Thromb Haemost** 1996 Dec; 76(6):1038-46

S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. Bardin N, et al. **Tissue Antigens** 1996 Nov;48(5):531-9

Monoclonal antibodies specific for porcine monocytes/macrophages: macrophage heterogeneity in the pig evidenced by the expression of surface antigens. Bullido R, et al. **Tissue Antigens** 1997 Apr;49(4):403-13

A functional monoclonal antibody recognizing the human alpha 1-integrin I-domain. Fabbri M, et al. **Tissue Antigens** 1996 Jul;48(1):47-51

Specificity of two anti-class I HLA monoclonal antibodies that block class I recognition by the NKB1 killer cell inhibitory receptor. Gumperz JE, et al. **Tissue Antigens** 1996 Oct;48(4 Pt 1):278-84

Signal transduction properties of the T cell activation monoclonal antibody panel: ubiquitous increase in cellular substrate tyrosine phosphorylation in the absence of detectable calcium mobilization. Levine BL, et al. **Tissue Antigens** 1996 Oct;48(4 Pt 1):319-24

Induction of nuclear factor kappa B/Rel nuclear activity in human peripheral blood T lymphocytes by anti-HLA class I monoclonal antibodies. Turco MC, et al. **Tissue Antigens** 1997 Jul;50(1):1-7

A feline homologue of CD1 is defined using a feline-specific monoclonal antibody. Woo JC, et al. **Tissue Antigens** 1997 Mar;49(3 Pt 1):244-51

The Fas antigen (CD95) on human lymphoid cells: epitope analysis with ten antibodies. Zola H, et al. **Tissue Antigens** 1996 Nov;48(5):519-30

Fab fragments of the monoclonal antibody BCF2 are capable of neutralizing the whole soluble venom from the scorpion Centruroides noxius Hoffmann. Licea AF, et al. **Toxicon** 1996 Aug;34(8):843-7

ADCC activity of monoclonal anti-D antibodies. Armstrong-Fisher SS, et al. **Transfus Clin Biol** 1996; 3(6):475-7

Monoclonal antibodies directed against human Rh antigens in tests with red cells of non-human primates. Blancher A, et al. **Transfus Clin Biol** 1996;3(6):339-45

Polyreactivity of human monoclonal antibodies: human IgM anti-rhesus monoclonal antibodies are frequently polyreactive. Blancher A, et al. **Transfus Clin Biol** 1996; 3(6):347-53

Functional (ADCC) study of 54 IgG MAb anti-RhD. Brossard Y, et al. **Transfus Clin Biol** 1996;3(6):459-63

Evaluation of monoclonal anti-D reagents using D variant cells. Condon J, et al. **Transfus Clin Biol** 1996;3(6):367-8

Serological investigation of Rh antibodies other than anti-D. Delsalle A, et al. **Transfus Clin Biol** 1996;3(6):381-4

Functional activity of Rh monoclonal antibodies in ADCC assay. Delsalle A, et al. **Transfus Clin Biol** 1996;3(6):469-71

A comparison of the functional activity of monoclonal and polyclonal Rh antibodies. Downing I, et al. **Transfus Clin Biol** 1996;3(6):479-81

Coordinator's report on the flow cytometric analysis of the Rh antibodies. Fletcher A, et al. **Transfus Clin Biol** 1996; 3(6):407-13

Anti-Rh(D) monoclonal antibodies: study of their in vitro functional properties. Glacet A, et al. **Transfus Clin Biol** 1996;3(6):465-8

Coordinator's report: an assessment of the functional activity of human Rh monoclonal antibodies after their evaluation by nine laboratories. Kumpel BM. **Transfus Clin Biol** 1996; 3(6):439-52

Characterization and functional activity of human Rh monoclonal antibodies. Kumpel BM, et al. **Transfus Clin Biol** 1996;3(6):453-8

Flow cytometric evaluation of non anti-RH1(D) monoclonal Rh antibodies. Le Pennec PY, et al. **Transfus Clin Biol** 1996;3(6):433-5

Serological studies of monoclonal RH1(D) antibodies with RH1(D) variants. Le Pennec PY, et al. **Transfus Clin Biol** 1996;3(6):401-4

Flow cytometric analysis of 68 monoclonal anti-D reagents. Lubenko A, et al. **Transfus Clin Biol** 1996;3(6):415-7

Reactivity of 62 Rh MAbs with weak and variant antigens. Morelati F, et al. **Transfus Clin Biol** 1996;3(6):359-66

Reactions of anti-D monoclonal antibodies with rhesus D variant cells. Overbeeke MA, et al. **Transfus Clin Biol** 1996; 3(6):397-9

Assessment of monoclonal antibodies by the monocyte-mediated ADCC assay. Overbeeke MA, et al. **Transfus Clin Biol** 1996;3(6):473-4

Results of serological testing of D variants and weak D antigens. Pisačka M, et al. **Transfus Clin Biol** 1996; 3(6):369-71

IgG anti-D MAbs in tests by flow cytometry. Roubinet F, et al. **Transfus Clin Biol** 1996;3(6):419-23

Specificity C and e: tests using Rh variant cells. Smart EA, et al. **Transfus Clin Biol** 1996;3(6):355-7

Human Rh monoclonal antibodies: assessment of functional activity by chemiluminescence and RhD antibody quantitation. Strachan AJ, et al. **Transfus Clin Biol** 1996; 3(6):483-7

Serological analysis of monoclonal anti-E and -e with Japanese E/e variant red cells. Uchikawa M, et al. **Transfus Clin Biol** 1996;3(6):387–9

Evaluation of Rh monoclonal antibodies for flow cytometry tests. Wendel RF, et al. **Transfus Clin Biol** 1996;3(6):425–7

Mechanism of cryoprecipitation of anti-blood group B murine monoclonal antibodies. Judson PA, et al. **Transfus Med**,1991 Jun;1(2):97–102

A murine monoclonal anti-N, BIRMA-N, suitable for blood grouping in an automated system. Thompson JM, et al. **Transfus Med** 1991 Dec;1(4):239–43

Human monoclonal antibodies to human blood group antigens Kidd Jka and Jkb. Thompson K, et al. **Transfus Med** 1991 Jun;1(2):91–6

Inhibition by CsA and FK506 of the in vitro proliferative response of gamma delta T cells on stimulation with anti-TCR delta monoclonal antibody. Chen BG, et al. **Transpl Immunol** 1996 Jun;4(2):158–62

Monoclonal antiidiotypic antibodies neutralize cytotoxic effects of anti-alphaGal antibodies. Koren E, et al. **Transplantation** 1996 Sep 27;62(6):837–43

Monoclonal antibodies against human blastocysts. Nilsson BO, et al. **Ups J Med Sci** 1995;100(3):217–21

Characterization of Schistosoma mansoni 44.7/56.8 kDa egg antigens recognized by human monoclonal antibodies which induce protection against experimental infection and proliferation of peripheral blood mononuclear cells from schistosomiasis patients. Hirsch C, et al. **Vaccine** 1997 Jun; 15(9):948–54

Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Pal S, et al. **Vaccine** 1997 Apr; 15(5):575–82

Immunohistological study on bovine lymph node using monoclonal antibodies to interleukin-2 receptor. Asahina M, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):411–3

Flow cytometric analysis of the reactivity of workshop monoclonal antibodies on sheep lymph node cells, after infection with Salmonella abortusovis. Bernard S, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):403–9

Immunohistochemical study on the reactivity of workshop monoclonal antibodies with sheep lymph nodes. Berthon P, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):393–401

Differential binding of two monoclonal antibodies directed against the chicken CD8 alpha molecule. Breed DG, et al. **Vet Immunol Immunopathol** 1996 Jun 15;52(1–2):117–25

Analysis of monoclonal antibodies specific for the gamma delta TcR. Davis WC, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):275–83

Analysis of monoclonal antibodies reactive with molecules upregulated or expressed only on activated lymphocytes. Davis WC, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):301–11

Reactivity of antibodies directed against human antigens with surface markers on canine leukocytes. Galkowska H, et al. **Vet Immunol Immunopathol** 1996 Oct;53(3–4):329–34

Reactivity of workshop antibodies with a non-ruminant species: crossreactivity with canine blood leukocytes. H-Joachim S, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):427–33

Ruminant cluster WC15. Howard CJ. **Vet Immunol Immunopathol** 1996 Aug;52(4):263

Ruminant cluster CD62L. Howard CJ. **Vet Immunol Immunopathol** 1996 Aug;52(4):255–6

Monoclonal antibodies detecting components of the bovine immune system in formaldehyde-fixed paraffin-embedded tissue specimens. Keresztes G, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):383–92

Biochemical characterization of antigens detected with anti-platelet monoclonal antibodies. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):363–70

Platelet activation studies with anti-CD41/61 monoclonal antibodies. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):357–62

Ruminant cluster WC13. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):259–60

Analysis of bovine B cell reactive monoclonal antibodies. Mukwedeya DT, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):285–94

Ruminant cluster CD71. Naessens J, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):257–8

Separation of carp (Cyprinus carpio L.) thrombocytes by using a monoclonal antibody, and their aggregation by collagen. Nakayasu C, et al. **Vet Immunol Immunopathol** 1997 Jul;57(3–4):337–46

Two monoclonal antibodies from the platelet panel recognize sheep plasma fibrinogen. Pérez de la Lastra JM, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):371–5

Reactivity of monoclonal antibodies of the B cell panel on PBM from BLV-infected and lymphocytotic cows. Poli G, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):295–9

Characterization of monoclonal antibodies directed to canine T lymphocyte markers expressed during development. Rivas AL, et al. **Vet Immunol Immunopathol** 1996 May; 51(1–2):1–11

Identification of monoclonal antibodies with specificity to alpha- or beta-chains of beta 2-integrins using peripheral blood leucocytes of normal and bovine leucocyte adhesion deficient (BLAD) cattle. Rutten VP, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):341–5

Reactivity of monoclonal antibodies with bovine blood mononuclear cells activated by mitogens and superantigens. Schuberth HJ, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):313–21

Immunohistochemical reactivity of anti-platelet monoclonal antibodies. Simon M, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):377–82

Identification of bovine CD14. Sopp P, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):323–8

Appendices. Sopp P. **Vet Immunol Immunopathol** 1996 Aug; 52(4):445–68

Investigation of PC36 (BoCD45R). Sopp P, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):271–4

Cluster analysis. Sopp P. **Vet Immunol Immunopathol** 1996 Aug;52(4):237–44

A platelet activation-specific monoclonal antibody that recognizes a receptor-induced binding site on canine fibrinogen. Boudreaux MK, et al. **Vet Pathol** 1996 Jul; 33(4):419–27

Rapid identification of porcine Serpulina species by colony blot assay using a genus-specific monoclonal antibody [see comments] Achacha M, et al. **Vet Rec** 1996 Nov 30; 139(22):539–41. Comment in: Vet Rec 1997 Jan 11;140(2):51–2.

Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Miettinen M, et al. **Virchows Arch** 1996 Nov;429(4–5):213–9

Probing phage PRD1-specific proteins with monoclonal and polyclonal antibodies. Hänninen AL, et al. **Virology** 1997 Jan 6;227(1):198–206

Monoclonal antibody C38 recognizes retinal ganglion cells in cats and rats. Wakabayashi T, et al. **Vision Res** 1996 Apr;36(8):1081–90

Fine characterization of a series of new monoclonal antibodies directed against glycophorin A. Rasamoelisolo M, et al. **Vox Sang** 1997;72(3):185–91

Commercially available antibodies to human interleukin-1 do not crossreact with porcine interleukin-1. Holst H, et al. **Zentralbl Veterinarmed [B]** 1996 Jul;43(5):317–9

[The sensitizing role of the anti-idiotypic monoclonal antibody-NP30 of Schistosoma japonicum in egg granuloma formation] Feng Z, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(4):249–54 (Eng. Abstr.) **(Chi)**

[Human monoclonal antibody against enzyme treated erythrocytes] Wagner FF, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:40–2 **(Ger)**

[Juvenile Adamantiades-Behçet disease in decreased stimulation with anti-CD3 monoclonal antibody] Krüger K, et al. **Hautarzt** 1997 Apr;48(4):258–61 (Eng. Abstr.) **(Ger)**

[Micrometastases and their relation to monoclonal antibodies] **J Cancer Res Clin Oncol** 1996;122(1 Suppl):1–4 **(Ger)**

[Monoclonal antibodies against squamous epithelial carcinomas of the upper aerodigestive tract] Görögh T, et al. **Laryngorhinootologie** 1996 Nov;75(11):677–81 (Eng. Abstr.) **(Ger)**

[Cytotoxic action of monoclonal antibodies OC125 and SH-9 on ovarian cancer cell lines] Murakami F. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Feb;48(2):125–32 (Eng. Abstr.) **(Jpn)**

[Measurements of spreading cells and inhibitory assay using anti-adhesion molecule monoclonal antibodies] Hattori H, et al. **Rinsho Byori** 1996 Sep;Suppl 102:119–25 (15 ref.) **(Jpn)**

[Chemotaxis assay and chemotaxis inhibition assay by anti-adhesion molecule monoclonal antibodies] Shibayama H, et al. **Rinsho Byori** 1996 Sep;Suppl 102:133–9 (12 ref.) **(Jpn)**

[Monoclonal antibodies to 8-oxo-2'-deoxyguanosine (8-hydroxyguanosine). Characteristics and use for determining DNA damage by active forms of oxygen] Bruskov VI, et al. **Biokhimiia** 1996 Apr;61(4):737–44 (Eng. Abstr.) **(Rus)**

[Anti-idiotypic monoclonal antibodies against latrotoxin interact with rat brain synaptosomes and modify latrotoxin-induced calcium entry into synaptosomes] Pashkov VN, et al. **Bioorg Khim** 1996 Jun;22(6):403–7 (Eng. Abstr.) **(Rus)**

[Phage mimotopes of monoclonal antibodies against plasma membrane Ca2+-ATPase] Pestov NB, et al. **Bioorg Khim** 1996 Sep;22(9):664–70 (Eng. Abstr.) **(Rus)**

[Selectin receptors. 5. Monoclonal antibodies to the synthetic antigens SiaLe(a) and SiaLe(x)] Vlasova EV, et al. **Bioorg Khim** 1996 May;22(5):358–65 (Eng. Abstr.) **(Rus)**

[Thermodynamic parameters of binding of murine antitheophylline monoclonal antibodies 2G3 with theophylline] Pokid'ko IuN, et al. **Biull Eksp Biol Med** 1997 Apr;123(4):442–5 **(Rus)**

[Effect of specific antibodies on morphological characteristics of murine oocytes] Verbitskiĭ MSh, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):115–9 **(Rus)**

[An analysis of the specificity of anti-Mycobacterium monoclonal antibodies and of the chemical nature of the antigenic determinants with which they react] Avdienko VG, et al. **Probl Tuberk** 1996;(1):6–8 (Eng. Abstr.) **(Rus)**

[Preparation of monoclonal antibodies to gp51 antigen and their use for early diagnosis of bovine leukemia] Mikalauskene GI, et al. **Ukr Biokhim Zh** 1996 May-Jun; 68(3):89–94 (Eng. Abstr.) **(Rus)**

[Polyclonal immunoenzyme system for determining hantaviral antigens: assessment of specificity using monoclonal antibodies and the polymerase chain reaction] Ivanov AP, et al. **Vopr Virusol** 1996 May-Jun;41(3):110–2 (Eng. Abstr.) **(Rus)**

[Monoclonal anti-idiotypic antibodies, imitating the antigenic determinant of hemagglutination site of Venezuelan equine encephalomyelitis virus glycoprotein E2] Lifke VV, et al. **Vopr Virusol** 1997 Jan-Feb;42(1):19–23 (Eng. Abstr.) **(Rus)**

[The characterization of Francisella tularensis mutants and subspecies by using monoclonal antibodies] Aleshkin GI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul-Aug; (4):18–22 (Eng. Abstr.) **(Rus)**

[The immunochemical and biological properties of monoclonal antibodies to Chlamydia trachomatis] Kutlin AV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jan-Feb;(1):3–6 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Characterization of antibody 444 using chromatographically purified enantiomers of juvenile hormones I, II, and III: implications for radioimmunoassays. Cusson M, et al. **Anal Biochem** 1997 Jun 15;249(1):83–7

Recovery of monoclonal antibody from its complex with ligand. Miller CE, et al. **Anal Biochem** 1997 Feb 15; 245(2):179–83

Immunoenzyme assessment of human apoB-lipoprotein binding to immobilized receptor of low density lipoproteins. 1. Preparation of anti-receptor monoclonal antibodies. Tsibulsky VP, et al. **Biochemistry (Mosc)** 1997 Jun;62(6):596–602

Perfusion immunoaffinity chromatography and its application in analysis and purification of biomolecules. Zou H, et al. **Biomed Chromatogr** 1996 May-Jun;10(3):122–6

Characterization of LHTric-1, a new monospecific monoclonal antibody to the trichocyte keratin Ha1. Westgate GE, et al. **Br J Dermatol** 1997 Jul;137(1):24–30

Mitotic arrest in Ptk(2) cells induced by microinjection of a rabbit antiserum and affinity-purified antibodies against a 66-kDa PtK(2) cell polypeptide. Byrd P, et al. **Cell Motil Cytoskeleton** 1996;34(1):57–68

New monoclonal antibody (4E9R) identifies mouse neural crest cells [published erratum appears in Dev Dyn 1997 Jan;208(1):137] Kubota Y, et al. **Dev Dyn** 1996 Aug; 206(4):368–78

A rapid method for purification of monoclonal human IgM from mass culture. Vollmers HP, et al. **Hum Antibodies Hybridomas** 1996;7(1):37–41

Isolation and characterization of six monoclonal antibodies raised against human RAD51 recombinant protein. Buchhop S, et al. **Hybridoma** 1996 Jun;15(3):205–10

Purification by affinity chromatography with anti-idiotypic monoclonal antibodies of immunoreactive monoclonal antibodies following labeling with 188Re. Hamby CV, et al. **Hybridoma** 1997 Feb;16(1):27–31

Purification of monoclonal antibodies by simulated moving-bed chromatography. Gottschlich N, et al. **J Chromatogr A** 1997 Mar 28;765(2):201–6

Purification of the monoclonal heparin antibody H-1.18. Malsch R, et al. **J Chromatogr A** 1996 Sep 13; 744(1–2):215–21

Isolation of monoclonal antibodies from cell containing hybridoma broth using a protein A coated adsorbent in expanded beds. Thömmes J, et al. **J Chromatogr A** 1996 Nov 1;752(1–2):111–22

Characterization of a monoclonal antibody reacting with the free human luteinizing hormone beta-subunit. Pantel J, et al. **J Endocrinol** 1996 Nov;151(2):251–8

Reduction of bovine immunoglobulin contamination from monoclonal antibodies by SOURCE 15PHE chromatography. Grunfeld H, et al. **J Immunol Methods** 1997 Feb 28;201(2):233–41

Pilot scale purification of human monoclonal IgM (COU-1) for clinical trials. Tornøe I, et al. **J Immunol Methods** 1997 Jun 23;205(1):11–7

Polyvinyl alcohol-coated perfluorocarbon supports for metal chelating affinity separation of a monoclonal antibody. Morgan PE, et al. **J Mol Recognit** 1996 Sep-Dec; 9(5–6):394–400

Development and application of a modified monoclonal hybridoma technique for isolating monoclonal antibodies to human brain regions. Fukuyama R, et al. **J Neurosci Methods** 1996 Jan;64(1):135

A novel method for the non-chromatographic purification of technetium-99m-labeled monoclonal antibodies: a study with B72.3 monoclonal antibody. Rosenzweig HS, et al. **Nucl Med Biol** 1994 Feb;21(2):171–8

Immunohistochemical differentiation of monoclonal GAD antibodies recognizing linear or conformational epitope regions. Augstein P, et al. **Pancreas** 1997 Aug;15(2):139–46

Non-specific binding of mouse IgG1 to Heligmosomoides polygyrus: parasite homogenate can affinity purify mouse monoclonal antibodies. Robinson M, et al. **Parasitology** 1997 Jan;114 (Pt 1):79–84

Monoclonal antibodies against heparin and heparinoids. Huhle G, et al. **Semin Thromb Hemost** 1997;23(1):17–22

[The isolation and characteristics of monoclonal antibodies to Mycobacterium smegmatis and M. kansasii] Kulikovskaia NV, et al. **Probl Tuberk** 1996;(1):43–6 (Eng. Abstr.) **(Rus)**

ANTIBODIES, MONOCLONAL

METABOLISM

In vitro evaluation of iodine-125-labeled monoclonal antibody (MAb 425) in human high-grade glioma cells. Emrich JG, et al. **Am J Clin Oncol** 1996 Dec;19(6):601-8

Endothelial cells internalize monoclonal antibody to angiotensin-converting enzyme. Muzykantov VR, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L704-13

Monitoring papain digestion of a monoclonal antibody by electrospray ionization mass spectrometry. Bennett KL, et al. **Anal Biochem** 1997 Feb 1;245(1):17-27

Phosphorylation sensitivity of the commonly used anti-p185neu/erbB2 monoclonal antibody clone 3B5 suggests selective usage of autophosphorylation sites. DiGiovanna MP. **Anal Biochem** 1997 Apr 5;247(1):167-70

Recovery of monoclonal antibody from its complex with ligand. Miller CE, et al. **Anal Biochem** 1997 Feb 15; 245(2):179-83

Proteolytic activity in amyotrophic lateral sclerosis IgG preparations [see comments] Nyormoi O. **Ann Neurol** 1996 Nov;40(5):701-6. Comment in: Ann Neurol 1996 Nov;40(5):691-3.

Modulation of antibody kinetics by the cell membrane active agent tween 80 in vivo. Kairemo KA, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3542-50

Identification of a phosphodiester hexanucleotide that inhibits HIV-1 infection in vitro on covalent linkage of its 5'-end with a dimethoxytrityl residue. Furukawa H, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):167-75

Unsaturated fatty acids enhance cell yields and perturb the energy metabolism of an antibody-secreting hybridoma. Butler M, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):615-23

Mutational analysis of an antigenic peptide shows recognition in a loop conformation. Rondard P, et al. **Biochemistry** 1997 Jul 22;36(29):8962-8

Specific photoaffinity labeling of Tyr-49 on the light chain in the steroid-combining site of a mouse monoclonal anti-estradiol antibody using two epimeric 6alpha- and 6beta-(5-azido-2-nitrobenzoyl)amidoestradiol photoreagents. Rousselot P, et al. **Biochemistry** 1997 Jun 24;36(25):7860-8

Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment. Wu C, et al. **Bioconjug Chem** 1997 May-Jun;8(3):365-9

Cell targeting of a pore-forming toxin, CytA delta-endotoxin from Bacillus thuringiensis subspecies israelensis, by conjugating CytA with anti-Thy 1 monoclonal antibodies and insulin. al-yahyaee SA, et al. **Bioconjug Chem** 1996 Jul-Aug;7(4):451-60

Accumulation of NCC-CO-411 monoclonal antibody in human colorectal adenocarcinoma through binding of the released carcinoembryonic antigen in nude mice. Wang DS, et al. **Biol Pharm Bull** 1996 Jul;19(7):915-21

Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients. de Bree R, et al. **Br J Cancer** 1997;75(7):1049-60

Antibody-mediated gene delivery for B-cell lymphoma in vitro. Schachtschabel U, et al. **Cancer Gene Ther** 1996 Nov-Dec;3(6):365-72

Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Heider KH, et al. **Cancer Immunol Immunother** 1996 Dec;43(4):245-53

Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy. Pietersz GA, et al. **Cancer Immunol Immunother** 1997 Aug;44(6):323-8

Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Reist CJ, et al. **Cancer Res** 1996 Nov 1;56(21):4970-7

Autoimmune MRL mice express high-affinity IgG2b monoclonal autoantibodies to heparin. Fillit H, et al. **Clin Immunol Immunopathol** 1996 Oct;81(1):62-7

Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor. Liautard J, et al. **Cytokine** 1997 Apr;9(4):233-41

Flow cytometric analysis of in vivo polyamine deprivation in Lewis lung carcinoma (3LL) cells using the monoclonal antibody SPM8-2. Delcros JG, et al. **Cytometry** 1997 Mar 1;27(3):255-61

Measurement of antibody-antigen dissociation constants using fast capillary electrophoresis with laser-induced fluorescence detection. Tao L, et al. **Electrophoresis** 1997 Jan;18(1):112-7

Efficient and selective p-nitrophenyl-ester-hydrolyzing antibodies elicited by a p-nitrobenzyl phosphonate hapten. Tawfik DS, et al. **Eur J Biochem** 1997 Mar 1;244(2):619-26

The influence of salts on the reaction between hGH and several of its monoclonal antibodies in fixed, paraffin-embedded human pituitary as a model system. Montero C, et al. **Eur J Histochem** 1996;40(2):153-8

Studies of high thermostability and peroxidase activity of recombinant antibody L chain-porphyrin Fe(III) complex. Kohda K, et al. **FEBS Lett** 1997 May 5;407(3):280-4

Establishment of monoclonal antibodies against carbohydrate moiety of gastric mucins distributed in the different sites and layers of rat gastric mucosa. Ishihara K, et al. **Glycoconj J** 1996 Oct;13(5):857-64

Anti-HLA antibody ligation to HLA class I molecules expressed by endothelial cells stimulates tyrosine phosphorylation, inositol phosphate generation, and proliferation. Bian H, et al. **Hum Immunol** 1997 Mar; 53(1):90-7

Two widely used anti-DR alpha monoclonal antibodies bind to an intracellular C-terminal epitope. Grüneberg U, et al. **Hum Immunol** 1997 Mar;53(1):34-8

Molecular requirements for polyamines binding to the antispermine monoclonal antibody Spm8-2. Delcros JG, et al. **Hybridoma** 1996 Jun;15(3):177-83

Monoclonal antibody to heparan sulfate from autoimmune tight skin (TSK) mice binds to the endothelial cell surface. Matic M, et al. **Immunol Invest** 1997 Apr;26(3):371-81

Modified antigen-binding of human antibodies with glycosylation variations of the light chains produced in sugar-limited human hybridoma cultures. Tachibana H, et al. **In Vitro Cell Dev Biol Anim** 1996 Mar;32(3):178-83

In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Nishimura Y, et al. **Int Immunol** 1997 Feb;9(2):307-16

CD4+ CD45RA+ T cells from adults respond to recall antigens after CD28 ligation. Pilling D, et al. **Int Immunol** 1996 Nov;8(11):1737-42

Monoclonal IgG as antigens: reduction is an early intracellular event of their processing by antigen-presenting cells. Santoro L, et al. **Int Immunol** 1996 Feb;8(2):211-9

Synthesis of a new class of isothiocyanatopeptide bifunctional chelating agents for coupling to monoclonal antibodies. Ram S, et al. **Int J Pept Protein Res** 1996 Jul;48(1):79-86

Kinetic characterization of antibody-catalyzed insertion of a metal ion into porphyrin. Kawamura-Konishi Y, et al. **J Biochem (Tokyo)** 1996 May;119(5):857-62

Structural interlock between ligand-binding site and stalk-like region of beta1 integrin revealed by a monoclonal antibody recognizing conformation-dependent epitope. Takagi J, et al. **J Biochem (Tokyo)** 1997 May;121(5):914-21

Mimicry between receptors and antibodies. Identification of snake toxin determinants recognized by the acetylcholine receptor and an acetylcholine receptor-mimicking monoclonal antibody. Ducancel F, et al. **J Biol Chem** 1996 Dec 6;271(49):31345-53

Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. Lin CY, et al. **J Biol Chem** 1997 Apr 4; 272(14):9147-52

Phosphorylation-dependent monoclonal Tau antibodies do not reliably report phosphorylation by extracellular signal-regulated kinase 2 at specific sites. Roder HM, et al. **J Biol Chem** 1997 Feb 14;272(7):4509-15

Changes in binding affinity of a monoclonal antibody to a platelet binding domain of fibrinogen adsorbed to biomaterials. Grunkemeier J, et al. **J Biomater Sci Polym Ed** 1996;8(3):189-209

Critical evaluation of the applicability of capillary zone electrophoresis for the study of hapten-antibody complex formation. Busch MH, et al. **J Chromatogr A** 1996 Sep 13;744(1-2):195-203

Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. Nussbaum G, et al. **J Exp Med** 1997 Feb 17;185(4):685-94

Triggering of motile behavior in T lymphocytes via cross-linking of alpha 4 beta 1 and alpha L beta 2. Hauzenberger D, et al. **J Immunol** 1997 Jan 1;158(1):76-84

Molecular characterization of Bip 1, a monoclonal antibody that modulates IgE binding to birch pollen allergen, Bet v 1. Laffer S, et al. **J Immunol** 1996 Dec 1;157(11):4953-62

Fc gamma receptor cross-linking activates p42, p38, and JNK/SAPK mitogen-activated protein kinases in murine macrophages: role for p42MAPK in Fc gamma receptor-stimulated TNF-alpha synthesis. Rose DM, et al. **J Immunol** 1997 Apr 1;158(7):3433-8

Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. Werther WA, et al. **J Immunol** 1996 Dec 1;157(11):4986-95

Dot-blot analysis of the degree of covalent modification of proteins and antibodies at amino groups. Morçöl T, et al. **J Immunol Methods** 1997 Apr 11;203(1):45-53

Use of a modified binding model for the investigation of affinity dependence on antibody concentration in immunoassay systems. Strohner P, et al. **J Immunol Methods** 1997 Apr 25;203(2):113-22

Comparative molecular field analysis of haptens docked to the multispecific antibody IgE(Lb4). Gamper AM, et al. **J Med Chem** 1996 Sep 27;39(20):3882-8

Development of a cell culture system to study antibody convection in tumors. DeSilva BS, et al. **J Pharm Sci** 1997 Jul;86(7):858-64

Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. Fox JA, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):1000-8

Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor. Friden PM, et al. **J Pharmacol Exp Ther** 1996 Sep; 278(3):1491-8

Binding and internalization of anti-sarcoma IgG and IgM antibodies. Chao TC, et al. **J Surg Res** 1997 Jun;70(1):27-33

Two chicken B cell lines resistant to ouabain for the production of chicken monoclonal antibodies. Nishinaka S, et al. **J Vet Med Sci** 1996 Nov;58(11):1053-6

Characterisation of the binding sites of monoclonal antibodies reacting with the Plasmodium falciparum rhoptry protein RhopH3. Doury JC, et al. **Mol Biochem Parasitol** 1997 Apr;85(2):149-59

Binding of monoclonal antibodies to platelet glycoproteins Ib and IIb/IIIa in uremic patients. Komarnicki M, et al. **Nephron** 1997;75(3):283-5

Cellular phosphorylation of neurofilament heavy-chain by cyclin-dependent kinase-5 masks the epitope for monoclonal antibody N52. Guidato S, et al. **Neurosci Lett** 1996 Oct 18;217(2-3):157-60

The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody. Hauck ML, et al. **Nucl Med Biol** 1996 May; 23(4):551-7

Thermodynamic analysis of monoclonal antibody binding to duplex DNA. Tanha J, et al. **Nucleic Acids Res** 1997 Apr 1;25(7):1442-9

Monoclonal antibodies specific for underphosphorylated retinoblastoma protein identify a cell cycle regulated phosphorylation site targeted by CDKs. Zarkowska T, et al. **Oncogene** 1997 Jan 16;14(2):249-54

Antibody mediated lung targeting of long-circulating emulsions. Song YK, et al. **PDA J Pharm Sci Technol** 1996 Nov-Dec;50(6):372-7

Direct in vivo measurement of targeted binding in a human tumor xenograft. Berk DA, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1785-90

A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing [published erratum appears in Protein Eng 1997 Feb;10(2):181] Roguska MA, et al. **Protein Eng** 1996 Oct; 9(10):895-904

Hyperexpression of chicken riboflavin carrier protein: antibodies to the recombinant protein curtail pregnancy in rodents. Sooryanarayana, et al. **Protein Expr Purif** 1996 Mar;7(2):147-54

Binding of site-directed monoclonal antibodies to an epitope located in the A/B region (amino acids 140-154) of human estrogen receptor-induced conformational changes in an epitope in the DNA-binding domain. Traish AM, et al. **Steroids** 1996 Sep;61(9):549-56

Production and characterization of monoclonal antibodies against stonustoxin from Synanceja horrida. Yuen R, et al. **Toxicon** 1995 Dec;33(12):1557-64

Differential binding of two monoclonal antibodies directed against the chicken CD8 alpha molecule. Breed DG, et al. **Vet Immunol Immunopathol** 1996 Jun 15;52(1-2):117-25

A platelet activation-specific monoclonal antibody that recognizes a receptor-induced binding site on canine fibrinogen. Boudreaux MK, et al. **Vet Pathol** 1996 Jul; 33(4):419-27

PHARMACOKINETICS

Effect of pre-irradiation on radiopharmaceutical localization in human colon tumor xenografts using mono- and bispecific monoclonal antibodies. Gridley DS, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3453-8

Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin. Wilbur DS, et al. **Bioconjug Chem** 1996 Nov-Dec;7(6):689-702

Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Mosure KW, et al. **Cancer Chemother Pharmacol** 1997; 40(3):251-8

Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft. Stribbling SM, et al. **Cancer Chemother Pharmacol** 1997; 40(4):277-84

Analysis of specific accumulation of radiolabeled anti-carcinoembryonic antigen monoclonal antibody CEA 102 in colorectal cancer using computed radiography. Watanabe T, et al. **Cancer Detect Prev** 1997;21(4):346-54

Postural effects on peritoneal transport and systemic uptake of radiolabeled monoclonal antibodies. Barrett JS, et al. **Cancer Immunol Immunother** 1997 May;44(3):173-8

Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Sharkey RM, et al. **Cancer Immunol Immunother** 1997 May; 44(3):179-88

Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice. van Gog FB, et al. **Cancer Immunol Immunother** 1997 Apr;44(2):103-11

Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose. van Hof AC, et al. **Cancer Res** 1996 Nov 15;56(22):5179-85

Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice. Newkirk MM, et al. **Clin Exp Immunol** 1996 Nov;106(2):259-64

Disposition of metabolically radiolabeled CE9.1--a macaque-human chimeric anti-human CD4 monoclonal antibody--in transgenic mice bearing human CD4. Davis CB, et al. **Drug Metab Dispos** 1996 Sep;24(9):1032-7

Biodistribution of 125I-MAb 425 in a human glioma xenograft model: effect of chloroquine. Emrich JG, et al. **Hybridoma** 1997 Feb;16(1):93-100

Biodistribution of anti-breast mucin HuBrE3-derived inverted Fabs (IFabs) in nude mice carrying MX-1 xenografts. Speck RR, et al. **Hybridoma** 1997 Jun; 16(3):243-8

Relationship between ZCE 025 blood clearance and liver accumulation in patients with colorectal cancer. Slater JB,

et al. **Immunopharmacology** 1996 Nov;35(2):111–8
Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer. Kievit E, et al. **Int J Cancer** 1997 Apr 10;71(2):237–45
Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas. Merlo A, et al. **Int J Cancer** 1997 May 29;71(5):810–6
A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Hauck ML, et al. **Int J Hyperthermia** 1997 May-Jun;13(3):307–16
Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy. Goldman DL, et al. **J Med Vet Mycol** 1997 Jul-Aug; 35(4):271–8
Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. Delaloye AB, et al. **J Nucl Med** 1997 Jun;38(6):847–53
Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. Lövqvist A, et al. **J Nucl Med** 1997 Mar;38(3):395–401
Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. Meijs WE, et al. **J Nucl Med** 1997 Jan;38(1):112–8
Tumor uptake and metabolism of copper-67-labeled monoclonal antibody chCE7 in nude mice bearing neuroblastoma xenografts. Novak-Hofer I, et al. **J Nucl Med** 1997 Apr;38(4):536–44
Manipulation of blood clearance to optimize delivery of residualizing label-antibody conjugates to tumor cells in vivo. Stein R, et al. **J Nucl Med** 1997 Sep;38(9):1392–400
A dose-searching trial of an anti-LFA1 monoclonal antibody in first kidney transplant recipients. Le Mauff B, et al. **Kidney Int Suppl** 1996 Jan;53:S44–50
125I-labelling of an internally 75Se-labelled monoclonal antibody--biodistribution in tumour-bearing nude mice. Grétarsdóttir J, et al. **Nucl Med Biol** 1994 Nov; 21(8):1017–21
Tumor-specific accumulation of 125I-labeled mouse-human chimeric anti-CEA antibody in a xenografted human cancer model demonstrated by whole-body autoradiography and immunostaining. Haruno M, et al. **Nucl Med Biol** 1996 Aug;23(6):821–6
The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody. Hauck ML, et al. **Nucl Med Biol** 1996 May; 23(4):551–7
Effect of induced hypertension with angiotensin II infusion on biodistribution of 111in-labeled monoclonal antibody. Kinuya S, et al. **Nucl Med Biol** 1996 Feb;23(2):137–40
Augmenting of tumor uptake of anti-melanoma antibody MEM136: influence of interferon. Li J, et al. **Nucl Med Biol** 1996 Oct;23(7):873–9
Preclinical evaluation and PET imaging of 18F-labeled Mel-14 F(ab')2 fragment in normal dogs. Page RL, et al. **Nucl Med Biol** 1994 Oct;21(7):911–9
Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. Zalutsky MR, et al. **Nucl Med Biol** 1996 May;23(4):449–58
Immunoreactivity, stability, pharmacokinetics and biodistribution of a monoclonal antibody to human leukemic B cells after three different methods of radioiodination. Zhu Z, et al. **Nucl Med Biol** 1994 Aug; 21(6):873–82
Factors influencing the in vivo pharmacokinetics of peptides and antibody fragments: the pharmacokinetics of two PET-labeled low molecular weight proteins. Lang L, et al. **Q J Nucl Med** 1997 Jun;41(2):53–61
Studies on metabolism of directly labeled 99mTc-antibody in mice. Xue LY, et al. **Q J Nucl Med** 1996 Dec; 40(4):341–50
Role of transchelation in the uptake of 99mTc-MAb in liver and kidney. Xue LY, et al. **Q J Nucl Med** 1997 Mar; 41(1):10–7
Distribution of monoclonal antibodies in intestinal and urogenital secretions of mice bearing hybridoma 'backpack' tumours. Haneberg B, et al. **Scand J Immunol** 1997 Feb; 45(2):151–9
Safety and kinetic properties of a humanized antibody to human interleukin-6 receptor in healthy non-human primates. Shinkura H, et al. **Toxicology** 1997 Oct 19; 122(3):163–70
Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients. Kovarik JM, et al. **Transpl Int** 1996; 9 Suppl 1:S32–3

PHARMACOLOGY

The effect of anti-VLA-4 monoclonal antibody on eosinophil accumulation and leukotriene production in nasal mucosa. Terada N, et al. **Acta Otolaryngol (Stockh)** 1996 Nov; 116(6):883–7
Effect of neonatal treatment with monoclonal antibody to thyrotropin (TSH) receptor on the thyroxin (T4) level and certain parameters of the internal genital organs of adult rats. Karabélyos C, et al. **Acta Physiol Hung** 1996; 84(1):25–32
Monoclonal antibodies to the distinct antigenic sites on glycoproteins C and B and their protective abilities in herpes simplex virus infection. Bystrická M, et al. **Acta Virol** 1997 Feb;41(1):5–12
Induction of fibroblast apoptosis by anti-CD44 antibody: implications for the treatment of fibroproliferative lung disease. Henke C, et al. **Am J Pathol** 1996 Nov; 149(5):1639–50
Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs. Perez RG, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H53–64
Human cytotrophoblastic cells absorb the NK blocking activity of monoclonal BA11. Cadavid AP, et al. **Am J Reprod Immunol** 1997 Jan;37(1):73–8
Immunosuppressive properties of monoclonal antibodies and human polyclonal alloantibodies to the R80K protein of trophoblast. Jalali GR, et al. **Am J Reprod Immunol** 1996 Sep;36(3):129–34
Effect of tumor necrosis factor antibody on synovial fluid cytokine activities in equine antebrachiocarpal joints injected with endotoxin. Hawkins DL, et al. **Am J Vet Res** 1995 Oct;56(10):1292–9
A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients. Greilich PE, et al. **Anesth Analg** 1997 Jan;84(1):31–8
Inhibition of monocyte and polymorphonuclear granulocyte immune phagocytosis by monoclonal antibodies specific for Fc gamma RI, II and III. Flesch BK, et al. **Ann Hematol** 1997 Jan;74(1):15–22
In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Maier JA, et al. **Anticancer Drugs** 1997 Mar;8(3):238–44
Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa. Lamp KC, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):247–52
Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Selvam MP, et al. **Antiviral Res** 1996 Dec; 33(1):11–20
Impaired CD25 expression and soluble CD25-IL-2R alpha receptor release by anti-CD3 stimulated peripheral blood mononuclear cells in Hodgkin's disease patients. Frydecka I, et al. **Arch Immunol Ther Exp (Warsz)** 1996; 44(2-3):127–30
Analysis of galanin and the galanin antagonist M40 on delayed non-matching-to-position performance in rats lesioned with the cholinergic immunotoxin 192 IgG-saporin. McDonald MP, et al. **Behav Neurosci** 1997 Jun;111(3):552–63
Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal antibody against P-glycoprotein. Kokubu N, et al. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):398–401
A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Reyes AE, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):652–5
Characterization of the novel murine monoclonal anti-von Willebrand factor (vWf) antibody GUR76-23 which inhibits vWf interaction with alpha IIb beta 3 but not alpha v beta 3 integrin. Yokoyama K, et al. **Biochem Biophys Res Commun** 1997 May 8;234(1):147–52
Intracellular single-chain antibody inhibits integrin VLA-4 maturation and function. Yuan Q, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):591–6
A monoclonal antibody specific for carboxy-terminal region of yeast translation elongation factor-3 inhibits ribosome-activated ATPase activity but not intrinsic ATPase activity. Masahiro U, et al. **Biochem Mol Biol Int** 1996 May;39(2):227–34
Inhibition of preprotein translocation and reversion of the membrane inserted state of SecA by a carboxyl terminus binding mAb. den Blaauwen T, et al. **Biochemistry** 1997 Jul 29;36(30):9159–68
Mapping of epitopes on porcine zona pellucida-3 alpha by monoclonal antibodies inhibiting oocyte-sperm interaction. Gupta SK, et al. **Biol Reprod** 1996 Aug;55(2):410–5
Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Katsuragawa H, et al. **Biol Reprod** 1997 Jan; 56(1):50–8
Antibodies to HLA class I alpha1 domain trigger apoptosis of CD40-activated human B lymphocytes. Genestier L, et al. **Blood** 1997 Jul 15;90(2):726–35
Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Hornick JL, et al. **Blood** 1997 Jun 15; 89(12):4437–47
Antibodies to transcobalamin II block in vitro proliferation of leukemic cells. McLean GR, et al. **Blood** 1997 Jan 1; 89(1):235–42
Hyaluronate-CD44 interactions can induce murine B-cell activation. Rafi A, et al. **Blood** 1997 Apr 15;89(8):2901–8
Differential effect of E-selectin antibodies on neutrophil rolling and recruitment to inflammatory sites. Ramos CL, et al. **Blood** 1997 Apr 15;89(8):3009–18
Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Schneider H, et al. **Blood** 1997 Jan 15;89(2):473–82
Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Tsai HM, et al. **Blood** 1997 Mar 15;89(6):1954–62
Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein Ib monoclonal antibody. Yanabu M, et al. **Blood** 1997 Mar 1;89(5):1590–8
Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity. Condiotti R, et al. **Bone Marrow Transplant** 1996 Oct;18(4):713–20
Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata. Di Massimo AM, et al. **Br J Cancer** 1997; 75(6):822–8
The effect of R 15.7/HO, an anti-CD18 antibody, on the late airway response and airway hyperresponsiveness in an allergic rabbit model. el-Hashim AZ, et al. **Br J Pharmacol** 1997 Jun;121(4):671–8
Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Kageyama S, et al. **Br J Pharmacol** 1997 Sep;122(1):165–71
Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Brennan FM, et al. **Br J Rheumatol** 1997 Jun;36(6):643–50
Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy [letter] Wendling D, et al. **Br J Rheumatol** 1996 Dec;35(12):1330
Intraseptal injection of the cholinergic immunotoxin 192-IgG saporin fails to disrupt latent inhibition in a conditioned taste aversion paradigm. Dougherty KD, et al. **Brain Res** 1996 Oct 14;736(1-2):260–9
The basal forebrain cholinergic system and object memory in the rat. Vnek N, et al. **Brain Res** 1996 Feb 26; 710(1-2):265–70
Injection of IgG 192-saporin into the medial septum produces cholinergic hypofunction and dose-dependent working memory deficits. Walsh TJ, et al. **Brain Res** 1996 Jul 8; 726(1-2):69–79
A specific and highly sensitive time-resolved fluoroimmunoassay for human proinsulin. Dalbosco IS, et al. **Braz J Med Biol Res** 1996 Feb;29(2):193–9
Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Witters LM, et al. **Breast Cancer Res Treat** 1997 Jan;42(1):1–5
Further characterization of cytotoxic T cells generated by short-term culture of human peripheral blood lymphocytes with interleukin-2 and anti-CD3 mAb. Jacobs N, et al. **Cancer Immunol Immunother** 1996 Jul;42(6):369–75
Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy. Pietersz GA, et al. **Cancer Immunol Immunother** 1997 Aug;44(6):323–8
Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: enhancement with interferon gamma. Takamuku K, et al. **Cancer Immunol Immunother** 1996 Dec;43(4):220–5
Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins. Vooijs WC, et al. **Cancer Immunol Immunother** 1996 Jul; 42(6):319–28
A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Hu P, et al. **Cancer Res** 1996 Nov 1; 56(21):4998–5004
CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Mazzoni A, et al. **Cancer Res** 1996 Dec 1;56(23):5443–9
Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Trail PA, et al. **Cancer Res** 1997 Jan 1;57(1):100–5
Visualization of Golgi apparatus in methacrylate embedded conifer embryo tissue using the monoclonal antibody JIM 84. Evans DE, et al. **Cell Biol Int** 1997 May;21(5):295–302
Monoclonal antibodies recognizing the N- and C-terminal regions of talin disrupt actin stress fibers when microinjected into human fibroblasts. Bolton SJ, et al. **Cell Motil Cytoskeleton** 1997;36(4):363–76
Inhibition of flagellar beat frequency by a new anti-beta-tubulin antibody. Cosson J, et al. **Cell Motil Cytoskeleton** 1996;35(2):100–12
Effect of monoclonal antibodies on the entry and development of Plasmodium vivax sporozoite in cultured cells. Luo S, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(4):284–9
In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Ammar T, et al. **Circulation** 1997 Feb 4;95(3):614–7
Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Coller BS, et al. **Circulation** 1997 Feb 18;95(4):860–7
Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Makkar RR, et al. **Circulation** 1997 Feb 18;95(4):1015–21
Effects of monoclonal antibody to P-selectin and analogue of sialyl Lewis X on cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. Ueyama T,

et al. **Circulation** 1997 Mar 18;95(6):1554–9

Inhibition of intimal hyperplasia after balloon injury by antibodies to intercellular adhesion molecule–1 and lymphocyte function–associated antigen–1 [see comments] Yasukawa H, et al. **Circulation** 1997 Mar 18;95(6):1515–22 . Comment in: Circulation 1997 Mar 18;95(6):1355–6.

The effect of anti–IL–4 monoclonal antibody, rapamycin and interferon–gamma on airway hyperreactivity to acetylcholine in mice. Nagai H, et al. **Clin Exp Allergy** 1997 Feb;27(2):218–24

Human monoclonal rheumatoid factors augment arthritis in mice by the activation of T cells. Ezaki I, et al. **Clin Exp Immunol** 1996 Jun;104(3):474–82

Anti–CD8 treatment reduces the severity of inflammatory arthritis, but not vasculitis, in mercuric chloride–induced autoimmunity. Kiely PD, et al. **Clin Exp Immunol** 1996 Nov;106(2):280–5

The mode of action of treatment by IgG of haemolytic anaemia induced by an anti–erythrocyte monoclonal antibody. Pottier Y, et al. **Clin Exp Immunol** 1996 Oct; 106(1):103–7

A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC–CE9.1) to human CD4. Anderson D, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):73–84

Modulation of bovine leukemia virus–associated spontaneous lymphocyte proliferation by monoclonal antibodies to lymphocyte surface molecules. Stone DM, et al. **Clin Immunol Immunopathol** 1997 May;83(2):156–64

The promise and pitfalls of monoclonal antibody therapeutics. Berkower I. **Curr Opin Biotechnol** 1996 Dec; 7(6):622–8 (50 ref.)

Specific inhibition of IL–6 signalling with monoclonal antibodies against the gp130 receptor. Liautard J, et al. **Cytokine** 1997 Apr;9(4):233–41

Enhancement of the insulin antagonistic effect of porcine somatotropin in swine using a monoclonal antibody. Kraft LA, et al. **Domest Anim Endocrinol** 1996 Nov;13(6):529–37

Soluble tumour necrosis factor receptor release after anti–CD3 monoclonal antibody treatment in mice is independent of tumour necrosis factor–alpha release. Vossen AC, et al. **Eur Cytokine Netw** 1996 Dec;7(4):751–5

Antigen–independent responsiveness to interleukin–4 demonstrates differential regulation of newborn human T cells. Early EM, et al. **Eur J Immunol** 1996 Dec; 26(12):2885–9

T cell sensitivity to HLA class I–mediated apoptosis is dependent on interleukin–2 and interleukin–4. Genestier L, et al. **Eur J Immunol** 1997 Feb;27(2):495–9

gp160 of HIV or anti–CD4 monoclonal antibody ligation of CD4 induces inhibition of JNK and ERK–2 activities in human peripheral CD4+ T lymphocytes. Jabado N, et al. **Eur J Immunol** 1997 Feb;27(2):397–404

Effect of CD80 and CD86 blockade and anti–interleukin–12 treatment on mouse acute graft–versus–host disease. Saito K, et al. **Eur J Immunol** 1996 Dec;26(12):3098–106

Differential response of CD4+ V7+ and CD4+ V7– T cells to T cell receptor–dependent signals: CD4+ V7+ T cells are co–stimulation independent and anti–V7 antibody blocks the induction of anergy by bacterial superantigen. Soares LR, et al. **Eur J Immunol** 1997 Jun;27(6):1413–21

Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants. Thilenius AR, et al. **Eur J Immunol** 1997 May; 27(5):1108–14

Neurite outgrowth inhibitor of gliotic brain tissue. Mode of action and cellular localization, studied with specific monoclonal antibodies. Bovolenta P, et al. **Eur J Neurosci** 1997 May;9(5):977–89

192 IgG–saporin–induced loss of cholinergic neurons in the septum abolishes cholinergic sprouting after unilateral entorhinal lesion in the rat. Naumann T, et al. **Eur J Neurosci** 1997 Jun;9(6):1304–13

Induction of apoptosis and potentiation of TNF– and Fas–mediated apoptosis in U937 cells by the xanthogenate compound D609. Pörn–Ares MI, et al. **Exp Cell Res** 1997 Aug 25;235(1):48–54

Stimulation of B–chronic lymphocytic leukemia cells by murine fibroblasts, IL–4, anti–CD40 antibodies, and the soluble CD40 ligand. Buske C, et al. **Exp Hematol** 1997 Apr;25(4):329–37

Monoclonal antibody crosslinking of the alpha 4 or beta 1 integrin inhibits committed clonogenic hematopoietic progenitor proliferation. Hurley RW, et al. **Exp Hematol** 1997 Apr;25(4):321–8

Antibodies to the beta 1–integrin chain, CD44, or ICAM–3 stimulate adhesion of blast colony–forming cells and may inhibit their growth. Oostendorp RA, et al. **Exp Hematol** 1997 Apr;25(4):345–9

Neurite outgrowth is enhanced by anti–idiotypic monoclonal antibodies to the ganglioside GM1. Riggott MJ, et al. **Exp Neurol** 1997 May;145(1):278–87

In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5–fluorouridine to antiadenocarcinoma monoclonal antibody. Brusa P, et al. **Farmaco** 1997 Feb; 52(2):71–81

Targeted delivery of diphtheria toxin via immunoliposomes: efficient antitumor activity in the presence of inactivating anti–diphtheria toxin antibodies. Vingerhoeds MH, et al. **FEBS Lett** 1996 Oct 21;395(2–3):245–50

Molecular analysis of the modulatory factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. Bouige P, et al. **FEMS Immunol Med Microbiol** 1996 Jan;13(1):71–9

Comparison of the antiplatelet agent potential of the whole molecule, F(ab)2 and Fab fragments of humanized anti–GPIIb/IIIa monoclonal antibody in monkeys. Kaku S, et al. **Gen Pharmacol** 1996 Apr;27(3):435–9

Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti–CD4 treatment of the host. Poller W, et al. **Gene Ther** 1996 Jun;3(6):521–30

A new procedure for establishing functional monoclonal antibodies capable of inhibiting E– or P–selectin–dependent cell adhesion. Handa K, et al. **Glycoconj J** 1997 Jan; 14(1):39–43

The effects of N–acetylcysteine and anti–intercellular adhesion molecule–1 monoclonal antibody against ischemia–reperfusion injury of the rat steatotic liver produced by a choline–methionine–deficient diet. Nakano H, et al. **Hepatology** 1997 Sep;26(3):670–8

Immune stimulatory and anti–tumor properties of anti–CD3 and BAT monoclonal antibodies: a comparative study. Hardy B, et al. **Hum Antibodies** 1997;8(2):95–8

Prevention of immune reactions triggered by first–generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Guérette B, et al. **Hum Gene Ther** 1996 Aug 1;7(12):1455–63

Anti–HLA antibody ligation to HLA class I molecules expressed by endothelial cells stimulates tyrosine phosphorylation, inositol phosphate generation, and proliferation. Bian H, et al. **Hum Immunol** 1997 Mar; 53(1):90–7

Monoclonal antibodies against the 43,000 Da glycoprotein from Paracoccidioides brasiliensis modulate laminin–mediated fungal adhesion to epithelial cells and pathogenesis. Gesztesi JL, et al. **Hybridoma** 1996 Dec; 15(6):415–22

Conformational changes in CD45 upon monoclonal antibody crosslinking. Hamann D, et al. **Hybridoma** 1996 Feb; 15(1):11–6

OVAREX MAb–B43.13:IFN–gamma could improve the ovarian tumor cell sensitivity to CA125–specific allogenic cytotoxic T cells. Madiyalakan R, et al. **Hybridoma** 1997 Feb;16(1):41–5

A potential mechanism of action of an antibody (HIS45) which has been shown to induce prolonged graft survival. Aspinall R. **Immunobiology** 1996;196(4):425–36

Binding of human leukocytes to fibronectin is augmented by an anti–CD44 mAb (TL–1) and blocked by another anti–CD44 mAb (Hermes–3) but not by anti–VLA–4/VLA–5 mAbs. Cao L, et al. **Immunobiology** 1996–97;196(5):504–12

Anti–CD53 monoclonal antibody induced LFA–1/ICAM–1–dependent and –independent lymphocyte homotypic cell aggregation. Cao L, et al. **Immunobiology** 1997 Jun;197(1):70–81

Immunosuppression by anti–ICAM–1 and anti–LFA–1 monoclonal antibodies of free and vascularized skin allograft rejection. Iwata T, et al. **Immunobiology** 1996 Jul; 195(2):160–71

Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection. Rukavina T, et al. **Infect Immun** 1997 May;65(5):1754–60

A monoclonal antibody to Borrelia burgdorferi flagellin modifies neuroblastoma cell neuritogenesis in vitro: a possible role for autoimmunity in the neuropathy of Lyme disease. Sigal LH, et al. **Infect Immun** 1997 May; 65(5):1722–8

Administration of neutralizing antibody against rabbit IL–1 receptor antagonist exacerbates lipopolysaccharide–induced arthritis in rabbits. Fukumoto T, et al. **Inflamm Res** 1996 Sep;45(9):479–85

ICAM–1–, –2– and LFA–1–independent homotypic T cell aggregation induced by a novel activating monoclonal antibody targeting the murine Thy–1 molecule. Fan X, et al. **Inflammation** 1996 Aug;20(4):401–11

Immobilized anti–CD3 mAb induces anergy in murine naive and memory CD4+ T cells in vitro. Chai JG, et al. **Int Immunol** 1997 Jul;9(7):935–44

Induction of Fas–dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis. Hasunuma T, et al. **Int Immunol** 1996 Oct;8(10):1595–602

An anti–CD2 mAb induces immunosuppression and hyporesponsiveness of CD2+ human T cells in vitro. Latinne D, et al. **Int Immunol** 1996 Jul;8(7):1113–9

A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system inflammation and increases virus expression after Theiler's virus–induced demyelination. Miller DJ, et al. **Int Immunol** 1996 Jan;8(1):131–41

IL–4 and anti–CD40 protect against Fas–mediated B cell apoptosis and induce B cell growth and differentiation. Nakanishi K, et al. **Int Immunol** 1996 May;8(5):791–8

In vivo analysis of Fas antigen–mediated apoptosis: effects of agonistic anti–mouse Fas mAb on thymus, spleen and liver. Nishimura Y, et al. **Int Immunol** 1997 Feb;9(2):307–16

External calcium–dependent, F–actin–independent and pertussis toxin–insensitive novel neutrophil locomotion induced by a mAb. Suzuki H, et al. **Int Immunol** 1997 May; 9(5):763–9

The anti–Fc gamma RIII mAb 3G8 induces neutrophil activation via a cooperative actin of Fc gamma RIIIb and Fc gamma RIIa. Vossebeld PJ, et al. **Int J Biochem Cell Biol** 1997 Mar;29(3):465–73

Induction of apoptosis by ribosome–inactivating proteins and related immunotoxins. Bolognesi A, et al. **Int J Cancer** 1996 Nov 4;68(3):349–55

Inhibition of growth and enhancement of differentiation of colorectal carcinoma cell lines by MAb MR6 and IL–4. Al–Tubuly AA, et al. **Int J Cancer** 1997 May 16; 71(4):605–11

Antigen–specific T–cell activations distinguished by in vivo anti–CD4 antibody treatment. Morrison WJ, et al. **Int J Immunopharmacol** 1995 Dec;17(12):1017–25

Effects of anti–intercellular adhesion molecule–1 and anti–lymphocyte–function–associated antigen–1 monoclonal antibodies on the metastasis of murine tumors. Sun R, et al. **Invasion Metastasis** 1996;16(1):39–48

Use of an anti–IgE humanized monoclonal antibody in ragweed–induced allergic rhinitis. Casale TB, et al. **J Allergy Clin Immunol** 1997 Jul;100(1):110–21

Depletion of CD8+ T cells enhances pulmonary inflammation but not airway responsiveness after antigen challenge in rats. Laberge S, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):617–27

An anti–adipocyte monoclonal antibody is cytotoxic to porcine preadipocytes in vitro and depresses the development of pig adipose tissue. De clercq L, et al. **J Anim Sci** 1997 Jul;75(7):1791–7

Combination of 5–flucytosine and capsule–binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro. Feldmesser M, et al. **J Antimicrob Chemother** 1996 Mar; 37(3):617–22

Anti–interleukin–4 inhibits immunoglobulin E production in a murine model of atopic asthma. Zhou CY, et al. **J Asthma** 1997;34(3):195–201

Slowed release of thrombin–cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. Saenko EL, et al. **J Biol Chem** 1996 Nov 1;271(44):27424–31

Monoclonal antibody alpha IR–3 inhibits non–small cell lung cancer growth in vitro and in vivo. Zia F, et al. **J Cell Biochem Suppl** 1996;24:269–75

Reversion of the malignant phenotype of human breast cells in three–dimensional culture and in vivo by integrin blocking antibodies. Weaver VM, et al. **J Cell Biol** 1997 Apr 7;137(1):231–45

Mechanism of first–dose cytokine–release syndrome by CAMPATH 1–H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA–1) on NK cells. Wing MG, et al. **J Clin Invest** 1996 Dec 15;98(12):2819–26

A monoclonal antibody against neural crest–stage Xenopus laevis lectin perturbs craniofacial development of Xenopus. Evanson JE, et al. **J Craniofac Genet Dev Biol** 1996 Apr–Jun;16(2):74–93

An anti–fusion regulatory protein–1 monoclonal antibody suppresses human parainfluenza virus type 2–induced cell fusion. Okamoto K, et al. **J Gen Virol** 1997 Jan;78 (Pt 1):83–9

Multi–organ reactivity of a monoclonal natural autoantibody that promotes remyelination in a mouse model of multiple sclerosis. Miller DJ, et al. **J Histochem Cytochem** 1996 Sep; 44(9):1005–11

Neoepitope immunoassay: an assay for human interleukin 1 beta based on an antibody induced conformational change. Towbin H, et al. **J Immunoassay** 1996 Nov;17(4):353–69

Infusion of anti–B7.1 (CD80) and anti–B7.2 (CD86) monoclonal antibodies inhibits murine graft–versus–host disease lethality in part via direct effects on CD4+ and CD8+ T cells. Blazar BR, et al. **J Immunol** 1996 Oct 15; 157(8):3250–9

Blockade of CD40 ligand–CD40 interaction impairs CD4+ T cell–mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. Blazar BR, et al. **J Immunol** 1997 Jan 1; 158(1):29–39

CD3 antibody–induced dominant self tolerance in overtly diabetic NOD mice. Chatenoud L, et al. **J Immunol** 1997 Mar 15;158(6):2947–54

The role of P–selectin and ICAM–1 in acute lung injury as determined using blocking antibodies and mutant mice. Doerschuk CM, et al. **J Immunol** 1996 Nov 15; 157(10):4609–14

Antibodies against sialophorin (CD43) enhance the capacity of dendritic cells to cluster and activate T lymphocytes. Fanales–Belasio E, et al. **J Immunol** 1997 Sep 1; 159(5):2203–11

Th1 development of naive CD4+ T cells is inhibited by co–activation with anti–CD4 monoclonal antibodies. Goedert S, et al. **J Immunol** 1996 Jul 15;157(2):566–73

Prevention by anti–LFA–1 of acute myoblast death following transplantation. Guérette B, et al. **J Immunol** 1997 Sep 1; 159(5):2522–31

CD94 ligation induces apoptosis in a subset of IL–2–stimulated NK cells. Ida H, et al. **J Immunol** 1997 Sep 1;159(5):2154–60

Induction of "infectious" tolerance to MHC–incompatible cardiac allografts in CD4 monoclonal antibody–treated sensitized rat recipients. Onodera K, et al. **J Immunol** 1996 Sep 1;157(5):1944–50

Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule–1 (MAdCAM–1) reduce inflammation in the colon of scid mice reconstituted

with CD45RBhigh CD4+ T cells. Picarella D, et al. **J Immunol** 1997 Mar 1;158(5):2099–106

Dual effects of LPS antibodies on cellular uptake of LPS and LPS-induced proinflammatory functions. Pollack M, et al. **J Immunol** 1997 Oct 1;159(7):3519–30

Human tryptase fibrinogenolysis is optimal at acidic pH and generates anticoagulant fragments in the presence of the anti-tryptase monoclonal antibody B12. Ren S, et al. **J Immunol** 1997 Oct 1;159(7):3540–8

Analysis of the promoter elements necessary for IL-4 and anti-CD40 antibody induction of murine Fc epsilon RII (CD23): comparison with the germline epsilon promoter. Richards ML, et al. **J Immunol** 1997 Jan 1;158(1):263–72

CD50 monoclonal antibodies inhibit neutrophil activation. Skubitz KM, et al. **J Immunol** 1997 Jul 15;159(2):820–8

Probing HLA-B7 conformational shifts induced by peptide-binding groove mutations and bound peptide with anti-HLA monoclonal antibodies. Smith KD, et al. **J Immunol** 1996 Sep 15;157(6):2470–8

Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice. Van Molle W, et al. **J Immunol** 1997 Oct 1;159(7):3555–64

Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. Visco V, et al. **J Immunol** 1996 Jul 15;157(2):956–62

A new and simple method to study the role of soluble factors in antibody-mediated cell modulation. Nizet Y, et al. **J Immunol Methods** 1996 Nov 29;199(1):1–4

Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. Funakoshi S, et al. **J Immunother Emphasis Tumor Immunol** 1996 Mar; 19(2):93–101

A new reagent for the induction of T-cell depletion, anti-CD3-CRM9. Neville DM Jr, et al. **J Immunother Emphasis Tumor Immunol** 1996 Mar; 19(2):85–92

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. Prewett M, et al. **J Immunother Emphasis Tumor Immunol** 1996 Nov; 19(6):419–27

Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2 [published erratum appears in J Immunother Emphasis Tumor Immunol 1996 Sep;19(5):386] Wojtowicz-Praga S, et al. **J Immunother Emphasis Tumor Immunol** 1996 May; 19(3):169–75

Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. Han Y, et al. **J Infect Dis** 1997 May;175(5):1169–75

Transient inhibition of capacitative calcium entry in human neutrophils by a monoclonal antibody directed against a 19-kDa antigen. Alonso MT, et al. **J Leukoc Biol** 1996 Sep;60(3):323–7

Inflammatory damage following first-generation replication-defective adenovirus controlled by anti-LFA-1. Guérette B, et al. **J Leukoc Biol** 1997 Apr; 61(4):533–8

Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation. Brinkmann U, et al. **J Mol Biol** 1997 Apr 25;268(1):107–17

Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. Ciardiello F, et al. **J Natl Cancer Inst** 1996 Dec 4;88(23):1770–6

In vivo neurogenesis is inhibited by neutralizing antibodies to basic fibroblast growth factor. Tao Y, et al. **J Neurobiol** 1997 Sep;33(3):289–96

Monoclonal remyelination-promoting natural autoantibody SCH 94.03: pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis. Hunter SF, et al. **J Neurol Sci** 1997 Sep 10; 150(2):103–13

Trans-synaptic stimulation of cortical acetylcholine release after partial 192 IgG-saporin-induced loss of cortical cholinergic afferents. Fadel J, et al. **J Neurosci** 1996 Oct 15;16(20):6592–600

Treatment of rat hemiparkinson model with xenogeneic neural transplantation: tolerance induction by anti-T-cell antibodies. Okura Y, et al. **J Neurosci Res** 1997 Jun 1; 48(5):385–96

Antibodies against Mac-1 attenuate neutrophil accumulation after traumatic brain injury in rats. Clark RS, et al. **J Neurotrauma** 1996 Jun;13(6):333–41

Limb allografts in rats treated with anti-ICAM-1 and anti-LFA-1 monoclonal antibodies. Tsuchida Y, et al. **J Reconstr Microsurg** 1997 Feb;13(2):107–10

Inhibition of bovine fertilization in vitro by antibodies to SP-10. Coonrod SA, et al. **J Reprod Fertil** 1996 Jul; 107(2):287–97

Regulation of tumor necrosis factor-alpha production: basic aspects and pharmacological modulation [editorial] Huizinga TW, et al. **J Rheumatol** 1996 Mar;23(3):416–8

Anti-T cell receptor antibody treatment of mice with lupus-like graft versus host disease: suppression of glomerulonephritis without reduction in anti-DNA antibody levels. Maeda T, et al. **J Rheumatol** 1995 Dec; 22(12):2259–65

Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis. Pruzanski W, et al. **J Rheumatol** 1995 Oct;22(10):1816–9

Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats. Seiffge D. **J Rheumatol** 1996 Dec; 23(12):2086–91

Effects of monoclonal anticardiolipin antibody on pregnant mice. Suzuki T, et al. **J Rheumatol** 1996 Jan;23(1):83–6

Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. Juhl H, et al. **J Surg Oncol** 1997 Mar;64(3):222–30

The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies. Liem TK, et al. **J Vasc Surg** 1997 Jan; 25(1):124–30

Anti-VLA-4 antibody reduces intimal hyperplasia in the endarterectomized carotid artery in nonhuman primates. Lumsden AB, et al. **J Vasc Surg** 1997 Jul;26(1):87–93

Inhibition of cell fusion by neutralizing monoclonal antibodies to F1 protein of turkey rhinotracheitis virus. Tanaka M, et al. **J Vet Med Sci** 1996 Jun;58(6):581–2

Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. McKnight A, et al. **J Virol** 1997 Feb;71(2):1692–6

Agonistic anti-Fas antibodies induce glomerular cell apoptosis in mice in vivo. González-Cuadrado S, et al. **Kidney Int** 1997 Jun;51(6):1739–46

Apoptosis of cultured rat glomerular mesangial cells induced by IgG2a monoclonal anti-Thy-1 antibodies. Sato T, et al. **Kidney Int** 1996 Feb;49(2):403–12

Effects of anti-IgE mAb on serum IgE, Fc epsilon RII/CD23 expression on splenic B cells and worm burden in mice infected with Paragonimus westermani. Shin MH, et al. **Korean J Parasitol** 1997 Mar;35(1):47–54

Attachment glycoproteins and receptor specificity of rat coronaviruses. Gagneten S, et al. **Lab Anim Sci** 1996 Apr; 46(2):159–66

Role of cytokines in the early stages of chronic colitis in TCR alpha-mutant mice. Mizoguchi E, et al. **Lab Invest** 1997 Mar;76(3):385–97

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study [see comments] **Lancet** 1997 May 17;349(9063):1429–35. Comment in: Lancet 1997 May 17;349(9063):1409–10.

Effect of beta 2glycoprotein I and human monoclonal anticardiolipin antibody on the protein S/C4b-binding protein system [see comments] Atsumi T, et al. **Lupus** 1997; 6(4):358–64. Comment in: Lupus 1997 ;6(4):351–2.

Characterization of interleukin-1 alpha-induced melanoma cell motility: inhibition by type I and type II receptor-blocking monoclonal antibodies. Dekker SK, et al. **Melanoma Res** 1997 Jun;7(3):223–30

Reduced anti-Pseudomonas aeruginosa activity of a cephalosporin, cefodizime, in rats whose neutrophils were selectively depleted by a monoclonal antibody. Araki A, et al. **Microbiol Immunol** 1996;40(5):333–8

A monoclonal antibody modulates neutrophil adherence while enhancing cell motility. Ohtake K, et al. **Microbiol Immunol** 1997;41(1):67–72

Immunochemical analysis of kinesin light chain function. Stenoien DL, et al. **Mol Biol Cell** 1997 Apr;8(4):675–89

Functional antagonism by a monoclonal antibody to digoxin in a test system of cultured rat heart myocytes. Wallukat G, et al. **Mol Cell Biochem** 1996 Jul–Aug;160–161:117–20

Neutralizing murine monoclonal anti-interleukin-10 antibodies enhance binding of antibodies against a different epitope. Sabat R, et al. **Mol Immunol** 1996 Oct; 33(14):1103–11

Antibodies fight fat cells in humans as well as in animals? [news] Jack DB. **Mol Med Today** 1997 Feb;3(2):49

Synergistic inhibition of human cell-mediated cytotoxicity by complement component antisera indicates that target cell lysis may result from an enzymatic cascade involving granzymes and perforin. Brahmi Z, et al. **Nat Immun** 1995 Sep;14(5–6):271–85

Roles of TGF-beta and latent TGF-beta-binding protein in glomerulosclerosis induced by two consecutive injections of monoclonal antibody 1-22-3 in rats. Nakayama M, et al. **Nephron** 1997;76(1):82–9

The effects of selective cholinergic basal forebrain lesions and aging upon expectancy in the rat. Stoehr JD, et al. **Neurobiol Learn Mem** 1997 May;67(3):214–27

Repeated exposure to cationic immunoliposomes activates effective gene transfer to human glioma cells. Mizuno M, et al. **Neurol Med Chir (Tokyo)** 1996 Mar;36(3):141–4

IB4, a monoclonal antibody against the CD18 leukocyte adhesion protein, reduces intracranial pressure following thromboembolic stroke in the rabbit. Bednar MM, et al. **Neurol Res** 1996 Apr;18(2):171–5

Persistence of CA1 hippocampal LTP after selective cholinergic denervation. Jouvenceau A, et al. **Neuroreport** 1996 Mar 22;7(4):948–52

Loss of nucleus basalis magnocellularis, but not septal, cholinergic neurons correlates with passive avoidance impairment in rats treated with 192-saporin. Zhang ZJ, et al. **Neurosci Lett** 1996 Jan 26;203(3):214–8

Effects of cholinergic depletion on experience-dependent plasticity in the cortex of the rat. Baskerville KA, et al. **Neuroscience** 1997 Oct;80(4):1159–69

Indefinite survival of neural xenografts induced with anti-CD4 monoclonal antibodies. Wood MJ, et al. **Neuroscience** 1996 Feb;70(3):775–89

A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Klapper LN, et al. **Oncogene** 1997 May 1; 14(17):2099–109

Inhibition of Raf-1 signaling by a monoclonal antibody, which interferes with Raf-1 activation and with Mek substrate binding. Kolch W, et al. **Oncogene** 1996 Sep 19; 13(6):1305–14

Combinatorial effects of monoclonal anti-p120 antibody (MAbp120), liposomes and hyperthermia on MCF-7 and LOX tumor cell lines. Perlaky L, et al. **Oncol Res** 1996; 8(9):363–9

An animal model of pain produced by systemic administration of an immunotherapeutic anti-ganglioside antibody. Slart R, et al. **Pain** 1997 Jan;69(1-2):119–25

Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Xiao WH, et al. **Pain** 1997 Jan;69(1-2):145–51

Increased cAMP and cAMP-dependent protein kinase activity mediate anti-CD2 induced suppression of anti-CD3-driven interleukin-2 production and CD25 expression. Lin J, et al. **Pathobiology** 1995;63(4):175–87

Apoptosis of T lymphoma cells and its inhibition by monoclonal antibodies against cell surface adhesion molecules. Tsuruo T, et al. **Princess Takamatsu Symp** 1994; 24:91–8 (18 ref.)

Disruption of hippocampal development in vivo by CR-50 mAb against reelin. Nakajima K, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8196–201

Retrovirally induced mouse anti-TCR monoclonals can synergize the in vitro proliferative T cell response to bacterial superantigens. Dehghanpisheh K, et al. **Scand J Immunol** 1997 Jun;45(6):645–54

IL-4 synergizes with IL-10 and anti-CD40 MoAbs to induce B-cell differentiation in patients with common variable immunodeficiency. Punnonen J, et al. **Scand J Immunol** 1997 Feb;45(2):203–12

Preparation of an activity-inhibiting monoclonal antibody against human placental aromatase cytochrome P450. Washida N, et al. **Steroids** 1996 Mar;61(3):126–32

Anti-interleukin-8 monoclonal antibody reduces free radical production and improves hemodynamics and survival rate in endotoxic shock in rabbits. Carvalho GL, et al. **Surgery** 1997 Jul;122(1):60–8

Anti-interleukin-10 antibody restores burn-induced defects in T-cell function. Kelly JL, et al. **Surgery** 1997 Aug; 122(2):146–52

Effect of a new monoclonal anti-glycoprotein IX antibody, KMP-9, on high shear-induced platelet aggregation. Miyake T, et al. **Thromb Haemost** 1997 Aug;78(2):902–9

Differential inhibition of fibrinogen binding to agonist- and RGDS peptide-activated states of GPIIb-IIIa by an anti-GPIIIa monoclonal antibody, PMA5. Nakatani S, et al. **Thromb Haemost** 1996 Dec;76(6):1030–7

The activation of human platelets mediated by two monoclonal antibodies raised against CD9. Peng L, et al. **Thromb Res** 1997 Jul 1;87(1):65–73

A novel monoclonal antibody mNI-58A against the alpha-chain of leukocyte function-associated antigen-1 (LFA-1) blocks the homotypic cell aggregation and actively regulates morphological changes in the phorbol myristate acetate (PMA)-activated human monocyte-like cell line, U937. Ikewaki N, et al. **Tissue Antigens** 1996 Sep; 48(3):161–73

Expression of Ki-67 by monoclonal antibody MIB-1 in carcinoma of the middle and lower bile duct. Yamada Y, et al. **Tohoku J Exp Med** 1995 Dec;177(4):375–7

Inhibition by CsA and FK506 of the in vitro proliferative response of gamma delta T cells on stimulation with anti-TCR delta monoclonal antibody. Chen BG, et al. **Transpl Immunol** 1996 Jun;4(2):158–62

Impact of adhesion molecules of the selectin family on liver microcirculation at reperfusion following cold ischemia. Hamamoto I, et al. **Transpl Int** 1996;9(5):454–60

Efficient myoblast transplantation in mice immunosuppressed with monoclonal antibodies and CTLA4 Ig. Guérette B, et al. **Transplant Proc** 1997 Jun;29(4):1932–4

Dominant infiltration by TH2 cells into grafts following treatment with anti-CD4 monoclonal antibody. Hamano K, et al. **Transplant Proc** 1997 Feb–Mar;29(1-2):1053

Effect of pretreatment with coenzyme Q10 and monoclonal antibodies to adhesion molecules on ischemic small intestine preservation. Marubayashi S, et al. **Transplant Proc** 1996 Oct;28(5):2600–1

An immunosuppressive effect of anti-p43 monoclonal antibody on human xenogeneic graft versus host response is mediated by CD8+ T cells. Moroz C, et al. **Transplant Proc** 1996 Dec;28(6):3196–8

Both donor and recipient adhesion molecules play a crucial role in inducing rejection of rat xenogeneic islets in mice. Ohta Y, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):953

In vitro system for evaluation of the immunomodulatory capacity of CD45(R) reagents. Poppema S, et al. **Transplant Proc** 1996 Dec;28(6):3263–4

Modulation of the CD4 molecule is a major event in the induction of transplantation tolerance with anti-CD4 monoclonal antibodies. Saitovitch D, et al. **Transplant Proc** 1997 Feb–Mar;29(1-2):1159

Inhibitory CD94 molecules identified by the Z199 monoclonal antibody recognize different HLA-class I

molecules. Sivori S, et al. **Transplant Proc** 1996 Dec; 28(6):3199–203

Indefinite islet allograft survival in mice after a short course of treatment with anti–CD45 monoclonal antibodies. Auersvald LA, et al. **Transplantation** 1997 May 15; 63(9):1355–8

Strain variation in susceptibility to monoclonal antibody–induced transplantation tolerance. Davies JD, et al. **Transplantation** 1997 Jun 15;63(11):1570–3

Immunosuppression with monoclonal antibodies and CTLA4–Ig after myoblast transplantation in mice. Guerette B, et al. **Transplantation** 1996 Oct 15;62(7):962–7

In vivo hyperexpression of transforming growth factor–beta1 in mice: stimulation by cyclosporine. Khanna A, et al. **Transplantation** 1997 Apr 15;63(7):1037–9

In vivo modulation of CD26 (dipeptidyl peptidase IV) in the mouse: effects of polyreactive and monoreactive antibodies. Yamaguchi N, et al. **Transplantation** 1996 Oct 15;62(7):973–85

Resistance to monoclonal antibody–induced CD8+ T–cell depletion in thymectomized MHC class II–deficient mice. Zhao Y, et al. **Transplantation** 1997 Aug 15;64(3):489–94

The use of antipoliovirus monoclonal antibodies as an improved safety test for oral live poliomyelitis vaccine. Horie H, et al. **Vaccine** 1996 Jan;14(1):35–41

Platelet activation studies with anti–CD41/61 monoclonal antibodies. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):357–62

Quantification of total sheep IgE concentration using anti–ovine IgE monoclonal antibodies in an enzyme immunoassay. Shaw RJ, et al.
Vet Immunol Immunopathol 1997 Jul;57(3–4):253–65

Inhibition of cytotoxic activity of carp lymphocytes (Cyprinus carpio) by anti–thymocyte monoclonal antibodies. Yamaguchi K, et al.
Vet Immunol Immunopathol 1996 May;51(1–2):211–21

Induction of apoptosis in a human hepatocellular carcinoma cell line by a neutralizing antibody to transforming growth factor–alpha. Seki S, et al. **Virchows Arch** 1997 Jan; 430(1):29–35

[The electron microscopic observation of the effect of monoclonal antibody on the form and structure of mutans streptococci OMZ176] Wen L, et al.
Chung Hua Kou Chiang Hsueh Tsa Chih 1996 Jan;31(1):38–9 (Eng. Abstr.) **(Chi)**

[CD4–CD8– to CD4–CD8+ transition induced by anti–CD3 mAb in vitro cell culture system] Tian L, et al.
Shih Yen Sheng Wu Hsueh Pao 1996 Mar;29(1):39–47 (Eng. Abstr.) **(Chi)**

[Quadruple induction therapy after liver transplantation with ATG or interleukin–2 receptor antibody BT563. A prospective randomized study] Langrehr JM, et al.
Langenbecks Arch Chir Suppl Kongressbd 1997;114:673–6 (Eng. Abstr.) **(Ger)**

[Effect of anti–CD11a with and without simultaneous anti–CD54 monoclonal antibody on cytokine release and level of soluble adhesion molecules on concordant xenogenic reperfusion experiment] Storck M, et al.
Langenbecks Arch Chir Suppl Kongressbd 1997;114:167–72 (Eng. Abstr.) **(Ger)**

[Inhibition of angiogenesis and growth of malignant gliomas in the athymic nude rat model: immunotherapy against "basic fibroblast growth factor"] Nemati MN, et al.
Zentralbl Neurochir 1996;57(1):12–9 (Eng. Abstr.) **(Ger)**

[Allo–cytotoxic T lymphocyte responses in corneal allografted mice treated with monoclonal antibodies to adhesion molecules] Hori J, et al.
Nippon Ganka Gakkai Zasshi 1996 Aug;100(8):582–6 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Characterization of monoclonal antibodies raised to C–terminal peptides of pS2: a major trefoil peptide and motility factor expressed in adenocarcinomas and regions of mucosal injury. Williams R, et al. **Hum Pathol** 1996 Dec; 27(12):1259–66

Recombinant anti–human melanoma antibodies are versatile molecules. Neri D, et al. **J Invest Dermatol** 1996 Aug; 107(2):164–70

Different CD3/T cell receptor monoclonal antibodies have distinct capacities to induce adhesion of T lymphocytes to endothelium. Buysmann S, et al. **J Lab Clin Med** 1997 Jul;130(1):91–101

Monoclonal antibodies for the identification of New World Leishmania species. Grimaldi G, et al.
Mem Inst Oswaldo Cruz 1996 Jan–Feb;91(1):37–42 (37 ref.)

Divergent signal transduction pathways and effects on natural killer cell functions induced by interaction of Fc receptors with physiologic ligands or antireceptor antibodies. Sulica A, et al. **Nat Immun** 1995;14(3):123–33 (58 ref.)

CD44 expression by leucocytes in rheumatoid arthritis and modulation by specific antibody: implications for lymphocyte adhesion to endothelial cells and synoviocytes in vitro. Brennan FR, et al. **Scand J Immunol** 1997 Feb; 45(2):213–20

Human polyreactive IgM monoclonal antibodies with blocking activity against self–reactive IgG. Melero J, et al. **Scand J Immunol** 1997 Apr;45(4):393–400

[Physiopathology of monoclonal IgM associated with peripheral neuropathy] Brouet JC. **Rev Neurol (Paris)** 1996 May;152(5):390–3 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Anti–tumor necrosis factor–alpha therapy of rheumatoid arthritis. Feldmann M, et al. **Adv Immunol** 1997;64:283–350 (271 ref.)

Anti–adhesion therapy. Cornejo CJ, et al. **Adv Pharmacol** 1997;39:99–142 (200 ref.)

Restenosis: is there a pharmacologic fix in the pipeline? Keiser JA, et al. **Adv Pharmacol** 1997;39:313–51 (250 ref.)

Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor. Wallace RC, et al. **AJNR Am J Neuroradiol** 1997 Aug;18(7):1257–60

Treatment of severe Crohn's disease with anti–CD4 monoclonal antibody. Canva–Delcambre V, et al.
Aliment Pharmacol Ther 1996 Oct;10(5):721–7

Monoclonal antibody therapy of inflammatory bowel disease. van Deventer SJ, et al. **Aliment Pharmacol Ther** 1996;10 Suppl 2:107–11; discussion 112 (35 ref.)

Inhibition of interleukin–5 with a monoclonal antibody attenuates allergic inflammation. Danzig M, et al.
Allergy 1997 Aug;52(8):787–94 (102 ref.)

Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Juergens CP, et al. **Am J Cardiol** 1997 Jul 1; 80(1):74–5

Partial reversal of heparin anticoagulation by intravenous protamine in abciximab–treated patients undergoing percutaneous intervention. Kereiakes DJ, et al.
Am J Cardiol 1997 Sep 1;80(5):633–4

In vivo CAMPATH–1 monoclonal antibodies: a novel mode of therapy for acute graft–versus–host disease [letter] Varadi G, et al. **Am J Hematol** 1996 Jul;52(3):236–7

Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Parmar R, et al. **Am J Med Sci** 1997 Jul; 314(1):31–6 (22 ref.)

Inhibitory effects of an anti–IgE antibody E25 on allergen–induced early asthmatic response [see comments] Boulet LP, et al. **Am J Respir Crit Care Med** 1997 Jun; 155(6):1835–40. Comment in: Am J Respir Crit Care Med 1997 Jun;155(6):1825–7.

Anti–IgE therapy for asthma [editorial; comment] Demoly P, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):1825–7 . Comment on: Am J Respir Crit Care Med 1997 Jun;155(6):1828–34. Comment on: Am J Respir Crit Care Med 1997 Jun;155(6):1828–34.

The effect of an anti–IgE monoclonal antibody on the early– and late–phase responses to allergen inhalation in asthmatic subjects [see comments] Fahy JV, et al.
Am J Respir Crit Care Med 1997 Jun;155(6):1828–34. Comment in: Am J Respir Crit Care Med 1997 Jun;155(6):1825–7.

Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Anderson GW Jr, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):471–3

CD–18 monoclonal antibody blocks the early events of aneurysm expansion. Strindberg G, et al.
Ann N Y Acad Sci 1996 Nov 18;800:266–7

Treatment of Hodgkin's disease with bispecific antibodies. Hartmann F, et al. **Ann Oncol** 1996;7 Suppl 4:143–6 (17 ref.)

ABCIXIMAB: a new antiaggregant used in angioplasty. Genetta TB, et al. **Ann Pharmacother** 1996 Mar;30(3):251–7 (28 ref.)

c–erbB–2/p185–directed therapy in human lung adenocarcinoma. Snider JM, et al. **Ann Thorac Surg** 1996 Nov;62(5):1454–9

Effect of intraperitoneally, intravenously and intralesionally administered monoclonal anti–beta–FGF antibodies on rat chondrosarcoma tumor vascularization and growth. Coppola G, et al. **Anticancer Res** 1997 May–Jun; 17(3C):2033–9

Yttrium–90/indium–111–DOTA–peptide–chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Denardo SJ, et al.
Anticancer Res 1997 May–Jun;17(3B):1735–44

Radioimmunotherapy for advanced breast cancer using I–131–ChL6 antibody. Denardo SJ, et al.
Anticancer Res 1997 May–Jun;17(3B):1745–51

Therapeutic potential of humanized anti–interleukin–6 receptor antibody: antitumor activity in xenograft model of multiple myeloma. Tsunenari T, et al.
Anticancer Res 1996 Sep–Oct;16(5A):2537–44

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. Maini RN, et al. **APMIS** 1997 Apr;105(4):257–63 (34 ref.)

Suppression of mouse contact hypersensitivity after treatment with antibodies to leukocyte function–associated antigen–1 and intracellular adhesion molecules–1. Murayama M, et al. **Arch Dermatol Res** 1997 Jan;289(2):98–103

Expectation bias in rheumatoid arthritis clinical trials. The anti–CD4 monoclonal antibody experience. Epstein WV. **Arthritis Rheum** 1996 Nov;39(11):1773–80 (22 ref.)

Repeat treatment of rheumatoid arthritis patients with a murine anti–intercellular adhesion molecule 1 monoclonal antibody. Kavanaugh AF, et al. **Arthritis Rheum** 1997 May; 40(5):849–53

Biologic agents for treating rheumatoid arthritis. Concepts and progress. Moreland LW, et al. **Arthritis Rheum** 1997 Mar;40(3):397–409 (123 ref.)

Decrease in cell adhesion molecules by treatment with anti–tumor necrosis factor alpha monoclonal antibody [letter; comment] Smith MD. **Arthritis Rheum** 1997 Apr; 40(4):789–90. Comment on: Arthritis Rheum 1996 Jul;39(7):1077–81.

Therapeutic effects of antibodies against adhesion molecules in murine collagen type II–induced arthritis. Zeidler A, et al. **Autoimmunity** 1995;21(4):245–52

Biological and monoclonal antibody therapy for high–grade gliomas. Hoang–Xuan K, et al. **Baillieres Clin Neurol** 1996 Jun;5(2):395–411 (98 ref.)

Antibody–based therapy targeting tumor vascular endothelial cells suppresses solid tumor growth in rats. Ohizumi I, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):493–6

Targeted anti–cancer therapy using rituximab, a chimaeric anti–CD20 antibody (IDEC–C2B8) in the treatment of non–Hodgkin's B–cell lymphoma. Anderson DR, et al.
Biochem Soc Trans 1997 May;25(2):705–8 (18 ref.)

Anti–myelin antibodies modulate experimental allergic encephalomyelitis in Biozzi ABH mice. Morris MM, et al.
Biochem Soc Trans 1997 May;25(2):168S

Development of a streptavidin–anti–carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development. Karacay H, et al. **Bioconjug Chem** 1997 Jul–Aug;8(4):585–94

Development of a streptavidin–anti–carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Sharkey RM, et al. **Bioconjug Chem** 1997 Jul–Aug;8(4):595–604

Therapeutic effect of cytomedicine on mesangio–proliferative glomerulonephritis in human interleukin–6 transgenic mice. Okada N, et al. **Biol Pharm Bull** 1997 Mar;20(3):255–8

Potential therapeutic use of antibodies directed towards HuIFN–gamma. Froyen G, et al. **Biotherapy** 1997; 10(1):49–57 (102 ref.)

A superantigen–antibody fusion protein for T–cell immunotherapy of human B–lineage malignancies. Gidlöf C, et al. **Blood** 1997 Mar 15;89(6):2089–97

Treatment of refractory Hodgkin's disease with an anti–CD16/CD30 bispecific antibody. Hartmann F, et al. **Blood** 1997 Mar 15;89(6):2042–7

IDEC–C2B8 (Rituximab) anti–CD20 monoclonal antibody therapy in patients with relapsed low–grade non–Hodgkin's lymphoma. Maloney DG, et al. **Blood** 1997 Sep 15; 90(6):2188–95

Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Wooldridge JE, et al. **Blood** 1997 Apr 15;89(8):2994–8

Purging autologous bone marrow with monoclonal antibodies for transplantation in acute myelogenous leukemia. Hammert LC, et al. **Blood Rev** 1997 Jun; 11(2):80–90 (76 ref.)

In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID). Dickinson AM, et al. **Bone Marrow Transplant** 1997 Feb; 19(4):323–9

Campath–1G in vivo confers a low incidence of graft–versus–host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA–identical sibling donors. Hamblin M, et al. **Bone Marrow Transplant** 1996 May;17(5):819–24

In vivo CAMPATH–1 followed by T cell–depleted bone marrow transplantation: a potential new mode of therapy for hepatitis–associated severe aplastic anemia (SAA). Nagler A, et al. **Bone Marrow Transplant** 1996 Aug; 18(2):475–8

Intratibial injection of an anti–doxorubicin monoclonal antibody prevents drug–induced myelotoxicity in mice. Morelli D, et al. **Br J Cancer** 1997;75(5):656–9

Therapy with CD7 monoclonal antibody TH–69 is highly effective for xenografted human T–cell ALL. Baum W, et al. **Br J Haematol** 1996 Nov;95(2):327–38

Subcutaneous CAMPATH–1H in fludarabine–resistant/relapsed chronic lymphocytic and B–prolymphocytic leukaemia. Bowen AL, et al.
Br J Haematol 1997 Mar;96(3):617–9

In vivo 'purging' of residual disease in CLL with Campath–1H. Dyer MJ, et al. **Br J Haematol** 1997 Jun; 97(3):669–72

Sustained remission of severe resistant autoimmune neutropenia with Campath–1H. Killick SB, et al.
Br J Haematol 1997 May;97(2):306–8

Suppression of fever and the acute–phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor–alpha (cA2). Elliott MJ, et al. **Br J Rheumatol** 1997 May;36(5):589–93

A phase I/IB trial of murine monoclonal anti–GD2 antibody 14.G2a plus interleukin–2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Frost JD, et al. **Cancer** 1997 Jul 15;80(2):317–33

Phase I/II trial of combined 131I anti–CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma. Mittal BB, et al. **Cancer** 1996 Nov 1;78(9):1861–70

Doxorubicin sensitizes human bladder carcinoma cells to Fas–mediated cytotoxicity. Mizutani Y, et al. **Cancer** 1997 Mar 15;79(6):1180–9

Induction of multiple anti–c–erbB–2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Clark JI, et al.
Cancer Immunol Immunother 1997 Jul;44(5):265–72

Treatment of human lung carcinoma xenografts with a combination of 131I-labelled monoclonal antibody Po66 and doxorubicin. Desrues B, et al. **Cancer Immunol Immunother** 1996 Dec;43(5):269–74

A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer. Zimmermann S, et al. **Cancer Immunol Immunother** 1997 Mar;44(1):1–9

Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Reist CJ, et al. **Cancer Res** 1997 Apr 15;57(8):1510–5

Use of c7E3 Fab in conjunction with primary coronary stenting for acute myocardial infarctions complicated by cardiogenic shock. Schultz RD, et al. **Cathet Cardiovasc Diagn** 1996 Oct;39(2):143–8

Control of inflammatory damage by anti-LFA-1: increase success of myoblast transplantation. Guérette B, et al. **Cell Transplant** 1997 Mar-Apr;6(2):101–7

Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Kelley MJ, et al. **Chest** 1997 Jul;112(1):256–61

Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Gold HK, et al. **Circulation** 1997 Apr 1; 95(7):1755–9

Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis. Shetler TJ, et al. **Circulation** 1996 Oct 1;94(7):1719–25

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Isaacs JD, et al. **Clin Exp Immunol** 1996 Dec;106(3):427–33

Effective treatment of experimental lupus nephritis by combined administration of anti-CD11a and anti-CD54 antibodies. Kootstra CJ, et al. **Clin Exp Immunol** 1997 May; 108(2):324–32

Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis. Santos LL, et al. **Clin Exp Immunol** 1997 Feb;107(2):248–53

Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1). Schulze-Koops H, et al. **Clin Exp Immunol** 1996 Nov;106(2):190–6

Rescue of DMARD failures by means of monoclonal antibodies or biological agents. Kalden JR. **Clin Exp Rheumatol** 1997 May-Jun;15 Suppl 17:S91–8 (42 ref.)

Anti-CD4 monoclonal antibody (mAb) and anti-idiotypic mAb to anti-CD4 in the therapy of autoimmune diseases. Perosa F, et al. **Clin Exp Rheumatol** 1997 Mar-Apr; 15(2):201–10 (51 ref.)

Assessment of chronic rejection in permanent accepted renal allografts in anti-CD4 treated rats. Risch K, et al. **Clin Nephrol** 1996 May;45(5):358–60

T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Brown SA, et al. **Clin Transplant** 1996 Dec;10(6 Pt 2):607–13

Anti-CD4 monoclonal antibody therapy. Delmonico FL, et al. **Clin Transplant** 1996 Oct;10(5):397–403

Monoclonal antibody to endotoxin attenuates hemorrhage-induced lung injury and mortality in rats. Bahrami S, et al. **Crit Care Med** 1997 Jun;25(6):1030–6

Myocardial and vascular adrenergic alterations in a rat model of endotoxin shock: reversal by an anti-tumor necrosis factor-alpha monoclonal antibody. Boillot A, et al. **Crit Care Med** 1997 Mar;25(3):504–11

Influence of alterations in foregoing life-sustaining treatment practices on a clinical sepsis trial. The HA-1A Sepsis Study Group [published erratum appears in Crit Care Med 1997 Jun;25(6):1092] Sprung CL, et al. **Crit Care Med** 1997 Mar; 25(3):383–7

The promise and pitfalls of monoclonal antibody therapeutics. Berkower I. **Curr Opin Biotechnol** 1996 Dec; 7(6):622–8 (50 ref.)

New monoclonal antibodies. Costanzo MR. **Curr Opin Cardiol** 1996 Mar;11(2):204–7 (40 ref.)

Monoclonal antibody-based therapy. von Mehren M, et al. **Curr Opin Oncol** 1996 Nov;8(6):493–8 (34 ref.)

Antibody-based therapies for emerging infectious diseases. Casadevall A. **Emerg Infect Dis** 1996 Jul-Sep;2(3):200–8 (68 ref.)

An overview of the results of the EPIC trial. Califf RM, et al. **Eur Heart J** 1995 Nov;16 Suppl L:43–9

Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3). van den Brand MJ, et al. **Eur Heart J** 1995 Nov;16 Suppl L:36–42

Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands. van Hout BA, et al. **Eur Heart J** 1995 Nov;16 Suppl L:81–5

Does an immunoscintigraphy with OC 125 affect the prognosis of ovarian cancer? Osmers RG, et al. **Eur J Gynaecol Oncol** 1997;18(3):177–82

Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Osterborg A, et al. **Eur J Haematol** 1997 Jan; 58(1):5–13

Sensitivity of Epstein-Barr virus-induced B cell tumor to apoptosis mediated by anti-CD95/Apo-1/fas antibody. Durandy A, et al. **Eur J Immunol** 1997 Feb;27(2):538–43

Genetic control of anti-idiotypic vaccination against coronavirus infection. Yu MW, et al. **Eur J Immunol** 1996 Dec;26(12):3230–3

A monoclonal antibody against ICAM-1 suppresses hepatic ischemia-reperfusion injury in rats. Kuzume M, et al. **Eur Surg Res** 1997;29(2):93–100

Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Hesterberg PE, et al. **Gastroenterology** 1996 Nov; 111(5):1373–80

Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Scaria A, et al. **Gene Ther** 1997 Jun;4(6):611–7

Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Watkins PE, et al. **Gut** 1997 May;40(5):628–33

The anti-GPIIb-IIIa agents: fundamental and clinical aspects. Coller BS, et al. **Haemostasis** 1996 Oct;26 Suppl 4:285–93 (36 ref.)

Monoclonal antibody against lymphocyte function-associated antigen 1 inhibits the formation of primary biliary cirrhosis-like lesions induced by murine graft-versus-host reaction. Kimura T, et al. **Hepatology** 1996 Oct;24(4):888–94

Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Kemp JD. **Histol Histopathol** 1997 Jan;12(1):291–6 (52 ref.)

Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Léger OJ, et al. **Hum Antibodies** 1997; 8(1):3–16

Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor. Udayachander M, et al. **Hum Antibodies** 1997;8(2):60–4

Effects of diagnostic application of monoclonal antibody on survival in melanoma patients. Bender H, et al. **Hybridoma** 1997 Feb;16(1):65–8

OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells. Madiyalakan R, et al. **Hybridoma** 1997 Feb;16(1):41–5

Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen-4 integrins suppresses neutrophil and T-lymphocyte migration to the joints and improves clinical disease. Issekutz AC, et al. **Immunology** 1996 Aug; 88(4):569–76

Immunoregulatory circuits and potential treatment of connective tissue diseases. Alcocer-Varela J, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):348–54 (51 ref.)

What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis? Feldmann M. **Int Arch Allergy Immunol** 1996 Dec;111(4):362–5 (25 ref.)

A monoclonal antibody against very late activation antigen-4 inhibits eosinophil accumulation and late asthmatic response in a guinea pig model of asthma. Sagara H, et al. **Int Arch Allergy Immunol** 1997 Mar;112(3):287–94

Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance. Nishioka Y, et al. **Int J Cancer** 1997 Apr 10; 71(2):170–7

Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Van Hal NL, et al. **Int J Cancer** 1996 Nov 15;68(4):520–7

Antibody response to islet antigens in anti-CD4/prednisolone immune intervention of type 1 diabetes. Kohnert KD, et al. **Int J Clin Lab Res** 1996;26(1):55–9

A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Hauck ML, et al. **Int J Hyperthermia** 1997 May-Jun;13(3):307–16

Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer. Kievit E, et al. **Int J Radiat Oncol Biol Phys** 1997 May 1;38(2):419–28

Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts. Kievit E, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 1;38(4):813–23

Monoclonal antibody-conjugated immunotherapy of cancer. Imai K, et al. **Int Rev Immunol** 1997;14(2-3):213–27 (31 ref.)

Anti-inflammatory therapies: application of molecular biology techniques in intensive care medicine. Liu M, et al. **Intensive Care Med** 1997 Jul;23(7):718–31 (127 ref.)

Antibody to very late activation antigen 4 prevents interleukin-5-induced airway hyperresponsiveness and eosinophil infiltration in the airways of guinea pigs. Kraneveld AD, et al. **J Allergy Clin Immunol** 1997 Aug; 100(2):242–50

CD4 monoclonal antibody administration in atopic dermatitis. Robinet E, et al. **J Am Acad Dermatol** 1997 Apr;36(4):582–8

Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. Lefkovits J, et al. **J Am Coll Cardiol** 1996 Oct;28(4):849–55

Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators.Evaluation of 7E3 in Preventing Ischemic Complications. Lincoff AM, et al. **J Am Coll Cardiol** 1997 Jul;30(1):149–56

Anti-CD11b monoclonal antibody in an infant rat model of Haemophilus influenzae type b sepsis and meningitis. Tan TQ, et al. **J Antimicrob Chemother** 1997 Feb;39(2):209–16

IIb/IIIa platelet inhibitors in the management of coronary artery disease. Talley JD. **J Ark Med Soc** 1996 Oct; 93(5):237–9 (8 ref.)

Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis. van der Lubbe PA, et al. **J Autoimmun** 1997 Feb;10(1):87–97

Identification of framework residues in a secreted recombinant antibody fragment that control production level and localization in Escherichia coli. Forsberg G, et al. **J Biol Chem** 1997 May 9;272(19):12430–6

Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. Rep MH, et al. **J Clin Invest** 1997 May 1;99(9):2225–31

Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. van Zaanen HC, et al. **J Clin Invest** 1996 Sep 15; 98(6):1441–8

Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. Giantonio BJ, et al. **J Clin Oncol** 1997 May;15(5):1994–2007

Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. Lynch TJ Jr, et al. **J Clin Oncol** 1997 Feb;15(2):723–34

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Osterborg A, et al. **J Clin Oncol** 1997 Apr;15(4):1567–74

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. Pawson R, et al. **J Clin Oncol** 1997 Jul; 15(7):2667–72

Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. Quan WD Jr, et al. **J Clin Oncol** 1997 May; 15(5):2103–10

Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. Steffens MG, et al. **J Clin Oncol** 1997 Apr;15(4):1529–37

Monoclonal antibodies in drug targeting. Panchagnula R, et al. **J Clin Pharm Ther** 1997 Feb;22(1):7–19 (141 ref.)

The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody. Linden PK, et al. **J Crit Care** 1995 Dec;10(4):154–64

Anti-CD18 antibodies improve cardiac function following cardiopulmonary bypass in dogs. Mayers I, et al. **J Crit Care** 1996 Dec;11(4):189–96

Applications of molecular biology and biotechnology: antibody therapy of sepsis. Wheeler AP, et al. **J Crit Care** 1996 Jun;11(2):77–94 (102 ref.)

Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. Portanova JP, et al. **J Exp Med** 1996 Sep 1; 184(3):883–91

Induction of Th2 cytokines and control of collagen-induced arthritis by nondepleting anti-CD4 Abs. Chu CQ, et al. **J Immunol** 1996 Sep 15;157(6):2685–9

Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. Early GS, et al. **J Immunol** 1996 Oct 1;157(7):3159–64

Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites. Riggs MW, et al. **J Immunol** 1997 Feb 15;158(4):1787–95

Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. Willenborg DO, et al. **J Immunol** 1996 Sep 1;157(5):1973–80

Prophylactic intervention in RadLV-induced lymphomagenesis with an anti-IL-4 monoclonal antibody. Epzsteyn S, et al. **J Immunother** 1997 Jul;20(4):287–91

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. Albertini MR, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):278–95

Adoptive immunotherapy involving recombinant human M-CSF and R24 anti-melanoma antibody induces human T-cell infiltration into human melanoma xenografts. Conlon KC, et al. **J Immunother Emphasis Tumor Immunol** 1996 Sep;

19(5):317–23
Phase Ia/Ib trial of anti–GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte–macrophage colony–stimulating factor (rhGM–CSF) in metastatic melanoma. Murray JL, et al. **J Immunother Emphasis Tumor Immunol** 1996 May; 19(3):206–17
The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease. Velders MP, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):245–56
Novel role of monoclonal antibody on virus clearance from central nervous system [editorial] Dutta JK. **J Indian Med Assoc** 1996 Jan;94(1):1–2
Mechanism of antibody–mediated reduction of nasopharyngeal colonization by Haemophilus influenzae type b studied in an infant rat model. Kauppi–Korkeila M, et al. **J Infect Dis** 1996 Dec;174(6):1337–40
The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. van Hensbroek MB, et al. **J Infect Dis** 1996 Nov;174(5):1091–7
Regression of established tumors expressing P–glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK–16 antibodies. Watanabe T, et al. **J Natl Cancer Inst** 1997 Apr 2;89(7):512–8
Successful treatment of established relapsing experimental autoimmune encephalomyelitis in mice with a monoclonal natural autoantibody. Miller DJ, et al. **J Neuroimmunol** 1997 May;75(1–2):204–9
Treatment of relapsing autoimmune encephalomyelitis with T cell receptor V beta–specific antibodies when proteolipid protein is the autoantigen. Whitham RH, et al. **J Neurosci Res** 1996 Jul 15;45(2):104–16
Variables influencing tumor dosimetry in radioimmunotherapy of CEA–expressing cancers with anti–CEA and antimucin monoclonal antibodies. Behr TM, et al. **J Nucl Med** 1997 Mar;38(3):409–18
Phase I/II clinical radioimmunotherapy with an iodine–131–labeled anti–carcinoembryonic antigen murine monoclonal antibody IgG. Behr TM, et al. **J Nucl Med** 1997 Jun;38(6):858–70
Extracorporeal whole–blood immunoadsorption enhances radioimmunotargeting of iodine–125–labeled BR96–biotin monoclonal antibody. Garkavij M, et al. **J Nucl Med** 1997 Jun;38(6):895–901
Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. Zhu H, et al. **J Nucl Med** 1997 May;38(5):731–41
Expression of sialyl Lewis(X) in rat heart with ischaemia/reperfusion and reduction of myocardial reperfusion injury by a monoclonal antibody against sialyl Lewis(X). Seko Y, et al. **J Pathol** 1996 Nov;180(3):305–10
The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target. Feldmann M. **J R Coll Physicians Lond** 1996 Nov–Dec;30(6):560–70 (86 ref.)
Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH–1H. Isaacs JD, et al. **J Rheumatol** 1996 Jun;23(6):1103–6
A phase I/II open label study of the safety and efficacy of an anti–ICAM–1 (intercellular adhesion molecule–1; CD54) monoclonal antibody in early rheumatoid arthritis. Kavanaugh AF, et al. **J Rheumatol** 1996 Aug;23(8):1338–44
Subcutaneous administration of CAMPATH–1H: clinical and biological outcomes. Schnitzer TJ, et al. **J Rheumatol** 1997 Jun;24(6):1031–6
Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis. Moreland LW. **J Rheumatol Suppl** 1996 Mar;44:78–83 (74 ref.)
Immunostimulatory therapy with anti–CD3 monoclonal antibodies and recombinant interleukin–2: heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma. Asano T, et al. **J Urol** 1997 Jun;157(6):2396–401
Anti–P–selectin antibody decreases inflammation and thrombus formation in venous thrombosis. Downing LJ, et al. **J Vasc Surg** 1997 May;25(5):816–27; discussion 828
Modulation of murine AIDS–related pathology by concurrent antibody treatment and coinfection with Leishmania major. Doherty TM, et al. **J Virol** 1997 May; 71(5):3702–9
A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin–specific antibodies that display very low virus–neutralizing activity in vitro. Mozdzanowska K, et al. **J Virol** 1997 Jun; 71(6):4347–55
The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty [editorial; comment] Fischman DL, et al. **JAMA** 1997 Aug 13; 278(6):518–9. Comment on: JAMA 1997 Aug 13;278(6):479–84.
Monoclonal antibody to treat lymphoma [news] Marwick C. **JAMA** 1997 Aug 27;278(8):616, 618
Biological response modifiers may yield a new class of drugs to treat arthritis [news] Skolnick AA. **JAMA** 1997 Jan 22–29;277(4):276–8
Long–term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication [see comments] Topol EJ, et al. **JAMA** 1997 Aug 13;278(6):479–84. Comment in: JAMA 1997 Aug 13;278(6):518–9.
Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin–8. Matsumoto T, et al. **Lab Invest** 1997 Aug;77(2):119–25
Prevention of endotoxemia–induced acute respiratory distress syndrome–like lung injury in rabbits by a monoclonal antibody to IL–8. Yokoi K, et al. **Lab Invest** 1997 Mar; 76(3):375–84
Cytokine therapy in rheumatoid arthritis [letter] Maini RN, et al. **Lancet** 1996 Sep 21;348(9030):824–5
The CAPTURE trial [letter] Umans VA, et al. **Lancet** 1997 Aug 9;350(9075):445
Monoclonal antibodies in the treatment of non–Hodgkin's lymphoma: recent results and future prospects. Renner C, et al. **Leukemia** 1997 Apr;11 Suppl 2:S55–9 (41 ref.)
Pitfalls in the use of surrogate markers for human immunodeficiency virus disease: further evidence on pathogenesis. Allen AD, et al. **Med Hypotheses** 1996 Jul; 47(1):27–30
Anti–tumoral effect of GM–CSF with or without cytokines and monoclonal antibodies in solid tumors. Ragnhammar P. **Med Oncol** 1996 Sep;13(3):167–76 (64 ref.)
Anti–idiotypic monoclonal antibodies as therapeutic vaccines [letter; comment] Ferrone S. **Melanoma Res** 1996 Apr; 6(2):179. Comment on: Melanoma Res 1996 Feb;6(1):5–10.
Resolution of CNS lesions following treatment of experimental allergic encephalomyelitis in macaques with monoclonal antibody to the CD18 leukocyte integrin. Rose LM, et al. **Mult Scler** 1997 Jan;2(6):259–66
Platelet glycoprotein IIb/IIIa receptor blockade and low–dose heparin during percutaneous coronary revascularization. The EPILOG Investigators [see comments] **N Engl J Med** 1997 Jun 12;336(24):1689–96. Comment in: N Engl J Med 1997 Jun 12;336(24):1748–9.
Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty [letter] Gambassi G, et al. **N Engl J Med** 1997 Oct 23;337(17):1243–4
Preventing coronary restenosis and complications [editorial; comment] Holmes DR Jr. **N Engl J Med** 1997 Jun 12; 336(24):1748–9. Comment on: N Engl J Med 1997 Jun 12;336(24):1689–96. Comment on: N Engl J Med 1997 Jun 12;336(24):1697–703.
Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty [letter] Khan SS, et al. **N Engl J Med** 1997 Oct 23;337(17):1243; discussion 1244–5
A short–term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. Targan SR, et al. **N Engl J Med** 1997 Oct 9;337(15):1029–35
Genentech and IDEC await approval of lymphoma Mab [news] **Nat Biotechnol** 1997 Apr;15(4):301
Monoclonal antibodies against the 4–1BB T–cell activation molecule eradicate established tumors. Melero I, et al. **Nat Med** 1997 Jun;3(6):682–5
Adhesion molecules and the mechanisms of kidney rejection [editorial] de Bustillo EM, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):949–52 (34 ref.)
New insights into therapy with monoclonal antibodies in allograft transplantation. Schena FP. **Nephrol Dial Transplant** 1997;12 Suppl 1:55–8 (29 ref.)
Effects of anti–CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM–T412. Llewellyn–Smith N, et al. **Neurology** 1997 Apr;48(4):810–6
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti–tumor necrosis factor antibody cA2. van Oosten BW, et al. **Neurology** 1996 Dec;47(6):1531–4
Treatment of multiple sclerosis with the monoclonal anti–CD4 antibody cM–T412: results of a randomized, double–blind, placebo–controlled, MR–monitored phase II trial. van Oosten BW, et al. **Neurology** 1997 Aug; 49(2):351–7
A phase I study of an anti–epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Faillot T, et al. **Neurosurgery** 1996 Sep; 39(3):478–83
Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG–72 antigen. Divgi CR, et al. **Nucl Med Biol** 1994 Jan;21(1):9–15
Immunologic advances in monoclonal antibody therapy: implications for oncology nursing. Karius D, et al. **Oncol Nurs Forum** 1997 Apr;24(3):483–94; QUIZ 495–6 (74 ref.)
Clinical trial to evaluate antitumor activity of epidermal growth factor in breast cancer [news] **Oncology (Huntingt)** 1996 May;10(5):709
Radiolabeled–M195 shows promise in myeloid leukemias [news] **Oncology (Huntingt)** 1995 Jul;9(7):671–2
Monoclonal antibody therapy of inflammatory bowel disease. van Deventer SJ, et al. **Pharm World Sci** 1997 Apr; 19(2):55–9 (35 ref.)
New peptide and protein drugs. Vermeij P, et al. **Pharm World Sci** 1996 Jun;18(3):87–93 (81 ref.)
A lymphocyte–activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice. Hardy B, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5756–60
T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Yuan RR, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2483–8
Clinical trials update [news] Kayser SR. **Prog Cardiovasc Nurs** 1997 Spring;12(2):30–3, 44 (10 ref.)
Exploration of novel strategies to enhance monoclonal antibodies targeting. Khawli LA, et al. **Q J Nucl Med** 1997 Mar;41(1):25–35 (80 ref.)
Treating Wegener's granulomatosis [letter; comment] Cameron JS. **QJM** 1997 Jun;90(6):431. Comment on: QJM 1996 Dec;89(12):903–12.
Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies [see comments] Lockwood CM, et al. **QJM** 1996 Dec;89(12):903–12. Comment in: QJM 1997 Jun;90(6):431.
Antibody–based immunotherapeutic strategies in colorectal cancer. Holz E, et al. **Recent Results Cancer Res** 1996; 142:381–400 (90 ref.)
NMR monitoring of rheumatoid arthritis patients receiving anti–TNF–alpha monoclonal antibody therapy. Kalden–Nemeth D, et al. **Rheumatol Int** 1997;16(6):249–55
TNF and anti–TNF treatment in rheumatoid arthritis (RA). What we know and what we still need to know. Weisman MH. **Ryumachi** 1997 Apr;37(2):142–3
New therapies for inflammatory bowel disease: an update on chimeric anti–TNF alpha antibodies and IL–10 therapy. van Hogezand RA, et al. **Scand J Gastroenterol Suppl** 1997; 223:105–7 (105 ref.)
Effect of monoclonal and polyclonal antibodies against conjugated neurotransmitter on experimental venous thrombosis. Belougne E, et al. **Semin Thromb Hemost** 1996; 22 Suppl 1:49–52
Hemostatic parameters in sepsis patients treated with anti–TNF alpha–monoclonal antibodies. Salat C, et al. **Shock** 1996 Oct;6(4):233–7
Anti–selectin therapy modifies skeletal muscle ischemia and reperfusion injury. Weiser MR, et al. **Shock** 1996 Jun; 5(6):402–7
Monoclonal antibodies in cancer therapy. Gruber R, et al. **Springer Semin Immunopathol** 1996;18(2):243–51 (57 ref.)
Protective effect of monoclonal antibodies to adhesion molecules on rat liver ischemia–reperfusion injury. Marubayashi S, et al. **Surgery** 1997 Jul;122(1):45–52
Tolerance to heart and kidney grafts induced by nondepleting anti–CD4 monoclonal antibody (RIB 5/2) versus depleting anti–CD4 monoclonal antibody (OX–38) with donor antigen administration. Motoyama K, et al. **Surgery** 1997 Aug;122(2):213–9; discussion 219–20
GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Coller BS. **Thromb Haemost** 1997 Jul;78(1):730–5 (42 ref.)
Monoclonal anti–D for prophylaxis of RhD haemolytic disease of the newborn. Kumpel BM. **Transfus Clin Biol** 1997 Jul;4(4):351–6
Monoclonal anti–D is not effective in the treatment of chronic autoimmune thrombocytopenic purpura [letter; comment] Atrah HI. **Transfusion** 1997 Apr;37(4):444; discussion 445–6. Comment on: Transfusion 1996 Apr;36(4):328–30.
Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti–D: lack of efficiency due to absence of Fc gammaR–inhibiting activity? [letter; comment] Neppert J, et al. **Transfusion** 1997 Apr; 37(4):444–5; discussion 445–6. Comment on: Transfusion 1996 Apr;36(4):328–30.
An anti–CD44 antibody does not enhance engraftment of DLA–identical marrow after low–dose total body irradiation. Sandmaier BM, et al. **Transpl Immunol** 1996 Dec;4(4):271–4
Treatment with monoclonal antibodies to ICAM–1 and LFA–1 in rat heart allograft rejection. Brandt M, et al. **Transpl Int** 1997;10(2):141–4
Anti–integrin (LFA–1, VLA–4, and Mac–1) antibody treatment and acute cardiac graft rejection in the rat. Paul LC, et al. **Transpl Int** 1996;9(4):420–5
Successful treatment of posttransplant lymphoproliferative disorder with renal graft preservation by monoclonal antibody therapy. Antoine C, et al. **Transplant Proc** 1996 Oct;28(5):2825–6
Anti–CD45RB treatment prolongs islet allograft survival in mice. Auersvald LA, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):771
Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. Bagshawe KD, et al. **Transplant Proc** 1996 Dec;28(6):3156–8
Prevention of rejection with BTI–322 after renal transplantation (results at 9 months). Besse T, et al. **Transplant Proc** 1997 Aug;29(5):2425–6
Combined monoclonal antibody therapy in experimental small bowel transplantation. Bowles MJ, et al. **Transplant Proc** 1996 Oct;28(5):2510
T10B9 action: the effect of anti–T–cell antibody mitogenicity and graft rejection on the first dose cytokine response. Brown S, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):315–6
Rescue therapy with interleukin–2 receptor antibody in high risk kidney transplant patients: a 3–year follow–up study. Carl S, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):320–2
Biological immunosuppressants: the way to clinical transplantation tolerance. Chatenoud L. **Transplant Proc** 1997 Feb–Mar;29(1–2):51–5 (44 ref.)
Modulation of graft–vs–host–related disease by host–specific natural killer cell activity following semiallogeneic small

bowel transplantation in the rat. Fändrich F, et al. **Transplant Proc** 1996 Dec;28(6):3267–8

Selective immunosuppression induces tolerance after liver transplantation: an immunohistochemical and cytofluorographic analysis of the graft and recipient immune system. Gassel HJ, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1163

Synergism of CTLA4–IG and anti–CD4 monoclonal antibody treatment in a rat kidney transplant model. Graser E, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1307–9

Treatment of murine cardiac allograft by monoclonal antibodies to IL–2 receptor alpha chain and beta chain. Isobe M, et al. **Transplant Proc** 1997 Jun;29(4):2301–2

Bidirectional blockade of CD4 and MHC class II molecules is an effective immunosuppressive treatment. Ito H, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1288–9

Effect of mycophenolate mofetil with and without anti–CD4 (GK1.5) on fetal islet iso–, allo–, and xenografts in NOD/Lt female mice. Koulmanda M, et al. **Transplant Proc** 1997 Jun;29(4):2161–2

Anti–CD4/CyA therapy causes prevention of autoimmune but not allogeneic destruction of grafted islets in BB rats. Kuttler B, et al. **Transplant Proc** 1997 Jun;29(4):2163–5

Therapy for mouse renal allograft rejection by monoclonal antibody to CD45RB. Lazarovits AI, et al. **Transplant Proc** 1996 Dec;28(6):3208–9

BTI–322 for acute rejection after renal transplantation. Mourad M, et al. **Transplant Proc** 1997 Aug;29(5):2353

BT563 significantly decreases sIL–2R plasma levels despite acute allograft rejection. Mueller AR, et al. **Transplant Proc** 1996 Dec;28(6):3103–5

Rat kidney graft survival after elimination of MHC class II–positive cells by perfusion with monoclonal antibody. Oko A, et al. **Transplant Proc** 1996 Dec;28(6):3480–2

CD4–targeted therapy induces "infectious" tolerance to cardiac allografts in sensitized rat recipients. Onodera K, et al. **Transplant Proc** 1997 May;29(3):1907–8

Influence of the anti–CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation. Otto G, et al. **Transplant Proc** 1996 Dec; 28(6):3210–1

Inhibition of chronic rejection after kidney transplantation by anti–CD4 treatment. Risch K, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):328–9

Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection: analysis beyond 4 years. Sharma LC, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):323–4

BTI–322 for induction therapy after renal transplantation: a randomized study. Squifflet JP, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):317–9

Monoclonal antibodies in organ transplantation. Valdés RH. **Transplant Proc** 1996 Dec;28(6):3293

Long–term follow–up after induction treatment with monoclonal anti–interleukin–2 receptor antibody (BT563) in kidney allograft recipients: a double–blind, placebo–controlled trial. van Gelder T, et al. **Transplant Proc** 1996 Dec;28(6):3221–2

Rejection mechanism and immunosuppression by FK 506 and anti–leukocyte function associated antigen–1 antibody in concordant corneal xenotransplantation. Yamagami S, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):943–4

Prolongation of corneal xenograft survival with deoxyspergualin and anti–LFA–1 monoclonal antibody. Yamagami S, et al. **Transplant Proc** 1997 Jun;29(4):2288–9

Impact of antibodies to leukocyte function–associated antigen–1 and intercellular adhesion molecule–1 on fetal bowel allo– and xenotransplantation in mice. Yamataka A, et al. **Transplant Proc** 1996 Oct;28(5):2494–5

CD45RB monoclonal antibody induces tolerance in the mouse kidney graft, but fails to prevent small bowel graft rejection. Zhang Z, et al. **Transplant Proc** 1996 Oct; 28(5):2514

Prevention of heart allograft and kidney xenograft rejection by monoclonal antibody to CD45RB. Zhang Z, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1253

Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Cooperative Clinical Trials in Transplantation Research Group. **Transplantation** 1997 May 15;63(9):1243–51

Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a Cooperative Clinical Trials in Transplantation pilot study. **Transplantation** 1997 Apr 27; 63(8):1087–95

Efficacy of rejection prophylaxis with OKT3 [letter; comment] Abramowicz D, et al. **Transplantation** 1996 Sep 15;62(5):700–1. Comment on: Transplantation 1995 Dec 15;60(11):1220–4.

Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX–38) anti–CD4 mAb plus intrathymic or intravenous donor alloantigen. Arima T, et al. **Transplantation** 1997 Jan 27;63(2):284–92

Anti–CD4 MoAb therapy in kidney transplantation––a pilot study in early prophylaxis of rejection. Dantal J, et al. **Transplantation** 1996 Nov 27;62(10):1502–6

Attenuation of rat lung isograft reperfusion injury with a combination of anti–ICAM–1 and anti–beta2 integrin monoclonal antibodies. DeMeester SR, et al. **Transplantation** 1996 Nov 27;62(10):1477–85

Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti–CD4 treated recipients. Hamano K, et al. **Transplantation** 1996 Sep 27;62(6):856–60

A randomized multicenter trial comparing leukocyte function–associated antigen–1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Hourmant M, et al. **Transplantation** 1996 Dec 15;62(11):1565–70

Acceptance of primary skin graft after treatment with anti–intercellular adhesion molecule–1 and anti–leukocyte function–associated antigen–1 monoclonal antibodies in mice. Isobe M, et al. **Transplantation** 1996 Aug 15; 62(3):411–3

A prospective randomized trial comparing interleukin–2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Langrehr JM, et al. **Transplantation** 1997 Jun 27;63(12):1772–81

Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. Markees TG, et al. **Transplantation** 1997 Jul 27; 64(2):329–35

Long–term survival of solid organ allografts by brief anti–lymphocyte function–associated antigen–1 monoclonal antibody monotherapy. Nakakura EK, et al. **Transplantation** 1996 Sep 15;62(5):547–52

A phase I trial of humanized anti–interleukin 2 receptor antibody in renal transplantation. Vincenti F, et al. **Transplantation** 1997 Jan 15;63(1):33–8

Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Waid TH, et al. **Transplantation** 1997 Jul 27;64(2):274–81

Immunosuppression by inhibition of cellular adhesion mediated by leukocyte function–associated antigen–1/intercellular adhesion molecule–1 in murine cardiac transplantation. Xu XY, et al. **Transplantation** 1997 Mar 27;63(6):876–85

Effect of anti–CD4 monoclonal antibody combined with human CTLA4Ig on the survival of hamster liver and heart xenografts in Lewis rats. Yin DP, et al. **Transplantation** 1997 Jul 27;64(2):317–21

Radioimmunodetection and radioimmunotherapy of breast cancer. Riva P, et al. **Tumori** 1997 Mar–Apr;83(2):552–7

Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2. Corbeil S, et al. **Vaccine** 1996 Apr; 14(6):521–5

Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231. Jeglum KA. **Vet Clin North Am Small Anim Pract** 1996 Jan;26(1):73–85 (19 ref.)

Coronary artery stenting during acute myocardial infarction in patients treated with IIb/IIIa anti–platelet antibodies: early outcome results. Murdock DK, et al. **Wis Med J** 1996 Dec;95(12):867–71

[Protective effect of lipid A monoclonal antibody against burn sepsis in rats] Xiao H, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 May;12(3):167–70 (Eng. Abstr.) **(Chi)**

[Campath–1H—a monoclonal antibody for treatment of non–Hodgkin's and chronic lymphatic leukemia] de Nully Brown P, et al. **Ugeskr Laeger** 1997 Jul 7;159(28):4389–93 (Eng. Abstr.) **(Dan)**

[Treatment of colorectal cancer with monoclonal antibodies (see comments)] Nielsen SE. **Ugeskr Laeger** 1997 May 19; 159(21):3134–9 (40 ref.) (Eng. Abstr.). Comment in: Ugeskr Laeger 1997 Aug 18;159(34):5110–1. **(Dan)**

[Attempt at preventing hyperacute xenogenic rejection by isotopic suppression of IgM in the recipient] Pitre J, et al. **Ann Chir** 1996;50(7):524–31 (37 ref.) (Eng. Abstr.) **(Fre)**

[Modern "antiplatelet agents" in unstable angina] Vahanian A, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1521–6 (27 ref.) (Eng. Abstr.) **(Fre)**

[Monoclonal antibodies and transplantation] Hourmant M. **Nephrologie** 1996;17(8):435–40 (64 ref.) (Eng. Abstr.) **(Fre)**

[Tumor targeting in colon cancer. Antibody therapy––a new adjuvant application] **Chirurg** 1995 Jul;66(7 Suppl):1–4 **(Ger)**

[Treatment of a large intracoronary thrombus with urokinase and a chimeric monoclonal platelet aggregation inhibitor] Eick B, et al. **Dtsch Med Wochenschr** 1997 May 30; 122(22):709–15 (Eng. Abstr.) **(Ger)**

[Therapeutic use of monoclonal antibodies] Baron D. **Naturwissenschaften** 1997 May;84(5):189–98 (7 ref.) (Eng. Abstr.) **(Ger)**

[Current therapy of multiple sclerosis. Therapy with monoclonal antibodies to T–cell antigens (CD3, CD4, CD52)] Schmidt S, et al. **Nervenarzt** 1996 Feb;67(2):170–6 (44 ref.) (Eng. Abstr.) **(Ger)**

[The adjuvant use of the monoclonal antibody c7E3 Fab in peripheral arterial thrombolysis] Tepe G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):254–7 (Eng. Abstr.) **(Ger)**

[Monoclonal antibody therapy (editorial)] Pitzalis C, et al. **Recenti Prog Med** 1997 Mar;88(3):128–33 (Eng. Abstr.) **(Ita)**

[New therapeutic approach to pancreatic cancer by monoclonal antibodies] Sawada T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1654–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Application of chimeric and humanized antibodies to autoimmune diseases therapy] Noguchi H. **Nippon Rinsho** 1997 Jun;55(6):1549–56 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Overcoming of multidrug resistance by anti–P–glycoprotein monoclonal antibody] Nokihara H, et al. **Nippon Rinsho** 1997 May;55(5):1128–34 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Monoclonal antibodies for treating autoimmune diseases] Takeno M, et al. **Nippon Rinsho** 1997 Jun;55(6):1543–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Antitumor effect of anti–myeloma cell antibody on human plasmacytoma model] Kosaka M, et al. **Rinsho Ketsueki** 1997 Apr;38(4):275–80 **(Jpn)**

TOXICITY

Collagen–induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Terato K, et al. **Autoimmunity** 1995; 22(3):137–47

Comparison of site–specific injections into the basal forebrain on water maze and radial arm maze performance in the male rat after immunolesioning with 192 IgG saporin. Dornan WA, et al. **Behav Brain Res** 1996 Dec;82(1):93–101

Oral administration of propentofylline, a stimulator of nerve growth factor (NGF) synthesis, recovers cholinergic neuronal dysfunction induced by the infusion of anti–NGF antibody into the rat septum. Nitta A, et al. **Behav Brain Res** 1997 Feb;83(1–2):201–4

Interferon–gamma mediates host resistance in a murine model of melioidosis. Santanirand P, et al. **Biochem Soc Trans** 1997 May;25(2):287S

Effects of intraseptal injection of 192–IgG–saporin in mature and aged Long–Evans rats. Bannon AW, et al. **Brain Res** 1996 Apr 29;718(1–2):25–36

192 IgG–saporin lesion of basal forebrain cholinergic neurons in neonatal rats. Pappas BA, et al. **Brain Res Dev Brain Res** 1996 Oct 23;96(1–2):52–61

Selective immunolesioning of the basal forebrain cholinergic system disrupts short–term memory in rats. Leanza G, et al. **Eur J Neurosci** 1996 Jul;8(7):1535–44

Propentofylline prevents neuronal dysfunction induced by infusion of anti–nerve growth factor antibody into the rat septum. Nitta A, et al. **Eur J Pharmacol** 1996 Jun 20; 307(1):1–6

Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Savoy AC, et al. **Infect Immun** 1997 May;65(5):1800–7

Identification of rat yolk sac target protein of teratogenic antibodies, gp280, as intrinsic factor–cobalamin receptor. Seetharam B, et al. **J Clin Invest** 1997 May 15; 99(10):2317–22

Cholinergic control of nerve growth factor in adult rats: evidence from cortical cholinergic deafferentation and chronic drug treatment. Rossner S, et al. **J Neurochem** 1997 Sep;69(3):947–53

Pathogenesis of the neurotoxicity caused by anti–GD2 antibody therapy. Yuki N, et al. **J Neurol Sci** 1997 Aug; 149(2):127–30

Electron microscopic evidence for microglial phagocytic activity and cholinergic cell death after administration of the immunotoxin 192IgG–saporin in rat. Seeger G, et al. **J Neurosci Res** 1997 Jun 1;48(5):465–76

Altered NGF protein levels in different brain areas after immunolesion. Yu J, et al. **J Neurosci Res** 1996 Jan 15; 43(2):213–23

Toxicity profile of the investigational new biotherapeutic agent, B43 (anti–CD19)–pokeweed antiviral protein immunotoxin. Gunther R, et al. **Leuk Lymphoma** 1996 Jun; 22(1–2):61–70, follow.186, color plate II–V

Immunolesion by 192IgG–saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. Schliebs R, et al. **Prog Brain Res** 1996;109:253–64 (57 ref.)

Safety and kinetic properties of a humanized antibody to human interleukin–6 receptor in healthy non–human primates. Shinkura H, et al. **Toxicology** 1997 Oct 19; 122(3):163–70

ULTRASTRUCTURE

Expression of an anti–H58A monoclonal antibody recognized molecule in rabbit tonsillar epithelium. Olah I, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:34–7

Crystal structures of the free and liganded form of an esterolytic catalytic antibody. Wedemayer GJ, et al. **J Mol Biol** 1997 May 2;268(2):390–400

URINE

Buflomedil interference with the monoclonal EMIT d.a.u. amphetamine/methamphetamine immunoassay. Papa P, et al. **Eur J Clin Chem Clin Biochem** 1997 May;35(5):369–70

ANTIBODIES, NEOPLASM

Ber–EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu–M1. Bailey ME, et al. **Acta Cytol** 1996 Nov–Dec; 40(6):1212–6

ANTIBODIES, NEOPLASM

ADMINISTRATION & DOSAGE

Immunoliposomes for cancer treatment. Park JW, et al. **Adv Pharmacol** 1997;40:399–435 (135 ref.)

A streptococcal preparation (OK–432) enhances monoclonal antibody NCC–ST–421 cytotoxicity against human colon cancer. Kawano Y, et al. **Anticancer Res** 1997 Jul–Aug; 17(4A):2449–53

Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism. Taylor VC, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):919–25

Postural effects on peritoneal transport and systemic uptake of radiolabeled monoclonal antibodies. Barrett JS, et al. **Cancer Immunol Immunother** 1997 May;44(3):173–8

Persistence of CD4+ T cells in the arthritic joint after CAMPATH–1H treatment [letter] Finnegan A, et al. **J Rheumatol** 1997 Jul;24(7):1448–9

ADVERSE EFFECTS

Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Tang SC, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):93–101

ANALYSIS

Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Jones RC, et al. **Ann Surg Oncol** 1996 Sep;3(5):437–45

p53 serum antibodies as prognostic indicator in head and neck cancer. Werner JA, et al. **Cancer Immunol Immunother** 1997 Apr;44(2):112–6

Humoral immune response against p53 protein in patients with colorectal carcinoma. Angelopoulou K, et al. **Int J Cancer** 1997 Jan 6;70(1):46–51

Fast, reproducible size–exclusion chromatography of biological macromolecules. Ricker RD, et al. **J Chromatogr A** 1996 Aug 30;743(1):43–50

Anti–Hu antibodies in patients with small–cell lung cancer: association with complete response to therapy and improved survival. Graus F, et al. **J Clin Oncol** 1997 Aug; 15(8):2866–72

Specificity of plasma cell antibody VS38 [letter; comment] Al–Janabi K, et al. **J Clin Pathol** 1996 Aug;49(8):694. Comment on: J Clin Pathol 1996 Mar;49(3):205–7.

Antibodies against mucin–associated sialyl–Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. MacLean GD, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jan; 19(1):59–68

Predominant downgaze ophthalmoparesis in anti–Hu encephalomyelitis [letter; comment] Schiff ND, et al. **J Neuroophthalmol** 1996 Dec;16(4):302–3. Comment on: J Neuroophthalmol 1996 Mar;16(1):44–8.

Infiltration of lung carcinomas with macrophages of the 27E10–positive phenotype. Endress H, et al. **Lung Cancer** 1997 Aug;18(1):35–46

[Antibodies to cardiolipin and tumor–associated antigens CA–125 and CA–19–9 in patients with ovarian tumors] Karpov NI, et al. **Klin Med (Mosk)** 1996;74(4):42–5 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Cellular cancer vaccine induces delayed–type hypersensitivity reaction and augments antibody response to tumor–associated carbohydrate antigens (sialyl Le(a), sialyl Le(x), GD3 and GM2) better than soluble lysate cancer vaccine. Ravindranath MH, et al. **Anticancer Drugs** 1997 Mar;8(3):217–24

Isolation of anti–colorectal tumour antibodies from a phage–display library. Topping KP, et al. **Biochem Soc Trans** 1997 May;25(2):268S

Efficiency of T cell triggering by anti–CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation. Jacobs N, et al. **Cancer Immunol Immunother** 1997 Jul;44(5):257–64

Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME–1 expression. Bateman AC, et al. **Histopathology** 1997 Jan;30(1):49–56

Lung cancer–reacting human recombinant antibody AE6F4: potential usefulness in the sputum cytodiagnosis. Shoji M, et al. **Hum Antibodies Hybridomas** 1996;7(1):27–36

Isotype–directed enrichment of B cells by magnetic beads in the generation of immunoreactive human monoclonal antibodies. McKnight ME, et al. **Hybridoma** 1996 Aug; 15(4):255–61

The humoral response to the tumor–suppressor gene–product p53 in human cancer: implications for diagnosis and therapy. Soussi T. **Immunol Today** 1996 Aug;17(8):354–6

Cell–cell adherence as a selection method for the generation of anti–melanoma monoclonal antibodies. Barral AM, et al. **J Immunol Methods** 1997 Apr 11;203(1):103–9

Construction and expression of single–chain Fv antibody against human bladder carcinoma. Yu LZ, et al. **Urol Res** 1996;24(5):273–7

BLOOD

Melanoma–associated hypopigmentation: where are the antibodies? Merimsky O, et al. **Am J Clin Oncol** 1996 Dec; 19(6):613–8

Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. Gadducci A, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3519–23

Selective decrease of serum immunoglobulin G1 as a marker of malignant transformation in colorectal tissue. Schauenstein E, et al. **Cancer** 1997 Apr 15;79(8):1482–6

Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Hammel P, et al. **Gut** 1997 Mar; 40(3):356–61

Characterisation and clinicopathological correlates of serum anti–p53 antibodies in breast and colon cancer. Coomber D, et al. **J Cancer Res Clin Oncol** 1996;122(12):757–62

Detection of hepatocellular carcinoma with a new alpha–fetoprotein antibody imaging kit. Dresel S, et al. **J Clin Oncol** 1997 Jul;15(7):2683–90

Antibodies to interferon–alpha in treated cancer patients: incidence and significance. McKenna RM, et al. **J Interferon Cytokine Res** 1997 Mar;17(3):141–3 (25 ref.)

Serum anti–p53 antibodies and prognosis of patients with small–cell lung cancer. Rosenfeld MR, et al. **J Natl Cancer Inst** 1997 Mar 5;89(5):381–5

Naturally occurring humoral cytotoxicity against neuroblastoma (NB) cells in healthy persons and NB patients. Erttmann R, et al. **Pediatr Hematol Oncol** 1996 Nov–Dec;13(6):545–8

Antineuronal antibody in a patient with neuroblastoma and opsoclonus–myoclonus–ataxia: a case report. Salmaggi A, et al. **Tumori** 1997 May–Jun;83(3):709–11

[Serological analysis of antibodies by anti–idiotypic monoclonal antibody 6B11 against ovarian carcinoma] Feng J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Aug; 31(8):493–5 (Eng. Abstr.) **(Chi)**

[Oncoproteins and anti–oncoproteins in blood serum as biomarkers of early health effects induced by occupational and environmental carcinogens] Lutz W, et al. **Med Pr** 1996;47(5):511–8 (29 ref.) (Eng. Abstr.) **(Pol)**

CEREBROSPINAL FLUID

Antineuronal antibody in a patient with neuroblastoma and opsoclonus–myoclonus–ataxia: a case report. Salmaggi A, et al. **Tumori** 1997 May–Jun;83(3):709–11

CHEMISTRY

Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha–linked galactose. Sheeley DM, et al. **Anal Biochem** 1997 Apr 5;247(1):102–10

Evaluation of a direct method for technetium labeling intact and F(ab')2 1A3, an anticolorectal monoclonal antibody. Schwarz SW, et al. **Nucl Med Biol** 1994 May;21(4):619–26

Homodimerization of tumor–reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Ghetie MA, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7509–14

Redesigned anti–human placental alkaline phosphatase single–chain Fv: soluble expression, characterization and in vivo tumour targeting. Deonarain MP, et al. **Protein Eng** 1997 Jan;10(1):89–98

DIAGNOSTIC USE

Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Delahaye M, et al. **Diagn Cytopathol** 1997 Aug;17(2):115–20

Limited value of the NKI/C3–antibody for the differential diagnosis of Paget's disease of the nipple and intra–epidermal malignant melanoma. Biesterfeld S, et al. **Histopathology** 1996 Mar;28(3):269–70

Diagnostic use of radiolabeled antibodies for cancer. Harrison KA, et al. **Oncology (Huntingt)** 1995 Jul;9(7):625–31 DISC 634, 636, 641 (45 ref.)

Radioimmunodetection and radioimmunotherapy of breast cancer. Riva P, et al. **Tumori** 1997 Mar–Apr;83(2):552–7

GENETICS

Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha–linked galactose. Sheeley DM, et al. **Anal Biochem** 1997 Apr 5;247(1):102–10

In vivo gene inoculation of a recombinant single–chain antitumor antibody induces anti–immunoglobulin response. Prasad GL, et al. **Cancer Gene Ther** 1997 Jul–Aug; 4(4):253–9

Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti–erbB–2 intracellular single–chain antibody for ovarian cancer gene therapy. Deshane J, et al. **Gynecol Oncol** 1997 Mar;64(3):378–85

Cloning and expression of cDNAs encoding the variable domains of the antibreast carcinoma antibody Mc5. Christian RB, et al. **Hybridoma** 1996 Apr;15(2):155–8

A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. Rosok MJ, et al. **J Biol Chem** 1996 Sep 13;271(37):22611–8

Redesigned anti–human placental alkaline phosphatase single–chain Fv: soluble expression, characterization and in vivo tumour targeting. Deonarain MP, et al. **Protein Eng** 1997 Jan;10(1):89–98

Construction and expression of single–chain Fv antibody against human bladder carcinoma. Yu LZ, et al. **Urol Res** 1996;24(5):273–7

IMMUNOLOGY

Targeted tumor cytotoxicity mediated by intracellular single–chain anti–oncogene antibodies. Curiel DT. **Adv Pharmacol** 1997;40:51–84 (76 ref.)

The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Pittaluga S, et al. **Am J Pathol** 1997 Aug;151(2):343–51

Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)–associated E2A/pbx1 chimeric protein: characterization and diagnostic utility. Sang BC, et al. **Blood** 1997 Apr 15;89(8):2909–14

Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Livingston P, et al. **Cancer Immunol Immunother** 1997 Jan; 43(6):324–30

Specificity of antibodies directed against Env protein of human endogenous retroviruses in patients with germ cell tumors. Sauter M, et al. **Cancer Res** 1996 Oct 1; 56(19):4362–5

Detection of activated platelet–derived growth factor receptors in human meningioma. Shamah SM, et al. **Cancer Res** 1997 Sep 15;57(18):4141–7

Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region. Petrarca C, et al. **Eur J Cancer** 1996 Nov;32A(12):2155–63

Synergy between an antibody and CD8+ cells in eliminating an established tumor. Vasović LV, et al. **Eur J Immunol** 1997 Feb;27(2):374–82

In vitro mimicry of CaMBr1 tumor–associated antigen by synthetic oligosaccharides. Adobati E, et al. **Glycobiology** 1997 Mar;7(2):173–8

Mesothelioma–binding antibodies: thrombomodulin, OV 632 and HBME–1 and their use in the diagnosis of malignant mesothelioma. Attanoos RL, et al. **Histopathology** 1996 Sep;29(3):209–15

VS38 immunostaining in neuroendocrine tumours. Banerjee SS, et al. **Histopathology** 1997 Mar;30(3):256–9

Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells. Xiang J, et al. **Hum Antibodies Hybridomas** 1996;7(1):2–10

Characterization of the ETSA–21 antigen, a glycosylphosphatidyl–inositol anchor glycoprotein identified in breast cancer cells using monoclonal antibody B21. Annibali NV, et al. **Hybridoma** 1997 Apr;16(2):139–45

Combinatorial antibodies against human malignant melanoma. Pereira S, et al. **Hybridoma** 1997 Feb;16(1):11–6

Anti–TAG–72 antibody B72.3––immunological and clinical effects in ovarian carcinoma. Schmolling J, et al. **Hybridoma** 1997 Feb;16(1):53–8

Generation and application of monoclonal antibody to human pancreatic carcinoma. Yuan S, et al. **Hybridoma** 1996 Aug; 15(4):289–93

How to overcome the disturbing effects of human anti–mouse antibodies (HAMA) on in vitro assays. Oltrogge JB, et al. **Int J Biol Markers** 1997 Jan–Mar;12(1):15–7

Localized diffuse large–cell lymphoma possibly coated with anti–tumor autoantibody: kappa lambda–dual–positive lymphoma. Nakano M, et al. **Int J Hematol** 1997 Apr; 65(3):299–304

Tissue distribution of a melanoma–associated antigen immunogenic in patients with melanoma as analyzed by polyclonal antibodies to recombinant peptide antigen. Kako S, et al. **J Dermatol** 1996 Apr;23(4):230–7

Multivalent antibody fragments with high functional affinity for a tumor–associated carbohydrate antigen. Rheinnecker M, et al. **J Immunol** 1996 Oct 1;157(7):2989–97

Differential CD45 isoform expression accompanies reduced natural antibody binding in L5178Y–F9 tumor progression. Zhang ZY, et al. **J Immunol** 1997 Jul 1;159(1):344–50

Paraneoplastic retinopathy: a novel autoantibody reaction associated with small–cell lung carcinoma. Murphy MA, et al. **J Neuroophthalmol** 1997 Jun;17(2):77–83

Influence of a syngeneic anti–idiotypic antibody response to a mouse anti–tumour monoclonal antibody on biodistribution of its radiolabelled Fc–intact monovalent Fab/c fragment. Pimm MV, et al. **Nucl Med Biol** 1994 Jan;21(1):125–7

Comparison of fusion phage libraries displaying VH or single–chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma–specific targeting molecules. Cai X, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9261–6

Complementarity determining region residues aspartic acid at H55, serine at H95 and tyrosines at H97 and L96 play important roles in the B72.3 antibody–TAG72 antigen interaction. Xiang J, et al. **Protein Eng** 1996 Jun;9(6):539–43

[Advances in the research of anti–idiotypic antibody against ovarian cancer] Zhang X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Sep;31(9):571–4 (26 ref.) **(Chi)**

[P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer (editorial)] Soussi T, et al. **Pathol Biol (Paris)** 1996 Apr;44(4):232–4 (13 ref.) (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Isolation of anti–colorectal tumour antibodies from a phage–display library. Topping KP, et al.

Biochem Soc Trans 1997 May;25(2):268S

High expression of a Lewis(x)-related epitope in gastric carcinomas indicates metastatic potential and poor prognosis. Mayer B, et al. **Gastroenterology** 1996 Dec; 111(6):1433–46

Pilot scale purification of human monoclonal IgM (COU-1) for clinical trials. Tornøe I, et al. **J Immunol Methods** 1997 Jun 23;205(1):11–7

Isolation of anti-mesothelin antibodies from a phage display library. Chowdhury PS, et al. **Mol Immunol** 1997 Jan; 34(1):9–20

METABOLISM

Overexpression of cysteine sulfinic acid decarboxylase stimulated by hepatocarcinogenesis results in autoantibody production in rats. Kishimoto T, et al. **Cancer Res** 1996 Nov 15;56(22):5230–7

Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Attanoos RL, et al. **Histopathology** 1996 Sep;29(3):209–15

PHARMACOLOGY

Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: a comparative study. Hardy B, et al. **Hum Antibodies** 1997;8(2):95–8

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. Wing MG, et al. **J Clin Invest** 1996 Dec 15;98(12):2819–26

Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis. Pruzanski W, et al. **J Rheumatol** 1995 Oct;22(10):1816–9

PHYSIOLOGY

Recombinant anti-human melanoma antibodies are versatile molecules. Neri D, et al. **J Invest Dermatol** 1996 Aug; 107(2):164–70

THERAPEUTIC USE

Immunoliposomes for cancer treatment. Park JW, et al. **Adv Pharmacol** 1997;40:399–435 (135 ref.)

In vivo CAMPATH-1 monoclonal antibodies: a novel mode of therapy for acute graft-versus-host disease [letter] Varadi G, et al. **Am J Hematol** 1996 Jul;52(3):236–7

Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses. Litton MJ, et al. **Am J Pathol** 1997 May; 150(5):1607–18

Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Wooldridge JE, et al. **Blood** 1997 Apr 15;89(8):2994–8

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Bowen AL, et al. **Br J Haematol** 1997 Mar;96(3):617–9

In vivo 'purging' of residual disease in CLL with Campath-1H. Dyer MJ, et al. **Br J Haematol** 1997 Jun; 97(3):669–72

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Killick SB, et al. **Br J Haematol** 1997 May;97(2):306–8

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Isaacs JD, et al. **Clin Exp Immunol** 1996 Dec;106(3):427–33

Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Osterborg A, et al. **Eur J Haematol** 1997 Jan; 58(1):5–13

Effects of diagnostic application of monoclonal antibody on survival in melanoma patients. Bender H, et al. **Hybridoma** 1997 Feb;16(1):65–8

Clinical and immunologic effects of monoclonal antibody CC49 and interleukin-2 in patients with metastatic colorectal cancer. Triozzi PL, et al. **Hybridoma** 1997 Apr; 16(2):147–51

The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Soussi T. **Immunol Today** 1996 Aug;17(8):354–6

The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-1-associated disorders. Waldmann TA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S179–85 (43 ref.)

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Osterborg A, et al. **J Clin Oncol** 1997 Apr;15(4):1567–74

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. Pawson R, et al. **J Clin Oncol** 1997 Jul; 15(7):2667–72

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. Tempero M, et al. **J Clin Oncol** 1997 Apr; 15(4):1518–28

Improved antibody targeting with interferon-alpha-2b conjugate. Thakur ML, et al. **J Immunother** 1997 May; 20(3):194–201

Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. Surfus JE, et al. **J Immunother Emphasis Tumor Immunol** 1996 May; 19(3):184–91

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. Isaacs JD, et al. **J Rheumatol** 1996 Jun;23(6):1103–6

Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes. Schnitzer TJ, et al. **J Rheumatol** 1997 Jun;24(6):1031–6

Radioimmunodetection and radioimmunotherapy of breast cancer. Riva P, et al. **Tumori** 1997 Mar-Apr;83(2):552–7

[Campath-1H—a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia] de Nully Brown P, et al. **Ugeskr Laeger** 1997 Jul 7;159(28):4389–93 (Eng. Abstr.) **(Dan)**

ANTIBODIES, PROTOZOAN

Identification of the C-terminal region of 70 kDa heat shock protein from Leishmania (Viannia) braziliensis as a target for the humoral immune response [published erratum appears in Cell Stress Chaperones 1996 Dec;1(4):263] Amorim AG, et al. **Cell Stress Chaperones** 1996 Sep; 1(3):177–87

ANALYSIS

Recognition of an immunogenetically selected Trypanosoma cruzi antigen by seropositive chagasic human sera. Aguillón JC, et al. **Acta Trop** 1997 Feb;63(2–3):159–66

Humoral immune response to the 72 kDa heat shock protein from Plasmodium falciparum in populations at hypoendemic areas of malaria in western Brazilian Amazon. Alexandre CO, et al. **Acta Trop** 1997 Apr 15;64(3–4):155–66

Exoantigens from trypanosoma cruzi contain cruzipain. Gruppi A, et al. **Acta Trop** 1997 Feb;63(2–3):141–9

Seasonal variation of anti-Plasmodium falciparum antibodies directed against a repetitive peptide of gametocyte antigen pfs2400 in inhabitants in the State of Amapá, Brazil. Marrelli MT, et al. **Acta Trop** 1997 Feb;63(2–3):167–77

The isotype composition and avidity of naturally acquired anti-Plasmodium falciparum antibodies: differential patterns in clinically immune Africans and Amazonian patients. Ferreira MU, et al. **Am J Trop Med Hyg** 1996 Sep;55(3):315–23

Prevalence of anti-Leishmania donovani antibody among Brazilian blood donors and multiply transfused hemodialysis patients. Luz KG, et al. **Am J Trop Med Hyg** 1997 Aug;57(2):168–71

Detection of anti-Entamoeba histolytica IgA salivary antibodies: evaluation of its diagnostic capability in a rural setting. Escandón Romero C, et al. **Arch Med Res** 1997; 28 Spec No:306–8

Anti-E. histolytica IgA antibodies in saliva of E. histolytica or E.dispar infected individuals: longitudinal study of cohorts. Ramos F, et al. **Arch Med Res** 1997;28 Spec No:327–9

Evanescent wave fibre optic sensor for detection of L. donovani specific antibodies in sera of kala azar patients. Nath N, et al. **Biosens Bioelectron** 1997;12(6):491–8

Evaluation of immuno-1 toxoplasma IgG assay in the prenatal screening of toxoplasmosis. Rao LV, et al. **Diagn Microbiol Infect Dis** 1997 Jan-Feb;27(1-2):13–5

Prevalence of Dientamoeba fragilis antibodies in children and recognition of a 39 kDa immunodominant protein antigen of the organism. Chan F, et al. **Eur J Clin Microbiol Infect Dis** 1996 Dec;15(12):950–4

Toxoplasmosis in heart transplant recipients. Gallino A, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):389–93

High predictive value of Toxoplasma gondii IgG antibody levels in HIV-infected patients for diagnosis of cerebral toxoplasmosis. Hellerbrand C, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):869–72

The prevalence of Toxoplasma antibody in patients with various ocular diseases in central Japan. Goto K, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234(8):493–5

Application of peptide ELISA in tribal malaria of Madhya Pradesh. Roy A, et al. **Indian J Malariol** 1996 Sep; 33(3):144–53

Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Soares IS, et al. **Infect Immun** 1997 May;65(5):1606–14

Epidemiology of Toxoplasma gondii in farm ecosystems. Dubey JP, et al. **J Eukaryot Microbiol** 1996 Sep-Oct; 43(5):124S

Anti-Toxoplasma gondii immunoglobulins A and G in human saliva and serum. Loyola AM, et al. **J Oral Pathol Med** 1997 Apr;26(4):187–91

Relationship between Chagas' disease immunoreactivity in pericardial fluid and survival of children. Almeida JA, et al. **J Parasitol** 1997 Jun;83(3):519–20

Dot ELISA for antibody detection in giardiasis. Baqai R, et al. **JPMA J Pak Med Assoc** 1995 Dec;45(12):324

Seroprevalence of antibodies to Toxoplasma gondii, with particular reference to obstetric history of patients in Rawalpindi-Islamabad, Pakistan. Pal RA, et al. **JPMA J Pak Med Assoc** 1996 Mar;46(3):56–8

Toxoplasma antibody titers by ELISA and indirect latex agglutination test in pregnant women. Ryu JS, et al. **Korean J Parasitol** 1996 Dec;34(4):233–8

Uveitis: is ocular toxoplasmosis only a clinical diagnosis? Bornand JE, et al. **Ophthalmologica** 1997;211(2):87–9

Comparison of oocyst shedding and the serum immune response to Cryptosporidium parvum in cattle and pigs. Quílez J, et al. **Parasitol Res** 1996;82(6):529–34

Application of local products R-phycoerythrin and monoclonal antibody as a fluorescent antibody probe to detect Entamoeba histolytica trophozoites. Thammapalerd N, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun;27(2):297–303

An indirect enzyme-linked immunoassay (ELISA) for demonstration of antibodies to Neospora caninum in serum and milk of cattle. Björkman C, et al. **Vet Parasitol** 1997 Feb;68(3):251–60

Novel ELISA for detection of Neospora-specific antibodies in cattle. Williams DJ, et al. **Vet Rec** 1997 Mar 29; 140(13):328–31

Asymptomatic carriers of Babesia canis in an enzootic area. Wlosniewski A, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):75–86 (Eng. Abstr.) **(Fre)**

[Ocular toxoplasmosis: value of immunoblotting for the determination of an intra-ocular synthesis of antibodies] Riss JM, et al. **Pathol Biol (Paris)** 1995 Nov;43(9):772–8 (Eng. Abstr.) **(Fre)**

[Anti-toxoplasma antibody levels in the main-land raccoon dog, Nyctereutes procyonoides viverrinus, in southeastern Kanagawa prefecture] Murasugi E, et al. **Kansenshogaku Zasshi** 1996 Oct;70(10):1068–71 (Eng. Abstr.) **(Jpn)**

[Detection of specific toxoplasma class A antibodies: a comparison of diagnostic usefulness of commercially available diagnostic kits] Bitkowska E, et al. **Med Dosw Mikrobiol** 1996;48(3–4):197–200 (Eng. Abstr.) **(Pol)**

[Antibody avidity in diagnosis of toxoplasmosis] Radkowski M, et al. **Pol Tyg Lek** 1996 Jun;51(23–26):336–7 (Eng. Abstr.) **(Pol)**

[Encephalitozoon cuniculi—clinical and epidemiologic significance. Results of a preliminary serologic study in humans] Cisláková L, et al. **Epidemiol Mikrobiol Imunol** 1997 Mar;46(1):30–3 (Eng. Abstr.) **(Slo)**

BIOSYNTHESIS

Humoral response to defined Plasmodium falciparum antigens in cerebral and uncomplicated malaria and their relationship to parasite genotype. Al-Yaman F, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):430–5

Both epidermal growth factor-like domains of the merozoite surface protein-1 from Plasmodium yoelii are required for protection from malaria. Calvo PA, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:260–2

Production of autoantibodies against DNA and collagen after inoculation of rabbits with Trypanosoma equiperdum. Hiepe F, et al. **Appl Parasitol** 1996 Dec;37(4):266–74

Giardia duodenalis: analysis of humoral immune response in experimentally infected gerbils (Meriones unguiculatus). Argüello-García R, et al. **Arch Med Res** 1997 Summer; 28(2):171–8

Humoral immune response to E. histolytica/E. dispar during the first year of life. A cohort study. Gómez-Delgado A, et al. **Arch Med Res** 1997;28 Spec No:325–6

Cholera toxin increases rat serum and mucosal antibody responses against Entamoeba histolytica trophozoites. Navarro-García F, et al. **Arch Med Res** 1997;28 Spec No:225–7

Serological response to in vitro-shed antigen(s) of Tritrichomonas foetus in cattle. Bondurant RH, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):432–7

Prevalence of anti-R-13 antibodies in human Trypanosoma cruzi infection. Aznar C, et al. **FEMS Immunol Med Microbiol** 1995 Dec;12(3–4):231–8

Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. Haddad D, et al. **FEMS Immunol Med Microbiol** 1995 Dec;12(3–4):175–86

Immune responses in congenic mice to multiple antigen peptides based on defined epitopes from the malaria antigen Pf332. Ahlborg N, et al. **Immunology** 1996 Aug;88(4):630–5

Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen. Mielcarek N, et al. **Infect Immun** 1997 Feb;65(2):544–50

Comparison of antibody and cytokine responses to primary Giardia muris infection in H-2 congenic strains of mice. Venkatesan P, et al. **Infect Immun** 1996 Nov;64(11):4525–33

Specific interferon-gamma, IgA and IgM responses after experimental infection of neonatal calves with Cryptosporidium parvum. de Graaf DC, et al. **Int J Parasitol** 1997 Jan;27(1):131–4

Systemic and local antibody response in mice induced by a recombinant peptide fragment from Giardia lamblia variant surface protein (VSP) H7 produced by a Salmonella typhimurium vaccine strain. Stäger S, et al. **Int J Parasitol** 1997 Aug;27(8):965–71

Identification of an epitope on the Entamoeba histolytica 170-kD lectin conferring antibody-mediated protection against invasive amebiasis. Lotter H, et al. **J Exp Med** 1997 May 19;185(10):1793–801

Glycoinositolphospholipids purified from Trypanosoma cruzi stimulate Ig production in vitro. Bento CA, et al.

J Immunol 1996 Dec 1;157(11):4996–5001

Complete protective immunity induced in mice by immunization with the 19–kilodalton carboxyl–terminal fragment of the merozoite surface protein–1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen–specific antibody titer, but not with effector CD4+ T cells. Hirunpetcharat C, et al. **J Immunol** 1997 Oct 1; 159(7):3400–11

The serum albumin–binding region of streptococcal protein G: a bacterial fusion partner with carrier–related properties. Sjölander A, et al. **J Immunol Methods** 1997 Feb 14; 201(1):115–23

Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Williamson KC, et al. **Mol Biochem Parasitol** 1995 Dec;75(1):33–42

Reproducing the immune response against the Plasmodium vivax merozoite surface protein 1 with mimotopes selected from a phage–displayed peptide library. Demangel C, et al. **Mol Immunol** 1996 Aug;33(11–12):909–16

Antibody responses to Plasmodium falciparum sporozoite–, liver– and blood–stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas. Ferreira–da–Cruz MF, et al. **Parasite** 1995 Mar;2(1):23–9

During canine viscero–cutaneous leishmaniasis the anti–Hsp70 antibodies are specifically elicited by the parasite protein. Quijada L, et al. **Parasitology** 1996 Mar; 112 (Pt 3):277–84

Induction of antibodies against the Plasmodium falciparum p126 antigen in non–responder H–2b and partial–responder H–2d mice using synthetic peptides. Gilardeau Truffinet M, et al. **Pept Res** 1996 Mar–Apr;9(2):61–70

Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. del Guercio MF, et al. **Vaccine** 1997 Mar;15(4):441–8

Stable expression and secretion of the B–cell epitope of rodent malaria from Mycobacterium bovis BCG and induction of long–lasting humoral response in mouse. Matsumoto S, et al. **Vaccine** 1996 Jan;14(1):54–60

Multiple antigen constructs (MACs): induction of sterile immunity against sporozoite stage of rodent malaria parasites, Plasmodium berghei and Plasmodium yoelii. Reed RC, et al. **Vaccine** 1997 Apr;15(5):482–8

Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin. Yang C, et al. **Vaccine** 1997 Mar;15(4):377–86

Feline ocular and cerebrospinal fluid Toxoplasma gondii–specific humoral immune responses following specific and nonspecific immune stimulation. Lappin MR, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1–3):23–31

The humoral immune response of turbot, Scophthalmus maximus L., to spore–surface antigens of microsporidian parasites. Leiro J, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1–3):235–42

Duration of protective immunity in experimental canine babesiosis after homologous and heterologous challenge. Vercammen F, et al. **Vet Parasitol** 1997 Jan;68(1–2):51–5

BLOOD

SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand. Migasena S, et al. **Acta Trop** 1997 Sep 30;67(3):215–27

Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV–infected patients. ANRS 005/ACTG 154 Trial Group. Derouin F, et al. **AIDS** 1996 Nov;10(13):1521–7

Toxoplasmosis in HIV–positive women: seroprevalence and the role of prophylaxis in preventing disease [letter; comment] Ruiz R, et al. **AIDS** 1997 Jan;11(1):119–20. Comment on: AIDS 1996 May;10(5):509–13.

Seroepidemiology of Entamoeba histolytica in a slum in northeastern Brazil. Braga LL, et al.
Am J Trop Med Hyg 1996 Dec;55(6):693–7

Significantly increased IgG2 subclass antibody levels to Blastocystis hominis in patients with irritable bowel syndrome. Hussain R, et al. **Am J Trop Med Hyg** 1997 Mar;56(3):301–6

Prevalence of antibody to Trypanosoma cruzi in three populations in Belize. Jaramillo R, et al.
Am J Trop Med Hyg 1997 Sep;57(3):298–301

Age–related prevalence of Plasmodium falciparum circumsporozoite antibody in an hyperendemic area of Madagascar, and its relationship with parasite prevalence. Sabatinelli G, et al. **Am J Trop Med Hyg** 1996 Sep; 55(3):278–81

Toxoplasma gondii antigen recognition by serum immunoglobulins M, G, and A of queens and their neonatally infected kittens. Cannizzo KL, et al.
Am J Vet Res 1996 Sep;57(9):1327–30

Antibody responses measured by various serologic tests in pigs orally inoculated with low numbers of Toxoplasma gondii oocysts. Dubey JP, et al. **Am J Vet Res** 1996 Dec; 57(12):1733–7

A time–course study of circulating antigen and parasite–specific antibody in cotton rats infected with Leishmania donovani. Azazy AA, et al.
Ann Trop Med Parasitol 1997 Mar;91(2):153–62

Immunoblot characterization of IgG, IgM and IgE antibodies elicited during the course of fatal and non–fatal infections of Plasmodium berghei in DBA/2 and Balb/c mice. Desowitz RS, et al. **Ann Trop Med Parasitol** 1997 Jan; 91(1):41–7

An attempt to demonstrate a serological immune response in patients infected with Cyclospora cayetanensis [letter] Clarke SC, et al. **Br J Biomed Sci** 1997 Mar;54(1):73–4

Value of detecting immunoglobulin E antibodies for the serological diagnosis of Toxoplasma gondii infection. Gross U, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):247–51

Serological response over time to recombinant Neospora caninum antigens in cattle after a neosporosis–induced abortion. Jenkins MC, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):270–4

Visceral leishmaniasis in a patient with hyper–IgM hypogammaglobulinemia. Martin JC, et al.
Clin Infect Dis 1996 Nov;23(5):1188–9

Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis [see comments] Montoya JG, et al.
Clin Infect Dis 1996 Aug;23(2):277–82. Comment in: Clin Infect Dis 1997 Apr;24(4):745–6.

Prevalence of Toxoplasma gondii antibodies in US military recruits in 1989: comparison with data published in 1965. Smith KL, et al. **Clin Infect Dis** 1996 Nov;23(5):1182–3

Toxopert–I: knowledge–based automatic interpretation of serological tests for toxoplasmosis. Nagy S, et al.
Comput Methods Programs Biomed 1997 Jun;53(2):119–33

Gamma delta T cell help of B cells is induced by repeated parasitic infection, in the absence of other T cells. Pao W, et al. **Curr Biol** 1996 Oct 1;6(10):1317–25

Serological recognition of Toxoplasma gondii cyst antigens. Smith JE, et al. **Curr Top Microbiol Immunol** 1996; 219:67–73 (27 ref.)

A simple Trypanosoma cruzi enzyme–linked immunoassay for control of human infection in nonendemic areas. Aznar C, et al. **FEMS Immunol Med Microbiol** 1997 May; 18(1):31–7

IgG1 and IgG2 antibody responses to Plasmodium falciparum exoantigens correlate inversely and positively, respectively, to the number of malaria attacks. Chumpitazi BF, et al. **FEMS Immunol Med Microbiol** 1996 Jun;14(2–3):151–8

Dog–DAT: a direct agglutination test using stabilized, freeze–dried antigen for the serodiagnosis of canine visceral leishmaniasis. Oskam L, et al.
FEMS Immunol Med Microbiol 1996 Dec 31;16(3–4):235–9

The spleen, IgG antibody subsets and immunity to Plasmodium berghei in rats. Smith NC, et al.
Immunol Cell Biol 1997 Jun;75(3):318–23

Isotypes of naturally acquired antibodies to a repetitive & non–repetitive epitope on Plasmodium falciparum surface proteins in an endemic area of Sri Lanka. Nagendran K, et al. **Indian J Med Res** 1996 Mar;103:142–5

Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine–rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti–V. cholerae antibody responses in mice. Ryan ET, et al. **Infect Immun** 1997 Aug;65(8):3118–25

Humoral immune responses of Solomon Islanders to the merozoite surface antigen 2 of Plasmodium falciparum show pronounced skewing towards antibodies of the immunoglobulin G3 subclass. Rzepczyk CM, et al.
Infect Immun 1997 Mar;65(3):1098–100

Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Taylor RR, et al.
Int Immunol 1996 Jun;8(6):905–15

Demonstration of common and stage–specific anti–Hepatozoon mocassini antibodies in experimentally infected unnatural lizard hosts. Wozniak EJ, et al.
Int J Parasitol 1996 Jan;26(1):131–3

Survival after AIDS–defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial Group. Pueyo S, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1997 Apr 15;14(5):459–64

Seroprevalence of antibodies to Sarcocystis neurona in horses residing in a county of southeastern Pennsylvania [see comments] Bentz BG, et al. **J Am Vet Med Assoc** 1997 Feb 15;210(4):517–8. Comment in: J Am Vet Med Assoc 1997 Feb 15;210(4):482–3.

Seroprevalence of antibodies to Sarcocystis neurona in horses residing in Oregon [see comments] Blythe LL, et al.
J Am Vet Med Assoc 1997 Feb 15;210(4):525–7. Comment in: J Am Vet Med Assoc 1997 Feb 15;210(4):482–3.

Serum antibodies to Sarcocystis neurona--half the horses in the United States have them! [comment] MacKay RJ.
J Am Vet Med Assoc 1997 Feb 15;210(4):482–3 (12 ref.) . Comment on: J Am Vet Med Assoc 1997 Feb 15;210(4):517–8. Comment on: J Am Vet Med Assoc 1997 Feb 15;210(4):519–24. Comment on: J Am Vet Med Assoc 1997 Feb 15;210(4):525–7.

Seroprevalence of antibodies to Sarcocystis neurona in horses residing in Ohio [see comments] Saville WJ, et al.
J Am Vet Med Assoc 1997 Feb 15;210(4):519–24. Comment in: J Am Vet Med Assoc 1997 Feb 15;210(4):482–3.

Evaluation of the second generation IMx Toxo IgG antibody assay for detection of antibodies to Toxoplasma gondii in human sera. De Champs C, et al. **J Clin Lab Anal** 1997; 11(4):214–9

Diagnosis of toxoplasmosis by joint detection of immunoglobulin A and immunoglobulin M. Arcavi M, et al. **J Clin Microbiol** 1997 Jun;35(6):1450–3

Serological diagnosis of bovine neosporosis by Neospora caninum monoclonal antibody–based competitive inhibition enzyme–linked immunosorbent assay. Baszler TV, et al.
J Clin Microbiol 1996 Jun;34(6):1423–8

Bicentric evaluation of Access Toxo immunoglobulin M (IgM) and IgG assays and IMx toxo IgM and IgG assays and comparison with Platelia Toxo IgM and IgG assays. Decoster A, et al. **J Clin Microbiol** 1996 Jul;34(7):1606–9

Multicenter evaluation of a fluorometric enzyme immunocapture assay to detect toxoplasma–specific immunoglobulin M in dried blood filter paper specimens from newborns. Eaton RB, et al. **J Clin Microbiol** 1996 Dec;34(12):3147–50

Diagnostic implications of kinetics of immunoglobulin M and A antibody responses to Toxoplasma gondii. Gorgievski–Hrisoho M, et al. **J Clin Microbiol** 1996 Jun; 34(6):1506–11

Evaluation of a rapid enzyme immunoassay for diagnosis of hepatic amoebiasis. Kraoul L, et al. **J Clin Microbiol** 1997 Jun;35(6):1530–2

Efficacy of immunoglobulin M serodiagnostic test for rapid diagnosis of acute babesiosis. Krause PJ, et al.
J Clin Microbiol 1996 Aug;34(8):2014–6

Study of Abbott Toxo IMx system for detection of immunoglobulin G and immunoglobulin M toxoplasma antibodies: value of confirmatory testing for diagnosis of acute toxoplasmosis. Liesenfeld O, et al.
J Clin Microbiol 1996 Oct;34(10):2526–30

False–positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test [see comments] Liesenfeld O, et al. **J Clin Microbiol** 1997 Jan;35(1):174–8 . Comment in: J Clin Microbiol 1997 Aug;35(8):2187.

Detection of anti–Toxoplasma immunoglobulin M in pregnant women [letter; comment] Pelloux H, et al.
J Clin Microbiol 1997 Aug;35(8):2187. Comment on: J Clin Microbiol 1997 Jan;35(1):174–8.

Early neonatal diagnosis of congenital toxoplasmosis: value of comparative enzyme–linked immunofiltration assay immunological profiles and anti–Toxoplasma gondii immunoglobulin M (IgM) or IgA immunocapture and implications for postnatal therapeutic strategies. Pinon JM, et al. **J Clin Microbiol** 1996 Mar;34(3):579–83

Prevalence of Toxoplasma gondii and cytomegalovirus antibodies in patients with chronic renal failure. Abbas MM, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):671–6

Toxoplasma antibodies in clinically suspected cases of toxoplasmosis. Ahmed JH, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):653–9

Immunological pattern in Syrian golden hamsters experimentally infected with Schistosoma mansoni and Leishmania d. infantum. Mangoud AM, et al.
J Egypt Soc Parasitol 1997 Aug;27(2):497–504

Antibodies against toxoplasma in children and adults with malignancy. el Shazly AM, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):781–7

Immunological and histopathological study on splenectomized mice infected with Giardia lamblia. Yassien NA, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):661–9

Serologic survey of Toxoplasma gondii antibodies in free–ranging wild hogs (Sus scrofa) from the Great Smoky Mountains National Park and from sites in South Carolina. Diderrich V, et al. **J Eukaryot Microbiol** 1996 Sep–Oct; 43(5):122S

Seroprevalence of Toxoplasma gondii in hogs in the National Animal Health Monitoring System (NAHMS). Patton S, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):121S

A simple SDS–PAGE immunoblotting technique using an enhanced chemiluminescence detection system to identify polyclonal antibody responses to complex cryptosporidial antigen preparations following a monoclonal antibody retest and image overlay technique. Patel S, et al.
J Immunol Methods 1997 Jul 14;205(2):157–61

Seroepidemiology of emerging tickborne infectious diseases in a Northern California community. Fritz CL, et al.
J Infect Dis 1997 Jun;175(6):1432–9

Long–lasting antibodies detected by a trans–sialidase inhibition assay of sera from parasite–free, serologically cured chagasic patients. Leguizamón MS, et al.
J Infect Dis 1997 May;175(5):1272–5

High seroprevalence of Encephalitozoon species in immunocompetent subjects. van Gool T, et al.
J Infect Dis 1997 Apr;175(4):1020–4

Recognition of tissue cyst–specific antigens in reactivating toxoplasmosis. McHugh TD, et al. **J Med Microbiol** 1997 Jul;46(7):587–95

Evaluation of different techniques in the diagnosis of Toxoplasma encephalitis. Rodriguez JC, et al.
J Med Microbiol 1997 Jul;46(7):597–601

Neospora caninum antibodies in cows during pregnancy as a predictor of congenital infection and abortion. Paré J, et al. **J Parasitol** 1997 Feb;83(1):82–7

Serological diagnosis of bovine fetal neosporosis. Wouda W, et al. **J Parasitol** 1997 Jun;83(3):545–7

Seroprevalence of antibodies to Neospora caninum in Belgian dogs. Barber JS, et al. **J Small Anim Pract** 1997 Jan; 38(1):15–6

Chronologic change of serum IgG antibody response in chickens reinfected with Cryptosporidium baileyi. Rhee JK, et al. **Korean J Parasitol** 1996 Dec;34(4):255–8

Detection of serum antibodies against Leishmania 94 kDa antigen in visceral and cutaneous leishmaniosis due to Leishmania infantum. Rolland L, et al. **Parasite** 1995 Mar; 2(1):13–21

Recombinant mouse IL-6 boosts specific serum anti-plasmodial IgG subtype titres and suppresses parasitaemia in Plasmodium chabaudi chabaudi infection. Akanmori BD, et al. **Parasite Immunol** 1996 Apr; 18(4):193–9

Humoral immune responses in Gambians to Pfs16, an immunodominant, Plasmodium falciparum integral membrane protein. Baker DA, et al. **Parasite Immunol** 1996 Oct;18(10):527–33

The IgG isotypes of specific antibodies in patients with American cutaneous leishmaniasis; relationship to the cell-mediated immune response. Rodríguez V, et al. **Parasite Immunol** 1996 Jul;18(7):341–5

Association between anti-Pfs48/45 reactivity and P. falciparum transmission-blocking activity in sera from Cameroon. Roeffen W, et al. **Parasite Immunol** 1996 Feb; 18(2):103–9

The role of anti-variable surface glycoprotein antibody responses in bovine trypanotolerance. Williams DJ, et al. **Parasite Immunol** 1996 Apr;18(4):209–18

The prevalence of serum antibodies to tick-borne infections in cattle in smallholder dairy farms in Murang'a District, Kenya; a cross-sectional study. Gitau GK, et al. **Prev Vet Med** 1997 May;30(2):95–107

Impact of biological factors on the interpretation of bovine trypanosomosis serology. Greiner M, et al. **Prev Vet Med** 1997 Apr;30(1):61–73

Cross-sectional estimation of Babesia bovis antibody prevalence in an area of Argentina used for extensive cattle breeding as an aid to control babesiosis. Guglielmone AA, et al. **Prev Vet Med** 1997 May;30(2):151–4

Chagas' disease in the Brazilian Amazon. III. A cross-sectional study (1). Coura JR, et al. **Rev Inst Med Trop Sao Paulo** 1995 Sep–Oct;37(5):415–20

Seropositivity for anti-trypanosoma cruzi antibodies among blood donors of the "Hospital Universitário Regional do Norte do Paraná", Londrina, Brazil. Reiche EM, et al. **Rev Inst Med Trop Sao Paulo** 1996 May–Jun;38(3):233–40 (45 ref.)

Diagnostic tests for amoebic liver abscess: comparison of enzyme-linked immunosorbent assay (ELISA) and counterimmunoelectrophoresis (CIE). Restrepo MI, et al. **Rev Soc Bras Med Trop** 1996 Jan–Feb;29(1):27–32

Risk of exposure to Chagas' disease among seroreactive Brazilian blood donors. Salles NA, et al. **Transfusion** 1996 Nov–Dec;36(11–12):969–73

Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Shulman IA, et al. **Transfusion** 1997 Jul;37(7):727–31

Epidemiology of tropical theileriosis (Theileria annulata infection of cattle) in an endemic region of Tunisia: characterisation of endemicity states. Darghouth ME, et al. **Vet Parasitol** 1996 Oct 25;65(3–4):199–211

Babesial antibody dynamics after cattle immunisation with live vaccines, measured with an indirect immunofluorescence test. Guglielmone AA, et al. **Vet Parasitol** 1997 Jun;70(1–3):33–9

The indirect fluorescent antibody test based on schizont antigen for study of the sheep parasite Theileria lestoquardi. Leemans I, et al. **Vet Parasitol** 1997 Apr;69(1–2):9–18

Comparison of indirect immunofluorescent antibody test and modified direct agglutination test methods for detection of Toxoplasma gondii antibodies in adult sheep in Spain. Marca MC, et al. **Vet Parasitol** 1996 Dec 2;67(1–2):99–103

Piroplasms of domestic animals in the Macedonia region of Greece. 1. Serological cross-reactions. Papadopoulos B, et al. **Vet Parasitol** 1996 May;63(1–2):41–56

Piroplasms of domestic animals in the Macedonia region of Greece. 2. Piroplasms of cattle. Papadopoulos B, et al. **Vet Parasitol** 1996 May;63(1–2):57–66

Piroplasms of domestic animals in the Macedonia region of Greece. 3. Piroplasms of small ruminants. Papadopoulos B, et al. **Vet Parasitol** 1996 May;63(1–2):67–74

Serological diagnosis of toxoplasmosis in sheep following vaccination and challenge. Maley SW, et al. **Vet Rec** 1997 May 24;140(21):558–9

Diagnosis of Theileria annulata infection of cattle in Tunisia: comparison of serology and blood smears. Darghouth ME, et al. **Vet Res** 1996;27(6):613–21

Detection of Cryptosporidium-specific serum immunoglobulins in captive snakes by a polyclonal antibody in the indirect ELISA. Graczyk TK, et al. **Vet Res** 1997;28(2):131–42

[Experimental study of immunity in anti-plasmodium infection on preserved spleen and splenectomized mice] Hou H, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Nov; 76(11):836–40 (Eng. Abstr.) **(Chi)**

[Detection of antibodies against Neospora caninum in cows on Hessian farms with abortion and fertility problems] Conraths FJ, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jun;103(6):221–4 (Eng. Abstr.) **(Ger)**

[Sudden deafness and increased toxoplasmosis IgM titer] Schlottmann A, et al. **Laryngorhinootologie** 1996 Nov; 75(11):687–90 (Eng. Abstr.) **(Ger)**

[Evaluation of cases with positive Toxoplasma IgM antibodies within the scope of prenatal care] Janitschke K, et al. **Z Geburtshilfe Neonatol** 1996 Nov–Dec; 200(6):218–20 (Eng. Abstr.) **(Ger)**

[The use of 4 immunological exams for the determination of Chagas disease prevalence in streetsweepers of the City Sanitation Service in the Federal District] Tinoco DL, et al. **Rev Soc Bras Med Trop** 1996 Jan–Feb;29(1):33–40 (Eng. Abstr.) **(Por)**

[The spread of antibodies to cytomegalovirus and Toxoplasma among donors of blood components] Zhiburt EB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb;(1):59–61 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Presence of antibodies in the aqueous humour and cerebrospinal fluid during Leishmania infections in dogs. Pathological features at the central nervous system. Garcia-Alonso M, et al. **Parasite Immunol** 1996 Nov; 18(11):539–46

Feline ocular and cerebrospinal fluid Toxoplasma gondii-specific humoral immune responses following specific and nonspecific immune stimulation. Lappin MR, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1–3):23–31

CHEMISTRY

Improved detection of human antibodies to a Plasmodium antigen using a peptide modified with Aib residues. Bossus M, et al. **J Pept Sci** 1997 Jan–Feb;3(1):47–53

CLASSIFICATION

Anti-Trypanosoma cruzi antibody isotype profiles in patients with different clinical manifestations of Chagas' disease. Morgan J, et al. **Am J Trop Med Hyg** 1996 Oct;55(4):355–9

Visceral leishmaniasis in Somalia. Significance of IgG subclasses and of IgE response. Shiddo SA, et al. **Immunol Lett** 1996 Apr;50(1–2):87–93

DIAGNOSTIC USE

Factors influencing Cryptosporidium testing in Connecticut. Roberts CL, et al. **J Clin Microbiol** 1996 Sep;34(9):2292–3

DRUG EFFECTS

Activity of antibodies against Salmonella dublin, Toxoplasma gondii, or Actinobacillus pleuropneumoniae in sera after treatment with electron beam irradiation or binary ethylenimine. Kyvsgaard NC, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):628–34

GENETICS

Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Taylor RR, et al. **Int Immunol** 1996 Jun;8(6):905–15

IMMUNOLOGY

Lack of association between levels of transplacentally acquired Plasmodium falciparum-specific antibodies and age of onset of clinical malaria in infants in a malaria endemic area of Nigeria. Achidi EA, et al. **Acta Trop** 1996 Aug;61(4):315–26

Humoral immune response to the 72 kDa heat shock protein from Plasmodium falciparum in populations at hypoendemic areas of malaria in western Brazilian Amazon. Alexandre CO, et al. **Acta Trop** 1997 Apr 15;64(3–4):155–66

Epitopes common to Trypanosoma cruzi and mammalian tissues are recognized by sera from Chagas' disease patients: prognosis value in Chagas disease. Laucella SA, et al. **Acta Trop** 1996 Dec 16;62(3):151–62

Heart muscle cells share common neutral glycosphingolipids with Trypanosoma cruzi. Vermelho AB, et al. **Acta Trop** 1997 Apr 15;64(3–4):131–43

Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors. Lopez JA, et al. **Am J Trop Med Hyg** 1996 Oct;55(4):424–9

Immunogenicity and efficacy trials with Plasmodium falciparum recombinant antigens identified as targets of opsonizing antibodies in the naive squirrel monkey Saimiri sciureus. Perraut R, et al. **Am J Trop Med Hyg** 1997 Mar; 56(3):343–50

Protection against amebic liver abscess formation in the severe combined immunodeficient mouse by human anti-amebic antibodies. Seydel KB, et al. **Am J Trop Med Hyg** 1996 Sep;55(3):330–2

Antibody reactivities to glutamate-rich peptides of Plasmodium falciparum parasites in humans from areas of different malaria endemicity. Jakobsen PH, et al. **APMIS** 1996 Oct;104(10):734–40

Eimeria tenella: localisation of rhoptry antigens during parasite-host cell interactions by a rhoptry-specific monoclonal antibody in PCKC culture. Greif G, et al. **Appl Parasitol** 1996 Dec;37(4):253–9

Wild isolates of Plasmodium falciparum malaria show decreased sensitivity to in vitro inhibition of parasite growth mediated by autologous host antibodies. Flyg BW, et al. **Clin Exp Immunol** 1997 Feb;107(2):321–7

Characterization of the antigenic determinants of the Leishmania infantum histone H3 recognized by antibodies elicited during canine visceral leishmaniasis. Soto M, et al. **Clin Exp Immunol** 1996 Dec;106(3):454–61

Evaluation of immuno-1 toxoplasma IgG assay in the prenatal screening of toxoplasmosis. Rao LV, et al. **Diagn Microbiol Infect Dis** 1997 Jan–Feb;27(1–2):13–5

Plasmodium falciparum: an epitope within a highly conserved region of the 47-kDa amino-terminal domain of the serine repeat antigen is a target of parasite-inhibitory antibodies. Fox BA, et al. **Exp Parasitol** 1997 Feb;85(2):121–34

Plasmodium falciparum: gp195 tripeptide repeat-specific monoclonal antibody inhibits parasite growth in vitro. Locher CP, et al. **Exp Parasitol** 1996 Oct;84(1):74–83

Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. Goin JC, et al. **FASEB J** 1997 Jan;11(1):77–83

Comparative study of DNA-based immunization vectors: effect of secretion signals on the antibody responses in mice. Haddad D, et al. **FEMS Immunol Med Microbiol** 1997 Jul; 18(3):193–202

Quantification and isotype analysis of the serum anti-amebic antibody response produced after mucosal and systemic immunization in male and female mice. Moreno-Fierros L, et al. **Folia Biol (Praha)** 1996;42(3):99–103

Malaria vaccine trials: the missing qualitative data. Ferreira M. **Immunol Cell Biol** 1996 Aug;74(4):301–5 (20 ref.)

Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes. Charoenvit Y, et al. **Infect Immun** 1997 Aug;65(8):3430–7

Baculovirus-mediated expression of Plasmodium falciparum erythrocyte binding antigen 175 polypeptides and their recognition by human antibodies. Daugherty JR, et al. **Infect Immun** 1997 Sep;65(9):3631–7

In vitro inhibition of Cryptosporidium parvum infection by human monoclonal antibodies. Elliot BC, et al. **Infect Immun** 1997 Sep;65(9):3933–5

Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Healer J, et al. **Infect Immun** 1997 Aug;65(8):3017–23

Trypanosome variant surface glycoproteins are recognized by self-reactive antibodies in uninfected hosts. Müller N, et al. **Infect Immun** 1996 Nov;64(11):4593–7

Characterization of secretory IgA responses in mice infected with Cryptosporidium parvum. Tarazona R, et al. **Int J Parasitol** 1997 Apr;27(4):417–23

Assembly and function of Chlamydomonas flagellar mastigonemes as probed with a monoclonal antibody. Nakamura S, et al. **J Cell Sci** 1996 Jan;109 (Pt 1):57–62

Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity. Jenum PA, et al. **J Clin Microbiol** 1997 Aug;35(8):1972–7

Neutralizing monoclonal antibody protects against Cryptosporidium parvum infection by inhibiting sporozoite attachment and invasion. Langer RC, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):76S–77S

Protective monoclonal antibodies define a distinct, conserved epitope on an apical complex exoantigen of Cryptosporidium parvum sporozoites. Riggs MW, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):74S–75S

Statistical analysis of highly skewed immune response data. McGuinness D, et al. **J Immunol Methods** 1997 Feb 14; 201(1):99–114

Participation of nitric oxide signaling system in the cardiac muscarinic cholinergic effect of human chagasic IgG. Sterin-Borda L, et al. **J Mol Cell Cardiol** 1997 Jul; 29(7):1851–65

Giardia lamblia variant surface protein H7 stimulates a heterogeneous repertoire of antibodies displaying differential cytological effects on the parasite. Stäger S, et al. **Mol Biochem Parasitol** 1997 Mar;85(1):113–24

A peptide derived from a B cell epitope of Plasmodium falciparum rhoptry associated protein 2 specifically raises antibodies to rhoptry associated protein 1. Stowers AW, et al. **Mol Biochem Parasitol** 1996 Nov 25;82(2):167–80

Reproducing the immune response against the Plasmodium vivax merozoite surface protein 1 with mimotopes selected from a phage-displayed peptide library. Demangel C, et al. **Mol Immunol** 1996 Aug;33(11–12):909–16

Association between anti-Pfs48/45 reactivity and P. falciparum transmission-blocking activity in sera from Cameroon. Roeffen W, et al. **Parasite Immunol** 1996 Feb; 18(2):103–9

Kinetics study of the localization and quantitation of target antigens of immunoglobulin a antibodies in acquired and congenital toxoplasmosis. Kumolosasi E, et al. **Parasitol Res** 1996;82(5):402–9

Immunogenicity of Leucocytozoon caulleryi sporozoites and their reactivity with specific immune sera. Morii T, et al. **Parasitol Res** 1996;82(5):454–8

Differentiation of Entamoeba histolytica from E. dispar facilitated by monoclonal antibodies against a 150-kDa surface antigen. Tachibana H, et al. **Parasitol Res** 1997; 83(5):435–9

Plasmodium falciparum: selection of parasite subpopulations with decreased sensitivity for antibody-mediated growth inhibition in vitro. Iqbal J, et al. **Parasitology** 1997 Apr;114 (Pt 4):317–24

Epitope mapping on the ookinete surface antigen Pbs21 of Plasmodium berghei: identification of the site of binding of transmission-blocking monoclonal antibody 13.1. Spano F, et al. **Parassitologia** 1996 Dec;38(3):559–63

Synthetic peptides from P. falciparum sexual stage 25-kDa

protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25. Quakyi IA, et al. **Pept Res** 1995 Nov-Dec;8(6):335-44

Recognition of phage-expressed peptides containing Asx-Pro sequences by monoclonal antibodies produced against Plasmodium falciparum circumsporozoite protein. Wilson DR, et al. **Protein Eng** 1997 May;10(5):531-40

Antibodies from immune African donors with a protective effect in Plasmodium falciparum human infection are also able to control asexual blood forms of the parasite in Saimiri monkeys. Gysin J, et al. **Res Immunol** 1996 Jul-Aug; 147(6):397-401

Leishmania (viannia) panamensis-Induced cutaneous leishmaniasis in susceptible and resistant mouse strains. Goto H, et al. **Rev Inst Med Trop Sao Paulo** 1995 Nov-Dec; 37(6):475-81

Cross-reactivity of antibodies in human infections by the kinetoplastid protozoa Trypanosoma cruzi, Leishmania chagasi and Leishmania (viannia) braziliensis. Vexenat A de C, et al. **Rev Inst Med Trop Sao Paulo** 1996 May-Jun; 38(3):177-85

Disruption of erythrocyte rosettes and agglutination of erythrocytes infected with Plasmodium falciparum by the sera of Papua New Guineans. Rogerson SJ, et al. **Trans R Soc Trop Med Hyg** 1996 Jan-Feb;90(1):80-4

Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Shulman IA, et al. **Transfusion** 1997 Jul;37(7):727-31

Mapping for B-cell epitopes in the GX3262 antigenic sequence derived from Eimeria tenella sporulated oocysts. O'Lorcain P, et al. **Vet Parasitol** 1996 Nov 15; 66(3-4):159-69

B-cell epitope mapping within the MA16 antigenic sequence found in Eimeria acervulina merozoites and sporozoites. O'Lorcain P, et al. **Vet Parasitol** 1996 Nov 15; 66(3-4):147-57

Mitogenic stimulation of bovine peripheral blood mononuclear cells by Theileria sergenti antigen and inhibition by antibody from experimentally infected cattle. Yanagisawa K, et al. **Vet Parasitol** 1997 Jul 15;71(1):53-8

[Detection of dsDNA antibodies in diagnosis of systemic lupus erythematosus--comparative studies of diagnostic effectiveness of 3 ELISA methods with different antigens and a Crithidia luciliae immunofluorescence test] Wigand R, et al. **Z Rheumatol** 1997 Mar-Apr;56(2):53-62 (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Comparison of the indirect immunofluorescent antibody test and the direct agglutination test for serodiagnosis of visceral leishmaniasis in HIV-infected subjects. Nigro L, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):832-5

Evaluation of a commercially available ELISA for detection of Giardia lamblia antigen in faeces: preliminary results in unconventional samples. Bisoffi Z, et al. **Eur J Epidemiol** 1995 Dec;11(6):703-5

Skin ulcer and immunoblot patterns by inoculation sites in BALB/c mice infected with Leishmania major. Lee M, et al. **Korean J Parasitol** 1997 Mar;35(1):31-8

METABOLISM

Elevated plasma levels of IgE in Plasmodium falciparum-primed individuals reflect an increased ratio of IL-4 to interferon-gamma (IFN-gamma)-producing cells. Elghazali G, et al. **Clin Exp Immunol** 1997 Jul;109(1):84-9

Antibodies from Trypanosoma cruzi infected mice recognize the second extracellular loop of the beta 1-adrenergic and M2-muscarinic receptors and regulate calcium channels in isolated cardiomyocytes. Mijares A, et al. **Mol Cell Biochem** 1996 Oct-Nov;163-164:107-12

Presence of antibodies in the aqueous humour and cerebrospinal fluid during Leishmania infections in dogs. Pathological features at the central nervous system. Garcia-Alonso M, et al. **Parasite Immunol** 1996 Nov; 18(11):539-46

Antibody kinetics during allopurinol treatment in canine leishmaniasis. Vercammen F, et al. **Vet Rec** 1996 Sep 14; 139(11):264

PHARMACOLOGY

Sera from chronic chagasic patients with complex cardiac arrhythmias depress electrogenesis and conduction in isolated rabbit hearts. de Oliveira SF, et al. **Circulation** 1997 Sep 16;96(6):2031-7

Survival of Blastocystis hominis clones after exposure to a cytotoxic monoclonal antibody. Tan SW, et al. **Int J Parasitol** 1997 Aug;27(8):947-54

Characterization of P0, a ribosomal phosphoprotein of Plasmodium falciparum. Antibody against amino-terminal domain inhibits parasite growth. Goswami A, et al. **J Biol Chem** 1997 May 2;272(18):12138-43

Involvement of nitric oxide synthase and protein kinase C activation on chagasic antibodies action upon cardiac contractility. Sterin-Borda L, et al. **Mol Cell Biochem** 1996 Jul-Aug;160-161:75-82

PHYSIOLOGY

Role of membrane-bound IgM in Trypanosoma cruzi evasion from immune clearance. Garcia IE, et al. **J Parasitol** 1997 Apr;83(2):230-3

RADIATION EFFECTS

Activity of antibodies against Salmonella dublin, Toxoplasma gondii, or Actinobacillus pleuropneumoniae in sera after treatment with electron beam irradiation or binary ethylenimine. Kyvsgaard NC, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):628-34

ANTIBODIES, THYROID-STIMULATING see **IMMUNOGLOBULINS, THYROID-STIMULATING**

ANTIBODIES, VIRAL

Virucidal activity of an oral fluid human immunodeficiency virus-1 antibody preservative. Bestwick RK, et al. **Am J Med** 1997 Apr 1;102(4A):26-9

Detection of canine parvovirus antigens with antibodies to synthetic peptides. Vihinen-Ranta M, et al. **Arch Virol** 1996;141(9):1741-8

Phage antibodies: new technology to obtain monoclonal antibodies to the multidrug-resistance gene product P-glycoprotein. McLaren S, et al. **Biochem Soc Trans** 1996 May;24(2):314S

Epitope mapping and functional characterization of monoclonal antibodies specific for herpes simplex virus type I DNA polymerase. Strick R, et al. **Intervirology** 1997; 40(1):41-9

Detection and typing of herpes simplex viruses by using recombinant immunoglobulin fragments produced in bacteria. Cattani P, et al. **J Clin Microbiol** 1997 Jun; 35(6):1504-9

Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. Vanderplasschen A, et al. **J Gen Virol** 1997 Aug;78 (Pt 8):2041-8

A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. Wang Z, et al. **J Gen Virol** 1997 Sep;78 (Pt 9):2209-15

High-level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies. Kretzschmar T, et al. **J Immunol Methods** 1996 Sep 9; 195(1-2):93-101

Novel role of monoclonal antibody on virus clearance from central nervous system [editorial] Dutta JK. **J Indian Med Assoc** 1996 Jan;94(1):1-2

Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. Ditzel HJ, et al. **J Mol Biol** 1997 Apr 4;267(3):684-95

Immunolocalization of the pseudorabies virus immediate-early protein IE180 by immunoperoxidase staining. Huang C, et al. **J Virol Methods** 1997 Jul; 66(2):219-26

Identification of a phosphatase-sensitive epitope of rabies virus nucleoprotein which is recognized by a monoclonal antibody 5-2-26. Anzal J, et al. **Microbiol Immunol** 1997; 41(3):229-40

Production and characterization of murine IgA monoclonal antibodies to the surface antigens of rhesus rotavirus. Giammarioli AM, et al. **Virology** 1996 Nov 1;225(1):97-110

Characterization of Tula virus antigenic determinants defined by monoclonal antibodies raised against baculovirus-expressed nucleocapsid protein. Lundkvist A, et al. **Virus Res** 1996 Nov;45(1):29-44

ADMINISTRATION & DOSAGE

No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Ruutu T, et al. **Bone Marrow Transplant** 1997 Feb;19(3):233-6

Effects of the passive transfer of anti-gB antibodies in a rabbit model of HSV-1-induced keratitis. Incorvaia C, et al. **Ophthalmologica** 1995;209(6):340-5

High-titered anti-HBs fresh frozen plasma for immunoprophylaxis against hepatitis B virus recurrence after liver transplantation. Mentha G, et al. **Transplant Proc** 1997 Aug;29(5):2369-73

Topically applied human recombinant monoclonal IgG1 antibody and its Fab and F(ab')2 fragments protect mice from vaginal transmission of HSV-2. Zeitlin L, et al. **Virology** 1996 Nov 1;225(1):213-5

Passive protection of specific pathogen free chicks against infectious bursal disease by in-ovo injection of semi-purified egg-yolk antiviral immunoglobulins. Eterradossi N, et al. **Zentralbl Veterinarmed [B]** 1997 Aug; 44(6):371-83

ANALYSIS

Measles virus in otosclerosis and the specific immune response of the inner ear. Arnold W, et al. **Acta Otolaryngol (Stockh)** 1996 Sep;116(5):705-9

Comparison of specific immunities to varicella-zoster virus following post-exposure prophylaxis of varicella by oral acyclovir observed in a family. Asano Y, et al. **Acta Paediatr Jpn** 1996 Dec;38(6):692-4

Evaluation of latex agglutination test for rapid detection of goat poxvirus antigen and antibodies. Rao TV, et al. **Acta Virol** 1996 Apr;40(2):95-7

Measles antibodies in the breast milk of nursing mothers. Adu FD, et al. **Afr J Med Med Sci** 1995 Dec;24(4):385-8

Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. Apetrei C, et al. **AIDS** 1996 Dec; 10(14):F57-60

Selective thymocyte depletion and immunoglobulin coating in the thymus of cats infected with feline immunodeficiency virus. Orandle MS, et al. **AIDS Res Hum Retroviruses** 1997 May 1;13(7):611-20

Future applications of oral fluid specimen technology. George JR, et al. **Am J Med** 1997 Apr 1;102(4A):21-5

Herpes simplex virus type 2 detection by culture and polymerase chain reaction and relationship to genital symptoms and cervical antibody status during the third trimester of pregnancy. Boggess KA, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):443-51

Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Aris RM, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1712-7

Active and passive immune responses to transmissible gastroenteritis virus (TGEV) in swine inoculated with recombinant baculovirus-expressed TGEV spike glycoprotein vaccines. Shoup DI, et al. **Am J Vet Res** 1997 Mar;58(3):242-50

Rubella seroprevalence in the Singapore Armed Forces (SAF) and the changing need of the SAF rubella immunisation programme. Lim MK, et al. **Ann Acad Med Singapore** 1997 Jan;26(1):37-9

Herpes simplex virus antibodies in the perilymph of patients with Menière disease [see comments] Arnold W, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jan;123(1):53-6. Comment in: Arch Otolaryngol Head Neck Surg 1997 Jul;123(7):768.

Determination of level of antibodies to bovine virus diarrhoea virus (BVDV) in bulk tank milk as a tool in the diagnosis and prophylaxis of BVDV infections in dairy herds. Niskanen R, et al. **Arch Virol Suppl** 1991;3:245-51

IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities. Gupta CK, et al. **Biologicals** 1996 Jun;24(2):117-24

Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia. Rocha-Zavaleta L, et al. **Br J Cancer** 1997;75(8):1144-50

Varicella zoster antibodies after herpes zoster, varicella and multiple sclerosis. Ross RT, et al. **Can J Neurol Sci** 1997 May;24(2):137-9

High titers of antibodies to two human polyomaviruses, JCV and BKV, correlate with increased frequency of chromosomal damage in human lymphocytes. Lazutka JR, et al. **Cancer Lett** 1996 Dec 3;109(1-2):177-83

Use of recombinant Epstein-Barr virus early antigen for detection of antibody in patients with nasopharyngeal carcinoma. Liu MT, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jan;57(1):7-15

Neutralizing antibodies to type 1 and 2 bovine viral diarrhea viruses: detection by inhibition of viral cytopathology and infectivity by immunoperoxidase assay. Fulton RW, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):380-3

An indirect double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) using baculovirus-expressed antigen for the detection of antibodies to glycoprotein E of pseudorabies virus and comparison of the method with blocking ELISAs. Kimman TG, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):167-74

Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques. Ohlin M, et al. **Clin Diagn Lab Immunol** 1997 Jan;4(1):107-11

Antibody response to human parvovirus B19 in patients with primary infection by immunoblot assay with recombinant proteins. Palmer P, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):236-8

Detection of rubella virus-specific immunoglobulin M antibodies with a baculovirus-expressed E1 protein. Schmidt M, et al. **Clin Diagn Lab Immunol** 1996 Mar; 3(2):216-8

Evaluation of a dipstick enzyme-linked immunosorbent assay for detection of antibodies to dengue virus. Wu SJ, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):452-7

Intrathecal IgM, IgA and IgG antibody response in tick-borne encephalitis. Long-term follow-up related to clinical course and outcome. Günther G, et al. **Clin Diagn Virol** 1997 May;8(1):17-29

Assessment of the specificity of a commercial human parvovirus B19 IgM assay. Jensen IP, et al. **Clin Diagn Virol** 1997 Feb;7(3):133-7

Quantification of IgA and IgG and specificities of antibodies to viral proteins in parotid saliva at different stages of HIV-1 infection. Cartry O, et al. **Clin Exp Immunol** 1997 Jul;109(1):47-53

Characteristics of asymptomatic secondary immune responses to measles virus in late convalescent donors. Huiss S, et al. **Clin Exp Immunol** 1997 Sep;109(3):416-20

The expression of human endogenous retrovirus-3 in fetal cardiac tissue and antibodies in congenital heart block. Li JM, et al. **Clin Exp Immunol** 1996 Jun;104(3):388-93

Antibodies against Chlamydia pneumoniae, cytomegalovirus, enteroviruses and respiratory syncytial virus in patients with polymyalgia rheumatica. Uddhammar A, et al.

Clin Exp Rheumatol 1997 May-Jun;15(3):299-302

Seroconversion to human herpesvirus 6 and human herpesvirus 7 among Brazilian children with clinical diagnoses of measles or rubella. Black JB, et al. **Clin Infect Dis** 1996 Nov;23(5):1156-8

Symptomatic primary infection with human herpesvirus 6 variant A. Hidaka Y, et al. **Clin Infect Dis** 1997 May; 24(5):1022-3

Antibody responses to two Epstein-Barr virus (EBV) nuclear antigens (EBNA-1 and EBNA-2) during EBV primary infection in children born to mothers infected with human immunodeficiency virus. Pedneault L, et al. **Clin Infect Dis** 1996 Oct;23(4):806-8

Seroepidemiology and control of genital herpes: the value of type specific antibodies to herpes simplex virus. Slomka MJ. **Commun Dis Rep CDR Rev** 1996 Mar 1;6(3):R41-5 (35 ref.)

Humoral immune response of chicks to different clinical isolates of avian adenovirus type-1. Maiti NK, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):59-62

Gloves-and-socks syndrome in a patient with Epstein-Barr virus infection [letter] Drago F, et al. **Dermatology** 1997; 194(4):374

Isotype-specific antibody responses to foot-and-mouth disease virus in sera and secretions of "carrier' and "non-carrier' cattle. Salt JS, et al. **Epidemiol Infect** 1996 Oct;117(2):349-60

Assessment of neutralizing antibodies elicited by a vaccine (Nakayama) strain of Japanese encephalitis virus in Taiwan. Shyu WR, et al. **Epidemiol Infect** 1997 Aug;119(1):79-83

The modification in measles vaccination age as a consequence of the earlier decline of transplacentally transferred antimeasles antibodies in Turkish infants. Altintaş DU, et al. **Eur J Epidemiol** 1996 Dec;12(6):647-8

Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Kaplan JM, et al. **Gene Ther** 1996 Feb; 3(2):117-27

Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. Van Hoecke C, et al. **Gerontology** 1996;42(4):190-8

A comparative study of the polymerase chain reaction and local antibody production in acute retinal necrosis syndrome and cytomegalovirus retinitis. Abe T, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jul;234(7):419-24

Human papillomavirus-specific serologic response in vulvar neoplasia. Sun Y, et al. **Gynecol Oncol** 1996 Nov; 63(2):200-3

Serological evidence for active Epstein-Barr virus infection in multifocal choroiditis. Bhende PS, et al. **Indian J Pathol Microbiol** 1997 Apr;40(2):129-31

Assays for antibodies to varicella-zoster virus. Krah DL. **Infect Dis Clin North Am** 1996 Sep;10(3):507-27 (111 ref.)

Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Nardelli-Haefliger D, et al. **Infect Immun** 1997 Aug;65(8):3328-36

Correlation between herpes and Epstein-Barr viruses and acute myocardial infarction [letter] Liguori A, et al. **Int J Cardiol** 1996 Dec 6;57(2):185-6

Papular-purpuric gloves-and-socks syndrome. Vargas-Díez E, et al. **Int J Dermatol** 1996 Sep;35(9):626-32 (25 ref.)

FeLV, FIV testing recommendations issued [news] **J Am Vet Med Assoc** 1996 Oct 15;209(8):1360

Whole saliva dried on filter paper or diagnosis of HIV-1 infection by detection of antibody IgG to HIV-1 with ultrasensitive enzyme immunoassay using recombinant reverse transcriptase as antigen. Ishikawa S, et al. **J Clin Lab Anal** 1996;10(1):35-41

Clear detection and typing of herpes simplex virus types 1 and 2 by an indirect ELISA assay: comparison with three different combined methods--capture ELISA, restriction enzymes, and polymerase chain reaction. Markoulatos P, et al. **J Clin Lab Anal** 1997;11(3):146-53

A reverse-type sandwich enzyme-linked immunosorbent assay for detecting antibodies to Borna disease virus. Horimoto T, et al. **J Clin Microbiol** 1997 Jul;35(7):1661-6

A subtype-specific peptide-based enzyme immunoassay for detection of antibodies to the G protein of human respiratory syncytial virus is more sensitive than routine serological tests. Langedijk JP, et al. **J Clin Microbiol** 1997 Jul;35(7):1656-60

New, ultrasensitive enzyme immunoassay for detecting vaccine- and disease-induced hepatitis A virus-specific immunoglobulin G in saliva. Ochnio JJ, et al. **J Clin Microbiol** 1997 Jan;35(1):98-101

Study of Norwalk virus and Mexico virus infections at Ga-Rankuwa Hospital, Ga-Rankuwa, South Africa. Smit TK, et al. **J Clin Microbiol** 1997 Sep;35(9):2381-5

Salivary antibodies to cytomegalovirus (CMV) glycoprotein B accurately predict CMV infections among preschool children. Wang JB, et al. **J Clin Microbiol** 1996 Oct; 34(10):2632-4

Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. Wang Z, et al. **J Clin Microbiol** 1996 Dec;34(12):3056-62

Assay of neutralizing antibodies to animal rotavirus strains and human rotavirus serotype G8 by a modified method in the residents of Pune, India. Kelkar SD, et al. **J Diarrhoeal Dis Res** 1996 Jun;14(2):101-6

Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6. Bhattacherjee V, et al. **J Gen Virol** 1995 Jul;76 (Pt 7):1737-48

Hepatitis C virus antibody, viral RNA and genotypes in leprous patients in Japan. Egawa K, et al. **J Hepatol** 1996 Apr;24(4):397-402

Deficiency of antibody response to hypervariable region of hepatitis C virus in patients with chronic hepatitis C. Yoshioka K, et al. **J Hepatol** 1996 Jun;24(6):649-57

Matching antibody class with pathogen type and portal of entry: cognate mechanisms regulate local isotype expression patterns in lymph nodes draining the respiratory tract of mice inoculated with respiratory viruses, according to virus replication competence and site of inoculation. Sangster MY, et al. **J Immunol** 1997 Aug 15; 159(4):1893-902

An ELISA for detection of antibodies to the E2 protein of GB virus C. Dille BJ, et al. **J Infect Dis** 1997 Feb; 175(2):458-61

Immune responses to individual rotavirus proteins following heterologous and homologous rotavirus infection in mice. Ishida SI, et al. **J Infect Dis** 1997 Jun;175(6):1317-23

Maternal antibodies against rabies in Thai puppies. A preliminary study. Kasempimolporn S, et al. **J Med Assoc Thai** 1996 Jan;79(1):36-9

Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan. Chiu HH, et al. **J Med Virol** 1997 Jan;51(1):32-5

A non-radioactive PCR enzyme-immunoassay enables a rapid identification of HPV 16 and 18 in cervical scrapes after GP5+/6+ PCR. Jacobs MV, et al. **J Med Virol** 1996 Jul;49(3):223-9

The role of rubella-immunoblot and rubella-peptide-EIA for the diagnosis of the congenital rubella syndrome during the prenatal and newborn periods. Meitsch K, et al. **J Med Virol** 1997 Apr;51(4):280-3

Evaluation of virological procedures to detect fetal human cytomegalovirus infection: avidity of IgG antibodies, virus detection in amniotic fluid and maternal serum. Ruellan-Eugene G, et al. **J Med Virol** 1996 Sep;50(1):9-15

Immunoblot detection of antibodies to Toscana virus. Schwarz TF, et al. **J Med Virol** 1996 Jun;49(2):83-6

No evidence of Borna disease virus-specific antibodies in multiple sclerosis patients in Germany [letter] Kitze B, et al. **J Neurol** 1996 Sep;243(9):660-2

Epitope mapping of a monoclonal antibody specific to feline panleukopenia virus and mink enteritis virus. Horiuchi M, et al. **J Vet Med Sci** 1997 Feb;59(2):133-6

Persistence of high virus neutralizing antibody titers in cats experimentally infected with feline immunodeficiency virus. Inoshima Y, et al. **J Vet Med Sci** 1996 Sep; 58(9):925-7

Detection of bovine leukemia viruses (BLV) in mammary tissues of BLV antibody-positive cows affected by subclinical mastitis. Yoshikawa H, et al. **J Vet Med Sci** 1997 Apr;59(4):301-2

Hepatitis E virus infection in north-east Italy: serological study in the open population and groups at risk. Gessoni G, et al. **J Viral Hepat** 1996 Jul;3(4):197-202

Development of tests for antibodies against foot-and-mouth disease virus in cattle milk. Armstrong RM. **J Virol Methods** 1997 Jan;63(1-2):175-80

Sensitivity and specificity of mu-capture ELISA for detection of enterovirus IgM. Bendig JW, et al. **J Virol Methods** 1996 May;59(1-2):23-32

Detection of parvovirus B19-specific IgM by antibody capture radioimmunoassay. Cohen BJ. **J Virol Methods** 1997 Jun;66(1):1-4

Shortening of the window period in diagnosis of HIV-1 infection by simultaneous detection of p24 antigen and antibody IgG to p17 and reverse transcriptase in serum with ultrasensitive enzyme immunoassay. Hashida S, et al. **J Virol Methods** 1996 Oct;62(1):43-53

Biotin-labeled antigen: a novel approach for detection of Puumala virus-specific IgM. Ivanov A, et al. **J Virol Methods** 1996 Oct;62(1):87-92

Detection of IgG antibody to Epstein-Barr virus viral capsid antigen in saliva by antibody capture radioimmunoassay. Vyse AJ, et al. **J Virol Methods** 1997 Jan;63(1-2):93-101

Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team [see comments] Ray P, et al. **JAMA** 1997 Aug 20;278(7):551-6. Comment in: **JAMA** 1997 Aug 20;278(7):594-5.

Various associations of human parvovirus B19 infection. Savasan S, et al. **JPMA J Pak Med Assoc** 1996 Oct; 46(10):235-9

Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females. Matsumoto K, et al. **Jpn J Cancer Res** 1997 Apr;88(4):369-75

A serological indication of the existence of a guineapig poliovirus. Hansen AK, et al. **Lab Anim** 1997 Jul; 31(3):212-8

Detection of antibodies to a putative hepatitis G virus envelope protein [see comments] Tacke M, et al. **Lancet** 1997 Feb 1;349(9048):318-20. Comment in: Lancet 1997 Mar 29;349(9056):954. Comment in: Lancet 1997 Mar 29;349(9056):954-5.

Prechallenge antibodies: moderators of infection rate, signs, and symptoms in adults experimentally challenged with rhinovirus type 39. Alper CM, et al. **Laryngoscope** 1996 Oct;106(10):1298-305

Follow-up of human papillomavirus (HPV) DNA and local anti-HPV antibodies in cytologically normal pregnant women. Veress G, et al. **Med Microbiol Immunol (Berl)** 1996 Nov;185(3):139-44

Hepatitis C after renal transplantation: histopathological correlations. Hestin D, et al. **Nephrol Dial Transplant** 1996; 11 Suppl 4:52-3

Beneficial use of inactivated porcine adenovirus vaccine and antibody response of young pigs. Kadoi K. **New Microbiol** 1997 Jan;20(1):89-91

Evaluation of a rapid enzyme immunoassay for the detection of herpes simplex virus antigen in children with herpetic gingivostomatitis. Amir J, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):627-9

Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Johnson CE, et al. **Pediatr Infect Dis J** 1996 Aug;15(8):687-92

Activated T lymphocytes in the cerebrospinal fluid of a patient with Epstein-Barr virus-associated meningoencephalitis. Lehrnbecher T, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):631-3

Effect of diarrhea on the humoral response to oral polio vaccination. Myaux JA, et al. **Pediatr Infect Dis J** 1996 Mar;15(3):204-9

Acute renal failure due to hemorrhagic fever with renal syndrome. Bren AF, et al. **Ren Fail** 1996 Jul;18(4):635-8

Assessment of the quality of tests for the detection of antibodies to Aujeszky's disease virus glycoprotein gE in a target population by the use of receiver operating characteristic curves. Stegeman JA, et al. **Res Vet Sci** 1996 Nov;61(3):263-7

Prevalence of antibodies to bluetongue, bovine herpesvirus 1 and bovine viral diarrhea/mucosal disease viruses in water buffaloes in Minas Gerais State, Brazil. Lage AP, et al. **Rev Elev Med Vet Pays Trop** 1996;49(3):195-7

Akabane virus: serological survey of antibodies in livestock in the Sudan. Mohamed ME, et al. **Rev Elev Med Vet Pays Trop** 1996;49(4):285-8

Hyperimmune antirabies sera titration by standard mouse neutralization and counterimmunoelectrophoresis tests, comparing results of different laboratories. Díaz AM, et al. **Rev Inst Med Trop Sao Paulo** 1995 Sep-Oct; 37(5):435-40

Rheumatic manifestations due to human parvovirus B19. A report of four cases. Golstein MA, et al. **Rev Rhum Engl Ed** 1996 Dec;63(11):854-8 (21 ref.)

Diagnosis of Epstein-Barr virus-related diseases. Linde A. **Scand J Infect Dis Suppl** 1996;100:83-8 (46 ref.)

Estimation of antibodies to Newcastle disease virus in tears. Elankumaran S, et al. **Trop Anim Health Prod** 1996 Nov; 28(4):293-7

Some observations on bovine leukosis virus antibodies in Ethiopia. Heinonen M, et al. **Trop Anim Health Prod** 1995 Nov;27(4):225-6

Prenatal ultrasonographic diagnosis of fetal hydrocephalus due to infection with parainfluenza virus type 3. Seidman DS, et al. **Ultrasound Obstet Gynecol** 1996 Jan;7(1):52-4

Longitudinal study of an epitope-biased serum haemagglutination-inhibition antibody response in rabbits immunized with type A influenza virions. Lambkin R, et al. **Vaccine** 1996 Feb;14(3):212-8

Ovine lentivirus antibody detection in serum, colostrum and milk using a recombinant transmembrane protein ELISA. Keen J, et al. **Vet Immunol Immunopathol** 1996 Jun 1; 51(3-4):253-75

Evaluation of tests for detection of antibodies to Aujeszky's disease (pseudorabies) virus glycoprotein E in the target population. Stegeman A, et al. **Vet Microbiol** 1997 Apr; 55(1-4):107-11

Probability of detecting antibodies to bovine herpesvirus 1 in bulk milk after the introduction of a positive animal on to a negative farm. Frankena K, et al. **Vet Rec** 1997 Jan 25;140(4):90-2

Typing of hepatitis C virus antibody with specific peptides in seropositive blood donors and comparison with genotyping of viral RNA. León P, et al. **Vox Sang** 1997; 72(2):71-5

Seroprevalence of rubella antibodies and effects of vaccination among healthy university women students in Korea. Park KS, et al. **Yonsei Med J** 1996 Dec;37(6):420-6

Study on the suitability of sow colostrum for the serological diagnosis of porcine reproductive and respiratory syndrome (PRRS). Eichhorn G, et al. **Zentralbl Veterinarmed [B]** 1997 Apr;44(2):65-72

[Serologic overview of rotavirus antibodies in children under 2 years of age] Pazdiora P, et al. **Epidemiol Mikrobiol Imunol** 1997 Mar;46(1):34-5 (Eng. Abstr.) **(Cze)**

[Parvovirus B19 in the Czech Republic. Seroepidemiologic study] Sodja I, et al. **Epidemiol Mikrobiol Imunol** 1997 Mar; 46(1):23-6 (Eng. Abstr.) **(Cze)**

[Detection of herpesvirus serum antibodies in red deer (Cervus elaphus) imported into the Czech Republic] Pospíšil Z, et al. **Vet Med (Praha)** 1996 Sep;41(9):279-82 (Eng. Abstr.) **(Cze)**

[Varicella and primary achalasia of the lower esophageal sphincter (letter)] Metman EH, et al. **Gastroenterol Clin Biol** 1996;20(12):1138-9 **(Fre)**

[Prevalence of serum anti-hepatitis E virus antibodies in patients with human immunodeficiency virus infection (letter)] Tran A, et al. **Gastroenterol Clin Biol** 1997; 21(5):440 **(Fre)**

[Simplified avidity assay of rubella IgG antibody in rubella virus infection] Hoshiba T, et al.

Nippon Sanka Fujinka Gakkai Zasshi 1996 Jun;48(6):413–8 (Eng. Abstr.) **(Jpn)**

[Virological tests] Shimada S, et al. **Rinsho Byori** 1996 Nov; Suppl 103:241–9 **(Jpn)**

[Infectious mononucleosis with IgM antibodies against cytomegalovirus] Patrzalek M, et al. **Przegl Epidemiol** 1995; 49(4):385–9 (Eng. Abstr.) **(Pol)**

[Comparative study of methods for determining antibodies to measles virus] Agafonov AP, et al. **Vopr Virusol** 1997 Jan–Feb;42(1):44–7 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection. Larson LJ, et al. **Am J Vet Res** 1997 Apr; 58(4):360–3

Long-term antibody production is sustained by antibody-secreting cells in the bone marrow following acute viral infection. Slifka MK, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:166–76

Neutralizing antiviral B cell responses. Bachmann MF, et al. **Annu Rev Immunol** 1997;15:235–70 (175 ref.)

Antibody responses to Haemophilus influenzae type b conjugate vaccine in sickle cell disease. Goldblatt D, et al. **Arch Dis Child** 1996 Aug;75(2):159–61

Characteristic of humoral response of elderly to inactivated influenza vaccine. Siennicka J. **Arch Immunol Ther Exp (Warsz)** 1996;44(5–6):389–94

Foot-and-mouth disease virus-infected but not vaccinated cattle develop antibodies against recombinant 3AB1 nonstructural protein. Silberstein E, et al. **Arch Virol** 1997; 142(4):795–805

Infectious bronchitis: effect of viral doses and routes on specific lacrimal and serum antibody responses in chickens. Toro H, et al. **Avian Dis** 1997 Apr–Jun;41(2):379–87

A single oral dose of inactivated rotavirus and ISCOM matrices induces partial protection in lambs. Van Pinxteren LA, et al. **Biochem Soc Trans** 1997 May;25(2):340S

Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. King SM, et al. **Bone Marrow Transplant** 1996 Apr;17(4):633–6

Functional analysis of antibody responses of feedlot cattle to bovine respiratory syncytial virus following vaccination with mixed vaccines. West K, et al. **Can J Vet Res** 1997 Jan;61(1):28–33

Humoral immune response to human papillomavirus infection. Carter JJ, et al. **Clin Dermatol** 1997 Mar–Apr; 15(2):249–59 (89 ref.)

Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Keitel WA, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):507–10

Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Powers DC, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):511–6

Antibody responses against the G and F proteins of bovine respiratory syncytial virus after experimental and natural infections. Schrijver RS, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):500–6

Possible correlation between low antigenic drift of A(H1N1) influenza viruses and induction of HI antibodies. Iorio AM, et al. **Eur J Epidemiol** 1996 Dec;12(6):589–94

Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts. Gahéry-Ségard H, et al. **Eur J Immunol** 1997 Mar;27(3):653–9

The effect of space flight on monoclonal antibody synthesis in a hybridoma mouse cell line. Smiley SA, et al. **Exp Cell Res** 1997 Feb 1;230(2):411–4

The influence of virus structure on antibody responses and virus serotype formation. Bachmann MF, et al. **Immunol Today** 1996 Dec;17(12):553–8 (48 ref.)

Gelatin-specific humoral and cellular immune responses in children with immediate- and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. Kumagai T, et al. **J Allergy Clin Immunol** 1997 Jul; 100(1):130–4

Effect of shipping and chromium supplementation on performance, immune response, and disease resistance of steers. Kegley EB, et al. **J Anim Sci** 1997 Jul;75(7):1956–64

Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. Centanni S, et al. **J Chemother** 1997 Aug;9(4):273–8

Viral superantigen drives extrafollicular and follicular B cell differentiation leading to virus-specific antibody production. Luther SA, et al. **J Exp Med** 1997 Feb 3; 185(3):551–62

Characterization of monoclonal antibody-escape mutants of tick-borne encephalitis virus with reduced neuroinvasiveness in mice. Holzmann H, et al. **J Gen Virol** 1997 Jan;78 (Pt 1):31–7

Control by Ig genes of the responsiveness to a neutralization viral B cell epitope. Leclerc C, et al. **J Immunol** 1997 Apr 1;158(7):3252–8

Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. Maldonado YA, et al. **J Infect Dis** 1997 Mar;175(3):545–53

The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. Schoppel K, et al. **J Infect Dis** 1997 Mar;175(3):533–44

Replication as a determinant of the intestinal response to rotavirus. Shaw RD, et al. **J Infect Dis** 1996 Dec; 174(6):1328–31

Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. Weber T, et al. **J Infect Dis** 1997 Jul;176(1):250–4

Herpes simplex virus induces appearance of interferon-alpha/beta-producing cells and partially interferon-alpha/beta-dependent accumulation of leukocytes in murine regional lymph nodes. Riffault S, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):1007–14

Mechanisms of protection induced by attenuated simian immunodeficiency virus. IV. Protection against challenge with virus grown in autologous simian cells. Almond N, et al. **J Med Primatol** 1997 Feb–Apr;26(1–2):34–43

A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys. Cole KS, et al. **J Med Primatol** 1997 Feb–Apr; 26(1–2):51–8

Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination. Fuller DH, et al. **J Med Primatol** 1996 Jun;25(3):236–41

Induction of antibodies to plant viral proteins by DNA-based immunization. Hinrichs J, et al. **J Virol Methods** 1997 Jul; 66(2):195–202

Measles reimmunization in children seronegative after initial immunization. Poland GA, et al. **JAMA** 1997 Apr 9; 277(14):1156–8

Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa [see comments] Benn CS, et al. **Lancet** 1997 Jul 12;350(9071):101–5. Comment in: Lancet 1997 Jul 12;350(9071):81–2.

Influenza (H1N1)-ISCOMs enhance immune responses and protection in aged mice. Sambhara S, et al. **Mech Ageing Dev** 1997 Jun;96(1–3):157–69

Decreased antibody response to influenza vaccine among nursing-home residents who received recalled vaccine--New York, 1996. **MMWR Morb Mortal Wkly Rep** 1996 Dec 20; 45(50):1100–2

Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. US Rhesus Rotavirus Vaccine Study Group. Dennehy PH, et al. **Pediatr Infect Dis J** 1996 Nov; 15(11):1012–8

Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. Jackson CR, et al. **Pediatr Infect Dis J** 1997 Feb;16(2):200–4

Recurrent chickenpox after natural infection. Terada K, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):179–81

Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Yusibov V, et al. **Proc Natl Acad Sci U S A** 1997 May 27; 94(11):5784–8

Immunopathogenesis and physical maps of fowl adenovirus serotype 9. Erny KM, et al. **Res Vet Sci** 1996 Sep; 61(2):174–5

Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity [see comments] Slifka MK, et al. **Trends Microbiol** 1996 Oct;4(10):394–400 (63 ref.). Comment in: Trends Microbiol 1997 May;5(5):180–1.

Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants. Benne CA, et al. **Vaccine** 1997 Jun;15(9):1039–44

Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Beyer WE, et al. **Vaccine** 1996 Oct;14(14):1331–9

Safety and immunogenicity of Lyssavac Berna human diploid cell rabies vaccine in healthy adults. Briggs DJ, et al. **Vaccine** 1996 Oct;14(14):1361–5

Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection. Cilla G, et al. **Vaccine** 1996 Apr;14(6):492–4

Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Deck RR, et al. **Vaccine** 1997 Jan;15(1):71–8

An Escherichia coli CS31A fibrillum chimera capable of inducing memory antibodies in outbred mice following booster immunization with the entero-pathogenic coronavirus transmissible gastroenteritis virus. Der Vartanian M, et al. **Vaccine** 1997 Feb;15(2):111–20

Immune responses following cocktails of inactivated measles vaccine and Arachis hypogaea L. (groundnut) or Cocos nucifera L. (coconut) oils adjuvant. Eghafona NO. **Vaccine** 1996 Dec;14(17–18):1703–6

Isotype-specific antibody responses to rotavirus and virus proteins in cows inoculated with subunit vaccines composed of recombinant SA11 rotavirus core-like particles (CLP) or virus-like particles (VLP). Fernandez FM, et al. **Vaccine** 1996 Oct;14(14):1303–12

Comparison of the efficacy of replication-defective adenovirus and Nyvac poxvirus as vaccine vectors in mice. Gonin P, et al. **Vaccine** 1996 Aug;14(11):1083–7

Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice. Hart MK, et al. **Vaccine** 1997 Mar;15(4):363–9

Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Hashigucci K, et al. **Vaccine** 1996 Feb; 14(2):113–9

Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems. Hassan Y, et al. **Vaccine** 1996 Dec;14(17–18):1581–9

Polymorphisms of the TAP2 gene may influence antibody response to live measles vaccine virus. Hayney MS, et al. **Vaccine** 1997 Jan;15(1):3–6

The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age. Hirota Y, et al. **Vaccine** 1996 Dec; 14(17–18):1597–602

The effect of Syntex adjuvant formulation (SAF-m) on humoral immunity to the influenza virus in the mouse. Hjorth RN, et al. **Vaccine** 1997 Apr;15(5):541–6

Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Jones DH, et al. **Vaccine** 1997 Jun;15(8):814–7

Immune response to tissue culture rabies vaccine in subjects who had previous postexposure treatment with Semple or suckling mouse brain vaccine. Khawplod P, et al. **Vaccine** 1996 Nov;14(16):1549–52

Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Künzel W, et al. **Vaccine** 1996 Aug;14(12):1108–10

Influence of the parental virus strain on the virulence and immunogenicity of recombinant vaccinia viruses expressing HBV preS2-S protein or VZV glycoprotein I. Kutinová L, et al. **Vaccine** 1996 Aug;14(11):1045–52

Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Neuzil KM, et al. **Vaccine** 1997 Apr;15(5):525–32

Kinetics of immunologic responses after primary MMR vaccination. Pabst HF, et al. **Vaccine** 1997 Jan;15(1):10–4

Correlation between the antibody response to influenza vaccine and helper T cell subsets in healthy aging. Remarque EJ, et al. **Vaccine** 1996 Feb;14(2):127–30

Antibody responses and protection in mice immunized orally against influenza virus. Takase H, et al. **Vaccine** 1996 Dec; 14(17–18):1651–6

Influence of host related factors on the antibody response to trivalent oral polio vaccine in Tunisian infants. Triki H, et al. **Vaccine** 1997 Jul;15(10):1123–9

Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine. Vodopija R, et al. **Vaccine** 1997 Apr;15(5):571–4

Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Williamson ED, et al. **Vaccine** 1996 Dec;14(17–18):1613–9

DNA immunization can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site. Yokoyama M, et al. **Vaccine** 1997 Apr; 15(5):553–60

Comparative antibody response in harbour and grey seals naturally infected by a morbillivirus. Duignan PJ, et al. **Vet Immunol Immunopathol** 1997 Mar;55(4):341–9

Local antibody production in the oviduct and gut of hens infected with a variant strain of infectious bronchitis virus. Raj GD, et al. **Vet Immunol Immunopathol** 1996 Sep; 53(1–2):147–61

Antibody isotype responses to experimental infection with bovine herpesvirus 1 in calves with colostrally derived antibody. Bradshaw BJ, et al. **Vet Microbiol** 1996 Nov; 53(1–2):143–51

Immune responses in goats to caprine arthritis-encephalitis virus. Ding EY, et al. **Viral Immunol** 1997;10(2):111–5

Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice. Konishi E, et al. **Virology** 1997 Jan 20; 227(2):353–60

Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies. Antón IM, et al. **Virus Res** 1996 Dec;46(1–2):111–24

[Development and study of immunoglobulins against Lassa fever] Krasniaskiĭ VP, et al. **Vopr Virusol** 1997 Mar–Apr; 42(2):71–4 (Eng. Abstr.) **(Rus)**

[The dynamics of the formation of IgG subclasses in Balb/c and CBA mice infected with the LCM, Lassa and Mopeia viruses and their role in diagnosis] Zaĭtseva VN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb; (1):47–51 (Eng. Abstr.) **(Rus)**

BLOOD

Elevated levels of soluble Fc epsilon RII/CD23 and antibodies to Epstein-Barr virus in patients with Sjögren's syndrome. Suzuki M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:108–12

A seroepidemiological study of Varicella-Zoster virus in Taipei City. Lin YJ, et al. **Acta Paediatr Sin** 1996 Jan–Feb; 37(1):11–5

Mast cells in lymph nodes of cows infected by bovine leukaemia virus. Kolodzieyski L, et al. **Acta Vet Hung** 1996; 44(2):173–7

Diagnostic importance of heterophile antibodies and immunoglobulins IgA, IgE, IgM and low-avidity IgG against Epstein-Barr virus capsid antigen in children. Votava M, et al. **Acta Virol** 1996 Apr;40(2):99-101

Control of initial viraemia coincides with neutralizing antibody response after SIVmac infection of rhesus macaques [letter] Beer B, et al. **AIDS** 1996 Jun;10(6):681-2

Antibodies against retroviral proteins and nuclear antigens in a subset of idiopathic CD4+ T lymphocytopenia patients. Garry RF, et al. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):931-40

Analysis of west African hunters for foamy virus infections. Goepfert PA, et al. **AIDS Res Hum Retroviruses** 1996 Dec 10;12(18):1725-30

The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: implications for organ allocation. Schnitzler MA, et al. **Am J Kidney Dis** 1997 Mar;29(3):428-34

Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. Hitti J, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):450-4

High prevalence of hantavirus antibodies in bank voles (Clethrionomys glareolus) captured in the vicinity of households afflicted with nephropathia epidemica. Ahlm C, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):674-8

Patterns of association with host and habitat: antibody reactive with Sin Nombre virus in small mammals in the major biotic communities of the southwestern United States. Mills JN, et al. **Am J Trop Med Hyg** 1997 Mar; 56(3):273-84

Age distribution of lymphocytic choriomeningitis virus serum antibody in Birmingham, Alabama: evidence of a decreased risk of infection. Park JY, et al. **Am J Trop Med Hyg** 1997 Jul;57(1):37-41

Prevalence of antibodies to mosquito-borne encephalitis viruses in residents of the Coachella Valley, California. Reisen WK, et al. **Am J Trop Med Hyg** 1996 Dec; 55(6):667-71

Oropouche virus transmission in the Amazon River basin of Peru. Watts DM, et al. **Am J Trop Med Hyg** 1997 Feb; 56(2):148-52

An outbreak of hantavirus pulmonary syndrome in western Paraguay. Williams RJ, et al. **Am J Trop Med Hyg** 1997 Sep;57(3):274-82

Induction of dual infections in newborn and three-week-old pigs by use of two plaque size variants of porcine reproductive and respiratory syndrome virus. Park BK, et al. **Am J Vet Res** 1997 Mar;58(3):257-9

Hantavirus antibodies in New York [letter] Wasser WG, et al. **Ann Intern Med** 1997 Jul 15;127(2):166-7

Prevalence of antibodies against simian immunodeficiency virus (SIV) and simian T-lymphotropic virus (STLV) in a colony of non-human primates in Kenya, East Africa. Otsyula M, et al. **Ann Trop Med Parasitol** 1996 Feb; 90(1):65-70

Seroprevalence of human parvovirus B19 in children of a desert region. Alsaeid K, et al. **Ann Trop Paediatr** 1996 Sep;16(3):255-7

Response to influenza virus vaccination in vertical HIV infection. Lyall EG, et al. **Arch Dis Child** 1997 Mar; 76(3):215-8

Serological confirmation of human herpesvirus type 6 infection in different age groups. Biesiadecka A, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(1):63-5

Antibody response of Mexican infants to Haemophilus influenzae type b capsular polyribosylribitol phosphate. Differences between natural and vaccine induced (oligosaccharide-CRM197 conjugated vaccine) immunization. Massó F, et al. **Arch Med Res** 1996 Winter; 27(4):539-45

Intrathecal reactivity for myelin components precedes development of neurological symptoms in AIDS patients. Silva AA, et al. **Arch Med Res** 1997 Autumn;28(3):391-6

Prevalence of anti-varicella zoster IgG antibody in undergraduate students. Bhattarakosol P, et al. **Asian Pac J Allergy Immunol** 1996 Dec;14(2):129-31

Demonstration of antibodies against human papillomavirus type-11 E6 and L2 proteins in patients with recurrent respiratory papillomatosis. Sameshima A, et al. **Auris Nasus Larynx** 1997 Apr;24(2):185-91

Serological survey for antibodies to infectious agents in beef cattle in northern South Australia [published erratum appears in Aust Vet J 1997 Apr;75(4):273] Durham PJ, et al. **Aust Vet J** 1997 Feb;75(2):139-40

Recombinant env-gp85 of HPRS-103 (subgroup J) avian leukosis virus: antigenic characteristics and usefulness as a diagnostic reagent. Venugopal K, et al. **Avian Dis** 1997 Apr-Jun;41(2):283-8

A serologic survey of antibody against chicken infectious anemia virus by indirect immunofluorescent assay in domestic poultry in China. Zhou W, et al. **Avian Dis** 1996 Apr-Jun;40(2):358-60

Herpes virus-specific immune responses in individuals experiencing recurrent genital herpes. Boswell CM, et al. **Biochem Soc Trans** 1997 May;25(2):278S

Evaluation of filamentous bacteriophage as immunogens in Atlantic salmon. Coull JJ, et al. **Biochem Soc Trans** 1996 May;24(2):255S

Persistence of antibody to human parvovirus B19 after allogeneic bone marrow transplantation: role of prior recipient immunity. Ang HA, et al. **Blood** 1997 Jun 15; 89(12):4646-51

Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes. Loughran TP Jr, et al. **Blood** 1997 Sep 1; 90(5):1977-81

Loss of seroreactivity against human papillomavirus (HPV) in bone marrow transplant recipients. Lewensohn-Fuchs I, et al. **Bone Marrow Transplant** 1996 Aug;18(2):333-7

Increased anti-Epstein-Barr virus antibodies in epidermotropic cutaneous T-cell lymphoma: a study of 64 patients. Jumbou O, et al. **Br J Dermatol** 1997 Feb; 136(2):212-6

Leucocytoclastic vasculitis associated with hepatitis C virus antibodies. Manna R, et al. **Br J Rheumatol** 1997 Jan; 36(1):124-5

Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes. Richardson G, et al. **Bull World Health Organ** 1995; 73(6):769-77

Comparative study of serological methods for the detection of antibodies to porcine reproductive and respiratory syndrome virus. Cho HJ, et al. **Can J Vet Res** 1997 Jul; 61(3):161-6

Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Shah KV, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Apr;6(4):233-7

Relation between HPV-16 serology and clinico-pathological data in cervical carcinoma patients: prognostic value of anti-E6 and/or anti-E7 antibodies. Baay MF, et al. **Cancer Immunol Immunother** 1997 Jun;44(4):211-5

Detection of IgM antibody to Japanese encephalitis virus infection by enzyme-linked immunosorbent assay (ELISA). Chow L, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jul;58(1):1-6

Time to earliest peak serum antibody response to influenza vaccine in the elderly. Gross PA, et al. **Clin Diagn Lab Immunol** 1997 Jul;4(4):491-2

Prevalence of antibodies to feline parvovirus, calicivirus, herpesvirus, coronavirus, and immunodeficiency virus and of feline leukemia virus antigen and the interrelationship of these viral infections in free-ranging lions in east Africa. Hofmann-Lehmann R, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):554-62

Detection of serum immunoglobulin M to human cytomegalovirus by western blotting correlates better with virological data than detection by conventional enzyme immunoassay. Lazzarotto T, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):597-600

Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions. Sasagawa T, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):403-10

Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in The United States. Suara RO, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):477-9

Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Viscidi RP, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):122-6

Determination of immunity to measles virus in young adults: comparative evaluation of a commercial enzyme immunoassay and the hemagglutination inhibition techniques. Duvdevani P, et al. **Clin Diagn Virol** 1996 Oct; 7(1):1-6

Evaluation of six commercially available kits using purified heterophile antigen for the rapid diagnosis of infectious mononucleosis compared with Epstein-Barr virus-specific serology. Elgh F, et al. **Clin Diagn Virol** 1996 Oct; 7(1):17-21

Multicentre evaluation of dengue IgM dot enzyme immunoassay. Lam SK, et al. **Clin Diagn Virol** 1996 Nov; 7(2):93-8

The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Blumberg EA, et al. **Clin Infect Dis** 1996 Feb;22(2):295-302

False-positive results of an enzyme immunoassay for rubella IgM in a case of measles. Donovan SM. **Clin Infect Dis** 1997 Feb;24(2):271-2

Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Rosenthal SL, et al. **Clin Infect Dis** 1997 Feb;24(2):135-9

Evidence against infection with hantaviruses among forest and park workers in the southwestern United States. Vitek CR, et al. **Clin Infect Dis** 1996 Aug;23(2):283-5

Serum antibodies to parvovirus B19 in patients with pityriasis rosea [letter] Marcus-Farber BS, et al. **Dermatology** 1997; 194(4):371

Variability in parvovirus B19 IgG levels in intravenous immunoglobulin samples. Dockrell DH, et al. **Diagn Microbiol Infect Dis** 1996 Nov-Dec;26(3-4):133-5

Comparison of the Vidas and Bio-Whittaker enzyme immunoassays for detecting IgG reactive with varicella-zoster virus and mumps virus. Doern GV, et al. **Diagn Microbiol Infect Dis** 1997 May;28(1):31-4

Evaluation of a gp 55 (E2) recombinant-based ELISA for the detection of antibodies induced by classical swine fever virus. Müller A, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Nov;103(11):451-3

Seroepidemiologic studies of hantavirus infection among wild rodents in California. Jay M, et al. **Emerg Infect Dis** 1997 Apr-Jun;3(2):183-90 (36 ref.)

A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women. Brugha R, et al. **Epidemiol Infect** 1996 Dec;117(3):519-24

A survey for antibodies to equine arteritis virus in donkeys, mules and zebra using virus neutralisation (VN) and enzyme linked immunosorbent assay (ELISA). Paweska JT, et al. **Equine Vet J** 1997 Jan;29(1):40-3

Prevalence of serum antibodies to synthetic peptides to HPV16 epitopes among Indian women with cervical neoplasia. Sharma BK, et al. **Eur J Cancer** 1996 May; 32A(5):872-6

Antipoliomyelitis neutralizing antibodies in maternal and neonatal serum. Tanzi ML, et al. **Eur J Epidemiol** 1997 Jul;13(5):559-65

Abortive chickenpox [letter] Aksoy L, et al. **Eur J Pediatr** 1997 Mar;156(3):248

Human papillomavirus in tissue of bladder and bladder carcinoma specimens. A preliminary study. Ludwig M, et al. **Eur Urol** 1996;30(1):96-102

Immunoglobulin G subclass antibodies to rubella virus in chronic liver disease, acute rubella and healthy controls. Kalvenes MB, et al. **FEMS Immunol Med Microbiol** 1996 Jan;13(1):43-50

A serological survey of influenza a antibody in human and pig sera in Calcutta. Chatterjee S, et al. **Folia Microbiol (Praha)** 1995;40(3):345-8

Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Smith TA, et al. **Gene Ther** 1996 Jun;3(6):496-502

Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Olsen AO, et al. **Genitourin Med** 1997 Apr;73(2):131-5

Measles virus serology in Crohn's disease. Fisher NC, et al. **Gut** 1997 Jul;41(1):66-9

Clinical relevance of hepatitis C virus genotypes. Simmonds P. **Gut** 1997 Mar;40(3):291-3

Detection of serologic neutralizing antibodies against HPV-11 in patients with condyloma acuminata and cervical dysplasia using an in vitro assay. Leiserowitz GS, et al. **Gynecol Oncol** 1997 Aug;66(2):295-9

Distribution of hepatitis G viremia and antibody response to recombinant proteins with special regard to risk factors in 709 patients. Feucht HH, et al. **Hepatology** 1997 Aug; 26(2):491-4

Humoral response after administration of E1-deleted adenoviruses: immune privilege of the subretinal space. Bennett J, et al. **Hum Gene Ther** 1996 Sep 10;7(14):1763-9

Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections. Fenyö EM, et al. **Immunol Lett** 1996 Jun;51(1-2):95-9

A direct ELISA technique to detect antibodies against polioviruses. Murthy N, et al. **Indian J Biochem Biophys** 1995 Oct;32(5):249-53

Immunogenicity of Edmonston-Zagreb measles vaccine. Parmar VR, et al. **Indian Pediatr** 1996 Oct;33(10):845-50

Prevalence of antibodies against HEp-2 cell antigen in infants and children hospitalized with respiratory syncytial virus infection. Forster J, et al. **Infection** 1996 Nov-Dec; 24(6):407-11

Adenovirus infection in cystic fibrosis patients: implications for the use of adenoviral vectors for gene transfer. Rosenecker J, et al. **Infection** 1996 Jan-Feb;24(1):5-8

Parvovirus B19 diagnosis in pregnant women--quantification of IgG antibody levels (IU/ml) with reference to the international parvovirus B19 standard serum. Searle K, et al. **Infection** 1997 Jan-Feb;25(1):32-4

Tick-borne encephalitis in the Saarland and the Rhineland-Palatinate. Treib J, et al. **Infection** 1996 May-Jun;24(3):242-4

A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Chua KL, et al. **Int J Cancer** 1996 Sep 27;68(1):54-9

Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. Enblad G, et al. **Int J Cancer** 1997 Jul 29;72(3):394-7

A population-based case-control study of human papillomavirus-type-16 seropositivity and incident high-grade dysplasia of the uterine cervix. Olsen AO, et al. **Int J Cancer** 1996 Nov 15;68(4):415-9

Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. Sanjeevi CB, et al. **Int J Cancer** 1996 Nov 15;68(4):409-14

Escherichia coli expressed herpes simplex virus gG1 and gG2 proteins in ELISA and immunoblotting assays. Kakkanas A, et al. **Intervirology** 1995;38(6):346-51

Prevalence of antibodies to cytomegalovirus in a parturient population in Israel. Stein O, et al. **Isr J Med Sci** 1997 Jan;33(1):53-8

Cytomegalovirus and simian immunodeficiency virus coinfection: longitudinal study of antibody responses and disease progression. Baroncelli S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 May 1;15(1):5-15

Proficiency testing of selected antigen and antibody tests for use in dogs and cats. Troy GC, et al. **J Am Vet Med Assoc** 1996 Sep 1;209(5):914-7

Relevance of intravenous cocaine use in relation to prevalence of HIV, hepatitis B and C virus markers among intravenous drug abusers in southern Italy. Guadagnino V, et al. **J Clin Lab Immunol** 1995;47(1):1–9

Detection of antibodies to respiratory syncytial virus attachment and nucleocapsid proteins with recombinant baculovirus–expressed antigens. Buraphacheep W, et al. **J Clin Microbiol** 1997 Feb;35(2):354–7

Evaluations of enzyme–linked immunosorbent assay procedure for determining specific Epstein–Barr virus serology and of rapid test kits for diagnosis for infectious mononucleosis. Gerber MA, et al. **J Clin Microbiol** 1996 Dec;34(12):3240–1

Evaluation of a new enzyme immunoassay based on recombinant Rubella virus–like particles for detection of immunoglobulin M antibodies to Rubella virus. Grangeot–Keros L, et al. **J Clin Microbiol** 1997 Feb; 35(2):398–401

Rapid and specific detection of Sin Nombre virus antibodies in patients with hantavirus pulmonary syndrome by a strip immunoblot assay suitable for field diagnosis. Hjelle B, et al. **J Clin Microbiol** 1997 Mar;35(3):600–8

A novel Western blot test containing both viral and recombinant proteins for anticytomegalovirus immunoglobulin M detection. Lazzarotto T, et al. **J Clin Microbiol** 1997 Feb;35(2):393–7

Serologic markers in early stages of African horse sickness virus infection. Martínez–Torrecuadrada JL, et al. **J Clin Microbiol** 1997 Feb;35(2):531–5

Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals. Mitchell LA, et al. **J Clin Microbiol** 1996 Sep;34(9):2210–8

Epidemiology of group C rotavirus infection in Western New York women of childbearing age. Riepenhoff–Talty M, et al. **J Clin Microbiol** 1997 Feb;35(2):486–8

Evaluation of a commercial enzyme–linked immunosorbent assay for detection of serum immunoglobulin G response to human herpesvirus 6. Sloots TP, et al. **J Clin Microbiol** 1996 Mar;34(3):675–9

Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. Viladiu P, et al. **J Clin Oncol** 1997 Feb;15(2):610–9

Japanese encephalitis virus antibody among normal individuals of Dibrugarh area, upper Assam. Mahanta J, et al. **J Commun Dis** 1996 Sep;28(3):181–4

HTLV–I in HIV seropositive Indian blood donors. Malhotra VL, et al. **J Commun Dis** 1996 Dec;28(4):270–2

Seroprevalence of cytomegalovirus antibodies in patients attending STD and antenatal clinics. Ray K, et al. **J Commun Dis** 1997 Jun;29(2):85–90

Cognitive–behavioral stress management decreases dysphoric mood and herpes simplex virus–type 2 antibody titers in symptomatic HIV–seropositive gay men. Lutgendorf SK, et al. **J Consult Clin Psychol** 1997 Feb;65(1):31–43

Prevalence of Toxoplasma gondii and cytomegalovirus antibodies in patients with chronic renal failure. Abbas MM, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):671–6

Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. Almond N, et al. **J Gen Virol** 1997 Aug;78 (Pt 8):1919–22

Serological and T–helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls. Luxton JC, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):917–23

Cloning and expression of the Epstein–Barr virus–encoded dUTPase: patients with acute, reactivated or chronic virus infection develop antibodies against the enzyme. Sommer P, et al. **J Gen Virol** 1996 Nov;77 (Pt 11):2795–805

Heterogeneity of hepatitis B virus (HBV) core gene in a patient with HBV–associated cirrhosis and serum negativity for anti–HBc. Zoulim F, et al. **J Hepatol** 1996 Feb;24(2):155–60

Antibody responses to different strains of coxsackie B4 virus in patients with newly diagnosed type I diabetes mellitus or aseptic meningitis. Frisk G, et al. **J Infect** 1997 May; 34(3):205–10

Adult primary IgA nephropathy and common viral infections. Hung KY, et al. **J Infect** 1996 May;32(3):227–30

Patients infected with the same hepatitis C virus strain display different kinetics of the isolate–specific antibody response. Allander T, et al. **J Infect Dis** 1997 Jan;175(1):26–31

The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. Carter JJ, et al. **J Infect Dis** 1996 Nov;174(5):927–36

Detection of serum antibodies to a Kaposi's sarcoma–associated herpesvirus–specific peptide. Davis DA, et al. **J Infect Dis** 1997 May;175(5):1071–9

Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. Grangeot–Keros L, et al. **J Infect Dis** 1997 Apr; 175(4):944–6

Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. Hagensee ME, et al. **J Infect Dis** 1997 Sep;176(3):625–31

Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin. Lemon SM, et al. **J Infect Dis** 1997 Jul;176(1):9–19

Prevalence of and risk factors for antibody to hepatitis E virus seroreactivity among blood donors in Northern California. Mast EE, et al. **J Infect Dis** 1997 Jul; 176(1):34–40

Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. Matter L, et al. **J Infect Dis** 1997 Apr;175(4):749–55

Demographic, ethnic, and geographic differences between human T cell lymphotropic virus (HTLV) type I–seropositive carriers and persons with HTLV–I Gag–indeterminate Western blots in Central Africa. Mauclère P, et al. **J Infect Dis** 1997 Aug;176(2):505–9

Increase in CD23+ B cells in infants with bronchiolitis is accompanied by appearance of IgE and IgG4 antibodies specific for respiratory syncytial virus. Rabatić S, et al. **J Infect Dis** 1997 Jan;175(1):32–7

Detection of human herpesvirus 8 DNA in Kaposi's sarcoma lesions and peripheral blood of human immunodeficiency virus–positive patients and correlation with serologic measurements. Smith MS, et al. **J Infect Dis** 1997 Jul; 176(1):84–93

Antibody and antibody–dependent cellular cytotoxicity responses against the BamHI A rightward open–reading frame–1 protein of Epstein–Barr virus (EBV) in EBV–associated disorders. Tanner JE, et al. **J Infect Dis** 1997 Jan;175(1):38–46

Dengue in the early febrile phase: viremia and antibody responses. Vaughn DW, et al. **J Infect Dis** 1997 Aug; 176(2):322–30

Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus–like particles in cervical HPV–16 DNA–positive and–negative women. Wideroff L, et al. **J Infect Dis** 1996 Nov;174(5):937–43

Surveillance for yellow fever virus in eastern Senegal during 1993. Traoré–Lamizana M, et al. **J Med Entomol** 1996 Sep; 33(5):760–5

Prevalence of Epstein–Barr virus (EBV) antibodies in primate stocks of zoological gardens. Fellinger J, et al. **J Med Primatol** 1996 Oct;25(5):327–32

Humoral immunity patterns based on antibody reactivity to rotavirus antigens in Brazilian children under 5 years of age. Andrade GP, et al. **J Med Virol** 1996 Jul;49(3):212–7

Effect of acyclovir and prednisolone on the serological response in herpes zoster. Bates CJ, et al. **J Med Virol** 1996 Nov;50(3):244–8

Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. Brandenburg AH, et al. **J Med Virol** 1997 May;52(1):97–104

Prevalence of antibodies to human caliciviruses (HuCVs) in Kuwait established by ELISA using baculovirus–expressed capsid antigens representing two genogroups of HuCVs. Dimitrov DH, et al. **J Med Virol** 1997 Feb;51(2):115–8

Seroepidemiological study of Epstein–Barr virus infection in Bangladesh. Haque T, et al. **J Med Virol** 1996 Jan; 48(1):17–21

Neutralizing antibody responses induced by varicella–zoster virus gE and gB glycoproteins following infection, reactivation or immunization. Haumont M, et al. **J Med Virol** 1997 Sep;53(1):63–8

Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick–borne encephalitis. Holzmann H, et al. **J Med Virol** 1996 Jan; 48(1):102–7

Seroepidemiology of Hantaan virus infection in Taiwan. Kao CL, et al. **J Med Virol** 1996 Dec;50(4):309–13

Follow–up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection. Kerr JR, et al. **J Med Virol** 1996 Jan;48(1):68–75

Evaluation of multiple antibodies to Epstein–Barr virus as markers for detecting patients with nasopharyngeal carcinoma. Liu MY, et al. **J Med Virol** 1997 Jul;52(3):262–9

Puumala and Dobrava viruses cause hemorrhagic fever with renal syndrome in Bosnia–Herzegovina: evidence of highly cross–neutralizing antibody responses in early patient sera. Lundkvist A, et al. **J Med Virol** 1997 Sep;53(1):51–9

Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa. Marais D, et al. **J Med Virol** 1997 Feb;51(2):126–31

Measles immunity and response to revaccination of a young adult population in Israel. Mendelson E, et al. **J Med Virol** 1996 Nov;50(3):249–53

ELISA for the detection of serum and saliva IgA against the BMRFI gene product of Epstein–Barr virus. Nadala EC, et al. **J Med Virol** 1996 Sep;50(1):93–6

Humoral immune response to functional regions of human cytomegalovirus glycoprotein B. Navarro D, et al. **J Med Virol** 1997 Aug;52(4):451–9

Seroepidemiological study of human herpesvirus–6 and –7 in children of different ages and detection of these two viruses in throat swabs by polymerase chain reaction. Tanaka–Taya K, et al. **J Med Virol** 1996 Jan;48(1):88–94

Human papillomavirus antibody responses among patients with incident cervical carcinoma. Wang Z, et al. **J Med Virol** 1997 Aug;52(4):436–40

Serologic association between human papillomavirus type 16 infection and esophageal cancer in Shaanxi Province, China [see comments] Han C, et al. **J Natl Cancer Inst** 1996 Oct 16;88(20):1467–71. Comment in: J Natl Cancer Inst 1996 Oct 16;88(20):1421–3.

Antibodies to diphtheria, tetanus and pertussis in infants before and after immunization with DTP (Triple Antigen) vaccine. Stewart TA, et al. **J Paediatr Child Health** 1996 Oct;32(5):378–81

Prevalence of antibodies to hepatitis C and herpes simplex virus type 1 is not increased in children with liver kidney microsomal type 1 autoimmune hepatitis. Gregorio GV, et al. **J Pediatr Gastroenterol Nutr** 1996 Dec;23(5):534–7

Donor insemination. Prevalence of antibodies to cytomegalovirus. Greenhalgh LF, et al. **J Reprod Med** 1997 Feb;42(2):111–3

Serological survey to determine the prevalence of bovine leukaemia virus antibodies in dairy cattle on selected farms in the Gauteng and Mpumalanga provinces. Morris SD, et al. **J S Afr Vet Assoc** 1996 Sep;67(3):146–7

Serological studies of bovine respiratory syncytial virus in feedlot cattle in South Africa. Van Vuuren M. **J S Afr Vet Assoc** 1990 Dec;61(4):168–9

Survey for antibodies to selected viruses in laboratory mice in South Africa. Van Vuuren M, et al. **J S Afr Vet Assoc** 1990 Dec;61(4):174–5

Evaluation of a competitive ELISA for detection of antibodies to epizootic hemorrhagic disease virus of deer. Afshar A, et al. **J Vet Diagn Invest** 1997 Jul;9(3):309–11

Prevalence of exposure to eastern equine encephalomyelitis virus in domestic and feral swine in Georgia. Elvinger F, et al. **J Vet Diagn Invest** 1996 Oct;8(4):481–4

Standardization of enzyme–linked immunosorbent assays (ELISAs) for quantitative estimation of antibodies specific for infectious bovine rhinotracheitis virus, respiratory syncytial virus, parainfluenza–3 virus, and bovine viral diarrhea virus. Graham DA, et al. **J Vet Diagn Invest** 1997 Jan;9(1):24–31

Comparative performance of four serodiagnostic procedures for detecting bovine and equine vesicular stomatitis virus antibodies. Katz JB, et al. **J Vet Diagn Invest** 1997 Jul; 9(3):329–31

A comparative study on the use of virus and antibody detection techniques for the diagnosis of La Piedad Michoacan paramyxovirus (LPMV) infection in pigs. McNeilly F, et al. **J Vet Diagn Invest** 1997 Jan;9(1):3–9

Detection of antibodies against foot–and–mouth disease virus using a liquid–phase blocking sandwich ELISA (LPBE) with a bioengineered 3D protein. O'Donnell VK, et al. **J Vet Diagn Invest** 1996 Apr;8(2):143–50

Evaluation of a semiautomated latex agglutination test for the detection of pseudorabies antibody in swine sera. Rodgers SJ, et al. **J Vet Diagn Invest** 1996 Apr;8(2):168–71

Distribution of cytopathic and noncytopathic bovine viral diarrhea virus antigens in tissues of calves following acute experimental infection. Spagnuolo–Weaver M, et al. **J Vet Diagn Invest** 1997 Jul;9(3):287–97

Assessment of maternal antibody decay and response to canine parvovirus vaccination using a clinic–based enzyme–linked immunosorbent assay. Waner T, et al. **J Vet Diagn Invest** 1996 Oct;8(4):427–32

Immunoblot assay as a confirmatory test of competitive ELISA for serodiagnosis of bluetongue. Zhou EM, et al. **J Vet Diagn Invest** 1996 Jul;8(3):365–7

Detection of antibodies against bovine immunodeficiency–like virus in daily cattle in Hokkaido. Hirai N, et al. **J Vet Med Sci** 1996 May;58(5):455–7

Virus neutralizing antibody titer to feline immunodeficiency virus isolates of subtypes A, B and D in experimentally or naturally infected cats. Hohdatsu T, et al. **J Vet Med Sci** 1997 May;59(5):377–81

Slow–reacting and complement–requiring neutralizing antibody in swine infected with porcine reproductive and respiratory syndrome (PRRS) virus. Jusa ER, et al. **J Vet Med Sci** 1996 Aug;58(8):749–53

Demonstration of serum–neutralising antibody to turkey rhinotracheitis virus in serum from chicken flocks in Japan. Otsuki K, et al. **J Vet Med Sci** 1996 Sep;58(9):869–74

Preparation of virus–infection–associated (VIA) antigen of foot–and–mouth disease (FMD) virus from inactivated vaccine. Sugimura T, et al. **J Vet Med Sci** 1996 Jun; 58(6):599–601

Early serodiagnosis of porcine reproductive and respiratory syndrome virus infection of pigs by detection of slow–reacting and complement–requiring neutralizing antibody. Takikawa N, et al. **J Vet Med Sci** 1997 Jan; 59(1):31–4

Detection of antibodies against porcine reproductive and respiratory syndrome (PRRS) virus in swine sera by enzyme–linked immunosorbent assay. Takikawa N, et al. **J Vet Med Sci** 1996 Apr;58(4):355–7

A serological survey of turkey rhinotracheitis virus infection in chickens in Japan. Tanaka M, et al. **J Vet Med Sci** 1996 Jul;58(7):689–91

High prevalence of hantavirus infection in a group of Chinese patients with acute hepatitis of unknown aetiology. Meng G, et al. **J Viral Hepat** 1997 Jul;4(4):231–4

Identification of an immunodominant neutralizing and protective epitope from measles virus fusion protein by using human sera from acute infection. Atabani SF, et al. **J Virol** 1997 Oct;71(10):7240–5

Specific N–linked and O–linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. Chackerian B, et al. **J Virol** 1997 Oct;71(10):7719–27

Maturation of the cellular and humoral immune responses

to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. Hammond SA, et al. **J Virol** 1997 May;71(5):3840–52

Detection of Borna disease virus (BDV) antibodies and BDV RNA in psychiatric patients: evidence for high sequence conservation of human blood-derived BDV RNA. Sauder C, et al. **J Virol** 1996 Nov;70(11):7713–24

Expression of the nonstructural protein NS1 of equine influenza A virus: detection of anti-NS1 antibody in post infection equine sera. Birch-Machin I, et al. **J Virol Methods** 1997 May;65(2):255–63

Detection of Maedi-Visna virus antibodies using a single fusion transmembrane-core p25 recombinant protein ELISA and a modified receiver-operating characteristic analysis to determine cut-off values. Boshoff CH, et al. **J Virol Methods** 1997 Jan;63(1–2):47–56

An indirect ELISA for the detection of antibodies against porcine reproductive and respiratory syndrome virus using recombinant nucleocapsid protein as antigen. Denac H, et al. **J Virol Methods** 1997 May;65(2):169–81

Efficient production of JC virus in SVG cells and the use of purified viral antigens for analysis of specific humoral and cellular immune response. Frye S, et al. **J Virol Methods** 1997 Jan;63(1–2):81–92

An evaluation of nine commercial EIA kits for the detection of measles specific IgG. Hesketh L, et al. **J Virol Methods** 1997 Jun;66(1):51–9

Evaluation of electrophoretic immunoblotting for the detection of antibodies against the bovine leukosis virus in cattle. Kittelberger R, et al. **J Virol Methods** 1996 Sep; 61(1–2):7–22

Competitive ELISA for detection of HHV-6 antibody: seroprevalence in a danish population. Nielsen L, et al. **J Virol Methods** 1996 Feb;56(2):221–30

The E7 protein of human papillomavirus (HPV) type 16 expressed by recombinant vaccinia virus can be used for detection of antibodies in sera from cervical cancer patients. Nindl I, et al. **J Virol Methods** 1996 Oct;62(1):81–5

Comparison of capillary blood versus venous blood samples in the assessment of immunity to measles. Novello F, et al. **J Virol Methods** 1996 Sep;61(1–2):73–7

Application of an immunoperoxidase monolayer assay for the detection of arboviral antibodies. Soliman AK, et al. **J Virol Methods** 1997 May;65(2):147–51

An enzyme-linked immunosorbent assay to detect antibodies against glycoprotein gE of bovine herpesvirus 1 allows differentiation between infected and vaccinated cattle. Van Oirschot JT, et al. **J Virol Methods** 1997 Aug;67(1):23–34

A solid-phase enzyme linked immunosorbent assay using monoclonal antibodies, for the detection of African swine fever virus antigens and antibodies. Vidal MI, et al. **J Virol Methods** 1997 Jul;66(2):211–8

Antibodies to arthropod-borne encephalitis viruses in small mammals from southern Florida. Day JF, et al. **J Wildl Dis** 1996 Jul;32(3):431–6

Hantavirus in Montana deer mouse populations: preliminary results. Douglass RJ, et al. **J Wildl Dis** 1996 Jul; 32(3):527–30

Prevalence of antibody to malignant catarrhal fever virus in wild and domestic ruminants by competitive-inhibition ELISA. Li H, et al. **J Wildl Dis** 1996 Jul;32(3):437–43

Seroprevalence of orthopox virus specific antibodies in red foxes (Vulpes vulpes) in the Federal State Brandenburg, Germany. Müller T, et al. **J Wildl Dis** 1996 Apr; 32(2):348–53

Serological evidence for zoonotic hantaviruses in North Carolina rodents. Weigler BJ, et al. **J Wildl Dis** 1996 Apr; 32(2):354–7

Seroepidemiological survey of wild rats for Seoul virus in Indonesia. Ibrahim IN, et al. **Jpn J Med Sci Biol** 1996 Apr; 49(2):69–74

Immunoassay for detection of antibodies to simian immunodeficiency virus and human immunodeficiency virus in serum. Otsyula MG, et al. **Lab Anim Sci** 1996 Apr; 46(2):198–201

Screening blood donors for markers of new viruses [comment] Allain JP. **Lancet** 1997 Mar 1;349(9052):584–5 . Comment on: Lancet 1997 Mar 1;349(9052):609–11.

Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16 [letter] Ellis JR, et al. **Lancet** 1997 Apr 12;349(9058):1069–70

Antibodies to human herpesvirus 8 in women and infants born in Haiti and the USA [letter] Goedert JJ, et al. **Lancet** 1997 May 10;349(9062):1368

Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients [see comments] Lennette ET, et al. **Lancet** 1996 Sep 28;348(9031):858–61 . Comment in: Lancet 1996 Dec 7;348(9041):1587–8.

Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen [see comments] Simpson GR, et al. **Lancet** 1996 Oct 26; 348(9035):1133–8. Comment in: Lancet 1996 Oct 26;348(9035):1110–1.

Demonstration of Borna disease virus (BDV) in specific regions of the brain from horses positive for serum antibodies to BDV but negative for BDV RNA in the blood and internal organs. Hagiwara K, et al. **Med Microbiol Immunol (Berl)** 1997 Jun;186(1):19–24

Herpes simplex virus-specific IgM, IgA and IgG subclass antibody responses in primary and nonprimary genital herpes patients. Hashido M, et al. **Microbiol Immunol** 1997; 41(5):415–20

Further search for small molecular inactivants capable of eliciting respiratory mucosal immunogenicity by modifying Sendai virus core RNA. Miyamae T. **Microbiol Immunol** 1996;40(10):761–6

Low prevalence of circulating anti-type 6 human herpes virus IgG-antibodies in Spanish children. Roldan C, et al. **Microbios** 1996;86(349):233–6

Herpes simplex virus type 2--a persistent problem [editorial; comment] Arvin AM, et al. **N Engl J Med** 1997 Oct 16; 337(16):1158–9. Comment on: N Engl J Med 1997 Oct 16;337(16):1105–11.

The acquisition of herpes simplex virus during pregnancy. Brown ZA, et al. **N Engl J Med** 1997 Aug 21;337(8):509–15

Herpes simplex virus type 2 in the United States, 1976 to 1994 [see comments] Fleming DT, et al. **N Engl J Med** 1997 Oct 16;337(16):1105–11. Comment in: N Engl J Med 1997 Oct 16;337(16):1158–9.

Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy [letter; comment] Smith K, et al. **N Engl J Med** 1997 Feb 20; 336(8):587; discussion 588. Comment on: N Engl J Med 1996 Aug 29;335(9):624–30.

Hepatitis C virus genotype in anti-HCV-positive hemodialysed patients. Colleoni N, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2258–64

Liver disease in dialysis patients with antibodies to hepatitis C virus. al-Wakeel J, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2265–8

Prevalence of Epstein-Barr virus antibody in the chronic hemodialysed population in the south of the Reunion Island [letter] Guiserix J, et al. **Nephron** 1996;74(2):475

Difficulties with the serologic diagnosis of infectious mononucleosis: a review of the RCPA quality assurance programs. Field PR, et al. **Pathology** 1996 Aug;28(3):270–6

Bluetongue virus seropositivity in sheep flocks in North West Frontier Province, Pakistan. Akhtar S, et al. **Prev Vet Med** 1997 Feb;29(4):293–8

Immune response following a vaccination campaign against rabies in dogs from northwestern Spain. Delgado S, et al. **Prev Vet Med** 1997 Aug;31(3–4):257–61

Risk factors for seroprevalence of ovine lentivirus in breeding ewe flocks in Nebraska, USA. Keen JE, et al. **Prev Vet Med** 1997 May;30(2):81–94

Effect of vitamin A supplementation on measles vaccination in nine-month-old infants. Semba RD, et al. **Public Health** 1997 Jul;111(4):245–7

Prevalence of foot-and-mouth disease antibodies in dairy herds in The Netherlands four years after vaccination. Dekker A, et al. **Res Vet Sci** 1996 Jul;61(1):89–91

Association of human herpesvirus 6 infection with exanthem subitum in Belem, Brazil. de Freitas RB, et al. **Rev Inst Med Trop Sao Paulo** 1995 Nov-Dec;37(6):489–92

Serological findings during a measles outbreak occurring in a population with high vaccine coverage. Oliveira SA, et al. **Rev Inst Med Trop Sao Paulo** 1995 Sep-Oct;37(5):421–5

Human parvovirus B19 infections among exanthematic diseases notified as measles. Cubel RC, et al. **Rev Soc Bras Med Trop** 1996 Jan-Feb;30(1):15–20

Rubella immunity and morbidity: impact of different vaccination programs in Finland 1979–1992. Ukkonen P. **Scand J Infect Dis** 1996;28(1):31–5

Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Andersson-Ellström A, et al. **Sex Transm Dis** 1996 May-Jun;23(3):234–8

Absence of retroviral antibodies in the sera of patients with systemic lupus erythematosus. Fong KY, et al. **Singapore Med J** 1996 Oct;37(5):479–81

A severe case of hemorrhagic fever with renal syndrome in Singapore. Chan KP, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):408–10

A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines [published erratum appears in Southeast Asian J Trop Med Public Health 1996 Mar;27(1):206] Nimmannitya S, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):689–93

Anti-dengue IgG detection by an indirect ELISA. Tio PH, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):673–6

Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: implications for donor selection. Schnitzler MA, et al. **Surgery** 1997 May; 121(5):563–8

Dried sera for confirming blood-borne virus infections (HCV, HTLV-I, HIV & HBsAg). Das PC, et al. **Transfus Med** 1996 Dec;6(4):319–23

Relative sensitivity of United States and European assays for screening blood donors for antibodies to human immunodeficiency viruses [letter] Busch MP, et al. **Transfusion** 1997 Mar;37(3):352–4

Six years' experience testing organ donors for viral markers in France [letter] Lefrère JJ, et al. **Transfusion** 1997 May; 37(5):565–6

Epidemiologic association between antibody titres against bovine virus diarrhoea virus, rinderpest disease virus and infectious bovine rhinotracheitis virus in a buffalo herd. Akhtar S, et al. **Trop Anim Health Prod** 1996 Aug; 28(3):207–12

Prevalence of antibodies against respiratory viruses (parainfluenza virus type 3, respiratory syncytial virus, reovirus and adenovirus) in relation to productivity in Syrian Awassi sheep. Giangaspero M, et al. **Trop Anim Health Prod** 1997 May;29(2):83–91

Serum immunoglobulin responses among broiler chickens fed Ugandan commercial poultry feeds and vaccinated against Newcastle disease. Opuda-Asibo J, et al. **Trop Anim Health Prod** 1996 May;28(2):163–73

Postvaccinal immune response to regimens of Newcastle disease vaccination by filter paper sampling technique. Roy P, et al. **Trop Anim Health Prod** 1997 Feb;29(1):20–4

Serological evidence of the occurrence of enzootic bovine leukosis (EBL) virus infection in cattle in Tanzania. Schoepf KC, et al. **Trop Anim Health Prod** 1997 Feb; 29(1):15–9

Use of dot-immunobinding assay for visual detection of rinderpest antibodies in vaccinated cattle. Singh G, et al. **Trop Anim Health Prod** 1997 May;29(2):73–6

Total and isotype humoral responses in cattle vaccinated with foot and mouth disease virus (FMDV) immunogen produced either in bovine tongue tissue or in BHK-21 cell suspension cultures. Capozzo AV, et al. **Vaccine** 1997 Apr-May;15(6–7):624–30

Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection. Cilla G, et al. **Vaccine** 1996 Apr;14(6):492–4

Annually repeated influenza vaccination improves humoral responses to several influenza virus strains in healthy elderly. de Bruijn IA, et al. **Vaccine** 1997 Aug-Sep; 15(12–13):1323–9

Passive immunity against measles during the first 8 months of life of infants born to vaccinated mothers or to mothers who sustained measles. De Serres G, et al. **Vaccine** 1997 Apr-May;15(6–7):620–3

Tick-borne encephalitis: development of a paediatric vaccine. A controlled, randomized, double-blind and multicentre study. Girgsdies OE, et al. **Vaccine** 1996 Oct;14(15):1421–8

Annual influenza vaccination: immune response in patients over 10 years. Gross PA, et al. **Vaccine** 1996 Sep; 14(13):1280–4

Immunity status against poliomyelitis in persons 13–14 years old living in Rome. Mastroeni I, et al. **Vaccine** 1997 Apr-May;15(6–7):747–50

Aqueous-based microencapsulation enhances virus-specific humoral immune responses in mice after parenteral inoculation. Moser CA, et al. **Vaccine** 1996 Sep; 14(13):1235–8

Two year old hepatitis A vaccine is as good as new. Rajan E, et al. **Vaccine** 1996 Oct;14(15):1439–41

Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly. Sankilampi U, et al. **Vaccine** 1997 Jul;15(10):1133–7

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Wyatt LS, et al. **Vaccine** 1996 Oct;14(15):1451–8

Ovine lentivirus antibody detection in serum, colostrum and milk using a recombinant transmembrane protein ELISA. Keen J, et al. **Vet Immunol Immunopathol** 1996 Jun 1; 51(3–4):253–75

Implementation of internal laboratory quality control procedures for the monitoring of ELISA performance at a regional veterinary laboratory. Blacksell SD, et al. **Vet Microbiol** 1996 Jul;51(1–2):1–9

Antigenically different pestivirus strains induce congenital infection in sheep: a model for bovine virus diarrhea virus vaccine efficacy studies. Bruschke CJ, et al. **Vet Microbiol** 1996 May;50(1–2):33–43

A monoclonal blocking-ELISA for detection of orthopoxvirus antibodies in feline sera. Czerny CP, et al. **Vet Microbiol** 1996 Oct;52(3–4):185–200

Antibody titers to pseudorabies virus in piglets immunized with gIII deleted pseudorabies vaccine in a pseudorabies infected herd. Elvinger F, et al. **Vet Microbiol** 1994 Dec; 42(4):341–8

Indirect fluorescent IgM antibody response of pigs infected with porcine reproductive and respiratory syndrome virus. Joo HS, et al. **Vet Microbiol** 1997 Apr; 55(1–4):303–7

Persistence of antibodies against bovine herpesvirus 1 and virus reactivation two to three years after infection. Kaashoek MJ, et al. **Vet Microbiol** 1996 Nov; 53(1–2):103–10

Evaluation of serological tests for the detection of pseudorabies gE antibodies during early infection. Kinker DR, et al. **Vet Microbiol** 1997 Apr;55(1–4):99–106

A European inter-laboratory trial to evaluate the reliability of serological diagnosis of bovine herpesvirus 1 infections. Kramps JA, et al. **Vet Microbiol** 1996 Nov;53(1–2):153–61

Effect of maternally acquired Aujeszky's disease (pseudorabies) virus-specific antibody in pigs on establishment of latency and seroconversion to differential glycoproteins after low dose challenge. McCaw MB, et al. **Vet Microbiol** 1997 Apr;55(1–4):91–8

Detection of antibodies against porcine parvovirus nonstructural protein NS1 may distinguish between vaccinated and infected pigs. Madsen ES, et al. **Vet Microbiol** 1997 Jan;54(1):1–16

Detection of antibodies against classical swine fever virus

in swine sera by indirect ELISA using recombinant envelope glycoprotein E2. Moser C, et al. **Vet Microbiol** 1996 Jul;51(1-2):41-53

Seroprevalence of porcine reproductive and respiratory syndrome virus in Dutch weaning pigs. Nodelijk G, et al. **Vet Microbiol** 1997 May;56(1-2):21-32

Evaluation of a blocking Elisa for screening of antibodies against porcine reproductive and respiratory syndrome (PRRS) virus. Sørensen KJ, et al. **Vet Microbiol** 1997 May; 56(1-2):1-8

Protective immune response of chickens against Newcastle disease, induced by the intranasal vaccination with inactivated virus. Takada A, et al. **Vet Microbiol** 1996 May; 50(1-2):17-25

Serum antibody responses of foals to virulence-associated 15- to 17-kilodalton antigens of Rhodococcus equi. Takai S, et al. **Vet Microbiol** 1996 Sep;52(1-2):63-71

Evaluation of a competitive enzyme-linked immunosorbent assay to detect infection of cattle in sentinel herds in Queensland, Australia with bluetongue viruses. Ward MP, et al. **Vet Microbiol** 1996 Mar;49(1-2):117-25

Serological survey for avian viruses in houbara bustards (Chlamydotis undulata macqueenii). Bailey TA, et al. **Vet Rec** 1996 Sep 7;139(10):238-9

Serological evidence of morbillivirus infection in polar bears (Ursus maritimus) from Alaska and Russia. Follmann EH, et al. **Vet Rec** 1996 Jun 22;138(25):615-8

Evaluation of a commercial gE blocking ELISA test for detection of antibodies to infectious bovine rhinotracheitis virus. Perrin B, et al. **Vet Rec** 1996 May 25;138(21):520

Transplacentally acquired antiviral antibodies and outcome in congenital human cytomegalovirus infection. Boppana SB, et al. **Viral Immunol** 1996;9(4):211-8

Evaluation of a new Epstein-Barr virus Combi Test for rapid serologic diagnosis of infectious mononucleosis. Dobec M, et al. **Zentralbl Bakteriol** 1996 Aug;284(4):565-76

The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Eis-Hübinger AM, et al. **Zentralbl Bakteriol** 1996 Jul;284(2-3):232-40

Comparison of seven commercial tests for the detection of parvovirus B19-specific IgM. Schwarz TF, et al. **Zentralbl Bakteriol** 1997 Apr;285(4):525-30

[Reconstitution of Hu-SCID mice transplanted with human tonsillar lymphocytes immunized with dengue virus-2 in vitro and its immune response] Zuo L, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Aug;76(8):597-9 (Eng. Abstr.) **(Chi)**

[Serological effect after immunization with rabies vaccine of different doses] Chen AZ, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Jun; 17(3):139-40 (Eng. Abstr.) **(Chi)**

[Limits of immunoserologic and molecular diagnosis of hepatitis C] Trepo C, et al. **Nucl Med Biol** 1994 Apr; 21(3):419-31 (Eng. Abstr.) **(Fre)**

[Serological investigations in the diagnosis of viral infections derived from cattle in sheep] Bechmann G. **DTW Dtsch Tierarztl Wochenschr** 1997 Aug;104(8):321-4 (Eng. Abstr.) **(Ger)**

[Epidemiologic studies of the occurrence of bovine virus diarrhea/mucosal disease in 2892 cattle in 95 dairy farms] Braun U, et al. **Schweiz Arch Tierheilkd** 1997;139(4):172-6 (Eng. Abstr.) **(Ger)**

[Distribution of influenza C virus infection in dogs and pigs in Bavaria] Youzbashi E, et al. **Tierarztl Prax** 1996 Aug; 24(4):337-42 (Eng. Abstr.) **(Ger)**

[Virologic and serologic study on subjects vaccinated with Sabin vaccine, living in a community] Andreoni G, et al. **Boll Ist Sieroter Milan** 1966 May-Jun;45(5-6):236-49 **(Ita)**

[Effect of antigenemia on diagnosis and determination of the result of therapy of cytomegalovirus infection in formerly healthy adults (letter)] Asai T. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jun;94(6):450 **(Jpn)**

[Interaction between Epstein-Barr virus (EBV) gene expression and antibodies to EBV in nasopharyngeal carcinomas] Furukawa M, et al. **Rinsho Byori** 1996 Sep; 44(9):832-7 (Eng. Abstr.) **(Jpn)**

[Relationship between the level of specific antibodies with disease outcome in Cercopithecus aethiops monkeys in experimental Marburg disease] Agafonova OA, et al. **Vopr Virusol** 1997 May-Jun;42(3):109-11 (Eng. Abstr.) **(Rus)**

[Characteristics of anti-respiratory syncytial humoral immunity during persistence of respiratory syncytial virus antigens in adult patients with chronic obstructive bronchitis] Krivitskaia VZ, et al. **Vopr Virusol** 1996 Sep-Oct;41(5):234-7 (Eng. Abstr.) **(Rus)**

[The spread of antibodies to cytomegalovirus and Toxoplasma among donors of blood components] Zhiburt EB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan-Feb;(1):59-61 (Eng. Abstr.) **(Rus)**

[Western blotting in the serologic diagnosis of enterovirus infections. I. Detection of coxsackie virus antibodies in reference sera and sera of experimentally infected mice] Petrovičová A, et al. **Epidemiol Mikrobiol Imunol** 1997 May;46(2):47-50 (Eng. Abstr.) **(Slo)**

[Western blotting in the serologic diagnosis of enterovirus infections. II. Detection of coxsackievirus antibodies in the sera of patients with suspected enterovirus infection and in paired specimens of sera and saliva] Petrovičová A, et al. **Epidemiol Mikrobiol Imunol** 1997 May;46(2):51-4 (Eng. Abstr.) **(Slo)**

[Mononucleosis syndromes with serology doubly positive to Epstein-Barr virus and cytomegalovirus] Sánchez Echániz J, et al. **An Esp Pediatr** 1996 Sep;45(3):242-4 (Eng. Abstr.) **(Spa)**

[Evaluation of a reagent for the diagnosis of Epstein-Barr virus infection (letter)] de Ory F. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):506-7 **(Spa)**

[Performance of the IgG avidity test in patients with cytomegalovirus disease] Lafarga B, et al. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):190-5 (Eng. Abstr.) **(Spa)**

[Seroprevalence of viral infections in llamas (Lama glama) in the Republic of Argentina] Puntel M. **Rev Argent Microbiol** 1997 Jan-Mar;29(1):38-46 (Eng. Abstr.) **(Spa)**

[Prevalence of human herpesvirus 7 in Mexican blood donors] Rojo Medina J, et al. **Rev Invest Clin** 1995 Nov-Dec; 47(6):467-71 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Clinical value of specific intrathecal production of antibodies. Treib J, et al. **Acta Virol** 1997 Feb;41(1):27-30

Intrathecal reactivity for myelin components precedes development of neurological symptoms in AIDS patients. Silva AA, et al. **Arch Med Res** 1997 Autumn;28(3):391-6

Cerebrospinal fluid viral antibodies in obsessive-compulsive disorder in an Indian population. Khanna S, et al. **Biol Psychiatry** 1997 Apr 15;41(8):883-90

Detection of both herpes simplex and varicella-zoster viruses in cerebrospinal fluid from patients with encephalitis. Casas I, et al. **J Med Virol** 1996 Sep;50(1):82-92

Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy. Sindic CJ, et al. **J Neuroimmunol** 1997 Jun;76(1-2):100-4

Dual detection of antibody to both herpes simplex and varicella-zoster viruses in cerebrospinal fluid: cross reactivity or dual infection? [letter] Echevarría JM, et al. **J Neurol** 1996 Aug;243(8):618-9

Diversity of intrathecal antibody synthesis against HTLV-I and its relation to HTLV-I associated myelopathy. Kitze B, et al. **J Neurol** 1996 May;243(5):393-400

Possible correlation between Borna disease virus infection and Japanese patients with chronic fatigue syndrome. Kitani T, et al. **Microbiol Immunol** 1996;40(6):459-62

CHEMISTRY

The reliability of saliva as a sample for the detection of hepatitis A immunoglobulins under various sampling conditions. O'Farrell BJ, et al. **Clin Diagn Virol** 1997 Feb; 7(3):153-7

Structure of the complex of an Fab fragment of a neutralizing antibody with foot-and-mouth disease virus: positioning of a highly mobile antigenic loop. Hewat EA, et al. **EMBO J** 1997 Apr 1;16(7):1492-500

Isolation of escape mutants of a hybrid poliovirus with the aid of insert-specific polyclonal antibodies. Hovi T, et al. **J Gen Virol** 1995 Jul;76 (Pt 7):1861-5

Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning. Ping T, et al. **J Immunol** 1996 Jul 15;157(2):772-80

Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay. Slifka MK, et al. **J Immunol Methods** 1996 Nov 29;199(1):37-46

Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge. Thouvenin E, et al. **J Mol Biol** 1997 Jul 11;270(2):238-46

Immunohistochemical detection of VHS virus in paraffin-embedded specimens of rainbow trout (Oncorhynchus mykiss): the influence of primary antibody, fixative, and antigen unmasking on method sensitivity. Evensen O, et al. **Vet Pathol** 1997 May;34(3):253-61

Different affinity of monoclonal antibodies for conserved neutralizing epitopes on two strains of rubella virus. Cordoba P, et al. **Viral Immunol** 1997;10(2):103-10

Antigenic features of foot-and-mouth disease virus serotype Asia1 as revealed by monoclonal antibodies and neutralization-escape mutants. Sanyal A, et al. **Virus Res** 1997 Aug;50(2):107-17

DIAGNOSTIC USE

[ELISA in the rapid diagnosis of influenza using as the detecting antibodies polyclonal antinucleoprotein sera] Lupulescu E, et al. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jan-Jun; 41(1-2):63-7 (Eng. Abstr.) **(Rum)**

GENETICS

Polygenic control of antibody production and correlation with vaccine induced resistance to rabies virus in high and low antibody responder mice. De Franco M, et al. **Arch Virol** 1996;141(8):1397-406

Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Schier R, et al. **Hum Antibodies Hybridomas** 1996;7(3):97-105

The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus. Kalinke U, et al. **Immunity** 1996 Dec; 5(6):639-52

Baculovirus expression of a human G2-specific, neutralizing IgG monoclonal antibody to Puumala virus. Liang M, et al. **Virology** 1997 Sep 1;235(2):252-60

Cloning and expression of a single-chain antibody fragment specific for foot-and-mouth disease virus. Mason P, et al. **Virology** 1996 Oct 15;224(2):548-54

IMMUNOLOGY

Human herpesvirus-6 immunoglobulin G antibodies in patients with multiple sclerosis. Nielsen L, et al. **Acta Neurol Scand Suppl** 1997;169:76-8

Partial antigenic characterization of potato virus S (Andean strain) by monoclonal antibodies. Ceřovská N, et al. **Acta Virol** 1996 Feb;40(1):23-6

Differences between original strains and their mouse-adapted variants of human (H1) and avian (H2) influenza A viruses in the reaction with cross-neutralizing monoclonal antibody recognizing conformational epitope. Lipatov AS, et al. **Acta Virol** 1996 Sep;40(4):227-30

Serological study of type A Indian foot-and-mouth disease virus isolates. Meer Azad H, et al. **Acta Virol** 1995 Sep; 39(4):193-6

Monoclonal antibodies against potato virus A — immunoblot analysis. Subr Z, et al. **Acta Virol** 1996 Nov-Dec; 40(5-6):289-92

HIV-specific cellular and humoral immune responses in primary HIV infection. Connick E, et al. **AIDS Res Hum Retroviruses** 1996 Aug 10;12(12):1129-40

Overexpression and purification of a recombinant chimeric HIV type 2/HIV type 1 envelope peptide and application in an accelerated immunobased HIV type 1/2 antibody detection system (AIBS): a new rapid serological screening assay. Ecker B, et al. **AIDS Res Hum Retroviruses** 1996 Aug 10;12(12):1081-91

Selective thymocyte depletion and immunoglobulin coating in the thymus of cats infected with feline immunodeficiency virus. Orandle MS, et al. **AIDS Res Hum Retroviruses** 1997 May 1;13(7):611-20

Accuracy of oral specimen testing for human immunodeficiency virus. Emmons W. **Am J Med** 1997 Apr 1;102(4A):15-20 (41 ref.)

Maternal antibodies protect immunoglobulin deficient neonatal mice from mouse hepatitis virus (MHV)-associated wasting syndrome. Gustafsson E, et al. **Am J Reprod Immunol** 1996 Jul;36(1):33-9

Recognition of synthetic oligopeptides from nonstructural proteins NS1 and NS3 of dengue-4 virus by sera from dengue virus-infected children. Garcia G, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):466-70

Characterization of adenovirus hexons by their epitope composition. Adám E, et al. **Arch Virol** 1996; 141(10):1891-907

Modified activity of a VP2-located neutralizing epitope on various vaccine, pathogenic and hypervirulent strains of infectious bursal disease virus. Eterradossi N, et al. **Arch Virol** 1997;142(2):255-70

Serological comparison of tospoviruses with polyclonal antibodies produced against the main structural proteins of tomato spotted wilt virus. Feldhoff A, et al. **Arch Virol** 1997;142(4):781-93

Correlation between the presence of anti HPV33 VLP antibodies and HPV DNA in cervical neoplasia patients. Hamsíková E, et al. **Arch Virol** 1997;142(2):413-6

Characterization of neutralizing domains on varicella-zoster virus glycoprotein E defined by monoclonal antibodies. Wu L, et al. **Arch Virol** 1997;142(2):349-62

VP4 and VP7 typing using monoclonal antibodies. Coulson BS. **Arch Virol Suppl** 1996;12:113-8 (23 ref.)

Prophylaxis of rotavirus gastroenteritis using immunoglobulin. Ebina T. **Arch Virol Suppl** 1996;12:217-23

Selective antibody reactivity with peptides from human endogenous retroviruses and nonviral poly(amino acids) in patients with systemic lupus erythematosus. Bengtsson A, et al. **Arthritis Rheum** 1996 Oct;39(10):1654-63

Antigenicity, pathogenicity, and immunogenicity of small and large plaque infectious bursal disease virus clones. Hassan MK, et al. **Avian Dis** 1996 Oct-Dec;40(4):832-6

Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135. Huang X, et al. **Biochemistry** 1997 Sep 9; 36(36):10846-56

Paget's disease of bone and unvaccinated dogs. Khan SA, et al. **Bone** 1996 Jul;19(1):47-50

Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Wright JF, et al. **Br J Haematol** 1996 Oct; 95(1):145-52

Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. Strickler HD, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Mar;6(3):183-8

Specificity of antibodies directed against Env protein of human endogenous retroviruses in patients with germ cell tumors. Sauter M, et al. **Cancer Res** 1996 Oct 1; 56(19):4362-5

Unusually high seroprevalence of Borna disease virus in clade E human immunodeficiency virus type 1-infected patients with sexually transmitted diseases in Thailand. Auwanit W, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):590-3

Presence of a neutralizing domain in isolates of rubella virus in Cordoba, Argentina. Cordoba P, et al.

Clin Diagn Lab Immunol 1997 Jul;4(4):493–5

Enzyme-linked immunosorbent assay-based detection of antibodies to antigenic subtypes of infectious bursal disease viruses of chickens. Jackwood DJ, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):456–63

Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Keitel WA, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):507–10

Detection of serum immunoglobulin M to human cytomegalovirus by western blotting correlates better with virological data than detection by conventional enzyme immunoassay. Lazzarotto T, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):597–600

Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. Lazzarotto T, et al. **Clin Diagn Lab Immunol** 1997 Jul; 4(4):469–73

Search for cytomegalovirus-specific immunoglobulin M: comparison between a new western blot, conventional western blot, and nine commercially available assays. Lazzarotto T, et al. **Clin Diagn Lab Immunol** 1997 Jul; 4(4):483–6

Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques. Ohlin M, et al. **Clin Diagn Lab Immunol** 1997 Jan;4(1):107–11

Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Powers DC, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):511–6

Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions. Sasagawa T, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):403–10

Detection of rubella virus-specific immunoglobulin M antibodies with a baculovirus-expressed E1 protein. Schmidt M, et al. **Clin Diagn Lab Immunol** 1996 Mar; 3(2):216–8

Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in The United States. Suara RO, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):477–9

Hepatitis C virus (HCV)-induced IgG-IgM rheumatoid factor (RF) complex may be the main causal factor for cold-dependent activation of complement in patients with rheumatic disease. Wei G, et al. **Clin Exp Immunol** 1997 Jan;107(1):83–8

Roles of the humoral response in coxsackievirus B-induced disease. Gauntt CJ. **Curr Top Microbiol Immunol** 1997; 223:259–82 (190 ref.)

Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection. Kalinke U, et al. **Eur J Immunol** 1996 Dec;26(12):2801–6

Persistence of respiratory syncytial virus (RSV) infection and development of RSV-specific IgG1 response in a guinea-pig model of acute bronchiolitis. Dakhama A, et al. **Eur Respir J** 1997 Jan;10(1):20–6

Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Yang Y, et al. **Gene Ther** 1996 May;3(5):412–20

Human monoclonal antibodies to viral peptides. Sidorova E, et al. **Hum Antibodies** 1997;8(2):65–9

Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections. Fenyö EM, et al. **Immunol Lett** 1996 Jun;51(1–2):95–9

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Haigwood NL, et al. **Immunol Lett** 1996 Jun;51(1–2):107–14

The influence of virus structure on antibody responses and virus serotype formation. Bachmann MF, et al. **Immunol Today** 1996 Dec;17(12):553–8 (48 ref.)

Differential activation of T cells by antibody-modulated processing of the flanking sequences of class II-restricted peptides. Fournier P, et al. **Int Immunol** 1996 Sep; 8(9):1441–51

Differentiation of primary from nonprimary genital herpes infections by a herpes simplex virus-specific immunoglobulin G avidity assay. Hashido M, et al. **J Clin Microbiol** 1997 Jul;35(7):1766–8

Characterization of monoclonal antibodies to the hemagglutinin-esterase glycoprotein of a bovine coronavirus associated with winter dysentery and cross-reactivity to field isolates. Milane G, et al. **J Clin Microbiol** 1997 Jan;35(1):33–40

Monoclonal antibodies capable of distinguishing epizootic from enzootic varieties of subtype 1 Venezuelan equine encephalitis viruses in a rapid indirect immunofluorescence assay. Roehrig JT, et al. **J Clin Microbiol** 1997 Jul; 35(7):1887–90

Evaluation of monoclonal antibodies for subtyping of currently circulating human type A influenza viruses. Tkáčová M, et al. **J Clin Microbiol** 1997 May;35(5):1196–8

Trojan Horse macrophages: studies with the murine lactate dehydrogenase-elevating virus and implications for sexually transmitted virus infection. Cafruny WA, et al. **J Gen Virol** 1996 Dec;77 (Pt 12):3005–12

Antibodies to a new linear site at the topographical or functional interface between the haemagglutinin and fusion proteins protect against measles encephalitis. Fournier P, et al. **J Gen Virol** 1997 Jun;78 (Pt 6):1295–302

Monoclonal antibodies specific for Semliki Forest virus replicase protein nsP2. Kujala P, et al. **J Gen Virol** 1997 Feb;78 (Pt 2):343–51

All rabbits immunized with type A influenza virions have a serum haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B. Lambkin R, et al. **J Gen Virol** 1995 Apr;76 (Pt 4):889–97

Antigenic analysis of human herpesvirus 7 (HHV-7) and HHV-6 using immune sera and monoclonal antibodies against HHV-7. Nakagawa N, et al. **J Gen Virol** 1997 May; 78 (Pt 5):1131–7

Duration of the foot-and-mouth disease virus antibody response in mice is closely related to the presence of antigen-specific presenting cells. Wigdorovitz A, et al. **J Gen Virol** 1997 May;78 (Pt 5):1025–32

Protection against measles virus encephalitis by monoclonal antibodies binding to a cystine loop domain of the H protein mimicked by peptides which are not recognized by maternal antibodies. Ziegler D, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2479–89

Mapping regions of herpes simplex virus type 1 glycoprotein I required for formation of the viral Fc receptor for monomeric IgG. Basu S, et al. **J Immunol** 1997 Jan 1; 158(1):209–15

Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. Epstein SL, et al. **J Immunol** 1997 Feb 1;158(3):1222–30

Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. Garrity RR, et al. **J Immunol** 1997 Jul 1;159(1):279–89

Early neutralizing antibody response against mouse mammary tumor virus: critical role of viral infection and superantigen-reactive T cells. Luther SA, et al. **J Immunol** 1997 Sep 15;159(6):2807–14

Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. Montefiori DC, et al. **J Immunol** 1996 Dec 15; 157(12):5528–35

Virus-specific IgD in acute viral infection of mice. Moskophidis D, et al. **J Immunol** 1997 Feb 1;158(3):1254–61

Quantitative analysis of the influenza virus-specific CD4+ T cell memory in the absence of B cells and Ig. Topham DJ, et al. **J Immunol** 1996 Oct 1;157(7):2947–52

Persistence of antibodies after inactivated hepatitis A vaccines in a comparative study [letter] Goilav C, et al. **J Infect** 1997 Mar;34(2):158

Unimmunized Gypsy populations and implications for the eradication of poliomyelitis in Europe. Aylward RB, et al. **J Infect Dis** 1997 Feb;175 Suppl 1:S86–8

A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections. Hamilton AA, et al. **J Infect Dis** 1997 Jul; 176(1):59–68

Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. Powers DC, et al. **J Infect Dis** 1997 Feb;175(2):342–51

Antiviral nonspecific immunity of human placenta at term: possible role of endogenous tumor necrosis factors and interferons. Paradowska E, et al. **J Interferon Cytokine Res** 1996 Nov;16(11):941–8

Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. de Souza VA, et al. **J Med Virol** 1997 Jul; 52(3):275–9

Avidity determination of IgG directed against tick-borne encephalitis virus improves detection of current infections. Gassmann C, et al. **J Med Virol** 1997 Mar;51(3):242–51

Enzyme-linked immunosorbent assay using recombinant antigens for serodiagnosis of Japanese encephalitis. Konishi E, et al. **J Med Virol** 1996 Jan;48(1):76–9

Antibody-dependent cell-mediated cytotoxicity (ADCC) in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) [published erratum appears in J Neurol Sci 1997 Apr 15;147(2):221] Fujihara K, et al. **J Neurol Sci** 1996 Oct;142(1–2):65–9

Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. Anderson R, et al. **J Virol** 1997 Jun;71(6):4226–32

Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells. Baldridge JR, et al. **J Virol** 1997 Jan;71(1):755–8

Characterization of the antibody response specific for the human endogenous retrovirus HTDV/HERV-K. Boller K, et al. **J Virol** 1997 Jun;71(6):4581–8

Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodies. Castilla J, et al. **J Virol** 1997 Jul;71(7):5251–8

Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. Cole KS, et al. **J Virol** 1997 Jul;71(7):5069–79

Characterization of monoclonal antibodies raised against p300: both p300 and CBP are present in intracellular TBP complexes. Dallas PB, et al. **J Virol** 1997 Feb;71(2):1726–31

Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies. Fiore L, et al. **J Virol** 1997 Sep;71(9):6905–12

Identification of amino acids controlling the low-pH-induced conformational change of rabies virus glycoprotein. Gaudin Y, et al. **J Virol** 1996 Nov;70(11):7371–8

Neutralizing antibodies to different proteins of African swine fever virus inhibit both virus attachment and internalization. Gómez-Puertas P, et al. **J Virol** 1996 Aug; 70(8):5689–94

Phage-displayed peptide targeting on the Puumala hantavirus neutralization site. Heiskanen T, et al. **J Virol** 1997 May; 71(5):3879–85

Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. Kreil TR, et al. **J Virol** 1997 Apr; 71(4):2921–7

Preferential selection of receptor-binding variants of influenza virus hemagglutinin by the neutralizing antibody repertoire of transgenic mice expressing a human immunoglobulin mu minigene. Laeeq S, et al. **J Virol** 1997 Apr;71(4):2600–5

Modification of the Sendai virus-specific antibody and CD8+ T-cell responses in mice homozygous for disruption of the interleukin-4 gene. Mo XY, et al. **J Virol** 1997 Mar; 71(3):2518–21

Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant. Nyambi PN, et al. **J Virol** 1997 Mar;71(3):2320–30

Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates. Periwal SB, et al. **J Virol** 1997 Apr;71(4):2844–50

Two 21-kilodalton components of the Epstein-Barr virus capsid antigen complex and their relationship to ZEBRA-associated protein p21 (ZAP21). Serio TR, et al. **J Virol** 1996 Nov;70(11):8047–54

CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection [published erratum appears in J Virol 1997 Feb;71(2):1736] Whitmire JK, et al. **J Virol** 1996 Dec;70(12):8375–81

Major linear antibody epitopes and capsid proteins differentially induce protective immunity against Theiler's virus-induced demyelinating disease. Yahikozawa H, et al. **J Virol** 1997 Apr;71(4):3105–13

Antiviral immune responses in CTLA4 transgenic mice. Zimmermann C, et al. **J Virol** 1997 Mar;71(3):1802–7

Booster immunization with a partially purified citrus tristeza virus (CTV) preparation after priming with recombinant CTV coat protein enhances the binding capacity of capture antibodies by ELISA. Bar-Joseph M, et al. **J Virol Methods** 1997 Aug;67(1):19–22

Production of the antigen and the antibody of the JC virus major capsid protein VP1. Chang D, et al. **J Virol Methods** 1996 May;59(1–2):177–87

Presence of rabbit haemorrhagic disease virus antigen in rabbit tissues as revealed by a monoclonal antibody dependent capture ELISA. Collins BJ, et al. **J Virol Methods** 1996 Apr 26;58(1–2):145–54

Improvement in establishing the period of rubella virus primary infection using a mild protein denaturant. Condorelli F, et al. **J Virol Methods** 1997 Jun;66(1):109–12

A scFv-alkaline phosphatase fusion protein which detects potato leafroll luteovirus in plant extracts by ELISA. Harper K, et al. **J Virol Methods** 1997 Jan;63(1–2):237–42

Fast neutralization/immunoperoxidase assay for viral haemorrhagic septicaemia with anti-nucleoprotein monoclonal antibody. Lorenzo G, et al. **J Virol Methods** 1996 Apr 26;58(1–2):1–6

Determination of affinities of a panel of IgGs and Fabs for whole enveloped (influenza A) virions using surface plasmon resonance. Schofield DJ, et al. **J Virol Methods** 1996 Oct;62(1):33–42

Highly sensitive immunoassays for detection of barley stripe mosaic virus and beet necrotic yellow vein virus. Sukhacheva E, et al. **J Virol Methods** 1996 Feb; 56(2):199–207

IgM-specific serodiagnosis of acute human cytomegalovirus infection using recombinant autologous fusion proteins. Vornhagen R, et al. **J Virol Methods** 1996 Jun;60(1):73–80

Evaluation of 11 enzyme immunoassays for the detection of immunoglobulin M antibodies to Epstein-Barr virus. Weber B, et al. **J Virol Methods** 1996 Mar;57(1):87–93

Hepatitis G virus infection [letter; comment] Karayiannis P, et al. **Lancet** 1997 Mar 29;349(9056):954. Comment on: Lancet 1997 Feb 1;349(9048):318–20.

Hepatitis G virus infection [letter; comment] Schleicher S, et al. **Lancet** 1997 Mar 29;349(9056):954–5. Comment on: Lancet 1997 Feb 1;349(9048):318–20.

Monoclonal antibody #5-2-26 recognizes the phosphatase-sensitive epitope of rabies virus nucleoprotein. Kawai A, et al. **Microbiol Immunol** 1997;41(1):33–42

Biological mimicry of the bluetongue virus core protein VP7 by rabbit anti-idiotype. Lin M, et al. **Microbiol Immunol** 1996;40(6):435–41

Antibody against synthetic multiple antigen peptides (MAP) of JC virus capsid protein (VP1) without cross reaction to BK virus: a diagnostic tool for progressive multifocal leukoencephalopathy. Aoki N, et al. **Neurosci Lett** 1996 Feb 23;205(2):111–4

Beneficial use of inactivated porcine adenovirus vaccine and

antibody response of young pigs. Kadoi K. **New Microbiol** 1997 Jan;20(1):89–91

Syncytium–inhibiting and neutralizing activity in maternal sera fail to prevent vertical transmission of human immunodeficiency virus type 1. Bal AK, et al. **Pediatr Infect Dis J** 1996 Apr;15(4):315–20

Expression of single–chain antibody fragments (scFv) specific for beet necrotic yellow vein virus coat protein or 25 kDa protein in Escherichia coli and Nicotiana benthamiana. Fecker LF, et al. **Plant Mol Biol** 1996 Dec;32(5):979–86

A critical role for neutralizing–antibody–producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Planz O, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24; 94(13):6874–9

Antibodies to several conformation–dependent epitopes of gp120/gp41 inhibit CCR–5–dependent cell–to–cell fusion mediated by the native envelope glycoprotein of a primary macrophage–tropic HIV–1 isolate. Verrier FC, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9326–31

Compact Epstein–Barr virus diagnosis based on a defined antigen mix and specific IgA. Dopatka HD, et al. **Res Virol** 1996 Jan–Feb;147(1):53–66

Measles antibodies and herd immunity in 20– and 40–year–old Norwegians. Flugsrud LB, et al. **Scand J Infect Dis** 1997; 29(2):137–40

The role of antibody concentration and avidity in antiviral protection. Bachmann MF, et al. **Science** 1997 Jun 27; 276(5321):2024–7

Virus versus antibody. Colman PM. **Structure** 1997 May 15; 5(5):591–3 (19 ref.)

Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants. Benne CA, et al. **Vaccine** 1997 Jun;15(9):1039–44

Induction of neutralizing antibody and T–cell responses to varicella–zoster virus (VZV) using Ty–virus–like particles carrying fragments of glycoprotein E (gE). Garcia–Valcarcel M, et al. **Vaccine** 1997 Apr–May; 15(6–7):709–19

Induction of feline immunodeficiency virus specific antibodies in cats with an attenuated Salmonella strain expressing the Gag protein. Tijhaar EJ, et al. **Vaccine** 1997 Apr–May;15(6–7):587–96

Recombinant feline herpesvirus type 1 expressing immunogenic proteins inducible virus neutralizing antibody against feline calicivirus in cats. Yokoyama N, et al. **Vaccine** 1996 Dec;14(17–18):1657–63

Field isolates of porcine reproductive and respiratory syndrome virus (PRRSV) vary in their susceptibility to antibody dependent enhancement (ADE) of infection. Yoon KJ, et al. **Vet Microbiol** 1997 Apr;55(1–4):277–87

Seroconversion in an industrial unit of rabbits infected with a non–pathogenic rabbit haemorrhagic disease–like virus. Capucci L, et al. **Vet Rec** 1997 Jun 21;140(25):647–50

A complex neutralization domain of bluetongue virus serotype 17 defines a virulence–associated marker. Bernard KA, et al. **Viral Immunol** 1996;9(2):97–106

Neutralizing and fusion–blocking antibodies induced by recombinant visna virus envelope glycoprotein. Huso DL. **Viral Immunol** 1997;10(1):15–20

Production of virus–specific antisera using synthetic peptides corresponding to sequences in the yellow fever E protein: brief report. Jackson RE, et al. **Viral Immunol** 1997; 10(1):11–4

Immunization with plasmid DNA encoding for the measles virus hemagglutinin and nucleoprotein leads to humoral and cell–mediated immunity. Cardoso AI, et al. **Virology** 1996 Nov 15;225(2):293–9

Monoclonal antibodies to HPV–6 L1 virus–like particles identify conformational and linear neutralizing epitopes on HPV–11 in addition to type–specific epitopes on HPV–6. Christensen ND, et al. **Virology** 1996 Oct 15;224(2):477–86

Surface conformational and linear epitopes on HPV–16 and HPV–18 L1 virus–like particles as defined by monoclonal antibodies. Christensen ND, et al. **Virology** 1996 Sep 1; 223(1):174–84

Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract. Gallichan WS, et al. **Virology** 1996 Oct 15; 224(2):487–97

Neutralization susceptibility of African swine fever virus is dependent on the phospholipid composition of viral particles. Gómez–Puertas P, et al. **Virology** 1997 Feb 17; 228(2):180–9

Probing phage PRD1–specific proteins with monoclonal and polyclonal antibodies. Hänninen AL, et al. **Virology** 1997 Jan 6;227(1):198–206

Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Hiramatsu K, et al. **Virology** 1996 Oct 15;224(2):437–45

The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. Palker TJ, et al. **Virology** 1996 Oct 15;224(2):415–26

A neutralization site of DA strain of Theiler's murine encephalomyelitis virus important for disease phenotype. Sato S, et al. **Virology** 1996 Dec 15;226(2):327–37

In vivo selection of duck hepatitis B virus pre–S variants which escape from neutralization. Sunyach C, et al. **Virology** 1997 Aug 4;234(2):291–9

Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies. Tschetter JR, et al. **Virology** 1997 Apr 14;230(2):275–80

Plasmas from lymphocyte– and macrophage–tropic SIVmac–infected macaques have antibodies with a broader spectrum of virus neutralization activity in macrophage versus lymphocyte cultures. Zhuge W, et al. **Virology** 1997 Jan 6;227(1):24–33

Epitope mapping of monoclonal antibodies raised to recombinant Mengo 3D polymerase. Duque H, et al. **Virus Genes** 1996;13(2):159–68

Antigenic diversity of Akabane virus detected by monoclonal antibodies. Akashi H, et al. **Virus Res** 1997 Feb;47(2):187–96

Characterization of Langat virus antigenic determinants defined by monoclonal antibodies to E, NS1 and preM and identification of a protective, non–neutralizing preM–specific monoclonal antibody. Iacono–Connors LC, et al. **Virus Res** 1996 Aug;43(2):125–36

A 27 amino acid coding region of JE virus E protein expressed in E. coli as fusion protein with glutathione–S–transferase elicit neutralizing antibody in mice. Seif SA, et al. **Virus Res** 1996 Jul;43(1):91–6

Does anti–HBc reactivity reflect 'lifestyle' risk in north London blood donors? Moore MC, et al. **Vox Sang** 1997; 72(2):79–84

[Immunogenicity of the avirulent strain RV194–2 of the rabies virus in mice] Marcovistz R, et al. **Rev Soc Bras Med Trop** 1996 Nov–Dec;29(6):579–83 (Eng. Abstr.) **(Por)**

[Effectiveness of virus–specific proteins in immunogenesis during experimental Marburg fever] Donchenko VV, et al. **Vopr Virusol** 1996 Sep–Oct;41(5):216–8 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Accuracy of oral specimen testing for human immunodeficiency virus. Emmons W. **Am J Med** 1997 Apr 1;102(4A):15–20 (41 ref.)

Oral diagnostic testing for detecting human immunodeficiency virus–1 antibodies: a technology whose time has come. Malamud D. **Am J Med** 1997 Apr 1; 102(4A):9–14 (37 ref.)

Testing sputum samples for HIV antibodies, using a rapid, saliva–card test system. Gilks CF, et al. **Ann Trop Med Parasitol** 1997 Jan;91(1):115–7

Hepatitis C virus infection in two groups of paediatric patients: one maintained on haemodialysis and the other on continuous ambulatory peritoneal dialysis. al–Mugeiren M, et al. **Ann Trop Paediatr** 1996 Dec;16(4):335–9

Humoral immune response of chicks to different clinical isolates of avian adenovirus type–1. Maiti NK, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):59–62

Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma. Hahn DL, et al. **Epidemiol Infect** 1996 Dec;117(3):513–7

Isolation of a neutralizing human RSV antibody from a dominant, non–neutralizing immune repertoire by epitope–blocked panning. Ping T, et al. **J Immunol** 1996 Jul 15;157(2):772–80

Hierarchical affinity maturation of a phage library derived antibody for the selective removal of cytomegalovirus from plasma. Pini A, et al. **J Immunol Methods** 1997 Aug 7; 206(1–2):171–82

Antibody responses to the hepatitis C virus E2 protein: relationship to viraemia and prevalence in anti–HCV seronegative subjects. Cerino A, et al. **J Med Virol** 1997 Jan;51(1):1–5

Susceptibility to varicella zoster virus infection in health care workers. Gallagher J, et al. **Occup Med (Oxf)** 1996 Aug; 46(4):289–92

Cytomegalovirus infection in a day–care center in the municipality of São Paulo. de Mello AL, et al. **Rev Inst Med Trop Sao Paulo** 1996 May–Jun;38(3):165–9

Evaluation of the effects of nursery depopulation on the persistence of porcine reproductive and respiratory syndrome virus and the productivity of 34 farms. Dee SA, et al. **Vet Rec** 1997 Mar 8;140(10):247–8

Detection of FIV antibodies [letter] Robinson A. **Vet Rec** 1997 Mar 1;140(9):240

METABOLISM

Intratesticular inoculation of avian leukosis virus (ALV) in chickens—production of neutralizing antibodies and lack of virus shedding into semen. Afanassieff M, et al. **Avian Dis** 1996 Oct–Dec;40(4):841–52

Comparison of the protective response induced by NYVAC vaccinia recombinants expressing either gp50 or gII and gp50 of pseudorabies virus. Brockmeier SL, et al. **Can J Vet Res** 1996 Oct;60(4):315–7

Increased plasma levels of soluble CD23 in haemorrhagic fever with renal syndrome; relation to virus–specific IgE. Alexeyev OA, et al. **Clin Exp Immunol** 1997 Aug; 109(2):351–5

Phage antibodies with pan–species recognition of the oncofoetal angiogenesis marker fibronectin ED–B domain. Carnemolla B, et al. **Int J Cancer** 1996 Nov 4;68(3):397–405

Supplemental dietary chromium does not influence ACTH, cortisol, or immune responses in young calves inoculated with bovine herpesvirus–1. Arthington JD, et al. **J Anim Sci** 1997 Jan;75(1):217–23

Real time observation of the binding of herpes simplex virus type 1 (HSV–1) to immobilized heparan sulfate and the neutralization of HSV–1 by sulfonated human immunoglobulin. Inoue K, et al. **J Biochem (Tokyo)** 1996 Aug;120(2):233–5

Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge. Thouvenin E, et al. **J Mol Biol** 1997 Jul 11;270(2):238–46

Local and systemic specific antibody response of different chicken lines after ocular vaccination against infectious bronchitis. Toro H, et al. **Zentralbl Veterinarmed [B]** 1996 Oct;43(8):449–54

PHARMACOLOGY

Monoclonal antibodies to the distinct antigenic sites on glycoproteins C and B and their protective abilities in herpes simplex virus infection. Bystrická M, et al. **Acta Virol** 1997 Feb;41(1):5–12

Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV–1 particles as a function of complement–mediated virolysis. Nakamura M, et al. **Microbiol Immunol** 1996;40(8):561–7

Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Rimensberger PC, et al. **Pediatr Infect Dis J** 1996 Mar;15(3):209–16

The use of antipoliovirus monoclonal antibodies as an improved safety test for oral live poliomyelitis vaccine. Horie H, et al. **Vaccine** 1996 Jan;14(1):35–41

Increased in vitro immunosuppressive action of anti–CMV and anti–HBs intravenous immunoglobulins due to higher amounts of interferon–gamma specific neutralizing antibodies. Denys C, et al. **Vox Sang** 1997;72(4):247–50

[Effects of tea catechin and specific antibody of influenza viruses] Nakayama M, et al. **Kansenshogaku Zasshi** 1996 Nov;70(11):1190–2 **(Jpn)**

PHYSIOLOGY

Retrovirus–induced lymphoproliferative disease in mice: role of humoral immunity in perinatally exposed mice. Zaleski MB, et al. **Immunobiology** 1995 Nov;194(4–5):390–402

HIV–1 gp120–specific antibody–dependent cell–mediated cytotoxicity correlates with rate of disease progression. Baum LL, et al. **J Immunol** 1996 Sep 1;157(5):2168–73

Blocking antibodies inhibit complete African swine fever virus neutralization. Gómez–Puertas P, et al. **Virus Res** 1997 Jun;49(2):115–22

THERAPEUTIC USE

Preventive effect of IgG from EBV–seropositive donors on the development of human lympho–proliferative disease in SCID mice. Abedi MR, et al. **Int J Cancer** 1997 May 16;71(4):624–9

A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin–specific antibodies that display very low virus–neutralizing activity in vitro. Mozdzanowska K, et al. **J Virol** 1997 Jun; 71(6):4347–55

Defining antibody protection against HIV–1 transmission in Hu–PBL–SCID mice. Koup RA, et al. **Semin Immunol** 1996 Aug;8(4):263–8 (52 ref.)

Should hepatitis B immunoglobulin therapy be discontinued after HBV reinfection following liver transplantation? Safadi R, et al. **Transplant Proc** 1997 Sep;29(6):2680–3

Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Hirota Y, et al. **Vaccine** 1997 Jun; 15(9):962–7

URINE

HIV–1 antibody testing. Jean JH. **Del Med J** 1997 Mar; 69(3):156

Diagnosis of respiratory virus infections using GACELISA of urinary antibodies. Ireland DC, et al. **J Immunol Methods** 1996 Sep 9;195(1–2):73–80

[The diagnostic importance of determining antibodies in the urine to the virus of hemorrhagic fever with renal syndrome] Shutov AM, et al. **Ter Arkh** 1996;68(11):35–7 (Eng. Abstr.) **(Rus)**

ANTIBODIES, XENOGENEIC see **ANTIBODIES, HETEROPHILE**

ANTIBODY AFFINITY

An investigation of the high–avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1. Binley JM, et al. **AIDS Res Hum Retroviruses** 1997 Aug 10;13(12):1007–15

The isotype composition and avidity of naturally acquired anti–Plasmodium falciparum antibodies: differential patterns in clinically immune Africans and Amazonian patients. Ferreira MU, et al. **Am J Trop Med Hyg** 1996 Sep;55(3):315–23

Real–time observation of affinity reactions using grating couplers: determination of the detection limit and calculation of kinetic rate constants. Polzius R, et al. **Anal Biochem** 1997 Jun 1;248(2):269–76

The functional affinity of IgM rheumatoid factor is related to the disease duration in patients with rheumatoid arthritis. Saraux A, et al. **Ann Rheum Dis** 1997 Feb;56(2):126–9

The measurement of affinity between ligand and antibody using ligand-induced antibody fluorescence change. Glaudemans CP, et al. **Carbohydr Res** 1997 May 12; 300(2):169-70

Immunoglobulin G avidity testing in serum and cerebrospinal fluid for analysis of measles virus infection. Narita M, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):211-5

Rat basophil leukaemia (RBL) cells sensitized with low affinity IgE respond to high valency antigen. Collins AM, et al. **Clin Exp Allergy** 1996 Aug;26(8):964-70

Affinity maturation and class switching. Wabl M, et al. **Curr Opin Immunol** 1996 Feb;8(1):89-92 (27 ref.)

The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. Smith KG, et al. **EMBO J** 1997 Jun 2;16(11):2996-3006

Fungal anti-A agglutinins with different affinities for subgroups A1 and A2 red cells. Ying R, et al. **Exp Clin Immunogenet** 1995;12(4):232-7

Anti-endotoxin antibodies directed against Escherichia coli R-1 oligosaccharide core-tetanus toxoid conjugate bind to smooth, live bacteria and smooth lipopolysaccharides and attenuate their tumor necrosis factor stimulating activity. Lugowski C, et al. **FEMS Immunol Med Microbiol** 1996 Nov;16(1):31-8

Low affinity, antibody binding of an Escherichia coli-derived component. Ohlin M, et al. **FEMS Immunol Med Microbiol** 1996 Feb;13(2):161-8

Monoclonal antibodies to thymidine glycol generated by different immunization techniques. Greferath R, et al. **Hybridoma** 1997 Apr;16(2):189-93

Editing disease-associated autoantibodies. Chen C, et al. **Immunity** 1997 Jan;6(1):97-105

Induction of somatic mutation in a human B cell line in vitro. Denépoux S, et al. **Immunity** 1997 Jan;6(1):35-46

In vitro immunization of naive human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display. Dueñas M, et al. **Immunology** 1996 Sep; 89(1):1-7

Is structural flexibility of antigen-binding loops involved in the affinity maturation of anti-DNA antibodies? Miyazaki S, et al. **Int Immunol** 1997 May;9(5):771-7

Heterogeneity of polyclonal IgE characterized by differential charge, affinity to protein A, and antigenicity. Peng Z, et al. **J Allergy Clin Immunol** 1997 Jul;100(1):87-95

Enhanced expression of high-affinity IgE receptor (Fc epsilon RI) alpha chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells. Rajakulasingam K, et al. **J Allergy Clin Immunol** 1997 Jul;100(1):78-86

Affinity of mouse immunoglobulin G subclasses for sialic acid derivatives immobilized on dextran-coated supports. Serres A, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7; 681(2):219-26

Differentiation of primary from nonprimary genital herpes infections by a herpes simplex virus-specific immunoglobulin G avidity assay. Hashido M, et al. **J Clin Microbiol** 1997 Jul;35(7):1766-8

Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity. Jenum PA, et al. **J Clin Microbiol** 1997 Aug;35(8):1972-7

High affinity antibodies against Lex and sialyl Lex from a phage display library. Dinh Q, et al. **J Immunol** 1996 Jul 15;157(2):732-8

Differential binding avidities of human IgM for staphylococcal protein A derive from specific germ-line VH3 gene usage. Hakoda M, et al. **J Immunol** 1996 Oct 1;157(7):2976-81

Contribution of heavy chain junctional amino acid diversity to antibody affinity among p-azophenylarsonate-specific antibodies. Parhami-Seren B, et al. **J Immunol** 1996 Sep 1;157(5):2066-72

Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. Price BE, et al. **J Immunol** 1996 Sep 1; 157(5):2201-8

High affinity rheumatoid factor transgenic B cells are eliminated in normal mice. Wang H, et al. **J Immunol** 1997 Aug 1;159(3):1125-34

Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. Benedict CA, et al. **J Immunol Methods** 1997 Feb 28;201(2):223-31

Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). McCloskey N, et al. **J Immunol Methods** 1997 Jun 23;205(1):67-72

Binding parameters of antibodies reacting with multivalent antigens: functional affinity or pseudo-affinity [letter] Mattes MJ. **J Immunol Methods** 1997 Mar 10;202(1):97-101 (27 ref.)

Assessment of affinity constants by rapid solid phase detection of equilibrium binding in a flow system. Piehler J, et al. **J Immunol Methods** 1997 Feb 28;201(2):189-206

Hierarchical affinity maturation of a phage library derived antibody for the selective removal of cytomegalovirus from plasma. Pini A, et al. **J Immunol Methods** 1997 Aug 7; 206(1-2):171-82

Use of a modified binding model for the investigation of affinity dependence on antibody concentration in immunoassay systems. Strohner P, et al. **J Immunol Methods** 1997 Apr 25;203(2):113-22

Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. Grangeot-Keros L, et al. **J Infect Dis** 1997 Apr; 175(4):944-6

Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. de Souza VA, et al. **J Med Virol** 1997 Jul; 52(3):275-9

Avidity determination of IgG directed against tick-borne encephalitis virus improves detection of current infections. Gassmann C, et al. **J Med Virol** 1997 Mar;51(3):242-51

Affinity of anti-GM1 antibodies in Guillain-Barré syndrome patients. Deisenhammer F, et al. **J Neuroimmunol** 1996 May;66(1-2):85-93

Gamma imaging of atherosclerotic lesions: the role of antibody affinity in in vivo target localization [see comments] Narula J, et al. **J Nucl Cardiol** 1996 May-Jun; 3(3):231-41. Comment in: J Nucl Cardiol 1996 May-Jun;3(3):278-80.

Somatic evolution in the immune system: the need for germinal centers for efficient affinity maturation. Pierre DM, et al. **J Theor Biol** 1997 May 21;186(2):159-71

Determination of affinities of a panel of IgGs and Fabs for whole enveloped (influenza A) virions using surface plasmon resonance. Schofield DJ, et al. **J Virol Methods** 1996 Oct;62(1):33-42

Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase. Atwell JL, et al. **Mol Immunol** 1996 Dec;33(17-18):1301-12

The role of antibody concentration and avidity in antiviral protection. Bachmann MF, et al. **Science** 1997 Jun 27; 276(5321):2024-7

Different affinity of monoclonal antibodies for conserved neutralizing epitopes on two strains of rubella virus. Cordoba P, et al. **Viral Immunol** 1997;10(2):103-10

[Simplified avidity assay of rubella IgG antibody in rubella virus infection] Hoshiba T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jun;48(6):413-8 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

The influence of salts on the reaction between hGH and several of its monoclonal antibodies in fixed, paraffin-embedded human pituitary as a model system. Montero C, et al. **Eur J Histochem** 1996;40(2):153-8

GENETICS

Can immunoglobulin C(H)1 constant region domain modulate antigen binding affinity of antibodies? Pritsch O, et al. **J Clin Invest** 1996 Nov 15;98(10):2235-43

Avidity maturation, repertoire shift, and strain differences in antibodies to bacterial levan, a type 2 thymus-independent polysaccharide antigen. Boswell CM, et al. **J Immunol** 1996 Sep 1;157(5):1996-2005

Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. Schier R, et al. **J Mol Biol** 1996 Nov 8;263(4):551-67

IMMUNOLOGY

Binding affinities of allergens from pollen, mites, and house dust for specific IgG subclass antibodies. Boluda L, et al. **Allergy** 1996 Oct;51(10):706-11

Incomplete dominance of the low antibody response to Cryptosporidium parvum antigens in mice selected for high and low antibody responsiveness. Teixeira MC, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1479-83

Structural and affinity studies of IgM polyreactive natural autoantibodies. Diaw L, et al. **J Immunol** 1997 Jan 15; 158(2):968-76

The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease. Velders MP, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):245-56

Are IgG antibody avidity assays useful in the diagnosis of infectious diseases? A review. Gutiérrez J, et al. **Microbios** 1996;87(351):113-21 (40 ref.)

PHYSIOLOGY

Age-related impaired affinity maturation and differential D-JH gene usage in human VH6-expressing B lymphocytes from healthy individuals. van Dijk-Härd I, et al. **Eur J Immunol** 1997 Jun;27(6):1381-6

ANTIBODY AVIDITY see **ANTIBODY AFFINITY**

ANTIBODY BINDING SITES see **BINDING SITES, ANTIBODY**

ANTIBODY DEFICIENCY SYNDROME see **IMMUNOLOGIC DEFICIENCY SYNDROMES**

ANTIBODY-DEPENDENT CELL CYTOTOXICITY

Antibody-dependent cellular cytotoxicity to clinical isolates of HIV-1 and SIVcpz: comparison of human and chimpanzees. Broliden K, et al. **AIDS** 1996 Sep; 10(11):1199-204

Experimental production and modulation of human cytotoxic dermatitis in human-murine chimeras. Christofidou-Solomidou M, et al. **Am J Pathol** 1997 Feb; 150(2):631-9

An assessment of cytokines expressed during antibody-mediated killing of colorectal tumour cells using murine and humanised antibodies. Gaskell KM, et al. **Biochem Soc Trans** 1997 May;25(2):267S

Signaling pathways regulating CD44-dependent cytolysis in natural killer cells. Sconocchia G, et al. **Blood** 1997 Jul 15;90(2):716-25

The role of apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayers of human squamous cell carcinoma of the head and neck targets. Sung MW, et al. **Cell Immunol** 1996 Jul 10;171(1):20-9

The correlation between NK cytotoxic activity and the production of the proinflammatory cytokines during the ageing process. Bryl E, et al. **Folia Histochem Cytobiol** 1997;35(2):75-6

Signal transduction during natural killer cell activation: inside the mind of a killer. Leibson PJ. **Immunity** 1997 Jun; 6(6):655-61 (117 ref.)

Survival of Blastocystis hominis clones after exposure to a cytotoxic monoclonal antibody. Tan SW, et al. **Int J Parasitol** 1997 Aug;27(8):947-54

Antibody-dependent cell-mediated cytotoxicity against orbital target cells in thyroid-associated ophthalmopathy and related disorders; close relationship between serum cytotoxic antibodies and parameters of eye muscle dysfunction. Barsouk A, et al. **J Endocrinol Invest** 1996 Jun;19(6):334-41

HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. Baum LL, et al. **J Immunol** 1996 Sep 1;157(5):2168-73

Antibody and antibody-dependent cellular cytotoxicity responses against the BamHI A rightward open-reading frame-1 protein of Epstein-Barr virus (EBV) in EBV-associated disorders. Tanner JE, et al. **J Infect Dis** 1997 Jan;175(1):38-46

IgM-mediated opsonization and cytotoxicity in the shark. McKinney EC, et al. **J Leukoc Biol** 1997 Feb;61(2):141-6

Human antibody-dependent cellular cytotoxicity mediated by interferon gamma-activated neutrophils is impaired by vasoactive intestinal peptide. Palermo MS, et al. **J Neuroimmunol** 1996 Sep;69(1-2):123-8

Antibody-dependent cell-mediated cytotoxicity (ADCC) in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) [published erratum appears in J Neurol Sci 1997 Apr 15;147(2):221] Fujihara K, et al. **J Neurol Sci** 1996 Oct;142(1-2):65-9

Characterization of natural killer and antibody-dependent cellular cytotoxicity of preterm infants against human immunodeficiency virus-infected cells. Merrill JD, et al. **Pediatr Res** 1996 Sep;40(3):498-503

Interleukin-10 down-regulates oxidative metabolism and antibody-dependent cellular cytotoxicity of human neutrophils. Capsoni F, et al. **Scand J Immunol** 1997 Mar; 45(3):269-75

Hodgkin's disease treated with neck radiation is associated with increased antibody-dependent cellular cytotoxicity against human extraocular muscle cells. Ringel MD, et al. **Thyroid** 1997 Jun;7(3):425-32

Functional activity of Rh monoclonal antibodies in ADCC assay. Delsalle A, et al. **Transfus Clin Biol** 1996;3(6):469-71

Assessment of monoclonal antibodies by the monocyte-mediated ADCC assay. Overbeeke MA, et al. **Transfus Clin Biol** 1996;3(6):473-4

Human NK cell-mediated direct and IgG-dependent cytotoxicity against xenogeneic porcine endothelial cells. Watier H, et al. **Transpl Immunol** 1996 Dec;4(4):293-9

[Antibody-dependent cell-mediated cytotoxicity] Mukaida N. **Nippon Rinsho** 1997 Mar;55 Suppl 1:193-5 (12 ref.) **(Jpn)**

DRUG EFFECTS

Effect of alpha-interferon on natural killer cell activity and lymphocyte subsets in thalassemia patients with chronic hepatitis C. Malaponte G, et al. **Acta Haematol** 1997; 98(2):83-8

Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: enhancement with interferon gamma. Takamuku K, et al. **Cancer Immunol Immunother** 1996 Dec;43(4):220-5

Inhibition of natural killer (NK) cell activity against varicella-zoster virus (VZV)-infected fibroblasts and lymphocyte activation in response to VZV antigen by nitric oxide-releasing agents. Ito M, et al. **Clin Exp Immunol** 1996 Oct;106(1):40-4

Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma. Muralikrishna K, et al. **Cytokines Cell Mol Ther** 1997 Mar;3(1):51-8

Plasma membrane hydroxyethyl radical adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to alcohol [see comments] Clot P, et al. **Gastroenterology** 1997 Jul;113(1):265-76. Comment in: Gastroenterology 1997 Jul;113(1):353-5.

Antibodies against ethanol-derived protein adducts: pathogenic implications [editorial; comment] Israel Y.

Gastroenterology 1997 Jul;113(1):353–5. Comment on: Gastroenterology 1997 Jul;113(1):265–76.

In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. See DM, et al. **Immunopharmacology** 1997 Jan;35(3):229–35

Effects of nordihydroguaiaretic acid on murine antibody-dependent cellular cytotoxicity. Hernández-Godoy J, et al. **Int J Clin Lab Res** 1996; 26(3):185–91

Effects of glycyrrhizin on immune-mediated cytotoxicity. Yoshikawa M, et al. **J Gastroenterol Hepatol** 1997 Mar; 12(3):243–8

Inhibition of TC-1 cytokine production, effector cytotoxic T lymphocyte development and alloantibody production by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Kerkvliet NI, et al. **J Immunol** 1996 Sep 15;157(6):2310–9

Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. Surfus JE, et al. **J Immunother Emphasis Tumor Immunol** 1996 May; 19(3):184–91

Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells. Kohl S, et al. **J Infect Dis** 1996 Nov;174(5):1105–8

Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation. Nagler A, et al. **Leuk Res** 1996 Aug;20(8):637–43

Effect of estrogen replacement therapy on natural killer cell activity in postmenopausal women. Albrecht AE, et al. **Maturitas** 1996 Nov;25(3):217–22

GENETICS

Enhanced natural but diminished antibody-mediated cytotoxicity in the lungs of MRLlpr/lpr mice. Nilsson N, et al. **Clin Exp Immunol** 1996 Sep;105(3):480–5

IMMUNOLOGY

Analysis of antibody-dependent cell-mediated cytotoxicity in autoimmune thyroid disease. Metcalfe RA, et al. **Autoimmunity** 1997;25(2):65–72

Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Renner C, et al. **Cancer Immunol Immunother** 1997 Apr;44(2):70–6

Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment. Fujieda M, et al. **Clin Exp Immunol** 1997 Jan;107(1):120–6

Specific recognition and rejection of the H-2-deficient cell line LR.4 by C57BL/6J mice. Verastegui E, et al. **Eur J Immunogenet** 1997 Apr;24(2):93–103

The roles of Fas and perforin in LAK T-cell/bispecific antibody-mediated killing of the murine B-lymphoma cells, BCL1. Armstrong JM, et al. **Int J Cancer** 1996 Dec 11; 68(6):822–7

Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein. Goldstein J, et al. **J Immunol** 1997 Jan 15; 158(2):872–9

Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model. Helfand SC, et al. **J Immunother** 1994 Oct; 16(3):188–97

Delayed generation of antibodies mediating human immunodeficiency virus type 1-specific antibody-dependent cellular cytotoxicity in vertically infected infants. WITS Study Group. Women and Infants Transmission Study. Pugatch D, et al. **J Infect Dis** 1997 Sep;176(3):643–8

Predominance of detrimental humoral immune responses to HIV-1 in AIDS patients with CD4 lymphocyte counts less than 400/mm3. McDougall B, et al. **Scand J Immunol** 1997 Jan;45(1):103–11

ADCC activity of monoclonal anti-D antibodies. Armstrong-Fisher SS, et al. **Transfus Clin Biol** 1996; 3(6):475–7

Monoclonal antiidiotypic antibodies neutralize cytotoxic effects of anti-alphaGal antibodies. Koren E, et al. **Transplantation** 1996 Sep 27;62(6):837–43

Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies. Tschetter JR, et al. **Virology** 1997 Apr 14;230(2):275–80

PHYSIOLOGY

Changes with aging, sex and physical exercise in murine natural killer activity and antibody-dependent cellular cytotoxicity. Ferrández MD, et al. **Mech Ageing Dev** 1996 Feb 24;86(2):83–94

ANTIBODY DIVERSITY

The clonal antibody response to Pseudomonas aeruginosa heat shock protein is highly diverse in cystic fibrosis patients. Ulanova M, et al. **APMIS** 1997 Jun;105(6):449–56

Intrastructural help in diversification of humoral autoimmune responses [editorial] Fatenejad S, et al. **Clin Exp Immunol** 1996 Oct;106(1):1–4 (35 ref.)

Targeted disruption of the V(H) 81X gene: influence on the B cell repertoire. Huetz F, et al. **Eur J Immunol** 1997 Jan; 27(1):307–14

Accumulation of somatic hypermutation and antigen-driven selection in rapidly cycling surface Ig+ germinal center (GC) B cells which occupy GC at a high frequency during the primary anti-hapten response in mice. Kimoto H, et al. **Eur J Immunol** 1997 Jan;27(1):268–79

Molecular mechanisms governing reading frame choice of immunoglobulin diversity genes. Raaphorst FM, et al. **Immunol Today** 1997 Jan;18(1):37–43 (58 ref.)

Immunoglobulin gene diversification in cattle. Meyer A, et al. **Int Rev Immunol** 1997;15(3–4):165–83 (45 ref.)

An unbiased analysis of V(H)-D-J(H) sequences from B-1a, B-1b, and conventional B cells. Kantor AB, et al. **J Immunol** 1997 Feb 1;158(3):1175–86

Contribution of heavy chain junctional amino acid diversity to antibody affinity among p-azophenylarsonate-specific antibodies. Parhami-Seren B, et al. **J Immunol** 1996 Sep 1;157(5):2066–72

Gene conversion contributes to Ig light chain diversity in cattle. Parng CL, et al. **J Immunol** 1996 Dec 15; 157(12):5478–86

Abbreviated junctional sequences impoverish antibody diversity in urodele amphibians. Patel HM, et al. **J Immunol** 1997 Oct 1;159(7):3391–9

Generation of diversity in mammalian gut-associated lymphoid tissues: restricted V gene usage does not preclude complex V gene organization. Reynaud CA, et al. **J Immunol** 1997 Oct 1;159(7):3093–5 (18 ref.)

Variable region gene segment utilization in rhesus monkey hybridomas producing human red blood cell-specific antibodies: predominance of the VH4 family but not VH4-21 (V4-34). Andris JS, et al. **Mol Immunol** 1997 Feb; 34(3):237–53

V(D)J recombination in mature B cells: a mechanism for altering antibody responses [see comments] Papavasiliou F, et al. **Science** 1997 Oct 10;278(5336):298–301. Comment in: Science 1997 Oct 10;278(5336):238–9.

GENETICS

Evidence for B cell oligoclonality in the blood and joints of patients with rheumatoid arthritis. Patki V, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:472–4

Expression of an Ig VH gene, 51p1, is proportional to its germline gene copy number. Sasso EH, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:478–80

Recurrent identical rearrangement and repeated expression of identical heavy and light chains in single anti-phosphatidylcholine B cells. Seidl KJ, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:484–8

Length diversity of immunoglobulin heavy-chain variable regions from rheumatoid arthritis synovium. Williams DG, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:516–9

Genomic organization of the sheep immunoglobulin JH segments and their contribution to heavy chain variable region diversity. Dufour V, et al. **Immunogenetics** 1997; 46(4):283–92

How adaptive antibodies facilitate the evolution of natural antibodies. Anderson RW. **Immunol Cell Biol** 1996 Jun; 74(3):286–91 (49 ref.)

Somatic diversification of antibody responses. Zheng B, et al. **J Clin Immunol** 1996 Jan;16(1):1–11 (129 ref.)

Constitutive expression of terminal deoxynucleotidyl transferase in transgenic mice is sufficient for N region diversity to occur at any Ig locus throughout B cell differentiation. Bentolila LA, et al. **J Immunol** 1997 Jan 15;158(2):715–23

Ig light chain gene in the Siberian sturgeon (Acipenser baeri). Lundqvist M, et al. **J Immunol** 1996 Sep 1;157(5):2031–8

Evolution and somatic learning in V-region genes. Perelson AS, et al. **Res Immunol** 1996 May;147(4):202–8 (8 ref.)

Darwinism and antibody diversity: a historical perspective. Podolsky SH, et al. **Res Immunol** 1996 May;147(4):199–202 (23 ref.)

Immunoglobulin gene organization and the mechanism of repertoire development. Butler JE. **Scand J Immunol** 1997 May;45(5):455–62 (69 ref.)

IMMUNOLOGY

Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping. Barin F, et al. **AIDS Res Hum Retroviruses** 1996 Sep 1; 12(13):1279–89

ANTIBODY ENZYME TECHNIQUE, UNLABELED see **IMMUNOENZYME TECHNIQUES**

ANTIBODY FORMATION

The effect of trace elements on the immune response of rats with intact or injured immune system. Elekes E, et al. **Acta Microbiol Immunol Hung** 1996;43(4):379–89

Intrathecal humoral immune response in HAM/TSP in relation to HLA haplotype analysis. Kitze B, et al. **Acta Neurol Scand** 1996 Oct;94(4):287–93

Antibodies to pneumolysin and pneumococcal capsular polysaccharides in middle ear fluid of children with acute otitis media. Virolainen A, et al. **Acta Otolaryngol (Stockh)** 1995 Nov;115(6):796–803

Antibody production to heat shock proteins with Mr 65 kD (HSP65) in cutaneous inflammation: a possible relation to focal infection. Izaki S, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:197–200

Reduced immune response to hepatitis B vaccine in children with insulin dependent diabetes. Fiçicioğlu C, et al. **Acta Paediatr Jpn** 1995 Dec;37(6):687–90

The role of adjuvants and delivery systems in modulation of immune response to vaccines. Gupta RK, et al. **Adv Exp Med Biol** 1996;397:105–13 (44 ref.)

Characterization of the humoral immune response in heparin-induced thrombocytopenia. Suh JS, et al. **Am J Hematol** 1997 Mar;54(3):196–201

Immunobiology of sensitization in transplant recipients. Stadlbauer TH, et al. **Am J Med Sci** 1997 May; 313(5):268–74

Enhancement of humoral immunity by interleukin-12. Metzger DW, et al. **Ann N Y Acad Sci** 1996 Oct 31; 795:100–15

The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Falconar AK. **Arch Virol** 1997; 142(5):897–916

Production of mouse anti-CD4 antibodies by DNA-based immunization. Kasinrerk W, et al. **Asian Pac J Allergy Immunol** 1996 Dec;14(2):99–105

Divergent antibody responses to vaccines and divergent body weights of chicken lines selected for high and low humoral responsiveness to sheep red blood cells. Parmentier HK, et al. **Avian Dis** 1996 Jul-Sep;40(3):634–44

Syntheses of haptens containing dioxaphosphorinan methoxyacetic acid linker arms for the production of antibodies to organophosphate pesticides. ten Hoeve W, et al. **Bioconjug Chem** 1997 May-Jun;8(3):257–66

Production of antibody against calmodulin which is a protein with poor antigenicity. Nagai M, et al. **Biol Pharm Bull** 1996 Nov;19(11):1503–5

Antibody-producing effects in mice by synthetic immunoactive lipopeptides with the conjugated amino acid sequence of gp120 in human immunodeficiency virus. Shimizu T, et al. **Biol Pharm Bull** 1996 Oct;19(10):1271–4

The culture fluid of Isaira japonica yasuda augments anti-sheep red blood cell antibody response in mice. Takano F, et al. **Biol Pharm Bull** 1996 Apr;19(4):641–3

Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. Zuckerman JN, et al. **BMJ** 1997 Feb 1;314(7077):329–33

Immunocompetence in relation to a heat-processed diet (Maillard reaction) in weanling rats. Varela P, et al. **Br J Nutr** 1997 Jun;77(6):947–56

Enhanced spontaneous antibody response after coronary artery bypass surgery. Salo M, et al. **Can J Anaesth** 1997 Jun;44(6):617–22

Cell surface expression of heat shock proteins and the immune response. Multhoff G, et al. **Cell Stress Chaperones** 1996 Sep;1(3):167–76 (90 ref.)

B lymphocyte physiology: the beginning and the end. Nossal GJ. **Ciba Found Symp** 1997;204:220–30; discussion 230–1 (29 ref.)

Lack of specific antibody response in common variable immunodeficiency (CVID) associated with failure in production of antigen-specific memory T cells. MRC Immunodeficiency Group. Kondratenko I, et al. **Clin Exp Immunol** 1997 Apr;108(1):9–13

Humoral immune response of chicks to different clinical isolates of avian adenovirus type-1. Maiti NK, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):59–62

Production of human antibody repertoires in transgenic mice. Brüggemann M, et al. **Curr Opin Biotechnol** 1997 Aug; 8(4):455–8 (24 ref.)

Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response. Villacres-Eriksson M, et al. **Cytokine** 1997 Feb;9(2):73–82

Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Abdul-Ahad AK, et al. **Cytokines Cell Mol Ther** 1997 Mar;3(1):27–32

Humoral immunity factors in cynomolgus macaques (Macaca fascicularis) serum: immunoglobulins and total light chains in nursing dams. D'Ovidio MC, et al. **Dev Comp Immunol** 1996 Mar-Apr;20(2):157–63

Modulation of DNA binding in vivo by specific humoral immunological response: a novel host factor in environmental carcinogenesis? Verdina A, et al. **Environ Health Perspect** 1996 May;104 Suppl 3:679–82

Gestational exposure to loud noise alters the development and postnatal responsiveness of humoral and cellular components of the immune system in offspring. Sobrian SK, et al. **Environ Res** 1997;73(1-2):227–41

Dexamethasone and cyclosporin A modulation of cytokine expression and specific antibody synthesis in an allergic bronchopulmonary aspergillosis murine model. Wang JM, et al. **Eur J Clin Invest** 1996 Nov;26(11):951–9

Accumulation of somatic hypermutation and antigen-driven selection in rapidly cycling surface Ig+ germinal center (GC) B cells which occupy GC at a high frequency during the primary anti-hapten response in mice. Kimoto H, et al. **Eur J Immunol** 1997 Jan;27(1):268–79

Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and -independent mechanisms. Metzger DW, et al. **Eur J Immunol** 1997 Aug; 27(8):1958–65

Induction of an epitope-specific humoral immune response by lipopeptide-hapten conjugates: enhancement of the anti-melittin response by a synthetic T helper (Th)-cell epitope. Hoffmann P, et al.
FEMS Immunol Med Microbiol 1997 Apr;17(4):225–34

Generation of a polyclonal antibody against lipid peroxide-modified proteins. Kim JG, et al.
Free Radic Biol Med 1997;23(2):251–9

Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization [see comments] Geissler M, et al. **Gastroenterology** 1997 Apr;112(4):1307–20. Comment in: Gastroenterology 1997 Apr;112(4):1410–4.

Immunological defects in mice with a targeted disruption in Bcl-3. Schwarz EM, et al. **Genes Dev** 1997 Jan 15; 11(2):187–97

Autologous anti-idiotypic antibody response is regulated by the level of circulating complementary idiotype. Borghesi C, et al. **Immunology** 1996 Oct;89(2):172–7

In vitro immunization of naive human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display. Dueñas M, et al. **Immunology** 1996 Sep; 89(1):1–7

pPV: a novel IRES-containing vector to facilitate plasmid immunization and antibody response characterization. Clarke NJ, et al. **Immunotechnology** 1997 Jun;3(2):145–53

Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Bergquist C, et al. **Infect Immun** 1997 Jul;65(7):2676–84

Extracellular proteins of Cryptococcus neoformans and host antibody response. Chen LC, et al. **Infect Immun** 1997 Jul; 65(7):2599–605

Mycobacterium tuberculosis Des protein: an immunodominant target for the humoral response of tuberculous patients. Jackson M, et al. **Infect Immun** 1997 Jul;65(7):2883–9

Humoral and cellular immunity in secondary infection due to murine Chlamydia trachomatis. Williams DM, et al. **Infect Immun** 1997 Jul;65(7):2876–82

Antibody response to measles vaccination in Turkish children. Kuyucu N, et al. **Infection** 1996 Mar-Apr; 24(2):156–8

Occurrence and specificity of human natural and in vitro induced antibodies to Nocardia opaca antigens. Prokešová L, et al. **Int J Immunopharmacol** 1996 Nov;18(11):661–8

Humoral and cellular immune reactivity to recombinant M. leprae antigens in HLA-typed leprosy patients and healthy controls. Klatser PR, et al.
Int J Lepr Other Mycobact Dis 1997 Jun;65(2):178–89

Induction and differential regulation of bee venom phospholipase A2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells. Akdis CA, et al.
J Allergy Clin Immunol 1997 Mar;99(3):345–53

The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. Ruff AL, et al.
J Biol Chem 1997 Mar 28;272(13):8671–8

Immune response prevalence to formaldehyde-human serum albumin molecular adduct in a healthy population. Carraro E, et al. **J Environ Pathol Toxicol Oncol** 1997;16(2-3):215–8

Mutant mice without B lymphocyte follicles [comment] Liu YJ, et al. **J Exp Med** 1996 Oct 1;184(4):1207–11. Comment on: J Exp Med 1996 Oct 1;184(4):1397–411.

Normal lymphocyte development but delayed humoral immune response in CD81-null mice. Maecker HT, et al. **J Exp Med** 1997 Apr 21;185(8):1505–10

Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response [see comments] Pasparakis M, et al.
J Exp Med 1996 Oct 1;184(4):1397–411. Comment in: J Exp Med 1996 Oct 1;184(4):1207–11.

Measles virus nucleocapsid protein binds to FcgammaRII and inhibits human B cell antibody production. Ravanel K, et al. **J Exp Med** 1997 Jul 21;186(2):269–78

Conversion of low antibody responders into high responders by up-regulating the T cell response to a selective epitope. Mikszta JA, et al. **J Immunol** 1996 Oct 1;157(7):2883–90

Humoral immune responses in L-selectin-deficient mice. Steeber DA, et al. **J Immunol** 1996 Dec 1;157(11):4899–907

Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. Torres CA, et al. **J Immunol** 1997 May 15;158(10):4529–32

Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases. Krause RM, et al.
J Infect Dis 1997 Sep;176(3):549–59 (72 ref.)

Application of the multiple antigenic peptides (MAP) strategy to the production of prohormone convertases antibodies: synthesis, characterization and use of 8-branched immunogenic peptides. Basak A, et al.
J Pept Sci 1995 Nov-Dec;1(6):385–95

Production and characterization of polyclonal anti-S 20499 antibodies: influence of the hapten structure on stereospecificity. Got PA, et al. **J Pharm Sci** 1997 Jun; 86(6):654–9

Rapid determination of in vivo and in vitro antibody responses by suspension hemolytic assay. Han SB, et al. **J Pharmacol Toxicol Methods** 1996 Sep;36(1):33–40

Exploring the mechanisms of primary antibody responses to T cell-dependent antigens. Oprea M, et al.
J Theor Biol 1996 Aug 7;181(3):215–36

Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Ragnhammar P, et al. **Med Oncol** 1996 Sep;13(3):161–6 (30 ref.)

Immunization with phage-displayed mimotopes. Galfrè G, et al. **Methods Enzymol** 1996;267:109–15

The generation of receptor-selective antibodies. Mackrill JJ. **Methods Mol Biol** 1997;83:65–79 (14 ref.)

Antibody formation in the transplanted spleen: a simple method of splenic transplantation in the rat using the cuff technique. Kobayashi E, et al. **Microsurgery** 1996; 17(4):221–5

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice [published erratum appears in Nat Genet 1997 Aug;16(4):410] Mendez MJ, et al. **Nat Genet** 1997 Feb; 15(2):146–56

Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Fabrizi F, et al. **Nephrol Dial Transplant** 1997 Jun; 12(6):1204–11

Humoral and cellular immune responses to experimental Fasciola hepatica infections in goats. Martínez-Moreno A, et al. **Parasitol Res** 1997;83(7):680–6

Quality assurance after process changes of the production of a therapeutic antibody. Brass JM, et al.
Pharm Acta Helv 1996 Dec;71(6):395–403

Dietary effects on immune response of fast-growing chicks to inoculation of sheep erythrocytes and Escherichia coli. Praharaj NK, et al. **Poult Sci** 1997 Feb;76(2):244–7

Impairment of antigen-specific antibody production in transgenic mice expressing a dominant-negative form of gp130. Kumanogoh A, et al.
Proc Natl Acad Sci U S A 1997 Mar 18;94(6):2478–82

Modulation of the antibody response to sheep red blood cells in normal and immunodeficient XID mice by myo-inositol. Tyan ML. **Proc Soc Exp Biol Med** 1997 Jul;215(3):258–63

Inducible humoral immune defense responses in insects. Karp RD. **Prog Mol Subcell Biol** 1996;15:67–87 (94 ref.)

Humoral factors in marine invertebrates. Leclerc M.
Prog Mol Subcell Biol 1996;15:1–9 (70 ref.)

SCID-hu-PBL: a model for making human antibodies? Ifversen P, et al. **Semin Immunol** 1996 Aug;8(4):243–8 (51 ref.)

Effect of alpha-interferons on immune function. Herberman RB. **Semin Oncol** 1997 Jun;24(3 Suppl 9):S9-78–S9-80 (11 ref.)

Production and characterization of monoclonal antibodies against stonustoxin from Synanceja horrida. Yuen R, et al. **Toxicon** 1995 Dec;33(12):1557–64

Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig. Cabrian KM, et al.
Transplant Proc 1996 Dec;28(6):3261–2

Humoral responses to xenografts: do concordant and discordant reactions share common immune responses? Cramer DV, et al. **Transplant Proc** 1997 Feb-Mar; 29(1-2):945

Antibody and complement in graft rejection. Sanfilippo F, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):179–80 (26 ref.)

Routine immunizations in adult renal transplant recipients. Huzly D, et al. **Transplantation** 1997 Mar 27;63(6):839–45

Use of gene therapy to suppress the antigen-specific immune responses in mice to an HLA antigen. Schumacher IK, et al. **Transplantation** 1996 Sep 27;62(6):831–6

Ascitic growth of a T cell lymphoma in mice alters the humoral and cellular immune response to exogenous antigens. Parajuli P, et al. **Tumour Biol** 1997;18(2):104–12

Size effect on the antibody production induced by biodegradable microspheres containing antigen. Nakaoka R, et al. **Vaccine** 1996 Sep;14(13):1251–6

Hamster polyomavirus-encoded proteins: gene cloning, heterologous expression and immunoreactivity. Ulrich R, et al. **Virus Genes** 1996;12(3):265–74

[A cross-sectional study of factors associated with production of Japanese cedar pollen specific IgE antibody and total IgE antibody, and symptoms of Japanese cedar pollinosis in primary school children] Ozasa K, et al.
Arerugi 1995 Dec;44(12):1361–8 (Eng. Abstr.) **(Jpn)**

[B cell function and its evaluation] Itoh C, et al.
Nippon Rinsho 1997 Mar;55 Suppl 1:166–71 (17 ref.) **(Jpn)**

[Changes of humoral and cellular immunity in schizophrenia] Wojtanowska M, et al. **Psychiatr Pol** 1996 Sep-Oct; 30(5):783–99 (83 ref.) (Eng. Abstr.) **(Pol)**

[Effect of a "running" pulse magnetic field on certain humoral indicators and physical ability to work in patients with neurocirculatory hypo- and hypertension] Orlov LL, et al. **Biofizika** 1996 Jul-Aug;41(4):944–8 (Eng. Abstr.) **(Rus)**

[Changes in immunological reactivity of C57Bl/6 mice during the zoosocial conflict] Al'perina EA, et al.
Biull Eksp Biol Med 1996 Nov;122(11):541–3 **(Rus)**

[A comparative analysis of humoral and cellular funcation activity indicators during in vivo viral infections] Makarov VV, et al. **Biull Eksp Biol Med** 1995 Dec;120(12):599–602 **(Rus)**

[Dynamics of immune response to single exposure to low-frequency acoustic oscillations] Voblikov IV, et al.
Gig Sanit 1996 Jul-Aug;(4):39–40 **(Rus)**

[Resistance of hybridoma cells, producing antibodies against the binding subunit of plant toxin MLI, to the cytotoxic effect of this toxin] Tonevitskiĭ AG, et al.
Mol Biol (Mosk) 1996 Mar-Apr;30(2):416–25 **(Rus)**

[Immune response of lymphocytes: new concepts] Titova NG. **Vestn Ross Akad Med Nauk** 1996;(5):18–24 (50 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Fumonisin B1-immunological effects. The influence of FB1 on the early stage of immune response. Martinova EA. **Adv Exp Med Biol** 1996;391:331–42 (70 ref.)

Modulation of the humoral immune response by placental secretory factors. Malan Borel I, et al.
Am J Reprod Immunol 1996 Jun;35(6):529–33

Increment of immune responses in mice perinatal stages after zinc supplementation. Lastra MD, et al. **Arch Med Res** 1997 Spring;28(1):67–72

Effect of onion extract on immune response in rabbits. Chisty MM, et al. **Bangladesh Med Res Counc Bull** 1996 Aug; 22(2):81–5

Nanomolar concentrations of gangliosides stimulate primary humoral response. Dozmorov IM, et al.
Biochem Mol Biol Int 1997 Jun;42(1):57–63

Reevaluation of the effect of a high alpha-linolenate and a high linoleate diet on antigen-induced antibody and anaphylactic responses in mice. Oh-hashi K, et al.
Biol Pharm Bull 1997 Mar;20(3):217–23

Effect of boar seminal immunosuppressive fraction on B lymphocytes and on primary antibody response. Veselský L, et al. **Biol Reprod** 1996 Jul;55(1):194–9

Conditioned immunosuppression of lipopolysaccharide-induced antibody response of orally immunized mice. Morato EF, et al. **Brain Behav Immun** 1997 Jun;11(2):133–9

Immunotoxic effects of carbon tetrachloride--the effect on morphology and function of the immune system in mice. Jírová D, et al. **Cent Eur J Public Health** 1996 Feb; 4(1):16–20

Immune response to exhaust gases derived from two-cycle combustion engine following experimental exposure. Reichrtová E, et al. **Cent Eur J Public Health** 1996 Feb; 4(1):7–10

Pesticides and the immune system: the public health risks. Executive summary. Repetto R, et al.
Cent Eur J Public Health 1996 Dec;4(4):263–5

Silicate antibodies in women with silicone breast implants: development of an assay for detection of humoral immunity. Shen GQ, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):162–6

Effect of intravenous gammaglobulin on organ specific antibodies and lymphocyte subsets. Kahaly GJ.
Clin Exp Rheumatol 1996 May-Jun;14 Suppl 15:S37–40

Serum immunoglobulin levels during contraceptive use of depot-medroxyprogesterone acetate in Indian women: a preliminary study. Lali P, et al. **Contraception** 1996 Jun; 53(6):363–5

Cytokines involving gp130 in signal transduction suppressed growth of a mouse hybridoma cell line and enhanced its antibody production. Terada S, et al. **Cytokine** 1996 Dec; 8(12):889–94

Characterization of the humoral immune response and hepatotoxicity after multiple halothane exposures in guinea pigs. Chen M, et al. **Drug Metab Rev** 1997 Feb-May; 29(1-2):103–22

Effect of interferon-alpha on immunoglobulin production by peripheral blood mononuclear cells in multiple myeloma. Säily M, et al. **Eur J Haematol** 1996 Aug;57(2):171–7

Modulation of the development of humoral immunity by topically applied acetone, ethanol, and 12-O-tetradecanoylphorbol-13-acetate. Singh KP, et al.
Fundam Appl Toxicol 1996 Sep;33(1):129–39

Opposite effects of 2,2',4,4',5,5'-hexachlorobiphenyl and 2,3,7,8-tetrachlorodibenzo-p-dioxin on the antibody response to sheep erythrocytes in mice. Smialowicz RJ, et al. **Fundam Appl Toxicol** 1997 Jun;37(2):141–9

Comparison of the T cell-independent antibody response of mice and rats exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Smialowicz RJ, et al.
Fundam Appl Toxicol 1996 Aug;32(2):293–7

Immune response to 17 beta-estradiol in polyelectrolyte complex: antigen specificity and affinity of hybridoma clones. Başalp A, et al. **Hybridoma** 1996 Jun;15(3):233–8

The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Tedder TF, et al. **Immunity** 1997 Feb;6(2):107–18 (94 ref.)

Immune responsiveness of splenocytes after chronic daily melatonin administration in male Syrian hamsters. Champney TH, et al. **Immunol Lett** 1997 Jul;58(2):95–100

Effect of DTC on humoral response of SRBC-immunized mice exposed to restraint stress. Comparison with calf thymus extract. Obmińska-Domoradzka B, et al.
Immunopharmacol Immunotoxicol 1996 Aug;18(3):421–31

Dietary Spirulina platensis enhances humoral and cell-mediated immune functions in chickens. Qureshi MA, et al. **Immunopharmacol Immunotoxicol** 1996 Aug;

18(3):465–76
Dietary curcumin enhances antibody response in rats. South EH, et al. **Immunopharmacol Immunotoxicol** 1997 Feb; 19(1):105–19
Influence of subchronic exposure to lindane on humoral immunity in mice. Banerjee BD, et al.
Indian J Exp Biol 1996 Nov;34(11):1109–13
Inhibitory action of sulfatide, a putative ligand for L-selectin, on B cell proliferation and Ig production. Konno A, et al. **Int Immunol** 1996 Dec;8(12):1905–13
IFN-gamma is a potent inducer of Ig secretion by sort-purified murine B cells activated through the mIg, but not the CD40, signaling pathway. Snapper CM, et al. **Int Immunol** 1996 Jun;8(6):877–85
Role of metabolism in ethyl carbamate-induced suppression of antibody response to sheep erythrocytes in female Balb/C mice. Jeong TC, et al. **Int J Immunopharmacol** 1995 Dec;17(12):1035–44
Stimulation of humoral and cell mediated immunity by polysaccharide from mushroom Phellinus linteus. Kim HM, et al. **Int J Immunopharmacol** 1996 May;18(5):295–303
Novel naphthalene derivatives as inhibitors of human immunoglobulin E antibody production. Hasegawa M, et al. **J Med Chem** 1997 Feb 14;40(4):395–407
Recovery from
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced immunosuppression in A/J mice by treatment with nonsteroidal anti-inflammatory drugs. Rioux N, et al.
J Natl Cancer Inst 1997 Jun 18;89(12):874–80
Modulation of humoral immune response by central administration of leucine-enkephalin: effects of mu, delta and kappa opioid receptor antagonists. Radulović J, et al. **J Neuroimmunol** 1996 Apr;65(2):155–61
The effect of methyl linoleate hydroperoxides and radical initiator 2,2'-azobis (2-amidinopropane) dihydrochloride on antibody production by mouse spleen cells. Oarada M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Jun;43(3):377–85
Role of corticosterone in the enhancement of the antibody response after acute cocaine administration. Stanulis ED, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):284–91
Selective suppression of in vitro T-dependent humoral immunity by synthetic food additive antioxidants. Kim HM, et al. **J Toxicol Sci** 1996 Feb;21(1):41–5
Influence on HMG-COA reductase inhibitors on plaque-forming cell (PFC) response in mice. Kimura T, et al. **J Toxicol Sci** 1995 Nov;20(5):603–8
Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. Birmingham DJ, et al. **Kidney Int** 1996 Aug;50(2):543–9
Nerve growth factor enhances antigen-specific antibody production in ascorbate-stimulated murine splenocytes. Yanagida M, et al. **Life Sci** 1996;59(24):2075–81
Effects of dietary arachidonic acid on human immune response. Kelley DS, et al. **Lipids** 1997 Apr;32(4):449–56
Dietary nucleotides may influence the humoral immunity in immunocompromised children. Martínez-Augustin O, et al. **Nutrition** 1997 May;13(5):465–9
Immunopharmacological activity of aporphinoid alkaloid oxoglaucine. Ivanovska N, et al. **Pharmacol Res** 1997 Apr; 35(4):267–72
Enhancement of humoral and cellular immunity by vitamin E after embryonic exposure. Gore AB, et al. **Poult Sci** 1997 Jul;76(7):984–91
The influence of IL12 on the development of Th1 and Th2 cells and its adjuvant effect for humoral immune responses. Germann T, et al. **Res Immunol** 1995 Sep-Oct; 146(7-8):481–6 (40 ref.)
The effects of IL12 on B-cell subset function. Metzger DW, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):499–505 (32 ref.)
IgG2b inducing factor from rheumatoid arthritis synovial fluid activates antibody production in highly purified mouse B lymphocytes. Lettesjö H, et al.
Scand J Immunol 1997 Jan;45(1):43–9
IgG2b inducing factor from rheumatoid arthritis synovial fluid synergizes with transforming growth factor-beta in promoting IgG2b antibody production in mouse B lymphocytes. Lettesjö H, et al. **Scand J Immunol** 1997 Jan; 45(1):50–4
Immunological alterations in sera of persons living in areas with different air pollution. Hadnagy W, et al.
Toxicol Lett 1996 Nov;88(1-3):147–53
Phenyl isocyanate is a potent chemical sensitizer. Karol MH, et al. **Toxicol Lett** 1996 Dec 16;89(2):139–46
Immunomodulating effects after perinatal exposure to methylmercury in mice. Thuvander A, et al. **Toxicology** 1996 Dec 2;114(2):163–75
Effect of Crotalus venom on the humoral and cellular immune response. Cardoso DF, et al. **Toxicon** 1997 Apr; 35(4):607–12
Effect of roundup and tordon 202C herbicides on antibody production in mice. Blakley BR. **Vet Hum Toxicol** 1997 Aug;39(4):204–6
The effect of cobalt supplementation on the immune response in vitamin B12 deficient Texel lambs. Vellema P, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1-3):151–61
[Changes in the humoral immune response in occupational exposure to metal aerosols] Altünkova I, et al.
Probl Khig 1996;21:122–30 (Eng. Abstr.) **(Bul)**
[Ambiguous effect of large and small doses of amino acid preparations on the immune response and phagocytosis in mice] Belokrylov GA, et al. **Biull Eksp Biol Med** 1994 May;117(5):500–1 **(Rus)**
[The effect of vitamin D on the humoral and cellular immune response and functional activity of peritoneal macrophages] Pletsityĭ KD, et al. **Biull Eksp Biol Med** 1997 Jan; 123(1):63–5 **(Rus)**
[Immunologic mechanisms for increasing radioresistance under the effect of cholinomimetics] Zabrodskiĭ PF.
Biull Eksp Biol Med 1996 May;121(5):541–3 **(Rus)**
[The immunobiological properties of trimezon and levamisole on models of humoral and cell-mediated immunogenesis] Liubin GS, et al. **Eksp Klin Farmakol** 1997 Jan-Feb; 60(1):50–2 (Eng. Abstr.) **(Rus)**
[Effect of occupational lead exposure on immunoglobulin concentration and cellular immune function in man] Castillo Méndez A, et al. **Rev Alerg** 1993 Mar-Apr; 40(2):33–6 (Eng. Abstr.) **(Spa)**

GENETICS

Characterization of isogenic carp (Cyprinus carpio L.) lines with a genetically determined high or low antibody production. Wiegertjes GF, et al. **Anim Genet** 1996 Oct; 27(5):313–9
Evidence for a selected humoral immune response encoded by VH4 family genes in the synovial membrane of a patient with RA. Voswinkel J, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:312–5
Genetic studies on primary antibody response to sheep erythrocytes in guinea fowl. Saxena VK, et al.
Br Poult Sci 1997 May;38(2):156–8
Genes responsible for quantitative regulation of antibody production. Puel A, et al. **Crit Rev Immunol** 1996; 16(3):223–50 (262 ref.)
Recombinant adenovirus synthesizing cell surface-anchored beta hCG induces bioneutralizing antibodies in rats. Raikwar SP, et al. **Gene** 1997 Apr 29;190(1):197–202
The in vivo antibody response against exogenous antigens is not influenced by the mouse Bcg (Nramp1) gene. Sírová M, et al. **Immunology** 1997 Apr;90(4):626–31
Quantification of the relative contribution of major histocompatibility complex (MHC) and non-MHC genes to human immune responses to foreign antigens. Jepson A, et al. **Infect Immun** 1997 Mar;65(3):872–6
Functional antibody production using cell-free translation: effects of protein disulfide isomerase and chaperones. Ryabova LA, et al. **Nat Biotechnol** 1997 Jan;15(1):79–84
Differences of nu/+ and nu/nu mice in some behaviors reflecting temperament traits. Vidal J. **Physiol Behav** 1996 Feb;59(2):341–8
Toward genetic dissection of high and low antibody responsiveness in Biozzi mice. Puel A, et al.
Proc Natl Acad Sci U S A 1996 Dec 10;93(25):14742–6
Limited T helper cell activity in C57BL/10 (B10) mice with inherited low IgG responsiveness. Sírová M, et al.
Scand J Immunol 1996 Nov;44(5):453–60
Polymorphisms of the TAP2 gene may influence antibody response to live measles vaccine virus. Hayney MS, et al. **Vaccine** 1997 Jan;15(1):3–6
[Genetic control of humoral immune response to xenografts. A monoclonal antibody that causes the hyperacute rejection of cardiac xenografts uses the genes in a native form] Borie DC, et al. **Chirurgie** 1996;121(6):453–60 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

A germinal center-like reaction in the nonlymphoid tissue of the synovial membrane. Berek C, et al.
Ann N Y Acad Sci 1997 Apr 5;815:211–7 (17 ref.)
Ig-specific T cells regulate the fate of the B cells during the immune response in a TCR transgenic mouse model. Granucci F, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:119–21
Lupus humoral autoimmunity after short peptide immunization. James JA, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:124–7
Analytic review of the scientific literature on silicone immune responses: comment on the article by Marcus [letter] Smalley DL, et al. **Arthritis Rheum** 1997 Sep;40(9):1730–2
Effects and mechanisms of environmental temperature on carp (Cyprinus carpio) anti-DNP antibody response and non-specific cytotoxic cell activity: a kinetic study. Le Morvan C, et al. **Dev Comp Immunol** 1996 Sep-Oct; 20(5):331–40
Plaque-forming cell responses and antibody titers following injection of sheep red blood cells in nonstressed, acute, and/or chronically stressed handled and nonhandled animals. Bhatnagar S, et al. **Dev Psychobiol** 1996 Mar; 29(2):171–81
Immunogenicity and reactogenicity of a combined DTPw-hepatitis B vaccine in Lithuanian infants. Usonis V, et al. **Eur J Pediatr** 1996 Mar;155(3):189–93
Immunocompetent cells in benign and malignant salivary gland tumors. Kärjä VJ, et al. **Gen Diagn Pathol** 1996 Oct; 142(2):75–81
Immune deviation: a historical perspective. Parish CR.
Immunol Cell Biol 1996 Oct;74(5):449–56 (53 ref.)
The changing preference of T and B cells for partners as T-dependent antibody responses develop. MacLennan IC, et al. **Immunol Rev** 1997 Apr;156:53–66 (95 ref.)
Soluble, antigen-specific T-cell proteins: T-cell-based humoral immunity? Cone RE, et al. **Immunol Today** 1996 Jul;17(7):318–22 (53 ref.)
Dietary Spirulina platensis enhances humoral and cell-mediated immune functions in chickens. Qureshi MA, et al. **Immunopharmacol Immunotoxicol** 1996 Aug; 18(3):465–76
Plasmapheresis in HLA-immunosensitized patients prior to kidney transplantation. Alarabi A, et al.
Int J Artif Organs 1997 Jan;20(1):51–6
Somatic evolution in the immune system: the need for germinal centers for efficient affinity maturation. Pierre DM, et al. **J Theor Biol** 1997 May 21;186(2):159–71
Natural and cellular immune responses in Flinders sensitive and resistant line rats. Friedman EM, et al.
Neuropsychopharmacology 1996 Sep;15(3):314–22
Effects of phototherapy on the production of cytokines by peripheral blood mononuclear cells and on systemic antibody responses in patients with psoriasis. Jones CD, et al. **Photodermatol Photoimmunol Photomed** 1996 Oct; 12(5):204–10
Humoral factors in tunicates. Saito Y.
Prog Mol Subcell Biol 1996;15:218–34 (73 ref.)
Multilevel statistical models for psychosomatic research [editorial; comment] Berry CC. **Psychosom Med** 1997 Jul-Aug;59(4):350–1. Comment on: Psychosom Med 1997 Jul-Aug;59(4):339–47.
Marital conflict in older adults: endocrinological and immunological correlates [see comments] Kiecolt-Glaser JK, et al. **Psychosom Med** 1997 Jul-Aug;59(4):339–49. Comment in: Psychosom Med 1997 Jul-Aug;59(4):350–1.
Life events, frontal electroencephalogram laterality, and functional immune status after acute psychological stressors in adolescents. Liang SW, et al. **Psychosom Med** 1997 Mar-Apr;59(2):178–86
The immune response to infectious diseases of the central nervous system: a tenuous balance. Pachner AR.
Springer Semin Immunopathol 1996;18(1):25–34 (55 ref.)
The binding of chimeric peptides to GM1 ganglioside enables induction of antibody responses after intranasal immunization. Delmas A, et al. **Vaccine** 1996 Aug; 14(11):1077–82
Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens. Phillips NC, et al. **Vaccine** 1996 Jun;14(9):898–904
[Immunologic effects of blood donation] Lange S, et al.
Beitr Infusionsther Transfusionsmed 1996;33:93–7 (Eng. Abstr.) **(Ger)**
[Donor specific antibody production after liver transplantation. A study of the rat model] Dahmen U, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:295–8 (Eng. Abstr.) **(Ger)**
[Cellular and humoral functions in acute pancreatitis] Schulz HU, et al. **Wien Med Wochenschr** 1997;147(1):10–3 (Eng. Abstr.) **(Ger)**
[Intramyocardial electrocardiogram (IMEG) in diagnosis of humoral rejection after heart transplantation] Grauhan O, et al. **Z Kardiol** 1996 Oct;85(10):745–52 (Eng. Abstr.) **(Ger)**
[Evaluation of the usefulness of using western immunoblotting for testing humoral immune response to Mycoplasma pneumoniae antigens during natural infection in humans] Rastawicki W. **Med Dosw Mikrobiol** 1996; 48(1-2):39–48 (Eng. Abstr.) **(Pol)**
[Incidence of humoral immunodeficiency in children with recurrent infections] Kowalczyk D, et al. **Przegl Lek** 1995; 52(10):492–495 (Eng. Abstr.) **(Pol)**
[Increase in the number of antibody-producing cells to syngeneic erythrocytes in the spleen of C57Bl/6 mice due to heterochronous parabiosis] Gubriĭ IB, et al.
Biull Eksp Biol Med 1996 Jul;122(7):71–4 **(Rus)**
[New vaccines and the immune response (I). Immunologic memory. Humoral response versus cellular response] Villarrubia VG, et al. **Med Clin (Barc)** 1996 Jun 22; 107(4):146–54 (93 ref.) **(Spa)**

PHYSIOLOGY

Frequency of clonal dominance in the specific antibody response to DNP-HSA in CBA and C57BL mice reflects their susceptibility to age-associated development of monoclonal gammopathies. van Arkel C, et al.
Clin Immunol Immunopathol 1997 Jun;83(3):272–80
Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice. Mackay F, et al. **Eur J Immunol** 1997 Aug; 27(8):2033–42
Cellular and humoral autoimmunity in insulin-dependent diabetes mellitus. Scherbaum WA, et al.
Exp Clin Endocrinol Diabetes 1995;103 Suppl 2:88–94 (68 ref.)
Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? O'Shea JJ.
Immunity 1997 Jul;7(1):1–11 (126 ref.)
Humoral and cell-mediated immune responses following lesions of the nucleus basalis magnocellularis in the rat. Popović M, et al. **Int J Neurosci** 1997 Feb;89(3-4):165–76
Dendritic cell maturation is required for initiation of the immune response. Rescigno M, et al. **J Leukoc Biol** 1997 Apr;61(4):415–21 (24 ref.)
The humoral immune response towards HLA class II determinants in renal transplantation [editorial] Feucht HE, et al. **Kidney Int** 1996 Nov;50(5):1464–75 (103 ref.)
Short and long restraint differentially affect humoral and cellular immune functions. Millán S, et al. **Life Sci** 1996; 59(17):1431–42
The effects of voluntary exercise and immobilization on

humoral immunity and endocrine responses in rats. Baldwin DR, et al. **Physiol Behav** 1997 Mar;61(3):447–53

Postoperative production of anti-donor antibody and chronic rejection in renal transplantation. Abe M, et al. **Transplantation** 1997 Jun 15;63(11):1616–9

[The "rapidity" factor in the specific immunity response after oral vaccination] Negretti F. **Minerva Med** 1997 Apr; 88(4):127–41 (82 ref.) (Eng. Abstr.) **(Ita)**

[Immunologic fetal and neonatal immaturity: influence on the clinical course of HIV-1 infection in children] Ortigão-de-Sampaio MB, et al. **Rev Assoc Med Bras** 1997 Jan–Mar;43(1):29–34 (62 ref.) (Eng. Abstr.) **(Por)**

[Changes in the level of met-enkephalin in various brain structures during formation of immune response] Podgornaia EK, et al. **Biull Eksp Biol Med** 1997 Feb; 123(2):170–2 **(Rus)**

[Relationship between the type of character accentuation and indices of humoral immunity] Zabrodskiĭ PF, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):70–2 **(Rus)**

RADIATION EFFECTS

Effects and mechanisms of environmental temperature on carp (Cyprinus carpio) anti-DNP antibody response and non-specific cytotoxic cell activity: a kinetic study. Le Morvan C, et al. **Dev Comp Immunol** 1996 Sep–Oct; 20(5):331–40

[Immunotropic effect of non-laser monochromatic irradiation] Kuznetsova TA, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):70–2 **(Rus)**

[Immunomodulating effect of weak magnetic fields on antibody formation in mice] Podkolzin AA, et al. **Biull Eksp Biol Med** 1994 May;117(5):482–3 **(Rus)**

[The effect of incorporation of various doses of 131I on the immunological reactions] Solov'ev AS, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):664–6 **(Rus)**

[The dynamics of the immunological indices of children from regions around Chernobyl during health-resort treatment] Shvedunova LN, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Sep–Oct;(5):37–9 **(Rus)**

[The immune status characteristics and kidney function in persons exposed to the effect of ionizing radiation] Danylash MM, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):18–20 **(Ukr)**

ANTIBODY FRAGMENTS see **IMMUNOGLOBULIN FRAGMENTS**

ANTIBODY-PRODUCING CELLS

see related
HEMOLYTIC PLAQUE TECHNIQUE

[Immunoglobulin heavy chain variable region(VH) genes in B cell clones producing anti-colon antibodies in ulcerative colitis] Inoue N, et al. **Nippon Rinsho** 1996 Apr; 54(4):1176–81 (27 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

ELISPOT for detecting antibody-secreting cells in response to infections and vaccination. Arvilommi H. **APMIS** 1996 Jun;104(6):401–10 (70 ref.)

CLASSIFICATION

Combined immunomagnetic cell sorting and ELISPOT assay for the phenotypic characterization of specific antibody-forming cells. Lakew M, et al. **J Immunol Methods** 1997 Apr 25;203(2):193–8

CYTOLOGY

Bone marrow immunoglobulin-secreting cells are not reduced in children with leukaemia as compared to children with solid tumours. Abrahamsson J, et al. **Acta Paediatr** 1997 Feb;86(2):165–9

Increase of murine splenic natural antibody-secreting cells after cyclophosphamide treatment. Portiansky EL, et al. **Clin Immunol Immunopathol** 1996 Nov;81(2):215–7

DRUG EFFECTS

Significant inhibition of spontaneous IgA secretion by selective peripheral-type benzodiazepine receptor ligands. Bessler H, et al. **Clin Neuropharmacol** 1997 Jun;20(3):215–23

The effects of traditional antirheumatic herbal medicines on immune response cells. Chang DM, et al. **J Rheumatol** 1997 Mar;24(3):436–41

[Differences in immune response, phagocytosis and detoxifying properties due to effect of peptide and amino acid preparations] Belokrylov GA, et al. **Biull Eksp Biol Med** 1996 May;121(5):509–12 **(Rus)**

IMMUNOLOGY

Long-term antibody production is sustained by antibody-secreting cells in the bone marrow following acute viral infection. Slifka MK, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:166–76

Study on adhesion factors in lymphocyte migration to the middle ear mucosa. Bundo J, et al. **Ann Otol Rhinol Laryngol** 1996 Oct;105(10):795–803

Standardization of measurement of immunoglobulin-secreting cells in human peripheral circulation. Baqar S, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):375–9

Induction of antibody-secreting cells and T-helper and memory cells in murine nasal lymphoid tissue. Wu HY, et al. **Immunology** 1996 Aug;88(4):493–500

Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization. Wu HY, et al. **Infect Immun** 1997 Jan;65(1):227–35

ELISPOT assay for Chlamydia-specific, antibody-producing cells correlated with conventional complement fixation and microimmunofluorescence. Daugharty H, et al. **J Clin Lab Anal** 1997;11(1):45–52

Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. Kantele A, et al. **J Immunol** 1997 Jan 15;158(2):574–9

Circulating antibody secreting cells and humoral antibody response after parenteral immunization with a meningococcal polysaccharide vaccine. Nieminen T, et al. **Scand J Infect Dis** 1996;28(1):53–8

[The role of dopaminergic mechanism in the realization of immunostimulating effect of substance P and its analog] Cheïdo MA. **Biull Eksp Biol Med** 1997 Feb;123(2):135–7 **(Rus)**

[Increase in the number of antibody-producing cells to syngeneic erythrocytes in the spleen of C57Bl/6 mice due to heterochronous parabiosis] Gubriĭ IB, et al. **Biull Eksp Biol Med** 1996 Jul;122(7):71–4 **(Rus)**

[Immunocorrecting, antianemia, and adaptogenic effects of polysaccharides from Melilotus officinalis] Podkolzin AA, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):661–3 **(Rus)**

METABOLISM

Low levels of spontaneously activated peripheral IgA-secreting cells in nontransplanted IgA nephropathy patients. Kennel-De March A, et al. **Am J Kidney Dis** 1997 Jul;30(1):64–70

Circulating immunoglobulin-secreting cells are heterogeneous in their expression of maturation markers and homing receptors. Kantele JM, et al. **Clin Exp Immunol** 1996 Jun;104(3):525–30

SECRETION

Antigen-specific IgA-secreting cells induced by peripheral vaccination. Rothel JS, et al. **Immunol Cell Biol** 1996 Jun; 74(3):298–300

ANTIBODY-SECRETING CELLS see **ANTIBODY-PRODUCING CELLS**

ANTIBODY SPECIFICITY

see related
ANTIBODIES, BISPECIFIC

Epitopes common to Trypanosoma cruzi and mammalian tissues are recognized by sera from Chagas' disease patients: prognosis value in Chagas disease. Laucella SA, et al. **Acta Trop** 1996 Dec 16;62(3):151–62

Immunophenotypic analysis of CD5 positivity in paraffin-embedded tissues. Still waiting for an effective diagnostic antibody [editorial;comment] Perkins SL. **Am J Clin Pathol** 1996 Sep;106(3):273–4. Comment on: Am J Clin Pathol 1996 Sep;106(3):370–3.

Preparation of biotinylated, affinity-purified antibodies for enzyme-linked immunoassays using blotting membrane as an antigen support [published erratum appears in Anal Biochem 1997 Mar 15;246(2):271] Rucklidge GJ, et al. **Anal Biochem** 1996 Dec 1;243(1):158–64

Fine specificity analysis of autoantibodies to T cell receptor CDR1 segments in rheumatoid arthritis. Landsperger WJ, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:459–61

Interplay of cigarette smoking and occupational exposure on specific immunoglobulin E antibodies to cobalt. Shirakawa T, et al. **Arch Environ Health** 1997 Mar–Apr;52(2):124–8

Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Loizou S, et al. **Arthritis Rheum** 1997 Jan;40(1):103–8

Probing for cerebrospinal fluid antibody specificities by a panel of random peptide libraries. Dybwad A, et al. **Autoimmunity** 1997;25(2):85–9

Agalactosyl IgG and antibody specificity in rheumatoid arthritis, tuberculosis, systemic lupus erythematosus and myasthenia gravis. Pilkington C, et al. **Autoimmunity** 1995; 22(2):107–11

Preparation and specificity of antibodies to an anti-tumor beta-glucan, lentinan. Mizono M, et al. **Biochem Mol Biol Int** 1996 Jul;39(4):679–85

Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Sharkey RM, et al. **Bioconjug Chem** 1997 Jul–Aug;8(4):595–604

Fluorescent microtiter screening assay for immunocytochemically reactive antibodies. Su JL, et al. **Biotechniques** 1997 Feb;22(2):320–4

Hemoglobin-specific antibody in a multiply transfused patient with sickle cell disease. Noronha PA, et al. **Blood** 1997 Mar 15;89(6):2155–8

IgG subclasses specific to Staphylococcus epidermidis and Propionibacterium acnes in patients with acne vulgaris. Ashbee HR, et al. **Br J Dermatol** 1997 May;136(5):730–3

Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders. Kurz M, et al. **Br J Haematol** 1996 Dec;95(3):564–9

Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Clark JI, et al. **Cancer Immunol Immunother** 1997 Jul;44(5):265–72

Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation. Jacobs N, et al. **Cancer Immunol Immunother** 1997 Jul;44(5):257–64

Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Liu H, et al. **Cancer Res** 1997 Sep 1;57(17):3629–34

Development of a human monoclonal antibody to ganglioside G(M2) with potential for cancer treatment. Nishinaka Y, et al. **Cancer Res** 1996 Dec 15;56(24):5666–71

Increased frequency of organ-specific cardiac antibodies in healthy relatives of patients with dilated cardiomyopathy: evidence for autoimmunity in Polish families. Bilinska ZT, et al. **Clin Cardiol** 1996 Oct;19(10):794–8

Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a. Hartman AB, et al. **Clin Diagn Lab Immunol** 1996 Sep; 3(5):584–9

Specific antibody response to oligomannosidic epitopes in Crohn's disease. Sendid B, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):219–26

Specific immunoglobulin measurements related to exposure and resistance to Schistosoma mansoni infection in Sudanese canal cleaners. Satti MZ, et al. **Clin Exp Immunol** 1996 Oct;106(1):45–54

Escape of HIV-1 is associated with lack of V3 domain-specific antibodies in vivo. Schreiber M, et al. **Clin Exp Immunol** 1997 Jan;107(1):15–20

Fine specificity of autoantibodies to La/SSB: epitope mapping, and characterization. Tzioufas AG, et al. **Clin Exp Immunol** 1997 May;108(2):191–8

Recognition of complement factor H by a monoclonal antibody used for "specifically" measuring IgA–alpha 1 antitrypsin complexes [letter; comment] Mattey DL, et al. **Clin Exp Rheumatol** 1997 Jan–Feb;15(1):117–8. Comment on: Clin Exp Rheumatol 1996 Mar–Apr;14(2):119–23.

Correction for antibody crosstalk [letter; comment] Shackney SE. **Cytometry** 1996 Sep 1;25(1):109–10. Comment on: Cytometry 1995 Sep 1;21(1):6–13.

Characterization of five monoclonal antibodies specific for swine class II major histocompatibility antigens and crossreactivity studies with leukocytes of domestic animals. Bullido R, et al. **Dev Comp Immunol** 1997 May–Jun; 21(3):311–22

Molecular basis for species and ligand specificity of a monoclonal antibody raised against human IGF-I. Van Wyk JJ, et al. **Endocrinology** 1997 Oct;138(10):4521–2

Mono- and bispecific single-chain antibody fragments for cancer therapy. Thirion S, et al. **Eur J Cancer Prev** 1996 Dec;5(6):507–11

The specificity of anti-HLA class II monoclonal antibodies in cattle. Nilsson PR, et al. **Eur J Immunogenet** 1997 Jun; 24(3):211–23

Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of sensitization with antigen-specific IgE. Machado DC, et al. **Eur J Immunol** 1996 Dec; 26(12):2972–80

Antibodies specific to the plasma membrane of rat lung microvascular endothelium. Ghitescu LD, et al. **Exp Cell Res** 1997 Apr 10;232(1):47–55

Synaptic distribution of the AMPA-GluR2 subunit and its colocalization with calcium-binding proteins in rat cerebral cortex: an immunohistochemical study using a GluR2-specific monoclonal antibody. Vissavajjhala P, et al. **Exp Neurol** 1996 Dec;142(2):296–312

Monoclonal antibodies that specifically recognize crystals of dinitrobenzene. Kessler N, et al. **FASEB J** 1996 Oct; 10(12):1435–42

Detection of specific IgE to human milk proteins in sera of atopic infants. Cantisani A, et al. **FEBS Lett** 1997 Aug 4;412(3):515–7

Characterization of monoclonal antibodies that recognize common epitopes located on O antigen of lipopolysaccharide of serotypes 1, 9 and 11 of Actinobacillus pleuropneumoniae. Rodriguez Barbosa JI, et al. **FEMS Immunol Med Microbiol** 1996 Dec 31; 16(3–4):173–81

Gal alpha 4Gal-binding antibodies: specificity and use for the mapping of glycolipids of Burkitt lymphoma and other human tumors. Lanne B, et al. **Glycobiology** 1996 Jun; 6(4):423–31

Specificity of xenoreactive anti-Gal alpha 1-3Gal IgM for alpha-galactosyl ligands. Parker W, et al. **Glycobiology** 1996 Jul;6(5):499–506

A novel monoclonal antibody, RM-4, specifically recognizes rat macrophages and dendritic cells in formalin-fixed, paraffin-embedded tissues. Iyonaga K, et al. **Histochem J** 1997 Feb;29(2):105–16

Evidence for restricted diversity of antigen-specific human

antibodies in immunized hu-PBL-SCID mice. Bazin R, et al. **Hum Antibodies Hybridomas** 1996;7(3):129–34
A humanized antibody with specificity for hepatitis B surface antigen. Ryu CJ, et al. **Hum Antibodies Hybridomas** 1996; 7(3):113–22
Detection of cytosine deaminase in genetically modified tumor cells by specific antibodies. Haack K, et al. **Hum Gene Ther** 1997 Jul 20;8(11):1395–401
Production and characterization of a novel monoclonal antibody against phosphorylated T cell receptor zeta chain. Conrad PJ, et al. **Hybridoma** 1997 Apr;16(2):167–73
Monoclonal antibodies to thymidine glycol generated by different immunization techniques. Greferath R, et al. **Hybridoma** 1997 Apr;16(2):189–93
Characterization of monoclonal antibodies specific to human tartrate-resistant acid phosphatase. Janckila AJ, et al. **Hybridoma** 1997 Apr;16(2):175–82
Characterization of monoclonal antibodies recognizing human merosin and their use in affinity purification of native merosin. Mizuta T, et al. **Hybridoma** 1996 Oct; 15(5):373–8
Development and characterization of monoclonal antibodies specific for amylin. Phelps JL, et al. **Hybridoma** 1996 Oct; 15(5):379–86
Mouse monoclonal antipeptide antibodies specific for cholesteryl ester transfer protein (CETP). Thomas AP, et al. **Hybridoma** 1996 Oct;15(5):359–64
Anti-IRS-1 monoclonal antibody, 6G5, cross-reacts to IRS-2. Yamauchi T, et al. **Hybridoma** 1996 Aug; 15(4):307–9
Detection of CD 14 on migrated monocytes by specific antibody: a possible quantification for blood monocyte chemotaxis. Tekstra J, et al. **Immunobiology** 1996 Oct; 195(4–5):491–8
Histones interact with immunoglobulins and give them polyspecificity. Abakushin DN, et al. **Immunol Lett** 1996 Nov;53(2–3):95–9
Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors. Colonna M. **Immunol Rev** 1997 Feb;155:127–33 (55 ref.)
Selection of antibodies to cell surface determinants on mouse thymic epithelial cells using a phage display library. Palmer DB, et al. **Immunology** 1997 Jul;91(3):473–8
Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Belay T, et al. **Infect Immun** 1997 Feb;65(2):718–28
The use of IgE immunoblotting as a diagnostic tool in Anisakis simplex allergy. García M, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):497–501
Cross-reactivity of skin and serum specific IgE responses and allergen analysis for three mosquito species with worldwide distribution. Peng Z, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):192–8
Production of a mouse/human chimeric IgE monoclonal antibody to the house dust mite allergen Der p 2 and its use for the absolute quantification of allergen-specific IgE. Schuurman J, et al. **J Allergy Clin Immunol** 1997 Apr; 99(4):545–50
Isoform-specific monoclonal antibodies to Na,K-ATPase alpha subunits. Evidence for a tissue-specific post-translational modification of the alpha subunit. Arystarkhova E, et al. **J Biol Chem** 1996 Sep 20; 271(38):23407–17
Investigations on the specificity of thiophilic interaction for monoclonal antibodies of different subclasses. Finger UB, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26; 675(2):197–204
Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B cell lineage and development. Parker W, et al. **J Clin Immunol** 1997 Jul; 17(4):311–21
Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. Hogan SP, et al. **J Clin Invest** 1997 Mar 15;99(6):1329–39
A novel quantitative immunoassay system for p53 using antibodies selected for optimum designation of p53 status. Thomas MD, et al. **J Clin Pathol** 1997 Feb;50(2):143–7
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. Nussbaum G, et al. **J Exp Med** 1997 Feb 17;185(4):685–94
Antiserum to the egg coats of the fat-tailed dunnart (Marsupialia, Dasyuridae) cross-reacts with egg coats of other marsupial and eutherian species. Roberts CT, et al. **J Exp Zool** 1997 Jun 15;278(3):133–9
Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6. Bhattacherjee V, et al. **J Gen Virol** 1995 Jul;76 (Pt 7):1737–48
Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression. Schreiber M, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2403–14
Donor-specific anti-human leukocyte antigen class I antibodies after implantation of cardiac valve allografts. Hoekstra F, et al. **J Heart Lung Transplant** 1997 May; 16(5):570–2
Specificity of antibodies against rodent transforming growth factor-alpha protein. Aoyama H, et al. **J Histochem Cytochem** 1997 May;45(5):695–701
A quantitative cell-ELISA for alpha-galactose specific antibodies in human malaria. Satapathy AK, et al. **J Immunoassay** 1996 Aug;17(3):245–56
Anti-human kappa opioid receptor antibodies: characterization of site-directed neutralizing antibodies specific for a peptide kappa R(33–52) derived from the predicted amino terminal region of the human kappa receptor. Buchner RR, et al. **J Immunol** 1997 Feb 15; 158(4):1670–80
Contribution of heavy chain junctional amino acid diversity to antibody affinity among p-azophenylarsonate-specific antibodies. Parhami-Seren B, et al. **J Immunol** 1996 Sep 1;157(5):2066–72
Construction and characterization of human CD7-specific single-chain Fv immunotoxins. Pauza ME, et al. **J Immunol** 1997 Apr 1;158(7):3259–69
Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. Pincus SH, et al. **J Immunol** 1997 Apr 1;158(7):3511–20
Modulation of the immune response in multiple sclerosis: production of monoclonal antibodies specific to HLA/myelin basic protein. Puri J, et al. **J Immunol** 1997 Mar 1;158(5):2471–6
Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. Kawakami Y, et al. **J Immunol Methods** 1997 Mar 10;202(1):13–25
Combined immunomagnetic cell sorting and ELISPOT assay for the phenotypic characterization of specific antibody-forming cells. Lakew M, et al. **J Immunol Methods** 1997 Apr 25;203(2):193–8
Quantitative analysis of the products of IgG chain recombination in hybrid hybridomas based on affinity chromatography and radioimmunoassay. Massino YS, et al. **J Immunol Methods** 1997 Feb 14;201(1):57–66
Renaturation of blotted allergens increases the sensitivity of specific IgE detection. Muro MD, et al. **J Investig Allergol Clin Immunol** 1996 May-Jun;6(3):166–71 (36 ref.)
Specific IgE to castor bean (Ricinus communis) pollen in the sera of clinically sensitive patients to seeds. Singh A, et al. **J Investig Allergol Clin Immunol** 1997 May-Jun; 7(3):169–74
Regional and ontogenic expression of the NMDA receptor subunit NR2D protein in rat brain using a subunit-specific antibody. Dunah AW, et al. **J Neurochem** 1996 Dec; 67(6):2335–45
MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR V beta CDR2 peptides: comparison with myelin basic protein-specific T cells. Chou YK, et al. **J Neurosci Res** 1996 Sep 15; 45(6):838–51
Human T lymphocytes specific for the immunodominant 83–99 epitope of myelin basic protein: recognition of golli MBP HOG 7. Tranquill LR, et al. **J Neurosci Res** 1996 Sep 15;45(6):820–8
Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis [see comments] Bjornson AB, et al. **J Pediatr** 1996 Dec;129(6):828–35. Comment in: J Pediatr 1996 Dec;129(6):788–9.
Sperm-associated and circulating IgA and IgG classes of antibodies recognise different antigens on the human sperm plasma membrane. Auer J, et al. **J Reprod Immunol** 1997 Sep;34(2):121–36
Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis. Swedler W, et al. **J Rheumatol** 1997 Jun;24(6):1037–44
Cytotoxicity of B72.3XOKT3 bispecific antibody recognizing human colon cancer. Shpitz B, et al. **J Surg Res** 1996 Feb 15;61(1):134–8
HLA antibodies specific for cryopreserved heart valve "homografts" in children. den Hamer I, et al. **J Thorac Cardiovasc Surg** 1997 Feb;113(2):417–9
Screening for colorectal cancer by immunochemical fecal occult blood testing. Saito H. **Jpn J Cancer Res** 1996 Oct; 87(10):1011–24 (89 ref.)
A simple solid-phase competition assay with labeled antigen. Kuroki M. **Methods Mol Biol** 1996;66:47–53
Enhancement of Streptococcus pneumoniae serotype 6B infection in mice after passive immunization with human serum. Aaberge IS, et al. **Microb Pathog** 1996 Aug; 21(2):125–37
Identification of a phosphatase-sensitive epitope of rabies virus nucleoprotein which is recognized by a monoclonal antibody 5–2–26. Anzal J, et al. **Microbiol Immunol** 1997; 41(3):229–40
Characterization of serotype II polysaccharide antigen of group E streptococci using a monoclonal antibody. Tomotake H, et al. **Microbiol Res** 1997 Jul;152(2):113–9
The Mycoplasma hominis P120 membrane protein contains a 216 amino acid hypervariable domain that is recognized by the human humoral immune response. Nyvold C, et al. **Microbiology** 1997 Feb;143 (Pt 2):675–88
Exploring antibody polyspecificity using synthetic combinatorial libraries. Appel JR, et al. **Mol Divers** 1996 Oct;2(1–2):29–34
Molecular mapping of the 8.12 SLE-associated idiotype specificity at the single amino acid level. Irigoyen M, et al. **Mol Immunol** 1996 Nov;33(16):1255–65
Generation and characterization of subtype-specific monoclonal antibodies to K+ channel alpha- and beta-subunit polypeptides. Bekele-Arcuri Z, et al. **Neuropharmacology** 1996;35(7):851–65
Immunohistochemical differentiation of monoclonal GAD antibodies recognizing linear or conformational epitope regions. Augstein P, et al. **Pancreas** 1997 Aug;15(2):139–46
The specificity of the human IgE response to Necator americanus. Pritchard DI, et al. **Parasite Immunol** 1995 Nov;17(11):605–7
Structural and molecular specificity of antibody responses in mice immune to third stage larvae of Onchocerca volvulus. Yutanawiboonchai W, et al. **Parasite Immunol** 1996 Feb;18(2):95–102
Immunohistochemical localization of type-II (AT2) angiotensin receptors with a polyclonal antibody against a peptide from the C-terminal tail. Yiu AK, et al. **Regul Pept** 1997 May 14;70(1):15–21
Polyreactive binding of antibodies generated by polyclonal B cell activation. II. Crossreactive and monospecific antibodies can be generated from an identical Ig rearrangement by differential glycosylation. Fernández C, et al. **Scand J Immunol** 1997 Mar;45(3):240–7
Comparison of surface properties of human IgA, IgE, IgG and IgM antibodies with identical and different specificities. Wingren C, et al. **Scand J Immunol** 1996 Nov;44(5):430–6
Naturally-occurring anti-thymocyte autoantibody which identifies a restricted CD4+CD8+CD3-/lo/int thymocyte subpopulation exhibits extensive polyspecificity. Underwood JR, et al. **Thymus** 1996;24(2):61–88
Antigenic cross-reactivity of venoms from medically important Loxosceles (Araneae) species in Brazil. Barbaro KC, et al. **Toxicon** 1994 Jan;32(1):113–20
Epitope specificity of HLA class I alloantibodies: II. Stability of cross-reactive group antibody patterns over extended time periods. Rodey GE, et al. **Transplantation** 1997 Mar 27;63(6):885–93
Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants. Rencher SD, et al. **Vaccine** 1997 Feb;15(3):265–72
Proceedings of the 3rd workshop on ruminant leukocyte antigens. Davis, California, 16 July 1995. **Vet Immunol Immunopathol** 1996 Aug;52(4):213–468
Feline ocular and cerebrospinal fluid Toxoplasma gondii-specific humoral immune responses following specific and nonspecific immune stimulation. Lappin MR, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1–3):23–31
Impaired specific immunoreactivity in cows with hepatic lipidosis. Wentink GH, et al. **Vet Immunol Immunopathol** 1997 May;56(1–2):77–83
Production and characterization of monoclonal antibodies against Taylorella equigenitalis. Gradinaru DA, et al. **Vet Res** 1997;28(1):65–76
[Study on the specificity of a monoclonal antibody against recombinant envelope proteins of a human endogenous retrovirus, ERV3] Shibata M. **Hokkaido Igaku Zasshi** 1996 Jul;71(4):463–73 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Interleukin-10 and interleukin-4 have similar effects on hapten-specific primary antibody responses to penicillin in vivo. Kerdine S, et al. **Eur J Immunol** 1996 Dec; 26(12):2890–4
Differential regulation of antigen-specific IgG4 and IgE antibodies in response to recombinant filarial proteins. Garraud O, et al. **Int Immunol** 1996 Dec;8(12):1841–8
Redirecting circulating antibodies via ligand-hapten conjugates eliminates target cells in vivo. Lussow AR, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):257–65
Antibody specificity to the chemical structures of organic acid anhydrides studied by in-vitro and in-vivo methods. Zhang XD, et al. **Toxicology** 1997 Mar 28;118(2–3):223–32
[The character of development of the immune response to sheep erythrocytes and parallel responses to exo- and endobiotics] Bykova AA, et al. **Eksp Klin Farmakol** 1997 May-Jun;60(3):58–60 (Eng. Abstr.) **(Rus)**

GENETICS

Cloning, sequencing, expression and characterization of three anti-estradiol-17beta Fab fragments. Pajunen M, et al. **Biochim Biophys Acta** 1997 Mar 20;1351(1–2):192–202
Myelin basic protein-specific and TCR V beta 8.2-specific T-cell lines from TCR V beta 8.2 transgenic mice utilize the same V alpha and V beta genes: specificity associated with the V alpha CDR3-J alpha region. Buenafe AC, et al. **J Neurosci Res** 1997 Mar 1;47(5):489–99

IMMUNOLOGY

Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Yamaguchi H, et al. **Acta Neuropathol (Berl)** 1996 Sep;92(3):232–41
Identification of cross-reactive antigenic target regions for HIV type 1-specific antibody-dependent cellular cytotoxicity. Broliden K, et al. **AIDS Res Hum Retroviruses** 1996 Dec 10;12(18):1699–702
Majority of thyroid peroxidase autoantibodies in patients with autoimmune thyroid disease are directed to a single TPO domain. Czarnocka B, et al. **Autoimmunity** 1996;

23(3):145–54
IgH and L chain variable region gene sequence analyses of twelve synovial tissue–derived B cell lines producing IgA, IgG, and IgM rheumatoid factors structure/function comparisons of antigenic specificity, V gene sequence, and Ig isotype. Jain RI, et al. **Autoimmunity** 1995;22(4):229–43
Monoclonal antibodies: epitope specificity and typing of Dpartial cells. Sonneborn HH, et al.
Beitr Infusionsther Transfusionsmed 1996;33:13–6
Specificity and role of anti–Trypanosoma cruzi clearance antibodies. Umekita LF, et al. **Braz J Med Biol Res** 1996 Jan;29(1):25–31
Lipopolysaccharide–specific antibodies in plasma and stools of children with Shigella–associated leukemoid reaction and hemolytic–uremic syndrome. Azim T, et al.
Clin Diagn Lab Immunol 1996 Nov;3(6):701–5
Specific antibody reactivity against a 110–kilodalton Actinobacillus actinomycetemcomitans protein in subjects with periodontitis. Fleming TF, et al.
Clin Diagn Lab Immunol 1996 Nov;3(6):678–81
Cytomegalovirus glycoprotein B–specific antibody analysis using electrochemiluminescence detection–based techniques. Ohlin M, et al. **Clin Diagn Lab Immunol** 1997 Jan;4(1):107–11
Neuraminidase–specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Powers DC, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):511–6
Assessment of the specificity of a commercial human parvovirus B19 IgM assay. Jensen IP, et al.
Clin Diagn Virol 1997 Feb;7(3):133–7
Allergenic and antigenic determinants of latex allergen Hev b 1: peptide mapping of epitopes recognized by human, murine and rabbit antibodies. Chen Z, et al.
Clin Exp Allergy 1996 Apr;26(4):406–15
Airborne dust antigen exposure and specific IgG response in the potato processing industry. Zock JP, et al.
Clin Exp Allergy 1996 May;26(5):542–8
Complexity of the bovine MHC class–II specificity DW3 as defined by alloantisera. Nilsson R, et al.
Eur J Immunogenet 1994 Jun;21(3):169–80
Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines. Rouppe van der Voort EM, et al. **FEMS Immunol Med Microbiol** 1997 Mar; 17(3):139–48
Lipopolysaccharide induces apoptotic cell death of B memory cells and regulates B cell memory in antigen–nonspecific manner. Yokochi T, et al.
FEMS Immunol Med Microbiol 1996 Aug;15(1):1–8
Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2–>6) T antigens. O'Boyle KP, et al. **Hybridoma** 1996 Dec; 15(6):401–8
Generation and characterization of a humanized antibody with specificity for preS2 surface antigen of hepatitis B virus. Park SS, et al. **Hybridoma** 1996 Dec;15(6):435–41
Human recombinant antibodies specific for hepatitis C virus core and envelope E2 peptides from an immune phage display library. Chan SW, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2531–9
All rabbits immunized with type A influenza virions have a serum haemagglutination–inhibition antibody response biased to a single epitope in antigenic site B. Lambkin R, et al. **J Gen Virol** 1995 Apr;76 (Pt 4):889–97
Redirecting circulating antibodies via ligand–hapten conjugates eliminates target cells in vivo. Lussow AR, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):257–65
Anti–Staphylococcus aureus, anti–Streptococcus pneumoniae and anti–Moraxella catarrhalis specific IgE in asthmatic children. Brarda OA, et al.
J Investig Allergol Clin Immunol 1996 Jul–Aug;6(4):266–9
Alternative routes for allergen–specific immunotherapy. Passalacqua G, et al. **J Investig Allergol Clin Immunol** 1996 Mar–Apr;6(2):81–7 (69 ref.)
Specific IgE determination in the diagnosis of beta–lactam allergy. Sanz ML, et al.
J Investig Allergol Clin Immunol 1996 Mar–Apr;6(2):89–93
Study of antibody–antigen interaction through site–directed mutagenesis of the VH region of a hybrid phage–antibody fragment. Li Y, et al. **Protein Eng** 1996 Dec;9(12):1211–7
Specificity of two anti–class I HLA monoclonal antibodies that block class I recognition by the NKB1 killer cell inhibitory receptor. Gumperz JE, et al. **Tissue Antigens** 1996 Oct;48(4 Pt 1):278–84
The humoral and cellular immune response to a lipid attenuated pore–forming toxin from the sea anemone Actinia equina L. Narat M, et al. **Toxicon** 1994 Jan; 32(1):65–71
Flow cytometric analysis of the reactivity of workshop monoclonal antibodies on sheep lymph node cells, after infection with Salmonella abortusovis. Bernard S, et al.
Vet Immunol Immunopathol 1996 Aug;52(4):403–9
Immunohistochemical study on the reactivity of workshop monoclonal antibodies with sheep lymph nodes. Berthon P, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):393–401
Analysis of monoclonal antibodies specific for the gamma delta TcR. Davis WC, et al.
Vet Immunol Immunopathol 1996 Aug;52(4):275–83
Reactivity of antibodies directed against human antigens with surface markers on canine leukocytes. Galkowska H, et al. **Vet Immunol Immunopathol** 1996 Oct;53(3–4):329–34
Two monoclonal antibodies from the platelet panel recognize sheep plasma fibrinogen. Pérez de la Lastra JM, et al.
Vet Immunol Immunopathol 1996 Aug;52(4):371–5
Identification of monoclonal antibodies with specificity to alpha– or beta–chains of beta 2–integrins using peripheral blood leucocytes of normal and bovine leucocyte adhesion deficient (BLAD) cattle. Rutten VP, et al.
Vet Immunol Immunopathol 1996 Aug;52(4):341–5
Reactivity of monoclonal antibodies with bovine blood mononuclear cells activated by mitogens and superantigens. Schuberth HJ, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):313–21
Restricted B–cell responses to microbial challenge of the respiratory tract. Walker J, et al.
Vet Immunol Immunopathol 1996 Nov;54(1–4):197–204 (28 ref.)
Human T–lymphotropic virus type I (HTLV–I)–specific antibodies and cell–free RNA in crevicular fluid–rich saliva from patients with tropical spastic paraparesis/HTLV–I–associated myelopathy.
Soto–Ramirez LE, et al. **Viral Immunol** 1995;8(3):141–50
[Donor specific antibody production after liver transplantation. A study of the rat model] Dahmen U, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:295–8 (Eng. Abstr.) **(Ger)**
[Occurrence of false positives in tests with synthetic peptides for the analysis of antibodies against the human immunodeficiency virus type 2 (HIV–2) in Brazilian patients infected with the human immunodeficiency virus type 1 (HIV–1)] Machado AA, et al.
Rev Soc Bras Med Trop 1996 Nov–Dec;29(6):615–7 **(Por)**
[An analysis of the specificity of anti–Mycobacterium monoclonal antibodies and of the chemical nature of the antigenic determinants with which they react] Avdienko VG, et al. **Probl Tuberk** 1996;(1):6–8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Allergen binding to specific IgE in the nasal mucosa of allergic patients. KleinJan A, et al.
J Allergy Clin Immunol 1997 Apr;99(4):515–21

ANTIBODY–TOXIN CONJUGATES see **IMMUNOTOXINS**

ANTIBODY–TOXIN HYBRIDS see **IMMUNOTOXINS**

ANTICANCER DRUG COMBINATIONS see **ANTINEOPLASTIC AGENTS, COMBINED**

ANTICANCER DRUG SENSITIVITY TESTS see **DRUG SCREENING ASSAYS, ANTITUMOR**

ANTICARCINOGENIC AGENTS

see related
ANTIMUTAGENIC AGENTS
ANTINEOPLASTIC AGENTS
Phloridzin derivatives; food additives/chemopreventative drugs of the future. Ridgway T, et al.
Biochem Soc Trans 1997 Feb;25(1):109S
Effect of food products on endogenous generation of N–nitrosamines in rats. Atanasova–Goranova VK, et al.
Br J Nutr 1997 Aug;78(2):335–45
International symposium on the role of lycopene and tomato products in disease prevention. Hoffmann I, et al.
Cancer Epidemiol Biomarkers Prev 1997 Aug;6(8):643–5
Inhibitory effects of curcumin–free aqueous turmeric extract on benzo[a]pyrene–induced forestomach papillomas in mice. Deshpande SS, et al. **Cancer Lett** 1997 Sep 16; 118(1):79–85
Modulatory potential of smokeless tobacco on the garlic, mace or black mustard–altered hepatic detoxication system enzymes, sulfhydryl content and lipid peroxidation in murine system. Singh A, et al. **Cancer Lett** 1997 Sep 16; 118(1):109–14
Mechanism of differential efficacy of garlic organosulfides in preventing benzo(a)pyrene–induced cancer in mice. Srivastava SK, et al. **Cancer Lett** 1997 Sep 16;118(1):61–7
Serum response of all–trans and 9–cis isomers of beta–carotene in humans. Johnson EJ, et al.
J Am Coll Nutr 1996 Dec;15(6):620–4
Cancer Chemopreventive Agents: Drug Development Status II. **J Cell Biochem Suppl** 1996;26:1–321
Conformationally defined 6–s–trans–retinoic acid analogs. 3. Structure–activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity. Muccio DD, et al.
J Med Chem 1996 Sep 13;39(19):3625–35
Effects of diet on urinary bladder carcinogenesis and cancer prevention. Cohen SM, et al. **J Nutr** 1997 May;127(5 Suppl):826S–829S (21 ref.)
Inhibitory activity of green and black tea in a free radical–generating system using 2–amino–3–methylimidazo[4,5–f]quinoline as substrate. Hasaniya N, et al. **Jpn J Cancer Res** 1997 Jun;88(6):553–8
Antiproliferative effect of fermented milk on the growth of a human breast cancer cell line. Biffi A, et al.
Nutr Cancer 1997;28(1):93–9
Lactobacillus– and bifidobacterium–mediated antigenotoxicity in the colon of rats. Pool–Zobel BL, et al. **Nutr Cancer** 1996;26(3):365–80
Japanese green tea as a cancer preventive in humans. Fujiki H, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S67–70 (25 ref.)
Garlic: its anticarcinogenic and antitumorigenic properties. Milner JA. **Nutr Rev** 1996 Nov;54(11 Pt 2):S82–6 (36 ref.)
An approach to functional food: cancer preventive potential of vegetables and fruits and their active constituents. Ohigashi H, et al. **Nutr Rev** 1996 Nov;54(11 Pt 2):S24–8 (26 ref.)
Experimental and epidemiological evidence of the cancer–preventive effects of Panax ginseng C.A. Meyer. Yun TK. **Nutr Rev** 1996 Nov;54(11 Pt 2):S71–81 (36 ref.)
Are breast implants anticarcinogenic? A 14–year follow–up of the Los Angeles Study. Deapen DM, et al.
Plast Reconstr Surg 1997 Apr;99(5):1346–53
Progress in clinical chemoprevention. Kelloff GJ, et al.
Semin Oncol 1997 Apr;24(2):241–52 (83 ref.)
[Theoretical basis for research of inhibitors of chemical carcinogenesis] Khudoleĭ VV, et al. **Vopr Onkol** 1996; 42(5):113–7 (25 ref.) **(Rus)**

ADMINISTRATION & DOSAGE

Treatment of recurrent respiratory papillomatosis with indole–3–carbinol. Coll DA, et al. **Am J Otolaryngol** 1997 Jul–Aug;18(4):283–5
Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Jacobson LP, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Apr; 6(4):257–65
Chemoprevention of 4–nitroquinoline 1–oxide–induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2–hydroxychalcone, and quercetin. Makita H, et al.
Cancer Res 1996 Nov 1;56(21):4904–9
Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Reddy BS, et al. **Cancer Res** 1997 Feb 1; 57(3):420–5
Outcomes of a placebo run–in period in a head and neck cancer chemoprevention trial. Hudmon KS, et al.
Control Clin Trials 1997 Jun;18(3):228–40
Different starting times of alpha–tocopherol and gamma–tocotrienol supplementation and tumor marker enzyme activities in the rat chemically induced with cancer. Makpol S, et al. **Gen Pharmacol** 1997 Apr;28(4):589–92
Risk factors for lung cancer and for intervention effects in CARET, the Beta–Carotene and Retinol Efficacy Trial [see comments] Omenn GS, et al. **J Natl Cancer Inst** 1996 Nov 6;88(21):1550–9. Comment in: J Natl Cancer Inst 1996 Nov 6;88(21):1513–5. Comment in: J Natl Cancer Inst 1997 Feb 19;89(4):325–6.
Controlled–release delivery system for the alpha–MSH analog melanotan–I using poloxamer 407. Bhardwaj R, et al. **J Pharm Sci** 1996 Sep;85(9):915–9
Systemic delivery of melanotan II through the ocular route in rabbits [letter] Pinsuwan S, et al. **J Pharm Sci** 1997 Mar; 86(3):396–7
Influence of isoflavones in soy protein isolates on development of induced prostate–related cancers in L–W rats. Pollard M, et al. **Nutr Cancer** 1997;28(1):41–5
Clinical trials referral resource. Breast cancer and prostate cancer. Brawley OW, et al. **Oncology (Huntingt)** 1996 Jan; 10(1):100, 102
[High concentrate A–mulsin, a new therapy concept in laryngeal leukoplakia] Issing WJ, et al.
Laryngorhinootologie 1996 Jan;75(1):29–33 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Phase I trial of alpha–tocopherol effects on 13–cis–retinoic acid toxicity. Dimery IW, et al. **Ann Oncol** 1997 Jan; 8(1):85–9
Enhancement by indole–3–carbinol of liver and thyroid gland neoplastic development in a rat medium–term multiorgan carcinogenesis model. Kim DJ, et al. **Carcinogenesis** 1997 Feb;18(2):377–81
Adverse effects of preventive therapy in humans. La Vecchia C, et al. **IARC Sci Publ** 1996;(139):135–42 (56 ref.)
Tamoxifen: the herald of a new era of preventive therapeutics [editorial; comment] Jordan VC. **J Natl Cancer Inst** 1997 Jun 4;89(11):747–9. Comment on: J Natl Cancer Inst 1997 Jun 4;89(11):776–82.
Chemoprevention of breast cancer with fenretinide (4–HPR): study of long–term visual and ophthalmologic tolerability. Mariani L, et al. **Tumori** 1996 Sep–Oct;82(5):444–9
Indices of differential endometrial: myometrial growth may be used to improve the reliability of detecting endometrial neoplasia in women on tamoxifen. Pepper JM, et al.
Ultrasound Obstet Gynecol 1996 Dec;8(6):408–11

ANALYSIS

Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Ueda T, et al.
Am J Pathol 1996 Nov;149(5):1435–40
Anomalous behaviour of lycopene by HPLC on cyano–amino polar phase. Piretti MV, et al.
Biomed Chromatogr 1996 Jan–Feb;10(1):43–5
cis–trans lycopene isomers, carotenoids, and retinol in the human prostate. Clinton SK, et al.
Cancer Epidemiol Biomarkers Prev 1996 Oct;5(10):823–33
Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Li D,

et al. **Cancer Res** 1997 Apr 15;57(8):1438–41

[Cancer preventive value of natural, non–nutritive food constituents] Fröhlich RH, et al. **Acta Med Austriaca** 1997; 24(3):108–13 (82 ref.) (Eng. Abstr.) **(Ger)**

[[HPLC–determination of tamoxifen dihydrogen citrate with the base selective column UltraSep ES Pharm RP8 in tablets] Gliesing S, et al. **Pharmazie** 1997 May; 52(5):399–401 **(Ger)**

BLOOD

Chemiluminescence–high–performance liquid chromatographic determination of tea catechin, (–)–epigallocatechin 3–gallate, at picomole levels in rat and human plasma. Nakagawa K, et al. **Anal Biochem** 1997 May 15;248(1):41–9

Delayed postprandial retinyl palmitate and squalene removal in a patient heterozygous for apolipoprotein A–IFIN mutation (Leu 159—>Arg) and low HDL cholesterol level without coronary artery disease. Gylling H, et al. **Atherosclerosis** 1996 Dec 20;127(2):239–43

The association between participant characteristics and serum concentrations of beta–carotene, retinol, retinyl palmitate, and alpha–tocopherol among participants in the Carotene and Retinol Efficacy Trial (CARET) for prevention of lung cancer. Goodman GE, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Oct;5(10):815–21

Bioavailability of the dietary antioxidant flavonol quercetin in man. Hollman PC, et al. **Cancer Lett** 1997 Mar 19; 114(1–2):139–40

Reproducibility of relative dose response (RDR) test and serum retinol and retinyl ester concentrations in children after a 2–week interval. Apgar J, et al. **J Am Coll Nutr** 1996 Oct;15(5):450–7

Determination of tamoxifen and metabolites in serum by capillary electrophoresis using a nonaqueous buffer system. Sanders JM, et al. **J Chromatogr B Biomed Appl** 1997 Jul 18;695(1):181–5

CHEMISTRY

Correlations between topological resonance energy of methyl–substituted benz[c]acridines, benzo[a]phenothiazines and chrysenes, and their carcinogenic or antitumor activities. Kurihara T, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2757–65

Indole–3–carbinol as a scavenger of free radicals. Arnao MB, et al. **Biochem Mol Biol Int** 1996 Aug;39(6):1125–34

Formation of the mutagenic/carcinogenic imidazoquinoxaline–type heterocyclic amines through the unstable free radical Maillard intermediates and its inhibition by phenolic antioxidants. Kato T, et al. **Carcinogenesis** 1996 Nov;17(11):2469–76

Evidence for thiol–dependent production of oxygen radicals by 4–methyl–5–pyrazinyl–3H–1,2–dithiole–3–thione (oltipraz) and 3H–1,2–dithiole–3–thione: possible relevance to the anticarcinogenic properties of 1,2–dithiole–3–thiones. Kim W, et al. **Chem Res Toxicol** 1997 Mar;10(3):296–301

Kinetics of the reaction of a potential chemopreventive agent, 2,6–dithiopurine, and its major metabolite, 2,6–dithiouric acid, with multiple classes of electrophilic toxicants. Qing WG, et al. **Chem Res Toxicol** 1996 Dec;9(8):1298–304

ISOLATION & PURIFICATION

Cows' milk fat components as potential anticarcinogenic agents. Parodi PW. **J Nutr** 1997 Jun;127(6):1055–60 (71 ref.)

Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Fahey JW, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16; 94(19):10367–72

METABOLISM

Effects of dietary broccoli on human drug metabolising activity. Kall MA, et al. **Cancer Lett** 1997 Mar 19; 114(1–2):169–70

Decomposition of anticarcinogen factors of the beetroot during juice and nectar production. Pátkai G, et al. **Cancer Lett** 1997 Mar 19;114(1–2):105–6

A proposed mechanism for the role of fermentation in protecting against colonic cancer. Ratcliffe B, et al. **Cancer Lett** 1997 Mar 19;114(1–2):57–8

Cytoskeletal and adhesion proteins as tumor suppressors. Ben–Ze'ev A. **Curr Opin Cell Biol** 1997 Feb;9(1):99–108 (96 ref.)

The potential role of lycopene for human health. Gerster H. **J Am Coll Nutr** 1997 Apr;16(2):109–26 (117 ref.)

2–hydroxyestrone: the 'good' estrogen. Bradlow HL, et al. **J Endocrinol** 1996 Sep;150 Suppl:S259–65 (37 ref.)

PHARMACOKINETICS

Lycopene is more bioavailable from tomato paste than from fresh tomatoes. Gärtner C, et al. **Am J Clin Nutr** 1997 Jul; 66(1):116–22

Skin pigmentation and pharmacokinetics of melanotan–I in humans. Ugwu SO, et al. **Biopharm Drug Dispos** 1997 Apr; 18(3):259–69

Metabolism, uptake, and excretion of a D–glucaric acid salt and its potential use in cancer prevention. Walaszek Z, et al. **Cancer Detect Prev** 1997;21(2):178–90

Selenium–enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis. Ip C, et al. **Carcinogenesis** 1996 Sep;17(9):1979–82

Ingestion by men of a combined dose of beta–carotene and lycopene does not affect the absorption of beta–carotene but improves that of lycopene. Johnson EJ, et al. **J Nutr** 1997 Sep;127(9):1833–7

Influence of vehicle, distant topical delivery, and biotransformation on the chemopreventive activity of apigenin, a plant flavonoid, in mouse skin. Li B, et al. **Pharm Res** 1996 Oct;13(10):1530–4

In vivo and in vitro percutaneous absorption of cancer preventive flavonoid apigenin in different vehicles in mouse skin. Li B, et al. **Pharm Res** 1996 Nov;13(11):1710–5

PHARMACOLOGY

Quercetin as a modulator of the cellular neoplastic phenotype. Effects on the expression of mutated H–ras and p53 in rodent and human cells. Avila MA, et al. **Adv Exp Med Biol** 1996;401:101–10

Recent results in the organosulfur and organoselenium chemistry of genus Allium and Brassica plants. Relevance for cancer prevention. Block E. **Adv Exp Med Biol** 1996; 401:155–69 (75 ref.)

Monoterpenes as regulators of malignant cell proliferation. Hohl RJ. **Adv Exp Med Biol** 1996;401:137–46 (43 ref.)

Anti–tumor–promoting activities or triterpenoid glycosides; cancer chemoprevention by saponins. Konoshima T. **Adv Exp Med Biol** 1996;404:87–100 (11 ref.)

Effects of lycopene, a carotenoid, on intrathymic T cell differentiation and peripheral CD4/CD8 ratio in a high mammary tumor strain of SHN retired mice. Kobayashi T, et al. **Anticancer Drugs** 1996 Feb;7(2):195–8

Effects of 1,4–phenylenebis(methylene)selenocyanate, phenethyl isothiocyanate, indole–3–carbinol, and d–limonene individually and in combination on the tumorigenicity of the tobacco–specific nitrosamine 4–(methylnitrosamino)–1–(3–pyridyl)–1–butanone in A/J mouse lung. el–Bayoumy K, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2709–12

Inhibitory effect of crocetin on benzo(a)pyrene genotoxicity and neoplastic transformation in C3H10T1/2 cells. Chang WC, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3603–8

Effects of conjugated dienoic derivatives of linoleic acid and beta–carotene in modulating lymphocyte and macrophage function. Chew BP, et al. **Anticancer Res** 1997 Mar–Apr; 17(2A):1099–106

Correlations between topological resonance energy of methyl–substituted benz[c]acridines, benzo[a]phenothiazines and chrysenes, and their carcinogenic or antitumor activities. Kurihara T, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2757–65

Further study on the effects of coffee cherry on spontaneous mammary tumourigenesis in mice: effects of methanol extract. Nagasawa H, et al. **Anticancer Res** 1996 Nov–Dec; 16(6B):3507–13

Glutathione S–transferases of female A/J mouse liver and forestomach and their differential induction by anti–carcinogenic organosulfides from garlic. Hu X, et al. **Arch Biochem Biophys** 1996 Dec 15;336(2):199–214

3,3'–Diindolylmethane induces apoptosis in human cancer cells. Ge X, et al. **Biochem Biophys Res Commun** 1996 Nov 1;228(1):153–8

Resveratrol inhibits metal ion–dependent and independent peroxidation of porcine low–density lipoproteins. Belguendouz L, et al. **Biochem Pharmacol** 1997 May 9; 53(9):1347–55

Anti–tumor–promoting activities of triterpenoids from ferns. I. Konoshima T, et al. **Biol Pharm Bull** 1996 Jul;19(7):962–5

Inhibitory effects of shouseiryu–to on two–stage carcinogenesis. II. Anti–tumor–promoting activities of lignans from Asiasarum heterotropoides var. mandshuricum. Takasaki M, et al. **Biol Pharm Bull** 1997 Jul;20(7):776–80

Inhibitory effects of sterols isolated from Chlorella vulgaris on 12–0–tetradecanoylphorbol–13–acetate–induced inflammation and tumor promotion in mouse skin. Yasukawa K, et al. **Biol Pharm Bull** 1996 Apr;19(4):573–6

Beta–carotene inhibits rat liver chromosomal aberrations and DNA chain break after a single injection of diethylnitrosamine. Sarkar A, et al. **Br J Cancer** 1997; 76(7):855–61

Complete inhibition of 4–(methylnitrosamino)–1–(3–pyridyl)–1–butanone–induced rat lung tumorigenesis and favorable modification of biomarkers by phenethyl isothiocyanate. Hecht SS, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):645–52

Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Kelloff GJ, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):657–66 (108 ref.)

Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Kelloff GJ, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Apr;6(4):267–82 (187 ref.)

Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin–albumin adducts and risk of liver cancer. Kensler TW, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Aug;6(8):603–10

A clinical trial to evaluate the effect of vitamin C supplementation on in vitro mutagen sensitivity. The University of Texas M. D. Anderson Clinical Community Oncology Program Network. King TM, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jul;6(7):537–42

Dietary calcium, vitamin D, and the risk of colorectal cancer in Stockholm, Sweden. Pritchard RS, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Nov;5(11):897–900

The role of apoptosis in the modulation of colon carcinogenesis by dietary fat and by the organoselenium compound 1,4–phenylenebis(methylene)selenocyanate. Samaha HS, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Sep;6(9):699–704

1 alpha,25–Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Schwartz GG, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Sep; 6(9):727–32

Effects of indole–3–carbinol on the metabolism of 4–(methylnitrosamino)–1–(3–pyridyl)–1–butanone in smokers. Taioli E, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jul;6(7):517–22

An international evaluation of the cancer–preventive potential of nonsteroidal anti–inflammatory drugs. Vainio H, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Sep; 6(9):749–53

Protease inhibitors and carcinogenesis: a review. Clawson GA. **Cancer Invest** 1996;14(6):597–608 (114 ref.)

Inhibitory effect of caffeic acid phenethyl ester on human leukemia HL–60 cells. Chen JH, et al. **Cancer Lett** 1996 Nov 29;108(2):211–4

The growth inhibitory effect of conjugated linoleic acid on MCF–7 cells is related to estrogen response system. Durgam VR, et al. **Cancer Lett** 1997 Jun 24;116(2):121–30

Dose–related preventive and therapeutic effects of antioxidants–anticarcinogens on experimentally induced malignant tumors in Wistar rats. Evangelou A, et al. **Cancer Lett** 1997 May 1;115(1):105–11

Assessment of the anticarcinogenic potential of raw garlic in humans. Hageman G, et al. **Cancer Lett** 1997 Mar 19; 114(1–2):161–2

Inhibition of 12–O–tetradecanoylphorbol–13–acetate induced Epstein–Barr virus early antigen activation by natural colorants. Kapadia GJ, et al. **Cancer Lett** 1997 May 19; 115(2):173–8

Inhibitory effects on Epstein–Barr virus activation of anthraquinones: correlation with redox potentials. Koyama J, et al. **Cancer Lett** 1997 May 19;115(2):179–83

Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Limtrakul P, et al. **Cancer Lett** 1997 Jun 24; 116(2):197–203

Mechanism of enhancement of esophageal tumorigenesis by 6–phenylhexyl isothiocyanate [published erratum appears in Cancer Lett 1997 Jun 3;116(1):117] Morse MA, et al. **Cancer Lett** 1997 Jan 15;112(1):119–25

Inhibitory effect of pheophorbide a, a chlorophyll–related compound, on skin tumor promotion in ICR mouse. Nakamura Y, et al. **Cancer Lett** 1996 Nov 29;108(2):247–55

Inhibitory effects of natural carotenoids, alpha–carotene, beta–carotene, lycopene and lutein, on colonic aberrant crypt foci formation in rats. Narisawa T, et al. **Cancer Lett** 1996 Oct 1;107(1):137–42

Long term dietary indole–3–carbinol inhibits diethylnitrosamine–initiated hepatocarcinogenesis in the infant mouse model. Oganesian A, et al. **Cancer Lett** 1997 Sep 16;118(1):87–94

Lack of involvement of p53 gene mutations in N–methyl–N–nitrosourea–induced bladder tumor progression in N–butyl–N–(4–hydroxybutyl)nitrosamine–treated rats and no suppression by indomethacin. Ozaki M, et al. **Cancer Lett** 1997 May 19;115(2):249–55

Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer. Stoner GD, et al. **Cancer Lett** 1997 Mar 19;114(1–2):113–9

Inhibition by the calmodulin antagonist trifluoperazine of experimental hepatocarcinogenesis induced by N–nitrosomorpholine in Sprague–Dawley rats. Tatsuta M, et al. **Cancer Lett** 1996 Oct 22;107(2):179–85

Inhibition by amiloride of experimental carcinogenesis induced by azaserine in rat pancreas. Tatsuta M, et al. **Cancer Lett** 1996 Aug 23;106(1):23–8

Flavonoids, dietary–derived inhibitors of cell proliferation and in vitro angiogenesis. Fotsis T, et al. **Cancer Res** 1997 Jul 15;57(14):2916–21

Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent. Gerhauser C, et al. **Cancer Res** 1997 Aug 15;57(16):3429–35

Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol–3' kinase. Huang C, et al. **Cancer Res** 1997 Jul 15;57(14):2873–8

Retinoids suppress phorbol ester–mediated induction of cyclooxygenase–2. Mestre JR, et al. **Cancer Res** 1997 Mar 15;57(6):1081–5

The chemopreventive agent oltipraz stimulates repair of damaged DNA. O'Dwyer PJ, et al. **Cancer Res** 1997 Mar 15;57(6):1050–3

Sulindac sulfone inhibits azoxymethane–induced colon carcinogenesis in rats without reducing prostaglandin levels. Piazza GA, et al. **Cancer Res** 1997 Jul 15; 57(14):2909–15

Enhancement of experimental colon cancer by genistein. Rao CV, et al. **Cancer Res** 1997 Sep 1;57(17):3717–22

Correspondence re: C.V. Rao, et al., Inhibition of 2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine–induced lymphoma formation by oltipraz. Cancer Res., 56: 3395–3398, 1996 [letter] Roebuck BD, et al. **Cancer Res**

1997 Jul 1;57(13):2806-7

Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Samaha HS, et al. **Cancer Res** 1997 Apr 1;57(7):1301-5

Evidence for an important role of DNA pyridyloxobutylation in rat lung carcinogenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: effects of dose and phenethyl isothiocyanate. Staretz ME, et al. **Cancer Res** 1997 Jan 15;57(2):259-66

Chemopreventive effects of myo-inositol and dexamethasone on benzo[a]pyrene and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone-induced pulmonary carcinogenesis in female A/J mice. Wattenberg LW, et al. **Cancer Res** 1996 Nov 15; 56(22):5132-5

Effects of chemopreventive selenium compounds on Jun N-kinase activities. Adler V, et al. **Carcinogenesis** 1996 Sep; 17(9):1849-54

Study of the post-natal effects of chemopreventive agents on ethylnitrosourea-induced transplacental carcinogenesis in rats. II. Influence of low-molecular-weight polypeptide factors from the thymus, pineal gland, bone marrow, anterior hypothalamus, brain cortex and brain white substance. Alexandrov VA, et al. **Carcinogenesis** 1996 Sep; 17(9):1931-4

Study of post-natal effect of chemopreventive agents on ethylnitrosourea-induced transplacental carcinogenesis in rats. III. Inhibitory action of indomethacin, voltaren, theophylline and epsilon-aminocaproic acid. Alexandrov VA, et al. **Carcinogenesis** 1996 Sep;17(9):1935-9

Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Anisimov VN, et al. **Carcinogenesis** 1997 Aug;18(8):1549-53

Inhibitory effects of 6-phenylhexyl isothiocyanate on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolic activation and lung tumorigenesis in rats. Hecht SS, et al. **Carcinogenesis** 1996 Sep;17(9):2061-7

Selenium-enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis. Ip C, et al. **Carcinogenesis** 1996 Sep;17(9):1979-82

Synergistic suppression of azoxymethane-induced foci of colonic aberrant crypts by the combination of beta-carotene and perilla oil in rats. Komaki C, et al. **Carcinogenesis** 1996 Sep;17(9):1897-901

Effects of administration of the chemoprotective agent oltipraz on CYP1A and CYP2B in rat liver and rat hepatocytes in culture. Langouët S, et al. **Carcinogenesis** 1997 Jul;18(7):1343-9

The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes. Lepley DM, et al. **Carcinogenesis** 1996 Nov;17(11):2367-75

Effect on an aqueous extract of selenium-enriched garlic on in vitro markers and in vivo efficacy in cancer prevention. Lu J, et al. **Carcinogenesis** 1996 Sep;17(9):1903-7

Re: Barcelo, S., Gardiner, J.M., and Gescher, A. and Chipman, J.K. (1996) CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. Carcinogenesis, 17, 277-282 [letter; comment] Paolini M, et al. **Carcinogenesis** 1997 Jul;18(7):1435-6. Comment on: Carcinogenesis 1996 Feb;17(2):277-82. Comment on: Carcinogenesis 1996 Apr;17(4):793-9.

The role of metabolism in mammary epithelial cell growth inhibition by the isoflavones genistein and biochanin A. Peterson TG, et al. **Carcinogenesis** 1996 Sep;17(9):1861-9

Induction of hepatic heme oxygenase-1 and ferritin in rats by cancer chemopreventive dithiolethiones. Primiano T, et al. **Carcinogenesis** 1996 Nov;17(11):2291-6

Isolation of cDNAs representing dithiolethione-responsive genes. Primiano T, et al. **Carcinogenesis** 1996 Nov; 17(11):2297-303

Placental glutathione S-transferase (GST-P) induction as a potential mechanism for the anti-carcinogenic effect of the coffee-specific components cafestol and kahweol. Schilter B, et al. **Carcinogenesis** 1996 Nov;17(11):2377-84

Growth features of aberrant crypt foci that resist modulation by cholic acid. Shirtliff N, et al. **Carcinogenesis** 1996 Sep; 17(9):2093-6

Chemopreventive agents-induced regression of azoxymethane-induced aberrant crypt foci with the recovery of hexosaminidase activity. Tao L, et al. **Carcinogenesis** 1997 Jul;18(7):1415-8

Effects of nonsteroidal anti-inflammatory drugs on glutathione S-transferases of the rat digestive tract. van Lieshout EM, et al. **Carcinogenesis** 1997 Mar;18(3):485-90

Dietary quercetin glycosides: antioxidant activity and induction of the anticarcinogenic phase II marker enzyme quinone reductase in Hepalclc7 cells. Williamson G, et al. **Carcinogenesis** 1996 Nov;17(11):2385-7

Dietary indole-3-carbinol inhibits FMO activity and the expression of flavin-containing monooxygenase form 1 in rat liver and intestine. Larsen-Su S, et al. **Drug Metab Dispos** 1996 Sep;24(9):927-31

Approaches to chemoprevention of lung cancer based on carcinogens in tobacco smoke. Hecht SS. **Environ Health Perspect** 1997 Jun;105 Suppl 4:955-63 (87 ref.)

Chemoprevention by inducers of carcinogen detoxication enzymes. Kensler TW. **Environ Health Perspect** 1997 Jun; 105 Suppl 4:965-70 (55 ref.)

Perspectives in cancer chemoprevention. Stoner GD, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:945-54 (164 ref.)

Polyphenols as inhibitors of carcinogenesis. Yang CS, et al. **Environ Health Perspect** 1997 Jun;105 Suppl 4:971-6 (72 ref.)

Induced differentiation of cancer cells: second generation potent hybrid polar compounds target cell cycle regulators. Marks PA, et al. **Eur J Cancer Prev** 1996 Dec;5 Suppl 2:75-7

Protective effects of diallyl sulfide on acetaminophen-induced toxicities. Hu JJ, et al. **Food Chem Toxicol** 1996 Oct;34(10):963-9

Effect of the active principle of garlic--diallyl sulfide--on cell viability, detoxification capability and the antioxidation system of primary rat hepatocytes. Sheen LY, et al. **Food Chem Toxicol** 1996 Oct;34(10):971-8

Comparison of the enhancing effects of dehydroepiandrosterone with the structural analog 16 alpha-fluoro-5-androsten-17-one on aflatoxin B1 hepatocarcinogenesis in rainbow trout. Orner GA, et al. **Fundam Appl Toxicol** 1996 Nov;34(1):132-40

Blocking the endogenous formation of N-nitroso compounds and related carcinogens. Bartsch H, et al. **IARC Sci Publ** 1996;(139):189-201 (82 ref.)

Regulation of glutathione S-transferases and aldehyde reductase by chemoprotectors: studies of mechanisms responsible for inducible resistance to aflatoxin B1. Hayes JD, et al. **IARC Sci Publ** 1996;(139):175-87 (75 ref.)

Use of carcinogen-DNA and carcinogen-protein adduct biomarkers for cohort selection and as modifiable end points in chemoprevention trials. Kensler TW, et al. **IARC Sci Publ** 1996;(139):237-48 (70 ref.)

Interaction of chemopreventive agents with hormone receptors. Wiseman H. **IARC Sci Publ** 1996;(139):159-64 (20 ref.)

Modulation of the cytochrome P450 system as a mechanism of chemoprotection. Wolf CR, et al. **IARC Sci Publ** 1996; (139):165-73 (24 ref.)

Chemopreventive efficacy of anethole trithione, N-acetyl-L-cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model. Lubet RA, et al. **Int J Cancer** 1997 Jul 3;72(1):95-101

Inhibitory effects of interleukin-4 on human renal cell carcinoma cells in vitro: in combination with interferon-alpha, tumor necrosis factor-alpha or interleukin-2. Cheon J, et al. **Int J Urol** 1996 May; 3(3):196-201

4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. Fanjul AN, et al. **J Biol Chem** 1996 Sep 13;271(37):22441-6

Reduction of dopamine beta-monooxygenase. A unified model for apparent negative cooperativity and fumarate activation. Wimalasena K, et al. **J Biol Chem** 1996 Oct 18;271(42):26032-43

Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. Steele VE, et al. **J Cell Biochem Suppl** 1996;26:29-53

Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. Miller VA, et al. **J Clin Oncol** 1997 Feb; 15(2):790-5

Antimutagenesis and anticancer effects. Bronzetti G, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2-4):59-64 (28 ref.)

Antitumour-promoting and antitumour activities of the crude extract from the leaves of Juniperus chinensis. Ali AM, et al. **J Ethnopharmacol** 1996 Sep;53(3):165-9

Effects of ethane-1-hydroxy-1, 1 diphosphonate on Dunn osteosarcoma cells. Kanamori M, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):39-43

Unoccluded retinol penetrates human skin in vivo more effectively than unoccluded retinyl palmitate or retinoic acid. Duell EA, et al. **J Invest Dermatol** 1997 Sep; 109(3):301-5

Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. Michnovicz JJ, et al. **J Natl Cancer Inst** 1997 May 21;89(10):718-23

Perilla oil prevents the excessive growth of visceral adipose tissue in rats by down-regulating adipocyte differentiation. Okuno M, et al. **J Nutr** 1997 Sep;127(9):1752-7

Evaluation of properties of apigenin and [G-3H]apigenin and analytic method development. Li B, et al. **J Pharm Sci** 1997 Jun;86(6):721-5

Triazine derivatives inhibit rat hepatocarcinogenesis but do not enhance gap junctional intercellular communication. Hori T, et al. **Jpn J Cancer Res** 1997 Jan;88(1):12-7

Anti-tumor promoting activity of canventol and its synthetic analogs through inhibition of protein isoprenylation. Komori A, et al. **Jpn J Cancer Res** 1996 Sep;87(9):875-81

Inhibitory effects of tea catechins, black tea extract and oolong tea extract on hepatocarcinogenesis in rat. Matsumoto N, et al. **Jpn J Cancer Res** 1996 Oct; 87(10):1034-8

Inhibitory effects of dietary protocatechuic acid and costunolide on 7,12-dimethylbenz[a]anthracene-induced hamster cheek pouch carcinogenesis. Ohnishi M, et al. **Jpn J Cancer Res** 1997 Feb;88(2):111-9

Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment. Okajima E, et al. **Jpn J Cancer Res** 1997 Jun;88(6):543-52

Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Sekine K, et al. **Jpn J Cancer Res** 1997 Jun;88(6):523-6

Inhibitory effect of chlorophyllin on diethylnitrosamine and phenobarbital-induced hepatocarcinogenesis in male F344 rats. Sugie S, et al. **Jpn J Cancer Res** 1996 Oct; 87(10):1045-51

S-methylcysteine and cysteine are inhibitors of induction of glutathione S-transferase placental form-positive foci during initiation and promotion phases of rat hepatocarcinogenesis. Takada N, et al. **Jpn J Cancer Res** 1997 May;88(5):435-42

IP6: a novel anti-cancer agent. Shamsuddin AM, et al. **Life Sci** 1997;61(4):343-54 (68 ref.)

A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Dong Z, et al. **Mol Carcinog** 1997 Jul;19(3):204-12

Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. Lepley DM, et al. **Mol Carcinog** 1997 Jun;19(2):74-82

Inhibition of protein kinase C and proto-oncogene expression by crocetin in NIH/3T3 cells. Wang CJ, et al. **Mol Carcinog** 1996 Dec;17(4):235-40

Antimutagenic and anticarcinogenic activity of natural and synthetic curcuminoids. Anto RJ, et al. **Mutat Res** 1996 Sep 13;370(2):127-31

Chemoprotection against the formation of colon DNA adducts from the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the rat. Huber WW, et al. **Mutat Res** 1997 May 12; 376(1-2):115-22

Antigenotoxic activity of natural chlorophylls. Negishi T, et al. **Mutat Res** 1997 May 12;376(1-2):97-100

Inhibition of carcinogenesis by tea [letter] Yang CS. **Nature** 1997 Sep 11;389(6647):134-5

No evidence for an inhibitory effect of beta-carotene or of canthaxanthin on the initiation of liver preneoplastic foci by diethylnitrosamine in the rat. Astorg P, et al. **Nutr Cancer** 1996;25(1):27-34

Reducing effects of garlic constituents on DNA adduct formation in human lymphocytes in vitro. Hageman GJ, et al. **Nutr Cancer** 1997;27(2):177-85

Modulation of rat hepatic cytochrome P-450 activity by garlic organosulfur compounds. Reicks MM, et al. **Nutr Cancer** 1996;25(3):241-8

Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor. Fujiuchi S, et al. **Oncology** 1997 Mar-Apr;54(2):134-40

Effects of quercetin and/or restraint stress on formation of aberrant crypt foci induced by azoxymethane in rat colons. Matsukawa Y, et al. **Oncology** 1997 Mar-Apr;54(2):118-21

Transcription regulation of rat glutathione S-transferase Ya subunit gene expression by chemopreventive agents. Fei P, et al. **Pharm Res** 1996 Jul;13(7):1043-8

Effect of a lignan-enriched extract of Schisandra chinensis on aflatoxin B1 and cadmium chloride-induced hepatotoxicity in rats. Ip SP, et al. **Pharmacol Toxicol** 1996 Jun;78(6):413-6

In vitro formation of crocetin glucosyl esters by Crocus sativus callus extract. Dufresne C, et al. **Planta Med** 1997 Apr;63(2):150-3

Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Huang C, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5826-30

Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Noguchi Y, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11798-801

Natural products and their derivatives as cancer chemopreventive agents. Ren S, et al. **Prog Drug Res** 1997; 48:147-71 (150 ref.)

Enhancement of radiation-induced hepatic microsomal epoxide hydrolase gene expression by oltipraz in rats. Nam SY, et al. **Radiat Res** 1997 May;147(5):613-20

Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Jang M, et al. **Science** 1997 Jan 10;275(5297):218-20

Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. Narisawa T, et al. **Tohoku J Exp Med** 1996 Oct;180(2):131-8

The isoflavones equol and genistein do not induce xenobiotic-metabolizing enzymes in mouse and in human cells. Helsby NA, et al. **Xenobiotica** 1997 Jun;27(6):587-96

[Studies on the anticarcinogenic and immunomodulatory actions of 4-seleno-carrageenan] Suo JL. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):43-6 (Eng. Abstr.) **(Chi)**

[Inhibition of RAS-transformation by SCH51344] Kumar CC. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1503-11 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of green tea polyphenol fraction on 1,2-dimethylhydrazine (DMH)-induced colorectal carcinogenesis in the rat] Kan H, et al. **Nippon Ika Daigaku Zasshi** 1996 Apr;63(2):106-16 (Eng. Abstr.) **(Jpn)**

[Mechanisms of antitumor activity of carotenoids] Vershinin AO, et al. **Vopr Med Khim** 1996 Oct-Dec;42(4):275-7 (37 ref.) (Eng. Abstr.) **(Rus)**

ANTICARCINOGENIC AGENTS

THERAPEUTIC USE

Cancer chemoprevention by polyphenols in green tea and artichoke. Agarwal R, et al. **Adv Exp Med Biol** 1996; 401:35–50 (107 ref.)

Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer. Crowell PL, et al. **Adv Exp Med Biol** 1996;401:131–6 (23 ref.)

Chemoprevention of lung cancer by isothiocyanates. Hecht SS. **Adv Exp Med Biol** 1996;401:1–11 (34 ref.)

The attributes of selenium-enriched garlic in cancer prevention. Ip C, et al. **Adv Exp Med Biol** 1996;401:179–87 (25 ref.)

Organosulfur compounds and cancer. Lea MA. **Adv Exp Med Biol** 1996;401:147–54 (60 ref.)

Plant phenolics as potential cancer prevention agents. Newmark HL. **Adv Exp Med Biol** 1996;401:25–34 (42 ref.)

Isothiocyanates as inhibitors of esophageal cancer. Stoner GD, et al. **Adv Exp Med Biol** 1996;401:13–23 (31 ref.)

Allium vegetables and the potential for chemoprevention of cancer. Wargovich MJ, et al. **Adv Exp Med Biol** 1996; 401:171–7 (34 ref.)

Effects of tea on carcinogenesis in animal models and humans. Yang CS, et al. **Adv Exp Med Biol** 1996;401:51–61 (82 ref.)

Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Pienta KJ, et al. **Am J Clin Oncol** 1997 Feb;20(1):36–9

Eating to beat breast cancer: potential role for soy supplements. Stoll BA. **Ann Oncol** 1997 Mar;8(3):223–5

Retinyl ethers as cancer chemopreventive agents. Suppression of mammary cancer. Shealy YF, et al. **Anticancer Drug Des** 1997 Jan;12(1):15–33

Anticarcinogenic and antimetastatic activity of Iscador. Kuttan G, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S15–6

Chemoprevention of mammary cancer by diallyl selenide, a novel organoselenium compound. el-Bayoumy K, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2911–5

Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Birt DF, et al. **Anticancer Res** 1997 Jan–Feb;17(1A):85–91

N-(4-hydroxyphenyl)retinamide prevents development of T-lymphomas in AKR/J mice. Chan LN, et al. **Anticancer Res** 1997 Jan–Feb;17(1A):499–503

Protection by indomethacin and aspirin against genotoxicity of ochratoxin A, particularly in the urinary bladder and kidney. Obrecht-Pflumio S, et al. **Arch Toxicol** 1996; 70(3–4):244–8

Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low-dose EPA and DHA. Noguchi M, et al. **Br J Cancer** 1997;75(3):348–53

Effects of lycopene-enriched tomato oleoresin on 7,12-dimethyl-benz[a]anthracene-induced rat mammary tumors. Sharoni Y, et al. **Cancer Detect Prev** 1997; 21(2):118–23

Lack of effect of daily N-acetylcysteine supplementation on mutagen sensitivity. Cloos J, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Nov;5(11):941–4

Potential preventive effects of Chelidonium majis L. (Papaveraceae) herb extract on glandular stomach tumor development in rats treated with N-methyl-N'-nitro-N nitrosoguanidine (MNNG) and hypertonic sodium chloride. Kim DJ, et al. **Cancer Lett** 1997 Jan 30; 112(2):203–8

Combination of melatonin and tamoxifen as a chemoprophylaxis against N-nitroso-N-methylurea-induced rat mammary tumors. Kothari A, et al. **Cancer Lett** 1997 Jan 1;111(1–2):59–66

Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses. Moglia D, et al. **Cancer Lett** 1996 Dec 20;110(1–2):87–91

Effect of Sobatum on tumour development and chemically induced carcinogenesis. Mohanan PV, et al. **Cancer Lett** 1997 Jan 30;112(2):219–23

Inhibition of aflatoxin B1-induced initiation of hepatocarcinogenesis in the rat by green tea. Qin G, et al. **Cancer Lett** 1997 Jan 30;112(2):149–54

Protective effect of food additives on aflatoxin-induced mutagenicity and hepatocarcinogenicity. Soni KB, et al. **Cancer Lett** 1997 May 19;115(2):129–33

Clinical studies in head and neck cancer chemoprevention. Gonzalez PM, et al. **Cancer Metastasis Rev** 1996 Mar; 15(1):113–8 (35 ref.)

Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. Gerhäuser C, et al. **Cancer Res** 1997 Jan 15;57(2):272–8

Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Gottardis MM, et al. **Cancer Res** 1996 Dec 15;56(24):5566–70

1,4-phenylenebis(methylene)selenocyanate exerts exceptional chemopreventive activity in rat tongue carcinogenesis. Tanaka T, et al. **Cancer Res** 1997 Sep 1;57(17):3644–8

Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in combination. Tanaka T, et al. **Cancer Res** 1997 Jan 15;57(2):246–52

Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Udeani GO, et al. **Cancer Res** 1997 Aug 15;57(16):3424–8

Characterization of early pulmonary hyperproliferation and tumor progression and their inhibition by black tea in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model with A/J mice. Yang G, et al. **Cancer Res** 1997 May 15;57(10):1889–94

Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Castonguay A, et al. **Carcinogenesis** 1997 Mar;18(3):491–6

Bifidobacterium longum and lactulose suppress azoxymethane-induced colonic aberrant crypt foci in rats. Challa A, et al. **Carcinogenesis** 1997 Mar;18(3):517–21

Organ specific, protocol dependent modulation of 7,12-dimethylbenz[a]anthracene carcinogenesis in rainbow trout (Oncorhynchus mykiss) by dietary ellagic acid. Harttig U, et al. **Carcinogenesis** 1996 Nov;17(11):2403–9

Chemoprevention of radiation-induced mammary tumors in rats by bezafibrate administered together with diethylstilbestrol as a promoter. Inano H, et al. **Carcinogenesis** 1996 Dec;17(12):2641–6

Protection against induction of mouse skin papillomas with low and high risk of conversion to malignancy by green tea polyphenols. Katiyar SK, et al. **Carcinogenesis** 1997 Mar;18(3):497–502

Comparative activity of N-(4-hydroxyphenyl)-all-trans-retinamide and alpha-difluoromethylornithine as inhibitors of lymphoma induction in PIM transgenic mice. McCormick DL, et al. **Carcinogenesis** 1996 Nov;17(11):2513–7

A review of mechanisms underlying anticarcinogenicity by brassica vegetables. Verhoeven DT, et al. **Chem Biol Interact** 1997 Feb 28;103(2):79–129 (220 ref.)

Successful treatment of sclerosing cervicitis and fibrosing mediastinitis with tamoxifen. Savelli BA, et al. **Chest** 1997 Apr;111(4):1137–40

Adjuvant therapy in breast cancer. Optimal use in the elderly. Plowman PN. **Drugs Aging** 1996 Sep;9(3):185–90 (20 ref.)

Cancer chemoprevention and therapy by monoterpenes. Gould MN. **Environ Health Perspect** 1997 Jun;105 Suppl 4:977–9 (15 ref.)

Positive impact of retinyl palmitate in leukoplakia of the larynx. Issing WJ, et al. **Eur Arch Otorhinolaryngol Suppl** 1997;1:S105–9

Efficacy of vitamin A in the prevention of loco-regional recurrence and second primaries in head and neck cancer. Jyothirmayi R, et al. **Eur J Cancer B Oral Oncol** 1996 Nov;32B(6):373–6

Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Kelloff GJ, et al. **Eur J Cancer Prev** 1996 Dec;5 Suppl 2:79–85

Biology of oral premalignant lesions: concepts and implications for chemoprevention. Papadimitrakopoulou VA, et al. **Eur J Cancer Prev** 1996 Dec;5 Suppl 2:87–93

Ultrasonographic appearance of endometrium in postmenopausal breast cancer patients receiving tamoxifen. Beşe T, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug; 67(2):157–62

Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. DuBois RN, et al. **Gastroenterol Clin North Am** 1996 Dec;25(4):773–91 (87 ref.)

Chemoprevention of colorectal cancer. Krishnan K, et al. **Gastroenterol Clin North Am** 1996 Dec;25(4):821–58 (219 ref.)

Long-term follow-up of larynx leukoplakia under treatment with retinyl palmitate. Issing WJ, et al. **Head Neck** 1996 Nov-Dec;18(6):560–5

Can a vitamin prevent hepatocellular carcinoma? Venook AP. **Hepatology** 1997 Jan;25(1):249–50

Evaluation of human trial design. Buiatti E. **IARC Sci Publ** 1996;(139):261–9 (30 ref.)

Chemoprevention of stomach cancer. Buiatti E, et al. **IARC Sci Publ** 1996;(136):35–9 (18 ref.)

Chemoprevention of breast cancer with tamoxifen. Cuzick J. **IARC Sci Publ** 1996;(136):95–109 (83 ref.)

Medicinal drugs with hormonal activity as chemopreventive agents. Cuzick J. **IARC Sci Publ** 1996;(139):99–114 (116 ref.)

Intervention trials on colorectal cancer prevention. Faivre J, et al. **IARC Sci Publ** 1996;(139):115–24 (27 ref.)

European intervention trials of colorectal cancer prevention. Faivre J, et al. **IARC Sci Publ** 1996;(136):45–51

Aspirin and other nonsteroid anti-inflammatory drugs as cancer-preventive agents. Greenberg ER, et al. **IARC Sci Publ** 1996;(139):91–8 (29 ref.)

The role of chemoprevention in cancer control. Greenwald P, et al. **IARC Sci Publ** 1996;(139):13–22 (44 ref.)

Why chemoprevention? Hakama M. **IARC Sci Publ** 1996; (136):1–5 (24 ref.)

Behavioural intervention versus chemoprevention. Henderson M, et al. **IARC Sci Publ** 1996;(136):123–30 (54 ref.)

Why did antioxidants not protect against lung cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study? Huttunen JK. **IARC Sci Publ** 1996;(136):63–5

Evaluation of human trial findings. Huttunen JK. **IARC Sci Publ** 1996;(139):271–6 (15 ref.)

Mechanistic considerations in the evaluation of chemopreventive data. Kelloff GJ, et al. **IARC Sci Publ** 1996;(139):203–19 (77 ref.)

Colon cancer: a USA viewpoint. Lipkin M. **IARC Sci Publ** 1996;(136):53–61 (11 ref.)

Chemoprevention of oesophageal cancer. Muñoz N, et al. **IARC Sci Publ** 1996;(136):27–33 (19 ref.)

Chemoprevention trial on precancerous lesions of the stomach in Venezuela: summary of study design and baseline data. Muñoz N, et al. **IARC Sci Publ** 1996; (139):125–33

Micronutrients (vitamins and minerals) as cancer-preventive agents. Omenn GS. **IARC Sci Publ** 1996;(139):33–45 (55 ref.)

Chemoprevention of lung cancer: the beta-Carotene and Retinol Efficacy Trial (CARET) in high-risk smokers and asbestos-exposed workers. Omenn GS, et al. **IARC Sci Publ** 1996;(136):67–85

Vegetables, fruit and phytoestrogens as preventive agents. Potter JD, et al. **IARC Sci Publ** 1996;(139):61–90 (205 ref.)

Micronutrients as chemopreventive agents. Reddy BS. **IARC Sci Publ** 1996;(139):221–35 (92 ref.)

Identifiability of food components for cancer chemoprevention. Riboli E, et al. **IARC Sci Publ** 1996; (139):23–31 (24 ref.)

Ethical issues of intervention trials in cancer. Sancho-Garnier H, et al. **IARC Sci Publ** 1996;(136):121–2

Chemoprevention of cancers of the oral cavity and the head and neck. Sankaranarayanan R, et al. **IARC Sci Publ** 1996; (136):13–25 (72 ref.)

Retinoids as cancer-preventive agents. Sankaranarayanan R, et al. **IARC Sci Publ** 1996;(139):47–59 (94 ref.)

Demonstration of organotropic effects of chemopreventive agents in multiorgan carcinogenesis models. Tsuda H, et al. **IARC Sci Publ** 1996;(139):143–50

Chemoprevention of breast cancer with fenretinide. Veronesi U, et al. **IARC Sci Publ** 1996;(136):87–94 (39 ref.)

Interpretation of short-term test data: implications for assessment of chemopreventive activity. Waters MD, et al. **IARC Sci Publ** 1996;(139):313–32 (105 ref.)

Inhibition of tumorigenesis in animals. Wattenberg LW. **IARC Sci Publ** 1996;(139):151–8 (43 ref.)

Chemoprevention research in Europe. Hakama M. **Int J Cancer** 1997;Suppl 10:30–3 (13 ref.)

Chemoprevention: will it work? Mettlin C. **Int J Cancer** 1997; Suppl 10:18–21 (35 ref.)

Clinical development plan: (+)-vorozole. **J Cell Biochem Suppl** 1996;26:308–15

Clinical development plan: curcumin. **J Cell Biochem Suppl** 1996;26:72–85

Clinical development plan: 13-cis-retinoic acid. **J Cell Biochem Suppl** 1996;26:168–201

Clinical development plan: l-Selenomethionine. **J Cell Biochem Suppl** 1996;26:202–18

Clinical development plan: 1,4-penylenebis(methylene)selenocyanate. **J Cell Biochem Suppl** 1996;26:219–26

Clinical development plan: sulindac sulfone. **J Cell Biochem Suppl** 1996;26:227–35

Clinical development plan: tea extracts. Green tea polyphenols. Epigallocatechin gallate. **J Cell Biochem Suppl** 1996;26:236–57

Clinical development plan: ursodiol. **J Cell Biochem Suppl** 1996;26:258–68

Clinical development plan: vitamin A. **J Cell Biochem Suppl** 1996;26:269–307

Clinical development plan: dehydroepiandrosterone (DHEA). **J Cell Biochem Suppl** 1996;26:86–99

Clinical development plan: folic acid. **J Cell Biochem Suppl** 1996;26:100–13

Clinical development plan: genistein. **J Cell Biochem Suppl** 1996;26:114–26

Clinical development plan: indole-3-carbinol. **J Cell Biochem Suppl** 1996;26:127–36

Clinical development plan: l-perillyl alcohol. **J Cell Biochem Suppl** 1996;26:137–48

Clinical development plan: phenethyl isothiocyanate. **J Cell Biochem Suppl** 1996;26:149–57

Clinical development plan: 9-cis-retinoic acid. **J Cell Biochem Suppl** 1996;26:158–67

Cohorts with familial disposition for colon cancers in chemoprevention trials. Burt RW. **J Cell Biochem Suppl** 1996;25:131–5 (18 ref.)

Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials. De Flora S, et al. **J Cell Biochem Suppl** 1996;25:92–8

Cancer risk factors for selecting cohorts for large-scale chemoprevention trials. Greenwald P. **J Cell Biochem Suppl** 1996;25:29–36 (37 ref.)

G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials. Hemstreet GP 3rd, et al. **J Cell Biochem Suppl** 1996;25:197–204 (46 ref.)

Risk biomarkers and current strategies for cancer chemoprevention. Kelloff GJ, et al. **J Cell Biochem Suppl** 1996;25:1–14 (73 ref.)

New agents for cancer chemoprevention. Kelloff GJ, et al. **J Cell Biochem Suppl** 1996;26:1–28 (413 ref.)

Strategy and planning for chemopreventive drug development: clinical development plans II. Kelloff GJ, et al. **J Cell Biochem Suppl** 1996;26:54–71

Classification of duct carcinoma in situ (DCIS) with a characterization of high grade lesions: defining cohorts for chemoprevention trials. Lagios MD. **J Cell Biochem Suppl** 1996;25:108–11 (21 ref.)

Inherited and acquired risk factors in colonic neoplasia and modulation by chemopreventive interventions. Lipkin M, et al. **J Cell Biochem Suppl** 1996;25:136–41 (9 ref.)

Application of molecular epidemiology to lung cancer chemoprevention. Mooney LA, et al. **J Cell Biochem Suppl** 1996;25:63–8 (33 ref.)

Ethical and scientific considerations for chemoprevention research in cohorts at genetic risk for breast cancer.

Nayfield SG. **J Cell Biochem Suppl** 1996;25:123–30
Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. Weinstein IB.
J Cell Biochem Suppl 1996;25:23–8 (19 ref.)
Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. O'Dwyer PJ, et al. **J Clin Invest** 1996 Sep 1; 98(5):1210–7
Current status of retinoids in chemoprevention of oral squamous cell carcinoma: an overview. Conley BA, et al. **J Craniomaxillofac Surg** 1996 Dec;24(6):339–45 (56 ref.)
Anticarcinogenic action of apple pectin on fecal enzyme activities and mucosal or portal prostaglandin E2 levels in experimental rat colon carcinogenesis. Tazawa K, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):33–8
Interferons in precancer and cancer prevention: where are we? Tanneberger S, et al. **J Interferon Cytokine Res** 1996 May;16(5):339–46 (113 ref.)
Re: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy trial [letter; comment] Challem JJ. **J Natl Cancer Inst** 1997 Feb 19;89(4):325–6. Comment on: J Natl Cancer Inst 1996 Nov 6;88(21):1550–9.
Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143. Homma Y, et al. **J Natl Cancer Inst** 1997 Jun 4;89(11):803–7
Tamoxifen: the herald of a new era of preventive therapeutics [editorial; comment] Jordan VC. **J Natl Cancer Inst** 1997 Jun 4;89(11):747–9. Comment on: J Natl Cancer Inst 1997 Jun 4;89(11):776–82.
Protective effects of silymarin against photocarcinogenesis in a mouse skin model. Katiyar SK, et al. **J Natl Cancer Inst** 1997 Apr 16;89(8):556–66
Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. Papadimitrakopoulou VA, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):257–8
Chemoprevention of colon cancer by organoselenium compounds and impact of high- or low-fat diets. Reddy BS, et al. **J Natl Cancer Inst** 1997 Apr 2;89(7):506–12
Cows' milk fat components as potential anticarcinogenic agents. Parodi PW. **J Nutr** 1997 Jun;127(6):1055–60 (71 ref.)
Lack of inhibitory effect of benzyl isothiocyanate on 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP)-induced mammary carcinogenesis in rats. Ino N, et al. **J Toxicol Sci** 1996 Aug;21(3):189–94
Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group [see comments] [published erratum appears in JAMA 1997 May 21;277(19):1520] Clark LC, et al. **JAMA** 1996 Dec 25;276(24):1957–63. Comment in: JAMA 1996 Dec 25;276(24):1984–5. Comment in: JAMA 1997 Mar 19;277(11):880; discussion 881. Comment in: JAMA 1997 Mar 19;277(11):880–1; discussion 881.
Selenium and cancer prevention. Promising results indicate further trials required [editorial; comment] Colditz GA. **JAMA** 1996 Dec 25;276(24):1984–5. Comment on: JAMA 1996 Dec 25;276(24):1957–63.
Auraptene, a citrus coumarin, inhibits 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in ICR mouse skin, possibly through suppression of superoxide generation in leukocytes. Murakami A, et al. **Jpn J Cancer Res** 1997 May;88(5):443–52
Suppressive effects of S-methyl methanethiosulfonate on promotion stage of diethylnitrosamine-initiated and phenobarbital-promoted hepatocarcinogenesis model. Sugie S, et al. **Jpn J Cancer Res** 1997 Jan;88(1):5–11
Conjugated linoleic acid and linoleic acid are distinctive modulators of mammary carcinogenesis. Ip C, et al. **Nutr Cancer** 1997;27(2):131–5
Effect of soya bean saponins on azoxymethane-induced preneoplastic lesions in the colon of mice. Koratkar R, et al. **Nutr Cancer** 1997;27(2):206–9
Chemoprevention of cancer: review of the literature. Swan DK, et al. **Oncol Nurs Forum** 1997 May;24(4):719–27 (48 ref.)
Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Sankaranarayanan R, et al. **Oral Oncol** 1997 Jul;33(4):231–6
Influence of vehicle, distant topical delivery, and biotransformation on the chemopreventive activity of apigenin, a plant flavonoid, in mouse skin. Li B, et al. **Pharm Res** 1996 Oct;13(10):1530–4
Anti-tumor promoting activities of lantadenes on mouse skin tumors and mouse hepatic tumors [letter] Inada A, et al. **Planta Med** 1997 Jun;63(3):272–4
Surveillance and intervention studies on respiratory cancers in asbestos-exposed workers. Merler E, et al. **Scand J Work Environ Health** 1997 Apr;23(2):83–92 (86 ref.)
Inhibitory effects of phenolic compounds on development of naturally occurring preneoplastic hepatocytic foci in long-term feeding studies using male F344 rats. Hagiwara A, et al. **Teratog Carcinog Mutagen** 1996;16(6):317–25
Chemoprevention of colorectal cancer. Biasco G. **Tumori** 1997 Jan-Feb;83(1 Suppl):S5–6 (15 ref.)
[The virtues of grapes] Bonard EC.
Rev Med Suisse Romande 1997 Apr;117(4):357–8 **(Fre)**
[Results and perspectives in the chemoprophylaxis of cancer] Aleksandrov VA. **Vopr Onkol** 1997;43(1):124–9 (13 ref.) **(Rus)**

TOXICITY

Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells). Styles JA, et al. **Carcinogenesis** 1997 Feb; 18(2):303–13
Cytotoxicity and genotoxicity of diallyl sulfide and diallyl disulfide towards Chinese hamster ovary cells. Musk SR, et al. **Food Chem Toxicol** 1997 Mar-Apr;35(3-4):379–85
Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, a potential chemopreventive agent. Crowell JA, et al. **Fundam Appl Toxicol** 1997 Jan;35(1):9–21
Teratogenicity of a single oral dose of retinyl palmitate in the rat, and the role of dietary vitamin A status. Piersma AH, et al. **Pharmacol Toxicol** 1996 Sep;79(3):131–5

URINE

Determination of melanotan II in rabbit urine using solid-phase extraction sample preparation followed by reversed-phase high-performance liquid chromatography. Walters AE, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1-2):99–103

ANTICARDIOLIPIN ANTIBODIES see **ANTIBODIES, ANTICARDIOLIPIN**

ANTICESTODAL AGENTS

ADVERSE EFFECTS

Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery. Sathyanarayana MV, et al. **Indian J Gastroenterol** 1996 Jul;15(3):104
Cetrimide overdose [letter] Bax NM, et al. **Surg Endosc** 1997 Sep;11(9):967–9

ANALYSIS

Application of differential scanning calorimetry and high performance liquid chromatography to determine the effects of mixture composition and preparation during the evaluation of niclosamide-excipient compatibility. Malan CE, et al. **J Pharm Biomed Anal** 1997 Jan;15(4):549–57
Estimation of anthelmintic compound 81/470 in cow's milk by high-performance liquid chromatography: method development and validation. Nagaraja NV, et al. **J Pharm Biomed Anal** 1997 May;15(8):1175–80

CHEMICAL SYNTHESIS

[The search for new antiparasitic agents. 17. The synthesis and study of the anti-echinococcal activity of the new preparation G-1697] Mikhallitsyn FS, et al.
Med Parazitol (Mosk) 1996 Jul-Sep;(3):38–42 (Eng. Abstr.) **(Rus)**
[The technology for manufacturing antiparasitic preparations. 6. The development of a technology for producing the anthelmintic Azinox (praziquantel) and the evaluation of its toxic and anthelmintic properties] Mikhallitsyn FS, et al. **Med Parazitol (Mosk)** 1996 Oct-Dec;(4):36–9 (Eng. Abstr.) **(Rus)**
[The technology for manufacturing antiparasitic preparations. 7. Preparation G-1460 and its use for the treatment of monieziasis and intestinal nematodiases] Petrov IuF, et al. **Med Parazitol (Mosk)** 1996 Oct-Dec;(4):40–2 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Cestocidal activity of Acacia auriculiformis. Ghosh NK, et al. **J Helminthol** 1996 Jun;70(2):171–2

ANTICHOLESTEREMIC AGENTS

Antihypercholesterolemic action of taurine on streptozotocin-diabetic rats or on rats fed a high cholesterol diet. Nanami K, et al. **Adv Exp Med Biol** 1996;403:561–8
Healthcare decisions and product labeling: results of a consumer comprehension study of prototype labeling for proposed over-the-counter cholestyramine. Friedman CP, et al. **Am J Med** 1997 Feb 17;102(2A):50–6
The cholesterol-lowering properties of a psyllium-based breakfast cereal in hamsters. Hicks VA, et al. **Artery** 1995; 21(6):352–61
A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Bakker-Arkema RG, et al. **Atherosclerosis** 1997 May;131(1):17–23 (31 ref.)
Environmental estrogens: effects on cholesterol lowering and bone in the ovariectomized rat. Dodge JA, et al. **J Steroid Biochem Mol Biol** 1996 Oct;59(2):155–61
FDA and Pharmanex clash over dietary supplemen. [news] **Nat Biotechnol** 1997 Jun;15(6):489
Fat substitute tastes good, say Penn State investigators [news] **Oncology (Huntingt)** 1996 Oct;10(10):1528
Dredging the digestive system [news] Gibbs WW. **Sci Am** 1997 Apr;276(4):38
Approaches for the design of novel anti-atherogenic compounds. Biessen EA, et al. **Subcell Biochem** 1997; 28:507–39 (204 ref.)
[Zocor and Sotacor (letter)] Tonstad S.
Tidsskr Nor Laegeforen 1997 Mar 20;117(8):1187 **(Nor)**

ADMINISTRATION & DOSAGE

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Davidson MH, et al. **Am J Cardiol** 1997 Jan 1;79(1):38–42
Changes in serum lipids when fluvastatin is substituted for lovastatin in the same doses. Rindone JP, et al. **Am J Cardiol** 1997 Aug 1;80(3):348–9
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs [editorial] Roberts WC. **Am J Cardiol** 1997 Jul 1; 80(1):106–7
Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group. Tamura A, et al. **Am J Cardiol** 1997 Apr 1;79(7):893–6
The use of alternate-day lovastatin in hypercholesterolemic men. Dennis VC, et al. **Ann Pharmacother** 1997 Jun; 31(6):708–12
Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs. Wiklund O, et al. **Atherosclerosis** 1996 Jan 5;119(1):57–67
Effects of lovastatin on the fatty acid desaturation in a human lung mucoepidermoid carcinoma grown in nude mice. de Bravo MG, et al. **Biochem Mol Biol Int** 1996 Apr; 38(5):929–35
Cholesterol lowering and cerebrospinal fluid neurotransmitters: increased levels of the anxiogenic cholecystokinin-tetrapeptide during simvastatin administration to healthy male volunteers. Eriksson M, et al. **Biol Psychiatry** 1996 Aug 15;40(4):302–4
Simvastatin inhibits myointimal hyperplasia following carotid artery injury in cholesterol-fed rabbits. Dol F, et al. **Blood Coagul Fibrinolysis** 1996 Nov;7(8):772–8
Hypolipidaemic, gastrointestinal and related responses of broiler chickens to chitosans of different viscosity. Razdan A, et al. **Br J Nutr** 1996 Sep;76(3):387–97
Broiler chicken body weights, feed intakes, plasma lipid and small-intestinal bile acid concentrations in response to feeding of chitosan and pectin. Razdan A, et al. **Br J Nutr** 1997 Aug;78(2):283–91
Dietary phytosterols as cholesterol-lowering agents in humans. Jones PJ, et al. **Can J Physiol Pharmacol** 1997 Mar;75(3):217–27 (40 ref.)
Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol. Sasaki S, et al. **Cardiology** 1997 Mar-Apr;88(2):160–5
Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS). Aengevaeren WR, et al. **Circulation** 1997 Jul 15;96(2):429–35
Psyllium husk fiber supplementation to the diets rich in soybean or coconut oil: hypocholesterolemic effect in healthy humans. Ganji V, et al. **Int J Food Sci Nutr** 1996 Mar;47(2):103–10
Effects of an HMG-CoA reductase inhibitor, pravastatin, and bile sequestering resin, cholestyramine, on plasma plant sterol levels in hypercholesterolemic subjects. Hidaka H, et al. **J Atheroscler Thromb** 1995;2(1):60–5
Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. McCrindle BW, et al. **J Pediatr** 1997 Feb;130(2):266–73
Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction. Lorena M, et al. **Thromb Res** 1997 Aug 15;87(4):397–403
[Cholesterol depression prevents heart disease (editorial)] Faergeman O, et al. **Ugeskr Laeger** 1997 Apr 7;159(15):2193 **(Dan)**
[Statin in the prevention of ischaemic heart disease (see comments)] Haastrup B, et al. **Ugeskr Laeger** 1997 Jan 13; 159(3):308–9. Comment in: Ugeskr Laeger 1997 Apr 28;159(18):2719–21. **(Dan)**
[Diet and secondary prevention of ischemic heart disease (letter)] Stender S, et al. **Ugeskr Laeger** 1997 Feb 17; 159(8):1119–21 **(Dan)**
[Value of the CSE-inhibitor Pravastatin in the lowering of cholesterol after heart and kidney transplantation] **Dtsch Med Wochenschr** 1997 Jan;122(3 Suppl):1–7 **(Ger)**
[Care Study. Secondary prevention after myocardial infarct in moderately elevated total cholesterol] Bönner G. **Fortschr Med** 1997 Jun 20;115(17):57–8 **(Ger)**
[Rationale for lipid therapy. Prevention or treatment of coronary heart disease?] Windler E, et al. **Herz** 1997 Jun; 22(3):125–33 (40 ref.) (Eng. Abstr.) **(Ger)**
[Long term treatment of moderate to severe hypercholesterolemia with low dose statin. Comparison of simvastatin and pravastatin] Spagnolli W, et al. **Recenti Prog Med** 1996 Nov;87(11):538–42 (Eng. Abstr.) **(Ita)**
[Influence of low high-density lipoprotein cholesterolemia induced by probucol on the progression of coronary atherosclerosis] Takahashi T, et al. **J Cardiol** 1997 Aug; 30(2):67–72 (Eng. Abstr.) **(Jpn)**
[Cholesterol lowering therapy after myocardial infarction. Consequences of the CARE study] Otterstad JE, et al. **Tidsskr Nor Laegeforen** 1997 Jun 20;117(16):2341–4 (Eng. Abstr.) **(Nor)**
[A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia]

ANTICHOLESTEREMIC AGENTS

Zambrana García JL, et al. **Rev Esp Cardiol** 1996 Dec; 49(12):892–8 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Lovastatin–induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Grunden JW, et al. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):859–63

HMG–CoA reductase inhibitor–induced impotence [letter] [see comments] Halkin A, et al. **Ann Pharmacother** 1996 Feb;30(2):192. Comment in: Ann Pharmacother 1996 Oct;30(10):1199.

Effect of withdrawal of pravastatin on biliary lipid composition in humans. Muraca M, et al. **Atherosclerosis** 1996 Jun;123(1–2):133–7

Depression and cholesterol–lowering chemotherapy: potential influence of smoking cessation, depression history, and dietary change [comment] Cinciripini PM. **Behav Med** 1996 Summer;22(2):85–6. Comment on: Behav Med 1996 Summer;22(2):82–4.

Increases in depression after cholesterol–lowering drug treatment [see comments] Davidson KW, et al. **Behav Med** 1996 Summer;22(2):82–4. Comment in: Behav Med 1996 Summer;22(2):85–6.

Risks of cholesterol–lowering therapies [letter] Hibbeln JR, et al. **Biol Psychiatry** 1996 Oct 1;40(7):686–7

Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo–controlled study. Oxford Cholesterol Study Group. Keech AC, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):483–90

Japanese and American reports of randomized trials: differences in the reporting of adverse effects. Hayashi K, et al. **Control Clin Trials** 1996 Apr;17(2):99–110

Hepatotoxicity of anticholesterol, cardiovascular, and endocrine drugs and hormonal agents. Lahoti S, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):907–22 (111 ref.)

Statin drugs: a double–edged sword? [letter; comment] Levin WM. **Hosp Pract (Off Ed)** 1997 Aug 15;32(8):44. Comment on: Hosp Pract (Off Ed) 1996 Jun 15;31(6):43–8, 53–5, 59; discussion 60.

Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E–deficient mice. Zhang SH, et al. **J Clin Invest** 1997 Jun 15;99(12):2858–66

Petechial eruptions due to simvastatin in a patient with diabetes mellitus and liver cirrhosis [letter] Horiuchi Y, et al. **J Dermatol** 1997 Aug;24(8):549–51

Polymyositis associated with simvastatin [letter] Giordano N, et al. **Lancet** 1997 May 31;349(9065):1600–1

Myoglobinuric renal failure due to long–standing lovastatin therapy in a patient with pre–existing chronic renal insufficiency [see comments] Biesenbach G, et al. **Nephrol Dial Transplant** 1996 Oct;11(10):2059–60. Comment in: Nephrol Dial Transplant 1996 Oct;11(10):1951–2.

Lovastatin–associated dermatomyositis [letter] Rodriguez–Garcia JL, et al. **Postgrad Med J** 1996 Nov; 72(853):694

Environmental hazard assessment of pharmaceuticals. Henschel KP, et al. **Regul Toxicol Pharmacol** 1997 Jun; 25(3):220–5

Prenatal exposures to lovastatin and simvastatin [letter; comment] Lione A. **Reprod Toxicol** 1997 Jul–Aug; 11(4):641–2. Comment on: Reprod Toxicol 1996 Nov–Dec;10(6):439–46.

Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy [see comments] Manson JM, et al. **Reprod Toxicol** 1996 Nov–Dec;10(6):439–46. Comment in: Reprod Toxicol 1997 Jul–Aug;11(4):641–2.

[Simvastatin and pregnancy] Freyssinges C, et al. **Therapie** 1996 Sep–Oct;51(5):537–42 (Eng. Abstr.) **(Fre)**

ANALYSIS

Micellar electrokinetic chromatography stability indicating assay and content uniformity determination for a cholesterol–lowering drug product. Bretnall AE, et al. **J Pharm Biomed Anal** 1997 May;15(8):1071–5

BLOOD

Determination of fluvastatin enantiomers and the racemate in human blood plasma by liquid chromatography and fluorometric detection. Toreson H, et al. **J Chromatogr A** 1996 Apr 5;729(1–2):13–8

Determination of simvastatin and its active metabolite in human plasma by column–switching high–performance liquid chromatography with fluorescence detection after derivatization with 1–bromoacetylpyrene. Ochiai H, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20;694(1):211–7

Enzyme–linked immunosorbent assay of pravastatin, a HMG–CoA reductase inhibitor, in human plasma. Muramatsu S, et al. **J Immunoassay** 1996 Feb;17(1):13–27

CHEMICAL SYNTHESIS

Inhibitors of acyl–CoA:cholesterol acyltransferase: novel trisubstituted ureas as hypocholesterolemic agents. Purchase TS, et al. **Bioorg Med Chem** 1997 Apr;5(4):739–47

Preparation and pharmacological activities of spiro[3,4–dihydro–6/7–R–1,2,4–benzotriazine–3,4'–(1'–substituted)piperi dines] Novelli F, et al. **Farmaco** 1996 Aug–Sep;51(8–9):541–50
(1 alpha, 2 beta, 3 beta, 4 alpha)–1,2–bis[N–propyl–N–(4–phenoxybenzyl) amino]carbonyl]cyclobutane–3,4–dicarboxylic acid (A–87049): a novel potent squalene synthase inhibitor. Fung AK, et al. **J Med Chem** 1997 Jul 4;40(14):2123–5

Heterocyclic amides: inhibitors of acyl–CoA:cholesterol O–acyl transferase with hypocholesterolemic activity in several species and antiatherosclerotic activity in the rabbit. White AD, et al. **J Med Chem** 1996 Sep 27;39(20):3908–19

CHEMISTRY

2–Azetidinone cholesterol absorption inhibitors: structure–activity relationships on the heterocyclic nucleus. Clader JW, et al. **J Med Chem** 1996 Sep 13;39(19):3684–93

Heterocyclic ureas: inhibitors of acyl–CoA:cholesterol O–acyltransferase as hypocholesterolemic agents. White AD, et al. **J Med Chem** 1996 Oct 25;39(22):4382–95

ECONOMICS

Pravastatin alone and in combination with low–dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease. Ito MK, et al. **Am J Cardiol** 1997 Sep 15;80(6):799–802

Cost–effectiveness of initial therapy with 3–hydroxy–3–methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed–care organization. Spearman ME, et al. **Clin Ther** 1997 May–Jun;19(3):582–602; discussion 538–9

Cost–effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) [see comments] Jönsson B, et al. **Eur Heart J** 1996 Jul; 17(7):1001–7. Comment in: Eur Heart J 1996 Jul;17(7):974–5.

More on pravastin and coronary disease [letter; comment] Grundy SM. **N Engl J Med** 1996 Oct 17;335(16):1239–40 . Comment on: N Engl J Med 1996 May 16;334(20):1333; discussion 1334–5.

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group [see comments] Johannesson M, et al. **N Engl J Med** 1997 Jan 30;336(5):332–6. Comment in: ACP J Club 1997 Jul–Aug;127(1):21.

[Pharmaco–economic aspects of hypolipidemic treatment] Scheen AJ. **Rev Med Liege** 1997;52(1):16–21 **(Fre)**

[Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients] Berger K, et al. **Med Klin** 1997 Jun 15;92(6):363–9 (40 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Effect of lipid peroxidation products and antioxidants on the formation of probucol radical in low density lipoproteins. Shumaev KB, et al. **Biochemistry (Mosc)** 1997 Jun; 62(6):657–60

Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Boberg M, et al. **Drug Metab Dispos** 1997 Mar;25(3):321–31

Metabolism of 14C–labelled sucrose esters of stearic acid in rats. Noker PE, et al. **Food Chem Toxicol** 1997 Jun; 35(6):589–95

SK&F 97426–A: a novel bile acid sequestrant with higher affinities and slower dissociation rates for bile acids in vitro than cholestyramine. Benson GM, et al. **J Pharm Sci** 1997 Jan;86(1):76–81

Is the cholesterol–lowering effect of simvastatin influenced by CYP2D6 polymorphism? [letter] Nordin C, et al. **Lancet** 1997 Jul 5;350(9070):29–30

PHARMACOKINETICS

Steady state serum concentrations of pravastatin and digoxin when given in combination. Triscari J, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):263–5

Combination of pravastatin and cyclosporin in transplant patients [letter; comment] Christians U. **Clin Pharmacokinet** 1997 Feb;32(2):173–4. Comment on: Clin Pharmacokinet 1996 Feb;30(2):141–79.

Pharmacodynamics and pharmacokinetics of the HMG–CoA reductase inhibitors. Similarities and differences. Lennernäs H, et al. **Clin Pharmacokinet** 1997 May;32(5):403–25 (118 ref.)

Disposition of ingested olestra in weanling mini–pigs. Daher GC, et al. **Food Chem Toxicol** 1996 Aug;34(8):693–9

PHARMACOLOGY

The effect of a non–absorbable fat substitute, sucrose polyester, on gastrointestinal function. Kelly SM, et al. **Aliment Pharmacol Ther** 1996 Oct;10(5):715–20

Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Bevilacqua M, et al. **Am J Cardiol** 1997 Jan 1;79(1):84–7

Sucrose polyester does not inhibit gastric acid secretion or stimulate cholecystokinin release in men. Maas MI, et al. **Am J Clin Nutr** 1997 Mar;65(3):761–5

Pravastatin reduces carotid intima–media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Mercuri M, et al. **Am J Med** 1996 Dec;101(6):627–34

Lipid lowering: an important factor in preventing adriamycin–induced heart failure. Iliskovic N, et al. **Am J Pathol** 1997 Feb;150(2):727–34

Cholesterol based antineoplastic strategies. Lenz M, et al. **Anticancer Res** 1997 Mar–Apr;17(2A):1143–6

In vitro activity of fluvastatin, a cholesterol–lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans. Chin NX, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):850–2

Effect of policosanol on in vitro and in vivo rat liver microsomal lipid peroxidation. Fraga V, et al. **Arch Med Res** 1997 Autumn;28(3):355–60

Effect of the ACAT inhibitor CL 277,082 on apolipoprotein B48 transport in mesenteric lymph and on plasma clearance of chylomicrons and remnants. Martins IJ, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):211–6

Simvastatin reduces forearm vascular responsiveness to norepinephrine [letter] Abbott D, et al. **Atherosclerosis** 1997 Jun;131(2):263–4

SR–12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis. Berkhout TA, et al. **Atherosclerosis** 1997 Sep;133(2):203–12

Probucol reduces hepatic cholesterol secretion in hyperlipidemic Yoshida rats. Bravo E, et al. **Atherosclerosis** 1996 Jan 26;119(2):223–33

Hypocholesterolemic effect of sesame lignan in humans [letter] Hirata F, et al. **Atherosclerosis** 1996 Apr 26; 122(1):135–36

ACAT inhibitor HL–004 accelerates the regression of hypercholesterolemia in stroke–prone spontaneously hypertensive rats (SHRSP): stimulation of bile acid production by HL–004. Murakami S, et al. **Atherosclerosis** 1997 Aug;133(1):97–104

Simvastatin increases plasma NO2– and NO3– levels in patients with hypercholesterolemia. Nakashima Y, et al. **Atherosclerosis** 1996 Nov 15;127(1):43–7

Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG–CoA reductase inhibitors in familial hypercholesterolaemia. Naoumova RP, et al. **Atherosclerosis** 1996 Jan 26;119(2):203–13

Effect of tincture of Crataegus on the LDL–receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Rajendran S, et al. **Atherosclerosis** 1996 Jun; 123(1–2):235–41

The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Regnström J, et al. **Atherosclerosis** 1996 Sep 6;125(2):217–29

Hypocholesterolemic effect of lycopene and beta–carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. Fuhrman B, et al. **Biochem Biophys Res Commun** 1997 Apr 28;233(3):658–62

Inhibition of proliferation of human smooth muscle cells by various HMG–CoA reductase inhibitors; comparison with other human cell types. Nègre–Aminou P, et al. **Biochim Biophys Acta** 1997 Apr 21;1345(3):259–68

Peroxisome proliferator–activated receptor (PPAR)–dependent and –independent transcriptional modulation of several non–peroxisomal genes by peroxisome proliferators. Motojima K. **Biochimie** 1997 Feb–Mar;79(2–3):101–6

Enhancement of oral bioavailability and pharmacological effect of 1–(3,4–dimethoxyphenyl)–2,3–bis(methoxycarbonyl)–4–hydroxy–6,7,8– trimethoxynaphthalene (TA–7552), a new hypocholesterolemic agent, by micronization in co–ground mixture with D–mannitol. Kubo H, et al. **Biol Pharm Bull** 1996 May;19(5):741–7

Alterations by clofibric acid of metabolism of phosphatidylethanolamine in rat–liver. Mizuguchi H, et al. **Biol Pharm Bull** 1996 Sep;19(9):1115–20

Drug interaction between simvastatin and cholestyramine in vitro and in vivo. Nakai A, et al. **Biol Pharm Bull** 1996 Sep;19(9):1231–3

Anti–hyperlipidemic and anti–atherosclerotic actions of shosaikoto (kampo medicine). Shen YR, et al. **Biol Pharm Bull** 1996 Sep;19(9):1160–5

Effect of Shosaikoto (Kampo medicine) on the adherence of monocytes in hypercholesterolemic rabbit. Shen YR, et al. **Biol Pharm Bull** 1996 Jan;19(1):149–52

Cholesterol–lowering effects of policosanol in rabbits. Arruzazabala ML, et al. **Biol Res** 1994;27(3–4):205–8

Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Menendez R, et al. **Biol Res** 1994; 27(3–4):199–203

Rice bran oil and human health. Sugano M, et al. **Biomed Environ Sci** 1996 Sep;9(2–3):242–6 (24 ref.)

Comparison of hypolipidemic effect of refined konjac meal with several common dietary fibers and their mechanisms of action. Wu J, et al. **Biomed Environ Sci** 1997 Mar; 10(1):27–37

The effects of combined treatment with beta 1–selective receptor antagonists and lipid–lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo–controlled study in healthy subjects. Eagles CJ, et al. **Br J Clin Pharmacol** 1997 Mar; 43(3):291–300

Cholesterol–lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch–casein diet. Menéndez R, et al. **Br J Nutr** 1997 Jun;77(6):923–32

Differences in hypolipidaemic effects of two statins on Hep

G2 cells or human hepatocytes in primary culture. Clerc T, et al. **Br J Pharmacol** 1996 Aug;118(7):1862–8

Action of probucol in arteries from normal and hypercholesterolaemic rabbits. Del Rio M, et al. **Br J Pharmacol** 1996 Aug;118(7):1639–44

Inhibitory effects of fluvastatin, a new HMG–CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol–fed rabbits. Mitani H, et al. **Br J Pharmacol** 1996 Nov;119(6):1269–75

Increased oxysterol contents in diabetic rat hearts: their involvement in diabetic cardiomyopathy. Matsui H, et al. **Can J Cardiol** 1997 Apr;13(4):373–9

Non–lipid–related effects of 3–hydroxy–3–methylglutaryl coenzyme A reductase inhibitors. Corsini A, et al. **Cardiology** 1996 Nov–Dec;87(6):458–68

Lovastatin lowers serum cholesterol levels in non–insulin–dependent diabetes mellitus patients without altering their insulin sensitivity. Hwu CM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Mar; 57(3):169–76

Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Reckless J, et al. **Circulation** 1997 Mar 18;95(6):1542–8

Cholesterol lowering: perspectives on the 4S and West of Scotland studies. Olin JW. **Cleve Clin J Med** 1996 Mar–Apr;63(2):80–3

The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Human JA, et al. **Clin Chim Acta** 1997 Jul 4;263(1):67–77

Effect of lovastatin and fluoromevalonate on phosphatidylinositol 3–kinase activity stimulated with PDGF. Iwama A, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S318–20

HMG–CoA reductase inhibitor affects blood pressure and vascular reactivity. Li N, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S316–7

Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine. Carrilho AJ, et al. **Clin Pharmacol Ther** 1997 Jul;62(1):82–8

Multiple–dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG–CoA reductase, in healthy subjects. Cilla DD Jr, et al. **Clin Pharmacol Ther** 1996 Dec;60(6):687–95

Inhibition of cholesterol absorption with CP–148,623 lowers serum cholesterol in humans. Harris WS, et al. **Clin Pharmacol Ther** 1997 Mar;61(3):385–9

3–Hydroxy–3–methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Huff MW, et al. **Curr Opin Lipidol** 1997 Jun;8(3):138–45 (74 ref.)

Effects of systemic treatment with statins on skin barrier function and stratum corneum water–holding capacity. Brazzelli V, et al. **Dermatology** 1996;192(3):214–6

Induction of cytochrome P4503A by the antiglucocorticoid mifepristone and a novel hypocholesterolaemic drug. Williams JA, et al. **Drug Metab Dispos** 1997 Jun; 25(6):757–61

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Haria M, et al. **Drugs** 1997 Feb;53(2):299–336 (267 ref.)

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Plosker GL, et al. **Drugs** 1996 Mar;51(3):433–59 (130 ref.)

Effects of reduced maternal lipoprotein–cholesterol availability on placental progesterone biosynthesis in the baboon. Henson MC, et al. **Endocrinology** 1997 Apr; 138(4):1385–91

Enhancement of membrane fluidity in cholesterol–poor endothelial cells pre–treated with simvastatin. Morita I, et al. **Endothelium** 1997;5(2):107–13

High–density lipoproteins from probucol–treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low–density lipoproteins. Ishigami M, et al. **Eur J Clin Invest** 1997 Apr;27(4):285–92

Effects of pravastatin on plasma and urinary mevalonate concentrations in subjects with familial hypercholesterolaemia: a comparison of morning and evening administration. Nozaki S, et al. **Eur J Clin Pharmacol** 1996;49(5):361–4

Effects of single administration of pravastatin sodium on hepatic cholesterol metabolism in rats. Fujioka T, et al. **Eur J Pharmacol** 1997 Apr 4;323(2–3):223–8

Fertility and general reproduction studies in rats with the HMG–CoA reductase inhibitor, atorvastatin. Dostal LA, et al. **Fundam Appl Toxicol** 1996 Aug;32(2):285–92

Pravastatin affects blood pressure and vascular reactivity. Li N, et al. **Heart Vessels** 1996;11(2):64–8

Hypocholesterolemic efficacy of garlic–smelling flower Adenocalymma alliaceum Miers. in experimental rats. Srinivasan MR, et al. **Indian J Exp Biol** 1995 Jan;33(1):64–6

Influence of cholestyramine on the pharmacokinetics of cerivastatin. Mück W, et al. **Int J Clin Pharmacol Ther** 1997 Jun;35(6):250–4

Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. Chen L, et al. **J Am Coll Cardiol** 1997 Aug; 30(2):569–75

Simvastatin further enhances the hypocholesterolemic effect of soy protein in rabbits. Giroux I, et al. **J Am Coll Nutr** 1997 Apr;16(2):166–74

Biological activities of novel zaragozic acids, the potent inhibitors of squalene synthase, produced by the fungus, Mollisia sp. SANK 10294. Tanimoto T, et al. **J Antibiot (Tokyo)** 1997 May;50(5):390–4

Farnesol–derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. Bostedor RG, et al. **J Biol Chem** 1997 Apr 4;272(14):9197–203

Inhibition of isoprenoid biosynthesis and arterial smooth–muscle cell proliferation. Soma MR, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 4:S20–4

Rate of low–density lipoprotein cholesterol and apolipoprotein B changes on initiation and discontinuation of atorvastatin treatment. Stern RH, et al. **J Clin Pharmacol** 1997 Apr;37(4):291–6

Relation of green tea consumption to serum lipids and lipoproteins in Japanese men. Kono S, et al. **J Epidemiol** 1996 Sep;6(3):128–33

The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering. Hughes AD. **J Hum Hypertens** 1996 Jun;10(6):387–90 (37 ref.)

Effect of hypocholesterolemic doses of 17 alpha–ethinyl estradiol on cholesterol balance in liver and extrahepatic tissues. Bertolotti M, et al. **J Lipid Res** 1996 Aug; 37(8):1812–22

LY295427, a novel hypocholesterolemic agent, enhances [3H]25–hydroxycholesterol binding to liver cytosolic proteins. Bowling N, et al. **J Lipid Res** 1996 Dec; 37(12):2586–98

Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. Conde K, et al. **J Lipid Res** 1996 Nov;37(11):2372–82

Additive hypocholesterolemic effect of psyllium and cholestyramine in the hamster: influence on fecal sterol and bile acid profiles. Daggy BP, et al. **J Lipid Res** 1997 Mar;38(3):491–502

Hypocholesterolemic action of beta–cyclodextrin and its effects on cholesterol metabolism in pigs fed a cholesterol–enriched diet. Férézou J, et al. **J Lipid Res** 1997 Jan;38(1):86–100

Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non–insulin–dependent diabetic men. Gylling H, et al. **J Lipid Res** 1996 Aug;37(8):1776–85

Normal and inhibited cholesterol synthesis in the cultured rat embryo. Llirbat B, et al. **J Lipid Res** 1997 Jan; 38(1):22–34

Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. Naoumova RP, et al. **J Lipid Res** 1997 Jul;38(7):1496–500

Quantitative analysis of hydrophobic amine inhibition of intracellular cholesterol transport. Underwood KW, et al. **J Lipid Res** 1996 Jul;37(7):1556–68

Inhibitors of acyl–CoA: cholesterol O–acyl transferase (ACAT) as hypocholesterolemic agents. CI–1011: an acyl sulfamate with unique cholesterol–lowering activity in animals fed noncholesterol–supplemented diets. Lee HT, et al. **J Med Chem** 1996 Dec 20;39(26):5031–4

Rice bran oil and cholesterol metabolism. Sugano M, et al. **J Nutr** 1997 Mar;127(3):521S–524S (27 ref.)

Dietary eritadenine modifies plasma phosphatidylcholine molecular species profile in rats fed different types of fat. Sugiyama K, et al. **J Nutr** 1997 Apr;127(4):593–9

Effect of policosanol on foam–cell formation in carrageenan–induced granulomas in rats. Noa M, et al. **J Pharm Pharmacol** 1996 Mar;48(3):306–9

RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol–lowering agent: comparison with inhibitors of HMG–CoA reductase. Amin D, et al. **J Pharmacol Exp Ther** 1997 May;281(2):746–52

Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. Kauffman RF, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):146–53

Evidence for more benefits of cholesterol–lowering drugs [news] Skolnick AA. **JAMA** 1997 Oct 1;278(13):1053

Pharmacological properties of YM17E, an acyl–CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs. Kashiwa M, et al. **Jpn J Pharmacol** 1997 Jan;73(1):41–50

Plasma cholesterol reducing effect of FR129169, a novel acyl–CoA:cholesterol acyltransferase inhibitor, in the rat. Sakuma Y, et al. **Jpn J Pharmacol** 1996 Jan;70(1):35–41

Inhibitor of proliferation of arterial smooth–muscle cells by fluvastatin [letter] Corsini A, et al. **Lancet** 1996 Dec 7; 348(9041):1584

Beneficial effects of statins. GISSI–Prevenzione Investigators [letter; comment] Marchioli R, et al. **Lancet** 1996 Dec 7; 348(9041):1582. Comment on: Lancet 1996 Oct 19;348(9034):1079–82.

Beneficial effects of statins [letter; comment] Mikhailidis DP, et al. **Lancet** 1996 Dec 7;348(9041):1582–3. Comment on: Lancet 1996 Oct 19;348(9034):1079–82.

Beneficial effects of statins [letter; comment] Rosenson RS, et al. **Lancet** 1996 Dec 7;348(9041):1583. Comment on: Lancet 1996 Oct 19;348(9034):1079–82.

S–8921, an ileal Na+/bile acid cotransporter inhibitor decreases serum cholesterol in hamsters. Hara S, et al. **Life Sci** 1997;60(24):PL 365–70

Decrease in oral bioavailability of cyclosporin A by coadministration of probucol in rats. Sugimoto K, et al. **Life Sci** 1997;60(3):173–9

Comparative hypocholesterolemic effects of six vegetable oils in cholesterol–fed rat. Fukushima M, et al. **Lipids** 1996 Apr; 31(4):415–9

Comparative hypocholesterolemic effects of capybara (Hydrochoerus hydrochaeris dabbenei) oil, horse oil, and sardine oil in cholesterol–fed rats. Fukushima M, et al. **Lipids** 1997 Apr;32(4):391–5

Dietary eritadenine–induced alteration of molecular species composition of phospholipids in rats. Sugiyama K, et al. **Lipids** 1996 Apr;31(4):399–404

Correlation of suppressed linoleic acid metabolism with the hypocholesterolemic action of eritadenine in rats. Sugiyama K, et al. **Lipids** 1997 Aug;32(8):859–66

Lovastatin decreases prolactin and growth hormone gene expression in GH4C1 cells through a cAMP dependent mechanism. Lasa M, et al. **Mol Cell Endocrinol** 1997 Jun 20;130(1–2):93–100

Rat 17 beta–hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator–inducible gene. Corton JC, et al. **Mol Pharmacol** 1996 Nov;50(5):1157–66

Beneficial effects of a novel thyromimetic on lipoprotein metabolism. Taylor AH, et al. **Mol Pharmacol** 1997 Sep; 52(3):542–7

Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Arruzazabala ML, et al. **Pharmacol Res** 1996 Nov–Dec;34(5–6):181–5

Simvastatin in the secondary prevention of coronary heart disease. Assmann G. **Pharmacol Res** 1997 Mar;35(3):161

The 4S study: a critical review. Crepaldi G. **Pharmacol Res** 1997 Mar;35(3):163

Cholesterol–lowering drugs for primary prevention? The WOSCOP Study. Muntoni S. **Pharmacol Res** 1997 Mar; 35(3):169–70

The 4S study: a critical review. Pauciullo P. **Pharmacol Res** 1997 Mar;35(3):165–6

Cholesterol synthesis inhibitors do not reduce Lp(a) levels in normocholesterolemic patients. Pazzucconi F, et al. **Pharmacol Res** 1996 Sep–Oct;34(3–4):131–3

The effect of pravastatin on hepatic 3–hydroxy–3–methylglutaryl CoA reductase obtained from poloxamer 407–induced hyperlipidemic rats. Johnston TP, et al. **Pharmacotherapy** 1997 Mar–Apr;17(2):342–7

Effect of replacement of fat by nonabsorbable fat (sucrose polyester) in meals or snacks as a function of dietary restraint. Westerterp–Plantenga MS, et al. **Physiol Behav** 1997 Jun;61(6):939–47

The beneficial effects of HMG–coenzyme A reductase inhibitor in the primary and secondary prevention of atherosclerosis in the coronaries. Drown DJ. **Prog Cardiovasc Nurs** 1996 Spring;11(2):38–9

Effect of probucol on the cytological and biochemical changes induced by adriamycin in Swiss albino mice. al–Gharably NM. **Res Commun Mol Pathol Pharmacol** 1996 Dec;94(3):289–303

Erythrocyte membrane cholesterol/phospholipid changes and hemorheological modifications in familial hypercholesterolemia treated with lovastatin. Martínez M, et al. **Thromb Res** 1996 Sep 1;83(5):375–88

Hepatic microsomal enzyme induction, beta–oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat. Amacher DE, et al. **Toxicol Appl Pharmacol** 1997 Jan;142(1):143–50

Multigeneration reproduction study of policosanol in rats. Rodríguez MD, et al. **Toxicol Lett** 1997 Feb 7; 90(2–3):97–106

[The growth of Rhodotorula rubra yeasts and their synthesis of ergosterol on media with lovastatin] Baranova NA, et al. **Antibiot Khimioter** 1996;41(11):3–6 (Eng. Abstr.) **(Rus)**

[Inhibition of cholesterol biosynthesis in rabbit hepatocytes by 3–beta–(omega–hydroxyalkoxy)cholest–5–enes] Maliugin AV, et al. **Bioorg Khim** 1996 Jul;22(7):541–7 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin. Kesteloot H, et al. **Acta Cardiol** 1997;52(2):107–16

Current and future therapeutic approaches to hyperlipidemia. Farmer JA, et al. **Adv Pharmacol** 1996;35:79–114 (125 ref.)

Treating hypercholesterolemia—without the hype [letter; comment] Bassan M, et al. **Am J Cardiol** 1997 Apr 1; 79(7):1001–3. Comment on: Am J Cardiol 1996 Aug 1;78(3):377–8.

A multicenter, double–blind, one–year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Dart A, et al. **Am J Cardiol** 1997 Jul 1;80(1):39–44

Comparison of one–year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Davidson M, et al. **Am J Cardiol** 1997 Jun 1;79(11):1475–81

Effectiveness of atorvastatin for reducing low–density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. Davidson MH, et al. **Am J Cardiol** 1997 Aug 1;80(3):347–8

Effects of short–term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia. de Divitiis M, et al. **Am J Cardiol** 1996 Oct 1;78(7):763–8

The clinical therapeutic implications of the Scandinavian Simvastatin Survival Study [editorial] Dujovne CA.

Am J Cardiol 1997 May 15;79(10):1387–8

Reduction of coronary events by pravastatin—is lowering low-density lipoprotein cholesterol the answer? [letter] Halle M, et al. **Am J Cardiol** 1997 Sep 1;80(5):683

Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease. Ito MK, et al. **Am J Cardiol** 1997 Sep 15;80(6):799–802

Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Mostaza JM, et al. **Am J Cardiol** 1997 May 1;79(9):1298–301

Results of intensive long-term treatment of familial hypercholesterolemia. Retterstøl K, et al. **Am J Cardiol** 1996 Dec 15;78(12):1369–74

Review of the major intervention trials of lowering coronary artery disease risk through cholesterol reduction. Stark RM. **Am J Cardiol** 1996 Sep 26;78(6A):13–9 (27 ref.)

Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin. Takagi T, et al. **Am J Cardiol** 1997 Jun 15;79(12):1673–6

Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study [editorial] Weintraub WS, et al. **Am J Cardiol** 1996 Nov 1;78(9):1036–8

Beneficial effect of lovastatin on sphincter of Oddi dyskinesia in hypercholesterolemia and hypertriglyceridemia. Szilvássy Z, et al. **Am J Gastroenterol** 1997 May;92(5):900–2

Should hyperlipidemia in the elderly be treated? Ito MK. **Am J Health Syst Pharm** 1996 Dec 1;53(23):2867–72

Considerations in the formulary selection of hydroxymethylglutaryl-coenzyme A reductase inhibitors. McMillan K. **Am J Health Syst Pharm** 1996 Sep 15; 53(18):2206–14 (51 ref.)

The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia. Fong RL, et al. **Am J Med** 1997 Apr;102(4):387–91

Cholesterol-lowering and coronary atherosclerosis: good news and bad news [editorial] Kreisberg RA. **Am J Med** 1996 Nov;101(5):455–8

Review of cholesterol-lowering therapy: coronary angiographic and events trials. Waters D, et al. **Am J Med** 1996 Oct 8;101(4A):4A34S–38S; discussion 39S (37 ref.)

Effect of simvastatin therapy on cell membrane cholesterol content and membrane function as assessed by polymorphonuclear cell NADPH oxidase activity. Day AP, et al. **Ann Clin Biochem** 1997 May;34 (Pt 3):269–75

Asymptomatic cholesteryl ester storage disease in an adult controlled with simvastatin. Iverson SA, et al. **Ann Clin Biochem** 1997 Jul;34 (Pt 4):433–6

Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Kroon AA, et al. **Ann Intern Med** 1996 Dec 15;125(12):945–54

Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Schectman G, et al. **Ann Intern Med** 1996 Dec 15;125(12):990–1000 (72 ref.)

Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy. Austen JL, et al. **Ann Pharmacother** 1996 Dec;30(12):1386–9

Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Gardner SF, et al. **Ann Pharmacother** 1997 Jun;31(6):677–82

Reductase inhibitor monotherapy and stroke prevention [see comments] Crouse JR 3rd, et al. **Arch Intern Med** 1997 Jun 23;157(12):1305–10. Comment in: Arch Intern Med 1997 Jun 23;157(12):1283–4.

A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Davidson MH, et al. **Arch Intern Med** 1997 Jun 9;157(11):1186–92

Stain therapy and reduced incidence of stroke. Implications of cholesterol-lowering therapy for cerebrovascular disease [editorial; comment] Gotto AM Jr. **Arch Intern Med** 1997 Jun 23;157(12):1283–4. Comment on: Arch Intern Med 1997 Jun 23;157(12):1305–10.

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Pedersen TR, et al. **Arch Intern Med** 1996 Oct 14;156(18):2085–92

A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy. Aguilar-Salinas CA, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan; 17(1):72–82

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Marais AD, et al. **Arterioscler Thromb Vasc Biol** 1997 Aug;17(8):1527–31

The hypocholesterolemic and antiatherogenic effects of topically applied phosphatidylcholine in rabbits with heritable hypercholesterolemia. Hsia SL, et al. **Artery** 1996; 22(1):1–23

Combined treatment of probucol with diltiazem regresses atherosclerosis induced by 196 cholesterol diet in rabbit aorta. Kouzuma R, et al. **Artery** 1995;21(6):337–51

Drug therapy of severe hypercholesterolemia in patients with coronary artery disease. Parhofer KG, et al. **Artif Organs** 1996 Apr;20(4):286–91 (40 ref.)

Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia. Hailer S, et al. **Arzneimittelforschung** 1996 Sep;46(9):879–83

Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Alaupovic P, et al. **Atherosclerosis** 1997 Aug; 133(1):123–33

Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Bertolini S, et al. **Atherosclerosis** 1997 Apr;130(1–2):191–7

The effect of the aged garlic extract, 'Kyolic', on the development of experimental atherosclerosis. Efendy JL, et al. **Atherosclerosis** 1997 Jul 11;132(1):37–42

Impaired radial artery compliance in normotensive subjects with familial hypercholesterolemia. Giannattasio C, et al. **Atherosclerosis** 1996 Aug 2;124(2):249–60

Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia. Homma Y, et al. **Atherosclerosis** 1997 Mar 21;129(2):241–8

Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Hussein O, et al. **Atherosclerosis** 1997 Jan 3;128(1):11–8

Comment on: effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia [letter; comment] Mikhailidis DP, et al. **Atherosclerosis** 1996 Dec 20;127(2):287–90. Comment on: Atherosclerosis 1996 May;122(2):225–33.

Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Muramatsu J, et al. **Atherosclerosis** 1997 Apr;130(1–2):179–82

Lymphatic transport of cholesterol in normocholesterolemic rats treated with pravastatin, an inhibitor of HMG-CoA reductase. Sakono M, et al. **Atherosclerosis** 1996 Jul; 124(1):95–102

Cholesterol lowering therapy inhibits the low-flow mediated vasoconstriction of the brachial artery in hypercholesterolaemic subjects. Megnien JL, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):187–93

Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Osamah H, et al. **Br J Clin Pharmacol** 1997 Jul;44(1):77–83

Statins and coronary artery disease—it's the clinical endpoints that count [editorial] Jackson G. **Br J Clin Pract** 1997 Jan–Feb;51(1):2–3

Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators. Teo KK, et al. **Can J Cardiol** 1997 Jun;13(6):591–9

Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study). Nakamura Y, et al. **Cardiovasc Drugs Ther** 1996 Sep;10(4):475–83

Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin. Sampietro T, et al. **Cardiovasc Drugs Ther** 1995 Dec;9(6):785–9

The conservative treatment of xanthoma of the Achilles tendon in patients affected with type IIA hypercholesterolemia. Valeo M, et al. **Chir Organi Mov** 1996 Jul-Sep;81(3):303–10 **(Eng, Ita)**

Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Böger RH, et al. **Circulation** 1997 Aug 19;96(4):1282–90

Clinical reality of lowering total and LDL cholesterol [editorial; comment] Frye RL. **Circulation** 1997 Jan 21; 95(2):306–7. Comment on: Circulation 1997 Jan 21;95(2):324–8.

When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Grundy SM, et al. **Circulation** 1997 Mar 18;95(6):1683–5

Prevastatin treatment in angina pectoris [letter; comment] Hellstrom HR. **Circulation** 1997 Aug 5;96(3):1059–60. Comment on: Circulation 1996 Oct 1;94(7):1503–5.

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. O'Driscoll G, et al. **Circulation** 1997 Mar 4;95(5):1126–31

Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial [see comments] Wenke K, et al. **Circulation** 1997 Sep 2; 96(5):1398–402. Comment in: Circulation 1997 Sep 2;96(5):1370–3.

Lipid-lowering therapy for average lipid levels: the CARE trial. Sprecher DL. **Cleve Clin J Med** 1997 Mar; 64(3):129–31

Lipid modifying agents: mechanisms of action and reduction of cardiovascular disease. Scott R. **Clin Exp Pharmacol Physiol** 1997 May;24(5):A26–8 (27 ref.)

Sesame lignans modulate cholesterol metabolism in the stroke-prone spontaneously hypertensive rat. Ogawa H, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S310–2

A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Rayner BL, et al. **Clin Nephrol** 1996 Oct;46(4):219–24

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H, et al. **Clin Pharmacokinet** 1997 May;32(5):403–25 (118 ref.)

Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. The Simvastatin Study Group. Itoh T, et al. **Clin Ther** 1997 May-Jun;19(3):487–97

Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization. Spearman ME, et al. **Clin Ther** 1997 May-Jun;19(3):582–602; discussion 538–9

Effect of lipid-lowering therapy on the progression of renal disease in nondiabetic nephrotic patients. Neverov NI, et al. **Contrib Nephrol** 1997;120:68–78

The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. West MS, et al. **Control Clin Trials** 1996 Dec;17(6):550–83

Lipid-lowering therapy for patients with or at risk of coronary artery disease. Kjekshus J, et al. **Curr Opin Cardiol** 1996 Jul;11(4):418–27 (84 ref.)

Therapy and clinical trials [editorial] Bhatnagar D. **Curr Opin Lipidol** 1997 Jun;8(3):U44–6

Therapy and clinical trials [editorial] Game F. **Curr Opin Lipidol** 1996 Jun;7(3):U105–7 (4 ref.)

Effects of pravastatin in heart transplant recipients: implications of Kobashigawa et al. Gotto AM Jr. **Curr Opin Lipidol** 1995 Dec;6(6):341–3

Effects of lipid-lowering therapy on total and coronary mortality. Holme I. **Curr Opin Lipidol** 1995 Dec;6(6):374–8 (30 ref.)

Therapy and clinical trials [editorial] Jialal I, et al. **Curr Opin Lipidol** 1995 Dec;6(6):U171–5

Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Kinlay S, et al. **Curr Opin Lipidol** 1996 Dec;7(6):389–97 (104 ref.)

Antioxidants in the prevention of atherosclerosis. Olsson AG, et al. **Curr Opin Lipidol** 1996 Dec;7(6):374–80 (45 ref.)

Trials of lipid-lowering therapy in secondary prevention of coronary heart disease. Olsson AG, et al. **Curr Opin Lipidol** 1995 Dec;6(6):369–73 (20 ref.)

Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Thompson GR, et al. **Curr Opin Lipidol** 1995 Dec;6(6):386–8

Statins: within-group comparisons, statin escape and combination therapy. Tikkanen MJ. **Curr Opin Lipidol** 1996 Dec;7(6):385–8 (28 ref.)

Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Watts GF, et al. **Curr Opin Lipidol** 1996 Dec;7(6):341–55 (108 ref.)

Hyperlipidaemia and cardiovascular disease [editorial] Wray R. **Curr Opin Lipidol** 1995 Dec;6(6):U160–4

Hyperlipidaemia and cardiovascular disease [editorial] Wright R, et al. **Curr Opin Lipidol** 1996 Jun;7(3):U92–8 (15 ref.)

Clinical prevention of coronary heart disease through cholesterol-lowering therapy. Grundy SM. **Curr Ther Endocrinol Metab** 1997;6:520–6 (6 ref.)

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [see comments] [published erratum appears in Diabetes Care 1997 Jun;20(6):1048] Pyörälä K, et al. **Diabetes Care** 1997 Apr;20(4):614–20. Comment in: Diabetes Care 1997 Apr;20(4):469–71.

Efficacy of low-dose pravastatin in patients with mild hyperlipidemia associated with type II diabetes mellitus. Krempf M, et al. **Diabetes Metab** 1997 Apr;23(2):131–6

A rational approach to treating hypercholesterolaemia in children. Weighing the risks and benefits. Tonstad S. **Drug Saf** 1997 May;16(5):330–41 (120 ref.)

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Haria M, et al. **Drugs** 1997 Feb;53(2):299–336 (267 ref.)

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Lea AP, et al. **Drugs** 1997 May;53(5):828–47 (133 ref.)

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Plosker GL, et al. **Drugs** 1996 Mar;51(3):433–59 (130 ref.)

Management of lipid disorders in the elderly. Playford DA, et al. **Drugs Aging** 1997 Jun;10(6):444–62 (146 ref.)

The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS). Bestehorn HP, et al. **Eur Heart J** 1997 Feb; 18(2):226–34

Interpretation of trials with drugs and devices; a double standard? Simoons ML. **Eur Heart J** 1996 Oct; 17(10):1463–5

Changes in biliary lipid output after interruption of pravastatin treatment in humans. Hillebrant CG, et al. **Eur J Clin Invest** 1996 Dec;26(12):1160–5

Magnesium pyridoxal-5'-phosphate glutamate, "A vitamin B6 derivative", does not affect lipoprotein levels in patients with familial hypercholesterolaemia. Knipscheer HC, et al. **Eur J Clin Pharmacol** 1997;51(6):499–503

Relationship between plasma fenofibric acid levels and the

effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia. Rašlová K, et al. **Eur J Clin Pharmacol** 1997;52(2):101–6

Drug therapy of severe hypercholesterolemia. Weizel A, et al. **Eur J Med Res** 1997 Jun 16;2(6):265–9 (40 ref.)

Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. Bandoh T, et al. **Eur J Pharmacol** 1996 Nov 7;315(1):37–42

Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. Palomäki A, et al. **FEBS Lett** 1997 Jun 30;410(2–3):254–8

Effect of HMG-CoA reductase inhibitors on red blood cell membrane lipids and haemorheological parameters, in patients affected by familial hypercholesterolemia. Martinez M, et al. **Haemostasis** 1996 Oct;26 Suppl 4:171–6

Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects. Chan P, et al. **Hypertension** 1996 Oct;28(4):647–51

Statins in coronary artery disease: beyond cholesterol reduction [editorial] Gambhir DS, et al. **Indian Heart J** 1997 May–Jun;49(3):257–61 (43 ref.)

Lipid-lowering effects of fluvastatin in renal transplant patients. A clinical observation. Lal SM, et al. **Int J Artif Organs** 1997 Jan;20(1):18–21

Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis. Schiel R, et al. **Int J Artif Organs** 1995 Dec;18(12):786–93

A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Canetti M, et al. **Int J Clin Pharmacol Res** 1995; 15(4):159–65

Fluvastatin (Lescol) treatment of hyperlipidaemia in patients with renal transplants. Löcsey L, et al. **Int Urol Nephrol** 1997;29(1):95–106

Platelet-dependent thrombin generation in patients with hyperlipidemia. Aoki I, et al. **J Am Coll Cardiol** 1997 Jul; 30(1):91–6

A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group. **J Atheroscler Thromb** 1996;3(2):95–104

Drug therapy for hypertension and hyperlipidemia. Hutchins LN. **J Cardiovasc Nurs** 1995 Jan;9(2):37–53 (4 ref.)

Effect of a reduced-fat diet with or without pravastatin on glucose tolerance and insulin sensitivity in patients with primary hypercholesterolemia. Galvan AQ, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):595–602

Inhibiting cholesterol absorption with CP-88,818 (beta-tigogenin cellobioside; tiqueside): studies in normal and hyperlipidemic subjects. Harris WS, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):55–60

Crossover trial of simvastatin versus pravastatin in patients with primary hypercholesterolemia. Sasaki S, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):142–7

Nutritional, metabolic, and genetic determinants of the progression of coronary heart disease. STARS Group. Watts GF. **J Cardiovasc Pharmacol** 1995;25 Suppl 4:S11–9

Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia. Chan P, et al. **J Clin Pharmacol** 1997 Jun;37(6):496–501

A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma. Fujita M, et al. **J Dermatol** 1996 Sep;23(9):598–602

Lipid lowering in post-MI patients with normal cholesterol. Lawless C, et al. **J Fam Pract** 1997 Jan;44(1):30

Cholesterol management and managed care [editorial; comment] McBride PE. **J Fam Pract** 1997 May; 44(5):449–50. Comment on: J Fam Pract 1997 May;44(5):462–7.

Bambuterol raises high-density lipoprotein levels in patients with hyperlipidaemia. Florén CH, et al. **J Intern Med** 1997 Aug;242(2):167–71

The problem of compliance to cholesterol altering therapy. Insull W. **J Intern Med** 1997 Apr;241(4):317–25 (24 ref.)

Guidelines and reported practice for the treatment of hypertension and hypercholesterolaemia. Troein M, et al. **J Intern Med** 1997 Aug;242(2):173–8

Effect of pravastatin in treatment of hypercholesterolemia in non-insulin-dependent diabetes patients. Soonthornpun S, et al. **J Med Assoc Thai** 1997 Jan;80(1):9–15

Direct drug control of the vascular wall. Paoletti R, et al. **J Med Liban** 1995;43(3):122–5 (44 ref.)

Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia [see comments] Tonstad S, et al. **J Pediatr** 1996 Jul;129(1):42–9. Comment in: J Pediatr 1996 Jul;129(1):4–7.

Medical management of coronary artery disease revisited: the endothelial factor. Siegel JA. **J S C Med Assoc** 1997 Sep;93(9):333–5 (14 ref.)

Evidence supporting cholesterol-lowering therapy for postmenopausal women with heart disease [letter; comment] Goldstein MR. **JAMA** 1997 Aug 27;278(8):633–4 . Comment on: JAMA 1997 Apr 23–30;277(16):1281–6.

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Hebert PR, et al. **JAMA** 1997 Jul 23–30;278(4):313–21 (53 ref.)

New treatment strategy for Smith-Lemli-Opitz syndrome [letter] Jira P, et al. **Lancet** 1997 Apr 26;349(9060):1222

Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial [letter] Strandberg TE, et al. **Lancet** 1997 Aug 9;350(9075):442

Statins do more than just lower cholesterol [see comments] [published erratum appears in Lancet 1997 Jan 18;349(9046):214] Vaughan CJ, et al. **Lancet** 1996 Oct 19; 348(9034):1079–82 (29 ref.). Comment in: Lancet 1996 Dec 7;348(9041):1582. Comment in: Lancet 1996 Dec 7;348(9041):1582–3. Comment in: Lancet 1996 Dec 7;348(9041):1583.

The effect of pravastatin in patients with primary hyperlipidaemia. Mafauzy M, et al. **Med J Malaysia** 1995 Sep;50(3):272–7

Atorvastatin--a new lipid-lowering drug. **Med Lett Drugs Ther** 1997 Mar 28;39(997):29–31

Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients. Kohno M, et al. **Metabolism** 1997 Mar;46(3):287–91

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators [see comments] **N Engl J Med** 1997 Jan 16;336(3):153–62. Comment in: N Engl J Med 1997 Jan 16;336(3):212–3. Comment in: N Engl J Med 1997 Jun 19;336(25):1839–40. Comment in: ACP J Club 1997 Jul–Aug;127(1):2.

The effect of pravastatin on coronary events after myocardial infarction [letter] Auerbach I, et al. **N Engl J Med** 1997 Mar 27;336(13):962

Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. Darling GM, et al. **N Engl J Med** 1997 Aug 28;337(9):595–601

Prevention of atherosclerosis in coronary-artery bypass grafts [editorial; comment] Fuster V, et al. **N Engl J Med** 1997 Jan 16;336(3):212–3. Comment on: N Engl J Med 1997 Jan 16;336(3):153–62.

The effect of pravastatin on coronary events after myocardial infarction [letter; comment] Hazzard WR, et al. **N Engl J Med** 1997 Mar 27;336(13):961; discussion 962. Comment on: N Engl J Med 1996 Oct 3;335(14):1001–9.

Cholesterol reduction and coronary prevention. Prabhakaran D. **Natl Med J India** 1997 Jan–Feb;10(1):24–5

LDL-cholesterol lowering and atherosclerosis--clinical benefit and possible mechanisms: an update [see comments] Kroon AA, et al. **Neth J Med** 1997 Jul;51(1):16–27 (140 ref.). Comment in: Neth J Med 1997 Jul;51(1):v–vii.

Tomorrow's world: atherosclerosis in the year 2000. Shepherd J. **Neth J Med** 1997 May;50(5):221–7

Effects of ketoconazole on plasma lipids and lipoprotein(a) in familial hypercholesterolaemia, compared with simvastatin [see comments] Stalenhoef AF, et al. **Neth J Med** 1997 Jul;51(1):10–5. Comment in: Neth J Med 1997 Jul;51(1):v–vii.

Benefits of hypercholesterolemia treatment [editorial] Soma M, et al. **Pharmacol Res** 1997 Mar;35(3):159

Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. Grundy SM. **Postgrad Med** 1997 Aug;102(2):81–4, 87–90 (13 ref.)

The one-stop coronary cholesterol clinic: a multidisciplinary approach to implementing evidence-based treatment. Giles PD, et al. **Postgrad Med J** 1996 Dec;72(854):744–8

Benefits beyond lipid-lowering. **S Afr Med J** 1997 Jun;87 Suppl 3:C183–4

Improved survival with statin therapy. Clem JR. **S D J Med** 1996 Aug;49(8):273–4

The statin trials: closing arguments in the case against cholesterol? Gaw A. **Scott Med J** 1996 Aug;41(4):99–100

Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. Tal A, et al. **South Med J** 1997 May;90(5):546–7

Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies. Elam MB, et al. **Tenn Med** 1997 May;90(5):189–92

Pravastatin prevents the progression of accelerated coronary artery disease after heart transplantation in a rabbit model. Ogawa N, et al. **Transpl Int** 1996;9 Suppl 1:S226–9

Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. Kliem V, et al. **Transplant Proc** 1996 Dec;28(6):3126–8

Treatment of metabolic disorders with fluvastatin after renal transplantation. Podder H, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):216–9

Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Goldberg R, et al. **Transplantation** 1996 Dec 15;62(11):1559–64

Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin. Imagawa DK, et al. **Transplantation** 1996 Oct 15;62(7):934–42

[How blind can one be? (letter; comment) (see comments)] Petersson BH. **Ugeskr Laeger** 1997 Apr 28;159(18):2719–21 . Comment on: Ugeskr Laeger 1997 Jan 13;159(3):308–9. Comment in: Ugeskr Laeger 1997 Aug 18;159(34):5112–3. **(Dan)**

[Comparative effects of captopril and atenolol on lipid metabolism in hypertensive hypercholesterolemic patients treated with pravastatin. A multicenter controlled trial] Witchitz S, et al. **Presse Med** 1996 Dec 21;25(40):2013–6 (Eng. Abstr.) **(Fre)**

[Congress information. Clinical benefits of the use of a statin following myocardial infarction in patients without frank hypercholesterolemia] Kulbertus H. **Rev Med Liege** 1996 Oct;51(10):668–9 **(Fre)**

[Drug of the month. Fluvastatin (Lescol)] Scheen AJ. **Rev Med Liege** 1997 Jun;52(6):442–4 **(Fre)**

[One year after WOSCOP, what is the correct pharmacological treatment of primary hypercholesterolemia? Réflexions du Groupe de Pharmacologie Clinique de la Société Française de Cardiologie] **Therapie** 1996 Nov–Dec;51(6):611–4 **(Fre)**

[Primary prevention with fibrate and cholesterol synthesis inhibitors] Lehnert H. **Dtsch Med Wochenschr** 1997 Aug 22;122(34–35):1057–8 **(Ger)**

[A break-through in infarct prevention. WOS (West-of-Scotland)-study confirms effectiveness of early intervention using Pravastin] **Fortschr Med Suppl** 1996; 172:1–12 **(Ger)**

[Cholesterol lowering--Quo vadis? WOS (West of Scotland)--study of pravastin--a milestone in the prevention of myocardial infarct?!] **Fortschr Med Suppl** 1995;170:1–7 **(Ger)**

[Lowering LDL cholesterol with Simvastatin. Also, economically reasonable!] **Internist (Berl)** 1995 Aug;36(8 Suppl):1–4 **(Ger)**

[Lowering cholesterol. New concepts with atorvastatin] **Internist (Berl)** 1997 Jan;38(1 Suppl):1–8 **(Ger)**

[Lipid therapy. Goal and use in prevention of coronary heart disease] Windler E, et al. **Internist (Berl)** 1996 Dec; 37(12):1244–8 (14 ref.) **(Ger)**

[Reducing cholesterol in cardiovascular rehabilitation--exercise versus drug therapy] Halle M, et al. **Wien Klin Wochenschr Suppl** 1997;2:29–32 (30 ref.) (Eng. Abstr.) **(Ger)**

[Effect of fluvastatin on serum lipid levels in essential hypertension] Járai Z, et al. **Orv Hetil** 1996 Aug 25; 137(34):1857–9 (Eng. Abstr.) **(Hun)**

[Data on cholesterol level screening of patients with ischemic heart disease in the light of the Scandinavian Simvastatin Survival Study] Márk L, et al. **Orv Hetil** 1997 Jun 29; 138(26):1679–82 (Eng. Abstr.) **(Hun)**

[Progress in hypocholesterolemic therapy in the prevention of recurrent infarction] Manzato E, et al. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:127S–131S (14 ref.) (Eng. Abstr.) **(Ita)**

[Dichotomy between cholesterol-lowering drugs in clinical trials and practice. Experience of the DiSCO Project (District of Serra Community Control of Chronic Degenerative Diseases)] Volpe R, et al. **Cardiologia** 1997 Aug;42(8):815–25 (70 ref.) **(Ita)**

[Cholesterol and statins (letter)] Ferrari M. **G Ital Cardiol** 1997 May;27(5):499–500 **(Ita)**

[The periodic flashes of E. Brunwald: lowering cholesterol levels in subjects with myocardial infarction and normal cholesterol levels (editorial) (see comments)] Prati PL. **G Ital Cardiol** 1997 Jan;27(1):76–8. Comment in: G Ital Cardiol 1997 Jul;27(7):727–9. **(Ita)**

[Effect of cholestyramine on angiopathies in cholesterol-fed mice and diabetic mice] Sugiura M, et al. **J Smooth Muscle Res** 1995 Dec;31(6):400–2 **(Jpn)**

[The effect of hypolipidemia treatment on the function of kidney transplanted from cadavers] Paczek L, et al. **Pol Arch Med Wewn** 1997 Feb;97(2):144–56 (Eng. Abstr.) **(Pol)**

[Risk factors in elderly patients selected by primary care physicians for hypolipemic treatment] Barretto AC, et al. **Arq Bras Cardiol** 1996 Aug;67(2):93–8 (Eng. Abstr.) **(Por)**

[Effects of enduracin on the level of cholesterol in flying personnel] Preobrazhenskii VN, et al. **Aviakosm Ekolog Med** 1997;31(3):43–4 **(Rus)**

[Effect of enduracin on the activity of a cholesterol ester transfer protein in blood plasma of people with hypercholesteremia] Gorshkova IN, et al. **Biull Eksp Biol Med** 1996 Feb;121(2):185–7 **(Rus)**

[The effect of phenol antioxidants on the development of alloxan diabetes in rats] Bobyreva LE. **Eksp Klin Farmakol** 1997 May–Jun;60(3):51–3 (Eng. Abstr.) **(Rus)**

[Current approaches to treatment of hypercholesterolemia] Preobrazhenskii VN, et al. **Klin Med (Mosk)** 1996; 74(9):61–2 (Eng. Abstr.) **(Rus)**

[The effect of fluvastatin (Lescol) treatment on the clinical status and function of the liver in patients with ischemic heart disease] Kuril'skaia TE, et al. **Ter Arkh** 1997; 69(2):55–8 (Eng. Abstr.) **(Rus)**

[New markers of atherogenic risk: hemorrheological profile in children and adolescents with familiar hypercholesterolemia] Dalmau Serra J, et al. **An Esp Pediatr** 1996 Oct;45(4):393–7 (Eng. Abstr.) **(Spa)**

[Clinical trial with sodium fluvastatin in patients with hypercholesterolemia associated with mild and moderate essential arterial hypertension] Granero R, et al. **Invest Clin** 1997 Jun;38(2):63–72 (Eng. Abstr.) **(Spa)**

[Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia] Alvarez-Sala LA, et al. **Rev Clin Esp** 1997 May;197(5):317–22 (Eng. Abstr.) **(Spa)**

[Gallstone dissolution in an adult female population: trial with

lovastatin therapy] Glasinovic JC, et al. **Rev Med Chil** 1996 Jul;124(7):793–8 (Eng. Abstr.) **(Spa)**

TOXICITY

Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Flint OP, et al. **Toxicol Appl Pharmacol** 1997 Jul;145(1):91–8

HMG CoA reductase inhibitor–induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low–molecular–weight proteins in neonatal rat muscle cell culture. Flint OP, et al. **Toxicol Appl Pharmacol** 1997 Jul;145(1):99–110

Down regulation of epidermal growth factor receptors in rat hepatocytes treated with clofibric acid. Tanaka K, et al. **Toxicol Lett** 1997 Mar 14;91(1):25–30

Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl–coenzyme A reductase inhibitor, in beagle dogs. Walsh KM, et al. **Toxicol Pathol** 1996 Jul–Aug;24(4):468–76

ANTICHOLINERGIC AGENTS see **CHOLINERGIC ANTAGONISTS**

ANTICHOLINESTERASE AGENTS see **CHOLINESTERASE INHIBITORS**

ANTICIPATORY VOMITING see **VOMITING, ANTICIPATORY**

ANTICOAGULANTS

Effect of anticoagulant choice on apparent antioxidant capacity [letter; comment] Doherty G, et al. **Ann Clin Biochem** 1996 Jan;33 (Pt 1):93–4. Comment on: Ann Clin Biochem 1995 Jul;32 (Pt 4):413–6.

Anticoagulants for total antioxidant activity assay [letter; comment] Miller NJ. **Ann Clin Biochem** 1996 Jan;33 (Pt 1):92–3. Comment on: Ann Clin Biochem 1995 Jul;32 (Pt 4):413–6.

Testing a community level research utilization intervention. Shively M, et al. **Appl Nurs Res** 1997 Aug;10(3):121–7

Heparin free hemodialysis using heparin coated hemophan. Mujais SK, et al. **ASAIO J** 1996 Sep–Oct;42(5):M538–41

Erroneous D–dimer result on a paediatric citrated specimen [letter] Carroll PA, et al. **Blood Coagul Fibrinolysis** 1996 Jun;7(4):502

Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle [see comments] Lindahl AK. **Cardiovasc Res** 1997 Feb;33(2):286–91 (44 ref.) . Comment in: Cardiovasc Res 1997 Feb;33(2):284–5.

Biting encounters—mahogany flats and a cascade of characters [comment] Weber KT. **Cardiovasc Res** 1997 Feb; 33(2):284–5. Comment on: Cardiovasc Res 1997 Feb;33(2):286–91.

Matas Lecture. Heparin—controversies and misconceptions. Blaisdell FW. **Cardiovasc Surg** 1996 Dec;4(6):691–700 (104 ref.)

Sarstedt Monovettes falsely increase total calcium results [letter] Collier J, et al. **Clin Chem** 1996 Oct;42(10):1722

Profound hypercalcemia in continuous veno–venous hemofiltration dialysis with trisodium citrate anticoagulation and hepatic failure [letter] Nowak MA, et al. **Clin Chem** 1997 Feb;43(2):412–3

Uniformity of anticoagulation for full blood counting [letter] O'Broin S, et al. **Clin Lab Haematol** 1997 Jun;19(2):159–60

Reoperations after dacron patch aortoplasty with heparinized femoro–femoral bypass. Roth M, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):997–1000

Clinical effects of the heparin coated surface in cardiopulmonary bypass. Svenmarker S, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):957–64

Histamine in plasma and bronchoalveolar lavage fluid during cardiac surgery: comparison of a heparin–coated and a non–coated circuit. Lin AH, et al. **Inflamm Res** 1997 Mar; 46 Suppl 1:S75–6

Heparin–coated bypass circuits in cardiopulmonary bypass: improved biocompatibility or not. Levy M, et al. **Int J Cardiol** 1996 Apr 26;53 Suppl:S81–7 (30 ref.)

Current perspectives on dental patients receiving coumarin anticoagulant therapy [see comments] Herman WW, et al. **J Am Dent Assoc** 1997 Mar;128(3):327–35 (60 ref.). Comment in: J Am Dent Assoc 1997 Jul;128(7):818, 820.

Epinephrine exerts anticoagulant effects during human endotoxemia. van der Poll T, et al. **J Exp Med** 1997 Mar 17;185(6):1143–8

Amyloid beta–protein precursor: a new anticoagulant? [editorial; comment] Schmaier AH. **J Lab Clin Med** 1997 Jul;130(1):5–7. Comment on: J Lab Clin Med 1997 Jul;130(1):21–32.

Why do patients with antiphospholipid antibody clot? [editorial; comment] Lockshin MD. **Lupus** 1997;6(4):351–2 . Comment on: Lupus 1997 ;6(4):358–64.

Inadequate quality of a blood collection tube containing an anticoagulant/platelet inhibitor mixture [letter] Polack B, et al. **Thromb Haemost** 1997 May;77(5):1035–6

[Resistance to activated protein C. The most common cause of familial thrombophilia] Larsen TB, et al. **Ugeskr Laeger** 1996 Nov 11;158(46):6584–8 (40 ref.) (Eng. Abstr.) **(Dan)**

ADMINISTRATION & DOSAGE

Modified oral anticoagulant potency in an amitriptyline–treated patient? Hampel H, et al. **Acta Haematol** 1996;96(3):178–80

Effect of ageing upon warfarin dose requirements: a longitudinal study. Wynne HA, et al. **Age Ageing** 1996 Nov; 25(6):429–31

Rapid heparin anticoagulation: use of a weight–based nomogram. Schaefer DC, et al. **Am Fam Physician** 1996 Dec;54(8):2517–21 (14 ref.)

Evolving models of warfarin management: anticoagulation clinics, patient self–monitoring, and patient self–management [editorial] Ansell JE, et al. **Am Heart J** 1996 Nov;132(5):1095–100 (42 ref.)

Low–dose heparin for routine coronary angioplasty and stenting. Vainer J, et al. **Am J Cardiol** 1996 Oct 15; 78(8):964–6

Effect of a pharmacist–managed anticoagulation clinic on warfarin–related hospital readmissions. Lee YP, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1580–3

Weight–based protocol for improving heparin therapy. Nemeth JS, et al. **Am J Health Syst Pharm** 1996 May 15; 53(10):1164–6

Establishing an outpatient anticoagulation clinic in a community hospital. Norton JL, et al. **Am J Health Syst Pharm** 1996 May 15;53(10):1151–7

Use of low–dose low molecular weight heparin in hemodialysis. Lai KN, et al. **Am J Kidney Dis** 1996 Nov; 28(5):721–6

Comparative risk of early postoperative pulmonary embolism after cemented total knee versus total hip arthroplasty with low–dose warfarin prophylaxis. Vresilovic EJ, et al. **Am J Knee Surg** 1996 Winter;9(1):2–6

Cloricromene reduces myocardial infarct size in rabbits when administered during the early reperfusion period. Zvara DA, et al. **Anesth Analg** 1997 Feb;84(2):266–70

Warfarin: less may be better [letter; comment] Adelman MD. **Ann Intern Med** 1997 Aug 15;127(4):332; discussion 333. Comment on: Ann Intern Med 1997 Jan 15;126(2):133–6.

Warfarin: less may be better [letter; comment] Atkins CD. **Ann Intern Med** 1997 Aug 15;127(4):332; discussion 333. Comment on: Ann Intern Med 1997 Jan 15;126(2):133–6.

Warfarin: less may be better [letter; comment] Camahan W, et al. **Ann Intern Med** 1997 Aug 15;127(4):332–3. Comment on: Ann Intern Med 1997 Jan 15;126(2):133–6.

Warfarin: less may be better [letter; comment] Casner PR. **Ann Intern Med** 1997 Aug 15;127(4):332; discussion 333. Comment on: Ann Intern Med 1997 Jan 15;126(2):133–6.

Comparison of 5–mg and 10–mg loading doses in initiation of warfarin therapy [see comments] Harrison L, et al. **Ann Intern Med** 1997 Jan 15;126(2):133–6. Comment in: Ann Intern Med 1997 Aug 15;127(4):332; discussion 333. Comment in: Ann Intern Med 1997 Aug 15;127(4):332–3.

Potential failure of the International Normalized Ratio (INR) System in the monitoring of oral anticoagulation in patients with lupus anticoagulants. Della Valle P, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:10–4

Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin [letter] Lane G. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):884–5

Low heparinization with heparin–bonded bypass circuits: is it a safe strategy? Bannan S, et al. **Ann Thorac Surg** 1997 Mar;63(3):663–8

Cardiopulmonary bypass with heparin–coated circuits and reduced systemic anticoagulation. Kuitunen AH, et al. **Ann Thorac Surg** 1997 Feb;63(2):438–44

Antithrombin III, leukocyte activation, and low systemic heparinization [letter; comment] Ranucci M. **Ann Thorac Surg** 1997 Apr;63(4):1211–2. Comment on: Ann Thorac Surg 1995 Dec;60(6):1755–61.

Effect of heparin loading during congenital heart operation on thrombin generation and blood loss. Turner–Gomes SO, et al. **Ann Thorac Surg** 1997 Feb;63(2):482–8

Development of chitosan/polyethylene vinyl acetate co–matrix: controlled release of aspirin–heparin for preventing cardiovascular thrombosis. Vasudev SC, et al. **Biomaterials** 1997 Mar;18(5):375–81

Antithrombotic efficacy in the guinea pig of a derivative of human protein C with enhanced activation by thrombin. Kurz KD, et al. **Blood** 1997 Jan 15;89(2):534–40

Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs. Bounameaux H, et al. **Blood Coagul Fibrinolysis** 1996 Jul;7(5):507–14 (37 ref.)

Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Lind SE, et al. **Blood Coagul Fibrinolysis** 1997 Jan;8(1):48–53

Concordance of phenprocoumon dose in married couples. Authors did not study patients' diets or compliance [letter] Kamali F, et al. **BMJ** 1997 Sep 6;315(7108):609

Treatment of pregnant women with recurrent miscarriage associated with phospholipid antibodies. During pregnancy, heparin should be stopped during labour and then restarted soon after delivery [letter; comment] Piette JC, et al. **BMJ** 1997 Aug 9;315(7104):372–3; discussion 373 . Comment on: BMJ 1997 Jan 25;314(7076):253–7.

Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. Vadher B, et al. **BMJ** 1997 Apr 26;314(7089):1252–6

Concordance of phenprocoumon dosage in married couples. van Haeften TW, et al. **BMJ** 1997 May 10;314(7091):1386

Prolongation of prothrombin time with the use of indomethacin and warfarin. Chan TY. **Br J Clin Pract** 1997 Apr–May;51(3):177–8

Oral anticoagulation in primary care [letter] Fitzmaurice D. **Br J Gen Pract** 1997 Aug;47(421):527

Evaluation of computerized decision support for oral anticoagulation management based in primary care. Fitzmaurice DA, et al. **Br J Gen Pract** 1996 Sep; 46(410):533–5

Where should oral anticoagulation monitoring take place? [editorial] Hobbs FD, et al. **Br J Gen Pract** 1997 Aug; 47(421):479–80

Warfarin therapy in primary care [letter; comment] Schofield HL. **Br J Gen Pract** 1996 Feb;46(403):123. Comment on: Br J Gen Pract 1995 Mar;45(392):153–8.

A short course of low–molecular–weight heparin to prevent deep venous thrombosis after elective total hip replacement. Gallay S, et al. **Can J Surg** 1997 Apr; 40(2):119–23

Infiltrator Angioplasty Balloon Catheter: a device for combined angioplasty and intramural site–specific treatment. Barath P, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):333–41

Site–specific intravascular administration of drugs: history of a method applicable in humans. Camenzind E, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):342–7 (39 ref.)

Cocktail attenuation of rotational ablation flow effects (CARAFE) study: pilot. Cohen BM, et al. **Cathet Cardiovasc Diagn** 1996;Suppl 3:69–72

Local delivery of heparin to balloon angioplasty sites with a new angiotherapy catheter: pharmacokinetics and effect on platelet deposition in the porcine model. Fram DB, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):275–86

When we "act" on ACT levels: activated clotting time measurements to guide heparin administration during and after interventional procedures [editorial] Klein LW, et al. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):154–7

Localized delivery of heparin to angioplasty sites with iontophoresis. Mitchel JF, et al. **Cathet Cardiovasc Diagn** 1997 Jul;41(3):315–23

Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time. Pesola GR, et al. **Cathet Cardiovasc Diagn** 1996 Feb;37(2):140–4

Predictors of arterial thrombosis after diagnostic cardiac catheterization in infants and children randomized to two heparin dosages. Saxena A, et al. **Cathet Cardiovasc Diagn** 1997 Aug;41(4):400–3

Is direct collection of pleural fluid into a heparinized syringe important for determination of pleural pH? A brief report. Goldstein LS, et al. **Chest** 1997 Sep;112(3):707–8

AREVA: multicenter randomized comparison of low–dose versus standard–dose anticoagulation in patients with mechanical prosthetic heart valves [see comments] Acar J, et al. **Circulation** 1996 Nov 1;94(9):2107–12. Comment in: Circulation 1996 Nov 1;94(9):2055–6.

Restenosis after coronary stent placement and randomization to a 4–week combined antiplatelet or anticoagulant therapy: six–month angiographic follow–up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial [see comments] Kastrati A, et al. **Circulation** 1997 Jul 15; 96(2):462–7. Comment in: Circulation 1997 Jul 15;96(2):383–5.

Inhibition of tissue factor–mediated coagulation markedly attenuates stenosis after balloon–induced arterial injury in minipigs. Oltrona L, et al. **Circulation** 1997 Jul 15; 96(2):646–52

Anticoagulation for prosthetic valves during pregnancy [letter; comment] Mayosi BM, et al. **Clin Cardiol** 1996 Dec; 19(12):921. Comment on: Clin Cardiol 1996 Sep;19(9):682.

An evaluation of empiric vs. nomogram–based dosing of heparin in an intensive care unit [see comments] Brown G, et al. **Crit Care Med** 1997 Sep;25(9):1534–8. Comment in: Crit Care Med 1997 Sep;25(9):1451–2.

Weight–based heparin dosing: maybe it's just a matter of time [editorial; comment] Susla GM. **Crit Care Med** 1997 Sep; 25(9):1451–2. Comment on: Crit Care Med 1997 Sep;25(9):1534–8.

Unresolved issues in the prevention of venous thromboembolism. Baglin T. **Drugs** 1996;52 Suppl 7:1–6; discussion 6–7 (30 ref.)

The postdischarge risk of venous thromboembolism after hip replacement. The role of prolonged prophylaxis. Bergqvist D. **Drugs** 1996;52 Suppl 7:55–9 (47 ref.)

Monitoring anticoagulant therapy by measuring haemostatic parameters [editorial; comment] Chek JB. **East Afr Med J** 1997 Jan;74(1):1–2 (20 ref.). Comment on: East Afr Med J 1997 Jan;74(1):3–5.

A randomized trial of a fixed high dose vs a weight–adjusted low dose of intravenous heparin during coronary angioplasty. Boccara A, et al. **Eur Heart J** 1997 Apr; 18(4):631–5

Treating the non–electrical risks of atrial fibrillation. Gershlick AH. **Eur Heart J** 1997 May;18 Suppl C:C19–26 (39 ref.)

Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5–fluorouracil (5–FU) in resectable colon cancer (EORTC GITCCG 1983–1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Nitti D, et al. **Eur J Cancer** 1997 Jul;33(8):1209–15

Self management of oral anticoagulant therapy after heart valve replacement. Hasenkam JM, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):935–42

A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. Riess FC, et al. **Eur J Cardiothorac Surg** 1996; 10(5):386–8

Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. The Fragmin Multicentre Study Group. Flordal PA, et al. **Eur J Surg** 1996 Oct;162(10):783–9

How to prevent stroke recurrence in patients with patent foramen ovale: anticoagulants, antiaggregants, foramen closure, or nothing? [see comments] Nendaz M, et al. **Eur Neurol** 1997;37(4):199–204 (45 ref.). Comment in: Eur Neurol 1997 ;37(4):205–6.

A randomized clinical trial of oxidized regenerated cellulose adhesion barrier (Interceed, TC7) alone or in combination with heparin. Reid RL, et al. **Fertil Steril** 1997 Jan; 67(1):23–9

Gastrointestinal endoscopy in patients taking antiplatelet agents and anticoagulants: survey of ASGE members. American Society for Gastrointestinal Endoscopy. Kadakia SC, et al. **Gastrointest Endosc** 1996 Sep;44(3):309–16

European concerted action on anticoagulation (ECAA). Poller L. **Haemostasis** 1996 Oct;26 Suppl 4:266–8

Safety of low dose heparin in elective coronary angioplasty. Koch KT, et al. **Heart** 1997 Jun;77(6):517–22

Induction of thrombolysis and prevention of thrombus formation by local drug delivery with a double–occlusion balloon catheter. Tomaru T, et al. **Heart Vessels** 1996; 11(3):123–32

Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium) [see comments] Haentjens P. **Injury** 1996 Jul;27(6):385–90. Comment in: Injury 1997 Apr;28(3):233–4.

Investigation in the use of topical solutions for management or prevention of thrombosis in traumatized vessels. Cooley BC, et al. **Int Angiol** 1995 Sep;14(3):297–302 (87 ref.)

Long–term effects of low molecular weight heparin on lipid parameters in hemodialysis patients. Elisaf MS, et al. **Int Angiol** 1996 Sep;15(3):252–6

Dose–ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. **J Am Coll Cardiol** 1997 Jun;29(7):1474–82

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double–blind, unfractionated heparin and placebo–controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double–Blind Unfractionated Heparin and Placebo–Controlled Evaluation. Karsch KR, et al. **J Am Coll Cardiol** 1996 Nov 15;28(6):1437–43

Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. Williams MJ, et al. **J Am Coll Cardiol** 1997 Aug;30(2):364–9

Low–dose warfarin prophylaxis to prevent symptomatic pulmonary embolism after total knee arthroplasty. Lieberman JR, et al. **J Arthroplasty** 1997 Feb;12(2):180–4

Covalent antithrombin–heparin complexes with high anticoagulant activity. Intravenous, subcutaneous, and intratracheal administration. Chan A, et al. **J Biol Chem** 1997 Aug 29;272(35):22111–7

The efficacy of prophylaxis with low–dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. Lieberman JR, et al. **J Bone Joint Surg Am** 1997 Mar;79(3):319–25

Enhanced blood conservation in primary coronary artery bypass surgery using heparin–bonded circuits with lower anticoagulation. Aldea GS, et al. **J Card Surg** 1996 Mar–Apr;11(2):85–95

Enhanced blood conservation and improved clinical outcome after valve surgery using heparin–bonded cardiopulmonary bypass circuits. Shapira OM, et al. **J Card Surg** 1996 Sep–Oct;11(5):307–17

Heparin eyedrops to prevent posterior capsule opacification. Mastropasqua L, et al. **J Cataract Refract Surg** 1997 Apr; 23(3):440–6

Treatment of hypercholesterolemia with heparin–induced extracorporeal low–density lipoprotein precipitation (HELP). Lees RS, et al. **J Clin Apheresis** 1996;11(3):132–7 (37 ref.)

Management of a second episode of DVT or PE. Lawless C, et al. **J Fam Pract** 1997 May;44(5):444–5

Antithrombotic potencies of enoxaparin in microvascular surgery: influence of dose and administration methods on patency rate of crushed arterial anastomoses. Korompilias AV, et al. **J Hand Surg [Am]** 1997 May;22(3):540–6

Effect of different oral anticoagulant intensities on prothrombin fragment 1 + 2 in Thai patients with mechanical heart valve prostheses. Tientadakul P, et al. **J Med Assoc Thai** 1997 Feb;80(2):81–6

Avoiding microvenous thrombosis [letter; comment] Simone C, et al. **J Oral Maxillofac Surg** 1997 Apr;55(4):434. Comment on: J Oral Maxillofac Surg 1996 Sep;54(9):1097–102.

Low–molecular–weight heparin in pediatric patients with thrombotic disease: a dose finding study. Massicotte P, et al. **J Pediatr** 1996 Mar;128(3):313–8

Multiple episodes of thrombosis with biventricular support devices with inadequate anticoagulation and evidence of accelerated intravascular coagulation. Despotis GJ, et al. **J Thorac Cardiovasc Surg** 1997 Feb;113(2):419–22

Low–intensity oral anticoagulation plus low–dose aspirin versus high–intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. Meschengieser SS, et al. **J Thorac Cardiovasc Surg** 1997 May;113(5):910–6

Local delivery of heparin with balloon angioplasty: results of a prospective randomized trial. Sheley RC, et al. **J Vasc Interv Radiol** 1996 Nov–Dec;7(6):853–8

Loading dose of warfarin [see comments] Lamb GC. **JAMA** 1997 Apr 16;277(15):1196. Comment in: JAMA 1997 Aug 20;278(7):548.

Loading dose and monitoring of warfarin therapy [letter; comment] Portnoi VA. **JAMA** 1997 Aug 20;278(7):548. Comment on: JAMA 1997 Apr 16;277(15):1196.

Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low–molecular–weight heparin anticoagulation in a canine model. Hulin MS, et al. **Lab Anim Sci** 1997 Apr; 47(2):153–60

Intracoronary stent implantation in native coronary arteries and saphenous vein grafts: a consecutive experience with six types of stents without prolonged anticoagulation [see comments] Itoh A, et al. **Mayo Clin Proc** 1997 Feb; 72(2):101–11. Comment in: Mayo Clin Proc 1997 Feb;72(2):185–7.

Platelet glycoprotein IIb/IIIa receptor blockade and low–dose heparin during percutaneous coronary revascularization. The EPILOG Investigators [see comments] **N Engl J Med** 1997 Jun 12;336(24):1689–96. Comment in: N Engl J Med 1997 Jun 12;336(24):1748–9.

Enoxaparin as prophylaxis against thromboembolism after total hip replacement [letter; comment] Anderson DR, et al. **N Engl J Med** 1997 Feb 20;336(8):585; discussion 586 . Comment on: N Engl J Med 1996 Sep 5;335(10):696–700.

Oral anticoagulant therapy for venous thromboembolism [editorial; comment] [see comments] Diuguid DL. **N Engl J Med** 1997 Feb 6;336(6):433–4. Comment on: N Engl J Med 1997 Feb 6;336(6):393–8. Comment in: N Engl J Med 1997 Jul 3;337(1):52–3.

Anticoagulation for nonrheumatic atrial fibrillation [letter; comment] Hart RG. **N Engl J Med** 1997 Feb 6; 336(6):441–2; discussion 442. Comment on: N Engl J Med 1996 Aug 22;335(8):540–6.

Enoxaparin as prophylaxis against thromboembolism after total hip replacement [letter; comment] Pedell L. **N Engl J Med** 1997 Feb 20;336(8):585; discussion 586. Comment on: N Engl J Med 1996 Sep 5;335(10):696–700.

Heparin versus hirudin for acute coronary syndromes [letter; comment] Schmaier AH. **N Engl J Med** 1997 Mar 6; 336(10):730; discussion 730–1. Comment on: N Engl J Med 1996 Sep 12;335(11):775–82.

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group [see comments] Schulman S, et al. **N Engl J Med** 1997 Feb 6;336(6):393–8 . Comment in: N Engl J Med 1997 Feb 6;336(6):433–4. Comment in: N Engl J Med 1997 Jul 3;337(1):51–2; discussion 52–3. Comment in: ACP J Club 1997 Jul–Aug;127(1):5.

Haemodialysis without anticoagulant: haemostasis parameters, fibrinogen kinetic, and dialysis efficiency. Romão JE Jr, et al. **Nephrol Dial Transplant** 1997 Jan; 12(1):106–10

Activated clotting time is not a sensitive parameter to monitor anticoagulation with low molecular weight heparin in hemodialysis. Greiber S, et al. **Nephron** 1997; 76(1):15–9

The activated clotting time loading dose response ratio (ACTLORR) as an indicator of heparin demand during cardiopulmonary bypass. Reece IJ, et al. **Perfusion** 1996 Mar;11(2):125–30

Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. Guerret M, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):767–73

Comparison of a weight–based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation. Shalansky KF, et al. **Pharmacotherapy** 1996 Nov–Dec;16(6):1076–84

Comparison of two methods for INR determination in a pharmacist–based oral anticoagulation clinic. Yamreudeewong W, et al. **Pharmacotherapy** 1996 Nov–Dec;16(6):1159–65

Characterization of a commercial liposome spray. Rades T, et al. **Pharmazie** 1997 Jan;52(1):44–50

Heparin therapy in the Chinese—lower doses are required. Yu CM, et al. **QJM** 1997 Aug;90(8):535–43

Factors determining the maintenance dose of warfarin in Chinese patients [see comments] Yu HC, et al. **QJM** 1996 Feb;89(2):127–35. Comment in: QJM 1996 Jul;89(7):557.

Oral anticoagulant prophylaxis and epidural catheter removal [see comments] Wu CL, et al. **Reg Anesth** 1996 Nov–Dec; 21(6):517–24. Comment in: Reg Anesth 1996 Nov–Dec;21(6):503–7.

Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration. Cella G, et al. **Semin Thromb Hemost** 1997;23(1):45–9

Dosage, anticoagulant, and antithrombotic effects of heparin and low–molecular–weight heparin in the treatment of deep vein thrombosis. Harenberg J, et al. **Semin Thromb Hemost** 1997;23(1):83–90

Treatment of deep vein thrombosis with low–molecular–weight heparins: a consensus statement of the Gesellschaft für Thrombose–und Hämostaseforschung (GTH). Harenberg J, et al. **Semin Thromb Hemost** 1997; 23(1):91–6 (28 ref.)

Long–term anticoagulation of outpatients with adverse events to oral anticoagulants using low–molecular–weight heparin. Harenberg J, et al. **Semin Thromb Hemost** 1997; 23(2):167–72

Heparin in patients with venous thromboembolism and contraindications to oral anticoagulant therapy. Monreal M. **Semin Thromb Hemost** 1997;23(1):69–75 (47 ref.)

Prevention of recurrences after deep venous thrombosis: role of low–molecular–weight heparins. Pini M. **Semin Thromb Hemost** 1997;23(1):51–4 (18 ref.)

Protective effects of DX–9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin–induced experimental disseminated intravascular coagulation in rats. Yamazaki M, et al. **Semin Thromb Hemost** 1996;22(3):255–9

Pericardiectomy for constrictive pericarditis using a percutaneous heparin–coated cardiopulmonary support system. Saito A, et al. **Thorac Cardiovasc Surg** 1996 Dec; 44(6):311–2

Predicting daily maintenance dose of fluindione, an oral anticoagulant drug. Cazaux V, et al. **Thromb Haemost** 1996 May;75(5):731–3

Prolonged thromboprophylaxis following hip replacement surgery—results of a double–blind, prospective, randomised, placebo–controlled study with dalteparin (Fragmin). Dahl OE, et al. **Thromb Haemost** 1997 Jan; 77(1):26–31

Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Francis CW, et al. **Thromb Haemost** 1996 May;75(5):706–11

Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double–blind, dose–ranging study. Ardeparin Arthroplasty Study Group. Heit JA, et al. **Thromb Haemost** 1997 Jan;77(1):32–8

A 6–month venographic follow–up in 164 patients with acute deep vein thrombosis. Holmström M, et al. **Thromb Haemost** 1997 Aug;78(2):803–7

Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Hunt BJ, et al. **Thromb Haemost** 1997 Jan;77(1):39–43

Enhanced response to chemotactic activation of polymorphonuclear leukocytes from patients with heart valve replacement. Maugeri N, et al. **Thromb Haemost** 1997 Jan;77(1):71–4

The antithrombotic potential of dalteparin in man assessed indirectly by Wessler's technique. Millet J, et al. **Thromb Haemost** 1996 Dec;76(6):989–92

The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs. Minamiguchi K, et al. **Thromb Haemost** 1997 Jun;77(6):1148–53

Effects of heparin therapy on fibrinolysis in patients with pulmonary embolism. Minnema MC, et al. **Thromb Haemost** 1997 Jun;77(6):1164–7

An evaluation and improvement program for inpatient anticoagulant control. Phillips WS, et al. **Thromb Haemost** 1997 Feb;77(2):283–8

Ticlopidine antagonizes acenocoumarol treatment [letter] Salar A, et al. **Thromb Haemost** 1997 Jan;77(1):223–4

A comparison of thromboelastography with heparinase or protamine sulfate added in vitro during heparinized cardiopulmonary bypass. Spiess BD, et al. **Thromb Haemost** 1997 Aug;78(2):820–6

Determination of the International Sensitivity Index of a new near–patient testing device to monitor oral anticoagulant therapy—overview of the assessment of conformity to the calibration model. Tripodi A, et al. **Thromb Haemost** 1997 Aug;78(2):855–8

Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin. Troy S, et al. **Thromb Haemost** 1997 Aug;78(2):871–5

Comparison of the effects of different low molecular weight heparins on the hemostatic system activation in vivo in man. Wolzt M, et al. **Thromb Haemost** 1997 Aug; 78(2):876–9

Relative efficacy of active site–blocked factors IXa, Xa in models of rabbit venous and arterio–venous thrombosis. Wong AG, et al. **Thromb Haemost** 1997 Jun;77(6):1143–7

Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries. Wysokinski W, et al. **Thromb Haemost** 1996 Dec;76(6):1108–13

Topical application of low molecular weight heparin in a rabbit traumatic anastomosis model. Fu K, et al. **Thromb Res** 1997 Jun 1;86(5):355–61

Practicability of patient self–testing of oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor. A pilot investigation. Hasenkam JM, et al. **Thromb Res** 1997 Jan 1;85(1):77–82

The quantitative reduction by acute–dose warfarin of venous thrombosis in normal and hyperthrombotic rats. Lavelle SM, et al. **Thromb Res** 1996 Dec 15;84(6):411–7

The antithrombotic effect of synthetic low molecular weight

human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Yamashita T, et al. **Thromb Res** 1997 Jan 1;85(1):45-51

Concentration of citrate anticoagulant in peripheral blood progenitor cell collections [see comments] Burger SR, et al. **Transfusion** 1996 Sep;36(9):798-801. Comment in: Transfusion 1997 Jul;37(7):768.

Citrate ratio in collection of peripheral blood progenitors [letter; comment] Gorlin JB, et al. **Transfusion** 1997 Jul; 37(7):768. Comment on: Transfusion 1996 Sep;36(9):798-801.

Evaluation of enoxaparin given before and after operation to prevent venous thromboembolism during digestive surgery: play-the-winner designed study. Bjerkeset O, et al. **World J Surg** 1997 Jul-Aug;21(6):584-8; discussion 588-9

[Prevention of postoperative thrombosis] Wille-Jørgensen PA. **Ugeskr Laeger** 1997 Jun 2;159(23):3556-7 **(Dan)**

[Optimal treatment with oral anticoagulants (letter; comment)] Erich WB, et al. **Ned Tijdschr Geneeskd** 1996 Sep 7;140(36):1830-1. Comment on: Ned Tijdschr Geneeskd 1996 May 18;140(20):1059-61. **(Dut)**

[Transplantation of aortic and mitral valves: permanent valve replacement without anticoagulation?] Vetter HO, et al. **Herz** 1997 Apr;22(2):120-1 **(Ger)**

[Anticoagulation of cerebral infarct] Lange R. **Internist (Berl)** 1997 Mar;38(3):259-60 **(Ger)**

[Indications and problems of long-term medicamentous inhibition of blood coagulation] Ostermann H. **Internist (Berl)** 1997 Jul;38(7):672-9 (63 ref.) **(Ger)**

[Thrombophlebitis--use of vitamin K antagonists] Schwieder G. **Internist (Berl)** 1997 Mar;38(3):261 **(Ger)**

[Anticoagulation for immobilized infarct patients] Stiegler H. **Internist (Berl)** 1997 Apr;38(4):362 **(Ger)**

[Anticoagulation after vascular surgery interventions] Breuer P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:870-4 (13 ref.) (Eng. Abstr.) **(Ger)**

[Self-monitoring of blood coagulation by patients. Principles, procedures and long-term outcome] Bernardo A. **Med Monatsschr Pharm** 1997 Feb;20(2):30-5 **(Ger)**

[Coumarin combined with low-dose acetylsalicylic acid in the prevention of thromboembolic complications in patients with mitral and aortic valve prostheses] Voith L, et al. **Orv Hetil** 1997 Apr 13;138(15):925-9 (Eng. Abstr.) **(Hun)**

[Anticoagulant therapy in patients with atrial fibrillation: the experience of the Centers of Surveillance. Study group of the "Italian Study on Complications of Oral Anticoagulant Therapy" (ISCOAT)] Palareti G. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:18S-20S (Eng. Abstr.) **(Ita)**

[Therapeutic ranges of oral anticoagulant therapy in different diseases. Guidelines of the Federation of Centers of Surveillance of Patients on Anticoagulation. Ad hoc Study Group] Prisco D, et al. **Ann Ital Med Int** 1996 Jul-Sep; 11(3):196-203 (Eng. Abstr.) **(Ita)**

[Evolution in coronary stenting: use of ticlopidine with and without oral anticoagulants] Zanini R, et al. **Cardiologia** 1997 Aug;42(8):837-43 (32 ref.) (Eng. Abstr.) **(Ita)**

[Contribution of a combination of alpha and beta benzopyrones, flavonoids and natural terpenes in the treatment of lymphedema of the lower limbs at the 2d stage of the surgical classification] Vettorello G, et al. **Minerva Cardioangiol** 1996 Sep;44(9):447-55 (Eng. Abstr.) **(Ita)**

[Effect of heparin-supplemented iopamidol on the blood coagulation] Kawai J, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Oct; 56(12):874-6 (Eng. Abstr.) **(Jpn)**

[Case of diabetic nephropathy with improvement in marked systemic edema following continuous subcutaneous infusion of heparin] Nishioka K, et al. **Nippon Naika Gakkai Zasshi** 1997 Apr 10;86(4):678-80 **(Jpn)**

[Results of heart valve replacement: especially on the selection criteria for valve prostheses and on a new anticoagulation regimen] Sugimura S, et al. **Rinsho Kyobu Geka** 1989 Jun;9(3):273-9 (Eng. Abstr.) **(Jpn)**

[Control of oral anticoagulant therapy. Should the International Normalized Ratio substitute the thrombosis test?] Brosstad F. **Tidsskr Nor Laegeforen** 1997 Feb 28; 117(6):844-5 **(Nor)**

[Control of peroral anticoagulation (letter; comment)] Madsen S. **Tidsskr Nor Laegeforen** 1997 Feb 28;117(6):851 . Comment on: Tidsskr Nor Laegeforen 1997 Feb 10;117(4):490-1. **(Nor)**

[The implantation of Palmaz-Schatz stents via 6F catheters without oral hypocoagulation] Carvalho H, et al. **Rev Port Cardiol** 1997 Feb;16(2):185-8 **(Por)**

[Changes in the functional status of the hemostatic system with the administration of heparin combined with aspirin to animals with experimental diabetes] Liapina LA, et al. **Izv Akad Nauk Ser Biol** 1996 Sep-Oct;(5):624-7 (Eng. Abstr.) **(Rus)**

[The use of low heparin doses for the prevention of postoperative thrombosis of the deep veins and of pulmonary artery thromboembolism] Shorokh GP, et al. **Klin Khir** 1994;(12):48-50 (Eng. Abstr.) **(Rus)**

[Time organization of blood coagulation in patients with rheumatic heart disease involving circulation insufficiency] Zaslavskaia RM, et al. **Klin Med (Mosk)** 1996;74(8):25-9 (Eng. Abstr.) **(Rus)**

[Changes in hemostasis and vagal tonus in healthy individuals and patients with facial neuropathy by micro-dose heparin stimulation of nasal receptors] Uryvaev IV, et al. **Vestn Ross Akad Med Nauk** 1997;(8):22-3 (Eng. Abstr.) **(Rus)**

[Use of intracoronary stents without anticoagulants. Experience of the Hospital Español de Mexico] Carrillo Anaya A, et al. **Arch Inst Cardiol Mex** 1996 Jul-Aug; 66(4):331-8 (Eng. Abstr.) **(Spa)**

[Use of low molecular weight heparins (letter; comment)] Llau JV, et al. **Rev Esp Anestesiol Reanim** 1997 Feb; 44(2):88-9. Comment on: Rev Esp Anestesiol Reanim 1996 Aug-Sep;43(7):258-60. **(Spa)**

ADVERSE EFFECTS

An unexpected complication of DVT prophylaxis. Manktelow AR, et al. **Acta Orthop Belg** 1997 Jun; 63(2):134-5

Delayed hypersensitivity skin reaction to enoxaparin. Méndez J, et al. **Allergy** 1996 Nov;51(11):853-4 (5 ref.)

Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Bovill EG, et al. **Am J Cardiol** 1997 Feb 15; 79(4):391-6

Deep vein thrombosis, pulmonary embolism, and the white clot syndrome. Melanson SW, et al. **Am J Emerg Med** 1996 Oct;14(6):558-60

Risk of withdrawing chronic anticoagulation without antithrombotic prophylaxis [letter; comment] Kadayifci A, et al. **Am J Gastroenterol** 1997 Feb;92(2):361-2. Comment on: Am J Gastroenterol 1996 Jun;91(6):1116-9.

Probable interaction of warfarin and acarbose [letter] Morreale AP, et al. **Am J Health Syst Pharm** 1997 Jul 1;54(13):1551-2

Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Nand S, et al. **Am J Hematol** 1997 Sep;56(1):12-6

Subdural hematoma following roller coaster ride while anticoagulated. Snyder RW, et al. **Am J Med** 1997 May; 102(5):488-9

A 14-year study of heparin-induced thrombocytopenia. Warkentin TE, et al. **Am J Med** 1996 Nov;101(5):502-7

Acute radial nerve compression following routine venipuncture in an anticoagulated patient. Davison BL, et al. **Am J Orthop** 1996 Oct;25(10):712-3

Enoxaparin (Clexane) HITS [letter] [see comments] James JK. **Anaesth Intensive Care** 1996 Apr;24(2):283-4. Comment in: Anaesth Intensive Care 1996 Oct;24(5):616-7.

Enoxaparin (Clexane) HITS [letter; comment] Watters M. **Anaesth Intensive Care** 1996 Oct;24(5):616-7. Comment on: Anaesth Intensive Care 1996 Apr;24(2):283-4.

Serious spinal cord injury due to haematomyelia caused by spinal anaesthesia in a patient treated with low-dose heparin [see comments] Greaves JD. **Anaesthesia** 1997 Feb; 52(2):150-4. Comment in: Anaesthesia 1997 Jul;52(7):716.

Heparin prophylaxis and central neural blocking techniques [letter; comment] Knowles P. **Anaesthesia** 1997 Jul; 52(7):716. Comment on: Anaesthesia 1997 Feb;52(2):150-4.

Spinal cord injury due to haematomyelia [letter; comment] Tan J, et al. **Anaesthesia** 1997 Jul;52(7):716. Comment on: Anaesthesia 1997 Feb;52(2):150-4.

Use of low molecular weight heparin in patients with heparin-induced thrombocytopenia undergoing carotid endarterectomy. Gottlieb A, et al. **Anesthesiology** 1996 Sep; 85(3):678-81

Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia. Insler SR, et al. **Anesthesiology** 1997 Feb;86(2):495-8

Heparin-associated thrombocytopenia and thrombosis: implications for perioperative management. Slaughter TF, et al. **Anesthesiology** 1997 Sep;87(3):667-75 (93 ref.)

Warfarin-related bleeding in the elderly [letter; comment] Fiore L. **Ann Intern Med** 1997 Apr 15;126(8):660-1. Comment on: Ann Intern Med 1996 Jun 1;124(11):970-9.

Correction of excessive anticoagulation with low-dose oral vitamin K1. Weibert RT, et al. **Ann Intern Med** 1997 Jun 15;126(12):959-62

Thrombocytosis associated with low-molecular-weight heparin [letter; comment] Williams E. **Ann Intern Med** 1997 May 1;126(9):742-3. Comment on: Ann Intern Med 1996 Jul 15;125(2):157.

Cervical spinal epidural haematoma: the double jeopardy. Phookan G, et al. **Ann Med** 1996 Oct;28(5):407-11

Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter] Darlington MR. **Ann Pharmacother** 1997 May;31(5):647

Potential warfarin-fluvastatin interaction [letter] Kline SS, et al. **Ann Pharmacother** 1997 Jun;31(6):790

Potential interaction between warfarin and dicloxacillin. Mailloux AT, et al. **Ann Pharmacother** 1996 Dec; 30(12):1402-7

Heparin-associated refractory bronchospasm [letter] Savas MC, et al. **Ann Pharmacother** 1997 Feb;31(2):253

Enoxaparin-associated dermal necrosis: a consequence of cross-reactivity with heparin-mediated antibodies. Tonn ME, et al. **Ann Pharmacother** 1997 Mar;31(3):323-6

Potential interaction between warfarin and fluvastatin. Trilli LE, et al. **Ann Pharmacother** 1996 Dec;30(12):1399-402

Comment: oral vitamin K1 to reverse warfarin activity [letter] Weathermon RA, et al. **Ann Pharmacother** 1996 Jul-Aug;30(7-8):886-7

Coumadin necrosis of the skin: report of four patients. Miura Y, et al. **Ann Plast Surg** 1996 Sep;37(3):332-7

Lower gastrointestinal bleeding during anticoagulant therapy: a life-saving complication? Norton SA, et al. **Ann R Coll Surg Engl** 1997 Jan;79(1):38-9

Mechanical valves [letter; comment] David TE, et al. **Ann Thorac Surg** 1996 Nov;62(5):1567-70. Comment on: Ann Thorac Surg 1995 Dec;60(6):1836-44.

Mechanical valve performance [letter; comment] O'Hair DP, et al. **Ann Thorac Surg** 1996 Nov;62(5):1570-1. Comment on: Ann Thorac Surg 1995 Dec;60(6):1836-44.

Anticoagulant therapy in patients aged 80 years or more with atrial fibrillation. More caution is needed [editorial; comment] Ackermann RJ. **Arch Fam Med** 1997 Mar-Apr; 6(2):105-10 (82 ref.). Comment on: Arch Fam Med 1995 Dec;4(12):1017-26.

Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Van Gelder IC, et al. **Arch Intern Med** 1996 Dec 9-23;156(22):2585-92

Necrotizing skin lesions induced by low-molecular-weight heparin after total knee arthroplasty. Plath J, et al. **Arch Orthop Trauma Surg** 1997;116(6-7):443-5

Management of acute vascular graft thrombosis associated with HIT syndrome: a case report. Wilson M, et al. **Aust N Z J Surg** 1997 May;67(5):302-3

Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Lewis BE, et al. **Blood Coagul Fibrinolysis** 1997 Jan;8(1):54-8

Potentiation of warfarin anticoagulant activity by miconazole oral gel. Ariyaratnam S, et al. **BMJ** 1997 Feb 1; 314(7077):349

Treating oral candidiasis: potentially fatal [letter] Evans J, et al. **Br Dent J** 1997 Jun 28;182(12):452

Treating oral candidiasis: potentially fatal [letter] Pemberton M, et al. **Br Dent J** 1997 Aug 9;183(3):87

High intensity of oral anticoagulant therapy in patients with cerebral haemorrhage: cause or consequence of the bleeding? Cannegieter SC, et al. **Br J Haematol** 1997 Mar; 96(3):497-9

Epistaxis in anticoagulated patients: educating an at-risk population. Lavy J. **Br J Haematol** 1996 Oct;95(1):195-7

Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Oldenburg J, et al. **Br J Haematol** 1997 Jul;98(1):240-4

Double-edged sword. Anticoagulation therapy for the elderly [news] Kermode-Scott B. **Can Fam Physician** 1997 Apr;43:803-4

The effects of time interval after venipuncture and of anticoagulation on platelet adhesion and aggregation. Bar J, et al. **Clin Lab Haematol** 1996 Dec;18(4):281-4

Osteoporosis and vertebral collapse following low-dose, low molecular weight heparin therapy in a young patient. Sivakumaran M, et al. **Clin Lab Haematol** 1996 Mar; 18(1):55-7

Tolerance to intravenous administration of heparin and heparinoid in a patient with delayed-type hypersensitivity to heparins and heparinoids. Boehncke WH, et al. **Contact Dermatitis** 1996 Aug;35(2):73-5

Atrial fibrillation, anticoagulation, and electroconvulsive therapy. Petrides G, et al. **Convuls Ther** 1996 Jun;12(2):91-8

Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding. Younossi ZM, et al. **Dig Dis Sci** 1997 Jan;42(1):79-82

Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers. Armstrong PW, et al. **Eur Heart J** 1995 Nov;16 Suppl L:75-80 (28 ref.)

Increased levels of plasma thrombomodulin are associated with vascular and all-cause mortality in patients on long-term anticoagulant treatment. Jansson JH, et al. **Eur Heart J** 1996 Oct;17(10):1503-5

Cardiopulmonary bypass leads to a preferential loss of activated platelets. A flow cytometric assay of platelet surface antigens. Wahba A, et al. **Eur J Cardiothorac Surg** 1996;10(9):768-73

Carbamazepine-phenprocoumon interaction. Böttcher T, et al. **Eur Neurol** 1997;38(2):132-3

Fatal cerebral venous sinus thrombosis in heparin-induced thrombotic thrombocytopenia. Meyer-Lindenberg A, et al. **Eur Neurol** 1997;37(3):191-2

Management of acute gastrointestinal hemorrhage in anticoagulated patients. Choudari CP. **Gastroenterologist** 1997 Sep;5(3):242-6 (32 ref.)

Warfarin therapy complicated by recurrent hemobilia in a patient with sarcoidosis. Pollack BJ, et al. **Gastrointest Endosc** 1997 Jul;46(1):72-6

Can the haemorrhagic component of heparin be identified? Or an attempt at clean thinking on a dirty drug [editorial] Hemker HC, et al. **Haemostasis** 1996 May-Jun;26(3):117-26 (50 ref.)

Treatment of the heparin-induced thrombosis-thrombocytopenia syndrome by very low dose streptokinase. Ferrari E, et al. **Heart** 1996 Aug;76(2):185-6

Ancrod: the use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting: nursing management. Lathan LO, et al. **Heart Lung** 1996 Nov-Dec; 25(6):451-60; quiz 461-2 (27 ref.)

A woman with abdominal pain and a history of thromboses.

Matfin G, et al. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):21–2
Severe arterial and venous thrombosis in a patient with heparin–induced thrombocytopenia type II [letter] Janssens U, et al. **Intensive Care Med** 1997 May;23(5):595–6
Risks of long–term oral anticoagulation in a non–trial medical environment. McKenna CJ, et al. **Ir Med J** 1996 Jul–Aug; 89(4):144–5
Warfarin and the apparent minor head injury. Saab M, et al. **J Accid Emerg Med** 1996 May;13(3):208–9
Massive choroidal hemorrhage in age–related macular degeneration: a complication of anticoagulant therapy. Edwards P. **J Am Optom Assoc** 1996 Apr;67(4):223–6
Brachial plexopathy secondary to anticoagulant–induced hematoma as a complication of axillary arteriography. Shoup DW, et al. **J Am Osteopath Assoc** 1997 Feb; 97(2):102–5 (18 ref.)
Transesophageal echocardiographic findings in blue toe syndrome exacerbated by anticoagulation. Willens HJ, et al. **J Am Soc Echocardiogr** 1996 Nov–Dec;9(6):882–4
Antibody–induced arterial thromboembolism resulting in amputation after total knee arthroplasty. Markovich GD, et al. **J Arthroplasty** 1997 Apr;12(3):350–2
Simultaneous phenytoin and warfarin toxicity on chronic concomitant therapy. Meisheri YV.
J Assoc Physicians India 1996 Sep;44(9):661–2
Con: heparin is not the best anticoagulant for cardiopulmonary bypass. Fitch JC.
J Cardiothorac Vasc Anesth 1996 Oct;10(6):819–21
Anticoagulation for cardiopulmonary bypass of a patient with "heparin allergy". Ochroch E, et al.
J Cardiothorac Vasc Anesth 1997 Aug;11(5):622–4
Neuraxial anesthesia is contraindicated in patients undergoing heparinization for surgery. Pro: neuraxial anesthesia should not be used in patients undergoing heparinization for surgery. Ralley FE. **J Cardiothorac Vasc Anesth** 1996 Dec; 10(7):957–60
Orgaran (Org 10172) for cardiopulmonary bypass in heparin–induced thrombocytopenia: role of adjunctive plasmapheresis [letter; comment] Schmahl KS, et al.
J Cardiothorac Vasc Anesth 1997 Apr;11(2):262–3. Comment on: J Cardiothorac Vasc Anesth 1996 Jun;10(4):521–30.
Heparin–induced thrombocytopenia [see comments] Shorten GD, et al. **J Cardiothorac Vasc Anesth** 1996 Jun; 10(4):521–30 (167 ref.). Comment in: J Cardiothorac Vasc Anesth 1997 Apr;11(2):262–3. Comment in: J Cardiothorac Vasc Anesth 1997 Jun;11(4):538–9.
Hematologic changes in a patient with heparin–induced thrombocytopenia who underwent cardiopulmonary bypass after ancrod defibrinogenation. Spiess BD, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):918–21
Case 5—1996. Thrombosis after the use of a heparin–coated cardiopulmonary bypass circuit in a patient with heparin–induced thrombocytopenia [clinical conference] Van Dyck MJ, et al. **J Cardiothorac Vasc Anesth** 1996 Oct; 10(6):809–15
Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease. Verheugt FW.
J Cardiovasc Risk 1996 Apr;3(2):229–32
Effect of anticoagulants on the incidence of late pericardial tamponade following open heart surgery. The Hawaii experience. Premaratne S, et al.
J Cardiovasc Surg (Torino) 1997 Apr;38(2):107–11
Drugs and ulcers: clues about mucosal protection from epidemiologic studies. Griffin MR, et al.
J Clin Gastroenterol 1995;21 Suppl 1:S113–9
CT of hemorrhagic complications of anticoagulant therapy. Pretorius ES, et al. **J Comput Assist Tomogr** 1997 Jan–Feb; 21(1):44–51
Severe cutaneous and venous damage after DIC therapy. Yuasa T, et al. **J Dermatol** 1997 Jul;24(7):466–70 (14 ref.)
Life–threatening retroperitoneal hematoma caused by anticoagulant therapy for myocardial infarction after SWL. Katz R, et al. **J Endourol** 1997 Feb;11(1):23–5
Acute carpal tunnel syndrome as a complication of oral anticoagulant therapy. Black PR, et al.
J Hand Surg [Br] 1997 Feb;22(1):50–1
Biceps rupture in a patient on long–term anticoagulation leading to compartment syndrome and nerve palsies. Richards AM, et al. **J Hand Surg [Br]** 1997 Jun;22(3):411–2
Anticoagulant related complications in elderly patients with St. Jude mechanical valve prostheses. Arom KV, et al.
J Heart Valve Dis 1996 Sep;5(5):505–10
Chinese herbs and warfarin potentiation by 'danshen'. Yu CM, et al. **J Intern Med** 1997 Apr;241(4):337–9
Heparin–induced thrombocytopenia: what the serologists have taught us [editorial; comment] Kelton JG, et al.
J Lab Clin Med 1996 Oct;128(4):346–8. Comment on: J Lab Clin Med 1996 Oct;128(4):376–83.
Heparin–associated thrombocytopenia and thrombosis as the cause of a fatal thrombus on extracorporeal membrane oxygenation. Butler TJ, et al. **J Pediatr Surg** 1997 May; 32(5):768–71
Complications of 32% dextran–70 in 10% dextrose. A case report. Schinco MA, et al. **J Reprod Med** 1996 Jun; 41(6):455–8
Hemorrhagic complications of long–term anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome. al–Sayegh FA, et al.
J Rheumatol 1997 Sep;24(9):1716–8
Heparin–associated intrathoracic pseudotumor. John LC, et al. **J Thorac Cardiovasc Surg** 1997 Jun;113(6):1115–6
Treatment of heparin–induced thrombocytopenia [letter] Peters FP. **J Thorac Cardiovasc Surg** 1997 Sep;114(3):517–8
Hyperkalemia secondary to concurrent pharmacotherapy in a patient receiving home parenteral nutrition. Brown RO, et al. **JPEN J Parenter Enteral Nutr** 1996 Nov–Dec; 20(6):429–32
Complications of anticoagulant therapy in ovulatory women. Bhutta SZ. **JPMA J Pak Med Assoc** 1995 Aug;45(8):219–20
Oral anticoagulants and fetal loss [letter; comment] Brown SA, et al. **Lancet** 1996 Dec 21–28;348(9043):1734. Comment on: Lancet 1996 Oct 5;348(9032):913–6.
Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial [letter] Członkowska A, et al. **Lancet** 1997 Aug 9;350(9075):441–2; discussion 443–4
Complications of oral anticoagulant treatment [letter; comment] Hsin M, et al. **Lancet** 1996 Oct 19;348(9034):1108 . Comment on: Lancet 1996 Aug 17;348(9025):423–8.
Complications of oral anticoagulant treatment [letter; comment] Kadayifci A, et al. **Lancet** 1996 Oct 19; 348(9034):1108. Comment on: Lancet 1996 Aug 17;348(9025):423–8.
Anticoagulation therapy: bleeding and thromboembolic complications [letter; comment] Sweeney KG, et al.
Lancet 1996 Nov 23;348(9039):1456–7. Comment on: Lancet 1996 Aug 17;348(9025):423–8.
Effect of low–molecular–weight heparin on serum concentrations of potassium [letter; comment] Wiggam MI, et al. **Lancet** 1997 Jul 26;350(9073):292–3. Comment on: Lancet 1997 May 17;349(9063):1447–8.
Heparin–induced osteoporosis in pregnancy. Nelson–Piercy C. **Lupus** 1997;6(6):500–4 (37 ref.)
Warfarin—topical salicylate interactions: case reports. Ramanathan M. **Med J Malaysia** 1995 Sep;50(3):278–9
Assessing hyperanticoagulation of dental patients undergoing warfarin therapy. Cripps K, et al. **Mil Med** 1996 Nov; 161(11):679–82
Nontraumatic intramural hematoma of the duodenum complicating warfarin therapy. Gutstein DE, et al.
Mt Sinai J Med 1997 Sep–Oct;64(4–5):339–41
Atrial arrhythmias after cardiac surgery [letter] Walker WE. **N Engl J Med** 1997 Sep 18;337(12):861
Interaction between miconazole oral gel (Daktarin) and warfarin [letter] Pillans P, et al. **N Z Med J** 1996 Sep 13; 109(1029):346
Heparin–associated thrombocytopenia during continuous venovenous hemofiltration [letter] Berlot G, et al.
Nephron 1996;74(1):241–2
Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient [letter] Maruyama H, et al.
Nephron 1996;74(2):468–9
Amoxicillin–related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses. Bandrowsky T, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Dec;82(6):610–2
Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5–fluorouracil. Brown MC. **Pharmacotherapy** 1997 May–Jun;17(3):631–3
Warfarin–fluoxetine and diazepam–fluoxetine interaction. Dent LA, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):170–2
Epidural hematoma after epidural anesthesia in a patient with peripheral vascular disease. Case report. Martínez–Pallí G, et al. **Reg Anesth** 1996 Jul–Aug;21(4):342–6
Incidence of acute oligoanuric renal failure in dextran 40 treated patients with acute ischemic stroke stage III or IV. Biesenbach G, et al. **Ren Fail** 1997 Jan;19(1):69–75
Heparin induced thrombocytopenia after low molecular weight heparin treatment: a case report. Illuminati G, et al. **Riv Eur Sci Med Farmacol** 1996 Sep–Dec;18(5–6):225–8
Long–term anticoagulation of outpatients with adverse events to oral anticoagulants using low–molecular–weight heparin. Harenberg J, et al. **Semin Thromb Hemost** 1997; 23(2):167–72
The role of individual risk factors in anticoagulant–associated hemorrhages. Toulemonde F. **Semin Thromb Hemost** 1996; 22 Suppl 1:53–60 (51 ref.)
Treatment of heparin–induced thrombocytopenia and thrombosis. Green RM. **Semin Vasc Surg** 1996 Dec; 9(4):292–5 (15 ref.)
Heparin–induced thrombocytopenia: pathophysiology. Kibbe MR, et al. **Semin Vasc Surg** 1996 Dec;9(4):284–91 (58 ref.)
Risk factors for cerebral hemorrhage in the era of well–controlled hypertension. Melbourne Risk Factor Study (MERFS) Group. Thrift AG, et al. **Stroke** 1996 Nov; 27(11):2020–5
Negligence in a good practice. Avery JK. **Tenn Med** 1996 Nov;89(11):400–1
Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Makris M, et al. **Thromb Haemost** 1997 Mar;77(3):477–80
Warfarin and heparin–induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Sallah S, et al. **Thromb Haemost** 1997 Aug; 78(2):785–90 (96 ref.)
Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. van der Meer FJ, et al. **Thromb Haemost** 1996 Jul;76(1):12–6
Assays for heparin–induced thrombocytopenia. Griffiths E, et al. **Transfus Med** 1997 Mar;7(1):1–11 (54 ref.)
Oral anticoagulation alone or in combination with aspirin: risks and benefits. Hafner J, et al. **Vasa** 1996;25(1):1–12 (75 ref.)
Anticoagulation with r–hirudin in regular haemodialysis with heparin–induced thrombocytopenia (HIT II). The first long–term application of r–hirudin in a haemodialysis patient [see comments] Nowak G, et al.
Wien Klin Wochenschr 1997 May 23;109(10):354–8. Comment in: Wien Klin Wochenschr 1997 May 23;109(10):343–5.
[Heparin–induced thrombocytopenia] Dulíček P, et al.
Vnitr Lek 1996 Oct;42(10):705–9 (36 ref.) (Eng. Abstr.) **(Cze)**
[Interaction between tramadol and oral anticoagulants] Jensen K. **Ugeskr Laeger** 1997 Feb 3;159(6):785–6 **(Dan)**
[Thrombopenia induced by heparin. From physiopathology to treatment] Gruel Y. **Ann Med Interne (Paris)** 1997; 148(2):136–41 (55 ref.) (Eng. Abstr.) **(Fre)**
[Pre– and intraoperative management of heparin cross hypersensitivity. Apropos of a case] Latrémouille C, et al.
Arch Mal Coeur Vaiss 1996 Oct;89(10):1305–9 (Eng. Abstr.) **(Fre)**
[Biological monitoring and prevention of complications from antithrombotic agents] Samama MM, et al.
Arch Mal Coeur Vaiss 1996 Nov;89(11 Suppl):1569–77 (28 ref.) (Eng. Abstr.) **(Fre)**
[Cytolytic hepatitis of immuno–allergic mechanism caused by fluindione (letter)] Andant C, et al.
Gastroenterol Clin Biol 1997;21(3):237–8 **(Fre)**
[Forensic medical implications of anticoagulant treatments] Samama M, et al. **J Mal Vasc** 1996 Nov;21(4):250–5 (Eng. Abstr.) **(Fre)**
[Spontaneous splenic rupture due to heparin. Report of a case and review of the literature] Jabbour M, et al.
J Med Liban 1995;43(2):107–9 (29 ref.) (Eng. Abstr.) **(Fre)**
[Multi–truncular nerve compression by hematoma of the pyramidal muscle during anticoagulant therapy (letter)] Bouscarat F, et al. **Presse Med** 1997 Mar 8;26(7):320 **(Fre)**
[Cervical extradural hematoma under coagulants. Review of etiologies and prognosis] Hage P, et al.
Rev Neurol (Paris) 1997 Feb;155(1):67–8 (Eng. Abstr.) **(Fre)**
[Spinal para–medullary conduction anesthesia in therapy with anticoagulant drugs] Hesse T, et al.
Anaesthesiol Reanim 1996;21(5):116–21 (74 ref.) (Eng. Abstr.) **(Ger)**
[Preoperative withdrawal of Marcumar] Schramm W, et al.
Anaesthesist 1997 May;46(5):466–7 **(Ger)**
[Surgery in patients treated with anticoagulation during emergency and elective interventions] Encke A. **Chirurg** 1997 Jul;68(7):670–4 (11 ref.) (Eng. Abstr.) **(Ger)**
[Heparin–associated platelet aggregation syndrome with skin necrosis during hemodialysis] Bredlich RO, et al.
Dtsch Med Wochenschr 1997 Mar 14;122(11):328–32 (Eng. Abstr.) **(Ger)**
[Successful lysis of iliofemoral and inferior vena cava thrombi in heparin–induced type–II thrombocytopenia] Emig U, et al. **Dtsch Med Wochenschr** 1997 Aug 1;122(31–32):965–8 (25 ref.) (Eng. Abstr.) **(Ger)**
["White clot syndrome"] Bruhn HD. **Internist (Berl)** 1997 May;38(5):479–80 **(Ger)**
[Are there guidelines for timing readministration of anticoagulation with marcumar in patients with artificial heart valves after intracerebral hemorrhage (stroke, subarachnoid hemorrhage, subdural hematoma)? Kienast J, et al. **Internist (Berl)** 1997 Jan;38(1):83–5 **(Ger)**
[Cataract surgery and anticoagulation—current status] Dick B, et al. **Klin Monatsbl Augenheilkd** 1996 Dec;209(6):340–6 (Eng. Abstr.) **(Ger)**
[Blood coagulation self–control (editorial)] Heinzl S.
Med Monatsschr Pharm 1996 Oct;19(10):283 **(Ger)**
[Cataract operation during therapy with anticoagulants. Principles, perioperative procedure, complications and recommendations] Dick B, et al. **Ophthalmologe** 1997 May; 94(5):372–84 (28 ref.) **(Ger)**
[Fatal central pulmonary embolism under heparin therapy: white–clot syndrome] Canova CR, et al.
Schweiz Med Wochenschr 1997 May 3;127(18):762–5 (Eng. Abstr.) **(Ger)**
[Liver injury caused by coumarin anticoagulants: experience of the IKS (Intercanton Monitoring Station) and the SANZ (Swiss Center for Drug Monitoring)] Ciorciaro C, et al.
Schweiz Med Wochenschr 1996 Dec 7;126(49):2109–13 (Eng. Abstr.) **(Ger)**
[Sudden death under anticoagulation for pulmonary embolism (clinical conference)] Carrel L, et al.
Schweiz Rundsch Med Prax 1997 Apr 9;86(15):619–25 **(Ger)**
[Heparin–induced thrombocytopenia (editorial; comment)] Greinacher A. **Wien Klin Wochenschr** 1997 May 23; 109(10):343–5. Comment on: Wien Klin Wochenschr 1997 May 23;109(10):354–8. **(Ger)**
[Anticoagulant therapy in patients with atrial fibrillation: the experience of the Centers of Surveillance. Study group of the "Italian Study on Complications of Oral Anticoagulant Therapy" (ISCOAT)] Palareti G. **Ann Ital Med Int** 1996 Oct;11 Suppl 2:18S–20S (Eng. Abstr.) **(Ita)**
[Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy)] Palareti G, et al. **G Ital Cardiol** 1997 Mar;27(3):231–43

(Eng. Abstr.) **(Ita)**

[Thrombocytopenia and thrombophilic state in heparin therapy] Faglieri N, et al. **Minerva Anestesiol** 1995 Oct; 61(10):431–5 (Eng. Abstr.) **(Ita)**

[Retroperitoneal hematoma during heparin therapy. Comments on 3 cases] Di Rosa C, et al. **Minerva Chir** 1997 Apr;52(4):493–7 (30 ref.) (Eng. Abstr.) **(Ita)**

[Seroxat combined with Meravean--increased risk of hemorrhage? (letter)] Haukeland JW. **Tidsskr Nor Laegeforen** 1996 Nov 30;116(29):3528–9 **(Nor)**

[Cerebral infarction as first manifestation of thrombocytopenia caused by pentosan polysulfate (letter)] Gironell A, et al. **Med Clin (Barc)** 1997 Apr 26;108(16):636 (10 ref.) **(Spa)**

[Hemorrhagic complications and thrombotic phenomena in oral anticoagulation of elderly patients] Selva O'Callaghan A, et al. **Rev Clin Esp** 1997 May;197(5):323–8 (Eng. Abstr.) **(Spa)**

[Spinal epidural hematoma in anticoagulated patient. Letter] Rodríguez J, et al. **Rev Neurol** 1997 Feb;25(138):308–9 **(Spa)**

[Thrombocytopenia caused by heparin. Report of a case of life-threatening conditions] Houltz B, et al. **Lakartidningen** 1997 Feb 5;94(6):416–9 **(Swe)**

[Follow-up studies of complications due to anticoagulants. Fewer severe bleedings after more stringent routines] Sjöberg KH, et al. **Lakartidningen** 1997 Aug 27; 94(35):2932–4 **(Swe)**

ANALYSIS

Analysis of heparin-like pharmaceuticals by capillary zone electrophoresis and isotachophoresis. Mala Z, et al. **Electrophoresis** 1996 Jan;17(1):125–9

In vitro study on the effect of larval excretory/secretory products and crude extracts from Anisakis simplex on blood coagulation. Perteguer MJ, et al. **Int J Parasitol** 1996 Jan; 26(1):105–8

High-performance liquid chromatographic method for determination of DX-9065a, a novel anticoagulant, in human urine and feces using cation-exchange solid-phase extraction. Murayama N, et al. **J Chromatogr B Biomed Appl** 1997 May 9;692(2):389–96

Development and validation of a reversed-phase liquid chromatographic method for analysis of aspirin and warfarin in a combination tablet formulation. Montgomery ER, et al. **J Pharm Biomed Anal** 1996 Oct;15(1):73–82

Radioimmunoassay method for DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma. Murayama N, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1435–45

The effect of heparin and its neutralisation on functional assays for factor VIIa, factor VII and TFPI. Cardigan RA, et al. **Thromb Res** 1996 Nov 15;84(4):237–42

Diluted Russell's viper venom time and colloidal silica clotting time for the identification of the phospholipid-dependent inhibitors of coagulation. Norbis F, et al. **Thromb Res** 1997 Mar 1;85(5):427–31

ANTAGONISTS & INHIBITORS

Biochemical and cellular effects of heparin-protamine injection in rabbits are partially inhibited by a PAF-acether receptor antagonist. Aïssa J, et al. **Eur J Pharmacol** 1996 Apr 29;302(1–3):123–8

Decreased hypoprothrombinemic effect of warfarin associated with furosemide. Laizure SC, et al. **Ther Drug Monit** 1997 Jun;19(3):361–3

BLOOD

Physiological inhibitors of blood coagulation and prothrombin fragment F 1 + 2 in type 2 diabetic patients with normoalbuminuria and incipient nephropathy. Mormile A, et al. **Acta Diabetol** 1996 Sep;33(3):241–5

Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Raskob GE, et al. **Am J Cardiol** 1996 Nov 1;78(9):1074–6

Evaluation of a new protamine titration method to assay heparin in whole blood and plasma. Schlueter AJ, et al. **Am J Clin Pathol** 1997 May;107(5):511–20

Tissue factor pathway inhibitor concentrations in cirrhotic patients with and without portal vein thrombosis. Oksüzoğlu G, et al. **Am J Gastroenterol** 1997 Feb; 92(2):303–6

Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Shimura M, et al. **Am J Hematol** 1997 Aug;55(4):169–74

Sensitivity and specificity of the Hemochron, Hemotec and APTT for the detection of low concentrations of heparin. Weightman WM, et al. **Anaesth Intensive Care** 1996 Aug; 24(4):472–6

Simultaneous determination of dermatan sulfate and oversulfated dermatan sulfate in plasma by high-performance liquid chromatography with postcolumn fluorescence derivatization. Huang Y, et al. **Anal Biochem** 1996 Sep 5;240(2):227–34

Detection of heparin in salvaged blood [letter] Loubser PG. **Anesthesiology** 1997 Sep;87(3):719–20

A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent. Brancaccio V, et al. **Blood Coagul Fibrinolysis** 1997 Apr;8(3):155–60

Convergence of three methods to resolve discrepant immunoassay digitoxin results. Jortani SA, et al. **Clin Chem** 1997 Sep;43(9):1805–8

Effect of sertraline on protein binding of warfarin. Apseloff G, et al. **Clin Pharmacokinet** 1997;32 Suppl 1:37–42

Procalcitonin--influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations. Meisner M, et al. **Eur J Clin Chem Clin Biochem** 1997 Aug;35(8):597–601

Coagulopathy of childhood nephrotic syndrome--a reappraisal of the role of natural anticoagulants and fibrinolysis. al-Mugeiren MM, et al. **Haemostasis** 1996 Nov-Dec;26(6):304–10

A screening procedure for the determination of 13 oral anticoagulants and rodenticides. Lotfi H, et al. **J Anal Toxicol** 1996 Mar-Apr;20(2):93–100

A simple, rapid gas-liquid chromatographic procedure for the determination of valproic acid in serum. Wohler AS, et al. **J Anal Toxicol** 1997 Jul-Aug;21(4):306–9

A new method of measuring heparin levels in whole blood by protamine titration using a heparin-responsive electrochemical sensor. Wahr JA, et al. **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):447–50

Quantitative determination of hirudin in blood and body fluids. Nowak G, et al. **Semin Thromb Hemost** 1996; 22(2):197–202

Influence of heparin on the assay of amitriptyline, clomipramine, and their metabolites. Levering SC, et al. **Ther Drug Monit** 1996 Jun;18(3):304–5

Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Leurs PB, et al. **Thromb Haemost** 1997 Mar; 77(3):472–6

The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities. Peyrou V, et al. **Thromb Haemost** 1997 Feb;77(2):312–6

Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Hansen JB, et al. **Thromb Res** 1997 Mar 1; 85(5):413–25

Blood-interaction performance of differently sulphated hyaluronic acids. Magnani A, et al. **Thromb Res** 1996 Feb 1;81(3):383–95

[Analysis of behaviors of plasma tissue factor and tissue factor pathway inhibitor in patients with various diseases] Saito M, et al. **Rinsho Ketsueki** 1996 Sep;37(9):794–8 (Eng. Abstr.) **(Jpn)**

CHEMICAL SYNTHESIS

Synthesis and anticoagulant activity of sulfated glucoside-bearing polymer. Akashi M, et al. **Bioconjug Chem** 1996 Jul-Aug;7(4):393–5

Synthesis of 4-cyanophenyl 4-azido-4-deoxy-1,5-dithio-beta-D-xylopyranoside. Bozó E, et al. **Carbohydr Res** 1997 Aug 7;302(3–4):149–62

Improvement of the biological performance of oral anticoagulant drugs. 1. Warfarin. Ammar HO, et al. **Pharmazie** 1997 Aug;52(8):627–31

CHEMISTRY

19 new steroidal saponins from Allium plants: isolation, structural elucidation and effect on blood coagulability. Peng JP, et al. **Adv Exp Med Biol** 1996;404:511–26

Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass. Kagisaki K, et al. **Artif Organs** 1997 Jul;21(7):836–40

Potent bifunctional anticoagulants: Kunitz domain-tissue factor fusion proteins. Lee GF, et al. **Biochemistry** 1997 May 13;36(19):5607–11

Electrostatic interactions in hirudin-thrombin binding. Sharp KA. **Biophys Chem** 1996 Aug 30;61(1):37–49

Isolation and characterization of an anticoagulant from the salivary glands of the tick, Ornithodoros savignyi (Acari: Argasidae). Gaspar AR, et al. **Exp Appl Acarol** 1996 Oct; 20(10):583–98

Antiherpetic and anticoagulant properties of carrageenans from the red seaweed Gigartina skottsbergii and their cyclized derivatives: correlation between structure and biological activity. Carlucci MJ, et al. **Int J Biol Macromol** 1997 Apr;20(2):97–105

Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant action. Mourão PA, et al. **J Biol Chem** 1996 Sep 27;271(39):23973–84

Structural analysis of heparin by raman spectroscopy. Atha DH, et al. **J Pharm Sci** 1996 Jan;85(1):52–6

Accelerated stability studies of heparin. Jandik KA, et al. **J Pharm Sci** 1996 Jan;85(1):45–51

Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin. Jeske W, et al. **Semin Thromb Hemost** 1997;23(2):119–28

Comparison of the anticoagulant action of sulfated and phosphorylated polysaccharides. Dace R, et al. **Thromb Res** 1997 Jul 1;87(1):113–21

CONTRAINDICATIONS

Oral anticoagulation nephrotic syndrome [letter; comment] Craig AR, et al. **Arch Dis Child** 1996 Nov;75(5):462. Comment on: Arch Dis Child 1996 Mar;74(3):228–31.

Warfarin use in patients with atrial fibrillation. Better surveillance is needed [letter] Bridger S. **BMJ** 1997 Sep 20;315(7110):750–1

Warfarin use in patients with atrial fibrillation. May increase risk of haemorrhage in elderly patients [letter] Sulch D. **BMJ** 1997 Sep 20;315(7110):750; discussion 751

Cataract surgery and anticoagulants. Koopmans SA, et al. **Doc Ophthalmol** 1996-97;92(1):11–6

Anticoagulation, antiplatelets and ocular haemorrhage [letter] Shyan WJ. **Singapore Med J** 1997 Jun;38(6):279

[Short-term change in sural venous thrombosis in patients in surgical intensive care when anticoagulants are contraindicated] Cracowski JL, et al. **J Mal Vasc** 1996; 21(5):290–3 (Eng. Abstr.) **(Fre)**

[Thromboembolism prevention with low dose heparin and spinal anesthesia--a risky combination?] Keser C, et al. **Anaesthesist** 1996 Dec;45(12):1203–10 (Eng. Abstr.) **(Ger)**

ECONOMICS

Reactions to fosphenytoin editorial and review article [letter; comment] Collette DR, et al. **Am J Health Syst Pharm** 1997 Feb 15;54(4):442. Comment on: Am J Health Syst Pharm 1996 Nov 15;53(22):2707–12.

Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Hawkins DW, et al. **Am J Health Syst Pharm** 1997 May 15;54(10):1185–90

Economic evaluation of the use of nadroparin in the treatment of deep-vein thrombosis in Switzerland. Lloyd AC, et al. **Ann Pharmacother** 1997 Jul-Aug;31(7–8):842–6

Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective [see comments] Hull RD, et al. **Arch Intern Med** 1997 Feb 10;157(3):289–94. Comment in: ACP J Club 1997 Jul-Aug;127(1):23.

Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective [see comments] Hull RD, et al. **Arch Intern Med** 1997 Feb 10; 157(3):298–303. Comment in: ACP J Club 1997 Jul-Aug;127(1):24.

Thromboprophylaxis with low molecular weight heparin after major orthopaedic surgery is cost effective. Borris LC, et al. **Drugs** 1996;52 Suppl 7:42–6

Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. Lindmarker P, et al. **J Intern Med** 1996 Dec;240(6):395–401

Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis. Kakkar VV. **Thromb Res** 1996;81(2 Suppl):S75–7 (2 ref.)

HISTORY

The development of heparin in Toronto. Marcum JA. **J Hist Med Allied Sci** 1997 Jul;52(3):310–37

[A quarter of a century of computer-assisted anticoagulant treatment] Visser J. **Ned Tijdschr Geneeskd** 1997 Jan 4; 141(1):55–7 (Eng. Abstr.) **(Dut)**

IMMUNOLOGY

Delayed hypersensitivity skin reaction to enoxaparin. Méndez J, et al. **Allergy** 1996 Nov;51(11):853–4 (5 ref.)

Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Bauer TL, et al. **Circulation** 1997 Mar 4; 95(5):1242–6

Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes [see comments] Visentin GP, et al. **J Lab Clin Med** 1996 Oct;128(4):376–83 . Comment in: J Lab Clin Med 1996 Oct;128(4):346–7.

The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies. Liem TK, et al. **J Vasc Surg** 1997 Jan; 25(1):124–30

Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use [letter] Luzzatto G, et al. **Thromb Haemost** 1996 Jan;75(1):211–2

ISOLATION & PURIFICATION

Anticoagulant low molecular weight fucans produced by radical process and ion exchange chromatography of high molecular weight fucans extracted from the brown seaweed Ascophyllum nodosum. Nardella A, et al. **Carbohydr Res** 1996 Aug 19;289:201–8

Isolation and characterization of americanin, a specific inhibitor of thrombin, from the salivary glands of the lone star tick Amblyomma americanum (L.). Zhu K, et al. **Exp Parasitol** 1997 Sep;87(1):30–8

The use of a heparin removal device: a valid alternative to protamine. Hendrikx M, et al. **Int J Artif Organs** 1997 Mar; 20(3):166–74

Purification of protein C a natural anticoagulant, from human

plasma by affinity chromatography with Convanavalin A. Pérez-Campos E, et al. **Prep Biochem Biotechnol** 1996 Aug-Nov;26(3-4):183-8

Expression of a synthetic gene encoding the anticoagulant-antimetastatic protein ghilanten by the methylotropic yeast Pichia pastoris. Brankamp RG, et al. **Protein Expr Purif** 1995 Dec;6(6):813-20

Purification, characterization and cDNA cloning of a novel anticoagulant of the intrinsic pathway, (prolixin-S) from salivary glands of the blood sucking bug, Rhodnius prolixus. Sun J, et al. **Thromb Haemost** 1996 Apr; 75(4):573-7

Purification of anticoagulant factor from the spine venom of the crown-of-thorns starfish, Acanthaster planci. Karasudani I, et al. **Toxicon** 1996 Aug;34(8):871-9

[The nature of an anticoagulant isolated from peonies in the central zone of Russia] Liapina LA, et al. **Izv Akad Nauk Ser Biol** 1997 Mar-Apr;(2):235-7 (Eng. Abstr.) **(Rus)**

METABOLISM

Probable interaction between cetirizine and acenocoumarol [letter] Berod T, et al. **Ann Pharmacother** 1997 Jan;31(1):122

Highly conserved residue arginine-15 is required for the Ca2+-dependent properties of the gamma-carboxyglutamic acid domain of human anticoagulation protein C and activated protein C. Thariath A, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):309-15

Macromolecule-macromolecule interaction in drug distribution. IV. Molecular weight dependency in the interaction of fractionated [3H]heparin with plasma proteins. Watanabe J, et al. **Biol Pharm Bull** 1996 Feb; 19(2):287-90

Probable regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo. Gouin-Thibault I, et al. **Br J Haematol** 1996 Dec; 95(4):738-46

HPLC determination of anticoagulant rodenticide residues in animal livers. Jones A. **Bull Environ Contam Toxicol** 1996 Jan;56(1):8-15

Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro-progestins. Olivieri O, et al. **Contraception** 1996 Sep;54(3):149-52

Platelet-derived growth factor-BB (PDGF-BB) in tear fluid: a potential modulator of corneal wound healing following photorefractive keratectomy. Vesaluoma M, et al. **Curr Eye Res** 1997 Aug;16(8):825-31

Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Cerneca F, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 May;73(1):31-6

Structure-function relationships in the heparin-binding C-terminal region of insulin-like growth factor binding protein-3. Booth BA, et al. **Growth Regul** 1996 Dec; 6(4):206-13

Blood interaction with a Bioline heparin coated HIA-VAD: a study on calves. van der Kamp KW, et al. **Int J Artif Organs** 1997 Jan;20(1):43-50

Identification of the antithrombin III heparin binding site. Ersdal-Badju E, et al. **J Biol Chem** 1997 Aug 1; 272(31):19393-400

Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes. Ho G, et al. **J Biol Chem** 1997 Jul 4;272(27):16838-44

Cell-free synthesis of anticoagulant heparan sulfate reveals a limiting converting activity that modifies an excess precursor pool. Shworak NW, et al. **J Biol Chem** 1996 Oct 25;271(43):27063-71

Novel anticoagulant from salivary glands of Simulium vittatum (Diptera: Simuliidae) inhibits activity of coagulation factor V. Abebe M, et al. **J Med Entomol** 1996 Jan;33(1):173-6

Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. Vorum H, et al. **J Pharm Pharmacol** 1996 Aug;48(8):870-5

Stability of heparin anticoagulant activity over time in parenteral nutrition solutions [published erratum appears in JPEN J Parenter Enteral Nutr 1996 Sep-Oct;20(5):370] Hensrud DD, et al. **JPEN J Parenter Enteral Nutr** 1996 May-Jun;20(3):219-21

Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Gale AJ, et al. **Protein Sci** 1997 Jan;6(1):132-40

Evidence that endogenous heparin activity deficiency may be an important factor in atherogenesis. Engelberg H. **Semin Thromb Hemost** 1997;23(2):159-66 (86 ref.)

Laboratory diagnosis of resistance to activated protein C (APC-resistance). Bertina RM. **Thromb Haemost** 1997 Jul; 78(1):478-82 (71 ref.)

Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Dahlbäck B. **Thromb Haemost** 1997 Jul; 78(1):483-8 (69 ref.)

The protein C pathway: new insights. Esmon CT, et al. **Thromb Haemost** 1997 Jul;78(1):70-4

The importance of the binding of factor Xa to phospholipids in the inhibitory mechanism of tissue factor pathway inhibitor: the transmembrane and cytoplasmic domains of tissue factor are not essential for the inhibitory action of tissue factor pathway inhibitor. Kazama Y. **Thromb Haemost** 1997 Mar;77(3):492-7

Modulation of thrombin's procoagulant and anticoagulant properties. Leung LL, et al. **Thromb Haemost** 1997 Jul; 78(1):577-80 (16 ref.)

beta 2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Mori T, et al. **Thromb Haemost** 1996 Jan;75(1):49-55

Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies. Nagase H, et al. **Thromb Haemost** 1997 Aug; 78(2):864-70

Thrombomodulin gene disruption and mutation in mice. Rosenberg RD. **Thromb Haemost** 1997 Jul;78(1):705-9

Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Tripodi A, et al. **Thromb Haemost** 1997 Mar;77(3):436-9

Anticoagulant properties of rabbit lungs in tissue thromboplastin-induced intravascular coagulation. Vad H, et al. **Thromb Haemost** 1997 Apr;77(4):679-84

Tissue factor pathway inhibitor production by human mesangial cells in culture. Yamabe H, et al. **Thromb Haemost** 1996 Aug;76(2):215-9

Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans. Iversen N, et al. **Thromb Res** 1996 Nov 15;84(4):267-78

Activation of recombinant human protein C. Lee TK, et al. **Thromb Res** 1996 May 1;82(3):225-34

Recombinant human tissue factor pathway inhibitor as a possible anticoagulant targeting hepatic sinusoidal walls. Yamanobe F, et al. **Thromb Res** 1997 Mar 15;85(6):493-501

Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Kopp CW, et al. **Transplantation** 1997 Mar 15;63(5):749-58

[Hemocoagulation, anticoagulant and fibrinolytic characteristics of human stomach tissue] Golyshenkov SP. **Fiziol Cheloveka** 1996 Jul-Aug;22(4):114-7 **(Rus)**

PHARMACOKINETICS

Potential interaction between tramadol and warfarin [letter] Scher ML, et al. **Ann Pharmacother** 1997 May;31(5):646-7

Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. Schall R, et al. **Arzneimittelforschung** 1996 Jan;46(1):41-6

Stereoselective interaction between piroxicam and acenocoumarol. Bonnabry P, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):525-30

Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients. McAleer SD, et al. **Chirality** 1997;9(1):13-6

Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Israel DS, et al. **Clin Infect Dis** 1996 Feb;22(2):251-6

Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations. Palareti G, et al. **Clin Pharmacokinet** 1996 Apr;30(4):300-13 (87 ref.)

Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Lefèvre G, et al. **Clin Pharmacol Ther** 1997 Jul;62(1):50-9

Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Ehrlich A, et al. **Eur J Clin Pharmacol** 1996;51(3-4):277-81

Metabolic and analytical interactions of grapefruit juice and 1,2-benzopyrone (coumarin) in man. Runkel M, et al. **Eur J Clin Pharmacol** 1996;50(3):225-30

Lack of interaction between meloxicam and warfarin in healthy volunteers. Türck D, et al. **Eur J Clin Pharmacol** 1997;51(5):421-5

Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. Stoysich AM, et al. **Int J Clin Pharmacol Ther** 1996 Feb;34(2):56-60

Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers. Liao S, et al. **J Clin Pharmacol** 1996 Nov;36(11):1072-7

The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Zhi J, et al. **J Clin Pharmacol** 1996 Jul;36(7):659-66

Generic warfarin: implications for patient care [editorial] Wittkowsky AK. **Pharmacotherapy** 1997 Jul-Aug; 17(4):640-3

Lack of pharmacokinetic interaction between dextromethorphan, coumarin and mephenytoin in man after simultaneous administration. Endres HG, et al. **Pharmazie** 1996 Jan;51(1):46-51

Comparison of the pharmacodynamic and pharmacokinetic profiles of two low-molecular-mass heparins in rats. Piazolo L, et al. **Semin Thromb Hemost** 1997;23(2):109-17

Inability to attain oral anticoagulation: warfarin-rifampin interaction revisited. Casner PR. **South Med J** 1996 Dec; 89(12):1200-3 (21 ref.)

Immunoassays in monitoring biotechnological drugs. Gygax D, et al. **Ther Drug Monit** 1996 Aug;18(4):405-9

Effect of a 15-minute infusion of DDAVP on the pharmacokinetics and pharmacodynamics of REVASC during a four-hour intravenous infusion in healthy male volunteers. Amin DM, et al. **Thromb Haemost** 1997 Jan; 77(1):127-32

Long-term persistence of biological activity following administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments--comparison with unfractionated heparin. Brieger D, et al. **Thromb Haemost** 1996 May; 75(5):740-6

Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Brieger D, et al. **Thromb Haemost** 1997 Feb;77(2):317-22

Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Vanholder R, et al. **Thromb Haemost** 1997 Apr;77(4):650-5

Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Andrassy K, et al. **Thromb Res** 1996;81(2 Suppl):S29-38 (25 ref.)

Impairment of citrate metabolism in acute hepatic failure. Apsner R, et al. **Wien Klin Wochenschr** 1997 Feb 28; 109(4):123-7

PHARMACOLOGY

Effects of heparin and low molecular weight heparin on lipid transport during parenteral feeding in the rat. Roth B, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):102-11

The effect of heparin-surface-modification on scar-tissue formation around a subconjunctival polymethylmethacrylate implant in the rabbit. Kivalo M. **Acta Ophthalmol Scand** 1997 Apr;75(2):189-93

A comparison of the lipolytic and anticoagulative properties of heparin and pentosan polysulphate in the thoroughbred horse. Orme CE, et al. **Acta Physiol Scand** 1997 Feb; 159(2):179-85

Anticoagulant activity of Triatoma infestans and Panstrongylus megistus saliva (Hemiptera/Triatominae). Pereira MH, et al. **Acta Trop** 1996 May;61(3):255-61

19 new steroidal saponins from Allium plants: isolation, structural elucidation and effect on blood coagulability. Peng JP, et al. **Adv Exp Med Biol** 1996;404:511-26

Effect of warfarin on regional left atrial coagulation activity in mitral stenosis. Peverill RE, et al. **Am J Cardiol** 1997 Feb 1;79(3):339-43

Assessment of vitamin K status in human subjects administered "minidose" warfarin. Bach AU, et al. **Am J Clin Nutr** 1996 Dec;64(6):894-902

Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. Elsayed YA, et al. **Am J Clin Pathol** 1996 Nov;106(5):574-83

Hypoprothrombinemia induced by warfarin sodium and cisapride [letter] Raburn M. **Am J Health Syst Pharm** 1997 Feb 1;54(3):320-1

Low molecular weight heparin stimulates megakaryocytopoiesis in bone-marrow transplantation patients. Or R, et al. **Am J Hematol** 1996 Sep;53(1):46-8

Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Murakami K, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):L197-202

Fibrin glue containing fibroblast growth factor type 1 and heparin decreases platelet deposition. Zarge JI, et al. **Am J Surg** 1997 Aug;174(2):188-92

Comparison of the effects of low-molecular-weight and unfractioned heparin in horses. Monreal L, et al. **Am J Vet Res** 1995 Oct;56(10):1281-5

Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Despotis GJ, et al. **Anesth Analg** 1997 Sep;85(3):498-506

A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients. Greilich PE, et al. **Anesth Analg** 1997 Jan;84(1):31-8

Anticoagulation with warfarin in infants and children. Buck ML. **Ann Pharmacother** 1996 Nov;30(11):1316-22 (56 ref.)

Dalteparin: a low-molecular-weight heparin. Howard PA. **Ann Pharmacother** 1997 Feb;31(2):192-203 (80 ref.)

Effect of citrate concentration in specimen collection tubes on the International Normalized Ratio. Danielson CF, et al. **Arch Pathol Lab Med** 1997 Sep;121(9):956-9

Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. McKenzie CR, et al. **Arterioscler Thromb Vasc Biol** 1996 Oct;16(10):1285-91

Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Rogers C, et al. **Arterioscler Thromb Vasc Biol** 1996 Oct;16(10):1312-8

Experimental studies on three types of heparin-coated cardiopulmonary bypass circuits. Baba T, et al. **Artif Organs** 1997 Jul;21(7):779-81

Immobilized heparin inhibits the increase in leukocyte surface expression of adhesion molecules. Garred P, et al. **Artif Organs** 1997 Apr;21(4):293-9

Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. Schall R, et al. **Arzneimittelforschung** 1996 Jan;46(1):41-6

Depolymerized holothurian glycosaminoglycan (DHG) prevents neointimal formation in balloon-injured rat carotid artery. Igarashi M, et al. **Atherosclerosis** 1997 Feb 28;129(1):27-31

Potent bifunctional anticoagulants: Kunitz domain-tissue factor fusion proteins. Lee GF, et al. **Biochemistry** 1997 May 13;36(19):5607-11

Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Tsiang M, et al. **Biochemistry** 1996 Dec 24;35(51):16449-57

Heparin-steroid conjugates lacking glucocorticoid or mineralocorticoid activities inhibit the proliferation of

vascular endothelial cells. Derbyshire EJ, et al. **Biochim Biophys Acta** 1997 Jan 10;1310(1):86–96

Reversal of RT–PCR inhibition observed in heparinized clinical specimens. Jung R, et al. **Biotechniques** 1997 Jul; 23(1):24, 26, 28

A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Kelley RF, et al. **Blood** 1997 May 1;89(9):3219–27

Anticoagulant effects of synthetic retinoids mediated via different receptors on human leukemia and umbilical vein endothelial cells. Shibakura M, et al. **Blood** 1997 Aug 15; 90(4):1545–51

Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin. Harenberg J, et al. **Blood Coagul Fibrinolysis** 1996 Jun; 7(4):477–83

Measurement of platelet volume using a variety of different anticoagulant and antiplatelet mixtures. O'Malley T, et al. **Blood Coagul Fibrinolysis** 1996 Jun;7(4):431–6

Long-term persistence of low-molecular-weight material with anti-factor Xa activity contributes to anticoagulant and antithrombotic effects after subcutaneous injection of CY 216 in the rabbit. Peyrou V, et al. **Blood Coagul Fibrinolysis** 1997 Apr;8(3):175–84

Interaction of reteplase with heparin. A comparison between reteplase and alteplase. Rijken DC, et al. **Blood Coagul Fibrinolysis** 1996 Jul;7(5):561–6

Activated protein C resistance: from phenotype to genotype and clinical practice. Hillarp A, et al. **Blood Rev** 1995 Dec; 9(4):201–12 (156 ref.)

Effects of anticoagulants and storage (4 degrees C) on packed cell volume (PCV) of Nigerian domestic fowl (Gallus domesticus) and guinea fowl (Numida meleagris). Uko OJ, et al. **Br Poult Sci** 1996 Dec;37(5):997–1002

Protein phosphorylation in response to PDGF stimulation in cultured neurons and astrocytes. Zhang FX, et al. **Brain Res Dev Brain Res** 1997 Apr 18;99(2):216–25

Diverse effects of heparin on mitogen-activated protein kinase-dependent signal transduction in vascular smooth muscle cells. Daum G, et al. **Circ Res** 1997 Jul;81(1):17–23

Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Cosmi B, et al. **Circulation** 1997 Jan 7;95(1):118–24

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Phillips DR, et al. **Circulation** 1997 Sep 2;96(5):1488–94

High-dose heparin decreases nitric oxide production by cultured bovine endothelial cells. Upchurch GR Jr, et al. **Circulation** 1997 Apr 15;95(8):2115–21

Clinically important drug interactions with anticoagulants. An update. Harder S, et al. **Clin Pharmacokinet** 1996 Jun; 30(6):416–44 (224 ref.)

The human pharmacology of thrombin inhibition [published erratum appears in Coron Artery Dis 1997 Jan;8(1):A4] FitzGerald GA. **Coron Artery Dis** 1996 Dec;7(12):911–8 (108 ref.)

Potential advantages of direct-acting thrombin inhibitors. Philippides GJ, et al. **Coron Artery Dis** 1996 Jul; 7(7):497–507 (100 ref.)

Novel anticoagulants for flow cytometric analysis of live leucocytes in whole blood. McCarthy DA, et al. **Cytometry** 1996 Mar 1;23(3):196–204

Activated protein C resistance in type I diabetes. Gruden G, et al. **Diabetes Care** 1997 Mar;20(3):424–5

New data on the pharmacology of heparin and low molecular weight heparins. Samama MM, et al. **Drugs** 1996;52 Suppl 7:8–14; discussion 14–5 (24 ref.)

Evaluation of the anticoagulant properties of aprotinin in vitro. Mortier E, et al. **Eur J Anaesthesiol** 1996 Sep; 13(5):468–70

Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model. Bannan S, et al. **Eur J Cardiothorac Surg** 1997 Aug; 12(2):268–75

Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model. Riess FC, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):739–45

The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Levi M, et al. **Eur J Clin Invest** 1997 Jan;27(1):3–9 (56 ref.)

Failure of heparin to inhibit the expression of the thrombin receptor following endothelial injury of the rabbit carotid artery. Guitteny AF, et al. **Eur J Pharmacol** 1997 May 30;327(2–3):157–62

Selective enhancement of antagonist ligand binding at muscarinic M2 receptors by heparin due to receptor uncoupling. Wang SZ, et al. **Eur J Pharmacol** 1996 Jan 18;296(1):113–8

Fibroblast growth factor-1 induction of delayed-early mRNA expression in NIH 3T3 cells is prolonged by heparin addition. Donohue PJ, et al. **Exp Cell Res** 1997 Jul 10;234(1):139–46

Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Hoult JR, et al. **Gen Pharmacol** 1996 Jun;27(4):713–22 (70 ref.)

Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Lapierre F, et al. **Glycobiology** 1996 Apr;6(3):355–66

Anticoagulant effect of unfractionated heparin in antithrombin-depleted plasma in vitro. Krulder JW, et al. **Haemostasis** 1996 Mar–Apr;26(2):85–9

Precision and accuracy of the international normalized ratio in oral anticoagulant control. van den Besselaar AM. **Haemostasis** 1996 Oct;26 Suppl 4:248–65 (44 ref.)

Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion in rat liver. Yamaguchi Y, et al. **Hepatology** 1997 May;25(5):1136–40

Low-dose heparin treatment does not inhibit SW480 human colon cancer growth and metastasis in vivo. Antachopoulos CT, et al. **In Vivo** 1996 Sep–Oct;10(5):527–31

Effect of anticoagulants on binding and neutralization of lipopolysaccharide by the peptide immunoglobulin conjugate CAP18(106–138)–immunoglobulin G in whole blood. Ogata M, et al. **Infect Immun** 1997 Jun;65(6):2160–7

Global and extended coagulation monitoring during extracorporeal lung assist with heparin-coated systems in ARDS patients. Gerlach M, et al. **Int J Artif Organs** 1997 Jan;20(1):29–36

Antiherpetic and anticoagulant properties of carrageenans from the red seaweed Gigartina skottsbergii and their cyclized derivatives: correlation between structure and biological activity. Carlucci MJ, et al. **Int J Biol Macromol** 1997 Apr;20(2):97–105

The anticoagulant, antithrombotic and haemorrhagic effect of long-term warfarin on experimental venous and arterial thrombosis in the rat. MacIomhair M, et al. **Ir J Med Sci** 1996 Jul–Sep;165(3):213–8

Anticoagulants and thyroid [letter] Agarwal A. **J Assoc Physicians India** 1995 Jan;43(1):70

In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft. Kim DI, et al. **J Atheroscler Thromb** 1996;2(2):110–6

Effect of depolymerized holothurian glycosaminoglycan (DHG) on the activation of factor VIII and factor V by thrombin. Nagase H, et al. **J Biochem (Tokyo)** 1996 Jan; 119(1):63–9

The mechanism of anticoagulant activity of a novel heparinoid sulfated glucoside-bearing polymer. Sakamoto N, et al. **J Biomater Sci Polym Ed** 1997;8(7):545–53

Platelet-derived growth factor stimulates sodium-dependent Pi transport in osteoblastic cells via phospholipase Cgamma and phosphatidylinositol 3'-kinase. Zhen X, et al. **J Bone Miner Res** 1997 Jan;12(1):36–44

Age-related differences in heparin sensitivity and heparin-protamine interactions in cardiac surgery patients. D'Errico C, et al. **J Cardiothorac Vasc Anesth** 1996 Jun; 10(4):451–7

The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. Martindale SJ, et al. **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):458–63

Methylene blue does not neutralize heparin after cardiopulmonary bypass. Metz S, et al. **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):474–6

Pro: heparin is the best anticoagulant for cardiopulmonary bypass. Rinder CS. **J Cardiothorac Vasc Anesth** 1996 Oct; 10(6):816–8

Inhibition of neointimal proliferation after coronary angioplasty by low-molecular-weight heparin (clivarine) and polyethyleneglycol-hirudin. Buchwald AB, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):481–7

Effect of methylprednisolone on complement activation during heparin neutralization. Loubser PG. **J Cardiovasc Pharmacol** 1997 Jan;29(1):23–7

Improved perfusion with rt-PA and hirulog in a rabbit model of embolic stroke. Yenari MA, et al. **J Cereb Blood Flow Metab** 1997 Apr;17(4):401–11

A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism [see comments] Chu K, et al. **J Clin Invest** 1996 Oct 1;98(7):1619–25. Comment in: J Clin Invest 1996 Oct 1;98(7):1508.

Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. Petäjä J, et al. **J Clin Invest** 1997 Jun 1;99(11):2655–63

Influence of anticoagulants on the level of soluble HLA class I and class II antigens measured in blood samples. Hausmann S, et al. **J Immunoassay** 1996 Aug;17(3):257–75

Facilitation of retinal function recovery by coumarin derivatives. Liu SX, et al. **J Ocul Pharmacol Ther** 1997 Feb;13(1):69–79

Increase of ocular blood flow by some phytogenic compounds. Liu SX, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):95–101

Porous polysulfone coated with platelet-derived growth factor-BB stimulates proliferation of human periodontal ligament fibroblasts. Mailhot JM, et al. **J Periodontol** 1996 Oct;67(10):981–5

Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. Fryer A, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):208–19

Enhancement of the leukocyte-endothelial cell interaction in collecting venules of skeletal muscle by protamine. Habazettl H, et al. **J Thorac Cardiovasc Surg** 1997 Apr; 113(4):784–91

Complement activation by heparin-protamine complexes during cardiopulmonary bypass: effect of C4A null allele. Shastri KA, et al. **J Thorac Cardiovasc Surg** 1997 Sep; 114(3):482–8

Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin. Nishiyama M, et al. **Jpn J Pharmacol** 1997 May; 74(1):59–68

Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. van Bruggen MC, et al. **Kidney Int** 1996 Nov;50(5):1555–64

Effect of low-molecular-weight heparin on serum potassium [letter] [see comments] Canova CR, et al. **Lancet** 1997 May 17;349(9063):1447–8. Comment in: Lancet 1997 Jul 26;350(9073):292–3.

Interaction between tramadol and phenprocoumon [letter] Madsen H, et al. **Lancet** 1997 Aug 30;350(9078):637

Protein C resistance and antiphospholipid antibodies [letter; comment] Ruiz-Argüelles GJ. **Lupus** 1996 Dec;5(6):633. Comment on: Lupus 1996 Apr;5(2):163–6.

Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients. Avellone G, et al. **Metabolism** 1997 Aug;46(8):930–4

Clinical effectiveness of venotonic drugs: a meta-analysis. Boada J, et al. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:15–8

Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Bos JC, et al. **Nephrol Dial Transplant** 1997 Jul; 12(7):1387–93

Effect of glucose and heparin on mesangial alpha 1(IV)COLL and MMP-2/TIMP-2 mRNA expression. Caenazzo C, et al. **Nephrol Dial Transplant** 1997 Mar; 12(3):443–8

Active inhibitory effect of nafamostat mesylate against the elevation of plasma myeloperoxidase during hemodialysis. Inose K, et al. **Nephron** 1997;75(4):420–5

Anticoagulant factor protein S inhibits the proliferation of rat astrocytes after injury. Tomobe YI, et al. **Neurosci Lett** 1996 Aug 16;214(1):57–60

Neurone-specific enolase and Sangtec 100 assays during cardiac surgery: Part I—The effects of heparin, protamine and propofol. Gao F, et al. **Perfusion** 1997 May;12(3):163–5

Complement consumption during cardiopulmonary bypass: comparison of Duraflo II heparin-coated and uncoated circuits in fully heparinized patients. Hamulu A, et al. **Perfusion** 1996 Jul;11(4):333–7

Biocompatibility in heparin-coated extracorporeal circuits. Hsu LC. **Perfusion** 1996 May;11(3):256–63 (32 ref.)

Clinical evidence of improved biocompatibility using heparin-coated surfaces. Matheve C. **Perfusion** 1996 May; 11(3):264–9 (14 ref.)

Unstable anticoagulation in the course of amitriptyline treatment. Hampel H, et al. **Pharmacopsychiatry** 1996 Jan; 29(1):33–7

The anticoagulated patient. Rauck RL. **Reg Anesth** 1996 Nov–Dec;21(6 Suppl):51–6 (28 ref.)

Warfarin monitoring independent of the international normalized ratio (INR): a pilot study. Carroll WE, et al. **Res Commun Mol Pathol Pharmacol** 1997 Feb;95(2):169–78

Sedimentation of formed elements in distally ischaemic flaps. Birk-Sørensen L, et al. **Scand J Plast Reconstr Surg Hand Surg** 1997 Sep; 31(3):203–11

Circulating cytokines and granulocyte-derived enzymes during complex heart surgery. A clinical study with special reference to heparin-coating of cardiopulmonary bypass circuits. Borowiec JW, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(4):167–74

Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits. Ernofsson M, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(4):157–65

Anticoagulants and extracorporeal circuits. Beijering RJ, et al. **Semin Thromb Hemost** 1997;23(2):225–33 (69 ref.)

Comparison of the anticoagulant activities of thrombin inhibitors as assessed by thromboelastographic analysis. Callas D, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:76–9

Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin. Jeske W, et al. **Semin Thromb Hemost** 1997;23(2):119–28

Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin. Pepe G, et al. **Semin Thromb Hemost** 1997; 23(2):135–41

Comparison of the pharmacodynamic and pharmacokinetic profiles of two low-molecular-mass heparins in rats. Piazolo L, et al. **Semin Thromb Hemost** 1997;23(2):109–17

Thromboelastographic modifications induced by intravenous and subcutaneous heparin administration. Traverso CI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:53–8 (47 ref.)

Role of thromboelastography in evaluating other anticoagulant agents: warfarin and heparin-dihydroergotamine. Traverso CI, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:59–62 (12 ref.)

Ancrod: understanding the agent. Illig KA, et al. **Semin Vasc Surg** 1996 Dec;9(4):303–14 (95 ref.)

A novel nonanticoagulant heparin prevents vascular endothelial cell dysfunction during hyperdynamic sepsis. Morrison AM, et al. **Shock** 1996 Jul;6(1):46–51

Heparin ameliorates brain injury by inhibiting leukocyte accumulation [letter; comment] Yanaka K, et al. **Stroke** 1996 Nov;27(11):2146–7. Comment on: Stroke 1996

Feb;27(2):303–9; discussion 310.
Modulation of blood cell activation by four commonly used anticoagulants. Engstad CS, et al. **Thromb Haemost** 1997 Apr;77(4):690–6
Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Hansen JB, et al. **Thromb Haemost** 1996 Nov;76(5):703–9
Heightened thrombin generation in individuals with resistance to activated protein C. Martinelli I, et al. **Thromb Haemost** 1996 May;75(5):703–5
In vitro effects of aprosulate sodium, a novel anticoagulant, on platelet activation: possible mechanism for antiplatelet action. Sugidachi A, et al. **Thromb Haemost** 1996 Nov; 76(5):786–90
Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Sundaram S, et al. **Thromb Haemost** 1996 Jan;75(1):76–82
The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis. Tosetto A, et al. **Thromb Haemost** 1997 Aug;78(2):859–63
Differential effects of warfarin on the intracellular processing of vitamin K–dependent proteins. Wu W, et al. **Thromb Haemost** 1996 Jul;76(1):46–52
Inhibition of blood coagulation activation and oral anticoagulants in patients with mechanical heart valve prostheses. Barcellona D, et al. **Thromb Res** 1996 Feb 1; 81(3):403–6
Comparison of the anticoagulant action of sulfated and phosphorylated polysaccharides. Dace R, et al. **Thromb Res** 1997 Jul 1;87(1):113–21
Anticoagulant fucoidan fractions from Fucus vesiculosus induce platelet activation in vitro. Dürig J, et al. **Thromb Res** 1997 Mar 15;85(6):479–91
Preclinical studies on a low molecular weight heparin. Fareed J, et al. **Thromb Res** 1996;81(2 Suppl):S1–27
Molecular insights into the anticoagulant–induced spontaneous activation of platelets in whole blood–various anticoagulants are not equal. Golański J, et al. **Thromb Res** 1996 Aug 1;83(3):199–216
A novel approach to inhibit the anticoagulant–induced spontaneous activation of blood platelets––effect of magnesium on platelet release reaction in whole blood. Golański J, et al. **Thromb Res** 1997 Jan 15;85(2):127–32
Degradation of human factor XIII by lonomin V, a purified fraction of Lonomia achelous caterpillar venom. Guerrero BA, et al. **Thromb Res** 1997 Jul 15;87(2):171–81
Species specificity of anticoagulant activity of activated human protein C: involvement of factor V as well as protein S. Katsuura Y, et al. **Thromb Res** 1996 Apr 15; 82(2):147–57
DHG, a new depolymerized holothurian glycosaminoglycan, exerts an antithrombotic effect with less bleeding than unfractionated or low molecular weight heparin, in rats. Kitazato K, et al. **Thromb Res** 1996 Oct 15;84(2):111–20
Very low doses of unfractionated heparin potentiate the anti–Xa activity of low molecular weight heparin (enoxaparin). Pèrez–Requejo JL, et al. **Thromb Res** 1997 Feb 1;85(3):259–65
Is platelet phospholipid–dependent thrombin generation altered by acute myocardial infarction or aspirin? [see comments] Rota S, et al. **Thromb Res** 1996 Aug 15; 83(4):329–38. Comment in: Thromb Res 1997 Feb 15;85(4):367–8.
Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Sakata T, et al. **Thromb Res** 1996 May 1;82(3):235–44
Hirudin stimulates prostacyclin but not endothelin–1 production in cultured human vascular endothelial cells. Turunen P, et al. **Thromb Res** 1996 Mar 15;81(6):635–40
Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin. Wallén NH, et al. **Thromb Res** 1997 Jul 1;87(1):151–7
The mechanism of cold–induced platelet aggregation in the presence of heparin. Akiyama M, et al. **Tohoku J Exp Med** 1995 Dec;177(4):365–74
A clinical trial of red–cell concentrate prepared from blood collected in half–strength citrate anticoagulant. Murphy WG, et al. **Transfus Med** 1991 Mar;1(1):25–9
Importance of ionized magnesium measurement for monitoring of citrate–anticoagulated plateletpheresis. Mercan D, et al. **Transfusion** 1997 Apr;37(4):418–22
Efficacy of low–molecular–weight heparin and unfractionated heparin to prevent adhesion of human prostate and bladder carcinoma and melanoma cells to bovine endothelial monolayers. An in vitro study and review of the literature. Lersch C, et al. **Urol Int** 1996; 56(4):230–3
Heparin attenuated neutrophil infiltration but did not affect renal injury induced by ischemia reperfusion. Shin CS, et al. **Yonsei Med J** 1997 Jun;38(3):133–41
[The paradox of thrombin (letter)] Samama MM. **J Mal Vasc** 1996;21(3):192 **(Fre)**
[Anticoagulant–induced pseudo–thrombocytopenia: an important laboratory artifact] Radaelli A, et al. **Schweiz Rundsch Med Prax** 1996 Nov 26;85(48):1550–2 (Eng. Abstr.) **(Ger)**
[General hematological tests. A. Effects of the blood sample containers and anticoagulants on the determination of lymphocyte surface markers] Bando S, et al. **Rinsho Byori** 1996 Nov;Suppl 103:123–8 **(Jpn)**
[Effects of anticoagulants used at blood specimen collection on clinical test results] Narayanan S. **Rinsho Byori** 1996 Nov;Suppl 103:73–91 **(Jpn)**
[Blood chemical analysis. G. Development of a new blood anticoagulant] Tamada Y, et al. **Rinsho Byori** 1996 Nov; Suppl 103:192–9 **(Jpn)**
[The anticoagulant activity of fucoidans] Gavrilova EA, et al. **Eksp Klin Farmakol** 1997 Jan–Feb;60(1):42–4 (Eng. Abstr.) **(Rus)**
[The anticoagulant action of the nitric acid ester of oxidized starch] Samal' AB, et al. **Eksp Klin Farmakol** 1996 Mar–Apr;59(2):27–30 (Eng. Abstr.) **(Rus)**
[Plausible pharmacologic interaction between fosinopril and acenocoumarol (letter)] de Tomás ME, et al. **Med Clin (Barc)** 1997 May 17;108(19):757 **(Spa)**

POISONING

Covert poisoning with difenacoum: clinical and toxicological observations. McCarthy PT, et al. **Hum Exp Toxicol** 1997 Mar;16(3):166–70

STANDARDS

Are the available low–molecular–weight heparin preparations the same? Fareed J, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:77–91 (34 ref.)
Prophylaxis of intravenous catheter–related thrombophlebitis in cattle. Pusterla N, et al. **Vet Rec** 1996 Sep 21; 139(12):287–9
[A study on anticoagulation for cardiovascular diseases using international normalized ratio (INR)] Izumi Y, et al. **Kyobu Geka** 1996 Nov;49(12):997–1000 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Thromboprophylaxis, coagulation disorders, and regional anaesthesia. Haljamäe H. **Acta Anaesthesiol Scand** 1996 Sep; 40(8 Pt 2):1024–40 (94 ref.)
The effects and uses of heparin in the care of burns that improves treatment and enhances the quality of life. Saliba MJ Jr. **Acta Chir Plast** 1997;39(1):13–6 (34 ref.)
Superior sagittal sinus thrombosis treated with combined local thrombolytic and systemic anticoagulation therapy. Aoki N, et al. **Acta Neurochir (Wien)** 1997;139(4):332–5
Comparison of carbogen inhalation and intravenous heparin infusion therapies in idiopathic sudden sensorineural hearing loss. Rahko T, et al. **Acta Otolaryngol Suppl (Stockh)** 1997;529:86–7
Transjugular intrahepatic portosystemic shunt (TIPS). Thrombogenicity in stents and its effect on shunt patency. Siegerstetter V, et al. **Acta Radiol** 1997 Jul;38(4 Pt 1):558–64
The approach to anticoagulation in patients treated with extracorporeal therapy in the intensive care unit. Ward DM. **Adv Ren Replace Ther** 1997 Apr;4(2):160–73 (134 ref.)
Atrial fibrillation and stroke prevention in the community. O'Connell JE, et al. **Age Ageing** 1996 Jul;25(4):307–9
Laser balloon angioplasty combined with local intracoronary heparin therapy: immediate and short–term follow–up results. Glazier JJ, et al. **Am Heart J** 1997 Aug;134(2 Pt 1):266–73
Effects of warfarin on markers of hypercoagulability in patients with heart failure. Jafri SM, et al. **Am Heart J** 1997 Jul;134(1):27–36
No subacute thrombosis and femoral bleeding complications under full anticoagulation in 150 consecutive patients receiving non–heparin–coated intracoronary Palmaz–Schatz stents. Lee SW, et al. **Am Heart J** 1996 Dec;132(6):1135–46
Reduction of thrombotic and hemorrhagic complications after stent implantation. Pan M, et al. **Am Heart J** 1996 Dec;132(6):1119–26
Fragmin in unstable angina pectoris or in non–Q–wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease. Klein W, et al. **Am J Cardiol** 1997 Sep 4;80(5A):30E–34E
Reactivation of the coagulation system: rationale for long–term antithrombotic treatment. Kontny F. **Am J Cardiol** 1997 Sep 4;80(5A):55E–60E (63 ref.)
Coronary stenting (Cordis) without anticoagulation. Park SW, et al. **Am J Cardiol** 1997 Apr 1;79(7):901–4
Hail stentors! How the hail do I stop the warfarin? [editorial; comment] Schatz RA. **Am J Cardiol** 1996 Oct 15; 78(8):940–2. Comment on: Am J Cardiol 1995 Aug 1;76(4):307–8.
Low–molecular–weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group. Swahn E, et al. **Am J Cardiol** 1997 Sep 4;80(5A):25E–29E
New frontiers in the management of unstable coronary artery disease. Turpie AG. **Am J Cardiol** 1997 Sep 4; 80(5A):21E–24E (30 ref.)
Long–term low–molecular–weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). Wallentin L, et al. **Am J Cardiol** 1997 Sep 4;80(5A):61E–63E
Performance of prothrombin–proconvertin time as a monitoring test of oral anticoagulation therapy. Haraldsson HM, et al. **Am J Clin Pathol** 1997 Jun;107(6):672–80
International normalized ratio in anticoagulant therapy: understanding the issues. Severson AL, et al. **Am J Crit Care** 1997 Mar;6(2):88–92; quiz 94
Anti–inflammatory properties of unfractioned heparin in patients with highly active ulcerative colitis: a pilot study [letter] Folwaczny C, et al. **Am J Gastroenterol** 1997 May; 92(5):911–2
Antithrombotic therapy after intracoronary stent placement. Clifton GD. **Am J Health Syst Pharm** 1997 Feb 15; 54(4):437–40
Determinants of compliance with anticoagulation: A case–control study. Arnsten JH, et al. **Am J Med** 1997 Jul; 103(1):11–7
Effects of conventional vs. low–molecular–weight heparin on lipid profile in hemodialysis patients. Elisaf MS, et al. **Am J Nephrol** 1997;17(2):153–7
Low–molecular–weight heparin for obstetric thromboprophylaxis: experience of sixty–nine pregnancies in sixty–one women at high risk. Nelson–Piercy C, et al. **Am J Obstet Gynecol** 1997 May;176(5):1062–8
Spontaneous orbital hemorrhage in pregnant women treated with subcutaneous heparin. Chang WJ, et al. **Am J Ophthalmol** 1996 Dec;122(6):907–8
Embolic stroke in a pregnant patient with a mechanical heart valve on optimal heparin therapy. Watson WJ, et al. **Am J Perinatol** 1996 Aug;13(6):371–2
Enoxaparin for thromboembolism prophylaxis in spinal injury: preliminary report on experience with 105 patients. Harris S, et al. **Am J Phys Med Rehabil** 1996 Sep–Oct; 75(5):326–7
Treating the syndrome before the complication [letter; comment] Fink M, et al. **Am J Psychiatry** 1996 Oct; 153(10):1371–2. Comment on: Am J Psychiatry 1995 Jul;152(7):1103–4.
Inhibition of antigen–induced acute bronchoconstriction, airway hyperresponsiveness, and mast cell degranulation by a nonanticoagulant heparin: comparison with a low molecular weight heparin. Ahmed T, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):1848–55
The role of anticoagulation in pylephlebitis. Baril N, et al. **Am J Surg** 1996 Nov;172(5):449–52; discussion 452–3
Prophylactic administration of histamine 1 and/or histamine 2 receptor blockers in the prevention of heparin– and protamine–related haemodynamic effects. Kanbak M, et al. **Anaesth Intensive Care** 1996 Oct;24(5):559–63
Antiphospholipid syndrome and neurosurgery [letter; comment] Kiyama S. **Anaesthesia** 1997 Jun;52(6):612. Comment on: Anaesthesia 1997 Jan;52(1):72–6.
Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Horlocker TT, et al. **Anesth Analg** 1997 Oct;85(4):874–85 (78 ref.)
Hypothenar hammer syndrome successfully managed with intravenous prostaglandin E1 and heparin and with correction of the thrombogenic risk profile. A case report. Wieczorek I, et al. **Angiology** 1996 Nov;47(11):1111–6
Case report of acute splenic and superior mesenteric vein thrombosis and its successful medical management. Foo E, et al. **Ann Acad Med Singapore** 1996 Sep;25(5):755–8 (36 ref.)
The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery––a comparison with the dihydroergotamine–heparin combination. Perhoniemi V, et al. **Ann Chir Gynaecol** 1996;85(4):359–63
Severe bleeding in two patients due to increased sensitivity of factor IX activity to phenprocoumon therapy. Quenzel EM, et al. **Ann Hematol** 1997 Jun;74(6):265–8
Prevention of venous thrombosis in knee arthroplasty [letter; comment] Basskin L. **Ann Intern Med** 1997 Jan 15; 126(2):172–3. Comment on: Ann Intern Med 1996 Apr 1;124(7):619–26.
Prevention of venous thrombosis in knee arthroplasty [letter; comment] Jacobson M. **Ann Intern Med** 1997 Jan 15; 126(2):173. Comment on: Ann Intern Med 1996 Apr 1;124(7):619–26.
Recurrence of venous thromboembolism after unfractionated heparin therapy [letter; comment] Kormas N, et al. **Ann Intern Med** 1996 Dec 15;125(12):1012–3. Comment on: Ann Intern Med 1996 Mar 1;124(5):532.
Pregnancy–related thromboembolism [letter; comment] Manoharan A. **Ann Intern Med** 1997 Jul 15;127(2):163–4. Comment on: Ann Intern Med 1996 Dec 15;125(12):955–60. Comment on: Ann Intern Med 1996 Dec 15;125(12):1001–3.
Monitoring warfarin therapy in patients with lupus anticoagulants. Moll S, et al. **Ann Intern Med** 1997 Aug 1;127(3):177–85
Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients. Moia M, et al. **Ann Ital Med Int** 1997 Apr–Jun;12(2):67–71
Sudden deafness: a comparison of anticoagulant therapy and carbogen inhalation therapy. Kallinen J, et al. **Ann Otol Rhinol Laryngol** 1997 Jan;106(1):22–6
Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force. Ansell JE, et al. **Ann Pharmacother** 1997 May;31(5):604–15 (60 ref.)
Interaction between clarithromycin and oral anticoagulants [letter] Grau E, et al. **Ann Pharmacother** 1996 Dec; 30(12):1495–6
Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Le AT, et al. **Ann Pharmacother** 1997 Sep;31(9):1006–8

ANTICOAGULANTS

Potential interaction between clarithromycin and warfarin. Recker MW, et al. **Ann Pharmacother** 1997 Sep;31(9):996–8

A technique to investigate microvascular mural thrombus formation in arteries and veins: II. Effects of aspirin, heparin, r–hirudin, and G–4120. Stockmans F, et al. **Ann Plast Surg** 1997 Jan;38(1):63–8

Morbidity of varicose vein surgery: auditing the benefit of clinical practice [letter; comment] St John P. **Ann R Coll Surg Engl** 1997 Jan;79(1):73. Comment on: Ann R Coll Surg Engl 1996 Jul;78(4):345–9.

Anticoagulation in children with mechanical valve prostheses. Bradley SM, et al. **Ann Thorac Surg** 1997 Jul; 64(1):30–4; discussion 35–6

Blockade of selectin–mediated leukocyte adhesion improves postischemic function in lamb hearts. Miura T, et al. **Ann Thorac Surg** 1996 Nov;62(5):1295–300

Warfarin use in Medicare patients with atrial fibrillation [letter; comment] Bratzler DW, et al. **Arch Intern Med** 1997 Jul 28;157(14):1613, 1617. Comment on: Arch Intern Med 1997 Feb 24;157(4):441–5.

Underuse of warfarin in atrial fibrillation [letter; comment] Cheng TO. **Arch Intern Med** 1997 Jul 14;157(13):1505. Comment on: Arch Intern Med 1996 Nov 11;156(20):2311–6.

Atrial fibrillation and stroke prevention with warfarin in the long–term care setting. Gurwitz JH, et al. **Arch Intern Med** 1997 May 12;157(9):978–84

National patterns of warfarin use in atrial fibrillation. Stafford RS, et al. **Arch Intern Med** 1996 Dec 9–23;156(22):2537–41

Is warfarin underused in the treatment of elderly persons with atrial fibrillation? [see comments] Whittle J, et al. **Arch Intern Med** 1997 Feb 24;157(4):441–5. Comment in: Arch Intern Med 1997 Jul 28;157(14):1613, 1617.

Subchronic centrifugal mechanical assist in an unheparinized calf model. Wagner–Mann C, et al. **Artif Organs** 1996 Jun; 20(6):666–9

Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. North RA, et al. **Aust N Z J Obstet Gynaecol** 1995 Nov;35(4):357–62

Cardiopulmonary bypass using lomoparan: monitoring of anticoagulation using anti–Xa levels and thromboelastography. Sharma S, et al. **Aust N Z J Surg** 1997 Jun;67(6):392–4

Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction. Metz BK, et al. **Biomed Pharmacother** 1996;50(6–7):243–53 (33 ref.)

Severe proximal deep vein thrombosis in a Glanzmann thrombasthenia variant successfully treated with a low molecular weight heparin [letter] Gruel Y, et al. **Blood** 1997 Jul 15;90(2):888–90

Is heparin the ideal anticoagulant in patients with a high plasma leukocyte elastase level? [letter; comment] Suzuki S, et al. **Blood Coagul Fibrinolysis** 1996 Apr;7(3):363–4. Comment on: Blood Coagul Fibrinolysis 1995 Sep;6(6):527–30.

Diagnosing pulmonary embolism. Morbidity should be taken into account when deciding on anticoagulant treatment [letter; comment] Fitzmaurice D, et al. **BMJ** 1997 May 24;314(7093):1551. Comment on: BMJ 1997 Feb 8;314(7078):425–9.

Monitoring oral anticoagulation in primary care. GPs in Wales send blood samples to clinic, get results in post, and decide dose [letter; comment] Gozzard DI, et al. **BMJ** 1996 Sep 28;313(7060):818. Comment on: BMJ 1996 Jun 8;312(7044):1431–2.

ABC of clinical haematology. Bleeding disorders, thrombosis, and anticoagulation. Hampton KK, et al. **BMJ** 1997 Apr 5;314(7086):1026–9 (0 ref.)

Clinical effects of anticoagulants in suspected acute myocardial infarction. Reduced intensity of anticoagulation may be indicated [letter; comment] Hood S, et al. **BMJ** 1997 Jan 18;314(7075):222; discussion 222–3. Comment on: BMJ 1996 Sep 14;313(7058):652–9.

Clinical effects of anticoagulants in suspected acute myocardial infarction. Adding heparin seems justified [letter; comment] James MA. **BMJ** 1997 Jan 18; 314(7075):222. Comment on: BMJ 1996 Sep 14;313(7058):652–9.

A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. Julian DG, et al. **BMJ** 1996 Dec 7;313(7070):1429–31

Clinical effects of anticoagulants in suspected acute myocardial infarction. Use of anticoagulants in suspected acute myocardial infarction in Europe varies [letter; comment] Ketley D, et al. **BMJ** 1997 Jan 18;314(7075):223 . Comment on: BMJ 1996 Sep 14;313(7058):652–9.

Treatment of pregnant women with recurrent miscarriage associated with phospholipid antibodies. No cytogenetic data were reported [letter; comment] Kingdom J, et al. **BMJ** 1997 Aug 9;315(7104):372. Comment on: BMJ 1997 Jan 25;314(7076):253–7.

Stroke prevention in atrial fibrillation [editorial] Lancaster T, et al. **BMJ** 1997 May 31;314(7094):1563–4

Monitoring oral anticoagulation in primary care. Shared care can work [letter; comment] Logan EC, et al. **BMJ** 1996 Sep 28;313(7060):819. Comment on: BMJ 1996 Jun 8;312(7044):1431–2.

Comorbidity increases benefit of anticoagulation in patients with atrial fibrillation [letter; comment] Morgan S. **BMJ** 1997 Mar 29;314(7085):978. Comment on: BMJ 1996 Dec 14;313(7071):1534.

Population based study of use of anticoagulants among patients with atrial fibrillation in the community. Sudlow M, et al. **BMJ** 1997 May 24;314(7093):1529–30

Monitoring oral anticoagulation in primary care. Integrated, proactive laboratory based approach is effective [letter; comment] Wilmot R, et al. **BMJ** 1996 Sep 28; 313(7060):818–9. Comment on: BMJ 1996 Jun 8;312(7044):1431–2.

Phase II trial of heparin prophylaxis for veno–occlusive disease of the liver in children undergoing bone marrow transplantation. Rosenthal J, et al. **Bone Marrow Transplant** 1996 Jul;18(1):185–91

Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group. Samama CM, et al. **Br J Anaesth** 1997 Jun;78(6):660–5

Warfarin therapy in primary care [letter; comment] Eisenberg JN, et al. **Br J Gen Pract** 1996 Feb;46(403):123–4. Comment on: Br J Gen Pract 1995 Mar;45(392):153–8.

Warfarin anticoagulation in primary care: a regional survey of present practice and clinicians' views. Rodgers H, et al. **Br J Gen Pract** 1997 May;47(418):309–10

Anticoagulation trials. Grahame–Clarke C, et al. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):25–8 (25 ref.)

Anticoagulants: when and how long? [editorial] Ozanne C, et al. **Br J Hosp Med** 1997 Jun 4–17;57(11):544–5

Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double–blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. **Br J Surg** 1997 Aug;84(8):1099–103

Do low molecular weight heparin and dextran increase the blood loss in transurethral resection of the prostate? Hjertberg H, et al. **Br J Urol** 1996 Dec;78(6):897–900

Antithrombotic therapy for patients with stroke symptoms. Guidelines for family physicians. Brown J, et al. **Can Fam Physician** 1996 Sep;42:1724–30 (27 ref.)

Double–edged sword. Anticoagulation therapy for the elderly [news] Kermode–Scott B. **Can Fam Physician** 1997 Apr;43:803–4

Utilization of the serosal scarification model of postoperative intestinal adhesion formation to investigate potential adhesion–preventing substances in the rabbit. Singer ER, et al. **Can J Vet Res** 1996 Oct;60(4):305–11

Low–molecular–weight heparin in the management of Trousseau's syndrome. Walsh–McMonagle D, et al. **Cancer** 1997 Aug 15;80(4):649–55

Heparin after acute myocardial infarction [see comments] Commerford PJ. **Cardiovasc Drugs Ther** 1997 Apr; 11(2):101–9 (43 ref.). Comment in: Cardiovasc Drugs Ther 1997 Apr;11(2):97–100.

Heparin and streptokinase [editorial; comment] Sobel BE. **Cardiovasc Drugs Ther** 1997 Apr;11(2):97–100 (31 ref.). Comment on: Cardiovasc Drugs Ther 1997 Apr;11(2):101–9. Comment on: Cardiovasc Drugs Ther 1997 Apr;11(2):111–9.

Is heparin of value in the management of acute myocardial infarction? [see comments] White HD. **Cardiovasc Drugs Ther** 1997 Apr;11(2):111–9 (73 ref.). Comment in: Cardiovasc Drugs Ther 1997 Apr;11(2):97–100.

Unstable coronary artery disease--need for long–term antithrombotic treatment. Aspirin alone is not sufficient, I would associate an anticoagulant. Wallentin L. **Cardiovasc Res** 1997 Feb;33(2):292–4

Treatment alternatives for axillary–subclavian vein thrombosis: long–term follow–up. AbuRahma AF, et al. **Cardiovasc Surg** 1996 Dec;4(6):783–7

Successful stenting after coumadin therapy and thrombus resolution in a stenotic saphenous vein graft [letter; comment] Chow WH, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):438–9. Comment on: Cathet Cardiovasc Diagn 1996 Aug;38(4):415–6.

Intracoronary stenting using slotted tubular stents with intravascular ultrasound and anticoagulation [see comments] Goods CM, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):341–5. Comment in: Cathet Cardiovasc Diagn 1996 Dec;39(4):346.

Successful repair of intimal dissection following coronary angioplasty with a 48–hour inflation of spiral inflation coil and local delivery of heparin. Shimabukuro M, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):103–5

The effect of anticoagulant therapy in primary and anorectic drug–induced pulmonary hypertension. Frank H, et al. **Chest** 1997 Sep;112(3):714–21

Fish oils and low–molecular–weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Cairns JA, et al. **Circulation** 1996 Oct 1;94(7):1553–60

Guidelines for use of anticoagulants [letter] Horton J, et al. **Circulation** 1997 Sep 16;96(6):2099

Comparison of low–molecular–weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) [see comments] Klein W, et al. **Circulation** 1997 Jul 1;96(1):61–8. Comment in: Circulation 1997 Jul 1;96(1):3–5.

Images in cardiovascular medicine. Atheroembolic disease in a female patient. Tack CJ, et al. **Circulation** 1997 Jul 15;96(2):700

Strategies for managing atrial fibrillation. Katcher MS, et al. **Cleve Clin J Med** 1996 Sep;63(5):282–94 (54 ref.)

Anticoagulation for prosthetic valves during pregnancy [editorial] [see comments] Conti CR. **Clin Cardiol** 1996 Sep; 19(9):682. Comment in: Clin Cardiol 1996 Dec;19(12):921.

Low molecular weight heparin for acute ischemic heart disease [editorial] Conti CR. **Clin Cardiol** 1997 May; 20(5):415–6

Resolution of an aortic mobile mass with anticoagulation without evidence of arterial embolism. Pasierski T, et al. **Clin Cardiol** 1996 Feb;19(2):151–2

Monitoring oral anticoagulant therapy with point–of–care devices: correlations and caveats. Gosselin RC, et al. **Clin Chem** 1997 Sep;43(9):1785–6

Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugs. Hoppensteadt DA, et al. **Clin Chem** 1997 Sep;43(9):1786–8

The use of low dose Orgaran in heparin–induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations. Hill GR, et al. **Clin Lab Haematol** 1997 Jun;19(2):155–7

Control of oral anticoagulation [letter] McArdle B. **Clin Lab Haematol** 1996 Dec;18(4):301–2

Pharmacokinetic optimisation of the treatment of deep vein thrombosis. Iorio A, et al. **Clin Pharmacokinet** 1997 Feb; 32(2):145–72 (265 ref.)

The usage of heparin in vascular intervention [letter; comment] Randi ML, et al. **Clin Radiol** 1997 Mar; 52(3):247–8. Comment on: Clin Radiol 1996 Feb;51(2):113–6.

Medical & surgical approaches to pulmonary hypertension. McLaughlin VV, et al. **Compr Ther** 1997 Sep;23(9):612–6 (21 ref.)

Heparin dosing: a comparison of weight–based dosing vs standard dosing. White CM. **Conn Med** 1997 Feb; 61(2):103–4

Angiographic studies demonstrating the need for conjunctive anticoagulation. Bleich SD. **Coron Artery Dis** 1996 Jul; 7(7):516–21 (29 ref.)

Clinical trials of conjunctive anticoagulant strategies in thrombolysis. Kleiman NS. **Coron Artery Dis** 1996 Jul; 7(7):508–15 (100 ref.)

Enhancement of recombinant tissue–type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model. Kornowski R, et al. **Coron Artery Dis** 1996 Dec;7(12):903–9

Anticoagulant and antiplatelet therapy in heart failure. Cleland JG. **Curr Opin Cardiol** 1997 May;12(3):276–87 (79 ref.)

Primary and secondary stroke prevention. Feinberg WM. **Curr Opin Neurol** 1996 Feb;9(1):46–52 (63 ref.)

Duration of anticoagulant treatment for venous thrombosis [see comments] Raskob GE. **Curr Opin Pulm Med** 1997 Jul;3(4):286–90 (16 ref.). Comment in: Curr Opin Pulm Med 1997 Jul;3(4):265–7.

Current status on new anticoagulant and antithrombotic drugs and devices [see comments] Walenga JM, et al. **Curr Opin Pulm Med** 1997 Jul;3(4):291–302 (96 ref.). Comment in: Curr Opin Pulm Med 1997 Jul;3(4):265–7.

Antithrombotic, anticoagulant, and thrombolytic agents. Terezhalmy GT, et al. **Dent Clin North Am** 1996 Jul; 40(3):649–64 (54 ref.)

Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Dunn CJ, et al. **Drugs** 1996 Aug;52(2):276–305 (118 ref.)

Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta–analysis. Leizorovicz A. **Drugs** 1996;52 Suppl 7:30–7

The risk of thromboembolism in patients undergoing colorectal surgery. McLeod RS. **Drugs** 1996;52 Suppl 7:38–41 (25 ref.)

Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations. Nurmohamed MT, et al. **Drugs** 1997 May;53(5):736–51 (105 ref.)

Prevention and treatment of venous thromboembolism. Pineo GF, et al. **Drugs** 1996 Jul;52(1):71–92 (163 ref.)

Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double–blind placebo–controlled trial. Planes A, et al. **Drugs** 1996;52 Suppl 7:47–54

Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Davis R, et al. **Drugs Aging** 1997 Apr;10(4):299–322 (110 ref.)

Is anticoagulation therapy underused in elderly patients with atrial fibrillation? Turazza FM, et al. **Drugs Aging** 1997 Mar;10(3):174–84 (37 ref.)

Atrial fibrillation and embolic complications [see comments] Maru M. **East Afr Med J** 1997 Jan;74(1):3–5. Comment in: East Afr Med J 1997 Jan;74(1):1–2.

The effect of low dose heparin therapy on complication and survival rates in horses following exploratory celiotomy. Young DR, et al. **Equine Vet J Suppl** 1989 Jun;(7):91–3

Is anticoagulation for intracoronary stenting justified? [editorial; comment] Corr L. **Eur Heart J** 1996 Sep; 17(9):1296–8. Comment on: Eur Heart J 1996 Sep;17(9):1373–80.

SPAF–III results. Cowburn P, et al. **Eur Heart J** 1996 Jul; 17(7):1129

Early recanalization of right coronary artery following selective thrombolysis in left coronary artery: angiographic demonstration of thrombus migration [letter] Fineschi M, et al. **Eur Heart J** 1996 Jun;17(6):963–4

Anticoagulation and left ventricular dysfunction: friend or foe? [editorial] Loh E, et al. **Eur Heart J** 1997 Jul; 18(7):1039–41

Large left atrial thrombus mimicking atrial myxoma: successful treatment with anticoagulant therapy [letter] Morelli S, et al. **Eur Heart J** 1996 Aug;17(8):1290

Heparin-coated circuit in coronary surgery. A clinical study. Sáenz A, et al. **Eur J Cardiothorac Surg** 1996;10(1):48–53

Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. Russmann S, et al. **Eur J Clin Pharmacol** 1997;52(1):31–5

Previous use of non-steroidal anti-inflammatory drugs and anticoagulants: the influence on clinical outcome of bleeding gastroduodenal ulcers. Vreeburg EM, et al. **Eur J Gastroenterol Hepatol** 1997 Jan;9(1):41–4

Low molecular heparin (Enoxaparin) as an alternative treatment of acute deep venous thrombosis in gynecologic oncology patients. Fishman A, et al. **Eur J Gynaecol Oncol** 1996;17(5):365–7

Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu–PA–40 kDa/Hir). Schneider J, et al. **Eur J Pharmacol** 1996 Apr 29; 302(1–3):69–77

Giving both enoxaparin and dextran increases the need for transfusion in revision hip arthroplasty. Lisander B, et al. **Eur J Surg** 1996 Nov;162(11):861–6

Heparin during aneurysm repair [letter; comment] Vahl AC, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):425. Comment on: Eur J Vasc Endovasc Surg 1996 Jul;12(1):86–90.

The role of dipyridamole in stroke prevention. Sivenius J, et al. **Eur Neurol** 1996;36(5):253–6 (20 ref.)

Medical management of primary pulmonary hypertension. Kneussl MP, et al. **Eur Respir J** 1996 Nov;9(11):2401–9 (104 ref.)

Impact of local evidence-based clinical guidelines—a Danish intervention study. Steffensen FH, et al. **Fam Pract** 1997 Jun;14(3):209–15

Prevention of venous thromboembolism in high risk patients. Agnelli G, et al. **Haematologica** 1997 Jul–Aug; 82(4):496–502 (56 ref.)

The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Prandoni P, et al. **Haematologica** 1997 Jul–Aug;82(4):423–8

Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Hirsh J. **Haemostasis** 1996 Oct;26 Suppl 4:189–98 (20 ref.)

Platelet count and the risk of bleeding in hospitalized patients with venous thromboembolism starting anticoagulant therapy. Monreal M, et al. **Haemostasis** 1997 Mar–Apr; 27(2):91–8

Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials. Palmer AJ, et al. **Haemostasis** 1997 Mar–Apr;27(2):75–84

Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials. Palmer AJ, et al. **Haemostasis** 1997 Mar–Apr;27(2):65–74

Long-term use of the low molecular weight heparin tinzaparin in haemodialysis. Simpson HK, et al. **Haemostasis** 1996 Mar–Apr;26(2):90–7

Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: a dose-finding study. Strandberg LE, et al. **Haemostasis** 1996 Sep–Oct;26(5):247–57

Management of venous thromboembolism: optimization by clinical trials. Turpie AG. **Haemostasis** 1996 Oct;26 Suppl 4:220–6 (20 ref.)

Prophylaxis of thromboembolic disease with RO–11 (ROVI), during abdominal surgery. EMRO1 (Grupo Fstudio Multicintrico RO–11). Moreno Gonzalez E, et al. **Hepatogastroenterology** 1996 May–Jun;43(9):744–7

Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial [see comments] Sauer P, et al. **Hepatology** 1996 Dec;24(6):1433–6. Comment in: Hepatology 1996 Dec;24(6):1533–5.

Can anticoagulation enhance TIPS patency? [editorial; comment] Shiffman ML. **Hepatology** 1996 Dec; 24(6):1533–5 (31 ref.). Comment on: Hepatology 1996 Dec;24(6):1433–6.

Paroxysmal atrial fibrillation: is anticoagulation justified? [editorial] [see comments] Aboaf AP, et al. **Hosp Pract (Off Ed)** 1996 Dec 15;31(12):11, 15–6, 19. Comment in: Hosp Pract (Off Ed) 1997 Mar 15;32(3):38, 41.

Issues of biocompatibility: heparin-coated extracorporeal circuit. Hsu LC. **Int Anesthesiol Clin** 1996 Spring; 34(2):109–22 (58 ref.)

Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. Kalodiki EP, et al. **Int Angiol** 1996 Jun;15(2):162–8

Are prothrombin fragment 1 + 2 and thrombin–antithrombin complexes useful in the management of oral anticoagulant therapy? Barcellona D, et al. **Int J Clin Lab Res** 1997; 27(1):76–8

A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study. Stone MH, et al. **Int Orthop** 1996;20(6):367–9

Prevention of fatal pulmonary embolism with warfarin after total hip replacement. Suomalainen O, et al. **Int Orthop** 1996;20(2):75–9

Does continuous heparinization influence platelet function in the intensive care patient? Boldt J, et al. **Intensive Care Med** 1997 May;23(5):567–73

Thrombolysis using plasminogen activator and heparin reduces cerebral no-reflow after resuscitation from cardiac arrest: an experimental study in the cat. Fischer M, et al. **Intensive Care Med** 1996 Nov;22(11):1214–23

Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration. Leslie GD, et al. **Intensive Care Med** 1996 Nov;22(11):1261–4

Benefits of various dextrans after delayed therapy in necrotizing pancreatitis of the rat. Schmidt J, et al. **Intensive Care Med** 1996 Nov;22(11):1207–13

Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Sciumbata T, et al. **Invasion Metastasis** 1996;16(3):132–43

Primary antiphospholipid syndrome: indications for long-term anticoagulation. Sengstaken EA. **J Am Board Fam Pract** 1996 Jul–Aug;9(4):282–4

Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. Moussa I, et al. **J Am Coll Cardiol** 1997 Jan; 29(1):6–12

High pressure assisted coronary stent implantation accomplished without intravascular ultrasound guidance and subsequent anticoagulation. Nakamura S, et al. **J Am Coll Cardiol** 1997 Jan;29(1):21–7

Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy [see comments] Schömig A, et al. **J Am Coll Cardiol** 1997 Jan;29(1):28–34. Comment in: ACP J Club 1997 Jul–Aug;127(1):4.

Treatment decision making [letter; comment] Lindsey EM Jr. **J Am Dent Assoc** 1997 Jul;128(7):818, 820. Comment on: J Am Dent Assoc 1997 Mar;128(3):327–35.

Using the international normalized ratio to standardize prothrombin time. Stern R, et al. **J Am Dent Assoc** 1997 Aug;128(8):1121–2

Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. Monette J, et al. **J Am Geriatr Soc** 1997 Sep; 45(9):1060–5

Bioprosthetic mitral valve thrombosis: clinical profile, transesophageal echocardiographic features, and follow-up after anticoagulant therapy. Oliver JM, et al. **J Am Soc Echocardiogr** 1996 Sep–Oct;9(5):691–9

Low-molecular weight heparins. Talley JD. **J Ark Med Soc** 1997 Apr;93(11):555–6

Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage. Meddahi A, et al. **J Biomed Mater Res** 1996 Jul;31(3):293–7

Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. Eriksson BI, et al. **J Bone Joint Surg Am** 1997 Mar;79(3):326–33

Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. Francis CW, et al. **J Bone Joint Surg Am** 1997 Sep; 79(9):1365–72

Effective use of heparin-bonded circuits and lower anticoagulation for coronary artery bypass grafting in Jehovah's Witnesses. Aldea GS, et al. **J Card Surg** 1996 Jan–Feb;11(1):12–7

Widening therapeutic spectrum of gabexate mesilate [letter; comment] Ceriana P, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):832–3. Comment on: J Cardiothorac Vasc Anesth 1996 Feb;10(2):235–7.

Gabexate mesilate, a new synthetic serine protease inhibitor: a pilot clinical trial in valvular heart surgery [see comments] Parodi F, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):235–7. Comment in: J Cardiothorac Vasc Anesth 1996 Oct;10(6):832–3.

Recombinant hirudin is a heparin alternative in cardiac surgery [letter; comment] Riess FC, et al. **J Cardiothorac Vasc Anesth** 1997 Jun;11(4):538–9. Comment on: J Cardiothorac Vasc Anesth 1996 Jun;10(4):521–30.

Neuraxial anesthesia is contraindicated in patients undergoing heparinization for surgery. Con: neuraxial block is useful in patients undergoing heparinization for surgery. Turnbull KW. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):961–2

Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? Dietrich W. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S50–7 (53 ref.)

Antithrombotic activity of oral unfractionated heparin. Hiebert LM, et al. **J Cardiovasc Pharmacol** 1996 Jul; 28(1):26–9

Enhancement of anticoagulant action by warfarin–benzbromarone interaction. Shimodaira H, et al. **J Clin Pharmacol** 1996 Feb;36(2):168–74

Low-molecular-weight heparin in the emergency department treatment of venous thromboembolism. Innes GD, et al. **J Emerg Med** 1997 Jul–Aug;15(4):563–6

Thromboprophylaxis and death after total hip replacement. Force R. **J Fam Pract** 1997 Mar;44(3):248–9

Anticoagulants in acute MI. Santiago T, et al. **J Fam Pract** 1997 Jan;44(1):28–9

Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation [see comments] Antani MR, et al. **J Gen Intern Med** 1996 Dec;11(12):713–20. Comment in: J Gen Intern Med 1996 Dec;11(12):768–70.

Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? [see comments] Beyth RJ, et al. **J Gen Intern Med** 1996 Dec;11(12):721–8. Comment in: J Gen Intern Med 1996 Dec;11(12):768–70.

Should we just let the anticoagulation service do it? [letter; comment] Cheng TO. **J Gen Intern Med** 1997 Apr; 12(4):258–9. Comment on: J Gen Intern Med 1996 Dec;11(12):768–70.

Should we just let the anticoagulation service do it? The conundrum of anticoagulation for atrial fibrillation [editorial; comment] [see comments] Matchar DB, et al. **J Gen Intern Med** 1996 Dec;11(12):768–70. Comment on: J Gen Intern Med 1996 Dec;11(12):713–20. Comment on: J Gen Intern Med 1996 Dec;11(12):721–8. Comment in: J Gen Intern Med 1997 Apr;12(4):258–9.

Thrombolysis for prosthetic valve thrombosis: indications and results. Renzulli A, et al. **J Heart Valve Dis** 1997 Mar; 6(2):212–8

Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. Lindmarker P, et al. **J Intern Med** 1996 Dec;240(6):395–401

Anticoagulation in nonvalvular atrial fibrillation. Borresen T. **J La State Med Soc** 1996 Nov;148(11):479–84

Cataract surgery and anticoagulants. Hall DL. **J La State Med Soc** 1996 Oct;148(10):431–3

Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. Johnston M, et al. **J Lab Clin Med** 1996 Aug;128(2):214–7

Management of thromboembolic disease associated with pregnancy. Evans W, et al. **J Matern Fetal Med** 1997 Jan–Feb;6(1):21–7

Evaluation of intraoperative anticoagulants in microvascular free-flap surgery. Pugh CM, et al. **J Natl Med Assoc** 1996 Oct;88(10):655–7

Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. Richards M, et al. **J Neurol Neurosurg Psychiatry** 1997 Mar;62(3):269–72

Anticoagulant therapy for Alzheimer's disease [letter; comment] Walsh AC. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):361–2. Comment on: J Neuropsychiatry Clin Neurosci 1996 Spring;8(2):202–5.

A patient-focused pathway for ambulatory anticoagulation care. Brosnan J. **J Nurs Care Qual** 1996 Dec;11(2):41–53

The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs. Andrew M, et al. **J Pediatr Hematol Oncol** 1997 Jan–Feb;19(1):7–22 (192 ref.)

Anticoagulation without catheter removal in children with catheter-related central vein thrombosis. Kenney BD, et al. **J Pediatr Surg** 1996 Jun;31(6):816–8

Evaluation of an extracorporeal membrane oxygenation system using a nonporous membrane oxygenator and a new method for heparin coating. Kitano Y, et al. **J Pediatr Surg** 1997 May;32(5):691–7

Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation—a preliminary report. Nagaya M, et al. **J Pediatr Surg** 1997 Apr; 32(4):531–5

Cardioversion of atrial arrhythmias: audit of anticoagulation management. Mayet J, et al. **J R Coll Physicians Lond** 1997 May–Jun;31(3):313–6

Anticoagulation in venous thrombosis. Schulman S. **J R Soc Med** 1996 Nov;89(11):624–30 (45 ref.)

Cardiopulmonary bypass for heparin-induced thrombocytopenia: management with a heparin-bonded circuit and enoxaparin. Ganjoo AK, et al. **J Thorac Cardiovasc Surg** 1996 Nov;112(5):1390–2

Posttrauma thromboembolism prophylaxis. Greenfield LJ, et al. **J Trauma** 1997 Jan;42(1):100–3

Re: Pathogenesis and prophylaxis of postoperative thromboembolic disease in urological pelvic surgery and Prospective randomized trial of warfarin and intermittent pneumatic leg compression as prophylaxis for postoperative deep venous thrombosis in major urological surgery [letter; comment] Pitts WR Jr. **J Urol** 1997 Aug;158(2):553. Comment on: J Urol 1995 Jun;153(6):1763–74.

Prevention of arterial thrombosis using a novel heparin with enhanced antiplatelet activity and reduced anticoagulant activity. Poletti LF, et al. **J Vasc Surg** 1997 Sep; 26(3):366–72

A blinded trial of local recombinant tissue factor pathway inhibitor versus either local or systemic heparin in a vein

bypass model. Rapp JH, et al. **J Vasc Surg** 1997 Apr; 25(4):726–9

Clinical Crossroads: a 36–year–old woman recuperating from stroke [letter] Palma L. **JAMA** 1997 Oct 1;278(13):1060–1; discussion 1061

Anticoagulant therapy during successful pregnancy and delivery in a Kawasaki disease patient with coronary aneurysm—a case report. Arakawa K, et al. **Jpn Circ J** 1997 Feb;61(2):197–200

Heparin and exercise treatment in a patient with arteriosclerosis obliterans. Shioji K, et al. **Jpn Circ J** 1997 Aug;61(8):715–8

Treatment of experimental mesangioproliferative glomerulonephritis with non–anticoagulant heparin: therapeutic efficacy and safety. Burg M, et al. **Lab Invest** 1997 Apr;76(4):505–16

The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group [see comments] **Lancet** 1997 May 31;349(9065):1569–81. Comment in: Lancet 1997 May 31;349(9065):1563.

Post–discharge deep–vein thrombosis after orthopaedic surgery [letter; comment] Atkins CD. **Lancet** 1996 Oct 26; 348(9035):1179; discussion 1179–80. Comment on: Lancet 1996 Jul 27;348(9022):224–8.

Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial [letter] Cohen A. **Lancet** 1997 Aug 9;350(9075):440; discussion 443–4

Antiplatelet rather than anticoagulant therapy with coronary stenting. More RS, et al. **Lancet** 1997 Jan 18; 349(9046):146–7

Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial [letter] Ricci S, et al. **Lancet** 1997 Aug 9;350(9075):441; discussion 443–4

Post–discharge deep–vein thrombosis after orthopaedic surgery [letter; comment] Simini B. **Lancet** 1996 Oct 26; 348(9035):1179; discussion 1179–80. Comment on: Lancet 1996 Jul 27;348(9022):224–8.

Anticoagulation therapy: bleeding and thromboembolic complications [letter; comment] Sweeney KG, et al. **Lancet** 1996 Nov 23;348(9039):1456–7. Comment on: Lancet 1996 Aug 17;348(9025):423–8.

In search of a superaspirin for the heart [comment] [see comments] Verheugt FW. **Lancet** 1997 May 17; 349(9063):1409–10. Comment on: Lancet 1997 May 17;349(9063):1422–8. Comment on: Lancet 1997 May 17;349(9063):1429–35. Comment in: Lancet 1997 Jun 28;349(9069):1914.

Low–molecular–weight heparin and serum potassium [letter] Wong KS, et al. **Lancet** 1997 Aug 30;350(9078):664

The use of 5,6 benzo–[alpha]–pyrone (coumarin) and heating by microwaves in the treatment of chronic lymphedema of the legs. Chang TS, et al. **Lymphology** 1996 Sep; 29(3):106–11

Pulmonary embolism after acute stroke [editorial; comment] Stein PD. **Mayo Clin Proc** 1997 Apr;72(4):381. Comment on: Mayo Clin Proc 1997 Apr;72(4):297–300.

Pentosan for interstitial cystitis. **Med Lett Drugs Ther** 1997 Jun 6;39(1002):56

Comparison of arterial and venous patency in a rat model of subendothelium–stimulated thrombosis. Hupkens P, et al. **Microsurgery** 1996;17(4):226–9

Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins. Zhang B, et al. **Microsurgery** 1996;17(2):89–96

Coumadin Clinic: a disease management enterprise. McIntire T. **Mo Med** 1997 Feb;94(2):65–6

Fifty years of experience with antithrombotic therapy in cardiac disease. A 1996 approach based on pathogenesis and risk. Freudenrerger RS, et al. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):342–58 (69 ref.)

Low–molecular–weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. **N Engl J Med** 1997 Sep 4;337(10):657–62

The effect of aggressive lowering of low–density lipoprotein cholesterol levels and low–dose anticoagulation on obstructive changes in saphenous–vein coronary–artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators [see comments] **N Engl J Med** 1997 Jan 16;336(3):153–62. Comment in: N Engl J Med 1997 Jan 16;336(3):212–3. Comment in: N Engl J Med 1997 Jun 19;336(25):1839–40. Comment in: ACP J Club 1997 Jul–Aug;127(1):2.

Venous thromboembolism [letter; comment] Block JA. **N Engl J Med** 1997 Jul 3;337(1):51–2; discussion 52–3. Comment on: N Engl J Med 1997 Feb 6;336(6):393–8.

Prevention of atherosclerosis in coronary–artery bypass grafts [editorial; comment] Fuster V, et al. **N Engl J Med** 1997 Jan 16;336(3):212–3. Comment on: N Engl J Med 1997 Jan 16;336(3):153–62.

Management of venous thromboembolism [see comments] Ginsberg JS. **N Engl J Med** 1996 Dec 12;335(24):1816–28 (106 ref.). Comment in: N Engl J Med 1997 May 22;336(21):1528; discussion 1529. Comment in: N Engl J Med 1997 May 22;336(21):1528–9; discussion 1529.

Continuous hemofiltration [letter; comment] Hsu CY, et al. **N Engl J Med** 1997 Sep 4;337(10):713; discussion 713–4. Comment on: N Engl J Med 1997 May 1;336(18):1303–9.

Management of anticoagulation before and after elective surgery. Kearon C, et al. **N Engl J Med** 1997 May 22; 336(21):1506–11 (66 ref.)

Venous thromboembolism during pregnancy [letter; comment] Lockshin MD. **N Engl J Med** 1996 Dec 12; 335(24):1847. Comment on: N Engl J Med 1996 Jul 11;335(2):108–14.

Anticoagulation and elective surgery [letter] Lowson SM, et al. **N Engl J Med** 1997 Sep 25;337(13):939; discussion 939–40

Prophylaxis against venous thromboembolism after major trauma [letter; comment] Osler T, et al. **N Engl J Med** 1997 Feb 20;336(8):586; discussion 586–7. Comment on: N Engl J Med 1996 Sep 5;335(10):701–7.

Management of venous thromboembolism [letter; comment] Rosendaal FR, et al. **N Engl J Med** 1997 May 22; 336(21):1528–9; discussion 1529. Comment on: N Engl J Med 1996 Dec 12;335(24):1816–28.

Anticoagulation and elective surgery [letter] Shalaby A, et al. **N Engl J Med** 1997 Sep 25;337(13):939; discussion 939–40

A comparison of low–molecular–weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. Simonneau G, et al. **N Engl J Med** 1997 Sep 4;337(10):663–9

Anticoagulation and elective surgery [letter] Spandorfer J, et al. **N Engl J Med** 1997 Sep 25;337(13):938–9; discussion 939–40

Prosthetic heart valves [letter; comment] Weiss RL. **N Engl J Med** 1997 Jan 16;336(3):222; discussion 223–4. Comment on: N Engl J Med 1996 Aug 8;335(6):407–16.

Low–molecular–weight heparins. Weitz JI. **N Engl J Med** 1997 Sep 4;337(10):688–98 (100 ref.)

Venous thromboembolism [letter; comment] White TM, et al. **N Engl J Med** 1997 Jul 3;337(1):52–3. Comment on: N Engl J Med 1997 Feb 6;336(6):433–4.

Ipsilateral deep venous thrombosis in renal transplant recipients: the need for prolonged anticoagulation [letter] Vachharajani TJ, et al. **Nephrol Dial Transplant** 1997 Mar; 12(3):627–8

Heparins for proliferative nephritides? Short review on an advancing topic. Wardle EN. **Nephron** 1996;73(4):515–9 (85 ref.)

New developments in the treatment of deep venous thrombosis. Janssen MC, et al. **Neth J Med** 1997 Jan; 50(1):36–45 (88 ref.)

Current concepts of anticoagulant therapy in pregnancy. Barbour LA. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):499–521 (113 ref.)

The effects of heparin flush on patency of the Groshong catheter: a pilot study. Mayo DJ, et al. **Oncol Nurs Forum** 1996 Oct;23(9):1401–5

Oculoplastic surgery in patients receiving warfarin: suggestions for management. Bartley GB. **Ophthal Plast Reconstr Surg** 1996 Dec;12(4):229–30 (5 ref.)

Comparison of warfarin use in total knee replacement vs total hip replacement. Alexander G, et al. **Orthopedics** 1997 Feb; 20(2):117–20

Managing the risk of venous thromboembolism in orthopedics: concluding remarks. Haas S. **Orthopedics** 1997 Feb;20 Suppl:26–7

Managing the risk of thrombosis in the perioperative period in patients undergoing orthopedic and trauma surgery with low–molecular–weight heparin: enoxaparin. Lassen MR, et al. **Orthopedics** 1997 Feb;20 Suppl:14–7

The post–discharge prophylactic management of the orthopedic patient with low–molecular–weight heparin: enoxaparin. Nilsson PE, et al. **Orthopedics** 1997 Feb;20 Suppl:22–5

The post–hospital discharge venous thrombosis risk of the orthopedic patient. Planes A, et al. **Orthopedics** 1997 Feb; 20 Suppl:18–21

Low–molecular–weight heparin: from the bench to the orthopedic patient. Turpie AG. **Orthopedics** 1997 Feb;20 Suppl:10–3 (12 ref.)

Vertebral artery dissection: issues in diagnosis and management. Khurana DS, et al. **Pediatr Neurol** 1996 Apr; 14(3):255–8

Role of imbalance of intracavity fibrin formation and removal in the pathogenesis of peritoneal lesions in CAPD [editorial] Dobbie JW, et al. **Perit Dial Int** 1997 Mar–Apr; 17(2):121–4 (41 ref.)

Warfarin resistance: diagnosis and therapeutic alternatives. Hulse ML. **Pharmacotherapy** 1996 Nov–Dec;16(6):1009–17 (31 ref.)

Differential effects of platelet–derived growth factor BB in accelerating wound healing in aged versus young animals: the impact of tissue hypoxia. Wu L, et al. **Plast Reconstr Surg** 1997 Mar;99(3):815–22; discussion 823–4

Safer anticoagulant therapy after heart valve replacement. Recommendations for less intense regimens. Turpie AG. **Postgrad Med** 1997 Mar;101(3):85–6, 89–90, 93–4 (20 ref.)

Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy. Lip GY. **Postgrad Med J** 1996 Dec;72(854):731–8 (64 ref.)

Anticoagulants for venous thrombosis. Toh CH. **Postgrad Med J** 1997 May;73(859):283–5

Anticoagulation for atrial fibrillation: epidemiology informing a difficult clinical decision. Singer DE. **Proc Assoc Am Physicians** 1996 Jan;108(1):29–36 (30 ref.)

Contemporary stent designs: technical considerations, complications, role of intravascular ultrasound, and anticoagulation therapy. Popma JJ, et al. **Prog Cardiovasc Dis** 1996 Sep–Oct;39(2):111–28 (166 ref.)

Antithrombotic therapy for non–rheumatic atrial fibrillation [letter; comment] Lip GY. **QJM** 1996 Oct;89(10):799–800; discussion 801–2. Comment on: QJM 1996 Jun;89(6):409–14.

Antithrombotic therapy for non–rheumatic atrial fibrillation [letter] Wheeldon NM. **QJM** 1996 Oct;89(10):800–1; discussion 801–2

Treatment of deep vein thrombosis. Cina G, et al. **Rays** 1996 Jul–Sep;21(3):397–416 (66 ref.) **(Eng, Ita)**

Medical treatment of pulmonary embolism. Marra R. **Rays** 1996 Jul–Sep;21(3):425–31 (13 ref.) **(Eng, Ita)**

Risk factors and prevention of venous thromboembolism. Storti S, et al. **Rays** 1996 Jul–Sep;21(3):439–60 (137 ref.) **(Eng, Ita)**

Regional anesthesia and analgesia in the patient receiving thromboprophylaxis [editorial; comment] Horlocker TT. **Reg Anesth** 1996 Nov–Dec;21(6):503–7. Comment on: Reg Anesth 1996 Nov–Dec;21(6):517–24.

Hemostasis–altering drugs and central neural block. A survey of anesthetic practice in Scotland and the United Kingdom. Millar FA, et al. **Reg Anesth** 1996 Nov–Dec;21(6):529–33

Bone mineral density in patients given oral vitamin K antagonists. Lafforgue P, et al. **Rev Rhum Engl Ed** 1997 Apr;64(4):249–54

Characterization of 'winners' to enoxaparin in the prevention of postoperative venous thromboembolism in digestive surgery. Reiertsen O, et al. **Scand J Gastroenterol** 1996 Jun; 31(6):616–21

Anticoagulant treatment in primary health care in Finland. Eskola K, et al. **Scand J Prim Health Care** 1996 Sep; 14(3):165–70

Antithrombin deficiency in special clinical syndromes—Part II: cardiovascular surgery. Levy JH. **Semin Hematol** 1995 Oct;32(4 Suppl 2):49–55 (14 ref.)

Anticoagulants and thrombolytics during pregnancy. Ramin SM, et al. **Semin Perinatol** 1997 Apr;21(2):149–53 (35 ref.)

Low–molecular–weight heparin for the out–of–hospital treatment of venous thrombosis: rationale and clinical results. Crowther M, et al. **Semin Thromb Hemost** 1997; 23(1):77–81 (32 ref.)

Heparin therapy in pediatric patients. Sutor AH, et al. **Semin Thromb Hemost** 1997;23(3):303–19 (219 ref.)

Current use of low molecular weight heparins. Donayre CE. **Semin Vasc Surg** 1996 Dec;9(4):362–71 (57 ref.)

Coumadin: principles of use. Liem TK, et al. **Semin Vasc Surg** 1996 Dec;9(4):354–61 (51 ref.)

Intraoperative heparin anticoagulation and its reversal. Wakefield TW, et al. **Semin Vasc Surg** 1996 Dec; 9(4):296–302 (86 ref.)

Ancrod: clinical indications and methods of use. Wright JG, et al. **Semin Vasc Surg** 1996 Dec;9(4):315–28 (87 ref.)

Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke. Alexandrov AV, et al. **Stroke** 1997 Jun; 28(6):1198–202

Thromboembolism prophylaxis in chronic atrial fibrillation: practice patterns in community and tertiary–care hospitals [letter; comment] Cheng TO. **Stroke** 1997 Apr;28(4):874. Comment on: Stroke 1997 Jan;28(1):72–6.

US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke. Medical therapy in patients with carotid artery stenosis. Goldstein LB, et al. **Stroke** 1996 Sep;27(9):1473–8

Influence of transesophageal echocardiography on therapy in stroke [letter; comment] Kaul S, et al. **Stroke** 1996 Oct; 27(10):1910–1. Comment on: Stroke 1996 Apr;27(4):691–4.

Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Morocutti C, et al. **Stroke** 1997 May;28(5):1015–21

Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary–care hospitals [see comments] Munschauer FE, et al. **Stroke** 1997 Jan; 28(1):72–6. Comment in: Stroke 1997 Apr;28(4):874.

Stroke prevention in non–rheumatic atrial fibrillation. Duncan GW. **Tenn Med** 1997 Jan;90(1):21–2

Tissue factor pathway inhibitor: potential therapeutic applications. Bajaj MS, et al. **Thromb Haemost** 1997 Jul; 78(1):471–7 (69 ref.)

A multicenter randomized double–blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in–patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Bergmann JF, et al. **Thromb Haemost** 1996 Oct;76(4):529–34

New approaches to prevention of deep vein thrombosis. Bergqvist D. **Thromb Haemost** 1997 Jul;78(1):684–8 (41 ref.)

Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy. Boda Z, et al. **Thromb Haemost** 1996 Jul; 76(1):128

Efficacy and safety of oral anticoagulation in patients with cancer. Bona RD, et al. **Thromb Haemost** 1997 Jul; 78(1):137–40 (31 ref.)

Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with constant vitamin K1 content. Booth SL, et al. **Thromb Haemost** 1997 Mar;77(3):504–9 (63 ref.)

Once–daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Fiessinger JN, et al. **Thromb Haemost** 1996 Aug;76(2):195–9

Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. Hirsh J, et al. **Thromb Haemost** 1997 Jul; 78(1):689–92 (33 ref.)

Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Iacoviello L, et al. **Thromb Haemost** 1996 Dec;76(6):1102–7

Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Kaiser B, et al. **Thromb Haemost** 1996 Oct;76(4):615–20

Drug trials that have influenced our practice in the treatment of venous thromboembolism. Kearon C. **Thromb Haemost** 1997 Jul;78(1):553–7 (60 ref.)

The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Kitchen S, et al. **Thromb Haemost** 1996 May;75(5):734–9

Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation. Koefoed BG, et al. **Thromb Haemost** 1997 May;77(5):845–8

Inhibition rather than enhancement of hemostatic system activation during initiation of oral anticoagulant treatment. Kyrle PA, et al. **Thromb Haemost** 1997 Apr;77(4):685–9

Decrease in factor VII coagulant activity during percutaneous transluminal coronary angioplasty by heparin-mediated lipolytic action. Mukherjee M, et al. **Thromb Haemost** 1997 Apr;77(4):675–8

A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses. Pengo V, et al. **Thromb Haemost** 1997 May;77(5):839–44

Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation [letter] [see comments] Prandoni P, et al. **Thromb Haemost** 1996 May; 75(5):859. Comment in: Thromb Haemost 1997 Jan;77(1):221-2.

Impact of factor V Leiden mutation on duration of anticoagulation after a single thromboembolic event [letter; comment] Rintelen C, et al. **Thromb Haemost** 1997 Feb; 77(2):405. Comment on: Thromb Haemost 1996 Nov;76(5):815–6.

Acute ischemic stroke and heparin treatments. Samama MM, et al. **Thromb Haemost** 1997 Jul;78(1):173–9 (54 ref.)

Tissue factor pathway inhibitor: clinical deficiency states. Sandset PM, et al. **Thromb Haemost** 1997 Jul;78(1):467–70 (45 ref.)

Optimal duration of oral anticoagulant therapy in venous thromboembolism. Schulman S. **Thromb Haemost** 1997 Jul; 78(1):693–8 (33 ref.)

The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group. Schulman S, et al. **Thromb Haemost** 1996 Apr;75(4):607–11

Blood coagulation and thrombosis in patients with ovarian malignancy. von Tempelhoff GF, et al. **Thromb Haemost** 1997 Mar;77(3):456–61

The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Wielders S, et al. **Thromb Haemost** 1997 Apr;77(4):629–36

Indications and drugs for anticoagulation therapy in children. Andrew M. **Thromb Res** 1996;81(2 Suppl):S61–73 (106 ref.)

Coronary heart disease, unstable angina, PTCA: new indications for low molecular weight heparins? Breddin HK. **Thromb Res** 1996;81(2 Suppl):S47–51 (21 ref.)

Enoxaparin, a low-molecular-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism. Grosset AB, et al. **Thromb Res** 1997 Jun 1;86(5):349–54

A modification of the APC resistance test and its application to the study of patients on coumarin therapy. Jorquera JI, et al. **Thromb Res** 1996 May 1;82(3):217–24

Patients at risk of venous thromboembolism--clinical results with reviparin. Kakkar VV, et al. **Thromb Res** 1996;81(2 Suppl):S39–45 (11 ref.)

Low molecular weight heparin and the heparin mobilisable pool of platelet factor 4 are reduced in young survivors of myocardial infarction. Lewandowski K, et al. **Thromb Res** 1996 Mar 15;81(6):615–22

The old manual tilt tube Thrombotest: still useful in the management of oral anticoagulants? Marongiu F, et al. **Thromb Res** 1996 Dec 1;84(5):379–84

Low molecular weight heparin in prevention of restenosis after PTCA. Preisack MB, et al. **Thromb Res** 1996;81(2 Suppl):S53–9

Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Reininger CB, et al. **Thromb Res** 1996 Mar 15;81(6):641–9

Flush heparin during cardiac catheterisation prevents long-term coagulation activation in children without APC-resistance-preliminary results. Vielhaber H, et al. **Thromb Res** 1996 Mar 15;81(6):651–6

Outcome after splenic vein thrombosis in the pancreas allograft. Kuo PC, et al. **Transplantation** 1997 Sep 27; 64(6):933–5

Thromboembolism prophylaxis in surgical patients. Owings JT. **West J Med** 1996 Feb;164(2):166–7

Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan). Muhm M, et al. **Wien Klin Wochenschr** 1997 Feb 28;109(4):128–31

Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. Kakkar VV, et al. **World J Surg** 1997 Jan;21(1):2–8; discussion 8–9

Low-molecular-weight heparins and Daflon for prevention of postoperative thromboembolism. Tsimoyiannis EC, et al. **World J Surg** 1996 Oct;20(8):968–71; discussion 972

[Evidence-based medicine and disseminated intravascular coagulation (DIC) (letter; comment)] Skadborg MK. **Ugeskr Laeger** 1997 May 19;159(21):3189–90. Comment on: Ugeskr Laeger 1997 Feb 3;159(6):730–1. **(Dan)**

[Anticoagulation in cerebral ischemia? (letter)] Vennervàld K. **Ugeskr Laeger** 1997 May 19;159(21):3193–4 **(Dan)**

[Residual presence of fibrinogen: frequent pitfall in the interpretation of serum protein electrophoresis] Lefèvre F, et al. **Ann Biol Clin (Paris)** 1997 May-Jun;55(3):238–40 **(Fre)**

[Efficacy and tolerability of fraxiparine in the prevention of thromboembolic complications in oncologic thoracic surgery] Azorin JF, et al. **Ann Cardiol Angeiol (Paris)** 1997 May-Jun;46(5–6):341–7 (Eng. Abstr.) **(Fre)**

[Veno-occlusive disease after bone marrow transplantation: preventive effect of heparin] Parquet N, et al. **Ann Med Interne (Paris)** 1997;148(2):132–5 (15 ref.) (Eng. Abstr.) **(Fre)**

[Prescription of heparin in the acute phase of myocardial infarction: expected and observed benefits...] Cador R, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1479–84 (Eng. Abstr.) **(Fre)**

[Antithrombotic therapy of atrial fibrillation] Chalon S, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1533–42 (47 ref.) (Eng. Abstr.) **(Fre)**

[Antithrombotic agents and diabetes. Benefits and recommendations for use] Guillausseau PJ, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1557–61 (Eng. Abstr.) **(Fre)**

[Low molecular weight heparin in unstable angina] Kher A, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1495–500 (Eng. Abstr.) **(Fre)**

[Search for the "optimal" dose of antithrombotic agents] Mismetti P, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1473–7 (Eng. Abstr.) **(Fre)**

[Duration of antivitamin K treatment in venous thromboembolic disease (letter; comment)] Pinede L, et al. **Arch Mal Coeur Vaiss** 1996 Jul;89(7):927–31. Comment on: Arch Mal Coeur Vaiss 1995 Dec;88(12):1891–4. **(Fre)**

[Antithrombotic therapy in patients with mechanical valve prostheses] Roudaut R, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1543–50 (30 ref.) (Eng. Abstr.) **(Fre)**

[Use of antithrombotic agents in peripheral arterial diseases] Wütschert R, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1551–5 (23 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of venous thrombosis with low molecular weight heparin. Progress and outlook] Fiessinger JN. **Bull Acad Natl Med** 1997 May;181(5):875–83; discussion 883–5 (27 ref.) (Eng. Abstr.) **(Fre)**

[Should we give up combining spinal anesthesia and anticoagulants?] Samama CM. **Cah Anesthesiol** 1996; 44(5):437–40 (Eng. Abstr.) **(Fre)**

[Acute cytolytic hepatitis caused by coumarin. 2 cases] Koch S, et al. **Gastroenterol Clin Biol** 1997;21(3):223–5 (19 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy in primary antiphospholipid syndrome. Proposal for a common management protocol] el Kouri D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):828–31 (Eng. Abstr.) **(Fre)**

[Use of Organan for extracorporeal circulation in a patient allergic to heparin (letter)] Bretelle C, et al. **Presse Med** 1996 Nov 30;25(37):1846–7 **(Fre)**

[Medical treatment after implantation of intracoronary stents] Caussin C, et al. **Presse Med** 1997 Apr 5;26(11):532–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Value of organan in hemodialysis during heparin-induced thrombopenia (letter)] Lamriben L, et al. **Presse Med** 1996 Sep 28;25(28):1303 **(Fre)**

[Anticoagulants and platelet aggregation inhibitors in urology] Verdy E. **Prog Urol** 1997 Apr;7(2):326–32 (4 ref.) (Eng. Abstr.) **(Fre)**

[Preventive management of patients presenting with an increased tendency to venous thrombosis] Demulder A, et al. **Rev Med Brux** 1997 Jun;18(3):113–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[Melatonin, methadone, tacrine, vitamin K antagonists and low-molecular-weight heparin] Sternon J. **Rev Med Brux** 1996 Sep;17(4):282–6 (Eng. Abstr.) **(Fre)**

[Preventing and treating venous thrombosis in 1997 (editorial)] Fiessinger JN. **Rev Med Interne** 1997; 18(6):439–42 **(Fre)**

[Antivitamin K, aspirin: treatments still of significance] Lechat P. **Rev Med Interne** 1997;18 Suppl 2:91s–92s **(Fre)**

[Clinical case of the month. Acute mesenteric venous thrombosis treated in a conservative manner] Kolh PH, et al. **Rev Med Liege** 1996 Dec;51(12):744–8 **(Fre)**

[Heparins and curative treatment of venous thromboembolic disease: meta-analysis] Mismetti P, et al. **Therapie** 1997 Jan-Feb;52(1):47–52 (Eng. Abstr.) **(Fre)**

[Anticoagulation in transitory ischemic attack after bypass surgery] Bruhn HD. **Dtsch Med Wochenschr** 1997 Feb 14; 122(7):210 **(Ger)**

[Secondary resistance to coumarin derivatives in a patient with a hypercoagulability syndrome] Marburger C, et al. **Dtsch Med Wochenschr** 1997 Aug 1;122(31–32):959–64 (Eng. Abstr.) **(Ger)**

[Oral anticoagulation in activated protein C resistance?] Stiegler H. **Dtsch Med Wochenschr** 1996 Dec 20; 121(51–52):1619 **(Ger)**

[Prevention with low dosage heparin. Selective or general?] Schmitz-Huebner U. **Internist (Berl)** 1997 Jul;38(7):667–71 (41 ref.) **(Ger)**

[Drug therapy of atrial fibrillation] Gloor HO. **Schweiz Med Wochenschr** 1996 Oct 12;126(41):1739–47 (43 ref.) (Eng. Abstr.) **(Ger)**

[Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients] Meyer BJ. **Schweiz Med Wochenschr** 1996 Nov 16;126(46):1961–9 (43 ref.) (Eng. Abstr.) **(Ger)**

[Anti-thrombosis therapy following coronary stent implantation] Schuiki E, et al. **Schweiz Rundsch Med Prax** 1996 Oct 15;85(42):1316–9 (28 ref.) (Eng. Abstr.) **(Ger)**

[Should every patient with atrial fibrillation get anticoagulants?] Turina J. **Schweiz Rundsch Med Prax** 1997 Feb 11;86(7):258–60 (Eng. Abstr.) **(Ger)**

[Restenosis after percutaneous transluminal angioplasty: II. Possibilities for pharmacologic intervention] Böger RH, et al. **Vasa** 1996;25(1):21–31 (105 ref.) (Eng. Abstr.) **(Ger)**

[Comparison between low-molecular and unfractionated heparin in the prevention of thrombosis in patients with total endoprosthetic replacement of hip and knee joint] Rader CP, et al. **Z Orthop Ihre Grenzgeb** 1997 Jan-Feb; 135(1):52–7 (Eng. Abstr.) **(Ger)**

[Oral surgical procedures during anticoagulant therapy] Blinder D, et al. **Harefuah** 1996 May 15;130(10):681–3, 727 (Eng. Abstr.) **(Heb)**

[Embolic splenic infarction: a rare complication of atrial fibrillation] Merims D, et al. **Harefuah** 1997 Jun 15; 132(12):844–6, 911 (Eng. Abstr.) **(Heb)**

[Oral anticoagulation therapy in the primary care setting] Vinker S, et al. **Harefuah** 1997 Jun 1;132(11):753–6, 824, 823 (Eng. Abstr.) **(Heb)**

[New agents and challenges in the antithrombotic management of arterial diseases] Udvardy M, et al. **Orv Hetil** 1997 Jan 12;138(2):59–65 (44 ref.) (Eng. Abstr.) **(Hun)**

[Low molecular weight heparin: the first 5 years (editorial)] Mannucci PM. **Ann Ital Med Int** 1997 Apr-Jun;12(2):61–2 **(Ita)**

[Heparin therapy and coronary cardiopathy] Branzi A, et al. **Cardiologia** 1996 Dec;41(12):1147–54 (67 ref.) **(Ita)**

[Atrial natriuretic factor (ANF) in massive pulmonary embolism: the effects of heparin treatment] Bartolucci L, et al. **Clin Ter** 1996 May;147(5):239–44 (Eng. Abstr.) **(Ita)**

[Anticoagulation and electrical cardioversion of chronic atrial fibrillation: proposal for an abbreviated protocol] Antonielli E, et al. **G Ital Cardiol** 1997 Aug;27(8):803–10 (Eng. Abstr.) **(Ita)**

[Anticoagulant or antiaggregant therapy in the secondary prevention of myocardial infarct?] De Caterina R, et al. **G Ital Cardiol** 1996 Nov;26(11):1309–21 (42 ref.) (Eng. Abstr.) **(Ita)**

[Assessment of complications of major orthopedic surgery: comparison of indobufen, calcium heparin, and low molecular heparin] Borghi B, et al. **Minerva Anestesiol** 1996 Mar;62(3):93–100 (Eng. Abstr.) **(Ita)**

[Perioperative drug management in surgery using revascularized flaps] Belli E, et al. **Minerva Stomatol** 1996 May;45(5):205–11 (Eng. Abstr.) **(Ita)**

[PT-INR as a parameter for anticoagulant therapy after valve replacement surgery. Ishibashi Y, et al. **Kyobu Geka** 1996 Oct;49(11):906–8 (Eng. Abstr.) **(Jpn)**

[Argatroban, a selective thrombin inhibitor, for anticoagulant therapy during and following vascular surgery] Fuji H, et al. **Masui** 1996 Oct;45(10):1289–92 (Eng. Abstr.) **(Jpn)**

[Anticoagulant therapy of thrombosis] Nakagawa M. **Nippon Naika Gakkai Zasshi** 1997 Jun 10;86(6):959–64 **(Jpn)**

[Thromboembolism prophylaxis in pregnancy and labor] Częstochowska E. **Ginekol Pol** 1996 Nov;67(11):548–51 (Eng. Abstr.) **(Pol)**

[Long-term prophylaxis of thromboembolism and fraxiparin] Częstochowska E, et al. **Pol Arch Med Wewn** 1997 Jan; 97(1):47–51 (Eng. Abstr.) **(Pol)**

[Preparation for delivery in patients with missed labor considering low-dose heparin and prostaglandins] Cyrkowicz A, et al. **Przegl Lek** 1996;53(3):174–7 (Eng. Abstr.) **(Pol)**

[Prophylaxis of postoperative thromboembolism. Randomized prospective study] Manso LC, et al. **Acta Med Port** 1996 Feb-Mar;9(2-3):87–90 (Eng. Abstr.) **(Por)**

[Use of heparin and oral anticoagulants to prevent and treat deep venous thrombosis and pulmonary embolism] Hamerschlak N, et al. **Arq Bras Cardiol** 1996 Sep; 67(3):209–13 (20 ref.) **(Por)**

[The use of the new anticoagulant Fraxiparin in preventing

ANTICOAGULANTS

and treating thromboembolism] Saenko VF, et al. **Klin Khir** 1995;(3):39–41 (31 ref.) **(Rus)**

[The initial experience of using fraxiparin in extracorporeal detoxication in clinical cardiology] Sirenko IuN, et al. **Klin Khir** 1994;(12):23–5 (Eng. Abstr.) **(Rus)**

[Treatment and prevention of thrombotic episodes with hereditary thrombophilia] Bauer KA. **Vestn Ross Akad Med Nauk** 1997;(1):32–7 (101 ref.) **(Rus)**

[Evolution of pulmonary scintigraphy in the follow-up of pulmonary embolism. Effect of anticoagulant treatment and other associated factors] Otero-Candelera R, et al. **Arch Bronconeumol** 1997 Mar;33(3):129–32 (Eng. Abstr.) **(Spa)**

[Antithrombotic treatment in acute ischemia stroke] Díez-Tejedor E, et al. **Neurologia** 1995 Dec;10 Suppl 2:48–54 (42 ref.) (Eng. Abstr.) **(Spa)**

[Low molecular weight heparins. Implications in anesthesia and resuscitation] Llau JV, et al. **Rev Esp Anestesiol Reanim** 1997 Feb;44(2):70–8 (142 ref.) (Eng. Abstr.) **(Spa)**

[Treatment protocol of cerebral vascular accident] Biller J. **Rev Neurol** 1997 Jan;25(137):114 (10 ref.) **(Spa)**

[Indication and management of anticoagulants in cerebrovascular disease] Biller J. **Rev Neurol** 1997 Jan; 25(137):120–1 (14 ref.) **(Spa)**

[Antithrombin III concentrate seeks its therapeutic role. Be careful and wait for the results of the studies!] Astermark J, et al. **Lakartidningen** 1996 Oct 23;93(43):3773–6, 3778 (55 ref.) **(Swe)**

TOXICITY

Comparison of hemorrhagic effect of heparin and human activated protein C with use of Thrombostat 4000. Katsuura Y, et al. **Haemostasis** 1996 Jul–Aug;26(4):203–9

Molecular hemostatic variant enhances warfarin toxicity [editorial; comment] Thompson AR. **J Clin Invest** 1996 Oct 1;98(7):1508. Comment on: J Clin Invest 1996 Oct 1;98(7):1619–25.

ANTICOCCIDIAL AGENTS see **COCCIDIOSTATS**

ANTICODON

Structural analysis of a bovine arginine tRNA(CCG) gene. Eubanks AC, et al. **Biochim Biophys Acta** 1997 May 30; 1352(2):138–44

Two nucleotides 5'-adjacent to the anticodon of rat cytoplasmic tRNA(Asp) are not edited. Tomita K, et al. **Biochimie** 1996;78(11–12):1001–6

Arginine aminoacylation identity is context-dependent and ensured by alternate recognition sets in the anticodon loop of accepting tRNA transcripts. Sissler M, et al. **EMBO J** 1996 Sep 16;15(18):5069–76

Three modified nucleosides present in the anticodon stem and loop influence the in vivo aa–tRNA selection in a tRNA-dependent manner. Li J, et al. **J Mol Biol** 1997 Aug 15;271(2):209–21

Analysis of interactions between the codon-anticodon duplexes within the ribosome: their role in translation. Lim VI. **J Mol Biol** 1997 Mar 14;266(5):877–90

The anticodon loop is a major identity determinant of Saccharomyces cerevisiae tRNA(Leu). Soma A, et al. **J Mol Biol** 1996 Nov 15;263(5):707–14

BIOSYNTHESIS

Mechanism, specificity and general properties of the yeast enzyme catalysing the formation of inosine 34 in the anticodon of transfer RNA. Auxilien S, et al. **J Mol Biol** 1996 Oct 4;262(4):437–58

CHEMISTRY

H-bond stability in the tRNA(Asp) anticodon hairpin: 3 ns of multiple molecular dynamics simulations. Auffinger P, et al. **Biophys J** 1996 Aug;71(2):940–54

The crystal structures of T. thermophilus lysyl-tRNA synthetase complexed with E. coli tRNA(Lys) and a T. thermophilus tRNA(Lys) transcript: anticodon recognition and conformational changes upon binding of a lysyl-adenylate analogue. Cusack S, et al. **EMBO J** 1996 Nov 15;15(22):6321–34

RNA hydration: three nanoseconds of multiple molecular dynamics simulations of the solvated tRNA(Asp) anticodon hairpin. Auffinger P, et al. **J Mol Biol** 1997 Jun 13; 269(3):326–41

On the conformation of the anticodon loops of initiator and elongator methionine tRNAs. Schweisguth DC, et al. **J Mol Biol** 1997 Apr 4;267(3):505–19

Codon recognition by tRNA molecules with a modified or unmodified uridine at the first position of the anticodon. Okumura S, et al. **Nucleic Acids Symp Ser** 1995;(34):203–4

Transfer RNA recognition by the Escherichia coli delta2-isopentenyl-pyrophosphate:tRNA delta2-isopentenyl transferase: dependence on the anticodon arm structure. Motorin Y, et al. **RNA** 1997 Jul; 3(7):721–33

GENETICS

Primary sequence of mitochondrial tRNA(Arg) of a nematode Ascaris suum: occurrence of unmodified adenosine at the first position of the anticodon. Watanabe Y, et al. **Biochim Biophys Acta** 1997 Feb 7;1350(2):119–22

Expression of a coronavirus ribosomal frameshift signal in Escherichia coli: influence of tRNA anticodon modification on frameshifting. Brierley I, et al. **J Mol Biol** 1997 Jul 18; 270(3):360–73

Unconventional structure of tRNA(Lys)SUU anticodon explains tRNA's role in bacterial and mammalian ribosomal frameshifting and primer selection by HIV-1. Agris PF, et al. **RNA** 1997 Apr;3(4):420–8

METABOLISM

The anticodon is the signal sequence for mitochondrial import of glutamine tRNA in Tetrahymena. Rusconi CP, et al. **Genes Dev** 1996 Nov 15;10(22):2870–80

Identification of 2'-hydroxyl groups required for interaction of a tRNA anticodon stem–loop region with the ribosome. von Ahsen U, et al. **RNA** 1997 Jan;3(1):49–56

ANTICONVULSANTS

Safety of fosphenytoin sodium [see comments] Fierro LS, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2707–12 (53 ref.). Comment in: Am J Health Syst Pharm 1996 Nov 15;53(22):2702. Comment in: Am J Health Syst Pharm 1997 Feb 15;54(4):441–2. Comment in: Am J Health Syst Pharm 1997 Feb 15;54(4):442. Comment in: Am J Health Syst Pharm 1997 Feb 15;54(4):442, 445.

Moderate anticonvulsant action of baclofen does not change during development. Kubová H, et al. **Biol Neonate** 1996; 69(6):405–12

A review of the newer antiepileptic drugs and the ketogenic diet. Barron TF, et al. **Clin Pediatr (Phila)** 1997 Sep; 36(9):513–21 (61 ref.)

Seizure disorders. **Curr Opin Neurol** 1997 Apr;10(2):B29–41

Propofol: pro- or anticonvulsant? Borgeat A. **Eur J Anaesthesiol Suppl** 1997 May;15:17–20 (32 ref.)

Phenytoin. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:175–237 (306 ref.)

Doxefazepam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:97–104 (12 ref.)

Diazepam. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:37–96 (255 ref.)

Resistant seizures [editorial] Kalra V. **Indian Pediatr** 1996 Jan;33(1):5–8

Current status of newer antiepileptic drugs. Rajeshwari K. **Indian Pediatr** 1997 Jan;34(1):77–8

Current view of advances in epilepsy [news] Phillips P. **JAMA** 1997 Sep 17;278(11):883–6

[Research and development of zonisamide, a new type of antiepileptic drug] Shimizu M, et al. **Yakugaku Zasshi** 1996 Jul;116(7):533–47 (55 ref.) (Eng. Abstr.) **(Jpn)**

[Topiramate, a new antiepileptic drug] Herranz JL. **Rev Neurol** 1997 Aug;25(144):1221–5 (23 ref.) (Eng. Abstr.) **(Spa)**

[Drug therapy in epilepsy. New preparations are not yet the drugs of first choice] Tomson T. **Lakartidningen** 1996 Oct 9;93(41):3557–8, 3563–5 (18 ref.) **(Swe)**

ADMINISTRATION & DOSAGE

Peri-operative prophylaxis with phenytoin: dosage and therapeutic plasma levels. Levati A, et al. **Acta Neurochir (Wien)** 1996;138(3):274–8; discussion 278–9

Totally implantable vascular access and emergent management of refractory recurrent grand mal status epilepticus [letter] Lafond P, et al. **Am J Emerg Med** 1997 Jul;15(4):441

Fosphenytoin injection introduced as replacement for Dilantin injection [news] **Am J Health Syst Pharm** 1996 Oct 1;53(19):2249

Clinical and economic impact of replacing divalproex sodium with valproic acid. Cranor CW, et al. **Am J Health Syst Pharm** 1997 Aug 1;54(15):1716–22

Equivalence dosing. Lilley LL, et al. **Am J Nurs** 1997 Mar; 97(3):12

Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in preterm infants. FineSmith RB, et al. **Am J Perinatol** 1997 May;14(5):303–7

Intranasal midazolam in patients with status epilepticus. Kendall JL, et al. **Ann Emerg Med** 1997 Mar;29(3):415–7

Comment: possible toxicity from propylene glycol in lorazepam infusion [letter; comment] Seay RE, et al. **Ann Pharmacother** 1997 May;31(5):647–8. Comment on: Ann Pharmacother 1996 Nov;30(11):1227–31.

High doses of carbamazepine for refractory partial epilepsy. Borges Pereira C, et al. **Arq Neuropsiquiatr** 1996 Mar; 54(1):42–6

The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs. Shinoda M, et al. **Biol Pharm Bull** 1996 Aug;19(8):1090–2

The effectiveness of clonazepam on the Rolandic discharges. Mitsudome A, et al. **Brain Dev** 1997 Jun;19(4):274–8

Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Wroblewski BA, et al. **Brain Inj** 1997 Jan;11(1):37–47

Liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats. Mori N, et al. **Brain Res** 1995 Dec 12;703(1–2):184–90

Carbamazepine levels in the hair of patients under long-term treatment: a preliminary study. Tsatsakis AM, et al. **Clin Chim Acta** 1997 Jul 25;263(2):187–95

Studies on quantitative beta activity in EEG background changes produced by intravenous diazepam in epilepsy. Huang ZC, et al. **Clin Electroencephalogr** 1997 Jul; 28(3):172–8

Stopping status epilepticus. **Drug Ther Bull** 1996 Oct; 34(10):73–5

A practical guide to when (and how) to withdraw antiepileptic drugs in seizure-free patients. Schmidt D, et al. **Drugs** 1996 Dec;52(6):870–4 (17 ref.)

Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy. Pisano P, et al. **Eur J Clin Pharmacol** 1996;51(2):167–9

Essential palatal tremor successfully treated with flunarizine. Cakmur R, et al. **Eur Neurol** 1997;38(2):133–4

Withdrawal of antiepileptic drugs after one year? Garg RK. **Indian Pediatr** 1997 Feb;34(2):167–9

Valproic acid for Kleine-Levin syndrome [letter] Crumley FE. **J Am Acad Child Adolesc Psychiatry** 1997 Jul; 36(7):868–9

The effects of antiepileptic drugs on serum zinc and copper levels in children. Sözüer DT, et al. **J Basic Clin Physiol Pharmacol** 1995;6(3–4):265–9

Valproic acid treatment of learning disorder: a comment [letter; comment] Duane DD. **J Child Neurol** 1996 Nov; 11(6):505–6. Comment on: J Child Neurol 1996 Jan;11(1):41–3.

Add-on therapy with nimodipine in intractable epilepsy of childhood. Malashkhia VY, et al. **J Child Neurol** 1996 Nov; 11(6):500–1

Treatment with high doses of lamotrigine in children and adolescents with refractory seizures. Mims J, et al. **J Child Neurol** 1997 Jan;12(1):64–7

Assessment of combined treatment in partial seizures by means of the N-1 design. Valdizán JR, et al. **J Child Neurol** 1996 Nov;11(6):492–4

Single-point phenytoin dosage predictions in Singapore Chinese. Chan E. **J Clin Pharm Ther** 1997 Feb;22(1):47–52

Clinical advocacy for persons with epilepsy and mental retardation living in community-based programs. Baribeault JJ. **J Neurosci Nurs** 1996 Dec;28(6):359–60, 366–72

Re: Practical use of rectal medications in palliative care [letter; comment] Kerr D. **J Pain Symptom Manage** 1997 May;13(5):250. Comment on: J Pain Symptom Manage 1996 Jun;11(6):378–87.

Nasal benzodiazepines for management of acute childhood seizures? Wallace SJ. **Lancet** 1997 Jan 25;349(9047):222

AED withdrawal [letter; comment] Davis BJ. **Neurology** 1997 Apr;48(4):1137. Comment on: Neurology 1996 Jul;47(1):76–8.

Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Dodrill CB, et al. **Neurology** 1997 Apr;48(4):1025–31

Discontinuation of anticonvulsant therapy in children free of seizures for 1 year: a prospective study. Dooley J, et al. **Neurology** 1996 Apr;46(4):969–74

Maternal and fetal implications of anticonvulsive therapy during pregnancy. Eller DP, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):523–34 (46 ref.)

A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Chamberlain JM, et al. **Pediatr Emerg Care** 1997 Apr;13(2):92–4

Neonatal diagnosis of Schwartz-Jampel syndrome with dramatic response to carbamazepine. Squires LA, et al. **Pediatr Neurol** 1996 Sep;15(2):172–4

Dosing errors in the use of antiepileptic drug suspensions. Shelov SP. **Pediatr Rev** 1996 Sep;17(9):329

Removal of phenobarbital during continuous cycling peritoneal dialysis in a child. Porto I, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):832–5

Effects of ORG-2766 on brain event-related potentials of autistic children. Verbaten MN, et al. **Psychiatry Res** 1996 Jun 26;63(1):33–45

Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid. Brasić JR, et al. **Psychol Rep** 1997 Feb;80(1):163–70

Anti-epileptic medications in children who lack oral/parenteral access. Deering W. **S D J Med** 1996 Oct; 49(10):361–3

Epilepsy management: the general practitioner's perspective. Averis AK. **Seizure** 1997 Apr;6(2):81–5

Vigabatrin dosing during haemodialysis. Bachmann D, et al. **Seizure** 1996 Sep;5(3):239–42

A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Beran RG, et al. **Seizure** 1996 Dec;5(4):259–65

A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Bhaumik S, et al. **Seizure** 1997 Apr;6(2):127–33

Factors influencing compliance with antiepileptic drug regimes. Buck D, et al. **Seizure** 1997 Apr;6(2):87–93

Managing epilepsy in general practice: the dissemination and uptake of a free audit package, and collated results from 12 practices in England and Wales. Chappell B, et al. **Seizure** 1997 Feb;6(1):9–12

Paediatric out-patient antiepileptic drug doses recorded in the medical charts are not reliable: implications for the notion of noncompliance. Whitehouse W, et al. **Seizure**

1997 Feb;6(1):41–2
Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. May TW, et al. **Ther Drug Monit** 1996 Oct;18(5):523–31
[Phenemal and pregnancy (editorial)] Henriksen TB, et al. **Ugeskr Laeger** 1996 Nov 11;158(46):6575 **(Dan)**
[Development of a practical guide for utilization of injectable drugs in neonatology and in pediatrics] Veillet B, et al. **Therapie** 1996 Jul–Aug;51(4):403–9 (Eng. Abstr.) **(Fre)**
[Acute chloroquine poisoning] Altrock G, et al. **Dtsch Med Wochenschr** 1997 Feb 21;122(8):225–8 (Eng. Abstr.) **(Ger)**
[Epileptic seizures in children: acupressure instead of diazepam! (interview by Elisabeth Moosmann M.A.)] Pothmann R. **Fortschr Med** 1997 Feb 28;115(6):45, 46 **(Ger)**
[Anticonvulsants are often used to early (news)] Reiss J. **Fortschr Med** 1997 Jun 30;115(18):4, 6 **(Ger)**
[Post-traumatic seizure prevention—results of a survey of 127 neurosurgery clinics] Dauch WA, et al. **Zentralbl Neurochir** 1996;57(4):190–5 (Eng. Abstr.) **(Ger)**
[Serum digitoxin in concomitant use of antiepileptics in routine therapy] Aass H, et al. **Tidsskr Nor Laegeforen** 1997 May 30;117(14):2032–5 (Eng. Abstr.) **(Nor)**
[The effect of aminooxyacetic acid on the antidote activity of diazepam after exposure to GABA-lytics] Golovko AI, et al. **Biull Eksp Biol Med** 1994 Apr;117(4):441–3 **(Rus)**
[A clinico-pharmacological basis for optimizing the treatment of therapy-resistant forms of epilepsy] Gromov SA, et al. **Eksp Klin Farmakol** 1996 Jul–Aug;59(4):11–4 (Eng. Abstr.) **(Rus)**
[Depakine syrup in the treatment of therapy-resistant epilepsy] Maksumova EL, et al. **Ter Arkh** 1996;68(10):72–4 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Seizure-inducing effects of antiepileptic drugs: a review. Bauer J. **Acta Neurol Scand** 1996 Dec;94(6):367–77 (146 ref.)
A quantitative study of daytime sleepiness induced by carbamazepine and add-on vigabatrin in epileptic patients. Bonanni E, et al. **Acta Neurol Scand** 1997 Apr;95(4):193–6
Adverse effects in epilepsy therapy. Wait and see or go for it? Deckers CL, et al. **Acta Neurol Scand** 1997 Apr; 95(4):248–52 (22 ref.)
Psychotic and severe behavioural reactions with vigabatrin: a review [see comments] Ferrie CD, et al. **Acta Neurol Scand** 1996 Jan;93(1):1–8 (73 ref.). Comment in: Acta Neurol Scand 1997 Mar;95(3):189–90.
Fatal hepatotoxicity in a child treated with vigabatrin [letter] Kellermann K, et al. **Acta Neurol Scand** 1996 May; 93(5):380–1
Vigabatrin and psychosis: is there a true correlation? [letter; comment] Veggiotti P, et al. **Acta Neurol Scand** 1997 Mar; 95(3):189–90. Comment on: Acta Neurol Scand 1996 Jan;93(1):1–8.
Motor impairments in children with epilepsy treated with carbamazepine. Braathen G, et al. **Acta Paediatr** 1997 Apr; 86(4):372–6
Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Koch S, et al. **Acta Paediatr** 1996 Jun;85(6):739–46
Antiepileptic drug treatment during pregnancy and neonatal screening results. Wide K, et al. **Acta Paediatr** 1996 Jul; 85(7):870–1
Mononucleosis-like illness as a manifestation of carbamazepine-induced anticonvulsant hypersensitivity syndrome. Maquiera E, et al. **Allergol Immunopathol (Madr)** 1996 Mar–Apr;24(2):87–8
Spina bifida and cleft lip among newborns of Norwegian women with epilepsy: changes related to the use of anticonvulsants. King PB, et al. **Am J Public Health** 1996 Oct;86(10):1454–6
Stuttering caused by gabapentin [letter] Nissani M, et al. **Ann Intern Med** 1997 Mar 1;126(5):410
Suspected lamotrigine-induced toxic epidermal necrolysis. Chaffin JJ, et al. **Ann Pharmacother** 1997 Jun;31(6):720–3
Phenytoin-induced thrombocytopenia. Holtzer CD, et al. **Ann Pharmacother** 1997 Apr;31(4):435–7
A woman with lung cancer and exfoliative dermatitis. Phenytoin-induced pseudo-mycosis fungoides syndrome (PMFS). Westhoven GS, et al. **Arch Dermatol** 1997 Apr; 133(4):499, 502
The new antiepileptic drugs [letter] Appleton RE. **Arch Dis Child** 1997 Jan;76(1):81
Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Ornoy A, et al. **Arch Dis Child** 1996 Dec;75(6):517–20
Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. Chudnow RS, et al. **Arch Neurol** 1997 Jul;54(7):910–2
Effect of valproate on cognitive functioning. Comparison with carbamazepine. The Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Prevey ML, et al. **Arch Neurol** 1996 Oct;53(10):1008–16
Cerebellar atrophy decreases the threshold of carbamazepine toxicity in patients with chronic focal epilepsy. Specht U, et al. **Arch Neurol** 1997 Apr;54(4):427–31
Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Li LM, et al. **Arq Neuropsiquiatr** 1996 Mar;54(1):47–9
Phenobarbital-induced gingival overgrowth? Report of two cases and complications in management. Gregoriou AP, et al. **ASDC J Dent Child** 1996 Nov–Dec;63(6):408–13
Allergic reactions to phenytoin in a general hospital in Singapore. Leong KP, et al. **Asian Pac J Allergy Immunol** 1996 Dec;14(2):65–8
Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Sullivan JR, et al. **Australas J Dermatol** 1996 Nov;37(4):208–12 (32 ref.)
Fetal valproate embryopathy in twins: genetic modification of the response to a teratogen. Hockey A, et al. **Birth Defects Orig Artic Ser** 1996;30(1):401–5
Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies [letter; comment] Backstrom JT, et al. **BMJ** 1997 Jun 7; 314(7095):1694–5. Comment on: BMJ 1997 Jan 18;314(7075):180–1.
Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing [letter; comment] Blackwell N, et al. **BMJ** 1997 Jun 7;314(7095):1694. Comment on: BMJ 1997 Jan 18;314(7075):180–1.
Severe persistent visual field constriction associated with vigabatrin [see comments] Eke T, et al. **BMJ** 1997 Jan 18; 314(7075):180–1. Comment in: BMJ 1997 Jun 7;314(7095):1693–4. Comment in: BMJ 1997 Jun 7;314(7095):1693. Comment in: BMJ 1997 Jun 7;314(7095):1694. Comment in: BMJ 1997 Jun 7;314(7095):1694–5.
Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist [letter; comment] Harding GF. **BMJ** 1997 Jun 7;314(7095):1694. Comment on: BMJ 1997 Jan 18;314(7075):180–1.
Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions [letter; comment] Wilson EA, et al. **BMJ** 1997 Jun 7;314(7095):1693. Comment on: BMJ 1997 Jan 18;314(7075):180–1.
Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent [letter; comment] Wong IC, et al. **BMJ** 1997 Jun 7; 314(7095):1693–4. Comment on: BMJ 1997 Jan 18;314(7075):180–1.
Drug toxicity and surveillance in children. Choonara I, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):407–10 (47 ref.)
EBV-positive non-Hodgkin's lymphoma developing after phenytoin therapy. Garcia-Suarez J, et al. **Br J Haematol** 1996 Nov;95(2):376–9
Cognitive impairment associated with lamotrigine [letter] Bouman WP, et al. **Br J Psychiatry** 1997 Apr;170:388–9
Phenytoin-induced pseudo-Sjögren's syndrome [letter] Chakravarty K, et al. **Br J Rheumatol** 1996 Oct; 35(10):1033–4
Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Hauser E, et al. **Brain Dev** 1996 Mar–Apr;18(2):105–9
Heat stroke-like episode in a child caused by zonisamide. Shimizu T, et al. **Brain Dev** 1997 Jul;19(5):366–8
Pure red cell aplasia during carbamazepine monotherapy. Tagawa T, et al. **Brain Dev** 1997 Jun;19(4):300–2
Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Corman CL, et al. **Can J Neurol Sci** 1997 Aug;24(3):240–4
Cross sensitivity of skin rashes with antiepileptic drugs. Hyson C, et al. **Can J Neurol Sci** 1997 Aug;24(3):245–9
Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change [see comments] Iwahashi K. **Clin Neuropharmacol** 1996 Jun;19(3):267–70. Comment in: Clin Neuropharmacol 1997 Apr;20(2):179.
Aggression in children treated with clobazam for epilepsy. Sheth RD, et al. **Clin Neuropharmacol** 1994 Aug; 17(4):332–7
Transient myeloid dysplasia due to valproic acid. Hongeng S, et al. **Clin Pediatr (Phila)** 1997 Jun;36(6):361–4
Tonic-clonic seizures: a systematic review of antiepilepsy drug efficacy and safety. Ramsay RE, et al. **Clin Ther** 1997 May–Jun;19(3):433–46; discussion 367–8 (20 ref.)
Acquired acromelanosis due to phenytoin [letter] Kanwar AJ, et al. **Dermatology** 1997;194(4):373–4
Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Sachs B, et al. **Dermatology** 1997;195(1):60–4
Hypothyroxinemia and phenytoin toxicity: a vicious circle. Sarich TC, et al. **Drug Metabol Drug Interact** 1996; 13(2):155–60
Anticonvulsant-induced psychiatric disorders. The role of forced normalisation. Trimble MR. **Drug Saf** 1996 Sep; 15(3):159–66 (47 ref.)
Dose-related adverse effects of anticonvulsants. Troupin AS. **Drug Saf** 1996 May;14(5):299–328 (53 ref.)
A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Wallace SJ. **Drug Saf** 1996 Dec;15(6):378–93 (76 ref.)
Effect of seizures and epileptiform discharges on cognitive function. Aldenkamp AP. **Epilepsia** 1997;38 Suppl 1:S52–5 (40 ref.)
An overview of the efficacy and tolerability of new antiepileptic drugs. Chadwick DW. **Epilepsia** 1997;38 Suppl 1:S59–62
Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Kondo T, et al. **Epilepsia** 1996 Dec;37(12):1242–4
Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Lau AH, et al. **Epilepsia** 1997 Apr;38(4):445–51
IgA and IgG2 deficiency associated with zonisamide therapy: a case report. Maeoka Y, et al. **Epilepsia** 1997 May; 38(5):611–3
Overview of the safety of newer antiepileptic drugs. Shorvon S, et al. **Epilepsia** 1997;38 Suppl 1:S45–51 (79 ref.)
The Neurotoxicity Scale—II. Results of a patient-based scale assessing neurotoxicity in patients with epilepsy. Aldenkamp AP, et al. **Epilepsy Res** 1997 Jun;27(3):165–73
Effect of topiramate on attention. Burton LA, et al. **Epilepsy Res** 1997 Apr;27(1):29–32
Parent-completed scales for measuring seizure severity and severity of side-effects of antiepileptic drugs in childhood epilepsy: development and psychometric analysis. Carpay HA, et al. **Epilepsy Res** 1996 Jul;24(3):173–81
Vigabatrin withdrawal randomized study in children. Chiron C, et al. **Epilepsy Res** 1996 Nov;25(3):209–15
Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments. Gillham R, et al. **Epilepsy Res** 1996 May;24(1):47–55
Carbamazepine and PIP-syndrome in temporal lobe epilepsy. Schmitz B, et al. **Epilepsy Res** 1995 Nov;22(3):215–20
Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Lam CW, et al. **Eur J Pediatr** 1997 Jul; 156(7):562–4
Recovery of decreased seizure threshold for pentylenetetrazole during diazepam withdrawal by NMDA receptor antagonists. Tsuda M, et al. **Eur J Pharmacol** 1997 Apr 11;324(1):63–6
Carbamazepine-phenprocoumon interaction. Böttcher T, et al. **Eur Neurol** 1997;38(2):132–3
Felbamate as add-on therapy. Li LM, et al. **Eur Neurol** 1996; 36(3):146–8
The effect of chronic carbamazepine, valproic acid and phenytoin medication on the periodontal condition of epileptic children and adolescents. Galas-Zgorzalewicz B, et al. **Funct Neurol** 1996 Jul–Aug;11(4):187–93
Hepatotoxicity of anesthetics and other central nervous system drugs. Holt C, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):853–74 (165 ref.)
Strategies to protect bone mass in the older patient with epilepsy. Cohen A, et al. **Geriatrics** 1997 Aug;52(8):70, 75–8, 81 (26 ref.)
Phenytoin-mediated oxidative stress in serum of female epileptics: a possible pathogenesis in the fetal hydantoin syndrome. Liu CS, et al. **Hum Exp Toxicol** 1997 Mar; 16(3):177–81
Sulthiame-associated mild compensated metabolic acidosis. Tröger U, et al. **Int J Clin Pharmacol Ther** 1996 Dec; 34(12):542–5
Cognitive performances in newly referred patients with temporal lobe epilepsy: comparison with normal subjects in basal condition and after treatment with controlled-release carbamazepine. Gigli GL, et al. **Int J Neurosci** 1996 Nov;88(1–2):97–107
Clinical case report: multiple idiosyncratic adverse effects of antiepileptic drugs in trisomy 9p. Gigli GL, et al. **Int J Neurosci** 1996 Nov;87(3–4):181–9
Ethosuximide-induced lupus-like syndrome with renal involvement [see comments] Takeda S, et al. **Intern Med** 1996 Jul;35(7):587–91. Comment in: Intern Med 1996 Jul;35(7):527–8.
Lamotrigine and pregnancy [letter] Quattrini A, et al. **Ital J Neurol Sci** 1996 Dec;17(6):441
Erythema multiforme to phenobarbital: involvement of eosinophils and T cells expressing the skin homing receptor. Gonzalez FJ, et al. **J Allergy Clin Immunol** 1997 Jul; 100(1):135–7
Fixed drug eruption to three anticonvulsant drugs: an unusual case of polysensitivity. Chan HL, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):259
Phenytoin-like hypersensitivity associated with lamotrigine. Jones D, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):1016–8
Simultaneous phenytoin and warfarin toxicity on chronic concomitant therapy. Meisheri YV. **J Assoc Physicians India** 1996 Sep;44(9):661–2
Carbamazepine induced sino-atrial block in a young adult [letter] Parihar PS, et al. **J Assoc Physicians India** 1996 Jun;44(6):431–2
Side effects associated with psychoactive medication in individuals with autism [letter] Aman MG, et al. **J Autism Dev Disord** 1997 Jun;27(3):342–4
Phenytoin-related chorea in children with deep hemispheric vascular malformations. Koukkari MW, et al. **J Child Neurol** 1996 Nov;11(6):490–1
Altered cognitive functioning in children with idiopathic epilepsy receiving valproate monotherapy. Legarda SB, et al. **J Child Neurol** 1996 Jul;11(4):321–30 (81 ref.)
Vitamin K-dependent coagulopathy in a child receiving anticonvulsant therapy. Tam DA Jr, et al. **J Child Neurol** 1996 May;11(3):244–6
Vigabatrin-induced gingival overgrowth. Katz J, et al. **J Clin Periodontol** 1997 Mar;24(3):180–2
Phenobarbital-induced disinhibition in the developmentally disabled: case report [letter] Barnhill J, et al.

J Clin Psychopharmacol 1997 Jun;17(3):229–30

Cutaneous eruptions as part of the "anticonvulsant hypersensitivity syndrome" [letter; comment] Knowles SR, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):263–4. Comment on: J Clin Psychopharmacol 1994 Dec;14(6):408–13.

Induction of superoxide dismutase isozymes by tumor necrosis factor–alpha and lipopolysaccharide in cultured normal and hyperplastic gingival fibroblasts. Liu TZ, et al. **J Formos Med Assoc** 1996 Mar;95(3):236–40

Phenytoin hypersensitivity syndrome. Sanders DY, et al. **J Miss State Med Assoc** 1996 Feb;37(2):471–5

Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. Kishi T, et al. **J Neurol Sci** 1997 Jan;145(1):109–12

Valproate induced lupus–like syndrome. Park–Matsumoto YC, et al. **J Neurol Sci** 1996 Nov;143(1–2):185–6

Psychiatric effects of felbamate [letter; comment] Ketter TA, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter; 9(1):118–9. Comment on: J Neuropsychiatry Clin Neurosci 1996 Summer;8(3):341–6.

Neuropsychiatric side effects related to treatment with felbamate [see comments] McConnell H, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):341–6 . Comment in: J Neuropsychiatry Clin Neurosci 1997 Winter;9(1):118–9.

Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. Verrotti A, et al. **J Paediatr Child Health** 1997 Jun;33(3):242–5

Effect of valproate on bone mineral density [letter; comment] Gilles P, et al. **J Pediatr** 1996 Mar;128(3):441. Comment on: J Pediatr 1995 Aug;127(2):256–62.

Thrombocytopenic purpura and anemia in a breast–fed infant whose mother was treated with valproic acid. Stahl MM, et al. **J Pediatr** 1997 Jun;130(6):1001–3

Immunohistochemical localization of transforming growth factor beta, basic fibroblast growth factor and heparan sulphate glycosaminoglycan in gingival hyperplasia induced by nifedipine and phenytoin. Saito K, et al. **J Periodontal Res** 1996 Nov;31(8):545–55

Plasma and saliva concentrations of phenytoin and 5–(4–hydroxyphenyl)–5–phenylhydantoin in relation to the incidence and severity of phenytoin–induced gingival overgrowth in epileptic patients. Ball DE, et al. **J Periodontol** 1996 Jun;67(6):597–602

Myofibroblasts in phenytoin–induced hyperplastic connective tissue in the rat and in human gingival overgrowth. Dill RE, et al. **J Periodontol** 1997 Apr; 68(4):375–80

Collagen synthesis in idiopathic and dilantin–induced gingival fibromatosis. Huang JS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Mar; 13(3):141–8

Lamotrigine and toxic epidermal necrolysis [letter; comment] Sachs B, et al. **Lancet** 1996 Dec 7;348(9041):1597. Comment on: Lancet 1996 Oct 12;348(9033):1041.

Lamotrigine and toxic epidermal necrolysis [letter] [published erratum appears in Lancet 1996 Nov 16;348(9038):1392] [see comments] Wadelius M, et al. **Lancet** 1996 Oct 12; 348(9033):1041. Comment in: Lancet 1996 Dec 7;348(9041):1597.

Vigabatrin overdose [letter] Davie MB, et al. **Med J Aust** 1996 Oct 7;165(7):403

Glaxo Wellcome epilepsy drug exhibits fatal side effects [news] **Nat Biotechnol** 1997 May;15(5):398

Carbamazepine–associated acute tubulointerstitial nephritis. Eijgenraam JW, et al. **Neth J Med** 1997 Jan;50(1):25–8

Color vision tests for early detection of antiepileptic drug toxicity. Bayer AU, et al. **Neurology** 1997 May;48(5):1394–7

AED withdrawal [letter; comment] Davis BJ. **Neurology** 1997 Apr;48(4):1137. Comment on: Neurology 1996 Jul;47(1):76–8.

Anemia associated with lamotrigine. Esfahani FE, et al. **Neurology** 1997 Jul;49(1):306–7

Incontinence during treatment with gabapentin. Gil–Nagel A, et al. **Neurology** 1997 May;48(5):1467–8

Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Tennis P, et al. **Neurology** 1997 Aug; 49(2):542–6

Carbamazepine–induced sinus node dysfunction. Johnson CD, et al. **P R Health Sci J** 1997 Mar;16(1):45–9 (37 ref.)

Exfoliative dermatitis due to immunologically confirmed carbamazepine hypersensitivity. Troost RJ, et al. **Pediatr Dermatol** 1996 Jul–Aug;13(4):316–20

Bromism: intoxication from a rare anticonvulsant therapy. James LP, et al. **Pediatr Emerg Care** 1997 Aug;13(4):268–70

Valproic acid and thrombocytopenia in children: a case–controlled retrospective study. Allarakhia IN, et al. **Pediatr Neurol** 1996 May;14(4):303–7

Pseudo valproate–induced hypofibrinogenemia. Breningstall GN, et al. **Pediatr Neurol** 1996 May;14(4):345

Growth suppression in children receiving acetazolamide with antiepileptic drugs. Futagi Y, et al. **Pediatr Neurol** 1996 Nov;15(4):323–6

Diet– and valproate–induced transient hyperammonemia: effect of L–carnitine. Gidal BE, et al. **Pediatr Neurol** 1997 May;16(4):301–5

Medium chain acyl–CoA dehydrogenase deficiency and fatal valproate toxicity. Njølstad PR, et al. **Pediatr Neurol** 1997 Feb;16(2):160–2

Valproate–induced liver failure in one of two siblings with Alpers disease. Schwabe MJ, et al. **Pediatr Neurol** 1997 May;16(4):337–43

Valproic–acid–associated pancreatitis and hepatic toxicity in children with endstage renal disease [letter] Levin TL, et al. **Pediatr Radiol** 1997 Feb;27(2):192–3

Hepatotoxic side–effect of clomethiazole. Heinemann F, et al. **Pharmacopsychiatry** 1996 Sep;29(5):196–7

The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Boucher BA, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):638–45

Anticonvulsants and congenital malformations. Jick SS, et al. **Pharmacotherapy** 1997 May–Jun;17(3):561–4

Effect of antiepileptic drugs on thyroid function. Kimura M, et al. **Psychiatry Clin Neurosci** 1995 Aug;49(4):227–9

A possible case of carbamazepine induced pancreatitis. Forte A, et al. **Riv Eur Sci Med Farmacol** 1996 Sep–Dec; 18(5–6):187–9

Lamotrigine and serious skin reactions [letter] Mehta U. **S Afr Med J** 1997 Jul;87(7):912, 914

Long–term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. Besag FM, et al. **Seizure** 1997 Feb;6(1):51–6

Serum carnitine levels in ambulatory epilepsy outpatients. Drake ME Jr, et al. **Seizure** 1996 Dec;5(4):251–3

Weight gain with valproate or carbamazepine—a reappraisal. Easter D, et al. **Seizure** 1997 Apr;6(2):121–5

Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal). Fogh K, et al. **Seizure** 1997 Feb;6(1):63–5

Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril). Lambert MV, et al. **Seizure** 1997 Jun;6(3):233–5

The care of pregnant women with epilepsy—a survey of obstetricians in Scotland. Russell AJ, et al. **Seizure** 1996 Dec;5(4):271–7

Mechanisms of drug reactions: the metabolic track. Shapiro LE, et al. **Semin Cutan Med Surg** 1996 Dec;15(4):217–27 (66 ref.)

Drugs in pregnancy: anticonvulsants. Malone FD, et al. **Semin Perinatol** 1997 Apr;21(2):114–23 (41 ref.)

Phyllodes tumor in epilepties: a report of two cases. Shiba E, et al. **Surg Today** 1996;26(2):131–4

Changes in body weight with chronic, high–dose gabapentin therapy. DeToledo JC, et al. **Ther Drug Monit** 1997 Aug; 19(4):394–6

Status epilepticus associated with the combination of valproic acid and clomipramine. DeToledo JC, et al. **Ther Drug Monit** 1997 Feb;19(1):71–3

The platelet aggregation in children with epilepsy receiving valproic acid. Tanindi S, et al. **Thromb Res** 1996 Feb 15; 81(4):471–6

Bone status after long–term anticonvulsant therapy in epileptic patients: evaluation using quantitative ultrasound of calcaneus and phalanges. Pluskiewicz W, et al. **Ultrasound Med Biol** 1997;23(4):553–8

Fetal malformations in an epileptic pregnant woman treated with carbamazepine. Ceci O, et al. **Zentralbl Gynakol** 1996; 118(3):169–71

[Delayed effects of prenatal exposure to phenobarbital on intelligence—Phenemal] Mortensen EL, et al. **Ugeskr Laeger** 1996 Nov 11;158(46):6589–94 (Eng. Abstr.) **(Dan)**

[Reversible dementia due to valproic acid therapy] Walstra GJ. **Ned Tijdschr Geneeskd** 1997 Feb 22;141(8):391–3 (Eng. Abstr.) **(Dut)**

[Embryo–fetopathy due to valproate (letter)] Chabrolle JP, et al. **Arch Pediatr** 1997 Mar;4(3):288–9 **(Fre)**

[Embryofetopathy due to valproate: a pathology only little known. Apropos of 4 cases] Espinasse M, et al. **Arch Pediatr** 1996 Sep;3(9):896–9 (Eng. Abstr.) **(Fre)**

[Example of teratogen detection using a birth defects registry: depakine and spina bifida] Robert E. **Rev Epidemiol Sante Publique** 1996;44 Suppl 1:S78–81 (Eng. Abstr.) **(Fre)**

[Management of cutaneous risk in pharmacovigilance: metabolic predisposition to Stevens–Johnson syndromes and toxic epidermal necrolysis] Wolkenstein P. **Therapie** 1996 Sep–Oct;51(5):500–1 **(Fre)**

[Anticonvulsive hypersensitivity syndrome (letter)] Stein J, et al. **Dtsch Med Wochenschr** 1997 Mar 7;122(10):314–5 **(Ger)**

[Rheumatism caused by anticonvulsants: presentation of 2 clinical cases with work reintegration] Saviola G, et al. **G Ital Med Lav Ergon** 1996 Jan–May;18(1–3):31–4 (Eng. Abstr.) **(Ita)**

[Intractable hiccup in two severely handicapped patients during phenytoin therapy] Nishimura M. **No To Hattatsu** 1996 Sep;28(5):430–3 (Eng. Abstr.) **(Jpn)**

[Valproate–induced pancytopenia in a patient with infantile spasms] Taniguchi Y, et al. **No To Hattatsu** 1997 Jan; 29(1):73–5 **(Jpn)**

[A case of myasthenia gravis associated with long–term phenytoin therapy] Ozawa T, et al. **Rinsho Shinkeigaku** 1996 Nov;36(11):1262–4 (Eng. Abstr.) **(Jpn)**

[Nephropathy induced by anticonvulsants] Hashimoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):536–8 (6 ref.) **(Jpn)**

[The effect of bemitil on the parameters of lipid peroxidation and nitrogen metabolism in epilepsy in children] Mikhallov IB, et al. **Eksp Klin Farmakol** 1997 May–Jun;60(3):20–2 (Eng. Abstr.) **(Rus)**

[Reflex sympathetic dystrophy syndrome associated with phenobarbital (letter)] Gabriel Botella F, et al. **An Med Interna** 1996 Jul;13(7):336–8 (Eng. Abstr.) **(Spa)**

[Isolated increased of blood alkaline phosphatases, induced by diphenylhydantoin. Clinical interest (letter)] Gil González I. **An Med Interna** 1995 Aug;12(8):409–10 **(Spa)**

[Temporal cerebellar atrophy following phenytoin therapy] Guerrero AL, et al. **Neurologia** 1997 Jun–Jul;12(6):259–61 (Eng. Abstr.) **(Spa)**

[Factors to consider in the evaluation of intellectual achievement of an epileptic child] Pestana EM, et al. **Rev Neurol** 1997 Aug;25(144):1225–8 (51 ref.) (Eng. Abstr.) **(Spa)**

[Adverse cutaneous reactions to drugs in neurology] Redondo Bellón P. **Rev Neurol** 1997 Sep;25 Suppl 3:S309–19 (73 ref.) (Eng. Abstr.) **(Spa)**

[Problems can be seen from different points of view (letter)] Gamstorp I. **Lakartidningen** 1997 Sep 3;94(36):3018 **(Swe)**

[Pacemaker in bradycardias is sometimes not necessary. Seponation of carbamazepine should be considered] Kennebäck G. **Lakartidningen** 1997 Mar 12;94(11):947–8 (9 ref.) **(Swe)**

ANALYSIS

Quantitative analysis of mixtures of metal–carbonyl complexes by Fourier–transform infrared spectroscopy: application to the simultaneous double immunoassay of antiepileptic drugs by the nonisotopic carbonyl metalloimmunoassay method. Varenne A, et al. **Anal Biochem** 1996 Nov 15;242(2):172–9

Examination of stability of anticonvulsants in a protease solution and assay of anticonvulsants in hairs. Fujii J, et al. **Biol Pharm Bull** 1996 Dec;19(12):1614–7

Simultaneous determination of carbamazepine and carbamazepine 10,11–epoxide by using microcolumn HPLC: study of pharmacokinetics of carbamazepine in a volunteer. Alexishvili MM, et al. **Biomed Chromatogr** 1997 Jan–Feb;11(1):36–41

Methods to reduce background interferences in electron–capture gas chromatographic analysis of valproic acid and its unsaturated metabolites after derivatization with pentafluorobenzyl bromide. Dills RL, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):139–52

High–performance liquid chromatographic determination of carbamazepine and metabolites in human hair. Saris LA, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11; 691(2):409–15

Measurement of a new anticonvulsant, (S)–3–(aminomethyl)–5–methylhexanoic acid, in plasma and milk by high–performance liquid chromatography. Windsor BL, et al. **J Chromatogr B Biomed Appl** 1995 Dec 1;674(1):143–8

Simultaneous determination of diazepam and pyridoxine in synthetic mixtures and pharmaceutical formulations using graphical and multivariate calibration–prediction methods. Bautista RD, et al. **J Pharm Biomed Anal** 1996 Nov; 15(2):183–92

Simultaneous determination of phenytoin and carbamazepine in human hair by high–performance liquid chromatography. Mei Z, et al. **Ther Drug Monit** 1997 Feb; 19(1):92–4

Totally automated analysis by robotized PrepStation and liquid chromatography: direct–sample analysis of felbamate. Wong SH, et al. **Ther Drug Monit** 1996 Oct; 18(5):573–80

ANTAGONISTS & INHIBITORS

Valproate–induced developmental modifications maybe partially prevented by coadministration of folinic acid and S–adenosylmethionine. Ubeda N, et al. **Int J Dev Biol** 1996; Suppl 1:291S–292S

Influence of aminophylline and strychnine on the protective activity of excitatory amino acid antagonists against maximal electroshock–induced convulsions in mice. Tutka P, et al. **J Neural Transm** 1996;103(3):307–14

BLOOD

The effects of long–term anticonvulsive treatment on serum lipid profile. Yalçin E, et al. **Acta Paediatr Jpn** 1997 Jun; 39(3):342–5

Effects of serum separation tubes on serum benzodiazepine and phenobarbital concentrations in clinically normal and epileptic dogs. Boothe DM, et al. **Am J Vet Res** 1996 Sep; 57(9):1299–303

Revised Winter–Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Anderson GD, et al. **Ann Pharmacother** 1997 Mar;31(3):279–84

Ciprofloxacin–phenytoin interaction [letter] Brouwers PJ, et al. **Ann Pharmacother** 1997 Apr;31(4):498

Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Tran A, et al. **Eur J Clin Pharmacol** 1996;50(6):497–500

Ciprofloxacin decreases plasma phenytoin concentrations in the rat. al–Humayyd MS. **Eur J Drug Metab Pharmacokinet** 1997 Jan–Mar;22(1):35–9

Circulating levels of anticonvulsant metabolites of progesterone in women with partial epilepsy in the

intercritical phase. Galli R, et al. **Ital J Neurol Sci** 1996 Aug;17(4):277–81

Chromatographic procedures for the determination of felbamate in serum. Gur P, et al. **J Anal Toxicol** 1995 Oct; 19(6):499–503

Determination of gabapentin in serum using solid–phase extraction and gas–liquid chromatography. Wolf CE, et al. **J Anal Toxicol** 1996 Oct;20(6):498–501

Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron [letter] Nagai K, et al. **J Antimicrob Chemother** 1997 Feb; 39(2):295–6

Assay for valproic acid and its E–delta2 metabolite in rat plasma by capillary gas chromatography without prior derivatization. Carlin A, et al.
J Chromatogr B Biomed Appl 1997 Jun 20;694(1):115–21

High–speed liquid chromatographic method for the monitoring of carbamazepine and its active metabolite, carbamazepine–10,11–epoxide, in human plasma. Chollet D, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30; 683(2):237–43

Simultaneous rapid high–performance liquid chromatographic determination of phenytoin and its prodrug, fosphenytoin in human plasma and ultrafiltrate. Cwik MJ, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):407–14

Lamotrigine analysis in plasma by gas chromatography–mass spectrometry after conversion to a tert.–butyldimethylsilyl derivative. Dasgupta A, et al.
J Chromatogr B Biomed Appl 1997 May 23;693(1):101–7

Determination of gabapentin in plasma by high–performance liquid chromatography. Forrest G, et al.
J Chromatogr B Biomed Appl 1996 Jun 7;681(2):421–5

New micromethod for the determination of lamotrigine in human plasma by high–performance liquid chromatography. Londero D, et al.
J Chromatogr B Biomed Appl 1997 Mar 28;691(1):139–44

Liquid chromatographic assay in plasma of one of the members of a new series of anticonvulsants: D,L–3–hydroxy–3–ethyl–3–phenylpropionamide. Martínez de Muñoz D, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):377–83

Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high–performance liquid chromatography. Pienimäki P, et al.
J Chromatogr B Biomed Appl 1995 Nov 3;673(1):97–105

Serum lamotrigine analysis by capillary electrophoresis. Shihabi ZK, et al. **J Chromatogr B Biomed Appl** 1996 Aug 9;683(1):119–23

Quantitative determination of clonazepam in plasma by gas chromatography–negative ion chemical ionization mass spectrometry. Song D, et al.
J Chromatogr B Biomed Appl 1996 Nov 15;686(2):199–204

Simultaneous determination of plasma phenytoin and its primary hydroxylated metabolites in carbon tetrachloride–intoxicated rats by high–performance liquid chromatography. Tanaka E, et al.
J Chromatogr B Biomed Appl 1995 Nov 3;673(1):147–51

Extrashot–ODS, a syringe–type minicolumn sample injector for a reversed–phase high–performance liquid chromatographic column. Application to antiepileptics in human sera. Kouno Y, et al.
J Chromatogr B Biomed Sci Appl 1997 Aug 1;695(2):349–53

Micellar electrokinetic capillary chromatography for therapeutic drug monitoring of zonisamide. Makino K, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1; 695(2):417–25

Plasma concentrations of vigabatrin in epileptic patients. Sánchez–Alcaraz A, et al. **J Clin Pharm Ther** 1996 Dec; 21(6):393–8

Liquid chromatographic determination of plasma lamotrigine in pediatric samples. Forssblad E, et al.
J Pharm Biomed Anal 1996 Apr;14(6):755–8

Micellar electrokinetic capillary chromatography of benzodiazepine antiepileptics and their desmethyl metabolites in blood. Imazawa M, et al.
J Pharm Biomed Anal 1997 Jun;15(9–10):1503–8

Contrasting nutrient effects on the plasma levels of an amino acid–like antiepileptic agent from jejunal administration in dogs. Stevenson CM, et al. **J Pharm Sci** 1997 Aug; 86(8):953–7

Influence of lactation on plasma phenobarbital concentrations in rats. Moriyama M, et al. **Jpn J Pharmacol** 1997 Mar; 73(3):191–6

Effects of various antiepileptic drugs on plasma levels of lamotrigine, a novel antiepileptic, in rats. Yamashita S, et al. **Pharmacology** 1997 Jun;54(6):319–27

Phenytoin–oxacillin interactions in normal and uremic sera. Dasgupta A, et al. **Pharmacotherapy** 1997 Mar–Apr; 17(2):375–8

Analysis of clobazam and its active metabolite norclobazam in plasma and serum using HPLC/DAD. Akerman KK. **Scand J Clin Lab Invest** 1996 Nov;56(7):609–14

The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Bartoli A, et al.
Ther Drug Monit 1997 Jun;19(3):252–60

A rapid and specific assay for the determination of lamotrigine in human plasma by normal–phase HPLC. Bartoli A, et al. **Ther Drug Monit** 1997 Feb;19(1):100–7

Determination of felbamate concentration in pediatric samples by high–performance liquid chromatography. Behnke CE, et al. **Ther Drug Monit** 1997 Jun;19(3):301–6

Valproic acid–ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: lack of interaction in uremic serum caused by the presence of inhibitor. Dasgupta A, et al. **Ther Drug Monit** 1997 Jun;19(3):281–5

A rapid cost–effective high–performance liquid chromatographic (HPLC) assay of serum lamotrigine after liquid–liquid extraction and using HPLC conditions routinely used for analysis of barbiturates. Hart AP, et al. **Ther Drug Monit** 1997 Aug;19(4):431–5

Population pharmacokinetics of felbamate in children. Kelley MT, et al. **Ther Drug Monit** 1997 Feb;19(1):29–36

Optimized high–performance liquid chromatographic method for determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine, and carbamazepine epoxide. Lensmeyer GL, et al.
Ther Drug Monit 1997 Jun;19(3):292–300

Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. May TW, et al.
Ther Drug Monit 1996 Oct;18(5):523–31

Relationships between carbamazepine–diol, carbamazepine–epoxide, and carbamazepine total and free steady–state concentrations in epileptic patients: the influence of age, sex, and comedication. Svinarov DA, et al. **Ther Drug Monit** 1996 Dec;18(6):660–5

A limited sampling method for the estimation of vigabatrin maximum plasma concentration and area under the curve. Tammara V, et al. **Ther Drug Monit** 1997 Feb;19(1):79–82

Carbamazepine: detection of another metabolite in serum, 9 hydroxymethyl–10–carbamoyl acridan. Wad N, et al.
Ther Drug Monit 1997 Jun;19(3):314–7

Analysis of the antiepileptic phenyltriazine compound lamotrigine using gas chromatography with nitrogen phosphorus detection. Watelle M, et al.
Ther Drug Monit 1997 Aug;19(4):460–4

CHEMICAL SYNTHESIS

Dibenz[b,f]azepines, Part 7. Synthesis of new, potentially CNS active dibenz[b,f]azepine derivatives. Haász F, et al.
Arch Pharm (Weinheim) 1996 Dec;329(12):551–3

Synthesis of N–aryl–N'–heteroaryl–substituted urea and thiourea derivatives and evaluation of their anticonvulsant activity. Heinisch G, et al. **Arch Pharm (Weinheim)** 1997 Jul;330(7):207–10

Synthesis of GABA–valproic acid derivatives and evaluation of their anticonvulsant and antioxidant activity. Rekatas GV, et al. **Arch Pharm (Weinheim)** 1996 Aug–Sep; 329(8–9):393–8

3–Hydroxymethylphenytoin valproic acid ester, a new prodrug combining two anticonvulsant drugs. Scriba GK.
Arch Pharm (Weinheim) 1996 Dec;329(12):554–5

Syntheses, calcium channel antagonist and anticonvulsant activities of substituted 1,4–dihydro–3,5–pyridinedicarboxylates containing various 3–alkyl ester substituents. Yiu SH, et al.
Arch Pharm (Weinheim) 1997 Jan–Feb;330(1–2):35–43

Synthesis, anticonvulsant and analgesic activities of some 6–substituted imidazo(2,1–b)–1,3,4–thiadiazole–2–sulfonamides and their 5–bromo derivatives. Khazi IA, et al.
Arzneimittelforschung 1996 Oct;46(10):949–52

Synthesis and anticonvulsant activity of new 3–[(2–furyl)carbonyl]amino–4–thiazolidinone and 2–[(2–furyl)carbonyl]hydrazono–4–thiazoline derivatives. Capan G, et al. **Farmaco** 1996 Nov;51(11):729–32

4–substituted–3–phenylquinolin–2(1H)–ones: acidic and nonacidic glycine site N–methyl–D–aspartate antagonists with in vivo activity. Carling RW, et al. **J Med Chem** 1997 Feb 28;40(5):754–65

Aroyl(aminoacyl)pyrroles, a new class of anticonvulsant agents. Carson JR, et al. **J Med Chem** 1997 May 23; 40(11):1578–84

Synthesis of novel trans–4–(substituted–benzamido)–3,4–dihydro–2H–benzo[b]–pyran–3–ol derivatives as potential anticonvulsant agents with a distinctive binding profile. Chan WN, et al.
J Med Chem 1996 Nov 8;39(23):4537–9

1–Aryl–3,5–dihydro–4H–2,3–benzodiazepin–4–ones: novel AMPA receptor antagonists. Chimirri A, et al.
J Med Chem 1997 Apr 11;40(8):1258–69

(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen. Dimmock JR, et al.
J Med Chem 1996 Sep 27;39(20):3984–97

Design, synthesis, and pharmacological characterization of (+)–2–aminobicyclo[3.1.0]hexane–2,6–dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. Monn JA, et al.
J Med Chem 1997 Feb 14;40(4):528–37

Synthesis and anticonvulsant activities of 3,3–dialkyl– and 3–alkyl–3–benzyl–2–piperidinones (delta–valerolactams) and hexahydro–2H–azepin–2–ones (epsilon–caprolactams). Reddy PA, et al. **J Med Chem** 1997 Jan 3;40(1):44–9

Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine–pyridinium salt redox chemical delivery system. Yiu S, et al. **J Med Chem** 1996 Nov 8; 39(23):4576–82

A new class of pyrrolidin–2–ones: synthesis and pharmacological study. Saturnino C, et al.
J Pharm Belg 1997 Mar–Apr;52(2):57–60

Synthesis and anticonvulsant activity of some 1,2,3,3a–tetrahydropyrrolo[2,1–b]–benzothiazol–, –thiazol– or –oxazol–1–ones in rodents. Trapani G, et al.
J Pharm Pharmacol 1996 Aug;48(8):834–40

Synthesis, stability and anticonvulsant activity of two new GABA prodrugs. Palagiano F, et al. **Pharmazie** 1997 Apr; 52(4):272–6

Synthesis and anticonvulsant activity of some amino acid derivatives. Part 1: alanine derivatives. Paruszewski R, et al. **Pharmazie** 1996 Mar;51(3):145–8

Synthesis of aminothienopyrimidine and thienotriazolopyrimidine derivatives as potential anticonvulsant agents. Santagati M, et al. **Pharmazie** 1996 Jan;51(1):7–11

CHEMISTRY

Search for New Anticonvulsant Compounds, Part 2. Structure–activity relationship studies of new N–substituted amides of alpha–piperazine–gamma–hydroxybutyric acid as active anticonvulsants. Malawska B, et al.
Arch Pharm (Weinheim) 1997 Apr;330(4):91–9

The anticonvulsant activities of functionalized N–benzyl 2–acetamidoacetamides. The importance of the 2–acetamido substituent. Choi D, et al.
Bioorg Med Chem 1996 Dec;4(12):2105–14

Structure–activity relationships of 2–aryl–2,5–dihydropyridazino [4,3–b]indol–3(3H)–ones at the benzodiazepine receptor. Palluotto F, et al.
Bioorg Med Chem 1996 Dec;4(12):2091–104

Further branching of valproate–related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Bojic U, et al. **Chem Res Toxicol** 1996 Jul–Aug; 9(5):866–70

3 alpha–Hydroxy–3 beta–(phenylethynyl)–5 beta–pregnan–20–ones: synthesis and pharmacological activity of neuroactive steroids with high affinity for GABAA receptors. Upasani RB, et al. **J Med Chem** 1997 Jan 3;40(1):73–84

The polymorphic drug substances of the European pharmacopoeia. Part 9. Physicochemical properties and crystal structure of acetazolamide crystal forms. Griesser UJ, et al. **J Pharm Sci** 1997 Mar;86(3):352–8

In vitro and in vivo activity of 16,17–dehydro–epipregnanolones: 17,20–bond torsional energy analysis and D–ring conformation. Bolger MB, et al. **Pharm Res** 1996 Oct;13(10):1488–94

ECONOMICS

Clinical and economic impact of replacing divalproex sodium with valproic acid. Cranor CW, et al.
Am J Health Syst Pharm 1997 Aug 1;54(15):1716–22

Reactions to fosphenytoin editorial and review article [letter; comment] Hopefl A. **Am J Health Syst Pharm** 1997 Feb 15;54(4):445. Comment on: Am J Health Syst Pharm 1996 Nov 15;53(22):2702.

Reactions to fosphenytoin editorial and review article [letter; comment] Matheson C. **Am J Health Syst Pharm** 1997 Feb 15;54(4):441–2. Comment on: Am J Health Syst Pharm 1996 Nov 15;53(22):2702. Comment on: Am J Health Syst Pharm 1996 Nov 15;53(22):2707–12. Comment on: Am J Health Syst Pharm 1997 Jan 1;54(1):30–1.

Reactions to fosphenytoin editorial and review article [letter; comment] Orr J. **Am J Health Syst Pharm** 1997 Feb 15; 54(4):442, 445. Comment on: Am J Health Syst Pharm 1996 Nov 15;53(22):2707–12.

Reactions to fosphenytoin editorial and review article [letter] Paloucek FP. **Am J Health Syst Pharm** 1997 Feb 15; 54(4):449

Fosphenytoin: worth the cost? [letter] Miller MH.
Ann Emerg Med 1997 Jun;29(6):823

A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Marchetti A, et al.
Clin Ther 1996 Sep–Oct;18(5):953–66

A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy [see comments] Hughes D, et al. **Seizure** 1996 Jun; 5(2):89–95 (38 ref.). Comment in: Seizure 1996 Sep;5(3):247–8.

If comparisons can be odious, so can assumptions [letter; comment] Jackson D, et al. **Seizure** 1996 Sep;5(3):247–8. Comment on: Seizure 1996 Jun;5(2):89–95.

[Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy] Dodel RC, et al. **Med Klin** 1996 Jul 15;91(7):479–85 (64 ref.) (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

A new bioactive metabolite from Xanthoria steineri el–Fattah HA. **Boll Chim Farm** 1997 Mar;136(3):257–61

METABOLISM

Structure–activity relationships of 2–aryl–2,5–dihydropyridazino [4,3–b]indol–3(3H)–ones at the benzodiazepine receptor. Palluotto F, et al.
Bioorg Med Chem 1996 Dec;4(12):2091–104

Evidence for both in vivo and in vitro interaction between vigabatrin and alanine transaminase. Richens A, et al.
Br J Clin Pharmacol 1997 Feb;43(2):163–8

Comparison of the uptake of [3H]–gabapentin with the uptake

of L-[3H]-leucine into rat brain synaptosomes. Thurlow RJ, et al. **Br J Pharmacol** 1996 Jun;118(3):449-56

Comparison of the autoradiographic binding distribution of [3H]-gabapentin with excitatory amino acid receptor and amino acid uptake site distributions in rat brain. Thurlow RJ, et al. **Br J Pharmacol** 1996 Jun;118(3):457-65

Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate. Thompson CD, et al. **Chem Res Toxicol** 1996 Dec;9(8):1225-9

Effects of pregnancy on various pathways of human antiepileptic drug metabolism. Bernus I, et al. **Clin Neuropharmacol** 1997 Feb;20(1):13-21

Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Heyn H, et al. **Drug Metab Dispos** 1996 Sep;24(9):948-54

Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes. Torchin CD, et al. **Drug Metab Dispos** 1996 Sep; 24(9):1002-8

Kinetics of drug metabolism in rat liver slices. II. Comparison of clearance by liver slices and freshly isolated hepatocytes. Worboys PD, et al. **Drug Metab Dispos** 1996 Jun; 24(6):676-81

Metabolism of 6-chloro n-butyl phthalide in rat. Peng SH, et al. **Eur J Drug Metab Pharmacokinet** 1996 Oct-Dec; 21(4):339-44

The novel anticonvulsant SB 204269 binds to a stereospecific site in the mouse brain. Herdon H, et al. **Eur J Pharmacol** 1996 Oct 31;314(3):R7-8

Comparison of binding parameters of sigma 1 and sigma 2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes. Nguyen VH, et al. **Eur J Pharmacol** 1996 Sep 12;311(2-3):233-40

Metabolites and DNA-binding of carbamazepine and oxcarbazepine in vitro by rat liver microsomes. Castrén K, et al. **Hum Exp Toxicol** 1996 Jul;15(7):577-82

On-column gas chromatographic-mass spectrometric assay for metabolic profiling of valproate in brain tissue and serum. Darius J. **J Chromatogr B Biomed Appl** 1996 Jun 28;682(1):67-72

The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. Kitamura S, et al. **J Pharm Pharmacol** 1997 Mar;49(3):253-6

Comparison of two binding equations for prediction of the concentration of unbound valproic acid in the serum of adult epileptic polytherapy patients. Kodama Y, et al. **J Pharm Pharmacol** 1996 Oct;48(10):1068-72

Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Goldstein JA, et al. **Methods Enzymol** 1996;272:210-8

Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam. Otani K, et al. **Neuropsychopharmacology** 1997 Jan;16(1):8-14

Alcohol intake decreases brain Zonisamide concentration in inbred EL mice. Nagatomo I, et al. **Neuroreport** 1997 Jan 20;8(2):391-4

[3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Bouchard P, et al. **Neuroscience** 1997 Jan;76(2):467-77

Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors. Dasgupta A, et al. **Ther Drug Monit** 1996 Dec;18(6):654-9

Heat treatment of human serum to inactivate HIV does not alter protein binding of selected drugs. Mosley AK, et al. **Ther Drug Monit** 1997 Aug;19(4):477-9

[Studies on metabolism of 6-chloro butyl phthalide by rat liver microsomes] Peng SH, et al. **Yao Hsueh Hsueh Pao** 1996;31(6):466-71 (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

Antiepileptic drug pharmacokinetics in patients with epilepsy using a new microdialysis probe: preliminary observations. Patsalos PN, et al. **Acta Neurochir Suppl (Wien)** 1996; 67:59-62

Lidocaine pharmacokinetics and toxicity in newborn pigs. Satas S, et al. **Anesth Analg** 1997 Aug;85(2):306-12

Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Silpakit O, et al. **Ann Pharmacother** 1997 May;31(5):548-52

Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Hashimoto Y, et al. **Biol Pharm Bull** 1996 Aug;19(8):1103-5

Reduction in blood free carnitine levels in association with changes in sodium valproate (VPA) disposition in epileptic patients treated with VPA and other anti-epileptic drugs. Hiraoka A, et al. **Biol Pharm Bull** 1997 Jan;20(1):91-3

Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Odani A, et al. **Biol Pharm Bull** 1996 Mar;19(3):444-8

Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid. Bialer M, et al. **Biopharm Drug Dispos** 1996 Oct;17(7):565-75

A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). Mahmood I, et al. **Biopharm Drug Dispos** 1997 Mar;18(2):117-26

Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers. Roberts D, et al. **Biopharm Drug Dispos** 1996 Mar;17(2):175-82

Steady state pharmacokinetics of carbamazepine-phenobarbital interaction in patients with epilepsy. Sennoune S, et al. **Biopharm Drug Dispos** 1996 Mar;17(2):155-64

Dose-dependent distribution volumes of total and unbound valproate in guinea-pigs: consequence of non-linear plasma protein binding. Yu HY, et al. **Biopharm Drug Dispos** 1996 Apr;17(3):237-47

Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. Basci NE, et al. **Br J Clin Pharmacol** 1996 Dec;42(6):771-3

The mechanism of the carbamazepine-valproate interaction in humans. Bernus I, et al. **Br J Clin Pharmacol** 1997 Jul; 44(1):21-7

Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. Davis JD, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):246-8

Single-dose pharmacokinetics of felbamate in patients with renal dysfunction. Glue P, et al. **Br J Clin Pharmacol** 1997 Jul;44(1):91-3

Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Hussein Z, et al. **Br J Clin Pharmacol** 1997 May;43(5):457-65

Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. Jacqz-Aigrain E, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):183-5

Single and multiple dose pharmacokinetics of felbamate in the elderly. Richens A, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):129-34

The effect of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate in healthy volunteers. al-Shareef A, et al. **Br J Clin Pharmacol** 1997 Jan;43(1):109-11

A computer model for the measurement of compliance using a dual tracer technique. Shine D, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):283-90

Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. van Steveninck AL, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):565-73

Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. Vauzelle-Kervroëdan F, et al. **Br J Clin Pharmacol** 1996 Dec;42(6):779-81

Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Wootton R, et al. **Br J Clin Pharmacol** 1997 Jan;43(1):23-7

Relationships between convulsive seizures and serum and brain concentrations of phenobarbital and zonisamide in mutant inbred strain EL mouse. Nagatomo I, et al. **Brain Res** 1996 Aug 26;731(1-2):190-8

Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Thompson CD, et al. **Chem Res Toxicol** 1997 Apr; 10(4):457-62

Carbamazepine levels in the hair of patients under long-term treatment: a preliminary study. Tsatsakis AM, et al. **Clin Chim Acta** 1997 Jul 25;263(2):187-95

Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers. Watanabe M, et al. **Clin Neuropharmacol** 1997 Aug;20(4):346-51

Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Elwes RD, et al. **Clin Pharmacokinet** 1996 Jun;30(6):403-15 (100 ref.)

The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Perucca E, et al. **Clin Pharmacokinet** 1996 Jul;31(1):29-46 (120 ref.)

Pharmacokinetic interactions of the new antiepileptic drugs. Rambeck B, et al. **Clin Pharmacokinet** 1996 Oct; 31(4):309-24 (121 ref.)

Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Riva R, et al. **Clin Pharmacokinet** 1996 Dec;31(6):470-93 (260 ref.)

Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Spina E, et al. **Clin Pharmacokinet** 1996 Sep;31(3):198-214 (214 ref.)

Bidirectional interaction of valproate and lamotrigine in healthy subjects. Anderson GD, et al. **Clin Pharmacol Ther** 1996 Aug;60(2):145-56

Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Barel S, et al. **Clin Pharmacol Ther** 1997 Apr;61(4):442-9

Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries. Russo H, et al. **Clin Pharmacol Ther** 1997 Jul;62(1):15-20

Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status. Sohn DR, et al. **Clin Pharmacol Ther** 1997 May;61(5):574-82

Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia. Zhou LX, et al. **Clin Pharmacol Ther** 1996 Aug;60(2):191-8

Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. Blotnik S, et al. **Drug Metab Dispos** 1996 May;24(5):560-4

Pharmacokinetics and metabolism of the novel anticonvulsant agent N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide (D2624) in rats and humans. Martin SW, et al. **Drug Metab Dispos** 1997 Jan;25(1):40-6

Disposition and metabolism of 2,6-dimethylbenzamide N-(5-methyl-3-isoxazolyl) (D2916) in male and female rats. Maurizis JC, et al. **Drug Metab Dispos** 1997 Jan; 25(1):33-9

Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations. Bernus I, et al. **Drugs Aging** 1997 Apr;10(4):278-89 (71 ref.)

Steady-state anticonvulsant drug levels in epileptic patients. Kokwaro GO, et al. **East Afr Med J** 1996 Oct;73(10):679-82

A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Bartoli A, et al. **Epilepsia** 1997 Jun;38(6):702-7

Preliminary observations on topiramate in pediatric epilepsies. Glauser TA. **Epilepsia** 1997;38 Suppl 1:S37-41

Pharmacokinetics of new antiepileptic drugs. Gram L. **Epilepsia** 1996;37 Suppl 6:S12-6 (56 ref.)

Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Johannessen SI. **Epilepsia** 1997;38 Suppl 1:S18-23 (43 ref.)

Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Lau AH, et al. **Epilepsia** 1997 Apr;38(4):445-51

Mutual interaction between remacemide hydrochloride and carbamazepine: two drugs with active metabolites. Leach JP, et al. **Epilepsia** 1996 Nov;37(11):1100-6

Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Pienimäki P, et al. **Epilepsia** 1997 Mar; 38(3):309-16

Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Rosenfeld WE, et al. **Epilepsia** 1997 Mar;38(3):324-33

Colonic absorption of antiepileptic agents. Stevenson CM, et al. **Epilepsia** 1997 Jan;38(1):63-7

Management of epilepsy in the elderly. Willmore LJ. **Epilepsia** 1996;37 Suppl 6:S23-33 (115 ref.)

Dose-dependent metabolism of carbamazepine in humans. Bernus I, et al. **Epilepsy Res** 1996 Jul;24(3):163-72

Lamotrigine pharmacokinetics in patients receiving felbamate. Gidal BE, et al. **Epilepsy Res** 1997 Apr;27(1):1-5

Effect of a high-protein meal on gabapentin pharmacokinetics. Gidal BE, et al. **Epilepsy Res** 1996 Feb; 23(1):71-6

Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. So EL, et al. **Epilepsy Res** 1995 Nov;22(3):221-6

Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Rambeck B, et al. **Eur J Clin Pharmacol** 1997;51(6):481-4

Pharmacokinetics of carbamazepine derived from a new tablet formulation. Popović J, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct-Dec; 20(4):297-300

Regional distribution of the anticonvulsant and behavioural effects of muscimol injected into the substantia nigra of rats. Shehab S, et al. **Eur J Neurosci** 1996 Apr;8(4):749-757

Hair analysis as a potential index of therapeutic compliance in the treatment of epilepsy. Williams J, et al. **Forensic Sci Int** 1997 Jan 17;84(1-3):113-22

Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Bliesath H, et al. **Int J Clin Pharmacol Ther** 1996 May;34(1 Suppl):S76-80

Pantoprazole does not interact with nifedipine in man under steady-state conditions. Bliesath H, et al. **Int J Clin Pharmacol Ther** 1996 May;34(1 Suppl):S81-5

Relative bioavailability of different valproic acid formulations. Franke G, et al. **Int J Clin Pharmacol Ther** 1995 Dec;33(12):653-7

Effect of cholestyramine resin on single dose valproate pharmacokinetics. Malloy MJ, et al. **Int J Clin Pharmacol Ther** 1996 May;34(5):208-11

No influence of pantoprazole on the pharmacokinetics of phenytoin. Middle MV, et al. **Int J Clin Pharmacol Ther** 1996 May;34(1 Suppl):S72-5

Clearance of phenytoin and valproic acid is affected by a small body weight reduction in an epileptic obese patient: a case study. Kuranari M, et al. **J Clin Pharm Ther** 1996 Apr;21(2):83-7

Effect of felbamate on the pharmacokinetics of lamotrigine. Colucci R, et al. **J Clin Pharmacol** 1996 Jul;36(7):634-8

Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. Doose DR, et al. **J Clin Pharmacol** 1996 Oct;36(10):884-91

Evaluation of pharmacokinetic interaction between bromfenac and phenytoin in healthy males. Gumbhir-Shah K, et al. **J Clin Pharmacol** 1997 Feb;37(2):160-8

Effect of acute phase response on phenytoin metabolism in neurotrauma patients. McKindley DS, et al. **J Clin Pharmacol** 1997 Feb;37(2):129-39

The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. Melia AT, et al. **J Clin Pharmacol** 1996 Jul;36(7):654-8

Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. Yukawa E, et al. **J Clin Pharmacol** 1996 Aug;36(8):752–9

The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects. Marino MR, et al. **J Clin Psychopharmacol** 1997 Feb; 17(1):27–33

Characterization of thiol-conjugated metabolites of 2-propylpent-4-enoic acid (4-ene VPA), a toxic metabolite of valproic acid, by electrospray tandem mass spectrometry. Tang W, et al. **J Mass Spectrom** 1996 Aug; 31(8):926–36

Single oral loading dose of phenytoin: a pharmacokinetics study. Ratanakorn D, et al. **J Neurol Sci** 1997 Mar 20; 147(1):89–92

Pharmacokinetic study of zonisamide in patients undergoing brain surgery. Ieiri I, et al. **J Pharm Pharmacol** 1996 Dec; 48(12):1270–5

A feasibility study of the multiple-peak approach for pharmacokinetic screening: population-based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data. Yukawa E. **J Pharm Pharmacol** 1995 Dec;47(12A):1048–52

Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. Brewster ME, et al. **J Pharm Sci** 1997 Mar;86(3):335–9

Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. Mahmood I, et al. **J Pharm Sci** 1996 Apr;85(4):411–4

Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation. Ludden LK, et al. **J Pharmacol Exp Ther** 1997 Jul; 282(1):391–6

Time course of alpha-fluorinated valproic acid in mouse brain and serum and its effect on synaptosomal gamma-aminobutyric acid levels in comparison to valproic acid. Tang W, et al. **J Pharmacol Exp Ther** 1997 Sep; 282(3):1163–72

Pharmacokinetics of oxcarbazepine in the dog. Schicht S, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):27–31

A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Gustavson LE, et al. **Neurology** 1997 Apr;48(4):1032–7

Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide. Bialer M, et al. **Pharm Res** 1996 Feb;13(2):284–9

The disposition of valproyl glycinamide and valproyl glycine in rats. Blotnik S, et al. **Pharm Res** 1997 Jul;14(7):873–8

Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives. Levi M, et al. **Pharm Res** 1997 Feb;14(2):213–7

Characterization of AUCs from sparsely sampled populations in toxicology studies. Pai SM, et al. **Pharm Res** 1996 Sep; 13(9):1283–90

Bioavailability of phenytoin and anticonvulsant activity after oral administration of phenytoin-bis-hydroxyisobutyrate to rats. Scriba GK, et al. **Pharm Res** 1997 Feb;14(2):251–3

Fosphenytoin: a novel phenytoin prodrug. Boucher BA. **Pharmacotherapy** 1996 Sep-Oct;16(5):777–91 (60 ref.)

The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Boucher BA, et al. **Pharmacotherapy** 1996 Jul-Aug;16(4):638–45

Lack of pharmacokinetic interaction between dextromethorphan, coumarin and mephenytoin in man after simultaneous administration. Endres HG, et al. **Pharmazie** 1996 Jan;51(1):46–51

Pharmacokinetics of slow-release preparations of sodium valproate. Yamatogi Y, et al. **Psychiatry Clin Neurosci** 1995 Dec;49(5-6):309–10

Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients. Leach JP, et al. **Seizure** 1997 Jun;6(3):179–84

The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Bartoli A, et al. **Ther Drug Monit** 1997 Jun;19(3):252–60

A limited sampling approach in bioequivalence studies. Mahmood I, et al. **Ther Drug Monit** 1997 Aug;19(4):413–9

Formation of 2-sulphamoylacetylphenol from zonisamide under aerobic conditions in rat liver microsomes. Nakasa H, et al. **Xenobiotica** 1996 May;26(5):495–501

[Topiramate: a broad-spectrum antiepileptic drug? Sixth meeting of the European Neurological Society. Den Haag, 8 June 1996] **Fortschr Neurol Psychiatr** 1996 Sep;64(9 Suppl):1–8 **(Ger)**

[Pharmacokinetic variations in anticonvulsants in Mexican epileptic women during different stages of the postpartum period] Belmont-Gomez A, et al. **Ginecol Obstet Mex** 1997 May;65:163–6 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Effects of Lamotrigine on brain nitrite and cGMP levels during focal cerebral ischemia in rats. Balkan S, et al. **Acta Neurol Scand** 1997 Mar;95(3):140–6

EEG changes induced by vigabatrin monotherapy in focal epilepsy. Marciani MG, et al. **Acta Neurol Scand** 1997 Feb; 95(2):115–20

Auditory event related potentials in patients with epilepsy on sodium valproate monotherapy. Panagopoulos GR, et al. **Acta Neurol Scand** 1997 Jul;96(1):62–4

A comparison of the effects of two antispastic drugs, tizanidine and baclofen, on synaptic transmission from muscle spindle afferents to spinal interneurones in cats. Skoog B. **Acta Physiol Scand** 1996 Jan;156(1):81–90

Selective depletion of mitochondrial glutathione content by pivalic acid and valproic acid in rat liver: possibility of a common mechanism. Zanelli U, et al. **Adv Exp Med Biol** 1996;387:107–11

Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS. Akula SK, et al. **Am J Med Sci** 1997 Apr;313(4):244–6

Acute in vitro neuromuscular effects of carbamazepine and carbamazepine-10,11-epoxide. Nguyen A, et al. **Anesth Analg** 1997 Apr;84(4):886–90

Combined valproate or carbamazepine and electroconvulsive therapy. Zarate CA Jr, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):19–25

Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study [see comments] Ziemann U, et al. **Ann Neurol** 1996 Sep; 40(3):367–78. Comment in: Ann Neurol 1996 Sep;40(3):344–5.

Assay interaction between oxaprozin and phenytoin [letter] Patel T, et al. **Ann Pharmacother** 1997 Feb;31(2):254

Synthesis of N-aryl-N'-heteroaryl-substituted urea and thiourea derivatives and evaluation of their anticonvulsant activity. Heinisch G, et al. **Arch Pharm (Weinheim)** 1997 Jul;330(7):207–10

Search for New Anticonvulsant Compounds, Part 2. Structure-activity relationship studies of new N-substituted amides of alpha-piperazine-gamma-hydroxybutyric acid as active anticonvulsants. Malawska B, et al. **Arch Pharm (Weinheim)** 1997 Apr;330(4):91–9

Syntheses, calcium channel antagonist and anticonvulsant activities of substituted 1,4-dihydro-3,5-pyridinedicarboxylates containing various 3-alkyl ester substituents. Yiu SH, et al. **Arch Pharm (Weinheim)** 1997 Jan-Feb;330(1-2):35–43

In vitro effects of the novel anti-epileptic agent vigabatrin on alanine aminotransferase and aspartate aminotransferase activities in rat serum. Okumura H, et al. **Arzneimittelforschung** 1996 May;46(5):459–62

Inhibition of carnitine biosynthesis by valproic acid in rats--the biochemical mechanism of inhibition. Farkas V, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1429–33

Actions of the anticonvulsant agent 2-amino-4-phosphonobutyrate on the release of [3H]D-aspartate from rat forebrain slices. Sundaralingam J, et al. **Biochem Soc Trans** 1996 May;24(2):294S

Suppression of nocturnal plasma melatonin levels by evening administration of sodium valproate in healthy humans. Monteleone P, et al. **Biol Psychiatry** 1997 Feb 1; 41(3):336–41

Anticonvulsant and neurotoxicological properties of 4-amino-N-(2-ethylphenyl)benzamide, a potent ameltolide analogue. Diouf O, et al. **Biomed Pharmacother** 1997; 51(3):131–6

Triazolines 26: 1-Aryl-5-amido-1,2,3-triazolines, a new group of triazoline anticonvulsants. Effect of 5-substitution on anticonvulsant activity. Kadaba PK. **Biomed Pharmacother** 1996;50(3-4):163–9

The anticonvulsant activities of functionalized N-benzyl 2-acetamidoacetamides. The importance of the 2-acetamido substituent. Choi D, et al. **Bioorg Med Chem** 1996 Dec;4(12):2105–14

Structure-activity relationships of 2-aryl-2,5-dihydropyridazino [4,3-b]indol-3(3H)-ones at the benzodiazepine receptor. Palluotto F, et al. **Bioorg Med Chem** 1996 Dec;4(12):2091–104

Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid. Bialer M, et al. **Biopharm Drug Dispos** 1996 Oct;17(7):565–75

Antiepileptic treatment and oculomotor neurons. Mameli O, et al. **Boll Soc Ital Biol Sper** 1995 Sep-Oct;71(9-10):235–40

Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs. Loan PB, et al. **Br J Anaesth** 1997 Jan;78(1):90–1

In vitro neuromuscular effects of valproic acid. Nguyen A, et al. **Br J Anaesth** 1997 Feb;78(2):197–200

Chronic carbamazepine therapy does not influence mivacurium-induced neuromuscular block. Spacek A, et al. **Br J Anaesth** 1996 Oct;77(4):500–2

The mechanism of the carbamazepine-valproate interaction in humans. Bernus I, et al. **Br J Clin Pharmacol** 1997 Jul; 44(1):21–7

Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. Giaccone M, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):575–9

Effect of lamotrigine on EEG paroxysmal abnormalities and background activity: a computerized analysis. Marciani MG, et al. **Br J Clin Pharmacol** 1996 Nov;42(5):621–7

Spermine modulation of specific [3H]-gabapentin binding to the detergent-solubilized porcine cerebral cortex alpha 2 delta calcium channel subunit. Dissanayake VU, et al. **Br J Pharmacol** 1997 Mar;120(5):833–40

Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones. Kuo CC, et al. **Br J Pharmacol** 1997 Jul;121(6):1231–8

The effects of anticonvulsants on 4-aminopyridine-induced bursting: in vitro studies on rat peripheral nerve and dorsal roots. Lees G. **Br J Pharmacol** 1996 Feb;117(3):573–579

Inhibition of delayed rectifier K+ channels by phenytoin in rat neuroblastoma cells. Nobile M, et al. **Br J Pharmacol** 1997 Feb;120(4):647–52

Interactions between loreclezole, chlormethiazole and pentobarbitone at GABA(A) receptors: functional and binding studies. Zhong Y, et al. **Br J Pharmacol** 1997 Aug; 121(7):1392–6

Lack of development of tolerance to anticonvulsant effects of two excitatory amino acid antagonists, CGP [corrected] 37849 and CGP 39551 in genetically epilepsy-prone rats [published erratum appears in Brain Res 1997 Mar 7;750(1-2):329] De Sarro G, et al. **Brain Res** 1996 Sep 23; 734(1-2):91–7

Excitoprotective effect of felbamate in cultured cortical neurons. Kanthasamy AG, et al. **Brain Res** 1995 Dec 24; 705(1-2):97–104

Non-NMDA but not NMDA blockade at deep prepiriform cortex protects against hippocampal cell death in status epilepticus. Kawaguchi K, et al. **Brain Res** 1997 Apr 4; 753(1):152–6

The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Löscher W, et al. **Brain Res** 1996 Oct 7;735(2):208–16

Enhancement of rat trigeminal ganglion neuron responses to piperine in a low-pH environment and block by capsazepine. Martenson ME, et al. **Brain Res** 1997 Jun 27; 761(1):71–6

The anticonvulsant action of fluoxetine in substantia nigra is dependent upon endogenous serotonin. Pasini A, et al. **Brain Res** 1996 Jun 10;724(1):84–8

Chronic and intra-amygdala administrations of the ACTH(4-9) analog ORG 2766 modulate behavioral changes after manipulation of NMDA-receptor activity. van Rijzingen IM, et al. **Brain Res** 1996 Apr 22; 717(1-2):200–3

Anticonvulsant activity of new and potent inhibitors of nitric oxide synthase. Dzoljic E, et al. **Brain Res Bull** 1997; 43(2):191–5

The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-EPSP, and GABA-IPSP in the rat hippocampus. Ko GY, et al. **Brain Res Bull** 1997;42(4):297–302

Permanent upregulation of hippocampal mineralocorticoid receptors after neonatal administration of ACTH-(4-9) analog ORG 2766 in rats. Nyakas C, et al. **Brain Res Dev Brain Res** 1997 Apr 18;99(2):142–7

Lamotrigine--an update. Brodie MJ. **Can J Neurol Sci** 1996 Nov;23(4):S6–9

Gabapentin. Bruni J. **Can J Neurol Sci** 1996 Nov;23(4):S10–2

Vigabatrin. Guberman A. **Can J Neurol Sci** 1996 Nov; 23(4):S13–7

Inhibition of mitochondrial calcium efflux by clonazepam in intact single rat cardiomyocytes and effects on NADH production. Griffiths EJ, et al. **Cell Calcium** 1997 Apr; 21(4):321–9

Quantitative pharmaco-EEG of sustained release valproate in epileptics. Wu X, et al. **Clin Electroencephalogr** 1997 Apr;28(2):117–20

Fosphenytoin (Cerebyx). Browne TR. **Clin Neuropharmacol** 1997 Feb;20(1):1–12 (51 ref.)

Felbamate pharmacology and use in epilepsy. Burdette DE, et al. **Clin Neuropharmacol** 1994 Oct;17(5):389–402 (47 ref.)

Kappa opioids: therapeutic considerations in epilepsy and CNS injury. Tortella FC, et al. **Clin Neuropharmacol** 1994 Oct;17(5):403–16 (77 ref.)

Pharmacokinetic interactions of the new antiepileptic drugs. Rambeck B, et al. **Clin Pharmacokinet** 1996 Oct; 31(4):309–24 (121 ref.)

In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam. Nims RW, et al. **Drug Metab Dispos** 1997 Jun;25(6):750–6

Comparative effects of carbamazepine and carbamazepine-10,11-epoxide on hepatic cytochromes P450 in the rat. Panesar SK, et al. **Drug Metab Dispos** 1996 Jun;24(6):619–27

Role of magnesium sulfate in seizure prevention in patients with eclampsia and pre-eclampsia. Anthony J, et al. **Drug Saf** 1996 Sep;15(3):188–99 (115 ref.)

Effects of vigabatrin on motor potentials evoked with magnetic stimulation. Mavroudakis N, et al. **Electroencephalogr Clin Neurophysiol** 1997 Apr; 105(2):124–7

Effects of valproate, phenytoin, and MK-801 in a novel model of epileptogenesis. Applegate CD, et al. **Epilepsia** 1997 Jun;38(6):631–6

Anticonvulsant activity of pyrid-3-yl-sulfonyl ureas and thioureas. Masereel B, et al. **Epilepsia** 1997 Mar;38(3):334–7

Update on the mechanism of action of antiepileptic drugs. Meldrum BS. **Epilepsia** 1996;37 Suppl 6:S4–11 (66 ref.)

Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Rosenfeld WE, et al. **Epilepsia** 1997 Mar;38(3):317–23

Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. White HS.

Epilepsia 1997;38 Suppl 1:S9-17 (80 ref.)

Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Zona C, et al. **Epilepsia** 1997 May;38(5):522-5

Effects of various valproic acid derivatives on low-calcium spontaneous epileptiform activity in hippocampal slices. Armand V, et al. **Epilepsy Res** 1995 Nov;22(3):185-92

Decreased density of lymphocyte benzodiazepine receptors in drug-resistant epileptic patients. Ferrarese C, et al. **Epilepsy Res** 1997 Jun;27(3):181-5

Felbamate and meprobamate: a comparison of their anticonvulsant properties. Frey HH, et al. **Epilepsy Res** 1997 Jun;27(3):151-64

Blockade of spreading depression in chronic epileptic rats: reversion by diazepam. Guedes RC, et al. **Epilepsy Res** 1997 Apr;27(1):33-40

The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Kapetanovic IM, et al. **Epilepsy Res** 1995 Nov;22(3):167-73

Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Kehne JH, et al. **Epilepsy Res** 1997 Apr; 27(1):41-54

Factors determining proconvulsant and anticonvulsant effects of inhibitors of nitric oxide synthase in rodents. Kirkby RD, et al. **Epilepsy Res** 1996 Jun;24(2):91-100

Neurochemical actions of gabapentin in mouse brain. Leach JP, et al. **Epilepsy Res** 1997 Jun;27(3):175-80

The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. VI. Seasonal influences on maximal electroshock and pentylenetetrazol seizure thresholds. Löscher W, et al. **Epilepsy Res** 1996 Sep;25(1):3-10

Effects of zonisamide on dopaminergic system. Okada M, et al. **Epilepsy Res** 1995 Nov;22(3):193-205

Propofol inhibits epileptiform activity in rat hippocampal slices. Rasmussen PA, et al. **Epilepsy Res** 1996 Nov; 25(3):169-75

D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Rostock A, et al. **Epilepsy Res** 1996 Apr;23(3):211-23

Effects of single and repeated administration of sulthiame on amygdaloid kindled seizures in rats. Song HK, et al. **Epilepsy Res** 1997 May;27(2):81-7

Remacemide HCl and its metabolite, FPL 12495AA, limit action potential firing frequency and block NMDA responses of mouse spinal cord neurons in cell culture. Wamil AW, et al. **Epilepsy Res** 1996 Feb;23(1):1-14

Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Wauquier A, et al. **Epilepsy Res** 1996 Jun;24(2):73-7

Effects of felbamate, gabapentin and lamotrigine on seizure parameters and excitability in the rat hippocampus. Xiong ZQ, et al. **Epilepsy Res** 1997 Jun;27(3):187-94

Substantia nigra GABA receptors can mediate anticonvulsant or proconvulsant effects. Moshé SL, et al. **Epilepsy Res Suppl** 1996;12:247-56

Selective liver enzyme induction by carbamazepine and phenytoin in Chinese epileptics. Tomlinson B, et al. **Eur J Clin Pharmacol** 1996;50(5):411-5

Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Tran A, et al. **Eur J Clin Pharmacol** 1996;50(6):497-500

Regional distribution of the anticonvulsant and behavioural effects of muscimol injected into the substantia nigra of rats. Shehab S, et al. **Eur J Neurosci** 1996 Apr;8(4):749-757

Serum lipids in epileptic children treated with carbamazepine and valproate. Sözüer DT, et al. **Eur J Pediatr** 1997 Jul; 156(7):565-7

The protective effect of 2-chloroadenosine against the development of amygdala kindling and on amygdala-kindled seizures. Abdul-Ghani AS, et al. **Eur J Pharmacol** 1997 May 12;326(1):7-14

The anticonvulsant gabapentin decreases firing rates of substantia nigra pars reticulata neurons. Bloms-Funke P, et al. **Eur J Pharmacol** 1996 Dec 5;316(2-3):211-8

N6-2-(4-aminophenyl)ethyl-adenosine enhances the anticonvulsive activity of antiepileptic drugs. Borowicz KK, et al. **Eur J Pharmacol** 1997 May 30;327(2-3):125-33

Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice. Borowicz KK, et al. **Eur J Pharmacol** 1997 Mar 26; 323(1):45-51

Time course of discriminative stimulus effects of bretazenil and chlordiazepoxide in rats. Bronson M, et al. **Eur J Pharmacol** 1996 Jun 3;305(1-3):7-12

Repeated treatment with adenosine A1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene. De Sarro G, et al. **Eur J Pharmacol** 1996 Dec 19;317(2-3):239-45

Losigamone decreases spontaneous synaptic activity in cultured hippocampal neurons. Draguhn A, et al. **Eur J Pharmacol** 1997 May 1;325(2-3):245-51

Anticonvulsant effects by combined treatment with a glycineB receptor antagonist and a polyamine site antagonist in amygdala-kindled rats. Ebert U, et al. **Eur J Pharmacol** 1997 Mar 19;322(2-3):179-84

Effects of 7-nitroindazole, NG-nitro-L-arginine, and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions. Eblen F, et al. **Eur J Pharmacol** 1996 Mar 28;299(1-3):9-16

Ca2+ channel blockade and the antielectroshock activity of NMDA receptor antagonists, CGP 40116 and CGP 43487, in mice. Gasior M, et al. **Eur J Pharmacol** 1996 Sep 19;312(1):27-33

Anticonvulsive action of (+/-)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Gleitz J, et al. **Eur J Pharmacol** 1996 Nov 7;315(1):89-97

Evidence that the NH2-terminus of substance P modulates N-methyl-D-aspartate-induced activity by an action involving sigma receptors. Hornfeldt CS, et al. **Eur J Pharmacol** 1996 Jun 13;306(1-3):15-22

The effect of the desglycinyl metabolite of remacemide on cortical wedges prepared from DBA/2 mice. Hu RQ, et al. **Eur J Pharmacol** 1995 Dec 20;287(3):251-6

Pharmacology of ACEA-1416: a potent systemically active NMDA receptor glycine site antagonist. Ilyin VI, et al. **Eur J Pharmacol** 1996 Aug 29;310(2-3):107-14

Anti- and proconvulsive actions of levcromakalim, an opener of ATP-sensitive K+ channel, in the model of hippocampus-generating partial seizures in rats. Katsumori H, et al. **Eur J Pharmacol** 1996 Sep 5;311(1):37-44

Motor effects of lamotrigine in naive and dopamine-depleted mice. Kaur S, et al. **Eur J Pharmacol** 1996 May 23; 304(1-3):1-6

Valproate and its major metabolite E-2-en-valproate induce different effects on behaviour and brain monoamine metabolism in rats. Löscher W, et al. **Eur J Pharmacol** 1996 Mar 28;299(1-3):61-7

Characterization of YM90K, a selective and potent antagonist of AMPA receptors, in rat cortical mRNA-injected Xenopus oocytes. Okada M, et al. **Eur J Pharmacol** 1996 Aug 15;309(3):299-306

Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. Okada M, et al. **Eur J Pharmacol** 1997 Feb 26;321(2):181-8

Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Sills GJ, et al. **Eur J Pharmacol** 1997 Apr 23;325(1):35-40

Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Stefani A, et al. **Eur J Pharmacol** 1996 Jun 20;307(1):113-6

D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Tober C, et al. **Eur J Pharmacol** 1996 May 15;303(3):163-9

Anticonvulsive activity of a new GABA mimetic drug. Capasso A, et al. **Eur Neuropsychopharmacol** 1997 Feb; 7(1):57-63

Glutamate receptor antagonists reduce spontaneous epileptiform activity in cortical wedges prepared from DBA/2 mice. Hu RQ, et al. **Exp Brain Res** 1997 Jun; 115(2):311-8

Anticonvulsant action of both NMDA and non-NMDA receptor antagonists against seizures induced by homocysteine in immature rats. Folbergrová J. **Exp Neurol** 1997 Jun;145(2 Pt 1):442-50

Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Stefani A, et al. **Exp Neurol** 1997 Sep;147(1):115-22

Azirino[1, 2-d][1, 4]benzodiazepine derivatives and related 1,4-benzodiazepines as anticonvulsant agents in DBA/2 mice. De Sarro G, et al. **Gen Pharmacol** 1996 Oct; 27(7):1155-62

1,4-Benzodiazepine derivatives as anticonvulsant agents in DBA/2 mice. De Sarro G, et al. **Gen Pharmacol** 1996 Sep; 27(6):935-41

Neurochemical actions of vigabatrin and tiagabine alone and in combination in mouse cortex. Leach JP, et al. **Gen Pharmacol** 1997 May;28(5):715-9

Picolinic acid and indole-2-carboxylic acid: two types of glycinergic compounds modulate motor function differentially. Tonohiro T, et al. **Gen Pharmacol** 1997 Apr; 28(4):555-60

Basis of the antiseizure action of phenytoin. Tunnicliff G. **Gen Pharmacol** 1996 Oct;27(7):1091-7 (105 ref.)

Co-administration of the neurotrophic ACTH(4-9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin. de Groot JC, et al. **Hear Res** 1997 Apr; 106(1-2):9-19

Phenobarbital promotes multistage pulmonary carcinogenesis in MNU-inoculated L-W rats. Pollard M, et al. **In Vivo** 1997 Jan-Feb;11(1):55-60

Effect of antiepileptic drugs and calcium channel blocker on hyperthermic seizures in rats: animal model for hot water epilepsy. Ullal GR, et al. **Indian J Physiol Pharmacol** 1996 Oct;40(4):303-8

A combined cobalt and C-14 2-deoxyglucose approach to antiepileptic drug assessment. Krenz NR, et al. **Int J Neurosci** 1996 Jul;86(1-2):55-66

Immunodepression induced by carbamazepine administration is mediated by CD 8+ spleen T cells. Andrade-Mena CE. **Int J Tissue React** 1996;18(2-3):81-5

Osteogenic actions of phenytoin in human bone cells are mediated in part by TGF-beta 1. Nakade O, et al. **J Bone Miner Res** 1996 Dec;11(12):1880-8

Effect of felbamate on the pharmacokinetics of lamotrigine. Colucci R, et al. **J Clin Pharmacol** 1996 Jul;36(7):634-8

Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. Samara EE, et al. **J Clin Pharmacol** 1997 May;37(5):442-50

Antiepileptic drug therapy: clinical laboratory significance. Naradzay JF, et al. **J Emerg Med** 1996 Jul-Aug; 14(4):473-81 (78 ref.)

Extracts from rhizomes of Cyperus articulatus (Cyperaceae) displace [3H]CGP39653 and [3H]glycine binding from cortical membranes and selectively inhibit NMDA receptor-mediated neurotransmission. Bum EN, et al. **J Ethnopharmacol** 1996 Nov;54(2-3):103-11

Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. Moog C, et al. **J Gen Virol** 1996 Sep; 77 (Pt 9):1993-9

New antiepileptic drugs--I. Basic characteristics. Lee BI. **J Korean Med Sci** 1996 Apr;11(2):99-110 (40 ref.)

New antiepileptic drugs. II. Clinical use. Lee BI. **J Korean Med Sci** 1996 Aug;11(4):289-304 (98 ref.)

Structure-activity relationships of alkyl- and alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones: potent and systemically active antagonists for the glycine site of the NMDA receptor. Cai SX, et al. **J Med Chem** 1997 Feb 28;40(5):730-8

Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system. Yiu S, et al. **J Med Chem** 1996 Nov 8; 39(23):4576-82

Influence of nicardipine, nimodipine and flunarizine on the anticonvulsant efficacy of antiepileptics against pentylenetetrazol in mice. Gasior M, et al. **J Neural Transm Gen Sect** 1996;103(7):819-31

Attenuation of cyclic AMP production by carbamazepine. Chen G, et al. **J Neurochem** 1996 Nov;67(5):2079-86

Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. Petroff OA, et al. **J Neurochem** 1996 Dec;67(6):2399-404

Up-regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: activation of calcium channel and catecholamine secretion in adrenal chromaffin cells. Yamamoto R, et al. **J Neurochem** 1997 Apr;68(4):1655-62

Lack of influence of histopathological changes on carbamazepine and carbamazepine-10, 11-epoxide concentrations in the brain cortex of epileptic patients [published erratum appears in J Neurol Sci 1997 Apr 15;147(2):223-4] Schnabel R, et al. **J Neurol Sci** 1996 Sep 15;141(1-2):87-94

In vivo modulation of vincristine-induced neurotoxicity in Lymnaea stagnalis, by the ACTH(4-9) analogue Org 2766. Kiburg B, et al. **J Neurooncol** 1996 Dec;30(3):173-80

Physiological and pharmacological alterations in postsynaptic GABA(A) receptor function in a hippocampal culture model of chronic spontaneous seizures. Gibbs JW 3rd, et al. **J Neurophysiol** 1997 Apr;77(4):2139-52

Repeated tetanic stimulation in piriform cortex in vitro: epileptogenesis and pharmacology. Pelletier MR, et al. **J Neurophysiol** 1996 Dec;76(6):4069-79

Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. Segal MM, et al. **J Neurophysiol** 1997 Jun; 77(6):3021-34

Interleukin-1 beta and phenytoin reduce alpha 1 (I) procollagen mRNA expression in human gingival fibroblasts. Modéer T, et al. **J Periodontal Res** 1996 Nov; 31(8):563-9

Synthesis and anticonvulsant activity of some 1,2,3,3a-tetrahydropyrrolo[2,1-b]-benzothiazol-, -thiazol- or -oxazol-1-ones in rodents. Trapani G, et al. **J Pharm Pharmacol** 1996 Aug;48(8):834-40

Anticonvulsant pharmacodynamics and disposition of triazolam in rats. Gaudreault J, et al. **J Pharm Sci** 1996 Sep;85(9):999-1004

Bioavailability and anticonvulsant activity of 2-cyanoguanidinophenytoin, a structural analogue of phenytoin. Lambert DM, et al. **J Pharm Sci** 1996 Oct; 85(10):1077-81

Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. Bristow LJ, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):492-501

Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. Carter RB, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1284-95

Genetic differences in behavioral sensitivity to a neuroactive steroid. Finn DA, et al. **J Pharmacol Exp Ther** 1997 Feb; 280(2):820-8

Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. Gasior M, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):543-53

Voltage-dependent calcium channels as targets for convulsant and anticonvulsant alkyl-substituted thiobutyrolactones. Gross RA, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):686-94

Pharmacokinetic/pharmacodynamic relationship of benzodiazepines in the direct cortical stimulation model of anticonvulsant effect. Hoogerkamp A, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):803-12

Long-term studies on anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. I. Comparison

of diazepam, clonazepam, clobazam and abecarnil. Löscher W, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):561–72

Long-term studies on anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. II. The novel imidazoquinazolines NNC 14–0185 and NNC 14–0189. Löscher W, et al. **J Pharmacol Exp Ther** 1996 Nov; 279(2):573–81

Anticonvulsant action of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline in immature rats: comparison with the effects on motor performance. Mares P, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1120–6

The stereo-isomers of the anticonvulsant ARL 12495AA limit sustained repetitive firing and modify action potential properties of rat hippocampal neurons in vitro. Norris SK, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1191–8

Direct inhibitions of the activities of steroidogenic cytochrome P-450 mono-oxygenase systems by anticonvulsants. Ohnishi T, et al. **J Steroid Biochem Mol Biol** 1997 Jan;60(1–2):77–85

Electrophysiological approach of the antiepileptic effect of dexamethasone on hippocampal slice culture using a multirecording system: the Physiocard. Duport S, et al. **Life Sci** 1997;60(17):PL 251–6

Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER). Kanda T, et al. **Life Sci** 1996;59(19):1607–16

Interactions of excitatory amino acid antagonists with conventional antiepileptic drugs. Czuczwar SJ, et al. **Metab Brain Dis** 1996 Jun;11(2):143–52

Effects of ethosuximide on the cerebral vasculature and hemodynamics of rats. Velkova K, et al. **Methods Find Exp Clin Pharmacol** 1995 Dec;17(10):677–84

Changes in brain putrescine concentration associated with nonconvulsant behavioral patterns induced by systemic N-methyl-D-aspartate injection. Giménez-Llort L, et al. **Mol Chem Neuropathol** 1997 Apr;30(3):289–302

Effects of valproate on amino acid and monoamine concentrations in striatum of audiogenic seizure-prone Balb/c mice. Vriend JP, et al. **Mol Chem Neuropathol** 1996 Apr;27(3):307–24

Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications. Kuo CC, et al. **Mol Pharmacol** 1997 Jun;51(6):1077–83

Anticonvulsant action of neuropeptide Y. Neuropeptide Y may act as an endogenous anticonvulsant through Y5 receptors suggesting a new target for antiepileptic drugs [news; comment] Sperk G, et al. **Nat Med** 1997 Jul; 3(7):728–9. Comment on: Nat Med 1997 Jul;3(7):761–4.

Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors [see comments] Woldbye DP, et al. **Nat Med** 1997 Jul;3(7):761–4. Comment in: Nat Med 1997 Jul;3(7):728–9.

A microdialysis study of glycinamide, glycine and other amino acid neurotransmitters in rat frontal cortex and hippocampus after the administration of milacemide, a glycine pro-drug. Doheny MH, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jul; 354(2):157–63

Abecarnil, a beta-carboline derivative, does not exhibit anticonvulsant tolerance or withdrawal effects in mice. Natolino F, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):612–7

Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Waldmeier PC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jul; 354(2):164–72

Comparative effects of the GABA uptake inhibitors, tiagabine and NNC-711, on extracellular GABA levels in the rat ventrolateral thalamus. Richards DA, et al. **Neurochem Res** 1996 Feb;21(2):135–40

A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices. Calabresi P, et al. **Neurology** 1996 Aug;47(2):557–62

Gabapentin interaction with felbamate. Hussein G, et al. **Neurology** 1996 Oct;47(4):1106

Chronic administration of Org2766 and morphine counteracts isolation-induced increase in social interest: implication of endogenous opioid systems. Hol T, et al. **Neuropeptides** 1996 Jun;30(3):283–91

Chronic administration of ORG 2766 for 6 months produces a subtle impairment in strategic learning by rats. Logan JA, et al. **Neuropeptides** 1996 Dec;30(6):541–5

Inhibitory effect of NPY on the picrotoxin-induced activity in the hippocampus: a behavioural and electrophysiological study. Smiałowska M, et al. **Neuropeptides** 1996 Feb; 30(1):7–12

Loreclezole enhances apparent desensitization of recombinant GABAA receptor currents. Donnelly JL, et al. **Neuropharmacology** 1996;35(9–10):1233–41

The protective action of tetrodotoxin and (+/-)-kavain on anaerobic glycolysis, ATP content and intracellular Na+ and Ca2+ of anoxic brain vesicles. Gleitz J, et al. **Neuropharmacology** 1996;35(12):1743–52

Anticonvulsant activity of novel derivatives of 2- and 3-piperidinecarboxylic acid in mice and rats. Hinko CN, et al. **Neuropharmacology** 1996;35(12):1721–35

Physiological comparison of alpha-ethyl-alpha-methyl-gamma-thiobutyrolactone with benzodiazepine and barbiturate modulators of GABAA receptors. Mathews GC, et al. **Neuropharmacology** 1996 Feb;35(2):123–36

Electrophysiological effects of the anticonvulsant remacemide hydrochloride and its metabolite ARL 12495AA on rat CA1 hippocampal neurons in vitro. Norris SK, et al. **Neuropharmacology** 1997 Jul;36(7):951–9

Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Sanna E, et al. **Neuropharmacology** 1996;35(12):1753–60

Effects of lithium and carbamazepine on thyroid hormone metabolism in rat brain. Baumgartner A, et al. **Neuropsychopharmacology** 1997 Jan;16(1):25–41

Increase in AP-1 transcription factor DNA binding activity by valproic acid. Chen G, et al. **Neuropsychopharmacology** 1997 Mar;16(3):238–45

Convulsant and anticonvulsant actions of agonists and antagonists of group III mGluRs. Ghauri M, et al. **Neuroreport** 1996 Jun 17;7(9):1469–74

Differential block of two types of sodium channels by anticonvulsants. Song JH, et al. **Neuroreport** 1996 Nov 25; 7(18):3031–6

Anticonvulsant doses of carbamazepine increase hippocampal extracellular serotonin in genetically epilepsy-prone rats: dose response relationships. Dailey JW, et al. **Neurosci Lett** 1997 May 9;227(1):13–6

Tiagabine exerts an anti-epileptogenic effect in amygdala kindling epileptogenesis in the rat. Dalby NO, et al. **Neurosci Lett** 1997 Jun 27;229(2):135–7

Effects of the antiepileptic drug felbamate on long-term potentiation in the CA1 region of rat hippocampal slices. Pugliese AM, et al. **Neurosci Lett** 1996 Aug 30;215(1):21–4

Spinal gabapentin is antinociceptive in the rat formalin test. Shimoyama N, et al. **Neurosci Lett** 1997 Jan 24;222(1):65–7

Anticonvulsant action of metabotropic glutamate receptor agonists in kindled amygdala of rats. Suzuki K, et al. **Neurosci Lett** 1996 Feb 2;204(1–2):41–4

Anticonvulsive and neuroprotective actions of a potent agonist (DCG-IV) for group II metabotropic glutamate receptors against intraventricular kainate in the rat. Miyamoto M, et al. **Neuroscience** 1997 Mar;77(1):131–40

Distinct electrophysiological effects of two spinally administered membrane stabilising drugs, bupivacaine and lamotrigine. Chapman V, et al. **Pain** 1997 Jul;71(3):285–95

An in vitro investigation of the effects of the ACTH/MSH(4–9) analogue, Org 2766, on guinea pig medial vestibular nucleus neurons. Gilchrist DP, et al. **Peptides** 1996;17(4):681–8

In vitro and in vivo activity of 16,17-dehydro-epipregnanolones: 17,20-bond torsional energy analysis and D-ring conformation. Bolger MB, et al. **Pharm Res** 1996 Oct;13(10):1488–94

Effects of four antiepileptic drugs on sleep and waking in the rat under both light and dark phases. Bertorelli R, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):559–65

Tolerance to anticonvulsant effects of some benzodiazepines in genetically epilepsy prone rats. De Sarro G, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):39–48

Anticonvulsant activity of azirino[1,2-d][1,4]benzodiazepines and related 1,4-benzodiazepines in mice. De Sarro G, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):281–9

Anticonvulsant activity of 5,7DCKA, NBQX, and felbamate against some chemoconvulsants in DBA/2 mice. De Sarro G, et al. **Pharmacol Biochem Behav** 1996 Oct;55(2):281–7

Evaluation of in vivo interactions in mice between flurazepam and two neuroactive steroids. Deutsch SI, et al. **Pharmacol Biochem Behav** 1996 Nov;55(3):323–6

Chronic caffeine and the anticonvulsant potency of antiepileptic drugs against maximal electroshock. Gasior M, et al. **Pharmacol Biochem Behav** 1996 Aug;54(4):639–44

Anticonvulsant and adverse effects of MK-801, LY 235959, and GYKI 52466 in combination with Ca2+ channel inhibitors in mice. Gasior M, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):629–35

Excitatory amino acid antagonists and pentylenetetrazol-induced seizures during ontogenesis. IV. Effects of CGP 39551. Velísek L, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):493–8

Diazepam--its effects on the development of pentylenetetrazol kindling, related learning impairments, and neuronal cell loss. Becker A, et al. **Pharmacol Res** 1997 Jan;35(1):27–32

Neuroprotective effects of felbamate on global ischaemia in Mongolian gerbils. Bertorelli R, et al. **Pharmacol Res** 1996 Jul-Aug;34(1–2):59–64

Behavioural effects of pinoline in the rat forced swimming, open field and elevated plus-maze tests. Pähkla R, et al. **Pharmacol Res** 1996 Jul-Aug;34(1–2):73–8

A pharmacological and clinical review on topiramate, a new antiepileptic drug. Perucca E. **Pharmacol Res** 1997 Apr; 35(4):241–56 (119 ref.)

Interaction of mu-opioid antagonistic drugs with antiepileptics. Frey HH, et al. **Pharmacol Toxicol** 1996 Apr; 78(4):264–8

Effects of various antiepileptic drugs on plasma levels of lamotrigine, a novel antiepileptic, in rats. Yamashita S, et al. **Pharmacology** 1997 Jun;54(6):319–27

The leaf essential oil of Psidium guyanensis offers protection against pentylenetetrazole-induced seizures. Santos FA, et al. **Planta Med** 1997 Apr;63(2):133–5

Inhibitory effect of neuropeptide y on epileptiform activity in the frontal cortex and hippocampus in vitro. Bijak M. **Pol J Pharmacol** 1995 Sep-Oct;47(5):461–3

Effects of opioid antagonists on anticonvulsant and hypnotic activity of benzodiazepines. Fidecka S, et al. **Pol J Pharmacol** 1996 Jul-Aug;48(4):409–14

Some behavioral effects of 1,3-di-o-tolylguanidine, opipramol and sertraline, the sigma site ligands. Maj J, et al. **Pol J Pharmacol** 1996 Jul-Aug;48(4):379–95

Effect of carbamazepine on the pharmacokinetics of promazine. Syrek M, et al. **Pol J Pharmacol** 1996 Nov-Dec; 48(6):601–8

Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Ragsdale DS, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9270–5

Epalons as anticonvulsants: actions mediated by the GABAA receptor complex. Gee KW. **Proc West Pharmacol Soc** 1996;39:55

Effects of convulsant and anticonvulsant agents on memory in squirrel monkeys. Pakarinen ED, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jul; 20(5):883–98

Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Walden J, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 May; 21(4):697–706

The effects of antiepileptic drugs on cognition in normal volunteers. Akaho R. **Psychiatry Clin Neurosci** 1996 Apr; 50(2):61–9

Bilobalide, a constituent of Ginkgo biloba L., potentiates drug-metabolizing enzyme activities in mice: possible mechanism for anticonvulsant activity against 4-O-methylpyridoxine-induced convulsions. Sasaki K, et al. **Res Commun Mol Pathol Pharmacol** 1997 Apr; 96(1):45–56

A new non-NMDA antagonist modifies the local cerebral glucose utilization in kainate-induced generalized seizure. Shiraishi K. **Sangyo Ika Daigaku Zasshi** 1997 Mar 1; 19(1):1–12

Mechanisms of action of antiepileptic drugs. Davies JA. **Seizure** 1995 Dec;4(4):267–71 (28 ref.)

Mechanisms of T-type calcium channel blockade by zonisamide. Kito M, et al. **Seizure** 1996 Jun;5(2):115–9

Effects of tiagabine and vigabatrin on GABA uptake into primary cultures of rat cortical astrocytes. Leach JP, et al. **Seizure** 1996 Sep;5(3):229–34

The effects of vigabatrin on attention, concentration and mood: an investigation in healthy volunteers. Thomas L, et al. **Seizure** 1996 Sep;5(3):205–8

Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons. Wang SJ, et al. **Synapse** 1996 Nov;24(3):248–55

In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices. McNeilly PJ, et al. **Xenobiotica** 1997 May;27(5):431–41

Xylazine impairs the anticonvulsant activity of conventional antiepileptic drugs in mice. Wlaź P, et al. **Zentralbl Veterinarmed A** 1996 Oct;43(8):495–500

[New antiepileptics in review] Holzgrabe U. **Pharm Unserer Zeit** 1997 May;26(3):152–6 (10 ref.) **(Ger)**

[Effects of carbamazepine and zonisamide on acetylcholine levels in rat striatum] Mizuno K. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Feb; 17(1):17–23 (Eng. Abstr.) **(Jpn)**

[Recent progress in development of psychotropic drugs (4)--Anticonvulsants: an overview on the mechanisms of action] Yamada N, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Oct; 16(5):151–9 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of phenytoin and carbamazepine on evoked potentials in patients with newly diagnosed epilepsy. Part I. Visual evoked potentials] Rysz A, et al. **Neurol Neurochir Pol** 1996 Nov-Dec;30(6):961–9 (Eng. Abstr.) **(Pol)**

[Effect of phenytoin and carbamazepine on evoked potentials in patients with newly diagnosed epilepsy. Part II. Brainstem auditory evoked potentials] Rysz A, et al. **Neurol Neurochir Pol** 1996 Nov-Dec;30(6):971–9 (Eng. Abstr.) **(Pol)**

[Efficacy of combined administration of various potential-dependent and receptor-activated Ca channel blockers with various antiepileptic agents] Karpova MN, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):46–9 **(Rus)**

[N-butylaspartic acid--a partial agonist of NMDA receptors?] Kamri M, et al. **Eksp Klin Farmakol** 1996 May-Jun;59(3):9–11 (Eng. Abstr.) **(Rus)**

[Mechanism of action of antiepileptic drugs] Velasco Martín A. **An R Acad Nac Med (Madr)** 1996;113(3):743–53 (37 ref.) **(Spa)**

[Antiepileptic drugs: mechanism of action] Mercadé Cerdá JM. **Neurologia** 1996 Dec;11 Suppl 4:93–9 (31 ref.) (Eng. Abstr.) **(Spa)**

[Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients] Navarro-Quesada FJ, et al. **Rev Neurol** 1997 Jul; 25(143):1037–44 (Eng. Abstr.) **(Spa)**

POISONING

Multiorgan system failure caused by valproic acid toxicity. Pinkston R, et al. **Am J Emerg Med** 1997 Sep;15(5):504–6

Carbamazepine poisoning in adolescent suicide attempters. Effectiveness of multiple-dose activated charcoal in enhancing carbamazepine elimination. Montoya-Cabrera MA, et al. **Arch Med Res** 1996 Winter;27(4):485-9

Cerebellar hypometabolism in focal epilepsy is related to age of onset and drug intoxication. Seitz RJ, et al. **Epilepsia** 1996 Dec;37(12):1194-9

Fatal sodium valproate poisoning [letter] Berthelot-Moritz F, et al. **Intensive Care Med** 1997 May;23(5):599

Valproic acid overdose and L-carnitine therapy. Ishikura H, et al. **J Anal Toxicol** 1996 Jan-Feb;20(1):55-8

Hemodialysis and hemoperfusion for treatment of valproic acid and gabapentin poisoning. Fernandez MC, et al. **Vet Hum Toxicol** 1996 Dec;38(6):438-43

THERAPEUTIC USE

Effects of Lamotrigine on brain nitrite and cGMP levels during focal cerebral ischemia in rats. Balkan S, et al. **Acta Neurol Scand** 1997 Mar;95(3):140-6

Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures. Boas J, et al. **Acta Neurol Scand** 1996 Oct;94(4):247-52

Fatal hepatotoxicity in a child treated with vigabatrin [letter] Kellermann K, et al. **Acta Neurol Scand** 1996 May; 93(5):380-1

Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy. Provinciali L, et al. **Acta Neurol Scand** 1996 Jul;94(1):12-8

Plasma tryptophan levels in children with epilepsy before and after antiepileptic treatment. Milovanovic DD, et al. **Adv Exp Med Biol** 1996;398:103-6

Sodium channels and therapy of central nervous system diseases. Taylor CP, et al. **Adv Pharmacol** 1997;39:47-98 (300 ref.)

Drug interactions with agents used in the treatment of epilepsy. Griffin JP. **Adverse Drug React Toxicol Rev** 1996 Nov;15(4):221-46 (150 ref.)

A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Mueller TI, et al. **Alcohol Clin Exp Res** 1997 Feb; 21(1):86-92

Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status. Baer MT, et al. **Am J Clin Nutr** 1997 Apr;65(4):1042-51

A new phenytoin prodrug, Cerebyx [letter] Roberge RJ. **Am J Emerg Med** 1997 Jul;15(4):444-5

Fosphenytoin safety and economics [editorial; comment] [see comments] Paloucek FP. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2702. Comment on: Am J Health Syst Pharm 1996 Nov 15;53(22):2707-12. Comment in: Am J Health Syst Pharm 1997 Feb 15;54(4):441-2. Comment in: Am J Health Syst Pharm 1997 Feb 15;54(4):445.

Criteria for use of valproate in adult psychiatric inpatients and outpatients. Puzantian T. **Am J Health Syst Pharm** 1996 May 15;53(10):1187-8 (24 ref.)

Lamotrigine treatment of rapid cycling bipolar disorder [letter; comment] Kusumakar V, et al. **Am J Psychiatry** 1997 Aug;154(8):1171-2. Comment on: Am J Psychiatry 1996 Sep;153(9):1236.

Lamotrigine for treatment-refractory bipolar disorder [letter] Labbate LA, et al. **Am J Psychiatry** 1997 Sep;154(9):1317

Gabapentin in the treatment of bipolar disorder [letter] Schaffer CB, et al. **Am J Psychiatry** 1997 Feb;154(2):291-2

Treatment of acute mania with gabapentin [letter] Stanton SP, et al. **Am J Psychiatry** 1997 Feb;154(2):287

Vigabatrin causes profound reduction in serum alanine transaminase activity. Ryan MF, et al. **Ann Clin Biochem** 1996 May;33 (Pt 3):257-8

A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. McElroy SL, et al. **Ann Clin Psychiatry** 1997 Jun;9(2):99-103

Midazolam in refractory status epilepticus. Denzel D, et al. **Ann Pharmacother** 1996 Dec;30(12):1481-3

Valproic acid: a migraine prophylaxis alternative. Shelton CE, et al. **Ann Pharmacother** 1996 Jul-Aug;30(7-8):865-6 (9 ref.)

Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Silpakit O, et al. **Ann Pharmacother** 1997 May;31(5):548-52

Treatment of Koro and panic attacks after stroke. Dantendorfer K, et al. **Anxiety** 1996;2(1):53-5

The new antiepileptic drugs. Appleton RE. **Arch Dis Child** 1996 Sep;75(3):256-62 (71 ref.)

Continuous midazolam infusion as treatment of status epilepticus. Lal Koul R, et al. **Arch Dis Child** 1997 May; 76(5):445-8

Lithium therapy in the treatment of manic-depressive illness. Present status and future perspectives. A critical review. Emilien G, et al. **Arch Int Pharmacodyn Ther** 1995 Nov-Dec;330(3):251-78 (137 ref.)

Seizures and epilepsy in the elderly. Thomas RJ. **Arch Intern Med** 1997 Mar 24;157(6):605-17 (203 ref.)

Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group. Sachdeo RC, et al. **Arch Neurol** 1997 May;54(5):595-601

Cerebellar atrophy decreases the threshold of carbamazepine toxicity in patients with chronic focal epilepsy. Specht U, et al. **Arch Neurol** 1997 Apr;54(4):427-31

Reflex sympathetic dystrophy treated with gabapentin. Mellick GA, et al. **Arch Phys Med Rehabil** 1997 Jan; 78(1):98-105

Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Mueller ME, et al. **Arch Phys Med Rehabil** 1997 May;78(5):521-4

Hepatic enzymes' level during chronic use of anticonvulsant drugs. Hoshino M, et al. **Arq Neuropsiquiatr** 1995 Dec; 53(4):719-23

Epilepsy in children. Arnold ST, et al. **Baillieres Clin Neurol** 1996 Dec;5(4):783-802 (77 ref.)

Epilepsy, anticonvulsant drugs and cognition. Drane DL, et al. **Baillieres Clin Neurol** 1996 Dec;5(4):877-85 (49 ref.)

Rational monotherapy for epilepsy. Leppik IE. **Baillieres Clin Neurol** 1996 Dec;5(4):749-55 (21 ref.)

Established antiepileptic drugs. Perucca E. **Baillieres Clin Neurol** 1996 Dec;5(4):693-722 (102 ref.)

Modern management of epilepsy: Rational polytherapy. Schmidt D. **Baillieres Clin Neurol** 1996 Dec;5(4):757-63 (18 ref.)

New antiepileptic drugs. Wilson EA, et al. **Baillieres Clin Neurol** 1996 Dec;5(4):723-47 (119 ref.)

Contraception, pregnancy and lactation in women with epilepsy. Yerby MS. **Baillieres Clin Neurol** 1996 Dec; 5(4):887-908 (125 ref.)

The ACTH(4-9) analog ORG 2766 and recovery after brain damage in animal models--a review. van Rijzingen IM, et al. **Behav Brain Res** 1996 Jan;74(1-2):1-15 (135 ref.)

Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease [letter] Selby R, et al. **Blood** 1997 Jul 15;90(2):891-3

New antiepileptic drugs. The drugs are not all the same [letter; comment] [see comments] Brodie MJ. **BMJ** 1997 Feb 22;314(7080):602-3. Comment on: BMJ 1996 Nov 9;313(7066):1169-74. Comment in: BMJ 1997 Jun 14;314(7096):1764.

New antiepileptic drugs. Register of women who take the drugs during pregnancy has been set up [letter; comment] [see comments] Craig JJ, et al. **BMJ** 1997 Feb 22; 314(7080):603. Comment on: BMJ 1996 Nov 9;313(7066):1157-8. Comment in: BMJ 1997 May 10;314(7091):1414-5.

New antiepileptic drugs. Analysis based on number needed to treat shows differences between drugs studied [letter; comment] [see comments] Elferink JA, et al. **BMJ** 1997 Feb 22;314(7080):603. Comment on: BMJ 1996 Nov 9;313(7066):1169-74. Comment in: BMJ 1997 Jun 14;314(7096):1764.

Large pragmatic randomised studies of new antiepileptic drugs are needed [letter; comment] Marson A, et al. **BMJ** 1997 Jun 14;314(7096):1764. Comment on: BMJ 1997 Feb 22;314(7080):602-3. Comment on: BMJ 1997 Feb 22;314(7080):603.

New antiepileptic drugs: a systematic review of their efficacy and tolerability [see comments] Marson AG, et al. **BMJ** 1996 Nov 9;313(7066):1169-74. Comment in: BMJ 1996 Nov 9;313(7066):1157-8. Comment in: BMJ 1996 Nov 9;313(7066):1158. Comment in: BMJ 1997 Feb 22;314(7080):602-3. Comment in: BMJ 1997 Feb 22;314(7080):603. Comment in: ACP J Club 1997 May-Jun;126(3):72.

Drug trials in epilepsy [editorial] [see comments] Mignot G. **BMJ** 1996 Nov 9;313(7066):1158. Comment in: BMJ 1996 Nov 9;313(7066):1157-8. Comment in: BMJ 1997 Feb 22;314(7080):603-4.

New antiepileptic drugs. Study suggests that under a quarter of patients will still be taking the new drugs after six years [letter; comment] Wong IC. **BMJ** 1997 Feb 22; 314(7080):603-4. Comment on: BMJ 1996 Nov 9;313(7066):1158.

CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors. Erer B, et al. **Bone Marrow Transplant** 1996 Jul;18(1):157-62

Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Bertilsson L, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):186-9

Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Hussein Z, et al. **Br J Clin Pharmacol** 1997 May;43(5):457-65

Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients. McKee PJ, et al. **Br J Clin Pharmacol** 1993 Sep; 36(3):257-61

The new generation of antiepileptic drugs: advantages and disadvantages. Perucca E. **Br J Clin Pharmacol** 1996 Nov; 42(5):531-43 (76 ref.)

Magnesium sulphate in the treatment of eclampsia and pre-eclampsia: an overview of the evidence from randomised trials [see comments] Chien PF, et al. **Br J Obstet Gynaecol** 1996 Nov;103(11):1085-91. Comment in: Br J Obstet Gynaecol 1996 Nov;103(11):vii. Comment in: Br J Obstet Gynaecol 1997 Jun;104(6):756-8.

Anticonvulsant effects of 7-nitroindazole in rodents with reflex epilepsy may result from L-arginine accumulation or a reduction in nitric oxide or L-citrulline formation. Smith SE, et al. **Br J Pharmacol** 1996 Sep;119(1):165-73

Adrenocorticotropic hormone and vigabatrin treatment of children with infantile spasms underlying cerebral palsy. Zafeiriou DI, et al. **Brain Dev** 1996 Nov-Dec;18(6):450-2

Anti-epileptogenic and anticonvulsant activity of L-2-amino-4-phosphonobutyrate, a presynaptic glutamate receptor agonist. Abdul-Ghani AS, et al. **Brain Res** 1997 May 2;755(2):202-12

Phenytoin pretreatment prevents hypoxic-ischemic brain damage in neonatal rats. Vartanian MG, et al. **Brain Res Dev Brain Res** 1996 Sep 2;95(2):169-75

The diagnosis and treatment of mania in the elderly. McDonald WM, et al. **Bull Menninger Clin** 1996 Spring; 60(2):174-96 (136 ref.)

Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Corman CL, et al. **Can J Neurol Sci** 1997 Aug;24(3):240-4

Add-on gabapentin for refractory seizures in patients with brain tumours. Perry JR, et al. **Can J Neurol Sci** 1996 May; 23(2):128-31

Antiepileptic drugs--current use. Wilder BJ. **Can J Neurol Sci** 1996 Nov;23(4):S18-23 (46 ref.)

Magnesium sulphate in the management of severe tetanus averts artificial ventilation and sedation [letter] Attygalle D. **Ceylon Med J** 1996 Sep;41(3):120

Lamotrigine as add-on therapy in adult patients with refractory epilepsy. Yen DJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 May;59(5):303-7

New treatment options for epilepsy. Morris HH 3rd. **Cleve Clin J Med** 1997 Mar;64(3):125-7

Treatment of restless legs syndrome with gabapentin. Adler CH. **Clin Neuropharmacol** 1997 Apr;20(2):148-51

Felbamate pharmacology and use in epilepsy. Burdette DE, et al. **Clin Neuropharmacol** 1994 Oct;17(5):389-402 (47 ref.)

Aggression in children treated with clobazam for epilepsy. Sheth RD, et al. **Clin Neuropharmacol** 1994 Aug; 17(4):332-7

Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring. Yukawa E. **Clin Pharmacokinet** 1996 Aug;31(2):120-30 (102 ref.)

Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Lehmann DF, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):225-9

Recent advances in the pharmacotherapy of epilepsy. Bazil MK, et al. **Clin Ther** 1997 May-Jun;19(3):369-82; discussion 367-8 (51 ref.)

Tonic-clonic seizures: a systematic review of antiepilepsy drug efficacy and safety. Ramsay RE, et al. **Clin Ther** 1997 May-Jun;19(3):433-46; discussion 367-8 (20 ref.)

Status epilepticus. Payne TA, et al. **Crit Care Clin** 1997 Jan; 13(1):17-38 (64 ref.)

Mechanisms of action of new antiepileptic drugs. Macdonald RL, et al. **Curr Opin Neurol** 1997 Apr;10(2):121-8 (99 ref.)

Comparing antiepileptic drugs. Marson AG, et al. **Curr Opin Neurol** 1996 Apr;9(2):103-6

New antiepileptic drugs. Bourgeois BF. **Curr Opin Pediatr** 1996 Dec;8(6):543-8 (54 ref.)

Topiramate--add-on drug for partial seizures. **Drug Ther Bull** 1996 Aug;34(8):62-4 (15 ref.)

Diagnosis and treatment of epilepsy in children and adolescents. Morton LD, et al. **Drugs** 1996 Mar; 51(3):399-414 (123 ref.)

Drug treatment of epilepsy in the 1990s. Achievements and new developments. Sabers A, et al. **Drugs** 1996 Oct; 52(4):483-93 (122 ref.)

Long term treatment of bipolar disorder [see comments] Silverstone T, et al. **Drugs** 1996 Mar;51(3):367-82 (105 ref.) . Comment in: Drugs 1997 Apr;53(4):726.

New antiepileptic drugs: from discovery to practical use. Clinical directions for the future. Proceedings of the 3rd International Merritt-Putnam Symposium. Sydney, Australia, September 6, 1995. **Epilepsia** 1996;37 Suppl 6:S1-55

New Options for the Treatment of Epilepsy: Topiramate in Perspective. Proceedings of an International Symposium. London, England, November 11-12, 1995. **Epilepsia** 1997; 38 Suppl 1:S1-62

A comparison between one and three years of treatment in uncomplicated childhood epilepsy: a prospective study. II. The EEG as predictor of outcome after withdrawal of treatment. Andersson T, et al. **Epilepsia** 1997 Feb; 38(2):225-32

Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: the European experience. Ben-Menachem E. **Epilepsia** 1997;38 Suppl 1:S28-30

Preliminary open-label experience with topiramate in primary generalized seizures. Biton V. **Epilepsia** 1997;38 Suppl 1:S42-4

Early discontinuation of treatment in children with uncomplicated epilepsy: a prospective study with a model for prediction of outcome. Braathen G, et al. **Epilepsia** 1997 May;38(5):561-9

Outcomes after seizure recurrence in people with well-controlled epilepsy and the factors that influence it. The MRC Antiepileptic Drug Withdrawal Group. Chadwick D, et al. **Epilepsia** 1996 Nov;37(11):1043-50

Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. Chadwick DW, et al. **Epilepsia** 1996;37 Suppl 6:S17-22

An overview of the efficacy and tolerability of new antiepileptic drugs. Chadwick DW. **Epilepsia** 1997;38 Suppl 1:S59-62

Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Deckers CL, et al. **Epilepsia** 1997 May;38(5):570-5 (41 ref.)

Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome). Donaldson JA, et al. **Epilepsia** 1997 Jan;38(1):68-73

Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience. Faught E. **Epilepsia** 1997;38 Suppl 1:S24–7

What trials, which designs? [editorial; comment] French JA. **Epilepsia** 1997 Mar;38(3):263–5. Comment on: Epilepsia 1997 Mar;38(3):294–300.

The concentration–effect relationship with lamotrigine (LTG) [letter] Gidal BE, et al. **Epilepsia** 1997 Feb;38(2):260

Preliminary observations on topiramate in pediatric epilepsies. Glauser TA. **Epilepsia** 1997;38 Suppl 1:S37–41

Don't test, do sell: legal implications of inclusion and exclusion of women in clinical drug trials. Herz SE. **Epilepsia** 1997;38 Suppl 4:S42–9 (21 ref.)

Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Hosford DA, et al. **Epilepsia** 1997 Apr; 38(4):408–14

The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps. Mattson RH. **Epilepsia** 1996;37 Suppl 6:S45–53 (82 ref.)

No effect of long–term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group. Mauguière F, et al. **Epilepsia** 1997 Mar;38(3):301–8

The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Morrell MJ. **Epilepsia** 1996;37 Suppl 6:S34–44 (107 ref.)

Maximizing the health of women with epilepsy: science and ethics in new drug development. Morrell MJ. **Epilepsia** 1997;38 Suppl 4:S32–41 (119 ref.)

Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five double–blind, placebo–controlled trials. Reife RA, et al. **Epilepsia** 1997; 38 Suppl 1:S31–3

Long–term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective survey of open–label treatment. Rosenfeld WE, et al. **Epilepsia** 1997;38 Suppl 1:S34–6

Topiramate monotherapy for partial onset seizures [see comments] Sachdeo RC, et al. **Epilepsia** 1997 Mar; 38(3):294–300. Comment in: Epilepsia 1997 Mar;38(3):263–5.

Practical aspects of the use of topiramate in patients with epilepsy. Sander JW. **Epilepsia** 1997;38 Suppl 1:S56–8

Felbamate in therapy–resistant epilepsy: an Italian experience. Felbamate Italian Study Group. Avanzini G, et al. **Epilepsy Res** 1996 Nov;25(3):249–55

Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference [published erratum appears in Epilepsy Res 1997 Mar;26(3):465] Bialer M, et al. **Epilepsy Res** 1996 Nov;25(3):299–319

A double–blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Bill PA, et al. **Epilepsy Res** 1997 Jun;27(3):195–204

Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Brodie MJ, et al. **Epilepsy Res** 1997 Mar;26(3):423–32

Gabapentin in generalized seizures. Chadwick D, et al. **Epilepsy Res** 1996 Nov;25(3):191–7

Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Chiron C, et al. **Epilepsy Res** 1997 Jan;26(2):389–95

A double–blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Christe W, et al. **Epilepsy Res** 1997 Mar;26(3):451–60

Effects of high–dose antiepileptic drugs on event–related potentials in epileptic children. Enoki H, et al. **Epilepsy Res** 1996 Sep;25(1):59–64

Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Gower AJ, et al. **Epilepsy Res** 1995 Nov;22(3):207–13

A double–blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Guerreiro MM, et al. **Epilepsy Res** 1997 Jun;27(3):205–13

Long–term cognitive and EEG effects of tiagabine in drug–resistant partial epilepsy. Kälviäinen R, et al. **Epilepsy Res** 1996 Nov;25(3):291–7

Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Kasteleijn–Nolst Trenité DG, et al. **Epilepsy Res** 1996 Nov;25(3):225–30

Felbamate monotherapy has stimulant–like effects in patients with epilepsy. Ketter TA, et al. **Epilepsy Res** 1996 Mar; 23(2):129–37

Mutual interaction between remacemide hydrochloride and phenytoin. Leach JP, et al. **Epilepsy Res** 1997 Jan; 26(2):381–8

Cost analysis of epilepsy surgery and of vigabatrin treatment in patients with refractory partial epilepsy. Malmgren K, et al. **Epilepsy Res** 1996 Nov;25(3):199–207

A decade of modern epilepsy therapy in institutionalized mentally retarded patients. Pellock JM, et al. **Epilepsy Res** 1996 Nov;25(3):263–8

The effect on maximal electroshock seizures induced by GABA agents and antiepileptic drugs microinfused into the nucleus reticularis pontis oralis. Peterson SL. **Epilepsy Res** 1996 Nov;25(3):161–7

Vigabatrin and carbamazepine have different efficacies in the prevention of status epilepticus induced neuronal damage in the hippocampus and amygdala. Pitkänen A, et al. **Epilepsy Res** 1996 May;24(1):29–45

Suppression of cortical epileptic afterdischarges in developing rats by anticonvulsants increasing GABAergic inhibition. Polášek R, et al. **Epilepsy Res** 1996 Nov; 25(3):177–84

A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Reunanen M, et al. **Epilepsy Res** 1996 Mar;23(2):149–55

Relationship between ischemic damage and concentrations of phenytoin and phenobarbital in the brain cortex of epileptic patients in vegetative state at death. Schnabel R, et al. **Epilepsy Res** 1996 Nov;25(3):231–41

Double–blind, placebo–controlled study of topiramate in patients with refractory partial epilepsy. Sharief M, et al. **Epilepsy Res** 1996 Nov;25(3):217–24

The development of antiepileptic drugs for children. Report from the NIH workshop, Bethesda, Maryland, February 17–18, 1994. Sheridan PH, et al. **Epilepsy Res** 1996 Feb; 23(1):87–92

Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference. Stables JP, et al. **Epilepsy Res** 1995 Nov;22(3):235–46

Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross–over study. Tanganelli P, et al. **Epilepsy Res** 1996 Nov;25(3):257–62

Vigabatrin and behaviour disorders: a retrospective survey. Thomas L, et al. **Epilepsy Res** 1996 Sep;25(1):21–7

Antiseizure activity of insulin: insulin inhibits pentylenetetrazole, penicillin and kainic acid–induced seizures in rats. Uysal H, et al. **Epilepsy Res** 1996 Nov; 25(3):185–90

Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. Walton NY, et al. **Epilepsy Res** 1996 May;24(1):19–28

Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Halonen T, et al. **Eur J Pharmacol** 1996 Mar 28;299(1–3):69–81

Anticonvulsant profile of the imidazoquinazolines NNC 14–0185 and NNC 14–0189 in rats and mice. Jackson HC, et al. **Eur J Pharmacol** 1996 Jul 11;308(1):21–30

Inhibition of morphine withdrawal by lamotrigine: involvement of nitric oxide. Lizasoain I, et al. **Eur J Pharmacol** 1996 Mar 28;299(1–3):41–5

Prognostic factors for childhood and juvenile absence epilepsies. Bartolomei F, et al. **Eur Neurol** 1997; 37(3):169–75

Analysis of urinary pyridinoline and deoxypyridinoline in patients undergoing long–term anticonvulsant drug therapy. Ohishi T, et al. **Eur Neurol** 1996;36(5):300–2

A controlled trial with ORG 2766, an ACTH–(4–9) analog, in 50 relatively able children with autism. Buitelaar JK, et al. **Eur Neuropsychopharmacol** 1996 Mar;6(1):13–9

Remacemide hydrochloride: a novel antiepileptic agent. Davies JA. **Gen Pharmacol** 1997 Apr;28(4):499–502 (31 ref.)

Seizure control: how to use the new antiepileptic drugs in older patients. Haider A, et al. **Geriatrics** 1996 Sep; 51(9):42–5 (16 ref.)

Effects of catecholamines and diazepam in chloroquine poisoning in barbiturate anaesthetised rats. Buckley NA, et al. **Hum Exp Toxicol** 1996 Nov;15(11):909–14

Opsoclonus---myoclonus syndrome in an adult: a case report and response to clonazepam. Garg RK, et al. **Indian J Ophthalmol** 1996 Jun;44(2):101–2

Brainstem auditory evoked potentials in epileptics on different anti–epileptic drugs. Panjwani U, et al. **Indian J Physiol Pharmacol** 1996 Jan;40(1):29–34

Approach to the management of a child with epilepsy. Singhi PD, et al. **Indian Pediatr** 1997 Jan;34(1):27–40 (33 ref.)

Antiepileptic drug utilization in out–patients—a prescribing pattern study. Peytchev L, et al. **Int J Clin Pharmacol Ther** 1996 Oct;34(10):444–5

Tolerability of clonazepam in demented and non–demented geropsychiatric patients. Calkin PA, et al. **Int J Geriatr Psychiatry** 1997 Jul;12(7):745–9

ACOG educational bulletin. Seizure disorders in pregnancy. Number 231, December 1996. Committee on Educational Bulletins of the American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1997 Mar; 56(3):279–86

Efficacy of phenytoin in eclampsia. Naidu S, et al. **Int J Gynaecol Obstet** 1997 Mar;56(3):275–6

Cognitive performances in newly referred patients with temporal lobe epilepsy: comparison with normal subjects in basal condition and after treatment with controlled–release carbamazepine. Gigli GL, et al. **Int J Neurosci** 1996 Nov;88(1–2):97–107

Therapeutic trial of diazepam versus placebo in acute chloroquine intoxications of moderate gravity. Clemessy JL, et al. **Intensive Care Med** 1996 Dec;22(12):1400–5

Lamotrigine for pain with hyperalgesia. Harbison J, et al. **Ir Med J** 1997 Mar;90(2):56

Discontinuation of anti–epileptic therapy: a retrospective study of 86 children and adolescents. Matricardi A, et al. **Ital J Neurol Sci** 1995 Dec;16(9):613–22

Lamotrigine and pregnancy [letter] Quattrini A, et al. **Ital J Neurol Sci** 1996 Dec;17(6):441

Efficacy and safety of topiramate in refractory epilepsy: a long–term prospective trial. Tartara A, et al. **Ital J Neurol Sci** 1996 Dec;17(6):429–32

Treatment of focal status epilepticus with lignocaine [letter] Kato H, et al. **J Accid Emerg Med** 1997 May;14(3):201

Carbamazepine use in children and adolescents with features of attention–deficit hyperactivity disorder: a meta–analysis. Silva RR, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Mar;35(3):352–8

Withdrawal of antiepileptic drugs: a therapeutic dilemma. Taly AB, et al. **J Assoc Physicians India** 1995 Jan;43(1):42–5 (25 ref.)

Open trial lamotrigine in the treatment of self–injurious behavior in an adolescent with profound mental retardation. Davanzo PA, et al. **J Child Adolesc Psychopharmacol** 1996 Winter;6(4):273–9

Optimizing the indication of vigabatrin in children with refractory epilepsy. Lortie A, et al. **J Child Neurol** 1997 Jun;12(4):253–9

Vigabatrin in partial seizures in children. Nabbout RC, et al. **J Child Neurol** 1997 Apr;12(3):172–7

The use of felbamate to treat infantile spasms. Stafstrom CE. **J Child Neurol** 1996 Mar;11(2):170–1

Interactions of clobazam with conventional antiepileptics in children. Theis JG, et al. **J Child Neurol** 1997 Apr; 12(3):208–13

Gabapentin in naive childhood absence epilepsy: results from two double–blind, placebo–controlled, multicenter studies. Trudeau V, et al. **J Child Neurol** 1996 Nov;11(6):470–5

Barbiturate anticonvulsants: a neuropsychological and quantitative electroencephalographic study. Willis J, et al. **J Child Neurol** 1997 Apr;12(3):169–71

Clinical pharmacology of antiepileptic drug use: "clinical pearls about the perils of patty". Schraeder PL, et al. **J Clin Pharmacol** 1995 Dec;35(12):1120–35

Lamotrigine treatment of refractory bipolar disorder. Fogelson DL, et al. **J Clin Psychiatry** 1997 Jun;58(6):271–3

A treatment for tardive dyskinesia and some other extrapyramidal symptoms. Cowen MA, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):190–3

Gabapentin for behavioral agitation in Alzheimer's disease [letter] Regan WM, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):59–60

The anticonvulsant lamotrigine in treatment–resistant manic–depressive illness. Sporn J, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):185–9

Mechanisms underlying the neuropathological consequences of epileptic activity in the rat hippocampus in vitro. Thompson SM, et al. **J Comp Neurol** 1996 Sep 2; 372(4):515–28

Antiepileptic drug therapy: clinical laboratory significance. Naradzay JF, et al. **J Emerg Med** 1996 Jul–Aug; 14(4):473–81 (78 ref.)

Differential effect of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Geisler J, et al. **J Endocrinol** 1997 May;153(2):307–12

Influence of a potential anti–asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock–induced seizures in mice. Czuczwar SJ, et al. **J Neural Transm** 1996;103(12):1371–9

Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports. Staedt J, et al. **J Neural Transm** 1996;103(3):355–61

Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Leach JP, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):372–6

Acetazolamide therapy improves action myoclonus in Ramsay Hunt Syndrome. Baig SM. **J Neurol Sci** 1997 Jan; 145(1):123–4

The effects of clonazepam and vigabatrin in hyperekplexia. Tijssen MA, et al. **J Neurol Sci** 1997 Jul;149(1):63–7

Gabapentin in bipolar disorder [letter] Ryback RS, et al. **J Neuropsychiatry Clin Neurosci** 1997 Spring;9(2):301

Using a health promotion model to enhance medication compliance. Lannon SL. **J Neurosci Nurs** 1997 Jun; 29(3):170–8

Elevated plasma alpha 1–acid glycoprotein levels: lack of connection to resistance to vecuronium blockade induced by anticonvulsant therapy. Hans P, et al. **J Neurosurg Anesthesiol** 1997 Jan;9(1):3–7

Electrographic tachyphylaxis to etomidate and ketamine used for refractory status epilepticus controlled with isoflurane. Kofke WA, et al. **J Neurosurg Anesthesiol** 1997 Jul; 9(3):269–72

The role of antiseizure prophylaxis following head injury. Brain Trauma Foundation. **J Neurotrauma** 1996 Nov; 13(11):731–4 (14 ref.)

Comparative study of different anticonvulsants in eclampsia. Chatterjee A, et al. **J Obstet Gynaecol Res** 1997 Jun; 23(3):289–93

Phenytoin as an alternative treatment for preeclampsia. Lucas LS, et al. **J Obstet Gynecol Neonatal Nurs** 1997 May–Jun; 26(3):263–9 (9 ref.)

Salivary protein composition in epileptic patients on different medications. Henskens YM, et al. **J Oral Pathol Med** 1996 Aug;25(7):360–6

Vigabatrin as first line therapy in infantile spasms: review of seven patients. Kwong L. **J Paediatr Child Health** 1997 Apr;33(2):121–4

Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. Verrotti A, et al. **J Paediatr Child Health** 1997 Jun;33(3):242–5

Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? [see comments] Gross–Tsur V, et al. **J Pediatr** 1997 Jan;130(1):40–4.

Comment in: J Pediatr 1997 Jan;130(1):6–9.
Evaluation of gabapentin and S–(+)–3–isobutylgaba in a rat model of postoperative pain. Field MJ, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1242–6
Clinical, epidemiological and treatment results of idiopathic epilepsy in 54 labrador retrievers: a long–term study. Heynold Y, et al. **J Small Anim Pract** 1997 Jan;38(1):7–14
The use of anticonvulsants in posttraumatic stress disorder: case study and overview. Ford N. **J Trauma Stress** 1996 Oct;9(4):857–63
Long–term anticonvulsant therapy in tuberculous meningitis––a four–year follow–up. Patwari AK, et al. **J Trop Pediatr** 1996 Apr;42(2):98–103
Antenatal phenobarbitone and neonatal outcome. Doyle L. **Lancet** 1996 Oct 12;348(9033):975–6
In the shadow of epilepsy [letter] Gledhill RF. **Lancet** 1997 Sep 13;350(9080):811
Epilepsy in women. Shuster EA. **Mayo Clin Proc** 1996 Oct; 71(10):991–9 (59 ref.)
Ethical issues in the planning and conduct of clinical trials of anti–epileptic drugs. Cramer JA. **Med Law** 1997; 16(2):209–14
Topiramate for epilepsy. **Med Lett Drugs Ther** 1997 May 23;39(1001):51–2
Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Ono H, et al. **Metabolism** 1997 Aug;46(8):959–62
Protective effects of GABAergic drugs and other anticonvulsants in lithium–pilocarpine–induced status epilepticus. George B, et al. **Methods Find Exp Clin Pharmacol** 1996 Jun;18(5):335–40
Resistance to rocuronium in an epileptic patient on long–term carbamazepine therapy––a case report. Baraka A, et al. **Middle East J Anesthesiol** 1996 Oct;13(6):561–4
A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala–kindled seizures. Post RM, et al. **Mol Neurobiol** 1996 Aug; 13(1):33–60 (132 ref.)
The electroencephalogram in acetazolamide–responsive periodic ataxia. Neufeld MY, et al. **Mov Disord** 1996 May; 11(3):283–8
Magnesium sulphate or phenytoin for prevention of eclampsia. Amy JJ. **Natl Med J India** 1996 Sep–Oct; 9(5):223–4
Anticonvulsant effect of felbamate in the pentylenetetrazole kindling model of epilepsy in the rat. Giorgi O, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jul; 354(2):173–8
Antagonism of convulsions but failure to enhance GABA(A) receptor function by felbamate in mice tolerant to diazepam. Serra M, et al. **Neurochem Res** 1997 Jun; 22(6):693–7
Practice parameter: a guideline for discontinuing antiepileptic drugs in seizure–free patients––summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology. **Neurology** 1996 Aug;47(2):600–2
Gabapentin monotherapy: I. An 8–day, double–blind, dose–controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. Bergey GK, et al. **Neurology** 1997 Sep;49(3):739–45
Gabapentin monotherapy: II. A 26–week, double–blind, dose–controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Beydoun A, et al. **Neurology** 1997 Sep;49(3):746–52
Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double–blind, concentration–response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group. Beydoun A, et al. **Neurology** 1997 Jan;48(1):182–8
Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht–Lundborg type with N–acetylcysteine. Hurd RW, et al. **Neurology** 1996 Nov; 47(5):1264–8
Placebo–controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Miller RG, et al. **Neurology** 1996 Dec;47(6):1383–8
Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Petroff OA, et al. **Neurology** 1996 Dec; 47(6):1567–71
Improvement of stiff–man syndrome with vigabatrin. Prevett MC, et al. **Neurology** 1997 Apr;48(4):1133–4
Lamotrigine trial in idiopathic parkinsonism: a double–blind, placebo–controlled, crossover study. Shinotoh H, et al. **Neurology** 1997 May;48(5):1282–5
Erroneous substitution of terbinafine for lamotrigine. Vossler DG. **Neurology** 1997 Sep;49(3):893
Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs. Walker MC, et al. **Neurology** 1997 Aug;49(2):333–7
The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Walker MC, et al. **Neurology** 1996 Apr;46(4):912–4 (26 ref.)
Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis (INCL). Aberg L, et al. **Neuropediatrics** 1997 Feb;28(1):77–9
Add–on therapy of fenfluramine in intractable self–induced epilepsy. Boel M, et al. **Neuropediatrics** 1996 Aug; 27(4):171–3
Landau–Kleffner syndrome and sulthiame [letter] Wakai S, et al. **Neuropediatrics** 1997 Apr;28(2):135–6
Effects of non–peptide angiotensin II–receptor antagonists on pentylenetetrazol kindling in mice. Georgiev VP, et al. **Neuropeptides** 1996 Oct;30(5):401–4
Lamotrigine potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. De Sarro G, et al. **Neuropharmacology** 1996 Feb;35(2):153–8
Exploration of P–type Ca2+ channels as drug targets for the treatment of epilepsy or ischemic stroke. Lingenhöhl K, et al. **Neuropharmacology** 1997 Jan;36(1):107–13
EEG findings in acetazolamide–responsive hereditary paroxysmal ataxia. Van Bogaert P, et al. **Neurophysiol Clin** 1996;26(5):335–40
Hydrocephalus and epilepsy: an actuarial analysis. Piatt JH Jr, et al. **Neurosurgery** 1996 Oct;39(4):722–7; discussion 727–8
Clinical characteristics and biotransformation of sevoflurane in paediatric patients during antiepileptic drug therapy. Komatsu H, et al. **Paediatr Anaesth** 1996;6(5):379–82
Lamotrigine control of central pain. Canavero S, et al. **Pain** 1996 Nov;68(1):179–81
Prospective, open–label, add–on study of lamotrigine in 56 children with intractable generalized epilepsy. Farrell K, et al. **Pediatr Neurol** 1997 Apr;16(3):201–5
Carbamazepine and myoclonus in SSPE subacute sclerosing panencephalitis. Hayashi T, et al. **Pediatr Neurol** 1996 May; 14(4):346
Status epilepticus in children with epilepsy: the role of antiepileptic drug levels in prevention [see comments] Maytal J, et al. **Pediatrics** 1996 Dec;98(6 Pt 1):1119–21. Comment in: Pediatrics 1997 Aug;100(2 Pt 1):277–8.
Antiepileptic drug treatment in the nineties in The Netherlands. Kasteleijn–Nolstlt Trenité DG, et al. **Pharm World Sci** 1997 Apr;19(2):60–9 (66 ref.)
Intracerebroventricular pertussis toxin enhances sensitivity to chemical convulsants and decreases the protective efficacy of carbamazepine in mice. Korolkiewicz R, et al. **Pharmacol Res** 1996 Mar;33(3):211–5
Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Leinonen E, et al. **Pharmacopsychiatry** 1996 Jul;29(4):156–8
Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Walden J, et al. **Pharmacopsychiatry** 1996 Sep;29(5):193–5
Fosphenytoin: a novel phenytoin prodrug. Boucher BA. **Pharmacotherapy** 1996 Sep–Oct;16(5):777–91 (60 ref.)
A pharmacokinetic study to determine the drug interaction between valproate and propranolol. Nemire RE, et al. **Pharmacotherapy** 1996 Nov–Dec;16(6):1059–62
Management of epilepsy: pharmacologic therapy and quality–of–life issues. Schachter SC, et al. **Postgrad Med** 1997 Feb;101(2):133–8, 141–4, 150–3 (21 ref.)
New antiepileptic drugs. Overcoming the limitations of traditional therapy. Sirven JI, et al. **Postgrad Med** 1997 Jul;102(1):147–50, 155, 159–60 passim (19 ref.)
Alprazolam dependence prevented by substituting with the beta–carboline abecarnil. Pinna G, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2719–23
Epalons as anticonvulsants: actions mediated by the GABAA receptor complex. Gee KW. **Proc West Pharmacol Soc** 1996;39:55
Effect of gabapentin (Neurontin) [corrected] on mood and well–being in patients with epilepsy [published erratum appears in Prog Neuropsychopharmacol Biol Psychiatry 1996 Aug;20(6):1081] Dimond KR, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Apr; 20(3):407–17
Psychopharmacologic treatment of pathologic aggression. Fava M. **Psychiatr Clin North Am** 1997 Jun;20(2):427–51 (176 ref.)
Oral administration of glycine and polyamine receptor antagonists blocks ethanol withdrawal seizures. Kotlinska J, et al. **Psychopharmacology (Berl)** 1996 Oct;127(3):238–44
The place of anticonvulsant therapy in bipolar illness. Post RM, et al. **Psychopharmacology (Berl)** 1996 Nov; 128(2):115–29 (160 ref.)
The Eclampsia trial, a model of international collaborative study with worldwide benefits [editorial] Atallah AN. **Rev Paul Med** 1995 Jul–Aug;113(4):927–8
Monotherapy antiepileptic drug trials in patients undergoing presurgical assessment: methodological problems and possibilities. Alarcon G, et al. **Seizure** 1995 Dec; 4(4):293–301
Absence epilepsy in children: the role of EEG in monitoring response to treatment. Appleton RE, et al. **Seizure** 1996 Jun;5(2):147–8
Managing the teenager with epilepsy: paediatric to adult care. Appleton RE, et al. **Seizure** 1997 Feb;6(1):27–30
Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. French Neurologists Sabril Study Group. Arzimanoglou AA, et al. **Seizure** 1997 Jun; 6(3):225–31
Established antiepileptic drugs. Brodie MJ, et al. **Seizure** 1997 Jun;6(3):159–74 (104 ref.)
Lamotrigine: clinical experience in 200 patients with epilepsy with follow–up to four years. Buchanan N. **Seizure** 1996 Sep;5(3):209–14
The use of lamotrigine in juvenile myoclonic epilepsy. Buchanan N. **Seizure** 1996 Jun;5(2):149–51
Mechanisms of action of antiepileptic drugs. Davies JA. **Seizure** 1995 Dec;4(4):267–71 (28 ref.)
Long–term outcomes of conventional therapy for infantile spasms. Holden KR, et al. **Seizure** 1997 Jun;6(3):201–5
Epilepsy in a children's hospital: an out–patient survey. Hughes AP, et al. **Seizure** 1995 Dec;4(4):279–85
A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy [see comments] Hughes D, et al. **Seizure** 1996 Jun; 5(2):89–95 (38 ref.). Comment in: Seizure 1996 Sep;5(3):247–8.
Basic haematological parameters, serum gamma–glutamyl–transferase activity, and erythrocyte folate and serum vitamin B12 levels during carbamazepine and oxcarbazepine therapy. Isojärvi JI, et al. **Seizure** 1997 Jun;6(3):207–11
An audit of the new antiepileptic drugs in clinical neurological practice. McDonnell GV, et al. **Seizure** 1996 Jun;5(2):127–30
Tiagabine and non–convulsive status epilepticus. Schapel G, et al. **Seizure** 1996 Jun;5(2):153–6
A survey comparing lamotrigine and vigabatrin in everyday clinical practice. Schapel G, et al. **Seizure** 1996 Dec; 5(4):267–70
New antiepileptic drug trials in developing countries: are they necessary? Walker MC, et al. **Seizure** 1996 Sep;5(3):165–9 (35 ref.)
Topiramate: a new antiepileptic drug for refractory epilepsy. Walker MC, et al. **Seizure** 1996 Sep;5(3):199–203 (33 ref.)
New antiepileptic drugs: case studies. Bannister SM, et al. **Semin Pediatr Neurol** 1997 Mar;4(1):64–7
Felbamate. Bourgeois BF. **Semin Pediatr Neurol** 1997 Mar; 4(1):3–8 (27 ref.)
Lamotrigine in childhood epilepsies. Dreifuss FE. **Semin Pediatr Neurol** 1997 Mar;4(1):19–23 (40 ref.)
Topiramate. Glauser TA. **Semin Pediatr Neurol** 1997 Mar; 4(1):34–42 (44 ref.)
New drug therapy for acute seizure management. Morton LD, et al. **Semin Pediatr Neurol** 1997 Mar;4(1):51–63 (76 ref.)
New antiepileptic drugs in children: present and future. Pellock JM, et al. **Semin Pediatr Neurol** 1997 Mar;4(1):9–18 (92 ref.)
Pediatric epilepsy in the 1990s. Pellock JM. **Semin Pediatr Neurol** 1997 Mar;4(1):1–2 (6 ref.)
Vigabatrin. Shields WD, et al. **Semin Pediatr Neurol** 1997 Mar;4(1):43–50 (37 ref.)
Tiagabine. Shinnar S. **Semin Pediatr Neurol** 1997 Mar; 4(1):24–33 (57 ref.)
Sudden arousals from slow wave sleep and panic disorder: successful treatment with anticonvulsants––a case report. Dantendorfer K, et al. **Sleep** 1996 Nov;19(9):744–6
Comparison of cognitive–behavioral therapy and clonazepam for treating periodic limb movement disorder. Edinger JD, et al. **Sleep** 1996 Jun;19(5):442–4
Management of restless legs syndrome with gabapentin (Neurontin) [letter] Mellick GA, et al. **Sleep** 1996 Apr; 19(3):224–6
Carbamazepine as a treatment for cataplexy. Vaughn BV, et al. **Sleep** 1996 Feb;19(2):101–3
Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances. Chapman DP, et al. **South Med J** 1997 May;90(5):471–80 (97 ref.)
Recent advancements in epilepsy. Wyler AR, et al. **Surg Neurol** 1997 Aug;48(2):106–9 (06 ref.)
Preventing post–traumatic epilepsy after brain injury: weighing the costs and benefits of anticonvulsant prophylaxis. Hernandez TD. **Trends Pharmacol Sci** 1997 Feb;18(2):59–62 (50 ref.)
[Treatment of convulsions in newborn infants (letter; comment)] Groenendaal F, et al. **Ned Tijdschr Geneeskd** 1996 Oct 26;140(43):2146–7. Comment on: Ned Tijdschr Geneeskd 1996 Jul 27;140(30):1557–60. **(Dut)**
[Severe preeclampsia: management. Is conservative treatment justified?] Merviel P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(3):238–49 (61 ref.) (Eng. Abstr.) **(Fre)**
[Magnesium sulfate in obstetrics: finally recognized! (editorial)] Treisser A. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(2):120–2 (8 ref.) **(Fre)**
[How I treat... epilepsy] Sadzot B. **Rev Med Liege** 1996 Sep; 51(9):557–61 **(Fre)**
[Therapeutic options provided by new antiepileptic drugs] Baulac M, et al. **Rev Neurol (Paris)** 1997 Feb;155(1):21–33 (140 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of juvenile myoclonic epilepsy with low–dose sodium valproate] De Toffol B, et al. **Rev Neurol (Paris)** 1996 Nov;152(11):708–10 (Eng. Abstr.) **(Fre)**
[Valproate i.v. Survey of its clinical application] **Dtsch Med Wochenschr** 1997 Jul;122(28–29 Suppl):1–8 **(Ger)**
[Anticonvulsant treatment in old age––principles and differential indications] Hetzel W. **Fortschr Neurol Psychiatr** 1997 Jun;65(6):261–77 (144 ref.) (Eng. Abstr.) **(Ger)**
[Modern therapy of epilepsy. Proven or innovative drugs?] Schmidt D. **Med Monatsschr Pharm** 1996 Aug;19(8):226–31 (13 ref.) **(Ger)**
[Gabapentin––a new anti–epileptic agent] **Nervenarzt** 1994 Jun;65(6 Suppl):1–8 **(Ger)**
[Therapy of the status epilepticus] **Nervenarzt** 1994 Jan;65(1

Suppl [therapie]):1–8 **(Ger)**
[Gabapentine—advances in the management of epilepsy] **Nervenarzt** 1994 Nov;65(11 Suppl):1–8 **(Ger)**
[Topiramate—a new anti-epileptic agent] **Nervenarzt** 1996 Feb;67(2 Suppl):1–8 **(Ger)**
[Successful carbamazepine therapy of 2 cases of music hallucinations] Gertz HJ, et al. **Nervenarzt** 1996 May; 67(5):387–9 (Eng. Abstr.) **(Ger)**
[Benzodiazepine withdrawal with carbamazepine] Kaendler SH, et al. **Nervenarzt** 1996 May;67(5):381–6 (Eng. Abstr.) **(Ger)**
[Topiramate: a broad-spectrum antiepileptic drug? Sixth meeting of the European Neurological Society. Den Haag, 8 June 1996] **Psychiatr Prax** 1996 Sep;23(5 Suppl):1–8 **(Ger)**
[Lamotrigine—a new antiepileptic drug for the treatment of epilepsy in childhood] Lahat E. **Harefuah** 1997 Feb 16; 132(4):290–3 **(Heb)**
[New antiepileptic drugs: a review and personal contribution] de Romanis F, et al. **Clin Ter** 1996 May;147(5):217–37 (173 ref.) (Eng. Abstr.) **(Ita)**
[Drug-resistant epilepsy treated with ketogenic diet] Tagliabue A, et al. **Recenti Prog Med** 1997 Feb;88(2):77–9 (Eng. Abstr.) **(Ita)**
[Implications of the International Classification of Seizures and Syndromes in the management of epilepsy] Watanabe K. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Feb; 17(1):39–43 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Outcome of initial treatment with high-dose vitamin B6, valproate sodium or clonazepam in West syndrome] Suzuki Y, et al. **No To Hattatsu** 1996 Sep;28(5):398–402 (Eng. Abstr.) **(Jpn)**
[Case report of sodium valproate treatment of aggression associated with Alzheimer's disease] Takahashi M, et al. **No To Shinkei** 1996 Aug;48(8):757–60 (Eng. Abstr.) **(Jpn)**
[Open randomized comparative trial of sodium valproate and carbamazepine in adult onset epilepsy] Czapiński P, et al. **Neurol Neurochir Pol** 1996 May–Jun;30(3):419–26 (Eng. Abstr.) **(Pol)**
[Effect of phenytoin and carbamazepine on evoked potentials in patients with newly diagnosed epilepsy. Part I. Visual evoked potentials] Rysz A, et al. **Neurol Neurochir Pol** 1996 Nov–Dec;30(6):961–9 (Eng. Abstr.) **(Pol)**
[Effect of phenytoin and carbamazepine on evoked potentials in patients with newly diagnosed epilepsy. Part II. Brainstem auditory evoked potentials] Rysz A, et al. **Neurol Neurochir Pol** 1996 Nov–Dec;30(6):971–9 (Eng. Abstr.) **(Pol)**
[Differential combined drug therapy of phantom pain syndrome after amputation of extremity] Kukushkin ML, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):39–42 (Eng. Abstr.) **(Rus)**
[The effect of lamotrigine and carbamazepine on the development of the audiogenic seizure reaction in rats of the Krushinskii–Molodkina strain] Fedotova IB, et al. **Eksp Klin Farmakol** 1996 Nov–Dec;59(6):6–9 (Eng. Abstr.) **(Rus)**
[The effect of perftoran on the resistance of mice to GABA receptor antagonists and on the antidote activity of anticonvulsant agents] Golovko AI, et al. **Eksp Klin Farmakol** 1996 Nov–Dec;59(6):34–7 (Eng. Abstr.) **(Rus)**
[Xanthurenic acid inhibits the activity of an experimental epileptogenic focus in the rat hippocampus] Mikhailov IB, et al. **Eksp Klin Farmakol** 1997 Mar–Apr;60(2):7–9 (Eng. Abstr.) **(Rus)**
[The cardioprotective action of the anticonvulsant preparation sodium valproate in disorders of cardiac contractile function caused by acute myocardial infarct in rats] Belkina LM, et al. **Patol Fiziol Eksp Ter** 1997 Apr–Jun; (2):18–21 (Eng. Abstr.) **(Rus)**
[The effect of enkorat on the course of epilepsy in children] Badalian LO, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(4):104–5 **(Rus)**
[The duration of antiepileptic treatment] Miakotnykh VS. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(2):30–3 (Eng. Abstr.) **(Rus)**
[The effect of difenin, valproate and phenobarbital on the development of an epileptiform seizure attack in Krushinskii–Molodkina rats] Fedotova IB, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Nov–Dec; 46(6):1104–8 (Eng. Abstr.) **(Rus)**
[The diagnosis and treatment of partial epilepsy in childhood and adolescence] Martinez Bermejo Z, et al. **Neurologia** 1996 Dec;11 Suppl 4:58–71 (178 ref.) (Eng. Abstr.) **(Spa)**
[Trigeminal neuralgia: new therapeutic possibilities (letter; comment)] Vaamonde J, et al. **Neurologia** 1997 Jun–Jul; 12(6):272. Comment on: Neurologia 1997 Jan;12(1):12–22. **(Spa)**
[Treatment of neurological complications: cerebral edema and epileptic seizures] Vivancos Mora J. **Neurologia** 1995 Dec;10 Suppl 2:23–9 (67 ref.) (Eng. Abstr.) **(Spa)**
[Which drugs should be chosen for the different types of epilepsy?] Armijo JA. **Rev Neurol** 1997 Mar;25(139):356–66 (96 ref.) (Eng. Abstr.) **(Spa)**
[When should long-term treatment of epilepsy be started] Campistol J. **Rev Neurol** 1997 Mar;25(139):350–5 (34 ref.) (Eng. Abstr.) **(Spa)**
[When and how should the long-term anti-epileptic treatment be stopped] Caviedes BE, et al. **Rev Neurol** 1997 Mar;25(139):372–8 (79 ref.) (Eng. Abstr.) **(Spa)**
[Neonatal seizures: the beginning and interruption of the treatment] Koenigsberger MR, et al. **Rev Neurol** 1997 May; 25(141):706–8 (28 ref.) (Eng. Abstr.) **(Spa)**
[Congenital hyperekplexia as a cause of neonatal hypertonia] Lobera E, et al. **Rev Neurol** 1997 Jan;25(137):86–8 (Eng. Abstr.) **(Spa)**
[Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients] López-Valdés E, et al. **Rev Neurol** 1996 Oct;24(134):1255–7 (Eng. Abstr.) **(Spa)**
[Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients] Navarro-Quesada FJ, et al. **Rev Neurol** 1997 Jul; 25(143):1037–44 (Eng. Abstr.) **(Spa)**
[New antiepileptic drugs] Padró L, et al. **Rev Neurol** 1997 Feb;25(138):291–4 (26 ref.) **(Spa)**
[Intercritical SPECT in drug-resistant partial epilepsy with normal MRI: a study of 33 cases] Vidal JA, et al. **Rev Neurol** 1997 Jan;25(137):48–55 (33 ref.) (Eng. Abstr.) **(Spa)**
[How often and what type of control tests should be done during long- term anti-epileptic treatment?] Viteri C, et al. **Rev Neurol** 1997 Mar;25(139):367–71 (43 ref.) (Eng. Abstr.) **(Spa)**
[Drug analysis during epilepsy treatment is valuable] Tomson T. **Lakartidningen** 1997 Jun 25;94(26–27):2461–4 (22 ref.) (Eng. Abstr.) **(Swe)**

TOXICITY

Observation of hepatotoxic effects of 2-n-pentylaminoacetamide (Milacemide) in rat liver by a combined in vivo/in vitro approach. Rogiers V, et al. **Arch Toxicol** 1997;71(5):271–82
Induction of microsomal epoxide hydrolase activity in inbred mice by chronic phenytoin exposure. Hartsfield JK Jr, et al. **Biochem Mol Med** 1995 Dec;56(2):144–51
Phenytoin embryopathy: effect of epoxide hydrolase inhibitor on phenytoin exposure in utero in C57BL/6J mice. Hartsfield JK Jr, et al. **Biochem Mol Med** 1995 Dec; 56(2):131–43
Carbamazepine induction of apoptosis in cultured cerebellar neurons: effects of N-methyl-D-aspartate, aurintricarboxylic acid and cycloheximide. Gao XM, et al. **Brain Res** 1995 Dec 12;703(1–2):63–71
Phenytoin-induced hyperglycaemia may confound rat cerebroprotection models. Qi H, et al. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):893–7
Low-dose vigabatrin (gamma-vinyl GABA)-induced damage in the immature rat brain. Sidhu RS, et al. **Exp Neurol** 1997 Apr;144(2):400–5
A rapid in vitro assay for evaluation of metabolism-dependent cytotoxicity of antiepileptic drugs on isolated human lymphocytes. Tabatabaei AR, et al. **Fundam Appl Toxicol** 1997 Jun;37(2):181–9
Valproate-induced developmental modifications maybe partially prevented by coadministration of folinic acid and S-adenosylmethionine. Ubeda N, et al. **Int J Dev Biol** 1996; Suppl 1:291S–292S
Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible molecular mechanism of drug-induced gingival hyperplasia. Iacopino AM, et al. **J Periodontol** 1997 Jan; 68(1):73–83
Teratogenicity of carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouse. Bennett GD, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1237–42
UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin. Kim PM, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):200–9
Developmental and behavioral effects of prenatal primidone exposure in the rat. Pizzi WJ, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):481–7
Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury. Raza M, et al. **Pharmacol Res** 1997 Feb;35(2):153–7
Binding of pinoline on the 5-hydroxytryptamine transporter: competitive interaction with [3H] citalopram. Pähkla R, et al. **Pharmacol Toxicol** 1997 Mar;80(3):122–6
Lithium and valproate combined administration: acute behavioural effects and drug plasma levels. Vargas C, et al. **Pharmacol Toxicol** 1996 Aug;79(2):87–91
Effect of retinoic acid and valproate on sea urchin development. Sconzo G, et al. **Pharmazie** 1996 Mar; 51(3):175–80
Sodium valproate augments spontaneous neural tube defects and axial skeletal malformations in TO mouse fetuses [corrected] [published erratum appears in Reprod Toxicol 1996 Nov–Dec;10(6):VI] Padmanabhan R, et al. **Reprod Toxicol** 1996 Sep–Oct;10(5):345–63
Valproate-induced limb malformations in mice associated with reduction of intracellular pH. Scott WJ Jr, et al. **Reprod Toxicol** 1997 Jul–Aug;11(4):483–93
Effects of the antiepileptic drug valproic acid on the development of the axolotl (Ambystoma mexicanum): histological investigations. Krätke R, et al. **Teratog Carcinog Mutagen** 1996;16(3):149–67
Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Menegola E, et al. **Teratog Carcinog Mutagen** 1996;16(2):97–108
Teratogenic effects of vigabatrin in TO mouse fetuses. Abdulrazzaq YM, et al. **Teratology** 1997 Mar;55(3):165–76
Phenytoin causes phalangeal hypoplasia in the rabbit fetus at clinically relevant free plasma concentrations. Danielsson BR, et al. **Teratology** 1995 Nov;52(5):252–9
Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo. Hansen DK, et al. **Teratology** 1995 Nov;52(5):277–85

URINE

Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. Tassaneeyakul W, et al. **Br J Clin Pharmacol** 1996 Dec; 42(6):774–8
Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry. Maggs JL, et al. **Drug Metab Dispos** 1997 Mar;25(3):275–80

ANTIDEPRESSANTS see **ANTIDEPRESSIVE AGENTS**

ANTIDEPRESSANTS, ATYPICAL see **ANTIDEPRESSIVE AGENTS, SECOND-GENERATION**

ANTIDEPRESSANTS, TRICYCLIC see **ANTIDEPRESSIVE AGENTS, TRICYCLIC**

ANTIDEPRESSIVE AGENTS

see related

MONOAMINE OXIDASE INHIBITORS

Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Goldberg RJ. **Drugs Aging** 1997 Aug;11(2):119–31 (86 ref.)
Sales of tranquillizers, hypnotics/sedatives and antidepressants and their relationship with underprivileged area score and mortality and suicide rates. Sundquist J, et al. **Eur J Clin Pharmacol** 1996;51(2):105–9
Abuse of sertraline [letter] D'Urso P. **J Clin Pharm Ther** 1996 Oct;21(5):359–60
Are benzodiazepines antidepressants? [letter] Laakmann G, et al. **Psychopharmacology (Berl)** 1996 Apr;124(3):291–2
[Biological study of anxiety and depression and the application for the pharmacological study] Yamamoto T, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):147–9 (6 ref.) **(Jpn)**
[Happy pills with a funny taste. Some reflections on a clinical paradox] Haakenaasen K. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1168–9 **(Nor)**
[Illegal sale of new antidepressive agents (letter)] Nilsen WJ. **Tidsskr Nor Laegeforen** 1997 Apr 10;117(9):1334–5 **(Nor)**
[Misleading facts in an advertisement of an antidepressive agent (letter)] Mattsson B. **Lakartidningen** 1997 Mar 19; 94(12):1051–2 **(Swe)**

ADMINISTRATION & DOSAGE

An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Thakore JH, et al. **Acta Psychiatr Scand** 1996 Sep;94(3):194–7
Antidepressant treatment of posttraumatic stress disorder and major depression in veterans. Dow B, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):1–5
Pergolide to augment the effectiveness of antidepressants: clinical experience and a small double-blind study. Mattes JA. **Ann Clin Psychiatry** 1997 Jun;9(2):87–8
Buprenorphine for depression: the un-adoptable orphan [editorial] Callaway E. **Biol Psychiatry** 1996 Jun 15; 39(12):989–90
Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Inoue T, et al. **Biol Psychiatry** 1996 Jul 15;40(2):151–3
Prescribing antidepressants in general practice. What is an effective dose? [letter; comment] Fish D. **BMJ** 1997 Mar 15;314(7083):826. Comment on: BMJ 1996 Oct 5;313(7061):829–30.
Prescribing antidepressants in general practice. Systematic review of all pertinent trials is required to establish guidelines [letter; comment] Gill D. **BMJ** 1997 Mar 15; 314(7083):826–7. Comment on: BMJ 1996 Oct 5;313(7061):829–30.
Patients receive an inadequate dose of antidepressants for an inadequate period [letter; comment] MacDonald TM, et al. **BMJ** 1997 Jul 5;315(7099):56. Comment on: BMJ 1997 Mar 15;314(7083):826. Comment on: BMJ 1997 Mar 15;314(7083):827. Comment on: BMJ 1997 Mar 15;314(7083):827–8.
A preliminary study to examine the adequacy of long-term treatment of depression and the extent of recovery in general practice. Hawley CJ, et al. **Br J Gen Pract** 1997 Apr;47(417):233–4
The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Donoghue JM, et al. **Br J Psychiatry** 1996 Feb;168(2):164–8
Augmentation strategies in patients with refractory depression. Nemeroff CB. **Depress Anxiety** 1996–97; 4(4):169–81 (95 ref.)
Long-term treatment of depression: is there a use for depot antidepressants? Baumann P, et al. **Int Clin Psychopharmacol** 1997 Mar;12(2):77–80 (33 ref.)
Minimum effective dose for antidepressants—an obligatory

requirement for antidepressant drug evaluation? Benkert O, et al. **Int Clin Psychopharmacol** 1996 Sep;11(3):177–85 (60 ref.)

Long–term treatment of elderly individuals with emotional disturbances: an open study with citalopram. Ragneskog H, et al. **Int Psychogeriatr** 1996 Winter;8(4):659–68

Compliance during treatment with antidepressants. Demyttenaere K. **J Affect Disord** 1997 Mar;43(1):27–39 (88 ref.)

The effect of sequential antidepressant treatment on geriatric depression. Flint AJ, et al. **J Affect Disord** 1996 Jan 22; 36(3–4):95–105

Does the duration of illness before treatment affect the time taken to recover on treatment in severely depressed women? Wilkinson P, et al. **J Affect Disord** 1996 Nov 25; 41(2):89–92

A double–blind, placebo–controlled study of citalopram with and without lithium in the treatment of therapy–resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. Baumann P, et al. **J Clin Psychopharmacol** 1996 Aug;16(4):307–14

Pindolol augmentation of tranylcypromine in psychotic depression [letter] Kraus RP. **J Clin Psychopharmacol** 1997 Jun;17(3):225–6

Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors. Kennedy SH. **J Psychiatry Neurosci** 1997 Mar; 22(2):127–31 (34 ref.)

A "therapeutic window" with citalopram in a case of depression [letter] Benazzi F. **Pharmacopsychiatry** 1996 Jan; 29(1):42

Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy–resistant depression. König F, et al. **Pharmacopsychiatry** 1997 Jul; 30(4):125–7

Psychiatrists' responses to failure of maintenance therapy with antidepressants. Byrne S, et al. **Psychiatr Serv** 1997 Jun;48(6):835–7

A double–blind trial of low– and high–dose ranges of gepirone–ER compared with placebo in the treatment of depressed outpatients. Wilcox CS, et al. **Psychopharmacol Bull** 1996;32(3):335–42

Twelve–hour brain lithium concentration in lithium maintenance treatment of manic–depressive disorder: daily versus alternate–day dosing schedule. Jensen HV, et al. **Psychopharmacology (Berl)** 1996 Apr;124(3):275–8

A double–blind, randomized, fixed–dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Taragano FE, et al. **Psychosomatics** 1997 May–Jun;38(3):246–52

[Treatment with selective and reversible monoamine oxidase inhibitors in depressed patients: is there a biological effect proportional to the dose?] Radat F, et al. **Ann Med Psychol (Paris)** 1996 Jun;154(3):204–6 **(Fre)**

[Evaluation by poison control centers of minaprine from the modification of tablet dosages] Jouglard J, et al. **Therapie** 1996 Sep–Oct;51(5):582–5 (Eng. Abstr.) **(Fre)**

[Recognizing and treating depression. 2: Drug therapy—psychotherapy—phased prevention] Riemann D. **Fortschr Med** 1996 Nov 20;114(32):437–8 **(Ger)**

[Hypericum perforatum in psychiatric practice (interview)] Kasper S. **Nervenarzt** 1997 Feb;68(2 Suppl):8 **(Ger)**

[High dosage tranylcypromine treatment of "therapy refractory" depressions] Schmauss M. **Nervenarzt** 1996 May;67(5):390–3 (Eng. Abstr.) **(Ger)**

[Survey and treatment strategy of antidepressant–resistant depression] Inoue T, et al. **Seishin Shinkeigaku Zasshi** 1996; 98(5):329–42 (Eng. Abstr.) **(Jpn)**

[Possibilities of correcting adverse effects of anti–arrhythmia agents] Skibitskiĭ VV, et al. **Vestn Ross Akad Med Nauk** 1996;(5):9–12 (Eng. Abstr.) **(Rus)**

[The number of individuals with prescribed antidepressive agents has doubled (letter; comment)] Ekedahl A. **Lakartidningen** 1996 Dec 4;93(49):4528. Comment on: Lakartidningen 1996 Nov 6;93(45):4000–2. **(Swe)**

[Increased use of antidepressive agents. A correctly aimed development] Isacsson G, et al. **Lakartidningen** 1997 Apr 16;94(16):1484–6 (46 ref.) **(Swe)**

[No relation between antidepressive agents and suicide is not necessarily a sign of ineffective treatment] Rutz W, et al. **Lakartidningen** 1997 Aug 20;94(34):2838–40 **(Swe)**

ADVERSE EFFECTS

Successful treatment of citalopram–induced anorgasmia by cyproheptadine. Lauerma H. **Acta Psychiatr Scand** 1996 Jan;93(1):69–70

Antidepressant withdrawal reactions. Wolfe RM. **Am Fam Physician** 1997 Aug;56(2):455–62 (50 ref.)

Antidepressant–induced manic switches [letter] Furukawa T. **Am J Psychiatry** 1996 Oct;153(10):1370

Heat intolerance induced by antidepressants. Epstein Y, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:553–8

Possible serotonin syndrome associated with tramadol and sertraline coadministration. Mason BJ, et al. **Ann Pharmacother** 1997 Feb;31(2):175–7

SIADH—compulsive drinking or SSRI influence? [letter] Robinson D, et al. **Ann Pharmacother** 1996 Jul–Aug; 30(7–8):885

Lithium–induced neurotoxicity at serum lithium levels within the therapeutic range. Arya DK. **Aust N Z J Psychiatry** 1996 Dec;30(6):871–3

Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Dailey JW, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1323–9 (65 ref.)

A case of paroxetine–induced akathisia. [letter] Olivera AA. **Biol Psychiatry** 1996 May 15;39(10):910

The Pisa syndrome (pleurothotonus) during antidepressant therapy. Suzuki T, et al. **Biol Psychiatry** 1997 Jan 15; 41(2):234–6

High rate of antidepressant treatment in elderly people who commit suicide. Waern M, et al. **BMJ** 1996 Nov 2; 313(7065):1118

Antidepressant therapy and behavioural competence. O'Hanlon JF. **Br J Clin Pract** 1996 Oct–Nov;50(7):381–5 (36 ref.)

Lithium and weight gain [letter] Armond AD. **Br J Psychiatry** 1996 Aug;169(2):251–2

Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia. Skeith KJ, et al. **Clin Rheumatol** 1997 May;16(3):291–5

Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Rosholm JU, et al. **Eur J Clin Pharmacol** 1997;52(3):205–9

Antidepressant induced mania in obsessive compulsive disorder. Berk M, et al. **Eur Neuropsychopharmacol** 1996 Mar;6(1):9–11

The role of sertraline in a patient with recurrent hyponatremia. Catalano G, et al. **Gen Hosp Psychiatry** 1996 Jul;18(4):278–83 (24 ref.)

Citalopram–associated clitoral priapism: a case series. Berk M, et al. **Int Clin Psychopharmacol** 1997 Mar;12(2):121–2

Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients. Ramaekers JG, et al. **Int Clin Psychopharmacol** 1997 May; 12(3):159–69

Antidepressant–induced hypomania in obsessive–compulsive disorder. Rihmer Z, et al. **Int Clin Psychopharmacol** 1996 Sep;11(3):203–5

Signal–averaged ECG in patients with antidepressant therapy. Mladosievicova B, et al. **Int J Cardiol** 1996 Apr 19;54(1):27–31

Immunologic effects of psychotropic drugs in HIV+ patients [letter] Rabkin JG, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 15;13(5):465–7

SSRI and sexual functioning [letter] Carek DJ. **J Am Acad Child Adolesc Psychiatry** 1996 Sep;35(9):1106–7

Medication–induced seizures [letter] Feeney DJ, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Aug;36(8):1018–9

Sertraline–induced behavioral activation during the treatment of an adolescent with major depression. Guilé JM. **J Child Adolesc Psychopharmacol** 1996 Winter;6(4):281–5 (10 ref.)

Lithium associated autoimmune thyroiditis. Shimizu M, et al. **J Clin Pathol** 1997 Feb;50(2):172–4

Sexual dysfunction and antidepressants. **J Clin Psychiatry** 1996 Dec;57(12):suppl 1–12

Antidepressant noncompliance as a factor in the discontinuation syndrome. Kaplan EM. **J Clin Psychiatry** 1997;58 Suppl 7:31–5; discussion 36

Antidepressant discontinuation: a review of the literature. Lejoyeux M, et al. **J Clin Psychiatry** 1997;58 Suppl 7:11–5; discussion 16 (39 ref.)

Clinical management of antidepressant discontinuation. Rosenbaum JF, et al. **J Clin Psychiatry** 1997;58 Suppl 7:37–40 (13 ref.)

Physicians' knowledge of antidepressant withdrawal effects: a survey. Young AH, et al. **J Clin Psychiatry** 1997;58 Suppl 7:28–30

Two cases of hair loss after sertraline use [letter] Bourgeois JA. **J Clin Psychopharmacol** 1996 Feb;16(1):91–2

A case of sertraline–induced stuttering [letter] Christensen RC, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):92–3

Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression. Hardy BG, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):22–6

Selective serotonin reuptake inhibitor–induced serotonin syndrome: review. Lane R, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):208–21 (149 ref.)

Patient prescribed sertraline charged with driving under the influence [letter] Lock J. **J Clin Psychopharmacol** 1997 Feb; 17(1):61

Comments on "Thrombocytopenia and delirium associated with tranylcypromine overdose" [letter; comment] Munjack DJ, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):264–5. Comment on: J Clin Psychopharmacol 1995 Apr;15(2):143–4.

Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy [letter] Benazzi F. **J Psychopharmacol (Oxf)** 1997;11(2):190–1

Antidepressants a turn–off for many patients [news] **J Psychosoc Nurs Ment Health Serv** 1996 Aug;34(8):7

Treatment of antidepressant–induced sexual side effects. Assalian P, et al. **J Sex Marital Ther** 1996 Fall;22(3):218–24

Anticholinergic overdose induced torsade de pointes successfully treated with verapamil. Liao WB, et al. **Jpn Heart J** 1996 Nov;37(6):925–31

CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side–effects. Vandel P, et al. **Med Hypotheses** 1996 Dec;47(6):439–42 (35 ref.)

Nephrogenic diabetes insipidus in a lethargic lithium–treated patient. Meinardi JR, et al. **Neth J Med** 1997 Mar; 50(3):105–9

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Richard IH, et al. **Neurology** 1997 Apr;48(4):1070–7

Nonconvulsive status epilepticus during antidepressant treatment. Yoshino A, et al. **Neuropsychobiology** 1997; 35(2):91–4

Orthostatic hypotension induced by sertraline withdrawal. Amsden GW, et al. **Pharmacotherapy** 1996 Jul–Aug; 16(4):684–6

Sertraline–associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature. Bradley ME, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):680–3 (24 ref.)

Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions. Spigset O, et al. **Pharmacotherapy** 1997 Mar–Apr; 17(2):348–52

Sertraline–induced agranulocytosis [letter] Trescoli–Serrano C, et al. **Postgrad Med J** 1996 Jul;72(849):446

The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). McElhatton PR, et al. **Reprod Toxicol** 1996 Jul–Aug;10(4):285–94

Response of patients with major depression and silent cerebral infarction to antidepressant drug therapy, with emphasis on central nervous system adverse reactions. Fujikawa T, et al. **Stroke** 1996 Nov;27(11):2040–2

Galactorrhoea induced by a pharmacodynamic interaction between citalopram, alprazolam and tramadol: a case report [letter] Bondolfi G, et al. **Therapie** 1997 Jan–Feb;52(1):76–7

Serotonin syndrome from venlafaxine–tranylcypromine interaction. Brubacher JR, et al. **Vet Hum Toxicol** 1996 Oct;38(5):358–61

Neonatal lithium toxicity as a result of maternal toxicity. Flaherty B, et al. **Vet Hum Toxicol** 1997 Apr;39(2):92–3

[Therapy and nursing (letter)] Iversen M. **Ugeskr Laeger** 1997 Feb 10;159(7):968 **(Dan)**

[Serotonin syndrome: critical review of the literature] Baubet T, et al. **Rev Med Interne** 1997;18(5):380–7 (60 ref.) (Eng. Abstr.) **(Fre)**

[Pharmacovigilance of new antidepressants: evaluation of neuro–psychobehavioral disorders] Blayac JP, et al. **Therapie** 1997 Mar–Apr;52(2):117–22 (Eng. Abstr.) **(Fre)**

[Neuroleptic malignant syndrome from treatment with antidepressives] Heinemann F, et al. **Fortschr Neurol Psychiatr** 1997 May;65(5):208–13 (34 ref.) (Eng. Abstr.) **(Ger)**

[Reversible increase in photosensitivity to UV–B caused by St. John's wort extract] Golsch S, et al. **Hautarzt** 1997 Apr;48(4):249–52 (Eng. Abstr.) **(Ger)**

[Mianserin–induced hypertension 2 weeks after discontinuation of tranylcypromine] Bottlender R, et al. **Nervenarzt** 1997 Jul;68(7):591–2 (Eng. Abstr.) **(Ger)**

[Multimodal iatrogenic apathy] Oliveira–Souza RD, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):216–21 (Eng. Abstr.) **(Por)**

[Are depressive states "sick" or "healthy"? Correct therapy may be blocked by antidepressive agents] Cullberg J. **Lakartidningen** 1996 Nov 13;93(46):4177–8, 4181–2 **(Swe)**

[Suicide and SSRI preparations. Antidepressive agents without psychotherapy are more hazardous than beneficial] Cullberg J. **Lakartidningen** 1997 Apr 9;94(15):1409–11 **(Swe)**

ANALYSIS

The GCMS analysis of tranylcypromine (Parnate) in a suspected overdose. Crifasi J, et al. **Forensic Sci Int** 1997 Apr 18;86(1–2):103–8

Hair analysis for drugs of abuse. XVI. Disposition of fenethylline and its metabolite into hair and discrimination between fenethylline use and amphetamine use by hair analysis. Kikura R, et al. **J Anal Toxicol** 1997 Jul–Aug; 21(4):291–6

[The analysis of grandaksin in cadaveric material] Bodrina DE, et al. **Sud Med Ekspert** 1996 Oct–Dec;39(4):45–7 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Nakagawa Y, et al. **Brain Res** 1996 Feb 19;709(2):215–20

BLOOD

High–performance liquid chromatographic–ultraviolet assay for the simultaneous quantitation of BMS–181101 and its putative hydroxy metabolites in rat and monkey plasma. Shah VR, et al. **Biomed Chromatogr** 1996 May–Jun; 10(3):135–8

Stereoselective determination of a new antidepressant, E2011, and its diastereoisomer as a metabolite by high–performance liquid chromatography. Naitoh T, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20;694(1):153–61

Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy–resistant depression. König F, et al. **Pharmacopsychiatry** 1997 Jul;

30(4):125–7
Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Leinonen E, et al. **Pharmacopsychiatry** 1996 Jul;29(4):156–8

CEREBROSPINAL FLUID

CSF inositol does not predict antidepressant response to inositol. Short communication. Levine J, et al. **J Neural Transm** 1996;103(12):1457–62

CHEMICAL SYNTHESIS

Synthesis and pharmacological profile of bicyclo[2.2.2]octane derivatives: N-(1-aryl-4-piperazinyl-butyl) derivatives of 7-isopropyl-6-methyl- and 1-isopropyl-4-methylbicyclo[2.2.2]oct-5-ene-2,3-dicarboxyimide. Zawadowski T, et al. **Acta Pol Pharm** 1995 Mar-Apr;52(2):129–32
Dibenz[b,f]azepines, Part 7. Synthesis of new, potentially CNS active dibenz[b,f]azepine derivatives. Haász F, et al. **Arch Pharm (Weinheim)** 1996 Dec;329(12):551–3
An efficient chemoenzymatic route to the antidepressants (R)-fluoxetine and (R)-tomoxetine. Bracher F, et al. **Bioorg Med Chem** 1996 Jun;4(6):877–80
Synthesis of [11C]dapoxetine.HCl, a serotonin re-uptake inhibitor: biodistribution in rat and preliminary PET imaging in the monkey. Livni E, et al. **Nucl Med Biol** 1994 May;21(4):669–75
Synthesis, conformational analysis and antidepressant activity of moclobemide new analogues. Ghanbarpour A, et al. **Pharm Acta Helv** 1997 Apr;72(2):119–22

CHEMISTRY

Improved CEDIA benzodiazepine assay eliminates sertraline crossreactivity. Fitzgerald RL, et al. **J Anal Toxicol** 1997 Jan-Feb;21(1):32–5
[Chemical composition of Hypericum perforatum and its effects] **Nervenarzt** 1997 Feb;68(2 Suppl):3–4 **(Ger)**

ECONOMICS

Prescription of antidepressants by general practitioners: recommendations by FHSAs and health boards [see comments] Thakore JH, et al. **Br J Gen Pract** 1996 Jun; 46(407):363–4. Comment in: Br J Gen Pract 1996 Aug;46(409):495.
Suicide and the cost-effectiveness of antidepressants [letter; comment] Henry JA. **Br J Psychiatry** 1997 Jan;170:88. Comment on: Br J Psychiatry 1996 Apr;168(4):404–9.
Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. Revicki DA, et al. **J Clin Psychiatry** 1997 Feb;58(2):47–58
Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization [see comments] Sclar DA, et al. **J Int Med Res** 1995 Nov-Dec;23(6):395–412. Comment in: J Int Med Res 1997 Jan-Feb;25(1):45–51.

METABOLISM

Phenotyping for CYP 11D6 alleles [letter] Synnott IH. **Aust N Z J Psychiatry** 1997 Jun;31(3):431
High-performance liquid chromatographic-ultraviolet assay for the simultaneous quantitation of BMS-181101 and its putative hydroxy metabolites in rat and monkey plasma. Shah VR, et al. **Biomed Chromatogr** 1996 May-Jun; 10(3):135–8
Regioselectivity and substrate concentration-dependency of involvement of the CYP2D subfamily in oxidative metabolism of amitriptyline and nortriptyline in rat liver microsomes. Masubuchi Y, et al. **J Pharm Pharmacol** 1996 Sep;48(9):925–9
Antidepressant and anxiolytic profiles of E-10-hydroxynortriptyline on electrocorticograms of rats. Nordin C, et al. **Neuropsychobiology** 1996;34(1):44–8
Brain imaging, antidepressants, and ethnicity: preliminary observations. Lesser IM, et al. **Psychopharmacol Bull** 1996; 32(2):235–42

PHARMACOKINETICS

Pharmacogenetics of antidepressants: clinical aspects. Bertilsson L, et al. **Acta Psychiatr Scand Suppl** 1997; 391:14–21 (63 ref.)
Clinical implications of antidepressant pharmacokinetics and pharmacogenetics. Cohen LJ, et al. **Ann Pharmacother** 1996 Dec;30(12):1471–80 (90 ref.)
Pharmacokinetics and toxicokinetics of an orally active tripeptide, IRI-695, in animals. Adusumalli V, et al. **Biopharm Drug Dispos** 1996 Jan;17(1):25–41
Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. Pellizzoni C, et al. **Biopharm Drug Dispos** 1996 Oct;17(7):623–33
Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers. Robbins DK, et al. **Biopharm Drug Dispos** 1997 May;18(4):325–34
Influence of liver cirrhosis on sertraline pharmacokinetics. Démolis JL, et al. **Br J Clin Pharmacol** 1996 Sep; 42(3):394–7
Comparison of the steady-state pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening. Marathe PH, et al. **Br J Clin Pharmacol** 1996 Jan;41(1):21–7
Pharmacokinetics of reboxetine enantiomers in the dog. Frigerio E, et al. **Chirality** 1997;9(3):303–6
Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Preskorn SH. **Clin Pharmacokinet** 1997;32 Suppl 1:1–21 (143 ref.)
Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Ronfeld RA, et al. **Clin Pharmacokinet** 1997;32 Suppl 1:22–30
Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects [letter] Priskorn M, et al. **Eur J Clin Pharmacol** 1997;52(3):241–2
Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Dostert P, et al. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S23–35; discussion S71–3 (80 ref.)
Pharmacokinetics of milnacipran in comparison with other antidepressants. Puozzo C, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:15–27 (90 ref.)
Platelet [3H]imipramine and [3H]paroxetine binding in depressed patients. Rosel P, et al. **J Affect Disord** 1997 Jun;44(1):79–85
Lithium pharmacokinetics in Chinese manic-depressive patients. Wing YK, et al. **J Clin Psychopharmacol** 1997 Jun; 17(3):179–84
Possible markers for postmortem drug redistribution. Langford AM, et al. **J Forensic Sci** 1997 Jan;42(1):88–92
Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography. Christian BT, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):325–31
Ethnicity and antidepressant response. Sramek JJ, et al. **Mt Sinai J Med** 1996 Oct-Nov;63(5–6):320–5 (36 ref.)
Synthesis of [11C]dapoxetine.HCl, a serotonin re-uptake inhibitor: biodistribution in rat and preliminary PET imaging in the monkey. Livni E, et al. **Nucl Med Biol** 1994 May;21(4):669–75
Steady-state kinetics of imipramine in transgenic mice with elevated serum AAG levels. Holladay JW, et al. **Pharm Res** 1996 Sep;13(9):1313–6
A limited sampling approach in bioequivalence studies. Mahmood I, et al. **Ther Drug Monit** 1997 Aug;19(4):413–9
[Minimal posology, optimal posology?] Diquet B. **Encephale** 1995 Dec;21 Spec No 4:33–6; discussion 37 **(Fre)**
[Pharmacokinetic study of nerisopam and its n-acetyl metabolite in rats] Ary K, et al. **Acta Pharm Hung** 1997 Mar-May;67(2-3):59–63 (Eng. Abstr.) **(Hun)**
[Human pharmacokinetic study of nerisopam and its n-acetyl metabolite] Róna K, et al. **Acta Pharm Hung** 1997 Mar-May;67(2-3):65–71 (Eng. Abstr.) **(Hun)**

PHARMACOLOGY

Prolonged treatment with antidepressants increases the 5-HT1A-mediated inhibition of hippocampal neurons without changing the 5-HT1A receptor binding. Tokarski K, et al. **Acta Physiol Hung** 1996;84(3):343–4
Designing a new generation of antidepressant drugs. Pinder RM. **Acta Psychiatr Scand Suppl** 1997;391:7–13
Adaptative changes of the serotonergic system after antidepressant treatments. Artigas F, et al. **Adv Exp Med Biol** 1996;398:51–9
Effects of antidepressants on the cytochrome P450 system [letter; comment] Preskorn SH. **Am J Psychiatry** 1996 Dec; 153(12):1655–7. Comment on: Am J Psychiatry 1996 Mar;153(3):311–20.
The effects of different monoaminergic antidepressants on the analgesia induced by spinal cord adrenal medullary transplants in the formalin test in rats. Ortega-Alvaro A, et al. **Anesth Analg** 1997 Apr;84(4):816–20
Drug targets in the embryo. Studies on the cocaine- and antidepressant-sensitive serotonin transporter. Schroeter S, et al. **Ann N Y Acad Sci** 1996 Oct 31;801:239–55 (83 ref.)
The pharmacologic treatment of anxiety and depression in African Americans. Considerations for the general practitioner. Strickland TL, et al. **Arch Fam Med** 1997 Jul-Aug;6(4):371–5 (43 ref.)
Different effects of the antidepressant drugs imipramine, maprotiline and bupropion on insulin secretion from mouse pancreatic islets. el-Dakhakhny M, et al. **Arzneimittelforschung** 1996 Jul;46(7):667–9
Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Perovic S, et al. **Arzneimittelforschung** 1995 Nov;45(11):1145–8
Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Detke MJ, et al. **Behav Brain Res** 1996;73(1-2):43–6 (20 ref.)
Transcriptional regulation of the 5-HT2A receptor. Toth M. **Behav Brain Res** 1996;73(1-2):183–6 (17 ref.)
Possible therapeutic effect of T-794, a novel reversible inhibitor of monoamine oxidase-A, on post-stroke emotional disturbances, assessed in animal models of depression. Kato M, et al. **Biol Pharm Bull** 1997 Apr; 20(4):349–53
Effects of antidepressants on intracellular Ca2+ mobilization in CHO cells transfected with the human 5-HT2C receptors. Akiyoshi J, et al. **Biol Psychiatry** 1996 Jun 15; 39(12):1000–8
Double-blind comparative study of the antidepressant, unwanted and cardiac effects of minaprine and amitriptyline. Edwards JG, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):491–8
The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance. Kerr JS, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):239–41
Chronic antidepressant drug treatment reduces turning behavior and increases dopamine levels in the medial prefrontal cortex. Carlson JN, et al. **Brain Res** 1996 Jan 22;707(1):122–6
Effects of tianeptine, sertraline and clomipramine on brain serotonin metabolism: a voltammetric approach in the rat. Marinesco S, et al. **Brain Res** 1996 Oct 14;736(1-2):82–90
Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Nakagawa Y, et al. **Brain Res** 1996 Feb 19;709(2):215–20
Involvement of GABAB receptor systems in action of antidepressants. II: Baclofen attenuates the effect of desipramine whereas muscimol has no effect in learned helplessness paradigm in rats. Nakagawa Y, et al. **Brain Res** 1996 Jul 29;728(2):225–30
Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Shirayama Y, et al. **Brain Res** 1996 Nov 11; 739(1-2):70–8
The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Mongeau R, et al. **Brain Res Brain Res Rev** 1997 Apr;23(3):145–95 (501 ref.)
Chronic administration of imipramine and lithium changes the phase-angle relationship between the activity and core body temperature circadian rhythms in rats. Nagayama H. **Chronobiol Int** 1996 Oct;13(4):251–9
Effect of sertraline on protein binding of warfarin. Apseloff G, et al. **Clin Pharmacokinet** 1997;32 Suppl 1:37–42
Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Gardner MJ, et al. **Clin Pharmacokinet** 1997;32 Suppl 1:43–9
A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Tremaine LM, et al. **Clin Pharmacokinet** 1997;32 Suppl 1:31–6
Molecular and cellular mechanisms of antidepressant drugs. Owens MJ. **Depress Anxiety** 1996-97;4(4):153–9 (35 ref.)
Moclobemide. An update of its pharmacological properties and therapeutic use [published erratum appears in Drugs 1996 Dec;52(6):869] Fulton B, et al. **Drugs** 1996 Sep; 52(3):450–74 (115 ref.)
In vitro activity of nonsteroidal anti-inflammatory agents, phenotiazines, and antidepressants against Brucella species. Muñoz-Criado S, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):418–20
Moxonidine and cognitive function: interactions with moclobemide and lorazepam. Wesnes K, et al. **Eur J Clin Pharmacol** 1997;52(5):351–8
Antidepressant drugs inhibit a glial 5-hydroxytryptamine transporter in rat brain. Bal N, et al. **Eur J Neurosci** 1997 Aug;9(8):1728–38
Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system. Hernando F, et al. **Eur J Pharmacol** 1996 Dec 30;318(2-3):221–9
Dibenzoazepine analogues: the electrophysiological properties of JL3, a potential atypical antidepressant. Liégeois JF, et al. **Eur J Pharmacol** 1996 Aug 22; 310(1):9–12
Hippocampal and cortical G protein (Gs alpha, G(o) alpha and Gi2 alpha) mRNA expression after electroconvulsive shock or lithium carbonate treatment. McGowan S, et al. **Eur J Pharmacol** 1996 Jun 13;306(1-3):249–55
Antidepressant drugs given repeatedly change the binding of the dopamine D2 receptor agonist, [3H]N-0437, to dopamine D2 receptors in the rat brain. Maj J, et al. **Eur J Pharmacol** 1996 May 23;304(1-3):49–54
Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Noda Y, et al. **Eur J Pharmacol** 1997 Apr 18; 324(2-3):135–40
The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. Redrobe JP, et al. **Eur J Pharmacol** 1996 Dec 30;318(2-3):213–20
Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Redrobe JP, et al. **Eur J Pharmacol** 1997 May 1; 325(2-3):129–35
Differential effects of clonidine, lithium and quinine in the forced swimming test in mice for antidepressants: possible roles of serotoninergic systems. Bourin M, et al. **Eur Neuropsychopharmacol** 1996 Aug;6(3):231–6
The effects of moclobemide on sexual desire and function in healthy volunteers. Kennedy SH, et al. **Eur Neuropsychopharmacol** 1996 Aug;6(3):177–81
Potential antidepressant effects of lemon odor in rats. Komori T, et al. **Eur Neuropsychopharmacol** 1995 Dec;5(4):477–80
Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Detke MJ, et al. **Exp Clin Psychopharmacol** 1997 May;5(2):107–12
Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Gardier AM, et al.

Fundam Clin Pharmacol 1996;10(1):16–27 (88 ref.)

The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice. Redrobe JP, et al. **Fundam Clin Pharmacol** 1996; 10(6):524–8

Effects of long–term treatment with dicyclic, tricyclic, tetracyclic, and noncyclic antidepressant drugs on monoamine oxidase activity in mouse brain. Egashira T, et al. **Gen Pharmacol** 1996 Jul;27(5):773–8

Effects of fluoxetine hydrochloride and fluvoxamine maleate on different preparations of isolated guinea pig and rat organ tissues. Velasco A, et al. **Gen Pharmacol** 1997 Apr; 28(4):509–12

Influence of antidepressant drugs on learning and memory paradigms in mice. Kumar S, et al. **Indian J Exp Biol** 1996 May;34(5):431–5

Preclinical pharmacology of milnacipran. Briley M, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:9–14 (24 ref.)

Epidemiological data suggest antidepressants reduce suicide risk among depressives. Isacsson G, et al. **J Affect Disord** 1996 Nov 4;41(1):1–8

Exploring the TPQ as a possible predictor of antidepressant response to nefazodone in a large multi–site study. Nelson E, et al. **J Affect Disord** 1997 Jul;44(2–3):197–200

Lack of effect of antidepressants on mononuclear leukocyte G–protein levels or function in depressed outpatients. Young LT, et al. **J Affect Disord** 1996 Jul 29;39(3):201–7

In–vitro activity of psychiatric drugs against Corynebacterium urealyticum (Corynebacterium group D2). Muñoz–Bellido JL, et al. **J Antimicrob Chemother** 1996 May;37(5):1005–9

Antidepressants. Frazer A. **J Clin Psychiatry** 1997;58 Suppl 6:9–25 (155 ref.)

Antidepressant effects of nicotine [letter] Hawkins JW. **J Clin Psychiatry** 1997 Jul;58(7):324–5

G protein–mediated signal transduction as a target of antidepressant and antibipolar drug action: evidence from model systems. Rasenick MM, et al. **J Clin Psychiatry** 1996; 57 Suppl 13:49–55; discussion 56–8 (38 ref.)

Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link. Stahl SM. **J Clin Psychiatry** 1997;58 Suppl 8:20–6 (64 ref.)

Pharmacology of antidepressants. Frazer A. **J Clin Psychopharmacol** 1997 Apr;17(2):2S–18S (158 ref.)

Roxindole, a potential antidepressant. I. Effect on the dopamine system. Maj J, et al. **J Neural Transm Gen Sect** 1996;103(5):627–41

Effects of long–term treatment with antidepressant drugs on proopiomelanocortin and neuropeptide Y mRNA expression in the hypothalamic arcuate nucleus of rats. Baker RA, et al. **J Neuroendocrinol** 1996 May;8(5):337–43

Potential antidepressant effects of novel tropane compounds, selective for serotonin or dopamine transporters. Hemby SE, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):727–33

S 15535, a novel benzodioxopiperazine ligand of serotonin (5–HT)1A receptors: I. Interaction with cloned human (h)5–HT1A, dopamine hD2/hD3 and h alpha2A–adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity. Millan MJ, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):132–47

Chronic antidepressant exposure enhances 5–hydroxytryptamine7 receptor–mediated cyclic adenosine monophosphate accumulation in rat frontocortical astrocytes. Shimizu M, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1551–8

ACTH 4–9 analogue facilitates the antiimmobility effect of antidepressants and dopamine agonists in swimming rats. Zebrowska–Lupina I, et al. **J Physiol Pharmacol** 1997 Jun; 48(2):263–75

[3H]8–OH–DPAT binding and serotonin content in rat cerebral cortex after acute fluoxetine, desipramine, or pargyline. Carli M, et al. **J Psychiatry Neurosci** 1996 Mar; 21(2):114–22

Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice. Da–Rocha MA Jr, et al. **J Psychopharmacol (Oxf)** 1997;11(3):211–8

Noradrenergic mechanisms in the prefrontal cortex. Nutt DJ, et al. **J Psychopharmacol (Oxf)** 1997;11(2):163–8 (45 ref.)

Treatment of antidepressant–induced sexual side effects. Assalian P, et al. **J Sex Marital Ther** 1996 Fall;22(3):218–24

Depression, Borna disease, and amantadine [letter; comment] Lieb K, et al. **Lancet** 1997 Mar 29;349(9056):958. Comment on: Lancet 1997 Jan 18;349(9046):178–9.

Chronic treatment with antidepressants, verapamil, or lithium inhibits the serotonin–induced intracellular calcium response in individual C6 rat glioma cells. Yamaji T, et al. **Life Sci** 1997;60(11):817–23

Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Richelson E. **Mayo Clin Proc** 1997 Sep;72(9):835–47 (105 ref.)

Effect of several antidepressant drugs on isolated rat vas deferens in vitro. Velasco A, et al. **Methods Find Exp Clin Pharmacol** 1996 Oct;18(8):507–11

Gender differences in psychotropic medications. Lewis–Hall F. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):326–9 (36 ref.)

Effect of chronic administration of the selective serotonin (5–HT) uptake inhibitor citalopram on extracellular 5–HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Auerbach SB, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec; 352(6):597–606

Repeated treatment with antidepressant drugs induces subsensitivity to the excitatory effect of 5–HT4 receptor activation in the rat hippocampus. Bijak M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jan; 355(1):14–9

Experimental anxiety and antidepressant drugs: the effects of moclobemide, a selective reversible MAO–A inhibitor, fluoxetine and imipramine in mice. de Angelis L. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug–Sep; 354(3):379–83

Different molecular forms of cholecystokinin and CCKB receptor binding in the rat brain after chronic antidepressant treatment. Harro J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jan; 355(1):57–63

Clinical pharmacokinetics of carbamazepine and valproate in children and adolescents with epilepsy. Galas–Zgorzalewicz B, et al. **Neurol Neurochir Pol** 1996; 30 Suppl 2:49–54

New drugs and vagal stimulation for treatment of epilepsy—the Israeli experience. Neufeld MY, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:113–20 (23 ref.)

Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5–HT2A receptor antagonistic activity. Hatanaka K, et al. **Neuropharmacology** 1996; 35(11):1621–6

Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the beta–adrenoceptor–linked adenylate cyclase system in the rat cerebral cortex. Neliat G, et al. **Neuropharmacology** 1996 May;35(5):589–93

Antidepressant–like effects of a partial agonist at strychnine–insensitive glycine receptors and a competitive NMDA receptor antagonist. Przegaliński E, et al. **Neuropharmacology** 1997 Jan;36(1):31–7

Indeloxazine hydrochloride improves impairment of passive avoidance performance after fluid percussion brain injury in rats. Yamaguchi T, et al. **Neuropharmacology** 1996 Mar; 35(3):329–36

Selective activation of postsynaptic 5–HT1A receptors induces rapid antidepressant response. Blier P, et al. **Neuropsychopharmacology** 1997 May;16(5):333–8

Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Bonson KR, et al. **Neuropsychopharmacology** 1996 Jun;14(6):425–36

Placebo run–in for antidepressant trials [letter; comment] Kramer M. **Neuropsychopharmacology** 1996 Jul;15(1):105, 107. Comment on: Neuropsychopharmacology 1994 Aug;11(1):33–43.

Inhibition of synaptosomal veratridine–induced sodium influx by antidepressants and neuroleptics used in chronic pain. Deffois A, et al. **Neurosci Lett** 1996 Dec 13;220(2):117–20

The 5–HT1A antagonist WAY–100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Romero L, et al. **Neurosci Lett** 1996 Nov 22; 219(2):123–6

Antidepressant–like effects of p–synephrine in mouse models of immobility tests. Song DK, et al. **Neurosci Lett** 1996 Aug 23;214(2–3):107–10

Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Baureithel KH, et al. **Pharm Acta Helv** 1997 Jun;72(3):153–7

Synthesis, conformational analysis and antidepressant activity of moclobemide new analogues. Ghanbarpour A, et al. **Pharm Acta Helv** 1997 Apr;72(2):119–22

Long–term antidepressant treatment restores clonidine's effect on growth hormone secretion in a genetic animal model of depression. Aulakh CS, et al. **Pharmacol Biochem Behav** 1996 Oct;55(2):265–8

Additive effects of glyburide and antidepressants in the forced swimming test: evidence for the involvement of potassium channel blockade. Guo W, et al. **Pharmacol Biochem Behav** 1996 Aug;54(4):725–30

Antidepressant–like effect of brain–derived neurotrophic factor (BDNF). Siuciak JA, et al. **Pharmacol Biochem Behav** 1997 Jan;56(1):131–7

The influence of various antidepressants on heart rate and electrodermal activity during psychophysiological examinations of depressive patients. Barg T, et al. **Pharmacopsychiatry** 1996 Nov;29(6):216–9

Roxindole, a dopamine autoreceptor agonist with a potential antidepressant activity. II. Effects on the 5–hydroxytryptamine system. Maj J, et al. **Pharmacopsychiatry** 1997 Mar;30(2):55–61

Adaptation of N–methyl–D–aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Skolnick P, et al. **Pharmacopsychiatry** 1996 Jan;29(1):23–6 (28 ref.)

Effects of a new oxazolidinone derivative AS–8 on serotonin metabolism in the brains of mouse, rat and chick. Chilmonczyk Z. **Pol J Pharmacol** 1995 Sep–Oct; 47(5):445–9

Some behavioral effects of 1,3–di–o–tolylguanidine, opipramol and sertraline, the sigma site ligands. Maj J, et al. **Pol J Pharmacol** 1996 Jul–Aug;48(4):379–95

Acute effect of dopamine agonists and some antidepressants in stress–induced deficit of fighting behavior. Ossowska G, et al. **Pol J Pharmacol** 1996 Jul–Aug;48(4):403–8

Comparison of the effects of antidepressant drugs on the level of cAMP in the rat striatum and nucleus accumbens septi. Rogoż R, et al. **Pol J Pharmacol** 1996 Sep–Oct;48(5):481–7

Antidepressant–induced adaptive changes in the effects of 5–HT, 5–HT1A and 5–HT4 agonists on the population spike recorded in hippocampal CA1 cells do not involve presynaptic effects on excitatory synaptic transmission. Tokarski K, et al. **Pol J Pharmacol** 1996 Nov–Dec; 48(6):565–73

The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5–trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates. Dixon JF, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4757–60

A schematic representation of the psychopharmacological profile of antidepressants. Bourin M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov; 20(8):1389–402

Behavioral effects of HT–90B, a putative novel anxiolytic agent with potent antidepressive activity. Inagawa K, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jan; 20(1):129–45

Bulbectomy–induced loss of raphe neurons is counteracted by antidepressant treatment. Nesterova IV, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan; 21(1):127–40

Effects of antidepressants on thyroid stimulating hormone release in rats under ether stress. Kadono Y, et al. **Psychiatry Clin Neurosci** 1995 Aug;49(4):231–6

Effects of desipramine and fluvoxamine on timing behavior investigated with the fixed–interval peak procedure and the interval bisection task. Ho MY, et al. **Psychopharmacology (Berl)** 1996 Jun;125(3):274–84

Differential responsiveness of inbred strains of rats to antidepressants in the forced swimming test: are Wistar Kyoto rats an animal model of subsensitivity to antidepressants? Lahmame A, et al. **Psychopharmacology (Berl)** 1996 Jan;123(2):191–8

Antidepressant treatment in helpless rats: effect on the electrophysiological activity of raphe dorsalis serotonergic neurons. Maudhuit C, et al. **Psychopharmacology (Berl)** 1997 Apr;130(3):269–75

Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Molewijk HE, et al. **Psychopharmacology (Berl)** 1996 Nov;128(1):31–8

Reflexes of the cutaneous microcirculation in amitriptyline and in fluoxetine treated patients. Mück–Weymann M, et al. **Psychopharmacology (Berl)** 1996 Apr;124(3):241–4

The antidepressant drug phenelzine produces antianxiety effects in the plus–maze and increases in rat brain GABA. Paslawski T, et al. **Psychopharmacology (Berl)** 1996 Sep; 127(1):19–24

GAP–43 phosphorylation by PKC in rat cerebrocortical synaptosomes: effect of antidepressants. Li Q, et al. **Res Commun Mol Pathol Pharmacol** 1997 Apr;96(1):3–13

The neurobiology and pharmacology of depression. A comparative overview of serotonin selective antidepressants. Harvey BH. **S Afr Med J** 1997 Apr;87(4 Suppl):540–50, 552 (92 ref.)

Regulation of c–Fos and NGF1–A by antidepressant treatments. Morinobu S, et al. **Synapse** 1997 Apr; 25(4):313–20

Awareness of potential drug interactions may aid avoidance [letter] DeVane CL, et al. **Ther Drug Monit** 1997 Jun; 19(3):366–7

Drug interaction potential of fluoxetine, sertraline, and paroxetine in four state psychiatric hospital populations [letter] Markowitz JS, et al. **Ther Drug Monit** 1997 Apr; 19(2):244–5

Acceleration of the effect of selected antidepressant drugs in major depression by 5–HT1A antagonists. Artigas F, et al. **Trends Neurosci** 1996 Sep;19(9):378–83 (66 ref.)

[Apropos of recent antidepressant drugs: some pharmacological comments] Montastruc JL, et al. **Therapie** 1997 Mar–Apr;52(2):143–9 (24 ref.) (Eng. Abstr.) **(Fre)**

[A study of the effects of antidepressants on the GABAA receptor and its complex based on the drug actions on the power–spectral changes of rat hippocampal EEG induced by GABA antagonists and inverse agonists] Matsubara M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1997 Apr; 17(2):75–83 (Eng. Abstr.) **(Jpn)**

[Effects of antidepressants on cerebral protein phosphorylation reaction] Miyamoto S, et al. **Seishin Shinkeigaku Zasshi** 1996;98(11):930–7 (25 ref.) **(Jpn)**

[Changes in cAMP signal transduction function and gene expression related to the onset of affective disturbance--the relationship between stress, antidepressants and expression of BDNF mRNA] Morinobu S, et al. **Seishin Shinkeigaku Zasshi** 1996;98(11):937–42; discussion 942–6 (7 ref.) **(Jpn)**

[Antidepressive agents and the cerebral signal transduction system--hippocampal neuromodulation and the action mechanism of antidepressants] Tajima O, et al. **Seishin Shinkeigaku Zasshi** 1996;98(11):909–15 (4 ref.) **(Jpn)**

[Effect of befol on the threshold of electric fibrillation of heart ventricles] Galenko–Iaroshevskiĭ PA, et al. **Biull Eksp Biol Med** 1997 Mar;123(3):305–7 **(Rus)**

[Features of the antidepressive effect of O–beta–chloroethyl–para–N–

dimethylaminophenylphosphinylacetic acid (amfazide)] **Semina II**, et al. **Biull Eksp Biol Med** 1996 May; 121(5):538–40 **(Rus)**

[Effect of lithium oxybutyrate on the circadian rhythm of brain level of serotonin and plasma level of corticosteroids in mice treated with reserpine] Zamoshchina TA, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):101–5 **(Rus)**

[A comparative pharmacological study of the serotoninergic antidepressants tetrindole and fluoxetin] Andreeva NI, et al. **Eksp Klin Farmakol** 1996 Jul–Aug;59(4):5–7 (Eng. Abstr.) **(Rus)**

[The influence of calcium channel blockers on antidepressant effects] Kozlovskiĭ VL, et al. **Eksp Klin Farmakol** 1996 Sep–Oct;59(5):9–11 (Eng. Abstr.) **(Rus)**

[The effect of dimethylethanolamine on the summation capacity of the central nervous system and on the work capacity of animals in a chronic experiment] Lukoshko SO, et al. **Fiziol Zh** 1997;43(1–2):19–22 (Eng. Abstr.) **(Ukr)**

POISONING

Sertraline overdose. Lau GT, et al. **Acad Emerg Med** 1996 Feb;3(2):132–6

Are suicide rates in Sweden associated with changes in the prescribing of medicines? Carlsten A, et al. **Acta Psychiatr Scand** 1996 Aug;94(2):94–100

Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Bolognesi R, et al. **Am J Cardiol** 1997 Jan 15;79(2):242–5

Seizure resulting from a venlafaxine overdose [see comments] White CM, et al. **Ann Pharmacother** 1997 Feb;31(2):178–80 . Comment in: Ann Pharmacother 1997 Jun;31(6):790–1.

Antidepressant deaths by overdose. Battersby MW, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):223–8

Depression and the safety of antidepressants [letter] Thacker S. **Br J Psychiatry** 1996 Nov;169(5):667

Re: Suicide in old age [letter] [see comments] Harris DJ. **Can J Psychiatry** 1996 Oct;41(8):535–6. Comment in: Can J Psychiatry 1997 Apr;42(3):321–3.

Epidemiology and relative toxicity of antidepressant drugs in overdose. Henry JA. **Drug Saf** 1997 Jun;16(6):374–90 (92 ref.)

The GCMS analysis of tranylcypromine (Parnate) in a suspected overdose. Crifasi J, et al. **Forensic Sci Int** 1997 Apr 18;86(1–2):103–8

Serotonin syndrome due to an overdose of moclobemide and clomipramine. A potentially life-threatening association. François B, et al. **Intensive Care Med** 1997 Jan;23(1):122–4

Suicide and antidepressants in south Alabama: evidence for improved treatment of depression. Rich CL, et al. **J Affect Disord** 1997 Sep;45(3):135–42

Fatal overdose with citalopram? [letter; comment] Brion F, et al. **Lancet** 1996 Nov 16;348(9038):1380. Comment on: Lancet 1996 Aug 3;348(9023):339–40.

Citalopram toxicity [letter] Glassman AH. **Lancet** 1997 Sep 13;350(9080):818

Symptoms and signs of severe citalopram overdose [letter] [see comments] Grundemar L, et al. **Lancet** 1997 May 31; 349(9065):1602. Comment in: Lancet 1997 Aug 16;350(9076):518–9.

Risks with citalopram in perspective [letter; comment] Isacsson G, et al. **Lancet** 1996 Oct 12;348(9033):1033. Comment on: Lancet 1996 Aug 3;348(9023):339–40.

Citalopram toxicity [letter; comment] Personne M, et al. **Lancet** 1997 Aug 16;350(9076):518–9. Comment on: Lancet 1996 Aug 3;348(9023):339–40. Comment on: Lancet 1997 May 31;349(9065):1602.

[Poisoning with a reversible and selective monoaminooxidase inhibitor] Pall M, et al. **Ugeskr Laeger** 1997 Aug 4; 159(32):4859–60 (Eng. Abstr.) **(Dan)**

[Serotonin syndrome in acute poisoning with antidepressive agents] Robert P, et al. **Ann Fr Anesth Reanim** 1996; 15(5):663–5 (Eng. Abstr.) **(Fre)**

[Suicide and psychotropic drugs] Lejoyeux M, et al. **Encephale** 1996 Dec;22 Spec No 4:40–5 (34 ref.) (Eng. Abstr.) **(Fre)**

[Acute encephalomyopathy and persistent cerebellar syndrome after lithium salt and haloperidol poisoning] Gille M, et al. **Rev Neurol (Paris)** 1997 May;153(4):268–70 (Eng. Abstr.) **(Fre)**

[Evaluation by poison control centers of minaprine from the modification of tablet dosages] Jouglard J, et al. **Therapie** 1996 Sep–Oct;51(5):582–5 (Eng. Abstr.) **(Fre)**

[Creutzfeldt–Jakob like syndrome due to lithium intoxication—a case report] Takahashi M, et al. **Rinsho Shinkeigaku** 1997 Apr;37(4):338–40 (Eng. Abstr.) **(Jpn)**

[Picture of poisoning in citalopram overdose. Convulsions and ECG symptoms can occur] Personne M, et al. **Lakartidningen** 1997 Apr 23;94(17):1603–4 **(Swe)**

THERAPEUTIC USE

Pharmacological approaches other than opioids in chronic non-cancer pain management. Merskey H. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):187–90

A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression. De Wilde JE, et al. **Acta Psychiatr Scand** 1996 Dec; 94(6):404–10

Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs. Maes M, et al. **Acta Psychiatr Scand** 1996 Jan;93(1):1–8

Paroxetine efficacy in the treatment of generalized anxiety disorder. Rocca P, et al. **Acta Psychiatr Scand** 1997 May; 95(5):444–50

Antecedent life events, social supports and response to antidepressants in depressed patients. Tomaszewska W, et al. **Acta Psychiatr Scand** 1996 Nov;94(5):352–7

Treating binge eating problems in primary care. Carter JC, et al. **Addict Behav** 1995 Nov–Dec;20(6):765–72 (36 ref.)

Predicting value of tryptophan/large neutral amino acids ratio on selective serotonin reuptake inhibitors. Lucini V, et al. **Adv Exp Med Biol** 1996;398:559

Major depression: selecting safe and effective treatment. Bhatia SC, et al. **Am Fam Physician** 1997 Apr;55(5):1683–98 (37 ref.)

Major depression: assessing the role of new antidepressants. Vanderhoff BT, et al. **Am Fam Physician** 1997 Jan; 55(1):249–54, 259–60 (22 ref.)

Anxious depression in elderly patients. Response to antidepressant treatment. Flint AJ, et al. **Am J Geriatr Psychiatry** 1997 Spring;5(2):107–15

Update in the pharmacotherapy of depression. Sussman N, et al. **Am J Med** 1996 Dec 30;101(6A):26S–36S (17 ref.)

Sleep deprivation combined with consecutive sleep phase advance as a fast-acting therapy in depression: an open pilot trial in medicated and unmedicated patients. Berger M, et al. **Am J Psychiatry** 1997 Jun;154(6):870–2

Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Brown C, et al. **Am J Psychiatry** 1996 Oct;153(10):1293–300

ECT response in medication-resistant patients [letter; comment] Chandragiri SS. **Am J Psychiatry** 1997 May; 154(5):721–2. Comment on: Am J Psychiatry 1996 Aug;153(8):985–92.

Rethinking treatment terminology [letter] Devane CL. **Am J Psychiatry** 1997 May;154(5):717

Antidepressants and suicide prevention [letter; comment] Isacsson G, et al. **Am J Psychiatry** 1996 Dec;153(12):1659 . Comment on: Am J Psychiatry 1995 Oct;152(10):1520–2.

Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Kocsis JH, et al. **Am J Psychiatry** 1997 Mar; 154(3):390–5

Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients. Koenig HG, et al. **Am J Psychiatry** 1997 Oct; 154(10):1369–75

Low use of neuroleptic drugs in the treatment of psychotic major depression. Mulsant BH, et al. **Am J Psychiatry** 1997 Apr;154(4):559–61

High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression. Reynolds CF 3rd, et al. **Am J Psychiatry** 1996 Nov;153(11):1418–22

The use of antidepressants and therapeutic drug monitoring by general practitioners and psychiatrists: findings from a questionnaire survey in two Swedish areas. Isacsson G, et al. **Ann Clin Psychiatry** 1996 Sep;8(3):153–60

Depression in the medically ill elderly: a focus on methylphenidate. Emptage RE, et al. **Ann Pharmacother** 1996 Feb;30(2):151–7 (43 ref.)

A multifaceted intervention to improve treatment of depression in primary care. Katon W, et al. **Arch Gen Psychiatry** 1996 Oct;53(10):924–32

Recent advances in the pharmacotherapy of major depression. Glod CA. **Arch Psychiatr Nurs** 1996 Dec; 10(6):355–64 (27 ref.)

Citalopram, depression and pseudo dementia: a neuropsychological case study. Mattos P. **Arq Neuropsiquiatr** 1995 Dec;53(4):841–8

The role of lithium in the affective disorders. Johnson G. **Aust N Z J Psychiatry** 1996 Dec;30(6):715–9 (19 ref.)

Recovery from depression: triggers and time patterns. Parker G. **Aust N Z J Psychiatry** 1996 Aug;30(4):442–4

Effect of sertraline on regional metabolic rate in patients with affective disorder. Buchsbaum MS, et al. **Biol Psychiatry** 1997 Jan 1;41(1):15–22

Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implications for therapeutics. Callahan AM, et al. **Biol Psychiatry** 1997 Feb 1; 41(3):264–72

Lateralized neuropsychological functioning in depressive patients before and after drug therapy. de Groot MH, et al. **Biol Psychiatry** 1996 Dec 15;40(12):1282–7

Treatment of bipolar depression with carbamazepine: results of an open study. Dilsaver SC, et al. **Biol Psychiatry** 1996 Nov 1;40(9):935–7

Estimation of the time course of slow-wave sleep over the night in depressed patients: effects of clomipramine and clinical response. Ehlers CL, et al. **Biol Psychiatry** 1996 Feb 1;39(3):171–81

Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy. Landmann R, et al. **Biol Psychiatry** 1997 Mar 15; 41(6):675–81

Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Maes M, et al. **Biol Psychiatry** 1997 Sep 1;42(5):349–58

National Institute of Mental Health Workshop Report on the Treatment of Bipolar Disorder. Prien RF, et al. **Biol Psychiatry** 1996 Aug 1;40(3):215–20

Dehydroepiandrosterone (DHEA) treatment of depression. Wolkowitz OM, et al. **Biol Psychiatry** 1997 Feb 1; 41(3):311–8

Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993–5 [see comments] Donoghue J, et al. **BMJ** 1996 Oct 5; 313(7061):861–2. Comment in: BMJ 1996 Oct 5;313(7061):829–30. Comment in: BMJ 1997 Mar 15;314(7083):827. Comment in: BMJ 1997 Mar 15;314(7083):828. Comment in: BMJ 1997 Mar 15;314(7083):828–9.

Prescribing antidepressants in general practice [editorial; comment] [see comments] Kendrick T. **BMJ** 1996 Oct 5; 313(7061):829–30. Comment on: BMJ 1996 Oct 5;313(7061):858–9. Comment on: BMJ 1996 Oct 5;313(7061):860–1. Comment on: BMJ 1996 Oct 5;313(7061):861–2. Comment in: BMJ 1997 Mar 15;314(7083):826. Comment in: BMJ 1997 Mar 15;314(7083):826–7. Comment in: BMJ 1997 Mar 15;314(7083):827. Comment in: BMJ 1997 Mar 15;314(7083):827–8. Comment in: BMJ 1997 Mar 15;314(7083):829.

Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland [see comments] MacDonald TM, et al. **BMJ** 1996 Oct 5;313(7061):860–1. Comment in: BMJ 1996 Oct 5;313(7061):829–30. Comment in: BMJ 1997 Mar 15;314(7083):827. Comment in: BMJ 1997 Mar 15;314(7083):827–8.

Antidepressants and chronic pain [editorial; comment] McQuay HJ, et al. **BMJ** 1997 Mar 15;314(7083):763–4. Comment on: BMJ 1997 Mar 15;314(7083):827.

The use of antidepressants [letter; comment] Martin CJ. **Br J Gen Pract** 1996 Aug;46(409):495. Comment on: Br J Gen Pract 1996 Jun;46(407):363–4.

Treatment-resistant affective disorders [letter; comment] Bowskill RJ, et al. **Br J Hosp Med** 1997 Feb 19–Mar 4; 57(4):171–2. Comment on: Br J Hosp Med 1995 Nov 15–Dec 12;54(10):501–6.

Lithium and weight gain [letter] Armond AD. **Br J Psychiatry** 1996 Aug;169(2):251–2

Antidepressant-treated patients in ambulatory care long-term use of non-psychotropic and psychotropic drugs. Bingefors K, et al. **Br J Psychiatry** 1996 Mar;168(3):292–8

Antidepressant-treated patients in ambulatory care. Mortality during a nine-year period after first treatment. Bingefors K, et al. **Br J Psychiatry** 1996 Nov;169(5):647–54

The effect of treatment on the two-year course of late-life depression. Flint AJ, et al. **Br J Psychiatry** 1997 Mar; 170:268–72

Treatment, outcome and predictors of response in elderly depressed in-patients. Heeren TJ, et al. **Br J Psychiatry** 1997 May;170:436–40

On brightening up: triggers and trajectories to recovery from depression [editorial] Parker G. **Br J Psychiatry** 1996 Mar; 168(3):263–4

Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Roth M, et al. **Br J Psychiatry** 1996 Feb;168(2):149–57

Brain [3H]cAMP binding sites are unaltered in depressed suicides, but decreased by antidepressants. Lowther S, et al. **Brain Res** 1997 May 30;758(1–2):223–8

Antidepressant treatment of depression: a metaanalysis [see comments] Joffe R, et al. **Can J Psychiatry** 1996 Dec; 41(10):613–6. Comment in: Can J Psychiatry 1996 Dec;41(10):609–10.

A review of the psychobiology and pharmacotherapy of posttraumatic stress disorder. Katz L, et al. **Can J Psychiatry** 1996 May;41(4):233–8 (46 ref.)

Efficacy and effectiveness in the antidepressant treatment of depression: beyond metaanalysis [editorial; comment] Kennedy SH, et al. **Can J Psychiatry** 1996 Dec; 41(10):609–10. Comment on: Can J Psychiatry 1996 Dec;41(10):613–6.

A double-blind, multicentre study of paroxetine and maprotiline in major depression. Schnyder U, et al. **Can J Psychiatry** 1996 May;41(4):239–44

Pharmacotherapy of affective disorders in old age. Tourigny-Rivard MF. **Can J Psychiatry** 1997 Jun;42 Suppl 1:10S–18S (107 ref.)

A comparative analysis of standard and alternative antidepressants in the treatment of human immunodeficiency virus patients. Wagner GJ, et al. **Compr Psychiatry** 1996 Nov–Dec;37(6):402–8

Discontinuation of antidepressant medications before ECT [letter] Hamner M, et al. **Convuls Ther** 1996 Jun;12(2):125–6

Depression in the medically ill: management considerations. Evans DL, et al. **Depress Anxiety** 1996–97;4(4):199–208 (110 ref.)

Bipolar depression: an underestimated treatment challenge. Hlastala SA, et al. **Depress Anxiety** 1997;5(2):73–83

Management of the depressive component of bipolar disorder. Kalin NH. **Depress Anxiety** 1996–97;4(4):190–8 (55 ref.)

Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Katz MM, et al. **Depress Anxiety** 1996–97;4(6):257–67 (61 ref.)

Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Penava SJ, et al. **Depress Anxiety** 1996–97;4(5):240–2 (22 ref.)

Moclobemide. An update of its pharmacological properties and therapeutic use [published erratum appears in Drugs 1996 Dec;52(6):869] Fulton B, et al. **Drugs** 1996 Sep; 52(3):450–74 (115 ref.)

Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. Möller HJ, et al. **Drugs** 1996 Nov;52(5):625–38 (84 ref.)

Prospects for the development of new treatments with a rapid onset of action in affective disorders. Soares JC, et al. **Drugs** 1996 Oct;52(4):477–82 (34 ref.)

The cost of depression in the elderly. Effects of drug therapy. Hughes D, et al. **Drugs Aging** 1997 Jan;10(1):59–68 (26 ref.)

Bereavement-related depression in the elderly. Is drug treatment justified? Rosenzweig AS, et al. **Drugs Aging** 1996 May;8(5):323–8 (26 ref.)

Optimal management of anxiety in older patients. Weiss KJ. **Drugs Aging** 1996 Sep;9(3):191–201 (76 ref.)

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. Berzewski H, et al. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S37–47; discussion S71–3

Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Bosc M, et al. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S57–70; discussion S71–3

Do G proteins have a role in antidepressant actions? Bourin M, et al. **Eur Neuropsychopharmacol** 1996 Mar;6(1):49–53 (68 ref.)

Do noradrenaline and serotonin differentially affect social motivation and behaviour? Dubini A, et al. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S49–55; discussion S71–3

The effects of antidepressants on psychomotor function with particular reference to reboxetine. Hindmarch I. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S17–21; discussion S71–3 (31 ref.)

Noradrenaline in basic models of depression. Leonard BE. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S11–6; discussion S71–3 (17 ref.)

Is there a role for a pure noradrenergic drug in the treatment of depression? Montgomery SA. **Eur Neuropsychopharmacol** 1997 Apr;7 Suppl 1:S3–9; discussion S71–3 (40 ref.)

Late-life depression: treatment strategies for primary care practice. Butler RN, et al. **Geriatrics** 1997 Apr;52(4):51–2, 58–60, 63–4 (10 ref.)

Understanding social phobia. Proceedings of the IVth International Symposium on Moclobemide. Oslo, Norway, 15–16 September 1995. **Int Clin Psychopharmacol** 1996 Jun; 11 Suppl 3:1–112

Moclobemide: a paradigm of research in clinical psychopharmacology. Angst J, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:3–7 (32 ref.)

Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. Haffmans PM, et al. **Int Clin Psychopharmacol** 1996 Sep;11(3):157–64

Long-term drug treatment of unipolar depression. Hirschfeld RM. **Int Clin Psychopharmacol** 1996 Dec;11(4):211–7 (41 ref.)

Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Kasper S, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:35–9 (19 ref.)

Clinical efficacy of milnacipran: placebo-controlled trials. Lecrubier Y, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:29–33 (13 ref.)

Milnacipran and selective serotonin reuptake inhibitors in major depression. Lopez-Ibor J, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:41–6 (32 ref.)

Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects. Menting JE, et al. **Int Clin Psychopharmacol** 1996 Sep; 11(3):165–75

Efficacy and tolerability of milnacipran: an overview. Montgomery SA, et al. **Int Clin Psychopharmacol** 1996 Sep; 11 Suppl 4:47–51 (24 ref.)

Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Patris M, et al. **Int Clin Psychopharmacol** 1996 Jun;11(2):129–36

Sertraline: lack of therapeutic efficacy in patients with delusions of parasitosis and dermatitis artefacta [letter] Kalivas J, et al. **Int J Dermatol** 1997 Jun;36(6):477

Sibutramine--a review of clinical efficacy. Lean ME. **Int J Obes Relat Metab Disord** 1997 Mar;21 Suppl 1:S30–6; discussion 37–9 (18 ref.)

New antidepressant drug opens up important treatment and safety options [news] **Ir Med J** 1996 Nov-Dec;89(6):214

The efficacy of imipramine and psychotherapy in early-onset chronic depression: a reanalysis of the National Institute of Mental health Treatment of Depression Collaborative Research Program. Agosti V, et al. **J Affect Disord** 1997 May;43(3):181–6

Autosomal recessive inheritance of affective disorders in families of responders to lithium prophylaxis? Alda M, et al. **J Affect Disord** 1997 Jul;44(2–3):153–7

The Major Depression Rating Scale (MDS). Inter-rater reliability and validity across different settings in randomized moclobemide trials. Danish University Antidepressant Group. Bech P, et al. **J Affect Disord** 1997 Jan;42(1):39–48

Cerebral hypoperfusion in medication resistant, depressed patients assessed by Tc99m HMPAO SPECT. Bonne O, et al. **J Affect Disord** 1996 Dec 16;41(3):163–71

Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study. Greil W, et al. **J Affect Disord** 1997 Apr;43(2):151–61

Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. Lecrubier Y, et al. **J Affect Disord** 1997 Apr;43(2):95–103

Interpersonal improvement in chronically depressed patients treated with desipramine. Markowitz JC, et al. **J Affect Disord** 1996 Nov 4;41(1):59–62

Depression-related cognitive impairment: possibilities for its pharmacological treatment. Mitchell AJ, et al. **J Affect Disord** 1996 Jan 22;36(3–4):79–87 (91 ref.)

Exploring the TPQ as a possible predictor of antidepressant response to nefazodone in a large multi-site study. Nelson E, et al. **J Affect Disord** 1997 Jul;44(2–3):197–200

Moclobemide and fluoxetine in treatment of seasonal affective disorder. Partonen T, et al. **J Affect Disord** 1996 Nov 25; 41(2):93–9

Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists. Shergill SS, et al. **J Affect Disord** 1997 Mar;43(1):19–25

Treatment for kleptomania [letter] Feeney DJ, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jun;36(6):723–4

"Standard of care" for MDD [letter] Klemm AL, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Aug;36(8):1016–7

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle [see comments] Spencer T, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Apr;35(4):409–32 (202 ref.). Comment in: J Am Acad Child Adolesc Psychiatry 1996 Dec;35(12):1569–70. Comment in: J Am Acad Child Adolesc Psychiatry 1997 Mar;36(3):301–2.

Sertraline for nocturnal enuresis [letter] Sprenger D. **J Am Acad Child Adolesc Psychiatry** 1997 Mar;36(3):304–5

Obsessive-compulsive disorder: diagnosis and treatment in the primary care setting. Gedenk M, et al. **J Am Board Fam Pract** 1997 Sep-Oct;10(5):349–56 (34 ref.)

Strategies for managing depression complicated by bipolar disorder, suicidal ideation, or psychotic features. Hartmann PM. **J Am Board Fam Pract** 1996 Jul-Aug;9(4):261–9 (69 ref.)

Pharmacotherapy of depression: focused considerations for primary care [published erratum of serious dosage error appears in J Am Pharm Assoc (Wash) 1996 Oct;NS36(10):564] Hartman T, et al. **J Am Pharm Assoc (Wash)** 1996 Aug;NS36(8):521–32; quiz 532–3

Managing depression among people with HIV disease. Valente SM, et al. **J Assoc Nurses AIDS Care** 1997 Jan-Feb;8(1):51–67 (76 ref.)

Algorithms for the treatment of affective illness, primary disorder of vigilance, and task-dependent attention disorders (learning disabilities) in children and adolescents. Weinberg WA, et al. **J Child Neurol** 1996 May;11(3):220–7

The treatment of depressed demented patients. Alexopoulos GS. **J Clin Psychiatry** 1996;57 Suppl 14:14–20 (70 ref.)

Antidepressant and double antidepressant treatment for the affective disorder of epilepsy. Blumer D. **J Clin Psychiatry** 1997 Jan;58(1):3–11

Efficacy issues with antidepressants. Fawcett J, et al. **J Clin Psychiatry** 1997;58 Suppl 6:32–9 (32 ref.)

Enhancing patient outcomes: treatment adherence. Frank E. **J Clin Psychiatry** 1997;58 Suppl 1:11–4 (7 ref.)

Antidepressants. Frazer A. **J Clin Psychiatry** 1997;58 Suppl 6:9–25 (155 ref.)

Antidepressants in panic disorder. Jefferson JW. **J Clin Psychiatry** 1997;58 Suppl 2:20–4; discussion 24–5 (64 ref.)

Coadministration of isoniazid and antidepressant drugs [letter] Malek-Ahmadi P, et al. **J Clin Psychiatry** 1996 Nov; 57(11):550

Patients excluded from an antidepressant efficacy trial. Partonen T, et al. **J Clin Psychiatry** 1996 Dec;57(12):572–5

Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. Revicki DA, et al. **J Clin Psychiatry** 1997 Feb;58(2):47–58

Clinical issues in the long-term treatment of panic disorder. Rosenbaum JF, et al. **J Clin Psychiatry** 1996;57 Suppl 10:44–8; discussion 49–50 (22 ref.)

Development of new antidepressants. Sambunaris A, et al. **J Clin Psychiatry** 1997;58 Suppl 6:40–53 (129 ref.)

The undertreatment of dysthymia. Shelton RC, et al. **J Clin Psychiatry** 1997 Feb;58(2):59–65

The role of the alliance in the pharmacologic treatment of depression. Weiss M, et al. **J Clin Psychiatry** 1997 May; 58(5):196–204

Sertraline treatment of hallucinogen persisting perception disorder [letter] Young CR. **J Clin Psychiatry** 1997 Feb; 58(2):85

Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment. Egberts AC, et al. **J Clin Psychopharmacol** 1997 Jun; 17(3):149–55

Pharmacology of antidepressants. Frazer A. **J Clin Psychopharmacol** 1997 Apr;17(2):2S–18S (158 ref.)

Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder? [letter] Koran LM, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):253–4

Symptomatic volunteers different from patients with depressive disorders? [letter; comment] Moleman P. **J Clin Psychopharmacol** 1997 Aug;17(4):323–4. Comment on: J Clin Psychopharmacol 1996 Jun;16(3):242–6.

Recovery from depressive illness does fit an exponential model. Priest RG, et al. **J Clin Psychopharmacol** 1996 Dec; 16(6):420–4

Synaptic effects of antidepressants. Richelson E. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):1S–7S; discussion 7S–9S (9 ref.)

Suspected complication of treatment with venlafaxine [letter] Wilson R, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):323

Recent developments in the pharmacotherapy of mood disorders. Thase ME, et al. **J Consult Clin Psychol** 1996 Aug;64(4):646–59 (209 ref.)

Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients. Ricca V, et al. **J Endocrinol Invest** 1996 Dec;19(11):727–33

Treatment of dysthymia. Buni TM. **J Fam Pract** 1997 Jun; 44(6):528–9

Recognizing and treating the patient with somatic manifestations of depression. De Wester JN. **J Fam Pract** 1996 Dec;43(6 Suppl):S3–15 (109 ref.)

Treating comorbid depression and anxiety. Kuzel RJ. **J Fam Pract** 1996 Dec;43(6 Suppl):S45–53 (75 ref.)

Treatment considerations for depression in patients with significant medical comorbidity. McCoy DM. **J Fam Pract** 1996 Dec;43(6 Suppl):S35–44 (73 ref.)

Depression in the patient with chronic pain. Ruoff GE. **J Fam Pract** 1996 Dec;43(6 Suppl):S25–33; discussion S34 (53 ref.)

Postpartum depressive disorders. Susman JL. **J Fam Pract** 1996 Dec;43(6 Suppl):S17–24 (54 ref.)

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. Syvälahti EK, et al. **J Int Med Res** 1997 Jan-Feb;25(1):24–32

Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect. Srisurapanont M, et al. **J Med Assoc Thai** 1997 Mar; 80(3):183–8

A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. van Balkom AJ, et al. **J Nerv Ment Dis** 1997 Aug;185(8):510–6

A preliminary study of possible psychoactive effects of intravenous forskolin in depressed and schizophrenic patients. Short communication. Bersudsky Y, et al. **J Neural Transm** 1996;103(12):1463–7

CSF inositol does not predict antidepressant response to inositol. Short communication. Levine J, et al. **J Neural Transm** 1996;103(12):1457–62

Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? Kornhuber J, et al. **J Neural Transm Suppl** 1995;46:315–23 (34 ref.)

Sustained antidepressant effect of PEA replacement. Sabelli H, et al. **J Neuropsychiatry Clin Neurosci** 1996 Spring; 8(2):168–71

Postherpetic neuralgia and its treatment: a retrospective survey of 191 patients. Bowsher D. **J Pain Symptom Manage** 1996 Nov;12(5):290–9

Moclobemide versus fluoxetine for double depression: a randomized double-blind study. Duarte A, et al. **J Psychiatr Res** 1996 Nov-Dec;30(6):453–8

Hostility changes following antidepressant treatment: relationship to stress and negative thinking. Fava M, et al. **J Psychiatr Res** 1996 Nov-Dec;30(6):459–67

Venlafaxine-fluoxetine-nortriptyline interaction [letter] Benazzi F. **J Psychiatry Neurosci** 1997 Jul;22(4):278–9

Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. Lapierre YD, et al. **J Psychiatry Neurosci** 1997 Mar;22(2):118–26

Brain 5-hydroxytryptamine uptake sites labeled with [3H]paroxetine in antidepressant drug-treated depressed suicide victims and controls. Lawrence KM, et al. **J Psychiatry Neurosci** 1997 May;22(3):185–91

Hypericum, an over the counter antidepressant? [letter] Rampes H. **J Psychopharmacol (Oxf)** 1997;11(2):191

The link between sleep and depression: the effects of antidepressants on EEG sleep. van Bemmel AL. **J Psychosom Res** 1997 Jun;42(6):555–64 (77 ref.)

Anxiety, depression and management of medically unexplained symptoms in medical clinics. Hamilton J, et al. **J R Coll Physicians Lond** 1996 Jan-Feb;30(1):18–20

Defeating depression--where do we stand? Roberts A. **J R Soc Health** 1996 Oct;116(5):290–4

Antidepressants in the treatment of premature ejaculation. Balon R. **J Sex Marital Ther** 1996 Summer;22(2):85–96 (51 ref.)

Sertraline in the treatment of rape victims with posttraumatic stress disorder. Rothbaum BO, et al. **J Trauma Stress** 1996 Oct;9(4):865–71

Curvaceous model of recovery from depression. Livingston MG, et al. **Lancet** 1997 Feb 15;349(9050):447

Antidepressant co-prescribing--how often does it occur? [letter; comment] [see comments] Parkes AJ. **Med J Aust** 1996 Sep 16;165(6):346. Comment on: Med J Aust 1996 Apr 15;164(8):509. Comment in: Med J Aust 1997 Feb 3;166(3):167.

Drug use in nursing homes: some new evidence [letter; comment] Walsh RA. **Med J Aust** 1997 Apr 21;166(8):447 . Comment on: Med J Aust 1996 Sep 2;165(5):295–6.

Review of clinical use of sertraline by family practice physicians in a small Air Force hospital. Bourgeois JA. **Mil Med** 1996 Jul;161(7):425–7

A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Como PG, et al. **Mov Disord** 1997 May;12(3):397–401

Treating tobacco addiction—nicotine or no nicotine? [editorial; comment] Benowitz NL. **N Engl J Med** 1997 Oct 23;337(17):1230–1. Comment on: N Engl J Med 1997 Oct 23;337(17):1195–202.

Depression. Sarin A. **Natl Med J India** 1997 Mar–Apr; 10(2):76–9 (6 ref.)

New drugs and vagal stimulation for treatment of epilepsy—the Israeli experience. Neufeld MY, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:113–20 (23 ref.)

Indeloxazine hydrochloride improves impairment of passive avoidance performance after fluid percussion brain injury in rats. Yamaguchi T, et al. **Neuropharmacology** 1996 Mar; 35(3):329–36

Influence of moclobemide on cognitive functions of nine depressed patients: pilot trial with neurophysiological and neuropsychological indices. Galderisi S, et al. **Neuropsychobiology** 1996;33(1):48–54

Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Sluzewska A, et al. **Neuropsychobiology** 1997;35(3):123–7

Lack of effect of chronic antidepressant treatment on Gs and Gi alpha-subunit protein and mRNA levels in the rat cerebral cortex. Emamghoreishi M, et al. **Neuropsychopharmacology** 1996 Sep;15(3):281–7

Can the effects of antidepressants be observed in the first two weeks of treatment? [letter] Katz MM, et al. **Neuropsychopharmacology** 1997 Aug;17(2):110–5

Can the effects of antidepressants be observed in the first two weeks of treatment? Quitkin FM, et al. **Neuropsychopharmacology** 1996 Oct;15(4):390–4

Treatment of depression in drug-dependent patients: effects on mood and drug use. Nunes EV, et al. **NIDA Res Monogr** 1997;172:61–85 (98 ref.)

Anxiety and depression. Diagnosis and treatment during pregnancy. Diket AL, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):535–58 (50 ref.)

A systematic review of antidepressants in neuropathic pain. McQuay HJ, et al. **Pain** 1996 Dec;68(2–3):217–27

Psychotropic drug use in a group of Dutch nursing home patients with dementia: many users, long-term use, but low doses. Koopmans RT, et al. **Pharm World Sci** 1996 Jan; 18(1):42–7

Are SSRIs true antidepressant drugs? A plea for the re-evaluation of their therapeutic potential and safety. Loonen AJ. **Pharm World Sci** 1997 Apr;19(2):70–2 (13 ref.)

Antidepressant drugs and experimental inflammation. Bianchi M, et al. **Pharmacol Res** 1996 Apr–May;33(4–5):235–8 (36 ref.)

Antidepressant treatment before hospitalization for major depression: often prescribed, often undertitrated. Ferreres F, et al. **Pharmacol Res** 1997 Jan;35(1):33–6

Circadian rhythms and the pharmacology of affective illness. Duncan WC Jr. **Pharmacol Ther** 1996;71(3):253–312 (493 ref.)

Antidepressant drug use: differences between psychiatrists and general practitioners. Results from a drug utilization observation study with fluoxetine. Dittmann RW, et al. **Pharmacopsychiatry** 1997 Jan;30(1 Suppl):28–34

Biological treatment of rapid-cycling bipolar disorder. Krüger S, et al. **Pharmacopsychiatry** 1996 Sep;29(5):167–75 (129 ref.)

What happens to patients after the end of a clinical trial? Systematic follow-up observational study of an open moclobemide trial in major depression. Linden M, et al. **Pharmacopsychiatry** 1997 Jan;30(1 Suppl):35–43

Low plasma thyroid indices of depressed patients are attenuated by antidepressant drugs and influence treatment outcome. Rao ML, et al. **Pharmacopsychiatry** 1996 Sep; 29(5):180–6

Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Stassen HH, et al. **Pharmacopsychiatry** 1996 May;29(3):87–96

Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Tiihonen J, et al. **Pharmacopsychiatry** 1996 Jan;29(1):27–9

Rational drug use in the treatment of depression. Cohen LJ. **Pharmacotherapy** 1997 Jan–Feb;17(1):45–61 (200 ref.)

Depression in late life. Special considerations in treatment. Zisook S. **Postgrad Med** 1996 Oct;100(4):161–2, 165–7, 171–2 (12 ref.)

Assessment and treatment of binge-eating disorder. Devlin MJ. **Psychiatr Clin North Am** 1996 Dec;19(4):761–72 (53 ref.)

Medications in the treatment of eating disorders. Jimerson DC, et al. **Psychiatr Clin North Am** 1996 Dec;19(4):739–54 (112 ref.)

Treatment of major depression in later life: a life cycle perspective. Reynolds CF 3rd. **Psychiatr Q** 1997 Fall; 68(3):221–46 (66 ref.)

Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Cavazzoni P, et al. **Psychiatry Res** 1996 Sep 27;64(2):91–6

Two-year outcome of elderly patients with anxious depression. Flint AJ, et al. **Psychiatry Res** 1997 Jan 15; 66(1):23–31

Platelet serotonergic indices in major depression: up-regulation of 5-HT2A receptors unchanged by antidepressant treatment. Hrdina PD, et al. **Psychiatry Res** 1997 Feb 7;66(2–3):73–85

Red blood cell L-tryptophan uptake in depression. II. Effect of an antidepressant treatment. Serres F, et al. **Psychiatry Res** 1997 Feb 7;66(2–3):87–96

Thyroid hormone levels before unsuccessful antidepressant therapy are associated with later response to T3 augmentation. Sokolov ST, et al. **Psychiatry Res** 1997 Mar 24;69(2–3):203–6

Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: relationships with immune-inflammatory markers. Maes M, et al. **Psychoneuroendocrinology** 1997 Feb;22(2):65–78

The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles. Raven PW, et al. **Psychoneuroendocrinology** 1996 Apr;21(3):277–86

Self-rating procedures in the evaluation of antidepressants. Möller HJ, et al. **Psychopathology** 1995;28(6):291–306 (82 ref.)

Pharmacokinetic and pharmacodynamic drug interactions with polypharmacotherapy of treatment-resistant affective and obsessive-compulsive disorders. Carson SW. **Psychopharmacol Bull** 1996;32(4):555–68 (59 ref.)

Issues in polypharmacotherapy: focus on depression in schizophrenia. Dufresne RL. **Psychopharmacol Bull** 1995; 31(4):789–96 (31 ref.)

A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Feiger AD. **Psychopharmacol Bull** 1996; 32(4):659–65

Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study Group. Finkelstein SN, et al. **Psychopharmacol Bull** 1996;32(1):33–40

Factors that influence the outcome of placebo-controlled antidepressant clinical trials. Niklson IA, et al. **Psychopharmacol Bull** 1997;33(1):41–51

Sertraline in the treatment of premenstrual dysphoric disorder. Yonkers KA, et al. **Psychopharmacol Bull** 1996; 32(1):41–6

Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Bondolfi G, et al. **Psychopharmacology (Berl)** 1996 Dec;128(4):421–5

Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study. Radat F, et al. **Psychopharmacology (Berl)** 1996 Oct;127(4):370–6

Dextromethorphan-induced manic symptoms in a bipolar patient on lithium [letter; comment] Bostwick JM. **Psychosomatics** 1996 Nov–Dec;37(6):571–3. Comment on: Psychosomatics 1996 Jan–Feb;37(1):71–4.

A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Taragano FE, et al. **Psychosomatics** 1997 May–Jun;38(3):246–52

Treatment of childhood obsessive-compulsive disorder with citalopram [letter] Maud C, et al. **S Afr Med J** 1996 Jun; 86(6 Suppl):746, 748

Drug selection for the treatment of depression in primary care: an introduction. Price PL. **S D J Med** 1996 Oct; 49(10):375–6

Antidepressant use in general practice. Weiller E, et al. **Therapie** 1996 Jul–Aug;51(4):429–30

[Progresses of psychiatry in China, 1996] Zhang M, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Dec;76(12):893 (0 ref.) **(Chi)**

[Antidepressive agents in the treatment of obsessive-compulsive disorder] Hansen ES, et al. **Ugeskr Laeger** 1997 Jan 6;159(2):183–4 **(Dan)**

[Antidepressive treatment in general practice (editorial)] Mabeck CE, et al. **Ugeskr Laeger** 1997 Jan 13;159(3):264 **(Dan)**

[Antidepressive treatment in general practice—an interview study] Rosholm JU, et al. **Ugeskr Laeger** 1997 Jan 13; 159(3):280–3 (Eng. Abstr.) **(Dan)**

[Prescription of antidepressants in family practice] de Waal MW, et al. **Ned Tijdschr Geneeskd** 1996 Oct 26; 140(43):2131–4 (Eng. Abstr.) **(Dut)**

[The good usage of antidepressants. Proceedings of a meeting. Laguiole, 7–9 June 1996] **Encephale** 1996 Dec;22 Spec No 7:1–74 **(Fre)**

[Good usage of antidepressants. Proceedings of a meeting. Laguiole, 23–25 June 1995] **Encephale** 1995 Dec;21 Spec No 4:1–65 **(Fre)**

[Administration of high dose levothyroxine in treatment of rapid cycling bipolar disorders. Review of the literature and initial therapeutic application apropos of 6 cases] Afflelou S, et al. **Encephale** 1997 May–Jun;23(3):209–17 (20 ref.) (Eng. Abstr.) **(Fre)**

[Response to antidepressive drugs: a useful trait marker for genetic characterization of depressed patients?] Canceil O. **Encephale** 1995 Dec;21 Spec No 4:61–3 **(Fre)**

[Antidepressive agents and neuroses] Chabannes JP. **Encephale** 1995 Dec;21 Spec No 4:7–9 **(Fre)**

[Efficacy of antidepressants in the management of demented patients] Clément JP, et al. **Encephale** 1995 Dec;21 Spec No 4:43–9 (91 ref.) **(Fre)**

[Indications for new antidepressants with reference to ICD-10: a waggish question or the future of psychiatry?] De Smet Y. **Encephale** 1997 Mar–Apr;23(2):77–82 (31 ref.) (Eng. Abstr.) **(Fre)**

[Psychosocial adjustment of unipolar and bipolar patients] Escande M, et al. **Encephale** 1995 Dec;21 Spec No 4:55–9 (29 ref.) **(Fre)**

[Acute manifestations and reversibility of depression] Hardy MC. **Encephale** 1995 Dec;21 Spec No 4:3–5 **(Fre)**

[Depressive disorders in management of drug dependent patients. Methadone maintenance] Laqueille X, et al. **Encephale** 1995 Dec;21 Spec No 4:11–4 **(Fre)**

[Antidepressants, anxiety and depression disorders] Lépine JP. **Encephale** 1996 Dec;22 Spec No 7:15–7 **(Fre)**

[Clinical criteria for choosing an antidepressive drug] Manus A. **Encephale** 1995 Dec;21 Spec No 4:19–21 (26 ref.) **(Fre)**

[The good usage of antidepressants (editorial)] Olié JP. **Encephale** 1996 Dec;22 Spec No 7:1–2 **(Fre)**

[The treatment of depression in central nervous system disorders] Schmitt L, et al. **Encephale** 1995 Dec;21 Spec No 4:15–8 (27 ref.) **(Fre)**

[Paraclinical monitoring of antidepressant prescription] Sechter D, et al. **Encephale** 1995 Dec;21 Spec No 4:39–41 **(Fre)**

[Treatment with antidepressive drugs: current practices] Spadone C, et al. **Encephale** 1995 Dec;21 Spec No 4:51–3 **(Fre)**

[Use of antidepressants in sleep disorders: practical considerations] Touchon J. **Encephale** 1995 Dec;21 Spec No 7:41–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Paraclinical factors for predicting response to antidepressive agents in depressive states] Vanelle JM. **Encephale** 1995 Dec;21 Spec No 4:23–6 (20 ref.) **(Fre)**

[Biological models of depression: effect of antidepressants on sleep] Viot-Blanc V. **Encephale** 1995 Dec;21 Spec No 7:35–40 (25 ref.) (Eng. Abstr.) **(Fre)**

[Range of activity of anxiolytic and antidepressant drugs] Linkowski P. **Rev Med Brux** 1996 Sep;17(4):220–3 (Eng. Abstr.) **(Fre)**

[Rational use of antidepressants in general medicine] Verbanck P, et al. **Rev Med Brux** 1996 Sep;17(4):224–9 (Eng. Abstr.) **(Fre)**

[Therapeutic monitoring of antidepressants] Charlier C, et al. **Rev Med Liege** 1997 May;52(5):336–44 (10 ref.) **(Fre)**

[Pharmacotherapy of depressed patients. Increasing the therapeutic arsenal with a new generation of antidepressive drugs] Möller HJ. **Fortschr Med** 1997 Apr 20;115(11):30–4, 36 (4 ref.) (Eng. Abstr.) **(Ger)**

[Combination therapies in antidepressive drug refractory depression—an overview] Schmauss M, et al. **Fortschr Neurol Psychiatr** 1996 Oct;64(10):390–402 (168 ref.) (Eng. Abstr.) **(Ger)**

[Depression. The incidence is underestimated—treatment is inadequate] Heinzl S. **Med Monatsschr Pharm** 1996 Mar; 19(3):76–8 (2 ref.) **(Ger)**

[Special aspects of antidepressive therapy] **Nervenarzt** 1994 Mar;65(3 Suppl [speziell]):1–8 **(Ger)**

[A plant extract with proven antidepressive effect] **Nervenarzt** 1997 Feb;68(2 Suppl):2 **(Ger)**

[Antidepressive effectiveness and good tolerance] **Nervenarzt** 1997 Feb;68(2 Suppl):5–7 **(Ger)**

[Predictive factors for therapeutic success in depressive syndrome] Faltermaier-Temizel M, et al. **Nervenarzt** 1997 Jan;68(1):62–6 (Eng. Abstr.) **(Ger)**

[Monoamine oxidase inhibitors in psychiatry. Status of current knowledge] Volz HP, et al. **Nervenarzt** 1996 May; 67(5):339–47 (62 ref.) (Eng. Abstr.) **(Ger)**

[Customary antidepressive treatment in Hungary: moclobemid therapy in everyday practice] Bartkó G. **Orv Hetil** 1997 Sep 14;138(37):2341–5 (Eng. Abstr.) **(Hun)**

[Antidepressive drugs in children and adolescents] Masi G, et al. **Minerva Pediatr** 1996 Jan–Feb;48(1–2):33–47 (60 ref.) (Eng. Abstr.) **(Ita)**

[Efficacy and tolerability of paroxetine in the treatment of the depressive phase of bipolar disorders] Ambrosio LA, et al. **Minerva Psichiatr** 1996 Jun;37(2):91–7 (Eng. Abstr.) **(Ita)**

[The pharmacological action of rubidium chloride in depression] Brundusino AO, et al. **Minerva Psichiatr** 1996 Mar;37(1):45–9 (Eng. Abstr.) **(Ita)**

[Differential combined drug therapy of phantom pain syndrome after amputation of extremity] Kukushkin ML, et al. **Anesteziol Reanimatol** 1996 Jul–Aug;(4):39–42 (Eng. Abstr.) **(Rus)**

[The comparative efficacy of Aurorix and amitriptyline in treating depressions] Iakovlev VA. **Voen Med Zh** 1997 Apr; 318(4):37–8 **(Rus)**

[The Russian antidepressant tetrindole] Mashkovskiĭ MD, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(4):93–5 **(Rus)**

[Critical evaluation of the use of antidepressives in childhood] Conde López VJ, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Mar–Apr;25(2):105–17 (63 ref.) (Eng. Abstr.) **(Spa)**

[Evolution of antidepressive drug consumption in Spain. The impact of selective serotonin re-uptake inhibitors] Alonso MP, et al. **Med Clin (Barc)** 1997 Feb 8;108(5):161–6 (Eng. Abstr.) **(Spa)**

[Antidepressive drugs: yesterday, today and tomorrow?

ANTIDEPRESSIVE AGENTS

(editorial)] Bernardo M. **Med Clin (Barc)** 1997 Feb 8; 108(5):180–1 **(Spa)**
[An approach to the pharmacological treatment of autism] Ruggieri VL. **Rev Neurol** 1996 Nov;24(135):1451–5 (58 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Pharmacokinetics and toxicokinetics of an orally active tripeptide, IRI–695, in animals. Adusumalli V, et al. **Biopharm Drug Dispos** 1996 Jan;17(1):25–41
Embryotoxic effects of B–193 in mouse. Anasiewicz A. **Folia Morphol (Warsz)** 1996;55(4):200–1
Effect of glycine on antidepressant– and anxiolytic–like action of 1–aminocyclopropanecarboxylic acid (ACPC) in rats. Chojnacka–Wójcik E, et al. **Pol J Pharmacol** 1996 Nov–Dec;48(6):627–9
[The genotoxicity and carcinogenic potential of gastrofenzin] Mirkova E. **Eksp Med Morfol** 1994;32(3–4):57–68 (Eng. Abstr.) **(Bul)**
[The toxicological characteristics of Gastrofenzin. III. Its chronic oral toxicity] Antov G, et al. **Probl Khig** 1996; 21:96–102 (Eng. Abstr.) **(Bul)**
[The toxicological characteristics of Gastrofenzin. IV. Its gonadotropic action] Ilieva P, et al. **Probl Khig** 1996; 21:102–6 (Eng. Abstr.) **(Bul)**
[The toxicological characteristics of Gastrofenzin. I. Its acute toxicity (oral, subcutaneous and intravenous)] Khalkova Zh, et al. **Probl Khig** 1996;21:81–8 (Eng. Abstr.) **(Bul)**
[The toxicological characteristics of Gastrofenzin. II. Its subacute oral toxicity] Mikhallova A, et al. **Probl Khig** 1996; 21:88–96 (Eng. Abstr.) **(Bul)**

ANTIDEPRESSIVE AGENTS, SECOND–GENERATION

Nefazodone: its place among antidepressants. Cyr M, et al. **Ann Pharmacother** 1996 Sep;30(9):1006–12 (39 ref.)
Three new antidepressants. **Drug Ther Bull** 1996 Sep; 34(9):65–8
Fluoxetine abuse [letter] Gross R. **J Clin Psychopharmacol** 1996 Dec;16(6):467–8
[Fluoxetine] Gleiter CH, et al. **Dtsch Med Wochenschr** 1997 Apr 11;122(15):481–2 **(Ger)**

ADMINISTRATION & DOSAGE

Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out–patients with inadequate treatment response. Benkert O, et al. **Acta Psychiatr Scand** 1997 Apr;95(4):288–96
Dexamethasone augmentation in treatment–resistant depression. Dinan TG, et al. **Acta Psychiatr Scand** 1997 Jan;95(1):58–61
Relapse prevention by means of paroxetine in ECT–treated patients with major depression: a comparison with imipramine and placebo in medium–term continuation therapy. Lauritzen L, et al. **Acta Psychiatr Scand** 1996 Oct; 94(4):241–51
A double–blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Sultzer DL, et al. **Am J Geriatr Psychiatry** 1997 Winter;5(1):60–9
Fluvoxamine augmentation in clozapine–resistant schizophrenia: an open pilot study. Silver H, et al. **Biol Psychiatry** 1996 Oct 1;40(7):671–4
SSRI combination treatment for depression [letter] Hunchak J. **Can J Psychiatry** 1997 Jun;42(5):531–2
Familial akathisia and depression treated with nefazodone [letter] Simpson JS. **Can J Psychiatry** 1996 Oct; 41(8):539–40
Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. Bakish D, et al. **Int Clin Psychopharmacol** 1997 Mar;12(2):91–7
Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. Maes M, et al. **J Affect Disord** 1996 Dec 16;41(3):201–10
Dose–response relationship with venlafaxine. Kelsey JE. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):21S–26S; discussion 26S–28S (22 ref.)
A randomized, double–blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Benkert O, et al. **J Psychiatr Res** 1996 Nov–Dec;30(6):441–51
A comparison of sustained–release bupropion and placebo for smoking cessation [see comments] Hurt RD, et al. **N Engl J Med** 1997 Oct 23;337(17):1195–202. Comment in: N Engl J Med 1997 Oct 23;337(17):1230–1.
Metabolic interaction between fluoxetine and clomipramine: a case report. Balant–Gorgia AE, et al. **Pharmacopsychiatry** 1996 Jan;29(1):38–41
Lower total serum protein, albumin, and beta– and gamma–globulin in major and treatment–resistant depression: effects of antidepressant treatments. Van Hunsel F, et al. **Psychiatry Res** 1996 Dec 20;65(3):159–69
[New atypical neuroleptics—what to believe? (letter)] Parnas J, et al. **Ugeskr Laeger** 1997 Jul 21;159(30):4661–2 **(Dan)**
[Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo–hypophyseal–thyroid axis] De Mendonça Lima CA, et al. **Encephale** 1997 Jan–Feb; 23(1):48–55 (Eng. Abstr.) **(Fre)**
[Maintenance therapy with 20 mg fluoxetine. Results of an administration study of 1,737 depressed patients] Kasper S, et al. **Wien Klin Wochenschr** 1997 Mar 28;109(6):197–201 (Eng. Abstr.) **(Ger)**
[The treatment with the antidepressant Lerivon of tension headaches and autonomic crises] Filatova EG, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(3):58–62 (Eng. Abstr.) **(Rus)**
[The new antidepressive agents. Is it rational to prescribe drugs or a "mental brace"? (see comments)] Håkansson J. **Lakartidningen** 1996 Nov 6;93(45):4000–2. Comment in: Lakartidningen 1996 Dec 4;93(49):4528. **(Swe)**

ADVERSE EFFECTS

Restless legs syndrome and paroxetine. Sanz–Fuentenebro FJ, et al. **Acta Psychiatr Scand** 1996 Dec;94(6):482–4
Spontaneous male orgasm in association with venlafaxine [letter] Ravsten DV, et al. **Am Fam Physician** 1997 Apr; 55(5):1561, 1564, 1574
Acute cholestasis by fluoxetine [letter] Cosme A, et al. **Am J Gastroenterol** 1996 Nov;91(11):2449–50
Chronic hepatitis related to use of fluoxetine. Johnston DE, et al. **Am J Gastroenterol** 1997 Jul;92(7):1225–6
Fluoxetine discontinuation in elderly dysthymic patients. Devanand DP, et al. **Am J Geriatr Psychiatry** 1997 Winter; 5(1):83–7
Nefazodone–induced mania [letter] Dubin H, et al. **Am J Psychiatry** 1997 Apr;154(4):578–9
Visual "trails" with nefazodone treatment [letter] Kraus RP. **Am J Psychiatry** 1996 Oct;153(10):1365–6
Nefazodone and visual side effects [letter] Schwartz K. **Am J Psychiatry** 1997 Jul;154(7):1038
Nefazodone–induced hypoglycemia in a diabetic patient with major depression [letter] Warnock JK, et al. **Am J Psychiatry** 1997 Feb;154(2):288–9
An open–label evaluation of the long–term safety of oral venlafaxine in depressed elderly patients. Dierick M. **Ann Clin Psychiatry** 1996 Sep;8(3):169–78
Retrospective study of selegiline–nefazodone drug interactions and a review of the literature. Ritter JL, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):7–13 (37 ref.)
Probable nefazodone–induced mania in a patient with unreported bipolar disorder. Zaphiris HA, et al. **Ann Clin Psychiatry** 1996 Dec;8(4):207–10
Serotonin syndrome associated with nefazodone and paroxetine. John L, et al. **Ann Emerg Med** 1997 Feb; 29(2):287–9
Hyperglycemia associated with paroxetine [letter] Petty KJ. **Ann Intern Med** 1996 Nov 1;125(9):782
Cisapride interaction with antidepressants [letter] Caley C. **Ann Pharmacother** 1996 Jun;30(6):684
Venlafaxine and urinary incontinence: possible association [letter] Cavanaugh GL, et al. **Ann Pharmacother** 1997 Mar; 31(3):372
Bruising associated with the use of fluoxetine. Pai VB, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):786–8
Fluoxetine–induced serum sickness–like reaction [letter] Shapiro LE, et al. **Ann Pharmacother** 1997 Jul–Aug; 31(7–8):927
Lactation associated with fluoxetine treatment [letter] Arya DK, et al. **Aust N Z J Psychiatry** 1995 Dec;29(4):697
Withdrawal after discontinuation of paroxetine [letter] Arya DK. **Aust N Z J Psychiatry** 1996 Oct;30(5):702
Fluoxetine and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) [see comments] Burke D, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):295–8 (13 ref.) . Comment in: Aust N Z J Psychiatry 1997 Apr;31(2):306–7.
Fluoxetine and involuntary recall of remote memories. Robertson AR. **Aust N Z J Psychiatry** 1997 Feb; 31(1):128–30
Sulpiride–induced cholestalic jaundice [letter] Sarfraz A, et al. **Aust N Z J Psychiatry** 1996 Oct;30(5):701–2
Fluvoxamine photosensitivity [letter] Gillet–Terver MN, et al. **Australas J Dermatol** 1996 Feb;37(1):62
Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use. Abraham JT, et al. **Biol Psychiatry** 1997 Jul 15; 42(2):144–6
Spontaneous orgasm with the combined use of bupropion and sertraline [letter] Grimes JB, et al. **Biol Psychiatry** 1996 Dec 1;40(11):1184–5
Fluoxetine–induced Raynaud's phenomenon. Rudnick A, et al. **Biol Psychiatry** 1997 Jun 15;41(12):1218–21
Paroxetine and hepatotoxicity. Benbow SJ, et al. **BMJ** 1997 May 10;314(7091):1387
Acute angle closure glaucoma associated with paroxetine. Eke T, et al. **BMJ** 1997 May 10;314(7091):1387
Paroxetine–induced chorea [letter] Fox GC, et al. **Br J Psychiatry** 1997 Feb;170:193–4
Nefazodone–induced spontaneous ejaculation [letter] Micheal A, et al. **Br J Psychiatry** 1996 Nov;169(5):672–3
Antidepressant withdrawal syndrome [letter] Young AH, et al. **Br J Psychiatry** 1997 Mar;170:288
First–trimester exposure to fluoxetine (prozac). Does it affect pregnancy outcome? Koren G. **Can Fam Physician** 1996 Jan;42:43–4
Urinary retention with fluoxetine–haloperidol combination in a young patient [letter] Benazzi F. **Can J Psychiatry** 1996 Nov;41(9):606–7
Venlafaxine withdrawal symptoms [letter] Benazzi F. **Can J Psychiatry** 1996 Sep;41(7):487
Venlafaxine and ecchymosis [letter] Kohn S, et al. **Can J Psychiatry** 1997 Feb;42(1):91
Fluoxetine–imipramine interaction [letter] Leroi I, et al. **Can J Psychiatry** 1996 Jun;41(5):318–9
Emergence of kleptomania during treatment for depression with serotonin selective reuptake inhibitors. Kindler S, et al. **Clin Neuropharmacol** 1997 Apr;20(2):126–9
A new case of fluoxetine–induced mania in poststroke depression [letter] Kulisevsky J, et al. **Clin Neuropharmacol** 1997 Apr;20(2):180–1
Tardive akathisia due to sulpiride. López de Munain A, et al. **Clin Neuropharmacol** 1994 Oct;17(5):481–3
Course of psychomotor agitation during pharmacotherapy of depression: analysis from double–blind controlled trials with fluoxetine. Tollefson GD, et al. **Depress Anxiety** 1996–97;4(6):294–311 (55 ref.)
Rapid cycling triggered by pindolol augmentation of paroxetine, but not with desipramine. Kraus RP. **Depression** 1996;4(2):92–4
Nefazodone. Psychomotor and cognitive effects [letter; comment] van Laar MW. **Drugs** 1997 Jul;54(1):186–7. Comment on: Drugs 1997 Apr;53(4):608–36.
The serotonin syndrome and psychosis–like side–effects of fluvoxamine clinical use—an estimation of incidence. Ebert D, et al. **Eur Neuropsychopharmacol** 1997 Feb;7(1):71–4
Subhyaloid haemorrhage with fluoxetine [letter] Wilmshurst PT, et al. **Eye** 1996;10 (Pt 1):141
A review of the psychomotor effects of paroxetine. Hawley CJ, et al. **Int Clin Psychopharmacol** 1997 Jan;12(1):13–8 (24 ref.)
Mianserin and restless legs. Markkula J, et al. **Int Clin Psychopharmacol** 1997 Jan;12(1):53–8
Serotonin syndrome associated with trazodone [letter] Rao R. **Int J Geriatr Psychiatry** 1997 Jan;12(1):129–30
Changes in fine motor retardation in depressed patients treated with fluoxetine. Sabbe B, et al. **J Affect Disord** 1996 Oct 14;40(3):149–57
Fluoxetine–induced SIADH [letter] Schattner A, et al. **J Am Geriatr Soc** 1996 Nov;44(11):1413
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents [letter] Castañeda R, et al. **J Clin Psychiatry** 1996 Oct; 57(10):485–6
Reversible dyskinesia during bupropion therapy [letter] Gardos G. **J Clin Psychiatry** 1997 May;58(5):218
Safety and tolerability of the new antidepressants. Nelson JC. **J Clin Psychiatry** 1997;58 Suppl 6:26–31 (30 ref.)
Nafazodone and symptoms suggesting neurotoxicity: a case report [letter] Puzantian T, et al. **J Clin Psychiatry** 1996 Dec;57(12):595
Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. Baker B, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):15–21
Drug–drug interactions involving antidepressants: focus on venlafaxine. Ereshefsky L. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):37S–50S; discussion 50S–53S (66 ref.)
Nefazodone– and/or sodium tetradecyl sulfate–associated leukopenia, fever, and shaking chills in a patient with premenstrual dysphoric disorder [letter] Fogelson DL. **J Clin Psychopharmacol** 1997 Jun;17(3):222–3
Venlafaxine–induced hyponatremia [letter] Gupta AK, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):223–5
Withdrawal hypomania associated with paroxetine [letter] Landry P, et al. **J Clin Psychopharmacol** 1997 Feb; 17(1):60–1
Dystonia associated with trazodone and sertraline [letter] Lewis CF, et al. **J Clin Psychopharmacol** 1997 Feb; 17(1):64–5
Fluoxetine–related suicidality and muscle aches in a patient with poststroke depression [letter] Liu CY, et al. **J Clin Psychopharmacol** 1996 Dec;16(6):466–7
The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. Rudolph RL, et al. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):54S–59S; discussion 59S–61S (13 ref.)
Relatively low doses of cisapride in the treatment of nausea in patients treated with venlafaxine for treatment–refractory depression. Russell JL. **J Clin Psychopharmacol** 1996 Feb;16(1):35–7
A case of fluvoxamine intoxication demonstrating nonlinear elimination pharmacokinetics [letter] Spigset O, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):254–5
SSRIs, bupropion, and sexual function. Edens N, et al. **J Fam Pract** 1997 Aug;45(2):101–2
Hair loss associated with nefazodone [letter] Gupta S, et al. **J Fam Pract** 1997 Jan;44(1):20–1
Venlafaxine–induced reset osmostat syndrome: case of a 79–year–old depressed woman. Ranieri P, et al. **J Geriatr Psychiatry Neurol** 1997 Apr;10(2):75–8
Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine. Girault C, et al. **J Toxicol Clin Toxicol** 1997;35(1):93–5
Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone [letter] Jacobson RH, et al. **JAMA** 1997 Jan 22–29;277(4):296–7
Fatality associated with combined fluoxetine–amitriptyline therapy [letter] Preskorn SH, et al. **JAMA** 1997 Jun 4; 277(21):1682
Dangers of fluoxetine [letter] [see comments] Bourguignon RP. **Lancet** 1997 Jan 18;349(9046):214. Comment in: Lancet 1997 Mar 15;349(9054):809.
Dangers of fluoxetine [letter; comment] Judge R. **Lancet** 1997 Mar 15;349(9054):809. Comment on: Lancet 1997 Jan 18;349(9046):214.
Complex movement disorders induced by fluoxetine.

Bharucha KJ, et al. **Mov Disord** 1996 May;11(3):324–6
Effects of first–trimester fluoxetine exposure on the newborn. Goldstein DJ, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):713–8
Urinary retention with venlafaxine–haloperidol combination [letter] Benazzi F. **Pharmacopsychiatry** 1997 Jan;30(1):27
Paroxetine and galactorrhea. Bonin B, et al. **Pharmacopsychiatry** 1997 Jul;30(4):133–4
Reversible hepatotoxicity of paroxetine in a patient with major depression. Helmchen C, et al. **Pharmacopsychiatry** 1996 Nov;29(6):223–6
Two cases of deep vein thrombosis associated with a combined paroxetine and zotepine therapy. Pantel J, et al. **Pharmacopsychiatry** 1997 May;30(3):109–11
Serotonin syndrome after lithium add–on medication to paroxetine. Sobanski T, et al. **Pharmacopsychiatry** 1997 May;30(3):106–7
Warfarin–fluoxetine and diazepam–fluoxetine interaction. Dent LA, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):170–2
Female sexual stimulation during antidepressant treatment. Elmore JL, et al. **Pharmacotherapy** 1997 May–Jun; 17(3):612–6
The safety of fluoxetine during pregnancy and lactation. Nulman I, et al. **Teratology** 1996 May;53(5):304–8 (33 ref.)
Paroxetine (Paxil) overdose: a pediatric focus. Myers LB, et al. **Vet Hum Toxicol** 1997 Apr;39(2):86–8
Hypoglycemia associated with the use of fluoxetine. Deeg MA, et al. **West J Med** 1996 Mar;164(3):262
[Severe hepatitis attributed to paroxetine (Seroxat)] de Man RA. **Ned Tijdschr Geneeskd** 1997 Mar 15;141(11):540–2 (Eng. Abstr.) **(Dut)**
[Can salivary gland swelling, edema and "direct" hyperbilirubinemia develop as sequelae of chronic administration of mianserin?] Gundert–Remy. **Internist (Berl)** 1996 May;37(5):518–9 **(Ger)**
[Mianserin–induced hypertension 2 weeks after discontinuation of tranylcypromine] Bottlender R, et al. **Nervenarzt** 1997 Jul;68(7):591–2 (Eng. Abstr.) **(Ger)**
[Bradycardia after beginning therapy with metoprolol and paroxetine] König F, et al. **Psychiatr Prax** 1996 Sep; 23(5):244–5 (Eng. Abstr.) **(Ger)**
[Blood glucose dysregulation with mianserin] Wolter–Henseler D. **Psychiatr Prax** 1996 Jul;23(4):200 **(Ger)**
[I give my patients a suicide weapon (letter; comment)] Egeland A. **Tidsskr Nor Laegeforen** 1997 Apr 10; 117(9):1336–7. Comment on: Tidsskr Nor Laegeforen 1997 Mar 10;117(7):1003. **(Nor)**
[Seroxat combined with Meravean––increased risk of hemorrhage? (letter)] Haukeland JW. **Tidsskr Nor Laegeforen** 1996 Nov 30;116(29):3528–9 **(Nor)**

ANALYSIS

A rapid electron–capture gas chromatographic method for the quantification of fluvoxamine in brain tissue. Rotzinger S, et al. **J Pharmacol Toxicol Methods** 1997 Apr; 37(3):129–33
[An analysis of Eglonyl in cadaveric material] Stepanova EN, et al. **Sud Med Ekspert** 1997 Jul–Sep;40(3):28–30 (Eng. Abstr.) **(Rus)**

BLOOD

Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral–chiral liquid chromatography. Suckow RF, et al. **Biomed Chromatogr** 1997 May–Jun;11(3):174–9
Distribution of venlafaxine in three postmortem cases. Levine B, et al. **J Anal Toxicol** 1996 Oct;20(6):502–5
Comparison of analytical methods in the determination of two venlafaxine fatalities. Long C, et al. **J Anal Toxicol** 1997 Mar–Apr;21(2):166–9
Quantitative determination of paroxetine in plasma by high–performance liquid chromatography and ultraviolet detection. Foglia JP, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):147–51
Seasonal variation in platelet [3H]paroxetine binding in healthy volunteers. Relationship to climatic variables. D'Hondt P, et al. **Neuropsychopharmacology** 1996 Aug; 15(2):187–98
Increases in plasma concentration of m–chlorophenylpiperazine, but not trazodone, with low–dose haloperidol. Mihara K, et al. **Ther Drug Monit** 1997 Feb;19(1):43–5
Bupropion plasma levels and CYP2D6 phenotype. Pollock BG, et al. **Ther Drug Monit** 1996 Oct;18(5):581–5

ECONOMICS

Economic analysis of treating depression with nefazodone v. imipramine. Montgomery SA, et al. **Br J Psychiatry** 1996 Jun;168(6):768–71
Cost–effectiveness of venlafaxine for the treatment of major depression in hospitalized patients. Priest RG. **Clin Ther** 1996 Mar–Apr;18(2):347–58; discussion 302 (37 ref.)
Economic evaluation of paroxetine and imipramine in depressed outpatients. Melton ST, et al. **Psychopharmacol Bull** 1997;33(1):93–100

METABOLISM

Lower 3H–paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high affinity, non–transporter sites. Mann JJ, et al. **J Neural Transm** 1996;103(11):1337–50

PHARMACOKINETICS

Antidepressants and breast–feeding [letter; comment] Ito S, et al. **Am J Psychiatry** 1997 Aug;154(8):1174. Comment on: Am J Psychiatry 1996 Sep;153(9):1132–7.
The lack effect of food on the bioavailability of nefazodone tablets. Dockens RC, et al. **Biopharm Drug Dispos** 1996 Mar;17(2):135–43
Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Barbhaiya RH, et al. **Br J Clin Pharmacol** 1996 Nov;42(5):573–81
Fluvoxamine in breast–milk and infant development [letter] Yoshida K, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):210–1
Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. Barbhaiya RH, et al. **Drug Metab Dispos** 1996 Jan;24(1):91–5
Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Spigset O, et al. **Eur J Clin Pharmacol** 1997;52(2):129–33
Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. Dockens RC, et al. **J Clin Pharmacol** 1996 Feb;36(2):160–7
Fluoxetine distribution in human milk [letter] Duffull SB, et al. **J Clin Pharmacol** 1996 Nov;36(11):1078–9
Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. Taddio A, et al. **J Clin Pharmacol** 1996 Jan;36(1):42–7
Pharmacokinetic interaction between multiple–dose venlafaxine and single–dose lithium. Troy SM, et al. **J Clin Pharmacol** 1996 Feb;36(2):175–81
Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. Alderman J, et al. **J Clin Psychopharmacol** 1997 Aug; 17(4):284–91
A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. Barbhaiya RH, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):19–25
Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. Barbhaiya RH, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):26–34
A case of fluvoxamine intoxication demonstrating nonlinear elimination pharmacokinetics [letter] Spigset O, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):254–5
Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Avenoso A, et al. **Pharmacol Res** 1997 Apr;35(4):335–9
The effect of activated charcoal on the absorption of fluoxetine, with special reference to delayed charcoal administration. Laine K, et al. **Pharmacol Toxicol** 1996 Nov; 79(5):270–3
Pharmacokinetic fluvoxamine–clomipramine interaction with favorable therapeutic consequences in therapy–resistant depressive patient. Conus P, et al. **Pharmacopsychiatry** 1996 May;29(3):108–10
Effects of age and gender on venlafaxine and O–desmethylvenlafaxine pharmacokinetics. Klamerus KJ, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):915–23
Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. Bertschy G, et al. **Ther Drug Monit** 1996 Oct;18(5):570–2

PHARMACOLOGY

Mirtazapine: pharmacology in relation to adverse effects. Nutt D. **Acta Psychiatr Scand Suppl** 1997;391:31–7
Propofol, fluoxetine and spontaneous movement [letter] Armstrong TS, et al. **Anaesthesia** 1997 Aug;52(8):809–10
Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Barr LC, et al. **Biol Psychiatry** 1997 May 1;41(9):949–54
Plasma levels of m–chlorophenylpiperazine following single oral dose administration of m–chlorophenylpiperazine and trazodone in human volunteers. Lawlor BA, et al. **Biol Psychiatry** 1997 Mar 15;41(6):756–7
Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450–3A isoforms. von Moltke LL, et al. **Biol Psychiatry** 1997 Feb 1;41(3):377–80
Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Ball SE, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):619–26
Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Modell JG, et al. **Clin Pharmacol Ther** 1997 Apr;61(4):476–87
Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression [see comments] Davis R, et al. **Drugs** 1997 Apr;53(4):608–36 (110 ref.). Comment in: Drugs 1997 Jul;54(1);186–7.
Behavioural sensitization of mesolimbic dopamine D2 receptors in chronic fluoxetine–treated rats. Collu M, et al. **Eur J Pharmacol** 1997 Mar 19;322(2–3):123–7
Potentiation of fluoxetine–induced penile erections by combined blockade of 5–HT1A and 5–HT1B receptors. Millan MJ, et al. **Eur J Pharmacol** 1997 Mar 5;321(3):R11–3
Use of fluoxetine for the treatment of stereotypical pacing behavior in a captive polar bear [see comments] Poulsen EM, et al. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1470–4 . Comment in: J Am Vet Med Assoc 1996 Dec 15;209(12):1995–6.
Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. Dockens RC, et al. **J Clin Pharmacol** 1996 Feb;36(2):160–7
Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. Barbhaiya RH, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):26–34
The effect of nefazodone on the single–dose pharmacokinetics of phenytoin in healthy male subjects. Marino MR, et al. **J Clin Psychopharmacol** 1997 Feb; 17(1):27–33
The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5–HT2A receptor status. Spigset O, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):292–7
Interactions between different antidepressants and morphine alter gastrointestinal transit in mice. Backer MM, et al. **Life Sci** 1997;61(9):PL109–13
Comparative electrophysiological effects of the antidepressants fluvoxamine and amitriptyline in the canine heart after myocardial infarction. Ikeda Y, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jun; 354(1):30–7
The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Jett MF, et al. **Pain** 1997 Jan;69(1–2):161–9
Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline, and fluvoxamine. I. Social interactions. Cutler MG, et al. **Pharmacol Biochem Behav** 1997 May–Jun; 57(1–2):119–25
Effects of fluvoxamine and dothiepin on psychomotor abilities in healthy volunteers. Fairweather DB, et al. **Pharmacol Biochem Behav** 1996 Feb;53(2):265–9
Fluoxetine alters the effects of cocaine on vigilance task performance of rats. Grilly DM, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):515–22
Fluoxetine reduces saccharin–induced elevation of fluid intake in alcohol–preferring Fawn–Hooded rats. Kampov–Polevoy AB, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):51–4
Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus–maze. Rodgers RJ, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):127–36
Anxiolytic and memory improving activity of fluoxetine. Nowakowska E, et al. **Pol J Pharmacol** 1996 May–Jun; 48(3):255–60
Studies on the interaction of antidepressant drugs with adrenocorticotropic hormone or prednisone in rats. Pietrasiewicz T, et al. **Pol J Pharmacol** 1996 Mar–Apr; 48(2):145–52
Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). García–Colunga J, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):2041–4
Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects. Röschke J, et al. **Psychopharmacology (Berl)** 1997 Jul;132(1):44–9
Effect of paroxetine and nefazodone on 5–HT1A receptor sensitivity. Sargent P, et al. **Psychopharmacology (Berl)** 1997 Aug;132(3):296–302
The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Sharpley AL, et al. **Psychopharmacology (Berl)** 1996 Jul;126(1):50–4
Phenacetin O–deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. von Moltke LL, et al. **Psychopharmacology (Berl)** 1996 Dec;128(4):398–407
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy [letter; comment] Boyeson MG. **Stroke** 1996 Nov; 27(11):2145–6. Comment on: Stroke 1996 Jul;27(7):1211–4.
Effect of acute and chronic fluoxetine on extracellular dopamine levels in the caudate–putamen and nucleus accumbens of rat. Clark RN, et al. **Synapse** 1996 Jul; 23(3):125–31
Fluoxetine–induced conditioned place preference: a preliminary study. Collu M, et al. **Synapse** 1997 Mar; 25(3):309–11
Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoin [letter] Vandel P, et al. **Therapie** 1997 Jan–Feb;52(1):74–6
[Effects of co–administration of an antidepressant and an anxiolytic drug in the "learned helplessness" paradigm: importance of hydroxyzine] Martin P, et al. **Encephale** 1996 Jul–Aug;22(4):270–9 (Eng. Abstr.) **(Fre)**
[A comparative pharmacological study of the serotoninergic antidepressants tetrindole and fluoxetin] Andreeva NI, et al. **Eksp Klin Farmakol** 1996 Jul–Aug;59(4):5–7 (Eng. Abstr.) **(Rus)**

POISONING

Fluoxetine–induced cardiotoxicity with response to bicarbonate therapy. Graudins A, et al. **Am J Emerg Med** 1997 Sep;15(5):501–3
Comment: seizure resulting from venlafaxine overdose [letter; comment] Durback LF, et al. **Ann Pharmacother** 1997 Jun;

31(6):790–1. Comment on: Ann Pharmacother 1997 Feb;31(2):178–80.
Gas chromatographic examination of postmortem specimens after maprotiline intoxication. Keller T, et al. **Forensic Sci Int** 1997 Aug 4;88(2):117–23
Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hodgman MJ, et al. **Hum Exp Toxicol** 1997 Jan;16(1):14–7
Trazodone and dothiepin poisoning [letter; comment] Esposito G. **J Anal Toxicol** 1996 Jan–Feb;20(1):59–60. Comment on: J Anal Toxicol 1994 May–Jun;18(3):176–9.
Two fatal cases of venlafaxine poisoning. Parsons AT, et al. **J Anal Toxicol** 1996 Jul–Aug;20(4):266–8
Toxicity in venlafaxine overdose [letter] Dagg PK. **J Psychiatry Neurosci** 1997 May;22(3):201–2
Fatal bupropion overdose. Harris CR, et al. **J Toxicol Clin Toxicol** 1997;35(3):321–4
Overdose of venlafaxine—a new antidepressant [letter] Adesanya A, et al. **Med J Aust** 1997 Jul 7;167(1):54
[Acute agitation after poisoning to viloxazine (letter)] Py P, et al. **Therapie** 1996 May–Jun;51(3):327 **(Fre)**
[A case report. Fatal case of acute fluoxetine poisoning] Druid H, et al. **Lakartidningen** 1996 Nov 13;93(46):4149–50 **(Swe)**

THERAPEUTIC USE

Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities. Andiné P, et al. **Acta Psychiatr Scand** 1997 Jul;96(1):82–3
Paroxetine and amitriptyline in the treatment of depression in general practice. Christiansen PE, et al. **Acta Psychiatr Scand** 1996 Mar;93(3):158–63
Efficacy of venlafaxine in depressive illness in general practice. Lecrubier Y, et al. **Acta Psychiatr Scand** 1997 Jun;95(6):485–93
The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Razavi D, et al. **Acta Psychiatr Scand** 1996 Sep;94(3):205–10
Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Stahl S, et al. **Acta Psychiatr Scand Suppl** 1997;391:22–30
Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Schneider LS, et al. **Am J Geriatr Psychiatry** 1997 Spring;5(2):97–106
Reassessment of nefazodone [letter; comment] Bryant SG. **Am J Health Syst Pharm** 1996 Oct 1;53(19):2339–40, 2343 . Comment on: Am J Health Syst Pharm 1995 Dec 15;52(24):2799–812.
Response of kleptomania and mixed mania to valproate [letter] Kmetz GF, et al. **Am J Psychiatry** 1997 Apr; 154(4):580–1
Fluoxetine treatment of anger attacks: a replication study. Fava M, et al. **Ann Clin Psychiatry** 1996 Mar;8(1):7–10
L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease. Patel SV, et al. **Ann Clin Psychiatry** 1996 Mar;8(1):23–6
Double-blind pilot trial of desipramine versus fluoxetine in panic patients. Bystritsky A, et al. **Anxiety** 1994–95; 1(6):287–90
Treatment of social phobia with fluoxetine. Perugi G, et al. **Anxiety** 1994–95;1(6):282–6
Fluoxetine-induced SIADH: most likely in the elderly? [letter] Burke D, et al. **Aust N Z J Psychiatry** 1996 Apr; 30(2):299–301
Nefazodone and akathisia. Eberstein S, et al. **Biol Psychiatry** 1996 Oct 15;40(8):798–9
Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine. Ko HC, et al. **Biol Psychiatry** 1997 Apr 1;41(7):774–81
Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? Nierenberg AA, et al. **Biol Psychiatry** 1996 Oct 15;40(8):691–6
A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. Pillay SS, et al. **Biol Psychiatry** 1997 Jul 15;42(2):79–84
Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Renshaw PF, et al. **Biol Psychiatry** 1997 Apr 15;41(8):837–43
Are study dropouts different from completers? Tedlow JR, et al. **Biol Psychiatry** 1996 Oct 1;40(7):668–70
A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression [see comments] Appleby L, et al. **BMJ** 1997 Mar 29; 314(7085):932–6. Comment in: BMJ 1997 Jul 12;315(7100):122.
Treatment of nodular prurigo with cyclosporin (treat the disease, not just the symptoms) [letter; comment] Koblenzer CS. **Br J Dermatol** 1996 Aug;135(2):330–1. Comment on: Br J Dermatol 1995 May;132(5):795–9.
Venlafaxine-induced increased libido and spontaneous erections [letter] Michael A, et al. **Br J Psychiatry** 1997 Feb;170:193
Controlled efficacy study of fluoxetine in dysthymia. Vanelle JM, et al. **Br J Psychiatry** 1997 Apr;170:345–50
Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. van Heeringen K, et al. **Br J Psychiatry** 1996 Oct;169(4):440–3
Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. Waldinger MD, et al. **Br J Urol** 1997 Apr;79(4):592–5
Advances in psychopharmacology: mood disorders and dementia. Cowen PJ. **Br Med Bull** 1996 Jul;52(3):539–55 (44 ref.)
Freud, Prozac, and the human condition [letter] Khouzam HR. **Can J Psychiatry** 1996 Apr;41(3):195
New antidepressants: more options for tailoring treatment. Muzina DJ, et al. **Cleve Clin J Med** 1996 Nov-Dec; 63(7):406–12; quiz 420 (20 ref.)
Venlafaxine: a novel antidepressant that has a dual mechanism of action. Andrews JM, et al. **Depression** 1996; 4(2):48–56 (40 ref.)
Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. Dunner DL, et al. **Depression** 1996; 4(1):34–41
Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression [see comments] Davis R, et al. **Drugs** 1997 Apr;53(4):608–36 (110 ref.). Comment in: Drugs 1997 Jul;54(1);186–7.
Comments and reply on Ikeguchi and Kuroda: Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs [letter] Friedman JH, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(2):106–7
Predicting factors for absenteeism in patients with major depressive disorders. Souêtre E, et al. **Eur J Epidemiol** 1997 Jan;13(1):87–93
Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment. Cavedini P, et al. **Eur Neuropsychopharmacol** 1997 Feb; 7(1):45–9
Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. López-Ibor JJ Jr, et al. **Eur Neuropsychopharmacol** 1996 May;6(2):111–8
A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. Sundblad C, et al. **Eur Neuropsychopharmacol** 1997 Aug; 7(3):201–6
The eight-item treatment-outcome post-traumatic stress disorder scale: a brief measure to assess treatment outcome in post-traumatic stress disorder. Davidson JR, et al. **Int Clin Psychopharmacol** 1997 Jan;12(1):41–5
Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Entsuah AR, et al. **Int Clin Psychopharmacol** 1996 Jun; 11(2):137–45
Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Fabre L, et al. **Int Clin Psychopharmacol** 1996 Jun;11(2):119–27
A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Milanfranchi A, et al. **Int Clin Psychopharmacol** 1997 May; 12(3):131–6
Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium. Nakamura J, et al. **Int Clin Psychopharmacol** 1997 May;12(3):147–52
A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Mahapatra SN, et al. **Int J Clin Pract** 1997 Jun; 51(4):209–13
Placebo-controlled treatment trial of depression in elderly physically ill patients. Evans M, et al. **Int J Geriatr Psychiatry** 1997 Aug;12(8):817–24
Serzone superior to Prozac [news] **Ir Med J** 1997 Jun-Jul; 90(4):156
Nefazodone-breakthrough therapy for depressive disorders with sexual dysfunction [news] **Ir Med J** 1996 Sep-Oct; 89(5):190
Personality disorder scores improve with effective pharmacotherapy of depression. Black KJ, et al. **J Affect Disord** 1997 Mar;43(1):11–8
Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. Franchini L, et al. **J Affect Disord** 1996 Apr 26;38(1):67–9
Right hemisphere abnormalities in major depression: quantitative electroencephalographic findings before and after treatment. Kwon JS, et al. **J Affect Disord** 1996 Oct 14;40(3):169–73
Moclobemide and fluoxetine in treatment of seasonal affective disorder. Partonen T, et al. **J Affect Disord** 1996 Nov 25; 41(2):93–9
Depressive retardation and treatment with fluoxetine: assessment of the motor component. Sabbe B, et al. **J Affect Disord** 1997 Mar;43(1):53–61
Bupropion hydrochloride in attention deficit disorder with hyperactivity. Conners CK, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Oct; 35(10):1314–21
Case study: nefazodone for juvenile mood disorders. Wilens TE, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Apr; 36(4):481–5
Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group. Small GW, et al. **J Am Geriatr Soc** 1996 Oct;44(10):1220–5
Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial. Entsuah R. **J Biopharm Stat** 1996 Nov;6(4):457–75 (30 ref.)
An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Olvera RL, et al. **J Child Adolesc Psychopharmacol** 1996 Winter;6(4):241–50
A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial [published erratum appears in J Clin Psychiatry 1997 Jun;58(6):275] Gillin JC, et al. **J Clin Psychiatry** 1997 May; 58(5):185–92
Safety and tolerability of the new antidepressants. Nelson JC. **J Clin Psychiatry** 1997;58 Suppl 6:26–31 (30 ref.)
Sertraline-induced anorgasmia treated with intermittent nefazodone [letter] Reynolds RD. **J Clin Psychiatry** 1997 Feb;58(2):89
A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. Armitage R, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):161–8
Clinical evaluation of venlafaxine. Ballenger JC. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):29S–35S; discussion 35S–36S (12 ref.)
Risperidone and fluoxetine in the treatment of pedophilia with comorbid dysthymia [letter] Bourgeois JA, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):257–8
Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. Fichter MM, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):9–18
An open clinical trial of fluoxetine in the treatment of premature ejaculation. Lee HS, et al. **J Clin Psychopharmacol** 1996 Oct;16(5):379–82
Paroxetine/bupropion combination treatment for refractory depression [letter] Marshall RD, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):80–1
Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. Mundo E, et al. **J Clin Psychopharmacol** 1997 Aug; 17(4):267–71
Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. Pearlstein TB, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):261–6
A comparison of fluvoxamine and fluoxetine in the treatment of major depression. Rapaport M, et al. **J Clin Psychopharmacol** 1996 Oct;16(5):373–8
Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases [letter] Rauch SL, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):81–4
Newer antidepressants: hypotheses and evidence [editorial] Shader RI, et al. **J Clin Psychopharmacol** 1997 Feb; 17(1):1–3 (20 ref.)
Fluvoxamine treatment of trichotillomania. Stanley MA, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):278–83
Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. Stein MB, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):218–22
Antidepressant options: venlafaxine in perspective. Thase ME. **J Clin Psychopharmacol** 1996 Jun;16(3 Suppl 2):10S–18S; discussion 18S–20S (70 ref.)
Paroxetine as a treatment for premenstrual dysphoric disorder. Yonkers KA, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):3–8
Paroxetine in depressed adolescents with intellectual disability: an open label study. Masi G, et al. **J Intellect Disabil Res** 1997 Jun;41 (Pt 3):268–72
Fluoxetine and restless legs syndrome. Bakshi R. **J Neurol Sci** 1996 Oct;142(1–2):151–2
Moclobemide versus fluoxetine for double depression: a randomized double-blind study. Duarte A, et al. **J Psychiatr Res** 1996 Nov-Dec;30(6):453–8
Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. Lapierre YD, et al. **J Psychiatry Neurosci** 1997 Mar;22(2):118–26
Fluoxetine vs. tricyclic antidepressants in women with major depressive disorder. Lewis-Hall FC, et al. **J Womens Health** 1997 Jun;6(3):337–43
Initial choice of antidepressant therapy in primary care [letter; comment] Bruhat A, et al. **JAMA** 1996 Oct 23–30; 276(16):1301; discussion 1302. Comment on: JAMA 1996 Jun 26;275(24):1897–902.
Initial choice of antidepressant therapy in primary care [letter; comment] Schwab PJ. **JAMA** 1996 Oct 23–30; 276(16):1301–2; discussion 1302. Comment on: JAMA 1996 Jun 26;275(24):1897–902.
Dichotic listening before and after fluoxetine treatment for major depression: relations of laterality to therapeutic response. Bruder GE, et al. **Neuropsychopharmacology** 1996 Aug;15(2):171–9
Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Meltzer H, et al. **Neuropsychopharmacology** 1997 Jul;17(1):1–11
Fluoxetine in the treatment of premenstrual dysphoria. Su TP, et al. **Neuropsychopharmacology** 1997 May;16(5):346–56
Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Lang E, et al. **Pain** 1996 Nov;68(1):151–5
Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Avenoso A, et

al. **Pharmacol Res** 1997 Apr;35(4):335–9

Ritanserin as adjunct to fluoxetine treatment of OCD patients with psychotic features [letter] Bach M, et al. **Pharmacopsychiatry** 1997 Jan;30(1):28–9

Pharmacokinetic fluvoxamine–clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Conus P, et al. **Pharmacopsychiatry** 1996 May;29(3):108–10

Antidepressant drug use: differences between psychiatrists and general practitioners. Results from a drug utilization observation study with fluoxetine. Dittmann RW, et al. **Pharmacopsychiatry** 1997 Jan;30(1 Suppl):28–34

Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Fichter MM, et al. **Pharmacopsychiatry** 1997 May;30(3):85–92

Efficacy of paroxetine for the treatment of depression in the context of HIV infection. Grassi B, et al. **Pharmacopsychiatry** 1997 Mar;30(2):70–1

An investigation of the representativity of neuropsychiatrists and their patients in a drug utilization observation study on fluoxetine. Schaaf B, et al. **Pharmacopsychiatry** 1997 Jan;30(1 Suppl):44–51

A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Szegedi A, et al. **Pharmacopsychiatry** 1997 May;30(3):97–105

The treatment of depression with paroxetine in psychiatric practice in Germany: the possibilities and current limitations of drug monitoring. Zaninelli R, et al. **Pharmacopsychiatry** 1997 Jan;30(1 Suppl):9–20

Venlafaxine and nefazodone, two pharmacologically distinct antidepressants. Augustin BG, et al. **Pharmacotherapy** 1997 May–Jun;17(3):511–30 (91 ref.)

Obsessive compulsive disorder and depression—first results of a prospective study on 74 patients. Demal U, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jul; 20(5):801–13

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Dierick M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jan; 20(1):57–71

The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviours: preliminary clinical experience. Eapen V, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 May; 20(4):737–43

Hostility in heroin abusers subtypes: fluoxetine and naltrexone treatment. Gerra G, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Dec; 19(8):1225–37

Acute stimulant response prediction of chronic trazodone effects. Little KY, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jul; 20(5):815–24

Efficacy of mianserin on symptoms of delirium in the aged: an open trial study. Uchiyama M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 May; 20(4):651–6

New antidepressant drugs and the treatment of depression in the medically ill patient. Stoudemire A. **Psychiatr Clin North Am** 1996 Sep;19(3):495–514 (85 ref.)

Open-label trial of venlafaxine in adults with attention deficit disorder. Adler LA, et al. **Psychopharmacol Bull** 1995; 31(4):785–8

Double-blind fluoxetine in depressed alcoholic smokers. Cornelius JR, et al. **Psychopharmacol Bull** 1997; 33(1):165–70

Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a meta-analysis. Entsuah AR, et al. **Psychopharmacol Bull** 1995;31(4):759–66

A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Fava M, et al. **Psychopharmacol Bull** 1997; 33(1):101–3

An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Hedges D, et al. **Psychopharmacol Bull** 1995;31(4):779–83

An open trial of nefazodone in adult patients with generalized anxiety disorder. Hedges DW, et al. **Psychopharmacol Bull** 1996;32(4):671–6

Venlafaxine in social phobia. Kelsey JE. **Psychopharmacol Bull** 1995;31(4):767–71

Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Khan A, et al. **Psychopharmacol Bull** 1995; 31(4):753–8

Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients. Laghrissi-Thode F, et al. **Psychopharmacol Bull** 1995; 31(4):659–63

Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls. Little JT, et al. **Psychopharmacol Bull** 1996;32(4):629–35

A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Luthringer R, et al. **Psychopharmacol Bull** 1996;32(4):637–46

Venlafaxine in the treatment of children and adolescents with major depression. Mandoki MW, et al. **Psychopharmacol Bull** 1997;33(1):149–54

Venlafaxine in the treatment of borderline personality disorder. Markovitz PJ, et al. **Psychopharmacol Bull** 1995; 31(4):773–7

Economic evaluation of paroxetine and imipramine in depressed outpatients. Melton ST, et al. **Psychopharmacol Bull** 1997;33(1):93–100

Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Pollack MH, et al. **Psychopharmacol Bull** 1996;32(4):667–70

Fluoxetine in the treatment of depression in Asian (Chinese and Indian) patients in Singapore. Tsoi WF, et al. **Singapore Med J** 1995 Aug;36(4):397–9

Venlafaxine hydrochloride and chronic pain. Taylor K, et al. **West J Med** 1996 Sep;165(3):147–8

[Meta-analysis of therapeutic trials: applications in psychiatry] Cucherat M, et al. **Encephale** 1996 Sep–Oct; 22(5):378–87 (Eng. Abstr.) **(Fre)**

[Evaluating quality of life of depressed patients in ambulatory care treatment] Dazord A, et al. **Encephale** 1996 Jul–Aug; 22(4):247–54 (Eng. Abstr.) **(Fre)**

[Is it feasible to develop a 5-HT basis for the treatment of depression?] Hamon M. **Encephale** 1995 Dec;21 Spec No 4:27–32 (26 ref.) **(Fre)**

[Therapy of affect incontinence with paroxetine] Erfurth A. **Psychiatr Prax** 1997 Jul;24(4):208–9 **(Ger)**

[Controlled long-term prevention of unipolar depression with antidepressive agents of the second generation (SSRI)] Zimmermann U. **Psychiatr Prax** 1996 Sep;23(5):240–3 (29 ref.) (Eng. Abstr.) **(Ger)**

[A test for using meta-analysis to evaluate antidepressive effects of fluoxetine] Jarema M. **Psychiatr Pol** 1996 Jul–Aug;30(4):569–81 (Eng. Abstr.) **(Pol)**

[A comparative clinical evaluation of the antidepressive activity of fluoxetine and fluvoxamine] Lopukhov IG. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(4):53–7 (Eng. Abstr.) **(Rus)**

[What anti-depressive agent is best? (letter)] Andréewitch S. **Lakartidningen** 1997 Jul 9;94(28–29):2529–30 **(Swe)**

TOXICITY

A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats. Fiçicioğlu C, et al. **Acta Eur Fertil** 1995 Mar–Apr;26(2):75–9

Comments on fluoxetine in carcinogenicity [letter; comment] Hoffman WP, et al. **J Clin Psychopharmacol** 1996 Aug; 16(4):335–9. Comment on: J Clin Psychopharmacol 1995 Feb;15(1):84–5.

Potential fluoxetine chloride (Prozac) toxicity in a newborn [letter] Mhanna MJ, et al. **Pediatrics** 1997 Jul;100(1):158–9

Fluoxetine hypophagia. Is there a role for serotonergic mechanisms in some circumstances? [letter; comment] Clifton PG, et al. **Trends Pharmacol Sci** 1997 Jun; 18(6):191–2 (4 ref.). Comment on: Trends Pharmacol Sci 1997 Jan;18(1):21–5.

ANTIDEPRESSIVE AGENTS, TRICYCLIC

Prescribing antidepressants in general practice. People may become psychologically dependent on antidepressants [letter; comment] Double DB. **BMJ** 1997 Mar 15; 314(7083):829. Comment on: BMJ 1996 Oct 5;313(7061):858–9.

Stereoselective and simultaneous measurement of cis- and trans-isomers of doxepin and N-desmethyldoxepin in plasma or urine by high-performance liquid chromatography. Yan J, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):131–8

[I prescribe suicide-weapons to my patients (letter; comment) (see comments)] Martinsen EW. **Tidsskr Nor Laegeforen** 1997 Mar 10;117(7):1003. Comment on: Tidsskr Nor Laegeforen 1997 Feb 28;117(6):851. Comment in: Tidsskr Nor Laegeforen 1997 Apr 10;117(9):1336–7. **(Nor)**

[The role of serotonergic system in the mechanism of action of antidepressant agents] Wielosz M. **Psychiatr Pol** 1996 Nov–Dec;30(6):963–72 (32 ref.) (Eng. Abstr.) **(Pol)**

[Prescription of Tofranil an mistake? (letter)] Jacobson NO. **Lakartidningen** 1997 Aug 27;94(35):2907 **(Swe)**

ADMINISTRATION & DOSAGE

Modified oral anticoagulant potency in an amitriptyline-treated patient? Hampel H, et al. **Acta Haematol** 1996;96(3):178–80

Oestradiol treatment helped a depressed postmenopausal woman to stop her psychotropic medication: a case report. Korhonen S, et al. **Acta Psychiatr Scand** 1996 Dec; 94(6):480–1

Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Lauritzen L, et al. **Acta Psychiatr Scand** 1996 Oct; 94(4):241–51

Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Inoue T, et al. **Biol Psychiatry** 1996 Jul 15;40(2):151–3

Prescribing antidepressants in general practice. Prescription does not mean that major depression is being treated [letter; comment] [published erratum appears in BMJ 1997 Apr 12;314(7087):1132] Ali IM. **BMJ** 1997 Mar 15;314(7083):827. Comment on: BMJ 1996 Oct 5;313(7061):861–2.

Prescribing antidepressants in general practice. Prescribing rates vary widely between practices [letter; comment] Bisset AF, et al. **BMJ** 1997 Mar 15;314(7083):828. Comment on: BMJ 1996 Oct 5;313(7061):861–2.

Prescribing antidepressants in general practice. Prescribing is short-term and follow up poor [letter; comment] Johnson T, et al. **BMJ** 1997 Mar 15;314(7083):828. Comment on: BMJ 1996 Oct 5;313(7061):861–2.

Prescribing antidepressants in general practice. Tricyclic antidepressants are also used for relief of chronic pain [letter; comment] [see comments] Milligan K. **BMJ** 1997 Mar 15;314(7083):827–8. Comment on: BMJ 1996 Oct 5;313(7061):829–30. Comment on: BMJ 1996 Oct 5;313(7061):860–1. Comment in: BMJ 1997 Mar 15;314(7083):703. Comment in: BMJ 1997 Jul 5;315(7099):56.

Prescribing antidepressants in general practice. More on what is an effective dose [letter; comment] [see comments] Moore MV. **BMJ** 1997 Mar 15;314(7083):826. Comment on: BMJ 1996 Oct 5;313(7061):829–30. Comment in: BMJ 1997 Jul 5;315(7099):56.

Prescribing antidepressants in general practice. Low dose tricyclic antidepressants re effective in treating major depression [letter; comment] [see comments] Tan RS. **BMJ** 1997 Mar 15;314(7083):827. Comment on: BMJ 1996 Oct 5;313(7061):829–30. Comment on: BMJ 1996 Oct 5;313(7061):860–1. Comment in: BMJ 1997 Jul 5;315(7099):56.

Re: A time to bury tricyclic antidepressants or to praise them? [letter] Berber MJ. **Can J Psychiatry** 1997 Aug;42(6):663

Predicting outcome of lithium added to antidepressants in resistant depression. Alvarez E, et al. **J Affect Disord** 1997 Feb;42(2–3):179–86

Concurrent treatment of nonresistant major depression with desipramine and lithium: a double-blind, placebo-controlled study. Bloch M, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):44–8

Pulse-dosing and conventional application of doxepin: effects on psychopathology and hypothalamus-pituitary-adrenal (HPA) system. Deuschle M, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):156–60

Interpersonal factors in brief treatment of depression: further analyses of the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Blatt SJ, et al. **J Consult Clin Psychol** 1996 Feb;64(1):162–71

The effect of drug therapy on the perceived symptom and ADL experiences of narcoleptics. Schumacher A, et al. **J Neurosci Nurs** 1997 Feb;29(1):15–23

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Benkert O, et al. **J Psychiatr Res** 1996 Nov–Dec;30(6):441–51

Loading dose imipramine—new approach to pharmacotherapy of melancholic depression. Malhotra S, et al. **J Psychiatr Res** 1996 Jan–Feb;30(1):51–8

A controlled trial of imipramine for the treatment of methamphetamine dependence. Galloway GP, et al. **J Subst Abuse Treat** 1996 Nov–Dec;13(6):493–7

Single dose imipramine reduces nocturnal urine output in patients with nocturnal enuresis and nocturnal polyuria. Hunsballe JM, et al. **J Urol** 1997 Sep;158(3 Pt 1):830–6

The treatment of panic disorder in a clinical setting: a 12-month naturalistic study. Marchesi C, et al. **Neuropsychobiology** 1997;36(1):25–31

On the problems of switching from intravenous to oral administration in drug treatment of endogenous depression—a placebo-controlled double-blind trial with doxepin. Adler L, et al. **Pharmacopsychiatry** 1997 Mar; 30(2):62–9

Metabolic interaction between fluoxetine and clomipramine: a case report. Balant-Gorgia AE, et al. **Pharmacopsychiatry** 1996 Jan;29(1):38–41

[Value of tianeptine in treating major recurrent unipolar depression. Study versus placebo for 16 1/2 months of treatment] Daléry J, et al. **Encephale** 1997 Jan–Feb; 23(1):56–64 (Eng. Abstr.) **(Fre)**

[Transcranial magnetic stimulation in depressed patients: a new antidepressive therapeutic principle? Presentation of a pilot trial] Koppi S, et al. **Wien Med Wochenschr** 1996; 146(3):49–54 (Eng. Abstr.) **(Ger)**

[I prescribe suicide agents to my patients (letter; comment)] Meland E. **Tidsskr Nor Laegeforen** 1997 Feb 28;117(6):851 . Comment on: Tidsskr Nor Laegeforen 1997 Mar 10;117(7):1003. **(Nor)**

[The use of the amitriptyline analog amizol in depressions] Avedisova AS. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(4):55–8 **(Rus)**

ADVERSE EFFECTS

Photosensitivity and thrombocytopenia due to amitriptyline [letter] Taniguchi S, et al. **Am J Hematol** 1996 Sep; 53(1):49–50

Recurrent hyponatremia associated with sertraline and lofepramine [letter] Bouman WP, et al. **Am J Psychiatry** 1997 Apr;154(4):580

Treating intraoperative hypotension in a patient on long-term tricyclic antidepressants: a case of aborted aortic surgery. Sprung J, et al. **Anesthesiology** 1997 Apr;86(4):990–2

Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ritter JL, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):7–13 (37 ref.)

Comment: Serotonin syndrome associated with combined sertraline-amitriptyline treatment [letter; comment]

Alderman CP, et al. **Ann Pharmacother** 1996 Dec; 30(12):1499–500. Comment on: Ann Pharmacother 1996 May;30(5):527–33.

Dibenzepin overdose causing pulmonary edema. Wirtheim E, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):789–90

Effect of naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study. Zimmermann U, et al. **Biol Psychiatry** 1997 Mar 15; 41(6):747–9

Inhibition by vitamin E of drug accumulation and of phospholipidosis induced by desipramine and other cationic amphiphilic drugs in human cultured cells. Scuntaro I, et al. **Br J Pharmacol** 1996 Nov;119(5):829–34

Fluoxetine–imipramine interaction [letter] Leroi I, et al. **Can J Psychiatry** 1996 Jun;41(5):318–9

Clomipramine–induced tourettism in obsessive–compulsive disorder: clinical and theoretical implications. Moshe K, et al. **Clin Neuropharmacol** 1994 Aug;17(4):338–43

A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs. Bagheri H, et al. **Eur J Clin Pharmacol** 1997;52(5):339–42

Tricyclic antidepressant–induced extrapyramidal side effects. Vandel P, et al. **Eur Neuropsychopharmacol** 1997 Aug; 7(3):207–12 (32 ref.)

Amineptine induced liver injury. Report of two cases and brief review of the literature. Lazaros GA, et al. **Hepatogastroenterology** 1996 Jul–Aug;43(10):1015–9 (20 ref.)

Imipramine induced acute colonic pseudo–obstruction (Ogilvie's syndrome): a report of two cases. Sood A, et al. **Indian J Gastroenterol** 1996 Apr;15(2):70–1

First report of mirtazapine overdose. Hoes MJ, et al. **Int Clin Psychopharmacol** 1996 Jun;11(2):147

Safety of mirtazapine: a review [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] Montgomery SA. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:37–45 (28 ref.)

Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients. Sommers DK, et al. **Int Clin Psychopharmacol** 1997 May;12(3):141–5

Acne–like eruption caused by amineptine [letter] Farella V, et al. **Int J Dermatol** 1996 Dec;35(12):892–3

Neuropathy associated with tricyclic antidepressants [letter] Benazzi F, et al. **Int J Geriatr Psychiatry** 1997 Aug; 12(8):868–9

Defibrillation in tricyclic antidepressant overdose [letter] Buratti T, et al. **Intensive Care Med** 1997 May;23(5):598–9

Neuroleptic malignant syndrome following tricyclic antidepressant overdose [letter; comment] Hund E, et al. **Intensive Care Med** 1997 Apr;23(4):480–1. Comment on: Intensive Care Med 1996 May;22(5):453–5.

Case study: two additional sudden deaths with tricyclic antidepressants. Varley CK, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Mar;36(3):390–4

Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. Wilens TE, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jan;36(1):45–8

Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. Wilens TE, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Nov; 35(11):1491–501 (75 ref.)

Concerns about possible drug interactions [letter] Simpson BS, et al. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1380–1

Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. Baker B, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):15–21

Hyponatremia during treatment with clomipramine, perphenazine, or clozapine: study of therapeutic drug monitoring samples [letter] Spigset O, et al. **J Clin Psychopharmacol** 1996 Oct;16(5):412–4

Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. Swanson JR, et al. **J Forensic Sci** 1997 Mar;42(2):335–9 (40 ref.)

Symptoms of major depression and tricyclic side effects in primary care patients. Rollman BL, et al. **J Gen Intern Med** 1997 May;12(5):284–91

Combined pharmacotherapy or polypharmacy? Levy F, et al. **J Paediatr Child Health** 1996 Jun;32(3):265–6

Antidepressant drugs and the cardiovascular system: a comparison of tricylics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. Coupland N, et al. **J Psychopharmacol (Oxf)** 1997; 11(1):83–92 (117 ref.)

Fatality associated with combined fluoxetine–amitriptyline therapy [letter] Preskorn SH, et al. **JAMA** 1997 Jun 4; 277(21):1682

Unstable anticoagulation in the course of amitriptyline treatment. Hampel H, et al. **Pharmacopsychiatry** 1996 Jan; 29(1):33–7

Modulation of electroconvulsive treatment induced beta–adrenergic down–regulation by previous chronic imipramine administration: the involvement of protein kinase C. Nalepa I, et al. **Pol J Pharmacol** 1996 Sep–Oct; 48(5):489–94

No interaction between desipramine and bromperidol. Suzuki A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Oct;20(7):1265–71

Status epilepticus associated with the combination of valproic acid and clomipramine. DeToledo JC, et al. **Ther Drug Monit** 1997 Feb;19(1):71–3

Safety of liver donation after fatal intoxication with the tricyclic antidepressant trimipramine. Fattinger KE, et al. **Transplantation** 1996 Nov 15;62(9):1259–62

[Acute mixed hepatitis caused by tianeptine (letter)] Balleyguier C, et al. **Gastroenterol Clin Biol** 1996; 20(6–7):607–8 **(Fre)**

[Acute painful and febrile hepatic involvement related to ingestion of tianeptine (letter)] Rifflet H, et al. **Gastroenterol Clin Biol** 1996;20(6–7):606–7 **(Fre)**

[Depressive stupor—malignant neuroleptic syndrome—serotonin syndrome. A case contribution to a difficult differential diagnosis] König F, et al. **Nervenarzt** 1996 May;67(5):407–12 (Eng. Abstr.) **(Ger)**

[Warning on antidepressive agents during pregnancy. Even low doses can affect the infant] Lidén K, et al. **Lakartidningen** 1997 May 28;94(22):2086, 2091 **(Swe)**

ANALYSIS

Quantitative analysis of amitriptyline and nortriptyline in human plasma and liver microsomal preparations by high–performance liquid chromatography. Ghahramani P, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25; 685(2):307–13

Sensitive microanalysis of imipramine and desipramine in single rat thyroids by gas chromatography–mass spectrometry. Rousseau A, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):93–100

Voltammetric determination of imipramine hydrochloride and amitriptyline hydrochloride using a polymer–modified carbon paste electrode. Biryol I, et al. **J Pharm Biomed Anal** 1996 Dec;15(3):371–81

ANTAGONISTS & INHIBITORS

[Chronic treatment with tween–80 (5%) or n–stearoyl glycine on the antimobility effects of imipramine in the forced swimming test in mice] Vamvakidès A. **Boll Chim Farm** 1996 Nov;135(10):603–4 (Eng. Abstr.) **(Fre)**

BLOOD

A fluconazole/amitriptyline drug interaction in three male adults. Newberry DL, et al. **Clin Infect Dis** 1997 Feb; 24(2):270–1

Imipramine distribution among red blood cells, plasma and brain tissue. Fišar Z, et al. **Gen Physiol Biophys** 1996 Feb; 15(1):51–64

2–Hydroxydesipramine and desipramine plasma levels: how are they related to antidepressant response? Stern SL, et al. **Int Clin Psychopharmacol** 1996 Dec;11(4):219–27

Predicting desipramine levels in children and adolescents: a naturalistic clinical study. Biederman J, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Mar;36(3):384–9

Application of HPLC with silica–phase and reversed–phase eluents for the determination of clomipramine and demethylated and 8–hydroxylated metabolites. Coudoré F, et al. **J Anal Toxicol** 1996 Mar–Apr;20(2):101–5

Simultaneous determination of imipramine, desipramine and their 2– and 10–hydroxylated metabolites in human plasma and urine by high–performance liquid chromatography. Chen AG, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):153–8

Forensic analysis of eleven cyclic antidepressants in human biological samples using a new reversed–phase chromatographic column of 2 microm porous microspherical silica gel. Tanaka E, et al. **J Chromatogr B Biomed Appl** 1997 May 9;692(2):405–12

Simultaneous determination of amitriptyline, nortriptyline and four hydroxylated metabolites in serum by capillary gas–liquid chromatography with nitrogen–phosphorus–selective detection. Ulrich S, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):81–9

Detection of tricyclic antidepressants in whole blood by headspace solid–phase microextraction and capillary gas chromatography. Lee XP, et al. **J Chromatogr Sci** 1997 Jul;35(7):302–8

Steady–state plasma concentrations of imipramine and desipramine in relation to S–mephenytoin 4'–hydroxylation status in Japanese depressive patients. Koyama E, et al. **J Clin Psychopharmacol** 1996 Aug;16(4):286–93

Monitoring serum concentrations of clomipramine and metabolites: fluorescence polarization immunoassay versus high performance liquid chromatography. Banger M, et al. **Pharmacopsychiatry** 1997 Jul;30(4):128–32

Low serum levels of tricyclic antidepressants in amitriptyline– and doxepin–treated inpatients with depressive syndromes are associated with nonresponse. Rao ML, et al. **Pharmacopsychiatry** 1996 May;29(3):97–102

Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state. Shimoda K, et al. **Psychiatry Clin Neurosci** 1997 Feb; 51(1):35–41

Influence of heparin on the assay of amitriptyline, clomipramine, and their metabolites. Levering SC, et al. **Ther Drug Monit** 1996 Jun;18(3):304–5

[Systematic analysis of basic drugs in plasma using X–5 solid–phase extraction GC–FID and GC–MS] Qiu FH, et al. **Yao Hsueh Hsueh Pao** 1996;31(4):296–9 (Eng. Abstr.) **(Chi)**

CHEMICAL SYNTHESIS

Selective inhibitors of monoamine oxidase. 4. SAR of tricyclic N–methylcarboxamides and congeners binding at the tricyclics' hydrophilic binding site. Harfenist M, et al. **J Med Chem** 1997 Aug 1;40(16):2466–73

CHEMISTRY

Spectroscopic analysis of charge transfer complex formation and peroxidase inhibition with tricyclic antidepressant drugs: potential anti–thyroid action. Rousseau A, et al. **Biol Pharm Bull** 1996 May;19(5):726–8

A comparison of the physicochemical and biological properties of mirtazapine and mianserin. Kelder J, et al. **J Pharm Pharmacol** 1997 Apr;49(4):403–11

ECONOMICS

Study addresses question of preferred initial therapy for depression [news] **Am J Health Syst Pharm** 1996 Sep 1; 53(17):1994

Prescribing antidepressants in general practice. Costs should have been considered [letter; comment] Gilbody S, et al. **BMJ** 1997 Mar 15;314(7083):828–9. Comment on: BMJ 1996 Oct 5;313(7061):861–2.

'Number needed to treat' [letter; comment] Gilbody S, et al. **Br J Psychiatry** 1996 Jul;169(1):113. Comment on: Br J Psychiatry 1996 Apr;168(4):404–9.

Economic analysis of treating depression with nefazodone v. imipramine. Montgomery SA, et al. **Br J Psychiatry** 1996 Jun;168(6):768–71

Influences on cost effectiveness [letter; comment] Patel V. **Br J Psychiatry** 1996 Sep;169(3):381. Comment on: Br J Psychiatry 1996 Apr;168(4):404–9.

SSRIs versus tricyclics [letter; comment] Rubinsztien JS, et al. **Br J Psychiatry** 1996 Jul;169(1):113–4. Comment on: Br J Psychiatry 1996 Apr;168(4):404–9.

Cost–effectiveness of antidepressant treatment reassessed. Woods SW, et al. **Br J Psychiatry** 1997 Mar;170:257–63

Economic evaluation of paroxetine and imipramine in depressed outpatients. Melton ST, et al. **Psychopharmacol Bull** 1997;33(1):93–100

IMMUNOLOGY

Bacterial expression and characterization of an anti–desipramine single–chain antibody fragment. Lin G, et al. **Int J Immunopharmacol** 1996 Dec;18(12):729–38

ISOLATION & PURIFICATION

Capillary electrophoretic separation of tricyclic antidepressants using charged carboxymethyl–beta–cyclodextrin as a buffer additive. Spencer BJ, et al. **Electrophoresis** 1997 May;18(5):736–44

METABOLISM

Antagonism by benzodiazepines of the effects of serotonin–, but not norepinephrine–, uptake blockers in the learned helplessness paradigm in rats. Martin P, et al. **Biol Psychiatry** 1996 May 15;39(10):882–90

Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Ball SE, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):619–26

Binding and competitive inhibition of amine uptake at postsynaptic neurones (transport–P) by tricyclic antidepressants. Al–Damluji S, et al. **Br J Pharmacol** 1996 Mar;117(5):811–6

Formation of mammalian metabolites of cyclobenzaprine by the fungus, Cunninghamella elegans. Zhang D, et al. **Chem Biol Interact** 1996 Oct 21;102(2):79–92

Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA–expressed human cytochrome P–450 isozymes. Olesen OV, et al. **Drug Metab Dispos** 1997 Jun;25(6):740–4

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Spina E, et al. **Eur J Clin Pharmacol** 1997;51(5):395–8

Quantitative analysis of amitriptyline and nortriptyline in human plasma and liver microsomal preparations by high–performance liquid chromatography. Ghahramani P, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25; 685(2):307–13

Imipramine: a model drug for P450 research. Brøsen K, et al. **Methods Enzymol** 1996;272:177–86

Cerebral metabolism of imipramine and a purified flavin–containing monooxygenase from human brain. Bhagwat SV, et al. **Neuropsychopharmacology** 1996 Aug; 15(2):133–42

Paroxetine shifts imipramine metabolism. Albers LJ, et al. **Psychiatry Res** 1996 Jan 31;59(3):189–96

Thioridazine interferences with imipramine metabolism and measurement. Maynard GL, et al. **Ther Drug Monit** 1996 Dec;18(6):729–31

PHARMACOKINETICS

Antidepressants and breast–feeding [letter; comment] Mammen O, et al. **Am J Psychiatry** 1997 Aug;154(8):1174–5 . Comment on: Am J Psychiatry 1996 Sep;153(9):1132–7.

Relative bioavailability of four clomipramine hydrochloride

tablet products. Müller FO, et al.
Biopharm Drug Dispos 1996 Jan;17(1):81–90

Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Spina E, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):315–8

Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. Wang JS, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):195–8

The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Kurtz DL, et al.
Clin Pharmacol Ther 1997 Aug;62(2):145–56

Managing rapid metabolizers of antidepressants. Kraus RP, et al. **Depress Anxiety** 1996–97;4(6):320–7

Biphasic kinetics of quaternary ammonium glucuronide formation from amitriptyline and diphenhydramine in human liver microsomes. Breyer-Pfaff U, et al.
Drug Metab Dispos 1997 Mar;25(3):340–5

Pharmacokinetic interaction between diltiazem and nortriptyline. Krähenbühl S, et al.
Eur J Clin Pharmacol 1996;49(5):417–9

Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? Vormfelde SV, et al. **Eur J Clin Pharmacol** 1997;52(5):387–90

Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal. Cohen M, et al.
Eur J Drug Metab Pharmacokinet 1997 Apr–Jun; 22(2):103–10

Structural and concentration effects on the deposition of tricyclic antidepressants in human hair. Pragst F, et al.
Forensic Sci Int 1997 Jan 17;84(1–3):225–36

Effect of pigmentation on the drug deposition in hair of grey-haired subjects. Rothe M, et al. **Forensic Sci Int** 1997 Jan 17;84(1–3):53–60

Pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites in streptozocin-induced diabetic rats. Coudoré F, et al. **Gen Pharmacol** 1996 Jul;27(5):803–7

Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after one and six half-life repeated administrations to rats. Coudore F, et al. **Gen Pharmacol** 1996 Mar;27(2):215–9

Imipramine distribution among red blood cells, plasma and brain tissue. Fišar Z, et al. **Gen Physiol Biophys** 1996 Feb; 15(1):51–64

Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. Yoshida K, et al. **J Affect Disord** 1997 May; 43(3):225–37

Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. Alderman J, et al. **J Clin Psychopharmacol** 1997 Aug; 17(4):284–91

The clinical relevance of preclinical data: mirtazapine, a model compound. Delbressine LP, et al.
J Clin Psychopharmacol 1997 Apr;17(2):29S–33S (16 ref.)

The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. Mulsant BH, et al. **J Clin Psychopharmacol** 1997 Aug; 17(4):318–21

Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations. Timmer CJ, et al.
Pharm Res 1997 Jan;14(1):98–102

Modelling of non-linear pharmacokinetics in sheep after short-term infusion of cardiotoxic doses of imipramine. Meineke I, et al. **Pharmacol Toxicol** 1997 Jun;80(6):266–71

Pharmacokinetic fluvoxamine–clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Conus P, et al. **Pharmacopsychiatry** 1996 May;29(3):108–10

Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Dahl ML, et al. **Psychopharmacology (Berl)** 1996 Feb;123(4):315–9

N-sulphation of desipramine in the rat brain. Wong KO, et al. **Xenobiotica** 1996 Jan;26(1):17–26

PHARMACOLOGY

A physiologic assessment of intrathecal amitriptyline in sheep. Cerda SE, et al. **Anesthesiology** 1997 May; 86(5):1094–103

Alfentanil, but not amitriptyline, reduces pain, hyperalgesia, and allodynia from intradermal injection of capsaicin in humans. Eisenach JC, et al. **Anesthesiology** 1997 Jun; 86(6):1279–87

High-dose subchronic imipramine treatment: effects on anxiety-like (conflict) behavior in rats. Commissaris RL, et al. **Anxiety** 1994–95;1(3):109–13

Clomipramine modifies fluctuations of forced swimming immobility in different phases of the rat estrous cycle. Marvan ML, et al. **Arch Med Res** 1996 Spring;27(1):83–6

Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Bonson KR, et al. **Behav Brain Res** 1996;73(1–2):229–33

Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Conrad CD, et al. **Behav Neurosci** 1996 Dec;110(6):1321–34

Identification of hypothalamic transcripts upregulated by antidepressants. Wong ML, et al.
Biochem Biophys Res Commun 1996 Dec 4;229(1):275–9

Stimulation of immediate early gene expression by desipramine in rat brain. Dahmen N, et al.
Biol Psychiatry 1997 Sep 1;42(5):317–23

Decreased dorsal raphe nucleus neuronal activity in adult chloral hydrate anesthetized rats following neonatal clomipramine treatment: implications for endogenous depression. Kinney GG, et al. **Brain Res** 1997 May 9; 756(1–2):68–75

Chronic amitriptyline exposure reduces 5-HT3 receptor-mediated cyclic GMP formation in NG 108–15 cells. Shimizu M, et al. **Brain Res** 1996 Nov 25; 741(1–2):89–94

Pregnancies from imipramine and xylazine-induced ex copula ejaculation in a disabled stallion. Card CE, et al.
Can Vet J 1997 Mar;38(3):171–4

Effect of desipramine on spontaneous activity of hippocampal CA1 neuron after transient cerebral ischemia in rats. Zhu ZT, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jan;17(1):35–8

Imipramine increases the 5-HT1A receptor-mediated inhibition of hippocampal neurons without changing the 5-HT1A receptor binding. Bijak M, et al.
Eur J Pharmacol 1996 Jun 3;305(1–3):79–85

Effect of pertussis toxin on morphine, diphenhydramine, baclofen, clomipramine and physostigmine antinociception. Galeotti N, et al. **Eur J Pharmacol** 1996 Jul 18; 308(2):125–33

Inhibition of contractions by tricyclic antidepressants and xylamine in rat vas deferens. Huang Y.
Eur J Pharmacol 1997 May 26;327(1):41–7

Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Narita N, et al.
Eur J Pharmacol 1996 Jun 20;307(1):117–9

In vivo and in vitro clomipramine treatment decreases the migration of macrophages in the rat. Sacerdote P, et al.
Eur J Pharmacol 1997 Jan 29;319(2–3):287–90

Amitriptyline inhibits the G protein and K+ channel in the cloned thyroid cell line. Yoshida A, et al.
Eur J Pharmacol 1996 Sep 19;312(1):115–9

Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression. Fekkes D, et al. **Eur Neuropsychopharmacol** 1997 Aug; 7(3):235–9

Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Kasper S, et al.
Eur Neuropsychopharmacol 1997 May;7(2):115–24

Implication of beta 1- and beta 2-adrenergic receptors in the antinociceptive effect of tricyclic antidepressants. Micó JA, et al. **Eur Neuropsychopharmacol** 1997 May;7(2):139–45

Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Xia Z, et al.
Immunopharmacology 1996 Aug;34(1):27–37

GABAergic agents modify imipramine analgesia. Ballal PM, et al. **Indian J Physiol Pharmacol** 1996 Jan;40(1):95–7

Actions and interactions of ethanol and imipramine on the rat sinus node. Standen DJ, et al. **Int J Cardiol** 1997 Jul 25;60(2):165–70

Suppression of the rat micturition reflex by imipramine. Sohn UD, et al. **J Auton Pharmacol** 1997 Feb;17(1):35–41

Selection of an antidepressant: mirtazapine. Preskorn SH.
J Clin Psychiatry 1997;58 Suppl 6:3–8 (17 ref.)

Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and -inhibiting fluvoxamine utilizing EEG mapping and psychometry. Saletu B, et al. **J Neural Transm** 1996;103(1–2):191–216

The effect of chronic administration of amitriptyline on the effects of subsequent electroconvulsive treatment on responsiveness of alpha 1-and beta-adrenoceptors in the rat cortical slices. Vetulani J, et al. **J Neural Transm** 1996; 103(3):363–76

The effect of prolonged treatment with imipramine and electroconvulsive shock on the levels of endogenous enkephalins in the nucleus accumbens and the ventral tegmentum of the rat. Dziedzicka-Wasylewska M, et al.
J Neural Transm Gen Sect 1995;102(3):221–28

Desipramine modulates 3H-ouabain binding in rat hypothalamus. Viola MS, et al. **J Neurosci Res** 1997 Jan 1;47(1):77–82

Effects of amitriptyline on rat plasma and brain content of monoamine precursors and other large neutral amino acids. Eriksson T, et al. **J Pharm Pharmacol** 1995 Dec; 47(12A):1007–14

Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate. Masubuchi Y, et al.
J Pharmacol Exp Ther 1996 Nov;279(2):724–31

Sexual side effects of antidepressants: a review. Margolese HC, et al. **J Sex Marital Ther** 1996 Fall;22(3):209–17 (68 ref.)

Influences of ovariectomy and continuous replacement of 17beta-estradiol on the tail skin temperature and behavior in the forced swimming test in rats. Okada M, et al.
Jpn J Pharmacol 1997 Jan;73(1):93–6

Dimeric tubulin-stimulated adenylyl cyclase activity is augmented after long-term amitriptyline treatment. Kamada H, et al. **Life Sci** 1997;60(1):57–66

Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Barker EL, et al. **Mol Pharmacol** 1996 Oct;50(4):957–65

Neurodevelopment of children exposed in utero to antidepressant drugs. Nulman I, et al. **N Engl J Med** 1997 Jan 23;336(4):258–62

The opposite effects of amitriptyline on noradrenaline- and methoxamine-evoked venoconstriction in man. Abdelmawla AH, et al.
Naunyn Schmiedebergs Arch Pharmacol 1996 Jun; 354(1):25–9

Comparative electrophysiological effects of the antidepressants fluvoxamine and amitriptyline in the canine heart after myocardial infarction. Ikeda Y, et al.
Naunyn Schmiedebergs Arch Pharmacol 1996 Jun; 354(1):30–7

Imipramine-induced changes in 5-HT2 receptor sites and inositoltrisphosphate levels in rat brain. Subhash MN, et al. **Neurochem Res** 1997 Sep;22(9):1095–9

The antidepressant metapramine is a low-affinity antagonist at N-methyl-D-aspartic acid receptors. Boireau A, et al.
Neuropharmacology 1996;35(12):1703–7

Effects of the (+) and (–) enantiomers of the antidepressant drug tianeptine on 5-HTP-induced behaviour. Oluyomi AO, et al. **Neuropharmacology** 1997 Mar;36(3):383–7

Addition of lithium to chronic antidepressant treatment potentiates presynaptic serotonergic function without changes in serotonergic receptors in the rat cerebral cortex. Okamoto Y, et al. **Neuropsychobiology** 1996;33(1):17–20

Rauwolscine potentiates the effect of desipramine on limbic noradrenaline efflux. Palij P, et al. **Neuroreport** 1996 Apr 26;7(6):1121–4

Imipramine-induced increase in 5-HT2C receptor mRNA level in the rat brain. Tohda M, et al. **Neurosci Res** 1996 Jan;24(2):189–93

The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Jett MF, et al.
Pain 1997 Jan;69(1–2):161–9

Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. I. Social interactions. Cutler MG, et al. **Pharmacol Biochem Behav** 1997 Feb; 56(2):287–93

Effects of fluvoxamine and dothiepin on psychomotor abilities in healthy volunteers. Fairweather DB, et al.
Pharmacol Biochem Behav 1996 Feb;53(2):265–9

Decreased hypothalamic serotonin levels in adult rats treated neonatally with clomipramine. Feenstra MG, et al.
Pharmacol Biochem Behav 1996 Dec;55(4):647–52

Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. II. The elevated plus-maze. Rodgers RJ, et al. **Pharmacol Biochem Behav** 1997 Feb; 56(2):295–303

Effects of neonatally administered iprindole on adult behaviors of rats. Vogel G, et al.
Pharmacol Biochem Behav 1996 Sep;55(1):157–61

Inhibitory effect of amitriptyline on contraction of the rat isolated trachea. Huang Y, et al. **Pharmacology** 1997 Jun; 54(6):312–8

Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Barden N. **Pharmacopsychiatry** 1996 Jan;29(1):12–22

Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Kubera M, et al. **Pol J Pharmacol** 1996 Sep–Oct;48(5):503–6

Studies on the interaction of antidepressant drugs with adrenocorticotropic hormone or prednisone in rats. Pietrasiewicz T, et al. **Pol J Pharmacol** 1996 Mar–Apr; 48(2):145–52

Raphe-septal neurons changes in sensitivity to desipramine following an early septal lesion in the rat. Molina M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov; 20(8):1427–34

Dopamine agonist amineptine prevents the antidepressant effect of sleep deprivation. Benedetti F, et al.
Psychiatry Res 1996 Dec 20;65(3):179–84

Long-term effects of antidepressants on balance, equilibrium, and postural reflexes. Li X, et al. **Psychiatry Res** 1996 Jul 31;63(2–3):191–6

Effect of imipramine treatments on the 5-HT1A-receptor-mediated inhibition of panic-like behaviours in rats. Mongeau R, et al.
Psychopharmacology (Berl) 1997 Jun;131(4):321–8

Initial increases in extracellular dopamine in the ventral tegmental area provide a mechanism for the development of desipramine-induced sensitization within the midbrain dopamine system. Stewart J, et al. **Synapse** 1996 Aug; 23(4):258–64

Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoin [letter] Vandel P, et al. **Therapie** 1997 Jan–Feb;52(1):74–6

[Inactivity of imipramine in the forced swimming test on old mice or on young mice undergone chronic glycinergic treatment] Vamvakides A. **Ann Pharm Fr** 1996;54(6):260–2 (Eng. Abstr.) **(Fre)**

[Effects of amitriptyline on the contractile function of the myocardium. Dobutrex in the role of a positive inotropic agent] Meledin VIu, et al. **Anesteziol Reanimatol** 1997 Jan–Feb;(1):76–9 (Eng. Abstr.) **(Rus)**

[The effect of imipramine on the dynamics of forced swimming in rats following enucleation and removal of the epiphysis] Arushanian EB, et al.
Zh Vyssh Nerv Deiat Im I P Pavlova 1996 Mar–Apr; 46(2):393–5 **(Rus)**

POISONING

Interrater agreement in the measurement of QRS interval

in tricyclic antidepressant overdose: implications for monitoring and research. Buckley NA, et al. **Ann Emerg Med** 1996 Nov;28(5):515–9

A time to bury the tricyclic antidepressants or to praise them? [letter] O'Reilly RL. **Can J Psychiatry** 1997 May; 42(4):427–8

Magnesium sulphate in the treatment of ventricular fibrillation in amitriptyline poisoning [letter] Knudsen K, et al. **Eur Heart J** 1997 May;18(5):881–2

Combined intoxication with a tricyclic antidepressive agent and a neuroleptic. Diltoer MW, et al. **Eur J Emerg Med** 1996 Mar;3(1):52–5

Death attributed to the toxic interaction of triazolam, amitriptyline and other psychotropic drugs. Kudo K, et al. **Forensic Sci Int** 1997 Apr 18;86(1–2):35–41

Hyperthermia complicating tricyclic antidepressant overdose [see comments] Hantson P, et al. **Intensive Care Med** 1996 May;22(5):453–5. Comment in: Intensive Care Med 1997 Apr;23(4):480–1

British poison centres' advice concerning dothiepin overdosage in young children [letter] Emerton D. **J Accid Emerg Med** 1997 May;14(3):200

Trazodone and dothiepin poisoning [letter; comment] Esposito G. **J Anal Toxicol** 1996 Jan–Feb;20(1):59–60. Comment on: J Anal Toxicol 1994 May–Jun;18(3):176–9.

Safety in overdose of mirtazapine: a case report [letter] Gerritsen AW. **J Clin Psychiatry** 1997 Jun;58(6):271

Fluoxetine versus tricyclic antidepressants: a prospective multicenter study of antidepressant drug overdoses. The Antidepressant Study Group. Phillips S, et al. **J Emerg Med** 1997 Jul–Aug;15(4):439–45

Index of suspicion. Case 3. Tricyclic antidepressant (TCA) overdose. White JR. **Pediatr Rev** 1997 Jan;18(1):32, 34–5

[Laboratory diagnosis of acute amitriptyline poisoning in children] Kuznetsova NI. **Klin Lab Diagn** 1996 May–Jun; (3):22–4 **(Rus)**

THERAPEUTIC USE

Paroxetine and amitriptyline in the treatment of depression in general practice. Christiansen PE, et al. **Acta Psychiatr Scand** 1996 Mar;93(3):158–63

A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Høyberg OJ, et al. **Acta Psychiatr Scand** 1996 Mar;93(3):184–90

A naturalistic 6-year follow-up study of patients with panic disorder. Lepola U, et al. **Acta Psychiatr Scand** 1996 Mar; 93(3):181–3

Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Stahl S, et al. **Acta Psychiatr Scand Suppl** 1997;391:22–30

Pharmacotherapy of bulimia nervosa and binge eating disorder. Walsh BT, et al. **Addict Behav** 1995 Nov–Dec; 20(6):757–64 (26 ref.)

Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Nicolodi M, et al. **Adv Exp Med Biol** 1996; 398:373–9

Pharmacological treatment for antisocial personality disorder alcoholics: a preliminary study. Penick EC, et al. **Alcohol Clin Exp Res** 1996 May;20(3):477–84

The posttreatment illness course of depression in bereaved elders. High relapse/recurrence rates. Pasternak RE, et al. **Am J Geriatr Psychiatry** 1997 Winter;5(1):54–9

Three years on clomipramine: before and after brain SPECT study. Amen DG, et al. **Ann Clin Psychiatry** 1997 Jun; 9(2):113–6

Doxepin in the management of pruritus associated with allergic cutaneous reactions. Smith PF, et al. **Ann Pharmacother** 1997 May;31(5):633–5

Double-blind pilot trial of desipramine versus fluoxetine in panic patients. Bystritsky A, et al. **Anxiety** 1994–95; 1(6):287–90

Panic disorder and social phobia: possible implications of comorbid depression for drug therapy. Lydiard RB. **Anxiety** 1996;2(2):61–70 (90 ref.)

Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Nair NP, et al. **Anxiety** 1996;2(4):192–8

Lactate-induced anxiety after imipramine and diazepam treatment. Pohl R, et al. **Anxiety** 1994;1(2):54–63

Nortriptyline–fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Gómez-Pérez FJ, et al. **Arch Med Res** 1996 Winter; 27(4):525–9

Tricyclic antidepressant in TBI [letter; comment] Wroblewski B, et al. **Arch Phys Med Rehabil** 1997 Jan; 78(1):109. Comment on: Arch Phys Med Rehabil 1996 Jan;77(1):80–3.

Lack of advantage for imipramine combined with lithium versus imipramine alone in the treatment of major depression—a double-blind controlled study. Shahal B, et al. **Biol Psychiatry** 1996 Dec 1;40(11):1181–3

Initial increase of plasma serotonin: a biological predictor for the antidepressant response to clomipramine? Spreux-Varoquaux O, et al. **Biol Psychiatry** 1996 Sep 15; 40(6):465–73

GPs' perceptions of tolerability of selective serotonin reuptake inhibitors and tricyclic antidepressants. Analysis should discriminate between newer and older tricyclic antidepressants [letter] Ali IM. **BMJ** 1997 Aug 30; 315(7107):547–8

GPs' perceptions of tolerability of selective serotonin reuptake inhibitors and tricyclic antidepressants. Research into long term use is needed [letter] Bhatti N, et al. **BMJ** 1997 Aug 30;315(7107):547; discussion 548

GPs' perceptions of tolerability of selective serotonin reuptake inhibitors and tricyclic antidepressants. Clinical assessments are liable to bias [letter] Grace J. **BMJ** 1997 Aug 30;315(7107):547; discussion 548

General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. Martin RM, et al. **BMJ** 1997 Mar 1;314(7081):646–51

Prescribing antidepressants in general practice. Shared care of people with major mental illness [letter; comment] Murray V, et al. **BMJ** 1997 Mar 15;314(7083):829. Comment on: BMJ 1996 Oct 5;313(7061):884–5.

Desmopressin and imipramine in the management of nocturnal enuresis: a multicentre study. Vertucci P, et al. **Br J Clin Pract** 1997 Jan–Feb;51(1):27–31

Which antidepressant? A commentary from general practice on evidence-based medicine and health economics [see comments] Kernick DP. **Br J Gen Pract** 1997 Feb; 47(415):95–8. Comment in: Br J Gen Pract 1997 May;47(418):327–8.

Tricyclics and SSRIs [letter; comment] Bowskill RJ, et al. **Br J Psychiatry** 1996 Aug;169(2):250–1. Comment on: Br J Psychiatry 1996 May;168(5):529–32.

Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Hotopf M, et al. **Br J Psychiatry** 1997 Feb;170:120–7

The Galway Study of Panic Disorder. IV. Temporal stability of diagnosis by present state examination test–retest. O'Rourke D, et al. **Br J Psychiatry** 1996 Jul;169(1):98–100

An integrated treatment approach to panic disorder. Craske MG. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A87–104 (68 ref.)

The pharmacotherapy of panic disorder. Rosenbaum JF, et al. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A54–75 (119 ref.)

Clomipramine-induced tourettism in obsessive-compulsive disorder: clinical and theoretical implications. Moshe K, et al. **Clin Neuropharmacol** 1994 Aug;17(4):338–43

Mirtazapine and ECT combination therapy [letter] Farah A. **Convuls Ther** 1997 Jun;13(2):116–7

Clomipramine augmentation in treatment-resistant depression. Amsterdam JD, et al. **Depress Anxiety** 1997; 5(2):84–90

Effect of continuation treatment on residual symptoms in late-life depression: how well is "well"? Opdyke KS, et al. **Depress Anxiety** 1996–97;4(6):312–9

Lack of association between thyroid and pineal responses to antidepressant treatment. Brown GM, et al. **Depression** 1996;4(2):73–6

Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Sonntag A, et al. **Depression** 1996;4(1):1–13

Depression and myocardial infarction. Implications for medical prognosis and options for treatment. Cleophas TJ. **Drugs Aging** 1997 Aug;11(2):111–8 (64 ref.)

Trimipramine: a challenge to current concepts on antidepressives. Berger M, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(5):235–9 (45 ref.)

Clinical response and plasma concentrations of amitriptyline and its metabolite-nortriptyline in depressive patients. Miljković B, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jul–Sep;21(3):251–5

Predicting factors for absenteeism in patients with major depressive disorders. Souêtre E, et al. **Eur J Epidemiol** 1997 Jan;13(1):87–93

Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Mansbach RS, et al. **Eur J Pharmacol** 1997 Mar 26;323(1):21–6

Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment. Cavedini P, et al. **Eur Neuropsychopharmacol** 1997 Feb; 7(1):45–9

Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression. Fekkes D, et al. **Eur Neuropsychopharmacol** 1997 Aug; 7(3):235–9

Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. López-Ibor JJ Jr, et al. **Eur Neuropsychopharmacol** 1996 May;6(2):111–8

A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Marttila M, et al. **Eur Neuropsychopharmacol** 1995 Dec;5(4):441–6

The course of major depression in diabetes. Lustman PJ, et al. **Gen Hosp Psychiatry** 1997 Mar;19(2):138–43

The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] de Boer T. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:19–23 (33 ref.)

Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Fabre L, et al. **Int Clin Psychopharmacol** 1996 Jun;11(2):119–27

Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] Haddjeri N, et al. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:11–7 (30 ref.)

Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data [published erratum appears in Int Clin Psychopharmacol 1996 Jun;11(2):153] Kasper S. **Int Clin Psychopharmacol** 1995 Dec;10 Suppl 4:25–35 (45 ref.)

Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Kasper S, et al. **Int Clin Psychopharmacol** 1996 Sep;11 Suppl 4:35–9 (19 ref.)

A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Milanfranchi A, et al. **Int Clin Psychopharmacol** 1997 May; 12(3):131–6

Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine. Pedersen L, et al. **Int Clin Psychopharmacol** 1997 Jan;12(1):59–60

A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Mahapatra SN, et al. **Int J Clin Pract** 1997 Jun; 51(4):209–13

Peripheral neuropathy in scleroderma successfully treated with amitriptyline [letter] Bondavalli P, et al. **Int J Dermatol** 1997 Mar;36(3):234–5

A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. Forder J, et al. **J Affect Disord** 1996 Jun 5;38(2–3):97–111

Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. Greil W, et al. **J Affect Disord** 1996 Oct 14;40(3):179–90

Quantitative EEG in the prediction of antidepressant response to imipramine. Knott VJ, et al. **J Affect Disord** 1996 Jul 29;39(3):175–84

Right hemisphere abnormalities in major depression: quantitative electroencephalographic findings before and after treatment. Kwon JS, et al. **J Affect Disord** 1996 Oct 14;40(3):169–73

Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. Lecrubier Y, et al. **J Affect Disord** 1997 Apr;43(2):95–103

Predictive value of tryptophan/large neutral amino acids ratio to antidepressant response. Lucini V, et al. **J Affect Disord** 1996 Jan 22;36(3–4):129–33

The failure of 'adult' interventions with adolescent depression: what does it mean for theory, research and practice? Mueller C, et al. **J Affect Disord** 1997 Jul; 44(2–3):203–15 (88 ref.)

Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. Perry PJ. **J Affect Disord** 1996 Jun 20;39(1):1–6 (22 ref.)

Predictors of outcome in panic disorder: a 5-year prospective follow-up study. Scheibe G, et al. **J Affect Disord** 1996 Nov 25;41(2):111–6

Brofaromine versus imipramine in in-patients with major depression—a controlled trial. Volz HP, et al. **J Affect Disord** 1997 Jul;44(2–3):91–9

A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. Kye CH, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Sep; 35(9):1139–44

A naturalistic assessment of protriptyline for attention-deficit hyperactivity disorder. Wilens TE, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Nov; 35(11):1485–90

Nortriptyline for the treatment of depression in progressive supranuclear palsy [letter] Tamai S, et al. **J Am Geriatr Soc** 1997 Aug;45(8):1033–4

Cardiovascular effects of tricyclic antidepressants in childhood asthma: a case series and review. Wamboldt MZ, et al. **J Child Adolesc Psychopharmacol** 1997 Spring; 7(1):45–64 (63 ref.)

Management of patients with depression associated with anxiety symptoms. Nutt D. **J Clin Psychiatry** 1997;58 Suppl 8:11–6 (67 ref.)

Selection of an antidepressant: mirtazapine. Preskorn SH. **J Clin Psychiatry** 1997;58 Suppl 6:3–8 (17 ref.)

Evaluation and monitoring of symptom severity and change in depressed outpatients. Senra C. **J Clin Psychol** 1996 May; 52(3):317–24

Mirtazapine: clinical advantages in the treatment of depression. Burrows GD, et al. **J Clin Psychopharmacol** 1997 Apr;17(2):34S–39S (36 ref.)

The clinical relevance of preclinical data: mirtazapine, a model compound. Delbressine LP, et al. **J Clin Psychopharmacol** 1997 Apr;17(2):29S–33S (16 ref.)

Management of breakthrough panic disorder symptoms during pregnancy [letter] Hendrick VC, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):228–9

Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. Kasper S. **J Clin Psychopharmacol** 1997 Apr;17(2):19S–28S (52 ref.)

Effectiveness of clomipramine for obsessive-compulsive symptoms and chronic pain in two patients with schizophrenia [letter] Kurokawa K, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):329–30

Neurotransmitters in depression: noradrenaline and serotonin

and their interactions [editorial] Leonard BE. **J Clin Psychopharmacol** 1997 Apr;17(2):1S

Phenomenology of panic attacks: responsiveness of individual symptoms to imipramine. Mavissakalian MR. **J Clin Psychopharmacol** 1996 Jun;16(3):233–7

Recent developments in the psychopharmacology of anxiety disorders. Lydiard RB, et al. **J Consult Clin Psychol** 1996 Aug;64(4):660–8 (85 ref.)

Fluoxetine and amitriptyline in the treatment of fibromyalgia. Johnson SP. **J Fam Pract** 1997 Feb;44(2):128–30

Pregnancy complicated by obsessive–compulsive disorder. Chelmow D, et al. **J Matern Fetal Med** 1997 Jan–Feb; 6(1):31–4

A double–blind placebo–controlled study of clomipramine in depressed patients with Alzheimer's disease. Petracca G, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer; 8(3):270–5

Fluoxetine vs. tricyclic antidepressants in women with major depressive disorder. Lewis–Hall FC, et al. **J Womens Health** 1997 Jun;6(3):337–43

Initial choice of antidepressant therapy in primary care [letter; comment] Bruhat A, et al. **JAMA** 1996 Oct 23–30; 276(16):1301; discussion 1302. Comment on: JAMA 1996 Jun 26;275(24):1897–902.

Initial choice of antidepressant therapy in primary care [letter; comment] Schwab PJ. **JAMA** 1996 Oct 23–30; 276(16):1301–2; discussion 1302. Comment on: JAMA 1996 Jun 26;275(24):1897–902.

The efficacy of antidepressants in post–stroke depression. Shima S. **Keio J Med** 1997 Mar;46(1):25–6

Antidepressant co–prescribing––how often does it occur? [letter; comment] [see comments] Parkes AJ. **Med J Aust** 1996 Sep 16;165(6):346. Comment on: Med J Aust 1996 Apr 15;164(8):509. Comment in: Med J Aust 1997 Feb 3;166(3):167.

Mirtazapine––a new antidepressant. **Med Lett Drugs Ther** 1996 Dec 20;38(990):113–4

Placebo–controlled study of tianeptine in major depressive episodes. Costa e Silva JA, et al. **Neuropsychobiology** 1997; 35(1):24–9

Do low levels of MHPG in depressive spectrum patients normalize after successful treatment? Garvey MJ, et al. **Neuropsychobiology** 1996;34(4):188–91

Fluoxetine, but not tricyclic antidepressants, potentiates the 5–hydroxytryptophan–mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Meltzer H, et al. **Neuropsychopharmacology** 1997 Jul;17(1):1–11

Psychosomatic treatment of phantom limb pain with post–traumatic stress disorder: a case report. Muraoka M, et al. **Pain** 1996 Aug;66(2–3):385–8

Amitriptyline versus vasopressin in the treatment of nocturnal enuresis [letter; comment] Robson WL, et al. **Pediatr Nephrol** 1996 Jun;10(3):396–7. Comment on: Pediatr Nephrol 1995 Aug;9(4):438–40.

Medication for children with attention disorders [letter; comment] Colson ER. **Pediatrics** 1997 Jun;99(6):922–3. Comment on: Pediatrics 1996 Aug;98(2 Pt 1):301–4.

An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression. Birkenhäger TK, et al. **Pharmacopsychiatry** 1997 Jan; 30(1):23–6

Pharmacokinetic fluvoxamine–clomipramine interaction with favorable therapeutic consequences in therapy–resistant depressive patient. Conus P, et al. **Pharmacopsychiatry** 1996 May;29(3):108–10

Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Hajak G, et al. **Pharmacopsychiatry** 1996 Sep;29(5):187–92

Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy–resistant depression. König F, et al. **Pharmacopsychiatry** 1997 May; 30(3):93–6

Low serum levels of tricyclic antidepressants in amitriptyline– and doxepin–treated inpatients with depressive syndromes are associated with nonresponse. Rao ML, et al. **Pharmacopsychiatry** 1996 May;29(3):97–102

Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Stimmel GL, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):10–21 (60 ref.)

Selecting an appropriate antidepressant. Fish D. **Practitioner** 1996 May;240(1562):321–5 (14 ref.)

Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state. Shimoda K, et al. **Psychiatry Clin Neurosci** 1997 Feb; 51(1):35–41

Paroxetine shifts imipramine metabolism. Albers LJ, et al. **Psychiatry Res** 1996 Jan 31;59(3):189–96

Predictors of treatment outcome for major depression in primary care. Mynors–Wallis L, et al. **Psychol Med** 1997 May;27(3):731–6

A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Fava M, et al. **Psychopharmacol Bull** 1997; 33(1):101–3

Double–blind comparison of paroxetine and nortriptyline on the postural stability of late–life depressed patients. Laghrissi–Thode F, et al. **Psychopharmacol Bull** 1995; 31(4):659–63

Economic evaluation of paroxetine and imipramine in depressed outpatients. Melton ST, et al. **Psychopharmacol Bull** 1997;33(1):93–100

A double–blind, fixed blood–level study comparing mirtazapine with imipramine in depressed in–patients. Bruijn JA, et al. **Psychopharmacology (Berl)** 1996 Oct; 127(3):231–7

Effects of nortriptyline on depression and glycemic control in diabetes: results of a double–blind, placebo–controlled trial. Lustman PJ, et al. **Psychosom Med** 1997 May–Jun; 59(3):241–50

Short gut syndrome, tricyclic antidepressants, and prolonged QT interval syndromes [letter] DiMartini A. **Psychosomatics** 1997 Jul–Aug;38(4):401–2

Applications of a mixture survival model with covariates to the analysis of a depression prevention trial. Greenhouse JB, et al. **Stat Med** 1996 Oct 15;15(19):2077–94

[Treatment of depression an the elderly] Kragh–Sørensen P, et al. **Nord Med** 1996 Oct;111(8):267–70 (14 ref.) (Eng. Abstr.) **(Dan)**

[Exploratory study of amitriptyline resistance in depressed patients: results of WHO French collaborating center on depressions resistant to treatments] Loas G, et al. **Ann Med Psychol (Paris)** 1996 Jun;154(3):202–3 (Eng. Abstr.) **(Fre)**

[Treatment of post–herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine] Göbel H, et al. **Drugs** 1997;53 Suppl 2:34–9 (Eng. Abstr.) **(Fre)**

[The future of antidepressant agents] Bourin B. **Encephale** 1996 Dec;22 Spec No 7:65–8 **(Fre)**

[New information on a classic antidepressive agent] **Nervenarzt** 1994 Mar;65(3 Suppl):1–12 **(Ger)**

[Current therapeutic possibilities with tricyclic antidepressive agents] **Nervenarzt** 1994 Aug;65(8 Suppl):1–8 **(Ger)**

[Pharmacological treatment of delusional depression] Amore M, et al. **Minerva Psichiatr** 1996 Mar;37(1):29–33 (28 ref.) (Eng. Abstr.) **(Ita)**

[The effect of clomipramine to nocturnal periodic hypoxemia in Duchenne muscular dystrophy] Ogata K, et al. **Rinsho Shinkeigaku** 1996 Apr;36(4):602–4 (Eng. Abstr.) **(Jpn)**

[Clinical significance of the pharmacogenetics in psychiatric and neurological syndromes] Milejski P, et al. **Neurol Neurochir Pol** 1996 Nov–Dec;30(6):997–1007 (28 ref.) (Eng. Abstr.) **(Pol)**

[The comparative efficacy of Aurorix and amitriptyline in treating depressions] Iakovlev VA. **Voen Med Zh** 1997 Apr; 318(4):37–8 **(Rus)**

[The treatment of the resistant obsessive–compulsive disorder: an update] Crespo Facorro B, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Jan–Feb;25(1):61–9 (106 ref.) (Eng. Abstr.) **(Spa)**

[Treatment with tianeptine for depressive disorders in the elderly] Saiz Ruiz J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1997 Mar–Apr;25(2):79–83 (Eng. Abstr.) **(Spa)**

[Are tricyclic antidepressants unsuitable in depression? (letter)] Runeberg S. **Lakartidningen** 1997 Sep 10; 94(37):3127–8 **(Swe)**

TOXICITY

Tricyclic antidepressant–induced lipidosis in human peripheral monocytes in vitro, as well as in a monocyte–derived cell line, as monitored by spectrofluorimetry and flow cytometry after staining with Nile red. Xia Z, et al. **Biochem Pharmacol** 1997 May 15; 53(10):1521–32

Epinephrine and sodium bicarbonate independently and additively increase survival in experimental amitriptyline poisoning. Knudsen K, et al. **Crit Care Med** 1997 Apr; 25(4):669–74

Dysregulation of bcl–2, c–myc, and Fas expression during tricyclic antidepressant–induced apoptosis in human peripheral lymphocytes. Xia Z, et al. **J Biochem Toxicol** 1996;11(4):203–4

The tricyclic antidepressants clomipramine and citalopram induce apoptosis in cultured human lymphocytes [letter] Xia Z, et al. **J Pharm Pharmacol** 1996 Jan;48(1):115–6

URINE

Simultaneous determination of imipramine, desipramine and their 2– and 10–hydroxylated metabolites in human plasma and urine by high–performance liquid chromatography. Chen AG, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):153–8

Evaluation of a colloidal metal immunoassay device for the detection of tricyclic antidepressants in urine. Poklis A, et al. **J Toxicol Clin Toxicol** 1997;35(1):77–82

ANTIDIABETICS see **HYPOGLYCEMIC AGENTS**

ANTIDIARRHEALS

A volunteer model for the comparison of laxatives in opioid–related constipation. Sykes NP. **J Pain Symptom Manage** 1996 Jun;11(6):363–9

ADMINISTRATION & DOSAGE

Broiler chicken body weights, feed intakes, plasma lipid and small–intestinal bile acid concentrations in response to feeding of chitosan and pectin. Razdan A, et al. **Br J Nutr** 1997 Aug;78(2):283–91

Optimization of the preparation of loperamide–loaded poly (L–lactide) nanoparticles by high pressure emulsification–solvent evaporation. Ueda M, et al. **J Microencapsul** 1997 Sep–Oct;14(5):593–605

CHEMISTRY

Physicochemical properties of calcium polycarbophil, a water–absorbing polymer. Yamada T, et al. **J Pharm Pharmacol** 1996 Jul;48(7):665–8

In vitro adsorption of mebeverine hydrochloride onto kaolin and its relationship to pharmacological effects of the drug in vivo. al Gohary OM. **Pharm Acta Helv** 1997 Feb; 72(1):11–21

PHARMACOKINETICS

Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. Kamali F, et al. **Br J Clin Pharmacol** 1996 Feb;41(2):125–8

A novel in vitro electrophysiological bioassay for transport of loperamide across intestinal epithelia. Brayden D, et al. **Pharm Res** 1997 Jul;14(7):942–5

PHARMACOLOGY

Influence of loperamide on lactose handling and oral–caecal transit time. Szilagyi A, et al. **Aliment Pharmacol Ther** 1996 Oct;10(5):765–70

Effect of polycarbophil on the absorption of nutrients. Yamada T, et al. **Biol Pharm Bull** 1996 May;19(5):771–3

Synthesis and pharmacological activity of 2–(substituted phenyl)–3–[2 or 3–[(4–substituted phenyl–4–hydroxy)piperidino]ethyl or propyl]–1,3–thiazolidin–4–ones. Diurno MV, et al. **Farmaco** 1997 Apr;52(4):237–41

Bromelain prevents secretion caused by Vibrio cholerae and Escherichia coli enterotoxins in rabbit ileum in vitro. Mynott TL, et al. **Gastroenterology** 1997 Jul;113(1):175–84

Inhibition of pancreaticobiliary secretion by loperamide in humans. Thimister PW, et al. **Hepatology** 1997 Aug; 26(2):256–61

Antidiarrhoeal activities of Ocimum gratissimum (Lamiaceae). Ilori M, et al. **J Diarrhoeal Dis Res** 1996 Dec; 14(4):283–5

Evaluation of the calcium–antagonist, antidiarrhoeic and central nervous system activities of Baccharis serraefolia. Tortoriello J, et al. **J Ethnopharmacol** 1996 Sep; 53(3):157–63

In vitro adsorption of mebeverine hydrochloride onto kaolin and its relationship to pharmacological effects of the drug in vivo. al Gohary OM. **Pharm Acta Helv** 1997 Feb; 72(1):11–21

Investigations on the gastroprotective and antidiarrhoeal properties of ternatin, a tetramethoxyflavone from Egletes viscosa. Rao VS, et al. **Planta Med** 1997 Apr;63(2):146–9

Analysis of antidiarrhoeic effect of plants used in popular medicine. Almeida CE, et al. **Rev Saude Publica** 1995 Dec; 29(6):428–33

Toxicity of cadmium in human trophoblast cells (JAr choriocarcinoma): role of calmodulin and the calmodulin inhibitor, zaldaride maleate. Powlin SS, et al. **Toxicol Appl Pharmacol** 1997 Jun;144(2):225–34

POISONING

Pancreatitis caused by loperamide overdose [letter] Epelde F, et al. **Ann Pharmacother** 1996 Nov;30(11):1339

Surveillance of loperamide ingestions: an analysis of 216 poison center reports [see comments] Litovitz T, et al. **J Toxicol Clin Toxicol** 1997;35(1):11–9. Comment in: J Toxicol Clin Toxicol 1997 ;35(1):21–3.

Loperamide poisoning in the dog. Hugnet C, et al. **Vet Hum Toxicol** 1996 Feb;38(1):31–3

THERAPEUTIC USE

American Academy of Pediatrics develops guidelines for acute gastroenteritis in young children. **Am Fam Physician** 1996 Oct;54(5):1796, 1799

Cholestyramine therapy for quinidine–induced diarrhea. Case reports. RuDusky BM. **Angiology** 1997 Feb;48(2):173–6

Treatment of refractory diarrhoea in AIDS with acetorphan and octreotide: a randomized crossover study. Beaugerie L, et al. **Eur J Gastroenterol Hepatol** 1996 May;8(5):485–9

Efficacy of a pectin–based anti–reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro–oesophageal reflux disease. Havelund T, et al. **Eur J Gastroenterol Hepatol** 1997 May;9(5):509–14

Antidiarrhoeal activity of new thiazolidinones related to loperamide. Diurno MV, et al. **J Pharm Pharmacol** 1996 Jul;48(7):760–2

A synopsis of the American Academy of Pediatrics' practice parameter on the management of acute gastroenteritis in young children. Nazarian LF. **Pediatr Rev** 1997 Jul; 18(7):221–3

[Opium drops in diarrhea caused by Crohn disease (letter; comment)] Ewe K. **Dtsch Med Wochenschr** 1997 Feb 7; 122(6):174–5. Comment on: Dtsch Med Wochenschr 1996 Jun 21;121(25–26):852–3. **(Ger)**

[Opium drops in diarrhea caused by Crohn disease (letter; comment)] Goerg KJ. **Dtsch Med Wochenschr** 1997 Feb 7;122(6):174. Comment on: Dtsch Med Wochenschr 1996 Jun 21;121(25–26):852–3. **(Ger)**

ANTIDIARRHEALS

[Possible mechanisms of the antimicrobial action of pectin in acute infectious diarrhea] Potievskiĭ EG. **Antibiot Khimioter** 1996;41(7–8):40–2 (12 ref.) **(Rus)**

[The use of Intetrix in acute diarrheal diseases] Bondarev LS, et al. **Lik Sprava** 1995 Sep–Dec;(9–12):153–5 (Eng. Abstr.) **(Rus)**

[Treatment of irritable colon with lidamidine and support psychotherapy] Rodríguez Magallán A, et al. **Rev Gastroenterol Mex** 1997 Jan–Mar;62(1):7–13 (Eng. Abstr.) **(Spa)**

ANTIDIURETIC HORMONE, INAPPROPRIATE SECRETION see **INAPPROPRIATE ADH SYNDROME**

ANTIDIURETIC HORMONES see **VASOPRESSINS**

ANTI-DNA ANTIBODIES see **ANTIBODIES, ANTINUCLEAR**

ANTIDOTES

see related
CHELATING AGENTS
CHOLINESTERASE REACTIVATORS

[Methods of diagnosis of thallium intoxication and its antidote therapy] Shabalina LP, et al. **Med Tr Prom Ekol** 1996;(10):25–30 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Advantage of high-surface-area charcoal for gastrointestinal decontamination in a human acetaminophen ingestion model [see comments] Roberts JR, et al. **Acad Emerg Med** 1997 Mar;4(3):167–74. Comment in: Acad Emerg Med 1997 Mar;4(3):161. Comment in: Acad Emerg Med 1997 Mar;4(3):162–3.

Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain. Feliu J, et al. **Am J Clin Oncol** 1996 Dec;19(6):577–80

Prevention of fetal and maternal cyanide toxicity from nitroprusside with coinfusion of sodium thiosulfate in gravid ewes. Curry SC, et al. **Anesth Analg** 1997 May; 84(5):1121–6

Effect of flumazenil on ventilatory drive during sedation with midazolam and alfentanil. Gross JB, et al. **Anesthesiology** 1996 Oct;85(4):713–20

Pralidoxime continuous infusion in the treatment of organophosphate poisoning. Tush GM, et al. **Ann Pharmacother** 1997 Apr;31(4):441–4

Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. Punt CJ, et al. **Anticancer Drugs** 1997 Jun;8(5):454–8

Reducing paracetamol overdoses. Methionine should be included in all paracetamol preparations [letter; comment] Spender Q. **BMJ** 1997 Mar 8;314(7082):751. Comment on: BMJ 1996 Dec 7;313(7070):1417–8.

The effect of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate in healthy volunteers. al-Shareef A, et al. **Br J Clin Pharmacol** 1997 Jan;43(1):109–11

Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma. Bajetta E, et al. **Cancer** 1996 Nov 15;78(10):2087–93

Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Feliu J, et al. **Cancer** 1997 May 15;79(10):1884–9

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Gebbia V, et al. **Cancer** 1996 Sep 15;78(6):1300–7

The effect of sustained release boli with ammoniumiron(III)–hexacyanoferrate(II) on radiocesium accumulation in sheep grazing contaminated pasture. Hansen HS, et al. **Health Phys** 1996 Nov;71(5):705–12

Reduction of cesium concentration in ovine tissues following treatment with Prussian Blue labeled with 59Fe. Ioannides KG, et al. **Health Phys** 1996 Nov;71(5):713–8

Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Minsky BD, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):289–95

Effectiveness of intramuscularly administered cyanide antidotes on methemoglobin formation and survival. Vick JA, et al. **J Appl Toxicol** 1996 Nov–Dec;16(6):509–16

Evaluation of two treatment regimens of pralidoxime (1 gm single bolus dose vs 12 gm infusion) in the management of organophosphorus poisoning. Johnson S, et al. **J Assoc Physicians India** 1996 Aug;44(8):529–31

Factors predictive of response and survival in patients with metastatic colorectal cancer in Taiwan. Wang WS, et al. **Jpn J Clin Oncol** 1997 Jun;27(3):174–9

Trends in gastrointestinal decontamination for deliberate self poisoning in Christchurch. Ardagh M, et al. **N Z Med J** 1996 Dec 13;109(1035):462–3

Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Klaassen U, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):32–7

[Acute chloroquine poisoning] Altrock G, et al. **Dtsch Med Wochenschr** 1997 Feb 21;122(8):225–8 (Eng. Abstr.) **(Ger)**

[Poisoning with Jimson weed. Five cases treated with physostigmine] Amlo H, et al. **Tidsskr Nor Laegeforen** 1997 Aug 10;117(18):2610–2 (Eng. Abstr.) **(Nor)**

[Vitamin B12-variant in cyanide poisoning. Hydroxycobalamin is a new effective antidote] Personne M, et al. **Lakartidningen** 1997 Mar 5;94(10):877–8 **(Swe)**

ADVERSE EFFECTS

Adverse effects of aluminium-chelating compounds for clinical use. Domingo JL. **Adverse Drug React Toxicol Rev** 1996 Aug;15(3):145–65 (159 ref.)

Flumazenil-induced seizure accompanying benzodiazepine and baclofen intoxication [letter] Chern TL, et al. **Am J Emerg Med** 1996 Mar;14(2):231–2

Angioedema with oral N-acetylcysteine [letter] Mroz LS, et al. **Ann Emerg Med** 1997 Aug;30(2):240–1

Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Grandi AM, et al. **Ann Oncol** 1997 Jul;8(7):705–8

Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report. Kronawitter U, et al. **Cancer** 1997 Aug 15;80(4):656–60

Sensorineural hearing loss in children with thalassemia major in Northern Greece. Kontzoglou G, et al. **Int J Pediatr Otorhinolaryngol** 1996 May;35(3):223–30

Flumazenil associated seizure in an 11-month-old child. Davis CO, et al. **J Emerg Med** 1996 May–Jun;14(3):331–3

High risk of retinal damage by desferrioxamine in dialysis patients [letter] Albalate M, et al. **Nephron** 1996;73(4):726–7

Suspected allergic reaction to penicillamine in mute swans [letter; comment] [see comments] Cooke SW. **Vet Rec** 1997 May 24;140(21):563–4. Comment on: Vet Rec 1997 Apr 26;140(17):464. Comment in: Vet Rec 1997 Jun 7;140(23):612.

[Amyl nitrite: drugs and intoxicants] Jacobsen P. **Ugeskr Laeger** 1996 Sep 30;158(40):5645–6 **(Dan)**

CLASSIFICATION

The relative efficacy of antidotes: the IPCS evaluation series. International Programme on Chemical Safety. Jacobsen D, et al. **Arch Toxicol Suppl** 1997;19:305–10 (20 ref.)

Evaluation of antidotes: activities of the International Programme on Chemical Safety. Pronczuk de Garbino J, et al. **J Toxicol Clin Toxicol** 1997;35(4):333–43

DIAGNOSTIC USE

Influence of iron status in the response to the deferoxamine test. Cannata JB, et al. **J Am Soc Nephrol** 1996 Jan; 7(1):135–9

Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients. Janssen MJ, et al. **Pharm World Sci** 1996 Oct;18(5):187–91

ECONOMICS

Antidotes: availability, use and cost in hospital and extra-hospital emergency services of Catalonia (Spain). Nogué S, et al. **Arch Toxicol Suppl** 1997;19:299–304

HISTORY

["Lingue di seripi", "serpents' tongues" and "glossopetrae". Highlights from the history of popular "cult" medicine in early modern times] Freller T. **Sudhoffs Arch Z Wissenschaftsgesch** 1997;81(1):62–83 (Eng. Abstr.) **(Ger)**

METABOLISM

Interactions of melphalan with glutathione and the role of glutathione S-transferase. Awasthi S, et al. **Drug Metab Dispos** 1996 Mar;24(3):371–4

Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b. Czejka MJ, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct–Dec; 20(4):255–62

Modulation of cisplatin chronotoxicity related to reduced glutathione in mice. Boughattas NA, et al. **Hum Exp Toxicol** 1996 Jul;15(7):563–72

Fluorescent estimation of H2O2-induced changes in cell viability and cellular nonprotein thiol level of dissociated rat thymocytes. Chikahisa L, et al. **Jpn J Pharmacol** 1996 Aug;71(4):299–305

Nitric oxide generation from sodium nitroprusside and hydroxylamine in brain. Ohta K, et al. **Neuroreport** 1997 Jul 7;8(9–10):2229–35

PHARMACOKINETICS

Glutathione kinetics in normal man and in patients with liver cirrhosis. Bianchi G, et al. **J Hepatol** 1997 Mar;26(3):606–13

Pharmacokinetics and kinetic-dynamic modelling of aminophenones as methaemoglobin formers. Marino MT, et al. **J Pharm Pharmacol** 1997 Mar;49(3):282–7

What target pralidoxime concentration? [letter; comment] Dawson A, et al. **J Toxicol Clin Toxicol** 1997;35(2):227–30 . Comment on: J Toxicol Clin Toxicol 1996;34(3):289–95.

PHARMACOLOGY

Toxicity and kinetics of amitraz in dogs. Hugnet C, et al. **Am J Vet Res** 1996 Oct;57(10):1506–10

Protective effect of deferoxamine on chromium (VI)-induced DNA single-strand breaks, cytotoxicity, and lipid peroxidation in primary cultures of rat hepatocytes. Susa N, et al. **Arch Toxicol** 1997;71(6):345–50

Effects of ubiquinone enriched diet on deterioration of mitochondrial respiratory function caused by fried beef derived mutagenic factor in rats. Sugiyama S, et al. **Biochem Mol Biol Int** 1996 Oct;40(2):305–14

Protective effects of GSH, vitamin E, and selenium on lipid peroxidation in cadmium-fed rats. Rana SV, et al. **Biol Trace Elem Res** 1996 Feb;51(2):161–8

A placebo controlled study of flumazenil in bronchoscopic procedures. Williamson BH, et al. **Br J Clin Pharmacol** 1997 Jan;43(1):77–83

Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas. Van Laar JA, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):79–89

L-oxothiazolidine 4-carboxylate pretreatment of isolated human peripheral blood lymphocytes reduces sulfur mustard cytotoxicity. Gross CL, et al. **Cell Biol Toxicol** 1997 Mar;13(3):167–73

Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Aeschlimann C, et al. **Drug Metab Dispos** 1996 Dec; 24(12):1336–9

Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Küpfer A, et al. **Eur J Clin Pharmacol** 1996;50(4):249–52

Superoxide release by human polymorphonuclear leukocytes in the presence of deferoxamine. Iacobini M, et al. **Haematologica** 1997 Jul–Aug;82(4):411–4

Effectiveness of intramuscularly administered cyanide antidotes on methemoglobin formation and survival. Vick JA, et al. **J Appl Toxicol** 1996 Nov–Dec;16(6):509–16

Involvement of altered cytoskeletal protein phosphorylation in aluminum-induced CNS dysfunction. Julka D, et al. **J Biochem Toxicol** 1996;11(5):227–33

The effect of three alpha-keto acids on 3-mercaptopyruvate sulfurtransferase activity. Porter DW, et al. **J Biochem Toxicol** 1996;11(1):45–50

5-Formyltetrahydrofolate regulates homocysteine remethylation in human neuroblastoma. Girgis S, et al. **J Biol Chem** 1997 Feb 21;272(8):4729–34

The effect of the calcium antagonist nimodipine on the detoxification of soman in anaesthetized rabbits. Karlsson BM, et al. **J Pharm Pharmacol** 1997 Mar;49(3):296–300

Pharmacokinetics and kinetic-dynamic modelling of aminophenones as methaemoglobin formers. Marino MT, et al. **J Pharm Pharmacol** 1997 Mar;49(3):282–7

Effect of activated charcoal and atropine on absorption and/or exsorption of organophosphorus compounds in rats. Tomimaru A, et al. **J Pharm Pharmacol** 1996 Apr; 48(4):351–6

DMPS-arsenic challenge test. I: Increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sulfonate. Aposhian HV, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):192–200

Full reversal of Pb++ block of L-type Ca++ channels requires treatment with heavy metal antidotes. Bernal J, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):172–80

Effect of delayed administration of activated charcoal on the absorption of conventional and slow-release verapamil. Laine K, et al. **J Toxicol Clin Toxicol** 1997;35(3):263–8

Superoxide involvement in excitotoxicity: a SOD-mimetic holds promise as a novel neuroprotective agent [news] Patel M. **Mol Psychiatry** 1996 Nov;1(5):362–3

Effect of mercuric chloride intoxication and dimercaprol treatment on delta-aminolevulinate dehydratase from brain, liver and kidney of adult mice. Emanuelli T, et al. **Pharmacol Toxicol** 1996 Sep;79(3):136–43

The effect of activated charcoal on the absorption of fluoxetine, with special reference to delayed charcoal administration. Laine K, et al. **Pharmacol Toxicol** 1996 Nov; 79(5):270–3

Effect of activated charcoal on the pharmacokinetics of pholcodine, with special reference to delayed charcoal ingestion. Laine K, et al. **Ther Drug Monit** 1997 Feb; 19(1):46–50

Phosphotriesterase, pralidoxime-2-chloride (2-PAM) and eptastigmine treatments and their combinations in DFP intoxication. Tuovinen K, et al. **Toxicol Appl Pharmacol** 1996 Dec;141(2):555–60

Comparison of the efficacy of single or repeated HI-6 treatment following soman poisoning in guinea pigs and marmoset monkeys. Busker RW, et al. **Toxicology** 1996 Sep 2;112(3):183–94

Importance of cholinolytic drug selection for the efficacy of HI-6 against soman in rats. Kassa J. **Toxicology** 1997 Jan 15;116(1–3):147–52

Prevention and treatment of dichlorvos-induced toxicosis in mice by diphenhydramine. Faris GA, et al. **Vet Hum Toxicol** 1997 Feb;39(1):22–5

Antidotal efficacy of glutamate and aspartate for colchicine toxicity. Wang RY, et al. **Vet Hum Toxicol** 1997 Aug; 39(4):207–10

[The effect of parasympatholytics on the therapeutic effectiveness of the oxime HI-6 against organophosphorus compounds (Soman, substance VX, Fosdrin) in mice] Kassa J, et al. **Cas Lek Cesk** 1997 Feb 12;136(4):124-6 (Eng. Abstr.) **(Cze)**

[Pharmacological study of antimutagenic properties of ubiquinone 10] Georgiev VN. **Vestn Ross Akad Med Nauk** 1997;(7):3-8 **(Rus)**

SUPPLY & DISTRIBUTION

On-site availability of selected antidotes: results of a survey of Massachusetts hospitals. Woolf AD, et al. **Am J Emerg Med** 1997 Jan;15(1):62-6

Antidotes dangerously understocked in Colorado, Montana, and Nevada [news] **Am J Health Syst Pharm** 1997 Jan 1; 54(1):16, 19

Need for antidote for aluminium phosphide poisoning [letter] Yadav J. **Indian J Physiol Pharmacol** 1997 Apr;41(2):189

Insufficient stocking of poisoning antidotes in hospital pharmacies. Dart RC, et al. **JAMA** 1996 Nov 13; 276(18):1508-10

THERAPEUTIC USE

High-surface-area charcoal--what's next? [editorial; comment] Harchelroad F. **Acad Emerg Med** 1997 Mar; 4(3):162-3. Comment on: Acad Emerg Med 1997 Mar;4(3):167-74.

Amrinone as an antidote in experimental verapamil overdose. Koury SI, et al. **Acad Emerg Med** 1996 Aug;3(8):762-7

Amrinone and verapamil overdose study design [letter] Manoach SM, et al. **Acad Emerg Med** 1997 Aug;4(8):839-40

Building a better mousetrap: high-surface-area charcoal [editorial; comment] Savitt DL. **Acad Emerg Med** 1997 Mar;4(3):161. Comment on: Acad Emerg Med 1997 Mar;4(3):167-74.

Glucagon and phenylephrine combination vs glucagon alone in experimental verapamil overdose [see comments] Stone CK, et al. **Acad Emerg Med** 1996 Feb;3(2):120-5. Comment in: Acad Emerg Med 1996 Feb;3(2):99-100.

Therapeutic efficacy of obidoxime or HI-6 with atropine against intoxication with some nerve agents in mice. Kassa J, et al. **Acta Medica (Hradec Kralove)** 1996;39(1):27-30

Resuscitation after nifedipine overdose exclusively with intravenous calcium chloride. Haddad LM. **Am J Emerg Med** 1996 Oct;14(6):602-3

Yohimbine as an antidote for clonidine overdose. Roberge RJ, et al. **Am J Emerg Med** 1996 Nov;14(7):678-80

Flumazenil reverses paradoxical reaction to midazolam in a child. Thakker P, et al. **Anaesth Intensive Care** 1996 Aug; 24(4):505-7

Methylene blue in anaphylactic shock [letter] Evora PR, et al. **Ann Emerg Med** 1997 Aug;30(2):240

Insulin improves survival in a canine model of acute beta-blocker toxicity. Kerns W 2nd, et al. **Ann Emerg Med** 1997 Jun;29(6):748-57

5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. Kok TC, et al. **Ann Oncol** 1996 Jul;7(5):533-4

Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Smyth JF, et al. **Ann Oncol** 1997 Jun;8(6):569-73

5-Fluorouracil-based treatment of patients with advanced colorectal carcinoma outside clinical trials: importance of limited toxicity [letter; comment] van Halteren HK, et al. **Ann Oncol** 1997 Feb;8(2):203. Comment on: Ann Oncol 1996 Aug;7(6):551-2.

Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. Punt CJ, et al. **Anticancer Drugs** 1997 Jun;8(5):454-8

Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Madasu R, et al. **Arch Otolaryngol Head Neck Surg** 1997 Sep;123(9):978-81

Antidotal efficacy of quinuclidinium oximes against soman poisoning. Lucić A, et al. **Arch Toxicol** 1997;71(7):467-70

A critical review of antidotal immunotherapy for low molecular weight toxins. Current antidotes and perspectives. Baud FJ, et al. **Arch Toxicol Suppl** 1997; 19:271-87 (45 ref.)

The use of antidotes in the management of central nervous system depression. Ferrer A, et al. **Arch Toxicol Suppl** 1997; 19:289-98 (35 ref.)

Evolution of antidotal therapy in recent decades. Pronczuk de Garbino J. **Arch Toxicol Suppl** 1997;19:261-70 (40 ref.)

Ultrastructural studies on organs of cadmium-poisoned rats treated with oxygen-ozone mixture. Kuryszko J, et al. **Arch Vet Pol** 1995;35(1-2):109-15

A phase I study of 5-fluorouracil, leucovorin and levamisole. Cleary JF, et al. **Cancer Chemother Pharmacol** 1997; 39(4):300-6

Clinical applications of commonly used contemporary antidotes. A US perspective. Bowden CA, et al. **Drug Saf** 1997 Jan;16(1):9-47 (186 ref.)

Flumazenil reversal of psychomotor impairment due to midazolam or diazepam for conscious sedation for upper endoscopy. Kankaria A, et al. **Gastrointest Endosc** 1996 Oct;44(4):416-21

Effects of catecholamines and diazepam in chloroquine poisoning in barbiturate anaesthetised rats. Buckley NA, et al. **Hum Exp Toxicol** 1996 Nov;15(11):909-14

The influence of pharmacological pretreatment on efficacy of HI-6 oxime in combination with benactyzine in soman poisoning in rats. Kassa J, et al. **Hum Exp Toxicol** 1996 May;15(5):383-8

Are we ready to replace dimercaprol (BAL) as an arsenic antidote? Mückter H, et al. **Hum Exp Toxicol** 1997 Aug; 16(8):460-5 (22 ref.)

Reappraisal of indications and limitations of oxime therapy in organophosphate poisoning. Worek F, et al. **Hum Exp Toxicol** 1997 Aug;16(8):466-72

Reversal of the haemodynamic features of acute liver failure by methylene blue [letter] McGinn PV. **Intensive Care Med** 1996 Jun;22(6):612

N-acetylcysteine (NAC)--a safe antidote in paracetamol poisoning? [letter; comment] Casey PB, et al. **Ir Med J** 1997 Jan-Feb;90(1):38. Comment on: Ir Med J 1996 Sep-Oct;89(5):156, 158.

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. O'Connell MJ, et al. **J Clin Oncol** 1997 Jan; 15(1):246-50

Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. Scheithauer W, et al. **J Clin Oncol** 1997 Mar;15(3):908-14

Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. Widemann BC, et al. **J Clin Oncol** 1997 May; 15(5):2125-34

Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. Zaniboni A. **J Clin Oncol** 1997 Jun; 15(6):2432-41 (59 ref.)

Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. Cascino TL, et al. **J Neurooncol** 1996 Dec;30(3):243-6

Intrathecal leukovorin after intrathecal methotrexate overdose [letter; comment] Trinkle R, et al. **J Pediatr Hematol Oncol** 1997 May-Jun;19(3):267-9. Comment on: J Pediatr Hematol Oncol 1996 Aug;18(3):302-4.

Antidotes for methanol and ethylene glycol poisoning--a REAL challenge! [editorial; comment] Becker C. **J Toxicol Clin Toxicol** 1997;35(2):147-8. Comment on: J Toxicol Clin Toxicol 1997 ;35(2):127-43.

Treating the serotonin syndrome--antidote or support? [editorial; comment] Brubacher JR. **J Toxicol Clin Toxicol** 1997;35(2):213-4. Comment on: J Toxicol Clin Toxicol 1997 ;35(2):211-2.

A perspective on the IPCS methanol and ethylene glycol document [editorial; comment] Goldfrank L. **J Toxicol Clin Toxicol** 1997;35(2):145-6. Comment on: J Toxicol Clin Toxicol 1997 ;35(2):127-43.

International Programme on Chemical Safety--Antidotes Project. Haines JA, et al. **J Toxicol Clin Toxicol** 1997; 35(2):125-6

Antidotes for methanol and ethylene glycol poisoning [see comments] Jacobsen D, et al. **J Toxicol Clin Toxicol** 1997; 35(2):127-43 (80 ref.). Comment in: J Toxicol Clin Toxicol 1997 ;35(2):145-6. Comment in: J Toxicol Clin Toxicol 1997 ;35(2):147-8. Comment in: J Toxicol Clin Toxicol 1997 ;35(2):149-50.

Treatment of severe thallium intoxication. Malbrain ML, et al. **J Toxicol Clin Toxicol** 1997;35(1):97-100

Effects of Prussian blue and N-acetylcysteine on thallium toxicity in mice. Meggs WJ, et al. **J Toxicol Clin Toxicol** 1997;35(2):163-6

Evaluation of antidotes: activities of the International Programme on Chemical Safety. Pronczuk de Garbino J, et al. **J Toxicol Clin Toxicol** 1997;35(4):333-43

Intravenous self-administration of metallic mercury: report of a case with a 5-year follow-up. Torres-Alanís O, et al. **J Toxicol Clin Toxicol** 1997;35(1):83-7

The protective role of zinc and N-acetylcysteine in modulating zidovudine induced hematopoietic toxicity. Gogu SR, et al. **Life Sci** 1996;59(16):1323-9

Efficacy of atropine/pralidoxime/diazepam or atropine/HI-6/prodiazepam in primates intoxicated by soman. Lallement G, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):325-32

A comparison of two oximes (HI-6 and obidoxime) for 2-dimethylaminoethyl-(dimethylamido)-phosphonofluoridate poisoning. Kassa J. **Pharmacol Toxicol** 1995 Dec;77(6):382-5

Continuous infusion of methylene blue for septic shock. Brown G, et al. **Postgrad Med J** 1996 Oct;72(852):612-4

Relief of jaundice by 5-fluorouracil and folinic acid in patients with recurrent gastric cancer. Kajiyama Y, et al. **Surg Oncol** 1996 Aug;5(4):177-81

Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to severe paraquat poisoning: a preliminary report [see comments] Lin JL, et al. **Thorax** 1996 Jul;51(7):661-3. Comment in: Thorax 1996 Jul;51(7):659-60. Comment in: Thorax 1997 Jun;52(6):588.

Cyclophosphamide treatment of paraquat poisoning [editorial; comment] Newstead CG. **Thorax** 1996 Jul; 51(7):659-60. Comment on: Thorax 1996 Jul;51(7):661-3.

A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced lung injury in vivo. Day BJ, et al. **Toxicol Appl Pharmacol** 1996 Sep;140(1):94-100

Protection of guinea pigs against soman poisoning by pretreatment with p-nitrophenyl phosphoramidates. Langenberg JP, et al. **Toxicol Appl Pharmacol** 1996 Oct; 140(2):444-50

Eptastigmine-phosphotriesterase combination in DFP intoxication. Tuovinen K, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):364-9

Testosterone pretreatment mitigates cadmium toxicity in male C57 mice but not in C3H mice. Shimada H, et al. **Toxicology** 1997 Jan 15;116(1-3):183-91

Intravenous 4-methylpyrazole as an antidote for diethylene glycol and triethylene glycol poisoning: a case report. Borron SW, et al. **Vet Hum Toxicol** 1997 Feb;39(1):26-8

Intestinal pseudo-obstruction (Ogilvie's syndrome) in theophylline overdose. Brubacher JR, et al. **Vet Hum Toxicol** 1996 Oct;38(5):368-70

Emergency department use of flumazenil prior to poison center consultation. Burda T, et al. **Vet Hum Toxicol** 1997 Aug;39(4):245-7

Hydrogen sulfide poisoning: an antidotal role for sodium nitrite? Hall AH, et al. **Vet Hum Toxicol** 1997 Jun; 39(3):152-4 (25 ref.)

Lead intoxication in rural Albania. Tabaku A, et al. **Vet Hum Toxicol** 1996 Dec;38(6):434-5

Treatment of cyanide poisoning in an industrial setting. Wurzburg H. **Vet Hum Toxicol** 1996 Feb;38(1):44-7

[Recommendations for treatment of paracetamol poisoning. Danish Medical Society, Study of the Liver] Clemmesen JO, et al. **Ugeskr Laeger** 1996 Nov 25;158(48):6892-5 (20 ref.) (Eng. Abstr.) **(Dan)**

[Activated charcoal as first-choice therapy in poisoning] Pronk MJ, et al. **Ned Tijdschr Geneeskd** 1997 Apr 5; 141(14):675-7 (Eng. Abstr.) **(Dut)**

[Physostigmine. From the God's judgment bean to modern antidote and therapeutic agent] Walter K, et al. **Med Monatsschr Pharm** 1996 Sep;19(9):252-60 (45 ref.) **(Ger)**

[Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use] Fujimoto T. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1901-6 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Changes in the morphofunctional status of the liver in rats with acute tetrachloromethane poisoning and their correction with antihypoxants, antioxidants and actoprotectors] Dubovaia TK, et al. **Eksp Klin Farmakol** 1996 Jul-Aug;59(4):51-4 (Eng. Abstr.) **(Rus)**

[The effect of perftoran on the resistance of mice to GABA receptor antagonists and on the antidote activity of anticonvulsant agents] Golovko AI, et al. **Eksp Klin Farmakol** 1996 Nov-Dec;59(6):34-7 (Eng. Abstr.) **(Rus)**

[The effect of acetylcysteine and dipyroxime on the immune reactions in acute dichloroethane poisoning] Zabrodskii PF, et al. **Eksp Klin Farmakol** 1997 Jan-Feb;60(1):47-9 (Eng. Abstr.) **(Rus)**

[Aminostigmine-a novel drug against home poisoning] Bonitenko II, et al. **Klin Med (Mosk)** 1996;74(8):58-61 (Eng. Abstr.) **(Rus)**

TOXICITY

Hydroxocobalamin vs cobalt toxicity on rat cardiac and diaphragmatic muscles. Pery-Man N, et al. **Intensive Care Med** 1996 Feb;22(2):108-15

Utilization of renal slices to evaluate the efficacy of chelating agents for removing mercury from the kidney. Keith RL, et al. **Toxicology** 1997 Jan 15;116(1-3):67-75

ANTIDROMIC POTENTIALS see **EVOKED POTENTIALS**

ANTI-DYSKINESIA AGENTS

ADMINISTRATION & DOSAGE

Treatment of achalasia by injection of botulinum toxin under endoscopic ultrasound guidance. Hoffman BJ, et al. **Gastrointest Endosc** 1997 Jan;45(1):77-9

Botulinum toxin injection for an esophageal muscular A-ring. Perez-Arroyo H, et al. **Gastrointest Endosc** 1997 Feb; 45(2):193-5

Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin [see comments] Cuillière C, et al. **Gut** 1997 Jul;41(1):87-92. Comment in: Gut 1997 Jul;41(1):131-2.

Being toxic to the oesophagus [comment] Vantrappen G. **Gut** 1997 Jul;41(1):131-2. Comment on: Gut 1997 Jul;41(1):87-92.

Botulinum neurotoxin injection after total laryngectomy. Hoffman HT, et al. **Head Neck** 1997 Mar;19(2):92-7

Periodic alternating nystagmus treated with retrobulbar botulinum toxin and large horizontal muscle recession. Thomas R, et al. **Indian J Ophthalmol** 1996 Sep;44(3):170-2

Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid. Brasić JR, et al. **Psychol Rep** 1997 Feb;80(1):163-70

ADVERSE EFFECTS

Neuroleptic malignant syndrome while on tiapride treatment

[letter] Duarte J, et al. **Clin Neuropharmacol** 1996 Dec; 19(6):539–40

Use of high-resolution endoscopic ultrasonography to assess esophageal wall damage after pneumatic dilation and botulinum toxin injection to treat achalasia. Schiano TD, et al. **Gastrointest Endosc** 1996 Aug;44(2):151–7

Sensitivity to vecuronium after botulinum toxin administration. Fiacchino F, et al.
J Neurosurg Anesthesiol 1997 Apr;9(2):149–53

A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Petzinger GM, et al. **Mov Disord** 1997 Mar;12(2):246–8

BLOOD

Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients. Meszaros K, et al. **Neuropsychobiology** 1997;36(2):69–72

Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Suzuki A, et al. **Ther Drug Monit** 1997 Jun; 19(3):261–4

DIAGNOSTIC USE

Botulinum toxin injection as a diagnostic tool for verification of sphincter of Oddi dysfunction causing recurrent pancreatitis. Muehldorfer SM, et al. **Endoscopy** 1997 Feb; 29(2):120–4

HISTORY

Botulinum toxin: the story of its development for the treatment of human disease. Schantz EJ, et al.
Perspect Biol Med 1997 Spring;40(3):317–27

METABOLISM

Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine. Kilbourn MR, et al. **Chirality** 1997;9(1):59–62

PHARMACOLOGY

[The duration of the retention of motor activity in rats evoked by a single injection of haloperidol] Bazian AS, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Sep–Oct; 46(5):944–8 **(Rus)**

THERAPEUTIC USE

Therapeutic uses of botulinum toxin. Wheeler AH.
Am Fam Physician 1997 Feb 1;55(2):541–5, 548 (13 ref.)

Tourette syndrome associated with mental retardation: a single-subject treatment study with haloperidol. Rosenquist PB, et al. **Am J Ment Retard** 1997 Mar;101(5):497–504

The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Blitzer A, et al.
Arch Otolaryngol Head Neck Surg 1997 Apr;123(4):389–92

Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Piccione F, et al. **Arch Phys Med Rehabil** 1997 May; 78(5):525–9

Medical treatments for abnormal eye movements: pharmacological, optical and immunological strategies. Averbuch-Heller L, et al. **Aust N Z J Ophthalmol** 1997 Feb;25(1):7–13 (36 ref.)

Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Sallee FR, et al.
Biol Psychiatry 1996 Nov 15;40(10):1044–50

Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. Mauriello JA Jr, et al.
Br J Ophthalmol 1996 Dec;80(12):1073–6

Automatic EMG-guided botulinum toxin treatment of spasticity. Finsterer J, et al. **Clin Neuropharmacol** 1997 Jun; 20(3):195–203

Pharmacological options for the management of dyskinesias. Shale H, et al. **Drugs** 1996 Dec;52(6):849–60 (89 ref.)

Botulinum toxin for refractory postoperative pyloric spasm. Wiesel PH, et al. **Endoscopy** 1997 Feb;29(2):132

Botulinum toxin injection for secondary achalasia with esophageal varices. Dufour JF, et al.
Gastrointest Endosc 1997 Feb;45(2):191–3 (13 ref.)

Frontalis suspension in the treatment of essential blepharospasm unresponsive to botulinum-toxin therapy: long-term results. Roggenkämper P, et al.
Graefes Arch Clin Exp Ophthalmol 1997 Aug;235(8):486–9

Botulinum toxin injection for cervicogenic headache. Hobson DE, et al. **Headache** 1997 Apr;37(4):253–5

Rheumatic chorea. Sudhindra BK. **Indian Pediatr** 1996 Jan; 33(1):47–9

Cosmetic botulinum toxin injections. Carter SR, et al.
Int Ophthalmol Clin 1997 Summer;37(3):69–79 (51 ref.)

The management of chronic fissure in ano with botulinum toxin [letter; comment] Moore AP.
J R Coll Surg Edinb 1997 Aug;42(4):289. Comment on: J R Coll Surg Edinb 1996 Aug;41(4):235–8.

The use of botulinum toxin for anal fissure [letter; comment] Parikh VA. **J R Coll Surg Edinb** 1997 Aug;42(4):288–9. Comment on: J R Coll Surg Edinb 1996 Aug;41(4):235–8.

The management of chronic fissure in ano with botulinum toxin [letter; comment] Wannas HR.
J R Coll Surg Edinb 1997 Aug;42(4):289–90. Comment on: J R Coll Surg Edinb 1996 Aug;41(4):235–8.

Botulinum toxin increases tearing in patients with Sjögren's syndrome: a preliminary report. Spiera H, et al.
J Rheumatol 1997 Sep;24(9):1842–3

Treatment of chronic tennis elbow with botulinum toxin [letter] Morré HH, et al. **Lancet** 1997 Jun 14;349(9067):1746

Treatment of ventricular dysphonia with botulinum toxin. Kendall KA, et al. **Laryngoscope** 1997 Jul;107(7):948–53

Long-term effects of tetrabenazine in hyperkinetic movement disorders. Jankovic J, et al. **Neurology** 1997 Feb; 48(2):358–62

Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Lew MF, et al. **Neurology** 1997 Sep;49(3):701–7

Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients. Meszaros K, et al. **Neuropsychobiology** 1997;36(2):69–72

Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm [see comments] Ainsworth JR, et al. **Ophthalmology** 1995 Dec;102(12):2036–40. Comment in: Ophthalmology 1996 Mar;103(3):348.

Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Price J, et al. **Ophthalmology** 1997 May; 104(5):865–8

Botulinum toxin as a therapeutic agent. Tsui JK.
Pharmacol Ther 1996;72(1):13–24 (107 ref.)

Tongue protrusion dystonia: treatment with botulinum toxin. Charles PD, et al. **South Med J** 1997 May;90(5):522–5

[Use of botulinum toxin in ophthalmology: current concepts and problems] Tapiero B, et al. **J Fr Ophtalmol** 1997; 20(2):134–45 (21 ref.) **(Fre)**

[Botulinum toxin: use in a case of achalasia of the lower sphincter of esophagus (letter)] Perlemuter G, et al.
Presse Med 1997 May 24;26(17):818 **(Fre)**

[Idiopathic focal dystonia of the foot in a 98-year-old-woman. Treatment with botulin toxin (letter)] Verlhac B, et al. **Presse Med** 1996 Dec 21;25(40):2042 **(Fre)**

[Blepharospasm: treatment with botulinum toxin] Barbosa ER, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Nov-Dec;51(6):220–3 (Eng. Abstr.) **(Por)**

[Botulinum toxin: clinical uses and anesthetic implications] Vidal-Marcos A, et al. **Rev Esp Anestesiol Reanim** 1996 Jun-Jul;43(6):208–11 (52 ref.) (Eng. Abstr.) **(Spa)**

[Cerebral palsy therapy] Papazian O, et al. **Rev Neurol** 1997 May;25(141):728–39 (69 ref.) (Eng. Abstr.) **(Spa)**

ANTIEMETICS

A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy. Wymenga AN, et al. **Ann Oncol** 1996 Jul;7(5):505–10

Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Balfour JA, et al. **Drugs** 1997 Aug;54(2):273–98 (86 ref.)

Clinical manifestations of transdermal scopolamine addiction. Luetje CM, et al. **Ear Nose Throat J** 1996 Apr;75(4):210–4

5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Cunningham RS. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):33–40 (54 ref.)

ADMINISTRATION & DOSAGE

Patient-controlled analgesia with morphine and droperidol following caesarean section under spinal anaesthesia. Russell D, et al. **Acta Anaesthesiol Scand** 1996 May; 40(5):600–5

Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Boike SC, et al. **Am J Health Syst Pharm** 1997 May 15; 54(10):1172–6

Expanded use of oral granisetron [letter] King RS, et al.
Am J Health Syst Pharm 1996 Aug 1;53(15):1849

Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery. Graczyk SG, et al. **Anesth Analg** 1997 Feb;84(2):325–30

Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group. Kovac AL, et al. **Anesth Analg** 1997 Sep;85(3):546–52

Optimal dose of granisetron for prophylaxis against postoperative emesis after gynecological surgery. Mikawa K, et al. **Anesth Analg** 1997 Sep;85(3):652–6

If nitrous oxide induces emesis, maybe 100% oxygen is an antiemetic [letter; comment] Overdyk FJ, et al.
Anesth Analg 1997 Jan;84(1):231–2. Comment on: Anesth Analg 1996 Jul;83(1):4–5. Comment on: Anesth Analg 1996 Jul;83(1):114–6.

Single-dose ondansetron prevents postoperative vomiting in pediatric outpatients. Patel RI, et al. **Anesth Analg** 1997 Sep;85(3):538–45

Intravenous ondansetron for postsurgical opioid-induced nausea and vomiting. S3A-255 Study Group. Rung GW, et al. **Anesth Analg** 1997 Apr;84(4):832–8

Small-dose propofol by continuous infusion does not prevent postoperative vomiting in females undergoing outpatient laparoscopy. Scuderi PE, et al. **Anesth Analg** 1997 Jan; 84(1):71–5

Acupressure versus intravenous metoclopramide to prevent nausea and vomiting during spinal anesthesia for cesarean section. Stein DJ, et al. **Anesth Analg** 1997 Feb;84(2):342–5

The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery. Sun R, et al. **Anesth Analg** 1997 Feb;84(2):331–6

Scopolamine patch can be confusing to the patient and anesthesiologist: a case report. Elias MA, et al.
Anesthesiology 1997 Mar;86(3):743–4

Antiemetic treatment with two different doses of methylprednisolone in breast cancer patients: a double-blind randomized cross-over study with evaluation of efficacy parameters. Havsteen H, et al.
Anticancer Drugs 1996 Jul;7(5):535–42

Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting. Diemunsch P, et al.
Can J Anaesth 1997 Feb;44(2):173–81

Granistron and dexamethasone provide more improved prevention of postoperative emesis than granisetron alone in children. Fujii Y, et al. **Can J Anaesth** 1996 Dec; 43(12):1229–32

Reduction of post-operative nausea and vomiting with the combination of morphine and droperidol in patient-controlled analgesia. Klahsen AJ, et al.
Can J Anaesth 1996 Nov;43(11):1100–7

Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. Rubenstein EB, et al. **Cancer** 1997 Mar 15;79(6):1216–24

A double-blind, randomized study of two different dosage regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapy. Kasimis BS, et al.
Cancer Invest 1997;15(4):304–10

Alert over sound-alike drugs [letter] Bailey B, et al.
CMAJ 1997 Jul 1;157(1):16, 18

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Audhuy B, et al. **Eur J Cancer** 1996 May; 32A(5):807–13

An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2. Brock P, et al. **Eur J Cancer** 1996 Sep;32A(10):1744–8

Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation [letter] Lawhorn S, et al. **J Heart Lung Transplant** 1997 Apr;16(4):472–3

The effect of a 4-mg preoperative intravenous dose of ondansetron in preventing nausea and vomiting after maxillofacial surgery. Rodrigo C, et al.
J Oral Maxillofac Surg 1996 Oct;54(10):1171–5

Ondansetron suppository: a randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea. The Ondansetron Suppository emesis study group. Davidson NG, et al. **Oncology** 1997 Sep-Oct;54(5):380–6

Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis. Pectasides D, et al. **Oncology** 1997 Jan-Feb; 54(1):1–6

Ondansetron reduces nausea and vomiting after paediatric adenotonsillectomy. Morton NS, et al. **Paediatr Anaesth** 1997;7(1):37–45

Prophylactic antiemetics in children undergoing tonsillectomy: high-dose vs low-dose ondansetron. Splinter WM, et al. **Paediatr Anaesth** 1997;7(2):125–9; discussion 130

Drug combinations in syringe drivers: the compatibility and stability of diamorphine with cyclizine and haloperidol. Grassby PF, et al. **Palliat Med** 1997 May;11(3):217–24

Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis. Garbe C, et al. **Semin Oncol** 1994 Oct;21(5 Suppl 9):12–6

Oral dolasetron mesilate (MDL 73,147EF) for the control of emesis during fractionated total-body irradiation and high-dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation. Fauser AA, et al.
Support Care Cancer 1997 May;5(3):219–22

Dose-finding study of oral metopimazine. Herrstedt J, et al.
Support Care Cancer 1997 Jan;5(1):38–43

[The combination of oral lysine-acetylsalicylate and metoclopramide compared with oral sumatriptan in the treatment of migraine attacks. A randomized, double-blind, placebo-controlled clinical trial] Tfelt-Hansen P, et al.
Ugeskr Laeger 1996 Nov 4;158(45):6435–9 (Eng. Abstr.) **(Dan)**

[Prevention of postoperative nausea and vomiting with single and repeat administration of ondansetron--review of the literature on different administration forms] Saur P, et al. **Anaesthesiol Reanim** 1996;21(5):131–5 (30 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation of the administration time of ondansetron, a preventive for postoperative nausea and vomiting: prospective, randomized, double-blind study in 120 patients] Ploner F, et al. **Anaesthesist** 1997 Jul;46(7):583–7 (Eng. Abstr.) **(Ger)**

[The use of granisetron per os in radiotherapy-induced emesis] Krengli M, et al. **Minerva Med** 1996 Dec;

87(12):605–8 (Eng. Abstr.) **(Ita)**

[Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis] Ariyoshi Y, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):995–1011 (Eng. Abstr.) **(Jpn)**

[Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer] Fujii M, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1095–101 (Eng. Abstr.) **(Jpn)**

[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP] Kimura E, et al. **Gan To Kagaku Ryoho** 1997 May; 24(7):855–9 (Eng. Abstr.) **(Jpn)**

[Granisetron versus granisetron plus methylprednisolone in the prevention of chemotherapy induced nausea and vomiting—in adjuvant chemotherapy, including CDDP against gastric cancer] Kurita A, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):49–54 (Eng. Abstr.) **(Jpn)**

[A comparative study of the effects of granisetron alone and a combination of granisetron plus steroids on CDDP-based combination chemotherapy-induced emesis—outcomes of a multicenter randomized comparative study using the central registration method. Nara Medical University Kytril Study Group] Ozono S, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):349–56 (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of 2 mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin] Takada M, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):987–94 (Eng. Abstr.) **(Jpn)**

[A randomized cross-over comparative study of granisetron alone and combination of granisetron, methylprednisolone and droperidol as antiemetic prophilaxis in CDDP-based chemotherapy for gynecologic cancer] Wataba K, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):691–7 (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of 2-mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin] Yoshiya N, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1141–7 (Eng. Abstr.) **(Jpn)**

[Epidural buprenorphine and epidural droperidol for post-operative nausea or vomiting] Yokoyama K, et al. **Masui** 1997 Jun;46(6):798–802 (Eng. Abstr.) **(Jpn)**

[Evaluation of the efficacy of anti-emetic therapy with ondansetron injected intravenously at a daily dose of 8mg (analysis of material)] Cieślińska A, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):337–9 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Acute intermittent porphyria precipitated by hyperemesis and metoclopramide treatment in pregnancy. Shenhav S, et al. **Acta Obstet Gynecol Scand** 1997 May;76(5):484–5

Late-onset major depression with delusions after metoclopramide treatment. Friend KD, et al. **Am J Geriatr Psychiatry** 1997 Winter;5(1):79–82

Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide. Baguley WA, et al. **Anesth Analg** 1997 Jun;84(6):1380–1

Scopolamine patch can be confusing to the patient and anesthesiologist: a case report. Elias MA, et al. **Anesthesiology** 1997 Mar;86(3):743–4

Dystonic reaction to a phenothiazine presenting as Bell's palsy. Bhopale S, et al. **Ann Emerg Med** 1997 Aug; 30(2):234–6

Akathisia associated with prochlorperazine as an antiemetic: a case report [letter] Dukoff R, et al. **Ann Oncol** 1996 Jan; 7(1):103

Extrapyramidal reaction caused by ondansetron [letter] Mathews HG 3d, et al. **Ann Pharmacother** 1996 Feb; 30(2):196

Compatibility of hydromorphone and prochlorperazine, and irritation due to subcutaneous prochlorperazine infusion [letter] Trinkle R. **Ann Pharmacother** 1997 Jun;31(6):789–90

Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis. Yarboro CH, et al. **Ann Pharmacother** 1996 Jul–Aug; 30(7–8):752–5

Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. Keung AC, et al. **Biopharm Drug Dispos** 1997 May;18(4):361–9

Fixed drug eruption due to dimenhydrinate [letter] Gonzalo-Garijo MA, et al. **Br J Dermatol** 1996 Oct; 135(4):661–2

Preoperative ketorolac increases bleeding after tonsillectomy in children [see comments] Splinter WM, et al. **Can J Anaesth** 1996 Jun;43(6):560–3. Comment in: Can J Anaesth 1996 Jun;43(6):544–8.

Venous thrombosis as a complication of antiemetic treatment [letter] Slee PH, et al. **Cancer Chemother Pharmacol** 1996; 38(6):574

Quality problems that result in adverse outcomes provide opportunities for quality improvement. **Int J Qual Health Care** 1996 Dec;8(6):597–8

Prochlorperazine-induced neuroleptic malignant syndrome. Pesola GR, et al. **J Emerg Med** 1996 Nov–Dec;14(6):727–9

Index of Suspicion. Case 1. Dystonic reaction to metoclopramide. Stille CJ. **Pediatr Rev** 1997 Feb;18(2):63, 64

Single-dose, placebo-controlled, phase I study of oral dolasetron. Dixon RM, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2):245–52

Multiple-dose, placebo-controlled, phase I study of oral dolasetron. Hunt TL, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2):253–60

Tardive dyskinesia as a result of long-term prochlorperazine use. Alberts VA, et al. **South Med J** 1996 Oct;89(10):989–91

[A 'suppository for vomiting prevention'] Poorter ME, et al. **Ned Tijdschr Geneeskd** 1997 Apr 5;141(14):665–6 (Eng. Abstr.) **(Dut)**

[Metaclopramide and depression: apropos of a case of a pregnant women (letter)] Feillet N, et al. **Therapie** 1996 Sep-Oct;51(5):600–1 **(Fre)**

[An unusual case of psychosis caused by long-term administration of a scopolamine membrane patch. Paranoid hallucinogenic and delusional symptoms] Rubner O, et al. **Nervenarzt** 1997 Jan;68(1):77–9 (Eng. Abstr.) **(Ger)**

[Cleft lip and palate associated with meclozine] Lastra-Lastra A, et al. **Ginecol Obstet Mex** 1996 Nov;64:485 **(Spa)**

[Domperidone: an alternative to orthopramides in the case of adverse reactions in the central nervous system (letter)] Buzo Sánchez LG, et al. **Med Clin (Barc)** 1996 Sep 14; 107(8):317–8 **(Spa)**

[Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs] Martí Massó JF, et al. **Neurologia** 1996 Jan;11(1):10–5 (Eng. Abstr.) **(Spa)**

[Acute postoperative pancreatitis, is it associated with the use of ondansetron? (letter)] Granados LM, et al. **Rev Esp Anestesiol Reanim** 1997 Feb;44(2):87 **(Spa)**

ANALYSIS

Application of packed capillary liquid chromatography/mass spectrometry with electrospray ionization to the study of the human biotransformation of the anti-emetic drug dolasetron. Ackermann BL, et al. **J Mass Spectrom** 1996 Jun;31(6):681–9

Partial least-squares regression for the quantitation of pharmaceutical dosages in control analyses. Blanco M, et al. **J Pharm Biomed Anal** 1996 Dec;15(3):329–38

BLOOD

Direct plasma liquid chromatographic-tandem mass spectrometric analysis of granisetron and its 7-hydroxy metabolite utilizing internal surface reversed-phase guard columns and automated column switching devices. Boppana VK, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):227–36

High-resolution liquid chromatographic method using ultraviolet detection for determination of ondansetron in human plasma. Dépôt M, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):399–406

High-performance liquid chromatographic analysis of ondansetron enantiomers in human serum using a reversed-phase cellulose-based chiral stationary phase and solid-phase extraction. Liu J, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20;694(1):179–84

Enantioselective determination of S-(+)- and R-(-)-ondansetron in human serum using derivatized cyclodextrin-modified capillary electrophoresis and solid-phase extraction. Siluveru M, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):217–22

CHEMICAL SYNTHESIS

A new series of 6-chloro-2,3-dihydro-4(1H)-quinazolinone derivatives as antiemetic and gastrointestinal motility enhancing agents. Baldazzi C, et al. **Arzneimittelforschung** 1996 Sep;46(9):911–8

CHEMISTRY

Stability of granisetron hydrochloride with dexamethasone sodium phosphate for 14 days. Chin A, et al. **Am J Health Syst Pharm** 1996 May 15;53(10):1174–6

Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride injection and in 5% dextrose injection. Evrard B, et al. **Am J Health Syst Pharm** 1997 May 1;54(9):1065–8

Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days [published erratum appears in Am J Health Syst Pharm 1997 May 1;54(9):1110] Hagan RL, et al. **Am J Health Syst Pharm** 1996 Jun 15;53(12):1431–5

21-day compatibility of hydromorphone hydrochloride and promethazine hydrochloride in a cassette [letter] Henderson F. **Am J Health Syst Pharm** 1996 Oct 1; 53(19):2338–9

Stability of granisetron hydrochloride in polypropylene syringes. Quercia RA, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2744–6

Stability of ondansetron hydrochloride and five antineoplastic medications. Stewart JT, et al. **Am J Health Syst Pharm** 1996 Jun 1;53(11):1297–300

Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Trissel LA, et al. **Am J Health Syst Pharm** 1997 Jan 1;54(1):56–60

DIAGNOSTIC USE

The use of metoclopramide for the small bowel meal examination: pre-procedural versus peri-procedural oral administration. Paul N, et al. **Br J Radiol** 1996 Dec; 69(828):1130–3

ECONOMICS

Medicare reimbursement for oral antiemetics in management of chemotherapy-induced emesis [letter] Ignoffo RJ. **Am J Health Syst Pharm** 1997 Apr 1;54(7):830–1

Cost effective prophylaxys of postoperative nausea and vomiting by anesthetic premedication. Rodolà F, et al. **Riv Eur Sci Med Farmacol** 1995 Nov–Dec;17(6):243–6

Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Grunberg SM, et al. **Support Care Cancer** 1996 Nov;4(6):435–9

ISOLATION & PURIFICATION

Method for the control of known impurities in hydroxyzine hydrochloride. Simpson D, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1371–5

METABOLISM

Chlorpromazine transport in membrane vesicles from multidrug resistant CCRF-CEM cells. Syed SK, et al. **Biochem Mol Biol Int** 1996 Jul;39(4):687–96

High affinity binding of azasetron hydrochloride to 5-hydroxytryptamine3 receptors in the small intestine of rats. Katayama K, et al. **Jpn J Pharmacol** 1997 Apr; 73(4):357–60

GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Gardner CJ, et al. **Regul Pept** 1996 Aug 27;65(1):45–53

PHARMACOKINETICS

Absorption characteristics of azasetron from rectal and oral routes in rabbits. Moriyama Y, et al. **Biol Pharm Bull** 1997 Jun;20(6):701–3

Pharmaceutical properties of freeze-dried formulations of egg albumin, several drugs and olive oil. Tsuji Y, et al. **Biol Pharm Bull** 1996 Apr;19(4):636–40

Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. Keung AC, et al. **Biopharm Drug Dispos** 1997 May;18(4):361–9

Bioavailability of the antiemetic metopimazine given as a microenema. Herrstedt J, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):613–5

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children. Lerman J, et al. **Clin Pharmacol Ther** 1996 Nov;60(5):485–92

Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Fauser AA, et al. **Eur J Cancer** 1996 Aug; 32A(9):1523–9

Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. Dempsey E, et al. **J Clin Pharmacol** 1996 Oct;36(10):903–10

Comparative central nervous system effects and pharmacokinetics of neu-metoclopramide and metoclopramide in healthy volunteers. Rotmensch HH, et al. **J Clin Pharmacol** 1997 Mar;37(3):222–8

Application of packed capillary liquid chromatography/mass spectrometry with electrospray ionization to the study of the human biotransformation of the anti-emetic drug dolasetron. Ackermann BL, et al. **J Mass Spectrom** 1996 Jun;31(6):681–9

Clinical pharmacokinetics of ondansetron. A review. Simpson KH, et al. **J Pharm Pharmacol** 1996 Aug; 48(8):774–81 (60 ref.)

Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, sensamide and neu-sensamide. Pero RW, et al. **Pharmacol Toxicol** 1997 May;80(5):231–9

PHARMACOLOGY

Is d-tubocurarine an antiemetic? [letter] Gyermek L. **Acta Anaesthesiol Sin** 1996 Mar;34(1):53

Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility. Feinle C, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):G591–7

The effect of ondansetron on the pharmacokinetics and pharmacodynamics of temazepam. Preston GC, et al. **Anaesthesia** 1996 Sep;51(9):827–30

Anti-emetic drug effects on cognitive and psychomotor performance: granisetron vs. ondansetron. Benline TA, et al. **Aviat Space Environ Med** 1997 Jun;68(6):504–11

Metoclopramide does not inhibit atrial natriuretic factor-stimulated diuresis in man. Farrow S, et al. **Aviat Space Environ Med** 1996 Mar;67(3):248–52

Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Okamoto S, et al. **Bone Marrow Transplant** 1996 May;17(5):679–83

The effect of CP-99994 on the responses to provocative motion in the cat. Lucot JB, et al. **Br J Pharmacol** 1997 Jan;120(1):116–20

The activity of dihydropyrimidine dehydrogenase from rat liver was not affected by any of five 5-hydroxytryptamine antagonists. Tateishi T, et al. **Cancer Lett** 1996 Nov 12;

108(1):1–5
Influence of metoclopramide on the pharmacokinetics of 8–methoxypsoralen. Studer–Sachsenberg EM, et al. **Dermatology** 1997;195(1):81–3
Physiology of chemotherapy–induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds. Veyrat–Follet C, et al. **Drugs** 1997 Feb; 53(2):206–34 (141 ref.)
An investigation of the effect of ondansetron on time to induction of anaesthesia with thiopentone and propofol. Mansfield M, et al. **Eur J Anaesthesiol** 1997 Jan;14(1):24–8
Evidence that cisplatin induces serotonin release from human peripheral blood mononuclear cells and that methylprednisolone inhibits this effect. Mantovani G, et al. **Eur J Cancer** 1996 Oct;32A(11):1983–5
Broad spectrum antiemetic effects of CP–122,721, a tachykinin NK1 receptor antagonist, in ferrets. Gonsalves S, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):181–5
Antiemetic effects of N–3389, a newly synthesized 5–HT3 and 5–HT4 receptor antagonist, in ferrets. Minami M, et al. **Eur J Pharmacol** 1997 Mar 5;321(3):333–42
In vitro and in vivo predictors of the anti–emetic activity of tachykinin NK1 receptor antagonists. Rupniak NM, et al. **Eur J Pharmacol** 1997 May 20;326(2–3):201–9
The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin–induced delayed emesis in the ferret. Singh L, et al. **Eur J Pharmacol** 1997 Feb 26;321(2):209–16
The effect of orally and rectally administered delta 9–tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Brenneisen R, et al. **Int J Clin Pharmacol Ther** 1996 Oct;34(10):446–52
Promethazine affects autonomic cardiovascular mechanisms minimally. Brown TE, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):839–44
Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs. Iwanaga Y, et al. **Jpn J Pharmacol** 1996 Jun;71(2):129–37
Ethanol–induced emesis in the house musk shrew, Suncus murinus. Chen Y, et al. **Life Sci** 1997;60(4–5):253–61
Neuropharmacological mechanisms of emesis. II. Effects of antiemetic drugs on cisplatin–induced pica in rats. Takeda N, et al. **Methods Find Exp Clin Pharmacol** 1995 Dec; 17(10):647–52
Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Tattersall FD, et al. **Neuropharmacology** 1996; 35(8):1121–9
Anti–emetic principles of Poria cocos. Tai T, et al. **Planta Med** 1995 Dec;61(6):527–30
[Does oral ondansetron reduce the incidence of nausea and vomiting after surgery for strabismus in children?] Mjahed K, et al. **Ann Fr Anesth Reanim** 1996;15(7):1018–21 (Eng. Abstr.) **(Fre)**
[A new antiemetic ramosetron hydrochloride] Tsukagoshi S. **Gan To Kagaku Ryoho** 1997 Feb;24(3):371–80 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Activity of ondansetron on the systemic vascular resistance and venous capacitance during cardiopulmonary bypass] Sánchez–Peña J, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):269–71 (Eng. Abstr.) **(Spa)**
[Effects of metoclopramide on the hypnotic dosages of propofol (letter)] Santiveri X, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):297–8 **(Spa)**

POISONING

[Tetanus: problems of differential diagnosis in the presence of contemporaneous administration of metoclopramide] Gaspari R, et al. **Minerva Anestesiol** 1996 Dec; 62(12):409–12 (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Granisetron reduces incidence of nausea and vomiting after breast surgery. Fujii Y, et al. **Acta Anaesthesiol Scand** 1997 Jun;41(6):746–9
Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double–blind, placebo–controlled study. Korttila K, et al. **Acta Anaesthesiol Scand** 1997 Aug;41(7):914–22
Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study. Sundström GM, et al. **Acta Oncol** 1997;36(2):229–30
Antiemetic activity of ondansetron in acute gastroenteritis. Cubeddu LX, et al. **Aliment Pharmacol Ther** 1997 Feb; 11(1):185–91
Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high–dose cisplatin–containing chemotherapy. Yeilding A, et al. **Am J Clin Oncol** 1996 Dec;19(6):619–23
The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Soykan I, et al. **Am J Gastroenterol** 1997 Jun;92(6):976–80
A pilot study of intravenous ondansetron for hyperemesis gravidarum. Sullivan CA, et al. **Am J Obstet Gynecol** 1996 May;174(5):1565–8
Can vomiting after squint surgery be prevented? [letter] Fry RA, et al. **Anaesth Intensive Care** 1997 Feb;25(1):94–5
The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double–blind comparison. van den Berg AA. **Anaesth Intensive Care** 1996 Oct;24(5):538–45
A randomized double–blinded comparison of metoclopramide, ondansetron and cyclizine in day–case laparoscopy. Watts SA. **Anaesth Intensive Care** 1996 Oct; 24(5):546–51
Comparison of ondansetron, metoclopramide and placebo as premedicants to reduce nausea and vomiting after major surgery. Alexander R, et al. **Anaesthesia** 1997 Jul; 52(7):695–8
Antiemetic effect of propofol [letter; comment] Borgeat A. **Anaesthesia** 1996 Nov;51(11):1073–4. Comment on: Anaesthesia 1996 Jun;51(6):554–7.
Antiemetic efficacy of ondansetron with patient–controlled analgesia [see comments] Davies PR, et al. **Anaesthesia** 1996 Sep;51(9):880–2. Comment in: Anaesthesia 1997 Jan;52(1):90–1.
The prevention of postoperative nausea and vomiting using a combination of ondansetron and droperidol [letter; comment] Kessell G. **Anaesthesia** 1997 Feb;52(2):191. Comment on: Anaesthesia 1996 Aug;51(8):776–8.
A comparison of prophylactic ondansetron and metoclopramide administration in patients undergoing major neurosurgical procedures. Pugh SC, et al. **Anaesthesia** 1996 Dec;51(12):1162–4
Efficacy of ondansetron and metoclopramide for preventing postoperative emesis following strabismus surgery in children. Shende D, et al. **Anaesthesia** 1997 May; 52(5):496–500
Study power inadequate to reject ondansetron [letter; comment] Slade JM. **Anaesthesia** 1997 Jan;52(1):90–1. Comment on: Anaesthesia 1996 Sep;5199):880–2.
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide [letter; comment] Bliss A, et al. **Anesth Analg** 1997 Apr;84(4):942–3 . Comment on: Anesth Analg 1996 Nov;83(5):1081–3.
The effects of dexamethasone on antiemetics in female patients undergoing gynecologic surgery. Fujii Y, et al. **Anesth Analg** 1997 Oct;85(4):913–7
Droperidol/ondansetron combination controls nausea and vomiting after tubal banding [published erratum appears in Anesth Analg 1997 Mar;84(3):704] [see comments] McKenzie R, et al. **Anesth Analg** 1996 Dec;83(6):1218–22 . Comment in: Anesth Analg 1997 Jun;84(6):1389–90.
Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia. Pan PH, et al. **Anesth Analg** 1996 Nov;83(5):982–6
Droperidol and/or ondansetron [letter; comment] Pinsker MC. **Anesth Analg** 1997 Jun;84(6):1389–90. Comment on: Anesth Analg 1996 Dec;83(6):1218–22.
Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting. Polati E, et al. **Anesth Analg** 1997 Aug;85(2):395–9
Comparison of tropisetron, droperidol, and saline in the prevention of postoperative nausea and vomiting after gynecologic surgery. Purhonen S, et al. **Anesth Analg** 1997 Mar;84(3):662–7
A comparison of the prophylactic antiemetic effect of ondansetron and droperidol on patients undergoing gynecologic laparoscopy. Sniadach MS, et al. **Anesth Analg** 1997 Oct;85(4):797–800
Prophylaxis for vomiting by children after tonsillectomy: dexamethasone versus perphenazine. Splinter W, et al. **Anesth Analg** 1997 Sep;85(3):534–7
Dexamethasone decreases vomiting by children after tonsillectomy. Splinter WM, et al. **Anesth Analg** 1996 Nov; 83(5):913–6
Prophylactic antiemetics for laparoscopic cholecystectomy: ondansetron versus droperidol plus metoclopramide [see comments] Steinbrook RA, et al. **Anesth Analg** 1996 Nov; 83(5):1081–3. Comment in: Anesth Analg 1997 Apr;84(4):942–3.
The dose–response relation and cost–effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis. Cieslak GD, et al. **Anesthesiology** 1996 Nov; 85(5):1076–85
Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research. **Ann Oncol** 1997 Jun; 8(6):561–7
Radiotherapy and drugs: 'setrons' once again [editorial; comment] [see comments] Aapro MS. **Ann Oncol** 1996 Aug; 7(6):553–4. Comment on: Ann Oncol 1996 Aug;7(6):553. Comment in: Ann Oncol 1997 Mar;8(3):302.
Optimum anti–emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. Cunningham D, et al. **Ann Oncol** 1996 Mar; 7(3):277–82
A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy [see comments] Franzén L, et al. **Ann Oncol** 1996 Aug; 7(6):587–92. Comment in: Ann Oncol 1996 Aug;7(6):553–4.
Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Koo WH, et al. **Ann Oncol** 1996 Jan; 7(1):71–4
A multicentre, double–blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin–induced delayed emesis. Ondansetron Delayed Emesis Study Group [see comments] Olver I, et al. **Ann Oncol** 1996 Nov;7(9):945–52. Comment in: Ann Oncol 1997 Jun;8(6):615–6.
The role of the 5–HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Pater JL, et al. **Ann Oncol** 1997 Feb; 8(2):181–5
The control of delayed nausea [letter; comment] Roila F, et al. **Ann Oncol** 1997 Jun;8(6):615–6. Comment on: Ann Oncol 1996 Nov;7(9):945–52.
Propofol in chemotherapy–associated nausea and vomiting. Phelps KC, et al. **Ann Pharmacother** 1996 Mar;30(3):290–2 (22 ref.)
Treatment of cisplatin–related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. Gebbia V, et al. **Anticancer Drugs** 1996 Sep; 7(7):734–7
Comparison of oral itasetron with oral ondansetron: results of a double–blind, active–controlled phase II study in chemotherapy–naive patients receiving moderately emetogenic chemotherapy. Goldschmidt H, et al. **Anticancer Drugs** 1997 Jun;8(5):436–44
Antiemetic efficacy of granisetron in patients with gynecological malignancies. Sismondi P, et al. **Anticancer Drugs** 1997 Mar;8(3):225–30
The efficacy of hyoscine hydrobromide in reducing side–effects induced during immersion in virtual reality. Regan EC, et al. **Aviat Space Environ Med** 1996 Mar; 67(3):222–6
Antiemetic effects of morphine on motion– and drug–induced emesis in Suncus murinus. Kakimoto S, et al. **Biol Pharm Bull** 1997 Jul;20(7):739–42
Impact of covert duplicate publication on meta–analysis: a case study. Tramèr MR, et al. **BMJ** 1997 Sep 13; 315(7109):635–40
A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. Tramèr MR, et al. **BMJ** 1997 Apr 12;314(7087):1088–92
Antiemetic effect of subhypnotic doses of propofol after thyroidectomy. Ewalenko P, et al. **Br J Anaesth** 1996 Oct; 77(4):463–7
Nausea and vomiting after cardiac surgery [see comments] Grebenik CR, et al. **Br J Anaesth** 1996 Sep;77(3):356–9. Comment in: Br J Anaesth 1997 Apr;78(4):476.
Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies. Tramèr M, et al. **Br J Anaesth** 1997 Mar; 78(3):247–55
Phase II study of high–dose dexamethasone–based association in acute and delayed high–dose cisplatin–induced emesis—JCOG study 9413. Sekine I, et al. **Br J Cancer** 1997;76(1):90–2
Drug therapies for hyperemesis gravidarum [letter] Linehan SJ. **Can Fam Physician** 1997 Sep;43:1499
A comparison of ranitidine, droperidol or placebo in the prevention of nausea and vomiting after hysterectomy. Cozanitis D, et al. **Can J Anaesth** 1996 Feb;43(2):106–9
Antiemetic effects of granisetron on postoperative nausea and vomiting in patients with and without motion sickness. Fujii Y, et al. **Can J Anaesth** 1996 Feb;43(2):110–4
Prophylactic antiemetic efficacy of granisetron in patients with and without previous postoperative emesis. Fujii Y, et al. **Can J Anaesth** 1997 Mar;44(3):273–7
Prevention of PONV with granisetron, droperidol and metoclopramide in female patients with history of motion sickness. Fujii Y, et al. **Can J Anaesth** 1997 Aug;44(8):820–4
Effective dose of granisetron for preventing postoperative emesis in children. Fujii Y, et al. **Can J Anaesth** 1996 Jul; 43(7):660–4
Granisetron reduces the incidence and severity of nausea and vomiting after laparoscopic cholecystectomy. Fujii Y, et al. **Can J Anaesth** 1997 Apr;44(4):396–400
Granisetron reduces postoperative nausea and vomiting throughout menstrual cycle. Fujii Y, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):489–93
Antiemetic efficacy of granisetron and metoclopramide in children undergoing ophthalmic or ENT surgery. Fujii Y, et al. **Can J Anaesth** 1996 Nov;43(11):1095–9
Treatment of postoperative nausea and vomiting: comparison of propofol, droperidol and metoclopramide. Lacroix G, et al. **Can J Anaesth** 1996 Feb;43(2):115–20
Dose–response of flurbiprofen on postoperative pain and emesis after paediatric strabismus surgery. Mikawa K, et al. **Can J Anaesth** 1997 Jan;44(1):95–8
Central antiemetic effect of atropine: our personal experience [letter] Ramaioli F, et al. **Can J Anaesth** 1996 Oct; 43(10):1079
Vomiting after strabismus surgery in children: ondansetron vs propofol. Splinter WM, et al. **Can J Anaesth** 1997 Aug; 44(8):825–9
A comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after tympanoplasty. van den Berg AA. **Can J Anaesth** 1996 Sep;43(9):939–45
Subhypnotic propofol does not treat postoperative vomiting in children after adenotonsillectomy. Zestos MM, et al. **Can J Anaesth** 1997 Apr;44(4):401–4
Controlling the toxicity of palliative radiotherapy: the role of 5–HT3 antagonists. Priestman TJ. **Can J Oncol** 1996 Feb;6 Suppl 1:17–22
Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Kris MG, et al. **Cancer** 1996 Nov 15;78(10):2193–8

Comparison of Granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. A randomized controlled trial [letter; comment] Tremont-Lukats IW, et al. **Cancer** 1996 Dec 1; 78(11):2450-3. Comment on: Cancer 1996 Mar 1;77(5):941-8.

Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. Beck TM, et al. **Cancer Invest** 1997;15(4):297-303

Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. Grote TH, et al. **Cancer J Sci Am** 1997 Jan-Feb;3(1):45-51

Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone. Hesketh PJ, et al. **Cancer J Sci Am** 1997 May-Jun;3(3):180-3

A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation. Gibbs SJ, et al. **Clin Oncol (R Coll Radiol)** 1996; 8(3):182-4

The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux. Bellissant E, et al. **Clin Pharmacol Ther** 1997 Mar;61(3):377-84

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life [corrected and republished article originally printed in Clin Ther 1996 May-Jun;18(3):508-18] Crucitt MA, et al. **Clin Ther** 1996 Jul-Aug;18(4):778-88

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life [corrected and republished in Clin Ther 1996 Jul-Aug;18(4):778-88] Crucitt MA, et al. **Clin Ther** 1996 May-Jun;18(3):508-18

Efficacy and safety of ondansetron in pediatric patients undergoing bone marrow transplantation. Nahata MC, et al. **Clin Ther** 1996 May-Jun;18(3):466-76

Antiemetic therapy. Axelrod RS. **Compr Ther** 1997 Aug; 23(8):539-45 (24 ref.)

Antiemetics revisited. Roila F, et al. **Curr Opin Oncol** 1997 Jul;9(4):321-6 (31 ref.)

Risks and benefits of drugs used in the management of postoperative nausea and vomiting. Sung YF. **Drug Saf** 1996 Mar;14(3):181-97 (140 ref.)

Drug treatment of chemotherapy-induced delayed emesis. Tavorath R, et al. **Drugs** 1996 Nov;52(5):639-48 (43 ref.)

Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting after major gynaecological surgery. Chen PP, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):485-91

Ondansetron, droperidol and their combination for the prevention of post-operative vomiting in children. Klockgether-Radke A, et al. **Eur J Anaesthesiol** 1997 Jul; 14(4):362-7

Comparison of metoclopramide and ondansetron for the prevention of nausea and vomiting after intrathecal morphine. Pitkänen MT, et al. **Eur J Anaesthesiol** 1997 Mar;14(2):172-7

Double-blind comparison of alizapride, droperidol and ondansetron in the treatment of post-operative nausea. Stienstra R, et al. **Eur J Anaesthesiol** 1997 May;14(3):290-4

An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Jantunen IT, et al. **Eur J Cancer** 1997 Jan;33(1):66-74

The actions of ondansetron and dexamethasone to antagonise cisplatin-induced emesis in the ferret. Rudd JA, et al. **Eur J Pharmacol** 1997 Mar 12;322(1):79-82

Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis. Parikh PM, et al. **Indian J Cancer** 1996 Mar;33(1):17-20

Comparison of dexamethasone and metoclopramide as antiemetics in children receiving cancer chemotherapy. Basade M, et al. **Indian Pediatr** 1996 Apr;33(4):321-3

Ondansetron decreases postoperative vomiting in pediatric patients undergoing tonsillectomy and adenoidectomy. Lawhorn CD, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jul;36(2):99-108

Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Belkacémi Y, et al. **Int J Radiat Oncol Biol Phys** 1996 Aug 1;36(1):77-82

Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. Markman M, et al. **J Cancer Res Clin Oncol** 1997;123(4):224-6

Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. Bosnjak SM, et al. **J Chemother** 1996 Aug;8(4):315-8

Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy. Massidda B, et al. **J Chemother** 1996 Jun;8(3):237-42

Ondansetron versus droperidol or placebo when given prophylactically for the prevention of postoperative nausea and vomiting in patients undergoing middle ear procedures. Jellish WS, et al. **J Clin Anesth** 1997 Sep;9(6):451-6

Ondansetron prevents postoperative emesis in male outpatients. S3A-379 Study Group. Kovac AL, et al. **J Clin Anesth** 1996 Dec;8(8):644-51

Effect of propofol for induction and ondansetron with or without dexamethasone for the prevention of nausea and vomiting after major gynecologic surgery. McKenzie R, et al. **J Clin Anesth** 1997 Feb;9(1):15-20

Prospective, randomized, double-blind, placebo-controlled comparison of metoclopramide and ondansetron for prevention of posttonsillectomy or adenotonsillectomy emesis. Stene FN, et al. **J Clin Anesth** 1996 Nov;8(7):540-4

Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. **J Clin Oncol** 1997 Jan;15(1):124-30

Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. Herrstedt J, et al. **J Clin Oncol** 1997 Apr; 15(4):1690-6

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. Kris MG, et al. **J Clin Oncol** 1997 May;15(5):2135-8

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. Lofters WS, et al. **J Clin Oncol** 1997 Aug; 15(8):2966-73

Antiemetic efficacy of ginger (Zingiber officinale) against cisplatin-induced emesis in dogs. Sharma SS, et al. **J Ethnopharmacol** 1997 Jul;57(2):93-6

Anti-emetic efficacy of tropisetron and metoclopramide. Yilmazlar A, et al. **J Int Med Res** 1996 May-Jun; 24(3):266-70

Efficacy of prophylactic ondansetron in Thai patients undergoing gastrointestinal tract surgery. Lekprasert V, et al. **J Med Assoc Thai** 1996 Jun;79(6):382-7

Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin [letter] Kris MG, et al. **J Natl Cancer Inst** 1997 Jun 4;89(11):817-8

Fighting nausea in the '90s: more and better anti-emetics can help [news] Saphir A. **J Natl Cancer Inst** 1997 Sep 3;89(17):1252-5

Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen [see comments] Bruera E, et al. **J Pain Symptom Manage** 1996 Mar;11(3):147-53. Comment in: J Pain Symptom Manage 1997 Apr;13(4):187-8. Comment in: J Pain Symptom Manage 1997 May;13(5):252-3.

Use of ondansetron in palliative medicine. Currow DC, et al. **J Pain Symptom Manage** 1997 May;13(5):302-7

Re: Metoclopramide for chronic nausea [letter; comment] Regnard CF, et al. **J Pain Symptom Manage** 1997 Apr; 13(4):187-8. Comment on: J Pain Symptom Manage 1996 Mar;11(3):147-53.

Re: Metoclopramide for chronic nausea [letter; comment] Twycross R. **J Pain Symptom Manage** 1997 May; 13(5):252-3. Comment on: J Pain Symptom Manage 1996 Mar;11(3):147-53.

Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy. Tyc VL, et al. **J Pediatr Psychol** 1997 Feb;22(1):45-58

Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet. Grélot L, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):255-61

Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy [letter; comment] Berberoglu S. **Med Pediatr Oncol** 1997 Mar; 28(3):241. Comment on: Med Pediatr Oncol 1995 Dec;25(6):457-62.

Prophylactic administration of ondansetron in emergency intraabdominal operations. Ulusoy HO, et al. **Middle East J Anesthesiol** 1996 Jun;13(5):513-26

Prophylactic administration of ondansetron in emergency intraabdominal operations. Ulusoy HO, et al. **Middle East J Anesthesiol** 1997 Feb;14(1):45-58

Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. Goodman M. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):20-32 (39 ref.)

Relieving nausea and vomiting in patients with cancer: a treatment algorithm. Johnson MH, et al. **Oncol Nurs Forum** 1997 Jan-Feb;24(1):51-7

A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. du Bois A, et al. **Oncology** 1997 Jan-Feb;54(1):7-14

Use of dexamethasone with 5-HT3-receptor antagonists [letter] Perez EA. **Oncology (Huntingt)** 1996 Jan;10(1):14

Prophylactic intravenous ondansetron in patients undergoing cataract extraction under general anesthesia. Ascaso FJ, et al. **Ophthalmologica** 1997;211(5):292-5

Posttonsillectomy vomiting. Ondansetron or metoclopramide during paediatric tonsillectomy: are two doses better than one? Rose JB, et al. **Paediatr Anaesth** 1996;6(1):39-44

A double-blind, placebo-controlled evaluation of intranasal metoclopramide in the prevention of postoperative nausea and vomiting. Wagner BK, et al. **Pharmacotherapy** 1996 Nov-Dec;16(6):1063-9

Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). Tincello DG, et al. **Postgrad Med J** 1996 Nov;72(853):688-9

Successful management of hyperemesis gravidarum using steroid therapy. Taylor R. **QJM** 1996 Feb;89(2):103-7

Cost effective prophylaxys of postoperative nausea and vomiting by anesthetic premedication. Rodolà F, et al. **Riv Eur Sci Med Farmacol** 1995 Nov-Dec;17(6):243-6

Tropisetron (Navoban): just another "setron"? Aapro MS. **Semin Oncol** 1994 Oct;21(5 Suppl 9):1-2

Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. Bruntsch U, et al. **Semin Oncol** 1994 Oct;21(5 Suppl 9):7-11

A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis. Madej G, et al. **Semin Oncol** 1994 Oct;21(5 Suppl 9):3-6

Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies. Otten J, et al. **Semin Oncol** 1994 Oct;21(5 Suppl 9):17-9

Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. Sorbe BG. **Semin Oncol** 1994 Oct;21(5 Suppl 9):20-6

Always more "setrons": how many do we need? [editorial; comment] Aapro MS. **Support Care Cancer** 1997 Jan; 5(1):1-2. Comment on: Support Care Cancer 1997 Jan;5(1):9-11. Comment on: Support Care Cancer 1997 Jan;5(1):12-6. Comment on: Support Care Cancer 1997 Jan;5(1):31-7.

Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer. Ballatori E, et al. **Support Care Cancer** 1997 Jul;5(4):269-73

A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Bey P, et al. **Support Care Cancer** 1996 Sep;4(5):378-83

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Chevallier B, et al. **Support Care Cancer** 1997 Jan;5(1):22-30

Antiemetic support: a continuous challenge [editorial] Dicato M. **Support Care Cancer** 1996 Jul;4(4):261-2

5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone. du Bois A, et al. **Support Care Cancer** 1996 Sep; 4(5):384-9

Acute and anticipatory emesis in breast cancer patients. Fernández-Marcos A, et al. **Support Care Cancer** 1996 Sep; 4(5):370-7

Innovative approaches in the treatment of emesis [see comments] Grunberg SM. **Support Care Cancer** 1997 Jan; 5(1):9-11 (22 ref.). Comment in: Support Care Cancer 1997 Jan;5(1):1-2.

New perspectives in antiemetic treatment. Herrstedt J. **Support Care Cancer** 1996 Nov;4(6):416-9 (41 ref.)

Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis [see comments] Perez EA, et al. **Support Care Cancer** 1997 Jan;5(1):31-7. Comment in: Support Care Cancer 1997 Jan;5(1):1-2.

Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Peterson C, et al. **Support Care Cancer** 1996 Nov;4(6):440-6

Comparative studies of various antiemetic regimens. Roila F, et al. **Support Care Cancer** 1996 Jul;4(4):270-80 (57 ref.)

Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy. Silva RR, et al. **Support Care Cancer** 1996 Jul;4(4):287-90

Methodology of trials with antiemetics. Tonato M, et al. **Support Care Cancer** 1996 Jul;4(4):281-6 (9 ref.)

Standard treatment of chemotherapy-induced emesis [see comments] Warr D. **Support Care Cancer** 1997 Jan; 5(1):12-6 (24 ref.). Comment in: Support Care Cancer 1997 Jan;5(1):1-2.

[A randomized trial of tropisetron in the prophylaxis of nausea and vomiting induced by chemotherapy] Zhang P, et al. **Chung Hua Chung Liu Tsa Chih** 1996 Mar;18(2):154-6 (Eng. Abstr.) **(Chi)**

[Antiemetics in oncology] Longueville J. **J Pharm Belg** 1996 Jul-Aug;51(4):220-5 (13 ref.) **(Fre)**

[Clinical use of antiemetic drugs for prevention and therapy of postoperative nausea and vomiting] Saur P, et al. **Anaesthesiol Reanim** 1996;21(6):153-8 (67 ref.) (Eng. Abstr.) **(Ger)**

[Transdermal scopolamine for prevention of postoperative nausea and vomiting. No clinically relevant result in spite of reduced postoperative vomiting in general surgical and gynecologic patients] Eberhart LHJ, et al. **Anaesthesist** 1996 Mar;45(3):259-67 (Eng. Abstr.) **(Ger)**

[Evaluation of the administration time of ondansetron, a

preventive for postoperative nausea and vomiting: prospective, randomized, double-blind study in 120 patients] Ploner F, et al. **Anaesthesist** 1997 Jul;46(7):583-7 (Eng. Abstr.) **(Ger)**

[Pharmacologic and clinical differentiation of prokinetic drugs] May B, et al. **Leber Magen Darm** 1996 Jul; 26(4):193-8 (52 ref.) (Eng. Abstr.) **(Ger)**

[Vomiting: causes and therapy] Neiger R. **Schweiz Arch Tierheilkd** 1996;138(9):421-8 (42 ref.) (Eng. Abstr.) **(Ger)**

[Prevention of postoperative nausea and vomiting with ondansetron: a prospective, randomized, double-blind study in 90 patients] Polati E, et al. **Minerva Anestesiol** 1995 Sep;61(9):373-9 (Eng. Abstr.) **(Ita)**

[Recent improvements in antiemetic therapy] Roila F, et al. **Tumori** 1997;83(2 Suppl):S3-14 (63 ref.) (Eng. Abstr.) **(Ita)**

[Clinical evaluation of ondansetron suppository] Kobayashi F, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):625-7 **(Jpn)**

[Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation] Park Y, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):573-7 (Eng. Abstr.) **(Jpn)**

[Use of Navoban in pediatric oncology] Safonova SA, et al. **Vopr Onkol** 1996;42(6):72-3 (Eng. Abstr.) **(Rus)**

[Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation] Jeremić B. **Srp Arh Celok Lek** 1996 May-Jun; 124(5-6):131-4 (Eng. Abstr.) **(Scc)**

[Efficacy of ondansetron in the prevention of nausea and vomiting after laparoscopic cholecystectomy] Cabrera JC, et al. **Rev Esp Anestesiol Reanim** 1997 Jan;44(1):36-8 (Eng. Abstr.) **(Spa)**

[Use of ondansetron for prevention of postoperative nausea and vomiting in major ambulatory surgery (letter; comment)] García del Valle S, et al. **Rev Esp Anestesiol Reanim** 1996 Oct;43(8):300-1. Comment on: Rev Esp Anestesiol Reanim 1996 Apr;43(4):138-41. **(Spa)**

[Antiemetic prophylaxis after laparoscopic cholecystectomy: comparative study of dehydrobenzperidol, metoclopramide, ondansetron and placebo] Pertusa V, et al. **Rev Esp Anestesiol Reanim** 1996 Aug-Sep;43(7):239-42 (Eng. Abstr.) **(Spa)**

[Tropisetron for the prevention of nausea and vomiting during chemotherapy: multicenter clinical study] Gutiérrez J, et al. **Rev Med Chil** 1996 Aug;124(8):967-74 (Eng. Abstr.) **(Spa)**

TOXICITY

Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, sensamide and neu-sensamide. Pero RW, et al. **Pharmacol Toxicol** 1997 May;80(5):231-9

ANTIEPILEPTIC AGENTS see **ANTICONVULSANTS**

ANTIESTROGENS see **ESTROGEN ANTAGONISTS**

ANTIFIBRILLATORY AGENTS see **ANTI-ARRHYTHMIA AGENTS**

ANTIFIBRINOLYSINS see **ANTIFIBRINOLYTIC AGENTS**

ANTIFIBRINOLYTIC AGENTS

A reference material for harmonisation of D-dimer assays. Fibrinogen Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Nieuwenhuizen W. **Thromb Haemost** 1997 May;77(5):1031-3

ADMINISTRATION & DOSAGE

Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects [see comments] Sokoll LJ, et al. **Am J Clin Nutr** 1997 Mar; 65(3):779-84. Comment in: Am J Clin Nutr 1997 Mar;65(3):883-4.

Tranexamic acid in oncology. Seto AH, et al. **Ann Pharmacother** 1996 Jul-Aug;30(7-8):868-70 (11 ref.)

Comment: oral vitamin K1 to reverse warfarin activity [letter] Weathermon RA, et al. **Ann Pharmacother** 1996 Jul-Aug;30(7-8):886-7

Topical aminocaproic acid in the treatment of traumatic hyphema [see comments] Crouch ER Jr, et al. **Arch Ophthalmol** 1997 Sep;115(9):1106-12. Comment in: Arch Ophthalmol 1997 Sep;115(9):1189-90.

The treatment of traumatic hyphema with topical epsilon-aminocaproic acid [editorial; comment] Goldberg MF. **Arch Ophthalmol** 1997 Sep;115(9):1189-90. Comment on: Arch Ophthalmol 1997 Sep;115(9):1106-12.

The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations [letter] Landymore RW, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):798-800

Does intramuscular vitamin K1 act as an unintended depot preparation? Loughnan PM, et al. **J Paediatr Child Health** 1996 Jun;32(3):251-4 (46 ref.)

ADVERSE EFFECTS

Rhabdomyolysis induced by epsilon-aminocaproic acid. Seymour BD, et al. **Ann Pharmacother** 1997 Jan;31(1):56-8

[Central retinal artery occlusion related to ingestion of tranexamic acid] Dighiero P, et al. **J Fr Ophtalmol** 1996; 19(12):785-6 (Eng. Abstr.) **(Fre)**

ANALYSIS

Erroneous D-dimer result on a paediatric citrated specimen [letter] Carroll PA, et al. **Blood Coagul Fibrinolysis** 1996 Jun;7(4):502

Comparison of immunofiltration assay of plasma D-dimer with diagnostic imaging in deep vein thrombosis. Killick SB, et al. **Br J Haematol** 1997 Mar;96(4):846-9

Comparison of four rapid D-Dimer tests for diagnosis of pulmonary embolism. Veitl M, et al. **Thromb Res** 1996 Jun 1;82(5):399-407

[A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer] Oikawa T, et al. **Nippon Jinzo Gakkai Shi** 1997 Mar;39(2):144-9 (Eng. Abstr.) **(Jpn)**

[Clinical usefulness of the measurements of plasmin-alpha 2-plasmin inhibitor complex and plasma tissue factor activity in patients with disseminated intravascular coagulation] Fukuda C, et al. **Rinsho Byori** 1996 Aug; 44(8):750-6 (12 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects [see comments] Sokoll LJ, et al. **Am J Clin Nutr** 1997 Mar; 65(3):779-84. Comment in: Am J Clin Nutr 1997 Mar;65(3):883-4.

epsilon-Aminocaproic acid plasma levels during cardiopulmonary bypass. Bennett-Guerrero E, et al. **Anesth Analg** 1997 Aug;85(2):248-51

The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis. Ginsberg JS, et al. **Arch Intern Med** 1997 May 26;157(10):1077-81

D-dimer plasma levels during normal pregnancy measured by specific ELISA. Francalanci I, et al. **Int J Clin Lab Res** 1997;27(1):65-7

Deep venous thrombosis: prediction by D-dimer? Kozman H, et al. **South Med J** 1997 Sep;90(9):907-10

Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. CALC Group. Violi F, et al. **Thromb Haemost** 1996 Aug; 76(2):177-83

D-dimers are degraded by human neutrophil elastase. Bach-Gansmo ET, et al. **Thromb Res** 1996 Apr 15; 82(2):177-86

CHEMICAL SYNTHESIS

Synthesis and activity of N epsilon-aminocaproyl-L-norleucine derivatives. Midura-Nowaczek K, et al. **Acta Pol Pharm** 1996 May-Jun; 53(3):221-3

Antifibrinolytic activity of epsilon-aminocaproyl derivatives of amino acids. Midura-Nowaczek K, et al. **Pharmazie** 1996 Oct;51(10):775-7

[Synthesis and properties of antifibrinolytic dipeptides containing E-aminocaproic acid] Midura-Nowaczek K, et al. **Acta Pol Pharm** 1992;49(1-2):89-92 (Eng. Abstr.) **(Pol)**

HISTORY

[The heparin treatment of toxic epidermal necrolysis. A Mexican priority (letter; comment)] Domínguez Soto L, et al. **Gac Med Mex** 1997 May-Jun;133(3):282. Comment on: Gac Med Mex 1997 Jan-Feb;133(1):41. **(Spa)**

METABOLISM

Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Kapiotis S, et al. **Circulation** 1997 Jul 1;96(1):19-21

High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. Taguchi O, et al. **Clin Chim Acta** 1996 Jan 15;244(1):69-81

Expression of a plasmin/trypsin Kunitz inhibitor by pig trophoblast. Duffy JY, et al. **Mol Reprod Dev** 1997 Apr; 46(4):443-9

Heterozygote for plasmin inhibitor deficiency developing hemorrhagic tendency with advancing age. Ikematsu S, et al. **Thromb Res** 1996 Apr 15;82(2):129-16

PHARMACOKINETICS

Menaquinone-4 accumulation in various tissues after an oral administration of phylloquinone in Wistar rats. Yamamoto R, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Feb; 43(1):133-43

PHARMACOLOGY

Aprotinin but not tranexamic acid inhibits cytokine-induced inducible nitric oxide synthase expression. Hill GE, et al. **Anesth Analg** 1997 Jun;84(6):1198-202

Nitric oxide reverses aspirin antagonism of t-PA thrombolysis in a rabbit model of thromboembolic stroke. Bednar MM, et al. **Exp Neurol** 1997 Aug;146(2):513-7

On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. Sakharov DV, et al. **J Biol Chem** 1997 May 30;272(22):14477-82

trans-4-(Aminomethyl)cyclohexane carboxylic acid (T-AMCHA), an anti-fibrinolytic agent, accelerates barrier recovery and prevents the epidermal hyperplasia induced by epidermal injury in hairless mice and humans. Denda M, et al. **J Invest Dermatol** 1997 Jul;109(1):84-90

Antithrombotic effect of enalapril, an angiotensin-converting enzyme inhibitor, on venous thrombosis in rats. Pawlak R, et al. **Pol J Pharmacol** 1996 Jan-Feb;48(1):117-20

Influence of dipeptide derivatives of S-substituted cysteines on the time of fibrinolysis. Midura-Nowaczek K, et al. **Rocz Akad Med Bialymst** 1996;41(2):412-6

Modulation of venous endothelial activity and transcellular calcium transport by defibrotide: the adenosine hypothesis. Pasini FL, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:15-20 (43 ref.)

Effect of defibrotide on platelet function. Ulutin ON, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:21-4 (32 ref.)

The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Benoni G, et al. **Thromb Res** 1997 Feb 1;85(3):195-206

Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor. Holst J, et al. **Thromb Res** 1996 Feb 15;81(4):461-70

[From physiology to pharmacology: the points of impact of antithrombotic agents] Schved JF. **Rev Med Interne** 1997; 18 Suppl 2:87s-90s (8 ref.) **(Fre)**

[Hepatoprotective and immunomodulating effect of phylloquinone in toxic damage to the liver] Konoplia EN, et al. **Eksp Klin Farmakol** 1997 May-Jun;60(3):75-7 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Laser balloon angioplasty combined with local intracoronary heparin therapy: immediate and short-term follow-up results. Glazier JJ, et al. **Am Heart J** 1997 Aug;134(2 Pt 1):266-73

Antifibrinolytic drugs and perioperative hemostasis. Slaughter TF, et al. **Am J Hematol** 1997 Sep;56(1):32-6 (56 ref.)

Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Hiippala ST, et al. **Anesth Analg** 1997 Apr;84(4):839-44

Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. Kaspar M, et al. **Anesth Analg** 1997 Aug; 85(2):281-5

The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery. Reid RW, et al. **Anesth Analg** 1997 May; 84(5):990-6

Reduction in requirements for allogeneic blood products: pharmacologic methods. Janssens M, et al. **Ann Thorac Surg** 1996 Dec;62(6):1944-50 (61 ref.)

Colchicine reduces hepatic fibrosis in mice infected with Schistosoma japonicum. Jiang J, et al. **Chin Med J (Engl)** 1996 Oct;109(10):795-800

Aminocaproic acid used to control upper gastrointestinal bleeding in radiation gastritis. Grover N, et al. **Dig Dis Sci** 1997 May;42(5):982-4

Tranexamic acid reduces blood loss after knee arthroplasty [letter] Howes JP, et al. **J Bone Joint Surg Br** 1996 Nov; 78(6):995-6

Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy [see comments] Leipzig TJ, et al. **J Neurosurg** 1997 Feb; 86(2):220-5. Comment in: J Neurosurg 1997 Sep;87(3):486-7.

Antifibrinolytic therapy [letter; comment] Schisano G, et al. **J Neurosurg** 1997 Sep;87(3):486-7. Comment on: J Neurosurg 1997 Feb;86(2):220-5.

Fibrinolytic inhibitors for cancer-associated bleeding problems. Dean A, et al. **J Pain Symptom Manage** 1997 Jan;13(1):20-4

Surgical repair of congenital diaphragmatic hernia during extracorporeal membrane oxygenation: hemorrhagic complications and the effect of tranexamic acid. van der Staak FH, et al. **J Pediatr Surg** 1997 Apr;32(4):594-9

Additional postbypass administration of tranexamic acid reduces blood loss after cardiac operations. Katoh J, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):802-4

Use of epsilon-aminocaproic acid to reduce bleeding [letter; comment] Lemmer JH Jr. **J Thorac Cardiovasc Surg** 1997 Jun;113(6):1125-7. Comment on: J Thorac Cardiovasc Surg 1996 Oct;112(4):1098-107.

Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid [see comments] Vander Salm TJ, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):1098-107.

Comment in: J Thorac Cardiovasc Surg 1997 Jun;113(6):1125–7.
Long–term treatment of C1 inhibitor deficiency with epsilon–aminocaproic acid in two patients. Van Dellen RG. **Mayo Clin Proc** 1996 Dec;71(12):1175–8
Influence of early fibrinolysis inhibition on thrombus formation following microvascular trauma. Zhang B, et al. **Microsurgery** 1996;17(5):278–85
Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. Teboul BK, et al. **Ophthalmology** 1995 Nov;102(11):1646–53
Amoxicillin–related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses. Bandrowsky T, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Dec;82(6):610–2
Hemophilia and EACA [letter] Radivoyevitch MA. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Aug;82(2):118
Major hemoptysis in a child with cystic fibrosis from multiple aberrant bronchial arteries treated with tranexamic acid. Chang AB, et al. **Pediatr Pulmonol** 1996 Dec;22(6):416–20
Treatment of recurrent hemoptysis in a child with cystic fibrosis by repeated bronchial artery embolizations and long–term tranexamic acid. Wong LT, et al. **Pediatr Pulmonol** 1996 Oct;22(4):275–9
The effect of low–dose epsilon–aminocaproic acid on patients following coronary artery bypass surgery. Montesano RM, et al. **Perfusion** 1996 Jan;11(1):53–6
Coagulation disturbance in profound hypothermia: the influence of anti–fibrinolytic therapy. Westaby S. **Semin Thorac Cardiovasc Surg** 1997 Jul;9(3):246–56 (62 ref.)
Clinical trials with defibrotide in vascular disorders. Cimminiello C. **Semin Thromb Hemost** 1996;22 Suppl 1:29–34 (42 ref.)
Defibrotide as a possible anti–ischemic drug. Coccheri S, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:9–14 (42 ref.)

ANTIFLATULENTS see **ANTIFOAMING AGENTS**

ANTIFOAMING AGENTS

ADMINISTRATION & DOSAGE

Cardiac depression after experimental air embolism in pigs: role of addition of a surface–active agent. van Blankenstein JH, et al. **Cardiovasc Res** 1997 Jun;34(3):473–82

PHARMACOLOGY

Unique susceptibility of Helicobacter pylori to simethicone emulsifiers in alimentary therapeutic agents. Kane AV, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):500–2

ANTIFOLATES see **FOLIC ACID ANTAGONISTS**

ANTIFUNGAL AGENTS

see related
FUNGICIDES, INDUSTRIAL

Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Burkhart GA, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):93–6
Recent developments in antifungal therapy [published erratum appears in Dermatol Clin 1996 Oct;14(4):xii] Lesher JL Jr. **Dermatol Clin** 1996 Jan;14(1):163–69 (63 ref.)
Clinical Dermatology 2000. Satellite symposia: topical lamisil, oral lamisil. Vancouver, Canada, May 28, 1996. **Dermatology** 1997;194 Suppl 1:1–50
Candidacidal activity of human salivary histatin recombinant variants produced by site–directed mutagenesis. Driscoll J, et al. **Gene** 1996 Oct 24;177(1–2):29–34
Investigators seeking new ways to stem rising tide of resistant fungi [news] Stephenson J. **JAMA** 1997 Jan 1;277(1):5–6
Do variations in molecular structure affect the clinical efficacy and safety of lipid–based amphotericin B preparations? Mehta J. **Leuk Res** 1997 Mar;21(3):183–8 (33 ref.)
International summit on cutaneous antifungal therapy, focus on tinea capitis, Boston, Massachusetts, November 11–13, 1994. Elewski BE, et al. **Pediatr Dermatol** 1996 Jan–Feb;13(1):69–77 (35 ref.)
Fruit–specific expression of a defensin–type gene family in bell pepper. Upregulation during ripening and upon wounding. Meyer B, et al. **Plant Physiol** 1996 Oct;112(2):615–22
[Amphotericin B deoxycholate (Fungizone): old drug, new versions] Chavanet P. **Rev Med Interne** 1997;18(2):153–65 (145 ref.) (Eng. Abstr.) **(Fre)**
[Amphotericin B—lipid complex] **Enferm Infecc Microbiol Clin** 1997 Jan;15(1):53 **(Spa)**

ADMINISTRATION & DOSAGE

Long–term results of patients with onychomycosis treated with itraconazole. Heikkilä H, et al. **Acta Derm Venereol** 1997 Jan;77(1):70–1
Oral terbinafine in toenail dermatophytosis. A double–blind, placebo–controlled multicenter study with 12 months' follow–up. Svejgaard EL, et al. **Acta Derm Venereol** 1997 Jan;77(1):66–9
Antifungal prophylaxis for secondary fungal peritonitis in peritoneal dialysis patients. Wadhwa NK, et al. **Adv Perit Dial** 1996;12:189–91
Relationship between fluconazole dosage regimens and the emergence of fluconazole–resistant Candida albicans. Goetz MB. **AIDS** 1996 Mar;10(3):335–6
Topical antifungal agents: an update. Diehl KB. **Am Fam Physician** 1996 Oct;54(5):1687–92
Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets [letter] Martins MD, et al. **Ann Intern Med** 1997 Feb 15;126(4):332–3
Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis. Karyotakis NC, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2907–8
New horizons in the treatment of psoriasis and cutaneous fungal infections. Cowen P. **Aust Fam Physician** 1996 Mar;25(3):317–22 (7 ref.)
A review of antifungal agents. Speed B. **Aust Fam Physician** 1996 May;25(5):717–9, 721 (0 ref.)
Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Mehta J, et al. **Bone Marrow Transplant** 1997 Jul;20(1):39–43
Effect of fluconazole dose on the extent of fluconazole–triazolam interaction. Varhe A, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):465–70
Trichophyton mentagrophytes kerion in a woman [letter] Aste N, et al. **Br J Dermatol** 1996 Dec;135(6):1010–1
A double–blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe–nail onychomycosis. Havu V, et al. **Br J Dermatol** 1997 Feb;136(2):230–4
Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double–blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. Tausch I, et al. **Br J Dermatol** 1997 May;136(5):737–42
Relapsing Aspergillus bronchitis in a double lung transplant patient, successfully treated with a new oral antimycotic agent [letter] Harari S, et al. **Chest** 1997 Mar;111(3):835–6
Elicitation thresholds for thiuram mix using petrolatum and ethanol/sweat as vehicles. Knudsen BB, et al. **Contact Dermatitis** 1996 Jun;34(6):410–3
Pityriasis versicolor: clinical experience with Lamisil cream and Lamisil DermGel. Faergemann J, et al. **Dermatology** 1997;194 Suppl 1:19–21
The use of oral terbinafine (Lamisil) in children. Krafchik B, et al. **Dermatology** 1997;194 Suppl 1:43–4
Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails. Roberts DT. **Dermatology** 1997;194 Suppl 1:37–9 (13 ref.)
The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo–controlled study. Vermeer BJ, et al. **Dermatology** 1997;194 Suppl 1:22–4
Inhalatory pentamidine therapy and the duration of the QT interval in HIV–infected patients. Cardoso JS, et al. **Int J Cardiol** 1997 May 23;59(3):285–9
Itraconazole in onychomycosis: intermittent dose schedule. Bonifaz A, et al. **Int J Dermatol** 1997 Jan;36(1):70–2
Comparison of single dose 400 mg versus 10–day 200 mg daily dose ketoconazole in the treatment of tinea versicolor. Fernandez–Nava HD, et al. **Int J Dermatol** 1997 Jan;36(1):64–6
Treatment of onychomycosis: a randomized, double–blind comparison study with topical bifonazole–urea ointment alone and in combination with short–duration oral griseofulvin. Friedman–Birnbaum R, et al. **Int J Dermatol** 1997 Jan;36(1):67–9
Single–dose systemic oral fluconazole for the treatment of vaginal candidiasis. Kaplan B, et al. **Int J Gynaecol Obstet** 1997 Jun;57(3):281–6
Empyema following the percutaneous instillation of antifungal agents in patients with aspergillosis. Nakanishi Y, et al. **Intern Med** 1996 Aug;35(8):657–9
Successful treatment of fungus ball in a patient with allergic bronchopulmonary aspergillosis: continuous percutaneous instillation of antifungal agents into the cavity. Tsushima K, et al. **Intern Med** 1996 Sep;35(9):736–41
Desensitization to itraconazole [letter; comment] Douglas R, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):269. Comment on: J Allergy Clin Immunol 1994 Aug;94(2 Pt 1):270–1.
A randomized trial to assess once–daily topical treatment of tinea corporis with butenafine, a new antifungal agent. Greer DL, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 1):231–5
Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. Gupta AK, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 1):789–92
A multicenter, placebo–controlled, double–blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. Odom RB, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):231–5
One–week therapy with twice–daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double–blind trial. Savin R, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):S15–9
Treatment of interdigital tinea pedis with a 4–week once–daily regimen of butenafine hydrochloride 1% cream. Tschen E, et al **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):S9–14
Treatment of onychomycosis and tinea pedis with intermittent itraconazole therapy. Del Rosso JQ. **J Am Osteopath Assoc** 1996 Oct;96(10):607–9 (19 ref.)
The use of commercially available lipid emulsions for the preparation of amphotericin B–lipid admixtures. Shadkhan Y, et al. **J Antimicrob Chemother** 1997 May;39(5):655–8
Intermittent therapy with terbinafine for dermatophyte toe–onychomycosis: a new approach. Alpsoy E, et al. **J Dermatol** 1996 Apr;23(4):259–62
Successful treatment of primary cutaneous Aspergillus flavus infection of the hand with oral itraconazole. Epstein MD, et al. **J Hand Surg [Br]** 1996 Nov;21(6):1106–8
A randomized, double–blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. Wilcox CM, et al. **J Infect Dis** 1997 Jul;176(1):227–32
Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and flucytosine in the treatment of cryptococcal meningitis in AIDS. Chotmongkol V, et al. **J Med Assoc Thai** 1997 Jul;80(7):416–25
Systemic antifungal drugs. **Med Lett Drugs Ther** 1997 Sep 12;39(1009):86–8
Topical butenafine for tinea pedis. **Med Lett Drugs Ther** 1997 Jul 4;39(1004):63–4
Treatment of presumed fungal endophthalmitis with oral fluconazole. Zarbin MA, et al. **Ophthalmic Surg Lasers** 1996 Jul;27(7):628–31
Topical antimycotics in ophthalmology. Behrens–Baumann W. **Ophthalmologica** 1997;211 Suppl 1:33–8 (79 ref.)
Tinea capitis. Smith ML. **Pediatr Ann** 1996 Feb;25(2):101–5 (20 ref.)
Lack of efficacy of 6–week treatment with oral terbinafine for tinea capitis due to Microsporum canis in children. Dragos V, et al. **Pediatr Dermatol** 1997 Jan–Feb;14(1):46–8
Aspergillus osteomyelitis in chronic granulomatous disease: treatment with recombinant gamma–interferon and itraconazole. Pasic S, et al. **Pediatr Infect Dis J** 1996 Sep;15(9):833–4
Nebulisers for patients with HIV infection and AIDS. Miller RF, et al. **Thorax** 1997 Apr;52 Suppl 2:S60–3
Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). Kramer MR, et al. **Transplant Proc** 1997 Sep;29(6):2657–9
Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients. Merhav H, et al. **Transplant Proc** 1997 Sep;29(6):2670–4
Amphotericin B: new life for an old drug. Hartsel S, et al. **Trends Pharmacol Sci** 1996 Dec;17(12):445–9 (51 ref.)
Computed tomographic assessment of noninvasive intranasal infusions in dogs with fungal rhinitis. Mathews KG, et al. **Vet Surg** 1996 Jul–Aug;25(4):309–19
[The treatment of vaginal candidiasis during pregnancy with a single dose of clotrimazole] Dukovski A. **Akush Ginekol (Sofiia)** 1996;35(4):46–8 (Eng. Abstr.) **(Bul)**
[Dermatomycoses. 18: Topical therapy of onychomycoses, vaginal and oral mycoses] Meinhof W. **Fortschr Med** 1996 Jan 30;114(3):21–3 **(Ger)**
[Dermatomycoses. 19: Systemic therapy of skin and mucous membrane mycoses] Meinhof W. **Fortschr Med** 1996 Feb 10;114(4):31–3 **(Ger)**
[Preventive antimycotic therapy of neutropenic and immunosuppressed patients] Ruhnke M, et al. **Med Klin** 1997 Jan 15;92(1):28–36 (76 ref.) (Eng. Abstr.) **(Ger)**
[The topical treatment of atrophic–erosive oral lichen planus with fluocinonide in a bioadhesive gel, chlorhexidine and miconazole gel. A totally open trial] Carbone M, et al. **Minerva Stomatol** 1996 Mar;45(3):61–8 (Eng. Abstr.) **(Ita)**
[Clinical study on a concomitant therapy with fluconazole and human recombinant granulocyte colony stimulating factor in the treatment of systemic fungal infections with hematological disorders] Kitamura K, et al. **Jpn J Antibiot** 1996 Dec;49(12):1062–72 (Eng. Abstr.) **(Jpn)**
[Conversion of chronic necrotizing pulmonary aspergillosis to invasive pulmonary aspergillosis, and successful treatment with fluconazole] Hirano K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Apr;35(4):408–13 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Treatment of scalp ringworm with oral terbinafine in childhood] Querol Nasarre I, et al. **An Esp Pediatr** 1997 May;46(5):487–9 **(Spa)**
[Amphotericin B. Lipid complex versus liposomes. Which, why, when? (editorial)] Pahissa A. **Enferm Infecc Microbiol Clin** 1997 Jan;15(1):1–3 **(Spa)**

ADVERSE EFFECTS

Co–trimoxazole desensitization syndrome: delayed hematologic toxicity complicating prophylactic therapy in AIDS patients [letter] Stricker RB, et al. **AIDS** 1996 Jul;10(8):927–9
Vein irritation from i.v. pentamidine [letter; comment] Herrero Ambrosio A, et al. **Am J Health Syst Pharm** 1996 Dec 1;53(23):2881–2. Comment on: Am J Health Syst Pharm 1996 Jan 15;53(2):185.
Uveitis associated with rifabutin prophylaxis and itraconazole therapy [letter] Lefort A, et al. **Ann Intern Med** 1996 Dec 1;125(11):939–40
Acute generalized exanthematous pustulosis induced by terbinafine [letter] Dupin N, et al. **Arch Dermatol** 1996 Oct;

132(10):1253–4
Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals [letter] Horn M. **Arch Dermatol** 1996 Oct;132(10):1254
Rhabdomyolysis after lung transplantation [letter] Malouf MA, et al. **Aust N Z J Med** 1997 Apr;27(2):186
Suspected drug eruption in seven dogs during administration of flucytosine. Malik R, et al. **Aust Vet J** 1996 Oct; 74(4):285–8
Potentiation of warfarin anticoagulant activity by miconazole oral gel. Ariyaratnam S, et al. **BMJ** 1997 Feb 1; 314(7077):349
Treating oral candidiasis: potentially fatal [letter] Evans J, et al. **Br Dent J** 1997 Jun 28;182(12):452
Treating oral candidiasis: potentially fatal [letter] Pemberton M, et al. **Br Dent J** 1997 Aug 9;183(3):87
Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. O'Sullivan DP, et al. **Br J Clin Pharmacol** 1996 Nov;42(5):559–65
Taste loss to terbinafine: a case–control study of potential risk factors. Stricker BH, et al. **Br J Clin Pharmacol** 1996 Sep;42(3):313–8
Cholestatic jaundice due to terbinafine [letter] Dwyer CM, et al. **Br J Dermatol** 1997 Jun;136(6):976–7
Congenital anomalies and fluconazole [news] Wray CM. **Can Med Assoc J** 1997 Jan 1;156(1):91, 95–6 **(Eng, Fre)**
A man with AIDS experiences near–syncope. **Chest** 1997 Feb;111(2):501–2
Rhinocerebral mucormycosis in a patient with AIDS: a complication of diabetic ketoacidosis following pentamidine therapy. Abril V, et al. **Clin Infect Dis** 1996 Oct;23(4):845–6
Cardiac arrhythmias associated with coadministration of azole compounds and cisapride [letter; comment] Chan–Tompkins NH, et al. **Clin Infect Dis** 1997 Jun; 24(6):1285. Comment on: Clin Infect Dis 1996 Aug;23(2):305–13.
A 5–year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus–infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. O'Brien JG, et al. **Clin Infect Dis** 1997 May;24(5):854–9
Fluconazole–induced congenital anomalies in three infants. Pursley TJ, et al. **Clin Infect Dis** 1996 Feb;22(2):336–40
Contact dermatitis due to octyldodecanol in clotrimazole cream. Dharmagunawardena B, et al. **Contact Dermatitis** 1997 Apr;36(4):231
Allergic contact dermatitis from tioconazole. Faria A, et al. **Contact Dermatitis** 1996 Oct;35(4):250–2
Systemic contact dermatitis from miconazole. Fernandez L, et al. **Contact Dermatitis** 1996 Mar;34(3):217
Contact dermatitis from neticonazole. Kawada A, et al. **Contact Dermatitis** 1997 Feb;36(2):106–7
Allergic contact dermatitis from lanoconazole. Nakano R, et al. **Contact Dermatitis** 1996 Jul;35(1):63
Allergic contact dermatitis due to diethyl sebacate. Sasaki E, et al. **Contact Dermatitis** 1997 Mar;36(3):172
Allergic contact dermatitis from croconazole without cross–sensitivity to clotrimazole and bifonazole. Steinmann A, et al. **Contact Dermatitis** 1996 Oct;35(4):255–6
What risk of piroxicam photodermatitis in thimerosal–positive patients? Stingeni L, et al. **Contact Dermatitis** 1996 Jan;34(1):60–1
Contact dermatitis from lanoconazole. Tanaka N, et al. **Contact Dermatitis** 1996 Oct;35(4):256–7
Facial contact dermatitis due to metronidazole. Vincenzi C, et al. **Contact Dermatitis** 1997 Feb;36(2):116–7
Oral antifungal drug interactions. Katz HI, et al. **Dermatol Clin** 1997 Jul;15(3):535–44 (92 ref.)
Terbinafine–induced prolonged cholestasis with reduction of interlobular bile ducts. Mallat A, et al. **Dig Dis Sci** 1997 Jul;42(7):1486–8
Acute cerebellopathy as a probable toxic effect of flucytosine. Cubo Delgado E, et al. **Eur J Clin Pharmacol** 1997; 51(6):505–6
Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents. Reddy KR, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):923–36 (99 ref.)
Ketoconazole–induced hepatotoxicity [letter] Bernuau J, et al. **Hepatology** 1997 Sep;26(3):802
Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Chien RN, et al. **Hepatology** 1997 Jan;25(1):103–7
Nausea and malaise during treatment of coccidioidomycosis. Lopez F, et al. **Hosp Pract (Off Ed)** 1997 May 15;32(5):21–2
Empyema following the percutaneous instillation of antifungal agents in patients with aspergillosis. Nakanishi Y, et al. **Intern Med** 1996 Aug;35(8):657–9
Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug–induced psoriasis. Gupta AK, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 2):858–62 (97 ref.)
Hypersensitivity reaction to terbinafine. Gupta AK, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):1018–9
Acute generalized exanthematous pustulosis induced by itraconazole. Park YM, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 1):794–6
Upper–airway obstruction and prolonged recovery from anesthesia following intranasal clotrimazole administration. Caulkett N, et al. **J Am Anim Hosp Assoc** 1997 May–Jun; 33(3):264–7
Primary cutaneous coccidioidomycosis and subsequent drug eruption to itraconazole in a dog. Plotnick AN, et al. **J Am Anim Hosp Assoc** 1997 Mar–Apr;33(2):139–43
Coprescription of terfenadine and erythromycin or ketaconazole: an assessment of potential harm. Carlson AM, et al. **J Am Pharm Assoc (Wash)** 1996 Apr;NS36(4):263–9
Combined use of astemizole and ketoconazole resulting in torsade de pointes. Tsai WC, et al. **J Formos Med Assoc** 1997 Feb;96(2):144–6
The association of itraconazole and methylprednisolone may give rise to important steroid–related side effects [letter] Linthoudt H, et al. **J Heart Lung Transplant** 1996 Nov; 15(11):1165
Terbinafine–induced cholestatic liver disease. Lazaros GA, et al. **J Hepatol** 1996 Jun;24(6):753–6
Reactive airways dysfunction syndrome in a nurse exposed to pentamidine [letter; comment] Stanbury M, et al. **J Occup Environ Med** 1996 Apr;38(4):330–1. Comment on: J Occup Environ Med 1995 Feb;37(2):145–50.
Diabetes mellitus associated with pentamidine use in HIV–infected patients [letter] Coyle P, et al. **Med J Aust** 1996 Nov 18;165(10):587–8
Microsporum canis infections in children: results of a new oral antifungal therapy. Ginter G. **Mycoses** 1996 Jul–Aug; 39(7–8):265–9
Interaction between miconazole oral gel (Daktarin) and warfarin [letter] Pillans P, et al. **N Z Med J** 1996 Sep 13; 109(1029):346
Erroneous substitution of terbinafine for lamotrigine. Vossler DG. **Neurology** 1997 Sep;49(3):893
Teratogenicity of fluconazole [letter; comment] Krcmery V Jr, et al. **Pediatr Infect Dis J** 1996 Sep;15(9):841. Comment on: Pediatr Infect Dis J 1992 Dec;11(12):1062–4.
Miconazole–induced fatal dysrhythmia. Coley KC, et al. **Pharmacotherapy** 1997 Mar–Apr;17(2):379–82
Itraconazole–related amaurosis and vomiting due to digoxin toxicity [letter] Cone LA, et al. **West J Med** 1996 Nov; 165(5):322
[Syncopes during simultaneous use of terfenadine and itraconazole] Romkes JH, et al. **Ned Tijdschr Geneeskd** 1997 May 10;141(19):950–3 (Eng. Abstr.) **(Dut)**
[Agranulocytosis during a treatment with terbinafine (letter)] Barete S, et al. **Rev Med Interne** 1997;18(3):258–9 **(Fre)**
[Anaphylactic reaction to ketoconazole (letter)] Beal M, et al. **Therapie** 1996 Sep–Oct;51(5):604–5 **(Fre)**
[Allergic contact dermatitis due to topical imidazole antimycotics. The sensitizing ability of active ingredients and cross–sensitivity] Yoneyama E. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):356–64 (Eng. Abstr.) **(Jpn)**

ANALYSIS

A double–blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair and nails during and after oral medication [letter] Faergemann J, et al. **Acta Derm Venereol** 1997 Jan;77(1):74–6
Determination of antifungals in rodent diet by supercritical fluid extraction followed by packed column supercritical fluid chromatography with ultraviolet detection. Dean JR, et al. **J AOAC Int** 1997 Jan–Feb;80(1):7–13
Potential interference by free fatty acids in determination of tricyclazole in brown rice by gas chromatography with flame thermionic detection. Tsumura Y, et al. **J AOAC Int** 1996 Nov–Dec;79(6):1471–6
High performance liquid chromatographic determination of phenoxetol, methyl paraben, ethyl paraben, n–propyl paraben, iso–butyl paraben, n–butyl paraben and croconazole.HCl. Akhtar MJ, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1609–13
A comparison between solid phase extraction and supercritical fluid extraction for the determination of fluconazole from animal feed. Khundker S, et al. **J Pharm Biomed Anal** 1995 Nov;13(12):1441–7
[Determination of bifonazole using HPLC in pharmacokinetic studies] Kadenatsi IB, et al. **Antibiot Khimioter** 1996 May;41(5):19–24 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Specificity in structure–based drug design: identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase. Gschwend DA, et al. **Proteins** 1997 Sep;29(1):59–67
[The resistance of opportunistic fungi to antifungals] Rodriguez Tudela JL. **Rev Clin Esp** 1997 Apr;197 Suppl 1:67–74 (63 ref.) **(Spa)**

BLOOD

Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Bhamra R, et al. **Antimicrob Agents Chemother** 1997 May;41(5):886–92
Microbiostatic activity of human plasma and its relation to zinc and iron availability. Clohessy PA, et al. **Biochem Soc Trans** 1996 May;24(2):311S
Rapid high performance liquid chromatographic assay for antifungal agents in human sera. Ng TK, et al. **J Antimicrob Chemother** 1996 Mar;37(3):465–72
Determination of fluconazole in human plasma by micellar electrokinetic capillary chromatography with detection at 190 nm. von Heeren F, et al. **J Chromatogr A** 1996 Sep 20;745(1–2):165–72
High–performance liquid chromatographic determination of fluconazole in plasma. Cociglio M, et al. **J Chromatogr B Biomed Appl** 1996 Nov 8;686(1):11–7
Rapid method for the analysis of itraconazole and hydroxyitraconazole in serum by high–performance liquid chromatography. Compas D, et al. **J Chromatogr B Biomed Appl** 1996 Dec 13;687(2):453–6
High–performance liquid chromatographic analysis for the determination of miconazole in human plasma using solid–phase extraction. Kobylińska M, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):191–5
Determination of a new antifungal agent, voriconazole, by multidimensional high–performance liquid chromatography with direct plasma injection onto a size–exclusion column. Stopher DA, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):441–8
Functional and clinical aspects of the myelomonocyte protein calprotectin. Johne B, et al. **Mol Pathol** 1997 Jun; 50(3):113–23 (142 ref.)
Valproic acid–ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: lack of interaction in uremic serum caused by the presence of inhibitor. Dasgupta A, et al. **Ther Drug Monit** 1997 Jun;19(3):281–5
A rapid and specific liquid chromatographic assay for the determination of itraconazole and hydroxyitraconazole in plasma [letter] Poirier JM, et al. **Ther Drug Monit** 1997 Apr;19(2):247–8

CHEMICAL SYNTHESIS

Synthesis of new (4–alkylamino–4'–fluoro)–diphenyl sulphones with potential biological activity. de Sousa Júnior PT, et al. **An Acad Bras Cienc** 1996;68(2):161–4
Research on antifungal and antimycobacterial agents. Synthesis and activity of 4–alkylthiopyridine–2–carbothioamides. Klimešová V, et al. **Arch Pharm (Weinheim)** 1996 Oct;329(10):438–42
Synthesis and antifungal activities of myristic acid analogs. Parang K, et al. **Arch Pharm (Weinheim)** 1996 Nov; 329(11):475–82
Synthesis and antimicrobial activities of 2–[(alpha–methylbenzylidene)–hydrazino]benzoxazoles. Ersan S, et al. **Arzneimittelforschung** 1997 Aug;47(8):963–5
Optically active antifungal azoles. VI. Synthesis and antifungal activity of N–[(1R,2R)–2–(2,4–difluorophenyl)–2–hydroxy–1–methyl–3–(1H–1,2,4–triazo l–1– yl)propyl]–N'–(4–substituted phenyl)–3(2H,4H)–1,2,4–triazolones and 5(1H,4H)–tetrazolones. Kitazaki T, et al. **Chem Pharm Bull (Tokyo)** 1996 Feb;44(2):314–27
Syntheses and antifungal activity of dl–griseofulvin and its congeners. II. Takeuchi Y, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb;45(2):327–32
Optically active antifungal azoles. VII. Synthesis and antifungal activity of stereoisomers of 2–[(1R,2R)–2–(2,4–difluorophenyl)–2–hydroxy–1–methyl–3–(1H–1,2,4–triazol–1–yl) propyl]–4–[4–(2,2,3,3–tetrafluoropropoxy)phenyl]–3 (2H,4H)–1,2,4–triazo lone (TAK–187). Tasaka A, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb;45(2):321–6
Synthesis and antifungal activity of novel thiazole–containing triazole antifungals. Tsuruoka A, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1169–76
A synthetic form of tracheal antimicrobial peptide has both bactericidal and antifungal activities. Lawyer C, et al. **Drug Des Discov** 1996 Dec;14(3):171–8
Pyridazine N–oxides. II. Synthesis and in vitro antimicrobial evaluation of 3–chloro–4–carbamoyl–5–aryl–6–methyl–pyridazine N–oxides. Gavini E, et al. **Farmaco** 1997 Jan;52(1):67–9
Synthesis, characterisation and antifungal activity of some N–bridged heterocycles derived from 3–(3–bromo–4–methoxyphenyl)–4–amino–5–mercapto–1,2,4–triazole. Holla BS, et al. **Farmaco** 1996 Dec; 51(12):793–9
Fungicidal activity of some o–nitrophenyl–hydrazones. Palomba M, et al. **Farmaco** 1996 Jan;51(1):79–84
Triorganosilicon (IV) compounds: synthesis, structural study, and biological activity. Singh D, et al. **J Inorg Biochem** 1996 Apr;62(1):67–73
Design and synthesis of novel imidazole–substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N–myristoyltransferase and identification of related tripeptide inhibitors with mechanism–based antifungal activity. Devadas B, et al. **J Med Chem** 1997 Aug 1;40(16):2609–25
Synthesis and antifungal activity of some imidazo, pyrazino and v–triazoloquinoxalines. Abd el–Samii ZK, et al. **Pharmazie** 1997 Aug;52(8):581–5
Synthesis and biological investigations of some novel thiazolylbenzimidazoles, and benzimidazolyl–thiazolo[4,5–d]pyrimidines. Habib NS, et al. **Pharmazie** 1997 May;52(5):346–50
Synthesis and reactions of some new 4H–pyrano[3,2–c]benzopyran–5–one derivatives and their potential biological activities. Shaker RM. **Pharmazie** 1996 Mar;51(3):148–51

CHEMISTRY

Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Allen LV Jr, et al. **Am J Health Syst Pharm** 1996 Sep 1;53(17):2073–8

Determination of the disulfide array of the first inducible antifungal peptide from insects: drosomycin from Drosophila melanogaster. Michaut L, et al. **FEBS Lett** 1996 Oct 14;395(1):6–10

Chemical and biological characterization of two FK506 analogs produced by targeted gene disruption in Streptomyces sp. MA6548. Shafiee A, et al. **J Antibiot (Tokyo)** 1997 May;50(5):418–23

Mutational analysis of a plant defensin from radish (Raphanus sativus L.) reveals two adjacent sites important for antifungal activity. De Samblanx GW, et al. **J Biol Chem** 1997 Jan 10;272(2):1171–9

Molecular structure of terrecyclodiol: a derivative of the antifungal metabolite terrecyclic acid A from Aspergillus terreus. Almassi F, et al. **J Nat Prod** 1996 Jan;59(1):59–61

Spectral characterization of fluconazole. Cyr TD, et al. **J Pharm Biomed Anal** 1996 Jan;14(3):247–55

Structural and antifungal properties of a pathogenesis-related protein from wheat kernel. Caruso C, et al. **J Protein Chem** 1996 Jan;15(1):35–44

Stability of nystatin in mouthrinses; effect of pH temperature, concentration and colloidal silver addition, studied using an in vitro antifungal activity. Vermerie N, et al. **Pharm World Sci** 1997 Aug;19(4):197–201

Purification and characterization of tobacco pathogenesis-related protein PR-5d, an antifungal thaumatin-like protein. Koiwa H, et al. **Plant Cell Physiol** 1997 Jul;38(7):783–91

Characterization of a new antifungal chitin-binding peptide from sugar beet leaves. Nielsen KK, et al. **Plant Physiol** 1997 Jan;113(1):83–91

Crystal structure of the ternary complex of 1,3,8-trihydroxynaphthalene reductase from Magnaporthe grisea with NADPH and an active-site inhibitor. Andersson A, et al. **Structure** 1996 Oct 15;4(10):1161–70

Pulvinatal, a novel bioactive metabolite from the basidiomycete Nidularia pulvinata (Schw.) Fr. Becker U, et al. **Z Naturforsch [C]** 1997 May-Jun;52(5-6):313–8

[The photostability of antimycotics. 3. Photostability of locally acting antimycotics] Thoma K, et al. **Pharmazie** 1997 May;52(5):362–73 (Eng. Abstr.) **(Ger)**

ECONOMICS

Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Einarson TR. **Clin Ther** 1997 May-Jun; 19(3):559–69; discussion 538–9

Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Van Doorslaer EK, et al. **Dermatology** 1996;193(3):239–44

Economic aspects of treatment for fungal infections in cancer patients. Torfs K. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):98–107

Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysis. Wakerly L, et al. **J Hosp Infect** 1996 May; 33(1):35–48

[Costs of antifungal agents should be reduced (letter)] Berglund O. **Lakartidningen** 1997 Jan 22;94(4):214, 219 **(Swe)**

IMMUNOLOGY

Desensitization to itraconazole [letter; comment] Douglas R, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):269. Comment on: J Allergy Clin Immunol 1994 Aug;94(2 Pt 1):270–1.

ISOLATION & PURIFICATION

Search for molluscicidal and antifungal saponins from tropical plants. Hostettmann K, et al. **Adv Exp Med Biol** 1996;404:117–28 (18 ref.)

Antifungal and hemolytic activity of aerial parts of alfalfa (Medicago) species in relation to saponin composition. Jurzysta M, et al. **Adv Exp Med Biol** 1996;404:565–74

Extraction of mercaptobenzothiazole compounds from rubber products. Hansson C, et al. **Contact Dermatitis** 1997 Apr;36(4):195–200

Antimicrobial activities of Streptomyces pulcher, S. canescens and S. citreofluorescens against fungal and bacterial pathogens of tomato in vitro. el-Abyad MS, et al. **Folia Microbiol (Praha)** 1996;41(4):321–8

Antifungal properties of yam (Dioscorea alata) peel extract. Aderiye BI, et al. **Folia Microbiol (Praha)** 1996;41(5):407–12

Maltophilin: a new antifungal compound produced by Stenotrophomonas maltophilia R3089. Jakobi M, et al. **J Antibiot (Tokyo)** 1996 Nov;49(11):1101–4

The effect of carbon source, temperature and aeration on the production of ascosteroside, a novel antifungal agent, by Ascotricha amphitricha. Lowe SE, et al. **J Antibiot (Tokyo)** 1997 May;50(5):412–7

Orbuticin, a new secondary metabolite from Acremonium butyri [letter] Roy K, et al. **J Antibiot (Tokyo)** 1996 Nov; 49(11):1186–7

Antifungal diterpenoid alkaloids from Delphinium denudatum. Atta-ur-Rahman, et al. **J Nat Prod** 1997 May; 60(5):472–4

Oxysporidinone: a novel, antifungal N-methyl-4-hydroxy-2-pyridone from Fusarium oxysporum. Breinhold J, et al. **J Nat Prod** 1997 Jan; 60(1):33–5

Phytogrowth-inhibitory and antifungal constituents of Helianthella quinquenervis. Castañeda P, et al. **J Nat Prod** 1996 Mar;59(3):323–6

Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives. Gopalakrishnan G, et al. **J Nat Prod** 1997 May;60(5):519–24

Bioactive amides from Glycosmis species. Greger H, et al. **J Nat Prod** 1996 Dec;59(12):1163–8

Phytogrowth-inhibitory compounds from Malmea depressa. Jimenez Arellanes A, et al. **J Nat Prod** 1996 Feb; 59(2):202–4

Halicylindramides D and E, antifungal peptides from the marine sponge Halichondria cylindrata. Li H, et al. **J Nat Prod** 1996 Feb;59(2):163–6

Stellettamide B, a new indolizidine alkaloid from a sponge of the genus Stelletta. Shin J, et al. **J Nat Prod** 1997 Jun; 60(6):611–3

New anti-HIV-1, antimalarial, and antifungal compounds from Terminalia bellerica. Valsaraj R, et al. **J Nat Prod** 1997 Jul;60(7):739–42

Anserinones A and B: new antifungal and antibacterial benzoquinones from the coprophilous fungus Podospora anserina. Wang H, et al. **J Nat Prod** 1997 Jun;60(6):629–31

Cercophorins A–C: novel antifungal and cytotoxic metabolites from the coprophilous fungus Cercophora areolata. Whyte AC, et al. **J Nat Prod** 1996 Aug; 59(8):765–9

Purification and characterization of an antifungal PR-5 protein from pumpkin leaves. Cheong NE, et al. **Mol Cells** 1997 Apr 30;7(2):214–9

Purification and antifungal activity of a basic 34 kDa beta-1,3-glucanase from soybean hypocotyls inoculated with Phytophthora sojae f. sp. glycines. Yi SY, et al. **Mol Cells** 1997 Jun 30;7(3):408–13

Antifungal activity of a new triterpenoid glycoside from Pithecellobium racemosum (M.). Khan IA, et al. **Pharm Res** 1997 Mar;14(3):358–61

Antibacterial and antifungal compounds from Kigelia pinnata [letter] Binutu OA, et al. **Planta Med** 1996 Aug;62(4):352–3

Antibacterial and antifungal compounds from Empetrum nigrum. Matsuura H, et al. **Planta Med** 1995 Dec;61(6):580

Xylaramide, a new antifungal compound, and other secondary metabolites from Xylaria longipes. Schneider G, et al. **Z Naturforsch [C]** 1996 Nov-Dec;51(11-12):802–6

METABOLISM

1-trityl-4-nitroimidazole. Skrzypczak-Jankun E, et al. **Acta Crystallogr C** 1996 Jan 15;52 (Pt 1):189–91

Formation of tomatine in tomato plants infected with Streptomyces species and treated with herbicides, correlated with reduction of Pseudomonas solanacearum and Fusarium oxysporum f. sp. lycopersici. El-Raheem A, et al. **Acta Microbiol Pol** 1995;44(3-4):255–66

Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Venkateswarlu K, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2443–6

Antifungal attributes of lactic acid bacteria—a review. Batish VK, et al. **Crit Rev Biotechnol** 1997;17(3):209–25 (61 ref.)

Metabolism of ketoconazole and deacetylated ketoconazole by rat hepatic microsomes and flavin-containing monooxygenases. Rodriguez RJ, et al. **Drug Metab Dispos** 1997 Jun;25(6):772–7

Reduced intracellular accumulation of azole antifungal results in resistance in Candida albicans isolate NCPF 3363. Lamb DC, et al. **FEMS Microbiol Lett** 1997 Feb 15;147(2):189–93

Production of antifungal substance by Lactococcus lactis subsp. lactis CHD-28.3. Roy U, et al. **Int J Food Microbiol** 1996 Sep;32(1-2):27–34

Bioassay methods for the detection of antifungal activity by Pseudomonas antimicrobica against the grey mould pathogen Botrytis cinerea. Walker R, et al. **J Appl Bacteriol** 1996 Nov;81(5):531–7

Antimicrobial peptides from Mirabilis jalapa and Amaranthus caudatus: expression, processing, localization and biological activity in transgenic tobacco. De Bolle MF, et al. **Plant Mol Biol** 1996 Aug;31(5):993–1008

A novel assay for drug-DNA binding mode, affinity, and exclusion number: scanning force microscopy. Coury JE, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12283–6

PHARMACOKINETICS

Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toe-nails with fluconazole 150 mg once weekly. Faergemann J, et al. **Acta Derm Venereol** 1996 May;76(3):219–21

Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. Boothe DM, et al. **Am J Vet Res** 1997 Aug;58(8):872–7

Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Bhamra R, et al. **Antimicrob Agents Chemother** 1997 May;41(5):886–92

Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Cañas E, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):230–3

Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Dixon R, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):556–60

Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Koks CH, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1935–7

Pharmacokinetics and metabolism of genaconazole, a potent antifungal drug, in men. Lin C, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):92–6

Systemic availability of itraconazole in lung transplantation. Patterson TF, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2217–20

Pharmacokinetics of oral fluconazole when used for prophylaxis in bone marrow transplant recipients. El-Yazigi A, et al. **Antimicrob Agents Chemother** 1997 May; 41(5):914–7

The effect of food on the pharmacokinetics of multiple-dose terbinafine in young and elderly healthy subjects. Nedelman J, et al. **Biopharm Drug Dispos** 1997 Mar; 18(2):127–38

Variability of plasma fluconazole levels in patients with hematologic malignancy. Ellis ME, et al. **Clin Infect Dis** 1997 Jan;24(1):86–7

Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Debruyne D. **Clin Pharmacokinet** 1997 Jul;33(1):52–77

Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Iatsimirskaia E, et al. **Clin Pharmacol Ther** 1997 May;61(5):554–62

Ocular penetration and pharmacokinetics of topical fluconazole. Yee RW, et al. **Cornea** 1997 Jan;16(1):64–71

Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Jaruratanasirikul S, et al. **Eur J Clin Pharmacol** 1997;52(3):235–7

Fluconazole concentrations in pulmonary tissue and pericardial fluid. Rieder-Nelissen CM, et al. **Infection** 1997 May-Jun;25(3):192–4

Intrapulmonary and systemic pharmacokinetics of aerosolized pentamidine used for prophylaxis of pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus. Conte JE Jr, et al. **J Clin Pharmacol** 1995 Dec;35(12):1166–73

Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. Lange D, et al. **J Clin Pharmacol** 1997 Jun;37(6):535–40

Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid. Vaden SL, et al. **J Vet Pharmacol Ther** 1997 Jun; 20(3):181–6

Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. Gamble KC, et al. **J Zoo Wildl Med** 1997 Mar;28(1):89–93

Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbiological and clinical aspects. Glasmacher A, et al. **Mycoses** 1996 Jul-Aug; 39(7-8):249–58 (117 ref.)

Plasma and tissue concentrations of fluconazole and their correlation to breakpoints. Pittrow L, et al. **Mycoses** 1997 Jan-Feb;40(1-2):25–32 (42 ref.)

A new pharmaceutical concept for the treatment of oropharyngeal and oesophageal candidosis with fluconazole. Wildfeuer A, et al. **Mycoses** 1996 Sep-Oct; 39(9-10):357–60

Fluconazole distribution to the brain: a crossover study in freely-moving rats using in vivo microdialysis. Yang H, et al. **Pharm Res** 1996 Oct;13(10):1570–5

Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. Yuan JH, et al. **Xenobiotica** 1997 May;27(5):489–97

[Plasma and tissue concentrations of fluconazole: discussion of the breakpoint problem] Pittrow L, et al. **Mycoses** 1996; 39 Suppl 2:58–65 (44 ref.) (Eng. Abstr.) **(Ger)**

[Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility of yeasts] Wildfeuer A, et al. **Mycoses** 1996;39 Suppl 2:51–7 (42 ref.) (Eng. Abstr.) **(Ger)**

[A new pharmaceutical concept for the therapy of oropharyngeal and esophageal candidiasis with fluconazole] Wildfeuer A, et al. **Mycoses** 1996;39 Suppl 1:123–6 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Ergosterol biosynthesis inhibition: a target for antifungal agents. Barrett-Bee K, et al. **Acta Biochim Pol** 1995; 42(4):465–79 (71 ref.)

Mechanisms of resistance to azole antifungals. Marichal P, et al. **Acta Biochim Pol** 1995;42(4):509–16 (57 ref.)

Fungal glycoproteins and their biosynthetic pathway as potential targets for antifungal agents. Tanner W, et al. **Acta Biochim Pol** 1995;42(4):505–8 (21 ref.)

The in vitro effect of fluconazole on the filamentous form of Pityrosporum ovale. Faergemann J, et al. **Acta Derm Venereol** 1996 Nov;76(6):444–6

Antifungal drugs and resistance. Graybill JR. **Adv Exp Med Biol** 1995;390:217–34 (98 ref.)

Fungitoxic activity of saponins: practical use and fundamental principles. Gruiz K. **Adv Exp Med Biol** 1996;404:527–34

Antifungal and hemolytic activity of aerial parts of alfalfa (Medicago) species in relation to saponin composition. Jurzysta M, et al. **Adv Exp Med Biol** 1996;404:565–74

Saponins as antimycotic agents: glycosides of medicagenic acid. Zehavi U, et al. **Adv Exp Med Biol** 1996;404:535–46 (37 ref.)

Cryptococcosis. Aberg JA, et al. **Adv Pharmacol** 1997;

37:215–51 (117 ref.)
DNA topoisomerase inhibitors as antifungal agents. Shen LL, et al. **Adv Pharmacol** 1994;29B:227–44 (45 ref.)
A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis. De Wit S, et al. **AIDS** 1997 May;11(6):759–63
Oral transmission of Candida albicans between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates. Dromer F, et al. **AIDS** 1997 Jul 15;11(9):1095–101
In vitro activity of Cinnamomum zeylanicum against azole resistant and sensitive Candida species and a pilot study of cinnamon for oral candidiasis. Quale JM, et al. **Am J Chin Med** 1996;24(2):103–9
In vitro susceptibility of clinical yeast isolates to fluconazole and terconazole. Cooper CR Jr, et al. **Am J Obstet Gynecol** 1996 Dec;175(6):1626–31
Inhibitors of cytochrome P-450 augment fever induced by interleukin-1 beta. Nakashima T, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1274–9
Inhibition of maxi-K currents in ferret portal vein smooth muscle cells by the antifungal clotrimazole. Rittenhouse AR, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C45–56
Inhibitory effects of seven organosulphur compounds on clinical isolates of Candida species in vitro. Shah DT, et al. **Ann Clin Lab Sci** 1997 Jul–Aug;27(4):282–6
Digoxin–itraconazole interaction: possible mechanisms. Alderman CP, et al. **Ann Pharmacother** 1997 Apr; 31(4):438–40
Comment: possible mechanism of digoxin–itraconazole interaction [letter] Ito S, et al. **Ann Pharmacother** 1997 Sep; 31(9):1091–2
Submicellar complexes may initiate the fungicidal effects of cationic amphiphilic compounds on Candida albicans. Ahlström B, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):544–50
Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Albertson GD, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2835–41
Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study. Anaissie EJ, et al. **Antimicrob Agents Chemother** 1996 Oct; 40(10):2387–91
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Barchiesi F, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1812–4
In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Barry AL, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1948–9
Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Belanger P, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1840–2
Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Calvet HM, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):535–9
In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans. Chin NX, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):850–2
Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Clark FS, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):419–25
A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents. Cushion MT, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):379–84
In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Del Poeta M, et al. **Antimicrob Agents Chemother** 1997 Aug; 41(8):1835–6
Fungicidal activity of cecropin A. DeLucca AJ, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):481–3
N-acetylcysteine inhibits germination of conidia and growth of Aspergillus spp. and Fusarium spp. De Lucca AJ, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1274–6
Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Favre B, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):443–7
New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents. Flattery AM, et al. **Antimicrob Agents Chemother** 1996 Jul; 40(7):1604–9
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Franzot SP, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):331–6
In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Franzot SP, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):822–4
In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Galgiani JN, et al. **Antimicrob Agents Chemother** 1997 Jan; 41(1):180–3
Antifungal agents: chemotherapeutic targets and immunologic strategies. Georgopapadakou NH, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):279–91 (300 ref.)
In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Hata K, et al. **Antimicrob Agents Chemother** 1996 Oct; 40(10):2237–42
Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. Kaltenbach G, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2043–6
Enhanced oxidative killing of azole-resistant Candida glabrata strains with ERG11 deletion. Kan VL, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1717–9
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Klepser ME, et al. **Antimicrob Agents Chemother** 1997 Jun; 41(6):1392–5
Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Lutz JE, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1558–61
In vitro evaluation of voriconazole against some clinically important fungi. McGinnis MR, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1832–4
In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates. Martinez-Suarez JV, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1277–9
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Moran GP, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):617–23
Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Murphy M, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):696–8
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Oakley KL, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1124–6
Susceptibilities of Candida spp. to antifungal agents visualized by two-dimensional scatterplots of relative growth. Odds FC, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):588–94
The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Odom A, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):156–61
Fungal virulence genes as targets for antifungal chemotherapy. Perfect JR. **Antimicrob Agents Chemother** 1996 Jul;40(7):1577–83 (85 ref.)
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Perfect JR, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1910–3
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Pfaller MA, et al. **Antimicrob Agents Chemother** 1997 Feb; 41(2):233–5
Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi. Pujol I, et al. **Antimicrob Agents Chemother** 1996 Sep; 40(9):2106–10
In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Radford SA, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):841–3
Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes [published erratum appears in Antimicrob Agents Chemother 1997 Feb;41(2):496] Rangel H, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2785–91
Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans. Rodriguez-Tudela JL, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):1998–2003
In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Ruhnke M, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):575–7
Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Sanati H, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1345–8
Candida norvegensis: a fluconazole-resistant species. Sandven P, et al. **Antimicrob Agents Chemother** 1997 Jun; 41(6):1375–6
Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Sanglard D, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2300–5
Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes. Schoofs A, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1625–35
Effect of fluconazole on viability of Candida albicans over extended periods of time. Sohnle PG, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2622–5
In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Sugar AM, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1314–6
In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Uzun O, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1156–7
Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model. Valentin A, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1342–5
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Vazquez JA, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1612–4
In vitro interaction between amphotericin B and azoles in Candida albicans. Vazquez JA, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2511–6
Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Venkateswarlu K, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2443–6
Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Venkateswarlu K, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):748–51
Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays. Venkateswarlu K, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1382–6
In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp. Wardle HM, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2229–31
The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. White TC. **Antimicrob Agents Chemother** 1997 Jul;41(7):1488–94
Modified agar dilution susceptibility testing method for determining in vitro activities of antifungal agents, including azole compounds. Yoshida T, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1349–51
T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations. Yotsuji A, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):30–4
Differential inhibition of fungal amd mammalian squalene epoxidases by the benzylamine SDZ SBA 586 in comparison with the allylamine terbinafine. Favre B, et al. **Arch Biochem Biophys** 1997 Apr 15;340(2):265–9
Research on antifungal and antimycobacterial agents. Synthesis and activity of 4-alkylthiopyridine-2-carbothioamides. Klimešová V, et al. **Arch Pharm (Weinheim)** 1996 Oct;329(10):438–42
In vitro synergistic activity of ketoconazole with valproic acid against Candida species. Krajewska-Kułak E, et al. **Arzneimittelforschung** 1996 Sep;46(9):934–6
Antifungal activity of organic and organometallic derivatives of benzimidazole and benzothiazole. Küçükbay H, et al. **Arzneimittelforschung** 1997 May;47(5):667–70
Wound healing effect of the new imidazole antimycotic lanoconazole in rats. Niwano Y, et al. **Arzneimittelforschung** 1996 Feb;46(2):218–23
The mechanism of calprotectin's candidastatic activity appears to involve zinc chelation. Clohessy PA, et al. **Biochem Soc Trans** 1996 May;24(2):309S
Trihydroxynaphthalene reductase from Magnaporthe grisea: realization of an active center inhibitor and elucidation of the kinetic mechanism. Thompson JE, et al. **Biochemistry** 1997 Feb 18;36(7):1852–60
Exploring an antifungal target in the plasma membrane H(+)-ATPase of fungi. Seto-Young D, et al. **Biochim Biophys Acta** 1997 Jun 12;1326(2):249–56
Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA: protein N-myristoyltransferase: a new approach to antifungal therapy. Sikorski JA, et al. **Biopolymers** 1997;43(1):43–71 (58 ref.)
The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. Gill HJ, et al. **Br J Clin Pharmacol** 1996 Sep;42(3):347–53
Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Lefebvre RA, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):319–22
Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Spina E, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):315–8
Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Varhe A, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):465–70
Selective calmodulin antagonists fail to inhibit phorbol ester-induced superoxide anion release from human neutrophils: effects of antifungal azole derivatives. Hegemann L, et al. **Br J Dermatol** 1996 Aug;135(2):199–203
Functional effects of econazole on inducible nitric oxide synthase: production of a calmodulin-dependent enzyme. Bogle RG, et al. **Br J Pharmacol** 1996 Mar;117(6):1053–8
The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea-pig model of arrhythmogenicity. Gras J, et al. **Br J Pharmacol** 1996 Sep;

119(2):187–8

A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus. Manavathu EK, et al. **Can J Microbiol** 1996 Sep;42(9):960–4

In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3. Dixon SC, et al. **Cancer Lett** 1997 Feb 26;113(1–2):111–6

Redox modulation of calcium entry and release of intracellular calcium by thimerosal in GH4C1 pituitary cells. Karhapää L, et al. **Cell Calcium** 1996 Dec; 20(6):447–57

Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. Tsuruoka A, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1169–76

Experimental evidences for a role of subinhibitory concentrations of rilopirox, nystatin and fluconazole on adherence of Candida spp. to vaginal epithelial cells. Braga PC, et al. **Chemotherapy** 1996 Jul–Aug;42(4):259–65

Influence of human serum on the postantifungal effect of four antifungal agents on Candida albicans. Mínguez F, et al. **Chemotherapy** 1996 Jul–Aug;42(4):273–9

Effects of systemic fluconazole therapy on in vitro adhesion of Candida albicans to buccal epithelial cells and changes of the cell surface proteins of the epithelial cells. Wu S, et al. **Chin Med Sci J** 1996 Mar;11(1):45–8

Effects of Microstop-treated anti-mite bedding on children with mite-sensitive asthma. Chen CC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1996 Nov–Dec;37(6):420–7

Cyclosporine a immunosuppression in sheep with response enhancement by concomitant ketoconazole. O'Donoghue HL, et al. **Clin Exp Pharmacol Physiol** 1996 Sep; 23(9):797–803

Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Laguna F, et al. **Clin Infect Dis** 1997 Feb;24(2):124–30

A fluconazole/amitriptyline drug interaction in three male adults. Newberry DL, et al. **Clin Infect Dis** 1997 Feb; 24(2):270–1

Strain variation and antifungal susceptibility among bloodstream isolates of Candida species from 21 different medical institutions. Pfaller MA, et al. **Clin Infect Dis** 1995 Dec;21(6):1507–9

Antifungal susceptibility testing: technical advances and potential clinical applications[see comments] Pfaller MA, et al. **Clin Infect Dis** 1997 May;24(5):776–84 (75 ref.). Comment in: Clin Infect Dis 1997 May;24(5):775.

Introduction. Issues concerning antifungal susceptibility testing [comment] Reller LB, et al. **Clin Infect Dis** 1997 May;24(5):775. Comment on: Clin Infect Dis 1997 May;24(5):776–84.

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards [see comments] Rex JH, et al. **Clin Infect Dis** 1997 Feb; 24(2):235–47 (123 ref.). Comment in: Clin Infect Dis 1997 Feb;24( ):248–9.

Making antifungal susceptibility testing a clinically useful tool [editorial; comment] Sugar AM. **Clin Infect Dis** 1997 Feb; 24(2):248–9. Comment on: Clin Infect Dis 1997 Feb;24(2):235–47.

Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing [see comments] Witt MD, et al. **Clin Infect Dis** 1996 Feb; 22(2):322–8. Comment in: Clin Infect Dis 1996 Feb;22(2):329–30. Comment in: Clin Infect Dis 1996 Dec;23(6):1337–8.

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Floren LC, et al. **Clin Pharmacol Ther** 1997 Jul;62(1):41–9

Itraconazole greatly increases plasma concentrations and effects of felodipine. Jalava KM, et al. **Clin Pharmacol Ther** 1997 Apr;61(4):410–5

The effect of ingestion time interval on the interaction between itraconazole and triazolam. Neuvonen PJ, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):326–31

The unusual inheritance of multidrug-resistance factors in Saccharomyces. Shallom JM, et al. **Curr Genet** 1996 Aug; 30(3):212–7

Effect of Lamisil and azole antifungals in experimental nail infection. Richardson MD. **Dermatology** 1997;194 Suppl 1:27–31

Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients. Barchiesi F, et al. **Diagn Microbiol Infect Dis** 1995 Nov;23(3):99–103

Rapid detection of susceptibility to fluconazole in Candida species by a bioluminescence assay of intracellular ATP. Kretschmar M, et al. **Diagn Microbiol Infect Dis** 1996 Jul; 25(3):117–21

Clinical evaluation of a dried commercially-prepared microdilution panel for antifungal susceptibility testing. Messer SA, et al. **Diagn Microbiol Infect Dis** 1996 Jun; 25(2):77–81

Cross-resistance phenotypes of fluconazole-resistant Candida species: results with 655 clinical isolates with different methods. Stevens DA, et al. **Diagn Microbiol Infect Dis** 1996 Nov–Dec;26(3–4):145–8

Variations in DNA subtype and antifungal susceptibility among clinical isolates of Candida tropicalis. Zhang J, et al. **Diagn Microbiol Infect Dis** 1997 Mar;27(3):63–7

A synthetic form of tracheal antimicrobial peptide has both bactericidal and antifungal activities. Lawyer C, et al. **Drug Des Discov** 1996 Dec;14(3):171–8

In vitro susceptibility of 115 isolates of Candida to amphotericin B, fluconazole and itraconazole. Mallié M, et al. **Drugs Exp Clin Res** 1996;22(6):301–7

When should Candida isolates be tested for susceptibility to azole antifungal agents? [editorial] Bille J. **Eur J Clin Microbiol Infect Dis** 1997 Apr;16(4):281–2

Evaluation of the E test for fluconazole susceptibility testing of Candida albicans isolates from oropharyngeal candidiasis. Dannaoui E, et al. **Eur J Clin Microbiol Infect Dis** 1997 Mar;16(3):228–32

Key issues concerning fungistatic versus fungicidal drugs. Graybill JR, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):42–50 (61 ref.)

Variable antifungal susceptibility of wild-type Candida albicans phenotypes from neutropenic hosts. Velegraki A, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov; 15(11):854–60

Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Ahonen J, et al. **Eur J Clin Pharmacol** 1997;51(5):415–9

Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Jalava KM, et al. **Eur J Clin Pharmacol** 1996;51(3–4):331–4

Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Lukkari E, et al. **Eur J Clin Pharmacol** 1997; 52(5):403–6

Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents. Poonwan N, et al. **Eur J Epidemiol** 1997 Apr;13(3):335–40

Quinoxaline chemistry. Part 7. 2-[aminobenzoates]- and 2-[aminobenzoylglutamate]-quinoxalines as classical antifolate agents. Synthesis and evaluation of in vitro anticancer, anti-HIV and antifungal activity. Loriga M, et al. **Farmaco** 1997 Mar;52(3):157–66

ESTs reveal a multigene family for plant defensins in Arabidopsis thaliana. Epple P, et al. **FEBS Lett** 1997 Jan 3;400(2):168–72

Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. Kelly SL, et al. **FEBS Lett** 1997 Jan 2;400(1):80–2

Biochemical characterisation of ketoconazole inhibitory action on Aspergillus fumigatus. Venkateswarlu K, et al. **FEMS Immunol Med Microbiol** 1996 Nov;16(1):11–20

Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. Fostel J, et al. **FEMS Microbiol Lett** 1996 May 1;138(2–3):105–11

Molecular mechanisms of azole resistance in fungi. Joseph-Horne T, et al. **FEMS Microbiol Lett** 1997 Apr 15;149(2):141–9 (33 ref.)

Inhibition of ergosterol biosynthesis is not accompanied by a change in fatty acid composition in Saccharomyces cerevisiae treated with the antifungal agent 6-amino-2-n-pentylthiobenzothiazole. Kuchta T, et al. **FEMS Microbiol Lett** 1997 May 1;150(1):43–7

Reduced intracellular accumulation of azole antifungal results in resistance in Candida albicans isolate NCPF 3363. Lamb DC, et al. **FEMS Microbiol Lett** 1997 Feb 15;147(2):189–93

Differential inhibition of Candida albicans CYP51 with azole antifungal stereoisomers. Lamb DC, et al. **FEMS Microbiol Lett** 1997 Apr 1;149(1):25–30

Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. Löffler J, et al. **FEMS Microbiol Lett** 1997 Jun 15;151(2):263–8

New azidometalkojates and their biological activity. Hudecová D, et al. **Folia Microbiol (Praha)** 1996; 41(6):473–6

Effect of alpha-tomatine and tomatidine on membrane potential of frog embryos and active transport of ions in frog skin. Blankemeyer JT, et al. **Food Chem Toxicol** 1997 Jul;35(7):639–46

The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Ahonen J, et al. **Fundam Clin Pharmacol** 1996;10(3):314–8

Modulation of human T-lymphocyte plasma membrane Ca2+ permeability by imidazole antimycotics. Hornstein EH, et al. **Immunopharmacol Immunotoxicol** 1996 May; 18(2):237–45

Changes in the cellular composition of Candida albicans resistant to miconazole. Sharma S, et al. **Indian J Biochem Biophys** 1996 Oct;33(5):420–4

Antifungal susceptibility pattern of non-albicans Candida species & distribution of species isolated from Candidaemia cases over a 5 year period. Chakrabarti A, et al. **Indian J Med Res** 1996 Aug;104:171–6

The inhibitory effect of pentamidine on the production of chemotactic cytokines by in vitro stimulated human blood cells. Van Wauwe J, et al. **Inflamm Res** 1996 Jul; 45(7):357–63

A screening method for antimitotic and antifungal substances using conidia of Pyricularia oryzae, modification and application to tropical marine fungi. Kobayashi H, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):873–9

Viridiofungins, novel inhibitors of sphingolipid synthesis. Mandala SM, et al. **J Antibiot (Tokyo)** 1997 Apr; 50(4):339–43

Antimicrobial activity of viridiofungins. Onishi JC, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):334–8

In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii. Cirioni O, et al. **J Antimicrob Chemother** 1997 Jan;39(1):45–51

Standardization of antifungal susceptibility testing. Cormican MG, et al. **J Antimicrob Chemother** 1996 Oct;38(4):561–78 (78 ref.)

Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro. Feldmesser M, et al. **J Antimicrob Chemother** 1996 Mar; 37(3):617–22

Effect of pH and buffer system on the in-vitro activity of five antifungals against yeasts. Gadea I, et al. **J Antimicrob Chemother** 1997 Apr;39(4):453–9

The effects of antifungal agents on the morphogenetic transformation by Candida albicans in vitro. Hawser S, et al. **J Antimicrob Chemother** 1996 Oct;38(4):579–87

Spectrophotometric determination of the morphogenetic transformation by synchronous Candida albicans: effects of antifungal agents. Hawser S, et al. **J Antimicrob Chemother** 1996 Jul;38(1):67–73

Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients. Jaruratanasirikul S, et al. **J Antimicrob Chemother** 1996 Nov;38(5):877–80

Effect of pentoxifylline on the course of systemic Candida albicans infection in mice. Louie A, et al. **J Antimicrob Chemother** 1996 May;37(5):943–54

ZD0870 treatment of murine candidiasis caused by fluconazole resistant isolates of Candida albicans. Najvar LK, et al. **J Antimicrob Chemother** 1996 Oct;38(4):671–7

In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. Pujol I, et al. **J Antimicrob Chemother** 1997 Feb;39(2):163–7

Antifungal drug susceptibility testing. Working Party of the British Society for Antimicrobial chemotherapy. Rogers TR, et al. **J Antimicrob Chemother** 1995 Dec;36(6):899–909 (61 ref.)

In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei. Venkateswarlu K, et al. **J Antimicrob Chemother** 1997 Jun;39(6):731–6

Stereoselective interaction of SCH 39304, a triazole, with sterol 14alpha-demethylase of Aspergillus fumigatus. Venkateswarlu K, et al. **J Antimicrob Chemother** 1997 May; 39(5):597–601

Novel antifungal agents which inhibit lanosterol 14alpha-demethylase in Candida albicans CCH442. Zakula D, et al. **J Antimicrob Chemother** 1997 Feb;39(2):261–4

Characterization of Saccharomyces cerevisiae CYP61, sterol delta22-desaturase, and inhibition by azole antifungal agents. Kelly SL, et al. **J Biol Chem** 1997 Apr 11; 272(15):9986–8

The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. Lamb DC, et al. **J Biol Chem** 1997 Feb 28;272(9):5682–8

Isolates of Cryptococcus neoformans serotype A or D from cerebrospinal fluid resistant to 5-fluorocytosine. Arsic V, et al. **J Chemother** 1995 Nov;7 Suppl 4:90–2

Susceptibility of Candida albicans pretreated with ketoconazole and 5-fluorocytosine to fungicidal activity of leukocytes and serum. Chiu ML, et al. **J Chemother** 1995 Nov;7 Suppl 4:21–2

In vitro antimicrobial activity of Pistacia lentiscus L. extracts: preliminary report. Iauk L, et al. **J Chemother** 1996 Jun; 8(3):207–9

Influence of human serum on the postantifungal effect induced by therapeutic concentrations of ketoconazole and 5-fluorocytosine. Lima JE, et al. **J Chemother** 1995 Nov; 7 Suppl 4:38–9

In vitro susceptibility of Trichosporon beigelii to antifungal agents. Perparim K, et al. **J Chemother** 1996 Dec;8(6):445–8

Overcoming Streptococcus agalactiae in vitro resistance to imidazoles. Simonetti N, et al. **J Chemother** 1997 Aug; 9(4):251–6

Interaction of Candida albicans, macrophages and fluconazole: in vitro and ex vivo observations. Tullio V, et al. **J Chemother** 1996 Dec;8(6):438–44

The antifungal antibiotic, clotriamzole, inhibits Cl- secretion by polarized monolayers of human colonic epithelial cells. Rufo PA, et al. **J Clin Invest** 1996 Nov 1;98(9):2066–75

Fluconazole disk diffusion procedure for determining susceptibility of Candida species. Barry AL, et al. **J Clin Microbiol** 1996 Sep;34(9):2154–7

Strain variation among and antifungal susceptibilities of isolates of Candida krusei. Berrouane YF, et al. **J Clin Microbiol** 1996 Jul;34(7):1856–8

Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients. D'Antonio D, et al. **J Clin Microbiol** 1996 Mar;34(3):753–5

Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

Espinel-Ingroff A, et al. **J Clin Microbiol** 1997 Jan; 35(1):139–43

Rapid susceptibility testing of Candida albicans by flow cytometry. Kirk SM, et al. **J Clin Microbiol** 1997 Feb; 35(2):358–63

Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. Nho S, et al. **J Clin Microbiol** 1997 Apr;35(4):1036–9

Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans. Patterson TF, et al. **J Clin Microbiol** 1996 Dec;34(12):3237–9

Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. Patterson TF, et al. **J Clin Microbiol** 1996 Jul;34(7):1794–7

Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates. Pfaller MA, et al. **J Clin Microbiol** 1996 Jul;34(7):1691–3

Rapid flow cytometric susceptibility testing of Candida albicans. Ramani R, et al. **J Clin Microbiol** 1997 Sep; 35(9):2320–4

Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection. Redding SW, et al. **J Clin Microbiol** 1997 Jul; 35(7):1761–5

Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test [letter; comment] Rodríguez-Tudela JL, et al. **J Clin Microbiol** 1997 Jan;35(1):336–7. Comment on: J Clin Microbiol 1996 Apr;34(4):842–7.

Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy. Ruhnke M, et al. **J Clin Microbiol** 1996 Dec;34(12):3208–11

Effects of incubation time and buffer concentration on in vitro activities of antifungal agents against Candida albicans. Tornatore MA, et al. **J Clin Microbiol** 1997 Jun; 35(6):1473–6

Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. von Moltke LL, et al. **J Clin Pharmacol** 1996 Sep;36(9):783–91

Different effects of azole-antifungal agents on the regulation of intracellular calcium concentration of Trichophyton rubrum. Inoue I, et al. **J Dermatol Sci** 1996 Jun;12(2):156–62

Antifungal activity of turmeric oil extracted from Curcuma longa (Zingiberaceae). Apisariyakul A, et al. **J Ethnopharmacol** 1995 Dec 15;49(3):163–9

Fungicide and fungiostatic effects of xanthoxyline. Cechinel Filho V, et al. **J Ethnopharmacol** 1996 Sep;53(3):171–3

An ethnobotanical study of the traditional medicine of the Mestizo people of Suni Miraño, Loreto, Peru. Jovel EM, et al. **J Ethnopharmacol** 1996 Sep;53(3):149–56

Investigation of antifungal and analgesic activities of extracts from Sium nodiflorum. Larhsini M, et al. **J Ethnopharmacol** 1996 Aug;53(2):105–10

Antifungal activity and kinetics of inhibition by essential oil isolated from leaves of Aegle marmelos. Rana BK, et al. **J Ethnopharmacol** 1997 Jun;57(1):29–34

Anticandidal activity of Santolina chamaecyparissus volatile oil. Suresh B, et al. **J Ethnopharmacol** 1997 Jan;55(2):151–9

Evaluation of sulfa drugs against recombinant Pneumocystis carinii dihydropteroate synthetase and in vivo. Hong YL, et al. **J Eukaryot Microbiol** 1996 Sep-Oct;43(5):40S

Sulfa resistance in mouse-derived Pneumocystis carinii [published erratum appears in J Eukaryot Microbiol 1996 Nov-Dec;43(6):512] Lane B, et al. **J Eukaryot Microbiol** 1996 Sep-Oct;43(5):39S

Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group. Brandt ME, et al. **J Infect Dis** 1996 Oct;174(4):812–20

Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. Cenci E, et al. **J Infect Dis** 1997 Jul;176(1):217–26

Role of extended culture time on synergy of fluconazole and human monocyte-derived macrophages in clearing Candida albicans. Gujral S, et al. **J Infect Dis** 1996 Oct; 174(4):888–90

Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. Tomee JF, et al. **J Infect Dis** 1997 Sep;176(3):740–7

His-X-X-X-His motif in S100 protein, calprotectin: relation to microbiostatic activity [letter] Clohessy PA, et al. **J Leukoc Biol** 1996 Nov;60(5):674

Neutral red assay in minimum fungicidal concentrations of antifungal agents. Fukuda T, et al. **J Med Vet Mycol** 1996 Sep-Oct;34(5):353–6

Discrepancy between in vitro and in vivo antifungal activity of albendazole. Hardin TC, et al. **J Med Vet Mycol** 1997 May-Jun;35(3):153–8

Lipopeptide inhibitors of fungal glucan synthase. Kurtz MB, et al. **J Med Vet Mycol** 1997 Mar-Apr;35(2):79–86 (52 ref.)

Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. Lynch ME, et al. **J Med Vet Mycol** 1996 Sep-Oct;34(5):337–9

In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. Nelson PW, et al. **J Med Vet Mycol** 1997 Jul-Aug;35(4):285–7

Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. Venkateswarlu K, et al. **J Med Vet Mycol** 1997 Jan-Feb;35(1):19–25

New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: implications for antifungal azole resistance. Walsh TJ, et al. **J Med Vet Mycol** 1997 Mar-Apr;35(2):133–7

The antifungal imidazole clotrimazole and its major in vivo metabolite are potent blockers of the calcium-activated potassium channel in murine erythroleukemia cells. Rittenhouse AR, et al. **J Membr Biol** 1997 May 15; 157(2):177–91

Phytogrowth-inhibitory compounds from Malmea depressa. Jimenez Arellanes A, et al. **J Nat Prod** 1996 Feb; 59(2):202–4

Halicylindramides D and E, antifungal peptides from the marine sponge Halichondria cylindrata. Li H, et al. **J Nat Prod** 1996 Feb;59(2):163–6

In vitro evaluation of antifungal properties of 8.O.4'-neolignans. Zacchino S, et al. **J Nat Prod** 1997 Jul; 60(7):659–62

Antifungal effect of zeolite-incorporated tissue conditioner against Candida albicans growth and/or acid production. Nikawa H, et al. **J Oral Rehabil** 1997 May;24(5):350–7

In vitro antifungal properties of mouthrinses containing antimicrobial agents. Giuliana G, et al. **J Periodontol** 1997 Aug;68(8):729–33

Identification of preussin as a selective inhibitor for cell growth of the fission yeast ts mutants defective in Cdc2-regulatory genes. Kasahara K, et al. **Jpn J Antibiot** 1997 Mar;50(3):267–9

Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients [letter] Kelly SL, et al. **Lancet** 1996 Nov 30;348(9040):1523–4

Antifungal activity against allergic fungal sinusitis organisms. Bent JP 3rd, et al. **Laryngoscope** 1996 Nov;106(11):1331–4

Influence of a subinhibitory dose of antifungal fatty acids from Sporothrix flocculosa on cellular lipid composition in fungi. Benyagoub M, et al. **Lipids** 1996 Oct; 31(10):1077–82

Ultrastructural alterations of Candida albicans induced by a new imidazole antimycotic omoconazole nitrate. Nishiyama Y, et al. **Microbiol Immunol** 1997;41(5):395–402

Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Wakabayashi H, et al. **Microbiol Immunol** 1996;40(11):821–5

An ATP bioluminescence assay applicable to rapid fluconazole susceptibility testing of dermatophytes. Yoshida T, et al. **Microbiol Immunol** 1997;41(5):377–86

In vitro activity of fluconazole on Candida albicans. Abecia LC, et al. **Microbiologia** 1996 Dec;12(4):613–20

N-myristoylation of Arf proteins in Candida albicans: an in vivo assay for evaluating antifungal inhibitors of myristoyl-CoA: protein N-myristoyltransferase. Lodge JK, et al. **Microbiology** 1997 Feb;143 (Pt 2):357–66

Inhibition of Paracoccidioides brasiliensis by ajoene is associated with blockade of phosphatidylcholine biosynthesis. San-Blas G, et al. **Microbiology** 1997 May;143 (Pt 5):1583–6

Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Sanglard D, et al. **Microbiology** 1997 Feb;143 (Pt 2):405–16

A disc plate assay for characterization of the effect of interaction between polyenes and azoles on growth of Candida albicans CA12. Cao B, et al. **Microbios** 1996; 87(352):161–7

Antifungal screening of seven new azole derivatives. Mares D, et al. **Microbios** 1996;86(348):185–93

Synthetic peptide combinatorial libraries: a method for the identification of bioactive peptides against phytopathogenic fungi. Reed JD, et al. **Mol Plant Microbe Interact** 1997 Jul;10(5):537–49

Synergy of human neutrophils with fluconazole in killing Candida species. Brummer E, et al. **Mycopathologia** 1996; 134(3):115–20

In vitro susceptibility of Trichophyton rubrum isolates to griseofulvin and tioconazole. Induction and isolation of a resistant mutant to both antimycotic drugs. Mutant of Trichophyton rubrum resistant to griseofulvin and tioconazole. Fachin AL, et al. **Mycopathologia** 1996; 135(3):141–3

Inhibition of yeast-to-mycelium conversion of Candida albicans by conjugated styryl ketones. Manavathu E, et al. **Mycopathologia** 1996;135(2):79–83

In vitro antifungal activity of the new triazole D0870 against Penicillium marneffei compared with that of amphotericin B, fluconazole, itraconazole, miconazole and flucytosine. Boon-Long J, et al. **Mycoses** 1996 Nov-Dec; 39(11-12):453–6

Effect of media on growth rate and susceptibility testing of Cryptococcus neoformans. St-Germain G, et al. **Mycoses** 1996 May-Jun;39(5-6):201–6

In vitro susceptibility of Malassezia furfur against azole compounds. Schmidt A, et al. **Mycoses** 1996 Jul-Aug; 39(7-8):309–12

Disturbance of withdrawal bleeding during concomitant use of itraconazole and oral contraceptives [letter] Meyboom RH, et al. **N Z Med J** 1997 Aug 8;110(1049):300

Inactivation of yeast and filamentous fungi by the lactoperoxidase-hydrogen peroxide-thiocyanate-system. Popper L, et al. **Nahrung** 1997 Feb;41(1):29–33

Ketoconazole resistant oral candidiasis in HIV-infected patients [letter] Diz Dios P, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jul;84(1):3–4

Use of a microtiter plate assay to detect the rate of killing of adherent Candida albicans by antifungal agents. Hamers AD, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jan;81(1):44–9

Antifungal activity of synthetic 15-mer peptides based on the Rs-AFP2 (Raphanus sativus antifungal protein 2) sequence. De Samblanx GW, et al. **Pept Res** 1996 Nov-Dec;9(6):262–8

Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake. Rogers MJ, et al. **Pharm Res** 1997 May;14(5):625–30

Stability of nystatin in mouthrinses; effect of pH temperature, concentration and colloidal silver addition, studied using an in vitro antifungal activity. Vermerie N, et al. **Pharm World Sci** 1997 Aug;19(4):197–201

Itraconazole increases serum digoxin concentration. Partanen J, et al. **Pharmacol Toxicol** 1996 Nov;79(5):274–6

Anti-inflammatory, antipyretic, and analgesic effects of Lawsonia inermis L. (henna) in rats. Ali BH, et al. **Pharmacology** 1995 Dec;51(6):356–63

Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. Guerret M, et al. **Pharmacotherapy** 1997 Jul-Aug;17(4):767–73

Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers. Tarral A, et al. **Pharmacotherapy** 1997 Jul-Aug;17(4):791–5

(-)-Usnic acid and its derivatives. Their inhibition of fungal growth and enzyme activity. Broksa B, et al. **Pharmazie** 1996 Mar;51(3):195–6

Cloning and expression of a PR5-like protein from Arabidopsis: inhibition of fungal growth by bacterially expressed protein. Hu X, et al. **Plant Mol Biol** 1997 Aug; 34(6):949–59

Antifungal activity from Alpinia galanga and the competition for incorporation of unsaturated fatty acids in cell growth. Haraguchi H, et al. **Planta Med** 1996 Aug;62(4):308–13

Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans. Shen J, et al. **Planta Med** 1996 Oct;62(5):415–8

Effect of naftifine on neutrophil adhesion. Choi TS, et al. **Skin Pharmacol** 1996;9(3):190–6

Antifungal activity of the essential oil of Melaleuca alternifolia (tea tree oil) against pathogenic fungi in vitro. Nenoff P, et al. **Skin Pharmacol** 1996;9(6):388–94

Antifungal sterol biosynthesis inhibitors. Guo DA, et al. **Subcell Biochem** 1997;28:89–116 (92 ref.)

Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Omar G, et al. **Ther Drug Monit** 1997 Aug;19(4):436–45

Effects of low-dose ketoconazole on thyroid hormones in renal transplant recipients. García R, et al. **Transplant Proc** 1996 Dec;28(6):3368–9

Effect of platinum (II) complexes of 4-methoxy- and 4-chlorobenzoic acid hydrazides on Saccharomyces cerevisiae. Tabakova S, et al. **Z Naturforsch [C]** 1997 Jan-Feb;52(1-2):45–8

Lactarane type sesquiterpenoids as inhibitors of leukotriene biosynthesis and other, new metabolites from submerged cultures of Lentinellus cochleatus (Pers. ex Fr.) Karst. Wunder A, et al. **Z Naturforsch [C]** 1996 Jul-Aug; 51(7-8):493–9

Factors affecting the results of a broth microdilution antifungal susceptibility testing in vitro. Buchta V, et al. **Zentralbl Bakteriol** 1996 Mar;283(3):375–90

Antimicrobial sensitivity in microorganisms isolated from canine otitis externa. Guedeja-Marron J, et al. **Zentralbl Veterinarmed [B]** 1997 Aug;44(6):341–6

In vitro activity of climbazole, clotrimazole and silver-sulphadiazine against isolates of Malassezia pachydermatis. Schmidt A. **Zentralbl Veterinarmed [B]** 1997 Jun;44(4):193–7

[Effect of monensin on the growth and secretion of exopolysaccharides in Botrytis cinerea Pers. and Sclerotium rolfsii Sacc.] Koulali Y, et al. **Can J Microbiol** 1996 Sep; 42(9):965–72 (Eng. Abstr.) **(Fre)**

[Methods for the determination of the sensitivity of Candida strains to fluconazole: focus of a micromethod and correlation with 2 other techniques] Goutaland C, et al. **Pathol Biol (Paris)** 1996 Oct;44(8):724–8 (Eng. Abstr.) **(Fre)**

[A new problem: multiresistant fungi (news)] Wehr A. **Dtsch Med Wochenschr** 1997 Mar 14;122(11):A9 **(Ger)**

[Hydroxy pyridone as antimycotic agent] **Hautarzt** 1996 Nov; 47(11 Suppl):1–12 **(Ger)**

[Fluconazole: advances in the testing of sensitivity of yeasts. 28th Session of the Clinical Mycology Study Group of the German-Speaking Society of Mycology. Illertissen, Germany, 26–27 April 1996] **Mycoses** 1996;39 Suppl 2:1–65 **(Ger)**

[Fluconazole and itraconazole susceptibility testing with clinical yeast isolates and algae of the genus Prototheca

by means of the Etest] Blaschke-Hellmessen R. **Mycoses** 1996;39 Suppl 2:39-43 (Eng. Abstr.) **(Ger)**

[Comparison of three antifungal susceptibility testing methods for the in vitro testing of Candida isolates from patients with HIV infection] Ruhnke M, et al. **Mycoses** 1996;39 Suppl 2:47-50 (Eng. Abstr.) **(Ger)**

[Susceptibility testing of yeasts against fluconazole: proposal for a standardized agar diffusion method with 25 microgram fluconazole paper discs] Schmalreck AF, et al. **Mycoses** 1996;39 Suppl 2:27-30 (Eng. Abstr.) **(Ger)**

[Susceptibility testing of yeasts against fluconazole: comparison of the Etest method with microdilution and agar dilution] Schmalreck AF, et al. **Mycoses** 1996;39 Suppl 2:31-8 (Eng. Abstr.) **(Ger)**

[Susceptibility testing of fluconazole: evaluation of a multicenter study of the working group "Clinical Mycology" of the German Speaking Mycological Society] Schmalreck AF. **Mycoses** 1996;39 Suppl 2:1-11 (Eng. Abstr.) **(Ger)**

[Criteria for a microdilution susceptibility testing method of fluconazole: proposal of a standardized testing method for yeasts] Schmalreck AF, et al. **Mycoses** 1996;39 Suppl 2:12-6 (Eng. Abstr.) **(Ger)**

[In vitro susceptibility testing of Candida species against fluconazole using the microdilution test with Alamar Blue] Schröder G, et al. **Mycoses** 1996;39 Suppl 2:17-21 (Eng. Abstr.) **(Ger)**

[The Etest--an alternative to the NCLLS standard for susceptibility testing of yeasts?] Seibold M. **Mycoses** 1996; 39 Suppl 2:44-6 (Eng. Abstr.) **(Ger)**

[Controversies in the standardization of susceptibility testing on yeasts to azole antimycotics] Tintelnot K, et al. **Mycoses** 1996;39 Suppl 2:22-6 (Eng. Abstr.) **(Ger)**

[In vitro antifungal activity of rilopirox, a new hydroxypyridone antimycotic agent] Harada I, et al. **Jpn J Antibiot** 1997 Feb;50(2):195-9 (Eng. Abstr.) **(Jpn)**

[In vitro antifungal activity of omoconazole nitrate, a novel imidazone antimycotic drug, against clinical isolates from patients with cutaneous mycosis] Uchida K, et al. **Jpn J Antibiot** 1996 Aug;49(8):818-23 (Eng. Abstr.) **(Jpn)**

[Preclinical and clinical studies on the efficacy of bifonazole in patients with tinea pedis at 10 years after approval. Part 1. Susceptibility to bifonazole of clinical isolates of dermatophytes] Yamaguchi H, et al. **Jpn J Antibiot** 1996 Dec;49(12):1085-94 (Eng. Abstr.) **(Jpn)**

[Multisite evaluation of a colorimetric broth microdilution antifungal susceptibility testing] Yamane N, et al. **Rinsho Byori** 1997 Feb;45(2):190-9 (Eng. Abstr.) **(Jpn)**

[In vitro susceptibility to antifungal agents of Candida strains isolated from patients with various diseases of the respiratory tract] Batura-Gabryel H, et al. **Pneumonol Alergol Pol** 1997;65(5-6):355-9 (Eng. Abstr.) **(Pol)**

[A new metabolite with fungistatic and bacteriostatic activity, produced by strain L-30 of Flavobacterium sp.] Shenin IuD, et al. **Antibiot Khimioter** 1996 May;41(5):6-12 (Eng. Abstr.) **(Rus)**

[Antifungal resistance in opportunistic pathogenic fungi (I). Polyenes and fluorocytosine] Martínez-Suárez JV, et al. **Enferm Infecc Microbiol Clin** 1996 Jun-Jul;14(6):384-9 (43 ref.) **(Spa)**

[Antifungal resistance in opportunistic pathogenic fungi (II). Imidazoles and triazoles] Martínez-Suárez JV, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):490-8 (79 ref.) **(Spa)**

[Yeast infections: causative agents and their antifungal resistance in hospitalized pediatric patients and HIV-positive adults] Rodero L, et al. **Rev Argent Microbiol** 1997 Jan-Mar;29(1):7-15 (Eng. Abstr.) **(Spa)**

POISONING

Henna (Lawsonia inermis Linn.) inducing haemolysis among G6PD-deficient newborns. A new clinical observation. Kandil HH, et al. **Ann Trop Paediatr** 1996 Dec;16(4):287-91

Effect of charcoal hemoperfusion on clearance of pentamidine isethionate after accidental overdose. Watts RG, et al. **J Toxicol Clin Toxicol** 1997;35(1):89-92

THERAPEUTIC USE

Long-term follow-up of toe-nail onychomycosis treated with terbinafine [letter] Brandrup F, et al. **Acta Derm Venereol** 1997 May;77(3):238

Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection. Jensen P, et al. **Acta Derm Venereol** 1996 Jul;76(4):280-1

New antifungal therapy for children. Suarez S. **Adv Dermatol** 1997;12:195-208; discussion 209 (56 ref.)

Antifungal drugs and resistance. Graybill JR. **Adv Exp Med Biol** 1995;390:217-34 (98 ref.)

Use of azoles for systemic antifungal therapy. Kauffman CA, et al. **Adv Pharmacol** 1997;39:143-89 (340 ref.)

Update on invasive candidiasis. Rodriguez LJ, et al. **Adv Pharmacol** 1997;37:349-400 (462 ref.)

Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. Cartledge JD, et al. **AIDS** 1997 Feb;11(2):163-8

Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. Heald AE, et al. **AIDS** 1996 Mar;10(3):263-8

Cryptococcal disease: implications of recent clinical trials on treatment and management. Aberg JA, et al. **AIDS Clin Rev** 1997-98;:229-48 (56 ref.)

Mucormycosis in diabetes. Hopkins MA, et al. **Am J Crit Care** 1997 Sep;6(5):363-7

Criteria for use of amphotericin B lipid complex injections in adults and children. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2751-2

Administering itraconazole via nasogastric tube [letter] Ong DL, et al. **Am J Health Syst Pharm** 1996 Aug 15; 53(16):1962

Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Wheat J, et al. **Am J Med** 1997 Sep;103(3):223-32

Etiology of esophageal disease in human immunodeficiency virus-infected patients who fail antifungal therapy. Wilcox CM, et al. **Am J Med** 1996 Dec;101(6):599-604

Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Mastroiacovo P, et al. **Am J Obstet Gynecol** 1996 Dec;175(6):1645-50

Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Schuman P, et al. **Ann Intern Med** 1997 May 1; 126(9):689-96

Chemoprophylaxis of fungal deterioration of the Provox silicone tracheoesophageal prosthesis in postlaryngectomy patients. van Weissenbruch R, et al. **Ann Otol Rhinol Laryngol** 1997 Apr;106(4):329-37

Oral terbinafine: a new antifungal agent. Abdel-Rahman SM, et al. **Ann Pharmacother** 1997 Apr;31(4):445-56 (117 ref.)

Treatment of tinea capitis. Abdel-Rahman SM, et al. **Ann Pharmacother** 1997 Mar;31(3):338-48 (134 ref.)

Fluconazole treatment for vulvovaginal candidiasis during pregnancy [letter] Campomori A, et al. **Ann Pharmacother** 1997 Jan;31(1):118-9

Fluconazole and amphotericin B for cryptococcal meningitis. Clark AB, et al. **Ann Pharmacother** 1996 Dec; 30(12):1408-10

Azole resistance in yeasts [letter] Craig JM, et al. **Ann Pharmacother** 1997 Feb;31(2):255

Neutrophil-mediated injury in ischemic skin flaps: amelioration of ischemic injury by cyclosporine in the rat. Cetinkale O, et al. **Ann Plast Surg** 1996 Jul;37(1):66-74

Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Barchiesi F, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1317-20

Comparison of fluconazole and amphotericin B in prophylaxis of experimental Candida endocarditis caused by non-C. albicans strains. Bayer AS, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):494-6

Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits. Chemlal K, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):263-6

Efficacies of two novel azole derivatives each containing a morpholine ring, UR-9746 and UR-9751, against systemic murine coccidioidomycosis. Clemons KV, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):200-3

Itraconazole resistance in Aspergillus fumigatus. Denning DW, et al. **Antimicrob Agents Chemother** 1997 Jun; 41(6):1364-8

Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Ding JC, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1589-93

Efficacy of D0870 treatment of experimental Candida vaginitis. Fidel PL Jr, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1455-9

Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women. Geletko SM, et al. **Antimicrob Agents Chemother** 1996 Jun; 40(6):1338-41

Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. George D, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):86-91

Treatment of murine disseminated candidiasis with L-743,872. Graybill JR, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1775-7

Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Hata K, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2243-7

Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors. Lacassin F, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1961-3

Stereoselective interaction of the azole antifungal agent SCH39304 with the cytochrome P-450 monooxygenase system isolated from Cryptococcus neoformans. Lamb DC, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1465-7

Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Larsen RA, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2178-82

Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Martin MV, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):13-6

Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis. Mazzolla R, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):802-7

Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations. Merali S, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1298-300

Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Murphy M, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):696-8

Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole. Natarajan U, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1575-8

Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Nguyen MH, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1120-3

Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Nolte FS, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):196-9

Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Oakley KL, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1504-7

In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Sugar AM, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1314-6

Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs. Walzer PD, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):251-8

Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Wheat J, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):410-4

Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. White TC. **Antimicrob Agents Chemother** 1997 Jul;41(7):1482-7

Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Manfredi R, et al. **Arch Intern Med** 1997 Jan 13;157(1):64-9

Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Stevens DA, et al. **Arch Intern Med** 1997 Sep 8; 157(16):1857-62

Onychomycosis. Sinclair R. **Aust Fam Physician** 1997 Jul; 26(7):867

Transfer factor in chronic mucocutaneous candidiasis. Masi M, et al. **Biotherapy** 1996;9(1-3):97-103

Candida parapsilopsis fungemias in bone marrow transplant recipients: implications for azole prophylactic therapy [letter; comment] López-Jiménez J, et al. **Blood** 1997 May 1;89(9):3491-2. Comment on: Blood 1996 Jan 15;87(2):838-9.

Itraconazole more bioavailable in solution [letter] Prentice AG, et al. **Blood** 1996 Nov 1;88(9):3662-3

Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. Gøtzsche PC, et al. **BMJ** 1997 Apr 26;314(7089):1238-44

Prophylactic and empirical antifungal treatment in cancer complicated by neutropenia. Combining different antifungal strategies in same systematic review is inappropriate [letter] Kibbler CC, et al. **BMJ** 1997 Aug 23;315(7106):488-9

Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol. Castagnola E, et al. **Bone Marrow Transplant** 1996 Nov;18 Suppl 2:97-106 (41 ref.)

Resolution of invasive central nervous system aspergillosis in a transplant recipient. Khoury H, et al. **Bone Marrow Transplant** 1997 Jul;20(2):179-80

Autologous bone marrow transplantation is feasible in patients with a prior history of invasive pulmonary aspergillosis. Michailov G, et al. **Bone Marrow Transplant** 1996 Apr;17(4):569-72

Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Wingard JR. **Bone Marrow Transplant** 1997 Feb;19(4):343-7

The interaction of terbinafine and cyclosporine A in renal transplant patients [letter] Lo AC, et al. **Br J Clin Pharmacol** 1997 Mar;43(3):340-1

Efficacy of terbinafine treatment of tinea capitis in children varies according to the dermatophyte species. [letter] Baudraz-Rosselet F, et al. **Br J Dermatol** 1996 Dec; 135(6):1011-2

A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Faergemann J, et al. **Br J Dermatol** 1997 Apr;136(4):575-7

Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. Gupta AK, et al. **Br J Dermatol** 1997 Aug;137(2):251–4

Atypical eumycetoma caused by Phialophora parasitica successfully treated with itraconazole and flucytosine. Hood SV, et al. **Br J Dermatol** 1997 Jun;136(6):953–6

Successful treatment with fluconazole of prototheca developing at the site of an intralesional corticosteroid injection. Kim ST, et al. **Br J Dermatol** 1996 Nov; 135(5):803–6

Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals. Tosti A, et al. **Br J Dermatol** 1996 Nov;135(5):799–802

Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Schwartz S, et al. **Br J Haematol** 1997 Jun;97(3):663–5

Unusual treatment of severe cutaneous lupus. Barrett CA, et al. **Br J Hosp Med** 1996 Oct 2–15;56(7):368–9

Fungal infections. Chimelli L, et al. **Brain Pathol** 1997 Jan; 7(1):613–27 (90 ref.)

Onychomycosis. Going for cure. Gupta AK, et al. **Can Fam Physician** 1997 Feb;43:299–305 (49 ref.)

Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis.Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group. de Repentigny L, et al. **Chemotherapy** 1996 Sep–Oct;42(5):374–83

Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Lake DE, et al. **Chemotherapy** 1996 Jul–Aug;42(4):308–14

Fungemia in patients with hematologic malignancies: therapeutic effects of concomitant administration of fluconazole and granulocyte-colony-stimulating factor. Niitsu N, et al. **Chemotherapy** 1996 May–Jun;42(3):215–19

Fluconazole vs itraconazole–flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group. Barbaro G, et al. **Chest** 1996 Dec;110(6):1507–14

Successful treatment of subcutaneous mycoses with fluconazole: a report of two cases. Yang SP, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Dec;56(6):432–5

The role of azole antifungal agents for systemic antifungal therapy. Lee YP, et al. **Cleve Clin J Med** 1997 Feb; 64(2):99–106 (67 ref.)

Fungal pulmonary complications. Davies SF, et al. **Clin Chest Med** 1996 Dec;17(4):725–44 (59 ref.)

Cutaneous Alternaria alternata infection successfully treated with itraconazole. Del Palacio A, et al. **Clin Exp Dermatol** 1996 May;21(3):241–3

Biometrological assessment of the preventive effect of a miconazole spray powder on athlete's foot. Piérard GE, et al. **Clin Exp Dermatol** 1996 Sep;21(5):344–6

Once-daily fluocinonide–bifonazole combination for the treatment of vulvar itching and vulvovaginal candidiasis. Preliminary study. Kaplan B, et al. **Clin Exp Obstet Gynecol** 1996;23(3):173–6

Rhinocerebral mucormycosis in a patient with AIDS: a complication of diabetic ketoacidosis following pentamidine therapy. Abril V, et al. **Clin Infect Dis** 1996 Oct;23(4):845–6

Long-term follow-up of multifocal osteoarticular sporotrichosis treated with itraconazole. Badley AD, et al. **Clin Infect Dis** 1996 Aug;23(2):394–5

Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus. Baily GG, et al. **Clin Infect Dis** 1997 Jul;25(1):161–3

Therapeutic outcome in invasive aspergillosis. Denning DW. **Clin Infect Dis** 1996 Sep;23(3):608–15 (110 ref.)

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [see comments] Edwards JE Jr, et al. **Clin Infect Dis** 1997 Jul;25(1):43–59 (89 ref.). Comment in: Clin Infect Dis 1997 Jul;25(1):60–2.

Successful treatment of fungal prosthetic valve endocarditis: case report and review [see comments] Gilbert HM, et al. **Clin Infect Dis** 1996 Feb;22(2):348–54 (52 ref.). Comment in: Clin Infect Dis 1996 Dec;23(6):1338–40.

Can we agree on the treatment of candidiasis? [editorial; comment] Graybill JR. **Clin Infect Dis** 1997 Jul;25(1):60–2. Comment on: Clin Infect Dis 1997 Jul;25(1):43–59.

Fluconazole monotherapy for candidal meningitis in a premature infant. Gürses N, et al. **Clin Infect Dis** 1996 Sep; 23(3):645–6

Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Kauffman CA, et al. **Clin Infect Dis** 1996 Jan;22(1):46–50

Resistance to fluconazole and amphotericin B in a patient with AIDS who was being treated for candidal esophagitis. Le TP, et al. **Clin Infect Dis** 1996 Sep;23(3):649–50

Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Maenza JR, et al. **Clin Infect Dis** 1997 Jan;24(1):28–34

Survival of a liver graft recipient treated for an aspergillar liver abscess. Mazza D, et al. **Clin Infect Dis** 1996 Oct; 23(4):831–2

Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Pons V, et al. **Clin Infect Dis** 1997 Jun; 24(6):1204–7

Editorial response: management of cryptococcal meningitis--have we answered all the questions? [editorial; comment] Powderly WG. **Clin Infect Dis** 1996 Feb; 22(2):329–30. Comment on: Clin Infect Dis 1996 Feb;22(2):315–21. Comment on: Clin Infect Dis 1996 Feb;22(2):322–8.

Treatment of cerebral Aspergillosis with itraconazole: do high doses improve the prognosis? [see comments] Sánchez C, et al. **Clin Infect Dis** 1995 Dec;21(6):1485–7 (12 ref.). Comment in: Clin Infect Dis 1996 Nov;23(5):1196–7.

Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS [see comments] Sharkey PK, et al. **Clin Infect Dis** 1996 Feb;22(2):315–21. Comment in: Clin Infect Dis 1996 Feb;22(2):329–30.

Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Sobel JD, et al. **Clin Infect Dis** 1997 Apr;24(4):649–52

Fluconazole-resistant Candida parapsilosis fungemia in a patient with AIDS. Tumbarello M, et al. **Clin Infect Dis** 1996 Jan;22(1):179–80

The contribution of fluconazole to the changing epidemiology of invasive candidal infections [editorial; comment] White MH. **Clin Infect Dis** 1997 Jun; 24(6):1129–30. Comment on: Clin Infect Dis 1997 Jun;24(6):1122–6.

Antifungal prophylaxis during neutropenia and immunodeficiency. Lortholary O, et al. **Clin Microbiol Rev** 1997 Jul;10(3):477–504 (390 ref.)

Newer systemic antifungal drugs for the treatment of onychomycosis. Chiritescu MM, et al. **Clin Podiatr Med Surg** 1996 Oct;13(4):741–58 (758 ref.)

Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Einarson TR. **Clin Ther** 1997 May–Jun; 19(3):559–69; discussion 538–9

Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Murray PA, et al. **Clin Ther** 1997 May–Jun;19(3):471–80

Fungal infections: a survey of laboratory services for diagnosis and treatment. Barnes RA, et al. **Commun Dis Rep CDR Rev** 1996 Apr 26;6(5):R69–75

Corneal chromoblastomycosis. Barton K, et al. **Cornea** 1997 Mar;16(2):235–9 (18 ref.)

Are we making progress in antifungal therapy? Martino P, et al. **Curr Opin Oncol** 1997 Jul;9(4):314–20 (56 ref.)

Itraconazole in the treatment of tinea capitis. Degreef H. **Cutis** 1996 Jul;58(1):90–3

Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis. Elewski BE, et al. **Cutis** 1996 Oct;58(4):305–7

Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Elewski BE, et al. **Cutis** 1997 Apr; 59(4):217–20

Itraconazole therapy for onychomycosis: case reports. Kirshbaum BA. **Cutis** 1996 Nov;58(5):371–4

Significance of non-dermatophyte moulds and yeasts in onychomycosis. Ellis DH, et al. **Dermatology** 1997;194 Suppl 1:40–2

Tinea pedis: clinical experience and efficacy of short treatment. Evans EG. **Dermatology** 1997;194 Suppl 1:3–6 (13 ref.)

Entomophthoramycosis: therapeutic success by using amphotericin B and terbinafine. Foss NT, et al. **Dermatology** 1996;193(3):258–60

Onychomycosis--treatment, relapse and re-infection. Hull PR. **Dermatology** 1997;194 Suppl 1:7–9 (18 ref.)

Controversies in medical mycology. Rinaldi MG. **Dermatology** 1997;194 Suppl 1:45–7

Tinea corporis/cruris: new treatment options. van Heerden JS, et al. **Dermatology** 1997;194 Suppl 1:14–8

Candida: a review of clinical experience with Lamisil. Zaias N. **Dermatology** 1997;194 Suppl 1:10–3 (5 ref.)

Antifungal agents in the 1990s. Current status and future developments. Kauffman CA, et al. **Drugs** 1997 Apr; 53(4):539–49 (109 ref.)

Treatment and prophylaxis of tinea infections. Piérard GE, et al. **Drugs** 1996 Aug;52(2):209–24 (188 ref.)

Oral fluconazole in the treatment of pulmonary cryptococcosis in non-AIDS patients. Yew WW, et al. **Drugs Exp Clin Res** 1996;22(1):25–8

Lichen planus esophagitis with secondary candidiasis: successful combination treatment with ketoconazole and a corticosteroid. Ali A, et al. **Endoscopy** 1996 Jun;28(5):460

Fungi fighting back [news] **Environ Health Perspect** 1997 Jan;105(1):26–7

Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Viscoli C, et al. **Eur J Cancer** 1996 May;32A(5):814–20

Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Fortún J, et al. **Eur J Clin Microbiol Infect Dis** 1997 Apr;16(4):314–8

A case of Alternaria keratitis treated with fluconazole [letter] Koç AN, et al. **Eur J Clin Microbiol Infect Dis** 1997 Apr; 16(4):322–3

Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Phillips P, et al. **Eur J Clin Microbiol Infect Dis** 1997 May;16(5):337–45

Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group. Troke PF. **Eur J Clin Microbiol Infect Dis** 1997 Apr;16(4):287–95

Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy [letter] Verweij PE, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):26–8

Pradimicins: a novel class of broad-spectrum antifungal compounds. Walsh TJ, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jan;16(1):93–7 (27 ref.)

Fluconazole monotherapy for cryptococcosis in non-AIDS patients. Yamaguchi H, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):787–92

Tribological and mycological consequences of the use of a miconazole nitrate-containing paste for the prevention of diaper dermatitis: an open pilot study. Piérard-Franchimont C, et al. **Eur J Pediatr** 1996 Sep; 155(9):756–8

Antifungal agents in neonatal systemic candidiasis [letter] van den Anker JN. **Eur J Pediatr** 1997 Aug;156(8):666

Effect of long-term primary aerosolized pentamidine prophylaxis on breakthrough Pneumocystis carinii pneumonia. Ewig S, et al. **Eur Respir J** 1996 May; 9(5):1006–12

The use of over-the-counter antifungal vaginitis preparations by college students. Lipsky MS, et al. **Fam Med** 1996 Jul–Aug;28(7):493–5

Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis. Barbaro G, et al. **Gastroenterology** 1996 Nov; 111(5):1169–77

Combined treatment with amphotericin-B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation. Catalano L, et al. **Haematologica** 1997 Jan–Feb;82(1):71–2

Fluconazole in the management of neonatal systemic candidiasis. Narang A, et al. **Indian Pediatr** 1996 Oct; 33(10):823–6

Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Walsh TJ, et al. **Infect Dis Clin North Am** 1996 Jun;10(2):365–400 (179 ref.)

A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Abele-Horn M, et al. **Infection** 1996 Nov–Dec;24(6):426–32

Nosocomial Cryptococcus laurentii fungemia in a bone marrow transplant patient after prophylaxis with ketoconazole successfully treated with oral fluconazole [letter] Krcméry V Jr, et al. **Infection** 1997 Mar–Apr; 25(2):130

Fatal Trichosporon pullulans breakthrough fungemia in cancer patients: report of three patients who failed on prophylaxis with itraconazole [letter] Kunová A, et al. **Infection** 1996 May–Jun;24(3):273–4

Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: case report and review of the literature. Weers-Pothoff G, et al. **Infection** 1997 Mar–Apr;25(2):109–11 (25 ref.)

Fluconazole in Candida albicans sepsis during pregnancy: case report and review of the literature. Wiesinger EC, et al. **Infection** 1996 May–Jun;24(3):263–6

Topical anti-inflammatory properties of flutrimazole, a new imidazole antifungal agent. Merlos M, et al. **Inflamm Res** 1996 Jan;45(1):20–5

Fungal peritonitis in continuous ambulatory peritoneal dialysis [editorial] Saran R, et al. **Int J Artif Organs** 1996 Aug;19(8):441–5 (55 ref.)

Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Ablon G, et al. **Int J Dermatol** 1996 Aug;35(8):591–3

Tinea versicolor with generalized anhidrosis [letter] Bhargava P, et al. **Int J Dermatol** 1996 Sep;35(9):683

Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of both. Bonifaz A, et al. **Int J Dermatol** 1997 Jul;36(7):542–7

Treatment of tinea capitis with itraconazole. Elewski BE. **Int J Dermatol** 1997 Jul;36(7):539–41

Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. Jones HE, et al. **Int J Dermatol** 1996 Aug;35(8):589–90

Econazole 1% shampoo versus selenium in the treatment of tinea versicolor: a single-blind randomized clinical study. Katsambas A, et al. **Int J Dermatol** 1996 Sep;35(9):667–8

Fluconazole in the treatment of severe onychomycosis. Montero-Gei F, et al. **Int J Dermatol** 1996 Aug;35(8):587–8

Rationalizing prescribing for oral and oesophageal candidiasis. Taylor CB, et al. **Int J STD AIDS** 1996 Oct; 7(6):452

Atovaquone as prophylaxis for Pneumocystis carinii [letter] Vilar FJ, et al. **Int J STD AIDS** 1996 Jul;7(4):302

Mycotic keratitis: susceptibility to antiseptic agents. Martin MJ, et al. **Int Ophthalmol** 1995-96;19(5):299–302

New antifungal drugs in ophthalmology. O'Day DM. **Int Ophthalmol Clin** 1996 Spring;36(2):45–51 (27 ref.)

Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU.

Nolla-Salas J, et al. **Intensive Care Med** 1997 Jan; 23(1):23–30

Effect of combined antibacterial and antifungal treatment in severe atopic dermatitis [see comments] Kolmer HL, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):702–7. Comment in: J Allergy Clin Immunol 1997 Jun;99(6 Pt 1):861.

Overview of topical therapy for common superficial fungal infections and the role of new topical agents. Brennan B, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):S3–8

Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. De Doncker PR, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):173–7

First report of mycetoma caused by Arthrographis kalrae: successful treatment with itraconazole. Degavre B, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):318–20 (15 ref.)

Treatment of tinea capitis with itraconazole. Greer DL. **J Am Acad Dermatol** 1996 Oct;35(4):637–8

Itraconazole in the prevention and management of dermatophytosis in competitive wrestlers. Hazen PG, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 1):481–2

Randomized single-blind study of efficacy and tolerability of terbinafine in the treatment of tinea capitis. Kullavanijaya P, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 1):272–3

Butenafine 1% cream in the treatment of tinea cruris: a multicenter, vehicle-controlled, double-blind trial. Lesher JL Jr, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):S20–4

Update on topical therapy for superficial fungal infections: focus on butenafine. Odom RB. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):S1–2

Treatment of Candida nail infection with terbinafine. Segal R, et al. **J Am Acad Dermatol** 1996 Dec;35(6):958–61

Fluconazole for the treatment of tinea capitis in children. Solomon BA, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 1):274–5

Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. Del Rosso JQ. **J Am Osteopath Assoc** 1997 Jun;97(6):339–46 (48 ref.)

Ocular blastomycosis in dogs: 73 cases, 108 eyes (1985–1993). Bloom JD, et al. **J Am Vet Med Assoc** 1996 Oct 1; 209(7):1271–4

Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs. Krawiec DR, et al. **J Am Vet Med Assoc** 1996 Dec 15;209(12):2073–5

Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. Böhme A, et al. **J Antimicrob Chemother** 1996 Dec; 38(6):953–61

Candida infections in the surgical intensive care unit [letter] Fass RJ, et al. **J Antimicrob Chemother** 1996 Nov; 38(5):915–6

Therapeutic effects of omoconazole nitrate on guinea-pigs experimentally infected with Trichophyton mentagrophytes. Itoyama T, et al. **J Antimicrob Chemother** 1997 Jun;39(6):825–7

Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. Leenders AC, et al. **J Antimicrob Chemother** 1996 Aug;38(2):215–25

Pneumocystis carinii infection: current treatment and prevention. Miller RF, et al. **J Antimicrob Chemother** 1996 May;37 Suppl B:33–53 (90 ref.)

ZD0870 treatment of murine candidiasis caused by fluconazole resistant isolates of Candida albicans. Najvar LK, et al. **J Antimicrob Chemother** 1996 Oct;38(4):671–7

The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole. Ohtsuka K, et al. **J Antimicrob Chemother** 1997 Jan; 39(1):71–7

Safety and efficacy of Intralipid emulsions of amphotericin B. Sievers TM, et al. **J Antimicrob Chemother** 1996 Sep; 38(3):333–47

Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. Tumbarello M, et al. **J Antimicrob Chemother** 1996 Oct;38(4):691–9

Ketoconazole in antimonial unresponsive cases of Kala-azar. Jha TK, et al. **J Assoc Physicians India** 1995 May;43(5):347

Susceptibility testing of fungi and correlation with clinical outcome. Ghannoum MA. **J Chemother** 1997 May;9 Suppl 1:19–24 (49 ref.)

Failure of ketoconazole in oriental sore in India. Singh S, et al. **J Chemother** 1995 Nov;7 Suppl 4:202–3

Fluconazole versus itraconazole in therapy of oropharyngeal candidiasis in cancer patients: a prospective comparative randomized trial. Studena V, et al. **J Chemother** 1995 Nov; 7 Suppl 4:204–5

Fluconazole therapy for postoperative Candida infections and in coccidioidomycosis. Thadepalli H, et al. **J Chemother** 1995 Nov;7 Suppl 4:193–5

Evaluation of the activities of rifabutin combined with atovaquone or low-dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model. Brun-Pascaud M, et al. **J Eukaryot Microbiol** 1996 Sep-Oct;43(5):14S–15S

Clinically achievable plasma deferoxamine concentrations eliminate Pneumocystis carinii trophozoites in a rat model. Merali S, et al. **J Eukaryot Microbiol** 1996 Sep-Oct; 43(5):52S

Onychomycosis [letter; comment] Domke H. **J Fam Pract** 1996 Oct;43(4):330. Comment on: J Fam Pract 1996 May;42(5):513–8.

Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis. Barnes AJ, et al. **J Infect** 1996 Jul;33(1):43–5

Treatment of non-meningeal cryptococcosis in patients with AIDS. Centre d'Informations et de Soins de l'Immunodéficience Humaine de l'Est Parisien. Meyohas MC, et al. **J Infect** 1996 Jul;33(1):7–10

Experience with infection by Scedosporium prolificans including apparent cure with fluconazole therapy. Pickles RW, et al. **J Infect** 1996 Nov;33(3):193–7

Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Revankar SG, et al. **J Infect Dis** 1996 Oct;174(4):821–7

Fluconazole treatment of neonates and infants with severe fungal infections. Gürpinar AN, et al. **J Int Med Res** 1997 Jul-Aug;25(4):214–8

Itraconazole for treatment of oral candidosis in pediatric cancer patients. Aanpreung P, et al. **J Med Assoc Thai** 1997 Jun;80(6):358–62

Clinical efficacy of itraconazole with initial flucytosine in AIDS-related cryptococcal meningitis: a preliminary study. Riantawan P, et al. **J Med Assoc Thai** 1996 Jul; 79(7):429–33

Therapy of systemic histoplasmosis in immunosuppressed mice with the triazole D0870. Clemons KV, et al. **J Med Vet Mycol** 1996 Jul-Aug;34(4):241–6

Meningitis caused by Rhodotorula rubra in an HIV-infected patient. Gyaurgieva OH, et al. **J Med Vet Mycol** 1996 Sep-Oct;34(5):357–9

Discrepancy between in vitro and in vivo antifungal activity of albendazole. Hardin TC, et al. **J Med Vet Mycol** 1997 May-Jun;35(3):153–8

Invasive Fusarium infections: a retrospective survey of 31 cases. The French 'Groupe d'Etudes des Mycoses Opportunistes' GEMO. Hennequin C, et al. **J Med Vet Mycol** 1997 Mar-Apr;35(2):107–14

Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. Spinillo A, et al. **J Reprod Med** 1997 Feb;42(2):83–7

New combination for the therapy of canine otitis externa. I. Microbiology of otitis externa. Kiss G, et al. **J Small Anim Pract** 1997 Feb;38(2):51–6

New combination for the therapy of canine otitis externa. II. Efficacy in vitro and in vivo. Kiss G, et al. **J Small Anim Pract** 1997 Feb;38(2):57–60

Treatment of coccidioidal spinal infection: experience in 16 cases. Herron LD, et al. **J Spinal Disord** 1997 Jun; 10(3):215–22 (11 ref.)

Nursery outbreak of neonatal fungal arthritis treated with fluconazole. Merchant RH, et al. **J Trop Pediatr** 1997 Apr; 43(2):106–8

Treatment of blastomycosis with itraconazole in 112 dogs. Legendre AM, et al. **J Vet Intern Med** 1996 Nov-Dec; 10(6):365–71

Contempo 1997: dermatology [letter] Del Rosso JQ. **JAMA** 1997 Oct 8;278(14):1148; discussion 1149

Open label trial of the efficacy and tolerability of Lamisil (Terbinafine) 500 mg once daily in the treatment of onychomycosis due to candida. Zaidi Z, et al. **JPMA J Pak Med Assoc** 1996 Nov;46(11):258–60

Tinea of the skin, hair and nails [letter; comment] Quinn DI. **Med J Aust** 1996 Sep 16;165(6):350–1. Comment on: Med J Aust 1996 May 6;164(9):552–6.

Systemic antifungal drugs. **Med Lett Drugs Ther** 1997 Sep 12;39(1009):86–8

Antiinflammatory activity of topically applied sertaconazole nitrate. Agut J, et al. **Methods Find Exp Clin Pharmacol** 1996 May;18(4):233–4

Primary cutaneous cryptococcosis following trauma of the right forearm. Bohne T, et al. **Mycoses** 1996 Nov-Dec; 39(11-12):457–9

Long-term observation of a case of cutaneous blastomycosis in Poland treated with fluconazole. Chodorowska G, et al. **Mycoses** 1996 Jul-Aug;39(7-8):283–7

Evaluation of himachalol in murine invasive aspergillosis. Chowdhry L, et al. **Mycoses** 1996 Nov-Dec; 39(11-12):449–52

Tracheobronchial aspergillosis in a patient with AIDS treated with aerosolized amphotericin B combined with itraconazole. Dal Conte I, et al. **Mycoses** 1996 Sep-Oct; 39(9-10):371–4

Fluconazole in the prophylaxis of fungal infection after bone marrow transplantation. Ehninger G, et al. **Mycoses** 1996 Jul-Aug;39(7-8):259–63

Microsporum canis infections in children: results of a new oral antifungal therapy. Ginter G. **Mycoses** 1996 Jul-Aug; 39(7-8):265–9

Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbiological and clinical aspects. Glasmacher A, et al. **Mycoses** 1996 Jul-Aug; 39(7-8):249–58 (117 ref.)

Oral terbinafine in tinea capitis in children. Gruseck E, et al. **Mycoses** 1996 May-Jun;39(5-6):237–40

Retrospective analysis of yeast colonization and infections in paediatric bone marrow transplant recipients. Hoppe JE, et al. **Mycoses** 1997 Jan-Feb;40(1-2):47–54

Disseminated infection with Trichosporon asahii. Itoh T, et al. **Mycoses** 1996 May-Jun;39(5-6):195–9

Efficacy of ajoene, an organosulphur derived from garlic, in the short-term therapy of tinea pedis. Ledezma E, et al. **Mycoses** 1996 Sep-Oct;39(9-10):393–5

Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Schäfer-Korting M, et al. **Mycoses** 1996 Sep-Oct;39(9-10):329–39 (35 ref.)

A new pharmaceutical concept for the treatment of oropharyngeal and oesophageal candidosis with fluconazole. Wildfeuer A, et al. **Mycoses** 1996 Sep-Oct; 39(9-10):357–60

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. van der Horst CM, et al. **N Engl J Med** 1997 Jul 3;337(1):15–21

Effects of ketoconazole on plasma lipids and lipoprotein(a) in familial hypercholesterolaemia, compared with simvastatin [see comments] Stalenhoef AF, et al. **Neth J Med** 1997 Jul;51(1):10–5. Comment in: Neth J Med 1997 Jul;51(1):v–vii.

Resistance to antifungal agents in the critical care setting: problems and perspectives. Martins MD, et al. **New Horiz** 1996 Aug;4(3):338–44 (37 ref.)

Antifungal powder helps to reduce skin reactions. Brown CN, et al. **Oncol Nurs Forum** 1996 Oct;23(9):1483

Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. Christmas NJ, et al. **Ophthalmic Surg Lasers** 1996 Dec;27(12):1012–8

Itraconazole in the treatment of orbital aspergillosis. Massry GG, et al. **Ophthalmology** 1996 Sep;103(9):1467–70

Implications of early systemic therapy on the incidence of endogenous fungal endophthalmitis. Scherer WJ, et al. **Ophthalmology** 1997 Oct;104(10):1593–8

Successful treatment of onychomycosis with fluconazole in two patients with hyperimmunoglobulin E syndrome. Aihara Y, et al. **Pediatr Dermatol** 1996 Nov-Dec; 13(6):493–5

The successful treatment of oral candidiasis (thrush) in a pediatric patient using itraconazole [letter] Crutchfield CE 3rd, et al. **Pediatr Dermatol** 1997 May-Jun;14(3):246

Itraconazole responsive tinea capitis in an HIV-infected child. Smith RL, et al. **Pediatr Dermatol** 1996 Jul-Aug; 13(4):313–5

Itraconazole in the treatment of two young brothers with chronic mucocutaneous candidiasis. Tosti A, et al. **Pediatr Dermatol** 1997 Mar-Apr;14(2):146–8

Treatment with bifonazole shampoo for scalp seborrhea in infants and young children. Zeharia A, et al. **Pediatr Dermatol** 1996 Mar-Apr;13(2):151–3

Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris. Bakos L, et al. **Pediatr Infect Dis J** 1997 Jun;16(6):545–8

Successful therapy of Candida albicans arthritis with a sequential intravenous amphotericin B and oral fluconazole regimen. Barson WJ, et al. **Pediatr Infect Dis J** 1996 Dec; 15(12):1119–22 (42 ref.)

Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Driessen M, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1107–12

Orbitofascial conidiobolomycosis in a child. al-Hajjar S, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1130–2 (15 ref.)

Treatment of oropharyngeal candidiasis in immunocompetent infants: a randomized multicenter study of miconazole gel vs. nystatin suspension. The Antifungals Study Group. Hoppe JE. **Pediatr Infect Dis J** 1997 Mar;16(3):288–93

Disseminated histoplasmosis in children: the role of itraconazole therapy. Tobón AM, et al. **Pediatr Infect Dis J** 1996 Nov;15(11):1002–8

Prospective study of fluconazole therapy in systemic neonatal fungal infection. Wainer S, et al. **Pediatr Infect Dis J** 1997 Aug;16(8):763–7

Fluconazole for treatment of fungal infections of the urinary tract in children. Zia-ul-Miraj M, et al. **Pediatr Surg Int** 1997 Jul;12(5-6):414–6

The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient. Kramer KM, et al. **Pharmacotherapy** 1997 May-Jun; 17(3):538–48 (44 ref.)

Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. Zeind CS, et al. **Pharmacotherapy** 1996 Jul-Aug;16(4):547–61 (127 ref.)

Superficial fungal infections. Errors to avoid in diagnosis and treatment. Brodell RT, et al. **Postgrad Med** 1997 Apr; 101(4):279–87 (29 ref.)

Nosocomial cerebral aspergillosis: a report of 3 cases. Darras-Joly C, et al. **Scand J Infect Dis** 1996;28(3):317–9 (28 ref.)

Treatment of Pneumocystis carinii pneumonia in adults with AIDS. Deresinski SC. **Semin Respir Infect** 1997 Jun; 12(2):79–97 (142 ref.)

Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Reichenspurner H, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):627–8

Update on antifungal resistance. Klepser ME, et al. **Trends Microbiol** 1997 Sep;5(9):372–5 (51 ref.)

Ketoconazole in the treatment of visceral leishmaniasis (kala-azar) [letter; comment] Ahasan HA, et al. **Trop Doct** 1996 Oct;26(4):197–8. Comment on: Trop Doct 1995 Apr;25(2):80–1.

Mucormycosis. Adjunctive therapy with hydrogen peroxide. Blaine DA, et al. **Va Med Q** 1996 Winter;123(1):30–2

Cutaneous protothecosis in a dog. Ginel PJ, et al. **Vet Rec** 1997 Jun 21;140(25):651–3

Onychomycosis—a different perspective [letter] Epstein E. **West J Med** 1997 Jul;167(1):52–3

Onychomycosis. New therapies for an old disease. Gupta AK, et al. **West J Med** 1996 Dec;165(6):349–51

Update on treatment of coccidioidomycosis [published erratum appears in West J Med 1997 Apr;166(4):291] Mirels LF, et al. **West J Med** 1997 Jan;166(1):58–9

[The treatment of acute mycotic colpitis with ciclopiroxolamine in patients using oral contraceptives] Damianov L, et al. **Akush Ginekol (Sofiia)** 1997;36(1):32–3 (Eng. Abstr.) **(Bul)**

[A multiple center clinical trial on fluconazole for deep-seated fungal infections] Liang D, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Dec;34(12):823–6 (Eng. Abstr.) **(Chi)**

[Failure of terbinafine treatment in 2 children with tinea capitis (letter; comment)] Stolz E. **Ned Tijdschr Geneeskd** 1996 Sep 7;140(36):1833. Comment on: Ned Tijdschr Geneeskd 1996 Aug 3;140(31):1611–2. **(Dut)**

[2 cases of cryptococcosis in cats] Tjalsma EJ. **Tijdschr Diergeneeskd** 1997 Mar 1;122(5):128–32 (Eng. Abstr.) **(Dut)**

[Oxiconazole cream versus ketoconazole cream. A prospective, randomized, double-blind, multicenter study in the treatment of inguinocrural dermatophytoses] Kalis B, et al. **Ann Dermatol Venereol** 1996;123(8):447–52 (Eng. Abstr.) **(Fre)**

[Azole antifungal agents in the prevention of fungal infections in neutropenic patients and bone marrow graft recipients] Lortholary O, et al. **Ann Med Interne (Paris)** 1997; 148(3):258–67 (106 ref.) (Eng. Abstr.) **(Fre)**

[Review of the latest treatments of vulvovaginal mycoses: role of fenticonazole nitrate (Lomexin) in their treatment] Cohen J. **Contracept Fertil Sex** 1997 May;25(5):396–403 (35 ref.) (Eng. Abstr.) **(Fre)**

[Info-congress. Itraconazole in the treatment of dermatomycoses and onychomycoses. Current concept of intermittent therapy using weekly units repeated monthly] Piérard GE, et al. **Rev Med Liege** 1996 Nov;51(11):729–30 **(Fre)**

[Example of active therapeutic follow-up: itraconazole] Levron JC, et al. **Therapie** 1996 Sep–Oct;51(5):502–6 (Eng. Abstr.) **(Fre)**

[News in the therapy of onychomycoses (Itraconazole)] **Hautarzt** 1995 Nov;46(11 Suppl):1–8 **(Ger)**

[Fungal infections of the skin. Itraconazol means a great advance in therapy] **Hautarzt** 1994 Sep;45(9 Suppl):1–4 **(Ger)**

[Clinical fluconazole and itraconazole resistance of oro-gastrointestinal candidiasis in a patient with AIDS] Tebbe B, et al. **Hautarzt** 1996 Feb;47(2):136–9 (Eng. Abstr.) **(Ger)**

[Focusing on therapy of systemic mycoses] **Internist (Berl)** 1995 Dec;36(12 Suppl):1–12 **(Ger)**

[Prevention, diagnosis and therapy of infections in patients with malignant diseases] Hiddemann W, et al. **Internist (Berl)** 1996 Dec;37(12):1212–24 (56 ref.) **(Ger)**

[Therapy of infections in patients with acute leukemia] Hiddemann W, et al. **Med Klin** 1997 Jul 15;92(7):406–9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Effect of orally administered polyene antimycotics on the intestinal colonization with yeasts: possibilities and limitations] Blaschke-Hellmessen R, et al. **Mycoses** 1996; 39 Suppl 1:33–9 (17 ref.) (Eng. Abstr.) **(Ger)**

[Antifungal prophylaxis in neutropenic cancer patients and in allogeneic bone marrow transplantation] Blau IW, et al. **Mycoses** 1996;39 Suppl 1:81–6 (52 ref.) (Eng. Abstr.) **(Ger)**

[Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis] Eichel M, et al. **Mycoses** 1996; 39 Suppl 1:102–6 (Eng. Abstr.) **(Ger)**

[Increasing frequency of onychomycoses—is there a change in the spectrum of infectious agents?] Ginter G, et al. **Mycoses** 1996;39 Suppl 1:118–22 (Eng. Abstr.) **(Ger)**

[Osteomyelitis from Cryptococcus neoformans] Hummel H, et al. **Mycoses** 1996;39 Suppl 1:94–6 (Eng. Abstr.) **(Ger)**

[Prerequisites for effective therapy of chronic recurrent vaginal candidiasis] Kunzelmann V, et al. **Mycoses** 1996; 39 Suppl 1:65–72 (Eng. Abstr.) **(Ger)**

[Plasma and tissue concentrations of fluconazole: discussion of the breakpoint problem] Pittrow L, et al. **Mycoses** 1996; 39 Suppl 2:58–65 (44 ref.) (Eng. Abstr.) **(Ger)**

[Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility of yeasts] Wildfeuer A, et al. **Mycoses** 1996;39 Suppl 2:51–7 (42 ref.) (Eng. Abstr.) **(Ger)**

[A new pharmaceutical concept for the therapy of oropharyngeal and esophageal candidiasis with fluconazole] Wildfeuer A, et al. **Mycoses** 1996;39 Suppl 1:123–6 (Eng. Abstr.) **(Ger)**

[Fungal infections in primary care] Schaffner A. **Schweiz Rundsch Med Prax** 1996 Oct 1;85(40):1236–9 (Eng. Abstr.) **(Ger)**

[A clinical evaluation of fluconazole in deep seated fungal infections associated with hematological disorders] Murakami S, et al. **Jpn J Antibiot** 1996 Jan;49(1):95–105 (Eng. Abstr.) **(Jpn)**

[Fundamental and clinical studies on the efficacy of bifonazole in patients with tinea pedis at 10 years after approval. Part 2. Clinical evaluation] Watanabe S, et al. **Jpn J Antibiot** 1996 Dec;49(12):1095–108 (Eng. Abstr.) **(Jpn)**

[Allergic bronchopulmonary aspergillosis successfully treated with itraconazole] Matsuzaki Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Mar;35(3):352–6 (Eng. Abstr.) **(Jpn)**

[Fungal myocarditis] Kubo N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):138–40 (14 ref.) **(Jpn)**

[Chronic semi-invasive aspergillosis with broncho-pleural fistula treated with itraconazole and surgically] Nalepa P, et al. **Pneumonol Alergol Pol** 1996;64(7–8):472–7 (Eng. Abstr.) **(Pol)**

[Use of Diflucan in the treatment of chronic and recurrent candidosis with involvement of the esophagus] Barantsevich EP, et al. **Klin Med (Mosk)** 1996;74(5):55–7 (Eng. Abstr.) **(Rus)**

[Systemic mycoses: therapy with a new antifungal drug diflucan] Barantsevich EP. **Klin Med (Mosk)** 1996; 74(4):52–4 (Eng. Abstr.) **(Rus)**

[Treatment of AIDS and associated diseases] Rytik PG. **Klin Med (Mosk)** 1997;75(1):5–10 (22 ref.) **(Rus)**

[Obstructive renal insufficiency due to Candida. Fluconazole as a valid alternative to classical therapy] Díez-Delgado Rubio J, et al. **An Esp Pediatr** 1997 Mar;46(3):296–8 **(Spa)**

[Systemic candidiasis in heroin addicts: therapeutic considerations (letter; comment)] Márquez de Prado Urquia M, et al. **An Med Interna** 1997 Mar;14(3):155–6. Comment on: An Med Interna 1994 Nov;11(11):537–40. **(Spa)**

[Curative treatment with fluconazole in 5 cases of invasive candidiasis] Martínez-Marcos FJ, et al. **Enferm Infecc Microbiol Clin** 1996 Nov;14(9):541–4 (Eng. Abstr.) **(Spa)**

[Fluconazole (Diflucan): its clinical spectrum and development] Espejo Martínez J, et al. **Rev Clin Esp** 1997 Apr;197 Suppl 1:86–93 (34 ref.) **(Spa)**

[Emergency of fluconazole-resistant infections by Candida krusei and Candida glabrata in neutropenic patients (letter)] Piemonte P, et al. **Rev Med Chil** 1996 Sep;124(9):1149 **(Spa)**

TOXICITY

Differential poisoning of human and Aspergillus nidulans DNA topoisomerase I by bi- and terbenzimidazoles. Goldman GH, et al. **Biochemistry** 1997 May 27; 36(21):6488–94

Increased frequencies of sister chromatid exchanges and micronuclei in "in vitro" lymphocyte cultures treated with the fungicides thiram and ziram. Ardito G, et al. **Boll Soc Ital Biol Sper** 1997 Jan–Feb;73(1–2):1–7

Ciprofloxacin was the culprit—not itraconazole [letter; comment] de'Clari F. **Clin Infect Dis** 1997 Jan;24(1):96. Comment on: Clin Infect Dis 1995 Aug;21(2):456.

Inhibition of mitochondrial function in isolated rate liver mitochondria by azole antifungals. Rodriquez RJ, et al. **J Biochem Toxicol** 1996;11(3):127–31

Ketoconazole and phorbol myristate acetate regulate osteoclast precursor fusion in primary murine marrow culture. Fan X, et al. **J Bone Miner Res** 1996 Sep; 11(9):1274–80

Characterization of pregnancy outcome following thiram-induced ovulatory delay in the female rat. Stoker TE, et al. **Neurotoxicol Teratol** 1996 May-Jun;18(3):277–82

N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Rodriguez RJ, et al. **Toxicology** 1997 Feb 28;117(2–3):123–31

Amphotericin B: new life for an old drug. Hartsel S, et al. **Trends Pharmacol Sci** 1996 Dec;17(12):445–9 (51 ref.)

ANTIGAMMA GLOBULIN ANTIBODIES see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTIGEN-ANTIBODY COMPLEX

see related
IMMUNE COMPLEX DISEASES

A cytosolic calcium transient is not necessary for degranulation or oxidative burst in immune complex-stimulated neutrophils. Seetoo KF, et al. **J Leukoc Biol** 1997 Sep;62(3):329–40

Monocytes/macrophages rather than PMN are involved in early cartilage degradation in cationic immune complex arthritis in mice. Van Lent PL, et al. **J Leukoc Biol** 1997 Mar;61(3):267–78

Epitope mapping antibody-antigen complexes by nuclear magnetic resonance spectroscopy. Kustanovich I, et al. **Methods Mol Biol** 1996;66:25–37

[Immune complexes induce the secretion of Th2 cytokines in human monocytes] Berger S, et al. **Verh Dtsch Ges Pathol** 1996;80:288–92 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Immune complex-mediated haemolytic anaemia and Evans syndrome induced by diclofenac. de Quirós JF, et al. **Vox Sang** 1997;72(2):121–3

ANALYSIS

Detection of microfilarial antigen in circulating immune complex from sera of Wuchereria bancrofti-infected individuals. Kobayashi M, et al. **Am J Trop Med Hyg** 1997 Aug;57(2):200–4

Antigen/antibody content of circulating immune complexes in HIV-infected patients. Stanojevic M, et al. **Biomed Pharmacother** 1996;50(10):488–93

Detection of hepatitis C virus RNA in circulating immune complexes by RT-PCR. Morita T, et al. **Hepatogastroenterology** 1996 May-Jun;43(9):582–5

A change in the localization of the region trapping immune complexes in rat popliteal lymph nodes during development of germinal centers, with regard to the distribution of follicular dendritic cells. Sato H, et al. **Histol Histopathol** 1996 Apr;11(2):293–302

Immune complex-dissociated p24 antigen in congenital or perinatal HIV infection: role in the diagnosis and assessment of risk of infection in infants. Rich KC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jul 1;15(3):198–203

Critical evaluation of the applicability of capillary zone electrophoresis for the study of hapten-antibody complex formation. Busch MH, et al. **J Chromatogr A** 1996 Sep 13;744(1–2):195–203

Improvements in a competition assay to detect scrapie prion protein by capillary electrophoresis. Schmerr MJ, et al. **J Chromatogr B Biomed Appl** 1996 May 31;681(1):29–35

Correspondence re: Mac-Moune Lai F, To KF, Wang A, et al.: ultrastructural calcification of glomerular immune complexes. Mod Pathol 9:36, 1996 [letter; comment] Trillo A. **Mod Pathol** 1996 Jul;9(7):800–1. Comment on: Mod Pathol 1996 Jan;9(1):36–40.

Autoantibodies, immunoglobulins, complement and circulating immune complexes in acute malaria. Jhaveri KN, et al. **Natl Med J India** 1997 Jan–Feb;10(1):5–7

Post-OKT3 induction therapy CD complex response predicts renal allograft rejection. Stephan RN, et al. **Transplantation** 1997 Apr 27;63(8):1183–6

Glomerular handling of immune complex in the acute phase of active in situ immune complex glomerulonephritis employing cationized ferritin in rats. Ultrastructural localization of immune complex, complements and inflammatory cells. Fujigaki Y, et al. **Virchows Arch** 1997 Jul;431(1):53–61

[The antigen (CANDTEC antigen) detected by CAND TEC test for diagnosis of candidiasis] Mitsuya M, et al. **Rinsho Byori** 1996 Jun;44(6):512–7 (Eng. Abstr.) **(Jpn)**

[Two cases of lupus nephritis having a high titer of anti-(histone-DNA) complex antibody without IgG anti-dsDNA antibody] Mizushima N, et al. **Rinsho Byori** 1996 Jun;44(6):585–9 (Eng. Abstr.) **(Jpn)**

[Study of immunological parameters in radiography and excretory urography] Vaganov NV. **Vestn Rentgenol Radiol** 1997 Mar-Apr;(2):36–8 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Differential expression of CLIP:MHC class II and conventional endogenous peptide:MHC class II complexes by thymic epithelial cells and peripheral antigen-presenting cells. Farr A, et al. **Eur J Immunol** 1996 Dec;26(12):3185–93

BLOOD

Fibrillary glomerulonephritis related to serum fibrillar immunoglobulin-fibronectin complexes. Rostagno A, et al. **Am J Kidney Dis** 1996 Nov;28(5):676–84

Prospective study of the clinical value of determining circulating IgA-alpha 1-antitrypsin complex using a prototype ELISA kit in patients with rheumatoid arthritis. Iwana K, et al. **Ann Rheum Dis** 1996 Nov;55(11):848–51

Characteristics of low density lipoprotein isolated from circulating immune complexes. Tertov VV, et al. **Atherosclerosis** 1996 May;122(2):191–9

Comparison of IgA-alpha 1-antitrypsin levels in rheumatoid and reactive arthritis. Scott LJ, et al. **Biochem Soc Trans** 1997 May;25(2):370S

Characterization of the aspartate aminotransferase-immunoglobulin M complex in a Japanese woman. Asanuma K, et al. **Clin Chem** 1997 Apr; 43(4):686–7

Practical usefulness of IgA-containing immune complex determination in the serum of patients with primary Sjögren's syndrome. Basset C, et al. **Clin Exp Rheumatol** 1997 Mar-Apr;15(2):157–61

Monoclonal antibodies to a tumour-associated antigen isolated from circulating immune complexes of bovine leukemia virus-infected cattle. Alexandrov II, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jun;20(3):241–51

Immunochemical and biomolecular studies of circulating immune complexes isolated from patients with acute and chronic hepatitis C virus infection. Sansonno D, et al. **Eur J Clin Invest** 1996 Jun;26(6):465–75

Circulating immune complexes in human tuberculosis sera: demonstration of specific antibodies against Mycobacterium tuberculosis glycolipid (DAT, PGLTb1, LOS) antigens in isolated circulating immune complexes. Simonney N, et al. **Eur J Clin Invest** 1997 Feb;27(2):128–34

Pneumococcal pneumonia in children; new data from circulating immune complexes [letter] Korppi M, et al. **Eur J Pediatr** 1997 Apr;156(4):341–2

Lactic dehydrogenase-immunoglobulin G kappa complex in a patient with idiopathic interstitial pneumonia. Fujishima T, et al. **Intern Med** 1996 May;35(5):413-5

Characterization of autoantibody activities in sera anti-DNA antibody and circulating immune complexes from 12 systemic lupus erythematosus patients. Adyel FZ, et al. **J Clin Lab Anal** 1996;10(6):451-7

Circulating immune complex of hepatitis virus C in patients with acute and chronic hepatitis C [letter] Tomiya T, et al. **J Hepatol** 1996 Jun;24(6):764

C3-containing IgE immune complexes in asthmatic patients. Nahm DH, et al. **J Korean Med Sci** 1996 Jun;11(3):217-21

Specific components found in circulating immune complexes (CIC) in paracoccidioidomycosis. Unterkircher CS, et al. **J Med Vet Mycol** 1996 Jul-Aug;34(4):273-7

Arthritis associated with circulating immune complexes following administration of intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. Lisak RP. **J Neurol Sci** 1996 Jan;135(1):85-8

Immunoglobulins and circulating immune complexes in nephrotic syndrome. Mishra OP, et al. **J Trop Pediatr** 1997 Apr;43(2):93-7

Serum concentration of circulating immune complexes in cats infected with feline immunodeficiency virus detected by immune adherence hemagglutination method. Matsumoto H, et al. **J Vet Med Sci** 1997 May;59(5):395-6

Detection of circulating immune complexes in dog sera by immune adherence hemagglutination method. Matsumoto H, et al. **J Vet Med Sci** 1996 Aug;58(8):727-30

Circulating immune complexes and renal function in canine leishmaniasis. Lopez R, et al.
Zentralbl Veterinarmed [B] 1996 Oct;43(8):469-74

[Standards for ranges of 13 items of blood proteins among Japanese adults--results of a joint project of 7 organizations based on NCCLS Document C28-P and International Reference CRM470. 5. A system for the analysis of 13 items of serum proteins--the analytical theory Saito K. **Rinsho Byori** 1996 May;Suppl 101:38-47 **(Jpn)**

[Circulating immune complexes as markers of Hodgkin's disease activity] Urbaniak-Kujda D. **Pol Tyg Lek** 1996 May;51(19-22):303-4 (12 ref.) (Eng. Abstr.) **(Pol)**

[The determination of diphtheria toxin in circulating immune complexes] Mel'nikova AV, et al. **Klin Lab Diagn** 1996 Nov-Dec;(6):39-40 (Eng. Abstr.) **(Rus)**

[The level of circulating immune complexes and the microhemodynamic status in chronic liver lesions] Petrunia AM, et al. **Lik Sprava** 1996 Jan-Feb;(1-2):77-9 (Eng. Abstr.) **(Rus)**

[New approaches in evaluating the antitumor immune response in breast cancer] Glushkov AN, et al.
Vopr Onkol 1996;42(6):33-6 (Eng. Abstr.) **(Rus)**

[The differentiation of the antigens making up the circulating immune complexes] Gorina LG, et al.
Zh Mikrobiol Epidemiol Immunobiol 1996 Jan-Feb;(1):58-61 (Eng. Abstr.) **(Rus)**

[Levels of immune complexes in fresh and frozen serum and plasma detected by precipitation with polyethylene glycol in patients with malignant diseases] Kovčin V, et al.
Srp Arh Celok Lek 1997 May-Jun;125(5-6):154-6 (Eng. Abstr.) **(Scc)**

[The participation of neutrophilic mechanisms in the pathogenesis of chronic elevated blood immune complexes] Bidiuk MM, et al. **Fiziol Zh** 1997;43(3-4):11-8 (Eng. Abstr.) **(Ukr)**

CHEMISTRY

Hydrogen bonding and solvent structure in an antigen-antibody interface. Crystal structures and thermodynamic characterization of three Fv mutants complexed with lysozyme. Fields BA, et al.
Biochemistry 1996 Dec 3;35(48):15494-503

Analysis of binding interactions in an idiotope-antiidiotope protein-protein complex by double mutant cycles. Goldman ER, et al. **Biochemistry** 1997 Jan 7;36(1):49-56

Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy. Zvi A, et al. **Biochemistry** 1997 Jul 15; 36(28):8619-27

Influence of heavy metal ions on antibodies and immune complexes investigated by dynamic light scattering and enzyme-linked immunosorbent assay. Bauer R, et al.
Biochim Biophys Acta 1997 Feb 11;1334(1):98-108

The formation of insoluble immune complexes between ovalbumin and anti-ovalbumin IgG occurs in at least two distinct phases dependent on reactant concentration and ionic strength. Gorgani NN, et al.
Biochim Biophys Acta 1996 Oct 7;1317(1):45-54

Mechanism of aggregates generated by heating human serum. Muratsugu M. **Biol Pharm Bull** 1996 Jan;19(1):132-5

Compared structures of the free nicotinic acetylcholine receptor main immunogenic region (MIR) decapeptide and the antibody-bound [A76]MIR analogue: a molecular dynamics simulation from two-dimensional NMR data. Orlewski P, et al. **Biopolymers** 1996;40(5):419-32

Crystallization of a complex between the Fab fragment of a human immunoglobulin M (IgM) rheumatoid factor (RF-AN) and the Fc fragment of human IgG4. Sohi MK, et al. **Immunology** 1996 Aug;88(4):636-41

Immune complexes from HIV-1+ patients contain infectious virus able to infect normal lymphocytes. García R, et al. **J Allergy Clin Immunol** 1996 Oct;98(4):827-30

Dissociation of monoclonal antibody-antigen complexes: implications for ELISA procedures. Venkatesh N, et al. **J Immunol Methods** 1996 Dec 15;199(2):167-74

Crystal structure of an Fv-Fv idiotope-anti-idiotope complex at 1.9 A resolution. Braden BC, et al.
J Mol Biol 1996 Nov 22;264(1):137-51

Structural basis of p21H-ras molecular switch inhibition by a neutralizing antibody. Gallagher WM, et al.
J Mol Graph 1996 Feb;14(1):42-50, 28-9

Crystallographic studies of antigen-antibody interactions. Saul FA, et al. **Methods Mol Biol** 1996;66:11-23 (36 ref.)

Refined structures of bobwhite quail lysozyme uncomplexed and complexed with the HyHEL-5 Fab fragment. Chacko S, et al. **Proteins** 1996 Sep;26(1):55-65

Bactericidal antibody recognition of a PorA epitope of Neisseria meningitidis: crystal structure of a Fab fragment in complex with a fluorescein-conjugated peptide. van den Elsen JM, et al. **Proteins** 1997 Sep;29(1):113-25

DRUG EFFECTS

Effect of licorice roots on carrageenan-induced decrease in immune complexes clearance in mice. Matsumoto T, et al. **J Ethnopharmacol** 1996 Jul 26;53(1):1-4

Mechanism and computer simulation of immune complex formation, opsonization, and clearance. Head M, et al.
J Lab Clin Med 1996 Jul;128(1):61-74 (42 ref.)

GENETICS

Sequence analysis of hypervariable region of hepatitis C virus (HCV) associated with immune complex in patients with chronic HCV infection. Aiyama T, et al. **J Infect Dis** 1996 Dec;174(6):1316-20

[CpG motif in DNA from immune complexes of SLE patients augments expression of intercellular adhesion molecule-1 on endothelial cells] Miyata M, et al. **Rinsho Byori** 1996 Dec;44(12):1125-31 (31 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The 52-kd protein as a target of intermolecular spreading of the immune response to components of the SS-A/Ro-SS-B/La complex. Tseng CE, et al.
Arthritis Rheum 1997 May;40(5):936-44

Evidence of direct recognition subset in xeno-reactive helper T cells. Hirota T, et al. **Artif Organs** 1996 Aug;20(8):890-4

Enrichment of antibodies against phospholipids in circulating immune complexes (CIC) in the anti-phospholipid syndrome (APLS). Arfors L, et al. **Clin Exp Immunol** 1997 Apr;108(1):47-51

Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells. Thornton BP, et al.
Clin Exp Immunol 1996 Jun;104(3):531-7

Hepatitis C virus (HCV)-induced IgG-IgM rheumatoid factor (RF) complex may be the main causal factor for cold-dependent activation of complement in patients with rheumatic disease. Wei G, et al. **Clin Exp Immunol** 1997 Jan;107(1):83-8

Practical usefulness of IgA-containing immune complex determination in the serum of patients with primary Sjögren's syndrome. Basset C, et al.
Clin Exp Rheumatol 1997 Mar-Apr;15(2):157-61

Circulating immune complexes in human tuberculosis sera: demonstration of specific antibodies against Mycobacterium tuberculosis glycolipid (DAT, PGLTb1, LOS) antigens in isolated circulating immune complexes. Simonney N, et al. **Eur J Clin Invest** 1997 Feb;27(2):128-34

Human dendritic cells handling of binding, uptake and degradation of free and IgG-immune complexed dinitrophenylated human serum albumin in vitro. Larsson M, et al. **Immunology** 1997 Jan;90(1):138-46

A human CD4+ T-cell line expresses functional CD64 (Fc gamma RI), CD32 (Fc gamma RII), and CD16 (Fc gamma RIII) receptors but these do not enhance the infectivity of HIV-1-IgG complexes. McLain L, et al.
Immunology 1997 Jan;90(1):109-14

The role of complement receptor type 1 (CR1, CD35) in determining the cellular distribution of opsonized immune complexes between whole blood cells: kinetic analysis of the buffering capacity of erythrocytes. Nielsen CH, et al. **Immunology** 1997 Jan;90(1):129-37

Anti-Ehrlichia chaffeensis antibody complexed with E. chaffeensis induces potent proinflammatory cytokine mRNA expression in human monocytes through sustained reduction of IkappaB-alpha and activation of NF-kappaB. Lee EH, et al. **Infect Immun** 1997 Jul;65(7):2890-7

Another function of erythrocytes: transport of circulating immune complexes. Pascual M, et al.
Infusionsther Transfusionsmed 1995 Oct;22(5):310-5 (39 ref.)

Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis. Ruiz-Ortega M, et al. **J Am Soc Nephrol** 1997 May;8(5):756-68

Association of non-receptor protein tyrosine kinases with the Fc gamma RI/gamma-chain complex in monocytic cells. Duchemin AM, et al. **J Immunol** 1997 Jan 15; 158(2):865-71

Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. Taylor RP, et al.
J Immunol 1997 Jan 15;158(2):842-50

Amplified follicular immune complex deposition in mice lacking the Fc receptor gamma-chain does not alter maturation of the B cell response. Vora KA, et al.
J Immunol 1997 Sep 1;159(5):2116-24

Leukocyte migration in immune complex glomerulonephritis: role of adhesion receptors. Lefkowith JB. **Kidney Int** 1997 May;51(5):1469-75 (54 ref.)

Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. van Bruggen MC, et al. **Kidney Int** 1996 Nov;50(5):1555-64

Treatment with dsDNA-anti-dsDNA antibody complexes extends survival, decreases anti-dsDNA antibody production and reduces severity of nephritis in MRLlpr mice. Burny W, et al. **Lupus** 1997;6(1):4-17

Role of IgE immune complexes in the regulation of HIV-1 replication and increased cell death of infected U1 monocytes: involvement of CD23/Fc epsilon RII-mediated nitric oxide and cyclic AMP pathways. Ouaaz F, et al. **Mol Med** 1996 Jan;2(1):38-49

Mediators of antigen-induced gastrin release: role of antigen-antibody complexes and the complement system. Domínguez Fernández E, et al. **Res Exp Med (Berl)** 1997; 197(1):37-43

Complement and immune complexes. Schifferli JA.
Res Immunol 1996 Feb;147(2):109-10 (10 ref.)

Complement and immune complexes. Walport MJ, et al.
Res Immunol 1996 Feb;147(2):103-9 (41 ref.)

Distinct antigen-induced cytokine pattern upon stimulation with antibody-complexed antigen consistent with a Th1-->Th2-shift. Berger S, et al. **Res Virol** 1996 Mar-Jun; 147(2-3):103-8

IL-10 plays a role in the modulation of human granulomatous hypersensitivity against Schistosoma mansoni eggs induced by immune complexes. Rezende SA, et al.
Scand J Immunol 1997 Jul;46(1):96-102

Early expansion of secondary B cells after primary immunization with antigen complexed with IgE. Westman S, et al. **Scand J Immunol** 1997 Jul;46(1):10-5

Interaction of platelet fc and complement receptors with circulating immune complexes involving the AB0 system. Heal JM, et al. **Vox Sang** 1996;71(4):205-11

[The interaction between the complement system and immune complexes] Vivanco-Martínez F. **Rev Clin Esp** 1996 Mar;196 Spec No:7-12 (29 ref.) **(Spa)**

METABOLISM

Effect of enalapril therapy on glomerular accumulation of immune complexes and mesangial matrix in experimental glomerulonephritis in the nonhuman primate. Hebert LA, et al. **Am J Kidney Dis** 1997 Aug;30(2):243-52

Detection of antigen-antibody binding events with the atomic force microscope. Allen S, et al. **Biochemistry** 1997 Jun 17;36(24):7457-63

Histidine-rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes. Gorgani NN, et al. **Biochemistry** 1997 Jun 3;36(22):6653-62

C1q is a nucleotide binding protein and is responsible for the ability of clusterin preparations to promote immune complex formation. Roeth PJ, et al.
Biochim Biophys Acta 1996 Oct 17;1297(2):159-66

Diagnosis of human immunodeficiency virus type 1 infection in infants by immune complex dissociation p24 assay. Paul MO, et al. **Clin Diagn Lab Immunol** 1997 Jan;4(1):75-8

The systemic lupus erythematosus (SLE) disease autoantigen-calreticulin can inhibit C1q association with immune complexes. Kishore U, et al. **Clin Exp Immunol** 1997 May;108(2):181-90

Immune complexes bound to the primate erythrocyte complement receptor (CR1) via anti-CR1 mAbs are cleared simultaneously with loss of CR1 in a concerted reaction in a rhesus monkey model. Taylor RP, et al.
Clin Immunol Immunopathol 1997 Jan;82(1):49-59

Interleukin-1beta expression is induced by adherence and is enhanced by Fc-receptor binding to immune complex in THP-1 cells. Cobb RR, et al. **FEBS Lett** 1996 Oct 7; 394(3):241-6

Antigen-antibody complexes enhance the production of complement component C3 by human mesangial cells. Timmerman JJ, et al. **J Am Soc Nephrol** 1997 Aug; 8(8):1257-65

Both IgG- and C1q-receptors play a role in the enhanced binding of IgG complexes to human mesangial cells. van den Dobbelsteen ME, et al. **J Am Soc Nephrol** 1996 Apr; 7(4):573-81

Critical evaluation of the applicability of capillary zone electrophoresis for the study of hapten-antibody complex formation. Busch MH, et al. **J Chromatogr A** 1996 Sep 13;744(1-2):195-203

Receptors for immune complexes activate gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: role of TGF-beta. López-Armada MJ, et al. **J Immunol** 1996 Sep 1;157(5):2136-42

Reduction in the amide hydrogen exchange rates of an anti-lysozyme Fv fragment due to formation of the Fv-lysozyme complex. Williams DC Jr, et al.
J Mol Biol 1997 Aug 1;270(5):751-62

ANTIGEN-ANTIBODY COMPLEX

Epitope mapping by proteolysis of antigen-antibody complexes. Protein footprinting. Jemmerson R. **Methods Mol Biol** 1996;66:97–108

Influence of isoelectric point on glomerular deposition of antibodies and immune complexes. Woitas RP, et al. **Nephron** 1996;74(4):713–9

Increased applied pressure enhances the uptake of IgG complexes by macrophages. Mattana J, et al. **Pathobiology** 1996;64(1):40–5

Complement and immune complexes. Schifferli JA. **Res Immunol** 1996 Feb;147(2):109–10 (10 ref.)

Complement and immune complexes. Walport MJ, et al. **Res Immunol** 1996 Feb;147(2):103–9 (41 ref.)

PHARMACOLOGY

Stimulation of primed neutrophils by soluble immune complexes. Watson F, et al. **Biologicals** 1996 Dec; 24(4):307–11

Stimulation of intracellular Ca2+ levels in human neutrophils by soluble immune complexes. Functional activation of FcgammaRIIIb during priming. Watson F, et al. **J Biol Chem** 1997 Jul 18;272(29):17944–51

PHYSIOLOGY

Nitric oxide and immune complexes are involved in the induction of a novel luminol chemiluminescence in cytotoxic macrophages. Muto S, et al. **Biol Pharm Bull** 1996 Nov;19(11):1521–3

Immune complex mediated vasculitis in hepatitis B and C infections and the effect of antiviral therapy. Nityanand S, et al. **Clin Immunol Immunopathol** 1997 Mar;82(3):250–7

Histones interact with immunoglobulins and give them polyspecificity. Abakushin DN, et al. **Immunol Lett** 1996 Nov;53(2–3):95–9

Mechanism and computer simulation of immune complex formation, opsonization, and clearance. Head M, et al. **J Lab Clin Med** 1996 Jul;128(1):61–74 (42 ref.)

Phospholipase D mediates Fc gamma receptor activation of neutrophils and provides specificity between high-valency immune complexes and fMLP signaling pathways. Gewirtz AT, et al. **J Leukoc Biol** 1997 Apr;61(4):522–8

TOXICITY

Regulatory effects of interleukin-6 in immunoglobulin G immune-complex-induced lung injury. Shanley TP, et al. **Am J Pathol** 1997 Jul;151(1):193–203

Efficacy of recombinant granulocyte colony-stimulating factor (rhG-CSF) in experimental colitis. Hommes DW, et al. **Clin Exp Immunol** 1996 Dec;106(3):529–33

Hepatitis C virus (HCV)-induced IgG-IgM rheumatoid factor (RF) complex may be the main causal factor for cold-dependent activation of complement in patients with rheumatic disease. Wei G, et al. **Clin Exp Immunol** 1997 Jan;107(1):83–8

Protective effects of IL-4, IL-10, IL-12, and IL-13 in IgG immune complex-induced lung injury: role of endogenous IL-12. Mulligan MS, et al. **J Immunol** 1997 Oct 1; 159(7):3483–9

Requirement for C-X-C chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant) in IgG immune complex-induced lung injury. Shanley TP, et al. **J Immunol** 1997 Apr 1; 158(7):3439–48

ULTRASTRUCTURE

Specific antigen/antibody interactions measured by force microscopy. Dammer U, et al. **Biophys J** 1996 May; 70(5):2437–41

Ultrastructural calcification of glomerular immune complexes [see comments] Lai FM, et al. **Mod Pathol** 1996 Jan; 9(1):36–40. Comment in: Mod Pathol 1996 Jul;9(7):800–1.

Correspondence re: Mac-Moune Lai F, To KF, Wang A, et al.: ultrastructural calcification of glomerular immune complexes. Mod Pathol 9:36, 1996 [letter; comment] Trillo A. **Mod Pathol** 1996 Jul;9(7):800–1. Comment on: Mod Pathol 1996 Jan;9(1):36–40.

Epidermolysis bullosa acquisita diagnosed by direct immunoelectron microscopy of the conjunctiva. Hoang-Xuan T, et al. **Ophthalmology** 1997 Sep; 104(9):1414–20

Recent structural solutions for antibody neutralization of viruses. Stewart PL, et al. **Trends Microbiol** 1997 Jun; 5(6):229–33 (36 ref.)

URINE

[Immune complexes and C3 and C4 of the complement in urine of patients with glomerulonephritis] Kacprzyk F, et al. **Pol Arch Med Wewn** 1996 Sep;96(3):215–23 (Eng. Abstr.) **(Pol)**

ANTIGEN-ANTIBODY REACTIONS

see related
BINDING SITES, ANTIBODY
HYPERSENSITIVITY, IMMEDIATE

Monoclonal antibodies as direct probes for human sperm acrosome reaction. Dorjee S, et al. **Am J Reprod Immunol** 1997 Apr;37(4):283–90

A chemiluminescence-based method for the detection and quantification of antigen-antibody interactions on the surface of eukaryotic cells. Lischke A, et al. **Anal Biochem** 1996 May 1;236(2):322–6

Analysis of antibody-antigen interactions using size-exclusion high-performance (pressure) liquid chromatography. Sanny CG, et al. **Anal Biochem** 1997 Mar 1;246(1):7–14

On the interaction between a bactericidal antibody and a PorA epitope of Neisseria meningitidis in outer membrane vesicles: a competitive fluorescence polarization immunoassay. van den Elsen JM, et al. **Anal Biochem** 1997 May 1;247(2):382–8

Thermodynamic analysis of antigen-antibody binding using biosensor measurements at different temperatures. Zeder-Lutz G, et al. **Anal Biochem** 1997 Mar 1; 246(1):123–32

Capacitance measurements of antibody-antigen interactions in a flow system. Berggren C, et al. **Anal Chem** 1997 Sep 15;69(18):3651–7

Application of redox enzymes for probing the antigen-antibody association at monolayer interfaces: development of amperometric immunosensor electrodes. Blonder R, et al. **Anal Chem** 1996 Sep 15;68(18):3151–7

Assessment of heterogeneity in antibody-antigen displacement reactions. Rabbany SY, et al. **Anal Chem** 1997 Jan 15;69(2):175–82

Recognition of tumor-associated antigens by T-lymphocytes: perspectives for peptide-based vaccines. Cerottini JC, et al. **Ann Oncol** 1996 Apr;7(4):339–42 (52 ref.)

Antigen-antibody binding kinetics for biosensor applications. A dual-fractal analysis. Sadana A, et al. **Appl Biochem Biotechnol** 1997 Feb-Mar;62(2–3):275–90

Antigen-antibody binding kinetics for biosensors. Changes in the fractal dimension (surface roughness) and in the binding rate coefficient. Sadana A, et al. **Appl Biochem Biotechnol** 1996 Aug;60(2):123–38 (37 ref.)

Specific stabilization of the 4F7 molecule on dendritic cells by contact allergens. Jonuleit H, et al. **Arch Dermatol Res** 1996 Nov;288(12):745–52

Alterations of Tamm-Horsfall protein immunoreactivity after partial desialylation and deglycosylation. Grabska T, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(4):241–8

Study of antigen-binding properties of bispecific antibodies. Smirnova MB, et al. **Biochemistry (Mosc)** 1997 Jan; 62(1):41–8

Dimerization of an antigenic peptide leads to strong interaction with its antibody. Jekel PA, et al. **Biochim Biophys Acta** 1996 Dec 6;1291(3):195–8

Kinetic analysis of a protein antigen-antibody interaction limited by mass transport on an optical biosensor. Myszka DG, et al. **Biophys Chem** 1997 Feb 28;64(1–3):127–37

Attractive adsorbate interaction in biological surface reactions. Nygren H. **Biophys Chem** 1996 Oct 30; 61(2–3):73–84

Effectiveness of protein A for antibody immobilization for a fiber optic biosensor. Anderson GP, et al. **Biosens Bioelectron** 1997;12(4):329–36

A cell-based immunobiosensor with engineered molecular recognition--Part I: Design feasibility. Pizziconi VB, et al. **Biosens Bioelectron** 1997;12(4):287–99

Kinetic modeling and analysis of a vesicle system for immunosensor development. Yu YY, et al. **Biosens Bioelectron** 1997;12(2):135–44

Cell surface display of a single-chain antibody for attaching polypeptides. Rode HJ, et al. **Biotechniques** 1996 Oct; 21(4):650, 652–3, 655–6, 658

Isolation of a monoclonal antibody reactive to brain microsome-associated antigen, lap-1, and its preferential localization in limbic system of rat brain. Fukuyama R, et al. **Brain Res** 1996 May 6;719(1–2):194–7

Coincident seronegative spondarthritis: a case report. Speed CA, et al. **Clin Rheumatol** 1996 May;15(3):301–2

Anti-(U1)snRNP autoantibodies inhibit homologous pairing activity of the human recombination complex. Dowjat K. **DNA Cell Biol** 1997 Jul;16(7):819–27

The repertoire of serum IgM in normal mice is largely independent of external antigenic contact. Haury M, et al. **Eur J Immunol** 1997 Jun;27(6):1557–63

Mimotopes of polyreactive anti-DNA antibodies identified using phage-display peptide libraries. Sibille P, et al. **Eur J Immunol** 1997 May;27(5):1221–8

Evidence for restricted diversity of antigen-specific human antibodies in immunized hu-PBL-SCID mice. Bazin R, et al. **Hum Antibodies Hybridomas** 1996;7(3):129–34

Dissociation of multivalent antibody-antigen interactions [letter; comment] Hubble J. **Immunol Today** 1997 Jun; 18(6):305–6. Comment on: Immunol Today 1996 Feb;17(2):77–80.

Enhancement in antigen binding by a combination of synergy and antibody capture. Klonisch T, et al. **Immunology** 1996 Oct;89(2):165–71

Characterization of human sperm antigens reacting with antisperm antibodies from autologous sera and seminal plasma: comparison among infertile subpopulations. Paradisi R, et al. **Int J Androl** 1996 Dec;19(6):345–52

Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1. Lebecque S, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):374–84

Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus. Brenner S, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):919–23

Role of salt bridge formation in antigen-antibody interaction. Entropic contribution to the complex between hen egg white lysozyme and its monoclonal antibody HyHEL10. Tsumoto K, et al. **J Biol Chem** 1996 Dec 20;271(51):32612–6

Biospecific polymers: recognition of phosphorylated polystyrene derivatives by anti-DNA antibodies. Migonney V, et al. **J Biomater Sci Polym Ed** 1997;8(7):533–44

Comparative docking studies on ligand binding to the multispecific antibodies IgE-La2 and IgE-Lb4. Sotriffer CA, et al. **J Comput Aided Mol Des** 1996 Aug;10(4):305–20

Interaction between antibodies and hapten-protein conjugates of different composition: theoretical predictions and experimental data. Zherdev AV, et al. **J Immunoassay** 1997 Feb;18(1):67–95

Interaction of anti-cholesterol antibodies with human lipoproteins. Dijkstra J, et al. **J Immunol** 1996 Sep 1; 157(5):2006–13

Staphylococcal protein A simultaneously interacts with framework region 1, complementarity-determining region 2, and framework region 3 on human VH3-encoded Igs. Potter KN, et al. **J Immunol** 1996 Oct 1;157(7):2982–8

Measurement of antibody/antigen association rate constants in solution by a method based on the enzyme-linked immunosorbent assay. Hardy F, et al. **J Immunol Methods** 1997 Jan 15;200(1–2):155–9

Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. Karlsson R, et al. **J Immunol Methods** 1997 Jan 15; 200(1–2):121–33

Binding parameters of antibodies reacting with multivalent antigens: functional affinity or pseudo-affinity [letter] Mattes MJ. **J Immunol Methods** 1997 Mar 10;202(1):97–101 (27 ref.)

Assessment of affinity constants by rapid solid phase detection of equilibrium binding in a flow system. Piehler J, et al. **J Immunol Methods** 1997 Feb 28;201(2):189–206

Dissociation of monoclonal antibody-antigen complexes: implications for ELISA procedures. Venkatesh N, et al. **J Immunol Methods** 1996 Dec 15;199(2):167–74

An antibody to a 17 amino acid synthetic peptide of the type I interleukin-1 receptor preferentially blocks interleukin-1 beta binding. Clark BD, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):1079–88

Antibody-antigen interactions: contact analysis and binding site topography. MacCallum RM, et al. **J Mol Biol** 1996 Oct 11;262(5):732–45

Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. Schendel DJ, et al. **J Mol Med** 1997 Jun;75(6):400–13 (119 ref.)

The effect of water activity on the association constant and the enthalpy of reaction between lysozyme and the specific antibodies D1.3 and D44.1. Goldbaum FA, et al. **J Mol Recognit** 1996 Jan-Feb;9(1):6–12

Sequence of bifurcations in an 'antigen-antibody' reaction. Grushevskaja GV, et al. **J Mol Recognit** 1996 Sep-Dec; 9(5–6):570–4

Prediction of IgE(Lb4)-ligand complex structures by automated docking. Winger RH, et al. **J Mol Recognit** 1996 May-Jun;9(3):239–46

Antibody that neutralizes myelin-associated inhibitors of axon growth does not interfere with recognition of target-specific guidance information by rat retinal axons. Bähr M, et al. **J Neurobiol** 1996 Jun;30(2):281–92

Preferential association of V lambda x light chains with gamma 2a heavy chains in naturally occurring human myelin basic protein reactive antibodies. Galin FS, et al. **J Neuroimmunol** 1996 Oct;70(1):15–20

Predicting differential antigen-antibody contact regions based on solvent accessibility. Lebeda FJ, et al. **J Protein Chem** 1997 Aug;16(6):607–18

Residual serologic reactivity in children with resolved Lyme arthritis. Rose CD, et al. **J Rheumatol** 1996 Feb;23(2):367–9

Characterization of cytotoxic T lymphocytes recognizing autologous tumor cells with plural HLA-class I alleles in a patient with esophageal cancer. Maeda T. **Kurume Med J** 1997;44(1):23–32

Crystallographic studies of antigen-antibody interactions. Saul FA, et al. **Methods Mol Biol** 1996;66:11–23 (36 ref.)

Probing antibody-antigen interactions by mass spectrometry. Zhao Y, et al. **Methods Mol Biol** 1996;66:129–36

Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. Slootstra JW, et al. **Mol Divers** 1996 Feb;1(2):87–96

Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Corper AL, et al. **Nat Struct Biol** 1997 May;4(5):374–81

Quantitation of radiolabeled antibody binding to cells by thin-layer chromatography. Zamora PO, et al. **Nucl Med Biol** 1994 Feb;21(2):205–10

Highly specific, cross-reactive sequences recognized by an anti-HBsAg antibody identified from a positional scanning synthetic combinatorial library. Appel JR, et al. **Pept Res** 1996 Jul-Aug;9(4):174–82

Internal image concept revisited. Bona CA. **Proc Soc Exp Biol Med** 1996 Oct;213(1):32–42 (126 ref.)

Complementarity determining region residues aspartic acid at H55, serine at H95 and tyrosines at H97 and L96 play important roles in the B72.3 antibody-TAG72 antigen interaction. Xiang J, et al. **Protein Eng** 1996 Jun;9(6):539–43

Evaluation of magnetic resonance imaging for the detection

of sacroiliitis in patients with early seronegative spondylarthropathy. Rémy M, et al. **Rev Rhum Engl Ed** 1996 Oct;63(9):577–83

Instability of natural antibody repertoires in systemic lupus erythematosus patients, revealed by multiparametric analysis of serum antibody reactivities. Ferreira C, et al. **Scand J Immunol** 1997 Mar;45(3):331–41

Site-directed estrogen receptor antibodies stabilize 4-hydroxytamoxifen ligand, but not estradiol, and indicate ligand-specific differences in the recognition of estrogen response element DNA in vitro. Klinge CM, et al. **Steroids** 1996 May;61(5):278–89

Monoclonal antibodies against the human mannose receptor that inhibit the binding of tissue-type plasminogen activator. Barrett-Bergshoeff M, et al. **Thromb Haemost** 1997 Apr;77(4):718–24

Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. Cugno M, et al. **Thromb Haemost** 1996 Aug;76(2):234–8

Monoclonal antibodies to human fibrin: interaction with other animal fibrins. Edgell T, et al. **Thromb Haemost** 1996 Apr;75(4):595–9

Naturally occurring IgG autoantibodies to platelet cytoskeleton tropomyosin. Hou M, et al. **Thromb Haemost** 1996 Apr;75(4):642–7

Autoantibody selectively inhibits binding of von Willebrand factor to glycoprotein ib. Recognition site is located in the A1 loop of von Willebrand factor. Mohri H, et al. **Thromb Haemost** 1997 Apr;77(4):760–6

Degree of polymer organization decreases the binding of a monoclonal antibody raised against the beta-chain amino terminus of fibrin. Morris TA, et al. **Thromb Haemost** 1997 Apr;77(4):704–9

Inhibition of human serum mediated lysis of porcine endothelial cells using a novel peptide which blocks C1Q binding to xenoantibody. Fryer JP, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):883

Serology of respiratory viruses in relation to asthma and bronchial hyperresponsiveness. Björnsson E, et al. **Ups J Med Sci** 1996;101(2):159–68

Construction, purification and immunogenicity of antigen-antibody-LTB complexes. Green EA, et al. **Vaccine** 1996 Jul;14(10):949–58

The effects of cromakalim on the mediator releases from guinea pig lung mast cell activated by specific antigen-antibody reactions. Ro JY, et al. **Yonsei Med J** 1996 Oct;37(5):325–38

[Eliciting immune reactions using a suspension of immunosorbents] Kniaz'kov NN, et al. **Biull Eksp Biol Med** 1996 May;121(5):568–70 **(Rus)**

[Electro-optic method of recording antigen-antibody interactions in detection of antiplatelet antibodies in hemorrhagic thrombocytopathies] Sirota AI, et al. **Klin Lab Diagn** 1993 May-Jun;(3):50–4 (Eng. Abstr.) **(Rus)**

[Immunological reactivity and the hypophyseal-ovarian system in patients with circumscribed scleroderma] Bolotnaia LA. **Lik Sprava** 1995 Mar-Apr;(3–4):116–8 (Eng. Abstr.) **(Rus)**

[The characteristics of the immune response to the polysaccharide determinants of Streptococcus group A in rheumatism] Borodiiuk NA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 May-Jun;(3):118–22 (Eng. Abstr.) **(Rus)**

[The local immunity reactions of swimmers on the Russian all-star team] Pershin BB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jan-Feb;(1):53–7 (Eng. Abstr.) **(Rus)**

[The immune response to Pseudomonas pseudomallei in vitro] Titova NG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jan-Feb;(1):62–5 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

The influence of salts on the reaction between hGH and several of its monoclonal antibodies in fixed, paraffin-embedded human pituitary as a model system. Montero C, et al. **Eur J Histochem** 1996;40(2):153–8

Preservation of spatial organization and antigenicity of leukocyte surface molecules by aldehyde fixation: flow cytometry and high-resolution FESEM studies of CD62L, CD11b, and Thy-1. Hasslen SR, et al. **J Histochem Cytochem** 1996 Oct;44(10):1115–22

The use of reporter antigens in the popliteal lymph node assay to assess immunomodulation by chemicals. Albers R, et al. **Toxicol Appl Pharmacol** 1997 Mar;143(1):102–9

GENETICS

Can immunoglobulin C(H)1 constant region domain modulate antigen binding affinity of antibodies? Pritsch O, et al. **J Clin Invest** 1996 Nov 15;98(10):2235–43

Study of antibody-antigen interaction through site-directed mutagenesis of the VH region of a hybrid phage-antibody fragment. Li Y, et al. **Protein Eng** 1996 Dec;9(12):1211–7

IMMUNOLOGY

Nonspecific binding of IgE to allergens. Jensen-Jarolim E, et al. **Allergy** 1997 Aug;52(8):844–52

A new isoform of the serine-rich E. histolytica protein recognized by human secretory IgA antibodies from patients with intestinal amebiasis. Carrero JC, et al. **Arch Med Res** 1997;28 Spec No:259–61

Effect of low ionic strength on anti-Pr reactions. Leo A, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:22–5

Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. Strickler HD, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Mar;6(3):183–8

Consideration of potential immunological problems in the application of xenogenic hybrid liver support. Bornemann R, et al. **Int J Artif Organs** 1996 Nov;19(11):655–63 (54 ref.)

Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. Kent M, et al. **J Rheumatol** 1997 Sep;24(9):1725–33

Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease. Schlegel PG, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):11–6 (47 ref.)

Reactivity of anti-glycophorin monoclonal antibodies (Mabs) in tests with red cells of non-human primates. Blancher A, et al. **Transfus Clin Biol** 1997;4(1):81–5

Use of recombinant DAF proteins to localize the epitopes recognized by monoclonal anti-CD55. Brodbeck WG, et al. **Transfus Clin Biol** 1997;4(1):125–6

Anti-M and anti-N reactivity with Tn and T activated cells. Harris T, et al. **Transfus Clin Biol** 1997;4(1):87–8

Reactivity of 62 Rh MAbs with weak and variant antigens. Morelati F, et al. **Transfus Clin Biol** 1996;3(6):359–66

Reactions of anti-D monoclonal antibodies with rhesus D variant cells. Overbeeke MA, et al. **Transfus Clin Biol** 1996;3(6):397–9

Coordinator's report: glycophorin/band 3 and associated antigens. Reid ME, et al. **Transfus Clin Biol** 1997;4(1):57–64

Recombinant blood group antigens are useful for studying the fine specificity of antibodies against glycophorin A encoded antigens. Rozmyslowicz T, et al. **Transfus Clin Biol** 1997;4(1):77–80

A comparison of monoclonal antibody immobilization of platelet antigen (MAIPA) and immunobead methods for detection of GPIIb/IIIa antiplatelet antibodies in immune thrombocytopenic purpura. Crossley A, et al. **Transfus Med** 1997 Jun;7(2):127–34

Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(alpha1,3)Galactose epitope. McMorrow IM, et al. **Transplantation** 1997 Aug 15;64(3):501–10

Synthesis of alpha-gal epitopes on influenza virus vaccines, by recombinant alpha 1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody. Henion TR, et al. **Vaccine** 1997 Aug;15(11):1174–82

Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Kochel T, et al. **Vaccine** 1997 Apr;15(5):547–52

Broadly reactive antibodies against a gp120 V3 loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1). Montero M, et al. **Vaccine** 1997 Aug;15(11):1200–8

Heating lyophilised factor VIII does not alter its recognition by specific antibodies. Gilles JG, et al. **Vox Sang** 1997;73(1):16–23

[The T-cell receptor—its participation in the pathological immune response] Bozhkov B. **Mol Med (Sofia)** 1996;1(2):9–15 (20 ref.) (Eng. Abstr.) **(Bul)**

[Regulation of the immune response: the TH1/TH2 concept] Pichler WJ. **Schweiz Med Wochenschr** 1997 Mar 1;127(9):341–8 (Eng. Abstr.) **(Ger)**

[Thermodynamic parameters of binding of murine antitheophylline monoclonal antibodies 2G3 with theophylline] Pokid'ko IuN, et al. **Biull Eksp Biol Med** 1997 Apr;123(4):442–5 **(Rus)**

[An analysis of the specificity of anti-Mycobacterium monoclonal antibodies and of the chemical nature of the antigenic determinants with which they react] Avdienko VG, et al. **Probl Tuberk** 1996;(1):6–8 (Eng. Abstr.) **(Rus)**

[The interaction between the complement system and immune complexes] Vivanco-Martinez F. **Rev Clin Esp** 1996 Mar;196 Spec No:7–12 (29 ref.) **(Spa)**

PHYSIOLOGY

Influence of diffusion to fractal surfaces on the binding kinetics for antibody-antigen, analyte-receptor, and analyte-receptorless (protein) systems. Sadana A, et al. **Biophys Chem** 1997 Mar 27;65(1):29–44

Observing interactions between the IgG antigen and anti-IgG antibody with AFM [see comments] Zhang PC, et al. **IEEE Eng Med Biol Mag** 1997 Mar-Apr;16(2):42–6. Comment in: IEEE Eng Med Biol Mag 1997 Mar-Apr;16(2):26–7.

ANTIGEN, B7 see **ANTIGENS, CD80**

ANTIGEN BRONCHIAL PROVOCATION TESTS see **BRONCHIAL PROVOCATION TESTS**

ANTIGEN CA-15-3 see **CA-15-3 ANTIGEN**

ANTIGEN CA-19-9 see **CA-19-9 ANTIGEN**

ANTIGEN CA-125 see **CA-125 ANTIGEN**

ANTIGEN KI-67 see **KI-67 ANTIGEN**

ANTIGEN, LYT-1 see **ANTIGENS, LY**

ANTIGEN P150,95

ANALYSIS

The natural history of monoclonal villous lymphocytosis: a chronic lymphoproliferative disorder of CD11c+ B cells. Bassan R, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):181–3

Effects of heparin coating on the expression of CD11b, CD11c and CD62L by leucocytes in extracorporeal circulation in vitro. Høgevold HE, et al. **Perfusion** 1997 Mar;12(1):9–20

Long-term continuous ambulatory peritoneal dialysis reduces the expression of CD11b, CD14, CD16, and CD64 on peritoneal macrophages. Cárcamo C, et al. **Perit Dial Int** 1996 Nov-Dec;16(6):582–9

GENETICS

PU.1 negatively regulates the CD11c integrin gene promoter through recognition of the major transcriptional start site. López-Rodríguez C, et al. **Eur J Immunol** 1997 Aug;27(8):1843–7

Expression of the alpha-subunit of CR4 (CD11c) by peripheral blood and crevicular fluid neutrophils. Mouynet P, et al. **Eur J Oral Sci** 1995 Dec;103(6):413–5

Sp3 mediates transcriptional activation of the leukocyte integrin genes CD11C and CD11B and cooperates with c-Jun to activate CD11C. Noti JD. **J Biol Chem** 1997 Sep 19;272(38):24038–45

An octamer element functions as a regulatory element in the differentiation-responsive CD11c integrin gene promoter: OCT-2 inducibility during myelomonocytic differentiation. López-Rodríguez C, et al. **J Immunol** 1997 Jun 15;158(12):5833–40

IMMUNOLOGY

The 25-kDa soluble CD23 activates type III constitutive nitric oxide-synthase activity via CD11b and CD11c expressed by human monocytes. Aubry JP, et al. **J Immunol** 1997 Jul 15;159(2):614–22

METABOLISM

Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. Inoue T, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1127–33

PHYSIOLOGY

Beta 2 (CD11/CD18) integrins can serve as signaling partners for other leukocyte receptors. Todd RF 3rd, et al. **J Lab Clin Med** 1997 May;129(5):492–8 (64 ref.)

ANTIGEN PRESENTATION

"HIV-peplotion vaccine"—a novel approach to protection against AIDS by transepithelial transport of viral peptides to Langerhans cells for long-term antiviral CTL response. (A review). Becker Y. **Acta Microbiol Immunol Hung** 1996;43(1):1–17 (83 ref.)

Proposed role of a gamma-interferon inducible proteasome-regulator in antigen presentation. Realini CA, et al. **Adv Exp Med Biol** 1996;389:51–61 (40 ref.)

Transporter associated with antigen processing. Elliott T. **Adv Immunol** 1997;65:47–109 (215 ref.)

Mechanism of class I assembly with beta 2 microglobulin and loading with peptide. Hansen TH, et al. **Adv Immunol** 1997;64:105–37 (170 ref.)

Proteasomes and antigen processing. Tanaka K, et al. **Adv Immunol** 1997;64:1–38 (123 ref.)

Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules. Shiga H, et al. **AIDS** 1996 Sep;10(10):1075–83

Capture and processing of exogenous antigens for presentation on MHC molecules. Watts C. **Annu Rev Immunol** 1997;15:821–50 (188 ref.)

Antigen processing and presentation by the class I major histocompatibility complex. York IA, et al. **Annu Rev Immunol** 1996;14:369–96 (187 ref.)

Cytokine expression and antigen-presenting capacity of 4F7+ dendritic cells derived from dermis, spleen, and lymph nodes. Mohamadzadeh M, et al. **Arch Dermatol Res** 1997 Jul;289(8):435–9

Endogenous antigen presentation by autoantigen-transfected Epstein-Barr virus-lymphoblastoid cells: T cell receptor N-region hydrophobicity relates to thyroid antigen recognition [published erratum appears in Autoimmunity 1996;23(1):75] Martin A, et al. **Autoimmunity** 1995;21(4):223–30

Peptide binding and antigen presentation by class II histocompatibility glycoproteins. Jensen PE. **Biopolymers** 1997;43(4):303–22 (160 ref.)

Activation of human T cells by major histocompatability complex class II expressing neutrophils: proliferation in the presence of superantigen, but not tetanus toxoid. Fanger NA, et al. **Blood** 1997 Jun 1;89(11):4128–35

Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy.

Fearnley DB, et al. **Blood** 1997 May 15;89(10):3708–16

Alloantigen presenting function of normal human CD34+ hematopoietic cells. Rondelli D, et al. **Blood** 1996 Oct 1; 88(7):2619–75

Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. Yi Q, et al. **Blood** 1997 Sep 1;90(5):1960–7

Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Alpan RS, et al. **Cancer Res** 1996 Oct 1;56(19):4358–61

Selective elimination of antigen-specific line T cells and ex vivo antigen-primed lymph node cells by antigen-targeted drug-labeled antigen-presenting cell membranes. Chang NH, et al. **Cell Immunol** 1997 Mar 15;176(2):135–45

Increased class Ib antigen display on TAP-2 mutant cells by a mitochondrial function inhibitor. Hermel E, et al. **Cell Immunol** 1997 Jul 10;179(1):10–5

A kinetic comparative study on lymphocyte responses to superantigen and phytohemagglutinin: reciprocal presentation of superantigen on the surface of activated lymphocytes. Ijichi S, et al. **Cell Immunol** 1996 Nov 1; 173(2):312–6

Homogeneous processing and presentation of a recombined T cell epitope in inbred mice of different non-MHC genetic background. Lo-Man R, et al. **Cell Immunol** 1996 Sep 15; 172(2):180–91

Defective antigen presentation by lavage cells from terminal patients with cystic fibrosis. Knight RA, et al. **Clin Exp Immunol** 1997 Mar;107(3):542–7

Membrane tumor necrosis factor-alpha (TNF-alpha) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation—characterization of membrane TNF-alpha. Higuchi M, et al. **Clin Immunol Immunopathol** 1997 Feb;82(2):133–40

Studies on the interaction of T-cells with major histocompatibility complex class II antigens. Warrens AN. **Clin Sci (Colch)** 1997 Jan;92(1):25–36

The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells. Bertolino P, et al. **Crit Rev Immunol** 1996;16(4):359–79 (189 ref.)

Accessory molecule and costimulation requirements for CD4 T cell response. Croft M, et al. **Crit Rev Immunol** 1997; 17(1):89–118 (159 ref.)

Nonclassical HLA-G molecules are classical peptide presenters. Diehl M, et al. **Curr Biol** 1996 Mar 1;6(3):305–14

Immune responses: tails to teach a B cell. Nussenzweig MC. **Curr Biol** 1997 Jun 1;7(6):R355–7 (11 ref.)

Antigen recognition. **Curr Opin Immunol** 1996 Feb; 8(1):136–54

Antigen processing and presentation in transplantation. Auchincloss H Jr, et al. **Curr Opin Immunol** 1996 Oct; 8(5):681–7 (52 ref.)

Developing and shedding inhibitions: how MHC class II molecules reach maturity. Busch R, et al. **Curr Opin Immunol** 1996 Feb;8(1):51–8 (77 ref.)

Origin, maturation and antigen presenting function of dendritic cells. Cella M, et al. **Curr Opin Immunol** 1997 Feb;9(1):10–6 (75 ref.)

Antigen recognition. Cresswell P, et al. **Curr Opin Immunol** 1997 Feb;9(1):71–4 (26 ref.)

Processing and delivery of peptides presented by MHC class I molecules. Lehner PJ, et al. **Curr Opin Immunol** 1996 Feb;8(1):59–67 (84 ref.)

Antigen presentation by CD1 and MHC-encoded class I-like molecules. Melián A, et al. **Curr Opin Immunol** 1996 Feb; 8(1):82–8 (41 ref.)

MHC class II restricted antigen presentation. Pieters J. **Curr Opin Immunol** 1997 Feb;9(1):89–96 (84 ref.)

T-cell recognition of non-peptide antigens. Porcelli SA, et al. **Curr Opin Immunol** 1996 Aug;8(4):510–6 (50 ref.)

T-cell epitope determination. Walden P. **Curr Opin Immunol** 1996 Feb;8(1):68–74 (60 ref.)

In vitro sensitization of human T cells with hapten-treated Langerhans cells: a screening test for the identification of contact allergens. Krasteva M, et al. **Curr Probl Dermatol** 1996;25:28–36

Analysis of the intracellular processing of proteins: application of fluorescence polarization and a novel fluorescent probe. Weaver DJ Jr, et al. **Cytometry** 1997 May 1;28(1):25–35

Acceleration of intracellular targeting of antigen by the B-cell antigen receptor: importance depends on the nature of the antigen-antibody interaction. Aluvihare VR, et al. **EMBO J** 1997 Jun;16(12):3553–62

Antigen endocytosis and presentation mediated by human membrane IgG1 in the absence of the Ig(alpha)/Ig(beta) dimer. Knight AM, et al. **EMBO J** 1997 Jul 1; 16(13):3842–50

Engagement of the B lymphocyte antigen receptor induces presentation of intrinsic immunoglobulin peptides on major histocompatibility complex class II molecules. Bartnes K, et al. **Eur J Immunol** 1997 May;27(5):1124–30

Fc gamma receptor II dependency of enhanced presentation of major histocompatibility complex class II peptides by a B cell lymphoma. Berg M, et al. **Eur J Immunol** 1997 Apr;27(4):1022–8

Excessive degradation of intracellular protein in macrophages prevents presentation in the context of major histocompatibility complex class II molecules. Brazil MI, et al. **Eur J Immunol** 1997 Jun;27(6):1506–14

TAP-dependent major histocompatibility complex class I presentation of soluble proteins using listeriolysin. Darji A, et al. **Eur J Immunol** 1997 Jun;27(6):1353–9

Epitope cleavage by Leishmania endopeptidase(s) limits the efficiency of the exogenous pathway of major histocompatibility complex class I-associated antigen presentation. Garcia MR, et al. **Eur J Immunol** 1997 Apr; 27(4):1005–13

Leishmania-infected macrophages sequester endogenously synthesized parasite antigens from presentation to CD4+ T cells. Kima PE, et al. **Eur J Immunol** 1996 Dec; 26(12):3163–9

Presentation of abundant endogenous class II DR-restricted antigens by DM-negative B cell lines. Kovats S, et al. **Eur J Immunol** 1997 Apr;27(4):1014–21

Selectivity of the major histocompatibility complex class II presentation pathway of cortical thymic epithelial cell lines. Oukka M, et al. **Eur J Immunol** 1997 Apr;27(4):855–9

Stress protein (hsp73)-mediated, TAP-independent processing of endogenous, truncated SV40 large T antigen for Db-restricted peptide presentation. Schirmbeck R, et al. **Eur J Immunol** 1997 Aug;27(8):2016–23

'Empty' Ld molecules capture peptides from endocytosed hepatitis B surface antigen particles for major histocompatibility complex class I-restricted presentation. Schirmbeck R, et al. **Eur J Immunol** 1996 Dec; 26(12):2812–22

HLA-DR-restricted presentation of purified myelin basic protein is independent of intracellular processing. Vergelli M, et al. **Eur J Immunol** 1997 Apr;27(4):941–51

Major histocompatibility complex class I presentation of ovalbumin peptide 257–264 from exogenous sources: protein context influences the degree of TAP-independent presentation. Wick MJ, et al. **Eur J Immunol** 1996 Nov; 26(11):2790–9

Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells by a model parasite antigen secreted into the parasitophorous vacuole or expressed on the amastigote surface. Wolfram M, et al. **Eur J Immunol** 1996 Dec;26(12):3153–62

Antigen processing: approaches for dissecting subcellular mechanisms that form the basis for T-cell responses modulating allergic reactions. Harding CV. **Eur Respir J Suppl** 1996 Aug;22:79s–84s

Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Schowalter DB, et al. **Gene Ther** 1997 Apr;4(4):351–60

Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. Castellino F, et al. **Hum Immunol** 1997 May;54(2):159–69 (88 ref.)

Peptide-MHC complexes assembled following multiple pathways: an opportunity for the design of vaccines and therapeutic molecules. Corradin G, et al. **Hum Immunol** 1997 May;54(2):137–47 (106 ref.)

Epitope context and reshaping of activated T helper cell repertoire. De Berardinis P, et al. **Hum Immunol** 1997 May; 54(2):189–93 (40 ref.)

Modulation of antigen processing and presentation by persistent virus infections and in tumors. Ehrlich R. **Hum Immunol** 1997 May;54(2):104–16 (126 ref.)

Influence of CD26 and integrins on the antigen sensitivity of human memory T cells. Falcioni F, et al. **Hum Immunol** 1996 Oct;50(2):79–90

Delivery of antigens to the MHC class I pathway using bacterial toxins. Goletz TJ, et al. **Hum Immunol** 1997 May; 54(2):129–36 (90 ref.)

MHC class I antigen processing pathways. Maffei A, et al. **Hum Immunol** 1997 May;54(2):91–103 (124 ref.)

Antigen processing differences among APC. Schneider SC, et al. **Hum Immunol** 1997 May;54(2):148–58 (72 ref.)

MHC class II-dependent peptide antigen versus superantigen presentation to T cells. Shoukry NH, et al. **Hum Immunol** 1997 May;54(2):194–201 (60 ref.)

Heterogeneity of mouse brain macrophages in alloantigen presentation to naive CD8+ T cells as revealed by a panel of microglial cell lines. Askew D, et al. **Immunobiology** 1996 Oct;195(4–5):417–30 (56 ref.)

Antigen presentation by MHC class I and II molecules. Neefjes JJ. **Immunobiology** 1996 Oct;195(4–5):456–60 (28 ref.)

Identification of immunogenic epitopes of GAD 65 presented by Ag7 in non-obese diabetic mice. Chao CC, et al. **Immunogenetics** 1997;46(1):29–34

CTL respond to a mitochondrial antigen presented by H2-Db. Dabhi VM, et al. **Immunogenetics** 1996;45(1):65–8

Dendritic cell presentation of PPD and 19 kDa protein of Mycobacterium tuberculosis and emergent T helper cell phenotype. Baird MA, et al. **Immunol Cell Biol** 1995 Dec; 73(6):537–43

Mechanisms of interference with the MHC class I-restricted pathway of antigen presentation by herpesviruses. Hill AB. **Immunol Cell Biol** 1996 Dec;74(6):523–6 (27 ref.)

Manipulation of the helper T cell response to influence antigenic competition occurring with a multivalent vaccine. Hunt JD, et al. **Immunol Cell Biol** 1996 Feb;74(1):81–9

Antigen presentation in allergic sensitization. Mudde GC, et al. **Immunol Cell Biol** 1996 Apr;74(2):167–73 (52 ref.)

B cell hybridoma presents both B-cell and T-cell epitopes for stimulating antibody production via CD23 pathway. Schmaltz R, et al. **Immunol Invest** 1996 Sep–Nov; 25(5–6):481–93

Peptide selection for presentation by HLA class I: a role for the human transporter associated with antigen processing? van Endert PM. **Immunol Res** 1996; 15(4):265–79 (34 ref.)

Regulation of antigen processing and presentation to class I MHC restricted CD8+ T lymphocytes. Hahn YS, et al. **Immunol Rev** 1996 Jun;151:31–49 (35 ref.)

H2-M3 restricted presentation of Listeria monocytogenes antigens. Lenz LL, et al. **Immunol Rev** 1996 Jun;151:107–21 (30 ref.)

How does TAP associate with MHC class I molecules? Elliott T. **Immunol Today** 1997 Aug;18(8):375–9 (18 ref.)

How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Kropshofer H, et al. **Immunol Today** 1997 Feb;18(2):77–82 (35 ref.)

A new foreign policy: MHC class I molecules monitor the outside world. Rock KL. **Immunol Today** 1996 Mar; 17(3):131–7 (56 ref.)

Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Sidney J, et al. **Immunol Today** 1996 Jun;17(6):261–6 (27 ref.)

Processing and presentation of an antigen of Mycobacterium avium require access to an acidified compartment with active proteases. Holsti MA, et al. **Infect Immun** 1996 Oct; 64(10):4091–8

Antigen presentation of mucosal pathogens: the players and the rules. Reyes VE, et al. **Int Arch Allergy Immunol** 1997 Feb;112(2):103–14 (98 ref.)

Recombinant vaccinia viruses for the characterization of Plasmodium falciparum-specific cytotoxic T lymphocytes: recognition of processed antigen despite limited re-stimulation efficacy. Aidoo M, et al. **Int Immunol** 1997 May;9(5):731–7

APC from mice harbouring the filarial nematode, Brugia malayi, prevent cellular proliferation but not cytokine production. Allen JE, et al. **Int Immunol** 1996 Jan; 8(1):143–51

Selective contact during TCR recognition. Feng MH, et al. **Int Immunol** 1996 Jan;8(1):45–55

Class I-restricted cytotoxic T cell recognition of split peptide ligands. Gillanders WE, et al. **Int Immunol** 1997 Jan; 9(1):81–9

The mode of protein antigen administration determines preferential presentation of peptide-class II complexes by lymph node dendritic or B cells. Guéry JC, et al. **Int Immunol** 1997 Jan;9(1):9–15

A model for antigen-induced T cell unresponsiveness based on autophosphorylative protein tyrosine kinase activity. Kaufman M, et al. **Int Immunol** 1996 Apr;8(4):613–24

Human T cell responses against the major cysteine proteinase (cruzipain) of Trypanosoma cruzi: role of the multifunctional alpha 2-macroglobulin receptor in antigen presentation by monocytes. Morrot A, et al. **Int Immunol** 1997 Jun;9(6):825–34

A broad cytotoxic T lymphocyte response to influenza type B virus presented by multiple HLA molecules. Robbins PA, et al. **Int Immunol** 1997 Jun;9(6):815–23

Monoclonal IgG as antigens: reduction is an early intracellular event of their processing by antigen-presenting cells. Santoro L, et al. **Int Immunol** 1996 Feb;8(2):211–9

Both invariant chain isoforms Ii31 and Ii41 promote class II antigen presentation. Serwe M, et al. **Int Immunol** 1997 Jul;9(7):983–91

Stimulation of human cytotoxic T cells with HIV-1-derived peptides presented by recombinant HLA-A2 peptide complexes. Walter JB, et al. **Int Immunol** 1997 Mar; 9(3):451–9

Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. Fleischhauer K, et al. **Int J Cancer** 1996 Nov 27;68(5):622–8

The contribution of peptides to T cell allorecognition and allograft rejection. Benichou G, et al. **Int Rev Immunol** 1996;13(3):231–43 (60 ref.)

Indirect T cell recognition in allograft rejection. Bradley JA. **Int Rev Immunol** 1996;13(3):245–55 (85 ref.)

New approaches to specific immunomodulation in transplantation. Colovai AI, et al. **Int Rev Immunol** 1996; 13(3):161–72 (83 ref.)

T cell receptor (TCR) repertoire in alloimmune responses. Finn OJ, et al. **Int Rev Immunol** 1996;13(3):187–207 (131 ref.)

Class II antigen processing compartments and the function of HLA-DM. Green JM, et al. **Int Rev Immunol** 1996; 13(3):209–19 (70 ref.)

Structure of HLA molecules and immunosuppressive effects of HLA derived peptides. Krensky AM, et al. **Int Rev Immunol** 1996;13(3):173–85 (56 ref.)

Role of indirect allorecognition in allograft rejection. Sayegh MH, et al. **Int Rev Immunol** 1996;13(3):221–9 (43 ref.)

Selective modulation of the major histocompatibility complex class II antigen presentation pathway following B cell receptor ligation and protein kinase C activation. Barois N, et al. **J Biol Chem** 1997 Feb 7;272(6):3641–7

Membrane topology of the ATP-binding cassette transporter associated with antigen presentation (Tap1) expressed in Escherichia coli. Gileadi U, et al. **J Biol Chem** 1997 Apr 25;272(17):11103–8

The Listeria monocytogenes-secreted p60 protein is an N-end rule substrate in the cytosol of infected cells. Implications for major histocompatibility complex class I

antigen processing of bacterial proteins. Sijts AJ, et al. **J Biol Chem** 1997 Aug 1;272(31):19261–8

CD1 presentation of microbial nonpeptide antigens to T cells. Jullien D, et al. **J Clin Invest** 1997 May 1;99(9):2071–4 (13 ref.)

Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway: transport of precursors of major histocompatibility complex class I–restricted peptides from the endoplasmic reticulum to the cytosol. Bacik I, et al. **J Exp Med** 1997 Aug 18;186(4):479–87

In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. Ingulli E, et al. **J Exp Med** 1997 Jun 16;185(12):2133–41

Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. Katz JF, et al. **J Exp Med** 1996 Nov 1; 184(5):1747–53

Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake. Ke Y, et al. **J Exp Med** 1996 Sep 1;184(3):1179–84

Class I–restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. Kurts C, et al. **J Exp Med** 1997 Jul 21;186(2):239–45

Proteolytic processing activates a viral superantigen. Mix D, et al. **J Exp Med** 1996 Oct 1;184(4):1549–54

Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. Tobery TW, et al. **J Exp Med** 1997 Mar 3;185(5):909–20

Human histocompatibility leukocyte antigen (HLA)–DM edits peptides presented by HLA-DR according to their ligand binding motifs. van Ham SM, et al. **J Exp Med** 1996 Nov 1;184(5):2019–24

Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen-major histocompatibility complex class II complexes after soluble protein exposure in vivo or in vitro. Zhong G, et al. **J Exp Med** 1997 Aug 29;186(5):673–82

Related leucine-based cytoplasmic targeting signals in invariant chain and major histocompatibility complex class II molecules control endocytic presentation of distinct determinants in a single protein. Zhong G, et al. **J Exp Med** 1997 Feb 3;185(3):429–38

The ectodomain of measles virus envelope glycoprotein does not gain access to the cytosol and MHC class I presentation pathway following virus-cell fusion. Cardoso AI, et al. **J Gen Virol** 1996 Nov;77 (Pt 11):2695–9

Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. Hengel H, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2287–96

Expression and presentation of endogenous mouse mammary tumor virus superantigens by thymic and splenic dendritic cells and B cells. Ardavín C, et al. **J Immunol** 1996 Oct 1;157(7):2789–94

CD1c restricts responses of mycobacteria-specific T cells. Evidence for antigen presentation by a second member of the human CD1 family. Beckman EM, et al. **J Immunol** 1996 Oct 1;157(7):2795–803

Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. Bullard DC, et al. **J Immunol** 1996 Oct 1;157(7):3153–8

Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. Cayeux S, et al. **J Immunol** 1997 Mar 15;158(6):2834–41

Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells. Croft M, et al. **J Immunol** 1997 Oct 1;159(7):3257–65

Absence of functional relevance of human transporter associated with antigen processing polymorphism for peptide selection. Daniel S, et al. **J Immunol** 1997 Sep 1; 159(5):2350–7

Defective TCR stimulation in anergized type 2 T helper cells correlates with abrogated p56(lck) and ZAP-70 tyrosine kinase activities. Faith A, et al. **J Immunol** 1997 Jul 1; 159(1):53–60

Human dendritic cells phagocytose and process Borrelia burgdorferi. Filgueira L, et al. **J Immunol** 1996 Oct 1; 157(7):2998–3005

The proteolytic environment involved in MHC class II–restricted antigen presentation can be modulated by the p41 form of invariant chain. Fineschi B, et al. **J Immunol** 1996 Oct 15;157(8):3211–5

Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3–encoded peptide to cytotoxic T cell clones. Fleischhauer K, et al. **J Immunol** 1997 Sep 1;159(5):2513–21

Delivery by Trypanosoma cruzi of proteins into the MHC class I antigen processing and presentation pathway. Garg N, et al. **J Immunol** 1997 Apr 1;158(7):3293–302

Identification of residues in the class II–associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II–mediated antigen presentation in an allele-dependent manner. Gautam AM, et al. **J Immunol** 1997 Sep 15;159(6):2782–8

IFN-gamma is a prerequisite for optimal antigen processing of viral peptides in vivo. Geginat G, et al. **J Immunol** 1997 Apr 1;158(7):3303–10

Antigen processing and presentation by human trophoblast-derived cell lines. Gobin SJ, et al. **J Immunol** 1997 Apr 15;158(8):3587–92

Generation of naturally processed peptide/MHC class I complexes is independent of the stability of endogenously synthesized precursors. Goth S, et al. **J Immunol** 1996 Sep 1;157(5):1894–904

Self gamma2a(b) protein is presented in vivo by gamma2a(b) B cells but not by dendritic cells. Granucci F, et al. **J Immunol** 1997 Aug 15;159(4):1794–9

Early endosomes and a late endocytic compartment generate different peptide–class II MHC complexes via distinct processing mechanisms. Griffin JP, et al. **J Immunol** 1997 Feb 15;158(4):1523–32

A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. Grohmann U, et al. **J Immunol** 1997 Apr 15;158(8):3593–602

CD40 ligand induction on T cell subsets by peptide-presenting B cells: implications for development of the primary T and B cell response. Jaiswal AI, et al. **J Immunol** 1997 Sep 1;159(5):2282–91

Presentation via the class I pathway by Leishmania amazonensis–infected macrophages of an endogenous leishmanial antigen to CD8+ T cells. Kima PE, et al. **J Immunol** 1997 Aug 15;159(4):1828–34

Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha– and Fc epsilon RI gamma-chains and can use this receptor for IgE–mediated allergen presentation. Maurer D, et al. **J Immunol** 1996 Jul 15;157(2):607–16

Chemical denaturation and modification of ovalbumin alters its dependence on ubiquitin conjugation for class I antigen presentation. Michalek MT, et al. **J Immunol** 1996 Jul 15; 157(2):617–24

Exogenously provided peptides fail to complex with intracellular class II molecules for presentation by antigen-presenting cells. Monji T, et al. **J Immunol** 1997 Apr 1;158(7):3155–64

Immunodominance is independent of structural constraints: each region within hen eggwhite lysozyme is potentially available upon processing of native antigen. Moudgil KD, et al. **J Immunol** 1997 Sep 15;159(6):2574–9

Presentation on class II MHC molecules of endogenous lysozyme targeted to the endocytic pathway. Parra-López CA, et al. **J Immunol** 1997 Mar 15;158(6):2670–9

Impaired class II expression and antigen uptake in monocytic cells after HIV-1 infection. Polyak S, et al. **J Immunol** 1997 Sep 1;159(5):2177–88

Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires. Raddrizzani L, et al. **J Immunol** 1997 Jul 15;159(2):703–11

The processing routes determined by negatively charged residues in DR1-restricted T cell determinants. Robadey C, et al. **J Immunol** 1997 Oct 1;159(7):3238–46

B7 costimulation and autoantigen specificity enable B cells to activate autoreactive T cells. Roth R, et al. **J Immunol** 1996 Oct 1;157(7):2924–31

Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. Salazar-Onfray F, et al. **J Immunol** 1997 Oct 1;159(7):3195–202

Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo. Schutze-Redelmeier MP, et al. **J Immunol** 1996 Jul 15;157(2):650–5

Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. Shen Z, et al. **J Immunol** 1997 Mar 15;158(6):2723–30

Prominence of beta 2-microglobulin, class I heavy chain conformation, and tapasin in the interactions of class I heavy chain with calreticulin and the transporter associated with antigen processing. Solheim JC, et al. **J Immunol** 1997 Mar 1;158(5):2236–41

Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors. Takamizawa M, et al. **J Immunol** 1997 Mar 1; 158(5):2134–42

Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation. Tiedemann RE, et al. **J Immunol** 1996 Nov 1;157(9):3958–66

Functional mapping of the orientation for TCR recognition of an H2-Kb–restricted ovalbumin peptide suggests that the beta-chain subunit can dominate the determination of peptide side chain specificity. Turner SJ, et al. **J Immunol** 1997 Sep 1;159(5):2312–7

The generation of MHC class I–associated peptides is only partially inhibited by proteasome inhibitors: involvement of nonproteasomal cytosolic proteases in antigen processing? Vinitsky A, et al. **J Immunol** 1997 Jul 15; 159(2):554–64

HEL–Flu: an influenza virus containing the hen egg lysozyme epitope recognized by CD4+ T cells from mice transgenic for an alphabeta TCR. Walker WS, et al. **J Immunol** 1997 Sep 15;159(6):2563–6

Regulation of class I–restricted epitope processing by local or distal flanking sequence. Yellen-Shaw AJ, et al. **J Immunol** 1997 Feb 15;158(4):1727–33

Coexpression of B7-1 and antigen blocks tolerance induction to antigen presented by resting B cells. Yuschenkoff VN, et al. **J Immunol** 1996 Sep 1;157(5):1987–95

Immunoisolation of tumor cells: generation of antitumor immunity through indirect presentation of antigen. Geller RL, et al. **J Immunother** 1997 Mar;20(2):131–7

Functional class II antigen presentation pathway in metastatic melanoma cell lines [comment] Akporiaye ET, et al. **J Immunother Emphasis Tumor Immunol** 1996 Nov; 19(6):398. Comment on: J Immunother Emphasis Tumor Immunol 1996 Nov;19(6):387–97.

MHC class II–mediated antigen presentation by melanoma cells [see comments] Brady MS, et al. **J Immunother Emphasis Tumor Immunol** 1996 Nov; 19(6):387–97. Comment in: J Immunother Emphasis Tumor Immunol 1996 Nov;19(6):398.

Rhinovirus inhibits antigen-specific T cell proliferation through an intercellular adhesion molecule-1–dependent mechanism. Gern JE, et al. **J Infect Dis** 1996 Dec; 174(6):1143–50

Two-photon fluorescence lifetime imaging microscopy of macrophage-mediated antigen processing. French T, et al. **J Microsc** 1997 Mar;185 (Pt 3):339–53

Antibacterial vaccines: impact of antigen handling and immune response. Kaufmann SH. **J Mol Med** 1997 May; 75(5):360–3 (17 ref.)

Multiple class I motifs revealed by sequencing naturally processed peptides eluted from rat T cell MHC molecules. Burrows GG, et al. **J Neurosci Res** 1997 Jul 1;49(1):107–16

Variation in H-2K(k) peptide motif revealed by sequencing naturally processed peptides from T-cell hybridoma class I molecules. Burrows GG, et al. **J Neurosci Res** 1996 Sep 15;45(6):803–11

Downregulation of IL-10 secretion and enhanced antigen-presenting abilities following HTLV-I infection of T cells. Scholz C, et al. **J Neurosci Res** 1996 Sep 15; 45(6):786–94

Use of a gel-forming dipeptide derivative as a carrier for antigen presentation. Vegners R, et al. **J Pept Sci** 1995 Nov-Dec;1(6):371–8

Antigen presentation in the CNS. Frei K, et al. **Mol Psychiatry** 1997 Mar;2(2):96–8 (27 ref.)

Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells [see comments] Cella M, et al. **Nature** 1997 Aug 21;388(6644):782–7. Comment in: Nature 1997 Aug 21;388(6644):724–5.

Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Gilbert MJ, et al. **Nature** 1996 Oct 24;383(6602):720–2

Immunology. Inside the gearbox of the dendritic cell [news; comment] Watts C. **Nature** 1997 Aug 21;388(6644):724–5 . Comment on: Nature 1997 Aug 21;388(6644):782–7. Comment on: Nature 1997 Aug 21;388(6644):787–92.

Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells. Cai Z, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14736–41

The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Groettrup M, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):8970–5

Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long-lived form of the antigen. Guéguen M, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14692–7

Antigen presentation in retroviral vector–mediated gene transfer in vivo. Song ES, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1943–8

Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. Uebel S, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):8976–81

Direct presentation of non–peptide prenyl pyrophosphate antigens to human gamma delta T cells. Morita CT, et al. **Res Immunol** 1996 Jun;147(5):347–53 (44 ref.)

MHC class I presentation of live and heat-inactivated Sendai virus antigen in T2Kb cells depends on an intracellular compartment with endosomal characteristics. Liu T, et al. **Scand J Immunol** 1997 May;45(5):527–33

Restoration of MHC class I surface expression and endogenous antigen presentation by a molecular chaperone. Wells AD, et al. **Scand J Immunol** 1997 Jun;45(6):605–12

Effect of transmembrane and cytoplasmic domains of IgE on the IgE response. Achatz G, et al. **Science** 1997 Apr 18;276(5311):409–11

Negative regulation by HLA-DO of MHC class II–restricted antigen processing. Denzin LK, et al. **Science** 1997 Oct 3;278(5335):106–9

The chameleon within: improving antigen delivery [comment] Madara JL. **Science** 1997 Aug 15; 277(5328):910–1. Comment on: Science 1997 Aug 15;277(5328):949–52.

Structural requirements for glycolipid antigen recognition by CD1b–restricted T cells. Moody DB, et al. **Science** 1997 Oct 10;278(5336):283–6

Antigen presentation by memory B cells: the sting is in the tail. Tarlinton D. **Science** 1997 Apr 18;276(5311):374–5

Endosomal targeting by the cytoplasmic tail of membrane immunoglobulin [retracted by Weiser P, Müller R, Braun U, Reth M. In: Science 1997 Jul 4;277(5322):20–1] Weiser P, et al. **Science** 1997 Apr 18;276(5311):407–9

The function of invariant chain in class II–restricted antigen presentation. Ceman S, et al. **Semin Immunol** 1995 Dec; 7(6):373–87 (88 ref.)

Binding domain regulation of MHC class II molecule assembly, trafficking, fate, and function. Germain RN. **Semin Immunol** 1995 Dec;7(6):361–72 (85 ref.)

Intracellular organelles involved in antigen processing and

the binding of peptides to class II MHC molecules. Harding CV. **Semin Immunol** 1995 Dec;7(6):355–60 (77 ref.)

Antigen unfolding and disulfide reduction in antigen presenting cells. Jensen PE. **Semin Immunol** 1995 Dec; 7(6):347–53 (45 ref.)

The structure of MHC class II: a role for dimer of dimers. Schafer PH, et al. **Semin Immunol** 1995 Dec;7(6):389–98 (54 ref.)

Binding of peptides naturally presented by HLA–B27 to the differentially disease–associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. Galocha B, et al. **Tissue Antigens** 1996 Nov;48(5):509–18

HLA–B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria. García F, et al. **Tissue Antigens** 1997 Jan;49(1):23–8

Mechanisms of indirect allorecognition in graft rejection: class II MHC allopeptide–specific T cell clones transfer delayed–type hypersensitivity responses in vivo. Chen W, et al. **Transplantation** 1996 Sep 27;62(6):705–10

The efficiency of antigen delivery from macrophage phagosomes into cytoplasm for MHC class I–restricted antigen presentation. Oh YK, et al. **Vaccine** 1997 Apr; 15(5):511–8

Combination of human cytomegalovirus recombinant immediate–early protein (IE1) with 80 nm cationic biovectors: protection from proteolysis and potentiation of presentation to CD4+ T–cell clones in vitro. Prieur E, et al. **Vaccine** 1996 Apr;14(6):511–20

[Selective induction of effector functions in a T cell clone following antigen presentation in the presence of thymic epithelial cells] Kaneda R. **Hokkaido Igaku Zasshi** 1997 Mar;72(2):195–210 (Eng. Abstr.) **(Jpn)**

[Molecular mechanism of immunological recognition and the abnormality] Tanaka K. **Nippon Rinsho** 1997 Jun; 55(6):1356–62 (18 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Ketotifen inhibits allergen–specific T lymphocytes' responses by suppressing antigen presentation with concomitant decrease of HLA–DQ antigen on macrophages. Kawano Y, et al. **Asian Pac J Allergy Immunol** 1996 Dec;14(2):69–79

Influence of n–3 polyunsaturated fatty acids (PUFA) on the antigen–presenting function of human monocytes. Hughes DA, et al. **Biochem Soc Trans** 1996 Aug;24(3):389S

Gangliosides block antigen presentation by human monocytes. Heitger A, et al. **Biochim Biophys Acta** 1996 Sep 27;1303(2):161–8

Iron salts and iron–containing porphyrins block presentation of protein antigens by macrophages to MHC class II–restricted T cells. Carrasco–Marín E, et al. **Cell Immunol** 1996 Aug 1;171(2):173–85

Nonionic triblock copolymers facilitate delivery of exogenous proteins into the MHC class I and class II processing pathways. Ke Y, et al. **Cell Immunol** 1997 Mar 15;176(2):113–21

Failure of carcinogen–altered dendritic cells to initiate T cell proliferation is associated with reduced IL–1 beta secretion. Ragg SJ, et al. **Cell Immunol** 1997 May 25;178(1):17–23

Immune effector cells induced by complete Freund's adjuvant exert an inhibitory effect on antigen–specific type 2 T helper responses. Chuang YH, et al. **Clin Exp Allergy** 1997 Mar;27(3):315–24

Calcium channel blockers suppress the contact hypersensitivity reaction (CHR) by inhibiting antigen transport and presentation by epidermal Langerhans cells in mice. Katoh N, et al. **Clin Exp Immunol** 1997 May; 108(2):302–8

The CD8 beta polypeptide is required for the recognition of an altered peptide ligand as an agonist. Renard V, et al. **Eur J Immunol** 1996 Dec;26(12):2999–3007

Defective antigen processing correlates with a low level of intracellular glutathione. Short S, et al. **Eur J Immunol** 1996 Dec;26(12):3015–20

A recombinant single–chain HLA–A2.1 molecule, with a cis active beta–2–microglobulin domain, is biologically active in peptide binding and antigen presentation. Lee L, et al. **Hum Immunol** 1996 Aug;49(1):28–37

A single residue exchange within a viral CTL epitope alters proteasome–mediated degradation resulting in lack of antigen presentation. Ossendorp F, et al. **Immunity** 1996 Aug;5(2):115–24

Selective increased presentation of type II collagen by leupeptin. Manoury–Schwartz B, et al. **Int Immunol** 1997 Apr;9(4):581–9

Lactacystin and clasto–lactacystin beta–lactone modify multiple proteasome beta–subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. Craiu A, et al. **J Biol Chem** 1997 May 16;272(20):13437–45

The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)–dependent and TAP–independent peptide epitopes by class I molecules. Bai A, et al. **J Immunol** 1997 Sep 1;159(5):2139–46

Receptor–mediated endocytosis of antigens overcomes the requirement for HLA–DM in class II–restricted antigen presentation. Ma C, et al. **J Immunol** 1997 Jan 1;158(1):1–4

The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft–versus–host disease. Schultz KR, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):201–10 (59 ref.)

Enhancing effects of (2S,3S,4R)–1–O–(alpha–D–galactopyranosyl)–2–(N–hexacosanoylamino) –1,3,4–octadecanetriol (KRN7000) on antigen–presenting function of antigen–presenting cells and antimetastatic activity of KRN7000–pretreated antigen–presenting cells. Yamaguchi Y, et al. **Oncol Res** 1996;8(10–11):399–407

Gallium arsenide augments antigen processing by peritoneal macrophages for CD4+ helper T cell stimulation. Hartmann CB, et al. **Toxicol Appl Pharmacol** 1996 Dec; 141(2):365–72

Evidence that cyclosporin A prevents clinical cardiac allograft rejection by blocking both direct and indirect antigen presentation pathways. van Besouw NM, et al. **Transpl Int** 1996;9 Suppl 1:S345–7

GENETICS

The genetics of proteasomes and antigen processing. Monaco JJ, et al. **Annu Rev Genet** 1995;29:729–54 (143 ref.)

Susceptibility to ankylosing spondylitis correlates with the C–terminal residue of peptides presented by various HLA–B27 subtypes. Fiorillo MT, et al. **Eur J Immunol** 1997 Feb;27(2):368–73

Antigen–processing polymorphisms in chronic hepatitis C infection. Höhler T, et al. **Exp Clin Immunogenet** 1996; 13(1):7–11

Successful retroviral mediated transduction of a reporter gene in human dendritic cells: feasibility of therapy with gene–modified antigen presenting cells. Aicher A, et al. **Exp Hematol** 1997 Jan;25(1):39–44

Effect of polymorphism of the HLA–DPA1 chain on presentation of antigenic peptides. Gaston JS, et al. **Hum Immunol** 1997 Apr 15;54(1):40–7

HLA–A11–mediated protection from NK cell–mediated lysis: role of HLA–A11–presented peptides. Gavioli R, et al. **Hum Immunol** 1996 Aug;49(1):1–12

Preferential presentation of herpes simplex virus T–cell antigen by HLA DQA1*0501/DQB1*0201 in comparison to HLA DQA1*0201/DQB1*0201. Koelle DM, et al. **Hum Immunol** 1997 Apr 1;53(2):195–205

Transporter associated with antigen–processing–1 (TAP1) alleles in Gorilla gorilla: diversification of the locus postspeciation. Laud PR, et al. **Hum Immunol** 1996 Oct; 50(2):91–102

Parameters affecting the immunogenicity of recombinant T cell epitopes inserted into hybrid proteins. Lo–Man R, et al. **Hum Immunol** 1997 May;54(2):180–8 (75 ref.)

A new human transporter associated with antigen processing alleles encodes a large C–terminal protein domain. Cesari MM, et al. **Immunogenetics** 1997;45(4):280–1

Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. German RN, et al. **Immunol Rev** 1996 Jun;151:5–30 (122 ref.)

The endogenous pathway of MHC class II antigen presentation. Lechler R, et al. **Immunol Rev** 1996 Jun; 151:51–79 (117 ref.)

Reactivity and specificity of CD8+ T cells in mice with defects in the MHC class I antigen–presenting pathway. Ljunggren HG, et al. **Immunol Rev** 1996 Jun;151:123–48 (89 ref.)

Nramp1 transfection transfers Ity/Lsh/Bcg–related pleiotropic effects on macrophage activation: influence on antigen processing and presentation. Lang T, et al. **Infect Immun** 1997 Feb;65(2):380–6

Molecular analysis of presentation by HLA–A2.1 of a promiscuously binding V3 loop peptide from the HIV–envelope protein to human cytotoxic T lymphocytes. Alexander–Miller MA, et al. **Int Immunol** 1996 May; 8(5):641–9

Genes in two MHC class I regions control recognition of a single rat NK cell allodeterminant. Naper C, et al. **Int Immunol** 1996 Nov;8(11):1779–85

Impaired antigen presentation by murine I–Ad class II MHC molecules expressed in normal and HLA–DM–defective human B cell lines. Weenink S, et al. **Int Immunol** 1997 Jun;9(6):889–96

The molecular basis of natural killer (NK) cell recognition and function. Moretta L, et al. **J Clin Immunol** 1996 Sep; 16(5):243–53 (69 ref.)

Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. La Cava A, et al. **J Clin Invest** 1997 Aug 1; 100(3):658–63

Effect of HLA–DM transfection on hen egg lysozyme presentation by T2.Ak cells. Albert LJ, et al. **J Immunol** 1996 Sep 15;157(6):2247–55

Multiple HLA–A alleles can present an immunodominant peptide of the human melanoma antigen Melan–A/MART–1 to a peptide–specific HLA–A*0201+ cytotoxic T cell line. Fleischhauer K, et al. **J Immunol** 1996 Jul 15;157(2):787–97

Reduced expression of Tap1 and Lmp2 antigen–processing genes in the nonobese diabetic (NOD) mouse due to a mutation in their shared bidirectional promoter. Yan G, et al. **J Immunol** 1997 Sep 15;159(6):3068–80

Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full–length viral protein. Yellen–Shaw AJ, et al. **J Immunol** 1997 Apr 1; 158(7):3227–34

Genetic control of immunity to Heligmosomoides polygyrus: presentation of promiscuous antigens to parasite–specific T cell hybridomas. Mason SD, et al. **Parasite Immunol** 1996 Sep;18(9):449–56

Major histocompatibility complex class II–transfected tumor cells present endogenous antigen and are potent inducers of tumor–specific immunity. Armstrong TD, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6886–91

Cloning and functional characterization of a subunit of the transporter associated with antigen processing. Li S, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8708–13

Functionality of major histocompatibility complex class II molecules in mice doubly deficient for invariant chain and H–2M complexes. Tourne S, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9255–60

Limited T helper cell activity in C57BL/10 (B10) mice with inherited low IgG responsiveness. Sírová M, et al. **Scand J Immunol** 1996 Nov;44(5):453–60

Linkage disequilibrium between HLA class II (DR, DQ, DP) and antigen processing (LMP, TAP, DM) genes of the major histocompatibility complex. Djilali–Saiah I, et al. **Tissue Antigens** 1996 Aug;48(2):87–92

IMMUNOLOGY

B cells present antigen to CD4+ T cells, but fail to produce IL–12. Selective APC for Th2 cell development? Adorini L, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:401–11

B cell presentation of cartilage type II collagen to T cells. Holmdahl R, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:350–2

Expression of CD80 (B7/BB–1) and CD28 in human white blood cells treated with urocanic acid. Laihia JK, et al. **Arch Dermatol Res** 1996 Sep;288(10):570–4

Macrophage mediated processing of an exogenous antigenic fluorescent probe: time–dependent elucidation of the processing pathway. Weaver DJ Jr, et al. **Biol Cell** 1996; 87(1–2):95–104

Proteasome inhibitors and antigen presentation. Bogyo M, et al. **Biopolymers** 1997;43(4):269–80 (73 ref.)

Inhibitory effects of thymus–independent type 2 antigens on MHC class II–restricted antigen presentation: comparative analysis of carbohydrate structures and the antigen presenting cell. González–Fernández M, et al. **Cell Immunol** 1997 Feb 25;176(1):1–13

Recognition and signaling by mouse Ly–49 receptors. Seaman WE, et al. **Chem Immunol** 1996;64:19–27 (31 ref.)

CD1d: outside–in antigen presentation in the intestinal epithelium? [editorial; comment] Blumberg RS, et al. **Clin Exp Immunol** 1997 Aug;109(2):223–5 (37 ref.). Comment on: Clin Exp Immunol 1997 Aug;109(2):317–20.

Molecular aberrations in the MHC class I–restricted pathway for antigen presentation in methylcholanthrene sarcomas from nude mice: discrepancies between MHC mRNA and surface protein. Engel AM, et al. **Clin Exp Immunol** 1997 Aug;109(2):323–31

Antigen presentation by common variable immunodeficiency (CVID) B cells and monocytes is unimpaired. Thon V, et al. **Clin Exp Immunol** 1997 Apr;108(1):1–8

Antigen recognition. **Curr Opin Immunol** 1997 Feb; 9(1):160–74

Mechanisms of antigen uptake for presentation. Lanzavecchia A. **Curr Opin Immunol** 1996 Jun;8(3):348–54 (93 ref.)

Recognition events that inhibit and activate natural killer cells. Raulet DH. **Curr Opin Immunol** 1996 Jun;8(3):372–7 (55 ref.)

Dendritic cells process exogenous viral proteins and virus–like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Bachmann MF, et al. **Eur J Immunol** 1996 Nov;26(11):2595–600

Normal B cells fail to secrete interleukin–12. Guéry JC, et al. **Eur J Immunol** 1997 Jul;27(7):1632–9

A wild–type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Lacabanne V, et al. **Eur J Immunol** 1996 Nov;26(11):2635–9

Epitope selection in major histocompatibility complex class I–mediated pathway is affected by the intracellular localization of an antigen. Yamazaki H, et al. **Eur J Immunol** 1997 Feb;27(2):347–53

Antigen–processing polymorphisms in chronic hepatitis C infection. Höhler T, et al. **Exp Clin Immunogenet** 1996; 13(1):7–11

Human thymic epithelial cells present superantigens to T–cell lines and thymocytes. Jirgensen A, et al. **Exp Clin Immunogenet** 1996;13(3–4):192–203

The TAP complex influences allorecognition of class II MHC molecules. Carmichael P, et al. **Hum Immunol** 1996 Sep 15;50(1):70–7

Parameters affecting the immunogenicity of recombinant T cell epitopes inserted into hybrid proteins. Lo–Man R, et al. **Hum Immunol** 1997 May;54(2):180–8 (75 ref.)

How HLA–DM affects the peptide repertoire bound to HLA–DR molecules. Vogt AB, et al. **Hum Immunol** 1997 May;54(2):170–9 (69 ref.)

The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules. Prigozy TI, et al. **Immunity** 1997 Feb;6(2):187–97

Allogeneic recognition of HLA–DRB1*0406 by T cells with HLA–DRB1*0403: role of amino acid residue 37 on the beta sheet in T cell recognition. Kaneko T, et al. **Immunobiology** 1996 Aug;195(3):261–70

Endogenous presentation of a nascent antigenic epitope to CD8+ CTL is more efficient than exogenous presentation. Hahn YS, et al. **Immunol Cell Biol** 1996 Oct;74(5):394–400

Peptide binding function and the paradox of HLA disease associations. Hughes AL, et al. **Immunol Cell Biol** 1996 Oct;74(5):444–8 (31 ref.)

Intracellular signaling and endosomal trafficking of immunoreceptors. Shared effectors underlying MHC class II-restricted antigen presentation. Bonnerot C, et al. **Immunol Lett** 1997 Jun 1;57(1-3):1-4 (35 ref.)
A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Teisserenc H, et al. **Immunol Lett** 1997 Jun 1;57(1-3):183-7
Role of the T cell receptor alpha-chain in superantigen recognition. Blackman MA, et al. **Immunol Res** 1996; 15(2):98-113 (84 ref.)
Molecular mechanisms of class I major histocompatibility complex antigen processing and presentation. Yang Y, et al. **Immunol Res** 1996;15(3):208-33 (204 ref.)
Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. German RN, et al. **Immunol Rev** 1996 Jun;151:5-30 (122 ref.)
The endogenous pathway of MHC class II antigen presentation. Lechler R, et al. **Immunol Rev** 1996 Jun; 151:51-79 (117 ref.)
Reactivity and specificity of CD8+ T cells in mice with defects in the MHC class I antigen-presenting pathway. Ljunggren HG, et al. **Immunol Rev** 1996 Jun;151:123-48 (89 ref.)
Aspects of cytotoxic T cell memory. Müllbacher A, et al. **Immunol Rev** 1996 Apr;150:113-27 (70 ref.)
Follicular dendritic cells and presentation of antigen and costimulatory signals to B cells. Tew JG, et al. **Immunol Rev** 1997 Apr;156:39-52 (83 ref.)
Evolution of allorecognition? [letter] Davenport MP, et al. **Immunol Today** 1996 Dec;17(12):589-90
Peptide antigen production by the proteasome: complexity provides efficiency. Groettrup M, et al. **Immunol Today** 1996 Sep;17(9):429-35 (75 ref.)
Could endogenous self-peptides presented by dendritic cells initiate rheumatoid arthritis? Thomas R, et al. **Immunol Today** 1996 Dec;17(12):559-64 (39 ref.)
Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Valitutti S, et al. **Immunol Today** 1997 Jun;18(6):299-304 (38 ref.)
Enhancement of antigen-presenting ability of B lymphoma cells by partial inhibition of protein synthesis through inducing B7-1 expression. Aoi T, et al. **Immunology** 1997 Jun;91(2):212-8
A comparison of the antigen-presenting capabilities of class II MHC-expressing human lung epithelial and endothelial cells. Cunningham AC, et al. **Immunology** 1997 Jul; 91(3):458-63
Generation of dendritic cell-like antigen-presenting cells in long-term mixed leucocyte culture: phenotypic and functional studies. Gao JX, et al. **Immunology** 1997 May; 91(1):135-44
Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network. Bodey B, et al. **In Vivo** 1997 Jul-Aug;11(4):351-70
Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes. Alexander-Miller MA, et al. **Int Immunol** 1996 May; 8(5):641-9
Differential activation of T cells by antibody-modulated processing of the flanking sequences of class II-restricted peptides. Fournier P, et al. **Int Immunol** 1996 Sep; 8(9):1441-51
Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing. Smith MC, et al. **Int Immunol** 1997 Aug;9(8):1085-93
B cell antigen receptor signaling links biochemical changes in the class II peptide-loading compartment to enhanced processing. Xu X, et al. **Int Immunol** 1996 Dec; 8(12):1867-76
Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells. Frisan T, et al. **Int J Cancer** 1996 Oct 9;68(2):251-8
Antigen processing and T cell repertoires as crucial aleatory features in induction of autoimmunity. Moudgil KD, et al. **J Autoimmun** 1996 Apr;9(2):227-34
The molecular basis of natural killer (NK) cell recognition and function. Moretta L, et al. **J Clin Immunol** 1996 Sep; 16(5):243-53 (69 ref.)
Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. Bennett SR, et al. **J Exp Med** 1997 Jul 7;186(1):65-70
Regulation of tumor antigen presentation by urocanic acid. Beissert S, et al. **J Immunol** 1997 Jul 1;159(1):92-6
Induction of thymocyte deletion by purified single peptide/major histocompatibility complex ligands. Lesage S, et al. **J Immunol** 1997 Sep 1;159(5):2078-81
Receptor-mediated endocytosis of antigens overcomes the requirement for HLA-DM in class II-restricted antigen presentation. Ma C, et al. **J Immunol** 1997 Jan 1;158(1):1-4
Are transporter associated with antigen processing (TAP) and tapasin class I MHC chaperones? Solheim JC, et al. **J Immunol** 1997 Jan 15;158(2):541-3
Presentation of an influenza nucleoprotein epitope incorporated into the H-2Db signal sequence requires the transporter-associated with antigen presentation. Uger RA, et al. **J Immunol** 1997 Jan 15;158(2):685-92
MHC class I expression on dendritic cells is sufficient to sensitize for transplantation immunity. Lenz P, et al. **J Invest Dermatol** 1996 Dec;107(6):844-8
Inhibition of MHC class I antigen presentation by viral proteins. Früh K, et al. **J Mol Med** 1997 Jan;75(1):18-27 (110 ref.)
Antigen presentation by autoreactive proteolipid protein peptide-specific T cell clones from chronic progressive multiple sclerosis patients: roles of co-stimulatory B7 molecules and IL-12. Correale J, et al. **J Neuroimmunol** 1997 Jan;72(1):27-43
The HLA system, antigen processing and presentation. Krensky AM. **Kidney Int Suppl** 1997 Mar;58:S2-7 (45 ref.)
Detachment activity but not cytotoxicity induced in a T-cell clone following antigen presentation in the presence of thymic epithelial cells. Kaneda R, et al. **Microbiol Immunol** 1997;41(1):51-61
Differential regulation of HLA-DR expression and antigen presentation in Toxoplasma gondii-infected melanoma cells by interleukin 6 and interferon gamma. Yang TH, et al. **Microbiol Immunol** 1996;40(6):443-9
Antigen processing by proteasomes: insights into the molecular basis of crypticity. Djaballah H. **Mol Biol Rep** 1997 Mar;24(1-2):63-7 (44 ref.)
Reversal of fortune for nascent proteins [news; comment] Bonifacino JS. **Nature** 1996 Dec 5;384(6608):405-6. Comment on: Nature 1996 Dec 5;384(6608):432-8.
The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Lehner PJ, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6904-9
The role of antigen-bound C3b in antigen processing. Colomb MG, et al. **Res Immunol** 1996 Feb;147(2):75-82; discussion 119 (28 ref.)
CD1: clues on a new antigen-presenting pathway. Jullien D, et al. **Res Immunol** 1996 Jun;147(5):321-8 (54 ref.)
Antigen-presenting function(s) of the non-classical HLA-E, -F and -G class I molecules: the beginning of a story. Le Bouteiller P, et al. **Res Immunol** 1996 Jun;147(5):301-13 (74 ref.)
On the semantics of immune recognition. Medzhitov R, et al. **Res Immunol** 1996 May;147(4):208-14 (31 ref.)
Evidence foe antigen presentation by the class Ib molecule, Qa-1. Stevens C, et al. **Res Immunol** 1996 Jun;147(5):286-90 (32 ref.)
Antigen processing and presentation [see comments] Brodsky FM, et al. **Tissue Antigens** 1996 Jun;47(6):464-71 (68 ref.) . Comment in: Tissue Antigens 1996 Jun;47(6):457-9.
Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Hicklin DJ, et al. **Tissue Antigens** 1996 Jul; 48(1):38-46
Subversion of the MHC class I antigen-presentation pathway by adenoviruses and herpes simplex viruses. Burgert HG. **Trends Microbiol** 1996 Mar;4(3):107-12 (61 ref.)
Modification of accessory activity of peritoneal cells from Fasciola hepatica infected rats. Masih DT, et al. **Vet Immunol Immunopathol** 1996 Oct;53(3-4):257-68
Novel adjuvants and vaccine delivery systems. Morein B, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):373-84
Mouse mammary tumor virus superantigens require N-linked glycosylation for effective presentation to T cells. McMahon CW, et al. **Virology** 1997 Feb 17;228(2):161-70
[Antigen-presenting mechanism of MHC class I molecules] Tanaka K. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec; 19(6):544-7 (15 ref.) **(Jpn)**

PHYSIOLOGY

Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Brossart P, et al. **Blood** 1997 Aug 15;90(4):1594-9
Dendritic cells presenting tumor antigen. Shurin MR. **Cancer Immunol Immunother** 1996 Nov;43(3):158-64 (71 ref.)
Functions of the proteasome in antigen presentation. Goldberg AL, et al. **Cold Spring Harb Symp Quant Biol** 1995;60:479-90 (74 ref.)
Antigen presentation: mixing oil and water. Porcelli SA, et al. **Curr Biol** 1997 Aug 1;7(8):R508-11 (12 ref.)
Intracellular location, complex formation, and function of the transporter associated with antigen processing in yeast. Urlinger S, et al. **Eur J Biochem** 1997 Apr 15;245(2):266-72
How HLA-DM affects the peptide repertoire bound to HLA-DR molecules. Vogt AB, et al. **Hum Immunol** 1997 May;54(2):170-9 (69 ref.)
Antigen presentation by MHC class II molecules. Weenink SM, et al. **Immunol Cell Biol** 1997 Feb;75(1):69-81 (106 ref.)
Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Chaux P, et al. **Int J Cancer** 1997 Aug 7;72(4):619-24
Antibodies against sialophorin (CD43) enhance the capacity of dendritic cells to cluster and activate T lymphocytes. Fanales-Belasio E, et al. **J Immunol** 1997 Sep 1; 159(5):2203-11
The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation. Shrikant P, et al. **J Immunol** 1996 Sep 1;157(5):1819-22 (69 ref.)
Mathematical modeling of helper T lymphocyte/antigen-presenting cell interactions: analysis of methods for modifying antigen processing and presentation. Agrawal NG, et al. **J Theor Biol** 1996 Oct 21;182(4):487-504
A short cut for the immune system [news] Brannigan JA, et al. **Nat Struct Biol** 1997 May;4(5):334-8

RADIATION EFFECTS

Heat shock increases antigenic peptide generation but decreases antigen presentation. Pépin E, et al. **Eur J Immunol** 1996 Dec;26(12):2939-43
Failed antigen presentation after UVB radiation correlates with modifications of Langerhans cell cytoskeleton. Bacci S, et al. **J Invest Dermatol** 1996 Dec;107(6):838-43

ANTIGEN-PRESENTING CELLS

see related
ANTIGEN PRESENTATION
HISTOCOMPATIBILITY ANTIGENS CLASS II
LYMPHOCYTE TRANSFORMATION

Efficient lysis of CD44v7/8-presenting target cells by genetically engineered cytotoxic T-lymphocytes--a model for immunogene therapy of cervical cancer. Dall P, et al. **Gynecol Oncol** 1997 Aug;66(2):209-16
Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Nair SK, et al. **Int J Cancer** 1997 Mar 17;70(6):706-15
Immunohistochemical localization of HLA-DR-positive cells in unerupted and erupted normal and carious human teeth. Yoshiba N, et al. **J Dent Res** 1996 Aug;75(8):1585-9
Antigen-presenting-cell function of interferon gamma-treated human gingival fibroblasts. Shimabukuro Y, et al. **J Periodontal Res** 1996 Apr;31(3):217-28
Polymorphic MHC class II promoters exhibit distinct expression pattern in various antigen-presenting cell lines. Janitz M, et al. **Tissue Antigens** 1997 Feb;49(2):99-106

CHEMISTRY

The accessory cell populations in ulcerative colitis: a comparison between the colon and appendix in colitis and acute appendicitis. Waraich T, et al. **Hum Pathol** 1997 Mar; 28(3):297-303
Transloading of tumor antigen-derived peptides into antigen-presenting cells. Buschle M, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3256-61

CYTOLOGY

Antigen-presenting cells but not lymphocytes in the joint may indicate the cause of reactive arthritis. Stagg AJ, et al. **Br J Rheumatol** 1996 Nov;35(11):1082-90
Accessory cells in the human gastrointestinal tract. MacDonald TT. **Histopathology** 1996 Jul;29(1):89-92 (30 ref.)
In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. Barratt-Boyes SM, et al. **J Immunol** 1997 May 15;158(10):4543-7

DRUG EFFECTS

Cholera toxin B subunit binding to an antigen-presenting cell directly co-stimulates cytokine production from a T cell clone. Li TK, et al. **Int Immunol** 1996 Dec;8(12):1849-56
Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. Lehmann D, et al. **J Neuroimmunol** 1997 Apr;74(1-2):102-10
Gallium arsenide selectively suppresses antigen processing by splenic macrophages for CD4+ T cell activation. Lewis TA, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1244-51
Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Reiter Y, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4631-6
Kupffer cells from halothane-exposed guinea pigs carry trifluoroacetylated protein adducts. Furst SM, et al. **Toxicology** 1997 Jun 27;120(2):119-32
TGF-beta 1 pretreatment impairs the allostimulatory function of human bone marrow-derived antigen-presenting cells for both naive and primed T cells. Bonham CA, et al. **Transpl Immunol** 1996 Sep;4(3):186-91
[Cell surface antigens on inflammatory cells in the paranasal mucosa of patients after macrolide therapy] Miyazawa T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1997 Jun; 100(6):671-7 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The role of accessory cell products in the regulation of T cell cytokine production. Kapsenberg ML, et al. **Adv Exp Med Biol** 1996;409:305-8 (15 ref.)
B lymphocytes as autoantigen-presenting cells in the amplification of autoimmunity. Roth R, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:88-104
Antigen presentation in the intestine. Panja A, et al. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):407-25 (94 ref.)
Antigen presentation of type II collagen by B cells. Catchpole B, et al. **Biochem Soc Trans** 1997 May;25(2):238S
Cellular immune response to foot-and-mouth disease virus. Cedillo-Barron L, et al. **Biochem Soc Trans** 1997 May; 25(2):275S
Do endothelial cells fit the paradigm of antigen-presenting cells? Lechler RI, et al. **Biochem Soc Trans** 1997 May; 25(2):723-7
Tumour-reactive cytotoxic T-lymphocytes specific for

normal cellular proteins. Stauss HJ, et al. **Biochem Soc Trans** 1997 May;25(2):540–3

Enhanced functional capacity of the peritoneal macrophages as antigen presenting cells after aclacinomycin treatment in mice. Bravo-Cuellar A, et al. **Biomed Pharmacother** 1997;51(4):181–4

Alloantigen presenting function of normal human CD34+ hematopoietic cells. Rondelli D, et al. **Blood** 1996 Oct 1; 88(7):2619–75

Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor. Triozzi PL, et al. **Bone Marrow Transplant** 1996 Jul;18(1):47–52

Antigen-presenting function of human peritoneum mesothelial cells isolated from a pancreatic carcinoma patient after mutant Ras peptide vaccination. Gjersten MK, et al. **Cancer Immunol Immunother** 1996 Dec;43(5):262–8

Activated T hybridomas induce upregulation of B7-1 on bystander B lymphoma cells by a contact-dependent interaction utilizing CD40 ligand. Jones KW, et al. **Cell Immunol** 1996 Nov 25;174(1):42–53

MHC class II-mediated T cell response to DNA. Waisman A, et al. **Cell Immunol** 1996 Oct 10;173(1):7–14

Elevated in vivo expression of the costimulatory molecule B7-BB1 (CD80) on antigen presenting cells from a patient with SLE. Kovacs B, et al. **Clin Exp Rheumatol** 1996 Nov-Dec;14(6):695–7

Characterization of the antigen-presenting cell and T cell requirements for induction of pulmonary eosinophilia in a murine model of asthma. Lambert LE, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):307–11

Fc epsilon RI on antigen-presenting cells. Bieber T. **Curr Opin Immunol** 1996 Dec;8(6):773–7 (26 ref.)

Antigen-specific T cell receptor antagonism by antigen-presenting cells treated with the hemolysin of Listeria monocytogenes: a novel type of immune escape. Darji A, et al. **Eur J Immunol** 1997 Jul;27(7):1696–703

Differential nuclear localization of p50, p52, and RelB proteins in human accessory cells of the immune response in situ. Feuillard J, et al. **Eur J Immunol** 1996 Nov; 26(11):2547–51

Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes. Frandji P, et al. **Eur J Immunol** 1996 Oct;26(10):2517–28

Antigen presentation by interferon-gamma-treated thyroid follicular cells inhibits interleukin-2 (IL-2) and supports IL-4 production by B7-dependent human T cells. Lombardi G, et al. **Eur J Immunol** 1997 Jan;27(1):62–71

Split activity of interleukin-10 on antigen capture and antigen presentation by human dendritic cells: definition of a maturative step. Morel AS, et al. **Eur J Immunol** 1997 Jan; 27(1):26–34

Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Nair SK, et al. **Eur J Immunol** 1997 Mar;27(3):589–97

Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Norbury CC, et al. **Eur J Immunol** 1997 Jan;27(1):280–8

Immunotoxic effects of smokeless tobacco on the accessory cell function of rat oral epithelium. Hasséus B, et al. **Eur J Oral Sci** 1997 Feb;105(1):45–51

Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Furuie H, et al. **Eur Respir J** 1997 Apr;10(4):787–94

Accessory cells in the human gastrointestinal tract. MacDonald TT. **Histopathology** 1996 Jul;29(1):89–92 (30 ref.)

Accessory cells in physiological lymphoid tissue from the intestine: an immunohistochemical study. Sarsfield P, et al. **Histopathology** 1996 Mar;28(3):205–11

Partial activation of human T cells by peptide analogs on live APC: induction of clonal anergy associated with protein tyrosine dephosphorylation. Matsushita S, et al. **Hum Immunol** 1997 Mar;53(1):73–80

MHC class I-restricted CTL responses to exogenous antigens. Jondal M, et al. **Immunity** 1996 Oct;5(4):295–302 (140 ref.)

V beta specificity of superantigen TSST-1 plus CD28 costimulation without APCs. Hu WG, et al. **Immunol Invest** 1996 Sep-Nov;25(5-6):405–11

The effect of immunomodulation of stimulator antigen presenting cells on subsequent responder T-cell function. Chung SW, et al. **Immunol Lett** 1997 Mar;55(3):133–7

T-cell anergy induced by antigen presenting cells treated with the hemolysin of Listeria monocytogenes. Darji A, et al. **Immunol Lett** 1997 Jun 1;57(1-3):33–7

Accessory molecule regulation of naive CD4 T cell activation. Dubey C, et al. **Immunol Res** 1996;15(2):114–25 (68 ref.)

Engineered APCs for tumor immunotherapy [letter] Bellone M. **Immunol Today** 1996 Apr;17(4):198

An early antigen-presenting cell defect in HIV-1-infected patients correlates with CD4 dependency in human T-cell clones. Fidler SJ, et al. **Immunology** 1996 Sep;89(1):46–53

Costimulatory signalling potential of murine MHC class II-positive T-clone cells. Frosch S, et al. **Immunology** 1996 Nov;89(3):384–90

Environmental regulation of T-cell function in mice: group housing of males affects accessory cell function. Grewal IS, et al. **Immunology** 1997 Feb;90(2):165–8

The role of small intestinal antigen-presenting cells in the induction of T-cell reactivity to soluble protein antigens: association between aberrant presentation in the lamina propria and oral tolerance. Harper HM, et al. **Immunology** 1996 Nov;89(3):449–56

Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells. Lens SM, et al. **Immunology** 1997 Jan;90(1):38–45

Alleviation of insulitis in NOD mice is associated with expression of transgenic MHC E molecules on primary antigen-presenting cells. Pilström B, et al. **Immunology** 1997 Apr;90(4):483–8

Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network. Bodey B, et al. **In Vivo** 1997 Jul-Aug;11(4):351–70

Cellular basis of decreased immune responses to pneumococcal vaccines in aged mice. Garg M, et al. **Infect Immun** 1996 Nov;64(11):4456–62

Monoclonal antibody LR-1 recognizes murine heat-stable antigen, a marker of antigen-presenting cells and developing hematopoietic cells. Hunt DW, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):218–29

B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses. Zhang YQ, et al. **Int Immunol** 1997 Aug;9(8):1095–102

Differential APC requirements of self- and nonself-reactive T cells and T cell hybridomas specific for retinal S-antigen. Prasad SA, et al. **J Autoimmun** 1997 Feb;10(1):1–9

Lack of B7-1/BB1 and B7-2/B70 expression on thyrocytes of patients with Graves' disease. Delivery of costimulatory signals from bystander professional antigen-presenting cells. Matsuoka N, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4137–43

F(c)gammaRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes. Liu C, et al. **J Clin Invest** 1996 Nov 1;98(9):2001–7

Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. Schnyder B, et al. **J Clin Invest** 1997 Jul 1;100(1):136–41

Understanding the mechanisms of sustained signaling and T cell activation [comment] Lanzavecchia A. **J Exp Med** 1997 May 19;185(10):1717–9 (20 ref.). Comment on: J Exp Med 1997 May 19;185(10):1803–13. Comment on: J Exp Med 1997 May 19;185(10):1815–25. Comment on: J Exp Med 1997 May 19;185(10):1859–64.

B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. Serreze DV, et al. **J Exp Med** 1996 Nov 1;184(5):2049–53

Leukosialin (CD43)-major histocompatibility class I molecule interactions involved in spontaneous T cell conjugate formation. Stöckl J, et al. **J Exp Med** 1996 Nov 1;184(5):1769–79

Duration of the foot-and-mouth disease virus antibody response in mice is closely related to the presence of antigen-specific presenting cells. Wigdorovitz A, et al. **J Gen Virol** 1997 May;78 (Pt 5):1025–32

Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. Bellone M, et al. **J Immunol** 1997 Jan 15;158(2):783–9

Exposure to T helper 2 cytokines in vivo before encounter with antigen selects for T helper subsets via alterations in antigen-presenting cell function. Cua DJ, et al. **J Immunol** 1996 Oct 1;157(7):2830–6

Human peptide transporter deficiency: importance of HLA-B in the presentation of TAP-independent EBV antigens. de la Salle H, et al. **J Immunol** 1997 May 15; 158(10):4555–63

Induction of anergy in CD8 T cells by B cell presentation of antigen. Höllsberg P, et al. **J Immunol** 1996 Dec 15; 157(12):5269–76

Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. Khoury SJ, et al. **J Immunol** 1996 Oct 15;157(8):3700–5

Antigen-specific B cells preferentially induce CD4+ T cells to produce IL-4. Macaulay AE, et al. **J Immunol** 1997 May 1;158(9):4171–9

Altered TCR ligands affect antigen-presenting cell responses: up-regulation of IL-12 by an analogue peptide. Matsuoka T, et al. **J Immunol** 1996 Dec 1;157(11):4837–43

Exogenously provided peptides fail to complex with intracellular class II molecules for presentation by antigen-presenting cells. Monji T, et al. **J Immunol** 1997 Apr 1;158(7):3155–64

Differential effects of a monoclonal antibody to cis-urocanic acid on the suppression of delayed and contact hypersensitivity following ultraviolet irradiation. Moodycliffe AM, et al. **J Immunol** 1996 Oct 1; 157(7):2891–9

Staphylococcal enterotoxin B induces an early and transient state of immunosuppression characterized by V beta-unrestricted T cell unresponsiveness and defective antigen-presenting cell functions. Muraille E, et al. **J Immunol** 1997 Mar 15;158(6):2638–47

Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell-dependent costimulatory signals. Palmer EM, et al. **J Immunol** 1997 Mar 15;158(6):2654–62

Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. Pechhold K, et al. **J Immunol** 1997 May 15;158(10):4921–9

CD40L is important for induction of, but not response to, costimulatory activity. ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L. Shinde S, et al. **J Immunol** 1996 Oct 1;157(7):2764–8

Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. Svensson M, et al. **J Immunol** 1997 May 1;158(9):4229–36

Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. Tomiyama H, et al. **J Immunol** 1997 May 15; 158(10):5026–34

Antigen-presenting cells in the thymus that can negatively select MHC class II-restricted T cells recognizing a circulating self antigen. Volkmann A, et al. **J Immunol** 1997 Jan 15;158(2):693–706

CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors. Wang R, et al. **J Immunol** 1996 Oct 1; 157(7):2961–8

Development of effector CD8+ T cells in contact hypersensitivity occurs independently of CD4+ T cells. Xu H, et al. **J Immunol** 1997 May 15;158(10):4721–8

Coexpression of B7-1 and antigen blocks tolerance induction to antigen presented by resting B cells. Yuschenkoff VN, et al. **J Immunol** 1996 Sep 1;157(5):1987–95

Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. Siesjö P, et al. **J Immunother Emphasis Tumor Immunol** 1996 Sep; 19(5):334–45

The influence of antigen-presenting cell type and interferon-gamma on priming and cytokine secretion of Leishmania major-specific T cells. Shankar AH, et al. **J Infect Dis** 1997 Jan;175(1):151–7

Accessory function of alveolar macrophages from patients with sarcoidosis and other granulomatous and nongranulomatous lung diseases. Zissel G, et al. **J Investig Med** 1997 Feb;45(2):75–86

A study of accessory cells in the acquired lymphoid tissue of helicobacter gastritis. Sarsfield P, et al. **J Pathol** 1996 Sep;180(1):18–25

Mathematical modeling of helper T lymphocyte/antigen-presenting cell interactions: analysis of methods for modifying antigen processing and presentation. Agrawal NG, et al. **J Theor Biol** 1996 Oct 21;182(4):487–504

Use of Epstein-Barr virus-transformed, autologous B-lymphoblastoid cells as antigen-presenting cells for establishment and maintenance of dengue virus-specific, human cytotoxic T lymphocyte clones. Livingston PG, et al. **J Virol Methods** 1997 Aug;67(1):77–84

Cutaneous leishmaniasis: a model for analysis of the immunoregulation by accessory cells. Moll H, et al. **Med Microbiol Immunol (Berl)** 1996 Feb;184(4):163–8 (54 ref.)

Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Fu TM, et al. **Mol Med** 1997 Jun;3(6):362–71

Involvement of accessory cells in the Trypanosoma cruzi-induced inhibition of the polyclonal response of T lymphocytes. Motrán C, et al. **Parasite Immunol** 1996 Jan; 18(1):43–8

The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Chesney J, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6307–12

Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules. Nelson CA, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21;94(2):628–33

The role of CD4-Lck in T-cell receptor antagonism: evidence for negative signaling. Racioppi L, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10360–5

Antigen organization regulates cluster formation and induction of cytotoxic T lymphocytes by helper T cell subsets. Stuhler G, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21;94(2):622–7

Handling of retroviral antigens by human antigen-presenting cells. Fenoglio D, et al. **Res Virol** 1996 Mar-Jun; 147(2-3):97–101

Priming to mycobacterial antigen in vivo using antigen-pulsed antigen presenting cells generated in vitro is influenced by the dose and presence of IL-4 in APC cultures. Dillon SM, et al. **Scand J Immunol** 1997 Jul; 46(1):1–9

Atopic disease and immunologic response [letter; comment] Shearer GM, et al. **Science** 1997 Apr 4;276(5309):17–8; discussion 18–9. Comment on: Science 1997 Jan 3;275(5296):77–9.

Immunodeficiency after allogeneic bone marrow transplantation in man: the role of antigen presenting cells. Møller J, et al. **Tokai J Exp Clin Med** 1996 Feb;21(1):13–7

Suppression of allorecognition by use of synthetic peptides. Colovai AI, et al. **Transplant Proc** 1996 Dec;28(6):3029–31

Mouse CD4 and CD8 T-cell clones that recognize xeno-antigens directly on xeno-antigen presenting cells in xeno MHC-restricted ways. Hirota T, et al.

Transplant Proc 1997 Feb-Mar;29(1-2):950-2
Role of costimulatory molecules on airway epithelial cells acting as alloantigen-presenting cells. Nakajima J, et al. **Transplant Proc** 1997 Jun;29(4):2297-300
CsA therapy affects the direct and indirect antigen-presentation pathway in cardiac allograft recipients. van Besouw NM, et al. **Transplant Proc** 1996 Dec;28(6):3135-6
Direct recognition of rat MHC antigens on rat antigen-presenting cells by mouse CD4+ and CD8+ T cells and establishment of T cell clones exhibiting a direct recognition pathway. Hirota T, et al. **Transplantation** 1997 Mar 15;63(5):705-10
Reduction of alloantibody response to class I major histocompatibility complex by targeting synthetic allopeptides for presentation by B cells. MacDonald CM, et al. **Transplantation** 1997 Apr 15;63(7):926-32
Antigen presenting cells in the porcine gut. Stokes CR, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):171-7 (32 ref.)
Characterization of antigen presenting cells and T-cells in progressing scabietic skin lesions. Stemmer BL, et al. **Vet Parasitol** 1996 Dec 31;67(3-4):247-58
[Selective induction of effector functions in a T cell clone following antigen presentation in the presence of thymic epithelial cells] Kaneda R. **Hokkaido Igaku Zasshi** 1997 Mar;72(2):195-210 (Eng. Abstr.) **(Jpn)**
[TCR peptide vaccination for autoimmune diseases: involvement of T-T interaction between autoimmune T cells presenting TCR peptide and CD4-CD8- regulatory T cells] Yamamura T. **Nippon Rinsho** 1997 Jun; 55(6):1519-24 (14 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Murine lymph node antigen presenting cells are the main source of interleukin-6 in the initiation of delayed-type hypersensitivity. Ulrich P, et al. **Eur Cytokine Netw** 1996 Sep;7(3):401-7
High and low doses of haptens dictate whether dermal or epidermal antigen-presenting cells promote contact hypersensitivity. Bacci S, et al. **Eur J Immunol** 1997 Feb; 27(2):442-8
Antigen-specific T cell receptor antagonism by antigen-presenting cells treated with the hemolysin of Listeria monocytogenes: a novel type of immune escape. Darji A, et al. **Eur J Immunol** 1997 Jul;27(7):1696-703
Differential expression of CLIP:MHC class II and conventional endogenous peptide:MHC class II complexes by thymic epithelial cells and peripheral antigen-presenting cells. Farr A, et al. **Eur J Immunol** 1996 Dec;26(12):3185-93
On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation. Takeuchi M, et al. **Eur J Immunol** 1997 Jul;27(7):1648-56
Fc epsilon RI-expressing antigen-presenting cells: new players in the atopic game. Bieber T. **Immunol Today** 1997 Jul;18(7):311-3 (17 ref.)
Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Valitutti S, et al. **Immunol Today** 1997 Jun;18(6):299-304 (38 ref.)
Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells. Fridkis-Hareli M, et al. **Int Immunol** 1997 Jul; 9(7):925-34
Cholera toxin B subunit binding to an antigen-presenting cell directly co-stimulates cytokine production from a T cell clone. Li TK, et al. **Int Immunol** 1996 Dec;8(12):1849-56
Monoclonal IgG as antigens: reduction is an early intracellular event of their processing by antigen-presenting cells. Santoro L, et al. **Int Immunol** 1996 Feb;8(2):211-9
B cells regulate CD40 ligand-induced IL-12 production in antigen-presenting cells (APC) during T cell/APC interactions. Maruo S, et al. **J Immunol** 1997 Jan 1; 158(1):120-6
Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. Schweitzer AN, et al. **J Immunol** 1997 Mar 15; 158(6):2713-22
Interleukin-12: an immunoregulatory cytokine produced by B cells and antigen-presenting cells. Sartori A, et al. **Methods** 1997 Jan;11(1):116-27
Immunoglobulin superfamily inhibitory receptors: from natural killer cells to antigen-presenting cells. Colonna M. **Res Immunol** 1997 Mar-Apr;148(3):169-71 (33 ref.)
Conversion of in vitro cultured human monocytes into effective presenters of an HER2/neu-encoded CTL peptide epitope. Wasserman K, et al. **Scand J Immunol** 1997 Jun;45(6):678-82
Antigen unfolding and disulfide reduction in antigen presenting cells. Jensen PE. **Semin Immunol** 1995 Dec; 7(6):347-53 (45 ref.)

MICROBIOLOGY

Enterobacteria-infected T cells as antigen-presenting cells for cytotoxic CD8 T cells: a contribution to the self-limitation of cellular immune reactions in reactive arthritis? Ackermann B, et al. **J Infect Dis** 1997 May; 175(5):1121-7

PATHOLOGY

Antigen presenting cells in the nasal mucosa of patients with allergic rhinitis during allergen provocation. Godthelp T, et al. **Clin Exp Allergy** 1996 Jun;26(6):677-88
High and low doses of haptens dictate whether dermal or epidermal antigen-presenting cells promote contact hypersensitivity. Bacci S, et al. **Eur J Immunol** 1997 Feb; 27(2):442-8
Accessory cells in Crohn's disease of the terminal ileum. Sarsfield P, et al. **Histopathology** 1996 Mar;28(3):213-9
Establishment of multipotential and antigen presenting cell lines derived from myeloid leukemias in GM-CSF transgenic mice. Rasko JE, et al. **Leukemia** 1997 May; 11(5):732-42
Tumors derived from antigen presenting cells. Levitsky HI. **Semin Immunol** 1996 Oct;8(5):281-7 (38 ref.)
[Connections between antigen presenting cells (synovial dendritic cells) and various histologic types of synovial membrane in rheumatoid arthritis] Becker R, et al. **Verh Dtsch Ges Pathol** 1996;80:328 **(Ger)**

PHYSIOLOGY

Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Demetris AJ, et al. **Am J Pathol** 1997 Feb;150(2):563-78
Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Nestle FO, et al. **Am J Pathol** 1997 Feb;150(2):641-51
Peripheral blood fibrocytes: novel fibroblast-like cells that present antigen and mediate tissue repair. Chesney J, et al. **Biochem Soc Trans** 1997 May;25(2):520-4 (30 ref.)
Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Szabolcs P, et al. **Blood** 1997 Sep 15;90(6):2160-7
Enhanced co-stimulatory ability of synovial fluid accessory cells in rheumatoid arthritis. Robertson SE, et al. **Br J Rheumatol** 1997 Apr;36(4):413-9
Antigen-presenting function of murine gonadal epithelial cell lines. Housseau F, et al. **Cell Immunol** 1997 Apr 10; 177(1):93-101
Accessory cell function of a human colonic epithelial cell line HT-29 for bacterial superantigens. Liu ZX, et al. **Clin Exp Immunol** 1997 Jun;108(3):384-91
CD21 augments antigen presentation in immune individuals. Boackle SA, et al. **Eur J Immunol** 1997 Jan;27(1):122-9
Carboxy-terminal residues of major histocompatibility complex class II-associated peptides control the presentation of the bacterial superantigen toxic shock syndrome toxin-1 to T cells. Wen R, et al. **Eur J Immunol** 1997 Mar;27(3):772-81
Modulation of T-cell cytokine secretion by accessory cell-derived products. Hilkens CM, et al. **Eur Respir J Suppl** 1996 Aug;22:90s-94s (33 ref.)
Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Valitutti S, et al. **Immunol Today** 1997 Jun;18(6):299-304 (38 ref.)
Different kinds of antigen-presenting cells exert different effects on T-helper cells development. Chuang YH, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):366-71
IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Stingl G, et al. **Int Arch Allergy Immunol** 1997 May-Jul;113(1-3):24-9 (46 ref.)
Kinetics and extent of T cell activation as measured with the calcium signal [see comments] Wülfing C, et al. **J Exp Med** 1997 May 19;185(10):1815-25. Comment in: J Exp Med 1997 May 19;185(10):1717-9.
Induction of antigen-presenting capacity in tumor cells upon infection with non-replicating recombinant vaccinia virus encoding murine MHC class II and costimulatory molecules. Marti WR, et al. **J Immunol Methods** 1997 Jan 15;200(1-2):191-8
The dendritic cell in clinical immunology: the AIDS example. Steinman RM. **J Lab Clin Med** 1996 Dec; 128(6):531-5 (18 ref.)
Fc gamma receptor I (CD64)-negative human monocytes are potent accessory cells in viral antigen-induced T cell activation and exhibit high IFN-alpha-producing capacity. Grage-Griebenow E, et al. **J Leukoc Biol** 1996 Sep; 60(3):389-96
Age-associated changes in lymphoid and antigen-presenting cell functions in mice immunized with Trypanosoma cruzi antigens. Maletto BA, et al. **Mech Ageing Dev** 1996 Jul 5;88(1-2):39-47
MHC class II positive retinal pigment epithelial (RPE) cells can function as antigen-presenting cells for microbial superantigen. Osusky R, et al. **Ocul Immunol Inflamm** 1997 Mar;5(1):43-50

RADIATION EFFECTS

UVA II exposure of human skin results in decreased immunization capacity, increased induction of tolerance and a unique pattern of epidermal antigen-presenting cell alteration. LeVee GJ, et al. **Photochem Photobiol** 1997 Apr; 65(4):622-9
Importance of the relative resistance of cord blood CD34+ cells to UVB in bone marrow transplantation. Yaron I, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):739

ULTRASTRUCTURE

[Dendritic antigen-presenting cells of the oral mucosa in health and in pathological conditions] Bykov VL. **Arkh Patol** 1997 Mar-Apr;59(2):71-5 (70 ref.) (Eng. Abstr.) **(Rus)**

ANTIGEN PROCESSING see **ANTIGEN PRESENTATION**

ANTIGEN, PROLIFERATING CELL NUCLEAR see **PROLIFERATING CELL NUCLEAR ANTIGEN**

ANTIGEN RECEPTORS see **RECEPTORS, ANTIGEN**

ANTIGEN RECEPTORS, B-CELL see **RECEPTORS, ANTIGEN, B-CELL**

ANTIGEN RECEPTORS, T-CELL see **RECEPTORS, ANTIGEN, T-CELL**

ANTIGEN RECEPTORS, T-CELL, ALPHA-BETA see **RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA**

ANTIGEN RECEPTORS, T-CELL, GAMMA-DELTA see **RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA**

ANTIGEN S 100 see **NERVE TISSUE PROTEIN S 100**

ANTIGEN SWITCHING see **ANTIGENIC VARIATION**

ANTIGENIC DETERMINANTS see **EPITOPES**

ANTIGENIC DETERMINANTS, IMMUNODOMINANT see **IMMUNODOMINANT EPITOPES**

ANTIGENIC MIMICRY see **MOLECULAR MIMICRY**

ANTIGENIC MODULATION

IMMUNOLOGY

Modulation of CD72 by ligation of B cell receptor complex molecules on CD5+ B cells. Jamin C, et al. **Int Immunol** 1997 Jul;9(7):1001-9

ANTIGENIC SPECIFICITY see **EPITOPES**

ANTIGENIC VARIATION

Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. Purtscher M, et al. **AIDS** 1996 Jun;10(6):587-93
Antigenic variation in trypanosomes. Borst P, et al. **Arch Med Res** 1996 Autumn;27(3):379-88 (83 ref.)
Epitope diversity of F strain Mycoplasma gallisepticum detected by flow cytometry. Brown JE, et al. **Avian Dis** 1997 Apr-Jun;41(2):289-95
Antigenic variation in trypanosomes: secrets surface slowly. Cross GA. **Bioessays** 1996 Apr;18(4):283-91 (77 ref.)
Virus load and antigenic diversity. Bittner B, et al. **Bull Math Biol** 1997 Sep;59(5):881-96
Antigenic variation among bovine viral diarrhea virus (BVDV) strains and the role of different cell fixation methods in immunoassays. Elahi SM, et al. **Can J Vet Res** 1997 Jan;61(1):34-8
Sequence of the VP7 gene of an atypical human rotavirus: evidence for genetic and antigenic drift. Palombo EA, et al. **DNA Seq** 1997;7(5):307-11
Antigenic and genetic analysis of equine influenza viruses from tropical Africa in 1991. Adeyefa CA, et al. **Epidemiol Infect** 1996 Oct;117(2):367-74
Plasmodium falciparum: altered expressions of erythrocyte membrane-associated antigens during antigenic variation. Le Scanf C, et al. **Exp Parasitol** 1997 Feb;85(2):135-48
Molecular and immunological characterization of the major outer membrane proteins of Brucella. Cloeckaert A, et al. **FEMS Microbiol Lett** 1996 Nov 15;145(1):1-8 (44 ref.)
Adaptive surface antigen variation in Mycoplasma bovis to the host immune response. Le Grand D, et al. **FEMS Microbiol Lett** 1996 Nov 1;144(2-3):267-75
Antigenic variation and immune evasion in Plasmodium falciparum malaria. Reeder JC, et al. **Immunol Cell Biol** 1996 Dec;74(6):546-54 (103 ref.)
Antigenic diversity in the periodontopathogen, Actinobacillus actinomycetemcomitans. Ebersole JL, et al. **Immunol Invest** 1996 May;25(3):203-14
Expression of CD44 splice variants in metastatic and non-metastatic mouse tumour cell lines. Tkach T, et al. **Immunol Lett** 1996 Sep;52(2-3):81-7
Fine mapping of outer membrane protein P2 antigenic sites which vary during persistent infection by Haemophilus influenzae. Duim B, et al. **Infect Immun** 1996 Nov; 64(11):4673-9
Antigenic variation in Neisseria gonorrhoeae: production of multiple lipooligosaccharides. Burch CL, et al. **J Bacteriol** 1997 Feb;179(3):982-6
Antigenic variability among North American and European strains of porcine reproductive and respiratory syndrome virus as defined by monoclonal antibodies to the matrix protein. Dea S, et al. **J Clin Microbiol** 1996 Jun; 34(6):1488-93
Antigenic and genetic analyses of H1N1 influenza A viruses from European pigs. Brown IH, et al. **J Gen Virol** 1997

Mar;78 (Pt 3):553–62
Effect of natural sequence variation at the H-2Ld-restricted CD8+ T cell epitope of the murine cytomegalovirus ie1-encoded pp89 on T cell recognition. Lyons PA, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2615–23
Antigenic and genetic variation of the HN protein of mumps virus strains. Yates PJ, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2491–7
The variation of Pf155/RESA gene in field isolates of Plasmodium falciparum from Thailand. Sueblinvong T, et al. **J Med Assoc Thai** 1996 Dec;79 Suppl 1:S40–8
Hyper-antigenic variation occurs with human rhinovirus type 17 [published erratum appears in J Virol 1997 Apr;71(4):3363] Patterson LJ, et al. **J Virol** 1997 Feb; 71(2):1370–4
Diversity of the immunodominant epitope of gp41 of HIV-1 subtype O and its validity for antibody detection. Eberle J, et al. **J Virol Methods** 1997 Aug;67(1):85–91
Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein. Londos-Gagliardi D, et al. **Leukemia** 1997 Apr;11 Suppl 3:38–41
Antigenic variability of an immunodominant region (239–261) of the surface glycoprotein of HTLV-I. Londos-Galgliardi D, et al. **Leukemia** 1997 Apr;11 Suppl 3:17–20
Antigenic diversity thresholds and hazard functions. May RM, et al. **Math Biosci** 1997 Jan 1;139(1):59–68
Antigenic and genetic variations among Japanese encephalitis virus strains belonging to genotype 1. Ali A, et al. **Microbiol Immunol** 1997;41(3):241–52
Shared themes of antigenic variation and virulence in bacterial, protozoal, and fungal infections. Deitsch KW, et al. **Microbiol Mol Biol Rev** 1997 Sep;61(3):281–93 (192 ref.)
A newly identified immunodominant membrane protein (pMB67) involved in Mycoplasma bovis surface antigenic variation. Behrens A, et al. **Microbiology** 1996 Sep;142 (Pt 9):2463–70
Antigenic polymorphism of the lipopolysaccharides from human and animal isolates of Bordetella bronchiseptica. Le Blay K, et al. **Microbiology** 1997 Apr;143 (Pt 4):1433–41
The Mycoplasma hominis P120 membrane protein contains a 216 amino acid hypervariable domain that is recognized by the human humoral immune response. Nyvold C, et al. **Microbiology** 1997 Feb;143 (Pt 2):675–88
Is point mutagenesis a mechanism for antigenic variation in Trypanosoma brucei? Graham VS, et al. **Mol Biochem Parasitol** 1996 Jul;79(1):35–45
Telomere exchange can be an important mechanism of variant surface glycoprotein gene switching in Trypanosoma brucei. Rudenko G, et al. **Mol Biochem Parasitol** 1996 Sep;80(1):65–75
Plasmodium falciparum: selection of parasite subpopulations with decreased sensitivity for antibody-mediated growth inhibition in vitro. Iqbal J, et al. **Parasitology** 1997 Apr;114 (Pt 4):317–24
Virus versus antibody. Colman PM. **Structure** 1997 May 15; 5(5):591–3 (19 ref.)
Antigenic variability of porcine reproductive and respiratory syndrome (PRRS) virus isolates. Influence of virus passage in pig. Le Gall A, et al. **Vet Res** 1997 May-Jun;28(3):247–57
Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Ryman KD, et al. **Virology** 1997 Apr 14;230(2):376–80
[Studies on peptide. XIX: Hepatitis C virus (HCV) immune selection] Liu G, et al. **Yao Hsueh Hsueh Pao** 1996; 31(5):358–63 (Eng. Abstr.) **(Chi)**

GENETICS

Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Zhang JR, et al. **Cell** 1997 Apr 18;89(2):275–85
Possible correlation between low antigenic drift of A(H1N1) influenza viruses and induction of HI antibodies. Iorio AM, et al. **Eur J Epidemiol** 1996 Dec;12(6):589–94
The rate of antigenic variation in fly-transmitted and syringe-passaged infections of Trypanosoma brucei. Turner CM. **FEMS Microbiol Lett** 1997 Aug 1;153(1):227–31
Mechanisms for variability in a member of the scavenger-receptor cysteine-rich superfamily. Kanan JH, et al. **Immunogenetics** 1997;46(4):276–82
Antigenic variation by telomeric recombination of major-surface-glycoprotein genes of Pneumocystis carinii. Wada M, et al. **J Eukaryot Microbiol** 1996 Sep-Oct;43(5):8S
Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. Haas G, et al. **J Immunol** 1996 Nov 1;157(9):4212–21
Evidence for distinct prototype sequences within the Plasmodium falciparum Pf60 multigene family. Bonnefoy S, et al. **Mol Biochem Parasitol** 1997 Jul;87(1):1–11
Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum. Hafalla JC, et al. **Mol Biochem Parasitol** 1997 Jul;87(1):97–9
Analysis of Trypanosoma brucei vsg expression site switching in vitro. Horn D, et al. **Mol Biochem Parasitol** 1997 Feb; 84(2):189–201
The chromosomal organization of the Plasmodium falciparum var gene family is conserved. Thompson JK, et al. **Mol Biochem Parasitol** 1997 Jul;87(1):49–60
Expressed var genes are found in Plasmodium falciparum subtelomeric regions. Hernandez-Rivas R, et al. **Mol Cell Biol** 1997 Feb;17(2):604–11
Gene conversions mediating antigenic variation in Trypanosoma brucei can occur in variant surface glycoprotein expression sites lacking 70-base-pair repeat sequences. McCulloch R, et al. **Mol Cell Biol** 1997 Feb; 17(2):833–43
Mechanism of antigenic variation in Mycoplasma pulmonis: interwoven, site-specific DNA inversions. Bhugra B, et al. **Mol Microbiol** 1995 Nov;18(4):703–14
Identification and comparison of point mutations associated in classic and variant infectious bursal disease viruses. Jackwood DJ, et al. **Virus Res** 1997 Jun;49(2):131–7

IMMUNOLOGY

Genetic and antigenic diversity of human caliciviruses (HuCVs) using RT-PCR and new EIAs. Jiang X, et al. **Arch Virol Suppl** 1996;12:251–62 (36 ref.)
Distinct antigenic subtypes of human beta interferon can be distinguished by neutralization. Golgher RR, et al. **Braz J Med Biol Res** 1996 Oct;29(10):1317–20
A novel relationship between O-antigen variation, matrix formation, and invasiveness of Salmonella enteritidis. Guard-Petter J, et al. **Epidemiol Infect** 1996 Oct; 117(2):219–31
Differential restrictions on antigenic variation among antigenic sites of foot-and-mouth disease virus in the absence of antibody selection. Holguín A, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):601–9
Biological consequences of human immunodeficiency virus type 1 envelope polymorphism: does variation matter? 1995 Fleming Lecture. McKeating JA. **J Gen Virol** 1996 Dec; 77 (Pt 12):2905–19 (145 ref.)
A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses. Estaquier J, et al. **J Pept Sci** 1996 May-Jun;2(3):165–75
The clinical significance of surface antigen variants of hepatitis B virus. Carman WF. **J Viral Hepat** 1997;4 Suppl 1:11–20 (47 ref.)
V3 peptide binding pattern and HIV-1 transmission route in Rio de Janeiro. Pinto ME, et al. **Mem Inst Oswaldo Cruz** 1995 Nov-Dec;90(6):683–5
Questions about gonococcal pilus phase- and antigenic variation. Seifert HS. **Mol Microbiol** 1996 Aug;21(3):433–40 (54 ref.)
Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Donnelly JJ, et al. **Vaccine** 1997 Jun;15(8):865–8
Antigenic variation of the Epstein-Barr virus nuclear antigen EBNA1 as revealed by monoclonal antibodies. Iwakiri D, et al. **Virus Res** 1997 Aug;50(2):139–49

ANTIGENS

see related
ANTIGEN-ANTIBODY REACTIONS
RECEPTORS, ANTIGEN

Moth-related antigens contained in the house dust of the Japanese house. Kitao S, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:90–2
Antigenic analysis of Cryptomeria japonica and Chamaecyparis obtusa using anti-Cry j 1 monoclonal antibodies. Suzuki M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:85–9
Screening panels of monoclonal antibodies using phage-displayed antigen. Lijnen HR, et al. **Anal Biochem** 1997 Jun 1;248(2):211–5
Designing immunogens for the generation of antibodies that catalyse the hydrolysis of cocaine. Hagi-Pavli E, et al. **Biochem Soc Trans** 1997 Feb;25(1):83S
Preparation, production and functional characterization of anti cAMP and cGMP antibodies. Defagot C, et al. **Biol Res** 1994;27(3-4):193–7
Hen egg yolk antibodies purified by antigen affinity under highly alkaline conditions provide new tools for diagnostics. Human intact parathyrin as a model antigen. Kuronen I, et al. **Eur J Clin Chem Clin Biochem** 1997 Jun; 35(6):435–40
Characterization of antigens specific for spermatozoa and germ cells during early gonadal development of carp (Cyprinus carpio, Cyprinidae, Teleostei) with monoclonal antibodies. Timmermans LP, et al. **Int J Dev Biol** 1996; Suppl 1:221S–222S
Beta 2-microglobulin-dependent NK1.1+ T cells are not essential for T helper cell 2 immune responses. Brown DR, et al. **J Exp Med** 1996 Oct 1;184(4):1295–304
Predominant appearance of NK1.1+ T cells producing IL-4 may be involved in the increased susceptibility of mice with the beige mutation during Salmonella infection. Enomoto A, et al. **J Immunol** 1997 Mar 1;158(5):2268–77
Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA. Schultz H, et al. **J Immunol Methods** 1997 Jul 14;205(2):127–33
Happy coupling: recruiting both antigen and effector function [news] Fearon D. **Nat Biotechnol** 1997 Jul;15(7):618–9

ADMINISTRATION & DOSAGE

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Des Roches A, et al. **Allergy** 1996 Jun;51(6):430–3
Effects of neurokinin depletion on airway inflammation induced by chronic antigen exposure. Tibério IF, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1739–47
Surface-modified diamond nanoparticles as antigen delivery vehicles. Kossovsky N, et al. **Bioconjug Chem** 1995 Sep-Oct;6(5):507–11
Analysis of Fc(epsilon)RI-mediated mast cell stimulation by surface-carried antigens. Schweitzer-Stenner R, et al. **Biophys J** 1997 Jun;72(6):2470–8
Transfer technique for minimizing waste of sonified adjuvant emulsions. Spack EG, et al. **Biotechniques** 1996 Jan; 20(1):28–30
Inductive events in oral tolerance in the TCR transgenic adoptive transfer model. Chen Y, et al. **Cell Immunol** 1997 May 25;178(1):62–8
Clonal anergy is a potent mechanism of oral tolerance in the suppression of acute antigen-induced arthritis in rats by oral administration of the inducing antigen. Inada S, et al. **Cell Immunol** 1997 Jan 10;175(1):67–75
The oral administration of low-dose antigen induces activation followed by tolerization, while high-dose antigen induces tolerance without activation. Yoshida T, et al. **Clin Immunol Immunopathol** 1997 Mar;82(3):207–15
Antigen uptake and immune responses after immersion vaccination. Nakanishi T, et al. **Dev Biol Stand** 1997; 90:59–68 (61 ref.)
Antigen uptake and immune responses after oral vaccination. Quentel C, et al. **Dev Biol Stand** 1997;90:69–78 (75 ref.)
Circular ruffle formation in rat basophilic leukemia cells in response to antigen stimulation. Edgar AJ, et al. **Eur J Cell Biol** 1997 Jun;73(2):132–40
Eosinophil accumulation and airway hyperreactivity [letter; comment] Chapman ID, et al. **Eur Respir J** 1996 Jun; 9(6):1331–3. Comment on: Eur Respir J 1995 Dec;8(12):2104–13.
Oral administration of lens homogenate suppresses antibody production in mice injected with beta-crystallin emulsified in CFA. Sueno T, et al. **Exp Eye Res** 1997 Mar;64(3):379–85
Antigens linked to synthetic microspheres induce immune responses in primates in the absence of adjuvant. Sedlik C, et al. **Immunobiology** 1996 Jan;195(1):105–18
Development and cytolytic function of intestinal intraepithelial T lymphocytes in antigen-minimized mice. Kawaguchi-Miyashita M, et al. **Immunology** 1996 Oct; 89(2):268–73
Intranasal antigen targeting to MHC class II molecules primes local IgA and serum IgG antibody responses in mice. Snider DP, et al. **Immunology** 1997 Mar;90(3):323–9
Reduction by a kallikrein inhibitor of the increased nasal airway resistance of allergic patients after antigen challenge. Katori M, et al. **Immunopharmacology** 1996 Jun; 33(1-3):308–10
Topical antigen provocation increases the number of immunoreactive IL-4-, IL-5- and IL-6-positive cells in the nasal mucosa of patients with perennial allergic rhinitis. Saito H, et al. **Int Arch Allergy Immunol** 1997 Sep; 114(1):81–5
Antigen delivery strategies for mucosal vaccines. Husband AJ, et al. **Int J Parasitol** 1996 Aug-Sep;26(8-9):825–34 (86 ref.)
Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. Des Roches A, et al. **J Allergy Clin Immunol** 1997 Apr; 99(4):450–3
Particle uptake and translocation across epithelial membranes. Thomas NW, et al. **J Anat** 1996 Dec;189 (Pt 3):487–90 (17 ref.)
Antibody to VLA-4, but not to L-selectin, protects neuronal M2 muscarinic receptors in antigen-challenged guinea pig airways. Fryer AD, et al. **J Clin Invest** 1997 Apr 15; 99(8):2036–44
An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. Kim TS, et al. **J Immunol** 1997 May 1;158(9):4137–44
Use of a gel-forming dipeptide derivative as a carrier for antigen presentation. Vegners R, et al. **J Pept Sci** 1995 Nov-Dec;1(6):371–8
Controlled delivery of antigens and adjuvants in vaccine development. Zhao Z, et al. **J Pharm Sci** 1996 Dec; 85(12):1261–70 (185 ref.)
Highlights of the symposium. Alexander NJ, et al. **J Reprod Fertil Suppl** 1996;50:191–4
Strategies for designing an immunocontraceptive vaccine based on zona pellucida synthetic peptides and recombinant antigen. Kaul R, et al. **J Reprod Fertil Suppl** 1996;50:127–34
Evaluation of zona pellucida antigens as potential candidates for immunocontraception. Paterson M, et al. **J Reprod Fertil Suppl** 1996;50:175–82
Phenotypic analysis of retinal leukocyte infiltration during combined cyclosporin A and nasal antigen administration of retinal antigens: delay and inhibition of macrophage and granulocyte infiltration. Dick AD, et al. **Ocul Immunol Inflamm** 1997 Jun;5(2):129–40
Comparative vaccination of cattle against Boophilus microplus with recombinant antigen Bm86 alone or in combination with recombinant Bm91. Willadsen P, et al. **Parasite Immunol** 1996 May;18(5):241–6
Autoradiographic mapping of pulmonary NK1 and NK2 tachykinin receptors and changes after repeated antigen

challenge in guinea pigs. Mak JC, et al. **Peptides** 1996; 17(8):1389–95

Inhaled albuterol does not inhibit cellular influx or lung injury produced by segmental antigen challenge in humans. O'Connor J, et al. **Pulm Pharmacol** 1995 Dec;8(6):237–43

Oral immunization of rainbow trout with antigen microencapsulated in poly(DL-lactide-co-glycolide) microparticles. Lavelle EC, et al. **Vaccine** 1997 Jul; 15(10):1070–8

Size effect on the antibody production induced by biodegradable microspheres containing antigen. Nakaoka R, et al. **Vaccine** 1996 Sep;14(13):1251–6

Preparation and characterization of a biodegradable microparticle antigen/cytokine delivery system. Rafferty DE, et al. **Vaccine** 1996 Apr;14(6):532–8

[Induction of passive cutaneous anaphylaxis by oral administration of antigen] Kawasumi K, et al. **Nippon Eka Daigaku Zasshi** 1997 Jun;64(3):225–31 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Are cockroaches really harmless? Frank J, et al. **Can Fam Physician** 1997 Sep;43:1529–30 (2 ref.)

Wheat antigen exposure assessment for epidemiological studies in bakeries using personal dust sampling and inhibition ELISA [see comments] Houba R, et al. **Clin Exp Allergy** 1996 Feb;26(2):154–63. Comment in: Clin Exp Allergy 1996 Feb;26(2):128–31.

Retrospective survey of a link between cat and dog antigens and allergic conjuctivitis. Fujishima H, et al. **Ophthalmologica** 1996;210(2):115–8

ANALYSIS

Group 5 determination in Pooideae grass pollen extracts by monoclonal antibody-based ELISA. Correlation with biologic activity. Ramírez J, et al. **Allergy** 1997 Aug; 52(8):806–13

HIERanarchy: the state of the art in immunohistochemistry [editorial] Swanson PE. **Am J Clin Pathol** 1997 Feb; 107(2):139–40 (14 ref.)

Immunofluorescence diagnosis of bullous dermatoses on formalin-fixed tissue sections after antigen retrieval [letter; comment] Al-Rifai I, et al. **Am J Dermatopathol** 1997 Feb; 19(1):103–5. Comment on: Am J Dermatopathol 1995 Dec;17(6):560–3.

Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Inoue Y, et al. **Am J Respir Crit Care Med** 1997 Jul;156(1):109–15

Detection of multiple antigens on western blots. Krajewski S, et al. **Anal Biochem** 1996 May 1;236(2):221–8

Immunohistochemical analysis of human embryos and fetuses: an insight into the mechanism of subversion of antigenic differentiation in neoplasia. Goel A, et al. **Arch Pathol Lab Med** 1997 Jul;121(7):719–23

Onset of protective immunity in chicks after vaccination with a recombinant herpesvirus of turkeys vaccine expressing Newcastle disease virus fusion and hemagglutinin-neuraminidase antigens. Heckert RA, et al. **Avian Dis** 1996 Oct–Dec;40(4):770–7

The universality of immuno-PCR for ultrasensitive antigen detection. Case M, et al. **Biochem Soc Trans** 1997 May; 25(2):374S

Comparative study of antigen retrieval heating methods: microwave, microwave and pressure cooker, autoclave, and steamer. Taylor CR, et al. **Biotech Histochem** 1996 Sep;71(5):263–70

Measurement of antigen by enhanced chemiluminescent western blot. Huang D, et al. **Biotechniques** 1997 Mar; 22(3):454–6, 458

Mosaic expression of uncein and 180-kDa bullous pemphigoid antigen in generalized atrophic benign epidermolysis bullosa. Matsumura Y, et al. **Br J Dermatol** 1997 May;136(5):757–61

The location of binding sites of pemphigus vulgaris and pemphigus foliaceus autoantibodies: a post-embedding immunoelectron microscopic study. Zhou S, et al. **Br J Dermatol** 1997 Jun;136(6):878–83

Non-HLA antigens and HLA-DR matching in corneal transplantation. Nicholls SM. **Br J Ophthalmol** 1996 Sep; 80(9):780–2

Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat. Kato H, et al. **Brain Res** 1996 Sep 23; 734(1–2):203–12

Optical tweezers-based immunosensor detects femtomolar concentrations of antigens [see comments] Helmerson K, et al. **Clin Chem** 1997 Feb;43(2):379–83. Comment in: Clin Chem 1997 Feb;43(2):251–3.

Wheat antigen exposure assessment for epidemiological studies in bakeries using personal dust sampling and inhibition ELISA [see comments] Houba R, et al. **Clin Exp Allergy** 1996 Feb;26(2):154–63. Comment in: Clin Exp Allergy 1996 Feb;26(2):128–31.

Monoclonal and polyclonal antibodies against casein components of cow milk for evaluation of residual antigenic activity in 'hypoallergenic' infant formulas. Plebani A, et al. **Clin Exp Allergy** 1997 Aug;27(8):949–56

Use of immunoblotting and monoclonal antibodies to evaluate the residual antigenic activity of milk protein hydrolysed formulae. Restani P, et al. **Clin Exp Allergy** 1996 Oct;26(10):1182–7

Species-specific measurement of the second group of Dermatophagoides mite allergens, Der p 2 and Der f 2, using a monoclonal antibody-based ELISA. Yasueda H, et al. **Clin Exp Allergy** 1996 Feb;26(2):171–7

von Willebrand factor antigen and adhesive molecules in Wegener's granulomatosis and microscopic polyangiitis [letter] Becvar R, et al. **Clin Rheumatol** 1997 May; 16(3):324–5

Phospholipase A2 activating protein and idiopathic inflammatory bowel disease. Peterson JW, et al. **Gut** 1996 Nov;39(5):698–704

Antigen retrieval in cryostat tissue sections and cultured cells by treatment with sodium dodecyl sulfate (SDS). Brown D, et al. **Histochem Cell Biol** 1996 Apr;105(4):261–7

Retrieval of estradiol receptor in paraffin sections of resting porcine uteri by microwave treatment. Immunostaining patterns obtained with different primary antibodies. Sierralta WD, et al. **Histochem Cell Biol** 1996 May; 105(5):357–63

Antigen retrieval, signal amplification and intensification in immunohistochemistry. Werner M, et al. **Histochem Cell Biol** 1996 Apr;105(4):253–60 (56 ref.)

Optimizing collagen antigen unmasking in paraffin-embedded tissues. Wakamatsu K, et al. **Histochem J** 1997 Jan; 29(1):65–72

Estimation and comparison of the contents of blood group B antigens in selected human tissues by microphotometric quantification of Griffonia simplicifolia agglutinin I-B4 staining with or without prior alpha-galactosidase digestion. Ito N, et al. **Histol Histopathol** 1997 Apr; 12(2):415–24

Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. Chen YH, et al. **Immunity** 1997 Apr;6(4):459–67

TCR-mediated target cell lysis by CD4+NK1+ liver T lymphocytes. Emoto M, et al. **Int Immunol** 1997 Apr; 9(4):563–71

IL-7 reverses NK1+ T cell-defective IL-4 production in the non-obese diabetic mouse. Gombert JM, et al. **Int Immunol** 1996 Nov;8(11):1751–8

NK1.1+ T cells from IL-7-deficient mice have a normal distribution and selection but exhibit impaired cytokine production. Vicari AP, et al. **Int Immunol** 1996 Nov; 8(11):1759–66

Expression of antigens associated with the individual stages of the inflammatory response in child and adult as a possible distinctive method for recurrent and chronic tonsillitis. Bussi M, et al. **Int J Pediatr Otorhinolaryngol** 1996 May; 35(3):243–50

Immunohistochemical study of amoeboid microglial cells in fetal rat brain. Wang CC, et al. **J Anat** 1996 Dec;189 (Pt 3):567–74

Double immunofluorescent staining using two unconjugated primary antisera raised in the same species. Shindler KS, et al. **J Histochem Cytochem** 1996 Nov;44(11):1331–5

Immunocytochemical detection of granzymes A and B in peripheral blood lymphocytes from healthy individuals after non-enzymatic antigen retrieval [letter] Wever PC, et al. **J Histochem Cytochem** 1997 Mar;45(3):467–9

A descriptive model for the kinetics of a homogeneous fluorometric immunoassay. Zuber E, et al. **J Immunoassay** 1997 Feb;18(1):21–47

Ontogeny of thymic NK1.1+ cells. Ballas ZK, et al. **J Immunol** 1997 Aug 1;159(3):1174–81

Development of CD4-CD8- alpha beta TCR+NK1.1+ T lymphocytes: thymic selection by self antigen. Schulz RJ, et al. **J Immunol** 1996 Nov 15;157(10):4379–89

Early production of IL-4 and induction of Th2 responses in the lymph node originate from an MHC class I-independent CD4+NK1.1- T cell population. von der Weid T, et al. **J Immunol** 1996 Nov 15;157(10):4421–7

Multiple immunoblots after non-electrophoretic bidirectional transfer of a single SDS-PAGE gel with multiple antigens. Kurien BT, et al. **J Immunol Methods** 1997 Jun 23; 205(1):91–4

Lactoseries carbohydrate antigen, Gal beta 1-4GlcNAc-R, is expressed by a subpopulation of capsaicin-sensitive rat sensory neurons. Del Mar LP, et al. **J Neurophysiol** 1996 Oct;76(4):2192–9

Expression of glial antigens in mouse astrocytes: species differences and regulation in vitro. Bambrick LL, et al. **J Neurosci Res** 1996 Nov 1;46(3):305–15

Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues [see comments] Connolly AM, et al. **J Pediatr** 1997 Jun; 130(6):878–84. Comment in: J Pediatr 1997 Jun;130(6):855–7.

Use of gold-labeled ovalbumin to correlate antigen deposition and localization with tissue response. Tengowski MW, et al. **J Pharmacol Toxicol Methods** 1997 Feb; 37(1):15–21

Simultaneous double immunoenzymatic labeling: a new procedure for the histopathologic routine. Chaubert P, et al. **Mod Pathol** 1997 Jun;10(6):585–91

Polymorphisms of the factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and poststroke mortality. Heywood DM, et al. **Stroke** 1997 Apr;28(4):816–21

Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels. Vischer UM, et al. **Thromb Haemost** 1997 Feb; 77(2):387–93

Molecular characterization, antigenicity and immunogenicity of anatoxic polymeric forms conferring protection against scorpion venoms. Kharrat R, et al. **Toxicon** 1997 Jun; 35(6):915–30

Challenges in the determination of clinically significant granulocyte antibodies and antigens. Bux J. **Transfus Med Rev** 1996 Jul;10(3):222–32 (58 ref.)

Measurement of antigen concentration by an ultrasound-enhanced latex immunoagglutination assay. Thomas NE, et al. **Ultrasound Med Biol** 1996;22(9):1277–84

Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis. Kuroki T, et al. **Virchows Arch** 1996 Oct;429(2–3):119–29

[Antigenic retrieval using a pressure cooker] Balaton AJ, et al. **Ann Pathol** 1996 Sep;16(4):307–9 (Eng. Abstr.) **(Fre)**

[Antigen retrieval: its significance and drawbacks in immunohistochemistry] Ezaki T. **Kaibogaku Zasshi** 1996 Dec;71(6):615–28 (53 ref.) (Eng. Abstr.) **(Jpn)**

[KL-6 in patients with interstitial pneumonitis] Hamada H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul; 34(7):771–7 (Eng. Abstr.) **(Jpn)**

[Major feline antigen—Fel d I clinical aspects] Zielonka TM. **Pneumonol Alergol Pol** 1996;64(7–8):505–14 (38 ref.) **(Pol)**

[The amino acid composition of the antigenic structures of the human heart conduction system] Bobrov VA, et al. **Ukr Biokhim Zh** 1996 Mar–Apr;68(2):48–50 (Eng. Abstr.) **(Rus)**

[The characteristics of the protein composition and antigenicity of whey subjected to enzymatic hydrolysis] Lind RM, et al. **Vopr Pitan** 1996;(3):20–3 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Hilden JM, et al. **Blood** 1997 May 15; 89(10):3801–5

Enhanced CREB phosphorylation and changes in c-Fos and FRA expression in striatum accompany amphetamine sensitization. f Turgeon SM, et al. **Brain Res** 1997 Feb 21; 749(1):120–6

Antigenic phenotypes common to rat oval cells, primary hepatocellular carcinomas and developing bile ducts. Hixson DC, et al. **Carcinogenesis** 1997 Jun;18(6):1169–75

Generation of antigenic peptides by lymphocyte granule serine proteases (granzymes). Carter CR, et al. **Cell Immunol** 1996 Sep 15;172(2):235–45

A central body region defined by a position-specific molecule in the planarian Dugesia (Girardia) tigrina: spatial and temporal variations during regeneration. Bueno D, et al. **Dev Biol** 1996 Sep 15;178(2):446–58

Persistent correlation between expression of a sulfated carbohydrate antigen and adrenergic differentiation in cultures of quail trunk neural crest cells. Hennig AK, et al. **Differentiation** 1995 Dec;59(5):299–306

Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy. Straetmans N, et al. **Hematopathol Mol Hematol** 1996;10(4):213–22

Peptide antigen production by the proteasome: complexity provides efficiency. Groettrup M, et al. **Immunol Today** 1996 Sep;17(9):429–35 (75 ref.)

Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? Yewdell JW, et al. **J Immunol** 1996 Sep 1;157(5):1823–6 (21 ref.)

MP84 expression in pyelonephritis and hydronephrosis kidney biopsy sections. Mukhta A, et al. **Minerva Urol Nefrol** 1997 Mar;49(1):1–3

Heterogeneity of antigen expression and lectin labeling on microglial cells in the olfactory bulb of adult rats. Wu CH, et al. **Neurosci Res** 1997 May;28(1):67–75

Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Bronte V, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3183–8

BLOOD

Tissue polypeptide-specific antigen (TPS) as tumour marker in epithelial ovarian cancer. Blokkebak-Poulsen J, et al. **Acta Oncol** 1997;36(4):433–5

Comparison of protein S functional and antigenic assays in normal pregnancy. Lefkowitz JB, et al. **Am J Obstet Gynecol** 1996 Sep;175(3 Pt 1):657–60

Identification of human sperm antigen recognized by serum of an immunoinfertile woman: a candidate for immunocontraception. Suri A, et al. **Am J Reprod Immunol** 1996 Dec;36(6):317–26

Relationship of venom effects to venom antigen and antivenom serum concentrations in a patient with Crotalus atrox envenomation treated with a Fab antivenom. Seifert SA, et al. **Ann Emerg Med** 1997 Jul;30(1):49–53

Assay development for a portable fiberoptic biosensor. Anderson GP, et al. **ASAIO J** 1996 Nov-Dec;42(6):942–6

Sperm auto - antibodies and anti-nuclear antigen antibodies in chronic dioxin - exposed veterans. Chinh TT, et al. **Chemosphere** 1996 Feb;32(3):525–30

Rapid single-step method for flow cytometric detection of surface and intracellular antigens using whole blood. Francis C, et al. **Cytometry** 1996 Sep 1;25(1):58–70

Is tolerance induction a possible mode of action of OM-89? Willis D, et al. **Drugs Exp Clin Res** 1995;21(6):207-10

Quantitation of hemopoietic cell antigens in flow cytometry. Poncelet P, et al. **Eur J Histochem** 1996;40 Suppl 1:15-32 (120 ref.)

The repertoire of serum IgM in normal mice is largely independent of external antigenic contact. Haury M, et al. **Eur J Immunol** 1997 Jun;27(6):1557-63

The usefulness of anti-fucosylated antigen antibody YB-2 for diagnosis of hepatocellular carcinoma. Nakamura J, et al. **Glycoconj J** 1997 Jan;14(1):81-7

Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1. Orth T, et al. **J Hepatol** 1997 Jan;26(1):37-47

Tissue polypeptide-specific antigen in pediatric patients: assessment of normal values. Rebhandl W, et al. **Med Pediatr Oncol** 1997 Sep;29(3):218-21

Coagulation- and fibrinolysis-related antigens in plasma and dialysate of CAPD patients. Goedde M, et al. **Perit Dial Int** 1997 Mar-Apr;17(2):162-6

Endothelial cell-associated tissue factor pathway inhibitor (TFPI) antigen in severe nondiabetic obese patients: effect of hyperinsulinemia. Cella G, et al. **Semin Thromb Hemost** 1997;23(2):129-34

The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Amirkhosravi A, et al. **Thromb Haemost** 1996 Jan;75(1):87-95

Low plasma levels of factor VIIc and antigen are more strongly associated with the 10 base pair promoter (-323) insertion than the glutamine 353 variant. Humphries S, et al. **Thromb Haemost** 1996 Apr;75(4):567-72

Flow cytometric analysis of coronary stent-induced alterations of platelet antigens in an in vitro model. Gutensohn K, et al. **Thromb Res** 1997 Apr 1;86(1):49-56

Clinical indicators of envenoming and serum levels of venom antigens in patients bitten by Bothrops lanceolatus in Martinique. Research Group on Snake Bites in Martinique. Bucher B, et al. **Trans R Soc Trop Med Hyg** 1997 Mar-Apr; 91(2):186-90

Adjuvant effect of biodegradable poly(DL-lactic acid) granules capable for antigen release following intraperitoneal injection. Nakaoka R, et al. **Vaccine** 1996 Dec;14(17-18):1671-6

[Pneumocystis carinii pneumonia associated with high levels of serum KL-6] Kawakami R, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec; 34(12):1420-6 (Eng. Abstr.) **(Jpn)**

[Hypersensitivity pneumonitis monitored with serum KL-6, a marker of interstitial pneumonia] Kobayashi J, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jul;34(7):837-42 (Eng. Abstr.) **(Jpn)**

[How can we monitor and treat patients with acute exacerbations of idiopathic interstitial pneumonia] Kobayashi J, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:195-9 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical usefulness of KL-6 as a serum marker of idiopathic interstitial pneumonia] Kohno N. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:186-9 (18 ref.) (Eng. Abstr.) **(Jpn)**

[The detection of the Glm(1) antigen by the indirect immunofluorescence reaction in a quantitative modification] Sidorov VL, et al. **Sud Med Ekspert** 1997 Jan-Mar;40(1):33-4 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Preparations of antigens and immunoadsorbents corresponding to the Streptococcus group A cell-wall polysaccharide. Auzanneau FI, et al. **Bioorg Med Chem** 1996 Nov;4(11):2003-10

Synthesis and evaluation of Ru-complexes as anisotropy probes for protein hydrodynamics and immunoassays of high-molecular-weight antigens. Szmacinski H, et al. **Biophys Chem** 1996 Nov 29;62(1-3):109-20

Concept and design of a new class of sequential oligopeptide carriers (SOC) for covalent attachment of multiple antigenic peptides. Tsikaris V, et al. **Biopolymers** 1996 Mar; 38(3):291-3

Use of pH 9.5 Tris-HCl buffer containing 5% urea for antigen retrieval immunohistochemistry. Shi SR, et al. **Biotech Histochem** 1996 Jul;71(4):190-6

Ligand function of antigenized antibodies expressing the RGD motif. Billetta R, et al. **Chem Immunol** 1997;65:159-78 (53 ref.)

Characterization of a dominant antigenic determinant of Par o I encoded by recombinant DNA. D'Abusco AS, et al. **Clin Exp Allergy** 1996 Feb;26(2):223-31

Characterization of target antigens from anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis type-I. Kellner R, et al. **Electrophoresis** 1997 Mar-Apr; 18(3-4):507-10

A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. Burg MA, et al. **Exp Cell Res** 1997 Aug 25; 235(1):254-64

Immunologic and physicochemical studies of Bermuda grass pollen antigen BG60. Su SN, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):486-94

The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein. Tillet E, et al. **J Biol Chem** 1997 Apr 18;272(16):10769-76

Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic epithelial antigen by the use of an optical biosensor. A comparison of immobilisation strategies. Catimel B, et al. **J Chromatogr A** 1997 Jul 25; 776(1):15-30

Development and application of an ELISA for Goodpasture's disease based on sheep alpha 3(IV)NC1 domains. Katbamna I, et al. **J Clin Lab Immunol** 1995; 47(1):11-24

Recent advances in multiple antigen peptides. Tam JP. **J Immunol Methods** 1996 Sep 13;196(1):17-32 (107 ref.)

Antibody-antigen recognition: a canonical structure paradigm. Lara-Ochoa F, et al. **J Mol Evol** 1996 Dec; 43(6):678-84

Mapping the detailed specificity of a calcium-dependent monoclonal antibody through the use of soluble positional scanning combinatorial libraries: identification of potent calcium-independent antigens. Pinilla C, et al. **Mol Divers** 1995 Sep;1(1):21-8

The ability of peptides to induce cytotoxic T cells in vitro does not strongly correlate with their affinity for the H-2Ld molecule: implications for vaccine design and immunotherapy. Ochoa-Garay J, et al. **Mol Immunol** 1997 Feb;34(3):273-81

Molecular cloning, structural analysis, and expression of carp ZP2 gene. Chang YS, et al. **Mol Reprod Dev** 1997 Mar; 46(3):258-67

Antigen analogs as tools to study T-cell activation function and activation. Sette A, et al. **Semin Immunol** 1996 Apr; 8(2):103-8 (29 ref.)

Preparation and characterization of a biodegradable microparticle antigen/cytokine delivery system. Rafferty DE, et al. **Vaccine** 1996 Apr;14(6):532-8

DIAGNOSTIC USE

Delayed-type hypersensitivity in palmoplantar pustulosis: effect of cyclosporin A treatment on skin testing with recall antigens. Remitz A, et al. **Acta Derm Venereol** 1996 Jul; 76(4):310-3

Evaluation of nasal passage patency after antigen and histamine challenge in guinea pigs by acoustic rhinometry. Nakamoto S, et al. **Am J Rhinol** 1997 Jan-Feb;11(1):85-9

[Value of the cellular antigen stimulation test (CAST)] Wedi B, et al. **Hautarzt** 1997 May;48(5):347-8 **(Ger)**

[The development of a latex antigenic diagnostic agent for the serological determination of tuberculous infection] Lonych LI, et al. **Mikrobiol Z** 1997 Jan-Feb;59(1):60-5 (Eng. Abstr.) **(Ukr)**

DRUG EFFECTS

Interleukin-12 prevents antigen-induced eosinophil recruitment into mouse airways. Iwamoto I, et al. **Am J Respir Crit Care Med** 1996 Nov;154(5):1257-60

Generation of antigenic peptides by lymphocyte granule serine proteases (granzymes). Carter CR, et al. **Cell Immunol** 1996 Sep 15;172(2):235-45

Brefeldin A inhibits antigen- or calcium ionophore-mediated but not PMA-induced phospholipase D activation in rat basophilic leukemia (RBL-2H3) cells. Nakamura Y, et al. **Immunobiology** 1996 Jul;195(2):231-42

Receptor-mediated endocytosis of antigens overcomes the requirement for HLA-DM in class II-restricted antigen presentation. Ma C, et al. **J Immunol** 1997 Jan 1;158(1):1-4

Epitope mapping by differential chemical modification of antigens. Bosshard HR. **Methods Mol Biol** 1996;66:85-95

The influence of dietary fat on postprandial lipaemia and factor VII coagulant activity in human subjects. Yahia N, et al. **Proc Nutr Soc** 1997 Mar;56(1B):489-96 (41 ref.)

GENETICS

Anomalous inheritance of a paternally derived trophoblast antigen. Rezai A, et al. **Am J Reprod Immunol** 1996 Mar; 35(3):245-51

Characterization by molecular cloning an antigen reactive with antireticulin antibodies. Uibo R, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:509-11

Biochemical characterization of the recombinant Boophilus microplus Bm86 antigen expressed by transformed Pichia pastoris cells. Montesino R, et al. **Biotechnol Appl Biochem** 1996 Feb;23 (Pt 1):23-8

Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Rydlander L, et al. **Eur J Biochem** 1996 Oct 15;241(2):309-14

Natural killer-like T cells develop in SJL mice despite genetically distinct defects in NK1.1 expression and in inducible interleukin-4 production. Beutner U, et al. **Eur J Immunol** 1997 Apr;27(4):928-34

Lack of directed V alpha 14-J alpha 281 rearrangements in NK1+ T cells. Shimamura M, et al. **Eur J Immunol** 1997 Jun;27(6):1576-9

A new series of mycobacterial expression vectors for the development of live recombinant vaccines. Baulard A, et al. **Gene** 1996 Oct 17;176(1-2):149-54

Localization of a human homolog of the mouse pericentrin gene (PCNT) to chromosome 21qter. Chen H, et al. **Genomics** 1996 Aug 1;35(3):620-4

Mapping to mouse chromosome 3 of the gene encoding latexin (Lxn) expressed in neocortical neurons in a region-specific manner. Jin M, et al. **Genomics** 1997 Feb 1;39(3):419-21

Ethnic differences in the expression of blood group antigens in the salivary gland secretory cells from German and Japanese non-secretor individuals. Tanegashima A, et al. **Glycoconj J** 1996 Aug;13(4):537-45

The STR systems HumVWA and HumACTBP2 in a Hungarian population. Csete K, et al. **Int J Legal Med** 1996; 108(6):316-7

Population study of the STRs HUMTH01 (including a new variant) and HUMVWA31A in Catalonia (northeast Spain). Gené M, et al. **Int J Legal Med** 1996;108(6):318-20

Developmental regulation and partial-length cloning of tubulointerstitial nephritis antigen of murine metanephros. Kumar A, et al. **Kidney Int** 1997 Sep;52(3):620-7

Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy [see comments] Takai T, et al. **Nat Biotechnol** 1997 Aug;15(8):754-8. Comment in: Nat Biotechnol 1997 Aug;15(8):718-9.

Selection of antigens for use in a virus-vectored immunocontraceptive vaccine: PH-20 as a case study. Holland MK, et al. **Reprod Fertil Dev** 1997;9(1):117-24 (22 ref.)

[Recombinant plasmids carrying yersinia pestis fra-operon: specific features of genetic transmission, inheritance and expression in attenuated enterobacterial cells] Fursova NK, et al. **Vestn Ross Akad Med Nauk** 1997;(6):44-7 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Antigen specific immunoglobulin production by NALT lymphocytes in rats. Asakura K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:80-3

Controversial issues and possible answers on the antigen-specific regulation of the IgE antibody response. Ishizaka K, et al. **Adv Exp Med Biol** 1996;409:317-25 (23 ref.)

Donor-specific bone marrow cells suppress lymphocyte reactivity to donor antigens and differentially modulate TH1 and TH2 cytokine gene expression in the responder cell population. Lagoo-Deenadayalan S, et al. **Adv Nephrol Necker Hosp** 1996;25:107-27

The nature of the antigen. Sela M, et al. **Adv Protein Chem** 1996;49:289-328 (173 ref.)

Immunogenicity and antigenicity of a partially hydrolyzed cow's milk infant formula. Chirico G, et al. **Allergy** 1997 Jan;52(1):82-8

Characterization of arterial antigens using arterial antigen-reactive T cell clones from spontaneously hypertensive rats. Ofosu-Appiah W, et al. **Am J Hypertens** 1997 May;10(5 Pt 1):535-40

Antibodies to glycosphingolipid antigens in patients with immune-mediated cochleovestibular disorders. Lake GM 3rd, et al. **Am J Otol** 1997 Mar;18(2):175-8

Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Gavett SH, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):L253-61

Effects of neuropeptide Y and substance P on antigen-induced ion secretion in rat jejunum. McKay DM, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):G987-92

Role of intercellular adhesion molecule-1 in antigen-induced lung inflammation in brown Norway rats. Richards IM, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):L267-76

B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Murphy TK, et al. **Am J Psychiatry** 1997 Mar;154(3):402-7

Update on the Center for Recombinant Gamete Contraceptive Vaccinogens. Herr JC. **Am J Reprod Immunol** 1996 Mar;35(3):184-9 (31 ref.)

Zona pellucida antigens: targets for contraceptive vaccines. Skinner SM, et al. **Am J Reprod Immunol** 1996 Mar; 35(3):163-74 (112 ref.)

Identification of human sperm antigen recognized by serum of an immunoinfertile woman: a candidate for immunocontraception. Suri A, et al. **Am J Reprod Immunol** 1996 Dec;36(6):317-26

Inhibition of antigen-induced acute bronchoconstriction, airway hyperresponsiveness, and mast cell degranulation by a nonanticoagulant heparin: comparison with a low molecular weight heparin. Ahmed T, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):1848-55

Endothelin receptor antagonists inhibit antigen-induced lung inflammation in mice. Fujitani Y, et al. **Am J Respir Crit Care Med** 1997 Jun;155(6):1890-4

Evaluation of affinity constants by competitive binding assays: removal of empiricism from the Müller method. Winzor DJ, et al. **Anal Biochem** 1996 Oct 15;241(2):180-5

Sperm acrosome antigen-1, a molecule intimately involved in the regulation of the acrosome reaction: analysis of expression on spermatozoa from infertile couples. Brucker C, et al. **Andrologia** 1997 Mar-Apr;29(2):91-6

Cross-allergenicity of the house dust mites Euroglyphus maynei and Blomia tropicalis. Morgan MS, et al. **Ann Allergy Asthma Immunol** 1996 Nov;77(5):386-92

Antigenic peptides and autoimmunity. Sinigaglia F, et al. **APMIS** 1997 Feb;105(2):81-8 (38 ref.)

On the correct determination of reference values for serum antibodies against pigeon serum antigen using a group of healthy blood donors. Bañales JL, et al. **Arch Med Res** 1997 Summer;28(2):289-91

Gene expression of a protein, JB70, related to rat alpha1-acid glycoprotein in Euglena gracilis. Durand G, et al.

Biochem Biophys Res Commun 1997 May 29;234(3):544–8
Identification and expression of antigens from Lepeophtheirus salmonis for use in vaccination trials. Labus MB, et al. **Biochem Soc Trans** 1996 May;24(2):254S
Study of antigen–binding properties of bispecific antibodies. Smirnova MB, et al. **Biochemistry (Mosc)** 1997 Jan; 62(1):41–8
A novel method for induction and detection of anaphylactic reaction using the mouse abdominal wall (AW method). Kataoka H, et al. **Biol Pharm Bull** 1997 Jun;20(6):714–6
How do antibodies and lectins recognize histo–blood group antigens? A 3D–QSAR study by comparative molecular field analysis (CoMFA). Imberty a, et al. **Bioorg Med Chem** 1996 Nov;4(11):1979–88
CD2 regulates the positive selection and function of antigen–specific CD4– CD8+ T cells. Teh SJ, et al. **Blood** 1997 Feb 15;89(4):1308–18
Unilateral ocular cicatricial pemphigoid with circulating IgA and IgG autoantibodies reactive with the 180 kD bullous pemphigoid antigen [letter] Matsuzaki T, et al. **Br J Ophthalmol** 1996 Aug;80(8):769
Anergy induction in human CD4+ T–cell clones by stimulation with soluble peptides does not require cell proliferation and is accompanied by elevated IL4 production. Grunow R, et al. **Cell Immunol** 1996 Oct 10; 173(1):79–86
Induction of T cell adhesion by antigen stimulation and modulation by the coreceptor CD4. Michel F, et al. **Cell Immunol** 1996 Nov 1;173(2):165–75
Activation of NK1.1+ T cells in vitro and their possible role in age–associated changes in inducible IL–4 production. Poynter ME, et al. **Cell Immunol** 1997 Jul 10; 179(1):22–9
Tracing antigen–driven B cell development in humans. Liu YJ. **Chem Immunol** 1997;67:14–26 (53 ref.)
A comparison of the development of antibody responses to the polysaccharide antigen (Candida albicans mannan) in atopic and healthy infants and children. Nermes M, et al. **Clin Exp Allergy** 1996 Feb;26(2):164–70
Monoclonal and polyclonal antibodies against casein components of cow milk for evaluation of residual antigenic activity in 'hypoallergenic' infant formulas. Plebani A, et al. **Clin Exp Allergy** 1997 Aug;27(8):949–56
Use of immunoblotting and monoclonal antibodies to evaluate the residual antigenic activity of milk protein hydrolysed formulae. Restani P, et al. **Clin Exp Allergy** 1996 Oct;26(10):1182–7
On the potential significance of the enzymatic activity of mite allergens to immunogenicity. Clues to structure and function revealed by molecular characterization. Robinson C, et al. **Clin Exp Allergy** 1997 Jan;27(1):10–21 (58 ref.)
Airborne dust antigen exposure and specific IgG response in the potato processing industry. Zock JP, et al. **Clin Exp Allergy** 1996 May;26(5):542–8
Therapeutic effects of preferential induction of mite–specific T helper 0 clones. Yamashita N, et al. **Clin Exp Immunol** 1997 Aug;109(2):332–41
Antigen–induced (Dumonde Glynn) arthritis in the sheep: a large joint animal model of arthritis. Highton J, et al. **Clin Exp Rheumatol** 1997 Jan–Feb;15(1):25–31
Skin testing with Mycobacterium avium sensitin to identify infection with M. avium complex in patients with cystic fibrosis. Pinto–Powell R, et al. **Clin Infect Dis** 1996 Mar; 22(3):560–2
Mechanisms of antigen uptake for presentation. Lanzavecchia A. **Curr Opin Immunol** 1996 Jun;8(3):348–54 (93 ref.)
Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta–cell antigens. Elias D, et al. **Diabetes** 1997 May;46(5):758–64
Immunization of cattle against Boophilus annulatus ticks using adult female tick antigen. Khalaf–Allah SS, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jun;103(6):219–21
Acceleration of intracellular targeting of antigen by the B–cell antigen receptor: importance depends on the nature of the antigen–antibody interaction. Aluvihare VR, et al. **EMBO J** 1997 Jun;16(12):3553–62
Relaxin counteracts asthma–like reaction induced by inhaled antigen in sensitized guinea pigs. Bani D, et al. **Endocrinology** 1997 May;138(5):1909–15
Indices of exposure to fetal and sperm antigens in relation to the occurrence of breast cancer. Rossing MA, et al. **Epidemiology** 1996 May;7(3):309–11
Accumulation of somatic hypermutation and antigen–driven selection in rapidly cycling surface Ig+ germinal center (GC) B cells which occupy GC at a high frequency during the primary anti–hapten response in mice. Kimoto H, et al. **Eur J Immunol** 1997 Jan;27(1):268–79
Constitutive macropinocytosis allows TAP–dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow–derived dendritic cells. Norbury CC, et al. **Eur J Immunol** 1997 Jan;27(1):280–8
Local exposure to salbutamol or Bt2 cyclic AMP inhibits pleural exudation and leukocyte influx caused by antigen in rats. Diaz BL, et al. **Eur J Pharmacol** 1996 Jan 25; 296(2):173–80
Expression of neuronal antigens by astrocytes derived from EGF–generated neuroprogenitor cells. Schinstine M, et al. **Exp Neurol** 1996 Sep;141(1):67–78
Monoclonal antibodies that specifically recognize crystals of dinitrobenzene. Kessler N, et al. **FASEB J** 1996 Oct; 10(12):1435–42
Colonic and jejunal motor disturbances after colonic antigen challenge of sensitized rat. Oliver MR, et al. **Gastroenterology** 1997 Jun;112(6):1996–2005
Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells. Leon MP, et al. **Hepatology** 1996 Sep;24(3):561–7
Mitogens, superantigens, and nominal antigens elicit distinctive patterns of TCRB CDR3 diversity. Currier JR, et al. **Hum Immunol** 1996 Jun–Jul;48(1–2):39–51
CD4+ cell oligoclonality in Crohn's disease: evidence for an antigen–specific response. Gulwani–Akolkar B, et al. **Hum Immunol** 1996 Jun–Jul;48(1–2):114–24
Antigen processing differences among APC. Schneider SC, et al. **Hum Immunol** 1997 May;54(2):148–58 (72 ref.)
Clonotypic analysis of T cells infiltrating the skin of patients with atopic dermatitis: evidence for antigen–driven accumulation of T cells. Tanaka A, et al. **Hum Immunol** 1996 Jun–Jul;48(1–2):107–13
Decreased amounts of antibodies to 22 and 18 kDa antigens in the peritoneal fluid of patients with endometriosis. LE Group d'Investigation en Gynecologie. Berkova N, et al. **Hum Reprod** 1996 Apr;11(4):861–7
CTL respond to a mitochondrial antigen presented by H2–Db. Dabhi VM, et al. **Immunogenetics** 1996;45(1):65–8
Mechanism of antigen–driven somatic hypermutation of rearranged immunoglobulin V(D)J genes in the mouse. Steele EJ, et al. **Immunol Cell Biol** 1997 Feb;75(1):82–95 (92 ref.)
Interleukin–15 acts as an immunological co–adjuvant for liposomal antigen in vivo. Gursel M, et al. **Immunol Lett** 1997 Mar;55(3):161–5
Lateral dynamics of major histocompatibility complex class II molecules bound with agonist peptide or altered peptide ligands. Qiu Y, et al. **Immunol Lett** 1996 Oct;53(1):19–23
Antigen localisation regulates immune responses in a dose– and time–dependent fashion: a geographical view of immune reactivity. Zinkernagel RM, et al. **Immunol Rev** 1997 Apr;156:199–209 (84 ref.)
Soluble, antigen–specific T–cell proteins: T–cell–based humoral immunity? Cone RE, et al. **Immunol Today** 1996 Jul;17(7):318–22 (53 ref.)
Mouse NK1.1+ T cells: a new family of T cells. Vicari AP, et al. **Immunol Today** 1996 Feb;17(2):71–6 (76 ref.)
Antigen–evoked mast cell degranulation in the isolated rat heart: no effect on subsequent ischemia–reperfusion induced damage. Engels W, et al. **Inflamm Res** 1997 Feb; 46(2):40–5
Kinetics of protein phosphorylation and mediator secretion following antigen challenge of mast cells sensitized with monoclonal IgE or with reaginic serum. Guérin–Marchand C, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S21–2
Does inhalation allergy to pig exist? Larsen FO, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S65–6
Gamma/delta T cells from tolerized alpha/beta–TCR–deficient mice antigen specifically inhibit contact sensitivity in vivo and IFN–gamma production in vitro. Szczepanik M, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):373–5
Matrix metalloproteinases in bronchoalveolar lavage fluid following antigen challenge. Warner JA, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):318–20
The mode of protein antigen administration determines preferential presentation of peptide–class II complexes by lymph node dendritic or B cells. Guéry JC, et al. **Int Immunol** 1997 Jan;9(1):9–15
Quaternary structure of a carrier protein influences antigenicity and immunogenicity of an inserted T cell determinant. Janssen R, et al. **Int Immunol** 1996 Jun; 8(6):829–36
Lack of Th1 or Th2 polarization of CD4+ T cell response induced by particulate antigen targeted to phagocytic cells. Sedlik C, et al. **Int Immunol** 1997 Jan;9(1):91–103
Integument ultrastructure of Oestrus ovis (L.) (Diptera:Oestridae) larvae: host immune response to various cuticular components. Innocenti L, et al. **Int J Parasitol** 1997 May;27(5):495–506
Apoptosis and the B cell response to antigen. Tarlinton DM, et al. **Int Rev Immunol** 1997;15(1–2):53–71 (38 ref.)
Implications of simultaneous tests for tuberculin and non–tuberculous mycobacteria antigen in the elderly. Shachor Y, et al. **Isr J Med Sci** 1997 Mar;33(3):170–4
Heterogeneity of polyclonal IgE characterized by differential charge, affinity to protein A, and antigenicity. Peng Z, et al. **J Allergy Clin Immunol** 1997 Jul;100(1):87–95
Immunologic and physicochemical studies of Bermuda grass pollen antigen BG60. Su SN, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):486–94
Meat allergy: III—Proteins involved and cross–reactivity between different animal species. Restani P, et al. **J Am Coll Nutr** 1997 Aug;16(4):383–9
Crosslinking of ANCA–antigens stimulates superoxide release by human neutrophils. Kettritz R, et al. **J Am Soc Nephrol** 1997 Mar;8(3):386–94
Evidence of proacrosin molecule abnormality as a possible cause of low acrosin activity and unexplained failure of fertilization in vitro. Shimizu Y, et al. **J Androl** 1997 May–Jun;18(3):281–8
Immunogenicity of cholecystokinin octapeptide–conjugated antigens in pigs. Pekas JC. **J Anim Sci** 1996 Aug; 74(8):1953–8
Expression and immune response to islet antigens following treatment with low doses of streptozotocin in H–2d mice. Herold KC, et al. **J Autoimmun** 1997 Feb;10(1):17–25
Limiting dilution analysis of the frequency of autoreactive lymph node cells isolated from mice with antigen–induced arthritis. Petrow PK, et al. **J Autoimmun** 1996 Oct; 9(5):629–35
Rho stimulates tyrosine phosphorylation of focal adhesion kinase, p130 and paxillin. Flinn HM, et al. **J Cell Sci** 1996 May;109 (Pt 5):1133–41
Granular cells are required for encapsulation of foreign targets by insect haemocytes. Pech LL, et al. **J Cell Sci** 1996 Aug;109 (Pt 8):2053–60
Use of monoclonal antibodies for weak affinity chromatography. Ohlson S, et al. **J Chromatogr A** 1997 Jan 17;758(2):199–208
Affinity of mouse immunoglobulin G subclasses for sialic acid derivatives immobilized on dextran–coated supports. Serres A, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7; 681(2):219–26
Determination of antigen–specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen–specific homeostatic mechanism in HIV–associated immunodeficiency. Waldrop SL, et al. **J Clin Invest** 1997 Apr 1;99(7):1739–50
Identification of autoantibody to melanocytes and characterization of vitiligo antigen in vitiligo patients. Park YK, et al. **J Dermatol Sci** 1996 Feb;11(2):111–20
The immunogenic effect of purified antigens of B. alexandrina against Schistosoma mansoni in experimental animals (I) as measured by worm load and viability of ova. Gamal–Eddin FM, et al. **J Egypt Soc Parasitol** 1996 Dec; 26(3):609–17
Failure to demonstrate cell–mediated immunity to orbital tissue antigens and epitopic fragments of a 64 kDa protein in the majority of patients with thyroid–associated ophthalmopathy. Kiljanski J, et al. **J Endocrinol Invest** 1996 May;19(5):284–92
The immunodominant antigen of an ultraviolet–induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. Dubey P, et al. **J Exp Med** 1997 Feb 17;185(4):695–705
How to examine the antigen–damaging effect of sodium ethoxide on deplasticized epoxy sections. Brorson SH. **J Histochem Cytochem** 1997 Jan;45(1):143–6
Non–MHC–linked Th2 cell development induced by soluble protein administration predicts susceptibility to Leishmania major infection. Guéry JC, et al. **J Immunol** 1997 Sep 1; 159(5):2147–53
CD40 ligand induction on T cell subsets by peptide–presenting B cells: implications for development of the primary T and B cell response. Jaiswal AI, et al. **J Immunol** 1997 Sep 1;159(5):2282–91
Gamma delta T lymphocytes regulate the induction and maintenance of oral tolerance. Ke Y, et al. **J Immunol** 1997 Apr 15;158(8):3610–8
Induction of antigen–specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis: a comparison between oral and peripheral tolerance. Kennedy KJ, et al. **J Immunol** 1997 Jul 15;159(2):1036–44
Antigen–dependent regulation of IgE antibody production by human antigen–specific B cells. Oshiba A, et al. **J Immunol** 1996 Dec 1;157(11):4870–5
Regulation of antigen–specific IgE, IgG1, and mast cell responses to ingested allergen by mucosal tolerance induction. van Halteren AG, et al. **J Immunol** 1997 Sep 15;159(6):3009–15
Direct thymic involvement in anterior chamber–associated immune deviation: evidence for a nondeletional mechanism of centrally induced tolerance to extrathymic antigens in adult mice. Wang Y, et al. **J Immunol** 1997 Mar 1; 158(5):2150–5
Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? Yewdell JW, et al. **J Immunol** 1996 Sep 1;157(5):1823–6 (21 ref.)
Binding parameters of antibodies reacting with multivalent antigens: functional affinity or pseudo–affinity [letter] Mattes MJ. **J Immunol Methods** 1997 Mar 10;202(1):97–101 (27 ref.)
Induction of antigen–specific isotype switching by in vitro immunization of human naive B lymphocytes. Zafiropoulos A, et al. **J Immunol Methods** 1997 Jan 15;200(1–2):181–90
Cross reactivity between the antigens of Periplaneta americana and Triatoma infestans. Alonso A, et al. **J Investig Allergol Clin Immunol** 1996 Sep–Oct;6(5):301–6
Evaluation of the efficacy of oral cromolyn sodium or an oligoantigenic diet in children with atopic dermatitis: a multicenter study of 1085 patients. Businco L, et al. **J Investig Allergol Clin Immunol** 1996 Mar–Apr;6(2):103–9
Proliferative responses of lymphocytes to food antigens are useful for detection of allergens in nonimmediate types of food allergy. Kondo N, et al. **J Investig Allergol Clin Immunol** 1997 Mar–Apr;7(2):122–6
Diagnostic reliability considerations of specific IgE determination. Sanz ML, et al. **J Investig Allergol Clin Immunol** 1996 May–Jun;6(3):152–61 (36 ref.)
Localization of immunogenic antigens on midgut of the human body louse Pediculus humanus humanus (Anoplura: Pediculidae). Mumcuoglu KY, et al. **J Med Entomol** 1996 Jan;33(1):74–7
Isolation and characterization of mouse monoclonal antibodies reactive with soft tick (Acari: Argasidae)

salivary antigens of high molecular weight. Wozniak EJ, et al. **J Med Entomol** 1996 Mar;33(2):216–9

Evaluation of anti-human antibodies for immunohistochemistry on archival nonhuman primate tissues. Wykrzykowska JJ, et al. **J Med Primatol** 1996 Apr; 25(2):71–7

Degenerate antigen recognition by CD4+ effector T cells in experimental autoimmune encephalomyelitis. McRae BL, et al. **J Neuroimmunol** 1997 May;75(1–2):156–62

Characterization of a unique T-cell clone established from a patient with HAM/TSP which recognized HTLV-I-infected T-cell antigens as well as spinal cord tissue antigens. Nagai M, et al. **J Neuroimmunol** 1996 Apr; 65(2):97–105

Expression of CD34 and other haematopoietic antigens on neuroblastoma cells: consequences for autologous bone marrow and peripheral blood stem cell transplantation. Voigt A, et al. **J Neuroimmunol** 1997 Sep;78(1–2):117–26

Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. Jicha GA, et al. **J Neurosci Res** 1997 Apr 15;48(2):128–32

Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome [see comments] Ameratunga R, et al. **J Pediatr** 1997 Jul;131(1 Pt 1):147–50 . Comment in: J Pediatr 1997 Jul;131(1 Pt 1):8–9.

Development of enzyme immunoassay of 2'-deoxycytidine. Omura K, et al. **J Pharm Biomed Anal** 1997 Jun; 15(9–10):1249–56

In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor. Foissier L, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1484–90

The influence of endogenous catecholamines on the inhibitory effects of rolipram against early- and late-phase response to antigen in the guinea pig. Underwood DC, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):210–9

Gastric antigen challenge releases gastrin and eicosanoids and protects against ethanol. Bacha EA, et al. **J Surg Res** 1997 Jun;70(1):69–74

Exploring the mechanisms of primary antibody responses to T cell-dependent antigens. Oprea M, et al. **J Theor Biol** 1996 Aug 7;181(3):215–36

Modeling T-cell proliferation: an investigation of the consequences of the Hayflick limit. Pilyugin S, et al. **J Theor Biol** 1997 May 7;186(1):117–29

Effect of Y-24180, a platelet-activating factor-receptor antagonist, on the antigen-induced airway microvascular leakage in guinea pigs. Iwahisa Y, et al. **Jpn J Pharmacol** 1996 Nov;72(3):209–15

Nerve growth factor enhances antigen-specific antibody production in ascorbate-stimulated murine splenocytes. Yanagida M, et al. **Life Sci** 1996;59(24):2075–81

Uniformity of protective antigens among isolates of the cattle tick, Boophilus microplus. Knowles AG, et al. **Med Vet Entomol** 1996 Oct;10(4):301–4

Immunogenic proteins in the body and faecal material of the human body louse, Pediculus humanus, and their homology to antigens of other lice species. Mumcuoglu KY, et al. **Med Vet Entomol** 1996 Jan;10(1):105–7

Production of antisera using peptide conjugates. Adrian TE. **Methods Mol Biol** 1997;73:239–49

A simple solid-phase competition assay with labeled antigen. Kuroki M. **Methods Mol Biol** 1996;66:47–53

Mapping epitopes on antigens by immunodiffusion in gel. Molinaro GA, et al. **Methods Mol Biol** 1996;66:39–46

Intravenous calcitriol therapy restores reduced antigen-induced T-lymphocyte response in 1,25-(OH)2D3-deficient hemodialysis patients. Antonen J, et al. **Nephron** 1996;74(4):680–6

Antigenicity and nutritional value of selected milk proteins and their hydrolysate in growing rats. Cezard JP, et al. **Nutrition** 1996 Nov-Dec;12(11–12):788–92

Nucleotide-free diet suppresses antigen-driven cytokine production by primed T cells: effects of supplemental nucleotides and dietary fatty acids. Jyonouchi H, et al. **Nutrition** 1996 Sep;12(9):608–15

Salivary antigens of the cat flea, Ctenocephalides felis felis. Lee SE, et al. **Parasite Immunol** 1997 Jan;19(1):13–9

Soluble adhesion molecules and oral antigen feeding in infants. Paronen J, et al. **Pediatr Res** 1996 Aug;40(2):276–9

Effect of pH and temperature on the immunogenicity of glycinin (Glycine max L.). Demonte A, et al. **Plant Foods Hum Nutr** 1997;50(1):63–9

Fertilization antigen-1: cDNA cloning, testis-specific expression, and immunocontraceptive effects. Zhu X, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4704–9

Internal image concept revisited. Bona CA. **Proc Soc Exp Biol Med** 1996 Oct;213(1):32–42 (126 ref.)

Prothrombin-related antigens in human aortic intima. Smith EB, et al. **Semin Thromb Hemost** 1996;22(4):347–50

S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. Bardin N, et al. **Tissue Antigens** 1996 Nov;48(5):531–9

Monoclonal antibodies directed against human Rh antigens in tests with red cells of non-human primates. Blancher A, et al. **Transfus Clin Biol** 1996;3(6):339–45

The abundance and organization of polypeptides associated with antigens of the Rh blood group system. Gardner B, et al. **Transfus Med** 1991 Jun;1(2):77–85

Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Peripheral mechanisms do not contribute to maintenance of tolerance. Khan A, et al. **Transplantation** 1996 Aug 15; 62(3):380–7

Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens. Phillips NC, et al. **Vaccine** 1996 Jun;14(9):898–904

Immunisation of rainbow trout Oncorhynchus mykiss with a multiple antigen peptide system (MAPS). Riley EM, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1–3):243–53

A new low-incidence antigen in the Kell blood group system: VLAN (KEL25). Jongerius JM, et al. **Vox Sang** 1996; 71(1):43–7

[Allergenicity and specific protein profiles of mange mites Chorioptes bovis, Psoroptes ovis (Acari: Psoroptidae), Saroptes suis and Notoedres cati (Acari: Sarcoptidae) using SDS-PAGE and immunoblotting] Beck W, et al. **Berl Munch Tierarztl Wochenschr** 1997 Apr;110(4):128–33 (Eng. Abstr.) **(Ger)**

[The correlation between interleukin-10 and interferon-gamma produced by peripheral blood mononuclear cells stimulated by house dust mite antigen in atopic dermatitis] Motoki Y, et al. **Arerugi** 1997 Apr; 46(4):376–83 (Eng. Abstr.) **(Jpn)**

[Antigenicity tests of a new antineoplastic agent S-1] Maeda Y, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:661–73 (Eng. Abstr.) **(Jpn)**

[Identification and characterization of allergens of Chironomus flaviplumus adults (Chironomidae, Diptera) in mice] Ree HI, et al. **Korean J Parasitol** 1996 Mar; 34(1):35–47 (Eng. Abstr.) **(Kor)**

[Major feline allergen--Fel d I immunologic-biochemical aspects] Zielonka TM. **Pneumonol Alergol Pol** 1996; 64(7–8):497–504 (38 ref.) **(Pol)**

[Structure and function of the major histocompatibility complex (MHC) class II antigens] Falkiewicz B, et al. **Postepy Biochem** 1996;42(4):340–9 (96 ref.) **(Pol)**

[Synthesis and antigenic properties of peptide fragments of beta2-glycoprotein-I] Pal'keeva ME, et al. **Bioorg Khim** 1996 Sep;22(9):678–85 (Eng. Abstr.) **(Rus)**

[Species specific antigens of glial and nuclear elements of mammalian brains] Veretennikov NA, et al. **Dokl Akad Nauk** 1997 Jan;352(3):424–6 **(Rus)**

[The characteristics of the protein composition and antigenicity of whey subjected to enzymatic hydrolysis] Lind RM, et al. **Vopr Pitan** 1996;(3):20–3 (Eng. Abstr.) **(Rus)**

[The new vaccines and immunologic response (and II). The antigenic presentation. Adjuvants as inducers of inducer T-lymphocyte cell-mediated response] Villarrubia VG, et al. **Med Clin (Barc)** 1996 Jun 29;107(5):185–96 (162 ref.) **(Spa)**

ISOLATION & PURIFICATION

Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Wetterwald A, et al. **Bone** 1996 Feb;18(2):125–32

Application of antibody adsorbed polyester cloth for the rapid screening of elution conditions for antigen immunopurification. Boyd S, et al. **Immunol Invest** 1996 Sep-Nov;25(5–6):447–53

Characterization of Aedes communis, Aedes aegypti and Anopheles stephensi mosquito saliva antigens by immunoblotting. Brummer-Korvenkontio H, et al. **Int Arch Allergy Immunol** 1997 Feb;112(2):169–74

Antigen retrieval immunohistochemistry: past, present, and future. Shi SR, et al. **J Histochem Cytochem** 1997 Mar; 45(3):327–43 (167 ref.)

Immunoaffinity chromatography. Jack GW, et al. **Methods Mol Biol** 1996;59:187–96

An enzyme-linked immunosorbent assay (ELISA) that discriminates between the venoms of Brazilian Bothrops species and Crotalus durissus. Chávez-Olórtegui C, et al. **Toxicon** 1997 Feb;35(2):253–60

METABOLISM

The presence of foetal ganglioside antigens 3'-isoLM1 and 3',6'-isoLD1 in both glioma tissue and surrounding areas from human brain. von Holst H, et al. **Acta Neurochir (Wien)** 1997;139(2):141–5

Anti-seminal plasma antibodies associated with infertility: II. Comparative investigation of human antibody binding to normo-, astheno-, and azoospermic seminal plasma antigens. Fichorova R, et al. **Am J Reprod Immunol** 1996 Oct;36(4):204–10

Comparison of proteins, IgE, and IgG binding antigens, and skin reactivity in commercial and laboratory-made mosquito extracts. Peng Z, et al. **Ann Allergy Asthma Immunol** 1996 Nov;77(5):371–6

Phage-displayed Fab fragments against anti-human interleukin-2 receptor alpha. Detection of antigen-bound phages with anti-cpIII monoclonal antibodies. Raivio E, et al. **APMIS** 1997 Feb;105(2):108–14

Subcellular distribution of 220 kDa antigen in the intercellular spaces of normal human epidermis. Suzuki H, et al. **Arch Dermatol Res** 1997 May;289(6):360–6

Perturbation of the antigen-binding site and staphylococcal protein A-binding site of IgG before significant changes in global conformation during denaturation: an equilibrium study. Wang XD, et al. **Biochem J** 1997 Aug 1;325 (Pt 3):707–10

Enhancement of HLA class II restricted antigen presentation by mannose-receptor-mediated uptake. Koning F. **Biochem Soc Trans** 1997 May;25(2):664–5

Influence of diffusion to fractal surfaces on the binding kinetics for antibody-antigen, analyte-receptor, and analyte-receptorless (protein) systems. Sadana A, et al. **Biophys Chem** 1997 Mar 27;65(1):29–44

Differential distribution of an endothelial barrier antigen between the pial and cortical microvessels of the rat. Cassella JP, et al. **Brain Res** 1997 Jan 9;744(2):335–8

Centrosomal deployment of gamma-tubulin and pericentrin: evidence for a microtubule-nucleating domain and a minus-end docking domain in certain mouse epithelial cells. Mogensen MM, et al. **Cell Motil Cytoskeleton** 1997; 36(3):276–90

Dynamic distribution of an antigen involved in differentiation of quail myoblasts transformed with Rous sarcoma virus: I. Requirement of its quantitative expression on the cell surface for myoblast fusion. Inoue-Hyodo N, et al. **Cell Struct Funct** 1996 Dec;21(6):515–24

Detection of psoriasis-associated antigen pso p27 in sarcoidosis bronchoalveolar lavage fluid using monoclonal antibodies. Jacobsen T, et al. **Clin Immunol Immunopathol** 1996 Oct;81(1):82–7

Mechanisms of antigen uptake for presentation. Lanzavecchia A. **Curr Opin Immunol** 1996 Jun;8(3):348–54 (93 ref.)

Antigen uptake and immune responses after immersion vaccination. Nakanishi T, et al. **Dev Biol Stand** 1997; 90:59–68 (61 ref.)

Antigen uptake and immune responses after oral vaccination. Quentel C, et al. **Dev Biol Stand** 1997;90:69–78 (75 ref.)

Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes. Frandji P, et al. **Eur J Immunol** 1996 Oct;26(10):2517–28

Split activity of interleukin-10 on antigen capture and antigen presentation by human dendritic cells: definition of a maturative step. Morel AS, et al. **Eur J Immunol** 1997 Jan; 27(1):26–34

A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. Burg MA, et al. **Exp Cell Res** 1997 Aug 25; 235(1):254–64

Rapid transepithelial antigen transport in rat jejunum: impact of sensitization and the hypersensitivity reaction [see comments] Berin MC, et al. **Gastroenterology** 1997 Sep; 113(3):856–64. Comment in: Gastroenterology 1997 Sep;113(3):1034–6.

Adsorption-induced antigenic changes and their significance in ELISA and immunological disorders. Butler JE, et al. **Immunol Invest** 1997 Jan-Feb;26(1–2):39–54

Why is it so hard to dissociate multivalent antigens from cell-surface antibodies? [see comments] Goldstein B, et al. **Immunol Today** 1996 Feb;17(2):77–80 (22 ref.). Comment in: Immunol Today 1997 Jun;18(6):305–6.

Engagement of CD45 during in vitro priming enhances antigen-specific Th cell frequencies. Harris PE, et al. **Int Immunol** 1996 Aug;8(8):1265–71

IL-2 and IL-7 differentially induce CD4-CD8- alpha beta TCR+NK1.1+ large granular lymphocytes and IL-4-producing cells from CD4-CD8- alpha beta TCR+NK1.1- cells: implications for the regulation of Th1- and Th2-type responses. Nishizawa K, et al. **Int Immunol** 1997 Aug;9(8):1123–9

Heat shock causes protein aggregation and reduced protein solubility at the centrosome and other cytoplasmic locations. Vidair CA, et al. **Int J Hyperthermia** 1996 Sep-Oct;12(5):681–95

Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. Burg MA, et al. **J Biol Chem** 1996 Oct 18;271(42):26110–6

Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. Sah VP, et al. **J Biol Chem** 1996 Dec 6; 271(49):31185–90

The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein. Tillet E, et al. **J Biol Chem** 1997 Apr 18;272(16):10769–76

Distribution of a reeler gene-related antigen in the developing cerebellum: an immunohistochemical study with an allogeneic antibody CR-50 on normal and reeler mice. Miyata T, et al. **J Comp Neurol** 1996 Aug 19; 372(2):215–28

Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles. Hsi ED, et al. **J Dermatol Sci** 1996 Jan;11(1):1–9

Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. Rothenberg ME, et al. **J Exp Med** 1997 Feb 17;185(4):785–90

Ceramide inhibits antigen uptake and presentation by dendritic cells. Sallusto F, et al. **J Exp Med** 1996 Dec 1; 184(6):2411–6

Relationship between immunostaining intensity and antigen content in sections. Watanabe J, et al. **J Histochem Cytochem** 1996 Dec;44(12):1451–8

Receptor-mediated endocytosis of antigens overcomes the requirement for HLA-DM in class II-restricted antigen presentation. Ma C, et al. **J Immunol** 1997 Jan 1;158(1):1–4

Impaired class II expression and antigen uptake in monocytic cells after HIV-1 infection. Polyak S, et al. **J Immunol** 1997 Sep 1;159(5):2177–88

Involvement of peptide antigens in the cytotoxicity between 70-kDa heat shock cognate protein-like molecule and

CD3+, CD4-, CD8-, TCR-alpha beta- killer T cells. Takashima S, et al. **J Immunol** 1996 Oct 15;157(8):3391-5

Follicular dendritic cell-derived antigen and accessory activity in initiation of memory IgG responses in vitro. Wu J, et al. **J Immunol** 1996 Oct 15;157(8):3404-11

Structure and function of the N-linked carbohydrate chains of pig zona pellucida glycoproteins. Nakano M, et al. **J Reprod Fertil Suppl** 1996;50:25-34 (40 ref.)

Tissue-factor antigen and activity in human coronary atherosclerotic plaques [published erratum appears in Lancet 1997 Jul 26;350(9073):298] Ardissino D, et al. **Lancet** 1997 Mar 15;349(9054):769-71

Age-related changes in proliferating cell nuclear antigen levels. Tanno M, et al. **Mech Ageing Dev** 1996 Nov 29; 92(1):53-66

Efficient secretion of the model antigen M6-gp41E in Lactobacillus plantarum NCIMB 8826. Hols P, et al. **Microbiology** 1997 Aug;143 (Pt 8):2733-41

NG2 proteoglycan and the actin-binding protein fascin define separate populations of actin-containing filopodia and lamellipodia during cell spreading and migration. Lin XH, et al. **Mol Biol Cell** 1996 Dec;7(12):1977-93

Cooperative effects of mutations in a recombinant Fab on the kinetics of antigen binding. Rauffer-Bruyre N, et al. **Mol Immunol** 1997 Feb;34(2):165-73

Antigens associated with specific retinal cells are affected by ischaemia caused by raised intraocular pressure: effect of glutamate antagonists. Osborne NN, et al. **Neurochem Int** 1996 Sep;29(3):263-70

Injections of okadaic acid, but not beta-amyloid peptide, induce Alz-50 immunoreactive dystrophic neurites in the cerebral cortex of sheep. Nelson PT, et al. **Neurosci Lett** 1996 Apr 19;208(2):77-80

Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules. Nelson CA, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21;94(2):628-33

The role of antigen-bound C3b in antigen processing. Colomb MG, et al. **Res Immunol** 1996 Feb;147(2):75-82; discussion 119 (28 ref.)

Out damned CLIP! Out, I say! [comment] Roche PA. **Science** 1996 Oct 25;274(5287):526-7. Comment on: Science 1996 Oct 25;274(5287):618-20.

Fibrinogen mRNA and antigen co-present in human trophoblasts in situ: possible implications. Galanakis D, et al. **Thromb Res** 1996 Jan 15;81(2):263-9

The effect of hormone replacement therapy of the age-related rise of factor VIIc, and its activity state. Wright D, et al. **Thromb Res** 1997 Mar 15;85(6):455-64

[Use of flow cytofluorimetry in the analysis of interactions of mononuclear phagocytes with protein antigens] Stenina MA, et al. **Klin Lab Diagn** 1997 Jul;(7):25-6, 31 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Lymphocytes from orally tolerized mice display enhanced susceptibility to death by apoptosis when cultured in the absence of antigen in vitro. Garside P, et al. **Am J Pathol** 1996 Dec;149(6):1971-9

Inhibitory effect of thromboxane A2 synthetase inhibitor, DP-1904, on antigen-induced contraction of human lung parenchyma. Fukushima C, et al. **Ann Allergy Asthma Immunol** 1996 Dec;77(6):483-7

Direct measurement of cytokines (IFN-gamma, IL-4, -5, and -6) from organs after antigenic challenge. Alkan SS, et al. **Ann N Y Acad Sci** 1996 Oct 31;796:82-90

Arachidonate-induced eicosanoid synthesis in RBL-2H3 cells: stimulation with antigen or A23187 induces prolonged activation of 5-lipoxygenase. Westcott JY, et al. **Biochim Biophys Acta** 1996 Sep 6;1303(1):74-81

Changes in blood and spleen lymphocyte populations following antigen challenge in immature male chickens. Trout JM, et al. **Br Poult Sci** 1996 Sep;37(4):819-27

Antigen stimulation of human pulmonary smooth muscle: an in vitro model of inflammation. Gorenne I, et al. **Cell Biol Toxicol** 1996 Dec;12(4-6):239-44

Prolongation of cardiac allograft survival by intraportal injection of donor antigens--differential mechanisms according to the timing of injection. Tanigawa T, et al. **Cell Transplant** 1996 Sep-Oct;5(5 Suppl 1):S79-80

Selective down-regulation of Th2 immune responses following treatment with antigen-coupled splenocytes. Soldera S, et al. **Eur J Immunol** 1997 Apr;27(4):848-54

Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides. Yokomizo H, et al. **Hum Immunol** 1997 Jan;52(1):22-32

Inhibition of antigen-specific IgE production by antigen coupled to membrane IgE peptide. Chen SS, et al. **Immunol Invest** 1996 Sep-Nov;25(5-6):495-505

B cell mitogenic activity of house dust mite, Dermatophagoides farinae, antigens. Fujii S, et al. **Immunol Lett** 1996 Jan;49(1-2):37-42

Involvement of thromboxane A2 in antigen-induced nasal blockage in guinea pigs. Yasui K, et al. **Int Arch Allergy Immunol** 1997 Apr;112(4):400-5

Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. Essayan DM, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):28-37

Late allergic airway response to segmental bronchopulmonary provocation in allergic subjects is related to peripheral blood basophil histamine release. Jarjour NN, et al. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):87-93

Effect of hemoglobin and immunization status on energy metabolism of weanling pigs. Gentry JL, et al. **J Anim Sci** 1997 Apr;75(4):1032-40

Generating monoclonal antibodies to neuronal antigens. Riggott MJ, et al. **J Neurosci Methods** 1996 Oct; 68(2):235-45

Termination by early deletion of V beta 8 + T cells of aged mice in response to staphylococcal enterotoxin B. Hosono M, et al. **Mech Ageing Dev** 1996 Jun 7;87(2):99-114

Release of adenosine from human sensitized lung fragments and its effect on antigen-induced mediator release. Konnaris K, et al. **Pulm Pharmacol** 1996 Jun;9(3):141-8

Mediators of antigen-induced gastrin release: role of antigen-antibody complexes and the complement system. Domínguez Fernández E, et al. **Res Exp Med (Berl)** 1997; 197(1):37-43

Thromboxane rather than platelet activating factor mediates pulmonary vasoconstriction after antigen challenge in rabbits. Enzan K, et al. **Shock** 1996 Sep;6(3):183-7

1,25-Dihydroxyvitamin D3 inhibits secretion of interferon-gamma by mitogen- and antigen-stimulated bovine mononuclear leukocytes. Ametaj BN, et al. **Vet Immunol Immunopathol** 1996 Jun 15;52(1-2):77-90

Canine leucocyte histamine release: response to antigen and to anti-IgE. Jackson HA, et al. **Vet Immunol Immunopathol** 1996 Oct;53(3-4):195-206

PHYSIOLOGY

Pulmonary response to inhaled antigen: neuroimmune interactions promote the recruitment of dendritic cells to the lung and the cellular immune response to inhaled antigen. Kradin R, et al. **Am J Pathol** 1997 May; 150(5):1735-43

Antigen presentation in the intestine. Panja A, et al. **Baillieres Clin Gastroenterol** 1996 Sep;10(3):407-25 (94 ref.)

Antigen-independent responsiveness to interleukin-4 demonstrates differential regulation of newborn human T cells. Early EM, et al. **Eur J Immunol** 1996 Dec; 26(12):2885-9

Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. Chen H, et al. **J Immunol** 1997 Sep 1;159(5):2240-9

Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. Toyabe S, et al. **J Immunol** 1997 Aug 1;159(3):1537-42

Glycosphingolipids as potential diagnostic markers and/or antigens in neurological disorders. Fredman P, et al. **Neurochem Res** 1997 Aug;22(8):1071-83 (97 ref.)

The NG2 chondroitin sulfate proteoglycan: a multifunctional proteoglycan associated with immature cells. Levine JM, et al. **Perspect Dev Neurobiol** 1996;3(4):245-59 (80 ref.)

Variant TCR ligands: new insights into the molecular basis of antigen-dependent signal transduction and T-cell activation. Madrenas J, et al. **Semin Immunol** 1996 Apr; 8(2):83-101 (99 ref.)

RADIATION EFFECTS

Evaluation of immunohistochemical staining of human duodenal endocrine cells after microwave antigen retrieval. Nyhlin N, et al. **Histochem J** 1997 Feb;29(2):177-81

Antigen retrieval by microwave oven heating for immunohistochemical analysis of bone marrow trephine biopsies. Erber WN, et al. **Pathology** 1996 Jan;28(1):45-50

THERAPEUTIC USE

Tolerance and uveitis [editorial; comment] Bach JF. **Am J Ophthalmol** 1997 May;123(5):684-7 (22 ref.). Comment on: Am J Ophthalmol 1997 May;123(5):583-92.

Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial [see comments] Nussenblatt RB, et al. **Am J Ophthalmol** 1997 May;123(5):583-92. Comment in: Am J Ophthalmol 1997 May;123(5):684-7.

Use of peptides to selectively modulate CD4+ T-cell responses. Hetzel C, et al. **Biochem Soc Trans** 1997 May; 25(2):398-403 (49 ref.)

A T helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. Falcone M, et al. **J Exp Med** 1997 Mar 3;185(5):901-7

Oral feeding of renal tubular antigen abrogates interstitial nephritis and renal failure in Brown Norway rats. Pham K, et al. **Kidney Int** 1997 Sep;52(3):725-32

Enhanced immunity to Hyalomma anatolicum anatolicum ticks in cross-bred (Bos indicus x Bos taurus) calves using ascaris extract immunomodulator with the tick salivary gland extract antigens. Sran HS, et al. **Vet Immunol Immunopathol** 1996 Jun 1;51(3-4):333-43

TOXICITY

Chemical carcinogens and antigens contribute to cutaneous tumor promotion by depleting epidermal Langerhans cells. Qu M, et al. **Carcinogenesis** 1997 Jun;18(6):1277-9

Subchronic effects of pulp and paper mill effluents on the immunoglobulin synthesis of roach, Rutilus rutilus. Jokinen EI, et al. **Ecotoxicol Environ Saf** 1995 Dec;32(3):219-25

Degradation of articular cartilage during the progression of antigen-induced arthritis in mice. A scanning and transmission electron microscopic study. Henzgen S, et al. **Exp Toxicol Pathol** 1996 Jun;48(4):255-63

Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. Tada Y, et al. **J Exp Med** 1997 Jan 20;185(2):231-8

Activation-secretion coupling in 10P2 murine mast cells challenged with IgE-antigen, ionophore A23187, thapsigargin and phorbol ester. Heiman AS, et al. **Pharmacology** 1997 Mar;54(3):153-61

Prevention of antigen-induced arthritis in rats by oral administration of the inducing antigen. Yoshino S. **Scand J Clin Lab Invest** 1996 Apr;56(2):111-5

ULTRASTRUCTURE

Electron spectroscopic imaging of antigens by reaction with boronated antibodies. Qualmann B, et al. **J Microsc** 1996 Jul;183 (Pt 1):69-77

Antibody-antigen interactions: contact analysis and binding site topography. MacCallum RM, et al. **J Mol Biol** 1996 Oct 11;262(5):732-45

URINE

Urinary antigens as markers of papillary toxicity. I. Identification and characterization of rat kidney papillary antigens with monoclonal antibodies. Falkenberg FW, et al. **Arch Toxicol** 1996;71(1-2):80-92

ANTIGENS, BACTERIAL

Phosphocholine-containing glycoglycerolipids (GGPL-I and GGPL-III) are species-specific major immunodeterminants of Mycoplasma fermentans. Matsuda K, et al. **Biochem Biophys Res Commun** 1997 Apr 28; 233(3):644-9

Measurement of antibodies against meningococcal capsular polysaccharides B and C in enzyme-linked immunosorbent assays: towards an improved surveillance of meningococcal disease. Andersen J, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):345-51

Immunoblot analysis for serodiagnosis of tuberculosis using a 45/47-kilodalton antigen complex of Mycobacterium tuberculosis. Diagbouga S, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):334-8

Monoclonal antibodies to P24 and P61 immunodominant antigens from Nocardia brasiliensis. Salinas-Carmona MC, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):133-7

Antibody and delayed-type hypersensitivity responses to Ochrobactrum anthropi cytosolic and outer membrane antigens in infections by smooth and rough Brucella spp. Velasco J, et al. **Clin Diagn Lab Immunol** 1997 May; 4(3):279-84

Lymphocyte responses to Chlamydia antigens in patients with coronary heart disease. Halme S, et al. **Eur Heart J** 1997 Jul;18(7):1095-101

Phase-variable outer membrane proteins in Escherichia coli. Owen P, et al. **FEMS Immunol Med Microbiol** 1996 Dec 1;16(2):63-76 (70 ref.)

Variable expression and geographic distribution of Mycoplasma agalactiae surface epitopes demonstrated with monoclonal antibodies. Bergonier D, et al. **FEMS Microbiol Lett** 1996 Oct 1;143(2-3):159-65

An indirect immunofluorescence assay using a cell culture-derived antigen for detection of antibodies to the agent of human granulocytic ehrlichiosis. Nicholson WL, et al. **J Clin Microbiol** 1997 Jun;35(6):1510-6

Evaluation of the recombinant 38-kilodalton antigen of Mycobacterium tuberculosis as a potential immunodiagnostic reagent. Wilkinson RJ, et al. **J Clin Microbiol** 1997 Mar;35(3):553-7

Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. Brandt L, et al. **J Immunol** 1996 Oct 15; 157(8):3527-33

Epitopes of Bordetella pertussis lipopolysaccharides as potential markers for typing of isolates with monoclonal antibodies. Le Blay K. et al. **Microbiology** 1996 Apr;142 (Pt 4):971-8

Expression, secretion and antigenic variation of bacterial S-layer proteins. Boot HJ, et al. **Mol Microbiol** 1996 Sep; 21(6):1117-23 (49 ref.)

Characterization of the delayed type hypersensitivity-inducing epitope of MPT64 from Mycobacterium tuberculosis. Oettinger T, et al. **Scand J Immunol** 1997 May;45(5):499-503

Induction of CD8+ CTL recognizing mycobacterial peptides. Vordermeier HM, et al. **Scand J Immunol** 1997 May;45(5):521-6

Evaluation of Chlamydia psittaci subfraction and subunit preparations for their protective capacities. Sandbulte J, et al. **Vet Microbiol** 1996 Feb;48(3-4):269-82

[Pathogenesis of IgA nephropathy: role of outer membranes of Haemophilus parainfluenzae antigens] Suzuki S, et al. **Nippon Rinsho** 1997 Jun;55(6):1580-7 (30 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Protection of rats against Mycoplasma arthritidis-induced arthritis by active and passive immunizations with two

surface antigens. Washburn LR, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):321-7

Development of antigen-delivery systems, based on the Escherichia coli hemolysin secretion pathway. Gentschev I, et al. **Gene** 1996 Nov 7;179(1):133-40

Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10. Nedialkov YA, et al. **Infect Immun** 1997 Apr;65(4):1196-203

Survival and quality of life in HIV-positive patients treated with a polyantigenic immunomodulator. Colón JI, et al. **P R Health Sci J** 1997 Mar;16(1):9-14

Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain. Attridge SR, et al. **Vaccine** 1997 Feb;15(2):155-62

The sensitizing effect of a Brucella abortus antigen in cattle after repeated intradermal inoculations. Bercovich Z, et al. **Vet Microbiol** 1996 Jul;51(1-2):85-93

ADVERSE EFFECTS

Evaluation of the safety of cantastim in normal humans. Olinescu A, et al. **Roum Arch Microbiol Immunol** 1996 Jul-Sep;55(3):183-92

ANALYSIS

Detection of streptococcal class I M protein in psoriasis by confocal immunofluorescent microscopy. Talanin NY, et al. **Acta Derm Venereol** 1997 May;77(3):175-80

Chlamydia trachomatis detected in cervical smears from Copper-T users by DFA test. Palayekar V, et al. **Adv Contracept** 1996 Jun;12(2):145-52

Analysis of Bordetella pertussis suspensions by ELISA and flow cytometry. Jiskoot W, et al. **Adv Exp Med Biol** 1996; 397:153-7

Pneumococcal capsular antigen detection after enrichment culture: an alternative to culture methods in epidemiologic research. Lankinen KS, et al. **Am J Trop Med Hyg** 1997 Feb;56(2):211-5

Specific antigens of Chlamydia pecorum and their homologues in C psittaci and C trachomatis. Baghian A, et al. **Am J Vet Res** 1996 Dec;57(12):1720-5

Limitations of serodiagnosis in chlamydial genital tract infections. Ngeow YF. **Ann Acad Med Singapore** 1996 Mar; 25(2):300-4 (38 ref.)

Rapid antigen testing for group A Streptococcus by DNA probe. Heelan JS, et al. **Diagn Microbiol Infect Dis** 1996 Feb;24(2):65-9

Serotyping of Streptococcus pyogenes isolated from common and severe invasive infections in Japan, 1990-5: implication of the T3 serotype strain-expansion in TSLS. The Working Group for Group A Streptococci in Japan. Inagaki Y, et al. **Epidemiol Infect** 1997 Aug;119(1):41-8

Influence of carriage of pneumococci in the nasopharynx of children on pneumococcal antigen detection [letter] Boersma WG, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):426-8

Bacterial virulence antigens and the pathogenesis of autoimmune thyroid diseases (AITD). Wenzel BE, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:75-8 (33 ref.)

Coagulase-negative staphylococci isolated from two cases of toxic shock syndrome lack superantigenic activity, but induce cytokine production. Lina G, et al. **FEMS Immunol Med Microbiol** 1996 Jan;13(1):81-6

Localization by immunoelectron microscopy of antigens of Chlamydia psittaci suitable for diagnosis or vaccine development. Buendia AJ, et al. **FEMS Microbiol Lett** 1997 May 1;150(1):113-9

Characterization of membrane surface proteins of Mycoplasma agalactiae during natural infection. Tola S, et al. **FEMS Microbiol Lett** 1997 Sep 15;154(2):355-62

Evaluation of two nonculture antigen tests and three serotests for detection of anti-chlamydial antibodies in the diagnosis of ocular chlamydial infections. Haller EM, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234(8):510-4

Immunological detection of lipopolysaccharide antigens of thermophilic campylobacters captured on polymyxin-coated polyester cloth. Gomi K, et al. **Immunol Invest** 1996 May;25(3):177-83

Histological and immunological correlates of suspected leprosy lesions. Ramu G, et al. **Indian J Lepr** 1996 Apr-Jun; 68(2):155-9

100 years of Widal test & its reappraisal in an endemic area. Shukla S, et al. **Indian J Med Res** 1997 Feb;105:53-7

Antigenic characterization and analysis of the human immune response to outer membrane protein E of Branhamella catarrhalis. Bhushan R, et al. **Infect Immun** 1997 Jul; 65(7):2668-75

Analysis of culture filtrate and cell wall-associated antigens of Mycobacterium paratuberculosis with monoclonal antibodies. Mutharia LM, et al. **Infect Immun** 1997 Feb; 65(2):387-94

Mycoplasma synoviae has two distinct phase-variable major membrane antigens, one of which is a putative hemagglutinin. Noormohammadi AH, et al. **Infect Immun** 1997 Jul;65(7):2542-7

Tick factors and in vitro cultivation influence the protein profile, antigenicity and pathogenicity of a cloned Borrelia garinii isolate from Ixodes ricinus hemolymph. Hu CM, et al. **Infection** 1996 May-Jun;24(3):251-7

Role of ELISA (enzyme-linked immunosorbent assay) in genital tuberculosis. Srivastava N, et al. **Int J Gynaecol Obstet** 1997 May;57(2):205-6

Heat-stable serotyping antigens expressed by strains of Campylobacter jejuni are probably capsular and not long-chain lipopolysaccharide. Chart H, et al. **J Appl Bacteriol** 1996 Dec;81(6):635-40

Distribution of colonization factor antigens among enterotoxigenic Escherichia coli strains isolated from patients with diarrhea in Nepal, Indonesia, Peru, and Thailand. Nirdnoy W, et al. **J Clin Microbiol** 1997 Feb; 35(2):527-30

Ehrlichia canis-like agent isolated from a man in Venezuela: antigenic and genetic characterization. Perez M, et al. **J Clin Microbiol** 1996 Sep;34(9):2133-9

Coli surface antigens associated with enterotoxigenic Escherichia coli strains isolated from persons with traveler's diarrhea in Asia. Serichantalergs O, et al. **J Clin Microbiol** 1997 Jun;35(6):1539-41

Detection of endocervical anti-Chlamydia trachomatis immunoglobulin A in pregnant women by a rapid, 6-minute enzyme-linked immunosorbent assay: comparison with PCR and chlamydial antigen detection methods. Witkin SS, et al. **J Clin Microbiol** 1997 Jul;35(7):1781-3

Pathogenesis of Chlamydia psittaci infection in sheep: detection of the organism in a serial study of the lymph node. Buxton D, et al. **J Comp Pathol** 1996 Apr; 114(3):221-30

Detection of porcine reproductive and respiratory syndrome virus and Mycoplasma hyorhinis antigens in pulmonary lesions of pigs suffering from respiratory distress. Kawashima K, et al. **J Comp Pathol** 1996 Apr;114(3):315-23

Quantification of cell-associated and free antigens in Bordetella pertussis suspensions by antigen binding ELISA. Westdijk J, et al. **J Immunoassay** 1997 Aug;18(3):267-84

Detection of meningitis antigens in buffer and body fluids by ultrasound-enhanced particle agglutination. Jenkins P, et al. **J Immunol Methods** 1997 Jul 14;205(2):191-200

Prevalence of spotted fever group rickettsiae in ticks from southern Israel. Guberman D, et al. **J Med Entomol** 1996 Nov;33(6):979-82

Extracts of periodontopathic microorganisms lack functional superantigenic activity for murine T cells. Petit MD, et al. **J Periodontal Res** 1996 Nov;31(8):517-24

Immunodiagnoses of community-acquired pneumonia in childhood. Requejo HI, et al. **J Trop Pediatr** 1997 Aug; 43(4):208-12

Serotyping Actinobacillus pleuropneumoniae by the use of monoclonal antibodies. Lacouture S, et al. **J Vet Diagn Invest** 1997 Jul;9(3):337-41

Demonstration of rat CAR bacillus using a labelled streptavidin biotin (LSAB) method. Orós J, et al. **J Vet Med Sci** 1996 Dec;58(12):1219-21

From the Food and Drug Administration. Nightingale SL. **JAMA** 1997 May 7;277(17):1343

Indeterminate leprosy: a seroimmunological and histochemical evaluation. Sekar B, et al. **Lepr Rev** 1994 Sep;65(3):167-74

Staphylococcus hyicus exfoliative toxin: purification and demonstration of antigenic diversity among toxins from virulent strains. Andresen LO, et al. **Microb Pathog** 1997 Feb;22(2):113-22

Expression of virulence-associated antigens of Rhodococcus equi is regulated by temperature and pH. Takai S, et al. **Microbiol Immunol** 1996;40(8):591-4

Antigenic profiles for the differentiation of Mobiluncus curtisii and Mobiluncus mulieris by immunoblotting technique. Gatti M, et al. **New Microbiol** 1997 Jul; 20(3):247-52

Evaluation of the Kodak Surecell Chlamydia test for the laboratory diagnosis of adult inclusion conjunctivitis. Tantisira JG, et al. **Ophthalmology** 1995 Jul;102(7):1035-7

Simultaneous presentation of Kawasaki disease and toxic shock syndrome in an adolescent male [see comments] Davies HD, et al. **Pediatr Infect Dis J** 1996 Dec; 15(12):1136-8 (14 ref.). Comment in: Pediatr Infect Dis J 1997 Jun;16(6):633-4.

Role of bacterial antigen tests in the diagnosis of invasive bacterial infections. Marshall GS. **Pediatr Infect Dis J** 1997 Jun;16(6):632-3

Rapid detection of pneumococcal antigen in lung aspirates: comparison with culture and PCR technique. Ruiz-González A, et al. **Respir Med** 1997 Apr;91(4):201-6

Evaluation of serological response to Bartonella henselae, Bartonella quintana and Afipia felis antigens in 64 patients with suspected cat-scratch disease. Dupon M, et al. **Scand J Infect Dis** 1996;28(4):361-6

Age at acquisition of Helicobacter pylori infection: comparison of a high and a low prevalence country. Lindkvist P, et al. **Scand J Infect Dis** 1996;28(2):181-4

Molecular biology of the Chlamydia pneumoniae surface. Christiansen G, et al. **Scand J Infect Dis Suppl** 1997; 104:5-10

Modulation of antigen-specific T and B cell responses influence bacterial clearance of non-typeable Haemophilus influenzae from the lung in a rat model. Kyd JM, et al. **Vaccine** 1996 Oct;14(15):1471-8

Detection of an antigenic protein of Leptospira interrogans which shares epitopes with the equine cornea and lens. Parma AE, et al. **Vet J** 1997 Jan;153(1):75-9

Colonization antigens of enterotoxigenic Escherichia coli strains isolated from piglets in Spain. Garabal JI, et al. **Vet Microbiol** 1997 Mar;54(3-4):321-8

Genomic, protein homogeneity and antigenic variability of Mycoplasma agalactiae. Solsona M, et al. **Vet Microbiol** 1996 May;50(1-2):45-58

Macroamphiphilic cell envelope components of Rhodococcus equi and closely related bacteria. Sutcliffe IC. **Vet Microbiol** 1997 Jun 16;56(3-4):287-99 (43 ref.)

Secreted antigens as virulence associated markers in Streptococcus bovis strains from pigeons. Vanrobaeys M, et al. **Vet Microbiol** 1996 Dec;53(3-4):339-48

Detection of Mycoplasma ovipneumoniae and Pasteurella haemolytica antigens by an immunoperoxidase technique in pneumonic ovine lungs. Haziroglu R, et al. **Vet Pathol** 1996 Jan;33(1):74-6

An immunohistochemical method of detecting Mycoplasma species antigens by use of monoclonal antibodies on paraffin sections of pneumonic bovine and caprine lungs. Rodriguez F, et al. **Zentralbl Veterinarmed [B]** 1996 Sep;43(7):429-38

[Distribution of antigenic glycolipids among Mycobacterium tuberculosis strains and their contribution to virulence] Fujiwara N. **Kekkaku** 1997 Apr;72(4):193-205 (Eng. Abstr.) **(Jpn)**

[Drug susceptibility test for Mycobacterium tuberculosis using non-radioactive substance, alpha-antigen] Shigeto E, et al. **Kekkaku** 1996 Mar;71(3):245-52 (Eng. Abstr.) **(Jpn)**

[Distribution of EIA reactive values and serum antibody titers of Chlamydia trachomatis urethritis and cervicitis at the first visit] Kojima H, et al. **Rinsho Byori** 1996 Feb; 44(2):153-8 (Eng. Abstr.) **(Jpn)**

[Bacterial antigenic structure of Shigella flexneri serotype 1B and its 3B serotype mutant and susceptibility to bacterial action of complement in normal bovine serum] Doroszkiewicz W, et al. **Postepy Hig Med Dosw** 1996; 50(5):519-23 (Eng. Abstr.) **(Pol)**

[Serologic studies of cross reactions between strains of Proteus mirabilis OXK (prO 10/52) and Proteus mirabilis S1959] Swierzko AS, et al. **Postepy Hig Med Dosw** 1996; 50(5):507-9 (Eng. Abstr.) **(Pol)**

[The content of mimicry antigens in bacteria of the genus Klebsiella when they are cultured in plant tissue] Turianitsa AI, et al. **Mikrobiol Z** 1994 Jul-Sep;56(4):20-5 (Eng. Abstr.) **(Rus)**

[Mycobacterial antigens and antitubercular antibodies in patients with tuberculosis salpingo-oophoritis] Bazarova AB, et al. **Probl Tuberk** 1997;(4):26-8 (Eng. Abstr.) **(Rus)**

[Designing the latex test system for express identification of legionella in the external medium and clinical materials] Eruslanov BV, et al. **Vestn Ross Akad Med Nauk** 1997; (6):40-4 (Eng. Abstr.) **(Rus)**

[The structure of the determinants of streptococcal group A polysaccharide common to epidermal antigens to which antibodies are formed at different stages of the rheumatic process] Bazanova EA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep-Oct;(5):16-9 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Isoniazid induces expression of the antigen 85 complex in Mycobacterium tuberculosis. Garbe TR, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1754-6

Influence of the culture media composition and pH on the synthesis of mucoid Yersinia factor. Bengoechea JA, et al. **Contrib Microbiol Immunol** 1995;13:168-71

Detection of virulent Shigella and enteroinvasive Escherichia coli by induction of the 43 kDa invasion plasmid antigen, ipaC. Shamlal R, et al. **FEMS Immunol Med Microbiol** 1997 Feb;17(2):73-8

Influence of medium composition on the growth and antigen expression of Helicobacter pylori. Walsh EJ, et al. **J Appl Microbiol** 1997 Jul;83(1):67-75

Cloning of the lipooligosaccharide alpha-2,3-sialyltransferase from the bacterial pathogens Neisseria meningitidis and Neisseria gonorrhoeae. Gilbert M, et al. **J Biol Chem** 1996 Nov 8;271(45):28271-6

The potential of the ESAT-6 antigen secreted by virulent mycobacteria for specific diagnosis of tuberculosis. Pollock JM, et al. **J Infect Dis** 1997 May;175(5):1251-4

Expression of mycobacterial antigens on murine dissociated Schwann cells infected with Mycobacterium leprae. Birdi TJ, et al. **Microb Pathog** 1997 Mar;22(3):181-5

Effects of growth conditions and incubation times on the expression of antigens of Haemophilus paragallinarum which are detected by monoclonal antibodies. Bragg RR, et al. **Onderstepoort J Vet Res** 1997 Mar;64(1):57-63

The isolation of recombinant plasmids expressing secreted antigens of Pasteurella haemolytica A1 and the characterization of an immunogenic 60 kDa antigen. Lo RY, et al. **Vet Microbiol** 1996 Aug;51(3-4):381-91

[Recombinant plasmids carrying yersinia pestis fra-operon: specific features of genetic transmission, inheritance and expression in attenuated enterobacterial cells] Fursova NK, et al. **Vestn Ross Akad Med Nauk** 1997;(6):44-7 (Eng. Abstr.) **(Rus)**

[The expression of Bordetella pertussis protective antigens during bacterial multiplication on a medium with a fixed chemical composition] Shmeleva EI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Mar-Apr; (2):47-50 (Eng. Abstr.) **(Rus)**

BLOOD

Serum antibodies against Borrelia afzelii, Borrelia burgdorferi sensu stricto and the 41-kiloDalton flagellin in patients from a Lyme borreliosis endemic area: analysis by EIA and immunoblot. Nilsson I, et al. **APMIS** 1996 Dec; 104(12):907–14

Western blot analysis of serological response in Helicobacter pylori in acid peptic dis_ases. Chatha L, et al. **Indian J Med Res** 1997 Apr;105:170–5

Evaluation of immunogenicity and tolerance of single dose haemophilus influenzae type B (PRP–T) vaccine. Acharya D, et al. **Indian Pediatr** 1995 Oct;32(10):1077–82

Selection of Opa+ Neisseria gonorrhoeae by limited availability of normal human serum. Bos MP, et al. **Infect Immun** 1997 Feb;65(2):645–50

Country-specific constancy by age in cagA+ proportion of Helicobacter pylori infections. Pérez-Pérez GI, et al. **Int J Cancer** 1997 Jul 29;72(3):453–6

Low rates of detection of mycobacterial secretory antigen 85 in sera of untreated leprosy patients [letter] Mistry NF, et al. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4):451–3

Evaluation of a five-antigen ELISA for diagnosis of tuberculosis in cattle and Cervidae. Gaborick CM, et al. **J Am Vet Med Assoc** 1996 Sep 1;209(5):962–6

Proficiency testing of selected antigen and antibody tests for use in dogs and cats. Troy GC, et al. **J Am Vet Med Assoc** 1996 Sep 1;209(5):914–7

One-way synergistic effect of low superantigen concentrations on lipopolysaccharide-induced cytokine production. Luhm J, et al. **J Interferon Cytokine Res** 1997 Apr;17(4):229–38

A serendipitous peek at tobacco. Hornsby RP. **J Tenn Med Assoc** 1996 Mar;89(3):90–1

Antigens for serological diagnosis of ovine footrot. Whittington RJ, et al. **Vet Microbiol** 1997 Mar; 54(3–4):255–74

Detection of ehrlichial antigen in plasma of beagle dogs with experimental acute Ehrlichia canis infection. Waner T, et al. **Vet Parasitol** 1996 Jun;63(3–4):331–5

[Behçet's disease and streptococcal antigens] Yoshikawa K, et al. **Nippon Ganka Gakkai Zasshi** 1996 Mar;100(3):173–80 (47 ref.) (Eng. Abstr.) **(Jpn)**

[The differentiation of the antigens making up the circulating immune complexes] Gorina LG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jan–Feb; (1):58–61 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Is BAT BAD in CSF? [editorial] Barlow JF. **S D J Med** 1996 Mar;49(3):85

[Detection of Neisseria meningitidis group B antigens by MB–Dot–Elisa test in patients with meningitis] Alkmin MG, et al. **Rev Panam Salud Publica** 1997 Mar;1(3):208–12 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Detection of strain-specific antigenic epitopes on the lipo-oligosaccharide of Haemophilus parasuis by use of monoclonal and polyclonal antibodies. Zucker BA, et al. **Am J Vet Res** 1996 Jan;57(1):63–7

Structure-function studies with Neisseria gonorrhoeae Opa outer membrane proteins expressed in Escherichia coli. Simon D, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:253–4

Coiled-coil structure of group A streptococcal M proteins. Different temperature stability of class A and C proteins by hydrophobic-nonhydrophobic amino acid substitutions at heptad positions a and d. Cedervall T, et al. **Biochemistry** 1997 Apr 22;36(16):4987–94

Structural basis of the Neisseria meningitidis immunotypes including the L4 and L7 immunotypes. Kogan G, et al. **Carbohydr Res** 1997 Mar 5;298(3):191–9

Structure of a new 6-deoxy-alpha-D-talan from Burkholderia (Pseudomonas) plantarii strain DSM 6535, which is different from the O-chain of the lipopolysaccharide. Zähringer U, et al. **Carbohydr Res** 1997 May 12;300(2):143–51

T-cell recognition of non-peptide antigens. Porcelli SA, et al. **Curr Opin Immunol** 1996 Aug;8(4):510–6 (50 ref.)

Structural and serological characterisation of the O-specific polysaccharide from lipopolysaccharide of Acinetobacter calcoaceticus strain 7 (DNA group 1). Vinogradov EV, et al. **Eur J Biochem** 1997 Jan 15;243(1–2):167–73

A novel nucleotide-containing antigen for human blood gamma delta T lymphocytes. Poquet Y, et al. **Eur J Immunol** 1996 Oct;26(10):2344–9

Structural and immunochemical studies on the lipopolysaccharide of the 'T-antigen'-containing mutant Proteus mirabilis R14/1959. Bartodziejska B, et al. **FEMS Immunol Med Microbiol** 1996 Feb;13(2):113–21

Bacterial surface structures--an update. Moran AP. **FEMS Immunol Med Microbiol** 1996 Dec 1;16(2):61–2

Low affinity, antibody binding of an Escherichia coli-derived component. Ohlin M, et al. **FEMS Immunol Med Microbiol** 1996 Feb;13(2):161–8

Outer membrane protein D15 is conserved among Haemophilus influenzae species and may represent a universal protective antigen against invasive disease. Loosmore SM, et al. **Infect Immun** 1997 Sep;65(9):3701–7

Analysis of the genes encoding the antigen 85 complex and MPT51 from Mycobacterium avium. Ohara N, et al. **Infect Immun** 1997 Sep;65(9):3680–5

The Oms66 (p66) protein is a Borrelia burgdorferi porin. Skare JT, et al. **Infect Immun** 1997 Sep;65(9):3654–61

Recognition of lipid antigens by sera of mice infected with Mycobacterium lepraemurium. Luna-Herrera J, et al. **Int J Lepr Other Mycobact Dis** 1996 Sep;64(3):299–305

Structural characterization of the K antigens from Rhizobium fredii USDA257: evidence for a common structural motif, with strain-specific variation, in the capsular polysaccharides of Rhizobium spp. Forsberg LS, et al. **J Bacteriol** 1997 Sep;179(17):5366–71

The 75-kilodalton antigen of Bartonella bacilliformis is a structural homolog of the cell division protein FtsZ. Padmalayam I, et al. **J Bacteriol** 1997 Jul;179(14):4545–52

Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis. Inhibition of arabinan biosynthesis by ethambutol. Khoo KH, et al. **J Biol Chem** 1996 Nov 8; 271(45):28682–90

The phosphatidyl-myo-inositol anchor of the lipoarabinomannans from Mycobacterium bovis bacillus Calmette Guérin. Heterogeneity, structure, and role in the regulation of cytokine secretion. Nigou J, et al. **J Biol Chem** 1997 Sep 12;272(37):23094–103

Species-dependent post-translational modification and position 2 allelism: effects on streptococcal superantigen SSA structure and V beta specificity. Stevens KR, et al. **J Immunol** 1996 Sep 15;157(6):2479–87

Interaction of the receptor binding domains of Pseudomonas aeruginosa pili strains PAK, PAO, KB7 and P1 to a cross-reactive antibody and receptor analog: implications for synthetic vaccine design. Campbell AP, et al. **J Mol Biol** 1997 Mar 28;267(2):382–402

Molecular structure of the lipoamide dehydrogenase domain of a surface antigen from Neisseria meningitidis. Li de la Sierra I, et al. **J Mol Biol** 1997 May 30;269(1):129–41

A structural and functional comparison of staphylococcal enterotoxins A and C2 reveals remarkable similarity and dissimilarity. Schad EM, et al. **J Mol Biol** 1997 Jun 6; 269(2):270–80

A 28 kDa major immunogen of Chlamydia psittaci shares identity with Mip proteins of Legionella spp. and Chlamydia trachomatis-cloning and characterization of the C. psittaci mip-like gene. Rockey DD, et al. **Microbiology** 1996 Apr;142 (Pt 4):945–53

Crystal structure of the streptococcal superantigen SPE-C: dimerization and zinc binding suggest a novel mode of interaction with MHC class II molecules. Roussel A, et al. **Nat Struct Biol** 1997 Aug;4(8):635–43

Mapping a conserved conformational epitope from the M protein of group A streptococci. Relf WA, et al. **Pept Res** 1996 Jan-Feb;9(1):12–20

Characterization of Chlamydia pneumoniae antigens using human T cell clones. Halme S, et al. **Scand J Immunol** 1997 Apr;45(4):378–84

Single shot with tetanus toxoid in biodegradable microspheres protects mice despite acid-induced denaturation of the antigen. Kersten GF, et al. **Vaccine** 1996 Dec;14(17–18):1627–32

Serological and biochemical properties of the major outer membrane protein within strains of the genus Actinobacillus. Hartmann L, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):255–62

[An analysis of the specificity of anti-Mycobacterium monoclonal antibodies and of the chemical nature of the antigenic determinants with which they react] Avdienko VG, et al. **Probl Tuberk** 1996;(1):6–8 (Eng. Abstr.) **(Rus)**

[The isolation of the antigenic substances of Mycobacterium tuberculosis and the characteristics of their basic chemical components] Lonych LI. **Mikrobiol Z** 1997 Mar-Apr; 59(2):67–72 (Eng. Abstr.) **(Ukr)**

DIAGNOSTIC USE

Antigenic epitope mapping of the M24 protein of Streptococcus pyogenes: implications for serodiagnosis of rheumatic fever. Norton RE, et al. **FEMS Immunol Med Microbiol** 1996 Dec 31; 16(3–4):267–71

Recombinant Treponema pallidum antigens in syphilis serology. Gerber A, et al. **Immunobiology** 1996–97; 196(5):535–49

Sensitivity of EIA in the diagnosis of tuberculosis using 38-kDa antigen. Chander J, et al. **J Indian Med Assoc** 1996 Oct;94(10):376–8

Widely used, commercially available Chlamydia pneumoniae antigen contaminated with mycoplasma. Verkooyen RP, et al. **J Med Microbiol** 1997 May;46(5):419–24

Serodiagnostic value of ELISA in pulmonary tuberculosis in Turkey where tuberculosis is highly prevalent. Doğan UB, et al. **Respiration** 1997;64(1):73–5

[The role of the outer-membrane antigens of Yersinia pseudotuberculosis in the pathogenesis and diagnosis of pseudotuberculosis] Kuliashova LB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb;(1):14–8 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization. Petre J, et al. **Dev Biol Stand** 1996;87:125–34

GENETICS

Sequence analysis and comparison of 190 K surface antigen gene fragment of a new species of spotted fever group rickettsiae. Zhang JZ, et al. **Acta Virol** 1997 Feb;41(1):41–5

Detection and differentiation of 3 K88 serogroups using polymerase chain reaction techniques. K88 serogroup detection and differentiation. Franklin MA, et al. **Adv Exp Med Biol** 1997;412:77–9

A novel regulatory mechanism for a novel phase-variable outer membrane protein of Escherichia coli. Henderson IR, et al. **Adv Exp Med Biol** 1997;412:349–55

CagA and the outcome of Helicobacter pylori infection [editorial; comment] Blaser MJ, et al. **Am J Clin Pathol** 1996 Nov;106(5):565–7. Comment on: Am J Clin Pathol 1996 Nov;106(5):670–5.

Gastric non-Hodgkin lymphomas of mucosa-associated lymphoid tissue are not associated with more aggressive Helicobacter pylori strains as identified by CagA [see comments] de Jong D, et al. **Am J Clin Pathol** 1996 Nov; 106(5):670–5. Comment in: Am J Clin Pathol 1996 Nov;106(5):565–7.

Antigenic and genetic characterization of Legionella proteins: contributions to taxonomy, diagnosis and pathogenesis. Bangsborg JM. **APMIS Suppl** 1997;70:1–53 (450 ref.)

Molecular cloning and expression of a novel Staphylococcus aureus antigen. Rieneck K, et al. **Biochim Biophys Acta** 1997 Feb 7;1350(2):128–32

Induction of humoral and cellular immune responses by vaccination with M. tuberculosis antigen 85 DNA. Montgomery DL, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 May;43(3):285–92

Expression of Yersinia pestis V antigen in attenuated salmonella typhimurium: development of a novel vaccine for plague. Leary SE, et al. **Contrib Microbiol Immunol** 1995;13:216–7

Studies on the contribution of the F1 capsule-associated plasmid pFra to the virulence of Yersinia pestis. Welkos SL, et al. **Contrib Microbiol Immunol** 1995;13:299–305

Ehrlichia sennetsu groE operon and antigenic properties of the GroEL homolog. Zhang Y, et al. **FEMS Immunol Med Microbiol** 1997 May;18(1):39–46

Antigen 43, a phase-variable bipartite outer membrane protein, determines colony morphology and autoaggregation in Escherichia coli K-12. Henderson IR, et al. **FEMS Microbiol Lett** 1997 Apr 1;149(1):115–20

Transformation of a virulence associated gene of Haemophilus somnus into a strain lacking the gene. Sanders JD, et al. **FEMS Microbiol Lett** 1997 Sep 15;154(2):251–8

Duplication of genes encoding the immunodominant 38 kDa antigen in Mycobacterium intracellulare. Thangaraj HS, et al. **FEMS Microbiol Lett** 1996 Nov 1;144(2–3):235–40

Molecular and genetic analysis of multiple changes in the levels of production of virulence factors in a subcultured variant of Streptococcus mutans. Yamashita Y, et al. **FEMS Microbiol Lett** 1996 Oct 15;144(1):81–7

The rfaD locus: a region of rearrangement in Vibrio cholerae O139. Vimont S, et al. **Gene** 1997 Jan 31;185(1):43–7

Cloning and sequencing of the gene for a 120-kDa immunodominant protein of Ehrlichia chaffeensis. Yu XJ, et al. **Gene** 1997 Jan 15;184(2):149–54

Antigenic diversity in the periodontopathogen, Actinobacillus actinomycetemcomitans. Ebersole JL, et al. **Immunol Invest** 1996 May;25(3):203–14

Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Abou-Zeid C, et al. **Infect Immun** 1997 May;65(5):1856–62

Functional analysis of the Shigella flexneri IpaC invasin by insertional mutagenesis. Bârzu S, et al. **Infect Immun** 1997 May;65(5):1599–605

Conservation of the 15-kilodalton lipoprotein among Treponema pallidum subspecies and strains and other pathogenic treponemes: genetic and antigenic analyses. Centurion-Lara A, et al. **Infect Immun** 1997 Apr; 65(4):1440–4

Characterization, occurrence, and molecular cloning of a 39-kilodalton Brucella abortus cytoplasmic protein immunodominant in cattle. Denoel PA, et al. **Infect Immun** 1997 Feb;65(2):495–502

Identification of a frameshift mutation resulting in premature termination and loss of cell wall anchoring of the PAc antigen of Streptococcus mutans GS-5. Murakami Y, et al. **Infect Immun** 1997 Feb;65(2):794–7

Role of the charged tail in localization of a surface protein antigen of Streptococcus mutans. Murakami Y, et al. **Infect Immun** 1997 Apr;65(4):1531–5

Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Roggenkamp A, et al. **Infect Immun** 1997 Feb;65(2):446–51

Antigenic variation in Neisseria gonorrhoeae: production of multiple lipooligosaccharides. Burch CL, et al. **J Bacteriol** 1997 Feb;179(3):982–6

Clonally diverse rfb gene clusters are involved in expression of a family of related D-galactan O antigens in Klebsiella species. Kelly RF, et al. **J Bacteriol** 1996 Sep; 178(17):5205–14

Identification, cloning, and characterization of the Ima operon, whose gene products are unique to Listeria monocytogenes. Schäferkordt S, et al. **J Bacteriol** 1997 Apr;179(8):2707–16

Characterization of cp18, a naturally truncated member of the cp32 family of Borrelia burgdorferi plasmids. Stevenson B, et al. **J Bacteriol** 1997 Jul;179(13):4285–91

Molecular characterization of the gene encoding H antigen in Escherichia coli and development of a PCR–restriction fragment length polymorphism test for identification of E. coli O157:H7 and O157:NM. Fields PI, et al. **J Clin Microbiol** 1997 May;35(5):1066–70

Characterization of a specific Mycobacterium paratuberculosis recombinant clone expressing 35,000–molecular–weight antigen and reactivity with sera from animals with clinical and subclinical Johne's disease. El–Zaatari FA, et al. **J Clin Microbiol** 1997 Jul;35(7):1794–9

Species–dependent post–translational modification and position 2 allelism: effects on streptococcal superantigen SSA structure and V beta specificity. Stevens KR, et al. **J Immunol** 1996 Sep 15;157(6):2479–87

Evidence for the simultaneous expression of two PspAs by a clone of capsular serotype 6B Streptococcus pneumoniae. Crain MJ, et al. **Microb Pathog** 1996 Oct;21(4):265–75

Cloning and nucleotide sequence analysis of a Brucella abortus gene encoding an 18 kDa immunoreactive protein. Kovach ME, et al. **Microb Pathog** 1997 Apr;22(4):241–6

Isolation of a new Orientia tsutsugamushi serotype. Seong SY, et al. **Microbiol Immunol** 1997;41(6):437–43

A 28 kDa major immunogen of Chlamydia psittaci shares identity with Mip proteins of Legionella spp. and Chlamydia trachomatis–cloning and characterization of the C. psittaci mip–like gene. Rockey DD, et al. **Microbiology** 1996 Apr;142 (Pt 4):945–53

Mutagenesis of an immunodominant T cell epitope can affect recognition of different T and B determinants within the same antigen. Harris DP, et al. **Mol Immunol** 1997 Mar; 34(4):315–22

Promoter strength influences phase variation of neisserial opa genes. Belland RJ, et al. **Mol Microbiol** 1997 Jan; 23(1):123–35

A mutation in the Bordetella bronchiseptica bvgS gene results in reduced virulence and increased resistance to starvation, and identifies a new class of Bvg–regulated antigens. Cotter PA, et al. **Mol Microbiol** 1997 May;24(4):671–85

Structure, function and immunogenicity of streptococcal antigen I/II polypeptides. Jenkinson HF, et al. **Mol Microbiol** 1997 Jan;23(2):183–90 (33 ref.)

Random shuttle mutagenesis: gonococcal mutants deficient in pilin antigenic variation. Mehr IJ, et al. **Mol Microbiol** 1997 Mar;23(6):1121–31

Opc– and pilus–dependent interactions of meningococci with human endothelial cells: molecular mechanisms and modulation by surface polysaccharides. Virji M, et al. **Mol Microbiol** 1995 Nov;18(4):741–54

Transcriptional regulation of the Yersinia pseudotuberculosis pH6 antigen adhesin by two envelope–associated components. Yang Y, et al. **Mol Microbiol** 1997 May; 24(3):499–510

cag, a pathogenicity island of Helicobacter pylori, encodes type I–specific and disease–associated virulence factors. Censini S, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10; 93(25):14648–53

Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. Ulmer JB, et al. **Vaccine** 1997 Jun;15(8):792–4

[New data on the specificity and genetic control of the capsular antigen (F1) in Yersinia pestis] Kosse LV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Mar–Apr; (2):29–33 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Interaction and immunological effect of very late antigen–4, 5, and fibronectin in tonsillar lymphocytes and their relation to age. Ohguro S, et al. **Acta Otolaryngol (Stockh)** 1996 Jan;116(1):104–11

Autoimmune component in individuals during immune response to inactivated combined vaccine against Q fever. Krutitskaya L, et al. **Acta Virol** 1996 Sep;40(4):173–7

Cutaneous anergy to streptococcal antigens in Whipple's disease [letter] Marth T, et al. **Am J Gastroenterol** 1996 Oct;91(10):2254–5

Prevalence of serum antibodies to Helicobacter pylori and to CagA protein in liver transplant recipients. Rudi J, et al. **Am J Gastroenterol** 1997 Sep;92(9):1492–5

In vitro cellular and cytokine responses to mycobacterial antigens: application to diagnosis of tuberculosis infection and assessment of response to mycobacterial vaccines. Lein AD, et al. **Am J Med Sci** 1997 Jun;313(6):364–71 (66 ref.)

In vitro cytokine and prostaglandin production by amnion cells in the presence of bacteria. Reisenberger K, et al. **Am J Obstet Gynecol** 1997 May;176(5):981–4

Evaluation of an enzyme–linked immunosorbent assay in Thai scrub typhus patients. Suwanabun N, et al. **Am J Trop Med Hyg** 1997 Jan;56(1):38–43

Comparison of whole–cell antigens of pressure– and formalin–killed Flexibacter columnaris from channel catfish (Ictalurus punctatus). Bader JA, et al. **Am J Vet Res** 1997 Sep;58(9):985–8

Antibody responses of cattle to outer membrane proteins of Pasteurella multocida A:3. Confer AW, et al. **Am J Vet Res** 1996 Oct;57(10):1453–7

Use of Rhodococcus equi virulence–associated protein for immunization of foals against R equi pneumonia. Prescott JF, et al. **Am J Vet Res** 1997 Apr;58(4):356–9

Microbial antigens can elicit autoantibody production. A potential pathway to autoimmune disease. Kuo P, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:230–6 (29 ref.)

Production and characterization of mouse monoclonal antibodies against Afipia felis. Engbaek K, et al. **APMIS** 1997 Mar;105(3):192–8

Identification of Afipia felis antigens in culture medium: reaction with human sera. Engbaek K, et al. **APMIS** 1997 Mar;105(3):199–206

Human immunoglobulin isotype and IgG subclass response to different antigens of Moraxella catarrhalis. Rahman M, et al. **APMIS** 1997 Mar;105(3):213–20

Activity of neutrophilic granulocytes in rabbits immunized with Chlamydia psittaci. Deptula W, et al. **Arch Vet Pol** 1995;35(1–2):27–34

Recognition of chlamydial antigen by HLA–B27–restricted cytotoxic T cells in HLA–B*2705 transgenic CBA (H–2k) mice. Kuon W, et al. **Arthritis Rheum** 1997 May; 40(5):945–54

Epitope diversity of F strain Mycoplasma gallisepticum detected by flow cytometry. Brown JE, et al. **Avian Dis** 1997 Apr–Jun;41(2):289–95

Protective immunity induced by a Yersinia enterocolitica serovar 0:8 cellular extract. Di Genaro MS, et al. **Biocell** 1996 Dec;20(3):235–41

Cellular and humoral responses to microencapsulated Yersinia pestis subunit vaccines following oral delivery. Sharp GJ, et al. **Biochem Soc Trans** 1997 May;25(2):338S

Association of erythrodermic cutaneous T–cell lymphoma, superantigen–positive Staphylococcus aureus, and oligoclonal T–cell receptor V beta gene expansion [see comments] [published erratum appears in Blood 1997 May 1;89(9):3496] Jackow CM, et al. **Blood** 1997 Jan 1; 89(1):32–40. Comment in: Blood 1997 Jul 1;90(1):472–3.

Subunit vaccines for complex tick–borne pathogens: dream or reality? [editorial; comment] Morrison WI. **Br Vet J** 1996 Nov;152(6):617–9. Comment on: Br Vet J 1996 Nov;152(6):621–39.

Prospects for subunit vaccines against tick–borne diseases [see comments] Musoke AJ, et al. **Br Vet J** 1996 Nov; 152(6):621–39 (125 ref.). Comment in: Br Vet J 1996 Nov;152(6):617–9.

Evaluation of IgA–mediated humoral immune response against the mycobacterial antigen P–90 in diagnosis of pulmonary tuberculosis. Alifano M, et al. **Chest** 1997 Mar; 111(3):601–5

The diagnosis of hypersensitivity pneumonitis [editorial; comment] Schuyler M, et al. **Chest** 1997 Mar;111(3):534–6 . Comment on: Chest 1997 Mar;111(3):813–6.

Diagnostic value of the indirect immunofluorescence assay in cat scratch disease with Bartonella henselae and Afipia felis antigens. Amerein MP, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):200–4

Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design. Feavers IM, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):444–50

Human humoral responses to antigens of Mycobacterium tuberculosis: immunodominance of high–molecular–mass antigens. Laal S, et al. **Clin Diagn Lab Immunol** 1997 Jan; 4(1):49–56

Modification of the Mycobacterium bovis extracellular protein MPB70 with fluorescein for rapid detection of specific serum antibodies by fluorescence polarization. Lin M, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):438–43

Collaborative study for the evaluation of enzyme–linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens. Lynn F, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):689–700

Studies of proliferative responses by long–term–cryopreserved peripheral blood mononuclear cells to bacterial components associated with periodontitis. Miller GA, et al. **Clin Diagn Lab Immunol** 1996 Nov; 3(6):710–6

Comparison of two 2,3–diacyl trehalose antigens from Mycobacterium tuberculosis and Mycobacterium fortuitum for serology in tuberculosis patients. Tórtola MT, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):563–6

Proliferation of distinct human T cell subsets in response to live, killed or soluble extracts of Mycobacterium tuberculosis and Myco. avium. Esin S, et al. **Clin Exp Immunol** 1996 Jun;104(3):419–25

T helper type–1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring. Holland MJ, et al. **Clin Exp Immunol** 1996 Sep;105(3):429–35

Synthetic peptides based on Chlamydia trachomatis antigens identify cytotoxic T lymphocyte responses in subjects from a trachoma–endemic population. Holland MJ, et al. **Clin Exp Immunol** 1997 Jan;107(1):44–9

Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette–Guérin (BCG) in patients with superficial bladder cancer. Zlotta AR, et al. **Clin Exp Immunol** 1997 Jul;109(1):157–65

Serum antibody concentrations of cytotoxin, exotoxin, A, lipopolysaccharide, protease, and elastase and survival of patients with Pseudomonas aeruginosa bacteremia. Baltch AL, et al. **Clin Infect Dis** 1996 Nov;23(5):1109–16

Association of antibodies to Chlamydia trachomatis heat–shock protein 60 kD with chronic nongonococcal urethritis. Horner PJ, et al. **Clin Infect Dis** 1997 Apr; 24(4):653–60

Skin testing with Mycobacterium avium sensitin to identify infection with M. avium complex in patients with cystic fibrosis. Pinto–Powell R, et al. **Clin Infect Dis** 1996 Mar; 22(3):560–2

Role of IgA, IgG, and IgM antibodies against Haemophilus parainfluenzae antigens in IgA nephropathy. Suzuki S, et al. **Clin Nephrol** 1996 Nov;46(5):287–95

T–cell recognition of non–peptide antigens. Porcelli SA, et al. **Curr Opin Immunol** 1996 Aug;8(4):510–6 (50 ref.)

Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease? Granoff DM, et al. **Dev Biol Stand** 1997;89:379–89 (39 ref.)

High seropositivity of anti–CagA antibody in Helicobacter pylori–infected patients irrelevant to peptic ulcers and normal mucosa in Japan. Maeda S, et al. **Dig Dis Sci** 1997 Sep;42(9):1841–7

Circulating immune complexes in human tuberculosis sera: demonstration of specific antibodies against Mycobacterium tuberculosis glycolipid (DAT, PGLTb1, LOS) antigens in isolated circulating immune complexes. Simonney N, et al. **Eur J Clin Invest** 1997 Feb;27(2):128–34

Tumor cells expressing a recall antigen are powerful cancer vaccines. Schweighoffer T. **Eur J Immunol** 1996 Nov; 26(11):2559–64

Proinflammatory effect of Pediococcus pentosaceus, a bacterium used as hay preservative. Duchaine C, et al. **Eur Respir J** 1996 Dec;9(12):2508–12

Structural and immunochemical studies on the lipopolysaccharide of the 'T–antigen'–containing mutant Proteus mirabilis R14/1959. Bartodziejska B, et al. **FEMS Immunol Med Microbiol** 1996 Feb;13(2):113–21

Human immune response to epitopes on the meningococcal outer membrane class 5 protein following natural infection. Danelli MG, et al. **FEMS Immunol Med Microbiol** 1996 Sep;15(2–3):159–68

Human IgG binding ability of streptococcal M3 protein: its related complement activation–dependent M3 protein polymerization. Hong K. **FEMS Immunol Med Microbiol** 1997 Jul;18(3):163–74

Structural and serological studies of lipopolysaccharides of Citrobacter O35 and O38 antigenically related to Salmonella. Kocharova NA, et al. **FEMS Immunol Med Microbiol** 1996 Jan;13(1):1–8

Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine. Milagres LG, et al. **FEMS Immunol Med Microbiol** 1996 Jan;13(1):9–17

Isolation of a new superantigen with potent mitogenic activity to murine T cells from Streptococcus pyogenes. Nemoto E, et al. **FEMS Immunol Med Microbiol** 1996 Sep; 15(2–3):81–91

Low affinity, antibody binding of an Escherichia coli–derived component. Ohlin M, et al. **FEMS Immunol Med Microbiol** 1996 Feb;13(2):161–8

Enzyme–linked immunosorbent assay (ELISA) using a glycolipid antigen for the serodiagnosis of melioidosis. Phung LV, et al. **FEMS Immunol Med Microbiol** 1995 Dec; 12(3–4):259–64

Macrophage release of tumor necrosis factor–alpha by Mycobacterium avium antigens. Rao SP, et al. **FEMS Immunol Med Microbiol** 1996 Aug;15(1):27–34

R–form lipopolysaccharides (LPS) of Gram–negative bacteria as possible vaccine antigens. Stanislavsky ES, et al. **FEMS Immunol Med Microbiol** 1997 Jul;18(3):139–45

Identification of antigenic sites on staphylococcal enterotoxin B and toxoid. Wood AC, et al. **FEMS Immunol Med Microbiol** 1997 Jan;17(1):1–10

Adaptive surface antigen variation in Mycoplasma bovis to the host immune response. Le Grand D, et al. **FEMS Microbiol Lett** 1996 Nov 1;144(2–3):267–75

Immunochemical characterization of a haemagglutinating antigen of Arcobacter spp. Tsang RS, et al. **FEMS Microbiol Lett** 1996 Feb 15;136(2):209–13

Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1–year follow–up study. van der Hulst RW, et al. **Gastroenterology** 1997 Jul; 113(1):25–30

Involvement of bacterial antigens in immunoglobulin A nephropathy. Hirabayashi A, et al. **Hiroshima J Med Sci** 1996 Dec;45(4):113–7

Streptococcus pyogenes type 5 M protein is an antigen, not a superantigen, for human T cells. Degnan B, et al. **Hum Immunol** 1997 Apr 1;53(2):206–15

Ultrastructural demonstration of spirochetal antigens in synovial fluid and synovial membrane in chronic Lyme disease: possible factors contributing to persistence of organisms. Nanagara R, et al. **Hum Pathol** 1996 Oct; 27(10):1025–34

The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules. Prigozy TI, et al. **Immunity** 1997 Feb;6(2):187–97

Immune deviation: a historical perspective. Parish CR. **Immunol Cell Biol** 1996 Oct;74(5):449–56 (53 ref.)

H2–M3 restricted presentation of Listeria monocytogenes antigens. Lenz LL, et al. **Immunol Rev** 1996 Jun;151:107–21 (30 ref.)

Delayed–type hypersensitivity elicited by synthetic peptides complexed with Mycobacterium tuberculosis hsp 70. Roman E, et al. **Immunology** 1997 Jan;90(1):52–6

Synthetic peptides non–covalently bound to bacterial hsp 70

elicit peptide-specific T-cell responses in vivo. Román E, et al. **Immunology** 1996 Aug;88(4):487–92

Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-alpha, IL-1 beta IL-10 by human leucocytes. van Furth AM, et al. **Immunology** 1997 Jun;91(2):193–6

Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Abou-Zeid C, et al. **Infect Immun** 1997 May;65(5):1856–62

Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Anderson GW Jr, et al. **Infect Immun** 1996 Nov;64(11):4580–5

Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Ausiello CM, et al. **Infect Immun** 1997 Jun;65(6):2168–74

Preferential recognition of human myocardial antigens by T lymphocytes from rheumatic heart disease patients. El-Demellawy M, et al. **Infect Immun** 1997 Jun; 65(6):2197–205

Induction of cytotoxic T-cell responses against culture filtrate antigens in Mycobacterium bovis bacillus Calmette-Guérin-infected mice. Denis O, et al. **Infect Immun** 1997 Feb;65(2):676–84

Induction of Th1 cytokine responses by mycobacterial antigens in leprosy. Dockrell HM, et al. **Infect Immun** 1996 Oct;64(10):4385–9

Fine mapping of outer membrane protein P2 antigenic sites which vary during persistent infection by Haemophilus influenzae. Duim B, et al. **Infect Immun** 1996 Nov; 64(11):4673–9

Oral immunization of mice with attenuated Salmonella typhimurium aroA expressing a recombinant Mycoplasma hyopneumoniae antigen (NrdF). Fagan PK, et al. **Infect Immun** 1997 Jun;65(6):2502–7

FlaA, a putative flagellar outer sheath protein, is not an immunodominant antigen associated with Lyme disease. Ge Y, et al. **Infect Immun** 1997 Jul;65(7):2992–5

Listeriolysin and IrpA are major protein targets of the human humoral response against Listeria monocytogenes. Grenningloh R, et al. **Infect Immun** 1997 Sep;65(9):3976–80

Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of coexpressed cholera toxin A2 and B subunits. Harokopakis E, et al. **Infect Immun** 1997 Apr;65(4):1445–54

Processing and presentation of an antigen of Mycobacterium avium require access to an acidified compartment with active proteases. Holsti MA, et al. **Infect Immun** 1996 Oct; 64(10):4091–8

Initial route of antigen administration alters the T-cell cytokine profile produced in response to the mouse pneumonitis biovar of Chlamydia trachomatis following genital infection [published erratum appears in Infect Immun 1997 Jun;65(6):2508] Kelly KA, et al. **Infect Immun** 1996 Dec;64(12):4976–83

Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Kossaczka Z, et al. **Infect Immun** 1997 Jun;65(6):2088–93

Antigenic characterization of the salmonid pathogen Piscirickettsia salmonis. Kuzyk MA, et al. **Infect Immun** 1996 Dec;64(12):5205–10

V antigen-polyhistidine fusion peptide: binding to LcrH and active immunity against plague. Motin VL, et al. **Infect Immun** 1996 Oct;64(10):4313–8

Predominant recognition of the ESAT-6 protein in the first phase of interferon with Mycobacterium bovis in cattle. Pollock JM, et al. **Infect Immun** 1997 Jul;65(7):2587–92

Induction of homologous immune response to Rickettsia tsutsugamushi Boryong with a partial 56-kilodalton recombinant antigen fused with the maltose-binding protein MBP-Bor56. Seong SY, et al. **Infect Immun** 1997 Apr;65(4):1541–5

Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T-helper-cell responses in gut-associated lymphoid tissues. Toida N, et al. **Infect Immun** 1997 Mar;65(3):909–15

A 35-kilodalton protein is a major target of the human immune response to Mycobacterium leprae. Triccas JA, et al. **Infect Immun** 1996 Dec;64(12):5171–7

Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Yamamoto M, et al. **Infect Immun** 1997 Feb;65(2):640–4

Importance of an immunodominant surface-exposed loop on outer membrane protein P2 of nontypeable Haemophilus influenzae. Yi K, et al. **Infect Immun** 1997 Jan;65(1):150–5

Low antigenicity of the polysaccharide region of Helicobacter pylori lipopolysaccharides derived from tumors of patients with gastric cancer. Yokota S, et al. **Infect Immun** 1997 Sep;65(9):3509–12

In vivo induction of type 1 and 2 immune responses against protein antigens. Comoy EE, et al. **Int Immunol** 1997 Apr; 9(4):523–31

Alteration of a polyclonal to an oligoclonal immune response to cecal aerobic bacterial antigens in TCR alpha mutant mice with inflammatory bowel disease. Mizoguchi A, et al. **Int Immunol** 1996 Sep;8(9):1387–94

Mapping of V beta 11+ helper T cell epitopes on mycobacterial antigen in mouse primed with Mycobacterium tuberculosis. Yanagisawa S, et al. **Int Immunol** 1997 Feb;9(2):227–37

Takayasu's arteritis: role of Mycobacterium tuberculosis and its 65 kDa heat shock protein. Aggarwal A, et al. **Int J Cardiol** 1996 Jul 5;55(1):49–55

Occurrence and specificity of human natural and in vitro induced antibodies to Nocardia opaca antigens. Prokešová L, et al. **Int J Immunopharmacol** 1996 Nov;18(11):661–8

Investigation of anti-Mycobacterium leprae antibodies in leprosy patients' sera by an A60 antigen immunoassay [letter] Casal M, et al. **Int J Lepr Other Mycobact Dis** 1996 Sep;64(3):325–7

Enzyme-linked immunosorbent assay (ELISA) with mycobacterial crude antigens for the sero-epidemiological diagnosis of active tuberculosis. Escobar-Gutierrez A, et al. **Int J Lepr Other Mycobact Dis** 1996 Dec;64(4):417–27

Humoral and cellular immune reactivity to recombinant M. leprae antigens in HLA-typed leprosy patients and healthy controls. Klatser PR, et al. **Int J Lepr Other Mycobact Dis** 1997 Jun;65(2):178–89

Recognition of lipid antigens by sera of mice infected with Mycobacterium lepraemurium. Luna-Herrera J, et al. **Int J Lepr Other Mycobact Dis** 1996 Sep;64(3):299–305

Dharmendra antigen but not integral M. leprae is an efficient inducer of immunostimulant cytokine production by human monocytes, and M. leprae lipids inhibit the cytokine production. Nakamura C, et al. **Int J Lepr Other Mycobact Dis** 1997 Mar;65(1):63–72

Implications of simultaneous tests for tuberculin and non-tuberculous mycobacteria antigen in the elderly. Shachor Y, et al. **Isr J Med Sci** 1997 Mar;33(3):170–4

A new serovar of Bacillus thuringiensis possessing 28a28c flagellar antigenic structure: Bacillus thuringiensis serovar jegathesan, selectively toxic against mosquito larvae. Seleena P, et al. **J Am Mosq Control Assoc** 1995 Dec; 11(4):471–3

Cytometric detection of mycobacterial surface antigens: exposure of mannosyl epitopes and of the arabinan segment of arabinomannans. Ozanne V, et al. **J Bacteriol** 1996 Dec; 178(24):7254–9

Lymphocyte proliferative response to Helicobacter pylori CagA protein in patients with duodenal ulcer or gastritis [letter] Tricerri A, et al. **J Clin Gastroenterol** 1996 Jul; 23(1):81–2

Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis. Gudmundsson G, et al. **J Clin Invest** 1997 May 15;99(10):2386–90

CD1 presentation of microbial nonpeptide antigens to T cells. Jullien D, et al. **J Clin Invest** 1997 May 1;99(9):2071–4 (13 ref.)

Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. La Cava A, et al. **J Clin Invest** 1997 Aug 1; 100(3):658–63

In utero exposure to helminth and mycobacterial antigens generates cytokine responses similar to that observed in adults. Malhotra I, et al. **J Clin Invest** 1997 Apr 1; 99(7):1759–66

ELISPOT assay for Chlamydia-specific, antibody-producing cells correlated with conventional complement fixation and microimmunofluorescence. Daugharty H, et al. **J Clin Lab Anal** 1997;11(1):45–52

Enzyme immunoassay to detect antituberculous glycolipid antigen (anti-TBGL antigen) antibodies in serum for diagnosis of tuberculosis. Kawamura M, et al. **J Clin Lab Anal** 1997;11(3):140–5

Polyclonal B-cell activation by Neisseria meningitidis capsular polysaccharides elicit antibodies protective against Trypanosoma cruzi infection in vitro. Oliveira TG, et al. **J Clin Lab Anal** 1996;10(4):220–8

Molecular characterization of a 35-kilodalton protein of Borrelia burgdorferi, an antigen of diagnostic importance in early Lyme disease. Gilmore RD Jr, et al. **J Clin Microbiol** 1997 Jan;35(1):86–91

Detection and characterization of the coli surface antigen 6 of enterotoxigenic Escherichia coli strains by using monoclonal antibodies. Helander A, et al. **J Clin Microbiol** 1997 Apr;35(4):867–72

Antibody against an Anaplasma marginale MSP5 epitope common to tick and erythrocyte stages identifies persistently infected cattle. Knowles D, et al. **J Clin Microbiol** 1996 Sep;34(9):2225–30

Characterization of an immunoreactive protein from the agent of human granulocytic ehrlichiosis. Kolbert CP, et al. **J Clin Microbiol** 1997 May;35(5):1172–8

Serologic diagnosis of canine and equine borreliosis: use of recombinant antigens in enzyme-linked immunosorbent assays. Magnarelli LA, et al. **J Clin Microbiol** 1997 Jan; 35(1):169–73

Identification of enteroinvasive Escherichia coli and Shigella strains in pediatric patients by an IpaC-specific enzyme-linked immunosorbent assay. Pal T, et al. **J Clin Microbiol** 1997 Jul;35(7):1757–60

Detection of Antibodies to Pasteurella multocida by capture enzyme immunoassay using a monoclonal antibody against P37 antigen. Peterson RR, et al. **J Clin Microbiol** 1997 Jan;35(1):208–12

GlpQ: an antigen for serological discrimination between relapsing fever and Lyme borreliosis. Schwan TG, et al. **J Clin Microbiol** 1996 Oct;34(10):2483–92

Production of monoclonal antibodies against Rickettsia massiliae and their use in antigenic and epidemiological studies. Xu W, et al. **J Clin Microbiol** 1997 Jul; 35(7):1715–21

Detection of IgM antibodies in pulmonary tuberculosis by ELISA using A60 antigen. Mahajan M, et al. **J Commun Dis** 1996 Sep;28(3):176–80

Formulation of poly(DL-lactide-co-glycolide) microspheres and their ingestion by bovine leukocytes. O'Brien CN, et al. **J Dairy Sci** 1996 Nov;79(11):1954–9

Extracellular 37-kDa antigenic protein from Actinobacillus actinomycetemcomitans induces TNF-alpha, IL-1 beta, and IL-6 in murine macrophages. Tani Y, et al. **J Dent Res** 1997 Sep;76(9):1538–47

Diversification of T cell responses to carboxy-terminal determinants within the 65-kD heat-shock protein is involved in regulation of autoimmune arthritis. Moudgil KD, et al. **J Exp Med** 1997 Apr 7;185(7):1307–16

N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. Pon RA, et al. **J Exp Med** 1997 Jun 2;185(11):1929–38

Enhanced intracellular dissociation of major histocompatibility complex class I-associated peptides: a mechanism for optimizing the spectrum of cell surface-presented cytotoxic T lymphocyte epitopes. Sijts AJ, et al. **J Exp Med** 1997 Apr 21;185(8):1403–11

The progeny of a single virgin B cell predominates the human recall B cell response to the capsular polysaccharide of Haemophilus influenzae type b. Barington T, et al. **J Immunol** 1996 Nov 1;157(9):4016–27

Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice. Bockenstedt LK, et al. **J Immunol** 1996 Dec 15;157(12):5496–502

Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. Brandwein SL, et al. **J Immunol** 1997 Jul 1;159(1):44–52

Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation. Chen YZ, et al. **J Immunol** 1996 Nov 1; 157(9):3783–90

Identification of a natural T cell epitope presented by Salmonella-infected macrophages and recognized by T cells from orally immunized mice. Cookson BT, et al. **J Immunol** 1997 May 1;158(9):4310–9

Human dendritic cells phagocytose and process Borrelia burgdorferi. Filgueira L, et al. **J Immunol** 1996 Oct 1; 157(7):2998–3005

Differential binding avidities of human IgM for staphylococcal protein A derive from specific germ-line VH3 gene usage. Hakoda M, et al. **J Immunol** 1996 Oct 1;157(7):2976–81

Activation of human dendritic cells following infection with Mycobacterium tuberculosis. Henderson RA, et al. **J Immunol** 1997 Jul 15;159(2):635–43

CD4+ T cell down-regulation in human intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens. Khoo UY, et al. **J Immunol** 1997 Apr 15; 158(8):3626–34

Superantigen activation of immune cells evokes epithelial (T84) transport and barrier abnormalities via IFN-gamma and TNF alpha: inhibition of increased permeability, but not diminished secretory responses by TGF-beta2. McKay DM, et al. **J Immunol** 1997 Sep 1;159(5):2382–90

Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity. Newton DW, et al. **J Immunol** 1996 Nov 1;157(9):3988–94

An endogenous sialoprotein and a bacterial B cell superantigen compete in their VH family-specific binding interactions with human Igs. Silverman GJ, et al. **J Immunol** 1996 Nov 15;157(10):4496–502

Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. Svensson M, et al. **J Immunol** 1997 May 1;158(9):4229–36

Human alveolar T lymphocyte responses to Mycobacterium tuberculosis antigens: role for CD4+ and CD8+ cytotoxic T cells and relative resistance of alveolar macrophages to lysis. Tan JS, et al. **J Immunol** 1997 Jul 1;159(1):290–7

Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation. Tiedemann RE, et al. **J Immunol** 1996 Nov 1;157(9):3958–66

Lipoprotein from Yersinia enterocolitica contains epitopes that cross-react with the human thyrotropin receptor. Zhang H, et al. **J Immunol** 1997 Feb 15;158(4):1976–83

Characterization of murine monoclonal antibodies specific for the 45/47 kDa antigen complex (APA) of Mycobacterium tuberculosis, M. bovis and BCG. Horn C, et al. **J Immunol Methods** 1996 Oct 16;197(1-2):151–9

Capture-ELISA: a new assay for the detection of immunoglobulin M isotype antibodies using Chlamydia trachomatis antigen. Poussin M, et al. **J Immunol Methods** 1997 May 12;204(1):1–12

Enterobacteria-infected T cells as antigen-presenting cells for cytotoxic CD8 T cells: a contribution to the self-limitation of cellular immune reactions in reactive arthritis? Ackermann B, et al. **J Infect Dis** 1997 May; 175(5):1121–7

Cross-reactivity to Borrelia burgdorferi proteins in serum samples from residents of a tropical country nonendemic

for Lyme disease. Burkot TR, et al. **J Infect Dis** 1997 Feb; 175(2):466–9

Bacterial antigen activation of Vdelta1 and Vdelta2 gammadelta T cells of persons infected with human immunodeficiency virus type 1. Chervenak KA, et al. **J Infect Dis** 1997 Feb;175(2):429–33

Antigen conformation dependence of Chlamydia trachomatis infectivity neutralization. Fan J, et al. **J Infect Dis** 1997 Sep;176(3):713–21

Surrogate marker of preclinical tuberculosis in human immunodeficiency virus infection: antibodies to an 88–kDa secreted antigen of Mycobacterium tuberculosis. Laal S, et al. **J Infect Dis** 1997 Jul;176(1):133–43

Seroprevalence of CagA–positive strains among Helicobacter pylori–infected, healthy young adults. Parsonnet J, et al. **J Infect Dis** 1997 May;175(5):1240–2

Interferon–gamma and interleukin–10 have cross–regulatory roles in modulating the class I and class II MHC–mediated presentation of epitopes of Listeria monocytogenes by infected macrophages. Hiltbold EM, et al. **J Interferon Cytokine Res** 1996 Jul;16(7):547–54

Microbial superantigens stimulate T cells by the superantigen bridge and independently by a cytokine pathway. Rink L, et al. **J Interferon Cytokine Res** 1997 Aug;17(8):489–99

Induction of a proinflammatory cytokine network by Mycoplasma arthritidis–derived superantigen (MAS). Rink L, et al. **J Interferon Cytokine Res** 1996 Oct;16(10):861–8

Identification of the major T–cell antigens present in the Brucella melitensis B115 protein preparation, Brucellergene OCB. Denoel PA, et al. **J Med Microbiol** 1997 Sep; 46(9):801–6

Characterisation and protective capacity of monoclonal antibodies elicited in mice against protein epitopes of antibiotic–exposed Escherichia coli. Lun MT, et al. **J Med Microbiol** 1997 Feb;46(2):122–8

Biovar–specific epitopes of the urease enzyme of Ureaplasma urealyticum. MacKenzie CR, et al. **J Med Microbiol** 1996 Nov;45(5):366–71

Immunization of Macaca mulatta with aroA attenuated Salmonella typhimurium expressing the SIVp27 antigen. Steger KK, et al. **J Med Primatol** 1997 Feb–Apr; 26(1–2):44–50

Epitope mapping by negative selection of randomized antigen libraries displayed on filamentous phage. Jespers L, et al. **J Mol Biol** 1997 Jun 27;269(5):704–18

Modifications of the follicle–associated epithelium by short–term exposure to a non–intestinal bacterium. Borghesi C, et al. **J Pathol** 1996 Nov;180(3):326–32

Elevated IgG titer against the C region of streptococcal M protein and its immunodeterminants in patients with poststreptococcal acute glomerulonephritis. Mori K, et al. **J Pediatr** 1997 Aug;131(2):293–9

Characterization of the Porphyromonas gingivalis antigen recognized by a monoclonal antibody which prevents colonization by the organism. Booth V, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 1):54–60

Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette–Guerin during intravesical treatment of superficial bladder cancer. Zlotta AR, et al. **J Urol** 1997 Feb;157(2):492–8

Comparative preparation methods of sialylated capsule antigen from Streptococcus suis type 2 with type specific antigenicity. Katsumi M, et al. **J Vet Med Sci** 1996 Oct; 58(10):947–52

A multivalent minigene vaccine, containing B–cell, cytotoxic T–lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen. An LL, et al. **J Virol** 1997 Mar;71(3):2292–302

A recombinant antigen from the heartwater agent (Cowdria ruminatium) reactive with antibodies in some southeastern United States white–tailed deer (Odocoileus virginianus), but not cattle, sera. Katz JB, et al. **J Wildl Dis** 1996 Jul; 32(3):424–30

Immunoprophylactic properties of 71–kDa cell wall–associated protein antigen of Mycobacterium tuberculosis H37Ra. Dhiman N, et al. **Med Microbiol Immunol (Berl)** 1997 Jun;186(1):45–51

Molecular analysis of putative pneumococcal virulence proteins. Paton JC, et al. **Microb Drug Resist** 1997 Spring; 3(1):1–10

Expression of mycobacterial antigens on murine dissociated Schwann cells infected with Mycobacterium leprae. Birdi TJ, et al. **Microb Pathog** 1997 Mar;22(3):181–5

Heat shock response of Streptococcus pneumoniae: identification of immunoreactive stress proteins. Hamel J, et al. **Microb Pathog** 1997 Jul;23(1):11–21

Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Leary SEC, et al. **Microb Pathog** 1997 Sep; 23(3):167–79

Differential expression of a Mycobacterium tuberculosis protein recognized by a mouse monoclonal antibody. Cummings PJ, et al. **Microbiol Immunol** 1996;40(11):883–6

Cellular immune responses to cell wall peptidoglycan associated protein antigens in tuberculosis patients and healthy subjects. Dhiman N, et al. **Microbiol Immunol** 1997; 41(6):495–502

Production, binding characteristics and protective immunity of monoclonal antibody to pneumococcal type–9V conjugate. Lee CJ, et al. **Microbiol Immunol** 1996; 40(11):857–65

Presence of common antigenic epitope in outer surface protein (Osp) A and OspB of Japanese isolates identified as Borrelia garinii. Masuzawa T, et al. **Microbiol Immunol** 1996;40(6):455–8

Immunochemical characteristics and localization on cells of protective antigen (PAg) prepared from Leptospira interrogans serovar lai. Masuzawa T, et al. **Microbiol Immunol** 1996;40(3):237–41

Demonstration of a heat–stable 120–kilodalton protein of Rickettsia japonica as a spotted fever group–common antigen. Uchiyama T, et al. **Microbiol Immunol** 1996; 40(2):133–9

Identification of novel species–specific antigens of Mycoplasma hyopneumoniae by preparative SDS–PAGE ELISA profiling. Scarman AL, et al. **Microbiology** 1997 Feb;143 (Pt 2):663–73

Generation of antiserum to specific epitopes. Marchion DC, et al. **Mol Biotechnol** 1996 Dec;6(3):231–40

Epitope mapping of homologous and cross–reactive antigens by monoclonal antibodies to streptococcal cell membrane (mAb to SCM). Lange CF, et al. **Mol Immunol** 1996 Jun; 33(9):777–86

Antigen–dependent B cell differentiation in the synovial tissue of a patient with reactive arthritis. Schröder AE, et al. **Mol Med** 1997 Apr;3(4):260–72

Development of ulcerative colitis: evidence from animal models. Alberti S. **Mol Med Today** 1996 Jul;2(7):272–4

Structure, function and immunogenicity of streptococcal antigen I/II polypeptides. Jenkinson HF, et al. **Mol Microbiol** 1997 Jan;23(2):183–90 (33 ref.)

Nickel binding and immunological properties of the C–terminal domain of the Helicobacter pylori GroES homologue (HspA). Kansau I, et al. **Mol Microbiol** 1996 Dec;22(5):1013–23

Questions about gonococcal pilus phase– and antigenic variation. Seifert HS. **Mol Microbiol** 1996 Aug;21(3):433–40 (54 ref.)

Immunological and functional characterization of Mycobacterium leprae protein antigens: an overview. Thole JE, et al. **Mol Microbiol** 1995 Dec;18(5):791–800 (53 ref.)

The N–domain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria meningitidis and Neisseria gonorrhoeae. Virji M, et al. **Mol Microbiol** 1996 Dec;22(5):929–39

Carcinoembryonic antigens (CD66) on epithelial cells and neutrophils are receptors for Opa proteins of pathogenic neisseriae. Virji M, et al. **Mol Microbiol** 1996 Dec; 22(5):941–50

Oral immunization with an anti–idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Whittum–Hudson JA, et al. **Nat Med** 1996 Oct;2(10):1116–21

Detection of IgA against the mycobacterial antigen A60 in serum and saliva in patients with active pulmonary tuberculosis: preliminary results. Del Pezzo M, et al. **New Microbiol** 1996 Oct;19(4):363–7

Immunization with meningococcal membrane–bound lipooligosaccharide accelerates granulocyte recovery and enhances lymphocyte proliferation in myelosuppressed mice. Quakyi EK, et al. **Pathobiology** 1997;65(1):26–38

False positive detection of group A Streptococcus antigen resulting from cross–reacting Streptococcus intermedius (Streptococcus milleri group). Rubin LG, et al. **Pediatr Infect Dis J** 1996 Aug;15(8):715–7

Bactericidal antibody recognition of a PorA epitope of Neisseria meningitidis: crystal structure of a Fab fragment in complex with a fluorescein–conjugated peptide. van den Elsen JM, et al. **Proteins** 1997 Sep;29(1):113–25

Stimulation of gamma delta T cells by phosphoantigens. Fournié JJ, et al. **Res Immunol** 1996 Jun;147(5):338–47 (60 ref.)

Direct presentation of non–peptide prenyl pyrophosphate antigens to human gamma delta T cells. Morita CT, et al. **Res Immunol** 1996 Jun;147(5):347–53 (44 ref.)

IgA immune response against the mycobacterial antigen A60 in patients with active pulmonary tuberculosis. Alifano M, et al. **Respiration** 1996;63(5):292–7

Experimental immunization of hamsters with an EDTA extract of Leptospira interrogans, serovar icterohaemorrhagiae. de Queiroz–Leite LT, et al. **Rev Latinoam Microbiol** 1996 Jan–Mar;38(1):39–43

Priming to mycobacterial antigen in vivo using antigen–pulsed antigen presenting cells generated in vitro is influenced by the dose and presence of IL–4 in APC cultures. Dillon SM, et al. **Scand J Immunol** 1997 Jul; 46(1):1–9

Characterization of Chlamydia pneumoniae antigens using human T cell clones. Halme S, et al. **Scand J Immunol** 1997 Apr;45(4):378–84

Cross–reactive immune responses against Mycobacterium bovis BCG in mice infected with non–tuberculous mycobacteria belonging to the MAIS–Group. Lozes E, et al. **Scand J Immunol** 1997 Jul;46(1):16–26

Synthesis of cytokines during tumour development in mice immunized with the mycobacterial antigen complex A60. Maes H, et al. **Scand J Immunol** 1996 Oct;44(4):369–74

Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts. Khoo SH, et al. **Thorax** 1996 Sep;51(9):932–5

Psoriasis and bacterial superantigens––formal or causal correlation? Boehncke WH. **Trends Microbiol** 1996 Dec; 4(12):485–9 (39 ref.)

Presentation of antigens derived from microorganisms residing in host–cell vacuoles. Ojcius DM, et al. **Trends Microbiol** 1996 Feb;4(2):53–9 (53 ref.)

Effective adjuvants for the induction of antigen–specific delayed–type hypersensitivity. Baldridge JR, et al. **Vaccine** 1997 Mar;15(4):395–401

Antigenicity, cross–reactivity and surface exposure of the Neisseria meningitidis 37 kDa protein (Fbp). Gómez JA, et al. **Vaccine** 1996 Oct;14(14):1340–6

Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Lozes E, et al. **Vaccine** 1997 Jun;15(8):830–3

Antibody response to Actinobacillus pleuropneumoniae antigens after vaccination of pigs bred for high and low immune response. Magnusson U, et al. **Vaccine** 1997 Jun; 15(9):997–1000

Anthrax post–vaccinal cell–mediated immunity in humans: kinetics pattern. Shlyakhov E, et al. **Vaccine** 1997 Apr–May;15(6–7):631–6

Effect of lipid modification on the physicochemical, structural, antigenic and immunoprotective properties of Haemophilus influenzae outer membrane protein P6. Yang YP, et al. **Vaccine** 1997 Jun;15(9):976–87

In vitro responses of cervine macrophages to bacterial stimulants. Cross ML, et al. **Vet Immunol Immunopathol** 1996 Oct;53(3–4):249–56

Separation of equine IgG subclasses (IgGa, IgGb and IgG(T)) using their differential binding characteristics for staphylococcal protein A and streptococcal protein G. Sheoran AS, et al. **Vet Immunol Immunopathol** 1996 Dec; 55(1–3):33–43

Immunoprophylaxis of Rhodococcus equi pneumonia in foals. Becú T, et al. **Vet Microbiol** 1997 Jun 16; 56(3–4):193–204

Protective effect against Rhodococcus equi infection in mice of IgG purified from horses vaccinated with virulence associated protein (VapA)–enriched antigens. Fernandez AS, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):187–92

Antigenic analysis of Rhodococcus equi preparations using different horse sera. Fontanals AM, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):247–55

Assessment of the immunogenic potential of Rhodococcus equi virulence associated protein (VapA) in mice. Prescott JF, et al. **Vet Microbiol** 1997 Jun 16;56(3–4):213–25

Immune responses towards intestinal bacteria––current concepts and future perspectives. Duchmann R, et al. **Z Gastroenterol** 1997 May;35(5):337–46 (78 ref.)

T–cell activation and proliferation in a case of recurrent menstrual toxic shock syndrome. Arvand M, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):164–9

Molecular diversity among the trypsin resistant surface proteins of group B streptococci. Flores AE, et al. **Zentralbl Bakteriol** 1996 Sep;285(1):44–51

A comparative study of the major outer membrane proteins of the avian haemophili and Pasteurella gallinarum. Hartmann L, et al. **Zentralbl Bakteriol** 1996 Jun; 284(1):47–51

Serum antibody reactivity to recombinant mig and whole cell antigens in Mycobacterium avium infection. Plum G, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):348–60

Protection against bacterial infection by urea extracts from Salmonella. Schlecht S, et al. **Zentralbl Bakteriol** 1996 Aug; 284(4):559–64

Macrorestriction analysis (PFGE) of serologically cross–reactive serovars of Acinetobacter baumannii and genospecies 3. Traub WH, et al. **Zentralbl Bakteriol** 1997 Feb;285(3):403–12

Seroreactivity of Salmonella–infected cattle herds against a fimbrial antigen in comparison with lipopolysaccharide antigens. Hoorfar J, et al. **Zentralbl Veterinarmed [B]** 1996 Oct;43(8):461–7

[Antigens in the serologic detection of Helicobacter pylori infection] Havlasová J, et al. **Vnitr Lek** 1997 Feb; 43(2):115–9 (Eng. Abstr.) **(Cze)**

[Primary biliary cirrhosis––cellular mechanisms and role of enterobacterial antigens] Lobeck H, et al. **Verh Dtsch Ges Pathol** 1996;80:267–71 (Eng. Abstr.) **(Ger)**

[Serodiagnosis with trehalose–6,6'–dimycolate of pulmonary tuberculosis] Wada M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Jan;35(1):43–8 (Eng. Abstr.) **(Jpn)**

[Structure and antigenicity of the major glycolipid from opportunistic bacteria Rhodococcus equi] Szponar B, et al. **Postepy Hig Med Dosw** 1996;50(5):533–5 (Eng. Abstr.) **(Pol)**

[Effect of lomefloxacin on the synthesis of antibodies to vaccine EV fraction I and hemagglutinins] Iordanova AI, et al. **Antibiot Khimioter** 1996 Apr;41(4):44–50 (Eng. Abstr.) **(Rus)**

[A comparative study of fluoroquinolones and 3rd–generation cephalosporins in the prevention and treatment of experimental plague caused by Yersinia pestis strains typical and serologically atypical with respect to F1] Ryzhko IV, et al. **Antibiot Khimioter** 1997;42(1):12–6 (Eng. Abstr.) **(Rus)**

[Antigenic properties of outer membrane porins in Yersinia genus] Novikova OD, et al. **Biull Eksp Biol Med** 1996 Jun; 121(6):657–60 **(Rus)**

[Comparative incidence of detection of specific antibodies to Yersinia pestis capsular antigen and lipopolysaccharide in humans immunized with pest vaccine] Devdariani ZL, et al. **Klin Lab Diagn** 1997 Apr;(4):39–41 (Eng. Abstr.) **(Rus)**

[Some immunochemical and immunobiological properties of Vibrio cholerae serovar 0139 capsule antigen] Fedorova VA, et al. **Mol Gen Mikrobiol Virusol** 1997;(3):18–20 (Eng. Abstr.) **(Rus)**

[Comparative study of the antigenic composition of Brucella canis strains by immunoblotting] Kulakov IuK, et al. **Mol Gen Mikrobiol Virusol** 1997;(3):15–7 (Eng. Abstr.) **(Rus)**

[A comparative analysis of Francisella protein antigens] Rodionova IV, et al. **Mol Gen Mikrobiol Virusol** 1997; (3):11–5 (Eng. Abstr.) **(Rus)**

[Immunogenic potential of glanders and melioidosis agents] Kalachev II, et al. **Vestn Ross Akad Med Nauk** 1997; (6):32–7 (Eng. Abstr.) **(Rus)**

[Elucidation of functionally active domains in molecules of protective antigen bacillus anthracis's toxin] Noskov AN, et al. **Vestn Ross Akad Med Nauk** 1997;(6):20–4 (Eng. Abstr.) **(Rus)**

[The evaluation of different agglutination and adhesion tests with erythrocytic reagents in determining antibodies to the O and H antigens of Salmonella typhimurium in comparison with immunoenzyme analysis (IEA)] Karal'nik BV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct;(5):76–80 (Eng. Abstr.) **(Rus)**

[New data on the specificity and genetic control of the capsular antigen (F1) in Yersinia pestis] Kosse LV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Mar–Apr; (2):29–33 (Eng. Abstr.) **(Rus)**

[The role of the outer-membrane antigens of Yersinia pseudotuberculosis in the pathogenesis and diagnosis of pseudotuberculosis] Kuliashova LB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb;(1):14–8 (Eng. Abstr.) **(Rus)**

[The unknown functions of heterologous antigens of different origins] Nikolaeva AI. **Zh Mikrobiol Epidemiol Immunobiol** 1997 May–Jun; (3):76–81 (Eng. Abstr.) **(Rus)**

[The immunogenicity and heterogeneity of Pseudomonas pseudomallei surface antigen 8] Piven' NN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul–Aug;(4):75–8 (Eng. Abstr.) **(Rus)**

[The characteristics of the protectiveness of a preparation of Vibrio cholerae outer membrane based on the data from a study using the ligated intestinal loop] Urbanovich LIa, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Mar–Apr; (2):43–6 (Eng. Abstr.) **(Rus)**

[A polyvalent complex of Bordetella pertussis antigens as the basis for an acellular pertussis vaccine] Zakharova NS, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 May–Jun; (3):70–2 (Eng. Abstr.) **(Rus)**

[The isolation of a transfer factor of the delayed-hypersensitivity type to the antigenic substances of Staphylococcus aureus in guinea pigs] Holieva OH, et al. **Fiziol Zh** 1996;42(5–6):58–65 (Eng. Abstr.) **(Ukr)**

[Human specific transfer factor to Staphylococcus aureus antigens] Liubchenko TA, et al. **Fiziol Zh** 1997; 43(3–4):25–32 (Eng. Abstr.) **(Ukr)**

ISOLATION & PURIFICATION

High-pH anion-exchange chromatographic analysis of phosphorylated compounds: application to isolation and characterization of nonpeptide mycobacterial antigens. Poquet Y, et al. **Anal Biochem** 1996 Dec 1;243(1):119–26

Monoclonal antibodies for use in detection of Bacillus and Clostridium spores. Quinlan JJ, et al. **Appl Environ Microbiol** 1997 Feb;63(2):482–7

New serovars of plesiomonas shigelloides—1996. Aldová E. **Cent Eur J Public Health** 1997 Mar;5(1):21–3

Antigenic characterization of fimbria preparations from Streptococcus mutans isolates from caries-free and caries-susceptible subjects. Perrone M, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):291–6

Purification of Mycobacterium bovis BCG Tokyo antigens by chromatofocusing, lectin-affinity chromatography, and hydrophobic interaction chromatography. Sugden EA, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):541–6

Occurrence of Y. enterocolitica antigens O:3, O:9 and O:8 in different Yersinia species, their corresponding H antigens and origin. Aleksić S. **Contrib Microbiol Immunol** 1995; 13:89–92

Large-scale purification of the F1 antigen of Yersinia pestis. Reddin KM, et al. **Contrib Microbiol Immunol** 1995; 13:329–30

A simplified antigenic scheme for serotyping of Yersinia pseudotuberculosis: phenotypic characterization of reference strains and preparation of O and H factor sera. Tsubokura M, et al. **Contrib Microbiol Immunol** 1995; 13:99–105

Surface antigens of the syphilis spirochete and their potential as virulence determinants. Blanco DR, et al. **Emerg Infect Dis** 1997 Jan–Mar;3(1):11–20 (47 ref.)

Purification and partial characterization of an antigen specific to Lactobacillus brevis strains with beer spoilage activity. Yasui T, et al. **FEMS Microbiol Lett** 1997 Jun 15; 151(2):169–76

Characterization, occurrence, and molecular cloning of a 39-kilodalton Brucella abortus cytoplasmic protein immunodominant in cattle. Denoel PA, et al. **Infect Immun** 1997 Feb;65(2):495–502

Antigenic and molecular analyses of different Chlamydia pneumoniae strains. Jantos CA, et al. **J Clin Microbiol** 1997 Mar;35(3):620–3

Immunoblot and ultrastructural analysis of antigens extracted from Dichelobacter nodosus with potassium thiocyanate. Whittington R. **J Vet Diagn Invest** 1996 Jul;8(3):315–23

Cloning, expression, and affinity purification of recombinant Shigella flexneri invasion plasmid antigens IpaB and IpaC. Picking WL, et al. **Protein Expr Purif** 1996 Dec;8(4):401–8

Rapid antigen tests for Neisseria gonorrhoeae and Chlamydia trachomatis are not accurate for screening women with disturbed vaginal lactobacillary flora. Donders GG, et al. **Scand J Infect Dis** 1996;28(6):559–62

Isolation of perchloric acid soluble, heat stable, ethanol extractable protein from Mycobacterium tuberculosis. Kim DS, et al. **Yonsei Med J** 1996 Oct;37(5):339–49

[The isolation of the surface antigen from vegetative cells of Bacillus anthracis STI-1 and study of its protective properties] Beznosov MV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb;(1):9–13 (Eng. Abstr.) **(Rus)**

[An acellular pertussis vaccine based on the natural complex of antigens isolated from the supernatant of a synthetic culture medium] Zakharova NS, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 May–Jun; (3):67–70 (Eng. Abstr.) **(Rus)**

[The isolation of the antigenic substances of Mycobacterium tuberculosis and the characteristics of their basic chemical components] Lonych LI. **Mikrobiol Z** 1997 Mar–Apr; 59(2):67–72 (Eng. Abstr.) **(Ukr)**

METABOLISM

Purification of Mycobacterium bovis BCG Tokyo antigens by chromatofocusing, lectin-affinity chromatography, and hydrophobic interaction chromatography. Sugden EA, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):541–6

CD66 carcinoembryonic antigens mediate interactions between Opa-expressing Neisseria gonorrhoeae and human polymorphonuclear phagocytes. Gray-Owen SD, et al. **EMBO J** 1997 Jun;16(12):3435–45

Modulation of bacterial entry into epithelial cells by association between vinculin and the Shigella IpaA invasin. Tran Van Nhieu G, et al. **EMBO J** 1997 May 15; 16(10):2717–29

A DR17-restricted T cell epitope from a secreted Mycobacterium tuberculosis antigen only binds to DR17 molecules at neutral pH. Geluk A, et al. **Eur J Immunol** 1997 Apr;27(4):842–7

A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens. Zhu X, et al. **Eur J Immunol** 1997 Aug; 27(8):1933–41

Purification of IpaC, a protein involved in entry of Shigella flexneri into epithelial cells and characterization of its interaction with lipid membranes. De Geyter C, et al. **FEBS Lett** 1997 Jan 3;400(2):149–54

The N-terminal half part of the oral streptococcal antigen I/IIf contains two distinct binding domains. Sciotti MA, et al. **FEMS Microbiol Lett** 1997 Aug 15;153(2):439–45

Incorporation of choline into Streptococcus pneumoniae cell wall antigens: evidence for choline kinase activity. Whiting GC, et al. **FEMS Microbiol Lett** 1996 May 1;138(2–3):141–5

Isolation of a cell surface component of Helicobacter pylori that binds H type 2, Lewis(a), and Lewis(b) antigens. Alkout AM, et al. **Gastroenterology** 1997 Apr; 112(4):1179–87

The role of the nodI and nodJ genes in the transport of Nod metabolites in Rhizobium etli. Cárdenas L, et al. **Gene** 1996 Sep 16;173(2):183–7

Expression of slime interferes with in vitro detection of host protein receptors of Staphylococcus epidermidis. Baldassarri L, et al. **Infect Immun** 1997 Apr;65(4):1522–6

Failure to detect binding of LcrH to the V antigen of Yersinia pestis. Fields KA, et al. **Infect Immun** 1997 Sep; 65(9):3954–7

Binding of vitronectin to opa-expressing Neisseria gonorrhoeae mediates invasion of HeLa cells. Gómez-Duarte OG, et al. **Infect Immun** 1997 Sep; 65(9):3857–66

Yersinia pestis LcrV forms a stable complex with LcrG and may have a secretion-related regulatory role in the low-Ca2+ response. Nilles ML, et al. **J Bacteriol** 1997 Feb;179(4):1307–16

Rate and equilibrium constants for phosphoryltransfer between active site histidines of Escherichia coli HPr and the signal transducing protein IIIGlc. Meadow ND, et al. **J Biol Chem** 1996 Dec 27;271(52):33440–5

Several carcinoembryonic antigens (CD66) serve as receptors for gonococcal opacity proteins. Chen T, et al. **J Exp Med** 1997 May 5;185(9):1557–64

Differential distribution of galactosylceramide, H antigen, and carcinoembryonic antigen in rhesus macaque digestive mucosa. Butor C, et al. **J Histochem Cytochem** 1996 Sep; 44(9):1021–31

Quantification of cell-associated and free antigens in Bordetella pertussis suspensions by antigen binding ELISA. Westdijk J, et al. **J Immunoassay** 1997 Aug;18(3):267–84

Multi-well ELISA based on independent peptide antigens for antibody capture. Application to Lyme disease serodiagnosis. Yu Z, et al. **J Immunol Methods** 1996 Oct 30;198(1):25–33

Molecular structure of the lipoamide dehydrogenase domain of a surface antigen from Neisseria meningitidis. Li de la Sierra I, et al. **J Mol Biol** 1997 May 30;269(1):129–41

Structural basis for the interaction of superantigen with the alternative superantigen-binding receptor p85. Rogers TJ, et al. **Mol Immunol** 1997 Feb;34(3):263–72

CGM1a antigen of neutrophils, a receptor of gonococcal opacity proteins. Chen T, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14851–6

[The electron immunochemical detection of mycobacterial antigens in the granulomas of leprosy patients] Maslov AK, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jan–Feb; (1):84–7 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Studies on the immunogenicity of an Escherichia coli extract after oral application in mice. Baier W, et al. **Arzneimittelforschung** 1997 Aug;47(8):980–5

Changes in blood and spleen lymphocyte populations following antigen challenge in immature male chickens. Trout JM, et al. **Br Poult Sci** 1996 Sep;37(4):819–27

Immunization with bacterial antigens: infections with streptococci and related organisms. Bercovier H, et al. **Dev Biol Stand** 1997;90:153–60 (25 ref.)

Immunization with bacterial antigens: Flavobacterium and Flexibacter infections. Bernardet JF. **Dev Biol Stand** 1997; 90:179–88 (46 ref.)

Immunization with bacterial antigens: furunculosis. Ellis AE. **Dev Biol Stand** 1997;90:107–16 (60 ref.)

Immunization with bacterial antigens: infections with motile aeromonads. Karunasagar I, et al. **Dev Biol Stand** 1997; 90:135–41

Immunization with bacterial antigens: pasteurellosis. Romalde JL, et al. **Dev Biol Stand** 1997;90:167–77 (42 ref.)

Immunization with bacterial antigens: piscirickettsiosis. Smith PA, et al. **Dev Biol Stand** 1997;90:161–6 (12 ref.)

Immunization with bacterial antigens: yersiniosis. Stevenson RM. **Dev Biol Stand** 1997;90:117–24 (41 ref.)

Immunization with bacterial antigens: edwardsiellosis. Thune RL, et al. **Dev Biol Stand** 1997;90:125–34 (46 ref.)

Immunization with bacterial antigens: Vibrio infections. Toranzo AE, et al. **Dev Biol Stand** 1997;90:93–105 (40 ref.)

Differential response of CD4+ V7+ and CD4+ V7- T cells to T cell receptor-dependent signals: CD4+ V7+ T cells are co-stimulation independent and anti-V7 antibody blocks the induction of anergy by bacterial superantigen. Soares LR, et al. **Eur J Immunol** 1997 Jun;27(6):1413–21

T cell responses to tuberculin purified protein derivative in primary biliary cirrhosis: evidence for defective T cell function. Jones DE, et al. **Gut** 1997 Feb;40(2):277–83

The proliferation of human T lymphocytes stimulated by Helicobacter pylori antigens. Chmiela M, et al. **Immunobiology** 1996 Jul;195(2):199–208

Human cell-mediated immune responses to antigenic fractions of Salmonella typhi. Pérez C, et al. **Immunology** 1996 Oct;89(2):262–7

Antigen-driven shedding of L-selectin from human gamma delta T cells. Sanchez-Garcia J, et al. **Immunology** 1996 Oct;89(2):213–9

Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Vouret-Craviari V, et al. **Infect Immun** 1997 Apr;65(4):1345–50

Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of Mycobacterium tuberculosis and synergism with fibronectin. Aung H, et al. **J Clin Invest** 1996 Sep 1;98(5):1261–8

Single-cell cytokine analysis of gamma delta T cell responses to nonpeptide mycobacterial antigens. García VE, et al. **J Immunol** 1997 Aug 1;159(3):1328–35

Biochemical and cytogenetical study of the mycoplasmal antigen and of the cyclophosphamide action in mammalians, in vivo. The action of some immunomodulatory antioxidants. Dumitrescu M, et al. **Roum Arch Microbiol Immunol** 1996 Jul–Sep;55(3):225–39

[A comparative analysis of the effect of Bordetella pertussis preparations on a primary culture of murine peritoneal macrophages] Tiukavkina SIu, et al. **Mikrobiol Z** 1996 Mar–Apr;58(2):58–63 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Pertussis antigens that abrogate bacterial adherence and elicit immunity. Brennan MJ, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 2):S145–9 (34 ref.)

Streptococcus mutans major adhesion surface protein, P1 (I/II), does not contribute to attachment to valvular vegetations or to the development of endocarditis in a rat model. Ryd M, et al. **Arch Oral Biol** 1996 Oct; 41(10):999–1002

Searching for superantigens. Schlievert PM. **Immunol Invest** 1997 Jan–Feb;26(1–2):283–90 (20 ref.)

Functional analysis of the Shigella flexneri IpaC invasin by insertional mutagenesis. Bârzu S, et al. **Infect Immun** 1997 May;65(5):1599–605

Differential recognition of members of the carcinoembryonic antigen family by Opa variants of Neisseria gonorrhoeae. Bos MP, et al. **Infect Immun** 1997 Jun;65(6):2353–61

ANTIGENS, BACTERIAL

Soluble invasion plasmid antigen C (IpaC) from Shigella flexneri elicits epithelial cell responses related to pathogen invasion. Marquart ME, et al. **Infect Immun** 1996 Oct; 64(10):4182–7

Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Roggenkamp A, et al. **Infect Immun** 1997 Feb;65(2):446–51

Effects of antibodies against cell surface protein antigen PAc-glucosyltransferase fusion proteins on glucan synthesis and cell adhesion of Streptococcus mutans. Yu H, et al. **Infect Immun** 1997 Jun;65(6):2292–8

Role of monocyte chemoattractant protein-1 (MCP-1) in Th1 (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation: relationship to local inflammation, Th cell expression, and IL-12 production. Chensue SW, et al. **J Immunol** 1996 Nov 15;157(10):4602–8

Immunomodulatory and superantigen activities of bacteria associated with adult periodontitis. Getka TP, et al. **J Periodontol** 1996 Sep;67(9):909–17

Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Belisle JT, et al. **Science** 1997 May 30;276(5317):1420–2

THERAPEUTIC USE

Specific and long-lasting suppression of rat adjuvant arthritis by low-dose Mycobacterium butyricum. Conforti A, et al. **Eur J Pharmacol** 1997 Apr 18;324(2–3):241–7

In vitro analysis of cancer prevention by a mycobacterial antigen complex and of cancer-promoted inhibition of immune reactions. Maes H, et al. **J Cancer Res Clin Oncol** 1996;122(12):727–34

Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. Martin D, et al. **J Exp Med** 1997 Apr 7;185(7):1173–83

The effect of OM-89 (Subreum) on the murine model of systemic lupus erythematosus MRL-lpr/lpr. Dhaher YY, et al. **Lupus** 1997;6(5):436–40

Synthesis of cytokines during tumour development in mice immunized with the mycobacterial antigen complex A60. Maes H, et al. **Scand J Immunol** 1996 Oct;44(4):369–74

Suppression of mouse skin allograft rejection by protein A-Yersiniae V antigen fusion peptide. Motin VL, et al. **Transplantation** 1997 Apr 15;63(7):1040–2

Airborne challenge of chickens vaccinated orally with the genetically-defined Salmonella enteritidis aroA strain CVL30. Cooper GL, et al. **Vet Rec** 1996 Nov 2; 139(18):447–8

Protection of experimentally infected pigs by suilysin, the thiol-activated haemolysin of Streptococcus suis. Jacobs AA, et al. **Vet Rec** 1996 Sep 7;139(10):225–8

TOXICITY

Regression of arteriosclerotic lesions induced by immunization with heat shock protein 65-containing material in normocholesterolemic, but not hypercholesterolemic, rabbits. Xu Q, et al. **Atherosclerosis** 1996 Jun;123(1–2):145–55

Experimental acute glomerulonephritis induced in the rabbit with a specific streptococcal antigen. Yoshizawa N, et al. **Clin Exp Immunol** 1997 Jan;107(1):61–7

Immunosuppressant activity of aflatoxin ingestion in rabbits measured by response to Mycobacterium bovis antigen I. Cell mediated immune response measured by skin test reaction. Dimitri RA, et al. **Vet Hum Toxicol** 1996 Oct; 38(5):333–6

ULTRASTRUCTURE

Immunoblot and ultrastructural analysis of antigens extracted from Dichelobacter nodosus with potassium thiocyanate. Whittington R. **J Vet Diagn Invest** 1996 Jul;8(3):315–23

URINE

Evaluation of ELISA to detect Chlamydia trachomatis antigen in urine samples from arthritis patients. Wollenhaupt J, et al. **Clin Exp Rheumatol** 1997 Mar-Apr; 15(2):169–74

Stability of Legionella urinary antigens over time. Rigby EW, et al. **Diagn Microbiol Infect Dis** 1997 May;28(1):1–3

Detection of Legionella pneumophila serogroup 1 antigen in nonconcentrated urine and urine concentrated by selective ultrafiltration. Domínguez JA, et al. **J Clin Microbiol** 1996 Sep;34(9):2334–6

Comparison of radioimmunoassay and enzyme immunoassay kits for detection of Legionella pneumophila serogroup 1 antigen in both concentrated and nonconcentrated urine samples. Domínguez JA, et al. **J Clin Microbiol** 1997 Jun; 35(6):1627–9

Comparison of Binax Legionella Urinary Antigen EIA kit with Binax RIA Urinary Antigen kit for detection of Legionella pneumophila serogroup 1 antigen. Hackman BA, et al. **J Clin Microbiol** 1996 Jun;34(6):1579–80

Antigen excretion in the urine after pneumococcal vaccination. Kelley R, et al. **Pediatr Infect Dis J** 1997 Jul; 16(7):720

ANTIGENS, CARBOHYDRATE, TUMOR-ASSOCIATED see **ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE**

ANTIGENS, CD

CD antigens 1996. **Immunol Today** 1997 Mar;18(3):100–1

Priming differentially regulates neutrophil adhesion molecule expression/function. Condliffe AM, et al. **Immunology** 1996 Sep;89(1):105–11

Inhibition of growth and enhancement of differentiation of colorectal carcinoma cell lines by MAb MR6 and IL-4. Al-Tubuly AA, et al. **Int J Cancer** 1997 May 16; 71(4):605–11

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. Du Bois JS, et al. **J Clin Oncol** 1997 Mar;15(3):1052–62

The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. Aiuti A, et al. **J Exp Med** 1997 Jan 6;185(1):111–20

Large-scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery. McNiece I, et al. **J Hematother** 1997 Feb; 6(1):5–11

Anticytokine therapy in rheumatoid arthritis [editorial; comment] Firestein GS, et al. **N Engl J Med** 1997 Jul 17; 337(3):195–7. Comment on: N Engl J Med 1997 Jul 17;337(3):141–7.

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [see comments] Moreland LW, et al. **N Engl J Med** 1997 Jul 17;337(3):141–7. Comment in: N Engl J Med 1997 Jul 17;337(3):195–7.

Effects of recombinant cytokines on colony formation by irradiated human cord blood CD34+ hematopoietic progenitor cells. Goff JP, et al. **Radiat Res** 1997 Jan; 147(1):61–9

Report on the 2nd International CD38 workshop. Berthelier V, et al. **Res Immunol** 1996 Jul-Aug;147(6):407–11

Establishment of a human DAF/HRF20 double transgenic mouse line is not sufficient to suppress hyperacute rejection. Koike C, et al. **Surg Today** 1996;26(12):993–8

6th International Workshop and Conference on Human Leukocyte Differentiation Antigens. Kobe, Japan, November 10–14, 1996. Abstracts. **Tissue Antigens** 1996 Oct;48(4 Pt 2):352–508

The international workshops and conferences on human leukocyte differentiation antigens. Birth, current status and future. Boumsell L. **Tissue Antigens** 1996 Oct;48(4 Pt 1):238–41

Immunomagnetic method of CD34(+) cell separation. Markiewicz M, et al. **Transplant Proc** 1996 Dec; 28(6):3526–7

[Interleukin 4 receptor (IL-4R)] Saito S. **Nippon Rinsho** 1997 Apr;55 Suppl 2:531–3 (3 ref.) **(Jpn)**

[Interleukin-6 (IL-6) receptor] Sakamoto K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:538–41 (10 ref.) **(Jpn)**

[Measles virus receptor CD46] Yanagi Y. **Uirusu** 1995 Dec; 45(2):159–64 (21 ref.) **(Jpn)**

ANALYSIS

In situ expression and serum levels of tumour necrosis factor alpha receptors in patients with lichen planus. Simon M Jr, et al. **Acta Derm Venereol** 1997 May;77(3):191–3

Expression of microglial markers in the human CNS after closed head injury. Engel S, et al. **Acta Neurochir Suppl (Wien)** 1996;66:89–95

2',5'-Oligoadenylate synthetase activity and T cell subset in the cerebrospinal fluid and peripheral blood of aseptic meningitis. Sakatoku H, et al. **Acta Paediatr Jpn** 1997 Feb; 39(1):48–53

Identification of cell subsets expressing intracytoplasmic cytokines within HIV-1-infected lymph nodes. Gray CM, et al. **AIDS** 1996 Nov;10(13):1467–75

Immunophenotype of Reed-Sternberg and Hodgkin's cells in sequential biopsy specimens of Hodgkin's disease: a paraffin-section immunohistochemical study using the heat-induced epitope retrieval method. Vasef MA, et al. **Am J Clin Pathol** 1997 Jul;108(1):54–9

Primary cutaneous Ewing's family sarcoma. Report of a case with immunostaining for glycoprotein p30/32 mic2. Sexton CW, et al. **Am J Dermatopathol** 1996 Dec;18(6):601–5

Plasma cells composing plasmacytoma have phenotypes different from those of myeloma cells. Sakai A, et al. **Am J Hematol** 1996 Dec;53(4):251–3

Glomerular Fc alphaR expression and disease activity in IgA nephropathy. Kashem A, et al. **Am J Kidney Dis** 1997 Sep; 30(3):389–96

CD79 alpha expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia. Arber DA, et al. **Am J Pathol** 1996 Oct;149(4):1105–10

Biochemical and morphological characterization of vascular and lymphocytic interleukin-4 receptors. Schnyder B, et al. **Am J Pathol** 1996 Oct;149(4):1369–79

Phenotypic analysis of alveolar macrophages and monocytes in allergic airway inflammation. I. Evidence for activation of alveolar macrophages, but not peripheral blood monocytes, in subjects with allergic rhinitis and asthma. Viksman MY, et al. **Am J Respir Crit Care Med** 1997 Mar; 155(3):858–63

The expression of interleukin-8 receptor in untreated and treated psoriasis. Beljaards RC, et al. **Arch Dermatol Res** 1997 Jul;289(8):440–3

Enkephalin-like immunoreactivity in human skin is found selectively in a fraction of CD68-positive dermal cells: increase in enkephalin-positive cells in lesional psoriasis. Nissen JB, et al. **Arch Dermatol Res** 1997 Apr;289(5):265–71

C5a receptors are detectable on mast cells in normal human skin and in psoriatic plaques but not in weal and flare reactions or in uticaria pigmentosa by immunohistochemistry. Werfel T, et al. **Arch Dermatol Res** 1997 Jan;289(2):83–6

CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ, et al. **Biol Blood Marrow Transplant** 1997 Apr;3(1):11–7

Membrane antigen and ligand receptor expression on neonatal monocytes. El-Mohandes AA, et al. **Biol Neonate** 1995;68(5):308–17

CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Soiffer RJ, et al. **Blood** 1997 Apr 15;89(8):3039–47

Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis. Håkansson L, et al. **Br J Cancer** 1997;75(3):374–80

Interleukin-7 receptor expression in cutaneous T-cell lymphomas. Bagot M, et al. **Br J Dermatol** 1996 Oct; 135(4):572–5

Distribution and subcellular localization of a lysosome-associated protein in human genital organs. Aumüller G, et al. **Cell Tissue Res** 1997 Feb;287(2):335–42

Analysis of data on leukocyte surface markers for recognition of leukemia/lymphoma phenotype pattern. Petrovecki M, et al. **Clin Biochem** 1996 Feb;29(1):21–5

IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases. Doré P, et al. **Clin Exp Immunol** 1997 Jan;107(1):182–8

Multiple antigens are altered on T and B lymphocytes from peripheral blood and spleen of patients with Wiskott-Aldrich syndrome. Gerwin N, et al. **Clin Exp Immunol** 1996 Nov;106(2):208–17

Simultaneous detection of genetic and immunological markers in non-small cell lung cancer: prediction of metastatic potential of tumor. Zborovskaya I, et al. **Clin Exp Metastasis** 1996 Nov;14(6):490–500

A cluster of cases of chronic fatigue and chronic fatigue syndrome: clinical and immunologic studies. Levine PH, et al. **Clin Infect Dis** 1996 Aug;23(2):408–9

Quantitative analysis of leukocyte membrane antigen expression: normal adult values. Bikoue A, et al. **Cytometry** 1996 Jun 15;26(2):137–47

Quantitative determination of surface antibody binding capacities of immune subsets present in peripheral blood of healthy adult donors. Denny TN, et al. **Cytometry** 1996 Dec 15;26(4):265–74

Analysis of variation in results of flow cytometric lymphocyte immunophenotyping in a multicenter study. Gratama JW, et al. **Cytometry** 1997 Aug 15;30(4):166–77

Establishing a pure lymphocyte gate for subset analysis by flow cytometry. Horvatinovich JM, et al. **Cytometry** 1996 Jun 15;26(2):172–7

Reference intervals of CD3, CD4, CD8, CD4/CD8, and absolute CD4 values in Asian and Non-Asian populations. Howard RR, et al. **Cytometry** 1996 Sep 15;26(3):231–2

Long lasting immunological effects of ethanol after withdrawal. Laso FJ, et al. **Cytometry** 1996 Dec 15; 26(4):275–80

CD34 progenitor cell subset analyses in normal human bone marrow and marrow harvested after intermediate-dose chemotherapy. Laughlin MJ, et al. **Cytometry** 1996 Dec 15;26(4):235–42

Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Liu Z, et al. **Cytometry** 1996 Mar 15;26(1):1–7

The Q-Prep system: effects on the apparent expression of leucocyte cell surface antigens. Macey MG, et al. **Cytometry** 1997 Apr 15;30(2):67–71

Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen- or antigen-induced proliferative capacity in normals. Mardiney M 3rd, et al. **Cytometry** 1996 Dec 15;26(4):305–10

Flow cytometric detection of intracellular platelet antigens. Sedlmayr P, et al. **Cytometry** 1996 Apr 1;23(4):284–9

On quantification of CD1a, HLA-DR, and HLA class I expression on viable human Langerhans cells and keratinocytes [letter] Sprogøe-Jakobsen U, et al. **Cytometry** 1997 Aug 15;30(4):206–7

Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity. Sun RX, et al. **Eur Cytokine Netw** 1997 Mar;8(1):51–6

Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease. Murakami T, et al. **Eur J Clin Invest** 1996 Nov; 26(11):996–1003

A new strategy for treating patients with CD7+, CD4-, CD8- acute lymphoblastic leukaemia [letter] Ono K, et al. **Eur J Haematol** 1997 Feb;58(2):130–2

Characteristic localization of gp130 (the signal-transducing receptor component used in common for IL-6/IL-11/CNTF/LIF/OSM) in the rat brain. Watanabe D, et al. **Eur J Neurosci** 1996 Aug;8(8):1630–40

Catfish thrombocytes express an integrin-like CD41/CD61 complex. **Passer BJ, et al. Exp Cell Res** 1997 Aug 1; 234(2):347-53

RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression. Rumi C, et al. **Exp Hematol** 1997 Mar;25(3):246-51

Establishment of a monoclonal antibody directed against Gb3Cer/CD77: a useful immunochemical reagent for a differentiation marker in Burkitt's lymphoma and germinal centre B cells. Miyamoto D, et al. **Glycoconj J** 1997 Apr; 14(3):379-88

Co-localization of CD9 and GPIIb-IIIa (alpha IIb beta 3 integrin) on activated platelet pseudopods and alpha-granule membranes. Brisson C, et al. **Histochem J** 1997 Feb;29(2):153-65

Expression of differentiation antigens and adhesion molecules on CD34+ cells in peripheral blood and bone marrow after chemotherapy followed by administration of granulocyte colony stimulating factor. Masauzi N. **Hokkaido Igaku Zasshi** 1996 Nov;71(6):771-83

CD99 reactivity in mesenchymal chondrosarcoma. Granter SR, et al. **Hum Pathol** 1996 Dec;27(12):1273-6

High fertilization prediction by flow cytometric analysis of the CD46 antigen on the inner acrosomal membrane of spermatozoa. Carver-Ward JA, et al. **Hum Reprod** 1996 Sep;11(9):1923-8

Expression of HIS50 Ag: a rat homologue of mouse heat-stable antigen and human CD24 on B lymphoid cells in the rat. Hermans MH, et al. **Immunology** 1997 Jan; 90(1):14-22

Interferons alpha/beta inhibit IL-7-induced proliferation of CD4- CD8- CD3- CD44+ CD25+ thymocytes, but do not inhibit that of CD4- CD8- CD3- CD44- CD25- thymocytes. Su DM, et al. **Immunology** 1997 Apr; 90(4):543-9

Expression of interleukin-6 receptor subunits in human macrophage subsets. Zwadlo-Klarwasser G, et al. **Int Arch Allergy Immunol** 1997 May-Jul;113(1-3):300-1

IL-4 receptor complexes containing or lacking the gamma C chain are inhibited by an overlapping set of antagonistic IL-4 mutant proteins. Schnarr B, et al. **Int Immunol** 1997 Jun;9(6):861-8

Localization of integrin beta 1, alpha 1, alpha 5 and alpha 9 subunits in the rat testis. Giebel J, et al. **Int J Androl** 1997 Feb;20(1):3-9

Complement-regulatory proteins in ovarian malignancies. Bjørge L, et al. **Int J Cancer** 1997 Jan 6;70(1):14-25

Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Young MR, et al. **Int J Cancer** 1997 Feb 20;74(1):69-74

A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. Berditchevski F, et al. **J Biol Chem** 1997 Jan 31; 272(5):2595-8

Expression of B7-1 and B7-2 costimulatory molecules by human gastric epithelial cells: potential role in CD4+ T cell activation during Helicobacter pylori infection. Ye G, et al. **J Clin Invest** 1997 Apr 1;99(7):1628-36

The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. Grouard G, et al. **J Exp Med** 1997 Mar 17;185(6):1101-11

Analysis of interleukin 6 receptor and gp130 expressions and proliferative capability of human CD34+ cells. Tajima S, et al. **J Exp Med** 1996 Oct 1;184(4):1357-64

Reactivation of herpes simplex virus type 1 in the mouse trigeminal ganglion: an in vivo study of virus antigen and immune cell infiltration [published erratum appears in J Gen Virol 1996 Dec;77(Pt 12):3165] Shimeld C, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2583-90

Optimization of CD34+ cell selection using immunomagnetic beads: implications for use in cryopreserved peripheral blood stem cell collections. Farley TJ, et al. **J Hematother** 1997 Feb;6(1):53-60

Ex vivo expansion of frozen/thawed CD34+ cells isolated from frozen human apheresis products. Martinson JA, et al. **J Hematother** 1997 Feb;6(1):69-75

Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. Papadopoulos KP, et al. **J Hematother** 1997 Feb;6(1):61-8

Changes in CD44 and ApoE immunoreactivities due to retinal pathology of man and rat. Kuhrt H, et al. **J Hirnforsch** 1997;38(2):223-9

Antisense homology boxes in C5a receptor and C5a anaphylatoxin: a new method for identification of potentially active peptides. Baranyi L, et al. **J Immunol** 1996 Nov 15;157(10):4591-601

The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression. Reichel M, et al. **J Immunol** 1997 Jun 15;158(12):5860-7

Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. Szöllösi J, et al. **J Immunol** 1996 Oct 1;157(7):2939-46

Alternative assay procedures for cytokines and soluble receptors of the IL-6 family. Oppmann B, et al. **J Immunol Methods** 1996 Sep 9;195(1-2):153-9

The influence of interleukin-6 on the growth of human esophageal cancer cell lines. Oka M, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):1001-6

Porcine bone marrow myeloid cells: phenotype and adhesion molecule expression. Summerfield A, et al. **J Leukoc Biol** 1997 Aug;62(2):176-85

Association of the tetraspan protein CD9 with integrins on the surface of S-16 Schwann cells. Hadjiargyrou M, et al. **J Neurochem** 1996 Dec;67(6):2505-13

Enhanced expression of chemotactic receptors in multiple sclerosis lesions. Müller-Ladner U, et al. **J Neurol Sci** 1996 Dec;144(1-2):135-41

Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. Bö L, et al. **J Neuropathol Exp Neurol** 1996 Oct;55(10):1060-72

In vitro differentiation of neural progenitor cells from prenatal rat brain: common cell surface glycoprotein on three glial cell subsets. Blass-Kampmann S, et al. **J Neurosci Res** 1997 Apr 15;48(2):95-111

Characterization of rat NCA/CD9 cell surface antigen and its expression by normal and malignant neural cells. Deissler H, et al. **J Neurosci Res** 1996 Mar 15;43(6):664-74

Hepatic overexpression of MHC class II antigens and macrophage-associated antigens (CD68) in patients with biliary atresia of poor prognosis. Kobayashi H, et al. **J Pediatr Surg** 1997 Apr;32(4):590-3

The monoclonal antibody GZS-1 detects a maturation-associated antigen of human spermatozoa that is also present on the surface of human mononuclear blood cells. Hutter H, et al. **J Reprod Immunol** 1996 May; 30(2-3):115-32

Possible association of infertility with sperm-specific abnormality of CD46. Kitamura M, et al. **J Reprod Immunol** 1997 Apr;33(1):83-8

Soluble CD46 (membrane cofactor protein, MCP) in human reproductive tract fluids. McLaughlin PJ, et al. **J Reprod Immunol** 1996 Oct;31(3):209-19

Cultured human decidual stromal cells express antigens associated with hematopoietic cells. Montes MJ, et al. **J Reprod Immunol** 1996 Feb;30(1):53-66

Relationship between the cellular distribution of the alpha(v)beta3/5 integrins and adenoviral infection in salivary glands. Delporte C, et al. **Lab Invest** 1997 Aug; 77(2):167-73

Expression of costimulatory molecules B7-1 and B7-2 in macrophages and granulomas of Crohn's disease: demonstration of cell-to-cell contact with T lymphocytes. Hara J, et al. **Lab Invest** 1997 Aug;77(2):175-84

Presence of inducible nitric oxide synthase, nitrotyrosine, CD68, and CD14 in the small intestine in celiac disease. ter Steege J, et al. **Lab Invest** 1997 Jul;77(1):29-36

Expression of glycosyl-phosphatidylinositol-linked glycoproteins in blood cells from paroxysmal nocturnal haemoglobinuria patients: a flow cytometry study using CD55, CD58 and CD59 monoclonal antibodies. Navenot JM, et al. **Leuk Lymphoma** 1996 Mar;21(1-2):143-51

In leukemic hematopoiesis CD34 antigen does not have the same significance as it does normal hematopoiesis. Del Cañizo MC, et al. **Leuk Res** 1997 Jul;21(7):651-6

CD34 expression on acute myelocytic leukemia cells. Geller RB, et al. **Leuk Res** 1997 May;21(5):387-9 (15 ref.)

Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Haase D, et al. **Leukemia** 1997 May;11(5):674-9

CD34+ megakaryoblastic leukaemic cells are CD38-, but CD61+ and glycophorin A+: improved criteria for diagnosis of AML-M7? Helleberg C, et al. **Leukemia** 1997 Jun;11(6):830-4

Normal G-CSF-mobilized CD34+ peripheral blood stem cells in paroxysmal nocturnal hemoglobinuria: a perspective for autologous transplantation [letter] Musto P, et al. **Leukemia** 1997 Jun;11(6):890-2

Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Zomas AP, et al. **Leukemia** 1996 Dec; 10(12):1966-70

Correlation between CD29 density on CD8+ lymphocytes and serum IgG in systemic lupus erythematosus. Pallis M, et al. **Lupus** 1997;6(4):379-84

Undifferentiated rhabdomyosarcoma with lymphoid phenotype expression. Pinto A, et al. **Med Pediatr Oncol** 1997 Mar;28(3):165-70

CD99 (p30/32MIC2) immunoreactivity in the diagnosis of leukemia cutis. Dorfman DM, et al. **Mod Pathol** 1997 Apr; 10(4):283-8

Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Li WV, et al. **Mod Pathol** 1996 Oct;9(10):982-8

013 (CD99) positivity in hematologic proliferations correlates with TdT positivity. Robertson PB, et al. **Mod Pathol** 1997 Apr;10(4):277-82

Integrins beta 5, beta 3 and alpha v are apically distributed in endometrial epithelium. Aplin JD, et al. **Mol Hum Reprod** 1996 Jul;2(7):527-34

CD52 is the 'major maturation-associated' sperm membrane antigen. Kirchhoff C. **Mol Hum Reprod** 1996 Jan;2(1):9-17

Leukemia-associated phenotypes: their characteristics and incidence in acute leukemia. Babuštková O, et al. **Neoplasma** 1996;43(6):367-72

Flow cytometric detection of some activation and proliferation markers in human hematopoietic cell lines. Glasová M, et al. **Neoplasma** 1996;43(6):381-8

Cell-associated adhesion molecules as early markers of bioincompatibility. Carreno MP, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2248-57

Membrane attack complex and membrane cofactor protein are related to tubulointerstitial inflammation in various human glomerulopathies. Mosolits S, et al. **Nephron** 1997; 75(2):179-87

Platelet-derived growth factor, interleukin (IL)-1 beta, IL-6R and tumor necrosis factor-alpha in IgA nephropathy. An immunohistochemical study. Taniguchi Y, et al. **Nephron** 1996;74(4):652-60

p55 tumour necrosis factor receptors distribution in neuroblastoma cells. Chambaut-Guérin AM, et al. **Neuroreport** 1997 Apr 14;8(6):1451-6

Presence of MHC-I and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA. Trojan J, et al. **Neurosci Lett** 1996 Jul 5;212(1):9-12

Immunophenotypic classification of canine malignant lymphoma on formalin-mixed paraffin wax-embedded tissue by means of CD3 and CD79a cell markers. Milner RJ, et al. **Onderstepoort J Vet Res** 1996 Dec;63(4):309-13

Appearance of cells expressing CD80 and CD86 costimulatory antigens in the pancreas of nonobese diabetic mice. Sainio-Pöllänen S, et al. **Pancreas** 1996 Nov; 13(4):388-94

Human amebic liver abscess: expression of intercellular adhesion molecules 1 and 2 and of von Willebrand factor in endothelial cells. Ventura-Juárez J, et al. **Parasitol Res** 1997;83(5):510-4

Intermediate lymphocytic lymphoma massively involving the gastrointestinal tract. Tsutsumi Y, et al. **Pathol Int** 1996 May;46(5):380-3

Hodgkin's cells express CD83, a dendritic cell lineage associated antigen. Sorg UR, et al. **Pathology** 1997 Aug; 29(3):294-9

EWS/FLI-1 fusion transcript detection and MIC2 immunohistochemical staining in the diagnosis of Ewing's sarcoma. Lee CS, et al. **Pediatr Pathol Lab Med** 1996 May-Jun;16(3):379-92

Soluble receptors and cytokine antagonists in human milk. Buescher ES, et al. **Pediatr Res** 1996 Dec;40(6):839-44

Shedding of soluble interleukin-6 receptor during peritonitis in patients on CAPD. Lu Y, et al. **Perit Dial Int** 1997 Jul-Aug;17(4):399-401

Zinc deficiency: changes in cytokine production and T-cell subpopulations in patients with head and neck cancer and in noncancer subjects. Prasad AS, et al. **Proc Assoc Am Physicians** 1997 Jan;109(1):68-77

Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Bhatia M, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):5320-5

Blood amounts and suppressive in vitro activity of CD8+11b(+)-lymphocytes from HIV-infected children, related to hepatitis B or C virus association. Voiculescu C, et al. **Rom J Virol** 1995 Jul-Dec;46(3-4):171-8

Lymphocytes subsets in normal individuals: analysis by four color immunofluorescence and flow cytometry on whole blood. Schiavon V, et al. **Tissue Antigens** 1996 Oct;48(4 Pt 1):312-8

Characterization of intracellular calcium responses produced by polycyclic aromatic hydrocarbons in surface marker-defined human peripheral blood mononuclear cells. Mounho BJ, et al. **Toxicol Appl Pharmacol** 1997 Aug; 145(2):323-30

Adhesion molecules and activation markers in acute rejection of human renal allografts. von Willebrand E, et al. **Transpl Immunol** 1996 Mar;4(1):57-8

Effects of end-stage renal disease on the expression of differentiation and HLA-DR markers on the surface of T and B lymphocytes. Malinowski K, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1020-4

Distribution of lymphocyte subtypes in liver transplant recipients. Rayes N, et al. **Transplant Proc** 1997 Feb-Mar; 29(1-2):501-2

Phenotypic analysis of a human hematopoietic cell line with lymphoid and myeloid features using simultaneous multicolor flow cytometry. Russo DA, et al. **Transplant Proc** 1997 Jun;29(4):1962

Ruminant cluster CD41/CD61. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):251-3

Ruminant cluster CD71. Naessens J, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):257-8

The Second International Swine CD Workshop. Saalmüller A, et al. **Vet Immunol Immunopathol** 1996 Nov; 54(1-4):155-8

An immunohistochemical study of IgG, complement C3, collagen type III and macrophage-marker Ki-M7 in epiretinal membranes. Shi Y, et al. **Yen Ko Hsueh Pao** 1996 Mar;12(1):10-4

[Contribution of flow cytometry to allergologic diagnosis] Sabbah A, et al. **Allerg Immunol (Paris)** 1997 Jan; 29(1):15-21 (Eng. Abstr.) **(Fre)**

[Flow cytometric characterization of maturation processes and primitive stem cell population in pre-B-cell ALL in childhood] Baersch G, et al. **Klin Padiatr** 1996 Jul-Aug; 208(4):160-7 (Eng. Abstr.) **(Ger)**

[Effect of macrophage colony-stimulating factor on complement receptors and complement regulatory proteins on human peripheral white blood cells] Nakahara R, et al. **Arerugi** 1996 Dec;45(12):1256-61 (Eng. Abstr.) **(Jpn)**

[Demonstration and characterization of CD 46, membrane cofactor protein, in gastric cancer tissue] Seto N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun;19(3):210–6 (Eng. Abstr.) **(Jpn)**

[KAI1/CD82 and ME491/CD63 expression in non-small-cell carcinoma of the lung and prognosis] Adachi M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Mar;45(3):398–401 **(Jpn)**

[Effects of a reduction or deviation of metastasis inhibitory factor MRP-1/CD9 on postoperative follow-up results in patients with lung cancer] O S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Mar;44(3):321–3 **(Jpn)**

BIOSYNTHESIS

Interleukin-10-induced HIV-1 expression is mediated by induction of both membrane-bound tumour necrosis factor (TNF)-alpha and TNF receptor type 1 in a promonocytic cell line. Barcellini W, et al. **AIDS** 1996 Jul;10(8):835–42

Absence of CD69 expression on peripheral eosinophils in episodic angioedema and eosinophilia. Kawano M, et al. **Am J Hematol** 1996 Sep;53(1):43–5

Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Gasque P, et al. **Am J Pathol** 1997 Jan;150(1):31–41

Dysregulation of carcinoembryonic antigen group members CGM2, CD66a (biliary glycoprotein), and nonspecific cross-reacting antigen in colorectal carcinomas. Comparative analysis by northern blot and in situ hybridization. Nollau P, et al. **Am J Pathol** 1997 Aug; 151(2):521–30

Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Ueda T, et al. **Am J Pathol** 1996 Nov;149(5):1435–40

Stage-specific expression of P2Y receptors, ecto-apyrase, and ecto-5'-nucleotidase in myeloid leukocytes. Clifford EE, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C973–87

Effect of SP-A and surfactant lipids on expression of cell surface markers in the THP-1 monocytic cell line. Kremlev SG, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):L1070–7

Downmodulation of IL-8 receptors, type A and type B, on human lung neutrophils in vivo. Soejima K, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):L618–25

Alveolar macrophages in sarcoidosis coexpress high levels of CD86 (B7.2), CD40, and CD30L. Nicod LP, et al. **Am J Respir Cell Mol Biol** 1997 Jul;17(1):91–6

Plasma IgE levels, activation marker expression, and cytokine production in non-atopic individuals. Prabhu A, et al. **Ann Allergy Asthma Immunol** 1997 Jan;78(1):45–53

Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines. Stickeler E, et al. **Anticancer Res** 1997 May-Jun;17(3C):1871–6

Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy. Baranda L, et al. **Arch Dermatol** 1997 Mar;133(3):325–9

In situ expression of B7 and CD28 receptor families in skin lesions of patients with lupus erythematosus. Denfeld RW, et al. **Arthritis Rheum** 1997 May;40(5):814–21

Solamargine purified from Solanum incanum Chinese herb triggers gene expression of human TNFR I which may lead to cell apoptosis. Hsu SH, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):1–5

The unique cytoplasmic domain of the human integrin variant beta4E is produced by partial retention of intronic sequences. van Leusden MR, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):826–30

Induction of the adhesion molecule CD44 by the pro-inflammatory cytokine interleukin-1 in endothelial cells. Fitzgerald K, et al. **Biochem Soc Trans** 1997 May; 25(2):185S

Characterisation and expression of the novel lymphocyte activation antigen using the monoclonal antibody 6B2D. O'Shea U, et al. **Biochem Soc Trans** 1997 May;25(2):196S

Multiple transcripts of human IgA Fc receptor CD89 in neutrophils, eosinophils and the monocyte-like cell line THP-1. Pleass RJ, et al. **Biochem Soc Trans** 1997 May; 25(2):327S

Identification of an intragenic promoter in the human CD45 gene. Timon M, et al. **Biochem Soc Trans** 1997 May; 25(2):177S

Molecular cloning of a complementary DNA for a membrane cofactor protein (MCP, CD46)/measles virus receptor on Vero cells and its functional characterization. Murakami Y, et al. **Biol Pharm Bull** 1996 Dec;19(12):1541–5

Heterogeneity of expression of CD68 and other macrophage-associated antigens in human long-term bone marrow culture. Wilkins BS, et al. **Biologicals** 1996 Dec; 24(4):333–7

Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blair A, et al. **Blood** 1997 May 1;89(9):3104–12

Expression of interleukin-7 receptor by lineage-negative human bone marrow progenitors with enhanced lymphoid proliferative potential and B-lineage differentiation capacity. Ryan DH, et al. **Blood** 1997 Feb 1;89(3):929–40

Signaling pathways regulating CD44-dependent cytolysis in natural killer cells. Sconocchia G, et al. **Blood** 1997 Jul 15;90(2):716–25

Binding of phosphorylated Sp1 protein to tandem Sp1 binding sites regulates alpha2 integrin gene core promoter activity. Zutter MM, et al. **Blood** 1997 Jul 15;90(2):678–89

Expression of adhesion molecules and activation markers on lymphocytes and monocytes during hemodialysis. Braun N. **Blood Purif** 1997;15(2):61–76

Isolation of the gene encoding lamp-1, a lysosomal membrane protein, by differential screening in an animal model of status epilepticus. Sun N, et al. **Brain Res Mol Brain Res** 1997 May;45(2):353–5

Beta 4 integrin subunit expression is downregulated in low metastatic carcinoma variants. Cimino L, et al. **Cancer Detect Prev** 1997;21(2):158–66

Increased expression of alpha6-integrin receptors and of mRNA encoding the putative 37 kDa laminin receptor precursor in pancreatic carcinoma. Halatsch ME, et al. **Cancer Lett** 1997 Sep 16;118(1):7–11

Cell surface accumulation of overexpressed hamster lysosomal membrane glycoproteins. Uthayakumar S, et al. **Cell Mol Biol Res** 1995;41(5):405–20

Quantitative analysis of leukocyte membrane antigen expression on human fetal and cord blood: normal values and changes during development. Bikoue A, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):56–64

Absence of the IL-7 receptor component CDw127 indicates that gamma(c) expression alone is insufficient for IL-7 to modulate human neutrophil responses. Girard D, et al. **Clin Immunol Immunopathol** 1997 Jun;83(3):264–71

The production of soluble interleukin 4 receptors is preferentially regulated by the murine Th2 cell subset. Fernandez-Botran R, et al. **Cytokine** 1997 Mar;9(3):166–77

Serum levels and in situ expression of TNF-alpha and TNF-alpha binding proteins in inflammatory liver diseases. Spengler U, et al. **Cytokine** 1996 Nov;8(11):864–72

Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Caruso A, et al. **Cytometry** 1997 Jan 1;27(1):71–6

Measurement of CD69 induction in the assessment of immune function in asymptomatic HIV-infected individuals. Perfetto SP, et al. **Cytometry** 1997 Feb 15;30(1):1–9

Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Hotamisligil GS, et al. **Diabetes** 1997 Mar;46(3):451–5

Identification of the human alpha6 integrin gene promoter. Lin CS, et al. **DNA Cell Biol** 1997 Aug;16(8):929–37

CD43 (leukosialin, sialophorin) expression is differentially regulated by retinoic acids. Babina M, et al. **Eur J Immunol** 1997 May;27(5):1147–51

High-level expression of the ER-MP58 antigen on mouse bone marrow hematopoietic progenitor cells marks commitment to the myeloid lineage. de Bruijn MF, et al. **Eur J Immunol** 1996 Dec;26(12):2850–8

Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. Mingari MC, et al. **Eur J Immunol** 1997 Jun;27(6):1374–80

Human keratinocytes constitutively express IL-4 receptor molecules and respond to IL-4 with an increase in B7/BB1 expression. Junghans V, et al. **Exp Dermatol** 1996 Dec; 5(6):316–24

Barrier disruption increases gene expression of cytokines and the 55 kD TNF receptor in murine skin. Wood LC, et al. **Exp Dermatol** 1997 Apr;6(2):98–104

Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7-1 and B7-2 and the B7 counter-receptor CTLA-4. Gerstmayer B, et al. **FEBS Lett** 1997 Apr 21;407(1):63–8

Anaphylatoxin C5a receptor mRNA is strongly expressed in Kupffer and stellate cells and weakly in sinusoidal endothelial cells but not in hepatocytes of normal rat liver. Schieferdecker HL, et al. **FEBS Lett** 1997 Apr 14; 406(3):305–9

Cloning and sequence of the cDNA encoding the beta 4 integrin subunit in rat peripheral nerve. Feltri ML, et al. **Gene** 1997 Feb 28;186(2):299–304

Cytokine response of B lymphocytes from splenic lymphoma with villous lymphocytes: correlation with TNF-RII (p75) and CD11c expression. Treton D, et al. **Hematol Cell Ther** 1996 Aug;38(4):345–52

Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Tatsumi T, et al. **Hepatology** 1997 May;25(5):1108–14

CD44 standard and variant isoform expression in normal human skin appendages and epidermis. Seelentag WK, et al. **Histochem Cell Biol** 1996 Sep;106(3):283–9

Allele-specific expression of the mouse B-cell surface protein CD72 on T cells. Robinson WH, et al. **Immunogenetics** 1997;45(3):195–200

Mouse CD6: sequence of cDNA and expression of mRNA. Pal A, et al. **Immunol Lett** 1996 Jan;49(1-2):133–7

Localization of IL-4 and IL-4 receptors in the human term placenta, decidua and amniochorionic membranes. de Moraes-Pinto MI, et al. **Immunology** 1997 Jan;90(1):87–94

Infection with Trypanosoma cruzi selectively upregulates B7-2 molecules on macrophages and enhances their costimulatory activity. Frosch S, et al. **Infect Immun** 1997 Mar;65(3):971–7

The direct effect of interferon-gamma on human eosinophilic leukemia cell lines: the induction of interleukin-5 mRNA and the presence of an interferon-gamma receptor. Ishizuka T, et al. **Inflammation** 1996 Apr;20(2):151–63

Primary porcine endothelial cells express membrane-bound B7-2 (CD86) and a soluble factor that co-stimulate cyclosporin A-resistant and CD28-dependent human T cell proliferation. Davis TA, et al. **Int Immunol** 1996 Jul; 8(7):1099–111

Differential expression of CD22 (Lyb8) on murine B cells. Erickson LD, et al. **Int Immunol** 1996 Jul;8(7):1121–9

Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Chaux P, et al. **Int J Cancer** 1997 Aug 7;72(4):619–24

Up-regulated expression of the beta3 integrin and the 92-kDa gelatinase in human HT-144 melanoma cell tumors grown in nude mice. Gouon V, et al. **Int J Cancer** 1996 Nov 27; 68(5):650–62

Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma. Leong CC, et al. **Int J Cancer** 1997 May 2;71(3):476–82

Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Murata T, et al. **Int J Cancer** 1997 Jan 17;70(2):230–40

Expression of the avian alpha 7-integrin in developing nervous system and myotome. Kil SH, et al. **Int J Dev Neurosci** 1996 Jun;14(3):181–90

Biosynthetic transport of a major lysosome-associated membrane glycoprotein 2, lamp-2: a significant fraction of newly synthesized lamp-2 is delivered to lysosomes by way of early endosomes. Akasaki K, et al. **J Biochem (Tokyo)** 1996 Dec;120(6):1088–94

Post-translational fate of a mucin-like leukocyte sialoglycoprotein (CD43) aberrantly expressed in a colon carcinoma cell line. Baeckström D. **J Biol Chem** 1997 Apr 25;272(17):11503–9

Isolation and characterization of the human gp130 promoter. Regulation by STATS. O'Brien CA, et al. **J Biol Chem** 1997 Jun 6;272(23):15003–10

Expression of the integrin alpha5 subunit and its mediated cell adhesion in hepatocellular carcinoma. Yao M, et al. **J Cancer Res Clin Oncol** 1997;123(8):435–40

A three-dimensional collagen lattice induces protein kinase C-zeta activity: role in alpha2 integrin and collagenase mRNA expression. Xu J, et al. **J Cell Biol** 1997 Jan 27; 136(2):473–83

Altered synthesis of interferon-gamma and expression of interferon-gamma receptor by peripheral blood mononuclear cells from patients with IgA nephropathy and non-IgA proliferative glomerulonephritis. Yano N, et al. **J Clin Immunol** 1996 Jan;16(1):71–9

The role of alpha E beta 7 integrin (CD103) and E-cadherin in epidermotropism in cutaneous T-cell lymphoma. Dietz SB, et al. **J Cutan Pathol** 1996 Aug;23(4):312–8

The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. Tsukada N, et al. **J Exp Clin Cancer Res** 1997 Jun;16(2):171–6

Follicular dendritic cells specifically express the long CR2/CD21 isoform. Liu YJ, et al. **J Exp Med** 1997 Jan 6;185(1):165–70

Downregulation of CD1 marks acquisition of functional maturation of human thymocytes and defines a control point in late stages of human T cell development. Res P, et al. **J Exp Med** 1997 Jan 6;185(1):141–51

Tumor necrosis factor-alpha modulates the expression of its p60 receptor and several cytokines in rat tracheal epithelial cells. Bader T, et al. **J Immunol** 1996 Oct 1;157(7):3089–96

Two distinct stimulus-dependent pathways lead to production of soluble murine interleukin-4 receptor. Blum H, et al. **J Immunol** 1996 Sep 1;157(5):1846–53

IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. Chakrabarti D, et al. **J Immunol** 1996 Jul 15;157(2):522–8

B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. Greenfield EA, et al. **J Immunol** 1997 Mar 1; 158(5):2025–34

Induction of germinal center B cell markers in vitro by activated CD4+ T lymphocytes: the role of CD40 ligand, soluble factors, and B cell antigen receptor cross-linking. Lahvis GP, et al. **J Immunol** 1997 Aug 15;159(4):1783–93

IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. Nikcevich KM, et al. **J Immunol** 1997 Jan 15; 158(2):614–21

Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor. Novelli F, et al. **J Immunol** 1996 Sep 1; 157(5):1935–43

Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. Schweitzer AN, et al. **J Immunol** 1997 Mar 15; 158(6):2713–22

TNF-alpha-mediated expression of the receptor for anaphylatoxin C5a on neurons in experimental Listeria meningoencephalitis. Stahel PF, et al. **J Immunol** 1997 Jul 15;159(2):861–9

Yeast expression of the cytokine receptor domain of the soluble interleukin-6 receptor. Vollmer P, et al. **J Immunol Methods** 1996 Nov 29;199(1):47–54

Both human alpha/beta and gamma interferons upregulate the expression of CD48 cell surface molecules. Tissot C, et al. **J Interferon Cytokine Res** 1997 Jan;17(1):17–26

Neuronal differentiation in SH-SY5Y human neuroblastoma cells induces synthesis and secretion of tenascin and upregulation of alpha(v) integrin receptors. Linnala A, et al. **J Neurosci Res** 1997 Jul 1;49(1):53–63

Soluble CD46 (membrane cofactor protein, MCP) in human reproductive tract fluids. McLaughlin PJ, et al. **J Reprod Immunol** 1996 Oct;31(3):209–19

Cultured human decidual stromal cells express antigens associated with hematopoietic cells. Montes MJ, et al. **J Reprod Immunol** 1996 Feb;30(1):53–66

Transgenic mice expressing human measles virus (MV) receptor CD46 provide cells exhibiting different permissivities to MV infections. Horvat B, et al. **J Virol** 1996 Oct;70(10):6673–81

CD46 expression does not overcome the intracellular block of measles virus replication in transgenic rats. Niewiesk S, et al. **J Virol** 1997 Oct;71(10):7969–73

Characterization of a newly established human bone marrow endothelial cell line: distinct adhesive properties for hematopoietic progenitors compared with human umbilical vein endothelial cells. Schweitzer KM, et al. **Lab Invest** 1997 Jan;76(1):25–36

Analysis of IL-2, IL-4 and their receptors in clonally-related cell lines derived from a patient with a progressive cutaneous T-cell lymphoproliferative disorder. Wasik MA, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):125–36

Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Bouscary D, et al. **Leukemia** 1997 Jun;11(6):839–45

Expression of B7-2 (CD86) molecules by Reed-Sternberg cells of Hodgkin's disease. Van Gool SW, et al. **Leukemia** 1997 Jun;11(6):846–51

Preferential histiotypic expression of CD44-isoforms in human lung cancer. Wimmel A, et al. **Lung Cancer** 1997 Mar;16(2-3):151–72

Abnormalities in CD69 expression, cytosolic pH and Ca2+ during activation of lymphocytes from patients with systemic lupus erythematosus. Portales-Pérez D, et al. **Lupus** 1997;6(1):48–56

Expression of interleukin-6 receptors and NF-kappa B in AIDS-related Kaposi sarcoma cell strains. Bailer RT, et al. **Lymphology** 1997 Jun;30(2):63–76

Human immunodeficiency virus type-1 envelope glycoprotein gp120 induces expression of fusion regulatory protein (FRP)-1/CD98 on CD4+ T cells: a possible regulatory mechanism of HIV-induced syncytium formation. Suga S, et al. **Med Microbiol Immunol (Berl)** 1997 Mar;185(4):237–43

In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Moretti S, et al. **Melanoma Res** 1997 Aug;7(4):313–21

Sp1 binding plays a critical role in Erb-B2- and v-ras-mediated downregulation of alpha2-integrin expression in human mammary epithelial cells. Ye J, et al. **Mol Cell Biol** 1996 Nov;16(11):6178–89

Expression of leukaemia inhibitory factor receptor subunits LIFR beta and gp130 in human oocytes and preimplantation embryos. van Eijk MJ, et al. **Mol Hum Reprod** 1996 May;2(5):355–60

Expression of tumor necrosis factor-alpha and its receptors type I and type II in human oocytes. Naz RK, et al. **Mol Reprod Dev** 1997 Jun;47(2):127–33

Homodimerization of the human interleukin 4 receptor alpha chain induces Cepsilon germline transcripts in B cells in the absence of the interleukin 2 receptor gamma chain. Fujiwara H, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5866–71

Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Hancock WW, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13967–72

Impairment of antigen-specific antibody production in transgenic mice expressing a dominant-negative form of gp130. Kumanogoh A, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2478–82

Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression. Schnorr JJ, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):5326–31

Preparation and characterization of two human carcinoembryonic antigen family proteins of neutrophils, CD66b and c, in silkworm larvae. Yamanaka T, et al. **Protein Expr Purif** 1996 Jun;7(4):438–46

Cloning, expression and purification of the ligand-binding region of human IL-6R in E. coli and its preliminary functional identification. Duan J, et al. **Sci China B** 1995 Nov;38(11):1321–31

Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Ostrand-Rosenberg S, et al. **Tissue Antigens** 1996 May; 47(5):414–21

CD69 expression on primitive progenitor cells and hematopoietic malignancies. Tassone P, et al. **Tissue Antigens** 1996 Jul;48(1):65–8

Production of transgenic rats for human regulators of complement activation. Charreau B, et al. **Transplant Proc** 1997 May;29(3):1770

In vitro expression of activation markers and lymphocyte proliferation in response to interleukin 12: effect of immunosuppressive agents. Degiannis D, et al. **Transplant Proc** 1996 Dec;28(6):3062–4

Evidence of CD28 upregulation in peripheral T cells before liver transplant acute rejection. Minguela A, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):499–500

The regulation of membrane cofactor protein (CD46) expression in transgenic mice: the importance of the first 125 BP of the 3' untranslated region. Miyagawa S, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):941–2

Expression of a negative dominant mutant of human p55 tumor necrosis factor-receptor inhibits TNF and monocyte-induced activation in porcine aortic endothelial cells. Stroka DM, et al. **Transplant Proc** 1997 Feb-Mar; 29(1-2):882

Expression of cell adhesion molecules and common acute lymphoblastic leukaemia antigen in hepatoblastoma. von Schweinitz D, et al. **Virchows Arch** 1996 Nov; 429(4-5):239–41

BLOOD

Soluble CD8 antigen, stimulated C-peptide and islet cell antibodies are predictors of insulin requirement in newly diagnosed patients with unclassifiable diabetes. Di Bonito P, et al. **Acta Diabetol** 1996 Sep;33(3):220–4

Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Papadaki H, et al. **Acta Haematol** 1997;97(4):191–5

Serum sAPO-1/Fas levels in multiple sclerosis. Bansil S, et al. **Acta Neurol Scand** 1997 Apr;95(4):208–10

Cleavage of the human C5A receptor by proteinases derived from Porphyromonas gingivalis: cleavage of leukocyte C5a receptor. Jagels MA, et al. **Adv Exp Med Biol** 1996; 389:155–64

Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. Bofill M, et al. **AIDS** 1996 Jul;10(8):827–34

Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. Rizzardi GP, et al. **AIDS** 1996 Nov;10(13):F45–50

Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer. Gadducci A, et al. **Anticancer Res** 1996 Sep-Oct;16(5B):3125–8

Pulsatile Ca2+ influx in human neutrophils undergoing CD11b/CD18 integrin engagement. Pettit EJ, et al. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):258–61

Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker. Meikle PJ, et al. **Clin Chem** 1997 Aug; 43(8 Pt 1):1325–35

Recurrent infectious diseases in human CD53 deficiency. Mollinedo F, et al. **Clin Diagn Lab Immunol** 1997 Mar; 4(2):229–31

Quantitative analysis of leukocyte membrane antigen expression on human fetal and cord blood: normal values and changes during development. Bikoue A, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):56–64

Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients [see comments] Folzenlogen D, et al. **Clin Immunol Immunopathol** 1997 Jun;83(3):199–204. Comment in: Clin Immunol Immunopathol 1997 Jun;83(3):195–8.

Interleukin-6 and its soluble receptor during acute meningococcal infections: effect of plasma or whole blood exchange. Frieling JT, et al. **Crit Care Med** 1996 Nov; 24(11):1801–5

Concentrations of soluble tumor necrosis factor and interleukin-6 receptors in heatstroke and heatstress [see comments] Hammami MM, et al. **Crit Care Med** 1997 Aug; 25(8):1314–9. Comment in: Crit Care Med 1997 Aug;25(8):1263–9.

Intramucosal acidosis and systemic host responses in abdominal aortic aneurysm surgery. Soong CV, et al. **Crit Care Med** 1997 Sep;25(9):1472–9

Relation between pro- and anti-inflammatory cytokines and the production of nitric oxide (NO) in severe sepsis. Groeneveld PH, et al. **Cytokine** 1997 Feb;9(2):138–42

IL-6 and soluble IL-6 receptor levels change differently after surgery both in the blood and in the operative field. Hisano S, et al. **Cytokine** 1997 Jun;9(6):447–52

Chemiluminescent enhanced CD47 detection on Western blotting. Yuan FF, et al. **Electrophoresis** 1996 Jan; 17(1):219–20

Interleukin-4, interleukin-10, and soluble tumor necrosis factor receptors in cord blood. Hata T, et al. **Gynecol Obstet Invest** 1997;43(3):155–7

Detection of soluble receptors for tumor necrosis factor, interleukin-2 and interleukin-6 in retroplacental serum from normal pregnant women. Lien E, et al. **Gynecol Obstet Invest** 1996;41(1):1–4

Plasma levels of sTNFR p75 and IL-8 in patients with HIV-1 infection. Hober D, et al. **Immunol Lett** 1996 Aug; 52(1):57–60

High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients. Hober D, et al. **Infection** 1996 May-Jun; 24(3):213–7

Increased serum levels of soluble tumor necrosis factor receptors (sTNF-Rs) in children and adolescents with vertically and horizontally transmitted HIV infection. Weiss M, et al. **Infection** 1996 Jul-Aug;24(4):301–8

Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery. Remes K, et al. **J Hematother** 1997 Feb;6(1):13–9

Anomalous expression of costimulatory molecules B7-1, B7-2 and CD28 in primary biliary cirrhosis. Spengler U, et al. **J Hepatol** 1997 Jan;26(1):31–6

Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice. Peters M, et al. **J Immunol** 1997 Aug 1; 159(3):1474–81

Reciprocal changes in circulating interleukin-6 and its soluble receptor during evolving sepsis in leukocytopenic patients. Ostermann H, et al. **J Infect Dis** 1997 Sep;176(3):825–8

Evaluation of interleukin-6 and soluble receptors of tumor necrosis factor for early diagnosis of neonatal infection. Messer J, et al. **J Pediatr** 1996 Oct;129(4):574–80

Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. Gabay C, et al. **J Rheumatol** 1997 Feb;24(2):303–8

Adult T-cell leukemia (ATL) with an unusual immunophenotype and a high cellular proliferation rate. Lorand-Metze I, et al. **Leuk Lymphoma** 1996 Aug; 22(5-6):523–6

Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Raspadori D, et al. **Leuk Res** 1997 Jul;21(7):603–7

Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas. Warzocha K, et al. **Leukemia** 1997 Apr;11 Suppl 3:441–3

Comparative study on age-dependent development of surface receptors on peripheral blood lymphocytes in children and young nonhuman primates (marmosets). Foerster M, et al. **Life Sci** 1997;60(10):773–85

CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity. Su CC, et al. **Lupus** 1997;6(5):449–54

In vitro T cell activation in elderly individuals: failure in CD69 and CD71 expression. Lio D, et al. **Mech Ageing Dev** 1996 Jul 31;89(1):51–8

Age-related tyrosine-specific protein phosphorylation defect in human T lymphocytes activated through CD3, CD4, CD8 or the IL-2 receptor. Quadri RA, et al. **Mech Ageing Dev** 1996 Jul 17;88(3):125–38

High levels of sTNFR p75 and TNF alpha in dengue-infected patients. Hober D, et al. **Microbiol Immunol** 1996;40(8):569–73

Leukocyte CD14 and CD45 expression during hemodialysis: polysulfone versus cuprophane. Dhondt AW, et al. **Nephron** 1996;74(2):342–8

Monocyte and granulocyte CD11b/CD18, CD62L expression and sICAM-1 concentration in the interdialytic period. Thylén P, et al. **Nephron** 1996;74(2):275–82

Ex vivo expansion of human peripheral blood progenitors. Chabannon C, et al. **Nouv Rev Fr Hematol** 1995;37(6):351–8

Platelet-surface glycoproteins in healthy and preeclamptic mothers and their newborn infants. Kühne T, et al. **Pediatr Res** 1996 Dec;40(6):876–80

The lysosomal granule membrane protein, LAMP-2, is also present in platelet dense granule membranes. Israels SJ, et al. **Thromb Haemost** 1996 Apr;75(4):623–9

[Soluble interleukin-6 receptors in the serum in multiple myeloma] Scudla V, et al. **Cas Lek Cesk** 1996 Nov 20; 135(22):719–22 (Eng. Abstr.) **(Cze)**

CHEMISTRY

Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides. Olbina G, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3525–30

Identification of the cleavage sites in the alpha6A integrin subunit: structural requirements for cleavage and functional analysis of the uncleaved alpha6Abeta1 integrin. Delwel GO, et al. **Biochem J** 1997 May 15;324 (Pt 1):263–72

Characterization of a soluble IL-6 receptor alpha mutant C277D/H280I expressed in E.coli. Duan J, et al. **Biochem Mol Biol Int** 1997 May;41(6):1101–8

Identification of residues in CD6 which are critical for ligand binding. Bodian DL, et al. **Biochemistry** 1997 Mar 4; 36(9):2637–41

Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction. Kalai M, et al. **Blood** 1997 Feb 15;89(4):1319–33

A three amino acid deletion in glycoprotein IIIa is responsible for type I Glanzmann's thrombasthenia: importance of residues Ile325Pro326Gly327 for beta3 integrin subunit association. Morel-Kopp MC, et al. **Blood** 1997 Jul 15; 90(2):669–77

Serine 752 in the cytoplasmic domain of the beta 3 integrin subunit is not required for alpha v beta 3 postreceptor signaling events. Kieffer N, et al. **Cell Adhes Commun** 1996 Jul;4(1):25–39

1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. Somers W, et al. **EMBO J** 1997 Mar 3;16(5):989–97

Characterisation of the low affinity interaction between rat cell adhesion molecules CD2 and CD48 by analytical ultracentrifugation. Silkowski H, et al. **Eur Biophys J** 1997; 25(5-6):455–62

Global and local determinants for the kinetics of

interleukin-4/interleukin-4 receptor alpha chain interaction. A biosensor study employing recombinant interleukin-4-binding protein. Shen BJ, et al. **Eur J Biochem** 1996 Aug 15;240(1):252-61

Characterization of the expression and gene promoter of CD22 in murine B cells. Andersson KB, et al. **Eur J Immunol** 1996 Dec;26(12):3170-8

CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Rubinstein E, et al. **Eur J Immunol** 1996 Nov; 26(11):2657-65

Characterization of rat HSA/CD24 protein bearing the B lineage-restricted epitope recognized by MAb HIS50. Pearce EI, et al. **Hybridoma** 1996 Feb;15(1):33-42

Phosphorous carbohydrates on chimeric CD22, CD44 and CD62L. Jönsson G, et al. **Immunol Lett** 1996 Aug; 52(1):31-5

Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. López-Botet M, et al. **Immunol Rev** 1997 Feb;155:165-74 (74 ref.)

Mapping of the primary binding site of measles virus to its receptor CD46. Buchholz CJ, et al. **J Biol Chem** 1997 Aug 29;272(35):22072-9

The recognition sites of the integrins alpha1beta1 and alpha2beta1 within collagen IV are protected against gelatinase A attack in the native protein. Eble JA, et al. **J Biol Chem** 1996 Nov 29;271(48):30964-70

I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. Hu S, et al. **J Biol Chem** 1997 Jul 11;272(28):17255-7

Homodimerization of interleukin-4 receptor alpha chain can induce intracellular signaling. Kammer W, et al. **J Biol Chem** 1996 Sep 27;271(39):23634-7

Identification of a binding site for integrin alphaEbeta7 in the N-terminal domain of E-cadherin. Karecla PI, et al. **J Biol Chem** 1996 Nov 29;271(48):30909-15

Molecular requirements for assembly and function of a minimized human integrin alphaIIbbeta3. McKay BS, et al. **J Biol Chem** 1996 Nov 29;271(48):30544-7

Functional expression of soluble human interleukin-11 (IL-11) receptor alpha and stoichiometry of in vitro IL-11 receptor complexes with gp130. Neddermann P, et al. **J Biol Chem** 1996 Nov 29;271(48):30986-91

Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line. Shen Y, et al. **J Biol Chem** 1997 Feb 7;272(6):3550-3

Two basic amino acids in the second inner loop of the interleukin-8 receptor are essential for Galpha16 coupling. Xie W, et al. **J Biol Chem** 1997 Oct 3;272(40):24948-51

Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains. Zhang JG, et al. **J Biol Chem** 1997 Apr 4; 272(14):9474-80

A minimal region on the integrin beta4 subunit that is critical to its localization in hemidesmosomes regulates the distribution of HD1/plectin in COS-7 cells. Niessen CM, et al. **J Cell Sci** 1997 Aug;110 (Pt 15):1705-16

Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. Lazetic S, et al. **J Immunol** 1996 Dec 1;157(11):4741-5

Purification and characterization of the pig analogue of human membrane cofactor protein (CD46/MCP). van den Berg CW, et al. **J Immunol** 1997 Feb 15;158(4):1703-9

A bivalent immunoadhesin of the human interferon-gamma receptor is an effective inhibitor of IFN-gamma activity. Moosmayer D, et al. **J Interferon Cytokine Res** 1995 Dec; 15(12):1111-5

C5aR ligand peptide 3D QSAR study performed with an applied linear conformation. Anderson CY, et al. **J Pept Res** 1997 Jun;49(6):476-83

Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding. Hsu EC, et al. **J Virol** 1997 Aug;71(8):6144-54

The membrane-cytoplasm interface of integrin alpha subunits is critical for receptor latency. Briesewitz R, et al. **Mol Biol Cell** 1996 Oct;7(10):1499-509

I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Fischer M, et al. **Nat Biotechnol** 1997 Feb;15(2):142-5

Crystal structure of ICAM-2 reveals a distinctive integrin recognition surface. Casasnovas JM, et al. **Nature** 1997 May 15;387(6630):312-5

Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs. Liu KY, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11819-24

Determination of the lifetime and force dependence of interactions of single bonds between surface-attached CD2 and CD48 adhesion molecules. Pierres A, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15114-8

Homology modeling study of the human interleukin-7 receptor complex. Kroemer RT, et al. **Protein Eng** 1996 Dec;9(12):1135-42

Interleukin-6: structure-function relationships. Simpson RJ, et al. **Protein Sci** 1997 May;6(5):929-55 (338 ref.)

Structures of the extracellular domain of the type I tumor necrosis factor receptor. Naismith JH, et al. **Structure** 1996 Nov 15;4(11):1251-62

Characterization of a chemokine receptor-related gene in human herpesvirus 8 and its expression in Kaposi's sarcoma. Guo HG, et al. **Virology** 1997 Feb 17;228(2):371-8

Measles virus recognizes its receptor, CD46, via two distinct binding domains within SCR1-2. Manchester M, et al. **Virology** 1997 Jun 23;233(1):174-84

CLASSIFICATION

CD antigens 1996. Kishimoto T, et al. **Blood** 1997 May 15; 89(10):3502 (1 ref.)

Moving towards the definition of new clusters of designation at the 6th International Workshop on Human Leukocyte Differentiation Antigens. A brief description of the recently clustered molecules. Lanza F, et al. **Eur J Histochem** 1996; 40 Suppl 1:63-74

Update of CD antigens, 1996. Kishimoto T, et al. **J Immunol** 1997 Apr 1;158(7):3035-6

In vivo functions mediated by the p41 isoform of the MHC class II-associated invariant chain. Takaesu NT, et al. **J Immunol** 1997 Jan 1;158(1):187-99

Update: new CD antigens, 1996. Kishimoto T, et al. **Tissue Antigens** 1997 Mar;49(3 Pt 1):287-8

DRUG EFFECTS

Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Gavett SH, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):L253-61

Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Puthier D, et al. **Blood** 1996 Dec 15;88(12):4659-66

Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and Fc alpha R (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-alpha) and IL-6 in human monocytes. Wolf HM, et al. **Clin Exp Immunol** 1996 Sep;105(3):537-43

CD43 (leukosialin, sialophorin) expression is differentially regulated by retinoic acids. Babina M, et al. **Eur J Immunol** 1997 May;27(5):1147-51

Chemoattractant receptors for interleukin-8 and C5a: expression on peripheral blood leukocytes and differential regulation on HL-60 and AML-193 cells by vitamin D3 and all-trans retinoic acid. Zahn S, et al. **Eur J Immunol** 1997 Apr;27(4):935-40

Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2. Jones SA, et al. **J Biol Chem** 1997 Jun 27;272(26):16166-9

Differential effect of the immunomodulator AS101 on B7-1 and B7-2 costimulatory molecules: role in the antitumoral effects of AS101. Kalechman Y, et al. **J Immunol** 1996 Jul 15;157(2):589-97

Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor [published erratum appears in J Virol 1997 Mar;71(3):1581] Herbein G, et al. **J Virol** 1996 Nov;70(11):7388-97

Enzymatic effect of hypodermin A, a parasite protease, on bovine lymphocyte membrane antigens. Moiré N, et al. **Parasite Immunol** 1997 Jan;19(1):21-7

Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. Walev I, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7882-7

GENETICS

Transcriptional up-regulation of interleukin 4 receptors by human immunodeficiency virus type 1 tat gene. Husain SR, et al. **AIDS Res Hum Retroviruses** 1996 Sep 20; 12(14):1349-59

CD9 antigen mRNA is induced by hypertonicity in two renal epithelial cell lines. Sheikh-Hamad D, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C253-8

The expression of alpha 6 and beta 4 integrin genes are differentially regulated by all-trans-retinoic acid (RA) in cultured human keratinocytes. Laurikainen L, et al. **Arch Dermatol Res** 1996 May;288(5-6):270-3

Increased release of the tumour necrosis factor receptor p75 by immortalized human keratinocytes results from an activated shedding mechanism and is not related to augmented steady-state levels of p75 mRNA. Neuner P, et al. **Arch Dermatol Res** 1996 Oct;288(11):691-6

Fc gammaRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus. Yee AM, et al. **Arthritis Rheum** 1997 Jun;40(6):1180-2

Common polymorphisms in the coding part of the IL4-receptor gene. Deichmann K, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):696-7

Mapping of the extracellular binding regions of the human interleukin-8 type B receptor. Katancik JA, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):663-8

The regulation of membrane cofactor protein (CD46) expression by the 3' untranslated region in transgenic mice. Miyagawa S, et al. **Biochem Biophys Res Commun** 1997 Apr 28;233(3):829-33

Functional expression on human trophoblasts of interleukin 4 and interleukin 7 receptor complexes with a common gamma chain. Saito S, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):429-34

The unique cytoplasmic domain of the human integrin variant beta4E is produced by partial retention of intronic sequences. van Leusden MR, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):826-30

Variants of integrin beta 4 subunit in human endometrial adenocarcinoma cells: mediators of ECM-induced differentiation? Strunck E, et al. **Biochem Cell Biol** 1996; 74(6):867-73

Alternative splicing of the human IgA Fc receptor CD89 in neutrophils and eosinophils. Pleass RJ, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):771-7

Characterization of a soluble IL-6 receptor alpha mutant C277D/H280I expressed in E.coli. Duan J, et al. **Biochem Mol Biol Int** 1997 May;41(6):1101-8

Identification and characterization of an RNA specific primer for human tumor necrosis factor receptor I (TNFR-I). Kuo KW, et al. **Biochem Mol Biol Int** 1996 Sep;40(1):119-25

Identification of an intragenic promoter in the human CD45 gene. Timon M, et al. **Biochem Soc Trans** 1997 May; 25(2):177S

Modified antisense oligonucleotides directed against tumor necrosis factor receptor type I inhibit tumor necrosis factor alpha-mediated functions. Ojwang JO, et al. **Biochemistry** 1997 May 20;36(20):6033-45

Both the H13 gene product and 4F2 antigen are involved in the induction of system y+ cationic amino-acid transport following activation of human peripheral blood mononuclear cells (PBM). Chen S, et al. **Biochim Biophys Acta** 1996 Oct 2;1284(1):1-3

Molecular cloning and characterization of a cDNA encoding the rat interleukin-8 receptor. Gobl AE, et al. **Biochim Biophys Acta** 1997 Jun 12;1326(2):171-7

Molecular cloning and expression of mouse homologue of SFA-1/PETA-3 (CD151), a member of the transmembrane 4 superfamily. Hasegawa H, et al. **Biochim Biophys Acta** 1997 Aug 7;1353(2):125-30

Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Arepally G, et al. **Blood** 1997 Jan 15; 89(2):370-5

CD84 leukocyte antigen is a new member of the Ig superfamily. de la Fuente MA, et al. **Blood** 1997 Sep 15; 90(6):2398-405

Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Elsner J, et al. **Blood** 1996 Dec 15;88(12):4684-93

A three amino acid deletion in glycoprotein IIIa is responsible for type I Glanzmann's thrombasthenia: importance of residues Ile325Pro326Gly327 for beta3 integrin subunit association. Morel-Kopp MC, et al. **Blood** 1997 Jul 15; 90(2):669-77

Altered erythrocytes and a leaky block in B-cell development in CD24/HSA-deficient mice. Nielsen PJ, et al. **Blood** 1997 Feb 1;89(3):1058-67

Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Thompson AA, et al. **Blood** 1997 Aug 15;90(4):1387-94

Cloning and characterization of Fc alpha Rb, a novel Fc alpha receptor (CD89) isoform expressed in eosinophils and neutrophils. van Dijk TB, et al. **Blood** 1996 Dec 1; 88(11):4229-38

Characterization of brain ecto-apyrase: evidence for only one ecto-apyrase (CD39) gene. Wang TF, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1-2):295-302

KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Guo X, et al. **Cancer Res** 1996 Nov 1;56(21):4876-80

Beta 4 integrin transfection of UM-UC-2 (human bladder carcinoma) cells: stable expression of a spontaneous cytoplasmic truncation mutant with rapid loss of clones expressing intact beta 4. Kim SY, et al. **Cancer Res** 1997 Jan 1;57(1):38-42

Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Akashi K, et al. **Cell** 1997 Jun 27; 89(7):1033-41

Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1-/- mice. Maraskovsky E, et al. **Cell** 1997 Jun 27;89(7):1011-9

Transfection of beta 4 integrin subunit into a neoplastic keratinocyte line fails to restore terminal differentiation capacity or influence proliferation. Jones J, et al. **Cell Adhes Commun** 1996 Nov;4(4-5):307-16

Differential mRNA regulation of integrin subunits alpha V, beta 1, beta 3, and beta 5 during mouse embryonic organogenesis. Yamada S, et al. **Cell Adhes Commun** 1995 Nov;3(4):311-25

Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins. Amberger A, et al. **Cell Stress Chaperones** 1997 Jun; 2(2):94-103

Proinflammatory cytokines regulate Fc alphaR expression by human mesangial cells in vitro. Bagheri N, et al. **Clin Exp Immunol** 1997 Feb;107(2):404-9

A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. Oh JW, et al. **Cytokine** 1996 May;8(5):401-9

A 68-kD antigen, which is probably an N-terminal fragment of the VLA-5 alpha 5-subunit, is specific for differentiating keratinocytes. De Strooper B, et al. **Dermatology** 1996; 193(3):212-20

Expression of the beta 4 integrin subunit in the mouse heart during embryonic development: retinoic acid advances beta

4 expression. Hierck BP, et al. **Dev Dyn** 1996 Sep; 207(1):89–103

Epidermal growth factor system is a physiological regulator of development of the mouse fetal submandibular gland and regulates expression of the alpha6–integrin subunit. Kashimata M, et al. **Dev Dyn** 1997 Feb;208(2):149–61

Differential expression of integrin alpha subunits supports distinct roles during lung branching morphogenesis. Wu JE, et al. **Dev Dyn** 1996 Jun;206(2):169–81

Multiple nuclear regulatory proteins bind a single cis–acting promoter element to control basal transcription of the human alpha 4 integrin gene in corneal epithelial cells. Larouche K, et al. **DNA Cell Biol** 1996 Sep;15(9):779–92

Identification of the human alpha6 integrin gene promoter. Lin CS, et al. **DNA Cell Biol** 1997 Aug;16(8):929–37

c–Myb and Ets proteins synergize to overcome transcriptional repression by ZEB. Postigo AA, et al. **EMBO J** 1997 Jul 1;16(13):3924–34

Body temperature (37 C) specifically down–regulates the messenger ribonucleic acid for the major sperm surface antigen CD52 in epididymal cell culture. Pera I, et al. **Endocrinology** 1996 Oct;137(10):4451–9

Characterization of the expression and gene promoter of CD22 in murine B cells. Andersson KB, et al. **Eur J Immunol** 1996 Dec;26(12):3170–8

Molecular characterization of a gene in the rat homologous to human CD94. Dissen E, et al. **Eur J Immunol** 1997 Aug; 27(8):2080–6

A novel 4–kb interleukin–13 receptor alpha mRNA expressed in human B, T, and endothelial cells encoding an alternate type–II interleukin–4/interleukin–13 receptor. Gauchat JF, et al. **Eur J Immunol** 1997 Apr;27(4):971–8

The beta 4 integrin subunit is expressed in mouse fibroblasts and modulated by transforming growth factor–beta 1. Scardigli R, et al. **Exp Cell Res** 1996 Sep 15;227(2):223–9

Interleukin–7R alpha mRNA expression increases as stem cells differentiate into T and B lymphocyte progenitors. Orlic D, et al. **Exp Hematol** 1997 Mar;25(3):217–22

Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin–6 signal transducer gp130. Diamant M, et al. **FEBS Lett** 1997 Jul 28;412(2):379–84

Cloning of the human IL–13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL–4/IL–13 receptor complex. Miloux B, et al. **FEBS Lett** 1997 Jan 20;401(2–3):163–6

Cloning and sequence of the cDNA encoding the beta 4 integrin subunit in rat peripheral nerve. Feltri ML, et al. **Gene** 1997 Feb 28;186(2):299–304

Genomic structure and promoter analysis of the gene encoding MM3, a member of transmembrane 4 superfamily. Kurihara T, et al. **Gene** 1997 Feb 7;185(2):277–83

Human CD46 aberrant splicing in transgenic mice. Mulder LC, et al. **Gene** 1997 Feb 20;186(1):83–6

Human gene encoding CD38 (ADP–ribosyl cyclase/cyclic ADP–ribose hydrolase): organization, nucleotide sequence and alternative splicing. Nata K, et al. **Gene** 1997 Feb 28; 186(2):285–92

Alternative splicing of IgA Fc receptor (CD89) transcripts. Reterink TJ, et al. **Gene** 1996 Oct 10;175(1–2):279–80

Gene transfer of the costimulatory molecules B7–1 and B7–2 into human multiple myeloma cells by recombinant adeno–associated virus enhances the cytolytic T cell response. Wendtner CM, et al. **Gene Ther** 1997 Jul; 4(7):726–35

A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejection [published erratum appears in Genes Cells 1996 Aug;1(8):785] Yannoutsos N, et al. **Genes Cells** 1996 Apr;1(4):409–19

Pax–5 (BSAP) recruits Ets proto–oncogene family proteins to form functional ternary complexes on a B–cell–specific promoter. Fitzsimmons D, et al. **Genes Dev** 1996 Sep 1; 10(17):2198–211

The mouse lysosomal membrane protein 1 gene as a candidate for the motorneuron degeneration (mnd) locus. Bermingham NA, et al. **Genomics** 1996 Mar 1;32(2):266–71

Genomic organization of the human KAI1 metastasis–suppressor gene. Dong JT, et al. **Genomics** 1997 Apr 1;41(1):25–32

Granulosa cells express integrin alpha 6: possible involvement of integrin alpha 6 in folliculogenesis. Fujiwara H, et al. **Horm Res** 1996;46 Suppl 1:24–30

Characterization of four short tandem repeat loci (THO1, VWA31/A, CD4, and TP53) in northern Portugal. Gusmão L, et al. **Hum Biol** 1997 Feb;69(1):31–40

Granulocyte–macrophage colony–stimulating factor and B7–2 combination immunogene therapy in an allogeneic Hu–PBL–SCID/beige mouse–human glioblastoma multiforme model. Parney IF, et al. **Hum Gene Ther** 1997 Jun 10;8(9):1073–85

Homozygous alpha6 integrin mutation in junctional epidermolysis bullosa with congenital duodenal atresia. Pulkkinen L, et al. **Hum Mol Genet** 1997 May;6(5):669–74

IL–7 receptor and VDJ recombination: trophic versus mechanistic actions. Candéias S, et al. **Immunity** 1997 May; 6(5):501–8 (104 ref.)

T cell–mediated elimination of B7.2 transgenic B cells. Fournier S, et al. **Immunity** 1997 Mar;6(3):327–39

Molecular evolution of the N–formyl peptide and C5a receptors in non–human primates. Alvarez V, et al. **Immunogenetics** 1996;44(6):446–52

The human natural killer gene complex is located on chromosome 12p12–p13. Renedo M, et al. **Immunogenetics** 1997;46(4):307–11

Defective T–cell receptor gamma gene rearrangement in interleukin–7 receptor knockout mice. Candéias S, et al. **Immunol Lett** 1997 Jun 1;57(1–3):9–14

The novel variants of mb–1 and B29 transcripts generated by alternative mRNA splicing. Koyama M, et al. **Immunol Lett** 1995 Sep;47(3):151–6

Mouse CD6: sequence of cDNA and expression of mRNA. Pal A, et al. **Immunol Lett** 1996 Jan;49(1–2):133–7

Relevance of immunoglobulin G Fc receptor polymorphism to recurrence of adult periodontitis in Japanese patients. Kobayashi T, et al. **Infect Immun** 1997 Sep;65(9):3556–60

Characterization of rat CD80 and CD86 by molecular cloning and mAb. Maeda K, et al. **Int Immunol** 1997 Jul; 9(7):993–1000

Differential function of CD80– and CD86–transfected human melanoma cells in the presence of IL–12 and IFN–gamma. Rudy W, et al. **Int Immunol** 1997 Jun;9(6):853–60

Molecular cloning of a pig homologue of membrane cofactor protein (CD46). Toyomura K, et al. **Int Immunol** 1997 Jun; 9(6):869–76

Involvement of IL–4 in human glomerulonephritis: an in situ hybridization study of IL–4 mRNA and IL–4 receptor mRNA. Furusu A, et al. **J Am Soc Nephrol** 1997 May; 8(5):730–41

Identification of two rat genes orthologous to the human interleukin–8 receptors. Dunstan CAN, et al. **J Biol Chem** 1996 Dec 20;271(51):32770–6

Complementary DNA cloning and sequencing of the chicken muscle ecto–ATPase. Homology with the lymphoid cell activation antigen CD39. Kirley TL. **J Biol Chem** 1997 Jan 10;272(2):1076–81

Interleukin–4–induced STAT6 recognizes and activates a target site in the promoter of the interleukin–4 receptor gene. Kotanides H, et al. **J Biol Chem** 1996 Oct 11; 271(41):25555–61

Cloning and characterization of a novel integrin beta3 subunit. Kumar CS, et al. **J Biol Chem** 1997 Jun 27; 272(26):16390–7

Evidence that the integrin beta3 and beta5 subunits contain a metal ion–dependent adhesion site–like motif but lack an I domain. Lin ECK, et al. **J Biol Chem** 1997 May 30; 272(22):14236–43

Isolation and characterization of the human gp130 promoter. Regulation by STATS. O'Brien CA, et al. **J Biol Chem** 1997 Jun 6;272(23):15003–10

The structure of the gene for the second chain of the human interferon–gamma receptor. Rhee S, et al. **J Biol Chem** 1996 Nov 15;271(46):28947–52

Identification and characterization of the cell type–specific and developmentally regulated alpha7 integrin gene promoter. Ziober BL, et al. **J Biol Chem** 1996 Sep 13; 271(37):22915–22

Different steady state subcellular distributions of the three splice variants of lysosome–associated membrane protein LAMP–2 are determined largely by the COOH–terminal amino acid residue. Gough NR, et al. **J Cell Biol** 1997 Jun 2;137(5):1161–9

Paramyxovirus–induced syncytium cell formation is suppressed by a dominant negative fusion regulatory protein–1 (FRP–1)/CD98 mutated construct: an important role of FRP–1 in virus–induced cell fusion. Okamoto K, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):775–83

Structure and chromosomal location of the human CD6 gene: detection of five human CD6 isoforms. Bowen MA, et al. **J Immunol** 1997 Feb 1;158(3):1149–56

A soluble chimeric complement inhibitory protein that possesses both decay–accelerating and factor I cofactor activities. Higgins PJ, et al. **J Immunol** 1997 Mar 15; 158(6):2872–81

Molecular cloning of guinea pig membrane cofactor protein: preferential expression in testis. Hosokawa M, et al. **J Immunol** 1996 Dec 1;157(11):4946–52

Soluble IL–6 receptor leads to a paracrine modulation of the IL–6–induced hepatic acute phase response in double transgenic mice. Peters M, et al. **J Immunol** 1997 Aug 1; 159(3):1474–81

Sequence, genomic organization, and chromosome localization of the mouse TRADD gene. Pan MG, et al. **J Inflamm** 1995–96;46(3):168–75

Characterization and biologic activities of recombinant rat soluble interleukin–6 receptor. Thibault V, et al. **J Interferon Cytokine Res** 1996 Nov;16(11):973–81

Novel ITGB4 mutations in a patient with junctional epidermolysis bullosa–pyloric atresia syndrome and altered basement membrane zone immunofluorescence for the alpha6beta4 integrin. Takizawa Y, et al. **J Invest Dermatol** 1997 Jun;108(6):943–6

Insertion of lysosomal targeting sequences to the amyloid precursor protein reduces secretion of beta A4. Schrader–Fischer G, et al. **J Neurochem** 1997 Apr; 68(4):1571–80

Overexpression of integrin–associated protein (CD47) in rat kidney treated with a renal carcinogen, ferric nitrilotriacetate. Nishiyama Y, et al. **Jpn J Cancer Res** 1997 Feb;88(2):120–8

Bone resorption and mRNA expression of IL–6 and IL–6 receptor in patients with renal osteodystrophy. Langub MC Jr, et al. **Kidney Int** 1996 Aug;50(2):515–20

Interferon–gamma receptor–deficiency renders mice highly susceptible to toxoplasmosis by decreased macrophage activation. Deckert–Schlüter M, et al. **Lab Invest** 1996 Dec; 75(6):827–41

Genomic organization of the integrin beta 4 gene (ITGB4): a homozygous splice–site mutation in a patient with junctional epidermolysis bullosa associated with pyloric atresia. Pulkkinen L, et al. **Lab Invest** 1997 Jun;76(6):823–33

The influence of restraint stress on the expression of mRNAs for IL–6 and the IL–6 receptor in the hypothalamus and midbrain of the rat. Shizuya K, et al. **Life Sci** 1997; 61(10):PL 135–40

Genomic organization of the human integrin beta4 gene. Iacovacci S, et al. **Mamm Genome** 1997 Jun;8(6):448–50

The costimulatory genes Cd80 and Cd86 are linked on mouse chromosome 16 and human chromosome 3. Reeves RH, et al. **Mamm Genome** 1997 Aug;8(8):581–2

cDNA cloning and characterization of rat C5a anaphylatoxin receptor. Akatsu H, et al. **Microbiol Immunol** 1997; 41(7):575–80

Regulatory elements of the mb–1 gene encoding the Ig–alpha component of the human B–cell antigen receptor. Leduc I, et al. **Mol Immunol** 1996 Dec;33(17–18):1277–86

Characterisation of mouse CD37: cDNA and genomic cloning. Tomlinson MG, et al. **Mol Immunol** 1996 Jul; 33(10):867–72

Interleukin–4 receptor expression on AIDS–associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin–4 and Pseudomonas exotoxin. Husain SR, et al. **Mol Med** 1997 May;3(5):327–38

Interferon–gamma–receptor deficiency in an infant with fatal bacille Calmette–Guérin infection. Jouanguy E, et al. **N Engl J Med** 1996 Dec 26;335(26):1956–61

A mutation in the interferon–gamma–receptor gene and susceptibility to mycobacterial infection. Newport MJ, et al. **N Engl J Med** 1996 Dec 26;335(26):1941–9

Concomitant down–regulation of expression of integrin subunits by N–myc in human neuroblastoma cells: differential regulation of alpha2, alpha3 and beta1. Judware R, et al. **Oncogene** 1997 Mar 20;14(11):1341–50

A simple PCR method for screening cDNA libraries. Alfandari D, et al. **PCR Methods Appl** 1994 Aug;4(1):46–9

Independent signals regulate development of primary and secondary follicle structure in spleen and mesenteric lymph node. Fu YX, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5739–43

Impairment of antigen–specific antibody production in transgenic mice expressing a dominant–negative form of gp130. Kumanogoh A, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2478–82

A transgenic mouse model for measles virus infection of the brain. Rall GF, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4659–63

Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Kawana Y, et al. **Prostate** 1997 Aug 1;32(3):205–13

Genomic organization and promoter analysis of the gene ifngr2 encoding the second chain of the mouse interferon–gamma receptor. Ebensperger C, et al. **Scand J Immunol** 1996 Dec;44(6):599–606

Analysis at the DNA level of human Fc gamma RII isoforms in relation to the polymorphic binding of murine IgG2b to human B cells. Tax WJ, et al. **Scand J Immunol** 1996 Dec;44(6):571–7

Polymorphisms of the human platelet antigens HPA–1, HPA–2, HPA–3, and HPA–5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Carlsson LE, et al. **Stroke** 1997 Jul;28(7):1392–5

Differential expression of CD44 splice variants in malignant and benign pleural effusions. Tojo N, et al. **Tohoku J Exp Med** 1996 Aug;179(4):273–9

Receptors for gamma–interferon encoded by poxviruses: implications for the unknown origin of vaccinia virus. Alcamí A, et al. **Trends Microbiol** 1996 Aug;4(8):321–6 (38 ref.)

Genomic structure of the bovine mb–1 gene encoding the Ig–alpha subunit of the B cell antigen receptor complex. Youn HY, et al. **Vet Immunol Immunopathol** 1997 May; 56(3–4):247–57

[Expression and prognostic significance of HLA–class I and II antigens, ICAM–1 and costimulatory molecule B7 in esophageal carcinoma] Stoecklein NH, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:785–8 (Eng. Abstr.) **(Ger)**

[A polymorphic markers for the p75 tumor necrosis factor receptor gene: use for analyzing disease linkage] Turetskaia RL, et al. **Dokl Akad Nauk** 1996 Dec;351(4):558–60 **(Rus)**

[Expression of cDNA for human interleukin–8 type one receptor in BALB 3T3 fibroblasts and characteristics of products of expression] Tikhonov II, et al. **Mol Biol (Mosk)** 1996 Sep–Oct;30(5):1014–21 **(Rus)**

IMMUNOLOGY

Autoimmunity due to defective Nur77, Fas, and TNF–RI apoptosis. Mountz JD, et al. **Adv Exp Med Biol** 1996; 406:241–62 (93 ref.)

Enhanced expression of activation antigens HLA–DR and CD69 on gamma delta T cells but impaired interleukin–2–induced upregulation in HIV–1 infection [letter] Gröttrup–Wolfers E, et al. **AIDS** 1997 May;

11(6):838–9
The degree of natural allergen exposure modifies eosinophil activity markers in the circulation of patients with mild asthma. Fernvik E, et al. **Allergy** 1996 Oct;51(10):697–705
Rapid expression of the CD69 antigen on T cells and natural killer cells upon antigenic stimulation of peripheral blood mononuclear cell suspensions. Werfel T, et al. **Allergy** 1997 Apr;52(4):465–9
Topographic distribution of homing receptors on B and T cells in human gut–associated lymphoid tissue: relation of L–selectin and integrin alpha 4 beta 7 to naive and memory phenotypes. Farstad IN, et al. **Am J Pathol** 1997 Jan; 150(1):187–99
Differential regulation of human, antigen–specific Th1 and Th2 responses by the B–7 homologues, CD80 and CD86. Bashian GG, et al. **Am J Respir Cell Mol Biol** 1997 Aug; 17(2):235–42
Complete sustained response of a refractory, post–transplantation, large B–cell lymphoma to an anti–CD22 immunotoxin. Senderowicz AM, et al. **Ann Intern Med** 1997 Jun 1;126(11):882–5
Abnormal lymphocyte surface antigen expression in peripheral blood of a Kuwaiti population. Mahmoud FF, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:498–503
Gp130 and the interleukin–6 family of cytokines. Taga T, et al. **Annu Rev Immunol** 1997;15:797–819 (130 ref.)
Effect of blocking TNF on IL–6 levels and metastasis in a B16–BL6 melanoma/mouse model. Cubillos S, et al. **Anticancer Res** 1997 May–Jun;17(3C):2207–11
Therapeutic potential of humanized anti–interleukin–6 receptor antibody: antitumor activity in xenograft model of multiple myeloma. Tsunenari T, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2537–44
Differential sensitivity to Escherichia coli infection in mice lacking tumor necrosis factor p55 or interleukin–1 p80 receptors. Acton RD, et al. **Arch Surg** 1996 Nov; 131(11):1216–21
Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism. Taylor VC, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):919–25
Characterization of RFB4–Pseudomonas exotoxin A immunotoxins targeted to CD22 on B–cell malignancies. Mansfield E, et al. **Bioconjug Chem** 1996 Sep–Oct; 7(5):557–63
Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Elsner J, et al. **Blood** 1996 Dec 15;88(12):4684–93
Inhibition of binding of anti–PLA1 antibodies to platelets with monoclonal antibody LK–4. Evidence for multiple PLA1 receptor sites on platelet GPIIIa. Liu LX, et al. **Blood** 1996 Nov 1;88(9):3601–7
Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22–bearing cells and tumors. Mansfield E, et al. **Blood** 1997 Sep 1;90(5):2020–6
New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin–6 receptor. Tsunenari T, et al. **Blood** 1997 Sep 15; 90(6):2437–44
Human T lymphocytes and hematopoietic cell lines express CD24–associated carbohydrate epitopes in the absence of CD24 mRNA or protein. Williams LA, et al. **Blood** 1996 Oct 15;88(8):3048–55
B7–mediated costimulation and the immune response. Schultze J, et al. **Blood Rev** 1996 Jun;10(2):111–27 (107 ref.)
Blockade of costimulatory molecules B7–1 (CD80) and B7–2 (CD86) down–regulates induction of contact sensitivity by haptenated epidermal cells. Katayama I, et al. **Br J Dermatol** 1997 Jun;136(6):846–52
Functional CD86 (B7–2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis. Ohki O, et al. **Br J Dermatol** 1997 Jun;136(6):838–45
Effect of soluble P55 tumour–necrosis factor binding fusion protein on the local Shwartzman and Arthus reactions. Norman KE, et al. **Br J Pharmacol** 1996 Feb;117(3):471–478
Adoptive transfer of cytotoxic T lymphocytes induced by CD86–transfected tumor cells suppresses multi–organ metastases of C1300 neuroblastoma in mice. Enomoto A, et al. **Cancer Immunol Immunother** 1997 Jun;44(4):204–10
Advantage of residualizing radiolabels for an internalizing antibody against the B–cell lymphoma antigen, CD22. Sharkey RM, et al. **Cancer Immunol Immunother** 1997 May; 44(3):179–88
CD72 ligation regulates defective naive newborn B cell responses. Howard LM, et al. **Cell Immunol** 1997 Feb 1; 175(2):179–88
Rapid modulation of T lymphocyte surface antigens induced by Fas (CD95, APO–1) ligation. Kabelitz D, et al. **Cell Immunol** 1996 Oct 10;173(1):108–15
CD48 delivers an accessory signal for CD40–mediated activation of human B cells. Klyushnenkova EN, et al. **Cell Immunol** 1996 Nov 25;174(1):90–8
Identification of fusion regulatory protein (FRP)–1/4F2 related molecules: cytoskeletal proteins are associated with FRP–1 molecules that regulate multinucleated giant cell formation of monocytes and HIV–induced cell fusion. Suga S, et al. **Cell Struct Funct** 1995 Dec;20(6):473–83
Association between long–term kidney graft survival and the presence of pre–transplant cytotoxic anti–HLA and/or non–MHC Fc gamma RII blocking' (anti–TLX) alloantibody. Padányi A, et al. **Clin Transplant** 1996 Oct; 10(5):455–60
Recent advances in tumor necrosis factor and CD40 signaling. Tewari M, et al. **Curr Opin Genet Dev** 1996 Feb; 6(1):39–44 (52 ref.)
Specific inhibition of IL–6 signalling with monoclonal antibodies against the gp130 receptor. Liautard J, et al. **Cytokine** 1997 Apr;9(4):233–41
Kinetics of circulating TNF–alpha and TNF soluble receptors following surgery in a clinical model of sepsis. Neilson D, et al. **Cytokine** 1996 Dec;8(12):938–43
Cytokines involving gp130 in signal transduction suppressed growth of a mouse hybridoma cell line and enhanced its antibody production. Terada S, et al. **Cytokine** 1996 Dec; 8(12):889–94
Immunophenotyping of congenital leukemia [letter; comment] Brissette M, et al. **Cytometry** 1996 Jun 15; 26(2):180–1. Comment on: Cytometry 1995 Jun 15;22(2):85–8. Comment on: Cytometry 1995 Jun 15;22(2):89–92.
CD69 expression after antigenic stimulation [letter] Gibbons DC, et al. **Cytometry** 1996 Mar 1;23(3):260–1
Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4–colour flow cytometry. King MA, et al. **Cytometry** 1996 Jun 15; 26(2):121–4
Rare event selection of fetal nucleated erythrocytes in maternal blood by flow cytometry. Lewis DE, et al. **Cytometry** 1996 Mar 1;23(3):218–27
Natural killer cell proliferation and renal disease: a functional and phenotypic study. Vargas JA, et al. **Cytometry** 1996 Jun 15;26(2):125–30
Enrichment of early fetal–liver hemopoietic stem cells of the rat using monoclonal antibodies against the transferrin receptor, Thy–1, and MRC–OX82. Crook K, et al. **Dev Immunol** 1996;4(4):235–46
Antigen endocytosis and presentation mediated by human membrane IgG1 in the absence of the Ig(alpha)/Ig(beta) dimer. Knight AM, et al. **EMBO J** 1997 Jul 1; 16(13):3842–50
Clonal CD8+ and CD52– T cells are induced in responding B cell lymphoma patients treated with Campath–1H (anti–CD52). Osterborg A, et al. **Eur J Haematol** 1997 Jan; 58(1):5–13
Activation of the gp130 signaling pathway by monoclonal antibodies directed against the gp130 molecule. Autissier P, et al. **Eur J Immunol** 1997 Mar;27(3):794–7
Effect of CD80 and CD86 blockade and anti–interleukin–12 treatment on mouse acute graft–versus–host disease. Saito K, et al. **Eur J Immunol** 1996 Dec;26(12):3098–106
CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies. Sivori S, et al. **Eur J Immunol** 1996 Oct; 26(10):2487–92
Immunomodulatory effects of a plasmid expressing B7–2 on human immunodeficiency virus–1–specific cell–mediated immunity induced by a plasmid encoding the viral antigen. Tsuji T, et al. **Eur J Immunol** 1997 Mar;27(3):782–7
Monoclonal antibody crosslinking of the alpha 4 or beta 1 integrin inhibits committed clonogenic hematopoietic progenitor proliferation. Hurley RW, et al. **Exp Hematol** 1997 Apr;25(4):321–8
Antifection: an antibody–mediated method to introduce genes into lymphoid cells in vitro and in vivo. Poncet P, et al. **Gene Ther** 1996 Aug;3(8):731–8
Philadelphia chromosome–positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Cuneo A, et al. **Haematologica** 1996 Sep–Oct;81(5):423–7
Lack of platelet response to collagen associated with autoantibodies against glycoprotein (GP) Ia/IIa and Ib/IX leading to the discovery of SLE. Dromigny A, et al. **Hematol Cell Ther** 1996 Aug;38(4):355–7
Humanization of a mouse antibody against human alpha–4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Léger OJ, et al. **Hum Antibodies** 1997; 8(1):3–16
CD48 may serve as an accessory molecule for the activation of a subset of human gamma/delta T cells. Flament C, et al. **Hum Immunol** 1996 Apr;46(2):82–92
A novel monoclonal antibody, L1A3, is directed to the functional site of the alpha v integrin subunit. Deryugina EI, et al. **Hybridoma** 1996 Aug;15(4):279–88
CD94 and a novel associated protein (94AP) form a NK cell receptor involved in the recognition of HLA–A, HLA–B, and HLA–C allotypes. Phillips JH, et al. **Immunity** 1996 Aug;5(2):163–72
Anti–CD53 monoclonal antibody induced LFA–1/ICAM–1–dependent and –independent lymphocyte homotypic cell aggregation. Cao L, et al. **Immunobiology** 1997 Jun;197(1):70–81
Tumour necrosis factor–alpha (TNF–alpha): the good, the bad and potentially very effective. Barbara JA, et al. **Immunol Cell Biol** 1996 Oct;74(5):434–43 (107 ref.)
The SHIP phosphatase becomes associated with Fc gammaRIIB1 and is tyrosine phosphorylated during 'negative' signaling. D'Ambrosio D, et al. **Immunol Lett** 1996 Dec;54(2–3):77–82
Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated Fc gammaRIIB during negative regulation of IgE–dependent mouse mast cell activation. Fong DC, et al. **Immunol Lett** 1996 Dec; 54(2–3):83–91
The function of the soluble IL–6 receptor in vivo. Peters M, et al. **Immunol Lett** 1996 Dec;54(2–3):177–84
Integration of activatory and inhibitory signals in human B–cells. Sármay G, et al. **Immunol Lett** 1996 Dec; 54(2–3):93–100
The role of receptors for tumour necrosis factor–alpha in the induction of human polymorphonuclear neutrophil chemiluminescence. Zeman K, et al. **Immunol Lett** 1996 Oct;53(1):45–50
Targeted disruption of the IL–6 related genes: gp130 and NF–IL–6. Akira S, et al. **Immunol Rev** 1995 Dec; 148:221–53 (135 ref.)
Lymphotoxin–alpha–deficient and TNF receptor–I–deficient mice define developmental and functional characteristics of germinal centers. Matsumoto M, et al. **Immunol Rev** 1997 Apr;156:137–44 (40 ref.)
Immune defence in mice lacking type I and/or type II interferon receptors. van den Broek MF, et al. **Immunol Rev** 1995 Dec;148:5–18 (61 ref.)
Priming differentially regulates neutrophil adhesion molecule expression/function. Condliffe AM, et al. **Immunology** 1996 Sep;89(1):105–11
Differential expression and function of CD80 (B7–1) and CD86 (B7–2) on human peripheral blood monocytes. Fleischer J, et al. **Immunology** 1996 Dec;89(4):592–8
Identification of a novel antigenic structure of the human receptor for interleukin–6 involved in the interaction with the glycoprotein 130 chain. Gaillard JP, et al. **Immunology** 1996 Sep;89(1):135–41
Interleukin–13 selectively induces monocyte chemoattractant protein–1 synthesis and secretion by human endothelial cells. Involvement of IL–4R alpha and Stat6 phosphorylation. Goebeler M, et al. **Immunology** 1997 Jul; 91(3):450–7
Costimulation regulates the kinetics of interleukin–2 response to bacterial superantigens. Muraille E, et al. **Immunology** 1996 Oct;89(2):245–9
Mitogenic stimulation of T cells reveals differing contributions for B7–1 (CD80) and B7–2 (CD86) costimulation. Perrin PJ, et al. **Immunology** 1997 Apr; 90(4):534–42
Role of the CD6 glycoprotein in antigen–specific and autoreactive responses of cloned human T lymphocytes. Singer NG, et al. **Immunology** 1996 Aug;88(4):537–43
Identification of a novel dendritic cell surface antigen defined by carbohydrate specific CD24 antibody cross–reactivity. Williams LA, et al. **Immunology** 1996 Sep;89(1):120–5
Either B7–1 or B7–2 is required for Listeria monocytogenes–specific production of gamma interferon and interleukin–2. Zhan Y, et al. **Infect Immun** 1996 Dec; 64(12):5439–41
Monoclonal antibody LR–1 recognizes murine heat–stable antigen, a marker of antigen–presenting cells and developing hematopoietic cells. Hunt DW, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):218–29
Modulation of CD72 by ligation of B cell receptor complex molecules on CD5+ B cells. Jamin C, et al. **Int Immunol** 1997 Jul;9(7):1001–9
Characterization of rat CD80 and CD86 by molecular cloning and mAb. Maeda K, et al. **Int Immunol** 1997 Jul; 9(7):993–1000
The differential role of CD86 and CD80 co–stimulatory molecules in the induction and the effector phases of contact hypersensitivity. Nuriya S, et al. **Int Immunol** 1996 Jun;8(6):917–26
Differential requirements for co–stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens. Yi–qun Z, et al. **Int Immunol** 1996 Jan;8(1):37–44
Anti–alpha3 integrin antibody induces the activated form of matrix metalloprotease–2 (MMP–2) with concomitant stimulation of invasion through matrigel by human rhabdomyosarcoma cells. Kubota S, et al. **Int J Cancer** 1997 Jan 6;70(1):106–11
The advantage of residualizing radiolabels for targeting B–cell lymphomas with a radiolabeled anti–CD22 monoclonal antibody. Mattes MJ, et al. **Int J Cancer** 1997 May 2;71(3):429–35
Defining the topology of integrin alpha5beta1–fibronectin interactions using inhibitory anti–alpha5 and anti–beta1 monoclonal antibodies. Evidence that the synergy sequence of fibronectin is recognized by the amino–terminal repeats of the alpha5 subunit. Mould AP, et al. **J Biol Chem** 1997 Jul 11;272(28):17283–92
The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway. Ruff AL, et al. **J Biol Chem** 1997 Mar 28;272(13):8671–8
Reversion of the malignant phenotype of human breast cells in three–dimensional culture and in vivo by integrin blocking antibodies. Weaver VM, et al. **J Cell Biol** 1997 Apr 7;137(1):231–45
CD24 (heat stable antigen, nectadrin), a novel keratinocyte differentiation marker, is preferentially expressed in areas of the hair follicle containing the colony–forming cells. Magnaldo T, et al. **J Cell Sci** 1996 Dec;109 (Pt 13):3035–45
A novel human monoclonal antibody rapidly induces homotypic cell aggregation and promotes antibody–secreting activity by human B lymphoblastoid cell line IM–9. Ikewaki N. **J Clin Immunol** 1997 Mar; 17(2):127–39
Phase II multicenter study of human CD52 antibody in

previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Osterborg A, et al. **J Clin Oncol** 1997 Apr;15(4):1567–74

A recombinant tumor necrosis factor–alpha p80 receptor:Fc fusion protein decreases circulating bioactive tumor necrosis factor–alpha but not lung injury or mortality during immunosuppression–related gram–negative bacteremia. Lechner AJ, et al. **J Crit Care** 1997 Mar; 12(1):28–38

Requirements for CD1d recognition by human invariant Valpha24+ CD4–CD8– T cells. Exley M, et al. **J Exp Med** 1997 Jul 7;186(1):109–20

Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. Höpken UE, et al. **J Exp Med** 1997 Aug 29;186(5):749–56

Costimulation of T cell activation by integrin–associated protein (CD47) is an adhesion–dependent, CD28–independent signaling pathway. Reinhold MI, et al. **J Exp Med** 1997 Jan 6;185(1):1–11

Rescue of thymocytes from glucocorticoid–induced cell death mediated by CD28/CTLA–4 costimulatory interactions with B7–1/B7–2. Wagner DH Jr, et al. **J Exp Med** 1996 Nov 1;184(5):1631–8

Non–replicating recombinant vaccinia virus encoding murine B–7 molecules elicits effective costimulation of naive CD4+ splenocytes in vitro. Oertli D, et al. **J Gen Virol** 1996 Dec;77 (Pt 12):3121–5

Inhibition of feline immunodeficiency virus infection by CD9 antibody operates after virus entry and is independent of virus tropism. Willett B, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):611–8

Infusion of anti–B7.1 (CD80) and anti–B7.2 (CD86) monoclonal antibodies inhibits murine graft–versus–host disease lethality in part via direct effects on CD4+ and CD8+ T cells. Blazar BR, et al. **J Immunol** 1996 Oct 15; 157(8):3250–9

Two distinct stimulus–dependent pathways lead to production of soluble murine interleukin–4 receptor. Blum H, et al. **J Immunol** 1996 Sep 1;157(5):1846–53

Clonotypic differences in signaling from CD94 (kp43) on NK cells lead to divergent cellular responses. Brumbaugh KM, et al. **J Immunol** 1996 Oct 1;157(7):2804–12

Clonal expansion of CD8+ T cells in Kawasaki disease. Choi IH, et al. **J Immunol** 1997 Jul 1;159(1):481–6

Roles of CD9 molecules in survival and activation of human eosinophils. Kim JT, et al. **J Immunol** 1997 Jul 15; 159(2):926–33

Porcine endothelial CD86 is a major costimulator of xenogeneic human T cells: cloning, sequencing, and functional expression in human endothelial cells. Maher SE, et al. **J Immunol** 1996 Nov 1;157(9):3838–44

The IL–13 receptor structure differs on various cell types and may share more than one component with IL–4 receptor. Obiri NI, et al. **J Immunol** 1997 Jan 15; 158(2):756–64

The CD94/NKG2–A inhibitory receptor complex is involved in natural killer cell–mediated recognition of cells expressing HLA–G1. Pérez–Villar JJ, et al. **J Immunol** 1997 Jun 15;158(12):5736–43

Biochemical and serologic evidence for the existence of functionally distinct forms of the CD94 NK cell receptor. Pérez–Villar JJ, et al. **J Immunol** 1996 Dec 15; 157(12):5367–74

Activation of human T cell lymphotropic virus type I–infected T cells is independent of B7 costimulation. Scholz C, et al. **J Immunol** 1996 Oct 1;157(7):2932–8

TNF receptor p55 controls early acute graft–versus–host disease. Speiser DE, et al. **J Immunol** 1997 Jun 1; 158(11):5185–90

B7–2 requirement for helminth–induced granuloma formation and CD4 type 2 T helper cell cytokine expression. Subramanian G, et al. **J Immunol** 1997 Jun 15; 158(12):5914–20

Integrin–associated protein (CD47) is a comitogenic molecule on CD3–activated human T cells. Ticchioni M, et al. **J Immunol** 1997 Jan 15;158(2):677–84

An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding: a model for unidirectional alloimmune responses. Wu S, et al. **J Immunol** 1997 Apr 1;158(7):3221–6

Blockade of CD86 ameliorates Leishmania major infection by down–regulating the Th2 response. Brown JA, et al. **J Infect Dis** 1996 Dec;174(6):1303–8

Expression and function of the early activation antigen CD69 in murine macrophages. Marzio R, et al. **J Leukoc Biol** 1997 Sep;62(3):349–55

IL–6 cytokine family and signal transduction: a model of the cytokine system. Hibi M, et al. **J Mol Med** 1996 Jan; 74(1):1–12 (168 ref.)

Antibody cross–reactivity with CD46 and lack of cell surface expression suggest that moesin might not mediate measles virus binding [published erratum appears in J Virol 1997 May;71(5):4186] Devaux P, et al. **J Virol** 1997 Feb; 71(2):1679–82

CD9, a tetraspan transmembrane protein, renders cells susceptible to canine distemper virus. Löffler S, et al. **J Virol** 1997 Jan;71(1):42–9

Identification of a cytoplasmic Tyr–X–X–Leu motif essential for down regulation of the human cell receptor CD46 in persistent measles virus infection. Yant S, et al. **J Virol** 1997 Jan;71(1):766–70

Autologous transplantation with CD52 monoclonal antibody–purged marrow for acute lymphoblastic leukemia: long–term follow–up. Mehta J, et al. **Leuk Lymphoma** 1997 May;25(5–6):479–86

Involvement of two types of TNF receptor in TNF–alpha induced neutrophil apoptosis. Gon S, et al. **Microbiol Immunol** 1996;40(6):463–5

Carcinoembryonic antigens (CD66) on epithelial cells and neutrophils are receptors for Opa proteins of pathogenic neisseriae. Virji M, et al. **Mol Microbiol** 1996 Dec; 22(5):941–50

The N–domain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria meningitidis and Neisseria gonorrhoeae. Virji M, et al. **Mol Microbiol** 1996 Dec;22(5):929–39

Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. Reiser H, et al. **N Engl J Med** 1996 Oct 31;335(18):1369–77 (69 ref.)

GPIIIa–(49–66) is a major pathophysiologically relevant antigenic determinant for anti–platelet GPIIIa of HIV–1–related immunologic thrombocytopenia. Nardi MA, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8; 94(14):7589–94

The epitopes for natural polyreactive antibodies are rich in proline. Tchernychev B, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6335–9

Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Tyagi S, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14714–9

'Knobs–into–holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Ridgway JB, et al. **Protein Eng** 1996 Jul;9(7):617–21

The effect of intravenous cyclophosphamide pulse on peripheral blood lymphocytes in lupus erythematosus patients. Lacki JK, et al. **Rheumatol Int** 1997;17(2):55–60

Unresponsiveness of CD4+ T cells from a non–responder strain to HgCl2 is not due to CD8(+)–mediated immunosuppression: an analysis of the very early activation antigen CD69. Jiang Y, et al. **Scand J Immunol** 1996 Dec; 44(6):565–70

Decreased resistance to bacterial infection and granulocyte defects in IAP–deficient mice. Lindberg FP, et al. **Science** 1996 Nov 1;274(5288):795–8

Hyperresponsive B cells in CD22–deficient mice. O'Keefe TL, et al. **Science** 1996 Nov 1;274(5288):798–801

The activation of human platelets mediated by two monoclonal antibodies raised against CD9. Peng L, et al. **Thromb Res** 1997 Jul 1;87(1):65–73

A functional monoclonal antibody recognizing the human alpha 1–integrin I–domain. Fabbri M, et al. **Tissue Antigens** 1996 Jul;48(1):47–51

Characterization of the porcine homologue to human platelet glycoprotein IIb–IIIa (CD41/CD61) by a monoclonal antibody. Pérez de la Lastra JM, et al. **Tissue Antigens** 1997 Jun;49(6):588–94

Safety and kinetic properties of a humanized antibody to human interleukin–6 receptor in healthy non–human primates. Shinkura H, et al. **Toxicology** 1997 Oct 19; 122(3):163–70

Flow cytometry and immunoblotting analysis of monoclonal antibodies directed to CD–related antigens. Blanchard D, et al. **Transfus Clin Biol** 1997;4(1):153–6

Summary of serological test results on the monoclonal antibodies to non–specific erythrocytes antigens. Lukasavage T, et al. **Transfus Clin Biol** 1997;4(1):147–8

Studies on section 2D3 monoclonal antibodies. Smart EA, et al. **Transfus Clin Biol** 1997;4(1):143–5

Human CD46 but not CD59 in transgenic mice protects against hyperacute rejection evoked by ex vivo perfusion with human serum. Marquet RL, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):931–2

Prevention of primary T–cell responses by immunotoxins directed against CD80 and CD86. Otten HG, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1034–5

In vitro system for evaluation of the immunomodulatory capacity of CD45(R) reagents. Poppema S, et al. **Transplant Proc** 1996 Dec;28(6):3263–4

Inhibitory CD94 molecules identified by the Z199 monoclonal antibody recognize different HLA–class I molecules. Sivori S, et al. **Transplant Proc** 1996 Dec; 28(6):3199–203

Costimulatory molecule–deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86–) prolong cardiac allograft survival in nonimmunosuppressed recipients. Fu F, et al. **Transplantation** 1996 Sep 15;62(5):659–65

Post–OKT3 induction therapy CD complex response predicts renal allograft rejection. Stephan RN, et al. **Transplantation** 1997 Apr 27;63(8):1183–6

Platelet activation studies with anti–CD41/61 monoclonal antibodies. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):357–62

Ruminant cluster CD41/CD61. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):251–3

Ruminant cluster CD71. Naessens J, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):257–8

The Second International Swine CD Workshop. Saalmüller A, et al. **Vet Immunol Immunopathol** 1996 Nov; 54(1–4):155–8

Cross–reactivity of monoclonal antibodies to defined human leucocyte differentiation antigens with bovine cells. Sopp P, et al. **Vet Immunol Immunopathol** 1997 May; 56(1–2):11–25

T cell hyperreactivity to IL–6 in chronic nonviremic HBV carriers despite normal IL–6 receptor or gp130 expression. Baroja ML, et al. **Viral Immunol** 1996;9(3):187–94

[Current therapy of multiple sclerosis. Therapy with monoclonal antibodies to T–cell antigens (CD3, CD4, CD52)] Schmidt S, et al. **Nervenarzt** 1996 Feb;67(2):170–6 (44 ref.) (Eng. Abstr.) **(Ger)**

[Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL–4 receptor] Knöchel B, et al. **Pneumologie** 1996 Aug;50(8):569–70 **(Ger)**

[Clinical application of interleukin–6 receptor antibody] Nishimoto N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Apr;20(2):87–94 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of humanized anti–interleukin–6 receptor antibody on new xenograft model of multiple myeloma] Shimazaki C, et al. **Rinsho Ketsueki** 1997 Apr;38(4):281–4 **(Jpn)**

ISOLATION & PURIFICATION

Differential expression of CD66a (BGP), a cell adhesion molecule of the carcinoembryonic antigen family, in benign, premalignant, and malignant lesions of the human mammary gland. Riethdorf L, et al. **J Histochem Cytochem** 1997 Jul;45(7):957–63

Purification and characterization of the pig analogue of human membrane cofactor protein (CD46/MCP). van den Berg CW, et al. **J Immunol** 1997 Feb 15;158(4):1703–9

METABOLISM

Expression of interleukin–8 receptors in the gestational tissues before and after initiation of labor: immunohistochemical study. el Maradny E, et al. **Acta Obstet Gynecol Scand** 1996 Oct;75(9):790–6

The alpha 7 integrin as a target protein for cell surface mono–ADP–ribosylation in muscle cells. Zolkiewska A, et al. **Adv Exp Med Biol** 1997;419:297–303

Tumor necrosis factor receptor p55 mediates induction of HIV type 1 expression in chronically infected U1 cells. Edfjäll C, et al. **AIDS Res Hum Retroviruses** 1996 Feb 10;12(3):199–204

Lesional psoriatic T cells contain the capacity to induce a T cell activation molecule CDw60 on normal keratinocytes. Skov L, et al. **Am J Pathol** 1997 Feb; 150(2):675–83

The expression of VLA integrins in the human tonsilla palatina. Karaöz E, et al. **Anat Anz** 1997 Apr;179(2):149–56

Human complement regulator expression by the normal female reproductive tract. Oglesby TJ, et al. **Anat Rec** 1996 Sep;246(1):78–86

Interleukin–6 receptor expression in the peripheral B cells of patients with multicentric Castleman's disease. Ishiyama T, et al. **Ann Hematol** 1996 Oct;73(4):179–82

The signal transducer gp130 is shared by interleukin–6 family of haematopoietic and neurotrophic cytokines. Taga T. **Ann Med** 1997 Feb;29(1):63–72 (88 ref.)

Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Lane P. **Ann N Y Acad Sci** 1997 Apr 5;815:392–400 (40 ref.)

CD22, a B lymphocyte–specific adhesion molecule that regulates antigen receptor signaling. Tedder TF, et al. **Annu Rev Immunol** 1997;15:481–504 (98 ref.)

Increased release of the tumour necrosis factor receptor p75 by immortalized human keratinocytes results from an activated shedding mechanism and is not related to augmented steady–state levels of p75 mRNA. Neuner P, et al. **Arch Dermatol Res** 1996 Oct;288(11):691–6

Soluble TNF alpha receptors are increased in chronic renal insufficiency and hemodialysis and inhibit neutrophil priming by TNF alpha. Ward R, et al. **Artif Organs** 1996 May;20(5):390–5

Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. de Boer OJ, et al. **Atherosclerosis** 1997 Sep;133(2):227–34

A 70–kDa protein facilitates interleukin–4 signal transduction in the absence of the common gamma receptor chain. Dawson CH, et al. **Biochem Biophys Res Commun** 1997 Apr 7;233(1):279–82

Mapping of the extracellular binding regions of the human interleukin–8 type B receptor. Katancik JA, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):663–8

Mouse CD24 as a signaling molecule for integrin–mediated cell binding: functional and physical association with src–kinases. Sammar M, et al. **Biochem Biophys Res Commun** 1997 May 19;234(2):330–4

Transmembrane domain mutations influence the cellular distribution of lysosomal membrane glycoprotein A. Wimer–Mackin S, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):472–8

Expression of the surface antigen 4F2hc affects system–L–like neutral–amino–acid–transport activity in mammalian cells. Bröer S, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):535–41

Identification of the cleavage sites in the alpha6A integrin subunit: structural requirements for cleavage and functional analysis of the uncleaved alpha6Abeta1 integrin. Delwel GO, et al. **Biochem J** 1997 May 15;324 (Pt 1):263–72

Phorbol esters modulate the coupling of the T cell costimulatory molecule CD28 to phosphatidylinositol 3–kinase. Parry RV, et al. **Biochem Soc Trans** 1997 May;

25(2):305S
Probing the Fc alpha R binding site on IgA by mutagenesis of the IgA Fc region. Pleass RJ, et al. **Biochem Soc Trans** 1997 May;25(2):328S
Identification of residues in CD6 which are critical for ligand binding. Bodian DL, et al. **Biochemistry** 1997 Mar 4; 36(9):2637–41
Changes in the NMR–derived motional parameters of the insulin receptor substrate 1 phosphotyrosine binding domain upon binding to an interleukin 4 receptor phosphopeptide. Olejniczak ET, et al. **Biochemistry** 1997 Apr 8;36(14):4118–24
Mutational analysis of the CD6 binding site in activated leukocyte cell adhesion molecule. Skonier JE, et al. **Biochemistry** 1996 Nov 26;35(47):14743–8
Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receptor binding site in the human CD6 ligand ALCAM. Skonier JE, et al. **Biochemistry** 1996 Sep 24;35(38):12287–91
Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties. Wuyts A, et al. **Biochemistry** 1997 Mar 4;36(9):2716–23
Influence of tyrosine phosphorylation on protein interaction with FcgammaRIIa. Ibarrola I, et al. **Biochim Biophys Acta** 1997 Jul 24;1357(3):348–58
Heat–stable antigen (mouse CD24) in the brain: dual but distinct interaction with P–selectin and L1. Sammar M, et al. **Biochim Biophys Acta** 1997 Feb 8;1337(2):287–94
Cultured human decidual stromal cells express B7–1 (CD80) and B7–2 (CD86) and stimulate allogeneic T cells. Olivares EG, et al. **Biol Reprod** 1997 Sep;57(3):609–15
CD24, a mucin–type glycoprotein, is a ligand for P–selectin on human tumor cells. Aigner S, et al. **Blood** 1997 May 1;89(9):3385–95
Evidence for the participation of interleukin–2 (IL–2) and IL–4 in the regulation of autonomous growth and tumorigenesis of transformed cells of lymphoid origin. Hassuneh MR, et al. **Blood** 1997 Jan 15;89(2):610–20
Interleukin–4 induces association of the c–fes proto–oncogene product with phosphatidylinositol–3 kinase. Izuhara K, et al. **Blood** 1996 Nov 15;88(10):3910–8
Disruption of a long–range disulfide bond between residues Cys406 and Cys655 in glycoprotein IIIa does not affect the function of platelet glycoprotein IIb–IIIa [letter] Wang R, et al. **Blood** 1997 Aug 15;90(4):1718–9
Correlation of GP53 and P–selectin expression in myeloproliferative disorders and normal controls. Cahill MR, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):169–71
Soluble IL–6 receptors (sIL–6R) in hematological patients receiving immunotherapy with IL–2/IFN–alpha or donor lymphocytes following bone marrow transplantation. Toren A, et al. **Bone Marrow Transplant** 1996 Oct; 18(4):721–4
Interferon–gamma differentially regulates CD80 (B7–1) and CD86 (B7–2/B70) expression on human Langerhans cells. Yokozeki H, et al. **Br J Dermatol** 1997 Jun;136(6):831–7
In–vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta–thalassaemia major. Ruf A, et al. **Br J Haematol** 1997 Jul;98(1):51–6
Analysis of CD9, CD32 and p67 signalling: use of degranulated platelets indicates direct involvement of CD9 and p67 in integrin activation. Slupsky JR, et al. **Br J Haematol** 1997 Feb;96(2):275–86
Absence of IL–6 receptor expression in fresh childhood Burkitt's lymphoma cells and induction of IL–6 receptors by Epstein–Barr virus in vitro. Tomeczkowski J, et al. **Br J Haematol** 1997 May;97(2):400–8
Coadministration of interleukin–6 (IL–6) and soluble IL–6 receptor delays progression of wobbler mouse motor neuron disease. Ikeda K, et al. **Brain Res** 1996 Jul 8; 726(1–2):91–7
The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: its regulation by interferon gamma and interleukin–10. Li J, et al. **Cancer Immunol Immunother** 1996 Dec;43(4):213–9
Differential display cloning identifies motility–related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cajot JF, et al. **Cancer Res** 1997 Jul 1;57(13):2593–7
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule–1 expression in cutaneous malignant melanoma lesions. Natali PG, et al. **Cancer Res** 1997 Apr 15;57(8):1554–60
Expression of CD66a (human C–CAM) and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas. Nollau P, et al. **Cancer Res** 1997 Jun 15;57(12):2354–7
Urokinase–type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Xue W, et al. **Cancer Res** 1997 May 1;57(9):1682–9
FAN, a novel WD–repeat protein, couples the p55 TNF–receptor to neutral sphingomyelinase. Adam–Klages S, et al. **Cell** 1996 Sep 20;86(6):937–47
The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Wary KK, et al. **Cell** 1996 Nov 15;87(4):733–43
Functional significance of CD9 association with beta 1 integrins in human epidermal keratinocytes. Jones PH, et al. **Cell Adhes Commun** 1996 Nov;4(4–5):297–305
Alpha 2 beta 1 integrin is required for the collagen and FGF–1 induced cell dispersion in a rat bladder carcinoma cell line. Vallés AM, et al. **Cell Adhes Commun** 1996 Sep; 4(3):187–99
Heterologous expression of alpha 1–integrin cDNA generates variable ligand specificities and alterations in cell shape. Wong LD, et al. **Cell Adhes Commun** 1996 Sep;4(3):201–21
Resistance to interleukin 6 in human non–small cell lung carcinoma cell lines: role of receptor components. Ganapathi MK, et al. **Cell Growth Differ** 1996 Jul; 7(7):923–9
Laminin–5 and modulation of keratin cytoskeleton arrangement in FG pancreatic carcinoma cells: involvement of IFAP300 and evidence that laminin–5/cell interactions correlate with a dephosphorylation of alpha 6A integrin. Baker SE, et al. **Cell Motil Cytoskeleton** 1997; 37(3):271–86
CD69 expression reliably predicts the anti–CD3–induced proliferative response of lymphocytes from human immunodeficiency virus type 1–infected patients. Prince HE, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):217–22
Differential expression of platelet activation markers in aspirin–sensitive asthmatics and normal subjects. Taylor ML, et al. **Clin Exp Allergy** 1996 Feb;26(2):202–15
Usefulness of flow cytometric detection of cell surface interleukin–6 receptors in human myeloma cell lines. Chen YH, et al. **Clin Lab Haematol** 1996 Sep;18(3):161–9
IL–8 and NAP–2 differ in their capacities to bind and chemoattract 293 cells transfected with either IL–8 receptor type A or type B. Ben–Baruch A, et al. **Cytokine** 1997 Jan;9(1):37–45
Long–term protection against the effects of tumour necrosis factor by controlled delivery of the soluble p55 TNF receptor. Eliaz R, et al. **Cytokine** 1996 Jun;8(6):482–7
IL–6 and soluble IL–6 receptor levels change differently after surgery both in the blood and in the operative field. Hisano S, et al. **Cytokine** 1997 Jun;9(6):447–52
Specific inhibition of IL–6 signalling with monoclonal antibodies against the gp130 receptor. Liautard J, et al. **Cytokine** 1997 Apr;9(4):233–41
Receptor–mediated endocytosis of IL–8: a fluorescent microscopic evidence and implication of the process in ligand–induced biological response in human neutrophils. Ray E, et al. **Cytokine** 1997 Aug;9(8):587–96
Differential expression of alpha–6 and other subunits of laminin binding integrins during development of the murine heart. Hierck BP, et al. **Dev Dyn** 1996 May;206(1):100–11
Distinct alpha 7A beta 1 and alpha 7B beta 1 integrin expression patterns during mouse development: alpha 7A is restricted to skeletal muscle but alpha 7B is expressed in striated muscle, vasculature, and nervous system. Velling T, et al. **Dev Dyn** 1996 Dec;207(4):355–71
Fine–needle aspirates of granular cell lesions of the breast: report of three cases, with emphasis on differential diagnosis and utility of immunostaining for CD68 (KP1). Sirgi KE, et al. **Diagn Cytopathol** 1996 Dec;15(5):403–8
The lysosomal–associated membrane protein LAMP–1 is a novel differentiation marker for HC11 mouse mammary epithelial cells. Cella N, et al. **Differentiation** 1996 Dec; 61(2):113–20
CD66 carcinoembryonic antigens mediate interactions between Opa–expressing Neisseria gonorrhoeae and human polymorphonuclear phagocytes. Gray–Owen SD, et al. **EMBO J** 1997 Jun;16(12):3435–45
The tyrosine–based lysosomal targeting signal in lamp–1 mediates sorting into Golgi–derived clathrin–coated vesicles. Höning S, et al. **EMBO J** 1996 Oct 1;15(19):5230–9
Interleukin–4–specific signal transduction events are driven by homotypic interactions of the interleukin–4 receptor alpha subunit. Lai SY, et al. **EMBO J** 1996 Sep 2; 15(17):4506–14
Tumor necrosis factor alpha–induced activation of c–jun N–terminal kinase is mediated by TRAF2. Reinhard C, et al. **EMBO J** 1997 Mar 3;16(5):1080–92
Diphtheria toxin–based receptor–specific chimaeric toxins as targeted therapies. Sweeney EB, et al. **Essays Biochem** 1995;30:119–31 (23 ref.)
Production of prostaglandin E2 and collagenase is inhibited by the recombinant soluble tumour necrosis factor receptor p55–human gamma 3 fusion protein at concentrations a hundred–fold lower than those decreasing T cell activation. Nicod LP, et al. **Eur Cytokine Netw** 1996 Dec;7(4):757–63
Global and local determinants for the kinetics of interleukin–4/interleukin–4 receptor alpha chain interaction. A biosensor study employing recombinant interleukin–4–binding protein. Shen BJ, et al. **Eur J Biochem** 1996 Aug 15;240(1):252–61
The platelet antigens CD9, CD42 and integrin alpha IIb beta IIIa can be topographically associated and transduce functionally similar signals. Slupsky JR, et al. **Eur J Biochem** 1997 Feb 15;244(1):168–75
The A–domain of integrin alpha 2 binds specifically to a range of collagens but is not a general receptor for the collagenous motif. Tuckwell DS, et al. **Eur J Biochem** 1996 Nov 1;241(3):732–9
Cardiopulmonary bypass leads to a preferential loss of activated platelets. A flow cytometric assay of platelet surface antigens. Wahba A, et al. **Eur J Cardiothorac Surg** 1996;10(9):768–73
Distribution of lymphocyte subsets in bone marrow and peripheral blood is associated with haptoglobin type. Binding of haptoglobin to the B–cell lectin CD22. Langlois M, et al. **Eur J Clin Chem Clin Biochem** 1997 Mar; 35(3):199–205
The C terminus of the human C5a receptor (CD88) is required for normal ligand–dependent receptor internalization. Bock D, et al. **Eur J Immunol** 1997 Jun; 27(6):1522–9
Characterization of mouse ALCAM (CD166): the CD6–binding domain is conserved in different homologs and mediates cross–species binding. Bowen MA, et al. **Eur J Immunol** 1997 Jun;27(6):1469–78
The CD94 and NKG2–A C–type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Carretero M, et al. **Eur J Immunol** 1997 Feb;27(2):563–7
A transgenic T cell receptor restores thymocyte differentiation in interleukin–7 receptor alpha chain–deficient mice. Crompton T, et al. **Eur J Immunol** 1997 Jan;27(1):100–4
L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to alpha v beta 3 integrin. Ebeling O, et al. **Eur J Immunol** 1996 Oct;26(10):2508–16
Cytotoxic T lymphocytes express a beta3 integrin which can induce the phosphorylation of focal adhesion kinase and the related PYK–2. Ma EA, et al. **Eur J Immunol** 1997 Jan;27(1):329–35
HLA–G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex. Pende D, et al. **Eur J Immunol** 1997 Aug;27(8):1875–80
CD9, but not other tetraspans, associates with the beta1 integrin precursor. Rubinstein E, et al. **Eur J Immunol** 1997 Aug;27(8):1919–27
Human T lymphocytes bind to germinal centers of human tonsils via integrin alpha4/VCAM–1 and LFA–1/ICAM–1 and –2. Schriever F, et al. **Eur J Immunol** 1997 Jan; 27(1):35–9
Chemoattractant receptors for interleukin–8 and C5a: expression on peripheral blood leukocytes and differential regulation on HL–60 and AML–193 cells by vitamin D3 and all–trans retinoic acid. Zahn S, et al. **Eur J Immunol** 1997 Apr;27(4):935–40
Identification of G–protein binding sites of the human interleukin–8 receptors by functional mapping of the intracellular loops. Damaj BB, et al. **FASEB J** 1996 Oct; 10(12):1426–34
Inhibition of protein tyrosine phosphatases causes phosphorylation of tyrosine–331 in the p60 TNF receptor and inactivates the receptor–associated kinase. Darnay BG, et al. **FEBS Lett** 1997 Jun 30;410(2–3):361–7
The p80 TNF receptor–associated kinase (p80TRAK) associates with residues 354–397 of the p80 cytoplasmic domain: similarity to casein kinase. Darnay BG, et al. **FEBS Lett** 1997 Apr 7;406(1–2):101–5
A complex of the soluble interleukin–6 receptor and interleukin–6 is internalized via the signal transducer gp130. Graeve L, et al. **FEBS Lett** 1996 Dec 9;399(1–2):131–4
The lysosomal/phagosomal membrane protein h–lamp–1 is a target of the IgA1 protease of Neisseria gonorrhoeae. Hauck CR, et al. **FEBS Lett** 1997 Mar 17;405(1):86–90
Vav is associated with signal transducing molecules gp130, Grb2 and Erk2, and is tyrosine phosphorylated in response to interleukin–6. Lee IS, et al. **FEBS Lett** 1997 Jan 20; 401(2–3):133–7
Association of phosphatidylinositol 3–kinase with the proto–oncogene product Cbl upon CD38 ligation by a specific monoclonal antibody in THP–1 cells. Matsuo T, et al. **FEBS Lett** 1996 Nov 11;397(1):113–6
Leptin receptor (OB–R) oligomerizes with itself but not with its closely related cytokine signal transducer gp130. Nakashima K, et al. **FEBS Lett** 1997 Feb 10;403(1):79–82
Overlapping and distinct signals through leptin receptor (OB–R) and a closely related cytokine signal transducer, gp130. Nakashima K, et al. **FEBS Lett** 1997 Jan 13; 401(1):49–52
The dependence of the association rate of surface–attached adhesion molecules CD2 and CD48 on separation distance. Pierres A, et al. **FEBS Lett** 1997 Feb 24;403(3):239–44
IL4 and IL13 receptors share the gamma c chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells. Rolling C, et al. **FEBS Lett** 1996 Sep 9;393(1):53–6
A selection system to study C5a–C5a–receptor interactions: phage display of a novel C5a anaphylatoxin, Fos–C5aAla27. Hennecke M, et al. **Gene** 1997 Jan 15; 184(2):263–72
Beta 4 integrin and other Schwann cell markers in axonal neuropathy. Quattrini A, et al. **Glia** 1996 Aug;17(4):294–306
Cell types of secondary cataract: an immunohistochemical analysis with antibodies to cytoskeletal elements and macrophages. Uusitalo M, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Aug;235(8):506–11
Intestinal intraepithelial lymphocytes have a promiscuous interleukin–8 receptor. Roberts AI, et al. **Gut** 1997 Mar; 40(3):333–8
Fc gammaRIIB1 inhibition of BCR–mediated phosphoinositide hydrolysis and Ca2+ mobilization is integrated by CD19 dephosphorylation. Hippen KL, et al. **Immunity** 1997 Jul;7(1):49–58
CD94 and a novel associated protein (94AP) form a NK cell receptor involved in the recognition of HLA–A, HLA–B, and HLA–C allotypes. Phillips JH, et al. **Immunity** 1996 Aug;5(2):163–72
CD22 is both a positive and negative regulator of B

lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Sato S, et al. **Immunity** 1996 Dec;5(6):551-62

Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin. Tooze RM, et al. **Immunity** 1997 Jul;7(1):59-67

Association of human NK cell surface receptors NKR-P1 and CD94 with Src-family protein kinases. Černý J, et al. **Immunogenetics** 1997;46(3):231-6

CD148, a membrane protein tyrosine phosphatase, is able to induce tyrosine phosphorylation on human lymphocytes. Palou E, et al. **Immunol Lett** 1997 Jun 1;57(1-3):101-3

Fc gamma receptor type IIb induced recruitment of inositol and protein phosphatases to the signal transductory complex of human B-cell. Sarmay G, et al. **Immunol Lett** 1997 Jun 1;57(1-3):159-64

The CD94/NKG2 C-type lectin receptor complex: involvement in NK cell-mediated recognition of HLA class I molecules. López-Botet M, et al. **Immunol Res** 1997; 16(2):175-85 (50 ref.)

The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Boussiotis VA, et al. **Immunol Rev** 1996 Oct;153:5-26 (170 ref.)

Regulation of signalling through B-lymphocyte antigen receptors by cell-cell interaction molecules. Law CL, et al. **Immunol Rev** 1996 Oct;153:123-54 (200 ref.)

The complexities of T-cell co-stimulation: CD28 and beyond. Sperling AI, et al. **Immunol Rev** 1996 Oct; 153:155-82 (100 ref.)

Immune defence in mice lacking type I and/or type II interferon receptors. van den Broek MF, et al. **Immunol Rev** 1995 Dec;148:5-18 (61 ref.)

CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Van Gool SW, et al. **Immunol Rev** 1996 Oct;153:47-83 (150 ref.)

The structure and ligand interactions of CD2: implications for T-cell function. Davis SJ, et al. **Immunol Today** 1996 Apr;17(4):177-87 (115 ref.)

Identification of a novel antigenic structure of the human receptor for interleukin-6 involved in the interaction with the glycoprotein 130 chain. Gaillard JP, et al. **Immunology** 1996 Sep;89(1):135-41

Expression and modulation of C5a receptor (CD88) on skin dendritic cells. Chemotactic effect of C5a on skin migratory dendritic cells. Morelli A, et al. **Immunology** 1996 Sep; 89(1):126-34

Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin. Benoit NE, et al. **Immunopharmacology** 1996 Nov;35(2):129-39

Interleukin 6 receptors on human outer root sheath cells and interfollicular epidermal keratinocytes in vitro: density-induced down regulation (DIDR) of receptors [letter] Waelti ER, et al. **In Vitro Cell Dev Biol Anim** 1996 May;32(5):255-8

Dipeptidyl-peptidase IV secreted by Aspergillus fumigatus, a fungus pathogenic to humans. Beauvais A, et al. **Infect Immun** 1997 Aug;65(8):3042-7

Adhesion molecules in atopic dermatitis: upregulation of alpha6 integrin expression in spontaneous lesional skin as well as in atopen, antigen and irritative induced patch test reactions. Jung K, et al. **Int Arch Allergy Immunol** 1997 Aug;113(4):495-504

gp 120s derived from four syncytium-inducing HIV-1 strains induce different patterns of CD4 association with lymphocyte surface molecules. Feito MJ, et al. **Int Immunol** 1997 Aug;9(8):1141-7

IL-4 receptor complexes containing or lacking the gamma C chain are inhibited by an overlapping set of antagonistic IL-4 mutant proteins. Schnarr B, et al. **Int Immunol** 1997 Jun;9(6):861-8

The anti-Fc gamma RIII mAb 3G8 induces neutrophil activation via a cooperative actin of Fc gamma RIIIb and Fc gamma RIIa. Vossebeld PJ, et al. **Int J Biochem Cell Biol** 1997 Mar;29(3):465-73

Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Higashiyama M, et al. **Int J Cancer** 1997 Apr 22;74(2):205-11

Stimulation of glioma-cell migration by laminin and inhibition by anti-alpha3 and anti-beta1 integrin antibodies. Tysnes BB, et al. **Int J Cancer** 1996 Sep 17;67(6):777-84

Functional characteristics of cord blood T lymphocytes after lectin and anti-CD3 stimulation. Differences in the way T cells express activation molecules and proliferate. Lucivero G, et al. **Int J Clin Lab Res** 1996;26(4):255-61

Design and evaluation of small peptides mapping the exposed surface of IL-8. Thompson SK, et al. **Int J Pept Protein Res** 1996 Mar;47(3):214-8

Localization of tumor necrosis factor receptor messenger RNA in normal and herpes simplex virus-infected mouse eyes. Cunningham ET Jr, et al. **Invest Ophthalmol Vis Sci** 1997 Jan;38(1):9-15

VCAM-1/alpha 4-integrin adhesion pathway: therapeutic target for allergic inflammatory disorders. Foster CA. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S270-7 (86 ref.)

Regulation of alpha 4 integrin-mediated adhesion of human eosinophils to fibronectin and vascular cell adhesion molecule-1. Matsumoto K, et al. **J Allergy Clin Immunol** 1997 May;99(5):648-56

Comparative flow cytometric analysis of the human sperm acrosome reaction using CD46 antibody and lectins. Carver-Ward JA, et al. **J Assist Reprod Genet** 1997 Feb; 14(2):111-9

Potentiation of chemotactic peptide-induced superoxide generation by CD38 ligation in human myeloid cell lines. Tsujimoto N, et al. **J Biochem (Tokyo)** 1997 May; 121(5):949-56

Fibroblasts spread on immobilized fibrin monomer by mobilizing a beta1-class integrin, together with a vitronectin receptor alphavbeta3 on their surface. Asakura S, et al. **J Biol Chem** 1997 Mar 28;272(13):8824-9

A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. Berditchevski F, et al. **J Biol Chem** 1997 Jan 31; 272(5):2595-8

Inducible tyrosine phosphorylation of the beta3 integrin requires the alphaV integrin cytoplasmic tail. Blystone SD, et al. **J Biol Chem** 1996 Dec 6;271(49):31458-62

The integrin alpha1 A-domain is a ligand binding site for collagens and laminin. Calderwood DA, et al. **J Biol Chem** 1997 May 9;272(19):12311-7

A novel interaction between the juxtamembrane region of the p55 tumor necrosis factor receptor and phosphatidylinositol-4-phosphate 5-kinase. Castellino AM, et al. **J Biol Chem** 1997 Feb 28;272(9):5861-70

Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. Debinski W, et al. **J Biol Chem** 1996 Sep 13; 271(37):22428-33

Agonistic and antagonistic variants of ciliary neurotrophic factor (CNTF) reveal functional differences between membrane-bound and soluble CNTF alpha-receptor. Di Marco A, et al. **J Biol Chem** 1997 Sep 12;272(37):23069-75

Stimulation of platelet activation and aggregation by a carboxyl-terminal peptide from thrombospondin binding to the integrin-associated protein receptor. Dorahy DJ, et al. **J Biol Chem** 1997 Jan 10;272(2):1323-30

A conserved sequence motif in the integrin beta3 cytoplasmic domain is required for its specific interaction with beta3-endonexin. Eigenthaler M, et al. **J Biol Chem** 1997 Mar 21;272(12):7693-8

Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways. Ernst M, et al. **J Biol Chem** 1996 Nov 22;271(47):30136-43

Exon 6 is essential for invariant chain trimerization and induction of large endosomal structures. Gedde-Dahl M, et al. **J Biol Chem** 1997 Mar 28;272(13):8281-7

Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. Greene JL, et al. **J Biol Chem** 1996 Oct 25;271(43):26762-71

Binding of the cytoplasmic domain of intercellular adhesion molecule-2 (ICAM-2) to alpha-actinin. Heiska L, et al. **J Biol Chem** 1996 Oct 18;271(42):26214-9

Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6).IL-6 receptor.gp130 complex. Horsten U, et al. **J Biol Chem** 1997 Sep 19;272(38):23748-57

A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. Hu S, et al. **J Biol Chem** 1997 Apr 11;272(15):9621-4

Molecular determinants of arg-gly-asp ligand specificity for beta3 integrins. Kunicki TJ, et al. **J Biol Chem** 1997 Feb 14;272(7):4103-7

Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6. Kuropatwinski KK, et al. **J Biol Chem** 1997 Jun 13;272(24):15135-44

Identification of a region in the integrin beta3 subunit that confers ligand binding specificity. Lin EC, et al. **J Biol Chem** 1997 Sep 19;272(38):23912-20

Tumor necrosis factor alpha enhances the expression of the interleukin (IL)-4 receptor alpha-chain on endothelial cells increasing IL-4 or IL-13-induced Stat6 activation. Lugli SM, et al. **J Biol Chem** 1997 Feb 28;272(9):5487-94

Membrane cofactor protein (CD46) is a basolateral protein that is not endocytosed. Importance of the tetrapeptide FTSL at the carboxyl terminus. Maisner A, et al. **J Biol Chem** 1997 Aug 15;272(33):20793-9

Protein-tyrosine phosphatase SHP-1 is dispensable for FcgammaRIIB-mediated inhibition of B cell antigen receptor activation. Nadler MJS, et al. **J Biol Chem** 1997 Aug 8;272(32):20038-43

Alpha4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity. Newham P, et al. **J Biol Chem** 1997 Aug 1; 272(31):19429-40

Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells. Pinckard JK, et al. **J Biol Chem** 1997 Apr 18;272(16):10784-9

Signaling of the cardiotrophin-1 receptor. Evidence for a third receptor component. Robledo O, et al. **J Biol Chem** 1997 Feb 21;272(8):4855-63

MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase. Schievella AR, et al. **J Biol Chem** 1997 May 2;272(18):12069-75

Distinct roles for leukemia inhibitory factor receptor alpha-chain and gp130 in cell type-specific signal transduction. Starr R, et al. **J Biol Chem** 1997 Aug 8; 272(32):19982-6

The role of conserved amino acid motifs within the integrin beta3 cytoplasmic domain in triggering focal adhesion kinase phosphorylation. Tahiliani PD, et al. **J Biol Chem** 1997 Mar 21;272(12):7892-8

Multiple dimeric forms of human CD69 result from differential addition of N-glycans to typical (Asn-X-Ser/Thr) and atypical (Asn-X-cys) glycosylation motifs. Vance BA, et al. **J Biol Chem** 1997 Sep 12; 272(37):23117-22

HMG-I(Y) phosphorylation status as a nuclear target regulated through insulin receptor substrate-1 and the I4R motif of the interleukin-4 receptor. Wang D, et al. **J Biol Chem** 1997 Oct 3;272(40):25083-90

Discrete steps in binding and signaling of interleukin-8 with its receptor. Wu L, et al. **J Biol Chem** 1996 Dec 6; 271(49):31202-9

Two basic amino acids in the second inner loop of the interleukin-8 receptor are essential for Galpha16 coupling. Xie W, et al. **J Biol Chem** 1997 Oct 3;272(40):24948-51

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. Kotake S, et al. **J Bone Miner Res** 1996 Jan;11(1):88-95

Non-RGD domains of osteopontin promote cell adhesion without involving alpha v integrins. Katagiri YU, et al. **J Cell Biochem** 1996 Jul;62(1):123-31

An intralysosomal hsp70 is required for a selective pathway of lysosomal protein degradation. Agarraberes FA, et al. **J Cell Biol** 1997 May 19;137(4):825-34

Affinity modulation of platelet integrin alphaIIbbeta3 by beta3-endonexin, a selective binding partner of the beta3 integrin cytoplasmic tail. Kashiwagi H, et al. **J Cell Biol** 1997 Jun 16;137(6):1433-43

Possible role of coexpression of CD9 with membrane-anchored heparin-binding EGF-like growth factor and amphiregulin in cultured human keratinocyte growth. Inui S, et al. **J Cell Physiol** 1997 Jun;171(3):291-8

Deficiency of the integrin beta 4 subunit in junctional epidermolysis bullosa with pyloric atresia: consequences for hemidesmosome formation and adhesion properties [published erratum appears in J Cell Sci 1996 Aug;109(Pt 8):preceding table of contents] Niessen CM, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1695-706

The effect of wortmannin on the localisation of lysosomal type I integral membrane glycoproteins suggests a role for phosphoinositide 3-kinase activity in regulating membrane traffic late in the endocytic pathway. Reaves BJ, et al. **J Cell Sci** 1996 Apr;109 (Pt 4):749-62

Leukosialin (CD43, sialophorin) redistribution in uropods of polarized neutrophils is induced by CD43 cross-linking by antibodies, by colchicine or by chemotactic peptides. Seveau S, et al. **J Cell Sci** 1997 Jul;110 (Pt 13):1465-75

Functional expression of the alpha 7 integrin receptor in differentiated smooth muscle cells. Yao CC, et al. **J Cell Sci** 1997 Jul;110 (Pt 13):1477-87

Laminins promote the locomotion of skeletal myoblasts via the alpha 7 integrin receptor. Yao CC, et al. **J Cell Sci** 1996 Dec;109 (Pt 13):3139-50

Lack of B7-1/BB1 and B7-2/B70 expression on thyrocytes of patients with Graves' disease. Delivery of costimulatory signals from bystander professional antigen-presenting cells. Matsuoka N, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4137-43

Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. Päth G, et al. **J Clin Endocrinol Metab** 1997 Jul; 82(7):2343-9

Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease [see comments] Salvi M, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2976-9. Comment in: J Clin Endocrinol Metab 1997 Apr;82(4):1307.

Embryonic regulation of integrins beta 3, alpha 4, and alpha 1 in human endometrial epithelial cells in vitro. Simón C, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2607-16

Shared gamma(c) subunit within the human interleukin-7 receptor complex. A molecular basis for the pathogenesis of X-linked severe combined immunodeficiency. Lai SY, et al. **J Clin Invest** 1997 Jan 15;99(2):169-77

Cytokine-dependent gp130 receptor subunit regulates human fetal pituitary adrenocorticotropin hormone and growth hormone secretion. Shimon I, et al. **J Clin Invest** 1997 Jul 15;100(2):357-63

NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. Brooks AG, et al. **J Exp Med** 1997 Feb 17;185(4):795-800

Involvement of Interleukin (IL) 8 receptor in negative regulation of myeloid progenitor cells in vivo: evidence from mice lacking the murine IL-8 receptor homologue. Broxmeyer HE, et al. **J Exp Med** 1996 Nov 1; 184(5):1825-32

Several carcinoembryonic antigens (CD66) serve as receptors for gonococcal opacity proteins. Chen T, et al. **J Exp Med** 1997 May 5;185(9):1557-64

The V-J recombination of T cell receptor-gamma genes is blocked in interleukin-7 receptor-deficient mice. Maki K, et al. **J Exp Med** 1996 Dec 1;184(6):2423-7

CD81 expressed on human thymocytes mediates integrin activation and interleukin 2-dependent proliferation. Todd

SC, et al. **J Exp Med** 1996 Nov 1;184(5):2055–60

Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD9, CD63, and alpha5beta1 integrin. Sincock PM, et al. **J Histochem Cytochem** 1997 Apr; 45(4):515–25

A Ca2+–dependent autoregulation of lipopolysaccharide–induced IL–8 receptor expression in human polymorphonuclear neutrophils. Bhattacharya C, et al. **J Immunol** 1997 Feb 1;158(3):1293–301

Differential regulation of the C3a and C5a receptors (CD88) by IFN–gamma and PMA in U937 cells and related myeloblastic cell lines. Burg M, et al. **J Immunol** 1996 Dec 15;157(12):5574–81

Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcription factor nuclear factor–kappa B and induces expression and synthesis of monocyte chemoattractant protein–1, IL–8, and IFN–inducible protein 10. Duque N, et al. **J Immunol** 1997 Oct 1;159(7):3474–82

A novel complex, p40/42, is constitutively associated with the B cell antigen receptor and phosphorylated upon receptor stimulation. Lee YJ, et al. **J Immunol** 1996 Nov 1;157(9):3828–37

Transmembrane–4 superfamily proteins CD81 (TAPA–1), CD82, CD63, and CD53 specifically associated with integrin alpha 4 beta 1 (CD49d/CD29). Mannion BA, et al. **J Immunol** 1996 Sep 1;157(5):2039–47

Enhancement of gp130–mediated tyrosine phosphorylation of STAT3 and its DNA–binding activity in dexamethasone–treated AIDS–associated Kaposi's sarcoma cells: selective synergy between dexamethasone and gp130–related growth factors in Kaposi's sarcoma cell proliferation. Murakami–Mori K, et al. **J Immunol** 1997 Jun 1;158(11):5518–26

Disregulated expression of CD43 (leukosialin, sialophorin) in the B cell lineage leads to immunodeficiency. Ostberg JR, et al. **J Immunol** 1996 Dec 1;157(11):4876–84

Inflammatory cytokines IFN–gamma plus TNF–alpha induce regulated expression of CD80 (B7–1) but not CD86 (B7–2) on murine fibroblasts. Pechhold K, et al. **J Immunol** 1997 May 15;158(10):4921–9

Chemoattractant cross–desensitization of the human neutrophil IL–8 receptor involves receptor internalization and differential receptor subtype regulation. Sabroe I, et al. **J Immunol** 1997 Feb 1;158(3):1361–9

Exacerbated viral hepatitis in IFN–gamma receptor–deficient mice is not suppressed by IL–12. Schijns VE, et al. **J Immunol** 1996 Jul 15;157(2):815–21

Intracellular CD22 rapidly moves to the cell surface in a tyrosine kinase–dependent manner following antigen receptor stimulation. Sherbina NV, et al. **J Immunol** 1996 Nov 15;157(10):4390–8

CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils. Skubitz KM, et al. **J Immunol** 1996 Oct 15; 157(8):3617–26

An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding: a model for unidirectional alloimmune responses. Wu S, et al. **J Immunol** 1997 Apr 1;158(7):3221–6

Cytokine priming reduces dependence on TNF–R2 for TNF–alpha–mediated induction of macrophage nitric oxide generation. Miller AR, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):1055–63

Expression of the human alpha2 integrin subunit in mouse melanoma cells confers the ability to undergo collagen–directed adhesion, migration and matrix reorganization. Schön M, et al. **J Invest Dermatol** 1996 Jun;106(6):1175–81

Inhibition and stimulation of LFA–1 and Mac–1 functions by antibodies against murine CD18. Evidence that the LFA–1 binding sites for ICAM–1, –2, and –3 are distinct. Driessens MH, et al. **J Leukoc Biol** 1996 Dec;60(6):758–65

Undifferentiated U937 cells transfected with chemoattractant receptors: a model system to investigate chemotactic mechanisms and receptor structure/function relationships. Kew RR, et al. **J Leukoc Biol** 1997 Mar;61(3):329–37

Interaction of murine dendritic cells with collagen up–regulates allostimulatory capacity, surface expression of heat stable antigen, and release of cytokines. Mahnke K, et al. **J Leukoc Biol** 1996 Oct;60(4):465–72

Biologically active conformer of the effector region of human C5a and modulatory effects of N–terminal receptor binding determinants on activity. Finch AM, et al. **J Med Chem** 1997 Mar 14;40(6):877–84

Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. Gasque P, et al. **J Neuroimmunol** 1996 May;66(1–2):29–40

Analysis of B7–1 and B7–2 costimulatory ligands in cultured mouse microglia: upregulation by interferon–gamma and lipopolysaccharide and downregulation by interleukin–10, prostaglandin E2 and cyclic AMP–elevating agents. Menéndez Iglesias B, et al. **J Neuroimmunol** 1997 Jan; 72(1):83–93

Interleukin–1 beta differentially affects interleukin–6 and soluble interleukin–6 receptor in the blood and central nervous system of the monkey. Reyes TM, et al. **J Neuroimmunol** 1996 May;66(1–2):135–41

Expression pattern of activation and adhesion molecules on peripheral blood CD4+ T–lymphocytes in relapsing–remitting multiple sclerosis patients: a serial analysis. Stüber A, et al. **J Neuroimmunol** 1996 May; 66(1–2):147–51

Soluble cytokine receptors as carrier proteins: effects of soluble interleukin–4 receptors on the pharmacokinetics of murine interleukin–4. Ma Y, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):340–50

Concentrations and origins of soluble interleukin 6 receptor–alpha in serum and synovial fluid. Desgeorges A, et al. **J Rheumatol** 1997 Aug;24(8):1510–6

Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17–1A. Juhl H, et al. **J Surg Oncol** 1997 Mar;64(3):222–30

Human cell receptor CD46 is down regulated through recognition of a membrane–proximal region of the cytoplasmic domain in persistent measles virus infection. Hirano A, et al. **J Virol** 1996 Oct;70(10):6929–36

The N–glycan of the SCR 2 region is essential for membrane cofactor protein (CD46) to function as a measles virus receptor. Maisner A, et al. **J Virol** 1996 Aug;70(8):4973–7

Comparative analysis of adenovirus fiber–cell interaction: adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment. Roelvink PW, et al. **J Virol** 1996 Nov; 70(11):7614–21

Tubulointerstitial responses in the progression of glomerular diseases: albuminuria modulates alpha v beta 5 integrin. Peruzzi L, et al. **Kidney Int** 1996 Oct;50(4):1310–20

Expression of costimulatory molecules B7–1 and B7–2 by macrophages along invasive margin of colon cancer: a possible antitumor immunity? Ohtani H, et al. **Lab Invest** 1997 Sep;77(3):231–41

Phenotypic analysis of receptor–ligand pairs on B–cells in B–chronic lymphocytic leukemia. Gagro A, et al. **Leuk Lymphoma** 1997 Apr;25(3–4):301–11

The combined differentiating effect of retinoic acid and vincristine on acute promyelocytic leukemia. Leung M, et al. **Leuk Res** 1997 Jan;21(1):81–4

Upregulation of CD9 expression during TPA treatment of K562 cells. Le Naour F, et al. **Leukemia** 1997 Aug; 11(8):1290–7

Elevated levels of type II soluble tumor necrosis factor receptors in the bronchoalveolar lavage fluids of patients with sarcoidosis. Hino T, et al. **Lung** 1997;175(3):187–93

Genomic organization of the human integrin beta4 gene. Iacovacci S, et al. **Mamm Genome** 1997 Jun;8(6):448–50

cDNA cloning and characterization of rat C5a anaphylatoxin receptor. Akatsu H, et al. **Microbiol Immunol** 1997; 41(7):575–80

Recruitment and phosphorylation of SH2–containing inositol phosphatase and Shc to the B–cell Fc gamma immunoreceptor tyrosine–based inhibition motif peptide motif. Tridandapani S, et al. **Mol Cell Biol** 1997 Aug; 17(8):4305–11

The expression of alpha v, alpha 5, beta 1, and beta 3 integrin chains on ejaculated human spermatozoa varies with their functional state. Fusi FM, et al. **Mol Hum Reprod** 1996 Mar;2(3):169–75

Regulatory elements of the mb–1 gene encoding the Ig–alpha component of the human B–cell antigen receptor. Leduc I, et al. **Mol Immunol** 1996 Dec;33(17–18):1277–86

The Neisseria type 2 IgA1 protease cleaves LAMP1 and promotes survival of bacteria within epithelial cells. Lin L, et al. **Mol Microbiol** 1997 Jun;24(5):1083–94

Arginine–glycine–aspartic acid mimics can identify a transitional activation state of recombinant alphaIIb beta3 in human embryonic kidney 293 cells. Abraham DG, et al. **Mol Pharmacol** 1997 Aug;52(2):227–36

Solution structure of human CTLA–4 and delineation of a CD80/CD86 binding site conserved in CD28 [letter] Metzler WJ, et al. **Nat Struct Biol** 1997 Jul;4(7):527–31

ICAM–2 redistributed by ezrin as a target for killer cells. Helander TS, et al. **Nature** 1996 Jul 18;382(6588):265–8

Cell surface phenotype and increased penetration of human multidrug–resistant ovarian carcinoma cells into in vitro collagen–fibroblasts matrix. Sedlák J, et al. **Neoplasma** 1996; 43(6):389–95

Interleukin–6 expression after renal transplantation. Waiser J, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):753–9

Unmasking by soluble IL–6 receptor of IL–6 effect on metastatic melanoma: growth inhibition and differentiation of B16–F10.9 tumor cells. Oh JW, et al. **Oncogene** 1997 Jul 31;15(5):569–77

Tec tyrosine kinase links the cytokine receptors to PI–3 kinase probably through JAK. Takahashi–Tezuka M, et al. **Oncogene** 1997 May 15;14(19):2273–82

CD3 and CD2 ligation alters CD49d epitope expression. Lin J, et al. **Pathobiology** 1995;63(3):119–32

Differential modulation of T cell functions by soluble IL–4R (sIL–4R) in two cases of severe atopic dermatitis. Nasert S, et al. **Pediatr Allergy Immunol** 1996 May;7(2):91–4

Death effector domain–containing herpesvirus and poxvirus proteins inhibit both Fas– and TNFR1–induced apoptosis. Bertin J, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18; 94(4):1172–6

Receptor–associated constitutive protein tyrosine phosphatase activity controls the kinase function of JAK1. Haque SJ, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5; 94(16):8563–8

Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55–kDa receptor [published erratum appears in Proc Natl Acad Sci U S A 1997 Aug 19;94(17):9510] Pasparakis M, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6319–23

Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Ramprasad MP, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14833–8

A mixed–charge pair in human interleukin 4 dominates high–affinity interaction with the receptor alpha chain. Wang Y, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4; 94(5):1657–62

Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Yamada Y, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1441–6

Functional and receptor binding characterization of recombinant murine macrophage inflammatory protein 2: sequence analysis and mutagenesis identify receptor binding epitopes. Jerva LF, et al. **Protein Sci** 1997 Aug;6(8):1643–52

IL–8 single–chain homodimers and heterodimers: interactions with chemokine receptors CXCR1, CXCR2, and DARC. Leong SR, et al. **Protein Sci** 1997 Mar;6(3):609–17

Monomeric variants of IL–8: effects of side chain substitutions and solution conditions upon dimer formation. Lowman HB, et al. **Protein Sci** 1997 Mar;6(3):598–608

A 3D model for the measles virus receptor CD46 based on homology modeling, Monte Carlo simulations, and hemagglutinin binding studies. Mumenthaler C, et al. **Protein Sci** 1997 Mar;6(3):588–97

CD6 recognizes the neural adhesion molecule BEN. Skonier JE, et al. **Protein Sci** 1997 Aug;6(8):1768–70

Structural change and receptor binding in a chemokine mutant with a rearranged disulfide: X–ray structure of E38C/C50AIL–8 at 2 A resolution. Eigenbrot C, et al. **Proteins** 1997 Apr;27(4):556–66

The family of the IL–6–type cytokines: specificity and promiscuity of the receptor complexes. Grötzinger J, et al. **Proteins** 1997 Jan;27(1):96–109

The CD94/NKG2C–type lectin receptor complex in recognition of HLA class I molecules. López–Botet M, et al. **Res Immunol** 1997 Mar–Apr;148(3):155–9 (30 ref.)

Functional differences between subpopulations of mobilized peripheral blood–derived CD34+ cells expressing different levels of HLA–DR, CD33, CD38 and c–kit antigens. Sakabe H, et al. **Stem Cells** 1997;15(1):73–81

Interaction of beta 3 integrin–derived peptides 214–218 and 217–231 with alpha IIb beta 3 complex and with fibrinogen A alpha–chain. Wierzbicka I, et al. **Thromb Res** 1997 Jan 15;85(2):115–26

Mapping amino acids of the measles virus hemagglutinin responsible for receptor (CD46) downregulation. Bartz R, et al. **Virology** 1996 Oct 1;224(1):334–7

Cell membrane vesicles are a major contaminant of gradient–enriched human immunodeficiency virus type–1 preparations. Gluschankof P, et al. **Virology** 1997 Mar 31; 230(1):125–33

Measles virus recognizes its receptor, CD46, via two distinct binding domains within SCR1–2. Manchester M, et al. **Virology** 1997 Jun 23;233(1):174–84

Is CD46 the cellular receptor for measles virus? Buckland R, et al. **Virus Res** 1997 Apr;48(1):1–9 (44 ref.)

PHARMACOLOGY

CD69–induced monocyte apoptosis involves multiple nonredundant signaling pathways. Ramírez R, et al. **Cell Immunol** 1996 Sep 15;172(2):192–9

CD66: role in the regulation of neutrophil effector function. Stocks SC, et al. **Eur J Immunol** 1996 Dec;26(12):2924–32

CD28 co–stimulatory regimes differ in their dependence on phosphatidylinositol 3–kinase: common co–signals induced by CD80 and CD86. Cefai D, et al. **Int Immunol** 1996 Oct; 8(10):1609–16

The soluble form of the IL–6 receptor (sIL–6R alpha) is a potent growth factor for AIDS–associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL–6R alpha–induced AIDS–KS cell growth. Murakami–Mori K, et al. **Int Immunol** 1996 Apr; 8(4):595–602

Antigen receptor–mediated B cell death is blocked by signaling via CD72 or treatment with dextran sulfate and is defective in autoimmunity–prone mice. Nomura T, et al. **Int Immunol** 1996 Jun;8(6):867–75

B7–2 (CD86) is essential for the development of IL–4–producing T cells. Ranger AM, et al. **Int Immunol** 1996 Oct;8(10):1549–60

The endothelial cell ecto–ADPase responsible for inhibition of platelet function is CD39. Marcus AJ, et al. **J Clin Invest** 1997 Mar 15;99(6):1351–60

B7.2 expressed by T cells does not induce CD28–mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. Greenfield EA, et al. **J Immunol** 1997 Mar 1; 158(5):2025–34

In vivo functions mediated by the p41 isoform of the MHC class II–associated invariant chain. Takaesu NT, et al. **J Immunol** 1997 Jan 1;158(1):187–99

Integrin–associated protein (CD47) is a comitogenic molecule on CD3–activated human T cells. Ticchioni M, et al. **J Immunol** 1997 Jan 15;158(2):677–84

CD28–CD80/CD86 interactions in testicular immunoregulation. Sainio–Pöllänen S, et al.

J Reprod Immunol 1996 Oct;31(3):145–63

ICAM-2 provides a costimulatory signal for T cell stimulation by allogeneic class II MHC. Carpenito C, et al. **Scand J Immunol** 1997 Mar;45(3):248–54

T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen. Chandraker A, et al. **Transplantation** 1997 Apr 27;63(8):1053–8

PHYSIOLOGY

The role of adhesion and costimulation molecules in graft–versus–host disease. Schlegel PG. **Acta Haematol** 1997;97(1–2):105–17 (191 ref.)

Abortive infection in HeLaCD4 cells by a primary HIV type 1 isolate: implications for differential host cell tropism. Smyth RJ, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10;13(9):759–69

Biochemical and morphological characterization of vascular and lymphocytic interleukin–4 receptors. Schnyder B, et al. **Am J Pathol** 1996 Oct;149(4):1369–79

Airway recruitment of leukocytes in mice is dependent on alpha4–integrins and vascular cell adhesion molecule–1. Chin JE, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):L219–29

Characterization of accessory molecules in murine lung dendritic cell function: roles for CD80, CD86, CD54, and CD40L. Masten BJ, et al. **Am J Respir Cell Mol Biol** 1997 Mar;16(3):335–42

The signal transducer gp130 is shared by interleukin–6 family of haematopoietic and neurotrophic cytokines. Taga T. **Ann Med** 1997 Feb;29(1):63–72 (88 ref.)

Multiple use of a signal transduction pathway in tumor cell invasion. Timár J, et al. **Anticancer Res** 1996 Nov–Dec; 16(6A):3299–306

Interleukin–1beta–stimulated invasion of articular cartilage by rheumatoid synovial fibroblasts is inhibited by antibodies to specific integrin receptors and by collagenase inhibitors. Wang AZ, et al. **Arthritis Rheum** 1997 Jul;40(7):1298–307

The role of alpha 4 integrin and intercellular adhesion molecule–1 (ICAM–1) in murine experimental autoimmune thyroiditis. McMurray RW, et al. **Autoimmunity** 1996; 23(1):9–23

Effect of soluble interleukin–6 receptor on interleukin–6 synthesis in human skin fibroblasts. Cichy J, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):318–21

Integrin beta4 is involved in apoptotic signal transduction in endothelial cells. Miao JY, et al. **Biochem Biophys Res Commun** 1997 Apr 7;233(1):182–6

Integrin alpha6 is involved in follicular growth in mice. Nakamura K, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):524–8

Interleukin–13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin–2 receptor–gamma and interleukin–4 receptor–alpha. Malabarba MG, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):865–72

The CD46 transmembrane domain is required for efficient formation of measles–virus–mediated syncytium. Seya T, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):135–44

Heterogeneity of interactions mediated by membrane glycoproteins of lymphocytes. Barclay AN, et al. **Biochem Soc Trans** 1997 Feb;25(1):224–8 (15 ref.)

Interleukin 4 and interleukin 13: same response, different receptors. Callard RE, et al. **Biochem Soc Trans** 1997 May; 25(2):451–5 (44 ref.)

Platelet membrane glycoprotein IV (CD36) is involved in arachidonic acid induced–platelet aggregation. Dutta–Roy AK, et al. **Biochem Soc Trans** 1996 May;24(2):167S

Adhesion molecules used by T lymphoblasts to interact with cultured high endothelial cells. Faveeuw C, et al. **Biochem Soc Trans** 1997 May;25(2):261S

Human neutrophil Fc alpha R and Fc gamma RIIa but not Fc gamma RIIIb generate intracellular calcium signals which trigger the respiratory burst. Lang ML, et al. **Biochem Soc Trans** 1997 May;25(2):333S

Recombinant RFB4 single–chain immunotoxin that is cytotoxic towards CD22–positive cells. Mansfield E, et al. **Biochem Soc Trans** 1997 May;25(2):709–14

Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signalling through CD40 and interleukin–4 receptor: role for inhibition of an early response gene, Berg36. Ning ZQ, et al. **Biochem Soc Trans** 1997 May;25(2):306S

CD6 ligation modulates the Bcl–2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti–IgM. Osorio LM, et al. **Blood** 1997 Apr 15;89(8):2833–41

Myeloma cell growth arrest, apoptosis, and interleukin–6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Puthier D, et al. **Blood** 1996 Dec 15;88(12):4659–66

CD2 regulates the positive selection and function of antigen–specific CD4– CD8+ T cells. Teh SJ, et al. **Blood** 1997 Feb 15;89(4):1308–18

Adhesion of multiple myeloma peripheral blood B cells to bone marrow fibroblasts: a requirement for CD44 and alpha4beta7. Masellis–Smith A, et al. **Cancer Res** 1997 Mar 1;57(5):930–6

Structure and function of interleukin–4 and its receptor. Puri RK. **Cancer Treat Res** 1995;80:143–85 (318 ref.)

Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF–kappaB activation prevents cell death. Liu ZG, et al. **Cell** 1996 Nov 1;87(3):565–76

Reduction of tumorigenicity by alpha 3 integrin in a rhabdomyosarcoma cell line. Weitzman JB, et al. **Cell Adhes Commun** 1996 Jul;4(1):41–52

Identification of a new biological function for the integrin alpha v beta 3: initiation of fibronectin matrix assembly. Wu C, et al. **Cell Adhes Commun** 1996 Sep;4(3):149–58

Lysosome–associated membrane proteins h–LAMP1 (CD107a) and h–LAMP2 (CD107b) are activation–dependent cell surface glycoproteins in human peripheral blood mononuclear cells which mediate cell adhesion to vascular endothelium. Kannan K, et al. **Cell Immunol** 1996 Jul 10;171(1):10–9

Ligation of CD53/OX44, a tetraspan antigen, induces homotypic adhesion mediated by specific cell–cell interactions. Lazo PA, et al. **Cell Immunol** 1997 Jun 15; 178(2):132–40

Potentiation of antitumor CTL response by GM–CSF involves a B7–dependent mechanism. Mokyr MB, et al. **Cell Immunol** 1997 Jun 15;178(2):152–61

Molecular cloning and comparative analysis of the rhesus macaque costimulatory molecules CD80 (B7–1) and CD86 (B7–2). Zhang D, et al. **Cell Immunol** 1997 Apr 10; 177(1):9–17

Functional resemblance between the Ig–related NK cell receptors specific for HLA class I molecules and the CD94 C–type lectin. López–Botet M, et al. **Chem Immunol** 1996; 64:116–34 (60 ref.)

Interleukin 4: signalling mechanisms and control of T cell differentiation. Paul WE. **Ciba Found Symp** 1997; 204:208–16; discussion 216–9 (40 ref.)

Emigrated rat neutrophils adhere to cardiac myocytes via alpha 4 integrin. Reinhardt PH, et al. **Circ Res** 1997 Aug; 81(2):196–201

Activation of JAK–STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes [see comments] [published erratum appears in Circulation 1997 Apr 1;95(7):1975] Kunisada K, et al. **Circulation** 1996 Nov 15;94(10):2626–32. Comment in: Circulation 1996 Nov 15;94(10):2361–3.

Anti–inflammatory properties of human serum IgA: induction of IL–1 receptor antagonist and Fc alpha R (CD89)–mediated down–regulation of tumour necrosis factor–alpha (TNF–alpha) and IL–6 in human monocytes. Wolf HM, et al. **Clin Exp Immunol** 1996 Sep;105(3):537–43

Absence of the IL–7 receptor component CDw127 indicates that gamma(c) expression alone is insufficient for IL–7 to modulate human neutrophil responses. Girard D, et al. **Clin Immunol Immunopathol** 1997 Jun;83(3):264–71

Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy [editorial; comment] Sfikakis PP, et al. **Clin Immunol Immunopathol** 1997 Jun; 83(3):195–8. Comment on: Clin Immunol Immunopathol 1997 Jun;83(3):199–204.

CD22 is a negative regulator of B–cell receptor signalling. Nitschke L, et al. **Curr Biol** 1997 Feb 1;7(2):133–43

Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1. Doody GM, et al. **Curr Opin Immunol** 1996 Jun;8(3):378–82 (47 ref.)

The role of the two TNF receptors in proliferation, NF–kappa B activation and discrimination between TNF and LT alpha signalling in the human myeloma cell line OH–2. Börset M, et al. **Cytokine** 1996 Jun;8(6):430–8

Ligand passing by the p75 tumour necrosis factor receptor enhances HIV–1 activation. Butera ST, et al. **Cytokine** 1996 Oct;8(10):745–50

Regulation of signal transducer, GP13O and the LIF receptor in acute inflammation in vivo. Geisterfer M, et al. **Cytokine** 1996 Apr;8(4):283–7

A fusion protein of IL–8 and a Fab antibody fragments binds to IL–8 receptors and induces neutrophil activation. Holzer W, et al. **Cytokine** 1996 Mar;8(3):214–21

Cardiotrophin–1: a multifunctional cytokine that signals via LIF receptor–gp 130 dependent pathways. Pennica D, et al. **Cytokine Growth Factor Rev** 1996 Jun;7(1):81–91 (63 ref.)

Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Kreidberg JA, et al. **Development** 1996 Nov; 122(11):3537–47

Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. Miyazaki T, et al. **EMBO J** 1997 Jul 16;16(14):4217–25

Interleukin–6 and its soluble receptor regulate the expression of insulin–like growth factor binding protein–5 in osteoblast cultures. Franchimont N, et al. **Endocrinology** 1997 Aug; 138(8):3380–6

Interleukin–6 (IL–6) inhibits thyroid function in the presence of soluble IL–6 receptor in cultured human thyroid follicles. Yamazaki K, et al. **Endocrinology** 1996 Nov; 137(11):4857–63

The C terminus of the human C5a receptor (CD88) is required for normal ligand–dependent receptor internalization. Bock D, et al. **Eur J Immunol** 1997 Jun; 27(6):1522–9

Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes. Frandji P, et al. **Eur J Immunol** 1996 Oct;26(10):2517–28

Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF–alpha–induced skin inflammation. Kondo S, et al. **Eur J Immunol** 1997 Jul;27(7):1713–8

Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane–bound TNF in experimental cerebral malaria. Lucas R, et al. **Eur J Immunol** 1997 Jul;27(7):1719–25

X–SCID B cell responses to interleukin–4 and interleukin–13 are mediated by a receptor complex that includes the interleukin–4 receptor alpha chain (p140) but not the gamma c chain. Matthews DJ, et al. **Eur J Immunol** 1997 Jan;27(1):116–21

Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signaling through CD40 and interleukin–4 receptor: role for inhibition of an early response gene, Berg36. Ning ZQ, et al. **Eur J Immunol** 1996 Oct; 26(10):2356–63

Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Speiser DE, et al. **Eur J Immunol** 1996 Dec;26(12):3055–60

Transgenic expression of a CD46 (membrane cofactor protein) minigene: studies of xenotransplantation and measles virus infection. Thorley BR, et al. **Eur J Immunol** 1997 Mar;27(3):726–34

Integrin alpha chain cytoplasmic tails regulate "antibody–redirected" cell adhesion, independently of ligand binding. Weitzman JB, et al. **Eur J Immunol** 1997 Jan;27(1):78–84

Expression of complement receptors and regulatory proteins on alveolar CD4+ lymphocytes from human immunodeficiency virus–1 infected individuals. Aries SP, et al. **Eur Respir J** 1997 Aug;10(8):1736–41

In Xenopus oocytes the human C3a and C5a receptors elicit a promiscuous response to the anaphylatoxins. Ames RS, et al. **FEBS Lett** 1996 Oct 21;395(2–3):157–9

Identification of residues in the putative 5th helical region of human interleukin–6, important for activation of the IL–6 signal transducer, gp130. Brakenhoff JP, et al. **FEBS Lett** 1996 Oct 21;395(2–3):235–40

Antibodies to rat soluble IL–6 receptor stimulate B9 hybridoma cell proliferation. Thibault V, et al. **FEBS Lett** 1997 May 19;408(2):182–6

B7–1 and B7–2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Borriello F, et al. **Immunity** 1997 Mar; 6(3):303–13

Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. Cyster JG, et al. **Immunity** 1997 May;6(5):509–17 (72 ref.)

Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti–apoptosis. Fukada T, et al. **Immunity** 1996 Nov; 5(5):449–60

Role of IL–6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Romano M, et al. **Immunity** 1997 Mar;6(3):315–25

ITIMs and ITAMs. The Yin and Yang of antigen and Fc receptor–linked signaling machinery. Isakov N. **Immunol Res** 1997 Feb;16(1):85–100 (112 ref.)

Structure and function of the CD94 C–type lectin receptor complex involved in recognition of HLA class I molecules. López–Botet M, et al. **Immunol Rev** 1997 Feb;155:165–74 (74 ref.)

IL–4 and IL–13 receptors: are they one and the same? Callard RE, et al. **Immunol Today** 1996 Mar;17(3):108–10 (33 ref.)

B7–1 and B7–2 monoclonal antibodies modulate the severity of murine Lyme arthritis. Anguita J, et al. **Infect Immun** 1997 Aug;65(8):3037–41

Role of epithelial interleukin–8 (IL–8) and neutrophil IL–8 receptor A in Escherichia coli–induced transuroepithelial neutrophil migration. Godaly G, et al. **Infect Immun** 1997 Aug;65(8):3451–6

Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor–deficient mice despite a strong local immunoglobulin A response. Johansson M, et al. **Infect Immun** 1997 Mar;65(3):1032–44

The soluble form of the IL–6 receptor (sIL–6R alpha) is a potent growth factor for AIDS–associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL–6R alpha–induced AIDS–KS cell growth. Murakami–Mori K, et al. **Int Immunol** 1996 Apr; 8(4):595–602

Requirement of CD28–CD86 co–stimulation in the interaction between antigen–primed T helper type 2 and B cells. Nakajima A, et al. **Int Immunol** 1997 May; 9(5):637–44

The IgV domain of human B7–2 (CD86) is sufficient to co–stimulate T lymphocytes and induce cytokine secretion. Rennert P, et al. **Int Immunol** 1997 Jun;9(6):805–13

Platelets mediate tumor cell adhesion to the subendothelium under flow conditions: involvement of platelet GPIIb–IIIa and tumor cell alpha(v) integrins. Dardik R, et al. **Int J Cancer** 1997 Jan 17;70(2):201–7

Contribution of the intracellular domain of murine Fc–gamma receptor type IIB1 to its tumor–enhancing potential. Zusman T, et al. **Int J Cancer** 1996 Oct 9; 68(2):219–27

CD46, a complement regulatory protein/measles virus receptor, and its relation to hematological disorders. Seya T. **Int J Hematol** 1996 Aug;64(2):101–9 (38 ref.)

IL–6–soluble IL–6 receptor complex inhibits the proliferation of dermal fibroblasts. Mihara M, et al. **Int J Immunopharmacol** 1996 Jan;18(1):89–94

Interleukin–4 and its receptor: essential mediators of the allergic response. Ryan JJ. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):1–5 (8 ref.)

The fertilizing ability of human epididymal sperm. Kitamura

M, et al. **J Assist Reprod Genet** 1996 Sep;13(8):652–6
Cleavage of PITSLRE kinases by ICE/CASP–1 and CPP32/CASP–3 during apoptosis induced by tumor necrosis factor. Beyaert R, et al. **J Biol Chem** 1997 May 2;272(18):11694–7
Characterization of a CD43/leukosialin–mediated pathway for inducing apoptosis in human T–lymphoblastoid cells. Brown TJ, et al. **J Biol Chem** 1996 Nov 1;271(44):27686–95
Regulation of ITAM signaling by specific sequences in Ig–beta B cell antigen receptor subunit. Cassard S, et al. **J Biol Chem** 1996 Sep 27;271(39):23786–91
Apoptotic activity of REAPER is distinct from signaling by the tumor necrosis factor receptor 1 death domain. Chen P, et al. **J Biol Chem** 1996 Oct 18;271(42):25735–7
Thrombspondin acts via integrin–associated protein to activate the platelet integrin alphaIIbbeta3. Chung J, et al. **J Biol Chem** 1997 Jun 6;272(23):14740–6
Interleukin–6 and its soluble receptor cause a marked induction of collagenase 3 expression in rat osteoblast cultures. Franchimont N, et al. **J Biol Chem** 1997 May 2;272(18):12144–50
CD86 (B7–2) on human B cells. A functional role in proliferation and selective differentiation into IgE– and IgG4–producing cells. Jeannin P, et al. **J Biol Chem** 1997 Jun 20;272(25):15613–9
Identification and characterization of CD39/vascular ATP diphosphohydrolase. Kaczmarek E, et al. **J Biol Chem** 1996 Dec 20;271(51):33116–22
Tumor necrosis factor receptors (Tnfr) in mouse fibroblasts deficient in Tnfr1 or Tnfr2 are signaling competent and activate the mitogen–activated protein kinase pathway with differential kinetics. Kalb A, et al. **J Biol Chem** 1996 Nov 8;271(45):28097–104
Mouse macrophages carrying both subunits of the human interferon–gamma (IFN–gamma) receptor respond to human IFN–gamma but do not acquire full protection against viral cytopathic effect. Lembo D, et al. **J Biol Chem** 1996 Dec 20;271(51):32659–66
A Kaposi's sarcoma–associated herpesvirus–encoded cytokine homolog (vIL–6) activates signaling through the shared gp130 receptor subunit. Molden J, et al. **J Biol Chem** 1997 Aug 1;272(31):19625–31
Human type II Fcgamma receptors inhibit B cell activation by interacting with the p21(ras)–dependent pathway. Sármay G, et al. **J Biol Chem** 1996 Nov 29; 271(48):30499–504
Fas–associated death domain protein interleukin–1beta–converting enzyme 2 (FLICE2), an ICE/Ced–3 homologue, is proximally involved in CD95– and p55–mediated death signaling. Vincenz C, et al. **J Biol Chem** 1997 Mar 7;272(10):6578–83
Leptin receptor action in hepatic cells. Wang Y, et al. **J Biol Chem** 1997 Jun 27;272(26):16216–23
Alpha7 integrin mediates cell adhesion and migration on specific laminin isoforms. Yao CC, et al. **J Biol Chem** 1996 Oct 11;271(41):25598–603
Invasive potentials of gastric carcinoma cell lines: role of alpha 2 and alpha 6 integrins in invasion. Koike N, et al. **J Cancer Res Clin Oncol** 1997;123(6):310–6
Expression of the integrin alpha5 subunit and its mediated cell adhesion in hepatocellular carcinoma. Yao M, et al. **J Cancer Res Clin Oncol** 1997;123(8):435–40
Roles of gp130 signaling pathways in cardiac myocytes: recent advances and implications for cardiovascular disease. Yamauchi–Takihara K, et al. **J Card Fail** 1996 Dec; 2(4 Suppl):S63–8 (44 ref.)
The localization of bullous pemphigoid antigen 180 (BP180) in hemidesmosomes is mediated by its cytoplasmic domain and seems to be regulated by the beta4 integrin subunit. Borradori L, et al. **J Cell Biol** 1997 Mar 24;136(6):1333–47
Thrombospondin modulates alpha v beta 3 function through integrin–associated protein. Gao AG, et al. **J Cell Biol** 1996 Oct;135(2):533–44
Cross talk between adhesion molecules: control of N–cadherin activity by intracellular signals elicited by beta1 and beta3 integrins in migrating neural crest cells. Monier–Gavelle F, et al. **J Cell Biol** 1997 Jun 30; 137(7):1663–81
Genetic analysis of alpha 4 integrin functions in the development of mouse skeletal muscle. Yang JT, et al. **J Cell Biol** 1996 Nov;135(3):829–35
Disruption of integrin alpha 5 beta 1 signaling does not impair PDGF–BB–mediated stimulation of the extracellular signal–regulated kinase pathway in smooth muscle cells. Hedin UL, et al. **J Cell Physiol** 1997 Jul;172(1):109–16
Regulation of cell migration by the integrin beta subunit ectodomain. Filardo EJ, et al. **J Cell Sci** 1996 Jun;109 (Pt 6):1615–22
Signals through gp130 upregulate bcl–x gene expression via STAT1–binding cis–element in cardiac myocytes. Fujio Y, et al. **J Clin Invest** 1997 Jun 15;99(12):2898–905
The role of alpha E beta 7 integrin (CD103) and E–cadherin in epidermotropism in cutaneous T–cell lymphoma. Dietz SB, et al. **J Cutan Pathol** 1996 Aug;23(4):312–8
Distinct roles for signals relayed through the common cytokine receptor gamma chain and interleukin 7 receptor alpha chain in natural T cell development. Boesteanu A, et al. **J Exp Med** 1997 Jul 21;186(2):331–6
The association between alpha4–integrin, P–selectin, and E–selectin in an allergic model of inflammation. Kanwar S, et al. **J Exp Med** 1997 Mar 17;185(6):1077–87
Membrane tumor necrosis factor (TNF) induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV–infected T cells. Lazdins JK, et al. **J Exp Med** 1997 Jan 6;185(1):81–90
Normal lymphocyte development but delayed humoral immune response in CD81–null mice. Maecker HT, et al. **J Exp Med** 1997 Apr 21;185(8):1505–10
Costimulation of T cell activation by integrin–associated protein (CD47) is an adhesion–dependent, CD28–independent signaling pathway. Reinhold MI, et al. **J Exp Med** 1997 Jan 6;185(1):1–11
Costimulation through B7–2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness. Tsuyuki S, et al. **J Exp Med** 1997 May 5;185(9):1671–9
Regulation of human immunodeficiency virus gp160–mediated cell fusion by antibodies against fusion regulatory protein 1. Ohgimoto S, et al. **J Gen Virol** 1996 Nov;77 (Pt 11):2747–56
An anti–fusion regulatory protein–1 monoclonal antibody suppresses human parainfluenza virus type 2–induced cell fusion. Okamoto K, et al. **J Gen Virol** 1997 Jan;78 (Pt 1):83–9
Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol–anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement–mediated destruction. Saifuddin M, et al. **J Gen Virol** 1997 Aug;78 (Pt 8):1907–11
Functions of domain 1 and 4 of vascular cell adhesion molecule–1 in alpha4 integrin–dependent adhesion under static and flow conditions are differentially regulated. Abe Y, et al. **J Immunol** 1996 Dec 1;157(11):5061–9
Weak peptide agonists reveal functional differences in B7–1 and B7–2 costimulation of human T cell clones. Anderson DE, et al. **J Immunol** 1997 Aug 15;159(4):1669–75
Apoptosis of immature thymocytes mediated by E2/CD99. Bernard G, et al. **J Immunol** 1997 Mar 15;158(6):2543–50
The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity. Cerutti A, et al. **J Immunol** 1996 Sep 1;157(5):1854–62
Costimulation of T cell proliferation by a chimeric B7–2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto–oncogene. Gerstmayer B, et al. **J Immunol** 1997 May 15;158(10):4584–90
Shc mediates IL–6 signaling by interacting with gp130 and Jak2 kinase. Giordano V, et al. **J Immunol** 1997 May 1; 158(9):4097–103
Effects of blocking B7–1 and B7–2 interactions during a type 2 in vivo immune response. Greenwald RJ, et al. **J Immunol** 1997 May 1;158(9):4088–96
CD99 (MIC2) regulates the LFA–1/ICAM–1–mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. Hahn JH, et al. **J Immunol** 1997 Sep 1;159(5):2250–8
CD94 ligation induces apoptosis in a subset of IL–2–stimulated NK cells. Ida H, et al. **J Immunol** 1997 Sep 1;159(5):2154–60
Regulation of human T lymphocyte coactivation with an alpha4 integrin antagonist peptide. McIntyre BW, et al. **J Immunol** 1997 May 1;158(9):4180–6
Impaired survival and proliferation in IL–7 receptor–deficient peripheral T cells. Maraskovsky E, et al. **J Immunol** 1996 Dec 15;157(12):5315–23
Attenuation of collagen–induced arthritis in 55–kDa TNF receptor type 1 (TNFR1)–IgG1–treated and TNFR1–deficient mice. Mori L, et al. **J Immunol** 1996 Oct 1;157(7):3178–82
Differential activation of human platelets induced by Fc gamma receptor II cross–linking and by anti–CD9 monoclonal antibody. Qi R, et al. **J Immunol** 1996 Dec 15;157(12):5638–45
Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. Radford KJ, et al. **J Immunol** 1997 Apr 1;158(7):3353–8
Corynebacterium parvum– and Mycobacterium bovis bacillus Calmette–Guerin–induced granuloma formation is inhibited in TNF receptor I (TNF–RI) knockout mice and by treatment with soluble TNF–RI. Senaldi G, et al. **J Immunol** 1996 Dec 1;157(11):5022–6
CD94/NKG2 is the predominant inhibitory receptor involved in recognition of HLA–G by decidual and peripheral blood NK cells. Söderström K, et al. **J Immunol** 1997 Aug 1;159(3):1072–5
Requirement of Fas(CD95), CD45, and CD11a/CD18 in monocyte–dependent apoptosis of human T cells. Wu MX, et al. **J Immunol** 1996 Jul 15;157(2):707–13
Blockade of CD86 ameliorates Leishmania major infection by down–regulating the Th2 response. Brown JA, et al. **J Infect Dis** 1996 Dec;174(6):1303–8
Pretreatment with a 55–kDa tumor necrosis factor receptor–immunoglobulin fusion protein attenuates activation of coagulation, but not of fibrinolysis, during lethal bacteremia in baboons. van der Poll T, et al. **J Infect Dis** 1997 Jul;176(1):296–9
Tumor necrosis factor (TNF)–induced cutaneous necrosis is mediated by TNF receptor 1. Amar S, et al. **J Inflamm** 1995–96;47(4):180–9
In vitro comparison of inhibiting ability of soluble TNF receptor p75 (TBP II) vs. soluble TNF receptor p55 (TBP I) against TNF–alpha and TNF–beta. Terlizzese M, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):1047–53
Calcitonin gene–related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. Fox FE, et al. **J Invest Dermatol** 1997 Jan; 108(1):43–8
Evidence for exclusive role of the p55 tumor necrosis factor (TNF) receptor in mediating the TNF–induced collagenase expression by human dermal fibroblasts. Rekdal O, et al. **J Invest Dermatol** 1996 Oct;107(4):565–8
The alpha4beta1 integrin can mediate leukocyte adhesion to casein and denatured protein substrates. Davis GE, et al. **J Leukoc Biol** 1997 Sep;62(3):318–28
Cardiotrophin–1 and the role of gp130–dependent signaling pathways in cardiac growth and development. Wollert KC, et al. **J Mol Med** 1997 Jul;75(7):492–501 (98 ref.)
TGF–B2 and soluble p55 TNFR modulate VCAM–1 expression in glioma cells and brain derived endothelial cells. Chen TC, et al. **J Neuroimmunol** 1997 Mar; 73(1–2):155–61
An antibody to the tetraspan membrane protein CD9 promotes neurite formation in a partially alpha3beta1 integrin–dependent manner. Banerjee SA, et al. **J Neurosci** 1997 Apr 15;17(8):2756–65
CD9 of mouse brain is implicated in neurite outgrowth and cell migration in vitro and is associated with the alpha 6/beta 1 integrin and the neural adhesion molecule L1. Schmidt C, et al. **J Neurosci Res** 1996 Jan 1;43(1):12–31
Molecular and cellular aspects of measles virus persistence in the CNS. ter Meulen V. **J Neurovirol** 1997 May;3 Suppl 1:S3–5 (25 ref.)
Blocking of feline immunodeficiency virus infection by a monoclonal antibody to CD9 is via inhibition of virus release rather than interference with receptor binding. de Parseval A, et al. **J Virol** 1997 Aug;71(8):5742–9
CD46 short consensus repeats III and IV enhance measles virus binding but impair soluble hemagglutinin binding. Devaux P, et al. **J Virol** 1997 May;71(5):4157–60
Role of alpha v integrins in mesangial cell adhesion to vitronectin and von Willebrand factor. Hafdi Z, et al. **Kidney Int** 1997 Jun;51(6):1900–7
Interferon–gamma receptor–deficiency renders mice highly susceptible to toxoplasmosis by decreased macrophage activation. Deckert–Schlüter M, et al. **Lab Invest** 1996 Dec; 75(6):827–41
Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation. Lundell BI, et al. **Leukemia** 1997 Jun;11(6):822–9
Sporozoites of Plasmodium yoelii infect mice with targeted deletions in ICAM–1 and ICAM–2 or complement components C3 and C4. Sultan AA, et al. **Mol Biochem Parasitol** 1997 Sep;88(1–2):263–6
Fibronectin receptor functions in embryonic cells deficient in alpha 5 beta 1 integrin can be replaced by alpha V integrins. Yang JT, et al. **Mol Biol Cell** 1996 Nov; 7(11):1737–48
CD22 regulates thymus–independent responses and the lifespan of B cells. Otipoby KL, et al. **Nature** 1996 Dec 19–26;384(6610):634–7
In U–937 promonocytes, misteltoe lectin I increases basal [Ca2+]i, enhances histamine H1– and complement C5a–receptor–mediated rises in [Ca2+]i, and induces cell death. Wenzel–Seifert K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):190–7
Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell–permeable peptide analogs. Liu KY, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11819–24
Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV–1 envelope spike protein. Mebatsion T, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11366–70
The tumor necrosis factor receptor 2 signal transducers TRAF2 and c–IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Shu HB, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13973–8
Interleukin–6: structure–function relationships. Simpson RJ, et al. **Protein Sci** 1997 May;6(5):929–55 (338 ref.)
Solution structure of a unique C5a semi–synthetic antagonist: implications in receptor binding. Zhang X, et al. **Protein Sci** 1997 Jan;6(1):65–72
Role of CD69 in NO production by human monocytes. Testi R, et al. **Res Immunol** 1995 Nov–Dec;146(9):682–3 (19 ref.)
CD11b/CD18 mediates the neutrophil chemotactic activity of fibrin degradation product D domain. Gross TJ, et al. **Thromb Haemost** 1997 May;77(5):894–900
Endothelial cell protein S synthesis is upregulated by the complex of IL–6 and soluble IL–6 receptor. Hooper WC, et al. **Thromb Haemost** 1997 May;77(5):1014–9
Prolonged allograft survival by the inhibition of costimulatory CD2 signals but not by modulation of CD48 (CD2 ligand) in the rat. Sido B, et al. **Transpl Int** 1996; 9 Suppl 1:S323–7
Cellular adhesion molecules in transplantation. Rodriguez–Iturbe B. **Transplant Proc** 1996 Dec; 28(6):3285–9 (53 ref.)
Persistent echovirus infection of mouse cells expressing the viral receptor VLA–2. Zhang S, et al. **Virology** 1997 Sep 1;235(2):293–301
[Kidney and complement regulatory factors] Matsuo S. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):643–6 (14 ref.) **(Jpn)**

[Complement regulatory membrane factors in experimental animal models] Okada N.
Nihon Rinsho Meneki Gakkai Kaishi 1995 Dec;18(6):631–3 (6 ref.) **(Jpn)**

RADIATION EFFECTS

Up-regulation of human epidermal Langerhans' cell B7-1 and B7-2 co-stimulatory molecules in vivo by solar-simulating irradiation. Laihia JK, et al.
Eur J Immunol 1997 Apr;27(4):984–9

ANTIGENS, CD1

ANALYSIS

IFN-gamma modulates CD1d surface expression on intestinal epithelia. Colgan SP, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C276–83

CD1a+ and CD1a- accessory cells from human bronchoalveolar lavage differ in allostimulatory potential and cytokine production. van Haarst JM, et al.
Am J Respir Cell Mol Biol 1996 Dec;15(6):752–9

IL-12 gene expression in human skin-derived CD1a+ dendritic lymph cells. Yawalkar N, et al.
Arch Dermatol Res 1996 Feb;288(2):79–84

CD1 expression in human peripheral nerve of GBS patients. Khalili-Shirazi A, et al. **Biochem Soc Trans** 1997 May; 25(2):172S

Generation of CD1+RelB+ dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes. Akagawa KS, et al. **Blood** 1996 Nov 15;88(10):4029–39

Localization of rat CD1 transcripts and protein in rat tissues--an analysis of rat CD1 expression by in situ hybridization and immunohistochemistry [see comments] Kasai K, et al. **Clin Exp Immunol** 1997 Aug;109(2):317–22 . Comment in: Clin Exp Immunol 1997 Aug;109(2):223–5.

Quantification of CD1a, HLA-DR, and HLA class I expression on viable human Langerhans cells and keratinocytes. Meunier L, et al. **Cytometry** 1996 Dec 15; 26(4):260–4

On quantification of CD1a, HLA-DR, and HLA class I expression on viable human Langerhans cells and keratinocytes [letter] Sprogøe-Jakobsen U, et al.
Cytometry 1997 Aug 15;30(4):206–7

Physical and functional association of CD45 and CD3-TCR complex on CD1+ human thymocytes. Evidence that the engagement of CD45 molecules can prevent CD1+ thymocytes from apoptosis. Poggi A, et al.
Int Immunol 1996 Dec;8(12):1947–53

Cd1a-positive cells in bronchoalveolar lavage samples from children with Langerhans cell histiocytosis. Réfabert L, et al. **J Pediatr** 1996 Dec;129(6):913–5

Surface and volume density of CD1a+ Langerhans cells in the human oral mucosa: a stereological study using vertical sections. Bahmer FA, et al. **Pathol Res Pract** 1997; 193(1):37–42

Discrimination of two subsets of CD1 molecules in the sheep. Rhind SM, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):265–70

BIOSYNTHESIS

IL-3 in combination with IL-4, induces the expression of functional CD1 molecules on monocytes. Thomssen H, et al. **Cytokine** 1996 Jun;8(6):476–81

Analysis of the requirement for beta 2-microglobulin for expression and formation of human CD1 antigens. Bauer A, et al. **Eur J Immunol** 1997 Jun;27(6):1366–73

Defective expression of HLA class I and CD1a molecules in boy with Marfan-like phenotype and deep skin ulcers. Plebani A, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 2):814–8

Downregulation of CD1 marks acquisition of functional maturation of human thymocytes and defines a control point in late stages of human T cell development. Res P, et al. **J Exp Med** 1997 Jan 6;185(1):141–51

Mouse CD1 is mainly expressed on hemopoietic-derived cells. Brossay L, et al. **J Immunol** 1997 Aug 1; 159(3):1216–24

Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine. Giuliani A, et al.
Pharmacol Res 1997 Feb;35(2):135–40

Rat CD1 antigen: structure, expression and function. Matsuura A, et al. **Transplant Proc** 1997 May;29(3):1705–6

CLASSIFICATION

Discrimination of two subsets of CD1 molecules in the sheep. Rhind SM, et al. **Vet Immunol Immunopathol** 1996 Aug; 52(4):265–70

GENETICS

Stable expression of CD1a molecule in human epithelial cell lines shows temperature-dependent expression and affects cell morphology and growth. Yu RC, et al.
Arch Dermatol Res 1997 May;289(6):352–9

Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. Chen YH, et al.
Immunity 1997 Apr;6(4):459–67

CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Mendiratta SK, et al.
Immunity 1997 Apr;6(4):469–77

The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules. Prigozy TI, et al. **Immunity** 1997 Feb;6(2):187–97

RT1.P, rat class Ib genes related to mouse TL: evidence that CD1 molecules but not authentic TL antigens are expressed by rat thymus. Matsuura A, et al.
Immunogenetics 1997;46(4):293–306

Rat CD1 antigen: structure, expression and function. Matsuura A, et al. **Transplant Proc** 1997 May;29(3):1705–6

IMMUNOLOGY

HIV-peplotion vaccine. A novel approach to vaccination against AIDS by transepithelial transport of viral peptides and antigens to Langerhans cells for induction of cytolytic T cells by HLA class I and CD1 molecules for long term protection. Becker Y. **Adv Exp Med Biol** 1996;397:97–104 (22 ref.)

CD1d: outside-in antigen presentation in the intestinal epithelium? [editorial; comment] Blumberg RS, et al.
Clin Exp Immunol 1997 Aug;109(2):223–5 (37 ref.). Comment on: Clin Exp Immunol 1997 Aug;109(2):317–20.

Antigen presentation by CD1 and MHC-encoded class I-like molecules. Melián A, et al. **Curr Opin Immunol** 1996 Feb; 8(1):82–8 (41 ref.)

CD1 presentation of microbial nonpeptide antigens to T cells. Jullien D, et al. **J Clin Invest** 1997 May 1;99(9):2071–4 (13 ref.)

CD1c restricts responses of mycobacteria-specific T cells. Evidence for antigen presentation by a second member of the human CD1 family. Beckman EM, et al.
J Immunol 1996 Oct 1;157(7):2795–803

Nonclassical behavior of the mouse CD1 class I-like molecule. Teitell M, et al. **J Immunol** 1997 Mar 1; 158(5):2143–9

CD1: clues on a new antigen-presenting pathway. Jullien D, et al. **Res Immunol** 1996 Jun;147(5):321–8 (54 ref.)

Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells. Moody DB, et al. **Science** 1997 Oct 10;278(5336):283–6

Differential effects of cytolytic T cell subsets on intracellular infection. Stenger S, et al. **Science** 1997 Jun 13; 276(5319):1684–7

A feline homologue of CD1 is defined using a feline-specific monoclonal antibody. Woo JC, et al. **Tissue Antigens** 1997 Mar;49(3 Pt 1):244–51

METABOLISM

Mouse CD1-specific NK1 T cells: development, specificity, and function. Bendelac A, et al. **Annu Rev Immunol** 1997; 15:535–62 (116 ref.)

Stable expression of CD1a molecule in human epithelial cell lines shows temperature-dependent expression and affects cell morphology and growth. Yu RC, et al.
Arch Dermatol Res 1997 May;289(6):352–9

Expression of secretory group II phospholipase A2 by CD1a positive cells-in human atherosclerotic plaques [letter; comment] Bobryshev YV, et al. **Atherosclerosis** 1996 Dec 20;127(2):283–5. Comment on: Atherosclerosis 1995 Dec;118(2):173–81.

Antigen presentation: mixing oil and water. Porcelli SA, et al. **Curr Biol** 1997 Aug 1;7(8):R508–11 (12 ref.)

Assembly and retention of CD1b heavy chains in the endoplasmic reticulum. Sugita M, et al. **J Immunol** 1997 Sep 1;159(5):2358–65

PHYSIOLOGY

Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. Chen H, et al. **J Immunol** 1997 Sep 1;159(5):2240–9

The CD1-restricted T-cell response to mycobacteria. Moody DB, et al. **Res Immunol** 1996 Oct-Dec;147(8-9):550–9 (31 ref.)

Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Smiley ST, et al. **Science** 1997 Feb 14;275(5302):977–9

ANTIGENS, CD2

ANALYSIS

Aberrant CD2 expression in precursor-B acute lymphoblastic leukemia of childhood. Dunphy CH, et al.
Am J Hematol 1996 Jul;52(3):224–6

CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Uckun FM, et al. **Blood** 1996 Dec 1;88(11):4288–95

Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study. Uckun FM, et al. **Blood** 1997 Apr 1;89(7):2488–93

Differential interaction of the CD2 extracellular and intracellular domains with the tyrosine phosphatase CD45 and the zeta chain of the TCR/CD3/zeta complex. Verhagen AM, et al. **Eur J Immunol** 1996 Dec; 26(12):2841–9

Quantitation of soluble E-receptor of T lymphocytes in serum from HIV-1 positive patients. Nuñez G, et al.
J Clin Lab Anal 1997;11(1):69–72

Increased acute-phase response and renal amyloidosis in aged CD2-fas-transgenic mice. Hsu HC, et al. **J Immunol** 1997 Jun 15;158(12):5988–96

Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors. Takamizawa M, et al. **J Immunol** 1997 Mar 1; 158(5):2134–42

BIOSYNTHESIS

Gamma delta T cells of the murine vagina: T cell response in vivo in the absence of the expression of CD2 and CD28 molecules. Rakasz E, et al. **Int Immunol** 1997 Jan;9(1):161–7

Dexamethasone modulates CD2 expression. Migliorati G, et al. **Int J Immunopharmacol** 1996 Dec;18(12):677–84

BLOOD

Improved detection of CD2 on formaldehyde-fixed non dehydrated cells [letter] Cruz C, et al.
Nouv Rev Fr Hematol 1995;37(6):385

CHEMISTRY

Amide backbone and water-related H/D isotope effects on the dynamics of a protein folding reaction. Parker MJ, et al. **Biochemistry** 1997 May 13;36(19):5786–94

Characterisation of the low affinity interaction between rat cell adhesion molecules CD2 and CD48 by analytical ultracentrifugation. Silkowski H, et al. **Eur Biophys J** 1997; 25(5-6):455–62

The structure and ligand interactions of CD2: implications for T-cell function. Davis SJ, et al. **Immunol Today** 1996 Apr;17(4):177–87 (115 ref.)

Determination of the lifetime and force dependence of interactions of single bonds between surface-attached CD2 and CD48 adhesion molecules. Pierres A, et al.
Proc Natl Acad Sci U S A 1996 Dec 24;93(26):15114–8

DRUG EFFECTS

Thiol-mediated inhibition of FAS and CD2 apoptotic signaling in activated human peripheral T cells. Déas O, et al. **Int Immunol** 1997 Jan;9(1):117–25

Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways. Woodward JE, et al. **Transplantation** 1996 Oct 15;62(7):1011–8

GENETICS

Transgene-encoded human CD2 acts in a dominant negative fashion to modify thymocyte selection signals in mice. Melton E, et al. **Eur J Immunol** 1996 Dec;26(12):2952–63

CD3 gamma, CD3 delta, and CD3 zeta mRNA in adult human marrow hematopoietic progenitors correlates with surface CD2 and CD7 expression. Long H, et al.
Exp Hematol 1996 Oct;24(12):1402–8

[The mRNA expression of CD2, CD4 and CD8 in peripheral blood lymphocytes from the patients with acute lymphoblastic leukemia and non-Hodgkin's lymphoma] Zhang Z, et al.
Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1995 Dec; 17(6):403–6 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Decreased T cell response to anti-CD2 in systemic lupus erythematosus and reversal by anti-CD28: evidence for impaired T cell-accessory cell interaction. Horwitz DA, et al. **Arthritis Rheum** 1997 May;40(5):822–33

Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen- or antigen-induced proliferative capacity in normals. Mardiney M 3rd, et al. **Cytometry** 1996 Dec 15;26(4):305–10

CD2 related immunoregulation in oral cancer. Balaram P, et al. **Eur J Cancer B Oral Oncol** 1994 Jan;30B(1):43–6

CD2 signaling in T cells involves tyrosine phosphorylation and activation of the Tec family kinase, EMT/ITK/TSK. King PD, et al. **Int Immunol** 1996 Nov;8(11):1707–14

An anti-CD2 mAb induces immunosuppression and hyporesponsiveness of CD2+ human T cells in vitro. Latinne D, et al. **Int Immunol** 1996 Jul;8(7):1113–9

A novel murine model for the assessment of human CD2-related reagents in vivo. Ding Y, et al.
J Immunol 1996 Sep 1;157(5):1863–9

Relationship between proliferation and susceptibility to CD95- and CD2-mediated apoptosis in stimulated primary T lymphocytes: T cells manifesting proliferative unresponsiveness are preferentially susceptible to CD95-mediated apoptosis. Mollereau B, et al.
J Immunol 1997 Sep 15;159(6):2668–77

Increased cAMP and cAMP-dependent protein kinase activity mediate anti-CD2 induced suppression of anti-CD3-driven interleukin-2 production and CD25 expression. Lin J, et al. **Pathobiology** 1995;63(4):175–87

Hypoproliferative human lamina propria T cells retain the capacity to secrete lymphokines when stimulated via CD2/CD28 pathways. Boirivant M, et al.
Proc Assoc Am Physicians 1996 Jan;108(1):55–67

CD2 induced apoptosis of peripheral T cells. Rouleau M, et al. **Transplant Proc** 1997 Aug;29(5):2377–8 (3 ref.)

Coexistence of Th1- and Th2-type cytokine profiles in anti-CD2 monoclonal antibody-induced tolerance. Krieger NR, et al. **Transplantation** 1996 Nov 15;62(9):1285–92

ANTIGENS, CD2

METABOLISM

CD2 ligation abrogates antigen-independent apoptosis in B cells. Baixeras E, et al. **Cell Immunol** 1996 Jul 10; 171(1):55–61

Differential interaction of the CD2 extracellular and intracellular domains with the tyrosine phosphatase CD45 and the zeta chain of the TCR/CD3/zeta complex. Verhagen AM, et al. **Eur J Immunol** 1996 Dec; 26(12):2841–9

The dependence of the association rate of surface-attached adhesion molecules CD2 and CD48 on separation distance. Pierres A, et al. **FEBS Lett** 1997 Feb 24;403(3):239–44

The role of CD2 as a regulator of human T-cell cytokine production. Holter W, et al. **Immunol Rev** 1996 Oct; 153:107–22 (70 ref.)

Stimulatory effect of low dose X-irradiation on the expression of the human T lymphocyte CD2 surface antigen. Sambani C, et al. **Int J Radiat Biol** 1996 Dec; 70(6):711–7

Adhesive bond dynamics in contacts between T lymphocytes and glass-supported planar bilayers reconstituted with the immunoglobulin-related adhesion molecule CD58. Dustin ML. **J Biol Chem** 1997 Jun 20;272(25):15782–8

Ligand-induced conformational change within the CD2 ectodomain accompanies receptor clustering: implication for molecular lattice formation. Li J, et al. **J Mol Biol** 1996 Oct 25;263(2):209–26

Blockade of CD2–LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Sultan P, et al. **Nat Biotechnol** 1997 Aug;15(8):759–62

CD3 and CD2 ligation alters CD49d epitope expression. Lin J, et al. **Pathobiology** 1995;63(3):119–32

Enhanced production of IL4 but not of IFN gamma and IL 10 by peripheral blood mononuclear cells from atopic children in response to CD2 plus CD28 stimulation. Holter W, et al. **Pediatr Allergy Immunol** 1996 May;7(2):75–82

The counterreceptor binding site of human CD2 exhibits an extended surface patch with multiple conformations fluctuating with millisecond to microsecond motions. Wyss DF, et al. **Protein Sci** 1997 Mar;6(3):534–42

Signaling via the CD2 receptor enhances HTLV-1 replication in T lymphocytes. Guyot DJ, et al. **Virology** 1997 Jul 21;234(1):123–9

[CD2 and CD8 expression in acute promyelocytic leukemia] Kawachi Y, et al. **Rinsho Ketsueki** 1996 Dec;37(12):1377–82 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

A novel murine model for the assessment of human CD2-related reagents in vivo. Ding Y, et al. **J Immunol** 1996 Sep 1;157(5):1863–9

Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12. Gollob JA, et al. **J Immunol** 1996 Sep 1;157(5):1886–93

PHYSIOLOGY

CD2–CD58 interaction and the control of T-cell interleukin-12 responsiveness. Adhesion molecules link innate and acquired immunity. Gollob JA, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:71–81

CD2 rescues T cells from T-cell receptor/CD3 apoptosis: a role for the Fas/Fas-L system. Ayroldi E, et al. **Blood** 1997 May 15;89(10):3717–26

CD2 regulates the positive selection and function of antigen-specific CD4– CD8+ T cells. Teh SJ, et al. **Blood** 1997 Feb 15;89(4):1308–18

Transgene-encoded human CD2 acts in a dominant negative fashion to modify thymocyte selection signals in mice. Melton E, et al. **Eur J Immunol** 1996 Dec;26(12):2952–63

Itk, a T cell-specific tyrosine kinase, is required for CD2-mediated interleukin-2 promoter activation in the human T cell line Jurkat. Tanaka N, et al. **Eur J Immunol** 1997 Apr;27(4):834–41

The role of adhesion molecules in the recruitment of hepatic natural killer cells (pit cells) in rat liver. Luo D, et al. **Hepatology** 1996 Dec;24(6):1475–80

Surface molecules that drive T cell development in vitro in the absence of thymic epithelium and in the absence of lineage-specific signals. Cibotti R, et al. **Immunity** 1997 Mar;6(3):245–55

Tyrosine phosphorylation and recruitment of ZAP-70 to the CD3–TCR complex are defective after CD2 stimulation. Hubert P, et al. **J Immunol** 1996 Nov 15;157(10):4322–32

Involvement of protein tyrosine kinase p72syk and phosphatidylinositol 3-kinase in CD2-mediated granular exocytosis in the natural killer cell line, NK3.3. Umehara H, et al. **J Immunol** 1997 Aug 1;159(3):1200–7

Relief of cyclin A gene transcriptional inhibition during activation of human primary T lymphocytes via CD2 and CD28 adhesion molecules. Plet A, et al. **Oncogene** 1997 May 29;14(21):2575–83

Prolonged allograft survival by the inhibition of costimulatory CD2 signals but not by modulation of CD48 (CD2 ligand) in the rat. Sido B, et al. **Transpl Int** 1996; 9 Suppl 1:S323–7

ANTIGENS, CD3

see related
RECEPTORS, ANTIGEN, T-CELL

Expansion of CD3+CD56+ lymphocytes correlates with induction of cytotoxicity by interleukin-2 gene transfer in human breast tumor cultures. Euhus DM, et al. **Ann Surg Oncol** 1997 Jul–Aug;4(5):432–9

CD3 cells in the intestine of broilers inoculated with intestinal homogenate. Sevčíková Z. **Br Poult Sci** 1997 Mar; 38(1):55–8

Murine monoclonal IgG antibodies: differences in their IgG isotypes can affect the antibody effector activity when using human cells. Lobo PI, et al. **Immunol Cell Biol** 1997 Jun;75(3):267–74

Particulate ANP-sensitive guanylyl cyclase: induction in cultured human peripheral CD3+ mononuclear blood cells. Heim JM, et al. **J Mol Med** 1996 Oct;74(10):629–35

Human immunodeficiency virus type 1 infection of mature CD3hiCD8+ thymocytes. Lee S, et al. **J Virol** 1997 Sep; 71(9):6671–6

ANALYSIS

Activated T cells and cytokine-induced CD3+CD56+ killer cells. Schmidt-Wolf GD, et al. **Ann Hematol** 1997 Feb; 74(2):51–6 (49 ref.)

The use of isotypic control antibodies in the analysis of CD3+ and CD3+, CD4+ lymphocyte subsets by flow cytometry. Are they really necessary? Sreenan JJ, et al. **Arch Pathol Lab Med** 1997 Feb;121(2):118–21

CD3-SmIg-lymphoblastic leukaemia in an outbred domestic guinea pig. Day MJ, et al. **Aust Vet J** 1997 Mar;75(3):217–8

CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Drénou B, et al. **Blood** 1997 Apr 15;89(8):2966–74

CD3+ CD8+ CD56- clonal large granular lymphocyte leukaemia and HIV infection. Pulik M, et al. **Br J Haematol** 1997 Aug;98(2):444–5

Expansion of an unusual population of Gr-1+CD3int cells in the lymph nodes and other peripheral organs of mice carrying the lpr gene. Honda S, et al. **Cell Immunol** 1997 May 1;177(2):144–53

Multiparametric cell-cycle analysis of peripheral blood-activated lymphocyte subsets using staining based on the TdT method for incorporated BrdUrd. Dolbeare F, et al. **Cytometry** 1996 Dec 1;25(4):317–23

Immunomagnetic isolation of magnetoferritin-labeled cells in a modified ferrograph. Zborowski M, et al. **Cytometry** 1996 Jul 1;24(3):251–9

Dermatopathologic advances in clinical research. The expression of antibody to CD34 in mucocutaneous lesions. off Cohen PR, et al. **Dermatol Clin** 1997 Jan;15(1):159–76 (76 ref.)

Increased HLA-DR and decreased CD3 on human intestinal intraepithelial lymphocytes: evidence of activation? Abuzakouk M, et al. **Gut** 1996 Sep;39(3):396–400

Transcription and demethylation of TCR beta gene initiate prior to the gene rearrangement in c-kit+ thymocytes with CD3 expression: evidence of T cell commitment in the thymus. Hozumi K, et al. **Int Immunol** 1996 Oct; 8(10):1473–81

Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis). Masucci G, et al. **J Hematother** 1997 Jun;6(3):253–60

Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. Satoh M, et al. **J Immunol** 1996 Nov 1;157(9):3886–92

Intermediate TCR cells in mouse lung: their effector function to induce pneumonitis in mice with autoimmune-like graft-versus-host disease. Watanabe T, et al. **J Immunol** 1997 Jun 15;158(12):5805–14

Herpes virus saimiri transformation of T cells in CD3 gamma immunodeficiency: phenotypic and functional characterization. Rodríguez-Gallego C, et al. **J Immunol Methods** 1996 Nov 13;198(2):177–86

Increases in CD3+CD4-CD8- T lymphocytes in AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection. Moreau JF, et al. **J Infect Dis** 1996 Nov;174(5):969–76

Resolution of autoimmune hemolytic anemia following splenectomy in CD3+ large granular lymphocyte leukemia. Gentile TC, et al. **Leuk Lymphoma** 1996 Oct; 23(3–4):405–8

Autoantibody production in healthy elderly people is not promoted by interleukin-10 although this cytokine is expressed in them by a peculiar CD8+CD3+ large granular cell subpopulation. Llorente L, et al. **Scand J Immunol** 1997 Apr;45(4):401–7

BLOOD

Dose titration during anti-thymocyte globulin therapy: monitoring by CD3 count or total lymphocyte count? Gorrie M, et al. **Clin Lab Haematol** 1997 Mar;19(1):53–6

CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity. Su CC, et al. **Lupus** 1997;6(5):449–54

Stimulatory roles of muscarinic acetylcholine receptors on T cell antigen receptor/CD3 complex-mediated interleukin-2 production in human peripheral blood lymphocytes. Fujino H, et al. **Mol Pharmacol** 1997 Jun; 51(6):1007–14

CHEMISTRY

1H-NMR analysis of CD3-epsilon reveals the presence of turn-helix structures around the ITAM motif in an otherwise random coil cytoplasmic tail. Borroto A, et al. **Biopolymers** 1997;42(1):75–88

Noncovalent associations of T lymphocyte surface proteins. Cerný J, et al. **Eur J Immunol** 1996 Oct;26(10):2335–43

The T cell antigen receptor beta chain interacts with the extracellular domain of CD3-gamma. Manolios N, et al. **Immunol Cell Biol** 1995 Dec;73(6):532–6

TCR repertoire to proteolipid protein (PLP) in multiple sclerosis (MS): homologies between PLP-specific T cells and MS-associated T cells in TCR junctional sequences. Kondo T, et al. **Int Immunol** 1996 Jan;8(1):123–30

Apoptosis but not other activation events is inhibited by a mutation in the transmembrane domain of T cell receptor beta that impairs CD3zeta association. Rodríguez-Tarduchy G, et al. **J Biol Chem** 1996 Nov 29; 271(48):30417–25

Regulation and function of the CD3gamma DxxxLL motif: a binding site for adaptor protein-1 and adaptor protein-2 in vitro. Dietrich J, et al. **J Cell Biol** 1997 Jul 28; 138(2):271–81

Development and function of T cells in T cell antigen receptor/CD3 zeta knockout mice reconstituted with Fc epsilon RI gamma. Liu CP, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21;94(2):616–21

DRUG EFFECTS

Effect of dexamethasone on T-cell receptor/CD3 expression. Migliorati G, et al. **Mol Cell Biochem** 1997 Feb; 167(1–2):135–44

GENETICS

Short-term dexamethasone treatment modulates the expression of the murine TCR zeta gene locus. Ronchetti S, et al. **Cell Immunol** 1997 Jun 15;178(2):124–31

CD3 delta deficiency arrests development of the alpha beta but not the gamma delta T cell lineage. Dave VP, et al. **EMBO J** 1997 Mar 17;16(6):1360–70

An amphibian CD3 homologue of the mammalian CD3 gamma and delta genes. Dzialo RC, et al. **Eur J Immunol** 1997 Jul;27(7):1640–7

Identification and analysis of the chicken CD3epsilon gene. Göbel TW, et al. **Eur J Immunol** 1997 Jan;27(1):194–8

Functional analysis of immunoreceptor tyrosine-based activation motif (ITAM)-mediated signal transduction: the two YxxL segments within a single CD3zeta-ITAM are functionally distinct. Sunder-Plassmann R, et al. **Eur J Immunol** 1997 Aug;27(8):2001–9

CD3 gamma, CD3 delta, and CD3 zeta mRNA in adult human marrow hematopoietic progenitors correlates with surface CD2 and CD7 expression. Long H, et al. **Exp Hematol** 1996 Oct;24(12):1402–8

Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Ager S, et al. **Hum Gene Ther** 1996 Nov 10;7(17):2157–64

Cloning and characterization of partial cDNAs for woodchuck cytokines and CD3epsilon with applications for the detection of RNA expression in tissues by RT-PCR assay. Nakamura I, et al. **J Med Virol** 1997 Sep;53(1):85–95

IMMUNOLOGY

Proliferative responses to PHA, anti-CD3 and antigens in patients with lymphoproliferative disease of granular lymphocytes. Mannoproteins of Candida albicans induce proliferation and cytotoxicity. Giovannetti A, et al. **Acta Haematol** 1997;98(2):65–71

Defective calcium increase and inositol phosphate production in anti-CD3-stimulated lymphocytes of alcoholics without progressive liver disease. Stefanini GF, et al. **Alcohol Clin Exp Res** 1996 May;20(3):523–7

Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody. Hombach A, et al. **Anticancer Res** 1997 May-Jun; 17(3C):2025–32

A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. Kuwahara M, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2661–7

Impaired CD25 expression and soluble CD25-IL-2R alpha receptor release by anti-CD3 stimulated peripheral blood mononuclear cells in Hodgkin's disease patients. Frydecka I, et al. **Arch Immunol Ther Exp (Warsz)** 1996; 44(2–3):127–30

T cell receptor alpha-chain and beta-chain junctional region homology in clonal CD3+, CD8+ T lymphocyte expansions in Felty's syndrome. Bowman SJ, et al. **Arthritis Rheum** 1997 Apr;40(4):615–23

Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells. Oyaizu N, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):670–5

Decrease of intracellular fluorescein fluorescence polarization (IFFP) in human peripheral blood lymphocytes undergoing stimulation with phytohaemagglutinin (PHA), concanavalin A (ConA), pokeweed mitogen (PWM) and anti-CD3 antibody.

Eisenthal A, et al. **Biol Cell** 1996;86(2-3):145-50

Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation. Jacobs N, et al. **Cancer Immunol Immunother** 1997 Jul;44(5):257-64

Further characterization of cytotoxic T cells generated by short-term culture of human peripheral blood lymphocytes with interleukin-2 and anti-CD3 mAb. Jacobs N, et al. **Cancer Immunol Immunother** 1996 Jul;42(6):369-75

CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Mazzoni A, et al. **Cancer Res** 1996 Dec 1;56(23):5443-9

Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2. Darrow TL, et al. **Cell Immunol** 1996 Aug 25;172(1):52-9

CD28-mediated activation of resting human T cells without costimulation of the CD3/TCR complex. Siefken R, et al. **Cell Immunol** 1997 Feb 25;176(1):59-65

Flow cytometric HLA-B27 typing using CD3 gating and molecules of equivalent soluble fluorochrome (MESF) quantitation. Chen JC, et al. **Cytometry** 1996 Dec 15; 26(4):286-92

Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow. Nowak R, et al. **Cytometry** 1997 Feb 15;30(1):47-53

Effects of oleic acid on murine CD4+ T cell death and anti-CD3 or superantigen induced proliferation at low temperature. Wooten RM, et al. **Dev Comp Immunol** 1997 Jul-Aug;21(4):375-84

Soluble tumour necrosis factor receptor release after anti-CD3 monoclonal antibody treatment in mice is independent of tumour necrosis factor-alpha release. Vossen AC, et al. **Eur Cytokine Netw** 1996 Dec;7(4):751-5

Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Kircheis R, et al. **Gene Ther** 1997 May;4(5):409-18

Production and characterization of a new monoclonal antibody effective in recognizing the CD3 T-cell associated antigen in formalin-fixed embedded tissue. Steward M, et al. **Histopathology** 1997 Jan;30(1):16-22

Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Ager S, et al. **Hum Gene Ther** 1996 Nov 10;7(17):2157-64

An anti-CD3 epsilon serum detects T lymphocytes in paraffin-embedded pathological tissues in many animal species. Keresztes G, et al. **Immunol Lett** 1996 May; 50(3):167-72

A physiological interaction of T cells and Mac-1+ cells is not necessary to induce the selective loss of CD3zeta chains in tumor-bearing state. Kosugi A, et al. **Immunol Lett** 1995 Sep;47(3):233-5

Different pathways of the release of cytotoxic proteins in LAK cells. Sashchenko LP, et al. **Immunol Lett** 1996 Oct; 53(1):25-9

Early T-cell development in CD3-deficient mice. Tanaka Y, et al. **Immunol Rev** 1995 Dec;148:171-99 (89 ref.)

Retinol (vitamin A) is a cofactor in CD3-induced human T-lymphocyte activation. Allende LM, et al. **Immunology** 1997 Mar;90(3):388-96

Preparation of monoclonal anti-porcine CD3 antibodies and preliminary characterization of porcine T lymphocytes. Yang H, et al. **Immunology** 1996 Aug;88(4):577-85

Immobilized anti-CD3 mAb induces anergy in murine naive and memory CD4+ T cells in vitro. Chai JG, et al. **Int Immunol** 1997 Jul;9(7):935-44

Functional characteristics of cord blood T lymphocytes after lectin and anti-CD3 stimulation. Differences in the way T cells express activation molecules and proliferate. Lucivero G, et al. **Int J Clin Lab Res** 1996;26(4):255-61

Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on anti-CD3-induced changes in T-cell subsets and cytokine production. Prell RA, et al. **Int J Immunopharmacol** 1995 Nov;17(11):951-61

IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. Brod SA, et al. **Int J Neurosci** 1997 Jun; 90(1-2):135-44

Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. Arakawa F, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):657-62

Nonatopic asthma: in vivo airway hyperreactivity adoptively transferred to naive mice by THY-1(+) and B220(+) antigen-specific cells that lack surface expression of CD3. Geba GP, et al. **J Clin Invest** 1997 Aug 1;100(3):629-38

The single positive T cells found in CD3-zeta/eta-/- mice overtly react with self-major histocompatibility complex molecules upon restoration of normal surface density of T cell receptor-CD3 complex. Lin SY, et al. **J Exp Med** 1997 Feb 17;185(4):707-15

Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. Smith JA, et al. **J Exp Med** 1997 Apr 21;185(8):1413-22

Commitment of immature CD4+8+ thymocytes to the CD4 lineage requires CD3 signaling but does not require expression of clonotypic T cell receptor (TCR) chains. Suzuki H, et al. **J Exp Med** 1997 Jul 7;186(1):17-23

CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. Chatenoud L, et al. **J Immunol** 1997 Mar 15;158(6):2947-54

Overexpression of the heat shock protein 70 enhances the TCR/CD3- and Fas/Apo-1/CD95-mediated apoptotic cell death in Jurkat T cells. Liossis SN, et al. **J Immunol** 1997 Jun 15;158(12):5668-75

Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. Mack M, et al. **J Immunol** 1997 Apr 15;158(8):3965-70

Integrin-associated protein (CD47) is a comitogenic molecule on CD3-activated human T cells. Ticchioni M, et al. **J Immunol** 1997 Jan 15;158(2):677-84

Alpha 4 beta 1 (CD49d/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation. Udagwa T, et al. **J Immunol** 1996 Sep 1; 157(5):1965-72

CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. White HD, et al. **J Immunol** 1997 Mar 15;158(6):3017-27

Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients. Curti BD, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):296-308

A new reagent for the induction of T-cell depletion, anti-CD3-CRM9. Neville DM Jr, et al. **J Immunother Emphasis Tumor Immunol** 1996 Mar; 19(2):85-92

Anti-CD3-activated killer T cells: interferon-gamma and interleukin-10 cross-regulate granzyme B expression and the induction of major histocompatibility complex-unrestricted cytotoxicity. Fitzpatrick L, et al. **J Interferon Cytokine Res** 1996 Jul;16(7):537-46

Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma. Asano T, et al. **J Urol** 1997 Jun;157(6):2396-401

Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody. Csóka M, et al. **Leukemia** 1996 Nov;10(11):1765-72

Diminished activation of the MAP kinase pathway in CD3-stimulated T lymphocytes from old mice. Gorgas G, et al. **Mech Ageing Dev** 1997 Mar;94(1-3):71-83

Increased apoptosis of CD45RO- T cells with aging. Herndon FJ, et al. **Mech Ageing Dev** 1997 Mar; 94(1-3):123-34

Purified protein from Salmonella typhimurium inhibits the interleukin-2 response of murine splenic T-lymphocytes activated with anti-CD3 antibody. Matsui K. **Microbiol Immunol** 1996;40(9):681-4

Kinetics of organ-associated natural killer cells and intermediate CD3 cells during pulmonary and hepatic granulomatous inflammation induced by mycobacterial cord factor. Tabata A, et al. **Microbiol Immunol** 1996; 40(9):651-8

Increased cAMP and cAMP-dependent protein kinase activity mediate anti-CD2 induced suppression of anti-CD3-driven interleukin-2 production and CD25 expression. Lin J, et al. **Pathobiology** 1995;63(4):175-87

CD3+, CD16+, CD56+ cells: a novel subset of T lymphocytes from patients with Balkanic nephropathy. Drugărin D, et al. **Roum Arch Microbiol Immunol** 1995 Oct-Dec;54(4):255-64

Hematopoietic changes induced by a single injection of anti-CD3 monoclonal antibody into normal mice. Schneider E, et al. **Stem Cells** 1997;15(2):154-60

The induction of cytotoxicity by a bispecific antibody against CEA positive cell line, in vitro. Hideshima T, et al. **Surg Today** 1996;26(2):83-8

Mechanisms of tolerance induced by an immunotoxin against CD3 epsilon in a rhesus kidney allograft model. Fechner JH Jr, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1158

In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Khanna A, et al. **Transplantation** 1997 Apr 15;63(7):1037-9

Idarubicin-anti-CD3: a new immunoconjugate that induces alloantigen-specific tolerance in mice. Mottram PL, et al. **Transplantation** 1997 Sep 15;64(5):684-90

Post-OKT3 induction therapy CD complex response predicts renal allograft rejection. Stephan RN, et al. **Transplantation** 1997 Apr 27;63(8):1183-6

Low expression of T-cell receptor-CD3 complex: a case with a clinical presentation resembling humoral immunodeficiency. Sanal O, et al. **Turk J Pediatr** 1996 Jan-Mar;38(1):81-4

Identification of duck T lymphocytes using an anti-human T cell (CD3) antiserum. Bertram EM, et al. **Vet Immunol Immunopathol** 1996 Jun 1;51(3-4):353-63

[CD4-CD8- to CD4-CD8+ transition induced by anti-CD3 mAb in vitro cell culture system] Tian L, et al. **Shih Yen Sheng Wu Hsueh Pao** 1996 Mar;29(1):39-47 (Eng. Abstr.) **(Chi)**

[Juvenile Adamantiades-Behçet disease in decreased stimulation with anti-CD3 monoclonal antibody] Krüger K, et al. **Hautarzt** 1997 Apr;48(4):258-61 (Eng. Abstr.) **(Ger)**

[Current therapy of multiple sclerosis. Therapy with monoclonal antibodies to T-cell antigens (CD3, CD4, CD52)] Schmidt S, et al. **Nervenarzt** 1996 Feb;67(2):170-6 (44 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Costimulation of the CD3 pathway by CD28 ligation in human intestinal lymphocytes. Ebert EC, et al. **Cell Immunol** 1996 Aug 1;171(2):211-6

CD69 expression reliably predicts the anti-CD3-induced proliferative response of lymphocytes from human immunodeficiency virus type 1-infected patients. Prince HE, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):217-22

Functional analysis of immunoreceptor tyrosine-based activation motif (ITAM)-mediated signal transduction: the two YxxL segments within a single CD3zeta-ITAM are functionally distinct. Sunder-Plassmann R, et al. **Eur J Immunol** 1997 Aug;27(8):2001-9

A purified protein from Salmonella typhimurium inhibits proliferation of murine splenic anti-CD3 antibody-activated T-lymphocytes. Matsui K. **FEMS Immunol Med Microbiol** 1996 Jun;14(2-3):121-7

The bone marrow peptide (myelopeptide-2) abolishes induced by human leukemia HL-60 cell suppression of T lymphocytes. Strelkov LA, et al. **Immunol Lett** 1996 May; 50(3):143-7

Autologous killing by a population of intermediate T-cell receptor cells and its NK1.1+ and NK1.1- subsets, using Fas ligand/Fas molecules. Moroda T, et al. **Immunology** 1997 Jun;91(2):219-26

Immobilized anti-CD3 mAb induces anergy in murine naive and memory CD4+ T cells in vitro. Chai JG, et al. **Int Immunol** 1997 Jul;9(7):935-44

Lck dependence of signaling pathways activated by gamma-irradiation and CD3 epsilon engagement in RAG-1(-/-)-immature thymocytes. Wu G, et al. **Int Immunol** 1996 Jul;8(7):1159-64

Regulation and function of the CD3gamma DxxxLL motif: a binding site for adaptor protein-1 and adaptor protein-2 in vitro. Dietrich J, et al. **J Cell Biol** 1997 Jul 28; 138(2):271-81

IL-7 upregulates T cell receptor/CD3 expression by cultured dendritic epidermal T cells. Ono M, et al. **J Dermatol Sci** 1996 Feb;11(2):89-96

A new 12-kilodalton dimer associated with pre-TCR complex and clonotype-independent CD3 complex on immature thymocytes. Takase K, et al. **J Immunol** 1997 Jul 15;159(2):741-7

Induction of apoptosis by anti-CD3 epsilon F(ab')2 in antigen receptor transgenic murine T cells activated by specific peptide. Yu XZ, et al. **J Immunol** 1996 Oct 15;157(8):3420-9

Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Baumann CA, et al. **Mech Ageing Dev** 1997 Mar;94(1-3):85-101

Effect of dexamethasone on T-cell receptor/CD3 expression. Migliorati G, et al. **Mol Cell Biochem** 1997 Feb; 167(1-2):135-44

CD3 and CD2 ligation alters CD49d epitope expression. Lin J, et al. **Pathobiology** 1995;63(3):119-32

PHARMACOLOGY

Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression. Roos MT, et al. **Clin Exp Immunol** 1996 Sep;105(3):409-15

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. Chang AE, et al. **J Clin Oncol** 1997 Feb; 15(2):796-807

Integrin-associated protein (CD47) is a comitogenic molecule on CD3-activated human T cells. Ticchioni M, et al. **J Immunol** 1997 Jan 15;158(2):677-84

PHYSIOLOGY

Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. Bohlen H, et al. **Cancer Res** 1997 May 1;57(9):1704-9

Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-alpha. Kovacs B, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):293-302

Gammalinolenic acid and dihomogammalinolenic acid suppress the CD3-mediated signal transduction pathway in human T cells. Vassilopoulos D, et al. **Clin Immunol Immunopathol** 1997 Jun;83(3):237-44

Separable functions of Nef disrupt two aspects of T cell receptor machinery: CD4 expression and CD3 signaling. Iafrate AJ, et al. **EMBO J** 1997 Feb 17;16(4):673-84

Restoration of thymopoiesis in pT alpha-/- mice by anti-CD3epsilon antibody treatment or with transgenes encoding activated Lck or tailless pT alpha. Fehling HJ, et al. **Immunity** 1997 Jun;6(6):703-14

Preferential requirement of CD3 zeta-mediated signals for development of immature rather than mature thymocytes. Aoe T, et al. **Int Immunol** 1996 Jul;8(7):1055-66

HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28. Roederer M, et al. **J Clin Invest** 1997 Apr

ANTIGENS, CD3

1;99(7):1555–64
Role of CD3gamma and CD3delta cytoplasmic domains in cytolytic T lymphocyte functions and TCR/CD3 down-modulation. Luton F, et al. **J Immunol** 1997 May 1;158(9):4162–70
Wortmannin, a phosphatidylinositol 3-kinase inhibitor, blocks antigen-mediated, but not CD3 monoclonal antibody-induced, activation of murine CD4+ T cells. Shi J, et al. **J Immunol** 1997 May 15;158(10):4688–95
Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes. Zauli G, et al. **J Immunol** 1996 Sep 1;157(5):2216–24
Targeted adenovirus-mediated gene delivery to T cells via CD3. Wickham TJ, et al. **J Virol** 1997 Oct;71(10):7663–9
CD3-epsilon overexpressed in prothymocytes acts as an oncogene. Wang B, et al. **Mol Med** 1997 Jan;3(1):72–81
Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3. Nishina H, et al. **Nature** 1997 Jan 23;385(6614):350–3

ANTIGENS, CD4

see related
CD4-CD8 RATIO
HIV ENVELOPE PROTEIN GP120
Nonrheumatoid IgM in human hepatitis C virus-associated type II cryoglobulinemia recognize mimotopes of the CD4-like LAG-3 protein. Mecchia M, et al. **J Immunol** 1996 Oct 15;157(8):3727–36

ADMINISTRATION & DOSAGE

Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. Aranda R, et al. **J Immunol** 1997 Apr 1; 158(7):3464–73

ANALYSIS

Flow cytometric analysis of bronchoalveolar lavage and venous blood lymphocyte phenotype for the diagnosis of acute graft rejection in lung transplant patients. The Lung Transplant Group, Ospedale Maggiore di Milano. Bonara P, et al. **Anal Quant Cytol Histol** 1996 Aug;18(4):293–7
Soluble CD4 and CD8 in serum from patients with localized scleroderma. Sato S, et al. **Arch Dermatol Res** 1996 Jun; 288(7):358–62
The use of isotypic control antibodies in the analysis of CD3+ and CD3+, CD4+ lymphocyte subsets by flow cytometry. Are they really necessary? Sreenan JJ, et al. **Arch Pathol Lab Med** 1997 Feb;121(2):118–21
Membrane antigen and ligand receptor expression on neonatal monocytes. El-Mohandes AA, et al. **Biol Neonate** 1995;68(5):308–17
Role of CD4+, CD8+ and double negative T-cells in the protection of SCID/beige mice against respiratory challenge with Rhodococcus equi. Ross TL, et al. **Can J Vet Res** 1996 Jul;60(3):186–92
The CD7- T cell subset represents the majority of IL-5-secreting cells within CD4+CD45RA- T cells. Reinhold U, et al. **Clin Exp Immunol** 1996 Dec;106(3):555–9
Immunomagnetic isolation of magnetoferritin-labeled cells in a modified ferrograph. Zborowski M, et al. **Cytometry** 1996 Jul 1;24(3):251–9
Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Baxter AG, et al. **Diabetes** 1997 Apr;46(4):572–82
Separable functions of Nef disrupt two aspects of T cell receptor machinery: CD4 expression and CD3 signaling. Iafrate AJ, et al. **EMBO J** 1997 Feb 17;16(4):673–84
A new strategy for treating patients with CD7+, CD4-, CD8- acute lymphoblastic leukaemia [letter] Ono K, et al. **Eur J Haematol** 1997 Feb;58(2):130–2
MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways. Benihoud K, et al. **Eur J Immunol** 1997 Feb;27(2):415–20
Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Ludewig B, et al. **Eur J Immunol** 1996 Dec;26(12):3137–43
A novel peripheral CD4+ CD8+ T cell population: inheritance of CD8alpha expression on CD4+ T cells. Luhtala M, et al. **Eur J Immunol** 1997 Jan;27(1):189–93
CD4+CD8- thymocytes that express L-selectin protect rats from diabetes upon adoptive transfer. Seddon B, et al. **Eur J Immunol** 1996 Nov;26(11):2702–8
TCR alpha/beta and TCR gamma/delta CD4-/CD8-HLA-DR alloreactive CTL clones do not use Fas/Fas ligand pathway to lyse their specific target cells. Mami-Chouaib F, et al. **Hum Immunol** 1996 Nov; 51(1):13–22
Human T cells expressing an invariant V alpha 24-J alpha Q TCR alpha are CD4- and heterogeneous with respect to TCR beta expression. Porcelli S, et al. **Hum Immunol** 1996 Jun-Jul;48(1-2):63–7
IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Launois P, et al. **Immunity** 1997 May;6(5):541–9
The appearance of unusual phenotypic cells (CD4+ Mac-1+ class II+) in the liver of (NZW x BXSB)F1 mice is possibly an animal model for autoimmune hepatitis. Amoh Y, et al. **Immunobiology** 1997 Jun;197(1):31–43
An unique CD4+CD8+ intestinal intraepithelial lymphocyte specific for DnaK (Escherichia coli HSP70) may be selected by intestinal microflora of rats. Kimura Y, et al. **Immunobiology** 1996-97;196(5):550–66
Peripheral blood CD4+CD8+ lymphocytes in cynomolgus monkeys are of resting memory T lineage. Akari H, et al. **Int Immunol** 1997 Apr;9(4):591–7
TCR-mediated target cell lysis by CD4+NK1+ liver T lymphocytes. Emoto M, et al. **Int Immunol** 1997 Apr; 9(4):563–71
Requirement of IL-7 for IL-4-producing potential of MHC class I-selected CD4-CD8-TCR alpha beta+ thymocytes. Leite-de-Moraes MC, et al. **Int Immunol** 1997 Jan;9(1):73–9
CD4+ CD45RA+ T cells from adults respond to recall antigens after CD28 ligation. Pilling D, et al. **Int Immunol** 1996 Nov;8(11):1737–42
Changes in immunologic variables (TNF-a, sCD8 and sCD4) during danazol treatment in patients with endometriosis. Matalliotakis I, et al. **Int J Fertil Womens Med** 1997 May-Jun;42(3):211–4
TH1 and TH2 CD4+ cells in human allergic diseases. Umetsu DT, et al. **J Allergy Clin Immunol** 1997 Jul; 100(1):1–6 (18 ref.)
Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR-CD8- thymocytes. Godfrey DI, et al. **J Autoimmun** 1997 Jun; 10(3):279–85
Analysis of the contact sites on the CD4 molecule with class II MHC molecule: co-ligand versus co-receptor function. Huang B, et al. **J Immunol** 1997 Jan 1;158(1):216–25
Development of CD4-CD8- alpha beta TCR+NK1.1+ T lymphocytes: thymic selection by self antigen. Schulz RJ, et al. **J Immunol** 1996 Nov 15;157(10):4379–89
A novel population of CD4+CD56+ myelin-reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. Vergelli M, et al. **J Immunol** 1996 Jul 15;157(2):679–88
Early production of IL-4 and induction of Th2 responses in the lymph node originate from an MHC class I-independent CD4+NK1.1- T cell population. von der Weid T, et al. **J Immunol** 1996 Nov 15;157(10):4421–7
Increases in CD3+CD4-CD8- T lymphocytes in AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection. Moreau JF, et al. **J Infect Dis** 1996 Nov;174(5):969–76
A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm3. Gordon M, et al. **J Med** 1995;26(5-6):193–207
Function of CD4 molecules in LEC rat thymocytes. Sakai T, et al. **J Vet Med Sci** 1996 Nov;58(11):1125–7
Extrathymic generation and antigen recognition of IL3-induced CD4-CD8 alpha beta T cells. Kubota H. **Jpn J Vet Res** 1996 Aug;44(2):131–2
Invasive thymoma with CD4+CD8+ double-positive T cell lymphocytosis. Tamaoki J, et al. **Respiration** 1997; 64(2):176–8
Tolerant cells infiltrating class I mismatched swine kidney allografts lack the CD4 single positive subset and down regulate TCR gene expression. Giangrande I, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1164
B-haplotype control of CD4/CD8 subsets and TCR V beta usage in chicken T lymphocytes. Ewald SJ, et al. **Vet Immunol Immunopathol** 1996 Oct;53(3-4):285–301

BIOSYNTHESIS

TGF beta 2 in rabbit blastocoelic fluid regulates CD4 membrane expression: possible role in the success of gestation. Ouellette MJ, et al. **Am J Reprod Immunol** 1997 Jan;37(1):125–36
CD4 and CD8 antigen coexpression: a flow cytometric study of peripheral blood, bone marrow, body fluid, and solid lymphoreticular specimens. Nah EH, et al. **Arch Pathol Lab Med** 1997 Apr;121(4):381–4
A spontaneously immortalized mouse microglial cell line expressing CD4. Alliot F, et al. **Brain Res Dev Brain Res** 1996 Aug 20;95(1):140–3
Impaired antigen presentation to CD4+ T-cells by HIV-infected monocytes is related to down-modulation of CD4 expression on helper T-cells: possible involvement of HIV-induced cellular factors. Louie AT, et al. **FEBS Lett** 1996 Nov 25;398(1):1–6
CD4 expression is important but not essential for infection with exogenous mouse mammary tumor virus. Ando Y, et al. **Immunobiology** 1996 Aug;195(3):376–84
A novel mouse thymocyte antigen (F3Ag): down-regulation during the CD4+CD8+ double-positive stage indicates positive selection. Barthlott T, et al. **Int Immunol** 1996 Jan; 8(1):101–13
Down-regulation of cell-surface CD4 co-receptor expression and modulation of experimental allergic encephalomyelitis. Fiori P, et al. **Int Immunol** 1997 Apr; 9(4):541–5
CD4 and CD8 expressions in African green monkey helper T lymphocytes: implication for resistance to SIV infection. Murayama Y, et al. **Int Immunol** 1997 Jun;9(6):843–51
Inhibition of re-expression of surface CD4, but not CD8, on activated human T-lymphocytes by the immunosuppressive drugs dexamethasone and cyclosporine A: correlation with inhibition of proliferation. Haczku AF, et al. **Int J Immunopharmacol** 1996 Jan;18(1):45–51
Asynchronous coreceptor downregulation after positive thymic selection: prolonged maintenance of the double positive state in CD8 lineage differentiation due to sustained biosynthesis of the CD4 coreceptor. Barthlott T, et al. **J Exp Med** 1997 Jan 20;185(2):357–62
Infection of SK-N-MC cells, a CD4-negative neuroblastoma cell line, with primary human immunodeficiency virus type 1 isolates. Harouse JM, et al. **J Virol** 1996 Oct;70(10):7290–4
Expression of MHC class II CD4+ and ED1 molecules in association with selective hippocampal neuronal degeneration after long-term adrenalectomy. Islam A, et al. **Neuroreport** 1997 Mar 3;8(4):987–90
In vivo tissue distribution of CD4 lymphocytes in mice determined by radioimmunoscintigraphy with an 111In-labeled anti-CD4 monoclonal antibody. Rubin RH, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7460–3
The immunologic basis for celiac disease and related disorders. Braegger CP, et al. **Semin Gastrointest Dis** 1996 Jul;7(3):124–33 (95 ref.)
T-cell responses to enteric antigens. Hurst SD, et al. **Semin Gastrointest Dis** 1996 Jul;7(3):118–23 (45 ref.)
In vivo activated rat monocytes up-regulate NKR-P1A and down-modulate CD4 and CD43. Scriba A, et al. **Transplant Proc** 1997 May;29(3):1748–9

BLOOD

Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. De Rie MA, et al. **Acta Derm Venereol** 1996 Sep;76(5):357–60
Changes in soluble CD4 and CD8 proteins in healthy pregnant and postpartum women. Watanabe M, et al. **Am J Reprod Immunol** 1996 Oct;36(4):220–7
Analysis of recombinant and native CD4 by one- and two-dimensional gel electrophoresis. Lynch GW, et al. **Electrophoresis** 1996 Jan;17(1):227–34
CD4 deficiency in myelodysplastic syndrome with monosomy 7. Weemaes CM, et al. **Eur J Pediatr** 1996 Feb; 155(2):96–8
A flowcytometric study of CD4+ & CD19+ cell lymphopenia in patients with alopecia areata. Sharma VK, et al. **Indian J Med Res** 1996 Nov;104:296–8
Early levels of CD4, neopterin, and beta 2-microglobulin indicate future disease progression. Shi M, et al. **J Clin Immunol** 1997 Jan;17(1):43–52
Expansion of blood CD34 positive cells: committed precursors expansion does not affect immature hematopoietic progenitors. David S, et al. **Nouv Rev Fr Hematol** 1995;37(6):343–9
In vitro expansion of CD34+ cells from peripheral blood of myeloma and lymphoma patients. Mahe B, et al. **Nouv Rev Fr Hematol** 1995;37(6):335–41

CHEMISTRY

Selective effects of electrostatic changes in the CD4 CDR-3-like loop on infection by different human immunodeficiency virus type 1 isolates. Signoret N, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):1001–13
Inhibitory effect of a CD4-CDR3 peptide analog on graft-versus-host disease across a major histocompatibility complex-haploidentical barrier. Townsend RM, et al. **Blood** 1996 Oct 15;88(8):3038–47
Functional design of potential inhibitors of human immunodeficiency virus (HIV) binding to CD4+ target cells: a molecular model of gp120 predicts ligand binding. Gabriel JL, et al. **Drug Des Discov** 1996 Oct;14(2):103–14
Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides. Sauzet JP, et al. **Int Immunol** 1996 Apr;8(4):457–65
Transduction of activation signal that follows HIV-1 binding to CD4 and CD4 dimerization involves the immunoglobulin CDR3-like region in domain 1 of CD4. Briant L, et al. **J Biol Chem** 1997 Aug 1;272(31):19441–50
Identification of a human CD4-CDR3-like surface involved in CD4+ T cell function. Friedman TM, et al. **J Biol Chem** 1996 Sep 13;271(37):22635–40
Bioactive peptide design based on protein surface epitopes. A cyclic heptapeptide mimics CD4 domain 1 CC' loop and inhibits CD4 biological function. Satoh T, et al. **J Biol Chem** 1997 May 2;272(18):12175–80
Molecular analysis of the cytoplasmic domain of CD4: overlapping but noncompetitive requirement for lck association and down-regulation by Nef. Gratton S, et al. **J Immunol** 1996 Oct 15;157(8):3305–11
Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule. Tiganos E, et al. **J Virol** 1997 Jun;71(6):4452–60
A new class of viral inhibitor [news; comment] **Nat Biotechnol** 1997 Feb;15(2):135. Comment on: Nat Biotechnol 1997 Feb;15(2):150–4.
Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes [see comments] Zhang X, et al. **Nat Biotechnol** 1997 Feb;15(2):150–4. Comment in: Nat Biotechnol 1997 Feb;15(2):135.
Dimeric association and segmental variability in the structure of human CD4. Wu H, et al. **Nature** 1997 May 29; 387(6632):527–30
Characterization of the major histocompatibility complex

class II binding site on LAG-3 protein. Huard B, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5744–9

Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding. Wu H, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15030–5

Normal-mode analysis suggests important flexibility between the two N-terminal domains of CD4 and supports the hypothesis of a conformational change in CD4 upon HIV binding. Sanejouand YH. **Protein Eng** 1996 Aug;9(8):671–7

Receptor function of CD4 structures from African green monkey and pig-tail macaque for simian immunodeficiency virus, SIVsm, SIVagm, and human immunodeficiency virus type-1. Fomsgaard A, et al. **Viral Immunol** 1995; 8(3):121–33

[Role of the conformation changement of CD4 in the HIV-cell fusion] Sanejouand YH. **C R Acad Sci III** 1997 Feb;320(2):163–70 (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Rusconi S, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):234–6

Bioactive peptide design based on protein surface epitopes. A cyclic heptapeptide mimics CD4 domain 1 CC' loop and inhibits CD4 biological function. Satoh T, et al. **J Biol Chem** 1997 May 2;272(18):12175–80

A computer screening approach to immunoglobulin superfamily structures and interactions: discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics. Li S, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):73–8

GENETICS

Mutations within the CD4-CDR-3-like loop allow replication in an immortalized T cell line of HIV type 1 viruses chimeric for envelope glycoproteins containing non-syncytium-inducing V3 loops [letter] Signoret N, et al. **AIDS Res Hum Retroviruses** 1997 Jan 20;13(2):121–3

Multiple negative and positive cis-acting elements control the expression of the murine CD4 gene. McCready PM, et al. **Biochim Biophys Acta** 1997 Mar 20;1351(1-2):181–91

Characterization of a promoter within the first intron of the human CD4 gene. Rushton JJ, et al. **Eur J Biochem** 1997 May 1;245(3):768–73

Induction of CD4+ T cell depletion in mice doubly transgenic for HIV gp120 and human CD4. Finco O, et al. **Eur J Immunol** 1997 Jun;27(6):1319–24

DNA-based immunization induces anti-CD4 antibodies directed primarily to native epitopes. Attanasio R, et al. **FEMS Immunol Med Microbiol** 1997 Apr;17(4):207–15

Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. Honorati MC, et al. **Gastroenterology** 1997 Jun;112(6):2017–27

Variability of the CD4 and F13A1 short tandem repeats in Corsicans, Sardinians and Piaroa Indians. Vona G, et al. **Gene Geogr** 1996 Apr;10(1):51–63

Transduction of human hematopoietic cells and cell lines using a retroviral vector containing a modified murine CD4 reporter gene. Bauer TR Jr, et al. **Hum Gene Ther** 1997 Feb 10;8(3):243–52

Two-step gene transfer using an adenoviral vector carrying the CD4 gene and human immunodeficiency viral vectors. Miyake K, et al. **Hum Gene Ther** 1996 Dec 1;7(18):2281–6

Impaired Th2 subset development in the absence of CD4. Fowell DJ, et al. **Immunity** 1997 May;6(5):559–69

Unrepresentative behavior of T cell receptor-transgenic CD4+ T cells upon adoptive transfer: lack of need for priming and an extended booster dose-response. Schuhbauer D, et al. **Immunobiology** 1996 Jul;195(2):152–9

Positive selection induces CD4 promoter and enhancer function. Adlam M, et al. **Int Immunol** 1997 Jun;9(6):877–87

LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice. Miyazaki T, et al. **Int Immunol** 1996 May;8(5):725–9

Thymocytes control the CD4 gene differently from mature T lymphocytes. Uematsu Y, et al. **Int Immunol** 1997 Jan; 9(1):179–87

Alterations in CD4 dependence accompany T cell development and differentiation. Yelon D, et al. **Int Immunol** 1996 Jul;8(7):1077–90

The use of CD4 and CD8 knockout mice to study the role of T-cell subsets in allotransplant rejection. Krieger NR, et al. **J Heart Lung Transplant** 1997 Mar;16(3):263–7 (40 ref.)

Position-dependent variegation of a CD4 minigene with targeted expression to mature CD4+ T cells. Boyer O, et al. **J Immunol** 1997 Oct 1;159(7):3383–90

The natural history of disease expression in CD4 and CD8 gene-deleted New Zealand black (NZB) mice. Chen SY, et al. **J Immunol** 1996 Sep 15;157(6):2676–84

Induction of CD4 expression and human immunodeficiency virus type 1 replication by mutants of the interferon-inducible protein kinase PKR. Nagai K, et al. **J Virol** 1997 Feb;71(2):1718–25

Human herpesvirus 7 infection of lymphoid and myeloid cell lines transduced with an adenovirus vector containing the CD4 gene. Yasukawa M, et al. **J Virol** 1997 Feb; 71(2):1708–12

CD4 deletion mutants evaluated for human immunodeficiency virus type 1 infectivity in a highly efficient system of expression and detection based on LTR-dependent reporter gene activation. Moir S, et al. **J Virol Methods** 1997 May;65(2):209–17

Affinity maturation of proteins displayed on surface of M13 bacteriophage as major coat protein fusions. Roberts BL, et al. **Methods Enzymol** 1996;267:68–82

Specific demethylation of the CD4 gene during CD4 T lymphocyte differentiation. Tutt Landolfi MM, et al. **Mol Immunol** 1997 Jan;34(1):53–61

Molecular haplotyping of genetic markers 10 kb apart by allele-specific long-range PCR. Michalatos-Beloin S, et al. **Nucleic Acids Res** 1996 Dec 1;24(23):4841–3

Expression and biological activity of genetic fusions between MalE, the maltose binding protein from Escherichia coli and portions of CD4, the T-cell receptor of the AIDS virus. Clément JM, et al. **Protein Expr Purif** 1996 Nov; 8(3):319–31

CD4 dependence of activation threshold and TCR signalling in mouse T lymphocytes. Feito MJ, et al. **Scand J Immunol** 1997 Feb;45(2):166–74

Genetic data and the African origin of humans [letter; comment] Pritchard JK, et al. **Science** 1996 Nov 29; 274(5292):1548–9. Comment on: Science 1996 Mar 8;271(5254):1380–7.

Mutant CD4 molecules with improved binding to HIV envelope protein gp120 selected by phage display. Krybaev R, et al. **Virology** 1997 Aug 4;234(2):196–202

Interaction between the cytoplasmic domains of HIV-1 Vpu and CD4: role of Vpu residues involved in CD4 interaction and in vitro CD4 degradation. Margottin F, et al. **Virology** 1996 Sep 15;223(2):381–6

[Mechanisms of reduction of CD4 receptor expression on the surface of HIV-1 infected cells] Geleziunas R, et al. **C R Acad Sci III** 1996 Aug;319(8):653–62 (60 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

CD8 and CD4 T cell-mediated polymyositis complicating the HTLV-1 associated myelopathy. Quantitative evaluation of corticosteroid treatment. Waclawik AJ, et al. **Acta Neurol Scand** 1996 Aug;94(2):115–9

Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals. Burastero SE, et al. **AIDS Res Hum Retroviruses** 1996 Mar 1;12(4):273–80

AIDS patient monocytes target CD4 T cells for cellular conjugate formation and deletion through the membrane expression of HIV-1 envelope molecules. Dudhane A, et al. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):893–9

Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages. Lewin SR, et al. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):877–83

A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. Reimann KA, et al. **AIDS Res Hum Retroviruses** 1997 Jul 20;13(11):933–43

Virologic and immunologic markers of disease progression in pediatric HIV infection. Viganò A, et al. **AIDS Res Hum Retroviruses** 1996 Sep 1;12(13):1255–62

Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Canva-Delcambre V, et al. **Aliment Pharmacol Ther** 1996 Oct;10(5):721–7

Mediation of entry of human immunodeficiency virus-1 into alveolar macrophages by CD4 without facilitation by surfactant-associated protein-A. Guay LA, et al. **Am J Respir Cell Mol Biol** 1997 Apr;16(4):421–8

Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Selvam MP, et al. **Antiviral Res** 1996 Dec; 33(1):11–20

Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience. Epstein WV. **Arthritis Rheum** 1996 Nov;39(11):1773–80 (22 ref.)

Production of mouse anti-CD4 antibodies by DNA-based immunization. Kasinrerk W, et al. **Asian Pac J Allergy Immunol** 1996 Dec;14(2):99–105

Abnormal signal transduction through CD4 leads to altered tyrosine phosphorylation in T cells derived from MRL-lpr/lpr mice. Duan JM, et al. **Autoimmunity** 1996; 23(4):231–43

Heterogeneity of the human CD4+ T-cell population: two distinct CD4+ T-cell subsets characterized by coexpression of CD45RA and CD45RO isoforms. Hamann D, et al. **Blood** 1996 Nov 1;88(9):3513–21

Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy [letter] Wendling D, et al. **Br J Rheumatol** 1996 Dec;35(12):1330

Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2. Darrow TL, et al. **Cell Immunol** 1996 Aug 25;172(1):52–9

A role for T cell CD4 in contact mediated T dependent B cell activation. Kruman II, et al. **Cell Immunol** 1996 Nov 1;173(2):236–45

Induction of T cell adhesion by antigen stimulation and modulation by the coreceptor CD4. Michel F, et al. **Cell Immunol** 1996 Nov 1;173(2):165–75

Ligation of CD4 concomitant to activation induces primary CD4+ T-cell adhesion and pseudopodia formation in vitro. Palomo LF, et al. **Cell Immunol** 1996 Aug 25; 172(1):43–51

Down-regulatory role of surface CD4 molecules on autoreactive helper T cells during B cell activation. Aizawa K, et al. **Clin Exp Immunol** 1997 Apr;108(1):160–6

Anti-CD4 monoclonal antibody (mAb) and anti-idiotypic mAb to anti-CD4 in the therapy of autoimmune diseases. Perosa F, et al. **Clin Exp Rheumatol** 1997 Mar-Apr; 15(2):201–10 (51 ref.)

A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Anderson D, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):73–84

Assessment of chronic rejection in permanent accepted renal allografts in anti-CD4 treated rats. Risch K, et al. **Clin Nephrol** 1996 May;45(5):358–60

Anti-CD4 monoclonal antibody therapy. Delmonico FL, et al. **Clin Transplant** 1996 Oct;10(5):397–403

Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mouse. Zekzer D, et al. **Diabetes** 1997 Jul;46(7):1124–32

gp160 of HIV or anti-CD4 monoclonal antibody ligation of CD4 induces inhibition of JNK and ERK-2 activities in human peripheral CD4+ T lymphocytes. Jabado N, et al. **Eur J Immunol** 1997 Feb;27(2):397–404

Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Poller W, et al. **Gene Ther** 1996 Jun;3(6):521–30

CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Stronkhorst A, et al. **Gut** 1997 Mar;40(3):320–7

Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats. Lei D, et al. **Hum Gene Ther** 1996 Dec 1;7(18):2273–9

Human CD4-reactive antibodies from SLE patients induce reversible inhibition of polyclonal T lymphocyte proliferation. Lenert G, et al. **Hum Immunol** 1996 Sep 1; 49(2):113–21

CD4-reactive antibodies in systemic lupus erythematosus. Lenert P, et al. **Hum Immunol** 1996 Aug;49(1):38–48

Structural diversity of monoclonal CD4 antibodies and their capacity to block the HIV gp120/CD4 interaction. Weissenhorn W, et al. **Hybridoma** 1996 Apr;15(2):117–24

CD4 expression is important but not essential for infection with exogenous mouse mammary tumor virus. Ando Y, et al. **Immunobiology** 1996 Aug;195(3):376–84

V beta 8+CD4-CD8- subpopulation induced by staphylococcal enterotoxin B. Chou MC, et al. **Immunol Lett** 1997 Feb;55(2):85–91

Collaboration of TCR-, CD4- and CD28-mediated signalling in antigen-specific MHC class II-restricted T-cells. Gogolák P, et al. **Immunol Lett** 1996 Dec; 54(2-3):135–44

Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Cobbold SP, et al. **Immunol Rev** 1996 Feb;149:5–33 (109 ref.)

Differential functional effects of a humanized anti-CD4 antibody on resting and activated human T cells. Brett SJ, et al. **Immunology** 1997 Jul;91(3):346–53

The role of CD4 molecules in the induction phase of contact hypersensitivity cytokine profiles in the skin and lymph nodes. Fujisawa H, et al. **Immunology** 1996 Oct;89(2):250–5

Down-regulation of cell-surface CD4 co-receptor expression and modulation of experimental allergic encephalomyelitis. Fiori P, et al. **Int Immunol** 1997 Apr; 9(4):541–5

Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides. Sauzet JP, et al. **Int Immunol** 1996 Apr;8(4):457–65

Alterations in CD4 dependence accompany T cell development and differentiation. Yelon D, et al. **Int Immunol** 1996 Jul;8(7):1077–90

Antibody response to islet antigens in anti-CD4/prednisolone immune intervention of type 1 diabetes. Kohnert KD, et al. **Int J Clin Lab Res** 1996;26(1):55–9

Antigen-specific T-cell activations distinguished by in vivo anti-CD4 antibody treatment. Morrison WJ, et al. **Int J Immunopharmacol** 1995 Dec;17(12):1017–25

Murine mercury-induced autoimmunity: the role of T-helper cells. Hultman P, et al. **J Autoimmun** 1995 Dec;8(6):809–23

Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis. van der Lubbe PA, et al. **J Autoimmun** 1997 Feb;10(1):87–97

A role for CD4 in peripheral T cell differentiation. Brown DR, et al. **J Exp Med** 1997 Jul 7;186(1):101–7

Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice. Hege KM, et al. **J Exp Med** 1996 Dec 1;184(6):2261–9

Replacement of pre-T cell receptor signaling functions by the CD4 coreceptor. Norment AM, et al. **J Exp Med** 1997 Jan 6;185(1):121–30

Human immunodeficiency virus grown in CD4-expressing cells is associated with CD4. Hartley CA, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2015–23

Human herpesvirus 7 infection of CD4+(+) T cells does not require expression of the OKT4 epitope. Yasukawa M, et al. **J Gen Virol** 1996 Dec;77 (Pt 12):3103–6

A TCR V alpha CDR3-specific motif associated with Lewis rat autoimmune encephalomyelitis and basic protein-specific T cell clones. Buenafe AC, et al. **J Immunol** 1997 Jun 1;158(11):5472–83

Induction of Th2 cytokines and control of collagen-induced arthritis by nondepleting anti-CD4 Abs. Chu CQ, et al.

J Immunol 1996 Sep 15;157(6):2685–9

Th1 development of naive CD4+ T cells is inhibited by co-activation with anti-CD4 monoclonal antibodies. Goedert S, et al. **J Immunol** 1996 Jul 15;157(2):566–73

Deviated overexpression of TCR-beta, TCR-gamma, CD4, and CD8 on thymic lymphomas induced by 1-propyl-1-nitrosourea: destruction of the allelic exclusion of TCR-beta and expression of functional TCR-betagamma heterodimer on a lymphoma, cFTL53. Kinebuchi M, et al. **J Immunol** 1997 Jul 15;159(2):748–56

Regulation of memory CD4 T cell adhesion by CD4–MHC class II interaction. Metz DP, et al. **J Immunol** 1997 Sep 15;159(6):2567–73

Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients. Onodera K, et al. **J Immunol** 1996 Sep 1;157(5):1944–50

B7-2 requirement for helminth-induced granuloma formation and CD4 type 2 T helper cell cytokine expression. Subramanian G, et al. **J Immunol** 1997 Jun 15; 158(12):5914–20

Protection from experimental autoimmune encephalomyelitis (EAE): non-depleting anti-CD4 mAb treatment induces peripheral T-cell tolerance to MBP in PL/J mice. Biasi G, et al. **J Neuroimmunol** 1997 Mar;73(1–2):117–23

Leukocyte chemotactic factor, a natural ligand to CD4, is expressed by lymphocytes and microglial cells of the MS plaque. Schluesener HJ, et al. **J Neurosci Res** 1996 Jun 15;44(6):606–11

Apoptosis induced by gamma-irradiation, but not CD4 ligation, of peripheral T lymphocytes in vivo is p53-dependent. Malcomson RD, et al. **J Pathol** 1997 Feb; 181(2):166–71

Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis. Moreland LW. **J Rheumatol Suppl** 1996 Mar;44:78–83 (74 ref.)

Generation of monoclonal antibodies against a feline CD antigen (CD4) expressed by a recombinant baculovirus. Shimojima M, et al. **J Vet Med Sci** 1997 Jun;59(6):467–9

CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. Kozak SL, et al. **J Virol** 1997 Feb;71(2):873–82

Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4. Moir S, et al. **J Virol** 1996 Nov;70(11):8019–28

Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. Platt EJ, et al. **J Virol** 1997 Feb;71(2):883–90

Role of CD4 epitopes outside the gp120-binding site during entry of human immunodeficiency virus type 1. Simon JH, et al. **J Virol** 1997 Feb;71(2):1476–84

Thymocyte progenitors and T cell development in aging. Yu S, et al. **Mech Ageing Dev** 1997 Mar;94(1–3):103–11

Heat shock cognate protein 71-associated peptides function as an epitope for Toxoplasma gondii-specific CD4+ CTL. Yang TH, et al. **Microbiol Immunol** 1997;41(7):553–61

The repertoire of CD4+ CD28- T cells in rheumatoid arthritis. Schmidt D, et al. **Mol Med** 1996 Sep;2(5):608–18

Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412. Llewellyn-Smith N, et al. **Neurology** 1997 Apr;48(4):810–6

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. van Oosten BW, et al. **Neurology** 1997 Aug; 49(2):351–7

Indefinite survival of neural xenografts induced with anti-CD4 monoclonal antibodies. Wood MJ, et al. **Neuroscience** 1996 Feb;70(3):775–89

Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Schnierle BS, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5; 94(16):8640–5

CD4 dependence of activation threshold and TCR signalling in mouse T lymphocytes. Feito MJ, et al. **Scand J Immunol** 1997 Feb;45(2):166–74

Tolerance to heart and kidney grafts induced by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) versus depleting anti-CD4 monoclonal antibody (OX-38) with donor antigen administration. Motoyama K, et al. **Surgery** 1997 Aug;122(2):213–9; discussion 219–20

An investigation of "tolerance" induction following islet allotransplantation in the mouse. Asakura T, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):1152

Synergism of CTLA4-IG and anti-CD4 monoclonal antibody treatment in a rat kidney transplant model. Graser E, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):1307–9

Dominant infiltration by TH2 cells into grafts following treatment with anti-CD4 monoclonal antibody. Hamano K, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):1053

Bidirectional blockade of CD4 and MHC class II molecules is an effective immunosuppressive treatment. Ito H, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):1288–9

Effect of mycophenolate mofetil with and without anti-CD4 (GK1.5) on fetal islet iso-, allo-, and xenografts in NOD/Lt female mice. Koulmanda M, et al. **Transplant Proc** 1997 Jun;29(4):2161–2

Anti-CD4/CyA therapy causes prevention of autoimmune but not allogeneic destruction of grafted islets in BB rats. Kuttler B, et al. **Transplant Proc** 1997 Jun;29(4):2163–5

CD4-targeted therapy induces "infectious" tolerance to cardiac allografts in sensitized rat recipients. Onodera K, et al. **Transplant Proc** 1997 May;29(3):1907–8

Inhibition of chronic rejection after kidney transplantation by anti-CD4 treatment. Risch K, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):328–9

Modulation of the CD4 molecule is a major event in the induction of transplantation tolerance with anti-CD4 monoclonal antibodies. Saitovitch D, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):1159

Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Cooperative Clinical Trials in Transplantation Research Group. **Transplantation** 1997 May 15;63(9):1243–51

Anti-CD4 MoAb therapy in kidney transplantation--a pilot study in early prophylaxis of rejection. Dantal J, et al. **Transplantation** 1996 Nov 27;62(10):1502–6

CD4 mAbs prevent progression of alloactivated CD4+ T cells into the S phase of the cell cycle without interfering with early activation signals. Fournel S, et al. **Transplantation** 1996 Oct 27;62(8):1136–43

Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients. Hamano K, et al. **Transplantation** 1996 Sep 27;62(6):856–60

Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig. Yin DP, et al. **Transplantation** 1996 Dec 15; 62(11):1537–9

Effect of anti-CD4 monoclonal antibody combined with human CTLA4Ig on the survival of hamster liver and heart xenografts in Lewis rats. Yin DP, et al. **Transplantation** 1997 Jul 27;64(2):317–21

A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. McInerney TL, et al. **Virology** 1997 Jul 7; 233(2):313–26

[Current therapy of multiple sclerosis. Therapy with monoclonal antibodies to T-cell antigens (CD3, CD4, CD52)] Schmidt S, et al. **Nervenarzt** 1996 Feb;67(2):170–6 (44 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Altered CD4 interactions of HIV type 1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4. Klasse PJ, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20; 12(11):1015–21

CD4 confers susceptibility to human immunodeficiency virus type 1 infection in a rat fibroblast cell line. Mizrachi Y, et al. **AIDS Res Hum Retroviruses** 1996 Sep 20; 12(14):1315–8

Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4. Weinberg J, et al. **AIDS Res Hum Retroviruses** 1997 May 20;13(8):657–64

Human immunodeficiency virus type 1 entry into murine cell lines and lymphocytes from transgenic mice expressing a glycoprotein 120-binding mutant mouse CD4. Wieder KJ, et al. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):867–76

Identification of a phosphodiester hexanucleotide that inhibits HIV-1 infection in vitro on covalent linkage of its 5'-end with a dimethoxytrityl residue. Furukawa H, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):167–75

Targeting of liposomes to HIV-1-infected cells by peptides derived from the CD4 receptor. Slepushkin VA, et al. **Biochem Biophys Res Commun** 1996 Oct 23;227(3):827–33

Analysis of the interaction of an anti-HIV peptide, T22 ([Tyr5, 12, Lys7]-polyphemusin II), with gp120 and CD4 by surface plasmon resonance. Tamamura H, et al. **Biochim Biophys Acta** 1996 Nov 14;1298(1):37–44

Phenotypic and functional evidence for the expression of CD4 by hematopoietic stem cells isolated from human fetal liver. Muench MO, et al. **Blood** 1997 Feb 15;89(4):1364–75

CD4 cross-linking (CD4XL) induces RAS activation and tumor necrosis factor-alpha secretion in CD4+ T cells. Tamma SM, et al. **Blood** 1997 Aug 15;90(4):1588–93

The development of human megakaryocytes. II. CD4 expression occurs during haemopoietic differentiation and is an early step in megakaryocyte maturation. Basch RS, et al. **Br J Haematol** 1996 Sep;94(3):433–42

The engagement of CD4 surface antigen in the HEL haemopoietic cell line up-regulates the transforming growth factor-beta1 (TGF-beta1) promoter activity. Gibellini D, et al. **Br J Haematol** 1997 Jun;97(3):571–8

Expression of CD8beta and alteration of cell surface phenotype in adult T-cell leukaemia cells. Joh T, et al. **Br J Haematol** 1997 Jul;98(1):151–6

HIV infection of human fetal neural cells is mediated by gp120 binding to a cell membrane-associated molecule that is not CD4 nor galactocerebroside. Hao HN, et al. **Brain Res** 1997 Aug 1;764(1–2):149–57

CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Endres MJ, et al. **Cell** 1996 Nov 15; 87(4):745–56

A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells [see comments] Mebatsion T, et al. **Cell** 1997 Sep 5;90(5):841–7 . Comment in: Cell 1997 Sep 5;90(5):821–4.

Physical association of CD4 and CD45 in primary, resting CD4+ T cells. Bonnard M, et al. **Cell Immunol** 1997 Jan 10;175(1):1–11

A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Anderson D, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):73–84

Disposition of metabolically radiolabeled CE9.1—a macaque-human chimeric anti-human CD4 monoclonal antibody—in transgenic mice bearing human CD4. Davis CB, et al. **Drug Metab Dispos** 1996 Sep;24(9):1032–7

Surface plasmon resonance analysis of gp17, a natural CD4 ligand from human seminal plasma inhibiting human immunodeficiency virus type-1 gp120-mediated syncytium formation. Autiero M, et al. **Eur J Biochem** 1997 Apr 1; 245(1):208–13

Differentiation of CD4(high)CD8(low) coreceptor-skewed thymocytes into mature CD8 single-positive cells independent of MHC class I recognition. Barthlott T, et al. **Eur J Immunol** 1997 Aug;27(8):2024–32

The interaction of sperm cells with exogenous DNA: a role of CD4 and major histocompatibility complex class II molecules. Lavitrano M, et al. **Exp Cell Res** 1997 May 25; 233(1):56–62

CD4+ T-cell population mediates development of inflammatory bowel disease in T-cell receptor alpha chain-deficient mice. Takahashi I, et al. **Gastroenterology** 1997 Jun;112(6):1876–86

Unexpectedly complex regulation of CD4/CD8 coreceptor expression supports a revised model for CD4+CD8+ thymocyte differentiation. Lucas B, et al. **Immunity** 1996 Nov;5(5):461–77

The HIV-1 Nef protein acts as a connector with sorting pathways in the Golgi and at the plasma membrane. Mangasarian A, et al. **Immunity** 1997 Jan;6(1):67–77

Isolation from a human seminal vesicle library of the cDNA for gp17, a CD4 binding factor. Autiero M, et al. **Immunogenetics** 1997;46(4):345–8

The bone marrow peptide (myelopeptide-2) abolishes induced by human leukemia HL-60 cell suppression of T lymphocytes. Strelkov LA, et al. **Immunol Lett** 1996 May; 50(3):143–7

A synthetic peptide mimicking the HLA-DR beta 2-binding site for CD4 inhibits antigen-independent CD4+ T cell adhesion to B cells and CD4+ T cell activation. Mazerolles F, et al. **Int Immunol** 1996 Feb;8(2):267–74

Ig VH-dependent interaction between immunoglobulins and CD4. Lenert P, et al. **Int Rev Immunol** 1997;14(4):351–62 (44 ref.)

Human immunodeficiency virus infection abolishes CD4-dependent activation of ZAP-70 by inhibition of p56lck. Guntermann C, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Mar 1;14(3):204–12

Comparative analysis of the gp120-binding area of murine and human CD4 molecules. Siddiqi MA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jan 1;14(1):7–12

Synthesis and inhibitory activities of isochromophilone analogues against gp120-CD4 binding. Sun XL, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):689–92

Binding of HIV-1 Nef to a novel thioesterase enzyme correlates with Nef-mediated CD4 down-regulation. Liu LX, et al. **J Biol Chem** 1997 May 23;272(21):13779–85

Changes in memory and naive CD4+ lymphocytes in lymph nodes and spleen after thermal injury. Lawrence MH, et al. **J Burn Care Rehabil** 1996 Jan-Feb;17(1):1–6

Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. Farzan M, et al. **J Exp Med** 1997 Aug 4;186(3):405–11

Two distinct steps during thymocyte maturation from CD4-CD8- to CD4+CD8+ distinguished in the early growth response (Egr)-1 transgenic mice with a recombinase-activating gene-deficient background. Miyazaki T. **J Exp Med** 1997 Sep 15;186(6):877–85

Bimodal down-regulation of CD4 in cells expressing human immunodeficiency virus type 1 Vpu and Env. Fujita K, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2393–401

Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors. Fujita K, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):619–25

Molecular analysis of the cytoplasmic domain of CD4: overlapping but noncompetitive requirement for lck association and down-regulation by Nef. Gratton S, et al. **J Immunol** 1996 Oct 15;157(8):3305–11

TCR engagement of CD4+CD8+ thymocytes in vitro induces early aspects of positive selection, but not apoptosis. Groves T, et al. **J Immunol** 1997 Jan 1; 158(1):65–75

Analysis of the contact sites on the CD4 molecule with class II MHC molecule: co-ligand versus co-receptor function. Huang B, et al. **J Immunol** 1997 Jan 1;158(1):216–25

CD4 ligands inhibit the formation of multifunctional transduction complexes involved in T cell activation. Jabado N, et al. **J Immunol** 1997 Jan 1;158(1):94–103

Phosphatidylinositol 3-kinase participates in p56(lck)/CD4-dependent down-regulation of LFA-1-mediated T cell adhesion. Mazerolles F, et al. **J Immunol** 1996 Dec 1;157(11):4844–54

Inhibition of protein kinase C-mediated CD4 down-regulation by oxidative stress in T lymphocytes. Nakamura K, et al. **J Immunol** 1996 Dec 15;157(12):5339–49

Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. Oyaizu N, et al. **J Immunol** 1997 Mar 1;158(5):2456–63

Human herpesvirus 7 induces the down-regulation of CD4 antigen in lymphoid T cells without affecting p56lck levels. Secchiero P, et al. **J Immunol** 1997 Oct 1;159(7):3412–23

CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. Theodore AC, et al. **J Immunol** 1996 Sep 1;157(5):1958–64

HIV-1 gp120 induces an association between CD4 and the chemokine receptor CXCR4. Ugolini S, et al. **J Immunol** 1997 Sep 15;159(6):3000–8

Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. Hill CM, et al. **J Virol** 1997 Sep;71(9):6296–304

Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus Nef use distinct but overlapping target sites for downregulation of cell surface CD4. Hua J, et al. **J Virol** 1997 Sep;71(9):6742–8

Induction of phosphorylation of human immunodeficiency virus type 1 Nef and enhancement of CD4 downregulation by phorbol myristate acetate. Luo T, et al. **J Virol** 1997 Mar;71(3):2535–9

A mechanism of restricted human immunodeficiency virus type 1 expression in human glial cells. Shahabuddin M, et al. **J Virol** 1996 Nov;70(11):7992–8002

CD4 deletion mutants evaluated for human immunodeficiency virus type 1 infectivity in a highly efficient system of expression and detection based on LTR-dependent reporter gene activation. Moir S, et al. **J Virol Methods** 1997 May;65(2):209–17

Glycodelins GdA and GdS modified by 3-hydroxyphthalic anhydride inhibit gp120-CD4 binding and HIV-1 infection in vitro. Seppälä M, et al. **Lab Invest** 1997 Aug;77(2):127–30

Affinity maturation of proteins displayed on surface of M13 bacteriophage as major coat protein fusions. Roberts BL, et al. **Methods Enzymol** 1996;267:68–82

Second-messenger regulation of receptor association with clathrin-coated pits: a novel and selective mechanism in the control of CD4 endocytosis. Foti M, et al. **Mol Biol Cell** 1997 Jul;8(7):1377–89

Specific demethylation of the CD4 gene during CD4 T lymphocyte differentiation. Tutt Landolfi MM, et al. **Mol Immunol** 1997 Jan;34(1):53–61

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 [see comments] Trkola A, et al. **Nature** 1996 Nov 14;384(6605):184–7. Comment in: Nature 1996 Nov 14;384(6605):117–8.

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 [see comments] Wu L, et al. **Nature** 1996 Nov 14; 384(6605):179–83. Comment in: Nature 1996 Nov 14;384(6605):117–8.

Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding. Wu H, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15030–5

Analysis of the interactions between Nef and cellular proteins. Coates K, et al. **Res Virol** 1997 Jan-Feb; 148(1):68–70 (14 ref.)

Regulation of Nef function. Luo T, et al. **Res Virol** 1997 Jan-Feb;148(1):64–8 (27 ref.)

The multifaceted role of HIV Nef. Mangasarian A, et al. **Res Virol** 1997 Jan-Feb;148(1):30–3 (41 ref.)

HIV gets a taste of its own medicine [news] Cohen J. **Science** 1997 Sep 12;277(5332):1606

Investigators detail HIV's fatal handshake [news; comment] Cohen J. **Science** 1996 Oct 25;274(5287):502. Comment on: Science 1996 Oct 25;274(5287):602–5.

Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines [see comments] Lapham CK, et al. **Science** 1996 Oct 25;274(5287):602–5. Comment in: Science 1996 Oct 25;274(5287):502.

Expression and function of a CD4-like molecule in parathyroid tissue. Hellman P, et al. **Surgery** 1996 Dec; 120(6):985–92

The expression of CD4 and CD8 molecules conditions the behavior of V beta + murine thymocytes upon superantigenic challenge. Fattorossi A, et al. **Thymus** 1997; 24(3):133–45

Postbinding functions of CD4 in HIV infection. Bachelder RE, et al. **Trends Microbiol** 1996 Sep;4(9):359–63 (48 ref.)

Receptor function of CD4 structures from African green monkey and pig-tail macaque for simian immunodeficiency virus, SIVsm, SIVagm, and human immunodeficiency virus type-1. Fomsgaard A, et al. **Viral Immunol** 1995; 8(3):121–33

How lysophosphatidylcholine inhibits cell-cell fusion mediated by the envelope glycoprotein of human immunodeficiency virus. Günther-Ausborn S, et al. **Virology** 1997 Sep 1;235(2):201–8

Identification of regions in HIV-1 Nef required for efficient downregulation of cell surface CD4. Hua J, et al. **Virology** 1997 May 12;231(2):231–8

Interaction between the cytoplasmic domains of HIV-1 Vpu and CD4: role of Vpu residues involved in CD4 interaction and in vitro CD4 degradation. Margottin F, et al. **Virology** 1996 Sep 15;223(2):381–6

Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4. Paul M, et al. **Virology** 1997 May 26;232(1):207–16

CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Reeves JD, et al. **Virology** 1997 Apr 28;231(1):130–4

Receptor interference mediated by the envelope glycoproteins of various HIV-1 and HIV-2 isolates. Martin RA, et al. **Virus Res** 1996 Dec;45(2):135–45

[Theoretical study of the spatial structure of the Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr segment of the HIV gp120 protein, responsible for binding of the virus with the T-cell T4 receptor] Andrianov AM, et al. **Mol Biol (Mosk)** 1997 Jan-Feb;31(1):180–8 **(Rus)**

PHARMACOLOGY

Further insights on the inhibition of HIV type 1 infection in vitro by CD4-modified synthetic peptides containing phenylalanine. Prieto I, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):1023–30

Soluble CD14 mediates lipopolysaccharide-induced intercellular adhesion molecule 1 expression in cultured human gingival fibroblasts. Hayashi J, et al. **Infect Immun** 1996 Dec;64(12):4946–51

Evidence for down-regulation of highly expressed TCR by CD4 and CD45 on non-selected CD4+CD8+ thymocytes. Sato T, et al. **Int Immunol** 1996 Oct; 8(10):1529–35

A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4+ T cell responses in experimental allergic encephalomyelitis. Marini JC, et al. **J Immunol** 1996 Oct 15;157(8):3706–15

Replication of primary HIV-1 isolates is inhibited in PM1 cells expressing sCD4-KDEL. Degar S, et al. **Virology** 1996 Dec 15;226(2):424–9

PHYSIOLOGY

Generation of lymphocyte cell lines coexpressing CD4 and wild-type or mutant HIV type 1 glycoproteins: implications for HIV type 1 Env-induced cell lysis. Krüger U, et al. **AIDS Res Hum Retroviruses** 1996 Jun 10; 12(9):783–92

Abortive infection in HeLaCD4 cells by a primary HIV type 1 isolate: implications for differential host cell tropism. Smyth RJ, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10;13(9):759–69

Human immunodeficiency virus (HIV)-resistant CD4+ UT-7 megakaryocytic human cell line becomes highly HIV-1 and HIV-2 susceptible upon CXCR4 transfection: induction of cell differentiation by HIV-1 infection. Baiocchi M, et al. **Blood** 1997 Apr 15;89(8):2670–8

Modulation of Bcl-2 protein by CD4 cross-linking: a possible mechanism for lymphocyte apoptosis in human immunodeficiency virus infection and for rescue of apoptosis by interleukin-2. Hashimoto F, et al. **Blood** 1997 Jul 15;90(2):745–53

Quantitative but not qualitative variation in MHC class II alters CD4 interaction and influences T cell repertoire formation. Fuller-Espie SL, et al. **Cell Immunol** 1997 Apr 10;177(1):49–61

Molecular basis of T lymphocyte CD4 antigen functions. Gaubin M, et al. **Eur J Clin Chem Clin Biochem** 1996 Sep; 34(9):723–8 (50 ref.)

Signals through CD8 or CD4 can induce commitment to the CD4 lineage in the thymus. Bommhardt U, et al. **Eur J Immunol** 1997 May;27(5):1152–63

Interleukin 16 and its function as a CD4 ligand. Center DM, et al. **Immunol Today** 1996 Oct;17(10):476–81 (45 ref.)

Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Nishimura H, et al. **Int Immunol** 1996 May; 8(5):773–80

Intrinsic signals in the unique domain target p56(lck) to the plasma membrane independently of CD4. Bijlmakers MJ, et al. **J Cell Biol** 1997 Jun 2;137(5):1029–40

CD4+ CD7- T cells: a separate subpopulation of memory T cells? Reinhold U, et al. **J Clin Immunol** 1997 Jul; 17(4):265–71 (36 ref.)

CXCR4/fusin is not a species-specific barrier in murine cells for HIV-1 entry. Tachibana K, et al. **J Exp Med** 1997 May 19;185(10):1865–70

Rapid commitment to negative selection of a thymocyte line independent of CD4 co-engagement. Kovalik JP, et al. **J Immunol** 1996 Dec 15;157(12):5290–9

Role of CD4+ T cells and of the CD4 molecule in contact sensitivity [letter; comment] Bour H, et al. **J Invest Dermatol** 1997 May;108(5):811–2. Comment on: J Invest Dermatol 1996 May;106(5):993–1000.

NMR and circular dichroism studies on the conformation of a 44-mer peptide from a CD4-binding domain of human immunodeficiency virus envelope glycoprotein. Chang DK, et al. **J Pept Res** 1997 May;49(5):432–43

Function of CD4 molecules in LEC rat thymocytes. Sakai T, et al. **J Vet Med Sci** 1996 Nov;58(11):1125–7

Mechanism of human immunodeficiency virus type 1 localization in CD4-negative thymocytes: differentiation from a CD4-positive precursor allows productive infection. Kitchen SG, et al. **J Virol** 1997 Aug;71(8):5713–22

Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody. Lee S, et al. **J Virol** 1997 Aug;71(8):6037–43

RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE). Schols D, et al. **J Virol** 1997 Oct;71(10):7300–4

Upregulation of human immunodeficiency virus (HIV) replication by CD4 cross-linking in peripheral blood mononuclear cells of HIV-infected adults. Than S, et al. **J Virol** 1997 Aug;71(8):6230–2

VH gene expression in CD5 positive and CD5 negative B cell chronic lymphoid malignancies. Maloum K, et al. **Leuk Lymphoma** 1997 Feb;24(5-6):437–48 (114 ref.)

Binding of human immunodeficiency virus type 1 to CD4 induces association of Lck and Raf-1 and activates Raf-1 by a Ras-independent pathway. Popik W, et al. **Mol Cell Biol** 1996 Nov;16(11):6532–41

Gene activating and proapoptotic potential are independent properties of different CD4 epitopes. Milia E, et al. **Mol Immunol** 1997 Mar;34(4):287–96

Fas (CD95) expression and death-mediating function are induced by CD4 cross-linking on CD4+ T cells. Desbarats J, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):11014–8

Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. Mebatsion T, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11366–70

The role of CD4-Lck in T-cell receptor antagonism: evidence for negative signaling. Racioppi L, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10360–5

Expression and function of a CD4-like molecule in parathyroid tissue. Hellman P, et al. **Surgery** 1996 Dec; 120(6):985–92

[Activation of T-lymphocytes in Crohn disease and in ulcerative hemorrhagic rectocolitis. Therapeutic implications] Voiglio E, et al. **Pathol Biol (Paris)** 1996 Apr; 44(4):287–92 (44 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Conformational transitions in CD4 due to complexation with HIV envelope glycoprotein gp120. Denisova G, et al. **J Immunol** 1997 Feb 1;158(3):1157–64

ANTIGENS, CD5

Marked reduction of mouse peritoneal CD5+ B cells by intraperitoneal administration of lipopolysaccharide. Paeng N, et al. **Infect Immun** 1997 Jan;65(1):122–6

ANALYSIS

CD5 immunoreactivity of epithelial cells in thymic carcinoma and CASTLE using paraffin-embedded tissue. Berezowski K, et al. **Am J Clin Pathol** 1996 Oct;106(4):483–6

CD5 immunostaining of lymphoid neoplasms in paraffin sections [letter; comment] Butmarc J, et al. **Am J Clin Pathol** 1997 Apr;107(4):496–7; discussion 497. Comment on: Am J Clin Pathol 1996 Sep;106(3):370–3.

Immunophenotypic analysis of CD5 positivity in paraffin-embedded tissues. Still waiting for an effective diagnostic antibody [editorial;comment] Perkins SL. **Am J Clin Pathol** 1996 Sep;106(3):273–4. Comment on: Am J Clin Pathol 1996 Sep;106(3):370–3.

CD5 immunostaining of lymphoid neoplasms in paraffin sections [letter; comment] Salhany KE, et al. **Am J Clin Pathol** 1997 Apr;107(4):496; discussion 497. Comment on: Am J Clin Pathol 1996 Sep;106(3):370–3.

Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity. Dorfman DM, et al. **Am J Surg Pathol** 1997 Aug;21(8):936–40

Clonal CD5-positive B lymphocytes in myelodysplastic syndrome with systemic vasculitis and trisomy 8. Billström R, et al. **Ann Hematol** 1997 Jan;74(1):37–40

Normal CD5+ B lymphocytes are poor stimulators in the autologous mixed lymphocyte reaction (AMLR). Fernandez LA, et al. **Clin Exp Immunol** 1997 Jun; 108(3):557–61

The study of circulating CD5 positive B lymphocytes in Chinese patients with rheumatoid arthritis. Liu ST, et al. **Clin Rheumatol** 1996 May;15(3):250–3

CD5+ B cells in Graves' disease: correlation with disease activity. Corrales JJ, et al. **Horm Metab Res** 1996 Jun; 28(6):280–5

The B/macrophage cell: an elusive link between CD5+ B lymphocytes and macrophages. Borrello MA, et al. **Immunol Today** 1996 Oct;17(10):471–5 (36 ref.)

Isotype and antibody specificity of spontaneously formed immunoglobulins in pig fetuses and germ-free piglets: production by CD5- B cells. Cukrowska B, et al. **Immunology** 1996 Aug;88(4):611–7

Modulation of CD72 by ligation of B cell receptor complex molecules on CD5+ B cells. Jamin C, et al. **Int Immunol** 1997 Jul;9(7):1001–9

IL-12 directly stimulates expression of IL-10 by CD5+ B cells and IL-6 by both CD5+ and CD5- B cells: possible involvement in age-associated cytokine dysregulation. Spencer NF, et al. **Int Immunol** 1997 May;9(5):745–54

Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes. Biancone L, et al.

ANTIGENS, CD5

J Exp Med 1996 Sep 1;184(3):811–9

B–1 cell (CD5+B220+) outgrowth in murine schistosomiasis is genetically restricted and is largely due to activation by polylactosamine sugars. Velupillai P, et al. **J Immunol** 1997 Jan 1;158(1):338–44

Synthesis of anti–acetylcholine receptor antibodies by CD5– B cells from peripheral blood of myasthenia gravis patients. Heidenreich F, et al. **J Neurol** 1996 Jan;243(1):57–62

CD5–expressing B–cell lymphomas/leukemias: relatively high frequency of CD5+ B–cell lymphomas with an overall poor prognosis in Nagasaki Japan. Kamihira S, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):137–42

Distinctive developmental origins and specificities of the CD5+ B–cell subset. Hardy RR, et al. **Semin Immunol** 1996 Feb;8(1):37–44 (39 ref.)

V–gene usage and N–region insertions in B–1a, B–1b and conventional B cells. Kantor AB. **Semin Immunol** 1996 Feb; 8(1):29–35 (73 ref.)

B–1 cells and their reactivity with the murine intestinal microflora. Kroese FG, et al. **Semin Immunol** 1996 Feb; 8(1):11–8 (52 ref.)

Introduction: B–1 cells: origins and functions. Stall AM, et al. **Semin Immunol** 1996 Feb;8(1):1–2

B–1 cells: unique origins and functions. Stall AM, et al. **Semin Immunol** 1996 Feb;8(1):45–59 (82 ref.)

Increased numbers of CD5+ B cells in the thymus of estradiol benzoate–treated rats. Martín A, et al. **Thymus** 1996;24(2):111–27

Decreased CD5+ B cells during the acute phase of Kawasaki disease. Kim HS, et al. **Yonsei Med J** 1996 Feb;37(1):52–8

BIOSYNTHESIS

CD5– CD8 alpha beta intestinal intraepithelial lymphocytes (IEL) are induced to express CD5 upon antigen–specific activation: CD5– and CD5+ CD8 alpha beta IEL do not represent separate T cell lineages. Müller S, et al. **Eur J Immunol** 1997 Jul;27(7):1756–61

BLOOD

CD5 B cells in autoimmune and non immune–mediated thyroid dysfunctions. Afeltra A, et al. **Endocr Res** 1997 Feb–May;23(1–2):81–94

Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(–)/IgM+ B cells. Brezinschek HP, et al. **J Clin Invest** 1997 May 15; 99(10):2488–501

GENETICS

Conservation of a polymorphic microsatellite at orthologous positions in the human and mouse CD5 gene promoter. Calvo J, et al. **Immunogenetics** 1997;45(3):233–4

Evolutionarily conserved transcription regulatory elements within the 5'–flanking region of the human CD5 gene. Calvo J, et al. **Tissue Antigens** 1996 Mar;47(3):257–61

The Ly–1.1 and Ly–1.2 epitopes of murine CD5 map to the membrane distal scavenger receptor cysteine–rich domain. Starling GC, et al. **Tissue Antigens** 1997 Jan;49(1):1–6

IMMUNOLOGY

Ly1– (CD5–) B cells produce interleukin (IL)–10. Gieni RS, et al. **Cell Immunol** 1997 Feb 1;175(2):164–70

Detection of T cells reactive to intestinal alkaline phosphatase, an autoantigen in acute bacterial infections, and discrimination between autoantigen–specific CD5+ and CD5– B cells. Kolbus N, et al. **Clin Exp Immunol** 1997 Apr;108(1):19–25

CD5/CD19/CD23 chronic lymphocytosis [letter] Manteiga R, et al. **Haematologica** 1997 Jul–Aug;82(4):510–1

CD5 is a potential selecting ligand for B cell surface immunoglobulin framework region sequences. Pospisil R, et al. **J Exp Med** 1996 Oct 1;184(4):1279–84

Bar Mitzvah for B–1 cells: how will they grow up? [comment] Tarakhovsky A. **J Exp Med** 1997 Mar 17; 185(6):981–4 (48 ref.). Comment on: J Exp Med 1997 Mar 17;185(6):1035–42.

Decreases in CD5+ B lymphocytes in children with the DiGeorge anomaly. Kourtis AP, et al. **Scand J Immunol** 1997 Sep;46(3):281–3

Long–term survival of hamster–to–rat heart xenografts based on mechanisms of accommodation and tolerance of CD5 B cells. Lin Y, et al. **Transplant Proc** 1997 Aug;29(5):2355

[CD5 positive b–lymphocytes in autoimmunity: possible role in Graves' disease] Afeltra A, et al. **Riv Eur Sci Med Farmacol** 1995 Sep–Oct;17(5):167–74 (64 ref.) (Eng. Abstr.) **(Ita)**

ISOLATION & PURIFICATION

Antibody NCL–CD5 fails to detect neoplastic CD5+ cells in paraffin sections [see comments] Ben–Ezra JM, et al. **Am J Clin Pathol** 1996 Sep;106(3):370–3. Comment in: Am J Clin Pathol 1996 Sep;106(3):273–4. Comment in: Am J Clin Pathol 1997 Apr;107(4):496; discussion 497. Comment in: Am J Clin Pathol 1997 Apr;107(4):496–7; discussion 497.

METABOLISM

CD5+ extranodal marginal zone B–cell (MALT) lymphoma [letter; comment] Wright DH. **Am J Clin Pathol** 1996 Sep; 106(3):438. Comment on: Am J Clin Pathol 1996 Jan;105(1):31–7.

Native soluble CD5 delivers a costimulatory signal to resting human B lymphocytes. Van de Velde H, et al. **Cell Immunol** 1996 Aug 25;172(1):84–91

Thymocyte activation induces the association of phosphatidylinositol 3–kinase and pp120 with CD5. Dennehy KM, et al. **Eur J Immunol** 1997 Mar;27(3):679–86

Adult bone marrow contains precursors for CD5+ B cells. Huang CA, et al. **Eur J Immunol** 1996 Oct;26(10):2537–40

Induction of murine CD5 expression by v–H–ras. Weichert TR, et al. **Immunology** 1997 Jan;90(1):30–7

Autoantibody formation after allogeneic bone marrow transplantation: correlation with the reconstitution of CD5+ B cells and occurrence of graft–versus–host disease. Chan EY, et al. **Pathology** 1997 May;29(2):184–8

PHYSIOLOGY

In vitro and in vivo functional analysis of CD5+ and CD5– B cells of autoimmune NZB x NZW F1 mice. Ye YL, et al. **Clin Exp Immunol** 1996 Nov;106(2):253–8

The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity. Cerutti A, et al. **J Immunol** 1996 Sep 1;157(5):1854–62

CD5–mediated negative regulation of antigen receptor–induced growth signals in B–1 B cells. Bikah G, et al. **Science** 1996 Dec 13;274(5294):1906–9

ANTIGENS, CD7

CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Suzuki R, et al. **Blood** 1997 Sep 15;90(6):2417–28

Wells' syndrome: a pathogenic role for circulating CD4+CD7– T cells expressing interleukin–5 mRNA. Yagi H, et al. **Br J Dermatol** 1997 Jun;136(6):918–23

ANALYSIS

The CD7– T cell subset represents the majority of IL–5–secreting cells within CD4+CD45RA– T cells. Reinhold U, et al. **Clin Exp Immunol** 1996 Dec;106(3):555–9

A new strategy for treating patients with CD7+, CD4–, CD8– acute lymphoblastic leukaemia [letter] Ono K, et al. **Eur J Haematol** 1997 Feb;58(2):130–2

Interstitial 9q deletion is associated with CD7+ acute leukemia of myeloid and T lymphoid lineage [letter] Ferrara F, et al. **Leukemia** 1996 Dec;10(12):1990–2

[CD7, HLA–DR, CD38 positive acute undifferentiated leukemia with subcutaneous tumor and thymoma] Doi T, et al. **Rinsho Ketsueki** 1996 Aug;37(8):676–81 (Eng. Abstr.) **(Jpn)**

[Smoldering leukemia with CD7,CD34(+), immunoglobulin heavy chain rearrangement (+) and hypoplastic marrow with myelofibrosis] Hara T, et al. **Rinsho Ketsueki** 1997 Jan;38(1):21–7 (Eng. Abstr.) **(Jpn)**

BLOOD

CD7–negative T cells represent a separate differentiation pathway in a subset of post–thymic helper T cells. Reinhold U, et al. **Immunology** 1996 Nov;89(3):391–6

Biochemical analysis of plasma–soluble invariant chains and their complex formation with soluble HLA–DR. Rebmann V, et al. **Tissue Antigens** 1997 May;49(5):438–42

CHEMISTRY

Functional association of CD7 with phosphatidylinositol 3–kinase: interaction via a YEDM motif. Lee DM, et al. **Int Immunol** 1996 Aug;8(8):1195–203

GENETICS

CD3 gamma, CD3 delta, and CD3 zeta mRNA in adult human marrow hematopoietic progenitors correlates with surface CD2 and CD7 expression. Long H, et al. **Exp Hematol** 1996 Oct;24(12):1402–8

IMMUNOLOGY

Immunophenotypic identification of Sezary cells in peripheral blood. Bogen SA, et al. **Am J Clin Pathol** 1996 Dec;106(6):739–48

Comparison of the potency and therapeutic efficacy of the anti–CD7 immunotoxin HB2–saporin constructed with one or two saporin moieties per immunotoxin molecule. Flavell DJ, et al. **Br J Cancer** 1997;75(7):1035–43

Interaction between the extracellular domain of CD7 and concanavalin A: a clue to the identity of the ligand for CD7. Leta E, et al. **Cell Immunol** 1996 Oct 10;173(1):15–21

GM–CSF– and IL–3–dependent CD34 expressing myeloid cell line (SAS–1) established from CD7 and CD34 expressing acute myeloblastic leukemic cells. Sasaki K, et al. **Int J Hematol** 1997 Jul;66(1):35–45

CD7–mediated regulation of integrin adhesiveness on human T cells involves tyrosine phosphorylation–dependent activation of phosphatidylinositol 3–kinase. Chan AS, et al. **J Immunol** 1997 Jul 15;159(2):934–42

Construction and characterization of human CD7–specific single–chain Fv immunotoxins. Pauza ME, et al. **J Immunol** 1997 Apr 1;158(7):3259–69

Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. Vallera DA, et al. **J Immunol Methods** 1996 Oct 16;197(1–2):69–83

METABOLISM

Putative normal counterparts of leukaemic cells from CD7–positive acute myeloid leukaemia can be demonstrated in human haemopoietic tissues. Tien HF, et al. **Br J Haematol** 1996 Sep;94(3):501–6

Functional association of CD7 with phosphatidylinositol 3–kinase: interaction via a YEDM motif. Lee DM, et al. **Int Immunol** 1996 Aug;8(8):1195–203

PHYSIOLOGY

CD4+ CD7– T cells: a separate subpopulation of memory T cells? Reinhold U, et al. **J Clin Immunol** 1997 Jul; 17(4):265–71 (36 ref.)

ANTIGENS, CD8

see related
CD4–CD8 RATIO

ANALYSIS

Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. O'Shaughnessy TC, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):852–7

Flow cytometric analysis of bronchoalveolar lavage and venous blood lymphocyte phenotype for the diagnosis of acute graft rejection in lung transplant patients. The Lung Transplant Group, Ospedale Maggiore di Milano. Bonara P, et al. **Anal Quant Cytol Histol** 1996 Aug;18(4):293–7

Soluble CD4 and CD8 in serum from patients with localized scleroderma. Sato S, et al. **Arch Dermatol Res** 1996 Jun; 288(7):358–62

CD3+ CD8+ CD56– clonal large granular lymphocyte leukaemia and HIV infection. Pulik M, et al. **Br J Haematol** 1997 Aug;98(2):444–5

CD8 lymphocyte subsets in active polymyalgia rheumatica: comparison with elderly–onset and adult rheumatoid arthritis and influence of prednisone therapy. Boiardi L, et al. **Br J Rheumatol** 1996 Jul;35(7):642–8

Role of CD4+, CD8+ and double negative T–cells in the protection of SCID/beige mice against respiratory challenge with Rhodococcus equi. Ross TL, et al. **Can J Vet Res** 1996 Jul;60(3):186–92

Anomalies of the CD8+ T cell pool in haemochromatosis: HLA–A3–linked expansions of CD8+CD28– T cells. Arosa FA, et al. **Clin Exp Immunol** 1997 Mar;107(3):548–54

Multiparametric cell–cycle analysis of peripheral blood–activated lymphocyte subsets using staining based on the TdT method for incorporated BrdUrd. Dolbeare F, et al. **Cytometry** 1996 Dec 1;25(4):317–23

Immunomagnetic isolation of magnetoferritin–labeled cells in a modified ferrograph. Zborowski M, et al. **Cytometry** 1996 Jul 1;24(3):251–9

Association between alphabetaTCR+CD4–CD8– T–cell deficiency and IDDM in NOD/Lt mice. Baxter AG, et al. **Diabetes** 1997 Apr;46(4):572–82

A new strategy for treating patients with CD7+, CD4–, CD8– acute lymphoblastic leukaemia [letter] Ono K, et al. **Eur J Haematol** 1997 Feb;58(2):130–2

MRL/lpr CD4– CD8– and CD8+ T cells, respectively, mediate Fas–dependent and perforin cytotoxic pathways. Benihoud K, et al. **Eur J Immunol** 1997 Feb;27(2):415–20

A novel peripheral CD4+ CD8+ T cell population: inheritance of CD8alpha expression on CD4+ T cells. Luhtala M, et al. **Eur J Immunol** 1997 Jan;27(1):189–93

CD5– CD8 alpha beta intestinal intraepithelial lymphocytes (IEL) are induced to express CD5 upon antigen–specific activation: CD5– and CD5+ CD8 alpha beta IEL do not represent separate T cell lineages. Müller S, et al. **Eur J Immunol** 1997 Jul;27(7):1756–61

CD4+CD8– thymocytes that express L–selectin protect rats from diabetes upon adoptive transfer. Seddon B, et al. **Eur J Immunol** 1996 Nov;26(11):2702–8

Synergy between an antibody and CD8+ cells in eliminating an established tumor. Vasović LV, et al. **Eur J Immunol** 1997 Feb;27(2):374–82

TCR alpha/beta and TCR gamma/delta CD4–/CD8– HLA–DR alloreactive CTL clones do not use Fas/Fas ligand pathway to lyse their specific target cells. Mami–Chouaib F, et al. **Hum Immunol** 1996 Nov; 51(1):13–22

An unique CD4+CD8+ intestinal intraepithelial lymphocyte specific for DnaK (Escherichia coli HSP70) may be selected by intestinal microflora of rats. Kimura Y, et al. **Immunobiology** 1996–97;196(5):550–66

Peripheral blood CD4+CD8+ lymphocytes in cynomolgus monkeys are of resting memory T lineage. Akari H, et al. **Int Immunol** 1997 Apr;9(4):591–7

Requirement of IL–7 for IL–4–producing potential of MHC class I–selected CD4–CD8–TCR alpha beta+ thymocytes. Leite–de–Moraes MC, et al. **Int Immunol** 1997 Jan;9(1):73–9

Changes in immunologic variables (TNF–a, sCD8 and sCD4) during danazol treatment in patients with endometriosis. Matalliotakis I, et al. **Int J Fertil Womens Med** 1997 May–Jun;42(3):211–4

Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR–CD8– thymocytes. Godfrey DI, et al. **J Autoimmun** 1997 Jun;

10(3):279–85

CD8 alphabeta+ TCR alphabeta(intermediate) lymphocytes expressing skewed TCRVbeta repertoire in the liver of aged athymic nu/nu mice. Emoto M, et al. **J Immunol** 1997 Feb 1;158(3):1041–50

Development of CD4–CD8– alpha beta TCR+NK1.1+ T lymphocytes: thymic selection by self antigen. Schulz RJ, et al. **J Immunol** 1996 Nov 15;157(10):4379–89

Increases in CD3+CD4–CD8– T lymphocytes in AIDS patients with disseminated Mycobacterium avium–intracellulare complex infection. Moreau JF, et al. **J Infect Dis** 1996 Nov;174(5):969–76

Extrathymic generation and antigen recognition of IL3–induced CD4–CD8 alpha beta T cells. Kubota H. **Jpn J Vet Res** 1996 Aug;44(2):131–2

Aggressive gastric peripheral T–cell lymphoma of CD8+ type associated with lymphomatous meningitis. Holst VA, et al. **Mod Pathol** 1997 May;10(5):504–9

Invasive thymoma with CD4+CD8+ double–positive T cell lymphocytosis. Tamaoki J, et al. **Respiration** 1997; 64(2):176–8

Autoantibody production in healthy elderly people is not promoted by interleukin–10 although this cytokine is expressed in them by a peculiar CD8+CD3+ large granular cell subpopulation. Llorente L, et al. **Scand J Immunol** 1997 Apr;45(4):401–7

B–haplotype control of CD4/CD8 subsets and TCR V beta usage in chicken T lymphocytes. Ewald SJ, et al. **Vet Immunol Immunopathol** 1996 Oct;53(3–4):285–301

[CD4–CD8– to CD4–CD8+ transition induced by anti–CD3 mAb in vitro cell culture system] Tian L, et al. **Shih Yen Sheng Wu Hsueh Pao** 1996 Mar;29(1):39–47 (Eng. Abstr.) **(Chi)**

BIOSYNTHESIS

CD4 and CD8 antigen coexpression: a flow cytometric study of peripheral blood, bone marrow, body fluid, and solid lymphoreticular specimens. Nah EH, et al. **Arch Pathol Lab Med** 1997 Apr;121(4):381–4

Post–transcriptional regulation associated with control of human CD8A expression of CD4+ T cells. Gao MH, et al. **Immunogenetics** 1996;45(2):130–5

The expression of CD8 on B lymphocytes in HIV–infected individuals. Schlesinger M, et al. **Immunol Lett** 1996 Apr; 50(1–2):23–7

A novel mouse thymocyte antigen (F3Ag): down–regulation during the CD4+CD8+ double–positive stage indicates positive selection. Barthlott T, et al. **Int Immunol** 1996 Jan; 8(1):101–13

Human CD8 alpha expression in NK cells but not cytotoxic T cells of transgenic mice. Kieffer LJ, et al. **Int Immunol** 1996 Oct;8(10):1617–26

CD4 and CD8 expressions in African green monkey helper T lymphocytes: implication for resistance to SIV infection. Murayama Y, et al. **Int Immunol** 1997 Jun;9(6):843–51

Inhibition of re–expression of surface CD4, but not CD8, on activated human T–lymphocytes by the immunosuppressive drugs dexamethasone and cyclosporine A: correlation with inhibition of proliferation. Haczku AF, et al. **Int J Immunopharmacol** 1996 Jan;18(1):45–51

Interaction of the nuclear matrix–associated region (MAR)–binding proteins, SATB1 and CDP/Cux, with a MAR element (L2a) in an upstream regulatory region of the mouse CD8a gene. Banan M, et al. **J Biol Chem** 1997 Jul 18;272(29):18440–52

Homodimerization of the human interleukin 4 receptor alpha chain induces Cepsilon germline transcripts in B cells in the absence of the interleukin 2 receptor gamma chain. Fujiwara H, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5866–71

BLOOD

Soluble interleukin–2 receptor (sIL–2R) is a marker of disease activity in psoriasis: a comparison of sIL–2R, sCD27, sCD4, sCD8 and sICAM–1. De Rie MA, et al. **Acta Derm Venereol** 1996 Sep;76(5):357–60

Soluble CD8 antigen, stimulated C–peptide and islet cell antibodies are predictors of insulin requirement in newly diagnosed patients with unclassifiable diabetes. Di Bonito P, et al. **Acta Diabetol** 1996 Sep;33(3):220–4

Soluble CD8 and ICAM–1 in serum and CSF of MS patients treated with 6–methylprednisolone. Franciotta D, et al. **Acta Neurol Scand** 1997 May;95(5):275–9

Changes in soluble CD4 and CD8 proteins in healthy pregnant and postpartum women. Watanabe M, et al. **Am J Reprod Immunol** 1996 Oct;36(4):220–7

Serum soluble interleukin 2 receptor alpha and soluble CD8 levels in patients with gynecological malignancies undergoing radiotherapy. Frydecka I, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(2–3):123–6

Increased serum soluble CD8 or suppressor/cytotoxic antigen concentrations in depression: suppressive effects of glucocorticoids. Maes M, et al. **Biol Psychiatry** 1996 Dec 15;40(12):1273–81

Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV–1 infection and clinical status. Jiang JD, et al. **J Clin Immunol** 1997 Mar;17(2):185–92

Serum concentrations of soluble HLA–class I and CD8 forms in patients with viral hepatic disorders. Hagihara M, et al. **J Gastroenterol** 1997 Jun;32(3):338–43

Soluble interleukin 2 receptor and soluble CD8 levels in previously treated human immunodeficiency virus–negative hemophiliacs multiply transfused with a monoclonal antibody–purified factor VIII concentrate. Smid WM, et al. **Transfusion** 1997 Jan;37(1):86–9

CEREBROSPINAL FLUID

Soluble CD8 and ICAM–1 in serum and CSF of MS patients treated with 6–methylprednisolone. Franciotta D, et al. **Acta Neurol Scand** 1997 May;95(5):275–9

CHEMISTRY

Disulfide bond formation between the n–terminal region of p56LCK and the cytoplasmic domain of CD8 studied by electrospray ionization and matrix–assisted desorption/ionization time–of–flight mass spectrometry. Yi GS, et al. **Biochem Mol Biol Int** 1996 Oct;40(2):409–16

Crystal structure of the complex between human CD8alpha(alpha) and HLA–A2. Gao GF, et al. **Nature** 1997 Jun 5;387(6633):630–4

GENETICS

Oligoclonality of CD8+ T cells in multiple sclerosis. Monteiro J, et al. **Autoimmunity** 1996;23(2):127–38

CD8 lineage commitment in the absence of CD8. Goldrath AW, et al. **Immunity** 1997 May;6(5):633–42

Polymorphism of chicken CD8–alpha, but not CD8–beta. Luhtala M, et al. **Immunogenetics** 1997;46(5):396–401

Molecular cloning of the feline CD8 beta–chain. Pecoraro MR, et al. **Immunology** 1996 Sep;89(1):84–8

Human CD8 alpha expression in NK cells but not cytotoxic T cells of transgenic mice. Kieffer LJ, et al. **Int Immunol** 1996 Oct;8(10):1617–26

Interaction of the nuclear matrix–associated region (MAR)–binding proteins, SATB1 and CDP/Cux, with a MAR element (L2a) in an upstream regulatory region of the mouse CD8a gene. Banan M, et al. **J Biol Chem** 1997 Jul 18;272(29):18440–52

The use of CD4 and CD8 knockout mice to study the role of T–cell subsets in allotransplant rejection. Krieger NR, et al. **J Heart Lung Transplant** 1997 Mar;16(3):263–7 (40 ref.)

The natural history of disease expression in CD4 and CD8 gene–deleted New Zealand black (NZB) mice. Chen SY, et al. **J Immunol** 1996 Sep 15;157(6):2676–84

Distinct methylation states of the CD8 beta gene in peripheral T cells and intraepithelial lymphocytes. Hamerman JA, et al. **J Immunol** 1997 Aug 1;159(3):1240–6

A CD8 genomic fragment that directs subset–specific expression of CD8 in transgenic mice. Hostert A, et al. **J Immunol** 1997 May 1;158(9):4270–81

IMMUNOLOGY

CD8 and CD4 T cell–mediated polymyositis complicating the HTLV–1 associated myelopathy. Quantitative evaluation of corticosteroid treatment. Waclawik AJ, et al. **Acta Neurol Scand** 1996 Aug;94(2):115–9

Targeting an anti–viral CD8+ T cell response to a growing tumor facilitates its rejection. Böhm W, et al. **Cancer Immunol Immunother** 1997 Jun;44(4):230–8

Recognition and lysis of human melanoma by a CD3+, CD4+, CD8– T–cell clone restricted by HLA–A2. Darrow TL, et al. **Cell Immunol** 1996 Aug 25;172(1):52–9

Anti–CD8 treatment reduces the severity of inflammatory arthritis, but not vasculitis, in mercuric chloride–induced autoimmunity. Kiely PD, et al. **Clin Exp Immunol** 1996 Nov;106(2):280–5

Depletion of IFN–gamma, CD8+ or Tcr gamma delta+ cells in vivo during primary infection with an enteric parasite (Trichostrongylus colubriformis) enhances protective immunity. McClure SJ, et al. **Immunol Cell Biol** 1995 Dec;73(6):552–5

A photobleaching energy transfer analysis of CD8/MHC–I and LFA–1/ICAM–1 interactions in CTL–target cell conjugates. Bacsó Z, et al. **Immunol Lett** 1996 Dec; 54(2–3):151–6

V beta 8+CD4–CD8– subpopulation induced by staphylococcal enterotoxin B. Chou MC, et al. **Immunol Lett** 1997 Feb;55(2):85–91

Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Cobbold SP, et al. **Immunol Rev** 1996 Feb;149:5–33 (109 ref.)

On T cell memory: arguments for antigen dependence. Kündig TM, et al. **Immunol Rev** 1996 Apr;150:63–90 (100 ref.)

Aspects of cytotoxic T cell memory. Müllbacher A, et al. **Immunol Rev** 1996 Apr;150:113–27 (70 ref.)

Unprimed T cells are inefficiently stimulated by glycosylphosphatidylinositol–linked H–2Kb because of its lipid anchor rather than defects in CD8 binding. Zamoyska R, et al. **Int Immunol** 1996 Apr;8(4):551–7

CD8 beta increases CD8 coreceptor function and participation in TCR–ligand binding. Renard V, et al. **J Exp Med** 1996 Dec 1;184(6):2439–44

Glu227—>Lys substitution in the acidic loop of major histocompatibility complex class I alpha 3 domain distinguishes low avidity CD8 coreceptor and avidity–enhanced CD8 accessory functions. Shen L, et al. **J Exp Med** 1996 Nov 1;184(5):1671–83

Deviated overexpression of TCR–beta, TCR–gamma, CD4, and CD8 on thymic lymphomas induced by 1–propyl–1–nitrosourea: destruction of the allelic exclusion of TCR–beta and expression of functional TCR–betagamma heterodimer on a lymphoma, cFTL53. Kinebuchi M, et al. **J Immunol** 1997 Jul 15;159(2):748–56

CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. White HD, et al. **J Immunol** 1997 Mar 15;158(6):3017–27

Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN–gamma [corrected] elicits antitumor CD8 MHC class I–restricted T cells that are cytolytic in vitro and tumoricidal in vivo [published erratum appears in J Interferon Cytokine Res 1997 Feb;17(2):120] Qi Y, et al. **J Interferon Cytokine Res** 1996 Oct;16(10):771–6

Thymocyte progenitors and T cell development in aging. Yu S, et al. **Mech Ageing Dev** 1997 Mar;94(1–3):103–11

Interaction of 2C T cells with a hybrid Ld molecule bearing an alpha 3 domain derived from the class IB molecule, Qa–2. Ungchusri T, et al. **Scand J Immunol** 1997 Jul; 46(1):41–50

Differential effectiveness of anti–CD8 treatment on ongoing graft–versus–host reactions in mice. Noort WA, et al. **Transpl Immunol** 1996 Sep;4(3):198–202

Recall response to cytomegalovirus in allograft recipients: mobilization of CD57+, CD28+ cells before expansion of CD57+, CD28– cells within the CD8+ T lymphocyte compartment. Hazzan M, et al. **Transplantation** 1997 Mar 15;63(5):693–8

Differential binding of two monoclonal antibodies directed against the chicken CD8 alpha molecule. Breed DG, et al. **Vet Immunol Immunopathol** 1996 Jun 15;52(1–2):117–25

Positive selection of EqCD8+ precursors increases equine lymphokine–activated killing. Lunn DP, et al. **Vet Immunol Immunopathol** 1996 Sep;53(1–2):1–13

[Analysis of the mechanism of the development of insulin–dependent diabetes mellitus and an attempt to prevent its onset by the functional T cell molecules] Yokono K, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):618–21 (4 ref.) **(Jpn)**

METABOLISM

Apoptosis and CD8–down–regulation in the thymus of chickens infected with Marek's disease virus. Morimura T, et al. **Arch Virol** 1996;141(11):2243–9

Expression of CD8beta and alteration of cell surface phenotype in adult T–cell leukaemia cells. Joh T, et al. **Br J Haematol** 1997 Jul;98(1):151–6

Down–modulation of CD8 beta–chain in response to an altered peptide ligand enables developing thymocytes to escape negative selection. Barnden MJ, et al. **Cell Immunol** 1997 Feb 1;175(2):111–9

Differentiation of CD4(high)CD8(low) coreceptor–skewed thymocytes into mature CD8 single–positive cells independent of MHC class I recognition. Barthlott T, et al. **Eur J Immunol** 1997 Aug;27(8):2024–32

Identification of Her–2/Neu CTL epitopes using double transgenic mice expressing HLA–A2.1 and human CD.8. Lustgarten J, et al. **Hum Immunol** 1997 Feb;52(2):109–18

Unexpectedly complex regulation of CD4/CD8 coreceptor expression supports a revised model for CD4+CD8+ thymocyte differentiation. Lucas B, et al. **Immunity** 1996 Nov;5(5):461–77

The HIV–1 Nef protein acts as a connector with sorting pathways in the Golgi and at the plasma membrane. Mangasarian A, et al. **Immunity** 1997 Jan;6(1):67–77

Two distinct steps during thymocyte maturation from CD4–CD8– to CD4+CD8+ distinguished in the early growth response (Egr)–1 transgenic mice with a recombinase–activating gene–deficient background. Miyazaki T. **J Exp Med** 1997 Sep 15;186(6):877–85

TCR engagement of CD4+CD8+ thymocytes in vitro induces early aspects of positive selection, but not apoptosis. Groves T, et al. **J Immunol** 1997 Jan 1; 158(1):65–75

CD8 enhances formation of stable T–cell receptor/MHC class I molecule complexes [see comments] [published erratum appears in Nature 1997 Jun 5;387(6633):634] Garcia KC, et al. **Nature** 1996 Dec 12;384(6609):577–81. Comment in: Nature 1996 Dec 12;384(6609):518–9.

Immunology. Two faces are better than one [news; comment] Malissen B. **Nature** 1996 Dec 12;384(6609):518–9. Comment on: Nature 1996 Dec 12;384(6609):577–81.

The expression of CD4 and CD8 molecules conditions the behavior of V beta + murine thymocytes upon superantigenic challenge. Fattorossi A, et al. **Thymus** 1997; 24(3):133–45

Differential binding of two monoclonal antibodies directed against the chicken CD8 alpha molecule. Breed DG, et al. **Vet Immunol Immunopathol** 1996 Jun 15;52(1–2):117–25

[CD2 and CD8 expression in acute promyelocytic leukemia] Kawachi Y, et al. **Rinsho Ketsueki** 1996 Dec;37(12):1377–82 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

The CD8 beta polypeptide is required for the recognition of an altered peptide ligand as an agonist. Renard V, et al. **Eur J Immunol** 1996 Dec;26(12):2999–3007

Influence on CD8 of TCR/CD3–generated signals in CTL clones and CTL precursor cells. Anel A, et al.

ANTIGENS, CD8

J Immunol 1997 Jan 1;158(1):19–28

PHYSIOLOGY

T cell receptor and CD8–dependent tyrosine phosphorylation events in cytotoxic T lymphocytes: activation of p56lck by CD8 binding to class I protein. Anel A, et al. **Eur J Immunol** 1996 Oct;26(10):2310–9

Co–receptor–independent signal transduction in a mismatched CD8+ major histocompatibility complex class II–specific allogeneic cytotoxic T lymphocyte. Eshima K, et al. **Eur J Immunol** 1997 Jan;27(1):55–61

Are CD8+ dendritic cells (DC) veto cells? The role of CD8 on DC in DC development and in the regulation of CD4 and CD8 T cell responses. Kronin V, et al. **Int Immunol** 1997 Jul;9(7):1061–4

Developmentally regulated expression of the PD–1 protein on the surface of double–negative (CD4–CD8–) thymocytes. Nishimura H, et al. **Int Immunol** 1996 May; 8(5):773–80

A novel CD8 molecule expressed by alveolar and peritoneal macrophages stimulates nitric oxide production. Hirji N, et al. **J Immunol** 1997 Feb 15;158(4):1833–40

ANTIGENS, CD10 see **NEPRILYSIN**

ANTIGENS, CD11

Leucocyte adhesion deficiency presenting as a chronic ileocolitis. D'Agata ID, et al. **Gut** 1996 Oct;39(4):605–8

Material–induced up–regulation of leukocyte CD11b during whole blood contact: material differences and a role for complement. Gemmell CH, et al. **J Biomed Mater Res** 1996 Sep;32(1):29–35

CNS microvascular pericytes express macrophage–like function, cell surface integrin alpha M, and macrophage marker ED–2. Balabanov R, et al. **Microvasc Res** 1996 Sep; 52(2):127–42

ANALYSIS

Glucocorticoid receptor regulates expression of L–selectin and CD11/CD18 on human neutrophils. Filep JG, et al. **Circulation** 1997 Jul 1;96(1):295–301

Localised and global cytosolic Ca2+ changes in neutrophils during engagement of Cd11b/CD18 integrin visualised using confocal laser scanning reconstruction. Pettit EJ, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1689–94

Temporal correlation between UV radiation locally–inducible tolerance and the sequential appearance of dermal, then epidermal, class II MHC+CD11b+ monocytic/macrophagic cells. Hammerberg C, et al. **J Invest Dermatol** 1996 Nov;107(5):755–63

Cell–associated adhesion molecules as early markers of bioincompatibility. Carreno MP, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2248–57

BIOSYNTHESIS

Effect of Clostridium difficile toxin A on CD11/CD18 expression in vitro. Warny M, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):605–7

Inhibition of PAF–induced expression of CD11b and shedding of L–selectin on human neutrophils and eosinophils by the type IV selective PDE inhibitor, rolipram. Berends C, et al. **Eur Respir J** 1997 May; 10(5):1000–7

Cytokine response of B lymphocytes from splenic lymphoma with villous lymphocytes: correlation with TNF–RII (p75) and CD11c expression. Treton D, et al. **Hematol Cell Ther** 1996 Aug;38(4):345–52

Hemodialysis–induced upregulation of granulocyte adhesion molecules CD11b/CD18 is independent from 5–lipoxygenase activity. Sellmayer A, et al. **Nephron** 1997; 76(4):418–24

Increased expression of intercellular adhesion molecule 1, CD11/CD18 cell surface adhesion glycoproteins and alpha 4 beta 1 integrin in a rat model of chronic interstitial lung fibrosis. Barquín N, et al. **Pathobiology** 1996;64(4):187–92

BLOOD

Plasma factors augment neutrophil and endothelial cell activation during aortic surgery. Barry MC, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):381–7

Relationship between interleukin–8 and neutrophil adhesion molecules in rheumatoid arthritis. De Gendt CM, et al. **Rheumatol Int** 1996;16(4):169–73

GENETICS

Targeted expression of MHC class II genes to dendritic cells in vivo. Riedinger M, et al. **Immunol Lett** 1997 Jun 1; 57(1–3):155–8

IMMUNOLOGY

Effects of conventional peritoneal dialysates on leukocyte adhesion and CD11b, CD18 and CD14 expression. Kaupke CJ, et al. **Kidney Int** 1996 Nov;50(5):1676–83

Identification of monoclonal antibodies with specificity to alpha– or beta–chains of beta 2–integrins using peripheral blood leucocytes of normal and bovine leucocyte adhesion deficient (BLAD) cattle. Rutten VP, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):341–5

METABOLISM

Endothelial adhesion molecules and leukocyte integrins in preeclamptic patients. Haller H, et al. **Hypertension** 1997 Jan;29(1 Pt 2):291–6

Mechanism of first–dose cytokine–release syndrome by CAMPATH 1–H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA–1) on NK cells. Wing MG, et al. **J Clin Invest** 1996 Dec 15;98(12):2819–26

CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils. Skubitz KM, et al. **J Immunol** 1996 Oct 15; 157(8):3617–26

Granulocyte dysplasia and dysfunction, and CD11/CD18 defects in myelodysplastic syndromes. Mazzone A, et al. **Leuk Lymphoma** 1996 Oct;23(3–4):267–75 (71 ref.)

Sequestration of neutrophils in the hepatic vasculature during endotoxemia is independent of beta 2 integrins and intercellular adhesion molecule–1. Jaeschke H, et al. **Shock** 1996 Nov;6(5):351–6

Increased production of hydrogen peroxide and expression of CD11b/CD18 on alveolar macrophages in patients with active pulmonary tuberculosis. Kuo HP, et al. **Tuber Lung Dis** 1996 Oct;77(5):468–75

PHYSIOLOGY

LPS–induced stimulation of phagocytosis in the sipunculan worm Themiste petricola: possible involvement of human CD14, CD11B and CD11C cross–reactive molecules. Blanco GA, et al. **Dev Comp Immunol** 1997 Jul–Aug; 21(4):349–62

The roles of CD11/CD18 and ICAM–1 in acute Pseudomonas aeruginosa–induced pneumonia in mice. Qin L, et al. **J Immunol** 1996 Dec 1;157(11):5016–21

Beta 2 (CD11/CD18) integrins can serve as signaling partners for other leukocyte receptors. Todd RF 3rd, et al. **J Lab Clin Med** 1997 May;129(5):492–8 (64 ref.)

Neutrophil emigration in the lungs. Doerschuk CM, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:141–5 (21 ref.)

Interactions of neutrophils and endothelial cells under low flow conditions in vitro. Yoshida N, et al. **Shock** 1997 Aug; 8(2):125–30

ANTIGENS, CD11A see **LYMPHOCYTE FUNCTION–ASSOCIATED ANTIGEN–1**

ANTIGENS, CD11B see **MACROPHAGE–1 ANTIGEN**

ANTIGENS, CD11C see **ANTIGEN P150,95**

ANTIGENS, CD13

ANALYSIS

Immunoelectron microscopic single and double labelling of aminopeptidase N (CD 13) and dipeptidyl peptidase IV (CD 26). Stange T, et al. **Acta Histochem** 1996 Jul; 98(3):323–31

Low molecular mass proteins and urinary enzymes in amniotic fluid of healthy pregnant women at progressive stages of gestation. Mussap M, et al. **Clin Biochem** 1996 Feb;29(1):51–6

Human aortic endothelial cell aminopeptidase N. Papapetropoulos A, et al. **Immunopharmacology** 1996 May; 32(1–3):153–6

ANTAGONISTS & INHIBITORS

Phebestin, a new inhibitor of aminopeptidase N, produced by Streptomyces sp. MJ716–m3. Nagai M, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):82–4

Development and in vitro evaluation of systems to protect peptide drugs from aminopeptidase N. Bernkop–Schnürch A, et al. **Pharm Res** 1997 Feb;14(2):181–5

Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Zini S, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11968–73

BIOSYNTHESIS

Induction of the membrane alanyl aminopeptidase gene and surface expression in human T–cells by mitogenic activation. Lendeckel U, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):817–21

Effect of dopaminergic drugs on processing and degradative neuropeptidase mRNA in rat frontal cortex and caudate–putamen. Waters SM, et al. **Brain Res** 1997 Apr 18;754(1–2):28–34

PKC–dependent long–term effect of PMA on protein cell surface expression in Caco–2 cells. Sapin C, et al. **Exp Cell Res** 1997 Mar 15;231(2):308–18

The activation–dependent induction of APN–(CD13) in T–cells is controlled at different levels of gene expression. Wex T, et al. **FEBS Lett** 1997 Jul 21;412(1):53–6

Rapid mitogen–induced aminopeptidase N surface expression in human T cells is dominated by mechanisms independent of de novo protein biosynthesis. Lendeckel U, et al. **Immunobiology** 1997 Jun;197(1):55–69

p161, a murine membrane protein expressed on mast cells and some macrophages, is mouse CD13/aminopeptidase N. Chen H, et al. **J Immunol** 1996 Sep 15;157(6):2593–600

Induction of aminopeptidase N/CD13 on human lymphocytes after adhesion to fibroblast–like synoviocytes, endothelial cells, epithelial cells, and monocytes/macrophages. Riemann D, et al. **J Immunol** 1997 Apr 1;158(7):3425–32

Rotenone, a mitochondrial NADH dehydrogenase inhibitor, induces cell surface expression of CD13 and CD38 and apoptosis in HL–60 cells. Matsunaga T, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):487–94

CHEMISTRY

Novel bioadhesive chitosan–EDTA conjugate protects leucine enkephalin from degradation by aminopeptidase N. Bernkop–Schnürch A, et al. **Pharm Res** 1997 Jul; 14(7):917–22

GENETICS

Alanyl aminopeptidase N (ANPEP) microsatellite: now a framework marker on porcine chromosome 7 map. Zhang W, et al. **Anim Genet** 1996 Oct;27(5):378–9

Keratinocyte–lymphocyte interaction in cutaneous T–cell lymphoma. Modulation of keratinocyte antigen My7 by a soluble factor produced by T lymphocytes. Célérier P, et al. **Arch Dermatol** 1997 Jul;133(7):837–40

An enhancer with cell–type dependent activity is located between the myeloid and epithelial aminopeptidase N (CD 13) promoters. Olsen J, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):899–908

The main neutral aminopeptidase activity of human lymphoid tumour cell lines does not originate from the aminopeptidase N–(APN; CD13) gene. Wex T, et al. **Biochim Biophys Acta** 1997 Feb 4;1355(2):147–54

IMMUNOLOGY

Cryptic and regulatory epitopes in CD13/aminopeptidase N. Xu Y, et al. **Exp Hematol** 1997 Jun;25(6):521–9

ISOLATION & PURIFICATION

p161, a murine membrane protein expressed on mast cells and some macrophages, is mouse CD13/aminopeptidase N. Chen H, et al. **J Immunol** 1996 Sep 15;157(6):2593–600

METABOLISM

Kidney and urine enzyme activity in experimental gentamicin nephrotoxicity in the Sprague–Dawley rat. Brown D, et al. **Biochem Soc Trans** 1996 May;24(2):317S

Effect of zinc on aminopeptidase N activity and L–threonine transport in rabbit jejunum. Rodriguez Yoldi MC, et al. **Biol Trace Elem Res** 1996 Summer;53(1–3):213–23

Aminopeptidase N from Bombyx mori as a candidate for the receptor of Bacillus thuringiensis Cry1Aa toxin. Yaoi K, et al. **Eur J Biochem** 1997 Jun 15;246(3):652–7

Alanine aminopeptidase activities in cancerous and non–cancerous human breast tissues [letter] Elgün S, et al. **Eur J Clin Chem Clin Biochem** 1997 Mar;35(3):249

Subchronic haloperidol administration decreases aminopeptidase N activity and [Met5]enkephalin metabolism in rat striatum and cortex. Konkoy CS, et al. **Eur J Pharmacol** 1996 Feb 15;297(1–2):47–51

Defectively N–glycosylated and non–O–glycosylated aminopeptidase N (CD13) is normally expressed at the cell surface and has full enzymatic activity. Norén K, et al. **Exp Cell Res** 1997 Feb 25;231(1):112–8

Aminopeptidase dependent pore formation of Bacillus thuringiensis Cry1Ac toxin on Trichoplusia ni membranes. Lorence A, et al. **FEBS Lett** 1997 Sep 8;414(2):303–7

Association of aminopeptidase N and endopeptidase 24.15 inhibitors potentiate behavioral effects mediated by nociceptin/orphanin FQ in mice. Noble F, et al. **FEBS Lett** 1997 Jan 20;401(2–3):227–9

Growth and propagation of normal rat intestinal epithelial cells. Odedra RM, et al. **In Vitro Cell Dev Biol Anim** 1996 Feb;32(2):107–115

Peptide degradation: effect of substrate phosphorylation on aminopeptidasic hydrolysis. Fernández Murray P, et al. **Int J Biochem Cell Biol** 1996 Apr;28(4):451–6

Localization of alanyl aminopeptidase and leucyl aminopeptidase in cells of Pseudomonas aeruginosa by application of different methods for periplasm release. Jensch T, et al. **J Basic Microbiol** 1997;37(2):115–28

Characterization of functional domains in the human coronavirus HCV 229E receptor. Kolb AF, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2515–21

Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup I. Tresnan DB, et al. **J Virol** 1996 Dec;70(12):8669–74

The relationship between enzymuria and kidney enzyme activities in experimental gentamicin nephrotoxicity. Whiting PH, et al. **Ren Fail** 1996 Nov;18(6):899–909

PHYSIOLOGY

Virus–receptor interactions in the enteric tract. Virus–receptor interactions. Holmes KV, et al. **Adv Exp Med Biol** 1997;412:125–33 (49 ref.)

URINE

Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta–lactam

antibiotics. Nix DE, et al. **Ann Pharmacother** 1997 Jun; 31(6):696–703

Age dependency of infradian rhythms in enzymuria of female volunteers. Gerasch A, et al.
Eur J Clin Chem Clin Biochem 1997 Apr;35(4):281–6

Cyclosporine nephrotoxicity and rejection crisis: diagnosis by urinary enzyme excretion. Bornstein B, et al.
Nephron 1996;72(3):402–6

[Urinary enzymes in insulin-dependent diabetes mellitus] Platonova LV, et al. **Vopr Med Khim** 1996 Jan–Mar; 42(1):70–6 (Eng. Abstr.) **(Rus)**

ANTIGENS, CD14

Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. Mendelson M, et al.
J Gen Virol 1996 Dec;77 (Pt 12):3099–102

ANALYSIS

Asthma and endotoxin: lipopolysaccharide-binding protein and soluble CD14 in bronchoalveolar compartment. Dubin W, et al. **Am J Physiol** 1996 May;270(5 Pt 1):L736–44

Bronchoalveolar macrophage CD14 expression: shift between membrane-associated and soluble pools. Hasday JD, et al. **Am J Physiol** 1997 May;272(5 Pt 1):L925–33

Relationship between soluble CD14, lipopolysaccharide binding protein, and the alveolar inflammatory response in patients with acute respiratory distress syndrome. Martin TR, et al. **Am J Respir Crit Care Med** 1997 Mar; 155(3):937–44

A rapid nylon-fiber syringe system to deplete CD14+ cells for positive selection of human blood CD34+ cells. Use of immunomagnetic microspheres. Yamaguchi M, et al.
Bone Marrow Transplant 1997 Feb;19(4):373–9

Differential influences of gold sodium thiomalate and bucillamine on the generation of CD14+ monocyte-lineage cells from bone marrow of rheumatoid arthritis patients. Hirohata S, et al.
Clin Immunol Immunopathol 1997 Sep;84(3):290–5

Detection of CD 14 on migrated monocytes by specific antibody: a possible quantification for blood monocyte chemotaxis. Tekstra J, et al. **Immunobiology** 1996 Oct; 195(4–5):491–8

Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Ziegler-Heitbrock HW.
Immunol Today 1996 Sep;17(9):424–8

Mo2+ HLA-DR- monocytosis in varicella zoster virus infection. Horiuchi Y. **J Dermatol** 1997 Mar;24(3):205–7

Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. Pickl WF, et al. **J Immunol** 1996 Nov 1; 157(9):3850–9

Isolation and purification of CD14-negative mucosal macrophages from normal human small intestine. Smith PD, et al. **J Immunol Methods** 1997 Mar 10;202(1):1–11

Modification of surface marker expression on CD14 monocytes of allergic patients after lysis or Ficoll purification. Souques F, et al. **J Immunol Methods** 1997 May 26;204(2):153–60

Immunodepressive effects of LPS on monocyte CD14 in vivo. Hojman H, et al. **J Surg Res** 1997 Apr;69(1):7–10

Presence of inducible nitric oxide synthase, nitrotyrosine, CD68, and CD14 in the small intestine in celiac disease. ter Steege J, et al. **Lab Invest** 1997 Jul;77(1):29–36

Long-term continuous ambulatory peritoneal dialysis reduces the expression of CD11b, CD14, CD16, and CD64 on peritoneal macrophages. Cárcamo C, et al.
Perit Dial Int 1996 Nov–Dec;16(6):582–9

Identification of bovine CD14. Sopp P, et al.
Vet Immunol Immunopathol 1996 Aug;52(4):323–8

[Immune paralysis in acute pancreatitis--HLA-DR antigen expression on CD14+DR+ monocytes] Richter A, et al.
Langenbecks Arch Chir 1996;381(1):38–41 (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Effect of SP-A and surfactant lipids on expression of cell surface markers in the THP-1 monocytic cell line. Kremlev SG, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):L1070–7

Induction of CD14 expression in Lpsn, Lpsd and tumor necrosis factor receptor-deficient mice. Takakuwa T, et al. **Eur J Immunol** 1996 Nov;26(11):2686–92

Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line. Heinemann M, et al. **Infect Immun** 1996 Nov; 64(11):4872–5

Regulation of CD14 expression on human adult central nervous system-derived microglia. Becher B, et al.
J Neurosci Res 1996 Aug 15;45(4):375–81

Enhanced expression of CD14 antigen on myeloid lineage cells derived from the bone marrow of patients with severe rheumatoid arthritis. Tomita T, et al. **J Rheumatol** 1997 Mar;24(3):465–9

Use of CD14 and lipopolysaccharide binding protein mRNA expression as markers for acute rejection in rat small bowel transplantation. Cicalese L, et al. **Transplant Proc** 1996 Oct; 28(5):2470

BLOOD

Serum levels of soluble CD14 in scleroderma [letter] Bruns M, et al. **Acta Derm Venereol** 1996 Nov;76(6):494

Serum levels of CD14 in neonatal sepsis by Gram-positive and Gram-negative bacteria. Blanco A, et al.
Acta Paediatr 1996 Jun;85(6):728–32

Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Anker SD, et al. **Am J Cardiol** 1997 May 15;79(10):1426–30

Release of lipopolysaccharide toxicity-modulating proteins in patients undergoing cardiopulmonary bypass using noncoated and heparin-coated extracorporeal circuits. A clinical pilot study. Bouma M, et al. **Chest** 1997 Mar; 111(3):577–83

Quantitation of surface CD14 on human monocytes and neutrophils. Antal-Szalmas P, et al. **J Leukoc Biol** 1997 Jun;61(6):721–8

Circulating prostate-specific antigen/CD14-double-positive cells: a biomarker indicating low risk for hematogeneous metastasis of prostate cancer [letter] Brandt B, et al.
J Natl Cancer Inst 1997 Jan 15;89(2):174

Leukocyte CD14 and CD45 expression during hemodialysis: polysulfone versus cuprophane. Dhondt AW, et al.
Nephron 1996;74(2):342–8

Serum soluble CD14 levels and ultrafiltered dialysate in hemodialysis patients [letter] Nakazawa R, et al.
Nephron 1996;73(3):493–4

Cytokine production precedes the expansion of CD14+CD16+ monocytes in human sepsis: a case report of a patient with self-induced septicemia. Blumenstein M, et al. **Shock** 1997 Jul;8(1):73–5

CHEMISTRY

Mutation of amino acids 39–44 of human CD14 abrogates binding of lipopolysaccharide and Escherichia coli. Stelter F, et al. **Eur J Biochem** 1997 Jan 15;243(1–2):100–9

Primary structure of rat CD14 and characteristics of rat CD14, cytokine, and NO synthase mRNA expression in mononuclear phagocyte system cells in response to LPS. Takai N, et al. **J Leukoc Biol** 1997 Jun;61(6):736–44

DRUG EFFECTS

Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. Walev I, et al.
Proc Natl Acad Sci U S A 1996 Jul 23;93(15):7882–7

IMMUNOLOGY

Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Mielcarek M, et al. **Blood** 1997 Mar 1;89(5):1629–34

Survival of Vi-capsulated and Vi-deleted Salmonella typhi strains in cultured macrophage expressing different levels of CD14 antigen. Hirose K, et al.
FEMS Microbiol Lett 1997 Feb 15;147(2):259–65

Detection of CD 14 on migrated monocytes by specific antibody: a possible quantification for blood monocyte chemotaxis. Tekstra J, et al. **Immunobiology** 1996 Oct; 195(4–5):491–8

Human macrophages respond to LPS in a serum-independent, CD14-dependent manner. Jungi TW, et al. **Immunol Lett** 1996 Dec 1;54(1):37–43

Granulocyte-macrophage colony-stimulating factor down-regulates CD14 expression on monocytes. Kruger M, et al. **Immunology** 1996 Sep;89(1):89–95

Differential expression of function-related antigens on newborn and adult monocyte subpopulations. Murphy FJ, et al. **Immunology** 1996 Dec;89(4):587–91

MUTZ-3, a monocytic model cell line for interleukin-4 and lipopolysaccharide studies. Quentmeier H, et al.
Immunology 1996 Dec;89(4):606–12

Role of CD14 molecules in internalization of Actinobacillus actinomycetemcomitans by macrophages and subsequent induction of apoptosis. Muro M, et al. **Infect Immun** 1997 Apr;65(4):1147–51

Antibodies against CD14 protect primates from endotoxin-induced shock. Leturcq DJ, et al.
J Clin Invest 1996 Oct 1;98(7):1533–8

Functional role for the myeloid differentiation antigen CD14 in the activation of human monocytes by IL-2. Bosco MC, et al. **J Immunol** 1997 Sep 15;159(6):2922–31

Stimulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) production and its role as an autocrine inducer of CD14 upregulation in human myeloid leukemia cells. Akin C, et al. **J Interferon Cytokine Res** 1996 Jun; 16(6):479–86

Effects of conventional peritoneal dialysates on leukocyte adhesion and CD11b, CD18 and CD14 expression. Kaupke CJ, et al. **Kidney Int** 1996 Nov;50(5):1676–83

The release of tumor necrosis factor alpha (TNF-alpha) by interferon gamma (IFN-gamma) induced THP-1 cells stimulated with smooth lipopolysaccharide is inhibited by MAbs against HLA-DR and CD14 receptors on the effector cell. Raponi G, et al. **New Microbiol** 1997 Jan; 20(1):1–6

Ruminant cluster CD14. Berthon P, et al.
Vet Immunol Immunopathol 1996 Aug;52(4):245–8

Identification of the sheep homologue of the monocyte cell surface molecule--CD14. Gupta VK, et al.
Vet Immunol Immunopathol 1996 May;51(1–2):89–99

Identification of bovine CD14. Sopp P, et al.
Vet Immunol Immunopathol 1996 Aug;52(4):323–8

ISOLATION & PURIFICATION

Analysis of the CD14 receptor associated with bovine alveolar macrophages. Yang Z, et al. **Inflammation** 1996 Feb;20(1):97–106

METABOLISM

Characteristics of CD14 shedding from human monocytes. Evidence for the competition of soluble CD14 (sCD14) with CD14 receptors for lipopolysaccharide (LPS) binding. Rokita E, et al. **APMIS** 1997 Jul;105(7):510–8

Induction of NO synthesis by lipoteichoic acid from Staphylococcus aureus in J774 macrophages: involvement of a CD14-dependent pathway. Hattor Y, et al.
Biochem Biophys Res Commun 1997 Apr 17;233(2):375–9

Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Park CT, et al. **Blood** 1997 Jun 15; 89(12):4268–74

Lipopolysaccharide-binding protein mediates CD14-independent intercalation of lipopolysaccharide into phospholipid membranes. Schromm AB, et al.
FEBS Lett 1996 Dec 16;399(3):267–71

Functional lipopolysaccharide receptors of low affinity are constitutively expressed on mouse bone marrow cells. Girard R, et al. **Immunology** 1997 Jul;91(3):391–8

Induction of tumor necrosis factor production from monocytes stimulated with mannuronic acid polymers and involvement of lipopolysaccharide-binding protein, CD14, and bactericidal/permeability-increasing factor. Jahr TG, et al. **Infect Immun** 1997 Jan;65(1):89–94

Diphosphoryl lipid A from Rhodobacter sphaeroides inhibits complexes that form in vitro between lipopolysaccharide (LPS)-binding protein, soluble CD14, and spectrally pure LPS. Jarvis BW, et al. **Infect Immun** 1997 Aug;65(8):3011–6

Identification of CD14 residues involved in specific lipopolysaccharide recognition. Shapiro RA, et al.
Infect Immun 1997 Jan;65(1):293–7

CD14-mediated signal pathway of Porphyromonas gingivalis lipopolysaccharide in human gingival fibroblasts. Watanabe A, et al. **Infect Immun** 1996 Nov;64(11):4488–94

Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes. Weidemann B, et al. **Infect Immun** 1997 Mar;65(3):858–64

CD14 is a cell-activating receptor for bacterial peptidoglycan. Gupta D, et al. **J Biol Chem** 1996 Sep 20; 271(38):23310–6

Cellular binding of soluble CD14 requires lipopolysaccharide (LPS) and LPS-binding protein. Tapping RI, et al.
J Biol Chem 1997 Sep 12;272(37):23157–64

Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. Yu B, et al.
J Clin Invest 1997 Jan 15;99(2):315–24

Chemical characteristics of Staphylococcus aureus molecules that have CD14-dependent cell-stimulating activity. Kusunoki T, et al. **J Immunol** 1996 Dec 1;157(11):5112–7

Expression and release of the monocyte lipopolysaccharide receptor antigen CD14 are suppressed by glucocorticoids in vivo and in vitro. Nockher WA, et al. **J Immunol** 1997 Feb 1;158(3):1345–52

Detection and biochemical characteristics of the receptor for complexes of soluble CD14 and bacterial lipopolysaccharide. Vita N, et al. **J Immunol** 1997 Apr 1; 158(7):3457–62

Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers: preferential interaction with particular classes of lipid. Wurfel MM, et al. **J Immunol** 1997 Apr 15;158(8):3925–34

Bacterial lipopolysaccharide binds to CD14 in low-density domains of the monocyte-macrophage plasma membrane. Wang PY, et al. **J Inflamm** 1995–96;47(3):126–37

Lipopolysaccharide dependent cellular activation. Tobias PS, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):99–103 (40 ref.)

Evidence that the receptor for soluble CD14:LPS complexes may not be the putative signal-transducing molecule associated with membrane-bound CD14. Haziot A, et al.
Scand J Immunol 1997 Sep;46(3):242–5

Bacterial lipopolysaccharide binding to host receptors [letter; comment] Hazlett LD. **Trends Microbiol** 1996 Nov; 4(11):418. Comment on: Trends Microbiol 1996 Oct;4(10):408–9.

PHYSIOLOGY

CD14-dependent mechanism for endotoxin-mediated nitric oxide synthesis in murine macrophages. Schroeder RA, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C1030–9

Involvement of diacylglycerol production in activation of nuclear factor kappaB by a CD14-mediated lipopolysaccharide stimulus. Yamamoto H, et al.
Biochem J 1997 Jul 1;325 (Pt 1):223–8

LPS-induced stimulation of phagocytosis in the sipunculan worm Themiste petricola: possible involvement of human CD14, CD11B and CD11C cross-reactive molecules. Blanco GA, et al. **Dev Comp Immunol** 1997 Jul–Aug; 21(4):349–62

Coexistence of CD14-dependent and independent pathways for stimulation of human monocytes by gram-positive bacteria. Cauwels A, et al. **Infect Immun** 1997 Aug; 65(8):3255–60

Serum factors, cell membrane CD14, and beta2 integrins are not required for activation of bovine macrophages by lipopolysaccharide. Jungi TW, et al. **Infect Immun** 1997

Sep;65(9):3577–84
Helicobacter pylori lipopolysaccharide can activate 70Z/3 cells via CD14. Kirkland T, et al. **Infect Immun** 1997 Feb; 65(2):604–8
Porphyromonas gingivalis lipopolysaccharide–stimulated bone resorption via CD14 is inhibited by broad–spectrum antibiotics. Miyata Y, et al. **Infect Immun** 1997 Sep; 65(9):3513–9
Saturable CD14–dependent binding of fluorescein–labeled lipopolysaccharide to human monocytes. Troelstra A, et al. **Infect Immun** 1997 Jun;65(6):2272–7
OM–85 BV upregulates the expression of adhesion molecules on phagocytes through a CD 14–independent pathway. Marchant A, et al. **Int J Immunopharmacol** 1996 Apr; 18(4):259–62
Monocytes can phagocytose Gram–negative bacteria by a CD14–dependent mechanism. Grunwald U, et al. **J Immunol** 1996 Nov 1;157(9):4119–25
Regulation of human monocyte apoptosis by the CD14 molecule. Heidenreich S, et al. **J Immunol** 1997 Oct 1; 159(7):3178–88
CD14–dependent and CD14–independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. Perera PY, et al. **J Immunol** 1997 May 1;158(9):4422–9
Mycobacterial lipoarabinomannan recognition requires a receptor that shares components of the endotoxin signaling system. Savedra R Jr, et al. **J Immunol** 1996 Sep 15; 157(6):2549–54
Dual effects of soluble CD14 on LPS priming of neutrophils. Troelstra A, et al. **J Leukoc Biol** 1997 Feb;61(2):173–8
[Monocyte endotoxin elimination: what is the role of membrane–associated CD 14?] Hiki N, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:373–7 (Eng. Abstr.) **(Ger)**

ANTIGENS, CD15

ANALYSIS

Spatiotemporal expression of CD15 in the developing chick retina. Andressen C, et al. **Brain Res Dev Brain Res** 1996 Sep 2;95(2):263–71
Decrease in Le(x) expression in esophageal adenocarcinomas arising in Barrett's epithelium. Engel U, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Apr;6(4):245–8
Involvement of carbohydrate antigen sialyl Lewis(x) in colorectal cancer metastasis. Nakamori S, et al. **Dis Colon Rectum** 1997 Apr;40(4):420–31
An improved ELISA for the determination of sialyl Lewis(x) structures on purified glycoconjugates. Katnik I, et al. **Glycoconj J** 1996 Dec;13(6):1043–7
CD15–containing glycoconjugates in the central nervous system. Gocht A, et al. **Histol Histopathol** 1996 Oct; 11(4):1007–28 (133 ref.)
Expression of the human cell surface glycoconjugates Lewis x and Lewis y by Helicobacter pylori isolates is related to cagA status. Wirth HP, et al. **Infect Immun** 1996 Nov; 64(11):4598–605
Cell–associated adhesion molecules as early markers of bioincompatibility. Carreno MP, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2248–57
Oncofetal expression of blood group–related antigen on morules in thyroid carcinoma. Okamoto Y, et al. **Pathol Int** 1996 Nov;46(11):867–73
Expression of SSEA–1 (Lewis(x)) on transitional cell carcinoma of the bladder. Konety BR, et al. **Urol Int** 1997; 58(2):69–74

BIOSYNTHESIS

Expression of CD15 (Lewisx) antigen on human sperm and its role in sperm–egg interaction. D'Cruz OJ, et al. **Am J Reprod Immunol** 1997 Feb;37(2):172–83
Distinct substrate specificities of five human alpha–1,3–fucosyltransferases for in vivo synthesis of the sialyl Lewis x and Lewis x epitopes. Kimura H, et al. **Biochem Biophys Res Commun** 1997 Aug 8;237(1):131–7
Transient developmental expression of CD15 in the motor and auditory cortex of the mouse. Ashwell KW, et al. **Brain Res Dev Brain Res** 1997 May 20;100(1):143–8
Cancer cell morphology at the invasive front and expression of cell adhesion–related carbohydrate in the primary lesion of patients with colorectal carcinoma with liver metastasis. Ono M, et al. **Cancer** 1996 Sep 15;78(6):1179–86
Developmental expression of the CD15 epitope in the hippocampus of the mouse. Ashwell KW, et al. **Cell Tissue Res** 1997 Jul;289(1):17–23
Stage–specific expression of fuco–neolacto– (Lewis X) and ganglio–series neutral glycosphingolipids during brain development: characterization of Lewis X and related glycosphingolipids in bovine, human and rat brain. Dasgupta S, et al. **Glycoconj J** 1996 Jun;13(3):367–75
Glucose–transporter–type–I–gene amplification correlates with sialyl–Lewis–X synthesis and proliferation in lung cancer. Ogawa J, et al. **Int J Cancer** 1997 Apr 22; 74(2):189–92
Pre– and postnatal expression of glycoconjugates (3–fucosyl–N–acetyllactosamine and HNK–1 epitopes) in the mouse inner ear. Meyer zum Gottesberge A, et al. **Int J Dev Neurosci** 1997 Jul;15(4–5):645–56
Cloning and heterologous expression of an alpha1,3–fucosyltransferase gene from the gastric pathogen Helicobacter pylori. Ge Z, et al. **J Biol Chem** 1997 Aug 22;272(34):21357–63
Lewis X biosynthesis in Helicobacter pylori. Molecular cloning of an alpha(1,3)–fucosyltransferase gene. Martin SL, et al. **J Biol Chem** 1997 Aug 22;272(34):21349–56

BLOOD

Increased serum levels of the carrier molecules of the carbohydrate antigen sialyl Lewis X in liver diseases. Sakai N, et al. **Acta Med Okayama** 1997 Apr;51(2):79–85
High sialic acid reactivity of sugar chain structure Lewis–X in patients with mental retardation. Masuda Y, et al. **Biol Psychiatry** 1997 Jul 1;42(1):68–71
Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study–2 [see comments] Jørgensen T, et al. **J Urol** 1997 Jul;158(1):164–70. Comment in: J Urol 1997 Jul;158(1):178.

CHEMISTRY

Structure of a selectin–like mutant of mannose–binding protein complexed with sialylated and sulfated Lewis(x) oligosaccharides. Ng KK, et al. **Biochemistry** 1997 Feb 4; 36(5):979–88
Glycosyl azides as building blocks in convergent syntheses of oligomeric lactosamine and Lewis(x) saccharides. Bröder W, et al. **Bioorg Med Chem** 1997 Jan;5(1):1–19
Synthesis and conformational studies of the tyvelose capped, Lewis–x like tetrasaccharide epitope of Trichinella spiralis. Zhang J, et al. **Bioorg Med Chem** 1996 Nov;4(11):1989–2001
Solution conformation and dynamics of a tetrasaccharide related to the Lewix(X) antigen deduced by 1H NMR NOESY, ROESY, and T–ROESY measurements. Poveda A, et al. **Carbohydr Res** 1997 May 9;300(1):3–10
Crystal and molecular structure of a histo–blood group antigen involved in cell adhesion: the Lewis x trisaccharide. Pérez S, et al. **Glycobiology** 1996 Jul;6(5):537–42

GENETICS

Helicobacter pylori Lewis expression is related to the host Lewis phenotype. Wirth HP, et al. **Gastroenterology** 1997 Oct;113(4):1091–8
A transgenic mouse line with alpha–1,3/4–fucosyl–transferase cDNA: production and characteristics. Obama H, et al. **Glycoconj J** 1995 Dec; 12(6):795–801
PCR analysis of Lewis–negative gene mutations and the distribution of Lewis alleles in a Japanese population. Liu Y, et al. **J Forensic Sci** 1996 Nov;41(6):1018–21

IMMUNOLOGY

Is apoptosis involved in alcoholic hepatitis? Kawahara H, et al. **Alcohol Alcohol** 1994;29 Suppl 1:113–8
Sulfated sialyl Lewis X, the putative L–selectin ligand, detected on endothelial cells of high endothelial venules by a distinct set of anti–sialyl Lewis X antibodies [published erratum appears in Biochem Biophys Res Commun 1997 Apr 17;233(2):576] Mitsuoka C, et al. **Biochem Biophys Res Commun** 1997 Jan 23;230(3):546–51
Schistosoma mansoni excretory circulating cathodic antigen shares Lewis–x epitopes with a human granulocyte surface antigen and evokes host antibodies mediating complement–dependent lysis of granulocytes. van Dam GJ, et al. **Blood** 1996 Dec 1;88(11):4246–51
High expression of a Lewis(x)–related epitope in gastric carcinomas indicates metastatic potential and poor prognosis. Mayer B, et al. **Gastroenterology** 1996 Dec; 111(6):1433–46
Rodents infected with Schistosoma mansoni produce cytolytic IgG and IgM antibodies to the Lewis x antigen. Nyame AK, et al. **Glycobiology** 1997 Mar;7(2):207–15
Differential diagnosis of L26–positive, CD15–negative Hodgkin's disease and large B–cell lymphoma with a high content of reactive T–cells: a morphologic and immunohistochemical study. Nguyen DT, et al. **Hematopathol Mol Hematol** 1996;10(3):135–50
Role of a sialyl Lewis(x)–like epitope selectively expressed on vascular endothelial cells in local skin inflammation of the rat. Akahori T, et al. **J Immunol** 1997 Jun 1; 158(11):5384–92
High affinity antibodies against Lex and sialyl Lex from a phage display library. Dinh Q, et al. **J Immunol** 1996 Jul 15;157(2):732–8
Characterization of a T cell line specific to an anti–Id antibody related to the carbohydrate antigen, sialyl SSEA–1, and the immundominant T cell antigenic site of the antibody. Tsuyuoka K, et al. **J Immunol** 1996 Jul 15; 157(2):661–9
Expression of leukocyte fucosyltransferases regulates binding to E–selectin: relationship to previously implicated carbohydrate epitopes. Wagers AJ, et al. **J Immunol** 1997 Aug 15;159(4):1917–29
Differential reactivity of HBME–1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Miettinen M, et al. **Virchows Arch** 1996 Nov;429(4–5):213–9

METABOLISM

Developmental expression of the CD15–epitope in the brainstem and spinal cord of the mouse. Ashwell KW, et al. **Anat Embryol (Berl)** 1997 Jul;196(1):13–25
Expression of tumor–related antigens Lewis(a) Lewis(b), X, Y, Span–1 and CEA in relation to differentiation and prognosis in rectal adenocarcinomas. Sun XF, et al. **APMIS** 1996 Nov;104(11):784–8
Sulfated sialyl Lewis X, the putative L–selectin ligand, detected on endothelial cells of high endothelial venules by a distinct set of anti–sialyl Lewis X antibodies [published erratum appears in Biochem Biophys Res Commun 1997 Apr 17;233(2):576] Mitsuoka C, et al. **Biochem Biophys Res Commun** 1997 Jan 23;230(3):546–51
L–selectin–carbohydrate interactions: relevant modifications of the Lewis x trisaccharide. Sanders WJ, et al. **Biochemistry** 1996 Nov 26;35(47):14862–7
Fucosyltransferase III and sialyl–Le(x) expression correlate in cultured colon carcinoma cells but not in colon carcinoma tissue. Hanski C, et al. **Glycoconj J** 1996 Oct; 13(5):727–33
Leu–M1 immunoreactivity and phaeochromocytoma. Masmiquel L, et al. **J Clin Pathol** 1997 Feb;50(2):168–70
Evaluation of sialyl Lewisx antigen in the skin and the sera of patients with psoriasis vulgaris. Ohta K, et al. **J Dermatol** 1996 Feb;23(2):95–9
Heterogenous expression of CD15 in acute lymphoblastic leukemia: a study of ten anti–CD15 monoclonal antibodies in 158 patients. Maynadié M, et al. **Leuk Lymphoma** 1997 Mar;25(1–2):135–43
Localization of the CD15 carbohydrate epitope in the vertebrate retina. Andressen C, et al. **Vis Neurosci** 1997 Mar–Apr;14(2):253–62

PHARMACOLOGY

Glycerol administration modulates the pattern of the 3–fucosyl–N–acetyl–lactosamine (CD15) epitope in the adult guinea pig inner ear. Meyer zum Gottesberge AM, et al. **ORL J Otorhinolaryngol Relat Spec** 1997 May–Jun; 59(3):127–30

PHYSIOLOGY

Expression of CD15 (Lewisx) antigen on human sperm and its role in sperm–egg interaction. D'Cruz OJ, et al. **Am J Reprod Immunol** 1997 Feb;37(2):172–83
Sialyl Lewis(x)/E–selectin–mediated rolling in a cell–free system. Brunk DK, et al. **Biophys J** 1996 Nov;71(5):2902–7
Engagement of the Lewis X antigen (CD15) results in monocyte activation. Lo SK, et al. **Blood** 1997 Jan 1; 89(1):307–14
[Sialosyl–Le(a) and Sialosyl–Le(x) antigens in adhesion of cancer cells and tumor progression] Ugorski M, et al. **Postepy Hig Med Dosw** 1996;50(3):209–31 (111 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Anti–selectin therapy modifies skeletal muscle ischemia and reperfusion injury. Weiser MR, et al. **Shock** 1996 Jun; 5(6):402–7

ANTIGENS, CD16 see **RECEPTORS, IGG**

ANTIGENS, CD18

see related
ANTIGEN P150,95
LEUKOCYTE–ADHESION DEFICIENCY SYNDROME
LYMPHOCYTE FUNCTION–ASSOCIATED ANTIGEN–1
MACROPHAGE–1 ANTIGEN

Leucocyte adhesion deficiency presenting as a chronic ileocolitis. D'Agata ID, et al. **Gut** 1996 Oct;39(4):605–8
Attenuation of the inflammatory response in an animal colitis model by neutrophil inhibitory factor, a novel beta 2–integrin antagonist. Meenan J, et al. **Scand J Gastroenterol** 1996 Aug;31(8):786–91

ANALYSIS

Glucocorticoid receptor regulates expression of L–selectin and CD11/CD18 on human neutrophils. Filep JG, et al. **Circulation** 1997 Jul 1;96(1):295–301
Differential patterns of neutrophil adhesion molecules during cardiopulmonary bypass in humans. Galiñanes M, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II364–9
Human blood monocytes, but not alveolar macrophages, reveal increased CD11b/CD18 expression and adhesion properties upon receptor–dependent activation. Lundahl J, et al. **Eur Respir J** 1996 Jun;9(6):1188–94
Effects of polymeric C3, C3b and iC3b on neutrophil expression of CD11b and CD18. Warner RL, et al. **Int Arch Allergy Immunol** 1997 May–Jul;113(1–3):368–9
Localised and global cytosolic Ca2+ changes in neutrophils during engagement of Cd11b/CD18 integrin visualised using confocal laser scanning reconstruction. Pettit EJ, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1689–94
Characterization of lymphocyte function–associated antigen 1 (LFA–1)–deficient T cell lines: the alphaL and beta2 subunits are interdependent for cell surface expression. Weber KS, et al. **J Immunol** 1997 Jan 1;158(1):273–9
Leukocyte mobilization to skin lesions, determination of cell surface receptors (CD11b/CD18) and phagocytic capacities of neutrophils in dogs with chronic deep

pyoderma. Wisselink MA, et al.
Vet Immunol Immunopathol 1997 Jul;57(3–4):179–86
Passage of CD18– and CD18+ bovine neutrophils into pulmonary alveoli during acute Pasteurella haemolytica pneumonia. Ackermann MR, et al. **Vet Pathol** 1996 Nov; 33(6):639–46

BIOSYNTHESIS

Bacterial cell wall products increase monocyte HLA–DR and ICAM–1 without affecting lymphocyte CD18 expression. Heinzelmann M, et al. **Cell Immunol** 1997 Mar 15;176(2):127–34
Effect of Clostridium difficile toxin A on CD11/CD18 expression in vitro. Warny M, et al.
Clin Diagn Lab Immunol 1996 Sep;3(5):605–7
Beta 2–integrin/intercellular adhesion molecule (ICAM) expression in the normal human intestine. Bernstein CN, et al. **Clin Exp Immunol** 1996 Oct;106(1):160–9
Hemodialysis–induced upregulation of granulocyte adhesion molecules CD11b/CD18 is independent from 5–lipoxygenase activity. Sellmayer A, et al. **Nephron** 1997; 76(4):418–24
Increased expression of intercellular adhesion molecule 1, CD11/CD18 cell surface adhesion glycoproteins and alpha 4 beta 1 integrin in a rat model of chronic interstitial lung fibrosis. Barquín N, et al. **Pathobiology** 1996;64(4):187–92
Folding of the beta–propeller domain of the integrin alphaL subunit is independent of the I domain and dependent on the beta2 subunit. Huang C, et al.
Proc Natl Acad Sci U S A 1997 Apr 1;94(7):3162–7
Biosynthesis of B2–integrin, intracellular calcium signalling and functional responses of normal and CD18–deficient bovine neutrophils. Nagahata H, et al. **Res Vet Sci** 1996 Sep;61(2):95–101

BLOOD

Neutrophil adhesion molecule expression is comparable in perinatal rabbits and humans. Ramamoorthy C, et al.
Anesthesiology 1997 Feb;86(2):420–7
Pulsatile Ca2+ influx in human neutrophils undergoing CD11b/CD18 integrin engagement. Pettit EJ, et al.
Biochem Biophys Res Commun 1997 Jan 13;230(2):258–61
Molecular dynamics of the transition from L–selectin– to beta 2–integrin–dependent neutrophil adhesion under defined hydrodynamic shear. Taylor AD, et al.
Biophys J 1996 Dec;71(6):3488–500
Neutrophil expression of CD11b/CD18 and IL–8 secretion during normothermic cardiopulmonary bypass. Paugam C, et al. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):575–9
Neutrophils from burn patients are unable to increase the expression of CD11b/CD18 in response to inflammatory stimuli. Rodeberg DA, et al. **J Leukoc Biol** 1997 May; 61(5):575–82
Ectodomain interactions of leukocyte integrins and pro–inflammatory GPI–linked membrane proteins. Petty HR, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1405–16 (94 ref.)
Monocyte and granulocyte CD11b/CD18, CD62L expression and sICAM–1 concentration in the interdialytic period. Thylén P, et al. **Nephron** 1996;74(2):275–82
Relationship between interleukin–8 and neutrophil adhesion molecules in rheumatoid arthritis. De Gendt CM, et al.
Rheumatol Int 1996;16(4):169–73
Increased surface expression of CD18 and CD11b in leukocytes after tourniquet ischemia during elective hand surgery. Sutter PM, et al. **World J Surg** 1997 Feb; 21(2):179–84; discussion 185

CHEMISTRY

Identifying the putative metal ion–dependent adhesion site in the beta2 (CD18) subunit required for alphaLbeta2 and alphaMbeta2 ligand interactions. Goodman TG, et al.
J Biol Chem 1996 Sep 27;271(39):23729–36
The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin. Qu A, et al. **Structure** 1996 Aug 15;4(8):931–42

DRUG EFFECTS

Topographic distribution of CD18 integrin on human neutrophils as related to shape changes and movement induced by chemotactic peptide and phorbol esters. Fernández–Segura E, et al. **Cell Immunol** 1996 Jul 10; 171(1):120–5
The neuronal glycoprotein telencephalin is a cellular ligand for the CD11a/CD18 leukocyte integrin. Tian L, et al.
J Immunol 1997 Jan 15;158(2):928–36

GENETICS

NSAIDs upregulate beta 2–integrin expression on human neutrophils through a calcium–dependent pathway. Fiorucci S, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):619–30
Scanning mutagenesis to localize DNA–protein interactions. Rosmarin AG, et al. **Biotechniques** 1997 Mar;22(3):434–6
Adhesion molecule CD11a/CD18–deficient Burkitt's lymphoma cells lack the transcript for the beta, but not the alpha, integrin subunit. Neira M, et al.
Eur J Haematol 1997 Jan;58(1):32–9
Functional characteristics of enhanced Fc receptor expression of beta 2 integrin–deficient bovine mononuclear phagocytes. Nagahata H, et al. **Microbiol Immunol** 1996; 40(5):389–95
Bovine leucocyte adhesion deficiency: a review of a modern disease and its implications. Gerardi AS. **Res Vet Sci** 1996 Nov;61(3):183–6 (18 ref.)
An improved DNA test for bovine leucocyte adhesion deficiency. Tammen I, et al. **Res Vet Sci** 1996 May; 60(3):218–21

IMMUNOLOGY

Factors modifying protective effect of anti–CD18 antibodies on myocardial reperfusion injury in dogs. Perez RG, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H53–64
Plasma activation of neutrophil CD18 after skeletal muscle ischemia: a potential mechanism for late systemic injury. Petrasek PF, et al. **Am J Physiol** 1996 May;270(5 Pt 2):H1515–20
CD–18 monoclonal antibody blocks the early events of aneurysm expansion. Strindberg G, et al.
Ann N Y Acad Sci 1996 Nov 18;800:266–7
The effect of R 15.7/HO, an anti–CD18 antibody, on the late airway response and airway hyperresponsiveness in an allergic rabbit model. el–Hashim AZ, et al.
Br J Pharmacol 1997 Jun;121(4):671–8
The effect of the selectin binding polysaccharide fucoidin on eosinophil recruitment in vivo. Teixeira MM, et al.
Br J Pharmacol 1997 Mar;120(6):1059–66
Cellular requirements for immunomodulatory effects caused by cell wall components of Paracoccidioides brasiliensis on antibody production. Silva MF, et al.
Clin Exp Immunol 1997 Aug;109(2):261–71
Protein phosphatase 2A plays a critical role in interleukin–2–induced beta 2–integrin dependent homotypic adhesion in human CD4+ T cell lines. Brockdorff J, et al. **Cytokine** 1997 May;9(5):333–9
Temperature–dependent surface expression of the beta–2–integrin analogue of Candida albicans and its role in adhesion to the human endothelium. Würzner R, et al.
Exp Clin Immunogenet 1996;13(3–4):161–72
CD18/ICAM–1–dependent nitric oxide production of Kupffer cells as a cause of mitochondrial dysfunction in hepatoma cells: influence of chronic alcohol feeding. Kurose I, et al. **Free Radic Biol Med** 1997;22(1–2):229–39
Treatment of established adjuvant arthritis in rats with monoclonal antibody to CD18 and very late activation antigen–4 integrins suppresses neutrophil and T–lymphocyte migration to the joints and improves clinical disease. Issekutz AC, et al. **Immunology** 1996 Aug; 88(4):569–76
Inhibition of CD18 or CD11b attenuates acute lung injury after acid instillation in rabbits. Folkesson HG, et al.
J Appl Physiol 1997 Jun;82(6):1743–50
Monoclonal antibody 2F4/11 recognizes the alpha chain of a porcine beta 2 integrin involved in adhesion and complement mediated phagocytosis. Bullido R, et al.
J Immunol Methods 1996 Sep 9;195(1–2):125–34
CD18 adhesion blockade decreases bacterial clearance and neutrophil recruitment after intrapulmonary E. coli, but not after S. aureus. Ramamoorthy C, et al.
J Leukoc Biol 1997 Feb;61(2):167–72
T–cell–mediated immunity to lymphocytic choriomeningitis virus in beta2–integrin (CD18)– and ICAM–1 (CD54)–deficient mice. Christensen JP, et al. **J Virol** 1996 Dec;70(12):8997–9002
Effects of conventional peritoneal dialysates on leukocyte adhesion and CD11b, CD18 and CD14 expression. Kaupke CJ, et al. **Kidney Int** 1996 Nov;50(5):1676–83
Resolution of CNS lesions following treatment of experimental allergic encephalomyelitis in macaques with monoclonal antibody to the CD18 leukocyte integrin. Rose LM, et al. **Mult Scler** 1997 Jan;2(6):259–66
IB4, a monoclonal antibody against the CD18 leukocyte adhesion protein, reduces intracranial pressure following thromboembolic stroke in the rabbit. Bednar MM, et al.
Neurol Res 1996 Apr;18(2):171–5
Attenuation of rat lung isograft reperfusion injury with a combination of anti–ICAM–1 and anti–beta2 integrin monoclonal antibodies. DeMeester SR, et al.
Transplantation 1996 Nov 27;62(10):1477–85
Identification of monoclonal antibodies with specificity to alpha– or beta–chains of beta 2–integrins using peripheral blood leucocytes of normal and bovine leucocyte adhesion deficient (BLAD) cattle. Rutten VP, et al.
Vet Immunol Immunopathol 1996 Aug;52(4):341–5
Role of adhesion molecules in natural killer cell–induced DNA fragmentation of cytomegalovirus–infected fibroblasts. Ito M, et al. **Viral Immunol** 1996;9(4):219–24

METABOLISM

Evidence for the involvement of phosphatidylinositol 4,5–bisphosphate 3–kinase in CD18–mediated adhesion of human neutrophils to fibrinogen. Metzner B, et al.
Biochem Biophys Res Commun 1997 Mar 27;232(3):719–23
Topographic distribution of CD18 integrin on human neutrophils as related to shape changes and movement induced by chemotactic peptide and phorbol esters. Fernández–Segura E, et al. **Cell Immunol** 1996 Jul 10; 171(1):120–5
CD45 regulates Src family member kinase activity associated with macrophage integrin–mediated adhesion. Roach T, et al. **Curr Biol** 1997 Jun 1;7(6):408–17
Moderate exercise leads to decreased expression of beta1 and beta2 integrins on leucocytes. Jordan J, et al.
Eur J Appl Physiol 1997;76(2):192–4
Expression of beta 2–integrins and L–selectin on polymorphonuclear leukocytes in septic patients. Thiel M, et al. **Eur Surg Res** 1997;29(3):160–75
The role of LFA–1 (CD11a/CD18) cytoplasmic domains in binding to intercellular adhesion molecule–1 (CD54) and in postreceptor cell spreading. Pyszniak AM, et al.
Exp Cell Res 1997 May 25;233(1):78–87
A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Coxon A, et al. **Immunity** 1996 Dec; 5(6):653–66
Cryptococcal polysaccharides bind to CD18 on human neutrophils. Dong ZM, et al. **Infect Immun** 1997 Feb; 65(2):557–63
Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses. Rinder C, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S6–12 (41 ref.)
Activation of the beta2 integrin Mac–1 (CD11b/CD18) by an endogenous lipid mediator of human neutrophils and HL–60 cells. Klugewitz K, et al. **J Cell Sci** 1997 Apr;110 (Pt 8):985–90
Engagement of L–selectin impairs the actin polymerizing capacity of beta 2–integrins on neutrophils. Ng–Sikorski J, et al. **J Cell Sci** 1996 Sep;109 (Pt 9):2361–9
Integrin–dependent induction of functional urokinase receptors in primary T lymphocytes. Bianchi E, et al.
J Clin Invest 1996 Sep 1;98(5):1133–41
Human leukocyte elastase is an endogenous ligand for the integrin CR3 (CD11b/CD18, Mac–1, alpha M beta 2) and modulates polymorphonuclear leukocyte adhesion. Cai TQ, et al. **J Exp Med** 1996 Oct 1;184(4):1213–23
GlyCAM–1, a physiologic ligand for L–selectin, activates beta 2 integrins on naive peripheral lymphocytes. Hwang ST, et al. **J Exp Med** 1996 Oct 1;184(4):1343–8
Outside–in signaling by lipopolysaccharide through a tailless integrin. Ingalls RR, et al. **J Immunol** 1997 Jul 1; 159(1):433–8
CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils. Skubitz KM, et al. **J Immunol** 1996 Oct 15; 157(8):3617–26
The neuronal glycoprotein telencephalin is a cellular ligand for the CD11a/CD18 leukocyte integrin. Tian L, et al.
J Immunol 1997 Jan 15;158(2):928–36
Generation of mutant cells with constitutively active beta 2–integrin LFA–1. Hedman H, et al.
J Immunol Methods 1996 Oct 30;198(1):59–66
Differential phosphorylation of the beta2 integrin CD11b/CD18 in the plasma and specific granule membranes of neutrophils. Buyon JP, et al.
J Leukoc Biol 1997 Mar;61(3):313–21
Inhibition and stimulation of LFA–1 and Mac–1 functions by antibodies against murine CD18. Evidence that the LFA–1 binding sites for ICAM–1, –2, and –3 are distinct. Driessens MH, et al. **J Leukoc Biol** 1996 Dec;60(6):758–65
Granulocyte dysplasia and dysfunction, and CD11/CD18 defects in myelodysplastic syndromes. Mazzone A, et al.
Leuk Lymphoma 1996 Oct;23(3–4):267–75 (71 ref.)
Expression and polarization of intercellular adhesion molecule–1 on human intestinal epithelia: consequences for CD11b/CD18–mediated interactions with neutrophils. Parkos CA, et al. **Mol Med** 1996 Jul;2(4):489–505
Arginine–glycine–aspartic acid mimics can identify a transitional activation state of recombinant alphaIIb beta3 in human embryonic kidney 293 cells. Abraham DG, et al. **Mol Pharmacol** 1997 Aug;52(2):227–36
Mac–1 (CD11b/CD18) is an oligodeoxynucleotide–binding protein [see comments] Benimetskaya L, et al. **Nat Med** 1997 Apr;3(4):414–20. Comment in: Nat Med 1997 Jul;3(7):702.
Folding of the conserved domain but not of flanking regions in the integrin beta2 subunit requires association with the alpha subunit. Huang C, et al.
Proc Natl Acad Sci U S A 1997 Apr 1;94(7):3156–61
Human leukaemic (HMC–1) and normal skin mast cells express beta 2–integrins: characterization of beta 2–integrins and ICAM–1 on HMC–1 cells. Weber S, et al. **Scand J Immunol** 1997 May;45(5):471–81
Time course of beta 2–integrin CD11b/CD18 (Mac–1, alpha M beta 2) upregulation on neutrophils and monocytes after coronary artery bypass grafting. CD11b upregulation after CABG surgery. Takala AJ, et al.
Scand J Thorac Cardiovasc Surg 1996;30(3–4):141–8
Adhesion molecule CD18 on polymorphonuclear cells correlates to the lung injury caused by continuous infusion of endotoxin in sheep. Kubo H, et al.
Tohoku J Exp Med 1995 Nov;177(3):213–22
Increased production of hydrogen peroxide and expression of CD11b/CD18 on alveolar macrophages in patients with active pulmonary tuberculosis. Kuo HP, et al.
Tuber Lung Dis 1996 Oct;77(5):468–75

PHARMACOLOGY

Cell adhesion molecules of experimental otitis media in the rat. Kamimura M, et al. **Acta Otolaryngol (Stockh)** 1996 Nov;116(6):857–62
Apoptosis following interleukin–2 withdrawal from T cells: evidence for a regulatory role of CD18 (beta 2–integrin)

molecules. Röpke C, et al. **Tissue Antigens** 1996 Aug; 48(2):127–35

PHYSIOLOGY

Ethanol–induced leukocyte adherence and albumin leakage in rat mesenteric venules: role of CD18/intercellular adhesion molecule–1. Takaishi M, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):347A–349A

CD18–dependent leukocyte adherence and vascular injury in pig cerebral circulation after ischemia. Gidday JM, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2622–9

CD18 integrin and CD54–dependent neutrophil adhesion to cytokine–stimulated human hepatocytes. Nagendra AR, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):G408–16

Monosodium urate crystals promote neutrophil adhesion via a CD18–independent and selectin–independent mechanism. Reinhardt PH, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):C31–9

Role of leukocyte beta 2–integrin in PAF–induced shock and intestinal injury. Sun XM, et al. **Am J Physiol** 1996 Jan; 270(1 Pt 1):G184–90

Inhibition of human neutrophil beta2–integrin–dependent adherence by hyperbaric O2. Thom SR, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C770–7

Dual action of cAMP–dependent protein kinase on granulocyte movement. Ydrenius L, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):445–50

Lipids derived from the mevalonate pathway in HL–60 cells modulate the interactions of beta 2 integrins with their ligands. Hill ME, et al. **Biochem Soc Trans** 1997 May; 25(2):349S

Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between P–selectin and the beta 2 integrin CD11b/CD18. Evangelista V, et al. **Blood** 1996 Dec 1; 88(11):4183–94

Mac–1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Simon DI, et al. **Blood** 1996 Oct 15;88(8):3185–94

Carbohydrate– and CD18–dependent neutrophil adhesion to cardiac myocytes: effects of adenosine. Bullough DA, et al. **Cardiovasc Res** 1996 Aug;32(2):328–34

The role of selectins and CD18 in leukotriene B4–mediated white blood cell emigration in human skin grafts transplanted on SCID mice. Yan HC, et al. **Cell Adhes Commun** 1996 Apr;3(6):475–86

Beta 2–integrin–mediated signal up–regulates counterreceptor ICAM–1 expression on human monocytic cell line THP–1 through tyrosine phosphorylation. Yamada A, et al. **Cell Immunol** 1997 May 25;178(1):9–16

Cross–talk between cell adhesion molecules regulates the migration velocity of neutrophils. Rainger GE, et al. **Curr Biol** 1997 May 1;7(5):316–25

Leukocyte adhesion––structure and function of human leukocyte beta2–integrins and their cellular ligands. Gahmberg CG, et al. **Eur J Biochem** 1997 Apr 15; 245(2):215–32 (226 ref.)

Monocytes induce E–selectin gene expression in endothelial cells: role of CD11/CD18 and extracellular matrix proteins. Noble KE, et al. **Eur J Immunol** 1996 Dec;26(12):2944–51

The role of adhesion molecules in the recruitment of hepatic natural killer cells (pit cells) in rat liver. Luo D, et al. **Hepatology** 1996 Dec;24(6):1475–80

Intercellular adhesion molecule–1 and CD18 are involved in neutrophil adhesion and its cytotoxicity to cultured sinusoidal endothelial cells in rats. Sakamoto S, et al. **Hepatology** 1997 Sep;26(3):658–63

Serum factors, cell membrane CD14, and beta2 integrins are not required for activation of bovine macrophages by lipopolysaccharide. Jungi TW, et al. **Infect Immun** 1997 Sep;65(9):3577–84

Nitric oxide inhibits neutrophil beta 2 integrin function by inhibiting membrane–associated cyclic GMP synthesis. Banick PD, et al. **J Cell Physiol** 1997 Jul;172(1):12–24

CD18/ICAM–1–dependent oxidative NF–kappaB activation leading to nitric oxide production in rat Kupffer cells cocultured with syngeneic hepatoma cells. Kurose I, et al. **J Clin Invest** 1997 Mar 1;99(5):867–78

Anti–CD18 antibodies improve cardiac function following cardiopulmonary bypass in dogs. Mayers I, et al. **J Crit Care** 1996 Dec;11(4):189–96

Neutrophil CD18–dependent arrest on intercellular adhesion molecule 1 (ICAM–1) in shear flow can be activated through L–selectin. Gopalan PK, et al. **J Immunol** 1997 Jan 1;158(1):367–75

IL–2 induces beta2–integrin adhesion via a wortmannin/LY294002–sensitive, rapamycin–resistant pathway. Phosphorylation of a 125–kilodalton protein correlates with induction of adhesion, but not mitogenesis. Nielsen M, et al. **J Immunol** 1996 Dec 15;157(12):5350–8

The roles of CD11/CD18 and ICAM–1 in acute Pseudomonas aeruginosa–induced pneumonia in mice. Qin L, et al. **J Immunol** 1996 Dec 1;157(11):5016–21

Characterization of lymphocyte function–associated antigen 1 (LFA–1)–deficient T cell lines: the alphaL and beta2 subunits are interdependent for cell surface expression. Weber KS, et al. **J Immunol** 1997 Jan 1;158(1):273–9

Beta 2 (CD11/CD18) integrins can serve as signaling partners for other leukocyte receptors. Todd RF 3rd, et al. **J Lab Clin Med** 1997 May;129(5):492–8 (64 ref.)

Enhanced aggregation of human neutrophils by MnCl2 or DTT differentiates the roles of L–selectin and beta 2–integrins. Lynam EB, et al. **J Leukoc Biol** 1996 Sep; 60(3):356–64

In vivo migration of radiolabelled lymphocytes in rheumatoid synovial tissue engrafted in SCID mice: implication of beta 2 and beta 7–integrin. Jorgensen C, et al. **J Rheumatol** 1996 Jan;23(1):32–5

Differing roles of CD18 and VLA–4 in leukocyte migration/activation during anti–GBM nephritis. Wu X, et al. **Kidney Int** 1996 Aug;50(2):462–72

Adhesiveness for extracellular matrices and lysosomal enzyme release from normal and beta 2 integrin–deficient bovine neutrophils. Nagahata H, et al. **Microbiol Immunol** 1996;40(10):783–6

Neutrophil emigration in the lungs. Doerschuk CM, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:141–5 (21 ref.)

Ischemia–reperfusion injury in skeletal muscle: CD 18–dependent neutrophil–endothelial adhesion and arteriolar vasoconstriction. Zamboni WA, et al. **Plast Reconstr Surg** 1997 Jun;99(7):2002–7; discussion 2008–9

Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils. Weber C, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10939–44

Monocyte aggregation and multinucleated giant–cell formation in vitro in Crohn's disease. The effect of cell adhesion molecules. Liu ZX, et al. **Scand J Gastroenterol** 1996 Jul;31(7):706–10

Interactions of neutrophils and endothelial cells under low flow conditions in vitro. Yoshida N, et al. **Shock** 1997 Aug; 8(2):125–30

CD11b/CD18 mediates the neutrophil chemotactic activity of fibrin degradation product D domain. Gross TJ, et al. **Thromb Haemost** 1997 May;77(5):894–900

Role of CD18–dependent and CD18–independent mechanisms in the increased leukocyte adhesiveness and in the variations of circulating white blood cell populations induced by anti–CD3 monoclonal antibodies. Kinnaert P, et al. **Transpl Int** 1996;9(4):386–91

ANTIGENS, CD19

Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Kay NE, et al. **Blood** 1997 Jul 1;90(1):340–5

ANALYSIS

Individual CD34+CD38lowCD19–CD10– progenitor cells from human cord blood generate B lymphocytes and granulocytes. Berardi AC, et al. **Blood** 1997 May 15; 89(10):3554–64

Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study. Uckun FM, et al. **Blood** 1997 Apr 1;89(7):2488–93

Lack of t(14;18) polymerase chain reaction–positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma. Voso MT, et al. **Blood** 1997 May 15;89(10):3763–8

Relationship between serum prolactin, lactation and changes in maternal blood B–cell (CD19+) percents during the first 8 months post–partum. Zimmer JP, et al. **J Reprod Immunol** 1996 May;30(2–3):81–95

BIOSYNTHESIS

Aberrant expression of CD19 as a marker of monocytic lineage in acute myelogenous leukemia [published erratum appears in Am J Clin Pathol 1997 May;107(5):621] Tisone JA, et al. **Am J Clin Pathol** 1997 Mar;107(3):283–91

Ig D(H) gene segment transcription and rearrangement before surface expression of the pan–B–cell marker CD19 in normal human bone marrow. Bertrand FE 3rd, et al. **Blood** 1997 Jul 15;90(2):736–44

CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient–specific IgH VDJ gene rearrangements. Szczepek AJ, et al. **Blood** 1997 Mar 1;89(5):1824–33

BLOOD

A flowcytometric study of CD4+ & CD19+ cell lymphopenia in patients with alopecia areata. Sharma VK, et al. **Indian J Med Res** 1996 Nov;104:296–8

CHEMISTRY

Regulation of B lymphocyte development and activation by the CD19/CD21/CD81/Leu 13 complex requires the cytoplasmic domain of CD19. Sato S, et al. **J Immunol** 1997 Oct 1;159(7):3278–87

GENETICS

In vivo footprinting and mutational analysis of the proximal CD19 promoter reveal important roles for an SP1/Egr–1 binding site and a novel site termed the PyG box. Riva A, et al. **J Immunol** 1997 Aug 1;159(3):1284–92

B lymphocyte–specific, Cre–mediated mutagenesis in mice. Rickert RC, et al. **Nucleic Acids Res** 1997 Mar 15; 25(6):1317–8

IMMUNOLOGY

Identification of differentially expressed genes in CD19+ve B lymphocytes in allergic asthma. Harun RB, et al. **Adv Exp Med Biol** 1996;409:375–80

Optimization of conditions for formation and analysis of anti–CD19 FVS191 single–chain Fv homodimer (scFv')2. Wang D, et al. **Bioconjug Chem** 1997 Jan–Feb;8(1):64–70

Clinical significance of HLA–DR+, CD19+, CD10+ immature B–cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura. Callea V, et al. **Haematologica** 1997 Jul–Aug;82(4):471–3

CD5/CD19/CD23 chronic lymphocytosis [letter] Manteiga R, et al. **Haematologica** 1997 Jul–Aug;82(4):510–1

The CD19–CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Tedder TF, et al. **Immunity** 1997 Feb;6(2):107–18 (94 ref.)

Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen–derived synthetic peptide. Hooijberg E, et al. **J Immunother Emphasis Tumor Immunol** 1996 Sep; 19(5):346–56

Toxicity profile of the investigational new biotherapeutic agent, B43 (anti–CD19)–pokeweed antiviral protein immunotoxin. Gunther R, et al. **Leuk Lymphoma** 1996 Jun; 22(1–2):61–70, follow.186, color plate II–V

Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody. Csóka M, et al. **Leukemia** 1996 Nov;10(11):1765–72

A comparison of two murine monoclonal antibodies humanized by CDR–grafting and variable domain resurfacing [published erratum appears in Protein Eng 1997 Feb;10(2):181] Roguska MA, et al. **Protein Eng** 1996 Oct; 9(10):895–904

METABOLISM

The protein product of the proto–oncogene c–cbl forms a complex with phosphatidylinositol 3–kinase p85 and CD19 in anti–IgM–stimulated human B–lymphoma cells. Beckwith M, et al. **Blood** 1996 Nov 1;88(9):3502–7

Fc gammaRIIB1 inhibition of BCR–mediated phosphoinositide hydrolysis and Ca2+ mobilization is integrated by CD19 dephosphorylation. Hippen KL, et al. **Immunity** 1997 Jul;7(1):49–58

Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin. Tooze RM, et al. **Immunity** 1997 Jul;7(1):59–67

Alteration of B–cell antigen receptor signaling by CD19 co–ligation. A study with bispecific antibodies. Lankester AC, et al. **J Biol Chem** 1996 Sep 13;271(37):22326–30

CD38 ligation in human B cell progenitors triggers tyrosine phosphorylation of CD19 and association of CD19 with lyn and phosphatidylinositol 3–kinase. Kitanaka A, et al. **J Immunol** 1997 Jul 1;159(1):184–92

PHARMACOLOGY

The CD19–CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Tedder TF, et al. **Immunity** 1997 Feb;6(2):107–18 (94 ref.)

CD19 regulates B lymphocyte signaling thresholds critical for the development of B–1 lineage cells and autoimmunity. Sato S, et al. **J Immunol** 1996 Nov 15;157(10):4371–8

PHYSIOLOGY

Conjugation of blocked ricin to an anti–CD19 monoclonal antibody increases antibody–induced cell calcium mobilization and CD19 internalization. Goulet AC, et al. **Blood** 1997 Sep 15;90(6):2364–75

Prevention of Epstein–Barr virus–induced human B–cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. Bohlen H, et al. **Cancer Res** 1997 May 1;57(9):1704–9

Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1. Doody GM, et al. **Curr Opin Immunol** 1996 Jun;8(3):378–82 (47 ref.)

Membrane IgM–induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex. Carter RH, et al. **J Immunol** 1997 Apr 1;158(7):3062–9

Role of CD19 tyrosine 391 in synergistic activation of B lymphocytes by coligation of CD19 and membrane Ig. Li X, et al. **J Immunol** 1997 Jun 15;158(12):5649–57

Regulation of B lymphocyte development and activation by the CD19/CD21/CD81/Leu 13 complex requires the cytoplasmic domain of CD19. Sato S, et al. **J Immunol** 1997 Oct 1;159(7):3278–87

CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19. Sato S, et al. **J Immunol** 1997 May 15; 158(10):4662–9

Complement: instructing the acquired immune system through the CD21/CD19 complex. Dempsey PW, et al. **Res Immunol** 1996 Feb;147(2):71–5; discussion 119–20 (34 ref.)

ANTIGENS, CD20

ANALYSIS

Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. Tefferi A, et al. **Am J Clin Pathol** 1996 Oct;106(4):457-61

High temperature antigen retrieval and loss of nuclear morphology: a comparison of microwave and autoclave techniques. Hunt NC, et al. **J Clin Pathol** 1996 Sep; 49(9):767-70

Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Li WV, et al. **Mod Pathol** 1996 Oct;9(10):982-8

IMMUNOLOGY

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Maloney DG, et al. **Blood** 1997 Sep 15; 90(6):2188-95

Characterization of a series of isotype switch variants of a new CD20 monoclonal antibody. Hooijberg E, et al. **Hybridoma** 1996 Feb;15(1):23-31

A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. Gazzano-Santoro H, et al. **J Immunol Methods** 1997 Mar 28;202(2):163-71

Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. Funakoshi S, et al. **J Immunother Emphasis Tumor Immunol** 1996 Mar; 19(2):93-101

Transient expression of CD20 antigen (pan B cell marker) in activated lymph node T cells. Murayama Y, et al. **Microbiol Immunol** 1996;40(6):467-71

METABOLISM

Activation of a calcium-permeable cation channel CD20 expressed in Balb/c 3T3 cells by insulin-like growth factor-I. Kanzaki M, et al. **J Biol Chem** 1997 Feb 21; 272(8):4964-9

PHYSIOLOGY

Activation of the calcium-permeable cation channel CD20 by alpha subunits of the Gi protein. Kanzaki M, et al. **J Biol Chem** 1997 Jun 6;272(23):14733-9

ANTIGENS, CD21 see **RECEPTORS, COMPLEMENT 3D**

ANTIGENS, CD23 see **RECEPTORS, IGE**

ANTIGENS, CD25 see **RECEPTORS, INTERLEUKIN-2**

ANTIGENS, CD26

Analysis of hepatocyte distribution and survival in vascular beds with cells marked by 99mTC or endogenous dipeptidyl peptidase IV activity. Gupta S, et al. **Cell Transplant** 1997 Jul-Aug;6(4):377-86

ANALYSIS

Immunoelectron microscopic single and double labelling of aminopeptidase N (CD 13) and dipeptidyl peptidase IV (CD 26). Stange T, et al. **Acta Histochem** 1996 Jul; 98(3):323-31

Histochemical evaluation of placental dipeptidyl peptidase IV (CD26) in pre-eclampsia: enzyme activity in villous trophoblast indicates an enhanced likelihood of gestational hypertensive disorders. Neudeck H, et al. **Am J Reprod Immunol** 1997 Jun;37(6):449-58

Histochemical and immunocytochemical localization of dipeptidyl peptidases II and IV in human gingiva. Kennett CN, et al. **J Periodontol** 1996 Sep;67(9):846-52

Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis. Mizokami A, et al. **J Rheumatol** 1996 Dec;23(12):2022-6

Adenosine deaminase in rodent median eminence: detection by antibody to the mouse enzyme and co-localization with adenosine deaminase-complexing protein (CD26). Nagy JI, et al. **Neuroscience** 1996 Jul;73(2):459-71

[Tumor markers in the cytodiagnosis of thyroid nodules. Detection of dipeptidyl aminopeptidase IV (DAP IV) activity] Zoro P, et al. **Ann Pathol** 1996 Sep;16(4):261-5 (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

PKC-dependent long-term effect of PMA on protein cell surface expression in Caco-2 cells. Sapin C, et al. **Exp Cell Res** 1997 Mar 15;231(2):308-18

Selective loss of the CD4+/CD26+ T-cell subset during HIV infection. Gougeon ML, et al. **Res Immunol** 1996 Jan; 147(1):5-8

The effects of CD26/DPP IV-targeted therapy on acute allograft rejection. Korom S, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1274-5

BLOOD

Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs. Maes M, et al. **Acta Psychiatr Scand** 1996 Jan;93(1):1-8

Serum dipeptidyl peptidase IV activities in Czernobyl zone inhabitants exposed to the power-station catastrophe [letter] Sedo A, et al. **Eur J Clin Chem Clin Biochem** 1996 May;34(5):447-8

Reduced expression of dipeptidyl peptidase (DPP) IV in peripheral blood T lymphocytes of oral cancer patients. Uematsu T, et al. **J Oral Pathol Med** 1996 Oct;25(9):507-12

Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: relationships with immune-inflammatory markers. Maes M, et al. **Psychoneuroendocrinology** 1997 Feb;22(2):65-78

[Effect of specific CD26/dipeptidylpeptidase IV (DPP IV) inhibition on acute transplant rejection and immune response in allotransplant recipients] Korom S, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:191-4 (Eng. Abstr.) **(Ger)**

CHEMISTRY

A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. Lambeir AM, et al. **Biochim Biophys Acta** 1997 Jul 18;1340(2):215-26

DRUG EFFECTS

Inhibition of dipeptidyl peptidase IV (CD26) by peptide boronic acid dipeptides. Pargellis CA, et al. **J Enzyme Inhib** 1997 Jan;11(3):151-69

The inhibition of intestinal dipeptidylaminopeptidase-IV promotes the absorption of enterostatin and des-arginine-enterostatin across rat jejunum in vitro. Bouras M, et al. **Life Sci** 1996;59(25-26):2147-55

GENETICS

Differential expression of dipeptidyl peptidase IV (CD26) and thyroid peroxidase in neoplastic thyroid tissues. Umeki K, et al. **Endocr J** 1996 Feb;43(1):53-60

cDNA cloning and expression of secreted Xenopus laevis dipeptidyl aminopeptidase IV. Vlasak R, et al. **Eur J Biochem** 1997 Jul 1;247(1):107-13

Dipeptidyl peptidase IV from Xanthomonas maltophilia: sequencing and expression of the enzyme gene and characterization of the expressed enzyme. Kabashima T, et al. **J Biochem (Tokyo)** 1996 Dec;120(6):1111-7

IMMUNOLOGY

Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Hegen M, et al. **Immunology** 1997 Feb; 90(2):257-64

Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Reinhold D, et al. **Immunology** 1997 Jul;91(3):354-60

Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. Willheim M, et al. **J Allergy Clin Immunol** 1997 Sep;100(3):348-55

Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. Valenzuela A, et al. **J Immunol** 1997 Apr 15;158(8):3721-9

Selective loss of the CD4+/CD26+ T-cell subset during HIV infection. Gougeon ML, et al. **Res Immunol** 1996 Jan; 147(1):5-8

CD26 and HIV infection. Callebaut C, et al. **Res Virol** 1996 Jan-Feb;147(1):67-9

HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells. Jacotot E, et al. **Virology** 1996 Sep 15;223(2):318-30

Expression of CD26 does not correlate with the replication of macrophage-tropic strains of HIV-1 in T-cell lines. Watkins BA, et al. **Virology** 1996 Oct 1;224(1):276-80

METABOLISM

Different enzyme activities in coronary capillary endothelial cells. Koyama T, et al. **Adv Exp Med Biol** 1997;411:359-64

Evaluation of the differentiation potential of WB-F344 rat liver epithelial stem-like cells in vivo. Differentiation to hepatocytes after transplantation into dipeptidylpeptidase-IV-deficient rat liver. Coleman WB, et al. **Am J Pathol** 1997 Aug;151(2):353-9

In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine). De Meester I, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):173-9

Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase. Jeanfavre DD, et al. **Biochem Pharmacol** 1996 Dec 13;52(11):1757-65

CD26/dipeptidyl peptidase IV does not work as an adenosine deaminase-binding protein in rat cells. Iwaki-Egawa S, et al. **Cell Immunol** 1997 Jun 15;178(2):180-6

Cytofluorographic evidence that thymocyte dipeptidyl peptidase IV (CD26) activity is altered with stage of ontogeny and apoptotic status. Ruiz P, et al. **Cytometry** 1996 Apr 1;23(4):322-9

Domain-specific N-glycosylation of the membrane glycoprotein dipeptidylpeptidase IV (CD26) influences its subcellular trafficking, biological stability, enzyme activity and protein folding. Fan H, et al. **Eur J Biochem** 1997 May 15;246(1):243-51

Transfer of CD26/dipeptidyl peptidase IV (E.C. 3.5.4.4) from prostasomes to sperm. Arienti G, et al. **FEBS Lett** 1997 Jun 30;410(2-3):343-6

The N-terminal X-X-Pro sequence of the HIV-1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen-induced proliferation of human T cells. Wrenger S, et al. **FEBS Lett** 1996 Apr 1;383(3):145-9

CD26 mediates the action of HIV-1 Tat protein on DNA synthesis and cytokine production in U937 cells. Reinhold D, et al. **Immunobiology** 1996 Jan;195(1):119-28

Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. Yamabe T, et al. **Immunology** 1997 May;91(1):151-8

Effects of substance P on human T cell function and the modulatory role of peptidase inhibitors. Covas MJ, et al. **Int J Clin Lab Res** 1997;27(2):129-34

Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. Willheim M, et al. **J Allergy Clin Immunol** 1997 Sep;100(3):348-55

Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. Pauly RP, et al. **J Biol Chem** 1996 Sep 20;271(38):23222-9

Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. Stecca BA, et al. **J Hepatol** 1997 Aug;27(2):337-45

Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Drucker DJ, et al. **Nat Biotechnol** 1997 Jul;15(7):673-7

Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors. Jiang JD, et al. **Res Virol** 1997 Jul-Aug; 148(4):255-66

The effects of CD26/DPP IV-targeted therapy on acute allograft rejection. Korom S, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1274-5

Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Korom S, et al. **Transplantation** 1997 May 27;63(10):1495-500

In vivo modulation of CD26 (dipeptidyl peptidase IV) in the mouse: effects of polyreactive and monoreactive antibodies. Yamaguchi N, et al. **Transplantation** 1996 Oct 15;62(7):973-85

[Function of proline-rich regions in proteins and proline specific peptidases] Maruyama S. **Tanpakushitsu Kakusan Koso** 1997 May;42(6):857-64 (56 ref.) **(Jpn)**

PHYSIOLOGY

Role of CD26 for CD4 memory T cell function and activation. Dong RP, et al. **Hum Cell** 1996 Sep;9(3):153-62 (47 ref.)

Influence of CD26 and integrins on the antigen sensitivity of human memory T cells. Falcioni F, et al. **Hum Immunol** 1996 Oct;50(2):79-90

Is CD26/dipeptidyl peptidase IV a really important molecule in T cell activation of a certain rat strain? Iwaki-Egawa S, et al. **Immunobiology** 1995 Nov;194(4-5):429-42

The T-cell receptor associated zeta-chain is required but not sufficient for CD26 (dipeptidylpeptidase IV) mediated signaling. von Bonin A, et al. **Immunol Lett** 1997 Mar; 55(3):179-82

Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Tanaka S, et al. **Int J Immunopharmacol** 1997 Jan;19(1):15-24

The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Pederson RA, et al. **Metabolism** 1996 Nov; 45(11):1335-41

Dipeptidyl peptidase IV in cell proliferation and differentiation. Sedo A, et al. **Sb Lek** 1994;95(4):285-88 (39 ref.)

URINE

Age dependency of infradian rhythms in enzymuria of female volunteers. Gerasch A, et al. **Eur J Clin Chem Clin Biochem** 1997 Apr;35(4):281-6

ANTIGENS, CD27

ANALYSIS

Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Vetto JT, et al. **Am J Surg** 1997 Sep;174(3):258-65

BIOSYNTHESIS

Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Tittle TV, et al. **Blood** 1997 Jun 15;89(12):4652-8

Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity. Orengo AM, et al. **Clin Exp Immunol** 1997 Mar;107(3):608-13

ANTIGENS, CD27

Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus. Font J, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):239–43

BLOOD

Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. De Rie MA, et al. **Acta Derm Venereol** 1996 Sep;76(5):357–60

Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus. Font J, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):239–43

GENETICS

Intragraft expression of T-cell activation genes in human renal allograft rejection. Pavlakis M, et al. **Kidney Int Suppl** 1996 Jan;53:S7–12 (49 ref.)

IMMUNOLOGY

Transfer of primed CD4+OX40– T lymphocytes induces increased immunity to experimental Salmonella typhimurium infections in rats. Thygesen P, et al. **APMIS** 1997 May;105(5):410–3

CD27/CD70 interaction contributes to the activation and the function of human autoreactive CD27+ regulatory T cells. Jacquot S, et al. **Cell Immunol** 1997 Jul 10; 179(1):48–54

CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. Jacquot S, et al. **J Immunol** 1997 Sep 15; 159(6):2652–7

OX-40 antibody enhances for autoantigen specific V beta 8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. Weinberg AD, et al. **J Neurosci Res** 1996 Jan 1;43(1):42–9

METABOLISM

B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Agematsu K, et al. **Eur J Immunol** 1997 Aug;27(8):2073–9

Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells. Al-Shamkhani A, et al. **J Biol Chem** 1997 Feb 21; 272(8):5275–82

CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Prasad KV, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6346–51

PHARMACOLOGY

Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity. Orengo AM, et al. **Clin Exp Immunol** 1997 Mar;107(3):608–13

PHYSIOLOGY

OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration. Imura A, et al. **Blood** 1997 Apr 15;89(8):2951–8

ANTIGENS, CD28

see related
ANTIGENS, CD80

ANALYSIS

Shortened telomeres in the expanded CD28–CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. Effros RB, et al. **AIDS** 1996 Jul; 10(8):F17–22

Anomalies of the CD8+ T cell pool in haemochromatosis: HLA-A3-linked expansions of CD8+CD28– T cells. Arosa FA, et al. **Clin Exp Immunol** 1997 Mar;107(3):548–54

Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28– T cells. Chu NR, et al. **J Immunol** 1997 Apr 1;158(7):3081–9

Costimulation of CD28– T lymphocytes by 4-1BB ligand. DeBenedette MA, et al. **J Immunol** 1997 Jan 15; 158(2):551–9

CD28–B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo. Akalin E, et al. **Transplantation** 1996 Dec 27;62(12):1942–5

[Expression of cluster of differentiation CD28 at different age] Ricci G, et al. **Recenti Prog Med** 1997 Jul-Aug; 88(7–8):328–9 **(Ita)**

BIOSYNTHESIS

The primary response to HIV infection is characterized by an expansion of activated CD8+ CD28– cells [letter] Brugnoni D, et al. **AIDS** 1996 Jan;10(1):104–6

In situ expression of B7 and CD28 receptor families in skin lesions of patients with lupus erythematosus. Denfeld RW, et al. **Arthritis Rheum** 1997 May;40(5):814–21

CD28 expression is increased in venom allergic patients but is not modified by specific immunotherapy [see comments] Tsicopoulos A, et al. **Clin Exp Allergy** 1996 Oct; 26(10):1119–24. Comment in: Clin Exp Allergy 1996 Oct;26(10):1101–4.

Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression. Roos MT, et al. **Clin Exp Immunol** 1996 Sep;105(3):409–15

CD28 expression on peripheral blood T lymphocytes after orthotopic liver transplant: upregulation in acute rejection. García-Alonso AM, et al. **Hum Immunol** 1997 Mar; 53(1):64–72

Gamma delta T cells of the murine vagina: T cell response in vivo in the absence of the expression of CD2 and CD28 molecules. Rakasz E, et al. **Int Immunol** 1997 Jan;9(1):161–7

CD28 expression by mouse mast cells is modulated by lipopolysaccharide and outer surface protein A lipoprotein from Borrelia burgdorferi. Marietta EV, et al. **J Immunol** 1997 Sep 15;159(6):2840–8

Oligonucleotide-mediated inhibition of CD28 expression induces human T cell hyporesponsiveness and manifests impaired contact hypersensitivity in mice. Tam RC, et al. **J Immunol** 1997 Jan 1;158(1):200–8

Manipulation of T cell response to tumors by targeting on costimulatory pathway. Chen L. **Leukemia** 1997 Apr;11 Suppl 3:567–9

Expansion of T cells negative for CD28 expression in HIV infection. Relation to activation markers and cell adhesion molecules, and correlation with prognostic markers. Kämmerer R, et al. **Med Microbiol Immunol (Berl)** 1996 May;185(1):19–25

Evidence of CD28 upregulation in peripheral T cells before liver transplant acute rejection. Minguela A, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):499–500

BLOOD

Expression of CD80 (B7/BB-1) and CD28 in human white blood cells treated with urocanic acid. Laihia JK, et al. **Arch Dermatol Res** 1996 Sep;288(10):570–4

Expansion of cytotoxic CD8+ CD28– T cells in healthy ageing people, including centenarians. Fagnoni FF, et al. **Immunology** 1996 Aug;88(4):501–7

Anomalous expression of costimulatory molecules B7-1, B7-2 and CD28 in primary biliary cirrhosis. Spengler U, et al. **J Hepatol** 1997 Jan;26(1):31–6

CHEMISTRY

CD28: a signalling perspective. Ward SG. **Biochem J** 1996 Sep 1;318 (Pt 2):361–77 (222 ref.)

Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Alvarez-Vallina L, et al. **Eur J Immunol** 1996 Oct;26(10):2304–9

DRUG EFFECTS

CD28 expression is increased in venom allergic patients but is not modified by specific immunotherapy [see comments] Tsicopoulos A, et al. **Clin Exp Allergy** 1996 Oct; 26(10):1119–24. Comment in: Clin Exp Allergy 1996 Oct;26(10):1101–4.

Analysis of CD28 cytoplasmic tail tyrosine residues as regulators and substrates for the protein tyrosine kinases, EMT and LCK. King PD, et al. **J Immunol** 1997 Jan 15; 158(2):580–90

Oligonucleotide-mediated inhibition of CD28 expression induces human T cell hyporesponsiveness and manifests impaired contact hypersensitivity in mice. Tam RC, et al. **J Immunol** 1997 Jan 1;158(1):200–8

Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways. Woodward JE, et al. **Transplantation** 1996 Oct 15;62(7):1011–8

GENETICS

Involvement of Rel, Fos, and Jun proteins in binding activity to the IL-2 promoter CD28 response element/AP-1 sequence in human T cells. McGuire KL, et al. **J Immunol** 1997 Aug 1;159(3):1319–27

Regulation of the interleukin-2 CD28-responsive element by NF-ATp and various NF-kappaB/Rel transcription factors. Maggirwar SB, et al. **Mol Cell Biol** 1997 May; 17(5):2605–14

IMMUNOLOGY

Regulation of T cell activation by CD28 and CTLA4. Noel PJ, et al. **Adv Exp Med Biol** 1996;406:209–17 (27 ref.)

Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody. Hombach A, et al. **Anticancer Res** 1997 May-Jun; 17(3C):2025–32

B7-mediated costimulation and the immune response. Schultze J, et al. **Blood Rev** 1996 Jun;10(2):111–27 (107 ref.)

A relationship between the generation of burn-associated type 2 T cells and their antagonistic cells in thermally injured mice. Utsunomiya T, et al. **Burns** 1997 Jun; 23(4):281–7

CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Mazzoni A, et al. **Cancer Res** 1996 Dec 1;56(23):5443–9

CD28-mediated activation of resting human T cells without costimulation of the CD3/TCR complex. Siefken R, et al. **Cell Immunol** 1997 Feb 25;176(1):59–65

High concentrations of antigenic ligand activate and do not tolerize naive CD4 T cells in the absence of CD28/B7 costimulation. Teh HS, et al. **Cell Immunol** 1997 Jul 10; 179(1):74–83

CD8+CD28– T cells in vertically HIV-infected children. Brugnoni D, et al. **Clin Exp Immunol** 1997 Sep;109(3):412–5

CD28 costimulation and T lymphocyte proliferative responses in HIV-1 infection. Carlesimo M, et al. **Clin Exp Immunol** 1997 Sep;109(3):406–11

Co-stimulation in T cell responses. Chambers CA, et al. **Curr Opin Immunol** 1997 Jun;9(3):396–404 (83 ref.)

Interleukin 12 and B7/CD28 interaction synergistically upregulate interleukin 10 production by human T cells. Peng X, et al. **Cytokine** 1997 Jul;9(7):499–506

Co-stimulatory pathways controlling activation and peripheral tolerance of human CD4+CD28– T cells. Park W, et al. **Eur J Immunol** 1997 May;27(5):1082–90

Memory alloreactive cytotoxic T cells do not require costimulation for activation in vitro. Flynn K, et al. **Immunol Cell Biol** 1996 Oct;74(5):413–20

Collaboration of TCR-, CD4- and CD28-mediated signalling in antigen-specific MHC class II-restricted T-cells. Gogolák P, et al. **Immunol Lett** 1996 Dec; 54(2–3):135–44

CD28/B7 regulation of autoimmune diabetes. Herold KG, et al. **Immunol Res** 1997 Feb;16(1):71–84 (78 ref.)

Surface expression of CD28 single chain Fv for costimulation by tumor cells. Winberg G, et al. **Immunol Rev** 1996 Oct; 153:209–23 (19 ref.)

TCR-independent CD28-mediated gene expression in peripheral blood lymphocytes from donors chronically infected with HIV-1. Wong JG, et al. **Immunology** 1997 Feb;90(2):281–5

Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Krummel MF, et al. **Int Immunol** 1996 Apr; 8(4):519–23

Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens. Yi-qun Z, et al. **Int Immunol** 1996 Jan;8(1):37–44

B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses. Zhang YQ, et al. **Int Immunol** 1997 Aug;9(8):1095–102

CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. Wu Y, et al. **J Exp Med** 1997 Apr 7; 185(7):1327–35

CD4 T cell anergy in murine AIDS: costimulation via CD28 and the addition of IL-12 are not sufficient to rescue anergic CD4 T cells. Andrews C, et al. **J Immunol** 1997 Sep 1;159(5):2132–8

Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. Daikh DI, et al. **J Immunol** 1997 Oct 1; 159(7):3104–8

Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. Lakkis FG, et al. **J Immunol** 1997 Mar 1; 158(5):2443–8

Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II. Lando PA, et al. **J Immunol** 1996 Oct 1;157(7):2857–63

Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. Riley JL, et al. **J Immunol** 1997 Jun 1;158(11):5545–53

CD28 costimulation promotes the production of Th2 cytokines. Rulifson IC, et al. **J Immunol** 1997 Jan 15; 158(2):658–65

CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. Sperling AI, et al. **J Immunol** 1996 Nov 1;157(9):3909–17

CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. Wang R, et al. **J Immunol** 1997 Mar 15;158(6):2856–61

Role of the CD28:B7 costimulatory interaction in alloimmune responses. Akalin E, et al. **Kidney Int Suppl** 1997 Mar; 58:S8–10 (21 ref.)

New strategy for allotransplantation [editorial] Granstein RD. **Lancet** 1996 Sep 28;348(9031):838–9

T lymphocyte proliferative capability to defined stimuli and costimulatory CD28 pathway is not impaired in healthy centenarians. Sansoni P, et al. **Mech Ageing Dev** 1997 Jun; 96(1–3):127–36

The repertoire of CD4+ CD28– T cells in rheumatoid arthritis. Schmidt D, et al. **Mol Med** 1996 Sep;2(5):608–18

Hyporoliferative human lamina propria T cells retain the capacity to secrete lymphokines when stimulated via CD2/CD28 pathways. Boirivant M, et al. **Proc Assoc Am Physicians** 1996 Jan;108(1):55–67

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Kwon ED, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8099–103

Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Carroll RG, et al. **Science** 1997 Apr 11;276(5310):273–6

Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Ott M, et al. **Science** 1997 Mar 7;275(5305):1481-5

Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Hayden MS, et al. **Tissue Antigens** 1996 Oct;48(4 Pt 1):242-54

Phosphorylation of each of the distal three tyrosines of the CD28 cytoplasmic tail is required for CD28-induced T cell IL-2 secretion. Teng JM, et al. **Tissue Antigens** 1996 Oct;48(4 Pt 1):255-64

Importance of the CD28/B7 costimulatory pathway in the development of chronic ductopenic rejection in a new model of orthotopic rat liver allotransplantation. Mark W, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1029

Recall response to cytomegalovirus in allograft recipients: mobilization of CD57+, CD28+ cells before expansion of CD57+, CD28- cells within the CD8+ T lymphocyte compartment. Hazzan M, et al. **Transplantation** 1997 Mar 15;63(5):693-8

Acute graft-versus-host disease without costimulation via CD28. Speiser DE, et al. **Transplantation** 1997 Apr 15; 63(7):1042-4

METABOLISM

Role of the CD28-B7 costimulatory pathways in T cell-dependent B cell responses. Hathcock KS, et al. **Adv Immunol** 1996;62:131-66 (152 ref.)

The presence of CD28-negative T cells in a patient with multicentric Castleman's disease. Ishiyama T, et al. **Ann Hematol** 1996 Oct;73(4):199-200

Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Lane P. **Ann N Y Acad Sci** 1997 Apr 5;815:392-400 (40 ref.)

Phorbol esters modulate the coupling of the T cell costimulatory molecule CD28 to phosphatidylinositol 3-kinase. Parry RV, et al. **Biochem Soc Trans** 1997 May; 25(2):305S

Costimulation of the CD3 pathway by CD28 ligation in human intestinal lymphocytes. Ebert EC, et al. **Cell Immunol** 1996 Aug 1;171(2):211-6

Preferential elimination of CD28+ T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis. Kaneko H, et al. **Clin Exp Immunol** 1996 Nov;106(2):218-29

Murine lymphotactin: gene structure, post-translational modification and inhibition of expression by CD28 costimulation. Hautamaa D, et al. **Cytokine** 1997 Jun; 9(6):375-82

CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors. Wen T, et al. **Eur J Immunol** 1997 Aug;27(8):1988-93

High mobility group protein I(Y) is required for function and for c-Rel binding to CD28 response elements within the GM-CSF and IL-2 promoters. Himes SR, et al. **Immunity** 1996 Nov;5(5):479-89

CD4+ CD45RA+ T cells from adults respond to recall antigens after CD28 ligation. Pilling D, et al. **Int Immunol** 1996 Nov;8(11):1737-42

Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. Greene JL, et al. **J Biol Chem** 1996 Oct 25;271(43):26762-71

Temporal and subunit-specific modulations of the Rel/NF-kappaB transcription factors through CD28 costimulation. Kahn-Perlès B, et al. **J Biol Chem** 1997 Aug 29;272(35):21774-83

Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. Krinzman SJ, et al. **J Clin Invest** 1996 Dec 15;98(12):2693-9

Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes. Nishina H, et al. **J Exp Med** 1997 Sep 15;186(6):941-53

CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. van der Merwe PA, et al. **J Exp Med** 1997 Feb 3;185(3):393-403

Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing. Bolling SF, et al. **J Heart Lung Transplant** 1996 Sep;15(9):928-35

CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. Blazar BR, et al. **J Immunol** 1997 Oct 1;159(7):3460-73

CD11b+CD28-CD4+ human T cells: activation requirements and association with HLA-DR alleles. Chapman A, et al. **J Immunol** 1996 Dec 1;157(11):4771-80

Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation. Doty RT, et al. **J Immunol** 1996 Oct 15;157(8):3270-9

Induction of activator protein (AP)-1 and nuclear factor-kappaB by CD28 stimulation involves both phosphatidylinositol 3-kinase and acidic sphingomyelinase signals. Edmead CE, et al. **J Immunol** 1996 Oct 15; 157(8):3290-7

The SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory receptor CD28. Marengère LE, et al. **J Immunol** 1997 Oct 1;159(7):3220-9

CD28 mediates a potent costimulatory signal for rapid degradation of IkappaBbeta which is associated with accelerated activation of various NF-kappaB/Rel heterodimers. Harhaj EW, et al. **Mol Cell Biol** 1996 Dec; 16(12):6736-43

Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28 [letter] Metzler WJ, et al. **Nat Struct Biol** 1997 Jul;4(7):527-31

Enhanced production of IL4 but not of IFN gamma and IL 10 by peripheral blood mononuclear cells from atopic children in response to CD2 plus CD28 stimulation. Holter W, et al. **Pediatr Allergy Immunol** 1996 May;7(2):75-82

PHARMACOLOGY

Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression. Roos MT, et al. **Clin Exp Immunol** 1996 Sep;105(3):409-15

CD8+ cells and not CD4+ T cells are hyporesponsive to CD28- and CD40L-mediated activation in HIV-infected subjects. Vingerhoets J, et al. **Clin Exp Immunol** 1997 Mar; 107(3):440-7

The generation of memory antigen-specific cytotoxic T cell responses by CD28/CD80 interactions in the absence of antigen. Flynn K, et al. **Eur J Immunol** 1997 Feb; 27(2):456-62

CD28-B7 interactions function to co-stimulate clonal deletion of double-positive thymocytes. Amsen D, et al. **Int Immunol** 1996 Dec;8(12):1927-36

CD28 co-stimulatory regimes differ in their dependence on phosphatidylinositol 3-kinase: common co-signals induced by CD80 and CD86. Cefai D, et al. **Int Immunol** 1996 Oct; 8(10):1609-16

Primary porcine endothelial cells express membrane-bound B7-2 (CD86) and a soluble factor that co-stimulate cyclosporin A-resistant and CD28-dependent human T cell proliferation. Davis TA, et al. **Int Immunol** 1996 Jul; 8(7):1099-111

CD28 co-stimulatory signals induce IL-2 receptor expression on antigen-stimulated virgin T cells by an IL-2-independent mechanism. Toyooka K, et al. **Int Immunol** 1996 Feb;8(2):159-69

CD28-costimulation activates cyclic AMP-responsive element-binding protein in T lymphocytes. Hsueh YP, et al. **J Immunol** 1997 Jan 1;158(1):85-93

Analysis of CD28 cytoplasmic tail tyrosine residues as regulators and substrates for the protein tyrosine kinases, EMT and LCK. King PD, et al. **J Immunol** 1997 Jan 15; 158(2):580-90

TNF receptor-2-triggered apoptosis is associated with the down-regulation of Bcl-xL on activated T cells and can be prevented by CD28 costimulation. Lin RH, et al. **J Immunol** 1997 Jan 15;158(2):598-603

CD28 costimulation prevents cell death during primary T cell activation. Noel PJ, et al. **J Immunol** 1996 Jul 15; 157(2):636-42

CD28 costimulation promotes the production of Th2 cytokines. Rulifson IC, et al. **J Immunol** 1997 Jan 15; 158(2):658-65

CD28-CD80/CD86 interactions in testicular immunoregulation. Sainio-Pöllänen S, et al. **J Reprod Immunol** 1996 Oct;31(3):145-63

PHYSIOLOGY

CD28/B7 system of T cell costimulation. Lenschow DJ, et al. **Annu Rev Immunol** 1996;14:233-58 (117 ref.)

CD28: a signalling perspective. Ward SG. **Biochem J** 1996 Sep 1;318 (Pt 2):361-77 (222 ref.)

CD28 co-receptor signal transduction in T-cell activation. Blair PJ, et al. **Biochem Soc Trans** 1997 May;25(2):651-7 (57 ref.)

A p38 MAP kinase inhibitor SB203580 inhibits CD28-dependent T cell proliferation and IL-2 production. Ward SG, et al. **Biochem Soc Trans** 1997 May;25(2):304S

Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. Bohlen H, et al. **Cancer Res** 1997 May 1;57(9):1704-9

Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity. Hombach A, et al. **Clin Exp Immunol** 1997 May;108(2):352-7

Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy [editorial; comment] Sfikakis PP, et al. **Clin Immunol Immunopathol** 1997 Jun; 83(3):195-8. Comment on: Clin Immunol Immunopathol 1997 Jun;83(3):199-204.

Blockade of CD28/B7 co-stimulation by mCTLA4-Hgamma1 inhibits antigen-induced lung eosinophilia but not Th2 cell development or recruitment in the lung. Harris N, et al. **Eur J Immunol** 1997 Jan; 27(1):155-61

CD28-deficient mice generate an impaired Th2 response to Schistosoma mansoni infection. King CL, et al. **Eur J Immunol** 1996 Oct;26(10):2448-55

CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Tacke M, et al. **Eur J Immunol** 1997 Jan;27(1):239-47

Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Webb LM, et al. **Eur J Immunol** 1996 Oct;26(10):2320-8

Interleukin-7 activates human naive CD4+ cells and primes for interleukin-4 production. Webb LM, et al. **Eur J Immunol** 1997 Mar;27(3):633-40

Critical role of Fas/Fas ligand interaction in CD28-independent pathway of allogeneic murine hepatocyte rejection. Kawahara T, et al. **Hepatology** 1997 Oct;26(4):944-8

V beta specificity of superantigen TSST-1 plus CD28 costimulation without APCs. Hu WG, et al. **Immunol Invest** 1996 Sep-Nov;25(5-6):405-11

Requirement of CD28-CD86 co-stimulation in the interaction between antigen-primed T helper type 2 and B cells. Nakajima A, et al. **Int Immunol** 1997 May; 9(5):637-44

HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28. Roederer M, et al. **J Clin Invest** 1997 Apr 1;99(7):1555-64

Limited role of CD28-mediated signals in T helper subset differentiation. Brown DR, et al. **J Exp Med** 1996 Sep 1; 184(3):803-10

Itk negatively regulates induction of T cell proliferation by CD28 costimulation. Liao XC, et al. **J Exp Med** 1997 Jul 21;186(2):221-8

Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway. Reinhold MI, et al. **J Exp Med** 1997 Jan 6;185(1):1-11

Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. Boussiotis VA, et al. **J Immunol** 1997 Oct 1; 159(7):3156-67

Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability. Finn PW, et al. **J Immunol** 1997 May 1; 158(9):4074-81

CD28 dependence of T cell differentiation to IL-4 production varies with the particular type 2 immune response. Gause WC, et al. **J Immunol** 1997 May 1; 158(9):4082-7

B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. Greenfield EA, et al. **J Immunol** 1997 Mar 1; 158(5):2025-34

CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. Herold KC, et al. **J Immunol** 1997 Jan 15;158(2):984-91

The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. Hunter CA, et al. **J Immunol** 1997 Mar 1; 158(5):2285-93

B7-CD28/CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens. Keane-Myers A, et al. **J Immunol** 1997 Mar 1;158(5):2042-9

Contribution of the CD28 molecule to allergic and irritant-induced skin reactions in CD28 -/- mice. Kondo S, et al. **J Immunol** 1996 Dec 1;157(11):4822-9

Regulation of CD28 costimulation in human CD8+ T cells. Lloyd TE, et al. **J Immunol** 1997 Feb 15;158(4):1551-8

Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation. McCusker ME, et al. **J Immunol** 1997 May 15;158(10):4984-91

CD28-induced cytokine production and proliferation by thymocytes are differentially regulated by the p59fyn tyrosine kinase. Ong CJ, et al. **J Immunol** 1997 Sep 1; 159(5):2169-76

CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses. Onodera K, et al. **J Immunol** 1997 Aug 15;159(4):1711-7

Ligation of the V7 molecule on T cells blocks anergy induction through a CD28-independent mechanism. Soares LR, et al. **J Immunol** 1997 Aug 1;159(3):1115-24

Increased secretion of TNF-alpha by costimulation of mast cells via CD28 and Fc epsilon RI. Tashiro M, et al. **J Immunol** 1997 Mar 1;158(5):2382-9

CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. Vella AT, et al. **J Immunol** 1997 May 15;158(10):4714-20

CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. Wang R, et al. **J Immunol** 1997 Mar 15;158(6):2856-61

The CD28-B7 costimulatory pathway and its role in autoimmune disease. Daikh D, et al. **J Leukoc Biol** 1997 Aug;62(2):156-62 (80 ref.)

CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Shapiro VS, et al. **Mol Cell Biol** 1997 Jul;17(7):4051-8

Relief of cyclin A gene transcriptional inhibition during activation of human primary T lymphocytes via CD2 and CD28 adhesion molecules. Plet A, et al. **Oncogene** 1997

ANTIGENS, CD28

May 29;14(21):2575–83

CD28 blockade alters cytokine mRNA profiles in cardiac transplantation. Lin H, et al. **Surgery** 1997 Aug; 122(2):129–37

Blocking of the B7–CD28 pathway increases apoptosis induced in activated T cells by in vitro–generated CD95L (FasL) positive dendritic cells. Lu L, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1094–5

Inhibition of CD28–B7 T–cell costimulatory activation pathway affects intragraft cytokine and growth factor expression in chronic renal allograft rejection. Nadeau K, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1038

Glucocorticoids modulate CD28 mediated pathways for interleukin 2 production in human T cells: evidence for posttranscriptional regulation. Fessler BJ, et al. **Transplantation** 1996 Oct 27;62(8):1113–8

[CD28/B7—an elementary, co–stimulatory signal of T–cell activation after orthotopic liver transplantation] Mark W, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997; 114:299–302 (Eng. Abstr.) **(Ger)**

[Costimulatory molecules in autoimmunity: role of CD28/CTLA4–CD80/CD86] Nakajima A, et al. **Nippon Rinsho** 1997 Jun;55(6):1419–24 (35 ref.) (Eng. Abstr.) **(Jpn)**

ANTIGENS, CD29

see related
RECEPTORS, FIBRONECTIN
RECEPTORS, VERY LATE ANTIGEN

Mechanisms of recovery from mechanical injury of cultured rat hepatocytes. Sponsel HT, et al. **Am J Physiol** 1996 Sep; 271(3 Pt 1):C721–7

ANALYSIS

Expression of beta–1 integrins in ganglionic and aganglionic segments of patients with Hirschsprung's disease. Tanyel FC, et al. **Eur J Pediatr Surg** 1997 Feb;7(1):16–20

Localization of integrin beta 1, alpha 1, alpha 5 and alpha 9 subunits in the rat testis. Giebel J, et al. **Int J Androl** 1997 Feb;20(1):3–9

A phospholipase D and protein kinase C inhibitor blocks the spreading of murine mammary adenocarcinoma cells altering f–actin and beta1–integrin point contact distribution. Aguirre Ghiso JA, et al. **Int J Cancer** 1997 May 29;71(5):881–90

Expression pattern of integrin beta 1 subunit in Purkinje cells of rat and cerebellar mutant mice. Murase S, et al. **J Comp Neurol** 1996 Nov 11;375(2):225–37

Evidence that beta1 integrins in keratinocyte cell–cell junctions are not in the ligand–occupied conformation. Kim LT, et al. **J Invest Dermatol** 1997 Jun;108(6):876–80

Correlation between CD29 density on CD8+ lymphocytes and serum IgG in systemic lupus erythematosus. Pallis M, et al. **Lupus** 1997;6(4):379–84

Detection of mRNA transcripts of beta 1 integrins in ejaculated human spermatozoa by nested reverse transcription–polymerase chain reaction. Rohwedder A, et al. **Mol Hum Reprod** 1996 Jul;2(7):499–505

Expression of beta 1 integrins in IgA nephropathy. Hillis GS, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1137–42

Correlation of alpha 2 beta 1 integrin expression with histological type and hormonal receptor status in breast carcinomas. Lanzafame S, et al. **Pathol Res Pract** 1996 Oct; 192(10):1031–8

Relations between absolute number of CD4 + CD29+ memory cells and levels of interleukin–6, rheumatoid factors, and acute phase proteins in rheumatoid synovial fluid. Lacki JK, et al. **Rev Rhum Engl Ed** 1997 Mar; 64(3):160–5

Increased production of B–cell growth factor by T lymphocytes in Graves' thyroid: possible role of CD4+ CD29+ cells. Goto Y, et al. **Thyroid** 1997 Aug;7(4):567–73

The use of MAB 1977 monoclonal antibody for the immunohistochemical localization of beta 1 integrins in paraffin–embedded human kidney. Bernardini N, et al. **Tumori** 1997 May–Jun;83(3):673–8

[Electrophoretic characteristics of integrin++ beta1 subunit from human smooth muscles] Belkin VM, et al. **Vopr Med Khim** 1997 Jan–Feb;43(1):13–9 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Hypertonic induction of the cell adhesion molecule beta 1–integrin in MDCK cells. Sheikh–Hamad D, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C902–8

Widespread expression of beta1 integrins in the developing chick retina: evidence for a role in migration of retinal ganglion cells. Cann GM, et al. **Dev Biol** 1996 Nov 25; 180(1):82–96

Defective expression of beta 1–integrins in cells with constitutively active alpha L beta 2–integrins. Hedman H, et al. **Exp Cell Res** 1997 May 1;232(2):270–6

Transforming growth factor–beta (TGF–beta) stimulates the expression of beta1 integrins and adhesion by rat mesangial cells. Kagami S, et al. **Exp Cell Res** 1996 Nov 25;229(1):1–6

Vla and alpha 6 beta 4 integrin expression in neuroendocrine carcinomas of the skin (their xenografts on nude mice and a corresponding primary culture). Perrin C, et al. **J Cutan Pathol** 1996 Jun;23(3):223–8

CHEMISTRY

Beta 1 integrin subunit dimerization via disulfide bonds. Belkin VM, et al. **Biochem Mol Biol Int** 1996 Sep; 40(1):53–60

CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA–DR and VLA integrins. Rubinstein E, et al. **Eur J Immunol** 1996 Nov; 26(11):2657–65

The recognition sites of the integrins alpha1beta1 and alpha2beta1 within collagen IV are protected against gelatinase A attack in the native protein. Eble JA, et al. **J Biol Chem** 1996 Nov 29;271(48):30964–70

ICAP–1, a novel beta1 integrin cytoplasmic domain–associated protein, binds to a conserved and functionally important NPXY sequence motif of beta1 integrin. Chang DD, et al. **J Cell Biol** 1997 Sep 8; 138(5):1149–57

Evidence that beta1 integrins in keratinocyte cell–cell junctions are not in the ligand–occupied conformation. Kim LT, et al. **J Invest Dermatol** 1997 Jun;108(6):876–80

GENETICS

Genomic organization of the mouse beta 1 gene: conservation of the beta 1D but not of the beta 1B and beta 1C integrin splice variants. Baudoin C, et al. **Cell Adhes Commun** 1996 Jul;4(1):1–11

Concomitant down–regulation of expression of integrin subunits by N–myc in human neuroblastoma cells: differential regulation of alpha2, alpha3 and beta1. Judware R, et al. **Oncogene** 1997 Mar 20;14(11):1341–50

Molecular evolution of integrins: genes encoding integrin beta subunits from a coral and a sponge. Brower DL, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9182–7

IMMUNOLOGY

Regulation and function of an activation–dependent epitope of the beta 1 integrins in vascular cells after balloon injury in baboon arteries and in vitro. Koyama N, et al. **Am J Pathol** 1996 Mar;148(3):749–61

Selective immunomodulation: utilization of CD29/VLA molecules. Morimoto C, et al. **Artif Organs** 1996 Aug; 20(8):828–31 (29 ref.)

Collagen interaction with apically expressed beta 1 integrins: loss of transepithelial resistance and reorganization of cultured thyroid cell monolayer. Garbi C, et al. **Eur J Cell Biol** 1996 Jan;69(1):64–75

Monoclonal antibody crosslinking of the alpha 4 or beta 1 integrin inhibits committed clonogenic hematopoietic progenitor proliferation. Hurley RW, et al. **Exp Hematol** 1997 Apr;25(4):321–8

Antibodies to the beta 1–integrin chain, CD44, or ICAM–3 stimulate adhesion of blast colony–forming cells and may inhibit their growth. Oostendorp RA, et al. **Exp Hematol** 1997 Apr;25(4):345–9

VLA–beta 1 integrin subunit–specific monoclonal antibodies MB1.1 and MB1.2: binding to epitopes not dependent on thymocyte development or regulated by phorbol ester and divalent cations. Von Ballestrem CG, et al. **Hybridoma** 1996 Apr;15(2):125–32

A novel activating anti–beta1 integrin monoclonal antibody binds to the cysteine–rich repeats in the beta1 chain. Faull RJ, et al. **J Biol Chem** 1996 Oct 11;271(41):25099–106

Defining the topology of integrin alpha5beta1–fibronectin interactions using inhibitory anti–alpha5 and anti–beta1 monoclonal antibodies. Evidence that the synergy sequence of fibronectin is recognized by the amino–terminal repeats of the alpha5 subunit. Mould AP, et al. **J Biol Chem** 1997 Jul 11;272(28):17283–92

Reversion of the malignant phenotype of human breast cells in three–dimensional culture and in vivo by integrin blocking antibodies. Weaver VM, et al. **J Cell Biol** 1997 Apr 7;137(1):231–45

Flow cytometric characterisation of the "false naive" (CD45RA+, CD45RO–, CD29 bright+) peripheral blood T–lymphocytes in health and in rheumatoid arthritis. Neidhart M, et al. **Rheumatol Int** 1996;16(2):77–87

METABOLISM

The expression of VLA integrins in the human tonsilla palatina. Karaöz E, et al. **Anat Anz** 1997 Apr;179(2):149–56

Expression of integrin subunits in normal and malignant human salivary gland cell clones and its regulation by transforming growth factor–beta 1. Azuma M, et al. **Cancer Lett** 1996 Dec 3;109(1–2):91–9

Urokinase–type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Xue W, et al. **Cancer Res** 1997 May 1;57(9):1682–9

The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Wary KK, et al. **Cell** 1996 Nov 15;87(4):733–43

Functional significance of CD9 association with beta 1 integrins in human epidermal keratinocytes. Jones PH, et al. **Cell Adhes Commun** 1996 Nov;4(4–5):297–305

Alpha 2 beta 1 integrin is required for the collagen and FGF–1 induced cell dispersion in a rat bladder carcinoma cell line. Vallés AM, et al. **Cell Adhes Commun** 1996 Sep; 4(3):187–99

Up–regulated beta1–integrin expression in autoimmune thyroid disorders. Marazuela M, et al. **Clin Exp Immunol** 1997 Jul;109(1):107–15

Genistein–stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta–1–integrin. Bergan R, et al. **Clin Exp Metastasis** 1996 Sep;14(4):389–98

Moderate exercise leads to decreased expression of beta1 and beta2 integrins on leucocytes. Jordan J, et al. **Eur J Appl Physiol** 1997;76(2):192–4

Clustering the adhesion molecules VLA–4 (CD49d/CD29) in Jurkat T cells or VCAM–1 (CD106) in endothelial (ECV 304) cells activates the phosphoinositide pathway and triggers Ca2+ mobilization. Ricard I, et al. **Eur J Immunol** 1997 Jun;27(6):1530–8

CD9, but not other tetraspans, associates with the beta1 integrin precursor. Rubinstein E, et al. **Eur J Immunol** 1997 Aug;27(8):1919–27

Evidence for beta 1–integrins on both apical and basal surfaces of Xenopus retinal pigment epithelium. Chen W, et al. **Exp Eye Res** 1997 Jan;64(1):73–84

Rapid onset of apoptosis in vitro follows disruption of beta 1–integrin/matrix interactions in human colonic crypt cells. Sträter J, et al. **Gastroenterology** 1996 Jun;110(6):1776–84

Functional role of alpha4beta1 and alpha5beta1 integrin fibronectin receptors expressed on adriamycin–resistant MCF–7 human mammary carcinoma cells. Nista A, et al. **Int J Cancer** 1997 Jul 3;72(1):133–41

Stimulation of glioma–cell migration by laminin and inhibition by anti–alpha3 and anti–beta1 integrin antibodies. Tysnes BB, et al. **Int J Cancer** 1996 Sep 17;67(6):777–84

Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line. Duensing S, et al. **Invasion Metastasis** 1996;16(2):65–72

Fibroblasts spread on immobilized fibrin monomer by mobilizing a beta1–class integrin, together with a vitronectin receptor alphavbeta3 on their surface. Asakura S, et al. **J Biol Chem** 1997 Mar 28;272(13):8824–9

Propolypeptide of von Willebrand factor is a novel ligand for very late antigen–4 integrin. Isobe T, et al. **J Biol Chem** 1997 Mar 28;272(13):8447–53

Regulation of plasminogen receptor expression on monocytoid cells by beta1–integrin–dependent cellular adherence to extracellular matrix proteins. Kim SO, et al. **J Biol Chem** 1996 Sep 27;271(39):23761–7

Integrin regulation by endogenous expression of 18–kDa fibroblast growth factor–2. Klein S, et al. **J Biol Chem** 1996 Sep 13;271(37):22583–90

VLA–4 integrin cross–linking on human monocytic THP–1 cells induces tissue factor expression by a mechanism involving mitogen–activated protein kinase. McGilvray ID, et al. **J Biol Chem** 1997 Apr 11;272(15):10287–94

Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). Sattler M, et al. **J Biol Chem** 1997 May 30;272(22):14320–6

Osteopontin N–terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. Smith LL, et al. **J Biol Chem** 1996 Nov 8;271(45):28485–91

Altered glycosylation of alpha(s)beta 1 integrins from rat colon carcinoma cells decreases their interaction with fibronectin. Ringeard S, et al. **J Cell Biochem** 1996 Jul; 62(1):40–9

ICAP–1, a novel beta1 integrin cytoplasmic domain–associated protein, binds to a conserved and functionally important NPXY sequence motif of beta1 integrin. Chang DD, et al. **J Cell Biol** 1997 Sep 8; 138(5):1149–57

Long–term treatment with lipoteichoic acid from Streptococcus faecalis affects differentiation and expression and cellular distribution of beta 1 integrins in human urothelial cells. Elgavish A, et al. **J Cell Physiol** 1996 Oct; 169(1):52–65

Differentiation and integrity of cardiac muscle cells are impaired in the absence of beta 1 integrin. Fässler R, et al. **J Cell Sci** 1996 Dec;109 (Pt 13):2989–99

NPXY motifs control the recruitment of the alpha5beta1 integrin in focal adhesions independently of the association of talin with the beta1 chain. Vignoud L, et al. **J Cell Sci** 1997 Jun;110 (Pt 12):1421–30

Integrin–dependent induction of functional urokinase receptors in primary T lymphocytes. Bianchi E, et al. **J Clin Invest** 1996 Sep 1;98(5):1133–41

CDw49b/CD29 integrin complex mediates the differentiation of human endothelial cells into capillary–like structures in vitro. Kubota Y, et al. **J Dermatol Sci** 1996 Apr;12(1):36–43

Structure and function of Cas–L, a 105–kD Crk–associated substrate–related protein that is involved in beta 1 integrin–mediated signaling in lymphocytes. Minegishi M, et al. **J Exp Med** 1996 Oct 1;184(4):1365–75

Ligation of L–selectin on T lymphocytes activates beta1 integrins and promotes adhesion to fibronectin. Giblin PA, et al. **J Immunol** 1997 Oct 1;159(7):3498–507

There is temporal and spatial expression of alpha1 (IV), alpha2 (IV), alpha5 (IV), alpha6 (IV) collagen chains and beta1 integrins during the development of the basal lamina in an "in vitro" skin model. Fleischmajer R, et al. **J Invest Dermatol** 1997 Oct;109(4):527–33

L1/HNK–1 carbohydrate– and beta 1 integrin–dependent neural cell adhesion to laminin–1. Hall H, et al. **J Neurochem** 1997 Feb;68(2):544–53

The A and B variants of the alpha 3 integrin subunit: tissue distribution and functional characterization. de Melker AA, et al. **Lab Invest** 1997 Apr;76(4):547–63

Blocking of alpha 1 beta 1 integrin strongly improves survival of hepatocytes in allogeneic transplantation. Kocken JM, et al. **Lab Invest** 1997 Jul;77(1):19–28

Correspondence re: Duncan LM, Bouffard D, Howard C, Mihm MC Jr, Byers HR: In situ distribution of integrin alpha 2 beta 1 and alpha-actinin in melanocytic proliferation. Mod Pathol 9:938, 1996 [letter] Cramer SF. **Mod Pathol** 1996 Dec;9(12):1178–9

In situ distribution of integrin alpha 2 beta 1 and alpha-actinin in melanocytic proliferations. Duncan LM, et al. **Mod Pathol** 1996 Sep;9(9):938–43

The expression of alpha v, alpha 5, beta 1, and beta 3 integrin chains on ejaculated human spermatozoa varies with their functional state. Fusi FM, et al. **Mol Hum Reprod** 1996 Mar;2(3):169–75

Ligand binding regulates the directed movement of beta1 integrins on fibroblasts [see comments] Felsenfeld DP, et al. **Nature** 1996 Oct 3;383(6599):438–40. Comment in: Nature 1996 Oct 3;383(6599):390–1.

PHARMACOLOGY

A 100-kDa protein tyrosine phosphorylation is concurrent with beta 1 integrin-mediated morphological differentiation in neuroblastoma and small cell lung cancer cells. Tachibana I, et al. **Exp Cell Res** 1996 Sep 15;227(2):230–9

Alpha 4 beta 1 (CD49d/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation. Udagwa T, et al. **J Immunol** 1996 Sep 1; 157(5):1965–72

PHYSIOLOGY

Beta-1-integrin expression in adult acute lymphoblastic leukemia: possible relationship with the stem cell antigen CD34. Cacciola RR, et al. **Acta Haematol** 1997; 97(1–2):63–6 (41 ref.)

Regulation and function of an activation-dependent epitope of the beta 1 integrins in vascular cells after balloon injury in baboon arteries and in vitro. Koyama N, et al. **Am J Pathol** 1996 Mar;148(3):749–61

Interleukin-1beta-stimulated invasion of articular cartilage by rheumatoid synovial fibroblasts is inhibited by antibodies to specific integrin receptors and by collagenase inhibitors. Wang AZ, et al. **Arthritis Rheum** 1997 Jul;40(7):1298–307

Beta 1 integrin ligation stimulates tyrosine phosphorylation of phospholipase C gamma 1 and elevates intracellular Ca2+ in pancreatic acinar cells. Wrenn RW, et al. **Biochem Biophys Res Commun** 1996 Sep 24;226(3):876–82

Requirement for beta 1 integrins in the development of mouse mammary gland. Klinowska TC, et al. **Biochem Soc Trans** 1996 Aug;24(3):349S

Function of beta 1 integrins on human decidual cells during implantation. Shiokawa S, et al. **Biol Reprod** 1996 Apr; 54(4):745–52

beta-1 Integrins mediate tumour cell adhesion to quiescent endothelial cells in vitro. Price EA, et al. **Br J Cancer** 1996 Dec;74(11):1762–6

Beta 1 integrins regulate axon outgrowth and glial cell spreading on a glial-derived extracellular matrix during development and regeneration. Sakaguchi DS, et al. **Brain Res Dev Brain Res** 1996 Dec 23;97(2):235–50

Adhesion of lymphoma cells to fibronectin: differential use of alpha 4 beta 1 and alpha 5 beta 1 integrins and stimulation by the 9EG7 mAb against the murine beta 1 integrin subunit. Driessens MH, et al. **Cell Adhes Commun** 1995 Nov;3(4):327–36

MAP kinase activation by flow in endothelial cells. Role of beta 1 integrins and tyrosine kinases. Ishida T, et al. **Circ Res** 1996 Aug;79(2):310–6

Differentiation of embryonal stem cells into keratinocytes: comparison of wild-type and beta 1 integrin-deficient cells. Bagutti C, et al. **Dev Biol** 1996 Oct 10;179(1):184–96

Characterization of the binding of recombinant mouse sperm fertilin beta subunit to mouse eggs: evidence for adhesive activity via an egg beta1 integrin-mediated interaction. Evans JP, et al. **Dev Biol** 1997 Jul 1;187(1):79–93

Perturbation of the developing Xenopus retinotectal projection following injections of antibodies against beta1 integrin receptors and N-cadherin. Stone KE, et al. **Dev Biol** 1996 Nov 25;180(1):297–310

Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Kreidberg JA, et al. **Development** 1996 Nov; 122(11):3537–47

Mouse polymorphonuclear granulocyte binding to extracellular matrix molecules involves beta 1 integrins. Frieser M, et al. **Eur J Immunol** 1996 Dec;26(12):3127–36

Functional relevance during lymphocyte migration and cellular localization of activated beta1 integrins. Gómez M, et al. **Eur J Immunol** 1997 Jan;27(1):8–16

Beta 1 integrin-mediated signaling in human T cells. Morimoto C, et al. **Hum Cell** 1996 Sep;9(3):163–8 (34 ref.)

Unmasking of intestinal epithelial lateral membrane beta1 integrin consequent to transepithelial neutrophil migration in vitro facilitates inv-mediated invasion by Yersinia pseudotuberculosis. McCormick BA, et al. **Infect Immun** 1997 Apr;65(4):1414–21

Beta1 integrin-mediated adhesion between renal tubular cells after anoxic injury. Lieberthal W, et al. **J Am Soc Nephrol** 1997 Feb;8(2):175–83

The related adhesion focal tyrosine kinase is tyrosine-phosphorylated after beta1-integrin stimulation in B cells and binds to p130cas. Astier A, et al. **J Biol Chem** 1997 Jan 3;272(1):228–32

A novel activating anti-beta1 integrin monoclonal antibody binds to the cysteine-rich repeats in the beta1 chain. Faull RJ, et al. **J Biol Chem** 1996 Oct 11;271(41):25099–106

Integrin-dependent role of human T cell matrix metalloproteinase activity in chemotaxis through a model basement membrane. Xia M, et al. **J Cell Biochem** 1996 Jun 1;61(3):452–8

Integrin-mediated activation of MAP kinase is independent of FAK: evidence for dual integrin signaling pathways in fibroblasts. Lin TH, et al. **J Cell Biol** 1997 Mar 24; 136(6):1385–95

Cross talk between adhesion molecules: control of N-cadherin activity by intracellular signals elicited by beta1 and beta3 integrins in migrating neural crest cells. Monier-Gavelle F, et al. **J Cell Biol** 1997 Jun 30; 137(7):1663–81

Disruption of integrin alpha 5 beta 1 signaling does not impair PDGF-BB-mediated stimulation of the extracellular signal-regulated kinase pathway in smooth muscle cells. Hedin UL, et al. **J Cell Physiol** 1997 Jul;172(1):109–16

Integrin alpha 6B beta 1 is involved in kidney tubulogenesis in vitro. Falk M, et al. **J Cell Sci** 1996 Dec;109 (Pt 12):2801–10

Apical beta 1 integrin in polarized MDCK cells mediates tubulocyst formation in response to type I collagen overlay. Zuk A, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1875–89

Yersinia invasin, a bacterial beta1-integrin ligand, is a potent inducer of lymphocyte motility and migration to collagen type IV and fibronectin. Arencibia I, et al. **J Immunol** 1997 Aug 15;159(4):1853–9

Beta1 integrin-mediated activation of focal adhesion kinase and its association with Fyn and Zap-70 in human NK cells. Rabinowich H, et al. **J Immunol** 1996 Nov 1; 157(9):3860–8

Specific inhibition of T lymphocyte coactivation by triggering integrin beta 1 reveals convergence of beta 1, beta 2, and beta 7 signaling pathways. Woodside DG, et al. **J Immunol** 1996 Jul 15;157(2):700–6

The alpha4beta1 integrin can mediate leukocyte adhesion to casein and denatured protein substrates. Davis GE, et al. **J Leukoc Biol** 1997 Sep;62(3):318–28

Cell surface amyloid beta-protein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cells. Yamazaki T, et al. **J Neurosci** 1997 Feb 1;17(3):1004–10

Anti-VLA-4 antibody reduces intimal hyperplasia in the endarterectomized carotid artery in nonhuman primates. Lumsden AB, et al. **J Vasc Surg** 1997 Jul;26(1):87–93

Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. Davison E, et al. **J Virol** 1997 Aug;71(8):6204–7

Selective homing of human leukemic B-cell precursors to specific lymphohematopoietic microenvironments in SCID mice: a role for the beta 1 integrin family surface adhesion molecules VLA-4 and VLA-5. Messinger Y, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):61–9

Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation. Lundell BI, et al. **Leukemia** 1997 Jun;11(6):822–9

Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils. Weber C, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10939–44

[The interaction between beta 1 integrin (VLA-5) and extracellular matrix protein (fibronectin)--activation of cultured monocytes by fibronectin] Nishinarita S, et al. **Rinsho Byori** 1996 Sep;Suppl 102:140–6 (19 ref.) **(Jpn)**

ANTIGENS, CD30

BCL-6 protein expression in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas. Carbone A, et al. **Blood** 1997 Sep 15; 90(6):2445–50

ANALYSIS

Posttransplant CD30 (Ki-1)-positive anaplastic large cell lymphoma. Report of a case with presentation as a pleural effusion. Jiménez-Heffernan JA, et al. **Acta Cytol** 1997 Sep-Oct;41(5):1519–24

Soluble CD30 levels in plasma and cerebrospinal fluid in multiple sclerosis, HIV infection and other nervous system diseases. Navikas V, et al. **Acta Neurol Scand** 1997 Feb; 95(2):99–102

CD 30+ cutaneous lymphoma [letter; comment] Orenstein M. **Am J Clin Pathol** 1996 Dec;106(6):800–1. Comment on: Am J Clin Pathol 1996 Apr;105(4):440–50.

CD30-positive multilobated peripheral T-cell lymphoma primarily involving the subcutaneous tissue. Marzano AV, et al. **Am J Dermatopathol** 1997 Jun;19(3):284–8

Transformation of follicular lymphoma into CD30-large cell lymphoma with anaplastic cytologic features. Alsabeh R, et al. **Am J Surg Pathol** 1997 May;21(5):528–36

Soluble CD30 antigen in human colostrum. Bertotto A, et al. **Biol Neonate** 1997;71(2):69–74

Cutaneous CD30 positive large T cell lymphoma of the upper lip: a rare presentation. Chandu A, et al. **Br J Oral Maxillofac Surg** 1997 Jun;35(3):193–5

Allergen-induced CD30 expression on T cells of atopic asthmatics. Leonard C, et al. **Clin Exp Allergy** 1997 Jul; 27(7):780–6

Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). Bengtsson A, et al. **Clin Exp Immunol** 1997 Sep;109(3):533–7

Xanthoerythrodermia perstans and alopecia mucinosa in a patient with CD-30 cutaneous T-cell lymphoma. Alagheband M, et al. **Cutis** 1997 Jul;60(1):41–2

Case report: primary CD30 (Ki-1)-positive anaplastic large cell lymphoma of the duodenum. Yoshikawa I, et al. **Dig Dis Sci** 1996 Dec;41(12):2343–7 (17 ref.)

Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis. Okumura M, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1757–60

Granulocytic sarcoma with expression of CD30. Fickers M, et al. **J Clin Pathol** 1996 Sep;49(9):762–3

Abortive mitoses and nuclear DNA fragmentation in CD30+ large cells of Hodgkin's disease. Leoncini L, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):119–24, follow. 186, color plate XI

Central nervous system involvement at diagnosis in a case of pediatric CD30+ anaplastic large cell lymphoma. Kaplinsky C, et al. **Med Pediatr Oncol** 1997 Feb;28(2):132–5

CD30-positive T cell lymphoma of the intestine, complicating ulcerative colitis. Tsutsuml Y, et al. **Pathol Int** 1996 May;46(5):384–8

[CD30-positive large B-cell lymphoma of the small intestine (letter)] Mainguené C, et al. **Ann Pathol** 1996 Dec; 16(6):485–6 **(Fre)**

BIOSYNTHESIS

CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's disease. Younes A, et al. **Ann Oncol** 1997;8 Suppl 2:97–100

CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Gattei V, et al. **Blood** 1997 Mar 15;89(6):2048–59

CD30 expression in seminoma. Hittmair A, et al. **Hum Pathol** 1996 Nov;27(11):1166–71

Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma. Nakamura T, et al. **J Immunol** 1997 Mar 1;158(5):2090–8

In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. D'Elios MM, et al. **J Leukoc Biol** 1997 May;61(5):539–44

Expression of CD30 and CD30 ligand in cultured cell lines from human germ-cell tumors. Pera MF, et al. **Lab Invest** 1997 Apr;76(4):497–504

Lack of correlation between membrane CD30 expression and cytokine secretion pattern in allergen-primed naive cord blood T-cell lines and clones. Spinozzi F, et al. **Scand J Immunol** 1997 Apr;45(4):417–22

BLOOD

Soluble CD30 serum antigen in Kawasaki disease. Vagliasindi C, et al. **Acta Paediatr** 1997 Mar;86(3):317–8

Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. Rizzardi GP, et al. **AIDS** 1996 Nov;10(13):F45–50

Soluble CD30 in pediatric patients with atopic dermatitis. Frezzolini A, et al. **Allergy** 1997 Jan;52(1):106–9

High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Wang G, et al. **Am J Med** 1997 Jun; 102(6):517–23

Elevated serum levels of soluble CD30 are associated with atopic dermatitis, but not with respiratory atopic disorders and allergic contact dermatitis. Dummer W, et al. **Br J Dermatol** 1997 Aug;137(2):185–7

Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Giacomelli R, et al. **Clin Exp Immunol** 1997 Apr;108(1):42–6

High serum level of soluble CD30 in acute primary HIV-1 infection. Pizzolo G, et al. **Clin Exp Immunol** 1997 May; 108(2):251–3

[Changes in the cytokine concentration (Il-6, Il-8, Il-1ra) and their cellular expression of membrane molecules (CD25, CD30, HLA-DR) after surgical trauma] Decker D, et al. **Zentralbl Chir** 1997;122(3):157–63; discussion 163–4 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Cloning and characterization of a cDNA for rat CD30 homolog and chromosomal assignment of the genomic gene. Aizawa S, et al. **Gene** 1996 Dec 5;182(1–2):155–62

DRUG EFFECTS

Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma. Nakamura T, et al. **J Immunol** 1997 Mar 1;158(5):2090–8

GENETICS

A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. Horie R, et al. **Blood** 1996 Oct 1; 88(7):2422–32

Spontaneous CD30 mRNA expression in peripheral blood mononuclear cells from atopic patients with high IgE serum levels. Esnault S, et al. **Clin Exp Immunol** 1996 Oct;

106(1):67–72
Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Duckett CS, et al. **Mol Cell Biol** 1997 Mar;17(3):1535–42

IMMUNOLOGY

Soluble CD30 serum antigen in Kawasaki disease. Vagliasindi C, et al. **Acta Paediatr** 1997 Mar;86(3):317–8
Solitary extranodal anaplastic large cell lymphoma, Ki-1+, of the eyelid. Segal ZI, et al. **Am J Ophthalmol** 1997 Jul; 124(1):105–7
Interleukin-12 activates interferon-gamma production by targeted activation of CD30+ T cells. Alzona M, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:127–36
Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Hartmann F, et al. **Blood** 1997 Mar 15;89(6):2042–7
Human CD30+ cells are induced by Mycobacterium tuberculosis and present in tuberculosis lesions. Munk ME, et al. **Int Immunol** 1997 May;9(5):713–20
CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. Woitas RP, et al. **J Immunol** 1997 Jul 15;159(2):1012–8
A CD30 responsive element in the germline epsilon promoter that is distinct from and inhibitory to the CD40 response element. Jumper MD, et al. **Mol Immunol** 1996 Aug; 33(11–12):965–72

METABOLISM

Circulating skin-homing T cells in atopic dermatitis. Selective up-regulation of HLA-DR, interleukin-2R, and CD30 and decrease after combined UV-A and UV-B phototherapy [see comments] Piletta PA, et al. **Arch Dermatol** 1996 Oct;132(10):1171–6. Comment in: Arch Dermatol 1996 Oct;132(10):1230–2.
Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Boucher LM, et al. **Biochem Biophys Res Commun** 1997 Apr 28;233(3):592–600
Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). Bengtsson A, et al. **Clin Exp Immunol** 1997 Sep;109(3):533–7
Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. Aizawa S, et al. **J Biol Chem** 1997 Jan 24; 272(4):2042–5
TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. Lee SY, et al. **J Exp Med** 1997 Apr 7;185(7):1275–85
CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. Agrawal B, et al. **J Immunol** 1996 Oct 15;157(8):3229–34
Reverse signaling via CD30 ligand. Wiley SR, et al. **J Immunol** 1996 Oct 15;157(8):3635–9
A CD30 responsive element in the germline epsilon promoter that is distinct from and inhibitory to the CD40 response element. Jumper MD, et al. **Mol Immunol** 1996 Aug; 33(11–12):965–72
Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Ansieau S, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):14053–8
CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2. Tsitsikov EN, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1390–5

PHARMACOLOGY

Role for CD30 in HIV expression. Romagnani S, et al. **Immunol Lett** 1996 Jun;51(1–2):83–8

PHYSIOLOGY

CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells. Gruss H-J, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):397–409 (79 ref.)

ANTIGENS, CD31

Antibody mediated ligation of platelet/endothelial cell adhesion molecule-1 (PECAM-1) on neutrophils enhances adhesion to cultured human dermal microvascular endothelial cells. Kuwabara H, et al. **Kobe J Med Sci** 1996 Aug;42(4):233–41

ANALYSIS

CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas: correlation with patient follow-up. Charpin C, et al. **Am J Clin Pathol** 1997 May;107(5):534–41
Platelet/endothelial cell adhesion molecule-1 (PECAM-1) expression by human brain microvessel endothelial cells in primary culture. Wong D, et al. **Brain Res** 1996 Aug 26;731(1–2):217–20
Differential patterns of neutrophil adhesion molecules during cardiopulmonary bypass in humans. Galiñanes M, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II364–9
Structural identification of the hematopoietic progenitor antigen ER-MP12 as the vascular endothelial adhesion molecule PECAM-1 (CD31). Ling V, et al. **Eur J Immunol** 1997 Feb;27(2):509–14
Expression of cell adhesion molecules in primary renal disease and renal allograft rejection. Hauser IA, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1122–31

BIOSYNTHESIS

The significance of adhesion molecules in nephrology. Burkhardt K, et al. **Artif Organs** 1996 May;20(5):433–6 (27 ref.)
Enhanced expression of CD31 and CD54 on tonsillar high endothelial venules in IgA nephropathy. Kennel-De March A, et al. **Clin Immunol Immunopathol** 1997 Aug; 84(2):158–65
CD45RA-expressing memory/effector Th cells committed to production of interferon-gamma lack expression of CD31. Thiel A, et al. **Immunol Lett** 1997 Jun 1; 57(1–3):189–92
Microvascular endothelium of human tumor xenografts expresses mouse (= host) CD31. Lehr HA, et al. **Int J Microcirc Clin Exp** 1997 May-Jun;17(3):138–42
Interferon gamma regulates platelet endothelial cell adhesion molecule 1 expression and neutrophil infiltration into herpes simplex virus-infected mouse corneas. Tang Q, et al. **J Exp Med** 1996 Oct 1;184(4):1435–47
Thrombospondin-1, a natural inhibitor of angiogenesis, regulates platelet-endothelial cell adhesion molecule-1 expression and endothelial cell morphogenesis. Sheibani N, et al. **Mol Biol Cell** 1997 Jul;8(7):1329–41

BLOOD

Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. Krauss T, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):443–9

CHEMISTRY

Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of platelet/endothelial cell adhesion molecule-1 (PECAM-1) that are required for the cellular association and activation of the protein-tyrosine phosphatase, SHP-2. Jackson DE, et al. **J Biol Chem** 1997 Oct 3;272(40):24868–75
Platelet endothelial cell adhesion molecule-1 is phosphorylatable by c-Src, binds Src-Src homology 2 domain, and exhibits immunoreceptor tyrosine-based activation motif-like properties. Lu TT, et al. **J Biol Chem** 1997 May 30;272(22):14442–6
Tyrosine residue in exon 14 of the cytoplasmic domain of platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) regulates ligand binding specificity. Famiglietti J, et al. **J Cell Biol** 1997 Sep 22;138(6):1425–35

GENETICS

Characterization of the human platelet/endothelial cell adhesion molecule-1 promoter: identification of a GATA-2 binding element required for optimal transcriptional activity. Gumina RJ, et al. **Blood** 1997 Feb 15;89(4):1260–9
Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease. Nichols WC, et al. **Blood** 1996 Dec 15;88(12):4429–34
Assignment of PECAM1 to human chromosome bands 17q22-->q23 by in situ hybridization. Xie Y, et al. **Cytogenet Cell Genet** 1996;74(1–2):156
The human PECAM1 gene maps to 17q23. Gumina RJ, et al. **Genomics** 1996 Jun 1;34(2):229–32
Fluorescence in situ hybridization mapping of the mouse platelet endothelial cell adhesion molecule-1 (PECAM1) to mouse chromosome 6, region F3-G1. Xie Y, et al. **Genomics** 1996 Oct 15;37(2):226–8
Tyrosine residue in exon 14 of the cytoplasmic domain of platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) regulates ligand binding specificity. Famiglietti J, et al. **J Cell Biol** 1997 Sep 22;138(6):1425–35
Cloning of the human platelet endothelial cell adhesion molecule-1 promoter and its tissue-specific expression. Structural and functional characterization. Almendro N, et al. **J Immunol** 1996 Dec 15;157(12):5411–21

IMMUNOLOGY

Does the adhesion molecule CD31 act as a minor histocompatibility antigen? [letter] Da Costa L, et al. **Blood** 1997 Aug 1;90(3):1332
Antibody to platelet/endothelial cell adhesion molecule-1 reduces myocardial infarct size in a rat model of ischemia-reperfusion injury. Gumina RJ, et al. **Circulation** 1996 Dec 15;94(12):3327–33
Isolation of microvascular endothelial cells using magnetic beads coated with anti-PECAM-1 antibodies [letter; comment] Hewett PW, et al. **In Vitro Cell Dev Biol Anim** 1996 Sep;32(8):462. Comment on: In Vitro Cell Dev Biol Anim 1995 Jun;31(6):473–81.
Identification of alpha v beta 3 as a heterotypic ligand for CD31/PECAM-1. Buckley CD, et al. **J Cell Sci** 1996 Feb; 109 (Pt 2):437–45
PECAM-1 (CD31) expression in the central nervous system and its role in experimental allergic encephalomyelitis in the rat. Williams KC, et al. **J Neurosci Res** 1996 Sep 15; 45(6):747–57

METABOLISM

Platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31) tyrosine phosphorylation state changes during vasculogenesis in the murine conceptus. Pinter E, et al. **Am J Pathol** 1997 May;150(5):1523–30
Hypoxia induces PECAM-1 phosphorylation and transendothelial migration of monocytes. Kalra VK, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H2025–34
Oxidant stress-induced transendothelial migration of monocytes is linked to phosphorylation of PECAM-1. Rattan V, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E453–61
Glucose-induced transmigration of monocytes is linked to phosphorylation of PECAM-1 in cultured endothelial cells. Rattan V, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):E711–7
Expression of platelet-endothelial cell adhesion molecule-1 (PECAM) by macaque trophoblast cells during invasion of the spiral arteries. Blankenship TN, et al. **Anat Rec** 1997 Mar;247(3):413–9
Identification and characterization of functional cation coordination sites in platelet endothelial cell adhesion molecule-1. Jackson DE, et al. **Biochemistry** 1997 Aug 5; 36(31):9395–404
Tyrosine phosphorylation of platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31) in mechanically stimulated vascular endothelial cells. Osawa M, et al. **Eur J Cell Biol** 1997 Mar;72(3):229–37
Platelet endothelial cell adhesion molecule-1 is a major SH-PTP2 binding protein in vascular endothelial cells. Masuda M, et al. **FEBS Lett** 1997 May 26;408(3):331–6
Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of platelet/endothelial cell adhesion molecule-1 (PECAM-1) that are required for the cellular association and activation of the protein-tyrosine phosphatase, SHP-2. Jackson DE, et al. **J Biol Chem** 1997 Oct 3;272(40):24868–75
Aggregation of the high affinity IgE receptor results in the tyrosine phosphorylation of the surface adhesion protein PECAM-1 (CD31). Sagawa K, et al. **J Biol Chem** 1997 May 16;272(20):13412–8
Tyrosine residue in exon 14 of the cytoplasmic domain of platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) regulates ligand binding specificity. Famiglietti J, et al. **J Cell Biol** 1997 Sep 22;138(6):1425–35
The biology of PECAM-1. Newman PJ. **J Clin Invest** 1997 Jan 1;99(1):3–8 (49 ref.)
Expression of endothelial adhesion molecules and recruitment of neutrophils after traumatic brain injury in rats. Carlos TM, et al. **J Leukoc Biol** 1997 Mar;61(3):279–85
PECAM-1 expression in human mesothelial cells: an in vitro study. Bittinger F, et al. **Pathobiology** 1996;64(6):320–7
Integrin engagement mediates tyrosine dephosphorylation on platelet-endothelial cell adhesion molecule 1. Lu TT, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11808–13

PHARMACOLOGY

Soluble domain 1 of platelet-endothelial cell adhesion molecule (PECAM) is sufficient to block transendothelial migration in vitro and in vivo. Liao F, et al. **J Exp Med** 1997 Apr 7;185(7):1349–57

PHYSIOLOGY

Involvement of endothelial PECAM-1/CD31 in angiogenesis. DeLisser HM, et al. **Am J Pathol** 1997 Sep; 151(3):671–7
Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease. Chen Y, et al. **Blood** 1997 Feb 15;89(4):1452–9
The protein-tyrosine phosphatase SHP-2 binds platelet/endothelial cell adhesion molecule-1 (PECAM-1) and forms a distinct signaling complex during platelet aggregation. Evidence for a mechanistic link between PECAM-1- and integrin-mediated cellular signaling. Jackson DE, et al. **J Biol Chem** 1997 Mar 14; 272(11):6986–93
The biology of PECAM-1. Newman PJ. **J Clin Invest** 1997 Jan 1;99(1):3–8 (49 ref.)
Neutrophil platelet endothelial cell adhesion molecule-1 participates in neutrophil recruitment at inflammatory sites and is down-regulated after leukocyte extravasation. Christofidou-Solomidou M, et al. **J Immunol** 1997 May 15;158(10):4872–8
Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. Matsumura T, et al. **J Immunol** 1997 Apr 1;158(7):3408–16
[Blockade of platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31) prevents endotoxin-induced microvascular leak syndrome in striated muscle of the BALB/c mouse] Nolte D, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:639–42 (Eng. Abstr.) **(Ger)**

ANTIGENS, CD32 see **RECEPTORS, IGG**

ANTIGENS, CD34

CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Caux C, et al. **Blood** 1997 Aug 15;90(4):1458–70

Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer. Hohaus S, et al. **Br J Haematol** 1997 Jun;97(4):881–8

Phase I/II trial of cure-oriented high-dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomagnetic bead method for refractory hematological malignancies. Nagoya CD34+ PBSCT Study Group. Ogura M, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S51–7

Transplantation of CD34+ hematopoietic progenitor cells [see comments] Berenson RJ, et al. **Cancer Invest** 1996; 14(6):589–96 (79 ref.). Comment in: Cancer Invest 1996;14(6):640–1.

Are CD34+ selected cells the better choice for grafting? [editorial; comment] Körbling M. **Cancer Invest** 1996; 14(6):640–1. Comment on: Cancer Invest 1996;14(6):589–96.

Promotion of differentiation and proliferation of peripheral blood CD34+ cells in vitro by G-CSF. Xu J, et al. **Chin Med J (Engl)** 1996 May;109(5):372–5

Nontransformed colony-derived stromal cell lines from normal human marrows. III. The maintenance of hematopoiesis from CD34+ cell populations. Li J, et al. **Exp Hematol** 1997 Jul;25(7):582–91

Colony-forming cells expressing high levels of CD34 are the main targets for granulocyte colony-stimulating factor and macrophage colony-stimulating factor in the human fetal liver. Muench MO, et al. **Exp Hematol** 1997 Apr; 25(4):277–87

Human CD34+ cells do not express glutathione S-transferases alpha. Czerwinski M, et al. **Gene Ther** 1997 Mar;4(3):268–70

Transduction of human CD34+ haemopoietic progenitors of various origin using an original retrovirus vector derived from Fr-MuLV and clinically relevant procedures. Cohen-Haguenauer O, et al. **Hematol Cell Ther** 1996 Apr; 38(2):205–6

Recovery and characterization of CD34+ cord blood cells after cryopreservation. Lu L, et al. **In Vivo** 1996 Mar-Apr; 10(2):229–32

Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. Demirer T, et al. **J Clin Oncol** 1997 Feb; 15(2):684–90

The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. Aiuti A, et al. **J Exp Med** 1997 Jan 6;185(1):111–20

Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells. Darley RL, et al. **J Exp Med** 1997 Apr 7; 185(7):1337–47

Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. Mendelson M, et al. **J Gen Virol** 1996 Dec;77 (Pt 12):3099–102

Large-scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery. McNiece I, et al. **J Hematother** 1997 Feb; 6(1):5–11

The 30/35 kDa chymotryptic fragment of fibronectin enhances retroviral-mediated gene transfer in purified chronic myelogenous leukemia bone marrow progenitors. Traycoff CM, et al. **Leukemia** 1997 Jan;11(1):159–67

Effects of recombinant cytokines on colony formation by irradiated human cord blood CD34+ hematopoietic progenitor cells. Goff JP, et al. **Radiat Res** 1997 Jan; 147(1):61–9

Immunomagnetic method of CD34(+) cell separation. Markiewicz M, et al. **Transplant Proc** 1996 Dec; 28(6):3526–7

CD34+ stem cell augmentation of allogeneic, elutriated marrow grafts improves engraftment but cyclosporine A is still required to reduce GVHD and morbidity. Noga SJ, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):728–32

Potential role of CD34 stem cells in tolerance induction. Rachamim N, et al. **Transplant Proc** 1997 Jun;29(4):1935–6

Importance of the relative resistance of cord blood CD34+ cells to UVB in bone marrow transplantation. Yaron I, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):739

[High-dose therapy of cancer with CD34 positive cells as stem cell support] Kvalheim G, et al. **Tidsskr Nor Laegeforen** 1996 Sep 10;116(21):2542–6 (Eng. Abstr.) **(Nor)**

ANALYSIS

Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Alsabeh R, et al. **Am J Clin Pathol** 1997 Apr;107(4):430–7

CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. Goldblum JR, et al. **Am J Dermatopathol** 1997 Apr; 19(2):147–53

Immunohistochemical study of CD34-positive dendritic cells of human dermis. Narvaez D, et al. **Am J Dermatopathol** 1996 Jun;18(3):283–8

Immunophenotyping of dermal spindle cell tumors: diagnostic value of monocyte marker Ki-M1p and histogenetic considerations. Rudolph P, et al. **Am J Surg Pathol** 1997 Jul;21(7):791–800

Immunoreactivity for the human hematopoietic progenitor cell antigen (CD34) in lipomatous tumors. Suster S, et al. **Am J Surg Pathol** 1997 Feb;21(2):195–200

Recombinant human granulocyte colony-stimulating factor increases circulating CD34-postive cells in patients with AIDS. Nielsen SD, et al. **Ann Hematol** 1997 May; 74(5):215–20

Flt3 ligand prolongs survival of CD34++ + human umbilical cord blood myeloid progenitors in serum-depleted culture medium. Takahira H, et al. **Ann Hematol** 1996 Mar;72(3):131–5

Improved automated bone marrow processing and enrichment of CD34+ cells by a large-volume apheresis procedure. Cassens U, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:175–9

Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Bensinger WI, et al. **Blood** 1996 Dec 1;88(11):4132–8

Individual CD34+CD38lowCD19-CD10- progenitor cells from human cord blood generate B lymphocytes and granulocytes. Berardi AC, et al. **Blood** 1997 May 15; 89(10):3554–64

Detection of trisomy 12 and Rb-deletion in CD34+ cells of patients with B-cell chronic lymphocytic leukemia. Gahn B, et al. **Blood** 1997 Jun 15;89(12):4275–81

Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Le Bousse-Kerdilès MC, et al. **Blood** 1996 Dec 15;88(12):4534–46

Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. Lemoli RM, et al. **Blood** 1997 Feb 15;89(4):1189–96

Frequency of fetal cells in sorted subpopulations of nucleated erythroid and CD34+ hematopoietic progenitor cells from maternal peripheral blood. Little MT, et al. **Blood** 1997 Apr 1;89(7):2347–58

Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Mapara MY, et al. **Blood** 1997 Jan 1;89(1):337–44

CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Mavroudis D, et al. **Blood** 1996 Oct 15;88(8):3223–9

Transendothelial migration of CD34+ and mature hematopoietic cells: an in vitro study using a human bone marrow endothelial cell line. Möhle R, et al. **Blood** 1997 Jan 1;89(1):72–80

Circulating immature cell counts on the harvest day predict the yields of CD34+ cells collected after granulocyte colony-stimulating factor plus chemotherapy-induced mobilization of peripheral blood stem cell [letter] Teshima T, et al. **Blood** 1997 Jun 15;89(12):4660–1

Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells. Vogel W, et al. **Blood** 1996 Oct 1; 88(7):2707–13

Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma. Voso MT, et al. **Blood** 1997 May 15;89(10):3763–8

Cationic phosphonolipids as non viral vectors for DNA transfection in hematopoietic cell lines and CD34+ cells. Floch V, et al. **Blood Cells Mol Dis** 1997;23(1):69–87

Counterflow centrifugal elutriation as a method of T cell depletion may cause loss of immature CD34+ cells. Chang Q, et al. **Bone Marrow Transplant** 1997 Jun;19(11):1145–50

Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the miltenyi CD34+ cell sorting system. Di Nicola M, et al. **Bone Marrow Transplant** 1996 Dec; 18(6):1117–21

Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. Finke J, et al. **Bone Marrow Transplant** 1996 Dec; 18(6):1081–6

Fibroblasts retrovirally transfected with the human IL-3 gene initiate and sustain multilineage human hematopoiesis in SCID mice: comparison of CD34-enriched vs CD34-enriched and in vitro expanded grafts. Goan SR, et al. **Bone Marrow Transplant** 1996 Sep;18(3):513–9

CD34 positive PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens. Holyoake TL, et al. **Bone Marrow Transplant** 1997 Jun;19(11):1095–101

Allogeneic bone marrow and peripheral stem cell transplantation from a haplo-identical mother and CD34 positive selection for CML. Kato K, et al. **Bone Marrow Transplant** 1996 Aug;18(2):449–52

Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Kiss JE, et al. **Bone Marrow Transplant** 1997 Feb;19(4):303–10

CD34 is not expressed on the cells of chronic lymphoproliferative disorders or in the vast majority of non-Hodgkin's lymphomas: a review of 1573 cases [letter] McCann LS, et al. **Bone Marrow Transplant** 1997 Apr; 19(7):757–8

Isolation of CD34+ hematopoietic progenitor cells in chronic myeloid leukemia by magnetic activated cell sorting (MACS). Martín-Henao GA, et al. **Bone Marrow Transplant** 1996 Sep;18(3):603–9

The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Schots R, et al. **Bone Marrow Transplant** 1996 Apr;17(4):509–15

Umbilical cord blood processing: volume reduction and recovery of CD34+ cells. Sousa T, et al. **Bone Marrow Transplant** 1997 Feb;19(4):311–3

Separation of chemotherapy plus G-CSF-mobilized peripheral blood mononuclear cells by counterflow centrifugal elutriation: in vitro characterization of two different CD34+ cell populations. Teofili L, et al. **Bone Marrow Transplant** 1996 Aug;18(2):421–5

Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures. Watts MJ, et al. **Bone Marrow Transplant** 1997 Jul;20(2):157–62

Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content. Weaver CH, et al. **Bone Marrow Transplant** 1997 Jun;19(11):1103–10

Successful engraftment of allogeneic CD34-enriched marrow cell transplantation from HLA-mismatched parental donors. Yabe H, et al. **Bone Marrow Transplant** 1996 Jun; 17(6):985–91

A rapid nylon-fiber syringe system to deplete CD14+ cells for positive selection of human blood CD34+ cells. Use of immunomagnetic microspheres. Yamaguchi M, et al. **Bone Marrow Transplant** 1997 Feb;19(4):373–9

Differential expression of p53, c-kit, and CD34 in prepubertal and postpubertal testicular germ cell tumors. Chou PM, et al. **Cancer** 1997 Jun 15;79(12):2430–4

Peripheral blood stem cell harvesting and CD34-positive cell selection. Shpall EJ, et al. **Cancer Treat Res** 1997;77:143–57 (65 ref.)

Analysis of variation in results of CD34+ hematopoietic progenitor cell enumeration in a multicenter study. Gratama JW, et al. **Cytometry** 1997 Jun 15;30(3):109–17

CD34 progenitor cell subset analyses in normal human bone marrow and marrow harvested after intermediate-dose chemotherapy. Laughlin MJ, et al. **Cytometry** 1996 Dec 15;26(4):235–42

Hollow-fibre affinity cell separation system for CD34+ cell enrichment. Nordon RE, et al. **Cytometry** 1996 Aug 1; 24(4):340–7

Expression of class I, II and III epitopes of the CD34 antigen by normal and leukemic hemopoietic cells. Serke S, et al. **Cytometry** 1996 Jun 15;26(2):154–60

Surface antigen expression on CD34+ cord blood cells: comparative analysis by flow cytometry and limiting dilution (LD) RT-PCR of chymopapain-treated or untreated cells. Ziegler BL, et al. **Cytometry** 1996 Sep 1; 25(1):46–57

A case of Bednar tumor. Immunohistochemical positivity for CD34. Kobayashi T, et al. **Dermatology** 1997;195(1):57–9

Characterization of MEC 14.7, a new monoclonal antibody recognizing mouse CD34: a useful reage for identifying and characterizing blood vessels and hematopoietic precursors. Garlanda C, et al. **Eur J Cell Biol** 1997 Aug; 73(4):368–77

Transduction of retrovirus-mediated NeoR gene into CD34+ cells purified from granulocyte colony-stimulating factor (G-CSF)-mobilized infant and cord blood. Abe T, et al. **Exp Hematol** 1997 Aug;25(9):966–71

Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both. Ho AD, et al. **Exp Hematol** 1996 Nov;24(13):1460–8

Efficiency of human HLA-mismatched CD34+ cells from unrelated donors in establishing in vitro hematopoiesis in allogeneic long-term marrow cultures. La Russa VF, et al. **Exp Hematol** 1996 Nov;24(13):1475–83

The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Maurer U, et al. **Exp Hematol** 1997 Aug;25(9):945–50

RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression. Rumi C, et al. **Exp Hematol** 1997 Mar;25(3):246–51

TGF-beta and MIP-1 alpha exert their main inhibitory activity on very primitive CD34+2CD38- cells but show opposite effects on more mature CD34+CD38+ human hematopoietic progenitors. Van Ranst PC, et al. **Exp Hematol** 1996 Nov;24(13):1509–15

Colony formation of human fetal CD34+ hematopoietic cells. Ek S, et al. **Fetal Diagn Ther** 1996 Sep-Oct; 11(5):326–34

Developmental regulation of alpha 1,3-fucosyltransferase expression in CD34 positive progenitors and maturing myeloid cells isolated from normal human bone marrow. Le Marer N, et al. **Glycobiology** 1997 Apr;7(3):357–65

Differences in phycoerythrin- or fluorescein-isothiocyanate conjugated 8G12 on CD34+ cell evaluation. Ortuño F, et al. **Haematologica** 1997 May-Jun;82(3):334–5

Flow cytometry for CD34 determination in hematopoietic grafts. Drénou B. **Hematol Cell Ther** 1996 Dec;38(6):505–12 (59 ref.)

Transduction and expression of the MDR gene in CD34+ cells from marrow and peripheral blood. Hesdorffer C, et

al. **Hematol Cell Ther** 1996 Apr;38(2):210

Expression of differentiation antigens and adhesion molecules on CD34+ cells in peripheral blood and bone marrow after chemotherapy followed by administration of granulocyte colony stimulating factor. Masauzi N. **Hokkaido Igaku Zasshi** 1996 Nov;71(6):771–83

Generation of dendritic cells expressing bcr–abl from CD34–positive chronic myeloid leukemia precursor cells. Smit WM, et al. **Hum Immunol** 1997 Apr 1;53(2):216–23

First trimester development of human chorionic villous vascularization studied with CD34 immunohistochemistry. te Velde EA, et al. **Hum Reprod** 1997 Jul;12(7):1577–81

Herpesvirus saimiri immortalization of alpha beta and gamma delta human T–lineage cells derived from CD34+ intrathymic precursors in vitro. Pacheco–Castro A, et al. **Int Immunol** 1996 Nov;8(11):1797–805

Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte–macrophage colony–stimulating factor and contained CD34+ natural suppressor cells. Young MR, et al. **Int J Cancer** 1997 Feb 20;74(1):69–74

Factors that influence the collection and engraftment of allogeneic peripheral–blood stem cells in patients with hematologic malignancies. Brown RA, et al. **J Clin Oncol** 1997 Sep;15(9):3067–74

Inverse correlation between CD34 expression and proline–4–hydroxylase immunoreactivity on spindle cells noted in hypertrophic scars and keloids. Aiba S, et al. **J Cutan Pathol** 1997 Feb;24(2):65–9

Pleomorphic hyalinizing angiectatic tumor of soft parts: immunohistochemical case study shows cellular composition by CD34+ fibroblasts and factor XIIIa+ dendrophages. Silverman JS, et al. **J Cutan Pathol** 1997 Jul;24(6):377–83

Spindle cell lipoma is strongly CD34 positive. An immunohistochemical study. Templeton SF, et al. **J Cutan Pathol** 1996 Dec;23(6):546–50

Analysis of interleukin 6 receptor and gp130 expressions and proliferative capability of human CD34+ cells. Tajima S, et al. **J Exp Med** 1996 Oct 1;184(4):1357–64

North American Multicenter Study on flow cytometric enumeration of CD34+ hematopoietic stem cells [see comments] Brecher ME, et al. **J Hematother** 1996 Jun; 5(3):227–36. Comment in: J Hematother 1996 Jun;5(3):209–10. Comment in: J Hematother 1996 Jun;5(3):211–2.

Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells. Briddell RA, et al. **J Hematother** 1997 Apr;6(2):145–50

Conditions affecting the isolation of human umbilical cord blood CD34+ cells. Case J, et al. **J Hematother** 1996 Jun; 5(3):255–60

Expansion of blood CD34+ cells: committed precursor expansion does not affect immature hematopoietic progenitors. David S, et al. **J Hematother** 1997 Apr; 6(2):151–8

Ex vivo expansion of CD34 + CD38– cord blood cells. De Bruyn C, et al. **J Hematother** 1997 Apr;6(2):93–102

Optimization of CD34+ cell selection using immunomagnetic beads: implications for use in cryopreserved peripheral blood stem cell collections. Farley TJ, et al. **J Hematother** 1997 Feb;6(1):53–60

Positive selection and transplantation of peripheral CD34+ progenitor cells: feasibility and purging efficacy in pediatric patients with neuroblastoma. Handgretinger R, et al. **J Hematother** 1997 Jun;6(3):235–42

Toward a worldwide standard for CD34+ enumeration? [letter] Johnsen HE. **J Hematother** 1997 Apr;6(2):83–9

Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: report from the second Nordic Workshop. Nordic Stem Cell Laboratory Group (NSCL–G). Johnsen HE, et al. **J Hematother** 1996 Jun;5(3):237–45

Standardization of absolute CD34 cell enumeration [letter; comment] Knape CC. **J Hematother** 1996 Jun;5(3):211–2. Comment on: J Hematother 1996 Jun;5(3):227–36.

Ex vivo expansion of frozen/thawed CD34+ cells isolated from frozen human apheresis products. Martinson JA, et al. **J Hematother** 1997 Feb;6(1):69–75

Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high–dose chemotherapy and peripheral blood progenitor cell support. Papadopoulos KP, et al. **J Hematother** 1997 Feb;6(1):61–8

Enumeration of CD34–positive stem cells: evaluation and comparison of three methods. Sims LC, et al. **J Hematother** 1997 Jun;6(3):213–26

Assessment of peripheral blood stem cell grafts by CD34+ cell enumeration: toward a standardized flow cytometric approach [editorial; comment] Sutherland DR. **J Hematother** 1996 Jun;5(3):209–10. Comment on: J Hematother 1996 Jun;5(3):227–36.

The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. Sutherland DR, et al. **J Hematother** 1996 Jun;5(3):213–26

Large–scale selection of CD34+ peripheral blood progenitors and expansion of neutrophil precursors for clinical applications. Zimmerman TM, et al. **J Hematother** 1996 Jun;5(3):247–53

Differential infection of CD34+ cell–derived dendritic cells and monocytes with lymphocyte–tropic and monocyte–tropic HIV–1 strains. Warren MK, et al. **J Immunol** 1997 May 15;158(10):5035–42

How should CD34+ cells be analysed? A study of three classes of antibody and five leucocyte preparation procedures. Macey MG, et al. **J Immunol Methods** 1997 May 26;204(2):175–88

Ultrastructural and immunohistochemical studies of stromal cells in lamina propria of human fallopian tube ampullar mucosa: the recognition of 'CD34 positive reticular network' and its putative function for immune surveillance. Yamazaki K, et al. **J Submicrosc Cytol Pathol** 1996 Jul; 28(3):325–37

Ultrastructural and immunohistochemical studies of intralobular fibroblasts in human submandibular gland: the recognition of a 'CD34 positive reticular network' connected by gap junctions. Yamazaki K, et al. **J Submicrosc Cytol Pathol** 1996 Oct;28(4):471–83

Allogeneic transplantation with CD34+–selected cells. Stockschläder M, et al. **Leuk Lymphoma** 1997 Mar; 25(1–2):145–51

In leukemic hematopoiesis CD34 antigen does not have the same significance as it does normal hematopoiesis. Del Cañizo MC, et al. **Leuk Res** 1997 Jul;21(7):651–6

CD34 expression on acute myelocytic leukemia cells. Geller RB, et al. **Leuk Res** 1997 May;21(5):387–9 (15 ref.)

Efficient long–term maintenance of chronic myeloid leukemic cobblestone area forming cells on a murine stromal cell line. Cornelissen JJ, et al. **Leukemia** 1997 Jan; 11(1):126–33

Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Haase D, et al. **Leukemia** 1997 May;11(5):674–9

CD34+ megakaryoblastic leukaemic cells are CD38–, but CD61+ and glycophorin A+: improved criteria for diagnosis of AML–M7? Helleberg C, et al. **Leukemia** 1997 Jun;11(6):830–4

Peripheral blood is a source of BCR–ABL–negative pre–progenitors in early chronic phase chronic myeloid leukemia. Lewis ID, et al. **Leukemia** 1997 Apr;11(4):581–7

Normal G–CSF–mobilized CD34+ peripheral blood stem cells in paroxysmal nocturnal hemoglobinuria: a perspective for autologous transplantation [letter] Musto P, et al. **Leukemia** 1997 Jun;11(6):890–2

Assays for the analysis of P–glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts. Sonneveld P, et al. **Leukemia** 1997 Jul;11(7):1160–5 (47 ref.)

HIV–1–related mechanisms of suppression of CD34+ hematopoietic progenitors. Zauli G, et al. **Pathobiology** 1996;64(1):53–8

An unusual soft tissue tumor with features of angiomatoid malignant fibrous histiocytoma composed of bimodal CD34 and factor XIIIa positive dendritic cell subsets. CD34 and factor XIIIa in angiomatoid MFH. Silverman JS, et al. **Pathol Res Pract** 1997;193(1):51–8; discussion 59–60

Flow cytometric analysis of megakaryocyte–associated antigens on CD34 cells and their progeny in liquid culture. Ayala IA, et al. **Stem Cells** 1996 May;14(3):320–9

Extensive amplification of single cells from CD34+ subpopulations in umbilical cord blood and identification of long–term culture–initiating cells present in two subsets. de Wynter EA, et al. **Stem Cells** 1996 Sep;14(5):566–76

Development of a method of thymocyte differentiation of bone marrow–enriched CD34+CD38– cells in postnatal allogeneic cultured thymic epithelia to evaluate immunodeficiency disorders. Knutsen AP, et al. **Stem Cells** 1996 Nov;14(6):702–13

Functional differences between subpopulations of mobilized peripheral blood–derived CD34+ cells expressing different levels of HLA–DR, CD33, CD38 and c–kit antigens. Sakabe H, et al. **Stem Cells** 1997;15(1):73–81

Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Anderlini P, et al. **Transfusion** 1997 May;37(5):507–12

Preapheresis peripheral blood CD34+ mononuclear cell counts as predictors of progenitor cell yield. Benjamin RJ, et al. **Transfusion** 1997 Jan;37(1):79–85

Evaluation of methods for preparing and thawing cryopreserved CD34+ and CD34– cell lines for use as reagents in flow cytometry of hematopoietic progenitor cells. Bowman CA, et al. **Transfusion** 1996 Nov–Dec; 36(11–12):985–8

Recruitment of CD34+ cells during large–volume leukapheresis [letter; comment] Cull G, et al. **Transfusion** 1997 Jun;37(6):672–3. Comment on: Transfusion 1996 Oct;36(10):879–85.

Quantification of CD34+ cells: comparison of methods. Fritsch G, et al. **Transfusion** 1997 Aug;37(8):775–84

Mobilization kinetics of CD34+/Thy–1dim progenitor cells during recombinant human granulocyte–colony–stimulating factor administration in normal donors. Seong C, et al. **Transfusion** 1997 Apr; 37(4):406–10

Estimation of the progenitor cell yield in a leukapheresis product by previous measurement of CD34+ cells in the peripheral blood. Möhle R, et al. **Vox Sang** 1996;71(2):90–6

[The diversity of human hematopoietic stem/progenitor cells. I. Two–color flow cytometric analysis of the different functional subpopulations of CD 34+ hematopoietic stem/progenitor cells riched from human bone marrow] Xi YZ, et al. **Shih Yen Sheng Wu Hsueh Pao** 1996 Mar; 29(1):49–57 (Eng. Abstr.) **(Chi)**

[Kinetics of peripheral blood CD34–positive cells and optimal timing of blood stem cell harvest after urological anticancer chemotherapy] Nishiyama T, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Oct;87(10):1183–90 (Eng. Abstr.) **(Jpn)**

[Smoldering leukemia with CD7.CD34(+), immunoglobulin heavy chain rearrangement (+) and hypoplastic marrow with myelofibrosis] Hara T, et al. **Rinsho Ketsueki** 1997 Jan;38(1):21–7 (Eng. Abstr.) **(Jpn)**

[CDw90 (Thy–1) expression on CD34 positive cells in peripheral blood stem cell harvest] Miyamoto K, et al. **Rinsho Ketsueki** 1997 Jan;38(1):9–13 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia. Fruchart C, et al. **Am J Hematol** 1996 Nov; 53(3):175–80

CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient–specific IgH VDJ gene rearrangements. Szczepek AJ, et al. **Blood** 1997 Mar 1;89(5):1824–33

Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma. Kimlinger T, et al. **Bone Marrow Transplant** 1997 Mar;19(6):553–6

Adult and childhood acute lymphoblastic leukemia: clinico–biological differences based on CD34 antigen expression. Cascavilla N, et al. **Haematologica** 1997 Jan–Feb;82(1):31–7

Partial cloning of rat CD34 cDNA and expression during stem cell–dependent liver regeneration in the adult rat. Omori N, et al. **Hepatology** 1997 Sep;26(3):720–7

Solitary fibrous tumour of the liver with CD34 expression [see comments] Barnoud R, et al. **Histopathology** 1996 Jun; 28(6):551–4. Comment in: Histopathology 1997 Apr;30(4):396–7.

Transduction of CD34+ hematopoietic progenitor cells with an antitat gene protects T–cell and macrophage progeny from AIDS virus infection. Rosenzweig M, et al. **J Virol** 1997 Apr;71(4):2740–6

Bcl–2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Bradbury DA, et al. **Leuk Lymphoma** 1997 Jan; 24(3–4):221–8 (48 ref.)

Enhanced CD34 expression of sinusoid–like vascular endothelial cells in hepatocellular carcinoma. Cui S, et al. **Pathol Int** 1996 Oct;46(10):751–6

BLOOD

Increased levels of CD34+ hemopoietic progenitor cells in atopic subjects. Sehmi R, et al. **Am J Respir Cell Mol Biol** 1996 Nov;15(5):645–55

Detection of trisomy 12 in CD34+ progenitor cells in a patient with B–cell chronic lymphocytic leukemia by fluorescence in situ hybridization. Gahn B, et al. **Ann Oncol** 1997;8 Suppl 2:55–7

Cord blood as an alternative source of haemopoietic stem cells. Hows J, et al. **Ann Oncol** 1996;7 Suppl 2:47–51 (19 ref.)

Storage of peripheral blood stem cell samples alters flow cytometric CD34+ results. Gutensohn K, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:170–4

Transient increase of leukocytes after transplantation of expanded and nonexpanded allogeneic CD34+ blood cells is of host origin [letter] Arseniev L, et al. **Blood** 1997 Feb 1;89(3):1116–8

Ex vivo manipulations of CD34+ peripheral blood progenitor cells. Brugger W, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S5–7 (25 ref.)

Pediatric experience with autologous peripheral blood progenitor cell transplantation: influence of CD34+ cell dose in engraftment kinetics. Diaz MA, et al. **Bone Marrow Transplant** 1996 Oct;18(4):699–703

Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Johnson RJ, et al. **Bone Marrow Transplant** 1996 May;17(5):723–7

External quality assurance for CD34 cell enumeration—results of a preliminary national trial. Royal Microscopical Society Clinical Flow Cytometry Group QA Schemes. Lowdell MW, et al. **Bone Marrow Transplant** 1996 May;17(5):849–53

Quality assurance of CD34+ cell estimation in leucapheresis products. Lumley MA, et al. **Bone Marrow Transplant** 1996 Oct;18(4):791–6

The dielectrophoresis enrichment of CD34+ cells from peripheral blood stem cell harvests. Stephens M, et al. **Bone Marrow Transplant** 1996 Oct;18(4):777–82

Ex vivo cytokine expansion of peripheral blood 5–fluorouracil–treated CD34–positive chronic myeloid leukaemia cells increases the selection of Ph–negative cells. Mahon FX, et al. **Br J Haematol** 1997 Aug;98(2):467–73

In–vitro clonogenicity of mobilized peripheral blood CD34–expressing cells: inverse correlation to both relative and absolute numbers of CD34–expressing cells. Serke S, et al. **Br J Haematol** 1996 Nov;95(2):234–40

Quantification of CD34+ cells mobilized into the peripheral blood predicts the yield of the leukapheresis product and can replace progenitor assays. D'Hondt L, et al. **Cytokines Cell Mol Ther** 1997 Mar;3(1):21–6

Human FLT3 ligand acts on myeloid as well as multipotential progenitors derived from purified CD34+ blood

progenitors expressing different levels of c-kit protein. Sonoda Y, et al. **Eur J Haematol** 1997 Apr;58(4):257–64

Change in FAS antigen expression during differentiation of CD34-positive cells isolated from peripheral blood stem cell harvest samples [letter] Yamane T, et al. **Eur J Haematol** 1997 Apr;58(4):289–90

Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery. Remes K, et al. **J Hematother** 1997 Feb;6(1):13–9

Circulating CD34+ cell counts as predictive parameter for the efficacy of peripheral stem cell apheresis in Ewing tumor patients. Engel BC, et al. **Klin Padiatr** 1997 Jul–Aug; 209(4):186–90

Lack of prognostic value of CD34 in adult AML [letter] Arslan O, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):185–6

Fas antigen (CD95) and hematopoietic progenitor cells. Nagafuji K, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):43–56 (49 ref.)

Differential expression of receptors for hemopoietic growth factors on subsets of CD34+ hemopoietic cells. Wognum AW, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):11–25 (92 ref.)

Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Raspadori D, et al. **Leuk Res** 1997 Jul;21(7):603–7

Peripheral blood CD34+ cells: method of purification and ex vivo expansion. Bohbot A, et al. **Nouv Rev Fr Hematol** 1995;37(6):359–65

The number of circulating CD34 positive cells is the best preleukapheresis parameter for predicting the quality of peripheral blood progenitor cell harvest. Feugier P, et al. **Nouv Rev Fr Hematol** 1995;37(6):301–5

Selection and expansion of CD34+ cells. McNiece IK. **Nouv Rev Fr Hematol** 1995;37(6):375–6

Engraftment of CD34+ peripheral blood progenitor cells into multiple myeloma patients following total body irradiation. Pico JL, et al. **Nouv Rev Fr Hematol** 1995; 37(6):381–3

Allogeneic transplantation of peripheral blood progenitor cells. Schmitz N. **Nouv Rev Fr Hematol** 1995;37(6):377–9

Comparison of two blood cell separators in collecting peripheral blood stem cell components. Stroncek DF, et al. **Transfus Med** 1997 Jun;7(2):95–9

[Flow cytometry analysis of CD34 expressing hematopoietic cells in blood and cytapheresis products] Gutensohn K, et al. **Infusionsther Transfusionsmed** 1996 Jun;23 Suppl 2:1–23 (68 ref.) **(Ger)**

[Kinetics of myelopoietic regeneration and mobilization of CD34-positive cells within the scope of the NB90 Neuroblastoma Therapy Study] Sauter S, et al. **Klin Padiatr** 1997 Jul–Aug;209(4):191–5 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Juvenile chronic myelogenous leukemia multilineage CD34+ cells: aberrant growth and differentiation properties. Freedman MH, et al. **Stem Cells** 1996 Nov;14(6):690–701

GENETICS

Functional characterization of the promoter for the gene encoding murine CD34. Yamaguchia Y, et al. **Biochim Biophys Acta** 1997 Feb 7;1350(2):141–6

A cell proliferation-dependent multiprotein complex NC-3A positively regulates the CD34 promoter via a TCATTT-containing element. Perrotti D, et al. **Blood** 1996 Nov 1;88(9):3336–48

Regulation of CD34 expression in differentiating M1 cells. Krause DS, et al. **Exp Hematol** 1997 Sep;25(10):1051–61

Retroviral transduction of CD34-enriched hematopoietic progenitor cells under serum-free conditions. Sekhar M, et al. **Hum Gene Ther** 1996 Jan;7(1):33–8

IMMUNOLOGY

Normal immunologic response to a neoantigen, bacteriophage phiX-174, in baboons with long-term lymphohematopoietic reconstitution from highly purified CD34+ Lin- allogeneic marrow cells. Andrews RG, et al. **Blood** 1997 Aug 15;90(4):1701–8

Concordant expression of class II and class III CD34 epitopes on haemopoietic cells in leukapheresis and cord blood samples with CD45/CD34 dual staining. Rudin CE, et al. **Br J Haematol** 1997 May;97(2):488–91

Alteration of the CD34+ Tf-1 beta cell line profile in response to long-term exposure to IL-15. Farner NL, et al. **Cytokine** 1997 May;9(5):316–27

Immunocytochemistry and flow cytometry evaluation of human megakaryocytes in fresh samples and cultures of CD34+ cells. Qiao X, et al. **Cytometry** 1996 Mar 1; 23(3):250–9

Clinical significance of HLA-DR+, CD19+, CD10+ immature B-cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura. Callea V, et al. **Haematologica** 1997 Jul–Aug;82(4):471–3

Human umbilical cord blood: immunophenotypic heterogeneity of CD34+ hematopoietic progenitor cells. D'Arena G, et al. **Haematologica** 1996 Sep–Oct;81(5):404–9

Hepatocellular carcinoma arising in an adenoma: value of QBend 10 immunostaining in diagnosis of liver cell carcinoma [see comments] Scott FR, et al. **Histopathology** 1996 May;28(5):472–4. Comment in: Histopathology 1996 Dec;29(6):593–4.

Long-term survival and differentiation of human peripheral blood CD34+ cells in SCID mice. Sakamaki S, et al. **Int J Hematol** 1997 Jun;65(4):375–84

GM-CSF- and IL-3-dependent CD34 expressing myeloid cell line (SAS-1) established from CD7 and CD34 expressing acute myeloblastic leukemic cells. Sasaki K, et al. **Int J Hematol** 1997 Jul;66(1):35–45

CD40 ligation on human cord blood CD34+ hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells. Flores-Romo L, et al. **J Exp Med** 1997 Jan 20;185(2):341–9

BIRMA-K3, a new monoclonal antibody for CD34 immunophenotyping and stem and progenitor cell assay. Höffkes HG, et al. **J Hematother** 1996 Jun;5(3):261–70

QBEnd10 (CD34) antibody is unsuitable for routine use in the ISHAGE CD34+ cell determination assay [letter] Weinberg DS, et al. **J Hematother** 1996 Dec;5(6):599–603

Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. Young MR, et al. **J Immunol** 1997 Jul 15;159(2):990–6

Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. Benedict CA, et al. **J Immunol Methods** 1997 Feb 28;201(2):223–31

Assessment of diagnostic utility of anti-CD34 in soft tissue tumors. Park HR, et al. **J Korean Med Sci** 1995 Dec; 10(6):436–41

Expression of CD34 and other haematopoietic antigens on neuroblastoma cells: consequences for autologous bone marrow and peripheral blood stem cell transplantation. Voigt A, et al. **J Neuroimmunol** 1997 Sep;78(1–2):117–26

NIH nixes appeal to bypass patent law [news] Marshall E. **Science** 1997 Aug 8;277(5327):759–60

IL-2 receptor gamma chain expression on CD34 positive hematopoietic progenitor cells from bone marrow and cord blood. Itano M, et al. **Tohoku J Exp Med** 1996 Apr; 178(4):389–98

ISOLATION & PURIFICATION

The CD34 antigen: potential clinical advantages of CD34 selection. Holyoake TL, et al. **Clin Oncol (R Coll Radiol)** 1996;8(4):214–21 (78 ref.)

Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. McQuaker IG, et al. **J Clin Oncol** 1997 Jun;15(6):2288–95

METABOLISM

Beta-1-integrin expression in adult acute lymphoblastic leukemia: possible relationship with the stem cell antigen CD34. Cacciola RR, et al. **Acta Haematol** 1997; 97(1–2):63–6 (41 ref.)

Gliosarcoma. A study of 13 tumors, including p53 and CD34 immunohistochemistry. Sreenan JJ, et al. **Arch Pathol Lab Med** 1997 Feb;121(2):129–33

Primitive hematopoietic cells in murine bone marrow express the CD34 antigen. Morel F, et al. **Blood** 1996 Nov 15; 88(10):3774–84

CD34 expression patterns during early mouse development are related to modes of blood vessel formation and reveal additional sites of hematopoiesis. Wood HB, et al. **Blood** 1997 Sep 15;90(6):2300–11

The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems. Roots-Weiss A, et al. **Bone Marrow Transplant** 1997 Jun;19(12):1239–46

GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression. Watanabe T, et al. **Bone Marrow Transplant** 1997 Jun;19(12):1175–81

Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Bradbury DA, et al. **Br J Haematol** 1996 Sep;94(4):671–5

Combined negative and positive selection of mobilized CD34 blood cells. Di Nicola M, et al. **Br J Haematol** 1996 Sep; 94(4):716–21

Myelomonoblastic leukaemia cells carrying the PEBP2beta/MYH11 fusion gene are CD34, c-KIT+ immature cells. Osato M, et al. **Br J Haematol** 1997 Jun; 97(3):656–8

G-CSF-mobilized CD34 peripheral blood stem cells are significantly less apoptotic than unstimulated peripheral blood CD34 cells: role of G-CSF as survival factor. Philpott NJ, et al. **Br J Haematol** 1997 Apr;97(1):146–52

Differences in the distribution of CD34 epitopes on normal haemopoietic progenitor cells and leukaemic blast cells. Steen R, et al. **Br J Haematol** 1996 Sep;94(4):597–605

A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance. Minderman H, et al. **Cancer** 1996 Dec 1;78(11):2427–36

Sulfation and sialylation requirements for a glycoform of CD34, a major endothelial ligand for L-selectin in porcine peripheral lymph nodes. Shailubhai K, et al. **Glycobiology** 1997 Mar;7(2):305–14

The ex vivo expansion capacity of normal human bone marrow cells is dependent on experimental conditions: role of the cell concentration, serum and CD34+ cell selection in stroma-free cultures. Poloni A, et al. **Hematol Cell Ther** 1997 Apr;39(2):49–58

QBend 10 (CD34) in the diagnosis of hepatocellular carcinoma [letter; comment] Ruck P, et al. **Histopathology** 1996 Dec;29(6):593–4. Comment on: Histopathology 1996 May;28(5):472–4.

Mammary fibroadenoma and some phyllodes tumour stroma are composed of CD34+ fibroblasts and factor XIIIa+ dendrophages. Silverman JS, et al. **Histopathology** 1996 Nov;29(5):411–9

Distinct mechanisms direct SCL/tal-1 expression in erythroid cells and CD34 positive primitive myeloid cells. Bockamp EO. et al. **J Biol Chem** 1997 Mar 28; 272(13):8781–90

CD34 expression by inflammatory fibroid polyps of the stomach. Hasegawa T, et al. **Mod Pathol** 1997 May; 10(5):451–6

PHYSIOLOGY

Leukosialin (CD43) behavior during adhesion of human monocytic THP-1 cells to red blood cells. Soler M, et al. **J Leukoc Biol** 1997 May;61(5):609–18

Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Reese JS, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):14088–93

[CD34+ cells: biological aspects] Benedetti F. **Tumori** 1996 Mar-Apr;82(2 Suppl):S3–13 (73 ref.) (Eng. Abstr.) **(Ita)**

RADIATION EFFECTS

Repair of gamma-irradiation-induced DNA single-strand breaks in human bone marrow cells: analysis of unfractionated and CD34+ cells using single-cell gel electrophoresis. Lankinen MH, et al. **Mutat Res** 1997 Jul 3;377(2):177–85

THERAPEUTIC USE

The CD34 antigen: potential clinical advantages of CD34 selection. Holyoake TL, et al. **Clin Oncol (R Coll Radiol)** 1996;8(4):214–21 (78 ref.)

ANTIGENS, CD35 see **RECEPTORS, COMPLEMENT 3B**

ANTIGENS, CD36

Extracorporeal photochemotherapy induces a significant increase in CD36+ circulating monocytes in patients with mycosis fungoides. Fimiani M, et al. **Dermatology** 1997; 194(2):107–10

ANALYSIS

Fatty acid composition and CD36 expression in breast adipose tissue of premenopausal and postmenopausal women. Abbadia Z, et al. **Anticancer Res** 1997 Mar-Apr; 17(2A):1217–21

An immunohistochemical study of contact irritant and contact allergic patch tests. Verheyen A, et al. **Curr Probl Dermatol** 1995;23:108–13

BLOOD

Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. Dorahy DJ, et al. **Biochem J** 1996 Oct 1;319 (Pt 1):67–72

Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Styles LA, et al. **Blood** 1997 Apr 1; 89(7):2554–9

Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy? Tanaka T, et al. **J Mol Cell Cardiol** 1997 Jan;29(1):121–7

CHEMISTRY

Structural characterization of bovine CD36 from the milk fat globule membrane. Berglund L, et al. **Biochim Biophys Acta** 1996 Nov 11;1309(1-2):63–8

Snmp-1, a novel membrane protein of olfactory neurons of the silk moth Antheraea polyphemus with homology to the CD36 family of membrane proteins. Rogers ME, et al. **J Biol Chem** 1997 Jun 6;272(23):14792–9

Evidence for an expression of blood group A antigen on platelet glycoproteins IV and V. Stockelberg D, et al. **Transfus Med** 1996 Sep;6(3):243–8

GENETICS

Cloning, characterization, and cellular distribution of rat scavenger receptor class B type I (SRBI) in the ovary. Mizutani T, et al. **Biochem Biophys Res Commun** 1997 May 19;234(2):499–505

Tamoxifen down-regulates CD36 messenger RNA levels in normal and neoplastic human breast tissues. Silva ID, et al. **Cancer Res** 1997 Feb 1;57(3):378–81

Ribonucleic acid expression of the CLA-1 gene, a human homolog to mouse high density lipoprotein receptor SR-BI, in human adrenal tumors and cultured adrenal cells. Liu J, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2522–7

Alternative forms of the scavenger receptor BI (SR-BI). Webb NR, et al. **J Lipid Res** 1997 Jul;38(7):1490–5

Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid

binding/transport. Sfeir Z, et al.
Prostaglandins Leukot Essent Fatty Acids 1997 Jul; 57(1):17–21

IMMUNOLOGY

Systemic lupus erythematosus, thrombocytopenia, microangiopathic haemolytic anaemia and anti–CD36 antibodies [clinical conference] al–Shahi R, et al.
Br J Rheumatol 1997 Jul;36(7):794–8

Characterization of two vaccinia CD36 recombinant–virus–generated monoclonal antibodies (10/5, 13/10): effects on malarial cytoadherence and platelet functions. Daviet L, et al. **Eur J Biochem** 1997 Jan 15; 243(1–2):344–9

CD36 participates in the phagocytosis of rod outer segments by retinal pigment epithelium. Ryeom SW, et al.
J Cell Sci 1996 Feb;109 (Pt 2):387–95

Vascular biology of CD36: roles of this new adhesion molecule family in different disease states. Daviet L, et al. **Thromb Haemost** 1997 Jul;78(1):65–9 (65 ref.)

CD36 autoantibodies and thrombotic diathesis, thrombocytopenia and repeated early fetal losses. Borzini P, et al. **Vox Sang** 1997;73(1):46–8

METABOLISM

Cloning, characterization, and cellular distribution of rat scavenger receptor class B type I (SRBI) in the ovary. Mizutani T, et al. **Biochem Biophys Res Commun** 1997 May 19;234(2):499–505

Scavenger receptor BI—a cell surface receptor for high density lipoprotein. Rigotti A, et al. **Curr Opin Lipidol** 1997 Jun;8(3):181–8 (113 ref.)

Translocation of the Csk homologous kinase (Chk/Hyl) controls activity of CD36–anchored Lyn tyrosine kinase in thrombin–stimulated platelets. Hirao A, et al.
EMBO J 1997 May 1;16(9):2342–51

CD36 expression is altered in retinal pigment epithelial cells of the RCS rat. Sparrow JR, et al. **Exp Eye Res** 1997 Jan; 64(1):45–56

Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. Han J, et al. **J Biol Chem** 1997 Aug 22; 272(34):21654–9

Evidence for cAMP–dependent platelet ectoprotein kinase activity that phosphorylates platelet glycoprotein IV (CD36). Hatmi M, et al. **J Biol Chem** 1996 Oct 4; 271(40):24776–80

Characterization of CLA–1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. Murao K, et al.
J Biol Chem 1997 Jul 11;272(28):17551–7

Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up–regulation of scavenger receptor class B type I. Ng DS, et al. **J Biol Chem** 1997 Jun 20;272(25):15777–81

Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR–BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland. Rigotti A, et al.
J Biol Chem 1996 Dec 27;271(52):33545–9

CD36 is palmitoylated on both N– and C–terminal cytoplasmic tails. Tao N, et al. **J Biol Chem** 1996 Sep 13; 271(37):22315–20

CD36 (OKM5) antigen expression on human mucosal epithelia is associated with keratinization type. Gomez RS, et al. **J Dermatol** 1997 Jul;24(7):435–40

Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR–BI, an HDL receptor that mediates selective lipid uptake. Xu S, et al. **J Lipid Res** 1997 Jul; 38(7):1289–98

Lack of myocardial iodine–123 15–(p–iodiphenyl)–3–R,S–methylpentadecanoic acid (BMIPP) uptake and CD36 abnormality—CD36 deficiency and hypertrophic cardiomyopathy [letter] Tanaka T, et al. **Jpn Circ J** 1997 Aug;61(8):724–5

Overexpression of the HDL receptor SR–BI alters plasma HDL and bile cholesterol levels. Kozarsky KF, et al.
Nature 1997 May 22;387(6631):414–7

Thrombospondin induces dimerization of membrane–bound, but not soluble CD36. Daviet L, et al.
Thromb Haemost 1997 Aug;78(2):897–901

PHYSIOLOGY

Scavenger receptor B1 (SR–B1) substrates inhibit the selective uptake of high–density–lipoprotein cholesteryl esters by rat parenchymal liver cells. Fluiter K, et al.
Biochem J 1997 Sep 1;326 (Pt 2):515–9

Platelet membrane glycoprotein IV (CD36) is involved in arachidonic acid induced–platelet aggregation. Dutta–Roy AK, et al. **Biochem Soc Trans** 1996 May;24(2):167S

Plasmodium falciparum gametocyte adhesion to C32 cells via CD36 is inhibited by antibodies to modified band 3. Rogers NJ, et al. **Infect Immun** 1996 Oct;64(10):4261–8

Scavenger receptor BI promotes high density lipoprotein–mediated cellular cholesterol efflux. Ji Y, et al. **J Biol Chem** 1997 Aug 22;272(34):20982–5

CD36 mediates the In vitro inhibitory effects of thrombospondin–1 on endothelial cells. Dawson DW, et al. **J Cell Biol** 1997 Aug 11;138(3):707–17

Human glomerular mesangial cell phagocytosis of apoptotic neutrophils: mediation by a novel CD36–independent vitronectin receptor/thrombospondin recognition mechanism that is uncoupled from chemokine secretion. Hughes J, et al. **J Immunol** 1997 May 1;158(9):4389–97

The human anion transport protein, band 3, contains a CD36–like binding domain for Plasmodium falciparum–infected erythrocytes. Crandall I, et al.
Parasitology 1996 Mar;112 (Pt 3):261–7

The carboxyl–terminal cytoplasmic domain of CD36 is required for oxidized low–density lipoprotein modulation of NF–kappaB activity by tumor necrosis factor–alpha. Lipsky RH, et al. **Recept Signal Transduct** 1997;7(1):1–11

ANTIGENS, CD40

ANALYSIS

CD40 is a prognostic marker in primary cutaneous malignant melanoma. van den Oord JJ, et al. **Am J Pathol** 1996 Dec; 149(6):1953–61

CD40 expression in epidermal tumors. Viac J, et al.
Anticancer Res 1997 Jan–Feb;17(1B):569–72

The functional CD40 antigen of fibroblasts may contribute to the proliferation of rheumatoid synovium. Rissoan MC, et al. **Clin Exp Immunol** 1996 Dec;106(3):481–90

Cognate T cell help for CD40–deficient B cells induces c–myc RNA expression, but DNA synthesis requires an additional signal through surface Ig. Schrader CE, et al.
J Immunol 1997 Jan 1;158(1):153–62

CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up–regulation of CD80 and CD86 costimulatory molecules. Van den Hove IE, et al.
Leukemia 1997 Apr;11(4):572–80

[Epstein–Barr virus associated gastric carcinoma: the genetic alteration and the expression of CD44 variant] Chong JM, et al. **Nippon Rinsho** 1997 Feb;55(2):381–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Alveolar macrophages in sarcoidosis coexpress high levels of CD86 (B7.2), CD40, and CD30L. Nicod LP, et al.
Am J Respir Cell Mol Biol 1997 Jul;17(1):91–6

CD30–ligand and CD40–ligand expression in lymph nodes involved with Hodgkin's disease. Younes A, et al.
Ann Oncol 1997;8 Suppl 2:97–100

Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Yellin MJ, et al. **Arthritis Rheum** 1997 Jan;40(1):124–34

Is the success of BCG tumour immunotherapy due to the induction of co–stimulatory molecules? Alexandroff AB, et al. **Biochem Soc Trans** 1997 May;25(2):201S

Induction of cognate and non–cognate T–cell help for B–cell IgE production in relation to CD40 ligand expression. Armerding D, et al. **Int Arch Allergy Immunol** 1996 Dec; 111(4):376–84

Regulation of CD40 ligand expression on naive CD4 T cells: a role for TCR but not co–stimulatory signals. Jaiswal AI, et al. **Int Immunol** 1996 Feb;8(2):275–85

Expression of the co–stimulatory molecule CD40 on melanoma cells. Thomas WD, et al. **Int J Cancer** 1996 Dec 11;68(6):795–801

Abnormal CD40–mediated activation pathway in B lymphocytes from patients with hyper–IgM syndrome and normal CD40 ligand expression. Durandy A, et al.
J Immunol 1997 Mar 15;158(6):2576–84

Stimulation of human lymphocyte proliferation and CD40 antigen expression by phosphorothioate oligonucleotides complementary to hepatitis B virus genome. Chen C, et al. **J Viral Hepat** 1996 Jul;3(4):167–72

CHEMISTRY

Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. Hsu YM, et al.
J Biol Chem 1997 Jan 10;272(2):911–5

Identification of distinct domains in CD40 involved in B7–1 induction or growth inhibition. Goldstein MD, et al.
J Immunol 1996 Oct 1;157(7):2837–43

DRUG EFFECTS

CD40 ligation counteracts Fas–induced apoptosis of human dendritic cells. Björck P, et al. **Int Immunol** 1997 Mar; 9(3):365–72

Blockade of CD40 ligand–CD40 interaction impairs CD4+ T cell–mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. Blazar BR, et al. **J Immunol** 1997 Jan 1; 158(1):29–39

Antigen–driven but not lipopolysaccharide–driven IL–12 production in macrophages requires triggering of CD40. DeKruyff RH, et al. **J Immunol** 1997 Jan 1;158(1):359–66

GENETICS

Coexpression of CD40 and class II antigen HLA–DR in Graves' disease thyroid epithelial cells. Faure GC, et al.
Clin Immunol Immunopathol 1997 Aug;84(2):212–5

CD40lbase: a database of CD40L gene mutations causing X–linked hyper–IgM syndrome. Notarangelo LD, et al.
Immunol Today 1996 Nov;17(11):511–6

Profound reduction of mature B cell numbers, reactivities and serum Ig levels in mice which simultaneously carry the XID and CD40 deficiency genes. Oka Y, et al.
Int Immunol 1996 Nov;8(11):1675–85

Construction, expression, and characterization of BD1–G28–5 sFv, a single–chain anti–CD40 immunotoxin containing the ribosome–inactivating protein bryodin 1. Francisco JA, et al. **J Biol Chem** 1997 Sep 26; 272(39):24165–9

Cognate T cell help for CD40–deficient B cells induces c–myc RNA expression, but DNA synthesis requires an additional signal through surface Ig. Schrader CE, et al.
J Immunol 1997 Jan 1;158(1):153–62

IMMUNOLOGY

The roles of CD40 and CD23 in IgE regulation. Yasui T, et al. **Adv Exp Med Biol** 1996;409:349–54 (28 ref.)

CD40–CD40 ligand: a multifunctional receptor–ligand pair. Van Kooten C, et al. **Adv Immunol** 1996;61:1–77 (371 ref.)

CD40 and its ligand in autoimmunity. Noelle RJ, et al.
Ann N Y Acad Sci 1997 Apr 5;815:384–91 (32 ref.)

Immune regulation by CD40 and its ligand GP39. Foy TM, et al. **Annu Rev Immunol** 1996;14:591–617 (111 ref.)

Involvement of a common 10–amino–acid segment in the cytoplasmic region of CD40 but different MAP kinases in different CD40–mediated responses. Hara T, et al.
Biochem Biophys Res Commun 1997 Apr 7;233(1):187–92

HIV–1 LTR activity in human CD40–activated B lymphocytes is dependent on NF–kappaB. Lapointe R, et al. **Biochem Biophys Res Commun** 1996 Dec 24; 229(3):959–64

In vivo efficacy and toxicity of a single–chain immunotoxin targeted to CD40. Francisco JA, et al. **Blood** 1997 Jun 15;89(12):4493–500

CD48 delivers an accessory signal for CD40–mediated activation of human B cells. Klyushnenkova EN, et al.
Cell Immunol 1996 Nov 25;174(1):90–8

Up–regulation of Bcl–xL expression protects CD40–activated human B cells from Fas–mediated apoptosis. Zhang X, et al. **Cell Immunol** 1996 Oct 10;173(1):149–54

Recent advances in tumor necrosis factor and CD40 signaling. Tewari M, et al. **Curr Opin Genet Dev** 1996 Feb; 6(1):39–44 (52 ref.)

Functions of CD40 on B cells, dendritic cells and other cells. van Kooten C, et al. **Curr Opin Immunol** 1997 Jun; 9(3):330–7 (64 ref.)

High CD40 membrane expression in AIDS–related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants. De Paoli P, et al.
Cytometry 1997 Feb 15;30(1):33–8

A T cell controlled molecular pathway regulating the IgH locus: CD40–mediated activation of the IgH 3' enhancer. Grant PA, et al. **EMBO J** 1996 Dec 2;15(23):6691–700

CD40 signaling induces interleukin–4–independent IgE switching in vivo. Ferlin WG, et al. **Eur J Immunol** 1996 Dec;26(12):2911–5

Pairs of surface molecules involved in human IgE regulation: CD23–CD21 and CD40–CD40L. Bonnefoy JY, et al.
Eur Respir J Suppl 1996 Aug;22:63s–66s (48 ref.)

Stimulation of B–chronic lymphocytic leukemia cells by murine fibroblasts, IL–4, anti–CD40 antibodies, and the soluble CD40 ligand. Buske C, et al. **Exp Hematol** 1997 Apr;25(4):329–37

Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Scaria A, et al.
Gene Ther 1997 Jun;4(6):611–7

Synergy between anti–CD40 MAb and Epstein–Barr virus in activation and transformation of human B lymphocytes. Tsuchiyama L, et al. **Hum Antibodies** 1997;8(1):43–7

Modulation of soluble CD40 ligand bioactivity with anti–CD40 antibodies. Schwabe RF, et al. **Hybridoma** 1997 Jun;16(3):217–26

Suppression of murine thyroiditis via blockade of the CD40–CD40L interaction. Carayanniotis G, et al.
Immunology 1997 Mar;90(3):421–6

Cloning, expression and biological function of the bovine CD40 homologue: role in B–lymphocyte growth and differentiation in cattle. Hirano A, et al. **Immunology** 1997 Feb;90(2):294–300

Locomotor properties of human germinal centre B cells: activation by anti–CD40 and IL–4 allows chemoattraction by anti–immunoglobulin. Komai–Koma M, et al.
Immunology 1997 Jan;90(1):23–9

Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice. Clegg CH, et al. **Int Immunol** 1997 Aug;9(8):1111–22

IL–4 and anti–CD40 protect against Fas–mediated B cell apoptosis and induce B cell growth and differentiation. Nakanishi K, et al. **Int Immunol** 1996 May;8(5):791–8

Cross–linking the murine heat–stable antigen induces apoptosis in B cell precursors and suppresses the anti–CD40–induced proliferation of mature resting B lymphocytes. Chappel MS, et al. **J Exp Med** 1996 Nov 1;184(5):1638–49

Human dendritic cells skew isotype switching of CD40–activated naive B cells towards IgA1 and IgA2. Fayette J, et al. **J Exp Med** 1997 Jun 2;185(11):1909–18

CD40 ligation on human cord blood CD34+ hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells. Flores–Romo L, et al.
J Exp Med 1997 Jan 20;185(2):341–9

Polymerase chain reaction selects a novel disintegrin proteinase from CD40-activated germinal center dendritic cells. Mueller CG, et al. **J Exp Med** 1997 Aug 29; 186(5):655-63

Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. Daikh DI, et al. **J Immunol** 1997 Oct 1; 159(7):3104-8

Isolation and characterization of murine fra-1: induction mediated by CD40 and surface Ig is protein kinase C dependent. Huo L, et al. **J Immunol** 1996 Nov 1; 157(9):3812-8

CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. Jacquot S, et al. **J Immunol** 1997 Sep 15; 159(6):2652-7

Memory, but not naive, peripheral blood B lymphocytes differentiate into Ig-secreting cells after CD40 ligation and costimulation with IL-4 and the differentiation factors IL-2, IL-10, and IL-3. Kindler V, et al. **J Immunol** 1997 Sep 1;159(5):2085-90

Antigen specificity of dual reactive T hybridomas determines the requirement for CD40 ligand-CD40 interactions. Ozaki ME, et al. **J Immunol** 1997 Jul 1;159(1):214-21

Analysis of the promoter elements necessary for IL-4 and anti-CD40 antibody induction of murine Fc epsilon RII (CD23): comparison with the germline epsilon promoter. Richards ML, et al. **J Immunol** 1997 Jan 1;158(1):263-72

Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. Funakoshi S, et al. **J Immunother Emphasis Tumor Immunol** 1996 Mar; 19(2):93-101

CD40 mediated activation of gingival and periodontal ligament fibroblasts. Sempowski GD, et al. **J Periodontol** 1997 Mar;68(3):284-92

New strategy for allotransplantation [editorial] Granstein RD. **Lancet** 1996 Sep 28;348(9031):838-9

Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis. Funakoshi S, et al. **Leuk Lymphoma** 1997 Jan;24(3-4):187-99 (32 ref.)

VH repertoire in human B lymphocytes stimulated by CD40 ligand and IL-4: evidence for positive and negative selection mechanisms coupled to CD40 activation. Pinchuk GV, et al. **Mol Immunol** 1996 Dec;33(17-18):1369-76

Epstein-Barr virus-induced human B-cell lymphoma arising in HuPBL-SCID chimeric mice: characterization and the role of CD40 stimulation in their treatment and prevention. Funakoshi S, et al. **Pathobiology** 1995;63(3):133-42

IL-4 synergizes with IL-10 and anti-CD40 MoAbs to induce B-cell differentiation in patients with common variable immunodeficiency. Punnonen J, et al. **Scand J Immunol** 1997 Feb;45(2):203-12

CD40 ligation inhibits IL-2 and SAC+IL-2 induced proliferation in chronic lymphocytic leukaemia cells. Söderberg O, et al. **Scand J Immunol** 1997 Jun;45(6):706-14

Tumour dormancy and cell signalling—III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Marches R, et al. **Ther Immunol** 1995 Jun;2(3):125-36

Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice. Resetkova E, et al. **Thyroid** 1996 Aug;6(4):267-73

[The TRAF family protein-mediated B cell proliferation signal and the mechanism of LMP1-induced B cell transformation] Inoue J. **Nippon Rinsho** 1997 Feb; 55(2):299-304 (18 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

CD40 and its ligand. Clark LB, et al. **Adv Immunol** 1996; 63:43-78 (152 ref.)

Analysis of CD40-CD40 ligand interactions in the regulation of human B cell function. Lipsky PE, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:372-83 (34 ref.)

Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Wang D, et al. **Br J Haematol** 1997 May;97(2):409-17

Endothelial expression of CD40 in renal cell carcinoma. Kluth B, et al. **Cancer Res** 1997 Mar 1;57(5):891-9

Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. Zimber-Strobl U, et al. **EMBO J** 1996 Dec 16; 15(24):7070-8

Interleukin-13 responsiveness and interleukin-13 receptor expression in non-Hodgkin's lymphoma and reactive lymph node B cells. Modulation by CD40 activation. Billard C, et al. **Eur Cytokine Netw** 1997 Mar;8(1):19-27

Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Buelens C, et al. **Eur J Immunol** 1997 Aug; 27(8):1848-52

CD40 is functionally expressed on human keratinocytes. Denfeld RW, et al. **Eur J Immunol** 1996 Oct;26(10):2329-34

CD40 engagement induces monocyte procoagulant activity through an interleukin-10 resistant pathway. Pradier O, et al. **Eur J Immunol** 1996 Dec;26(12):3048-54

Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity. Sad S, et al. **Eur J Immunol** 1997 Apr; 27(4):914-22

Expression of the CD40 antigen on normal endothelial cells and in benign and malignant tumours of vascular origin. Pammer J, et al. **Histopathology** 1996 Dec;29(6):517-24

Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Hanissian SH, et al. **Immunity** 1997 Apr;6(4):379-87

The CD40 ligand. At the center of the immune universe? Grewal IS, et al. **Immunol Res** 1997 Feb;16(1):59-70 (71 ref.)

The role of CD40 ligand in costimulation and T-cell activation. Grewal IS, et al. **Immunol Rev** 1996 Oct; 153:85-106 (100 ref.)

CD40-CD40L interactions in atherosclerosis. Laman JD, et al. **Immunol Today** 1997 Jun;18(6):272-7 (31 ref.)

Co-ligation of surface IgM and CD40 on naive B lymphocytes generates a blast population with an ambiguous extrafollicular/germinal centre cell phenotype. Wheeler K, et al. **Int Immunol** 1996 Jun;8(6):815-28

Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. Ishida T, et al. **J Biol Chem** 1996 Nov 15; 271(46):28745-8

Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes [see comments] Dubois B, et al. **J Exp Med** 1997 Mar 3;185(5):941-51. Comment in: J Exp Med 1997 Mar 3;185(5):801-3.

Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. Guo Y, et al. **J Exp Med** 1996 Sep 1;184(3):955-61

Assembly and regulation of the CD40 receptor complex in human B cells. Kuhné MR, et al. **J Exp Med** 1997 Jul 21;186(2):337-42

Thymic overexpression of CD40 ligand disrupts normal thymic epithelial organization. Dunn RJ, et al. **J Histochem Cytochem** 1997 Jan;45(1):129-41

Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. DeKruyff RH, et al. **J Immunol** 1997 Jan 1;158(1):359-66

IL-10 inhibits lipopolysaccharide-induced murine B cell proliferation and cross-linking of surface antigen receptors or ligation of CD40 restores the response. Marcelletti JF. **J Immunol** 1996 Oct 15;157(8):3323-33

CD40, but not lipopolysaccharide and anti-IgM stimulation of primary B lymphocytes, leads to a persistent nuclear accumulation of RelB. Neumann M, et al. **J Immunol** 1996 Dec 1;157(11):4862-9

CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. Péguet-Navarro J, et al. **J Immunol** 1997 Jan 1; 158(1):144-52

Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. Pinchuk LM, et al. **J Immunol** 1996 Nov 15;157(10):4363-70

IL-4 and IL-10 modulation of CD40-mediated signaling of monocyte IL-1beta synthesis and rescue from apoptosis. Poe JC, et al. **J Immunol** 1997 Jul 15;159(2):846-52

CD40 is a functional activation antigen and B7-independent T cell costimulatory molecule on normal human lung fibroblasts. Sempowski GD, et al. **J Immunol** 1997 May 15;158(10):4670-7

Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. Sutherland CL, et al. **J Immunol** 1996 Oct 15;157(8):3381-90

Exogenous CD40 ligand induces a pulmonary inflammation response. Wiley JA, et al. **J Immunol** 1997 Mar 15; 158(6):2932-8

Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. van Kooten C, et al. **Kidney Int** 1997 Mar;51(3):711-21

CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Gruss HJ, et al. **Leuk Lymphoma** 1997 Feb;24(5-6):393-422 (236 ref.)

Regulation of bcl-xL expression and Fas susceptibility in mouse B cells by CD40 ligation, surface IgM crosslinking and IL-4. Koizumi T, et al. **Mol Immunol** 1996 Nov; 33(16):1247-53

Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Mach F, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1931-6

Construction and analysis of a detailed three-dimensional model of the ligand binding domain of the human B cell receptor CD40. Bajorath J, et al. **Proteins** 1997 Jan; 27(1):59-70

CD40 ligation inhibits IL-2 and SAC+IL-2 induced proliferation in chronic lymphocytic leukaemia cells. Söderberg O, et al. **Scand J Immunol** 1997 Jun;45(6):706-14

PHARMACOLOGY

The functional CD40 antigen of fibroblasts may contribute to the proliferation of rheumatoid synovium. Rissoan MC, et al. **Clin Exp Immunol** 1996 Dec;106(3):481-90

CD40 signaling induces interleukin-4-independent IgE switching in vivo. Ferlin WG, et al. **Eur J Immunol** 1996 Dec;26(12):2911-5

CD40-mediated stimulation of B1 and B2 cells: implication in autoantibody production in murine lupus. Kaneko Y, et al. **Eur J Immunol** 1996 Dec;26(12):3061-5

CD40 engagement induces monocyte procoagulant activity through an interleukin-10 resistant pathway. Pradier O, et al. **Eur J Immunol** 1996 Dec;26(12):3048-54

IFN-gamma is a potent inducer of Ig secretion by sort-purified murine B cells activated through the mIg, but not the CD40, signaling pathway. Snapper CM, et al. **Int Immunol** 1996 Jun;8(6):877-85

CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. Péguet-Navarro J, et al. **J Immunol** 1997 Jan 1; 158(1):144-52

CD40-CD40L interactions provide "third-party" costimulation for T cell response against B7-1-transfected human breast tumor cells. Pericle F, et al. **J Leukoc Biol** 1997 Feb;61(2):201-8

CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Eliopoulos AG, et al. **Oncogene** 1996 Nov 21;13(10):2243-54

PHYSIOLOGY

Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation. Greiner A, et al. **Am J Pathol** 1997 May; 150(5):1583-93

CD40 inhibits B cell apoptosis by upregulating bcl-xL expression and blocking oxidant accumulation. Fang W, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C950-6

Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Kelsall BL, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:116-26

Immune regulation by CD40 and its ligand GP39. Foy TM, et al. **Annu Rev Immunol** 1996;14:591-617 (111 ref.)

Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signalling through CD40 and interleukin-4 receptor: role for inhibition of an early response gene, Berg36. Ning ZQ, et al. **Biochem Soc Trans** 1997 May;25(2):306S

CD40 signalling in B cell apoptosis and rescue. Reid SD, et al. **Biochem Soc Trans** 1997 May;25(2):299S

Antibodies to HLA class I alpha1 domain trigger apoptosis of CD40-activated human B lymphocytes. Genestier L, et al. **Blood** 1997 Jul 15;90(2):726-35

CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Bergamo A, et al. **Br J Haematol** 1997 Jun;97(3):652-5

Proliferation of precursor B-lineage acute lymphoblastic leukaemia by activating the CD40 antigen. Planken EV, et al. **Br J Haematol** 1996 Nov;95(2):319-26

Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Mackey MF, et al. **Cancer Res** 1997 Jul 1;57(13):2569-74

Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Rathmell JC, et al. **Cell** 1996 Oct 18; 87(2):319-29

CD40-triggered protein tyrosine phosphorylation on Vav and on phosphatidylinositol 3-kinase correlates with survival of the Ramos-Burkitt lymphoma B cell line. Padmore L, et al. **Cell Immunol** 1997 May 1;177(2):119-28

Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Mach F, et al. **Circulation** 1997 Jul 15;96(2):396-9

Functions of CD40 and its ligand, gp39 (CD40L). Laman JD, et al. **Crit Rev Immunol** 1996;16(1):59-108 (220 ref.)

Apoptosis through CD95 (Fas/APO-1), but not a CD40/CD95 chimeric receptor, is inhibited by phorbol-12-myristate-13-acetate. Rudert F, et al. **DNA Cell Biol** 1997 Feb;16(2):197-205

Human interdigitating dendritic cells directly stimulate CD40-activated naive B cells. Björck P, et al. **Eur J Immunol** 1997 May;27(5):1266-74

Differential modulation of cyclin-dependent kinase inhibitor p27Kip1 by negative signaling via the antigen receptor of B cells and positive signaling via CD40. Han H, et al. **Eur J Immunol** 1996 Oct;26(10):2425-32

Germinal center B cells rescued from apoptosis by CD40 ligation or attachment to follicular dendritic cells, but not by engagement of surface immunoglobulin or adhesion receptors, become resistant to CD95-induced apoptosis. Koopman G, et al. **Eur J Immunol** 1997 Jan;27(1):1-7

Tyrosine kinase and cAMP-dependent protein kinase activities in CD40-activated human B lymphocytes. Lapointe R, et al. **Eur J Immunol** 1996 Oct;26(10):2376-82

Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signaling through CD40 and interleukin-4 receptor: role for inhibition of an early response gene, Berg36. Ning ZQ, et al. **Eur J Immunol** 1996 Oct; 26(10):2356-63

Maturation of Peyer's patch dendritic cells in vitro upon stimulation via cytokines or CD40 triggering. Ruedl C, et al. **Eur J Immunol** 1997 Jun;27(6):1325-30

The CD40-ligand stimulates T-lymphocytes via the neutral sphingomyelinase: a novel function of the CD40-ligand as signalling molecule. Koppenhoefer U, et al. **FEBS Lett** 1997 Sep 8;414(2):444-8

A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Grewal IS, et al. **Immunol Today** 1996 Sep;17(9):410-4 (41 ref.)

The many roles of CD40 in cell-mediated inflammatory

responses. Stout RD, et al. **Immunol Today** 1996 Oct; 17(10):487–92 (59 ref.)
Functional role of CD40 and its ligand. van Kooten C, et al. **Int Arch Allergy Immunol** 1997 Aug;113(4):393–9 (47 ref.)
A new multivalent B cell activation model—anti–IgD bound to Fc gamma RI: properties and comparison with CD40L–mediated activation. Cho S, et al. **Int Immunol** 1997 Feb;9(2):239–48
Impaired B cell maturation in mice lacking Bruton's tyrosine kinase (Btk) and CD40. Khan WN, et al. **Int Immunol** 1997 Mar;9(3):395–405
Ligation of MHC class I induces apoptosis in human pre–B cell lines, in promyelocytic cell lines and in CD40–stimulated mature B cells. Wallén–Ohman M, et al. **Int Immunol** 1997 Apr;9(4):599–606
CD40: a pivotal receptor in the determination of life/death decisions in B lymphocytes. Klaus GG, et al. **Int Rev Immunol** 1997;15(1–2):5–31 (95 ref.)
Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice. Funakoshi S, et al. **J Clin Invest** 1997 Feb 1;99(3):484–91
A new mechanism of NK cell cytotoxicity activation: the CD40–CD40 ligand interaction. Carbone E, et al. **J Exp Med** 1997 Jun 16;185(12):2053–60
Abnormal CD40–mediated activation pathway in B lymphocytes from patients with hyper–IgM syndrome and normal CD40 ligand expression. Durandy A, et al. **J Immunol** 1997 Mar 15;158(6):2576–84
gamma1 heavy chain transgenes are responsive to IFN–gamma repression and CD40 ligation. Elenich LA, et al. **J Immunol** 1997 May 15;158(10):4564–73
Activation of the Ras signaling pathway by the CD40 receptor. Gulbins E, et al. **J Immunol** 1996 Oct 1; 157(7):2844–50
CD40 cross–linking induces Ig epsilon germline transcripts in B cells via activation of NF–kappaB: synergy with IL–4 induction. Iciek LA, et al. **J Immunol** 1997 May 15; 158(10):4769–79
The effects of IFN–gamma on CD40–mediated activation of B cells from X–linked immunodeficient or normal mice. Johnson–Léger C, et al. **J Immunol** 1997 Aug 1; 159(3):1150–9
Bidirectional regulation of human B cell responses by CD40–CD40 ligand interactions. Miyashita T, et al. **J Immunol** 1997 May 15;158(10):4620–33
alpha beta T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. Peng SL, et al. **J Immunol** 1997 Mar 1;158(5):2464–70
CD40L is important for induction of, but not response to, costimulatory activity. ICAM–1 as the second costimulatory molecule rapidly up–regulated by CD40L. Shinde S, et al. **J Immunol** 1996 Oct 1;157(7):2764–8
The transcription factor B cell–specific activator protein (BSAP) enhances both IL–4– and CD40–mediated activation of the human epsilon germline promoter. Thienes CP, et al. **J Immunol** 1997 Jun 15;158(12):5874–82
T cell rescue of monocytes from apoptosis: role of the CD40–CD40L interaction and requirement for CD40–mediated induction of protein tyrosine kinase activity. Suttles J, et al. **J Leukoc Biol** 1996 Nov; 60(5):651–7
The role of the CD40 antigen on malignant B cells. Planken EV, et al. **Leuk Lymphoma** 1996 Jul;22(3–4):229–35 (63 ref.)
CD40 and the effect of anti–CD40–binding on human multiple myeloma clonogenicity. Tong AW, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):1–8 (83 ref.)
Epstein–Barr virus–encoded LMP1 and CD40 mediate IL–6 production in epithelial cells via an NF–kappaB pathway involving TNF receptor–associated factors. Eliopoulos AG, et al. **Oncogene** 1997 Jun 19;14(24):2899–916
[CD40 as a mediator of proliferation in normal ans neoplastic thymic epithelium] Schultz A, et al. **Verh Dtsch Ges Pathol** 1996;80:250–5 (Eng. Abstr.) **(Ger)**
[The essential region of CD40 cytoplasmic domain for signal transduction in WEHI231 cells] Hara T. **Hokkaido Igaku Zasshi** 1997 May;72(3):309–17 (Eng. Abstr.) **(Jpn)**
[Role of LFA–1/ICAM–1–dependent cell adhesion in CD40–mediated inhibition of anti–IgM antibody–induced B–cell death] Sumimoto S, et al. **Nippon Rinsho** 1996 Jul; 54(7):1779–83 (12 ref.) (Eng. Abstr.) **(Jpn)**

ANTIGENS, CD41 see **PLATELET GLYCOPROTEIN GPIIB–IIIA COMPLEX**

ANTIGENS, CD42A see **PLATELET GLYCOPROTEIN GPIB–IX COMPLEX**

ANTIGENS, CD42B see **PLATELET GLYCOPROTEIN GPIB–IX COMPLEX**

ANTIGENS, CD42C see **PLATELET GLYCOPROTEIN GPIB–IX COMPLEX**

ANTIGENS, CD42D see **PLATELET GLYCOPROTEIN GPIB–IX COMPLEX**

ANTIGENS, CD44

Therapeutic effects of antibodies against adhesion molecules in murine collagen type II–induced arthritis. Zeidler A, et al. **Autoimmunity** 1995;21(4):245–52
Efficient lysis of CD44v7/8–presenting target cells by genetically engineered cytotoxic T–lymphocytes—a model for immunogene therapy of cervical cancer. Dall P, et al. **Gynecol Oncol** 1997 Aug;66(2):209–16

ANALYSIS

Expression of CD44 isoforms is increased in the airway epithelium of asthmatic subjects. Lackie PM, et al. **Am J Respir Cell Mol Biol** 1997 Jan;16(1):14–22
Expression of CD44 in duct cell carcinomas and in intraductal neoplasms of the pancreas. Satoh K, et al. **Anticancer Res** 1997 Jan–Feb;17(1A):215–9
Localization of glycosaminoglycans and CD44 in the human lacrimal gland. Yoshida K, et al. **Arch Histol Cytol** 1996 Dec;59(5):505–13
Detection of circulating tumour cells and nodal metastasis by reverse transcriptase–polymerase chain reaction technique. Wong LS, et al. **Br J Surg** 1997 Jun;84(6):834–9
Evidence for receptors for hyaluronan in discrete nerve cell populations of the brain. Fuxe K, et al. **Brain Res** 1996 Oct 14;736(1–2):329–37
Distribution of CD44 in the retina during development and the rds degeneration. Chaitin MH, et al. **Brain Res Dev Brain Res** 1996 Jun 14;94(1):92–8
CD44 immunostaining of thyroid fine–needle aspirates differentiates thyroid papillary carcinoma from other lesions with nuclear grooves and inclusions. Chhieng DC, et al. **Cancer** 1997 Jun 25;81(3):157–62
The expression of CD44 adhesion molecules on seminoma cells. A new marker for early detection of the tumor [letter; comment] Rajpert–De Meyts E, et al. **Cancer** 1996 Dec 1;78(11):2443–5. Comment on: Cancer 1996 Feb 1;77(3):429–30.
CD44 as a marker in human cancers. Sy MS, et al. **Curr Opin Oncol** 1997 Jan;9(1):108–12 (57 ref.)
Selective expression of CD44 cell–adhesion molecule in thyroid papillary carcinoma fine–needle aspirates. Ross JS, et al. **Diagn Cytopathol** 1996 Jun;14(4):287–91
Biotinylated hyaluronan: a versatile and highly sensitive probe capable of detecting nanogram levels of hyaluronan binding proteins (hyaladherins) on electroblots by a novel affinity detection procedure. Melrose J, et al. **Electrophoresis** 1996 Jan;17(1):205–12
Expression of CD44 isoforms in human skin cancer. Simon JC, et al. **Eur J Cancer** 1996 Jul;32A(8):1394–400
Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7–8 in human breast cancer. Tempfer C, et al. **Eur J Cancer** 1996 Oct; 32A(11):2023–5
Fibroblast dependency during early thymocyte development maps to the CD25+ CD44+ stage and involves interactions with fibroblast matrix molecules. Anderson G, et al. **Eur J Immunol** 1997 May;27(5):1200–6
Expression of CD44 and integrins in bronchial mucosa of normal and mildly asthmatic subjects. Peroni DG, et al. **Eur Respir J** 1996 Nov;9(11):2236–42
CD4 memory T cell levels predict life span in genetically heterogeneous mice. Miller RA, et al. **FASEB J** 1997 Aug; 11(10):775–83
CD44 isoform expression in the diffuse neuroendocrine system. I. Normal cells and hyperplasia. Seelentag WK, et al. **Histochem Cell Biol** 1996 Dec;106(6):543–50
Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Charpin C, et al. **Hum Pathol** 1997 Mar;28(3):289–96
CD44 expression in benign and malignant nevomelanocytic lesions. Leigh CJ, et al. **Hum Pathol** 1996 Dec; 27(12):1288–94
Cell surface CD44v5 levels correlate with progesterone receptors and a tumor size > 2 cm in infiltrating ductal carcinomas of the breast [letter] Nuñez MI, et al. **Int J Biol Markers** 1996 Oct–Dec;11(4):220–2
Expression of CD44 variants in gastric carcinoma with or without Epstein–Barr virus. Chong JM, et al. **Int J Cancer** 1997 Aug 22;74(4):450–4
CD44 is an independent prognostic factor in early–stage cervical cancer. Speiser P, et al. **Int J Cancer** 1997 Apr 22;74(2):185–8
Hyaluronan–independent lodgment of CD44+ lymphoma cells in lymphoid organs. Vogt Sionov R, et al. **Int J Cancer** 1997 May 2;71(3):462–9
Immunolocalization of CD44 and the ERM family in bone cells of mouse tibiae. Nakamura H, et al. **J Bone Miner Res** 1996 Nov;11(11):1715–22
Changes in CD44 and ApoE immunoreactivities due to retinal pathology of man and rat. Kuhrt H, et al. **J Hirnforsch** 1997;38(2):223–9
CD44 substituted with heparan sulfate and endo–beta–galactosidase–sensitive oligosaccharides: a major proteoglycan in adult human epidermis. Tuhkanen AL, et al. **J Invest Dermatol** 1997 Aug;109(2):213–8
Analysis of human articular chondrocyte CD44 isoform expression and function in health and disease. Salter DM, et al. **J Pathol** 1996 Aug;179(4):396–402
Enhanced tubular epithelial CD44 expression in MRL–lpr lupus nephritis. Benz PS, et al. **Kidney Int** 1996 Jul; 50(1):156–63
CD44 in glomerulonephritis: expression in human renal biopsies, the Thy 1.1 model, and by cultured mesangial cells. Roy–Chaudhury P, et al. **Kidney Int** 1996 Jul; 50(1):272–81
Flow cytometric detection of CD44 (H–CAM) in hairy cell leukemia. Rutella S, et al. **Leuk Lymphoma** 1996 May; 21(5–6):497–500
Upregulated renal tubular CD44, hyaluronan, and osteopontin in kdkd mice with interstitial nephritis. Sibalic V, et al. **Nephrol Dial Transplant** 1997 Jul;12(7):1344–53
Fatty acid unsaturation increases expression and capping of murine lymphocyte CD44 and CD45. Peck MD, et al. **Nutrition** 1996 Sep;12(9):616–22
Selective modulation of T cell memory markers CD62L and CD44 on murine draining lymph node cells following allergen and irritant treatment. Gerberick GF, et al. **Toxicol Appl Pharmacol** 1997 Sep;146(1):1–10

BIOSYNTHESIS

The hyaluronan–binding adhesion molecule CD44: expression in normal and diseased kidneys and by cultured mesangial cells. Lesavre P, et al. **Adv Nephrol Necker Hosp** 1997;26:317–39
Altered expression of CD44 in human prostate cancer during progression. Nagabhushan M, et al. **Am J Clin Pathol** 1996 Nov;106(5):647–51
Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Woodman AC, et al. **Am J Pathol** 1996 Nov;149(5):1519–30
Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines. Stickeler E, et al. **Anticancer Res** 1997 May–Jun;17(3C):1871–6
Hyaluronan and hyaluronectin production in injured rat thoracic aorta. Chajara A, et al. **Atherosclerosis** 1996 Sep 6;125(2):193–207
CD44 expression in human breast cancer cell lines is related to oestrogen receptor (ER) status and confluency in vitro. Bolodeoku J, et al. **Biochem Soc Trans** 1997 May;25(2):356S
Induction of the adhesion molecule CD44 by the pro–inflammatory cytokine interleukin–1 in endothelial cells. Fitzgerald K, et al. **Biochem Soc Trans** 1997 May; 25(2):185S
Signaling pathways regulating CD44–dependent cytolysis in natural killer cells. Sconocchia G, et al. **Blood** 1997 Jul 15;90(2):716–25
Constitutive expression of a CD44 variant isoform on T cells facilitates regaining of immunocompetence in allogeneic bone marrow transplantation. Zöller M, et al. **Blood** 1997 Jul 15;90(2):873–85
Clinical relevance of TRKA expression on neuroblastoma: comparison with N–MYC amplification and CD44 expression. Combaret V, et al. **Br J Cancer** 1997; 75(8):1151–5
Functional activity of CD44 isoforms in haemopoiesis of the rat. Khaldoyanidi S, et al. **Br J Haematol** 1997 Jan; 96(1):31–45
CD44 variant expression and estrogen receptor status in breast cancer. Hole AK, et al. **Breast Cancer Res Treat** 1997 Apr;43(2):165–73
Increased connexin–43 and gap junctional communication correlate with altered phenotypic characteristics of cells overexpressing the receptor for hyaluronic acid–mediated motility. Nagy JI, et al. **Cell Growth Differ** 1996 Jun; 7(6):745–51
CD44 and hyaluronan expression in the development of experimental crescentic glomerulonephritis. Jun Z, et al. **Clin Exp Immunol** 1997 Apr;108(1):69–77
Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis. Gardner MJ, et al. **Clin Exp Metastasis** 1996 Sep; 14(4):325–34
Transient expression of CD44 variant isoforms in the ontogeny of the rat: ectoderm–, endoderm– and mesoderm–derived cells express different exon combinations. Weber B, et al. **Differentiation** 1996 Mar; 60(1):17–29
CD44 expression in the developing human retina. Nishina S, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Feb; 235(2):92–6
Immunohistochemical detection of CD44 splice variant expression in premalignant lesions of the cervix and benign cervical epithelium. Kohlberger PD, et al. **Gynecol Oncol** 1997 Aug;66(2):227–32
The expression patterns of standard and variant CD44 molecules in normal uterine cervix and cervical cancer [published erratum appears in Gynecol Oncol 1997 Apr;65(1):192] Shimabukuro K, et al. **Gynecol Oncol** 1997 Jan;64(1):26–34
Differential expression of CD44s and CD44v10 proteins and syndecan in normal and irradiated mouse epidermis. Liu K, et al. **Histochem Cell Biol** 1997 Feb;107(2):159–67
CD44 standard and variant isoform expression in normal human skin appendages and epidermis. Seelentag WK, et al. **Histochem Cell Biol** 1996 Sep;106(3):283–9
CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma. Attanoos RL, et al. **Histopathology** 1997 Mar;30(3):260–3
Soluble CD44 splice variants in metastasizing human breast cancer. Martin S, et al. **Int J Cancer** 1997 Aug 22; 74(4):443–5
De novo CD44 expression by proliferating mesangial cells in rat anti–Thy–1 nephritis. Nikolic–Paterson DJ, et al. **J Am Soc Nephrol** 1996 Jul;7(7):1006–14
Distribution of CD44 variant isoforms in human skin:

differential expression in components of benign and malignant epithelia. Hale LP, et al. **J Cutan Pathol** 1995 Dec;22(6):536–45

Expression of CD44 isoforms and beta - 1,6-branched oligosaccharides in human malignant melanoma is correlated with tumor progression but not with metastatic potential. Seelentag WK, et al. **J Cutan Pathol** 1997 Apr; 24(4):206–11

CD44 expression in neuroblastoma and related tumors. Comito MA, et al. **J Pediatr Hematol Oncol** 1997 Jul–Aug; 19(4):292–6

Preferential histiotypic expression of CD44–isoforms in human lung cancer. Wimmel A, et al. **Lung Cancer** 1997 Mar;16(2–3):151–72

Bcl–2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung. Coppola D, et al. **Mod Pathol** 1996 May;9(5):484–90

CD44v6 expression in primary bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma. Ohori NP, et al. **Mod Pathol** 1996 May;9(5):507–12

Suppressed expression of CD44 variant isoforms during human glioma A172 cell differentiation induced by cyclic AMP. Sakai H, et al. **Neurosci Lett** 1996 Jun 7; 210(3):189–92

CD44 expression by leucocytes in rheumatoid arthritis and modulation by specific antibody: implications for lymphocyte adhesion to endothelial cells and synoviocytes in vitro. Brennan FR, et al. **Scand J Immunol** 1997 Feb; 45(2):213–20

Differential expression of CD44 splice variants in malignant and benign pleural effusions. Tojo N, et al. **Tohoku J Exp Med** 1996 Aug;179(4):273–9

The receptor for hyaluronan–mediated motility is expressed in human renal allografts and is correlated with Banff chronic rejection scores. Routledge MW, et al. **Transplant Proc** 1997 Sep;29(6):2603–4

Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study. Castellà EM, et al. **Virchows Arch** 1996 Nov;429(4–5):191–5

BLOOD

Increased serum levels of soluble CD44–isoform v5 in rheumatic diseases are restricted to seropositive rheumatoid arthritis. Haberhauer G, et al. **Acta Med Austriaca** 1997; 24(1):23–5

Circulating standard CD44 isoform in patients with liver disease: relationship with other soluble adhesion molecules and evaluation of diagnostic usefulness. Falleti E, et al. **Clin Biochem** 1997 Feb;30(1):69–73

Significant elevation of tumour–associated isoforms of soluble CD44 in serum of normal individuals caused by cigarette smoking. Kittl EM, et al. **Eur J Clin Chem Clin Biochem** 1997 Feb;35(2):81–4

Serum hyaluronate predicts response to interferon–alpha therapy in patients with chronic hepatitis C. Ueno T, et al. **Hepatogastroenterology** 1995 Sep–Oct;42(5):522–7

Circulating adhesion molecules as prognostic factors for cutaneous melanoma. Schaider H, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):209–13

Purification and characterization of a novel hyaluronan–binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator. Choi–Miura NH, et al. **J Biochem (Tokyo)** 1996 Jun;119(6):1157–65

Origin and function of circulating CD44 in non–Hodgkin's lymphoma. Ristämaki R, et al. **J Immunol** 1997 Mar 15; 158(6):3000–8

Serological evaluation of soluble CD44 in renal cancer. Kan M, et al. **Jpn J Cancer Res** 1996 Nov;87(11):1191–4

Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. De Rossi G, et al. **Leukemia** 1997 Jan;11(1):134–41

Soluble CD44 variants in the serum of patients with urological malignancies. Lein M, et al. **Oncology** 1997 May–Jun;54(3):226–30

Soluble CD44 variants in serum of patients with prostate cancer and other urological malignancies [letter; comment] Lein M, et al. **Prostate** 1996 Nov;29(5):334–5. Comment on: Prostate 1996 Mar;28(3):153–61.

Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis. Kittl EM, et al. **Rheumatol Int** 1997; 16(5):181–6

CHEMISTRY

Soluble CD44 is not elevated in blood products. Munker R, et al. **Acta Haematol** 1996;96(3):187–8

Benzyl–alpha–GalNAc inhibits sialylation of O–glycosidic sugar chains on CD44 and enhances experimental metastatic capacity in B16BL6 melanoma cells. Nakano T, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3577–84

A chondroitin/dermatan sulfate form of CD44 is a receptor for collagen XIV (undulin). Ehnis T, et al. **Exp Cell Res** 1996 Dec 15;229(2):388–97

CD44 isoform expression in the diffuse neuroendocrine system. II. Benign and malignant tumors. Komminoth P, et al. **Histochem Cell Biol** 1996 Dec;106(6):551–62

CD44 isoform expression in the diffuse neuroendocrine system. I. Normal cells and hyperplasia. Seelentag WK, et al. **Histochem Cell Biol** 1996 Dec;106(6):543–50

CD44 substituted with heparan sulfate and endo–beta–galactosidase–sensitive oligosaccharides: a major proteoglycan in adult human epidermis. Tuhkanen AL, et al. **J Invest Dermatol** 1997 Aug;109(2):213–8

Increased expression of CD44 variants in differentiated thyroid cancers. Takano T, et al. **Jpn J Cancer Res** 1996 Dec;87(12):1245–50

DRUG EFFECTS

Tyrosine kinase–dependent activation of human NK cell functions upon triggering through CD44 receptor. Galandrini R, et al. **Eur J Immunol** 1996 Dec; 26(12):2807–11

GENETICS

Alteration of CD44 expression in HIV type 1–infected T cell lines. Giordanengo V, et al. **AIDS Res Hum Retroviruses** 1996 Nov 20;12(17):1615–22

Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Woodman AC, et al. **Am J Pathol** 1996 Nov;149(5):1519–30

Expression of the CD44 variant isoforms 6 and 4/5 in breast cancer. Correlation with established prognostic parameters. Regidor PA, et al. **Arch Gynecol Obstet** 1996;258(3):125–35

Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Stauder R, et al. **Blood** 1996 Oct 15; 88(8):3101–8

Constitutive expression of a CD44 variant isoform on T cells facilitates regaining of immunocompetence in allogeneic bone marrow transplantation. Zöller M, et al. **Blood** 1997 Jul 15;90(2):873–85

Expression of CD44 splice variants in colorectal cancer. Wong LS, et al. **Br J Surg** 1997 Mar;84(3):363–7

CD44 isoforms with exon v6 and metastasis of primary N0M0 breast carcinomas. Guriec N, et al. **Breast Cancer Res Treat** 1997 Jul;44(3):261–8

CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Gao AC, et al. **Cancer Res** 1997 Mar 1;57(5):846–9

Rapid analysis of distinctive CD44 RNA splicing preferences that characterize colonic tumors. Goodison S, et al. **Cancer Res** 1997 Aug 1;57(15):3140–4

Regulation of CD44v6–containing isoforms during proliferation of normal and malignant epithelial cells. Soukka T, et al. **Cancer Res** 1997 Jun 1;57(11):2281–9

Developmentally regulated expression of metastasis–associated antigens in the rat. Claas C, et al. **Cell Growth Differ** 1996 May;7(5):663–78

Tissue–specific and growth–regulated expression of CD44 variable exon determinants in the mouse. Yamashita Y, et al. **Cell Immunol** 1997 Feb 25;176(1):22–33

CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Guriec N, et al. **Clin Exp Metastasis** 1996 Oct;14(5):434–9

Common pattern of CD44 isoforms is expressed in morphogenetically active epithelia. Yu Q, et al. **Dev Dyn** 1997 Jan;208(1):1–10

Transient expression of CD44 variant isoforms in the ontogeny of the rat: ectoderm–, endoderm– and mesoderm–derived cells express different exon combinations. Weber B, et al. **Differentiation** 1996 Mar; 60(1):17–29

Complex CD44 splicing combinations in synovial fibroblasts from arthritic joints. Croft DR, et al. **Eur J Immunol** 1997 Jul;27(7):1680–4

The characterization of a human RHAMM cDNA: conservation of the hyaluronan–binding domains. Wang C, et al. **Gene** 1996 Oct 3;174(2):299–306

Differential display of messenger RNA expressed in bronchoalveolar lavage cells in pulmonary sarcoidosis patients. Wiwien HW, et al. **Hiroshima J Med Sci** 1996 Mar;45(1):1–10

Expression of CD44 alternative splicing variants in primary and lymph node metastatic lesions of gynecological cancer. Yorishima T, et al. **Hiroshima J Med Sci** 1997 Mar; 46(1):21–9

CD44 isoform expression in the diffuse neuroendocrine system. II. Benign and malignant tumors. Komminoth P, et al. **Histochem Cell Biol** 1996 Dec;106(6):551–62

Expression of CD44 splice variants in metastatic and non–metastatic mouse tumour cell lines. Tkach T, et al. **Immunol Lett** 1996 Sep;52(2–3):81–7

Soluble CD44 splice variants in metastasizing human breast cancer. Martin S, et al. **Int J Cancer** 1997 Aug 22; 74(4):443–5

Down–regulated expression of CD44 variant 6 in oral squamous cell carcinomas and its relationship to regional lymph node metastasis. Kunishi M, et al. **Int J Oral Maxillofac Surg** 1997 Aug;26(4):280–3

Epidermal growth factor induces CD44 gene expression through a novel regulatory element in mouse fibroblasts. Zhang M, et al. **J Biol Chem** 1997 May 30;272(22):14139–46

Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. Sleeman J, et al. **J Cell Biol** 1996 Nov;135(4):1139–50

Coexpression of CD44 variant (v10/ex14) and CD44S in human mammary epithelial cells promotes tumorigenesis. Iida N, et al. **J Cell Physiol** 1997 May;171(2):152–60

Detection of CD44 splice variants in formalin–fixed, paraffin–embedded specimens of human skin cancer. Dietrich A, et al. **J Cutan Pathol** 1997 Jan;24(1):37–42

Differential expression of CD44 splice variants in the normal human central nervous system. Kaaijk P, et al. **J Neuroimmunol** 1997 Mar;73(1–2):70–6

Unaltered strong immunohistochemical expression of CD44–v6 and –v5 isoforms during development and progression of oral squamous cell carcinomas. Piffkò J, et al. **J Oral Pathol Med** 1996 Oct;25(9):502–6

AP–1–mediated invasion requires increased expression of the hyaluronan receptor CD44. Lamb RF, et al. **Mol Cell Biol** 1997 Feb;17(2):963–76

Hyaluronan, CD44 and its variant exons in human trophoblast invasion and placental angiogenesis. Goshen R, et al. **Mol Hum Reprod** 1996 Sep;2(9):685–91

Expression of CD44 variant exons by normal oral epithelia. Oliveira DT, et al. **Oral Oncol** 1997 Jul;33(4):260–2

Differential expression of CD44 splice variants in malignant and benign pleural effusions. Tojo N, et al. **Tohoku J Exp Med** 1996 Aug;179(4):273–9

[Are the products of CD44 exons v5 and v6 markers for metastasis of laryngeal carcinomas? Ostwald J, et al. **Laryngorhinootologie** 1997 May;76(5):295–9 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Induction of fibroblast apoptosis by anti–CD44 antibody: implications for the treatment of fibroproliferative lung disease. Henke C, et al. **Am J Pathol** 1996 Nov; 149(5):1639–50

Diverse effects of anti–CD44 antibodies on the stromal cell–mediated support of normal but not leukaemic (CML) haemopoiesis in vitro. Ghaffari S, et al. **Br J Haematol** 1997 Apr;97(1):22–8

Development of a bispecific F(ab')2 conjugate against the complement receptor CR3 of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage–mediated tumor cytotoxicity. Somasundaram C, et al. **Cancer Immunol Immunother** 1996 Jul;42(6):343–50

Antibodies to the beta 1–integrin chain, CD44, or ICAM–3 stimulate adhesion of blast colony–forming cells and may inhibit their growth. Oostendorp RA, et al. **Exp Hematol** 1997 Apr;25(4):345–9

Binding of human leukocytes to fibronectin is augmented by an anti–CD44 mAb (TL–1) and blocked by another anti–CD44 mAb (Hermes–3) but not by anti–VLA–4/VLA–5 mAbs. Cao L, et al. **Immunobiology** 1996–97;196(5):504–12

Functional activity of murine CD44 variant isoforms in allergic and delayed type hypersensitivity. Wittig B, et al. **Immunol Lett** 1997 Jun 1;57(1–3):217–23

CD44–stimulated dendrite formation ('spreading') in activated B cells. Santos–Argumedo L, et al. **Immunology** 1997 Jan;90(1):147–53

Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6–specific scFv:zeta–chimera. Hekele A, et al. **Int J Cancer** 1996 Oct 9;68(2):232–8

Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous–cell carcinoma, recognizes a CD44 isoform. Van Hal NL, et al. **Int J Cancer** 1996 Nov 15;68(4):520–7

CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. DeGrendele HC, et al. **J Immunol** 1997 Sep 15;159(6):2549–53

CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages. Hart SP, et al. **J Immunol** 1997 Jul 15; 159(2):919–25

CD44 is a cytotoxic triggering molecule on human polymorphonuclear cells. Pericle F, et al. **J Immunol** 1996 Nov 15;157(10):4657–63

Differential expression of CD44 splice variants in the normal human central nervous system. Kaaijk P, et al. **J Neuroimmunol** 1997 Mar;73(1–2):70–6

Altered patterns of CD44 epitope expression in human chronic and acute myeloid leukemia. Ghaffari S, et al. **Leukemia** 1996 Nov;10(11):1773–81

Thymocyte progenitors and T cell development in aging. Yu S, et al. **Mech Ageing Dev** 1997 Mar;94(1–3):103–11

CD44v6 expression in primary bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma. Ohori NP, et al. **Mod Pathol** 1996 May;9(5):507–12

CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Knutson JR, et al. **Mol Biol Cell** 1996 Mar;7(3):383–96

Expression of CD44v9 on peritoneal T cells from patients on continuous ambulatory peritoneal dialysis [letter] Fricke H. **Nephron** 1996;73(2):373–4

Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Weber GF, et al. **Proc Assoc Am Physicians** 1997 Jan;109(1):1–9 (67 ref.)

ISOLATION & PURIFICATION

CD44 and its v6 spliced variant in lung tumors: a role in histogenesis? Fasano M, et al. **Cancer** 1997 Jul 1;80(1):34–41

METABOLISM

CD44 distribution in sweat gland tumors suggests it has different functional roles in the various cell types. Fernández–Figueras MT, et al. **Am J Dermatopathol** 1996

Oct;18(5):483–9
Relationship between CD44 expression and cell proliferation in epithelium and stroma of colorectal neoplasms. Furuta K, et al. **Am J Pathol** 1996 Oct;149(4):1147–55
Expression of CD44, ICAM–1 and N–CAM in colorectal cancer. Correlation with the tumor stage and the phenotypical characteristics of tumor–infiltrating lymphocytes. Wimmenauer S, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2395–400
O–linked glycosylation modifies CD44 adhesion to hyaluronate in colon carcinoma cells. Dasgupta A, et al. **Biochem Biophys Res Commun** 1996 Oct 3;227(1):110–7
Hyaluronic acid induced hyaluronic acid binding protein phosphorylation and inositol triphosphate formation in lymphocytes. Rao CM, et al. **Biochem Mol Biol Int** 1996 Oct;40(2):327–37
CD44 expression in melanocytic lesions: a marker of malignant progression? Harwood CA, et al. **Br J Dermatol** 1996 Dec;135(6):876–82
Expression of adhesion molecule CD44 on human corneas. Zhu SN, et al. **Br J Ophthalmol** 1997 Jan;81(1):80–4
Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Kallakury BV, et al. **Cancer** 1996 Oct 1;78(7):1461–9
Characterization of a high–affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Heider KH, et al. **Cancer Immunol Immunother** 1996 Dec;43(4):245–53
Soluble forms of CD44 and CD54 (ICAM–1) cellular adhesion molecules are released by human prostatic cancer cell lines. Rokhlin OW, et al. **Cancer Lett** 1996 Oct 1; 107(1):29–35
Absence of functional CD44 hyaluronan receptor on human NMYC–amplified neuroblastoma cells. Gross N, et al. **Cancer Res** 1997 Apr 1;57(7):1387–93
Regulation of CD44v6–containing isoforms during proliferation of normal and malignant epithelial cells. Soukka T, et al. **Cancer Res** 1997 Jun 1;57(11):2281–9
Binding of CD44 to hyaluronic acid can be induced by multiple signals and requires the CD44 cytoplasmic domain. Liu D, et al. **Cell Immunol** 1996 Nov 25; 174(1):73–83
Hyaluronan mediates sperm motility by enhancing phosphorylation of proteins including hyaluronan binding protein. Ranganathan S, et al. **Cell Mol Biol Res** 1995; 41(5):467–76
CD44 phosphorylation regulates melanoma cell and fibroblast migration on, but not attachment to, a hyaluronan substratum. Peck D, et al. **Curr Biol** 1996 Jul 1;6(7):884–90
Expression of multiple CD44 isoforms in the apical ectodermal ridge of the embryonic mouse limb. Yu Q, et al. **Dev Dyn** 1996 Oct;207(2):204–14
High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Dietrich A, et al. **Eur J Cancer** 1997 May;33(6):926–30
Tyrosine kinase–dependent activation of human NK cell functions upon triggering through CD44 receptor. Galandrini R, et al. **Eur J Immunol** 1996 Dec; 26(12):2807–11
A chondroitin/dermatan sulfate form of CD44 is a receptor for collagen XIV (undulin). Ehnis T, et al. **Exp Cell Res** 1996 Dec 15;229(2):388–97
CD44–anchored hyaluronan–rich pericellular matrices: an ultrastructural and biochemical analysis. Knudson W, et al. **Exp Cell Res** 1996 Nov 1;228(2):216–28
Multifunctional activities of human fibroblast 34–kDa hyaluronic acid–binding protein. Das S, et al. **Gene** 1997 Apr 29;190(1):223–5
Identification of a 175 kDa protein as the ligand–binding subunit of the rat liver sinusoidal endothelial cell hyaluronan receptor. Yannariello–Brown J, et al. **Glycobiology** 1997 Feb;7(1):15–21
p53 and CD44 as clinical markers of tumour progression in colorectal carcinogenesis. Mulder JW, et al. **Histochem J** 1997 Jun;29(6):439–52 (163 ref.)
Role of CD44 in nonpalpable T1a and T1b breast cancer. Lyzak JS, et al. **Hum Pathol** 1997 Jul;28(7):772–8
Expression of CD44 standard form and variant isoforms in non–small cell lung carcinomas. Tran TA, et al. **Hum Pathol** 1997 Jul;28(7):809–14
Heparan sulfate proteoglycan expression in human lung–cancer cells. Nackaerts K, et al. **Int J Cancer** 1997 Jun 20;74(3):335–45
Histochemical studies of hyaluronan and the hyaluronan receptor ICAM–1 in psoriasis. Gustafson S, et al. **Int J Tissue React** 1995;17(4):167–73
Expression of CD44 and variant isoforms in cultured human retinal pigment epithelial cells. Liu NP, et al. **Invest Ophthalmol Vis Sci** 1997 Sep;38(10):2027–37
Functional cloning of the cDNA for a human hyaluronan synthase. Shyjan AM, et al. **J Biol Chem** 1996 Sep 20; 271(38):23395–9
Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. Takahashi K, et al. **J Biol Chem** 1997 Sep 12;272(37):23371–5
Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. Sleeman J, et al. **J Cell Biol** 1996 Nov;135(4):1139–50
CD44 protein levels and its biological activity are regulated in Balb/c 3T3 fibroblasts by serum factors and by transformation with the ras but not with the sis oncogene. Kogerman P, et al. **J Cell Physiol** 1996 Nov;169(2):341–9
Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. Goebeler M, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1957–64
CD44 variant expression in cutaneous T–cell lymphoma. Orteu CH, et al. **J Cutan Pathol** 1997 Jul;24(6):342–9
CD44–hyaluronate interaction participates in the adherence of T–lymphocytes to gingival fibroblasts. Murakami S, et al. **J Dent Res** 1996 Aug;75(8):1545–52
Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. Guo Y, et al. **J Exp Med** 1996 Sep 1;184(3):955–61
Phorbol myristate acetate stimulates the dimerization of CD44 involving a cysteine in the transmembrane domain. Liu D, et al. **J Immunol** 1997 Sep 15;159(6):2702–11
CD44 expression on epidermal melanocytes. Herbold KW, et al. **J Invest Dermatol** 1996 Jun;106(6):1230–5
Metastatic potential of lymphoma/leukemia cell lines in SCID mice is closely related to expression of CD44. Kawasaki N, et al. **Jpn J Cancer Res** 1996 Oct; 87(10):1070–7
CD44 and hyaluronan binding by human myeloid cells. Smadja–Joffe F, et al. **Leuk Lymphoma** 1996 May; 21(5–6):407–20, color plates following 528 (112 ref.)
Expression of CD44 variant isoforms in peripheral blood leukocytes in malignant lymphoma and leukemia: inverse correlation between expression and tumor progression. Khaldoyanidi S, et al. **Leuk Res** 1996 Oct;20(10):839–51
Localization of hyaluronan in human liver sinusoids: a histochemical study using hyaluronan–binding protein. Ichida T, et al. **Liver** 1996 Dec;16(6):365–71
Expression of cell adhesion molecule CD44 in primary tumors of the liver: an immunohistochemical study. Washington K, et al. **Liver** 1997 Feb;17(1):17–23
Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Ross JS, et al. **Mod Pathol** 1996 Aug;9(8):854–60
Hyaluronan, CD44 and its variant exons in human trophoblast invasion and placental angiogenesis. Goshen R, et al. **Mol Hum Reprod** 1996 Sep;2(9):685–91
Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3–kinase and protein kinase C. Fichter M, et al. **Oncogene** 1997 Jun 12;14(23):2817–24
Expression of CD44 variant exons by normal oral epithelia. Oliveira DT, et al. **Oral Oncol** 1997 Jul;33(4):260–2
The standard isoform of CD44 is preferentially expressed in atypical papillomas and carcinomas of the choroid plexus. Varga Z, et al. **Pathol Res Pract** 1996 Dec; 192(12):1225–31
The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer. Nihei Z, et al. **Surg Today** 1996;26(9):760–1
Leucocyte rheological properties are altered in patients with diffuse atherosclerosis. Galante A, et al. **Thromb Haemost** 1997 Jun;77(6):1073–6
Neoplastic human tissue mast cells express the adhesion molecule CD44/HCAM. Horny HP, et al. **Virchows Arch** 1996 Oct;429(2–3):91–4

PHARMACOLOGY

CD44 is a cytotoxic triggering molecule on human polymorphonuclear cells. Pericle F, et al. **J Immunol** 1996 Nov 15;157(10):4657–63

PHYSIOLOGY

CD44: structure, function, and association with the malignant process. Naot D, et al. **Adv Cancer Res** 1997;71:241–319 (489 ref.)
CD44 is involved in migration but not spreading of astrocytoma cells in vitro. Radotra B, et al. **Anticancer Res** 1997 Mar–Apr;17(2A):945–9
Regulation of endothelial CD44 expression and endothelium–tumour cell interactions by hepatocyte growth factor/scatter factor. Hiscox S, et al. **Biochem Biophys Res Commun** 1997 Apr 7;233(1):1–5
CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells. Griffioen AW, et al. **Blood** 1997 Aug 1;90(3):1150–9
CD44–mediated adhesiveness of human hematopoietic progenitors to hyaluronan is modulated by cytokines. Legras S, et al. **Blood** 1997 Mar 15;89(6):1905–14
Hyaluronate–CD44 interactions can induce murine B–cell activation. Rafi A, et al. **Blood** 1997 Apr 15;89(8):2901–8
CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Schmits R, et al. **Blood** 1997 Sep 15;90(6):2217–33
Migration of highly aggressive MV3 melanoma cells in 3–dimensional collagen lattices results in local matrix reorganization and shedding of alpha2 and beta1 integrins and CD44. Friedl P, et al. **Cancer Res** 1997 May 15; 57(10):2061–70
Adhesion of multiple myeloma peripheral blood B cells to bone marrow fibroblasts: a requirement for CD44 and alpha4beta7. Masellis–Smith A, et al. **Cancer Res** 1997 Mar 1;57(5):930–6
In vivo inhibition of CD44 limits intra–abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Strobel T, et al. **Cancer Res** 1997 Apr 1;57(7):1228–32
Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue–specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Kaya G, et al. **Genes Dev** 1997 Apr 15;11(8):996–1007
Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas. Gilcrease MZ, et al. **Hum Pathol** 1996 Dec;27(12):1355–60
The role of hyaluronan and its receptors in restenosis after balloon angioplasty: development of a potential therapy. Savani RC, et al. **Int J Tissue React** 1995;17(4):141–51 (53 ref.)
The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation. Lokeshwar VB, et al. **J Biol Chem** 1996 Sep 27;271(39):23853–64
HA receptors: regulators of signalling to the cytoskeleton. Entwistle J, et al. **J Cell Biochem** 1996 Jun 15;61(4):569–77 (51 ref.)
An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function. Weiss JM, et al. **J Cell Biol** 1997 Jun 2;137(5):1137–47
CD44v10 expression in the mouse and functional activity in delayed type hypersensitivity. Rösel M, et al. **J Cell Physiol** 1997 Jun;171(3):305–17
CD44: one ligand, two functions [editorial] Aruffo A. **J Clin Invest** 1996 Nov 15;98(10):2191–2
Acute lung injury fibroblast migration and invasion of a fibrin matrix is mediated by CD44. Svee K, et al. **J Clin Invest** 1996 Oct 15;98(8):1713–27
Growth as a solid tumor or reduced glucose concentrations in culture reversibly induce CD44–mediated hyaluronan recognition by Chinese hamster ovary cells. Zheng Z, et al. **J Clin Invest** 1997 Sep 1;100(5):1217–29
CD44 and melanocytic tumors: a possible role for standard CD44 in the epidermotropic spread of melanoma. Fernández–Figueras MT, et al. **J Cutan Pathol** 1996 Apr; 23(2):133–9
Induction of IL–12 and chemokines by hyaluronan requires adhesion–dependent priming of resident but not elicited macrophages. Hodge–Dufour J, et al. **J Immunol** 1997 Sep 1;159(5):2492–500
Origin and function of circulating CD44 in non–Hodgkin's lymphoma. Ristämaki R, et al. **J Immunol** 1997 Mar 15; 158(6):3000–8
Requirement for CD44 in proliferation and homing of hematopoietic precursor cells. Khaldoyanidi S, et al. **J Leukoc Biol** 1996 Nov;60(5):579–92
Binding of malignant lymphoid cells to the white matter of the human central nervous system: role of different CD44 isoforms, beta 1, beta 2 and beta 7 integrins, and L–selectin. Aho R, et al. **J Neuropathol Exp Neurol** 1997 May; 56(5):557–68
Glioma invasion in vitro is mediated by CD44–hyaluronan interactions. Radotra B, et al. **J Pathol** 1997 Apr; 181(4):434–8
CD44 is not required for poliovirus replication. Bouchard MJ, et al. **J Virol** 1997 Apr;71(4):2793–8
CD44H plays an important role in peritoneal dissemination of scirrhous gastric cancer cells. Nishimura S, et al. **Jpn J Cancer Res** 1996 Dec;87(12):1235–44
Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation. Lundell BI, et al. **Leukemia** 1997 Jun;11(6):822–9
x82p4and the adhesion of neoplastic cells. Rudzki Z, et al. **Mol Pathol** 1997 Apr;50(2):57–71 (146 ref.)
pp60(c–src) is required for cell locomotion regulated by the hyaluronanreceptor RHAMM. Hall CL, et al. **Oncogene** 1996 Nov 21;13(10):2213–24
Analysis of molecular functions of the tumor metastasis promoting surface molecule CD44v4–v7 using transgenic mice. Moll J, et al. **Princess Takamatsu Symp** 1994; 24:142–51 (34 ref.)
An anti–CD44 antibody does not enhance engraftment of DLA–identical marrow after low–dose total body irradiation. Sandmaier BM, et al. **Transpl Immunol** 1996 Dec;4(4):271–4
CD44 is not required for poliovirus replication in cultured cells and does not limit replication in monocytes. Freistadt MS, et al. **Virology** 1996 Oct 15;224(2):542–7
[CD 44] Toyaha–Sorimachi N. **Rinsho Byori** 1996 Sep;Suppl 102:40–8 (25 ref.) **(Jpn)**
[CD44—cell receptor for hyaluronate. Clinical aspects of structure and function] Matysiak W. **Pol Arch Med Wewn** 1996 Sep;96(3):297–302 (35 ref.) **(Pol)**

URINE

Expression of CD44V2 in transitional cell carcinoma of the urinary bladder and in urine. Müller M, et al. **Urol Res** 1997;25(3):187–92

ANTIGENS, CD45

Essential role of the thymus to reconstitute naive (CD45RA+) T–helper cells after human allogeneic bone marrow transplantation. Heitger A, et al. **Blood** 1997 Jul 15;90(2):850–7
Syk, but not Lyn, recruitment to B cell antigen receptor and activation following stimulation of CD45– B cells. Pao LI,

et al. **J Immunol** 1997 Mar 15;158(6):2663–9

CD45RA+ and CD45RO+ T cells differ in susceptibility to cyclosporin A mediated inhibition of interleukin-2 production. Schwinzer R, et al. **Transpl Immunol** 1996 Mar; 4(1):61–3

[CD45 gating of acute leukemia] Nishikawa K, et al. **Rinsho Byori** 1996 Jun;44(6):548–53 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. Aranda R, et al. **J Immunol** 1997 Apr 1; 158(7):3464–73

ANALYSIS

Comparative analysis of CD45RA- and CD45RO-positive CD4+T cells in peripheral blood, synovial fluid, and synovial tissue in patients with rheumatoid arthritis and osteoarthritis. Ezawa K, et al. **Acta Med Okayama** 1997 Feb;51(1):25–31

Expression of microglial markers in the human CNS after closed head injury. Engel S, et al. **Acta Neurochir Suppl (Wien)** 1996;66:89–95

Severe combined immunodeficiency with abnormalities in expression of the common leucocyte antigen, CD45. Cale CM, et al. **Arch Dis Child** 1997 Feb;76(2):163–4

Expression of haematopoietic cell markers by retinal pigment epithelial cells and Muller cells. Russell W, et al. **Biochem Soc Trans** 1997 May;25(2):251S

Markedly disturbed glutathione redox status in CD45RA+CD4+ lymphocytes in human immunodeficiency virus type 1 infection is associated with selective depletion of this lymphocyte subset. Aukrust P, et al. **Blood** 1996 Oct 1;88(7):2626–33

Susceptibility to clinically manifest cyclosporine A (CsA)-induced autoimmune disease is associated with interferon-gamma (IFN-gamma)-producing CD45RC+RT6- T helper cells [published erratum appears in Clin Exp Immunol 1997 Jan;107(1):224] Beijleveld LJ, et al. **Clin Exp Immunol** 1996 Sep;105(3):486–96

Diagnostic value of CD45RO expression on circulating T lymphocytes of fetuses and newborn infants with pre-, peri- or early post-natal infections. Brüning T, et al. **Clin Exp Immunol** 1997 Feb;107(2):306–11

HIV infection of CD45RA+ and CD45RO+ CD4+ T cells. Helbert MR, et al. **Clin Exp Immunol** 1997 Feb;107(2):300–5

The CD7- T cell subset represents the majority of IL-5-secreting cells within CD4+CD45RA- T cells. Reinhold U, et al. **Clin Exp Immunol** 1996 Dec;106(3):555–9

Apoptosis of cells in aged samples as detected by the ProCOUNT reagent. Manion K, et al. **Cytometry** 1996 Dec 15;26(4):317–22

Detection of myeloma cells in the peripheral blood by flow cytometry. Witzig TE, et al. **Cytometry** 1996 Jun 15; 26(2):113–20

Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability. Yacyshyn B, et al. **Dig Dis Sci** 1996 Dec;41(12):2493–8

Constitutive and inducible protein/DNA interactions of the interferon-gamma promoter in vivo in [corrected] CD45RA and CD45R0 T helper subsets [published erratum appears in Eur J Immunol 1997 Jul;27(7):1830] Barbulescu K, et al. **Eur J Immunol** 1997 May;27(5):1098–107

Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Ludewig B, et al. **Eur J Immunol** 1996 Dec;26(12):3137–43

Selective migration of highly differentiated primed T cells, defined by low expression of CD45RB, across human umbilical vein endothelial cells: effects of viral infection on transmigration. Borthwick NJ, et al. **Immunology** 1997 Feb;90(2):272–80

Identical expression of CD45R isoforms by CD45RC+ 'revertant' memory and CD45RC+ naive CD4 T cells. Hargreaves M, et al. **Immunology** 1997 Jul;91(3):323–30

Immune memory in CD4+ CD45RA+ T cells. Richards D, et al. **Immunology** 1997 Jul;91(3):331–9

CD4+ CD45RA+ T cells from adults respond to recall antigens after CD28 ligation. Pilling D, et al. **Int Immunol** 1996 Nov;8(11):1737–42

Enhanced expression of HLA-DR, Fc gamma receptor 1 (CD64) and leukocyte common antigen (CD45) indicate activation of monocytes in regenerative training periods of endurance athletes. Gabriel H, et al. **Int J Sports Med** 1997 Feb;18(2):136–41

Oligoclonal expansion of CD45RO+ T lymphocytes in Omenn syndrome. Harville TO, et al. **J Clin Immunol** 1997 Jul;17(4):322–32

Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. Spina CA, et al. **J Clin Invest** 1997 Apr 1;99(7):1774–85

Presence of B cell progenitors in the thymus. Mori S, et al. **J Immunol** 1997 May 1;158(9):4193–9

Aberrant TCR-mediated signaling in CD45-null thymocytes involves dysfunctional regulation of Lck, Fyn, TCR-zeta, and ZAP-70. Stone JD, et al. **J Immunol** 1997 Jun 15; 158(12):5773–82

B-1 cell (CD5+B220+) outgrowth in murine schistosomiasis is genetically restricted and is largely due to activation by polylactosamine sugars. Velupillai P, et al. **J Immunol** 1997 Jan 1;158(1):338–44

Transgenic expression of VpreB-3 under the control of the immunoglobulin heavy chain enhancer and SV40 promoter. Hagiwara S. **Kobe J Med Sci** 1996 Feb;42(1):43–59

Fatty acid unsaturation increases expression and capping of murine lymphocyte CD44 and CD45. Peck MD, et al. **Nutrition** 1996 Sep;12(9):616–22

BIOSYNTHESIS

Expression of RT6, but not CD45RC, is disturbed on immature peripheral T cells in the BB rat. Groen H, et al. **Adv Exp Med Biol** 1997;419:253–6

Expression of CD45-restricted form B in (NZW x BXSB) F1 and MRL/Mp-lpr/lpr mice. Sugihara A, et al. **Autoimmunity** 1996;24(4):237–46

Identification of an intragenic promoter in the human CD45 gene. Timon M, et al. **Biochem Soc Trans** 1997 May; 25(2):177S

CD45RA-expressing memory/effector Th cells committed to production of interferon-gamma lack expression of CD31. Thiel A, et al. **Immunol Lett** 1997 Jun 1; 57(1-3):189–92

CD45 up-regulation during lymphocyte maturation. Kirberg J, et al. **Int Immunol** 1996 Nov;8(11):1743–9

B220 expression by T lymphoid progenitor cells in mouse fetal liver. Sagara S, et al. **J Immunol** 1997 Jan 15; 158(2):666–76

Alterations in the level of CD45 surface expression affect the outcome of thymic selection. Wallace VA, et al. **J Immunol** 1997 Apr 1;158(7):3205–14

The differences in the expression of CD45 isoforms on peripheral blood lymphocytes derived from patients with seasonal or perennial atopic allergy. Pawlik I, et al. **Tohoku J Exp Med** 1997 May;182(1):1–8

BLOOD

Use of CD45 fluorescence and side-scatter characteristics for gating lymphocytes when using the whole blood lysis procedure and flow cytometry. Nicholson JK, et al. **Cytometry** 1996 Mar 15;26(1):16–21

Cord blood CD4+ CD45RA+ T cells achieve a lower magnitude of activation when compared with their adult counterparts. Hassan J, et al. **Immunology** 1997 Mar; 90(3):397–401

Leukocyte CD14 and CD45 expression during hemodialysis: polysulfone versus cuprophane. Dhondt AW, et al. **Nephron** 1996;74(2):342–8

CHEMISTRY

Conformational changes in CD45 upon monoclonal antibody crosslinking. Hamann D, et al. **Hybridoma** 1996 Feb; 15(1):11–6

Identification of in vivo phosphorylation sites of CD45 protein-tyrosine phosphatase in 70Z/3.12 cells. Kang S, et al. **J Biol Chem** 1997 Apr 25;272(17):11588–96

Monoclonal antibodies to a high molecular weight isoform of porcine CD45: biochemical and tissue distribution analyses. Bullido R, et al. **Vet Immunol Immunopathol** 1997 May;56(1-2):151–62

GENETICS

Identification of an intragenic promoter in the human CD45 gene. Timon M, et al. **Biochem Soc Trans** 1997 May; 25(2):177S

An analysis of alternatively spliced CD45 mRNA transcripts during T cell maturation in humans. Ratech H, et al. **Cell Immunol** 1997 May 1;177(2):109–18

The mammalian homolog of suppressor-of-white-apricot regulates alternative mRNA splicing of CD45 exon 4 and fibronectin IIICS. Sarkissian M, et al. **J Biol Chem** 1996 Dec 6;271(49):31106–14

T cell development in mice expressing splice variants of the protein tyrosine phosphatase CD45. Kozieradzki I, et al. **J Immunol** 1997 Apr 1;158(7):3130–9

Surface expression of hemopoietic cell phosphatase fails to complement CD45 deficiency and inhibits TCR-mediated signal transduction in a Jurkat T cell clone. Musci MA, et al. **J Immunol** 1997 Feb 15;158(4):1565–71

IMMUNOLOGY

Syncytium-inducing HIV-1 variants replicate equally well in all types of T-helper cell clones [letter] Meyaard L, et al. **AIDS** 1996 Nov;10(13):1598–600

CD4+ memory T cells are the predominant population of HIV-1-infected lymphocytes in neonates and children. Sleasman JW, et al. **AIDS** 1996 Nov;10(13):1477–84

Immunity to experimental Salmonella typhimurium infections in rats. Transfer of immunity with primed CD45RC+ and CD45RC- CD4 T-cell subpopulations. Thygesen P, et al. **APMIS** 1996 Oct;104(10):750–4

Heterogeneity of the human CD4+ T-cell population: two distinct CD4+ T-cell subsets characterized by coexpression of CD45RA and CD45RO isoforms. Hamann D, et al. **Blood** 1996 Nov 1;88(9):3513–21

Loss of inducible virus in CD45RA naive cells after human immunodeficiency virus-1 entry accounts for preferential viral replication in CD45RO memory cells. Woods TC, et al. **Blood** 1997 Mar 1;89(5):1635–41

Concordant expression of class II and class III CD34 epitopes on haemopoietic cells in leukapheresis and cord blood samples with CD45/CD34 dual staining. Rudin CE, et al. **Br J Haematol** 1997 May;97(2):488–91

Naive (CD45RA+) T lymphocytes are more sensitive to oxidative stress-induced signals than memory (CD45RO+) cells. Lahdenpohja N, et al. **Cell Immunol** 1996 Nov 1; 173(2):282–6

Coexpression of GD3 ganglioside with CD45RO in resting and activated human T lymphocytes. Merritt WD, et al. **Cell Immunol** 1996 Oct 10;173(1):131–48

Role of phosphatases in lymphocyte activation. Neel BG. **Curr Opin Immunol** 1997 Jun;9(3):405–20 (124 ref.)

High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants. De Paoli P, et al. **Cytometry** 1997 Feb 15;30(1):33–8

Inhibition of T cell mitogenesis by a novel anti-CD45R monoclonal antibody. Robson SC, et al. **Immunol Cell Biol** 1996 Feb;74(1):65–71

Defective depletion of CD45-null thymocytes by the Staphylococcus aureus enterotoxin B superantigen. Conroy LA, et al. **Immunol Lett** 1996 Dec;54(2-3):119–22

CD45 enhances positive selection and is expressed at a high level in large, cycling, positively selected CD4+CD8+ thymocytes. Ong CJ, et al. **Immunology** 1997 May; 91(1):95–103

Severe allergic reactions to foods are predicted by increases of CD4+CD45RO+ T cells and loss of L-selectin expression. Beyer K, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):522–9

Nonatopic asthma: in vivo airway hyperreactivity adoptively transferred to naive mice by THY-1(+) and B220(+) antigen-specific cells that lack surface expression of CD3. Geba GP, et al. **J Clin Invest** 1997 Aug 1;100(3):629–38

The activation status of ovine CD45R+ and CD45R- efferent lymph T cells after orf virus reinfection. Haig DM, et al. **J Comp Pathol** 1996 Aug;115(2):163–74

The role of MT2 and anti-bcl-2 protein antibodies in the differentiation of benign from malignant cutaneous infiltrates of B-lymphocytes with germinal center formation. Chimenti S, et al. **J Cutan Pathol** 1996 Aug; 23(4):319–22

CD45RC isoforms define two types of CD4 memory T cells, one of which depends on persisting antigen. Bunce C, et al. **J Exp Med** 1997 Feb 17;185(4):767–76

Inhibition of CD45 during neutrophil activation. Fialkow L, et al. **J Immunol** 1997 Jun 1;158(11):5409–17

Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. Picarella D, et al. **J Immunol** 1997 Mar 1;158(5):2099–106

Differential CD45 isoform expression accompanies reduced natural antibody binding in L5178Y-F9 tumor progression. Zhang ZY, et al. **J Immunol** 1997 Jul 1;159(1):344–50

Increased apoptosis of CD45RO- T cells with aging. Herndon FJ, et al. **Mech Ageing Dev** 1997 Mar; 94(1-3):123–34

Flow cytometric characterisation of the "false naive" (CD45RA+, CD45RO-, CD29 bright+) peripheral blood T-lymphocytes in health and in rheumatoid arthritis. Neidhart M, et al. **Rheumatol Int** 1996;16(2):77–87

Anti-CD45RB treatment prolongs islet allograft survival in mice. Auersvald LA, et al. **Transplant Proc** 1997 Feb-Mar; 29(1-2):771

Therapy for mouse renal allograft rejection by monoclonal antibody to CD45RB. Lazarovits AI, et al. **Transplant Proc** 1996 Dec;28(6):3208–9

In vitro system for evaluation of the immunomodulatory capacity of CD45(R) reagents. Poppema S, et al. **Transplant Proc** 1996 Dec;28(6):3263–4

Effect of anti CD45 on different immunosuppressive regimes in renal transplantation. Talbot D, et al. **Transplant Proc** 1996 Dec;28(6):3212–3

Prevention of heart allograft and kidney xenograft rejection by monoclonal antibody to CD45RB. Zhang Z, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1253

CD45RB monoclonal antibody induces tolerance in the mouse kidney graft, but fails to prevent small bowel graft rejection. Zhang Z, et al. **Transplant Proc** 1996 Oct; 28(5):2514

Indefinite islet allograft survival in mice after a short course of treatment with anti-CD45 monoclonal antibodies. Auersvald LA, et al. **Transplantation** 1997 May 15; 63(9):1355–8

Monoclonal antibodies to a high molecular weight isoform of porcine CD45: biochemical and tissue distribution analyses. Bullido R, et al. **Vet Immunol Immunopathol** 1997 May;56(1-2):151–62

Investigation of PC36 (BoCD45R). Sopp P, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):271–4

[The study of the relationship between the granule size of immunoliposomes and the conjugate ratio of F(ab')2 of McAb HI30 (CD45)] Liu J, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Dec; 17(6):424–7 (Eng. Abstr.) **(Chi)**

ISOLATION & PURIFICATION

CD45 isoforms expression on CD4+ and CD8+ peripheral blood T-lymphocytes is related to auto-immune processes and hematological manifestations in systemic lupus erythematosus. Neidhart M, et al. **Schweiz Med Wochenschr** 1996 Nov 9;126(45):1922–5

ANTIGENS, CD45

METABOLISM

Definition of amino acids sufficient for plasma membrane association of CD45 and CD45-associated protein. Cahir McFarland ED, et al. **Biochemistry** 1997 Jun 10; 36(23):7169–75

Large granular lymphocyte expansions in Felty's syndrome have an unusual phenotype of activated CD45RA+ cells. Bowman SJ, et al. **Br J Rheumatol** 1996 Dec;35(12):1252–5

T-cell–independent antiviral B cell responses in CD45-deficient mice. Bachmann MF, et al. **Cell Immunol** 1997 Jan 10;175(1):12–5

Physical association of CD4 and CD45 in primary, resting CD4+ T cells. Bonnard M, et al. **Cell Immunol** 1997 Jan 10;175(1):1–11

Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus erythematosus (SLE). Takeuchi T, et al. **Clin Exp Immunol** 1997 Jul;109(1):20–6

CD45 regulates Src family member kinase activity associated with macrophage integrin-mediated adhesion. Roach T, et al. **Curr Biol** 1997 Jun 1;7(6):408–17

Differential interaction of the CD2 extracellular and intracellular domains with the tyrosine phosphatase CD45 and the zeta chain of the TCR/CD3/zeta complex. Verhagen AM, et al. **Eur J Immunol** 1996 Dec; 26(12):2841–9

The MBP fusion protein restores the activity of the first phosphatase domain of CD45. Lorenzo HK, et al. **FEBS Lett** 1997 Jul 14;411(2–3):231–5

Engagement of CD45 during in vitro priming enhances antigen-specific Th cell frequencies. Harris PE, et al. **Int Immunol** 1996 Aug;8(8):1265–71

Physical and functional association of CD45 and CD3-TCR complex on CD1+ human thymocytes. Evidence that the engagement of CD45 molecules can prevent CD1+ thymocytes from apoptosis. Poggi A, et al. **Int Immunol** 1996 Dec;8(12):1947–53

Identification of the CD45-associated 116-kDa and 80-kDa proteins as the alpha- and beta-subunits of alpha-glucosidase II. Arendt CW, et al. **J Biol Chem** 1997 May 16;272(20):13117–25

CD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B cells. Yanagi S, et al. **J Biol Chem** 1996 Nov 29;271(48):30487–92

Changes in memory and naive CD4+ lymphocytes in lymph nodes and spleen after thermal injury. Lawrence MH, et al. **J Burn Care Rehabil** 1996 Jan–Feb;17(1):1–6

Exclusion of CD45 inhibits activity of p56lck associated with glycolipid-enriched membrane domains. Rodgers W, et al. **J Cell Biol** 1996 Dec;135(6 Pt 1):1515–23

CD45 immunostaining in T-cell–rich B-cell lymphoma and lymphocyte predominance Hodgkin's disease [letter; comment] Ashton-Key M, et al. **J Pathol** 1997 Apr; 181(4):462–3. Comment on: J Pathol 1996 Jun;179(2):138–44.

CD45 isoforms expression on CD4+ and CD8+ T cells throughout life, from newborns to centenarians: implications for T cell memory. Cossarizza A, et al. **Mech Ageing Dev** 1996 Mar 29;86(3):173–95

PHARMACOLOGY

Physical and functional association of CD45 and CD3-TCR complex on CD1+ human thymocytes. Evidence that the engagement of CD45 molecules can prevent CD1+ thymocytes from apoptosis. Poggi A, et al. **Int Immunol** 1996 Dec;8(12):1947–53

Evidence for down-regulation of highly expressed TCR by CD4 and CD45 on non-selected CD4+CD8+ thymocytes. Sato T, et al. **Int Immunol** 1996 Oct; 8(10):1529–35

PHYSIOLOGY

CD45 regulates apoptosis induced by extracellular adenosine triphosphate and cytotoxic T lymphocytes. Macino B, et al. **Biochem Biophys Res Commun** 1996 Sep 24; 226(3):769–76

T-cell antigen receptor signal transduction in CD45-/- thymocytes. Stone JD, et al. **Biochem Soc Trans** 1997 May; 25(2):302S

Role of c-myc and CD45 in spontaneous and anti-receptor-induced apoptosis in adult murine B cells. Scott DW, et al. **Int Immunol** 1996 Sep;8(9):1375–85

CD45-mediated signals can trigger shedding of lymphocyte L-selectin. Wroblewski M, et al. **Int Immunol** 1997 Apr; 9(4):555–62

T cell receptor-induced phosphorylation of Sos requires activity of CD45, Lck, and protein kinase C, but not ERK. Zhao H, et al. **J Biol Chem** 1997 Aug 22;272(34):21625–34

The motheaten mutation rescues B cell signaling and development in CD45-deficient mice. Pani G, et al. **J Exp Med** 1997 Aug 18;186(4):581–8

CD100 is associated with CD45 at the surface of human T lymphocytes. Role in T cell homotypic adhesion. Hérold C, et al. **J Immunol** 1996 Dec 15;157(12):5262–8

Molecular targets of CD45 in B cell antigen receptor signal transduction. Pao LI, et al. **J Immunol** 1997 Feb 1; 158(3):1116–24

Alterations in the level of CD45 surface expression affect the outcome of thymic selection. Wallace VA, et al. **J Immunol** 1997 Apr 1;158(7):3205–14

"Normal" development of Vgamma3 dendritic epidermal T cells in CD45-deficient mice? [letter; comment] Kawai K, et al. **J Invest Dermatol** 1997 Aug;109(2):250–1. Comment on: J Invest Dermatol 1997 Jan;108(1):49–52.

CD45 molecule in gammadelta T-cell generation: disruption of CD45 exon 6 does not affect Vgamma3 dendritic epidermal T-cell development [see comments] Wang B, et al. **J Invest Dermatol** 1997 Jan;108(1):49–52. Comment in: J Invest Dermatol 1997 Aug;109(2):250–1.

ANTIGENS, CD54 see **INTERCELLULAR ADHESION MOLECULE-1**

ANTIGENS, CD55

ANALYSIS

Complement-regulatory proteins in ovarian malignancies. Bjørge L, et al. **Int J Cancer** 1997 Jan 6;70(1):14–25

Complement and complement regulatory proteins in human tears. Willcox MD, et al. **Invest Ophthalmol Vis Sci** 1997 Jan;38(1):1–8

Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV-1 particles as a function of complement-mediated virolysis. Nakamura M, et al. **Microbiol Immunol** 1996;40(8):561–7

Elastic fiber-associated proteins of skin in development and photoaging. Werth VP, et al. **Photochem Photobiol** 1996 Mar;63(3):308–13

X-irradiation does not affect the levels of complement regulatory proteins, CD35 (CR1), CD55 (DAF) and CD59 on concentrated red cells [letter] Fukumori Y, et al. **Vox Sang** 1996;71(4):243–4

[Increased expression of decay-accelerating factor in patients with colonic neoplasms and the analysis of their feces] Mizuno M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):647–50 (7 ref.) **(Jpn)**

BIOSYNTHESIS

Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. Song WC, et al. **J Immunol** 1996 Nov 1;157(9):4166–72

Activation of the gene encoding decay accelerating factor following nerve growth factor treatment of sensory neurons is mediated by promoter sequences within 206 bases of the transcriptional start site. Kendall G, et al. **J Neurosci Res** 1996 Jul 15;45(2):96–103

Differentiation-dependent changes in human trophoblast expression of decay-accelerating factor are modulated by 3',5' cyclic adenosine monophosphate. Zarkadis IK, et al. **J Soc Gynecol Investig** 1997 Jan–Feb;4(1):47–53

Novel responses by transgenic pig endothelial cells to stimulation by human cytokines in terms of H-DAF, E-selectin and major histocompatibility complex class II expression. Carrington CA, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):887

Production of transgenic rats for human regulators of complement activation. Charreau B, et al. **Transplant Proc** 1997 May;29(3):1770

Adenovirus-mediated gene transfer to the xenogeneic liver in liver xenotransplantation: the transduction of complement regulatory factor genes (DAF and HRF20). Hayashi S, et al. **Transplant Proc** 1997 Jun;29(4):2211

Endothelial cells from human decay acceleration factor transgenic pigs are protected against complement mediated tissue factor expression in vitro. Tucker AW, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):888

Combination of decay-accelerating factor expression and alpha1,3-galactosyltransferase knockout affords added protection from human complement-mediated injury. van Denderen BJ, et al. **Transplantation** 1997 Sep 27;64(6):882–8

BLOOD

Reduction in erythrocyte complement receptor 1 (CR1, CD35) and decay accelerating factor (DAF, CD55) during normal pregnancy. Imrie HJ, et al. **J Reprod Immunol** 1996 Oct;31(3):221–7

CHEMISTRY

Molecular modeling and mechanism of action of human decay-accelerating factor. Kuttner-Kondo L, et al. **Protein Eng** 1996 Dec;9(12):1143–9

GENETICS

Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cells. Andoh A, et al. **Gastroenterology** 1996 Oct;111(4):911–8

Expression of human decay accelerating factor may protect pig lung from hyperacute rejection by human blood. Pierson RN 3rd, et al. **J Heart Lung Transplant** 1997 Feb; 16(2):231–9

A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities. Higgins PJ, et al. **J Immunol** 1997 Mar 15; 158(6):2872–81

Activation of the gene encoding decay accelerating factor following nerve growth factor treatment of sensory neurons is mediated by promoter sequences within 206 bases of the transcriptional start site. Kendall G, et al. **J Neurosci Res** 1996 Jul 15;45(2):96–103

Inhibitory effect of double transfection to xenoendothelial cells using both decay accelerating factor and homologous restriction factor 20 genes on complement dependent cytolysis. Hayashi S, et al. **J Surg Res** 1996 Feb 15; 61(1):165–9

Production of pigs transgenic for human DAF to overcome complement-mediated hyperacute xenograft rejection in man. White DJ, et al. **Res Immunol** 1996 Feb;147(2):88–94 (28 ref.)

Immunopathological observations after xenogeneic liver perfusions using donor pigs transgenic for human decay-accelerating factor. Pascher A, et al. **Transplantation** 1997 Aug 15;64(3):384–91

Morphology of hDAF (CD55) transgenic pig kidneys following ex-vivo hemoperfusion with human blood. Storck M, et al. **Transplantation** 1997 Jan 27;63(2):304–10

IMMUNOLOGY

Decay-accelerating factor (DAF, CD55)-negative T lymphocytes in the peripheral blood of Sjögren's syndrome patients. Ichikawa Y, et al. **Tokai J Exp Clin Med** 1996 Oct;21(3):121–8

Flow cytometry and immunoblotting analysis of monoclonal antibodies directed to complement regulatory proteins. Blanchard D, et al. **Transfus Clin Biol** 1997;4(1):131–4

Use of recombinant DAF proteins to localize the epitopes recognized by monoclonal anti-CD55. Brodbeck WG, et al. **Transfus Clin Biol** 1997;4(1):125–6

Antibodies to complement regulatory proteins. Daniels G, et al. **Transfus Clin Biol** 1997;4(1):127–9

Coordinator's report: complement regulatory proteins. Moulds JM, et al. **Transfus Clin Biol** 1997;4(1):117–9

Complement regulatory proteins of human and non-human primates. Moulds JM, et al. **Transfus Clin Biol** 1997; 4(1):121–3

Disappearance of antibodies to Cromer blood group system antigens during mid pregnancy. Reid ME, et al. **Vox Sang** 1996;71(1):48–50

METABOLISM

Human complement regulator expression by the normal female reproductive tract. Oglesby TJ, et al. **Anat Rec** 1996 Sep;246(1):78–86

Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay. Astori C, et al. **Br J Haematol** 1997 Jun;97(3):586–8

Tumour necrosis factor-alpha up-regulates decay-accelerating factor gene expression in human intestinal epithelial cells. Andoh A, et al. **Immunology** 1997 Mar;90(3):358–63

The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). Hamann J, et al. **J Exp Med** 1996 Sep 1;184(3):1185–9

Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression. Spiller OB, et al. **J Neuroimmunol** 1996 Dec;71(1–2):97–106

Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. Juhl H, et al. **J Surg Oncol** 1997 Mar;64(3):222–30

The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). Karnauchow TM, et al. **J Virol** 1996 Aug;70(8):5143–52

Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. Shafren DR, et al. **J Virol** 1997 Jun;71(6):4736–43

[Expression of decay-accelerating factor on CD8-positive lymphocytes as an index of aging and of host defense function] Fuchino Y, et al. **Nippon Ronen Igakkai Zasshi** 1996 Aug;33(8):580–5 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers. Navenot JM, et al. **Muscle Nerve** 1997 Jan;20(1):92–6

PHYSIOLOGY

Inhibition of human complement-dependent cell lysis by bovine aortic endothelial cells transfected with membrane-bound complement-regulatory factor (DAF and HRF20) gene using a retroviral vector. Hayashi S, et al. **Eur Surg Res** 1996;28(6):440–6

Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. Saifuddin M, et al. **J Gen Virol** 1997 Aug;78 (Pt 8):1907–11

Transgenic human decay accelerating factor makes normal pigs function as a concordant species. Schmoeckel M, et al. **J Heart Lung Transplant** 1997 Jul;16(7):758–64

Expression of human decay accelerating factor (hDAF) in transgenic pigs regulates complement activation during ex vivo liver perfusion--immunopathological findings. Pascher A, et al. **Transpl Int** 1996;9 Suppl 1:S385–7

The function of transgenic human DAF-expressing porcine

livers during hemoperfusion with human blood. Pöhlein C, et al. **Transpl Int** 1996;9 Suppl 1:S392–6
Transplantation of normal and DAF-transgenic fetal pig pancreas into cynomolgus monkeys. Mandel TE, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2 /01):940
Pig-to-primate cardiac xenotransplantation and cyclophosphamide therapy. Waterworth PD, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):899–900
Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Byrne GW, et al. **Transplantation** 1997 Jan 15;63(1):149–55
Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts. Schmoeckel M, et al. **Transplantation** 1996 Sep 27; 62(6):729–34
[Kidney and complement regulatory factors] Matsuo S. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):643–6 (14 ref.) **(Jpn)**
[Complement regulatory membrane factors in experimental animal models] Okada N. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):631–3 (6 ref.) **(Jpn)**

ANTIGENS, CD56

Expansion of CD3+CD56+ lymphocytes correlates with induction of cytotoxicity by interleukin-2 gene transfer in human breast tumor cultures. Euhus DM, et al. **Ann Surg Oncol** 1997 Jul–Aug;4(5):432–9
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Suzuki R, et al. **Blood** 1997 Sep 15;90(6):2417–28

ANALYSIS

Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma. Kaiser U, et al. **Ann Hematol** 1996 Sep;73(3):121–6
Activated T cells and cytokine-induced CD3+CD56+ killer cells. Schmidt-Wolf GD, et al. **Ann Hematol** 1997 Feb; 74(2):51–6 (49 ref.)
Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation. Studies in unselected patients and monozygotic disease-discordant twins. Stohl W, et al. **Arthritis Rheum** 1996 Nov;39(11):1840–51
Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Chan JK, et al. **Blood** 1997 Jun 15;89(12):4501–13 (84 ref.)
CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Drénou B, et al. **Blood** 1997 Apr 15;89(8):2966–74
CD3+ CD8+ CD56- clonal large granular lymphocyte leukaemia and HIV infection. Pulik M, et al. **Br J Haematol** 1997 Aug;98(2):444–5
Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry. King MA, et al. **Cytometry** 1996 Jun 15; 26(2):121–4
CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Carson WE, et al. **Eur J Immunol** 1997 Feb; 27(2):354–60
Inconsistent association of Epstein-Barr virus with CD56 (NCAM)-positive angiocentric lymphoma occuring in sites other than the upper and lower respiratory tract. Kobashi Y, et al. **Histopathology** 1996 Feb;28(2):111–20
Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. Satoh M, et al. **J Immunol** 1996 Nov 1;157(9):3886–92
A novel population of CD4+CD56+ myelin-reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. Vergelli M, et al. **J Immunol** 1996 Jul 15;157(2):679–88
[Rapidly progressive T-cell angiocentric lymphoma with CD56+ phenotype involving bilateral orbits and skin in a patient with anti-HTLV-I antibody] Kato K, et al. **Rinsho Ketsueki** 1996 Feb;37(2):145–51 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Baer MR, et al. **Blood** 1997 Aug 15;90(4):1643–8
Structure of the murine CD156 gene, characterization of its promoter, and chromosomal location. Kataoka M, et al. **J Biol Chem** 1997 Jul 18;272(29):18209–15

GENETICS

CD56/neural cell adhesion molecule expression in primary extranodal Ki-1/CD30+ lymphoma. Report of a pediatric case with simultaneous cutaneous and bone localizations. Paulli M, et al. **Am J Dermatopathol** 1997 Aug;19(4):384–90
Structure of the murine CD156 gene, characterization of its promoter, and chromosomal location. Kataoka M, et al. **J Biol Chem** 1997 Jul 18;272(29):18209–15

IMMUNOLOGY

A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing [published erratum appears in Protein Eng 1997 Feb;10(2):181] Roguska MA, et al. **Protein Eng** 1996 Oct; 9(10):895–904
CD3+, CD16+, CD56+ cells: a novel subset of T lymphocytes from patients with Balkanic nephropathy. Drugărin D, et al. **Roum Arch Microbiol Immunol** 1995 Oct–Dec;54(4):255–64

METABOLISM

Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Mann KP, et al. **Am J Clin Pathol** 1997 Jun;107(6):653–60
CD56+ NK lymphomas: clinicopathological features and prognosis. Kwong YL, et al. **Br J Haematol** 1997 Jun; 97(4):821–9

PHYSIOLOGY

[Granulated CD56 lymphocytes of decidual tissue] Calatayud S, et al. **Pathol Biol (Paris)** 1995 Nov;43(9):788–98 (101 ref.) (Eng. Abstr.) **(Fre)**

ANTIGENS, CD57

ANALYSIS

CD8high+ (CD57+) T cells in patients with rheumatoid arthritis. Wang EC, et al. **Arthritis Rheum** 1997 Feb; 40(2):237–48
An immunohistochemical study of leu 7 and PCNA expression in thyroid neoplasms. Fucich LF, et al. **Biotech Histochem** 1996 Nov;71(6):298–303
Immunoelectron microscopic localization of the HNK-1 carbohydrate epitope in the anterior segment of pseudoexfoliation and normal eyes. Kubota T, et al. **Curr Eye Res** 1997 Mar;16(3):231–8
Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. Serrano D, et al. **J Immunol** 1997 Feb 1; 158(3):1482–9

BIOSYNTHESIS

Differential expression of PSA-NCAM and HNK-1 epitopes in the developing cardiac conduction system of the chick. Chuck ET, et al. **Dev Dyn** 1997 Jun;209(2):182–95
Pre- and postnatal expression of glycoconjugates (3-fucosyl-N-acetyllactosamine and HNK-1 epitopes) in the mouse inner ear. Meyer zum Gottesberge A, et al. **Int J Dev Neurosci** 1997 Jul;15(4–5):645–56
Cloning and functional expression of a novel glucuronyltransferase involved in the biosynthesis of the carbohydrate epitope HNK-1. Terayama K, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6093–8

CHEMISTRY

Structure of the HNK-1 carbohydrate epitope on bovine peripheral myelin glycoprotein P0. Voshol H, et al. **J Biol Chem** 1996 Sep 20;271(38):22957–60
L1/HNK-1 carbohydrate- and beta 1 integrin-dependent neural cell adhesion to laminin-1. Hall H, et al. **J Neurochem** 1997 Feb;68(2):544–53

DRUG EFFECTS

Increase in CD57 + CD16-lymphocytes in workers exposed to benzidine and beta-naphthylamine: assessment of natural killer cell subpopulations. Tanigawa T, et al. **Int Arch Occup Environ Health** 1996;69(1):69–72

IMMUNOLOGY

Comparison between two HNK-1-related antibodies immunoreactivity (HNK-1-anti-leu 7 and anti-HNK-1/N-CAM) during rat cephalogenesis. Louryan S, et al. **Eur J Morphol** 1996 Nov;34(4):295–300
Recall response to cytomegalovirus in allograft recipients: mobilization of CD57+, CD28+ cells before expansion of CD57+, CD28- cells within the CD8+ T lymphocyte compartment. Hazzan M, et al. **Transplantation** 1997 Mar 15;63(5):693–8

METABOLISM

HNK-1 epitope in the lens-ciliary zonular region in normal and pseudoexfoliative eyes. Immunohistochemistry and ultrastructure. Qi Y, et al. **Arch Ophthalmol** 1997 May; 115(5):637–44
HNK-1 carbohydrate-mediated cell adhesion to laminin-1 is different from heparin-mediated and sulfatide-mediated cell adhesion. Hall H, et al. **Eur J Biochem** 1997 May 15; 246(1):233–42
Immunohistochemical evidence for increased numbers of 'classic' CD57+ natural killer cells in the endometrium of women suffering spontaneous early pregnancy loss. Vassiliadou N, et al. **Hum Reprod** 1996 Jul;11(7):1569–74
The HNK-1 epitope and the elastic fiber system of the human ciliary body. An immunoelectron microscopic study. Uusitalo M, et al. **Invest Ophthalmol Vis Sci** 1997 Jun; 38(7):1426–33
HNK-1 antigens on uveal and cutaneous melanoma cell lines. Tang NE, et al. **Melanoma Res** 1996 Dec;6(6):411–8

ANTIGENS, CD58

ANALYSIS

Characterization of a soluble form of CD58 in synovial fluid of patients with rheumatoid arthritis (RA). Hoffmann JC, et al. **Clin Exp Immunol** 1996 Jun;104(3):460–6

BIOSYNTHESIS

Comparison of effects of beta-carotene and lycopene supplementation on the expression of functionally associated molecules on human monocytes. Hughes DA, et al. **Biochem Soc Trans** 1997 May;25(2):206S
Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Matsuoka N, et al. **Clin Exp Immunol** 1996 Jun;104(3):501–8
Defective expression of adhesion molecules on human bladder tumour and human tumour cell lines. Nouri AM, et al. **Urol Int** 1996;56(1):6–12

BLOOD

Epidemiologic investigation of serum levels of the soluble forms of CD25, CD54 and CD58, and T cell responsiveness after stimulation via the CD2-dependent pathway in a random sample of the general population. Becker N, et al. **Immunobiology** 1996 Jan;195(1):47–60
Detection of a soluble form of the human adhesion receptor lymphocyte function-associated antigen-3 (LFA-3) in patients with chronic liver disease. Hoffmann JC, et al. **J Hepatol** 1996 Oct;25(4):465–73
Reduced serum levels of a soluble form of the human adhesion receptor CD58 (LFA-3) in patients with inflammatory bowel disease. Hoffmann JC, et al. **Z Gastroenterol** 1996 Sep;34(9):522–7
Circulating ICAM-1 (sCD54) and LFA-3 (sCD58) in chronic hepatitis B--a longitudinal study in patients treated with interferon-alpha. Knolle PA, et al. **Z Gastroenterol** 1997 Jun;35(6):459–67

METABOLISM

The structure and ligand interactions of CD2: implications for T-cell function. Davis SJ, et al. **Immunol Today** 1996 Apr;17(4):177–87 (115 ref.)
Adhesive bond dynamics in contacts between T lymphocytes and glass-supported planar bilayers reconstituted with the immunoglobulin-related adhesion molecule CD58. Dustin ML. **J Biol Chem** 1997 Jun 20;272(25):15782–8
Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Sultan P, et al. **Nat Biotechnol** 1997 Aug;15(8):759–62

PHARMACOLOGY

Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12. Gollob JA, et al. **J Immunol** 1996 Sep 1;157(5):1886–93
The role of B7-1 and LFA-3 in costimulation of CD8+ T cells. Parra E, et al. **J Immunol** 1997 Jan 15;158(2):637–42
Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Meier W, et al. **Ther Immunol** 1995 Jun;2(3):159–71
IL-1, ICAM-1, LFA-3, and hydrocortisone differentially regulate cytokine secretion by human fetal thymic epithelial cells. Shu S, et al. **Thymus** 1996;24(2):89–99

PHYSIOLOGY

CD2-CD58 interaction and the control of T-cell interleukin-12 responsiveness. Adhesion molecules link innate and acquired immunity. Gollob JA, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:71–81
Costimulation by B7-1 and LFA-3 targets distinct nuclear factors that bind to the interleukin-2 promoter: B7-1 negatively regulates LFA-3-induced NF-AT DNA binding. Parra E, et al. **Mol Cell Biol** 1997 Mar; 17(3):1314–23
Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Craigen JL, et al. **Transplantation** 1996 Oct 27;62(8):1102–8

ANTIGENS, CD59

Establishment of a human DAF/HRF20 double transgenic mouse line is not sufficient to suppress hyperacute rejection. Koike C, et al. **Surg Today** 1996;26(12):993–8

ANALYSIS

Complement-regulatory proteins in ovarian malignancies. Bjørge L, et al. **Int J Cancer** 1997 Jan 6;70(1):14–25
Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV-1 particles as a function of complement-mediated virolysis. Nakamura M, et al. **Microbiol Immunol** 1996;40(8):561–7
CD59 expression and complement susceptibility of human neuronal cell line (NTera2). Agoropoulou C, et al.

Neuroreport 1996 Apr 10;7(5):997–1004

X-irradiation does not affect the levels of complement regulatory proteins, CD35 (CR1), CD55 (DAF) and CD59 on concentrated red cells [letter] Fukumori Y, et al. **Vox Sang** 1996;71(4):243–4

BIOSYNTHESIS

Decreased expression of 20–kD homologous restriction factor (HRF20, CD59) on T lymphocytes in Epstein–Barr virus (EBV)–induced infectious mononucleosis. Kawano M, et al. **Clin Exp Immunol** 1997 May;108(2):260–5

Expression of recombinant CD59 with an N–terminal peptide epitope facilitates analysis of residues contributing to its complement–inhibitory function. Zhou Q, et al. **Mol Immunol** 1996 Oct;33(14):1127–34

Analysis of human CD59 tissue expression directed by the CMV–IE–1 promoter in transgenic rats. Charreau B, et al. **Transgenic Res** 1996 Nov;5(6):443–50

Production of transgenic rats for human regulators of complement activation. Charreau B, et al. **Transplant Proc** 1997 May;29(3):1770

Adenovirus–mediated gene transfer to the xenogeneic liver in liver xenotransplantation: the transduction of complement regulatory factor genes (DAF and HRF20). Hayashi S, et al. **Transplant Proc** 1997 Jun;29(4):2211

CHEMISTRY

Structure–function relationships of the complement regulatory protein, CD59. Petranka J, et al. **Blood Cells Mol Dis** 1996;22(3):281–96

Effect of the sugar chain of soluble recombinant CD59 on complement inhibitory activity. Suzuki H, et al. **FEBS Lett** 1996 Dec 16;399(3):272–6

Elimination of potential sites of glycosylation fails to abrogate complement regulatory function of cell surface CD59. Rother RP, et al. **J Biol Chem** 1996 Sep 27;271(39):23842–5

Brain contains HNK–1 immunoreactive O–glycans of the sulfoglucuronyl lactosamine series that terminate in 2–linked or 2,6–linked hexose (mannose). Yuen CT, et al. **J Biol Chem** 1997 Apr 4;272(14):8924–31

GENETICS

Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Jarvis GA, et al. **Int J Cancer** 1997 Jun 11; 71(6):1049–55

Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. Powell MB, et al. **J Immunol** 1997 Feb 15; 158(4):1692–702

Inhibitory effect of double transfection to xenoendothelial cells using both decay acceierating factor and homologous restriction factor 20 genes on complement dependent cytolysis. Hayashi S, et al. **J Surg Res** 1996 Feb 15; 61(1):165–9

Analysis of human CD59 tissue expression directed by the CMV–IE–1 promoter in transgenic rats. Charreau B, et al. **Transgenic Res** 1996 Nov;5(6):443–50

IMMUNOLOGY

Herpesvirus saimiri CD59—baculovirus expression and characterisation of complement inhibitory activity. Bramley JC, et al. **Biochem Soc Trans** 1997 May;25(2):354S

Flow cytometry and immunoblotting analysis of monoclonal antibodies directed to complement regulatory proteins. Blanchard D, et al. **Transfus Clin Biol** 1997;4(1):131–4

Antibodies to complement regulatory proteins. Daniels G, et al. **Transfus Clin Biol** 1997;4(1):127–9

Complement regulatory proteins of human and non–human primates. Moulds JM, et al. **Transfus Clin Biol** 1997; 4(1):121–3

Coordinator's report: complement regulatory proteins. Moulds JM, et al. **Transfus Clin Biol** 1997;4(1):117–9

Human CD46 but not CD59 in transgenic mice protects against hyperacute rejection evoked by ex vivo perfusion with human serum. Marquet RL, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):931–2

METABOLISM

Human complement regulator expression by the normal female reproductive tract. Oglesby TJ, et al. **Anat Rec** 1996 Sep;246(1):78–86

Mapping the regions of the complement inhibitor CD59 responsible for its species selective activity. Yu J, et al. **Biochemistry** 1997 Aug 5;36(31):9423–8

Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay. Astori C, et al. **Br J Haematol** 1997 Jun;97(3):586–8

Binding of human and rat CD59 to the terminal complement complexes. Lehto T, et al. **Immunology** 1997 Jan; 90(1):121–8

Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function. Rushmere NK, et al. **Immunology** 1997 Apr;90(4):640–6

The glycosylation of the complement regulatory protein, human erythrocyte CD59. Rudd PM, et al. **J Biol Chem** 1997 Mar 14;272(11):7229–44

Mapping the active site of CD59. Yu J, et al. **J Exp Med** 1997 Feb 17;185(4):745–53

Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. Gasque P, et al. **J Neuroimmunol** 1996 May;66(1–2):29–40

Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17–1A. Juhl H, et al. **J Surg Oncol** 1997 Mar;64(3):222–30

Unique expression of HRF20 (CD59) in human nervous tissue. Akatsu H, et al. **Microbiol Immunol** 1997;41(4):321–9

Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers. Navenot JM, et al. **Muscle Nerve** 1997 Jan;20(1):92–6

Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction. Tada T, et al. **Virchows Arch** 1997 Apr; 430(4):327–32

PHARMACOLOGY

Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Harris CL, et al. **Clin Exp Immunol** 1997 Feb;107(2):364–71

Protection of porcine endothelial cells from complement–mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1. Analysis in a pig–to–human in vitro model relevant to hyperacute xenograft rejection. Heckl–Ostreicher B, et al. **Transplantation** 1996 Dec 15; 62(11):1693–6

PHYSIOLOGY

The effects of functional suppression of a membrane–bound complement regulatory protein, CD59, in the synovial tissue in rats. Mizuno M, et al. **Arthritis Rheum** 1997 Mar; 40(3):527–33

Inhibition of human complement–dependent cell lysis by bovine aortic endothelial cells transfected with membrane–bound complement–regulatory factor (DAF and HRF20) gene using a retroviral vector. Hayashi S, et al. **Eur Surg Res** 1996;28(6):440–6

Melanoma cells constitutively release an anchor–positive soluble form of protectin (sCD59) that retains functional activities in homologous complement–mediated cytotoxicity. Brasoveanu LI, et al. **J Clin Invest** 1997 Sep 1;100(5):1248–55

Mutational analysis of the active site and antibody epitopes of the complement–inhibitory glycoprotein, CD59. Bodian DL, et al. **J Exp Med** 1997 Feb 3;185(3):507–16

Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol–anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement–mediated destruction. Saifuddin M, et al. **J Gen Virol** 1997 Aug;78 (Pt 8):1907–11

CD59 homologue regulates complement–dependent cytolysis of rat Schwann cells. Sawant–Mane S, et al. **J Neuroimmunol** 1996 Sep;69(1–2):63–71

Connective tissue activating peptide–V and CD59: a molecule in search of a job [editorial] Cabral AR, et al. **J Rheumatol** 1996 Jul;23(7):1126–9

Transfected CD59 protects mesangial cells from injury induced by antibody and complement. Nangaku M, et al. **Kidney Int** 1996 Jul;50(1):257–66

Transgenic pigs expressing human CD59 and decay–accelerating factor produce an intrinsic barrier to complement–mediated damage. Byrne GW, et al. **Transplantation** 1997 Jan 15;63(1):149–55

[Kidney and complement regulatory factors] Matsuo S. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):643–6 (14 ref.) **(Jpn)**

[Complement regulatory membrane factors in experimental animal models] Okada N. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):631–3 (6 ref.) **(Jpn)**

ANTIGENS, CD62E see **E-SELECTIN**

ANTIGENS, CD62L see **L-SELECTIN**

ANTIGENS, CD62P see **P-SELECTIN**

ANTIGENS, CD64 see **RECEPTORS, IGG**

ANTIGENS, CD73 see **5'-NUCLEOTIDASE**

ANTIGENS, CD80

Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta–1b therapy. Genç K, et al. **J Clin Invest** 1997 Jun 1;99(11):2664–71

ADMINISTRATION & DOSAGE

Tumor cells transfected with B7–1 and interleukin–12 cDNA induce protective immunity. Chen PW, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:325–7

Mechanism of the induction of anti–tumor immunity by B7.1 and interleukin–12. Wysocka M, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:429–33

ANALYSIS

Polyreactive antigen–binding B cells in the peripheral circulation are IgD+ and B7–. Chen ZJ, et al. **Eur J Immunol** 1996 Dec;26(12):2916–23

CD80 expression on monocytes in HIV–infected patients. Löw P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Aug 1;15(4):264–8

Expression of B7–1 and B7–2 costimulatory molecules by human gastric epithelial cells: potential role in CD4+ T cell activation during Helicobacter pylori infection. Ye G, et al. **J Clin Invest** 1997 Apr 1;99(7):1628–36

B7–negative versus B7–positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes. Yang G, et al. **J Immunol** 1997 Jan 15; 158(2):851–8

Constitutive expression of costimulatory molecules by human microglia and its relevance to CNS autoimmunity. Dangond F, et al. **J Neuroimmunol** 1997 Jun;76(1–2):132–8

Expression of costimulatory molecules B7–1 and B7–2 in macrophages and granulomas of Crohn's disease: demonstration of cell–to–cell contact with T lymphocytes. Hara J, et al. **Lab Invest** 1997 Aug;77(2):175–84

CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up–regulation of CD80 and CD86 costimulatory molecules. Van den Hove IE, et al. **Leukemia** 1997 Apr;11(4):572–80

Presence of MHC–I and B–7 molecules in rat and human glioma cells expressing antisense IGF–I mRNA. Trojan J, et al. **Neurosci Lett** 1996 Jul 5;212(1):9–12

Appearance of cells expressing CD80 and CD86 costimulatory antigens in the pancreas of nonobese diabetic mice. Sainio–Pöllänen S, et al. **Pancreas** 1996 Nov; 13(4):388–94

BIOSYNTHESIS

In situ expression of B7 and CD28 receptor families in skin lesions of patients with lupus erythematosus. Denfeld RW, et al. **Arthritis Rheum** 1997 May;40(5):814–21

Is the success of BCG tumour immunotherapy due to the induction of co–stimulatory molecules? Alexandroff AB, et al. **Biochem Soc Trans** 1997 May;25(2):201S

Cloning of avian and bovine CD80 using chimeric fusion proteins to detect expression. Parsons KR, et al. **Biochem Soc Trans** 1997 May;25(2):203S

Dual expression of human leukocyte antigen molecules and the B7–1 costimulatory molecule (CD80) on human melanoma cells after particle–mediated gene transfer. Albertini MR, et al. **Cancer Gene Ther** 1996 May–Jun; 3(3):192–201

Activated T hybridomas induce upregulation of B7–1 on bystander B lymphoma cells by a contact–dependent interaction utilizing CD40 ligand. Jones KW, et al. **Cell Immunol** 1996 Nov 25;174(1):42–53

Lack of correlation between rejection of tumor cells co–expressing interleukin–2 and B7.1 and vaccine efficiency. Cayeux S, et al. **Eur J Immunol** 1997 Jul; 27(7):1657–62

Human keratinocytes constitutively express IL–4 receptor molecules and respond to IL–4 with an increase in B7/BB1 expression. Junghans V, et al. **Exp Dermatol** 1996 Dec; 5(6):316–24

Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7–1 and B7–2 and the B7 counter–receptor CTLA–4. Gerstmayer B, et al. **FEBS Lett** 1997 Apr 21;407(1):63–8

Expression of costimulatory molecules B7–1 (CD80) and B7–2 (CD86) on human hepatocellular carcinoma. Tatsumi T, et al. **Hepatology** 1997 May;25(5):1108–14

Transient CD80 expression defect in a patient with variable immunodeficiency and cyclic neutropenia. Moser C, et al. **Int Arch Allergy Immunol** 1997 Jan;112(1):96–9

Tumor–infiltrating dendritic cells are defective in their antigen–presenting function and inducible B7 expression in rats. Chaux P, et al. **Int J Cancer** 1997 Aug 7;72(4):619–24

Transfection of the gene for B7–1 but not B7–2 can induce immunity to murine malignant mesothelioma. Leong CC, et al. **Int J Cancer** 1997 May 2;71(3):476–82

The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. Tsukada N, et al. **J Exp Clin Cancer Res** 1997 Jun;16(2):171–6

Identification of a promoter element that regulates tissue–specific expression of the human CD80 (B7.1) gene. Fong TC, et al. **J Immunol** 1996 Nov 15;157(10):4442–50

Identification of distinct domains in CD40 involved in B7–1 induction or growth inhibition. Goldstein MD, et al. **J Immunol** 1996 Oct 1;157(7):2837–43

IFN–gamma–activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen–specific T cells. Nikcevich KM, et al. **J Immunol** 1997 Jan 15; 158(2):614–21

Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma. Prell RA, et al. **J Immunol** 1997 Mar 15;158(6):2695–703

Role of costimulators in T cell differentiation: studies using antigen–presenting cells lacking expression of CD80 or CD86. Schweitzer AN, et al. **J Immunol** 1997 Mar 15;

158(6):2713–22
Coexpression of B7–1 and antigen blocks tolerance induction to antigen presented by resting B cells. Yuschenkoff VN, et al. **J Immunol** 1996 Sep 1;157(5):1987–95
Manipulation of T cell response to tumors by targeting on costimulatory pathway. Chen L. **Leukemia** 1997 Apr;11 Suppl 3:567–9
Protective and therapeutic immunity against leukemia induced by irradiated B7–1 (CD80)–transduced leukemic cells. Hirano N, et al. **Leukemia** 1997 Apr;11 Suppl 3:577–81
Immunoregulation by B7 and IL–12 gene transfer. Kato K, et al. **Leukemia** 1997 Apr;11 Suppl 3:572–6
Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Hancock WW, et al.
Proc Natl Acad Sci U S A 1996 Nov 26;93(24):13967–72
Efficient infection of a human T–cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector. Sharma S, et al.
Proc Natl Acad Sci U S A 1996 Oct 15;93(21):11842–7
Expression of MHC Class II and B7–1 and B7–2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Ostrand–Rosenberg S, et al. **Tissue Antigens** 1996 May; 47(5):414–21

BLOOD

Expression of CD80 (B7/BB–1) and CD28 in human white blood cells treated with urocanic acid. Laihia JK, et al. **Arch Dermatol Res** 1996 Sep;288(10):570–4
Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients [see comments] Folzenlogen D, et al.
Clin Immunol Immunopathol 1997 Jun;83(3):199–204. Comment in: Clin Immunol Immunopathol 1997 Jun;83(3):195–8.
Anomalous expression of costimulatory molecules B7–1, B7–2 and CD28 in primary biliary cirrhosis. Spengler U, et al. **J Hepatol** 1997 Jan;26(1):31–6

CEREBROSPINAL FLUID

Increased expression of B7–1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease. Svenningsson A, et al. **J Neuroimmunol** 1997 May;75(1–2):59–68

CHEMISTRY

Cloning of avian and bovine CD80 using chimeric fusion proteins to detect expression. Parsons KR, et al.
Biochem Soc Trans 1997 May;25(2):203S

DRUG EFFECTS

BCL–2 inhibits B7–induced MHC–unrestricted cytolysis mediated by a human NK cell line. Sun LX, et al.
Immunol Invest 1996 Jul;25(4):307–19
Differential effect of the immunomodulator AS101 on B7–1 and B7–2 costimulatory molecules: role in the antitumoral effects of AS101. Kalechman Y, et al. **J Immunol** 1996 Jul 15;157(2):589–97

GENETICS

Expressions of very late antigen–6 and vitronectin receptor, and their interactions to laminin and vitronectin during tonsillar B–cell activation. Ohguro S, et al.
Auris Nasus Larynx 1996;23:111–20
Increased immunogenicity of tumors bearing mutant p53 and P1A epitopes after transduction of B7–1 via recombinant adenovirus. Lee CT, et al. **Cancer Gene Ther** 1996 Jul–Aug; 3(4):238–44
Induction and maintenance of T–cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7–1 and the capacity to upregulate class II major histocompatibility complex expression. Leong C, et al. **Cancer Gene Ther** 1996 Sep–Oct;3(5):321–30
Nonreplicating recombinant vaccinia virus encoding human B–7 molecules elicits effective costimulation of naive and memory CD4+ T lymphocytes in vitro. Marti WR, et al. **Cell Immunol** 1997 Aug 1;179(2):146–52
Construction of adenoviral and retroviral vectors coexpressing the genes encoding the hepatitis B surface antigen and B7–1 protein. He XS, et al. **Gene** 1996 Oct 10;175(1–2):121–5
Isolation and promoter mapping of the gene encoding murine co–stimulatory factor B7–1. Zhang H, et al. **Gene** 1996 Dec 12;183(1–2):1–6
Selected strategies to augment polynucleotide immunization. Conry RM, et al. **Gene Ther** 1996 Jan;3(1):67–74
Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus–mediated gene transfer of B7.1. Hirst WJ, et al. **Gene Ther** 1997 Jul; 4(7):691–9
Gene transfer of the costimulatory molecules B7–1 and B7–2 into human multiple myeloma cells by recombinant adeno–associated virus enhances the cytolytic T cell response. Wendtner CM, et al. **Gene Ther** 1997 Jul; 4(7):726–35
Retrovirus–mediated gene transfer of B7–1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one. Heuer JG, et al.
Hum Gene Ther 1996 Nov 10;7(17):2059–68
Primary T–cell responses induced by B7–transfected keratinocytes [letter] Otten HG, et al. **Immunol Today** 1996 Jun;17(6):292
Characterization of rat CD80 and CD86 by molecular cloning and mAb. Maeda K, et al. **Int Immunol** 1997 Jul; 9(7):993–1000
Differential function of CD80– and CD86–transfected human melanoma cells in the presence of IL–12 and IFN–gamma. Rudy W, et al. **Int Immunol** 1997 Jun;9(6):853–60
B7.1 gene transduction of human renal–cell–carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. Bain C, et al.
Int J Cancer 1996 Sep 17;67(6):769–76
B7–1–transfected tumor vaccine counteracts chemotherapy–induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells. Hayakawa M, et al. **Int J Cancer** 1997 Jun 11; 71(6):1091–102
Influence of gene–modified (IL–7, IL–4, and B7) tumor cell vaccines on tumor antigen presentation. Cayeux S, et al. **J Immunol** 1997 Mar 15;158(6):2834–41
Identification of a promoter element that regulates tissue–specific expression of the human CD80 (B7.1) gene. Fong TC, et al. **J Immunol** 1996 Nov 15;157(10):4442–50
Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma. Prell RA, et al. **J Immunol** 1997 Mar 15;158(6):2695–703
The costimulatory genes Cd80 and Cd86 are linked on mouse chromosome 16 and human chromosome 3. Reeves RH, et al. **Mamm Genome** 1997 Aug;8(8):581–2
Induction of antigen–specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte–macrophage colony–stimulating factor and B7–1. Büeler H, et al.
Mol Med 1996 Sep;2(5):545–55

IMMUNOLOGY

Monocytes in HIV type 1–infected individuals lose expression of costimulatory B7 molecules and acquire cytotoxic activity. Dudhane A, et al.
AIDS Res Hum Retroviruses 1996 Jul 1;12(10):885–92
Differential regulation of human, antigen–specific Th1 and Th2 responses by the B–7 homologues, CD80 and CD86. Bashian GG, et al. **Am J Respir Cell Mol Biol** 1997 Aug; 17(2):235–42
The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T–cell line with potent in vivo graft–versus–leukemia properties. Boyer MW, et al. **Blood** 1997 May 1;89(9):3477–85
CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment.
Dunussi–Joannopoulos K, et al. **Blood** 1997 Apr 15; 89(8):2915–24
B7–mediated costimulation and the immune response. Schultze J, et al. **Blood Rev** 1996 Jun;10(2):111–27 (107 ref.)
Blockade of costimulatory molecules B7–1 (CD80) and B7–2 (CD86) down–regulates induction of contact sensitivity by haptenated epidermal cells. Katayama I, et al.
Br J Dermatol 1997 Jun;136(6):846–52
Immune responsiveness to a murine mammary carcinoma modified to express B7–1, interleukin–12, or GM–CSF. Aruga E, et al. **Cancer Gene Ther** 1997 May–Jun; 4(3):157–66
High concentrations of antigenic ligand activate and do not tolerize naive CD4 T cells in the absence of CD28/B7 costimulation. Teh HS, et al. **Cell Immunol** 1997 Jul 10; 179(1):74–83
Elevated in vivo expression of the costimulatory molecule B7–BB1 (CD80) on antigen presenting cells from a patient with SLE. Kovacs B, et al. **Clin Exp Rheumatol** 1996 Nov–Dec;14(6):695–7
Interleukin 12 and B7/CD28 interaction synergistically upregulate interleukin 10 production by human T cells. Peng X, et al. **Cytokine** 1997 Jul;9(7):499–506
Effect of CD80 and CD86 blockade and anti–interleukin–12 treatment on mouse acute graft–versus–host disease. Saito K, et al. **Eur J Immunol** 1996 Dec;26(12):3098–106
H. polygyrus: B7–independence of the secondary type 2 response. Gause WC, et al. **Exp Parasitol** 1996 Nov; 84(2):264–73
Expression of co–stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Chong H, et al. **Hum Gene Ther** 1996 Sep 10;7(14):1771–9
Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin–2 induce CD4+–mediated rejection of established tumors. Gaken JA, et al. **Hum Gene Ther** 1997 Mar 1;8(4):477–88
Retrovirus–mediated gene transfer of B7–1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one. Heuer JG, et al.
Hum Gene Ther 1996 Nov 10;7(17):2059–68
Protective and therapeutic immunity against leukemia induced by irradiated B7–1 (CD80)–transduced leukemic cells. Hirano N, et al. **Hum Gene Ther** 1997 Jul 20; 8(11):1375–84
Triggering of natural killer cells by the costimulatory molecule CD80 (B7–1) Chambers BJ, et al. **Immunity** 1996 Oct;5(4):311–7
Memory alloreactive cytotoxic T cells do not require costimulation for activation in vitro. Flynn K, et al.
Immunol Cell Biol 1996 Oct;74(5):413–20
CD28/B7 regulation of autoimmune diabetes. Herold KG, et al. **Immunol Res** 1997 Feb;16(1):71–84 (78 ref.)
Enhancement of antigen–presenting ability of B lymphoma cells by partial inhibition of protein synthesis through inducing B7–1 expression. Aoi T, et al. **Immunology** 1997 Jun;91(2):212–8
Costimulation regulates the kinetics of interleukin–2 response to bacterial superantigens. Muraille E, et al.
Immunology 1996 Oct;89(2):245–9
Mitogenic stimulation of T cells reveals differing contributions for B7–1 (CD80) and B7–2 (CD86) costimulation. Perrin PJ, et al. **Immunology** 1997 Apr; 90(4):534–42
Either B7–1 or B7–2 is required for Listeria monocytogenes–specific production of gamma interferon and interleukin–2. Zhan Y, et al. **Infect Immun** 1996 Dec; 64(12):5439–41
Induction of B cell apoptosis by co–cross–linking CD23 and sIg involves aberrant regulation of c–myc and is inhibited by bcl–2. Campbell KA, et al. **Int Immunol** 1997 Aug; 9(8):1131–40
Characterization of rat CD80 and CD86 by molecular cloning and mAb. Maeda K, et al. **Int Immunol** 1997 Jul; 9(7):993–1000
The differential role of CD86 and CD80 co–stimulatory molecules in the induction and the effector phases of contact hypersensitivity. Nuriya S, et al. **Int Immunol** 1996 Jun;8(6):917–26
Differential requirements for co–stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens. Yi–qun Z, et al. **Int Immunol** 1996 Jan;8(1):37–44
B7–CD28 interaction is a late acting co–stimulatory signal for human T cell responses. Zhang YQ, et al.
Int Immunol 1997 Aug;9(8):1095–102
Distinct costimulatory molecules are required for the induction of effector and memory cytotoxic T lymphocytes. Liu Y, et al. **J Exp Med** 1997 Jan 20; 185(2):251–62
CTLA–4–B7 interaction is sufficient to costimulate T cell clonal expansion. Wu Y, et al. **J Exp Med** 1997 Apr 7; 185(7):1327–35
Non–replicating recombinant vaccinia virus encoding murine B–7 molecules elicits effective costimulation of naive CD4+ splenocytes in vitro. Oertli D, et al.
J Gen Virol 1996 Dec;77 (Pt 12):3121–5
Infusion of anti–B7.1 (CD80) and anti–B7.2 (CD86) monoclonal antibodies inhibits murine graft–versus–host disease lethality in part via direct effects on CD4+ and CD8+ T cells. Blazar BR, et al. **J Immunol** 1996 Oct 15; 157(8):3250–9
CD28/B7 interactions are required for sustaining the graft–versus–leukemia effect of delayed post–bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. Blazar BR, et al.
J Immunol 1997 Oct 1;159(7):3460–73
Long–term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. Daikh DI, et al. **J Immunol** 1997 Oct 1; 159(7):3104–8
Blocking the CD28–B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL–4. Lakkis FG, et al. **J Immunol** 1997 Mar 1; 158(5):2443–8
Regulation of superantigen–induced T cell activation in the absence and the presence of MHC class II. Lando PA, et al. **J Immunol** 1996 Oct 1;157(7):2857–63
A mechanism for selective recruitment of CD8 T cells into B7–1–transfected plasmacytoma: role of macrophage–inflammatory protein 1alpha. Maric M, et al.
J Immunol 1997 Jul 1;159(1):360–8
B7 costimulation and autoantigen specificity enable B cells to activate autoreactive T cells. Roth R, et al.
J Immunol 1996 Oct 1;157(7):2924–31
Activation of human T cell lymphotropic virus type I–infected T cells is independent of B7 costimulation. Scholz C, et al. **J Immunol** 1996 Oct 1;157(7):2932–8
CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. Sperling AI, et al. **J Immunol** 1996 Nov 1;157(9):3909–17
MHC class I expression on dendritic cells is sufficient to sensitize for transplantation immunity. Lenz P, et al.
J Invest Dermatol 1996 Dec;107(6):844–8
Antigen presentation by autoreactive proteolipid protein peptide–specific T cell clones from chronic progressive multiple sclerosis patients: roles of co–stimulatory B7 molecules and IL–12. Correale J, et al.
J Neuroimmunol 1997 Jan;72(1):27–43
Role of the CD28:B7 costimulatory interaction in alloimmune responses. Akalin E, et al. **Kidney Int Suppl** 1997 Mar; 58:S8–10 (21 ref.)
Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. Reiser H, et al.
N Engl J Med 1996 Oct 31;335(18):1369–77 (69 ref.)
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Kwon ED, et al.
Proc Natl Acad Sci U S A 1997 Jul 22;94(15):8099–103
Importance of the CD28/B7 costimulatory pathway in the

development of chronic ductopenic rejection in a new model of orthotopic rat liver allotransplantation. Mark W, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1029

Prevention of primary T-cell responses by immunotoxins directed against CD80 and CD86. Otten HG, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1034-5

Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Fu F, et al. **Transplantation** 1996 Sep 15;62(5):659-65

METABOLISM

Role of the CD28-B7 costimulatory pathways in T cell-dependent B cell responses. Hathcock KS, et al. **Adv Immunol** 1996;62:131-66 (152 ref.)

Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Lane P. **Ann N Y Acad Sci** 1997 Apr 5;815:392-400 (40 ref.)

Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. de Boer OJ, et al. **Atherosclerosis** 1997 Sep;133(2):227-34

Cultured human decidual stromal cells express B7-1 (CD80) and B7-2 (CD86) and stimulate allogeneic T cells. Olivares EG, et al. **Biol Reprod** 1997 Sep;57(3):609-15

Interleukin-1 but not tumour necrosis factor alpha synergistically upregulates the granulocyte-macrophage colony-stimulating factor-induced B7-1 expression of murine Langerhans cells. Furue M, et al. **Br J Dermatol** 1996 Aug;135(2):194-8

Interferon-gamma differentially regulates CD80 (B7-1) and CD86 (B7-2/B70) expression on human Langerhans cells. Yokozeki H, et al. **Br J Dermatol** 1997 Jun;136(6):831-7

Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Ramesh R, et al. **Cancer Gene Ther** 1996 Nov-Dec;3(6):373-84

The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: its regulation by interferon gamma and interleukin-10. Li J, et al. **Cancer Immunol Immunother** 1996 Dec;43(4):213-9

B7/BB-1 expression and hepatitis activity in liver tissues of patients with chronic hepatitis C. Mochizuki K, et al. **Hepatology** 1997 Mar;25(3):713-8

Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. Greene JL, et al. **J Biol Chem** 1996 Oct 25;271(43):26762-71

Lack of B7-1/BB1 and B7-2/B70 expression on thyrocytes of patients with Graves' disease. Delivery of costimulatory signals from bystander professional antigen-presenting cells. Matsuoka N, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4137-43

CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. van der Merwe PA, et al. **J Exp Med** 1997 Feb 3;185(3):393-403

Tissue immunogenicity: the role of MHC antigen and the lymphocyte costimulator B7-1. Coulombe M, et al. **J Immunol** 1996 Dec 1;157(11):4790-5

Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation. Doty RT, et al. **J Immunol** 1996 Oct 15;157(8):3270-9

Phosphatidylinositol 3 kinase activity is not essential for B7-1-mediated costimulation of proliferation or development of cytotoxicity in murine T cells. Ni HT, et al. **J Immunol** 1996 Sep 15;157(6):2243-6

Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. Pechhold K, et al. **J Immunol** 1997 May 15;158(10):4921-9

Analysis of B7-1 and B7-2 costimulatory ligands in cultured mouse microglia: upregulation by interferon-gamma and lipopolysaccharide and downregulation by interleukin-10, prostaglandin E2 and cyclic AMP-elevating agents. Menéndez Iglesias B, et al. **J Neuroimmunol** 1997 Jan; 72(1):83-93

Allogeneic lymphocyte responses to B7-1 expressing human cancer cell lines. Dessureault S, et al. **J Surg Res** 1996 Jul 15;64(1):42-8

Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible antitumor immunity? Ohtani H, et al. **Lab Invest** 1997 Sep;77(3):231-41

Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28 [letter] Metzler WJ, et al. **Nat Struct Biol** 1997 Jul;4(7):527-31

PHARMACOLOGY

The generation of memory antigen-specific cytotoxic T cell responses by CD28/CD80 interactions in the absence of antigen. Flynn K, et al. **Eur J Immunol** 1997 Feb; 27(2):456-62

BCL-2 inhibits B7-induced MHC-unrestricted cytolysis mediated by a human NK cell line. Sun LX, et al. **Immunol Invest** 1996 Jul;25(4):307-19

Transmembrane signaling through CD80 (B7-1) induces growth arrest and cell spreading of human B lymphocytes accompanied by protein tyrosine phosphorylation. Hirokawa M, et al. **Immunol Lett** 1996 Apr;50(1-2):95-8

CD28-B7 interactions function to co-stimulate clonal deletion of double-positive thymocytes. Amsen D, et al. **Int Immunol** 1996 Dec;8(12):1927-36

CD28 co-stimulatory regimes differ in their dependence on phosphatidylinositol 3-kinase: common co-signals induced by CD80 and CD86. Cefai D, et al. **Int Immunol** 1996 Oct; 8(10):1609-16

CD80 (B7.1) and CD54 (intracellular adhesion molecule-1) induce target cell susceptibility to promiscuous cytotoxic T cell lysis. Nishio M, et al. **J Immunol** 1996 Nov 15; 157(10):4347-53

The role of B7-1 and LFA-3 in costimulation of CD8+ T cells. Parra E, et al. **J Immunol** 1997 Jan 15;158(2):637-42

Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD80) costimulation. Wang YC, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jan;19(1):1-8

CD40-CD40L interactions provide "third-party" costimulation for T cell response against B7-1-transfected human breast tumor cells. Pericle F, et al. **J Leukoc Biol** 1997 Feb;61(2):201-8

CD28-CD80/CD86 interactions in testicular immunoregulation. Sainio-Pöllänen S, et al. **J Reprod Immunol** 1996 Oct;31(3):145-63

PHYSIOLOGY

The role of adhesion and costimulation molecules in graft-versus-host disease. Schlegel PG. **Acta Haematol** 1997;97(1-2):105-17 (191 ref.)

CD28/B7 system of T cell costimulation. Lenschow DJ, et al. **Annu Rev Immunol** 1996;14:233-58 (117 ref.)

Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism. Mokyr MB, et al. **Cell Immunol** 1997 Jun 15;178(2):152-61

Molecular cloning and comparative analysis of the rhesus macaque costimulatory molecules CD80 (B7-1) and CD86 (B7-2). Zhang D, et al. **Cell Immunol** 1997 Apr 10; 177(1):9-17

Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy [editorial; comment] Sfikakis PP, et al. **Clin Immunol Immunopathol** 1997 Jun; 83(3):195-8. Comment on: Clin Immunol Immunopathol 1997 Jun;83(3):199-204.

B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells. Deeths MJ, et al. **Eur J Immunol** 1997 Mar; 27(3):598-608

Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes. Frandji P, et al. **Eur J Immunol** 1996 Oct;26(10):2517-28

Blockade of CD28/B7 co-stimulation by mCTLA4-Hgamma1 inhibits antigen-induced lung eosinophilia but not Th2 cell development or recruitment in the lung. Harris N, et al. **Eur J Immunol** 1997 Jan; 27(1):155-61

Antigen presentation by interferon-gamma-treated thyroid follicular cells inhibits interleukin-2 (IL-2) and supports IL-4 production by B7-dependent human T cells. Lombardi G, et al. **Eur J Immunol** 1997 Jan;27(1):62-71

Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Webb LM, et al. **Eur J Immunol** 1996 Oct;26(10):2320-8

B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Borriello F, et al. **Immunity** 1997 Mar; 6(3):303-13

B7-1 and B7-2 monoclonal antibodies modulate the severity of murine Lyme arthritis. Anguita J, et al. **Infect Immun** 1997 Aug;65(8):3037-41

The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. Takada M, et al. **J Clin Invest** 1997 Sep 1;100(5):1199-203

CD80 costimulation is essential for the induction of airway eosinophilia. Harris N, et al. **J Exp Med** 1997 Jan 6; 185(1):177-82

Weak peptide agonists reveal functional differences in B7-1 and B7-2 costimulation of human T cell clones. Anderson DE, et al. **J Immunol** 1997 Aug 15;159(4):1669-75

Do effector and memory T helper cells also need B7 ligand costimulatory signals? Gause WC, et al. **J Immunol** 1997 Aug 1;159(3):1055-8 (49 ref.)

Effects of blocking B7-1 and B7-2 interactions during a type 2 in vivo immune response. Greenwald RJ, et al. **J Immunol** 1997 May 1;158(9):4088-96

CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. Herold KC, et al. **J Immunol** 1997 Jan 15;158(2):984-91

The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. Hunter CA, et al. **J Immunol** 1997 Mar 1; 158(5):2285-93

The role of the B7-1a molecule, an alternatively spliced form of murine B7-1 (CD80), on T cell activation. Inobe M, et al. **J Immunol** 1996 Jul 15;157(2):582-8

B7-CD28/CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens. Keane-Myers A, et al. **J Immunol** 1997 Mar 1;158(5):2042-9

Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. Lu L, et al. **J Immunol** 1997 Jun 15; 158(12):5676-84

Phosphatidylinositol 3 kinase activity is not essential for B7-1-mediated costimulation of proliferation or development of cytotoxicity in murine T cells. Ni HT, et al. **J Immunol** 1996 Sep 15;157(6):2243-6

CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses. Onodera K, et al. **J Immunol** 1997 Aug 15;159(4):1711-7

CD40 is a functional activation antigen and B7-independent T cell costimulatory molecule on normal human lung fibroblasts. Sempowski GD, et al. **J Immunol** 1997 May 15;158(10):4670-7

CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. Vella AT, et al. **J Immunol** 1997 May 15;158(10):4714-20

B7-blocking agents, alone or in combination with cyclosporin A, induce antigen-specific anergy of human memory T cells. Yi-qun Z, et al. **J Immunol** 1997 May 15; 158(10):4734-40

The role of donor and recipient B7-1 (CD80) in allograft rejection. Zheng XX, et al. **J Immunol** 1997 Aug 1; 159(3):1169-73

Induction of antigen-presenting capacity in tumor cells upon infection with non-replicating recombinant vaccinia virus encoding murine MHC class II and costimulatory molecules. Marti WR, et al. **J Immunol Methods** 1997 Jan 15;200(1-2):191-8

B7-1(CD80)-transfected human glioma cells and interleukin-12 directly stimulate allogeneic CD8+ T cells. Komata T, et al. **J Immunother** 1997 Jul;20(4):256-64

The CD28-B7 costimulatory pathway and its role in autoimmune disease. Daikh D, et al. **J Leukoc Biol** 1997 Aug;62(2):156-62 (80 ref.)

Costimulation by B7-1 and LFA-3 targets distinct nuclear factors that bind to the interleukin-2 promoter: B7-1 negatively regulates LFA-3-induced NF-AT DNA binding. Parra E, et al. **Mol Cell Biol** 1997 Mar; 17(3):1314-23

Blocking of the B7-CD28 pathway increases apoptosis induced in activated T cells by in vitro-generated CD95L (FasL) positive dendritic cells. Lu L, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1094-5

Inhibition of CD28-B7 T-cell costimulatory activation pathway affects intragraft cytokine and growth factor expression in chronic renal allograft rejection. Nadeau K, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1038

Analysis of the B7 costimulatory pathway in allograft rejection. Pearson TC, et al. **Transplantation** 1997 May 27; 63(10):1463-9

RADIATION EFFECTS

Up-regulation of human epidermal Langerhans' cell B7-1 and B7-2 co-stimulatory molecules in vivo by solar-simulating irradiation. Laihia JK, et al. **Eur J Immunol** 1997 Apr;27(4):984-9

ANTIGENS, CD90 see **ANTIGENS, THY-1**

ANTIGENS, CD95

Fas/APO-1-mediated apoptosis of human renal cell carcinoma. Nonomura N, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):945-51

Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils. Kasahara Y, et al. **Blood** 1997 Mar 1; 89(5):1748-53

Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells. Komada Y, et al. **Br J Haematol** 1997 Jan;96(1):147-57

Apoptosis of Fashigh CD4+ synovial T cells by borrelia-reactive Fas-ligand(high) gamma delta T cells in Lyme arthritis. Vincent MS, et al. **J Exp Med** 1996 Dec 1;184(6):2109-17

The Fas counterattack: a molecular mechanism of tumor immune privilege. O'Connell J, et al. **Mol Med** 1997 May; 3(5):294-300 (75 ref.)

Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-1) or perforin-mediated cytotoxicity. Renggli J, et al. **Parasite Immunol** 1997 Mar;19(3):145-8

[Expression of Fas/Fas ligand and proto-oncogenes in rheumatoid synovial tissues] Asahara H, et al. **Nippon Rinsho** 1996 Jul;54(7):1960-4 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Fas antigen is expressed in human diseased muscles, but does not link to apoptosis] Inukai A, et al. **Nippon Rinsho** 1996 Jul;54(7):1992-6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of Fas and Fas-ligand in epithelium of ulcerative colitis] Iwamoto M, et al. **Nippon Rinsho** 1996 Jul; 54(7):1970-4 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Metalloproteinase-mediated release of human fas ligand] Kayagaki N, et al. **Nippon Rinsho** 1996 Jul;54(7):1747-52 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Programmed thymic T cell death and negative selection via Fas and TCR/CD3 complex] Kishi S. **Nippon Rinsho** 1996 Jul;54(7):1760-7 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The molecular structure and biological significance of soluble Fas] Kobayashi S, et al. **Nippon Rinsho** 1996 Jul; 54(7):1741-6 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular biology of Fas antigen-Fas ligand system] Mita

E, et al. **Nippon Rinsho** 1996 Jul;54(7):1736–40 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Involvement of Fas and Fas ligand in case of human fulminant hepatitis] Ryo K, et al. **Nippon Rinsho** 1996 Jul; 54(7):1965–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Fas antigen (CD95) expressions and apoptosis of neoplastic cells from various lymphoid malignancies including adult T-cell leukemia/lymphoma] Sasao T, et al. **Nippon Rinsho** 1996 Jul;54(7):1986–91 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of apoptosis-related gene products in human brain tumors and apoptosis-inducing therapy] Tabuchi K, et al. **Nippon Rinsho** 1996 Jul;54(7):1922–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome. Baiocchi RA, et al. **Blood** 1997 Sep 1;90(5):1737–46

Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Vollmers HP, et al. **Cancer** 1997 Feb 1;79(3):433–40

Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Okazaki M, et al. **Dig Dis Sci** 1996 Dec;41(12):2453–8

Frequent expression of Fas in gonadotropin-releasing hormone receptor-bearing tumors. Imai A, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jul;74(1):73–8

Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis. Molica S, et al. **Haematologica** 1996 Jul–Aug;81(4):302–9

Fas antigen expression in liver tissues of patients with chronic hepatitis B. Mochizuki K, et al. **J Hepatol** 1996 Jan; 24(1):1–7

Increased serum soluble Fas (sFas) concentrations in HCV-positive patients with liver cirrhosis [letter] Seishima M, et al. **J Hepatol** 1997 Aug;27(2):424–5

Increased acute-phase response and renal amyloidosis in aged CD2-fas-transgenic mice. Hsu HC, et al. **J Immunol** 1997 Jun 15;158(12):5988–96

Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. Inoue A, et al. **J Neuroimmunol** 1997 May;75(1–2):141–6

Immunohistochemical detection of Fas antigen in oral epithelia. Muraki Y, et al. **J Oral Pathol Med** 1997 Feb; 26(2):57–62

Novel mechanisms of selective apoptosis in synovial T cells of patients with rheumatoid arthritis. Hoa TT, et al. **J Rheumatol** 1996 Aug;23(8):1332–7

Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts. Matsumoto S, et al. **J Rheumatol** 1996 Aug;23(8):1345–52

Expression of Fas antigen and its mediation of apoptosis in human gastric cancer cell lines. Hayashi H, et al. **Jpn J Cancer Res** 1997 Jan;88(1):49–55

Activation of the CD95 system increases with disease progression in human immunodeficiency virus type 1-infected children and adolescents. Böhler T, et al. **Pediatr Infect Dis J** 1997 Aug;16(8):754–9

[Apoptosis and myopathies] Inukai A, et al. **Rinsho Byori** 1997 Jul;45(7):621–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

The Fas receptor in HIV infection: expression on peripheral blood lymphocytes and role in the depletion of T cells. Gehri R, et al. **AIDS** 1996 Jan;10(1):9–16

Fas expression in pulmonary alveolar type II cells. Fine A, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):L64–71

Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Hagimoto N, et al. **Am J Respir Cell Mol Biol** 1997 Jan;16(1):91–101

Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Cantwell MJ, et al. **Arthritis Rheum** 1997 Sep;40(9):1644–52

Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Hasunuma T, et al. **Arthritis Rheum** 1997 Jan;40(1):80–6

Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Kong L, et al. **Arthritis Rheum** 1997 Jan;40(1):87–97

A hammerhead ribozyme that cleaves perforin and fas-ligand RNAs in vitro. Du Z, et al. **Biochem Biophys Res Commun** 1996 Sep 24;226(3):595–600

Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody. Moulian N, et al. **Blood** 1997 May 1;89(9):3287–95

In vitro expansion of hematopoietic progenitor cells induces functional expression of Fas antigen (CD95). Takenaka K, et al. **Blood** 1996 Oct 15;88(8):2871–7

Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: a preliminary report. Hellquist HB, et al. **Br J Cancer** 1997;76(2):175–9

CD4+ T cells reactivated with superantigen are both more sensitive to FasL-mediated killing and express a higher level of FasL. Wang JKM, et al. **Cell Immunol** 1997 Aug 1;179(2):153–64

Expression of ductal Fas antigen in sialoadenitis of Sjögren's syndrome [see comments] Matsumura R, et al. **Clin Exp Rheumatol** 1996 May–Jun;14(3):309–11. Comment in: Clin Exp Rheumatol 1996 May–Jun;14(3):231–4.

Mouse islet cell lysis mediated by interleukin-1-induced Fas. Yamada K, et al. **Diabetologia** 1996 Nov;39(11):1306–12

Change in FAS antigen expression during differentiation of CD34-positive cells isolated from peripheral blood stem cell harvest samples [letter] Yamane T, et al. **Eur J Haematol** 1997 Apr;58(4):289–90

Activation and activation-induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO-1) ligand expression and function. Daniel PT, et al. **Eur J Immunol** 1997 Apr;27(4):1029–34

Thiols prevent Fas (CD95)-mediated T cell apoptosis by down-regulating membrane Fas expression. Delneste Y, et al. **Eur J Immunol** 1996 Dec;26(12):2981–8

Expression of Fas-Fas ligand system associated with atresia through apoptosis in murine ovary. Mori T, et al. **Horm Res** 1997;48 Suppl 3:11–9

Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Muruve DA, et al. **Hum Gene Ther** 1997 May 20;8(8):955–63

Fas expression and apoptosis in human B cells. Schattner E, et al. **Immunol Res** 1996;15(3):246–57 (82 ref.)

Expression of Fas and apoptosis of a Hodgkin's disease cell line (HD–70) [letter] Kubonishi I, et al. **Int J Hematol** 1997 Apr;65(3):305–7

Expression of the apoptosis-mediator Fas is enhanced by dysfunctional mitochondria. Asoh S, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):600–7

Expression of Fas and anti-Fas-mediated apoptosis in human hepatocellular carcinoma cell lines. Yano H, et al. **J Hepatol** 1996 Oct;25(4):454–64

Transcription factor Egr-1 activity down-regulates Fas and CD23 expression in B cells. Dinkel A, et al. **J Immunol** 1997 Sep 15;159(6):2678–84

Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. Oyaizu N, et al. **J Immunol** 1997 Mar 1;158(5):2456–63

Viral regulation of CD95 expression and apoptosis in T lymphocytes. Sieg S, et al. **J Immunol** 1997 Aug 1; 159(3):1192–9

Expression of Fas and Fas ligand in renal grafts with acute and chronic rejection in the rat model. Wang J, et al. **J Interferon Cytokine Res** 1997 Jun;17(6):369–73

Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Bouscary D, et al. **Leukemia** 1997 Jun;11(6):839–45

2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Yue TL, et al. **Mol Pharmacol** 1997 Jun;51(6):951–62

Immunotolerance induced by intratesticular antigen priming: expression of TGF-beta, Fas and Fas ligand. Li H, et al. **Ocul Immunol Inflamm** 1997 Jun;5(2):75–84

Fas antigen expression and its relationship with apoptosis in transplanted kidney. Kato S, et al. **Pathol Int** 1997 Apr; 47(4):230–7

Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewis(y) and p53) in human cholangiocarcinomas and hepatocellular carcinomas. Terada T, et al. **Pathol Int** 1996 Oct;46(10):764–70

Induction of lymphocyte apoptosis by a novel immunosuppressant FTY720: relation with Fas, Bcl-2 and Bax expression. Li XK, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1267–8

Fas antigen expression and apoptosis in kidney allografts. Matsuno T, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):177–8

Decreased Fas antigen expression of cultured hepatocytes with FK 506. Yokoyama I, et al. **Transplant Proc** 1996 Dec;28(6):3189–90

Molecular executors of cell death—differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Sharma VK, et al. **Transplantation** 1996 Dec 27; 62(12):1860–6

BLOOD

Serum sAPO-1/Fas levels in multiple sclerosis. Bansil S, et al. **Acta Neurol Scand** 1997 Apr;95(4):208–10

Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. Rizzardini G, et al. **AIDS** 1996 Nov; 10(13):1535–42

Serum levels of soluble form of Fas molecule in patients with congestive heart failure. Okuyama M, et al. **Am J Cardiol** 1997 Jun 15;79(12):1698–701

Use of sensitive assays to detect soluble Fas in patients with systemic lupus erythematosus: comment on the article by Knipping et al and the article by Goel et al [letter; comment] Mountz JD, et al. **Arthritis Rheum** 1996 Sep; 39(9):1611–2. Comment on: Arthritis Rheum 1995 Dec;38(12):1735–7. Comment on: Arthritis Rheum 1995 Dec;38(12):1738–43.

Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Nozawa K, et al. **Arthritis Rheum** 1997 Jun;40(6):1126–9

Elevated levels of soluble Fas in systemic lupus erythematosus: comment on the article by Knipping et al [letter; comment] Okubo M, et al. **Arthritis Rheum** 1996 Sep;39(9):1612–4. Comment on: Arthritis Rheum 1995 Dec;38(12):1735–7.

Elevated serum levels of soluble Fas/APO-1 in human immunodeficiency virus-infected individuals [letter] Fadeel B, et al. **Blood** 1996 Dec 15;88(12):4727–30

Highly sensitive ELISA for soluble Fas in serum: increased soluble Fas in the elderly. Seishima M, et al. **Clin Chem** 1996 Dec;42(12):1911–4

Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Jodo S, et al. **Clin Exp Immunol** 1997 Jan;107(1):89–95

Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines. Sugahara K, et al. **Int J Cancer** 1997 Jul 3;72(1):128–32

Increased levels of soluble Fas antigen in the plasma of the patients with refractory anemia [letter] Shinohara K, et al. **Int J Hematol** 1997 Jun;65(4):413–4

Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases. Kamihira S, et al. **Intern Med** 1997 Mar;36(3):166–70

Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status. Jiang JD, et al. **J Clin Immunol** 1997 Mar;17(2):185–92

Soluble Fas molecule in the serum of patients with systemic lupus erythematosus. Tokano Y, et al. **J Clin Immunol** 1996 Sep;16(5):261–5

Fas/Apo-1 (CD95)-mediated and CD95-independent apoptosis of malignant plasma cells. Hata H, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):35–42 (21 ref.)

Fas antigen (CD95) and hematopoietic progenitor cells. Nagafuji K, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):43–56 (49 ref.)

Susceptibility to apoptosis of T lymphocytes from elderly humans is associated with increased in vivo expression of functional Fas receptors. Phelouzat MA, et al. **Mech Ageing Dev** 1997 Jun;96(1–3):35–46

CEREBROSPINAL FLUID

Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. Inoue A, et al. **J Neuroimmunol** 1997 May;75(1–2):141–6

CHEMISTRY

Characterization of the interactions between PDZ domains of the protein-tyrosine phosphatase PTPL1 and the carboxyl-terminal tail of Fas. Saras J, et al. **J Biol Chem** 1997 Aug 22;272(34):20979–81

Identification of amino acid residues important for ligand binding to Fas. Starling GC, et al. **J Exp Med** 1997 Apr 21;185(8):1487–92

NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Huang B, et al. **Nature** 1996 Dec 19–26; 384(6610):638–41

DRUG EFFECTS

Selection for drug resistance results in resistance to Fas-mediated apoptosis. Landowski TH, et al. **Blood** 1997 Mar 15;89(6):1854–61

The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Fulda S, et al. **Cancer Res** 1997 Sep 1;57(17):3823–9

Thiols prevent Fas (CD95)-mediated T cell apoptosis by down-regulating membrane Fas expression. Delneste Y, et al. **Eur J Immunol** 1996 Dec;26(12):2981–8

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Egle A, et al. **Eur J Immunol** 1996 Dec;26(12):3119–26

Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Brunner T, et al. **Int Immunol** 1996 Jul;8(7):1017–26

Thiol-mediated inhibition of FAS and CD2 apoptotic signaling in activated human peripheral T cells. Déas O, et al. **Int Immunol** 1997 Jan;9(1):117–25

Bcl-2 protects against Fas-based but not perforin-based T cell-mediated cytolysis. Lee RK, et al. **Int Immunol** 1996 Jul;8(7):991–1000

GENETICS

Fas splicing variants and their effect on apoptosis. Ruberti G, et al. **Adv Exp Med Biol** 1996;406:125–34 (67 ref.)

Aging accelerates but life-long dietary restriction suppresses apoptosis-related Fas expression on hepatocytes. Higami Y, et al. **Am J Pathol** 1997 Sep;151(3):659–63

Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Hagimoto N, et al. **Am J Respir Cell Mol Biol** 1997 Sep;17(3):272–8

Structure of the promoter for the rat Fas antigen gene. Kimura K, et al. **Biochim Biophys Acta** 1997 Jun 26; 1352(3):238–42

Quantitative RT-PCR for human Fas (CD95) expression. Mitra D, et al. **Biotechniques** 1997 Mar;22(3):442–6

Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Bettinardi A, et al. **Blood** 1997 Feb 1;89(3):902–9

Localization of Fas antigen mRNA induced in postischemic murine forebrain by in situ hybridization. Matsuyama T, et al. **Brain Res Mol Brain Res** 1995 Dec 1;34(1):166–72

Rapid induction of Fas antigen mRNA expression in vivo by cycloheximide. Kimura K, et al. **Cell Biochem Funct** 1997 Jun;15(2):81–6

Distinct patterns of Fas cell surface expression during development of T- or B-lymphocyte lineages in normal, scid, and mutant mice lacking or overexpressing p53, bcl-2, or rag-2 genes. Li T, et al. **Cell Growth Differ** 1996 Jan; 7(1):107–14

Role of macrophages in the development of arteritis in MRL strains of mice with a deficit in Fas-mediated apoptosis. Taniguchi Y, et al. **Clin Exp Immunol** 1996 Oct; 106(1):26–34

B cells in systemic autoimmune disease: recent insights from Fas-deficient mice and men. Elkon KB, et al. **Curr Opin Immunol** 1996 Dec;8(6):852–9 (64 ref.)

Genomic organization and chromosomal mapping of the bovine Fas/APO-1 gene. Yoo J, et al. **DNA Cell Biol** 1996 May;15(5):377–85

Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. Benkerrou M, et al. **Eur J Immunol** 1997 Aug;27(8):2043–7

Fas-independent apoptosis of photoreceptor cells in C3H mice. Nambu H, et al. **Exp Anim** 1996 Oct;45(4):309–15

Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Pensati L, et al. **Gastroenterology** 1997 Oct;113(4):1384–9

Expression of CD95(FAS) by gene transfer does not sensitize K562 to Fas-killing. Munker R, et al. **Hematol Cell Ther** 1997 Apr;39(2):75–8

Regulation of bcl-2 and fas expression in primary activation of human peripheral lymphocytes is not sensitive to dexamethasone or cyclosporin-A. Sfikakis PP, et al. **Hum Immunol** 1996 Oct;50(2):121–6

Induction of cell death by chimeric L-selectin-Fas receptors. Ishiwatari-Hayasaka H, et al. **Int Immunol** 1997 Apr; 9(4):627–35

Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Cai Z, et al. **Int J Cancer** 1996 Nov 15;68(4):535–46

Vascular lesions in mice with a deficit in Fas-mediated apoptosis and their transfer. Nose M, et al. **Int J Cardiol** 1997 Aug;54 Suppl:S11–20

Fas-induced changes in cdc2 and cdk2 kinase activity are not sufficient for triggering apoptosis in HUT-78 cells. De Luca A, et al. **J Cell Biochem** 1997 Mar 15;64(4):579–85

Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. Dou QP, et al. **J Cell Biochem** 1997 Mar 15; 64(4):586–94

Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. Waldner H, et al. **J Immunol** 1997 Oct 1;159(7):3100–3

Spontaneous autoimmune skin lesions of MRL/n mice: autoimmune disease-prone genetic background in relation to Fas-defect MRL/lpr mice [see comments] Furukawa F, et al. **J Invest Dermatol** 1996 Jul;107(1):95–100. Comment in: J Invest Dermatol 1996 Jul;107(1):3–4.

Mechanism of intestinal mucosal immune dysfunction following trauma-hemorrhage: increased apoptosis associated with elevated Fas expression in Peyer's patches. Xu YX, et al. **J Surg Res** 1997 Jun;70(1):55–60

Accelerated progression of a murine retrovirus-induced immunodeficiency syndrome in Fas mutant C57BL/6 lpr/lpr mice. Hiromatsu K, et al. **Microbiol Immunol** 1997; 41(3):221–7

Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity [see comments] Drappa J, et al. **N Engl J Med** 1996 Nov 28;335(22):1643–9. Comment in: N Engl J Med 1997 May 15;336(20):1457; discussion 1457–8.

The Canale-Smith syndrome [letter; comment] Straus SE, et al. **N Engl J Med** 1997 May 15;336(20):1457; discussion 1457–8. Comment on: N Engl J Med 1996 Nov 28;335(22):1643–9.

NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Huang B, et al. **Nature** 1996 Dec 19–26; 384(6610):638–41

A fas antigen receptor mutation allows development of toxic shock syndrome toxin-1-induced lethal shock in V beta 8.2 T-cell receptor transgenic mice. Cullen CM, et al. **Pathobiology** 1995;63(6):293–304

Effect of neonatal exposure to DES in Fas and Bcl-2 expression in the adult mouse vagina and approach to the DES syndrome. Suzuki A, et al. **Reprod Toxicol** 1996 Nov-Dec;10(6):465–70

ALPS: an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Puck JM, et al. **Semin Immunol** 1997 Feb;9(1):77–84

IMMUNOLOGY

Autoimmunity due to defective Nur77, Fas, and TNF-RI apoptosis. Mountz JD, et al. **Adv Exp Med Biol** 1996; 406:241–62 (93 ref.)

Fas-mediated apoptosis. Nagata S. **Adv Exp Med Biol** 1996; 406:119–24 (36 ref.)

Inducible resistance to Fas-mediated apoptosis in primary B lymphocytes. Rothstein TL, et al. **Adv Exp Med Biol** 1996;406:177–89

Cytotoxic monocytes in the blood of HIV type 1-infected subjects destroy targeted T cells in a CD95-dependent fashion. Orlikowsky T, et al. **AIDS Res Hum Retroviruses** 1997 Jul 20;13(11):953–60

Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Hagimoto N, et al. **Am J Respir Cell Mol Biol** 1997 Sep;17(3):272–8

Apoptosis induced in human colorectal carcinoma by anti-Fas antibody. Meterissian SH, et al. **Ann Surg Oncol** 1997 Mar;4(2):169–75

The role of Fas/FasL interactions in the regulation of B cell function. Jacobson BA, et al. **Behring Inst Mitt** 1996 Oct; (97):185–99 (44 ref.)

Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Baker MB, et al. **Biol Blood Marrow Transplant** 1995 Dec;1(2):69–73

Differential susceptibility to HIV-GP120-sensitized apoptosis in CD4+ T-cell clones with different T-helper phenotypes: role of CD95/CD95L interactions. Accornero P, et al. **Blood** 1997 Jan 15;89(2):558–69

Downregulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy [letter; comment] Böhler T, et al. **Blood** 1997 Jul 15;90(2):886–8 . Comment on: Blood 1997 Jan 15;89(2):550–7.

Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: Fas-mediated killing by CD4+ and CD8+ cytotoxic T-cell clones and tumor necrosis factor beta production by CD4+ T-cell clones. Nishimura M, et al. **Blood** 1997 Feb 15;89(4):1440–5

Fc gammaRIII-mediated regulation of hematopoiesis in murine bone marrow cells by interleukin-3 and CD95 (Fas/Apo-1). Yoshikawa H, et al. **Blood** 1997 Sep 1; 90(5):1911–9

Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Zeytun A, et al. **Blood** 1997 Sep 1;90(5):1952–9

Anti-Fas/Apo-1 monoclonal antibody CH-11 depletes glutathione and kills multidrug-resistant human leukemic cells. Efferth T, et al. **Blood Cells Mol Dis** 1996;22(1):2–9; discussion 10

Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Mizutani Y, et al. **Cancer** 1997 Mar 15;79(6):1180–9

Requirement of p34cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1beta-converting enzyme-related proteases. Yao SL, et al. **Cancer Res** 1996 Oct 15;56(20):4551–5

Hyaluronidase induces murine L929 fibrosarcoma cells resistant to tumor necrosis factor and Fas cytotoxicity in the presence of actinomycin D. Chang NS. **Cell Biochem Biophys** 1995–96;27(2):109–32

Functional expression of Fas (CD95) protein in autoimmune lpr mice. Cui H, et al. **Cell Immunol** 1996 Nov 25; 174(1):35–41

Rapid modulation of T lymphocyte surface antigens induced by Fas (CD95, APO-1) ligation. Kabelitz D, et al. **Cell Immunol** 1996 Oct 10;173(1):108–15

Up-regulation of Bcl-xL expression protects CD40-activated human B cells from Fas-mediated apoptosis. Zhang X, et al. **Cell Immunol** 1996 Oct 10;173(1):149–54

Hypogammaglobulinaemia occurs in Fas-deficient MRL-lpr mice following deletion of MHC class II molecules. Anderson CC, et al. **Clin Exp Immunol** 1997 Sep; 109(3):473–9

Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Jodo S, et al. **Clin Exp Immunol** 1997 Jan;107(1):89–95

Ductal Fas antigen and the pathobiology of Sjögren's syndrome [editorial; comment] De Vita S. **Clin Exp Rheumatol** 1996 May-Jun;14(3):231–4. Comment on: Clin Exp Rheumatol 1996 May-Jun;14(3):309–11.

Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Spencer DM, et al. **Curr Biol** 1996 Jul 1;6(7):839–47

Killing mechanisms of cytotoxic lymphocytes. Berke G. **Curr Opin Hematol** 1997 Jan;4(1):32–40 (83 ref.)

High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants. De Paoli P, et al. **Cytometry** 1997 Feb 15;30(1):33–8

MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways. Benihoud K, et al. **Eur J Immunol** 1997 Feb;27(2):415–20

Sensitivity of Epstein-Barr virus-induced B cell tumor to apoptosis mediated by anti-CD95/Apo-1/fas antibody. Durandy A, et al. **Eur J Immunol** 1997 Feb;27(2):538–43

Death in the Fas lane [news] **Gastroenterology** 1997 Jun; 112(6):1784

Fas-mediated cytotoxicity by intestinal intraepithelial lymphocytes during acute graft-versus-host disease in mice [see comments] Sakai T, et al. **Gastroenterology** 1997 Jul; 113(1):168–74. Comment in: Gastroenterology 1997 Jul;113(1):345–8.

Potential deleterious effect of anti-viral cytotoxic lymphocyte through the CD95 (FAS/APO-1)-mediated pathway during chronic HIV infection. Garcia S, et al. **Immunol Lett** 1997 Jun 1;57(1–3):53–8

A vision of cell death: insights into immune privilege. Ferguson TA, et al. **Immunol Rev** 1997 Apr;156:167–84 (86 ref.)

The role of FasL-induced apoptosis in immune privilege [published erratum appears in Imunol Today 1997 Jul;18(7):361] Griffith TS, et al. **Immunol Today** 1997 May; 18(5):240–4 (46 ref.)

Apoptosis in a Fas-resistant, T-cell receptor-sensitive human leukaemic T-cell clone. Delehanty LL, et al. **Immunology** 1997 Mar;90(3):383–7

Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Martínez-Lorenzo MJ, et al. **Immunology** 1996 Dec; 89(4):511–7

Autologous killing by a population of intermediate T-cell receptor cells and its NK1.1+ and NK1.1- subsets, using Fas ligand/Fas molecules. Moroda T, et al. **Immunology** 1997 Jun;91(2):219–26

CD95 (Fas) may control the expansion of activated T cells after elimination of bacteria in murine listeriosis. Fuse Y, et al. **Infect Immun** 1997 May;65(5):1883–91

CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells. Björck P, et al. **Int Immunol** 1997 Mar; 9(3):365–72

Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro. Fadeel B, et al. **Int Immunol** 1997 Feb;9(2):201–9

Induction of Fas-dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis. Hasunuma T, et al. **Int Immunol** 1996 Oct;8(10):1595–602

Comparison of Fas(Apo-1/CD95)- and perforin-mediated cytotoxicity in primary T lymphocytes. Lowin B, et al. **Int Immunol** 1996 Jan;8(1):57–63

In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Nishimura Y, et al. **Int Immunol** 1997 Feb;9(2):307–16

Fas (CD95)-independent regulation of immune responses by antigen-specific CD4-CD8+ T cells. Teh SJ, et al. **Int Immunol** 1996 May;8(5):675–81

Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines. Fellenberg J, et al. **Int J Cancer** 1997 Jul 29;72(3):536–42

Selective depletion of cyclin-dependent kinases is associated with Fas-mediated apoptosis in human leukemia T-cell lines. Oguri-Hyakumachi N, et al. **Int J Immunopharmacol** 1995 Nov;17(11):913–21

Immunoregulatory effects of Fas-mediated signalling. Lynch DH, et al. **J Cell Biochem** 1996 Jan;60(1):39–46 (34 ref.)

Cell death and the immune response: a lesson from the privileged. Ferguson TA, et al. **J Clin Immunol** 1997 Jan; 17(1):1–10 (51 ref.)

Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. Müller M, et al. **J Clin Invest** 1997 Feb 1;99(3):403–13

CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. Stuart PM, et al. **J Clin Invest** 1997 Feb 1;99(3):396–402

Resistance to fas-mediated apoptosis of peripheral T cells in human T lymphocyte virus type I (HTLV-I) transgenic mice with autoimmune arthropathy. Kishi S, et al. **J Exp Med** 1997 Jul 7;186(1):57–64

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. O'Connell J, et al. **J Exp Med** 1996 Sep 1;184(3):1075–82

Cross-linking of Fas by antibodies to a peculiar domain of gp120 V3 loop can enhance T cell apoptosis in HIV-1-infected patients. Silvestris F, et al. **J Exp Med** 1996 Dec 1;184(6):2287–300

The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. Susin SA, et al. **J Exp Med** 1997 Jul 7;186(1):25–37

Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. Ando K, et al. **J Immunol** 1997 Jun 1;158(11):5283–91

Increased lymphocyte apoptosis in Fas ligand transgenic mice. Cheng J, et al. **J Immunol** 1997 Jul 15;159(2):674–84

IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones. Esser MT, et al. **J Immunol** 1997 Jun 15;158(12):5612–8

Intracellular signaling for inducible antigen receptor-mediated Fas resistance in B cells. Foote LC, et al. **J Immunol** 1996 Sep 1;157(5):1878–85

Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a T helper 1 phenotype. Gougeon ML, et al. **J Immunol** 1997 Mar 15;158(6):2964–76

Dissociation of T cell anergy from apoptosis by blockade of Fas/Apo-1 (CD95) signaling. Hargreaves RG, et al. **J Immunol** 1997 Apr 1;158(7):3099–107

Leukocyte function-associated antigen-1-dependent lysis of Fas+ (CD95+/Apo-1+) innocent bystanders by antigen-specific CD8+ CTL. Kojima H, et al. **J Immunol** 1997 Sep 15;159(6):2728–34

Overexpression of the heat shock protein 70 enhances the

TCR/CD3- and Fas/Apo-1/CD95-mediated apoptotic cell death in Jurkat T cells. Liossis SN, et al. **J Immunol** 1997 Jun 15;158(12):5668-75

Relationship between proliferation and susceptibility to CD95- and CD2-mediated apoptosis in stimulated primary T lymphocytes: T cells manifesting proliferative unresponsiveness are preferentially susceptible to CD95-mediated apoptosis. Mollereau B, et al. **J Immunol** 1997 Sep 15;159(6):2668-77

Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. Oshimi Y, et al. **J Immunol** 1996 Oct 1;157(7):2909-15

Administration of IL-12 induces a CD3+ CD4- CD8- B220+ lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells. Tsutsui T, et al. **J Immunol** 1997 Sep 15;159(6):2599-605

Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice. Van Molle W, et al. **J Immunol** 1997 Oct 1;159(7):3555-64

CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors. Wang R, et al. **J Immunol** 1996 Oct 1; 157(7):2961-8

Fas (CD95) expression on CD4+ T cells from HIV-infected patients increases with disease progression. Aries SP, et al. **J Mol Med** 1995 Dec;73(12):591-3

Augmentation of anti-Fas antibody-mediated apoptosis on human glioma cells by liposomes associated with the antibody. Ohta S, et al. **J Neurooncol** 1997 Oct;35(1):7-11

Epstein-Barr virus BHRF1 protein protects intestine 407 epithelial cells from apoptosis induced by tumor necrosis factor alpha and anti-Fas antibody. Kawanishi M. **J Virol** 1997 Apr;71(4):3319-22

T-lymphocyte downregulation after acute viral infection is not dependent on CD95 (Fas) receptor-ligand interactions. Lohman BL, et al. **J Virol** 1996 Nov;70(11):8199-203

Apoptosis by CD95 (Fas)-dependent and -independent mechanisms in Peyer's patch lymphocytes in murine retrovirus-induced immunodeficiency syndrome. Usami J, et al. **J Virol** 1996 Dec;70(12):8917-25

Agonistic anti-Fas antibodies induce glomerular cell apoptosis in mice in vivo. González-Cuadrado S, et al. **Kidney Int** 1997 Jun;51(6):1739-46

Fas ligand and immune evasion [news; comment] Nagata S. **Nat Med** 1996 Dec;2(12):1306-7. Comment on: Nat Med 1996 Dec;2(12):1361-6.

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? [see comments] Strand S, et al. **Nat Med** 1996 Dec;2(12):1361-6. Comment in: Nat Med 1996 Dec;2(12):1306-7. Comment in: Nat Med 1997 Mar;3(3):253-4.

Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Wakahara Y, et al. **Oncology** 1997 Jan-Feb;54(1):48-54

Fas-ligand: privilege and peril [see comments] Green DR, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):5986-90 (37 ref.). Comment in: Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3914-9. Comment in: Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3943-7.

Precursor B cells for autoantibody production in genomically Fas-intact autoimmune disease are not subject to Fas-mediated immune elimination. Hirose S, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9291-5

Fas-dependent CD4+ cytotoxic T-cell-mediated pathogenesis during virus infection. Zajac AJ, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14730-5

Role for NK-cell-associated Fas ligand in cell-mediated cytotoxicity and apoptosis. Eischen CM, et al. **Res Immunol** 1997 Mar-Apr;148(3):164-9 (43 ref.)

The renal cell carcinoma lysis by a specific cytotoxic T cell clone is independent of the Fas/Fas-L cytotoxic pathway. Caignard A, et al. **Tissue Antigens** 1996 Oct;48(4 Pt 1):295-300

The Fas antigen (CD95) on human lymphoid cells: epitope analysis with ten antibodies. Zola H, et al. **Tissue Antigens** 1996 Nov;48(5):519-30

Involvement of Fas and Fas ligand interaction in allogeneic hepatocyte rejection in the spleen. Kawahara T, et al. **Transplant Proc** 1997 Jun;29(4):2187-8

Functional Fas and Fas-ligand activities in activated T cells of kidney transplant recipients. Nakajima H, et al. **Transplant Proc** 1997 Sep;29(6):2533-4

[CD95 (APO-1/Fas) and CD95-ligand (CD95L). Implications of these apoptosis mediating receptor/ligand systems in the pathogenesis of autoimmune diseases] Möller P, et al. **Verh Dtsch Ges Pathol** 1996;80:12-20 (38 ref.) (Eng. Abstr.) **(Ger)**

[Expression of Fas/APO-1/CD95 antigen mediating the apoptosis in human leukemic cells] Shishkin IuV, et al. **Biull Eksp Biol Med** 1996 Nov;122(11):544-6 **(Rus)**

ISOLATION & PURIFICATION

Immunohistochemical analysis of murine CD95/Fas/Apo-1 receptor and its ultrastructural distribution in the thymus. Ramos P, et al. **APMIS** 1997 Aug;105(8):597-602

Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. Dowling P, et al. **J Exp Med** 1996 Oct 1;184(4):1513-8

METABOLISM

Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. Silvestris F, et al. **AIDS** 1996 Feb;10(2):131-41

Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis. DiGiuseppe JA, et al. **Am J Clin Pathol** 1996 Sep; 106(3):345-51

Bcl-2 and Fas expression in eutopic and ectopic human endometrium during the menstrual cycle in relation to endometrial cell apoptosis. Watanabe H, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):360-8

Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease [published erratum appears in Am J Pathol 1996 Jul;149(1):346] Nguyen PL, et al. **Am J Pathol** 1996 Mar; 148(3):847-53

Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. Ortiz-Arduan A, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):F1193-201

Inducible Fas-resistance mediated by IL-4 in activated B cells. Foote LC, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:114-5

Prevention of autoantibody production in lpr/lpr mice by transgenic expression of Fas on B cells. Shinohara N, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:489-91

Upregulated expression of Fas antigen on cultured human keratinocytes with induction of apoptosis by cisplatin. Matsumoto Y, et al. **Arch Dermatol Res** 1996 May; 288(5-6):267-9

Multiple pathways of Fas-induced apoptosis in primary culture of hepatocytes. Rouquet N, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):27-35

HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. Truman JP, et al. **Blood** 1997 Mar 15;89(6):1996-2007

Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines. Dirks W, et al. **Br J Haematol** 1997 Mar;96(3):584-93

Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. Egle A, et al. **Br J Haematol** 1997 May;97(2):418-28

Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Perzova R, et al. **Br J Haematol** 1997 Apr;97(1):123-6

Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Wang D, et al. **Br J Haematol** 1997 May;97(2):409-17

Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Behrens L, et al. **Brain** 1997 Jun; 120 (Pt 6):929-38

Expression of Fas-estrogen receptor fusion protein induces cell death in pancreatic cancer cell lines. Kawaguchi Y, et al. **Cancer Lett** 1997 Jun 3;116(1):53-9

Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Villunger A, et al. **Cancer Res** 1997 Aug 15;57(16):3331-4

Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Yang X, et al. **Cell** 1997 Jun 27;89(7):1067-76

Persistent expression of a soluble form of Fas/APO1 in continuously activated T cells from a patient with SLE. Kovacs B, et al. **Clin Exp Rheumatol** 1997 Jan-Feb; 15(1):19-23

Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. Asahara H, et al. **Clin Immunol Immunopathol** 1996 Oct;81(1):27-34

Transducing signals of life and death. Yuan J. **Curr Opin Cell Biol** 1997 Apr;9(2):247-51 (31 ref.)

Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Medvedev AE, et al. **Cytokine** 1997 Jun;9(6):394-404

Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. Dubrez L, et al. **EMBO J** 1996 Oct 15;15(20):5504-12

Caspase activity is required for commitment to Fas-mediated apoptosis. Longthorne VL, et al. **EMBO J** 1997 Jul 1; 16(13):3805-12

FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). Medema JP, et al. **EMBO J** 1997 May 15;16(10):2794-804

The Fas system is a key regulator of germ cell apoptosis in the testis. Lee J, et al. **Endocrinology** 1997 May; 138(5):2081-8

Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. Benkerrou M, et al. **Eur J Immunol** 1997 Aug;27(8):2043-7

Th1 and Th2 subsets equally undergo Fas-dependent and -independent activation-induced cell death. Watanabe N, et al. **Eur J Immunol** 1997 Aug;27(8):1858-64

Involvement of cytoplasmic serine proteinase and CPP32 subfamily in the molecular machinery of caspase 3 activation during Fas-mediated apoptosis. Suzuki A, et al. **Exp Cell Res** 1997 May 25;233(1):48-55

Interaction of Fas(Apo-1/CD95) with proteins implicated in the ubiquitination pathway. Becker K, et al. **FEBS Lett** 1997 Jul 21;412(1):102-6

Apoptosis induced by HIV-gp120 in a Th1 clone involves the generation of reactive oxygen intermediates downstream CD95 triggering. Radrizzani M, et al. **FEBS Lett** 1997 Jul 7;411(1):87-92

Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. Wagenknecht B, et al. **FEBS Lett** 1997 Jun 2;409(1):17-23

Essential role of active nuclear transport in apoptosis. Yasuhara N, et al. **Genes Cells** 1997 Jan;2(1):55-64

PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3. Inazawa J, et al. **Genomics** 1996 Jan 15;31(2):240-2

Fas modulation of apoptosis during negative selection of thymocytes. Castro JE, et al. **Immunity** 1996 Dec; 5(6):617-27

Activation-induced peripheral blood T cell apoptosis is Fas independent in HIV-infected individuals. Katsikis PD, et al. **Int Immunol** 1996 Aug;8(8):1311-7

Bcl-2 and the outer mitochondrial membrane in the inactivation of cytochrome c during Fas-mediated apoptosis. Adachi S, et al. **J Biol Chem** 1997 Aug 29; 272(35):21878-82

Specific triggering of the Fas signal transduction pathway in normal human keratinocytes. Freiberg RA, et al. **J Biol Chem** 1996 Dec 6;271(49):31666-9

Fas-induced apoptosis is mediated by activation of a Ras and Rac protein-regulated signaling pathway. Gulbins E, et al. **J Biol Chem** 1996 Oct 18;271(42):26389-94

A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. Hu S, et al. **J Biol Chem** 1997 Apr 11;272(15):9621-4

I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. Hu S, et al. **J Biol Chem** 1997 Jul 11;272(28):17255-7

Activation-induced aggregation and processing of the human Fas antigen. Detection with cytoplasmic domain-specific antibodies. Kamitani T, et al. **J Biol Chem** 1997 Aug 29; 272(35):22307-14

Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity. Martin SJ, et al. **J Biol Chem** 1996 Nov 15;271(46):28753-6

FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. Muzio M, et al. **J Biol Chem** 1997 Jan 31;272(5):2952-6

Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. Schneider P, et al. **J Biol Chem** 1997 Jul 25; 272(30):18827-33

Autocrine nitric oxide modulates CD95-induced apoptosis in gammadelta T lymphocytes. Sciorati C, et al. **J Biol Chem** 1997 Sep 12;272(37):23211-5

CD95/Fas-induced ceramide formation proceeds with slow kinetics and is not blocked by caspase-3/CPP32 inhibition. Tepper AD, et al. **J Biol Chem** 1997 Sep 26; 272(39):24308-12

Association of human fas (CD95) with a ubiquitin-conjugating enzyme (UBC-FAP). Wright DA, et al. **J Biol Chem** 1996 Dec 6;271(49):31037-43

Proteases in Fas-mediated apoptosis. Zhivotovsky B, et al. **J Cell Biochem** 1997 Jan;64(1):43-9 (54 ref.)

Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. Redondo C, et al. **J Clin Invest** 1996 Sep 1; 98(5):1245-52

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? Saas P, et al. **J Clin Invest** 1997 Mar 15;99(6):1173-8

Apoptosis is induced by anti-Fas antibody alone in cultured human keratinocytes. Sung KJ, et al. **J Dermatol** 1997 Jul; 24(7):427-34

Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. Rodriguez I, et al. **J Exp Med** 1996 Nov 1;184(5):2067-72

Perforin and Fas killing by CD8+ T cells limits their cytokine synthesis and proliferation. Sad S, et al. **J Exp Med** 1996 Oct 1;184(4):1543-7

Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. Kettle S, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):677-85

Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. Okura T, et al. **J Immunol** 1996 Nov 15;157(10):4277-81

Increased Fas antigen on T cells in multiple sclerosis. Ichikawa H, et al. **J Neuroimmunol** 1996 Dec;71(1-2):125-9

Apoptosis in autoimmune and non-autoimmune thyroid disease [editorial] Ludgate M, et al. **J Pathol** 1997 Jun; 182(2):123-4

Regulation of bcl-xL expression and Fas susceptibility in mouse B cells by CD40 ligation, surface IgM crosslinking and IL-4. Koizumi T, et al. **Mol Immunol** 1996 Nov; 33(16):1247-53

The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure. Leist M, et al. **Mol Med** 1996 Jan; 2(1):109-24

Looking beneath the surface: the cell death pathway of Fas/APO-1 (CD95). Stanger BZ. **Mol Med** 1996 Jan;

2(1):7–20 (112 ref.)
Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Xerri L, et al. **Mol Pathol** 1997 Apr;50(2):87–91
Involvement of Fas antigen in ovarian follicular atresia and luteolysis. Sakamaki K, et al. **Mol Reprod Dev** 1997 May; 47(1):11–8
Expression of Fas antigen is not associated with apoptosis in human myopathies. Inukai A, et al. **Muscle Nerve** 1997 Jun;20(6):702–9
Thyroiditis and hepatitis: Fas on the road to disease [news; comment] French LE, et al. **Nat Med** 1997 Apr;3(4):387–8 . Comment on: Nat Med 1997 Apr;3(4):409–13.
Essential roles of the Fas ligand in the development of hepatitis [see comments] Kondo T, et al. **Nat Med** 1997 Apr;3(4):409–13. Comment in: Nat Med 1997 Apr;3(4):387–8.
The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Mogi M, et al. **Neurosci Lett** 1996 Dec 20; 220(3):195–8
Influence of L–carnitine on CD95 cross–lining–induced apoptosis and ceramide generation in human cell lines: correlation with its effects on purified acidic and neutral sphingomyelinases in vitro. Di Marzio L, et al.
Proc Assoc Am Physicians 1997 Mar;109(2):154–63
Death effector domain–containing herpesvirus and poxvirus proteins inhibit both Fas– and TNFR1–induced apoptosis. Bertin J, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18; 94(4):1172–6
Fas (CD95) expression and death–mediating function are induced by CD4 cross–linking on CD4+ T cells. Desbarats J, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):11014–8
Mitogen–activated protein kinase–mediated Fas apoptotic signaling pathway. Goillot E, et al.
Proc Natl Acad Sci U S A 1997 Apr 1;94(7):3302–7
Thymineless death in colon carcinoma cells is mediated via fas signaling. Houghton JA, et al.
Proc Natl Acad Sci U S A 1997 Jul 22;94(15):8144–9
Differential inhibition of the Fas– and granule–mediated cytolysis pathways by the orthopoxvirus cytokine response modifier A/SPI–2 and SPI–1 protein. Macen JL, et al.
Proc Natl Acad Sci U S A 1996 Aug 20;93(17):9108–13
Molecular ordering of the Fas–apoptotic pathway: the Fas/APO–1 protease Mch5 is a CrmA–inhibitable protease that activates multiple Ced–3/ICE–like cysteine proteases. Srinivasula SM, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14486–91
Apoptosis mediated by the Fas system. Nagata S.
Prog Mol Subcell Biol 1996;16:87–103 (70 ref.)
Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis [see comments] Giordano C, et al. **Science** 1997 Feb 14;275(5302):960–3. Comment in: Science 1997 Feb 14;275(5302):926.
Thyroid disease: a case of cell suicide? [news; comment] Williams N. **Science** 1997 Feb 14;275(5302):926. Comment on: Science 1997 Feb 14;275(5302):960–3.
Portrait of an executioner: the molecular mechanism of FAS/APO–1–induced apoptosis. Chinnaiyan AM, et al.
Semin Immunol 1997 Feb;9(1):69–76 (84 ref.)
The CD95 system and the death of a lymphocyte. Matiba B, et al. **Semin Immunol** 1997 Feb;9(1):59–68 (108 ref.)
Cell death induction by TNF: a matter of self control. Wallach D. **Trends Biochem Sci** 1997 Apr;22(4):107–9 (29 ref.)
[Detection of apoptosis and expression of Fas antigen in human colorectal cancer] Hashimoto S, et al.
Nippon Rinsho 1996 Jul;54(7):1912–5 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Fas antigen expression on human hematopoietic progenitor cells] Nagafuji K, et al. **Nippon Rinsho** 1996 Jul; 54(7):1790–6 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Abnormal Fas and Fas ligand expression of lymphocytes in patients with SLE] Suzuki N, et al. **Nippon Rinsho** 1996 Jul;54(7):1955–9 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Up–regulation of NGF, trkA, Fas, down–regulation of bcl–2, and induction of apoptosis by propentofylline in human glioma cell lines] Kamada H, et al.
No To Shinkei 1996 Nov;48(11):1022–8 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Selective activation of the JNK/AP–1 pathway in Fas–mediated apoptosis of rheumatoid arthritis synoviocytes. Okamoto K, et al. **Arthritis Rheum** 1997 May; 40(5):919–26
RIP mediates tumor necrosis factor receptor 1 activation of NF–kappaB but not Fas/APO–1–initiated apoptosis. Ting AT, et al. **EMBO J** 1996 Nov 15;15(22):6189–96
Fas, apoptosis and the cell cycle [letter; comment] Manfredi AA, et al. **Immunol Today** 1996 Jul;17(7):345–6. Comment on: Immunol Today 1995 Dec;16(12):569–74.
Fas–induced programmed cell death is mediated by a Ras–regulated O2– synthesis. Gulbins E, et al.
Immunology 1996 Oct;89(2):205–12
Role of oxidative damage and IL–1 beta–converting enzyme–like proteases in Fas–based cytotoxicity exerted by effector T cells. Anel A, et al. **Int Immunol** 1996 Jul; 8(7):1173–83
Induction of Fas–dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis. Hasunuma T, et al.
Int Immunol 1996 Oct;8(10):1595–602
In vivo analysis of Fas antigen–mediated apoptosis: effects of agonistic anti–mouse Fas mAb on thymus, spleen and liver. Nishimura Y, et al. **Int Immunol** 1997 Feb;9(2):307–16
Fas– or ceramide–induced apoptosis is mediated by a Rac1–regulated activation of Jun N–terminal kinase/p38 kinases and GADD153. Brenner B, et al. **J Biol Chem** 1997 Aug 29;272(35):22173–81
Specific cleavage of alpha–fodrin during Fas– and tumor necrosis factor–induced apoptosis is mediated by an interleukin–1beta–converting enzyme/Ced–3 protease distinct from the poly(ADP–ribose) polymerase protease. Cryns VL, et al. **J Biol Chem** 1996 Dec 6;271(49):31277–82
Transcriptional activation of the cdc2 gene is associated with Fas–induced apoptosis of human hematopoietic cells. Furukawa Y, et al. **J Biol Chem** 1996 Nov 8; 271(45):28469–77
Selective involvement of ceramide in cytokine–induced apoptosis. Ceramide inhibits phorbol ester activation of nuclear factor kappaB. Gamard CJ, et al. **J Biol Chem** 1997 Jun 27;272(26):16474–81
Degradation of retinoblastoma protein in tumor necrosis factor– and CD95–induced cell death. Tan X, et al.
J Biol Chem 1997 Apr 11;272(15):9613–6
Kinetics of Fas–induced apoptosis in thymic organ culture. Zhou T, et al. **J Clin Immunol** 1997 Jan;17(1):74–84
Human T cells require IL–2 but not G1/S transition to acquire susceptibility to Fas–mediated apoptosis. Fournel S, et al. **J Immunol** 1996 Nov 15;157(10):4309–15
CD4+ T cells kill CD8+ T cells via Fas/Fas ligand–mediated apoptosis. Piazza C, et al. **J Immunol** 1997 Feb 15;158(4):1503–6
IL–1 beta convertase (ICE) does not play a requisite role in apoptosis induced in T lymphoblasts by Fas–dependent or Fas–independent CTL effector mechanisms. Smith DJ, et al. **J Immunol** 1997 Jan 1;158(1):163–70
TCR in Fas–sensitive T cells from labial salivary glands of patients with Sjögren's syndrome. Sumida T, et al.
J Immunol 1997 Jan 15;158(2):1020–5
CD95 (APO–1/Fas) induces activation of SAP kinases downstream of ICE–like proteases. Cahill MA, et al.
Oncogene 1996 Nov 21;13(10):2087–96

PHYSIOLOGY

Functional aspects of apoptosis in hematopoiesis and consequences of failure. McKenna SL, et al.
Adv Cancer Res 1997;71:121–64 (284 ref.)
Fas–dependent and Fas–independent mechanisms for selection of the mature human B cell repertoire. Defrance T, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:67–74 (20 ref.)
Unique site of autoantibody production in Fas–deficient mice. Jacobson BA, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:218–29 (43 ref.)
Markedly diminished radiation–induced lymphocyte apoptosis in lpr mice suggests a role for Fas in eliminating damaged cells. Reap EA, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:116–8
Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti–Fas monoclonal antibody. Nakamura S, et al. **Anticancer Res** 1997 Jan–Feb; 17(1A):173–9
Regulation and mechanisms of apoptosis in T lymphocytes. van den Dobbelsteen DJ, et al. **Arch Toxicol Suppl** 1997; 19:77–85 (30 ref.)
Impaired nonrestricted cytolytic activity in systemic lupus erythematosus: involvement of a pathway independent of Fas, tumor necrosis factor, and extracellular ATP that is associated with little detectable perforin. Stohl W, et al.
Arthritis Rheum 1997 Jun;40(6):1130–7
The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions. Cai W, et al.
Atherosclerosis 1997 Jun;131(2):177–86
Regulation of CD95 ligand expression: a key element in immune regulation? Brunner T, et al. **Behring Inst Mitt** 1996 Oct;(97):161–74 (81 ref.)
FasL/Fas and TNF/TNFR interactions in the regulation of immune responses and disease. Lynch DH, et al.
Behring Inst Mitt 1996 Oct;(97):175–84 (36 ref.)
CD95 (APO–1/Fas) and its ligand in the mouse immune system. Mariani SM, et al. **Behring Inst Mitt** 1996 Oct; (97):12–23 (77 ref.)
A death factor—the other side of the coin. Nagata S.
Behring Inst Mitt 1996 Oct;(97):1–11 (48 ref.)
Bcl–2 completely blocks Fas–mediated apoptosis in mtDNA–depleted HeLa cells. Asoh S, et al.
Biochem Biophys Res Commun 1997 Aug 28;237(3):659–62
Regulation of tumor necrosis factor–and Fas–mediated apoptotic cell death by a novel cDNA TR2L. Cao H, et al. **Biochem Biophys Res Commun** 1996 Oct 3;227(1):266–72
Fas/APO–1(CD95)–induced apoptosis of primary hepatocytes is inhibited by cAMP. Fladmark KE, et al.
Biochem Biophys Res Commun 1997 Mar 6;232(1):20–5
Inhibition of Fas–induced apoptotic cell death by osmotic cell shrinkage. Gulbins E, et al.
Biochem Biophys Res Commun 1997 Jul 18;236(2):517–21
The role of phorbol ester–sensitive protein kinase C isoforms in lymphokine–activated killer cell–mediated cytotoxicity: dissociation between perforin–dependent and Fas–dependent cytotoxicity. Ohmi Y, et al.
Biochem Biophys Res Commun 1997 Jun 27;235(3):461–4
Fas–mediated stimulation induces IL–8 secretion by rheumatoid arthritis synoviocytes independently of CPP32–mediated apoptosis. Sekine C, et al.
Biochem Biophys Res Commun 1996 Nov 1;228(1):14–20
Fas–signaling and effects on receptor tyrosine kinase signal transduction in human breast epithelial cells. Shen K, et al. **Biochem Biophys Res Commun** 1997 Jan 3;230(1):89–93
A trial to kill tumor cells through Fas (CD95)–mediated apoptosis in vivo. Shimizu M, et al.
Biochem Biophys Res Commun 1996 Nov 12;228(2):375–9
Evidence against an early signalling role for ceramide in Fas–mediated apoptosis. Sillence DJ, et al. **Biochem J** 1997 May 15;324 (Pt 1):29–32
Regulation of apoptosis through CD95 (APO–I/Fas) receptor–ligand interaction. Debatin KM, et al.
Biochem Soc Trans 1997 May;25(2):405–10 (48 ref.)
Activation of phosphatidylinositol 3–kinase following Fas engagement is not required for Fas–mediated apoptosis in Jurkat T cells. McLeod JD, et al. **Biochem Soc Trans** 1997 May;25(2):241S
CD2 rescues T cells from T–cell receptor/CD3 apoptosis: a role for the Fas/Fas–L system. Ayroldi E, et al.
Blood 1997 May 15;89(10):3717–26
Interleukin–6 inhibits Fas–induced apoptosis and stress–activated protein kinase activation in multiple myeloma cells. Chauhan D, et al. **Blood** 1997 Jan 1; 89(1):227–34
Fc gammaRII (CD32) is linked to apoptotic pathways in murine granulocyte precursors and mature eosinophils. de Andrés B, et al. **Blood** 1997 Aug 1;90(3):1267–74
Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Dianzani U, et al.
Blood 1997 Apr 15;89(8):2871–9
Comparison of apoptosis in wild–type and Fas–resistant cells: chemotherapy–induced apoptosis is not dependent on Fas/Fas ligand interactions. Eischen CM, et al. **Blood** 1997 Aug 1;90(3):935–43
Fas–mediated apoptosis of the hematopoietic progenitor cells in mice infected with murine cytomegalovirus. Mori T, et al. **Blood** 1997 May 15;89(10):3565–73
Involvement of Fas–mediated apoptosis in the inhibitory effects of interferon–alpha in chronic myelogenous leukemia. Selleri C, et al. **Blood** 1997 Feb 1;89(3):957–64
Role of Fas ligand and receptor in the mechanism of T–cell depletion in acquired immunodeficiency syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication. Sloand EM, et al.
Blood 1997 Feb 15;89(4):1357–63
Clincial, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Sneller MC, et al. **Blood** 1997 Feb 15;89(4):1341–8
Augmented intracellular glutathione inhibits Fas–triggered apoptosis of activated human neutrophils. Watson RW, et al. **Blood** 1997 Jun 1;89(11):4175–81
CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Bergamo A, et al.
Br J Haematol 1997 Jun;97(3):652–5
Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Eguchi Y, et al. **Cancer Res** 1997 May 15;57(10):1835–40
p53–dependent DNA damage–induced apoptosis requires Fas/APO–1–independent activation of CPP32beta. Fuchs EJ, et al. **Cancer Res** 1997 Jul 1;57(13):2550–4
Fas expression and function in normal and malignant breast cell lines. Keane MM, et al. **Cancer Res** 1996 Oct 15; 56(20):4791–8
Dominant nature of the resistance to Fas– and tumor necrosis factor–alpha–mediated apoptosis in human prostatic carcinoma cell lines. Rokhlin OW, et al. **Cancer Res** 1997 Sep 15;57(18):3941–3
Fas–mediated apoptosis in human prostatic carcinoma cell lines. Rokhlin OW, et al. **Cancer Res** 1997 May 1; 57(9):1758–68
Apoptosis by death factor. Nagata S. **Cell** 1997 Feb 7; 88(3):355–65 (85 ref.)
Expansion or elimination of B cells in vivo: dual roles for CD40– and Fas (CD95)–ligands modulated by the B cell antigen receptor. Rathmell JC, et al. **Cell** 1996 Oct 18; 87(2):319–29
The testis–derived cultured Sertoli cell as a natural Fas–L secreting cell for immunosuppressive cellular therapy [comment] Sanberg PR, et al. **Cell Transplant** 1997 Mar–Apr;6(2):191–3. Comment on: Cell Transplant 1997 Mar–Apr;6(2):185–9.
Role of macrophages in the development of arteritis in MRL strains of mice with a deficit in Fas–mediated apoptosis. Taniguchi Y, et al. **Clin Exp Immunol** 1996 Oct; 106(1):26–34
Role of Fas–mediated cell death in the regulation of immune responses. van Parijs L, et al. **Curr Opin Immunol** 1996 Jun;8(3):355–61 (70 ref.)
Regulation of Fas–mediated apoptosis. Gottlieb RA, et al.
Curr Top Cell Regul 1997;35:69–105 (213 ref.)
Apoptosis through CD95 (Fas/APO–1), but not a CD40/CD95 chimeric receptor, is inhibited by phorbol–12–myristate–13–acetate. Rudert F, et al.
DNA Cell Biol 1997 Feb;16(2):197–205
CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO–1)–transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease. Smith KG, et al. **EMBO J** 1996 Oct 1;15(19):5167–76
Thyroid–stimulating hormone inhibits Fas antigen–mediated apoptosis of human thyrocytes in vitro. Kawakami A, et al. **Endocrinology** 1996 Aug;137(8):3163–9

Activation and activation-induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO-1) ligand expression and function. Daniel PT, et al. **Eur J Immunol** 1997 Apr;27(4):1029-34

Germinal center B cells rescued from apoptosis by CD40 ligation or attachment to follicular dendritic cells, but not by engagement of surface immunoglobulin or adhesion receptors, become resistant to CD95-induced apoptosis. Koopman G, et al. **Eur J Immunol** 1997 Jan;27(1):1-7

Regulatory role of CD95 ligation on human B cells induced in vivo capable of spontaneous and high-rate Ig secretion. Medina F, et al. **Eur J Immunol** 1997 Mar;27(3):700-6

Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Peter ME, et al. **Eur J Immunol** 1997 May;27(5):1207-12

Activation of protein kinase C attenuates early signals in Fas-mediated apoptosis. Ruiz-Ruiz MC, et al. **Eur J Immunol** 1997 Jun;27(6):1442-50

Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants. Thilenius AR, et al. **Eur J Immunol** 1997 May; 27(5):1108-14

Homeostatic regulation of CD8+ T cells after antigen challenge in the absence of Fas (CD95). Zimmermann C, et al. **Eur J Immunol** 1996 Dec;26(12):2903-10

Fas/Fas ligand interaction contributes to UV-induced apoptosis in human keratinocytes. Leverkus M, et al. **Exp Cell Res** 1997 May 1;232(2):255-62

Induction of apoptosis and potentiation of TNF- and Fas-mediated apoptosis in U937 cells by the xanthogenate compound D609. Pörn-Ares MI, et al. **Exp Cell Res** 1997 Aug 25;235(1):48-54

Cell cycle specificity of Fas-mediated apoptosis in WIL-2 cells. Beletskaya IV, et al. **FEBS Lett** 1997 Jul 21; 412(1):91-3

Fas and the immunologically underprivileged intestine [editorial; comment] Ma A. **Gastroenterology** 1997 Jul; 113(1):345-8. Comment on: Gastroenterology 1997 Jul;113(1):160-7. Comment on: Gastroenterology 1997 Jul;113(1):168-74.

A possible involvement of Fas-Fas ligand signaling in the pathogenesis of murine autoimmune gastritis. Nishio A, et al. **Gastroenterology** 1996 Oct;111(4):959-67

Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Seino K, et al. **Gastroenterology** 1997 Oct; 113(4):1315-22

CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis [see comments] Sträter J, et al. **Gastroenterology** 1997 Jul;113(1):160-7. Comment in: Gastroenterology 1997 Jul;113(1):345-8.

Possible participation of Fas-mediated apoptosis in the mechanism of atherosclerosis. Fukuo K, et al. **Gerontology** 1997;43 Suppl 1:35-42

Critical role of Fas/Fas ligand interaction in CD28-independent pathway of allogeneic murine hepatocyte rejection. Kawahara T, et al. **Hepatology** 1997 Oct;26(4):944-8

Concanavalin A induces perforin-mediated but not Fas-mediated hepatic injury. Watanabe Y, et al. **Hepatology** 1996 Sep;24(3):702-10

The Fas-based mechanism of lymphocytotoxicity. Berke G. **Hum Immunol** 1997 Apr 15;54(1):1-7 (61 ref.)

TCR alpha/beta and TCR gamma/delta CD4-/CD8-HLA-DR alloreactive CTL clones do not use Fas/Fas ligand pathway to lyse their specific target cells. Mami-Chouaib F, et al. **Hum Immunol** 1996 Nov; 51(1):13-22

Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Huang S, et al. **Immunity** 1997 Jun;6(6):739-49

Casper is a FADD- and caspase-related inducer of apoptosis. Shu HB, et al. **Immunity** 1997 Jun;6(6):751-63

Induction of cell death via Fas (CD95, Apo-1) may be associated with but is not dependent on Fas-induced tyrosine phosphorylation. Janssen O, et al. **Immunol Lett** 1996 Jan;49(1-2):63-9

Dissociation of Fas-mediated cytotoxicity and FasL expression in a cytotoxic CD4+ T-cell clone. Comparative analysis of Fas-mediated cytotoxicity between a T-hybridoma and a T-cell clone. Kaneda R, et al. **Immunol Lett** 1997 Jan;55(1):53-60

ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha. Künstle G, et al. **Immunol Lett** 1997 Jan;55(1):5-10

TNFalpha and anti-Fas antibodies regulate Ly-6E.1 expression by tumor cells: a possible link between angiogenesis and Ly-6E.1. Sagi-Assif O, et al. **Immunol Lett** 1996 Dec;54(2-3):207-13

FasL expression on epithelial cells: the Bottazzo-Feldman hypothesis revisited. Dayan CM, et al. **Immunol Today** 1997 May;18(5):203 (15 ref.)

Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro. Fadeel B, et al. **Int Immunol** 1997 Feb;9(2):201-9

HIV type 1 Tat protein enhances activation-but not Fas (CD95)-induced peripheral blood T cell apoptosis in healthy individuals. Katsikis PD, et al. **Int Immunol** 1997 Jun;9(6):835-41

IL-4 and anti-CD40 protect against Fas-mediated B cell apoptosis and induce B cell growth and differentiation. Nakanishi K, et al. **Int Immunol** 1996 May;8(5):791-8

S-adenosylhomocysteine as a physiological modulator of Apo-1-mediated apoptosis. Ratter F, et al. **Int Immunol** 1996 Jul;8(7):1139-47

Contribution of Fas ligand to cardiac allograft rejection. Seino K, et al. **Int Immunol** 1996 Sep;8(9):1347-54

The roles of Fas and perforin in LAK T-cell/bispecific antibody-mediated killing of the murine B-lymphoma cells, BCL1. Armstrong JM, et al. **Int J Cancer** 1996 Dec 11; 68(6):822-7

Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines. Fellenberg J, et al. **Int J Cancer** 1997 Jul 29;72(3):536-42

Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1(CD95)-mediated apoptosis in renal-cell-cancer cells. Tomita Y, et al. **Int J Cancer** 1996 Sep 27;68(1):132-5

Reversal of phenobarbital-induced hyperplasia and hypertrophy in the livers of lpr mice. Sarraf CE, et al. **Int J Exp Pathol** 1997 Feb;78(1):49-56

Vesnarinone inhibits immune-mediated but not Fas (CD95) agonist-mediated hepatic injury. Lazarus DD, et al. **Int J Immunopharmacol** 1997 Jan;19(1):49-58

Bcl-2 prevents CD95 (Fas/APO-1)-induced degradation of lamin B and poly(ADP-ribose) polymerase and restores the NF-kappaB signaling pathway. Mandal M, et al. **J Biol Chem** 1996 Nov 29;271(48):30354-9

Nitric oxide inhibits Fas-induced apoptosis. Mannick JB, et al. **J Biol Chem** 1997 Sep 26;272(39):24125-8

The large subunit of the DNA replication complex C (DSEB/RF-C140) cleaved and inactivated by caspase-3 (CPP32/YAMA) during Fas-induced apoptosis. Ubeda M, et al. **J Biol Chem** 1997 Aug 1;272(31):19562-8

Fas-associated death domain protein interleukin-1beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling. Vincenz C, et al. **J Biol Chem** 1997 Mar 7;272(10):6578-83

Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. Boirivant M, et al. **J Clin Invest** 1996 Dec 1;98(11):2616-22

Development of inflammatory angiogenesis by local stimulation of Fas in vivo. Biancone L, et al. **J Exp Med** 1997 Jul 7;186(1):147-52

Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. Bieganowska KD, et al. **J Exp Med** 1997 May 5; 185(9):1585-94

Multiple sclerosis: Fas signaling in oligodendrocyte cell death. D'Souza SD, et al. **J Exp Med** 1996 Dec 1; 184(6):2361-70

Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. Itoh N, et al. **J Exp Med** 1997 Aug 18;186(4):613-8

Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. Kiener PA, et al. **J Exp Med** 1997 Apr 21;185(8):1511-6

A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. Peng SL, et al. **J Exp Med** 1996 Sep 1;184(3):1149-54

Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. Wang J, et al. **J Exp Med** 1996 Sep 1;184(3):831-8

Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. Zhang X, et al. **J Exp Med** 1997 May 19; 185(10):1837-49

Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. Boussiotis VA, et al. **J Immunol** 1997 Oct 1; 159(7):3156-67

B cell receptor cross-linking prevents Fas-induced cell death by inactivating the IL-1 beta-converting enzyme protease and regulating Bcl-2/Bcl-x expression. Brás A, et al. **J Immunol** 1997 Oct 1;159(7):3168-77

ZAP-70 tyrosine kinase is required for the up-regulation of Fas ligand in activation-induced T cell apoptosis. Eischen CM, et al. **J Immunol** 1997 Aug 1;159(3):1135-9

IL-4 induces Fas resistance in B cells. Foote LC, et al. **J Immunol** 1996 Oct 1;157(7):2749-53

Apoptosis induced by HIV infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas(CD95) antagonist. Glynn JM, et al. **J Immunol** 1996 Oct 1; 157(7):2754-8

Dissociation of T cell anergy from apoptosis by blockade of Fas/Apo-1 (CD95) signaling. Hargreaves RG, et al. **J Immunol** 1997 Apr 1;158(7):3099-107

HLA-DR-triggered inhibition of hemopoiesis involves Fas/Fas ligand interactions and is prevented by c-kit ligand. Lee JW, et al. **J Immunol** 1997 Oct 1;159(7):3211-9

The DNA-dependent protein kinase catalytic subunit (p460) is cleaved during Fas-mediated apoptosis in Jurkat cells. McConnell KR, et al. **J Immunol** 1997 Mar 1;158(5):2083-9

Apoptosis signaling pathways in normal T cells: differential activity of Bcl-2 and IL-1beta-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity. Moreno MB, et al. **J Immunol** 1996 Nov 1; 157(9):3845-9

Cyclosporine-insensitive partial signaling and multiple roles of Ca2+ in Fas ligand-induced lysis. Rogers AM, et al. **J Immunol** 1997 Oct 1;159(7):3140-7

Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. Sabelko KA, et al. **J Immunol** 1997 Oct 1;159(7):3096-9

Fas ligand-mediated bystander lysis of syngeneic cells in response to an allogeneic stimulus. Smyth MJ. **J Immunol** 1997 Jun 15;158(12):5765-72

T cell receptor of Fas-sensitive T cells in rheumatoid synovium. Sumida T, et al. **J Immunol** 1997 Feb 15; 158(4):1965-70

Lack of requirement for SHP-1 in both Fas-mediated and perforin-mediated cell death induced by CTL. Takayama H, et al. **J Immunol** 1996 Nov 1;157(9):3943-8

Intracellular IL-1beta is an inhibitor of Fas-mediated apoptosis. Tatsuta T, et al. **J Immunol** 1996 Nov 1; 157(9):3949-57

Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. Vergelli M, et al. **J Immunol** 1997 Mar 15;158(6):2756-61

A major role for the Fas pathway in acute graft-versus-host disease. Via CS, et al. **J Immunol** 1996 Dec 15; 157(12):5387-93

Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway. Woodle ES, et al. **J Immunol** 1997 Mar 1; 158(5):2156-64

The Fas-deficient SCID mouse exhibits the development of T cells in the thymus. Yasutomo K, et al. **J Immunol** 1997 May 15;158(10):4729-33

Fas system-mediated apoptosis suppresses lymphopoiesis. Yasutomo K, et al. **J Immunol** 1996 Sep 1;157(5):1981-6

The effect of cyclophosphamide on Fas-mediated apoptosis. Lee JH, et al. **J Korean Med Sci** 1997 Jun;12(3):185-9

Monocytic differentiation modulates apoptotic response to cytotoxic anti-Fas antibody and tumor necrosis factor alpha in human monoblast U937 cells. Kikuchi H, et al. **J Leukoc Biol** 1996 Dec;60(6):778-83

Fas involvement in human NK cell apoptosis: lack of a requirement for CD16-mediated events. Ortaldo JR, et al. **J Leukoc Biol** 1997 Feb;61(2):209-15

Activation of Src-family tyrosine kinases during Fas-induced apoptosis. Schlottmann KE, et al. **J Leukoc Biol** 1996 Oct; 60(4):546-54

Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. Micheau O, et al. **J Natl Cancer Inst** 1997 Jun 4;89(11):783-9

The apoptotic death of neuroblastoma cells caused by serum from patients with insulin-dependent diabetes and neuropathy may be Fas-mediated. Pittenger GL, et al. **J Neuroimmunol** 1997 Jun;76(1-2):153-60

The cytocidal activity of OK-432-activated mononuclear cells against human glioma cells is partly mediated through the Fas ligand/Fas system. Toda K, et al. **Jpn J Cancer Res** 1996 Sep;87(9):972-6

Fas receptor (CD95)-mediated apoptosis in leukemic cells. Komada Y, et al. **Leuk Lymphoma** 1997 Mar;25(1-2):9-21 (65 ref.)

Fas antigen/APO-1 (CD95) expression on myeloma cells. Shima Y, et al. **Leuk Lymphoma** 1996 Nov;23(5-6):521-31 (92 ref.)

Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Karawajew L, et al. **Leukemia** 1997 Aug;11(8):1245-52

Role of p53 tumor suppressor gene and Fas/Apo-1 in induction of apoptosis and differentiation of cancer cells. Takahashi R. **Leukemia** 1997 Apr;11 Suppl 3:331-3

HIV-1-infected myelomonocytic cells are resistant to Fas-mediated apoptosis: effect of tumor necrosis factor-alpha on their Fas expression and apoptosis. Okamoto M, et al. **Med Microbiol Immunol (Berl)** 1997 Jun;186(1):11-7

Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases [published erratum appears in Mol Cell Biol 1997 Mar;17(3):1757] Juo P, et al. **Mol Cell Biol** 1997 Jan; 17(1):24-35

Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis. Lenczowski JM, et al. **Mol Cell Biol** 1997 Jan; 17(1):170-81

MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Malinin NL, et al. **Nature** 1997 Feb 6;385(6616):540-4

Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3. Nishina H, et al. **Nature** 1997 Jan 23;385(6614):350-3

Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: a potential role for transcription factor NF-kappa B. Ivanov VN, et al. **Oncogene** 1997 May 22;14(20):2455-64

Involvement of caspase-4(-like) protease in Fas-mediated apoptotic pathway. Kamada S, et al. **Oncogene** 1997 Jul 17;15(3):285-90

CD95-induced apoptosis contributes to loss of primed/memory but not resting/naive T cells in children infected with human immunodeficiency virus type 1. Böhler T, et al. **Pediatr Res** 1997 Jun;41(6):878-85

Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Boise LH, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3759-64

Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. Reap EA, et al.

Proc Natl Acad Sci U S A 1997 May 27;94(11):5750–5
Fas–induced apoptosis of T cells occurs independently of ceramide generation. Watts JD, et al.
Proc Natl Acad Sci U S A 1997 Jul 8;94(14):7292–6
Requirement for GD3 ganglioside in CD95– and ceramide–induced apoptosis. De Maria R, et al. **Science** 1997 Sep 12;277(5332):1652–5
Melanoma cell expression of Fas(Apo–1/CD95) ligand: implications for tumor immune escape [see comments] Hahne M, et al. **Science** 1996 Nov 22;274(5291):1363–6. Comment in: Science 1996 Nov 22;274(5291):1302.
Tumor cells fight back to beat immune system [news; comment] Williams N. **Science** 1996 Nov 22;274(5291):1302. Comment on: Science 1996 Nov 22;274(5291):1363–6.
Fas and other cell death signaling pathways. Depraetere V, et al. **Semin Immunol** 1997 Apr;9(2):93–107 (186 ref.)
Induction of apoptosis following antigen presentation by T cells: anergy and apoptosis are two separate phenomena. Hargreaves RG, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):1102–4
Analysis of biochemical and biological functions of Fas–ligand (FasL) and Fas on activated T cells in allo–immune response. Nakajima H, et al.
Transplant Proc 1997 Feb–Mar;29(1–2):1096–100
Class I MHC mediates programmed cell death in a Fas–independent manner. Woodle ES, et al.
Transplant Proc 1997 Feb–Mar;29(1–2):1101
Islet rejection in perforin–deficient mice: the role of perforin and Fas. Ahmed KR, et al. **Transplantation** 1997 Apr 15; 63(7):951–7
Sensitization to Fas–mediated apoptosis by hepatitis C virus core protein. Ruggieri A, et al. **Virology** 1997 Mar 3; 229(1):68–76
[Normal colon epithelium is highly sensitive to CD95–induced apoptosis.Indication for a role of cell death–induced CD95/CL95L systems under inflammatory inflammatory conditions?] Sträter J, et al.
Verh Dtsch Ges Pathol 1996;80:217 **(Ger)**
[Development of anti cancer drugs targeted on Fas–mediated apoptosis signal] Takahashi M, et al.
Gan To Kagaku Ryoho 1997 Jan;24(2):222–8 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Physiological roles of Fas, an apoptosis inductor cell surface receptor molecule] Yonehara N.
Nihon Rinsho Meneki Gakkai Kaishi 1995 Dec;18(6):581–2 (0 ref.) **(Jpn)**
[Apoptosis in human diseases: role of Fas system in liver cell injury by viral hepatitis] Mita E, et al.
Rinsho Byori 1997 May;45(5):477–82 (15 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Roth W, et al. **Cancer Immunol Immunother** 1997 Mar;44(1):55–63

TOXICITY

CD4+ T cells reactivated with superantigen are both more sensitive to FasL–mediated killing and express a higher level of FasL. Wang JKM, et al. **Cell Immunol** 1997 Aug 1;179(2):153–64
Reduced susceptibility to Fas–mediated apoptosis in B–1 cells. Masuda K, et al. **Eur J Immunol** 1997 Feb; 27(2):449–55
Inhibition of CPP32–like proteases prevents granzyme B– and Fas–, but not granzyme A–based cytotoxicity exerted by CTL clones. Anel A, et al. **J Immunol** 1997 Mar 1; 158(5):1999–2006
Protection against Fas/APO–1– and tumor necrosis factor–mediated cell death by a novel protein, sentrin. Okura T, et al. **J Immunol** 1996 Nov 15;157(10):4277–81
Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. Tanaka M, et al. **J Immunol** 1997 Mar 1;158(5):2303–9

ANTIGENS, CD106 see **VASCULAR CELL ADHESION MOLECULE–1**

ANTIGENS, CD115 see **RECEPTORS, MACROPHAGE COLONY–STIMULATING FACTOR**

ANTIGENS, CD116 see **RECEPTORS, GRANULOCYTE–MACROPHAGE COLONY–STIMULATING FACTOR**

ANTIGENS, CD117 see **PROTO–ONCOGENE PROTEINS C–KIT**

ANTIGENS, CDW121A see **RECEPTORS, INTERLEUKIN–1**

ANTIGENS, CDW121B see **RECEPTORS, INTERLEUKIN–1**

ANTIGENS, CD122 see **RECEPTORS, INTERLEUKIN–2**

ANTIGENS, DIFFERENTIATION

Human peripheral B cell development. sIgM–IgD+CD38+ hypermutated germinal center centroblasts preferentially express Ig lambda light chain and have undergone mu–to–delta switch. Arpin C, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:193–8
Somatic sex–determining signals act on XX germ cells in Drosophila embryos. Staab S, et al. **Development** 1996 Dec; 122(12):4065–71
Nomenclature and characterization of leukocyte differentiation antigens in ruminants. Naessens J, et al. **Immunol Today** 1997 Aug;18(8):365–8
Identification of novel lymphoid tissues in murine intestinal mucosa where clusters of c–kit+ IL–7R+ Thy1+ lympho–hemopoietic progenitors develop [see comments] Kanamori Y, et al. **J Exp Med** 1996 Oct 1;184(4):1449–59. Comment in: J Exp Med 1996 Oct 1;184(4):1203–6.
A comparative analysis of neuroblastic and substrate–adherent human neuroblastoma cell lines. La Quaglia MP, et al. **J Pediatr Surg** 1996 Feb;31(2):315–8
Report on the 2nd International CD38 workshop. Berthelier V, et al. **Res Immunol** 1996 Jul–Aug;147(6):407–11

ADMINISTRATION & DOSAGE

Preventing allograft rejection with CTLA4IG: effect of donor–specific transfusion route or timing. Bolling SF, et al. **J Heart Lung Transplant** 1996 Sep;15(9):928–35
Ex vivo treatment of antigen–presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. Khoury SJ, et al. **J Immunol** 1996 Oct 15;157(8):3700–5
B7–blocking agents, alone or in combination with cyclosporin A, induce antigen–specific anergy of human memory T cells. Yi–qun Z, et al. **J Immunol** 1997 May 15; 158(10):4734–40
Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS–188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. Srinivas NR, et al. **Pharm Res** 1997 Jul;14(7):911–6
CTLA4–Ig and anti–CD40 ligand prevent renal allograft rejection in primates. Kirk AD, et al.
Proc Natl Acad Sci U S A 1997 Aug 5;94(16):8789–94

ANALYSIS

Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Wu PC, et al. **Am J Pathol** 1996 Oct;149(4):1167–75
Elevated expression of the neutrophil calcium–binding protein, MRP–14, in metastasis–enhancing neutrophils. McGary CT, et al. **Anticancer Res** 1997 Jan–Feb; 17(1A):1–6
Altered mononuclear phagocyte differentiation associated with genetic defects of the lysosomal acid lipase. Rothe G, et al. **Atherosclerosis** 1997 Apr;130(1–2):215–21
Refinement of the differentiated phenotype of the spermatogenic cell line GC–2spd(ts) [published erratum appears in Biol Reprod 1996 Dec;55(6):1458] Wolkowicz MJ, et al. **Biol Reprod** 1996 Oct;55(4):923–32
Individual CD34+CD38lowCD19–CD10– progenitor cells from human cord blood generate B lymphocytes and granulocytes. Berardi AC, et al. **Blood** 1997 May 15; 89(10):3554–64
Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study. Uckun FM, et al. **Blood** 1997 Apr 1;89(7):2488–93
Ultrastructural localization of CD38 immunoreactivity in rat brain. Yamada M, et al. **Brain Res** 1997 May 9; 756(1–2):52–60
Dual CD38 and DNA staining of plasma cells in monoclonal gammopathies attained by a rapid, non–wash and automated method. Gómez–Arbonés X, et al.
Clin Lab Haematol 1996 Jun;18(2):95–7
Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow–up. Liu Z, et al. **Cytometry** 1996 Mar 15;26(1):1–7
Detection of myeloma cells in the peripheral blood by flow cytometry. Witzig TE, et al. **Cytometry** 1996 Jun 15; 26(2):113–20
TGF–beta and MIP–1 alpha exert their main inhibitory activity on very primitive CD34+2CD38– cells but show opposite effects on more mature CD34+CD38+ human hematopoietic progenitors. Van Ranst PC, et al.
Exp Hematol 1996 Nov;24(13):1509–15
Expression of galectins in head and neck squamous cell carcinoma. Gillenwater A, et al. **Head Neck** 1996 Sep–Oct; 18(5):422–32
Distribution of plasma cell markers and intracellular IgE in cell line U266. Lagging E, et al. **Immunol Lett** 1996 Jan; 49(1–2):71–7
Accumulation of CTLA–4 expressing T lymphocytes in the germinal centres of human lymphoid tissues. Castan J, et al. **Immunology** 1997 Feb;90(2):265–71
Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids. Funaro A, et al. **Int Immunol** 1996 Nov;8(11):1643–50
Characterization of olfactory receptor neurons and other cell types in dissociated rat olfactory cell cultures. Pixley SK. **Int J Dev Neurosci** 1996 Nov;14(7–8):823–39
CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV–1–infected patients. Mocroft A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Feb 1;14(2):158–62
Strikingly different localization of galectin–3 and galectin–4 in human colon adenocarcinoma T84 cells. Galectin–4 is localized at sites of cell adhesion. Huflejt ME, et al.
J Biol Chem 1997 May 30;272(22):14294–303
Definition of a natural killer NKR–P1A+/CD56–/CD16– functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12 [published erratum appears in J Exp Med 1997 Mar 17;185(6):1150–1] Bennett IM, et al. **J Exp Med** 1996 Nov 1;184(5):1845–56
Ex vivo expansion of CD34 + CD38– cord blood cells. De Bruyn C, et al. **J Hematother** 1997 Apr;6(2):93–102
Lineage commitment of HLA–DR/CD38–defined progenitor cell subpopulations in bone marrow and mobilized peripheral blood assessed by four–color immunofluorescence. Harvey K, et al. **J Hematother** 1997 Jun;6(3):243–52
Mapping of the catalytic and epitopic sites of human CD38/NAD+ glycohydrolase to a functional domain in the carboxyl terminus. Hoshino S, et al. **J Immunol** 1997 Jan 15;158(2):741–7
Evaluation of the cross–reactivity between human and feline or canine leucocyte antigens using commercially available antibodies. Darbès J, et al. **J Vet Diagn Invest** 1997 Jan; 9(1):94–7
Efficient long–term maintenance of chronic myeloid leukemic cobblestone area forming cells on a murine stromal cell line. Cornelissen JJ, et al. **Leukemia** 1997 Jan; 11(1):126–33
IgE–binding proteins in fish and fish steam. Pascual CY, et al. **Monogr Allergy** 1996;32:174–80
Development of a method of thymocyte differentiation of bone marrow–enriched CD34+CD38– cells in postnatal allogeneic cultured thymic epithelia to evaluate immunodeficiency disorders. Knutsen AP, et al.
Stem Cells 1996 Nov;14(6):702–13
Characterization of baboon vertebral body marrow. Kenyon NS, et al. **Transplant Proc** 1997 Jun;29(4):1952
[CD7, HLA–DR, CD38 positive acute undifferentiated leukemia with subcutaneous tumor and thymoma] Doi T, et al. **Rinsho Ketsueki** 1996 Aug;37(8):676–81 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Expression of RT6, but not CD45RC, is disturbed on immature peripheral T cells in the BB rat. Groen H, et al. **Adv Exp Med Biol** 1997;419:253–6
Dysregulation of carcinoembryonic antigen group members CGM2, CD66a (biliary glycoprotein), and nonspecific cross–reacting antigen in colorectal carcinomas. Comparative analysis by northern blot and in situ hybridization. Nollau P, et al. **Am J Pathol** 1997 Aug; 151(2):521–30
A differentiation antigen of human large luteal cells in corpora lutea of the menstrual cycle and early pregnancy. Fujiwara H, et al. **Biol Reprod** 1996 Jun;54(6):1173–83
Differential expression of two beta–galactoside–binding lectins in the reproductive tracts of pregnant mice. Phillips B, et al. **Biol Reprod** 1996 Sep;55(3):548–58
An immunocytochemical technique for analysis of regulation of genes encoding early differentiation marker antigens in an oocyte translation system. Nishizawa K, et al.
Biotech Histochem 1996 Mar;71(2):73–8
Involvement of retinoic acid receptor–alpha–mediated signaling pathway in induction of CD38 cell–surface antigen. Mehta K, et al. **Blood** 1997 May 15;89(10):3607–14
Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7–1 and B7–2 and the B7 counter–receptor CTLA–4. Gerstmayer B, et al.
FEBS Lett 1997 Apr 21;407(1):63–8
Human gene encoding CD38 (ADP–ribosyl cyclase/cyclic ADP–ribose hydrolase): organization, nucleotide sequence and alternative splicing. Nata K, et al. **Gene** 1997 Feb 28; 186(2):285–92
Expression of the S–100 proteins MRP–8 and –14 in ischemic brain lesions. Postler E, et al. **Glia** 1997 Jan;19(1):27–34
Expression of the 67–kD laminin receptor, galectin–1, and galectin–3 in advanced human uterine adenocarcinoma. van den Brule FA, et al. **Hum Pathol** 1996 Nov;27(11):1185–91
Extracellular synthesis of cADP–ribose from nicotinamide–adenine dinucleotide by rat cortical astrocytes in culture. Pawlikowska L, et al. **J Neurosci** 1996 Sep 1;16(17):5372–81
Rotenone, a mitochondrial NADH dehydrogenase inhibitor, induces cell surface expression of CD13 and CD38 and apoptosis in HL–60 cells. Matsunaga T, et al.
Leuk Lymphoma 1996 Feb;20(5–6):487–94
Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Haase D, et al. **Leukemia** 1997 May;11(5):674–9
Large–scale production of human CD38 in yeast by fermentation. Munshi CB, et al. **Methods Enzymol** 1997; 280:318–30
Definition by specific antisense oligonucleotides of a role for protein kinase C alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes. Lee YS, et al. **Mol Carcinog** 1997 Jan; 18(1):44–53
mCD24 expression in the developing mouse brain and in zones of secondary neurogenesis in the adult. Calaora V,

et al. **Neuroscience** 1996 Jul;73(2):581–94

Preparation and characterization of two human carcinoembryonic antigen family proteins of neutrophils, CD66b and c, in silkworm larvae. Yamanaka T, et al. **Protein Expr Purif** 1996 Jun;7(4):438–46

In vitro expression of activation markers and lymphocyte proliferation in response to interleukin 12: effect of immunosuppressive agents. Degiannis D, et al. **Transplant Proc** 1996 Dec;28(6):3062–4

Genetic modification of an islet tumor cell line inhibits its rejection. Georgiou HM, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1032–3

Effect of CTLA4–Ig gene transfer using adenoviral vector in organ and cell transplantation. Hayashi S, et al. **Transplant Proc** 1997 Jun;29(4):2212

Evidence that the adenoviral vector containing the CTLA4–Ig gene improves transgene expression and graft survival. Namii Y, et al. **Transplant Proc** 1997 May; 29(3):1738–9

BLOOD

Elevated plasma levels of L1L and L1H in CF patients. Clohessy PA, et al. **Biochem Soc Trans** 1996 May; 24(2):310S

MRP 8/14 as marker for Plasmodium falciparum–induced malaria episodes in individuals in a holoendemic area. Bordmann G, et al. **Clin Diagn Lab Immunol** 1997 Jul; 4(4):435–9

Enzyme–linked immunosorbent assay for human MRP–8/MRP–14 proteins and their quantitation in plasma of hematological patients. Ivanov GE, et al. **Immunol Lett** 1996 Jan;49(1–2):7–13

delta IK17: an antigen expressed on human lymphocytes. Sotiriadou R, et al. **Int J Biol Markers** 1996 Oct–Dec; 11(4):183–9

Cytolytic T cell reactivity against melanoma–associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Jäger E, et al. **Melanoma Res** 1996 Dec;6(6):419–25

Time–scale of interleukin–6, myeloid related proteins (MRP), C reactive protein (CRP), and endotoxin plasma levels during the postoperative acute phase reaction. Berger D, et al. **Shock** 1997 Jun;7(6):422–6

IgE binding to a new cross–reactive structure: a 35 kDa protein in birch pollen, exotic fruit and other plant foods. Wellhausen A, et al. **Z Ernahrungswiss** 1996 Dec; 35(4):348–55

CHEMISTRY

Adipocyte differentiation–related protein is secreted into milk as a constituent of milk lipid globule membrane. Heid HW, et al. **Biochem J** 1996 Dec 15;320 (Pt 3):1025–30

CD38 and ADP–ribosyl cyclase catalyze the synthesis of a dimeric ADP–ribose that potentiates the calcium–mobilizing activity of cyclic ADP–ribose. De Flora A, et al. **J Biol Chem** 1997 May 16;272(20):12945–51

Capillary electrophoretic examination of underivatized oligosaccharide mixtures released from immunoglobulin G antibodies and CTLA4Ig fusion protein. Greve KF, et al. **J Chromatogr A** 1996 Oct 18;749(1–2):237–45

Liquid chromatographic and capillary electrophoretic examination of intact and degraded fusion protein CTLA4Ig and kinetics of conformational transition. Greve KF, et al. **J Chromatogr A** 1996 Feb 9;723(2):273–84

Solution structure of human CTLA–4 and delineation of a CD80/CD86 binding site conserved in CD28 [letter] Metzler WJ, et al. **Nat Struct Biol** 1997 Jul;4(7):527–31

Crystal structure of Aplysia ADP ribosyl cyclase, a homologue of the bifunctional ectozyme CD38. Prasad GS, et al. **Nat Struct Biol** 1996 Nov;3(11):957–64

DRUG EFFECTS

Lysine 129 of CD38 (ADP–ribosyl cyclase/cyclic ADP–ribose hydrolase) participates in the binding of ATP to inhibit the cyclic ADP–ribose hydrolase. Tohgo A, et al. **J Biol Chem** 1997 Feb 14;272(7):3879–82

GENETICS

Non–HLA genes and the susceptibility to insulin dependent diabetes: the role of the CTLA–4 gene. Pozzilli P, et al. **Acta Diabetol** 1996 Dec;33(4):250–2 (20 ref.)

There is an increase in expression of the cytotoxic T–lymphocyte antigen–2 alpha gene during pregnancy. Campo MA, et al. **Am J Obstet Gynecol** 1996 May; 174(5):1605–7

Transformation but not ras–transfection increases the expression of galectin–3 in human HOS cells. Hébert E, et al. **C R Acad Sci III** 1996 Oct;319(10):871–7

A CTLA–4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Kotsa K, et al. **Clin Endocrinol (Oxf)** 1997 May;46(5):551–4

Human gene encoding CD38 (ADP–ribosyl cyclase/cyclic ADP–ribose hydrolase): organization, nucleotide sequence and alternative splicing. Nata K, et al. **Gene** 1997 Feb 28; 186(2):285–92

Ex vivo adenovirus–mediated gene transfer and immunomodulatory protein production in human cornea. Oral HB, et al. **Gene Ther** 1997 Jul;4(7):639–47

The genomic structure of the human Charcot–Leyden crystal protein gene is analogous to those of the galectin genes. Dyer KD, et al. **Genomics** 1997 Mar 1;40(2):217–21

Association of polymorphism at COL3A and CTLA4 loci on chromosome 2q31–33 with the clinical phenotype and in–vitro CMI status in healthy and leprosy subjects: a preliminary study. Kaur G, et al. **Hum Genet** 1997 Jul; 100(1):43–50

The CTLA–4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Nisticò L, et al. **Hum Mol Genet** 1996 Jul; 5(7):1075–80

CTLA4 alanine–17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. Donner H, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):143–6

Synergistic induction of CTLA–4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability. Finn PW, et al. **J Immunol** 1997 May 1; 158(9):4074–81

Mapping of the galectin–3 gene (LGALS3) to human chromosome 14 at region 14q21–22. Raimond J, et al. **Mamm Genome** 1997 Sep;8(9):706–7

Thymocyte development is normal in CTLA–4–deficient mice. Chambers CA, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9296–301

[Genetic structure of the Mari population and its genetic position in the system of other Finno–Ugrian population groups] Kravchuk OI, et al. **Genetika** 1996 Sep; 32(9):1277–86 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Characterisation of the swine swC1 antigen. Magyar A, et al. **Acta Vet Hung** 1997;45(1):17–31

Regulation of T cell activation by CD28 and CTLA4. Noel PJ, et al. **Adv Exp Med Biol** 1996;406:209–17 (27 ref.)

Myeloma bone marrow plasma cells: evidence for their capacity as antigen–presenting cells. Yi Q, et al. **Blood** 1997 Sep 1;90(5):1960–7

Endothelial–selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma. Ravindranath MH, et al. **Cancer** 1997 May 1;79(9):1686–97

Secretion of IFN–gamma, IL–6, granulocyte–macrophage colony–stimulating factor and IL–10 cytokines after activation of human purified T lymphocytes upon CD38 ligation. Ausiello CM, et al. **Cell Immunol** 1996 Nov 1; 173(2):192–7

The mechanism of interleukin 4–induced down–regulation of CD38 on human B cells. Shubinsky G, et al. **Cell Immunol** 1996 Oct 10;173(1):87–95

Poly–N–acetyllactosaminyl saccharide chains of band 3 as determinants for anti–band 3 autoantibody binding to senescent and oxidized erythrocytes. Beppu M, et al. **Cell Mol Biol (Noisy–le–grand)** 1996 Nov;42(7):1007–24 (95 ref.)

Co–stimulation in T cell responses. Chambers CA, et al. **Curr Opin Immunol** 1997 Jun;9(3):396–404 (83 ref.)

New monoclonal antibody (4E9R) identifies mouse neural crest cells [published erratum appears in Dev Dyn 1997 Jan;208(1):137] Kubota Y, et al. **Dev Dyn** 1996 Aug; 206(4):368–78

Structural identification of the hematopoietic progenitor antigen ER–MP12 as the vascular endothelial adhesion molecule PECAM–1 (CD31). Ling V, et al. **Eur J Immunol** 1997 Feb;27(2):509–14

Human CD38, a cell–surface protein with multiple functions. Mehta K, et al. **FASEB J** 1996 Oct;10(12):1408–17 (69 ref.)

Osteoclast differentiation antigen. Kukita T, et al. **Histol Histopathol** 1996 Jul;11(3):821–30 (91 ref.)

Induction of peripheral T cell tolerance in vivo requires CTLA–4 engagement. Perez VL, et al. **Immunity** 1997 Apr; 6(4):411–7

The monoclonal antibody Mac 387 recognizes three S100 proteins in human neutrophils. Guignard F, et al. **Immunol Cell Biol** 1996 Feb;74(1):105–7

Surface expression of CD28 single chain Fv for costimulation by tumor cells. Winberg G, et al. **Immunol Rev** 1996 Oct; 153:209–23 (19 ref.)

Characterization of swine leukocyte differentiation antigens. Saalmüller A. **Immunol Today** 1996 Aug;17(8):352–4

Enhancement of CD3–mediated thymocyte apoptosis by the cross–linkage of heat–stable antigen. Hitsumoto Y, et al. **Immunology** 1996 Oct;89(2):200–4

Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids. Funaro A, et al. **Int Immunol** 1996 Nov;8(11):1643–50

Superantigen responses and co–stimulation: CD28 and CTLA–4 have opposing effects on T cell expansion in vitro and in vivo. Krummel MF, et al. **Int Immunol** 1996 Apr; 8(4):519–23

Cross–linking the murine heat–stable antigen induces apoptosis in B cell precursors and suppresses the anti–CD40–induced proliferation of mature resting B lymphocytes. Chappel MS, et al. **J Exp Med** 1996 Nov 1;184(5):1638–49

CTLA–4–B7 interaction is sufficient to costimulate T cell clonal expansion. Wu Y, et al. **J Exp Med** 1997 Apr 7; 185(7):1327–35

Non–replicating recombinant vaccinia virus encoding murine B–7 molecules elicits effective costimulation of naive CD4+ splenocytes in vitro. Oertli D, et al. **J Gen Virol** 1996 Dec;77 (Pt 12):3121–5

Interaction of CTLA–4 with the clathrin–associated protein AP50 results in ligand–independent endocytosis that limits cell surface expression. Chuang E, et al. **J Immunol** 1997 Jul 1;159(1):144–51

Mapping of the catalytic and epitopic sites of human CD38/NAD+ glycohydrolase to a functional domain in the carboxyl terminus. Hoshino S, et al. **J Immunol** 1997 Jan 15;158(2):741–7

Mouse CD38 is down–regulated on germinal center B cells and mature plasma cells. Oliver AM, et al. **J Immunol** 1997 Feb 1;158(3):1108–15

CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA–4–deficient mice. Tivol EA, et al. **J Immunol** 1997 Jun 1;158(11):5091–4

Specific blockade of CTLA–4/B7 interactions results in exacerbated clinical and histologic disease in an actively–induced model of experimental allergic encephalomyelitis. Hurwitz AA, et al. **J Neuroimmunol** 1997 Mar;73(1–2):57–62

Immunohistochemical characterization of monoclonal antibodies (PDs) as markers of the periderm in the developing chicken embryo. Isokawa K, et al. **J Nihon Univ Sch Dent** 1996 Dec;38(3–4):131–40

Atypical antineutrophil cytoplasmic antibodies sera do not react with MRP8/14 neutrophil cytosolic proteins [letter] Ivanov GE, et al. **J Rheumatol** 1997 May;24(5):1019–20

Antiviral immune responses in CTLA4 transgenic mice. Zimmermann C, et al. **J Virol** 1997 Mar;71(3):1802–7

Carcinoembryonic antigens (CD66) on epithelial cells and neutrophils are receptors for Opa proteins of pathogenic neisseriae. Virji M, et al. **Mol Microbiol** 1996 Dec; 22(5):941–50

The N–domain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria meningitidis and Neisseria gonorrhoeae. Virji M, et al. **Mol Microbiol** 1996 Dec;22(5):929–39

Anti–CD38 prevents the development of the adaptive response induced by X–rays in human lymphocytes. Wojewódzka M, et al. **Mutagenesis** 1996 Nov;11(6):593–6

Efficient epitope mapping by bacteriophage lambda surface display. Kuwabara I, et al. **Nat Biotechnol** 1997 Jan; 15(1):74–8

Thymocyte development is normal in CTLA–4–deficient mice. Chambers CA, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9296–301

Cross–linking of CD38 molecules induced expression of interleukin–2 receptor (IL–2R) and HLA–DR on human thymocytes. Amirghofran Z, et al. **Roum Arch Microbiol Immunol** 1995 Oct–Dec;54(4):265–70

Role of the human CD38 molecule in B cell activation and proliferation. Funaro A, et al. **Tissue Antigens** 1997 Jan; 49(1):7–15

Adenovirus–mediated gene transfer of CTLA4Ig to liver allografts results in prolonged survival and local T–cell anergy. Olthoff KM, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):1030–1

Tolerance to a second donor–matched allograft following local immune modulation using transfer of sequences encoding CTLA4Ig. Shaked A, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1026

ISOLATION & PURIFICATION

Differential expression of CD66a (BGP), a cell adhesion molecule of the carcinoembryonic antigen family, in benign, premalignant, and malignant lesions of the human mammary gland. Riethdorf L, et al. **J Histochem Cytochem** 1997 Jul;45(7):957–63

Identification of the mouse calcium–binding proteins, MRP 8 and MRP 14, in Schistosoma mansoni–induced granulomas: biochemical and functional characterization. Yang TH, et al. **J Leukoc Biol** 1997 Mar;61(3):258–66

METABOLISM

Signal transduction via the CD38/NAD+ glycohydrolase. Kontani K, et al. **Adv Exp Med Biol** 1997;419:421–30

ADP–ribosyl cyclase and CD38. Multi–functional enzymes in Ca+2 signaling. Lee HC, et al. **Adv Exp Med Biol** 1997; 419:411–9 (29 ref.)

Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Lane P. **Ann N Y Acad Sci** 1997 Apr 5;815:392–400 (40 ref.)

Sarcoplasmic reticulum–associated and protein kinase C–regulated ADP–ribosyl cyclase in cardiac muscle. Mészáros LG, et al. **Biochem Biophys Res Commun** 1997 May 8;234(1):252–6

Identification of bovine liver mitochondrial NAD+ glycohydrolase as ADP–ribosyl cyclase. Ziegler M, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):401–5

Expression of the endogenous galactose–binding protein galectin–3 correlates with the malignant potential of tumors in the central nervous system. Bresalier RS, et al. **Cancer** 1997 Aug 15;80(4):776–87

Colon cancer mucin: a new ligand for the beta–galactoside–binding protein galectin–3. Bresalier RS, et al. **Cancer Res** 1996 Oct 1;56(19):4354–7

Interactions between galectin–3 and Mac–2–binding protein mediate cell–cell adhesion. Inohara H, et al. **Cancer Res** 1996 Oct 1;56(19):4530–4

Expression of CD66a (human C–CAM) and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas. Nollau P, et al.

Cancer Res 1997 Jun 15;57(12):2354–7
Lymphocyte activation: T–cell regulation by CTLA–4. Linsley PS, et al. **Curr Biol** 1996 Apr 1;6(4):398–400
Gap junction formation between cultured embryonic lens cells is inhibited by antibody to N–cadherin. Frenzel EM, et al. **Dev Biol** 1996 Oct 10;179(1):1–16
CD66 carcinoembryonic antigens mediate interactions between Opa–expressing Neisseria gonorrhoeae and human polymorphonuclear phagocytes. Gray–Owen SD, et al. **EMBO J** 1997 Jun;16(12):3435–45
Phosphorylation of myeloid–related proteins MRP–14 and MRP–8 during human neutrophil activation. Guignard F, et al. **Eur J Biochem** 1996 Oct 1;241(1):265–71
The role of matrix contact and of cell–cell interactions in choriocarcinoma cell differentiation. Hohn HP, et al. **Eur J Cell Biol** 1996 Jan;69(1):76–85
Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor–transgenic CTLA–4–deficient mice. Waterhouse P, et al. **Eur J Immunol** 1997 Aug;27(8):1887–92
The heterodimer of the Ca2+–binding proteins MRP8 and MRP14 binds to arachidonic acid. Klempt M, et al. **FEBS Lett** 1997 May 12;408(1):81–4
Oscillation of ADP–ribosyl cyclase activity during the cell cycle and function of cyclic ADP–ribose in a unicellular organism, Euglena gracilis. Masuda W, et al. **FEBS Lett** 1997 Mar 17;405(1):104–6
Association of phosphatidylinositol 3–kinase with the proto–oncogene product Cbl upon CD38 ligation by a specific monoclonal antibody in THP–1 cells. Matsuo T, et al. **FEBS Lett** 1996 Nov 11;397(1):113–6
NAD+–dependent internalization of the transmembrane glycoprotein CD38 in human Namalwa B cells. Zocchi E, et al. **FEBS Lett** 1996 Nov 4;396(2–3):327–32
Macrophage surface glycoproteins binding to galectin–3 (Mac–2–antigen). Dong S, et al. **Glycoconj J** 1997 Feb; 14(2):267–74
Induction of peripheral T cell tolerance in vivo requires CTLA–4 engagement. Perez VL, et al. **Immunity** 1997 Apr; 6(4):411–7
Tyrosine phosphorylation controls internalization of CTLA–4 by regulating its interaction with clathrin–associated adaptor complex AP–2. Shiratori T, et al. **Immunity** 1997 May;6(5):583–9
The role of B7–1/B7–2:CD28/CLTA–4 pathways in the prevention of anergy, induction of productive immunity and down–regulation of the immune response. Boussiotis VA, et al. **Immunol Rev** 1996 Oct;153:5–26 (170 ref.)
The role of CTLA–4 in the regulation and initiation of T–cell responses. Chambers CA, et al. **Immunol Rev** 1996 Oct; 153:27–46 (90 ref.)
The complexities of T–cell co–stimulation: CD28 and beyond. Sperling AI, et al. **Immunol Rev** 1996 Oct; 153:155–82 (100 ref.)
CTLA–4, a negative regulator of T–lymphocyte activation. Waterhouse P, et al. **Immunol Rev** 1996 Oct;153:183–207 (130 ref.)
Importance of combined treatment with IL–10 and IL–4, but not IL–13, for inhibition of monocyte release of the Ca(2+)–binding protein MRP8/14. Lügering N, et al. **Immunology** 1997 May;91(1):130–4
Pseudomonas aeruginosa lipopolysaccharide binds galectin–3 and other human corneal epithelial proteins. Gupta SK, et al. **Infect Immun** 1997 Jul;65(7):2747–53
B7–CD28 interaction is a late acting co–stimulatory signal for human T cell responses. Zhang YQ, et al. **Int Immunol** 1997 Aug;9(8):1095–102
Potentiation of chemotactic peptide–induced superoxide generation by CD38 ligation in human myeloid cell lines. Tsujimoto N, et al. **J Biochem (Tokyo)** 1997 May; 121(5):949–56
Covalent dimerization of CD28/CTLA–4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. Greene JL, et al. **J Biol Chem** 1996 Oct 25;271(43):26762–71
A heterocomplex formed by the calcium–binding proteins MRP8 (S100A8) and MRP14 (S100A9) binds unsaturated fatty acids with high affinity. Siegenthaler G, et al. **J Biol Chem** 1997 Apr 4;272(14):9371–7
Lysine 129 of CD38 (ADP–ribosyl cyclase/cyclic ADP–ribose hydrolase) participates in the binding of ATP to inhibit the cyclic ADP–ribose hydrolase. Tohgo A, et al. **J Biol Chem** 1997 Feb 14;272(7):3879–82
Expression and regulation of galectin 3 in rat osteoblastic cells. Aubin JE, et al. **J Cell Physiol** 1996 Dec; 169(3):468–80
Novel alphaGalNAc containing glycans on cytokeratins are recognized invitro by galectins with type II carbohydrate recognition domains. Goletz S, et al. **J Cell Sci** 1997 Jul; 110 (Pt 14):1585–96
Plasma membrane targetting, vesicular budding and release of galectin 3 from the cytoplasm of mammalian cells during secretion. Mehul B, et al. **J Cell Sci** 1997 May;110 (Pt 10):1169–78
Relevance of major histocompatibility complex class II expression as a hallmark for the cellular differentiation in the human adrenal cortex. Marx C, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3136–40
CD80 (B7–1) binds both CD28 and CTLA–4 with a low affinity and very fast kinetics. van der Merwe PA, et al. **J Exp Med** 1997 Feb 3;185(3):393–403
Regulation of surface and intracellular expression of CTLA4 on mouse T cells. Alegre ML, et al. **J Immunol** 1996 Dec 1;157(11):4762–70
Tyrosine kinase–dependent regulation of L–selectin expression through the Leu–13 signal transduction molecule: evidence for a protein kinase C–independent mechanism of L–selectin shedding. Frey M, et al. **J Immunol** 1997 Jun 1;158(11):5424–34
B7.2 expressed by T cells does not induce CD28–mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. Greenfield EA, et al. **J Immunol** 1997 Mar 1; 158(5):2025–34
CD38 ligation in human B cell progenitors triggers tyrosine phosphorylation of CD19 and association of CD19 with lyn and phosphatidylinositol 3–kinase. Kitanaka A, et al. **J Immunol** 1997 Jul 1;159(1):184–92
Selective induction of CD73 expression in human lymphocytes by CD38 ligation: a novel pathway linking signal transducers with ecto–enzyme activities. Peola S, et al. **J Immunol** 1996 Nov 15;157(10):4354–62
1alpha,25–Dihydroxyvitamin D3 modulates CD38 expression on human lymphocytes. Stoeckler JD, et al. **J Immunol** 1996 Dec 1;157(11):4908–17
CD38 ligation results in activation of the Raf–1/mitogen–activated protein kinase and the CD3–zeta/zeta–associated protein–70 signaling pathways in Jurkat T lymphocytes. Zubiaur M, et al. **J Immunol** 1997 Jul 1;159(1):193–205
Galectin–3 and laminin expression in neoplastic and non–neoplastic thyroid tissue. Fernández PL, et al. **J Pathol** 1997 Jan;181(1):80–6
A sensitive enzyme immunoassay for the quantitation of human CTLA4Ig fusion protein in mouse serum: pharmacokinetic application to optimizing cell line selection. Weiner RS, et al. **J Pharm Biomed Anal** 1997 Feb;15(5):571–9
Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS–188667), a novel immunosuppressive agent, in monkeys following multiple doses. Srinivas NR, et al. **J Pharm Sci** 1996 Jan;85(1):1–4
Synthesis and hydrolysis of cyclic ADP–ribose by human leukocyte antigen CD38: inhibition of hydrolysis by ATP and physiological significance. Okamoto H, et al. **Methods Enzymol** 1997;280:306–18
Solution structure of human CTLA–4 and delineation of a CD80/CD86 binding site conserved in CD28 [letter] Metzler WJ, et al. **Nat Struct Biol** 1997 Jul;4(7):527–31
Changes in the distribution pattern of galectin–1 and galectin–3 in human placenta correlates with the differentiation pathways of trophoblasts. Maquoi E, et al. **Placenta** 1997 Jul–Aug;18(5–6):433–9
A critical role of Lyn and Fyn for B cell responses to CD38 ligation and interleukin 5. Yasue T, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10307–12
Interaction of CTLA–4 with AP50, a clathrin–coated pit adaptor protein. Zhang Y, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9273–8
Functional differences between subpopulations of mobilized peripheral blood–derived CD34+ cells expressing different levels of HLA–DR, CD33, CD38 and c–kit antigens. Sakabe H, et al. **Stem Cells** 1997;15(1):73–81
Expression of CTLA4–Ig by biolistically transfected mouse islets promotes islet allograft survival. Gainer AL, et al. **Transplantation** 1997 Apr 15;63(7):1017–21

PHARMACOLOGY

Murine CTLA4–IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Van Oosterhout AJ, et al. **Am J Respir Cell Mol Biol** 1997 Sep;17(3):386–92
Expression of PrP mRNA is regulated by a fragment of MRP8 in human fibroblasts. Kniazeva M, et al. **Biochem Biophys Res Commun** 1997 May 8;234(1):59–63
CTLA4Ig inhibits alloantibody responses to repeated blood transfusions. Ibrahim S, et al. **Blood** 1996 Dec 15; 88(12):4594–600
The role of tyrosine phosphorylation and PTP–1C in CTLA–4 signal transduction. Chambers CA, et al. **Eur J Immunol** 1996 Dec;26(12):3224–9
CD66: role in the regulation of neutrophil effector function. Stocks SC, et al. **Eur J Immunol** 1996 Dec;26(12):2924–32
Inhibition of corneal allograft reaction by CTLA4–Ig. Hoffmann F, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Aug;235(8):535–40
Prevention of immune reactions triggered by first–generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Guérette B, et al. **Hum Gene Ther** 1996 Aug 1;7(12):1455–63
Galectin–3 inhibits granulocyte–macrophage colony–stimulating factor (GM–CSF)–driven rat bone marrow cell proliferation and GM–CSF–induced gene transcription. Krugluger W, et al. **Immunobiology** 1997 Jun; 197(1):97–109
CD80 costimulation is essential for the induction of airway eosinophilia. Harris N, et al. **J Exp Med** 1997 Jan 6; 185(1):177–82
Preventing allograft rejection with CTLA4IG: effect of donor–specific transfusion route or timing. Bolling SF, et al. **J Heart Lung Transplant** 1996 Sep;15(9):928–35
Selective induction of CD73 expression in human lymphocytes by CD38 ligation: a novel pathway linking signal transducers with ecto–enzyme activities. Peola S, et al. **J Immunol** 1996 Nov 15;157(10):4354–62
Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4–Fc treatment. Tran HM, et al. **J Immunol** 1997 Sep 1;159(5):2232–9
The CD28–B7 costimulatory pathway and its role in autoimmune disease. Daikh D, et al. **J Leukoc Biol** 1997 Aug;62(2):156–62 (80 ref.)
Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS–188667), a novel immunosuppressive agent, in monkeys following multiple doses. Srinivas NR, et al. **J Pharm Sci** 1996 Jan;85(1):1–4
Long–term acceptance of major histocompatibility complex–mismatched cardiac allograft induced by a low dose of CTLA4IgM plus FK506. Yamada A, et al. **Microbiol Immunol** 1996;40(7):513–8
Blockade of T–cell costimulation prevents development of experimental chronic renal allograft rejection [see comments] Azuma H, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12439–44. Comment in: Proc Natl Acad Sci U S A 1996 Oct 29;93(22):12072–5.
CD28 blockade alters cytokine mRNA profiles in cardiac transplantation. Lin H, et al. **Surgery** 1997 Aug; 122(2):129–37
Suppression of T–cell–dependent immune responses in monkeys by CTLA4Ig. Cabrian KM, et al. **Transplant Proc** 1996 Dec;28(6):3261–2
Efficient myoblast transplantation in mice immunosuppressed with monoclonal antibodies and CTLA4 Ig. Guérette B, et al. **Transplant Proc** 1997 Jun;29(4):1932–4
CTLA4Ig inhibits alloantibody responses to transfusions and transplants. Ibrahim S, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1025
CD28–B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell–mediated and humoral immune responses in vivo. Akalin E, et al. **Transplantation** 1996 Dec 27;62(12):1942–5
Immunosuppression with monoclonal antibodies and CTLA4–Ig after myoblast transplantation in mice. Guerette B, et al. **Transplantation** 1996 Oct 15;62(7):962–7
CTLA4Ig attenuates accelerated rejection (presensitization) in the mouse islet allograft model. Roy–Chaudhury P, et al. **Transplantation** 1997 Jul 15;64(1):172–5
Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways. Woodward JE, et al. **Transplantation** 1996 Oct 15;62(7):1011–8
Induction of tolerance to small bowel allografts in high–responder rats by combining anti–CD4 with CTLA4Ig. Yin DP, et al. **Transplantation** 1996 Dec 15; 62(11):1537–9
[Intrathymic immunomodulation brings about a therapeutic window for systemic administration of CTLA4Ig in a model of accelerated rejection] Stadlbauer TH, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:195–9 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

CD28: a signalling perspective. Ward SG. **Biochem J** 1996 Sep 1;318 (Pt 2):361–77 (222 ref.)
Enhanced induction of antitumor T–cell responses by cytotoxic T lymphocyte–associated molecule–4 blockade: the effect is manifested only at the restricted tumor–bearing stages. Yang YF, et al. **Cancer Res** 1997 Sep 15; 57(18):4036–41
Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy [editorial; comment] Sfikakis PP, et al. **Clin Immunol Immunopathol** 1997 Jun; 83(3):195–8. Comment on: Clin Immunol Immunopathol 1997 Jun;83(3):199–204.
Blockade of CD28/B7 co–stimulation by mCTLA4–Hgamma1 inhibits antigen–induced lung eosinophilia but not Th2 cell development or recruitment in the lung. Harris N, et al. **Eur J Immunol** 1997 Jan; 27(1):155–61
Galectin–3 stimulates uptake of extracellular Ca2+ in human Jurkat T–cells. Dong S, et al. **FEBS Lett** 1996 Oct 21; 395(2–3):165–9
Investigation of the potential role of membrane CD38 in protection against cell death induced by HIV–1. Savarino A, et al. **J Biol Regul Homeost Agents** 1996 Jan–Mar; 10(1):13–8
Protective immunity to nematode infection is induced by CTLA–4 blockade. McCoy K, et al. **J Exp Med** 1997 Jul 21;186(2):183–7
Is CTLA–4 a master switch for peripheral T cell tolerance? Bluestone JA. **J Immunol** 1997 Mar 1;158(5):1989–93 (37 ref.)
B7–CD28/CTLA–4 costimulatory pathways are required for the development of T helper cell 2–mediated allergic airway responses to inhaled antigens. Keane–Myers A, et al. **J Immunol** 1997 Mar 1;158(5):2042–9
CD28–B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell–mediated and humoral immune responses. Onodera K, et al. **J Immunol** 1997 Aug 15;159(4):1711–7

THERAPEUTIC USE

Toxic shock syndrome toxin–1–induced death is prevented by CTLA4Ig. Saha B, et al. **J Immunol** 1996 Nov 1;

157(9):3869–75
Differential effect of CTLA4Ig on murine graft–versus–host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. Via CS, et al. **J Immunol** 1996 Nov 1; 157(9):4258–67
Donor–specific transfusions enhance the immunosuppressive effects of single–dose cyclosporine A and CTLA4–Ig but do not result in long–term graft acceptance in a histoincompatible model of rat lung allograft rejection. Jordan SC, et al. **Transpl Immunol** 1996 Mar;4(1):33–7
Reversal of CTLA4Ig–mediated tolerance to cardiac allografts by exogenous interleukin–2. Arima T, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1305–6
Synergism of CTLA4–IG and anti–CD4 monoclonal antibody treatment in a rat kidney transplant model. Graser E, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1307–9
Immunomodulation with intrathymic injection of donor splenocytes followed by CTLA4Ig therapy prolongs small intestinal allograft survival. Greenstein SM, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1065–6
Prolongation of skin allograft survival in mice treated with CTLA–4 Ig in combination with rapamycin or cyclosporine. Hale DA, et al. **Transplant Proc** 1996 Dec; 28(6):3270–1
Importance of the CD28/B7 costimulatory pathway in the development of chronic ductopenic rejection in a new model of orthotopic rat liver allotransplantation. Mark W, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1029
CTLA4–Ig treatment prolongs rat orthotopic liver graft survival. Tu Y, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):1036–7
Use of CTLA4–Ig in combination with conventional immunosuppressive agents to prolong allograft survival. Hale DA, et al. **Transplantation** 1997 Sep 27;64(6):897–900
Effect of anti–CD4 monoclonal antibody combined with human CTLA4Ig on the survival of hamster liver and heart xenografts in Lewis rats. Yin DP, et al. **Transplantation** 1997 Jul 27;64(2):317–21

ANTIGENS, DIFFERENTIATION, B–CELL see **ANTIGENS, DIFFERENTIATION, B–LYMPHOCYTE**

ANTIGENS, DIFFERENTIATION, B–LYMPHOCYTE

ANALYSIS

LN–2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Lazova R, et al. **Cancer** 1997 Jun 1;79(11):2115–24
MHC class II antigen–associated invariant chain on renal cell cancer may contribute to the anti–tumor immune response of the host [corrected and republished in Cancer Lett 1997 May 1;115(1):121–7] Saito T, et al. **Cancer Lett** 1996 Dec 3;109(1–2):15–21
Simultaneous detection of genetic and immunological markers in non–small cell lung cancer: prediction of metastatic potential of tumor. Zborovskaya I, et al. **Clin Exp Metastasis** 1996 Nov;14(6):490–500
Establishment of a monoclonal antibody directed against Gb3Cer/CD77: a useful immunochemical reagent for a differentiation marker in Burkitt's lymphoma and germinal centre B cells. Miyamoto D, et al. **Glycoconj J** 1997 Apr; 14(3):379–88
The value of the monoclonal antibody, DBA44, in the diagnosis of B–lymphoid disorders. Salomon–Nguyen F, et al. **Leuk Res** 1996 Nov–Dec;20(11–12):909–13
Some early differentiation markers detected in cytoplasm of pre–B cells by flow cytometry. Koníková E, et al. **Neoplasma** 1996;43(6):373–9
Ruminant cluster CD41/CD61. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):251–3
Ruminant cluster CD71. Naessens J, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):257–8
Identification of chicken Bu–1 alloantigens using the monoclonal antibody AV20. Rothwell CJ, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1–3):225–34

BIOSYNTHESIS

Regulation of HLA–DR and invariant chain expression by human peripheral blood mononuclear cells with lead, interferon–gamma, or interleukin–4. Guo TL, et al. **Cell Immunol** 1996 Jul 10;171(1):1–9
Differential expression of CLIP:MHC class II and conventional endogenous peptide:MHC class II complexes by thymic epithelial cells and peripheral antigen–presenting cells. Farr A, et al. **Eur J Immunol** 1996 Dec;26(12):3185–93
Allele–specific expression of the mouse B–cell surface protein CD72 on T cells. Robinson WH, et al. **Immunogenetics** 1997;45(3):195–200
Granulocyte–macrophage colony–stimulating factor elevates invariant chain expression in immature myelomonocytic cell lines. Klagge I, et al. **Immunology** 1997 May; 91(1):114–20
Differential expression of CD22 (Lyb8) on murine B cells. Erickson LD, et al. **Int Immunol** 1996 Jul;8(7):1121–9
In the absence of the invariant chain, HLA–DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA–DM. Lightstone L, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5772–7
Discordant expression of major histocompatibility complex class II antigens and invariant chain in interstitial dendritic cells. Implications for self–tolerance and immunity. Saleem M, et al. **Transplantation** 1997 Apr 27;63(8):1134–8

BLOOD

Cell surface marker evaluation of infant Macaca monkey leukocytes in peripheral whole blood using simultaneous dual–color immunophenotypic analysis. Tryphonas H, et al. **J Med Primatol** 1996 Apr;25(2):89–105
In vitro T cell activation in elderly individuals: failure in CD69 and CD71 expression. Lio D, et al. **Mech Ageing Dev** 1996 Jul 31;89(1):51–8

CHEMISTRY

Molecular modeling and design of invariant chain peptides with altered dissociation kinetics from class II MHC. Liang MN, et al. **Biochemistry** 1996 Nov 26;35(47):14734–42
Characterization of the expression and gene promoter of CD22 in murine B cells. Andersson KB, et al. **Eur J Immunol** 1996 Dec;26(12):3170–8
The T cell antigen receptor beta chain interacts with the extracellular domain of CD3–gamma. Manolios N, et al. **Immunol Cell Biol** 1995 Dec;73(6):532–6
Both invariant chain isoforms Ii31 and Ii41 promote class II antigen presentation. Serwe M, et al. **Int Immunol** 1997 Jul;9(7):983–91
Trimeric interactions of the invariant chain and its association with major histocompatibility complex class II alpha beta dimers. Newcomb JR, et al. **J Biol Chem** 1996 Sep 27; 271(39):24249–56
Characterization of differentiation antigens expressed in bovine lymphosarcomas. Sasaki Y, et al. **J Comp Pathol** 1997 Jan;116(1):13–20
Identification of residues in the class II–associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II–mediated antigen presentation in an allele–dependent manner. Gautam AM, et al. **J Immunol** 1997 Sep 15;159(6):2782–8

CLASSIFICATION

In vivo functions mediated by the p41 isoform of the MHC class II–associated invariant chain. Takaesu NT, et al. **J Immunol** 1997 Jan 1;158(1):187–99

GENETICS

Identification and cloning of genes expressed by human tonsillar B lymphocyte subsets. Frazer JK, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:316–8
CD84 leukocyte antigen is a new member of the Ig superfamily. de la Fuente MA, et al. **Blood** 1997 Sep 15; 90(6):2398–405
Characterization of the expression and gene promoter of CD22 in murine B cells. Andersson KB, et al. **Eur J Immunol** 1996 Dec;26(12):3170–8
The mouse BP–1 gene: structure, chromosomal localization, and regulation of expression by type I interferons and interleukin–7. Wang J, et al. **Genomics** 1996 Apr 15; 33(2):167–76
CCAAT–binding factor NF–Y and RFX are required for in vivo assembly of a nucleoprotein complex that spans 250 base pairs: the invariant chain promoter as a model. Linhoff MW, et al. **Mol Cell Biol** 1997 Aug;17(8):4589–96

IMMUNOLOGY

Complete sustained response of a refractory, post–transplantation, large B–cell lymphoma to an anti–CD22 immunotoxin. Senderowicz AM, et al. **Ann Intern Med** 1997 Jun 1;126(11):882–5
Characterization of RFB4–Pseudomonas exotoxin A immunotoxins targeted to CD22 on B–cell malignancies. Mansfield E, et al. **Bioconjug Chem** 1996 Sep–Oct; 7(5):557–63
Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22–bearing cells and tumors. Mansfield E, et al. **Blood** 1997 Sep 1;90(5):2020–6
Terminal maturation of resting B cells induced by macrophage factors. Mengel I, et al. **Braz J Med Biol Res** 1996 Feb;29(2):229–37
Advantage of residualizing radiolabels for an internalizing antibody against the B–cell lymphoma antigen, CD22. Sharkey RM, et al. **Cancer Immunol Immunother** 1997 May; 44(3):179–88
MHC class II antigen–associated invariant chain on renal cell cancer may contribute to the anti–tumor immune response of the host [corrected and republished article originally printed in Cancer Lett 1996 Dec 3;109(1–2):15–21] Saito T, et al. **Cancer Lett** 1997 May 1; 115(1):121–7
CD72 ligation regulates defective naive newborn B cell responses. Howard LM, et al. **Cell Immunol** 1997 Feb 1; 175(2):179–88
Rare event selection of fetal nucleated erythrocytes in maternal blood by flow cytometry. Lewis DE, et al. **Cytometry** 1996 Mar 1;23(3):218–27
Modulation of CD72 by ligation of B cell receptor complex molecules on CD5+ B cells. Jamin C, et al. **Int Immunol** 1997 Jul;9(7):1001–9
Induction of T cell responses to the invariant chain derived peptide CLIP in mice immunized with the group 1 allergen of house dust mite. Kristensen NM, et al. **Int Immunol** 1996 Jul;8(7):1091–8
The advantage of residualizing radiolabels for targeting B–cell lymphomas with a radiolabeled anti–CD22 monoclonal antibody. Mattes MJ, et al. **Int J Cancer** 1997 May 2;71(3):429–35
Hyperresponsive B cells in CD22–deficient mice. O'Keefe TL, et al. **Science** 1996 Nov 1;274(5288):798–801
Specificity of effector mechanisms in syngeneic graft–vs–host disease: recognition of the MHC class II invariant chain peptide (CLIP). Hess A, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):725–7
Ruminant cluster CD41/CD61. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):251–3
Ruminant cluster CD71. Naessens J, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):257–8
Identification of chicken Bu–1 alloantigens using the monoclonal antibody AV20. Rothwell CJ, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1–3):225–34

METABOLISM

CD22, a B lymphocyte–specific adhesion molecule that regulates antigen receptor signaling. Tedder TF, et al. **Annu Rev Immunol** 1997;15:481–504 (98 ref.)
Abnormal association between invariant chain and HLA class II alpha and beta chains in chronic lymphocytic leukemia. Veenstra H, et al. **Cell Immunol** 1996 Jul 10;171(1):68–73
Antigen presentation: Kissing cousins exchange CLIP. Sanderson F, et al. **Curr Biol** 1995 Dec 1;5(12):1372–6 (18 ref.)
Editing of the HLA–DR–peptide repertoire by HLA–DM. Kropshofer H, et al. **EMBO J** 1996 Nov 15;15(22):6144–54
Distribution of lymphocyte subsets in bone marrow and peripheral blood is associated with haptoglobin type. Binding of haptoglobin to the B–cell lectin CD22. Langlois M, et al. **Eur J Clin Chem Clin Biochem** 1997 Mar; 35(3):199–205
Expression of B cell markers on SR–4987 cells derived from murine bone marrow stroma. Pessina A, et al. **Exp Hematol** 1997 Jun;25(6):536–41
CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22–deficient mice. Sato S, et al. **Immunity** 1996 Dec;5(6):551–62
Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin. Tooze RM, et al. **Immunity** 1997 Jul;7(1):59–67
Impact of a truncated invariant chain on in vitro assembly of class II MHC molecules depends on the affinity of invariant chain for a given alpha beta dimer. Han R. **Immunol Invest** 1997 Jun;26(4):421–37
B cell hybridoma presents both B–cell and T–cell epitopes for stimulating antibody production via CD23 pathway. Schmaltz R, et al. **Immunol Invest** 1996 Sep–Nov; 25(5–6):481–93
A continuous central motif of invariant chain peptides, CLIP, is essential for binding to various I–A MHC class II molecules. Weenink SM, et al. **Int Immunol** 1997 Feb; 9(2):317–25
Exon 6 is essential for invariant chain trimerization and induction of large endosomal structures. Gedde–Dahl M, et al. **J Biol Chem** 1997 Mar 28;272(13):8281–7
Structural requirements for major histocompatibility complex class II invariant chain trafficking in polarized Madin–Darby canine kidney cells. Odorizzi G, et al. **J Biol Chem** 1997 May 2;272(18):11757–62
Decreased endosomal delivery of major histocompatibility complex class II–invariant chain complexes in dynamin–deficient cells. Wang K, et al. **J Biol Chem** 1997 Jul 4;272(27):17055–60
Sorting of MHC class II molecules and the associated invariant chain (Ii) in polarized MDCK cells. Simonsen A, et al. **J Cell Sci** 1997 Mar;110 (Pt 5):597–609
Human histocompatibility leukocyte antigen (HLA)–DM edits peptides presented by HLA–DR according to their ligand binding motifs. van Ham SM, et al. **J Exp Med** 1996 Nov 1;184(5):2019–24
Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. Villadangos JA, et al. **J Exp Med** 1997 Aug 18;186(4):549–60
The proteolytic environment involved in MHC class II–restricted antigen presentation can be modulated by the p41 form of invariant chain. Fineschi B, et al. **J Immunol** 1996 Oct 15;157(8):3211–5
HLA–DM is present in one–fifth the amount of HLA–DR in the class II peptide–loading compartment where it associates with leupeptin–induced peptide (LIP)–HLA–DR complexes. Schafer PH, et al. **J Immunol** 1996 Dec 15; 157(12):5487–95
Intracellular CD22 rapidly moves to the cell surface in a tyrosine kinase–dependent manner following antigen receptor stimulation. Sherbina NV, et al. **J Immunol** 1996 Nov 15;157(10):4390–8
DM–mediated release of a naturally occurring invariant chain degradation intermediate from MHC class II molecules. Stebbins CC, et al. **J Immunol** 1996 Dec 1;157(11):4892–8
Invariant chain association with MHC class I: preference for HLA class I/beta 2–microglobulin heterodimers, specificity, and influence of the MHC peptide–binding groove. Vigna JL, et al. **J Immunol** 1996 Nov 15; 157(10):4503–10

GTP-bound forms of rab6 induce the redistribution of Golgi proteins into the endoplasmic reticulum. Martinez O, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1828–33

Out damned CLIP! Out, I say! [comment] Roche PA. **Science** 1996 Oct 25;274(5287):526–7. Comment on: Science 1996 Oct 25;274(5287):618–20.

Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM [see comments] Weber DA, et al. **Science** 1996 Oct 25;274(5287):618–20. Comment in: Science 1996 Oct 25;274(5287):526–7.

PHARMACOLOGY

A fragment of the major histocompatibility complex class II-associated p41 invariant chain inhibits cruzipain, the major cysteine proteinase from Trypanosoma cruzi. Bevec T, et al. **FEBS Lett** 1997 Jan 20;401(2–3):259–61

Antigen receptor-mediated B cell death is blocked by signaling via CD72 or treatment with dextran sulfate and is defective in autoimmunity-prone mice. Nomura T, et al. **Int Immunol** 1996 Jun;8(6):867–75

In vivo functions mediated by the p41 isoform of the MHC class II-associated invariant chain. Takaesu NT, et al. **J Immunol** 1997 Jan 1;158(1):187–99

PHYSIOLOGY

Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Mansfield E, et al. **Biochem Soc Trans** 1997 May;25(2):709–14

Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Hess AD, et al. **Blood** 1997 Mar 15;89(6):2203–9

The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells. Bertolino P, et al. **Crit Rev Immunol** 1996;16(4):359–79 (189 ref.)

CD22 is a negative regulator of B-cell receptor signalling. Nitschke L, et al. **Curr Biol** 1997 Feb 1;7(2):133–43

Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1. Doody GM, et al. **Curr Opin Immunol** 1996 Jun;8(3):378–82 (47 ref.)

Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. Cyster JG, et al. **Immunity** 1997 May;6(5):509–17 (72 ref.)

Comparison of thymocyte development in normal and invariant chain-deficient mice provides evidence that maturation-related changes in TCR and co-receptor levels play a critical role in cell fate. Huang LY, et al. **Int Immunol** 1996 Sep;8(9):1429–40

Both invariant chain isoforms Ii31 and Ii41 promote class II antigen presentation. Serwe M, et al. **Int Immunol** 1997 Jul;9(7):983–91

Related leucine-based cytoplasmic targeting signals in invariant chain and major histocompatibility complex class II molecules control endocytic presentation of distinct determinants in a single protein. Zhong G, et al. **J Exp Med** 1997 Feb 3;185(3):429–38

The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity. Cerutti A, et al. **J Immunol** 1996 Sep 1;157(5):1854–62

CD22 regulates thymus-independent responses and the lifespan of B cells. Otipoby KL, et al. **Nature** 1996 Dec 19–26;384(6610):634–7

The function of invariant chain in class II-restricted antigen presentation. Ceman S, et al. **Semin Immunol** 1995 Dec; 7(6):373–87 (88 ref.)

ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE

Markers of Th1 and Th2 cells. Almerigogna F, et al. **Chem Immunol** 1996;63:30–50 (61 ref.)

ANALYSIS

CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ, et al. **Biol Blood Marrow Transplant** 1997 Apr;3(1):11–7

CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Soiffer RJ, et al. **Blood** 1997 Apr 15;89(8):3039–47

Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen- or antigen-induced proliferative capacity in normals. Mardiney M 3rd, et al. **Cytometry** 1996 Dec 15;26(4):305–10

Characterisation of leucocytic somatic cells in bovine milk. Schmaltz R, et al. **Res Vet Sci** 1996 Sep;61(2):179–81

Adhesion molecules and activation markers in acute rejection of human renal allografts. von Willebrand E, et al. **Transpl Immunol** 1996 Mar;4(1):57–8

BIOSYNTHESIS

Absence of CD69 expression on peripheral eosinophils in episodic angioedema and eosinophilia. Kawano M, et al. **Am J Hematol** 1996 Sep;53(1):43–5

Measurement of CD69 induction in the assessment of immune function in asymptomatic HIV-infected individuals. Perfetto SP, et al. **Cytometry** 1997 Feb 15;30(1):1–9

Mouse CD6: sequence of cDNA and expression of mRNA. Pal A, et al. **Immunol Lett** 1996 Jan;49(1–2):133–7

Correlation between clonotypic T-cell receptor beta chain variable region (TCR-V beta) gene expression and aberrant T-cell antigen expression in cutaneous T-cell lymphoma. Finn DT, et al. **J Cutan Pathol** 1996 Aug;23(4):306–11

Abnormalities in CD69 expression, cytosolic pH and Ca2+ during activation of lymphocytes from patients with systemic lupus erythematosus. Portales-Pérez D, et al. **Lupus** 1997;6(1):48–56

Stimulated rapid expression in vitro for early detection of in vivo T-cell receptor mutations induced by radiation exposure. Ishioka N, et al. **Mutat Res** 1997 May 23; 390(3):269–82

CD69 expression on primitive progenitor cells and hematopoietic malignancies. Tassone P, et al. **Tissue Antigens** 1996 Jul;48(1):65–8

Transcription of the gene for the rat T cell differentiation marker RT6 is mainly mediated by a promoter 5' of exon 2. Kuhlenbäumer G, et al. **Transplant Proc** 1997 May; 29(3):1701–2

Suppression of lectin, alloantigen, and xenoantigen-induced T-cell proliferation by Genistein. Rapaport FT, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):1261–4

In vitro survival and RT6 expression kinetics in peripheral T cells of diabetes prone BB and Lewis rats. Thiele HG, et al. **Transplant Proc** 1997 May;29(3):1681–3

Expression profiles of RT6 and other T lymphocyte surface markers in the black rat (Rattus rattus). Thiele HG, et al. **Transplant Proc** 1997 May;29(3):1697–8

BLOOD

Recurrent infectious diseases in human CD53 deficiency. Mollinedo F, et al. **Clin Diagn Lab Immunol** 1997 Mar; 4(2):229–31

Identification of a T lineage antigen in the catfish. Passer BJ, et al. **Dev Comp Immunol** 1996 Nov-Dec;20(6):441–50

Cell surface marker evaluation of infant Macaca monkey leukocytes in peripheral whole blood using simultaneous dual-color immunophenotypic analysis. Tryphonas H, et al. **J Med Primatol** 1996 Apr;25(2):89–105

CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity. Su CC, et al. **Lupus** 1997;6(5):449–54

In vitro T cell activation in elderly individuals: failure in CD69 and CD71 expression. Lio D, et al. **Mech Ageing Dev** 1996 Jul 31;89(1):51–8

CHEMISTRY

Identification of residues in CD6 which are critical for ligand binding. Bodian DL, et al. **Biochemistry** 1997 Mar 4; 36(9):2637–41

Noncovalent associations of T lymphocyte surface proteins. Cerný J, et al. **Eur J Immunol** 1996 Oct;26(10):2335–43

Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. Hsu YM, et al. **J Biol Chem** 1997 Jan 10;272(2):911–5

Characterization of differentiation antigens expressed in bovine lymphosarcomas. Sasaki Y, et al. **J Comp Pathol** 1997 Jan;116(1):13–20

MUC18/MCAM (CD146), an activation antigen of human T lymphocytes. Pickl WF, et al. **J Immunol** 1997 Mar 1; 158(5):2107–15

Molecular characterization of mouse T-cell ecto-ADP-ribosyltransferase Rt6: cloning of a second functional gene and identification of the Rt6 gene products. Hollmann C, et al. **Mol Immunol** 1996 Jun;33(9):807–17

GENETICS

Expression of the RT6 mono(ADP-ribosyl)transferases is regulated by two promoter regions. Kuhlenbäumer G, et al. **Adv Exp Med Biol** 1997;419:265–70

Mouse CD6: sequence of cDNA and expression of mRNA. Pal A, et al. **Immunol Lett** 1996 Jan;49(1–2):133–7

TLiSA1 (PTA1) activation antigen implicated in T cell differentiation and platelet activation is a member of the immunoglobulin superfamily exhibiting distinctive regulation of expression. Sherrington PD, et al. **J Biol Chem** 1997 Aug 29;272(35):21735–44

Structure and chromosomal location of the human CD6 gene: detection of five human CD6 isoforms. Bowen MA, et al. **J Immunol** 1997 Feb 1;158(3):1149–56

Development of a procedure for the direct cloning of T-cell epitopes using bacterial expression systems. Neophytou PI, et al. **J Immunol Methods** 1996 Sep 13;196(1):63–72

Molecular characterization of mouse T-cell ecto-ADP-ribosyltransferase Rt6: cloning of a second functional gene and identification of the Rt6 gene products. Hollmann C, et al. **Mol Immunol** 1996 Jun;33(9):807–17

Polymorphic microsatellite within the main promoter of the rat T cell differentiation antigen RT6 on chromosome 1. Haag F, et al. **Transplant Proc** 1997 May;29(3):1703–4

Transcription of the gene for the rat T cell differentiation marker RT6 is mainly mediated by a promoter 5' of exon 2. Kuhlenbäumer G, et al. **Transplant Proc** 1997 May; 29(3):1701–2

IMMUNOLOGY

Enhanced expression of activation antigens HLA-DR and CD69 on gamma delta T cells but impaired interleukin-2-induced upregulation in HIV-1 infection [letter] Gröttrup-Wolfers E, et al. **AIDS** 1997 May; 11(6):838–9

Rapid expression of the CD69 antigen on T cells and natural killer cells upon antigenic stimulation of peripheral blood mononuclear cell suspensions. Werfel T, et al. **Allergy** 1997 Apr;52(4):465–9

CD69 expression after antigenic stimulation [letter] Gibbons DC, et al. **Cytometry** 1996 Mar 1;23(3):260–1

Anti-CD53 monoclonal antibody induced LFA-1/ICAM-1-dependent and -independent lymphocyte homotypic cell aggregation. Cao L, et al. **Immunobiology** 1997 Jun;197(1):70–81

Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes. Singer NG, et al. **Immunology** 1996 Aug;88(4):537–43

Antigen specificity of dual reactive T hybridomas determines the requirement for CD40 ligand-CD40 interactions. Ozaki ME, et al. **J Immunol** 1997 Jul 1;159(1):214–21

Expression and function of the early activation antigen CD69 in murine macrophages. Marzio R, et al. **J Leukoc Biol** 1997 Sep;62(3):349–55

Unresponsiveness of CD4+ T cells from a non-responder strain to HgCl2 is not due to CD8(+)-mediated immunosuppression: an analysis of the very early activation antigen CD69. Jiang Y, et al. **Scand J Immunol** 1996 Dec; 44(6):565–70

METABOLISM

Lesional psoriatic T cells contain the capacity to induce a T cell activation molecule CDw60 on normal keratinocytes. Skov L, et al. **Am J Pathol** 1997 Feb; 150(2):675–83

Identification of residues in CD6 which are critical for ligand binding. Bodian DL, et al. **Biochemistry** 1997 Mar 4; 36(9):2637–41

Mutational analysis of the CD6 binding site in activated leukocyte cell adhesion molecule. Skonier JE, et al. **Biochemistry** 1996 Nov 26;35(47):14743–8

Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receptor binding site in the human CD6 ligand ALCAM. Skonier JE, et al. **Biochemistry** 1996 Sep 24;35(38):12287–91

CD69 expression reliably predicts the anti-CD3-induced proliferative response of lymphocytes from human immunodeficiency virus type 1-infected patients. Prince HE, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):217–22

B cell hybridoma presents both B-cell and T-cell epitopes for stimulating antibody production via CD23 pathway. Schmaltz R, et al. **Immunol Invest** 1996 Sep-Nov; 25(5–6):481–93

Multiple dimeric forms of human CD69 result from differential addition of N-glycans to typical (Asn-X-Ser/Thr) and atypical (Asn-X-cys) glycosylation motifs. Vance BA, et al. **J Biol Chem** 1997 Sep 12; 272(37):23117–22

Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associated with integrin alpha 4 beta 1 (CD49d/CD29). Mannion BA, et al. **J Immunol** 1996 Sep 1;157(5):2039–47

Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. Peña SV, et al. **J Immunol** 1997 Mar 15;158(6):2680–8

Ligation of the V7 molecule on T cells blocks anergy induction through a CD28-independent mechanism. Soares LR, et al. **J Immunol** 1997 Aug 1;159(3):1115–24

CD6 recognizes the neural adhesion molecule BEN. Skonier JE, et al. **Protein Sci** 1997 Aug;6(8):1768–70

Rat T cell differentiation alloantigens RT6.1 and RT6.2 are NAD(+)-metabolizing ecto-enzymes that differ in their enzymatic activities. Haag F, et al. **Transplant Proc** 1997 May;29(3):1699–700

PHARMACOLOGY

CD69-induced monocyte apoptosis involves multiple nonredundant signaling pathways. Ramírez R, et al. **Cell Immunol** 1996 Sep 15;172(2):192–9

PHYSIOLOGY

CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Osorio LM, et al. **Blood** 1997 Apr 15;89(8):2833–41

Ligation of CD53/OX44, a tetraspan antigen, induces homotypic adhesion mediated by specific cell-cell interactions. Lazo PA, et al. **Cell Immunol** 1997 Jun 15; 178(2):132–40

Functions of CD40 and its ligand, gp39 (CD40L). Laman JD, et al. **Crit Rev Immunol** 1996;16(1):59–108 (220 ref.)

T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Wingren AG, et al. **Crit Rev Immunol** 1995;15(3–4):235–53 (97 ref.)

Characterization of H4: a mouse T lymphocyte activation molecule functionally associated with the CD3/T cell receptor. Redoglia V, et al. **Eur J Immunol** 1996 Nov; 26(11):2781–9

A gamma delta T cell specific surface receptor (WC1) signaling G0/G1 cell cycle arrest. Takamatsu HH, et al. **Eur J Immunol** 1997 Jan;27(1):105–10

Uncovered: the family relationship of a T-cell-membrane protein and bacterial toxins. Koch-Nolte F, et al.

Immunol Today 1996 Sep;17(9):402–5 (30 ref.)
Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. Peña SV, et al. **J Immunol** 1997 Mar 15;158(6):2680–8
Role of CD69 in NO production by human monocytes. Testi R, et al. **Res Immunol** 1995 Nov–Dec;146(9):682–3 (19 ref.)
Granulysin, a new human cytolytic granule–associated protein with possible involvement in cell–mediated cytotoxicity. Peña SV, et al. **Semin Immunol** 1997 Apr; 9(2):117–25 (50 ref.)

ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC

Macrophage membrane molecules: markers of tissue differentiation and heterogeneity. Martinez–Pomares L, et al. **Immunobiology** 1996 Oct;195(4–5):407–16 (64 ref.)

ANALYSIS

Expression of microglial markers in the human CNS after closed head injury. Engel S, et al.
Acta Neurochir Suppl (Wien) 1996;66:89–95
Enkephalin–like immunoreactivity in human skin is found selectively in a fraction of CD68–positive dermal cells: increase in enkephalin–positive cells in lesional psoriasis. Nissen JB, et al. **Arch Dermatol Res** 1997 Apr;289(5):265–71
RhG–CSF–mobilized CD34+ peripheral blood progenitors are myeloperoxidase–negative and noncycling irrespective of CD33 or CD13 coexpression. Rumi C, et al.
Exp Hematol 1997 Mar;25(3):246–51
Hepatic overexpression of MHC class II antigens and macrophage–associated antigens (CD68) in patients with biliary atresia of poor prognosis. Kobayashi H, et al.
J Pediatr Surg 1997 Apr;32(4):590–3
Presence of inducible nitric oxide synthase, nitrotyrosine, CD68, and CD14 in the small intestine in celiac disease. ter Steege J, et al. **Lab Invest** 1997 Jul;77(1):29–36
Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Li WV, et al.
Mod Pathol 1996 Oct;9(10):982–8
Adhesion molecules and activation markers in acute rejection of human renal allografts. von Willebrand E, et al.
Transpl Immunol 1996 Mar;4(1):57–8
An immunohistochemical study of IgG, complement C3, collagen type III and macrophage–marker Ki–M7 in epiretinal membranes. Shi Y, et al. **Yen Ko Hsueh Pao** 1996 Mar;12(1):10–4

BIOSYNTHESIS

Heterogeneity of expression of CD68 and other macrophage–associated antigens in human long–term bone marrow culture. Wilkins BS, et al. **Biologicals** 1996 Dec; 24(4):333–7
Identification of a novel surface molecule, RM3/1, that contributes to the adhesion of glucocorticoid–induced human monocytes to endothelial cells. Wenzel I, et al.
Eur J Immunol 1996 Nov;26(11):2758–63

CHEMISTRY

MNDA dimerizes through a complex motif involving an N–terminal basic region. Xie J, et al. **FEBS Lett** 1997 May 19;408(2):151–5

GENETICS

Characterization of the human myeloid cell nuclear differentiation antigen gene promoter. Kao WY, et al.
Biochim Biophys Acta 1996 Sep 11;1308(3):201–4
CD84 leukocyte antigen is a new member of the Ig superfamily. de la Fuente MA, et al. **Blood** 1997 Sep 15; 90(6):2398–405
Structure and function analysis of the human myeloid cell nuclear differentiation antigen promoter: evidence for the role of Sp1 and not of c–Myb or PU.1 in myelomonocytic lineage–specific expression. Kao WY, et al.
J Cell Biochem 1997 May;65(2):231–44

IMMUNOLOGY

Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Uckun FM, et al. **Blood** 1997 Jul 1;90(1):28–35
Flow cytometric identification of murine neutrophils and monocytes. Lagasse E, et al. **J Immunol Methods** 1996 Oct 16;197(1–2):139–50
Identification of three myeloid–specific differentiation antigens in sheep. Hopkins J, et al.
Vet Immunol Immunopathol 1996 Aug;52(4):329–39

METABOLISM

Fine–needle aspirates of granular cell lesions of the breast: report of three cases, with emphasis on differential diagnosis and utility of immunostaining for CD68 (KP1). Sirgi KE, et al. **Diagn Cytopathol** 1996 Dec;15(5):403–8
Cell types of secondary cataract: an immunohistochemical analysis with antibodies to cytoskeletal elements and macrophages. Uusitalo M, et al.
Graefes Arch Clin Exp Ophthalmol 1997 Aug;235(8):506–11
Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Ramprasad MP, et al.
Proc Natl Acad Sci U S A 1996 Dec 10;93(25):14833–8
Functional differences between subpopulations of mobilized peripheral blood–derived CD34+ cells expressing different levels of HLA–DR, CD33, CD38 and c–kit antigens. Sakabe H, et al. **Stem Cells** 1997;15(1):73–81

PHYSIOLOGY

Identification of a novel surface molecule, RM3/1, that contributes to the adhesion of glucocorticoid–induced human monocytes to endothelial cells. Wenzel I, et al.
Eur J Immunol 1996 Nov;26(11):2758–63

ANTIGENS, DIFFERENTIATION, T–CELL see **ANTIGENS, DIFFERENTIATION, T–LYMPHOCYTE**

ANTIGENS, FUNGAL

Fatal cases of farmer's lung in a Canadian family. Probable new antigens, Penicillium brevicompactum and P olivicolor. Nakagawa–Yoshida K, et al. **Chest** 1997 Jan; 111(1):245–8
Use of a recombinant Coccidioides immitis complement fixation antigen–chitinase in conventional serological assays. Johnson SM, et al. **J Clin Microbiol** 1996 Dec; 34(12):3160–4
Epidemiologic skin test survey of sensitivity to paracoccidioidin, histoplasmin and sporotrichin among gold mine workers of Morro Velho Mining, Brazil. Rodrigues MT, et al. **Mycopathologia** 1996;135(2):89–98

ANALYSIS

A latex cryptococcal antigen agglutination test for diagnosis and monitoring of therapy for cryptococcosis. Malik R, et al. **Aust Vet J** 1996 Nov;74(5):358–64
Candida antigen titre dilution and death after injury. Rosemurgy AS 2nd, et al. **Br J Surg** 1997 Jun;84(6):771–4
Serum cryptococcal antigen in patients with AIDS [editorial] Feldmesser M, et al. **Clin Infect Dis** 1996 Oct;23(4):827–30
Immunohistochemistry with monoclonal antibody against Candida albicans mannan antigen demonstrates cutaneous Candida granulomas as evidence of Candida sepsis in an immunosuppressed host. Breier F, et al. **Dermatology** 1997; 194(3):293–6
Impaired systemic immunity and frequent infection in patients with Candida antigen after hepatectomy. Shirabe K, et al.
Hepatogastroenterology 1997 Jan–Feb;44(13):199–204
Hospital epidemiologic surveillance for invasive aspergillosis: patient demographics and the utility of antigen detection. Patterson JE, et al. **Infect Control Hosp Epidemiol** 1997 Feb;18(2):104–8
Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Verweij PE, et al. **Infection** 1997 Mar–Apr; 25(2):86–9
The glycolytic enzyme glyceraldehyde–3–phosphate dehydrogenase of Candida albicans is a surface antigen. Gil–Navarro I, et al. **J Bacteriol** 1997 Aug;179(16):4992–9
Comparison of radioimmunoassay and enzyme–linked immunoassay methods for detection of Histoplasma capsulatum var. capsulatum antigen. Durkin MM, et al.
J Clin Microbiol 1997 Sep;35(9):2252–5
Assessment of detection of Candida mannoproteinemia as a method to differentiate central venous catheter–related candidemia from invasive disease. Girmenia C, et al.
J Clin Microbiol 1997 Apr;35(4):903–6
Candidin in immediate hypersensitivity. Comparison of two antigens. Netto CF, et al.
J Investig Allergol Clin Immunol 1996 Nov–Dec;6(6):392–4
Release of Candida albicans yeast antigens upon interaction with human neutrophils in vitro. Ashley C, et al.
J Med Microbiol 1997 Sep;46(9):747–55
Pneumocystis carinii from pigs and humans are antigenically distinct. Christensen CB, et al. **J Med Vet Mycol** 1996 Nov–Dec;34(6):431–3
Identification of a concanavalin A–binding antigen of the cell surface of Sporothrix schenckii. Lima OC, et al.
J Med Vet Mycol 1997 May–Jun;35(3):167–72
Western immunoblot analysis of protein antigens of Penicillium marneffei. Vanittanakom N, et al.
J Med Vet Mycol 1997 Mar–Apr;35(2):123–31
Paracoccidioides brasiliensis antigen batches from the same isolate show immunological and biochemical differences. Franco M, et al. **Mycopathologia** 1996;135(1):13–9
Non–value of Aspergillus antigen detection in bronchoalveolar lavage fluids of patients undergoing bone marrow transplantation. Rath PM, et al. **Mycoses** 1996 Sep–Oct;39(9–10):367–70
Light and electron microscopy study of carbohydrate antigens found in the electron–lucent layer of Pneumocystis carinii cysts. Roth A, et al. **Parasitol Res** 1997;83(2):177–84
[The antigen (CANDTEC antigen) detected by CAND TEC test for diagnosis of candidiasis] Mitsuya M, et al.
Rinsho Byori 1996 Jun;44(6):512–7 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

African strains of Blastomyces dermatitidis that do not express surface adhesin WI–1. Klein BS, et al.
Infect Immun 1997 Apr;65(4):1505–9

BLOOD

Clinical and serologic evaluation of cats with cryptococcosis. Flatland B, et al. **J Am Vet Med Assoc** 1996 Sep 15; 209(6):1110–3
Comparison between Wako–WB003 and Fungitec G tests for detection of (1—>3)–beta–D–glucan in systemic mycosis. Hossain MA, et al. **J Clin Lab Anal** 1997; 11(2):73–7
Enolase antigen, mannan antigen, Cand–Tec antigen, and beta–glucan in patients with candidemia. Mitsutake K, et al. **J Clin Microbiol** 1996 Aug;34(8):1918–21
Cryptococcal infection in cats: factors influencing treatment outcome, and results of sequential serum antigen titers in 35 cats. Jacobs GJ, et al. **J Vet Intern Med** 1997 Jan–Feb; 11(1):1–4
Detection of Cryptococcus neoformans capsular polysaccharide antigen in asymptomatic HIV–infected patients. Negroni R, et al.
Rev Inst Med Trop Sao Paulo 1995 Sep–Oct;37(5):385–9
Association between incidence of Aspergillus antigenemia and exposure to construction works at a hospital site. Ansorg R, et al. **Zentralbl Bakteriol** 1996 Jul; 284(2–3):146–52
[Immunodiagnosis and blood biochemical diagnosis of visceral candidiasis and the cutoff limits of positive] Kume H, et al. **Rinsho Byori** 1996 Jun;44(6):505–11 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Sero–diagnosis for pulmonary aspergillosis—its utility in early diagnosis] Niki Y. **Rinsho Byori** 1996 Jun;44(6):518–23 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Structure and antigenicity of the mannans of Candida famata and Candida saitoana: comparative study with the mannan of Candida guilliermondii. Shibata N, et al.
Arch Biochem Biophys 1996 Dec 1;336(1):49–58
Differential humoral response against alpha– and beta–linked mannose residues associated with tissue invasion by Candida albicans. Jouault T, et al.
Clin Diagn Lab Immunol 1997 May;4(3):328–33
Influence of culture period on the allergenic composition of Pityrosporum orbiculare extracts. Zargari A, et al.
Clin Exp Allergy 1995 Dec;25(12):1235–45
Hemagglutinins in fungus extracts and their blood group specificity. Furukawa K, et al. **Exp Clin Immunogenet** 1995; 12(4):223–31
Structure of the N–linked oligosaccharide of the main diagnostic antigen of the pathogenic fungus Paracoccidioides brasiliensis. Almeida IC, et al.
Glycobiology 1996 Jul;6(5):507–15
Biochemical and antigenic characterization of a new dipeptidyl–peptidase isolated from Aspergillus fumigatus. Beauvais A, et al. **J Biol Chem** 1997 Mar 7;272(10):6238–44

GENETICS

Immunological characterization of a recombinant 27–kilodalton antigenic protein from Paracoccidioides brasiliensis. Ortiz BL, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):239–41
Molecular cloning, nucleotide sequencing, and characterization of a 27–kDa antigenic protein from Paracoccidioides brasiliensis. McEwen JG, et al.
Fungal Genet Biol 1996 Jun;20(2):125–31
In vivo analysis reveals that the interdomain region of the yeast proliferating cell nuclear antigen is important for DNA replication and DNA repair. Amin NS, et al.
Genetics 1996 Oct;144(2):479–93
The Saccharomyces cerevisiae RTG2 gene is a regulator of aconitase expression under catabolite repression conditions. Vélot C, et al. **Genetics** 1996 Nov;144(3):893–903
Characterization of the Aspergillus nidulans aspnd1 gene demonstrates that the ASPND1 antigen, which it encodes, and several Aspergillus fumigatus immunodominant antigens belong to the same family. Calera JA, et al.
Infect Immun 1997 Apr;65(4):1335–44
Cloning and expression of the complement fixation antigen–chitinase of Coccidioides immitis. Zimmermann CR, et al. **Infect Immun** 1996 Dec;64(12):4967–75
Identification of a mannoprotein present in the inner layer of the cell wall of Saccharomyces cerevisiae. Moukadiri I, et al. **J Bacteriol** 1997 Apr;179(7):2154–62
Molecular cloning and characterization of a recombinant Histoplasma capsulatum antigen for antibody–based diagnosis of human histoplasmosis. Chandrashekar R, et al. **J Clin Microbiol** 1997 May;35(5):1071–6
The highly immunogenic enolase and Hsp70p are adventitious Candida albicans cell wall proteins. Eroles P, et al. **Microbiology** 1997 Feb;143 (Pt 2):313–20
Translocation of surface antigen genes to a unique telomeric expression site in Pneumocystis carinii. Sunkin SM, et al.
Mol Microbiol 1996 Jan;19(2):283–95

HISTORY

Aspergillus fumigatus antigens: the Pepys' years. Longbottom JL. **Clin Exp Allergy** 1997 May;27 Suppl 1:6–8

IMMUNOLOGY

Fungal allergens from important allergenic fungi imperfecti. Cruz A, et al. **Allergol Immunopathol (Madr)** 1997 May–Jun;25(3):153–8 (25 ref.)

Alternaria as a major allergen for asthma in children raised in a desert environment. Halonen M, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1356–61

In vitro synthesis of Alternaria allergens and their recognition by murine monoclonal and human IgE antibodies. Bush RK, et al. **Ann Allergy Asthma Immunol** 1997 Mar; 78(3):287–92

Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL–2, IL–10, IFN gamma) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Neuber K, et al. **Arch Dermatol Res** 1996 Aug; 288(9):532–6

Reduced proliferative responses of peripheral blood mononuclear cells specifically to Candida albicans antigen in patients with atopic dermatitis—comparison with their normal reactivity to bacterial superantigens. Tanaka M, et al. **Arch Dermatol Res** 1996 Aug;288(9):495–9

Immunological characterization of a recombinant 27–kilodalton antigenic protein from Paracoccidioides brasiliensis. Ortiz BL, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):239–41

Specific antibody response to oligomannosidic epitopes in Crohn's disease. Sendid B, et al. **Clin Diagn Lab Immunol** 1996 Mar;3(2):219–26

Recombinant Coccidioides immitis complement–fixing antigen: detection of an epitope shared by C. immitis, Histoplasma capsulatum, and Blastomyces dermatitidis. Yang MC, et al. **Clin Diagn Lab Immunol** 1997 Jan; 4(1):19–22

IgE antibodies to protein and mannan antigens of pityrosporum ovale in atopic dermatitis patients. Lintu P, et al. **Clin Exp Allergy** 1997 Jan;27(1):87–95

Characterization of the 33–kilodalton major allergen of Penicillium citrinum by using MoAbs and N–terminal amino acid sequencing. Shen HD, et al. **Clin Exp Allergy** 1997 Jan;27(1):79–86

Allergenic components in three different species of Penicillium: crossreactivity among major allergens. Shen HD, et al. **Clin Exp Allergy** 1996 Apr;26(4):444–51

Cell surface expression of two major yeast allergens in the Pityrosporum genus. Zargari A, et al. **Clin Exp Allergy** 1997 May;27(5):584–92

Isolated detection of cryptococcal polysaccharide antigen in cerebrospinal fluid samples from patients with AIDS. Manfredi R, et al. **Clin Infect Dis** 1996 Oct;23(4):849–50

Identification of the antigenic determinants of factors 8, 9, and 34 of genus Candida. Kobayashi H, et al. **FEBS Lett** 1996 Oct 21;395(2–3):109–12

Recognition of cytoplasmic yeast antigens of Cryptococcus neoformans var. neoformans and Cryptococcus neoformans var. gattii by immune human sera. Hamilton AJ, et al. **FEMS Immunol Med Microbiol** 1997 Feb;17(2):111–9

Coccidioides immitis antigen 2: analysis of gene and protein. Zhu Y, et al. **Gene** 1996 Nov 28;181(1–2):121–5

A monoclonal antibody directed to terminal residue of beta–galactofuranose of a glycolipid antigen isolated from Paracoccidioides brasiliensis: cross–reactivity with Leishmania major and Trypanosoma cruzi. Suzuki E, et al. **Glycobiology** 1997 Jun;7(4):463–8

Monoclonal antibodies against the 43,000 Da glycoprotein from Paracoccidioides brasiliensis modulate laminin–mediated fungal adhesion to epithelial cells and pathogenesis. Gesztesi JL, et al. **Hybridoma** 1996 Dec; 15(6):415–22

Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed–type hypersensitivity reaction. Buchanan KL, et al. **Immunology** 1997 Feb; 90(2):189–97

Peptide epitopes recognized by a human anti–cryptococcal glucuronoxylomannan antibody. Zhang H, et al. **Infect Immun** 1997 Apr;65(4):1158–64

Identification of a Coccidioides immitis antigen 2 domain that expresses B–cell–reactive epitopes. Zhu Y, et al. **Infect Immun** 1997 Aug;65(8):3376–80

Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Verweij PE, et al. **Infection** 1997 Mar–Apr; 25(2):86–9

Are fungi–specific IgE found in staff suffering from nonallergic sick building syndrome? Larsen FO, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S79–80

Mannoproteins from Candida albicans elicit a Th–type–1 cytokine profile in human Candida specific long–term T cell cultures. La Sala A, et al. **J Biol Regul Homeost Agents** 1996 Jan–Mar;10(1):8–12

Immunoreactivity of a 38–kilodalton Penicillium marneffei antigen with human immunodeficiency virus–positive sera. Chongtrakool P, et al. **J Clin Microbiol** 1997 Sep; 35(9):2220–3

Reactivity of Candida albicans germ tubes with salivary secretory IgA. Pontón J, et al. **J Dent Res** 1996 Dec; 75(12):1979–85

Western blot analysis of rat Pneumocystis carinii antigens using convalescent rat sera and rabbit anti–gp120. Pascale JM, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):30S

Bacterial antigen activation of Vdelta1 and Vdelta2 gammadelta T cells of persons infected with human immunodeficiency virus type 1. Chervenak KA, et al. **J Infect Dis** 1997 Feb;175(2):429–33

Vaginal–associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th1–type responses following intravaginal challenge with Candida antigen. Fidel PL Jr, et al. **J Infect Dis** 1997 Sep; 176(3):728–39

Interstitial pneumonitis induced in guinea pigs by the antigens of Rhizopus nigricans. Alonso A, et al. **J Investig Allergol Clin Immunol** 1997 Mar–Apr;7(2):103–9

MIP–1 alpha contributes to the anticryptococcal delayed–type hypersensitivity reaction and protection against Cryptococcus neoformans. Doyle HA, et al. **J Leukoc Biol** 1997 Feb;61(2):147–55

Evaluation of Paracoccidioides brasiliensis exoantigen in the detection of delayed dermal hypersensitivity in experimental and human paracoccidioidomycosis. Marques M, et al. **J Med Vet Mycol** 1996 Jul–Aug;34(4):265–72

Differences in reactivity of paracoccidioidomycosis sera with gp43 isoforms. Souza MC, et al. **J Med Vet Mycol** 1997 Jan–Feb;35(1):13–8

Serological characterization of Trichosporon cutaneum and related species. Ikeda R, et al. **Microbiol Immunol** 1996; 40(11):813–9

Kinetics of anti–mannan antibodies useful in confirming invasive candidiasis in immunocompromised patients. van Deventer AJ, et al. **Microbiol Immunol** 1996;40(2):125–31

Monoclonal antibodies as probes for fungal wall structure during morphogenesis. Marshall M, et al. **Microbiology** 1997 Jul;143 (Pt 7):2255–65

Re–expression by Candida albicans germ tubes of antigens lost during subculture of blastospores. Hernando FL, et al. **Mycopathologia** 1996;134(1):1–6

Immunotherapy in the treatment of allergic fungal sinusitis. Mabry RL, et al. **Otolaryngol Head Neck Surg** 1997 Jan; 116(1):31–5

Glycoprotein A is the immunodominant antigen of Pneumocystis carinii in mice following immunization. Gigliotti F, et al. **Parasitol Res** 1996;82(1):90–1

Prospective sandwich enzyme–linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Rohrlich P, et al. **Pediatr Infect Dis J** 1996 Mar;15(3):232–7

Antibodies against Candida: potential therapeutics? Matthews R, et al. **Trends Microbiol** 1996 Sep;4(9):354–8 (41 ref.)

ISOLATION & PURIFICATION

Purification of a major allergen, Asp f 2 binding to IgE in allergic bronchopulmonary aspergillosis, from culture filtrate of Aspergillus fumigatus. Banerjee B, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):821–7

Purification and characterization of a 93 kDa Aspergillus fumigatus antigen with diagnostic potential. Haynes KA, et al. **J Med Vet Mycol** 1996 Nov–Dec;34(6):421–6

Immunochemical and subcellular localization of the 43 kDa glycoprotein antigen of Paracoccidioides brasiliensis with monoclonal antibodies. Straus AH, et al. **J Med Vet Mycol** 1996 Jun–Jul;34(3):181–6

Identification of 45 kD antigen in immune complexes of patients of allergic bronchopulmonary aspergillosis. Madan T, et al. **Mol Cell Biochem** 1997 Jan;166(1–2):111–6

METABOLISM

Cell surface expression of two major yeast allergens in the Pityrosporum genus. Zargari A, et al. **Clin Exp Allergy** 1997 May;27(5):584–92

Polysaccharide antigen in brain tissue of AIDS patients with cryptococcal meningitis. Lee SC, et al. **Clin Infect Dis** 1996 Jul;23(1):194–5

Paracoccidioides brasiliensis antigen batches from the same isolate show immunological and biochemical differences. Franco M, et al. **Mycopathologia** 1996;135(1):13–9

PHARMACOLOGY

Cycloactive, aneugenic and clastogenic effects of Paracoccidioides brasiliensis exoantigen in human lymphocyte cultures. Balarin MA, et al. **J Med Vet Mycol** 1996 Jul–Aug;34(4):247–50

PHYSIOLOGY

Development of bone marrow eosinophilia in mice induced by Aspergillus fumigatus antigens. Murali PS, et al. **Clin Immunol Immunopathol** 1997 Aug;84(2):216–20

Role of particulate antigens of Aspergillus in murine eosinophilia. Kurup VP, et al. **Int Arch Allergy Immunol** 1997 Mar;112(3):270–8

TOXICITY

Identification and evaluation of a major cytotoxin of A. fumigatus. Madan T, et al. **Mol Cell Biochem** 1997 Feb; 167(1–2):89–97

URINE

Cross–reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Wheat J, et al. **Clin Infect Dis** 1997 Jun;24(6):1169–71

ANTIGENS, HELMINTH

Adult Onchocerca volvulus from east and west Africa exhibit similar antigenicity with pooled sera from onchocerciasis patients. Tawill SA, et al. **Ann Trop Med Parasitol** 1996 Dec;90(6):651–4

Mediastinal lymph node cells of Angiostrongylus cantonensis–infected rats respond to antigens and release interleukin–5 in vitro. Sugaya H, et al. **Int J Parasitol** 1996 May;26(5):543–51

Cross–reactive idiotypes on rabbit anti–SEA antibodies stimulate anti–idiotype spleen and lymph node cell responses of mice infected with Schistosoma mansoni. Amano T, et al. **Parasite Immunol** 1996 Jan;18(1):21–8

Immunological responses to antigen B from Echinococcus granulosus cyst fluid in hydatid patients. Ioppolo S, et al. **Parasite Immunol** 1996 Nov;18(11):571–8

Carbohydrates on the surface of Echinococcus granulosus protoscoleces are immunodominant in mice. Míguez M, et al. **Parasite Immunol** 1996 Nov;18(11):559–69

Urea/DTT solubilization of a recombinant Taenia ovis antigen, 45W, expressed as a GST fusion protein results in enhanced protective immune response to the 45W moiety. Rothel JS, et al. **Vaccine** 1997 Apr;15(5):469–72

ADMINISTRATION & DOSAGE

Elastase contributes to antigen–induced mucociliary dysfunction in ovine airways. O'Riordan TG, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1522–8

Increase of eosinophilic cell population in bone marrow of rats by immunization with Ascaris suum antigen. Nittoh T, et al. **Immunol Invest** 1997 Jun;26(4):439–51

Correlation between degree of protection and humoral antibody response in hamsters immunized with somatic and excretory secretory antigens of Ancylostoma ceylanicum. Khan AM, et al. **Indian J Exp Biol** 1996 Oct;34(10):1015–8

Schistosomal–specific nephropathy in Syrian golden hamsters: treatment by induction of antigen excess. Sobh M, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2178–84

Vaccination against hydatidosis using a defined recombinant antigen. Lightowlers MW, et al. **Parasite Immunol** 1996 Sep;18(9):457–62

HPLC fractionated soluble egg antigen from Schistosoma mansoni elicits a heterogeneous human immune response. Moyes RB, et al. **Parasite Immunol** 1996 Dec;18(12):625–33

Immune responses associated with protection in sheep vaccinated with a recombinant antigen from Taenia ovis. Rothel JS, et al. **Parasite Immunol** 1996 Apr;18(4):201–8

ADVERSE EFFECTS

Effect of the 21–aminosteroid U–74006F on antigen–induced bronchoconstriction and bronchoalveolar eosinophilia in allergic sheep. Fujimoto K, et al. **Eur Respir J** 1996 Oct; 9(10):2044–9

Cooking and freezing may not protect against allergenic reactions to ingested Anisakis simplex antigens in humans. Audicana L, et al. **Vet Rec** 1997 Mar 1;140(9):235

ANALYSIS

Detection of specific Echinococcus granulosus antigen 5 in liver cyst bioptate from human patients. Paul M, et al. **Acta Trop** 1997 Apr 1;64(1–2):65–77

Countercurrent immunoelectrophoresis test for detection of hydatid antigen in the fluid from hydatid cysts: a preliminary report. Ravinder PT, et al. **Acta Trop** 1997 Sep 10;66(3):169–73

Periodate treatment of Anisakis simplex allergens. Moneo I, et al. **Allergy** 1997 May;52(5):565–9

Detection of microfilarial antigen in circulating immune complex from sera of Wuchereria bancrofti–infected individuals. Kobayashi M, et al. **Am J Trop Med Hyg** 1997 Aug;57(2):200–4

Overview of immunology [letter; comment] [published erratum appears in Arch Med Res 1997 Summer;28(2):313] Flisser A. **Arch Med Res** 1997 Spring;28(1):145, 147. Comment on: Arch Med Res 1995;26 Spec No:S85–6.

Echinococcus multilocularis coproantigen detection in golden hamster, an alternative definitive host. Sakai H, et al. **Exp Anim** 1996 Jul;45(3):275–8

Fasciola hepatica: detection of antigenemia and coproantigens in experimentally infected rats. Espino AM, et al. **Exp Parasitol** 1997 Feb;85(2):117–20

Echinococcus multilocularis metacestodes: immunological and immunocytochemical analysis of the relationships between alkaline phosphatase and the Em2 antigen. Lawton P, et al. **Exp Parasitol** 1997 Oct;87(2):142–9

Time course of coproantigen excretion in Echinococcus multilocularis infections in foxes and an alternative definitive host, golden hamsters. Nonaka N, et al. **Int J Parasitol** 1996 Nov;26(11):1271–8

Recognition of low molecular weight Cooperia oncophora antigens after primary and trickle infection of calves with third–stage infective larvae. van Diemen PM, et al. **Int J Parasitol** 1996 Nov;26(11):1305–10

Identification of surface tegumental antigens of normal and irradiated schistosomula. Charmy RA, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):479–91

Electrophoretic differentiation of soluble egg antigens from Schistosoma mansoni isolates using SDS–PAGE. Pillay D. **J Helminthol** 1996 Mar;70(1):91–3

Studies on coproantigen detection for diagnosis of Echinococcus infection in definitive hosts. Sakai H. **Jpn J Vet Res** 1996 Aug;44(2):125–7

Immunoblot patterns of clonorchiasis. Hong ST, et al. **Korean J Parasitol** 1997 Jun;35(2):87–93

Localization of worm antigen in Neodiplostomum seoulense by immuno–electronmicroscopy. Lee JC, et al.

Korean J Parasitol 1997 Jun;35(2):95–104

A carbohydrate antigen of Clonorchis sinensis recognized by a species-specific monoclonal antibody. Yong TS, et al. **Korean J Parasitol** 1996 Dec;34(4):279–81

A dominant B-cell epitope on the 22 kDa tegumental membrane-associated antigen of Schistosoma japonicum maps to an EF-hand calcium binding domain. Waine GJ, et al. **Parasite Immunol** 1997 Aug;19(8):337–45

Strongyloides stercoralis: identification of antigens in natural human infections from endemic areas of the United States. Siddiqui AA, et al. **Parasitol Res** 1997;83(7):655–8

Identification and partial characterization of a myosin-like protein from cysticerci and adults of Taenia solium using a monoclonal antibody. Ambrosio J, et al. **Parasitology** 1997 Jun;114 (Pt 6):545–53

The protein antigens secreted in vivo by adult male Schistosoma mansoni. Cutts L, et al. **Parasitology** 1997 Mar; 114 (Pt 3):245–55

Cloning, heterologous expression and antigenicity of a schistosome cercarial protease. Price HP, et al. **Parasitology** 1997 May;114 (Pt 5):447–53

Detection of Fasciola hepatica antigen in cattle faeces by a monoclonal antibody-based sandwich immunoassay. Duménigo BE, et al. **Res Vet Sci** 1996 May;60(3):278–9

Comparison of adult somatic and excretory-secretory antigens in enzyme-linked immunosorbent assay for serodiagnosis of human infection with Fasciola gigantica. Maleewong W, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):566–9

Antigen detection assay to monitor the efficacy of praziquantel for treatment of Paragonimus westermani infections. Zhang Z, et al. **Trans R Soc Trop Med Hyg** 1996 Jan–Feb;90(1):43

A Trichuris specific diagnostic antigen from culture fluids of Trichuris suis adult worms. Hill DE, et al. **Vet Parasitol** 1997 Jan;68(1–2):91–102

[The use of immunoblotting for studying Opisthorchis felineus (Rivolta, 1884) antigens] Glupov VV, et al. **Med Parazitol (Mosk)** 1997 Jan–Mar;(1):17–9 (Eng. Abstr.) **(Rus)**

[A comparative study of the somatic, excretory-secretory and egg antigens of Opisthorchis felineus] Kotelkin AT, et al. **Med Parazitol (Mosk)** 1997 Jan–Mar;(1):12–6 (Eng. Abstr.) **(Rus)**

[Comparison of 2 serologic methods for the diagnosis of hydatidosis] Arienti HM, et al. **Bol Oficina Sanit Panam** 1996 Sep;121(3):221–7 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Developmentally regulated expression of a Haemonchus contortus surface antigen. Raleigh JM, et al. **Int J Parasitol** 1996 Jun;26(6):673–5

Molecular characterization of a 20.8-kDa Schistosoma mansoni antigen. Sequence similarity to tegumental associated antigens and dynein light chains. Hoffmann KF, et al. **J Biol Chem** 1997 Jun 6;272(23):14509–15

Sequence analysis of a gene family encoding Taenia ovis vaccine antigens expressed during embryogenesis of eggs. Waterkeyn J, et al. **Mol Biochem Parasitol** 1997 May; 86(1):75–84

Stage-specific expression of surface molecules by the larval stages of Haemonchus contortus. Raleigh JM, et al. **Parasite Immunol** 1996 Mar;18(3):125–32

Fasciola hepatica: rapid switching of stage-specific antigen expression after infection. Tkalcevic J, et al. **Parasite Immunol** 1996 Mar;18(3):139–47

Identification and in situ and in vitro characterization of secreted proteins produced by plant-parasitic nematodes. Curtis RH. **Parasitology** 1996 Dec;113 (Pt 6):589–97

BLOOD

A comparative study on specific antibodies and circulating antigen (CAA) in serum and parasitological findings for diagnosis of schistosomiasis mansoni in an endemic area in Tanzania. Håkangård C, et al. **Acta Trop** 1996 May; 61(3):213–22

Detection of circulating antigen by monoclonal antibodies for immunodiagnosis of angiostrongyliasis. Chye SM, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):408–12

Monoclonal antibodies to Paragonimus heterotremus and their potential for diagnosis of paragonimiasis. Maleewong W, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):413–7

Parasite antigenemia without microfilaremia in bancroftian filariasis. Weil GJ, et al. **Am J Trop Med Hyg** 1996 Sep; 55(3):333–7

Collaborative study on evaluation of immunodiagnostic assays in schistosomiasis japonica by treatment efficacy assessment. Collaboration Group. Guan X, et al. **Chin Med J (Engl)** 1996 Sep;109(9):659–64

Collaborative study on detection of circulating antigens in schistosomiasis japonica. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(4):277–83

Fasciola hepatica: detection of antigenemia and coproantigens in experimentally infected rats. Espino AM, et al. **Exp Parasitol** 1997 Feb;85(2):117–20

Analysis and potential of excretory-secretory antigens of Setaria cervi for immunodiagnosis of human filariasis. Mustafa H, et al. **Indian J Exp Biol** 1996 Jun;34(6):508–12

Detection of circulating antigens in blood to evaluate treatment of fascioliasis. Hammouda NA, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):365–71

Evaluating the detection of circulating filarial antigen in diagnosis of bancroftian filariasis and filarial hydrocele. Hassan MM, et al. **J Egypt Soc Parasitol** 1996 Dec; 26(3):687–96

A monoclonal antibody-based enzyme immunoassay for detecting parasite antigenaemia and antigenuria in Schistosomiasis mansoni. Kamel MA, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):789–95

Wuchereria bancrofti recombinant antigen-derived poly- and monoclonal antibodies for the detection of circulating antigen(s) in the sera of lymphatic filarial patients. Theodore JG, et al. **J Helminthol** 1996 Mar;70(1):69–74

Circulating antigens in schistosomiasis: detection of 31/32-kDa proteins in sera from patients infected with Schistosoma japonicum, S. mansoni, S. haematobium, or S. intercalatum. Li YL, et al. **Parasitol Res** 1996;82(1):14–8

Circulating antigen levels in serum of cattle naturally infected with Schistosoma mattheei. De Bont J, et al. **Parasitology** 1996 Nov;113 (Pt 5):465–71

Experimental Schistosoma bovis infection in goats. Circulating antigen and antibody responses to egg and adult worm antigens during infection and following treatment with praziquantel. Johansen MV, et al. **Parasitology** 1996 Oct;113 (Pt 4):367–75

Evaluation of serological assays for diagnosis of onchocercosis. Lavebratt C, et al. **Scand J Infect Dis** 1997; 29(1):65–70

Detection of circulating antigens of Parastrongylus cantonensis in human sera by sandwich ELISA with specific monoclonal antibody. Eamsobhana P, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):712–5

The evaluation of the 29 and 31 kDa antigens in female Angiostrongylus cantonensis for serodiagnosis of human angiostrongyliasis. Nuamtanong S. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):291–6

Circulating anodic and cathodic antigen in serum and urine of mixed Schistosoma haematobium and S. mansoni infections in Office du Niger, Mali. De Clercq D, et al. **Trop Med Int Health** 1997 Jul;2(7):680–5

Antigenicity and specificity of very low molecular weight Onchocerca volvulus polypeptides in the range 2.2–12.5 kD. Hoffmann WH, et al. **Trop Med Int Health** 1997 Jul; 2(7):635–45

Evaluation of a monoclonal antibody-based sandwich-ELISA for detection of circulating Schistosoma japonicum antigen (Sj31/32) in an endemic area of China. Li YL, et al. **Trop Med Int Health** 1996 Dec;1(6):847–50

Evaluation of the Og4C3 ELISA in Wuchereria bancrofti infection: infected persons with undetectable or ultra-low microfilarial densities. Rocha A, et al. **Trop Med Int Health** 1996 Dec;1(6):859–64

Detection of the circulating antigens CAA and CCA in a group of Dutch travellers with acute schistosomiasis. van Lieshout L, et al. **Trop Med Int Health** 1997 Jun;2(6):551–7

Detection of circulating antigens in Gabonese patients with Loa loa filariasis. Walker-Deemin A, et al. **Trop Med Int Health** 1996 Dec;1(6):772–8

The isolation of Fasciola gigantica-specific antigens and their use in the serodiagnosis of fasciolosis in sheep by the detection of circulating antigens. Guobadia EE, et al. **Vet Parasitol** 1997 Feb;68(3):269–82

Detection of circulating Fasciola gigantica antigen in experimental and natural infections of sheep with fasciolosis. Guobadia EE, et al. **Vet Parasitol** 1996 Oct 15; 65(1–2):29–39

Antibody and circulating antigen profiles before and after chemotherapy in goats infected with Fasciola gigantica. Mbuh JV, et al. **Vet Parasitol** 1996 Nov 15;66(3–4):171–9

[Allergic granulomatous angiitis in a patient with positive reactions on serological tests for parasite antigens] Kobayashi A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Oct; 34(10):1130–5 (Eng. Abstr.) **(Jpn)**

CEREBROSPINAL FLUID

Identification of Angiostrongylus cantonensis in infected rats with a coagglutination assay. Rojas Rivero L, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):716–8

CHEMISTRY

Periodate treatment of Anisakis simplex allergens. Moneo I, et al. **Allergy** 1997 May;52(5):565–9

Characterization of fucosyllactose determinant-bearing glycoproteins probed by a Biomphalaria alexandrina lectin in Schistosoma mansoni cercariae. Negm HI. **Dev Comp Immunol** 1996 Mar–Apr;20(2):87–96

Terminal beta-linked tyvelose creates unique epitopes in Trichinella spiralis glycan antigens. Ellis LA, et al. **Glycobiology** 1997 Apr;7(3):383–90

Are the 26-kDa somatic and the 24-kDa excretory/secretory antigens of Haemonchus contortus one and the same? Cornelissen AW. **Int J Parasitol** 1996 Oct;26(10):1131 (9 ref.)

Molecular characterization of a 20.8-kDa Schistosoma mansoni antigen. Sequence similarity to tegumental associated antigens and dynein light chains. Hoffmann KF, et al. **J Biol Chem** 1997 Jun 6;272(23):14509–15

OvB20, an Onchocerca volvulus-cloned antigen selected by differential immunoscreening with vaccination serum in a cattle model of onchocerciasis. Abdel-Wahab N, et al. **Mol Biochem Parasitol** 1996 Feb–Mar;76(1–2):187–99

A major allergen of lymphatic filarial nematodes is a parasite homolog of the gamma-glutamyl transpeptidase. Lobos E, et al. **Mol Med** 1996 Nov;2(6):712–24

Structural characteristics of the Ascaris allergen, ABA-1. McGibbon AM, et al. **Parasite** 1995 Mar;2(1):41–8

Two different 8 kDa monomers are involved in the oligomeric organization of the native Echinococcus granulosus antigen B. González G, et al. **Parasite Immunol** 1996 Dec;18(12):587–96

DIAGNOSTIC USE

Enzyme-linked immunosorbent assay using cysteine proteinase antigens for immunodiagnosis of human paragonimiasis. Ikeda T, et al. **Am J Trop Med Hyg** 1996 Oct;55(4):435–7

The immunodiagnostic potential of Echinococcus granulosus adult-worm antigens in human cystic echinococcosis. Ersfeld K, et al. **Parasitol Res** 1997;83(1):90–2

Diagnostic potential of fractionated Brugia malayi microfilarial excretory/secretory antigen for bancroftian filariasis. Chenthamarakshan V, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):252–4

An enzyme-linked immunosorbent assay using Schistosoma mansoni purified egg antigen for the diagnosis of schistosomiasis in Saudi Arabia. Ghandour AM, et al. **Trans R Soc Trop Med Hyg** 1997 May–Jun;91(3):287–9

Immunodiagnosis of swine cysticercosis by indirect ELISA employing a heterologous antigen from Taenia crassiceps metacestode. Biondi GF, et al. **Vet Parasitol** 1996 Sep 16; 64(4):261–6

DRUG EFFECTS

Reduction of Wuchereria bancrofti adult worm circulating antigen after annual treatments of diethylcarbamazine combined with ivermectin in French Polynesia. Nicolas L, et al. **J Infect Dis** 1997 Feb;175(2):489–92

GENETICS

The immunogenetics of resistance to Trichostrongylus colubriformis and Haemonchus contortus parasites in sheep [see comments] Hohenhaus MA, et al. **Br Vet J** 1995 Mar–Apr;151(2):119–40 (65 ref.). Comment in: Br Vet J 1995 Mar–Apr;151(2):111–3.

Taenia ovis: copy number of genes encoding host-protective antigens determined by competitive PCR. Waterkeyn JG, et al. **Exp Parasitol** 1997 May;86(1):84–8

Identification and molecular cloning of a 67-kilodalton protein in Schistosoma japonicum homologous to a family of actin-binding proteins. Kurtis JD, et al. **Infect Immun** 1997 Jan;65(1):344–7

A complementary DNA encoding an antigen from Trichinella spiralis muscle larvae and its analog from Trichinella T5 of bobcat origin: sequence, cloning and expressions. Yao C, et al. **Int J Parasitol** 1997 Apr; 27(4):425–30

Use of cloned excretory/secretory low-molecular-weight proteins of Cooperia oncophora in a serological assay. Poot J, et al. **J Clin Microbiol** 1997 Jul;35(7):1728–33

Cloning and sequencing of the gene encoding the principal 18-kDa secreted antigen of activated oncospheres of Taenia saginata. Benitez L, et al. **Mol Biochem Parasitol** 1996 Jun;78(1–2):265–8

Molecular characterisation of a novel 8-kDa subunit of Echinococcus granulosus antigen B. Fernández V, et al. **Mol Biochem Parasitol** 1996 May;77(2):247–50

Cloning and characterisation of strain-specific transcripts encoding triosephosphate isomerase, a candidate vaccine antigen from Schistosoma japonicum. Hooker CW, et al. **Mol Biochem Parasitol** 1996 Nov 25;82(2):265–9

Characterization of a schistosome T cell-stimulating antigen (Sm10) associated with protective immunity in humans. Kohlstädt S, et al. **Mol Biochem Parasitol** 1997 Feb; 84(2):155–65

Molecular cloning and characterisation of a developmentally regulated putative metallopeptidase present in a host protective extract of Haemonchus contortus. Redmond DL, et al. **Mol Biochem Parasitol** 1997 Mar;85(1):77–87

Host-protective fragments and antibody binding epitopes of the Taenia ovis 45W recombinant antigen. Lightowlers MW, et al. **Parasite Immunol** 1996 Oct;18(10):507–13

Echinococcus granulosus antigen 5 may be a serine proteinase [letter] Willis AC, et al. **Parasite Immunol** 1997 Aug; 19(8):385

Purification and N-terminal amino acid sequencing of Echinococcus granulosus antigen 5. Zhang LH, et al. **Parasite Immunol** 1996 Dec;18(12):597–606

pOVEX vector: prokaryotic expression and purification of onchocerciasis vaccine candidate antigens as fusion proteins with the 24 kD Onchocerca volvulus glutathione S-transferase. Liebau E, et al. **Trop Med Int Health** 1997 Jul;2(7):691–4

IMMUNOLOGY

Expression and immunological characterisation of

Echinococcus granulosus recombinant antigen B for IgG4 subclass detection in human cystic echinococcosis. McVie A, et al. **Acta Trop** 1997 Sep 15;67(1–2):19–35

Adult Schistosoma mansoni worms positively modulate soluble egg antigen–induced inflammatory hepatic granuloma formation in vivo. Stereological analysis and immunophenotyping of extracellular matrix proteins, adhesion molecules, and chemokines. Jacobs W, et al. **Am J Pathol** 1997 Jun;150(6):2033–45

Cyclosporine A inhibits airway reactivity and remodeling after chronic antigen challenge in cats. Padrid PA, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1812–8

Immunoblot with cerebrospinal fluid from patients with neurocysticercosis using antigen from cysticerci of Taenia solium and Taenia crassiceps. Vaz AJ, et al. **Am J Trop Med Hyg** 1997 Sep;57(3):354–7

Evaluation of recombinant chitinase and SXP1 antigens as antimicrofilarial vaccines. Wang SH, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):474–81

Human interleukin–12 upregulates proliferation and interferon–gamma production by parasite antigen–stimulated Th cell clones and gamma/delta T cells of cattle. Brown WC, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:321–4

Humoral and cellular immune response within the subarachnoid space of patients with neurocysticercosis. Ostrosky–Zeichner L, et al. **Arch Med Res** 1996 Winter; 27(4):513–7

Schistosoma mansoni excretory circulating cathodic antigen shares Lewis–x epitopes with a human granulocyte surface antigen and evokes host antibodies mediating complement–dependent lysis of granulocytes. van Dam GJ, et al. **Blood** 1996 Dec 1;88(11):4246–51

The basis of IgE responses to specific antigenic determinants in helminthiasis. Lobos E. **Chem Immunol** 1997;66:1–25 (126 ref.)

Immunodiagnosis of alveolar echinococcosis by enzyme–linked immunosorbent assay using a partially purified Em18/16 enriched fraction. Ito A, et al. **Clin Diagn Lab Immunol** 1997 Jan;4(1):57–9

Differential antigen recognition by T cell populations from strains of mice developing polar forms of granulomatous inflammation in response to eggs of Schistosoma mansoni. Hernandez HJ, et al. **Eur J Immunol** 1997 Mar;27(3):666–70

Taenia saginata: vaccination against cysticercosis in cattle with recombinant oncosphere antigens. Lightowlers MW, et al. **Exp Parasitol** 1996 Dec;84(3):330–8

Stage–specific induction of cytokines regulates the immune response in lymphatic filariasis. Mahanty S, et al. **Exp Parasitol** 1996 Nov;84(2):282–90

Regulation of parasite antigen–driven immune responses by interleukin–10 (IL–10) and IL–12 in lymphatic filariasis. Mahanty S, et al. **Infect Immun** 1997 May;65(5):1742–7

The novel cuticular collagen Ovcol–1 of Onchocerca volvulus is preferentially recognized by immunoglobulin G3 from putatively immune individuals. Stewart GR, et al. **Infect Immun** 1997 Jan;65(1):164–70

Interleukin–12 and –10 and gamma interferon regulate polyclonal and ligand–specific expansion of murine B–1 cells. Velupillai P, et al. **Infect Immun** 1996 Nov; 64(11):4557–60

Human immunoglobulin E responses to a recombinant 22.6–kilodalton antigen from Schistosoma mansoni adult worms are associated with low intensities of reinfection after treatment. Webster M, et al. **Infect Immun** 1996 Oct; 64(10):4042–6

The effect of 5–lipoxygenase inhibition on Ascaris antigen (Ag)–induced responses in atopic monkeys. Turner CR, et al. **Inflamm Res** 1996 Jan;45(1):42–9

In vivo induction of type 1 and 2 immune responses against protein antigens. Comoy EE, et al. **Int Immunol** 1997 Apr; 9(4):523–31

Production of both IFN–gamma and IL–5 by Onchocerca volvulus S1 antigen–specific CD4+ T cells from putatively immune individuals. Doetze A, et al. **Int Immunol** 1997 May;9(5):721–9

Differential regulation of antigen–specific IgG4 and IgE antibodies in response to recombinant filarial proteins. Garraud O, et al. **Int Immunol** 1996 Dec;8(12):1841–8

Selective usage of defined TCRBV genes in response to filarial antigens. Sartono E, et al. **Int Immunol** 1997 Jul; 9(7):955–62

Inhibition of spleen cell proliferative response to mitogens by excretory–secretory antigens of Fasciola hepatica. Cervi L, et al. **Int J Parasitol** 1997 May;27(5):573–9

Immunomodulation of sheep and human lymphocytes by Fasciola hepatica excretory–secretory products. Jefferies JR, et al. **Int J Parasitol** 1996 Oct;26(10):1119–21

Rational design of nematode vaccines; natural antigens. Meeusen EN. **Int J Parasitol** 1996 Aug–Sep;26(8–9):813–8 (35 ref.)

Rational design of nematode vaccines: hidden antigens. Munn EA. **Int J Parasitol** 1997 Apr;27(4):359–66 (30 ref.)

Immunological interactions between Trichinella spiralis and Heligmosomoides polygyrus: cross reactivity between muscle larvae and antibodies raised to unrelated antigens. Robinson M, et al. **Int J Parasitol** 1997 Jul;27(7):865–72

Low molecular weight Cooperia oncophora antigens. Potential to discriminate between susceptible and resistant calves after infection. van Diemen PM, et al. **Int J Parasitol** 1997 May;27(5):587–93

The use of IgE immunoblotting as a diagnostic tool in Anisakis simplex allergy. García M, et al. **J Allergy Clin Immunol** 1997 Apr;99(4):497–501

In utero exposure to helminth and mycobacterial antigens generates cytokine responses similar to that observed in adults. Malhotra I, et al. **J Clin Invest** 1997 Apr 1; 99(7):1759–66

Specific recognition of hydatid cyst antigens by serum IgG, IgE, and IgA using western blot. Sbihi Y, et al. **J Clin Lab Anal** 1997;11(3):154–7

Reliability of immunoassays in diagnosis of neurocysticercosis [letter; comment] Katti MK. **J Clin Microbiol** 1996 Sep; 34(9):2239. Comment on: J Clin Microbiol 1995 Dec;33(12):3124–8.

Immunocharacterization of Taenia solium oncosphere and metacestode antigens. Garcia–Allan C, et al. **J Helminthol** 1996 Dec;70(4):271–80

Antibody responses against Echinococcus multilocularis antigens in naturally infected Rattus norvegicus. Ito A, et al. **J Helminthol** 1996 Dec;70(4):355–7

Larval somatic antigens effective in inducing an IgG response and protection against Strongyloides papillosus infection. Ooba C, et al. **J Helminthol** 1996 Sep;70(3):231–5

Calpain is the target antigen of a Th1 clone that transfers protective immunity against Schistosoma mansoni. Jankovic D, et al. **J Immunol** 1996 Jul 15;157(2):806–14

Immunoregulatory idiotypes stimulate T helper 1 cytokine responses in experimental Schistosoma mansoni infections. Montesano MA, et al. **J Immunol** 1997 Apr 15; 158(8):3800–4

Vaccination with alum–precipitated recombinant Ancylostoma–secreted protein 1 protects mice against challenge infections with infective hookworm (Ancylostoma caninum) larvae. Ghosh K, et al. **J Infect Dis** 1996 Dec;174(6):1380–3

Depression of antigen–specific interleukin–5 and interferon–gamma responses in human lymphatic filariasis as a function of clinical status and age. Sartono E, et al. **J Infect Dis** 1997 May;175(5):1276–80

Relationship among circulating interferon, tumor necrosis factor–alpha, and interleukin–6 and serologic reaction against parasitic antigen in human hydatidosis. Touil–Boukoffa C, et al. **J Interferon Cytokine Res** 1997 Apr;17(4):211–7

A recombinant protein from Schistosoma mansoni useful for the detection of S. mansoni and Schistosoma haematobium antibodies. Hancock K, et al. **J Parasitol** 1997 Aug; 83(4):612–8

Production of monoclonal antibodies against excretory–secretory products of adult male Onchocerca gibsoni. Harnett W, et al. **J Parasitol** 1997 Apr;83(2):316–9

Adoptive transfer of granulomatous inflammation to Brugia antigens in jirds. Klei TR, et al. **J Parasitol** 1997 Aug; 83(4):626–9

Exposure of swine to Trichinella spiralis antigen as determined by consecutive ELISAs and western blot. Shin SS, et al. **J Parasitol** 1997 Jun;83(3):430–3

Local transient induction of inflammatory cytokines after intranasal administration of recombinant Bordetella pertussis. Remoué F, et al. **Microb Pathog** 1997 May; 22(5):305–13

Sequence and immunogenicity of Taenia saginata ferritin. Benitez L, et al. **Mol Biochem Parasitol** 1996 Nov 12; 82(1):113–6

Specific cellular and humoral immune responses induced by different antigen preparations of Echinococcus multilocularis metacestodes in patients with alveolar echinococcosis. Nicod L, et al. **Parasite** 1994 Sep; 1(3):261–70

A preliminary assessment of the recombinant antigen PLA2 in the diagnosis of human dirofilariosis. Vieira C, et al. **Parasite** 1997 Jun;4(2):193–6

Immunological cross reactivity between Schistosoma mansoni and cholera toxin. Akhiani AA, et al. **Parasite Immunol** 1997 Aug;19(8):355–61

Evidence that cellular immune responses to soluble and membrane associated antigens are independently regulated during human schistosomiasis mansoni. Bahia–Oliveira LM, et al. **Parasite Immunol** 1996 Feb;18(2):53–63

Acquisition and expression of humoral reactivity to antigens of infective stages of filarial larvae. Bailey JW, et al. **Parasite Immunol** 1995 Dec;17(12):617–23

Intranasal immunization of mice with Echinococcus granulosus surface antigens iscoms evokes a strong immune response, biased towards glucidic epitopes. Carol H, et al. **Parasite Immunol** 1997 May;19(5):197–205

Serological reactivity to heat shock protein 70 in patients with hydatid disease. Colebrook AL, et al. **Parasite Immunol** 1997 Jan;19(1):41–6

Sm480: a high molecular weight Schistosoma mansoni antigen associated with protective immunity. Curtis RH, et al. **Parasite Immunol** 1996 Mar;18(3):149–57

The isolation of a 22 kDa band after SDS–PAGE of Schistosoma mansoni adult worms and its use to demonstrate that IgE responses against the antigen(s) it contains are associated with human resistance to reinfection. Dunne DW, et al. **Parasite Immunol** 1997 Feb; 19(2):79–89

Analysis of the immune response elicited by a multiple antigen peptide (MAP) composed of two distinct protective antigens derived from the parasite Schistosoma mansoni. Ferru I, et al. **Parasite Immunol** 1997 Jan;19(1):1–11

Recognition of Schistosoma mansoni cathepsins B and L by human IgG1 and IgG4 antibodies. Grogan J, et al. **Parasite Immunol** 1997 May;19(5):215–20

Immunomodulation by hydatid cyst fluid toxin (Echinococcus granulosus). Janssen D, et al. **Parasite Immunol** 1997 Apr;19(4):149–60

Heterogeneity in the recognition of Ostertagia circumcincta antigens by serum antibody from mature, infected sheep. McCririe L, et al. **Parasite Immunol** 1997 May;19(5):235–42

Antibodies against Echinococcus multilocularis alkaline phosphatase as markers for the specific diagnosis and the serological monitoring of alveolar echinococcosis. Sarciron EM, et al. **Parasite Immunol** 1997 Feb;19(2):61–8

Specific T cell unresponsiveness in human filariasis: diversity in underlying mechanisms. Sartono E, et al. **Parasite Immunol** 1995 Nov;17(11):587–94

Protective immunity induced by vaccination with Onchocerca volvulus tropomyosin in rodents. Taylor MJ, et al. **Parasite Immunol** 1996 May;18(5):219–25

A dominant B–cell epitope on the 22 kDa tegumental membrane–associated antigen of Schistosoma japonicum maps to an EF–hand calcium binding domain. Waine GJ, et al. **Parasite Immunol** 1997 Aug;19(8):337–45

B cell mitogenic activity of Toxocara canis adult worm antigen. Wang MQ, et al. **Parasite Immunol** 1995 Dec; 17(12):609–15

Eosinophil chemotactic factor release from neutrophils induced by stimulation with Schistosoma japonicum eggs. Owhashi M, et al. **Parasitol Res** 1997;83(1):42–6

Differential responsiveness of humans with early–stage schistosomiasis haematobium to Schistosoma haematobium soluble adult–worm and egg antigens. El Ridi R, et al. **Parasitol Res** 1997;83(5):471–7

Carbohydrate epitopes on Haemonchus contortus antigens. Schallig HD, et al. **Parasitol Res** 1996;82(1):38–42

Immunosuppression and inhibition of inflammation in mice induced by a small Taenia solium RNA–peptide to implanted T. solium metacestodes. Tato P, et al. **Parasitol Res** 1996;82(7):590–7

The protein antigens secreted in vivo by adult male Schistosoma mansoni. Cutts L, et al. **Parasitology** 1997 Mar; 114 (Pt 3):245–55

Neutral glycolipids of Schistosoma mansoni as feasible antigens in the detection of schistosomiasis. Dennis RD, et al. **Parasitology** 1996 Mar;112 (Pt 3):295–307

Induction of protective immunity and modulation of granulomatous hypersensitivity in mice using PIII, an anionic fraction of Schistosoma mansoni adult worm. Hirsch C, et al. **Parasitology** 1997 Jul;115 (Pt 1):21–8

The ultrastructural localization of Echinococcus granulosus antigen 5. Jones MK, et al. **Parasitology** 1996 Sep;113 (Pt 3):213–22

Ultrastructural localization of Sm28 GST protective antigen in Schistosoma mansoni adult worms. Liu JL, et al. **Parasitology** 1996 Oct;113 (Pt 4):377–91

Protective immunity to the blood–feeding nematode Haemonchus contortus induced by vaccination with parasite low molecular weight antigens. Schallig HD, et al. **Parasitology** 1997 Mar;114 (Pt 3):293–9

Experimental granulomatous vasculitis induced by sensitization with Ascaris suum antigen in mice. Alwie ML, et al. **Pathol Int** 1995 Dec;45(12):914–24

Comparison of the immune response elicited by a free peptide and a lipopeptide construct. Ferru I, et al. **Pept Res** 1996 May–Jun;9(3):136–43

Echinococcus granulosus antigen B and seroreactivity in natural ovine hydatidosis. Ibrahem MM, et al. **Res Vet Sci** 1996 Sep;61(2):102–6

Induction of cytotoxic T–cell activity by the protective antigen of Schistosoma mansoni Sm28GST or its derived C–terminal lipopeptide. Pancré V, et al. **Scand J Immunol** 1996 Nov;44(5):485–92

IL–10 plays a role in the modulation of human granulomatous hypersensitivity against Schistosoma mansoni eggs induced by immune complexes. Rezende SA, et al. **Scand J Immunol** 1997 Jul;46(1):96–102

Human schistosomiasis: modulation of in vitro granulomatous hypersensitivity and lymphocyte proliferative response by macrophages undergoing differentiation. Silva–Teixeira DN, et al. **Scand J Immunol** 1996 Nov;44(5):522–9

Immunohistochemical localization of Gnathostoma spinigerum larval antigens by monoclonal antibodies: II. Electron microscopy. Rojekittikhun W, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):570–3

pOVEX vector: prokaryotic expression and purification of onchocerciasis vaccine candidate antigens as fusion proteins with the 24 kD Onchocerca volvulus glutathione S–transferase. Liebau E, et al. **Trop Med Int Health** 1997 Jul;2(7):691–4

Characterization of Schistosoma mansoni 44.7/56.8 kDa egg antigens recognized by human monoclonal antibodies which induce protection against experimental infection and proliferation of peripheral blood mononuclear cells from schistosomiasis patients. Hirsch C, et al. **Vaccine** 1997 Jun; 15(9):948–54

Immunological responses in the mouse host to a cloned antigen of Taenia crassiceps. Hill DE, et al. **Vet Parasitol** 1996 Oct 25;65(3–4):247–58

Bovine humoral immune responses to Haemonchus placei excretory secretory antigens. Schallig HD, et al. **Vet Parasitol** 1996 Oct 25;65(3–4):289–96

[A comparative biochemical and immunological study of the

somatic and metabolic antigens of Opisthorchis felineus] Kotelkin AT, et al. **Med Parazitol (Mosk)** 1996 Apr–Jun; (2):18–23 **(Rus)**

ISOLATION & PURIFICATION

Identification of larval-stage-specific antigens of Onchocerca volvulus uniquely recognized by putative immune sera from humans and vaccination sera from animal models. Irvine M, et al. **Ann Trop Med Parasitol** 1997 Jan; 91(1):67–77

Serologic recognition of hydatid cyst antigens using different purification methods. Sbihi Y, et al. **Diagn Microbiol Infect Dis** 1996 Apr;24(4):205–11

Evaluation of purified antigens in haemagglutination test (IHA) for determination of cross reactivities in diagnosis of fascioliasis and schistosomiasis. Azab M el-S, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):677–85

Antigenic polypeptides of Echinococcus granulosus oncospheres and definition of protective molecules. Heath DD, et al. **Parasite Immunol** 1996 Jul;18(7):347–57

Characterization of a secreted antigen of Onchocerca volvulus with host-protective potential. Jenkins RE, et al. **Parasite Immunol** 1996 Jan;18(1):29–42

HPLC fractionated soluble egg antigen from Schistosoma mansoni elicits a heterogeneous human immune response. Moyes RB, et al. **Parasite Immunol** 1996 Dec;18(12):625–33

Workshop on a detailed characterization of Trichinella spiralis antigens: a platform for future studies on antigens and antibodies to this parasite. Ortega-Pierres MG, et al. **Parasite Immunol** 1996 Jun;18(6):273–84 (37 ref.)

Paramyosin: a candidate vaccine antigen against Schistosoma japonicum. Ramirez BL, et al. **Parasite Immunol** 1996 Jan; 18(1):49–52

Purification and N-terminal amino acid sequencing of Echinococcus granulosus antigen 5. Zhang LH, et al. **Parasite Immunol** 1996 Dec;18(12):597–606

Detection of hydatid antigen by co-agglutination in fluid samples from hydatid cysts. Parija SC, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):255–6

Use of recombinant Onchocerca volvulus antigens for diagnosis and surveillance of human onchocerciasis. Chandrashekar R, et al. **Trop Med Int Health** 1996 Oct; 1(5):575–80

Evaluation of IgG4 response in ascariasis by ELISA for serodiagnosis. Chatterjee BP, et al. **Trop Med Int Health** 1996 Oct;1(5):633–9

Characterization of Schistosoma mansoni 44.7/56.8 kDa egg antigens recognized by human monoclonal antibodies which induce protection against experimental infection and proliferation of peripheral blood mononuclear cells from schistosomiasis patients. Hirsch C, et al. **Vaccine** 1997 Jun; 15(9):948–54

METABOLISM

Strongyloides venezuelensis: adhesion of adult worms to culture vessels by orally secreted mucosubstances. Maruyama H, et al. **Exp Parasitol** 1997 Jan;85(1):10–5

Regulation of schistosome egg granuloma formation: host-soluble L-selectin enters tissue-trapped eggs and binds to carbohydrate antigens on surface membranes of miracidia. El Ridi R, et al. **Infect Immun** 1996 Nov; 64(11):4700–5

Trichinella spiralis: ultrastructural localization of a target antigen recognized by a monoclonal antibody. Niimura M, et al. **Int J Parasitol** 1996 May;26(5):553–5

Genetic control of immunity to Heligmosomoides polygyrus: presentation of promiscuous antigens to parasite-specific T cell hybridomas. Mason SD, et al. **Parasite Immunol** 1996 Sep;18(9):449–56

Variation in the nature of attachment of phosphorylcholine to excretory-secretory products of adult Brugia pahangi. Nor ZM, et al. **Parasitology** 1997 Mar;114 (Pt 3):257–62

[A comparative biochemical and immunological study of the somatic and metabolic antigens of Opisthorchis felineus] Kotelkin AT, et al. **Med Parazitol (Mosk)** 1996 Apr–Jun; (2):18–23 **(Rus)**

PHARMACOLOGY

Requirement of CD28–CD86 co-stimulation in the interaction between antigen-primed T helper type 2 and B cells. Nakajima A, et al. **Int Immunol** 1997 May; 9(5):637–44

Induction and suppression of lymphocyte proliferation by antigen extracts of Ostertagia ostertagi. De Marez T, et al. **Vet Immunol Immunopathol** 1997 Jun;57(1-2):69–77

PHYSIOLOGY

Antigens with application toward immune control of blood-feeding parasitic nematodes. Jasmer DP, et al. **Br Vet J** 1995 May;152(3):251–68 (89 ref.)

Role of monocyte chemoattractant protein-1 (MCP-1) in Th1 (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation: relationship to local inflammation, Th cell expression, and IL-12 production. Chensue SW, et al. **J Immunol** 1996 Nov 15;157(10):4602–8

RADIATION EFFECTS

Irradiated larval vaccination and antibody responses evaluated in relation to the expression of immunity to Heligmosomoides polygyrus. Pleass RJ, et al. **Parasitol Res** 1996;82(5):445–53

THERAPEUTIC USE

Immunotherapy for porcine cysticercosis: implications for prevention of human disease. Cysticercosis Working Group in Peru. Evans CA, et al. **Am J Trop Med Hyg** 1997 Jan; 56(1):33–7

A 41-kDa antigen of the rodent filaria Acanthocheilonema viteae with homologies to tropomyosin induces host-protective immune responses. Hartmann S, et al. **Parasitol Res** 1997;83(4):390–3

TOXICITY

Induction of cerebrospinal fluid eosinophilia in rats by the intraventricular injection of Angiostrongylus cantonensis antigen. Sugaya H, et al. **Int J Parasitol** 1997 Jan; 27(1):113–7

URINE

Extraction of Schistosoma haematobium antigens from infected human urine and generation of potential diagnostic monoclonal antibodies to urinary antigens. Bosompem KM, et al. **Acta Trop** 1996 Oct;62(2):91–103

Enhanced detection of Schistosoma circulating antigens by testing 1 ml urine samples using immunomagnetic beads. Nibbeling HA, et al. **Acta Trop** 1997 Aug;66(2):85–92

Day-to-day variation of egg output and schistosome circulating antigens in urine of Schistosoma haematobium-infected school children from Gabon and follow-up after chemotherapy. Van Etten L, et al. **Am J Trop Med Hyg** 1997 Sep;57(3):337–41

Characterization of monoclonal antibodies reactive with Schistosoma haematobium-soluble egg and infected human urinary antigens. Amanor JD, et al. **Hybridoma** 1996 Jun; 15(3):219–24

Detection of hydatid antigen in urine by countercurrent immunoelectrophoresis. Parija SC, et al. **J Clin Microbiol** 1997 Jun;35(6):1571–4

Daily fluctuation of levels of circulating cathodic antigen in urine of children infected with Schistosoma mansoni in Brazil. Disch J, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):222–5

Circulating anodic and cathodic antigen in serum and urine of mixed Schistosoma haematobium and S. mansoni infections in Office du Niger, Mali. De Clercq D, et al. **Trop Med Int Health** 1997 Jul;2(7):680–5

ANTIGENS, HEPATITIS see **HEPATITIS ANTIGENS**

ANTIGENS, HETEROGENETIC see **ANTIGENS, HETEROPHILE**

ANTIGENS, HETEROPHILE

ANALYSIS

Pig islet xenoantigens recognized by human preformed natural antibodies: a preliminary definition. Inverardi L, et al. **Transplant Proc** 1997 Jun;29(4):2260–1

[The membrane hetero-organic antigens of tumors of hepatocellular and myogenic origins] Teriukova NP, et al. **Tsitologiia** 1996;38(10):1092–7 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Suppression of the xenoantigen Gal alpha(1,3)Gal by N-acetylglucosaminyltransferase III (GnT-III) in transgenic mice. Tanemura M, et al. **Transplant Proc** 1997 Feb–Mar;29(1-2):895–6

BLOOD

"Heterophile" antigen in sera of human recipients of renal allografts. Milgrom F, et al. **Proc Soc Exp Biol Med** 1996 Oct;213(1):80–4

GENETICS

Interval mapping of quantitative trait loci controlling humoral immunity to exogenous antigens: evidence that non-MHC immune response genes may also influence susceptibility to autoimmunity. Wu J, et al. **J Immunol** 1996 Sep 15;157(6):2498–505

IMMUNOLOGY

Evaluation of six commercially available kits using purified heterophile antigen for the rapid diagnosis of infectious mononucleosis compared with Epstein-Barr virus-specific serology. Elgh F, et al. **Clin Diagn Virol** 1996 Oct; 7(1):17–21

HLA-Cw3 expression on porcine endothelial cells protects against xenogeneic cytotoxicity mediated by a subset of human NK cells. Seebach JD, et al. **J Immunol** 1997 Oct 1;159(7):3655–61

Interval mapping of quantitative trait loci controlling humoral immunity to exogenous antigens: evidence that non-MHC immune response genes may also influence susceptibility to autoimmunity. Wu J, et al. **J Immunol** 1996 Sep 15;157(6):2498–505

Teratogen-induced apoptosis may be affected by immunopotentiation. Toder V, et al. **J Reprod Immunol** 1996 May;30(2-3):173–85

Removal of anti-Gal alpha (1,3)Gal antibodies diminishes the cytotoxic effect of primate xenoreactive antibodies on rat endothelial cells. Azimzadeh A, et al. **Transplant Proc** 1997 Aug;29(5):2337

Rebound in complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxic activity in primate serum after pig liver perfusion. Azimzadeh A, et al. **Transplant Proc** 1997 Aug;29(5):2385–6

Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver. Baquerizo A, et al. **Transplant Proc** 1997 Feb–Mar;29(1-2):964–5

Mouse CD4 and CD8 T-cell clones that recognize xeno-antigens directly on xeno-antigen presenting cells in xeno MHC-restricted ways. Hirota T, et al. **Transplant Proc** 1997 Feb–Mar;29(1-2):950–2

Leflunomide-mediated tolerance of B lymphocytes for T-independent xenoantigens needs the presence of these xenoantigens. Lin Y, et al. **Transplant Proc** 1997 Feb–Mar; 29(1-2):1304

Strategies to overcome hyperacute rejection of pig-to-human xenografts. McKenzie IF, et al. **Transplant Proc** 1997 Feb–Mar;29(1-2):973–4

Genetic evidence that the antibody response to xenografts is directed at a restricted number of target antigens. Wu GD, et al. **Transplant Proc** 1997 Feb–Mar;29(1-2):954

Comparison between aortic and sinusoidal liver endothelial cells as targets of hyperacute xenogeneic rejection in the pig to human combination. Cattan P, et al. **Transplantation** 1996 Sep 27;62(6):803–10

[The unknown functions of heterologous antigens of different origins] Nikolaeva AI. **Zh Mikrobiol Epidemiol Immunobiol** 1997 May–Jun; (3):76–81 (Eng. Abstr.) **(Rus)**

METABOLISM

Significant downregulation of the major swine xenoantigen by N-acetylglucosaminyltransferase III gene transfection. Tanemura M, et al. **Biochem Biophys Res Commun** 1997 Jun 18;235(2):359–64

Reduction of the major swine xenoantigen Gal alpha (1,3)Gal by transfection of N-acetylglucosaminyl transferase III (GnT-III) gene. Tanemura M, et al. **Transplant Proc** 1997 Feb–Mar;29(1-2):891–2

PHARMACOLOGY

Suppression of lectin, alloantigen, and xenoantigen-induced T-cell proliferation by Genistein. Rapaport FT, et al. **Transplant Proc** 1997 Feb–Mar;29(1-2):1261–4

[A comparative study of the nonhistone chromosomal proteins (pp23) from rat and bull kidneys] Kushner VP, et al. **Tsitologiia** 1996;38(6):596–9 (Eng. Abstr.) **(Rus)**

ANTIGENS, HLA-A see **HLA-A ANTIGENS**

ANTIGENS, HLA-B see **HLA-B ANTIGENS**

ANTIGENS, HLA-C see **HLA-C ANTIGENS**

ANTIGENS, HLA-D see **HLA-D ANTIGENS**

ANTIGENS, HUMAN PLATELET

Analysis of CD9, CD32 and p67 signalling: use of degranulated platelets indicates direct involvement of CD9 and p67 in integrin activation. Slupsky JR, et al. **Br J Haematol** 1997 Feb;96(2):275–86

Platelet membrane receptors during short cardiopulmonary bypass--a flow cytometric study. Holada K, et al. **Perfusion** 1996 Sep;11(5):401–6

ADVERSE EFFECTS

Simultaneous occurrence of posttransfusion purpura due to anti-HPA-1a and a delayed transfusion reaction due to anti-Jk(b) [letter] Swanson JL, et al. **Transfusion** 1997 Apr; 37(4):449–50

ANALYSIS

Comparison of the direct platelet immunofluorescence test (direct PIFT) with a modified direct monoclonal antibody-specific immobilization of platelet antigens (direct MAIPA) in detection of platelet-associated IgG. Joutsi L, et al. **Br J Haematol** 1997 Jan;96(1):204–9

Interlaboratory variation in the detection of clinically significant alloantibodies against human platelet alloantigens. Metcalfe P, et al. **Br J Haematol** 1997 Apr; 97(1):204–7

Efficient RT-PCR on platelet mRNA after long-term storage. Peyruchaud O, et al. **Br J Haematol** 1997 Jan; 96(1):183–5

Fetal alloimmune thrombocytopenia: consensus and controversy. Bussel JB, et al. **J Matern Fetal Med** 1996 Sep–Oct;5(5):281–92 (56 ref.)

Frequency of platelet-specific alloantigens in a Danish population. Steffensen R, et al. **Tissue Antigens** 1996 Aug; 48(2):93–6

A monoclonal antibody (SZ21) specific for platelet GPIIIa distinguishes P1A1 from P1A2. Weiss EJ, et al. **Tissue Antigens** 1995 Nov;46(5):374–81

A simple and rapid competitive enzyme-linked

immunosorbent assay to identify HPA-1a (PlA1)-negative donor platelet units. Denomme G, et al. **Transfusion** 1996 Sep;36(9):805-8

[Alloimmune neonatal thrombocytopenia caused by serologic incompatibility of HPA-1a platelet antigen--case report] Rogowska A, et al. **Ginekol Pol** 1996 Nov;67(11):577-80 (Eng. Abstr.) **(Pol)**

BLOOD

Antenatal screening for HPA-1a by flow cytometry. Lavu EK, et al. **Aust N Z J Obstet Gynaecol** 1997 May; 37(2):180-3

Tantalum stents induce expression of GMP140 and GP53 on platelets after contact in an in vitro model. Gutensohn K, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:61-5

A comparison of monoclonal antibody immobilization of platelet antigen (MAIPA) and immunobead methods for detection of GPIIb/IIIa antiplatelet antibodies in immune thrombocytopenic purpura. Crossley A, et al. **Transfus Med** 1997 Jun;7(2):127-34

The effect of intravenous immunoglobulin on placental transfer of a platelet-specific antibody: anti-P1A1. Morgan CL, et al. **Transfus Med** 1991 Dec;1(4):209-16

Flow cytometric analysis of platelet membrane antigens during and after continuous-flow plateletpheresis. Gutensohn K, et al. **Transfusion** 1997 Aug;37(8):809-15

CHEMISTRY

Evidence for an expression of blood group A antigen on platelet glycoproteins IV and V. Stockelberg D, et al. **Transfus Med** 1996 Sep;6(3):243-8

GENETICS

Genotyping for human platelet antigen-1 directly from dried blood spots on cards [letter] Hughes D, et al. **Blood** 1996 Oct 15;88(8):3242-3

HPA-10w(b) (La(a)): genetic determination of a new platelet-specific alloantigen on glycoprotein IIIa and its expression in COS-7 cells. Peyruchaud O, et al. **Blood** 1997 Apr 1;89(7):2422-8

A dinucleotide deletion in exon 4 of the PlA2 allelic form of glycoprotein IIIa: implications for the correlation of serologic versus genotypic analysis of human platelet alloantigens. Skogen B, et al. **Blood** 1996 Nov 15; 88(10):3831-6

HPA-1 genotype in arterial thrombosis--role of HPA-1b polymorphism in platelet function. Corral J, et al. **Blood Coagul Fibrinolysis** 1997 Jul;8(5):284-90

Red cells with the rare Rh phenotype rG express some C antigen [letter; comment] Daniels G, et al. **Br J Haematol** 1996 Sep;94(4):768. Comment on: Br J Haematol 1996 May;93(2):472-4.

Large-scale DNA typing for human platelet alloantigens by PCR-PHFA (preferential homoduplex formation assay). Fujiwara K, et al. **Br J Haematol** 1996 Oct;95(1):198-203

The Arg633His substitution responsible for the private platelet antigen Gro(a) unravelled by SSCP analysis and direct sequencing. Simsek S, et al. **Br J Haematol** 1997 May;97(2):330-5

Genetic typing of human platelet antigen 1 (HPA-1) by oligonucleotide ligation assay in a specific and reliable semi-automated system. Zotz RB, et al. **Br J Haematol** 1997 Jan;96(1):198-203

Platelet alloantigens: cardiovascular as well as immunological risk factors? [comment] Newman PJ. **Lancet** 1997 Feb 8; 349(9049):370-1. Comment on: Lancet 1997 Feb 8;349(9049):385-8.

Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Carlsson LE, et al. **Stroke** 1997 Jul;28(7):1392-5

The human platelet antigen HPA-1a/1b (PI(A1)/PI(A2)) polymorphism and cerebral ischaemia [letter] Reuner KH, et al. **Thromb Haemost** 1997 Aug;78(2):964-5

A rapid genotype assay for Pla haplotypes. Pfaffenbach GM, et al. **Thromb Res** 1996 Feb 1;81(3):353-65

DNA typing of human platelet antigen systems 1, 2, 3 and 5 in B-lymphoblastoid cell lines of the International Histocompatibility Workshop. Bein G, et al. **Tissue Antigens** 1997 May;49(5):443-7

HPA genotyping by PCR sequence-specific priming (PCR-SSP): a streamlined method for rapid routine investigations. Cavanagh G, et al. **Transfus Med** 1997 Mar; 7(1):41-5

Allele-specific restriction analysis of human platelet antigen system 4. Matsuo K, et al. **Transfusion** 1996 Sep; 36(9):809-12

Gene frequencies of human platelet antigens on glycoprotein IIIa in Japanese. Tanaka S, et al. **Transfusion** 1996 Sep; 36(9):813-7

Simultaneous genotyping of human platelet antigens by hot start sequence-specific polymerase chain reaction with DNA polymerase AmpliTaq Gold. Chen DF, et al. **Vox Sang** 1997;72(3):192-6

Rapid typing for human platelet antigen systems-1, -2, -3 and -5 by PCR amplification with sequence-specific primers. Klüter H, et al. **Vox Sang** 1996;71(2):121-5

The use of DNA typing for human platelet-specific antigens in the daily routine: a case report [letter] Stein S, et al. **Vox Sang** 1996;71(2):131

Genotype frequencies of the human platelet antigen, Ca/Tu, in Japanese, determined by a PCR-RFLP method. Tanaka S, et al. **Vox Sang** 1996;70(1):40-4

IMMUNOLOGY

Neonatal alloimmune thrombocytopenia associated with anti-human platelet antigen-3a antibody. Takada H, et al. **Acta Paediatr Jpn** 1997 Jun;39(3):371-4

Antibody studies in a patient with acute thrombocytopenia following infusion of plasma containing anti-PI(A1). Brunner-Bolliger S, et al. **Am J Hematol** 1997 Oct; 56(2):119-21

Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Immune Thrombocytopenia Working Group. Durand-Zaleski I, et al. **Am J Perinatol** 1996 Oct;13(7):423-31

Neonatal thrombocytopenia: incidence, serological and clinical observations. Uhrynowska M, et al. **Am J Perinatol** 1997 Aug;14(7):415-8

Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome. Panzer S, et al. **Ann Hematol** 1997 May;74(5):239-42

Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Dreyfus M, et al. **Blood** 1997 Jun 15;89(12):4402-6

Alloimmunization to platelets in heavily transfused patients with sickle cell disease. Friedman DF, et al. **Blood** 1996 Oct 15;88(8):3216-22

Drawbacks of the MAIPA technique in characterising human antiplatelet antibodies. Morel-Kopp MC, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):144-6

Quantitation of platelet-specific autoantibodies in platelet eluates of ITP patients measured by a novel ELISA using the purified glycoprotein complexes GPIIb/IIIa and GPIb/IX as antigens. Hurlimann-Forster M, et al. **Br J Haematol** 1997 Aug;98(2):328-35

Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Wright JF, et al. **Br J Haematol** 1996 Oct; 95(1):145-52

A study of platelet specific antibody (anti-Sib(a)). Liu D, et al. **Chin Med J (Engl)** 1996 Aug;109(8):615-7

Alloimmunization against platelet antigens in renal transplant patients with acute vascular rejection. Kekomäki S, et al. **Clin Transplant** 1997 Feb;11(1):19-24

Genotyping of the platelet-specific alloantigen HPA-5 (Br(a)/Br(b)) using polymerase chain reaction with sequencespecific primers (PCR-SSP). Hou M, et al. **Eur J Haematol** 1996 Sep;57(3):208-13

Incidence of anti-mouse antibodies in thrombocytopenic patients with autoimmune disorders. Clofent-Sanchez G, et al. **Hum Antibodies** 1997;8(2):50-9

Genetic susceptibility and anti-human platelet antigen 5b alloimmunization role of HLA class II and TAP genes. Semana G, et al. **Hum Immunol** 1996 Apr;46(2):114-9

Molecular identification of T cells that respond in a primary bulk culture to a peptide derived from a platelet glycoprotein implicated in neonatal alloimmune thrombocytopenia. Maslanka K, et al. **J Clin Invest** 1996 Oct 15;98(8):1802-8

Platelet alloantigens: cardiovascular as well as immunological risk factors? [comment] Newman PJ. **Lancet** 1997 Feb 8; 349(9049):370-1. Comment on: Lancet 1997 Feb 8;349(9049):385-8.

Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalus. Murphy MF, et al. **Prenat Diagn** 1996 Dec;16(12):1152-5

PAICA: a method for characterizing platelet-associated antibodies--its application to the study of idiopathic thrombocytopenic purpura and to the detection of platelet-bound c7E3. Macchi L, et al. **Thromb Haemost** 1996 Dec;76(6):1020-9

Frequency of platelet-specific alloantigens in a Danish population. Steffensen R, et al. **Tissue Antigens** 1996 Aug; 48(2):93-6

The immune response to the HPA-1a antigen: association with HLA-DRw52a. Décary F, et al. **Transfus Med** 1991 Mar;1(1):55-62

A backdoor approach for selecting platelet typing sera: the lymphocytotoxicity test [letter] Kalinowski A, et al. **Transfus Med** 1997 Mar;7(1):65-6

In pursuit of enigmatic platelet antibodies--anti-HPA-2b and anti-HPA-3a [letter] Minchinton RM, et al. **Transfus Med** 1996 Sep;6(3):289-91

Maternal immunization to Gov system alloantigens on human platelets. Bordin JO, et al. **Transfusion** 1997 Aug; 37(8):823-8

Detection and differentiation of platelet-specific antibodies by flow cytometry: the bead-mediated platelet assay. Helmberg W, et al. **Transfusion** 1997 May;37(5):502-6

Human monoclonal Fab fragments recovered from a combinatorial library bind specifically to the platelet HPA-1a alloantigen on glycoprotein IIb-IIIa. Proulx C, et al. **Vox Sang** 1997;72(1):52-60

Platelet alloimmunization after transfusion. A prospective study in 117 heart surgery patients. Taaning E, et al. **Vox Sang** 1997;72(4):238-41

Spontaneous rise of fetal platelet counts despite increasing anti-HPA-5b antibodies. Ulm B, et al. **Vox Sang** 1997; 72(2):111-3

Provision of random-donor platelets (HPA-1a positive) in neonatal alloimmune thrombocytopenia due to anti HPA-1a alloantibodies [letter] Win N. **Vox Sang** 1996; 71(2):130-1

Blood components--transfusion support in post-transfusion purpura due to HPA-1a Immunization [letter] Win N, et al. **Vox Sang** 1996;71(3):191-3

[Thrombocytopenia after cardiac surgery due to anti-platelet allo-immunization. Apropos of a case] Boccara F, et al. **Arch Mal Coeur Vaiss** 1997 Jan;90(1):107-10 (Eng. Abstr.) **(Fre)**

[Neonatal alloimmune thrombopenia in anti-HPA-3a (Baka) immunization] Mokhtari M, et al. **Arch Pediatr** 1997 Apr; 4(4):339-42 (Eng. Abstr.) **(Fre)**

[Thrombomatch--an ELISA test for detection of antibodies to HLA antigens and platelet-specific antigens. Clinical experiences in compatibility testing of platelet transfusions] Barz D, et al. **Beitr Infusionsther Transfusionsmed** 1996; 33:47-54 (Eng. Abstr.) **(Ger)**

[Fetal weight-adjusted intrauterine IgG therapy in neonatal alloimmune thrombocytopenia] Giers G, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:160-4 (Eng. Abstr.) **(Ger)**

[Prenatal management of fetuses with alloimmune thrombocytopenia] Kroll H, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:150-5 (Eng. Abstr.) **(Ger)**

[Severe neonatal alloimmune thrombocytopenia with delayed antibody detection] Schabel A, et al. **Beitr Infusionsther Transfusionsmed** 1996;33:156-9 (Eng. Abstr.) **(Ger)**

ANTIGENS, IMMUNE RESPONSE see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

ANTIGENS, IMMUNODOMINANT see **IMMUNODOMINANT EPITOPES**

ANTIGENS, KI-1 see **ANTIGENS, CD30**

ANTIGENS, LEUKEMIA, COMMON ACUTE LYMPHOBLASTIC see **NEPRILYSIN**

ANTIGENS, LY

ANALYSIS

Mouse bone marrow stromal cell line MC3T3-G2/PA6 with hematopoietic-supporting activity expresses high levels of stem cell antigen Sca-1. Satoh M, et al. **Exp Hematol** 1997 Aug;25(9):972-9

Ly-6-domain proteins--new insights and new members: a C-terminal Ly-6 domain in sperm acrosomal protein SP-10. Palfree RG. **Tissue Antigens** 1996 Aug;48(2):71-9 (77 ref.)

BIOSYNTHESIS

Expression of the Ly-6E.1 (Sca-1) transgene in adult hematopoietic stem cells and the developing mouse embryo. Miles C, et al. **Development** 1997 Jan;124(2):537-47

TNFalpha and anti-Fas antibodies regulate Ly-6E.1 expression by tumor cells: a possible link between angiogenesis and Ly-6E.1. Sagi-Assif O, et al. **Immunol Lett** 1996 Dec;54(2-3):207-13

BLOOD

Structural characterization of an Lyt-2/3 homolog expressed on Bufo regularis lymphocytes. Negm HI, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Jan; 113(1):79-87

GENETICS

The differentiation antigen Ly-6E.1 is expressed in mouse metastatic tumor cell lines. Cohn MA, et al. **FEBS Lett** 1997 Feb 17;403(2):181-5

Polymorphism of chicken CD8-alpha, but not CD8-beta. Luhtala M, et al. **Immunogenetics** 1997;46(5):396-401

Polymorphism in the Ly-17 alloantigenic system of the mouse FcgRII gene. Slingsby JH, et al. **Immunogenetics** 1997;46(4):361-2

The NK2.1 receptor is encoded by Ly-49C and its expression is regulated by MHC class I alleles. Gosselin P, et al. **Int Immunol** 1997 Apr;9(4):533-40

IMMUNOLOGY

Natural cell-mediated cytotoxicity (NCMC) against NK-sensitive tumours in vitro by murine spleen Ly-6C+ natural T cells. Martiniello R, et al. **Int J Cancer** 1997 Feb 7;70(4):450-60

Altered proliferative response by T lymphocytes of Ly-6A (Sca-1) null mice. Stanford WL, et al. **J Exp Med** 1997 Aug 29;186(5):705-17

Ly-6C regulates endothelial adhesion and homing of CD8(+) T cells by activating integrin-dependent adhesion pathways. Hänninen A, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6898-903

METABOLISM

Distribution of Ly-6C on lymphocyte subsets: I. Influence of allotype on T lymphocyte expression. Schlueter AJ, et

al. **J Immunol** 1997 May 1;158(9):4211–22

PHYSIOLOGY

Ly49A transgenic mice provide evidence for a major histocompatibility complex–dependent education process in natural killer cell development. Held W, et al. **J Exp Med** 1997 Jun 16;185(12):2079–88

ANTIGENS, MINOR LYMPHOCYTE STIMULATORY
see **MINOR LYMPHOCYTE STIMULATORY ANTIGENS**

ANTIGENS, NEOPLASM

Human tumor antigens are ready to fly. Henderson RA, et al. **Adv Immunol** 1996;62:217–56 (169 ref.)

Melanoma–associated antigens as messenger RNA detection markers for melanoma. Sarantou T, et al. **Cancer Res** 1997 Apr 1;57(7):1371–6

Oncogenic proteins as tumor antigens. Disis ML, et al. **Curr Opin Immunol** 1996 Oct;8(5):637–42 (42 ref.)

Human tumor antigens recognized by T cells. Robbins PF, et al. **Curr Opin Immunol** 1996 Oct;8(5):628–36 (81 ref.)

Characterization of antigenic peptides presented by HLA–B44 molecules on tumor cells expressing the gene MAGE–3. Fleischhauer K, et al. **Int J Cancer** 1996 Nov 27;68(5):622–8

Regression of tumors in mice vaccinated with professional antigen–presenting cells pulsed with tumor extracts. Nair SK, et al. **Int J Cancer** 1997 Mar 17;70(6):706–15

Immunomodulation induced by synthetic peptides derived from tumor–rejection antigens. Perez–Diez A, et al. **Int J Dev Biol** 1996;Suppl 1:311S

Anti–tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor–associated antigen. Wang M, et al. **J Immunother Emphasis Tumor Immunol** 1995 Oct; 18(3):139–46

Epitope recognition of recoverin in cancer associated retinopathy: evidence for calcium–dependent conformational epitopes. Adamus G, et al. **J Neurosci Res** 1996 Sep 15;45(6):863–72

Re: Initial evaluation of the bladder tumor antigen test in superficial bladder cancer [letter; comment] Kirollos MM. **J Urol** 1997 Feb;157(2):627. Comment on: J Urol 1996 Feb;155(2):475–6.

[Tumor specific antigens a reality (letter; comment)] Claësson MH. **Ugeskr Laeger** 1997 Aug 18;159(34):5110–1. Comment on: Ugeskr Laeger 1997 May 19;159(21):3134–9. **(Dan)**

ADMINISTRATION & DOSAGE

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART–1/Melan A [see comments] Cormier JN, et al. **Cancer J Sci Am** 1997 Jan–Feb;3(1):37–44. Comment in: Cancer J Sci Am 1997 Jan–Feb;3(1):4–5.

Antigen–presenting cells pulsed with unfractionated tumor–derived peptides are potent tumor vaccines. Nair SK, et al. **Eur J Immunol** 1997 Mar;27(3):589–97

ANALYSIS

Multiparameter absorption measurements in automated microscopy. Simultaneous quantitative determination of DNA and nuclear antigen. Oud PS, et al. **Acta Cytol** 1997 Jan–Feb;41(1):188–96

High serum SCC antigen levels in two patients with ovarian cancer. Yamada T, et al. **Acta Obstet Gynecol Scand** 1997 Mar;76(3):283–5

The 43 kDa papain–inhibiting protein in psoriatic epidermis is identical to squamous cell carcinoma antigen (SCC–antigen). Järvinen M, et al. **Adv Exp Med Biol** 1996; 389:87–93

Expression of mucin–like carcinoma–associated antigen in the cyst fluid differentiates mucinous from nonmucinous pancreatic cysts. Sperti C, et al. **Am J Gastroenterol** 1997 Apr;92(4):672–5

Plasma cells composing plasmacytoma have phenotypes different from those of myeloma cells. Sakai A, et al. **Am J Hematol** 1996 Dec;53(4):251–3

p53 overexpression in advanced–stage endometrial adenocarcinoma [see comments] Kohler MF, et al. **Am J Obstet Gynecol** 1996 Nov;175(5):1246–52. Comment in: Am J Obstet Gynecol 1997 Jul;177(1):243.

Characteristics of antigens from an HCG alpha secreting cell line (ElCo) derived from human breast carcinoma in a Native American patient. Pattillo RA, et al. **Am J Obstet Gynecol** 1997 Jun;176(6):S246–54

CD79 alpha expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia. Arber DA, et al. **Am J Pathol** 1996 Oct;149(4):1105–10

Molecular detection of tumor–associated antigens shared by human cutaneous melanomas and gliomas. Chi DD, et al. **Am J Pathol** 1997 Jun;150(6):2143–52

Isolation and characterization of the canine melanoma antigen recognized by the murine monoclonal antibody IBF9 and its distribution in cultured canine melanoma cell lines. Oliver JL, et al. **Am J Vet Res** 1997 Jan;58(1):46–52

Limits of flow–cytometry histogram analysis methods to assess bladder tumour antigen expression. Chabanas A, et al. **Anal Cell Pathol** 1997;13(1):39–47

Expression of proliferating cell nuclear antigen in node–negative human prostate cancer. Idikio HA. **Anticancer Res** 1996 Sep–Oct;16(5A):2607–11

Luminal epithelial antigen (LEA.135) expression correlates with tumor progression for transitional carcinoma of the bladder. Jones HL, et al. **Anticancer Res** 1997 Jan–Feb; 17(1B):685–7

Mib–1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Marx D, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):775–80

Enhancement of tumor antigen expression and inhibition of pulmonary metastasis of rat fibrosarcoma cells by local radiotherapy. Shibata T, et al. **Anticancer Res** 1997 Jan–Feb;17(1A):317–22

CD40 expression in epidermal tumors. Viac J, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):569–72

Expression of the cutaneous lymphocyte antigen and the alpha IEL beta 7 integrin by intraepithelial lymphocytes in healthy and diseased human gingiva. Tonetti MS, et al. **Arch Oral Biol** 1995 Dec;40(12):1125–32

Evaluation of tumor–associated antigens and total sialic acid levels in effusions of malignant and benign origin. Yenisey C, et al. **Biochem Soc Trans** 1996 May;24(2):301S

Effects of fixation and tissue processing on immunohistochemical demonstration of specific antigens. Arnold MM, et al. **Biotech Histochem** 1996 Sep; 71(5):224–30

Immunohistochemical double staining of microwave enhanced and nonenhanced nuclear and cytoplasmic antigens. Bohle RM, et al. **Biotech Histochem** 1997 Jan; 72(1):10–5

Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Chan JK, et al. **Blood** 1997 Jun 15;89(12):4501–13 (84 ref.)

CD2 antigen expression on leukemic cells as a predictor of event–free survival after chemotherapy for T–lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Uckun FM, et al. **Blood** 1996 Dec 1;88(11):4288–95

Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study. Uckun FM, et al. **Blood** 1997 Apr 1;89(7):2488–93

Human T lymphocytes and hematopoietic cell lines express CD24–associated carbohydrate epitopes in the absence of CD24 mRNA or protein. Williams LA, et al. **Blood** 1996 Oct 15;88(8):3048–55

A quantitative reverse transcriptase polymerase chain reaction–based assay to detect carcinoma cells in peripheral blood. Helfrich W, et al. **Br J Cancer** 1997;76(1):29–35

Loss of interleukin 4 receptor–associated molecule gp200–MR6 in human breast cancer: prognostic significance. Kaklamanis L, et al. **Br J Cancer** 1996 Nov; 74(10):1627–31

Identification of second malignancies on effusions and fine–needle aspirates using a panel of monoclonal antibodies. Mottolese M, et al. **Br J Cancer** 1997;75(4):572–8

Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA–targeted radiotherapy using Auger electron emitters. Neshasteh–Riz A, et al. **Br J Cancer** 1997;75(4):493–9

Expression of an antigen homologous to the human CO17–1A/GA733 colon cancer antigen in animal tissues. Zaloudik J, et al. **Br J Cancer** 1997;76(7):909–16

Expression and ultrastructural localization of HMB–45 antigen. Kikuchi A, et al. **Br J Dermatol** 1996 Sep; 135(3):400–5

Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki–67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract. Lee CS. **Cancer** 1996 Nov 1; 78(9):1881–7

Breast carcinoma detection with a combination of radiolabeled monoclonal antibodies. Promising results from immunohistochemistry studies. Mangili F, et al. **Cancer** 1996 Dec 1;78(11):2334–9

The expression of CD44 adhesion molecules on seminoma cells. A new marker for early detection of the tumor [letter; comment] Rajpert–De Meyts E, et al. **Cancer** 1996 Dec 1;78(11):2443–5. Comment on: Cancer 1996 Feb 1;77(3):429–30.

Characterization of the DD23 tumor–associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer. Bonner RB, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Dec;5(12):971–8

Enhanced expression of PP1 gamma 1, a catalytic subunit isoform of protein phosphatase type 1, in invasive ductal carcinoma of the breast. Sogawa K, et al. **Cancer Lett** 1997 Jan 30;112(2):263–8

Correlation between tumor–associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72–4 immunoassay. Guadagni F, et al. **Cancer Res** 1996 Nov 15;56(22):5293–8

Circulating tumor markers in gynecological tumors. Rustin GJ. **Curr Opin Oncol** 1996 Sep;8(5):426–31 (51 ref.)

CD44 as a marker in human cancers. Sy MS, et al. **Curr Opin Oncol** 1997 Jan;9(1):108–12 (57 ref.)

Neural net–based identification of cells expressing the p300 tumor–related antigen using fluorescence image analysis. Hurst RE, et al. **Cytometry** 1997 Jan 1;27(1):36–42

Nuclear autoantigen p330d/CENP–F: a marker for cell proliferation in human malignancies. Landberg G, et al. **Cytometry** 1996 Sep 1;25(1):90–8

Correction for antibody crosstalk [letter; comment] Shackney SE. **Cytometry** 1996 Sep 1;25(1):109–10. Comment on: Cytometry 1995 Sep 1;21(1):6–13.

Expression of NM23 protein in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma: an immunohistological assessment in human skin. Reichrath J, et al. **Dermatology** 1997;194(2):136–9

TAG–72 expression in lymph nodes and RIGS [letter; comment] Hitchcock CL, et al. **Dis Colon Rectum** 1996 Apr;39(4):473–5. Comment on: Dis Colon Rectum 1995 Sep;38(9):983–7.

Expression of CD44 isoforms in human skin cancer. Simon JC, et al. **Eur J Cancer** 1996 Jul;32A(8):1394–400

The endoplasmic reticulum–resident stress protein gp96 binds peptides translocated by TAP. Lammert E, et al. **Eur J Immunol** 1997 Apr;27(4):923–7

HLA–DR expression and lymphocytic infiltration in metastatic and non–metastatic papillary carcinoma of the thyroid. Feinmesser M, et al. **Eur J Surg Oncol** 1996 Oct; 22(5):494–501

Expression of GD3 disialoganglioside antigen on peripheral T–lymphocytes in patients with disseminated malignant melanoma. Welte B, et al. **Exp Dermatol** 1997 Apr;6(2):64–9

Relationship between squamous cell carcinoma antigen levels and tumor volumes in patients with cervical carcinomas undergoing neoadjuvant chemotherapy. Kim BG, et al. **Gynecol Oncol** 1996 Oct;63(1):105–13

Distribution of epithelial–specific antigen in uterine cervix with endocervical glandular dysplasia. Umezaki K, et al. **Gynecol Oncol** 1997 Sep;66(3):393–8

Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB–1 monoclonal antibodies. Abele MC, et al. **Haematologica** 1997 May–Jun;82(3):281–5

The expression of proliferation and quiescence associated antigens in acute myeloid leukemia correlates with survival duration: analysis of 15 refractory cases. Visani G, et al. **Haematologica** 1997 May–Jun;82(3):338–40

Effect of hyperthermia on proliferation and deviation of carcinoembryonic antigen and squamous cell carcinoma–related antigen of human esophageal carcinoma cells in culture. Saito M, et al. **Hum Cell** 1996 Mar;9(1):63–8

Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD–2 antiserum compared with monoclonal antibody HBME–1 and a review of the literature on so–called antimesothelioma antibodies. Donna A, et al. **Hum Pathol** 1997 Aug;28(8):929–37

Immunoassay of neuron–specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis. Giovanella L, et al. **Int J Biol Markers** 1997 Jan–Mar;12(1):22–6

Detection of gastric mucins (M1 antigens) in cyst fluid for the diagnosis of cystic lesions of the pancreas. Hammel PR, et al. **Int J Cancer** 1997 Jun 20;74(3):286–90

CD44 is an independent prognostic factor in early–stage cervical cancer. Speiser P, et al. **Int J Cancer** 1997 Apr 22;74(2):185–8

Human pancreas–specific protein. A diagnostic and prognostic marker in acute pancreatitis and pancreas transplantation. Schmid SW, et al. **Int J Pancreatol** 1996 Jun;19(3):165–70

Adult respiratory distress syndrome with increased serum and bronchoalveolar lavage fluid levels of squamous cell carcinoma–related antigen. Ashitani J, et al. **Intern Med** 1996 Jun;35(6):497–501

Detection of antibodies to human melanoma cells in vitiligo and alopecia areata by Western blot analysis. Hann SK, et al. **J Dermatol** 1996 Feb;23(2):100–3

Identification of tyrosinase–related protein 2 as a tumor rejection antigen for the B16 melanoma. Bloom MB, et al. **J Exp Med** 1997 Feb 3;185(3):453–9

Recognition of a B cell leukemia–associated minor histocompatibility antigen by CTL. Dolstra H, et al. **J Immunol** 1997 Jan 15;158(2):560–5

Identification of subdominant CTL epitopes of the GP100 melanoma–associated tumor antigen by primary in vitro immunization with peptide–pulsed dendritic cells. Tsai V, et al. **J Immunol** 1997 Feb 15;158(4):1796–802

Immunocytochemical detection of MART–1 in fresh and paraffin–embedded malignant melanomas. Fetsch PA, et al. **J Immunother** 1997 Jan;20(1):60–4

Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. Rosenberg SA, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jan; 19(1):81–4

A rapid serological detection method for squamous cell carcinoma. Yoshizawa H, et al. **J Obstet Gynaecol Res** 1996 Dec;22(6):575–83

Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. Sokoloff MH, et al. **J Urol** 1996 Nov;156(5):1560–6

Molecular diagnosis of circulating cancer cells using MAGE gene assays [letter] Mori M, et al. **JAMA** 1997 Aug 13; 278(6):476–7

Detection of MAGE–1 tumor antigen in brain tumor. Kuramoto T. **Kurume Med J** 1997;44(1):43–51

Tumor–associated glycoprotein (TAG–72) in chronic submandibular sialadenitis and normal minor salivary glands defined by monoclonal antibody B72.3. Epivatianos

A, et al. **Laryngoscope** 1997 Aug;107(8):1138–41

CD5–expressing B–cell lymphomas/leukemias: relatively high frequency of CD5+ B–cell lymphomas with an overall poor prognosis in Nagasaki Japan. Kamihira S, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):137–42

Abortive mitoses and nuclear DNA fragmentation in CD30+ large cells of Hodgkin's disease. Leoncini L, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):119–24, follow. 186, color plate XI

Flow cytometric detection of CD44 (H–CAM) in hairy cell leukemia. Rutella S, et al. **Leuk Lymphoma** 1996 May; 21(5–6):497–500

The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK. Shiota M, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):25–32 (25 ref.)

A child case of CD34+, CD33–, HLA–DR–, CD7+, CD56+ stem cell leukemia with thymic involvement. Nagata T, et al. **Leuk Res** 1996 Nov–Dec;20(11–12):983–5

The value of the monoclonal antibody, DBA44, in the diagnosis of B–lymphoid disorders. Salomon–Nguyen F, et al. **Leuk Res** 1996 Nov–Dec;20(11–12):909–13

The role of tumor–associated antigen in bovine leukemia virus–induced lymphosarcoma. Aida Y, et al. **Leukemia** 1997 Apr;11 Suppl 3:216–8

Tumor–associated antigen in lymph nodes during the progression of enzootic bovine leukosis. Koguchi A, et al. **Leukemia** 1997 Apr;11 Suppl 3:221–2

Simultaneous double immunoenzymatic labeling: a new procedure for the histopathologic routine. Chaubert P, et al. **Mod Pathol** 1997 Jun;10(6):585–91

CD99 (p30/32MIC2) immunoreactivity in the diagnosis of leukemia cutis. Dorfman DM, et al. **Mod Pathol** 1997 Apr; 10(4):283–8

Lack of correlation between flow cytometric and immunohistologic proliferation measurements of tumors. Linden MD, et al. **Mod Pathol** 1996 Jun;9(6):682–9

013 (CD99) positivity in hematologic proliferations correlates with TdT positivity. Robertson PB, et al. **Mod Pathol** 1997 Apr;10(4):277–82

Anti–MOC–31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Sosolik RC, et al. **Mod Pathol** 1997 Jul;10(7):716–9

Two tumor–associated membrane antigens defined by monoclonal antibodies in a transplantable sarcoma induced by Rous sarcoma virus in rat. Alexandrov I, et al. **Neoplasma** 1996;43(4):275–82

Clinical significance of Ki–67 staining index in acoustic neurinoma. Yokoyama M, et al. **Neurol Med Chir (Tokyo)** 1996 Oct;36(10):698–702; discussion 702–3 (27 ref.)

Delineation of antigenic pathways of ethionine–induced liver cancer in the rat. Hixson DC, et al. **Pathobiology** 1996; 64(2):79–90

Immunohistochemical analysis of the nm23 gene products in testicular seminoma. Hori K, et al. **Pathol Int** 1997 May; 47(5):288–92

Expression of mucin antigens and Lewis X–related antigens in carcinomas and dysplasia of the pharynx and larynx. Itoh T, et al. **Pathol Int** 1996 Sep;46(9):646–55

Intermediate lymphocytic lymphoma massively involving the gastrointestinal tract. Tsutsumi Y, et al. **Pathol Int** 1996 May;46(5):380–3

Sporadic fundic gland polyps: an immunohistochemical study of their antigenic profile. Declich P, et al. **Pathol Res Pract** 1996 Aug;192(8):808–15

Expression of proliferation–associated antigens in cervical carcinoma: correlations among indexes. Oka K, et al. **Pathol Res Pract** 1995 Oct;191(10):997–1003

Polyclonal Ki–67 expression in transitional cell carcinoma of the bladder. Jones HL, et al. **Pathology** 1997 Feb; 29(1):84–7

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Chen YT, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1914–8

Prostate–specific membrane antigen. Fair WR, et al. **Prostate** 1997 Jul 1;32(2):140–8 (52 ref.)

Immunohistochemical study of CA 19–9 and SPan–1 in cases of hydronephrosis. Inayama Y, et al. **Urol Int** 1996; 57(2):93–8

Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic–specific membrane reverse transcription polymerase chain reaction. Su SL, et al. **Urology** 1997 Mar;49(3A Suppl):95–101 (37 ref.)

[Detection of T–antigen in colorectal adenocarcinoma and polyps] Xu S, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):693–5 (Eng. Abstr.) **(Chi)**

[Establishing a new human pancreatic carcinoma cell line as an in vitro and in vivo model for adaptive immunotherapy and identification of tumor–specific antigens in pancreatic carcinoma] Bernstorff W, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:47–50 (Eng. Abstr.) **(Ger)**

[Evaluation of SCC antigen in patients with advanced cervix cancer treated with radiation] Roszak A, et al. **Ginekol Pol** 1996 Sep;67(9):457–9 (Eng. Abstr.) **(Pol)**

[Immunohistochemistry characterization of neurocytoma of the cerebral hemispheres] Korshunov AG, et al. **Arkh Patol** 1997 Jan–Feb;59(1):51–7 (Eng. Abstr.) **(Rus)**

[Immunomorphologic markers in breast cancer] Volchenko NN, et al. **Arkh Patol** 1996 Jan–Feb;58(1):6–10 (Eng. Abstr.) **(Rus)**

[The membrane hetero–organic antigens of tumors of hepatocellular and myogenic origins] Teriukova NP, et al. **Tsitologiia** 1996;38(10):1092–7 (Eng. Abstr.) **(Rus)**

[Immunogammagraphy with anti–CEA and anti–TAG–72 monoclonal antibodies in the diagnosis of colorectal carcinoma (see comments)] Muxí Pradas MA, et al. **Med Clin (Barc)** 1996 Nov 9;107(16):601–7 (Eng. Abstr.) . Comment in: Med Clin (Barc) 1996 Nov 9;107(16):617–9. **(Spa)**

[Identification of a tumor antigen associated to the estrogen receptor in axillary lymph nodes of breast cancer patients] Laguens G, et al. **Medicina (B Aires)** 1996;56(3):269–72 (Eng. Abstr.) **(Spa)**

[Immunohistochemical detection of bcl–2 and MIB–1/Ki–67 in breast cancer: retrospective analysis of 238 cases] Sundlad AS, et al. **Medicina (B Aires)** 1996;56(3):252–8 (Eng. Abstr.) **(Spa)**

[Diagnostic and prognostic value of the immunohistochemical study of proliferating cell nuclear antigen (PCNA) expression in paraffin sections from non–hodgkin's lymphoma (letter)] Gómez Arbonés X, et al. **Sangre (Barc)** 1995 Dec;40(6):520–1 **(Spa)**

BIOSYNTHESIS

The prediction of lymph node metastases in colorectal cancer by expression of the nucleoside diphosphate kinase/nm23–H1 and histopathological variables. Tannapfel A, et al. **Am J Gastroenterol** 1997 Jul; 92(7):1182–6

Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia. Fruchart C, et al. **Am J Hematol** 1996 Nov; 53(3):175–80

Progesterone induced blocking factor seen in pregnancy lymphocytes soon after implantation. Check JH, et al. **Am J Reprod Immunol** 1996 Mar;35(3):277–80

Enhancement of tumor associated antigen expression during the regression phase of xenogenized tumor cell growth in vivo. Shibata T, et al. **Anticancer Res** 1997 May–Jun; 17(3C):2135–40

MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Hilden JM, et al. **Blood** 1997 May 15; 89(10):3801–5

Differential expression of DNA topoisomerase II alpha and –beta in P–gp and MRP–negative VM26, mAMSA and mitoxantrone–resistant sublines of the human SCLC cell line GLC4. Withoff S, et al. **Br J Cancer** 1996 Dec; 74(12):1869–76

Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Gratas C, et al. **Brain Pathol** 1997 Jul;7(3):863–9

Reduction of LAK–sensitivity and changes in antigen expression on hepatoma cells by sodium butyrate. Tada S, et al. **Cancer Biochem Biophys** 1996 Apr;15(3):177–86

Decreased expression of HLA class I on ocular melanoma cells following in vitro photodynamic therapy. Blom DJ, et al. **Cancer Lett** 1997 Jan 30;112(2):239–43

Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC–1 mucin) in breast carcinomas. Peterson JA, et al. **Cancer Res** 1997 Mar 15;57(6):1103–8

Antigenic phenotypes common to rat oval cells, primary hepatocellular carcinomas and developing bile ducts. Hixson DC, et al. **Carcinogenesis** 1997 Jun;18(6):1169–75

PKC–dependent long–term effect of PMA on protein cell surface expression in Caco–2 cells. Sapin C, et al. **Exp Cell Res** 1997 Mar 15;231(2):308–18

Cell density regulates crypticity of GM3 ganglioside on human glioma cells. Tatewaki K, et al. **Exp Cell Res** 1997 May 25;233(1):145–54

Adult and childhood acute lymphoblastic leukemia: clinico–biological differences based on CD34 antigen expression. Cascavilla N, et al. **Haematologica** 1997 Jan–Feb;82(1):31–7

Significance of the expression of proliferation–associated nucleolar antigen p120 in human colorectal tumors. Ueki T, et al. **Hum Pathol** 1997 Jan;28(1):74–9

Expression of MAGE–1, MAGE–3 and MART–1 genes in neuroblastoma. Corrias MV, et al. **Int J Cancer** 1996 Oct 21;69(5):403–7

MAGE–1 and MAGE–3 or –6 expression in neuroblastoma–related pediatric solid tumors. Ishida H, et al. **Int J Cancer** 1996 Oct 21;69(5):375–80

Altered mRNA expression of specific molecular species of fucosyl– and sialyl–transferases in human colorectal cancer tissues. Ito H, et al. **Int J Cancer** 1997 May 16;71(4):556–64

Interleukin–10 is a growth factor for human melanoma cells and down–regulates HLA class–I, HLA class–II and ICAM–1 molecules. Yue FY, et al. **Int J Cancer** 1997 May 16;71(4):630–7

Expression of melanoma–associated antigen of thermotolerant human cells. Davies CD, et al. **Int J Hyperthermia** 1996 Jul–Aug;12(4):539–49

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP–1 and loss of expression of the immunodominant MART–1/Melan–A antigen. Maeurer MJ, et al. **J Clin Invest** 1996 Oct 1; 98(7):1633–41

Changes in the distribution of cells expressing tumour–associated antigen in lymph nodes during the progression of enzootic bovine leukosis. Koguchi A, et al. **J Comp Pathol** 1996 Nov;115(4):343–52

Demodex mites of human skin express Tn but not T (Thomsen–Friedenreich) antigen immunoreactivity [letter] Kanitakis J, et al. **J Cutan Pathol** 1997 Aug;24(7):454–5

Induction of nonspecific cross–reacting antigen mRNA by interferon–gamma and anti–fibronectin receptor antibody in colon cancer cells. Hinoda Y, et al. **J Gastroenterol** 1997 Apr;32(2):200–5

Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen–presenting cells. Bellone M, et al. **J Immunol** 1997 Jan 15;158(2):783–9

Analysis of expression of the melanoma–associated antigens MART–1 and gp100 in metastatic melanoma cell lines and in in situ lesions. Marincola FM, et al. **J Immunother Emphasis Tumor Immunol** 1996 May; 19(3):192–205

Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL–2. Scheibenbogen C, et al. **J Immunother Emphasis Tumor Immunol** 1996 Sep; 19(5):375–80

Tumor–associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladder. Lee E, et al. **J Urol** 1997 Mar;157(3):1070–3

Production of murine leukemia RLmale1 rejection antigen peptide pRL1a by proteolysis of natural precursor pRL1b. Ono T, et al. **Jpn J Cancer Res** 1996 Nov;87(11):1165–70

Bcl–2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Bradbury DA, et al. **Leuk Lymphoma** 1997 Jan; 24(3–4):221–8 (48 ref.)

Rotenone, a mitochondrial NADH dehydrogenase inhibitor, induces cell surface expression of CD13 and CD38 and apoptosis in HL–60 cells. Matsunaga T, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):487–94

Induction of PA2.26, a cell–surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Gandarillas A, et al. **Mol Carcinog** 1997 Sep;20(1):10–8

Expression of 65–kDa oncofetal protein in experimental hepatoma after anticancer therapy. Mirowski M, et al. **Neoplasma** 1997;44(2):85–9

Prostate–specific membrane antigen. Fair WR, et al. **Prostate** 1997 Jul 1;32(2):140–8 (52 ref.)

Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Srivastava PK. **Semin Immunol** 1996 Oct;8(5):295–302 (47 ref.)

Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha– and gamma–interferon. Abril E, et al. **Tissue Antigens** 1996 May;47(5):391–8

Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes. Bernhard H, et al. **Tissue Antigens** 1996 Jul;48(1):22–31

Mechanisms of loss of HLA class I expression on colorectal tumor cells. Browning M, et al. **Tissue Antigens** 1996 May; 47(5):364–71

Expression of Ki–67 by monoclonal antibody MIB–1 in carcinoma of the middle and lower bile duct. Yamada Y, et al. **Tohoku J Exp Med** 1995 Dec;177(4):375–7

BLOOD

High serum SCC antigen levels in two patients with ovarian cancer. Yamada T, et al. **Acta Obstet Gynecol Scand** 1997 Mar;76(3):283–5

Importance of a new tumor marker TRA–1–60 in the follow–up of patients with clinical stage I nonseminomatous testicular germ cell tumors. Gels ME, et al. **Ann Surg Oncol** 1997 Jun;4(4):321–7

Cyfra 21–1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Bonfrer JM, et al. **Anticancer Res** 1997 May–Jun; 17(3C):2329–34

Cancer of the uterine cervix: clinical value of squamous cell carcinoma antigen (SCC) measurements. Lozza L, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):525–9

Clinical relevance of CYFRA 21–1, TPA–IRMA and TPA–LIA–mat in urinary bladder cancer. Stieber P, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3793–8

CYFRA 21–1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Wollenberg B, et al. **Anticancer Res** 1996 Sep–Oct;16(5B):3117–24

Serum level of squamous cell carcinoma antigen as a new indicator of disease activity in patients with psoriasis [letter] Hamanaka S, et al. **Arch Dermatol** 1997 Mar;133(3):393–5

Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer. Yenisey C, et al. **Biochem Soc Trans** 1996 May;24(2):302S

Validation of an algorithm able to differentiate small–cell lung cancer (SCLC) from non–small–cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors. Paone G, et al. **Br J Cancer** 1997; 75(3):448–50

Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens. Touitou Y, et al. **Br J Cancer** 1996 Oct;74(8):1248–52

Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Douglas TH, et al. **Cancer** 1997 Jul 1;80(1):107–14

Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma. Kohno N, et al. **Cancer Detect Prev** 1997; 21(2):124-8

Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients. Jezersek B, et al. **Cancer Lett** 1996 Dec 20;110(1-2):137-44

Monoclonal antibodies to a tumour-associated antigen isolated from circulating immune complexes of bovine leukemia virus-infected cattle. Alexandrov II, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jun;20(3):241-51

Squamous cell carcinoma antigen levels in patients with different stages of laryngeal cancer. Namyslowski G, et al. **Eur Arch Otorhinolaryngol Suppl** 1997;1:S154-6

Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Bréchot JM, et al. **Eur J Cancer** 1997 Mar;33(3):385-91

Significant elevation of tumour-associated isoforms of soluble CD44 in serum of normal individuals caused by cigarette smoking. Kittl EM, et al. **Eur J Clin Chem Clin Biochem** 1997 Feb;35(2):81-4

Tumour marker detection in oesophageal carcinoma. Mealy K, et al. **Eur J Surg Oncol** 1996 Oct;22(5):505-7

Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer. Morita T, et al. **Eur Urol** 1997;32(2):237-44

Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix. Bae SN, et al. **Gynecol Oncol** 1997 Mar;64(3):418-24

Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Bolger BS, et al. **Gynecol Oncol** 1997 May; 65(2):309-13

Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations. Massuger LF, et al. **Gynecol Oncol** 1997 Mar;64(3):473-6

Expression of tumor-associated carbohydrate antigens correlates with hepatic metastasis of pancreatic cancer: clinical and experimental studies. Takamori H, et al. **Hepatogastroenterology** 1996 May-Jun;43(9):748-55

A primary adenosquamous carcinoma of the liver with an elevated level of serum squamous cell carcinoma related antigen. Yamamoto K, et al. **Hepatogastroenterology** 1996 May-Jun;43(9):658-62

Comparative study of the role of serum levels of p53 antigen and its tumor cell concentration in colon cancer detection. Zusman I, et al. **Hum Antibodies Hybridomas** 1996; 7(3):123-8

Preoperative CEA and TAG-72 serum levels as prognostic indicators in resectable gastric carcinoma. González A, et al. **Int J Biol Markers** 1996 Jul-Sep;11(3):165-71

The clinical value of Cyfra 21-1 estimation for lung cancer patients. Szturmowicz M, et al. **Int J Biol Markers** 1996 Jul-Sep;11(3):172-7

Detection of squamous-cell carcinoma antigen-expressing tumour cells in blood by reverse transcriptase-polymerase chain reaction in cancer of the uterine cervix. Stenman J, et al. **Int J Cancer** 1997 Feb 20;74(1):75-80

Anal canal cancer diagnosis: usefulness of serum tumor markers. Indinnimeo M, et al. **J Chemother** 1997 Apr; 9(2):121-2

Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. Marincola FM, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):266-77

Serum levels of squamous cell carcinoma antigen and carcinoembryonic antigen as tumor markers of vulvar cancer. Yamawaki T, et al. **J Obstet Gynaecol Res** 1996 Aug;22(4):341-6

A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma. Kim YC, et al. **Korean J Intern Med** 1996 Jan;11(1):50-7

Fas/Apo-1 (CD95)-mediated and CD95-independent apoptosis of malignant plasma cells. Hata H, et al. **Leuk Lymphoma** 1996 Dec;24(1-2):35-42 (21 ref.)

Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. De Rossi G, et al. **Leukemia** 1997 Jan;11(1):134-41

Usefulness of longitudinal evaluation of Cyfra 21-1 variations in advanced lung cancer monitoring. Hamzaoui A, et al. **Lung Cancer** 1997 Mar;16(2-3):191-202

Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Jäger E, et al. **Melanoma Res** 1996 Dec;6(6):419-25

Presence in bovine fetal serum of the protein antigenically related to p65-tumor associated antigen: its isolation and polyclonal antibody production. Mirowski M, et al. **Neoplasma** 1996;43(2):83-8

Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen. Tsai SC, et al. **Neoplasma** 1996;43(1):27-9

Cyfra 21-1, a new marker of lung cancer. Grenier J, et al. **Nucl Med Biol** 1994 Apr;21(3):471-6

CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer. Takei Y, et al. **Oncology** 1997 Jan-Feb; 54(1):43-7

Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Angelsen A, et al. **Prostate** 1997 Jan 1;30(1):1-6

PSA-based screening for prostate cancer in asymptomatic younger males: pilot study in blood donors. Reissigl A, et al. **Prostate** 1997 Jan 1;30(1):20-5

Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Huang MS, et al. **Respir Med** 1997 Mar; 91(3):135-42

Prostate-specific membrane antigen and other prostatic tumor markers on the horizon. Israeli RS, et al. **Urol Clin North Am** 1997 May;24(2):439-50 (79 ref.)

[Serum concentrations of the MCA tumor marker during pregnancy] Pütz I, et al. **Zentralbl Gynakol** 1996; 118(7):409-11 (Eng. Abstr.) **(Ger)**

[MSA--a new sensitive tumor marker in breast carcinoma] Zahm DM, et al. **Zentralbl Gynakol** 1996;118(12):659-64 (Eng. Abstr.) **(Ger)**

[Investigation of the usefulness of CYFRA 21-1 as a tumor marker in squamous cell carcinomas of the head and neck] Sano K, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1997 Jul; 100(7):790-7 (Eng. Abstr.) **(Jpn)**

[Studies of serum markers in patients with interstitial pneumonia/pulmonary fibrosis complicated with collagen diseases: clinical evaluation of CYFRA21-1] Suzuki A, et al. **Ryumachi** 1996 Dec;36(6):837-43 (Eng. Abstr.) **(Jpn)**

[Clinical significance of tumor markers CYFRA 21-1 and neuron-specific enolase in lung cancer] Kushlinskiĭ NE, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):98-100 **(Rus)**

[The antigen associated with squamous cell carcinoma in patients with benign hepatopathies (letter; comment)] Collazos J. **Med Clin (Barc)** 1997 Feb 1;108(4):157. Comment on: Med Clin (Barc) 1996 Feb 17;106(6):205-8. **(Spa)**

CHEMISTRY

Synthesis of alpha- and beta-biotinylated T-antigen. Bay S, et al. **Carbohydr Res** 1997 Mar 5;298(3):153-61

The primary structure of UK114 tumor antigen. Ceciliani F, et al. **FEBS Lett** 1996 Sep 16;393(2-3):147-50

The tumor association of a trisaccharide epitope: specificity of antiserum developed to galactose beta1->3 N-acetyl glucosamine beta1->3 galactose. Diakun KR, et al. **Immunol Invest** 1996 May;25(3):253-66

Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (I). Immuno-dominant and immuno-recessive area. Xuan JW, et al. **J Cell Biochem** 1997 May;65(2):172-85

Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (II). Epitope mapping by monoclonal antibodies. Xuan JW, et al. **J Cell Biochem** 1997 May;65(2):186-97

Detection of human topoisomerase II alpha in cell lines and tissues: characterization of five novel monoclonal antibodies. Kellner U, et al. **J Histochem Cytochem** 1997 Feb;45(2):251-63

Immunotherapy of established murine tumors with large multivalent immunogen and cyclophosphamide. Mescher MF, et al. **J Immunother Emphasis Tumor Immunol** 1996 Mar;19(2):102-12

Transloading of tumor antigen-derived peptides into antigen-presenting cells. Buschle M, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3256-61

Cell-free tumor antigen peptide-based cancer vaccines. Schmidt W, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3262-7

Complementarity determining region residues aspartic acid at H55, serine at H95 and tyrosines at H97 and L96 play important roles in the B72.3 antibody-TAG72 antigen interaction. Xiang J, et al. **Protein Eng** 1996 Jun;9(6):539-43

[Molecular weight determination and protein analysis of GCF-5 antigens of giant cell tumor of bone] Ren X, et al. **Chung Hua Wai Ko Tsa Chih** 1996 Jan;34(1):57-60 (Eng. Abstr.) **(Chi)**

CLASSIFICATION

Identification of human skin from a tissue fragment by detection of squamous cell carcinoma-related antigen using an enzyme immunoassay. Kitao T, et al. **Forensic Sci Int** 1996 Dec 2;83(2):81-6

DIAGNOSTIC USE

Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms. Wallace ML, et al. **Mod Pathol** 1995 Dec;8(9):897-901

[Value of tumor markers for screening and diagnosis (except prognostic and surveillance values) in primary bronchial cancers] Grivaux M. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S15-9 (41 ref.) **(Fre)**

[CYFRA 21-1] Pujol JL. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S31-6 (32 ref.) **(Fre)**

[Value of serial tumor markers for the detection of recurrences] Quoix E. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S27-9 (32 ref.) **(Fre)**

[Which tumor markers should be used in primary bronchial cancers?] Schuller MP, et al. **Rev Mal Respir** 1997 Apr; 14 Suppl 3:S9-14 (29 ref.) **(Fre)**

[Value of tumor markers in surveillance of primary bronchial cancers and to evaluate therapy] Sculier JP. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S23-6 (29 ref.) **(Fre)**

[Value of serial tumor markers for determining the prognosis and predicting treatment response and survival] Souquet PJ. **Rev Mal Respir** 1997 Apr;14 Suppl 3:S20-2 (23 ref.) **(Fre)**

DRUG EFFECTS

Relationship between tumor (T) antigen expression and substituent effects on benzo [a] phenothiazines. Pusztai R, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2961-4

GENETICS

Expression of the MAGE-1, -2, -3, -4, and -6 genes in non-squamous cell carcinoma lesions of the head and neck. Lee KD, et al. **Acta Otolaryngol (Stockh)** 1996 Jul; 116(4):633-9

Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Rosenberg SA, et al. **Adv Cancer Res** 1996;70:145-77 (156 ref.)

Expression of MAGE and BAGE genes in Japanese breast cancers. Fujie T, et al. **Ann Oncol** 1997 Apr;8(4):369-72

Expression of MAGE genes in esophageal squamous-cell carcinoma. Quillien V, et al. **Anticancer Res** 1997 Jan-Feb; 17(1A):387-91

Melanotransferrin gene expression in melanoma cells is correlated with high levels of Jun/Fos family transcripts and with the presence of a specific AP1-dependent ternary complex. Rozé-Heusse A, et al. **Biochem J** 1996 Sep 15; 318 (Pt 3):883-8

Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Stauder R, et al. **Blood** 1996 Oct 15; 88(8):3101-8

Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. Bertoni F, et al. **Br J Haematol** 1997 Jun;97(4):830-6

Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Alpan RS, et al. **Cancer Res** 1996 Oct 1;56(19):4358-61

Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Reeves ME, et al. **Cancer Res** 1996 Dec 15;56(24):5672-7

The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Türeci O, et al. **Cancer Res** 1996 Oct 15;56(20):4766-72

Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products. Wolf DA, et al. **Cancer Res** 1996 Nov 1;56(21):5012-22

Developmentally regulated expression of metastasis-associated antigens in the rat. Claas C, et al. **Cell Growth Differ** 1996 May;7(5):663-78

Differential H-2 antigen expression in teratocarcinoma-fibroblast hybrids. Sionov RV, et al. **Exp Clin Immunogenet** 1995;12(4):238-44

Cis-acting elements required for expression of the nonspecific cross-reacting antigen gene in colorectal carcinoma. Jones DV Jr, et al. **Gastroenterology** 1997 Mar;112(3):776-82

Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions. Butterfield LH, et al. **Gene** 1997 Jun 3;191(2):129-34

Assignment of the squamous cell carcinoma antigen locus (SCC) to 18q21 by in situ hybridization. Kuwano A, et al. **Genomics** 1995 Dec 10;30(3):626

CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Rosato A, et al. **Hum Gene Ther** 1997 Aug 10;8(12):1451-8

Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Wan Y, et al. **Hum Gene Ther** 1997 Jul 20; 8(11):1355-63

Ectopic expression of target genes may represent an inherent limitation of RT-PCR assays used for micrometastasis detection: studies on the epithelial glycoprotein gene EGP-2. de Graaf H, et al. **Int J Cancer** 1997 Jul 3; 72(1):191-6

Detection of circulating tumor cells in patients with prostate cancer using prostate specific membrane-derived primers in the polymerase chain reaction. Noguchi M, et al. **Int J Urol** 1997 Jul;4(4):374-9

A point mutation of human nucleoside diphosphate kinase A found in aggressive neuroblastoma affects protein folding. Lascu I, et al. **J Biol Chem** 1997 Jun 20; 272(25):15599-602

A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. Mandruzzato S, et al. **J Exp Med** 1997 Aug 29;186(5):785-93

Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. Li W, et al. **J Immunol** 1997 Jul 15; 159(2):763-9

Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory

molecule B7. Akagi J, et al. **J Immunother** 1997 Jan; 20(1):38–47

Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. Zhai Y, et al. **J Immunother** 1997 Jan; 20(1):15–25

The 105-kDa basement membrane autoantigen p105 is N-terminally homologous to a tumor-associated antigen. Chan LS, et al. **J Invest Dermatol** 1996 Aug;107(2):209–14

Identification of aberrantly regulated genes in diseased skin using the cDNA differential display technique. Rivas MV, et al. **J Invest Dermatol** 1997 Feb;108(2):188–94

Expression of HuD (a paraneoplastic encephalomyelitis antigen) mRNA in lung cancer. Cho JH, et al. **J Korean Med Sci** 1997 Aug;12(4):305–10

Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. Rosenberg SA. **J Natl Cancer Inst** 1996 Nov 20; 88(22):1635–44 (61 ref.)

Unaltered strong immunohistochemical expression of CD44–v6 and –v5 isoforms during development and progression of oral squamous cell carcinomas. Piffkò J, et al. **J Oral Pathol Med** 1996 Oct;25(9):502–6

Expression of MAGE genes in osteosarcoma. Sudo T, et al. **J Orthop Res** 1997 Jan;15(1):128–32

Mart1 is located on mouse chromosome 19 and is excluded as a candidate for ep and ru. Wright A, et al. **Mamm Genome** 1997 May;8(5):377–8

Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. De Plaen E, et al. **Methods** 1997 Jun;12(2):125–42 (85 ref.)

p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. Sandri MI, et al. **Nucleic Acids Res** 1996 Nov 15;24(22):4464–70

Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Asano T, et al. **Oncol Res** 1996; 8(3):101–10

The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Heath JK, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21; 94(2):469–74

Unique tumor antigens redefined as mutant tumor-specific antigens. Mumberg D, et al. **Semin Immunol** 1996 Oct; 8(5):289–93 (31 ref.)

HLA-G transcription studies during the different stages of normal and malignant hematopoiesis. Amiot L, et al. **Tissue Antigens** 1996 May;47(5):408–13

Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Torres MJ, et al. **Tissue Antigens** 1996 May;47(5):372–81

[Induction of tumor-specific cytotoxic T-lymphocytes by non-replicating, Melan-A27–35 expressing recombinant Vaccinia viruses in vitro] Marti WR, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:85–9 (Eng. Abstr.) **(Ger)**

[Significance of prostate-specific membrane antigen (PSMA). A neurocarboxypeptidase and membrane folate hydrolase] Heston WD. **Urologe A** 1996 Sep;35(5):400–7 (17 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Presence of t(8;21)(q22;q22) in myeloperoxidase-positive, myeloid surface antigen-negative acute myeloid leukemia. Arber DA, et al. **Am J Clin Pathol** 1997 Jan;107(1):68–73

Heterophilic antibodies produce spuriously elevated concentrations of the MB isoenzyme of creatine kinase in a selected patient population. Sosolik RC, et al. **Am J Clin Pathol** 1997 May;107(5):506–10

Recognition of tumor-associated antigens by T-lymphocytes: perspectives for peptide-based vaccines. Cerottini JC, et al. **Ann Oncol** 1996 Apr;7(4):339–42 (52 ref.)

Molecular cloning and primary characterization of a single-chain antibody against human sarcoma-associated antigen p200. Chen H, et al. **Anticancer Res** 1996 Nov–Dec; 16(6B):3551–6

Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies. Tinari N, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):367–72

Antigens recognized by T-lymphocytes on human tumours. Coulie PG, et al. **Biochem Soc Trans** 1997 May;25(2):544–8 (40 ref.)

Development of a human IgA antibody specific for the tumour antigen TAG-72. Ingram PE, et al. **Biochem Soc Trans** 1997 May;25(2):330S

Induction of human T cell responses to tumour-associated neoantigens and virus antigens using cultured dendritic cells. Li J, et al. **Biochem Soc Trans** 1997 May;25(2):204S

Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells. Cho BK, et al. **Bioconjug Chem** 1997 May–Jun;8(3):338–46

Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. Borowitz MJ, et al. **Blood** 1997 Jun 1;89(11):3960–6

Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Carbone A, et al. **Blood** 1997 May 15;89(10):3787–94

VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection. Chapman CJ, et al. **Blood** 1996 Nov 1;88(9):3562–8

In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Francisco JA, et al. **Blood** 1997 Jun 15;89(12):4493–500

Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models. Lindhofer H, et al. **Blood** 1996 Dec 15;88(12):4651–8

HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells. Mutis T, et al. **Blood** 1997 Aug 1;90(3):1083–90

Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: characterization and diagnostic utility. Sang BC, et al. **Blood** 1997 Apr 15;89(8):2909–14

Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Uckun FM, et al. **Blood** 1997 Jul 1;90(1):28–35

Immunosuppression by breast cancer associated p43-effect of immunomodulators. Rosen HR, et al. **Breast Cancer Res Treat** 1996;41(2):171–6

Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Fishman P, et al. **Cancer** 1997 Apr 15; 79(8):1461–4

Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma. Ravindranath MH, et al. **Cancer** 1997 May 1;79(9):1686–97

Making the most of mucin: a novel target for tumor immunotherapy. Barratt-Boyes SM. **Cancer Immunol Immunother** 1996 Nov;43(3):142–51 (65 ref.)

Efficient induction of antitumor cytotoxic T lymphocytes from a healthy donor using HLA-A2-restricted MAGE-3 peptide in vitro. Tanaka F, et al. **Cancer Immunol Immunother** 1997 Mar;44(1):21–6

A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer. Zimmermann S, et al. **Cancer Immunol Immunother** 1997 Mar;44(1):1–9

Immunotherapy II: Antigens, receptors and costimulation. Searle PF, et al. **Cancer Metastasis Rev** 1996 Sep; 15(3):329–49 (103 ref.)

Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes. Fisk B, et al. **Cancer Res** 1997 Jan 1; 57(1):87–93

Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Liu H, et al. **Cancer Res** 1997 Sep 1;57(17):3629–34

Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Ribas A, et al. **Cancer Res** 1997 Jul 15;57(14):2865–9

Specificity of antibodies directed against Env protein of human endogenous retroviruses in patients with germ cell tumors. Sauter M, et al. **Cancer Res** 1996 Oct 1; 56(19):4362–5

Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Trail PA, et al. **Cancer Res** 1997 Jan 1;57(1):100–5

Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Valmori D, et al. **Cancer Res** 1997 Feb 15;57(4):735–41

Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules. Frey AB, et al. **Cell Immunol** 1997 May 25;178(1):79–90

Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients. Takahashi T, et al. **Cell Immunol** 1997 Jun 15;178(2):162–71

Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. Yang S, et al. **Cell Immunol** 1997 Jul 10; 179(1):84–95

Molecular aberrations in the MHC class I-restricted pathway for antigen presentation in methylcholanthrene sarcomas from nude mice: discrepancies between MHC mRNA and surface protein. Engel AM, et al. **Clin Exp Immunol** 1997 Aug;109(2):323–31

High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants. De Paoli P, et al. **Cytometry** 1997 Feb 15;30(1):33–8

Flow cytometric analysis of cell surface antigen recognized by monoclonal antibody (MSN-1) in normal, hyperplasia, and carcinoma of endometrial cells: its diagnostic value for endometrial carcinoma. Kobayashi Y, et al. **Cytometry** 1997 Feb 15;30(1):23–7

Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow. Nowak R, et al. **Cytometry** 1997 Feb 15;30(1):47–53

The HER2/neu-derived peptide p654–662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Peiper M, et al. **Eur J Immunol** 1997 May;27(5):1115–23

Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules. Bubeník J. **Folia Biol (Praha)** 1996;42(6):295–304 (114 ref.)

T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Hombach A, et al. **Gastroenterology** 1997 Oct; 113(4):1163–70

High expression of a Lewis(x)-related epitope in gastric carcinomas indicates metastatic potential and poor prognosis. Mayer B, et al. **Gastroenterology** 1996 Dec; 111(6):1433–46

In vitro mimicry of CaMBr1 tumor-associated antigen by synthetic oligosaccharides. Adobati E, et al. **Glycobiology** 1997 Mar;7(2):173–8

VS38 immunostaining in neuroendocrine tumours. Banerjee SS, et al. **Histopathology** 1997 Mar;30(3):256–9

Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors. Gaken JA, et al. **Hum Gene Ther** 1997 Mar 1;8(4):477–88

CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Rosato A, et al. **Hum Gene Ther** 1997 Aug 10;8(12):1451–8

Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Ras E, et al. **Hum Immunol** 1997 Mar;53(1):81–9

Characterization of the ETSA-21 antigen, a glycosylphosphatidyl-inositol anchor glycoprotein identified in breast cancer cells using monoclonal antibody B21. Annibali NV, et al. **Hybridoma** 1997 Apr;16(2):139–45

Generation of a monoclonal antibody directed against a human cell substrate adhesion molecule and the expression of the antigen in human tissues. Coene E, et al. **Hybridoma** 1997 Feb;16(1):77–83

Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2—>6) T antigens. O'Boyle KP, et al. **Hybridoma** 1996 Dec; 15(6):401–8

Anti-TAG-72 antibody B72.3—immunological and clinical effects in ovarian carcinoma. Schmolling J, et al. **Hybridoma** 1997 Feb;16(1):53–8

Clinical and immunologic effects of monoclonal antibody CC49 and interleukin-2 in patients with metastatic colorectal cancer. Triozzi PL, et al. **Hybridoma** 1997 Apr; 16(2):147–51

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Ikeda H, et al. **Immunity** 1997 Feb;6(2):199–208

Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Heikema A, et al. **Immunol Lett** 1997 Jun 1;57(1-3):69–74

T-cell recognition of self peptides as tumor rejection antigens. Kawakami Y, et al. **Immunol Res** 1996; 15(3):179–90 (51 ref.)

Tumor antigens recognized by T cells. Boon T, et al. **Immunol Today** 1997 Jun;18(6):267–8 (14 ref.)

Cytokines, tumour-cell death and immunogenicity: a question of choice. Musiani P, et al. **Immunol Today** 1997 Jan; 18(1):32–6 (38 ref.)

The tumour associated cell surface antigen A6H is costimulatory for human CD4+ but not CD8+ T cells. Labuda T, et al. **Immunology** 1997 Feb;90(2):236–43

Humanization of an antibody recognizing a breast cancer specific epitope by CDR-grafting. Fiorentini S, et al. **Immunotechnology** 1997 Mar;3(1):45–59

Identification of tumor-regression antigens in melanoma. Kawakami Y, et al. **Important Adv Oncol** 1996;:3–21 (140 ref.)

Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens. Farina C, et al. **Int Immunol** 1996 Sep;8(9):1463–6

Diversity of epitopes recognized by cytotoxic T lymphocytes that are specific for rejection antigen peptide pRL1a presented on BALB/c leukemia RL Male 1. Yokoi T, et al. **Int Immunol** 1997 Aug;9(8):1195–201

Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. Brinkmann U, et al. **Int J Cancer** 1997 May 16;71(4):638–44

Human monoclonal antibodies specific for the tumour associated Thomsen-Friedenreich antigen. Dahlenborg K, et al. **Int J Cancer** 1997 Jan 6;70(1):63–71

Dominant TCRB-V-J chain usage and clonal expansion of sarcoma-reactive CD4+ HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma antigens. Heike M, et al. **Int J Cancer** 1997 Jul 29;72(3):403–7

Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Scheibenbogen C, et al. **Int J Cancer** 1997 Jun 11; 71(6):932–6

Inhibition of growth and enhancement of differentiation of colorectal carcinoma cell lines by MAb MR6 and IL-4. Al-Tubuly AA, et al. **Int J Cancer** 1997 May 16; 71(4):605–11

The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Uyttenhove C, et al. **Int J Cancer** 1997 Jan

27;70(3):349–56

Altered MHC class I antigens in tumors. Algarra I, et al. **Int J Clin Lab Res** 1997;27(2):95–102 (63 ref.)

T-cell recognition of melanoma antigens and its therapeutic applications. Castelli C, et al. **Int J Clin Lab Res** 1997; 27(2):103–10 (46 ref.)

Inhibitory receptors for HLA class I molecules on cytolytic T lymphocytes. Functional relevance and implications for anti-tumor immune responses. Mingari MC, et al. **Int J Clin Lab Res** 1997;27(2):87–94 (57 ref.)

Tumor antigens recognized by T lymphocytes. Van den Eynde BJ, et al. **Int J Clin Lab Res** 1997;27(2):81–6 (56 ref.)

Localized diffuse large-cell lymphoma possibly coated with anti-tumor autoantibody: kappa lambda-dual-positive lymphoma. Nakano M, et al. **Int J Hematol** 1997 Apr; 65(3):299–304

Development of cancer vaccine by tumor rejection antigens. Itoh K, et al. **Int Rev Immunol** 1997;14(2–3):153–71 (29 ref.)

Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Kawakami Y, et al. **Int Rev Immunol** 1997;14(2–3):173–92 (103 ref.)

Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Adamus G, et al. **Invest Ophthalmol Vis Sci** 1997 Feb;38(2):283–91

Identification of framework residues in a secreted recombinant antibody fragment that control production level and localization in Escherichia coli. Forsberg G, et al. **J Biol Chem** 1997 May 9;272(19):12430–6

Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. Blanco I, et al. **J Clin Immunol** 1997 Jan;17(1):96–106

Influences of transporter associated with antigen processing (TAP) on the repertoire of peptides associated with the endoplasmic reticulum-resident stress protein gp96. Arnold D, et al. **J Exp Med** 1997 Aug 4;186(3):461–6

Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. Speiser DE, et al. **J Exp Med** 1997 Aug 29;186(5):645–53

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. Wang RF, et al. **J Exp Med** 1996 Dec 1;184(6):2207–16

Regulation of tumor antigen presentation by urocanic acid. Beissert S, et al. **J Immunol** 1997 Jul 1;159(1):92–6

Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. Bellone M, et al. **J Immunol** 1997 Jan 15;158(2):783–9

Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. Dolstra H, et al. **J Immunol** 1997 Jan 15;158(2):560–5

Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. Dufour E, et al. **J Immunol** 1997 Apr 15;158(8):3787–95

Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. Fleischhauer K, et al. **J Immunol** 1997 Sep 1;159(5):2513–21

Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line. Fleischhauer K, et al. **J Immunol** 1996 Jul 15;157(2):787–97

Heterogeneity of biologic responses of melanoma-specific CTL. Fonteneau JF, et al. **J Immunol** 1997 Sep 15; 159(6):2831–9

A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. Grohmann U, et al. **J Immunol** 1997 Apr 15;158(8):3593–602

Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. Labarriere N, et al. **J Immunol** 1997 Feb 1;158(3):1238–45

Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. Mack M, et al. **J Immunol** 1997 Apr 15;158(8):3965–70

A mechanism for selective recruitment of CD8 T cells into B7-1-transfected plasmacytoma: role of macrophage-inflammatory protein 1alpha. Maric M, et al. **J Immunol** 1997 Jul 1;159(1):360–8

Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. Mazzocchi A, et al. **J Immunol** 1996 Oct 1;157(7):3030–8

Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. Rheinnecker M, et al. **J Immunol** 1996 Oct 1;157(7):2989–97

The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. Robbins PF, et al. **J Immunol** 1997 Jul 1;159(1):303–8

Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. Romero P, et al. **J Immunol** 1997 Sep 1;159(5):2366–74

Requirement of CD4 T cells for skin graft rejection against thymus leukemia (TL) antigen and multiple epitopes on the TL molecule recognized by CD4 T cells. Tsuji K, et al. **J Immunol** 1997 Jul 1;159(1):159–66

Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. Yee C, et al. **J Immunol** 1996 Nov 1;157(9):4079–86

Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. Kawakami Y, et al. **J Immunol Methods** 1997 Mar 10;202(1):13–25

Inhibition of tumor growth by peptide specific cytotoxic T lymphocytes in a three-dimensional collagen matrix. Wei WZ, et al. **J Immunol Methods** 1997 Jan 15;200(1–2):47–54

Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. Kim CJ, et al. **J Immunother** 1997 Jul;20(4):276–86

Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. Marincola FM, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):266–77

The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. Zarour H, et al. **J Invest Dermatol** 1996 Jul;107(1):63–7

Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. Wang RF, et al. **J Leukoc Biol** 1996 Sep;60(3):296–309 (120 ref.)

A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. Ashley DM, et al. **J Neuroimmunol** 1997 Sep; 78(1–2):34–46

Binding and internalization of anti-sarcoma IgG and IgM antibodies. Chao TC, et al. **J Surg Res** 1997 Jun;70(1):27–33

Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer. Gohara R, et al. **Jpn J Cancer Res** 1997 Feb; 88(2):198–204

Cytotoxicity of histocompatibility leukocyte antigen-DR8-restricted CD4 killer T cells against human autologous squamous cell carcinoma. Miyazaki A, et al. **Jpn J Cancer Res** 1997 Feb;88(2):191–7

Characterization of cytotoxic T lymphocytes recognizing autologous tumor cells with plural HLA-class I alleles in a patient with esophageal cancer. Maeda T. **Kurume Med J** 1997;44(1):23–32

Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma-associated antigen. Luiten RM, et al. **Lab Invest** 1996 Feb;74(2):467–75

The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: pharmacokinetics and biodistribution of two divalent, ricin-based immunotoxins in xenografted athymic mice. Faguet GB, et al. **Leuk Lymphoma** 1997 May;25(5–6):509–20

The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: assessment of LD50 and MTD of four ricin-based anti-cCLLa immunotoxins (ITs) in Balb/c mice. Faguet GB, et al. **Leuk Lymphoma** 1997 May; 25(5–6):531–7

Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis. Funakoshi S, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):187–99 (32 ref.)

Reactivity of anti-AraC-resistant cell monoclonal antibody, YU-311, in formalin-fixed paraffin-embedded specimens of various hematopoietic disorders. Fukuda T, et al. **Leuk Res** 1996 Nov-Dec;20(11–12):953–61

Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Melero I, et al. **Life Sci** 1997;60(23):2035–41 (62 ref.)

Stimulation of tumor-specific immunity using tumor cell plasma membrane antigen. Mescher MF, et al. **Methods** 1997 Jun;12(2):155–64

Isolation of anti-mesothelin antibodies from a phage display library. Chowdhury PS, et al. **Mol Immunol** 1997 Jan; 34(1):9–20

Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Coulie PG. **Mol Med Today** 1997 Jun;3(6):261–8 (39 ref.)

Cancer vaccines: challenges and potential solutions. Hellström KE, et al. **Mol Med Today** 1997 Jul;3(7):286–90

Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Gimmi CD, et al. **Nat Med** 1996 Dec;2(12):1367–70

Setback to immunotherapy strategies of breast cancer. Naresh KN. **Natl Med J India** 1997 May-Jun;10(3):128–9

Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. Divgi CR, et al. **Nucl Med Biol** 1994 Jan;21(1):9–15

Experimental, cancer-induced retinopathy. Thirkill CE. **Ocul Immunol Inflamm** 1997 Mar;5(1):55–65

Diagnostic use of radiolabeled antibodies for cancer. Harrison KA, et al. **Oncology (Huntingt)** 1995 Jul;9(7):625–31 DISC 634, 636, 641 (45 ref.)

Sporadic fundic gland polyps: an immunohistochemical study of their antigenic profile. Declich P, et al. **Pathol Res Pract** 1996 Aug;192(8):808–15

Naturally occurring humoral cytotoxicity against neuroblastoma (NB) cells in healthy persons and NB patients. Erttmann R, et al. **Pediatr Hematol Oncol** 1996 Nov-Dec;13(6):545–8

Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies. Markiewski M, et al. **Pol J Pathol** 1996;47(4):189–94

Apoptosis of T lymphoma cells and its inhibition by monoclonal antibodies against cell surface adhesion molecules. Tsuruo T, et al. **Princess Takamatsu Symp** 1994; 24:91–8 (18 ref.)

Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Naftzger C, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14809–14

Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Barren RJ 3rd, et al. **Prostate** 1997 Jan 1;30(1):65–8

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Tamura Y, et al. **Science** 1997 Oct 3;278(5335):117–20

Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Blachere NE, et al. **Semin Cancer Biol** 1995 Dec;6(6):349–55 (56 ref.)

Epitope selection and development of peptide based vaccines to treat cancer. Celis E, et al. **Semin Cancer Biol** 1995 Dec; 6(6):329–36 (52 ref.)

The next wave of recombinant and synthetic anticancer vaccines. Irvine KR, et al. **Semin Cancer Biol** 1995 Dec; 6(6):337–47 (121 ref.)

Definition of tumor antigens suitable for vaccine construction. Lewis JJ, et al. **Semin Cancer Biol** 1995 Dec; 6(6):321–7 (47 ref.)

Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Srivastava PK. **Semin Immunol** 1996 Oct;8(5):295–302 (47 ref.)

Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Gattoni-Celli S, et al. **Semin Oncol** 1996 Dec;23(6):754–8 (39 ref.)

Tumor antigens and tumor vaccines: peptides as immunogens. Slingluff CL Jr. **Semin Surg Oncol** 1996 Nov-Dec; 12(6):446–53 (89 ref.)

Direct identification of tumor-associated peptide antigens. Engelhard VH. **Springer Semin Immunopathol** 1996; 18(2):171–83 (83 ref.)

Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. Romero P. **Springer Semin Immunopathol** 1996;18(2):185–98 (78 ref.)

HLA and cancer [editorial] Garrido F. **Tissue Antigens** 1996 May;47(5):361–3

Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Van Waes C, et al. **Tissue Antigens** 1996 May;47(5):399–407

Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Wang Z, et al. **Tissue Antigens** 1996 May;47(5):382–90

Characterization of a new breast cancer-associated antigen and its relationship to MUC1 and TAG-72 antigens. Harada Y, et al. **Tohoku J Exp Med** 1996 Nov; 180(3):273–88

Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Carroll MW, et al. **Vaccine** 1997 Mar;15(4):387–94

[Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"] Peiper M, et al. **Zentralbl Chir** 1997;122(3):141–8 (50 ref.) (Eng. Abstr.) **(Ger)**

[Antigen showing alternative to alpha-fetoprotein expression in rat hepatomas] Eraizer TL, et al. **Biull Eksp Biol Med** 1996 Nov;122(11):536–40 **(Rus)**

ISOLATION & PURIFICATION

Identification of a 35 kD tumor-associated autoantigen in papillary thyroid carcinoma. Lucas SD, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2493–6

Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Halder T, et al. **Cancer Res** 1997 Aug 1; 57(15):3238–44

Murine tumor antigens: is it worth the search? Jaffee EM, et al. **Curr Opin Immunol** 1996 Oct;8(5):622–7 (47 ref.)

A model system for detection and isolation of a tumor cell surface antigen using antibody phage display. Pereira S, et al. **J Immunol Methods** 1997 Apr 11;203(1):11–24

Poly (alpha 2,8-deaminoneuraminic acid) is expressed in lung on a single 150-kDa glycoprotein and is an oncodevelopmental antigen. Qu B, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):8995–8

METABOLISM

Relationship between CD44 expression and cell proliferation in epithelium and stroma of colorectal neoplasms. Furuta K, et al. **Am J Pathol** 1996 Oct;149(4):1147–55

Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Litvinov SV, et al. **Am J Pathol** 1996 Mar;148(3):865–75

Relationship between MDR1 gene and surface markers in acute myeloid leukemia. Zöchbauer S, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):749–52

T-cell population of primary and secondary cutaneous B-cell

lymphomas does not express the cutaneous lymphocyte-associated antigen (CLA). Marti RM, et al. **Arch Dermatol Res** 1997 May;289(6):327–30

Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. Ritter G, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):682–6

Anti-Sia-lb (anti-Gd) cold agglutinins bind the domain NeuNAc alpha2-3Gal in sialyl Lewis(x), sialyl Lewis(a), and related carbohydrates on nucleated cells and in soluble cancer-associated mucins. Gallart T, et al. **Blood** 1997 Aug 15;90(4):1576–87

The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Turley H, et al. **Br J Cancer** 1997;75(9):1340–6

CD56+ NK lymphomas: clinicopathological features and prognosis. Kwong YL, et al. **Br J Haematol** 1997 Jun; 97(4):821–9

The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Keen JC, et al. **Breast Cancer Res Treat** 1997 Jun; 44(2):123–33

Prognostic significance of T antigen expression in patients with gastric carcinoma [letter; comment] Carneiro F, et al. **Cancer** 1996 Dec 1;78(11):2448–50. Comment on: Cancer 1996 May 1;77(9):1768–73.

Investigation of Vicia graminea lectin- and Vicia unijuga lectin-binding glycoproteins as novel oncofetal antigens in cyst and ascitic fluids of human ovarian tumors in benign, dysplastic, and malignant stages. Ohyama K, et al. **Cancer Detect Prev** 1997;21(4):304–11

Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Kawakami M, et al. **Cancer Res** 1997 Jun 15;57(12):2321–4

The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation. Mainiero F, et al. **EMBO J** 1997 May 1; 16(9):2365–75

High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Dietrich A, et al. **Eur J Cancer** 1997 May;33(6):926–30

A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Brewer CA, et al. **Gynecol Oncol** 1996 Dec;63(3):337–44

Effects of irradiation on the expression of surface antigens in human ovarian cancer. Santin AD, et al. **Gynecol Oncol** 1996 Mar;60(3):468–74

Expression of oncogene products, anti-oncogene products and oncofetal antigens in intraductal papillary-mucinous neoplasm of the pancreas. Terada T, et al. **Histopathology** 1996 Oct;29(4):355–61

Role of CD44 in nonpalpable T1a and T1b breast cancer. Lyzak JS, et al. **Hum Pathol** 1997 Jul;28(7):772–8

Tumor antigen expression in compound dysplastic nevi and superficial spreading melanoma defined by a panel of nevomelanoma monoclonal antibodies. Lazzaro B, et al. **Hybridoma** 1996 Apr;15(2):141–6

Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer. Kievit E, et al. **Int J Cancer** 1997 Apr 10;71(2):237–45

Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Marth C, et al. **Int J Cancer** 1996 Sep 17;67(6):826–30

Expression of an oncofetal 65-kDa phosphoprotein in lymphocytic and granulocytic leukemias. Hanausek M, et al. **Int J Hematol** 1996 Apr;63(3):193–203

Ki-67 immunostaining as a tool in the diagnosis of central cartilage lesions. Weinstein LJ, et al. **Iowa Orthop J** 1996; 16:39–45

Co-regulation and physical association of the 67-kDa monomeric laminin receptor and the alpha6beta4 integrin. Ardini E, et al. **J Biol Chem** 1997 Jan 24;272(4):2342–5

Exon 6 is essential for invariant chain trimerization and induction of large endosomal structures. Gedde-Dahl M, et al. **J Biol Chem** 1997 Mar 28;272(13):8281–7

Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. Yamamoto M, et al. **J Biol Chem** 1997 May 9;272(19):12492–4

Zollinger-Ellison syndrome, acromegaly, and colorectal neoplasia. Tobi M, et al. **J Clin Gastroenterol** 1997 Jan; 24(1):21–4

Tissue distribution of a melanoma-associated antigen immunogenic in patients with melanoma as analyzed by polyclonal antibodies to recombinant peptide antigen. Kako S, et al. **J Dermatol** 1996 Apr;23(4):230–7

Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers. Polette M, et al. **J Histochem Cytochem** 1997 May;45(5):703–9

Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. Cayeux S, et al. **J Immunol** 1997 Mar 15;158(6):2834–41

Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. Skipper JC, et al. **J Immunol** 1996 Dec 1;157(11):5027–33

Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons. Sivinski CL, et al. **J Immunother Emphasis Tumor Immunol** 1995 Oct; 18(3):156–65

Characterization of peptides that bind the tumor-associated Thomsen-Friedenreich antigen selected from bacteriophage display libraries. Peletskaya EN, et al. **J Mol Biol** 1997 Jul 18;270(3):374–84

Metastatic potential of lymphoma/leukemia cell lines in SCID mice is closely related to expression of CD44. Kawasaki N, et al. **Jpn J Cancer Res** 1996 Oct; 87(10):1070–7

Chaperoning tumour antigens into the immune system [news] Featherstone C. **Lancet** 1996 Nov 23;348(9039):1438

The combined differentiating effect of retinoic acid and vincristine on acute promyelocytic leukemia. Leung M, et al. **Leuk Res** 1997 Jan;21(1):81–4

Inhibition of proliferation and CD25 down-regulation by retinoic acid in human adult T cell leukemia cells. Miyatake JI, et al. **Leukemia** 1997 Mar;11(3):401–7

Cytokine modulation of antigen expression in human melanoma cell lines derived from primary and metastatic tumour tissues. Andalib AR, et al. **Melanoma Res** 1997 Feb; 7(1):32–42

Topoisomerase II alpha expression in normal, inflammatory, and neoplastic conditions of the gastric and colonic mucosa. Fogt F, et al. **Mod Pathol** 1997 Apr;10(4):296–302

Immunohistochemical study of Ki-67 and DNA topoisomerase II in human endometrium. Ito K, et al. **Mod Pathol** 1997 Apr;10(4):289–94

The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo. Buckanovich RJ, et al. **Mol Cell Biol** 1997 Jun;17(6):3194–201

Binding and transport of melanoma-specific antigenic peptides by the transporter associated with antigen processing. Chang SA, et al. **Mol Immunol** 1996 Oct; 33(15):1165–9

Placental isoferritin-associated p43 in pregnancy and breast cancer. Minireview. Rosen HR. **Neoplasma** 1996; 43(6):357–62 (21 ref.)

Expression of MAGE genes in colorectal carcinomas. Nishimura S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Apr;20(2):95–101

Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin. Kawanami K, et al. **Oncol Res** 1996;8(5):197–206

[An immunohistochemical study of intestinal mucinous antigens and CEA in ovarian epithelial tumors] Liu A, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Dec; 24(6):366–8 (Eng. Abstr.) **(Chi)**

[Human squamous cell carcinoma regression antigen] Ito K, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec; 18(6):616–9 (7 ref.) **(Jpn)**

[Diagnostic utility of carcinoembryonic antigen, neuron-specific enolase and squamous cell carcinoma antigen in malignant pleural effusion] Sánchez de Cos Escuín J, et al. **An Med Interna** 1996 Aug;13(8):369–73 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Electrophoretic analysis of the "cross-class" interaction between novel inhibitory serpin, squamous cell carcinoma antigen-1 and cysteine proteinases. Nawata S, et al. **Electrophoresis** 1997 May;18(5):784–9

Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. Schick C, et al. **J Biol Chem** 1997 Jan 17;272(3):1849–55

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. Parkhurst MR, et al. **J Immunol** 1996 Sep 15;157(6):2539–48

PHYSIOLOGY

CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Osorio LM, et al. **Blood** 1997 Apr 15;89(8):2833–41

A function for the integrin alpha6beta4 in the invasive properties of colorectal carcinoma cells. Chao C, et al. **Cancer Res** 1996 Oct 15;56(20):4811–9

Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma. Asadullah K, et al. **J Invest Dermatol** 1997 May;108(5):743–7

Immunosuppressive activity of lymphocyte mitogenesis by breast cancer-associated p43. Reinerová M, et al. **Neoplasma** 1996;43(6):363–6

Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Heston WD. **Urology** 1997 Mar;49(3A Suppl):104–12

THERAPEUTIC USE

Glycosphingolipid antigens and cancer therapy. Hakomori S, et al. **Chem Biol** 1997 Feb;4(2):97–104 (47 ref.)

Immunotherapy of established murine tumors with large multivalent immunogen and cyclophosphamide. Mescher MF, et al. **J Immunother Emphasis Tumor Immunol** 1996 Mar;19(2):102–12

Update on active specific immunotherapy with melanoma vaccines. Conforti AM, et al. **J Surg Oncol** 1997 Sep; 66(1):55–64 (93 ref.)

Urotherapy for patients with cancer. Eldor J. **Med Hypotheses** 1997 Apr;48(4):309–15 (96 ref.)

[Cancer vaccine therapy using peptides derived from tumor-rejection antigens] Akiyoshi T. **Gan To Kagaku Ryoho** 1997 Mar;24(5):511–9 (38 ref.) (Eng. Abstr.) **(Jpn)**

URINE

The performance characteristics of the bladder tumour antigen test. Kirollos MM, et al. **Br J Urol** 1997 Jul; 80(1):30–4

Standardization of assay for cytokeratin-related tumor marker CYFRA21.1 in urine samples. Dittadi R, et al. **Clin Chem** 1996 Oct;42(10):1634–8

Urotherapy for patients with cancer. Eldor J. **Med Hypotheses** 1997 Apr;48(4):309–15 (96 ref.)

Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Leyh H, et al. **Urology** 1997 Jul; 50(1):49–53

Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Sarosdy MF, et al. **Urology** 1997 Sep; 50(3):349–53

ANTIGENS, NEOPLASM, VIRAL see **ANTIGENS, VIRAL, TUMOR**

ANTIGENS, PLATELET-SPECIFIC see **ANTIGENS, HUMAN PLATELET**

ANTIGENS, POLYOMAVIRUS TRANSFORMING

Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. Sheibani N, et al. **Cancer Lett** 1996 Oct 1; 107(1):45–52

Gene transfer into mammalian cells using histone-condensed plasmid DNA. Fritz JD, et al. **Hum Gene Ther** 1996 Aug 1;7(12):1395–404

Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system. Sabapathy KT, et al. **J Cell Biol** 1997 May 19;137(4):953–63

The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. Plymate SR, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3709–16

DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. Schirmbeck R, et al. **J Immunol** 1996 Oct 15;157(8):3550–8

SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics. Greenwood J, et al. **J Neuroimmunol** 1996 Dec;71(1-2):51–63

ANALYSIS

The development and characterisation of a SV40 T-antigen positive cell line of human hepatic origin. Harvey TJ, et al. **J Virol Methods** 1997 Apr;65(1):67–74

BIOSYNTHESIS

Transgenic mice bearing the polyomavirus large T antigen directed by 2.1 kb of the keratin 19 promoter develop bronchiolar papillary tumors with progression to lung adenocarcinomas. Lebel M, et al. **Cell Growth Differ** 1995 Dec;6(12):1591–600

Immunofluorescent study after transient transfection of myoblast cells with the plasmid PSV40-beta-globin. Pironcheva GL, et al. **Cytobios** 1996;86(347):243–6

The development and characterisation of a SV40 T-antigen positive cell line of human hepatic origin. Harvey TJ, et al. **J Virol Methods** 1997 Apr;65(1):67–74

Establishment and characterization of a line of adipose-derived human microvascular endothelial cells (HADMEC-5) transformed by simian virus 40 large T antigen expression: application to endotoxin research. Flynn JT, et al. **Shock** 1997 Jul;8(1):45–54

Production of active polyomavirus large T antigen in yeast Pichia pastoris. Peng YC, et al. **Virus Res** 1997 May; 49(1):41–7

CHEMISTRY

Six molecules of SV40 large T antigen assemble in a propeller-shaped particle around a channel. San Martín MC, et al. **J Mol Biol** 1997 Apr 25;268(1):15–20

Identification of a novel antiapoptotic functional domain in simian virus 40 large T antigen. Conzen SD, et al. **J Virol** 1997 Jun;71(6):4536–43

A DNA polymerase alpha accessory protein exhibits structural and functional similarities to SV40 large tumor antigen. Crouch E, et al. **Mutat Res** 1997 Mar 4; 374(1):109–23

Solution structure of the origin DNA-binding domain of SV40 T-antigen. Luo X, et al. **Nat Struct Biol** 1996 Dec; 3(12):1034–9

GENETICS

Preferential loss of heterozygosity of chromosome 7 loci in simian virus 40 t/T antigen-induced mouse hepatocellular

carcinomas does not involve H-ras mutations. Casola S, et al. **Acta Genet Med Gemellol (Roma)** 1996;45(1-2):221-5
Deregulation of hexose transporter expression in Caco-2 cells by ras and polyoma middle T oncogenes. Baron-Delage S, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G314-23
Tumor progression and cellular differentiation of pulmonary adenocarcinomas in SV40 large T antigen transgenic mice. Wikenheiser KA, et al. **Am J Respir Cell Mol Biol** 1997 Jun;16(6):713-23
Cisplatin-induced toxicity in immortalized renal cell lines established from transgenic mice harboring temperature sensitive SV40 large T-antigen gene. Hosoyamada M, et al. **Arch Toxicol** 1996;70(5):284-92
Deregulated expression and function of CFTR and Cl- secretion after activation of the Ras and Src/PyMT pathways in Caco-2 cells. Davenport SE, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):663-72
Transcriptional activation of the human c-myc gene by simian virus 40 large T antigen without binding to p53 and RB proteins in the transient expression system. Shimazu T, et al. **Biochem Biophys Res Commun** 1997 Jun 9; 235(1):153-7
Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the src or polyoma middle T oncogenes: cooperation between src and HGF/Met in invasion. Empereur S, et al. **Br J Cancer** 1997;75(2):241-50
Inhibition of proliferation and expression of T-antigen in SV40 large T-antigen gene-induced immortalized cells following transplantations. La Rosa FG, et al. **Cancer Lett** 1997 Feb 26;113(1-2):55-60
Development of thymic carcinoma in transgenic mice expressing SV40 T antigen. Park WY, et al. **Cancer Lett** 1996 Oct 22;107(2):293-300
Stepwise transformation of astrocytes by simian virus 40 large T antigen and epidermal growth factor receptor overexpression. Frisa PS, et al. **Cell Growth Differ** 1996 Feb;7(2):223-33
Expression of a viral oncoprotein during mammary gland development alters cell fate and function: induction of p53-independent apoptosis is followed by impaired milk protein production in surviving cells. Li M, et al. **Cell Growth Differ** 1996 Jan;7(1):3-11
Down-regulation of cytokeratin 14 gene expression by the polyoma virus middle T antigen is dependent on c-Src association but independent of full transformation in rat liver nonparenchymal epithelial cells. Royal I, et al. **Cell Growth Differ** 1996 Jun;7(6):737-43
A temperature-conditional mutant of simian virus 40 large T antigen requires serum to inhibit myogenesis and does not induce DNA synthesis in myotubes. Salvatori G, et al. **Cell Growth Differ** 1997 Feb;8(2):157-64
A retinal pigment epithelium-derived cell line from transgenic mouse harboring temperature-sensitive simian virus 40 large T-antigen gene. Kato K, et al. **Cell Struct Funct** 1996 Dec;21(6):459-68
Growth properties of neural cell lines immortalized with the tsA58 allele of SV40 large T antigen. Truckenmiller ME, et al. **Cell Transplant** 1997 May-Jun;6(3):231-8
Characterization of SV40-transfected cell strains from rabbit keratocytes. Barry-Lane PA, et al. **Cornea** 1997 Jan; 16(1):72-8
Suppression of gonadotropins inhibits gonadal tumorigenesis in mice transgenic for the mouse inhibin alpha-subunit promoter/simian virus 40 T-antigen fusion gene. Kananen K, et al. **Endocrinology** 1997 Aug;138(8):3521-31
Beta-adrenergic receptor activation promotes process outgrowth in an embryonic rat basal forebrain cell line and in primary neurons. Kwon JH, et al. **Eur J Neurosci** 1996 Oct;8(10):2042-55
Unscheduled DNA replication precedes apoptosis of photoreceptors expressing SV40 T antigen. Al-Ubaidi MR, et al. **Exp Eye Res** 1997 Apr;64(4):573-85
Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco-2 cells. Status of the pRb1 and pRb2 tumor suppressor gene products. Djelloul S, et al. **FEBS Lett** 1997 Apr 14;406(3):234-42
SV40 T1-mRNA trans-splicing and translation requires that the in vitro synthesized cRNA is capped before microinjection. Graessmann M, et al. **FEBS Lett** 1996 Sep 30;394(2):233-6
Neurocristopathy resembling neurofibromatosis type 1 in an NGF-SV40 transgenic line. Mazarakis ND, et al. **Genes Cells** 1996 Jan;1(1):125-37
Rat islet cell lines produced by retroviral transduction of SV40 T antigen [letter] Kaung HC, et al. **In Vitro Cell Dev Biol Anim** 1996 Apr;32(4):185-8
Establishment of permanent human endothelial cells achieved by transfection with SV40 large T antigen that retain typical phenotypical and functional characteristics. Moldovan F, et al. **In Vitro Cell Dev Biol Anim** 1996 Jan; 32(1):16-23
Immortalized glomerular endothelial cells transfected [letter] Nitta K. **In Vitro Cell Dev Biol Anim** 1996 Jan;32(1):5-7
Establishment of a novel chondrocyte-like cell line derived from transgenic mice harboring the temperature-sensitive simian virus 40 large T-antigen gene. Mataga N, et al. **J Bone Miner Res** 1996 Nov;11(11):1646-54
Establishment and characterization of conditionally immortalized cells from the mouse urogenital ridge. Capel B, et al. **J Cell Sci** 1996 May;109 (Pt 5):899-909
Conditional differentiation of heart- and smooth muscle-derived cells transformed by a temperature-sensitive mutant of SV40 T antigen. Jahn L, et al. **J Cell Sci** 1996 Feb;109 (Pt 2):397-407
Tissue culture adaptation of natural isolates of simian virus 40: changes occur in viral regulatory region but not in carboxy-terminal domain of large T-antigen. Lednicky JA, et al. **J Gen Virol** 1997 Jul;78 (Pt 7):1697-705
Fusigenic liposome-mediated DNA transfer into cardiac myocytes. Ellison KE, et al. **J Mol Cell Cardiol** 1996 Jul; 28(7):1385-99
Modification of the radiosensitivity of human cells to which simian virus 40 T-antigen was transfected. Yamagishi N, et al. **J Radiat Res (Tokyo)** 1995 Dec;36(4):239-47
The N terminus of hamster polyomavirus middle T antigen carries a determinant for specific activation of p59c-Fyn. Goutebroze L, et al. **J Virol** 1997 Feb;71(2):1436-42
Replication of simian virus 40 origin-containing DNA during infection with a recombinant Autographa californica multiple nuclear polyhedrosis virus expressing large T antigen. Martin DW, et al. **J Virol** 1997 Jan;71(1):501-6
Tiny T antigen: an autonomous polyomavirus T antigen amino-terminal domain. Riley MI, et al. **J Virol** 1997 Aug; 71(8):6068-74
Simian virus 40 T antigen can regulate p53-mediated transcription independent of binding p53. Rushton JJ, et al. **J Virol** 1997 Jul;71(7):5620-3
Characterization of immortalized rabbit corneal epithelial cells with SV40 large T antigen. Okamoto S, et al. **Jpn J Ophthalmol** 1995;39(4):323-33
The amino-terminal transforming region of simian virus 40 large T and small t antigens functions as a J domain. Srinivasan A, et al. **Mol Cell Biol** 1997 Aug;17(8):4761-73
The mouse inhibin alpha-subunit promoter directs SV40 T-antigen to Leydig cells in transgenic mice [published erratum appears in Mol Cell Endocrinol 1996 Aug 30;122(1):109-10] Kananen K, et al. **Mol Cell Endocrinol** 1996 May 31;119(2):135-46
Gonadectomy permits adrenocortical tumorigenesis in mice transgenic for the mouse inhibin alpha-subunit promoter/simian virus 40 T-antigen fusion gene: evidence for negative autoregulation of the inhibin alpha-subunit gene. Kananen K, et al. **Mol Endocrinol** 1996 Dec; 10(12):1667-77
3'-5' L-capped-antisense oligodeoxynucleotides targeted at the SV40 T-antigen gene: pharmacological and biological properties. Pettenazzo E, et al. **New Microbiol** 1996 Oct; 19(4):273-84
A polyoma-based episomal vector efficiently expresses exogenous genes in mouse embryonic stem cells. Camenisch G, et al. **Nucleic Acids Res** 1996 Oct 1;24(19):3707-13
A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Morris MC, et al. **Nucleic Acids Res** 1997 Jul 15;25(14):2730-6
Multiple neuroendocrine tumours in transgenic mice induced by c-kit-SV40 T antigen fusion genes. Bossé P, et al. **Oncogene** 1997 Jun 5;14(22):2661-70
Down-regulation of NF-kappaB activity and NF-kappaB p65 subunit expression by ras and polyoma middle T oncogenes in human colonic Caco-2 cells. Cadoret A, et al. **Oncogene** 1997 Apr 3;14(13):1589-600
Immortalization of neuro-endocrine cells from adrenal tumors arising in SV40 T-transgenic mice. Cairns LA, et al. **Oncogene** 1997 Jun 26;14(25):3093-8
Polyomavirus large T antigen-dependent DNA amplification. Stiegler P, et al. **Oncogene** 1997 Feb 27; 14(8):987-95
Characterization of human amniotic epithelial cells transformed with origin-defective SV40 T-antigen gene. Tohyama J, et al. **Tohoku J Exp Med** 1997 May; 182(1):75-82
The nuclear localization sequence of the SV40 T antigen promotes transgene uptake and expression in zebrafish embryo nuclei. Collas P, et al. **Transgenic Res** 1996 Nov; 5(6):451-8
SV40 and adenovirus may act as cocarcinogens by downregulating glutathione S-transferase expression. Sompayrac L. **Virology** 1997 Jun 23;233(1):130-5

IMMUNOLOGY

Characterization of neural cell lines derived from SV40 large T-induced primitive neuroectodermal tumors. Weggen S, et al. **Brain Pathol** 1997 Apr;7(2):731-9
Experimental expression in mice and spontaneous expression in human SLE of polyomavirus T-antigen. A molecular basis for induction of antibodies to DNA and eukaryotic transcription factors. Rekvig OP, et al. **J Clin Invest** 1997 Apr 15;99(8):2045-54
Altered susceptibility to tumor necrosis factor alpha-induced apoptosis of mouse cells expressing polyomavirus middle and small T antigens. Bergqvist A, et al. **J Virol** 1997 Jan; 71(1):276-83
p300 family members associate with the carboxyl terminus of simian virus 40 large tumor antigen. Lill NL, et al. **J Virol** 1997 Jan;71(1):129-37
Use of sequential immunoprecipitation to reveal discrete, separable populations of SV40 T-antigen binding to host cellular proteins. Ludlow JW. **J Virol Methods** 1996 May; 59(1-2):105-12

METABOLISM

Differential regulation by SV40 T-antigen binding at site I defines two distinct classes of nucleosome-free promoter. Kube D, et al. **Anat Rec** 1996 Jan;244(1):28-32
Evidence for multiple mechanisms for membrane binding and integration via carboxyl-terminal insertion sequences. Kim PK, et al. **Biochemistry** 1997 Jul 22;36(29):8873-82
The helix-loop-helix protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts. Hara E, et al. **Dev Genet** 1996;18(2):161-72
c-Jun stimulates origin-dependent DNA unwinding by polyomavirus large Tantigen. Ito K, et al. **EMBO J** 1996 Oct 15;15(20):5636-46
Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Plymate SR, et al. **Endocrinology** 1997 Apr;138(4):1728-35
Stress protein (hsp73)-mediated, TAP-independent processing of endogenous, truncated SV40 large T antigen for Db-restricted peptide presentation. Schirmbeck R, et al. **Eur J Immunol** 1997 Aug;27(8):2016-23
Intranuclear redistribution of SV40T, p53, and PML in a conditionally SV40T-immortalized cell line. Jiang WQ, et al. **Exp Cell Res** 1996 Dec 15;229(2):289-300
SV40 large T antigen binds to the TBP-TAF(I) complex SL1 and coactivates ribosomal RNA transcription. Zhai W, et al. **Genes Dev** 1997 Jun 15;11(12):1605-17
Immortalized gastric epithelial cell line GSM06 synthesizes hyaluronan under the influence of simian virus 40 large T-antigen expression. Goso Y, et al. **J Biochem (Tokyo)** 1997 Jul;122(1):96-100
Kinetic characterization of the human retinoblastoma protein bipartite nuclear localization sequence (NLS) in vivo and in vitro. A comparison with the SV40 large T-antigen NLS. Efthymiadis A, et al. **J Biol Chem** 1997 Aug 29; 272(35):22134-9
SV40 large tumor antigen nuclear import is regulated by the double-stranded DNA-dependent protein kinase site (serine 120) flanking the nuclear localization sequence. Xiao CY, et al. **J Biol Chem** 1997 Aug 29;272(35):22191-8
Evidence for a mechanism of demyelination by human JC virus: negative transcriptional regulation of RNA and protein levels from myelin basic protein gene by large tumor antigen in human glioblastoma cells. Devireddy LR, et al. **J Med Virol** 1996 Jul;49(3):205-11
Six molecules of SV40 large T antigen assemble in a propeller-shaped particle around a channel. San Martín MC, et al. **J Mol Biol** 1997 Apr 25;268(1):15-20
pp60c-src binding to polyomavirus middle T-antigen (MT) requires residues 185 to 210 of the MT sequence. Brewster CE, et al. **J Virol** 1997 Jul;71(7):5512-20
Functional interaction between the SH2 domain of Fyn and tyrosine 324 of hamster polyomavirus middle-T antigen. Dunant NM, et al. **J Virol** 1997 Jan;71(1):199-206
Purification of the simian virus 40 (SV40) T antigen DNA-binding domain and characterization of its interactions with the SV40 origin. Joo WS, et al. **J Virol** 1997 May;71(5):3972-85
Multimerization of polyomavirus middle-T antigen. Senften M, et al. **J Virol** 1997 Sep;71(9):6990-5
Induction of cyclins E and A in response to mitogen removal: a basic alteration associated with the arrest of differentiation of C2 myoblasts transformed by simian virus 40 large T antigen. Tedesco D, et al. **J Virol** 1997 Mar; 71(3):2217-24
Adding an Rb-binding site to an N-terminally truncated simian virus 40 T antigen restores growth to high cell density, and the T common region in trans provides anchorage-independent growth and rapid growth in low serum concentrations. Tevethia MJ, et al. **J Virol** 1997 Mar; 71(3):1888-96
The same sequence mediates activation of the human urokinase promoter by cAMP in mouse Sertoli cells and by SV40 large T antigen in COS cells. Grimaldi P, et al. **Mol Cell Endocrinol** 1996 Mar 25;117(2):167-73
Nuclear localization signal of SV40 T antigen directs import of plasmid DNA into sea urchin male pronuclei in vitro. Collas P, et al. **Mol Reprod Dev** 1996 Dec;45(4):431-8
Simian virus-40 large-T antigen binds p53 in human mesotheliomas [see comments] Carbone M, et al. **Nat Med** 1997 Aug;3(8):908-12. Comment in: Nat Med 1997 Aug;3(8):839-40.
The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas [see comments] De Luca A, et al. **Nat Med** 1997 Aug;3(8):913-6. Comment in: Nat Med 1997 Aug;3(8):839-40.
The SV40 large T-antigen helicase can unwind four stranded DNA structures linked by G-quartets. Baran N, et al. **Nucleic Acids Res** 1997 Jan 15;25(2):297-303
Identification of p53 unbound to T-antigen in human cells transformed by simian virus 40 T-antigen. O'Neill FJ, et al. **Oncogene** 1997 Feb 27;14(8):955-65
Localization of large-T oncoprotein during the embryonic and fetal development of transgenic mice. Miosge N, et al. **Teratology** 1996 Dec;54(6):278-83
Simian virus 40 large T antigen binds to topoisomerase I. Simmons DT, et al. **Virology** 1996 Aug 15;222(2):365-74
The elevation of cellular phosphatidic acid levels caused by polyomavirus transformation can be disassociated from the activation of phospholipase D. Vasudevan C, et al. **Virology** 1997 Jul 7;233(2):392-401
Polyomavirus large T-antigen binds the 'pRb related' protein

p130 through sequences in conserved region 2. Desjardins P, et al. **Virus Res** 1997 Jan;47(1):85–90

PHARMACOLOGY

ANP–stimulated cGMP egression in renal principal cells: abrogation of polarity by SV40 large T. Millul V, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):C1051–60

Inactivation of retinoblastoma family proteins by SV40 T antigen results in creation of a hepatocyte growth factor/scatter factor autocrine loop associated with an epithelial–fibroblastoid conversion and invasiveness. Martel C, et al. **Cell Growth Differ** 1997 Feb;8(2):165–78

Constitutive expression of glutamic acid decarboxylase (GAD) by striatal cell lines immortalized using the tsA58 allele of the SV40 large T antigen. Giordano M, et al. **Cell Transplant** 1996 Sep–Oct;5(5):563–75

IL–6 is an in vitro and in vivo autocrine growth factor for middle T antigen–transformed endothelial cells. Giraudo E, et al. **J Immunol** 1996 Sep 15;157(6):2618–23

Regulation of interleukin (IL)–1beta gene transcription induced by IL–1beta in rheumatoid synovial fibroblast–like cells, E11, transformed with simian virus 40 large T antigen. Abe M, et al. **J Rheumatol** 1997 Mar;24(3):420–9

Inactivation of pRB–related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen. Stubdal H, et al. **Mol Cell Biol** 1997 Sep;17(9):4979–90

Susceptibility to cell death induced by mutant SV40 T–antigen correlates with Purkinje neuron functional development. Feddersen RM, et al. **Mol Cell Neurosci** 1997 Jan;9(1):42–62

PHYSIOLOGY

Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. Shibata MA, et al. **Cancer Res** 1996 Nov 1;56(21):4894–903

Apoptosis and remodeling of mammary gland tissue during involution proceeds through p53–independent pathways. Li M, et al. **Cell Growth Differ** 1996 Jan;7(1):13–20

Cyclin–dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice. Magdaleno SM, et al. **Cell Growth Differ** 1997 Feb;8(2):145–55

Cellular ras gene activity is required for full neoplastic transformation by the large tumor antigen of SV40. Raptis L, et al. **Cell Growth Differ** 1997 Aug;8(8):891–901

T antigen of human papovavirus JC stimulates transcription of the POU domain factor Tst–1/Oct6/SCIP. Renner K, et al. **DNA Cell Biol** 1996 Dec;15(12):1057–62

Expression of SV40 large T antigen stimulates reversion of a chromosomal gene duplication in human cells. Cheng RZ, et al. **Exp Cell Res** 1997 Aug 1;234(2):300–12

DnaJ/hsp40 chaperone domain of SV40 large T antigen promotes efficient viral DNA replication. Campbell KS, et al. **Genes Dev** 1997 May 1;11(9):1098–110

The role of the Shc phosphotyrosine interaction/phosphotyrosine binding domain and tyrosine phosphorylation sites in polyoma middle T antigen–mediated cell transformation. Blaikie PA, et al. **J Biol Chem** 1997 Aug 15;272(33):20671–7

Loss of T–antigen sequences allows SV40–transformed human cells in crisis to acquire a senescent–like phenotype. Rubelj I, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep; 52(5):B229–34

Phosphorylation sites in polyomavirus large T antigen that regulate its function in viral, but not cellular, DNA synthesis. Chatterjee A, et al. **J Virol** 1997 Sep;71(9):6472–8

Cyclin–dependent kinase regulation of the replication functions of polyomavirus large T antigen. Li H, et al. **J Virol** 1997 Sep;71(9):6479–85

Transformation and tumorigenic properties of a mutant polyomavirus containing a middle T antigen defective in Shc binding. Yi X, et al. **J Virol** 1997 Sep;71(9):6279–86

An old acquaintance resurfaces in human mesothelioma [news; comment] Wiman KG, et al. **Nat Med** 1997 Aug; 3(8):839–40. Comment on: Nat Med 1997 Aug;3(8):908–12. Comment on: Nat Med 1997 Aug;3(8):913–6.

Polyomavirus large T antigen overcomes p53 dependent growth arrest. Doherty J, et al. **Oncogene** 1997 Apr 24; 14(16):1923–31

Suppression of interleukin–1beta converting enzyme (ICE)–induced apoptosis by SV40 large T antigen. Jung YK, et al. **Oncogene** 1997 Mar 13;14(10):1207–14

A role for the small GTPase Rac in polyomavirus middle–T antigen–mediated activation of the serum response element and in cell transformation. Urich M, et al. **Oncogene** 1997 Mar 13;14(10):1235–41

Co–operation of simian virus 40 T antigen and insulin receptor substrate–1 in protection from apoptosis induced by interleukin–3 withdrawal. Zhou–Li F, et al. **Oncogene** 1997 Aug 18;15(8):961–70

Oncogenic H–ras stimulates tumor angiogenesis by two distinct pathways. Arbiser JL, et al. **Proc Natl Acad Sci U S A** 1997 Feb 4;94(3):861–6

Polyomavirus large T antigen zinc finger is not required for efficient cellular immortalization of primary rat embryo fibroblasts. Pilon AA, et al. **Virus Res** 1996 Dec; 46(1–2):171–5

ANTIGENS, PROTOZOAN

Transfer of the Gal/GalNAc–specific amebic lectin from trophozoites to frozen sections of human colon mucosa. Leroy A, et al. **Arch Med Res** 1997;28 Spec No:170–2

Mapping of the linear antigenic determinants of the Leishmania infantum hsp70 recognized by leishmaniasis sera. Quijada L, et al. **Immunol Lett** 1996 Sep;52(2–3):73–9

Montenegro skin test—evaluation of the composition and stability of the antigen preparation. da Costa CA, et al. **Mem Inst Oswaldo Cruz** 1996 Mar–Apr;91(2):193–4

A recombinant circumsporozoite protein vaccine against malaria [letter; comment] Bloom BR. **N Engl J Med** 1997 Jun 12;336(24):1760; discussion 1760–1. Comment on: N Engl J Med 1997 Jan 9;336(2):86–91.

ADMINISTRATION & DOSAGE

The flagellar fraction of Trypanosoma cruzi depleted of an immunosuppressive antigen enhances protection to infection and elicits spontaneous T cell responses. Hansen DS, et al. **Parasite Immunol** 1996 Dec;18(12):607–15

ANALYSIS

Toxoplasma lymphadenitis. Analysis of cytologic and histopathologic criteria and correlation with serologic tests. Jayaram N, et al. **Acta Cytol** 1997 May–Jun;41(3):653–8

The evaluation of a dipstick test for Plasmodium falciparum in mining areas of Venezuela. Caraballo A, et al. **Am J Trop Med Hyg** 1996 Nov;55(5):482–4

Toxoplasma gondii antigen recognition by serum immunoglobulins M, G, and A of queens and their neonatally infected kittens. Cannizzo KL, et al. **Am J Vet Res** 1996 Sep;57(9):1327–30

Early in vivo interaction of Entamoeba histolytica trophozoites with hepatic parenchymal and inflammatory cells of hamster. Ventura–Juarez J, et al. **Arch Med Res** 1997;28 Spec No:211–3

Development of monoclonal antibodies directed against cysts of Entamoeba histolytica and Entamoeba dispar. Walderich B, et al. **Arch Med Res** 1997;28 Spec No:147–9

Immunologic and molecular characteristics of Encephalitozoon–like microsporidia isolated from humans and rabbits indicate that Encephalitozoon cuniculi is a zoonotic parasite. Deplazes P, et al. **Clin Infect Dis** 1996 Mar;22(3):557–9

Evaluation of an antigen–capture enzyme immunoassay for detection of Entamoeba histolytica in stool samples. Jelinek T, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep; 15(9):752–5

A novel 70–kDa Triton X–114–soluble antigen of Plasmodium falciparum that contains interspecies–conserved epitopes. Ma HW, et al. **Exp Parasitol** 1996 Aug;83(3):322–34

Naegleria fowleri: location of a specific antigen using an immunogold labeling method. Sparagano O, et al. **Exp Parasitol** 1997 Mar;85(3):299–302

Antigenic variation and immune evasion in Plasmodium falciparum malaria. Reeder JC, et al. **Immunol Cell Biol** 1996 Dec;74(6):546–54 (103 ref.)

Antigenic differences between axenic amastigotes & promastigotes of Leishmania donovani. Chattopadhayay R, et al. **Indian J Med Res** 1996 Dec;104:349–54

Immunoblot assay using excreted–secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute, and chronic Chagas' disease. Umezawa ES, et al. **J Clin Microbiol** 1996 Sep;34(9):2143–7

Distribution of epitopes of Trypanosoma cruzi amastigotes during the intracellular life cycle within mammalian cells. Barros HC, et al. **J Eukaryot Microbiol** 1997 Jul–Aug; 44(4):332–44

A single–step immunochromatographic test for the detection of Entamoeba histolytica antigen in stool samples. Bhaskar S, et al. **J Immunol Methods** 1996 Sep 27;196(2):193–8

Plasmodium falciparum and P. vivax circumsporozoite proteins in anophelines (Diptera: Culicidae) collected in eastern Thailand. Frances SP, et al. **J Med Entomol** 1996 Nov;33(6):990–1

Evaluation of different techniques in the diagnosis of Toxoplasma encephalitis. Rodriguez JC, et al. **J Med Microbiol** 1997 Jul;46(7):597–601

Western blot and immunofluorescence analysis of a human isolate of Encephalitozoon cuniculi established in culture from the urine of a patient with AIDS. Croppo GP, et al. **J Parasitol** 1997 Feb;83(1):66–9

Characterization of some Theileria parva stocks from Zambia using monoclonal antibodies. Nambota AM, et al. **J Vet Med Sci** 1997 Jan;59(1):1–4

Analysis of antigenic domain of GST fused major surface protein (p30) fragments of Toxoplasma gondii. Nam HW, et al. **Korean J Parasitol** 1996 Jun;34(2):135–41

In vitro biosynthesis and in vivo processing of the major microneme antigen of Sarcocystis muris cyst merozoites. Klein H, et al. **Parasitol Res** 1996;82(5):468–74

Kinetics study of the localization and quantitation of target antigens of immunoglobulin a antibodies in acquired and congenital toxoplasmosis. Kumolosasi E, et al. **Parasitol Res** 1996;82(5):402–9

Comparison of oocyst shedding and the serum immune response to Cryptosporidium parvum in cattle and pigs. Quilez J, et al. **Parasitol Res** 1996;82(6):529–34

Application of local products R–phycoerythrin and monoclonal antibody as a fluorescent antibody probe to detect Entamoeba histolytica trophozoites. Thammapalerd N, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun;27(2):297–303

An indirect enzyme–linked immunoassay (ELISA) for demonstration of antibodies to Neospora caninum in serum and milk of cattle. Björkman C, et al. **Vet Parasitol** 1997 Feb;68(3):251–60

Collagen cross–reactive antigen of Sarcocystis cruzi. Inoue N, et al. **Vet Parasitol** 1996 May;63(1–2):17–23

Nonimmunological factors affecting the release of excreted/secreted antigens from Toxoplasma gondii cysts. Reiter–Owona I, et al. **Zentralbl Bakteriol** 1996 Jul; 284(2–3):378–89

[Immunological properties of the 30 kDa antigen of toxoplasma gondii] Shin DW, et al. **Korean J Parasitol** 1997 Mar;35(1):55–62 (Eng. Abstr.) **(Kor)**

BIOSYNTHESIS

Transfection of Entamoeba dispar: inhibition of expression of the lysine–rich 30 kDa surface antigen by the transcription of its antisense RNA. Alon RN, et al. **Arch Med Res** 1997;28 Spec No:52–5

Leishmania–infected macrophages sequester endogenously synthesized parasite antigens from presentation to CD4+ T cells. Kima PE, et al. **Eur J Immunol** 1996 Dec; 26(12):3163–9

Plasmodium falciparum: altered expressions of erythrocyte membrane–associated antigens during antigenic variation. Le Scanf C, et al. **Exp Parasitol** 1997 Feb;85(2):135–48

Expression and immunogenicity of the C–terminus of a major blood–stage surface protein of Plasmodium vivax, Pv200(19), secreted from Saccharomyces cerevisiae. Kaslow DC, et al. **Immunol Lett** 1996 Jul;51(3):187–9

Babesia bovis: biosynthesis and localisation of 12D3 antigen in bovine erythrocytes. Harper GS, et al. **Int J Parasitol** 1996 Nov;26(11):1255–62

A Trypanosoma cruzi polyantigen obtained by gene fusion: its expression in Staphylococcus aureus and rapid purification. Moreno JI. **Protein Expr Purif** 1996 Nov; 8(3):332–40

Leishmania (viannia) panamensis–Induced cutaneous leishmaniasis in susceptible and resistant mouse strains. Goto H, et al. **Rev Inst Med Trop Sao Paulo** 1995 Nov–Dec; 37(6):475–81

Induction of anti–malarial transmission blocking immunity with a recombinant ookinete surface antigen of Plasmodium berghei produced in silkworm larvae using the baculovirus expression vector system. Matsuoka H, et al. **Vaccine** 1996 Feb;14(2):120–6

[Serologic diagnosis of human african trypanosomiasis caused by Trypanosoma brucei gambiense. 1—Production and use of rough antigens in ELISA and latex agglutination tests] Diallo PB, et al. **Bull Soc Pathol Exot** 1996;89(4):262–8 (Eng. Abstr.) **(Fre)**

BLOOD

Human chagasic disease is not associated with an antiheart humoral response. Baig MK, et al. **Am J Cardiol** 1997 Apr 15;79(8):1135–7

A time–course study of circulating antigen and parasite–specific antibody in cotton rats infected with Leishmania donovani. Azazy AA, et al. **Ann Trop Med Parasitol** 1997 Mar;91(2):153–62

Identification of A 35 kDa glycoprotein from the outer membrane of Entamoeba histolytica by sera from patients with amebic liver abscess and with mouse monoclonal antibody. Agundis–Mata C, et al. **Arch Med Res** 1997;28 Spec No:264–6

Serologic characterization of Entamoeba histolytica asymptomatic carriers from a community of Puebla state, Mexico. Sánchez–Guillén MC, et al. **Arch Med Res** 1997; 28 Spec No:322–4

Detection of Trypanosoma brucei, T. congolense and T. vivax infections in cattle, sheep and goats using latex agglutination. Kayang BB, et al. **Int J Parasitol** 1997 Jan; 27(1):83–7

Not peripheral parasitaemia but the level of soluble parasite antigen in plasma correlates with vaccine efficacy against Babesia canis. Schetters TP, et al. **Parasite Immunol** 1996 Jan;18(1):1–6

[Detection of blood antigens in Trypanosoma brucei brucei experimental infection in Boru, Lagoon cattle and Boro white zebus] Doko A, et al. **Rev Elev Med Vet Pays Trop** 1996;49(3):207–11 (Eng. Abstr.) **(Fre)**

[Allergic granulomatous angiitis in a patient with positive reactions on serological tests for parasite antigens] Kobayashi A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Oct; 34(10):1130–5 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Variations in the C–terminal repeats of the knob–associated histidine–rich protein of Plasmodium falciparum. Hirawake H, et al. **Biochim Biophys Acta** 1997 Apr 12;1360(2):105–8

Molecular characterization of a protozoan parasite target antigen recognized by nonspecific cytotoxic cells. Jaso–Friedmann L, et al. **Cell Immunol** 1997 Mar 15; 176(2):93–102

The disulfide bond structure of Plasmodium apical membrane

antigen-1. Hodder AN, et al. **J Biol Chem** 1996 Nov 15; 271(46):29446-52

Molecular structure of the "low molecular weight antigen" of Toxoplasma gondii: a glucose alpha 1-4 N-acetylgalactosamine makes free glycosyl-phosphatidylinositols highly immunogenic. Striepen B, et al. **J Mol Biol** 1997 Mar 7;266(4):797-813

Predominance of H-2d- and H-2k-restricted T-cell epitopes in the highly repetitive Plasmodium falciparum antigen Pf332. Ahlborg N, et al. **Mol Immunol** 1997 Apr; 34(5):379-89

Evidence for the existence of ganglioside molecules in the antigen of Entamoeba histolytica. Sorice M, et al. **Parasite Immunol** 1996 Mar;18(3):133-7

DIAGNOSTIC USE

Specific serodiagnosis of human leishmaniasis with recombinant Leishmania P2 acidic ribosomal proteins. Soto M, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):387-91

Use of Leishmania major derived leishmanin for skin test surveys of visceral leishmaniasis in Ethiopia. Hailu A, et al. **East Afr Med J** 1997 Jan;74(1):41-5

Dog-DAT: a direct agglutination test using stabilized, freeze-dried antigen for the serodiagnosis of canine visceral leishmaniasis. Oskam L, et al. **FEMS Immunol Med Microbiol** 1996 Dec 31;16(3-4):235-9

Differentiation of Entamoeba histolytica and Entamoeba dispar in cyst-passers by immunoblot. Lee M, et al. **Korean J Parasitol** 1996 Dec;34(4):247-54

Production of a recombinant fusion protein of Sarcocystis tenella and evaluation of its diagnostic potential in an ELISA. Mertens CM, et al. **Vet Parasitol** 1996 Oct 25; 65(3-4):185-97

[Serologic diagnosis of human african trypanosomiasis caused by Trypanosoma brucei gambiense. 1--Production and use of rough antigens in ELISA and latex agglutination tests] Diallo PB, et al. **Bull Soc Pathol Exot** 1996;89(4):262-8 (Eng. Abstr.) **(Fre)**

GENETICS

Limited spatial clustering of individual Plasmodium falciparum alleles in field isolates from coastal Kenya. Kyes S, et al. **Am J Trop Med Hyg** 1997 Aug;57(2):205-15

Identification and location of the cell-binding domain in the 112 kDa adhesin gene of Entamoeba histolytica. García-Rivera G, et al. **Arch Med Res** 1997;28 Spec No:164-5

Biodiversity in Toxoplasma gondii. Dardé ML. **Curr Top Microbiol Immunol** 1996;219:27-41 (27 ref.)

The trypanosoma brucei autoantigen I/6 is an internally repetitive cytoskeletal protein. Detmer E, et al. **Eur J Cell Biol** 1997 Apr;72(4):378-84

Localization of ribosomal RNA and Pbs21-mRNA in the sexual stages of Plasmodium berghei using electron microscope in situ hybridization. Shaw MK, et al. **Eur J Cell Biol** 1996 Nov;71(3):270-6

Cloning of genes and expression and antigenicity analysis of the Leishmania infantum KMP-11 protein. Berberich C, et al. **Exp Parasitol** 1997 Jan;85(1):105-8

Plasmodium falciparum: allelic variation in the merozoite surface protein 1 gene in wild isolates from southern Vietnam. Kaneko O, et al. **Exp Parasitol** 1997 May; 86(1):45-57

Plasmodium chabaudi: cDNA of Pc96, a protective antigen associated with the erythrocyte membrane of infected erythrocytes. Wanidworanun C, et al. **Exp Parasitol** 1997 Jan;85(1):92-8

Crossreactions and sequence homologies between recombinant polypeptides from Leishmania aethiopica and human IgG and IgM. Osland A, et al. **FEMS Immunol Med Microbiol** 1997 Jan;17(1):11-9

Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Taylor RR, et al. **Int Immunol** 1996 Jun;8(6):905-15

Analysis of immunodominant piroplasm surface antigen alleles in mixed populations of Theileria sergenti and T. buffeli. Kubota S, et al. **Int J Parasitol** 1996 Jul;26(7):741-7

Molecular characterization of the D surface protein gene subfamily in Paramecium primaurelia. Bourgain-Guglielmetti FM, et al. **J Eukaryot Microbiol** 1996 Jul-Aug;43(4):303-13

Molecular characterization of the D surface protein gene subfamily in Paramecium tetraurelia. Breuer M, et al. **J Eukaryot Microbiol** 1996 Jul-Aug;43(4):314-22

Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. Webb JR, et al. **J Immunol** 1996 Dec 1;157(11):5034-41

The merozoite surface protein 2 (MSP2) gene of Plasmodium falciparum from a Thai isolate. Jongwutiwes S, et al. **J Med Assoc Thai** 1996 Dec;79 Suppl 1:S33-9

The variation of Pf155/RESA gene in field isolates of Plasmodium falciparum from Thailand. Sueblinvong T, et al. **J Med Assoc Thai** 1996 Dec;79 Suppl 1:S40-8

Plasmodium falciparum asparagine and aspartate rich protein 2 is an evolutionary conserved protein whose repeats identify a new family of parasite antigens. Barale JC, et al. **Mol Biochem Parasitol** 1997 Aug;87(2):169-81

Evidence for distinct prototype sequences within the Plasmodium falciparum Pf60 multigene family. Bonnefoy S, et al. **Mol Biochem Parasitol** 1997 Jul;87(1):1-11

Is point mutagenesis a mechanism for antigenic variation in Trypanosoma brucei? Graham VS, et al. **Mol Biochem Parasitol** 1996 Jul;79(1):35-45

Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum. Hafalla JC, et al. **Mol Biochem Parasitol** 1997 Jul;87(1):97-9

Compartmentalization of genes coding for immunodominant antigens to fragile chromosome ends leads to dispersed subtelomeric gene families and rapid gene evolution in Plasmodium falciparum. Hernandez-Rivas R, et al. **Mol Biochem Parasitol** 1996 Jun;78(1-2):137-48

Dimorphic sequences of rap-1 genes encode B and CD4+ T helper lymphocyte epitopes in the Babesia bigemina rhoptry associated protein-1. Hötzel I, et al. **Mol Biochem Parasitol** 1996 Oct 18;81(1):89-99

Limited RAP-1 sequence diversity in field isolates of Plasmodium falciparum. Howard RF, et al. **Mol Biochem Parasitol** 1996 Apr;77(1):95-8

Sequence analysis of the apical membrane antigen-1 genes (ama-1) of Plasmodium yoelii yoelii and Plasmodium berghei. Kappe SH, et al. **Mol Biochem Parasitol** 1996 Jun; 78(1-2):279-83

Identification and cloning of a locus of serine repeat antigen (sera)-related genes from Plasmodium vivax. Kiefer MC, et al. **Mol Biochem Parasitol** 1996 Jun;78(1-2):55-65

Cloning and characterization of a gene encoding a novel immunodominant antigen of Trypanosoma cruzi. Lesénéchal M, et al. **Mol Biochem Parasitol** 1997 Aug; 87(2):193-204

Conservation of structure and function of the erythrocyte-binding domain of Plasmodium falciparum EBA-175. Liang H, et al. **Mol Biochem Parasitol** 1997 Feb; 84(2):241-5

Identification of two alleles in the GRA4 locus of Toxoplasma gondii determining a differential epitope which allows discrimination of type I versus type II and III strains. Meisel R, et al. **Mol Biochem Parasitol** 1996 Oct 30;81(2):259-63

Sequence diversity in the amino-terminal 47 kDa fragment of the Plasmodium falciparum serine repeat antigen. Morimatsu K, et al. **Mol Biochem Parasitol** 1997 Jun; 86(2):249-54

Characterization of the Trypanosoma brucei homologue of a Trypanosoma cruzi flagellum-adhesion glycoprotein. Nozaki T, et al. **Mol Biochem Parasitol** 1996 Nov 25; 82(2):245-55

A cloned gene of Cryptosporidium parvum encodes neutralization-sensitive epitopes. Perryman LE, et al. **Mol Biochem Parasitol** 1996 Oct 1;80(2):137-47

Cloning, sequencing and expression of a cDNA encoding an antigen from the Myxosporean parasite causing the proliferative kidney disease of salmonid fish. Saulnier D, et al. **Mol Biochem Parasitol** 1996 Dec 20;83(2):153-61

Primary structure of a novel ookinete surface protein from Plasmodium berghei. Tsuboi T, et al. **Mol Biochem Parasitol** 1997 Mar;85(1):131-4

Cloning and characterization of heat shock protein DnaJ homologues from Plasmodium falciparum and comparison with ring infected erythrocyte surface antigen. Watanabe J. **Mol Biochem Parasitol** 1997 Sep;88(1-2):253-8

A group of Giardia lamblia variant-specific surface protein (VSP) genes with nearly identical 5' regions. Yang Y, et al. **Mol Biochem Parasitol** 1995 Dec;75(1):69-74

A single gene copy merozoite surface antigen and immune evasion? O'Dea KP, et al. **Parasite Immunol** 1996 Apr; 18(4):165-72

Identification and characterization of human B-cell epitopes in recombinant antigens of Leishmania aethiopica. Osland A, et al. **Parasite Immunol** 1996 May;18(5):265-9

Differential antibody recognition of FC27-like Plasmodium falciparum merozoite surface protein MSP2 antigens which lack 12 amino acid repeats. Ranford-Cartwright LC, et al. **Parasite Immunol** 1996 Aug;18(8):411-20

Primary structure of a BiP homologue in Eimeria spp. Dunn PP, et al. **Parasitol Res** 1996;82(6):566-8

Comparison of genetic groups determined by molecular and immunological analyses of Giardia isolated from animals and humans in Switzerland and Australia. Ey PL, et al. **Parasitol Res** 1996;82(1):52-60

High prevalence of the third form of merozoite surface protein-1 in Plasmodium falciparum in asymptomatic children in Gabon. Ntoumi F, et al. **Trans R Soc Trop Med Hyg** 1996 Nov-Dec;90(6):701-2

Production of recombinant SERA proteins of Plasmodium falciparum in Escherichia coli by using synthetic genes. Sugiyama T, et al. **Vaccine** 1996 Aug;14(11):1069-76

IMMUNOLOGY

Recognition of an immunogenetically selected Trypanosoma cruzi antigen by seropositive chagasic human sera. Aguillón JC, et al. **Acta Trop** 1997 Feb;63(2-3):159-66

Epitopes common to Trypanosoma cruzi and mammalian tissues are recognized by sera from Chagas' disease patients: prognosis value in Chagas disease. Laucella SA, et al. **Acta Trop** 1996 Dec 16;62(3):151-62

Trypanosoma cruzi and mammalian heart cross-reactive antigens. Laucella SA, et al. **Acta Trop** 1996 May; 61(3):223-38

Cell surface molecules of pathogenic and nonpathogenic Entamoeba histolytica and their relation to virulence. Mirelman D, et al. **Adv Exp Med Biol** 1996;408:225-7 (13 ref.)

Protective immunity induced in squirrel monkeys with a multiple antigen construct against the circumsporozoite protein of Plasmodium vivax. Collins WE, et al. **Am J Trop Med Hyg** 1997 Feb;56(2):200-10

Antigenic components of partially purified antigens of Leishmania donovani infantum recognized by sera from dogs with asymptomatic or active visceral leishmaniasis. Da Costa JM, et al. **Am J Trop Med Hyg** 1996 Nov; 55(5):511-5

Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Higuchi MD, et al. **Am J Trop Med Hyg** 1997 May;56(5):485-9

Immunogenicity and efficacy trials with Plasmodium falciparum recombinant antigens identified as targets of opsonizing antibodies in the naive squirrel monkey Saimiri sciureus. Perraut R, et al. **Am J Trop Med Hyg** 1997 Mar; 56(3):343-50

Immunogenicity of the nonrepetitive regions of the circumsporozoite protein of Plasmodium knowlesi. Sharma S, et al. **Am J Trop Med Hyg** 1996 Dec;55(6):635-41

Evaluation of immunogenicity of an oral Salmonella vaccine expressing recombinant Plasmodium berghei merozoite surface protein-1. Toebe CS, et al. **Am J Trop Med Hyg** 1997 Feb;56(2):192-9

Humoral response to defined Plasmodium falciparum antigens in cerebral and uncomplicated malaria and their relationship to parasite genotype. Al-Yaman F, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):430-5

Human interleukin-12 upregulates proliferation and interferon-gamma production by parasite antigen-stimulated Th cell clones and gamma/delta T cells of cattle. Brown WC, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:321-4

Both epidermal growth factor-like domains of the merozoite surface protein-1 from Plasmodium yoelii are required for protection from malaria. Calvo PA, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:260-2

Molecular mimicry in human aortic aneurysmal diseases. Ozsvath KJ, et al. **Ann N Y Acad Sci** 1996 Nov 18; 800:288-93

Synthetic polypeptides corresponding to the non-repeat regions from the circumsporozoite protein of Plasmodium falciparum: recognition by human T-cells and immunogenicity in owl monkeys. López JA, et al. **Ann Trop Med Parasitol** 1997 Apr;91(3):253-65

Eimeria tenella: localisation of rhoptry antigens during parasite-host cell interactions by a rhoptry-specific monoclonal antibody in PCKC culture. Greif G, et al. **Appl Parasitol** 1996 Dec;37(4):253-9

Cross reactivity of mouse monoclonal antibodies to glycoprotein with two different antigens from the outer membrane of Entamoeba histolytica. Agundis-Mata C, et al. **Arch Med Res** 1997;28 Spec No:239-41

A new isoform of the serine-rich E. histolytica protein recognized by human secretory IgA antibodies from patients with intestinal amebiasis. Carrero JC, et al. **Arch Med Res** 1997;28 Spec No:259-61

Identification of an idiotype on mouse monoclonal antibody directed to a 35 kDa glycoprotein from Entamoeba histolytica. Chávez-Rueda K, et al. **Arch Med Res** 1997; 28 Spec No:242-4

Vaccination of different strains of mice against cutaneous leishmaniosis: usefulness of membrane antigens encapsulated into liposomes by intraperitoneal and subcutaneous administration. Lezama-Dávila CM. **Arch Med Res** 1997 Spring;28(1):47-53

Structure and function of the galactose/N-acetyl D-galactosamine inhibitable adhesin of Entamoeba dispar. Mann BJ, et al. **Arch Med Res** 1997;28 Spec No:168-9

Preliminary study of the 220 kDa lectin-elicited immune response in hamster: possible vaccine candidate. Martínez-Gómez F, et al. **Arch Med Res** 1997;28 Spec No:267-8

Rapid isolation of lymphocytes of the large and small intestine to assess anti Entamoeba histolytica immune response. Moreno Fierros L, et al. **Arch Med Res** 1997;28 Spec No:253-5

The galactose adherence lectin of Entamoeba histolytica activates primed macrophages for amebicidal activity mediated by nitric oxide. Seguin R, et al. **Arch Med Res** 1997;28 Spec No:228-9

Frequency of HLA in adult E.histolytica/E.dispar cyst passer population [published erratum appears in Arch Med Res 1997 Summer;28(2):313] Valdez-Martinez E, et al. **Arch Med Res** 1997;28 Spec No:248-9

Theileria annulata "superantigen" activity--TCB usage by responding bovine CD4+ cells from uninfected donors. Campbell JD, et al. **Biochem Soc Trans** 1997 May; 25(2):277S

Evanescent wave fibre optic sensor for detection of L. donovani specific antibodies in sera of kala azar patients. Nath N, et al. **Biosens Bioelectron** 1997;12(6):491-8

In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Angus BJ, et al. **Blood** 1997 Sep 1;90(5):2037-40

Subunit vaccines for complex tick-borne pathogens: dream or reality? [editorial; comment] Morrison WI. **Br Vet J** 1996 Nov;152(6):617-9. Comment on: Br Vet J 1996 Nov;152(6):621-39.

Prospects for subunit vaccines against tick-borne diseases

[see comments] Musoke AJ, et al. **Br Vet J** 1996 Nov; 152(6):621–39 (125 ref.). Comment in: Br Vet J 1996 Nov;152(6):617–9.

Molecular characterization of a protozoan parasite target antigen recognized by nonspecific cytotoxic cells. Jaso–Friedmann L, et al. **Cell Immunol** 1997 Mar 15; 176(2):93–102

Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Murata K, et al. **Cell Immunol** 1996 Oct 10;173(1):96–107

Identification of the C–terminal region of 70 kDa heat shock protein from Leishmania (Viannia) braziliensis as a target for the humoral immune response [published erratum appears in Cell Stress Chaperones 1996 Dec;1(4):263] Amorim AG, et al. **Cell Stress Chaperones** 1996 Sep; 1(3):177–87

Serological response to in vitro–shed antigen(s) of Trittrichomonas foetus in cattle. Bondurant RH, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):432–7

Specific serodiagnosis of human leishmaniasis with recombinant Leishmania P2 acidic ribosomal proteins. Soto M, et al. **Clin Diagn Lab Immunol** 1996 Jul;3(4):387–91

Immune response to Plasmodium falciparum antigens in Cameroonian primigravidae: evolution after delivery and during second pregnancy. Fievet N, et al. **Clin Exp Immunol** 1997 Mar;107(3):462–7

Characterization of the antigenic determinants of the Leishmania infantum histone H3 recognized by antibodies elicited during canine visceral leishmaniasis. Soto M, et al. **Clin Exp Immunol** 1996 Dec;106(3):454–61

Intragastric immunization of rats with Entamoeba histolytica trophozoites induces cecal mucosal IgE, eosinophilic infiltration, and type I hypersensitivity. Navarro–García F, et al. **Clin Immunol Immunopathol** 1997 Mar;82(3):221–9

Toxoplasma proteins recognized by protective T lymphocytes. Fischer HG, et al. **Curr Top Microbiol Immunol** 1996;219:175–82

Serological recognition of Toxoplasma gondii cyst antigens. Smith JE, et al. **Curr Top Microbiol Immunol** 1996; 219:67–73 (27 ref.)

Lipopeptide immunization without adjuvant induces potent and long–lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. BenMohamed L, et al. **Eur J Immunol** 1997 May;27(5):1242–53

Leishmania–infected macrophages sequester endogenously synthesized parasite antigens from presentation to CD4+ T cells. Kima PE, et al. **Eur J Immunol** 1996 Dec; 26(12):3163–9

Antigen presentation by Leishmania mexicana–infected macrophages: activation of helper T cells by a model parasite antigen secreted into the parasitophorous vacuole or expressed on the amastigote surface. Wolfram M, et al. **Eur J Immunol** 1996 Dec;26(12):3153–62

T–cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Coutinho SG, et al. **Exp Parasitol** 1996 Nov;84(2):144–55

Plasmodium falciparum: an epitope within a highly conserved region of the 47–kDa amino–terminal domain of the serine repeat antigen is a target of parasite–inhibitory antibodies. Fox BA, et al. **Exp Parasitol** 1997 Feb;85(2):121–34

Plasmodium falciparum: gp195 tripeptide repeat–specific monoclonal antibody inhibits parasite growth in vitro. Locher CP, et al. **Exp Parasitol** 1996 Oct;84(1):74–83

Plasmodium yoelii: peptide immunization induces protective CD4+ T cells against a previously unrecognized cryptic epitope of the circumsporozoite protein. Takita–Sonoda Y, et al. **Exp Parasitol** 1996 Nov;84(2):223–30

Leishmania major: targeting IL–4 in successful immunomodulation of murine infection. Wakil AE, et al. **Exp Parasitol** 1996 Nov;84(2):214–22

Plasmodium chabaudi: immunogenicity of a highly antigenic glutamate–rich protein. Wiser MF, et al. **Exp Parasitol** 1997 Jan;85(1):43–54

IgG1 and IgG2 antibody responses to Plasmodium falciparum exoantigens correlate inversely and positively, respectively, to the number of malaria attacks. Chumpitazi BF, et al. **FEMS Immunol Med Microbiol** 1996 Jun;14(2–3):151–8

Crossreactions and sequence homologies between recombinant polypeptides from Leishmania aethiopica and human IgG and IgM. Osland A, et al. **FEMS Immunol Med Microbiol** 1997 Jan;17(1):11–9

IL–12 enhances proliferation of peripheral blood mononuclear cells from Chagas' disease patients to Trypanosoma cruzi antigen. de Barros–Mazon S, et al. **Immunol Lett** 1997 Jun 1;57(1–3):39–45

Expression and immunogenicity of the C–terminus of a major blood–stage surface protein of Plasmodium vivax, Pv200(19), secreted from Saccharomyces cerevisiae. Kaslow DC, et al. **Immunol Lett** 1996 Jul;51(3):187–9

Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis. Soto M, et al. **Immunol Lett** 1995 Dec;48(3):209–14

Trypanosoma cruzi: analysis of cellular and humoral response against a protective recombinant antigen during experimental Chagas' disease. Taibi A, et al. **Immunol Lett** 1995 Dec;48(3):193–200

Effects of crude antigenic fractions of Leishmania major on natural killer cell cytotoxicity, interferon–gamma and interleukin–4 secretion from peripheric blood lymphocytes of unexposed individuals. Turhan A, et al. **Immunol Lett** 1997 Feb;55(2):115–8

Immune responses in congenic mice to multiple antigen peptides based on defined epitopes from the malaria antigen Pf332. Ahlborg N, et al. **Immunology** 1996 Aug;88(4):630–5

The response of gamma delta T cells to Plasmodium falciparum is dependent on activated CD4+ T cells and the recognition of MHC class I molecules. Jones SM, et al. **Immunology** 1996 Nov;89(3):405–12

Saponin adjuvant primes for a dominant interleukin–10 production to ovalbumin and to Trypanosoma cruzi antigen. Tadokoro CE, et al. **Immunology** 1996 Nov; 89(3):368–74

Novel putative protective antigens of Plasmodium falciparum. Sharma S, et al. **Indian J Med Res** 1997 Aug; 106:63–9 (42 ref.)

Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Afrin F, et al. **Infect Immun** 1997 Jun; 65(6):2371–7

Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model. Beyrodt CG, et al. **Infect Immun** 1997 Jun; 65(6):2052–9

Characterization of immune response to Eimeria tenella antigens in a natural immunity model with hosts which differ serologically at the B locus of the major histocompatibility complex. Brake DA, et al. **Infect Immun** 1997 Apr;65(4):1204–10

Protective immunity against Plasmodium yoelii malaria induced by immunization with particulate blood–stage antigens. Burns JM Jr, et al. **Infect Immun** 1997 Aug; 65(8):3138–45

Baculovirus–mediated expression of Plasmodium falciparum erythrocyte binding antigen 175 polypeptides and their recognition by human antibodies. Daugherty JR, et al. **Infect Immun** 1997 Sep;65(9):3631–7

A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission–blocking vaccines. Duffy PE, et al. **Infect Immun** 1997 Mar;65(3):1109–13

Passive transfer of a monoclonal antibody specific for a sialic acid–dependent epitope on the surface of Trypanosoma cruzi trypomastigotes reduces infection in mice. Franchin G, et al. **Infect Immun** 1997 Jul;65(7):2548–54

Passive immunization of channel catfish (Ictalurus punctatus) against the ciliated protozoan parasite Ichthyophthirius multifiliis by use of murine monoclonal antibodies. Lin TL, et al. **Infect Immun** 1996 Oct;64(10):4085–90

Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen. Mielcarek N, et al. **Infect Immun** 1997 Feb;65(2):544–50

Oral vaccination against coccidiosis: responses in strains of mice that differ in susceptibility to infection with Eimeria vermiformis. Rose ME, et al. **Infect Immun** 1997 May; 65(5):1808–13

Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission–blocking immunity. Tsuboi T, et al. **Infect Immun** 1997 Jun;65(6):2260–4

Human T cell responses against the major cysteine proteinase (cruzipain) of Trypanosoma cruzi: role of the multifunctional alpha 2–macroglobulin receptor in antigen presentation by monocytes. Morrot A, et al. **Int Immunol** 1997 Jun;9(6):825–34

Trypanosoma cruzi: the major cysteinyl proteinase (cruzipain) is a relevant immunogen of parasite acidic antigens (FIII). Laderach D, et al. **Int J Parasitol** 1996 Nov;26(11):1249–54

Systemic and local antibody response in mice induced by a recombinant peptide fragment from Giardia lamblia variant surface protein (VSP) H7 produced by a Salmonella typhimurium vaccine strain. Stäger S, et al. **Int J Parasitol** 1997 Aug;27(8):965–71

Survival of Blastocystis hominis clones after exposure to a cytotoxic monoclonal antibody. Tan SW, et al. **Int J Parasitol** 1997 Aug;27(8):947–54

Two–site immunoradiometric assay (IRMA): detection, efficiency, and procedural modifications. Nanda N, et al. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 1):225–7

Serological diagnosis of Chagas' disease: a potential confirmatory assay using preserved protein antigens of Trypanosoma cruzi. Mendes RP, et al. **J Clin Microbiol** 1997 Jul;35(7):1829–34

Nucleic acid vaccination against Toxoplasma gondii in mice. Angus CW, et al. **J Eukaryot Microbiol** 1996 Sep–Oct; 43(5):117S

Identification of an epitope on the Entamoeba histolytica 170–kD lectin conferring antibody–mediated protection against invasive amebiasis. Lotter H, et al. **J Exp Med** 1997 May 19;185(10):1793–801

Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. Calvo–Calle JM, et al. **J Immunol** 1997 Aug 1; 159(3):1362–73

Complete protective immunity induced in mice by immunization with the 19–kilodalton carboxyl–terminal fragment of the merozoite surface protein–1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen–specific antibody titer, but not with effector CD4+ T cells. Hirunpetcharat C, et al. **J Immunol** 1997 Oct 1; 159(7):3400–11

Presentation via the class I pathway by Leishmania amazonensis–infected macrophages of an endogenous leishmanial antigen to CD8+ T cells. Kima PE, et al. **J Immunol** 1997 Aug 15;159(4):1828–34

Precursor frequency analysis of cytotoxic T lymphocytes to pre–erythrocytic antigens of Plasmodium falciparum in West Africa. Plebanski M, et al. **J Immunol** 1997 Mar 15; 158(6):2849–55

Protective monoclonal antibody defines a circumsporozoite–like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites. Riggs MW, et al. **J Immunol** 1997 Feb 15;158(4):1787–95

High prevalence of antibodies against circumsporozoite antigen of Plasmodium falciparum without development of symptomatic malaria in travelers returning from sub–Saharan Africa. Jelinek T, et al. **J Infect Dis** 1996 Dec; 174(6):1376–9

Activation of gammadelta T cells in malaria: interaction of cytokines and a schizont–associated Plasmodium falciparum antigen. Pichyangkul S, et al. **J Infect Dis** 1997 Jul;176(1):233–41

Immunization with Babesia bigemina rhoptry–associated protein 1 induces a type 1 cytokine response. Ruef BJ, et al. **J Interferon Cytokine Res** 1997 Jan;17(1):45–54

Recognition of tissue cyst–specific antigens in reactivating toxoplasmosis. McHugh TD, et al. **J Med Microbiol** 1997 Jul;46(7):587–95

Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. Ali N, et al. **J Parasitol** 1997 Feb;83(1):70–5

Immunogenicity of the recombinant SAPA protein of Trypanosoma cruzi for mice. Nasser JR, et al. **J Parasitol** 1997 Feb;83(1):76–81

Improved detection of human antibodies to a Plasmodium antigen using a peptide modified with Aib residues. Bossus M, et al. **J Pept Sci** 1997 Jan–Feb;3(1):47–53

Protective immunity induced with the antigens fractionated by affinity chromatography from the second generation schizonts of Leucocytozoon caulleryi. Onaga H, et al. **J Vet Med Sci** 1996 Jul;58(7):677–9

Age–associated changes in lymphoid and antigen–presenting cell functions in mice immunized with Trypanosoma cruzi antigens. Maletto BA, et al. **Mech Ageing Dev** 1996 Jul 5;88(1–2):39–47

Trypanosoma rangeli and trypanosoma cruzi: cross–reaction among their immunogenic components. Saldaña A, et al. **Mem Inst Oswaldo Cruz** 1996 Jan–Feb;91(1):81–2

Antigenicity of recombinant proteins derived from Plasmodium falciparum merozoite surface protein 1. Cavanagh DR, et al. **Mol Biochem Parasitol** 1997 Apr; 85(2):197–211

Giardia lamblia variant surface protein H7 stimulates a heterogeneous repertoire of antibodies displaying differential cytological effects on the parasite. Stäger S, et al. **Mol Biochem Parasitol** 1997 Mar;85(1):113–24

A peptide derived from a B cell epitope of Plasmodium falciparum rhoptry associated protein 2 specifically raises antibodies to rhoptry associated protein 1. Stowers AW, et al. **Mol Biochem Parasitol** 1996 Nov 25;82(2):167–80

Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Williamson KC, et al. **Mol Biochem Parasitol** 1995 Dec;75(1):33–42

Reproducing the immune response against the Plasmodium vivax merozoite surface protein 1 with mimotopes selected from a phage–displayed peptide library. Demangel C, et al. **Mol Immunol** 1996 Aug;33(11–12):909–16

A malaria vaccine based on a sporozoite antigen [editorial; comment] Nussenzweig RS, et al. **N Engl J Med** 1997 Jan 9;336(2):128–30. Comment on: N Engl J Med 1997 Jan 9;336(2):86–91.

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group [see comments] Stoute JA, et al. **N Engl J Med** 1997 Jan 9;336(2):86–91 . Comment in: N Engl J Med 1997 Jan 9;336(2):128–30. Comment in: N Engl J Med 1997 Jun 12;336(24):1759; discussion 1760–1. Comment in: N Engl J Med 1997 Jun 12;336(24):1760; discussion 1760–1.

Antibody responses to Plasmodium falciparum sporozoite–, liver– and blood–stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas. Ferreira–da–Cruz MF, et al. **Parasite** 1995 Mar;2(1):23–9

Detection of serum antibodies against Leishmania 94 kDa antigen in visceral and cutaneous leishmaniosis due to Leishmania infantum. Rolland L, et al. **Parasite** 1995 Mar; 2(1):13–21

Intranasal administration of Schistosoma mansoni adult worm antigen in combination with cholera toxin induces a Th2 cell response. Akhiani AA, et al. **Parasite Immunol** 1997 Apr;19(4):183–90

Humoral immune responses in Gambians to Pfs16, an immunodominant, Plasmodium falciparum integral membrane protein. Baker DA, et al. **Parasite Immunol** 1996 Oct;18(10):527–33

Cross–reactive cellular immune response to circumsporozoite

proteins of Plasmodium vivax and P. falciparum in malaria-exposed individuals. Carvalho LH, et al. **Parasite Immunol** 1997 Feb;19(2):47-59

Can software be used to predict antigenic regions in Plasmodium falciparum peptides? Ferreira-da-Cruz M de F, et al. **Parasite Immunol** 1996 Mar;18(3):159-61

Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys. Herrera S, et al. **Parasite Immunol** 1997 Apr; 19(4):161-70

Murine Th1 clone defines a 60 kD tachyzoite antigen of Toxoplasma gondii. Reichmann G, et al. **Parasite Immunol** 1997 May;19(5):229-34

Immunogenicity of recombinant Plasmodium falciparum rhoptry associated proteins 1 and 2. Stowers A, et al. **Parasite Immunol** 1995 Dec;17(12):631-42

Biochemical and immunological characterization of soluble antigens of Giardia lamblia. Chaudhuri PP, et al. **Parasitol Res** 1997;83(6):604-10

Comparison of genetic groups determined by molecular and immunological analyses of Giardia isolated from animals and humans in Switzerland and Australia. Ey PL, et al. **Parasitol Res** 1996;82(1):52-60

Identification of a major surface protein on Neospora caninum tachyzoites. Hemphill A, et al. **Parasitol Res** 1996; 82(6):497-504

Identification of a Trypanosoma cruzi antigenic epitope implicated in the infectivity of fibroblast LLC-MK2 cells. Martín F, et al. **Parasitol Res** 1997;83(3):226-32

Isolates of Encephalitozoon cuniculi from farmed blue foxes (Alopex lagopus) from Norway differ from isolates from Swiss domestic rabbits (Oryctolagus cuniculus). Mathis A, et al. **Parasitol Res** 1996;82(8):727-30

Plasmodium vivax and P. chabaudi: inter-species cross-reacting antigens. Perez HA, et al. **Parasitol Res** 1997;83(3):246-51

Plasmodium falciparum: surface modifications of infected erythrocytes from clinical isolates. Evidence of antigenic diversity using Venezuelan human malarial sera. Riggione F, et al. **Parasitol Res** 1996;82(6):490-6

Differentiation of Entamoeba histolytica from E. dispar facilitated by monoclonal antibodies against a 150-kDa surface antigen. Tachibana H, et al. **Parasitol Res** 1997; 83(5):435-9

Identification of a Plasmodium berghei antigen sharing common features with P. falciparum and P. chabaudi parasitophorous-vacuole membrane antigens. Tan TM, et al. **Parasitol Res** 1996;82(2):130-35

Mapping of the antigenic determinants of the Leishmania infantum gp63 protein recognized by antibodies elicited during canine visceral leishmaniasis. Morales G, et al. **Parasitology** 1997 Jun;114 (Pt 6):507-16

Epitope mapping on the ookinete surface antigen Pbs21 of Plasmodium berghei: identification of the site of binding of transmission-blocking monoclonal antibody 13.1. Spano F, et al. **Parassitologia** 1996 Dec;38(3):559-63

Induction of antibodies against the Plasmodium falciparum p126 antigen in non-responder H-2b and partial-responder H-2d mice using synthetic peptides. Gilardeau Truffinet M, et al. **Pept Res** 1996 Mar-Apr;9(2):61-70

Tandem use of PCR and synthetic peptides to map helper T-cell epitopes on 27-kDa sexual stage antigen of Plasmodium falciparum. Koski GK, et al. **Pept Res** 1996 May-Jun;9(3):127-35

Use of sequential oligopeptide carriers (SOCn) in the design of potent Leishmania gp63 immunogenic peptides. Tsikaris V, et al. **Pept Res** 1996 Sep-Oct;9(5):240-7

Histopathology and immunocytochemical study of type 3 and type 4 complement receptors in the liver and spleen of dogs naturally and experimentally infected with Leishmania (Leishmania) chagasi. Tafuri WL, et al. **Rev Inst Med Trop Sao Paulo** 1996 Mar-Apr;38(2):81-9

Resistance to Leishmania major induced by tolerance to a single antigen. Julia V, et al. **Science** 1996 Oct 18; 274(5286):421-3

Pyruvate: ferredoxin oxidoreductase from Entamoeba histolytica recognized by a monoclonal antibody. Thammapalerd N, et al. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):63-70

Presentation of antigens derived from microorganisms residing in host-cell vacuoles. Ojcius DM, et al. **Trends Microbiol** 1996 Feb;4(2):53-9 (53 ref.)

Evaluation of an antigen detection-ELISA test for the diagnosis of trypanosomiasis in naturally infected cattle. Bengaly Z, et al. **Trop Med Parasitol** 1995 Dec;46(4):284-6

Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres. Men Y, et al. **Vaccine** 1997 Aug-Sep;15(12-13):1405-12

Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Nixon DF, et al. **Vaccine** 1996 Nov;14(16):1523-30

Multiple antigen constructs (MACs): induction of sterile immunity against sporozoite stage of rodent malaria parasites, Plasmodium berghei and Plasmodium yoelii. Reed RC, et al. **Vaccine** 1997 Apr;15(5):482-8

Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani. Santos WR, et al. **Vaccine** 1997 Jun;15(9):1024-9

Expression of the serine rich Entamoeba histolytica protein (SREHP) in the avirulent vaccine strain Salmonella typhi TY2 chi 4297 (delta cya delta crp delta asd): safety and immunogenicity in mice. Zhang T, et al. **Vaccine** 1997 Aug-Sep;15(12-13):1319-22

Feline ocular and cerebrospinal fluid Toxoplasma gondii-specific humoral immune responses following specific and nonspecific immune stimulation. Lappin MR, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1-3):23-31

Toxoplasma gondii recombinant antigens H4 and H11: use in ELISAs for detection of toxoplasmosis in swine. Andrews CD, et al. **Vet Parasitol** 1997 Jun;70(1-3):1-11

Collagen cross-reactive antigen of Sarcocystis cruzi. Inoue N, et al. **Vet Parasitol** 1996 May;63(1-2):17-23

The indirect fluorescent antibody test based on schizont antigen for study of the sheep parasite Theileria lestoquardi. Leemans I, et al. **Vet Parasitol** 1997 Apr;69(1-2):9-18

B-cell epitope mapping within the MA16 antigenic sequence found in Eimeria acervulina merozoites and sporozoites. O'Lorcain P, et al. **Vet Parasitol** 1996 Nov 15; 66(3-4):147-57

Mapping for B-cell epitopes in the GX3262 antigenic sequence derived from Eimeria tenella sporulated oocysts. O'Lorcain P, et al. **Vet Parasitol** 1996 Nov 15; 66(3-4):159-69

Mitogenic stimulation of bovine peripheral blood mononuclear cells by Theileria sergenti antigen and inhibition by antibody from experimentally infected cattle. Yanagisawa K, et al. **Vet Parasitol** 1997 Jul 15;71(1):53-8

ISOLATION & PURIFICATION

Micropreparative high resolution purification of proteins by a combination of sodium dodecyl sulfate-polyacrylamide gel electrophoresis, isoelectric focusing, and membrane blotting. Liang FT, et al. **Anal Biochem** 1997 Jul 15; 250(1):61-5

Prevalence of Dientamoeba fragilis antibodies in children and recognition of a 39 kDa immunodominant protein antigen of the organism. Chan F, et al. **Eur J Clin Microbiol Infect Dis** 1996 Dec;15(12):950-4

Glutamate dehydrogenase antigen detection in Plasmodium falciparum infections. de Dominguez N, et al. **Korean J Parasitol** 1996 Dec;34(4):239-46

Evaluation of Leishmania antigens preparation and storage for use in enzyme immunoassays. Celeste BJ, et al. **Rev Soc Bras Med Trop** 1997 Jul-Aug;30(4):303-8

METABOLISM

Correlation between direct binding ability of synthetic T. gondii SAG1 peptides to HLA-A2 measured by a sensor for surface plasmon resonance and antigenicity of the peptides for T. gondii-infected cell-specific CTL. Yano A, et al. **Biochem Biophys Res Commun** 1997 Jul 18; 236(2):257-61

Characterization of the substrate specificity of the major cysteine protease (cruzipain) from Trypanosoma cruzi using a portion-mixing combinatorial library and fluorogenic peptides. Nery ED, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):427-33

Cytotoxic T cell reactivity and HLA-B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults. Udhayakumar V, et al. **Eur J Immunol** 1997 Aug; 27(8):1952-7

Recombinant vaccinia viruses for the characterization of Plasmodium falciparum-specific cytotoxic T lymphocytes: recognition of processed antigen despite limited re-stimulation efficacy. Aidoo M, et al. **Int Immunol** 1997 May;9(5):731-7

Evidence for superantigenic activity during murine malaria infection. Pied S, et al. **Int Immunol** 1997 Jan;9(1):17-25

A novel structural component of the Dictyostelium centrosome. Kalt A, et al. **J Cell Sci** 1996 Dec;109 (Pt 13):3103-12

PHARMACOLOGY

Effect of Leishmania donovani antigens on superoxide anion generation by mice polymorph in vitro. Jain A, et al. **Indian J Med Res** 1996 Oct;104:250-3

Human gamma delta T cell subset-proliferative response to malarial antigen in vitro depends on CD4+ T cells or cytokines that signal through components of the IL-2R. Elloso MM, et al. **J Immunol** 1996 Sep 1;157(5):2096-102

PHYSIOLOGY

Involvement of the 112 kDa adhesin in Entamoeba histolytica phagocytosis. García-Rivera G, et al. **Arch Med Res** 1997; 28 Spec No:166-7

Induction of macrophage killing of Leishmania donovani by human CD4+ T cell clones. Melby PC, et al. **Arch Med Res** 1996 Winter;27(4):473-9

THERAPEUTIC USE

Use of a recombinant antigen, SAG2, expressed as a glutathione-S-transferase fusion protein to immunize mice against Toxoplasma gondii. Lundén A, et al. **Parasitol Res** 1997;83(1):6-9

Induction of anti-malarial transmission blocking immunity with a recombinant ookinete surface antigen of Plasmodium berghei produced in silkworm larvae using the baculovirus expression vector system. Matsuoka H, et al. **Vaccine** 1996 Feb;14(2):120-6

URINE

Detection and characterization of antigens in urine of patients with acute, congenital, and chronic Chagas' disease. Corral RS, et al. **J Clin Microbiol** 1996 Aug;34(8):1957-62

ANTIGENS, SURFACE

Transfer of the Gal/GalNAc-specific amebic lectin from trophozoites to frozen sections of human colon mucosa. Leroy A, et al. **Arch Med Res** 1997;28 Spec No:170-2

Variable expression and geographic distribution of Mycoplasma agalactiae surface epitopes demonstrated with monoclonal antibodies. Bergonier D, et al. **FEMS Microbiol Lett** 1996 Oct 1;143(2-3):159-65

The outer surface protein A (OspA) of Borrelia burgdorferi: a vaccine candidate and bioactive mediator. Kramer MD, et al. **Infection** 1996 Mar-Apr;24(2):190-4 (35 ref.)

Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview. Sadziene A, et al. **Infection** 1996 Mar-Apr;24(2):195-202 (89 ref.)

Lyme disease vaccine. Wormser GP. **Infection** 1996 Mar-Apr;24(2):203-7 (54 ref.)

Carbohydrates on the surface of Echinococcus granulosus protoscoleces are immunodominant in mice. Miguez M, et al. **Parasite Immunol** 1996 Nov;18(11):559-69

ADMINISTRATION & DOSAGE

Effect of immunization with human SP-10 in male rodents. Sehgal S, et al. **Am J Reprod Immunol** 1996 Sep; 36(3):167-74

Protection of rats against Mycoplasma arthritidis-induced arthritis by active and passive immunizations with two surface antigens. Washburn LR, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):321-7

Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain. Attridge SR, et al. **Vaccine** 1997 Feb;15(2):155-62

ANALYSIS

Distribution of K88-adhesive and non-adhesive phenotypes among four popular breeds of pigs. Baker DR, et al. **Adv Exp Med Biol** 1997;412:209-11

IFN-gamma modulates CD1d surface expression on intestinal epithelia. Colgan SP, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C276-83

Immunophenotyping of dermal spindle cell tumors: diagnostic value of monocyte marker Ki-M1p and histogenetic considerations. Rudolph P, et al. **Am J Surg Pathol** 1997 Jul;21(7):791-800

Distribution of leukocytes in the epithelium and interstitium of four regions of the Lewis rat epididymis. Flickinger CJ, et al. **Anat Rec** 1997 Jul;248(3):380-90

Luminal epithelial antigen (LEA.135) expression correlates with tumor progression for transitional carcinoma of the bladder. Jones HL, et al. **Anticancer Res** 1997 Jan-Feb; 17(1B):685-7

A subclone (5C6) of the human mast cell line HMC-1 represents a more differentiated phenotype than the original cell line. Weber S, et al. **Arch Dermatol Res** 1996 Nov; 288(12):778-82

Association of the putative B-lymphocyte surface molecule B7.3 with a protein kinase activity [published erratum appears in Biochem Biophys Res Commun 1997 Feb 24;231(3):868] Angelisová P, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):489-93

ED2+ macrophages increase selectively myoblast proliferation in muscle cultures. Massimino ML, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):754-9

Detection of cell-surface antigens using antibody-conjugated fluorospheres (ACF): application for six-color immunofluorescence. Beavis AJ, et al. **Biotechniques** 1996 Sep;21(3):498-503

Optimization of cellular ELISA for assay of surface antigens on human synoviocytes. Smith DD, et al. **Biotechniques** 1997 May;22(5):952-7

Cell surface localization of the 60 kDa heat shock chaperonin protein (hsp60) in mammalian cells. Soltys BJ, et al. **Cell Biol Int** 1997 May;21(5):315-20

Analysis of data on leukocyte surface markers for recognition of leukemia/lymphoma phenotype pattern. Petrovecki M, et al. **Clin Biochem** 1996 Feb;29(1):21-5

The Q-Prep system: effects on the apparent expression of leucocyte cell surface antigens. Macey MG, et al. **Cytometry** 1997 Apr 15;30(2):67-71

Analogs of cord red blood cell membrane components displayed on placenta, amnion and amniotic cells in culture. Lunghi M, et al. **Eur J Histochem** 1996;40(2):129-36

Ultrastructural localization of blood group antigens in human salivary glands. Cossu M, et al. **Eur J Morphol** 1996 Aug; 34(3):191-5

Characterization of prosomes in human lymphocyte subpopulations and their presence as surface antigens. Bureau JP, et al. **Exp Cell Res** 1997 Feb 25;231(1):50-60

Modulation of myoepithelial-associated alpha6beta4 integrin in a breast cancer cell line alters invasive potential. Jones JL, et al. **Exp Cell Res** 1997 Sep 15;235(2):325-33

Differential distribution of immunoreactivity in the adult rat spinal cord revealed by the monoclonal antibody, Py: a light and electron microscopic study. Brook GA, et al.

Exp Neurol 1997 Jul;146(1):265–76

Identification of leucocyte surface antigens in paraffin-embedded bovine tissues using a modified formalin dichromate fixation. Rathkolb B, et al. **Histochem J** 1997 Jun;29(6):487–93

An optimized method for cell-based phage display panning. Watters JM, et al. **Immunotechnology** 1997 Mar;3(1):21–9

Identification of a subpopulation of human renal microvascular endothelial cells with capacity to form capillary-like cord and tube structures. Martin M, et al. **In Vitro Cell Dev Biol Anim** 1997 Apr;33(4):261–9

Immunophenotypic characterization of canine lymphoproliferative disorders. Ruslander DA, et al. **In Vivo** 1997 Mar–Apr;11(2):169–72

Ontogeny of four blood-brain barrier markers: an immunocytochemical comparison of pial and cerebral cortical microvessels. Cassella JP, et al. **J Anat** 1996 Oct; 189 (Pt 2):407–15

Immunohistochemical and ultrastructural analysis of an extracellular matrix bound antigen preferentially associated with mucosal postcapillary venules. Spencer J, et al. **J Anat** 1996 Oct;189 (Pt 2):335–40

The glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase of Candida albicans is a surface antigen. Gil-Navarro I, et al. **J Bacteriol** 1997 Aug;179(16):4992–9

Identification of surface tegumental antigens of normal and irradiated schistosomula. Charmy RA, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):479–91

Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA. Ravindranath MH, et al. **J Immunol Methods** 1996 Oct 16;197(1-2):51–67

Novel ITGB4 mutations in a patient with junctional epidermolysis bullosa-pyloric atresia syndrome and altered basement membrane zone immunofluorescence for the alpha6beta4 integrin. Takizawa Y, et al. **J Invest Dermatol** 1997 Jun;108(6):943–6

Identification of a concanavalin A-binding antigen of the cell surface of Sporothrix schenckii. Lima OC, et al. **J Med Vet Mycol** 1997 May-Jun;35(3):167–72

A search for sex-specific antigens on bovine spermatozoa using immunological and biochemical techniques to compare the protein profiles of X and Y chromosome-bearing sperm populations separated by fluorescence-activated cell sorting. Howes EA, et al. **J Reprod Fertil** 1997 Jul;110(2):195–204

Presence of ribosomal P protein on the surface of human umbilical vein endothelial cells [editorial] Reichlin M. **J Rheumatol** 1996 Jul;23(7):1123–5

Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. Sokoloff MH, et al. **J Urol** 1996 Nov;156(5):1560–6

A monoclonal antibody, 169.1, against canine leukocyte surface antigen identifies cytoskeletal components in epithelial cells and peripheral neurons. Iwami Y, et al. **Jpn J Vet Res** 1997 Feb;44(4):193–206

Microwave antigen retrieval in formaldehyde-fixed human brain tissue. Newman SJ, et al. **Methods Mol Biol** 1997; 72:145–52

Monoclonal antibodies against unfertilized zona-free mouse oocytes: characterization and effects on fertilization. Jin M, et al. **Mol Reprod Dev** 1996 Jan;43(1):47–54

Two tumor-associated membrane antigens defined by monoclonal antibodies in a transplantable sarcoma induced by Rous sarcoma virus in rat. Alexandrov I, et al. **Neoplasma** 1996;43(4):275–82

Cell surface expression of paraneoplastic encephalomyelitis/sensory neuronopathy-associated Hu antigens in small-cell lung cancers and neuroblastomas. Torà M, et al. **Neurology** 1997 Mar;48(3):735–41

Flow cytometric analysis of surface antigens on human conjunctival epithelial cells. Fujihara T, et al. **Ophthalmic Res** 1997;29(2):103–9

Limited surface exposure of Borrelia burgdorferi outer surface lipoproteins. Cox DL, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7973–8

Prostate-specific membrane antigen. Fair WR, et al. **Prostate** 1997 Jul 1;32(2):140–8 (52 ref.)

Flow cytometric analysis of megakaryocyte-associated antigens on CD34 cells and their progeny in liquid culture. Ayala IA, et al. **Stem Cells** 1996 May;14(3):320–9

Ly-6-domain proteins—new insights and new members: a C-terminal Ly-6 domain in sperm acrosomal protein SP-10. Palfree RG. **Tissue Antigens** 1996 Aug;48(2):71–9 (77 ref.)

Monoclonal antibodies to the cell surface of a unique human lymphoid/myeloid cell line detect epitopes absent from peripheral blood mononuclear cells. Cusano G, et al. **Transplant Proc** 1997 Jun;29(4):2046

Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Su SL, et al. **Urology** 1997 Mar;49(3A Suppl):95–101 (37 ref.)

Ruminant cluster WC14. Howard CJ. **Vet Immunol Immunopathol** 1996 Aug;52(4):261–2

Lymphocyte subpopulations in the mammary gland of the goat. Ismail HI, et al. **Vet Immunol Immunopathol** 1996 Jul;52(3):201–12

Ruminant cluster WC13. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):259–60

Study of lymphocyte subpopulations in peripheral blood and secondary lymphoid organs in the goat using monoclonal antibodies to surface markers of bovine lymphocytes. Navarro JA, et al. **Vet Immunol Immunopathol** 1996 May; 51(1-2):147–56

The Epstein-Barr virus (EBV) alters the B cell glycolipid which is recognized by the human monoclonal antibody to i-blood group antigen. Nagatsuka Y, et al. **Virus Res** 1996 Jul;43(1):57–68

Apodemus sp. rodents, reservoir hosts for Borrelia afzelii in an endemic area in Switzerland. Hu CM, et al. **Zentralbl Bakteriol** 1997 Apr;285(4):558–64

[Analysis of lymphocyte surface marker from periferal blood in lung tuberculosis] Imaizumi T. **Kekkaku** 1996 Nov; 71(11):615–8 (Eng. Abstr.) **(Jpn)**

[Cell surface antigens on inflammatory cells in the paranasal mucosa of patients after macrolide therapy] Miyazawa T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1997 Jun; 100(6):671–7 (Eng. Abstr.) **(Jpn)**

[General hematological tests. A. Effects of the blood sample containers and anticoagulants on the determination of lymphocyte surface markers] Bando S, et al. **Rinsho Byori** 1996 Nov;Suppl 103:123–8 **(Jpn)**

BIOSYNTHESIS

Norepinephrine induced growth and expression of virulence associated factors in enterotoxigenic and enterohemorrhagic strains of Escherichia coli. Lyte M, et al. **Adv Exp Med Biol** 1997;412:331–9

Increased expression of cell surface markers on endometrial gamma delta T-cell receptor+ intraepithelial lymphocytes induced by the local presence of the sheep conceptus. Liu WJ, et al. **Am J Reprod Immunol** 1997 Feb;37(2):199–205

Transfection of Entamoeba dispar: inhibition of expression of the lysine-rich 30 kDa surface antigen by the transcription of its antisense RNA. Alon RN, et al. **Arch Med Res** 1997;28 Spec No:52–5

Norepinephrine-induced expression of the K99 pilus adhesin of enterotoxigenic Escherichia coli. Lyte M, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):682–6

Characterisation and expression of the novel lymphocyte activation antigen using the monoclonal antibody 6B2D. O'Shea U, et al. **Biochem Soc Trans** 1997 May;25(2):196S

A human homolog of the 150 kD avian osteoclast membrane antigen related to superoxide dismutase and essential for bone resorption is induced by developmental agents and opposed by estrogen in FLG 29.1 cells. Khalkhali-Ellis Z, et al. **Calcif Tissue Int** 1997 Feb;60(2):187–93

Human retinoblastoma: in vitro differentiation and immunoglobulin superfamily antigen modulation by retinoic acid. Conway RM, et al. **Cancer Immunol Immunother** 1997 Jun;44(4):189–96

Transfection of beta 4 integrin subunit into a neoplastic keratinocyte line fails to restore terminal differentiation capacity or influence proliferation. Jones J, et al. **Cell Adhes Commun** 1996 Nov;4(4-5):307–16

Surface antigen expression in spleen cells of C57B1/6 mice during ageing: influence of sex and parity. Barrat F, et al. **Clin Exp Immunol** 1997 Mar;107(3):593–600

Quantitative analysis of leukocyte membrane antigen expression on human fetal and cord blood: normal values and changes during development. Bikoue A, et al. **Clin Immunol Immunopathol** 1997 Jul;84(1):56–64

Influence of the culture media composition and pH on the synthesis of mucoid Yersinia factor. Bengoechea JA, et al. **Contrib Microbiol Immunol** 1995;13:168–71

Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Bellinghausen I, et al. **Eur J Immunol** 1997 May; 27(5):1131–9

PKC-dependent long-term effect of PMA on protein cell surface expression in Caco-2 cells. Sapin C, et al. **Exp Cell Res** 1997 Mar 15;231(2):308–18

Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Vibhakar R, et al. **Exp Cell Res** 1997 Apr 10;232(1):25–8

Expression of the large I antigen forming beta-1,6-N-acetylglucosaminyltransferase in various tissues of adult mice. Magnet AD, et al. **Glycobiology** 1997 Mar;7(2):285–95

Expression of Fas-Fas ligand system associated with atresia through apoptosis in murine ovary. Mori T, et al. **Horm Res** 1997;48 Suppl 3:11–9

Expression and immunogenicity of the C-terminus of a major blood-stage surface protein of Plasmodium vivax, Pv200(19), secreted from Saccharomyces cerevisiae. Kaslow DC, et al. **Immunol Lett** 1996 Jul;51(3):187–9

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Agata Y, et al. **Int Immunol** 1996 May;8(5):765–72

Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Nishimura H, et al. **Int Immunol** 1996 May; 8(5):773–80

Changes in antigen densities on leukocyte subsets correlate with progression of HIV disease. Roederer M, et al. **Int Immunol** 1996 Jan;8(1):1–11

Expression of the surface antigen A2B7 in adult and developing honeybee olfactory pathway. Gascuel J, et al. **Int J Dev Neurosci** 1996 Nov;14(7-8):997–1011

Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epithelium. Catimel B, et al. **J Biol Chem** 1996 Oct 11; 271(41):25664–70

Vla and alpha 6 beta 4 integrin expression in neuroendocrine carcinomas of the skin (their xenografts on nude mice and a corresponding primary culture). Perrin C, et al. **J Cutan Pathol** 1996 Jun;23(3):223–8

Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+-dependent mechanism. Josien R, et al. **J Exp Med** 1997 Aug 4;186(3):467–72

Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. Verhasselt V, et al. **J Immunol** 1997 Mar 15;158(6):2919–25

Both human alpha/beta and gamma interferons upregulate the expression of CD48 cell surface molecules. Tissot C, et al. **J Interferon Cytokine Res** 1997 Jan;17(1):17–26

Expression of the 4C5 antigen during development and after injury of the rat sciatic nerve. Thomaidou D, et al. **J Neurosci Res** 1996 Oct 1;46(1):24–33

Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Gandarillas A, et al. **Mol Carcinog** 1997 Sep;20(1):10–8

Developing brain cells produce factors capable of inducing the HT7 antigen, a blood-brain barrier-specific molecule, in chick endothelial cells. Ikeda E, et al. **Neurosci Lett** 1996 May 17;209(3):149–52

Transient decrease of HPC-1/syntaxin-1A mRNA in the rat hippocampus by kainic acid. Fujino I, et al. **Neurosci Res** 1997 Jul;28(3):243–7

Effects of growth conditions and incubation times on the expression of antigens of Haemophilus paragallinarum which are detected by monoclonal antibodies. Bragg RR, et al. **Onderstepoort J Vet Res** 1997 Mar;64(1):57–63

Stage-specific expression of surface molecules by the larval stages of Haemonchus contortus. Raleigh JM, et al. **Parasite Immunol** 1996 Mar;18(3):125–32

Prostate-specific membrane antigen. Fair WR, et al. **Prostate** 1997 Jul 1;32(2):140–8 (52 ref.)

In vivo activated rat monocytes up-regulate NKR-P1A and down-modulate CD4 and CD43. Scriba A, et al. **Transplant Proc** 1997 May;29(3):1748–9

[Clinical value of the study of proliferation and cell activation antigens with flow cytometry in bladder cancer] Lacombe L, et al. **Prog Urol** 1996 Dec;6(6):907–12 (Eng. Abstr.) **(Fre)**

[Messenger RNA expression of alternatively spliced CS-1 fibronectin isoforms in Rheumatoid arthritis (RA) synovium] Müller-Ladner U, et al. **Verh Dtsch Ges Pathol** 1996;80:329 **(Ger)**

BLOOD

Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Douglas TH, et al. **Cancer** 1997 Jul 1;80(1):107–14

The Oka blood group antigen is a marker for the M6 leukocyte activation antigen, the human homolog of OX-47 antigen, basigin and neurothelin, an immunoglobulin superfamily molecule that is widely expressed in human cells and tissues. Spring FA, et al. **Eur J Immunol** 1997 Apr;27(4):891–7

Search for the optimal fetal cell antibody: results of immunophenotyping studies using flow cytometry. Zheng YL, et al. **Hum Genet** 1997 Jul;100(1):35–42

The cell surface marker phenotype of macrophages from HIV-1-infected subjects reflects an IL-10-Enriched and IFN-gamma-deprived donor environment. Orlikowsky T, et al. **J Interferon Cytokine Res** 1996 Nov;16(11):957–62

Age-related changes in T cell surface markers: a longitudinal analysis in genetically heterogeneous mice. Miller RA. **Mech Ageing Dev** 1997 Jun;96(1-3):181–96

Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Angelsen A, et al. **Prostate** 1997 Jan 1;30(1):1–6

PSA-based screening for prostate cancer in asymptomatic younger males: pilot study in blood donors. Reissigl A, et al. **Prostate** 1997 Jan 1;30(1):20–5

Prostate-specific membrane antigen and other prostatic tumor markers on the horizon. Israeli RS, et al. **Urol Clin North Am** 1997 May;24(2):439–50 (79 ref.)

Ruminant cluster WC15. Howard CJ. **Vet Immunol Immunopathol** 1996 Aug;52(4):263

CEREBROSPINAL FLUID

Simultaneous expression of Borrelia OspA and OspC and IgM response in cerebrospinal fluid in early neurologic Lyme disease. Schutzer SE, et al. **J Clin Invest** 1997 Aug 15;100(4):763–7

CHEMISTRY

Analysis of the lipidated recombinant outer surface protein A from Borrelia burgdorferi by mass spectrometry. Bouchon B, et al. **Anal Biochem** 1997 Mar 1;246(1):52–61

Novel isoform of syntaxin 1 is expressed in mammalian cells. Jagadish MN, et al. **Biochem J** 1997 Jan 1;321 (Pt 1):151–6

An alpha-helical minimal binding domain within the H3 domain of syntaxin is required for SNAP-25 binding.

Zhong P, et al. **Biochemistry** 1997 Apr 8;36(14):4317–26

Thy cytoplamic domain of rat NKR–P1 receptor interacts with the N–terminal domain of p56(lck) via cysteine residues. Campbell KS, et al. **Eur J Immunol** 1997 Mar; 27(3):802

DN4: a novel cell surface molecule on cortical epithelial cells of the human thymus. Chung DH, et al. **Hum Immunol** 1996 Feb;45(2):124–30

A lymphocyte cell surface heat shock protein homologous to the endoplasmic reticulum chaperone, immunoglobulin heavy chain binding protein BIP. Berger CL, et al. **Int J Cancer** 1997 Jun 11;71(6):1077–85

Structural characterization of the K antigens from Rhizobium fredii USDA257: evidence for a common structural motif, with strain–specific variation, in the capsular polysaccharides of Rhizobium spp. Forsberg LS, et al. **J Bacteriol** 1997 Sep;179(17):5366–71

Flotillin and epidermal surface antigen define a new family of caveolae–associated integral membrane proteins. Bickel PE, et al. **J Biol Chem** 1997 May 23;272(21):13793–802

Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epithelium. Catimel B, et al. **J Biol Chem** 1996 Oct 11; 271(41):25664–70

p126 (CDw101), a costimulatory molecule preferentially expressed on mucosal T lymphocytes. Russell GJ, et al. **J Immunol** 1996 Oct 15;157(8):3366–74

Bacterial adhesins as a drug carrier: covalent attachment of K99 fimbriae to 6–methylprednisolone. Bernkop–Schnürch A, et al. **Pharmazie** 1997 Jan;52(1):41–4

Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Li H, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3584–9

Immunohistochemical demonstration of cellular antigens of the cat defined by anti–human antibodies. Joling P, et al. **Vet Immunol Immunopathol** 1996 Sep;53(1–2):115–27

DIAGNOSTIC USE

[The role of the outer–membrane antigens of Yersinia pseudotuberculosis in the pathogenesis and diagnosis of pseudotuberculosis] Kuliashova LB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jan–Feb;(1):14–8 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

[The effect of immunosuppressive drugs on expression of surface antigens of lymphocytes in patients with rheumatoid arthritis] Lącki JK, et al. **Pol Arch Med Wewn** 1997 Feb;97(2):134–43 (Eng. Abstr.) **(Pol)**

GENETICS

Sequence analysis and comparison of 190 K surface antigen gene fragment of a new species of spotted fever group rickettsiae. Zhang JZ, et al. **Acta Virol** 1997 Feb;41(1):41–5

Adhesion of K88ab fimbriated E. coli in piglet small intestines in relation with iron transport molecules. Grange P, et al. **Adv Exp Med Biol** 1997;412:357–61

Regulators of Escherichia coli K99 region 1 genes. Lo–Tseng T, et al. **Adv Exp Med Biol** 1997;412:303–10

Compositional similarities between the human immunodeficiency virus and surface antigens of pathogens. Fitzgerald DJ, et al. **AIDS Res Hum Retroviruses** 1996 Jan 20;12(2):99–106

Hemizygous deletion of the syntaxin 1A gene in individuals with Williams syndrome [letter] Osborne LR, et al. **Am J Hum Genet** 1997 Aug;61(2):449–52

Identification and location of the cell–binding domain in the 112 kDa adhesin gene of Entamoeba histolytica. García–Rivera G, et al. **Arch Med Res** 1997;28 Spec No:164–5

Human BST–1 expressed on myeloid cells functions as a receptor molecule. Okuyama Y, et al. **Biochem Biophys Res Commun** 1996 Nov 21;228(3):838–45

Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Elsner J, et al. **Blood** 1996 Dec 15;88(12):4684–93

Isolation and analysis of different subpopulations of normal human breast epithelial cells after their infection with a retroviral vector encoding a cell surface marker. Bardy P, et al. **Breast Cancer Res Treat** 1997 Jun;44(2):153–65

Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP–like sequence cassettes. Zhang JR, et al. **Cell** 1997 Apr 18;89(2):275–85

Body temperature (37 C) specifically down–regulates the messenger ribonucleic acid for the major sperm surface antigen CD52 in epididymal cell culture. Pera I, et al. **Endocrinology** 1996 Oct;137(10):4451–9

Molecular cloning of human RP105. Fugier–Vivier I, et al. **Eur J Immunol** 1997 Jul;27(7):1824–7

Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter. Simon MM, et al. **Eur J Immunol** 1996 Dec;26(12):2831–40

Molecular analysis of clinical group B streptococcal strains by use of alpha and beta gene probes. Suvorov A, et al. **FEMS Immunol Med Microbiol** 1997 Mar;17(3):149–54

Characterization of Borrelia garinii isolated from Lyme disease patients in Hokkaido, Japan, by sequence analysis of OspA and OspB genes. Wang J, et al. **FEMS Microbiol Lett** 1997 Sep 15;154(2):371–5

Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae. McDaniel LS, et al. **Gene Ther** 1997 Apr;4(4):375–7

Drosophila syntaxin is required for cell viability and may function in membrane formation and stabilization. Schulze KL, et al. **Genetics** 1996 Dec;144(4):1713–24

Mapping of the human HPC–1/syntaxin 1A gene (STX1A) to chromosome 7 band q11.2. Nakayama T, et al. **Genomics** 1997 May 15;42(1):173–6

CD156 (human ADAM8): expression, primary amino acid sequence, and gene location. Yoshiyama K, et al. **Genomics** 1997 Apr 1;41(1):56–62

Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Ager S, et al. **Hum Gene Ther** 1996 Nov 10;7(17):2157–64

Genomic organization and chromosomal localization of the mouse Bp3 gene, a member of the CD38/ADP–ribosyl cyclase family. Dong C, et al. **Immunogenetics** 1996; 45(1):35–43

Mechanisms for variability in a member of the scavenger–receptor cysteine–rich superfamily. Kanan JH, et al. **Immunogenetics** 1997;46(4):276–82

Alternatively spliced Ly–49D and H transcripts are found in IL–2–activated NK cells. Silver ET, et al. **Immunogenetics** 1996;44(6):478–82

Detection of circulating tumor cells in patients with prostate cancer using prostate specific membrane–derived primers in the polymerase chain reaction. Noguchi M, et al. **Int J Urol** 1997 Jul;4(4):374–9

Polymorphism, duplication, and IS1–mediated rearrangement in the chromosomal his–rfb–gnd region of Escherichia coli strains with group IA and capsular K antigens. Drummelsmith J, et al. **J Bacteriol** 1997 May; 179(10):3232–8

Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors. McNagny KM, et al. **J Cell Biol** 1997 Sep 22; 138(6):1395–407

Overexpression of human aspartyl(asparaginyl)beta–hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. Lavaissiere L, et al. **J Clin Invest** 1996 Sep 15;98(6):1313–23

A homozygous mutation in the integrin alpha6 gene in junctional epidermolysis bullosa with pyloric atresia. Ruzzi L, et al. **J Clin Invest** 1997 Jun 15;99(12):2826–31

Culturing selects for specific genotypes of Borrelia burgdorferi in an enzootic cycle in Colorado. Norris DE, et al. **J Clin Microbiol** 1997 Sep;35(9):2359–64

Molecular characterization of the D surface protein gene subfamily in Paramecium primaurelia. Bourgain–Guglielmetti FM, et al. **J Eukaryot Microbiol** 1996 Jul–Aug;43(4):303–13

Molecular characterization of the D surface protein gene subfamily in Paramecium tetraurelia. Breuer M, et al. **J Eukaryot Microbiol** 1996 Jul–Aug;43(4):314–22

Antigenic phenotype and gene expression pattern of lymphohemopoietic progenitors during early mouse ontogeny. Marcos MA, et al. **J Immunol** 1997 Mar 15; 158(6):2627–37

Baculovirus cDNA libraries for expression cloning of genes encoding cell–surface antigens. Granziero L, et al. **J Immunol Methods** 1997 Apr 25;203(2):131–9

Immunization with outer surface protein (Osp) A, but not OspC, provides cross–protection of mice challenged with North American isolates of Borrelia burgdorferi. Probert WS, et al. **J Infect Dis** 1997 Feb;175(2):400–5

Novel ITGB4 mutations in a patient with junctional epidermolysis bullosa–pyloric atresia syndrome and altered basement membrane zone immunofluorescence for the alpha6beta4 integrin. Takizawa Y, et al. **J Invest Dermatol** 1997 Jun;108(6):943–6

The merozoite surface protein 2 (MSP2) gene of Plasmodium falciparum from a Thai isolate. Jongwutiwes S, et al. **J Med Assoc Thai** 1996 Dec;79 Suppl 1:S33–9

Hydrocephalus and Hirschsprung's disease in a patient with a mutation of L1CAM. Okamoto N, et al. **J Med Genet** 1997 Aug;34(8):670–1

Sequence diversity and molecular evolution of the merozoite surface antigen 2 of Plasmodium falciparum. Felger I, et al. **J Mol Evol** 1997 Aug;45(2):154–60

Diversity of OspA and OspC among cerebrospinal fluid isolates of Borrelia burgdorferi sensu lato from patients with neuroborreliosis in Germany. Wilske B, et al. **Med Microbiol Immunol (Berl)** 1996 Feb;184(4):195–201

Consensus sequence on the genes encoding the major outer surface proteins (OspA and OspB) of Borrelia garinii isolate. Wang J, et al. **Microbiol Immunol** 1997;41(2):83–91

Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum. Hafalla JC, et al. **Mol Biochem Parasitol** 1997 Jul;87(1):97–9

Sequence analysis of the apical membrane antigen–1 genes (ama–1) of Plasmodium yoelii yoelii and Plasmodium berghei. Kappe SH, et al. **Mol Biochem Parasitol** 1996 Jun; 78(1–2):279–83

Primary structure of a novel ookinete surface protein from Plasmodium berghei. Tsuboi T, et al. **Mol Biochem Parasitol** 1997 Mar;85(1):131–4

Proteins binding to the promoter region of the operon encoding the major outer surface proteins OspA and OspB of Borrelia burgdorferi. Margolis N, et al. **Mol Biol Rep** 1995;21(3):159–64

Mechanism of antigenic variation in Mycoplasma pulmonis: interwoven, site–specific DNA inversions. Bhugra B, et al. **Mol Microbiol** 1995 Nov;18(4):703–14

Molecular characterization of the Bacillus anthracis main S–layer component: evidence that it is the major cell–associated antigen. Mesnage S, et al. **Mol Microbiol** 1997 Mar;23(6):1147–55

Molecular cloning and characterization of rat sperm surface antigen 2B1, a glycoprotein implicated in sperm–zona binding. Hou ST, et al. **Mol Reprod Dev** 1996 Oct; 45(2):193–203

A low, adaptive dose of gamma–rays reduced the number and altered the spectrum of S1– mutants in human–hamster hybrid AL cells. Ueno AM, et al. **Mutat Res** 1996 Nov 4;358(2):161–9

A single gene copy merozoite surface antigen and immune evasion? O'Dea KP, et al. **Parasite Immunol** 1996 Apr; 18(4):165–72

Differential antibody recognition of FC27–like Plasmodium falciparum merozoite surface protein MSP2 antigens which lack 12 amino acid repeats. Ranford–Cartwright LC, et al. **Parasite Immunol** 1996 Aug;18(8):411–20

Comparison of genetic groups determined by molecular and immunological analyses of Giardia isolated from animals and humans in Switzerland and Australia. Ey PL, et al. **Parasitol Res** 1996;82(1):52–60

Environmental induction and genetic control of surface antigen switching in the nematode Caenorhabditis elegans. Grenache DG, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12388–93

[Significance of prostate–specific membrane antigen (PSMA). A neurocarboxypeptidase and membrane folate hydrolase] Heston WD. **Urologe A** 1996 Sep;35(5):400–7 (17 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

The effect of respiratory virus infection on expression of cell surface antigens associated with binding of potentially pathogenic bacteria. Elahmer OR, et al. **Adv Exp Med Biol** 1996;408:169–77 (26 ref.)

Presence of t(8;21)(q22;q22) in myeloperoxidase–positive, myeloid surface antigen–negative acute myeloid leukemia. Arber DA, et al. **Am J Clin Pathol** 1997 Jan;107(1):68–73

Effect of immunization with human SP–10 in male rodents. Sehgal S, et al. **Am J Reprod Immunol** 1996 Sep; 36(3):167–74

A chemiluminescence–based method for the detection and quantification of antigen–antibody interactions on the surface of eukaryotic cells. Lischke A, et al. **Anal Biochem** 1996 May 1;236(2):322–6

3–D representation of cell surface antigens for helper lymphocytes [letter] Gaillard J, et al. **Anal Cell Pathol** 1996 May;10(3):281–6

Systemic and mucosal protective immunity to pneumococcal surface protein A. Briles DE, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:118–26 (42 ref.)

Antibody responses of rats and humans to flagella–less cells and OspA protein of Borrelia burgdorferi. Sadziene A, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:140–50

Specific stabilization of the 4F7 molecule on dendritic cells by contact allergens. Jonuleit H, et al. **Arch Dermatol Res** 1996 Nov;288(12):745–52

Cross reactivity of mouse monoclonal antibodies to glycoprotein with two different antigens from the outer membrane of Entamoeba histolytica. Agundis–Mata C, et al. **Arch Med Res** 1997;28 Spec No:239–41

Vaccination of different strains of mice against cutaneous leishmaniosis: usefulness of membrane antigens encapsulated into liposomes by intraperitoneal and subcutaneous administration. Lezama–Dávila CM. **Arch Med Res** 1997 Spring;28(1):47–53

The galactose adherence lectin of Entamoeba histolytica activates primed macrophages for amebicidal activity mediated by nitric oxide. Seguin R, et al. **Arch Med Res** 1997;28 Spec No:228–9

Induction of immunotolerance in rats by intratesticular administration of an eicosapeptide of bovine S–antigen. Ren J, et al. **Autoimmunity** 1996;25(1):19–31

Monoclonal antibodies against pupa–specific surface antigens of Sarcophaga peregrina (flesh fly) hemocytes. Hori S, et al. **Biochem Biophys Res Commun** 1997 Jul 18; 236(2):497–501

Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Elsner J, et al. **Blood** 1996 Dec 15;88(12):4684–93

Monoclonal antibodies to the extracellular domain of prostate–specific membrane antigen also react with tumor vascular endothelium. Liu H, et al. **Cancer Res** 1997 Sep 1;57(17):3629–34

TCR alpha beta+ anti–tumor cytolytic T lymphocytes express NKR–P1 whilethe anti–tumor activity of TCR gamma delta+ T lymphocytes is not correlated to NKR–P1 expression. Yrlid U, et al. **Cell Immunol** 1996 Nov 1;173(2):287–94

Cell surface expression of two major yeast allergens in the Pityrosporum genus. Zargari A, et al. **Clin Exp Allergy** 1997 May;27(5):584–92

Coagglutination with antisera to MyfA and PsaA to distinguish Yersinia enterocolitica from Yersinia pseudotuberculosis pathogenic isolates. Leiva J, et al. **Contrib Microbiol Immunol** 1995;13:158–64

Flow cytometric analysis of cell surface antigen recognized

by monoclonal antibody (MSN-1) in normal, hyperplasia, and carcinoma of endometrial cells: its diagnostic value for endometrial carcinoma. Kobayashi Y, et al. **Cytometry** 1997 Feb 15;30(1):23-7

The outer surface lipoprotein OspA of Borrelia burgdorferi provides co-stimulatory signals to normal human peripheral CD4+ and CD8+ T lymphocytes. Knigge H, et al. **Eur J Immunol** 1996 Oct;26(10):2299-303

Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter. Simon MM, et al. **Eur J Immunol** 1996 Dec;26(12):2831-40

Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo. Zhong W, et al. **Eur J Immunol** 1996 Nov;26(11):2749-57

Pairs of surface molecules involved in human IgE regulation: CD23-CD21 and CD40-CD40L. Bonnefoy JY, et al. **Eur Respir J Suppl** 1996 Aug;22:63s-66s (48 ref.)

Alloantigen presentation to naive CD8+ T cells by mouse microglia: evidence for a distinct phenotype based on expression of surface-associated and soluble costimulatory molecules. Askew D, et al. **Glia** 1996 Oct;18(2):118-28

Identification and characterization of differentiation-dependent Schwann cell surface antigens by novel monoclonal antibodies: introduction of a marker common to the non-myelin-forming phenotype. Wewetzer K, et al. **Glia** 1997 Mar;19(3):213-26

Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Ager S, et al. **Hum Gene Ther** 1996 Nov 10;7(17):2157-64

IL-12 enhances proliferation of peripheral blood mononuclear cells from Chagas' disease patients to Trypanosoma cruzi antigen. de Barros-Mazon S, et al. **Immunol Lett** 1997 Jun 1;57(1-3):39-45

Expression and immunogenicity of the C-terminus of a major blood-stage surface protein of Plasmodium vivax, Pv200(19), secreted from Saccharomyces cerevisiae. Kaslow DC, et al. **Immunol Lett** 1996 Jul;51(3):187-9

The influence of virus structure on antibody responses and virus serotype formation. Bachmann MF, et al. **Immunol Today** 1996 Dec;17(12):553-8 (48 ref.)

OspA antibodies inhibit the acquisition of Borrelia burgdorferi by Ixodes ticks. de Silva AM, et al. **Infect Immun** 1997 Aug;65(8):3146-50

Characterization of the physiological requirements for the bactericidal effects of a monoclonal antibody to OspB of Borrelia burgdorferi by confocal microscopy. Escudero R, et al. **Infect Immun** 1997 May;65(5):1908-15

Passive transfer of a monoclonal antibody specific for a sialic acid-dependent epitope on the surface of Trypanosoma cruzi trypomastigotes reduces infection in mice. Franchin G, et al. **Infect Immun** 1997 Jul;65(7):2548-54

Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Golde WT, et al. **Infect Immun** 1997 Mar;65(3):882-9

Characterization of two distinct opsonic and protective epitopes within the alpha C protein of the group B Streptococcus. Kling DE, et al. **Infect Immun** 1997 Apr; 65(4):1462-7

Resistance to tick-borne spirochete challenge induced by Borrelia burgdorferi strains that differ in expression of outer surface proteins. Kurtti TJ, et al. **Infect Immun** 1996 Oct; 64(10):4148-53

Antigenic characterization of the salmonid pathogen Piscirickettsia salmonis. Kuzyk MA, et al. **Infect Immun** 1996 Dec;64(12):5205-10

The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine. Wallich R, et al. **Infection** 1996 Sep-Oct;24(5):396-7 (12 ref.)

Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development. Wilske B, et al. **Infection** 1996 Mar-Apr;24(2):208-12 (32 ref.)

A novel mouse thymocyte antigen (F3Ag): down-regulation during the CD4+CD8+ double-positive stage indicates positive selection. Barthlott T, et al. **Int Immunol** 1996 Jan; 8(1):101-13

Systemic and local antibody response in mice induced by a recombinant peptide fragment from Giardia lamblia variant surface protein (VSP) H7 produced by a Salmonella typhimurium vaccine strain. Stäger S, et al. **Int J Parasitol** 1997 Aug;27(8):965-71

Modulation and detection of IDDM by membrane associated antigens from the islet beta cell line NIT-1. Reid BD, et al. **J Autoimmun** 1997 Feb;10(1):27-34

Cytometric detection of mycobacterial surface antigens: exposure of mannosyl epitopes and of the arabinan segment of arabinomannans. Ozanne V, et al. **J Bacteriol** 1996 Dec; 178(24):7254-9

A novel human monoclonal antibody rapidly induces homotypic cell aggregation and promotes antibody-secreting activity by human B lymphoblastoid cell line IM-9. Ikewaki N. **J Clin Immunol** 1997 Mar; 17(2):127-39

Acquired resistance to Borrelia burgdorferi infection in the rabbit. Comparison between outer surface protein A vaccine- and infection-derived immunity. Foley DM, et al. **J Clin Invest** 1997 Apr 15;99(8):2030-5

Detection and characterization of the coli surface antigen 6 of enterotoxigenic Escherichia coli strains by using monoclonal antibodies. Helander A, et al. **J Clin Microbiol** 1997 Apr;35(4):867-72

Recommendation to include OspA and OspB in the new immunoblotting criteria for serodiagnosis of Lyme disease. Hilton E, et al. **J Clin Microbiol** 1996 Jun;34(6):1353-4

Antibody against an Anaplasma marginale MSP5 epitope common to tick and erythrocyte stages identifies persistently infected cattle. Knowles D, et al. **J Clin Microbiol** 1996 Sep;34(9):2225-30

Extracellular 37-kDa antigenic protein from Actinobacillus actinomycetemcomitans induces TNF-alpha, IL-1 beta, and IL-6 in murine macrophages. Tani Y, et al. **J Dent Res** 1997 Sep;76(9):1538-47

Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice. Bockenstedt LK, et al. **J Immunol** 1996 Dec 15;157(12):5496-502

NK1.1+ CD4+ T cells lose NK1.1 expression upon in vitro activation. Chen H, et al. **J Immunol** 1997 Jun 1; 158(11):5112-9

IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones. Esser MT, et al. **J Immunol** 1997 Jun 15;158(12):5612-8

A newly recognized pathway for the negative regulation of mast cell-dependent hypersensitivity and inflammation mediated by an endogenous cell surface receptor of the gp49 family. Katz HR, et al. **J Immunol** 1997 Jun 1; 158(11):5065-70 (32 ref.)

Borrelia burgdorferi outer surface protein A (OspA) activates and primes human neutrophils. Morrison TB, et al. **J Immunol** 1997 May 15;158(10):4838-45

Intracellular CD22 rapidly moves to the cell surface in a tyrosine kinase-dependent manner following antigen receptor stimulation. Sherbina NV, et al. **J Immunol** 1996 Nov 15;157(10):4390-8

Transgenic expression of a novel thymic epithelial cell antigen stimulates abberant development of thymocytes. Takeuchi T, et al. **J Immunol** 1997 Jul 15;159(2):726-33

Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry. Kipriyanov SM, et al. **J Immunol Methods** 1996 Sep 13; 196(1):51-62

Isolation of cell surface-specific human monoclonal antibodies using phage display and magnetically-activated cell sorting: applications in immunohematology. Siegel DL, et al. **J Immunol Methods** 1997 Aug 7;206(1-2):73-85

Lyme borreliosis in transgenic mice tolerant to OspA from Borrelia burgdorferi 25015. Fikrig E, et al. **J Infect Dis** 1997 Apr;175(4):1000-3

An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. Luke CJ, et al. **J Infect Dis** 1997 Jan;175(1):91-7

Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine. Padilla ML, et al. **J Infect Dis** 1996 Oct;174(4):739-46

Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. Probert WS, et al. **J Infect Dis** 1997 Feb;175(2):400-5

Bullous pemphigoid and linear IgA dermatosis sera recognize a similar 120-kDa keratinocyte collagenous glycoprotein with antigenic cross-reactivity to BP180. Pas HH, et al. **J Invest Dermatol** 1997 Apr;108(4):423-9

Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis. Martinez-Taboada V, et al. **J Mol Med** 1996 Nov;74(11):695-703

Characterization of HPC-1 antigen, an isoform of syntaxin-1, with the isoform-specific monoclonal antibody, 14D8. Kushima Y, et al. **J Mol Neurosci** 1997 Feb;8(1):19-27

Elevated IgG titer against the C region of streptococcal M protein and its immunodeterminants in patients with poststreptococcal acute glomerulonephritis. Mori K, et al. **J Pediatr** 1997 Aug;131(2):293-9

Inhibition of bovine fertilization in vitro by antibodies to SP-10. Coonrod SA, et al. **J Reprod Fertil** 1996 Jul; 107(2):287-97

Production of a monoclonal antibody (59.4) against canine lymphocyte surface antigen and its immunohistochemical application. Iwami Y, et al. **J Vet Med Sci** 1997 Apr; 59(4):239-44

Anti-OspA antibody reduces reservoir competence of mice for Borrelia burgdorferi, the agent of Lyme disease. Brunet LR, et al. **Med Vet Entomol** 1997 Apr;11(2):198-200

Presence of common antigenic epitope in outer surface protein (Osp) A and OspB of Japanese isolates identified as Borrelia garinii. Masuzawa T, et al. **Microbiol Immunol** 1996;40(6):455-8

Comparison of OspA serotypes for Borrelia burgdorferi sensu lato from Japan, Europe and North America. Masuzawa T, et al. **Microbiol Immunol** 1996;40(8):539-45

Giardia lamblia variant surface protein H7 stimulates a heterogeneous repertoire of antibodies displaying differential cytological effects on the parasite. Stäger S, et al. **Mol Biochem Parasitol** 1997 Mar;85(1):113-24

Reproducing the immune response against the Plasmodium vivax merozoite surface protein 1 with mimotopes selected from a phage-displayed peptide library. Demangel C, et al. **Mol Immunol** 1996 Aug;33(11-12):909-16

Detection of Lyme disease after OspA vaccine [letter] Schutzer SE, et al. **N Engl J Med** 1997 Sep 11;337(11):794-5

A monoclonal antibody (1F3) to human glomerular epithelial cells: a new marker for renal epithelial cell injury. Kagami S, et al. **Nephron** 1997;75(1):65-71

Cellular immunity to merozoite surface protein 2 (FC27 and 3D7) in Papua New Guinean children. Temporal variation and relation to clinical and parasitological status. al-Yaman F, et al. **Parasite Immunol** 1997 May;19(5):207-14

Comparison of genetic groups determined by molecular and immunological analyses of Giardia isolated from animals and humans in Switzerland and Australia. Ey PL, et al. **Parasitol Res** 1996;82(1):52-60

Identification of a major surface protein on Neospora caninum tachyzoites. Hemphill A, et al. **Parasitol Res** 1996; 82(6):497-504

Epitope mapping on the ookinete surface antigen Pbs21 of Plasmodium berghei: identification of the site of binding of transmission-blocking monoclonal antibody 13.1. Spano F, et al. **Parassitologia** 1996 Dec;38(3):559-63

Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells. Cai Z, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14736-41

Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Barren RJ 3rd, et al. **Prostate** 1997 Jan 1;30(1):65-8

Late complications of immune deviation therapy in a nonhuman primate [see comments] Genain CP, et al. **Science** 1996 Dec 20;274(5295):2054-7. Comment in: Science 1996 Dec 20;274(5295):2037-8.

Monoclonal antibodies specific for porcine monocytes/macrophages: macrophage heterogeneity in the pig evidenced by the expression of surface antigens. Bullido R, et al. **Tissue Antigens** 1997 Apr;49(4):403-13

Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Hayden MS, et al. **Tissue Antigens** 1996 Oct;48(4 Pt 1):242-54

Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Ferry BL, et al. **Transpl Immunol** 1997 Mar; 5(1):17-24

PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Briles DE, et al. **Vaccine** 1996 Jun;14(9):858-67

OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant. Erdile LF, et al. **Vaccine** 1997 Jun;15(9):988-96

Effect of context and adjuvant on the immunogenicity of recombinant proteins and peptide conjugates derived from the polymorphic malarial surface antigen MSA2. Jones GL, et al. **Vaccine** 1996 Jan;14(1):77-84

Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi. Luke CJ, et al. **Vaccine** 1997 Apr-May;15(6-7):739-46

Antibodies to OspB prevent infection of C3H mice challenged with Borrelia burgdorferi isolates expressing truncated OspB antigens. Probert WS, et al. **Vaccine** 1997 Jan;15(1):15-9

Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults. Van Hoecke C, et al. **Vaccine** 1996 Dec;14(17-18):1620-6

Reactivity of antibodies directed against human antigens with surface markers on canine leukocytes. Galkowska H, et al. **Vet Immunol Immunopathol** 1996 Oct;53(3-4):329-34

Ruminant cluster WC14. Howard CJ. **Vet Immunol Immunopathol** 1996 Aug;52(4):261-2

Ruminant cluster WC15. Howard CJ. **Vet Immunol Immunopathol** 1996 Aug;52(4):263

Immunohistochemical demonstration of cellular antigens of the cat defined by anti-human antibodies. Joling P, et al. **Vet Immunol Immunopathol** 1996 Sep;53(1-2):115-27

The humoral immune response of turbot, Scophthalmus maximus L., to spore-surface antigens of microsporidian parasites. Leiro J, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1-3):235-42

Ruminant cluster WC13. Mateo A, et al. **Vet Immunol Immunopathol** 1996 Aug;52(4):259-60

Characterization of monoclonal antibodies directed to canine T lymphocyte markers expressed during development. Rivas AL, et al. **Vet Immunol Immunopathol** 1996 May; 51(1-2):1-11

[The immunogenicity and heterogeneity of Pseudomonas pseudomallei surface antigen 8] Piven' NN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul-Aug;(4):75-8 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

The characterization, molecular cloning, and expression of a novel hematopoietic cell antigen from CD34+ human bone marrow cells. Uchida N, et al. **Blood** 1997 Apr 15; 89(8):2706-16

Distribution of laminin variants and their integrin receptors in human secondary lymphoid tissue. Colocalization suggests that the alpha 6 beta 4-integrin is a receptor for laminin-5 in lymphoid follicles. Jaspars LH, et al. **Cell Adhes Commun** 1996 Nov;4(4-5):269-79

Surface antigens of the syphilis spirochete and their potential as virulence determinants. Blanco DR, et al. **Emerg Infect Dis** 1997 Jan-Mar;3(1):11-20 (47 ref.)

A model system for detection and isolation of a tumor cell surface antigen using antibody phage display. Pereira S, et al. **J Immunol Methods** 1997 Apr 11;203(1):11-24

Fimbriae extracts from enterotoxigenic Escherichia coli strains of bovine and porcine origin with K99 and/or F41

antigens. Vázquez F, et al. **Vet Microbiol** 1996 Feb; 48(3-4):231-41

PEL, a 'new' high-frequency red cell surface antigen. Daniels GL, et al. **Vox Sang** 1996;70(1):31-3

METABOLISM

A three-receptor model for the interaction of the K88 fimbrial adhesin variants of Escherichia coli with porcine intestinal epithelial cells. Erickson AK, et al. **Adv Exp Med Biol** 1997;412:167-73

Binding of human enterotoxigenic Escherichia coli expressing coli surface antigen 6 to rabbit intestinal enterocytes and glycoproteins. Helander A, et al. **Adv Exp Med Biol** 1997; 412:257-8

Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Moen O, et al. **Ann Thorac Surg** 1997 Jan;63(1):105-11

Relationship between MDR1 gene and surface markers in acute myeloid leukemia. Zöchbauer S, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):749-52

NKR-P1A protein, an activating receptor of rat natural killer cells, binds to the chitobiose core of uncompletely glycosylated N-linked glycans, and to linear chitooligomers. Bezouška K, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):149-53

Evidence for the formation of multimeric forms of the 5A11/HT7 antigen. Fadool JM, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):280-6

Interaction of HPC-1/syntaxin 1A with the cytoskeletal protein, tubulin. Fujiwara T, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):352-5

Distribution of 105-kDa sperm unique antigen on goat epididymal mature spermatozoa. Sarkar M, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):662-6

Polysulfated derivatives of beta-cyclodextrin and myo-inositol as potent inhibitors of the interaction between L-selectin and peripheral addressin: implying a requirement for highly clustered sulfate groups. Shailubhai K, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):488-93

Inhibition of insulin release by synthetic peptides shows that the H3 region at the C-terminal domain of syntaxin-1 is crucial for Ca(2+)- but not for guanosine 5'-[gamma-thio]triphosphate-induced secretion. Martin F, et al. **Biochem J** 1996 Nov 15;320 (Pt 1):201-5

A hematopoietic cell L-selectin ligand exhibits sulfate-independent binding activity. Sackstein R, et al. **Blood** 1997 Apr 15;89(8):2773-81

Immunochemical analysis of the Kx protein from human red cells of different Kell phenotypes using antibodies raised against synthetic peptides. Carbonnet F, et al. **Br J Haematol** 1997 Mar;96(4):857-63

Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Kawakami M, et al. **Cancer Res** 1997 Jun 15;57(12):2321-4

Neuropilin is a semaphorin III receptor. Kolodkin AL, et al. **Cell** 1997 Aug 22;90(4):753-62

Selective changes in laminin adhesion and alpha 6 beta 4 integrin regulation are associated with the initial steps in keratinocyte maturation. Tennenbaum T, et al. **Cell Growth Differ** 1996 May;7(5):615-28

The distribution of alpha 2 beta 1, alpha 3 beta 1 and alpha 6 beta 4 integrins identifies distinct subpopulations of basal keratinocytes in the outer root sheath of the human anagen hair follicle. Commo S, et al. **Cell Mol Life Sci** 1997 May; 53(5):466-71

Localization of HPC-1/syntaxin 1 in developing rat cerebellar cortex. Miya F, et al. **Cell Struct Funct** 1996 Dec;21(6):525-32

Cell surface expression of two major yeast allergens in the Pityrosporum genus. Zargari A, et al. **Clin Exp Allergy** 1997 May;27(5):584-92

Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. Taylor MR, et al. **DNA Cell Biol** 1997 Jul; 16(7):861-9

The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation. Mainiero F, et al. **EMBO J** 1997 May 1; 16(9):2365-75

The role of the cytoplasmic domain of alpha 6 integrin in the assembly and function of alpha 6 beta 1 and alpha 6 beta 4. De Melker AA, et al. **Eur J Biochem** 1996 Oct 1;241(1):254-64

The leukocyte/neuron cell surface antigen OX2 binds to a ligand on macrophages. Preston S, et al. **Eur J Immunol** 1997 Aug;27(8):1911-8

Degradation studies on Escherichia coli capsular polysaccharides by bacteriophages. Nimmich W. **FEMS Microbiol Lett** 1997 Aug 1;153(1):105-10

Sulfation and sialylation requirements for a glycoform of CD34, a major endothelial ligand for L-selectin in porcine peripheral lymph nodes. Shailubhai K, et al. **Glycobiology** 1997 Mar;7(2):305-14

Effects of irradiation on the expression of surface antigens in human ovarian cancer. Santin AD, et al. **Gynecol Oncol** 1996 Mar;60(3):468-74

Association of human NK cell surface receptors NKR-P1 and CD94 with Src-family protein kinases. Černý J, et al. **Immunogenetics** 1997;46(3):231-6

Comparison of surface antigens on eosinophils from patients with eosinophilia. Sakamoto S, et al. **Int Arch Allergy Immunol** 1996;111 Suppl 1:26-8

Co-regulation and physical association of the 67-kDa monomeric laminin receptor and the alpha6beta4 integrin. Ardini E, et al. **J Biol Chem** 1997 Jan 24;272(4):2342-5

Cysteine protease activated by expression of HIV-1 protease in transgenic mice. MIP26 (aquaporin-0) cleavage and cataract formation in vivo and ex vivo. Mitton KP, et al. **J Biol Chem** 1996 Dec 13;271(50):31803-6

A minimal region on the integrin beta4 subunit that is critical to its localization in hemidesmosomes regulates the distribution of HD1/plectin in COS-7 cells. Niessen CM, et al. **J Cell Sci** 1997 Aug;110 (Pt 15):1705-16

The subcellular distribution of the high molecular mass protein, HD1, is determined by the cytoplasmic domain of the integrin beta 4 subunit. Sánchez-Aparicio P, et al. **J Cell Sci** 1997 Jan;110 (Pt 2):169-78

The role of laminin-5 and its receptors in mammary epithelial cell branching morphogenesis. Stahl S, et al. **J Cell Sci** 1997 Jan;110 (Pt 1):55-63

NKR-P1A stimulation of arachidonate-generating enzymes in rat NK cells is associated with granule release and cytotoxic activity. Grazia Cifone M, et al. **J Immunol** 1997 Jul 1;159(1):309-17

Intracellular CD22 rapidly moves to the cell surface in a tyrosine kinase-dependent manner following antigen receptor stimulation. Sherbina NV, et al. **J Immunol** 1996 Nov 15;157(10):4390-8

Defective integrin alpha 6 beta 4 expression in the skin of patients with junctional epidermolysis bullosa and pyloric atresia [published erratum appears in J Invest Dermatol 1997 Feb;108(2):237] Brown TA, et al. **J Invest Dermatol** 1996 Sep;107(3):384-91

Selective induction of peripheral and mucosal endothelial cell addressins with peripheral lymph nodes and Peyer's patch cell-conditioned media. Denis V, et al. **J Leukoc Biol** 1996 Dec;60(6):744-52

Changes in L1 antigen expression in the rat striatum after substantia nigra lesions. Poltorak M, et al. **J Neural Transplant Plast** 1997 Jan-Mar;6(1):59-62

N-acetylated alpha-linked acidic dipeptidase may be involved in axon-Schwann cell signalling. Berger UV, et al. **J Neurocytol** 1996 Sep;25(9):499-512

Effect of mutations in vesicle-associated membrane protein (VAMP) on the assembly of multimeric protein complexes. Hao JC, et al. **J Neurosci** 1997 Mar 1;17(5):1596-603

Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. Evander M, et al. **J Virol** 1997 Mar; 71(3):2449-56

Expression of sialosyl-T and disialosyl-T antigens in erythroid cells. Muroi K, et al. **Leuk Lymphoma** 1997 May; 25(5-6):403-14 (31 ref.)

Integrin alpha 6 beta 4 forms a complex with the cytoskeletal protein HD1 and induces its redistribution in transfected COS-7 cells. Niessen CM, et al. **Mol Biol Cell** 1997 Apr; 8(4):555-66

Cross-linking CTX, a novel thymocyte-specific molecule, inhibits the growth of lymphoid tumor cells in Xenopus. Robert J, et al. **Mol Immunol** 1997 Feb;34(2):133-43

Structural basis for the interaction of superantigen with the alternative superantigen-binding receptor p85. Rogers TJ, et al. **Mol Immunol** 1997 Feb;34(3):263-72

Cell surface molecules (NCAM and L1) in intrastriatal transplants of embryonic mesencephalon in rats. Gopinath G, et al. **Neuroscience** 1996 Jul;73(1):161-9

Synapsin I and syntaxin 1B: key elements in the control of neurotransmitter release are regulated by neuronal activation and long-term potentiation in vivo. Hicks A, et al. **Neuroscience** 1997 Jul;79(2):329-40

Two different RNA binding activities for the AU-rich element and the poly(A) sequence of the mouse neuronal protein mHuC. Abe R, et al. **Nucleic Acids Res** 1996 Dec 15;24(24):4895-901

Vascular expression of endothelial antigen PAL-E indicates absence of blood-ocular barriers in the normal eye. Schlingemann RO, et al. **Ophthalmic Res** 1997;29(3):130-8

Direct in vivo measurement of targeted binding in a human tumor xenograft. Berk DA, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1785-90

A developmental switch in lymphocyte homing receptor and endothelial vascular addressin expression regulates lymphocyte homing and permits CD4+ CD3- cells to colonize lymph nodes. Mebius RE, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):11019-24

O-glycosylation of fibrinogen from different mammalian species as revealed by the binding of Escherichia coli biotinylated lectins. L'Hôte C, et al. **Thromb Haemost** 1996 Nov;76(5):710-4

[Increased expression of apoptosis-inducing proteins Fas antigen and Fas ligand on mononuclear cells of septic patients] Ungethüm U, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:623-5 (Eng. Abstr.) **(Ger)**

[Restricted expression of ganglioside GD1C on mouse naive helper T cells] Nakamura K. **Seikagaku** 1996 Dec; 68(12):1812-6 (16 ref.) **(Jpn)**

PHARMACOLOGY

Borrelia burgdorferi outer membrane protein A induces nuclear translocation of nuclear factor-kappa B and inflammatory activation in human endothelial cells. Wooten RM, et al. **J Immunol** 1996 Nov 15;157(10):4584-90

Intravital microscopy of the peripheral lymph node microcirculation in mice. von Andrian UH. **Microcirculation** 1996 Sep;3(3):287-300

[Use of cell-surface antigens of Bacteroides thetaiotaomicron in the passive hemagglutination test and in the inhibition of passive hemagglutination] Rokosz A, et al. **Med Dosw Mikrobiol** 1995;47(3-4):189-95 (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

L antigens of sheep red blood cell membranes and modulation of ion transport. Dunham PB, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C357-68 (82 ref.)

Unique site of autoantibody production in Fas-deficient mice. Jacobson BA, et al. **Ann N Y Acad Sci** 1997 Apr 5; 815:218-29 (43 ref.)

Involvement of the 112 kDa adhesin in Entamoeba histolytica phagocytosis. García-Rivera G, et al. **Arch Med Res** 1997; 28 Spec No:166-7

Overexpressed syntaxin 1A/HPC-1 inhibits insulin secretion via a regulated pathway, but does not influence glucose metabolism and intracellular Ca2+ in insulinoma cell line beta TC3 cells. Nagamatsu S, et al. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):89-93

The integrin alpha 6 beta 4 and the biology of carcinoma. Rabinovitz I, et al. **Biochem Cell Biol** 1996;74(6):811-21 (112 ref.)

A function for the integrin alpha6beta4 in the invasive properties of colorectal carcinoma cells. Chao C, et al. **Cancer Res** 1996 Oct 15;56(20):4811-9

The cytoplasmic domain of rat NKR-P1 receptor interacts with the N-terminal domain of p56(lck) via cysteine residues. Campbell KS, et al. **Eur J Immunol** 1997 Jan; 27(1):72-7

Antibody cross-linking of the thymocyte-specific cell surface molecule CTX causes abnormal mitosis and multinucleation of tumor cells. Robert J, et al. **Exp Cell Res** 1997 Aug 25;235(1):227-37

NKRP1A molecule is involved in transendothelial migration of CD4+ human T lymphocytes. Poggi A, et al. **Immunol Lett** 1997 Jun 1;57(1-3):121-3

Characterization of the physiological requirements for the bactericidal effects of a monoclonal antibody to OspB of Borrelia burgdorferi by confocal microscopy. Escudero R, et al. **Infect Immun** 1997 May;65(5):1908-15

Cloning, functional activities and in vivo tissue distribution of rat NKR-P1+ TCR alpha beta + cells. Knudsen E, et al. **Int Immunol** 1997 Jul;9(7):1043-51

Signal transduction by the alpha 6 beta 4 integrin: charting the path between laminin binding and nuclear events. Giancotti FG. **J Cell Sci** 1996 Jun;109 (Pt 6):1165-72 (84 ref.)

Lineage relationships and differentiation of natural killer (NK) T cells: intrathymic selection and interleukin (IL)-4 production in the absence of NKR-P1 and Ly49 molecules. Lantz O, et al. **J Exp Med** 1997 Apr 21;185(8):1395-401

MRC OX-2 defines a novel T cell costimulatory pathway. Borriello F, et al. **J Immunol** 1997 May 15;158(10):4548-54

Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. Lu L, et al. **J Immunol** 1997 Jun 15; 158(12):5676-84

Cell surface peptidases in human endometrium. Imai K, et al. **Mol Hum Reprod** 1996 Jun;2(6):425-31 (123 ref.)

NKRP1A and p40 molecules are involved in regulation of activation and maturation of human NK cells. Poggi A, et al. **Res Immunol** 1997 Mar-Apr;148(3):179-84 (34 ref.)

Rapid disruption of an astrocyte interaction with the extracellular matrix mediated by integrin alpha 6 beta 4 during focal cerebral ischemia/reperfusion. Wagner S, et al. **Stroke** 1997 Apr;28(4):858-65

Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Heston WD. **Urology** 1997 Mar;49(3A Suppl):104-12

THERAPEUTIC USE

Use of a recombinant antigen, SAG2, expressed as a glutathione-S-transferase fusion protein to immunize mice against Toxoplasma gondii. Lundén A, et al. **Parasitol Res** 1997;83(1):6-9

Biologic agents for the treatment of rheumatoid arthritis. Strand V, et al. **Rheum Dis Clin North Am** 1996 Feb; 22(1):117-32 (56 ref.)

TOXICITY

Differential pathogenesis of lethal mousepox in congenic DBA/2 mice implicates natural killer cell receptor NKR-P1 in necrotizing hepatitis and the fifth component of complement in recruitment of circulating leukocytes to spleen. Brownstein DG, et al. **Am J Pathol** 1997 Apr; 150(4):1407-20

ANTIGENS, SYNTHETIC see **VACCINES, SYNTHETIC**

ANTIGENS, T-INDEPENDENT

IMMUNOLOGY

Inhibitory effects of thymus-independent type 2 antigens on MHC class II-restricted antigen presentation: comparative

ANTIGENS, T-INDEPENDENT

analysis of carbohydrate structures and the antigen presenting cell. González-Fernández M, et al. **Cell Immunol** 1997 Feb 25;176(1):1-13

Avidity maturation, repertoire shift, and strain differences in antibodies to bacterial levan, a type 2 thymus-independent polysaccharide antigen. Boswell CM, et al. **J Immunol** 1996 Sep 1;157(5):1996-2005

Lack of type 2 T cell-independent B cell responses and defect in isotype switching in TNF-lymphotoxin alpha-deficient mice. Ryffel B, et al. **J Immunol** 1997 Mar 1;158(5):2126-33

A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. Snapper CM, et al. **J Immunol** 1996 Sep 15;157(6):2229-33 (72 ref.)

Restoration of T cell-independent type 2 induction of Ig secretion by neonatal B cells in vitro. Snapper CM, et al. **J Immunol** 1997 Mar 15;158(6):2731-5

T cell-independent response to Brucella-insulin identifies a preimmune repertoire for insulin. Thomas JW, et al. **J Immunol** 1997 Sep 1;159(5):2334-41

Primary human immune response to Neisseria meningitidis serogroup C in interleukin-12-treated severe combined immunodeficient mice engrafted with human peripheral blood lymphocytes. Westerink MA, et al. **J Infect Dis** 1997 Jan;175(1):84-90

ANTIGENS, THY-1

Contribution of Thy-1-CD4+ T cells to the disorganization of lymphoid follicles in retrovirus-induced immunodeficiency syndrome, MAIDS. Masuda A, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):253-60

ANALYSIS

Thy-1 immunolabeled thymocyte microdomains studied with the atomic force microscope and the electron microscope. Thimonier J, et al. **Biophys J** 1997 Sep;73(3):1627-32

Transplantation and gene transfer of the human glucocerebrosidase gene into immunoselected primate CD34+Thy-1+ cells. Donahue RE, et al. **Blood** 1996 Dec 1;88(11):4166-72

Preservation of spatial organization and antigenicity of leukocyte surface molecules by aldehyde fixation: flow cytometry and high-resolution FESEM studies of CD62L, CD11b, and Thy-1. Hasslen SR, et al. **J Histochem Cytochem** 1996 Oct;44(10):1115-22

Thy-1 expression on blast cells from adult patients with acute myeloid leukemia. Kozii R, et al. **Leuk Res** 1997 May; 21(5):381-5

Mobilization kinetics of CD34+/Thy-1dim progenitor cells during recombinant human granulocyte-colony-stimulating factor administration in normal donors. Seong C, et al. **Transfusion** 1997 Apr; 37(4):406-10

BIOSYNTHESIS

Cyclic AMP potentiates the induction of Thy-1 mRNA expression in murine B cells. Kuzin II, et al. **Biochem Soc Trans** 1997 May;25(2):163S

Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blair A, et al. **Blood** 1997 May 1;89(9):3104-12

Differential Thy-1 expression by splenic fibroblasts defines functionally distinct subsets. Borrello MA, et al. **Cell Immunol** 1996 Nov 1;173(2):198-206

Human Thy-1 is cytokine-inducible on vascular endothelial cells and is a signaling molecule regulated by protein kinase C. Mason JC, et al. **J Immunol** 1996 Jul 15;157(2):874-83

Interleukin-1alpha regulates Thy-1 expression on rat vascular endothelial cells. Ishizu A, et al. **Microvasc Res** 1997 Jan;53(1):73-8

Decrease in Thy-1 expression on peripheral CD34 positive cells induced by G-CSF mobilization. The Tohoku Children Leukemia Study Group. Tsuchiya S, et al. **Tohoku J Exp Med** 1997 Jun;182(2):157-62

BLOOD

The appearance of Thy-1- donor T cells in the peripheral circulation 3-6 weeks after bone marrow transplantation suggests an extrathymic origin. Zhong RK, et al. **Int Immunol** 1996 Feb;8(2):171-6

DRUG EFFECTS

Human Thy-1 is cytokine-inducible on vascular endothelial cells and is a signaling molecule regulated by protein kinase C. Mason JC, et al. **J Immunol** 1996 Jul 15;157(2):874-83

GENETICS

High-efficiency transduction of human lymphoid progenitor cells and expression in differentiated T cells. An DS, et al. **J Virol** 1997 Feb;71(2):1397-404

IMMUNOLOGY

Thy-1 molecule associates with protein tyrosine kinase(s) in rat mesangial cells. Narisawa-Saito M, et al. **Clin Exp Immunol** 1996 Oct;106(1):86-90

C1q, a subunit of the first component of complement, enhances antibody-mediated apoptosis of cultured rat glomerular mesangial cells. Sato T, et al. **Clin Exp Immunol** 1997 Sep;109(3):510-7

Enrichment of early fetal-liver hemopoietic stem cells of the rat using monoclonal antibodies against the transferrin receptor, Thy-1, and MRC-OX82. Crook K, et al. **Dev Immunol** 1996;4(4):235-46

In vivo effect of OPC15161, a superoxide scavenger, on anti-Thy1 nephritis. Hamada N, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):123-8

Expression of blood-brain barrier characteristics following neuronal loss and astroglial damage after administration of anti-Thy-1 immunotoxin. Krum JM, et al. **Exp Neurol** 1997 Jul;146(1):33-45

De novo CD44 expression by proliferating mesangial cells in rat anti-Thy-1 nephritis. Nikolic-Paterson DJ, et al. **J Am Soc Nephrol** 1996 Jul;7(7):1006-14

Nonatopic asthma: in vivo airway hyperreactivity adoptively transferred to naive mice by THY-1(+) and B220(+) antigen-specific cells that lack surface expression of CD3. Geba GP, et al. **J Clin Invest** 1997 Aug 1;100(3):629-38

T helper cells in murine germinal centers are antigen-specific emigrants that downregulate Thy-1. Zheng B, et al. **J Exp Med** 1996 Sep 1;184(3):1083-91

Apoptosis of cultured rat glomerular mesangial cells induced by IgG2a monoclonal anti-Thy-1 antibodies. Sato T, et al. **Kidney Int** 1996 Feb;49(2):403-12

Efficient induction of apoptosis in cultured rat glomerular mesangial cells by dimeric monoclonal IgA anti-Thy-1 antibodies. Sato T, et al. **Kidney Int** 1997 Jan;51(1):173-81

Induction of microhematuria by an IgA isotype switch variant of a monoclonal anti-Thy-1.1 antibody in the rat. van Dixhoorn MG, et al. **Kidney Int** 1996 Nov; 50(5):1612-23

Posttransplant antibody response and chronic rejection. Paul LC, et al. **Transplant Proc** 1997 Sep;29(6):2529-30

METABOLISM

Thy-3, a developmentally regulated T-cell glycoprotein associated to Thy-1 in detergent-resistant membrane microdomains. Aurrand-Lions M, et al. **Cell Immunol** 1997 Mar 15;176(2):173-9

Thy-1 molecule associates with protein tyrosine kinase(s) in rat mesangial cells. Narisawa-Saito M, et al. **Clin Exp Immunol** 1996 Oct;106(1):86-90

A specific Thy-1 molecular epitope expressed on rat mesangial cells. Oite T, et al. **Exp Nephrol** 1996 Nov-Dec; 4(6):350-60

The glycosylphosphatidylinositol-anchored surface glycoprotein Thy-1 is a receptor for the channel-forming toxin aerolysin. Nelson KL, et al. **J Biol Chem** 1997 May 2;272(18):12170-4

[Thy-1 induction and its tissue-specific regulation in the rat--studies on acute rejection and granulomatous inflammation] Takeuchi E. **Hokkaido Igaku Zasshi** 1996 Jul;71(4):531-42 (Eng. Abstr.) **(Jpn)**

[CDw90 (Thy-1) expression on CD34 positive cells in peripheral blood stem cell harvest] Miyamoto K, et al. **Rinsho Ketsueki** 1997 Jan;38(1):9-13 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Aggregation of Thy-1 glycoprotein induces thymocyte apoptosis through activation of CPP32-like proteases. Fujita N, et al. **Exp Cell Res** 1997 May 1;232(2):400-6

ICAM-1-, -2- and LFA-1-independent homotypic T cell aggregation induced by a novel activating monoclonal antibody targeting the murine Thy-1 molecule. Fan X, et al. **Inflammation** 1996 Aug;20(4):401-11

Thy-1 antigen mediates apoptosis of rat glomerular cells in vitro and in vivo. Morita H, et al. **Nephron** 1996;73(2):293-8

ULTRASTRUCTURE

Thy-1 immunolabeled thymocyte microdomains studied with the atomic force microscope and the electron microscope. Thimonier J, et al. **Biophys J** 1997 Sep;73(3):1627-32

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE

Total synthesis of the potential anticancer vaccine KH-1 adenocarcinoma antigen [published erratum appears in Nature 1997 Jul 10;388(6638):210] Deshpande PP, et al. **Nature** 1997 May 8;387(6629):164-6

ANALYSIS

Identification of a meiotically expressed carbohydrate antigen in ovarian carcinoma: I. Immunohistochemical localization. Skinner SM, et al. **Anticancer Res** 1997 Mar-Apr; 17(2A):901-6

Identification of a meiotically expressed carbohydrate antigen in ovarian carcinoma: II. Association with proteins in tumors and peritoneal fluid. Skinner SM, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):907-11

Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy. Wagner SN, et al. **Cancer Immunol Immunother** 1997 Jun;44(4):239-47

Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer. Pålsson B, et al. **Eur J Surg Oncol** 1997 Apr;23(2):151-6

Tn and sialyl-Tn antigens as potential prognostic markers in human ovarian carcinoma. Ogawa H, et al. **Gynecol Obstet Invest** 1996;41(4):278-83

Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Cao Y, et al. **Histochem Cell Biol** 1996 Aug; 106(2):197-207

Gal-GalNAc: a biomarker of colon carcinogenesis. Yang GY, et al. **Histol Histopathol** 1996 Jul;11(3):801-6

Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: relationship with histopathology and prognosis. Ghazizadeh M, et al. **Hum Pathol** 1997 Aug; 28(8):960-6

Histological diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc alpha 2-6GalNAc epitope. Kobayashi H, et al. **Hum Pathol** 1997 Apr;28(4):428-33

CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer. Banfi G, et al. **Int J Biol Markers** 1996 Apr-Jun;11(2):77-81

CA549 and TPS patterns in the diagnosis and staging of patients with breast carcinoma. Vibert HG, et al. **Int J Biol Markers** 1996 Oct-Dec;11(4):198-202

Expression of mucin-associated tumor antigens is altered by cell density. Yamashita Y, et al. **Int J Cancer** 1997 Jul 29; 72(3):457-66

Expression of carbohydrate antigen sialyl Le(a): a new functional prognostic factor in gastric cancer. Nakamori S, et al. **J Clin Oncol** 1997 Feb;15(2):816-25

Quantitative computerized image analysis of Tn and T (Thomsen-Friedenreich) epitopes in prognostication of human breast carcinoma. Wang BL, et al. **J Histochem Cytochem** 1997 Oct;45(10):1393-400

Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA. Ravindranath MH, et al. **J Immunol Methods** 1996 Oct 16;197(1-2):51-67

Preparation of a multiple antigen glycopeptide (MAG) carrying the Tn antigen. A possible approach to a synthetic carbohydrate vaccine. Bay S, et al. **J Pept Res** 1997 Jun; 49(6):620-5

Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Yiannakou JY, et al. **Lancet** 1997 Feb 8;349(9049):389-92

O-glycosylation of fibrinogen from different mammalian species as revealed by the binding of Escherichia coli biotinylated lectins. L'Hôte C, et al. **Thromb Haemost** 1996 Nov;76(5):710-4

Detection of Tn, sialosyl-Tn and T antigens in hereditary nonpolyposis colorectal cancer. Giuffrè G, et al. **Virchows Arch** 1996 Dec;429(6):345-52

[T antigen test of sputum--a new simple method for the screening of lung cancer] Li X, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Oct; 18(5):285-6, 317 (Eng. Abstr.) **(Chi)**

[The detection of laryngeal carcinoma-associated antigens in tissue and serum using three mixed monoclonal antibodies against laryngeal cancer] Chen O, et al. **Chung Hua Erh Pi Yen Hou Ko Tsa Chih** 1996;31(1):43-6 (Eng. Abstr.) **(Chi)**

[Detection of T-antigen in colorectal adenocarcinoma and polyps] Xu S, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):693-5 (Eng. Abstr.) **(Chi)**

[The use of a new marker and test systems for the diagnosis of lung cancer with a study of bronchoalveolar washings] Vikha GV, et al. **Ter Arkh** 1997;69(3):50-2 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Post-translational fate of a mucin-like leukocyte sialoglycoprotein (CD43) aberrantly expressed in a colon carcinoma cell line. Baeckström D. **J Biol Chem** 1997 Apr 25;272(17):11503-9

Stable expression of the Golgi form and secretory variants of human fucosyltransferase III from BHK-21 cells. Purification and characterization of an engineered truncated form from the culture medium. Costa J, et al. **J Biol Chem** 1997 Apr 25;272(17):11613-21

Demodex mites of human skin express Tn but not T (Thomsen-Friedenreich) antigen immunoreactivity [letter] Kanitakis J, et al. **J Cutan Pathol** 1997 Aug;24(7):454-5

BLOOD

CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Pectasides D, et al. **Am J Clin Oncol** 1997 Aug;20(4):348-53

Tumour markers in uraemia: carbohydrate antigen CA 72-4, carcinoembryonic antigen and carbohydrate antigen CA 19-9. Fernández-Fernández L, et al. **Ann Clin Biochem** 1996 Nov;33 (Pt 6):563-4

Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Carpelan-Holmström M, et al. **Br J Cancer** 1996 Sep; 74(6):925-9

Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma. Kohno N, et al. **Cancer Detect Prev** 1997; 21(2):124-8

Performance of immunoassays for ca 19-9, ca 15-3 and ca 125 tumour markers evaluated from an international quality assessment survey. Pilo A, et al. **Eur J Clin Chem Clin Biochem** 1996 Feb;34(2):145-50

A multicentre evaluation of the CA 15-3 assay, CA 19-9 assay and CA 125 II assay on the Bayer Immuno 1 System.

Römer M, et al. **Eur J Clin Chem Clin Biochem** 1997 Aug; 35(8):637–44

Tumour marker detection in oesophageal carcinoma. Mealy K, et al. **Eur J Surg Oncol** 1996 Oct;22(5):505–7

Constitutively hyposialylated human T-lymphocyte clones in the Tn-syndrome: binding characteristics of plant and animal lectins. Mrkoci K, et al. **Glycoconj J** 1996 Aug; 13(4):567–73

Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon. Bon GG, et al. **Gynecol Obstet Invest** 1996;42(1):58–62

Is OVX1 a suitable marker for endometrial cancer? Beck EP, et al. **Gynecol Oncol** 1997 May;65(2):291–6

Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Ikeguchi M, et al. **Hepatogastroenterology** 1997 May-Jun;44(15):866–71

Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability. Caird LE, et al. **Hum Reprod** 1997 Mar; 12(3):436–40

Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer. Fernández-Fernández L, et al. **Int Surg** 1996 Oct-Dec;81(4):400–2

Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. Chan DW, et al. **J Clin Oncol** 1997 Jun; 15(6):2322–8

A comparison of the clinical usefulness of CA 19-9 and CA 50 in the diagnosis and monitoring of gastrointestinal cancers. Kokocińska D, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2-4):283–7

Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. Bottini A, et al. **Tumour Biol** 1997;18(5):301–10

[Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV] Riedinger JM, et al. **Bull Cancer** 1996 Aug;83(8):654–63 (Eng. Abstr.) **(Fre)**

[Adenocarcinoma of the bladder producing carcinoembryonic antigen and carbohydrate antigen 19-9: report of a case] Iwaki H, et al. **Hinyokika Kiyo** 1997 May; 43(5):355–8 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Synthesis of alpha- and beta-biotinylated T-antigen. Bay S, et al. **Carbohydr Res** 1997 Mar 5;298(3):153–61

Chemoenzymatic synthesis of the Thomsen-Friedenreich antigen determinant. Gambert U, et al. **Carbohydr Res** 1997 Mar 26;299(1-2):85–9

Synthesis and characterisation of highly glycosylated glycopeptides with Tn-antigenic structures corresponding to human glycophorin AN. Klich G, et al. **Carbohydr Res** 1997 Mar 26;299(1-2):33–48

The Thomsen-Friedenreich (TF) antigen: a critical review on the structural, biosynthetic and histochemical aspects of a pancarcinoma-associated antigen. Hanisch FG, et al. **Histol Histopathol** 1997 Jan;12(1):263–81 (214 ref.)

Peptide mimicry of adenocarcinoma-associated carbohydrate antigens. Kieber-Emmons T, et al. **Hybridoma** 1997 Feb; 16(1):3–10

Multiple column synthesis of a library of T-cell stimulating Tn-antigenic glycopeptide analogues for the molecular characterization of T-cell-glycan specificity. Frische K, et al. **J Pept Sci** 1996 Jul-Aug;2(4):212–22

GENETICS

A potential H-DNA element in the MUC1 promoter does not influence transcription. Pahwa GS, et al. **J Biol Chem** 1996 Oct 25;271(43):26543–6

IMMUNOLOGY

Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Le(a), sialyl Le(x), GD3 and GM2) better than soluble lysate cancer vaccine. Ravindranath MH, et al. **Anticancer Drugs** 1997 Mar;8(3):217–24

Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody. Hombach A, et al. **Anticancer Res** 1997 May-Jun; 17(3C):2025–32

Carbohydrate antigens as targets for active specific immunotherapy. Ragupathi G. **Cancer Immunol Immunother** 1996 Nov;43(3):152–7 (61 ref.)

T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Galli-Stampino L, et al. **Cancer Res** 1997 Aug 1;57(15):3214–22

Increase of rat colon carcinoma cells tumorigenicity by alpha(1-2) fucosyltransferase gene transfection. Goupille C, et al. **Glycobiology** 1997 Mar;7(2):221–9

Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-->6) T antigens. O'Boyle KP, et al. **Hybridoma** 1996 Dec; 15(6):401–8

Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Avichezer D, et al. **Int J Cancer** 1997 Jul 3;72(1):119–27

Human monoclonal antibodies specific for the tumour associated Thomsen-Friedenreich antigen. Dahlenborg K, et al. **Int J Cancer** 1997 Jan 6;70(1):63–71

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. MacLean GD, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jan; 19(1):59–68

Antibodies to GM1 and Gal(beta 1-3)GalNAc at the nodes of Ranvier in human and experimental autoimmune neuropathy. Thomas FP. **Microsc Res Tech** 1996 Aug 15; 34(6):536–43 (124 ref.)

Augmenting the immunogenicity of carbohydrate tumor antigens. Livingston PO. **Semin Cancer Biol** 1995 Dec; 6(6):357–66 (56 ref.)

METABOLISM

Valency dependent patterns of binding of human L-selectin toward sialyl and sulfated oligosaccharides of Le(a) and Le(x) types: relevance to anti-adhesion therapeutics. Galustian C, et al. **Biochemistry** 1997 Apr 29;36(17):5260–6

Amino acid sequence and three-dimensional structure of the Tn-specific isolectin B4 from Vicia villosa. Osinaga E, et al. **FEBS Lett** 1997 Jul 21;412(1):190–6

Bandeiraea (Griffonia) simplicifolia lectin-I, isolectin A4, reacting with Tn (GalNAc alpha1 --> Ser/Thr) or galabiose (Gal alpha1 --> 4Gal) containing ligands. Wu AM, et al. **FEBS Lett** 1996 Dec 2;398(2-3):183–6

Mucin antigen expression in gastric carcinomas of young and old adults. Sakamoto H, et al. **Hum Pathol** 1997 Sep; 28(9):1056–65

Adhesion of human uroepithelial cells to E-selectin: possible involvement of sialosyl LewisA-ganglioside. Klopocki AG, et al. **Int J Cancer** 1996 Oct 9;68(2):239–44

Influence of Lewis alpha1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels. Orntoft TF, et al. **J Biol Chem** 1996 Dec 13; 271(50):32260–8

Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma. Hareyama H, et al. **J Clin Pathol** 1996 Dec;49(12):967–70

Alpha-fetoprotein, carcinoembryonic antigen, and carbohydrate antigen 19-9-producing gallbladder cancer. Ono T, et al. **J Gastroenterol** 1996 Oct;31(5):742–6 (14 ref.)

Characterization of peptides that bind the tumor-associated Thomsen-Friedenreich antigen selected from bacteriophage display libraries. Peletskaya EN, et al. **J Mol Biol** 1997 Jul 18;270(3):374–84

Tissue expression of Sialyl Tn antigen in gynecologic tumors. Numa F, et al. **J Obstet Gynaecol** 1995 Aug;21(4):385–9

Cell surface carbohydrates as prognostic markers in human carcinomas. Dabelsteen E. **J Pathol** 1996 Aug; 179(4):358–69 (141 ref.)

Lectin-histochemical study of O-linked glycoconjugates in dysplastic retina of Norrie disease. Uehara F, et al. **Jpn J Ophthalmol** 1996;40(2):251–4

Identification of peptide sequences that bind the Thomsen-Friedenreich cancer-associated glycoantigen from bacteriophage peptide display libraries. Peletskaya EN, et al. **Mol Divers** 1996 Oct;2(1-2):13–8

Analysis of lectin binding properties on human Burkitt's lymphoma cell lines that show high spontaneous metastasis to distant organs in SCID mice: the binding sites for soybean agglutinin lectin masked by sialylation are closely associated with metastatic lymphoma cells. Abe M, et al. **Pathol Int** 1996 Dec;46(12):977–83

Expression of sialyl-Tn in breast cancer. Correlation with prognostic parameters. Soares R, et al. **Pathol Res Pract** 1996 Dec;192(12):1181–6

PHYSIOLOGY

Carbohydrate antigens aberrantly expressed in colorectal carcinoma. Matsushita Y, et al. **Crit Rev Oncol Hematol** 1997 Jan;25(1):27–54 (303 ref.)

THERAPEUTIC USE

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Miles DW, et al. **Br J Cancer** 1996 Oct;74(8):1292–6

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. MacLean GD, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jan; 19(1):59–68

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. MacLean GD, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):309–16

ANTIGENS, VIRAL

Antigenic epitope characterization of matrix protein of Newcastle disease virus using monoclonal antibody approach: contrasting variability amongst NDV strains. Panshin A, et al. **Comp Immunol Microbiol Infect Dis** 1997 Feb;20(2):177–89

Overcoming the crypticity of a viral T cell determinant by insertion into a chimeric bacterial protein. Lo-Man R, et al. **Int Immunol** 1996 Aug;8(8):1245–55

Antigenic variability among North American and European strains of porcine reproductive and respiratory syndrome virus as defined by monoclonal antibodies to the matrix protein. Dea S, et al. **J Clin Microbiol** 1996 Jun; 34(6):1488–93

MHC class I presentation of live and heat-inactivated Sendai virus antigen in T2Kb cells depends on an intracellular compartment with endosomal characteristics. Liu T, et al. **Scand J Immunol** 1997 May;45(5):527–33

A major antigenic domain of hantaviruses is located on the aminoproximal site of the viral nucleocapsid protein. Gött P, et al. **Virus Genes** 1997;14(1):31–40

[Examination of antigen preparations from the virus of enzootic bovine leukosis with regard to suitability for immunoblotting] Bünger I, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Dec;103(12):516–9 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts. Gahéry-Ségard H, et al. **Eur J Immunol** 1997 Mar;27(3):653–9

Mucosal immunization with a measles virus CTL epitope encapsulated in biodegradable PLG microparticles. Partidos CD, et al. **J Immunol Methods** 1996 Sep 9; 195(1-2):135–8

Survival and quality of life in HIV-positive patients treated with a polyantigenic immunomodulator. Colón JI, et al. **P R Health Sci J** 1997 Mar;16(1):9–14

ANALYSIS

Direct detection of Epstein-Barr viral antigen in nasopharyngeal swabs from patients with infectious mononucleosis. Bills ND, et al. **Acad Emerg Med** 1996 Aug; 3(8):776–81

Measles virus in otosclerosis and the specific immune response of the inner ear. Arnold W, et al. **Acta Otolaryngol (Stockh)** 1996 Sep;116(5):705–9

First findings of plum pox virus in walnut trees (Juglans Regia L.) [letter] Baumgartnerová H. **Acta Virol** 1996 Feb; 40(1):59–60

Immunodetection of beet necrotic yellow vein virus RNA3-encoded protein in different host plants and tissues. Li Y, et al. **Acta Virol** 1996 Apr;40(2):67–72

Evaluation of latex agglutination test for rapid detection of goat poxvirus antigen and antibodies. Rao TV, et al. **Acta Virol** 1996 Apr;40(2):95–7

Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. Dodt KK, et al. **AIDS** 1997 Mar;11(3):F21–8

Cytomegalovirus antigenemia in acquired immunodeficiency syndrome patients with untreated cytomegalovirus retinitis. Pannuti CS, et al. **Am J Ophthalmol** 1996 Dec; 122(6):847–52

Comparison of the proteins of bovine and ovine parainfluenza-3 viruses. Kita J, et al. **Arch Vet Pol** 1994; 34(3-4):195–204

Replication of herpes simplex virus type 1 and 2 in the medulla of the adrenal gland after vaginal infection of mice. Podlech J, et al. **Arch Virol** 1996;141(10):1999–2008

Detection of canine parvovirus antigens with antibodies to synthetic peptides. Vihinen-Ranta M, et al. **Arch Virol** 1996;141(9):1741–8

Distribution of antigen of noncytopathogenic and cytopathogenic bovine virus diarrhea virus biotypes in the intestinal tract of calves following experimental production of mucosal disease. Liebler EM, et al. **Arch Virol Suppl** 1991;3:109–24

Production and characterization of monoclonal antibodies against avian reovirus strain S1133. Li L, et al. **Avian Dis** 1996 Apr-Jun;40(2):349–57

A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines. Wood DJ, et al. **Biologicals** 1995 Dec;23(4):301–11

Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Niedobitek G, et al. **Blood** 1997 Aug 15;90(4):1664–72

Immunohistochemical identification of B and T lymphocytes in formalin-fixed, paraffin-embedded feline lymphosarcomas: relation to feline leukemia virus status, tumor site, and patient age. Jackson ML, et al. **Can J Vet Res** 1996 Jul;60(3):199–204

Study of the duration and distribution of equine influenza virus subtype 2 (H3N8) antigens in experimentally infected ponies in vivo. Sutton GA, et al. **Can J Vet Res** 1997 Apr; 61(2):113–20

Immunogenicity of viral epitopes expressed on genetically and enzymatically engineered immunoglobulins. Bona CA, et al. **Chem Immunol** 1997;65:179–206 (70 ref.)

Enzyme-linked immunosorbent assay-based detection of antibodies to antigenic subtypes of infectious bursal disease viruses of chickens. Jackwood DJ, et al.

Clin Diagn Lab Immunol 1996 Jul;3(4):456–63

HHV–6 antigen and viral DNA detected in cervical cells from archived tissue using histochemical staining and hybridization. Yadav M, et al. **Clin Diagn Virol** 1996 Oct; 7(1):23–33

Hantavirus antigen detection in kidney biopsies from patients with nephropathia epidemica. Groen J, et al. **Clin Nephrol** 1996 Dec;46(6):379–83

Detection of viral antigen in the endolymphatic sac. Kumagami H. **Eur Arch Otorhinolaryngol** 1996; 253(4–5):264–7

The generation of memory antigen–specific cytotoxic T cell responses by CD28/CD80 interactions in the absence of antigen. Flynn K, et al. **Eur J Immunol** 1997 Feb; 27(2):456–62

Persistence of airway hyperresponsiveness and viral antigen following respiratory syncytial virus bronchiolitis in young guinea–pigs. Riedel F, et al. **Eur Respir J** 1997 Mar; 10(3):639–45

Hepatitis C virus–related proteins in kidney tissue from hepatitis C virus–infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Sansonno D, et al. **Hepatology** 1997 May;25(5):1237–44

Uses of biosensors in the study of viral antigens. Van Regenmortel MH, et al. **Immunol Invest** 1997 Jan–Feb; 26(1–2):67–82 (48 ref.)

An epidemic of viral acute haemorrhagic conjunctivitis in Delhi in 1994. Satpathy G, et al. **Indian J Ophthalmol** 1996 Mar;44(1):19–21

Antigenic differences between HSV–1 and HSV–2 glycoproteins and their importance for type–specific serology. Bergström T, et al. **Intervirology** 1996; 39(3):176–84 (79 ref.)

Evaluation of a saliva test kit for feline leukemia virus antigen. Babyak SD, et al. **J Am Anim Hosp Assoc** 1996 Sep–Oct;32(5):397–400

FeLV, FIV testing recommendations issued [news] **J Am Vet Med Assoc** 1996 Oct 15;209(8):1360

Comparative peptide mapping of a hepatitis C viral recombinant protein by capillary electrophoresis and matrix–assisted laser desorption time–of–flight mass spectrometry. Winkler MA, et al. **J Chromatogr A** 1996 Sep 13;744(1–2):177–85

Comparison of culture and the antigenemia assay for detection of cytomegalovirus in blood specimens submitted to a reference laboratory. Brumback BG, et al. **J Clin Microbiol** 1997 Jul;35(7):1819–21

Antigen detection: the method of choice in comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in human immunodeficiency virus–infected patients. Dahl H, et al. **J Clin Microbiol** 1997 Feb; 35(2):347–9

Identification of a variant subgroup A strain of respiratory syncytial virus. Mufson MA, et al. **J Clin Microbiol** 1996 Oct;34(10):2493–6

Detection of porcine reproductive and respiratory syndrome virus and Mycoplasma hyorhinis antigens in pulmonary lesions of pigs suffering from respiratory distress. Kawashima K, et al. **J Comp Pathol** 1996 Apr;114(3):315–23

Viral antigen and B and T lymphocytes in lymphoid tissues of gnotobiotic piglets infected with hog cholera virus. Narita M, et al. **J Comp Pathol** 1996 Apr;114(3):257–63

An Epstein–Barr virus–associated superantigen. Sutkowski N, et al. **J Exp Med** 1996 Sep 1;184(3):971–80

Characterization of virus–specific and cross–reactive monoclonal antibodies to Herpesvirus simiae (B virus). Blewett EL, et al. **J Gen Virol** 1996 Nov;77 (Pt 11):2787–93

Quantitative determination and visualization of herpes simplex virus type 1 antigen, free and cell–bound by ELISA. Tirado R, et al. **J Immunoassay** 1996 Aug; 17(3):277–91

Human papillomavirus and p53 oncoprotein in verrucous carcinoma of the larynx. López–Amado M, et al. **J Laryngol Otol** 1996 Aug;110(8):742–7

Bluetongue virus in laboratory–reared Culicoides variipennis sonorensis: applications of dot–blot, ELISA, and immunoelectron microscopy. Nunamaker RA, et al. **J Med Entomol** 1997 Jan;34(1):18–23

A monoclonal antibody pool for routine immunohistochemical detection of human respiratory syncytial virus antigens in formalin–fixed, paraffin–embedded tissue. Wright C, et al. **J Pathol** 1997 Jun;182(2):238–44

Fatal experimental equine arteritis virus infection of a pregnant mare: immunohistochemical staining of viral antigens. MacLachlan NJ, et al. **J Vet Diagn Invest** 1996 Jul;8(3):367–74

Immunohistochemistry of transmissible gastroenteritis virus antigens in fixed paraffin–embedded tissues. Shoup DI, et al. **J Vet Diagn Invest** 1996 Apr;8(2):161–7

Distribution of cytopathic and noncytopathic bovine viral diarrhea virus antigens in tissues of calves following acute experimental infection. Spagnuolo–Weaver M, et al. **J Vet Diagn Invest** 1997 Jul;9(3):287–97

Immunohistochemical detection of porcine reproductive and respiratory syndrome virus antigen in neurovascular lesions. Thanawongnuwech R, et al. **J Vet Diagn Invest** 1997 Jul;9(3):334–7

Antigenic and plaque variations of serotype II feline infectious peritonitis coronaviruses. Mochizuki M, et al. **J Vet Med Sci** 1997 Apr;59(4):253–8

Demonstration of infectious bovine rhinotracheitis virus antigen by immunoperoxidase method in tissues of aborted bovine fetuses preserved for 25 years in paraffin blocks. Ogino H, et al. **J Vet Med Sci** 1996 May;58(5):459–60

The transneuronal spread phenotype of herpes simplex virus type 1 infection of the mouse hind footpad. Engel JP, et al. **J Virol** 1997 Mar;71(3):2425–35

Development and application of HHV–6 antigen capture assay for the detection of HHV–6 infections. Marsh S, et al. **J Virol Methods** 1996 Sep;61(1–2):103–12

A sensitive one–step immunocapture EIA for rapid diagnosis of influenza A. Ťkáčová M, et al. **J Virol Methods** 1996 Jun;60(1):65–71

Procedures for reproducible detection of rabies virus antigen mRNA and genome in situ in formalin–fixed tissues. Warner CK, et al. **J Virol Methods** 1997 Aug;67(1):5–12

A method for detection of HHV–6 antigens and its use for evaluating antiviral drugs. Yoshida M, et al. **J Virol Methods** 1996 Apr 26;58(1–2):137–43

Prevalence of Herpesvirus papio 2 in baboons and identification of immunogenic viral polypeptides. Eberle R, et al. **Lab Anim Sci** 1997 Jun;47(3):256–62

Increased enzyme–linked immunosorbent assay specificity with solubilized simian retrovirus 2–infected cell membranes. Thouless ME, et al. **Lab Anim Sci** 1996 Dec; 46(6):619–22

Distribution of viral antigen in tissues of new–born lambs infected with Rift Valley fever virus. Van der Lugt JJ, et al. **Onderstepoort J Vet Res** 1996 Dec;63(4):341–7

Association of torovirus with acute and persistent diarrhea in children. Koopmans MP, et al. **Pediatr Infect Dis J** 1997 May;16(5):504–7

Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue. Pepper C, et al. **Thorax** 1996 Nov;51(11):1074–6

Methanol–precipitated, detergent–treated Newcastle disease virus as an agar–gel precipitation test antigen. Roy P, et al. **Trop Anim Health Prod** 1997 Feb;29(1):25–8

Coagglutination test for rapid detection of infectious bursal disease virus antigen. Shakya S, et al. **Trop Anim Health Prod** 1997 May;29(2):105–7

Implementation of internal laboratory quality control procedures for the monitoring of ELISA performance at a regional veterinary laboratory. Blacksell SD, et al. **Vet Microbiol** 1996 Jul;51(1–2):1–9

Ultrastructural study of turkey rhinotracheitis virus infection in turbinates of experimentally infected chickens. Majó N, et al. **Vet Microbiol** 1996 Sep;52(1–2):37–48

Immunocytochemical study of the pathogenesis of Pacheco's parrot disease in budgerigars. Ramis A, et al. **Vet Microbiol** 1996 Sep;52(1–2):49–61

Subgrouping of bovine respiratory syncytial virus strains detected in lung tissue. Schrijver RS, et al. **Vet Microbiol** 1996 Dec;53(3–4):253–60

Immunohistochemical identification of porcine respiratory coronavirus antigen in the lung of conventional pigs. Ahn K, et al. **Vet Pathol** 1997 Mar;34(2):167–9

Immunohistochemical detection of VHS virus in paraffin–embedded specimens of rainbow trout (Oncorhynchus mykiss): the influence of primary antibody, fixative, and antigen unmasking on method sensitivity. Evensen O, et al. **Vet Pathol** 1997 May;34(3):253–61

Immunohistochemical demonstration of equine herpesvirus–1 antigen in neurons and astrocytes of horses with acute paralysis. Schultheiss PC, et al. **Vet Pathol** 1997 Jan; 34(1):52–4

BVD virus antigen in Purkinje fibres in a calf [letter] Del Piero F, et al. **Vet Rec** 1997 Apr 12;140(15):407–8

Production and characterization of murine IgA monoclonal antibodies to the surface antigens of rhesus rotavirus. Giammarioli AM, et al. **Virology** 1996 Nov 1;225(1):97–110

A novel strategy for determining protective antigens of the parapoxvirus, orf virus. Mercer AA, et al. **Virology** 1997 Mar 3;229(1):193–200

Antigenic and genetic comparisons of Japanese and Australian Simbu serogroup viruses: evidence for the recovery of natural virus reassortants. Akashi H, et al. **Virus Res** 1997 Aug;50(2):205–13

Detection of rabies virus antigen in animals by avidin–biotin dot ELISA. Jayakumar R, et al. **Zentralbl Bakteriol** 1996 Sep;285(1):82–5

Epithelial neoplasms of the skin, the cutaneous mucosa and the transitional epithelium in dogs: an immunolocalization study for papillomavirus antigen. Schwegler K, et al. **Zentralbl Veterinarmed A** 1997 Apr;44(2):115–23

Diagnosis of rabbit haemorrhagic disease (RHD) and European brown hare syndrome (EBHS) by indirect sandwich polyclonal ELISA. Nardelli S, et al. **Zentralbl Veterinarmed [B]** 1996 Sep;43(7):393–400

[Virological tests] Shimada S, et al. **Rinsho Byori** 1996 Nov; Suppl 103:241–9 **(Jpn)**

[Development of the immunoenzyme test–system for detection of Ebola virus antigen] Borisevich IV, et al. **Vopr Virusol** 1996 Sep–Oct;41(5):232–4 (Eng. Abstr.) **(Rus)**

[A system of immunoenzyme analysis using biotinylated monoclonal antibodies for typing hantavirus antigens] Ivanov AP, et al. **Vopr Virusol** 1996 Nov–Dec;41(6):263–5 (Eng. Abstr.) **(Rus)**

[Polyclonal immunoenzyme system for determining hantaviral antigens: assessment of specificity using monoclonal antibodies and the polymerase chain reaction] Ivanov AP, et al. **Vopr Virusol** 1996 May–Jun;41(3):110–2 (Eng. Abstr.) **(Rus)**

[An analysis of the stability of the antigenic structure in productive strain 205 of the tick–borne encephalitis virus during prolonged passage] Karpova MR, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul–Aug;(4):11–3 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Enhancement of tumor associated antigen expression during the regression phase of xenogenized tumor cell growth in vivo. Shibata T, et al. **Anticancer Res** 1997 May–Jun; 17(3C):2135–40

Immunogenic, non–infectious polio subviral particles synthesized in Saccharomyces cerevisiae. Rombaut B, et al. **J Gen Virol** 1997 Aug;78 (Pt 8):1829–32

Inhibition of the expression of hepatitis A and B viruses (HAV and HBV) proteins by interferon in a human hepatocarcinoma cell line (PLC/PRF/5). Berthillon P, et al. **J Hepatol** 1996 Jul;25(1):15–9

Human immunodeficiency virus type 1 gp120 stimulates cytomegalovirus replication in monocytes: possible role of endogenous interleukin–8. Capobianchi MR, et al. **J Virol** 1997 Feb;71(2):1591–7

Toward a poliovirus–based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity. Tang S, et al. **J Virol** 1997 Oct; 71(10):7841–50

BLOOD

Identification of cattle infected with bovine virus diarrhoea virus using a monoclonal antibody capture ELISA. Fenton A, et al. **Arch Virol Suppl** 1991;3:169–74

Cytomegalovirus pp65 antigenemia–guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double–blind study. Boeckh M, et al. **Blood** 1996 Nov 15; 88(10):4063–71

Monitoring of CMV infection: a comparison of PCR from whole blood, plasma–PCR, pp65–antigenemia and virus culture in patients after bone marrow transplantation. Hebart H, et al. **Bone Marrow Transplant** 1996 May; 17(5):861–8

Comparison of cytomegalovirus (CMV) antigenemia and CMV in bronchoalveolar lavage fluid for diagnosis of CMV pulmonary infection after bone marrow transplantation. Sakamaki H, et al. **Bone Marrow Transplant** 1997 Jul;20(2):143–7

Correlation between human cytomegalovirus quantitative p72 antigenemia and viremia. Reina J, et al. **Clin Diagn Virol** 1996 Oct;7(1):63–7

Cytomegalovirus (CMV) DNA amplification from plasma compared with CMV pp65 antigen (ppUL83) detection in leukocytes for early diagnosis of symptomatic CMV infection in kidney transplant patients. Wirgart BZ, et al. **Clin Diagn Virol** 1996 Nov;7(2):99–110

Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Gotti E, et al. **Clin Transplant** 1996 Dec;10(6 Pt 1):550–5

Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay. Lo CY, et al. **Clin Transplant** 1997 Aug;11(4):286–93

Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients. Niubò J, et al. **Diagn Microbiol Infect Dis** 1996 Jan;24(1):19–24

Proficiency testing of selected antigen and antibody tests for use in dogs and cats. Troy GC, et al. **J Am Vet Med Assoc** 1996 Sep 1;209(5):914–7

Dot immunoperoxidase assay for detection of parvovirus B19 antigens in serum samples. Gentilomi G, et al. **J Clin Microbiol** 1997 Jun;35(6):1575–8

Interest of quantitative pp65 cytomegalovirus antigenemia assay for human immunodeficiency virus–positive patients [letter; comment] Ranger–Rogez S, et al. **J Clin Microbiol** 1996 Dec;34(12):3255–6. Comment on: J Clin Microbiol 1996 Feb;34(2):457–9.

Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leukocytes compared to results of an antigenemia assay. Schäfer P, et al. **J Clin Microbiol** 1997 Mar;35(3):741–4

Comparative study of three PCR assays with antigenaemia and serology for the diagnosis of HCMV infection in thoracic transplant recipients. Barber L, et al. **J Med Virol** 1996 Jun;49(2):137–44

Significance of cytomegalovirus (CMV)–pp65 antigenemia in the diagnosis of CMV disease in human immunodeficiency virus–infected patients. Reynes J, et al. **J Med Virol** 1996 Jul;49(3):195–8

A solid–phase enzyme linked immunosorbent assay using monoclonal antibodies, for the detection of African swine fever virus antigens and antibodies. Vidal MI, et al. **J Virol Methods** 1997 Jul;66(2):211–8

Changing seroepidemiology of HHV–8 [comment] Rickinson AB. **Lancet** 1996 Oct 26;348(9035):1110–1. Comment on: Lancet 1996 Oct 26;348(9035):1133–8.

Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid

protein and latent immunofluorescence antigen [see comments] Simpson GR, et al. **Lancet** 1996 Oct 26; 348(9035):1133–8. Comment in: Lancet 1996 Oct 26;348(9035):1110–1.

"Heterophile" antigen in sera of human recipients of renal allografts. Milgrom F, et al. **Proc Soc Exp Biol Med** 1996 Oct;213(1):80–4

Food and Drug Administration conference on the feasibility of genetic technology to close the HIV window in donor screening. Hewlett IK, et al. **Transfusion** 1997 Mar; 37(3):346–51

Virological diagnosis of cytomegalovirus in renal transplantation: comparison of three diagnostic methods: DNA in plasma by PCR, PP65 leukocytic antigenemia, and viremia. Eckart P, et al. **Transplant Proc** 1996 Oct; 28(5):2806–7

Utility of the pp65 direct antigenemia test in the diagnosis of cytomegalovirus (CMV) in renal transplant recipients. Sharma AK, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):799

Antigens of bovine respiratory syncytial virus in peripheral blood lymphocytes of experimentally infected lambs. Sharma AK, et al. **Vet Immunol Immunopathol** 1996 Mar; 50(1–2):93–104

Detection by ELISA of bluetongue antigen directly in the blood of experimentally infected sheep. Stanislawek WL, et al. **Vet Microbiol** 1996 Sep;52(1–2):1–12

[Detection of human cytomegalovirus-antigen in peripheral blood cells by using flow-cytometer] Honda J, et al. **Kansenshogaku Zasshi** 1996 Sep;70(9):923–30 (Eng. Abstr.) **(Jpn)**

[Effect of antigenemia on diagnosis and determination of the result of therapy of cytomegalovirus infection in formerly healthy adults (letter)] Asai T. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jun;94(6):450 **(Jpn)**

[Successful diagnosis and treatment of a case of cytomegalovirus infection in a previously healthy adult by antigenemia assay] Nagata S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Mar;94(3):225–8 (15 ref.) **(Jpn)**

[The use of synthetic peptides for detection of antibodies against foot-and-mouth disease virus in the blood from convalescent animals] Petrov VN, et al. **Mol Gen Mikrobiol Virusol** 1996 Jul–Sep;(3):27–31 (Eng. Abstr.) **(Rus)**

[Antigenemia in people infected with tick-borne encephalitis virus] Leonova GN, et al. **Vopr Virusol** 1996 Nov–Dec; 41(6):260–3 (Eng. Abstr.) **(Rus)**

[Secretion of tick-borne encephalitis virus glycoproteins E and NS1 heterocomplex in the late stage of infection] Matveeva VA, et al. **Vopr Virusol** 1997 Jul–Aug; 42(4):179–82 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Diagnosis of cytomegalovirus (CMV) polyradiculopathy and documentation of in vivo anti-CMV activity in cerebrospinal fluid by using branched DNA signal amplification and antigen assays. Flood J, et al. **J Infect Dis** 1997 Aug;176(2):348–52

CHEMISTRY

Identification and characterization of differentiating soluble antigens of sheep and goat poxviruses. Rao TV, et al. **Acta Virol** 1996 Nov–Dec;40(5–6):259–62

Conformational preferences of a peptide corresponding to the major antigenic determinant of foot-and-mouth disease virus: implications for peptide-vaccine approaches. de Prat-Gay G. **Arch Biochem Biophys** 1997 May 15; 341(2):360–9

Regulation of N-linked core glycosylation: use of a site-directed mutagenesis approach to identify Asn-Xaa-Ser/Thr sequons that are poor oligosaccharide acceptors. Kasturi L, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):415–9

An epitope chimeric antigen for the hepatitis C virus serological screening test. Yagi S, et al. **Biol Pharm Bull** 1996 Oct;19(10):1254–60

Interaction with phospholipid mono- and bilayers of HAV-VP3 (102–121) sequence by using spectroscopic techniques. Garcia M, et al. **Biomed Chromatogr** 1997 Mar–Apr;11(2):121–3

Improved reactivity of hepatitis C virus core protein epitopes in a conformational antigen-presenting system. Buratti E, et al. **Clin Diagn Lab Immunol** 1997 Mar;4(2):117–21

Structure of the complex of an Fab fragment of a neutralizing antibody with foot-and-mouth disease virus: positioning of a highly mobile antigenic loop. Hewat EA, et al. **EMBO J** 1997 Apr 1;16(7):1492–500

NMR studies on the flexibility of the poliovirus C3 linear epitope inserted into different sites of the maltose-binding protein. Lecroisey A, et al. **J Biol Chem** 1997 Jan 3; 272(1):362–8

The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. Schoppel K, et al. **J Infect Dis** 1997 Mar;175(3):533–44

Biochemical and functional analysis of the Borna disease virus G protein. Schneider PA, et al. **J Virol** 1997 Jan;71(1):331–6

Structural requirements for synthetic immunogens to induce measles virus specific CTL responses. Partidos CD, et al. **Mol Immunol** 1996 Nov;33(16):1223–9

Human rhinovirus 3 at 3.0 A resolution. Zhao R, et al. **Structure** 1996 Oct 15;4(10):1205–20

Structural analysis of a mutation in canine parvovirus which controls antigenicity and host range. Llamas-Saiz AL, et al. **Virology** 1996 Nov 1;225(1):65–71

Genetic and antigenic heterogeneity among feline calicivirus isolates from distinct disease manifestations. Geissler K, et al. **Virus Res** 1997 May;48(2):193–206

Characterization and expression of the Marek's disease virus serotype 2 glycoprotein E in recombinant baculovirus-infected cells: initial analysis of its DNA sequence and antigenic properties. Jang HK, et al. **Virus Res** 1997 May;48(2):111–23

CLASSIFICATION

[The antigenic differentiation of hantaviruses by using monoclonal antibodies] Dzagurova TK, et al. **Med Parazitol (Mosk)** 1996 Jul–Sep;(3):47–52 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Simian immunodeficiency virus (SIV)-specific CD8+ cytotoxic T lymphocyte responses of naive and vaccinated cynomolgus macaques infected with SIVmac32H(J5): quantitative analysis by in vitro antigenic stimulation. Geretti AM, et al. **Vaccine** 1997 Aug;15(11):1269–75

Use of a related ELISA antigen for efficient TRT serological testing following live vaccination. Toquin D, et al. **Vet Rec** 1996 Jul 20;139(3):71–2

DRUG EFFECTS

Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced Epstein-Barr virus early antigen activation by natural colorants. Kapadia GJ, et al. **Cancer Lett** 1997 May 19; 115(2):173–8

Inhibitory effects of quassinoid derivatives on Epstein-Barr virus early antigen activation. Rahman S, et al. **Chem Pharm Bull (Tokyo)** 1997 Apr;45(4):675–7

[Effects of processing on specific toxicity and pharmacodynamics of radix Kansui, radix Achyranthis bidentatae and semen Armeniacae amarum] Nie S, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Mar;21(3):153–6, 190 (Eng. Abstr.) **(Chi)**

GENETICS

Sequence of the VP7 gene of an atypical human rotavirus: evidence for genetic and antigenic drift. Palombo EA, et al. **DNA Seq** 1997;7(5):307–11

Plasmodium yoelii: resistance to disease is linked to the mtv-7 locus in BALB/c mice. Swardson CJ, et al. **Exp Parasitol** 1997 Jun;86(2):102–9

Intracellular production of a major cytomegalovirus antigenic protein in the methylotrophic yeast Pichia pastoris. Battista MC, et al. **Gene** 1996 Oct 17; 176(1–2):197–201

Peptide display on functional tailspike protein of bacteriophage P22. Carbonell X, et al. **Gene** 1996 Oct 17; 176(1–2):225–9

Periplasmic expression of part of the major rotavirus capsid protein VP7 containing all the three antigenic regions in Escherichia coli. Wang L, et al. **Gene** 1996 Oct 24; 177(1–2):155–62

The Mtv29 gene encoding endogenous lymphoma superantigen in SJL mice, mapped to proximal chromosome 6. Zhang DJ, et al. **Immunogenetics** 1997; 46(2):163–6

Regulation of human cytomegalovirus immediate-early gene expression. Meier JL, et al. **Intervirology** 1996; 39(5–6):331–42 (114 ref.)

Activation and regulation of human cytomegalovirus early genes. Spector DH. **Intervirology** 1996;39(5–6):361–77 (107 ref.)

The human cytomegalovirus major immediate-early gene. Stenberg RM. **Intervirology** 1996;39(5–6):343–9 (56 ref.)

Splicing factors associate with nuclear HCMV-IE transcripts after transcriptional activation of the gene, but dissociate upon transcription inhibition: evidence for a dynamic organization of splicing factors. Dirks RW, et al. **J Cell Sci** 1997 Feb;110 (Pt 4):515–22

Expression and self-assembly of recombinant capsid protein from the antigenically distinct Hawaii human calicivirus. Green KY, et al. **J Clin Microbiol** 1997 Jul;35(7):1909–14

Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. Addison CL, et al. **J Gen Virol** 1997 Jul;78 (Pt 7):1653–61

Nucleotide sequence analysis of a major antigenic domain of the E1 glycoprotein of 22 rubella virus isolates. Bosma TJ, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2523–30

Antigenic and genetic analyses of H1N1 influenza A viruses from European pigs. Brown IH, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):553–62

Long-term evolution of the 5'UTR and a region of NS4 containing a CTL epitope of hepatitis C virus in two haemophilic patients. Devereux HL, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):583–90

cAMP response element of murine cytomegalovirus immediate early gene enhancer is transactivated by ras oncogene products. Gaboli M, et al. **J Gen Virol** 1995 Apr; 76 (Pt 4):751–8

Mapping the neutralizing epitopes on the glycoprotein of infectious haematopoietic necrosis virus, a fish rhabdovirus. Huang C, et al. **J Gen Virol** 1996 Dec;77 (Pt 12):3033–40

Effect of natural sequence variation at the H-2Ld-restricted CD8+ T cell epitope of the murine cytomegalovirus ie1-encoded pp89 on T cell recognition. Lyons PA, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2615–23

Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. Mendelson M, et al. **J Gen Virol** 1996 Dec;77 (Pt 12):3099–102

Sequence analysis of hypervariable region of hepatitis C virus (HCV) associated with immune complex in patients with chronic HCV infection. Aiyama T, et al. **J Infect Dis** 1996 Dec;174(6):1316–20

Molecular epidemiology of rubella by nucleotide sequences of the rubella virus E1 gene in three East Asian countries. Katow S, et al. **J Infect Dis** 1997 Sep;176(3):602–16

Enhancement of varicella-zoster virus infection in cell lines expressing ORF4- or ORF62-encoded proteins. Schoonbroodt S, et al. **J Med Virol** 1996 Aug;49(4):264–73

Infection with GB virus C (GBV-C) in patients with chronic liver disease or on maintenance hemodialysis in Indonesia. Tsuda F, et al. **J Med Virol** 1996 Jul;49(3):248–52

Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus major immediate-early promoters in monocyte and T-lymphocyte cell types. Chan YJ, et al. **J Virol** 1996 Dec;70(12):8590–605

DNA immunization confers protection against murine cytomegalovirus infection. González Armas JC, et al. **J Virol** 1996 Nov;70(11):7921–8

Retention of viral infectivity after extensive mutation of the highly conserved immunodominant domain of the feline immunodeficiency virus envelope. Pancino G, et al. **J Virol** 1997 Jun;71(6):4339–46

Detection of Borna disease virus (BDV) antibodies and BDV RNA in psychiatric patients: evidence for high sequence conservation of human blood-derived BDV RNA. Sauder C, et al. **J Virol** 1996 Nov;70(11):7713–24

Recombinational history and molecular evolution of western equine encephalomyelitis complex alphaviruses. Weaver SC, et al. **J Virol** 1997 Jan;71(1):613–23

An indirect ELISA for the detection of antibodies against porcine reproductive and respiratory syndrome virus using recombinant nucleocapsid protein as antigen. Denac H, et al. **J Virol Methods** 1997 May;65(2):169–81

Expression and purification of an Epstein-Barr virus encoded 23-kDa protein and characterization of its immunological properties. Reischl U, et al. **J Virol Methods** 1996 Mar; 57(1):71–85

Emerging foot-and-mouth disease virus variants with antigenically critical amino acid substitutions predicted by model studies using reference viruses. Feigelstock DA, et al. **Vaccine** 1996 Feb;14(2):97–102

Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Kochel T, et al. **Vaccine** 1997 Apr;15(5):547–52

Characterization of enzootic nasal tumor virus capsid antigen. Rosati S, et al. **Vet Microbiol** 1996 Dec;53(3–4):261–9

Sequence conservation in the attachment glycoprotein and antigenic diversity among bovine respiratory syncytial virus isolates. Stine LC, et al. **Vet Microbiol** 1997 Mar; 54(3–4):201–21

Antigenic variability of porcine reproductive and respiratory syndrome (PRRS) virus isolates. Influence of virus passage in pig. Le Gall A, et al. **Vet Res** 1997 May-Jun;28(3):247–57

Two amino acid changes at the N-terminus of transmissible gastroenteritis coronavirus spike protein result in the loss of enteric tropism. Ballesteros ML, et al. **Virology** 1997 Jan 20;227(2):378–88

Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Ryman KD, et al. **Virology** 1997 Apr 14;230(2):376–80

Rat cytomegalovirus has a unique immediate early gene enhancer. Sandford GR, et al. **Virology** 1996 Aug 15; 222(2):310–7

Differential immune recognition of LCMV nucleoprotein and glycoprotein in transgenic mice expressing LCMV cDNA genes. Zeller JC, et al. **Virology** 1997 May 12; 231(2):290–300

Sequence and phylogenetic analysis of the VP7 gene of a bovine rotavirus with G6 subtype [letter] Mummidi S, et al. **Virus Genes** 1996;12(3):203–4

Characterization of the 3' proximal gene of the citrus tristeza closterovirus genome. Pappu SS, et al. **Virus Res** 1997 Jan; 47(1):51–7

Prokaryotic expression of an immediate-early gene of human herpesvirus 6 and analysis of its viral antigen expression in human cells. Takeda K, et al. **Virus Res** 1996 Apr; 41(2):193–200

[High homology between antigen of HFRSV with anti-idiotype antibody against HFRSY] Gao L, et al. **Chung Hua I Hsueh Tsa Chih** 1996 May;76(5):349–51 (Eng. Abstr.) **(Chi)**

[Cloning and sequencing of genes coding the glycoproteins of antigens A and B of oncogenic strain JM of Marek disease virus (MDV)] Bedristov AI, et al. **Mol Gen Mikrobiol Virusol** 1996 Jul–Sep;(3):6–11 (Eng. Abstr.) **(Rus)**

ANTIGENS, VIRAL

IMMUNOLOGY

Partial antigenic characterization of potato virus S (Andean strain) by monoclonal antibodies. Ceřovská N, et al. **Acta Virol** 1996 Feb;40(1):23–6

Differences between original strains and their mouse-adapted variants of human (H1) and avian (H2) influenza A viruses in the reaction with cross-neutralizing monoclonal antibody recognizing conformational epitope. Lipatov AS, et al. **Acta Virol** 1996 Sep;40(4):227–30

Serological study of type A Indian foot-and-mouth disease virus isolates. Meer Azad H, et al. **Acta Virol** 1995 Sep; 39(4):193–6

Identification and characterization of differentiating soluble antigens of sheep and goat poxviruses. Rao TV, et al. **Acta Virol** 1996 Nov-Dec;40(5–6):259–62

Diagnostic importance of heterophile antibodies and immunoglobulins IgA, IgE, IgM and low-avidity IgG against Epstein-Barr virus capsid antigen in children. Votava M, et al. **Acta Virol** 1996 Apr;40(2):99–101

Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. Li A, et al. **AIDS Res Hum Retroviruses** 1997 May 20; 13(8):647–56

Evaluation of recombinant bluetongue virus antigens, using dot immunobinding assay with serum from sheep and cattle. Naresh A, et al. **Am J Vet Res** 1996 Nov;57(11):1556–8

Molecular mimicry in human aortic aneurysmal diseases. Ozsvath KJ, et al. **Ann N Y Acad Sci** 1996 Nov 18; 800:288–93

Initiation of autoimmunity to self-proteins complexed with viral antigens. Reeves WH, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:139–54 (51 ref.)

Immunotyping HIV-1 in the 1990s. WHO Collaborating Network. Nara PL. **Antibiot Chemother** 1996;48:56–62 (4 ref.)

The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (IE62) expressed in recombinant herpes simplex virus-1. Lowry PW, et al. **Antiviral Res** 1997 Feb;33(3):187–200

Glycoprotein E2 of bovine viral diarrhea virus expressed in insect cells provides calves limited protection from systemic infection and disease. Bolin SR, et al. **Arch Virol** 1996;141(8):1463–77

Identification of three distinct antigenic sites in parapoxviruses. Czerny CP, et al. **Arch Virol** 1997; 142(4):807–21

The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Falconar AK. **Arch Virol** 1997; 142(5):897–916

Neutralization of rotavirus and recognition of immunologically important epitopes on VP4 and VP7 by human IgA. Johansen K, et al. **Arch Virol** 1997; 142(7):1491–8

Antigenic analysis of type O foot-and-mouth disease virus in the persistently infected bovine. Salt JS, et al. **Arch Virol** 1996;141(8):1407–21

Characterization of neutralizing domains on varicella-zoster virus glycoprotein E defined by monoclonal antibodies. Wu L, et al. **Arch Virol** 1997;142(2):349–62

Epitope mapping of capsid proteins VP2 and VP3 of infectious bursal disease virus. Yamaguchi T, et al. **Arch Virol** 1996;141(8):1493–507

Genetic and antigenic diversity of human caliciviruses (HuCVs) using RT-PCR and new EIAs. Jiang X, et al. **Arch Virol Suppl** 1996;12:251–62 (36 ref.)

Antigenic characterization of an Arkansas isolate of infectious bursal disease virus. Bayyari GR, et al. **Avian Dis** 1996 Jul-Sep;40(3):588–99

Comparison between antigen-capture ELISA and conventional methods used for titration of infectious bursal disease virus. Hassan MK, et al. **Avian Dis** 1996 Jul-Sep; 40(3):562–6

Recombinant env-gp85 of HPRS-103 (subgroup J) avian leukosis virus: antigenic characteristics and usefulness as a diagnostic reagent. Venugopal K, et al. **Avian Dis** 1997 Apr-Jun;41(2):283–8

Induction of human T cell responses to tumour-associated neoantigens and virus antigens using cultured dendritic cells. Li J, et al. **Biochem Soc Trans** 1997 May;25(2):204S

Normal immunologic response to a neoantigen, bacteriophage phiX-174, in baboons with long-term lymphohematopoietic reconstitution from highly purified CD34+ Lin- allogeneic marrow cells. Andrews RG, et al. **Blood** 1997 Aug 15;90(4):1701–8

Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Diamond DJ, et al. **Blood** 1997 Sep 1; 90(5):1751–67

Bone marrow contains virus-specific cytotoxic T lymphocytes. Slifka MK, et al. **Blood** 1997 Sep 1; 90(5):2103–8

Th1 and Th2 cytokine responses after measles antigen stimulation in vitro in bone marrow transplant patients: response to measles vaccination. Pauksen K, et al. **Bone Marrow Transplant** 1997 Aug;20(4):317–23

Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D. Chow KC, et al. **Cancer Epidemiol Biomarkers Prev** 1997 May;6(5):363–8

Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. Strickler HD, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Mar;6(3):183–8

The immunogenicity of experimental tumors is strongly biased by the expression of dominant viral cytotoxic T-lymphocyte epitopes. Iezzi G, et al. **Cancer Res** 1997 Jul 1;57(13):2564–8

Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Murata K, et al. **Cell Immunol** 1996 Oct 10;173(1):96–107

Use of recombinant Epstein-Barr virus early antigen for detection of antibody in patients with nasopharyngeal carcinoma. Liu MT, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jan;57(1):7–15

Prevalence of antibodies to feline parvovirus, calicivirus, herpesvirus, coronavirus, and immunodeficiency virus and of feline leukemia virus antigen and the interrelationship of these viral infections in free-ranging lions in east Africa. Hofmann-Lehmann R, et al. **Clin Diagn Lab Immunol** 1996 Sep;3(5):554–62

Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein. Iyengar S, et al. **Clin Diagn Lab Immunol** 1996 Nov;3(6):733–9

Evaluation of six commercially available kits using purified heterophile antigen for the rapid diagnosis of infectious mononucleosis compared with Epstein-Barr virus-specific serology. Elgh F, et al. **Clin Diagn Virol** 1996 Oct; 7(1):17–21

Comparison of commercially available antibody reagents for the cytomegalovirus pp65 antigenemia assay. St George K, et al. **Clin Diagn Virol** 1997 Feb;7(3):147–52

Inhibition of natural killer (NK) cell activity against varicella-zoster virus (VZV)-infected fibroblasts and lymphocyte activation in response to VZV antigen by nitric oxide-releasing agents. Ito M, et al. **Clin Exp Immunol** 1996 Oct;106(1):40–4

Detection and comparison of viral antigens in measles and rubella rashes. Takahashi H, et al. **Clin Infect Dis** 1996 Jan;22(1):36–9

Immunopathogenesis of virus diseases affecting the central nervous system. Bilzer T, et al. **Crit Rev Immunol** 1996; 16(2):145–222 (890 ref.)

Mimicry of viral epitopes with retro-inverso peptides of increased stability. Benkirane N, et al. **Dev Biol Stand** 1996; 87:283–91

Superantigens of mouse mammary tumour virus: implications for diabetes? Acha-Orbea H. **Diabetes Metab Rev** 1996 Jul; 12(2):111–9 (59 ref.)

Proliferative lymphocyte responses to virus antigens homologous to GAD65 in IDDM. Jones DB, et al. **Diabetologia** 1996 Nov;39(11):1318–24

Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. Inchauspe G, et al. **DNA Cell Biol** 1997 Feb; 16(2):185–95

Differential immunogenicity of Epstein-Barr virus (EBV) encoded growth transformation-associated antigens in a murine model system. Trivedi P, et al. **Eur J Cancer** 1997 May;33(6):912–7

Possible correlation between low antigenic drift of A(H1N1) influenza viruses and induction of HI antibodies. Iorio AM, et al. **Eur J Epidemiol** 1996 Dec;12(6):589–94

The generation of memory antigen-specific cytotoxic T cell responses by CD28/CD80 interactions in the absence of antigen. Flynn K, et al. **Eur J Immunol** 1997 Feb; 27(2):456–62

Major histocompatibility complex recognition by immune receptors: differences among T cell receptor versus antibody interactions with the VSV8/H-2Kb complex. Witte T, et al. **Eur J Immunol** 1997 Jan;27(1):227–33

Homeostatic regulation of CD8+ T cells after antigen challenge in the absence of Fas (CD95). Zimmermann C, et al. **Eur J Immunol** 1996 Dec;26(12):2903–10

Converging antigenic structure of a recombinant viral peptide displayed on different frameworks of carrier proteins. Carbonell X, et al. **FEBS Lett** 1996 Nov 18;397(2–3):169–72

Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Yang Y, et al. **Gene Ther** 1996 Feb; 3(2):137–44

Human monoclonal antibodies to viral peptides. Sidorova E, et al. **Hum Antibodies** 1997;8(2):65–9

Modulation of antigen processing and presentation by persistent virus infections and in tumors. Ehrlich R. **Hum Immunol** 1997 May;54(2):104–16 (126 ref.)

Substitutions in the HLA-DR alpha chain differentially affect DR7-restricted T-cell recognition of rabies virus antigen. Fu XT, et al. **Hum Immunol** 1996 Feb;45(2):111–6

Preferential presentation of herpes simplex virus T-cell antigen by HLA DQA1*0501/DQB1*0201 in comparison to HLA DQA1*0201/DQB1*0201. Koelle DM, et al. **Hum Immunol** 1997 Apr 1;53(2):195–205

Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Heikema A, et al. **Immunol Lett** 1997 Jun 1;57(1–3):69–74

Enhanced TNF alpha production by monocytic-like cells exposed to dengue virus antigens. Lee DH, et al. **Immunol Lett** 1996 Nov;53(2–3):115–20

On T cell memory: arguments for antigen dependence. Kündig TM, et al. **Immunol Rev** 1996 Apr;150:63–90 (100 ref.)

The influence of virus structure on antibody responses and virus serotype formation. Bachmann MF, et al. **Immunol Today** 1996 Dec;17(12):553–8 (48 ref.)

Antiviral immunity. Zinkernagel RM, et al. **Immunol Today** 1997 Jun;18(6):258–60 (17 ref.)

Spontaneous priming for anti-viral envelope cytotoxic T lymphocytes in mice transgenic for a murine leukaemia virus envelope gene (Fv4). Nihrane A, et al. **Immunology** 1997 Feb;90(2):219–28

Characterization of the HLA-restrictive elements of a rubella virus-specific cytotoxic T cell clone: influence of HLA-DR4 beta chain residue 74 polymorphism on antigenic peptide-T cell interaction. Ou D, et al. **Int Immunol** 1996 Oct;8(10):1577–86

Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein. Bryden H, et al. **Int J Cancer** 1997 Aug 7;72(4):614–8

Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Scheibenbogen C, et al. **Int J Cancer** 1997 Jun 11; 71(6):932–6

Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27–35 epitope. Zajac P, et al. **Int J Cancer** 1997 May 2;71(3):491–6

Isolation of Japanese encephalitis virus from Culex sitiens mosquitoes in Selangor, Malaysia. Vythilingam I, et al. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 1):228–9

Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. La Cava A, et al. **J Clin Invest** 1997 Aug 1; 100(3):658–63

Indeterminate results of the second-generation hepatitis C virus (HCV) recombinant immunoblot assay: significance of high-level c22-3 reactivity and influence of HCV genotypes. Zein NN, et al. **J Clin Microbiol** 1997 Jan; 35(1):311–2

Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. Steven NM, et al. **J Exp Med** 1997 May 5; 185(9):1605–17

Pathogenesis of an infectious mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral superantigen? Tripp RA, et al. **J Exp Med** 1997 May 5; 185(9):1641–50

HLA B44-restricted cytotoxic T lymphocyte responses to the peptides of HCV nucleoprotein residues 81–100 in patients with chronic hepatitis C. Kita H, et al. **J Gastroenterol** 1995 Dec;30(6):809–12

A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice. Flanagan B, et al. **J Gen Virol** 1997 May;78 (Pt 5):991–7

Coronavirus-induced encephalomyelitis: balance between protection and immune pathology depends on the immunization schedule with spike protein S. Flory E, et al. **J Gen Virol** 1995 Apr;76 (Pt 4):873–9

CD8+ cytotoxic T lymphocytes of a cynomolgus macaque infected with simian immunodeficiency virus (SIV) mac32H-J5 recognize a nine amino acid epitope in SIV Gag p26. Geretti AM, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):821–4

Mapping of the target antigens of the rotavirus-specific cytotoxic T cell response. Heath RR, et al. **J Gen Virol** 1997 May;78 (Pt 5):1065–75

Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. Karem KL, et al. **J Gen Virol** 1997 Feb;78 (Pt 2):427–34

Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. Kettle S, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):677–85

All rabbits immunized with type A influenza virions have a serum haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B. Lambkin R, et al. **J Gen Virol** 1995 Apr;76 (Pt 4):889–97

Expression of muscovy duck parvovirus capsid proteins (VP2 and VP3) in a baculovirus expression system and demonstration of immunity induced by the recombinant proteins. Le Gall-Reculé G, et al. **J Gen Virol** 1996 Sep; 77 (Pt 9):2159–63

Antigenic analysis of human herpesvirus 7 (HHV-7) and HHV-6 using immune sera and monoclonal antibodies against HHV-7. Nakagawa N, et al. **J Gen Virol** 1997 May; 78 (Pt 5):1131–7

Monoclonal antibodies to the ORF5 product of porcine reproductive and respiratory syndrome virus define linear neutralizing determinants. Pirzadeh B, et al. **J Gen Virol** 1997 Aug;78 (Pt 8):1867–73

Antigenic and molecular analyses of the variability of bovine respiratory syncytial virus G glycoprotein. Prozzi D, et al. **J Gen Virol** 1997 Feb;78 (Pt 2):359–66

A porcine CD8+ T cell clone with heterotypic specificity

for foot-and-mouth disease virus. Rodríguez A, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2089-96

Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge. Roy P, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2053-7

Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. Sinzger C, et al. **J Gen Virol** 1995 Apr;76 (Pt 4):741-50

Differential T cell response induced by certain recombinant oligopeptides of herpes simplex virus glycoprotein B in mice. Tizard ML, et al. **J Gen Virol** 1997 Jul;78 (Pt 7):1625-32

Mapping of antigenic sites involved in neutralization on the capsid protein of feline calicivirus. Tohya Y, et al. **J Gen Virol** 1997 Feb;78 (Pt 2):303-5

Classical swine fever virus (CSFV) envelope glycoprotein E2 containing one structural antigenic unit protects pigs from lethal CSFV challenge. van Rijn PA, et al. **J Gen Virol** 1996 Nov;77 (Pt 11):2737-45

African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge. Wade-Evans AM, et al. **J Gen Virol** 1997 Jul;78 (Pt 7):1611-6

Quantitative determination and visualization of herpes simplex virus type 1 antigen, free and cell-bound by ELISA. Tirado R, et al. **J Immunoassay** 1996 Aug; 17(3):277-91

Correlation of tolerogenicity of a viral antigen with its immunogenicity. Bachmann MF, et al. **J Immunol** 1997 Jun 1;158(11):5106-11

Efficient priming of CD8+ memory T cells specific for a subdominant epitope following Sendai virus infection. Cole GA, et al. **J Immunol** 1997 May 1;158(9):4301-9

Human peptide transporter deficiency: importance of HLA-B in the presentation of TAP-independent EBV antigens. de la Salle H, et al. **J Immunol** 1997 May 15; 158(10):4555-63

Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. Khanna R, et al. **J Immunol** 1997 Apr 15;158(8):3619-25

Control by Ig genes of the responsiveness to a neutralization viral B cell epitope. Leclerc C, et al. **J Immunol** 1997 Apr 1;158(7):3252-8

Protection against lethal viral infection by vaccination with nonimmunodominant peptides. Oukka M, et al. **J Immunol** 1996 Oct 1;157(7):3039-45

Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning. Ping T, et al. **J Immunol** 1996 Jul 15;157(2):772-80

Immune response to a Murray Valley encephalitis virus epitope expressed in the flagellin of an attenuated strain of Salmonella. Whittle BL, et al. **J Med Microbiol** 1997 Feb;46(2):129-38

Humoral immunity patterns based on antibody reactivity to rotavirus antigens in Brazilian children under 5 years of age. Andrade GP, et al. **J Med Virol** 1996 Jul;49(3):212-7

Analysis of linear epitopes recognised by the primary human antibody response to a variable region of the attachment (G) protein of respiratory syncytial virus. Cane PA. **J Med Virol** 1997 Apr;51(4):297-304

Construction of four double gene substitution human x bovine rotavirus reassortant vaccine candidates: each bears two outer capsid human rotavirus genes, one encoding P serotype 1A and the other encoding G serotype 1, 2, 3, or 4 specificity. Hoshino Y, et al. **J Med Virol** 1997 Apr; 51(4):319-25

Different patterns of cytokine induction in cultures of respiratory syncytial (RS) virus-specific human TH cell lines following stimulation with RS virus and RS virus proteins. Jackson M, et al. **J Med Virol** 1996 Jul;49(3):161-9

Enzyme-linked immunosorbent assay using recombinant antigens for serodiagnosis of Japanese encephalitis. Konishi E, et al. **J Med Virol** 1996 Jan;48(1):76-9

Amino-terminal epitopes are exposed when full-length open reading frame 2 of hepatitis E virus is expressed in Escherichia coli, but carboxy-terminal epitopes are masked. Li F, et al. **J Med Virol** 1997 Jul;52(3):289-300

ELISA for the detection of serum and saliva IgA against the BMRFI gene product of Epstein-Barr virus. Nadala EC, et al. **J Med Virol** 1996 Sep;50(1):93-6

Lymphocyte responses to human cytomegalovirus in different groups of patients in Britain and in adults from west Africa and the Middle East. Omisakin KA, et al. **J Med Virol** 1996 Aug;49(4):311-8

Hodgkin disease occurring in a patient with extremely high serum antibody titers to Epstein-Barr virus--associated antigens without chronic illness. Azuma H, et al. **J Pediatr Hematol Oncol** 1996 Nov;18(4):387-91

Detection of antibodies against foot-and-mouth disease virus using a liquid-phase blocking sandwich ELISA (LPBE) with a bioengineered 3D protein. O'Donnell VK, et al. **J Vet Diagn Invest** 1996 Apr;8(2):143-50

A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen. An LL, et al. **J Virol** 1997 Mar;71(3):2292-302

Identification of a T-helper cell epitope on the rotavirus VP6 protein. Baños DM, et al. **J Virol** 1997 Jan;71(1):419-26

Expression of Aleutian mink disease parvovirus capsid proteins in defined segments: localization of immunoreactive sites and neutralizing epitopes to specific regions. Bloom ME, et al. **J Virol** 1997 Jan;71(1):705-14

Characterization of the antibody response specific for the human endogenous retrovirus HTDV/HERV-K. Boller K, et al. **J Virol** 1997 Jun;71(6):4581-8

Identification of amino acids controlling the low-pH-induced conformational change of rabies virus glycoprotein. Gaudin Y, et al. **J Virol** 1996 Nov;70(11):7371-8

Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus. Grigera PR, et al. **J Virol** 1996 Dec;70(12):8492-501

The reovirus nonstructural protein sigma1NS is recognized by murine cytotoxic T lymphocytes. Hoffman LM, et al. **J Virol** 1996 Nov;70(11):8160-4

Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection. Hosie MJ, et al. **J Virol** 1996 Nov;70(11):7561-8

Analysis of the serotype-specific epitopes of avian infectious bronchitis virus strains Ark99 and Mass41. Jia W, et al. **J Virol** 1996 Oct;70(10):7255-9

Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus. Kerr BM, et al. **J Virol** 1996 Dec;70(12):8858-64

Characterization of the Borna disease virus phosphoprotein, p23. Kliche S, et al. **J Virol** 1996 Nov;70(11):8133-7

Identification, expression, and immunogenicity of Kaposi's sarcoma-associated herpesvirus-encoded small viral capsid antigen. Lin SF, et al. **J Virol** 1997 Apr;71(4):3069-76

Endogenous Mtv-encoded superantigens are not required for development of murine AIDS. McCarty TC, et al. **J Virol** 1996 Nov;70(11):8148-50

Antigenic structure of soluble herpes simplex virus (HSV) glycoprotein D correlates with inhibition of HSV infection. Nicola AV, et al. **J Virol** 1997 Apr;71(4):2940-6

Progression to persistent lymphocytosis and tumor development in bovine leukemia virus (BLV)-infected cattle correlates with impaired proliferation of CD4+ T cells in response to gag- and env-encoded BLV proteins. Orlik O, et al. **J Virol** 1996 Nov;70(11):7584-93

Hyper-antigenic variation occurs with human rhinovirus type 17 [published erratum appears in J Virol 1997 Apr;71(4):3363] Patterson LJ, et al. **J Virol** 1997 Feb; 71(2):1370-4

Two 21-kilodalton components of the Epstein-Barr virus capsid antigen complex and their relationship to ZEBRA-associated protein p21 (ZAP21). Serio TR, et al. **J Virol** 1996 Nov;70(11):8047-54

Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunizations with adenovirus vectors is dependent on haplotype. Sparer TE, et al. **J Virol** 1997 Mar;71(3):2277-84

Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. Srikiatkhachorn A, et al. **J Virol** 1997 Jan;71(1):678-85

Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice. van der Most RG, et al. **J Virol** 1997 Jul;71(7):5110-4

Lymphoproliferative responses after infection with human parvovirus B19. von Poblotzki A, et al. **J Virol** 1996 Oct; 70(10):7327-30

Definition of human immunodeficiency virus type 1 gp120 and gp41 cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I alleles in simian-human immunodeficiency virus-infected rhesus monkeys. Voss G, et al. **J Virol** 1996 Oct;70(10):7335-40

The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. Wills MR, et al. **J Virol** 1996 Nov; 70(11):7569-79

Major linear antibody epitopes and capsid proteins differentially induce protective immunity against Theiler's virus-induced demyelinating disease. Yahikozawa H, et al. **J Virol** 1997 Apr;71(4):3105-13

Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. Yang Y, et al. **J Virol** 1996 Oct;70(10):7209-12

Booster immunization with a partially purified citrus tristeza virus (CTV) preparation after priming with recombinant CTV coat protein enhances the binding capacity of capture antibodies by ELISA. Bar-Joseph M, et al. **J Virol Methods** 1997 Aug;67(1):19-22

Detection of Maedi-Visna virus antibodies using a single fusion transmembrane-core p25 recombinant protein ELISA and a modified receiver-operating characteristic analysis to determine cut-off values. Boshoff CH, et al. **J Virol Methods** 1997 Jan;63(1-2):47-56

Production of the antigen and the antibody of the JC virus major capsid protein VP1. Chang D, et al. **J Virol Methods** 1996 May;59(1-2):177-87

Presence of rabbit haemorrhagic disease virus antigen in rabbit tissues as revealed by a monoclonal antibody dependent capture ELISA. Collins BJ, et al. **J Virol Methods** 1996 Apr 26;58(1-2):145-54

A major antigenic domain for the human humoral response to Puumala virus nucleocapsid protein is located at the amino-terminus. Elgh F, et al. **J Virol Methods** 1996 May; 59(1-2):161-72

Identification of peptides mimicking the antigenicity and immunogenicity of conformational epitopes on Japanese encephalitis virus protein using synthetic peptide libraries. Hirabayashi Y, et al. **J Virol Methods** 1996 Sep; 61(1-2):23-36

Biotin-labeled antigen: a novel approach for detection of Puumala virus-specific IgM. Ivanov A, et al. **J Virol Methods** 1996 Oct;62(1):87-92

Demonstration of specific detection of anti-HCV IgM core antibodies. Kapprell HP, et al. **J Virol Methods** 1996 May; 59(1-2):121-6

Fast neutralization/immunoperoxidase assay for viral haemorrhagic septicaemia with anti-nucleoprotein monoclonal antibody. Lorenzo G, et al. **J Virol Methods** 1996 Apr 26;58(1-2):1-6

Demonstration of rabbit haemorrhagic disease virus antigen by Staphylococcus protein A coagglutination test. Peshev R, et al. **J Virol Methods** 1996 Mar;57(1):15-8

Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing. Rooijakkers EJ, et al. **J Virol Methods** 1996 Apr 26;58(1-2):111-9

The development of an antigen capture polymerase chain reaction assay to detect and type human enteroviruses. Shen S, et al. **J Virol Methods** 1997 Apr;65(1):139-44

Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein. Staropoli I, et al. **J Virol Methods** 1996 Feb;56(2):179-89

Highly sensitive immunoassays for detection of barley stripe mosaic virus and beet necrotic yellow vein virus. Sukhacheva E, et al. **J Virol Methods** 1996 Feb; 56(2):199-207

IgM-specific serodiagnosis of acute human cytomegalovirus infection using recombinant autologous fusion proteins. Vornhagen R, et al. **J Virol Methods** 1996 Jun;60(1):73-80

Detection of IgG antibody to Epstein-Barr virus viral capsid antigen in saliva by antibody capture radioimmunoassay. Vyse AJ, et al. **J Virol Methods** 1997 Jan;63(1-2):93-101

Polyoma induced autoimmunity to DNA; experimental systems and clinical observations in human SLE. Rekvig O. **Lupus** 1997;6(3):325-6

Dengue 3 virus distribution in the mosquito Aedes aegypti: an immunocytochemical study. Linthicum KJ, et al. **Med Vet Entomol** 1996 Jan;10(1):87-92

Possible correlation between Borna disease virus infection and Japanese patients with chronic fatigue syndrome. Kitani T, et al. **Microbiol Immunol** 1996;40(6):459-62

Biological mimicry of the bluetongue virus core protein VP7 by rabbit anti-idiotype. Lin M, et al. **Microbiol Immunol** 1996;40(6):435-41

Virus-encoded superantigens. Huber BT, et al. **Microbiol Rev** 1996 Sep;60(3):473-82 (91 ref.)

Recombinant fusion peptides containing single or multiple repeats of a ubiquitous T-helper epitope are highly immunogenic. Astori M, et al. **Mol Immunol** 1996 Sep; 33(13):1017-24

Structural requirements for synthetic immunogens to induce measles virus specific CTL responses. Partidos CD, et al. **Mol Immunol** 1996 Nov;33(16):1223-9

Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Gilbert MJ, et al. **Nature** 1996 Oct 24;383(6602):720-2

Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Ahn K, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10990-5

Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Sedlik C, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7503-8

Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Yusibov V, et al. **Proc Natl Acad Sci U S A** 1997 May 27; 94(11):5784-8

Phage display of intact domains at high copy number: a system based on SOC, the small outer capsid protein of bacteriophage T4. Ren ZJ, et al. **Protein Sci** 1996 Sep; 5(9):1833-43

Induction of rat CD4+ proliferative and mouse CD8+ cytotoxic T-cell lines specific for human papillomavirus type 16 antigens. Bagot M, et al. **Res Virol** 1996 Sep-Oct; 147(5):301-11

Compact Epstein-Barr virus diagnosis based on a defined antigen mix and specific IgA. Dopatka HD, et al. **Res Virol** 1996 Jan-Feb;147(1):53-66

The antigen-specific cell-mediated immune response in mice is suppressed by infection with pathogenic lyssaviruses. Perrin P, et al. **Res Virol** 1996 Sep-Oct;147(5):289-99

Hierarchic T-cell help to non-linked B-cell epitopes. Brons NH, et al. **Scand J Immunol** 1996 Nov;44(5):478-84

Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Ambinder RF, et al. **Semin Cancer Biol** 1996 Aug;7(4):217-26 (69 ref.)

Perturbations in the surface structure of A22 Iraq foot-and-mouth disease virus accompanying coupled changes in host cell specificity and antigenicity. Curry S, et al. **Structure** 1996 Feb 15;4(2):135-45

Outcome of HBs antigen positive kidneys after renal transplantation. Turc Baron C, et al. **Transplant Proc** 1997 Aug;29(5):2446

Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant. Bengtsson KL, et al. **Vaccine** 1996 Jun;14(8):753-60

Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A

subunit vaccine using various adjuvants. Benne CA, et al. **Vaccine** 1997 Jun;15(9):1039–44

A new family of carriers (biovectors) enhances the immunogenicity of rabies antigens. Castignolles N, et al. **Vaccine** 1996 Oct;14(14):1353–60

Emerging foot-and-mouth disease virus variants with antigenically critical amino acid substitutions predicted by model studies using reference viruses. Feigelstock DA, et al. **Vaccine** 1996 Feb;14(2):97–102

Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems. Hassan Y, et al. **Vaccine** 1996 Dec;14(17–18):1581–9

Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Nixon DF, et al. **Vaccine** 1996 Nov;14(16):1523–30

Subgroup specific protection of mice from respiratory syncytial virus infection with peptides encompassing the amino acid region 174–187 from the G glycoprotein: the role of cysteinyl residues in protection. Simard C, et al. **Vaccine** 1997 Mar;15(4):423–32

Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge. Sundaram P, et al. **Vaccine** 1997 Apr–May; 15(6–7):664–71

Serum antibody responses of foals to virulence-associated 15- to 17-kilodalton antigens of Rhodococcus equi. Takai S, et al. **Vet Microbiol** 1996 Sep;52(1–2):63–71

A complex neutralization domain of bluetongue virus serotype 17 defines a virulence-associated marker. Bernard KA, et al. **Viral Immunol** 1996;9(2):97–106

Transplacentally acquired antiviral antibodies and outcome in congenital human cytomegalovirus infection. Boppana SB, et al. **Viral Immunol** 1996;9(4):211–8

Detection of lymphoproliferative responses against pseudorabies virus immediate early protein (IE180) in swine immunized with a modified live virus vaccine. Garmendia AE, et al. **Viral Immunol** 1996;9(4):247–56

Neutralizing and fusion-blocking antibodies induced by recombinant visna virus envelope glycoprotein. Huso DL. **Viral Immunol** 1997;10(1):15–20

Production of virus-specific antisera using synthetic peptides corresponding to sequences in the yellow fever E protein: brief report. Jackson RE, et al. **Viral Immunol** 1997; 10(1):11–4

Detection of enhanced cytotoxic T lymphocyte response with spleenic dendritic cells enriched by a simple sequential adherence method. Saikh KU, et al. **Viral Immunol** 1996; 9(2):121–9

Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Boppana SB, et al. **Virology** 1996 Aug 1;222(1):293–6

Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Christensen ND, et al. **Virology** 1996 Sep 1; 223(1):174–84

Mouse mammary tumor virus superantigens require N-linked glycosylation for effective presentation to T cells. McMahon CW, et al. **Virology** 1997 Feb 17;228(2):161–70

Syngeneic Marek's disease virus (MDV)-specific cell-mediated immune responses against immediate early, late, and unique MDV proteins. Omar AR, et al. **Virology** 1996 Aug 1;222(1):87–99

Characterization of an overlapping CD8+ and CD4+ T-cell epitope on rubella capsid protein. Ou D, et al. **Virology** 1997 Sep 1;235(2):286–92

In vivo longitudinal analysis of a dominant TCR repertoire selected in human response to influenza virus. Prevost-Blondel A, et al. **Virology** 1997 Jun 23; 233(1):93–104

Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B*3501 transgenic mice. Schönbach C, et al. **Virology** 1996 Dec 1;226(1):102–12

Antigenically profound amino acid substitutions occur during large population passages of foot-and-mouth disease virus. Sevilla N, et al. **Virology** 1996 Nov 15;225(2):400–5

In vivo selection of duck hepatitis B virus pre-S variants which escape from neutralization. Sunyach C, et al. **Virology** 1997 Aug 4;234(2):291–9

Identification of a variant A-specific neutralizing epitope on glycoprotein B (gB) of human herpesvirus-6 (HHV-6). Takeda K, et al. **Virology** 1996 Aug 1;222(1):176–83

Immunogenicity of JHM virus proteins: characterization of a CD4+ T cell epitope on nucleocapsid protein which induces different T-helper cell subsets. van der Veen KC. **Virology** 1996 Nov 15;225(2):339–46

Neutralization of SIVmac239/17E in lymphocyte cultures involves virus strain-specific linear and conformational epitopes encoded by different regions of the env gene including the "V3" domain. Wu Z, et al. **Virology** 1996 Aug 1;222(1):184–92

Fine mapping of a C-terminal linear epitope highly conserved among the major envelope glycoprotein E2 (gp51 to gp54) of different pestiviruses. Yu M, et al. **Virology** 1996 Aug 1;222(1):289–92

Epitope mapping of monoclonal antibodies raised to recombinant Mengo 3D polymerase. Duque H, et al. **Virus Genes** 1996;13(2):159–68

Prediction of potential cytotoxic T lymphocyte epitopes of bovine herpesvirus 1 based on allele-specific peptide motifs and proteolytic cleavage specificities. Hegde NR, et al. **Virus Genes** 1996;13(2):121–33

Antigenic diversity of Akabane virus detected by monoclonal antibodies. Akashi H, et al. **Virus Res** 1997 Feb;47(2):187–96

Expression cloning and antigenic analysis of the nucleocapsid protein of equine arteritis virus. Chirnside ED, et al. **Virus Res** 1995 Dec;39(2–3):277–88

Single amino acid substitutions in Puumala virus envelope glycoproteins G1 and G2 eliminate important neutralization epitopes. Hörling J, et al. **Virus Res** 1997 Apr;48(1):89–100

Characterization of Langat virus antigenic determinants defined by monoclonal antibodies to E, NS1 and preM and identification of a protective, non-neutralizing preM-specific monoclonal antibody. Iacono-Connors LC, et al. **Virus Res** 1996 Aug;43(2):125–36

Expression of the major inner capsid protein of the epizootic haemorrhagic disease virus in baculovirus and potential diagnostic use. Nagesha HS, et al. **Virus Res** 1996 Aug; 43(2):163–9

Antigenic features of foot-and-mouth disease virus serotype Asia1 as revealed by monoclonal antibodies and neutralization-escape mutants. Sanyal A, et al. **Virus Res** 1997 Aug;50(2):107–17

The production of a truncated form of baculovirus expressed EHV-1 glycoprotein C and its role in protection of C3H (H-2Kk) mice against virus challenge. Stokes A, et al. **Virus Res** 1996 Oct;44(2):97–109

[The antigenic-immunogenic activity of the trivalent polymer-subunit influenza vaccine Grippol in a controlled epidemiological trial (2)] El'shina GA, et al. **Voen Med Zh** 1996 Nov;317(11):53–5 **(Rus)**

[Effect of inactivated Ebola virus on colony forming activity of human hematopoietic stem cells] Chepurnov AA, et al. **Vopr Virusol** 1997 Mar–Apr;42(2):91–2 (Eng. Abstr.) **(Rus)**

[The use of monoclonal antibodies for the study of California serogroup viruses] Larichev VF, et al. **Vopr Virusol** 1996 Nov–Dec;41(6):242–4 (28 ref.) **(Rus)**

[A comparative analysis of proteins from persistent and antigen-defective strains of tick-borne encephalitis virus] Pressman EK, et al. **Vopr Virusol** 1997 Mar–Apr;42(2):53–6 (Eng. Abstr.) **(Rus)**

[Evaluation of a reagent for the diagnosis of Epstein-Barr virus infection (letter)] de Ory F. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):506–7 **(Spa)**

[Antigenic and genomic characterization of Herpes simplex virus isolated from double genital infections] Martínez MJ, et al. **Rev Med Chil** 1996 Feb;124(2):153–9 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Localization of simian immunodeficiency virus nucleic acid and antigen in brains of fetal macaques inoculated in utero. Lane JH, et al. **Am J Pathol** 1996 Oct;149(4):1097–104

Preparation of virus-infection-associated (VIA) antigen of foot-and-mouth disease (FMD) virus from inactivated vaccine. Sugimura T, et al. **J Vet Med Sci** 1996 Jun; 58(6):599–601

Efficient production of JC virus in SVG cells and the use of purified viral antigens for analysis of specific humoral and cellular immune response. Frye S, et al. **J Virol Methods** 1997 Jan;63(1–2):81–92

Simultaneous purification of influenza haemagglutinin and neuraminidase proteins by immunochromatography. Gerentes L, et al. **J Virol Methods** 1996 Apr 26; 58(1–2):155–65

Rapid, efficient, large-scale purification of unfused, non-denatured E7 protein of cottontail rabbit papillomavirus. Sundaram P, et al. **J Virol Methods** 1996 Mar;57(1):61–70

Purification of rubella virus E1-E2 protein complexes by immunoaffinity chromatography. van Sommeren AP, et al. **J Virol Methods** 1997 Jan;63(1–2):37–46

FIV, FeLV, and FIPV: interpretation and misinterpretation of serological test results. Barr MC. **Semin Vet Med Surg (Small Anim)** 1996 Aug;11(3):144–53 (34 ref.)

When viral serological testing is not enough: diagnosing disease in vaccinated animals. Dubovi EJ. **Semin Vet Med Surg (Small Anim)** 1996 Aug;11(3):183–6

Seroepidemiological studies on Silk Road ethnic groups. Mizuki N, et al. **Tokai J Exp Clin Med** 1996 Oct; 21(3):117–20

Comparative study on four enzyme-linked immunosorbent assays and a cocultivation assay for the detection of antigens associated with the bovine viral diarrhoea virus in persistently infected cattle. Brinkhof J, et al. **Vet Microbiol** 1996 May;50(1–2):1–6

[Concentration of hepatitis A and B virus antigens using water-soluble polymers] Leshchuk SI, et al. **Vopr Virusol** 1996 May–Jun;41(3):135–7 (Eng. Abstr.) **(Rus)**

METABOLISM

Production and characterization of bovine herpesvirus 1 glycoprotein B ectodomain derivatives in an hsp70A gene promoter-based expression system. Li Y, et al. **Arch Virol** 1996;141(10):2019–29

Anti-tumor promoting effects of naphthoquinone derivatives on short term Epstein-Barr early antigen activation assay and in mouse skin carcinogenesis. Kapadia GJ, et al. **Cancer Lett** 1997 Feb 26;113(1–2):47–53

Quassinoids as inhibitors of Epstein-Barr virus early antigen activation. Kubota K, et al. **Cancer Lett** 1997 Feb 26; 113(1–2):165–8

Localization of the major NF-kappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. Brodeur SR, et al. **J Biol Chem** 1997 Aug 8;272(32):19777–84

Expression of epstein-barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV. Oudejans JJ, et al. **J Clin Pathol** 1996 Nov;49(11):897–902

Rhinovirus inhibits antigen-specific T cell proliferation through an intercellular adhesion molecule-1-dependent mechanism. Gern JE, et al. **J Infect Dis** 1996 Dec; 174(6):1143–50

Human cytomegalovirus IE2 86-kilodalton protein binds p53 but does not abrogate G1 checkpoint function. Bonin LR, et al. **J Virol** 1997 Aug;71(8):5861–70

Foot-and-mouth disease virus 2A protease mediates cleavage in attenuated Sabin 3 poliovirus vectors engineered for delivery of foreign antigens. Mattion NM, et al. **J Virol** 1996 Nov;70(11):8124–7

Generation and neutralization of pseudovirions of human papillomavirus type 33. Unckell F, et al. **J Virol** 1997 Apr; 71(4):2934–9

Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication. Zhang Q, et al. **J Virol** 1996 Aug;70(8):5131–42

Immunoreactive core peptides of hepatitis C virus produced in Escherichia coli and in vitro DNA amplification-restricted transcription-translation system. Esumi M, et al. **J Virol Methods** 1996 May;59(1–2):91–8

Discrete cleavage patterns of pseudorabies virus immediate early protein (IE180) seen in some cell lines upon extraction after cycloheximide reversal. Garmendia AE, et al. **J Virol Methods** 1997 Mar;64(2):171–9

Expression of herpes simplex associated antigens in ocular tissues following induced herpetic anterior uveitis. Shirane M. **Jpn J Ophthalmol** 1996;40(4):491–501

Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Fu TM, et al. **Mol Med** 1997 Jun;3(6):362–71

Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without "memory T cells"? Bachmann MF, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21;94(2):640–5

Structural and antigenic identification of the ORF12 protein (alpha TIF) of equine herpesvirus 1. Lewis JB, et al. **Virology** 1997 Apr 14;230(2):369–75

The Epstein-Barr virus (EBV) DNA polymerase accessory protein, BMRF1, activates the essential downstream component of the EBV oriLyt. Zhang Q, et al. **Virology** 1997 Mar 31;230(1):22–34

[Clinical and experimental study on treatment of rotaviral enteritis with qiwei baizhu powder] He ST, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Mar; 16(3):132–5 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Immunization with viral antigens: infectious pancreatic necrosis. Christie KE. **Dev Biol Stand** 1997;90:191–9 (54 ref.)

Immunization with viral antigens: viral diseases of carp and catfish. Dixon P. **Dev Biol Stand** 1997;90:221–32 (31 ref.)

Immunization with viral antigens: viral haemorrhagic septicaemia. Lorenzen N, et al. **Dev Biol Stand** 1997; 90:201–9 (37 ref.)

Immunization with viral antigens: infectious haematopoietic necrosis. Winton JR. **Dev Biol Stand** 1997;90:211–20 (35 ref.)

Enhanced TNF alpha production by monocytic-like cells exposed to dengue virus antigens. Lee DH, et al. **Immunol Lett** 1996 Nov;53(2–3):115–20

Fc gamma receptor I (CD64)-negative human monocytes are potent accessory cells in viral antigen-induced T cell activation and exhibit high IFN-alpha-producing capacity. Grage-Griebenow E, et al. **J Leukoc Biol** 1996 Sep; 60(3):389–96

Cytokine production by dengue virus antigen-responsive human T lymphocytes in vitro examined using a double immunocytochemical technique. Mori M, et al. **J Leukoc Biol** 1997 Mar;61(3):338–45

PHYSIOLOGY

Biology and neurobiology of Borna disease viruses (BDV), defined by antibodies, neutralizability and their pathogenic potential. Ludwig H, et al. **Arch Virol Suppl** 1993;7:111–33

Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced Epstein-Barr virus early antigen activation by natural colorants. Kapadia GJ, et al. **Cancer Lett** 1997 May 19; 115(2):173–8

Searching for superantigens. Schlievert PM. **Immunol Invest** 1997 Jan–Feb;26(1–2):283–90 (20 ref.)

T cells bearing Vbeta8 are preferentially infected with exogenous mouse mammary tumor virus. Upragarin N, et al. **J Immunol** 1997 Sep 1;159(5):2189–95

THERAPEUTIC USE

In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Madrigal M, et al. **Gynecol Oncol** 1997 Jan;64(1):18–25

ULTRASTRUCTURE

Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. Stewart PL, et al. **EMBO J** 1997 Mar 17;16(6):1189-98

ANTIGENS, VIRAL, TUMOR

Cell lines with heterogeneous phenotypes result from a single isolation of albumin-sv40 T-antigen transgenic rat hepatocytes. Bulera SJ, et al. **Hepatology** 1997 May; 25(5):1192-203

Long-term growth and steroidogenic potential of human granulosa-lutein cells immortalized with SV40 large T antigen. Lie BL, et al. **Mol Cell Endocrinol** 1996 Jul 1; 120(2):169-76

Characterization of SV40T antigen immortalized human synovial fibroblasts: maintained expression patterns of EGR-1, HLA-DR and some surface receptors. Haas C, et al. **Rheumatol Int** 1997;16(6):241-7

ANALYSIS

SV40 early region and large T antigen in human brain tumors, peripheral blood cells, and sperm fluids from healthy individuals [see comments] Martini F, et al. **Cancer Res** 1996 Oct 15;56(20):4820-5. Comment in: Cancer Res 1997 Aug 1;57(15):3319-20.

Detection of Tn, sialosyl-Tn and T antigens in hereditary nonpolyposis colorectal cancer. Giuffrè G, et al. **Virchows Arch** 1996 Dec;429(6):345-52

BIOSYNTHESIS

Immortalized hepatocytes from transgenic mice. Kramer K, et al. **Biochem Soc Trans** 1997 Feb;25(1):42S

Polyomavirus-induced malignant transformation: comparative analysis of wild type and mutant middle T-overexpressing cell lines. Armelin MC, et al. **Braz J Med Biol Res** 1996 Sep;29(9):1133-40

Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer. Xing X, et al. **Cancer Gene Ther** 1996 May-Jun;3(3):168-74

Transformation of liver by SV-40 T-antigen in transgenic mice is unaffected by metallothionein. Quaife CJ, et al. **Cancer Lett** 1996 Aug 23;106(1):125-31

Expression of p53, Ki-67 and cytokeratin-4 (CK4) in oral papillomas. Copete MA, et al. **J Oral Pathol Med** 1997 May;26(5):211-6

Rapid targeting of plasmid DNA to zebrafish embryo nuclei by the nuclear localization signal of SV40 T antigen. Collas P, et al. **Mol Mar Biol Biotechnol** 1997 Mar;6(1):48-58

Increase in the proliferative capacity of human myoblasts by using the T antigen under the vimentin promoter control. Deschênes I, et al. **Muscle Nerve** 1997 Apr; 20(4):437-45

Initiation of SV40 DNA replication in vitro: analysis of the role played by sequences flanking the core origin on initial synthesis events. Bullock PA, et al. **Virology** 1997 Jan 20; 227(2):460-73

CHEMISTRY

Bovine papillomavirus type 1 E1 and simian virus 40 large T antigen share regions of sequence similarity required for multiple functions. Mansky KC, et al. **J Virol** 1997 Oct; 71(10):7600-8

Tumor marker disaccharide D-Gal-beta 1, 3-GalNAc complexed to heat-labile enterotoxin from Escherichia coli. van den Akker F, et al. **Protein Sci** 1996 Jun;5(6):1184-8

GENETICS

Conditionally immortalized cell lines with differentiated functions established from temperature-sensitive T-antigen transgenic mice. Obinata M. **Genes Cells** 1997 Apr; 2(4):235-44 (47 ref.)

The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Naik P, et al. **Genes Dev** 1996 Sep 1;10(17):2105-16

Establishment and characterization of conditionally immortalized stromal cell lines from a temperature-sensitive T-Ag transgenic mouse. Feuerbach D, et al. **J Bone Miner Res** 1997 Feb;12(2):179-90

trans-Dominant and non-trans-dominant mutant simian virus 40 large T antigens show distinct responses to ATP. Castellino AM, et al. **J Virol** 1997 Oct;71(10):7549-59

A novel simian virus 40 early-region domain mediates transactivation of the cyclin A promoter by small-t antigen and is required for transformation in small-t antigen-dependent assays. Porrás A, et al. **J Virol** 1996 Oct;70(10):6902-8

Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. Perez-Stable C, et al. **Lab Invest** 1996 Feb;74(2):363-73

The T/t common exon of simian virus 40, JC, and BK polyomavirus T antigens can functionally replace the J-domain of the Escherichia coli DnaJ molecular chaperone. Kelley WL, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3679-84

IMMUNOLOGY

Mouse mammary tumor virus and the immune system. Ross SR. **Adv Pharmacol** 1997;39:21-46 (95 ref.)

Modulation of antigen processing and presentation by persistent virus infections and in tumors. Ehrlich R. **Hum Immunol** 1997 May;54(2):104-16 (126 ref.)

A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Ossendorp F, et al. **Immunity** 1996 Aug;5(2):115-24

Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Avichezer D, et al. **Int J Cancer** 1997 Jul 3;72(1):119-27

Survey of emm gene sequences and T-antigen types from systemic Streptococcus pyogenes infection isolates collected in San Francisco, California; Atlanta, Georgia; and Connecticut in 1994 and 1995. Beall B, et al. **J Clin Microbiol** 1997 May;35(5):1231-5

METABOLISM

Prognostic significance of T antigen expression in patients with gastric carcinoma [letter; comment] Carneiro F, et al. **Cancer** 1996 Dec 1;78(11):2448-50. Comment on: Cancer 1996 May 1;77(9):1768-73.

Immortalization and transformation are associated with specific alterations in choline metabolism. Bhakoo KK, et al. **Cancer Res** 1996 Oct 15;56(20):4630-5

The protein kinase CK2 site (Ser111/112) enhances recognition of the simian virus 40 large T-antigen nuclear localization sequence by importin. Hübner S, et al. **J Biol Chem** 1997 Jul 4;272(27):17191-5

Replication activity of JC virus large T antigen phosphorylation and zinc finger domain mutants [see comments] Swenson JJ, et al. **J Neurovirol** 1996 Apr; 2(2):78-86. Comment in: J Neurovirol 1996 Apr;2(2):57-9.

trans-Dominant and non-trans-dominant mutant simian virus 40 large T antigens show distinct responses to ATP. Castellino AM, et al. **J Virol** 1997 Oct;71(10):7549-59

AP1 enhances polyomavirus DNA replication by promoting T-antigen-mediated unwinding of DNA. Guo W, et al. **J Virol** 1996 Aug;70(8):4914-8

MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection. Henning W, et al. **J Virol** 1997 Oct;71(10):7609-18

Bovine papillomavirus type 1 E1 and simian virus 40 large T antigen share regions of sequence similarity required for multiple functions. Mansky KC, et al. **J Virol** 1997 Oct; 71(10):7600-8

Differential interaction of temperature-sensitive simian virus 40 T antigens with tumor suppressors pRb and p53. Ray S, et al. **J Virol** 1996 Oct;70(10):7224-7

Simian virus 40 small t antigen activates the carboxyl-terminal transforming p53-binding domain of large T antigen. Zerrahn J, et al. **J Virol** 1996 Oct; 70(10):6781-9

Second messengers induced by the envelope protein of a retrovirus. Bolander FF Jr. **Mol Cell Endocrinol** 1997 Apr 25;129(1):27-32

Disregulation of mitotic checkpoints and regulatory proteins following acute expression of SV40 large T antigen in diploid human cells. Chang TH, et al. **Oncogene** 1997 May 22;14(20):2383-93

Induction of cyclin D1 by simian virus 40 small tumor antigen. Watanabe G, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):12861-6

ANTIGENS, XENOGENEIC see **ANTIGENS, HETEROPHILE**

ANTIGLOBULIN CONSUMPTION TEST see **COOMBS' TEST**

ANTIGLOBULIN TEST see **COOMBS' TEST**

ANTIGLOBULINS see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTIGOUT AGENTS see **GOUT SUPPRESSANTS**

ANTIGRAVITY SUITS see **G SUITS**

ANTI-HBAG see **HEPATITIS B ANTIBODIES**

ANTI-HCV ANTIBODIES see **HEPATITIS C ANTIBODIES**

ANTIHEMOPHILIC FACTOR see **FACTOR VIII**

ANTIHEPARIN FACTOR see **PLATELET FACTOR 4**

ANTI-HEPATITIS B ANTIGENS see **HEPATITIS B ANTIBODIES**

ANTI-HEPATITIS C VIRUS ANTIBODIES see **HEPATITIS C ANTIBODIES**

ANTIHISTAMINES see **HISTAMINE H1 ANTAGONISTS**

ANTIHISTAMINES, CLASSICAL see **HISTAMINE H1 ANTAGONISTS**

ANTIHISTAMINICS, CLASSICAL see **HISTAMINE H1 ANTAGONISTS**

ANTIHISTAMINICS, H1 see **HISTAMINE H1 ANTAGONISTS**

ANTIHISTAMINICS, H2 see **HISTAMINE H2 ANTAGONISTS**

ANTI-HIV AGENTS

Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents. Hara H, et al. **AIDS Res Hum Retroviruses** 1997 May 20;13(8):695-705

New drugs--reports of new drugs recently approved by the FDA. Lamivudine. Ohta Y, et al. **Bioorg Med Chem** 1997 Apr;5(4):639-40

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Noble S, et al. **Drugs** 1996 Jul;52(1):93-112 (75 ref.)

Inhibition of recombinant human immunodeficiency virus type 1 replication by a site-specific recombinase. Flowers CC, et al. **J Virol** 1997 Apr;71(4):2685-92

Bioinformatics speeds HIV-1 drug development [news] Fishman RH. **Lancet** 1996 Dec 14;348(9042):1648

Antiretroviral drugs for AIDS. Lipsky JJ. **Lancet** 1996 Sep 21;348(9030):800-3 (45 ref.)

Anti-HIV ribozymes. Sun LQ, et al. **Mol Biotechnol** 1997 Jun;7(3):241-51 (76 ref.)

Virodene--support misguided [letter; comment] Bloch C. **S Afr Med J** 1997 Apr;87(4):468. Comment on: S Afr Med J 1997 Mar;87(3):253.

[Approval of HIV protease inhibitors as the AIDS therapeutics of next generation] Kiso Y. **Nippon Rinsho** 1997 May;55(5):1287-95 (22 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Transfer of antivirals to skin Langerhans cells--a novel approach to anti-HIV treatment by "antiviral peplotion". Becker Y. **Acta Biochim Pol** 1996;43(1):175-81 (30 ref.)

Recommendations for the development of vaginal microbicides. International Working Group on Vaginal Microbicides. **AIDS** 1996 Jul;10(8):1-6

The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee. **AIDS** 1996 Jul;10(8):867-80

Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens. Brouwers P, et al. **AIDS** 1997 Jan;11(1):59-66

HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy [letter] Gisslén M, et al. **AIDS** 1997 Jul 15;11(9):1194

Totally implantable venous access device infections in patients with AIDS [letter] Hellard M, et al. **AIDS** 1997 Apr;11(5):697-8

Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC. Ruiz L, et al. **AIDS** 1996 Dec;10(14):F61-6

Risks and synergies from drug interactions. Sahai J. **AIDS** 1996 Nov;10 Suppl 1:S21-5 (6 ref.)

Potential role of dideoxyinosine and hydroxyurea combination in prophylaxis of HIV infection after accidental percutaneous exposure [letter] Raharinivo B, et al. **AIDS Res Hum Retroviruses** 1997 Mar 20;13(5):367-9

Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. Brewster ME, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):122-8

Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Borin MT, et al. **Antiviral Res** 1997 Jun;35(1):53-63

Lymphatic targeting of anti-HIV nucleosides: distribution of 2',3'-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice. Manouilov KK, et al. **Antiviral Res** 1997 May;34(3):91-9

The challenge of maternal-infant transmission of HIV. Gallagher MA, et al. **J Assoc Nurses AIDS Care** 1996 Jan-Feb;7(1):47-9

Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. Sparano JA, et al. **J Clin Oncol** 1996 Nov; 14(11):3026-35

Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. Zhou XJ, et al. **J Clin Pharmacol** 1997 Mar; 37(3):201-13

Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype. Holodniy M, et al. **J Infect Dis** 1996 Oct;174(4):854-7

Sequential versus simultaneous combination antiretroviral regimens for the treatment of human immunodeficiency virus type 1 infection in vitro. Oh M, et al. **J Infect Dis** 1997 Aug;176(2):510-4

Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study. van Leeuwen R, et al. **J Infect Dis** 1997 Jun;175(6):1344-51

ANTI-HIV AGENTS

HIV post-exposure prophylaxis: complex issues in health care worker management [editorial] Ball RT Jr. **J S C Med Assoc** 1996 Oct;92(10):437-40 (6 ref.)

Hit early, hit hard: new strategies for HIV [editorial] Bryan CS. **J S C Med Assoc** 1996 Aug;92(8):361-3

British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals [letter; comment] Carey PB, et al. **Lancet** 1997 Jun 21;349(9068):1837. Comment on: Lancet 1997 Apr 12;349(9058):1086-92.

Cure or control of HIV/AIDS? Collins DO, et al. **Med Hypotheses** 1997 Jun;48(6):489-90

Retroviral delivery and anti-HIV testing of hammerhead ribozymes. Cagnon L, et al. **Methods Mol Biol** 1997; 74:451-7

HIV and HAART in 1997. Highly active antiretroviral therapy [news] Klaus BD, et al. **Nurse Pract** 1997 Aug; 22(8):139-42

HIV case study [letter; comment] Leiner S. **Nurse Pract** 1997 Jul;22(7):7, 157-8. Comment on: Nurse Pract 1997 Mar;22(3):94-6, 99-100.

Survival and quality of life in HIV-positive patients treated with a polyantigenic immunomodulator. Colón JI, et al. **P R Health Sci J** 1997 Mar;16(1):9-14

Role of brain tissue localized purine metabolizing enzymes in the central nervous system delivery of anti-HIV agents 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats. Singhal D, et al. **Pharm Res** 1997 Jun;14(6):786-92

[Centralized preparation in the pharmacy of dilute solutions of ganciclovir: (Cymevan): work load change and economic potential] Teissier R, et al. **J Pharm Belg** 1997 May-Jun;52(3):105-9 (Eng. Abstr.) **(Fre)**

[HIV: less resistance due to combined treatment (news)] **Dtsch Med Wochenschr** 1996 Dec 6;121(49):A47-8 **(Ger)**

[Nevirapine: a new principle of action against HIV (news)] **Dtsch Med Wochenschr** 1996 Dec 6;121(49):A48-9 **(Ger)**

[HIV: to administer protease inhibitors early (news)] **Dtsch Med Wochenschr** 1996 Dec 6;121(49):A49 **(Ger)**

[Prognosis depends on viral load. AIDS: frequently too much time is wasted (news)] **Fortschr Med** 1997 Jun 10;115(16):14 **(Ger)**

[HIV prevention after needlestick injury: preventive possibilities not proven, but likely. Official recommendations are still unavailable] Schweiger A. **Fortschr Med** 1996 Oct 10;114(28):16, 18 **(Ger)**

[HIV and pregnancy: risks of transmission and therapeutic possibilities] Ibe M, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(4):188-93 (36 ref.) (Eng. Abstr.) **(Ger)**

[New possibilities of medicamentous prophylaxis of occupational HIV infection] Petzoldt D, et al. **Hautarzt** 1997 May;48(5):295-6 **(Ger)**

[Viral load--significance for individualized therapy] Jäger H. **Med Klin** 1997 Jun 15;92(6):344-6 (Eng. Abstr.) **(Ger)**

[Post-exposure drug prevention of HIV infection] Rave K, et al. **Med Klin** 1996 Sep 15;91(9):589-99 (99 ref.) **(Ger)**

[New AIDS study confirms: triple combination therapy with the protease inhibitor indinavir lowers the risk of mortality by 50% (news)] **Schweiz Rundsch Med Prax** 1997 May 14; 86(20):860 **(Ger)**

[Effect of treatment with nucleoside analogues in subjects with primary genotypic resistance to zidovudine (letter)] Leal M, et al. **Med Clin (Barc)** 1996 Nov 30;107(19):755 **(Spa)**

ADVERSE EFFECTS

Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. White A, et al. **Acta Paediatr Suppl** 1997 Jun;421:86-8

Xerostomia: a symptom which acts like a disease [letter; comment] Harry TC. **Age Ageing** 1997 May;26(3):239. Comment on: Age Ageing 1996 Sep;25(5):409-12.

Retinal toxicity associated with didanosine in HIV-infected adults [letter] Cobo J, et al. **AIDS** 1996 Sep;10(11):1297-300

Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. Famularo G, et al. **AIDS** 1997 Feb;11(2):185-90

Unusual occurrence of spontaneous haematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment [letter] Ginsburg C, et al. **AIDS** 1997 Mar;11(3):388-9

Gout secondary to ritonavir and didanosine [letter] Mehlhaff DL, et al. **AIDS** 1996 Dec;10(14):1744

Risks and synergies from drug interactions. Sahai J. **AIDS** 1996 Nov;10 Suppl 1:S21-5 (6 ref.)

Side-effects of ritonavir and its combination with saquinavir with special regard to renal function [letter] Witzke O, et al. **AIDS** 1997 May;11(6):836-8

The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Whitfield RM, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):122-7

Lamivudine-stavudine-induced liver failure in hepatitis B cirrhosis. Schiano TD, et al. **Am J Gastroenterol** 1997 Sep; 92(9):1563-4

New safety information emerges from postmarketing use of ritonavir [news] **Am J Health Syst Pharm** 1997 Jan 15; 54(2):126

Crystalluria and urinary tract abnormalities associated with indinavir. Kopp JB, et al. **Ann Intern Med** 1997 Jul 15; 127(2):119-25

Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter] Darlington MR. **Ann Pharmacother** 1997 May;31(5):647

Hearing loss and antiretroviral therapy in patients infected with HIV-1. Marra CM, et al. **Arch Neurol** 1997 Apr; 54(4):407-10

Fatal toxic epidermolysis induced by zidovudine. Murri R, et al. **Clin Infect Dis** 1996 Sep;23(3):640-1

Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Sundar K, et al. **Crit Care Med** 1997 Aug;25(8):1425-30 (26 ref.)

Treatment of HIV infection. Tolerability of commonly used antiretroviral agents. Notermans DW, et al. **Drug Saf** 1996 Sep;15(3):176-87 (118 ref.)

Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2. Heylen R, et al. **Genitourin Med** 1997 Feb; 73(1):5-11 (103 ref.)

Indinavir nephrolithiasis in warm climates [letter] Bach MC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Mar 1;14(3):296-7

Reverse transcriptase mutations in HIV-1-infected children treated with zidovudine. Unal A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Oct 1;13(2):140-5

Puerperal febrile morbidity associated with the reverse transcriptase inhibitor stavudine. Wax JR, et al. **J Matern Fetal Med** 1997 Mar-Apr;6(2):118-9

Lack of muscle toxicity with didanosine (ddI). Clinical and experimental studies. Pedrol E, et al. **J Neurol Sci** 1996 Jun;138(1-2):42-8

Urinary stones in HIV-1-positive patients treated with indinavir [letter] Daudon M, et al. **Lancet** 1997 May 3; 349(9061):1294-5

Anaphylactoid reaction, angioedema, and urticaria associated with lamivudine [letter] Kainer MA, et al. **Lancet** 1996 Nov 30;348(9040):1519

Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection [letter] Stricker RB, et al. **Lancet** 1997 Jun 14;349(9067):1745-6

Type B lactic acidosis in an AIDS patient treated with zidovudine. Aggarwal A, et al. **Md Med J** 1996 Nov; 45(11):929-31

Adverse drug reactions in HIV positive hospitalized patients. A one-year drug surveillance program: study design. Calvo G, et al. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:27-8 (6 ref.)

Dideoxyinosine-induced pancreatitis in human immunodeficiency virus-infected children. Levin TL, et al. **Pediatr Radiol** 1997 Feb;27(2):189-91

Virodene--support misguided [letter] Folb PI, et al. **S Afr Med J** 1997 Apr;87(4):466

[Rhabdomyolysis in antiretroviral therapy with Lamivudin] Mendila M, et al. **Dtsch Med Wochenschr** 1997 Aug 15; 122(33):1003-6 (Eng. Abstr.) **(Ger)**

[Kidney colic under Indinavir [correction of indiavir] therapy in HIV infection] Junghanss BG. **Schweiz Rundsch Med Prax** 1997 Apr 30;86(18):767-8 **(Ger)**

[Anti-retroviral treatment. Treatment modification: toxicity management] Ocaña I, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14 Suppl 1:31-5 (38 ref.) **(Spa)**

ANTAGONISTS & INHIBITORS

Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides. Clayette P, et al. **Antimicrob Agents Chemother** 1997 Apr; 41(4):875-7

BLOOD

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. Hoggard PG, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1231-6

Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Polis MA, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1709-14

Determination of saquinavir in human plasma by high-performance liquid chromatography. Ha HR, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):427-33

Stereospecific determination of an HIV aspartyl protease inhibitor, PNU-103017, in rat, dog and human plasma using a Pirkle-concept high-performance liquid chromatographic column. Williams MG, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20;694(1):169-77

Rapid quantitation of (-)-2'-deoxy-3'-thiacytidine in human serum by high-performance liquid chromatography with ultraviolet detection. Zhou XJ, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):417-24

High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. Wu EY, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1;695(2):373-80

Specific radioimmunoassays for the measurement of stavudine in human plasma and urine. Kaul S, et al. **J Pharm Biomed Anal** 1996 Nov;15(2):165-74

CHEMICAL SYNTHESIS

2-Mercapto-N-(azolyl)benzenesulphonamides. II. Syntheses, anti-HIV-1 and anticancer activity of some S-substituted 4-chloro-2-mercapto-5-methyl-N-(5-amino-1,2,4-triazol-3-yl) benzenesulphonamides. Brzozowski Z. **Acta Pol Pharm** 1995 Jul-Aug;52(4):287-92

2-Mercapto-N-(azolyl)benzenesulphonamides. I. Synthesis of N-(1,1-dioxo-1,4,2-benzodithiazin-3-yl)guanidines and their transformations into 2-mercapto-N-(5-amino-1,2,4-triazol-3-yl) benzenesulphonamide derivatives with potential anti-HIV or anticancer activity. Brzozowski Z. **Acta Pol Pharm** 1995 Mar-Apr;52(2):91-101

Synthesis and in vitro anti-HIV activity of certain 2-(1H-benzimidazol-2-ylamino)pyrimidin-4(3H)-ones and related derivatives. Badawey el-S, et al. **Arch Pharm (Weinheim)** 1997 Mar;330(3):59-62

Pyridazines 82. Synthesis of pyridazino [3,4-b][1,5]benzodiazepin-5-ones and their biological evaluation as non-nucleoside HIV reverse transcriptase inhibitors. Heinisch G, et al. **Arch Pharm (Weinheim)** 1997 Jan-Feb;330(1-2):29-34

A new class of anti-HIV-1 agents targeted toward the nucleocapsid protein NCp7: the 2,2'-dithiobisbenzamides. Domagala JM, et al. **Bioorg Med Chem** 1997 Mar; 5(3):569-79

Stereoselective syntheses of substituted pterocarpans with anti-HIV activity, and 5-aza-/5-thia-pterocarpan and 2-aryl-2,3-dihydrobenzofuran analogues. Engler TA, et al. **Bioorg Med Chem** 1996 Oct;4(10):1755-69

Synthesis of N-glyoxylyl peptides and their in vitro evaluation as HIV-1 protease inhibitors. Qasmi D, et al. **Bioorg Med Chem** 1997 Apr;5(4):707-14

Synthesis and evaluation of new Reissert analogs as HIV-1 reverse transcriptase inhibitors. 1. Quinoline and quinoxaline derivatives. Font M, et al. **Drug Des Discov** 1997 Apr;14(4):305-32

Synthesis and evaluation of new Reissert analogs as HIV-1 RT inhibitors. 2. Benzo[f]quinoline and pyridine derivatives. Monge A, et al. **Drug Des Discov** 1997 Apr; 14(4):291-303

Specific interaction between HIV-1 proteinase and 5'-phosphate peptidomimetic derivatives of nucleoside analogues. Nillroth U, et al. **Drug Des Discov** 1995 Aug; 13(1):43-54

Synthesis and biological activity of acylated and telomerized peptides as potential HIV-fixation inhibitors. Lacoux X, et al. **Farmaco** 1996 Dec;51(12):767-73

Sulfone derivatives with anti-HIV activity. Silvestri R, et al. **Farmaco** 1997 May;52(5):323-9

Synthesis of a series of Homopterocarpane derivatives with potential antitumor and anti-AIDS activity. Valenti P, et al. **Farmaco** 1997 Jan;52(1):13-9

Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. Jadhav PK, et al. **J Med Chem** 1997 Jan 17;40(2):181-91

Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils. Kim DK, et al. **J Med Chem** 1997 Jul 18;40(15):2363-73

Synthesis and HIV inhibition activity of 2',3'-dideoxy-3'-C-hydroxymethyl nucleosides. Lee-Ruff E, et al. **J Med Chem** 1996 Dec 20;39(26):5276-80

Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors. Romero DL, et al. **J Med Chem** 1996 Sep 13;39(19):3769-89

Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships. Romines KR, et al. **J Med Chem** 1996 Sep 27;39(20):4125-30

Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1. Rosowsky A, et al. **J Med Chem** 1997 Aug 1;40(16):2482-90

Phosphodiester amidates of unsaturated nucleoside analogues: synthesis and anti-HIV activity. Winter H, et al. **J Med Chem** 1997 Jul 4;40(14):2191-5

Coumarin-based inhibitors of HIV integrase. Zhao H, et al. **J Med Chem** 1997 Jan 17;40(2):242-9

HIV-1 fusion mechanism could be target for new drugs [news] Morris K. **Lancet** 1997 Apr 26;349(9060):1227

Development of nonnucleoside HIV reverse transcriptase inhibitors. Tucker TJ, et al. **Methods Enzymol** 1996; 275:440-72 (67 ref.)

Chemokine inhibitors for HIV [news] Eccleston A. **Nat Biotechnol** 1997 Aug;15(8):709, 710

Synthesis of novel thiazolo[4,5-d]pyrimidine derivatives for antimicrobial, anti-HIV and anticancer investigation. Rida SM, et al. **Pharmazie** 1996 Dec;51(12):927-31

Synthesis and mass spectrometric behavior of some new nucleosides as potential anti-HIV agents. Fadda AM, et al. **Rapid Commun Mass Spectrom** 1997;11(7):774-80

Profile of CGP 61755: a novel and potent HIV-1 protease inhibitor that shows enhanced anti-HIV activity when combined with other antiretroviral agents in vitro. Lazdins JK, et al. **Schweiz Med Wochenschr** 1996 Oct 26; 126(43):1849-51

[New phospholipids--inhibitors of human immunodeficiency virus reproduction. Synthesis and antiviral activity] Vodovozova EL, et al. **Bioorg Khim** 1996 Jun;22(6):451-7 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Anti-HIV active naphthyl analogues of HEPT and DABO. Danel K, et al. **Acta Chem Scand** 1997 Mar;51(3 Suppl):426-30

Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation [published erratum appears in Antisense Nucleic Acid Drug Dev 1997 Apr;7(2):131] Lederman S, et al. **Antisense Nucleic Acid Drug Dev** 1996 Winter;6(4):281-9

Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Gustafson KR, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):223-8

The anti-HIV activity and mechanisms of action of pure compounds isolated from Rosa damascena. Mahmood N, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):73-9

Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein. Mori T, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):218-22

An anti-HIV peptide, T22, forms a highly active complex with Zn(II). Tamamura H, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):648-52

Exploration of the effects of linker chain modifications on anti-HIV activities in a series of cosalane analogues. Golebiewski WM, et al. **Bioorg Med Chem** 1996 Oct; 4(10):1637-48

Hybrid oligonucleotides: synthesis, biophysical properties, stability studies, and biological activity. Yu D, et al. **Bioorg Med Chem** 1996 Oct;4(10):1685-92

Model compounds in elucidating the structural basis of HIV retrovirus activity. Synthesis of trisodium O-monoalkyl- and O-monoaryldiphosphates. Gregán F, et al. **Boll Chim Farm** 1996 Apr;135(4):229-31

Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. II. Structure elucidation of chloropeptin I. Matsuzaki K, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):66-9

QSAR based on multiple linear regression and PLS methods for the anti-HIV activity of a large group of HEPT derivatives. Luco JM, et al. **J Chem Inf Comput Sci** 1997 Mar-Apr;37(2):392-401

Quantitative structure-activity relationship studies on some viral reverse transcriptase inhibitors acting as anti-HIV-1 agents. Garg R, et al. **J Enzyme Inhib** 1997 Jan;11(3):171-81

Structure-activity modifications of the HIV-1 inhibitors (+)-calanolide A and (-)-calanolide B. Galinis DL, et al. **J Med Chem** 1996 Oct 25;39(22):4507-10

HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis. Wilkerson WW, et al. **J Med Chem** 1996 Oct 11; 39(21):4299-312

Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C). Zembower DE, et al. **J Med Chem** 1997 Mar 14; 40(6):1005-17

Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. Burke DH, et al. **J Mol Biol** 1996 Dec 13;264(4):650-66

Solid phases of delavirdine mesylate. Bergren MS, et al. **J Pharm Sci** 1996 Aug;85(8):834-41

A new class of viral inhibitor [news; comment] **Nat Biotechnol** 1997 Feb;15(2):135. Comment on: Nat Biotechnol 1997 Feb;15(2):150-4.

Intrinsic solubility estimation and pH-solubility behavior of cosalane (NSC 658586), an extremely hydrophobic diprotic acid. Venkatesh S, et al. **Pharm Res** 1996 Oct;13(10):1453-9

Synthesis and mass spectrometric behavior of some new nucleosides as potential anti-HIV agents. Fadda AM, et al. **Rapid Commun Mass Spectrom** 1997;11(7):774-80

ECONOMICS

Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Pinkerton SD, et al. **Arch Intern Med** 1997 Sep 22;157(17):1972-80

New AIDS drugs affect US state assistance [news] Firshein J. **Lancet** 1997 Jul 19;350(9072):195

Postexposure treatment of HIV [letter; comment] Li RW, et al. **N Engl J Med** 1997 Aug 14;337(7):499-500; discussion 501. Comment on: N Engl J Med 1997 Apr;10;336(15):1097-100.

Postexposure treatment of HIV [letter; comment] Pinkerton SD, et al. **N Engl J Med** 1997 Aug 14;337(7):500-1. Comment on: N Engl J Med 1997 Apr 10;336(15):1097-100.

[Centralized preparation in the pharmacy of dilute solutions of ganciclovir: (Cymevan): work load change and economic potential] Teissier R, et al. **J Pharm Belg** 1997 May-Jun;52(3):105-9 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Preliminary observations using HIV-specific transfer factor in AIDS. Pizza G, et al. **Biotherapy** 1996;9(1-3):41-7

Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. Furci L, et al. **J Exp Med** 1997 Aug 4;186(3):455-60

ISOLATION & PURIFICATION

Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Boyd MR, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1521-30

Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Gustafson KR, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):223-8

Substituent effects on the enantioselective retention of anti-HIV 5-aryl-delta 2-1,2,4-oxadiazolines on R,R-DACH-DNB chiral stationary phase. Altomare C, et al. **Chirality** 1996;8(8):556-66

Isolation and characterization of niphatevirin, a human-immunodeficiency-virus-inhibitory glycoprotein from the marine sponge Niphates erecta. O'Keefe BR, et al. **Eur J Biochem** 1997 Apr 1;245(1):47-53

Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. I. Taxonomy, fermentation, isolation, and physico-chemical properties and biological activities. Tanaka H, et al. **J Antibiot (Tokyo)** 1997 Jan;50(1):58-65

Two new lignans, interiotherins A and B, as anti-HIV principles from Kadsura interior. Chen DF, et al. **J Nat Prod** 1996 Nov;59(11):1066-8

Flavonol and chalcone ester glycosides from Bidens leucantha. De Tommasi N, et al. **J Nat Prod** 1997 Mar; 60(3):270-3

Michellamines D-F, new HIV-inhibitory dimeric naphthylisoquinoline alkaloids, and korupensamine E, a new antimalarial monomer, from Ancistrocladus korupensis. Hallock YF, et al. **J Nat Prod** 1997 Jul; 60(7):677-83

Isolation and characterization of new anti-HIV and cytotoxic leads from plants, marine, and microbial organisms. McKee TC, et al. **J Nat Prod** 1997 May;60(5):431-8

Three new naphthyldihydroisoquinoline alkaloids from Ancistrocladus tectorius. Manfredi KP, et al. **J Nat Prod** 1996 Sep;59(9):854-9

Antiviral sulfated steroids from the ophiuroid Ophioplocus januarii. Roccatagliata AJ, et al. **J Nat Prod** 1996 Sep; 59(9):887-9

New anti-HIV-1, antimalarial, and antifungal compounds from Terminalia bellerica. Valsaraj R, et al. **J Nat Prod** 1997 Jul;60(7):739-42

Construction of a cell-based high-flux assay for the rev protein of HIV-1. Tang RY, et al. **J Virol Methods** 1997 May;65(2):153-8

Compounds with anti-HIV activity from plants. Houghton PJ. **Trans R Soc Trop Med Hyg** 1996 Nov-Dec;90(6):601-4 (19 ref.)

METABOLISM

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Faletto MB, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1099-107

Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea. Palmer S, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):460-4

Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine. Rahn JJ, et al. **Antimicrob Agents Chemother** 1997 May;41(5):918-23

Clarithromycin does not affect phosphorylation of zidovudine in vitro. Rana KZ, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1945-7

In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite. Chaput AJ, et al. **Antiviral Res** 1996 Oct;32(2):81-9

Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Chiba M, et al. **Biochem Pharmacol** 1997 Apr 25;53(8):1187-95

Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Fitzsimmons ME, et al. **Drug Metab Dispos** 1997 Feb;25(2):256-66

Harziphilone and fleephilone, two new HIV REV/RRE binding inhibitors produced by Trichoderma harzianum. Qian-Cutrone J, et al. **J Antibiot (Tokyo)** 1996 Oct; 49(10):990-7

Radioimmunoassay for ziovudine in rat placenta and fetus. Huang CS, et al. **J Pharm Biomed Anal** 1996 May; 14(7):855-60

Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion host shutoff protein. Hamouda T, et al. **J Virol** 1997 Jul;71(7):5521-7

Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Esnouf RM, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3984-9

Hepatitis C virus core protein inhibits human immunodeficiency virus type 1 replication. Srinivas RV, et al. **Virus Res** 1996 Dec;45(2):87-92

PHARMACOKINETICS

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. Merry C, et al. **AIDS** 1997 Mar 15;11(4):F29-33

Macrophage targeting of azidothymidine: a promising strategy for AIDS therapy. Löbenberg R, et al. **AIDS Res Hum Retroviruses** 1996 Dec 10;12(18):1709-15

The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Bloom SL, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):291-3

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Daluge SM, et al. **Antimicrob Agents Chemother** 1997 May; 41(5):1082-93

Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Morse GD, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):169-74

Prenatal and postpartum pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) and didanosine (dideoxyinosine) in pigtailed macaques (Macaca nemestrina). Odinecs A, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2423-5

In vivo maternal-fetal pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Odinecs A, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):196-202

Pharmacokinetics of a water-soluble fullerene in rats. Rajagopalan P, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2262-5

In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide. Temsamani J, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):159-65

Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Borin MT, et al. **Antiviral Res** 1997 Jun;35(1):53-63

Lymphatic targeting of anti-HIV nucleosides: distribution of 2',3'-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice. Manouilov KK, et al. **Antiviral Res** 1997 May;34(3):91-9

Intestinal absorption and first-pass elimination of 2',3'-dideoxynucleosides following oral administration in rats. Hasegawa T, et al. **Biol Pharm Bull** 1996 Apr;19(4):599-603

Nasal absorption of 2',3'-didehydro-3'-deoxythymidine (D4T) and its esters in rats. Yajima T, et al. **Biol Pharm Bull** 1996 Sep;19(9):1234-7

A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic. Knupp CA, et al. **Biopharm Drug Dispos** 1997 Jan;18(1):65-77

Investigation of the uptake of drugs by individual cells using a scanning proton microprobe (SPM). Cholewa M, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Feb;42(1):69-76

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Borin MT, et al. **Clin Pharmacol Ther** 1997 May;61(5):544-53

Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Cheng CL, et al. **Clin Pharmacol Ther** 1997 May; 61(5):531-43

Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis. Knupp CA, et al. **Clin Pharmacol Ther** 1996 Nov; 60(5):535-42

Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus. Peter K, et al. **Clin Pharmacol Ther** 1996 Aug;60(2):168-76

Decay rates of anti-HIV dideoxynucleotides in tissue culture systems: a simple correction for the effect of cell replication. Ahluwalia GS, et al. **Drug Metab Dispos** 1997 Jul;25(7):893-6

Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys. Chang M, et al. **Drug Metab Dispos** 1997 Jul;25(7):814-27

Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice. Chang M, et al. **Drug Metab Dispos** 1997 Jul;25(7):828-39

Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats. Chang M, et al. **Drug Metab Dispos** 1997 Feb;25(2):228-42

Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late-term rhesus macaques after maternal infusion. Patterson TA, et al. **Drug Metab Dispos** 1997 Apr; 25(4):453-9

Role of altered metabolism in dideoxynucleoside pharmacokinetics. Studies of 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats. Singhal D, et al. **Drug Metab Dispos** 1996 Oct;24(10):1155-61

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. Japour AJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Nov 1;13(3):235-46

Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. Rolinski B, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jul 1;15(3):192-7

ANTI-HIV AGENTS

Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. Zhou XJ, et al. **J Clin Pharmacol** 1997 Mar; 37(3):201-13

Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team. Bakshi SS, et al. **J Infect Dis** 1997 May;175(5):1039-50

Bioequivalence of a generic preparation of oral zidovudine in healthy Thai volunteers. Theekachunhatean S, et al. J Med Assoc Thai 1996 Sep;79(9):558-62

High-performance liquid chromatographic analysis of 2'-fluoro-2',3'-dideoxyadenosine and 2'-fluoro-2',3'-dideoxyinosine in dog plasma and urine. Campbell DA, et al. **J Pharm Sci** 1996 Aug;85(8):890-2

Maternal-fetal pharmacokinetics of zidovudine in rats. Huang CS, et al. **J Pharm Sci** 1996 Sep;85(9):965-70

In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. Takasawa K, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):369-75

Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. Takasawa K, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1509-17

Pharmacokinetics and distribution of a 33P-labeled anti-human immunodeficiency virus oligonucleotide (AR177) after single- and multiple-dose intravenous administration to rats. Wallace TL, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1480-8

Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. Wallace TL, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1306-12

Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys. Wallace TL, et al. **J Pharmacol Exp Ther** 1996 Sep; 278(3):1313-7

Effect of trimethoprim on lamivudine bioavailability [letter; comment] Hudson M, et al. **JAMA** 1996 Oct 9;276(14):1140 . Comment on: JAMA 1996 Jul 10;276(2):118-25.

The bottleneck in AZT activation [see comments] Lavie A, et al. **Nat Med** 1997 Aug;3(8):922-4. Comment in: Nat Med 1997 Aug;3(8):836-7.

Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat. Yang Z, et al. **Pharm Res** 1997 Jul;14(7):865-72

Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. Acosta EP, et al. **Pharmacotherapy** 1997 May-Jun;17(3):424-30

Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. Shelton MJ, et al. **Pharmacotherapy** 1997 May-Jun;17(3):438-44

Pharmacokinetic and toxicity studies of AZT (zidovudine) following perfusion of human term placenta for 14 hours. Boal JH, et al. **Toxicol Appl Pharmacol** 1997 Mar; 143(1):13-21

PHARMACOLOGY

Antiretroviral resistance and HIV vertical transmission. McIntosh K. **Acta Paediatr Suppl** 1997 Jun;421:29-32

N-acetyl-cysteine and L-2-oxothiazolidine-4-carboxylic acid enhance contact-dependent growth of HIV in resting peripheral blood mononuclear cells (PBMC) in vitro and increase recovery of HIV from human-PBMC SCID mice. Chen P, et al. **AIDS** 1997 Jan;11(1):33-41

HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity. Ercoli L, et al. **AIDS** 1997 Aug; 11(10):1211-7

HIV cDNA integration: molecular biology and inhibitor development. Farnet CM, et al. **AIDS** 1996;10 Suppl A:S3-11 (140 ref.)

Prevalence of zidovudine-resistant HIV-1 among rapid progressors [letter; comment] García-Lerma G, et al. **AIDS** 1996 Sep;10(11):1292-3. Comment on: AIDS 1996 Jan;10(1):77-80.

Zidovudine-resistant variants of HIV-1 in lung [letter] Gates A, et al. **AIDS** 1997 Apr;11(5):702-3

Newer nucleosides: lamivudine and stavudine. Katlama C, et al. **AIDS** 1996;10 Suppl A:S135-43 (58 ref.)

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. Kuritzkes DR, et al. **AIDS** 1996 Aug;10(9):975-81

Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1. Piras G, et al. **AIDS** 1997 Mar 15;11(4):469-75

Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors [letter] Quigg M, et al. **AIDS** 1997 May;11(6):835-6

Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naive patients from 1989 to 1996 [letter] Rubio A, et al. **AIDS** 1997 Jul 15;11(9):1184-6

In vitro effects of continuous pressure with zidovudine (ZDV) and lamivudine on a ZDV-resistant HIV-1 isolate [letter] Rusconi S, et al. **AIDS** 1997 Sep;11(11):1406-10

Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase. Wainberg MA, et al. **AIDS** 1996 Dec; 10 Suppl 5:S3-10

HIV protease inhibitors. Winslow DL, et al. **AIDS** 1995;9 Suppl A:S183-92 (129 ref.)

Effect of the oral anti-ulcer agent, cimetidine, on HIV type 1 replication [letter] Bourinbaiar AS, et al. **AIDS Res Hum Retroviruses** 1997 Mar 1;13(4):281-2

Potent inhibition of replication of primary HIV type 1 isolates in peripheral blood lymphocytes by negatively charged human serum albumins. Groenink M, et al. **AIDS Res Hum Retroviruses** 1997 Jan 20;13(2):179-85

Stavudine selectively induces apoptosis in HIV type 1-infected cells. Hashimoto KI, et al. **AIDS Res Hum Retroviruses** 1997 Jan 20;13(2):193-9

Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages. Javan CM, et al. **AIDS Res Hum Retroviruses** 1997 Jul 1;13(10):875-80

Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. Moreira AL, et al. **AIDS Res Hum Retroviruses** 1997 Jul 1;13(10):857-63

Lecithinized superoxide dismutase: an inhibitor of human immunodeficiency virus replication. Premanathan M, et al. **AIDS Res Hum Retroviruses** 1997 Mar 1;13(4):283-90

In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy. Veal GJ, et al. **AIDS Res Hum Retroviruses** 1997 Apr 10;13(6):481-4

Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. Witvrouw M, et al. **AIDS Res Hum Retroviruses** 1997 Jan 20;13(2):187-92

Synthesis, antiviral and antiproliferative activity of a new class of 5-(alkyl or arylthio)-6-vinyl uracils. Baraldi PG, et al. **Anticancer Drug Des** 1996 Dec;11(8):597-609

Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Baba M, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1250-5

Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Boucher CA, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2404-9

Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Buckheit RW Jr, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):831-7

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Kempf DJ, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):654-60

The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors. Kew Y, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1711-4

Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy. Mathes LE, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2183-6

Inhibition of Trypanosoma cruzi growth in mammalian cells by purine and pyrimidine analogs. Nakajima-Shimada J, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2455-8

Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Rice WG, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):419-26

Potent activity of 2'-beta-fluoro-2',3'-dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice. Ruxrungtham K, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2369-74

In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine. Tanaka M, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1313-8

Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Tisdale M, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1094-8

Native oligodeoxynucleotides specifically active against human immunodeficiency virus type 1 in vitro: a G-quartet-driven effect? Tondelli L, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2034-8

The human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein zinc ejection activity of disulfide benzamides and benzisothiazolones: correlation with anti-HIV and virucidal activities. Tummino PJ, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):394-400

SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. Witvrouw M, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):262-8

Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine. Zhu YQ, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):1983-7

Identification of a phosphodiester hexanucleotide that inhibits HIV-1 infection in vitro on covalent linkage of its 5'-end with a dimethoxytrityl residue. Furukawa H, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):167-75

Guanine-rich oligonucleotide modified at the 5' terminal by dimethoxytrityl residue inhibits HIV-1 replication by specific interaction with the envelope glycoprotein. Agatsuma T, et al. **Antiviral Res** 1996 Jul;31(3):137-48

Protection of hu-PBL-SCID/beige mice from HIV-1 infection by a 6-mer modified oligonucleotide, R-95288. Agatsuma T, et al. **Antiviral Res** 1997 May;34(3):121-30

Cellular factors as alternative targets for inhibition of HIV-1. Baba M. **Antiviral Res** 1997 Feb;33(3):141-52 (92 ref.)

Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Chong KT, et al. **Antiviral Res** 1997 Mar; 34(1):51-63

In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Foli A, et al. **Antiviral Res** 1996 Oct;32(2):91-8

Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Gulakowski RJ, et al. **Antiviral Res** 1997 Jan;33(2):87-97

Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro. Hostetler KY, et al. **Antiviral Res** 1996 Jun;31(1-2):59-67

Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. Ijichi K, et al. **Antiviral Res** 1996 Jun;31(1-2):115-20

Anti-HIV-1 activity of thiadiazole derivatives: structure-activity relationship, reverse transcriptase inhibition, and lipophilicity. Ijichi K, et al. **Antiviral Res** 1996 Jun;31(1-2):87-94

Novel L-lyxo and 5'-deoxy-5'-modified TSAO-T analogs: synthesis and anti-HIV-1 activity. Ingate S, et al. **Antiviral Res** 1996 Nov;32(3):149-64

Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Keulen W, et al. **Antiviral Res** 1996 Jun;31(1-2):45-57

The role of genotypic heterogeneity in wild type virus populations on the selection of nonnucleoside reverse transcriptase inhibitor-resistant viruses. Kinjerski TL, et al. **Antiviral Res** 1997 Jan;33(2):109-15

2-Glycineamide-5-chlorophenyl 2-pyrryl ketone, a non-benzodiazepin Tat antagonist, is effective against acute and chronic HIV-1 infections in vitro. Kira T, et al. **Antiviral Res** 1996 Oct;32(2):55-62

Pharmacokinetics and anti-HIV-1 efficacy of negatively charged human serum albumins in mice. Kuipers ME, et al. **Antiviral Res** 1997 Jan;33(2):99-108

In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses. Parang K, et al. **Antiviral Res** 1997 May;34(3):75-90

Evaluation of anti-AIDS drugs in conventional mice implanted with a permeable membrane device containing human T cells infected with HIV. Quenelle DC, et al. **Antiviral Res** 1997 Jul;35(2):123-9

Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Schols D, et al. **Antiviral Res** 1997 Aug;35(3):147-56

(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibits HIV-1 replication in epithelial cells, but not T-lymphocytes. Srinivas RV, et al. **Antiviral Res** 1997 Jun;35(1):23-7

Inhibition of bovine immunodeficiency virus by anti-HIV-1 compounds in a cell culture-based assay. Tobin GJ, et al. **Antiviral Res** 1996 Dec;33(1):21-31

Sulfated colominic acid: an antiviral agent that inhibits the human immunodeficiency virus type 1 in vitro. Yang DW, et al. **Antiviral Res** 1996 Jun;31(1-2):95-104

Human immunodeficiency virus type 1 protease inhibitors. McDonald CK, et al. **Arch Intern Med** 1997 May 12; 157(9):951-9 (86 ref.)

Pyridazines 82. Synthesis of pyridazino [3,4-b][1,5]benzodiazepin-5-ones and their biological evaluation as non-nucleoside HIV reverse transcriptase inhibitors. Heinisch G, et al. **Arch Pharm (Weinheim)** 1997 Jan-Feb;330(1-2):29-34

The anti-HIV activity and mechanisms of action of pure compounds isolated from Rosa damascena. Mahmood N, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):73-9

Inhibition of HIV-1 replication by triple-helix-forming phosphorothioate oligonucleotides targeted to the polypurine tract. Tsukahara S, et al. **Biochem Biophys Res Commun** 1997 Apr 28;233(3):742-7

Further study of the mechanism underlying the cellular resistance to AZT. Turriziani O, et al. **Biochem Biophys Res Commun** 1996 Nov 21;228(3):797-801

Insensitivity of cultured rat cortical neurons to mitochondrial DNA synthesis inhibitors: evidence for a slow turnover of mitochondrial DNA. Wang GJ, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):181-7

A basic compositional requirement of agents having heparin-like cell-modulating activities. Weisz PB, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):149-57

Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives. Ratmeyer L, et al. **Biochemistry** 1996 Oct 22; 35(42):13689-96

Analysis of the interaction of an anti-HIV peptide, T22 ([Tyr5, 12, Lys7]-polyphemusin II), with gp120 and CD4 by surface plasmon resonance. Tamamura H, et al.

Biochim Biophys Acta 1996 Nov 14;1298(1):37–44

In vitro and ex vivo anti-human immunodeficiency virus (HIV) activities of a new water-soluble HIV protease inhibitor, R-87366, containing (2S,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid. Komai T, et al. **Biol Pharm Bull** 1997 Feb;20(2):175–80

Anti-HIV activity of extracts from Calendula officinalis flowers. Kalvatchev Z, et al. **Biomed Pharmacother** 1997; 51(4):176–80

5H-pyrrolo[1,2-b] [1,2,5]benzothiadiazepines (PBTDs): a novel class of non-nucleoside reverse transcriptase inhibitors. Artico M, et al. **Bioorg Med Chem** 1996 Jun; 4(6):837–50

Discovery of selective, small-molecule inhibitors of RNA complexes--I. The Tat protein/TAR RNA complexes required for HIV-1 transcription. Mei HY, et al. **Bioorg Med Chem** 1997 Jun;5(6):1173–84

Modulation of the Rev-RRE interaction by aromatic heterocyclic compounds. Zapp ML, et al. **Bioorg Med Chem** 1997 Jun;5(6):1149–55

Inhibition of in vitro HIV infection by dialysable leucocyte extracts. Fernandez-Ortega C, et al. **Biotherapy** 1996; 9(1–3):33–40

Effect of zidovudine (AZT) on the structure and function of rat skeletal muscle. Engbretson BG. **Can J Physiol Pharmacol** 1996 Jun;74(6):679–86

L-2-oxothiazolidine-4-carboxylic acid inhibits human immunodeficiency virus type 1 replication in mononuclear phagocytes and lymphocytes. Ho WZ, et al. **Clin Diagn Lab Immunol** 1997 May;4(3):352–7

A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex. Gries JM, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):70–82

Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Chiang G, et al. **Clin Ther** 1996 Nov-Dec;18(6):1080–92

Indinavir: a pharmacologic and clinical review of a new HIV protease inhibitor. Lacy MK, et al. **Conn Med** 1996 Dec; 60(12):723–7 (20 ref.)

Structure-activity relationships in quinoline Reissert derivatives with HIV-1 reverse transcriptase inhibitory activity. Font M, et al. **Drug Des Discov** 1997 Apr; 14(4):259–72

Specific interaction between HIV-1 proteinase and 5'-phosphate peptidomimetic derivatives of nucleoside analogues. Nillroth U, et al. **Drug Des Discov** 1995 Aug; 13(1):43–54

Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Adkins JC, et al. **Drugs** 1997 Jun;53(6):1054–80 (178 ref.)

Ritonavir. Lea AP, et al. **Drugs** 1996 Oct;52(4):541–6; discussion 547–8 (37 ref.)

Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Lea AP, et al. **Drugs** 1996 May;51(5):846–64 (114 ref.)

Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Perry CM, et al. **Drugs** 1996 Dec;52(6):928–62 (221 ref.)

Nelfinavir. Perry CM, et al. **Drugs** 1997 Jul;54(1):81–7; discussion 88 (30 ref.)

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Perry CM, et al. **Drugs** 1997 Apr;53(4):657–80 (114 ref.)

Structure/function relationship study of Tyr14 and Arg22 in trichosanthin, a ribosome-inactivating protein. Shaw PC, et al. **Eur J Biochem** 1997 Apr 15;245(2):423–7

3,6-Disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles: synthesis, antimicrobial and antiviral activity. II. Invidiata FP, et al. **Farmaco** 1996 Oct;51(10):659–64

Quinoxaline chemistry. Part 7. 2-[aminobenzoates]- and 2-[aminobenzoylglutamate]-quinoxalines as classical antifolate agents. Synthesis and evaluation of in vitro anticancer, anti-HIV and antifungal activity. Loriga M, et al. **Farmaco** 1997 Mar;52(3):157–66

TPSg, an anti-human immunodeficiency virus (HIV-1) agent, isolated from the Cupressaceae Thuja occidentale L. (Arborvitae) enhances in vivo hemopoietic progenitor cells recovery in sublethally irradiated mice. Hassan HT, et al. **Immunol Lett** 1996 Apr;50(1-2):119–22

Inhibition of HIV infection of H9 cells by chlorpromazine derivatives. Hewlett I, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 May 1;15(1):16–20

Zidovudine potentiates local and systemic inflammatory responses in the rat. Raymond P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 15;14(5):399–407

HIV-induced cytopathology and viral load in a pentamidine-treated lymphocytic cell line. Arnott MA, et al. **J Antimicrob Chemother** 1996 Mar;37(3):535–43

In-vitro activity of antiviral agents used in AIDS against Salmonella typhi and non-typhoid salmonella [letter] Sanchez-Carrillo C, et al. **J Antimicrob Chemother** 1996 Jul;38(1):153–4

Effect of antiretroviral therapy on plasma HIV RNA. Saag MS. **J Biol Regul Homeost Agents** 1995 Jul-Sep;9(3):105–6 (23 ref.)

Immunomodulatory effects of antiretroviral chemotherapy. Schooley RT. **J Biol Regul Homeost Agents** 1995 Jul-Sep; 9(3):110–3 (34 ref.)

Alteration of thymidine kinase activity in cells treated with an antiviral agent. Turriziani O, et al. **J Biol Regul Homeost Agents** 1995 Apr-Jun;9(2):47–51

QSAR based on multiple linear regression and PLS methods for the anti-HIV activity of a large group of HEPT derivatives. Luco JM, et al. **J Chem Inf Comput Sci** 1997 Mar-Apr;37(2):392–401

In vitro inhibitory activity of citreoviridin against HIV-1 and an HIV-associated opportunist: Candida albicans. Vieta I, et al. **J Chemother** 1996 Oct;8(5):351–7

Standardized peripheral blood mononuclear cell culture assay for zidovudine susceptibility testing of clinical human immunodeficiency virus type 1 isolates: effect of reducing the numbers of replicates and concentrations. Marschner IC, et al. **J Clin Microbiol** 1997 Mar;35(3):756–8

Quantitative structure-activity relationship studies on some anti-human-immunodeficiency-virus-1 (anti-HIV-1) drugs: viral reverse transcriptase inhibitors. Garg R, et al. **J Enzyme Inhib** 1997 Apr;12(1):1–12

Quantitative structure-activity relationship studies on anti-HIV-1 TIBO derivatives as inhibitors of viral reverse transcriptase. Gupta SP, et al. **J Enzyme Inhib** 1996 Aug; 11(1):23–32

Inhibition of octapeptide N-myristoylation by acyl amino acids and acyl alkanolamines. Tabuchi M, et al. **J Enzyme Inhib** 1997 Apr;12(1):27–36

AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. Macchi B, et al. **J Gen Virol** 1997 May;78 (Pt 5):1007–16

Drug sensitivity of human immunodeficiency virus type 1 isolates after ribavirin therapy. Bernier R, et al. **J Infect Dis** 1997 Jan;175(1):176–8

Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. Imrie A, et al. **J Infect Dis** 1997 Jun;175(6):1502–6

A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates. Jellinger RM, et al. **J Infect Dis** 1997 Mar; 175(3):561–6

In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. Lazdins JK, et al. **J Infect Dis** 1997 May;175(5):1063–70

Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro. Merrill DP, et al. **J Infect Dis** 1997 Jul;176(1):265–8

Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. Nijhuis M, et al. **J Infect Dis** 1997 Aug;176(2):398–405

Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. van 't Wout AB, et al. **J Infect Dis** 1996 Oct;174(4):845–9

Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. Aquaro S, et al. **J Leukoc Biol** 1997 Jul;62(1):138–43 (39 ref.)

Preparation and anti-HIV activity of N-3-substituted thymidine nucleoside analogs. Adams DR, et al. **J Med Chem** 1997 May 9;40(10):1550–8

Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. Cantrell AS, et al. **J Med Chem** 1996 Oct 11; 39(21):4261–74

Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. Jadhav PK, et al. **J Med Chem** 1997 Jan 17;40(2):181–91

Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils. Kim DK, et al. **J Med Chem** 1997 Jul 18;40(15):2363–73

In vitro and in vivo evaluation of 6-azido-2',3'-dideoxy-2'-fluoro-beta-D-arabinofuranosylpurine and N6-methyl-2',3'-dideoxy-2'-fluoro-beta-D-arabinofuranosyladenine as prodrugs of the anti-HIV nucleosides 2'-F-ara-ddA and 2'-F-ara-ddI. Koudriakova T, et al. **J Med Chem** 1996 Nov 8;39(23):4676–81

Polyanion inhibitors of human immunodeficiency virus and other viruses. 5. Telomerized anionic surfactants derived from amino acids. Leydet A, et al. **J Med Chem** 1997 Jan 31;40(3):342–9

Polyanion inhibitors of human immunodeficiency virus and other viruses. 6. Micelle-like anti-HIV polyanionic compounds based on a carbohydrate core. Leydet A, et al. **J Med Chem** 1997 Jan 31;40(3):350–6

Biophysical characterization of zinc ejection from HIV nucleocapsid protein by anti-HIV 2,2'-dithiobis[benzamides] and benzisothiazolones. Loo JA, et al. **J Med Chem** 1996 Oct 11;39(21):4313–20

Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. Neamati N, et al. **J Med Chem** 1997 Mar 14; 40(6):942–51

Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors. Rice WG, et al. **J Med Chem** 1996 Sep 13;39(19):3606–16

Coumarin-based inhibitors of HIV integrase. Zhao H, et al. **J Med Chem** 1997 Jan 17;40(2):242–9

Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. Currens MJ, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):645–51

Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A. Currens MJ, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):652–61

Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retroviricidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. Borkow G, et al. **J Virol** 1997 Apr; 71(4):3023–30

Human immunodeficiency virus type 2 preintegration complexes: activities in vitro and response to inhibitors. Hansen MS, et al. **J Virol** 1997 Apr;71(4):3351–6

Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists. Mhashilkar AM, et al. **J Virol** 1997 Sep;71(9):6486–94

Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry. Pleskoff O, et al. **J Virol** 1996 Nov;70(11):8247–51

Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1. Quan Y, et al. **J Virol** 1996 Aug;70(8):5642–5

Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes. Veres G, et al. **J Virol** 1996 Dec;70(12):8792–800

Glycodelins GdA and GdS modified by 3-hydroxyphthalic anhydride inhibit gp120-CD4 binding and HIV-1 infection in vitro. Seppälä M, et al. **Lab Invest** 1997 Aug;77(2):127–30

The ups and downs of T-cell recovery in HIV-1 disease [news] Rowe PM. **Lancet** 1997 Sep 6;350(9079):720

Anti-human immunodeficiency virus activity of oligosaccharides from rooibos tea (Aspalathus linearis) extracts in vitro. Nakano M, et al. **Leukemia** 1997 Apr;11 Suppl 3:128–30

Inhibition of HIV-1 replication by targeting the Rev protein. Nakaya T, et al. **Leukemia** 1997 Apr;11 Suppl 3:134–7 (24 ref.)

Peptide inhibitors of HIV-1 and HIV-2 proteases: a comparative study. Pichová I, et al. **Leukemia** 1997 Apr; 11 Suppl 3:120–2

The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents. Bourinbaiar AS, et al. **Life Sci** 1996;59(23):PL 365–70

The role of carboxy-terminal portion of beta subunit of human chorionic gonadotropin in human immunodeficiency virus infection. Bourinbaiar AS, et al. **Life Sci** 1997;61(11):PL 149–57

Polysaccharopeptide from Coriolus versicolor has potential for use against human immunodeficiency virus type 1 infection. Collins RA, et al. **Life Sci** 1997;60(25):PL383–7

Anti-human immunodeficiency virus (anti-HIV) natural products with special emphasis on HIV reverse transcriptase inhibitors. Ng TB, et al. **Life Sci** 1997; 61(10):933–49 (67 ref.)

Retroviral delivery and anti-HIV testing of hammerhead ribozymes. Cagnon L, et al. **Methods Mol Biol** 1997; 74:451–7

FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes. Ono M, et al. **Nat Biotechnol** 1997 Apr;15(4):343–8

Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Grob PM, et al. **Nat Med** 1997 Jun; 3(6):665–70

Failure of AZT: a molecular perspective [news; comment] Hazuda D, et al. **Nat Med** 1997 Aug;3(8):836–7. Comment on: Nat Med 1997 Aug;3(8):922–4.

HIV blocked by chemokine antagonist [letter] Arenzana-Seisdedos F, et al. **Nature** 1996 Oct 3; 383(6599):400

The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Bleul CC, et al. **Nature** 1996 Aug 29;382(6594):829–33

Role of IL-16 in HIV replication [letter; comment] Mackewicz CE, et al. **Nature** 1996 Oct 10;383(6600):488–9 . Comment on: Nature 1995 Dec 7;378(6557):563.

The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Oberlin E, et al. **Nature** 1996 Aug 29;382(6594):833–5

Effects of ddC and AZT on locomotion and acoustic startle. I: Acute effects in female rats. Morse DE, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):221–8

Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine. Giuliani A, et al. **Pharmacol Res** 1997 Feb;35(2):135–40

Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies.

Agrawal S, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2620–5

A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Gervaix A, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4653–8

Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr–containing protease cleavage site residues on virus replication. Serio D, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3346–51

Inhibition of human immunodeficiency virus type 1 infection in a T–cell line (CEM) by new dipeptidyl–peptidase IV (CD26) inhibitors. Jiang JD, et al. **Res Virol** 1997 Jul–Aug; 148(4):255–66

In vitro determination of antiviral activity of MS8209, a new amphotericin B derivative, against primary isolates of HIV1. Magierowska–Jung M, et al. **Res Virol** 1996 Sep–Oct;147(5):313–8

NCI plans attack on HIV resistance [news] **Science** 1997 May 2;276(5313):667

Reverse transcriptase fidelity and HIV–1 variation [letter; comment] Balzarini J, et al. **Science** 1997 Jan 10; 275(5297):229–30; discussion 230–1. Comment on: Science 1996 Mar 1;271(5253):1282–5.

Reverse transcriptase fidelity and HIV–1 variation [letter; comment] Keulen W, et al. **Science** 1997 Jan 10; 275(5297):229; discussion 230–1. Comment on: Science 1996 Mar 1;271(5253):1282–5.

Reverse transcriptase fidelity and HIV–1 variation [letter; comment] Preston BD. **Science** 1997 Jan 10; 275(5297):228–9; discussion 230–1. Comment on: Science 1996 Mar 1;271(5253):1282–5.

Rule–based ranking schemes for antiretroviral trials. Bjorling LE, et al. **Stat Med** 1997 May 30;16(10):1175–91

Structure of unliganded HIV–1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Hsiou Y, et al. **Structure** 1996 Jul 15;4(7):853–60

[Nevirapine: a new principle of action against HIV (news)] **Dtsch Med Wochenschr** 1996 Dec 6;121(49):A48–9 **(Ger)**

[HIV: less resistance due to combined treatment (news)] **Dtsch Med Wochenschr** 1996 Dec 6;121(49):A47–8 **(Ger)**

[Preliminary screening for antiviral AIDS drugs. VII. Report for fiscal year 1994] Ohmuki N, et al. **Eisei Shikenjo Hokoku** 1996;(114):50–2 (Eng. Abstr.) **(Jpn)**

[Preliminary screening for antiviral AIDS drugs. VI. Report for fiscal year 1993] Ushijima H, et al. **Eisei Shikenjo Hokoku** 1996;(114):48–9 (Eng. Abstr.) **(Jpn)**

[New phospholipids—inhibitors of human immunodeficiency virus reproduction. Synthesis and antiviral activity] Vodovozova EL, et al. **Bioorg Khim** 1996 Jun;22(6):451–7 (Eng. Abstr.) **(Rus)**

[Effect of L–lysine–alpha–oxidase on the synthesis of cell proteins, targets of autoimmune pathology in HIV infection] Berezov TT, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):36–8 **(Rus)**

[4–branched nucleosides. I. Molecular structure of conformationally limited nucleoside analogs—4'–oxymethyl–2',3'–anhydroiboadnosine and 2',3'–anhydrolyxocytidine. Synthesis and antiviral activity] Gurskaia GV, et al. **Mol Biol (Mosk)** 1996 Jul–Aug; 30(4):911–20 **(Rus)**

[Study of anti–HIV activity of the yeast RNA–tilorone molecular complex] Karpov AV, et al. **Vopr Virusol** 1997 Jan–Feb;42(1):17–9 (Eng. Abstr.) **(Rus)**

[Sensitivity of Russian HIV–1 isolates to anti–HIV agents] Nosik NN, et al. **Vopr Virusol** 1997 May–Jun;42(3):111–5 (Eng. Abstr.) **(Rus)**

[Anti–retrovirals] Roca B, et al. **Med Clin (Barc)** 1997 Jun 7;109(2):62–7 **(Spa)**

SUPPLY & DISTRIBUTION

An ethical dilemma. Availability of antiretroviral therapy after clinical trials with HIV infected patients are ended [see comments] Cleaton–Jones PE. **BMJ** 1997 Mar 22; 314(7084):887–8. Comment in: BMJ 1997 Mar 22;314(7084):840–1. Comment in: BMJ 1997 Mar 22;314(7084):888–9. Comment in: BMJ 1997 Mar 22;314(7084):889. Comment in: BMJ 1997 Mar 22;314(7084):890. Comment in: BMJ 1997 Mar 22;314(7084):890–1.

Access to antiviral therapies in African countries [letter] Kerouedan D. **Lancet** 1997 Jun 7;349(9066):1704

[Growing supply of AIDS drugs (news)] **Schweiz Rundsch Med Prax** 1997 Feb 25;86(9):365 **(Ger)**

THERAPEUTIC USE

Progress in prevention of perinatal HIV–1. Fowler MG, et al. **Acta Paediatr Suppl** 1997 Jun;421:97–103

Reducing the risk of perinatal HIV–1 transmission with zidovudine: results and implications of AIDS Clinical Trials Group protocol 076. Mofenson LM. **Acta Paediatr Suppl** 1997 Jun;421:89–96 (44 ref.)

Increase of tryptophan in serum and in cerebrospinal fluid of patients with HIV infection during zidovudine therapy. Fuchs D, et al. **Adv Exp Med Biol** 1996;398:131–4

Antiretroviral therapy: evaluating the new era in HIV treatment. McKinney RE Jr. **Adv Pediatr Infect Dis** 1996; 12:297–323 (48 ref.)

3rd International Congress on Drug Therapy in HIV Infection. Birmingham, United Kingdom, 3–7 November 1996. Abstracts. **AIDS** 1996 Nov;10 Suppl 2:S1–59

Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein–1 and interleukin–16 following treatment of severely immunodeficient HIV–infected individuals with indinavir. Bisset LR, et al. **AIDS** 1997 Mar 15;11(4):485–91

Prevention of simian immunodeficiency virus, SIVsm, or HIV–2 infection in cynomolgus monkeys by pre– and postexposure administration of BEA–005. Böttiger D, et al. **AIDS** 1997 Feb;11(2):157–62

Rational approaches to resistance: using saquinavir. Boucher C. **AIDS** 1996 Nov;10 Suppl 1:S15–9 (16 ref.)

Independent evolution of the env and pol genes of HIV–1 during zidovudine therapy. Brown AJ, et al. **AIDS** 1996 Sep;10(10):1067–73

A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV–infected patients. The Dutch–Italian–Australian Nevirapine Study Group. Carr A, et al. **AIDS** 1996 Jun;10(6):635–41

Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir [letter] Conant MA, et al. **AIDS** 1997 Aug;11(10):1300–1

The development of resistance of HIV–1 to zalcitabine [editorial] Craig C, et al. **AIDS** 1997 Mar;11(3):271–9 (88 ref.)

Summary of track B: clinical science. De Cock KM, et al. **AIDS** 1996 Dec;10 Suppl 3:S107–13 (41 ref.)

Overshoot of HIV–1 viraemia after early discontinuation of antiretroviral treatment. de Jong MD, et al. **AIDS** 1997 Sep;11(11):F79–84

Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study. Dorrucci M, et al. **AIDS** 1997 Mar 15;11(4):461–7

The treatment of antiretroviral–naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. Eron JJ Jr. **AIDS** 1996 Dec;10 Suppl 5:S11–9

What we know so far. Gazzard B. **AIDS** 1996 Nov;10 Suppl 1:S3–7 (15 ref.)

Advances in antiretroviral therapy and viral load monitoring. Hammer SM. **AIDS** 1996 Dec;10 Suppl 3:S1–11 (84 ref.)

Combination therapy: look before you leap. Kashkari MA, et al. **AIDS** 1996;10 Suppl A:S145–9 (58 ref.)

Clinical significance of drug resistance in HIV–1 infection. Kuritzkes DR. **AIDS** 1996 Dec;10 Suppl 5:S27–31 (52 ref.)

Antiretroviral effect of zidovudine–didanosine combination on blood and lymph nodes. Lafeuillade A, et al. **AIDS** 1997 Jan;11(1):67–72

Changing therapy in HIV. Lange JM. **AIDS** 1996 Nov;10 Suppl 1:S27–30 (18 ref.)

Rational approaches to resistance: nucleoside analogues. Mayers D. **AIDS** 1996 Nov;10 Suppl 1:S9–13 (32 ref.)

Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy. Nielsen C, et al. **AIDS** 1996 Jun;10(6):625–33

Combined therapy with zidovudine and L–697,661 in primary HIV infection. Perrin L, et al. **AIDS** 1996 Sep; 10(11):1233–7

Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. Phillips AN, et al. **AIDS** 1997 Feb;11(2):169–75

Efficacy of a combined zidovudine plus didanosine therapy in one case of HIV–related thrombocytopenia non–responder to zidovudine alone or to anti–Rho immunoglobulin administration [letter] Pizzigallo E, et al. **AIDS** 1996 Dec;10(14):1741–2

Adding saquinavir to stavudine in patients with advanced HIV–1 infection [letter] Rutschmann OT, et al. **AIDS** 1997 Mar 15;11(4):548

Long–term zidovudine responders: is there still rationale for HIV monotherapy? [letter] Soriano V, et al. **AIDS** 1996 Dec;10(14):1741

Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy [letter] Soriano V, et al. **AIDS** 1997 Apr;11(5):696–7

Short–term response to indinavir in patients with advanced HIV disease with prior heavy exposure to nucleoside analogues [letter] Soriano V, et al. **AIDS** 1997 Mar; 11(3):391–2

Development of zidovudine–resistant HIV genotypes following postnatal prophylaxis in a perinatally infected infant [letter] Srinivas RV, et al. **AIDS** 1996 Jun;10(7):795–7

Reductions in HIV–1 disease progression for zidovudine/lamivudine relative to control treatments: a meta–analysis of controlled trials. Staszewski S, et al. **AIDS** 1997 Mar 15;11(4):477–83

Rapid plasma virus and CD4+ T–cell turnover in HIV–1 infection: evidence for an only transient interruption by treatment. Stellbrink HJ, et al. **AIDS** 1996 Jul;10(8):849–57

Quantification of HIV–1 viral load in lymphoid and blood cells: assessment during four–drug combination therapy. Tamalet C, et al. **AIDS** 1997 Jun;11(7):895–901

Effects of indinavir treatment on platelet and neutrophil counts in patients with advanced HIV disease [letter] Tozzi V, et al. **AIDS** 1997 Jul;11(8):1067–8

Effect of antiviral treatment on the shedding of HIV–1 in semen. Vernazza PL, et al. **AIDS** 1997 Aug;11(10):1249–54

Response of HIV–associated thrombocytopenia to triple agent antiretroviral therapy [letter] Walsh JC, et al. **AIDS** 1997 Mar;11(3):399–400

Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. Singh N, et al. **AIDS Care** 1996 Jun;8(3):261–9

Pediatric HIV disease: new developments in treatment and prevention. Melvin AJ, et al. **AIDS Clin Rev** 1997–98; :109–27 (67 ref.)

Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. Andreoni M, et al. **AIDS Res Hum Retroviruses** 1997 May 1;13(7):555–61

Constraints on the sequence diversity of the protease of human immunodeficiency virus type 1: a guide for drug design. Kaplan AH. **AIDS Res Hum Retroviruses** 1996 Jul 1;12(10):849–53 (50 ref.)

Use of floxuridine to modulate the antiviral activity of zidovudine. Medina DJ, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):965–8 (7 ref.)

Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent antiretroviral therapies: clues from the Fourth Conference on Retroviruses and Opportunistic Diseases. Schnittman SM, et al. **AIDS Res Hum Retroviruses** 1997 Jul 1;13(10):815–8

The in vitro anti–HIV efficacy of negatively charged human serum albumin is antagonized by heparin. Swart PJ, et al. **AIDS Res Hum Retroviruses** 1997 May 20;13(8):677–83

FDA approval of nevirapine for HIV [news] **Am Fam Physician** 1996 Oct;54(5):1805–6

Preventing perinatal HIV transmission: zidovudine use during pregnancy. Carmichael C. **Am Fam Physician** 1997 Jan;55(1):171–4, 177–8 (16 ref.)

2',3'–Dideoxyinosine–induced Mallory bodies in patients with HIV. Hu B, et al. **Am J Clin Pathol** 1997 Sep;108(3):280–3

Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Ferrando SJ, et al. **Am J Drug Alcohol Abuse** 1996 Nov;22(4):475–87

PHS updates guidelines on chemoprophylaxis after occupational HIV exposure [news] **Am J Health Syst Pharm** 1996 Aug 1;53(15):1764–6

Low infant infection rate halts study of perinatal HIV transmission [news] **Am J Health Syst Pharm** 1997 May 1;54(9):1018, 1021

Federal panel backs early, aggressive HIV therapy [news] **Am J Health Syst Pharm** 1997 Aug 1;54(15):1681, 1685–7

New products and research bring guarded optimism, new questions about AIDS therapy [news] Miller JL. **Am J Health Syst Pharm** 1996 Sep 15;53(18):2129–30, 2132

Antiretroviral therapy for pregnant women. Minkoff H, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):478–89 (83 ref.)

The impact of patient education about the effect of zidovudine on HIV perinatal transmission: knowledge gain, attitudes, and behavioral intent among women with and at risk of HIV. Healton C, et al. **Am J Prev Med** 1996 Jul–Aug;12(4 Suppl):47–52

Maintenance of chemoprophylaxis against Pneumocystis carinii despite combination antiretroviral treatment associated CD4+ T–lymphocytosis [letter] Macher AM, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1491

Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV–infected, zidovudine–experienced patients. A randomized, double–blind, controlled trial. Bristol–Myers Squibb Stavudine/019 Study Group. Spruance SL, et al. **Ann Intern Med** 1997 Mar 1; 126(5):355–63

Phase I/II trial of filgrastim (r–metHuG–CSF), CEOP chemotherapy and antiretroviral therapy in HIV–related non–Hodgkin's lymphoma. Newell M, et al. **Ann Oncol** 1996 Dec;7(10):1029–36

New approaches to using antiretroviral therapy for the management of HIV Infection. Doran CM. **Ann Pharmacother** 1997 Feb;31(2):228–36 (51 ref.)

Pharmacotherapy of HIV dementia. Melton ST, et al. **Ann Pharmacother** 1997 Apr;31(4):457–73 (90 ref.)

Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus–infected individuals. Been–Tiktak AM, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2664–8

Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus–infected individuals receiving concomitant zidovudine. Chien SC, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1765–9

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U–90152S) and conventional nucleosides in human immunodeficiency virus type 1–infected patients. Davey RT Jr, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1657–64

Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. Li RC, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1566–70

Effects of 2',3'–dideoxyinosine on Toxoplasma gondii cysts in mice. Sarciron ME, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1531–6

Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir. Stein DS, et al. **Antimicrob Agents Chemother** 1997 Feb; 41(2):449–53

9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Van Rompay KK, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2586-91

Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Winters MA, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):757-62

Therapeutic potential of anti-HIV immunotoxins. Pincus SH. **Antiviral Res** 1996 Dec;33(1):1-9 (39 ref.)

Dramatic cutaneous psoriasis improvement in a patient with the human immunodeficiency virus treated with 2',3'-dideoxycytidine and ritonavir [letter] Berthelot P, et al. **Arch Dermatol** 1997 Apr;133(4):531

Successful zidovudine (AZT) treatment in a case of human immunodeficiency virus (HIV)-1-associated dementia complex [letter] Sobanski T, et al. **Biol Psychiatry** 1996 Jun 15;39(12):1065-6

New drugs--reports of new drugs recently approved by the FDA. Ritonavir. **Bioorg Med Chem** 1997 Mar;5(3):461-2

New drugs--reports of new drugs recently approved by the FDA. Indinavir. **Bioorg Med Chem** 1997 Mar;5(3):463-4

New drugs--reports of new drugs recently approved by the FDA. Saquinavir. **Bioorg Med Chem** 1997 Mar;5(3):465-6

Preliminary observations using HIV-specific transfer factor in AIDS. Pizza G, et al. **Biotherapy** 1996;9(1-3):41-7

Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine (ZDV). Raise E, et al. **Biotherapy** 1996;9(1-3):49-54

AIDS and transfer factor: myths, certainties and realities. Viza D. **Biotherapy** 1996;9(1-3):17-26 (88 ref.)

HIV trial stopped early after good results [news] Boulton A. **BMJ** 1997 Mar 8;314(7082):699

Strident, but essential: the voices of people with AIDS [comment] Busse P. **BMJ** 1997 Mar 22;314(7084):888-9. Comment on: BMJ 1997 Mar 22;314(7084):887-8.

Drug companies have a duty to continue treatment [comment] Emery S, et al. **BMJ** 1997 Mar 22;314(7084):889 . Comment on: BMJ 1997 Mar 22;314(7084):887-8.

A partnership to resolve the conundrum [comment] King P. **BMJ** 1997 Mar 22;314(7084):890-1. Comment on: BMJ 1997 Mar 22;314(7084):887-8.

A case for goodwill [comment] McLean GR. **BMJ** 1997 Mar 22;314(7084):890. Comment on: BMJ 1997 Mar 22;314(7084):887-8. Comment on: BMJ 1997 Mar 22;314(7084):890-1.

South African research into AIDS "cure" severely criticised [news] Sidley P. **BMJ** 1997 Mar 15;314(7083):771

Saquinavir in the management of HIV infection. Moyle G. **Br J Hosp Med** 1997 Jun 4-17;57(11):560-4

Understanding drug resistance for monotherapy treatment of HIV infection. Kirschner DE, et al. **Bull Math Biol** 1997 Jul;59(4):763-85

Therapy of HIV infections: problems and prospects. Ho DD. **Bull N Y Acad Med** 1996 Summer;73(1):37-45

The time has come. One world, one hope [news] Elliott EB. **Can Fam Physician** 1996 Nov;42:2302-3

HIV postexposure prophylaxis: new recommendations [see comments] Patrick DM. **Can Med Assoc J** 1997 Jan 15; 156(2):233-4. Comment in: Can Med Assoc J 1997 May 1;156(9):1267-8. **(Eng, Fre)**

Zidovudine therapy and left ventricular function and mass in human immunodeficiency virus-infected patients. Cardoso JS, et al. **Cardiology** 1997 Jan-Feb;88(1):26-8

Antitumor, immunomodulatory and anti-HIV effect of mangiferin, a naturally occurring glucosylxanthone. Guha S, et al. **Chemotherapy** 1996 Nov-Dec;42(6):443-51

Treatment of HIV infection and its complications. Polsky B. **Clin Chest Med** 1996 Dec;17(4):647-63 (68 ref.)

Lack of effect of cimetidine on lymphocyte subsets in patients infected with human immunodeficiency virus type 1. Cohen CJ, et al. **Clin Infect Dis** 1996 Nov;23(5):1049-54

Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. Hicks CB, et al. **Clin Infect Dis** 1997 May;24(5):1023-5

Early initiation of antiretroviral therapy for infection with human immunodeficiency virus: considerations in 1996. Nadler JP. **Clin Infect Dis** 1996 Aug;23(2):227-30 (37 ref.)

Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient coinfected with human immunodeficiency virus type. Schnittman SM, et al. **Clin Infect Dis** 1996 Sep;23(3):638-9

Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus. Spooner KM, et al. **Clin Infect Dis** 1996 Jul;23(1):15-27 (45 ref.)

Prevention of perinatal transmission of human immunodeficiency virus: a progress report 2 years after completion of AIDS Clinical Trials Group trial 076. Wilfert CM. **Clin Infect Dis** 1996 Sep;23(3):438-41 (19 ref.)

Don't abandon AIDS prevention, warns WHO [news] **CMAJ** 1997 Jul 15;157(2):129

Antiretroviral agents. Current usage. Chaudry MN, et al. **Dermatol Clin** 1997 Apr;15(2):319-29 (66 ref.)

Major advances in the treatment of HIV-1 infection. **Drug Ther Bull** 1997 Apr;35(4):25-9 (36 ref.)

Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Lea AP, et al. **Drugs** 1996 May;51(5):846-64 (114 ref.)

Current knowledge and future prospects for the use of HIV protease inhibitors. Moyle G, et al. **Drugs** 1996 May; 51(5):701-12 (77 ref.)

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Moyle GJ. **Drugs** 1996 Aug;52(2):168-85

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Perry CM, et al. **Drugs** 1997 Apr;53(4):657-80 (114 ref.)

Resistance, remission, and qualitative differences in HIV chemotherapy. Kirschner DE, et al. **Emerg Infect Dis** 1997 Jul-Sep;3(3):273-83 (28 ref.)

HIV-1 viraemia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: a case-control study. Leal M, et al. **Eur J Clin Invest** 1996 Oct;26(10):923-8

Predictive value of HIV-1 RNA detection in plasma by branched DNA assay during long-term zidovudine therapy. Cotte L, et al. **Eur J Clin Microbiol Infect Dis** 1996 Aug;15(8):639-45

Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group. d'Arminio Monforte A, et al. **Eur J Clin Microbiol Infect Dis** 1997 Feb;16(2):135-42

Addition of lamivudine to the drug regimen in patients with advanced HIV disease on nucleoside therapy [letter] Soriano V, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jun; 16(6):477-9

Acquisition of syncytium-inducing HIV-1 strains during therapy with zidovudine alone or combined with alpha interferon or didanosine. Torres Y, et al. **Eur J Clin Microbiol Infect Dis** 1996 Apr;15(4):324-7

Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: the case for. Moyle GJ, et al. **Genitourin Med** 1997 Jun;73(3):216-20

New strategies to combat HIV drug resistance [see comments] Richman DD. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):47-50, 53-8 (10 ref.). Comment in: Hosp Pract (Off Ed) 1996 Aug 15;31(8):11, 15-6.

Making drugs work against HIV [editorial; comment] Sande MA. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):11, 15-6 (5 ref.). Comment on: Hosp Pract (Off Ed) 1996 Aug 15;31(8):47-58.

Proposed antiretroviral therapy guidelines for prophylaxis of occupationally related HIV seroconversion: a practical approach. Glatt AE. **Infect Control Hosp Epidemiol** 1996 Oct;17(10):672-4

Zidovudine and thymus humoral factor gamma-2 in the treatment of HIV infection: preliminary clinical experience. Maggiolo F, et al. **Infection** 1997 Jan-Feb;25(1):35-8

Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment. Zazzi M, et al. **Infection** 1996 Nov-Dec;24(6):419-25

Inhibition of HIV-1 infectivity by low molecular weight heparin. Results of in vitro studies and a pilot clinical trial in patients with advanced AIDS. Howell AL, et al. **Int J Clin Lab Res** 1996;26(2):124-31

Difference of virus populations in HIV carriers in relation to AZT treatment. Sakamoto T, et al. **Int J STD AIDS** 1997 Jun;8(6):378-81

HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. Demeter LM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Feb 1;14(2):136-44

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. Japour AJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Nov 1;13(3):235-46

Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. Melvin AJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Mar 1;14(3):232-6

Should we embrace new drugs with open arms? Experience from a community-based, open-arm, randomized clinical trial of combination antiretroviral therapy in advanced HIV disease. Montaner JS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 15;13(5):422-6

Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. Simpson BJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Feb 1;14(2):145-52

CD8 T-cell response to antiretroviral therapy [letter] Stricker RB, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jun 1;15(2):176-7

Reverse transcriptase mutations in HIV-1-infected children treated with zidovudine. Unal A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Oct 1;13(2):140-5

Treatment of AIDS and HIV-related conditions--1997. Goldschmidt RH, et al. **J Am Board Fam Pract** 1997 Mar-Apr;10(2):144-67 (50 ref.)

Delavirdine approved for use in treating HIV [news] **J Am Osteopath Assoc** 1997 May;97(5):266

New combinations of drug therapies for the treatment of the human immunodeficiency virus (HIV) [editorial] **J Am Osteopath Assoc** 1996 Aug;96(8):450

Combination drug therapy for the human immunodeficiency virus (HIV) [editorial] **J Am Osteopath Assoc** 1997 Mar; 97(3):128

Polypharmacy and the treatment of HIV/AIDS. Bretzel R, et al. **J Am Pharm Assoc (Wash)** 1996 Dec; NS36(12):722a-722e

Pediatric HIV infection: a primer for pharmacists. Cohen LG, et al. **J Am Pharm Assoc (Wash)** 1996 Oct; NS36(10):580-95 (72 ref.)

Antiviral therapy and the transmission dynamics of HIV-1. Garnett GP, et al. **J Antimicrob Chemother** 1996 May;37 Suppl B:135-50 (25 ref.)

Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. Ives KJ, et al. **J Antimicrob Chemother** 1997 Jun;39(6):771-9

HIV-proteinase inhibitors in the management of HIV-infection. Moyle GJ, et al. **J Antimicrob Chemother** 1996 Dec;38(6):921-5 (32 ref.)

Drug discovery for human immunodeficiency virus infection: conquests and hurdles. Whitley RJ. **J Antimicrob Chemother** 1996 May;37 Suppl B:151-9 (4 ref.)

Antivirals in the context of HIV disease. Wood MJ. **J Antimicrob Chemother** 1996 May;37 Suppl B:97-112 (97 ref.)

Lamivudine. Porche DJ. **J Assoc Nurses AIDS Care** 1996 May-Jun;7(3):51-3 (3 ref.)

Viral resistance: a major challenge in managing HIV disease. Boucher CA, et al. **J Biol Regul Homeost Agents** 1995 Jul-Sep;9(3):91-4 (22 ref.)

HIV biological phenotype: prognosis marker for transmission, disease progression and therapy. Fenyö EM. **J Biol Regul Homeost Agents** 1995 Jul-Sep;9(3):88-90

A clinician's perspective: when to start antiretroviral treatment and when to change therapy. Montaner JS, et al. **J Biol Regul Homeost Agents** 1995 Jul-Sep;9(3):114-8

The eleventh international conference on AIDS: cautious celebration in Vancouver. Gibaldi M. **J Clin Pharmacol** 1997 Jan;37(1):20-4

Treatment of late-state HIV infection. Millard PS. **J Fam Pract** 1997 Feb;44(2):132-4

Zidovudine adherence in persons with AIDS. The relation of patient beliefs about medication to self-termination of therapy. Smith MY, et al. **J Gen Intern Med** 1997 Apr; 12(4):216-23

Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team. Bakshi SS, et al. **J Infect Dis** 1997 May;175(5):1039-50

Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. Barditch-Crovo P, et al. **J Infect Dis** 1997 Aug; 176(2):406-13

After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. Cooper ER, et al. **J Infect Dis** 1996 Dec; 174(6):1207-11

The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels. Dezube BJ, et al. **J Infect Dis** 1997 Sep;176(3):807-10

A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection. Floridia M, et al. **J Infect Dis** 1997 Feb;175(2):255-64

Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. Frenkel LM, et al. **J Infect Dis** 1997 Apr; 175(4):971-4

High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. Frissen PH, et al. **J Infect Dis** 1997 Sep;176(3):811-4

The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. Gisslén M, et al. **J Infect Dis** 1997 Feb; 175(2):434-7

Issues in the design of trials of therapies for subjects with human immunodeficiency virus infection that use plasma RNA level as an outcome. Raboud JM, et al. **J Infect Dis** 1997 Mar;175(3):576-82

Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. Sei S, et al. **J Infect Dis** 1996 Dec;174(6):1200-6

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. Welles SL, et al. **J Infect Dis** 1996 Oct;174(4):696-703

ANTI-HIV AGENTS

Optimal control of the chemotherapy of HIV. Kirschner D, et al. **J Math Biol** 1997 Aug;35(7):775–92

Additional mutations detected in sequential HIV-1 isolates from ZDV-treated patients. Magierowska-Jung M, et al. **J Med Virol** 1997 Jan;51(1):48–55

Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologic response and survival. Shepp DH, et al. **J Med Virol** 1996 Aug; 49(4):303–10

Stable neurological function in subjects treated with 2'3'-dideoxyinosine. Sidtis JJ, et al. **J Neurovirol** 1997 Jun; 3(3):233–40

Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus. Sölder B, et al. **J Pediatr** 1997 Feb;130(2):293–9

Hit early, hit hard: new strategies for HIV [editorial] Bryan CS. **J S C Med Assoc** 1996 Aug;92(8):361–3

Antiretroviral [correction of antiretrovial] therapy in mid-1996 [editorial] Postic B, et al. **J S C Med Assoc** 1996 Sep;92(9):400–3

Human immunodeficiency virus drug therapy and virus load. Bonhoeffer S, et al. **J Virol** 1997 Apr;71(4):3275–8

High viral load in semen of human immunodeficiency virus type 1–infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. Gupta P, et al. **J Virol** 1997 Aug; 71(8):6271–5

Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. Keulen W, et al. **J Virol** 1997 Apr;71(4):3346–50

Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. Zhang YM, et al. **J Virol** 1997 Sep; 71(9):6662–70

From the Centers for Disease Control and Prevention. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. **JAMA** 1996 Nov 20;276(19):1546

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society–USA panel. Carpenter CC, et al. **JAMA** 1997 Jun 25; 277(24):1962–9

HIV-1 protease inhibitors. A review for clinicians. Deeks SG, et al. **JAMA** 1997 Jan 8;277(2):145–53 (59 ref.)

Issues regarding antiretroviral treatment for patients with HIV-1 infection [letter] Fischer C. **JAMA** 1997 Oct 15; 278(15):1234; discussion 1235

Issues regarding antiretroviral treatment for patients with HIV-1 infection [letter] Frenkel LM, et al. **JAMA** 1997 Oct 15;278(15):1234; discussion 1235

Hospital variation in intrapartum use of zidovudine [letter] Gwinn M, et al. **JAMA** 1997 Jan 22–29;277(4):299

Issues regarding antiretroviral treatment for patients with HIV-1 infection [letter] Ickovics J, et al. **JAMA** 1997 Oct 15;278(15):1233–4; discussion 1235

Long-term suppression of HIV-1 by hydroxyurea and didanosine [letter] Lori F, et al. **JAMA** 1997 May 14; 277(18):1437–8

Prescribing protease inhibitors for the homeless [letter] Lyman A. **JAMA** 1997 Oct 15;278(15):1235–6

Issues regarding antiretroviral treatment for patients with HIV-1 infection [letter] Macher AM, et al. **JAMA** 1997 Oct 15;278(15):1234–5

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Dec 4;276(21):1710

Lamivudine-zidovudine treatment and clinical end points [letter; comment] Schattner A. **JAMA** 1996 Nov 27; 276(20):1637–8. Comment on: JAMA 1996 Jul 10;276(2):111–7.

The art of 'HAART': researchers probe the potential and limits of aggressive HIV treatments [news] Stephenson J. **JAMA** 1997 Feb 26;277(8):614–6

Debating dual AIDS guidelines [news] Voelker R. **JAMA** 1997 Aug 27;278(8):613–4

Physicians face new contradictions in HIV care [news] Voelker R. **JAMA** 1997 May 21;277(19):1504–5

Perinatal transmission of HIV-1 [letter; comment] Wood L. **JAMA** 1996 Oct 23–30;276(16):1300–1; discussion 1301. Comment on: JAMA 1996 Feb 28;275(8):599–605.

Should directly observed therapy be considered for treatment of HIV? [letter] Woodward WC. **JAMA** 1996 Dec 25; 276(24):1956

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial [see comments] **Lancet** 1997 May 17;349(9063):1413–21. Comment in: Lancet 1997 May 17;349(9063):1408–9.

British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee [see comments] **Lancet** 1997 Apr 12;349(9058):1086–92 (40 ref.). Comment in: Lancet 1997 Apr 12;349(9058):1042. Comment in: Lancet 1997 Jun 21;349(9068):1837. Comment in: Lancet 1997 Jun 21;349(9068):1837; discussion 1838–9. Comment in: Lancet 1997 Jun 21;349(9068):1837–8. Comment in: Lancet 1997 Jun 21;349(9068):1838.

USA outlines standard of care for HIV/AIDS [news] Ault A. **Lancet** 1997 Jun 28;349(9069):1891

Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy [letter; comment] Baldeweg T, et al. **Lancet** 1997 May 24;349(9064):1554–5. Comment on: Lancet 1997 Mar 22;349(9055):850.

British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals [letter; comment] Brettle RP, et al. **Lancet** 1997 Jun 21;349(9068):1837–8. Comment on: Lancet 1997 Apr 12;349(9058):1086–92.

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [letter; comment] Carr A, et al. **Lancet** 1997 Aug 23;350(9077):589; discussion 590. Comment on: Lancet 1997 May 17;349(9063):1443–5.

Genotypic-resistance assays and antiretroviral therapy. Deeks SG, et al. **Lancet** 1997 May 24;349(9064):1489–90

Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy [letter; comment] Domingo P, et al. **Lancet** 1997 May 24;349(9064):1554–5. Comment on: Lancet 1997 Mar 22;349(9055):850.

2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy [letter] [see comments] Elliot B, et al. **Lancet** 1997 Mar 22;349(9055):850. Comment in: Lancet 1997 May 24;349(9064):1554–5.

Hidden dangers of incompletely suppressive antiretroviral therapy [comment] Feinberg M. **Lancet** 1997 May 17; 349(9063):1408–9. Comment on: Lancet 1997 May 17;349(9063):1413–21.

British HIV Association guidelines for antiretroviral treatment of HIV Seropositive individuals [letter; comment] Harindra V. **Lancet** 1997 Jun 21;349(9068):1838 . Comment on: Lancet 1997 Apr 12;349(9058):1086–92.

Decline in deaths from AIDS due to new antiretrovirals [letter] Hogg RS, et al. **Lancet** 1997 May 3;349(9061):1294

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [see comments] Jacobson MA, et al. **Lancet** 1997 May 17;349(9063):1443–5. Comment in: Lancet 1997 Aug 23;350(9077):588; discussion 590. Comment in: Lancet 1997 Aug 23;350(9077):588–9; discussion 590. Comment in: Lancet 1997 Aug 23;350(9077):589; discussion 590. Comment in: Lancet 1997 Aug 23;350(9077):589–90.

Investigators study morning-after AIDS treatment [news] Macready N. **Lancet** 1997 Mar 15;349(9054):780

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [letter; comment] Mitchell SM, et al. **Lancet** 1997 Aug 23;350(9077):588; discussion 590. Comment on: Lancet 1996 May 17;349(9063):1443–5.

Emerging international consensus for use of antiretroviral therapy [see comments] Montaner JS, et al. **Lancet** 1997 Apr 12;349(9058):1042. Comment in: Lancet 1997 Apr 12;349(9058):1086–92.

Never say never to a cure for HIV-1 infection [news] Morris K. **Lancet** 1997 May 10;349(9062):1371

British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals [comment] Payne N. **Lancet** 1997 Jun 21;349(9068):1837; discussion 1838–9. Comment on: Lancet 1997 Apr 12;349(9058):1086–92.

Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor [letter] Rizzieri DA, et al. **Lancet** 1997 Mar 15;349(9054):775–6

US expert panel reaffirms benefit of perinatal zidovudine [news] Rowe PM. **Lancet** 1997 Jan 25;349(9047):258

Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load [letter] Rübsamen-Waigmann H, et al. **Lancet** 1997 May 24; 349(9064):1517

No news is good news at Washington AIDS meeting [news] Schechter MT. **Lancet** 1997 Feb 1;349(9048):331

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [letter; comment] Stein DS. **Lancet** 1997 Aug 23;350(9077):589–90. Comment on: Lancet 1997 May 17;349(9063):1443–5.

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [letter; comment] Stricker RB, et al. **Lancet** 1997 Aug 23;350(9077):589; discussion 590. Comment on: Lancet 1997 May 17;349(9063):1443–5.

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [letter; comment] Uthayakumar S, et al. **Lancet** 1997 Aug 23;350(9077):588–9; discussion 590 . Comment on: Lancet 1997 May 17;349(9063):1443–5.

Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide [letter] Vila J, et al. **Lancet** 1997 Aug 30;350(9078):635–6

The Delta trial [letter; comment] Zaretsky MD. **Lancet** 1997 Feb 1;349(9048):358–9. Comment on: Lancet 1996 Nov 2;348(9036):1237; discussion 1237–8.

Improving the cytogenetic response to interferon alpha by zidovudine (AZT) in an HIV-positive chronic myelogenous leukemia patient. Mahon FX, et al. **Leuk Lymphoma** 1997 Jun;26(1–2):205–7

Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials. Wainberg MA. **Leukemia** 1997 Apr;11 Suppl 3:85–8

Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset. Fiala M, et al. **Lymphology** 1997 Sep;30(3):128–36

Making treatment decisions with HIV infection: a pilot study of patient preferences. Rosenfeld BD, et al. **Med Decis Making** 1997 Jul–Sep;17(3):307–14

Combination therapy in the management of HIV infection. Vella S, et al. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl C:23–6 (22 ref.)

Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. **MMWR Morb Mortal Wkly Rep** 1996 Oct 25; 45(42):921–5

Prevention of mother-to-infant transmission of HIV-1. Melvin AJ, et al. **Mol Med Today** 1997 Jun;3(6):242–5 (27 ref.)

Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. Englund JA, et al. **N Engl J Med** 1997 Jun 12;336(24):1704–12

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [see comments] Gulick RM, et al. **N Engl J Med** 1997 Sep 11;337(11):734–9. Comment in: N Engl J Med 1997 Sep 11;337(11):779–80.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team [see comments] Hammer SM, et al. **N Engl J Med** 1997 Sep 11;337(11):725–33. Comment in: N Engl J Med 1997 Sep 11;337(11):779–80.

Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use [see comments] Katz MH, et al. **N Engl J Med** 1997 Apr 10;336(15):1097–100. Comment in: N Engl J Med 1997 Aug 14;337(7):499–500; discussion 501. Comment in: N Engl J Med 1997 Aug 14;337(7):500–1.

Postexposure treatment of HIV [letter; comment] Li RW, et al. **N Engl J Med** 1997 Aug 14;337(7):499–500; discussion 501. Comment on: N Engl J Med 1997 Apr;10;336(15):1097–100.

Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. Luzuriaga K, et al. **N Engl J Med** 1997 May 8;336(19):1343–9

Viral load and combination therapy for human immunodeficiency virus [letter; comment] Phillips AN, et al. **N Engl J Med** 1997 Mar 27;336(13):958–9; discussion 960. Comment on: N Engl J Med 1996 Oct 10;335(15):1142–4.

Postexposure treatment of HIV [letter; comment] Pinkerton SD, et al. **N Engl J Med** 1997 Aug 14;337(7):500–1. Comment on: N Engl J Med 1997 Apr 10;336(15):1097–100.

Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection [letter] Power C, et al. **N Engl J Med** 1997 Feb 27;336(9):661–2

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group [see comments] Sperling RS, et al. **N Engl J Med** 1996 Nov 28;335(22):1621–9. Comment in: N Engl J Med 1996 Nov 28;335(22):1678–80.

Viral load and combination therapy for human immunodeficiency virus [letter; comment] Srinivasan V, et al. **N Engl J Med** 1997 Mar 27;336(13):960; discussion 961. Comment on: N Engl J Med 1996 Oct 10;335(15):1091–8.

Battling HIV on many fronts [editorial; comment] Steinbrook R. **N Engl J Med** 1997 Sep 11;337(11):779–81. Comment on: N Engl J Med 1997 Sep 11;337(11):725–33. Comment on: N Engl J Med 1997 Sep 11;337(11):734–9.

Beginning to make progress against HIV [editorial; comment] [see comments] Wilfert CM. **N Engl J Med** 1996 Nov 28; 335(22):1678–80. Comment on: N Engl J Med 1996 Nov 28;335(22):1621–9. Comment in: N Engl J Med 1997 May 8;336(19):1392.

Recommendations for HIV occupational exposure. Paul SM, et al. **N J Med** 1996 Nov;93(11):49–54

AIDS researchers emphasize new drug combinations [news] Fox JL. **Nat Biotechnol** 1997 Mar;15(3):215

FDA rapidly approves HIV protease inhibitors for children [news] Fox JL. **Nat Biotechnol** 1997 May;15(5):404

Sealing the fate of HIV [editorial; comment] **Nat Med** 1997 May;3(5):473. Comment on: Nat Med 1997 May;3(5):483–90. Comment on: Nat Med 1997 May;3(5):526–32. Comment on: Nat Med 1997 May;3(5):553–7.

AIDS patients demand drugs as government hesitates [news] Jayaraman KS. **Nat Med** 1997 Sep;3(9):943

HIV antivirals and immune recovery [letter; comment] Neumann AU, et al. **Nat Med** 1997 Jul;3(7):703–4. Comment on: Nat Med 1997 May;3(5):533–40.

How immune-based interventions can change HIV therapy [see comments] Pantaleo G. **Nat Med** 1997 May;3(5):483–6 . Comment in: Nat Med 1997 May;3(5):473.

What went right: why is HIV a treatable infection? Wurtman RJ. **Nat Med** 1997 Jul;3(7):714–7

AIDS 'cure' researchers guilty of misconduct [news] **Nature** 1997 Jul 10;388(6638):112

Placebo use defended in Third World studies [news] **Nature** 1997 May 15;387(6630):225

AIDS drug row embroils health minister [news] Cherry M. **Nature** 1997 Mar 6;386(6620):6

AIDS 'cure' scientists go to top for funds [news] Cherry M. **Nature** 1997 Feb 6;385(6616):474

Decay characteristics of HIV-1-infected compartments during combination therapy [see comments] Perelson AS, et al. **Nature** 1997 May 8;387(6629):188–91. Comment in:

Nature 1997 May 8;387(6629):123–4.
Down or out in blood and lymph? [news; comment] Wain-Hobson S. **Nature** 1997 May 8;387(6629):123–4. Comment on: Nature 1997 May 8;387(6629):183–8. Comment on: Nature 1997 May 8;387(6629):188–91.
Patterns of morbidity and mortality in AIDS patients on Pneumocystis carinii prophylaxis who died during hospital admission: a report of 50 diseased patients. Hentzen BT, et al. **Neth J Med** 1996 Sep;49(3):101–5
Update on recommendations for HIV postexposure prophylaxis. Grodesky MJ. **Nurse Pract** 1996 Dec;21(12 Pt 1):74, 77–8 (6 ref.)
Antiretroviral therapy during pregnancy. Beyond AZT (ZDV). Dattel BJ. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):645–57 (24 ref.)
Viramune, new antiretroviral agent, crosses the blood-brain barrier [news] **Oncology (Huntingt)** 1997 May;11(5):741
Evolution of tumor necrosis factor-alpha serum concentrations in HIV infected individuals treated with zidovudine. Morlat P, et al. **Pathol Biol (Paris)** 1996 Oct; 44(8):716–9
Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. AIDS Clinical Trials Group Protocol 152 Study Team. Englund JA, et al. **Pediatr Infect Dis J** 1996 Nov;15(11):1025–36
Comparative trial of two dosages of zalcitabine in zidovudine-experienced children with advanced human immunodeficiency virus disease. Pediatric AIDS Clinical Trials Group. Spector SA, et al. **Pediatr Infect Dis J** 1997 Jun;16(6):623–6
Chemotherapy of human immunodeficiency virus (HIV) infection based on chemotherapeutic intervention with early steps of the virus replicative cycle. De Clercq E. **Postepy Biochem** 1995;41(5 Suppl):338–42 (50 ref.)
HIV/AIDS management in office practice. Antiretroviral therapy. Hartman AF. **Prim Care** 1997 Sep;24(3):531–60 (46 ref.)
Psychopharmacology in HIV-positive patients: research perspectives. Vitiello B, et al. **Psychopharmacol Bull** 1996; 32(3):293–7
Update on antiretroviral therapy. Hicks CB. **Radiol Clin North Am** 1997 Sep;35(5):995–1005 (59 ref.)
Virodene—support misguided [letter] Hugo BW. **S Afr Med J** 1997 May;87(5):613
Virodene—support misguided [letter] Mahomed F. **S Afr Med J** 1997 May;87(5):613–4
Virodene—support misguided [letter] Spencer DC. **S Afr Med J** 1997 May;87(5):613
Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection. The Alter Study. Nordic HIV Therapy Group. Gerstoft J, et al. **Scand J Infect Dis** 1997;29(2):121–8
Intrathecal immunoactivation in patients with HIV-1 infection is reduced by zidovudine but not by didanosine. Hagberg L, et al. **Scand J Infect Dis** 1996;28(4):329–33
Antiretroviral therapy: a guide to the most important trials. Rutschmann O, et al. **Schweiz Med Wochenschr** 1997 Mar 15;127(11):436–43 (38 ref.)
Group brands AIDS trials unethical [news] **Science** 1997 Apr 25;276(5312):519
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease [see comments] Autran B, et al. **Science** 1997 Jul 4; 277(5322):112–6. Comment in: Science 1997 Jul 4;277(5322):33.
New hope in HIV disease [news] [see comments] Balter M. **Science** 1996 Dec 20;274(5295):1988–9. Comment in: Science 1997 Jan 10;275(5297):141; discussion 142.
Breakthroughs of the year, 1996 [editorial] Bloom FE. **Science** 1996 Dec 20;274(5295):1987
Antiretroviral drug trials [letter; comment] Breckenridge A, et al. **Science** 1997 Jun 6;276(5318):1481–2; discussion 1443–4. Comment on: Science 1997 Apr 25;276(5312):548–50.
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection [see comments] [published erratum appears in Science 1997 May 30;276(5317):1321] Cavert W, et al. **Science** 1997 May 9;276(5314):960–4. Comment in: Science 1997 May 9;276(5314):898–9. Comment in: Science 1997 Jun 13;276(5319):1629–30.
Stubborn AIDS reservoirs vulnerable to new treatments [news; comment] [see comments] Cohen J. **Science** 1997 May 9;276(5314):898–9. Comment on: Science 1997 May 9;276(5314):960–4. Comment in: Science 1997 Jun 13;276(5319):1629–30.
The media's love affair with AIDS research: hope vs. hype [news] [see comments] Cohen J. **Science** 1997 Jan 17; 275(5298):298–9. Comment in: Science 1997 Feb 21;275(5303):1049.
HIV suppressed long after treatment [news] Cohen J. **Science** 1997 Sep 26;277(5334):1927
Exploiting the HIV-chemokine nexus [news] Cohen J. **Science** 1997 Feb 28;275(5304):1261–4
The daunting challenge of keeping HIV suppressed [news] Cohen J. **Science** 1997 Jul 4;277(5322):32–3
Recovering from the ravages HIV [news; comment] Cohen J. **Science** 1997 Jul 4;277(5322):33. Comment on: Science 1997 Jul 4;277(5322):112–6.
AIDS trials ethics questioned [news; comment] [see comments] Cohen J. **Science** 1997 Apr 25;276(5312):520–3 . Comment on: Science 1997 Apr 25;276(5312):548–50. Comment in: Science 1997 Jun 6;276(5318):1482–4.
Ethics of AZT studies in poorer countries attacked [news] Cohen J. **Science** 1997 May 16;276(5315):1022
Advances painted in shades of gray at a D.C. conference [news] Cohen J. **Science** 1997 Jan 31;275(5300):615–6
Current problems and the future of antiretroviral drug trials [see comments] Lange JM. **Science** 1997 Apr 25; 276(5312):548–50. Comment in: Science 1997 Apr 25;276(5312):520–2. Comment in: Science 1997 Jun 6;276(5318):1481–2; discussion 1443–4. Comment in: Science 1997 Jun 6;276(5318):1482–4.
Treating AIDS dementia [letter; comment] Lipton SA. **Science** 1997 Jun 13;276(5319):1629–30. Comment on: Science 1997 May 9;276(5314):898–9. Comment on: Science 1997 May 9;276(5314):960–4.
Antiretroviral drug trials [letter; comment] Van Rompay KK, et al. **Science** 1997 Jun 6;276(5318):1482–4. Comment on: Science 1997 Apr 25;276(5312):520–3. Comment on: Science 1997 Apr 25;276(5312):548–50.
HIV-infected women: barriers to AZT use. Siegel K, et al. **Soc Sci Med** 1997 Jul;45(1):15–22
HIV treatment strategies utilizing virologic and immunologic markers as criteria for changing treatments. Elashoff M, et al. **Stat Med** 1996 Nov 15–30;15(21–22):2425–43; discussion 2455–8
Use of observational data, including surveillance studies, for evaluating AIDS therapies. Gail MH. **Stat Med** 1996 Nov 15–30;15(21–22):2273–88 (39 ref.)
Analysis of repeated virological measurements based on cell dilution assays. Zackin R, et al. **Stat Med** 1997 Mar 15; 16(5):571–82
[AIDS; new developments. II. Treatment of HIV infection] Borleffs JC, et al. **Ned Tijdschr Geneeskd** 1997 May 24; 141(21):1036–43 (Eng. Abstr.) **(Dut)**
[Resistance to antiretroviral drugs] Tamalet C, et al. **Med Trop (Mars)** 1997;57(2):121–6 (20 ref.) **(Fre)**
[Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients] Reynes J, et al. **Pathol Biol (Paris)** 1997 May;45(5):441–4 (Eng. Abstr.) **(Fre)**
[Stavudine: current information] Saimot AG. **Presse Med** 1997 Apr 5;26(11):514–5 **(Fre)**
[Anti-retrovirus agents in AIDS: therapeutic strategy and prospectives for the future] **Rev Med Interne** 1997; 18(2):100–5 (37 ref.) **(Fre)**
[HIV infection: future perspective for a so-called fatal disease?] von Overbeck J, et al. **Schweiz Med Wochenschr** 1997 Mar 29;127(13):521–7 (16 ref.) (Eng. Abstr.) **(Fre)**
[AIDS: early treatment too seldom implemented (news)] **Dtsch Med Wochenschr** 1997 Aug 22;122(34–35):A27 **(Ger)**
[Therapy of HIV infection: combination drug therapy effective, immunotherapy still experimental] **Dtsch Med Wochenschr** 1997 Apr 11;122(15):A32 **(Ger)**
[The combination of saquinavir and ddC ensures longer survival (news)] Hoof T. **Dtsch Med Wochenschr** 1996 Sep 13;121(37):A30 **(Ger)**
[HIV protease inhibitors. A new drug class in antiretroviral therapy] Mauss S, et al. **Dtsch Med Wochenschr** 1996 Nov 1;121(44):1369–74 (33 ref.) **(Ger)**
[Lamivudine-zidovudine combination treatment (news)] Mörike EM. **Dtsch Med Wochenschr** 1996 Oct 4; 121(40):A8, A11 **(Ger)**
[Efficacy of 2 combined drugs for HIV infected patients (news)] **Fortschr Med** 1996 Dec 10;114(34):61 **(Ger)**
[Therapeutic strategies against HIV: status in 1994 and future prospectives] **Internist (Berl)** 1994 Jul;35(7 Suppl):1–24 **(Ger)**
[New virostatic drugs, psychopharmaceuticals and cytostatic drugs (editorial)] **Med Monatsschr Pharm** 1996 Sep; 19(9):251 **(Ger)**
[AIDS therapy: cautious optimism (editorial)] Heinzl S. **Med Monatsschr Pharm** 1996 Aug;19(8):225 **(Ger)**
[The battle against AIDS in not yet won] **Pharm Unserer Zeit** 1997 Mar;26(2):103–4 **(Ger)**
[New drugs for treatment of HIV infection receive europewide approval] Stipsits H. **Pharm Unserer Zeit** 1996 Nov;25(6):334–5 **(Ger)**
[Nevirapine—the first non-nucleoside inhibitor of reverse transcriptase in the battle against AIDS] Wiese E. **Pharm Unserer Zeit** 1997 Mar;26(2):99–100 **(Ger)**
[Current AIDS drugs (news)] **Schweiz Rundsch Med Prax** 1997 Feb 25;86(9):364–5 **(Ger)**
[Can HIV/AIDS be healed with new therapies? (editorial)] Battegay M. **Schweiz Rundsch Med Prax** 1997 May 28; 86(22):931–2 **(Ger)**
[Anti-HIV chemotherapy targeted at host-cellular factors] Baba M. **Uirusu** 1996 Dec;46(2):155–60 (42 ref.) **(Jpn)**
[Treatment of AIDS and associated diseases] Rytik PG. **Klin Med (Mosk)** 1997;75(1):5–10 (22 ref.) **(Rus)**
[Surface-active substances in the arsenal of agents against AIDS] Krivoshein IuS, et al. **Mikrobiol Z** 1997 Jan–Feb; 59(1):87–97 (69 ref.) (Eng. Abstr.) **(Rus)**
[Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection] Aguirrebengoa K, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14 Suppl 1:3–9 (99 ref.) **(Spa)**
[Anti-retroviral treatment. Approach to previously treated patients] Antela A, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14 Suppl 1:24–30 (48 ref.) **(Spa)**
[Other anti-retroviral agents] Clotet B, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14 Suppl 1:15–9 (39 ref.) **(Spa)**
[Initial anti-retroviral treatment (therapeutic approach to patients without previous treatment)] Gatell JM, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14 Suppl 1:20–3 (24 ref.) **(Spa)**
[Anti-retroviral treatment. Treatment in special situations: acute infection, pregnancy, central nervous system involvement, thrombocytopenia, accidental exposure] Iribarren JA, et al. **Enferm Infecc Microbiol Clin** 1996 Oct; 14 Suppl 1:36–43 (106 ref.) **(Spa)**
[Monitoring anti-retroviral treatment] Miró JM, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14 Suppl 1:44–50 (60 ref.) **(Spa)**
[HIV protease inhibitors] Rubio R, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14 Suppl 1:10–4 (40 ref.) **(Spa)**
[The molecular bases of AIDS therapy] Benítez-Bribiesca L. **Gac Med Mex** 1997 Mar–Apr;133(2):151–3 (8 ref.) **(Spa)**
[Antiretroviral treatment for HIV infection (letter)] González Lahoz J, et al. **Med Clin (Barc)** 1996 Oct 26;107(14):556–7 **(Spa)**
[Viral load and monitoring of antiretroviral treatment] Soriano V, et al. **Rev Clin Esp** 1996 Dec;196(12):872–7 (53 ref.) **(Spa)**
[Antiretroviral treatment. Present and future of the combinations] Gatell-Artigas JM. **Rev Neurol** 1996 Dec; 24(136):1627–31 (16 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Lack of mitochondrial toxicity in CEM cells treated with carbovir. Parker WB, et al. **Antiviral Res** 1997 May; 34(3):131–6
2',3'-Dideoxycytidine cytotoxicity in human macrophages. Antonelli A, et al. **Biochim Biophys Acta** 1997 Aug 21; 1358(1):39–45
Carcinogenicity of 2',3'-dideoxycytidine in mice. Rao GN, et al. **Cancer Res** 1996 Oct 15;56(20):4666–72
A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Ayers KM, et al. **Fundam Appl Toxicol** 1997 Aug;38(2):195–8
Nonclinical toxicology studies with zidovudine: acute, subacute, and chronic toxicity in rodents, dogs, and monkeys. Ayers KM, et al. **Fundam Appl Toxicol** 1996 Aug; 32(2):129–39
Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Ayers KM, et al. **Fundam Appl Toxicol** 1996 Aug; 32(2):148–58
Nonclinical toxicology studies with zidovudine: reproductive toxicity studies in rats and rabbits. Greene JA, et al. **Fundam Appl Toxicol** 1996 Aug;32(2):140–7
Irreversible ototoxicity associated with zalcitabine. Monte S, et al. **Int J STD AIDS** 1997 Mar;8(3):201–2
Skeletal muscle mitochondria from AZT-treated rats have a diminished response to chronic electrical stimulation. McCurdy DT 3rd, et al. **J Appl Physiol** 1996 Jul; 81(1):326–34
Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. Benbrik E, et al. **J Neurol Sci** 1997 Jul; 149(1):19–25
Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys. Wallace TL, et al. **J Pharmacol Exp Ther** 1996 Sep; 278(3):1313–7
Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. Wallace TL, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1306–12
Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia. Inoue T, et al. **Leukemia** 1997 Apr;11 Suppl 3:123–7
Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3'-azido-2',3'-dideoxythymidine. Agarwal RP, et al. **Mutat Res** 1997 May 23;390(3):223–31
Pharmacokinetic and toxicity studies of AZT (zidovudine) following perfusion of human term placenta for 14 hours. Boal JH, et al. **Toxicol Appl Pharmacol** 1997 Mar; 143(1):13–21
"Have you seen this?" Protease inhibitor toxicity. Alden C, et al. **Toxicol Pathol** 1997 Jan-Feb;25(1):113–5

URINE

High-performance chromatographic assay for the sulphoxide metabolite of 2'-deoxy-3'-thiacytidine in human urine. Plumb RS, et al. **J Chromatogr B Biomed Appl** 1996 Dec 13;687(2):457–61

ANTI-HIV POSITIVITY see **HIV SEROPOSITIVITY**

ANTI-HUMAN GLOBULIN COMPLEMENT-DEPENDENT CYTOTOXICITY TESTS see **CYTOTOXICITY TESTS, IMMUNOLOGIC**

ANTI-HUMAN GLOBULIN CONSUMPTION TEST see **COOMBS' TEST**

ANTIHYPERTENSIVE AGENTS

see related
ADRENERGIC ALPHA-ANTAGONISTS
ADRENERGIC BETA-ANTAGONISTS
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
DIURETICS
GANGLIONIC BLOCKERS
VASODILATOR AGENTS

A Reappraisal of Therapeutic Issues in Hypertension. Symposium proceedings. **Am J Med** 1996 Sep 30; 101(3A):1S–92S

The clinical pharmacology of losartan in Japanese subjects and patients. Nakashima M, et al. **Blood Press Suppl** 1996; 2:62–6 (13 ref.)

Behaviour of adrenomedullin during acute and chronic salt loading in normotensive and hypertensive subjects. Ishimitsu T, et al. **Clin Sci (Colch)** 1996 Sep;91(3):293–8

Losartan (Cozaar). Baldinger S. **Conn Med** 1996 May; 60(5):281–4

A 1996 update on antihypertensive agents. Sullivan JM. **Curr Opin Cardiol** 1996 Sep;11(5):496–500 (24 ref.)

Kinins are implicated of the hypotensive effect of acidic fibroblast growth factor. Saenz de Tejada I, et al. **Eur J Med Res** 1997 Jul 28;2(7):302–4

Do we need new antihypertensive drugs? Brunner HR, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S1–4

Identification of an antihypertensive peptide from casein hydrolysate produced by a proteinase from Lactobacillus helveticus CP790. Maeno M, et al. **J Dairy Sci** 1996 Aug; 79(8):1316–21

Cost–effectiveness calculations from trials. Ambrosioni E, et al. **J Hypertens Suppl** 1996 Sep;14(2):S47–52; discussion S52–4 (33 ref.)

Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? [see comments] Grossman E, et al. **JAMA** 1996 Oct 23–30;276(16):1328–31 (65 ref.). Comment in: JAMA 1996 Oct 23–30;276(16):1342–3. Comment in: JAMA 1997 Mar 12;277(10):787; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):787–8; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):788; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):788–9; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):789–90; discussion 790–1. Comment in: JAMA 1997 Mar 12;277(10):790; discussion 790–1.

Withdrawal of nifedipine capsules: jeopardizing the treatment of acute severe hypertension in pregnancy? Australasian Society for the Study of Hypertension in Pregnancy. Brown MA, et al. **Med J Aust** 1997 Jun 16;166(12):640–3

A minoxidil–related compound lacking a C6 substitution still exhibits strong anti–lysyl hydroxylase activity in vitro. Mahé YF, et al. **Skin Pharmacol** 1996;9(3):177–83

[Clonidine—potential dependence risk in psychiatric patients?] Agelink MW, et al. **Nervenarzt** 1996 Mar; 67(3):253–5 (Eng. Abstr.) **(Ger)**

[Clinical effects of beni–koji in mild essential hypertension—a multi–center double–blind comparison with placebo] Kushiro T, et al. **Nippon Jinzo Gakkai Shi** 1996 Dec; 38(12):625–33 (Eng. Abstr.) **(Jpn)**

[New development on hypertension studies—the molecular biology and drug design of the therapeutic agents] Saito H, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):138–40 (0 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Sex– and age–related antihypertensive effects of amlodipine [letter; comment] Spratt KA. **Am J Cardiol** 1997 Mar 15; 79(6):843–4. Comment on: Am J Cardiol 1996 Apr 1;77(9):713–22.

Effects of verapamil SR, trandolapril, and their fixed combination on 24–h blood pressure: the Veratran Study. **Am J Hypertens** 1997 May;10(5 Pt 1):492–9

The effects of isradipine and spirapril as monotherapy and combined therapy on blood pressure, renal hemodynamics, natriuresis, and urinary kallikrein in hypertensive nephropathy. Maccariello ER, et al. **Am J Hypertens** 1997 May;10(5 Pt 1):541–5

Blood pressure and metabolic responses to moderate sodium restriction in isradipine–treated hypertensive patients. McCarron DA, et al. **Am J Hypertens** 1997 Jan;10(1):68–76

Effects of SC–52458, an angiotensin AT1 receptor antagonist, in the dog. McMahon EG, et al. **Am J Hypertens** 1997 Jun;10(6):671–7

When hypertension is resistant...we think it over! [letter] Mazza A, et al. **Am J Hypertens** 1997 May;10(5 Pt 1):578

Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Pool JL, et al. **Am J Hypertens** 1997 Jan;10(1):117–23

Adrenomedullin microinjection into the area postrema increases blood pressure. Allen MA, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1698–703

Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Monane M, et al. **Am J Public Health** 1996 Dec; 86(12):1805–8

Inhaled prostacyclin as a selective pulmonary vasodilator [letter; comment] Doyle P, et al. **Anaesth Intensive Care** 1996 Aug;24(4):514–5. Comment on: Anaesth Intensive Care 1996 Feb;24(1):87–90.

Inhaled prostacyclin (PGI2) versus nitric oxide (NO) [letter; comment] Tibballs J. **Anaesth Intensive Care** 1996 Aug; 24(4):515–6. Comment on: Anaesth Intensive Care 1996 Feb;24(1):87–90.

Prevention of fetal and maternal cyanide toxicity from nitroprusside with coinfusion of sodium thiosulfate in gravid ewes. Curry SC, et al. **Anesth Analg** 1997 May; 84(5):1121–6

Analysis of blood pressure rhythms for drug efficacy evaluation. Germanò G, et al. **Ann N Y Acad Sci** 1996 Aug 15;783:254–62

Chronopharmacology of hypertension. Lemmer B. **Ann N Y Acad Sci** 1996 Aug 15;783:242–53 (62 ref.)

Drug effects on BP rhythm in secondary hypertension. Middeke M. **Ann N Y Acad Sci** 1996 Aug 15;783:270–7 (29 ref.)

Isradipine therapy in hypertensive pediatric patients. Johnson CE, et al. **Ann Pharmacother** 1997 Jun;31(6):704–7

Newer approaches to antihypertensive therapy. Use of fixed–dose combination therapy [see comments] Epstein M, et al. **Arch Intern Med** 1996 Sep 23;156(17):1969–78 (88 ref.). Comment in: Arch Intern Med 1997 May 12;157(9):1044.

A case of renin–producing juxtaglomerular tumor: effect of ACE inhibitor or angiotensin II receptor antagonist. Kashiwabara H, et al. **Blood Press** 1997 May;6(3):147–53

Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial. Schmitz G, et al. **Blood Press** 1996 Nov;5(6):354–9

Lipid metabolism and renal protection by chronic cicletanine treatment in Dahl salt–sensitive rats with salt–induced hypertension. Uehara Y, et al. **Blood Press** 1997 May; 6(3):180–7

Efficacy and tolerability of manidipine hydrochloride in the long–term treatment of mild–moderate hypertension. Manidipine Efficacy in Long–Term Treatment Group. Fogari R, et al. **Blood Press Suppl** 1996;5:24–8

A dose–response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose–Response Study Group. Myers MG. **Can J Cardiol** 1996 Nov;12(11):1191–6

24 hour blood pressure control with once–daily versus twice–daily formulations of diltiazem. Ruddy TD, et al. **Cardiovasc Drugs Ther** 1995 Dec;9(6):799–807

Administration–time–dependent effects of diltiazem on the 24–hour blood pressure profile of essential hypertension patients. Kohno I, et al. **Chronobiol Int** 1997 Jan;14(1):71–84

Aortic function in arterial hypertension determined by pressure–diameter relation: effects of diltiazem. Stefanadis C, et al. **Circulation** 1997 Sep 16;96(6):1853–8

Hypotensive effect of chronically infused adrenomedullin in conscious Wistar–Kyoto and spontaneously hypertensive rats. Khan AI, et al. **Clin Exp Pharmacol Physiol** 1997 Feb; 24(2):139–42

Comparison of once daily and twice daily nisoldipine as monotherapy in essential hypertension. Davidsson GK, et al. **Control Clin Trials** 1996 Apr;17(2):117–22

Dose–finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Pinto YM, et al. **Eur J Clin Pharmacol** 1996; 50(4):265–8

Sustained normotension in hypertensive patients withdrawn from medication for 1 year. Ruoff GE. **Fam Med** 1997 May;29(5):344–6

Preclinical assessment of a new transdermal delivery system for clonidine (M–5041T). Naruse T, et al. **Fundam Clin Pharmacol** 1996;10(1):47–55

Effect of antihypertensive therapy in preeclampsia on levels of serum interleukin–4. Omu AE, et al. **Gynecol Obstet Invest** 1996;42(4):230–6

Different concepts in first–line treatment of essential hypertension. Comparison of a low–dose reserpine–thiazide combination with nitrendipine monotherapy. German Reserpine in Hypertension Study Group. Krönig B, et al. **Hypertension** 1997 Feb;29(2):651–8

Suboptimal dual adaptive control for blood pressure management. Maitelli AL, et al. **IEEE Trans Biomed Eng** 1997 Jun;44(6):486–92

Vascular effects of chlorthalidone in mild hypertensives. Bagatin J, et al. **Int J Clin Pharmacol Res** 1995; 15(5–6):201–8

Withdrawal of antihypertensive medications [see comments] Froom J, et al. **J Am Board Fam Pract** 1997 Jul–Aug; 10(4):249–58 (53 ref.). Comment in: J Am Board Fam Pract 1997 Jul–Aug;10(4):305–7.

Primary pulmonary hypertension: improved long–term effects and survival with continuous intravenous epoprostenol infusion. Shapiro SM, et al. **J Am Coll Cardiol** 1997 Aug;30(2):343–9

The impact of thiazide diuretics on the initiation of lipid–reducing agents in older people: a population–based analysis. Monane M, et al. **J Am Geriatr Soc** 1997 Jan; 45(1):71–5

Double–blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin–converting enzyme inhibitor–induced cough. Chan P, et al. **J Clin Pharmacol** 1997 Mar;37(3):253–7

Chronopharmacologic considerations when treating the patient with hypertension: a review. Straka RJ, et al. **J Clin Pharmacol** 1996 Sep;36(9):771–82 (47 ref.)

Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. Saló J, et al. **J Hepatol** 1996 Dec;25(6):916–23

Therapy in old patients with isolated systolic hypertension: fourth progress report on the Syst–Eur trial. Antikainen R, et al. **J Hum Hypertens** 1997 May;11(5):263–9

A multicenter, parallel comparative study of the antihypertensive efficacy of once–daily lisinopril vs enalapril with 24–h ambulatory blood pressure monitoring in essential hypertension. Coca A, et al. **J Hum Hypertens** 1996 Dec;10(12):837–41

Effects of antihypertensive therapy on left atrial function. Dernellis JM, et al. **J Hum Hypertens** 1996 Dec; 10(12):789–94

The effects of atenolol and zofenopril on plasma atrial natriuretic peptide are due to their interactions with target organ damage of essential hypertensive patients. Elijovich F, et al. **J Hum Hypertens** 1997 May;11(5):313–9

Antihypertensive efficacy and orthostatic tolerance of bunazosin vs nitrendipine: a multicentre double–blind randomized controlled study. Langenfeld MR, et al. **J Hum Hypertens** 1996 Dec;10(12):831–6

Lack of effect of a diuretic added to diltiazem [letter; comment] MacGregor GA, et al. **J Hum Hypertens** 1997 Apr;11(4):249–50. Comment on: J Hum Hypertens 1996 Jul;10(7):441–2. Comment on: J Hum Hypertens 1996 Jul;10(7):443–8.

Losartan mediated improvement in insulin action is mainly due to an increase in non–oxidative glucose metabolism and blood flow in insulin–resistant hypertensive patients. Paolisso G, et al. **J Hum Hypertens** 1997 May;11(5):307–12

Antihypertensive treatment with moexipril plus HCTZ vs metoprolol plus HCTZ in patients with mild–to–moderate hypertension. Stimpel M, et al. **J Hum Hypertens** 1997 Feb; 11(2):133–7

A dose–response trial of nebivolol in essential hypertension. Van Nueten L, et al. **J Hum Hypertens** 1997 Feb; 11(2):139–44

Comparison of different fixed antihypertensive combination drugs: a double–blind, placebo–controlled parallel group study. de Leeuw PW, et al. **J Hypertens** 1997 Jan; 15(1):87–91

Antihypertensive action of non–natriuretic doses of furosemide in Dahl salt–sensitive rats. Haugan K, et al. **J Hypertens** 1997 Jul;15(7):775–82

Placebo–controlled comparison of the efficacy and tolerability of once–daily moxonidine and enalapril in mild–to–moderate essential hypertension. Küppers HE, et al. **J Hypertens** 1997 Jan;15(1):93–7

An equivalence study of the safety and efficacy of a fixed–dose combination of perindopril with indapamide versus fixed–dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. Luccioni R, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1847–51

Acute renal excretory actions of losartan in spontaneously hypertensive rats: role of AT2 receptors, prostaglandins, kinins and nitric oxide. Munoz–Garcia R, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1779–84

Hydrochlorothiazide exerts no direct vasoactivity in the human forearm. Pickkers P, et al. **J Hypertens** 1995 Dec; 13(12 Pt 2):1833–6

Choosing the optimal antihypertensive dose regimen. Hansson L. **J Hypertens Suppl** 1995 Dec;13(4):S1–4

Low–dose combinations versus monotherapies in the treatment of hypertension. Waeber B, et al. **J Hypertens Suppl** 1997 Mar;15(2):S17–20 (17 ref.)

Dynamic swelling behaviour of gelatin/poly(acrylic acid) bioadhesive microspheres loaded with oxprenolol. Leucuta SE, et al. **J Microencapsul** 1997 Jul–Aug;14(4):501–10

Oxprenolol release from bioadhesive gelatin/poly(acrylic acid) microspheres. Leucuta SE, et al. **J Microencapsul** 1997 Jul–Aug;14(4):511–22

Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. Masuda O, et al. **J Nutr** 1996 Dec;126(12):3063–8

Nifedipine for hypertensive emergencies [letter; comment] Woods DJ, et al. **JAMA** 1997 Mar 12;277(10):790; discussion 790–1. Comment on: JAMA 1996 Oct 23–30;276(16):1328–31.

Lack of a beneficial effect of PD123319, an AT2–angiotensin receptor antagonist, on the course of ablation nephropathy in the rat. Cervenka L, et al. **Kidney Blood Press Res** 1996; 19(5):241–4

A short–term antihypertensive treatment–induced fall in glomerular filtration rate predicts long–term stability of renal function. Apperloo AJ, et al. **Kidney Int** 1997 Mar; 51(3):793–7

Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR. Geiger H, et al. **Kidney Int** 1997 Mar;51(3):750–61

Effect of long–acting and short–acting calcium antagonists on cardiovascular outcomes in hypertensive patients [see comments] Alderman MH, et al. **Lancet** 1997 Mar 1; 349(9052):594–8. Comment in: Lancet 1997 Mar 1;349(9052):585–6.

Clonidine as premedication for rhinoplasty [letter] Britto JA, et al. **Plast Reconstr Surg** 1997 Aug;100(2):548–9

Lidocaine–clonidine retrobulbar block for cataract surgery in the elderly. Mjahed K, et al. **Reg Anesth** 1996 Nov–Dec;

21(6):569–75
Treatment of posttransplant erythrocytosis with losartan. Ducloux D, et al. **Transplant Proc** 1997 Aug;29(5):2407–8
Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Kuo PC, et al. **Transplantation** 1997 Feb 27;63(4):604–6
Terlipressin (glypressin) versus somatostatin in the treatment of bleeding esophageal varices—final report of a placebo-controlled, double-blind study. Walker S, et al. **Z Gastroenterol** 1996 Oct;34(10):692–8
Monitoring antihypertensive therapy through blood pressure measurements taken casually, at rest, during exercise, and under outpatient conditions. Hammerschmidt R, et al. **Z Kardiol** 1996;85 Suppl 3:115–7
[First intention treatment of arterial hypertension using a combination of two drugs] Girerd X, et al. **Presse Med** 1996 Dec 14;25(39):1941–4 (19 ref.) (Eng. Abstr.) **(Fre)**
[Therapy of hypertensive crises. Profile of intravenous Ebrantil] **Anaesthesist** 1994 Jun;43(6 Suppl):1–4 **(Ger)**
[Effectiveness of dorzolamide as added therapy in glaucoma patients with maximum tolerated drug therapy. A pilot study] Denk PO, et al. **Klin Monatsbl Augenheilkd** 1997 Jun;210(6):360–4 (Eng. Abstr.) **(Ger)**
[Comparative antihypertensive action of 20 mg delayed-action nifedipine with either 25 or 50 mg atenolol. A study on the treatment of patients with mild to moderately severe arterial hypertension] Kraft K, et al. **Schweiz Rundsch Med Prax** 1996 Sep 3;85(36):1081–6 (Eng. Abstr.) **(Ger)**
[Value of diuretics in hypertension] Franz M, et al. **Wien Med Wochenschr** 1996;146(16):432–5 (37 ref.) (Eng. Abstr.) **(Ger)**
[ACE inhibitors and the kidney] Hörl WH. **Wien Med Wochenschr** 1996;146(16):450–3 (32 ref.) (Eng. Abstr.) **(Ger)**
[Therapy of hypertension in general practice with Renitec and Co-Renitec—analysis of an administration study] Magometschnigg D, et al. **Wien Med Wochenschr** 1996; 146(24):624–8 (Eng. Abstr.) **(Ger)**
[Diuretics in renal failure] Ritz E. **Wien Med Wochenschr** 1996;146(16):443–6 (9 ref.) (Eng. Abstr.) **(Ger)**
[Basic principles and possible variations in combination antihypertensive therapy] Scholze J. **Z Arztl Fortbild Qualitatssich** 1997 Mar;91(2):155–63 (77 ref.) (Eng. Abstr.) **(Ger)**
[Antihypertensive effects of long-term treatment with AE0047, a novel long-lasting calcium antagonist, in hypertensive models of rats and dogs] Kido H, et al. **Nippon Yakurigaku Zasshi** 1997 Jun;109(6):291–301 (Eng. Abstr.) **(Jpn)**
[A chronobiological approach to correcting disorders of time organization of clofelin hemodynamics in patients with stage II essential hypertension] Tokbaeva KK, et al. **Klin Med (Mosk)** 1996;74(8):52–4 (Eng. Abstr.) **(Rus)**
[The prolonged-action form of Lomir (isradipine) in the treatment of mild and moderate essential hypertension] Dmitriev VV, et al. **Ter Arkh** 1996;68(9):35–7 (Eng. Abstr.) **(Rus)**
[The hypotensive action and side effects of the carboanhydrase inhibitor dorzolamide hydrochloride] Egorov AE. **Vestn Oftalmol** 1996 Apr-Jun;112(2):3–4 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Haemodynamic ischaemia in paediatric moyamoya disease associated with renovascular hypertension. Takagi Y, et al. **Acta Neurochir (Wien)** 1997;139(3):257–8
Effect of atenolol on birth weight. Lip GY, et al. **Am J Cardiol** 1997 May 15;79(10):1436–8
Overview of the safety of felodipine based on clinical trials in patients with hypertension. Welin L, et al. **Am J Cardiol** 1997 Apr 1;79(7):996–9
Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Heath CW Jr, et al. **Am J Epidemiol** 1997 Apr 1;145(7):607–13
Possible losartan-induced rash [letter] Haddad AM, et al. **Am J Health Syst Pharm** 1997 Jun 1;54(11):1333–4
More news about calcium antagonists [editorial] Alderman MH. **Am J Hypertens** 1996 Jul;9(7):710–2
Calcium channel blockers and cancer: is an association biologically plausible? [editorial] Daling JR. **Am J Hypertens** 1996 Jul;9(7):713–4
Do calcium channel blockers increase the risk of cancer? [see comments] Pahor M, et al. **Am J Hypertens** 1996 Jul; 9(7):695–9. Comment in: Am J Hypertens 1996 Oct;9(10 Pt 1):1045–6; discussion 1051–3. Comment in: Am J Hypertens 1996 Oct;9(10 Pt 1):1046–7; discussion 1051–3. Comment in: Am J Hypertens 1996 Oct;9(10 Pt 1):1047–9; discussion 1051–3. Comment in: Am J Hypertens 1996 Oct;9(10 Pt 1):1049–50; discussion 1051–3. Comment in: Am J Hypertens 1996 Oct;9(10 Pt 1):1050–1; discussion 1051–3. Comment in: Am J Hypertens 1997 Jan;10(1):141.
Effects of cicletanine on prostaglandin I2 and E2 levels in patients with essential hypertension. Yasu T, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 1):750–5
Exacerbation of respiratory symptoms in patients with panic disorder [letter] Bouwer CD, et al. **Am J Psychiatry** 1997 May;154(5):712–3
Limb-shaking carotid transient ischemic attacks successfully treated with modification of the antihypertensive regimen. Leira EC, et al. **Arch Neurol** 1997 Jul;54(7):904–5
Possible roles of medullasin in nifedipine-induced human gingival overgrowth. Kunimatsu K, et al. **Arch Oral Biol** 1996 Jan;41(1):111–5
Hypertension medication and periodontosis [letter] Bowell GR. **Aust Dent J** 1997 Apr;42(2):140
Brief report: acute renal failure after losartan treatment in a patient with bilateral renal artery stenosis. Holm EA, et al. **Blood Press** 1996 Nov;5(6):360–2
Marked hepatotoxicity associated with losartan treatment. Nygaard B, et al. **Blood Press** 1996 May;5(3):190–1
Use and adverse reactions of antihypertensive drugs in Spain. Part I of the RAAE Study. Aranda P, et al. **Blood Press Suppl** 1997;1:11–6
Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. Mallion JM, et al. **Blood Press Suppl** 1996; 2:82–6 (14 ref.)
Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Rosen RC. **Blood Press Suppl** 1997;1:47–51 (19 ref.)
From the monitoring of severe to a survey of mild adverse effects of current antihypertensive therapy: the hidden side of the iceberg. The Scientific Committee of the Italian Pharmacoepidemiology Survey on Antihypertensive Therapy. Zanchetti A, et al. **Blood Press Suppl** 1997;1:40–1 (4 ref.)
Drug induced psychosis with doxazosin. Evans M, et al. **BMJ** 1997 Jun 28;314(7098):1869
"Drug may have caused huge number of deaths": lessons learned during an encounter with The Fifth Estate [editorial] Myers MG. **Can Med Assoc J** 1996 Sep 15; 155(6):772–5
Erythema multiforme and nifedipine [news] Springuel P. **Can Med Assoc J** 1997 Jan 1;156(1):90–1
Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine. Rupp H, et al. **Cardiovasc Drugs Ther** 1996 Jun;10 Suppl 1:251–62
Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses. Sarlis NJ, et al. **Clin Auton Res** 1996 Apr;6(2):115–7
Effect of felodipine treatment and withdrawal on blood pressure and cardiovascular structure in New Zealand genetically hypertensive rats. Ledingham JM, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S326–8
Reserpine: a tragic victim of myths, marketing, and fashionable prescribing. Fraser HS. **Clin Pharmacol Ther** 1996 Oct;60(4):368–73 (57 ref.)
Occupational contact dermatitis from propranolol, hydralazine and bendroflumethiazide. Pereira F, et al. **Contact Dermatitis** 1996 Nov;35(5):303–4
Acute generalized exanthematous pustulosis secondary to diltiazem therapy. Blodgett TP, et al. **Cutis** 1997 Jul; 60(1):45–7
Perindopril-induced acute pancreatitis. Gallego-Rojo FJ, et al. **Dig Dis Sci** 1997 Aug;42(8):1789–91 (13 ref.)
A risk-benefit assessment of losartan potassium in the treatment of hypertension. Burrell LM. **Drug Saf** 1997 Jan; 16(1):56–65 (33 ref.)
Adverse metabolic effects of antihypertensive drugs. Implications for treatment. Preuss HG, et al. **Drug Saf** 1996 Jun;14(6):355–64 (93 ref.)
Antihypertensive drugs and fatal myocardial infarction in persons with uncomplicated hypertension. Jick H, et al. **Epidemiology** 1997 Jul;8(4):446–8
Formulation of diltiazem affects cyclosporin-sparing activity. Jones TE, et al. **Eur J Clin Pharmacol** 1997;52(1):55–8
Calcium channel blockers and hypertension: 2. Safety issues. Epstein M. **Hosp Pract (Off Ed)** 1996 Dec 15;31(12):93–6, 99–104 (23 ref.)
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS) [see comments] Grimm RH Jr, et al. **Hypertension** 1997 Jan;29(1 Pt 1):8–14. Comment in: ACP J Club 1997 Jul-Aug;127(1):6.
Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol. Cleophas TJ, et al. **Int J Clin Pharmacol Ther** 1996 Jul;34(7):312–7
Losartan-induced bronchospasm. Dicpinigaitis PV, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 1):1128–30
Atenolol-induced lupus erythematosus. McGuiness M, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):298–9 (16 ref.)
Clinical approaches to male infertility with a case report of possible nifedipine-induced sperm dysfunction. Enders G. **J Am Board Fam Pract** 1997 Mar-Apr;10(2):131–6 (27 ref.)
Warning—the physician's clinical judgement can be hazardous to your health: withdrawing drugs in patients with high blood pressure [editorial; comment] Grimm RH Jr. **J Am Board Fam Pract** 1997 Jul-Aug;10(4):305–7. Comment on: J Am Board Fam Pract 1997 Jul-Aug;10(4):249–58.
Aspects of tolerability of centrally acting antihypertensive drugs. Webster J, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S49–54 (29 ref.)
A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient. Kwan WF, et al. **J Clin Anesth** 1996 Aug;8(5):392–7
Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. Benz J, et al. **J Clin Pharmacol** 1997 Feb;37(2):101–7
Vascular events during antihypertensive treatment. Madren EM. **J Fam Pract** 1996 Dec;43(6):534
Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation [letter] Lawhorn S, et al. **J Heart Lung Transplant** 1997 Apr;16(4):472–3
Commentary: do angiotensin II receptor antagonists regress left ventricular hypertrophy? Lip GY. **J Hum Hypertens** 1996 Nov;10(11):725–7 (28 ref.)
Safety profile of the combination of verapamil and trandolapril. Holzgreve H. **J Hypertens Suppl** 1997 Mar; 15(2):S51–3 (4 ref.)
Assessing the safety profile of a new antihypertensive agent. Lindholm LH. **J Hypertens Suppl** 1995 Dec;13(4):S5–9 (10 ref.)
Does antihypertensive therapy protect the kidney in essential hypertension? Rodicio JL. **J Hypertens Suppl** 1996 Sep; 14(2):S69–75; discussion S75–6 (60 ref.)
Metabolic effects of antihypertensive drugs. Suter PM, et al. **J Hypertens Suppl** 1995 Dec;13(4):S11–7 (74 ref.)
The effect of verapamil on the prevalence and severity of cyclosporine-induced gingival overgrowth in renal allograft recipients. Cebeci I, et al. **J Periodontol** 1996 Nov; 67(11):1201–5
Scleroderma and eosinophilic fasciitis in patients taking fosinopril [letter] Biasi D, et al. **J Rheumatol** 1997 Jun; 24(6):1242
From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada, and Israel, 1987–1995. **JAMA** 1997 Apr 16;277(15):1193–4
Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. Shorr RI, et al. **JAMA** 1997 Jul 2;278(1):40–3
Biochemical changes during moduretic treatment of hypertension in African patients. Ahaneku JE, et al. **Kobe J Med Sci** 1995 Aug;41(4):83–93
Adverse event with first-dose perindopril in congestive heart failure [letter] [see comments] Bagger JP. **Lancet** 1997 Jun 7;349(9066):1671–2. Comment in: Lancet 1997 Aug 16;350(9076):520; discussion 521–2. Comment in: Lancet 1997 Aug 16;350(9076):520–1; discussion 521–2. Comment in: Lancet 1997 Aug 16;350(9076):521.
Methaemoglobinaemia after inhalation of nitric oxide for treatment of hydrochlorothiazide-induced pulmonary oedema [letter] Hovenga S, et al. **Lancet** 1996 Oct 12; 348(9033):1035–6
Lowering of blood pressure and artery stiffness [letter; comment] Lehmann ED, et al. **Lancet** 1997 Mar 29; 349(9056):955–6. Comment on: Lancet 1997 Feb 1;349(9048):362.
Lowering of blood pressure and artery stiffness [letter; comment] [see comments] Sleight P. **Lancet** 1997 Feb 1; 349(9048):362. Comment on: Lancet 1996 Sep 14;348(9029):696–7. Comment in: Lancet 1997 Mar 29;349(9056):955–6.
ACE-inhibitor cough in the Australian pink galah. Watts RW. **Med J Aust** 1996 Dec 2–16;165(11–12):682
Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada, and Israel, 1987–1995. **MMWR Morb Mortal Wkly Rep** 1997 Mar 21;46(11):240–2
"Scalded mouth syndrome" caused by angiotensin converting enzyme inhibitors: two case reports. Brown RS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Jun;83(6):665–7
Reversible acute renal failure induced by losartan in a renal transplant recipient. Ostermann M, et al. **Postgrad Med J** 1997 Feb;73(856):105–7
Letter to the editor. Bachen E. **Psychosom Med** 1996 Mar-Apr;58(2):192
Antenatal exposure to atenolol and retroperitoneal fibromatosis. Satgé D, et al. **Reprod Toxicol** 1997 Jul-Aug; 11(4):539–41
Angioedema associated with angiotensin II receptor antagonist losartan. Sharma PK, et al. **South Med J** 1997 May;90(5):552–3
Acute renal failure after administration of losartan [letter] Lamb RV, et al. **W V Med J** 1996 Sep-Oct;92(5):241
Effects of antihypertensive therapy on glucose and lipid metabolism. Zehetgruber M, et al. **Wien Klin Wochenschr** 1996 Dec 27;108(24):775–80 (61 ref.)
[Cozaar (Losartan, MSD) and depression (letter)] Christensen KB. **Ugeskr Laeger** 1997 Mar 31;159(14):2106 **(Dan)**
[Losartan (Cozaar) and depression] Jensen JB. **Ugeskr Laeger** 1997 Mar 31;159(14):2108 **(Dan)**
[Agranulocytosis caused by perindopril (letter)] Hamidou M, et al. **Ann Med Interne (Paris)** 1996;147(7):523–4 **(Fre)**
[Angioedema of the mucous membranes of the upper aerodigestive tract after administration of ACE inhibitors] Tisch M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Feb; 32(2):122–3 (Eng. Abstr.) **(Ger)**
[Comment on A Regenauer: Prognostic aspects of the metabolic syndrome (letter)] Weyer C. **Versicherungsmedizin** 1997 Apr 1;49(2):59–60 **(Ger)**
[Effects of diuretic therapy on electrolyte and acid-base homeostasis] Mayer G. **Wien Med Wochenschr** 1996; 146(16):436–8 (8 ref.) (Eng. Abstr.) **(Ger)**
[Renal side effects of angiotensin converting enzyme inhibitors] Schmidt A, et al. **Wien Med Wochenschr** 1996;

146(16):454–6 (28 ref.) (Eng. Abstr.) **(Ger)**
[Diuretics and diabetes mellitus] Teuscher AU. **Wien Med Wochenschr** 1996;146(16):439–42 (45 ref.) (Eng. Abstr.) **(Ger)**
[The tolerability of antihypertensive therapy: limits and dimensions of a summary phenomenon] Ambrosioni E, et al. **Cardiologia** 1997 Jun;42 Suppl 2:1–13 (28 ref.) **(Ita)**
[Atenolol: its cardiorespiratory effects at birth in a premature infant] Zanardo V, et al. **Pediatr Med Chir** 1997 May–Jun; 19(3):149–51 (8 ref.) **(Ita)**
[Renal complications of anti-hypertensive drugs] Kaname S, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):531–5 (11 ref.) **(Jpn)**
[Drug-induced pericarditis] Ohnishi A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):612–4 (22 ref.) **(Jpn)**
[Disturbances of water–electrolyte and acid–base balance due to pharmacologic treatment of hypertension] Kokot F, et al. **Przegl Lek** 1996;53(9):693–6 (7 ref.) (Eng. Abstr.) **(Pol)**
[Angioedema and taking captopril (letter)] Ràfola Crestani A, et al. **Aten Primaria** 1997 Mar 31;19(5):275–6 **(Spa)**
[Lichenioid reaction induced by captopril (letter)] Revenga Arranz F, et al. **Rev Clin Esp** 1996 Jun;196(6):412 **(Spa)**
[News on side effects. 59 reports on losartan. Even cough is reported] **Lakartidningen** 1996 Oct 9;93(41):3601 **(Swe)**
[Cancer risks and lacidipine—an explanation (letter)] Lindholm LH. **Lakartidningen** 1996 Oct 23;93(43):3770 **(Swe)**

ANALYSIS

Application of arylosulfonic acids in analysis of antihypertensive drugs. Gajewska M, et al. **Acta Pol Pharm** 1995 Jan–Feb;52(1):1–4
Performance of micellar mobile phases in reversed-phase chromatography for the analysis of pharmaceuticals containing beta-blockers and other antihypertensive drugs. Rapado-Martínez I, et al. **Analyst** 1996 Nov; 121(11):1677–82
Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester. Francotte E, et al. **J Chromatogr B Biomed Appl** 1996 Nov 8;686(1):77–83
Quantitation of a new potent angiotensin II receptor antagonist, TCV–116, and its metabolites in human serum and urine. Miyabayashi T, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23;677(1):123–32
An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Ritter MA, et al. **J Pharm Biomed Anal** 1997 Apr;15(7):1021–9
Comparison of liquid chromatography, capillary electrophoresis and super-critical fluid chromatography in the determination of Losartan Potassium drug substance in Cozaar tablets. Williams RC, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1539–46

ANTAGONISTS & INHIBITORS

Pretreatment with quinpirole inhibits the central antihypertensive effects of rilmenidine and alpha-methyldopa in conscious rats. Van den Buuse M. **Eur J Pharmacol** 1997 Mar 19;322(2–3):191–9
Inhibition of calcium influx and tonic response to K+ of intestinal smooth muscle by hydralazine. Nasu T, et al. **J Auton Pharmacol** 1996 Jun;16(3):169–76
[The antagonistic effect of aspirin on the expression of prostaglandin participation in the antihypertensive activity of ACE inhibitors] Alimento M, et al. **Cardiologia** 1997 Jun;42(6):605–10 (Eng. Abstr.) **(Ita)**
[Reduction of the antihypertensive effects of enalapril by indomethacin. Its independence from renal sodium retention] Polónia J, et al. **Rev Port Cardiol** 1996 Jun; 15(6):485–92, 460 (Eng. Abstr.) **(Por)**

BLOOD

Effects of enalapril on lipid profile in diabetic and non-diabetic essential hypertensive patients. Satia MC, et al. **Indian J Physiol Pharmacol** 1996 Jan;40(1):83–6
Analysis of through:peak ratio and the assessment of antihypertensive drug action. Elliott HL. **Isr J Med Sci** 1996 Oct;32(10):798–9
Determination of 1–[5–(2–cyclopropyl–5,7–dimethyl–imidazo[4,5–b] pyridin–3–ylmethyl)thiophen–2–yl]cyclopent–3–enecarboxylic acid (CP–191,166), an angiotensin II antagonist, in dog and rat plasma by high-performance liquid chromatography. Allen MC, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26;675(2):265–71
Determination of captopril in plasma by high-performance liquid chromatography for pharmacokinetic studies. Arroyo C, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):339–44
Efficient assay for the determination of atenolol in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Chiu FC, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):473–7
Quantitative determination of BMS186716, a thiol compound, in dog plasma by high-performance liquid chromatography–positive ion electrospray mass spectrometry after formation of the methyl acrylate adduct. Jemal M, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):109–16
Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling. Kok RJ, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):181–9
Stereoselective high-performance liquid chromatography determination of propranolol and 4-hydroxypropranolol in human plasma after pre-column derivatization. Wu ST, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25; 692(1):133–40
Determination of captopril in human serum by high performance liquid chromatography using solid-phase extraction. Bahmaei M, et al. **J Pharm Biomed Anal** 1997 May;15(8):1181–6
A micro liquid chromatographic assay for the determination of plasma-unbound atenolol. Cheng FC, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1169–74
Low level determination of dorzolamide and its de-ethylated metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. Constanzer ML, et al. **J Pharm Biomed Anal** 1997 Apr;15(7):1001–8
Pharmacokinetic and pharmacodynamic study of imidaprilat, an active metabolite of imidapril, a new angiotensin-converting enzyme inhibitor, in spontaneously hypertensive rats. Yamanaka K, et al. **J Pharm Biomed Anal** 1997 Aug;15(12):1851–9
Characteristics of serum protein binding of felodipine. Valle M, et al. **Res Commun Mol Pathol Pharmacol** 1996 Oct; 94(1):73–88

CHEMICAL SYNTHESIS

Synthesis and biological activity of thiazolo–1,2,4–triazoles. Foks H, et al. **Acta Pol Pharm** 1995 Sep–Oct;52(5):415–20
Search for new antiarrhythmic and hypotensive compounds. Synthesis, antiarrhythmic, antihypertensive, and alpha-adrenoceptor blocking activity of novel 1–[(2–hydroxy–3–amino)]–propylpyrrolidin–2–one derivatives. Filipek B, et al. **Arch Pharm (Weinheim)** 1997 Jul;330(7):225–31
Synthesis and pharmacological evaluation of N–(6–functionalized–amino–3–pyridyl)–N'–bicycloalkyl–N''–cyanoguanidine s as antihypertensive agents. Eda M, et al. **Chem Pharm Bull (Tokyo)** 1996 Feb;44(2):307–13
Synthesis biological evaluation of alkyl, alkoxy, alkylthio, or amino–substituted 2,3–dihydro–1,5–benzothiazepin–4(5H)–ones. Inoue H, et al. **Chem Pharm Bull (Tokyo)** 1997 Jun;45(6):1008–26
Transposition of the imidazole ring substituents of angiotensin mimetics related to Losartan. Smith JR, et al. **Drug Des Discov** 1994 Nov;12(2):113–9
Synthesis and pharmacological profile of novel N–substituted N–[5H–[1]benzopyrano[4,3–d]pyrimidin–2–YL]–N–methylglycinamides. Bruno O, et al. **Farmaco** 1996 Feb; 51(2):137–40
Preparation and pharmacological activities of spiro[3,4–dihydro–6/7–R–1,2,4–benzotriazine–3,4'–(1'–substituted)piperi dines] Novelli F, et al. **Farmaco** 1996 Aug–Sep;51(8–9):541–50
Synthesis and preliminary pharmacological evaluation of 3–[2–(1–aryl–piperazin–4–yl)ethyl]–3,4–dihydro–3–methyl–6–R–1,2, 4–benzotriazines. Novelli F, et al. **Farmaco** 1996 Aug–Sep;51(8–9):551–8
Synthesis and pharmacological evaluation of 4,4a,5,6–tetrahydro–7,8–disubstituted–benzo[h]cinnolin–3 (2H)–ones. Pinna GA, et al. **Farmaco** 1997 Jan;52(1):25–8
Synthesis and pharmacological evaluation of 4a–methyl–4,4a,5,6–tetrahydrothieno[2,3–h]cinnolin–3(2H) –ones. Pinna GA, et al. **Farmaco** 1997 Jan;52(1):29–33
Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity. Ahn HS, et al. **J Med Chem** 1997 Jul 4;40(14):2196–210
Synthesis and structure–activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5–(biphenyl–4–ylmethyl)pyrazoles. Almansa C, et al. **J Med Chem** 1997 Feb 14;40(4):547–58
New non–peptide endothelin–A receptor antagonists: synthesis, biological properties, and structure–activity relationships of 5–(dimethylamino)–N–pyridyl–,–N–pyrimidinyl–,–N–pyridazinyl–, and –N–pyrazinyl–1–naphthalenesulfonamides. Bradbury RH, et al. **J Med Chem** 1997 Mar 14;40(6):996–1004
17 beta–(3–furyl)–5 beta–androstane–3 beta, 14 beta, 17 alpha–triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. Quadri L, et al. **J Med Chem** 1997 May 23;40(11):1561–4
Synthesis and antihypertensive activity of novel 1–(4–benzyl–1–phthalazinyl)–pyrazolo[3,4–d]pyrimidines. el–Feky SA, et al. **Pharmazie** 1996 Aug;51(8):540–3

CHEMISTRY

Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. Allen LV Jr, et al. **Am J Health Syst Pharm** 1996 Oct 1;53(19):2304–9
Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Allen LV Jr, et al. **Am J Health Syst Pharm** 1996 Sep 1;53(17):2073–8
Incompatibility between ceftriaxone sodium and labetalol hydrochloride [letter] Leader WG, et al. **Am J Health Syst Pharm** 1996 Nov 1;53(21):2639
Carvedilol–liposome interaction: evidence for strong association with the hydrophobic region of the lipid bilayers. Cheng HY, et al. **Biochim Biophys Acta** 1996 Oct 2;1284(1):20–8
Antihypertensive peptides derived from food proteins. Yamamoto N. **Biopolymers** 1997;43(2):129–34 (67 ref.)
Bioactivities and secondary structures of constrained analogues of human parathyroid hormone: cyclic lactams of the receptor binding region. Barbier JR, et al. **J Med Chem** 1997 Apr 25;40(9):1373–80
Photostability profiles of minoxidil solutions. Chinnian D, et al. **PDA J Pharm Sci Technol** 1996 Mar–Apr;50(2):94–8

CLASSIFICATION

Which one of the following antihypertensive medications is the least appropriate choice for patients with diabetic nephropathy. Nifedipine (e.g., Adalat) is the least appropriate choice for patients with diabetic nephropathy. **Can Fam Physician** 1997 Sep;43:1515, 1522

DIAGNOSTIC USE

Diagnosis of renovascular hypertension by echo–Doppler velocimetry. Fuse S, et al. **Acta Paediatr Jpn** 1996 Aug; 38(4):370–3
Variable kidney position mimicking renal artery branch stenosis in a Tc–99m–DTPA captopril scintigraphy. Demirçali AE, et al. **Ann Nucl Med** 1996 May;10(2):237–9
Application of isotope–selective nondispersive infrared spectrometry (IRIS) for evaluation of [13C]octanoic acid gastric–emptying breath tests: comparison with isotope ratio–mass spectrometry (IRMS). Schadewaldt P, et al. **Clin Chem** 1997 Mar;43(3):518–22
Renovascular hypertension due to Takayasu's arteritis demonstrated by Tc–99m ethylenedicysteine captopril scintigraphy. Uğur O, et al. **Clin Nucl Med** 1996 Sep; 21(9):714–6
[13C]octanoic acid breath test for non–invasive assessment of gastric emptying in diabetic patients: validation and relationship to gastric symptoms and cardiovascular autonomic function. Ziegler D, et al. **Diabetologia** 1996 Jul; 39(7):823–30
Steady–state captopril renography: continuous monitoring of the captopril–induced increase in 99mTc–MAG3 mean parenchymal transit time in renovascular hypertension. Esper IE, et al. **Eur J Nucl Med** 1997 Jul;24(7):739–44
Interpretation of captopril transplant renography using a feed forward neural network. Hamilton D, et al. **J Nucl Med** 1996 Oct;37(10):1649–52
The use of captopril testing in the selection of patients for renal artery repair. Duschek S, et al. **Semin Vasc Surg** 1996 Sep;9(3):182–7 (26 ref.)

ECONOMICS

Antihypertensive therapy: how to evaluate the benefits. Zanchetti A. **Am J Cardiol** 1997 May 22;79(10A):3–8; discussion 47–8 (26 ref.)
Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients. Briscoe TA, et al. **Am J Health Syst Pharm** 1996 Sep 15;53(18):2191–3
Medical and cost–economy aspects of modern antihypertensive therapy—with special reference to 2 years of clinical experience with losartan. Hansson L. **Blood Press Suppl** 1997;1:52–5 (27 ref.)
Drug expenditures for hypertension: an empirical test of an economic model in a French population. Huttin C, et al. **Cah Sociol Demogr Med** 1997 Jan–Mar;37(1):33–52
Reference–based pricing in British Columbia: implications for cardiologists—an analysis [see comments] Boulet AP, et al. **Can J Cardiol** 1997 Jan;13(1):46–51 (23 ref.). Comment in: Can J Cardiol 1997 Jan;13(1):31–2. Comment in: Can J Cardiol 1997 Jul;13(7):640, 689.
The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial. Schulman KA, et al. **Control Clin Trials** 1996 Aug; 17(4):304–15
The cost–effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment. Johannesson M. **J Hum Hypertens** 1996 Feb;10 Suppl 2:S23–6
Hypertension can be treated effectively without increasing the cost of care. Moser M. **J Hum Hypertens** 1996 Feb; 10 Suppl 2:533–8 (42 ref.)
Pharmacoeconomics of hypertension control: basic principles of economic evaluation. Wilson TW, et al. **J Hum Hypertens** 1996 Feb;10 Suppl 2:S19–22
Benefits and cost–effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach [editorial] [see comments] Zanchetti A, et al. **J Hypertens** 1996 Jul;14(7):809–11. Comment in: J Hypertens 1997 Jan;15(1):1–2.
Cost containment for treating hypertension in African Americans: impact of a combined ACE inhibitor–calcium channel blocker. Kountz DS. **J Natl Med Assoc** 1997 Jul; 89(7):457–60

Willingness to pay for antihypertensive care: evidence from a staff-model HMO. Ramsey SD, et al. **Soc Sci Med** 1997 Jun;44(12):1911-7

[Money, hypertension and calcium antagonists (letter; comment)] Hernborg A. **Lakartidningen** 1996 Sep 25; 93(39):3348. Comment on: Lakartidningen 1996 Aug 28;93(35):2918. **(Swe)**

HISTORY

Evolution of the treatment of hypertension from the 1940s to JNC V. Moser M. **Am J Hypertens** 1997 Mar; 10(3):2S-8S

History of fixed-dose combination therapy for hypertension [letter; comment] Wofford JL. **Arch Intern Med** 1997 May 12;157(9):1044. Comment on: Arch Intern Med 1996 Sep 23;156(17):1969-78.

Historical development of losartan (DuP 753) and angiotensin II receptor subtypes. Wong PC, et al. **Blood Press Suppl** 1996;3:11-4 (29 ref.)

METABOLISM

Detect of adrenomedullin, a hypotensive peptide, in amniotic fluid and fetal membranes. Macri CJ, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):906-11

Microlocalization and effects of adrenomedullin in nephron segments and in mesangial cells of the rat. Owada A, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):F691-7

Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture. Saijonmaa O, et al. **Blood Press** 1997 Jan;6(1):24-8

Case for lack of metabolic effects has not been made [letter; comment] [correction of Metabolic effects of antihypertensive treatment should not be overstated] [published erratum appears in BMJ 1997 Jan 25;314(7076):307] Winocour PH. **BMJ** 1997 Jan 18; 314(7075):223-4. Comment on: BMJ 1996 Sep 14;313(7058):660-3.

Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz. Clement B, et al. **Chem Res Toxicol** 1996 Jun;9(4):682-8

Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Johnson JA, et al. **Drug Metab Dispos** 1996 Mar;24(3):350-5

Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. Miller MJ, et al. **J Biol Chem** 1996 Sep 20;271(38):23345-51

Interaction of lacidipine with its receptor binding site supports a slow onset and long duration of action. Graziani F, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):290-6

Stereoselective metabolism of fenoldopam and its metabolites in human liver microsomes, cytosol, and slices. Klecker RW, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):69-74

Interactions of nonpeptide angiotensin II receptor antagonists at imidazoline/guanidinium receptor sites in rat forebrain. Li Z, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):425-31

Altered prostaglandin metabolism induced by angiotensin-converting enzyme inhibitors in broncho-alveolar lavage fluid of the guinea pig. Umemura K, et al. **Jpn J Pharmacol** 1996 Sep;72(1):17-21

Role of erythropoietin in pathogenesis of post transplant erythrocytosis (PTE) and mechanism of losartan's efficiency [letter; comment] Altun B, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):626-7. Comment on: Nephrol Dial Transplant 1996 Aug;11(8):1668.

PHARMACOKINETICS

Phenoxybenzamine placental transfer during the third trimester. Santeiro ML, et al. **Ann Pharmacother** 1996 Nov; 30(11):1249-51

Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 4th communication: metabolism in rats and dogs. Hirota T, et al. **Arzneimittelforschung** 1997 Feb;47(2):175-81

Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 2nd communication: tissue levels and enzyme activity in rats after repeated administration, and placental and milk transfer after single administration. Nakamura A, et al. **Arzneimittelforschung** 1997 Feb;47(2):160-8

Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 3rd communication: plasma concentrations of the unchanged drug and its deethylated metabolite in rats, dogs and monkeys. Nakamura A, et al. **Arzneimittelforschung** 1997 Feb; 47(2):169-74

A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril. Macdonald NJ, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):201-4

The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. Macdonald NJ, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):205-9

The central distribution of adrenomedullin and its effects on blood pressure and heart rate in rats. Wei Y, et al. **Chin Med Sci J** 1996 Mar;11(1):1-7

Fosinopril. Clinical pharmacokinetics and clinical potential. Shionoiri H, et al. **Clin Pharmacokinet** 1997 Jun; 32(6):460-80 (95 ref.)

Gender differences in toxicokinetics, liver metabolism, and plasma esterase activity: observations from a chronic (27-week) toxicity study of enalapril/diltiazem combinations in rats. Los LE, et al. **Drug Metab Dispos** 1996 Jan;24(1):28-33

Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension. Plosker GL, et al. **Drugs** 1996 Aug;52(2):232-53 (112 ref.)

Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Bindschedler M, et al. **Eur J Clin Pharmacol** 1997;52(5):371-8

Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Flesch G, et al. **Eur J Clin Pharmacol** 1997;52(2):115-20

Pharmacokinetic interaction between diltiazem and nortriptyline. Krähenbühl S, et al. **Eur J Clin Pharmacol** 1996;49(5):417-9

Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Weber C, et al. **Eur J Clin Pharmacol** 1996; 51(1):87-90

Determining the trough-to-peak ratio in parallel-group trials. Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Staessen JA, et al. **Hypertension** 1997 Feb; 29(2):659-67

Influences of bathing and hot weather on the pharmacokinetics of a new transdermal clonidine, M-5041T. Fujimura A, et al. **J Clin Pharmacol** 1996 Oct; 36(10):892-6

Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. McCrea JB, et al. **J Clin Pharmacol** 1995 Dec;35(12):1200-6

Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. Masuda O, et al. **J Nutr** 1996 Dec;126(12):3063-8

Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan. Wong PC, et al. **Pharmacology** 1996 Jan;52(1):25-9

Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Waldmeier F, et al. **Xenobiotica** 1997 Jan;27(1):59-71

PHARMACOLOGY

The role of labetalol and propofol in the management of HELLP syndrome--a case report. Chu YL, et al. **Acta Anaesthesiol Sin** 1996 Mar;34(1):43-6

Deliberate hypotensive anesthesia with labetalol in reconstructive surgery for scoliosis [published erratum appears in Acta Anaesthesiol Sin 19997 Mar;35(1):59] Sum DC, et al. **Acta Anaesthesiol Sin** 1996 Dec;34(4):203-7

Effects of topical dorzolamide on retinal and retrobulbar hemodynamics. Harris A, et al. **Acta Ophthalmol Scand** 1996 Dec;74(6):569-72

Losartan does not influence the blood platelet aggregation in normotensive rats. Chabielska E, et al. **Acta Physiol Hung** 1996;84(3):271-2

The effects of enalapril on the natriuretic response evoked by an oral sodium load in sodium deprived normotensive and hypertensive rats. Mu JY, et al. **Acta Physiol Scand** 1997 Jun;160(2):157-64

Synthesis and biological activity of thiazolo-1,2,4-triazoles. Foks H, et al. **Acta Pol Pharm** 1995 Sep-Oct;52(5):415-20

Interactions of minoxidil with vasoconstrictive agents in isolated rat tail artery. Wasiński R, et al. **Acta Pol Pharm** 1995 May-Jun;52(3):253-6

Drug-induced alteration of endothelial permeability in the rat aorta. Potential consequences on the vessel wall. Plante GE, et al. **Adv Exp Med Biol** 1996;416:249-53

Contrasting effects of urethane, ketamine, and thiopental anesthesia on ethanol-clonidine hemodynamic interaction. el-Mas MM, et al. **Alcohol Clin Exp Res** 1997 Feb; 21(1):19-27

Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men. Gordon NF, et al. **Am J Cardiol** 1997 Apr 15;79(8):1065-9

Acute reversibility of pulmonary hypertension predicts neither long-term hemodynamic response nor outcome in patients awaiting heart transplantation. Levine TB, et al. **Am J Cardiol** 1997 Jan 1;79(1):105-6

Effects of calcium antagonists on insulin sensitivity and other metabolic parameters. Sowers JR. **Am J Cardiol** 1997 May 22;79(10A):24-8; discussion 47-8 (57 ref.)

Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers). COER-Verapamil Study Group. White WB, et al. **Am J Cardiol** 1997 Aug 15;80(4):469-74

Effects of tetramethylpyrazine phosphate and sodium ferulate alone or in combination on hemodynamics in anesthetized dog. Huang X, et al. **Am J Chin Med** 1996;24(2):169-76

Effect of cilazapril and salt on Ca2+ extrusion in arterial smooth muscle of Dahl rats. Ashida T, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):107S-111S

Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Bhalla RC, et al. **Am J Hypertens** 1996 Jun;9(6):570-6

Calculation of trough-to-peak ratio in the research unit setting. Advantages and disadvantages. Elliott HL, et al. **Am J Hypertens** 1996 Oct;9(10 Pt 2):71S-75S; discussion 87S-90S (6 ref.)

Effects of chronic treatment with losartan and enalaprilat on [3H]-norepinephrine release from isolated atria of Wistar-Kyoto and spontaneously hypertensive rats. Foucart S, et al. **Am J Hypertens** 1996 Jan;9(1):61-9

Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade. Himmelmann A, et al. **Am J Hypertens** 1996 Sep;9(9):850-3

Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade [published erratum appears in Am J Hypertens 1996 Oct;9(10 Pt 1):1054] Hulthén UL, et al. **Am J Hypertens** 1996 Sep;9(9):895-901

Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. Iyer SN, et al. **Am J Hypertens** 1996 Jul;9(7):662-8

Concentration-effect relationships and implications for trough-to-peak ratio. Meredith PA, et al. **Am J Hypertens** 1996 Oct;9(10 Pt 2):66S-70S; discussion 87S-90S (13 ref.)

Renal and vascular consequences of the chronic nitric oxide synthase inhibition. Effects of antihypertensive drugs. Navarro-Cid J, et al. **Am J Hypertens** 1996 Nov; 9(11):1077-83

Effects of antihypertensive drugs on blood pressure and metabolic alterations in the fructose-induced hypertensive rat. Navarro-Cid J, et al. **Am J Hypertens** 1996 Jul; 9(7):669-74

Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension. Siewert-Delle A, et al. **Am J Hypertens** 1996 Sep;9(9):841-9

The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension. Smith MC, et al. **Am J Hypertens** 1995 Dec; 8(12 Pt 1):1177-83

Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Stasch JP, et al. **Am J Hypertens** 1996 Aug;9(8):795-802

Effects of 2,3-butanedione monoxime on blood pressure, myocardial Ca2+ currents, and action potentials of rats. Xiao YF, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 1):1232-40

Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency. Mitchell HC, et al. **Am J Kidney Dis** 1997 Jun;29(6):897-906

Drug actions in preeclampsia: aspirin, but not magnesium chloride or dihydralazine, differentially inhibits cultured human trophoblast release of thromboxane and prostacyclin without affecting angiotensin II, endothelin-1, or leukotriene B4 secretion. Cervar M, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):66-72

Cardiac output mediates the antihypertensive effect of vasopressin in spontaneous hypertension. Balakrishnan S, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1728-33

Proadrenomedullin NH2-terminal 20 peptide has direct vasodilator activity in the cat. Champion HC, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1047-54

Effects of natriuretic peptides and nitroprusside on venous function in trout. Olson KR, et al. **Am J Physiol** 1997 Aug; 273(2 Pt 2):R527-39

Microlocalization and effects of adrenomedullin in nephron segments and in mesangial cells of the rat. Owada A, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):F691-7

Effect of calcium channel blockade on skin blood flow in diabetic hypertension: a comparison of isradipine and atenolol. Rendell MS, et al. **Angiology** 1997 Mar; 48(3):203-13

Angiotensin II receptor antagonists: the prototype losartan. Schaefer KL, et al. **Ann Pharmacother** 1996 Jun; 30(6):625-36 (81 ref.)

Inhibitory effects of bFGF, VEGF and minoxidil on collagen synthesis by cultured hair dermal papilla cells. Lachgar S, et al. **Arch Dermatol Res** 1996 Jul;288(8):469-73

Patterns of heart rate responses to hydralazine in normotensive and hypertensive rats. Vidrio H. **Arch Med Res** 1996 Autumn;27(3):299-303

Search for new antiarrhythmic and hypotensive compounds. Synthesis, antiarrhythmic, antihypertensive, and alpha-adrenoceptor blocking activity of novel 1-[(2-hydroxy-3-amino)]-propylpyrrolidin-2-one derivatives. Filipek B, et al. **Arch Pharm (Weinheim)** 1997 Jul;330(7):225-31

Effects of clonidine in a primed rat model of acute hepatic porphyria. Goerz G, et al. **Arzneimittelforschung** 1997 Jun; 47(6):731-3

Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs. Hayashi N, et al. **Arzneimittelforschung** 1997

May;47(5):620–5

Antihypertensive effects of a new transdermal delivery system for clonidine in genetic and experimental hypertensive rats. Ishii R, et al. **Arzneimittelforschung** 1996 Mar;46(3):261–8

Pharmacological profile of valsartan, a non–peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end–organ damage in spontaneously hypertensive stroke–prone rats during 1–year treatment. Kometani M, et al. **Arzneimittelforschung** 1997 May;47(5):613–9

Possible involvement of ATP–dependent K–channel related mechanisms in the antihypertensive and cough suppressant effects of the novel ACE inhibitor (2S, 3aS, 7aS)–1–(N2–nicotinoyl–L–lysyl–gamma–D–glutamyl) octahydro–1H– indole–2–carboxylic acid. Nagata S, et al. **Arzneimittelforschung** 1997 Jun;47(6):726–30

General pharmacology of the new non–xanthine adenosine A1 receptor antagonist (+)–(R)–[(E)–3–(2–phenylpyrazolo[1,5–a]pyridin–3–yl) acryloyl]–2– piperidine ethanol. Terai T, et al. **Arzneimittelforschung** 1996 Feb;46(2):185–91

Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically–instrumented transgenic rats. van Meel JC, et al. **Arzneimittelforschung** 1996 Aug;46(8):755–9

Pharmacological profile of valsartan, a non–peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models. Yamamoto S, et al. **Arzneimittelforschung** 1997 May;47(5):604–12

Pharmacological profile of valsartan, a non–peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models. Yamamoto S, et al. **Arzneimittelforschung** 1997 May;47(5):630–4

Actions of magnesium, nifedipine and clonidine on the fetal vasculature of the human placenta. David R, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):267–71

Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels. Cabell KS, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):133–41

The treatment of hypertension in older people and its effect on cognitive function. Prince MJ. **Biomed Pharmacother** 1997;51(5):208–12 (23 ref.)

Tissue–specific regulation of angiotensin–converting enzyme by angiotensin II and losartan in the rat. Metsärinne KP, et al. **Blood Press** 1996 Nov;5(6):363–70

Carvedilol and its metabolites suppress endothelin–1 production in human endothelial cell culture. Saijonmaa O, et al. **Blood Press** 1997 Jan;6(1):24–8

Benidipine counteracts sodium–induced alterations in systemic and regional hemodynamics. Shimamoto H, et al. **Blood Press** 1997 Jan;6(1):18–23

Angiotensin II–receptor (AT1) blockade in the human forearm. Ritter JM, et al. **Blood Press Suppl** 1996;2:67–70 (31 ref.)

The diversified pharmacology of angiotensin II–receptor blockade. Timmermans PB, et al. **Blood Press Suppl** 1996; 2:53–61 (112 ref.)

Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Martin DE, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):661–4

Antagonism by idazoxan at low dose but not high dose, of the natriuretic action of moxonidine. Allan DR, et al. **Br J Pharmacol** 1996 Jan;117(1):29–34

The cardiovascular and renal functional responses to the 5–HT1A receptor agonist flesinoxan in two rat models of hypertension. Chamienia AL, et al. **Br J Pharmacol** 1996 Aug;118(8):1891–8

Further investigations into the mechanism of the antihypertensive activity of the angiotensin AT1 receptor antagonist, GR138950. Hilditch A, et al. **Br J Pharmacol** 1996 Jun;118(3):711–9

Modulation by low sodium intake of glomerular response to cicletanine and atrial natriuretic factor. Kalinowski L, et al. **Br J Pharmacol** 1997 Jun;121(4):635–42

Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Kim S, et al. **Br J Pharmacol** 1996 Jun;118(3):549–56

The antihypertensive effect of orally administered nifedipine–loaded nanoparticles in spontaneously hypertensive rats. Kim YI, et al. **Br J Pharmacol** 1997 Feb; 120(3):399–404

Involvement of nitric oxide, but not prostaglandins, in the vascular sympathoinhibitory effects of losartan in the pithed spontaneously hypertensive rat. Richer C, et al. **Br J Pharmacol** 1996 Jan;117(2):315–24

Effect of chronic ETA–selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Schiffrin EL, et al. **Br J Pharmacol** 1997 Jul;121(5):935–40

The in vitro pulmonary vascular effects of FK409 (nitric oxide donor): a study in normotensive and pulmonary hypertensive rats. Wanstall JC, et al. **Br J Pharmacol** 1997 May;121(2):280–6

Allosteric interactions between cyclothiazide and AMPA/kainate receptor antagonists. Yamada KA, et al. **Br J Pharmacol** 1996 Apr;117(8):1663–72

Inhibition of [3H]–U69593 binding and the cardiac effects of U50, 488H by calcium channel blockers in the rat heart. Zhang WM, et al. **Br J Pharmacol** 1997 Mar;120(5):827–32

Cardiovascular effects of central administration of clonidine in conscious cats. Ally A. **Brain Res** 1997 Jul 4;761(2):283–9

Losartan inhibition of angiotensin–related drinking and Fos immunoreactivity in hypertensive and hypotensive contexts. Rowland NE, et al. **Brain Res** 1996 Dec 2; 742(1–2):253–9

Activation of phosphatidylcholine–selective phospholipase C by I1–imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Separovic D, et al. **Brain Res** 1997 Feb 28;749(2):335–9

Potassium channel opener reduces extracellular glutamate concentration in rat focal cerebral ischemia. Fujita H, et al. **Brain Res Bull** 1997;43(4):365–8

Stimulation of the A2A adenosine receptor increases expression of the tyrosine hydroxylase gene. Chae HD, et al. **Brain Res Mol Brain Res** 1997 Feb;44(1):31–8

Cardiovascular effects of adrenomedullin in teleost fishes. Aota S. **Braz J Med Biol Res** 1995 Nov–Dec; 28(11–12):1223–6

Effect of angiotensin receptor blockade in the rabbit aorta: influence of the endothelium. le Tran Y, et al. **Can J Physiol Pharmacol** 1996 Dec;74(12):1277–86

Sympathetic nervous system in salt–sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent. Ernsberger P, et al. **Cardiovasc Drugs Ther** 1996 Jun;10 Suppl 1:275–82

Pathologic consequences of increased angiotensin II activity. Ferrario CM, et al. **Cardiovasc Drugs Ther** 1996 Nov; 10(5):511–8 (100 ref.)

Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Ruffolo RR Jr, et al. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:247–56 (77 ref.)

Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine. Rupp H, et al. **Cardiovasc Drugs Ther** 1996 Jun;10 Suppl 1:251–62

Modulation of sympathetic outflow by centrally acting antihypertensive drugs. van Zwieten PA. **Cardiovasc Drugs Ther** 1996 Jun;10 Suppl 1:283–9 (37 ref.)

Effects of nitrendipine on capacity of calcium binding of erythrocyte membrane and total intraerythrocyte calcium content in SHR rats. Wang YL, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jan;17(1):38–40

Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. Mitchell GF, et al. **Circulation** 1996 Dec 1;94(11):2923–9

Central imidazoline receptors and centrally acting anti–hypertensive agents. Head GA, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):591–605

Effect of losartan on right ventricular hypertrophy and cardiac angiotensin I–converting enzyme activity in pulmonary hypertensive rats. Kreutz R, et al. **Clin Exp Hypertens** 1996 Jan;18(1):101–11

Antihypertensive drugs in the stroke–prone spontaneously hypertensive rat. Richer C, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):925–36 (37 ref.)

Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study. Whitlock G, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):843–55

Renal effects of rilmenidine in volume–loaded anaesthetized dogs. Evans RG, et al. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):64–7

Current status of putative imidazoline (I1) receptors and renal mechanisms in relation to their antihypertensive therapeutic potential. Evans RG. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov;23(10–11):845–54 (90 ref.)

In vitro inhibitory effects of chebulinic acid on the contractile responses of cardiovascular muscles. Guan YY, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):747–50

Hypotensive effect of chronically infused adrenomedullin in conscious Wistar–Kyoto and spontaneously hypertensive rats. Khan AI, et al. **Clin Exp Pharmacol Physiol** 1997 Feb; 24(2):139–42

Antihypertensive effects of DL–tetrahydropalmatine: an active principle isolated from Corydalis. Lin MT, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):738–42

Blood pressure lowering in patients with cerebrovascular disease: results of the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) pilot phase. Neal B, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):444–6

Effects of losartan on the cardiovascular system, renal haemodynamics and function and lung liquid flow in fetal sheep. Stevenson KM, et al. **Clin Exp Pharmacol Physiol** 1996 Feb;23(2):125–33

Antihypertensive effects, determined by a telemetry method, of trichloromethiazide and 7–O–ethylfangchinoline, a derivative of tetrandrine, in spontaneously hypertensive rats. Kawashima K, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S300–1

Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. Kwan CY. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S297–9 (12 ref.)

Effect of felodipine on blood pressure, body sodium, plasma renin activity and plasma aldosterone in hypertensive and normotensive rats. Ledingham JM, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S323–5

Effect of barnidipine on blood flow to major organs and renal function in anaesthetized dogs and spontaneously hypertensive rats. Saitoh M, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S339–40

Effects of moxonidine and clonidine on renal function and blood pressure in anesthetized rats. Hohage H, et al. **Clin Nephrol** 1997 May;47(5):316–24

Pharmacokinetic–pharmacodynamic profile of angiotensin II receptor antagonists. Csajka C, et al. **Clin Pharmacokinet** 1997 Jan;32(1):1–29 (112 ref.)

Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Laganière S, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):255–64

The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Morgan JM, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):35–44

Coadministration of glyburide and minoxidil, drugs with opposing effects on potassium channels. Stein CM, et al. **Clin Pharmacol Ther** 1997 Jun;61(6):662–8

Adrenomedullin: a hypotensive hormone in man. Lainchbury JG, et al. **Clin Sci (Colch)** 1997 May;92(5):467–72

Rilmenidine–induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Chu TC, et al. **Curr Eye Res** 1996 Sep;15(9):943–50

New or developing antihypertensive agents. Evans RR, et al. **Curr Opin Cardiol** 1997 Jul;12(4):382–8 (93 ref.)

Transposition of the imidazole ring substituents of angiotensin mimetics related to Losartan. Smith JR, et al. **Drug Des Discov** 1994 Nov;12(2):113–9

Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus. Goa KL, et al. **Drugs** 1997 Jun;53(6):1081–105 (157 ref.)

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Goa KL, et al. **Drugs** 1996 May;51(5):820–45 (138 ref.)

Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Wagstaff AJ, et al. **Drugs** 1996 May;51(5):777–91 (75 ref.)

Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Balfour JA, et al. **Drugs Aging** 1997 May; 10(5):384–403 (81 ref.)

Sex–related differences in the response of spontaneously hypertensive rats to angiotensin–converting enzyme inhibitor. Nigro D, et al. **Endothelium** 1997;5(1):63–71

Effects of ramipril on the hormone concentrations in serum of hypertensive patients. Grönroos PE, et al. **Eur J Clin Chem Clin Biochem** 1997 Jun;35(6):411–4

Antihypertensive drugs and cerebral circulation. Strandgaard S, et al. **Eur J Clin Invest** 1996 Aug;26(8):625–30 (55 ref.)

Effects of hydrochlorothiazide and captopril on lipoprotein lipid composition in patients with essential hypertension. Bagdade JD, et al. **Eur J Clin Pharmacol** 1996;49(5):355–9

A drug interaction study between cicletanine and tolbutamide in healthy volunteers. Bayés MC, et al. **Eur J Clin Pharmacol** 1996;50(5):381–4

Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Bindschedler M, et al. **Eur J Clin Pharmacol** 1997;52(5):371–8

Moxonidine and cognitive function: interactions with moclobemide and lorazepam. Wesnes K, et al. **Eur J Clin Pharmacol** 1997;52(5):351–8

Preclinical safety profile of brimonidine. Angelov OV, et al. **Eur J Ophthalmol** 1996 Jan–Mar;6(1):21–5

Effects of the antihypertensive drug captopril on human salivary secretion rate and composition. Nederfors T, et al. **Eur J Oral Sci** 1995 Dec;103(6):351–4

Effect of rilmenidine on arterial pressure and urinary output in the spontaneously hypertensive rat. Cechetto DF, et al. **Eur J Pharmacol** 1997 Apr 23;325(1):47–55

Vincamine and vincanol are potent blockers of voltage–gated Na+ channels. Erdo SA, et al. **Eur J Pharmacol** 1996 Oct 24;314(1–2):69–73

Y–26763 protects the canine heart from a stunning injury through opening of the KATP channels. Fukunari A, et al. **Eur J Pharmacol** 1997 Apr 4;323(2–3):197–204

Antihypertensive effect of angiotensin I–converting enzyme inhibitory peptides derived from hemoglobin. Mito K, et al. **Eur J Pharmacol** 1996 May 23;304(1–3):93–8

Effects of adenosine A2A receptor agonist, CGS 21680, on blood pressure, cardiac index and arterial conductance in anaesthetized rats. Nekooeian AA, et al. **Eur J Pharmacol** 1996 Jun 27;307(2):163–9

Nifedipine, losartan and captopril effects on hyperplasia of vascular smooth muscle from Ren–2 transgenic rats. Peiró C, et al. **Eur J Pharmacol** 1997 Apr 18;324(2–3):257–65

Y–26763 protects the working rat myocardium from ischemia/reperfusion injury through opening of KATP channels. Rahman F, et al. **Eur J Pharmacol** 1996 Dec 19; 317(2–3):293–9

Cardiovascular and respiratory actions of U50,488H in the unanaesthetized ovine foetus. Szeto HH, et al. **Eur J Pharmacol** 1996 Feb 15;297(1–2):77–82

U50,488H–induced pressor effect in the ovine foetus is mediated by sympathetic activation and vasopressin. Szeto HH, et al. **Eur J Pharmacol** 1996 Aug 8;309(2):183–7

Comparison of the in vitro and in vivo pharmacology of adrenomedullin, calcitonin gene–related peptide and amylin in rats. Vine W, et al. **Eur J Pharmacol** 1996 Oct 24; 314(1–2):115–21

In–vivo activity and enzymatic hydrolysis of novel

prostaglandin F2 alpha prodrugs in ocular tissues. Woodward DF, et al. **Exp Eye Res** 1996 Oct;63(4):411–23

3–Nitropropionic acid increases the intracellular Ca2+ in cultured astrocytes by reverse operation of the Na+–Ca2+ exchanger. Deshpande SB, et al. **Exp Neurol** 1997 May; 145(1):38–45

Antihypertensive effect of dithiocarbamate derivatives. Kirkiacharian S, et al. **Farmaco** 1996 Nov;51(11):753–5

Synthesis and pharmacological evaluation of 5,6–dihydrobenzo[f] cinnolin–2(3H)ones analogues of antihypertensive and antiaggregating benzo[h]cinnolinones. Pinna GA, et al. **Farmaco** 1996 Oct;51(10):653–8

Effects of SC–52458, a new nonpeptide angiotensin II receptor antagonist, on increase in cytoplasmic Ca2+ concentrations and contraction induced by angiotensin II and K(+)–depolarization in guinea–pig taenia coli. Usune S, et al. **Gen Pharmacol** 1996 Oct;27(7):1179–85

Daily variation in portal blood flow and the effect of propranolol administration in a randomized study of patients with cirrhosis. Alvarez D, et al. **Hepatology** 1997 Mar;25(3):548–50

Restoration of endothelial cell function by chronic cicletanine treatment in Dahl salt–sensitive rats with salt–induced hypertension. Hirawa N, et al. **Hypertens Res** 1996 Dec; 19(4):263–70

Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV–116) and other classes of antihypertensive drugs in spontaneously hypertensive rats. Wada T, et al. **Hypertens Res** 1996 Dec;19(4):247–54

Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Alonso–Galicia M, et al. **Hypertension** 1996 Dec;28(6):1047–54

Additive effects of losartan and enalapril on blood pressure and plasma active renin. Azizi M, et al. **Hypertension** 1997 Feb;29(2):634–40

Catecholamine release mediates pressor effects of adrenomedullin–(15–22) in the rat. Champion HC, et al. **Hypertension** 1996 Dec;28(6):1041–6

Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. deBlois D, et al. **Hypertension** 1997 Jan;29(1 Pt 2):340–9

Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Gandhi SK, et al. **Hypertension** 1996 Dec;28(6):961–6

Brain "ouabain" and angiotensin II in salt–sensitive hypertension in spontaneously hypertensive rats. Huang BS, et al. **Hypertension** 1996 Dec;28(6):1005–12

Adrenomedullin stimulates renin release and renin mRNA in mouse juxtaglomerular granular cells. Jensen BL, et al. **Hypertension** 1997 May;29(5):1148–55

Effects of renin–angiotensin blockade on sympathetic reactivity and beta–adrenergic pathway in the spontaneously hypertensive rat. K.–Laflamme A, et al. **Hypertension** 1997 Aug;30(2 Pt 1):278–87

Spinal nicotinic receptor expression in spontaneously hypertensive rats. Khan IM, et al. **Hypertension** 1996 Dec; 28(6):1093–9

Pressure natriuresis after adrenomedullin in anesthetized spontaneously hypertensive rats. Kurashina T, et al. **Hypertension** 1997 Sep;30(3 Pt 2):660–3

Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors. Maeso R, et al. **Hypertension** 1996 Dec;28(6):967–72

Clonidine and ST–91 may activate imidazoline binding sites in the heart to release atrial natriuretic peptide. Mukaddam–Daher S, et al. **Hypertension** 1997 Jul;30(1 Pt 1):83–7

Improvement in baroreflex function by an oral angiotensin receptor antagonist in rats with myocardial infarction. Nishizawa M, et al. **Hypertension** 1997 Jan;29(1 Pt 2):458–63

Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Nunez E, et al. **Hypertension** 1997 Jan;29(1 Pt 2):519–24

Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Price DA, et al. **Hypertension** 1997 Aug;30(2 Pt 1):240–6

Hypotensive effect of a newly identified peptide, proadrenomedullin N–terminal 20 peptide. Shimosawa T, et al. **Hypertension** 1996 Sep;28(3):325–9

A comparison of the effect of enalapril and metoprolol on renal function, potassium balance, lipid profile, cardiac function, exercise tolerance and quality of life in hypertensive dialysis patients. Wong KC, et al. **Int J Artif Organs** 1995 Dec;18(12):757–62

Effects of the dihydropyridine calcium channel blocker amlodipine on ventricular and atrial protein synthesis in an aortic constriction model of hypertension and, following chronic treatment, in the left ventricle of SHR rats. Patel VB, et al. **Int J Cardiol** 1997 Feb;58(3):241–55

The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. Middeke M, et al. **Int J Clin Pharmacol Ther** 1997 Jun;35(6):231–4

Urinary calcium excretion in treated and untreated essential hypertension. Quereda C, et al. **J Am Soc Nephrol** 1996 Jul;7(7):1058–65

Manidipine improves spermatogenesis in the stroke–prone spontaneously hypertensive rat. Akagashi K, et al. **J Androl** 1997 Mar–Apr;18(2):210–6

Angiotensin receptor 1 blockade does not prevent physiological cardiac hypertrophy in the adult rat. Geenen DL, et al. **J Appl Physiol** 1996 Aug;81(2):816–21

Effects of renal denervation on cardiovascular and renal responses to ACE inhibition in conscious lambs. Smith FG, et al. **J Appl Physiol** 1997 Aug;83(2):414–9

Effects of the angiotensin AT1 receptor antagonist GRI38950 on haemodynamic function in dogs. Hunt AA, et al. **J Auton Pharmacol** 1997 Feb;17(1):1–11

The in vitro effects of captopril on the levels of lipid peroxidation and glutathione of erythrocytes in type II diabetes. Altuntaş Y, et al. **J Basic Clin Physiol Pharmacol** 1995;6(3–4):281–8

Blood pressure effects of hydrochlorothiazide, applied to the rat hypothalamus. Bergmann F, et al. **J Basic Clin Physiol Pharmacol** 1996;7(4):331–9

The cardiac and vascular effects of lacidipine. Agabiti–Rosei E. **J Cardiovasc Pharmacol** 1995;25 Suppl 3:S1–5 (17 ref.)

Mechanism and pressor relevance of the short–term cardiovascular and renin excitatory actions of the selective A2A–adenosine receptor agonists. Alberti C, et al. **J Cardiovasc Pharmacol** 1997 Sep;30(3):320–4

Reduction by (–)–cicletanine of the vascular reactivity to angiotensin II in rats. Alvarez–Guerra M, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):564–70

Effects of clonidine and flesinoxan on blood pressure variability in conscious spontaneously hypertensive rats. Chaouche–Teyara K, et al. **J Cardiovasc Pharmacol** 1997 Aug;30(2):241–4

Hypotensive and reflex bradycardic effects of ketanserin, but not of prazosin, enhanced selectively in aging conscious rats. Davidow LW, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):294–301

Effects of losartan on renal function in patients with essential hypertension. Fauvel JP, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):259–63

SC–52458, an orally active angiotensin II–receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers. Hagmann M, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):444–50

The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist. Hashimoto Y, et al. **J Cardiovasc Pharmacol** 1997 Feb;29(2):284–90

KRN4884, a novel K channel opener: antihypertensive effects in conscious renal hypertensive dogs. Kawahara J, et al. **J Cardiovasc Pharmacol** 1997 Jun;29(6):814–9

Pharmacological studies on a new antihypertensive agent, S–2150, a benzothiazepine derivative: 3. Hypotensive and antimyocardial–stunning effects in dogs. Kimoto S, et al. **J Cardiovasc Pharmacol** 1997 Feb;29(2):180–7

Alteration of cytochrome P–450 isozymes by captopril and idrapril in hepatic and renal microsomes of normotensive and spontaneously hypertensive rats. Moretti A, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):12–8

Neurons and receptors in the rostroventrolateral medulla mediating the antihypertensive actions of drugs acting at imidazoline receptors. Reis DJ. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S11–18 (65 ref.)

Therapeutic, but not low–dose, angiotensin–converting enzyme inhibition causes regression of cardiovascular changes in spontaneously hypertensive rats. Wahlander H, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):327–34

Use of losartan to examine the role of the cardiac renin–angiotensin system in myocardial dysfunction during ischemia and reperfusion. Werrmann JG, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):177–82

Electrical and mechanical effects of a novel antihypertensive quinazoline derivative, 3–[[4–(2–methoxyphenyl) piperazin–1–ly]methyl]–5–(methylthio)–2,3–dihydroimidazo [1,2–c]quinazoline, on guinea pig ventricular muscles. Yang JM, et al. **J Cardiovasc Pharmacol** 1997 Aug;30(2):229–34

Pharmacology of moxonidine, an I1–imidazoline receptor agonist. Ziegler D, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S26–37 (52 ref.)

3–Nitropropionic acid produces striatum selective lesions accompanied by iNOS expression. Nishino H, et al. **J Chem Neuroanat** 1996 Jun;10(3–4):209–12

Effects of adrenomedullin on the human adrenal glands: an in vitro study. Andreis PG, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1167–70

Angiotensin receptor antagonists—a new class of antihypertensive drug. Gibbs CR, et al. **J Clin Pharm Ther** 1996 Jun;21(3):127–30 (25 ref.)

Gender differences in exercise and recovery blood pressure responses in normal volunteers given diltiazem. Klassen GA, et al. **J Clin Pharmacol** 1995 Dec;35(12):1144–9

Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus. Martin DE, et al. **J Clin Pharmacol** 1997 Feb;37(2):155–9

Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension. Yu A, et al. **J Clin Pharmacol** 1996 Feb;36(2):98–111 (100 ref.)

Octanoate increases cytosolic Ca2+ concentration and membrane conductance in ovine pancreatic acinar cells. Katoh K, et al. **J Comp Physiol [B]** 1996;166(6):369–74

Characterization of the AT1 angiotensin II receptor expressed in guinea pig liver. García–Sáinz JA, et al. **J Endocrinol** 1997 Jul;154(1):133–8

The effects of clonidine on blood pressure, catecholamine and growth hormone release in hypogonadal men is preserved and not influenced by testosterone replacement therapy. Del Rio G, et al. **J Endocrinol Invest** 1996 Sep; 19(8):505–10

Hypotensive effect of crude root extract of Solanum sisymbriifolium (Solanaceae) in normo– and hypertensive rats. Ibarrola DA, et al. **J Ethnopharmacol** 1996 Oct; 54(1):7–12

Effects of captopril and propranolol on cognitive function and cerebral blood flow in aged hypertensive rats. Skinner MH, et al. **J Gerontol A Biol Sci Med Sci** 1996 Nov; 51(6):B454–60

Effect of terlipressin on in vitro vascular hyporeactivity of portal hypertensive rats. Heinemann A, et al. **J Hepatol** 1996 Jun;24(6):739–46

Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. Agrawal B, et al. **J Hum Hypertens** 1996 Aug;10(8):551–5

Adrenomedullin acts via stimulation of cyclic AMP and not via calcium signalling in vascular cells in culture. Barker S, et al. **J Hum Hypertens** 1996 Jun;10(6):421–3

Resting blood pressure and cardiovascular reactivity to mental arithmetic in mild hypertensive males supplemented with blackcurrant seed oil. Deferne JL, et al. **J Hum Hypertens** 1996 Aug;10(8):531–7

Effect of captopril on intracellular free calcium ([Ca2+]i) of thymocytes in spontaneously hypertensive rats. Xie L, et al. **J Hum Hypertens** 1996 Jun;10(6):425–7

Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine. Chan CK, et al. **J Hypertens** 1996 Jul;14(7):855–64

Renal function in one–kidney, one clip sodium–restricted rats: influence of enalapril and losartan. Demeilliers B, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1764–6

The angiotensin converting enzyme inhibitors fosinopril and enalapril differ in their central nervous effects in humans. Derad I, et al. **J Hypertens** 1996 Nov;14(11):1309–15

Midwall left ventricular performance in salt–loaded Dahl rats: effect of AT1 angiotensin II inhibition. de Simone G, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1808–12

Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition. London GM, et al. **J Hypertens** 1996 Sep; 14(9):1139–46

Effects of chronic treatment with losartan on blood pressure, endothelin–like immunoreactivity and nitric oxide in normotensive rats. Sacerdote A, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1670–3

The I1–imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. Ernsberger P, et al. **J Hypertens Suppl** 1997 Jan;15(1):S9–23 (102 ref.)

Imidazoline I1 receptor agonists: new data on hypertension and related pathologies: introduction. Fernandez–Cruz A. **J Hypertens Suppl** 1997 Jan;15(1):S1–2

Assessing renal effects and renal protection. Rodicio JL, et al. **J Hypertens Suppl** 1995 Dec;13(4):S19–25 (80 ref.)

Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose–fed rat. Rösen P, et al. **J Hypertens Suppl** 1997 Jan;15(1):S31–8

Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. van Zwieten PA. **J Hypertens Suppl** 1997 Jan;15(1):S3–8 (56 ref.)

AMPA receptor flip/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate. Partin KM, et al. **J Neurosci** 1996 Nov 1;16(21):6634–47

Adrenomedullin, a novel vasoactive hormone, binds to mouse astrocytes and stimulates cyclic AMP production. Yeung VT, et al. **J Neurosci Res** 1996 Nov 1;46(3):330–5

Comparative cardiovascular effects of the angiotensin II type 1 receptor antagonists ZD 7155 and losartan in the rat. Junggren IL, et al. **J Pharm Pharmacol** 1996 Aug; 48(8):829–33

Antihypertensive drugs reduce noradrenaline–induced hypertrophy of cultured myocardial cells. Lähteenmäki TA, et al. **J Pharm Pharmacol** 1996 Mar;48(3):323–6

Portal hypotensive effects of tetrandrine and verapamil in portal hypertensive rats. Liu TB, et al. **J Pharm Pharmacol** 1997 Jan;49(1):85–8

Synthesis of 3–amino–2–(3–indolyl)propanol and propanoate derivatives and preliminary cardiovascular evaluation in rats. Pérez–Alvarez V, et al. **J Pharm Pharmacol** 1997 Mar; 49(3):246–52

Pharmacological and pharmacokinetic evaluation of EXP3312, an orally–active non–peptide angiotensin II–receptor antagonist. Wong YN, et al. **J Pharm Pharmacol** 1996 May;48(5):492–7

Chronic carvedilol reduces mortality and renal damage in hypertensive stroke–prone rats. Barone FC, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):948–55

Effects of renal papillary–medullary lesion on the antihypertensive effect of furosemide and development of salt–sensitive hypertension in Dahl–S rats. Haugan K, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1415–22

Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2–induced contractions in canine coronary arteries. Li P, et al. **J Pharmacol Exp Ther** 1997 Jun; 281(3):1065–70

Blood pressure and age–dependent changes of endothelium–dependent tension oscillations in different strains of spontaneously hypertensive rats. Shimamura K, et al. **J Smooth Muscle Res** 1996 Aug;32(4):145–54

Effects of chronic treatment with carvedilol on smooth

muscle tone and endothelium-dependent relaxation of aorta in stroke-prone spontaneously hypertensive rats. Sunano S, et al. **J Smooth Muscle Res** 1997 Feb;33(1):23-35

Effects of antihypertensive drugs on maternal and fetal hemodynamics and uterine blood flow in pregnant goats—comparison of nicardipine and labetalol. Sakamoto H, et al. **J Vet Med Sci** 1996 Jun;58(6):515-9

Biochemical changes during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients. Ahaneku JE, et al. **JPMA J Pak Med Assoc** 1996 Apr;46(4):71-3

Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats. Kanagawa R, et al. **Jpn J Pharmacol** 1997 Mar;73(3):185-90

Hypotensive effects of YM430, a 1,4-dihydropyridine derivative, in spontaneously hypertensive rats and renal hypertensive dogs. Shibasaki K, et al. **Jpn J Pharmacol** 1997 Feb;73(2):113-24

Antihypertensive effect of repeatedly administered YM358, an angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats. Yamaguchi N, et al. **Jpn J Pharmacol** 1997 Jan;73(1):83-91

Angiotensin II-induced pulmonary edema in a rabbit model. Yamamoto T, et al. **Jpn J Pharmacol** 1997 Jan;73(1):33-40

Effects of antihypertensive drugs on nitric oxide synthase activity in rat kidney. Tojo A, et al. **Kidney Int Suppl** 1996 Jun;55:S138-40

The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Ziai F, et al. **Kidney Int Suppl** 1996 Dec;57:S132-6

Increased left-ventricular mass after losartan treatment [letter] Cheung B. **Lancet** 1997 Jun 14;349(9067):1743-4

Blood-pressure control in the hypertensive population [see comments] Mancia G, et al. **Lancet** 1997 Feb 15; 349(9050):454-7. Comment in: Lancet 1997 Jul 26;350(9073):290-1.

Effects of blood flow modifiers on tumor metabolism observed in vivo by proton magnetic resonance spectroscopic imaging. Bhujwalla ZM, et al. **Magn Reson Med** 1996 Aug;36(2):204-11

Effects of long-term hydralazine treatment on myocardial structure and expression of myosin isogenes in cardiac pressure overload in rats. Reddy DS, et al. **Methods Find Exp Clin Pharmacol** 1996 May;18(4):261-71

Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations. Perlman S, et al. **Mol Pharmacol** 1997 Feb; 51(2):301-11

Presynaptic imidazoline receptors and alpha 2-adrenoceptors in the human heart: discrimination by clonidine and moxonidine. Likungu J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):689-92

Influence of different dietary salts on the cardiovascular and renal effects of moxonidine in spontaneously hypertensive rats. Mervaala EM, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jul; 356(1):107-14

Inhibition of centrally induced ventricular arrhythmias by rilmenidine and idazoxan in rabbits. Roegel JC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):598-605

A long-lasting hypotensive effect of topical diltiazem on the intraocular pressure in conscious rabbits. Santafé J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 May; 355(5):645-50

Is the level of arterial pressure reduction important for preservation of renal function [editorial] Bakris GL. **Nephrol Dial Transplant** 1996 Dec;11(12):2383-4

Hydralazine inhibits human peritoneal mesothelial cell proliferation and collagen synthesis. Fang CC, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2276-81

Enalaprilat inhibits hydrogen peroxide production by murine mesangial cells exposed to high glucose concentrations. Ruiz-Muñoz LM, et al. **Nephrol Dial Transplant** 1997 Mar; 12(3):456-64

Effects of indapamide on Ca2+ entry into vascular smooth muscle cells. Zempel G, et al. **Nephron** 1997;76(4):460-5

Serotonin synthesis increased in terminals four days after reserpine treatment: an autoradiographic study in rat brain. Mück-Seler D, et al. **Neurochem Res** 1997 Jan;22(1):11-6

Adenosine A2A agonists: a potential new type of atypical antipsychotic. Rimondini R, et al. **Neuropsychopharmacology** 1997 Aug;17(2):82-91

3-Nitropropionic acid animal model and Huntington's disease. Borlongan CV, et al. **Neurosci Biobehav Rev** 1997 May;21(3):289-93 (33 ref.)

Increase in levels of total free fatty acids in rat brain regions following 3-nitropropionic acid administration. Binienda Z, et al. **Neurosci Lett** 1997 Jul 25;230(3):199-201

Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease. Kodsi MH, et al. **Neurosci Lett** 1997 Aug 8;231(2):103-7

Delayed progression of cytotoxic oedema in focal cerebral ischemia after treatment with a torasemide derivative: a diffusion-weighted magnetic resonance imaging study. Le Bars E, et al. **Neurosci Lett** 1996 Aug 2;213(2):123-6

Intracerebroventricular injection of adrenomedullin inhibits vasopressin release in conscious rats. Yokoi H, et al. **Neurosci Lett** 1996 Sep 20;216(1):65-7

Metabolic alterations produced by 3-nitropropionic acid in rat striata and cultured astrocytes: quantitative in vitro 1H nuclear magnetic resonance spectroscopy and biochemical characterization. Tsai MJ, et al. **Neuroscience** 1997 Aug; 79(3):819-26

Adrenomedullin increases pulmonary blood flow in fetal sheep. de Vroomen M, et al. **Pediatr Res** 1997 Apr;41(4 Pt 1):493-7

Protein kinase Cs and tyrosine kinases in permissive action of prostacyclin on cerebrovascular regulation in newborn pigs. Rama GP, et al. **Pediatr Res** 1997 Jan;41(1):83-9

Vasorelaxation by casomokinin L, a derivative of beta-casomorphin and casoxin D, is mediated by NK1 receptor. Fujita H, et al. **Peptides** 1996;17(4):635-9

Adrenomedullin stimulates steroid secretion by the isolated perfused rat adrenal gland in situ: comparison with calcitonin gene-related peptide effects. Mazzocchi G, et al. **Peptides** 1996;17(5):853-7

Improved activity of a new angiotensin receptor antagonist by an injectable spray-dried polymer microsphere preparation. Lacasse FX, et al. **Pharm Res** 1997 Jul; 14(7):887-91

Chlorthalidone-modulated vascular responses to vasodilator stimuli in DOCA-salt hypertensive rats. Bissoli NS, et al. **Pharmacol Res** 1996 Jan;33(1):47-54

Effect of 2-methyltaurine and its enantiomers on arterial blood pressure. Braghiroli D, et al. **Pharmacol Res** 1996 Jul-Aug;34(1-2):33-6

Effects of chronic treatment with lisinopril on cardiovascular complications in streptozotocin diabetic and DOCA hypertensive rats. Sevak AR, et al. **Pharmacol Res** 1996 Nov-Dec;34(5-6):201-9

Nifedipine reduces thromboxane A2 production by platelets without changing aggregation in hypertensive pregnancy. Manninen A. **Pharmacol Toxicol** 1996 Jun;78(6):387-91

Inhibition of the natriuretic action of the imidazoline receptor agonist moxonidine by indometacin in the rat. Darkwa FK, et al. **Pharmacology** 1995 Dec;51(6):347-55

The hemodynamic effects of AT-112, an analog of ketanserin, in portal hypertensive rats. Lin HC, et al. **Pharmacology** 1997 Jan;54(1):16-23

Vanidilol: a vanilloid-type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2-agonist activity. Sheu MM, et al. **Pharmacology** 1997 Apr;54(4):211-24

The renin-angiotensin-aldosterone system: focus on its distinct role in arterial hypertension and its various inhibitors as a therapeutic strategy to effectively lower blood pressure. Soldner A, et al. **Pharmazie** 1996 Nov; 51(11):783-99 (239 ref.)

Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. Bernátová I, et al. **Physiol Res** 1996;45(4):311-6

Antihypertensive drugs and endothelial cell function. Lehoux S, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Jan; 54(1):65-70

Thromboxane inhibition potentiates antihypertensive effects of alpha 1 adrenoceptor antagonists in the rat. Takada S, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Feb; 56(2):127-34

Effects of chronic central administration of losartan on the cardiovascular and hormonal responses to hemorrhage in conscious rats. Yang EK, et al. **Regul Pept** 1996 Dec 3; 67(2):107-13

The effects of Cicletanine, a new antihypertensive agent on insulin release in rat isolated pancreas by the perfusion technique. Mashori GR, et al. **Singapore Med J** 1996 Jun; 37(3):278-81

Hydralazine reduces elevated sleep apnea index in spontaneously hypertensive (SHR) rats to equivalence with normotensive Wistar-Kyoto rats. Carley DW, et al. **Sleep** 1996 Jun;19(5):363-6

Cerebrovascular changes in chronic hypertension. Protective effects of enalapril in rats. Nag S, et al. **Stroke** 1997 May; 28(5):1028-34

The effect of anti-hypertensive drugs on DNA synthesis and proliferation of cultured rat aortic smooth muscle cells. Kang SW, et al. **Yonsei Med J** 1997 Jun;38(3):160-6

[Recent progresses in pharmacological and clinical studies of paeonol] Zhang LH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Mar; 16(3):187-90 (24 ref.) **(Chi)**

[Urapidil during surgery of pheochromocytoma: should begin in the preoperative period (letter)] Valat P, et al. **Ann Fr Anesth Reanim** 1996;15(5):698-9 **(Fre)**

[Effects of rilmenidine on rats made insulin resistant and hypertensive by a high fructose diet] Berthault MF, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89(8):1103-6 (Eng. Abstr.) **(Fre)**

[Hyaluronic acid (hyaluronan) levels in pathological human saphenous veins. Effects of procyanidol oligomers] Drubaix I, et al. **Pathol Biol (Paris)** 1997 Jan;45(1):86-91 (Eng. Abstr.) **(Fre)**

[Prolongation of fentanyl-induced decreased arousal by clonidine] Walz R, et al. **Anaesthesiol Reanim** 1997; 22(2):42-5 (Eng. Abstr.) **(Ger)**

[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors] Erley CM, et al. **Dtsch Med Wochenschr** 1997 Aug 1;122(31-32):953-8 (Eng. Abstr.) **(Ger)**

[Endothelial receptor antagonists] Bornkessel B. **Med Monatsschr Pharm** 1997 Jul;20(7):174-6 (3 ref.) **(Ger)**

[Change in corneal sensitivity after topical dorzolamide administration. A comparative study] Kohlhaas M, et al. **Ophthalmologe** 1997 Jun;94(6):424-7 (Eng. Abstr.) **(Ger)**

[Effect of cilazapril in patients with essential hypertension: effect on cardiac hypertrophy] Abrahám G, et al. **Orv Hetil** 1996 Jul 21;137(29):1583-6 (Eng. Abstr.) **(Hun)**

[Effects of prostacyclin (PGI2) on pial vessel diameter and carbon-dioxide reactivity in cats] Nagahata T, et al. **Masui** 1996 Feb;45(2):194-9 (Eng. Abstr.) **(Jpn)**

[The effects of prostaglandin I2 on membrane Na+, K+ transport systems in cultured vascular smooth muscle cells] Uchida H. **Nippon Jinzo Gakkai Shi** 1996 Sep;38(9):399-406 (Eng. Abstr.) **(Jpn)**

[Antihypertensive effects of a novel calcium antagonist, AE0047, in various hypertensive models] Kido H, et al. **Nippon Yakurigaku Zasshi** 1997 Jun;109(6):279-89 (Eng. Abstr.) **(Jpn)**

[Anti-atherosclerotic action of hypotensive drugs] Gmiński J, et al. **Wiad Lek** 1996;49(7-12):182-98 (0 ref.) (Eng. Abstr.) **(Pol)**

[The pharmacological effect of betapressin in hypertension] Zaslavskaia RM, et al. **Eksp Klin Farmakol** 1996 Nov-Dec; 59(6):23-5 (Eng. Abstr.) **(Rus)**

[A comparison of the effect of Capoten (captopril) and ramipril on the circadian profile of the arterial pressure and peripheral hemodynamics in patients with hypertension combined with diabetes mellitus] Filatova EV, et al. **Ter Arkh** 1996;68(5):67-70 (Eng. Abstr.) **(Rus)**

[A decrease in arterial pressure by using organic nitrates] Kleist P, et al. **Ter Arkh** 1993;65(2):90-3 **(Rus)**

POISONING

Clonidine poisoning in Jefferson County, Alabama. Nichols MH, et al. **Ann Emerg Med** 1997 Apr;29(4):511-7 (64 ref.)

[The forensic medical aspects of acute Clofelin poisonings] Kedrov VS, et al. **Sud Med Ekspert** 1997 Jul-Sep; 40(3):18-20 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Hypertensive urgency concern [letter; comment] Krause RS. **Acad Emerg Med** 1996 Jun;3(6):646-8. Comment on: Acad Emerg Med 1995 Nov;2(11):947-8. Comment on: Acad Emerg Med 1995 Nov;2(11):959-65.

Sodium nitroprusside after cardiac surgery: systemic and splanchnic blood flow and oxygen transport. Parviainen I, et al. **Acta Anaesthesiol Scand** 1996 May;40(5):606-11

High dose intravenous labetalol for the resection of metastatic pheochromocytoma [published erratum appears in Acta Anaesthesiol Sin 1997 Mar;35(1):59] Chung PC, et al. **Acta Anaesthesiol Sin** 1996 Dec;34(4):235-8

Treatment of hypertensive patients according to the conventional or ambulatory pressure: a progress report on the APTH trial. APTH Investigators. Ambulatory Blood Pressure and Treatment of Hypertension. Bieniaszewski L, et al. **Acta Cardiol** 1996;51(3):243-51

Successful management of acute aortic dissection in a heart transplant recipient. Defraigne JO, et al. **Acta Chir Belg** 1997 Jun;97(3):141-4 (15 ref.)

Hypertension in pregnancy: use of antihypertensive drugs. Henriksen T. **Acta Obstet Gynecol Scand** 1997 Feb; 76(2):96-106 (87 ref.)

Peripheral perfusion and tissue oxygenation improvement induced by antihypertensive medication combined with lipoidoproteinosis treatment. Cicco G, et al. **Adv Exp Med Biol** 1997;411:261-6

Open trial of doxazosin in hypertensive Africans: dose finding, efficacy and safety studies. Sowunmi A, et al. **Afr J Med Med Sci** 1996 Mar;25(1):53-9

Drug therapy for hypertension. Gavras I, et al. **Am Fam Physician** 1997 Apr;55(5):1823-6, 1829-34 (29 ref.)

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Califf RM, et al. **Am Heart J** 1997 Jul;134(1):44-54

Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance. Jeng JR, et al. **Am Heart J** 1996 Oct;132(4):783-9

Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension. Aepfelbacher FC, et al. **Am J Cardiol** 1997 Mar 15;79(6):826-8

Evolution of left ventricular hypertrophy and function during long-term treatment of systemic hypertension with enalapril. González-Juanatey JR, et al. **Am J Cardiol** 1997 Feb 1;79(3):373-6

Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Gradman AH, et al. **Am J Cardiol** 1997 Feb 15;79(4):431-5

Effects of aerobic training on exaggerated blood pressure response to exercise in African-Americans with severe systemic hypertension treated with indapamide +/- verapamil +/- enalapril. Kokkinos PF, et al. **Am J Cardiol** 1997 May 15;79(10):1424-6

Felodipine as monotherapy and associated with enalapril for essential hypertension [letter] Navarro JF, et al. **Am J Cardiol** 1997 Sep 1;80(5):683-4

Antihypertensive therapy: how to evaluate the benefits.

Zanchetti A. **Am J Cardiol** 1997 May 22;79(10A):3–8; discussion 47–8 (26 ref.)

Managing patients with primary pulmonary hypertension: prostacyclin therapy. Albert NM, et al. **Am J Crit Care** 1997 Jul;6(4):274–80 (13 ref.)

Trandolapril approved for marketing [news] **Am J Health Syst Pharm** 1996 Jul 15;53(14):1649

Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients. Briscoe TA, et al. **Am J Health Syst Pharm** 1996 Sep 15;53(18):2191–3

Pharmacological properties of combination therapies for hypertension. Abernethy DR. **Am J Hypertens** 1997 Mar; 10(3):13S–16S (20 ref.)

Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy. Alli C, et al. **Am J Hypertens** 1996 Nov;9(11):1068–76

Short-term antihypertensive medication does not exacerbate sleep-disordered breathing in newly diagnosed hypertensive patients. Bartel PR, et al. **Am J Hypertens** 1997 Jun;10(6):640–5

Protecting the residual renal function: which drugs of choice? Bretzel RG. **Am J Hypertens** 1997 Jul;10(7 Pt 2):159S–166S (75 ref.)

Additive effects of diltiazem and lisinopril in the treatment of elderly patients with mild-to-moderate hypertension. Chan P, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 1):743–9

The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Dahlöf B, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 1):705–13

Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group. DeQuattro V, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 2):138S–145S

Comparison of nifedipine GITS and hydrochlorothiazide in the management of elderly patients with stage I–III diastolic hypertension. Dey HM, et al. **Am J Hypertens** 1996 Jun;9(6):598–606

Calcium antagonists: still appropriate as first line antihypertensive agents. Epstein M. **Am J Hypertens** 1996 Feb;9(2):110–21 (64 ref.)

On the trough-to-peak ratio of drug effect in antihypertensive trials. Fenichel RR, et al. **Am J Hypertens** 1996 Oct;9(10 Pt 2):105S–107S; discussion 108S–109S (2 ref.)

Results of hypertension treatment with low-dose combinations of a beta-adrenergic blocker and a diuretic. Frishman WH. **Am J Hypertens** 1997 Mar;10(3):17S–23S (35 ref.)

Calcium antagonists: not appropriate as first line antihypertensive agents. Furberg CD, et al. **Am J Hypertens** 1996 Feb;9(2):122–5 (13 ref.)

Has the use of angiotensin converting enzyme inhibitors and calcium channel blockers improved the outcome for hypertensive patients? Gifford RW Jr. **Am J Hypertens** 1997 Mar;10(3):9S–12S (19 ref.)

The alterations in insulin sensitivity during angiotensin converting enzyme inhibitor treatment are related to changes in the calcium/magnesium balance. Haenni A, et al. **Am J Hypertens** 1997 Feb;10(2):145–51

Major antihypertensive intervention trials conducted outside the United States. Hansson L. **Am J Hypertens** 1996 Aug; 9(8):45S–49S (11 ref.)

Remikiren (Ro 42–5892)—an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. Himmelmann A, et al. **Am J Hypertens** 1996 Jun;9(6):517–22

The effect of blood pressure reduction on end stage renal disease. Jamerson K. **Am J Hypertens** 1996 Aug; 9(8):60s–64s (22 ref.)

Combination therapy: a key to comprehensive patient care. Kaplan NM, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 2):127S

The challenge of managing multiple cardiovascular risk factors. Kaplan NM. **Am J Hypertens** 1997 Jul;10(7 Pt 2):167S–169S (7 ref.)

Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure. Kario K, et al. **Am J Hypertens** 1997 Mar;10(3):261–8

Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). Kostis JB, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 1):1147–53

Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension. Lacourcière Y, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 1):1154–9

Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. Multicenter Study Group. Larochelle P. **Am J Hypertens** 1996 Jun; 9(6):551–9

Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Lee JY, et al. **Am J Hypertens** 1996 Aug;9(8):719–25

Use of antihypertensive drugs in an intensive care unit [letter] Leeman M. **Am J Hypertens** 1997 Jan;10(1):144

Combination treatment in hypertension: the VeraTran Study. Mancia G, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 2):153S–158S (18 ref.)

Metabolic effects of long-term treatments with nifedipine-retard and captopril in young hypertensive patients. Masuo K, et al. **Am J Hypertens** 1997 Jun; 10(6):600–10

The effects on cardiac arrhythmias of antihypertensive therapy causing regression of left ventricular hypertrophy. Mayet J, et al. **Am J Hypertens** 1997 Jun;10(6):611–8

Cardiac effects of combination therapy. Messerli FH, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 2):146S–152S (54 ref.)

The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Monane M, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 1):697–704

Suggested guidelines for determining the trough-to-peak ratio of antihypertensive drugs. Myers MG. **Am J Hypertens** 1996 Oct;9(10 Pt 2):76S–82S; discussion 87S–90S (19 ref.)

Discussion: recent data on the safety and efficacy of newer therapies in the management of hypertension. Neutel J, et al. **Am J Hypertens** 1997 Mar;10(3):24S–26S

Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators [published erratum appears in Am J Hypertens 1997 Jun;10(6):696] Opie LH, et al. **Am J Hypertens** 1997 Mar;10(3):250–60

Orthostatic hypotension: how to avoid it during antihypertensive therapy. Rieckert H. **Am J Hypertens** 1996 Nov;9(11):155S–159S

Blood pressure control for the hypertensive patient: what can we do better? Sever PS. **Am J Hypertens** 1997 Jul;10(7 Pt 2):128S–130S (13 ref.)

Trough-to-peak ratios: some statistical considerations. Stewart WH. **Am J Hypertens** 1996 Oct;9(10 Pt 2):83S–86S; discussion 87S–90S

Effects of gender and ethnic group on blood pressure control in the elderly. Svetkey LP, et al. **Am J Hypertens** 1996 Jun;9(6):529–35

Treatment of non-insulin-dependent diabetic hypertensive patients with Ca2+ channel blockers is associated with increased platelet sensitivity to insulin. Touyz RM, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 1):1214–21

A new adenosine subtype-1 receptor antagonist, FK-838, attenuates salt-induced hypertension in Dahl salt-sensitive rats. Uehara Y, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 1):1189–99

Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy. Villa E, et al. **Am J Hypertens** 1997 Feb;10(2):202–8

Combination antihypertensive therapy: does it have a role in rational therapy? Waeber B, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 2):131S–137S (32 ref.)

Antihypertensive therapy and quality of life. Influence of blood pressure reduction, adverse events, and prior antihypertensive therapy. Weir MR, et al. **Am J Hypertens** 1996 Sep;9(9):854–9

Relevance of the trough-to-peak ratio to the 24 h blood pressure load. White WB. **Am J Hypertens** 1996 Oct;9(10 Pt 2):91S–96S; discussion 108S–109S (18 ref.)

Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. Hall WD, et al. **Am J Kidney Dis** 1997 May;29(5):720–8

The impact of ethnicity on response to antihypertensive therapy. Jamerson K, et al. **Am J Med** 1996 Sep 30; 101(3A):22S–32S (107 ref.)

ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats. Kaneko K, et al. **Am J Med Sci** 1997 Jul;314(1):21–7

Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Chan JC, et al. **Am J Nephrol** 1997;17(1):72–80

Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. Scardo JA, et al. **Am J Obstet Gynecol** 1996 Aug;175(2):336–8; discussion 338–40

Chronic effects of ANG II antagonist in heart failure: improvement of cGMP generation from ANP. Maeda Y, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2139–45

Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia. Parker TA, et al. **Am J Respir Crit Care Med** 1997 Feb; 155(2):743–6

Nicardipine versus nitroprusside for controlled hypotension during spinal surgery in adolescents. Hersey SL, et al. **Anesth Analg** 1997 Jun;84(6):1239–44

Clonidine for major vascular surgery in hypertensive patients: a double-blind, controlled, randomized study. Quintin L, et al. **Anesth Analg** 1996 Oct;83(4):687–95

Platelet function and adrenoceptors during and after induced hypotension using nitroprusside. Dietrich GV, et al. **Anesthesiology** 1996 Dec;85(6):1334–40

Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Giatras I, et al. **Ann Intern Med** 1997 Sep 1;127(5):337–45

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Giugliano D, et al. **Ann Intern Med** 1997 Jun 15;126(12):955–9

Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Gueyffier F, et al. **Ann Intern Med** 1997 May 15;126(10):761–7

Effects of hypertension and propranolol upon aneurysm expansion in the Anidjar/Dobrin aneurysm model. Ricci MA, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:89–96

Drug effects on blood pressure rhythms in essential hypertension. Rosenthal T. **Ann N Y Acad Sci** 1996 Aug 15;783:263–9 (32 ref.)

Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hong Kong. Lau GS, et al. **Ann Pharmacother** 1996 Mar;30(3):232–7

Factors associated with antihypertensive prescribing. Nichol MB, et al. **Ann Pharmacother** 1997 Feb;31(2):154–9

Inappropriate prescribing and health outcomes in elderly veteran outpatients [see comments] Schmader KE, et al. **Ann Pharmacother** 1997 May;31(5):529–33. Comment in: Ann Pharmacother 1997 May;31(5):643–4.

Low-dose sodium nitroprusside reduces pulmonary reperfusion injury. King RC, et al. **Ann Thorac Surg** 1997 May;63(5):1398–404

Hypertension in pregnancy: current concepts of preeclampsia. Witlin AG, et al. **Annu Rev Med** 1997; 48:115–27 (47 ref.)

Controlling hypertension. A research success story. Dustan HP, et al. **Arch Intern Med** 1996 Sep 23;156(17):1926–35 (67 ref.)

Hypertension treatment. Its past and (perhaps) its future [editorial] Dustan HP. **Arch Intern Med** 1996 Sep 23; 156(17):1913–4

Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study [see comments] Grimm RH Jr, et al. **Arch Intern Med** 1997 Mar 24;157(6):638–48. Comment in: ACP J Club 1997 Sep–Oct;127(2):37.

Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension. Malik AS, et al. **Arch Intern Med** 1997 Mar 24;157(6):621–5

Angiotensin II receptor inhibition. A new therapeutic principle. Messerli FH, et al. **Arch Intern Med** 1996 Sep 23;156(17):1957–65 (100 ref.)

Treatment of active gastroesophageal variceal bleeding with terlipressin or hemostatic balloon in patients with cirrhosis. A randomized controlled trial. García-Compeán D, et al. **Arch Med Res** 1997 Summer;28(2):241–5

LDL apheresis with dextran sulfate and angiotension receptor antagonist (Losartan). Elicio N, et al. **Artif Organs** 1997 Apr;21(4):334–5

Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan. Hayashi N, et al. **Arzneimittelforschung** 1997 May;47(5):625–9

Effects of lisinopril or lisinopril/hydrochlorothiazide compared with adjusting of previous medication and intensifying non-pharmacological treatment in patients with mild to moderate hypertension. Keinänen-Kiukaanniemi S, et al. **Arzneimittelforschung** 1997 Feb;47(2):144–50

Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs. Sironi G, et al. **Arzneimittelforschung** 1996 Feb;46(2):145–52

Antihypertensive effect of drugs: statistical distribution of the trough-to-peak ratio. Chi VX, et al. **Biometrics** 1996 Mar;52(1):286–90

Low dose of ACE-inhibitor enhances sodium excretion in volume expanded patients with borderline hypertension. Borghi C, et al. **Blood Press** 1996 Mar;5(2):105–12

Effect of angiotensin converting enzyme inhibition [Cilazapril] on blood pressure recording in hypertensive obstructive sleep apneic patients. Grote L, et al. **Blood Press** 1997 Jul;6(4):235–41

Antihypertensive therapy—a viable branch of medicine [editorial] Hansson L, et al. **Blood Press** 1997 Jan;6(1):4

Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Ikeda LS, et al. **Blood Press** 1997 Jan; 6(1):35–43

Parathyroid hypertensive factor predicts efficacy in the treatment of essential hypertension with verapamil. Lewanczuk RZ, et al. **Blood Press** 1996 Mar;5(2):98–104

The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): a progress report. Lindholm LH, et al. **Blood Press** 1996 Sep;5(5):300–4

Considerations on current and future trials in hypertension. Mancia G, et al. **Blood Press** 1996 Nov;5(6):327–32 (49 ref.)

Comparison of temocapril and atenolol in the long-term treatment of mild to moderate essential hypertension. Sierakowski B, et al. **Blood Press** 1997 Jul;6(4):229–34

Calcium antagonists in hypertension: first-line antihypertensive agents? Ambrosioni E. **Blood Press Suppl** 1996;5:5–6 (10 ref.)

Use and adverse reactions of antihypertensive drugs in Spain. Part I of the RAAE Study. Aranda P, et al. **Blood Press Suppl** 1997;1:11–6

Patients' experiences of antihypertensive drugs in routine use: results of a Danish general practice survey. Borrild NJ. **Blood Press Suppl** 1997;1:23–5

Angiotensin II antagonism: a new avenue of hypertension

management. Gavras H. **Blood Press Suppl** 1997;1:42–6 (24 ref.)
Compliance studies in ELSA. European Lacidipine Study of Atherosclerosis. Giannattasio C, et al. **Blood Press Suppl** 1996;4:39–43
Physician and patient evaluation of hypertension–related risks and benefits from treatment. Hedner T, et al. **Blood Press Suppl** 1997;1:26–34 (54 ref.)
Treatment situation of hypertensive patients in Finnish primary health care. Kumpusalo E, et al. **Blood Press Suppl** 1997;1:35–9
Ambulatory blood pressure monitoring in the ELSA study. European Lacidipine Study on Atherosclerosis. Mancia G, et al. **Blood Press Suppl** 1996;4:36–8
The clinical efficacy and tolerability of the angiotensin II–receptor antagonist losartan in Japanese patients with hypertension. Ogihara T, et al. **Blood Press Suppl** 1996; 2:78–81 (9 ref.)
Hypertension, atherosclerosis and microalbuminuria in ELSA. European Lacidipine Study of Atherosclerosis. Ruilope LM, et al. **Blood Press Suppl** 1996;4:48–52 (60 ref.)
Prevalence of carotid atherosclerosis in hypertension: preliminary baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). Zanchetti A. **Blood Press Suppl** 1996;4:30–5
Case–control study of stroke and the quality of hypertension control in north west England. Du X, et al. **BMJ** 1997 Jan 25;314(7076):272–6
Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. Philipp T, et al. **BMJ** 1997 Jul 19;315(7101):154–9
Drug treatment of hypertension in acute intermittent porphyria: doxazosin and amlodipine [letter] Gorchein A. **Br J Clin Pharmacol** 1997 Mar;43(3):339–40
Persistence of anti–hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half–life. Leenen FH, et al. **Br J Clin Pharmacol** 1996 Feb;41(2):83–8
New therapeutic agents for hypertension. Reid JL. **Br J Clin Pharmacol** 1996 Jul;42(1):37–41 (48 ref.)
Efficacy of ramipril versus enalapril in patients with mild to moderate essential hypertension. Yasky J, et al. **Br J Clin Pract** 1996 Sep;50(6):302–10
The effect of nifedipine and methyldopa on maternal cerebral circulation. Serra–Serra V, et al. **Br J Obstet Gynaecol** 1997 May;104(5):532–7
Evaluation of protein and peptide hydrolases in DOCA–salt hypertensive rat treated with chlorthalidone. Santos–Costa JL, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1431–5
Resistant hypertension: an overview. McAlister FA, et al. **Can J Cardiol** 1996 Sep;12(9):822–8 (82 ref.)
What can angiotensin antagonists do that converting–enzyme inhibition can't: the case of post–angioplastic restenosis. Pham D, et al. **Can J Physiol Pharmacol** 1996 Jul; 74(7):867–77
Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine. Di Somma S, et al. **Cardiologia** 1996 Jul;41(7):635–43
Treatment of high blood pressure. From diuretics to the present and future. Nogueira da Costa J. **Cardiologia** 1995 Dec;40(12):893–8 (45 ref.)
Evaluation of the sympathetic nervous system using heart rate variability and plasma hormones in hypertensive patients treated with cilazapril and atenolol. Campelo M, et al. **Cardiology** 1996 Sep–Oct;87(5):402–8
Discontinuation of antihypertensive therapy: prevalence of relapses and predictors of successful withdrawal in a hypertensive community. Schmieder RE, et al. **Cardiology** 1997 May–Jun;88(3):277–84
Effect of antihypertensive treatment on lipids and fibrinogen: Greek multicentre study of cilazapril. Tsagadopoulos D, et al. **Cardiology** 1996 Nov–Dec;87(6):524–8
Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension. Bönner G, et al. **Cardiovasc Drugs Ther** 1997 Mar; 11(1):21–6
An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. Byyny RL, et al. **Cardiovasc Drugs Ther** 1996 Jul;10(3):313–9
Effects of antihypertensive drugs on various aspects of renal function. de Leeuw PW, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):803–8 (27 ref.)
Calcium channel blockers and hypertension: evolving perspective—1996. Epstein M. **Cardiovasc Drugs Ther** 1997 Jan;10 Suppl 3:883–91 (50 ref.)
Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. Fodor JG. **Cardiovasc Drugs Ther** 1997 Jan;10 Suppl 3:873–9 (48 ref.)
Prediction of the changes in cardiac output in association with preload reduction therapy in patients with hypertensive heart failure. Nagano R, et al. **Cardiovasc Drugs Ther** 1997 Mar;11(1):49–56
Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors. Ranieri G, et al. **Cardiovasc Drugs Ther** 1996 May;10(2):119–23
Acute hemodynamic effects of amlodipine 15 days after a myocardial infarction in normotensive patients treated with atenolol. Rocha P, et al. **Cardiovasc Drugs Ther** 1997 Apr; 11(2):139–47
Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Weber K, et al. **Cardiovasc Drugs Ther** 1996 May;10(2):113–7
Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Kiely DG, et al. **Cardiovasc Res** 1997 Jan; 33(1):201–8
Effect of quinapril therapy on blood pressure and serotonin change in patients with mild to moderate hypertension. Huang JL, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Nov;58(5):329–34
Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? [editorial; comment] Devereux RB. **Circulation** 1997 Apr 15;95(8):1983–5. Comment on: Circulation 1997 Apr 15;95(8):2007–14.
Additional hypotensive effect of endothelin–1 receptor antagonism in hypertensive dogs under angiotensin–converting enzyme inhibition. Donckier JE, et al. **Circulation** 1997 Aug 19;96(4):1250–6
Effect of single–drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents [see comments] Gottdiener JS, et al. **Circulation** 1997 Apr 15;95(8):2007–14. Comment in: Circulation 1997 Apr 15;95(8):1983–5.
Effects of long–term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Hinderliter AL, et al. **Circulation** 1997 Mar 18; 95(6):1479–86
Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment–induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation [published erratum appears in Circulation 1997 Aug 5;96(3):1065] Mancia G, et al. **Circulation** 1997 Mar 18;95(6):1464–70
Images in cardiovascular medicine. An "ACE" of a test. Narula J, et al. **Circulation** 1997 May 20;95(10):2456–7
Inhibition of tissue angiotensin–converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Nong Z, et al. **Circulation** 1996 Oct 15;94(8):1941–7
Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. Parodi O, et al. **Circulation** 1997 Aug 5;96(3):864–73
Antihypertensive therapy and diabetic microvascular disease. Cooper ME. **Clin Exp Hypertens** 1997 Jul–Aug; 19(5–6):769–78 (19 ref.)
Efficacy of combination therapy with trandolapril and verapamil sr in primary hypertension: a 4 x 4 trial design. The Trandolapril Study Group. DeQuattro V, et al. **Clin Exp Hypertens** 1997 Apr;19(3):373–87
Transdermal clonidine therapy and blood pressure nocturnal fall in mild hypertensive male subjects. Guagnano MT, et al. **Clin Exp Hypertens** 1997 Apr;19(3):331–41
Effects of quinapril hydrochloride in patients with essential hypertension and impaired renal function. Owada A, et al. **Clin Exp Hypertens** 1997 May;19(4):495–502
Effects of antihypertensive drugs on coronary artery disease risk: a meta–analysis. Howes LG, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul;23(6–7):555–8
Protective effects of ME3221 on hypertensive complications and lifespan in salt–loaded stroke–prone spontaneously hypertensive rats. Nagura J, et al. **Clin Exp Pharmacol Physiol** 1996 Mar;23(3):229–35
Antihypertensive effect of thermolysin digest of dried bonito in spontaneously hypertensive rat. Fujita H, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S304–5
Protective effect of thromboxane synthetase inhibitor on hypertensive renal damage in Dahl salt–sensitive rats. Gomi T, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S371–3
Ocular fundus changes in malignant or precocious stroke–prone spontaneously hypertensive rats after administration of antihypertensive drugs. Hamada Y, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S132–3
Baroreceptor function is restored by antihypertensive therapy through lowering of blood pressure in adult SHR. Ichikawa M, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S67–9
Hypotensive effects of a new transdermal delivery system for clonidine (M–5041T) in spontaneously and renal hypertensive rats. Ishii R, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S374–6
Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus. Kohzuki M, et al. **Clin Exp Pharmacol Physiol Suppl** 1995; 1:S366–7
Effect of felodipine treatment and withdrawal on blood pressure and cardiovascular structure in New Zealand genetically hypertensive rats. Ledingham JM, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S326–8
Renin–angiotensin system in the antihypertensive effect of isoteoline in spontaneously hypertensive rats. Markov M, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S368–70
Effect of chronic treatment with ME3221 on blood pressure and mortality in aged stroke–prone spontaneously hypertensive rats. Nagura J, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S363–5
Electroencephalographic evaluation of the therapeutic efficiency of antihypertensive agents on M–SHRSP. Ohta Y, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S377–9
Effects of (–)–epigallocatechin–3–O–gallate (green tea tannin) on the life span of stroke–prone spontaneously hypertensive rats. Uchida S, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S302–3
Rheological changes in hypertensive patients treated with ramipril. Rosenson RS, et al. **Clin Hemorheol Microcirc** 1997 Jan–Feb;17(1):41–6
Lacunar stroke in a hypertensive football player: implications in managing hypertension in athletes. Mann SJ, et al. **Clin J Sport Med** 1997 Jan;7(1):69–72 (27 ref.)
Proteinuria in mild to moderate hypertension: results of the VA cooperative study of six antihypertensive agents and placebo. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Preston RA, et al. **Clin Nephrol** 1997 May;47(5):310–5
Pregnancy in the chronically hypertensive patient. Neerhof MG. **Clin Perinatol** 1997 Jun;24(2):391–406 (56 ref.)
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Corea L, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):341–6
Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes. De Cesaris R, et al. **Clin Pharmacol Ther** 1996 Oct; 60(4):472–8
Risk factors for antihypertensive medication refill failure by patients under Medicaid managed care. Bailey JE, et al. **Clin Ther** 1996 Nov–Dec;18(6):1252–62
Quality–of–life measures in the evaluation of antihypertensive drug therapy: reliability, validity, and quality–of–life domains. Gandhi SK, et al. **Clin Ther** 1996 Nov–Dec; 18(6):1276–95
The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Gavras HP, et al. **Clin Ther** 1996 Nov–Dec;18(6):1058–67; discussion 1057 (10 ref.)
The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real–World Efficacy (CARE) Investigators. Kaplan NM. **Clin Ther** 1996 Jul–Aug;18(4):658–70
Dorzolamide versus pilocarpine as adjunctive therapies to timolol: a comparison of patient preference and impact on daily life. Laibovitz R, et al. **Clin Ther** 1996 Sep–Oct; 18(5):821–32
Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Neutel J, et al. **Clin Ther** 1997 May–Jun;19(3):447–58; discussion 367–8
Effect of manidipine chloride on various aspects of endocrine function, including plasma levels of endothelin–1 and human atrial natriuretic peptide, in patients with essential hypertension. Nishikawa T, et al. **Clin Ther** 1996 Jul–Aug; 18(4):680–6
Usefulness of low–dose, once–daily quinapril as monotherapy for patients with hypertension. Olvera S, et al. **Clin Ther** 1996 Sep–Oct;18(5):864–73
The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Oparil S, et al. **Clin Ther** 1996 Sep–Oct;18(5):797–810
Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Oparil S, et al. **Clin Ther** 1996 Jul–Aug; 18(4):608–25
Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance. Shionoiri H, et al. **Clin Ther** 1997 May–Jun; 19(3):527–36
Efficacy and tolerability of doxazosin versus enalapril in the treatment of patients with mild–to–moderate hypertension. Tan KW, et al. **Clin Ther** 1997 May–Jun;19(3):459–70
Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Weir MR, et al. **Clin Ther** 1996 May–Jun;18(3):411–28
Contemporary practice patterns in the management of newly diagnosed hypertension. McAlister FA, et al. **CMAJ** 1997 Jul 1;157(1):23–30
Medical & surgical approaches to pulmonary hypertension. McLaughlin VV, et al. **Compr Ther** 1997 Sep;23(9):612–6 (21 ref.)
'Hypertension resistant to two–drug treatment' is a useful criterion to select patients for angiography: the 'Dutch Renal Artery Stenosis Intervention Cooperative' (DRASTIC) study. van Jaarsveld BC, et al. **Contrib Nephrol** 1996;119:54–8
Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Kusek JW, et al. **Control Clin Trials** 1996 Aug;17(4 Suppl):40S–46S
Participant satisfaction in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Kusek JW, et al. **Control Clin Trials** 1996 Aug;17(4 Suppl):47S–54S
Appointment attendance, pill counts, and achievement of goal blood pressure in the African American Study of Kidney Disease and Hypertension Pilot Study. Lee JY, et al. **Control Clin Trials** 1996 Aug;17(4 Suppl):34S–39S
Design and baseline characteristics of participants in the African American Study of Kidney Disease and

Hypertension (AASK) Pilot Study. Wright JT Jr, et al. **Control Clin Trials** 1996 Aug;17(4 Suppl):3S–16S

Management of hypertension in acute intracerebral hemorrhage. Adams RE, et al. **Crit Care Clin** 1997 Jan; 13(1):131–61 (184 ref.)

N-acetylcysteine improves indocyanine green extraction and oxygen transport during hepatic dysfunction. Devlin J, et al. **Crit Care Med** 1997 Feb;25(2):236–42

Treating hypertensive patients with intracranial pathology [letter; comment] Hirschl MM, et al. **Crit Care Med** 1996 Dec;24(12):2072–3; discussion 2073–4. Comment on: Crit Care Med 1996 Feb;24(2):311–22.

Treating hypertensive patients with intracranial pathology [letter; comment] Malbrain ML, et al. **Crit Care Med** 1996 Dec;24(12):2072; discussion 2073–4. Comment on: Crit Care Med 1996 Feb;24(2):311–22.

Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy. Poisson P, et al. **Curr Med Res Opin** 1996;13(8):445–56

n-3 fatty acids and human hypertension. Knapp HR. **Curr Opin Lipidol** 1996 Feb;7(1):30–3 (37 ref.)

Pre-eclampsia-eclampsia 1996: preventable? Have disputes on its treatment been resolved? Lindheimer MD. **Curr Opin Nephrol Hypertens** 1996 Sep;5(5):452–8 (46 ref.)

The explosion of morbidity and mortality trials in hypertension. Nwachuku CE, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):230–6 (44 ref.)

Treatment of renal failure and blood pressure. Silverman M, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):237–42 (55 ref.)

Systolic hypertension. Smith WM. **Curr Ther Endocrinol Metab** 1997;6:637–9 (9 ref.)

Pharmacotherapy for hypertension. Cowper TR, et al. **Dent Clin North Am** 1996 Jul;40(3):585–610 (83 ref.)

Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Nielsen FS, et al. **Diabetes** 1997 Jul; 46(7):1182–8

Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Rossing P, et al. **Diabetes** 1997 Mar; 46(3):481–7

Effect of nifedipine, captopril and prazosin on secretory function of pancreatic beta-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics. Jasik M, et al. **Diabetes Res Clin Pract** 1996 Jun;33(1):59–66

Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension. Suzuki S, et al. **Diabetes Res Clin Pract** 1996 Jun;33(1):43–51

Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control [published erratum appears in Diabetologia 1997 Mar;40(3):366] **Diabetologia** 1996 Dec;39(12):1554–61

Pharmacologic modulation of autonomic tone: implications for the diabetic patient [see comments] Aronson D. **Diabetologia** 1997 Apr;40(4):476–81 (62 ref.). Comment in: Diabetologia 1997 Apr;40(4):482–4.

Role of magnesium sulfate in seizure prevention in patients with eclampsia and pre-eclampsia. Anthony J, et al. **Drug Saf** 1996 Sep;15(3):188–99 (115 ref.)

Benefits and risks of torasemide in congestive heart failure and essential hypertension. Brater DC. **Drug Saf** 1996 Feb; 14(2):104–20 (77 ref.)

How important is 24-hour control of blood pressure? Morgan T, et al. **Drug Saf** 1996 Oct;15(4):243–8 (20 ref.)

Moxonidine for hypertension. **Drug Ther Bull** 1997 May; 35(5):33–6 (16 ref.)

Novel drugs and current therapeutic approaches in the treatment of heart failure. Bonarjee VV, et al. **Drugs** 1996 Mar;51(3):347–58 (122 ref.)

Current drug treatment and treatment patterns with antihypertensive drugs. Freis ED, et al. **Drugs** 1996 Jul; 52(1):1–16 (136 ref.)

The implications of noncompliance with antihypertensive medication. Girvin B, et al. **Drugs** 1996 Aug;52(2):186–95 (72 ref.)

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Goa KL, et al. **Drugs** 1996 May;51(5):820–45 (138 ref.)

The therapeutic potential of neuropeptide Y. Analgesic, anxiolytic and antihypertensive. Munglani R, et al. **Drugs** 1996 Sep;52(3):371–89 (213 ref.)

Management of isolated systolic hypertension. Tonkin A, et al. **Drugs** 1996 May;51(5):738–49 (47 ref.)

Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Wagstaff AJ, et al. **Drugs** 1996 May;51(5):777–91 (75 ref.)

Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Burrell LM, et al. **Drugs Aging** 1997 Jun;10(6):421–34 (65 ref.)

Drug selection for optimal treatment of hypertension in the elderly. Shammas E, et al. **Drugs Aging** 1997 Jul;11(1):19–26 (43 ref.)

Is cigarette smoking an effect modifier of the relation between antihypertensive therapy and blood lipids? Derby CA, et al. **Epidemiology** 1997 Jan;8(1):48–54

Oral therapy with combined enalapril, prazosin and hydrochlorothiazide in the acute treatment of severe hypertension in Nigerians. Ajayi AA, et al. **Eur J Clin Pharmacol** 1996;51(1):45–8

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Hegner G, et al. **Eur J Clin Pharmacol** 1997;52(3):173–7

Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Himmelmann A, et al. **Eur J Clin Pharmacol** 1996;51(3–4):259–64

Metabolic effects of carvedilol in hypertensive patients. Lithell H, et al. **Eur J Clin Pharmacol** 1997;52(1):13–7

Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Persson B, et al. **Eur J Clin Pharmacol** 1996;50(4):259–64

Fixed combination of carteolol and pilocarpine eye-drops: a double-blind randomized cross-over trial versus carteolol alone on intra-ocular pressure. The Study Group. Hostyn P, et al. **Eur J Ophthalmol** 1996 Jan-Mar;6(1):17–20

Effects on salivary flow rate and composition of withdrawal of and re-exposure to the beta 1-selective antagonist metoprolol in a hypertensive patient population. Nederfors T, et al. **Eur J Oral Sci** 1996 Jun;104(3):262–8

New drugs and clinical trials in diabetes and hypertension. Nilsson P. **Exp Clin Endocrinol Diabetes** 1997;105 Suppl 2:64–9 (68 ref.)

Selections from current literature: mild hypertension. Robbins AC. **Fam Pract** 1997 Feb;14(1):73–7

Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. **Fundam Clin Pharmacol** 1997;11(2):138–42

Which drug for which orthostatic hypotension? Senard JM, et al. **Fundam Clin Pharmacol** 1996;10(3):225–33 (112 ref.)

Further evidence in favor of pharmacological portal pressure reduction in the prevention of variceal hemorrhage. García-Tsao G. **Gastroenterology** 1997 May;112(5):1770–1

Terlipressin or somatostatin for acute variceal hemorrhage [letter; comment] Walker S, et al. **Gastroenterology** 1997 May;112(5):1777. Comment on: Gastroenterology 1996 Nov;111(5):1291–9.

Antihypertensive therapy and arterial function in experimental hypertension. Kähönen M, et al. **Gen Pharmacol** 1996 Mar;27(2):221–38 (263 ref.)

Deterioration in renal function with enalapril but not losartan in a patient with renal artery stenosis in a solitary kidney [letter] Missouris CG, et al. **Heart** 1997 Apr;77(4):391–2

Nicardipine as antihypertensive therapy in liver transplant recipients: results of long-term use. Duvoux C, et al. **Hepatology** 1997 Feb;25(2):430–3

Antihypertensive treatment in insulin resistant patients. Lithell HO, et al. **Hypertens Res** 1996 Jun;19 Suppl 1:S75–9 (30 ref.)

Left ventricular hypertrophy and QT dispersion in hypertension. Mayet J, et al. **Hypertension** 1996 Nov; 28(5):791–6

Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Reisin E, et al. **Hypertension** 1997 Jul;30(1 Pt 1):140–5

Erythrocyte sodium-lithium countertransport in non-modulating offspring and essential hypertensive individuals: response to enalapril. Sánchez RA, et al. **Hypertension** 1997 Jul;30(1 Pt 1):99–105

The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Schunkert H, et al. **Hypertension** 1997 Feb;29(2):628–33

Lisinopril reverses left ventricular hypertrophy through improved aortic compliance. Shimamoto H, et al. **Hypertension** 1996 Sep;28(3):457–63

Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries. Thürmann PA, et al. **Hypertension** 1996 Sep;28(3):450–6

Study on the effectiveness of enalapril as a monotherapy in mild to moderate hypertension. Poulose M, et al. **Indian J Med Sci** 1996 Jan;50(1):1–3

Effects of magnesium on blood pressure and intracellular ion levels of Brazilian hypertensive patients. Sanjuliani AF, et al. **Int J Cardiol** 1996 Oct 11;56(2):177–83

Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol. Cleophas TJ, et al. **Int J Clin Pharmacol Ther** 1996 Jul;34(7):312–7

Metabolic effects of spirapril and atenolol: results from a randomized, long-term study. Hakamäki T, et al. **Int J Clin Pharmacol Ther** 1997 Jun;35(6):227–30

Once-daily fixed dose combinations of verapamil and trandolapril in black patients with mild to moderate hypertension: a new choice for first line treatment. Skoularigis J, et al. **Int J Clin Pharmacol Ther** 1997 Feb; 35(2):51–5

Comparison of captopril-thiazide and enalapril-thiazide combinations in the management of mild to moderate black hypertensive patients: how important is diuretic dose and duration of action of the ACE-inhibitor? Skoularigis J, et al. **Int J Clin Pharmacol Ther** 1996 Jun;34(6):263–8

High blood pressure in women. Calhoun DA, et al. **Int J Fertil Womens Med** 1997 May-Jun;42(3):198–205

Aerosolized prostacyclin and inhaled nitric oxide in septic shock--different effects on splanchnic oxygenation? Eichelbrönner O, et al. **Intensive Care Med** 1996 Sep; 22(9):880–7

Intravenous nicardipine does not alter hepatic blood flow after orthotopic liver transplant. Raucoules-Aimé M, et al. **Intensive Care Med** 1996 May;22(5):420–5

The diagnosis of renovascular hypertension with technetium-99m-ethylenedicysteine captopril scintigraphy. Ugur O, et al. **Invest Radiol** 1996 Aug;31(8):497–501

Treatment of systemic hypertension in cats with amlodipine besylate. Henik RA, et al. **J Am Anim Hosp Assoc** 1997 May-Jun;33(3):226–34

Baseline correlates with quality of life among men and women with medication-controlled hypertension. The trial of nonpharmacologic interventions in the elderly (TONE). Anderson RT, et al. **J Am Geriatr Soc** 1997 Sep; 45(9):1080–5

Antihypertensive medication use among recruits for the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Espeland MA, et al. **J Am Geriatr Soc** 1996 Oct; 44(10):1183–9

Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study. **J Am Soc Nephrol** 1996 Apr;7(4):556–66

Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. **J Am Soc Nephrol** 1996 Oct;7(10):2097–109

Angiotensin II and calcium blockers prevent glomerular phenotypic changes in remnant kidney model. Hamaguchi A, et al. **J Am Soc Nephrol** 1996 May;7(5):687–93

Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine. Törnig J, et al. **J Am Soc Nephrol** 1996 May;7(5):667–75

Nifedipine, captopril, metoprolol and nifedipine with metoprolol in hypertensive crisis in non-intensive care setting. Karnik ND, et al. **J Assoc Physicians India** 1996 Jul;44(7):480–2

Hypotensive mechanisms of captopril--a counter-view [letter] Lazar AI. **J Assoc Physicians India** 1996 Oct; 44(10):753

Evaluation of amlodipine in mild to moderate hypertension--a clinical report. Yajnik VH, et al. **J Assoc Physicians India** 1995 Jan;43(1):34–5

Antihypertensive treatment and heart rate variability in diabetic patients: role of cardiac autonomic neuropathy. Salo TM, et al. **J Auton Nerv Syst** 1996 Aug 27; 60(1-2):61–70

Drug therapy for hypertension and hyperlipidemia. Hutchins LN. **J Cardiovasc Nurs** 1995 Jan;9(2):37–53 (4 ref.)

Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension. Böhlen L, et al. **J Cardiovasc Pharmacol** 1996 Jun;27(6):770–6

Fixed combination of benazepril and low-dose amlodipine in the treatment of mild to moderate essential hypertension: evaluation by 24-hour noninvasive ambulatory blood pressure monitoring. Fogari R, et al. **J Cardiovasc Pharmacol** 1997 Aug;30(2):176–81

Fosinopril versus enalapril in the treatment of hypertension: a double-blind study in 195 patients. Hansson L, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):1–5

Pharmacological studies on a new antihypertensive agent, S-2150, a benzothiazepine derivative: 2. Hypotensive effects in normotensive and hypertensive rats. Kawakami M, et al. **J Cardiovasc Pharmacol** 1996 Nov;28(5):695–702

Physical performance is preserved after regression of left ventricular hypertrophy. Lacourcière Y, et al. **J Cardiovasc Pharmacol** 1997 Sep;30(3):383–91

Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomized double-blind study. Lau CP, et al. **J Cardiovasc Pharmacol** 1996 Aug;28(2):328–31

Antihypertensive therapy and renal function. Mimran A. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S19–25 (47 ref.)

Indapamide is as effective as captopril in the control of microalbuminuria in diabetes. Molyneaux LM, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):424–7

Effective antihypertensive therapy: blood pressure control with moxonidine. Prichard BN, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 3:S38–48 (40 ref.)

Additive hypotensive effect of a dihydropyridine calcium antagonist to that produced by a thiazide diuretic: a double-blind placebo-controlled crossover trial with ambulatory blood pressure monitoring. Stergiou GS, et al. **J Cardiovasc Pharmacol** 1997 Mar;29(3):412–6

Assessment of antihypertensive effect by blood pressure monitoring: applications to bisoprolol and lisinopril in a double-blind study. Vaïsse B, et al. **J Cardiovasc Pharmacol** 1997 May;29(5):612–7

Effects of antihypertensive drugs on the circadian blood pressure profile. Voogel AJ, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):463–9

Autoregulation of total and zonal glomerular filtration rate in spontaneously hypertensive rats during antihypertensive therapy. Wang X, et al. **J Cardiovasc Pharmacol** 1996 Dec; 28(6):833–41

A possible clonidine-trazodone-dextroamphetamine interaction in a 12-year-old boy. Bhatara VS, et al. **J Child Adolesc Psychopharmacol** 1996 Fall;6(3):203–9

Health status and hypertension: a population-based study. Lawrence WF, et al. **J Clin Epidemiol** 1996 Nov; 49(11):1239–45

Losartan: first of a new class of angiotensin antagonists for the management of hypertension. Carr AA, et al.

J Clin Pharmacol 1996 Jan;36(1):3–12 (34 ref.)

Perindopril/hydrochlorothiazide dose combinations for the treatment of hypertension: a multicenter study. Chrysant SG. **J Clin Pharmacol** 1997 Jan;37(1):47–52

Use of beta-adrenergic receptor blockers in blacks. Prisant LM, et al. **J Clin Pharmacol** 1996 Oct;36(10):867–73 (34 ref.)

Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy. Bretzel RG. **J Diabetes Complications** 1997 Mar–Apr;11(2):112–22 (127 ref.)

Hyperglycemia counterbalances the antihypertensive effect of glutathione in diabetic patients: evidence linking hypertension and glycemia through the oxidative stress in diabetes mellitus. Cerielo A, et al. **J Diabetes Complications** 1997 Jul–Aug;11(4):250–5

When to treat the hypertensive diabetic patient. Fuller JH. **J Diabetes Complications** 1996 May–Jun;10(3):144–5 (13 ref.)

Hypertension as a risk factor in non-insulin-dependent diabetes mellitus: how far should blood pressure be reduced? Hasslacher C. **J Diabetes Complications** 1997 Mar–Apr;11(2):90–1 (11 ref.)

Renal mortality associated with non-insulin-dependent diabetes mellitus. Kilaru P, et al. **J Diabetes Complications** 1997 Mar–Apr;11(2):104–11 (78 ref.)

Managing the diabetic hypertensive patient. Poulter NR. **J Diabetes Complications** 1996 May–Jun;10(3):141–3 (16 ref.)

Development of ischemic stroke in normotensive and hypertensive diabetic patients with or without antihypertensive treatment: an 8-year followup study. Yoshinari M, et al. **J Diabetes Complications** 1997 Jan–Feb; 11(1):9–14

Vascular events during antihypertensive treatment. Madren EM. **J Fam Pract** 1996 Dec;43(6):534

Safety and efficacy of first-line antihypertensives. Strickland C. **J Fam Pract** 1997 Jun;44(6):530–1

Ambulatory blood pressure monitoring for evaluation of long-acting beta-blockers in Taiwan. Tseng CD, et al. **J Formos Med Assoc** 1996 Apr;95(4):320–4

Haemodynamic effects of chronic tetrandrine treatment in portal hypertensive rats. Huang YT, et al. **J Gastroenterol Hepatol** 1997 Aug;12(8):585–9

Correlates of controlled hypertension in indigent, inner-city hypertensive patients. Ahluwalia JS, et al. **J Gen Intern Med** 1997 Jan;12(1):7–14

The J-curve interpreted. An alternative explanation of the results [editorial; comment] Sekeres MA, et al. **J Gen Intern Med** 1996 Jun;11(6):379–80. Comment on: J Gen Intern Med 1996 Jun;11(6):350–6.

Diastolic blood pressure and the risk of primary cardiac arrest among pharmacologically treated hypertensive patients [see comments] Siscovick DS, et al. **J Gen Intern Med** 1996 Jun;11(6):350–6. Comment in: J Gen Intern Med 1996 Jun;11(6):379–80.

Time profile of the haemodynamic effects of terlipressin in portal hypertension. Escorsell A, et al. **J Hepatol** 1997 Mar; 26(3):621–7

Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. Gadano A, et al. **J Hepatol** 1997 Jun; 26(6):1229–34

Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. Oberti F, et al. **J Hepatol** 1997 Jan;26(1):167–73

Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. Agrawal B, et al. **J Hum Hypertens** 1996 Aug;10(8):551–5

Correlation between peripheral hemodynamic changes and left ventricular diastolic function in hypertensive patients treated with urapidil. Arosio E, et al. **J Hum Hypertens** 1996 Mar;10(3):171–6

Impact of antihypertensive therapy on progression of experimental renal disease. Dworkin LD. **J Hum Hypertens** 1996 Oct;10(10):663–8 (20 ref.)

Antihypertensive therapy and orthostatic responses in elderly hospital in-patients. Fotherby MD, et al. **J Hum Hypertens** 1997 May;11(5):291–4

Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. Himmelmann A, et al. **J Hum Hypertens** 1996 Nov; 10(11):729–34

Efficacy of different antihypertensive drugs in the emergency department. Hirschl MM, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S143–6

Hemodynamic and 24-h blood pressure profile of amlodipine monotherapy. Ibrahim MM, et al. **J Hum Hypertens** 1996 Jul;10(7):489–94

Adherence to and population impact of non-pharmacological and pharmacological antihypertensive therapy. Karppanen H, et al. **J Hum Hypertens** 1996 Feb;10 Suppl 1:S57–61

Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? Marques-Vidal P, et al. **J Hum Hypertens** 1997 Apr;11(4):213–20 (78 ref.)

Effects of combination therapy on the heart. Messerli FH, et al. **J Hum Hypertens** 1997 Jan;11(1):29–33 (39 ref.)

High-altitude pulmonary hypertension: effects of captopril on pulmonary and systemic arterial pressures. Niazova ZA, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S141–2

Commentary: calcium antagonist controversy, does the accusing finger also point to beta-blockers and methyldopa? Opie LH. **J Hum Hypertens** 1997 Apr; 11(4):201–4 (21 ref.)

Obesity-related hypertension: its physiological basis and pharmacological approaches to its treatment. Richards RJ, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S59–64 (60 ref.)

Prescribing pattern of antihypertensive drugs in the community. Rotmensch HH, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S169–72

Appropriate choice of antihypertensive therapy. Velasco M, et al. **J Hum Hypertens** 1996 Feb;10 Suppl 1:S77–80 (11 ref.)

Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study. Yodfat Y, et al. **J Hum Hypertens** 1996 Feb; 10(2):117–22

Assessment of drug efficacy using home self-blood pressure measurement: the SMART study. Self Measurement for the Assessment of the Response to Trandolapril. Zannad F, et al. **J Hum Hypertens** 1996 Jun;10(6):341–7

Blood pressure effects of antihypertensive drugs and changes in lifestyle in a Brazilian hypertensive cohort. Fuchs FD, et al. **J Hypertens** 1997 Jul;15(7):783–92

Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event. Gustafsson F, et al. **J Hypertens** 1997 Jul;15(7):793–8

Does drug treatment improve survival in mild-to-moderate hypertension? [letter] Hansson L. **J Hypertens** 1995 Nov; 13(11):1354–5

Meta-analysis and the Hippocratic principle of primum non nocere--authors' reply [letter] Hoes AW, et al. **J Hypertens** 1995 Nov;13(11):1353–4

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. Holwerda NJ, et al. **J Hypertens** 1996 Sep;14(9):1147–51

Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. Klungel OH, et al. **J Hypertens** 1997 Jun;15(6):591–600 (77 ref.)

Effect of antihypertensive treatment and N omega-nitro-L-arginine methyl ester on cardiovascular structure in deoxycorticosterone acetate-salt hypertensive rats. Li JS, et al. **J Hypertens** 1996 Nov;14(11):1331–9

Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension [see comments] Luque M, et al. **J Hypertens** 1996 Jun; 14(6):799–805. Comment in: J Hypertens 1996 Nov;14(11):1380–1.

Guidelines for antihypertensive therapy [see comments] MacMahon S. **J Hypertens** 1996 Jun;14(6):691–3. Comment in: J Hypertens 1997 Jan;15(1):1–2.

The Bergen blood pressure study: offspring of two hypertensive parents have significantly higher blood pressures than offspring of one hypertensive and one normotensive parent. Mo R, et al. **J Hypertens** 1995 Dec; 13(12 Pt 2):1614–7

Difference between office and ambulatory blood pressure and response to antihypertensive treatment. Parati G, et al. **J Hypertens** 1996 Jun;14(6):791–7

Structural changes of small resistance arteries in spontaneously hypertensive rats after treatment with various doses of lacidipine. Porteri E, et al. **J Hypertens** 1997 Jun;15(6):619–25

Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension [letter; comment] Reneland R, et al. **J Hypertens** 1996 Nov; 14(11):1380–1. Comment on: J Hypertens 1996 Jun;14(6):799–805.

Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. Rodrigo E, et al. **J Hypertens** 1997 Jun; 15(6):613–8

Blood pressure and renal function: therapeutic implications [editorial] Ruilope LM, et al. **J Hypertens** 1996 Nov; 14(11):1259–63 (54 ref.)

Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk, reply to comments [editorial; comment] Simpson FO. **J Hypertens** 1997 Jan;15(1):1–2. Comment on: J Hypertens 1996 Jun;14(6):691–3. Comment on: J Hypertens 1996 Jul;14(7):809–11. Comment on: J Hypertens 1996 Jul;14(7):813–4.

Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. Simpson FO. **J Hypertens** 1996 Jun;14(6):683–9 (44 ref.)

Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach [editorial] [see comments] Zanchetti A, et al. **J Hypertens** 1996 Jul;14(7):809–11. Comment in: J Hypertens 1997 Jan;15(1):1–2.

Antihypertensive therapy: pride and prejudice. Zanchetti A. **J Hypertens** 1995 Dec;13(12 Pt 2):1522–8 (47 ref.)

Intervention trials in hypertension, present and future. Workshop proceedings. Rome, Italy, 12–13 April 1996. **J Hypertens Suppl** 1996 Sep;14(2):S1–141

Modern combination therapy: the way forward in the management of hypertensive patients. Proceedings of an international symposium. Barcelona, Spain, 1–2 November 1996. **J Hypertens Suppl** 1997 Mar;15(2):S1–125

From vascular protection to secondary prevention in cardiovascular diseases. Proceedings of satellite symposium to the 16th Scientific Meeting of the International Society of Hypertension. Glasgow, United Kingdom, 23 June 1996. **J Hypertens Suppl** 1996 Dec;14(6):S1–53

Can we further slow down the progression to end-stage renal disease in diabetic hypertensive patients? Bretzel RG. **J Hypertens Suppl** 1997 Mar;15(2):S83–8 (74 ref.)

Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials [published erratum appears in J Hypertens 1997 Jan;15(1):103] Devereux RB, et al. **J Hypertens Suppl** 1996 Sep;14(2):S95–101; discussion S101–2 (50 ref.)

Angiotensin converting enzyme inhibitor-calcium antagonist combination: an alliance for cardioprotection? Ferrari R. **J Hypertens Suppl** 1997 Mar;15(2):S109–17 (87 ref.)

Chinese contribution to trials on antihypertensive therapy. Hamet P, et al. **J Hypertens Suppl** 1996 Sep;14(2):S123–7 (38 ref.)

The optimal blood pressure reduction. Hansson L. **J Hypertens Suppl** 1996 Sep;14(2):S55–8; discussion S58–9 (22 ref.)

Success in the treatment of hypertension: a status report. Hansson L. **J Hypertens Suppl** 1997 Mar;15(2):S11–5 (36 ref.)

Hypertension in the elderly. Hansson L. **J Hypertens Suppl** 1996 Oct;14(3):S17–21 (31 ref.)

Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond. Kirchengast M. **J Hypertens Suppl** 1997 Mar; 15(2):S27–33 (41 ref.)

Assessment of antihypertensive treatment by ambulatory blood pressure. Mancia G, et al. **J Hypertens Suppl** 1997 Mar;15(2):S43–50 (26 ref.)

Blood pressure variability, cardiovascular risk and antihypertensive treatment. Parati G, et al. **J Hypertens Suppl** 1995 Dec;13(4):S27–34 (30 ref.)

The use of moxonidine in the treatment of hypertension. Prichard BN, et al. **J Hypertens Suppl** 1997 Jan; 15(1):S47–55 (50 ref.)

Risk factors and drugs in the treatment of hypertension. Robertson JI. **J Hypertens Suppl** 1997 Jan;15(1):S43–6 (38 ref.)

The hypertension trials. Sever PS, et al. **J Hypertens Suppl** 1996 Sep;14(2):S29–33; discussion S33–4 (30 ref.)

Clinical trials: what more is needed? A critical view. Swales JD. **J Hypertens Suppl** 1996 Sep;14(2):S83–6; discussion S86–7 (25 ref.)

Requirements for antihypertensive therapy in diabetic patients: metabolic aspects. Teuscher AU, et al. **J Hypertens Suppl** 1997 Mar;15(2):S67–75 (98 ref.)

Clinical pharmacology of calcium antagonists as antihypertensive and anti-anginal drugs. van Zwieten PA. **J Hypertens Suppl** 1996 Oct;14(3):S3–9 (46 ref.)

Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). Zanchetti A. **J Hypertens Suppl** 1995 Dec;13(4):S35–9 (28 ref.)

Trials investigating the anti-atherosclerotic effects of antihypertensive drugs. Zanchetti A. **J Hypertens Suppl** 1996 Sep;14(2):S77–80; discussion S80–1 (14 ref.)

1995 survey on the management of hypertension in Belgium. The Board of the Belgian Hypertension Committee [letter; comment] Carlier J, et al. **J Intern Med** 1997 Jan; 241(1):90–1. Comment on: J Intern Med 1995 May;237(5):473–8. Comment on: J Intern Med 1995 Sep;238(3):215–21.

Relationship between sodium-lithium countertransport and insulin sensitivity in mild hypertension. Herlitz H, et al. **J Intern Med** 1996 Mar;239(3):235–40

Guidelines and reported practice for the treatment of hypertension and hypercholesterolaemia. Troein M, et al. **J Intern Med** 1997 Aug;242(2):173–8

Chronic hypertension in pregnancy. Frangieh AY, et al. **J Med Liban** 1996;44(2):68–74 (50 ref.)

The application of meta-analysis in assessing racial differences in the effects of antihypertensive medication. Messeri P, et al. **J Natl Med Assoc** 1997 Jul;89(7):477–85

A new antihypertensive strategy for black patients: low-dose multimechanism therapy. Saunders E, et al. **J Natl Med Assoc** 1996 Mar;88(3):171–5

Randomised controlled trial of methyldopa and isradipine in preeclampsia--effects on uteroplacental and fetal hemodynamics. Montan S, et al. **J Perinat Med** 1996; 24(2):177–84

Pharmacokinetics and pharmacodynamics of a sustained-release biodegradable pellet containing imidapril, a new angiotensin-converting enzyme inhibitor in spontaneously hypertensive rats. Yamanaka K, et al. **J Pharm Biomed Anal** 1997 Aug;15(12):1861–6

Antihypertensive effect of some oxazolo[3,2-a]pyridines, thiazolo[3,2-a]pyridines and pyrido[2,1-b]oxazines in conscious spontaneously hypertensive rats. Moran A, et al. **J Pharm Pharmacol** 1997 Apr;49(4):421–5

Treatment of the hyperventilation syndrome with bisoprolol: a placebo-controlled clinical trial. Van De Ven LL, et al. **J Psychosom Res** 1995 Nov;39(8):1007–13

Doxazosin for benign prostatic hyperplasia: long-term

efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. Lepor H, et al. **J Urol** 1997 Feb;157(2):525–30

Nifedipine for hypertensive emergencies [letter; comment] Bloomfield RL, et al. **JAMA** 1997 Mar 12;277(10):788; discussion 790–1. Comment on: JAMA 1996 Oct 23–30;276(16):1328–31.

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group [published erratum appears in JAMA 1997 May 7;277(17):1356] [see comments] Curb JD, et al. **JAMA** 1996 Dec 18; 276(23):1886–92. Comment in: ACP J Club 1997 May–Jun;126(3):57.

Nifedipine for hypertensive emergencies [letter; comment] DiMichele JM. **JAMA** 1997 Mar 12;277(10):787; discussion 790–1. Comment on: JAMA 1996 Oct 23–30;276(16):1328–31.

Reversal of left ventricular hypertrophy [letter; comment] Fagard R. **JAMA** 1996 Nov 27;276(20):1636–7. Comment on: JAMA 1996 May 15;275(19):1507–13.

Nifedipine for hypertensive emergencies [letter; comment] Fanning GL. **JAMA** 1997 Mar 12;277(10):789–90; discussion 790–1. Comment on: JAMA 1996 Oct 23–30;276(16):1328–31.

Nifedipine for hypertensive emergencies [letter; comment] Fenichel RR. **JAMA** 1997 Mar 12;277(10):790; discussion 790–1. Comment on: JAMA 1996 Oct 23–30;276(16):1328–31.

Nifedipine for hypertensive emergencies [letter; comment] Kelly PJ. **JAMA** 1997 Mar 12;277(10):788–9; discussion 790–1. Comment on: JAMA 1996 Oct 23–30;276(16):1328–31.

Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. Kostis JB, et al. **JAMA** 1997 Jul 16;278(3):212–6

Nifedipine for hypertensive emergencies [letter; comment] Meggs WJ. **JAMA** 1997 Mar 12;277(10):787; discussion 790–1. Comment on: JAMA 1996 Oct 23–30;276(16):1328–31.

Primary prevention of cardiovascular disease endpoints using beta-blockers [letter; comment] Michalewiz L, et al. **JAMA** 1997 Jun 11;277(22):1759–60. Comment on: JAMA 1997 Mar 5;277(9):739–45.

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis [see comments] Psaty BM, et al. **JAMA** 1997 Mar 5;277(9):739–45. Comment in: JAMA 1997 Jun 11;277(22):1759–60. Comment in: ACP J Club 1997 Sep–Oct;127(2):36.

Nifedipine for hypertensive emergencies [letter; comment] Semplicini A, et al. **JAMA** 1997 Mar 12;277(10):787–8; discussion 790–1. Comment on: JAMA 1996 Oct 23–30;276(16):1328–31. Comment on: JAMA 1996 Oct 23–30;276(16):1342–3.

Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators [see comments] Staessen JA, et al. **JAMA** 1997 Oct 1; 278(13):1065–72. Comment in: JAMA 1997 Oct 1;278(13):1110.

Nifedipine for hypertensive emergencies [letter; comment] Thomas SR. **JAMA** 1997 Mar 12;277(10):788; discussion 790–1. Comment on: JAMA 1996 Oct 23–30;276(16):1328–31.

A case report of angioedema during long-term (66 months) angiotensin converting enzyme inhibition therapy with enalapril. Shionoiri H, et al. **Jpn Circ J** 1996 Mar; 60(3):166–70

Antihypertensive therapy in patients with diabetic nephropathy. Mehler PS, et al. **Kidney Blood Press Res** 1997;20(2):74–81 (104 ref.)

Enalapril and pressure-diuresis in hypertensive rats transgenic for mouse renin gene. Springate J, et al. **Kidney Blood Press Res** 1997;20(1):1–5

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Bakris GL, et al. **Kidney Int** 1996 Nov; 50(5):1641–50

Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Parving HH, et al. **Kidney Int** 1996 Jun;49(6):1778–82

Losartan protects the rat kidney from ischemic injury. Heller J, et al. **Kidney Int Suppl** 1996 Jun;55:S113–4

The role of arterial hypertension in progression of renal failure. Kes P, et al. **Kidney Int Suppl** 1996 Jun;55:S72–4

Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. Omata K, et al. **Kidney Int Suppl** 1996 Jun;55:S57–62

Antihypertensive agents and renal protection: calcium channel blockers. Saruta T, et al. **Kidney Int Suppl** 1996 Jun;55:S52–6

TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats. Shibouta Y, et al. **Kidney Int Suppl** 1996 Jun;55:S115–8

Antihypertensive activity and renal effects of benazepril in humans. Tramonti G, et al. **Kidney Int Suppl** 1996 Jun; 55:S107–8

Renal effects of prolonged antihypertensive treatment with diltiazem. Tramonti G, et al. **Kidney Int Suppl** 1996 Jun; 55:S78–80

Blood pressure and blood glucose levels during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients. Ahaneku JE. **Kobe J Med Sci** 1996 Feb;42(1):19–29

Changes of vasoactive peptides and effects of inhaled nitric oxide after pneumonectomy. Ohtsuka S. **Kurume Med J** 1996;43(4):295–304

Failure of losartan to control blood pressure in scleroderma renal crisis [letter] [see comments] Caskey FJ, et al. **Lancet** 1997 Mar 1;349(9052):620. Comment in: Lancet 1997 Apr 26;349(9060):1255.

Angiotensin receptor antagonists [letter; comment] Goldsmith DJ. **Lancet** 1997 Apr 26;349(9060):1255. Comment on: Lancet 1997 Mar 1;349(9052):620.

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Staessen JA, et al. **Lancet** 1997 Sep 13;350(9080):757–64

Valsartan for hypertension. **Med Lett Drugs Ther** 1997 Apr 25;39(999):43–4

Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension. Haenni A, et al. **Metabolism** 1996 Oct;45(10):1221–9

Effects of perindopril treatment on plasma and urine of kallikrein activity and the stable metabolite of prostaglandin E2 in patients with essential hypertension. Zacharieva S, et al. **Methods Find Exp Clin Pharmacol** 1996 Apr; 18(3):205–9

Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night? Buter H, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:53–6

The long-term tolerability of enalapril in hypertensive patients with renal impairment. Keane WF, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:75–81

Successful long-term treatment of post-transplant erythrocytosis with losartan. Midtvedt K, et al. **Nephrol Dial Transplant** 1996 Dec;11(12):2495–7

Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nielsen S, et al. **Nephrol Dial Transplant** 1997;12 Suppl 2:19–23

Antihypertensive treatment in nephropathy of type II diabetes: role of the pharmacological blockade of the renin–angiotensin system [editorial] Rodby RA. **Nephrol Dial Transplant** 1997 Jun;12(6):1095–6

Volume sensitivity of blood pressure in end-stage renal disease. Ventura JE, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):485–91

Anti-atherosclerotic properties of antihypertensive drugs: effect of antihypertensive therapy on platelet receptors for von Willebrand factor and for fibrinogen [letter] Liani M, et al. **Nephron** 1996;73(2):361–2

Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes. Tang Z, et al. **Nephron** 1997;76(3):323–30

Reproducibility and validity of quality of life measurements in hypertensive patients on stable medication. Krijnen P, et al. **Neth J Med** 1997 Apr;50(4):137–52

Changes in cerebral blood flow accompanied with reduction of blood pressure treatment in patients with hypertensive intracerebral hemorrhages. Kuroda K, et al. **Neurol Res** 1997 Apr;19(2):169–73

Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Urbistondo M, et al. **P R Health Sci J** 1996 Sep;15(3):195–9

Nicardipine to control mean arterial pressure during extracorporeal membrane oxygenation. Tobias JD, et al. **Paediatr Anaesth** 1996;6(1):57–60

Hypertensive crisis in children. Groshong T. **Pediatr Ann** 1996 Jul;25(7):368–71, 375–6

Potassium channel activation: a potential therapeutic approach? Lawson K. **Pharmacol Ther** 1996;70(1):39–63 (301 ref.)

Effects of perindopril and hydrochlorothiazide on the long-term progression of lithium-induced chronic renal failure in rats. Christensen S, et al. **Pharmacol Toxicol** 1997 Mar;80(3):132–41

A new class of antihypertensive therapy: angiotensin II receptor antagonists. Ellis ML, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):849–60 (55 ref.)

Pharmacists' ability to influence outcomes of hypertension therapy. Erickson SR, et al. **Pharmacotherapy** 1997 Jan–Feb;17(1):140–7

A pharmacokinetic study to determine the drug interaction between valproate and propranolol. Nemire RE, et al. **Pharmacotherapy** 1996 Nov–Dec;16(6):1059–62

Options in antihypertensive drug therapy. Help in choosing from among the many agents. Barron HV, et al. **Postgrad Med** 1996 Oct;100(4):89–94 (13 ref.)

Resistant hypertension. Suggestions for dealing with the problem. Gandhi S, et al. **Postgrad Med** 1996 Oct; 100(4):97–102, 107–8 (30 ref.)

Hypertension in women and the elderly. Some puzzling and some expected findings of treatment studies. Reynolds E, et al. **Postgrad Med** 1996 Oct;100(4):58–63, 67–70 (27 ref.)

Antihypertensive therapy and wave reflections. Safar ME, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Jan; 54(1):71–6 (27 ref.)

Letter to the editor. Bachen E. **Psychosom Med** 1996 Mar–Apr;58(2):192

Quality of life claims in trials of anti-hypertensive therapy. Hunt SM. **Qual Life Res** 1997 Mar;6(2):185–91 (49 ref.)

Hypertension and menopausal syndrome: effects of hormone replacement therapy and antihypertensive drugs. Amoroso A, et al. **Riv Eur Sci Med Farmacol** 1996 Jul–Aug; 18(4):149–52

Role of ketanserin in the treatment of the essential arterial hypertension associated with ischemic heart disease. Podoleanu D, et al. **Rom J Intern Med** 1996 Jan–Jun; 34(1–2):49–54

New treatment approach for high blood pressure patients defined as cardioprotective by physicians. **S Afr Med J** 1997 Feb;87 Suppl 1:C60

Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Nielsen FS, et al. **Scand J Clin Lab Invest** 1997 Aug;57(5):427–34

Treatment of hypertension. Fogo A, et al. **Semin Nephrol** 1996 Nov;16(6):555–66 (114 ref.)

Angiotensin converting enzyme inhibitors in pregnancy. Mastrobattista JM. **Semin Perinatol** 1997 Apr;21(2):124–34 (46 ref.)

The effects of health and treatment perceptions on the use of prescribed medication and home remedies among African American and white American hypertensives. Brown CM, et al. **Soc Sci Med** 1996 Sep;43(6):903–17

Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange. Jolliet P, et al. **Thorax** 1997 Apr;52(4):369–72

Potentiation of the bronchoprotective effects of vasoactive intestinal peptide, isoprenaline, and theophylline against histamine challenge in anaesthetised guinea pigs by adrenomedullin. Kanazawa H, et al. **Thorax** 1996 Dec; 51(12):1199–202

Efficacy of enalapril in the treatment of erythrocytosis in patients with renal allografts. Carvalho MF, et al. **Transplant Proc** 1996 Dec;28(6):3377

Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Effect on structure and function. Benediktsson H, et al. **Transplantation** 1996 Dec 15; 62(11):1634–42

Isradipine for the prevention of cyclosporine-induced hpertension in allogeneic bone marrow transplant recipients: a randomized, double-blind study. Bursztyn M, et al. **Transplantation** 1997 Apr 15;63(7):1034–6

Scorpion envenoming and the cardiovascular system. Bawaskar HS, et al. **Trop Doct** 1997 Jan;27(1):6–9

Prazosin: scorpion envenoming and the cardiovascular system [editorial] Warrell DA. **Trop Doct** 1997 Jan;27(1):1

Blood pressure self-measurement in upper arm and in wrist for treatment control of arterial hypertension compared to ABPM. Eckert S, et al. **Z Kardiol** 1996;85 Suppl 3:109–11

[Image morphological quantitative analysis of pathological changes of intra-acinar arteries in experimental pulmonary artery hypertension and outcomes of treatment] Wang B, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Apr;18(2):147–52 (Eng. Abstr.) **(Chi)**

[Terlipressin acetate] Becker PU, et al. **Ugeskr Laeger** 1997 Sep 1;159(36):5399–402 **(Dan)**

[The significance of trandelapril for mortality after AMI in patients with reduced left ventricular function. TRACE Study Group] Køber L, et al. **Ugeskr Laeger** 1997 Mar 10;159(11):1616–22 (Eng. Abstr.) **(Dan)**

[Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril] Pedersen EB. **Ugeskr Laeger** 1996 Oct 7;158(41):5798–9 **(Dan)**

[The influence of antihypertensive treatment on progression of chronic nephropathy] Petersen LJ, et al. **Ugeskr Laeger** 1997 Jul 28;159(31):4745–51 (32 ref.) (Eng. Abstr.) **(Dan)**

[Efficacy and tolerability of trandolapril in overweight hypertensive patients] Maarek M, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jun;45(6):343–51 (Eng. Abstr.) **(Fre)**

[Effects of rilmenidine (hyperium) on lipid balance in hyperlipidemic hypertensive patients. Randomized, controlled, double-blind 8-week study vs. captopril in parallel groups] Scemama M, et al. **Ann Cardiol Angeiol (Paris)** 1996 Dec;45(10):595–601 (Eng. Abstr.) **(Fre)**

[Use of urapidil during surgery for pheochromocytoma] Steib A, et al. **Ann Fr Anesth Reanim** 1996;15(2):142–8 (Eng. Abstr.) **(Fre)**

[Course of ischemic risk in treated atheromatous hypertensive patients. The PRIHAM study (Prognosis of Ischemic Risk in Atheromatous Patients under Mediatensyl)] Godeau P, et al. **Ann Med Interne (Paris)** 1996;147(6):403–7 (Eng. Abstr.) **(Fre)**

[Treatment of hypertension with indapamide 1.5 mg sustained-release form: synthesis of results] Guez D, et al. **Arch Mal Coeur Vaiss** 1996 Sep;89 Spec No 4:17–25 (Eng. Abstr.) **(Fre)**

[Short and long-term clinical tolerance of hypertensive treatment during the HOT study (Hypertension Optimal Treatment)] Mallion JM, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89(8):1093–6 (Eng. Abstr.) **(Fre)**

[Prevalence, treatment and control of hypertension in family practice patients in France during 1994] Poggi L, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89(8):1075–80 (Eng.

Abstr.) (Fre)
[Preclinical study of the action of a calcium channel blocker during salt load] Godfraind T, et al.
Bull Acad Natl Med 1997 Feb;181(2):289–98; discussion 299–300 (Eng. Abstr.) (Fre)
[Severe preeclampsia: management. Is conservative treatment justified?] Merviel P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1997;26(3):238–49 (61 ref.) (Eng. Abstr.) (Fre)
[Therapeutic approach in malignant hypertension in developing countries] Frances Y. **Med Trop (Mars)** 1996; 56(3 Suppl):14–6 (0 ref.) (Fre)
[Treatment of arterial hypertension in diabetic nephropathy. Certainties and hypotheses] Castiglioni A, et al.
Presse Med 1996 Jul 6–13;25(24):1119–23 (40 ref.) (Eng. Abstr.) (Fre)
[Calcium channel blockers in pregnancy] Tchobroutsky C.
Presse Med 1996 Sep 28;25(28):1297–300 (28 ref.) (Eng. Abstr.) (Fre)
[Angiotensin II antagonists: a distinct therapeutic class (editorial)] Waeber B, et al. **Presse Med** 1996 Oct 26; 25(32):1533–5 (Eng. Abstr.) (Fre)
[Comparative effects of captopril and atenolol on lipid metabolism in hypertensive hypercholesterolemic patients treated with pravastatin. A multicenter controlled trial] Witchitz S, et al. **Presse Med** 1996 Dec 21;25(40):2013–6 (Eng. Abstr.) (Fre)
[Arterial hypertension and cardiac decompensation] Degaute JP. **Rev Med Brux** 1996 Sep;17(4):272–4 (Eng. Abstr.) (Fre)
[The value of renal angioscintigraphy with captopril administration in renovascular hypertension] Barreto dos Santos A, et al. **Rev Med Liege** 1996 Oct;51(10):627–31 (Fre)
[How I treat... refractory hypertension] Krzesinski JM.
Rev Med Liege 1997;52(1):2–6 (23 ref.) (Fre)
[Drug of the month. Maxsoten] Kulbertus H.
Rev Med Liege 1996 May;51(5):382–4 (Fre)
The medicine of the month. Losartan (Cozaar)] Scheen AJ.
Rev Med Liege 1997 May;52(5):367–9 (8 ref.) (Fre)
[Example of a phase IV trial involving several physicians and aiming at answering a scientific question: EOL] Boissel JP, et al. **Therapie** 1996 Nov–Dec;51(6):667–76 (Eng. Abstr.) (Fre)
[Losartan (LORZAAR) and Losartan/hydrochlorothiazide (LORZAAR–PLUS)—their value in hypertension therapy. Symposium on the occasion of the 103rd Session of the German Society. Wiesbaden, 7 April 1997]
Dtsch Med Wochenschr 1997 Sep;122(36 Suppl Losartan):1–4 (Ger)
[Moxonidin in heart failure: new therapeutic principles suppress neurohumoral activation. Supplement to the Congress on "Heart Failure" of the working group on cardiac insufficiency at the European Society for Cardiology. Cologne, May 1997]
Dtsch Med Wochenschr 1997 Sep;122(36 Suppl Moxonidin):1–4 (Ger)
[Irbesartan—a new AT1-receptor antagonist (AT1-blocker). Angiotensin-II-receptor antagonists: perspectives of a new therapeutic principle, Wiesbaden, 6 April 1997]
Dtsch Med Wochenschr 1997 Sep;122(37 Suppl):1–4 (Ger)
[Carvedilol] Antepohl W, et al. **Dtsch Med Wochenschr** 1997 Jun 20;122(25–26):833–4 (Ger)
[In what way and how intensively should blood pressure be lowered in diabetic nephropathy?] Krämer BK, et al. **Dtsch Med Wochenschr** 1997 Jun 20;122(25–26):829–32 (34 ref.) (Ger)
[AT1 receptor antagonists in treatment of hypertension] Franz IW. **Fortschr Med** 1997 Jul 10;115(19):38–40 (Ger)
[Organ protection by antihypertensive treatment. Also conceivable for kidney diseases? (interview by Dr. med. Monika Flasnoecker)] Mann J. **Fortschr Med** 1996 Nov 20;114(32):15 (Ger)
[Does lowering blood pressure also prevent stroke? (interview by Dr. med. Monika Flasnoecker)] Schrader J. **Fortschr Med** 1997 Feb 20;115(5):49–50 (Ger)
[Modern antihypertensive drug therapy] Spieker C, et al.
Fortschr Med 1996 Nov 20;114(32):425–30 (21 ref.) (Eng. Abstr.) (Ger)
[What is the benefit of the new AT1 receptor antagonists?] Unger T. **Fortschr Med** 1997 Feb 28;115(6):31–3 (Ger)
[Avoiding compliance problems. Selection of the right drugs is important] **Internist (Berl)** 1996 Dec;37(12 Suppl Compliance):1–4 (Ger)
[Antihypertensive therapy with fixed combinations] Holzgreve H. **Internist (Berl)** 1996 Aug;37(8):852–6 (5 ref.) (Ger)
[Blood pressure monitoring in left ventricular hypertrophy] Kraft K. **Internist (Berl)** 1997 Jun;38(6):616 (Ger)
[Diuretics in therapy of hypertension?] Ritz E.
Internist (Berl) 1997 Feb;38(2):167 (Ger)
[Combination antihypertensive therapy in patients with an increased risk profile] Bartens W, et al. **Med Klin** 1996 Oct 15;91(10):626–31 (Eng. Abstr.) (Ger)
[Effect of different single agent antihypertensive therapies on peri-foveal microcirculation in patients with arterial hypertension] Kutschbach P, et al. **Ophthalmologe** 1996 Dec;93(6):699–702 (Eng. Abstr.) (Ger)
[The clinical spectrum of potassium-sparing diuretics] Greminger P, et al. **Schweiz Rundsch Med Prax** 1997 Apr 2;86(14):556–60 (Eng. Abstr.) (Ger)
[Significance of left ventricular hypertrophy in primary hypertension and therapeutic modification by antihypertensive drugs] Schiemann AL, et al.
Schweiz Rundsch Med Prax 1997 Jul 2;86(27–28):1101–6 (41 ref.) (Eng. Abstr.) (Ger)
[Significance of diuretics in the treatment of hypertension] Suter PM, et al. **Schweiz Rundsch Med Prax** 1997 Apr 2; 86(14):561–5 (45 ref.) (Eng. Abstr.) (Ger)
[Stroke prevention with a high risk strategy of treating hypertension in patients after a transient ischemic attack] Brainin M, et al. **Wien Med Wochenschr** 1997;147(2):34–6 (Eng. Abstr.) (Ger)
[Etiology and treatment of diuretic resistance] Risler T, et al. **Wien Med Wochenschr** 1996;146(16):447–50 (21 ref.) (Eng. Abstr.) (Ger)
[The hypertensive type II diabetic patient treated with captopril in free general practice (Austrian Safety Study). An indications study] Stanek B, et al.
Wien Med Wochenschr 1997;147(11):267–74 (Eng. Abstr.) (Ger)
[Antihypertensive therapy in elderly patients] Schrader J, et al. **Z Arztl Fortbild (Jena)** 1995 Dec;89(8):825–32 (24 ref.) (Eng. Abstr.) (Ger)
[Indapamide—a substitute diuretic for hypertensives with hyperglycemia and/or dyslipidemia] Sharabi Y, et al.
Harefuah 1996 Oct;131(7–8):233–6, 295 (Eng. Abstr.) (Heb)
[Calcium channel blockers scare] Zimlichman R.
Harefuah 1997 Feb 2;132(3):223–5 (11 ref.) (Heb)
[Angiotensin-2 receptor blockade—new therapeutic approach to treatment of hypertension] Zimlichman R.
Harefuah 1996 Jul;131(1–2):43–5 (27 ref.) (Heb)
[Use of captopril in therapeutic combinations] Alföldi S.
Acta Pharm Hung 1997 Jul;67(4):149–53 (18 ref.) (Eng. Abstr.) (Hun)
[Captopril treatment of hypertension] Farsang C.
Acta Pharm Hung 1997 Jul;67(4):141–8 (21 ref.) (Eng. Abstr.) (Hun)
[Efficacy of benazepril monotherapy in moderate essential hypertension studied by automatic ambulatory blood pressure monitoring] Páll D, et al. **Orv Hetil** 1996 Sep 8; 137(36):1973–8 (Eng. Abstr.) (Hun)
[Experience with benazepril, a long-acting ACE inhibitor, in the management of diabetic hypertension] Winkler G, et al. **Orv Hetil** 1997 Jul 6;138(27):1737–42 (27 ref.) (Eng. Abstr.) (Hun)
[The antagonistic effect of aspirin on the expression of prostaglandin participation in the antihypertensive activity of ACE inhibitors] Alimento M, et al. **Cardiologia** 1997 Jun;42(6):605–10 (Eng. Abstr.) (Ita)
[The tolerability of antihypertensive therapy: limits and dimensions of a summary phenomenon] Ambrosioni E, et al. **Cardiologia** 1997 Jun;42 Suppl 2:1–13 (28 ref.) (Ita)
[Antihypertensive treatment in the nephropathic patient] Andreucci VE, et al. **Cardiologia** 1996 May;41 Suppl 1:25–9 (19 ref.) (Ita)
[History of the pharmacologic therapy of arterial hypertension: from diuretics to angiotensin II receptor antagonists] Salvetti A, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):181–6 (30 ref.) (Ita)
[Effect of antihypertensive treatment on the clinical course of coronary disease] Sciomer S, et al. **Cardiologia** 1995 Dec; 40(12 Suppl 1):249–54 (Ita)
[Gradual reduction of arterial pressure and 24-hour blood pressure control as objective of antihypertensive therapy] Stella ML, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):189–91 (Ita)
[[Antihypertensive therapy and organ protection] Stella ML, et al. **Cardiologia** 1996 May;41 Suppl 1:19–23 (28 ref.) (Ita)
[The first clinical experience in Italy with angiotensin II receptor antagonists: results of a multicenter study on the efficacy and tolerance in arterial hypertension] Trimarco B. **Cardiologia** 1995 Dec;40(12 Suppl 1):193–5 (Ita)
[Valley/peak ratio and pressure changes during treatment with fosinopril in hypertensive elderly patients] Cicconetti P, et al. **Clin Ter** 1996 Jul–Aug;147(7–8):359–64 (Eng. Abstr.) (Ita)
[The therapy of arterial hypertension: a comparison between ACE inhibitors and angiotensin-II-receptor antagonists] Rossi F, et al. **Clin Ter** 1996 Oct;147(10):475–88 (54 ref.) (Eng. Abstr.) (Ita)
[Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension] Bignotti M, et al. **Minerva Cardioangiol** 1996 Jun;44(6):331–5 (Eng. Abstr.) (Ita)
[Transcutaneous oximetry in smokers with moderate hypertension and peripheral arterial disease treated with amlodipine and defibrotide, also with total smoking cessation] Cicco G, et al. **Minerva Cardioangiol** 1995 Oct; 43(10):423–8 (Eng. Abstr.) (Ita)
[A quinapril-hydrochlorothiazide combination in the treatment of essential arterial hypertension] Dominici P, et al. **Minerva Cardioangiol** 1997 Jan–Feb;45(1–2):25–9 (Eng. Abstr.) (Ita)
Quinapril versus lisinopril in the treatment of essential hypertension in elderly patients with low blood renin] Rengo F, et al. **Minerva Cardioangiol** 1996 Dec; 44(12):631–5 (Eng. Abstr.) (Ita)
[Prevention of hypertensive crises in the perioperative period. Efficacy and safety of the use of urapidil] Mastronardi P, et al. **Minerva Chir** 1996 Apr;51(4):227–33 (Eng. Abstr.) (Ita)
[Antihypertensive effect of ramipril. Ambultory monitoring of arterial blood pressure in mild to moderate hypertension] Galiè M, et al. **Recenti Prog Med** 1996 Sep;87(9):428–30 (Ita)
[Treatment of elderly patients with hypertension—complications and current drug therapy] Takagawa Y, et al. **Nippon Ronen Igakkai Zasshi** 1997 Jan; 34(1):30–7 (Eng. Abstr.) (Jpn)
[Clinical characteristics of patients with hypertension resistant to antihypertensive drug therapy] Gluszek J, et al. **Pol Arch Med Wewn** 1996 Dec;96(6):570–6 (Eng. Abstr.) (Pol)
–Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension– Kokot F, et al.
Pol Arch Med Wewn 1995 Oct;94(4):342–8 (Eng. Abstr.) (Pol)
[Monitoring kidney function in patients with essential hypertension treated with enalapril]
Orzechowska-Juzwenko K, et al. **Pol Arch Med Wewn** 1997 Jan;97(1):15–21 (Eng. Abstr.) (Pol)
[Hypertension crises and their treatment (editorial)] Halawa B. **Pol Merkuriusz Lek** 1996 Dec;1(6):367–70 (Pol)
[Imidazoline receptors and use of drug blocking receptors I1] Lada W. **Pol Merkuriusz Lek** 1996 Aug;1(2):124–5 (10 ref.) (Eng. Abstr.) (Pol)
[Ambulatory blood pressure monitoring in the therapeutic assessment of arterial hypertension] Amodeo C.
Arq Bras Cardiol 1996 Aug;67(2):143–4 (Por)
[Pharmacologic regression of cardiac and vascular structural changes in the hypertensive patient. A question that goes beyond the exclusive medical bias] Antonio Francischetti E, et al. **Arq Bras Cardiol** 1995 Dec;65(6):555–63 (90 ref.) (Por)
[Antihypertensive effect of fosinopril in mild hypertension] Pizarro M, et al. **Rev Port Cardiol** 1996 Jun;15(6):495–7, 460 (Eng. Abstr.) (Por)
[Angiotensin-II receptor blockers in the treatment of arterial hypertension] Ol'binskaia LI, et al. **Eksp Klin Farmakol** 1996 Sep–Oct;59(5):76–80 (Rus)
[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy] Krasnikova TL.
Klin Med (Mosk) 1996;74(3):17–21 (38 ref.) (Rus)
[The clinical efficacy of Korinfar-retard in combination with Cordanum, triampur and Capoten in patients with arterial hypertension] Kukes VG, et al. **Klin Med (Mosk)** 1996; 74(2):20–3 (Eng. Abstr.) (Rus)
[A comparative study of the membrane-protector efficacy of anaprilin and korinfar in hypertension patients] Gapon LI, et al. **Lik Sprava** 1996 Oct–Dec;(10–12):69–71 (Eng. Abstr.) (Rus)
[Changes in the central hemodynamics during the treatment of hypertension with Renitec and its combination with hydrochlorothiazide] Malaia LT, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):57–60 (Eng. Abstr.) (Rus)
[The structural-functional status of the myocardium and central and regional hemodynamics in patients with essential hypertension under the influence of treatment with korinfar and its combination with anaprilin] Polivoda SN, et al. **Lik Sprava** 1995 Sep–Dec;(9–12):32–4 (Rus)
[Isradipine in arterial hypertension in motor vehicle drivers] Aramisova RM, et al. **Med Tr Prom Ekol** 1996;(8):21–3 (Eng. Abstr.) (Rus)
[The treatment of hypertension patients with Estulic] Baliakina EV, et al. **Ter Arkh** 1996;68(12):57–60 (Eng. Abstr.) (Rus)
[The treatment with antihypertensive and nootropic preparations of hypertension patients working under neuroemotional stress] Dasaeva LA, et al. **Ter Arkh** 1996; 68(12):60–3 (Eng. Abstr.) (Rus)
[Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus] Lazebnik LB, et al. **Ter Arkh** 1997;69(6):59–64 (Rus)
[The effect of long-term uncontrolled antihypertensive therapy on the echocardiographic signs of left-heart hypertrophy in patients with mild and moderate arterial hypertension] Lerman OV, et al. **Ter Arkh** 1997;69(1):43–6 (Eng. Abstr.) (Rus)
[The Multicenter Captopril and the Quality of Life Study: the effect of antihypertensive agents from the basic groups on the quality of life of patients in different populations. The working group of the Multicenter Captopril and the Quality of Life Study] Metelitsa VI, et al. **Ter Arkh** 1996; 68(4):29–36 (Eng. Abstr.) (Rus)
[The activity of the neurohumoral regulatory systems, the status of the electrolyte balance and the clinical efficacy of Renitec in hypertension patients] Ol'binskaia LI, et al. **Ter Arkh** 1996;68(4):54–7 (Eng. Abstr.) (Rus)
[A decrease in left ventricular hypertrophy and the dynamics of the parameters of circadian BP monitoring under the influence of ramipril in patients with essential arterial hypertension] Pekarskiĭ SE, et al. **Ter Arkh** 1997; 69(4):18–20 (Eng. Abstr.) (Rus)
[Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients] Oliván J, et al.
An Med Interna 1996 Nov;13(11):531–6 (Eng. Abstr.) (Spa)
[Calcium channel blockers and cardiovascular morbidity mortality (editorial)] Robles NR. **An Med Interna** 1997 May;14(5):217–9 (Spa)
[Randomized, comparative study to evaluate efficacy and

safety of doxazosin versus nitrendipine in the treatment of mild to moderate hypertension] Sanz Guajardo D, et al. **An Med Interna** 1997 Jan;14(1):15-9 (Eng. Abstr.) **(Spa)**

[Primary pulmonary hypertension: treatment with prostacyclin before lung transplantation] Morales P, et al. **Arch Bronconeumol** 1997 Mar;33(3):148-50 (Eng. Abstr.) **(Spa)**

[The validity of 6 indirect methods for assessing drug treatment compliance in arterial hypertension] Piñeiro F, et al. **Aten Primaria** 1997 Apr 30;19(7):372-4, 376 (Eng. Abstr.) **(Spa)**

[Antihypertensive prescribing habits in primary care (letter)] Gil Miguel A, et al. **Med Clin (Barc)** 1997 Feb 15; 108(6):236-7 **(Spa)**

[Calcium antagonists and their impact on risk of coronary disease (editorial)] Roca-Cusachs A, et al. **Med Clin (Barc)** 1996 Oct 26;107(14):533-4 **(Spa)**

[Emergency treatment of hypertension with lacidipine (letter)] Sobrino Martínez J, et al. **Rev Clin Esp** 1997 Mar; 197(3):211 **(Spa)**

[Hypertensive patients treated in Spain, 1990-1993] García Ruiz AJ, et al. **Rev Esp Salud Publica** 1997 Jan-Feb; 71(1):9-17 (Eng. Abstr.) **(Spa)**

[A comparative study of the hemodynamic and antioxidant effects of Capoten and prazosin in patients with refractory heart failure] Sabadyshyn RO, et al. **Lik Sprava** 1997 Mar-Apr;(2):72-6 (Eng. Abstr.) **(Ukr)**

[The effect of the angiotensin-converting enzyme inhibitor Capoten on the volume-regulation indices of patients with stage-II hypertension] Vladkovs'kyĭ IK, et al. **Lik Sprava** 1996 Mar-Apr;(3-4):113-7 (Eng. Abstr.) **(Ukr)**

TOXICITY

Genetic effects of binazine and hydralazine in vitro and in vivo. Chłopkiewicz B, et al. **Acta Pol Pharm** 1995 Jan-Feb; 52(1):31-3

Studies on the mechanism of hydralazine induced mutagenicity and genotoxicity. Chopkiewicz B, et al. **Acta Pol Pharm** 1995 May-Jun;52(3):219-22

Prevention of fetal and maternal cyanide toxicity from nitroprusside with coinfusion of sodium thiosulfate in gravid ewes. Curry SC, et al. **Anesth Analg** 1997 May; 84(5):1121-6

Eight hours' inhalation of prostacyclin (PGI2) in healthy lambs: effects on tracheal, bronchial, and alveolar morphology. Habler O, et al. **Intensive Care Med** 1996 Nov; 22(11):1232-8

Cardiovascular effects of ethanolic and aqueous extracts of Pimenta dioica in Sprague-Dawley rats. Suárez A, et al. **J Ethnopharmacol** 1997 Jan;55(2):107-11

Preclinical toxicology studies with the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril). McGuire EJ, et al. **J Toxicol Sci** 1996 Nov;21(4):207-14 (21 ref.)

Case studies defining non-toxic and toxic dose of pharmaceuticals. Naeshiro I. **J Toxicol Sci** 1996 Dec; 21(5):425-35 (6 ref.)

Toxicokinetic analysis of losartan during gestation and lactation in the rat. Spence SG, et al. **Teratology** 1996 Apr; 53(4):245-52

[Pharmacological correction of behavioral and memory disorders in rats with vasorenal arterial hypertension given propranolol] Petrov VI, et al. **Eksp Klin Farmakol** 1997 May-Jun;60(3):6-8 (Eng. Abstr.) **(Rus)**

URINE

Separation and quantitation of debrisoquine and 4-hydroxydebrisoquine in human urine by capillary electrophoresis and high-performance liquid chromatography. Cifuentes A, et al. **J Chromatogr A** 1997 Aug 22;778(1-2):389-96

Efficient assay for the determination of atenolol in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Chiu FC, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):473-7

On-line solid-phase extraction and high-performance liquid chromatographic determination of chlorthalidone in urine. Salado S, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1-2):195-202

ANTI-IDIOTYPE ANTIBODIES see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTI-INFECTIVE AGENTS

see related
ANTHELMINTICS
ANTIPROTOZOAL AGENTS

Marine microorganisms as a source of new natural products. Bernan VS, et al. **Adv Appl Microbiol** 1997;43:57-90 (74 ref.)

Role of human milk constituents in blocking the adherence of enteric pathogens. Ashkenazi S. **Adv Exp Med Biol** 1996; 408:187-92 (18 ref.)

Inhibitors of Candida albicans adhesion to prevent candidiasis. Segal E. **Adv Exp Med Biol** 1996;408:197-206 (25 ref.)

Elicitors triggering the simultaneous gene expression of antibacterial proteins of the silkworm, Bombyx mori. Taniai K, et al. **Biochem Biophys Res Commun** 1996 Sep 24; 226(3):783-90

Antibacterial activity of formic and propionic acids in the diet of hens on Salmonellas in the crop. Thompson JL, et al. **Br Poult Sci** 1997 Mar;38(1):59-65

Assessment of the anti-microbial agent C31G as a spermicide: comparison with nonoxynol-9. Thompson KA, et al. **Contraception** 1996 May;53(5):313-8

Six antimicrobial peptide genes of the cathelicidin family map to bovine chromosome 22q24 by fluorescence in situ hybridization. Castiglioni B, et al. **Cytogenet Cell Genet** 1996;75(4):240-2

Cloning of the gene encoding the antibacterial peptide drosocin involved in Drosophila immunity. Expression studies during the immune response. Charlet M, et al. **Eur J Biochem** 1996 Nov 1;241(3):699-706

Characterization and ion channel activities of novel antibacterial proteins from the skin mucosa of carp (Cyprinus carpio). Lemaître C, et al. **Eur J Biochem** 1996 Aug 15;240(1):143-9

Cystic fibrosis, lung infections, and a human tracheal antimicrobial peptide (hTAP). Ko YH, et al. **FEBS Lett** 1997 Mar 24;405(2):200-8

Phytoalexin production elicited by exogenously applied jasmonic acid in rice leaves (Oryza sativa L.) is under the control of cytokinins and ascorbic acid. Tamogami S, et al. **FEBS Lett** 1997 Jul 21;412(1):61-4

Structure of genes for dermaseptins B, antimicrobial peptides from frog skin. Exon 1-encoded prepropeptide is conserved in genes for peptides of highly different structures and activities. Vouille V, et al. **FEBS Lett** 1997 Sep 1; 414(1):27-32

cDNA cloning of three cecropin-like antimicrobial peptides (Styelins) from the tunicate, Styela clava. Zhao C, et al. **FEBS Lett** 1997 Jul 21;412(1):144-8

Molecular characterization of a defensin gene from the mosquito, Aedes aegypti. Cho WL, et al. **Insect Biochem Mol Biol** 1997 May;27(5):351-8

Differential induction of antibacterial transcripts in Drosophila susceptible and resistant to parasitism by Leptopilina boulardi. Coustau C, et al. **Insect Mol Biol** 1996 Aug;5(3):167-72

Thermophilin 13, a nontypical antilisterial poration complex bacteriocin, that functions without a receptor. Marciset O, et al. **J Biol Chem** 1997 May 30;272(22):14277-84

Advances in antimicrobial chemotherapy. A selection of papers from the 9th Mediterranean Congress of Chemotherapy. Milan, Italy, June 1994. **J Chemother** 1995 Nov;7 Suppl 4:9-210

Determination of the furazolidone metabolite, 3-amino-2-oxazolidinone, in porcine tissues using liquid chromatography-thermospray mass spectrometry and the occurrence of residues in pigs produced in Northern Ireland. McCracken RJ, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):87-94

Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. Fang FC. **J Clin Invest** 1997 Jun 15;99(12):2818-25 (73 ref.)

New directions in antibacterial research. Chu DT, et al. **J Med Chem** 1996 Sep 27;39(20):3853-74 (199 ref.)

Identification and characterization of the Cecropin antibacterial protein gene locus in Drosophila virilis. Zhou X, et al. **J Mol Evol** 1997 Mar;44(3):272-81

Wakely prize essay. Microbes, chemotherapy, evolution, and folly [see comments] Loefler IJ. **Lancet** 1996 Dec 21-28; 348(9043):1703-4. Comment in: Lancet 1996 Dec 21-28;348(9043):1676.

New antimycobacterial agents. Yew WW, et al. **Monaldi Arch Chest Dis** 1996 Oct;51(5):394-404 (143 ref.)

A sensitive defense: salt and cystic fibrosis [news] Wine JJ. **Nat Med** 1997 May;3(5):494-5

21-Aminosteroid U-74389G (lazaroid) inhibits bacterial translocation after small bowel transplantation in rats. de Oca J, et al. **Transplant Proc** 1997 May;29(3):1803

ADMINISTRATION & DOSAGE

The effect of cranberry juice on the presence of bacteria and white blood cells in the urine of elderly women. What is the role of bacterial adhesion? Avorn J. **Adv Exp Med Biol** 1996;408:185-6

One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. de Boer WA, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):109-12

Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy. Kung NN, et al. **Am J Gastroenterol** 1997 Mar;92(3):438-41

Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility. Zamin MT, et al. **Ann Pharmacother** 1997 May;31(5):564-70

Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection. Kansal RG, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):17-23

Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Mehta RT. **Antimicrob Agents Chemother** 1996 Aug;40(8):1893-902

One week treatment for Helicobacter pylori infection. Walsh D, et al. **Arch Dis Child** 1997 Apr;76(4):352-5

Antibody levels to Clostridium perfringens and response to sulphasalazine [letter] Bradley SM, et al. **Br J Rheumatol** 1996 Dec;35(12):1327-8

Antimicrobial dosing in obese patients. Wurtz R, et al. **Clin Infect Dis** 1997 Jul;25(1):112-8 (83 ref.)

Subgingival delivery of therapeutic agents in the treatment of periodontal diseases. Soskolne WA. **Crit Rev Oral Biol Med** 1997;8(2):164-74 (64 ref.)

Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Yamada M, et al. **Eur J Pediatr** 1997 Mar;156(3):182-5

Regression of duodenal mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. Nagashima R, et al. **Gastroenterology** 1996 Dec; 111(6):1674-8

Two cases of severe bronchiectasis successfully treated with a prolonged course of trimethoprim/sulfamethoxazole. Honda T, et al. **Intern Med** 1996 Dec;35(12):979-83

Altered trimethoprim-sulfamethoxazole ratios for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii dual infections in rat model. Brun-Pascaud M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Nov 1;13(3):201-7

Clinical rationale for topical antimicrobial preparations. Langford JH, et al. **J Antimicrob Chemother** 1996 Mar; 37(3):399-402 (33 ref.)

Sustained-release microcapsules of nitrofurantoin and amoxicillin; preparation, in-vitro release rate, kinetic and micromeritic studies. Ertan G, et al. **J Microencapsul** 1997 May-Jun;14(3):379-88

An improved method for monensin in feeds. Stahr HM, et al. **J Vet Diagn Invest** 1996 Jan;8(1):140-2

Outpatient antimicrobial protocol for febrile neutropenia: a nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents. Sahu S, et al. **Pediatr Hematol Oncol** 1997 May-Jun;14(3):205-11

Textural analysis and flow rheometry of novel, bioadhesive antimicrobial oral gels. Jones DS, et al. **Pharm Res** 1997 Apr;14(4):450-7

Organotypic raft cultures for the in vitro evaluation of vaginal microbicidal agents. Microbicides have epithelium-specific effects when repeatedly added onto organotypic human keratinocyte cultures. Aebischer F, et al. **Sex Transm Dis** 1997 Feb;24(2):69-76

Ciprofloxacin for gonorrhea—250 mg or 500 mg? [letter; comment] Moran JS. **Sex Transm Dis** 1996 Mar-Apr; 23(2):165-7. Comment on: Sex Transm Dis 1994 Nov-Dec;21(6):345-52.

[Value of desensitization for reintroducing trimethoprim-sulfamethoxazole in hypersensitive patients with HIV infection] Caumes E. **Ann Med Interne (Paris)** 1997;148(2):172-6 (21 ref.) (Eng. Abstr.) **(Fre)**

[Hyperkalemia and acute renal insufficiency during overdose of trimethoprim-sulfamethoxazole in a patient with AIDS (letter)] Giraud O, et al. **Ann Med Interne (Paris)** 1997; 148(2):185-6 **(Fre)**

[Desensitization to trimethoprim-sulfamethoxazole in patients with HIV infection] Piketty C, et al. **Ann Med Interne (Paris)** 1996;147(5):327-30 (Eng. Abstr.) **(Fre)**

[Health and environmental risks after the use of anti-infective agents and antiparasitic agents in domestic animal husbandry--avoidance strategies and ways out] Blaha T. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):278-80 (Eng. Abstr.) **(Ger)**

[Dapsone in granulomatous rosacea] Krause MH, et al. **Hautarzt** 1997 Apr;48(4):246-8 (Eng. Abstr.) **(Ger)**

[Good results with Helicobacter pylori eradication for treatment of non-ulcer dyspepsia (letter)] Bock H, et al. **Leber Magen Darm** 1996 Sep;26(5):268 **(Ger)**

[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment] Tokushima H, et al. **Nippon Jinzo Gakkai Shi** 1996 Aug;38(8):349-55 (Eng. Abstr.) **(Jpn)**

[A case of gastric MALT lymphoma regressed endoscopically and pathologically after eradication of Helicobacter pylori] Seko A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):21-6 **(Jpn)**

[Time course of disappearance of Helicobacter pylori after topical therapy and new triple therapy] Wang XM, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jan;94(1):79 **(Jpn)**

[Single-dose administration in the treatment with penicillin G (PG) and metronidazole (Me) in primary pulmonary abscesses (a preliminary study)] Chiotan D, et al. **Pneumoftiziologia** 1997 Jan-Mar;46(1):29-34 (Eng. Abstr.) **(Rum)**

[The new pathogenetic agent lipin for the treatment of patients with respiratory failure] Iukhimets VA. **Lik Sprava** 1995 Sep-Dec;(9-12):60-3 (Eng. Abstr.) **(Rus)**

[Effect of ultrasonic aerosol treatment of wounds on the anaerobic microflora of purulent maxillofacial foci] Shulakov VV, et al. **Vestn Ross Akad Med Nauk** 1996; (8):22-6 (Eng. Abstr.) **(Rus)**

[The intra-aortic antibacterial therapy of wounded patients with gunshot meningoencephalitis] Murashkin SV, et al. **Voen Med Zh** 1996 Dec;317(12):21-2, 80 (Eng. Abstr.) **(Rus)**

[The differentiated correction of the local immunity of the reproductive tract by using lysozyme and immunoglobulins in pregnant women with a genital infection] Dolgushin II, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Jul–Aug; (4):111–5 (Eng. Abstr.) **(Rus)**

[The physiological characteristics of the antioxidant properties of Lipin in bronchial asthma in children] Tymchenko OH, et al. **Fiziol Zh** 1996;42(1–2):47–52 (Eng. Abstr.) **(Ukr)**

ADVERSE EFFECTS

Acute generalized exanthematous pustulosis induced by lansoprazole [letter] Dewerdt S, et al. **Acta Derm Venereol** 1997 May;77(3):250

Adverse reactions to sulphonamide and sulphonamide–trimethoprim antimicrobials: clinical syndromes and pathogenesis. Cribb AE, et al. **Adverse Drug React Toxicol Rev** 1996 Mar;15(1):9–50 (219 ref.)

Does dapsone increase mortality when given for prophylaxis of Pneumocystis carinii pneumonia? [letter; comment] Opravil M, et al. **AIDS** 1996 Aug;10(9):1045–6. Comment on: AIDS 1995 Dec;9(12):1343–50.

Trimethoprim–sulfamethoxazole–induced vanishing bile duct syndrome. Yao F, et al. **Am J Gastroenterol** 1997 Jan; 92(1):167–9

Restarting trimethoprim–sulfamethoxazole after a hypersensitivity reaction in patients infected with the human immunodeficiency virus. Everson–Mays RE, et al. **Am J Health Syst Pharm** 1997 Jul 1;54(13):1545–50

Sensitization and exposure to methylisothiazolinones (Kathon) in the pulp and paper industry—a report of two cases. Torén K, et al. **Am J Ind Med** 1997 May;31(5):551–3

Hyperkalemia and trimethoprim–sulfamethoxazole. Ellison DH. **Am J Kidney Dis** 1997 Jun;29(6):959–62; discussion 962–5

Hyperkalemia and trimethoprim–sulfamethoxazole [letter; comment] [published erratum appears in Ann Intern Med 1996 Dec 15;125(12):1015] Ougorets I, et al. **Ann Intern Med** 1996 Nov 1;125(9):779; discussion 779–80 . Comment on: Ann Intern Med 1996 Feb 1;124(3):316–20.

Hyperkalemia and trimethoprim–sulfamethoxazole [letter; comment] [published erratum appears in Ann INtern Med 1996 Dec 15;125(12):1015] Parker MG. **Ann Intern Med** 1996 Nov 1;125(9):778–9; discussion 779–80. Comment on: Ann Intern Med 1996 Feb 1;124(3):316–20.

Hyperkalemia and trimethoprim–sulfamethoxazole [letter; comment] [published erratum appears in Ann Intern Med 1996 Dec 15;125(12):1015] Postelnick M, et al. **Ann Intern Med** 1996 Nov 1;125(9):778; discussion 779–80 . Comment on: Ann Intern Med 1996 Feb 1;124(3):316–20.

Hyperkalemia and trimethoprim–sulfamethoxazole [letter; comment] [published erratum appears in Ann Intern Med 1996 Dec 15;125(12):1015] Thomas RJ. **Ann Intern Med** 1996 Nov 1;125(9):778; discussion 779–80. Comment on: Ann Intern Med 1996 Feb 1;124(3):316–20.

Hyperkalemia and trimethoprim–sulfamethoxazole [letter; comment] [published erratum appears in Ann Intern Med 1996 Dec 15;125(12):1015] Watanakunakorn C. **Ann Intern Med** 1996 Nov 1;125(9):778; discussion 779–80 . Comment on: Ann Intern Med 1996 Feb 1;124(3):316–20.

Sulfadiazine–induced sialadenitis. Añíbarro B, et al. **Ann Pharmacother** 1997 Jan;31(1):59–60

Trimethoprim/sulfamethoxazole–induced hypoglycemia in a patient with acute renal failure. Lee AJ, et al. **Ann Pharmacother** 1997 Jun;31(6):727–32

Heterotopic ossification as a complication of toxic epidermal necrolysis. Gibson CJ, et al. **Arch Phys Med Rehabil** 1997 Jul;78(7):774–6

Hospitalization for serious blood and skin disorders following use of co–trimoxazole. Myers MW, et al. **Br J Clin Pharmacol** 1997 Apr;43(4):446–8

Hospitalization for serious blood and skin disorders following co–trimoxazole. Myers MW, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):649–51

A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV–infected patients. Girgis I, et al. **Chest** 1997 Sep; 112(3):646–53

Antecedent antimicrobial use increases the risk of uncomplicated cystitis in young women. Smith HS, et al. **Clin Infect Dis** 1997 Jul;25(1):63–8

Rapid disease progression in human immunodeficiency virus type 1–infected individuals with adverse reactions to trimethoprim–sulfamethoxazole prophylaxis. Veenstra J, et al. **Clin Infect Dis** 1997 May;24(5):936–41

Trimethoprim–sulfamethoxazole and hypouricemia. Chertow GM, et al. **Clin Nephrol** 1996 Sep;46(3):193–8

Trimethoprim–sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Perazella MA, et al. **Clin Nephrol** 1996 Sep;46(3):187–92 (32 ref.)

Adverse reactions to trimethoprim–sulfamethoxazole. Lee BL. **Clin Rev Allergy Immunol** 1996–97 Winter;14(4):451–5

Hyperkalemia and trimethoprim–sulfamethoxazole: a new problem emerges 25 years later. Perazella MA. **Conn Med** 1997 Aug;61(8):451–8 (31 ref.)

Acute generalized exanthematous pustulosis induced by nifuroxazide. Machet L, et al. **Contact Dermatitis** 1997 Jun; 36(6):308–9

Airborne contact dermatitis due to methylchloro– and methylisothiazolinone (MCI/MI). Schubert H. **Contact Dermatitis** 1997 May;36(5):274

Drug–induced Clostridium difficile–associated disease. Job ML, et al. **Drug Saf** 1997 Jul;17(1):37–46 (62 ref.)

Trimethoprim/sulfamethoxazole–induced hypoglycemia in a malnourished patient with severe infection. Hekimsoy Z, et al. **Eur J Endocrinol** 1997 Mar;136(3):304–6

Mild rhabdomyolysis after high–dose trimethoprim–sulfamethoxazole in a patient with HIV infection. Anders HJ, et al. **Eur J Med Res** 1997 May 28; 2(5):198–200

Reactive airways dysfunction syndrome due to chlorine: sequential bronchial biopsies and functional assessment. Lemière C, et al. **Eur Respir J** 1997 Jan;10(1):241–4

Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients. Heylen R, et al. **Genitourin Med** 1996 Aug; 72(4):237–46 (71 ref.)

Regarding Brasil, et al.'s adverse effects in leprosy's WHO/MDT and paramedic's role in leprosy control program [letter; comment] Cunha M da G, et al. **Int J Lepr Other Mycobact Dis** 1997 Jun;65(2):257–9. Comment on: Int J Lepr Other Mycobact Dis 1996 Jun;64(2):97–104.

Acute renal failure and multidrug therapy for leprosy [letter; comment] Nishioka S de A. **Int J Lepr Other Mycobact Dis** 1997 Jun;65(2):259–60. Comment on: Int J Lepr Other Mycobact Dis 1996 Jun;64(2):97–104.

Obstructive renal failure requiring surgical intervention in an AIDS patient being treated with sulphadiazine. Mir N, et al. **Int J STD AIDS** 1997 Jan;8(1):61–2

Trimethoprim–sulfamethoxazole–induced sepsis–like syndrome in a patient with AIDS. O'Kane EB, et al. **J Am Board Fam Pract** 1996 Nov–Dec;9(6):448–50

Adverse reactions to co–trimoxazole in HIV infection: a reappraisal of the glutathione–hydroxylamine hypothesis. van der Ven AJ, et al. **J Antimicrob Chemother** 1996 May; 37 Suppl B:55–60 (22 ref.)

Comparisons of oxidative metabolism and reductive capacity in sulfonamide–tolerant and –intolerant patients with human immunodeficiency virus. Lehmann DF, et al. **J Clin Pharmacol** 1996 Dec;36(12):1149–53

Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin–converting enzyme inhibitor in a patient with transplanted lungs. Bugge JF. **J Intern Med** 1996 Oct;240(4):249–51

Association of hepatic necrosis with trimethoprim sulfonamide administration in 4 dogs. Twedt DC, et al. **J Vet Intern Med** 1997 Jan–Feb;11(1):20–3

Worsening oxygen saturation during treatment with oxidative drugs: a clinical reminder [letter] Driver JA, et al. **JAMA** 1996 Oct 16;276(15):1221–2

Tremor caused by trimethoprim–sulfamethoxazole in a patient with AIDS. Van Gerpen JA. **Neurology** 1997 Feb; 48(2):537–8

Aseptic meningitis from trimethoprim–sulfamethoxazole in an HIV–infected adolescent. Rudy BJ, et al. **Pediatr Emerg Care** 1997 Jun;13(3):216–7

Adverse reactions in children during long–term antimicrobial therapy. Uhari M, et al. **Pediatr Infect Dis J** 1996 May; 15(5):404–8

Hydroxamic acid: a potential human teratogen that could be recommended to treat ureaplasma. Holmes LB. **Teratology** 1996 Apr;53(4):227–9

Gingival hyperplasia: a new side effect associated with trimethoprim–sulfamethoxazole (TML–SMX) treatment in pulmonary nocardiosis [letter] Caron F, et al. **Therapie** 1997 Jan–Feb;52(1):73–4

Hyperpigmented dermal macules in children following the administration of Maloprim for malaria chemoprophylaxis. David KP, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):204–8

[A frequently used drug with fatal outcome! (letter)] Pijls H. **Tijdschr Diergeneeskd** 1997 Apr 15;122(8):230 **(Dut)**

[Acute hepatitis caused by the combination of tiliquinol and tilbroquinol (Intétrix) (letter)] Caroli–Bosc FX, et al. **Gastroenterol Clin Biol** 1996;20(6–7):605–6 **(Fre)**

[Hyperkalemia under treatment with high–dose trimethoprim–sulfamethoxazole (letter)] Fouché R, et al. **Presse Med** 1996 Dec 21;25(40):2044 **(Fre)**

[Trimethoprim–sulphamethoxazole–induced meningitis] Poles L, et al. **Harefuah** 1996 Jun 16;130(12):817–9, 879 (Eng. Abstr.) **(Heb)**

[Prolonged cholestasis following single dose of cotrimoxazole++ (letter)] Ruiz–Irastorza G, et al. **Rev Clin Esp** 1996 Dec;196(12):879–80 **(Spa)**

ANALYSIS

Immunohistochemical localization of defensin in human coronary vessels. Barnathan ES, et al. **Am J Pathol** 1997 Mar;150(3):1009–20

p15s (15–kD antimicrobial proteins) are stored in the secondary granules of Rabbit granulocytes: implications for antibacterial synergy with the bactericidal/permeability–increasing protein in inflammatory fluids. Zarember K, et al. **Blood** 1997 Jan 15;89(2):672–9

Antimicrobial peptides of leukocytes. Ganz T, et al. **Curr Opin Hematol** 1997 Jan;4(1):53–8 (75 ref.)

Residues of some veterinary drugs in animals and foods. Joint FAO/WHO Expert Committee on Food Additives [published erratum appears in FAO Food Nutr Pap 1997;41(9):141, 127–34] **FAO Food Nutr Pap** 1996; 41(8):1–166

Residues of some veterinary drugs in animals and foods. Monographs prepared by the Forty–Seventh meeting of the Joint FAO/WHO Expert Committee on Food Additives. Rome, 4–13 June 1996. **FAO Food Nutr Pap** 1997;41(9):1–139

The production of pig tissue sulphadimidine reference material. Crooks SR, et al. **Food Addit Contam** 1996 Feb–Mar;13(2):211–9

Planar chromatography for the multiclass, multiresidue screening of chloramphenicol, nitrofuran, and sulfonamide residues in pork and beef. Abjean JP. **J AOAC Int** 1997 Jul–Aug;80(4):737–40

Determination of sulfonamides in edible salmon tissue by liquid chromatography with postcolumn derivatization and fluorescence detection. Gehring TA, et al. **J AOAC Int** 1997 Jul–Aug;80(4):751–5

Determination and confirmation of identities of flumequine and nalidixic, oxolinic, and piromidic acids in salmon and shrimp. Pfenning AP, et al. **J AOAC Int** 1996 Sep–Oct; 79(5):1227–35

Improved determination of sulfadiazine in human plasma and urine by high–performance liquid chromatography. Metz R, et al. **J Chromatogr A** 1996 Apr 5;729(1–2):243–9

Micellar electrokinetic chromatography as a generalized alternative to high–performance liquid chromatography for purity determination of a class of investigational antibacterial drugs. Scholl JP, et al. **J Chromatogr B Biomed Appl** 1997 Jul 18;695(1):147–56

High–performance liquid chromatographic method for the rapid and simultaneous determination of sulfamonomethoxine, miloxacin and oxolinic acid in serum and muscle of cultured fish. Ueno R, et al. **J Chromatogr B Biomed Appl** 1996 Jun 28;682(1):179–81

Rapid ultraviolet spectrophotometric determination of bronopol: application to raw material analysis and kinetic studies of bronopol degradation. Sanyal AK, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1447–53

Detection of inhibitors in milk by microbial tests. A review. Suhren G, et al. **Nahrung** 1996 Feb;40(1):1–7 (42 ref.)

A peptide antibiotic from human skin [letter] [see comments] Harder J, et al. **Nature** 1997 Jun 26;387(6636):861. Comment in: Nature 1997 Jul 31;388(6641):416.

Nightmare antibiotics [letter; comment] Inglehearn CF. **Nature** 1997 Jul 31;388(6641):416. Comment on: Nature 1997 Jun 26;387(6636):861.

Chemical and biological studies on two Helichrysum species of Greek origin [letter] Chinou IB, et al. **Planta Med** 1996 Aug;62(4):377–9

Chemical composition and antimicrobial activity of essential oil of Piper angustifolium [letter] Tirillini B, et al. **Planta Med** 1996 Aug;62(4):372–3

Sulfamethazine, sulfothiazole and albendazole residue dosage in food products determined by liquid chromatography/tandem mass spectrometry. Casetta B, et al. **Rapid Commun Mass Spectrom** 1996;10(12):1497–503

Multiresidue determination of sulfonamide antibiotics in milk by short–column liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Volmer DA. **Rapid Commun Mass Spectrom** 1996;10(13):1615–20

High–performance liquid chromatography determination of pyrimethamine, dapsone, monoacetyldapsone, sulfadoxine, and N–acetyl–sulfadoxine after rapid solid–phase extraction. Eljaschewitsch J, et al. **Ther Drug Monit** 1996 Oct;18(5):592–7

NK–lysin, structure and function of a novel effector molecule of porcine T and NK cells. Andersson M, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1–4):123–6 (11 ref.)

Localization of benzoxazinones that occur constitutively in wheat seedlings. Iwamura H, et al. **Z Naturforsch [C]** 1996 Nov–Dec;51(11–12):807–12

[Evaluation of pharmacopoeia methods for determination of antimicrobial agents, especially of natural substances] Brantner A. **Pharmazie** 1997 Jan;52(1):34–40 (Eng. Abstr.) **(Ger)**

[The detection of furacillin and no–shpa in the forensic chemical study of cadaveric material] Iaremenko EF, et al. **Sud Med Ekspert** 1996 Jul–Sep;39(3):44–5 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? Annibale B, et al. **Am J Gastroenterol** 1997 May;92(5):790–4

Highly effective twice–daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Lerang F, et al. **Am J Gastroenterol** 1997 Feb;92(2):248–53

[The antibiotic and chemotherapeutic resistance of Shigella strains isolated in the Microbiology Laboratory of I.P.S.M.P. Neamț in 1991–1995] Păltineanu R, et al. **Bacteriol Virusol Parazitol Epidemiol** 1997 Jan–Jun; 42(1–2):33–8 **(Rum)**

BLOOD

cDNA cloning of Clavanins: antimicrobial peptides of tunicate hemocytes. Zhao C, et al. **FEBS Lett** 1997 Jun 30;410(2–3):490–2

Bactericidal/permeability increasing factors [letter; comment] Shaldon S. **J Am Soc Nephrol** 1996 Oct;

7(10):2268. Comment on: J Am Soc Nephrol 1996 Mar;7(3):479–87.

Quantitation of beta-lapachone and 3-hydroxy-beta-lapachone in human plasma samples by reversed-phase high-performance liquid chromatography. Glen VL, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):181–6

An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. Sørensen O, et al. **J Immunol Methods** 1997 Aug 7;206(1–2):53–9

[Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer] Orzechowska-Juzwenko K, et al. **Przegl Lek** 1997; 54(2):103–6 (Eng. Abstr.) **(Pol)**

CEREBROSPINAL FLUID

Dapsone penetrates cerebrospinal fluid during Pneumocystis carinii pneumonia prophylaxis. Rich JD, et al. **Diagn Microbiol Infect Dis** 1996 Feb;24(2):77–9

CHEMICAL SYNTHESIS

Synthesis of new (4-alkylamino-4'-fluoro)-diphenyl sulphones with potential biological activity. de Sousa Júnior PT, et al. **An Acad Bras Cienc** 1996;68(2):161–4

Synthetic combinatorial libraries: novel discovery strategy for identification of antimicrobial agents. Blondelle SE, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1067–71 (45 ref.)

Synthesis and antimicrobial properties of new 4-(alkylidene/arylidene)-amino-5-(2-furanyl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones and 6-aryl-3-(2-furanyl)-7H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazines. Ergenç N, et al. **Arch Pharm (Weinheim)** 1996 Aug-Sep;329(8–9):427–30

Research on antifungal and antimycobacterial agents. Synthesis and activity of 4-alkylthiopyridine-2-carbothioamides. Klimešová V, et al. **Arch Pharm (Weinheim)** 1996 Oct;329(10):438–42

Synthesis and antibacterial activity of 1-beta-methylcarbapenem having a 1,3-diazabicyclo[3.3.0]octan-4-one moiety. Nam KH, et al. **Arch Pharm (Weinheim)** 1996 Oct;329(10):443–6

Synthesis and antimicrobial activity of electron rich olefin derived cyclic ureas. Cetinkaya B, et al. **Arzneimittelforschung** 1996 Dec;46(12):1154–8

Synthesis of ethanone derived from 2-benzoxazolinones and their antimicrobial activities. Erol DD, et al. **Arzneimittelforschung** 1996 Feb;46(2):205–6

Synthesis and antimicrobial activities of 2-[(alpha-methylbenzylidene)-hydrazino]benzoxazoles. Ersan S, et al. **Arzneimittelforschung** 1997 Aug;47(8):963–5

Synthesis and antimicrobial activity of 1-dialkylaminomethyl- 2-(p-substituted phenyl)-5-substituted benzimidazole derivatives. Ersan S, et al. **Arzneimittelforschung** 1997 Apr;47(4):410–2

Synthesis and antimycobacterial activity of nitroxanthones. 1st communication: synthesis and differential scanning calorimetry analysis. Ibrom WG, et al. **Arzneimittelforschung** 1997 May;47(5):662–7

Synthesis and antimicrobial evaluation of indole containing derivatives of 1,3,4-thiadiazole, 1,2,4-triazole and their open-chain counterparts. Tsotinis A, et al. **Arzneimittelforschung** 1997 Mar;47(3):307–10

Synthesis and antibacterial activities of some 4,5-dihydro-1H-1,2,4-triazol-5-ones. Yüksek H, et al. **Arzneimittelforschung** 1997 Apr;47(4):405–9

1,3-Dimethylpyrimidoheterocycles as antibacterial agents. Zoorob HH, et al. **Arzneimittelforschung** 1997 Aug; 47(8):958–62

Synthesis of reversed magainin 2 analogs enhanced antibacterial activity. Iwahori A, et al. **Biol Pharm Bull** 1997 Mar;20(3):267–70

Synthesis and evaluation of some new substituted benzofuran derivatives as potentially active antimicrobial agents. Abdel-Rahman AH, et al. **Boll Chim Farm** 1997 Mar; 136(3):262–5

Synthesis of indole-N-propionitrile, N-propionic acid and N-propionamide derivatives of potential biological activity. El-Desokey SI, et al. **Boll Chim Farm** 1996 Jan; 135(1):24–30

Synthesis and antimicrobial activities of some dithiocarbamate derivatives of Kojic acid. Erol DD, et al. **Boll Chim Farm** 1995 Dec;134(11):620–3

Studies on arylfuran derivatives—Part V. Synthesis and antibacterial properties of 7H,6-[5-(4-nitrophenyl)-2-furyl]-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazines. Holla BS, et al. **Boll Chim Farm** 1996 Jul-Aug;135(7):447–51

Studies on arylfuran derivatives—Part IV. Synthesis and antibacterial properties of arylfurylvinylquinazolinones. Holla BS, et al. **Boll Chim Farm** 1996 May;135(5):351–4

Synthesis and biological activity studies of 1,3,4-thiadiazolo[2,3-c]-as-triazines. Kalluraya B, et al. **Boll Chim Farm** 1997 Mar;136(3):266–71

Studies on the synthesis and biological activity of 3-(substituted anilinomethyl)-4-(5-substituted-2-furfurylidene)amino-1,2,4 -triazole-5- thiones and their Mannich bases. Kalluraya B, et al. **Boll Chim Farm** 1996 Dec; 135(11):638–42

Aminoazoles in heterocyclic synthesis. Synthesis of some new pyrimidobenzimidazoles and pyrazolonopyridines as well as triazolo-, tetrazolo- and pyrazolo-pyrimidines of pharmaceutical interest. Kandeel EM, et al. **Boll Chim Farm** 1996 Apr;135(4):232–5

Behaviour of hexahydrobenzodipyrazolones towards chloroacetylation, aminoalkylation, Grignard reagent and their antimicrobial activity. Metwally MA, et al. **Boll Chim Farm** 1995 Dec;134(11):616–9

Synthesis and biological activity of some pyrimidine derivatives. Pluta J, et al. **Boll Chim Farm** 1996 Sep; 135(8):459–64

Synthesis and biological activity of nifuroxazide and analogs. Tavares LC, et al. **Boll Chim Farm** 1997 Mar;136(3):244–9

Development of bioactive functions in hydrangeae dulcis folium. VI. Syntheses of thunberginols A and F and their 3'-deoxy-derivatives using regiospecific lactonization of stilbene carboxylic acid: structures and inhibitory activity on histamine release of hydramacrophyllols A and B. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Oct; 44(10):1890–8

A synthetic form of tracheal antimicrobial peptide has both bactericidal and antifungal activities. Lawyer C, et al. **Drug Des Discov** 1996 Dec;14(3):171–8

Synthesis of some 1-(2-arylvinyl)-3-arylpyrazino[1,2-a]benzimidazole derivatives and their antimicrobial activities. Demirayak S, et al. **Farmaco** 1996 Dec;51(12):825–7

Synthesis and antimicrobial assays of 3-diazoindole-2-carboxamides. Garuti L, et al. **Farmaco** 1996 Nov;51(11):757–60

Pyridazine N-oxides. II. Synthesis and in vitro antimicrobial evaluation of 3-chloro-4-carbamoyl-5-aryl-6-methyl-pyridazine N-oxides. Gavini E, et al. **Farmaco** 1997 Jan;52(1):67–9

Synthesis and antimicrobial evaluation of 2 beta-chloromethyl-6 beta-carbamoylmethyl-penam-1,1-dioxide-3-carboxylic acid. Gaviraghi G, et al. **Farmaco** 1996 Jul;51(7):535–8

Synthesis of 1,2-disubstituted benzimidazole-5(6)-carboxamides and evaluation of their antimicrobial activity. Göker H, et al. **Farmaco** 1996 Jan; 51(1):53–8

Studies on arylfuran derivatives-Part VI. Synthesis, characterization and antibacterial activities of some 6-(5-aryl-2-furyl)-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazoles and 6-(5-nitro-2-furyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles. Holla BS, et al. **Farmaco** 1996 Dec; 51(12):785–92

3,6-Disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles: synthesis and evaluation for antimicrobial and antiviral activity. III. Invidiata FP, et al. **Farmaco** 1997 Apr; 52(4):259–61

Synthesis and antimicrobial activity of benzo[a]dihydrocarbazole and benzotetrahydrocyclohept[1,2-b]indole derivatives. Macchia M, et al. **Farmaco** 1996 Jan;51(1):75–8

Synthesis and antimicrobial activity of some 2,5-disubstituted 1,3,4,-thiadiazole derivatives. Mamolo MG, et al. **Farmaco** 1996 Jan;51(1):71–4

Biological studies on 1,2-benzisothiazole derivatives V. Antimicrobial properties of N-alkanoic, N-arylalkanoic and N-aryloxyalkanoic derivatives of 1,2-benzisothiazolin-3-one: QSAR study and genotoxicity evaluation. Mor M, et al. **Farmaco** 1996 Jul;51(7):493–501

Synthesis and biological activity of platinum group metal complexes of o-vanillin thiosemicarbazones. Offiong OE, et al. **Farmaco** 1996 Dec;51(12):801–8

Synthesis of some novel pyrazoline and cyanopyridine derivatives as antimicrobial agents. Patel P, et al. **Farmaco** 1996 Jan;51(1):59–63

Synthesis and antimicrobial activity of some 1,4-disubstituted thiosemicarbazide and 2,5-disubstituted 1,3,4-thiadiazole derivatives. Rollas S, et al. **Farmaco** 1996 Dec;51(12):811–4

Synthesis, antimicrobial and cytostatic activity of 1,2:5,6-di-O-isopropylidene-alpha-D-glucofuranosyl (-)-(S)-propanesulfinate. Saenz MT, et al. **Farmaco** 1996 Aug-Sep;51(8–9):613–5

Antimicrobial activity of 5,6-dihydrobenzo-[a]-carbazoles. Part II. Segall A, et al. **Farmaco** 1996 Jul;51(7):513–6

Synthesis and structure-activity relationships of some 2,5-disubstituted benzoxazoles and benzimidazoles as antimicrobial agents. Sener E, et al. **Farmaco** 1997 Feb; 52(2):99–103

Synthesis and antimicrobial activity of N-(1,2-benzisothiazol-3-yl)amidines. Vicini P, et al. **Farmaco** 1997 Jan;52(1):21–4

Selective interaction of synthetic antimicrobial peptides derived from sapecin B with lipid bilayers. Hirakura Y, et al. **J Biochem (Tokyo)** 1996 Dec;120(6):1130–40

Triorganosilicon (IV) compounds: synthesis, structural study, and biological activity. Singh D, et al. **J Inorg Biochem** 1996 Apr;62(1):67–73

The chemistry of pseudomonic acid. 18. Heterocyclic replacement of the alpha,beta-unsaturated ester: synthesis, molecular modeling, and antibacterial activity. Brown P, et al. **J Med Chem** 1997 Aug 1;40(16):2563–70

Anti-Helicobacter pylori agents. 1. 2-(Alkylguanidino)-4-furylthiazoles and related compounds. Katsura Y, et al. **J Med Chem** 1997 Aug 1; 40(16):2462–5

Design of active analogues of a 15-residue peptide using D-optimal design, QSAR and a combinatorial search algorithm. Mee RP, et al. **J Pept Res** 1997 Jan;49(1):89–102

Synthesis and antibacterial action of cecropin and proline-arginine-rich peptides from pig intestine. Vunnam S, et al. **J Pept Res** 1997 Jan;49(1):59–66

Synthesis of some Mannich bases of 1-cyclohexylidene-N(1,2-dihydro-2-oxo-3H-indol-3-ylidene) thiosemicarbazones and their antibacterial activity. Gupta RP, et al. **Pharm Acta Helv** 1997 Feb;72(1):43–5

Synthesis and antimicrobial testing of thiazolinyl-, thiazolidinonyl-quinoxalines and 1,2,4-triazolo[4,3-a]quinoxalines. Habib NS, et al. **Pharmazie** 1997 Aug;52(8):594–8

A novel synthesis of 1,2,4-triazolo[1,5-a]isoindolinetrione, 1,2,4-triazolo[1,5-a]pyrimidine and 1,2,4-triazolo[2,3-a]quinazolinedione derivatives and their antibacterial activity. Hassan AA, et al. **Pharmazie** 1997 Jan;52(1):23–8

Synthesis of some 2,6-bis(alkylthio)-4-pyridine carboxamides and carboxthioamides and their antimycobacterial and antialgal activity. Miletin M, et al. **Pharmazie** 1997 Jul; 52(7):558–60

Synthesis of novel thiazolo[4,5-d]pyrimidine derivatives for antimicrobial, anti-HIV and anticancer investigation. Rida SM, et al. **Pharmazie** 1996 Dec;51(12):927–31

Synthesis and antimicrobial activities of some new 2-substituted benzoxazoie/benzothiazole derivatives. el-Shaaer HM, et al. **Pharmazie** 1997 Aug;52(8):585–9

Synthesis of acyclo-C-nucleosides: 2-(alditol-1-yl)-5-methylthio- and -5-benzylthio-1,3,4-thiadiazoles. Shaban MA, et al. **Pharmazie** 1997 May;52(5):350–7

Synthesis and reactions of some new 4H-pyrano[3,2-c]benzopyran-5-one derivatives and their potential biological activities. Shaker RM. **Pharmazie** 1996 Mar;51(3):148–51

Synthesis and antimicrobial activity of some bis-quinazoline derivatives. Shiba SA, et al. **Pharmazie** 1997 Mar; 52(3):189–94

Antimicrobial activity of pseudohalogeno(N-salicylidene-alpha-alaninato)cupr ates(II). Sokolik J, et al. **Pharmazie** 1997 May;52(5):408–9

Synthesis and antimicrobial activity of N, N-dialkyl-2-substituted-5-diazo-imidazole-4-carboxamides. Varoli L, et al. **Pharmazie** 1997 Aug; 52(8):578–81

[Synthesis and antimicrobial activities of tetrahydro-2H-1,3,5-thiadiazine-2-thiones] Chen GQ, et al. **Yao Hsueh Hsueh Pao** 1996;31(6):425–30 (Eng. Abstr.) **(Chi)**

CHEMISTRY

A clerodane diterpene with antibacterial activity from Ajuga lupulina. Chen H, et al. **Acta Crystallogr C** 1997 Jun 15; 53 (Pt 6):814–6

Biological activity of 4-(4-bromophenyl)-thiosemicarbazide. Seth S, et al. **Acta Crystallogr C** 1996 Sep 15;52 (Pt 9):2377–9

Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration [published erratum appears in Am J Health Syst Pharm 1997 Mar 1;54(5):587] Hall PD, et al. **Am J Health Syst Pharm** 1997 Jan 15; 54(2):185–9

A matrix-assisted laser desorption ionization time-of-flight mass spectrometry approach to identify the origin of the glycan heterogeneity of diptericin, an O-glycosylated antibacterial peptide from insects. Uttenweiler-Joseph S, et al. **Anal Biochem** 1997 May 1;247(2):366–75

Correlation of trimethoprim and brodimoprim physicochemical and lipid membrane interaction properties with their accumulation in human neutrophils. Fresta M, et al. **Antimicrob Agents Chemother** 1996 Dec; 40(12):2865–73

Expression of cecropin CMIV fusion protein in E. coli under T7 promoter. Xie W, et al. **Biochem Mol Biol Int** 1996 Jun;39(3):487–92

Secondary structure and location of a magainin analogue in synthetic phospholipid bilayers. Hirsh DJ, et al. **Biochemistry** 1996 Oct 1;35(39):12733–41

Mechanisms of action of the bactericidal/permeability-increasing protein BPI on endotoxin and phospholipid monolayers and aggregates. Wiese A, et al. **Biochemistry** 1997 Aug 19;36(33):10301–10

Synthesis and biological evaluation of an electronically activated isooxacephem. Hakimelahi GH, et al. **Bioorg Med Chem** 1996 Aug;4(8):1361–4

Synthesis and structure-activity relationships of cephalosporins, 2-isocephems, and 2-oxaisocephems with C-3' or C-7 catechol or related aromatics. Tsuji K, et al. **Bioorg Med Chem** 1996 Dec;4(12):2135–49

Crystallographic structure of a multiple beta-turn containing, glycine-rich heptapeptide: a synthetic precursor of the lipopeptaibol antibiotic trichodecenin I. Monaco V, et al. **Biopolymers** 1996 Jul;39(1):31–42

CD and NMR structural characterization of ceratotoxins, natural peptides with antimicrobial activity. Ragona L, et al. **Biopolymers** 1996 Nov;39(5):653–64

Solution structure of protegrin-1, a broad-spectrum antimicrobial peptide from porcine leukocytes. Fahrner RL, et al. **Chem Biol** 1996 Jul;3(7):543–50

Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Elmore RL, et al.

Clin Ther 1996 Mar-Apr;18(2):246-55

Gloverin, an antibacterial protein from the immune hemolymph of Hyalophora pupae. Axén A, et al. **Eur J Biochem** 1997 Jul 15;247(2):614-9

Sequence and expression of an Eisenia-fetida-derived cDNA clone that encodes the 40-kDa fetidin antibacterial protein. Lassegues M, et al. **Eur J Biochem** 1997 Jun 15; 246(3):756-62

Temporins, antimicrobial peptides from the European red frog Rana temporaria. Simmaco M, et al. **Eur J Biochem** 1996 Dec 15;242(3):788-92

The solution structure and activity of caerin 1.1, an antimicrobial peptide from the Australian green tree frog, Litoria splendida. Wong H, et al. **Eur J Biochem** 1997 Jul 15;247(2):545-57

A novel antimicrobial peptide from the loach, Misgurnus anguillicaudatus. Park CB, et al. **FEBS Lett** 1997 Jul 14; 411(2-3):173-8

Identification of the region that plays an important role in determining antibacterial activity of bovine seminalplasmin. Sitaram N, et al. **FEBS Lett** 1997 Jan 6;400(3):289-92

Homology modelling of an antimicrobial protein, Ace-AMP1, from lipid transfer protein structures. Gomar J, et al. **Fold Des** 1997;2(3):183-92

Protegrin structure and activity against Neisseria gonorrhoeae. Qu XD, et al. **Infect Immun** 1997 Feb; 65(2):636-9

Novel antibacterial peptides isolated from a European bumblebee, Bombus pascuorum (Hymenoptera, Apoidea). Rees JA, et al. **Insect Biochem Mol Biol** 1997 May; 27(5):413-22

The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. Erah PO, et al. **J Antimicrob Chemother** 1997 Jan;39(1):5-12

Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein. Implications in biological activity. Abrahamson SL, et al. **J Biol Chem** 1997 Jan 24;272(4):2149-55

Isolation and characterization of pleurocidin, an antimicrobial peptide in the skin secretions of winter flounder. Cole AM, et al. **J Biol Chem** 1997 May 2;272(18):12008-13

ASABF, a novel cysteine-rich antibacterial peptide isolated from the nematode Ascaris suum. Purification, primary structure, and molecular cloning of cDNA. Kato Y, et al. **J Biol Chem** 1996 Nov 29;271(48):30493-8

A repertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity. Oren Z, et al. **J Biol Chem** 1997 Jun 6;272(23):14643-9

Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. Skerlavaj B, et al. **J Biol Chem** 1996 Nov 8;271(45):28375-81

Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173-194 from bovine adrenal medullary chromaffin granules. Strub JM, et al. **J Biol Chem** 1996 Nov 8;271(45):28533-40

Two-dimensional 1H NMR experiments show that the 23-residue magainin antibiotic peptide is an alpha-helix in dodecylphosphocholine micelles, sodium dodecylsulfate micelles, and trifluoroethanol/water solution. Gesell J, et al. **J Biomol NMR** 1997 Feb;9(2):127-35

A novel peptide-IgG conjugate, CAP18(106-138)-IgG, that binds and neutralizes endotoxin and kills gram-negative bacteria. Fletcher MA, et al. **J Infect Dis** 1997 Mar; 175(3):621-32

Synthesis, crystal structure, and characterization of two metal-quinolone compounds. Turel I, et al. **J Inorg Biochem** 1997 May 1;66(2):77-82

An electron spin resonance study and antimicrobial activity of copper(II)-phenanthroline complexes. Zoroddu MA, et al. **J Inorg Biochem** 1996 Sep;63(4):291-300

Location of the three disulfide bonds in an antimicrobial peptide from Amaranthus caudatus using mass spectrometry. el Bouyoussfi M, et al. **J Pept Res** 1997 Apr; 49(4):336-40

Determination of disulphide bridges in PG-2, an antimicrobial peptide from porcine leukocytes. Harwig SS, et al. **J Pept Sci** 1995 May-Jun;1(3):207-15

X-ray structural studies and physicochemical characterization of the 1-butanol, 1-pentanol, and 1,4-dioxane solvates of succinylsulfathiazole. Bourne SA, et al. **J Pharm Sci** 1994 Jun;83(6):887-92

QSAR and CAMM study of amphiphilic antimicrobially active 2,2'-bipyridyl monoammonium salts. Devinsky F, et al. **Pharmazie** 1996 Oct;51(10):727-31

Content of the essential oil of the carrot and its antibacterial activity. Kilibarda V, et al. **Pharmazie** 1996 Oct; 51(10):777-8

Micellization and other associations of amphiphilic antimicrobial quaternary ammonium salts in aqueous solutions. Kopecky F. **Pharmazie** 1996 Mar;51(3):135-44 (121 ref.)

Bioactive polyacetylenes from Bidens pilosa [letter] Alvarez L, et al. **Planta Med** 1996 Aug;62(4):355-7

Chemical and antibacterial studies of two Helichrysum species of Greek origin [letter] Chinou IB, et al. **Planta Med** 1997 Apr;63(2):181-3

PR-39, a proline-rich peptide antibiotic from pig, and FALL-39, a tentative human counterpart. Agerberth B, et al. **Vet Immunol Immunopathol** 1996 Nov;54(1-4):127-31 (19 ref.)

ECONOMICS

Over-the-counter antimicrobials: the hidden costs of resistance [letter; comment] Smith RD, et al. **J Antimicrob Chemother** 1996 May;37(5):1031-2. Comment on: J Antimicrob Chemother 1995 Sep;36(3):577-9. Comment on: J Antimicrob Chemother 1995 Sep;36(3):579-84.

Viral load and combination therapy for human immunodeficiency virus [letter; comment] Feder HM Jr, et al. **N Engl J Med** 1997 Mar 27;336(13):959-60; discussion 960. Comment on: N Engl J Med 1996 Aug 8;335(6):428-30. Comment on: N Engl J Med 1996 Oct 10;335(15):1142-4.

A pharmacist-initiated program of intravenous to oral antibiotic conversion. Przybylski KG, et al. **Pharmacotherapy** 1997 Mar-Apr;17(2):271-6

HISTORY

[The 75th anniversary of the discovery of lysozyme] Sazykin IuO. **Antibiot Khimioter** 1997;42(5):38-9 **(Rus)**

IMMUNOLOGY

Trimethoprim/sulfamethoxazole desensitization. Cortese LM, et al. **Ann Pharmacother** 1996 Feb;30(2):184-6 (10 ref.)

ISOLATION & PURIFICATION

6'-O-apiosyl-verbascoside in the flowers of mullein (Verbascum species). Klimek B. **Acta Pol Pharm** 1996 Mar-Apr;53(2):137-40

A new bioactive metabolite from Xanthoria steineri . el-Fattah HA. **Boll Chim Farm** 1997 Mar;136(3):257-61

Development of bioactive functions in hydrangeae dulcis folium. V. On the antiallergic and antimicrobial principles of hydrangeae dulcis folium. (2). Thunberginols C, D, and E, thunberginol G 3'-O-glucoside, (-)-hydrangenol 4'-o-glucoside, and (+)-hydrangenol 4'-O-glucoside. Yoshikawa M, et al. **Chem Pharm Bull (Tokyo)** 1996 Aug; 44(8):1440-7

A member of the arthropod defensin family from edible Mediterranean mussels (Mytilus galloprovincialis) [published erratum appears in Eur J Biochem 1996 Sep 15;240(3):815] Hubert F, et al. **Eur J Biochem** 1996 Aug 15;240(1):302-6

Purification, characterisation and cDNA cloning of an antimicrobial peptide from Macadamia integrifolia. Marcus JP, et al. **Eur J Biochem** 1997 Mar 15;244(3):743-9

Molecular characterization of ceratotoxin C, a novel antibacterial female-specific peptide of the ceratotoxin family from the medfly Ceratitis capitata. Rosetto M, et al. **Eur J Biochem** 1996 Oct 15;241(2):330-7

Purification and characterization of a proline-rich antibacterial peptide, with sequence similarity to bactenecin-7, from the haemocytes of the shore crab, Carcinus maenas. Schnapp D, et al. **Eur J Biochem** 1996 Sep 15;240(3):532-9

Purification and in vitro activities of rabbit platelet microbicidal proteins. Yeaman MR, et al. **Infect Immun** 1997 Mar;65(3):1023-31

Comparison of supercritical CHF3 and CO2 and methanol-modified CHF3 and CO2 for extraction of sulfonamides from chicken liver. Ashraf-Khorassani M, et al. **J AOAC Int** 1996 Sep-Oct;79(5):1043-9

A novel family of small cysteine-rich antimicrobial peptides from seed of Impatiens balsamina is derived from a single precursor protein. Tailor RH, et al. **J Biol Chem** 1997 Sep 26;272(39):24480-7

Supercritical fluid extraction of sulphamethazine and its metabolites from meat tissues. Din N, et al. **J Chromatogr Sci** 1997 Jan;35(1):31-7

Antibacterial activity of the phenolic acids fractions of Scrophularia frutescens and Scrophularia sambucifolia. Fernández MA, et al. **J Ethnopharmacol** 1996 Jul 26; 53(1):11-4

Chemical composition and antimicrobial activity of Croton urucurana Baillon (Euphorbiaceae). Peres MT, et al. **J Ethnopharmacol** 1997 May;56(3):223-6

Antimicrobial activity of flavonoids from leaves of Tagetes minuta. Tereschuk ML, et al. **J Ethnopharmacol** 1997 May; 56(3):227-32

Compounds from Syzygium aromaticum possessing growth inhibitory activity against oral pathogens. Cai L, et al. **J Nat Prod** 1996 Oct;59(10):987-90

Triterpene saponins from Cyclamen mirabile and their biological activities. Calis T, et al. **J Nat Prod** 1997 Mar; 60(3):315-8

Identification of the novel antimicrobial fatty acid (5Z,9Z)-14-methyl-5,9-pentadecadienoic acid in Eunicea succinea. Carballeira NM, et al. **J Nat Prod** 1997 May; 60(5):502-4

Antibacterial neoclerodane diterpenoids from Ajuga lupulina. Chen H, et al. **J Nat Prod** 1996 Jul;59(7):668-70

Massetolides A-H, antimycobacterial cyclic depsipeptides produced by two pseudomonads isolated from marine habitats. Gerard J, et al. **J Nat Prod** 1997 Mar;60(3):223-9

Spinonin, a novel glycoside from Ononis spinosa subsp. leiosperma. Kirmizigül S, et al. **J Nat Prod** 1997 Apr; 60(4):378-81

A new glycoside antimicrobial agent from Persoonia linearis x pinifolia. MacLeod JK, et al. **J Nat Prod** 1997 Jun; 60(6):620-2

Macrocarpals H, I, and J from the Leaves of Eucalyptus globulus. Osawa K, et al. **J Nat Prod** 1996 Sep;59(9):823-7

Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru. Perry NB, et al. **J Nat Prod** 1997 Jun;60(6):623-6

Isolation and structure of hemibastadinols 1-3 from the Papua New Guinea marine sponge Ianthella basta. Pettit GR, et al. **J Nat Prod** 1996 Oct;59(10):927-34

New macrocyclic spermine (budmunchiamine) alkaloids from Albizia gummifera: with some observations on the structure--activity relationships of the budmunchiamines. Rukunga GM, et al. **J Nat Prod** 1996 Sep;59(9):850-3

Isolation of guaianoid pigments from the gorgonian Calicogorgia granulosa. Seo Y, et al. **J Nat Prod** 1996 Oct; 59(10):985-6

Anserinones A and B: new antifungal and antibacterial benzoquinones from the coprophilous fungus Podospora anserina. Wang H, et al. **J Nat Prod** 1997 Jun;60(6):629-31

Separation of diastereoisomers of DuP 105, a novel oxazolidinone antibacterial agent, by supercritical fluid chromatography on a Chiralcel OD column. Alasandro M. **J Pharm Biomed Anal** 1996 May;14(7):807-14

Antibacterial activity of xanthones from guttiferaeous plants against methicillin-resistant Staphylococcus aureus. Iinuma M, et al. **J Pharm Pharmacol** 1996 Aug;48(8):861-5

Biology and biological action of the defensive secretion from a Jamaican millipede. Williams LA, et al. **Naturwissenschaften** 1997 Apr;84(4):143-4

A new flavone glycoside with antimicrobial activity from Carduus pycnocephalus L. el-Lakany AM, et al. **Pharmazie** 1997 Jan;52(1):78-9

Antibacterial and antifungal compounds from Kigelia pinnata [letter] Binutu OA, et al. **Planta Med** 1996 Aug;62(4):352-3

Phenolic and antibacterial constituents of Vahlia capensis [letter] Majinda RR, et al. **Planta Med** 1997 Jun; 63(3):268-70

Antibacterial and antifungal compounds from Empetrum nigrum. Matsuura H, et al. **Planta Med** 1995 Dec;61(6):580

Uptake and exudation of phenolic compounds by wheat and antimicrobial components of the root exudate. Kobayashi A, et al. **Z Naturforsch [C]** 1996 Jul-Aug;51(7-8):527-33

[Preparation of fiber materials containing both the immobilized proteolytic enzyme and antimicrobial substance, and study of their properties] Virnik AD, et al. **Prikl Biokhim Mikrobiol** 1996 Nov-Dec;32(6):615-9 (Eng. Abstr.) **(Rus)**

METABOLISM

Endogenous vertebrate antibiotics. Defensins, protegrins, and other cysteine-rich antimicrobial peptides. Lehrer RI, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:228-39 (55 ref.)

Multidrug efflux in intrinsic resistance to trimethoprim and sulfamethoxazole in Pseudomonas aeruginosa. Köhler T, et al. **Antimicrob Agents Chemother** 1996 Oct; 40(10):2288-90

Active efflux of antimicrobial agents in wild-type strains of enterococci. Lynch C, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):869-71

Transport of the antibacterial agent oxazolidin-2-one and derivatives across intestinal (Caco-2) and renal (MDCK) epithelial cell lines. Ranaldi G, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):652-8

Macrophages expressing a fusion protein derived from bactericidal/permeability-increasing protein and IgG are resistant to endotoxin. Dahlberg PS, et al. **Arch Surg** 1996 Nov;131(11):1173-7; discussion 1177-8

Membrane permeabilization mechanisms of a cyclic antimicrobial peptide, tachyplesin I, and its linear analog. Matsuzaki K, et al. **Biochemistry** 1997 Aug 12; 36(32):9799-806

The tendency of magainin to associate upon binding to phospholipid bilayers. Schümann M, et al. **Biochemistry** 1997 Apr 8;36(14):4345-51

Peptide hydrophobicity controls the activity and selectivity of magainin 2 amide in interaction with membranes. Wieprecht T, et al. **Biochemistry** 1997 May 20; 36(20):6124-32

Bilayer interactions of indolicidin, a small antimicrobial peptide rich in tryptophan, proline, and basic amino acids. Ladokhin AS, et al. **Biophys J** 1997 Feb;72(2 Pt 1):794-805

The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. Gill HJ, et al. **Br J Clin Pharmacol** 1996 Sep;42(3):347-53

Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Goldman MJ, et al. **Cell** 1997 Feb 21;88(4):553-60

Photodegradation products of a new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution. Morimura T, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb;45(2):373-7

Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level. Guo R, et al. **Chin Med J (Engl)** 1996 Dec;109(12):933-6

Expression of antimicrobial peptide genes after infection by parasitoid wasps in Drosophila. Nicolas E, et al. **Dev Comp Immunol** 1996 May-Jun;20(3):175-81

Periodontal disease, oral microbial flora and salivary antibacterial factors in diabetes mellitus type 1 patients. Pinducciu G, et al. **Eur J Epidemiol** 1996 Dec;12(6):631-6

Cryptic domains of a 60 kDa heat shock protein of Helicobacter pylori bound to bovine lactoferrin. Amini HR, et al. **FEMS Immunol Med Microbiol** 1996 Dec 31; 16(3–4):247–55

Binding of 14C-furazolidone metabolites to the muscular and hepatic proteins of trout. Law FC, et al. **Food Addit Contam** 1996 Feb–Mar;13(2):199–209

The prevalence and possible causes of bound and extractable residues of the furazolidone metabolite 3-amino-2-oxazolidinone in porcine tissues. McCracken RJ, et al. **Food Addit Contam** 1997 Apr;14(3):287–94

Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis. van der Ven AJ, et al. **J Antimicrob Chemother** 1996 May; 37 Suppl B:55–60 (22 ref.)

Multidrug efflux pumps of gram-negative bacteria. Nikaido H. **J Bacteriol** 1996 Oct;178(20):5853–9 (57 ref.)

Deposition profile of antibacterial anodic silver in root canal systems of teeth. Aydin M, et al. **J Biomed Mater Res** 1997 Spring;38(1):49–54

N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. Spielberg SP. **J Pharmacokinet Biopharm** 1996 Oct;24(5):509–19

The biotransformation of sulfadimethoxine, sulfadimidine, sulfamethoxazole, trimethoprim and aditoprim by primary cultures of pig hepatocytes. Mengelers MJ, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):24–32

Binding of sulphamethazine to pig plasma proteins and albumin. Munsey T, et al. **J Vet Pharmacol Ther** 1996 Apr; 19(2):135–41

Antibiotic and biocide resistance in bacteria. Russell AD, et al. **Microbios** 1996;85(342):45–65 (118 ref.)

A single amino acid substitution in the antimicrobial defense protein cecropin B is associated with diminished degradation by leaf intercellular fluid. Owens LD, et al. **Mol Plant Microbe Interact** 1997 May;10(4):525–8

Origin of the thiazole ring of camalexin, a phytoalexin from Arabidopsis thaliana. Zook M, et al. **Plant Physiol** 1997 Feb;113(2):463–8

Expression of recombinant alpha Ains-crystallin and not alpha A-crystallin inhibits bacterial growth. Bhat SP, et al. **Protein Eng** 1996 Aug;9(8):713–8

A mechanism of drug action revealed by structural studies of enoyl reductase. Baldock C, et al. **Science** 1996 Dec 20;274(5295):2107–10

[Effects of residues of anti-infective agents in animal excretions on slurry treatment and the soil] Böhm R. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):264–8 (12 ref.) (Eng. Abstr.) **(Ger)**

[Coupled transbilayer transport of peptides, lipids, and ions mediated by a peptide-lipid supramolecular complex pore] Matsuzaki K, et al. **Seikagaku** 1997 Feb;69(2):119–22 (14 ref.) **(Jpn)**

PHARMACOKINETICS

Accumulation of trimethoprim, sulfamethoxazole, and N-acetylsulfamethoxazole in fish and shrimp fed medicated Artemia franciscana. Chair M, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1649–52

Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. Gatti G, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2743–8

Disposition of intravenous metronidazole in Asian surgical patients. Ti TY, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2248–51

Alteration of the pharmacokinetics of small proteins by iodination. Bauer RJ, et al. **Biopharm Drug Dispos** 1996 Dec;17(9):761–74

Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. Kim YG, et al. **Biopharm Drug Dispos** 1996 Apr;17(3):183–95

Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: a critical view. Mahmood I. **Biopharm Drug Dispos** 1997 Aug;18(6):465–73

Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. Yoon EJ, et al. **Biopharm Drug Dispos** 1996 Jul; 17(5):373–420

Depletion of dietary sulphamonomethoxine and sulphadimethoxine from various tissues of laying hens. Furusawa N, et al. **Br Poult Sci** 1996 May;37(2):435–42

Comparing non-hierarchical models: application to non-linear mixed effects modeling. Ette EI. **Comput Biol Med** 1996 Nov;26(6):505–12

Reductive activation of nitroheterocyclic compounds. Tocher JH. **Gen Pharmacol** 1997 Apr;28(4):485–7 (27 ref.)

Determining equivalence and the impact of sample size in anti-infective studies: a point to consider. Bristol DR. **J Biopharm Stat** 1996 Jul;6(3):319–26

The effect of acetylation and deacetylation on the disposition of dapsone and monoacetyl dapsone hydroxylamines in human erythrocytes in-vitro. Coleman MD, et al. **J Pharm Pharmacol** 1996 Apr;48(4):401–6

Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. Takeda S, et al. **J Pharm Pharmacol** 1996 Sep;48(9):902–5

Bioavailability of ruminally protected sulfamethoxazole after oral administration in ruminating calves. Nishida Y, et al. **J Vet Med Sci** 1997 Apr;59(4):289–91

Relative bioavailability of microgranulated sulfadimidine in veal calves. Anfossi P, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):300–4

The disposition of five therapeutically important antimicrobial agents in llamas. Christensen JM, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):431–8

A study of the pharmacokinetics and tissue residues of an oral trimethoprim/sulphadiazine formulation in healthy pigs. Garwacki S, et al. **J Vet Pharmacol Ther** 1996 Dec; 19(6):423–30

Evaluation of the dorsal aorta cannulation technique for pharmacokinetic studies in Atlantic salmon (Salmo salar) in sea water. Sohlberg S, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):460–5

Penetration of dapsone into lung of human immunodeficiency virus-infected children. Gatti G, et al. **Pediatr Infect Dis J** 1997 May;16(5):523–4

Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Rubio TT, et al. **Pediatr Infect Dis J** 1997 Jan;16(1):112–7; discussion 123–6

Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS. Klepser ME, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):656–62

A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods. Jelliffe RW, et al. **Ther Drug Monit** 1997 Aug;19(4):450–9

Pharmacokinetics of antimicrobial agents in the respiratory tract. Cruciani M, et al. **Zentralbl Bakteriol** 1996 Jun; 284(1):1–31 (154 ref.)

PHARMACOLOGY

Biological activity of 4-(4-bromophenyl)-thiosemicarbazide. Seth S, et al. **Acta Crystallogr C** 1996 Sep 15;52 (Pt 9):2377–9

Antibacterial effects of amalgams on mutans streptococci in an in vitro biofilm test procedure. Netuschil L, et al. **Acta Stomatol Belg** 1996 Jun;93(2):73–8

Anti-Escherichia coli adhesin activity of cranberry and blueberry juices. Ofek I, et al. **Adv Exp Med Biol** 1996; 408:179–83 (16 ref.)

In-vitro evaluation of the antimicrobial activities of Enantia chlorantha Oliv. extractives. Moody JO, et al. **Afr J Med Med Sci** 1995 Sep;24(3):269–73

Dapsone and HIV-1 replication in primary cultures of lymphocytes and monocyte-derived macrophages [letter] Duval X, et al. **AIDS** 1997 Jun;11(7):943–4

The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Lin CC, et al. **Am J Chin Med** 1996;24(1):31–6

Effects of Glycyrrhizae and Glycyrrhizic acid on radiation injury in mice. Lin IH, et al. **Am J Chin Med** 1996; 24(3–4):279–88

Mechanisms of bacterial resistance to antimicrobial agents. McManus MC. **Am J Health Syst Pharm** 1997 Jun 15; 54(12):1420–33; quiz 1444–6 (131 ref.)

Demonstration of synergistic effects of sulfonamides and dihydrofolate reductase/thymidylate synthase inhibitors against Neospora caninum tachyzoites in cultured cells, and characterization of mutants resistant to pyrimethamine. Lindsay DS, et al. **Am J Vet Res** 1996 Jan;57(1):68–72

Bismuth-dimercaprol exposes surface components of Klebsiella pneumoniae camouflaged by the polysaccharide capsule. Domenico P, et al. **Ann N Y Acad Sci** 1996 Oct 25;797:269–70

Screening of in vitro antibacterial activity from Syzygium Guineense (Willd) hydrosoluble dry extract. Tsakala TM, et al. **Ann Pharm Fr** 1996;54(6):276–9

Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Arain TM, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1536–41

Reporter gene technology to assess activity of antimycobacterial agents in macrophages. Arain TM, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1542–4

Small, anionic, and charge-neutralizing propeptide fragments of zymogens are antimicrobial. Brogden KA, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1615–7

Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type beta-lactamases. Caniça MM, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):374–8

Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Cappelletty DM, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):677–83

The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Chopra I, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):497–503 (72 ref.)

Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Collins L, et al. **Antimicrob Agents Chemother** 1997 May; 41(5):1004–9 **(Eng, Eng)**

Genetic characterization of trimethoprim resistance in Haemophilus influenzae. de Groot R, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2131–6

Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Doern GV, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):292–7

Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Doern GV, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2884–6

In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Dubreuil L, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2266–70

In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Eliopoulos GM, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1745–7

Influence of external factors in resistance of Corynebacterium urealyticum to antimicrobial agents. Garcia-Bravo M, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):497–9

Susceptibility testing of Mycobacterium avium complex isolates. Heifets L. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1759–67 (117 ref.)

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Jones RN, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):720–6

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Jorgensen JH, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):465–7

Susceptibilities of bovine summer mastitis bacteria to antimicrobial agents. Jousimies-Somer H, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):157–60

In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Kaatz GW, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):799–801

In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. Klugman KP, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2802–4

Increasing antibiotic resistance in clinical isolates of Aeromonas strains in Taiwan. Ko WC, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1260–2

Problem of antimicrobial resistance of fecal aerobic gram-negative bacilli in the elderly. Leistevuo T, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2399–403

The population dynamics of antimicrobial chemotherapy. Lipsitch M, et al. **Antimicrob Agents Chemother** 1997 Feb; 41(2):363–73

Antimicrobial susceptibility pattern of Corynebacterium striatum. Martínez-Martínez L, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2671–2

Antimicrobial action of rabbit leukocyte CAP18(106–137). Mason DJ, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):624–9

Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Midolo PD, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1531–3

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Mulazimoglu L, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2428–30

In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Ohba F, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):298–307

Enhanced in vitro activity of pyrimethamine in combination with dapsone against Mycobacterium avium complex. Shah LM, et al. **Antimicrob Agents Chemother** 1996 Oct; 40(10):2426–7

Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex. Shah LM, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2644–5

Antibacterial activity of a synthetic peptide (PR-26) derived from PR-39, a proline-arginine-rich neutrophil antimicrobial peptide. Shi J, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):115–21

Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Spangler SK, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):481–4

Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Spangler SK, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):772–5

Evaluation of susceptibility of gram-positive and -negative bacteria to human defensins by using radial diffusion assay. Takemura H, et al. **Antimicrob Agents Chemother** 1996 Oct; 40(10):2280–4

In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs. Viora M, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1294–7

The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro. Wyrick PB, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1335–44

Substratum topography influences susceptibility of Salmonella enteritidis biofilms to trisodium phosphate. Korber DR, et al. **Appl Environ Microbiol** 1997 Sep;

63(9):3352–8
Growth inhibition of metronidazole-susceptible and metronidazole-resistant strains of Gardnerella vaginalis by Lactobacilli in vitro. McLean NW, et al. **Appl Environ Microbiol** 1996 Mar;62(3):1089–92
Inhibition of microbial growth by ajoene, a sulfur-containing compound derived from garlic. Naganawa R, et al. **Appl Environ Microbiol** 1996 Nov;62(11):4238–42
Functional mapping of amino acid residues responsible for the antibacterial action of apidaecin. Taguchi S, et al. **Appl Environ Microbiol** 1996 Dec;62(12):4652–5
Respiratory stimulation and generation of superoxide radicals in Pseudomonas aeruginosa by fungal naphthoquinones. Haraguchi H, et al. **Arch Microbiol** 1997 Jan;167(1):6–10
Research on antifungal and antimycobacterial agents. Synthesis and activity of 4-alkylthiopyridine-2-carbothioamides. Klimešová V, et al. **Arch Pharm (Weinheim)** 1996 Oct;329(10):438–42
Synthesis and antibacterial activity of 1-beta-methylcarbapenem having a 1,3-diazabicyclo[3.3.0]octan-4-one moiety. Nam KH, et al. **Arch Pharm (Weinheim)** 1996 Oct;329(10):443–6
Antimicrobial effects of oligoamines. Rehse K, et al. **Arch Pharm (Weinheim)** 1996 Mar;329(3):155–60
Antimicrobial activity of carbene complexes of rhodium(I) and ruthenium(II). Cetinkaya B, et al. **Arzneimittelforschung** 1996 Aug;46(8):821–3
Synthesis and antimicrobial activity of electron rich olefin derived cyclic ureas. Cetinkaya B, et al. **Arzneimittelforschung** 1996 Dec;46(12):1154–8
Synthesis and antimicrobial activity of beta-[(2-benzimidazolyl)thio]-beta-benzoyl styrene derivatives. Ersan S, et al. **Arzneimittelforschung** 1997 Jun; 47(6):773–5
Antibacterial activity of benzydamine and antibiotic-benzydamine combinations against multifold resistant clinical isolates. Fanaki NH, et al. **Arzneimittelforschung** 1996 Mar;46(3):320–3
Synthesis and antimycobacterial activity of nitroxanthones. 2nd communication: antimycobacterial activity. Ibrom WG, et al. **Arzneimittelforschung** 1997 Jun;47(6):767–73
Activity of cytotoxin P4 from the venom of the cobra snake Naja nigricollis on gram-positive bacteria and eukaryotic cell lines. Möllmann U, et al. **Arzneimittelforschung** 1997 May;47(5):671–3
Inhibition of protein tyrosine kinase by 5-S-GAD, a novel antibacterial substance from an insect. Hijikata M, et al. **Biochem Biophys Res Commun** 1997 Aug 18;237(2):423–6
The concentration-dependent membrane activity of cecropin A. Silvestro L, et al. **Biochemistry** 1997 Sep 23; 36(38):11452–60
Mechanisms of action of bactericidal/permeability-increasing protein BPI on reconstituted outer membranes of gram-negative bacteria. Wiese A, et al. **Biochemistry** 1997 Aug 19;36(33):10311–9
Reactive liposomes encapsulating a glucose oxidase-peroxidase system with antibacterial activity. Hill KJ, et al. **Biochim Biophys Acta** 1997 May 22;1326(1):37–46
Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Matsuzaki K, et al. **Biochim Biophys Acta** 1997 Jul 5; 1327(1):119–30
Purification, characterization and activities of two hemolytic and antibacterial proteins from coelomic fluid of the annelid Eisenia fetida andrei. Milochau A, et al. **Biochim Biophys Acta** 1997 Jan 4;1337(1):123–32
Antibacterial activity of some Garcinia benzophenone derivatives against methicillin-resistant Staphylococcus aureus. Iinuma M, et al. **Biol Pharm Bull** 1996 Feb; 19(2):311–4
On the antibacterial activity of normal and reversed magainin 2 analogs against Helicobacter pylori. Iwahori A, et al. **Biol Pharm Bull** 1997 Jul;20(7):805–8
Antibacterial activity of two alkylamines integrated an indane scaffold: mimicry of a complementary unit on magainin 2. Numao N, et al. **Biol Pharm Bull** 1997 Jul;20(7):800–4
Extraction and purification of effective antimicrobial constituents of Terminalia chebula RETS. against methicillin-resistant Staphylococcus aureus. Sato Y, et al. **Biol Pharm Bull** 1997 Apr;20(4):401–4
Synthesis and structure-activity relationships of cephalosporins, 2-isocephems, and 2-oxaisocephems with C-3' or C-7 catechol or related aromatics. Tsuji K, et al. **Bioorg Med Chem** 1996 Dec;4(12):2135–49
Synthesis and antimicrobial activities of some dithiocarbamate derivatives of Kojic acid. Erol DD, et al. **Boll Chim Farm** 1995 Dec;134(11):620–3
Synthesis and biological activity of nifuroxazide and analogs. Tavares LC, et al. **Boll Chim Farm** 1997 Mar;136(3):244–9
In vitro induction of anti-type 2 T cells by glycyrrhizin. Nakajima N, et al. **Buras** 1996 Dec;22(8):612–7
Antibiotic resistance of Shigella spp., Salmonella spp., and Yersinia spp. isolated in Quebec. Gaudreau C, et al. **Can Commun Dis Rep** 1997 Apr 15;23(8):57–9 **(Eng, Fre)**
The effect of environmental aneuploidy-inducing agents on the microtubule architecture of mitotic meristematic root cells in Hordeum vulgare. Voutsinas G, et al. **Cell Biol Int** 1997 Jul;21(7):411–8
In vitro time-kill curves of cefepime and cefpirome combined with amikacin, gentamicin or ciprofloxacin against Klebsiella pneumoniae producing extended-spectrum beta-lactamase. Elkhaïli H, et al. **Chemotherapy** 1997 Jul-Aug;43(4):245–53
Effect of the growth rate of Pseudomonas aeruginosa biofilms on the susceptibility to antimicrobial agents. Shigeta M, et al. **Chemotherapy** 1997 Mar-Apr;43(2):137–41
Antibacterial activities of tosufloxacin against anaerobic bacteria and the electron micrograph of its bactericidal effects. Takahata M, et al. **Chemotherapy** 1997 May-Jun; 43(3):153–8
Susceptibility of Moraxella catarrhalis to 21 antimicrobial drugs: validity of current NCCLS criteria for the interpretation of agar disk diffusion antibiograms. Traub WH, et al. **Chemotherapy** 1997 May-Jun;43(3):159–67
Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Traub WH, et al. **Chemotherapy** 1997 Jan-Feb; 43(1):10–20
A study of the optimum bacteriostatic action of a synthetic medicine on bacteria using a microcalorimetric method. Liu Y, et al. **Chin J Biotechnol** 1996;12(1):61–5
Effector molecules of the host defence mechanism against Mycobacterium avium complex: the evidence showing that reactive oxygen intermediates, reactive nitrogen intermediates, and free fatty acids each alone are not decisive in expression of macrophage antimicrobial activity against the parasites. Tomioka H, et al. **Clin Exp Immunol** 1997 Aug;109(2):248–54
The antimicrobial agent melittin exhibits powerful in vitro inhibitory effects on the Lyme disease spirochete. Lubke LL, et al. **Clin Infect Dis** 1997 Jul;25 Suppl 1:S48–51
Bacteriologic profile and drug resistance in pediatric patients with symptomatic bacteriuria. al-Mugeiren MM, et al. **Clin Ther** 1996 Mar-Apr;18(2):295–300
Effect of hybrid peptides of cecropin A and melittin in an experimental model of bacterial keratitis. Nos-Barbera S, et al. **Cornea** 1997 Jan;16(1):101–6
Rapid assessment of ceftazidime, ciprofloxacin, and gentamicin susceptibility in exponentially-growing E. coli cells by means of flow cytometry. Walberg M, et al. **Cytometry** 1997 Feb 1;27(2):169–78
Reproducibility of broth microdilution and disk diffusion susceptibility tests of nine antimicrobial agents against Streptococcus pneumoniae ATCC 49619. Fuchs PC, et al. **Diagn Microbiol Infect Dis** 1997 May;28(1):27–9
A synthetic form of tracheal antimicrobial peptide has both bactericidal and antifungal activities. Lawyer C, et al. **Drug Des Discov** 1996 Dec;14(3):171–8
Estimation of direct influence of Ukrain preparation on influenza viruses and the bacteria E. coli and S. aureus. Ciebiada I, et al. **Drugs Exp Clin Res** 1996;22(3-5):219–23
Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands. van der Wouden EJ, et al. **Emerg Infect Dis** 1997 Jul-Sep;3(3):385–9
Intramolecular disulfide bonds enhance the antimicrobial and lytic activities of protegrins at physiological sodium chloride concentrations. Harwig SS, et al. **Eur J Biochem** 1996 Sep 1;240(2):352–7
Antibiotic susceptibility of pneumococci isolated in Austria over a four-year period. Mittermayer H, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):817–20
Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia. Muñoz JL, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):879–82
Pentoxifylline, cyclosporine A and taurolidine inhibit endotoxin-stimulated tumor necrosis factor-alpha production in rat mesangial cell cultures. Leithäuser ML, et al. **Exp Nephrol** 1997 Jan-Feb;5(1):100–4
Synthesis, antimicrobial and genotoxic properties of some benzoimidazole derivatives. Benvenuti S, et al. **Farmaco** 1997 Apr;52(4):231–5
Synthesis and microbiological evaluations of (N-heteroaryl) arylmethanamines and their Schiff bases. Fioravanti R, et al. **Farmaco** 1996 Oct;51(10):643–52
3,6-Disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles: synthesis, antimicrobial and antiviral activity. II. Invidiata FP, et al. **Farmaco** 1996 Oct;51(10):659–64
Biological studies on 1,2-benzisothiazole derivatives VI Antimicrobial activity of 1,2-benzisothiazole and 1,2-benzisothiazolin-3-one derivatives and of some corresponding 1,2-benzisoxazoles. Zani F, et al. **Farmaco** 1996 Nov;51(11):707–13
Differential effects of five types of antipathogenic plant peptides on model membranes. Caaveiro JM, et al. **FEBS Lett** 1997 Jun 30;410(2-3):338–42
Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides. Dathe M, et al. **FEBS Lett** 1997 Feb 17;403(2):208–12
Limulus factor D, a 43-kDa protein isolated from horseshoe crab hemocytes, is a serine protease homologue with antimicrobial activity. Kawabata S, et al. **FEBS Lett** 1996 Dec 2;398(2-3):146–50
Clavanins, alpha-helical antimicrobial peptides from tunicate hemocytes. Lee IH, et al. **FEBS Lett** 1997 Jan 3; 400(2):158–62
Direct expression of PCR products in a cell-free transcription/translation system: synthesis of antibacterial peptide cecropin. Martemyanov KA, et al. **FEBS Lett** 1997 Sep 8;414(2):268–70
Protective effect of lysozyme-galactomannan or lysozyme-palmitic acid conjugates against Edwardsiella tarda infection in carp, Cyprinus carpio L. Nakamura S, et al. **FEBS Lett** 1996 Apr 1;383(3):251–4
Requirements for antibacterial and hemolytic activities in the bovine neutrophil derived 13-residue peptide indolicidin. Subbalakshmi C, et al. **FEBS Lett** 1996 Oct 14;395(1):48–52
Inhibition of Helicobacter pylori by garlic extract (Allium sativum). Cellini L, et al. **FEMS Immunol Med Microbiol** 1996 Apr;13(4):273–7
Relationship between antibacterial activity and cell surface binding of lactoferrin in species of genus Micrococcus. de Lillo A, et al. **FEMS Microbiol Lett** 1997 May 1; 150(1):89–94
Growth inhibition of Prevotella ruminicola by protamine. Madeira HM, et al. **FEMS Microbiol Lett** 1997 May 1; 150(1):81–8
Microbiological activity of whole and fractionated crude extracts of tea (Camellia sinensis), and of tea components. Yam TS, et al. **FEMS Microbiol Lett** 1997 Jul 1; 152(1):169–74
Antimicrobial efficacy of quaternary bisammonium salts and the effect of their sub-MICs on Pseudomonas aeruginosa virulence factors. Hoštacká A, et al. **Folia Microbiol (Praha)** 1995;40(3):283–7
Bactericidal properties of hydrogen peroxide and copper or iron-containing complex ions in relation to leukocyte function. Elzanowska H, et al. **Free Radic Biol Med** 1995 Mar;18(3):437–49
A novel approach to study antibacterial properties of volatile components of selected Indian medicinal herbs. Agnihotri S, et al. **Indian J Exp Biol** 1996 Jul;34(7):712–5
Antibiotic sensitivity patterns of actinomycetes isolated from patients of actinomycetoma. Chaudhuri BN, et al. **Indian J Med Res** 1997 Apr;105:162–6
Antibacterial activity of antileukoprotease. Hiemstra PS, et al. **Infect Immun** 1996 Nov;64(11):4520–4
Isolation, antimicrobial activities, and primary structures of hamster neutrophil defensins. Mak P, et al. **Infect Immun** 1996 Nov;64(11):4444–9
Broad-spectrum antimicrobial activity of human intestinal defensin 5. Porter EM, et al. **Infect Immun** 1997 Jun; 65(6):2396–401
Protegrin structure and activity against Neisseria gonorrhoeae. Qu XD, et al. **Infect Immun** 1997 Feb; 65(2):636–9
Bactericidal activity of a synthetic peptide (CG 117-136) of human lysosomal cathepsin G is dependent on arginine content. Shafer WM, et al. **Infect Immun** 1996 Nov; 64(11):4842–5
Protegrins: structural requirements for inactivating elementary bodies of Chlamydia trachomatis. Yasin B, et al. **Infect Immun** 1996 Nov;64(11):4863–6
The effects of ciprofloxacin on human chondrocytes in cell culture. Mont MA, et al. **Infection** 1996 Mar-Apr; 24(2):151–5
Antimicrobial activity of hop extracts against Listeria monocytogenes in media and in food. Larson AE, et al. **Int J Food Microbiol** 1996 Dec;33(2-3):195–207
Immunomodulatory activity of amphiphilic antimicrobials on mouse macrophages. Bukovský M, et al. **Int J Immunopharmacol** 1996 Jun-Jul;18(6-7):423–6
Study on the anti-inflammatory action of Berberis vulgaris root extract, alkaloid fractions and pure alkaloids. Ivanovska N, et al. **Int J Immunopharmacol** 1996 Oct; 18(10):553–61
Organisms isolated from dogs and cats with anaerobic infections and susceptibility to selected antimicrobial agents. Jang SS, et al. **J Am Vet Med Assoc** 1997 Jun 1; 210(11):1610–4
Serum insulin-like growth factor I (IGF-I) concentrations are increased in pigs fed antimicrobials. Hathaway MR, et al. **J Anim Sci** 1996 Jul;74(7):1541–7
The mode of antibacterial action of the novel agent ZM240304 (D-arabino-2,3,4-tris(4-chlorobenzyl) pentane-1,5-diamine). Barrett-Bee K, et al. **J Antimicrob Chemother** 1996 Oct;38(4):605–14
In-vitro activity of the essential oil of Melaleuca alternifolia against Streptococcus spp [letter] Carson CF, et al. **J Antimicrob Chemother** 1996 Jun;37(6):1177–8
In-vitro studies of two 5-nitroimidazole derivatives. Castelli M, et al. **J Antimicrob Chemother** 1997 Jul;40(1):19–25
In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii. Cirioni O, et al. **J Antimicrob Chemother** 1997 Jan;39(1):45–51
Antimicrobial activities in vitro and in vivo of transition element complexes containing gold(I) and osmium(VI). Elsome AM, et al. **J Antimicrob Chemother** 1996 May; 37(5):911–8
In-vitro activity of lansoprazole against Helicobacter pylori. Figura N, et al. **J Antimicrob Chemother** 1997 May; 39(5):585–90
Kill kinetics of antimicrobial agents against Helicobacter pylori. Flamm RK, et al. **J Antimicrob Chemother** 1996 Oct;38(4):719–25
Bacterial biofilms: resistance to antimicrobial agents. Gander S. **J Antimicrob Chemother** 1996 Jun;37(6):1047–50 (33 ref.)
Enhancement of antibacterial activity of clofazimine against Mycobacterium avium-Mycobacterium intracellulare complex infection induced by IFN-gamma is mediated by TNF-alpha. Gomez-Flores R, et al. **J Antimicrob Chemother** 1997 Feb;39(2):189–97

Inhibitory effects of metronidazole on anaerobic metabolism of phenylalanine and leucine by Peptostreptococcus anaerobius. Hamid A, et al. **J Antimicrob Chemother** 1997 Feb;39(2):129–34

Formulation of 'idealized' topical antimicrobial mixtures for use with cultured skin grafts. Holder IA, et al. **J Antimicrob Chemother** 1996 Sep;38(3):457–63

In-vitro and in-vivo antibacterial activity of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori. Koga T, et al. **J Antimicrob Chemother** 1996 May; 37(5):919–29

Comparison of the Etest with agar dilution for antimicrobial susceptibility testing of Haemophilus ducreyi. Lagergård T, et al. **J Antimicrob Chemother** 1996 Nov;38(5):849–52

Effects of synthetic form of tracheal antimicrobial peptide on respiratory pathogens. Lawyer C, et al. **J Antimicrob Chemother** 1996 Mar;37(3):599–604

Antimicrobial activity of cecropins. Moore AJ, et al. **J Antimicrob Chemother** 1996 Jun;37(6):1077–89

Treatment of experimental systemic mycoses with BRL 49594A. Najvar LK, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1005–1011

The effect of antimicrobial agents on the induction of tumour necrosis factor by alveolar macrophages in vitro in response to endotoxin. Nwariaku FE, et al. **J Antimicrob Chemother** 1997 Feb;39(2):265–7

Evolution of the bacterial dihydrofolate reductase inhibitors. Periti P. **J Antimicrob Chemother** 1995 Dec;36(6):887–90 (27 ref.)

Brodimoprim synergy against Enterococcus faecalis evaluated in vitro. Richards RM, et al. **J Antimicrob Chemother** 1996 Jul;38(1):27–37

Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects. Shah A, et al. **J Antimicrob Chemother** 1996 Jul;38(1):103–16

Oxygen scavenging, NADH oxidase and metronidazole resistance in Helicobacter pylori. Smith MA, et al. **J Antimicrob Chemother** 1997 Mar;39(3):347–53

Trends in-original research published from the United Kingdom in the antimicrobial chemotherapy literature, 1980–1994. Williams AR, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1097–101

Flow cytometry for rapid assessment of viability after exposure to a quaternary ammonium compound. Langsrud S, et al. **J Appl Bacteriol** 1996 Oct;81(4):411–8

Antibacterial activity of anacardic acid and totarol, alone and in combination with methicillin, against methicillin-resistant Staphylococcus aureus. Muroi H, et al. **J Appl Bacteriol** 1996 Apr;80(4):387–94

Adaptation to sulfonamide resistance in Neisseria meningitidis may have required compensatory changes to retain enzyme function: kinetic analysis of dihydropteroate synthases from N. meningitidis expressed in a knockout mutant of Escherichia coli. Fermér C, et al. **J Bacteriol** 1997 Feb; 179(3):831–7

PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance. Gunn JS, et al. **J Bacteriol** 1996 Dec;178(23):6857–64

A repertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity. Oren Z, et al. **J Biol Chem** 1997 Jun 6;272(23):14643–9

A new anti-infective collagen dressing containing antibiotics. Grzybowski J, et al. **J Biomed Mater Res** 1997 Aug; 36(2):163–6

A study of the influence of biphase calcium phosphate ceramics on bacterial strains: in vitro approach. Opalchenova G, et al. **J Biomed Mater Res** 1996 Jun; 31(2):219–26

The contributions of animal research to care of the burn victim: the development of topical antimicrobials. Peck MD, et al. **J Burn Care Rehabil** 1996 Jan–Feb; 17(1):27A–8A

Antibiotic susceptibility of clinical isolates of Prevotella bivia in Lagos, Nigeria. Egwari LO, et al. **J Chemother** 1996 Feb;8(1):47–51

Type frequency and antimicrobial susceptibility of Mycobacterium avium-intracellulare complex strains isolated in Italy from AIDS and non-AIDS patients. Fattorini L, et al. **J Chemother** 1996 Feb;8(1):37–42

The prohost effect of antimicrobial agents as a predictor of clinical outcome. Labro MT. **J Chemother** 1997 May;9 Suppl 1:100–8 (50 ref.)

Overcoming Streptococcus agalactiae in vitro resistance to imidazoles. Simonetti N, et al. **J Chemother** 1997 Aug; 9(4):251–6

Influence of subinhibitory concentrations of ceftazidime, ciprofloxacin and azithromycin on the morphology and adherence of P-fimbriated escherichia coli. Vranes J, et al. **J Chemother** 1996 Aug;8(4):254–60

Susceptibilities to co-trimoxazole of pathogens isolated from blood and stool specimens in Abidjan, Ivory Coast, 1994 to 1996 [letter] Anglaret X, et al. **J Clin Microbiol** 1997 Jul;35(7):1915

Interpretive criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. The Antimicrobial Susceptibility Testing OC Group. Fuchs PC, et al. **J Clin Microbiol** 1997 Jan;35(1):125–31

A simple method for determining metronidazole resistance of Helicobacter pylori. Henriksen TH, et al. **J Clin Microbiol** 1997 Jun;35(6):1424–6

Comparison of Etest and agar dilution method for antimicrobial susceptibility testing of Flavobacterium isolates. Hsueh PR, et al. **J Clin Microbiol** 1997 Apr; 35(4):1021–3

Direct activity of recombinant human lactoferrin against Helicobacter pylori. Miehlke S, et al. **J Clin Microbiol** 1996 Oct;34(10):2593–4

Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. Piccolomini R, et al. **J Clin Microbiol** 1997 Jul;35(7):1842–6

Prolonged antimicrobial effect of tissue conditioners containing silver-zeolite. Matsuura T, et al. **J Dent** 1997 Sep;25(5):373–7

Sensitivity of periodontal pathogens to the bactericidal activity of synthetic protegrins, antibiotic peptides derived from porcine leukocytes. Miyasaki KT, et al. **J Dent Res** 1997 Aug;76(8):1453–9

Antimicrobial and immunological activity of ethanol extracts and fractions from Isopyrum thalictroides. Ivanovska N, et al. **J Ethnopharmacol** 1996 Nov;54(2–3):143–51

Antibacterial activity of Helichrysum pedunculatum used in circumcision rites. Meyer JJ, et al. **J Ethnopharmacol** 1996 Jul 26;53(1):51–4

Biological studies of Bolax gummifera, a plant of the Falkland Islands used as a treatment of wounds. Mongelli E, et al. **J Ethnopharmacol** 1997 Apr;56(2):117–21

Screening of Uruguayan medicinal plants for antimicrobial activity. Part II. Olano I, et al. **J Ethnopharmacol** 1996 Aug;53(2):111–5

Antibacterial activity of South African plants used for medicinal purposes. Rabe T, et al. **J Ethnopharmacol** 1997 Mar;56(1):81–7

Flavones with antibacterial activity against cariogenic bacteria. Sato M, et al. **J Ethnopharmacol** 1996 Nov; 54(2–3):171–6

Antimicrobial activity of flavonoids from leaves of Tagetes minuta. Tereschuk ML, et al. **J Ethnopharmacol** 1997 May; 56(3):227–32

Etiology of bloody diarrhea in Bolivian children: implications for empiric therapy. Bolivian Dysentery Study Group. Townes JM, et al. **J Infect Dis** 1997 Jun;175(6):1527–30

Potent 6-desfluoro-8-methylquinolones as new lead compounds in antibacterial chemotherapy. Cecchetti V, et al. **J Med Chem** 1996 Dec 6;39(25):4952–7

Antimicrobial alpha, alpha-dialkylated amino acid rich peptides with in-vivo activity against an intracellular pathogen. Yokum TS, et al. **J Med Chem** 1996 Sep 13; 39(19):3603–5

Indigenous bacterial flora of medicinal leeches and their susceptibilities to 15 antimicrobial agents. Nonomura H, et al. **J Med Microbiol** 1996 Dec;45(6):490–3

Development of antibiotic resistance: a vet's tale. Wray C. **J Med Microbiol** 1997 Jan;46(1):26–33 (228 ref.)

Montiporic acids A and B, cytotoxic and antimicrobial polyacetylene carboxylic acids from eggs of the scleractinian coral Montipora digitata. Fusetani N, et al. **J Nat Prod** 1996 Aug;59(8):796–7

Antimicrobial and hemolytic activities of crabrolin, a 13-residue peptide from the venom of the European hornet, Vespa crabro, and its analogs. Krishnakumari V, et al. **J Pept Res** 1997 Aug;50(2):88–93

Effects of metronidazole on Porphyromonas gingivalis biofilms. Wright TL, et al. **J Periodontal Res** 1997 Jul; 32(5):473–7

Studies on the inhibitory effects of analogues of dapsone on neutrophil function in-vitro. Coleman MD, et al. **J Pharm Pharmacol** 1997 Jan;49(1):53–7

Antibacterial activity of xanthones from guttiferaeous plants against methicillin-resistant Staphylococcus aureus. Iinuma M, et al. **J Pharm Pharmacol** 1996 Aug;48(8):861–5

Mechanism for synergism between sulphonamides and trimethoprim clarified. Richards RM, et al. **J Pharm Pharmacol** 1996 Sep;48(9):981–4

Photosensitizing activity of the anti-bacterial drugs sulfamethoxazole and trimethoprim. Zhou W, et al. **J Photochem Photobiol B** 1997 May;39(1):63–72

Minimum inhibitory concentrations for selected antimicrobial agents against Fusobacterium necrophorum isolated from hepatic abscesses in cattle and sheep. Mateos E, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):21–3 (24 ref.)

In vitro activity of fifteen antimicrobial agents against methicillin-resistant and methicillin-susceptible Staphylococcus intermedius. Piriz S, et al. **J Vet Pharmacol Ther** 1996 Apr;19(2):118–23

Effect of trimethoprim on lamivudine bioavailability [letter; comment] Hudson M, et al. **JAMA** 1996 Oct 9;276(14):1140 . Comment on: JAMA 1996 Jul 10;276(2):118–25.

Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori. Shibata K, et al. **Jpn J Antibiot** 1997 Jun; 50(6):525–31

Generation and use of nonsupport-bound peptide and peptidomimetic combinatorial libraries. Ostresh JM, et al. **Methods Enzymol** 1996;267:220–34

Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. Gotoh A, et al. **Microbiol Immunol** 1997;41(1):7–12

Supernatant from cultured intestinal cells inhibits the growth of gram-negative bacteria. Kops SK, et al. **Microbiol Immunol** 1997;41(3):265–9

The antibacterial action of protamine: evidence for disruption of cytoplasmic membrane energization in Salmonella typhimurium. Aspedon A, et al. **Microbiology** 1996 Dec; 142 (Pt 12):3389–97

Antibacterial and antifungal activity of ten essential oils in vitro. Pattnaik S, et al. **Microbios** 1996;86(349):237–46

Antibacterial and antifungal activity of aromatic constituents of essential oils. Pattnaik S, et al. **Microbios** 1997; 89(358):39–46

Recombinant expression of the antimicrobial peptide polyphemusin and its activity against the protozoan oyster pathogen Perkinsus marinus. Pierce JC, et al. **Mol Mar Biol Biotechnol** 1997 Sep;6(3):248–59

Susceptibility patterns of bacterial isolates from intensive care and haematology/oncology patients in New Zealand. Morris AJ, et al. **N Z Med J** 1997 May 23;110(1044):187–9

Resistant Streptococcus pneumoniae in the community [letter] Riley D, et al. **N Z Med J** 1997 Mar 28; 110(1040):107–8

The DAP pathway to lysine as a target for antimicrobial agents. Cox RJ. **Nat Prod Rep** 1996 Feb;13(1):29–43 (159 ref.)

The molecular epidemiology of trimethoprim-sulphamethoxazole- resistance of Shigella flexneri in the Trakya region of Turkey. Otkun M, et al. **New Microbiol** 1997 Jul;20(3):227–31

Helicobacter pylori--in vitro susceptibility to garlic (Allium sativum) extract. Sivam GP, et al. **Nutr Cancer** 1997; 27(2):118–21

Killing kinetics of RP 59500 and pristinamycin against penicillin-resistant pneumococci. Barakett V, et al. **Pathol Biol (Paris)** 1997 May;45(5):438–40

In vitro activity of cefixime versus ceftizoxime against Salmonella typhi. Rastegar Lari A, et al. **Pathol Biol (Paris)** 1997 May;45(5):415–9

Synthesis of some Mannich bases of 1-cyclohexylidene-N(1,2-dihydro-2-oxo-3H-indol-3-ylidene) thiosemicarbazones and their antibacterial activity. Gupta RP, et al. **Pharm Acta Helv** 1997 Feb;72(1):43–5

Antimicrobial evaluation and chromatographic analysis of some essential and fixed oils. Aboul Ela MA, et al. **Pharmazie** 1996 Dec;51(12):993–4

Biological activities of buddlejasaponin isolated from Buddleja madagascariensis and Scrophularia scorodonia. Emam AM, et al. **Pharmazie** 1997 Jan;52(1):76–7

The antimicrobial activity of Tanacetum parthenium extract. Kalodera Z, et al. **Pharmazie** 1996 Dec;51(12):995–6

Content of the essential oil of the carrot and its antibacterial activity. Kilibarda V, et al. **Pharmazie** 1996 Oct; 51(10):777–8

Effect of beta-cyclodextrin on antimicrobial and photosynthesis inhibiting activity of the cationic surfactant N,N'-bis[4-(4-tert.butylphenoxy)butyl-dimethyl]-1,6-hexanediammonium dibromide. Král'ová K, et al. **Pharmazie** 1996 Aug;51(8):606–8

Chemical and antibacterial studies of two Helichrysum species of Greek origin [letter] Chinou IB, et al. **Planta Med** 1997 Apr;63(2):181–3

Quantitative assay of photoinduced antibiotic activities of naturally-occurring 2,2':5',2"-terthiophenes [letter] Ciofalo M, et al. **Planta Med** 1996 Aug;62(4):374–5

Cytotoxic and antibacterial activities of sesquiterpene lactones isolated from Tanacetum praeteritum subsp. praeteritum. Gören N, et al. **Planta Med** 1996 Oct; 62(5):419–22

Lanigerol: a new antimicrobial icetexane diterpene from Salvia lanigera. El-Lakany AM, et al. **Planta Med** 1995 Dec;61(6):559–60

Induction of epithelial chloride secretion by channel-forming cryptdins 2 and 3. Lencer WI, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8585–9

Specific antimicrobial and hemolytic activities of 18-residue peptides derived from the amino terminal region of the toxin pardaxin. Thennarasu S, et al. **Protein Eng** 1996 Dec; 9(12):1219–24

Bactericidal activity of 0.5% bupivacaine with preservatives on microorganisms in the human skin flora. Sakuragi T, et al. **Reg Anesth** 1997 Mar-Apr;22(2):178–84

Antibacterial agents that inhibit lipid A biosynthesis [see comments] Onishi HR, et al. **Science** 1996 Nov 8; 274(5289):980–2. Comment in: Science 1996 Nov 8;274(5289):939–40.

Lipid A: target for antibacterial drugs [comment] Vaara M. **Science** 1996 Nov 8;274(5289):939–40 (12 ref.). Comment on: Science 1996 Nov 8;274(5289):980–2.

A new method for in vivo evaluation of antimicrobial agents by translocation of complex dense populations of cutaneous bacteria. Leyden JJ, et al. **Skin Pharmacol** 1996;9(1):60–8

Oxazolidinones: new antibacterial agents. Ford CW, et al. **Trends Microbiol** 1997 May;5(5):196–200 (30 ref.)

Combined effect of pyrazinamide and ofloxacin within the human macrophage. Sbarbaro JA, et al. **Tuber Lung Dis** 1996 Dec;77(6):491–5

In vivo and in vitro effect of sulfamethazine on hepatic mixed function oxidases in rats. Kodam KM, et al. **Vet Hum Toxicol** 1997 Jun;39(3):141–6

Effect of antibacterial growth promoters on the immune system of broiler chicks. al-Ankari AS, et al. **Vet Immunol Immunopathol** 1996 Oct;53(3–4):277–83

Influence of flumequine and oxytetracycline on the resistance of the European eel against the parasitic swimbladder

nematode Anguillicola crassus. van der Heijden MH, et al. **Vet Immunol Immunopathol** 1996 Jun 15;52(1–2):127–34

The effects of magainin 2, cecropin, mastoparan and melittin on Brucella abortus. Halling SM. **Vet Microbiol** 1996 Jul; 51(1–2):187–92

Clinical studies on the use of antibiotic– and antiseptic–bonded catheters to prevent catheter–related infection. Bach A. **Zentralbl Bakteriol** 1995 Dec; 283(2):208–14 (32 ref.)

Arsenate resistance as a possible marker in the differentiation of environmental and clinical isolates of Vibrio parahaemolyticus. Chauhan BS, et al. **Zentralbl Bakteriol** 1997 Apr;285(4):486–90

Antibacterial activity of trichorabdal A from Rabdosia trichocarpa against Helicobacter pylori. Kadota S, et al. **Zentralbl Bakteriol** 1997 Jun;286(1):63–7

Applications of pyrolysis mass spectrometry in studies on the mode of action of antimicrobial agents. Magee JT, et al. **Zentralbl Bakteriol** 1997 Jan;285(2):305–10

The immunomodulatory effects of antibiotics: in vitro and ex vivo investigations of 21 substances by means of the lymphocyte transformation test. Schubert S, et al. **Zentralbl Bakteriol** 1996 Jul;284(2–3):402–38

Isolation and antimicrobial susceptibility of obligate anaerobic bacteria recovered from the uteri of dairy cows with retained fetal membranes and postparturient endometritis. Cohen RO, et al. **Zentralbl Veterinarmed [B]** 1996 Jun;43(4):193–9

[Synthesis and antimicrobial activities of tetrahydro–2H–1,3,5–thiadiazine–2–thiones] Chen GQ, et al. **Yao Hsueh Hsueh Pao** 1996;31(6):425–30 (Eng. Abstr.) **(Chi)**

[Antimicrobial activity of new pyridazine derivatives] Ungureanu M, et al. **Ann Pharm Fr** 1997;55(2):69–72 (Eng. Abstr.) **(Fre)**

[Evaluation of bactericidal activity of cefpirome–aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta–lactam resistance] Canis F, et al. **Pathol Biol (Paris)** 1997 May;45(5):420–3 (Eng. Abstr.) **(Fre)**

[Futile intra–amnion Rivanol administration and prostaglandin labor induction in uterus unicornis unicollis with a noncommunicating right–sided horn] Neff A, et al. **Zentralbl Gynakol** 1997;119(5):246–8 (Eng. Abstr.) **(Ger)**

[Bactericidal effect of acidic electrolyzed water—comparison of chemical acidic sodium hydrochloride (NaOCl) solution] Iwasawa A, et al. **Kansenshogaku Zasshi** 1996 Sep; 70(9):915–22 (Eng. Abstr.) **(Jpn)**

[The sensitivity of Pseudomonas mallei strains to antibacterial preparations in in–vitro experiments on a cell culture model] Manzeniuk IN, et al. **Antibiot Khimioter** 1996; 41(11):14–7 (Eng. Abstr.) **(Rus)**

[Prophenin and PR39X—novel antimicrobial leukocyte peptides regulating functional activity of thrombocytes] Tkachenko SB, et al. **Dokl Akad Nauk** 1996 Oct; 350(5):704–6 **(Rus)**

[The antimicrobial activity of thio–, thioxo– and oxo–derivatives of acridine] Novosad NV. **Mikrobiol Z** 1996 Jul–Aug;58(4):55–8 (Eng. Abstr.) **(Rus)**

[Lytic action of lysoamidase from Xanthomonas sp. correlates with the presence of the target ribitol teichoic acids in the cell wall of gram–positive bacteria] Kulaev IS, et al. **Mikrobiologiia** 1996 May–Jun;65(3):326–32 (Eng. Abstr.) **(Rus)**

[The nature of hematopoiesis in animals with experimentally depressed immune system: natural and bifidumbacterin–induced recovery] Fedorova IM, et al. **Vestn Ross Akad Med Nauk** 1997;(3):40–3 (Eng. Abstr.) **(Rus)**

[Immunomodulating action of eubiotics] Lopatina TK, et al. **Vestn Ross Akad Med Nauk** 1997;(3):30–4 (Eng. Abstr.) **(Rus)**

[The antimicrobial activity and cytotoxicity of anti–infective preparations in a human cell–culture model] Afinogenov GE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct;(5):3–7 (Eng. Abstr.) **(Rus)**

[Changes in the sensitivity of Escherichia coli to 6 antimicrobial agents during the last 12 years. Group of Microbiologists of County Hospitals of Catalonia] Sauca G, et al. **Aten Primaria** 1997 Mar 31;19(5):226–9 (Eng. Abstr.) **(Spa)**

[The antibacterial activity of preparations with highly dispersed iron] Hvozdiak RI, et al. **Mikrobiol Z** 1996 Nov–Dec;58(6):45–9 (Eng. Abstr.) **(Ukr)**

[The validation of the possible use of monosugars and 6–azacytidine for the elimination of Mollicutes associated with HIV/AIDS from the human urogenital tract] Skrypal' IH, et al. **Mikrobiol Z** 1996 Sep–Oct;58(5):80–5 (Eng. Abstr.) **(Ukr)**

STANDARDS

[Microbiological control of drugs with antimicrobial properties with membrane filtration: problems, proposals, prospects] Negretti F. **Boll Chim Farm** 1997 Jan; 136(1):28–38 (43 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Comparison of hyperbaric oxygen and dapsone therapy for loxosceles envenomation. Hobbs GD, et al. **Acad Emerg Med** 1996 Aug;3(8):758–61

Ofloxacin versus co–trimoxazole in the treatment of typhoid fever in children. Seçmeer G, et al. **Acta Paediatr Jpn** 1997 Apr;39(2):218–21

Trends in development of anti–infective agents in Japan. Yagisawa M, et al. **Acta Paediatr Jpn** 1997 Feb;39(1):105–13

Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. Trigg JK, et al. **Acta Trop** 1997 Feb;63(2–3):185–9

Development of anti–adhesion carbohydrate drugs for clinical use. Zopf D, et al. **Adv Exp Med Biol** 1996;408:35–8 (7 ref.)

Low–dose dapsone, co–trimoxazole, and survival in Pneumocystis carinii primary prophylaxis [letter] Antinori A, et al. **AIDS** 1996 Aug;10(9):1046–7

Community–acquired bacteremia in HIV–positive patients: protective benefit of co–trimoxazole [see comments] Edge MD, et al. **AIDS** 1996 Dec;10(14):1635–9. Comment in: AIDS 1997 Jul;11(8):1070–1.

Prior antimicrobials and staphylococcal bacteremia in HIV–infected patients. Styrt BA, et al. **AIDS** 1997 Aug; 11(10):1243–8

Role of trimethoprim–sulphamethoxazole in preventing HIV–associated bacteraemia [letter; comment] Tumbarello M, et al. **AIDS** 1997 Jul;11(8):1070–1. Comment on: AIDS 1996 Dec;10(14):1635–9.

Gastric MALT–lymphoma and Helicobacter pylori infection. Bayerdörffer E, et al. **Aliment Pharmacol Ther** 1997 Apr; 11 Suppl 1:89–94 (32 ref.)

Helicobacter pylori eradication and its implications for the future. Blaser MJ. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:103–7 (26 ref.)

Outcomes research in Helicobacter pylori infection. Fendrick AM. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:95–101 (19 ref.)

Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Harris AW, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):1005–8

Comparison of two low–dose one–week triple therapy regimens with and without metronidazole for cure of H. pylori infection. Jaup BH, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):275–7

Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid–related dyspepsia in general practice. Jones RH, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):541–6

Comparison of ranitidine and lansoprazole in short–term low–dose triple therapy for Helicobacter pylori infection. Kihira K, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):511–4

Long–term follow–up after cure of Helicobacter pylori infection with 4 days of quadruple therapy. Lai JY, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):645–50

The actions of bismuth in the treatment of Helicobacter pylori infection. Lambert JR, et al. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:27–33 (62 ref.)

The treatment of Helicobacter pylori infection. Pounder RE, et al. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:35–41 (35 ref.)

Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Segura AM, et al. **Aliment Pharmacol Ther** 1997 Jun;11(3):529–32

Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori. Ström M, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):311–6

One–week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance. Thijs JC, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):305–9

Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week. Van Zwet AA, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):533–5

1997 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV: Part II. Prevention of first episode of disease. **Am Fam Physician** 1997 Sep 15;56(4):1131–46

Cerebrospinal fluid broth culture isolates: their significance for antibiotic treatment. Sturgis CD, et al. **Am J Clin Pathol** 1997 Aug;108(2):217–21

Lansoprazole and ranitidine affect the accuracy of the 14C–urea breath test by a pH–dependent mechanism. Chey WD, et al. **Am J Gastroenterol** 1997 Mar;92(3):446–50

Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. Chey WD, et al. **Am J Gastroenterol** 1997 Sep;92(9):1483–6

Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual–therapy study. Gupta VK, et al. **Am J Gastroenterol** 1997 Jul;92(7):1140–2

Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection after antibiotic treatment [see comments] Rollán A, et al. **Am J Gastroenterol** 1997 Aug; 92(8):1268–74. Comment in: Am J Gastroenterol 1997 Aug;92(8):1245–7.

Lanzoprazole and ranitidine affect the accuracy of the 14C–urea breath test by a pH–dependent mechanism [letter] Stermer E, et al. **Am J Gastroenterol** 1997 Sep;92(9):1575–6

Restarting trimethoprim–sulfamethoxazole after a hypersensitivity reaction in patients infected with the human immunodeficiency virus. Everson–Mays RE, et al. **Am J Health Syst Pharm** 1997 Jul 1;54(13):1545–50

Development of a patient–focused, interdisciplinary antimicrobial management program involving staff pharmacists. Lacy MK, et al. **Am J Health Syst Pharm** 1997 Aug 15;54(16):1837–41

Prudent selection of antimicrobials for neonatal sepsis. McManus MC. **Am J Health Syst Pharm** 1996 Aug 15; 53(16):1956–60 (52 ref.)

Effect of constructive feedback on pharmacist handling of orders for monitored antimicrobials. Zaran FK, et al. **Am J Health Syst Pharm** 1996 Sep 15;53(18):2196–8

Skin involvement with Pneumocystis despite dapsone prophylaxis: a rare cause of skin nodules in a patient with AIDS. Bundow DL, et al. **Am J Med Sci** 1997 Mar; 313(3):182–6 (25 ref.)

A derivative of cationic antimicrobial protein attenuates lung injury by suppressing cell adhesion. Tasaka S, et al. **Am J Respir Cell Mol Biol** 1996 Dec;15(6):738–44

Short report: case report of Cyclospora infection acquired in Indonesia and treated with cotrimoxazole. Fryauff DJ, et al. **Am J Trop Med Hyg** 1996 Dec;55(6):584–5

Reducing the risk for catheter–related infections: a new strategy [editorial; comment] Pearson ML, et al. **Ann Intern Med** 1997 Aug 15;127(4):304–6. Comment on: Ann Intern Med 1997 Aug 15;127(4):257–60. Comment on: Ann Intern Med 1997 Aug 15;127(4):267–74.

Treatment of Rocky Mountain spotted fever in children. Cale DF, et al. **Ann Pharmacother** 1997 Apr;31(4):492–4 (23 ref.)

Nontuberculous mycobacterial infections. Guay DR. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):819–30 (199 ref.)

Development of an intravenous–to–oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility. Zamin MT, et al. **Ann Pharmacother** 1997 May;31(5):564–70

In vivo activities of U–100592 and U–100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Ford CW, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1508–13

Synergistic effect of a recombinant N–terminal fragment of bactericidal/permeability–increasing protein and cefamandole in treatment of rabbit gram–negative sepsis. Lin Y, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):65–9

Protegrin–1: a broad–spectrum, rapidly microbicidal peptide with in vivo activity. Steinberg DA, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1738–42

Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies. Walzer PD, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):242–50

Eimeria alabamensis coccidiosis in grazing calves: control by a long–acting baquiloprim/sulphadimidine bolus. Svensson C, et al. **Appl Parasitol** 1996 Sep;37(3):168–76

Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Caumes E, et al. **Arch Dermatol** 1997 Apr;133(4):465–9

Antimicrobial management of Helicobacter pylori–associated gastrointestinal tract disease. Guay DR, et al. **Arch Fam Med** 1997 Mar–Apr;6(2):173–80 (00 ref.)

Pregnancy and active Wegener granulomatosis. Parnham AP, et al. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):361–3

Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Kiani A, et al. **Blood** 1997 Aug 15;90(4):1673–83

Lansoprazole plus clarithromycin: evaluation of a new dual therapy for Helicobacter pylori eradication. Phull PS, et al. **Br J Clin Pract** 1996 Oct–Nov;50(7):360–2

Utilization of the serosal scarification model of postoperative intestinal adhesion formation to investigate potential adhesion–preventing substances in the rabbit. Singer ER, et al. **Can J Vet Res** 1996 Oct;60(4):305–11

Antimicrobial therapy of skin and ear infections. Dowling PM. **Can Vet J** 1996 Nov;37(11):695–9 (6 ref.)

Empiric treatments impair the diagnostic yield of BAL in HIV–positive patients. Gracia JD, et al. **Chest** 1997 May; 111(5):1180–6

The within–host population dynamics of antibacterial chemotherapy: conditions for the evolution of resistance. Lipsitch M, et al. **Ciba Found Symp** 1997;207:112–27; discussion 127–30 (27 ref.)

Pyrimethamine–clindamycin vs. pyrimethamine–sulfadiazine as acute and long–term therapy for toxoplasmic encephalitis in patients with AIDS. Katlama C, et al. **Clin Infect Dis** 1996 Feb;22(2):268–75

Epidemiology and treatment of Cyclospora cayetanensis infection in Peruvian children. Madico G, et al. **Clin Infect Dis** 1997 May;24(5):977–81

Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes. Peloquin CA. **Clin Pharmacokinet** 1997 Feb;32(2):132–44 (60 ref.)

The use of oral antibiotics in lower–extremity infections. Joseph WS, et al. **Clin Podiatr Med Surg** 1996 Oct; 13(4):683–99

Treatment regimens for patients with toxoplasmic encephalitis. Fung HB, et al. **Clin Ther** 1996 Nov–Dec; 18(6):1037–56; discussion 1036 (67 ref.)

Ofloxacin versus trimethoprim–sulfamethoxazole in the

treatment of patients with acute exacerbation of chronic bronchitis. Study of Ofloxacin in Lower Respiratory Tract Infections Research Group. Pérez-Gonzalvo ME, et al. **Clin Ther** 1996 May-Jun;18(3):440-7

Recombinant N-terminal fragment of bactericidal/permeability increasing protein (rBPI21) prevents shock-induced microcirculatory alterations in the liver. Bauer C, et al. **Crit Care Med** 1997 Aug;25(8):1283-8

A comparison of bactericidal/permeability-increasing protein variant versus recombinant endotoxin-neutralizing protein for the treatment of Escherichia coli sepsis in rats [published erratum appears in Crit Care Med 1997 Mar;25(3):558] Stack AM, et al. **Crit Care Med** 1997 Jan; 25(1):101-5

Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. Verwaest C, et al. **Crit Care Med** 1997 Jan;25(1):63-71

Alternative treatments in the patient with intractable asthma. Spector SL. **Curr Opin Pulm Med** 1997 Jan;3(1):23-9 (64 ref.)

Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii. Gross U, et al. **Curr Top Microbiol Immunol** 1996;219:235-45 (39 ref.)

Persistent diarrhea caused by Isospora belli: therapeutic response to pyrimethamine and sulfadiazine. Ebrahimzadeh A, et al. **Diagn Microbiol Infect Dis** 1996 Oct;26(2):87-9

A practical guide to the management of complicated urinary tract infection. Nicolle LE. **Drugs** 1997 Apr;53(4):583-92 (39 ref.)

Nursing home-acquired pneumonia. Treatment options. Marrie TJ, et al. **Drugs Aging** 1996 May;8(5):338-48 (64 ref.)

Does the Ukrain preparation protect mice against lethal doses of bacteria? Ciebiada I, et al. **Drugs Exp Clin Res** 1996; 22(3-5):207-11

Antibody-based therapies for emerging infectious diseases. Casadevall A. **Emerg Infect Dis** 1996 Jul-Sep;2(3):200-8 (68 ref.)

Treatment of bacterial tarsal tenosynovitis and osteitis of the sustentaculum tali of the calcaneus in five horses. Santschi EM, et al. **Equine Vet J** 1997 May;29(3):244-7

Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. Araujo FG, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):394-7

Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. Avsar E, et al. **Eur J Gastroenterol Hepatol** 1996 May;8(5):449-52

Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. Caselli M, et al. **Eur J Gastroenterol Hepatol** 1997 Jan;9(1):45-8

Effect of the bradykinin B2 receptor antagonist Hoe140 in experimental pneumococcal meningitis in the rat. Lorenzl S, et al. **Eur J Pharmacol** 1996 Jul 25;308(3):335-41

Primary and secondary prophylaxis for Pneumocystis carinii related complications in HIV patients [editorial] Held M, et al. **Eur Respir J** 1996 May;9(5):868-71 (47 ref.)

Do quantitative cultures of protected brush specimens modify the initial empirical therapy in ventilated patients with suspected pneumonia? Rodriguez de Castro F, et al. **Eur Respir J** 1996 Jan;9(1):37-41

Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine. Seal D, et al. **Eye** 1996;10 (Pt 4):413-21

Quinoxaline-2-carboxylic acid (QCA) in swine liver and muscle. Rutalj M, et al. **Food Addit Contam** 1996 Nov-Dec; 13(8):879-82

Failure of trimethoprim in the treatment of donovanosis [letter] Birthistle K, et al. **Genitourin Med** 1997 Jun; 73(3):224-5

How to interpret an overview: a meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Easterbrook PJ. **Genitourin Med** 1997 Apr; 73(2):139-43

Of magic bullets and social justice: emerging challenges of recent advances in AIDS treatment. Linsk NL, et al. **Health Soc Work** 1997 Feb;22(1):70-4

Helicobacter pylori eradication--evaluation of triple therapy containing omeprazole. Goenka MK, et al. **Indian J Gastroenterol** 1996 Jan;15(1):1-3

Healing of chronic antral gastritis: effect of sucralfate and colloidal bismuth subcitrate. Kumar M, et al. **Indian J Gastroenterol** 1996 Jul;15(3):90-3

Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group. **Indian J Lepr** 1997 Apr-Jun; 69(2):121-9

Furazolidone in typhoid fever [letter; comment] Santhoshkumar A. **Indian Pediatr** 1996 Aug;33(8):701-2. Comment on: Indian Pediatr 1996 May;33(5):437.

Controlling use of antimicrobial agents. Duncan RA. **Infect Control Hosp Epidemiol** 1997 Apr;18(4):260-6

Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Shlaes DM, et al. **Infect Control Hosp Epidemiol** 1997 Apr; 18(4):275-91

Antiendotoxin activity of cationic peptide antimicrobial agents. Gough M, et al. **Infect Immun** 1996 Dec; 64(12):4922-7

Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions [letter] Ganapati R, et al. **Int J Lepr Other Mycobact Dis** 1997 Jun;65(2):264-6

Fixed-duration multidrug therapy in multibacillary leprosy. Li HY, et al. **Int J Lepr Other Mycobact Dis** 1997 Jun; 65(2):230-7

Risk of relapse in leprosy after fixed-duration multidrug therapy. Li HY, et al. **Int J Lepr Other Mycobact Dis** 1997 Jun;65(2):238-45

Helicobacter pylori gastritis and non-ulcer dyspepsia in childhood. Efficacy of one-week triple antimicrobial therapy in eradicating the organism. Cucchiara S, et al. **Ital J Gastroenterol** 1996 Oct-Nov;28(8):430-5

Altered trimethoprim-sulfamethoxazole ratios for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii dual infections in rat model. Brun-Pascaud M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Nov 1;13(3):201-7

Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. Bucher HC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jun 1;15(2):104-14

Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin. Epstein ME, et al. **J Am Acad Dermatol** 1997 Sep;37(3 Pt 1):365-81; quiz 382-4 (181 ref.)

The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. Erah PO, et al. **J Antimicrob Chemother** 1997 Jan;39(1):5-12

Optimising antimicrobial drug use in surgery: an intervention study in a Dutch university hospital. Gyssens IC, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1001-12

Patient packs and the prescribing of antimicrobial agents. Humphreys H, et al. **J Antimicrob Chemother** 1996 Sep; 38(3):329-31

Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea. MacGowan AP, et al. **J Antimicrob Chemother** 1997 Apr;39(4):537-41

One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy. Phull PS, et al. **J Antimicrob Chemother** 1995 Dec; 36(6):1085-8

Over-the-counter availability of antimicrobial agents, self-medication and patterns of resistance in Karachi, Pakistan. Sturm AW, et al. **J Antimicrob Chemother** 1997 Apr;39(4):543-7

Anti-toxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. van der Ven AJ, et al. **J Antimicrob Chemother** 1996 Jul;38(1):75-80

Comparison of colloidal bismuth subcitrate and metronidazole, both in combination with an H2-antagonist as therapy for Helicobacter pylori. Baffone W, et al. **J Chemother** 1997 Jun;9(3):208-12

Antimicrobial treatment in acute maxillary sinusitis: a meta-analysis. de Bock GH, et al. **J Clin Epidemiol** 1997 Aug;50(8):881-90

Effects of metronidazole in patients with "refractory" periodontitis associated with Bacteroides forsythus. Winkel EG, et al. **J Clin Periodontol** 1997 Aug;24(8):573-9

Efficacy of teat dips containing a hypochlorous acid germicide against experimental challenge with Staphylococcus aureus and Streptococcus agalactiae. Boddie RL, et al. **J Dairy Sci** 1996 Sep;79(9):1683-8

Erythromycin and trimethoprim-sulphamethoxazole in the treatment of cholera in children. Kabir I, et al. **J Diarrhoeal Dis Res** 1996 Dec;14(4):243-7

Antibiotic use in the emergency department. II The aminoglycosides, macrolides, tetracyclines, sulfa drugs, and urinary antiseptics. Graeme KA, et al. **J Emerg Med** 1996 May-Jun;14(3):361-71 (90 ref.)

Can urinary nitrite results be used to guide antimicrobial choice for urinary tract infection? Larson MJ, et al. **J Emerg Med** 1997 Jul-Aug;15(4):435-8

Antibiotic use in the emergency department. III. The quinolones, new beta lactams, beta lactam combination agents, and miscellaneous antibiotics. Schmidt J, et al. **J Emerg Med** 1996 Jul-Aug;14(4):483-96 (101 ref.)

Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients. Shimoyama T, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:59-62

Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection. Hazell SL, et al. **J Gastroenterol Hepatol** 1997 Feb;12(2):93-9

The effect of topical 0.75% metronidazole gel on malodorous cutaneous ulcers. Finlay IG, et al. **J Pain Symptom Manage** 1996 Mar;11(3):158-62

Clinical and microbiological effects of subgingival antimicrobial irrigation with citric acid as evaluated by an enzyme immunoassay and culture analysis. Renvert S, et al. **J Periodontol** 1997 Apr;68(4):346-52

Bactericidal eradication from carious lesions of prepared abutments by an antibacterial temporary cement. Hori R, et al. **J Prosthet Dent** 1997 Apr;77(4):348-52

Sulfamethoxazole/trimethoprim therapy for polymyalgia rheumatica. Report of 5 cases [letter] Galezowski N, et al. **J Rheumatol** 1997 Jul;24(7):1451-2

Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Horowitz HW, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):159-63

New prospects for antibacterial agents against multidrug-resistant pneumococci. Appelbaum PC. **Microb Drug Resist** 1995 Spring;1(1):43-8 (42 ref.)

The prospects of treatment failure in the chemotherapy of infectious diseases in the 1990s [editorial] Armstrong D, et al. **Microb Drug Resist** 1995 Spring;1(1):1-4 (11 ref.)

Co-trimoxazole in Wegener's granulomatosis [letter; comment] Weir A, et al. **N Engl J Med** 1996 Dec 5; 335(23):1769-70. Comment on: N Engl J Med 1996 Jul 4;335(1):16-20.

Co-trimoxazole and Wegener's granulomatosis: more than a coincidence? [editorial] Stegeman CA, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):652-5 (20 ref.)

Sexually transmitted diseases in pregnancy. Jackson SL, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):631-44 (41 ref.)

A twelve-month follow-up after Helicobacter pylori eradication. A clinical and histological evaluation. Bruno M, et al. **Panminerva Med** 1996 Sep;38(3):139-44

Alternative dapsone dosage regimen for prophylaxis of Pneumocystis carinii pneumonia [letter] Gatti G, et al. **Pediatr Infect Dis J** 1996 Feb;15(2):183-4

Adverse reactions in children during long-term antimicrobial therapy. Uhari M, et al. **Pediatr Infect Dis J** 1996 May; 15(5):404-8

Consumption of anti-infective drugs in Bulgaria for the period from 1979 to 1994. Popova M, et al. **Pharm World Sci** 1997 Apr;19(2):93-100

Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen. Penzak SR, et al. **Pharmacotherapy** 1997 Mar-Apr;17(2):293-301 (88 ref.)

Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia. Warnock AC, et al. **Pharmacotherapy** 1996 Nov-Dec;16(6):1030-8

New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials. Cunha BA. **Postgrad Med** 1997 Apr;101(4):68-70, 73-4, 79-80 passim (19 ref.)

Staphylococcus aureus, trimethoprim-sulfamethoxazole, and Wegener's granulomatosis. Kallenberg CG, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1996 Oct;13(3):253-5 (19 ref.)

Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever. Engervall P, et al. **Scand J Infect Dis** 1996;28(3):297-303

Treatment and prevention of Lyme disease, with emphasis on antimicrobial therapy for neuroborreliosis and vaccination. Wormser GP. **Semin Neurol** 1997 Mar; 17(1):45-52 (91 ref.)

Treatment of Pneumocystis carinii pneumonia in adults with AIDS. Deresinski SC. **Semin Respir Infect** 1997 Jun; 12(2):79-97 (142 ref.)

Maloprim malaria prophylaxis in children living in a holoendemic village in north-eastern Tanzania. Lemnge MM, et al. **Trans R Soc Trop Med Hyg** 1997 Jan-Feb; 91(1):68-73

FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. Kliem V, et al. **Transplant Proc** 1996 Dec;28(6):3166-8

Toxoplasmosis in kidney transplant recipients: a life-threatening but treatable disease. Renoult E, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):821-2

A survey of horses with acute diarrhoea: diagnosis, assessment of the prognosis, and comparison of two antibiotic therapies. van Duijkeren E, et al. **Vet Q** 1996 Dec;18(4):153-6

The effect of cotrimoxazole on experimental Cryptosporidium parvum infection in kids. Koudela B, et al. **Vet Res** 1997 Jul-Aug;28(4):405-12

[Methyl thionine (methylene blue) in the treatment of sepsis] Bindels AJ, et al. **Ned Tijdschr Geneeskd** 1996 Dec 7; 140(49):2447-50 (20 ref.) **(Dut)**

[Current viewpoints on diagnosis and treatment of Helicobacter pylori infections] Veenendaal RA, et al. **Ned Tijdschr Geneeskd** 1996 Dec 7;140(49):2469-72 **(Dut)**

[High percentage of antibiotic resistance in Shigella infections in children in Curaçao] Wolfs TF, et al. **Ned Tijdschr Geneeskd** 1996 Dec 14;140(50):2510-3 (Eng. Abstr.) **(Dut)**

[Efficacy of pyrimethamine in monotherapy for preventing toxoplasmosis in AIDS (letter)] De Truchis P, et al. **Presse Med** 1996 Jul 6-13;25(24):1125 **(Fre)**

[Antimicrobial therapy in neutropenia] Maschmeyer G, et al. **Dtsch Med Wochenschr** 1997 Jul 4;122(27):864-9 (24 ref.) **(Ger)**

[Antibiotic use in necrotizing pancreatitis. Results of a controlled study] Schwarz M, et al. **Dtsch Med Wochenschr** 1997 Mar 21;122(12):356-61 (Eng. Abstr.) **(Ger)**

[Basic principles in treatment of endophthalmitis] Kain HL. **Klin Monatsbl Augenheilkd** 1997 May;210(5):274-88 (62

ref.) (Eng. Abstr.) **(Ger)**

[Adjuvant therapy of peritonitis with taurolidine. Modulation of mediator liberation] Staubach KH.
Langenbecks Arch Chir 1997;382(4 Suppl 1):S26–30 (17 ref.) (Eng. Abstr.) **(Ger)**

[Empirical antimicrobial therapy in neutropenic patients] Maschmeyer G. **Ther Umsch** 1996 Nov;53(11):854–62 (36 ref.) (Eng. Abstr.) **(Ger)**

[Azithromycin combined with pyrimethamine in the treatment of neurotoxoplasmosis, in an AIDS patient] Trotta M, et al. **Minerva Med** 1997 Mar;88(3):117–9 (Eng. Abstr.) **(Ita)**

[Criteria for the clinical evaluation of antimicrobial drugs in neonates] Fujii R, et al. **Jpn J Antibiot** 1996 Jul; 49(7):743–53 **(Jpn)**

[A possibility of therapeutic trial with tetrahydrobiopterin, which was suggested by the administration of sulfamethoxazole–trimethoprim] Sakai T.
Rinsho Shinkeigaku 1996 Dec;36(12):1324–5 (Eng. Abstr.) **(Jpn)**

[Dapsone (4,4'-diaminodiphenyl sulfone) resolved severe leukocytopenia and thrombocytopenia in a patient with systemic lupus erythematosus] Nishina M, et al.
Ryumachi 1996 Oct;36(5):757–61 (Eng. Abstr.) **(Jpn)**

[Early results of treating Helicobacter pylori infections in patients with gastric ulcer and gastritis] Jarczyk G, et al.
Pol Merkuriusz Lek 1996 Sep;1(3):174–8 (Eng. Abstr.) **(Pol)**

[Secondary prophylaxis in rheumatic fever. Oral antibiotic therapy versus benzathine penicillin] Herdy GV, et al.
Arq Bras Cardiol 1996 Nov;67(5):331–3 (Eng. Abstr.) **(Por)**

[Increased effectiveness of etiotropic therapy of experimental plague in albino mice at the stage of generalized infection] Ryzhkova VV, et al. **Antibiot Khimioter** 1996 Feb; 41(2):35–9 (Eng. Abstr.) **(Rus)**

[Antibacterial therapy in irritable bowel syndrome] Parfenov AI, et al. **Klin Med (Mosk)** 1996;74(5):41–3 **(Rus)**

[The experimental evaluation of the efficacy of using a Rhodiola rosea extract for treating odontogenic inflammatory diseases] Alekhova TM, et al.
Stomatologiia (Mosk) 1996;Spec No:42–3 **(Rus)**

[Ligenten treatment of sinusitis] Poliakova TS, et al.
Vestn Otorinolaringol 1997;(2):38–40 (Eng. Abstr.) **(Rus)**

[Makmiror–complex in the treatment of post–radiation infectious vulvovaginitis in cancer patients] Borovtsova TM, et al. **Vopr Onkol** 1996;42(6):69–71 (Eng. Abstr.) **(Rus)**

[The action of lactoperoxidase, lactoferrin and lactoglobulin on Shigella sonnei in an in–vivo experiment] Denisova II, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jan–Feb; (1):66–9 (Eng. Abstr.) **(Rus)**

[The efficacy of the new bacterial preparation biosporin in treating acute intestinal infections] Gracheva NM, et al.
Zh Mikrobiol Epidemiol Immunobiol 1996 Jan–Feb;(1):75–7 (Eng. Abstr.) **(Rus)**

[The development and clinical evaluation of the probiotic Bifidumbacterin forte] Grigor'ev AV, et al.
Zh Mikrobiol Epidemiol Immunobiol 1997 May–Jun; (3):92–6 (Eng. Abstr.) **(Rus)**

[A new approach to the prevention and treatment of lesions caused by bacterial toxins: prospects for using inhibitors of ADP ribosylation] Krasil'nikov II, et al.
Zh Mikrobiol Epidemiol Immunobiol 1996 Jan–Feb;(1):11–3 (Eng. Abstr.) **(Rus)**

[Prospective double–blind randomized study of the efficacy and tolerance of topical ciprofloxacin vs topical gentamicin in the treatment of simple chronic otitis media and diffuse external otitis] Sabater F, et al.
Acta Otorrinolaringol Esp 1996 May–Jun;47(3):217–20 (Eng. Abstr.) **(Spa)**

[The treatment of children with Helicobarter pylory by triple therapy can be shortened without the risk of losing it eradicating efficacy. Letter] Cilleruelo ML, et al.
An Esp Pediatr 1996 Nov;45(5):550 **(Spa)**

[Extra–hospital consumption of anti–infective agents in a defined daily doses per thousand inhabitants per day] Goldaracena Tanco M, et al. **Aten Primaria** 1996 Oct 31; 18(7):357–61 (Eng. Abstr.) **(Spa)**

[Changes in the use of antibacterial agents in Catalonia, Impact of new marketed drugs] Llop JC.
Aten Primaria 1997 Mar 31;19(5):230–6 (Eng. Abstr.) **(Spa)**

[Extent of the use of systemic anti–infective agents in a rural health area in Asturias. Comparison of the years 1994 and 1995] Yáñez Gómez P. **Aten Primaria** 1997 Mar 31; 19(5):243–9 (Eng. Abstr.) **(Spa)**

[Primary prophylaxis of spontaneous bacterial peritonitis (editorial)] Soriano G, et al. **Gastroenterol Hepatol** 1997 Jun–Jul;20(6):312–4 (24 ref.) **(Spa)**

[Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients] Gisbert JP, et al. **Rev Clin Esp** 1996 Sep;196(9):588–93 (Eng. Abstr.) **(Spa)**

[Nodal nocardiosis in 2 patients with HIV infection treated with cotrimoxazole (letter)] Valencia Ortega ME, et al.
Rev Clin Esp 1997 Apr;197(4):298–9 **(Spa)**

TOXICITY

Nitrofurazone: reproductive assessment by continuous breeding in Swiss mice. George JD, et al.
Fundam Appl Toxicol 1996 Nov;34(1):56–66

In vitro effects of MOCA and dapsone on rat hepatic and splenic immune cells. Kelso JM, et al.
Immunopharmacology 1997 Jan;35(3):183–93

Involvement of the gonococcal MtrE protein in the resistance of Neisseria gonorrhoeae to toxic hydrophobic agents. Delahay RM, et al. **Microbiology** 1997 Jul;143 (Pt 7):2127–33

Lichen acids as uncouplers of oxidative phosphorylation of mouse–liver mitochondria. Abo–Khatwa AN, et al.
Nat Toxins 1996;4(2):96–102

The developmental toxicity of three antimicrobial agents observed only in nonroutine animal studies. Stahlmann R, et al. **Reprod Toxicol** 1997 Jan–Feb;11(1):1–7 (43 ref.)

Mutagenic and cytotoxic activity of an isocoumarin (Paepalantine) isolated from Paepalanthus vellozioides. Varanda EA, et al. **Teratog Carcinog Mutagen** 1997; 17(2):85–95

Hypersegmented megakaryocytes and megakaryocytes with multiple separate nuclei in dogs treated with PNU–100592, an oxazolidinone antibiotic. Lund JE, et al.
Toxicol Pathol 1997 Jul–Aug;25(4):339–43

URINE

Acute renal failure due to sulphadiazine crystalluria in AIDS patients. de Sequera P, et al. **Postgrad Med J** 1996 Sep; 72(851):557–8

ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE

Infection with ciprofloxacin–resistant Campylobacter jejuni in travellers returning from Asia [letter] Slavin MA, et al.
Eur J Clin Microbiol Infect Dis 1996 Apr;15(4):348–50

[Fluoroquinolones. Pharmacokinetic properties and new pharmacodynamic concepts] Bergogne–Bérézin E.
Presse Med 1997 Apr 12;26(12):577–82 (37 ref.) **(Fre)**

[Fleroxacin––a new quinolone antibiotic] Kostić D.
Vojnosanit Pregl 1996 Jul–Aug;53(4):311–24 (100 ref.) **(Scr)**

ADMINISTRATION & DOSAGE

A new drug delivery system utilizing piggyback contact lenses. Sano K, et al. **Acta Ophthalmol Scand** 1996 Jun; 74(3):243–8

Avoiding adverse reactions. Lilley LL, et al. **Am J Nurs** 1996 Sep;96(9):18–20

Aerosol delivery of liposome–encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Conley J, et al.
Antimicrob Agents Chemother 1997 Jun;41(6):1288–92

Comparison of single–dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group. Hook EW 3rd, et al.
Antimicrob Agents Chemother 1997 Aug;41(8):1843–5

New antiinfectious biomaterials. Ciprofloxacin containing polyurethanes as potential drug delivery systems to prevent foreign–body infections. Schierholz JM, et al.
Arzneimittelforschung 1997 Jan;47(1):70–4

Ofloxacin once daily versus twice daily in community–acquired pneumonia and acute exacerbation of chronic bronchitis. A randomized multicenter study. Rayman J, et al. **Chemotherapy** 1996 May–Jun;42(3):227–30

One–dose treatment with pefloxacin for infection due to multidrug–resistant Shigella dysenteriae type 1 in Burundi. Gendrel D, et al. **Clin Infect Dis** 1997 Jan;24(1):83

Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. Bailey RR, et al.
Clin Nephrol 1996 Sep;46(3):183–6

Fluoroquinolone therapy in pediatrics: where we stand [editorial; comment] Sabella C, et al.
Clin Pediatr (Phila) 1997 Aug;36(8):445–8 (36 ref.). Comment on: Clin Pediatr (Phila) 1997 Aug;36(8):435–44.

Efficacy and tolerability of brodimoprim at two different dosage schedules in the treatment of acute uncomplicated bacterial cystitis: comparative study vs. pefloxacin. Cosmi EV, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Feb; 64(2):207–11

Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis [see comments] Navasa M, et al. **Gastroenterology** 1996 Oct; 111(4):1011–7. Comment in: Gastroenterology 1996 Oct;111(4):1147–50.

Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial. Carlson JW, et al. **Gynecol Oncol** 1997 May;65(2):325–9

Blastomycosis–like pyoderma (Pyoderma vegetans) responding to antibiotics and topical disodium chromoglycate. Rongioletti F, et al. **Int J Dermatol** 1996 Nov;35(11):828–30

In vitro ciprofloxacin release from poly(lactide–co–glycolide) microspheres. Martinez B, et al. **J Microencapsul** 1997 Mar–Apr;14(2):155–61

Successful treatment of atypical mycobacterial meningitis by fluoroquinolone. Komachi H, et al. **J Neurol Sci** 1996 Nov; 143(1–2):170–2

Intravitreal delivery of ciprofloxacin. Hainsworth DP, et al.
J Ocul Pharmacol Ther 1996 Summer;12(2):183–91

The preparation of norfloxacin–loaded liposomes and their in–vitro evaluation in pig's eye. Lin HH, et al.
J Pharm Pharmacol 1996 Aug;48(8):801–5

Once–daily fleroxacin versus twice–daily ciprofloxacin in the treatment of complicated urinary tract infections. Frankenschmidt A, et al. **J Urol** 1997 Oct;158(4):1494–9

Post–intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women. Melekos MD, et al. **J Urol** 1997 Mar;157(3):935–9

Hospital–acquired Clostridium difficile diarrhoea [letter; comment] Jones EM, et al. **Lancet** 1997 Apr 19; 349(9059):1176–7. Comment on: Lancet 1997 Feb 8;349(9049):426–8.

Bacterial keratitis therapy in guinea pigs with lomefloxacin by initially high–followed by low–dosage regimen. Malet F, et al. **Ophthalmic Res** 1995;27(6):322–9

IV vancomycin–oral ciprofloxacin: a safe and efficient therapeutic protocol for CAPD peritonitis (preliminary report). Goffin E, et al. **Perit Dial Int** 1996 Mar–Apr; 16(2):174–7

Validation of a method to study the dissolution behaviour of norfloxacin tablets. Córdoba Borrego M, et al.
Pharm Acta Helv 1995 Dec;70(4):339–42

Prolonged ciprofloxacin administration does not accelerate neutrophil recovery after autologous bone marrow transplantation. Hsu J, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):652–5

Norfloxacin monodose use in patients with cholera in Salta Argentina. Seijo AC, et al.
Rev Inst Med Trop Sao Paulo 1996 May–Jun;38(3):217–9

Influence of low dose ciprofloxacin on microbial colonization of the digestive tract in healthy volunteers during normal and during impaired colonization resistance. van de Leur JJ, et al. **Scand J Infect Dis** 1997;29(3):297–300

Derivation of Pasteurella multocida–free rabbit litters by enrofloxacin treatment. Suckow MA, et al.
Vet Microbiol 1996 Jul;51(1–2):161–8

Pharmacokinetics of ciprofloxacin in sheep after single intravenous or intramuscular administration. Muñoz MJ, et al. **Vet Q** 1996 Jun;18(2):45–8

[Value of the use of the oral route versus the injectable route for fluoroquinolones. Pharmacoeconomic incidence and bibliographical study] Douet C, et al. **Therapie** 1996 Jul–Aug;51(4):464–75 (115 ref.) (Eng. Abstr.) **(Fre)**

[Ciprofloxacin in treatment of common bacterial skin infections. Results of an open study in general practice] Braun H. **Fortschr Med** 1996 Feb 20;114(5):55–6 **(Ger)**

[Stage–oriented antibiotic therapy of peritonitis. Prospective study] Winkeltau GJ, et al. **Langenbecks Arch Chir** 1997; 382(4 Suppl 1):S22–5 (Eng. Abstr.) **(Ger)**

[Oral therapy with ciprofloxacin in the prophylaxis of urinary infections in surgical patients with permanent bladder catheter] Salvestrini F, et al. **Minerva Chir** 1996 Jul–Aug; 51(7–8):625–8 (Eng. Abstr.) **(Ita)**

[Measurement of antibody titers to chlamydial infection and effects of levofloxacin in cystic cervicitis and chlamydial infection] Chimura T. **Jpn J Antibiot** 1997 May; 50(5):479–84 (Eng. Abstr.) **(Jpn)**

[Anti–Mycobacterium avium complex activities of KRM–1648, clarithromycin and levofloxacin in 7H9F medium at peak or average blood concentrations after their oral administration of clinical dosages] Sato K, et al.
Kekkaku 1997 Jul;72(7):449–53 (Eng. Abstr.) **(Jpn)**

[Pilot studies on the treatment of Mycobacterium avium complex lung disease––new macrolides and new quinolones. (2) Multi–drug chemotherapy for initial cases on trial] Tanaka E. **Kekkaku** 1996 Sep;71(9):547–9 **(Jpn)**

[Legionella pneumonia successfully treated despite late diagnosis] Tsuji H, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1997 May; 35(5):566–70 (Eng. Abstr.) **(Jpn)**

[Clinical trials of ofloxacin in sequential use (intravenous and oral) in patients with serious hospital infection] Iakovlev SV, et al. **Antibiot Khimioter** 1996;41(9):53–6 (Eng. Abstr.) **(Rus)**

[Stepdown ofloxacin therapy in bronchopulmonary diseases] Nonikov VE, et al. **Antibiot Khimioter** 1996;41(9):50–2 (Eng. Abstr.) **(Rus)**

[A method of sequential (intravenous and oral) use of ofloxacin in the treatment of patients with infections of organs of the peritoneal cavity] Savitskaia KI, et al.
Antibiot Khimioter 1996;41(9):60–7 (Eng. Abstr.) **(Rus)**

[Experience in the combined treatment using ciprofloxacin of urethrogenic prostatitis] Barabash TM, et al.
Lik Sprava 1995 Sep–Dec;(9–12):126–7 **(Rus)**

ADVERSE EFFECTS

Cutaneous adverse reaction to ciprofloxacin: demonstration of specific lymphocyte proliferation and cross–reactivity to ofloxacin in vitro. Rönnau AC, et al.
Acta Derm Venereol 1997 Jul;77(4):285–8

Myasthenia gravis and ciprofloxacin [letter] Roquer J, et al.
Acta Neurol Scand 1996 Dec;94(6):419–20

Risk for ovulation in women taking a low–dose oral contraceptive (Microgynon) when receiving antibacterial treatment with a fluoroquinolone (ofloxacin). Csemiczky G, et al. **Adv Contracept** 1996 Jun;12(2):101–9

Fixed drug eruption (FDE) caused by norfloxacin. Fernandez–Rivas M. **Allergy** 1997 Apr;52(4):477–8

Ciprofloxacin–induced cutaneous vasculitis. Lieu PK, et al.
Allergy 1997 May;52(5):593–4 (5 ref.)

Ciprofloxacin–induced vasculitis. Reaño M, et al. **Allergy** 1997 May;52(5):599–600

Tendinitis associated with ciprofloxacin [letter] Carrasco JM, et al. **Ann Pharmacother** 1997 Jan;31(1):120

Hypersensitivity anaphylactoid reaction to pefloxacin in a patient with AIDS. al-Hedaithy MA, et al. **Ann Pharmacother** 1996 Jun;30(6):612-4

Ciprofloxacin-induced delirium [letter] Jay GT, et al. **Ann Pharmacother** 1997 Feb;31(2):252

Anaphylactoid reaction to ciprofloxacin versus toxic shock syndrome [letter] Salon EJ, et al. **Ann Pharmacother** 1997 Jan;31(1):119-20

Association of a Tourette-like syndrome with ofloxacin. Thomas RJ, et al. **Ann Pharmacother** 1996 Feb;30(2):138-41

Ciprofloxacin-induced toxic epidermal necrolysis [letter] Yerasi AB, et al. **Ann Pharmacother** 1996 Mar;30(3):297

Achilles tendon rupture and fluoroquinolones use: report of two cases. de la Garza Estrada VA, et al. **Arch Med Res** 1997 Autumn;28(3):429-30

Quinolones may induce hepatitis. Jones SF, et al. **BMJ** 1997 Mar 22;314(7084):869

Fixed drug eruption induced by ofloxacin. Kawada A, et al. **Contact Dermatitis** 1996 Jun;34(6):427

Deposits of topical norfloxacin in the treatment of bacterial keratitis. Castillo A, et al. **Cornea** 1997 Jul;16(4):420-3

Cholestatic jaundice induced by ciprofloxacin. Labowitz JK, et al. **Dig Dis Sci** 1997 Jan;42(1):192-4

Torsades de pointe probably related to sparfloxacin [letter] Dupont H, et al. **Eur J Clin Microbiol Infect Dis** 1996 Apr; 15(4):350-1

Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. McGarvey WC, et al. **Foot Ankle Int** 1996 Aug; 17(8):496-8 (25 ref.)

Pathology of the Achilles tendon in association with ciprofloxacin treatment. Movin T, et al. **Foot Ankle Int** 1997 May;18(5):297-9

Adverse drug reactions--how common to quinolones? [letter; comment] Pradhan SC, et al. **Indian J Physiol Pharmacol** 1996 Oct;40(4):389-90. Comment on: Indian J Physiol Pharmacol 1993 Jul;37(3):232-4.

Ciprofloxacin use: acute arthropathy and long-term follow up. Karande S, et al. **Indian Pediatr** 1996 Nov;33(11):910-6

The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects. Bron NJ, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1023-9

Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. Teng R, et al. **J Antimicrob Chemother** 1996 May;37(5):955-63

Neuropsychiatric manifestations of salmonella infection [letter; comment] Gohel DR, et al. **J Assoc Physicians India** 1995 Feb;43(2):146-7. Comment on: J Assoc Physicians India 1994 Aug;42(8):661.

An unusual hallucination with norfloxacin. Rataboli PV, et al. **J Assoc Physicians India** 1996 Jul;44(7):504

Parenteral ciprofloxacin in persistent diarrhoea in children [letter] Bhattacharya D. **J Indian Med Assoc** 1996 Feb; 94(2):74-5

Acute gout in a patient taking pefloxacin--a case report. Kundu AK. **J Indian Med Assoc** 1996 Nov;94(11):427

Growth and development in preterm infants receiving fluoroquinolones. Martell M, et al. **J Perinat Med** 1996; 24(3):287-91

Magnetic resonance imaging in fluoroquinolone induced tendinopathy [letter; comment] Koeger AC, et al. **J Rheumatol** 1997 May;24(5):1015-7. Comment on: J Rheumatol 1996 Jul;23(7):1313-4.

Fluoroquinolone induced arthralgia and magnetic resonance imaging [letter; comment] [see comments] Loeuille D, et al. **J Rheumatol** 1996 Jul;23(7):1313-4. Comment on: J Rheumatol 1995 Apr;22(4):793-4. Comment in: J Rheumatol 1997 May;24(5):1015-7.

What is the risk of Achilles tendon rupture with ciprofloxacin? [letter] Shinohara YT, et al. **J Rheumatol** 1997 Jan;24(1):238-9

Fluoroquinolone induced tendinopathy: report of 6 cases. Zabraniecki L, et al. **J Rheumatol** 1996 Mar;23(3):516-20

Fluoroquinolone associated bladder stone. Nakano M, et al. **J Urol** 1997 Mar;157(3):946

Spontaneous bilateral Achilles tendon rupture associated with ciprofloxacin [letter] Poon CC, et al. **Med J Aust** 1997 Jun 16;166(12):665

Inhibition of rat parotid gland growth response induced by chronic isoproterenol following treatment with quinolone antibiotics. Kelentey B, et al. **Mol Cell Biochem** 1996 Dec 6;165(1):55-63

Nephrotic syndrome after norfloxacin [letter] Hanson B, et al. **Nephron** 1996;74(2):446

Ciprofloxacin safety in a pediatric population. Jick S. **Pediatr Infect Dis J** 1997 Jan;16(1):130-3; discussion 133-4, 160-2

Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. Warren RW. **Pediatr Infect Dis J** 1997 Jan;16(1):118-22; discussion 123-6 (34 ref.)

Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction. Spivey JM, et al. **Pharmacotherapy** 1996 Mar-Apr;16(2):314-6

Pefloxacin-induced arthropathy in an adolescent with brain abscess. Chang H, et al. **Scand J Infect Dis** 1996;28(6):641-3

Fluoroquinolones and anaphylaxis. Blayac JP, et al. **Therapie** 1996 Jul-Aug;51(4):417-8

Quinolones-induced acral erythema [letter] Bonnetblanc JM, et al. **Therapie** 1996 Sep-Oct;51(5):601-2

Renal failure with fluoroquinolones. Moore N, et al. **Therapie** 1996 Jul-Aug;51(4):421-3

Tendon disorders with fluoroquinolones. Pierfitte C, et al. **Therapie** 1996 Jul-Aug;51(4):419-20

Adverse drug reactions with fluoroquinolones. Royer RJ. **Therapie** 1996 Jul-Aug;51(4):414-6

[Repeated rupture of the extensor tendons of the hand due to fluoroquinolones. Apropos of a case] Levadoux M, et al. **Ann Chir Main Memb Super** 1997;16(2):130-3 (Eng. Abstr.) **(Fre)**

[Rhabdomyolysis and unexplained malaise. Role of combination of ciprofibrate and norfloxacin (letter)] Blain H, et al. **Rev Med Interne** 1996;17(10):859-60 **(Fre)**

[Convulsion caused by ofloxacin (letter)] Sire S, et al. **Rev Med Interne** 1996;17(7):601-2 **(Fre)**

[Psychopathological syndromes in treatment with gyrase inhibitors] Hollweg M, et al. **Nervenarzt** 1997 Jan; 68(1):38-47 (Eng. Abstr.) **(Ger)**

[Paranoid psychosis after treatment with the antibiotic ofloxacin] Hollweg M, et al. **Psychiatr Prax** 1996 Sep; 23(5):251 **(Ger)**

[Effects of intravitreal levofloxacin on the rabbit retina] Ohkubo S, et al. **Nippon Ganka Gakkai Zasshi** 1996 Aug; 100(8):592-8 (Eng. Abstr.) **(Jpn)**

[Ciprofloxacin nephropathy, acyclovir nephropathy] Ohno I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):556-9 (18 ref.) **(Jpn)**

[Ciprofloxacin and Clostridium difficile associated diarrhea (letter)] Zabala López S, et al. **An Med Interna** 1996 Dec; 13(12):613-4 **(Spa)**

ANALYSIS

Photochemical stability of norfloxacin in solutions, bulk form and tablets. al-Deeb OA, et al. **Boll Chim Farm** 1996 Jun; 135(6):397-400

Colorimetric determination of the fluoroquinolones. Eboka CJ, et al. **J Antimicrob Chemother** 1997 May;39(5):639-41

Determination of ofloxacin in human aqueous humour by high-performance liquid chromatography with fluorescence detection. Basci NE, et al. **J Pharm Biomed Anal** 1997 Feb;15(5):663-6

Determination of norfloxacin by fluorescence in the presence of different antacids: quantification of analytical interferences. Córdoba-Borrego M, et al. **J Pharm Biomed Anal** 1996 Jun;14(8-10):977-82

HPLC analysis of ciprofloxacin and ciprofloxacin metabolites in body fluids. Krol GJ, et al. **J Pharm Biomed Anal** 1995 Dec;14(1-2):181-90

Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine. Wong FA, et al. **J Pharm Biomed Anal** 1997 Mar;15(6):765-71

Compositional analysis surveillance of eleven brands of enrofloxacin including Baytril for veterinary use. Sumano H, et al. **Zentralbl Veterinarmed A** 1995 Dec;42(10):669-73

ANTAGONISTS & INHIBITORS

Mechanistic investigation of the reduction in antimicrobial activity of ciprofloxacin by metal cations. Ma HH, et al. **Pharm Res** 1997 Mar;14(3):366-70

[The appearance of ciprofloxacin resistance in the microbial strains isolated from gynecologic patients] Shopova E. **Akush Ginekol (Sofiia)** 1997;36(1):14-6 (Eng. Abstr.) **(Bul)**

BLOOD

Effect of phagocytosis of bacteria on the uptake of sparfloxacin by human neutrophils. García I, et al. **Chemotherapy** 1996 Nov-Dec;42(6):465-7

Simultaneous determination of rufloxacin, fenbufen and felbinac in human plasma using high-performance liquid chromatography. Carlucci G, et al. **J Chromatogr B Biomed Appl** 1996 Jul 12;682(2):315-9

Rapid and economical high-performance liquid chromatographic method for the determination of norfloxacin in serum using a microparticulate C18 guard cartridge. Wallis SC, et al. **J Chromatogr B Biomed Appl** 1995 Dec 15;674(2):306-9

Simultaneous determination of furprofen and rufloxacin in human plasma by high-performance liquid chromatography. Carlucci G, et al. **J Chromatogr Sci** 1996 Apr;34(4):182-4

Automated analytical systems for drug development studies. Part IV. A microdialysis system to study the partitioning of lomefloxacin across an erythrocyte membrane in vitro. Knaub SR, et al. **J Pharm Biomed Anal** 1995 Dec; 14(1-2):121-9

Application of terbium sensitized fluorescence for the determination of fluoroquinolone antibiotics pefloxacin, ciprofloxacin and norfloxacin in serum. Veiopoulou CJ, et al. **J Pharm Biomed Anal** 1997 Aug;15(12):1839-44

CEREBROSPINAL FLUID

Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin. Cutler NR, et al. **Antimicrob Agents Chemother** 1997 Jun; 41(6):1298-300

CHEMICAL SYNTHESIS

Copper(II) complexes of the fluoroquinolone antimicrobial ciprofloxacin. Synthesis, X-ray structural characterization, and potentiometric study. Wallis SC, et al. **J Inorg Biochem** 1996 Apr;62(1):1-16

18F-labeling and biodistribution of the novel fluoro-quinolone antimicrobial agent, trovafloxacin (CP 99,219). Babich JW, et al. **Nucl Med Biol** 1996 Nov; 23(8):995-8

The synthesis of fluorine-18 lomefloxacin and its preliminary use in human studies. Tewson TJ, et al. **Nucl Med Biol** 1996 Aug;23(6):767-72

CHEMISTRY

Electrochemical studies of some quinolone antibiotics. Part II. Determination by differential pulse polarography in substance and in pharmaceutical formulations. Warowna-Grześkiewicz M, et al. **Acta Pol Pharm** 1995 Nov-Dec;52(6):441-5

Electrochemical studies of some quinolone antibiotics. Part I. Qualitative analysis on mercury and carbon electrodes. Warowna-Grześkiewicz M, et al. **Acta Pol Pharm** 1995 May-Jun;52(3):187-92

Ciprofloxacin and sodium phosphates not compatible during actual Y-site injection [letter] [see comments] Benjamin BE. **Am J Health Syst Pharm** 1996 Aug 1;53(15):1850-1 . Comment in: Am J Health Syst Pharm 1996 Dec 15;53(24):2990.

Compatibility of ciprofloxacin lactate with sodium bicarbonate during simulated Y-site administration. Gilbert DL Jr, et al. **Am J Health Syst Pharm** 1997 May 15; 54(10):1193-5

Everything in a compatibility study is important [letter; comment] Trissel LA. **Am J Health Syst Pharm** 1996 Dec 15;53(24):2990. Comment on: Am J Health Syst Pharm 1996 Aug 1;53(15):1850-1.

Zwitterions and pH-dependent solubility [letter; comment] Williams DA. **Am J Health Syst Pharm** 1996 Jul 15; 53(14):1732. Comment on: Am J Health Syst Pharm 1996 Jan 1;53(1):84-5.

Stability of levofloxacin in intravenous solutions in polyvinyl chloride bags. Williams NA, et al. **Am J Health Syst Pharm** 1996 Oct 1;53(19):2309-13

Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Takenouchi T, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1835-42

Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Elmore RL, et al. **Clin Ther** 1996 Mar-Apr;18(2):246-55

In vitro release of new quinolones from biodegradable systems: a comparative study. Andreopoulos AG, et al. **J Biomater Appl** 1996 Apr;10(4):338-47

Crystal structure and characterization of the bismuth(III) compound with quinolone family member (ciprofloxacin). Antibacterial study. Turel I, et al. **J Inorg Biochem** 1997 Jun;66(4):241-5

Copper(II) complexes of the fluoroquinolone antimicrobial ciprofloxacin. Synthesis, X-ray structural characterization, and potentiometric study. Wallis SC, et al. **J Inorg Biochem** 1996 Apr;62(1):1-16

Physicochemical properties of enrofloxacin. Lizondo M, et al. **J Pharm Biomed Anal** 1997 Aug;15(12):1845-9

Structure elucidation of a photodegradation product of ciprofloxacin. Torniainen K, et al. **J Pharm Biomed Anal** 1997 Apr;15(7):887-94

Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects. Gootz TD, et al. **Med Res Rev** 1996 Sep;16(5):433-86 (277 ref.)

Photogeneration of fluoride by the fluoroquinolone antimicrobial agents lomefloxacin and fleroxacin. Martinez LJ, et al. **Photochem Photobiol** 1997 Mar;65(3):599-602

CONTRAINDICATIONS

Fluoroquinolone induced tendinopathy: report of 6 cases. Zabraniecki L, et al. **J Rheumatol** 1996 Mar;23(3):516-20

[A patient with theophylline-quinolone interaction. Not all quinolones are equal (letter)] Cárdenas Rodríguez M, et al. **Aten Primaria** 1996 Sep 15;18(4):204-5 **(Spa)**

DIAGNOSTIC USE

Clinical evaluation of technetium-99m infecton for the localisation of bacterial infection. Britton KE, et al. **Eur J Nucl Med** 1997 May;24(5):553-6

ECONOMICS

Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis. Amodio-Groton M, et al. **Ann Pharmacother** 1996 Jun;30(6):596-602

HISTORY

Historical perspective--use of ciprofloxacin in children. Echols RM. **Pediatr Infect Dis J** 1997 Jan;16(1):89-90

ISOLATION & PURIFICATION

Analytical chiral separation of a new quinolone compound in biological fluids by high-performance liquid chromatography. Matsuoka M, et al. **J Chromatogr B Biomed Appl** 1996 Feb 9;676(1):117-24

ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE

METABOLISM

A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase. Hilliard JJ, et al. **Adv Exp Med Biol** 1995;390:59-69

Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes. Ozaki M, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):739-42

Degradation of the fluoroquinolone enrofloxacin by wood-rotting fungi. Martens R, et al. **Appl Environ Microbiol** 1996 Nov;62(11):4206-9

Comparative uptake of sparfloxacin and ciprofloxacin into human THP 1 monocytic cells. Rispal P, et al. **Arzneimittelforschung** 1996 Mar;46(3):316-9

Simultaneous determination of danofloxacin and N-desmethyldanofloxacin in cattle and chicken edible tissues by liquid chromatography with fluorescence detection. Strelevitz TJ, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26;675(2):243-50

Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis [see comments] Høiby N, et al. **Lancet** 1997 Jan 18;349(9046):167-9. Comment in: Lancet 1997 Jan 18;349(9046):148-9. Comment in: Lancet 1997 Mar 1;349(9052):649. Comment in: Lancet 1997 Apr 5;349(9057):1030.

Column-switching high-performance liquid chromatography of ofloxacin in human saliva and correlation of ofloxacin level in saliva and serum. Ohkubo T, et al. **Ther Drug Monit** 1996 Oct;18(5):598-603

Intermolecular interactions of antimicrobial fluoroquinolones with purified rat liver CYP1A2 studied by proton nuclear magnetic resonance spectroscopy. Mizuki Y, et al. **Xenobiotica** 1996 Oct;26(10):1057-66

[Uptake of 5 fluoroquinolones into human polymorphonuclear cells] Ballesta S, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):470-3 (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

The effect of trauma on the ocular penetration of intravenous ciprofloxacin [see comments] Alfaro DV, et al. **Am J Ophthalmol** 1996 Nov;122(5):678-83. Comment in: Am J Ophthalmol 1996 Nov;122(5):724-6.

Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids, and endometrial tissues after repeated intragastrically administered doses. Giguère S, et al. **Am J Vet Res** 1996 Jul;57(7):1025-30

Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and intramuscular administrations in sheep. Mengozzi G, et al. **Am J Vet Res** 1996 Jul;57(7):1040-3

AUIC--a general target for the optimization of dosing regimens of antibiotics? [see comments] Dalla Costa T, et al. **Ann Pharmacother** 1996 Sep;30(9):1024-8. Comment in: Ann Pharmacother 1996 Sep;30(9):1029-31.

Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers. Bertino JS Jr, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):789-91

Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Bethell DB, et al. **Antimicrob Agents Chemother** 1996 Sep; 40(9):2167-72

Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. Chien SC, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1765-9

Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Chien SC, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1562-5

Antibacterial activity and pharmacokinetics of four new 7-azetidinyl fluoroquinolones. Coll R, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):274-7

Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Conte JE Jr, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1617-22

Penetration of ciprofloxacin and fleroxacin into biliary tract. Edmiston CE Jr, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):787-91

Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Firsov AA, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1281-7

Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. Fischman AJ, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):659-64

Ciprofloxacin pharmacokinetics in burn patients. Garrelts JC, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1153-6

Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Healy DP, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):6-10

Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects. Kozawa O, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2824-8

Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Müller M, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2703-9

Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers. Nix DE, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1108-14

Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. Owens RC Jr, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1508-11

Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process. Rabbaa L, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2126-30

Excretion of ciprofloxacin into the large bowel of the rabbit. Ramon J, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):11-3

Circadian variation in urinary excretion of ciprofloxacin after a single-dose oral administration at 1000 and 2200 hours in human subjects. Rao VV, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1802-4

Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies. Reigner BG, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):575-80

Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Schaefer HG, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):29-34

Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. Trautmann M, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):776-9

Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. Uehlinger DE, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1903-9

Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract. van den Hazel SJ, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2658-60

Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics. Vrany JD, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1352-8

Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Wise R, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):47-9

Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Zix JA, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1668-72

Intracorneal, aqueous humor, and vitreous humor penetration of topical and oral ofloxacin. Donnenfeld ED, et al. **Arch Ophthalmol** 1997 Feb;115(2):173-6

Aqueous humor penetration of topically applied ciprofloxacin, ofloxacin and tobramycin. Durmaz B, et al. **Arzneimittelforschung** 1997 Apr;47(4):413-5

Pharmacokinetics of pruliflоxacin. 3rd communication: metabolism in rats, dogs and monkeys. Okuyama Y, et al. **Arzneimittelforschung** 1997 Mar;47(3):293-8

Pharmacokinetics of pruliflоxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration. Okuyama Y, et al. **Arzneimittelforschung** 1997 Mar;47(3):276-84

Pharmacokinetics of pruliflоxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats. Okuyama Y, et al. **Arzneimittelforschung** 1997 Mar; 47(3):285-92

Pharmaceutical properties of freeze-dried formulations of egg albumin, several drugs and olive oil. Tsuji Y, et al. **Biol Pharm Bull** 1996 Apr;19(4):636-40

A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic. Knupp CA, et al. **Biopharm Drug Dispos** 1997 Jan;18(1):65-77

Lack of gender effect on ciprofloxacin pharmacokinetics in humans. Gallicano K, et al. **Br J Clin Pharmacol** 1996 Nov; 42(5):632-4

A comparative study of the distribution of ofloxacin and ciprofloxacin in prostatic tissues after simultaneous oral ingestion. Png JC, et al. **Br J Urol** 1997 May;79(5):781-4

Pharmacokinetic evaluation of enrofloxacin in chickens. Abd el-Aziz MI, et al. **Br Poult Sci** 1997 May;38(2):164-8

Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Stein GE. **Clin Infect Dis** 1996 Dec;23 Suppl 1:S19-24 (54 ref.)

The clinical pharmacokinetics of levofloxacin. Fish DN, et al. **Clin Pharmacokinet** 1997 Feb;32(2):101-19 (78 ref.)

Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Jungersten L, et al. **Clin Physiol** 1996 Jul;16(4):369-79

Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways. Dalvie DK, et al. **Drug Metab Dispos** 1996 Nov;24(11):1231-40

Excretion and metabolism of trovafloxacin in humans. Dalvie DK, et al. **Drug Metab Dispos** 1997 Apr;25(4):423-7

Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. Verho M, et al. **Drug Metabol Drug Interact** 1996;13(1):57-67

Trovafloxacin. Haria M, et al. **Drugs** 1997 Sep;54(3):435-45; discussion 446 (48 ref.)

Bioavailability of ciprofloxacin in patients with acute infectious diarrhoe [letter] Beckebaum S, et al. **Eur J Clin Pharmacol** 1996;50(6):511-2

Penetration of pefloxacin and its desmethyl metabolite into the uroepithelium after a 800-mg single oral dose in human patients. Moreau JL, et al. **Eur J Clin Pharmacol** 1996; 49(5):401-5

Effect of ranitidine on renal clearance of lomefloxacin. Sudoh T, et al. **Eur J Clin Pharmacol** 1996;51(1):95-8

Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Schüler P, et al. **Eur Respir J** 1997 May;10(5):1130-6

Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. Madu AA, et al. **Exp Eye Res** 1996 Aug;63(2):129-36

Penetration of gentamicin and ofloxacin in human vitreous after systemic administration. Verbraeken H, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234 Suppl 1:S59-65

Tissue penetration of sparfloxacin in a rat model of experimental Escherichia coli epididymitis. Ludwig M, et al. **Infection** 1997 May-Jun;25(3):178-84

Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis. Smith A, et al. **Infection** 1997 Mar-Apr;25(2):106-8

Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. Akkan AG, et al. **Int J Clin Pharmacol Ther** 1997 May; 35(5):214-7

Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. Andrews JM, et al. **J Antimicrob Chemother** 1997 Jun;39(6):797-802

Pefloxacin penetration into human necrotic pancreatic tissue. Bertazzoni Minelli E, et al. **J Antimicrob Chemother** 1996 Aug;38(2):237-43

The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects. Bron NJ, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1023-9

Enteric absorption of ciprofloxacin during tube feeding in the critically ill. Cohn SM, et al. **J Antimicrob Chemother** 1996 Nov;38(5):871-6

Pharmacodynamics and pharmacokinetics of A-80556 using microdialysis in a Streptococcus pneumoniae meningitis model. Destache CJ, et al. **J Antimicrob Chemother** 1996 Dec;38(6):977-85

Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils. García I, et al. **J Antimicrob Chemother** 1996 Nov;38(5):859-63

The pharmacokinetics of once-daily oral 400 mg ofloxacin in patients with peritonitis complicating continuous ambulatory peritoneal dialysis. McMullin CM, et al. **J Antimicrob Chemother** 1997 Jun;39(6):829-31

Is the uptake of pefloxacin in human blood monocytes a simple diffusion process? Memin E, et al. **J Antimicrob Chemother** 1996 Nov;38(5):787-98

Characterisation of DNA gyrase and measurement of drug accumulation in clinical isolates of Acinetobacter baumannii resistant to fluoroquinolones. Moreau NJ, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1079-83

Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. Teng R, et al. **J Antimicrob Chemother** 1996 May;37(5):955-63

Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. Teng R, et al. **J Antimicrob Chemother** 1997 Jun;39 Suppl B:93-7

Oral bioavailability of trovafloxacin with and without food in healthy volunteers. Teng R, et al. **J Antimicrob Chemother** 1997 Jun;39 Suppl B:87-92

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. Vincent J, et al. **J Antimicrob Chemother** 1997 Jun;39 Suppl B:75-80

Comparative bioavailability of two brands of ciprofloxacin. Seth SD, et al. **J Assoc Physicians India** 1995 May; 43(5):327-30

Comparative bioavailability of two brands of norfloxacin. Seth SD, et al. **J Assoc Physicians India** 1995 May; 43(5):324-6

Corneal tissue levels of topically applied ofloxacin. Price FW Jr, et al. **J Cataract Refract Surg** 1997 Jul-Aug; 23(6):898-902

Pharmacokinetics of pefloxacin in human prostatic tissue. Salpigides G, et al. **J Chemother** 1995 Nov;7 Suppl 4:105-6

Regulation of ciprofloxacin uptake in human promyelocytic leukemia cells and polymorphonuclear leukocytes. Loo KC, et al. **J Leukoc Biol** 1997 May;61(5):619-23

Effect of collagen cross-linking in collagen corneal shields on ocular drug delivery. Kuwano M, et al. **J Ocul Pharmacol Ther** 1997 Feb;13(1):31-40

Absorption of ciprofloxacin and norfloxacin when administered as niosome-encapsulated inclusion complexes. D'Souza SA, et al. **J Pharm Pharmacol** 1997 Feb; 49(2):145-9

Evidence for a passive diffusion mechanism for sparfloxacin uptake at the brush-border membrane of the human intestinal cell-line Caco-2. Cormet E, et al. **J Pharm Sci** 1997 Jan;86(1):33-6

Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1-piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic

in rats. Yu IL, et al. **J Pharm Sci** 1997 May;86(5):550–3
Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. Ito T, et al. **J Pharmacol Exp Ther** 1997 Aug; 282(2):955–60
Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. Sasabe H, et al. **J Pharmacol Exp Ther** 1997 Jul; 282(1):162–71
Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. Park SC, et al. **J Vet Med Sci** 1996 Oct;58(10):1039–40
Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. Gips M, et al. **J Vet Pharmacol Ther** 1996 Apr;19(2):130–4
Disposition of single-dose oral enrofloxacin in the horse. Langston VC, et al. **J Vet Pharmacol Ther** 1996 Aug; 19(4):316–9 (11 ref.)
Pharmacokinetics of enrofloxacin in the red pacu (Colossoma brachypomum) after intramuscular, oral and bath administration. Lewbart G, et al. **J Vet Pharmacol Ther** 1997 Apr;20(2):124–8
Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. Schneider M, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):56–61
Multiple route and dose pharmacokinetics of enrofloxacin in juvenile Atlantic salmon. Stoffregen DA, et al. **J Vet Pharmacol Ther** 1997 Apr;20(2):111–23
Pharmacokinetics of a single intravenous enrofloxacin dose in scimitar-horned oryx (Oryx dammah). Gamble KC, et al. **J Zoo Wildl Med** 1997 Mar;28(1):36–42
Disposition of single-dose intravenously administered enrofloxacin in emus (Dromaius novaehollandiae). Helmick KE, et al. **J Zoo Wildl Med** 1997 Mar;28(1):43–8
Disposition of enrofloxacin and its metabolite ciprofloxacin after intramuscular injection in juvenile Burmese pythons (Python molurus bivittatus). Young LA, et al. **J Zoo Wildl Med** 1997 Mar;28(1):71–9
18F-labeling and biodistribution of the novel fluoro-quinolone antimicrobial agent, trovafloxacin (CP 99,219). Babich JW, et al. **Nucl Med Biol** 1996 Nov; 23(8):995–8
The synthesis of fluorine-18 lomefloxacin and its preliminary use in human studies. Tewson TJ, et al. **Nucl Med Biol** 1996 Aug;23(6):767–72
Absorption of topically administered ciprofloxacin, ofloxacin and gentamicin in the inflamed rabbit eye. Behrens-Baumann W. **Ophthalmologica** 1996;210(2):119–22
Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. Yano I, et al. **Pharm Res** 1997 Apr; 14(4):508–11
Bioavailability of enrofloxacin after oral administration to fed and fasted pigs. Nielsen P, et al. **Pharmacol Toxicol** 1997 May;80(5):246–50
Prospective validation of an optimal sparse plasma-sampling strategy for estimating ciprofloxacin pharmacokinetics. Amsden GW, et al. **Pharmacotherapy** 1996 Sep-Oct; 16(5):937–41
A prospective, open-label study of single-dose ciprofloxacin absorption after chemotherapy in patients with malignancy. Gattis WA, et al. **Pharmacotherapy** 1997 Jul-Aug; 17(4):836–40
Pharmacokinetics of ciprofloxacin in sheep after single intravenous or intramuscular administration. Muñoz MJ, et al. **Vet Q** 1996 Jun;18(2):45–8
The plasma kinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Muscovy duck [published erratum appears in Vet Res Commun 1997 May;21(4):240] Intorre L, et al. **Vet Res Commun** 1997 Feb; 21(2):127–36
Disposition of enrofloxacin (Baytril) into the udder after intravenous and intra-arterial injections into dairy cows. Malbe M, et al. **Zentralbl Veterinarmed A** 1996 Aug; 43(6):377–86
[Pharmacokinetic properties of ofloxacin (review of the literature] Iakovlev VP. **Antibiot Khimioter** 1996; 41(9):24–32 (69 ref.) **(Rus)**
[The pharmacokinetics of fluoroquinolones in different diseases] Iakovlev VP, et al. **Antibiot Khimioter** 1997; 42(1):23–9 (49 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase. Hilliard JJ, et al. **Adv Exp Med Biol** 1995;390:59–69
Bacterial resistance to fluoroquinolones: mechanisms and patterns. Hooper DC. **Adv Exp Med Biol** 1995;390:49–57 (65 ref.)
Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Osheroff N, et al. **Adv Pharmacol** 1994;29B:105–26 (130 ref.)
Resistance of Helicobacter pylori to antibiotics. Mégraud F. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:43–53 (39 ref.)
Fluoroquinolone inhibition of clozapine metabolism [letter] Markowitz JS, et al. **Am J Psychiatry** 1997 Jun;154(6):881
Ciprofloxacin-phenytoin interaction [letter] Brouwers PJ, et al. **Ann Pharmacother** 1997 Apr;31(4):498
Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers. Aguilar L, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):17–21
Suspicion of quinolone active metabolite following discrepancy between predicted and experimental urine bactericidal activities. Aguilar L, et al. **Antimicrob Agents Chemother** 1997 May;41(5):927–30
Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Aldridge KE, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):709–11
Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes. Aldridge KE, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):484–7
In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Bahl D, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1293–7
Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies. Bajaksouzian S, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1073–6
Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Baranova NN, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1396–8
In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents. Barry AL, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2431–3
Resistance to fluoroquinolones in Escherichia coli isolated from poultry. Bazile-Pham-Khac S, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1504–7
Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones. Bebear CM, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):269–73
Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Bermudez LE, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):546–51
Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Bisognano C, et al. **Antimicrob Agents Chemother** 1997 May;41(5):906–13
Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group. Blondeau JM, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1729–32
Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Boswell FJ, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1377–9
Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Breines DM, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):175–9
Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods. Chang JC, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1301–6
Antibacterial activity and pharmacokinetics of four new 7-azetidinyl fluoroquinolones. Coll R, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):274–7
Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Cormican MG, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):204–11
Fluoroquinolone action in mycobacteria: similarity with effects in Escherichia coli and detection by cell lysate viscosity. Drlica K, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1594–9
Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Edelstein PH, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):314–19
Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Everett MJ, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2380–6
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Fass RJ. **Antimicrob Agents Chemother** 1997 Aug; 41(8):1818–24
In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Fass RJ, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1412–8
Treatment of experimental endocarditis due to ampicillin-susceptible or ampicillin-resistant Salmonella enteritidis. Fernández Guerrero ML, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1589–93
Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Firsov AA, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1281–7
In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains. Frosco MB, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2529–34
Sensitization of bacteria to danofloxacin by temperate prophages. Froshauer S, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1561–3
Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group. Fuchs PC, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1633–9
Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Garrison MW, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2859–64
Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Georgiou M, et al. **Antimicrob Agents Chemother** 1996 Jul; 40(7):1741–4
Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. Gerardo SH, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2413–5
Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. Gillum JG, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1715–6
Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones. Goldman JD, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1266–9
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Goldstein EJ, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1552–7
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Gootz TD, et al. **Antimicrob Agents Chemother** 1996 Dec; 40(12):2691–7
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem. Hoppe JE, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):807–8
High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Janoir C, et al. **Antimicrob Agents Chemother** 1996 Dec; 40(12):2760–4
Trovafloxacin is active against Toxoplasma gondii. Khan AA, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1855–9
N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies. Klopman G, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2637–43
Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Kocagöz T, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1768–74
Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate. Krueger WA, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1725–30
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Kumagai Y, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):710–14
Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae. Licata L, et al. **Antimicrob Agents Chemother** 1997 May;41(5):950–5
Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Madaras-Kelly KJ, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):627–32
Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus [letter] Markham PN, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2673–4
In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella. Martin SJ, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1419–21
In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone. Masuda N, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1201–7
Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole, or rifampin, against intracellular Listeria monocytogenes. Michelet C, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):60–5
In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Miyashita N, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1331–4
Structure-related inhibitory effect of antimicrobial enoxacin and derivatives on theophylline metabolism by rat liver microsomes. Mizuki Y, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1875–80
Induction of DnaK and GroEL heat shock proteins by fluoroquinolones in Escherichia coli. Mizushima T, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):193–5

Mechanism of differential activities of ofloxacin enantiomers. Morrissey I, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1775–84

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin–quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Mulazimoglu L, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2428–30

ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Muñoz R, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2252–7

Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Ng EY, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1881–8

In vitro and in vivo antichlamydial activities of HSR–903, a new fluoroquinolone antibiotic. Niki Y, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):857–9

Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers. Nix DE, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1108–14

Molecular epidemiology of fluoroquinolone–resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Oethinger M, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):387–92

In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Oh JI, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1564–8

Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes. Ozaki M, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):739–42

Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet–fibrin clots. Palmer SM, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):701–5

Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Pan XS, et al. **Antimicrob Agents Chemother** 1996 Oct; 40(10):2321–6

Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Pan XS, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):471–4

Antipneumococcal activities of RP 59500 (quinupristin–dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time–kill methodologies. Pankuch GA, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1653–6

Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue–cultured epithelial cells. Pascual A, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):274–7

Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Perichon B, et al. **Antimicrob Agents Chemother** 1997 May; 41(5):1166–7

Differential intracellular efficacies of ciprofloxacin and cefixime against Neisseria gonorrhoeae in human fallopian tube organ culture. Phanucharas JP, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1547–51

Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Rastogi N, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2483–7

NorA plasmid resistance to fluoroquinolones: role of copy number and norA frameshift mutations. Sun L, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1665–9

In vitro activity of HSR–903, a new quinolone. Takahashi Y, et al. **Antimicrob Agents Chemother** 1997 Jun; 41(6):1326–30

Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux–mediated resistant mutants of Staphylococcus aureus. Takenouchi T, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1835–42

Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Tankovic J, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2505–10

Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene. Tankovic J, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2558–61

Cloning and nucleotide sequence of the gyrA gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of ciprofloxacin–resistant laboratory and clinical isolates. Taylor DE, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):665–71

Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Thomson KS, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):478–80

Insufficient evidence of synergistic effect of levofloxacin and rifampin against Legionella pneumophila [letter; comment] van Ogtrop ML. **Antimicrob Agents Chemother** 1996 Feb; 40(2):524–5. Comment on: Antimicrob Agents Chemother 1995 Aug;39(8):1661–6.

Detection of mutations in parC in quinolone–resistant clinical isolates of Escherichia coli. Vila J, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):491–3

MIC and time–kill study of activities of DU–6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin–susceptible and –resistant pneumococci. Visalli MA, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):362–6

Comparative activity of trovafloxacin, alone and in combination with other agents, against gram–negative nonfermentative rods. Visalli MA, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1475–81

In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Wexler HM, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2232–5

In vitro activity of BAY 12–8039, a new fluoroquinolone. Woodcock JM, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):101–6

Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin: pulsed–field gel electrophoresis typing of strains from North America, Hawaii, and the Philippines [letter] Xia M, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2439–40

Uptake and intracellular activity of AM–1155 in phagocytic cells. Yamamoto T, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2756–9

Influence of tetracyclines or cetylpyridinium bromide on activity of fluoroquinolones in Euglena gracilis. Ebringer L, et al. **Arzneimittelforschung** 1997 May;47(5):683–7

One–month oral toxicity study of the new quinolone antibacterial agent (S)–10–[(S)–(8–amino–6–azaspiro[3,4]octan–6–yl)–9–fluoro–2,3–dihydro–3– methyl–7–oxo–7H–pyrido [1,2,3–de] [1,4] benzoxazine–6–carboxylic acid hemihydrate in rats and cynomolgus monkeys. Sugawara T, et al. **Arzneimittelforschung** 1996 Jul;46(7):705–10

Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice. Tomii Y, et al. **Arzneimittelforschung** 1996 Dec;46(12):1169–73

In vitro susceptibility of Escherichia coli O157 to several antimicrobial agents. Oie S, et al. **Biol Pharm Bull** 1997 May;20(5):584–5

Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. Demolis JL, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):499–503

Emergence of Neisseria gonorrhoeae strains with decreased susceptibility to ciprofloxacin—Quebec, 1994–1995. Ringuette L, et al. **Can Commun Dis Rep** 1996 Aug 1; 22(15):121–4; discussion 124–5 **(Eng, Fre)**

In vitro activity of BAY 12–8039, a new 8–methoxyquinolone. Dalhoff A, et al. **Chemotherapy** 1996 Nov–Dec;42(6):410–25

Comparison of in vitro antimicrobial activity of AM–1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. Deguchi T, et al. **Chemotherapy** 1997 Jul–Aug;43(4):239–44

Pharmacodynamic effects of ciprofloxacin, fleroxacin and lomefloxacin in vivo and in vitro. Fuentes F, et al. **Chemotherapy** 1996 Sep–Oct;42(5):354–62

The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin–susceptible and vancomycin–resistant enterococci. Itokazu GS, et al. **Chemotherapy** 1996 Jul–Aug;42(4):235–9

Fleroxacin enhancement of superoxide production by polymorphonuclear leukocytes: the role of protein kinases. Matsumoto T, et al. **Chemotherapy** 1996 Jul–Aug; 42(4):280–5

Anti–Salmonella activity of CP–99,219, a novel azabicyclo–naphthridone fluoroquinolone. Qadri SM, et al. **Chemotherapy** 1996 Nov–Dec;42(6):439–42

In vitro activity of sparfloxacin against Salmonella typhi. Qadri SM, et al. **Chemotherapy** 1997 Jan–Feb;43(1):6–9

Effect of subinhibitory concentrations of ceftazidime, ciprofloxacin, and azithromycin on the hemagglutination and adherence of uropathogenic Escherichia coli strains. Vranes J. **Chemotherapy** 1996 May–Jun;42(3):177–85

Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells. Yoshimura T, et al. **Chemotherapy** 1996 Nov–Dec; 42(6):459–64

Comparison of activities of trovafloxacin (CP–99,219) and five other agents against 585 anaerobes with use of three media. Hecht DW, et al. **Clin Infect Dis** 1996 Dec;23 Suppl 1:S44–50

In vitro susceptibility of anaerobes to quinolones in the United States. Hecht DW, et al. **Clin Infect Dis** 1996 Dec; 23 Suppl 1:S2–8

Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Israel DS, et al. **Clin Infect Dis** 1996 Feb;22(2):251–6

Comparison of in vitro activities of DU–6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria. Kato N, et al. **Clin Infect Dis** 1996 Dec;23 Suppl 1:S31–5

Antibiotic therapy for diabetic foot infections: comparison of two parenteral–to–oral regimens. Lipsky BA, et al. **Clin Infect Dis** 1997 Apr;24(4):643–8

In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Nord CE. **Clin Infect Dis** 1996 Dec;23 Suppl 1:S15–8

Comparative in vitro activity of meropenem versus other extended–spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers. Pitkin DH, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S238–48

Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Stein GE. **Clin Infect Dis** 1996 Dec;23 Suppl 1:S19–24 (54 ref.)

The effect of ofloxacin on the human corneal endothelium. McDermott ML, et al. **Cornea** 1997 Mar;16(2):209–14

Effect of ciprofloxacin on the accumulation of interleukin–6, interleukin–8, and nitrite from a human endothelial cell model of sepsis [see comments] Galley HF, et al. **Crit Care Med** 1997 Aug;25(8):1392–5. Comment in: Crit Care Med 1997 Aug;25(8):1270–1.

Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin–resistant Streptococcus pneumoniae isolates. Barrett MS, et al. **Diagn Microbiol Infect Dis** 1996 Feb;24(2):113–6

The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Biedenbach DJ, et al. **Diagn Microbiol Infect Dis** 1996 May;25(1):47–51

Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices. Biedenbach DJ, et al. **Diagn Microbiol Infect Dis** 1997 Jan–Feb;27(1–2):1–5

Susceptibility of ciprofloxacin–resistant staphylococci and enterococci to trovafloxacin. Bonilla HF, et al. **Diagn Microbiol Infect Dis** 1996 Sep;26(1):17–21

Sparfloxacin worldwide in vitro literature: isolate data available through 1994. Cohen MA, et al. **Diagn Microbiol Infect Dis** 1996 Jun;25(2):53–64 (114 ref.)

Accurate characterization of ofloxacin susceptibility with Enterobacteriaceae using a modified GNS F6 card and the bioMerieux Vitek System. Doern GV, et al. **Diagn Microbiol Infect Dis** 1996 Jul;25(3):133–5

Comparative in vitro activity of levofloxacin and ofloxacin against gram–positive bacteria. Eliopoulos GM, et al. **Diagn Microbiol Infect Dis** 1996 May;25(1):35–41

Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones. Fuchs PC, et al. **Diagn Microbiol Infect Dis** 1996 Sep; 26(1):23–7

Bactericidal activity of the fluoroquinolone DU–6859a alone and in combination with other antimicrobial agents against multiresistant enterococci. Korten V, et al. **Diagn Microbiol Infect Dis** 1996 Oct;26(2):79–85

Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Franklin County Pneumonia Study Group. Plouffe JF. **Diagn Microbiol Infect Dis** 1996 May;25(1):43–5

Timed killing kinetic studies of the interaction between ciprofloxacin and beta–lactams against gram–negative bacilli. Pohlman JK, et al. **Diagn Microbiol Infect Dis** 1996 Sep;26(1):29–33

Assessment of the synergistic interactions of levofloxacin and ampicillin against Enterococcus faecium by the checkerboard agar dilution and time–kill methods. Smith CE, et al. **Diagn Microbiol Infect Dis** 1997 Mar;27(3):85–92

Susceptibility of twenty penicillin–susceptible and –resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time–kill. Visalli MA, et al. **Diagn Microbiol Infect Dis** 1997 Jul;28(3):131–7

Fluoroquinolone antibiotics inhibit cytochrome P450–mediated microsomal drug metabolism in rat and human. McLellan RA, et al. **Drug Metab Dispos** 1996 Oct; 24(10):1134–8

Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Goa KL, et al. **Drugs** 1997 Apr;53(4):700–25 (150 ref.)

Susceptibility of microorganisms isolated from chronic suppurative otitis media to ciprofloxacin. Altuntas A, et al. **Eur Arch Otorhinolaryngol** 1996;253(6):364–6

Methods of measuring susceptibility of anaerobic bacteria to trovafloxacin, including quality control parameters. Barry AL, et al. **Eur J Clin Microbiol Infect Dis** 1996 Aug; 15(8):676–8

In vitro activity of trovafloxacin (CP–99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. Crokaert F, et al. **Eur J Clin Microbiol Infect Dis** 1996 Aug;15(8):696–8

In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. Fuchs PC, et al. **Eur J Clin Microbiol Infect Dis** 1996 Aug; 15(8):678–82

Activity of trovafloxacin against blood isolates of Streptococcus pneumoniae in Sweden. Liljequist BO, et al. **Eur J Clin Microbiol Infect Dis** 1996 Aug;15(8):671–5

In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. Milatovic D, et al. **Eur J Clin Microbiol Infect Dis** 1996 Aug;15(8):688–93

Antibacterial activity of trovafloxacin against gram–positive blood culture isolates from nosocomial infections. Qadri SM, et al. **Eur J Clin Microbiol Infect Dis** 1996 Aug; 15(8):694–6

Nonradioactive single–strand conformation polymorphism analysis for detection of fluoroquinolone resistance in mycobacteria. Sougakoff W, et al. **Eur J Clin Microbiol Infect Dis** 1997 May;16(5):395–8

In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against

Pseudomonas aeruginosa. Tessier F, et al.
Eur J Clin Microbiol Infect Dis 1997 Feb;16(2):159–62
In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia. Urbášková P, et al.
Eur J Clin Microbiol Infect Dis 1996 Aug;15(8):686–8
In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates. Verbist L, et al.
Eur J Clin Microbiol Infect Dis 1996 Aug;15(8):683–5
Ciprofloxacin decreases plasma phenytoin concentrations in the rat. al-Humayyd MS.
Eur J Drug Metab Pharmacokinet 1997 Jan–Mar;22(1):35–9
Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones. Shalit I, et al.
Eur J Haematol 1997 Feb;58(2):92–8
In vitro plasmid-encoded resistance to quinolones. Gómez-Gómez JM, et al. **FEMS Microbiol Lett** 1997 Sep 15;154(2):271–6
Mutations in the gyrA and parC genes associated with fluoroquinolone resistance in clinical isolates of Citrobacter freundii. Nishino Y, et al. **FEMS Microbiol Lett** 1997 Sep 15;154(2):409–14
Postantibiotic effects of subinhibitory concentrations of some antibiotics and their influence on Pseudomonas aeruginosa enzymic activity. Hoštacká A. **Folia Microbiol (Praha)** 1996;41(1):39–42
Mutation in DNA gyrase of norfloxacin-resistant clinical isolates of Neisseria gonorrhoeae. Tanaka M, et al.
Genitourin Med 1996 Aug;72(4):295–7
In vitro activities of tetracycline & ciprofloxacin against Chlamydia trachomatis isolates from conjunctivitis patients. Madhavan HN, et al. **Indian J Med Res** 1996 Mar; 103:138–41
Endothelial cell compatibility of fluoroquinolone solutions for intravenous use. Vorbach H, et al.
Int J Clin Pharmacol Ther 1997 Jun;35(6):235–8
Are ciprofloxacin susceptibility tests relevant for Streptococcus pneumoniae? [letter] Barry AL, et al.
J Antimicrob Chemother 1996 Jul;38(1):151–3
In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219) -letter- Barry AL, et al.
J Antimicrob Chemother 1996 Aug;38(2):324–7
Isolation and characterization of a ciprofloxacin-resistant isolate of Haemophilus influenzae from The Netherlands [letter] Bootsma HJ, et al. **J Antimicrob Chemother** 1997 Feb;39(2):292–3
Postantibiotic effect of trovafloxacin on Pseudomonas aeruginosa. Boswell FJ, et al. **J Antimicrob Chemother** 1997 Jun;39(6):811–4
The in-vitro activity of trovafloxacin and nine other antimicroblals against 413 anaerobic bacteria. Bowker KE, et al. **J Antimicrob Chemother** 1996 Aug;38(2):271–81
The chemistry and biological profile of trovafloxacin. Brighty KE, et al. **J Antimicrob Chemother** 1997 Jun;39 Suppl B:1–14 (67 ref.)
gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. Conrad S, et al.
J Antimicrob Chemother 1996 Sep;38(3):443–55
Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. Cunha BA, et al. **J Antimicrob Chemother** 1997 Jun;39 Suppl B:29–34
Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV. Deguchi T, et al. **J Antimicrob Chemother** 1997 Feb; 39(2):247–9
In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest. Dembry LM, et al.
J Antimicrob Chemother 1997 Jun;39 Suppl B:35–42
Pharmacodynamics and pharmacokinetics of A-80556 using microdialysis in a Streptococcus pneumoniae meningitis model. Destache CJ, et al. **J Antimicrob Chemother** 1996 Dec;38(6):977–85
In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. Felmingham D, et al.
J Antimicrob Chemother 1997 Jun;39 Suppl B:43–9
Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin [letter] Fuchs PC, et al. **J Antimicrob Chemother** 1997 May;39(5):671–2
Is Escherichia coli ATCC 25922 useful for monitoring broth microdilution tests of fluoroquinolones? [letter] Fuchs PC, et al. **J Antimicrob Chemother** 1997 Apr;39(4):549–50
The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae. George J, et al. **J Antimicrob Chemother** 1997 Jun;39(6):719–23
Intracellular activity of trovafloxacin (CP-99,219) against Enterococcus faecium [letter] Herrera-Insúa I, et al.
J Antimicrob Chemother 1997 Apr;39(4):552–3
Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin. Hoogkamp-Korstanje JA, et al. **J Antimicrob Chemother** 1997 Mar;39(3):411–4
The efficacy of antibiotics enhanced by electrical currents against Pseudomonas aeruginosa biofilms. Jass J, et al.
J Antimicrob Chemother 1996 Dec;38(6):987–1000
In-vitro activity of levofloxacin (l-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales [letter; comment] Johnson AP, et al. **J Antimicrob Chemother** 1996 Nov;38(5):907–8. Comment on: J Antimicrob Chemother 1996 Feb;37(2):365–9.
Susceptibility of Chlamydia trachomatis to trovafloxacin. Jones RB, et al. **J Antimicrob Chemother** 1997 Jun;39 Suppl B:63–5
Critical appraisal of E test for the detection of fluoroquinolone resistance [see comments] Jones RN, et al. **J Antimicrob Chemother** 1996 Jul;38(1):21–5. Comment in: J Antimicrob Chemother 1997 Apr;39(4):551–2.
In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae. Klugman KP, et al.
J Antimicrob Chemother 1997 Jun;39 Suppl B:51–5
Bacteriostatic and bactericidal activity of levofloxacin against Rickettsia rickettsii, Rickettsia conorii, Israeli spotted fever group rickettsia' and Coxiella burnetii. Maurin M, et al.
J Antimicrob Chemother 1997 Jun;39(6):725–30
Determination of the in vivo post-antibiotic effects of ciprofloxacin and rifampicin. Meng X, et al.
J Antimicrob Chemother 1995 Dec;36(6):987–96
Characteristics of quinolone-induced small colony variants in Staphylococcus aureus. Mitsuyama J, et al.
J Antimicrob Chemother 1997 Jun;39(6):697–705
Bactericidal index: a new way to assess quinolone bactericidal activity in vitro. Morrissey I. **J Antimicrob Chemother** 1997 Jun;39(6):713–7
Bactericidal activity of trovafloxacin (CP-99,219). Morrissey I. **J Antimicrob Chemother** 1996 Dec;38(6):1061–6
Trovafloxacin delays the antibiotic-induced inflammatory response in experimental pneumococcal meningitis. Nau R, et al. **J Antimicrob Chemother** 1997 Jun;39(6):781–8
The effect of quinolones on the intracellular killing of Staphylococcus aureus in neutrophil granulocytes. Nielsen SL, et al. **J Antimicrob Chemother** 1997 May;39(5):617–22
The synergic effects of quinolones and oral cephem antibiotics on Serratia marcescens. Otsuki M, et al.
J Antimicrob Chemother 1996 Nov;38(5):771–6
In-vitro susceptibilities of multiresistant strains of Acinetobacter baumannii to eight quinolones [letter] Pascual A, et al. **J Antimicrob Chemother** 1997 Jul; 40(1):140–2
Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages. Pellegrin I, et al. **J Antimicrob Chemother** 1996 Mar;37(3):501–10
Non-gyrA-mediated ciprofloxacin resistance in laboratory mutants of Streptococcus pneumoniae. Piddock LJ, et al.
J Antimicrob Chemother 1997 May;39(5):609–15
Quinolone resistance and Campylobacter spp. Piddock LJ.
J Antimicrob Chemother 1995 Dec;36(6):891–8 (41 ref.)
Antimicrobial susceptibilities of blood culture isolates obtained before and after the introduction of ciprofloxacin. Pieroni P, et al. **J Antimicrob Chemother** 1997 Mar; 39(3):419–22
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. Rolston KV, et al.
J Antimicrob Chemother 1997 Jun;39 Suppl B:15–22
A multinational European survey on the in-vitro activity of rufloxacin and other comparative antibiotics on respiratory and urinary bacterial pathogens. Schito GC, et al. **J Antimicrob Chemother** 1996 Oct;38(4):627–39
The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. Sefton AM, et al.
J Antimicrob Chemother 1997 Jun;39 Suppl B:57–62
Comparison of the activity of fluoroquinolones against Mycobacterium avium in cell-free systems and a human monocyte in-vitro infection model. Shiratsuchi H, et al.
J Antimicrob Chemother 1996 Mar;37(3):491–500
Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. Shonekan D, et al.
J Antimicrob Chemother 1997 Mar;39(3):405–9
Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes. Spangler SK, et al. **J Antimicrob Chemother** 1997 Jun;39 Suppl B:23–7
Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus. Takahata M, et al. **J Antimicrob Chemother** 1996 Sep;38(3):543–6
Effect of ciprofloxacin on ciliary motility of rabbit airway epithelium. Takemura H, et al. **J Antimicrob Chemother** 1996 Jul;38(1):139–43
Sequential mutations of gyrA in Escherichia coli associated with quinolone therapy. Truong QC, et al.
J Antimicrob Chemother 1995 Dec;36(6):1055–9
Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. Vincent J, et al.
J Antimicrob Chemother 1997 Jun;39 Suppl B:81–6
In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci. von Eiff C, et al.
J Antimicrob Chemother 1996 Aug;38(2):259–63
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones. Wise R, et al. **J Antimicrob Chemother** 1997 Apr;39(4):447–52
In-vitro activity of a new quinolone, clinafloxacin, against clinical isolates of Corynebacterium species [letter] Yagüe G, et al. **J Antimicrob Chemother** 1996 Oct;38(4):740–2
Bacteriophage PSP3 and phi R73 activator proteins: analysis of promoter specificities. Clerch B, et al. **J Bacteriol** 1996 Oct;178(19):5568–72
Effect of topical fluoroquinolones on corneal re-epithelialization after excimer laser keratectomy. Moreira LB, et al. **J Cataract Refract Surg** 1997 Jul–Aug; 23(6):845–8
Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. Barry AL, et al. **J Chemother** 1997 Feb;9(1):9–16
In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains. Flynn CM, et al. **J Chemother** 1996 Dec;8(6):411–5
In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa. Garcia-Rodriguez JA, et al. **J Chemother** 1996 Oct; 8(5):358–64
Rufloxacin enhances susceptibility of Escherichia coli to leukocyte activity. Herrera I, et al. **J Chemother** 1995 Nov; 7 Suppl 4:36–7
Performance of the fractional maximal effect method: comparative interaction studies of ciprofloxacin and protein synthesis inhibitors. Li RC, et al. **J Chemother** 1996 Feb; 8(1):25–32
Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method. Marone P, et al.
J Chemother 1997 Aug;9(4):247–50
Quinolones and serum butyryl-cholinesterase activity. Paradelis AG, et al. **J Chemother** 1995 Nov;7 Suppl 4:34–5
Susceptibility of 2,000 strains of Gram-negative bacteria to four quinolones. Paradelis AG, et al. **J Chemother** 1995 Nov;7 Suppl 4:56–7
In vitro activity of sparfloxacin against selected enterobacteriaceae and pseudomonaceae including Ps. pseudomallei (melioidosis). Siristonpun Y, et al.
J Chemother 1995 Nov;7 Suppl 4:54–5
Detection of quinolone-resistant Neisseria gonorrhoeae. Kam KM, et al. **J Clin Microbiol** 1996 Jun;34(6):1462–4
Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance. Lehn N, et al. **J Clin Microbiol** 1996 Mar;34(3):597–602
Phase I pilot study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men. Dickens GR, et al. **J Clin Pharmacol** 1997 Mar;37(3):248–52
Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers. Liao S, et al. **J Clin Pharmacol** 1996 Nov;36(11):1072–7
Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide. Martin DE, et al.
J Clin Pharmacol 1996 Jan;36(1):85–91
In vitro activity of ofloxacin against Mycobacterium tuberculosis. Yu MC, et al. **J Formos Med Assoc** 1997 Jan; 96(1):13–6
Effect of quinolone antibiotics on hepatic growth and protein synthesis following partial hepatectomy in rats [see comments] Minuk GY, et al. **J Gastroenterol Hepatol** 1997 Jan;12(1):54–7. Comment in: J Gastroenterol Hepatol 1997 Jan;12(1):44–6.
Development of quinolone resistance in salmonella: failure to prevent splenic abscess [letter] Boswell TC, et al.
J Infect 1997 Jan;34(1):86–7
Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988–1994: the emergence of decreased susceptibility to the fluoroquinolones. Fox KK, et al.
J Infect Dis 1997 Jun;175(6):1396–403
Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis [published erratum appears in J Infect Dis 1997 Apr;175(4):1027] Xu C, et al.
J Infect Dis 1996 Nov;174(5):1127–30
Crystal structure and characterization of the bismuth(III) compound with quinolone family member (ciprofloxacin). Antibacterial study. Turel I, et al. **J Inorg Biochem** 1997 Jun;66(4):241–5
Transient relaxation of plasmid DNA in Escherichia coli by fluoroquinolones. Matsuo M, et al. **J Pharm Pharmacol** 1996 Sep;48(9):985–7
The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. Engel LS, et al. **Jpn J Ophthalmol** 1996;40(2):212–9
Ciprofloxacin-resistant Staphylococcus epidermidis and hands [letter; comment] Burnie JP, et al. **Lancet** 1997 Mar 1;349(9052):649. Comment on: Lancet 1997 Jan 18;349(9046):167–9.
Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Cambau E, et al. **Lancet** 1997 Jan 11;349(9045):103–4
Ciprofloxacin and multiresistant staphylococci [letter; comment] Cimolai N. **Lancet** 1997 Apr 5;349(9057):1030. Comment on: Lancet 1997 Jan 18;349(9046):167–9.
Quinolones in sweat and quinolone resistance [comment] Hawkey PM. **Lancet** 1997 Jan 18;349(9046):148–9. Comment on: Lancet 1997 Jan 18;349(9046):167–9.
Ciprofloxacin-resistant Enterobacteriaceae [letter; comment] Murphy OM, et al. **Lancet** 1997 Apr 5;349(9057):1028–9. Comment on: Lancet 1997 Feb 8;349(9049):403.
High-level resistance to ciprofloxacin in Escherichia coli [letter] [see comments] Threlfall EJ, et al. **Lancet** 1997 Feb 8;349(9049):403. Comment in: Lancet 1997 Apr 5;349(9057):1028–9.
Streptococcus pneumoniae resistance to fluoroquinolones

[letter] Wise R, et al. **Lancet** 1996 Dec 14;348(9042):1660

Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects. Gootz TD, et al. **Med Res Rev** 1996 Sep;16(5):433–86 (277 ref.)

Risk factor assessment for the acquisition of fluoroquinolone-resistant isolates of Pseudomonas aeruginosa in a community-based hospital. Baddour LM, et al. **Microb Drug Resist** 1995 Fall;1(3):219–22

Identification of DNA gyrase A mutations in ciprofloxacin-resistant isolates of Salmonella typhimurium from men and cattle in Germany. Heisig P, et al. **Microb Drug Resist** 1995 Fall;1(3):211–8

Quinolone resistance mutations in the gyrA gene of clinical isolates of Salmonella. Ouabdesselam S, et al. **Microb Drug Resist** 1996 Fall;2(3):299–302

Influence on Pseudomonas aeruginosa elastase, proteinase and alginate by supra-inhibitory and supra-subinhibitory concentrations of quinolones. Hoštacká A, et al. **Microbios** 1996;87(352):141–7

Inhibition of rat parotid gland growth response induced by chronic isoproterenol following treatment with quinolone antibiotics. Kelentey B, et al. **Mol Cell Biochem** 1996 Dec 6;165(1):55–63

Evidence that a hybrid molecule of norfloxacin and biphenylacetic acid is a potent antagonist at the GABAA receptor. Imanishi T, et al. **Neuropharmacology** 1996; 35(9–10):1271–7

Inhibition of GABAA receptor chloride channel by quinolones and norfloxacin-biphenylacetic acid hybrid compounds. Ito Y, et al. **Neuropharmacology** 1996; 35(9–10):1263–9

In vitro postantibiotic effect of imipenem and enoxacin alone and in combination against Pseudomonas aeruginosa. Hoštacká A. **Pharmazie** 1997 Jul;52(7):544–6

Postantibiotic effect of norfloxacin and its influence on profiles of outer membrane proteins of Pseudomonas aeruginosa. Hoštacká A, et al. **Pharmazie** 1997 Mar; 52(3):238–9

Photohaptenic properties of fluoroquinolones. Tokura Y, et al. **Photochem Photobiol** 1996 Nov;64(5):838–44

Avoiding fluoroquinolone resistance. Strategies for primary care practice. Stratton CW. **Postgrad Med** 1997 Mar; 101(3):247–50, 255 (12 ref.)

Quinolone-resistant Neisseria gonorrhoeae in Hong Kong. Kam KM, et al. **Sex Transm Dis** 1996 Mar–Apr;23(2):103–8

Antimicrobial susceptibilities of strains of Neisseria gonorrhoeae in Bangkok, Thailand: 1994–1995. Knapp JS, et al. **Sex Transm Dis** 1997 Mar;24(3):142–8

Relation between plasma and saliva concentrations of enoxacin, ciprofloxacin, and theophylline. Zhai S, et al. **Ther Drug Monit** 1996 Dec;18(6):666–71

A fluoroquinolone antibiotic with a methoxy group at the 8 position yields reduced generation of 8-oxo-7,8-dihydro-2'-deoxyguanosine after ultraviolet-A irradiation. Rosen JE, et al. **Toxicol Appl Pharmacol** 1997 Aug;145(2):381–7

Sequential development of resistance to fluoroquinolones and erythromycin in an isolate of Campylobacter jejuni. Burnens AP, et al. **Zentralbl Bakteriol** 1996 Mar; 283(3):314–21

Postantibiotic effect and virulence factors depression induced by ciprofloxacin and by aminoglycosides in a clinical isolate of Pseudomonas aeruginosa. Hostacka A. **Zentralbl Bakteriol** 1996 Mar;283(3):322–7

[In vitro antibacterial activity of a new fluoroquinolone, sparfloxacin, against nosocomial bacteria, and concordance curve] Soussy CJ, et al. **Pathol Biol (Paris)** 1996 Apr; 44(4):241–8 (Eng. Abstr.) **(Fre)**

[Bactericidal activity of quinolones (including sparfloxacin) against Enterococcus; in vitro antagonisms with gentamicin] Watine J, et al. **Pathol Biol (Paris)** 1997 May; 45(5):430–2 (Eng. Abstr.) **(Fre)**

[Antimicrobial activities of tosufloxacin against recently obtained clinical isolates] Ishihara R, et al. **Jpn J Antibiot** 1996 Jul;49(7):715–42 (Eng. Abstr.) **(Jpn)**

[Development of multi-drug resistant mutants of clinical isolates of Pseudomonas aeruginosa after exposure to fluoroquinolone] Hasegawa M, et al. **Kansenshogaku Zasshi** 1996 Feb;70(2):123–31 (Eng. Abstr.) **(Jpn)**

[Evolution of susceptibilities of Campylobacter jejuni isolated from diarrhoeal cases to fluoroquinolones in Tokyo] Tadano K, et al. **Kansenshogaku Zasshi** 1996 Dec; 70(12):1227–33 (Eng. Abstr.) **(Jpn)**

[In vitro anti-MAC activities of new quinolones in focus (2)] Kawahara S, et al. **Kekkaku** 1996 Sep;71(9):537–9 **(Jpn)**

[Preclinical study of therapeutic agents used against Mycobacterium avium complex infections—with special reference to new macrolides and new quinolones] Tomioka H, et al. **Kekkaku** 1996 Sep;71(9):531–5 **(Jpn)**

[In vitro anti-MAC activities of new quinolones in focus (1)] Tsuyuguchi K. **Kekkaku** 1996 Sep;71(9):536–7 **(Jpn)**

[Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media] Yamane N, et al. **Kekkaku** 1996 Aug;71(8):453–8 (Eng. Abstr.) **(Jpn)**

[Mechanisms for the development of quinolone resistance] Kojima M. **Nippon Rinsho** 1997 May;55(5):1252–60 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Pharmacology, clinical indications and toxicity of modern fluoroquinolones] Carvalho WA. **Rev Assoc Med Bras** 1995 Jul–Aug;41(4):293–304 (55 ref.) **(Por)**

[Effect of lomefloxacin on the synthesis of antibodies to vaccine EV fraction I and hemagglutinins] Iordanova AI, et al. **Antibiot Khimioter** 1996 Apr;41(4):44–50 (Eng. Abstr.) **(Rus)**

[Effect of lomefloxacin on luminol-dependent chemiluminescence and adhesion of leukocytes] Iordanova AI, et al. **Antibiot Khimioter** 1996 Jan;41(1):3–6 (Eng. Abstr.) **(Rus)**

[Effect of drugs of the fluoroquinolone series on morphokinetic parameters of the cellular elements of lung tissue] Kunichan AD, et al. **Antibiot Khimioter** 1996 Apr; 41(4):51–3 (Eng. Abstr.) **(Rus)**

[Effect of lomefloxacin on the functional activity of the phagocytic system] Mozhokina GN, et al. **Antibiot Khimioter** 1996 Mar;41(3):25–8 (Eng. Abstr.) **(Rus)**

[Antimicrobial activity and action mechanism of ofloxacin] Padeĭskaia EN. **Antibiot Khimioter** 1996;41(9):13–23 (66 ref.) **(Rus)**

[Mechanisms of resistance to quinolones and current level of sensitivity of clinically important microorganisms to ofloxacin] Sidorenko SV, et al. **Antibiot Khimioter** 1996; 41(9):33–8 (Eng. Abstr.) **(Rus)**

[Elimination of virulence plasmids of Yersinia pseudotuberculosis as affected by fluoroquinolones] Zaĭtseva EA, et al. **Antibiot Khimioter** 1996 Jun;41(6):34–8 (Eng. Abstr.) **(Rus)**

[Bactericidal effects of maxaquin on mycobacterium tuberculosis] Kunichian AD, et al. **Probl Tuberk** 1997; (1):53–4 (Eng. Abstr.) **(Rus)**

[The effect of pharmacodynamic parameters of pefloxacin on elastase and protease activity in Pseudomonas aeruginosa] Hoštacká A. **Epidemiol Mikrobiol Imunol** 1996 Sep;45(3):119–22 (Eng. Abstr.) **(Slo)**

[Effect of five fluoroquinolones on the bactericidal activity of human polymorphonuclear leukocytes against Staphylococcus aureus] Ballesta S, et al. **Enferm Infecc Microbiol Clin** 1996 Dec;14(10):600–3 (Eng. Abstr.) **(Spa)**

[The E test and quinolone-resistant Campylobacter jejuni] Cogollos R, et al. **Enferm Infecc Microbiol Clin** 1995 Dec; 13(10):587–91 (Eng. Abstr.) **(Spa)**

[Fluoroquinolone and aminoglycoside resistance in chromosomal cephalosporinase-overproducing gram-negative bacilli strains with inducible beta-lactamase] López-Yeste M, et al. **Enferm Infecc Microbiol Clin** 1996 Apr;14(4):211–4 (Eng. Abstr.) **(Spa)**

POISONING

An unlikely childhood overdose: temafloxacin. Muñiz AE. **Pediatr Emerg Care** 1996 Jun;12(3):215–6 (13 ref.)

THERAPEUTIC USE

Topical lomefloxacin twice daily compared with fucidic acid in acute bacterial conjunctivitis. Malminiemi K, et al. **Acta Ophthalmol Scand** 1996 Jun;74(3):280–4

Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Bhattacharya K, et al. **Acta Paediatr** 1997 Mar;86(3):319–20

A relapse of paratyphoid fever after treatment with ciprofloxacin in a child with congenital biliary atresia. Eltringham IJ, et al. **Acta Paediatr** 1997 May;86(5):547–8

Ofloxacin versus co-trimoxazole in the treatment of typhoid fever in children. Seçmeer G, et al. **Acta Paediatr Jpn** 1997 Apr;39(2):218–21

Role of newer broad-spectrum beta-lactam and fluoroquinolone antibiotics in children. Bonafede ME, et al. **Adv Pediatr Infect Dis** 1996;12:71–108 (124 ref.)

Treatment of CAPD-related peritonitis with ciprofloxacin: results after seven years. Bouza P, et al. **Adv Perit Dial** 1996;12:185–8

Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study. Gupta VK, et al. **Am J Gastroenterol** 1997 Jul;92(7):1140–2

A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Mantzaris GJ, et al. **Am J Gastroenterol** 1997 Mar;92(3):454–6

Gram-positive infections and quinolones in neutropenia [letter; comment] Altclas J, et al. **Ann Intern Med** 1997 May 15;126(10):830; discussion 831. Comment on: Ann Intern Med 1996 Aug 1;125(3):183–90.

Gram-positive infections and quinolones in neutropenia [letter; comment] Castagnola E, et al. **Ann Intern Med** 1997 May 15;126(10):830–1. Comment on: Ann Intern Med 1996 Aug 1;125(3):183–90.

Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Khan WA, et al. **Ann Intern Med** 1997 May 1; 126(9):697–703

Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis. Amodio-Groton M, et al. **Ann Pharmacother** 1996 Jun;30(6):596–602

Recurrent Clostridium difficile disease following ciprofloxacin use. Bauwens JE, et al. **Ann Pharmacother** 1997 Sep;31(9):1090

Quinolones for the treatment and prophylaxis of tuberculosis [see comments] Kaplan JA, et al. **Ann Pharmacother** 1996 Sep;30(9):1020–2. Comment in: Ann Pharmacother 1996 Sep;30(9):1034–5.

Quinolones and tuberculosis [editorial; comment] Peloquin CA. **Ann Pharmacother** 1996 Sep;30(9):1034–5. Comment on: Ann Pharmacother 1996 Sep;30(9):1020–2.

Efficacies of ofloxacin, rifampin, and clindamycin in treatment of Staphylococcus aureus abscesses and correlation with results of an in vitro assay of intracellular bacterial killing. Bamberger DM, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1178–81

Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin. Beauchamp D, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1237–45

In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Brueggemann AB, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1594–7

Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Carratala J, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):503–5

Efficacy of sparfloxacin and autoradiographic diffusion pattern of [14C]Sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection. Crémieux AC, et al. **Antimicrob Agents Chemother** 1996 Sep; 40(9):2111–6

In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urinary tract infections. Deguchi T, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1609–11

Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations. Del Río G, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):408–12

Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin. Düzgüneş N, et al. **Antimicrob Agents Chemother** 1996 Nov; 40(11):2618–21

Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Entenza JM, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1662–7

Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates. Goldstein EJ, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1193–5

Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. Hidalgo M, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1175–7

Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea. Hook EW 3rd, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1720–1

Modeling the response of pneumonia to antimicrobial therapy. Hyatt JM, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1269–74

Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Ji B, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):393–9

Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. Khan AA, et al. **Antimicrob Agents Chemother** 1997 May;41(5):893–7

Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Kim YS, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1186–9

Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Lounis N, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):607–10

In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic. Niki Y, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):857–9

Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Plouffe JF, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1175–9

In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Thadepalli H, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):583–6

Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae strains. Thorpe EM, et al. **Antimicrob Agents Chemother** 1996 Dec; 40(12):2775–80

In vitro activity of premafloxacin, a new extended-spectrum fluoroquinolone, against pathogens of veterinary importance. Watts JL, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1190–2

In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia. Yagel SK, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2894–7

Mycobacterium marinum skin infection successfully treated with levofloxacin. Iijima S, et al. **Arch Dermatol** 1997 Aug;

133(8):947–9
A case of relapsed leprosy successfully treated with sparfloxacin [letter] Sugita Y, et al. **Arch Dermatol** 1996 Nov;132(11):1397–8
Ciprofloxacin treatment of bacterial endocarditis involving prosthetic material after cardiac surgery. Brown NM, et al. **Arch Dis Child** 1997 Jan;76(1):68–9
In vitro susceptibility of Entamoeba histolytica to fluoroquinolones, nitrofurans and other antiamebic agents. Cedillo-Rivera R, et al. **Arch Med Res** 1997;28 Spec No:295–7
A clinical comparison of typhoid fever caused by susceptible and multidrug-resistant strains of Salmonella typhi. Alsoub H, et al. **Br J Clin Pract** 1997 Jan–Feb;51(1):8–10
Indications and restrictions of fluoroquinolone use in children. Green SD. **Br J Hosp Med** 1996 Oct 16–Nov 5;56(8):420–3 (23 ref.)
Experimental Bacillus cereus post-traumatic endophthalmitis and treatment with ciprofloxacin. Alfaro DV, et al. **Br J Ophthalmol** 1996 Aug;80(8):755–8
Experimental Yersinia-triggered reactive arthritis: effect of a 3-week course of ciprofloxacin. Zhang Y, et al. **Br J Rheumatol** 1997 May;36(5):541–6
Osteomyelitis of the spine due to Salmonella infection--conservative treatment with quinolone: a case report. Tsui HF, et al. **Can J Surg** 1997 Feb;40(1):48–50
Single oral dose treatment of uncomplicated urinary tract infection in women. Bailey RR. **Chemotherapy** 1996 Mar; 42 Suppl 1:10–6
Quinolone prophylaxis in transurethral surgery. Gasser TC. **Chemotherapy** 1996 Mar;42 Suppl 1:28–32 (30 ref.)
Fleroxacin in complicated urinary tract infections. Giamarellou H. **Chemotherapy** 1996 Mar;42 Suppl 1:17–27 (29 ref.)
Quinolones in gastrointestinal infections. Graninger W, et al. **Chemotherapy** 1996 Mar;42 Suppl 1:43–53 (84 ref.)
Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia. Marklein G. **Chemotherapy** 1996 Mar;42 Suppl 1:33–42
The place of quinolones in everyday clinical practice. Moellering RC Jr. **Chemotherapy** 1996 Mar;42 Suppl 1:54–61 (18 ref.)
Fleroxacin overview. Naber KG. **Chemotherapy** 1996 Mar; 42 Suppl 1:1–9 (27 ref.)
Complicated urinary infection in spinal injury patients: fleroxacin compared with ciprofloxacin. Whitby M, et al. **Chemotherapy** 1996 Nov–Dec;42(6):468–72
Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Ortqvist A, et al. **Chest** 1996 Dec;110(6):1499–506
New fluoroquinolones and anaerobic infections. Symposium proceedings. San Juan, Puerto Rico, November 1995. **Clin Infect Dis** 1996 Dec;23 Suppl 1:S1–106
Trends in bacterial resistance to fluoroquinolones. Acar JF, et al. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S67–73 (82 ref.)
An unusual case of refractory Campylobacter jejuni infection in a patient with X-linked agammaglobulinemia: successful combined therapy with maternal plasma and ciprofloxacin. Autenrieth IB, et al. **Clin Infect Dis** 1996 Sep;23(3):526–31
Oral ciprofloxacin therapy for prosthetic valve endocarditis due to Actinobacillus actinomycetemcomitans. Babinchak TJ. **Clin Infect Dis** 1995 Dec;21(6):1517–8
The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Bradley JS, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S213–21 (58 ref.)
Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Cruciani M, et al. **Clin Infect Dis** 1996 Oct;23(4):795–805
One-dose treatment with pefloxacin for infection due to multidrug-resistant Shigella dysenteriae type 1 in Burundi. Gendrel D, et al. **Clin Infect Dis** 1997 Jan;24(1):83
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Goldstein EJ. **Clin Infect Dis** 1996 Dec;23 Suppl 1:S25–30 (41 ref.)
Streamlining antimicrobial therapy for lower respiratory tract infections. Hitt CM, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S231–7 (58 ref.)
Acalculous nontyphoidal salmonellal cholecystitis requiring surgical intervention despite ciprofloxacin therapy: report of three cases. McCarron B, et al. **Clin Infect Dis** 1997 Apr;24(4):707–9
Oral ciprofloxacin to treat bacterial peritonitis associated with peritoneal dialysis [letter] Leblanc M. **Clin Nephrol** 1997 May;47(5):350
A double blind, prospective trial of topical ciprofloxacin versus normal saline solution in the treatment of otorrhoea. Kasemsuwan L, et al. **Clin Otolaryngol** 1997 Feb;22(1):44–6
A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children [see comments] Gross RD, et al. **Clin Pediatr (Phila)** 1997 Aug;36(8):435–44. Comment in: Clin Pediatr (Phila) 1997 Aug;36(8):445–8.
Ceftazidime and ciprofloxacin as empiric therapy in febrile neutropenic patients undergoing hematopoietic stem cell transplantation. Ghazal HH, et al. **Clin Ther** 1997 May–Jun; 19(3):520–6
Ofloxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbation of chronic bronchitis. Study of Ofloxacin in Lower Respiratory Tract Infections Research Group. Pérez-Gonzalvo ME, et al. **Clin Ther** 1996 May–Jun;18(3):440–7
Trovafloxacin. Haria M, et al. **Drugs** 1997 Sep;54(3):435–45; discussion 446 (48 ref.)
Fluoroquinolones in urinary tract infections. Proper and improper use. Naber KG. **Drugs** 1996;52 Suppl 2:27–33 (40 ref.)
Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections. Patel SS, et al. **Drugs** 1996 Jan;51(1):137–60 (201 ref.)
The appropriate use of quinolones. Percival A. **Drugs** 1996; 52 Suppl 2:34–6 (16 ref.)
Fluoroquinolone resistance in Neisseria gonorrhoeae. Knapp JS, et al. **Emerg Infect Dis** 1997 Jan–Mar;3(1):33–9 (44 ref.)
Evolution of susceptibility of non-typhi Salmonella in a Spanish hospital (1992–1994) and report of a Salmonella ser. Typhimurium isolate resistant to quinolones. Campo P, et al. **Eur J Epidemiol** 1997 Feb;13(2):239–41
Comparative evaluation of efficacy and safety of ciprofloxacin and norfloxacin ophthalmic solutions. Adenis JP, et al. **Eur J Ophthalmol** 1996 Jul–Sep;6(3):287–92
Ciprofloxacin ophthalmic solution in the treatment of conjunctivitis and blepharitis: a comparison with fusidic acid. Adenis JP, et al. **Eur J Ophthalmol** 1996 Oct–Dec; 6(4):368–74
The value of antibiotic prophylaxis during extracorporeal shock wave lithotripsy in the prevention of urinary tract infections in patients with urine proven sterile prior to treatment. Bierkens AF, et al. **Eur Urol** 1997;31(1):30–5
Treatment of spontaneous bacterial peritonitis with oral ofloxacin: inpatient or outpatient therapy? [editorial; comment] García-Tsao G. **Gastroenterology** 1996 Oct; 111(4):1147–50. Comment on: Gastroenterology 1996 Oct;111(4):1011–7.
Rapid emergence of 4-fluroquinolone resistance with associated decline in penicillinase-producing Neisseria gonorrhoeae in Colombo, Sri Lanka [letter] [see comments] Abeyewickereme I, et al. **Genitourin Med** 1996 Aug; 72(4):302. Comment in: Genitourin Med 1997 Apr;73(2):149.
Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Novella M, et al. **Hepatology** 1997 Mar;25(3):532–6
Dosage adjustment of antiinfective therapy in patients with renal impairment. Eckhardt A, et al. **Int J Clin Pharmacol Ther** 1997 Mar;35(3):99–102
Treatment of acute biliary tract infections with ofloxacin: a randomized, controlled clinical trial. Karachalios GN, et al. **Int J Clin Pharmacol Ther** 1996 Dec;34(12):555–7
Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions [letter] Ganapati R, et al. **Int J Lepr Other Mycobact Dis** 1997 Jun;65(2):264–6
Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. Mane I, et al. **Int J Lepr Other Mycobact Dis** 1997 Jun;65(2):224–9
Malacoplakia of the bladder: efficacy of enoxacine therapy. Sawamura T, et al. **Int Urol Nephrol** 1996;28(2):175–9
Active leprosy treated effectively with ofloxacin. Mochizuki Y, et al. **Intern Med** 1996 Sep;35(9):749–51
Oral ciprofloxacin for the first-phase treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Zacherle BJ. **J Am Soc Nephrol** 1996 May;7(5):811–2
The impact of rufloxacin given as prophylaxis to patients with cancer on their oral and faecal microflora. D'Antonio D, et al. **J Antimicrob Chemother** 1996 Nov;38(5):839–47
'Cost-effectiveness'--is it always effective? [letter] Dorrian I, et al. **J Antimicrob Chemother** 1997 Feb;39(2):286
Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection. Dutta D, et al. **J Antimicrob Chemother** 1996 Mar;37(3):575–81
Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up. Galanakis N, et al. **J Antimicrob Chemother** 1997 Feb;39(2):241–6
Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model. Sato A, et al. **J Antimicrob Chemother** 1997 Feb;39(2):217–22
Comparative therapeutic efficacy of clinafloxacin in leucopenic mice. Shapiro MA, et al. **J Antimicrob Chemother** 1997 Feb;39(2):273–6
Development of in-vivo resistance after quinolone treatment of gonococcal urethritis [letter] Vila J, et al. **J Antimicrob Chemother** 1997 Jun;39(6):841
Premafloxacin: a projected veterinary use fluoro-quinolone with significant activity against multi-resistant gram-positive human pathogens [letter] Zerva L, et al. **J Antimicrob Chemother** 1996 Oct;38(4):742–4
Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor of the uninflamed human eye. Akkan AG, et al. **J Chemother** 1997 Aug; 9(4):257–62
Comparative trial of azithromycin and ciprofloxacin in the treatment of gonorrhea. Gruber F, et al. **J Chemother** 1997 Aug;9(4):263–6
Pefloxacin versus cefuroxime axetil for single-dose therapy of acute uncomplicated lower urinary tract infections in women. Krcmery S, et al. **J Chemother** 1995 Nov;7 Suppl 4:168–9
Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study. Pisani E, et al. **J Chemother** 1996 Jun;8(3):210–3
Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study. Tsutsumi M, et al. **J Gastroenterol Hepatol** 1996 Nov;11(11):1006–11
Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. Llovet JM, et al. **J Hepatol** 1997 Jan;26(1):88–95
An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. Younossi ZM, et al. **J Hepatol** 1997 Aug;27(2):295–8
Clinical audit of ciprofloxacin use in adults admitted to hospital with gastroenteritis. Fox R, et al. **J Infect** 1996 Jul;33(1):39–42
An audit of the clinical features and use of antimicrobials in adult diarrhoea. Laing RB, et al. **J Infect** 1996 Jan; 32(1):17–21
Emergence of ciprofloxacin resistance during treatment of Salmonella osteomyelitis in three patients with sickle cell disease. Workman MR, et al. **J Infect** 1996 Jan;32(1):27–32
Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. Campos J, et al. **J Infect Dis** 1996 Dec;174(6):1345–7
Clinical and microbiological evaluation of pefloxacin in lower respiratory tract infections. Tatsis G, et al. **J Int Med Res** 1996 Nov–Dec;24(6):478–81
Oral antimicrobials in compound fracture of the hand: comparison of dicloxacillin and ofloxacin. Waikakul S, et al. **J Med Assoc Thai** 1996 Sep;79(9):585–8
Resolution of dysrhythmias and conduction abnormalities following treatment for bacterial endocarditis in a dog. Boswood A. **J Small Anim Pract** 1996 Jul;37(7):327–32
Selective intestinal decontamination in multiple trauma patients: prospective, controlled trial. Lingnau W, et al. **J Trauma** 1997 Apr;42(4):687–94
Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. Sieber PR, et al. **J Urol** 1997 Jun; 157(6):2199–200 (13 ref.)
Fluoroquinolones in animal health. Brown SA. **J Vet Pharmacol Ther** 1996 Feb;19(1):1–14 (131 ref.)
Efficacy of various therapeutic regimens in eliminating Pasteurella pneumotropica from the mouse. Goelz MF, et al. **Lab Anim Sci** 1996 Jun;46(3):280–5
Ciprofloxacin for treating cholera [letter; comment] Maggi P, et al. **Lancet** 1996 Nov 23;348(9039):1446–7. Comment on: Lancet 1996 Aug 3;348(9023):296–300.
Treatment of pig bites [letter; comment] Morgan MS. **Lancet** 1996 Nov 2;348(9036):1246. Comment on: Lancet 1996 Sep 28;348(9031):888.
Ofloxacin-containing combined drug regimens in the treatment of lepromatous leprosy. Rao PS, et al. **Lepr Rev** 1994 Sep;65(3):181–9
Ciprofloxacin treatment for Australian spotted fever [letter] Hudson BJ, et al. **Med J Aust** 1996 Nov 18;165(10):588
Ciprofloxacin-resistant Salmonella typhi: an emerging problem [letter] Mitchell DH. **Med J Aust** 1997 Aug 4; 167(3):172
Sparfloxacin and levofloxacin. **Med Lett Drugs Ther** 1997 Apr 25;39(999):41–3
Pefloxacin in adriamycin induced nephrotic syndrome in the rat. Korzets Z, et al. **Nephrol Dial Transplant** 1997 Feb; 12(2):286–8
Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Hyndiuk RA, et al. **Ophthalmology** 1996 Nov; 103(11):1854–62; discussion 1862–3
Multicenter study of the efficacy and safety of oral ciprofloxacin in the treatment of chronic suppurative otitis media in adults. The French Study Group. Gehanno P. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):83–90
Efficacy of ototopical ciprofloxacin in pediatric patients with otorrhea. Wintermeyer SM, et al. **Otolaryngol Head Neck Surg** 1997 Apr;116(4):450–3
Ciprofloxacin use in pediatric and cystic fibrosis patients. Proceedings of a symposium. Nantucket, Massachusetts, July 28–29, 1995. **Pediatr Infect Dis J** 1997 Jan;16(1):87–162
Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Church DA, et al. **Pediatr Infect Dis J** 1997 Jan;16(1):97–105; discussion 123–6
Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. Freifeld A, et al. **Pediatr Infect Dis J** 1997 Jan;16(1):140–5; discussion 145–6, 160–2
Use of ciprofloxacin in developing countries. Green S, et al. **Pediatr Infect Dis J** 1997 Jan;16(1):150–9; discussion 160–2
Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report. Hampel B, et al. **Pediatr Infect Dis J** 1997 Jan;16(1):127–9; discussion 160–2 (10 ref.)
Use of fluoroquinolones as prophylactic agents in patients with neutropenia. Patrick CC. **Pediatr Infect Dis J** 1997 Jan;16(1):135–9; discussion 160–2
Risk-benefit experience of ciprofloxacin use in pediatric patients in the United Kingdom. Redmond AO. **Pediatr Infect Dis J** 1997 Jan;16(1):147–9; discussion 160–2

Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Schaad UB, et al. **Pediatr Infect Dis J** 1997 Jan;16(1):106–11; discussion 123–6

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis [see comments] Frederiksen B, et al. **Pediatr Pulmonol** 1997 May;23(5):330–5. Comment in: Pediatr Pulmonol 1997 May;23(5):323–4. Comment in: Pediatr Pulmonol 1997 May;23(5):325–1.

Avoiding fluoroquinolone resistance. Strategies for primary care practice. Stratton CW. **Postgrad Med** 1997 Mar; 101(3):247–50, 255 (12 ref.)

Efficacy of combined clarithromycin and sparfloxacin therapy in a patient with discitis: due to Mycobacterium xenopi [letter] Roche B, et al. **Rev Rhum Engl Ed** 1997 Jan;64(1):64–5

Selection of multiple resistance in Salmonella enteritidis during treatment with ciprofloxacin. Pers C, et al. **Scand J Infect Dis** 1996;28(5):529–31

Norfloxacin and Salmonella excretion in acute gastroenteritis—a 6-month follow-up study. Pitkäjärvi T, et al. **Scand J Infect Dis** 1996;28(2):177–80

Fluoroquinolone treatment failure in gonorrhea. Emergence of a Neisseria gonorrhoeae strain with enhanced resistance to fluoroquinolones. Deguchi T, et al. **Sex Transm Dis** 1997 May;24(5):247–50

Evaluation of the efficacy of sequential intravenous-oral administration of pefloxacin in community-acquired lower respiratory tract infections in patients with underlying conditions. Yap JC, et al. **Singapore Med J** 1995 Oct; 36(5):484–6

Staphylococcal bacteremia in cancer patients: risk factors and outcome in 134 episodes prior to and after introduction of quinolones into infection prevention in neutropenia. Kukuckova E, et al. **Support Care Cancer** 1996 Nov; 4(6):427–34

Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue. Meisenberg B, et al. **Support Care Cancer** 1996 Sep;4(5):364–9

Short courses of ofloxacin for the treatment of enteric fever. Nguyen TC, et al. **Trans R Soc Trop Med Hyg** 1997 May-Jun;91(3):347–9

Parenteral fluoroquinolones prevent translocation of enterobacteria following combined liver-small bowel transplantation in pigs. Privitera G, et al. **Transplant Proc** 1996 Oct;28(5):2669–70

Prevention of surgical infections in dogs with a single intravenous injection of marbofloxacin: an experimental model. Gruet P, et al. **Vet Rec** 1997 Feb 22;140(8):199–202

Excellent activity of newer quinolones on Legionella pneumophila in J774 macrophages. Walz A, et al. **Zentralbl Bakteriol** 1997 Feb;285(3):431–9

[The present status and future perspectives of fluorinated quinolones from the aspect of clinical microbiology] Lochmann O. **Cas Lek Cesk** 1997 Mar 19;136(6):191–5 (24 ref.) (Eng. Abstr.) **(Cze)**

[Results of therapy using Ciloxan-Alcon in clinical practice] Válková Z, et al. **Cesk Slov Oftalmol** 1997 May;53(2):101–5 (Eng. Abstr.) **(Cze)**

[Fluorquinones and tendinitis] Schou HS. **Ugeskr Laeger** 1997 Feb 3;159(6):784–5 **(Dan)**

[Treatment of uncomplicated recurrent cystitis in women: lomefloxacin versus norfloxacin (published erratum appears in Contracept Fertil Sex 1997 Feb;25(2):129)] Guibert J, et al. **Contracept Fertil Sex** 1997 Jan;25(1):79–84 (Eng. Abstr.) **(Fre)**

[Treatment of non-complicated acute cystitis in women: lomefloxacin versus pefloxacin] Guibert J, et al. **Presse Med** 1996 Sep 28;25(28):1271–5 (Eng. Abstr.) **(Fre)**

[Antibiotic use in necrotizing pancreatitis. Results of a controlled study] Schwarz M, et al. **Dtsch Med Wochenschr** 1997 Mar 21;122(12):356–61 (Eng. Abstr.) **(Ger)**

[Cyprofloxacin eyedrops. Cyprofloxacin for topical therapy] **HNO** 1995 Jun;43(6 Suppl):1–8 **(Ger)**

[Current antibiotics for clinical practice] Zimmerli W. **Schweiz Rundsch Med Prax** 1996 Oct 1;85(40):1240–4 (20 ref.) (Eng. Abstr.) **(Ger)**

[Ciprofloxacin treatment for pregnant or lactating women and children?] Aizenstein O, et al. **Harefuah** 1997 Feb 16; 132(4):283–8 (41 ref.) **(Heb)**

[Urinary tract infections: risk factors and therapeutic trends] Margariti PA, et al. **Recenti Prog Med** 1997 Feb;88(2):65–8 (28 ref.) (Eng. Abstr.) **(Ita)**

[Clinical efficacy of lomefloxacin for associated infection in patients with hematological diseases] Suzuki T, et al. **Kansenshogaku Zasshi** 1997 Feb;71(2):143–52 (Eng. Abstr.) **(Jpn)**

[Preclinical study of therapeutic agents used against Mycobacterium avium complex infections—with special reference to new macrolides and new quinolones] Tomioka H, et al. **Kekkaku** 1996 Sep;71(9):531–5 **(Jpn)**

[Microbiological evaluation of ciprofloxacin efficacy for treatment of urinary tract infections] Kalisz J, et al. **Med Dosw Mikrobiol** 1996;48(3–4):169–75 (Eng. Abstr.) **(Pol)**

[Use of ofloxacin in the treatment of suppurative-inflammatory complications in surgery] Bogomolova NS, et al. **Anesteziol Reanimatol** 1997 May-Jun;(3):18–20 (Eng. Abstr.) **(Rus)**

[Ciprofloxacin in the treatment of urogenital infections in women] Bakalova LA, et al. **Antibiot Khimioter** 1997; 42(6):45–6 (Eng. Abstr.) **(Rus)**

[Clinical and pharmacokinetic evaluation of ofloxacin under various regimens of administration in patients with bronchopulmonary infections] Belousov OB, et al. **Antibiot Khimioter** 1996;41(9):47–9 (Eng. Abstr.) **(Rus)**

[Ten-year experience with the use of ofloxacin in the treatment of wound infection] Blatun LA, et al. **Antibiot Khimioter** 1996;41(9):73–6 (Eng. Abstr.) **(Rus)**

[Ten-year experience with the use of ofloxacin in reconstructive surgery] Bogomolova NS, et al. **Antibiot Khimioter** 1996;41(9):68–72 (Eng. Abstr.) **(Rus)**

[An attempt to use ofloxacin in patients with mucoviscidosis] Chuchalin AG, et al. **Antibiot Khimioter** 1996;41(9):43–6 (Eng. Abstr.) **(Rus)**

[Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract] Chuchalin AG, et al. **Antibiot Khimioter** 1997;42(6):34–8 (Eng. Abstr.) **(Rus)**

[Ciprofloxacin—a highly effective drug from the fluoroquinolone group] Iakovlev VP. **Antibiot Khimioter** 1997;42(6):4–14 **(Rus)**

[Use of pefloxacin in the treatment of infected burn wounds] Iakovlev VP, et al. **Antibiot Khimioter** 1996 Jun;41(6):39–43 (Eng. Abstr.) **(Rus)**

[Use of ciprofloxacin in children with mucoviscidosis] Kapranov NI, et al. **Antibiot Khimioter** 1997;42(6):39–41 (Eng. Abstr.) **(Rus)**

[Ofloxacin in comprehensive treatment of infections in burn patients] Krutikov MG, et al. **Antibiot Khimioter** 1996; 41(9):77–80 (Eng. Abstr.) **(Rus)**

[Clinico-pharmacologic aspects of the use of ofloxacin] Kukes VG, et al. **Antibiot Khimioter** 1996;41(9):39–42 (Eng. Abstr.) **(Rus)**

[An attempt to use ofloxacin in the treatment of acute intestinal infections] Lobzin IuV. **Antibiot Khimioter** 1996; 41(9):96–8 (Eng. Abstr.) **(Rus)**

[Experience with the use of ciprofloxacin in patients with acute uncomplicated cystitis] Loran OB, et al. **Antibiot Khimioter** 1997;42(6):42–4 (Eng. Abstr.) **(Rus)**

[Antitubercular activity of lomefloxacin in an experiment] Mozhokina GN, et al. **Antibiot Khimioter** 1996;41(7–8):31–3 (Eng. Abstr.) **(Rus)**

[Ten-year experience with the use of ofloxacin (Tarivid®). New treatment regimens] Navashin SM, et al. **Antibiot Khimioter** 1996;41(9):99–103 (22 ref.) **(Rus)**

[Fluoroquinolones—current value in antibacterial therapy, outlook for development] Navashin SM, et al. **Antibiot Khimioter** 1996;41(9):4–10 (13 ref.) **(Rus)**

[Value of ciprofloxacin in the therapy of tuberculosis and other mycobacterioses] Padeiskaia EN. **Antibiot Khimioter** 1997;42(6):15–25 (69 ref.) **(Rus)**

[Pefloxacin mesylate—clinical effectiveness in various forms of infectious-inflammatory diseases] Pozdniakova VP, et al. **Antibiot Khimioter** 1997;42(7):20–3 (Eng. Abstr.) **(Rus)**

[Treatment of Flexner's dysentery with ofloxacin] Rakhmanova AG, et al. **Antibiot Khimioter** 1996;41(9):95 (Eng. Abstr.) **(Rus)**

[A chronobiological study of the function of the epithelial proliferative system of the murine esophagus after its infection with typhoid and the use of lomefloxacin] Romanov IuA, et al. **Antibiot Khimioter** 1996;41(11):18–24 (Eng. Abstr.) **(Rus)**

[A comparative study of fluoroquinolones and 3rd-generation cephalosporins in the prevention and treatment of experimental plague caused by Yersinia pestis strains typical and serologically atypical with respect to F1] Ryzhko IV, et al. **Antibiot Khimioter** 1997;42(1):12–6 (Eng. Abstr.) **(Rus)**

[Comparative evaluation of the effectiveness of ofloxacin in comprehensive treatment of acute inflammatory diseases of the uterus and uterine appendages] Savel'eva GM, et al. **Antibiot Khimioter** 1996;41(9):81–3 (Eng. Abstr.) **(Rus)**

[Ciprofloxacin in the treatment of intestinal infections of bacterial etiology] Sidorenko SV. **Antibiot Khimioter** 1997; 42(6):26–33 (60 ref.) **(Rus)**

[Chronic osteitis—modern therapy] Vittver V, et al. **Antibiot Khimioter** 1996;41(9):57–9 (Eng. Abstr.) **(Rus)**

[Comparative study of the antimicrobial activity of pefloxacin, ciprofloxacin, norfloxacin and azithromycin with respect to Strains of Yersinia pseudotuberculosis] Zaitseva EA, et al. **Antibiot Khimioter** 1996 Jan;41(1):19–21 (Eng. Abstr.) **(Rus)**

[Use of ofloxacin in infections which do not readily respond to treatment] Zalaudek G. **Antibiot Khimioter** 1996; 41(9):11–2 (Eng. Abstr.) **(Rus)**

[The efficacy of using Zanocin in infectious diseases] Rudenko AA, et al. **Lik Sprava** 1996 Mar-Apr;(3–4):140–3 **(Rus)**

[Use of maxaquin in the treatment of progressive pulmonary tuberculosis occurring with standard chemotherapy regimens] Mar'iandyshev AO, et al. **Probl Tuberk** 1997; (4):19–21 (Eng. Abstr.) **(Rus)**

[Effects of a synthetic carbon-mineral sorbent and antibiotics on the development of combined radiation and thermal injury] Nesterenko VS, et al. **Radiats Biol Radioecol** 1996 Sep-Oct;36(5):727–30 (Eng. Abstr.) **(Rus)**

[Clinical and laboratory assessment of therapeutic efficacy of maxaquin in treatment of chlamydial conjunctivitis] Maĭchuk IF, et al. **Vestn Oftalmol** 1997 Mar-Apr; 113(2):19–21 (Eng. Abstr.) **(Rus)**

[Use of fluoroquinolones in rheumatology] Belov BS, et al. **Vestn Ross Akad Med Nauk** 1996;(12):12–5 (Eng. Abstr.) **(Rus)**

[Visceral leishmaniasis and ciprofloxacin (letter; comment)] Muñoz Sanz A. **Med Clin (Barc)** 1996 Oct 26;107(14):556 . Comment on: Med Clin (Barc) 1996 Apr 20;106(15):590–6. **(Spa)**

[Antibiotic treatment of acute gastroenteritis] Segura Porta F, et al. **Rev Clin Esp** 1997 Apr;197(4):241–4 (Eng. Abstr.) **(Spa)**

TOXICITY

Studies on the mechanism of phototoxicity of BAY y 3118 and other quinolones. Schmidt U, et al. **Adv Exp Med Biol** 1996;387:117–20

Participation of reactive oxygen species in phototoxicity induced by quinolone antibacterial agents. Umezawa N, et al. **Arch Biochem Biophys** 1997 Jun 15;342(2):275–81

Quinolone-induced cartilage lesions are not reversible in rats. Förster C, et al. **Arch Toxicol** 1996;70(8):474–81

Integrins on joint cartilage chondrocytes and alterations by ofloxacin or magnesium deficiency in immature rats. Förster C, et al. **Arch Toxicol** 1996;70(5):261–70

Lack of potentiation with felbinac patch on the convulsive toxicity of enoxacin in rats. Ohtani H, et al. **Biol Pharm Bull** 1996 Jul;19(7):995–7

Ciprofloxacin was the culprit—not itraconazole [letter; comment] de Clari F. **Clin Infect Dis** 1997 Jan;24(1):96. Comment on: Clin Infect Dis 1995 Aug;21(2):456.

Quinolone arthropathy in immature rabbits treated with the fluoroquinolone, PD 117596. Gough A, et al. **Exp Toxicol Pathol** 1996 Jun;48(4):225–32

Effect of antioxidants, anti-inflammatory drugs, and histamine antagonists on sparfloxacin-induced phototoxicity in mice. Shimoda K, et al. **Fundam Appl Toxicol** 1996 May;31(1):133–40

Interaction of ciprofloxacin with diclofenac and paracetamol in relation to it's epileptogenic effect. Shrivastava MP, et al. **Indian J Physiol Pharmacol** 1997 Apr;41(2):164–6

Interaction between enoxacin, a new antimicrobial, and nimesulide, a new non-steroidal anti-inflammatory agent in mice. Taniguchi Y, et al. **Inflamm Res** 1996 Aug; 45(8):376–9

Lack of chondrotoxicity of ofloxacin otic solution on the auditory ossicle cartilages of juvenile guinea pigs. Kato M, et al. **J Antimicrob Chemother** 1997 Feb;39(2):269–71

A study of the phototoxic potential of trovafloxacin in BALB/c mice. Mayne JT, et al. **J Antimicrob Chemother** 1997 Jun;39 Suppl B:67–73

Retinal safety of oral and topical ofloxacin in rabbits. Cohen RG, et al. **J Ocul Pharmacol Ther** 1997 Aug;13(4):369–79

Quinolone antibiotic with potential to photosensitize skin tumorigenesis. Johnson BE, et al. **J Photochem Photobiol B** 1997 Feb;37(3):171–3

Fluoroquinolone antibacterials enhance UVA-induced skin tumors. Klecak G, et al. **J Photochem Photobiol B** 1997 Feb;37(3):174–81

Quinolone antibacterials: a new class of photochemical carcinogens. Mäkinen M, et al. **J Photochem Photobiol B** 1997 Feb;37(3):182–7

Phototoxicity and possible enhancement of photocarcinogenesis by fluorinated quinolone antibiotics. Urbach F. **J Photochem Photobiol B** 1997 Feb;37(3):169–70 (12 ref.)

Diagnosis of quinolone-induced arthropathy in juvenile dogs by use of magnetic resonance (MR) imaging. Yabe K, et al. **J Vet Med Sci** 1997 Jul;59(7):597–9

Circadian variation in enoxacin-induced convulsions in mice coadministered with fenbufen. Masukawa T, et al. **Jpn J Pharmacol** 1997 Feb;73(2):175–7

Epileptogenic activity induced by combined treatment with antiinflammatory drugs and enoxacin and its inhibition by a calcium antagonist, nicardipine. Kamei C, et al. **Methods Find Exp Clin Pharmacol** 1996 Nov;18(9):579–88

Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Lawrence JW, et al. **Mol Pharmacol** 1996 Nov;50(5):1178–88

The photomutagenicity of fluoroquinolones in tests for gene mutation, chromosomal aberration, gene conversion and DNA breakage (Comet assay). Chételat AA, et al. **Mutagenesis** 1996 Sep;11(5):497–504

Photosensitization by norfloxacin is a function of pH. Bilski P, et al. **Photochem Photobiol** 1996 Sep;64(3):496–500

Photogenotoxicity of skin phototumorigenic fluoroquinolone antibiotics detected using the comet assay. Reavy HJ, et al. **Photochem Photobiol** 1997 Sep;66(3):368–73

Inhibitory effect of new quinolones on GABA(A) receptor-mediated response and its potentiation with felbinac in Xenopus oocytes injected with mouse-brain mRNA: correlation with convulsive potency in vivo. Kawakami J, et al. **Toxicol Appl Pharmacol** 1997 Aug; 145(2):246–54

In vitro and in vivo study of the effects of enrofloxacin on hepatic cytochrome P-450. Potential for drug interactions. Vancutsem PM, et al. **Vet Hum Toxicol** 1996 Aug; 38(4):254–9

[The genotoxic effect of ciprofloxacin on cultured cells from the kangaroo rat kidney and on skin fibroblasts from the Indian muntjac] Polianskaia GG, et al. **Tsitologiia** 1996;

38(9):958–73 (Eng. Abstr.) **(Rus)**

URINE

Suspicion of quinolone active metabolite following discrepancy between predicted and experimental urine bactericidal activities. Aguilar L, et al. **Antimicrob Agents Chemother** 1997 May;41(5):927–30

Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose. Hofbauer H, et al. **Infection** 1997 Mar–Apr; 25(2):121–6

High concentration of ciprofloxacin in urine invalidates EMIT results. Lora-Tamayo C, et al. **J Anal Toxicol** 1996 Sep;20(5):334

Effect of probenecid and ranitidine on urinary excretion of lomefloxacin in rats. Sasaki M, et al. **Jpn J Pharmacol** 1996 Jul;71(3):263–4

ANTI-INFECTIVE AGENTS, LOCAL

see related

DISINFECTANTS

Microbial contamination of antiseptics and disinfectants. Oie S, et al. **Am J Infect Control** 1996 Oct;24(5):389–95

Microbial contamination of antiseptic-soaked cotton balls. Oie S, et al. **Biol Pharm Bull** 1997 Jun;20(6):667–9

Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial [see comments] Taha TE, et al. **BMJ** 1997 Jul 26;315(7102):216–9; discussion 220. Comment in: BMJ 1997 Jul 26;315(7102):199–200.

Serratia marcescens nosocomial outbreak due to contamination of hexetidine solution. Bosi C, et al. **J Hosp Infect** 1996 Jul;33(3):217–24

[Clinical and preclinical efficacy of antimicrobial catheters] Schierholz JM, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 May; 32(5):298–305 (102 ref.) (Eng. Abstr.) **(Ger)**

[Clinical experience with a new antimicrobially coated InterGard-IgK/AM vascular prosthesis in surgical treatment of deep wound infection with involvement of the synthetic bypass: report of 2 cases] Manouguian S. **Zentralbl Chir** 1996;121(9):768–72; discussion 772–3 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Triclosan: applications and safety. Bhargava HN, et al. **Am J Infect Control** 1996 Jun;24(3):209–18

The efficacy of exit site povidone-iodine ointment in the prevention of early peritoneal dialysis-related infections. Waite NM, et al. **Am J Kidney Dis** 1997 May;29(5):763–8

Povidone-iodine gel vaginal antisepsis for abdominal hysterectomy. Eason EL, et al. **Am J Obstet Gynecol** 1997 May;176(5):1011–6

Effect of repeated treatment with sustained-release chlorhexidine mouth guards on salivary levels of mutans streptococci. Hildebrandt GH. **Caries Res** 1996; 30(6):445–53

The effect of chlorhexidine/xylitol chewing-gum on cariogenic salivary microflora: a clinical trial in elderly patients. Simons D, et al. **Caries Res** 1997;31(2):91–6

Neonatal thyroid function is unaffected by maternal topical iodine disinfection for cesarean section or vaginal delivery. Jeng MJ, et al. **Clin Pediatr (Phila)** 1997 Feb;36(2):109–11

Povidone-iodine (betadine) in the treatment of experimental Pseudomonas aeruginosa keratitis. Michalová K, et al. **Cornea** 1996 Sep;15(5):533–6

A double blind clinical study on the effectiveness of a chlorhexidine containing lozenge (Septofort) in the treatment of chronic gingivitis. Gera I, et al. **Fogorv Sz** 1997 Apr;90 Spec No:38–47 (30 ref.)

The risk of peripheral vein phlebitis associated with chlorhexidine-coated catheters: a randomized, double-blind trial [see comments] Sherertz RJ, et al. **Infect Control Hosp Epidemiol** 1997 Apr;18(4):230–6. Comment in: Infect Control Hosp Epidemiol 1997 Apr;18(4):227–9.

Surgical pearl: bacteriostatic sodium chloride injection USP 0.9%. Daniel CR 3rd, et al. **J Am Acad Dermatol** 1997 Jan;36(1):92

The effect of hexetidine spray on dental plaque following periodontal surgery. Bokor M. **J Clin Periodontol** 1996 Dec;23(12):1080–3

2 multi-center trials assessing the clinical efficacy of 5% sanguinarine in a biodegradable drug delivery system. Polson AM, et al. **J Clin Periodontol** 1996 Aug;23(8):782–8

An evaluation of five protocols for surgical handwashing in relation to skin condition and microbial counts. Pereira LJ, et al. **J Hosp Infect** 1997 May;36(1):49–65

Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. I. Study design, procedures, and management. Polson AM, et al. **J Periodontol** 1997 Feb; 68(2):110–8

Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results. Polson AM, et al. **J Periodontol** 1997 Feb;68(2):119–26

Full- versus partial-mouth disinfection in the treatment of periodontal infections. Long-term clinical observations of a pilot study. Vandekerckhove BN, et al. **J Periodontol** 1996 Dec;67(12):1251–9

Five day and ten day triple therapy (amoxicillin, furazolidone and metronidazole) in the treatment of duodenal ulcer. Zaterka S, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Sep-Oct;51(5):162–5

[Surgical therapy of pleural empyema with tauroline] Bieselt R. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S42–6 (Eng. Abstr.) **(Ger)**

[Clinical efficacy of silver sulfadiazine (AgSD: Geben cream) for ulcerative skin lesions infected with MRSA] Yoshida T, et al. **Jpn J Antibiot** 1997 Jan;50(1):39–44 (Eng. Abstr.) **(Jpn)**

[Cyclophosphane in the treatment of trophic ulcers of lower extremities with allergic and autoimmune components] Khokhlov AM, et al. **Khirurgiia (Mosk)** 1997;(4):36–7 (Eng. Abstr.) **(Rus)**

[The use of new drug forms of decamethoxin for the prevention and treatment of postinjection complications] Palii GK, et al. **Klin Khir** 1995;(2):8–9 **(Rus)**

[Clinical effectiveness of the use of liposomes with antibiotics and ecterocide in purulent-inflammatory thoracic and abdominal complications] Bashtan VP. **Klin Khir** 1997; (1):14–6 (Eng. Abstr.) **(Ukr)**

ADVERSE EFFECTS

Pathogenesis of abnormal keratinization in ichthyosiform cetrimide dermatitis: an ultrastructural study. Lee JY. **Am J Dermatopathol** 1997 Apr;19(2):162–7

Sclerosing encapsulating peritonitis after intraperitoneal use of povidone iodine. Keating JP, et al. **Aust N Z J Surg** 1997 Oct;67(10):742–4 (19 ref.)

Handle with care [letter; comment] Seward GR. **Br Dent J** 1997 May 24;182(10):370. Comment on: Br Dent J 1997 Feb 8;182(3):87.

An investigation into the effect of ischaemia and pressure on irritant inflammation. Parslew R, et al. **Br J Dermatol** 1997 May;136(5):734–6

Oxygen venous embolism after the use of hydrogen peroxide during lumbar discectomy. Despond O, et al. **Can J Anaesth** 1997 Apr;44(4):410–3 (18 ref.)

Neonatal thyroid function is unaffected by single treatment with different preparations of povidone-iodine on a wide skin surface. Jeng MJ, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1997 Jan-Feb;38(1):28–31

Allergic contact dermatitis from benzyl alcohol. Corazza M, et al. **Contact Dermatitis** 1996 Jan;34(1):74–5

Chemical burns following irritant contact with povidone-iodine. Corazza M, et al. **Contact Dermatitis** 1997 Feb;36(2):115–6

Compound allergy to skin swabs [letter; comment] Freeman S. **Contact Dermatitis** 1996 Jul;35(1):66. Comment on: Contact Dermatitis 1996 Jan;34(1):62–3.

Allergic contact dermatitis from pyoctanin. Schoppelrey HP, et al. **Contact Dermatitis** 1997 Apr;36(4):221–4

Thyroid function in infants following cardiac surgery: comparative effects of iodinated and noniodinated topical antiseptics. Brogan TV, et al. **Crit Care Med** 1997 Sep; 25(9):1583–7

Hebiclens keratitis and the TCA Masque [letter; comment] Steinsapir KD. **Dermatol Surg** 1997 Jun;23(6):499. Comment on: Dermatol Surg 1996 Aug;22(8):687–90.

Oral, perioral and systemic pathosis in HgCl2-induced autoimmunity in the BN rat. Warfvinge G, et al. **Eur J Oral Sci** 1997 Apr;105(2):153–61

Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery. Sathyanarayana MV, et al. **Indian J Gastroenterol** 1996 Jul;15(3):104

The antilesion actions of anticholinergic agents on ethanol-induced injury in rat stomachs: the importance of gastric vascular integrity and tonicity. Ko JK, et al. **J Auton Pharmacol** 1996 Jun;16(3):117–24

Reduced chlorhexidine tooth stain coverage by sequential administration of monoperoxyphthalic acid in the beagle dog. Charbonneau DL, et al. **J Dent Res** 1997 Sep; 76(9):1596–601

Bacterial contamination of commercially available ethacridine lactate (acrinol) products. Oie S, et al. **J Hosp Infect** 1996 Sep;34(1):51–8

Routine skin cleansing with povidone-iodine is not a common cause of transient neonatal hypothyroidism in North America: a prospective controlled study. Brown RS, et al. **Thyroid** 1997 Jun;7(3):395–400

[Allergy and preservatives. Apropos of 3 cases of allergy to benzalkonium chloride] Chiambaretta F, et al. **J Fr Ophtalmol** 1997;20(1):8–16 (41 ref.) (Eng. Abstr.) **(Fre)**

[Allergy-inducing potency of tea tree oil] Kränke B. **Hautarzt** 1997 Mar;48(3):203–4 **(Ger)**

ANALYSIS

Liquid chromatographic determination of acriflavine and proflavine residues in channel catfish muscle. Plakas SM, et al. **J AOAC Int** 1997 May-Jun;80(3):486–90

Validated capillary electrophoretic method for the quantitative analysis of histamine acid phosphate and/or benzalkonium chloride. Altria KD, et al. **J Chromatogr B Biomed Appl** 1996 Nov 8;686(1):111–7

New stability-indicating high performance liquid chromatography assay and proposed hydrolytic pathways of chlorhexidine. Ha Y, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1327–34

ANTAGONISTS & INHIBITORS

Does the nature of the solvent affect the anti-inflammatory capacity of triclosan? An experimental study. Skaare AB, et al. **J Clin Periodontol** 1997 Feb;24(2):124–8

[The dynamics of the antiseptic resistance of the causative agents of soft-tissue suppurative-inflammatory diseases in children] Abaev IuK, et al. **Vestn Khir Im I I Grek** 1996; 155(4):35–7 (Eng. Abstr.) **(Rus)**

CHEMISTRY

A study on the stability of bronopol in bronopol lotion by ion-paired reversed-phase high performance liquid chromatography. Lian HZ, et al. **J Pharm Biomed Anal** 1997 Feb;15(5):667–71

[Kinetics of in vitro bactericidal activity of the antiseptic biseptine combining 3 active principles] Reverdy ME, et al. **Pathol Biol (Paris)** 1996 Sep;44(7):675–80 (Eng. Abstr.) **(Fre)**

[Collagen membranes of increased absorption as carriers of antiseptics] Antiszko M, et al. **Polim Med** 1996;26(3–4):21–8 (Eng. Abstr.) **(Pol)**

ECONOMICS

Ophthalmia neonatorum prophylaxis--can we do it more cost-effectively? [letter; comment] Meyer D. **S Afr Med J** 1997 Apr;87(4):471–2. Comment on: S Afr Med J 1997 Jan;87(1):76–7.

HISTORY

Dakin's solution revisited. McDonnell KJ, et al. **Am J Orthop** 1997 Jul;26(7):471–3

Centenary year of scientific papers in the British Dental Journal [published erratum appears in Br Dent J 1997 Jan 11;182(1):36] McGowan D. **Br Dent J** 1996 Sep 21; 181(6):226–7

IMMUNOLOGY

Anaphylaxis to topical bacitracin. Dyck ED, et al. **Allergy** 1997 Aug;52(8):870–1

PHARMACOKINETICS

Direct evidence for uptake of intact liposomes encapsulating silver sulfadiazine by cultured human keratinocytes based on combined transmission electron microscopy and X-ray microanalysis. Schaller M, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):717–9

125I uptake competing with iodine absorption by the thyroid gland following povidone-iodine skin application. Furudate S, et al. **Exp Anim** 1997 Jul;46(3):197–202

PHARMACOLOGY

Effects of oral hygiene products containing lactoperoxidase, lysozyme, and lactoferrin on the composition of whole saliva and on subjective oral symptoms in patients with xerostomia. Kirstilä V, et al. **Acta Odontol Scand** 1996 Dec; 54(6):391–7

Comparison of the immediate, residual, and cumulative antibacterial effects of Novaderm R,* Novascrub R,* Betadine Surgical Scrub, Hibiclens, and liquid soap. Faoagali J, et al. **Am J Infect Control** 1995 Dec; 23(6):337–43

Clinical investigation of topical antimicrobials in healthy volunteers. Langford JH, et al. **Ann Pharmacother** 1997 Jan;31(1):34–8

Expression of Escherichia coli TehA gives resistance to antiseptics and disinfectants similar to that conferred by multidrug resistance efflux pumps. Turner RJ, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):440–4

Inhibition by ethanol of the growth of biofilm and dispersed microcosm dental plaques. Sissons CH, et al. **Arch Oral Biol** 1996 Jan;41(1):27–34

Antimicrobial activities of iodinated polystyrene derivatives. Lin KJ, et al. **Artif Organs** 1996 Nov;20(11):1191–5

Does tea tree oil have a place in the topical treatment of burns? Faoagali J, et al. **Burns** 1997 Jun;23(4):349–51

Efficacy of a chlorhexidine and a chlorhexidine-fluoride varnish mixture to decrease interdental levels of mutans streptococci. Twetman S, et al. **Caries Res** 1997;31(5):361–5

Reduced susceptibility of methicillin-resistant Staphylococcus aureus to cetylpyridinium chloride and chlorhexidine. Irizarry L, et al. **Chemotherapy** 1996 Jul-Aug;42(4):248–52

The possible role of yeast cell walls in modifying cellular response to chlorhexidine diacetate. Hiom SJ, et al. **Cytobios** 1996;86(345):123–35

Assessment of the effects of gramicidin, formaldehyde, and surfactants on Escherichia coli by flow cytometry using nucleic acid and membrane potential dyes. Comas J, et al. **Cytometry** 1997 Sep 1;29(1):58–64

Antibacterial effect of chlorhexidine on bacteria adsorbed onto experimental dental plaque. Steinberg D, et al. **Diagn Microbiol Infect Dis** 1996 Nov-Dec;26(3–4):109–15

Effect of titanium on selected oral bacterial species in vitro. Leonhardt A, et al. **Eur J Oral Sci** 1995 Dec;103(6):382–7

Flow cytometric analysis of chlorhexidine action. Sheppard FC, et al. **FEMS Microbiol Lett** 1997 Sep 15;154(2):283–8

Effects of pteridines on chloramine-T-induced growth

inhibition in E. coli strains: correlations with molecular structure. Horejsi R, et al. **Free Radic Biol Med** 1996; 21(2):133–8

A chemical treatment regimen to reduce bacterial contamination in dental waterlines. Eleazer PD, et al. **J Am Dent Assoc** 1997 May;128(5):617–23

The effect of chlorhexidine on defined, mixed culture oral biofilms grown in a novel model system. Kinniment SL, et al. **J Appl Bacteriol** 1996 Aug;81(2):120–5

Impact of chlorhexidine-silver sulfadiazine-impregnated central venous catheters on in vitro quantitation of catheter-associated bacteria [see comments] Schmitt SK, et al. **J Clin Microbiol** 1996 Mar;34(3):508–11. Comment in: J Clin Microbiol 1996 Oct;34(10):2640–1.

Effects of sublethal exposure to an antiseptic mouthrinse on representative plaque bacteria. Fine DH, et al. **J Clin Periodontol** 1996 May;23(5):444–51

Effect of chlorhexidine on the adherence properties of Porphyromonas gingivalis. Grenier D. **J Clin Periodontol** 1996 Feb;23(2):140–2

Triclosan reduces prostaglandin biosynthesis in human gingival fibroblasts challenged with interleukin-1 in vitro. Modéer T, et al. **J Clin Periodontol** 1996 Oct;23(10):927–33

The effect of toothpaste containing triclosan on oral mucosal desquamation. A model study. Skaare A, et al. **J Clin Periodontol** 1996 Dec;23(12):1100–3

Studies on stannous fluoride toothpaste and gel (1). Antimicrobial properties and staining potential in vitro. Wade W, et al. **J Clin Periodontol** 1997 Feb;24(2):81–5

Effect of use of 0.05% cetylpyridinium chloride mouthwash on normal oral flora. Radford JR, et al. **J Dent** 1997 Jan; 25(1):35–40

Hydrolysis of triclosan monophosphate by dental plaque and selected species of oral micro-organisms. Greenman J, et al. **J Dent Res** 1996 Aug;75(8):1578–84

Incorporation of antibacterial monomer MDPB into dentin primer. Imazato S, et al. **J Dent Res** 1997 Mar;76(3):768–72

An in-vitro evaluation of the activity of povidone-iodine against nosocomial bacterial strains. Traoré O, et al. **J Hosp Infect** 1996 Nov;34(3):217–22

Semisynthetic derivatives of purpuromycin as potential topical agents for vaginal infections. Trani A, et al. **J Med Chem** 1997 Mar 14;40(6):967–71

Susceptibilities of Actinobacillus actinomycetemcomitans biofilms to oral antiseptics. Thrower Y, et al. **J Med Microbiol** 1997 May;46(5):425–9

Dietary Iodine and selenium interact to affect thyroid hormone metabolism of rats. Hotz CS, et al. **J Nutr** 1997 Jun;127(6):1214–8

Triclosan inhibits sodium lauryl sulphate-induced changes in expression of cytokeratin genes in hamster cheek pouch epithelium. Baert JH, et al. **J Oral Pathol Med** 1997 Apr; 26(4):181–6

Benzalkonium chloride: a potential disinfecting irrigation solution. Gainor BJ, et al. **J Orthop Trauma** 1997 Feb–Mar; 11(2):121–5

In vitro antifungal properties of mouthrinses containing antimicrobial agents. Giuliana G, et al. **J Periodontol** 1997 Aug;68(8):729–33

A simple in vitro model to test the efficacy of antimicrobial agents released from dressings. Grzybowski J, et al. **J Pharmacol Toxicol Methods** 1996 Oct;36(2):73–6

In vitro evaluation of antibacterial effects of photo-cured glass ionomer liners and dentin bonding agents during setting. Fraga RC, et al. **J Prosthet Dent** 1996 Nov; 76(5):483–6

The origin of the antiseptic-resistance gene ebr in Staphylococcus aureus. Sasatsu M, et al. **Microbios** 1995; 84(340):161–9

Antiseptic myramistin possesses the strong anti-HIV properties. Kryvorutchenko IuL, et al. **Mikrobiol Z** 1996 Sep–Oct;58(5):90–2

Management of contaminated bone grafts: an experimental in vitro study. Hooe W, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jul;82(1):34–7

Inhibition of pure cultures of oral bacteria by root canal filling materials. Tchaou WS, et al. **Pediatr Dent** 1996 Nov–Dec;18(7):444–9

Excipient interaction with cetylpyridinium chloride activity in tablet based lozenges. Richards RM, et al. **Pharm Res** 1996 Aug;13(8):1258–64

High incidence of line-related infection and mechanical failure of an antiseptic impregnated central venous catheter in highly immunocompromised patients. Ellis ME, et al. **Scand J Infect Dis** 1996;28(1):91–3

The vaginal microflora of pig-tailed macaques and the effects of chlorhexidine and benzalkonium on this ecosystem [published erratum appears in Sex Transm Dis 1997 Mar;24(3):180] Patton DL, et al. **Sex Transm Dis** 1996 Nov–Dec;23(6):489–93

Evaluation of donor skin disinfection methods. Goldman M, et al. **Transfusion** 1997 Mar;37(3):309–12

Skin antisepsis at the donor site: is there room for improvement? [editorial; comment] Schaffner W. **Transfusion** 1997 Mar;37(3):249–50. Comment on: Transfusion 1997 Mar;37(3):309–12.

Tumoricidal activity of antiseptics with assessment of cell viability in mice with severe combined immunodeficiency. Basha G, et al. **Tumour Biol** 1997;18(4):213–8

Chlorhexidine gluconate versus chloroxylenol for preoperative skin preparation in dogs. Stubbs WP, et al. **Vet Surg** 1996 Nov–Dec;25(6):487–94

Irgasan DP 300 (5-chloro-2-(2,4-dichlorophenoxy)-phenol) induces cytochrome P450s and inhibits haem biosynthesis in rat hepatocytes cultured on Matrigel. Jinno H, et al. **Xenobiotica** 1997 Jul;27(7):681–92

Clinical studies on the use of antibiotic- and antiseptic-bonded catheters to prevent catheter-related infection. Bach A. **Zentralbl Bakteriol** 1995 Dec; 283(2):208–14 (32 ref.)

[The effect of antiseptic agents on the growth of mouse skin] Zhu Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Dec; 33(12):749–51 (Eng. Abstr.) **(Chi)**

[Antimicrobial properties of Flos Lonicerae against oral pathogens] Sun Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Apr;21(4):242–3 inside backcover (Eng. Abstr.) **(Chi)**

[Antimicrobial and physico-chemical aspects of antiseptics based on the iodine-polyvinylpyrrolidone complex] Hartmanová M, et al. **Epidemiol Mikrobiol Imunol** 1996 Dec;45(4):148–52 (Eng. Abstr.) **(Cze)**

[Antiseptic properties of essential oil of Lippia sidoides Cham. Application to the cutaneous microflora] Lacoste E, et al. **Ann Pharm Fr** 1996;54(5):228–30 (Eng. Abstr.) **(Fre)**

[Bactericidal activity determination of Biseptine, combination of chlorhexidine, benzalkonium chloride and benzylic alcohol, on 124 hospital bacterial strains] Reverdy ME, et al. **Pathol Biol (Paris)** 1997 Apr;45(4):331–5 (Eng. Abstr.) **(Fre)**

[Kinetics of in vitro bactericidal activity of the antiseptic biseptine combining 3 active principles] Reverdy ME, et al. **Pathol Biol (Paris)** 1996 Sep;44(7):675–80 (Eng. Abstr.) **(Fre)**

[Peritoneal instillation of taurolidine and heparin for preventing intraperitoneal tumor growth and trocar metastases in laparoscopic operations in the rat model] Jacobi CA, et al. **Langenbecks Arch Chir** 1997;382(4 Suppl 1):S31–6 (Eng. Abstr.) **(Ger)**

[Effect of taurolidine on intra- and extraperitoneal tumor growth in laparoscopy. Results of a new therapy concept for prevention of trocar metastases] Ordemann J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:271–4 (Eng. Abstr.) **(Ger)**

[Antiseptic-resistance in Staphylococcus aureus] Sasatsu M. **Nippon Saikingaku Zasshi** 1996 Aug;51(3):755–65 (61 ref.) **(Jpn)**

[General tests. A. A need for preservatives in saving urinary samples] Matsuda Y, et al. **Rinsho Byori** 1996 Nov;Suppl 103:92–6 **(Jpn)**

[Effect of cell wall polyphosphates on the sensitivity of the yeast Saccharomyces carlsbergensis to the damaging action of cetyltrimethylammonium bromide] Ivanov AIu, et al. **Mikrobiologiia** 1996 Sep–Oct;65(5):607–12 (Eng. Abstr.) **(Rus)**

[The comparative characteristics of the antibacterial activity of new antiseptics and the prospects for their use in dental practice] Dmitrieva LA, et al. **Stomatologiia (Mosk)** 1997; 76(2):26–7 (Eng. Abstr.) **(Rus)**

[The antimicrobial activity and cytotoxicity of anti-infective preparations in a human cell-culture model] Afinogenov GE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct;(5):3–7 (Eng. Abstr.) **(Rus)**

POISONING

Unusual cause of seizure. Gouin S, et al. **Pediatr Emerg Care** 1996 Aug;12(4):298–300 (13 ref.)

Campho-Phenique ingestion: an intentional overdose. Lahoud CA, et al. **South Med J** 1997 Jun;90(6):647–8 (11 ref.)

THERAPEUTIC USE

Peroxyacetic acid effect on the bacteriologic status of war wound. Turčić J, et al. **Acta Med Croatica** 1997; 51(3):159–62

Therapeutic efficacy of povidone-iodine (Betadine) and dichloroxylenol (Septocid) in Holstein cows affected with endometritis and/or cervicitis. Koujan A, et al. **Acta Vet Hung** 1996;44(1):111–9

Elimination study of silver in a hemodialyzed burn patient treated with silver sulfadiazine cream. Iwasaki S, et al. **Am J Kidney Dis** 1997 Aug;30(2):287–90

Chlorhexidine versus sterile water vaginal wash during labor to prevent peripartum infection. Sweeten KM, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):426–30

Efficacy of topical povidone-iodine during the first week after ophthalmic surgery. Isenberg SJ, et al. **Am J Ophthalmol** 1997 Jul;124(1):31–5

Clinical effects of chlorhexidine mouthwashes on patients undergoing orthodontic treatment. Anderson GB, et al. **Am J Orthod Dentofacial Orthop** 1997 Jun;111(6):606–12

Human skin flora as a potential source of epidural abscess. Sato S, et al. **Anesthesiology** 1996 Dec;85(6):1276–82

Effect of applying chlorhexidine antibacterial agent on the shear bond strength of orthodontic brackets [see comments] Bishara SE, et al. **Angle Orthod** 1996;66(4):313–6. Comment in: Angle Orthod 1996;66(4):243.

Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial [see comments] Maki DG, et al. **Ann Intern Med** 1997 Aug 15;127(4):257–66. Comment in: Ann Intern Med 1997 Aug 15;127(4):304–6.

Topical antimicrobial prophylaxis in minor wounds. Langford JH, et al. **Ann Pharmacother** 1997 May; 31(5):559–63

Protective effect of povidone-iodine ointment against skin lesions induced by sulphur and nitrogen mustards and by non-mustard vesicants. Wormser U, et al. **Arch Toxicol** 1997;71(3):165–70

Effects of formalin, chloramine-T, and low salinity dip on the behavior and hemolymph biochemistry of the American lobster. Speare DJ, et al. **Can Vet J** 1996 Dec;37(12):729–34

Effect of chlorhexidine varnish on Actinomyces naeslundii genospecies in plaque from dental fissures. Schaeken MJ, et al. **Caries Res** 1996;30(1):40–4

Effect of different chlorhexidine varnish regimens on mutans streptococci levels in interdental plaque and saliva. Twetman S, et al. **Caries Res** 1997;31(3):189–93

Protection of bovine enamel and dentine by chlorhexidine and fluoride varnishes in a bacterial demineralization model. van Loveren C, et al. **Caries Res** 1996;30(1):45–51

Photo quiz. Contact dermatitis secondary to Neosporin ointment. Dasaraju P, et al. **Clin Infect Dis** 1997 Jul; 25(1):33, 145

Prospective, randomized trial of two antiseptic solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients. Mimoz O, et al. **Crit Care Med** 1996 Nov;24(11):1818–23

Lasers and allergic contact dermatitis to topical antibiotics, with particular reference to bacitracin [news] Fisher AA. **Cutis** 1996 Oct;58(4):252–4

Use of intraperitoneal 5-fluorouracil and chlorhexidine for prevention of recurrence of perforated colorectal carcinoma in a rat model. Stuntz M, et al. **Dis Colon Rectum** 1997 Sep;40(9):1085–8

Antiplaque, antibacterial, and anti-inflammatory properties of triclosan mouthrinses in combination with zinc citrate or polyvinylmethylether maleic acid (PVM-MA) copolymer. Kjaerheim V, et al. **Eur J Oral Sci** 1996 Oct–Dec;104(5–6):529–34

Effects of chlorhexidine on the bacterial colonization and degradation of dentin and completely demineralized dentin in situ. van Strijp AJ, et al. **Eur J Oral Sci** 1997 Feb; 105(1):27–35

Evaluation of scolicidal agents in an experimental hydatid disease model. Landa García JI, et al. **Eur Surg Res** 1997; 29(3):202–8

Furazolidone in uncomplicated enteric fever [letter; comment] [see comments] Letha S. **Indian Pediatr** 1996 May;33(5):437. Comment on: Indian Pediatr 1995 Jan;32(1):109. Comment in: Indian Pediatr 1996 Aug;33(8):701–2.

Otitis media with effusion and S-carboxymethylcysteine and/or its lysine salt: a critical overview. Pignataro O, et al. **Int J Pediatr Otorhinolaryngol** 1996 May;35(3):231–41

Recurrent bacterial vaginosis--an old approach to a new problem [see comments] Winceslaus SJ, et al. **Int J STD AIDS** 1996 Jul;7(4):284–7. Comment in: Int J STD AIDS 1997 Mar;8(3):210.

Mycotic keratitis: susceptibility to antiseptic agents. Martin MJ, et al. **Int Ophthalmol** 1995–96;19(5):299–302

Topical triclosan treatment of atopic dermatitis [letter; comment] Sporik R, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):861. Comment on: J Allergy Clin Immunol 1996 Sep;98(3):702–7.

Soap and home care [letter] Arzt AH. **J Am Dent Assoc** 1997 Aug;128(8):1064

The management of burns under conditions of limited resources using topical aqueous sulfamylon (mafenide) hydrochloride spray. Mendelson JA. **J Burn Care Rehabil** 1997 May–Jun;18(3):238–44

Pulsed electromagnetic fields in experimental cutaneous wound healing in rats. Patiño O, et al. **J Burn Care Rehabil** 1996 Nov–Dec;17(6 Pt 1):528–31

Two independent clinical trials comparing pre-brush mouthrinse formulations in reducing supragingival plaque. Cronin M, et al. **J Can Dent Assoc** 1997 May;63(5):347–55

Studies on stannous fluoride toothpaste and gel (2). Effects on salivary bacterial counts and plaque regrowth in vivo. Addy M, et al. **J Clin Periodontol** 1997 Feb;24(2):86–91

0.1%/0.2% commercial chlorhexidine solutions as subgingival irrigants in chronic periodontitis. Asari AM, et al. **J Clin Periodontol** 1996 Apr;23(4):320–5

A 3-month home use study comparing the oral hygiene and gingival health benefits of triclosan and conventional fluoride toothpastes. Binney A, et al. **J Clin Periodontol** 1996 Nov;23(11):1020–4

A comparison of triclosan and stannous fluoride toothpastes for inhibition of plaque regrowth. A crossover study designed to assess carry over. Binney A, et al. **J Clin Periodontol** 1997 Mar;24(3):166–70

Full- versus partial-mouth disinfection in the treatment of periodontal infections. A pilot study: long-term microbiological observations. Bollen CM, et al. **J Clin Periodontol** 1996 Oct;23(10):960–70

An evaluation of an antiadhesive copolymer agent on plaque inhibition by chlorhexidine. Claydon N, et al. **J Clin Periodontol** 1996 Oct;23(10):952–4

The effects of a 0.12% chlorhexidine-digluconate-containing mouthrinse versus a placebo on plaque and gingival inflammation over a 3-month period. A multicentre study carried out in general dental practices. Eaton KA, et al. **J Clin Periodontol** 1997 Mar;24(3):189–97

Some effects of mouthrinses containing salifluor on de novo plaque formation and developing gingivitis. Furuichi Y,

et al. **J Clin Periodontol** 1996 Aug;23(8):795–802

Inhibitory effects of acid water prepared by an electrolysis apparatus on early plaque formation on specimens of dentine [published erratum appears in J Clin Periodontol 1996 Aug;23(8):803] Ito K, et al. **J Clin Periodontol** 1996 May;23(5):471–6

In vitro and in vivo studies on salifluor/PVM/MA copolymer/NaF combination as an antiplaque agent. Nabi N, et al. **J Clin Periodontol** 1996 Dec;23(12):1084–92

A clinical and microbiological evaluation of systemic and local metronidazole delivery in adult periodontitis patients [published erratum appears in J Clin Periodontol 1997 Jun;24(6):447–8] Noyan U, et al. **J Clin Periodontol** 1997 Mar;24(3):158–65

The effect of mouthrinses containing zinc and triclosan on plaque accumulation, development of gingivitis and formation of calculus in a 28-week clinical test. Schaeken MJ, et al. **J Clin Periodontol** 1996 May;23(5):465–70

Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU). Skaare AB, et al. **J Clin Periodontol** 1996 Aug;23(8):778–81

Evaluation of two iodophor teat germicides: activity against Staphylococcus aureus and Streptococcus agalactiae. Boddie RL, et al. **J Dairy Sci** 1997 Aug;80(8):1846–50

Topical ointments and wound healing. Thakur N. **J Fam Pract** 1997 Jan;44(1):26–7

A randomized trial of alcohol 70% versus alcoholic iodine 2% in skin disinfection before insertion of peripheral infusion catheters. de Vries JH, et al. **J Hosp Infect** 1997 Aug;36(4):317–20

The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD). Wilson AP, et al. **J Hosp Infect** 1997 Apr;35(4):287–93

Antimicrobial effect of a chlorhexidine-thymol varnish (Cervitec) in orthodontic patients. A prospective, randomized clinical trial. Ogaard B, et al. **J Orofac Orthop** 1997;58(4):206–13 **(Eng, Ger)**

A short-term study of the effects of SBHAN, a novel compound, on gingival inflammation in the beagle dog. Cutler CW, et al. **J Periodontol** 1997 May;68(5):448–55

Effects of combined topical metronidazole and mechanical treatment on the subgingival flora in deep periodontal pockets in cuspids and bicuspids. Hitzig C, et al. **J Periodontol** 1997 Jul;68(7):613–7

Otomycosis--a clinico-mycological study and efficacy of mercurochrome in its treatment. Chander J, et al. **Mycopathologia** 1996;135(1):9–12

Prophylactic use of topical anti-infectives in ophthalmology. Kramer A, et al. **Ophthalmologica** 1997;211 Suppl 1:68–76 (43 ref.)

Advancing wave-like epitheliopathy. Clinical features and treatment. D'Aversa G, et al. **Ophthalmology** 1997 Jun; 104(6):962–9

Prevention of urinary tract infection in patients with spinal cord injury--a microbiological review. Galloway A. **Spinal Cord** 1997 Apr;35(4):198–204 (87 ref.)

Are closed dressing of burns in children effective? Hess A, et al. **West Afr J Med** 1996 Apr–Jun;15(2):117–22

[Comparison of the efficacy of 2 antiseptic solutions in the prevention of infection from peridural catheters] Adam MN, et al. **Cah Anesthesiol** 1996;44(5):465–7 (Eng. Abstr.) **(Fre)**

[Subgingival irrigation: a heresy?] Bouclin R, et al. **J Can Dent Assoc** 1996 Apr;62(4):358–62 (52 ref.) (Eng. Abstr.) **(Fre)**

[Iodine--the place of an old disinfectant in the modern infectious disease specialty (letter)] König B, et al. **Dtsch Med Wochenschr** 1997 Jan 31;122(5):141 **(Ger)**

[The efficacy of dequalinium chloride/benzalkonium chloride as well as medicinal plants on the gingiva] Gruber I, et al. **Dtsch Zahn Mund Kieferheilkd Zentralbl** 1991;79(1):3–8 (Eng. Abstr.) **(Ger)**

[Treatment of skin lesions with Katogel] Ricci E. **Minerva Chir** 1996 May;51(5):369–75 (Eng. Abstr.) **(Ita)**

[Symptomatic efficacy of clotrimazole combined with surgery in the treatment of recurring anal and genital condylomatosis in seropositive and AIDS patients] Erenbourg L, et al. **Minerva Med** 1996 Sep;87(9):433–5 (Eng. Abstr.) **(Ita)**

[Mechanism of action of a new anti-inflammatory analgesic drug in some eye disorders] Manusia M. **Minerva Oftalmol** 1967 Jul–Aug;9(4):137–9 (Eng. Abstr.) **(Ita)**

[Effectiveness of local application of cidipol in the treatment and prevention of infectious-inflammatory diseases of the urogenital organs in women] Vasil'ev MM, et al. **Antibiot Khimioter** 1996 May;41(5):46–8 (Eng. Abstr.) **(Rus)**

[Use of miramistin in the treatment of experimental suppurative wounds in states of impaired peripheral blood circulation] Fesenko VP, et al. **Klin Khir** 1996;(8):30–2 **(Rus)**

[The antimicrobial activity of a new wound-healing compound ointment] Iakushchenko VA, et al. **Mikrobiol Z** 1996 May–Jun;58(3):78–82 (Eng. Abstr.) **(Rus)**

[Antiseptics in the combined treatment of patients with perimaxillary abscesses and phlegmons] Biberman IaM, et al. **Stomatologiia (Mosk)** 1996;75(6):25–7 (Eng. Abstr.) **(Rus)**

[A clinical and experimental validation of the use of Stimuloss in patients with chronic generalized periodontitis] Fedosenko TD, et al. **Stomatologiia (Mosk)** 1997; 76(3):18–22 (Eng. Abstr.) **(Rus)**

[The immunomodulating therapy of odontogenic phlegmons with complexes of antibacterial preparations and water-soluble polymers for medical use] Tsarev VN, et al. **Stomatologiia (Mosk)** 1996;Spec No:88 **(Rus)**

[The bactericidal efficacy of the Betadine preparation] Maksimov AN, et al. **Voen Med Zh** 1996 Aug;317(8):60–2 **(Rus)**

[An antibacterial sorptive preparation for preparing the large intestine for a surgical intervention] Rudichenko VM, et al. **Klin Khir** 1995;(3):28–9 **(Ukr)**

[The sodium form of sudamate--a new low-toxicity antimicrobial preparation] Rudychenko VM, et al. **Lik Sprava** 1995 Mar–Apr;(3–4):132–5 (Eng. Abstr.) **(Ukr)**

TOXICITY

Glomerular compromise in mercuric chloride-induced nephrotoxicity. Girardi G, et al. **J Biochem Toxicol** 1996; 11(4):189–96

Effects of sanguinarium, chlorhexidine and tetracycline on neutrophil viability and functions in vitro. Agarwal S, et al. **J Periodontal Res** 1997 Apr;32(3):335–44

Effect of furazolidone on sister-chromatid exchanges, cell proliferation kinetics, and mitotic index in vivo and in vitro. Madrigal-Bujaidar E, et al. **J Toxicol Environ Health** 1997 May;51(1):89–96

Nasal lesions induced by intranasal administration of benzalkonium chloride in rats. Kuboyama Y, et al. **J Toxicol Sci** 1997 May;22(2):153–60

Sodium lauryl sulfate and triclosan: in vitro cytotoxicity studies with gingival cells. Babich H, et al. **Toxicol Lett** 1997 May 16;91(3):189–96

ANTI-INFECTIVE AGENTS, QUINOLONE

Quinolone-resistant Neisseria gonorrhoeae isolated in Sydney, Australia, 1991 to 1995. Tapsall JW, et al. **Sex Transm Dis** 1996 Sep–Oct;23(5):425–8

ADMINISTRATION & DOSAGE

In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Fournet A, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2447–51

Pharmacodynamics of antimicrobial agents and rationale for their dosing. MacGowan AP, et al. **J Chemother** 1997 May; 9 Suppl 1:64–73 (90 ref.)

[The therapeutic potentials of the vaginal antimicrobial preparation Chlorchinaldin] Zlatkov V, et al. **Akush Ginekol (Sofiia)** 1996;35(4):49–50 (Eng. Abstr.) **(Bul)**

[Clinical study of prulifloxacin on infectious enteritis. Japan Research Committee of Prulifloxacin, Research Group on Infectious Enteritis] Tomizawa I, et al. **Kansenshogaku Zasshi** 1996 Jul;70(7):727–45 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Antibiotic-associated hepatitis: update from 1990. Vial T, et al. **Ann Pharmacother** 1997 Feb;31(2):204–20 (162 ref.)

Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Schaefer C, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Nov; 69(2):83–9

ANALYSIS

Liquid chromatographic determination of nalidixic acid in pharmaceutical preparations. Walker ST. **J AOAC Int** 1996 Mar–Apr;79(2):431–3

High-performance liquid chromatographic method for the rapid and simultaneous determination of sulfamonomethoxine, miloxacin and oxolinic acid in serum and muscle of cultured fish. Ueno R, et al. **J Chromatogr B Biomed Appl** 1996 Jun 28;682(1):179–81

CEREBROSPINAL FLUID

Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. Ooie T, et al. **Pharm Res** 1996 Jul;13(7):1065–8

CHEMICAL SYNTHESIS

The synthesis and in vitro antibacterial activity of conformationally restricted quinolone antibacterial agents. Cooper CS, et al. **Bioorg Med Chem** 1996 Aug;4(8):1307–15

Synthesis and antibacterial testing of some new quinolines, pyridazinoquinolines and spiroindoloquinolines. el-Ahl AA, et al. **Boll Chim Farm** 1996 May;135(5):297–300

CHEMISTRY

SRS-A antagonist pyranoquinolone alkaloids from east African Fagara plants and their synthesis. Kamikawa T, et al. **Bioorg Med Chem** 1996 Aug;4(8):1317–20

Chemometric methodologies in a quantitative structure-activity relationship study: the antibacterial activity of 6-aminoquinolones. Cecchetti V, et al. **J Med Chem** 1997 May 23;40(11):1698–706

ECONOMICS

Sequential antimicrobial therapy--the role of quinolones. Nathwani D, et al. **J Antimicrob Chemother** 1997 Apr; 39(4):441–6 (54 ref.)

METABOLISM

Stability constants of copper(II) mixed complexes with some 4-quinolone antibiotics and (N-N) donors. Mendoza-Díaz G, et al. **J Inorg Biochem** 1996 Nov 15;64(3):207–14

PHARMACOKINETICS

Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. Teng R, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):561–6

Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system. Ooie T, et al. **Drug Metab Dispos** 1997 Jul;25(7):784–9

Species differences in the disposition and metabolism of nalidixic acid. Nomeir AA, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):222–30

Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. Ooie T, et al. **Pharm Res** 1996 Jul;13(7):1065–8

PHARMACOLOGY

Uncommon occurrence of mutations in the gyrB gene associated with quinolone resistance in clinical isolates of Neisseria gonorrhoeae [letter] Deguchi T, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2437–8

In vitro modulation of hippocampal pyramidal cell response by quinolones: effects of HA 966 and gamma-hydroxybutyric acid. Dimpfel W, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2573–6

Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Endtz HP, et al. **Antimicrob Agents Chemother** 1997 May; 41(5):1146–9

Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. Klein MB, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):76–9

Identification for mar mutants among quinolone-resistant clinical isolates of Escherichia coli. Maneewannakul K, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1695–8

Cloning and sequencing of a novel gene (recG) that affects the quinolone susceptibility of Staphylococcus aureus. Niga T, et al. **Antimicrob Agents Chemother** 1997 Aug; 41(8):1770–4

Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. Renau TE, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2363–8

Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis. Revel-Viravau V, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2054–61

A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics. Truong QC, et al. **Antimicrob Agents Chemother** 1997 Jan; 41(1):85–90

From chloroquine to antineoplastic drugs? the story of antibacterial quinolones. Rádl S. **Arch Pharm (Weinheim)** 1996 Mar;329(3):115–9 (31 ref.)

Structure-antibacterial activity and cytotoxicity relationships of thiazolo and thiazetoquinolone derivatives. Ozaki M, et al. **Biol Pharm Bull** 1996 Nov;19(11):1457–62

Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Maeda N, et al. **Br J Pharmacol** 1996 Jan;117(2):372–6

Emerging quinolone-resistant Salmonella in the United States. Herikstad H, et al. **Emerg Infect Dis** 1997 Jul–Sep; 3(3):371–2

Resistance of Vibrio cholerae 01 to nalidixic acid. Jesudason MV, et al. **Indian J Med Res** 1997 Apr;105:153–4

Emergence of nalidixic acid resistant Shigella dysenteriae type 1 in Thailand: an outbreak associated with consumption of a coconut milk dessert. Hoge CW, et al. **Int J Epidemiol** 1995 Dec;24(6):1228–32

Quinolone resistance and Campylobacter species [letter] Bowler IC, et al. **J Antimicrob Chemother** 1996 Aug; 38(2):315

The effects of quinolones on the adherence of type-1 fimbriated Escherichia coli to mannosylated agarose beads. Breines DM, et al. **J Antimicrob Chemother** 1995 Dec; 36(6):911–25

Pharmacodynamics of antimicrobial agents and rationale for their dosing. MacGowan AP, et al. **J Chemother** 1997 May; 9 Suppl 1:64–73 (90 ref.)

Prevalence of bacterial resistance to quinolones and other antimicrobials among avian Escherichia coli strains isolated from septicemic and healthy chickens in Spain. Blanco JE, et al. **J Clin Microbiol** 1997 Aug;35(8):2184–5

Simultaneous identification of campylobacters and prediction of quinolone resistance by comparative sequence analysis. Husmann M, et al. **J Clin Microbiol** 1997 Sep; 35(9):2398–400

Chemometric methodologies in a quantitative structure-activity relationship study: the antibacterial activity of 6-aminoquinolones. Cecchetti V, et al. **J Med Chem** 1997 May 23;40(11):1698-706

Analysis of Neisseria gonorrhoeae in Ontario, Canada, with decreased susceptibility to quinolones by pulsed-field gel electrophoresis, auxotyping, serotyping and plasmid content. Harnett N, et al. **J Med Microbiol** 1997 May; 46(5):383-90

Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium. Ruiz J, et al. **J Med Microbiol** 1997 Jul; 46(7):623-8

Increase in synthesis and stability of sigma 32 on treatment with inhibitors of DNA gyrase in Escherichia coli. Mizushima T, et al. **Mol Gen Genet** 1996 Dec 13; 253(3):297-302

Synergy and mechanism of interaction between pefloxacin and penicillin G against enterococci. Grossato A, et al. **New Microbiol** 1997 Jul;20(3):221-5

The influence of postantibiotic effects and postantibiotic effects of sub-inhibitory concentrations of quinolones and aminoglycosides on phospholipase C of Pseudomonas aeruginosa. Hybenová D, et al. **Pharmazie** 1997 Feb; 52(2):157-9

[In vitro and in vivo antibacterial activities of a new quinolone derivative, FD501] Imamori K, et al. **Jpn J Antibiot** 1996 Mar;49(3):264-72 (Eng. Abstr.) **(Jpn)**

[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). III. Secular changes in susceptibility] Kumamoto Y, et al. **Jpn J Antibiot** 1996 Jun; 49(6):555-657 (Eng. Abstr.) **(Jpn)**

[In vitro antibacterial activity of pazufloxacin (PZFX) against clinical isolates from infectious enteritis] Fukuyama M, et al. **Kansenshogaku Zasshi** 1996 Jan;70(1):51-9 (Eng. Abstr.) **(Jpn)**

[Basic and clinical studies of pazufloxacin on infectious enteritis research group of T-3761 on infectious enteritis] Sagara H, et al. **Kansenshogaku Zasshi** 1996 Jan;70(1):60-72 (Eng. Abstr.) **(Jpn)**

[The possibility of drug design of quinolones effective for multiresistant gram-positive pathogens] Hayakawa I. **Nippon Rinsho** 1997 May;55(5):1266-71 (8 ref.) (Eng. Abstr.) **(Jpn)**

[The effect of new quinolone antimicrobial agents and macrolide antibiotics on the clearance of theophylline] Honma M. **Nippon Rinsho** 1996 Nov;54(11):3125-9 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanisms of bacterial resistance to quinolones] Yoshida H. **Nippon Saikingaku Zasshi** 1996 Oct;51(4):973-92 (126 ref.) **(Jpn)**

[The sensitivity of Salmonella strains in diarrheal disease to new quinolones compared with other antimicrobial substances] David E, et al. **Bacteriol Virusol Parazitol Epidemiol** 1996 Jan-Jun; 41(1-2):43-6 (Eng. Abstr.) **(Rum)**

[Mechanisms of resistance to quinolones and current level of sensitivity of clinically important microorganisms to ofloxacin] Sidorenko SV, et al. **Antibiot Khimioter** 1996; 41(9):33-8 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Efficacy of antimicrobial treatment in non-dysenteric persistent diarrhoea in a community setting. Bahl R, et al. **Acta Paediatr** 1996 Nov;85(11):1290-4

In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Fournet A, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2447-51

Treatment of enteric fever with pefloxacin for 7 days versus 5 days: a randomized clinical trial. Unal S, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2898-900

Treating diarrhoea [editorial] Gorbach SL. **BMJ** 1997 Jun 21;314(7097):1776-7

Present situation of multidrug-resistant tuberculosis in Asian countries and the possibility of MDR-TB treatment by new quinolones. Proceedings of a satellite symposium for the 14th Asia Pacific Congress on Diseases of the Chest. Bali, June 26, 1996. **Chemotherapy** 1996;42 Suppl 3:1-35

New generations of quinolones: with particular attention to levofloxacin. Ambrose PG, et al. **Conn Med** 1997 May; 61(5):269-72 (11 ref.)

Sequential antimicrobial therapy--the role of quinolones. Nathwani D, et al. **J Antimicrob Chemother** 1997 Apr; 39(4):441-6 (54 ref.)

First report of vancomycin-resistant Streptococcus mitis bacteremia in a leukemic patient after prophylaxis with quinolones and during treatment with vancomycin [letter] Krcmery V Jr, et al. **J Chemother** 1996 Aug;8(4):325-6

Gonococcal susceptibility to antimicrobials in Baltimore, 1988-1994. What was the impact of ciprofloxacin as first-line therapy for gonorrhea? Zenilman JM. **Sex Transm Dis** 1996 May-Jun;23(3):213-8

Prophylactic antibiotics in renal transplantation. Melchor JL, et al. **Transplant Proc** 1996 Dec;28(6):3305

The Gonococcal Antimicrobial Surveillance Programme (GASP). WHO western Pacific region, 1995. **Wkly Epidemiol Rec** 1997 Jan 31;72(5):25-7 **(Eng, Fre)**

The Gonococcal Antimicrobial Surveillance Programme (GASP). WHO Western Pacific Region. **Wkly Epidemiol Rec** 1996 Oct 11;71(41):309-11 **(Eng, Fre)**

[Basic and clinical studies of pazufloxacin on infectious enteritis research group of T-3761 on infectious enteritis] Sagara H, et al. **Kansenshogaku Zasshi** 1996 Jan;70(1):60-72 (Eng. Abstr.) **(Jpn)**

[Diagnostic criteria and therapy of malignant external otitis] Crovetto de la Torre MA, et al. **Acta Otorrinolaringol Esp** 1996 May-Jun;47(3):175-80 (Eng. Abstr.) **(Spa)**

[The future of quinolones (editorial)] Gomis M, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):463-5 **(Spa)**

TOXICITY

Stimulation of prostaglandin production by quinolone phototoxicity in Balb/c 3T3 mouse fibroblast cells in vitro. Shimoda K, et al. **Fundam Appl Toxicol** 1997 Apr; 36(2):157-62

URINE

False-positive EMIT II opiates from ofloxacin. Meatherall R, et al. **Ther Drug Monit** 1997 Feb;19(1):98-9

ANTI-INFECTIVE AGENTS, TOPICAL see **ANTI-INFECTIVE AGENTS, LOCAL**

ANTI-INFECTIVE AGENTS, URINARY

ADMINISTRATION & DOSAGE

Experiences with the rectal use of trimethoprim. Sallai J, et al. **J Pharm Pharmacol** 1997 May;49(5):496-9

Antikaliuretic action of trimethoprim is minimized by raising urine pH. Schreiber M, et al. **Kidney Int** 1996 Jan;49(1):82-7

Severe hyperkalaemia after cotrimoxazole administration in a patient with hyporeninaemic hypoaldosteronism. Elisaf M, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1254-5

ADVERSE EFFECTS

Bilateral anterior uveitis and retinal haemorrhages after administration of trimethoprim. Kristinsson JK, et al. **Acta Ophthalmol Scand** 1997 Jun;75(3):314-5

Sulfonamide-induced iritis. Northrop CV, et al. **Am J Emerg Med** 1996 Oct;14(6):577-9

You're the flight surgeon. Thrombocytopenia. Bachmann RE Jr. **Aviat Space Environ Med** 1996 Mar;67(3):285-6

Patch testing in an unusual case of toxic epidermal necrolysis. Klein CE, et al. **Contact Dermatitis** 1996 Sep;35(3):175-6

Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection. Hekimsoy Z, et al. **Eur J Endocrinol** 1997 Mar;136(3):304-6

Megaloblastic anaemia and pancytopenia secondary to prophylactic cotrimoxazole therapy. Tapp H, et al. **J Paediatr Child Health** 1997 Apr;33(2):166-7

Trimethoprim-induced aseptic meningitis and uveitis [letter] Gilroy N, et al. **Lancet** 1997 Jul 12;350(9071):112

Acute interstitial nephritis associated with nitrofurantoin [letter] Kahn SR. **Lancet** 1996 Oct 26;348(9035):1177-8

Nitrofurantoin toxicity to both liver and lungs [letter] Yalçin S, et al. **Liver** 1997 Jun;17(3):166-7

Reversible voltage-dependent distal renal tubular acidosis in a patient receiving standard doses of trimethoprim-sulphamethoxazole. Lin SH, et al. **Nephrol Dial Transplant** 1997 May;12(5):1031-3

Nitrofurantoin-induced pulmonary toxicity during pregnancy: a report of a case and review of the literature. Boggess KA, et al. **Obstet Gynecol Surv** 1996 Jun; 51(6):367-70 (19 ref.)

Adverse reactions in children during long-term antimicrobial therapy. Uhari M, et al. **Pediatr Infect Dis J** 1996 May; 15(5):404-8

Nitrofurantoin rechallenge and recurrent toxicity. Bialas MC, et al. **Postgrad Med J** 1997 Aug;73(862):519-20

[Inflammation of the salivary glands attributed to the use of nitrofurantoin] Slappendel AM, et al. **Ned Tijdschr Geneeskd** 1997 Feb 15;141(7):342-3 (Eng. Abstr.) **(Dut)**

ANALYSIS

Determination of trimethoprim and sulphadoxine residues in porcine tissues and plasma. Boison JO, et al. **Can J Vet Res** 1996 Oct;60(4):281-7

Liquid chromatographic determination of nitrofuran residues in bovine muscle tissues. Angelini NM, et al. **J AOAC Int** 1997 May-Jun;80(3):481-5

Determination of methylene blue in channel catfish (Ictalurus punctatus) tissue by liquid chromatography with visible detection. Turnipseed SB, et al. **J AOAC Int** 1997 Jan-Feb; 80(1):31-5

Determination of nitrofurantoin, furazolidone and furaltadone in milk by high-performance liquid chromatography with electrochemical detection. Galeano Díaz T, et al. **J Chromatogr A** 1997 Mar 14;764(2):243-8

Sensitive determination of nitrofurantoin in human plasma and urine by high-performance liquid chromatography. Muth P, et al. **J Chromatogr A** 1996 Apr 5;729(1-2):251-8

Routine determination of flumequine in kidney tissue of pig using automated liquid chromatography. Guyonnet J, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26; 679(1-2):177-84

SPE-HPLC determination of trimetoprim in tissue samples. Brandšteterová E, et al. **Pharmazie** 1996 Dec;51(12):984-6

BLOOD

Contribution of alpha 1-acid glycoprotein to plasma protein binding of some basic antimicrobials in pigs. Son DS, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):176-83

CHEMISTRY

3(3) factorial design-based optimization of the formulation of nitrofurantoin microcapsules. Karasulu HY, et al. **Pharm World Sci** 1996 Jan;18(1):20-5

PHARMACOKINETICS

Analysis of protein-bound metabolites of furazolidone and furaltadone in pig liver by high-performance liquid chromatography and liquid chromatography-mass spectrometry. Horne E, et al. **Analyst** 1996 Oct; 121(10):1463-8

A comparative study of the distribution of ofloxacin and ciprofloxacin in prostatic tissues after simultaneous oral ingestion. Png JC, et al. **Br J Urol** 1997 May;79(5):781-4

Penetration of pefloxacin and its desmethyl metabolite into the uroepithelium after a 800-mg single oral dose in human patients. Moreau JL, et al. **Eur J Clin Pharmacol** 1996; 49(5):401-5

In vivo/in vitro correlations of nitrofurantoin matrix tablet formulations. Karasulu HY, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jan-Mar; 21(1):27-31

In vitro and in vivo binding of trimethoprim and sulphachlorpyridazine to equine food and digesta and their stability in caecal contents. Van Duijkeren E, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):281-7

PHARMACOLOGY

Influence of Uro-Vaxom on sIgA level in urine in children with recurrent urinary tract infections. Czerwionka-Szaflarska M, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(2-3):195-7

In vitro activity of trimethoprim against Borrelia burgdorferi. Reisinger EC, et al. **Eur J Clin Microbiol Infect Dis** 1997 Jun;16(6):458-60

The effect of furazolidone and furaltadone on drug metabolism in rats. Ali BH, et al. **Eur J Drug Metab Pharmacokinet** 1996 Oct-Dec; 21(4):327-32

Effect of cotrimoxazole (Bactrim) on cholesterol metabolism. Pugalendi KV, et al. **Indian J Biochem Biophys** 1996 Apr; 33(2):141-4

[Pharmacology, clinical indications and toxicity of modern fluoroquinolones] Carvalho WA. **Rev Assoc Med Bras** 1995 Jul-Aug;41(4):293-304 (55 ref.) **(Por)**

THERAPEUTIC USE

Managing urinary tract infections. Part 1: diagnosing and treating adults. Duffield P. **Am J Nurs** 1996 Sep; 96(9):16B-16D

In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urinary tract infections. Deguchi T, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1609-11

3-day course of ofloxacin versus cefalexin in the treatment of urinary tract infections in postmenopausal women. Raz R, et al. **Antimicrob Agents Chemother** 1996 Sep; 40(9):2200-1

Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice. Tomii Y, et al. **Arzneimittelforschung** 1996 Dec;46(12):1169-73

Effect of lactobacilli and antibiotics on E. coli urinary infections in mice. Silva de Ruiz C, et al. **Biol Pharm Bull** 1996 Jan;19(1):88-93

Can pregnant patients safely take nitrofurantoin? Koren G. **Can Fam Physician** 1996 Feb;42:245-6

Increases in rates of resistance to trimethoprim. Huovinen P. **Clin Infect Dis** 1997 Jan;24 Suppl 1:S63-6 (37 ref.)

Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections. Mavromanolakis E, et al. **J Chemother** 1997 Jun;9(3):203-7

Antibiotic use in the emergency department. II The aminoglycosides, macrolides, tetracyclines, sulfa drugs, and urinary antiseptics. Graeme KA, et al. **J Emerg Med** 1996 May-Jun;14(3):361-71 (90 ref.)

Urinary tract infection in women [letter; comment] Dodds WN. **J R Coll Physicians Lond** 1997 May-Jun;31(3):341. Comment on: J R Coll Physicians Lond 1997 Mar-Apr;31(2):130-3.

Sulfamethoxazole/trimethoprim therapy for polymyalgia rheumatica. Report of 5 cases [letter] Galezowski N, et al. **J Rheumatol** 1997 Jul;24(7):1451-2

Cotrimoxazole: rationale for re-examining its indications for use. Schaeffer AJ. **J Urol** 1997 Oct;158(4):1651-2

Adverse reactions in children during long-term antimicrobial therapy. Uhari M, et al. **Pediatr Infect Dis J** 1996 May; 15(5):404-8

Intermittent trimethoprim-sulfamethoxazole in children with vesicoureteral reflux. Hori C, et al. **Pediatr Nephrol** 1997 Jun;11(3):328-30

Urinary tract infection. Current management strategies. Wisinger DB. **Postgrad Med** 1996 Nov;100(5):229–36, 239 (25 ref.)

Management of nonobstructive idiopathic feline lower urinary tract disease. Kruger JM, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):571–88 (65 ref.)

[Pefloxacin as a treatment for nephrotic syndrome caused by minimal glomerular lesions in the adult: promises or deception? (editorial; comment)] Moulin B. **Nephrologie** 1997;18(3):79–80. Comment on: Nephrologie 1997 ;18(3):95–101. **(Fre)**

[Pefloxacin as a first-line treatment for nephrotic syndrome in minimal glomerular lesions in the adult. Multicenter study of 32 patients (see comments)] Pruna A, et al. **Nephrologie** 1997;18(3):95–101 (Eng. Abstr.). Comment in: Nephrologie 1997 ;18(3):79–80. **(Fre)**

[Cystitis treatment with immunoactive Escherichia coli fractions] Conrad S, et al. **Dtsch Med Wochenschr** 1997 Apr 4;122(14):460 **(Ger)**

[Infectiology of the urogenital tract. 4: Quality assurance—antibiotic selection in uncomplicated urinary tract infections] Naber KG. **Fortschr Med** 1997 May 30; 115(15):38–42 **(Ger)**

[Infectiology of the urogenital tract. 5. Therapy of complicated and nosocomial urinary tract infections and of unusual pathogens—selection of antibiotics] Naber KG. **Fortschr Med** 1997 Jun 10;115(16):48–50 **(Ger)**

[Urinary tract infections: risk factors and therapeutic trends] Margariti PA, et al. **Recenti Prog Med** 1997 Feb;88(2):65–8 (28 ref.) (Eng. Abstr.) **(Ita)**

[Clinical study on sulbactam/cefoperazone in urinary tract infections in elderly patients] Oyabu Y. **Jpn J Antibiot** 1996 Mar;49(3):250–5 (Eng. Abstr.) **(Jpn)**

[Evaluation of the effectiveness of Uro-Vaxom in recurrent urinary tract infections in children] Czerwionka-Szaflarska M, et al. **Pediatr Pol** 1996 Jul;71(7):599–604 (Eng. Abstr.) **(Pol)**

[Outlook and experience in using ofloxacin in urology] Derevianko II, et al. **Antibiot Khimioter** 1996;41(9):89–94 (Eng. Abstr.) **(Rus)**

[Clinical experience with the use of ofloxacin in infections of the upper and lower urinary tracts: demonstrations of the results of clinical trials] Liudvig G. **Antibiot Khimioter** 1996;41(9):84–5 (Eng. Abstr.) **(Rus)**

[Various indices of the infectious process in treatment of glanders in monkeys] Manzeniuk IN, et al. **Antibiot Khimioter** 1996 Jan;41(1):13–8 (Eng. Abstr.) **(Rus)**

[Comprehensive treatment with ofloxacin in pyo-inflammatory urologic diseases] Pytel' IuA, et al. **Antibiot Khimioter** 1996;41(9):86–8 (Eng. Abstr.) **(Rus)**

TOXICITY

Mitigation of nitrofurantoin-induced toxicity in the perfused rat liver. Shen W, et al. **Hum Exp Toxicol** 1996 May; 15(5):428–34

Roles of DT diaphorase in the genotoxicity of nitroaromatic compounds in human and fish cell lines. Hasspieler BM, et al. **J Toxicol Environ Health** 1997 Oct 10;52(2):137–48

Reversal of trimethoprim-induced antikaliuresis. Reiser IW, et al. **Kidney Int** 1996 Dec;50(6):2063–9

Reversibility of furazolidone-induced changes in testes and secondary sex characters of White Leghorn cockerels. Siddique M, et al. **Vet Hum Toxicol** 1996 Dec;38(6):413–7

URINE

Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose. Hofbauer H, et al. **Infection** 1997 Mar-Apr; 25(2):121–6

ANTI-INFLAMMATORY AGENTS

Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. Stringer KA, et al. **Free Radic Biol Med** 1997;22(6):985–8

Interleukin-1 receptor antagonist: a "novel" acute phase protein with antiinflammatory activities [editorial; comment] Cominelli F, et al. **J Clin Invest** 1997 Jun 15; 99(12):2813. Comment on: J Clin Invest 1997 Jun 15;99(12):2930–40.

Nitric oxide as antiinflammatory agent. Granger DN, et al. **Methods Enzymol** 1996;269:434–42 (26 ref.)

ADMINISTRATION & DOSAGE

Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study. Mahrle G, et al. **Br J Dermatol** 1996 Nov;135(5):752–7

Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Bessis N, et al. **Eur J Immunol** 1996 Oct; 26(10):2399–403

Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Janson C, et al. **Eur Respir J** 1997 Aug;10(8):1795–802

[Anti-inflammatory and anti-allergic oral vaccines?] Lomholt HB, et al. **Ugeskr Laeger** 1996 Sep 16; 158(38):5273–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Drug therapy of ulcerative colitis] Rückert Y. **Z Arztl Fortbild Qualitatssich** 1997 Mar;91(2):175–9 (31 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

An overview of the adverse reactions to adrenal corticosteroids. Frauman AG. **Adverse Drug React Toxicol Rev** 1996 Nov;15(4):203–6 (12 ref.)

5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Walker AM, et al. **Am J Gastroenterol** 1997 May;92(5):816–20

Holoprosencephaly in a fetus with maternal medication of sulfasalazine in early gestation. A case report. Koyama N, et al. **Clin Exp Obstet Gynecol** 1996;23(3):136–40

Decreased HbA1c levels due to sulfonamide-induced hemolysis in two IDDM patients. Tack CJ, et al. **Diabetes Care** 1996 Jul;19(7):775–6

Hepatotoxicity of analgesics and anti-inflammatory agents. Fry SW, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):875–905 (171 ref.)

Long-term anti-inflammatory drug use and Helicobacter pylori infection: a clinical, endoscopic and histological study. Kulkarni SG, et al. **Indian J Gastroenterol** 1996 Oct; 15(4):118–21

Salazosulfapyridine-induced angioimmunoblastic lymphadenopathy. Nakano A, et al. **Intern Med** 1996 Nov; 35(11):894–7

Pneumonitis induced by sulphasalazine. Peters FP, et al. **Postgrad Med J** 1997 Feb;73(856):99–100

Drug-induced rheumatic disorders. Bannwarth B. **Rev Rhum Engl Ed** 1996 Nov;63(10):639–47 (125 ref.)

CHEMICAL SYNTHESIS

Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors. Hirayama R, et al. **Bioorg Med Chem** 1997 Apr;5(4):765–78

Synthesis and pharmacological profile of novel N-substituted N-[5H-[1]benzopyrano[4,3-d]pyrimidin-2-YL]-N-methylglycinamides. Bruno O, et al. **Farmaco** 1996 Feb; 51(2):137–40

Synthesis and antiinflammatory activity of some imidazolinylpyrazole derivatives. Savelli F, et al. **Farmaco** 1996 Feb;51(2):141–3

CHEMISTRY

Evaluation of propolis. I. Evaluation of Brazilian and Chinese propolis by enzymatic and physico-chemical methods. Miyataka H, et al. **Biol Pharm Bull** 1997 May;20(5):496–501

Chemical and pharmacological studies on fixed oil of Ocimum sanctum. Singh S, et al. **Indian J Exp Biol** 1996 Dec;34(12):1212–5

Modelling of the void space of tablets compacted over a range of pressures. Ridgway CJ, et al. **J Pharm Pharmacol** 1997 Apr;49(4):377–83

Polymorphism and crystallization behavior of Abbott-79175, a second-generation 5-lipoxygenase inhibitor. Li R, et al. **J Pharm Sci** 1996 Jul;85(7):773–80

ISOLATION & PURIFICATION

Tolypodiol, an antiinflammatory diterpenoid from the cyanobacterium Tolypothrix nodosa. Prinsep MR, et al. **J Nat Prod** 1996 Aug;59(8):786–8

PHARMACOKINETICS

Pharmacokinetic considerations in the camel (Camelus dromedarius): a review. Ali BH, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Sep;115(1):1–9 (61 ref.)

Is local biotransformation the key to understanding the pharmacological activity of salicylates and gold drugs? Whitehouse MW, et al. **Inflamm Res** 1996 Dec; 45(12):579–82

PHARMACOLOGY

Cyclosporin A down-regulates the LTA4 hydrolase level in human keratinocyte cultures. Iversen L, et al. **Acta Derm Venereol** 1996 Nov;76(6):424–8

NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Baeuerle PA, et al. **Adv Immunol** 1997;65:111–37 (105 ref.)

Anti-inflammatory and radical scavenge effects of Arctium lappa. Lin CC, et al. **Am J Chin Med** 1996;24(2):127–37

Morelloflavone, a novel biflavonoid inhibitor of human secretory phospholipase A2 with anti-inflammatory activity [published erratum appears in Biochem Pharmacol 1997 Jun 15;53(12):1946] Gil B, et al. **Biochem Pharmacol** 1997 Mar 7;53(5):733–40

Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Pruzanski W, et al. **Biochem Pharmacol** 1997 Jun 15;53(12):1901–7

Evaluation of propolis. I. Evaluation of Brazilian and Chinese propolis by enzymatic and physico-chemical methods. Miyataka H, et al. **Biol Pharm Bull** 1997 May;20(5):496–501

Effect of polyol fatty acid esters on diclofenac permeation through rat skin. Takahashi K, et al. **Biol Pharm Bull** 1996 Jun;19(6):893–6

Assessment of the effect of candidate anti-inflammatory treatments on the interaction between meningococci and inflammatory cells in vitro in a whole blood model. Chan B, et al. **Biotherapy** 1996;9(4):221–8

IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity in PC12 cells. Fagarasan MO, et al. **Brain Res** 1996 Jun 3;723(1-2):231–4

Inhibition of Fc gamma R-dependent functions by N-formylmethionylleucylphenylalanine in human neutrophils. Alves Rosa MF, et al. **Clin Immunol Immunopathol** 1997 May;83(2):147–55

TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. Wisniewski HG, et al. **Cytokine Growth Factor Rev** 1997 Jun;8(2):143–56 (135 ref.)

Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol. Pfeifer S, et al. **Eur J Med Res** 1997 Mar 24;2(3):129–32

Carbamazepine exerts anti-inflammatory effects in the rat. Bianchi M, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):71–4

Modulation of the inflammatory response by corticotropin-releasing factor. Correa SG, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):85–90

Action of anti-inflammatory drugs on interleukin-1 beta-mediated glucose uptake by synoviocytes. Hernvann A, et al. **Eur J Pharmacol** 1996 Oct 24;314(1-2):193–6

Experimental analysis of progressive necrosis after spinal cord trauma in the rat: etiological role of the inflammatory response. Zhang Z, et al. **Exp Neurol** 1997 Jan; 143(1):141–52

New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Tilg H. **Gastroenterology** 1997 Mar;112(3):1017–21 (24 ref.)

Chemokines and liver inflammation: the battle between pro- and anti-inflammatory mediators. Jaeschke H. **Hepatology** 1997 Jan;25(1):252–3

Anti-inflammatory activity of seed extracts of Pongamia pinnata in rat. Singh RK, et al. **Indian J Physiol Pharmacol** 1996 Oct;40(4):355–8

Role of pertussis toxin A subunit in neutrophil migration and vascular permeability. Brito GA, et al. **Infect Immun** 1997 Mar;65(3):1114–8

The use of the chorio-allantoic membrane of the chick embryo as test for anti-inflammatory activity. Beckers M, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S29–30

Ion channel modulation as a drug discovery target in inflammatory diseases. Hanson DC, et al. **Inflamm Res** 1996 Sep;45(9):435–7

Role of endotoxin-like contaminants in the apparent anti-inflammatory activity of bovine superoxide dismutase. Iida M, et al. **Inflamm Res** 1996 Jun;45(6):268–71

Rifamycins inhibit human neutrophil functions: new derivatives with potential antiinflammatory activity. Spisani S, et al. **Inflammation** 1997 Aug;21(4):391–400

Potential role of tachykinins in inflammatory diseases. Canning BJ. **J Allergy Clin Immunol** 1997 May;99(5):579–82 (30 ref.)

Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. Pierce JW, et al. **J Biol Chem** 1997 Aug 22;272(34):21096–103

A novel anti-inflammatory peptide inhibits endothelial cell cytoskeletal rearrangement, nitric oxide synthase translocation, and paracellular permeability increases. Wang Q, et al. **J Cell Physiol** 1997 Aug;172(2):171–82

Antiinflammatory activity of some medicinal plant extracts form Venezuela. Abad MJ, et al. **J Ethnopharmacol** 1996 Dec;55(1):63–8

Antiinflammatory effect of petroleum ether extract of leaves of Litchi chinensis Gaertn. (Sapindaceae). Besra SE, et al. **J Ethnopharmacol** 1996 Oct;54(1):1–6

Antimicrobial and immunological activity of ethanol extracts and fractions from Isopyrum thalictroides. Ivanovska N, et al. **J Ethnopharmacol** 1996 Nov;54(2-3):143–51

Anti-inflammatory effect of Arnebia euchroma root extracts in rats. Kaith BS, et al. **J Ethnopharmacol** 1996 Dec; 55(1):77–80

Evaluation of anti-inflammatory potential of fixed oil of Ocimum sanctum (Holybasil) and its possible mechanism of action. Singh S, et al. **J Ethnopharmacol** 1996 Oct; 54(1):19–26

Antiinflammatory activity of extracts from Aloe vera gel. Vázquez B, et al. **J Ethnopharmacol** 1996 Dec;55(1):69–75

In vivo assessment of hepatic alterations following gadolinium chloride-induced Kupffer cell blockade. Rüttinger D, et al. **J Hepatol** 1996 Dec;25(6):960–7

Novel anti-inflammatory compounds induce shedding of L-selectin and block primary capture of neutrophils under flow conditions. Endemann G, et al. **J Immunol** 1997 May 15;158(10):4879–85

Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect. Pitzalis C, et al. **J Immunol** 1997 May 15;158(10):5007–16

Effects of dexamethasone treatment on IL-1 receptor mRNA levels in vivo. Yu PW, et al. **J Leukoc Biol** 1997 Sep; 62(3):401–4

Antiinflammatory activity of coumarins from Santolina oblongifolia. Silván AM, et al. **J Nat Prod** 1996 Dec; 59(12):1183–5

Tetracycline inhibits Porphyromonas gingivalis lipopolysaccharide-induced lesions in vivo and TNF alpha processing in vitro. Shapira L, et al. **J Periodontal Res** 1997 Jan;32(1 Pt 2):183–8

Variabilin: a dual inhibitor of human secretory and cytosolic phospholipase A2 with anti-inflammatory activity. Escrig

V, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):123-31

BMS-190394, a selectin inhibitor, prevents rat cutaneous inflammatory reactions. Todderud G, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1298-304

Effect of FR133605, a novel cytokine suppressive agent, on bone and cartilage destruction in adjuvant arthritic rats. Yamamoto N, et al. **J Rheumatol** 1996 Oct;23(10):1778-83

Regulation of prostaglandin synthesis by antiinflammatory drugs. Robinson DR. **J Rheumatol Suppl** 1997 Feb;47:32-9 (33 ref.)

Sulfo-Lewis(x) diminishes neutrophil infiltration and free radicals with minimal effect on serum cytokines after liver ischemia and reperfusion. Garcia-Criado FJ, et al. **J Surg Res** 1997 Jul 1;70(2):187-94

Attenuation of acute lung injury caused by hind-limb ischemia-reperfusion injury by butyrolactone anti-inflammatory agent FL1003. Cohen SM, et al. **J Trauma** 1997 Aug;43(2):247-52; discussion 252

Antiinflammatory activity of topically applied sertaconazole nitrate. Agut J, et al. **Methods Find Exp Clin Pharmacol** 1996 May;18(4):233-4

Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Vayssière BM, et al. **Mol Endocrinol** 1997 Aug; 11(9):1245-55

T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease. Manolios N, et al. **Nat Med** 1997 Jan;3(1):84-8

Inhibition of hind-paw edema and cutaneous vascular plasma extravasation by 2-chloro-3-methoxycarbonylpropionamido-1,4-naphthoquinone (PP1D1) in mice. Wang JP, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Dec; 354(6):779-84

Pharmacological studies of cardamom oil in animals. al-Zuhair H, et al. **Pharmacol Res** 1996 Jul-Aug; 34(1-2):79-82

Anti-inflammatory, antipyretic, and analgesic effects of Lawsonia inermis L. (henna) in rats. Ali BH, et al. **Pharmacology** 1995 Dec;51(6):356-63

Anti-inflammatory effects of beraprost sodium, a stable analogue of PGI2, and its mechanisms. Ueno Y, et al. **Prostaglandins** 1997 Apr;53(4):279-89

Granulocyte-macrophage colony stimulating factors (GM-CSF) and interleukin 8 (IL-8) production by human bronchial epithelial cells (HBEC) in asthmatics and controls. Lack of in vitro effect of salbutamol compared to sodium nedocromil. Gormand F, et al. **Pulm Pharmacol** 1995 Apr-Jun;8(2-3):107-13

A quantitative structure activity study on a new class of highly potent antiinflammatory agents. Dimitra HL. **Res Commun Mol Pathol Pharmacol** 1997 Mar;95(3):331-41

Gadolinium chloride reduces cytochrome P450: relevance to chemical-induced hepatotoxicity. Badger DA, et al. **Toxicology** 1997 Aug 15;121(2):143-53

Gadolinium chloride-induced macrophage blockade prevents rejection of human insulinoma cell xenograft in rats. Lázár G Jr, et al. **Transplantation** 1997 Mar 15;63(5):729-32

[Inhibitory effect of interleukin-10 on inflammatory reaction in rat mesangial cells] Dai Z, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jun;76(6):407-10 (Eng. Abstr.) **(Chi)**

[Animal models used for the evaluation of anti-osteoarthritis drugs] Smith MM, et al. **Pathol Biol (Paris)** 1997 Apr; 45(4):313-20 (Eng. Abstr.) **(Fre)**

[Pharmacology of airway inflammation--special reference to hypersecretion of the mucous] Miyata K, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):144-6 (0 ref.) **(Jpn)**

[Chemotactic activity of neutrophils from atopic and non-atopic subjects--effect of sodium cromoglycate (DSCG)] Szkudlińska B, et al. **Pneumonol Alergol Pol** 1996; 64(7-8):379-85 (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Anti-inflammatory effects of emodin from ventilago leiocarpa. Chang CH, et al. **Am J Chin Med** 1996; 24(2):139-42

Treatment strategies designed to minimize medical complications of allergic rhinitis. Fireman P. **Am J Rhinol** 1997 Mar-Apr;11(2):95-102 (42 ref.)

Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial. Egsmose C, et al. **Ann Rheum Dis** 1997 Jan;56(1):32-6

Anti-inflammatory therapy reduces wheezing after bronchiolitis [letter; comment] Hakim A. **Arch Pediatr Adolesc Med** 1997 Jan;151(1):108-9. Comment on: Arch Pediatr Adolesc Med 1996 May;150(5):512-7.

Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Clegg DO, et al. **Arthritis Rheum** 1996 Dec;39(12):2021-7

Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Clegg DO, et al. **Arthritis Rheum** 1996 Dec;39(12):2004-12

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Clegg DO, et al. **Arthritis Rheum** 1996 Dec;39(12):2013-20

Treatment of collagenous colitis with methotrexate [letter] Bhullar DS, et al. **Aust N Z J Med** 1996 Feb;26(1):114

Therapeutic strategies for the inhibition of inducible nitric oxide synthase--potential for a novel class of anti-inflammatory agents. Pfeilschifter J, et al. **Cell Biol Int** 1996 Jan;20(1):51-8 (40 ref.)

Effect of the basidiomycete Poria cocos on experimental dermatitis and other inflammatory conditions. Cuellar MJ, et al. **Chem Pharm Bull (Tokyo)** 1997 Mar;45(3):492-4

Anti-inflammatory effect of suplatast tosilate on mild asthma [letter] Sano Y, et al. **Chest** 1997 Sep;112(3):862-3

Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment [editorial; comment] Zeni F, et al. **Crit Care Med** 1997 Jul;25(7):1095-100 (38 ref.). Comment on: Crit Care Med 1997 Jul;25(7):1115-24.

Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Moody GA, et al. **Eur J Gastroenterol Hepatol** 1996 Dec;8(12):1179-83

Antiplaque, antibacterial, and anti-inflammatory properties of triclosan mouthrinses in combination with zinc citrate or polyvinylmethylether maleic acid (PVM-MA) copolymer. Kjaerheim V, et al. **Eur J Oral Sci** 1996 Oct-Dec;104(5-6):529-34

Anti-inflammatory properties of interleukin-10 administration in hapten-induced colitis. Ribbons KA, et al. **Eur J Pharmacol** 1997 Apr 4;323(2-3):245-54

Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Compliance Working Group. Braunstein GL, et al. **Eur Respir J** 1996 May; 9(5):893-8

Nedocromil sodium in obstructive airways disease: effect on symptoms and plasma protein leakage in sputum. Schoonbrood DF, et al. **Eur Respir J** 1997 Jul;10(7):1500-6

A stepped-care approach to asthma management. Stoloff SW. **Hosp Pract (Off Ed)** 1996 Nov 15;31(11):33-4, 39

Investigations of anti-inflammatory activity of Jigrine. Karunakar N, et al. **Indian J Physiol Pharmacol** 1997 Apr; 41(2):134-8

The effect of prostaglandin E1 on experimental colitis in the rat. Terzioğlu T, et al. **Int J Colorectal Dis** 1997;12(2):63-6

Efficacy of sulfasalazine in discoid lupus erythematosus. Artüz F, et al. **Int J Dermatol** 1996 Oct;35(10):746-8

New directions in therapy for ocular allergy. el-Defrawy S, et al. **Int Ophthalmol Clin** 1996 Spring;36(2):25-44 (121 ref.)

A rationale for the use of nedocromil sodium in the treatment of asthma. Holgate ST. **J Allergy Clin Immunol** 1996 Nov; 98(5 Pt 2):S157-60

New insights into the pathogenesis and management of steroid-resistant asthma. Spahn JD, et al. **J Asthma** 1997; 34(3):177-94 (150 ref.)

Anti-inflammatory activity of Salacia oblonga Wall. and Azima tetracantha Lam. Ismail TS, et al. **J Ethnopharmacol** 1997 Apr;56(2):145-52

Effects of doxycycline and antiinflammatory agents on experimentally induced chlamydial upper genital tract infection in female macaques. Patton DL, et al. **J Infect Dis** 1997 Mar;175(3):648-54

Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide. Bahr GM, et al. **J Interferon Cytokine Res** 1996 Apr;16(4):297-306

Medical treatment for inflammatory bowel disease--refinements and new modalities [editorial] Löfberg R. **J Intern Med** 1997 Jan;241(1):1-4 (24 ref.)

Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. Hanifin JM, et al. **J Invest Dermatol** 1996 Jul;107(1):51-6

Methotrexate treatment of Wegener granulomatosis in children. Gottlieb BS, et al. **J Pediatr** 1996 Oct;129(4):604-7

New ulcerative colitis model induced by sulfhydryl blockers in rats and the effects of antiinflammatory drugs on the colitis. Satoh H, et al. **Jpn J Pharmacol** 1997 Apr; 73(4):299-309

Colchicine versus prednisone as treatment of usual interstitial pneumonia [see comments] Douglas WW, et al. **Mayo Clin Proc** 1997 Mar;72(3):201-9. Comment in: Mayo Clin Proc 1997 Mar;72(3):285-7.

Antiinflammatory activity of topically applied sertaconazole nitrate. Agut J, et al. **Methods Find Exp Clin Pharmacol** 1996 May;18(4):233-4

Therapeutic applications of anti-cytokine strategies. Poole S. **Mol Psychiatry** 1997 Mar;2(2):137-8 (20 ref.)

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies [see comments] McGeer PL, et al. **Neurology** 1996 Aug;47(2):425-32. Comment in: Neurology 1997 May;48(5):1473-4.

Anti-inflammatory therapy in cystic fibrosis. Dinwiddie R, et al. **Pediatr Allergy Immunol** 1996;7(9 Suppl):70-3 (24 ref.)

Effects of various analgesic and anti-inflammatory drugs on endotoxin-induced hyperalgesia in rats and mice. Kanaan SA, et al. **Pharmacology** 1997 Jun;54(6):285-97

Automated application of clinical practice guidelines for asthma management. Ertle AR, et al. **Proc AMIA Annu Fall Symp** 1996;:552-6

Effective asthma control--time for physician and pharmacist to join forces [letter] Morris A. **S Afr Med J** 1997 Jul; 87(7):908

Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug. Evidence for chronic encephalopathic processes following ischemia. Coimbra C, et al. **Stroke** 1996 Sep;27(9):1578-85

Behavioral and pharmacologic approaches to problem urination in cats. Hart BL. **Vet Clin North Am Small Anim Pract** 1996 May;26(3):651-8 (12 ref.)

Management of nonobstructive idiopathic feline lower urinary tract disease. Kruger JM, et al. **Vet Clin North Am Small Anim Pract** 1996 May; 26(3):571-88 (65 ref.)

[Treatment of vasculitis] Friman C. **Duodecim** 1995; 111(10):978-89 (64 ref.) **(Fin)**

[Use of an experimental Chlamydia trachomatis salpingitis model for evaluating the effectiveness of antibiotics and anti-inflammatory agents on fertility] Verhoest P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1997;26(3):309-14 (Eng. Abstr.) **(Fre)**

[Animal models used for the evaluation of anti-osteoarthritis drugs] Smith MM, et al. **Pathol Biol (Paris)** 1997 Apr; 45(4):313-20 (Eng. Abstr.) **(Fre)**

[Icelandic moss lozenges in the prevention or treatment of oral mucosa irritation and dried out throat mucosa] Kempe C, et al. **Laryngorhinootologie** 1997 Mar;76(3):186-8 (Eng. Abstr.) **(Ger)**

[Comprehensive treatment with ofloxacin in pyo-inflammatory urologic diseases] Pytel' IuA, et al. **Antibiot Khimioter** 1996;41(9):86-8 (Eng. Abstr.) **(Rus)**

[Tailed. New options in therapy of bronchial asthma] Pribylova NN, et al. **Klin Med (Mosk)** 1997;75(1):38-40 (Eng. Abstr.) **(Rus)**

[The characteristics of the anti-inflammatory action of preparations used in dentistry] Krylov IuF, et al. **Stomatologiia (Mosk)** 1995;74(6):58-63 **(Rus)**

[The use of serpens for treating patients with benign prostatic hyperplasia] Mazo EB, et al. **Ter Arkh** 1996;68(10):47-9 (Eng. Abstr.) **(Rus)**

[Anti-inflammatory activity of aqua-bis(2,Y-diacetoxybenzoate)-copper complexes (Y=4, 5 or 6)] Sokolík J, et al. **Ceska Slov Farm** 1997 Apr; 46(2):88-90 (Eng. Abstr.) **(Slo)**

[Colchicine treatment for recurrent pericarditis] Rodríguez Blanco VM, et al. **An Med Interna** 1997 Feb;14(2):98-100 (24 ref.) (Eng. Abstr.) **(Spa)**

[Tetracyclines as anti-inflammatory treatment in skin diseases] Autio P, et al. **Nord Med** 1996 Dec;111(10):348-51 (15 ref.) (Eng. Abstr.) **(Swe)**

TOXICITY

Mechanistic studies on genotoxicity and carcinogenicity of salicylazosulfapyridine an anti-inflammatory medicine. Iatropoulos MJ, et al. **Exp Toxicol Pathol** 1997 Feb; 49(1-2):15-28

Epileptogenic activity induced by combined treatment with antiinflammatory drugs and enoxacin and its inhibition by a calcium antagonist, nicardipine. Kamei C, et al. **Methods Find Exp Clin Pharmacol** 1996 Nov;18(9):579-88

ANTI-INFLAMMATORY AGENTS, GOLD see **ANTIRHEUMATIC AGENTS, GOLD**

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL

Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Appleyard CB, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):G42-8

Local analgesia effect of nonsteroidal antiinflammatory drugs [letter; comment] Reuben SS, et al. **Anesth Analg** 1997 May; 84(5):1168-9. Comment on: Anesth Analg 1996 Dec;83(6):1239-43.

Comparative efficacy and tolerability of two diclofenac formulations in the treatment of painful osteoarthritis. Bakshi R. **Br J Clin Pract** 1996 Sep;50(6):294-7

Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Brogden RN, et al. **Drugs** 1996 Jul;52(1):113-24 (52 ref.)

Nimesulide. Rajeshwari K, et al. **Indian Pediatr** 1997 Feb; 34(2):119-22 (22 ref.)

Recent Advances on NSAID and NSAID Gastropathy, 1st annual meeting. Ferrara, Italy, 6-7 December 1996. Proceedings. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:1-41

High-performance liquid chromatography of flufenamic acid in rat plasma. Cerretani D, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):365-8

The indomethacin-induced gastric mucosal damage in rats. Effect of gastric acid, acid inhibition, capsaicin-type agents and prostacyclin. Abdel Salam OM, et al. **J Physiol Paris** 1997 Feb;91(1):7-19

Mode of food intake reduction in Lewis rats with indomethacin-induced ulcerative ileitis. Veerabagu MP, et al. **Physiol Behav** 1996 Aug;60(2):381-7

Risk factors between analgesic use and chronic nephropathy in Thailand. Kantachuvesiri S, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):350-5

[Selective inhibitors of cyclooxygenase-2 in upgrade in nonsteroidal anti-inflammatory drugs] Sherer Y, et al. **Harefuah** 1997 Mar 16;132(6):411-6 (28 ref.) **(Heb)**

[Selective inhibitors of COX-2: new anti-inflammatory

agents without gastric-damaging effects (editorial)] Clària J. **Gastroenterol Hepatol** 1997 Jun-Jul;20(6):309-11 **(Spa)**
[Selective inhibitors of cyclooxygenase-2. New agents against pain and inflammation] Oliw E. **Lakartidningen** 1997 May 7;94(19):1797-801 (14 ref.) (Eng. Abstr.) **(Swe)**

ADMINISTRATION & DOSAGE

Timing of perioperative non-steroidal anti-inflammatory drug treatment. Camu F, et al. **Acta Anaesthesiol Belg** 1996; 47(3):125-8 (25 ref.)

Intra-articular tenoxicam relieves post-arthroscopy pain. Elhakim M, et al. **Acta Anaesthesiol Scand** 1996 Nov; 40(10):1223-6

Intravenous ketoprofen for pain relief after total hip or knee replacement. Kostamovaara PA, et al.
Acta Anaesthesiol Scand 1996 Jul;40(6):697-703

Preoperative application of piroxicam gel compared to a local anaesthetic field block for postoperative analgesia. O'Hanlon JJ, et al. **Acta Anaesthesiol Scand** 1996 Jul; 40(6):715-8

Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis. Lucidarme D, et al.
Aliment Pharmacol Ther 1997 Apr;11(2):335-40

Optimizing postoperative pain management [see comments] Carpenter RL. **Am Fam Physician** 1997 Sep 1;56(3):835-44, 847-50 (23 ref.). Comment in: Am Fam Physician 1997 Sep 1;56(3):726, 731-2.

Using balanced analgesia for postoperative pain. Pasero CL, et al. **Am J Nurs** 1996 Dec;96(12):17

Preemptive analgesia: it starts before surgery [published erratum appears in Am J Nurs 1997 Feb;97(2):16] Pasero CL, et al. **Am J Nurs** 1996 Dec;96(12):17-8

IPDAS: a novel technology brings new benefits when applied to naproxen sodium. Devane JG, et al. **Am J Orthop** 1996 Sep;25(9 Suppl):7-13

Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma. Shimizu T, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):170-3

A comparison of intramuscular ketorolac with indomethacin suppositories in the treatment of pain after oral surgery. Turner GA, et al. **Anaesth Intensive Care** 1996 Dec; 24(6):665-8

Patient consent and rectal drug administration [letter; comment] Vyvyan HA. **Anaesthesia** 1996 Sep;51(9):895. Comment on: Anaesthesia 1996 Apr;51(4):402.

The addition of continuous intravenous infusion of ketorolac to a patient-controlled analgetic morphine regime reduced postoperative myocardial ischemia in patients undergoing elective total hip or knee arthroplasty [see comments] Beattie WS, et al. **Anesth Analg** 1997 Apr;84(4):715-22. Comment in: Anesth Analg 1997 Apr;84(4):709-11.

Effect on postoperative analgesia of small-dose lysine acetylsalicylate added to prilocaine during intravenous regional anesthesia. Corpataux JB, et al. **Anesth Analg** 1997 May;84(5):1081-5

Effects of ketorolac versus bupivacaine coadministration during patient-controlled hydromorphone epidural analgesia after thoracotomy procedures. Singh H, et al. **Anesth Analg** 1997 Mar;84(3):564-9

Isobolographic analysis of interactions between intravenous morphine, propacetamol, and diclofenac in carrageenin-injected rats. Fletcher D, et al.
Anesthesiology 1997 Aug;87(2):317-26

Ultralow concentrations of ibuprofen activate cell prostaglandin synthesis. Sergeeva MG, et al.
Appl Biochem Biotechnol 1996 Oct-Nov;61(1-2):167-71

Topical 0.5% ketorolac vs 0.03% flurbiprofen for inhibition of miosis during cataract surgery. Solomon KD, et al.
Arch Ophthalmol 1997 Sep;115(9):1119-22

Aspirin in chloroform as an effective adjuvant in the management of chronic neurogenic pain. Tharion G, et al. **Arch Phys Med Rehabil** 1997 Apr;78(4):437-9

Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Youssef PP, et al.
Arthritis Rheum 1997 Aug;40(8):1400-8

Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Dominkus M, et al.
Arzneimittelforschung 1996 Dec;46(12):1138-43

Pharmacokinetics and drug input characteristics for a diclofenac-codeine phosphate combination following oral and rectal administration. Hanses A, et al.
Arzneimittelforschung 1996 Jan;46(1):57-63

Evaluation of topical 0.03% flurbiprofen drops in the treatment of herpetic stromal keratitis. Vajpayee RB, et al. **Aust N Z J Ophthalmol** 1996 May;24(2):131-5

Sustained release of flufenamic acid from a drug-triacetyl-beta-cyclodextrin complex. Nakanishi K, et al. **Biol Pharm Bull** 1997 Jan;20(1):66-70

In vivo/in vitro correlations for four differently dissolving ketorolac tablets. Gordon MS, et al.
Biopharm Drug Dispos 1996 Aug;17(6):481-92

Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain. Potter M, et al. **Blood** 1997 Jul 1;90(1):260-9

Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats. al Gohary OM, et al. **Boll Chim Farm** 1996 Jul-Aug; 135(7):421-8

Topical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis [letter] Rymes N, et al. **Bone Marrow Transplant** 1996 Aug;18(2):484

A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. Leitich H, et al.
Br J Obstet Gynaecol 1997 Apr;104(4):450-9

Effects of indomethacin administration on bone turnover and bone mass in adjuvant-induced arthritis in rats. Aota S, et al. **Calcif Tissue Int** 1996 Nov;59(5):385-91

Postoperative analgesia with i.v. propacetamol and ketoprofen combination after disc surgery. Fletcher D, et al. **Can J Anaesth** 1997 May;44(5 Pt 1):479-85

Improved postoperative analgesia with preoperative piroxicam [see comments] O'Hanlon JJ, et al.
Can J Anaesth 1996 Feb;43(2):102-5. Comment in: Can J Anaesth 1996 Feb;43(2):97-101.

Pre-emptive analgesia: what does it mean to the clinical anaesthetist? [editorial; comment] [see comments] Penning JP. **Can J Anaesth** 1996 Feb;43(2):97-101. Comment on: Can J Anaesth 1996 Feb;43(2):102-5. Comment in: Can J Anaesth 1997 Jan;44(1):101-2.

Transdermal fentanyl system plus im ketorolac for the treatment of postoperative pain. Reinhart DJ, et al.
Can J Anaesth 1997 Apr;44(4):377-84

Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Hirota C, et al. **Cancer** 1996 Oct 15;78(8):1660-5

Topical administration of racemic ibuprofen. Millership JS, et al. **Chirality** 1997;9(3):313-6

Oral indomethacin and ranitidine in advanced melanoma: a phase II study. Mertens WC, et al.
Clin Oncol (R Coll Radiol) 1996;8(2):112-5

Efficacy and tolerability of a topical NSAID patch (local action transcutaneous flurbiprofen) and oral diclofenac in the treatment of soft-tissue rheumatism. Martens M.
Clin Rheumatol 1997 Jan;16(1):25-31

A clinical evaluation of flurbiprofen LAT and piroxicam gel: a multicentre study in general practice. Ritchie LD.
Clin Rheumatol 1996 May;15(3):243-7

Clinical evaluation of indomethacin-containing patches for osteoarthritis and extremity trauma. Hatori M, et al.
Curr Med Res Opin 1997;13(9):511-5

Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Muir N, et al. **Curr Med Res Opin** 1997; 13(9):491-500

Nonsteroidal antiinflammatory drugs and breast cancer. Harris RE, et al. **Epidemiology** 1996 Mar;7(2):203-5

Risk factors for pregnancy-induced hypertension in women at high risk for the condition. Italian Study of Aspirin in Pregnancy Group. Parazzini F, et al. **Epidemiology** 1996 May;7(3):306-8

Intravenous administration of tenoxicam 40 mg for post-operative analgesia: a double-blind, placebo-controlled multicentre study. Vandermeulen EP, et al. **Eur J Anaesthesiol** 1997 May;14(3):250-7

Comparison of the antinociception produced by two oral formulations of ibuprofen: ibuprofen effervescent vs ibuprofen tablets. Hummel T, et al.
Eur J Clin Pharmacol 1997;52(2):107-14

Comparative pharmacokinetics of Aspegic 1000 mg i.v. versus 1000 mg i.m. thrice daily. Nia B, et al.
Eur J Drug Metab Pharmacokinet 1996 Oct-Dec; 21(4):333-8

Antiflammin 1 peptide delivered non-invasively by iontophoresis reduces irritant-induced inflammation in vivo. Mize NK, et al. **Exp Dermatol** 1997 Aug;6(4):181-5

Prescribing nonsteroidal anti-inflammatory drugs together with antisecretory agents is safe but may be useless [editorial; comment] Guarner F. **Gastroenterology** 1996 Oct;111(4):1145-6. Comment on: Gastroenterology 1996 Oct;111(4):990-5.

Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats [see comments] Lichtenberger LM, et al.
Gastroenterology 1996 Oct;111(4):990-5. Comment in: Gastroenterology 1996 Oct;111(4):1145-7.

Gastrointestinal endoscopy in patients taking antiplatelet agents and anticoagulants: survey of ASGE members. American Society for Gastrointestinal Endoscopy. Kadakia SC, et al. **Gastrointest Endosc** 1996 Sep;44(3):309-16

Regression of gastric polyps in Gardner's syndrome with use of indomethacin suppositories: a case report. Hirata K, et al. **Hepatogastroenterology** 1997 May-Jun;44(15):918-20

Topical flurbiprofen therapy in vernal keratoconjunctivitis. Sud RN, et al. **Indian J Med Sci** 1995 Sep;49(9):205-9

Topical drug vehicle effects on skin and inflammation [letter] Seed MP, et al. **Inflamm Res** 1997 Jun;46(6):191-2

The use of low-dose aspirin to prevent preeclampsia. Herabutya Y, et al. **Int J Gynaecol Obstet** 1996 Aug; 54(2):177-8

Efficacy of ketorolac tromethamine and extrapleural intercostal nerve block on post-thoracotomy pain. A prospective, randomized study. Carretta A, et al.
Int Surg 1996 Jul-Sep;81(3):224-8

Patient attitudes to perioperative suppository administration for postoperative analgesia. Carroll M, et al.
Ir J Med Sci 1996 Oct-Dec;165(4):286-8

Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments. Caron D, et al.
J Am Acad Dermatol 1997 Jun;36(6 Pt 2):S113-5

Adapalene 0.1% gel has low skin-irritation potential. Verschoore M, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 2):S104-9

Short-course indomethacin prevents heterotopic ossification in a high-risk population following total hip arthroplasty. Amstutz HC, et al. **J Arthroplasty** 1997 Feb;12(2):126-32

Polymeric drugs derived from ibuprofen with improved antiinflammatory profile. Liso PA, et al.
J Biomed Mater Res 1996 Dec;32(4):553-60

Effectiveness of topical diclofenac in relieving photophobia after pupil dilation. Chitkara DK, et al.
J Cataract Refract Surg 1997 Jun;23(5):740-4

Efficacy and tolerance of diclofenac sodium 0.1%, flurbiprofen 0.03%, and indomethacin 1.0% in controlling postoperative inflammation. Diestelhorst M, et al.
J Cataract Refract Surg 1996;22 Suppl 1:788-93

Effect of intraocular sustained release of indomethacin on postoperative inflammation and posterior capsule opacification. Nishi O, et al. **J Cataract Refract Surg** 1996; 22 Suppl 1:806-10

Inhibition of posterior capsule opacification by an intraocular-lens-bound sustained drug delivery system: an experimental animal study and literature review. Tetz MR, et al. **J Cataract Refract Surg** 1996 Oct;22(8):1070-8 (49 ref.)

Use of topical NSAIDs in patients receiving systemic NSAID treatment: a pharmacy-based study in Germany. Sift Carter R, et al. **J Clin Epidemiol** 1997 Feb;50(2):217-8

Immune thrombocytopenia and ulcerative colitis: response to nonoperative therapy. McCaulley ME.
J Clin Gastroenterol 1996 Oct;23(3):242-3

5-Aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis. Odes HS. **J Clin Gastroenterol** 1997 Jun;24(4):287-8

Improving drug use in rheumatic disorders. Peterson GM, et al. **J Clin Pharm Ther** 1996 Aug;21(4):215-20

Targeting naproxen to non-parenchymal liver cells protects against endotoxin induced liver damage. Lebbe C, et al.
J Drug Target 1997;4(5):303-10

Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. Takaya T, et al.
J Drug Target 1997;4(5):271-6

Oral vs i.v. steroids for asthma. Margo K, et al.
J Fam Pract 1997 May;44(5):441

Aspirin preparation and risk of GI bleeding. Rao G.
J Fam Pract 1997 Mar;44(3):242-3

Topical piroxicam and conjunctivitis. Kosrirukvongs P.
J Med Assoc Thai 1997 May;80(5):287-92

Randomized controlled trial of dexamethasone in infectious croup. Sumboonnanonda A, et al. **J Med Assoc Thai** 1997 Apr;80(4):262-5

Topical analgesics, indomethacin plaster and diclofenac emulgel for low back pain: a parallel study. Waikakul S, et al. **J Med Assoc Thai** 1996 Aug;79(8):486-90

Chemical, dissolution stability and microscopic evaluation of suspensions of ibuprofen and sustained release ibuprofen-wax microspheres. Adeyeye CM, et al.
J Microencapsul 1997 May-Jun;14(3):357-77

Stereospecific formulation and characterization of sustained release ibuprofen microspheres. Janjikhel RK, et al.
J Microencapsul 1997 Jul-Aug;14(4):409-26

Indomethacin loaded chitosan microspheres. Correlation between the erosion process and release kinetics. Orienti I, et al. **J Microencapsul** 1996 Jul-Aug;13(4):463-72

The influence of microencapsulation using Eudragit RS100 on the hydrolysis kinetics of acetylsalicylic acid. Vachon MG, et al. **J Microencapsul** 1997 May-Jun;14(3):281-301

Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. Ruffin MT 4th, et al. **J Natl Cancer Inst** 1997 Aug 6;89(15):1152-60

One course versus two courses of antithymocyte globulin for the treatment of severe aplastic anemia in children. Matloub YH, et al. **J Pediatr Hematol Oncol** 1997 Mar-Apr;19(2):110-4

Effect of particle shape of acetyl salicylic acid powders on gastric damages in rats. Zolfaghari ME, et al.
J Pharm Belg 1997 Jan-Feb;52(1):1-6

Biodegradable injectable implant systems for long term drug delivery using poly (lactic-co-glycolic) acid copolymers. Chandrashekar G, et al. **J Pharm Pharmacol** 1996 Jul; 48(7):669-74

Anti-inflammatory activity of polyphosphazene-based naproxen slow-release systems. Conforti A, et al.
J Pharm Pharmacol 1996 May;48(5):468-73

Diclofenac sodium attenuates neural activity after photorefractive keratectomy in rabbits. Beuerman RW, et al. **J Refract Surg** 1996 Nov-Dec;12(7):783-91

Topical diclofenac sodium after excimer laser phototherapeutic keratectomy. Förster W, et al.
J Refract Surg 1997 May-Jun;13(3):311-3

Diclofenac and ketorolac in the treatment of pain after photorefractive keratectomy. Weinstock VM, et al.
J Refract Surg 1996 Nov-Dec;12(7):792-4

The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. Batlle-Gualda E, et al. **J Rheumatol** 1996 Jul; 23(7):1200-6

Efficacy and safety of meloxicam in patients with rheumatoid arthritis. Lemmel EM, et al. **J Rheumatol** 1997 Feb; 24(2):282-90

Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac

in Ankylosing Spondylitis. Villa Alcázar LF, et al. **J Rheumatol** 1996 Jul;23(7):1194–9

Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group. Lightfoot R. **J Rheumatol Suppl** 1997 Feb;47:10–6

Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. Neustadt DH. **J Rheumatol Suppl** 1997 Feb;47:17–22

Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. Schnitzer TJ, et al. **J Rheumatol Suppl** 1997 Feb; 47:23–31

Low dose etodolac in rheumatoid arthritis: a review of early studies. Spencer-Green G. **J Rheumatol Suppl** 1997 Feb; 47:3–9; discussion 48–50

Effects of early indomethacin administration on oxygenation and surfactant requirement in low birth weight infants. Yaseen H, et al. **J Trop Pediatr** 1997 Feb;43(1):42–6

A nonsurgical approach to the treatment of phimosis: local nonsteroidal anti-inflammatory ointment application. Atilla MK, et al. **J Urol** 1997 Jul;158(1):196–7

Gastric safety and enteric-coated aspirin [letter] Elwood P. **Lancet** 1997 Feb 8;349(9049):432

Copper-salicylate gel for pain relief in osteoarthritis: a randomised controlled trial. Shackel NA, et al. **Med J Aust** 1997 Aug 4;167(3):134–6

Risk of Alzheimer's disease and duration of NSAID use [see comments] Stewart WF, et al. **Neurology** 1997 Mar; 48(3):626–32. Comment in: ACP J Club 1997 Sep–Oct;127(2):46–7.

Effects of ketoprofen and mesosalpinx infiltration on postoperative pain after laparoscopic sterilization. Van Ee R, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):568–72

A study of topical nonsteroidal anti-inflammatory drops and no pressure patching in the treatment of corneal abrasions. Corneal Abrasion Patching Study Group. Kaiser PK, et al. **Ophthalmology** 1997 Aug;104(8):1353–9

Doxymycine-cyanoacrylate treatment of recurrent aphthous ulcers. Ylikontiola L, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Mar;83(3):329–33

Diclofenac vs oxybuprocaine eyedrops for analgesia in paediatric strabismus surgery. Morton NS, et al. **Paediatr Anaesth** 1997;7(3):221–6

A freeze-dried injectable form of ibuprofen: development and optimisation using response surface methodology. Kagkadis KA, et al. **PDA J Pharm Sci Technol** 1996 Sep–Oct;50(5):317–23

In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolysed glycerides. Vial-Bernasconi AC, et al. **Pharm Acta Helv** 1995 Dec;70(4):307–13

Long-circulating lipospheres targeted to the inflammed tissue. Khopade AJ, et al. **Pharmazie** 1997 Feb;52(2):165–6

Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Adu D, et al. **QJM** 1997 Jun;90(6):401–9

Use of preincisional ketorolac in hernia patients: intravenous versus surgical site. Connelly NR, et al. **Reg Anesth** 1997 May–Jun;22(3):229–32

Inhaled nedocromil sodium in symptomatic young children born prematurely. Yüksel B, et al. **Respir Med** 1996 Sep; 90(8):467–71

A comparison between bucillamine and D-penicillamine in the treatment of rheumatoid arthritis. Kim HA, et al. **Rheumatol Int** 1997;17(1):5–9

Detection of naproxen-induced intestinal permeability change may be facilitated by adding a standardized meal but not by forming marker ratios. Oman H, et al. **Scand J Gastroenterol** 1996 Dec;31(12):1182–8

Combination of suppository diclofenac and intravenous morphine infusion in post-caesarean section pain relief—a step towards balanced analgesia? Sia AT, et al. **Singapore Med J** 1997 Feb;38(2):68–70

Analgesia in cats [letter] Balmer T, et al. **Vet Rec** 1997 Apr 19;140(16):435

Comparison of fluid and flunixin meglumine therapy in combination and individually in the treatment of toxic mastitis. Green MJ, et al. **Vet Rec** 1997 Feb 8;140(6):149–52

[Clinical and experimental study of RA mixture in treatment of rheumatoid arthritis] Xu DS, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Jan; 16(1):14–7, 23 (Eng. Abstr.) **(Chi)**

[Preparation of diclofenac sodium controlled release pellets and multiple-dose evaluation in healthy volunteers] Long XY, et al. **Yao Hsueh Hsueh Pao** 1996;31(3):209–13 (Eng. Abstr.) **(Chi)**

[Effect of indomethacin on the intracranial pressure] Bundgaard H, et al. **Ugeskr Laeger** 1997 Jun 30; 159(27):4261–5 (Eng. Abstr.) **(Dan)**

[Cerebral blood flow and indomethacin. The effect of different doses administered as continuous intravenous infusions or as suppositories in healthy adults] Jensen KA, et al. **Ugeskr Laeger** 1997 Jun 30;159(27):4257–60 (Eng. Abstr.) **(Dan)**

[The combination of oral lysine-acetylsalicylate and metoclopramide compared with oral sumatriptan in the treatment of migraine attacks. A randomized, double-blind, placebo-controlled clinical trial] Tfelt-Hansen P, et al. **Ugeskr Laeger** 1996 Nov 4;158(45):6435–9 (Eng. Abstr.) **(Dan)**

[Malignant bone pain] Thomsen CB, et al. **Ugeskr Laeger** 1997 Apr 14;159(16):2364–9 (40 ref.) (Eng. Abstr.) **(Dan)**

[Focus on the safety of ibuprofen at the analgesic-antipyretic dose] Moore N, et al. **Therapie** 1996 Jul–Aug;51(4):458–63 (13 ref.) (Eng. Abstr.) **(Fre)**

[High dose ibuprofen in low back pain] Baum K, et al. **Fortschr Med** 1997 Mar 30;115(9):51–2 **(Ger)**

[Topical treatment of soft tissue rheumatism and athletic injuries. Effectiveness and tolerance of a new ketoprofen gel] Link R, et al. **Fortschr Med** 1996 Sep 10;114(25):311–4 (Eng. Abstr.) **(Ger)**

[Perioperative prevention of thromboembolism in ENT medicine] Wilhelm T, et al. **HNO** 1996 Jan;44(1):31–2 **(Ger)**

[Minor effect of anti-inflammatory therapy on intraocular inflammation after minimally invasive phacoemulsification] Hessemer V, et al. **Ophthalmologe** 1997 Jan;94(1):30–2 (Eng. Abstr.) **(Ger)**

[Laser flare measurement with 3 different nonsteroidal anti-inflammatory drugs after phacoemulsification with posterior chamber lens implantation] Schmidl B, et al. **Ophthalmologe** 1997 Jan;94(1):33–7 (Eng. Abstr.) **(Ger)**

[Sports-induced acute epicondylitis of the elbow and conservative therapy] Förster KK, et al. **Sportverletz Sportschaden** 1997 Mar;11(1):16–20 (Eng. Abstr.) **(Ger)**

[Double-blind comparative study of the effectiveness and tolerance of 900 mg dexibuprofen and 150 mg diclofenac sodium in patients with painful gonarthrosis] Hawel R, et al. **Wien Klin Wochenschr** 1997 Jan 31;109(2):53–9 (Eng. Abstr.) **(Ger)**

[Drug therapy of activated arthrosis. On the effectiveness of an enzyme mixture versus diclofenac] Singer F, et al. **Wien Med Wochenschr** 1996;146(3):55–8 (Eng. Abstr.) **(Ger)**

[Does regular administration of aspirin reduce the risk of gastrointestinal carcinomas?] Folwaczny C, et al. **Z Gastroenterol** 1996 Dec;34(12):823–5 **(Ger)**

[Pharmacokinetic and pharmacodynamic profile of the trioxyethylene ester of indomethacin in a new oral prodrug] Palagiano F, et al. **Boll Chim Farm** 1996 Feb;135(2):89–91 **(Ita)**

[Five cases of drug-induced pneumonitis due to Sho-saiko-to or interferon-alpha or both] Nakagawa A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec; 33(12):1361–1366 (Eng. Abstr.) **(Jpn)**

[Indication and effect of inhaled DSCG for the treatment of adult asthmatics] Arai Y. **Nippon Rinsho** 1996 Nov; 54(11):3023–8 (19 ref.) (Eng. Abstr.) **(Jpn)**

[A role of inhaled disodium cromoglycate in child asthma] Nishikawa K. **Nippon Rinsho** 1996 Nov;54(11):3017–22 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment for gouty arthritis] Shimizu T. **Nippon Rinsho** 1996 Dec;54(12):3267–71 (10 ref.) (Eng. Abstr.) **(Jpn)**

[A case of pancreatic pleural effusion and ascites treated successfully with conservative measures including octreotide and nafamostat mesilate] Miyasaka Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Dec;93(12):937–41 **(Jpn)**

[Short-term treatment with naproxen (letter)] Finholt E. **Tidsskr Nor Laegeforen** 1997 Apr 20;117(10):1510–1 **(Nor)**

[Strain tendinitis—short-term treatment with antiphlogistics. Experiences from a four-day march in Nijmegen 1996] Hysing J, et al. **Tidsskr Nor Laegeforen** 1997 Mar 20; 117(8):1092–3 (Eng. Abstr.) **(Nor)**

[Diclofenac in the short-term prevention of recurrent colic from ureteral calculi. A placebo controlled double-blind study] Laerum E, et al. **Tidsskr Nor Laegeforen** 1996 Oct 10;116(24):2873–4 (Eng. Abstr.) **(Nor)**

[Reduce the dosage of ketorolac! Following EEC recommendations reduces the risk of hemorrhage with a marginal reduction of the analgesic effect] Lagerkranser M, et al. **Lakartidningen** 1996 Dec 4;93(49):4543–4 **(Swe)**

ADVERSE EFFECTS

NSAIDs and the gastrointestinal tract. Lanza FL. **Abdom Imaging** 1997 Jan–Feb;22(1):1–4 (33 ref.)

Side effects of NSAIDs and dosing recommendations for ketorolac. Camu F, et al. **Acta Anaesthesiol Belg** 1996; 47(3):143–9 (29 ref.)

Risk/benefit evaluation of NSAIDs in postoperative pain therapy. Nuutinen LS. **Acta Anaesthesiol Belg** 1996; 47(3):129–33

Phototoxicity of non-steroidal anti-inflammatory drugs: in vitro studies with visible light. Becker L, et al. **Acta Derm Venereol** 1996 Sep;76(5):337–40

NSAID-induced ulcers. Go MF. **Acta Gastroenterol Latinoam** 1996;26(2):115–8

Systemic complications of nonsteroidal anti-inflammatory drug use. Palmer BF, et al. **Adv Intern Med** 1996;41:605–39 (153 ref.)

Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Blower AL, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):283–91

Effects of misoprostol on healing and prevention of biopsy-induced gastroduodenal lesions occurring during the administration of diclofenac to volunteers [published erratum appears in Aliment Pharmacol Ther 1996 Oct;10(5):833] Dorta G, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):563–9

Prescribing of nonsteroidal anti-inflammatory drugs in general practice: determinants and consequences. Hawkey CJ, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):293–8

Gastric microbleeding following single and repeated dosing with naproxen. McAlindon ME, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):655–9

Adverse events in patients treated with 5-aminosalicyclic acid: 1993–1994 pharmacovigilance report for Pentasa in France. Marteau P, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):949–56 (83 ref.)

The effect of indomethacin-induced gastric mucosal injury on 24-h intragastric acidity and plasma gastrin concentration in healthy volunteers. Rademaker JW, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):625–31

High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. ten Wolde S, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):347–51

Drug-related Henoch-Schönlein Purpura. Escudero A, et al. **Allergol Immunopathol (Madr)** 1996 Jan–Feb;24(1):22–4

Cutaneous reaction to naproxen. Gonzalo Garijo MA, et al. **Allergol Immunopathol (Madr)** 1996 Mar–Apr;24(2):89–92 (14 ref.)

Drug-dependent exercise-induced anaphylaxis. van Wijk RG, et al. **Allergy** 1995 Dec;50(12):992–4

Prophylaxis and treatment of NSAID-induced gastropathy. Ament PW, et al. **Am Fam Physician** 1997 Mar; 55(4):1323–6, 1331–2 (34 ref.)

Nonsteroidal anti-inflammatory drugs (NSAIDs) and blood pressure [editorial] Fierro-Carrion GA, et al. **Am J Cardiol** 1997 Sep 15;80(6):775–6

Cross-reactions in patch testing and photopatch testing with ketoprofen, thiaprophenic acid, and cinnamic aldehyde. Pigatto P, et al. **Am J Contact Dermat** 1996 Dec;7(4):220–3

Sulindac-associated ulcerative pouchitis in familial adenomatous polyposis. Bertoni G, et al. **Am J Gastroenterol** 1996 Nov;91(11):2431–2

Primary amino-bisphosphonates: a new class of gastrotoxic drugs—comparison of alendronate and aspirin. Graham DY, et al. **Am J Gastroenterol** 1997 Aug;92(8):1322–5

Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Graham DY. **Am J Gastroenterol** 1996 Oct;91(10):2080–6 (92 ref.)

Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients. Miglioli M, et al. **Am J Gastroenterol** 1996 Nov;91(11):2367–71

Could a fibroid polyp be a manifestation of enteropathy induced by nonsteroidal anti-inflammatory drugs? Muñiz-Grijalvo O, et al. **Am J Gastroenterol** 1997 Jan; 92(1):170–1

Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients. Porro GB, et al. **Am J Gastroenterol** 1997 Apr;92(4):663–7

Guilty as charged: bugs and drugs in gastric ulcer. Sontag SJ. **Am J Gastroenterol** 1997 Aug;92(8):1255–61 (76 ref.)

5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Walker AM, et al. **Am J Gastroenterol** 1997 May;92(5):816–20

Prevalence of upper gastrointestinal lesions in patients taking chronic nonsteroidal anti-inflammatory drug therapy [letter; comment] Zuckerman MJ, et al. **Am J Gastroenterol** 1997 Feb;92(2):363–4. Comment on: Am J Gastroenterol 1987 Nov;82(11):1153–8.

Toxicity of nonsteroidal anti-inflammatory drugs in the elderly: is advanced age a risk factor? Solomon DH, et al. **Am J Med** 1997 Feb;102(2):208–15 (97 ref.)

The effect of nonsteroidal antiinflammatory drugs on electrolyte homeostasis and blood pressure in young and elderly persons with and without renal insufficiency. Murray MD, et al. **Am J Med Sci** 1997 Aug;314(2):80–8

Fracture healing: role of NSAIDs [letter; comment] Khan MI. **Am J Orthop** 1997 Jun;26(6):413. Comment on: Am J Orthop 1997 Feb;26(2):161–4.

The effect of pretreatment with ketorolac on pain during intravenous injection of propofol [letter; comment] Dexter TJ. **Anaesthesia** 1997 Jan;52(1):94. Comment on: Anaesthesia 1996 Sep;51(9):883–5.

Transient paraparesis after postdural puncture spinal hematoma in a patient receiving ketorolac. Gerancher JC, et al. **Anesthesiology** 1997 Feb;86(2):490–4 (26 ref.)

Perioperative acute renal failure associated with preoperative intake of ibuprofen. Sivarajan M, et al. **Anesthesiology** 1997 Jun;86(6):1390–2

Immediate rhinoconjunctivitis induced by metamizole and metronidazole. Añíbarro B, et al. **Ann Allergy Asthma Immunol** 1997 Apr;78(4):345–6

Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs. Giuseppe P, et al. **Ann Allergy Asthma Immunol** 1997 Jan; 78(1):74–8

Anaphylactoid reactions due to nonsteroidal antiinflammatory drugs: clinical and cross-reactivity studies. Quiralte J, et al. **Ann Allergy Asthma Immunol** 1997 Mar;78(3):293–6

Acute renal failure and ketorolac [letter] Buller GK, et al. **Ann Intern Med** 1997 Sep 15;127(6):493–4

Over-the-counter naproxen sodium and esophageal injury [letter] Kahn LH, et al. **Ann Intern Med** 1997 Jun 15; 126(12):1006

Henoch-Schönlein purpura associated with acetylsalicylic acid [letter] Solà Alberich R, et al. **Ann Intern Med** 1997

Apr 15;126(8):665

Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice [see comments] Tamblyn R, et al. **Ann Intern Med** 1997 Sep 15;127(6):429–38. Comment in: Ann Intern Med 1997 Sep 15;127(6):483–5.

Increased serum lithium concentration secondary to treatment with tiaprofenic acid and fosinopril. Alderman CP, et al. **Ann Pharmacother** 1996 Dec;30(12):1411–3

Ibuprofen-induced aseptic meningitis in rheumatoid arthritis. Horn AC, et al. **Ann Pharmacother** 1997 Sep;31(9):1009–11

Necrotizing soft tissue infections reported with nonsteroidal antiinflammatory drugs. Kahn LH, et al. **Ann Pharmacother** 1997 Sep;31(9):1034–9 (69 ref.)

Tolmetin-induced esophageal ulceration [letter] Palop V, et al. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):929

Interstitial pneumonitis due to mesalamine [letter] Pascual-Lledó JF, et al. **Ann Pharmacother** 1997 Apr; 31(4):499

Incidence of hepatitis induced by non-steroidal anti-inflammatory drugs (NSAID) [letter] Trechot P, et al. **Ann Rheum Dis** 1996 Dec;55(12):936

Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin. Grosfeld JL, et al. **Ann Surg** 1996 Sep; 224(3):350–5; discussion 355–7

Oxaprozin-induced pseudoporphyria [letter] Ingrish G, et al. **Arch Dermatol** 1996 Dec;132(12):1519–20

Non-steroidal anti-inflammatory drugs may predispose to invasive group A streptococcal infections [letter; comment] Curtis N. **Arch Dis Child** 1996 Dec;75(6):547. Comment on: Arch Dis Child 1996 Feb;74(2):164–7.

Nonsteroidal anti-inflammatory agents and acute renal failure [editorial; comment] Gutch CF. **Arch Intern Med** 1996 Nov 25;156(21):2414. Comment on: Arch Intern Med 1996 Nov 25;156(21):1996 Nov 25;156(21):2433–9.

Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials [see comments] Koch M, et al. **Arch Intern Med** 1996 Nov 11;156(20):2321–32. Comment in: ACP J Club 1997 Mar–Apr;126(2):36.

Mesalamine-induced lung disease [letter] Lázaro MT, et al. **Arch Intern Med** 1997 Feb 24;157(4):462

Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure [see comments] Pérez Gutthann S, et al. **Arch Intern Med** 1996 Nov 25; 156(21):2433–9. Comment in: Arch Intern Med 1996 Nov 25;156(21):2414.

NSAID gastropathy [letter; comment] Yood RA. **Arch Intern Med** 1997 Feb 10;157(3):364. Comment on: Arch Intern Med 1996 Aug 12–26;156(15):1623–8.

Exacerbation of asthma by topical diclofenac [letter] Sharir M. **Arch Ophthalmol** 1997 Feb;115(2):294–5

Corneal sensitivity debate [letter; comment] Villain M, et al. **Arch Ophthalmol** 1997 May;115(5):686. Comment on: Arch Ophthalmol 1996 Aug;114(8):921–4.

Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Walker AM. **Arthritis Rheum** 1997 Feb;40(2):201–8 (11 ref.)

Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers. Puscas I, et al. **Arzneimittelforschung** 1997 Apr;47(4A):565–8

Epidemiological study of angioedema and ACE inhibitors. Gabb GM, et al. **Aust N Z J Med** 1996 Dec;26(6):777–82

Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Bougie D, et al. **Blood** 1997 Jul 1;90(1):407–13

Meta-analysis of risk of gastrointestinal complications with NSAIDs. Authors should not have included data from one study [letter; comment] Henry D. **BMJ** 1997 Feb 8; 314(7078):445. Comment on: BMJ 1996 Jun 22;312(7046):1563–6.

Systematic reviews provide information not contained in traditional narrative reviews [letter; comment] Henry D. **BMJ** 1997 Jun 21;314(7097):1832–3. Comment on: BMJ 1997 Feb 8;314(7078):445–6.

Meta-analysis of risk of gastrointestinal complications with NSAIDs. Narrative review should have been used [letter; comment] [see comments] Kaufman DW, et al. **BMJ** 1997 Feb 8;314(7078):445–6. Comment on: BMJ 1996 Jun 22;312(7046):1563–6. Comment in: BMJ 1997 Jun 21;314(7097):1832–3.

Acute eosinophilic pneumonia associated with tenidap. Martinez BM, et al. **BMJ** 1997 Feb 1;314(7077):349

Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment. Ramachandran S, et al. **BMJ** 1997 May 31;314(7094):1593

Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Henry D, et al. **Br J Clin Pharmacol** 1997 Jul;44(1):85–90

Patient awareness of the adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs). Wynne HA, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):253–6

Bilateral ureteric obstruction secondary to the prolonged use of tiaprofenic acid. Crew JP, et al. **Br J Clin Pract** 1997 Jan–Feb;51(1):59–60 (9 ref.)

Hypersensitivity vasculitis related to aceclofenac [letter] Morros R, et al. **Br J Rheumatol** 1997 Apr;36(4):503–4

New NSAIDs--inhibitors of cyclooxygenase 2--and renal damage [letter] Navarro JF, et al. **Br J Rheumatol** 1996 Dec;35(12):1332

NSAIDs and fertility [letter; comment] Thylan S. **Br J Rheumatol** 1997 Jan;36(1):145–6. Comment on: Br J Rheumatol 1996 Jan;35(1):76–8.

Infertility may sometimes be associated with non-steroidal anti-inflammatory drug consumption [letter; comment] van der Weiden RM, et al. **Br J Rheumatol** 1997 May;36(5):605 . Comment on: Br J Rheumatol 1996 Jan;35(1):76–8.

No association between non-steroidal anti-inflammatory drugs and acute appendicitis in a case-control study. Evans JM, et al. **Br J Surg** 1997 Mar;84(3):372–4

Severe cystitis associated with tiaprofenic acid. Crawford ML, et al. **Br J Urol** 1997 Apr;79(4):578–84

Cystitis associated with tiaprofenic acid: a survey of British and Irish urologists. Henley MJ, et al. **Br J Urol** 1997 Apr; 79(4):585–7

Drug induced cystitis: the need for vigilance [letter] Jeremy JY, et al. **Br J Urol** 1997 Sep;80(3):511–2

Acetylsalicylic acid (ASA) and nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy. Are they safe? Theis JG. **Can Fam Physician** 1996 Dec; 42:2347–9

Tonsillectomies, ketorolac, and the march of progress [editorial; comment] Hall SC. **Can J Anaesth** 1996 Jun; 43(6):544–8. Comment on: Can J Anaesth 1996 Jun;43(6):560–3. **(Eng, Fre)**

NSAID gastroenteropathy: past, present and future. Wallace JL. **Can J Gastroenterol** 1996 Nov–Dec;10(7):451–9 (88 ref.)

New drug to prevent NSAID-related ulcers [letter; comment] Liss GM. **Can Med Assoc J** 1996 Oct 15; 155(8):1043. Comment on: Can Med Assoc J 1996 Jul 1;155(1):77–88.

A case of eosinophilic pneumonia and vasculitis induced by diflunisal. Rich MW, et al. **Chest** 1997 Jun;111(6):1767–9 (7 ref.)

Vasospastic angina induced by nonsteroidal anti-inflammatory drugs. Mori E, et al. **Clin Cardiol** 1997 Jul;20(7):656–8

Membranous nephropathy associated with the use of flurbiprofen [letter] MacKay K. **Clin Nephrol** 1997 Apr; 47(4):279–80

Ketorolac induced acute reversible hearing loss in a patient maintained on CAPD [letter] Otti T, et al. **Clin Nephrol** 1997 Mar;47(3):208–9

Prevention of NSAID-induced gastroduodenal complications [editorial] Hiele M. **Clin Rheumatol** 1996 Sep; 15(5):431–4

Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia. Skeith KJ, et al. **Clin Rheumatol** 1997 May;16(3):291–5

The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Van Groenendael JH, et al. **Clin Rheumatol** 1996 Sep; 15(5):450–6

Problem drugs for the patient with asthma. Craig T, et al. **Compr Ther** 1996 Jun;22(6):339–44 (21 ref.)

No evidence of cross-reaction between fepradinol and other phenylethanolamines. Goday JJ, et al. **Contact Dermatitis** 1997 Mar;36(3):170–1

Topical and systemic provocation of fixed drug eruption due to phenazone. Schick E, et al. **Contact Dermatitis** 1996 Jul; 35(1):58–9

What risk of piroxicam photodermatitis in thimerosal-positive patients? Stingeni L, et al. **Contact Dermatitis** 1996 Jan;34(1):60–1

Ampiroxicam-induced photosensitivity. Toyohara A, et al. **Contact Dermatitis** 1996 Aug;35(2):101–2

Delayed-type hypersensitivity to mofebutazone underlying a severe drug reaction. Walchner M, et al. **Contact Dermatitis** 1997 Jan;36(1):54–5

Japanese and American reports of randomized trials: differences in the reporting of adverse effects. Hayashi K, et al. **Control Clin Trials** 1996 Apr;17(2):99–110

A new triad: sensitivity to aspirin, allergic rhinitis, and severe allergic reaction to ingested aeroallergens. Sánchez-Borges M, et al. **Cutis** 1997 Jun;59(6):311–4 (11 ref.)

Multiple cutaneous sensitization to nonsteroidal anti-inflammatory drugs. Gonzalo MA, et al. **Dermatology** 1996;193(1):59–60

Diclofenac: a new trigger of pemphigus vulgaris? Matz H, et al. **Dermatology** 1997;195(1):48–9

Hypersensitivity to 5-ASA suppositories. Borum ML, et al. **Dig Dis Sci** 1997 May;42(5):1076–8 (44 ref.)

Association of nonsteroidal antiinflammatory drugs with outcome in upper and lower gastrointestinal bleeding. Wilcox CM, et al. **Dig Dis Sci** 1997 May;42(5):985–9

Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Wilcox CM, et al. **Dig Dis Sci** 1997 May;42(5):990–7

Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding. Younossi ZM, et al. **Dig Dis Sci** 1997 Jan;42(1):79–82

5-Aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease. Hämling J, et al. **Digestion** 1997;58(3):304–7

Helicobacter pylori-negative duodenal and pyloric ulcer: role of NSAIDs. Hyvärinen H, et al. **Digestion** 1996;57(5):305–9

Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Manoukian AV, et al. **Drug Saf** 1996 Jul;15(1):64–71 (59 ref.)

The clinical implications of inhibition of the inducible form of cyclo-oxygenase. Richardson C, et al. **Drug Saf** 1996 Oct;15(4):249–60 (61 ref.)

NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus. Champion GD, et al. **Drugs** 1997 Jan;53(1):6–19 (112 ref.)

Nonsteroidal anti-inflammatory drugs and acute renal failure in the elderly. A risk-benefit assessment. Ailabouni W, et al. **Drugs Aging** 1996 Nov;9(5):341–51 (74 ref.)

Tolerability of topical NSAIDs in the elderly: do they really convey a safety advantage? Evans JM, et al. **Drugs Aging** 1996 Aug;9(2):101–8 (70 ref.)

Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists. Lazzaroni M, et al. **Drugs Aging** 1996 Oct;9(4):251–61 (72 ref.)

NSAIDs and the elderly. Toxicity and economic implications. Phillips AC, et al. **Drugs Aging** 1997 Feb; 10(2):119–30 (62 ref.)

Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Gutthann SP, et al. **Epidemiology** 1997 Jan;8(1):18–24

Use of dipyrone during pregnancy and risk of Wilms' tumor. Brazilian Wilms' Tumor Study Group. Sharpe CR, et al. **Epidemiology** 1996 Sep;7(5):533–5

Tenoxicam-associated hepatic injury: a case report and review. Katsinelos P, et al. **Eur J Gastroenterol Hepatol** 1997 Apr;9(4):403–6 (24 ref.)

Post cesarean analgesia with ketorolac tromethamine and uterine atonia. Diemunsch P, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Apr;72(2):205–6

Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Ishizaki T, et al. **Eur Respir J** 1996 Dec;9(12):2691–6

A novel approach to reduce the unwanted gastric side-effects of orally administered non-steroidal anti-inflammatory drugs in rats. Balint GA. **Exp Toxicol Pathol** 1997 Feb; 49(1–2):61–3

Vortex keratopathy associated with ibuprofen therapy [letter] Fitt A, et al. **Eye** 1996;10 (Pt 1):145–6

Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Simon LS, et al. **Fam Med** 1996 Mar;28(3):204–10

Epileptic seizure during aspirin and caffeine withdrawal in a drug induced headache. Antonaci F, et al. **Funct Neurol** 1996 Nov–Dec;11(6):333–7

NSAIDs, gastrointestinal injury, and cytoprotection. Scheiman JM. **Gastroenterol Clin North Am** 1996 Jun; 25(2):279–98 (94 ref.)

The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Smalley WE, et al. **Gastroenterol Clin North Am** 1996 Jun;25(2):373–96 (99 ref.)

High-dose famotidine for prevention of NSAID ulcers? [editorial; comment] Graham DY. **Gastroenterology** 1997 Jun;112(6):2143–5. Comment on: Gastroenterology 1997 Jun;112(6):1817–22.

Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration [see comments] Hudson N, et al. **Gastroenterology** 1997 Jun;112(6):1817–22. Comment in: Gastroenterology 1997 Jun;112(6):2143–5.

Evidence of aspirin use in both upper and lower gastrointestinal perforation [see comments] Lanas A, et al. **Gastroenterology** 1997 Mar;112(3):683–9. Comment in: ACP J Club 1997 Sep–Oct;127(2):47.

Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Wallace JL. **Gastroenterology** 1997 Mar;112(3):1000–16 (179 ref.)

Diaphragm-like strictures of the right colon induced by indomethacin suppositories: evidence of a systemic effect. Hooker GD, et al. **Gastrointest Endosc** 1996 Aug; 44(2):199–202

Non-nonsteroidal anti-inflammatory drug, nonmalignant gastric ulcers. Bjorkman DJ, et al. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):527–44 (102 ref.)

Nonsteroidal anti-inflammatory drug gastropathy. Laine L. **Gastrointest Endosc Clin N Am** 1996 Jul;6(3):489–504 (76 ref.)

Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy [see comments] Bianchi Porro G, et al. **Gut** 1996 Jul;39(1):22–6. Comment in: Gut 1997 Apr;40(4):560–1.

Co-existence of hepatitis A and adult Reye's syndrome. Duerksen DR, et al. **Gut** 1997 Jul;41(1):121–4

Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Evans JM, et al. **Gut** 1997 May;40(5):619–22

Effect of sucralfate on aspirin induced mucosal injury and impaired haemostasis in humans. Hudson N, et al. **Gut** 1997 Jul;41(1):19–23

Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration [see comments] Hull MA, et al. **Gut** 1997 Feb;40(2):204–10. Comment in: Gut 1997 Feb;40(2):286–7.

Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Lanas AI, et al. **Gut** 1996 Nov;39(5):654–60

Reduction of non-steroidal anti-inflammatory drug induced

gastric injury and leucocyte endothelial adhesion by octreotide. Scheiman JM, et al. **Gut** 1997 Jun;40(6):720–5
Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Schreiber S, et al. **Gut** 1997 Jun;40(6):761–6
Effects of aspirin on human psychophysical tuning curves in forward and simultaneous masking. Beveridge HA, et al. **Hear Res** 1996 Sep 15;99(1–2):110–8
Hypereosinophilic syndrome: endomyocardial fibrosis [see comments] Pitt M, et al. **Heart** 1996 Oct;76(4):377–8. Comment in: Heart 1997 Apr;77(4):391.
Serum pepsinogen I and gastrin in peptic ulcer patients using nonsteroidal anti-inflammatory drugs. Kemppainen H, et al. **Hepatogastroenterology** 1997 Jul–Aug;44(16):1143–6
Effect of gastric mucosal protection in nonrheumatoid patients with short-term nonsteroidal anti-inflammatory drug therapy: a prospective randomized multicenter study. Miller K. **Hepatogastroenterology** 1997 May–Jun; 44(15):872–9
Acute onset of dermatitis, hepatitis, and eosinophilia. Reichmuth DA, et al. **Hosp Pract (Off Ed)** 1997 Jul 15; 32(7):45–8
NSAIDs and the gastrointestinal mucosa. Wolfe MM. **Hosp Pract (Off Ed)** 1996 Dec 15;31(12):37–44, 47–8 (6 ref.)
Histological features do not define NSAID-induced gastritis. El-Zimaity HM, et al. **Hum Pathol** 1996 Dec; 27(12):1348–54
Effect of a short course of indomethacin on gastric mucosal blood flow using endoscopic laser-Doppler velocimetry. Sawant P, et al. **Indian J Gastroenterol** 1995 Oct; 14(4):137–8
Gastrointestinal protection by NO from NSAIDs induced injury. Rishi RK, et al. **Indian J Physiol Pharmacol** 1996 Oct;40(4):377–9 (22 ref.)
Clinical immunotoxicity of antirheumatic drugs. Bálint G, et al. **Inflamm Res** 1996 Dec;45 Suppl 2:S91–5 (70 ref.)
Gastric mucosal injury by nonsteroidal anti-inflammatory drugs is reduced by (R)-alpha-methylhistamine and its pro-drugs in the rat. Morini G, et al. **Inflamm Res** 1997 Mar;46 Suppl 1:S101–2
Non-steroidal anti-inflammatory drug-induced colitis. Faucheron JL, et al. **Int J Colorectal Dis** 1996;11(2):99–101 (59 ref.)
Droxicam photosensitivity with dyshidrotic hand dermatitis [letter] Anonide A, et al. **Int J Dermatol** 1997 Apr; 36(4):318–20
Tolerability of nabumetone: a pilot in vitro study showing absence of injury to articular cartilage. Giordano N, et al. **Int J Tissue React** 1996;18(4–6):105–8
Acute renal failure after binge drinking of alcohol and nonsteroidal antiinflammatory drug ingestion [see comments] Tsuboi N, et al. **Intern Med** 1997 Feb; 36(2):102–6. Comment in: Intern Med 1997 Feb;36(2):80.
Prevention of NSAID-gastropathy. Ardizzone S, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:33–6 (19 ref.)
Early pathogenic events in NSAID-induced gastrointestinal damage. Bjarnason I, et al. **Ital J Gastroenterol** 1996 Dec; 28 Suppl 4:19–22
Ultrastructural damage of gastric epithelium in patients taking NSAIDs. Caselli M, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:16–8 (12 ref.)
NSAID gastropathy: state of the art. Cervini C, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:1–5 (36 ref.)
New directions in cyclooxygenase research and their implications for NSAID-gastropathy. Flower RJ. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:23–7 (26 ref.)
New NSAIDs and gastroduodenal damage. Folco GC. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:28–9 (10 ref.)
Epidemiological aspects of NSAID gastropathy. Guslandi M. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:6–8 (21 ref.)
Therapy of NSAIDs-induced gastropathy. La Corte R, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:37–41 (34 ref.)
Endoscopic aspects of gastroduodenal mucosa due to NSAIDs. Ruina M, et al. **Ital J Gastroenterol** 1996 Dec; 28 Suppl 4:9–11
Histopathological aspects of mucosal injury related to non-steroidal anti-inflammatory drugs. Taha AS. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:12–5
Prevalence of cross-sensitivity with acetaminophen and other nonsteroidal antiinflammatory drugs in asthmatic patients [letter; comment] Kalyoncu AF, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):713–4. Comment on: J Allergy Clin Immunol 1995 Oct;96(4):480–5.
Acetaminophen-induced urticaria and tolerance of ibuprofen in an eight-year-old child. Ownby DR. **J Allergy Clin Immunol** 1997 Jan;99(1 Pt 1):151–2
Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. Quiralte J, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):678–85
Atopy and NSAID sensitivity [letter] Sánchez-Borges M, et al. **J Allergy Clin Immunol** 1997 Jul;100(1):143–4
Dipyrone in the induction of pemphigus. Brenner S, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 1):488–90
Fixed drug eruptions with feprazone are linked to HLA-B22. Pellicano R, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 1):782–4
Massive gastric hemorrhage induced by buffered aspirin in a greyhound. Shaw N, et al. **J Am Anim Hosp Assoc** 1997 May–Jun;33(3):215–9
Surgical complications of nonsteroidal antiinflammatory drug-induced small bowel ulceration. Kessler WF, et al. **J Am Coll Surg** 1997 Sep;185(3):250–4
GI effects of OTC analgesics: implications for product selection. Garnett WR. **J Am Pharm Assoc (Wash)** 1996 Sep;NS36(9):565–72
Naproxen sodium. Sutton LB. **J Am Pharm Assoc (Wash)** 1996 Nov;NS36(11):663–7 (15 ref.)
Prostaglandins and renal damage [letter; comment] Navarro JF. **J Am Soc Nephrol** 1996 Aug;7(8):1245–6. Comment on: J Am Soc Nephrol 1996 Jan;7(1):8–17.
Drug induced gastrointestinal diseases. Kalro RH, et al. **J Assoc Physicians India** 1996 Oct;44(10):715–9 (54 ref.)
Nephrotic syndrome from 5-ASA for ulcerative colitis? Complicated by carcinoma of the colon and sclerosing cholangitis. Fornaciari G, et al. **J Clin Gastroenterol** 1997 Jan;24(1):37–9
Drugs and ulcers: clues about mucosal protection from epidemiologic studies. Griffin MR, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S113–9
Nonsteroidal antiinflammatory drug colopathy: mimicry of Crohn's disease and colon carcinoma. Kirsch M. **J Clin Gastroenterol** 1997 Mar;24(2):121–3
Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. Kurata JH, et al. **J Clin Gastroenterol** 1997 Jan;24(1):2–17
Growth markers in the human gastric mucosa during adaptation to continued aspirin administration. Stachura J, et al. **J Clin Gastroenterol** 1996 Jun;22(4):282–7
Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature. Sviri S, et al. **J Clin Gastroenterol** 1997 Jan;24(1):34–6
Improving drug use in rheumatic disorders. Peterson GM, et al. **J Clin Pharm Ther** 1996 Aug;21(4):215–20
Prevention of NSAID-induced GI mucosal injury. Gerritz S, et al. **J Fam Pract** 1997 Feb;44(2):130–1
NSAIDs increase risk of gastrointestinal bleeding in primary care patients with dyspepsia. Kurata JH, et al. **J Fam Pract** 1997 Sep;45(3):227–35
Prevention of NSAID-induced ulcers. Lawless C, et al. **J Fam Pract** 1996 Sep;43(3):239–40
Aspirin preparation and risk of GI bleeding. Rao G. **J Fam Pract** 1997 Mar;44(3):242–3
Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. Davies NM, et al. **J Gastroenterol** 1997 Feb;32(1):127–33 (89 ref.)
Bosentan, a novel synthetic mixed-type endothelin receptor antagonist, attenuates acute gastric mucosal lesions induced by indomethacin and HCl in the rat: role of endogenous endothelin-1. Matsumaru K, et al. **J Gastroenterol** 1997 Apr;32(2):164–70
Recovery of mucin content in surface layer of rat gastric mucosa after HCl-aspirin-induced mucosal damage. Sakai T, et al. **J Gastroenterol** 1997 Apr;32(2):157–63
Do non-steroidal anti-inflammatory drugs cause duodenal ulcer? Evaluation of basal acid output and ulcer complications. Collen MJ, et al. **J Gastroenterol Hepatol** 1996 Jun;11(6):520–3
Case report: gastrointestinal haemorrhage from jejunal diverticulosis, probably induced by low dose aspirin. Kaushik SP, et al. **J Gastroenterol Hepatol** 1996 Oct; 11(10):908–10
Non-steroidal anti-inflammatory drugs and variceal bleeding: a case-control study. de Lédinghen V, et al. **J Hepatol** 1996 May;24(5):570–3
Cholestasis associated with mesalazine therapy in a patient with Crohn's disease. Stoschus B, et al. **J Hepatol** 1997 Feb;26(2):425–8
Efficacy of lansoprazole against peptic ulcers induced by non-steroidal anti-inflammatory drugs: endoscopic evaluation of ulcer healing. Matsukawa Y, et al. **J Int Med Res** 1997 Jul–Aug;25(4):190–5
Delayed hypersensitivity to flurbiprofen. Romano A, et al. **J Intern Med** 1997 Jan;241(1):81–3 (15 ref.)
Adverse effects of sulindac used for prevention of colorectal cancer [letter] Ishikawa H, et al. **J Natl Cancer Inst** 1997 Sep 17;89(18):1381
Safety of intravenous ketorolac therapy [letter; comment] Mofenson HC, et al. **J Pediatr** 1997 May;130(5):846. Comment on: J Pediatr 1996 Aug;129(2):292–6.
Effect of particle shape of acetyl salicylic acid powders on gastric damages in rats. Zolfaghari ME, et al. **J Pharm Belg** 1997 Jan–Feb;52(1):1–6
Ibuprofen and paracetamol: relative safety in non-prescription dosages. Rainsford KD, et al. **J Pharm Pharmacol** 1997 Apr;49(4):345–76 (234 ref.)
Model development and analysis of tenidap-induced proteinuria in the rat. Aleo MD, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1318–26
The acute uraemic emergency [letter] Jolobe OM. **J R Coll Physicians Lond** 1997 May–Jun;31(3):343
Bucillamine induced pulmonary injury occurs with immunoglobulin decrease. Inokuma S, et al. **J Rheumatol** 1996 Jul;23(7):1282–5
Nonsteroidal antiinflammatory drug induced hypersensitivity vasculitis clinically mimicking temporal arteritis. Lie JT, et al. **J Rheumatol** 1996 Jan;23(1):183–5 (22 ref.)
Safety of nonsteroidal antiinflammatory drugs in pregnant patients with rheumatic disease. Ostensen M, et al. **J Rheumatol** 1996 Jun;23(6):1045–9
Leukocytoclastic vasculitis induced by a nonsteroidal antiinflammatory drug [letter] Peters F, et al. **J Rheumatol** 1996 Nov;23(11):2008–9
Association of NSAID with red cell aplasia [letter; comment] Weinberger KA. **J Rheumatol** 1997 Jul;24(7):1444. Comment on: J Rheumatol 1996 Oct;23(10):1803–5.
Gastric safety and enteric-coated aspirin [letter; comment] Guslandi M. **Lancet** 1997 Feb 8;349(9049):431. Comment on: Lancet 1996 Nov 23;348(9039):1413–6.
Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product [see comments] Kelly JP, et al. **Lancet** 1996 Nov 23; 348(9039):1413–6. Comment in: Lancet 1996 Nov 23;348(9039):1394–5. Comment in: Lancet 1997 Feb 8;349(9049):430–1. Comment in: Lancet 1997 Feb 8;349(9049):431.
Gastric safety and enteric-coated aspirin [letter; comment] Petroski D. **Lancet** 1997 Feb 8;349(9049):430–1. Comment on: Lancet 1996 Nov 23;348(9039):1413–6.
Gastric safety and enteric-coated aspirin [letter] Sullivan JL. **Lancet** 1997 Feb 8;349(9049):431–2
Ketorolac tromethamine and hemorrhage in tonsillectomy: a prospective, randomized, double-blind study. Bailey R, et al. **Laryngoscope** 1997 Feb;107(2):166–9
80-year-old woman with dizziness. Steensma DP, et al. **Mayo Clin Proc** 1997 Aug;72(8):781–4
Colitis induced by non-steroidal anti-inflammatory drugs. Khanna R, et al. **Md Med J** 1997 Jan;46(1):15–7
Pattern of non-steroidal anti-inflammatory drug use in Australia 1990–1994 [letter; comment] Roughead EE, et al. **Med J Aust** 1996 Nov 4;165(9):530–1. Comment on: Med J Aust 1996 May 20;164(10):589–92.
Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Uejima M, et al. **Microbiol Immunol** 1996;40(8):553–60
Famotidine to prevent peptic ulcer caused by NSAIDs [letter] Graham DY. **N Engl J Med** 1996 Oct 24; 335(17):1322; discussion 1322–3
Famotidine to prevent peptic ulcer caused by NSAIDs [letter; comment] Singh G, et al. **N Engl J Med** 1996 Oct 24;335(17):1322; discussion 1322–3. Comment on: N Engl J Med 1996 May 30;334(22):1435–9.
Acute renal failure induced by nimesulide in a patient suffering from temporal arteritis. Apostolou T, et al. **Nephrol Dial Transplant** 1997 Jul;12(7):1493–6
Mesalazine-associated interstitial nephritis [letter; comment] Mani V. **Nephrol Dial Transplant** 1997 Mar;12(3):622–3. Comment on: Nephrol Dial Transplant 1996 Apr;11(4):614–21.
Membranous nephropathy associated with oxaprozin treatment [letter] Ogawa M, et al. **Nephron** 1996; 74(2):439–40
Comparison of effect of an anti-inflammatory drug and a narcotic analgesic on renal function in sickle cell anemia [letter] Paydas S, et al. **Nephron** 1996;73(3):498
Acute renal failure associated with amoxicillin and ibuprofen in an 11-year-old boy [letter] Primack WA, et al. **Pediatr Nephrol** 1997 Feb;11(1):125–6
Relationship between upper gastrointestinal bleeding and non steroidal anti-inflammatory drugs in children. Li Voti G, et al. **Pediatr Surg Int** 1997 Apr;12(4):264–5
Acute gastrointestinal toxic effects of suspensions of unencapsulated and encapsulated ibuprofen in rats. Adeyeye CM, et al. **Pharm Res** 1996 May;13(5):784–93
How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. ADR Signals Analysis Project (ASAP) Team. Lindquist M, et al. **Pharmacol Toxicol** 1997 May;80(5):211–7
A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. García Rodríguez LA, et al. **Pharmacotherapy** 1997 Jul–Aug;17(4):721–8
Gastrointestinal effects of NSAIDs. Difficulties in detection and management. Pearson SP, et al. **Postgrad Med** 1996 Nov;100(5):131–2, 135–6, 141–3 (20 ref.)
Nonsteroidal anti-inflammatory drug associated diaphragm disease. McGonigal A, et al. **Postgrad Med J** 1997 Aug; 73(862):505–6
'Relapse' of chronic active hepatitis—not always what it seems. Muller AF, et al. **Postgrad Med J** 1996 Jul; 72(849):431–2
A copper-complex reduced gastric damage caused by acetylsalicylic acid and ethanol. Franco L, et al. **Prostaglandins** 1996 May;51(5):331–8
Increased salt retention and hypertension from non-steroidal agents in the elderly. Mulkerrin EC, et al. **QJM** 1997 Jun; 90(6):411–5
Drug nephrotoxicity: an overview. Bennett WM. **Ren Fail** 1997 Mar;19(2):221–4 (28 ref.)
Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis. Bhaumik SK, et al. **Ren Fail** 1996 Jan;18(1):97–104
Gastropathy and NSAIDs: healing gastric and duodenal lesions and prophylaxis with PGs. Agrawal N. **Rev Gastroenterol Mex** 1996 Oct–Dec;61(4 Suppl 2):S30–2
Efficacy of misoprostol in the prophylaxis of gastroduodenal lesions induced by short-term nonsteroidal antiinflammatory drug therapy in elderly patients. A multicenter double-blind, placebo-controlled trial. Piette F, et al. **Rev Rhum Engl Ed** 1997 Apr;64(4):259–66
Greater curvature antral flattening due to nonsteroidal antiinflammatory drugs. Catalano O. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997

Aug;167(2):122–4

A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Bjarnason I, et al. **Scand J Gastroenterol** 1997 Feb;32(2):126–30

Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study [see comments] Ekström P, et al. **Scand J Gastroenterol** 1996 Aug;31(8):753–8. Comment in: Scand J Gastroenterol 1997 Jan;32(1):95.

The effects of chronic administration of indomethacin and misoprostol on renal function in cirrhotic patients with and without ascites. Hsia HC, et al. **Scand J Gastroenterol** 1995 Dec;30(12):1194–9

Is there a relationship between the use of analgesics and non-steroidal anti-inflammatory drugs and acute upper gastrointestinal bleeding? A Finnish case-control prospective study. Matikainen M, et al. **Scand J Gastroenterol** 1996 Sep;31(9):912–6

Quality of life in users of non-steroidal anti-inflammatory drugs. Hawkey CJ. **Scand J Gastroenterol Suppl** 1996; 221:23–4

Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Hawkey CJ. **Scand J Gastroenterol Suppl** 1996;220:124–7 (34 ref.)

Ulcer bleeding and perforation: non-steroidal anti-inflammatory drugs or Helicobacter pylori. Svanes C, et al. **Scand J Gastroenterol Suppl** 1996;220:128–31 (43 ref.)

Leukaemia during podophyllotoxin treatment in a patient with juvenile chronic arthritis [letter] Kauppi M, et al. **Scand J Rheumatol** 1996;25(5):340

Considerations for nonsteroidal anti-inflammatory drug therapy: safety. Blower AL. **Scand J Rheumatol Suppl** 1996; 105:13–24; discussion 25–7 (51 ref.)

Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. García Rodríguez LA. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):16–20

The gastroenterologist's caseload: contribution of the rheumatologist. Hawkey CJ. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):11–5 (13 ref.)

The effects of nonsteroidal anti-inflammatory drugs on posterior spinal fusions in the rat. Dimar JR 2nd, et al. **Spine** 1996 Aug 15;21(16):1870–6

Bleeding esophageal ulcers caused by NSAIDs. Sugawa C, et al. **Surg Endosc** 1997 Feb;11(2):143–6 (22 ref.)

Immune complex-mediated haemolytic anaemia and Evans syndrome induced by diclofenac. de Quirós JF, et al. **Vox Sang** 1997;72(2):121–3

[NSAID and ulcer complications. An analysis of risk factors] Hansen JM, et al. **Ugeskr Laeger** 1997 Jun 9; 159(24):3787–91 (Eng. Abstr.) **(Dan)**

[Should one take the safe measures in the prevention of NSAID-induced ulcers...] Schaffalitzky de Muckadell OB. **Ugeskr Laeger** 1996 Nov 18;158(47):6783–4 **(Dan)**

[Do NSAIDs damage articular cartilage? (letter)] Schiøtz-Christensen E. **Ugeskr Laeger** 1997 May 19; 159(21):3194–6 **(Dan)**

[Heart failure and fluid retention attributed to the use of non-steroidal anti-inflammatory drugs] Feenstra J, et al. **Ned Tijdschr Geneeskd** 1996 Oct 5;140(40):2000–3 **(Dut)**

[Importance of in vivo and in vitro studies of leukotrienes. Application to the particular instance of aspirin] Sainte-Laudy J. **Allerg Immunol (Paris)** 1997 Feb; 29(2):28–35 (65 ref.) (Eng. Abstr.) **(Fre)**

[Hypersensitivity to 5-aminosalicylic acid. Value of desensitization by oral route] Lachaux A, et al. **Arch Pediatr** 1997 Feb;4(2):144–6 (Eng. Abstr.) **(Fre)**

[Side effects of 5-aminosalicylic acid] Marteau P, et al. **Gastroenterol Clin Biol** 1997;21(5):377–86 (118 ref.) **(Fre)**

[Non-gastroduodenal digestive toxicity of non-steroidal anti-inflammatory agents] Lesur G. **Presse Med** 1996 Oct 12;25(30):1376–80 (25 ref.) (Eng. Abstr.) **(Fre)**

[Acute cervical necrotizing fasciitis of pharyngeal origin: possible role of steroidal and non-steroidal anti-inflammatory agents. Apropos of 5 cases] Chaplain A, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996; 117(5):377–80 (20 ref.) (Eng. Abstr.) **(Fre)**

[Digestive and extra-digestive complications of nonsteroidal anti-inflammatory drugs. Preventive and curative strategies] Sternon J, et al. **Rev Med Brux** 1997 Apr; 18(2):52–8 (43 ref.) (Eng. Abstr.) **(Fre)**

[A rare cause of chronic diarrhea] Gatel A, et al. **Rev Med Interne** 1997;18 Suppl 3:288s–290s **(Fre)**

[Side effects of mesotherapy] Doutre MS, et al. **Therapie** 1997 Mar-Apr;52(2):93–6 (15 ref.) **(Fre)**

[Focus on the safety of ibuprofen at the analgesic-antipyretic dose] Moore N, et al. **Therapie** 1996 Jul-Aug;51(4):458–63 (13 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of drug-induced agranulocytosis with granulocyte colony stimulating factor (G-CSF) in a surgical intensive care unit] Huss B, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Oct; 31(8):529–30 (Eng. Abstr.) **(Ger)**

[Oral exposure testing in non-aspirin-induced analgesic intolerance] Wiedow O, et al. **Hautarzt** 1996 Dec; 47(12):901–8 (Eng. Abstr.) **(Ger)**

[Analgesic nephropathy] Pommer W, et al. **Internist (Berl)** 1996 Nov;37(11):1129–36 (65 ref.) **(Ger)**

[Prevention and therapy of NSAID-induced ulcers: fact versus myth] Fried M, et al. **Schweiz Med Wochenschr** 1996 Sep 14;126(37):1569–72 (15 ref.) (Eng. Abstr.) **(Ger)**

[Is misoprostol effective in NSAID-induced gastrointestinal complications?] Stucki G, et al. **Schweiz Med Wochenschr** 1996 Sep 14;126(37):1573–8 (26 ref.) (Eng. Abstr.) **(Ger)**

[Gastroduodenal tolerance and clinical effectiveness of therapy with lonazolac-calcium in rheumatic diseases] Kullich W, et al. **Wien Med Wochenschr** 1996; 146(17):459–64 (Eng. Abstr.) **(Ger)**

[Helicobacter pylori associated gastrointestinal mucosal lesions: is there an increased risk during therapy with nonsteroidal antirheumatic agents?] Pöllmann G, et al. **Z Rheumatol** 1997 Mar-Apr;56(2):71–5 (Eng. Abstr.) **(Ger)**

[Leukocytoclastic vasculitis associated with naproxen] Lossos IS, et al. **Harefuah** 1996 May 1;130(9):600–1, 655 (9 ref.) (Eng. Abstr.) **(Heb)**

[Gastric mucosa changes caused by anti-inflammatory agents in childhood] Berni Canani M, et al. **Pediatr Med Chir** 1996 Jul-Aug;18(4):377–81 (Eng. Abstr.) **(Ita)**

[Report of 3 cases of greater curvature antral flattening caused by non-steroidal anti-inflammatory agents] Catalano O. **Radiol Med (Torino)** 1996 Sep;92(3):320–1 **(Ita)**

[The epidemiology of the gastroduodenal damage induced by aspirin and other nonsteroidal anti-inflammatory drugs] Dobrilla G, et al. **Recenti Prog Med** 1997 May;88(5):202–11 (78 ref.) (Eng. Abstr.) **(Ita)**

[Aspirin-induced asthma as an important type of bronchial asthma] Sakakibara H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:106–15 (Eng. Abstr.) **(Jpn)**

[Adverse reaction of drugs in the field of orthopaedic surgery] Azuma T. **Nippon Seikeigeka Gakkai Zasshi** 1997 Feb;71(2):106–11 (13 ref.) **(Jpn)**

[Pathogenesis and therapy of non-steroidal anti-inflammatory drug (NSAID)-induced gastric mucosal injury] Yoshikawa T, et al. **Nippon Seikeigeka Gakkai Zasshi** 1996 May;70(5):269–73 (20 ref.) **(Jpn)**

[Nephrotoxicity of non steroidal anti-inflammatory drugs (NSAID)] Ozono Y, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):574–6 (9 ref.) **(Jpn)**

[Drug-induced renal disorders in patients with rheumatoid arthritis] Nakano M, et al. **Ryumachi** 1996 Oct;36(5):775–82 (40 ref.) **(Jpn)**

[Reactivation of ulcerative rectocolitis with the use of non-steroidal anti-inflammatory drugs. Report of a case and review of the literature] Dichi I, et al. **Arq Gastroenterol** 1995 Oct-Dec;32(4):172–7 (40 ref.) (Eng. Abstr.) **(Por)**

[Side effects of treatment with non-steroidal antiinflammatory agents and ways of their corrections] Grebneva LS, et al. **Klin Med (Mosk)** 1997;75(5):42–5 (45 ref.) **(Rus)**

[Gastroduodenal lesions induced by non-steroidal antiinflammatory drugs] Grigorév PI, et al. **Klin Med (Mosk)** 1997;75(3):69–71 **(Rus)**

[Allergic drug-dependent lesions of the lungs] Sinopal'nikov AI. **Klin Med (Mosk)** 1996;74(4):59–62 **(Rus)**

[The prevention of stress-related postoperative and drug-induced erosive-ulcerative lesions of the upper digestive tract] Degtiareva II, et al. **Lik Sprava** 1995 Mar-Apr;(3-4):61–4 (Eng. Abstr.) **(Rus)**

[Aspirin-induced asthma (its clinical picture, pathogenesis and treatment)] Fedoseev GB, et al. **Ter Arkh** 1997; 69(3):64–8 (43 ref.) **(Rus)**

[The endoscopic assessment of the effect of ranitidine and pirenzepine on the manifestations of the gastropathy induced by nonsteroidal anti-inflammatory preparations] Karateev AE, et al. **Ter Arkh** 1997;69(5):67–9 (Eng. Abstr.) **(Rus)**

[Liver damage caused by sensitivity to anti-inflammatory agents] Bogić M, et al. **Srp Arh Celok Lek** 1997 Sep-Oct; 125(9-10):291–4 (Eng. Abstr.) **(Scc)**

[Recall of metamizole from the market in countries with modern pharmacotherapy] Mihajlović G. **Srp Arh Celok Lek** 1996 Jan-Feb;124(1-2):44–6 (Eng. Abstr.) **(Scc)**

[Comparative study of the occurrence of gastrointestinal side-effects of tenoxicam and other nonsteroidal antirheumatic agents in patients with rheumatoid arthritis] Vlak T, et al. **Reumatizam** 1996;43(1):1–9 (Eng. Abstr.) **(Scr)**

[Pneumonitis caused by mesalazine] Pascual Lledó F, et al. **Arch Bronconeumol** 1997 Jun;33(6):309–11 (Eng. Abstr.) **(Spa)**

[Alopecia secondary to tenoxicam. An undescribed adverse effect? (letter)] Aroca Garcia MD, et al. **Aten Primaria** 1997 Jul-Aug;20(3):157 **(Spa)**

[Gastric protection in the treatment with NSAIDs (see comments)] Gené Badla J, et al. **Aten Primaria** 1997 Mar 15;19(4):207–10 (23 ref.). Comment in: Aten Primaria 1997 Jun 15;20(1):1–2. **(Spa)**

[HIV infection and Lyell syndrome: a wake-up call concerning anti-inflammatory agents (letter)] de Luis DA, et al. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):231–2 **(Spa)**

[Chronic anemia protects against gastric damage by alcohol and aspirin. The role of the toxic radicals and lipid peroxidation] Marroni NP, et al. **Gastroenterol Hepatol** 1996 Dec;19(10):497–502 (Eng. Abstr.) **(Spa)**

[Hepatic toxicity caused by aceclofenac (letter)] Prieto de Paula JM, et al. **Gastroenterol Hepatol** 1997 Mar;20(3):165 **(Spa)**

[Acute hepatitis caused by diclofenac (letter)] Vilà Santasuana A, et al. **Gastroenterol Hepatol** 1997 Mar; 20(3):164–5 **(Spa)**

[Toxic hepatitis caused by aceclofenac (letter)] Pérez Moreno JM, et al. **Rev Esp Enferm Dig** 1996 Nov;88(11):815–6 **(Spa)**

[Contact dermatitis caused by ketoprofen] **Lakartidningen** 1997 Jul 23;94(30–31):2664–5 **(Swe)**

[Steroids and NSAID: combination increases risk for stomach ulcer] Aly A. **Lakartidningen** 1997 Feb 12;94(7):545–6 **(Swe)**

[A reminder of bleeding risk with diclofenac administration (letter)] Flodström A. **Lakartidningen** 1997 May 14; 94(20):1868 **(Swe)**

[NSAID-induced ulcer and its complications] Aly A. **Nord Med** 1997 Jun;112(6):195–7 (Eng. Abstr.) **(Swe)**

ANALYSIS

Phosphorimetric determination of indomethacin in pharmaceutical formulations. Arruda AF, et al. **Analyst** 1997 Jun;122(6):559–62

Clean method for the simultaneous determination of propyphenazone and caffeine in pharmaceuticals by flow injection Fourier transform infrared spectrometry. Bouhsain Z, et al. **Analyst** 1997 May;122(5):441–5

Ibuprofen in human milk [letter] Walter K, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):211–2

Determination of phenylbutazone residues in bovine milk by liquid chromatography with UV detection. De Veau EJ. **J AOAC Int** 1996 Sep-Oct;79(5):1050–3

Extractionless high-performance liquid chromatographic method for the simultaneous determination of piroxicam and 5'-hydroxypiroxicam in human plasma and urine. Avgerinos A, et al. **J Chromatogr B Biomed Appl** 1995 Nov 3;673(1):142–6

Methods of analysis of chiral non-steroidal anti-inflammatory drugs. Davies NM. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):229–61 (157 ref.)

Stable isotope labelling and determination of ketoprofen in human plasma and urine by gas chromatography/negative ion chemical ionization mass spectrometry. Leis HJ, et al. **J Mass Spectrom** 1996 May;31(5):486–92

Determination of enantiomeric composition of ibuprofen in bulk drug by proton nuclear magnetic resonance spectroscopy with a chiral lanthanide chelate. Hanna GM. **J Pharm Biomed Anal** 1997 Aug;15(12):1805–11

Development and validation of a reversed-phase liquid chromatographic method for analysis of aspirin and warfarin in a combination tablet formulation. Montgomery ER, et al. **J Pharm Biomed Anal** 1996 Oct;15(1):73–82

Determination of FGN-1 (an active metabolite of sulindac) in human plasma, urine, and feces by HPLC. Ray GF, et al. **J Pharm Biomed Anal** 1995 Dec;14(1–2):213–20

Indirect enantiomeric separation of 2-arylpropionic acids and structurally related compounds by reversed phase HPLC. Thomason MJ, et al. **J Pharm Biomed Anal** 1997 Jul; 15(11):1765–74

Simultaneous determination of tenoxicam and 2-aminopyridine using derivative spectrophotometry and high-performance liquid chromatography. el Walily AF, et al. **J Pharm Biomed Anal** 1997 Aug;15(12):1923–8

Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations [see comments] Day RO, et al. **J Rheumatol** 1995 Dec;22(12):2295–303. Comment in: J Rheumatol 1996 Oct;23(10):1826; discussion 1827–8. Comment in: J Rheumatol 1996 Oct;23(10):1826–7; discussion 1827–8.

A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. Krivosíková Z, et al. **Methods Find Exp Clin Pharmacol** 1996 Oct;18(8):527–32

Covalent binding of acidic drugs via reactive intermediates: detection of benoxaprofen and flunoxaprofen protein adducts in biological material. Dahms M, et al. **Pharmazie** 1996 Nov;51(11):874–81

[Extraction technology of effervescent granules for arresting cold pain optimized by orthogonal tests] Sun X, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Mar;21(3):159–61, 190 (Eng. Abstr.) **(Chi)**

[Methodologic comparison of the quantitative profile of aceclofenac in biological fluids] Gambaro V, et al. **Boll Chim Farm** 1997 Apr;136(4):368–71 **(Ita)**

ANTAGONISTS & INHIBITORS

Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Palop D, et al. **Arzneimittelforschung** 1997 Apr;47(4A):439–46

Does the nature of the solvent affect the anti-inflammatory capacity of triclosan? An experimental study. Skaare AB, et al. **J Clin Periodontol** 1997 Feb;24(2):124–8

Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Kirchner T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jun;56(6):417–23

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL

Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs. Li EK, et al. **Scand J Rheumatol** 1996;25(1):42–6

BLOOD

Diflunisal cross-reactivity with the Trinder method for salicylate determination [letter] Nordt SP. **Ann Pharmacother** 1996 Sep;30(9):1041–2

Pharmacokinetic profile of piroxicam beta-cyclodextrin, in rat plasma and lymph. Kimura E, et al. **Gen Pharmacol** 1997 May;28(5):695–8

Quantification of ketoprofen enantiomers in human plasma based on solid-phase extraction and enantioselective column chromatography. Boisvert J, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):189–93

Sensitive capillary gas chromatographic-mass spectrometric-selected-ion monitoring method for the determination of diclofenac concentrations in human plasma. Borenstein MR, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):59–66

Simultaneous determination of rufloxacin, fenbufen and felbinac in human plasma using high-performance liquid chromatography. Carlucci G, et al. **J Chromatogr B Biomed Appl** 1996 Jul 12;682(2):315–9

High-performance thin-layer chromatographic determination of flurbiprofen in plasma. Dhavse VV, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):449–53

Ketoprofen analysis in serum by capillary electrophoresis. Friedberg M, et al. **J Chromatogr B Biomed Appl** 1997 Jul 18;695(1):193–8

Determination of flunixin in equine urine and serum by capillary electrophoresis. Gu X, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):187–98

High-performance thin-layer chromatographic determination of ibuprofen in plasma. Save TK, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):315–9

Analysis of ibuprofen in serum by capillary electrophoresis. Shihabi ZK, et al. **J Chromatogr B Biomed Appl** 1996 Aug 9;683(1):115–8

Determination of sulindac and its metabolites in human serum by reversed-phase high-performance liquid chromatography using on-line post-column ultraviolet irradiation and fluorescence detection. Siluveru M, et al. **J Chromatogr B Biomed Appl** 1995 Nov 3;673(1):91–6

Evaluation of a benchtop ion trap gas chromatographic-tandem mass spectrometric instrument for the analysis of a model drug, tebufelone, in plasma using a stable-isotope internal standard. Wehmeyer KR, et al. **J Chromatogr B Biomed Appl** 1996 Feb 9;676(1):53–9

Simultaneous determination of furprofen and rufloxacin in human plasma by high-performance liquid chromatography. Carlucci G, et al. **J Chromatogr Sci** 1996 Apr;34(4):182–4

Development of a radioimmunoassay for SR 31747A, a new sigma ligand, in human plasma. Dussossoy D, et al. **J Pharm Biomed Anal** 1996 May;14(7):783–91

Solid-phase extraction and HPLC analysis of kebuzone and its metabolites in blood. Klimes J, et al. **Pharmazie** 1996 Sep;51(9):651–3

[HPLC analysis of non-steroidal antirheumatic agents in biological material. II. Profens] Sochor J, et al. **Ceska Slov Farm** 1997 Apr;46(2):78–83 (Eng. Abstr.) **(Cze)**

[The effect of ovariectomy in women on metabolism of phenazone] Konieczny M. **Ginekol Pol** 1996 Sep; 67(9):451–6 (Eng. Abstr.) **(Pol)**

[Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer] Orzechowska-Juzwenko K, et al. **Przegl Lek** 1997; 54(2):103–6 (Eng. Abstr.) **(Pol)**

CHEMICAL SYNTHESIS

Synthesis, antioxidant and anti-inflammatory activity of novel substituted ethylenediamines and ethanolamines. A preliminary quantitative structure-activity relationship study. Andreadou I, et al. **Arzneimittelforschung** 1997 May; 47(5):643–7

Synthesis and anti-inflammatory properties of 8-(3-dimethylaminopropionyl)-1,6-benzodioxocane. Daukšas V, et al. **Arzneimittelforschung** 1995 Nov; 45(11):1202–6

Studies on analgesic and anti-inflammatory activities of 1-dialkylaminomethyl-2-(p-substituted phenyl)-5-substituted benzimidazole derivatives. Ersan S, et al. **Arzneimittelforschung** 1997 Jul;47(7):834–6

Synthesis, analgesic and anti-inflammatory activities of some 1-acyl/aracyl-5-aminopyrazole derivatives. Gadad AK, et al. **Arzneimittelforschung** 1996 Nov;46(11):1082–5

Synthesis and evaluation of the anti-inflammatory effects of niflumic acid lipophilic prodrugs in brain edema. el Kihel L, et al. **Arzneimittelforschung** 1996 Nov;46(11):1040–4

Some new 1,2-benzothiazine derivatives with analgesic and anti-inflammatory activities. Kwon SK, et al. **Arzneimittelforschung** 1996 Oct;46(10):966–71

Synthesis and anti-inflammatory activity of polyazaheterocyclic derivatives of 6-amino-2,4-lutidine and their precursors. Robert JM, et al. **Arzneimittelforschung** 1997 May;47(5):635–42

Synthesis of some new quinazolines and quinoxalines of potential antiinflammatory activity. el-Bendary ER, et al. **Boll Chim Farm** 1996 Dec;135(11):617–20

Substituted quinazolinones and their anti-inflammatory activity. Hitkari A, et al. **Boll Chim Farm** 1995 Dec; 134(11):609–15

Synthesis and antiinflammatory activity of certain thienopyrimidine derivatives. el-Kerdawy MM, et al. **Boll Chim Farm** 1996 May;135(5):301–5

In the search for new antiinflammatory drugs: synthesis and antiinflammatory activity of some Thiazolo(3,2-a)pyrimidine derivatives containing a thioether group. Passarotti CM, et al. **Boll Chim Farm** 1995 Dec;134(11):639–43

Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives. Tsuji K, et al. **Chem Pharm Bull (Tokyo)** 1997 Jun;45(6):987–95

1,8-Naphthyridines. III. N,N-dialkyl-5-chloro[1,2,4]-triazolo[4,3-a][1,8]naphthyridine-6-carboxa mides with anti-inflammatory activity. Di Braccio M, et al. **Farmaco** 1997 Jan;52(1):49–53

Synthesis and SAR study of imidazo[2,1-b]benzothiazole acids and some related compounds with anti-inflammatory and analgesic activities. Palagiano F, et al. **Farmaco** 1996 Jul;51(7):483–91

Synthesis of amides with anti-inflammatory and analgesic activities. Pau A, et al. **Farmaco** 1997 Feb;52(2):93–8

Studies on o-[2,6-dichlorophenyl-1-amino] phenyl acetic acid. I. Synthesis, antiinflammatory, analgesic and ulcerogenic activities of some new amino acid conjugates. Shalaby AM, et al. **Farmaco** 1997 Feb;52(2):83–7

3,3'-Bi(1,3-thiazolidin-4-one) system. VIII. 3,3'-(1,2-Ethanediyl) derivatives and corresponding 1,1'-disulfones: synthesis, stereochemistry and antiinflammatory activity. Vigorita MG, et al. **Farmaco** 1997 Jan;52(1):43–8

3,4-Dimethoxy cinnamic acid tertiary amides: synthesis and evaluation of antiinflammatory and analgesic activities. Yeşilada A, et al. **Farmaco** 1996 Aug-Sep;51(8–9):595–9

Anti-inflammatory and analgesic activities of 1-[2-(substituted benzothiazole)]-1,3-diethyl-4-aryl guanidines [letter] Naik PR, et al. **Indian J Physiol Pharmacol** 1996 Apr;40(2):189–90

1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. Boehm JC, et al. **J Med Chem** 1996 Sep 27;39(20):3929–37

1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. Khanna IK, et al. **J Med Chem** 1997 May 23;40(11):1619–33

1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents. Khanna IK, et al. **J Med Chem** 1997 May 23;40(11):1634–47

Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl] propenamide and related compounds. Kuo EA, et al. **J Med Chem** 1996 Nov 8; 39(23):4608–21

Synthesis and anti-inflammatory effects of xanthone derivatives. Lin CN, et al. **J Pharm Pharmacol** 1996 May; 48(5):532–8

Synthesis, antiinflammatory, and cytotoxic activities of 2-alkyl and 2-benzyl-2-dimethylaminomethyl-5-(E)-arylidene cyclopentanone hydrochlorides. Chen H, et al. **Pharm Res** 1996 Oct;13(10):1482–7

Analgesic and antiinflammatory effects of some 2-mercaptobenzoxazole derivatives. Safak C, et al. **Pharmazie** 1996 Mar;51(3):180–2

[2-Aryl-pyrrolo[2,1-b]benzothiazoles as a selective or dual inhibitors of cyclo-oxygenases and 5-lipoxygenases. 21. Non-steroidal anti-inflammatory agents] Dannhardt G, et al. **Pharmazie** 1997 Jun;52(6):428–36 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Non-steroidal anti-inflammatory agents, Part 24. Pyrrolidino enaminones as models to mimic arachidonic acid. Dannhardt G, et al. **Arch Pharm (Weinheim)** 1997 Mar; 330(3):74–82

In vitro studies of some 2,4-disubstituted thiazolyl-aminoketones with anti-inflammatory activity. Correlation with lipophilicity and structural characteristics. Geronikaki AA, et al. **Arzneimittelforschung** 1996 Dec; 46(12):1134–7

Effects of extracts from Populus tremula L., solidago virgaurea L. and Fraxinus excelsior L. on various myeloperoxidase systems. von Kruedener S, et al. **Arzneimittelforschung** 1996 Aug;46(8):809–14

Novel approach for determination of correlation between in vivo and in vitro dissolution using the optimization technique. Ishii K, et al. **Chem Pharm Bull (Tokyo)** 1996 Aug;44(8):1550–5

The reaction of ebselen with peroxynitrite. Masumoto H, et al. **Chem Res Toxicol** 1996 Jan-Feb;9(1):262–7

Stereoselective disposition of flurbiprofen from a mutual prodrug with a histamine H2-antagonist to reduce gastrointestinal lesions in the rat. Fukuhara A, et al. **Chirality** 1996;8(7):494–502

Chirality and nonsteroidal anti-inflammatory drugs. Hayball PJ. **Drugs** 1996;52 Suppl 5:47–58 (87 ref.)

Antiflammins: endogenous nonapeptides with regulatory effect on inflammation. Moreno JJ. **Gen Pharmacol** 1997 Jan;28(1):23–6 (41 ref.)

Physical aspects of dexibuprofen and racemic ibuprofen. Leising G, et al. **J Clin Pharmacol** 1996 Dec;36(12 Suppl):3S–6S

Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors. Kolasa T, et al. **J Med Chem** 1997 Feb 28;40(5):819–24

Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. Lazer ES, et al. **J Med Chem** 1997 Mar 14; 40(6):980–9

Synthesis of carboranes containing an azulene framework and in vitro evaluation as boron carriers. Nakamura H, et al. **J Med Chem** 1997 Aug 29;40(18):2825–30

In-vitro studies of enteric coated diclofenac sodium-carboxymethylcellulose microspheres. Arica B, et al. **J Microencapsul** 1996 Nov-Dec;13(6):689–99

Investigation of in-vitro release characteristics of NSAID-loaded polylactic acid microspheres. Guiziou B, et al. **J Microencapsul** 1996 Nov-Dec;13(6):701–8

Stereospecific formulation and characterization of sustained release ibuprofen microspheres. Janjikhel RK, et al. **J Microencapsul** 1997 Jul-Aug;14(4):409–26

The influence of microencapsulation using Eudragit RS100 on the hydrolysis kinetics of acetylsalicylic acid. Vachon MG, et al. **J Microencapsul** 1997 May-Jun;14(3):281–301

Complexes of Fe(III) ions with mefenamic acid. Bojarowicz H, et al. **J Pharm Biomed Anal** 1996 Dec;15(3):339–42

4-(6-methoxy-2-naphthyl)-2-butyl chloroformate enantiomers: new reagents for the enantiospecific analysis of amino compounds in biogenic matrices. Büschges R, et al. **J Pharm Biomed Anal** 1996 Nov;15(2):201–20

hP, the component of log P controlling structure-activity relationships amongst non-steroidal anti-inflammatory drugs. Dean FM. **J Pharm Pharmacol** 1996 Mar;48(3):233–9

A QSAR study of anti-inflammatory N-arylanthranilic acids. Duffy JC, et al. **J Pharm Pharmacol** 1996 Sep;48(9):883–6

Interactions of nonsteroidal antiinflammatory drugs with phospholipids: comparison between octanol/buffer partition coefficients and chromatographic indexes on immobilized artificial membranes. Barbato F, et al. **J Pharm Sci** 1997 Feb;86(2):225–9

Physicochemical characterization of diclofenac N-(2-hydroxyethyl)pyrrolidine: anhydrate and dihydrate crystalline forms. Ledwidge MT, et al. **J Pharm Sci** 1996 Jan;85(1):16–21

Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes. Piel G, et al. **J Pharm Sci** 1997 Apr;86(4):475–80

Dissolution mechanism of diclofenac sodium from wax matrix granules. Sato H, et al. **J Pharm Sci** 1997 Aug;86(8):929–34

Determination of the optical purity of ibuprofen using X-ray powder diffraction [letter] Stahly GP, et al. **J Pharm Sci** 1997 Aug;86(8):970–1

Chirality: a major issue in veterinary pharmacology. Landoni MF, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):82–4 (17 ref.)

In-vitro evaluation of sustained release ibuprofen microspheres. Ghaly ES, et al. **P R Health Sci J** 1996 Jun; 15(2):97–100

Oxidative degradation of antiflammin 2. Ye JM, et al. **Pharm Res** 1996 Feb;13(2):250–5

Radical scavenger activity of bendazac, an anticataract non-steroidal anti-inflammatory agent. Guglielmotti A, et al. **Pharmacol Res** 1995 Dec;32(6):369–73

Interaction of ibuprofen and indomethacin with caffeine. Khalil RM. **Pharmazie** 1996 Dec;51(12):970–3

Cosolvent solubilization and formulation of an aqueous injection of ketoprofen. Singhai AK, et al. **Pharmazie** 1996 Oct;51(10):737–40

CLASSIFICATION

A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Frölich JC. **Trends Pharmacol Sci** 1997 Jan;18(1):30–4 (55 ref.)

CONTRAINDICATIONS

Severe asthmatic reaction to contraindicated anti-inflammatory drug [letter] Hailemeskel B, et al. **Am J Health Syst Pharm** 1997 Jan 15;54(2):199–200

No basis for associating nonprescription ibuprofen and similar agents with necrotizing fasciitis [letter; comment] Melis R. **Am J Health Syst Pharm** 1996 Sep 15;53(18):2218–9. Comment on: Am J Health Syst Pharm 1996 Feb 1;53(3):265–9.

Prolongation of prothrombin time with the use of indomethacin and warfarin. Chan TY. **Br J Clin Pract** 1997 Apr-May;51(3):177–8

Should nursing mothers take ibuprofen? [letter; comment] Anderson PD, et al. **MCN Am J Matern Child Nurs** 1996 May-Jun;21(3):122, 161. Comment on: MCN Am J Matern Child Nurs 1996 Jan-Feb;21(1):56.

Should nursing mothers take ibuprofen? [letter; comment] Burroughs MW. **MCN Am J Matern Child Nurs** 1996 May-Jun;21(3):122. Comment on: MCN Am J Matern Child Nurs 1996 Jan-Feb;21(1):56.

[Treatment with NSAID can delay the diagnosis in GAS-sepsis (letter)] Bäcklund U, et al. **Lakartidningen** 1997

Feb 19;94(8):602 **(Swe)**

DIAGNOSTIC USE

Is diclofenac helpful in the diagnosis of partial epididymal obstruction? [letter] Martin-Du Pan R, et al. **Hum Reprod** 1997 Feb;12(2):396-7

[The in-vivo test of the inhibition of leukocyte natural migration with aspirin and analgin in the specific diagnosis of the asthmatic triad] Kanchurina NA, et al. **Ter Arkh** 1996;68(12):25-8 (Eng. Abstr.) **(Rus)**

ECONOMICS

Evaluation of the financial impact of ketorolac tromethamine therapy in hospitalized patients. Burke JP, et al. **Clin Ther** 1996 Jan-Feb;18(1):197-211

NSAIDs and the elderly. Toxicity and economic implications. Phillips AC, et al. **Drugs Aging** 1997 Feb; 10(2):119-30 (62 ref.)

Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. Smalley WE, et al. **J Gen Intern Med** 1996 Aug;11(8):461-9

Changing physician prescribing behavior: a low-cost administrative policy that reduced the use of brand name nonsteroidal anti-inflammatory drugs. Ahluwalia JS, et al. **Prev Med** 1996 Nov-Dec;25(6):668-72

HISTORY

Facing the future: drug discovery reconsidered. Bliven ML, et al. **Inflamm Res** 1996 Aug;45(8):365-9

IMMUNOLOGY

Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. Quiralte J, et al. **J Allergy Clin Immunol** 1996 Sep;98(3):678-85

ISOLATION & PURIFICATION

Enantioseparation of nonsteroidal anti-inflammatory drugs by capillary electrophoresis using mixtures of anionic and uncharged beta-cyclodextrins as chiral additives. Fillet M, et al. **Electrophoresis** 1997 Jun;18(6):1013-8

Supercritical fluid extraction of selected pharmaceuticals from water and serum. Simmons BR, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):291-302

Separation of the stereoisomers of the main metabolite of a non-steroidal anti-inflammatory drug, flobufen, by chiral high-performance liquid chromatography. Wsól V, et al. **J Chromatogr B Biomed Appl** 1997 Feb 7;689(1):205-14

Three new oleanane saponins from Zanha africana. Cuéllar MJ, et al. **J Nat Prod** 1997 Feb;60(2):191-4

Preliminary studies on the antiinflammatory, analgesic and diuretic activity of stagninol, a sesquiterpene isolated from Persicaria stagnina. Ahmed M, et al. **Pharmazie** 1997 Jun; 52(6):472-5

Topical anti-inflammatory lignans from Haplophyllum hispanicum. Prieto JM, et al. **Z Naturforsch [C]** 1996 Sep-Oct;51(9-10):618-22

METABOLISM

5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Stretch GL, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):941-7

Modelling of indometacin and diclofenac sodium binding to the molecule of human serum albumin. Russeva V, et al. **Arzneimittelforschung** 1996 Mar;46(3):288-92

Lactoperoxidase-catalysed oxidation of indomethacin, a nonsteroidal antiinflammatory drug, through the formation of a free radical. Chatterjee R, et al. **Biochem Pharmacol** 1996 Oct 25;52(8):1169-75

Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Hamman MA, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):33-41

Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Tracy TS, et al. **Biochem Pharmacol** 1996 Oct 25; 52(8):1305-9

Pharmacokinetic analysis of enterohepatic circulation of etodolac and effect of hepatic and renal injury on the pharmacokinetics. Ogiso T, et al. **Biol Pharm Bull** 1997 Apr;20(4):405-10

Effect of portal vein ligation and silymarin treatment on aspirin metabolism and disposition in rats. Favari L, et al. **Biopharm Drug Dispos** 1997 Jan;18(1):53-64

Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Miyamoto G, et al. **Chem Res Toxicol** 1997 Apr;10(4):414-9

Cytochrome P4502C11 is a target of diclofenac covalent binding in rats. Shen S, et al. **Chem Res Toxicol** 1997 Apr; 10(4):420-3

Immunochemical identification of mouse hepatic protein adducts derived from the nonsteroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen. Wade LT, et al. **Chem Res Toxicol** 1997 May;10(5):546-55

Stereoselective metabolic pathways of ketoprofen in the rat: incorporation into triacylglycerols and enantiomeric inversion. Carabaza A, et al. **Chirality** 1996;8(2):163-72

Bi-directional chiral inversion of ketoprofen in CD-1 mice. Jamali F, et al. **Chirality** 1997;9(1):29-31

Stereoselective metabolism of famprofazone in humans: N-dealkylation and beta- and p-hydroxylation. Shin HS. **Chirality** 1997;9(1):52-8

Synthesis, chromatographic resolution and chiroptical properties of carboxyibuprofen stereoisomers: major metabolites of ibuprofen in man. Tan SC, et al. **Chirality** 1997;9(1):75-87

Vesico-hepato-renal cycling of acidic drugs via their reactive acyl glucuronide metabolites? Studies with diflunisal in rats. Dickinson RG, et al. **Clin Exp Pharmacol Physiol** 1996 Aug;23(8):665-8

Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human. Bort R, et al. **Drug Metab Dispos** 1996 Sep; 24(9):969-75

Metabolism of aceclofenac in humans. Bort R, et al. **Drug Metab Dispos** 1996 Aug;24(8):834-41

Biliary excretion and enterohepatic cycling of R- and S-flurbiprofen in the rat. Eeckhoudt SL, et al. **Drug Metab Dispos** 1997 Apr;25(4):428-30

Disposition and metabolism of tenidap in the rat. Fouda HG, et al. **Drug Metab Dispos** 1997 Feb;25(2):140-8

Reactivity of mefenamic acid 1-o-acyl glucuronide with proteins in vitro and ex vivo. McGurk KA, et al. **Drug Metab Dispos** 1996 Aug;24(8):842-9

Purification and 1H NMR spectroscopic characterization of phase II metabolites of tolfenamic acid. Sidelmann UG, et al. **Drug Metab Dispos** 1997 Jun;25(6):725-31

Involvement of the rat gut epithelial and muscular layer, and microflora in chiral inversion and acyl-glucuronidation of R-fenoprofen. Sattari S, et al. **Eur J Drug Metab Pharmacokinet** 1997 Apr-Jun; 22(2):97-101

Nonsteroidal antiinflammatory drugs interact with horseradish peroxidase in an in vitro assay system for hydrogen peroxide scavenging. Parij N, et al. **Eur J Pharmacol** 1996 Sep 12;311(2-3):259-64

Kinetic study of the reaction of ebselen with peroxynitrite. Masumoto H, et al. **FEBS Lett** 1996 Dec 2;398(2-3):179-82

Structure/activity studies of anti-inflammatory peptides based on a conserved peptide region of the lectin domain of E-, L- and P-selectin. Briggs JB, et al. **Glycobiology** 1996 Dec;6(8):831-6

Mechanisms of active oxygen species reduction by non-steroidal anti-inflammatory drugs. Kimura K. **Int J Biochem Cell Biol** 1997 Mar;29(3):437-46

Cloning and functional characterization of the ornithokinin receptor. Recognition of the major kinin receptor antagonist, HOE140, as a full agonist. Schroeder C, et al. **J Biol Chem** 1997 May 9;272(19):12475-81

Determination of fenbufen and its metabolites in serum by reversed-phase high-performance liquid chromatography using solid-phase extraction and on-line post-column ultraviolet irradiation and fluorescence detection. Siluveru M, et al. **J Chromatogr B Biomed Appl** 1996 Jun 28; 682(1):89-94

Ibuprofen enantiomers and lipid metabolism. Mayer JM. **J Clin Pharmacol** 1996 Dec;36(12 Suppl):27S-32S

Lipid metabolism is altered by nebacitin in rats fed cooked-stored polished rice as the only dietary carbohydrate with or without exogenous cholesterol. Cheng HH, et al. **J Nutr** 1997 Jan;127(1):153-7

A quantitative circular dichroic investigation of the binding of the enantiomers of ibuprofen and naproxen to human serum albumin. Cheruvallath VK, et al. **J Pharm Biomed Anal** 1997 Jul;15(11):1719-24

Inhibitory effect of pentobarbital on biliary excretion of diclofenac in a rat liver perfusion system. Fukuyama T, et al. **J Pharm Pharmacol** 1996 Jul;48(7):734-7

Characteristics of shed snake skin permeability to indomethacin and fatty alcohols. Kuramoto M, et al. **J Pharm Pharmacol** 1996 Jul;48(7):680-4

Alterations in renal uptake kinetics of the xanthine derivative enprofylline in endotoxaemic mice. Nadai M, et al. **J Pharm Pharmacol** 1996 Jul;48(7):744-8

Effectiveness and mode of action of isopropyl myristate as a permeation enhancer for naproxen through shed snake skin. Suh H, et al. **J Pharm Pharmacol** 1996 Aug; 48(8):812-6

In-vivo assessment of extrahepatic metabolism of paeoniflorin in rats: relevance to intestinal floral metabolism. Takeda S, et al. **J Pharm Pharmacol** 1997 Jan; 49(1):35-9

Degradation of antiflammin 2 under acidic conditions. Ye JM, et al. **J Pharm Sci** 1996 Jul;85(7):695-9

Stereoselective binding properties of naproxen glucuronide diastereomers to proteins. Bischer A, et al. **J Pharmacokinet Biopharm** 1995 Aug;23(4):379-95

The utility of the bile-exteriorized rat as a source of reactive acyl glucuronides: studies with zomepirac. King AR, et al. **J Pharmacol Toxicol Methods** 1996 Nov;36(3):131-6

Molecular cloning and expression of a 2-arylpropionyl-coenzyme A epimerase: a key enzyme in the inversion metabolism of ibuprofen. Reichel C, et al. **Mol Pharmacol** 1997 Apr;51(4):576-82

The cyclooxygenase-2 structure: new drugs for an old target? [news] Garavito RM. **Nat Struct Biol** 1996 Nov; 3(11):897-901

Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Luong C, et al. **Nat Struct Biol** 1996 Nov;3(11):927-33

Purification and partial characterization of an indomethacin hydrolyzing enzyme from pig liver. Terashima K, et al. **Pharm Res** 1996 Sep;13(9):1327-35

Neurokinin receptors in the guinea pig ileum. Nguyen-Le XK, et al. **Pharmacology** 1996 Jan;52(1):35-45

Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors. Dasgupta A, et al. **Ther Drug Monit** 1996 Dec;18(6):654-9

Glucuronidation of diflunisal in liver and kidney microsomes of rat and man. Brunelle FM, et al. **Xenobiotica** 1996 Feb; 26(2):123-31

PHARMACOKINETICS

Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Gionchetti P, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):601-5

Distribution of mesalazine enemas in active and quiescent ulcerative colitis. van Bodegraven AA, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):327-32

A double-blind, randomized, parallel-group study of the pharmacokinetics and onset of action of Naprelan in patients following oral surgery. Gaston G. **Am J Orthop** 1996 Sep;25(9 Suppl):37-41

Pharmacokinetics of flunixin meglumine in healthy foals less than twenty-four hours old. Crisman MV, et al. **Am J Vet Res** 1996 Dec;57(12):1759-61

Ketoprofen concentrations in plasma and milk after intravenous administration in dairy cattle. De Graves FJ, et al. **Am J Vet Res** 1996 Jul;57(7):1031-3

Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys. Mealey KL, et al. **Am J Vet Res** 1997 Jan; 58(1):53-5

Pharmacokinetics of phenylbutazone in camels. Wasfi IA, et al. **Am J Vet Res** 1997 Jun;58(6):636-40

Oral tenoxicam for peripheral orthopaedic surgery: a pharmacokinetic study. Blake DW, et al. **Anaesth Intensive Care** 1997 Apr;25(2):142-6

Serum concentrations of salicylic acid following topically applied salicylate derivatives. Morra P, et al. **Ann Pharmacother** 1996 Sep;30(9):935-40

Absorption of oral lornoxicam in healthy volunteers using a granular formulation in comparison with standard tablets. Bareggi SR, et al. **Arzneimittelforschung** 1997 Jun; 47(6):755-7

Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Dominkus M, et al. **Arzneimittelforschung** 1996 Dec;46(12):1138-43

Pharmacokinetics and drug input characteristics for a diclofenac-codeine phosphate combination following oral and rectal administration. Hanses A, et al. **Arzneimittelforschung** 1996 Jan;46(1):57-63

Absorption and distribution of naproxen in rats orally treated with naproxen betainate sodium salt monohydrate. Comparison with naproxen. Marzo A, et al. **Arzneimittelforschung** 1997 Apr;47(4):381-4

Comparative bioavailability study on naproxen betainate sodium salt monohydrate and naproxen sodium salt in healthy volunteers. Marzo A, et al. **Arzneimittelforschung** 1997 Apr;47(4):385-9

Comparative pharmacokinetic evaluation of compressed suppositories of diclofenac sodium in humans. Ramakrishna S, et al. **Arzneimittelforschung** 1996 Feb;46(2):175-7

Clinical pharmacokinetics of meloxicam. Türck D, et al. **Arzneimittelforschung** 1997 Mar;47(3):253-8

Preliminary toxicokinetic study with different crystal forms of S (+)-ibuprofen (dexibuprofen) and R,S-ibuprofen in rats. Walser S, et al. **Arzneimittelforschung** 1997 Jun; 47(6):750-4

Assessment of total body water in hemodialysis patients by a single oral dose of antipyrine. Odar-Cederlöf I, et al. **ASAIO J** 1996 Jul-Aug;42(4):271-4

Effect of pulsed output ultrasound on the transdermal absorption of indomethacin from an ointment in rats. Asano J, et al. **Biol Pharm Bull** 1997 Mar;20(3):288-91

Pharmacokinetics of indomethacin ester prodrugs: gastrointestinal and hepatic toxicity and the hydrolytic capacity of various tissues in rats. Ogiso T, et al. **Biol Pharm Bull** 1996 Sep;19(9):1178-83

Relationship between pharmacokinetics and the analgesic effect of indomethacin in the rat. Suzuki T, et al. **Biol Pharm Bull** 1997 Apr;20(4):438-42

Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. González-Martín G, et al. **Biomed Pharmacother** 1997;51(4):170-5

In vivo/in vitro correlations for four differently dissolving ketorolac tablets. Gordon MS, et al. **Biopharm Drug Dispos** 1996 Aug;17(6):481-92

Absorption of sulindac from a novel (Pro-SorbTM) liquid formulation. Kanfer I, et al. **Biopharm Drug Dispos** 1996 Apr;17(3):209-21

The effect of experimental renal failure on tolfenamic acid disposition in the dog. Lefebvre HP, et al. **Biopharm Drug Dispos** 1997 Jan;18(1):79-91

The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. Pargal A, et al. **Biopharm Drug Dispos** 1996 Aug;17(6):511-9

'Pavlovian' food effect on the enterohepatic recirculation of piroxicam. Polli JE, et al. **Biopharm Drug Dispos** 1996 Oct; 17(7):635-41

Meloxicam pharmacokinetics in renal impairment. Boulton-Jones JM, et al. **Br J Clin Pharmacol** 1997 Jan;

43(1):35-40

The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis. Hayball PJ, et al. **Br J Clin Pharmacol** 1993 Sep;36(3):185-93

Pharmacokinetics and tolerability of meloxicam after i.m. administration. Narjes H, et al. **Br J Clin Pharmacol** 1996 Feb;41(2):135-9

Disposition and effects of flurbiprofen enantiomers in human serum and blister fluid. Oelkers R, et al. **Br J Clin Pharmacol** 1997 Feb;43(2):145-53

Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. Pedrazzoli Júnior J, et al. **Br J Clin Pharmacol** 1997 Jan; 43(1):104-8

Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Shedlofsky SI, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):627-32

The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen. Skeith KJ, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):163-9

Are the pharmacokinetics of ibuprofen important determinants for the drug's efficacy in postoperative pain after third molar surgery? Jones K, et al. **Br J Oral Maxillofac Surg** 1997 Jun;35(3):173-6

Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by beta-cyclodextrin derivatives in hydrophilic ointment. Arima H, et al. **Chem Pharm Bull (Tokyo)** 1996 Mar;44(3):582-6

l-Menthol, oleic acid and lauricidin in absorption enhancement of free and sodium salt of diclofenac using ethanol treated silicone membrane as model for skin. Maitani Y, et al. **Chem Pharm Bull (Tokyo)** 1996 Feb; 44(2):403-8

Disposition of CS-670, a novel nonsteroidal anit-inflammatory drug, and its metabolites in healthy human volunteers. Asami M, et al. **Chirality** 1996; 8(2):207-13

Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. Fornasini G, et al. **Chirality** 1997;9(3):297-302

Stereoselective disposition of flurbiprofen from a mutual prodrug with a histamine H2-antagonist to reduce gastrointestinal lesions in the rat. Fukuhara A, et al. **Chirality** 1996;8(7):494-502

Stereoselective pharmacokinetics of ibuprofen in rats: effect of enantiomer-enantiomer interaction in plasma protein binding. Itoh T, et al. **Chirality** 1997;9(4):354-61

Bi-directional chiral inversion of ketoprofen in CD-1 mice. Jamali F, et al. **Chirality** 1997;9(1):29-31

Studies on the in vitro inversion of flurbiprofen. Lombard A, et al. **Chirality** 1997;9(3):317-9

Topical administration of racemic ibuprofen. Millership JS, et al. **Chirality** 1997;9(3):313-6

Clinical pharmacokinetics of tiaprofenic acid and its enantiomers. Davies NM. **Clin Pharmacokinet** 1996 Nov; 31(5):331-47 (96 ref.)

Clinical pharmacokinetics of naproxen. Davies NM, et al. **Clin Pharmacokinet** 1997 Apr;32(4):268-93 (139 ref.)

Clinical pharmacokinetics of sulindac. A dynamic old drug. Davies NM, et al. **Clin Pharmacokinet** 1997 Jun; 32(6):437-59 (158 ref.)

Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods. Mehvar R, et al. **Clin Pharmacokinet** 1997 Aug;33(2):122-41 (88 ref.)

Bromfenac disposition in patients with impaired kidney function. Ermer JC, et al. **Clin Pharmacol Ther** 1997 Mar; 61(3):312-8

Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis B virus. Levy M, et al. **Clin Pharmacol Ther** 1997 Jul;62(1):6-14

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Sotaniemi EA, et al. **Clin Pharmacol Ther** 1997 Mar;61(3):331-9

Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Muir N, et al. **Curr Med Res Opin** 1997; 13(9):491-500

Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. Oelkers R, et al. **Drug Metab Dispos** 1996 Oct;24(10):1107-10

Pharmacokinetics of tolfenamic acid in the horse. Jaussaud P, et al. **Equine Vet J Suppl** 1992 Feb;(11):69-72

Influence of feeding schedule on the absorption of orally administered flunixin in the horse. Welsh JC, et al. **Equine Vet J Suppl** 1992 Feb;(11):62-5

Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Bonnabry P, et al. **Eur J Clin Pharmacol** 1996;49(4):305-8

Lack of significant stereoselectivity in pharmacokinetics of tiaprofenic acid [letter; comment] Jamali F. **Eur J Clin Pharmacol** 1997;52(3):243-6. Comment on: Eur J Clin Pharmacol 1996;50(4):283-7.

Stereoselective distribution of tiaprofenic acid in synovium and cartilage in osteoarthritic patients [see comments] Lapicque F, et al. **Eur J Clin Pharmacol** 1996;50(4):283-7 . Comment in: Eur J Clin Pharmacol 1997;52(3):243-6.

Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. Türck D, et al. **Eur J Clin Pharmacol** 1996; 51(3-4):309-13

A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. Maya MT, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct-Dec; 20(4):275-9

Comparative pharmacokinetics of Aspegic 1000 mg i.v. versus 1000 mg i.m. thrice daily. Nia B, et al. **Eur J Drug Metab Pharmacokinet** 1996 Oct-Dec; 21(4):333-8

Pharmacokinetics of tolfenamic acid in pediatric patients after single oral dose. Niopas I, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct-Dec; 20(4):293-6

Fasting and postprandial disposition of R(-)- and S(+)-ibuprofen following oral administration of racemic drug in healthy individuals. Siemon D, et al. **Eur J Med Res** 1997 May 28;2(5):215-9

Effect of pigmentation on the drug deposition in hair of grey-haired subjects. Rothe M, et al. **Forensic Sci Int** 1997 Jan 17;84(1-3):53-60

Activation of CGS 12094 (prinomide metabolite) to 1,4-benzoquinone by myeloperoxidase: implications for human idiosyncratic agranulocytosis. Parrish DD, et al. **Fundam Appl Toxicol** 1997 Feb;35(2):197-204

Pharmacokinetic profile of piroxicam beta-cyclodextrin, in rat plasma and lymph. Kimura E, et al. **Gen Pharmacol** 1997 May;28(5):695-8

Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man. Depré M, et al. **Int J Clin Pharmacol Res** 1996; 16(1):1-8

Effect of cimetidine on the pharmacokinetics of the metabolites of metamizol. Bacracheva N, et al. **Int J Clin Pharmacol Ther** 1997 Jul;35(7):275-81

Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Bliesath H, et al. **Int J Clin Pharmacol Ther** 1996 Apr;34(4):152-6

Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Bliesath H, et al. **Int J Clin Pharmacol Ther** 1996 May;34(1 Suppl):S76-80

Pharmacokinetics of tiaprofenic acid in infants after a single oral dose. Pariente-Khayat A, et al. **Int J Clin Pharmacol Ther** 1996 Aug;34(8):342-4

Influence of gastric acid secretion blockade and food intake on the bioavailability of a potassium diclofenac suspension in healthy male volunteers. Poli A, et al. **Int J Clin Pharmacol Ther** 1996 Feb;34(2):76-9

Comparative bioavailability of two capsule formulations of mefenamic acid. Rawashdeh NM, et al. **Int J Clin Pharmacol Ther** 1997 Aug;35(8):329-33

Lack of influence of glycine on the single dose pharmacokinetics of acetylsalicylic acid in man. Schurer M, et al. **Int J Clin Pharmacol Ther** 1996 Jul;34(7):282-7

Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. Suri A, et al. **Int J Clin Pharmacol Ther** 1997 Jan;35(1):1-8

Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability. Zmeili S, et al. **Int J Clin Pharmacol Ther** 1996 Dec;34(12):564-70

Skin distribution and pharmaceutical aspects of adapalene gel. Allec J, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 2):S119-25

Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. Bisogno T, et al. **J Biol Chem** 1997 Feb 7;272(6):3315-23

Human plasma concentrations of R, S, and racemic flurbiprofen given as a toothpaste. Forland SC, et al. **J Clin Pharmacol** 1996 Jun;36(6):546-53

Calculation of inversion half-lives of aryl propionic acid class nonsteroidal antiinflammatory drugs. Kantoci D, et al. **J Clin Pharmacol** 1996 Jun;36(6):500-4 (12 ref.)

Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. Karim A, et al. **J Clin Pharmacol** 1997 Apr;37(4):267-78

Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications. Karim A. **J Clin Pharmacol** 1996 Nov; 36(11):985-97

Chiral kinetics and dynamics of ketorolac. Mroszczak E, et al. **J Clin Pharmacol** 1996 Jun;36(6):521-39

Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. Ruffin MT 4th, et al. **J Natl Cancer Inst** 1997 Aug 6;89(15):1152-60

Accuracy of the one-sample method for determination of antipyrine clearance in elderly subjects. Jorquera F, et al. **J Pharm Biomed Anal** 1996 Oct;15(1):7-11

Improved ocular bioavailability of indomethacin by novel ocular drug carriers. Calvo P, et al. **J Pharm Pharmacol** 1996 Nov;48(11):1147-52

Pharmacokinetic analysis of the absorption characteristics of diclofenac sodium in man by use of a multi-segment absorption model. Mahmood I. **J Pharm Pharmacol** 1996 Dec;48(12):1260-3

Enhancing effects of unsaturated fatty acids with various structures on the permeation of indomethacin through rat skin. Morimoto K, et al. **J Pharm Pharmacol** 1996 Nov; 48(11):1133-7

Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. Tabata K, et al. **J Pharm Pharmacol** 1996 Aug;48(8):866-9

Absorption and excretion of paeoniflorin in rats. Takeda S, et al. **J Pharm Pharmacol** 1995 Dec;47(12A):1036-40

Control of poorly soluble drug dissolution in conditions simulating the gastrointestinal tract flow. 2. Cocompression of drugs with buffers. Chakrabarti S, et al. **J Pharm Sci** 1997 Apr;86(4):465-9

A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs. Cordero JA, et al. **J Pharm Sci** 1997 Apr;86(4):503-8

Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits. Madhu C, et al. **J Pharm Sci** 1996 Apr;85(4):415-8

Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. Hübner G, et al. **J Rheumatol** 1997 May;24(5):845-51

Tolfenamic acid in the control of ocular inflammation in the dog: pharmacokinetics and clinical results obtained in an experimental model. Roze M, et al. **J Small Anim Pract** 1996 Aug;37(8):371-5

Pharmacokinetics and pharmacodynamics of phenylbutazone and oxyphenbutazone in the donkey. Cheng Z, et al. **J Vet Pharmacol Ther** 1996 Apr;19(2):149-51

Bioavailability of ketoprofen in horses after rectal administration. Corveleyn S, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):359-63

Pharmacokinetics of indomethacin in cattle. Cristofol C, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):72-4

The effect of experimental fascioliasis on the pharmacokinetics of antipyrine and sulphadimidine in desert sheep. Elsheikh HA, et al. **J Vet Pharmacol Ther** 1997 Jun;20(3):167-72

Influence of closure of the reticular groove on the bioavailability and disposition kinetics of meclofenamate in sheep. Encinas T, et al. **J Vet Pharmacol Ther** 1996 Feb; 19(1):15-21

Pharmacokinetics of antipyrine in calves after intravenous and oral administration. Janus K, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):408-10

The effect of cimetidine on antipyrine metabolism in calves. Janus K, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):73-6

Phenylbutazone pharmacokinetics and bioavailability in the dromedary camel (Camelus dromedarius). Kadir A, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):54-60

Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in the horse. Landoni MF, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):466-74

The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses. Mills PC, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):475-81

Bioavailability and pharmacokinetics of ibuprofen in the broiler chicken. Roder JD, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):200-4

Pharmacokinetic interactions between repeated dose phenylbutazone and gentamicin in the horse. Whittem T, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):454-9

Gastrointestinal permeability following aspirin intake and prolonged running. Ryan AJ, et al. **Med Sci Sports Exerc** 1996 Jun;28(6):698-705

Percutaneous absorption of ketoprofen. I. In vitro release and percutaneous absorption of ketoprofen from different ointment bases. Gürol Z, et al. **Pharm Acta Helv** 1996 Aug; 71(3):205-12

Effects of excipients on the bioavailability of sodium salicylate from orally administered, oily suspensions. al-Hammami OM, et al. **Pharm Acta Helv** 1996 Oct; 71(4):297-303

Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. Hosny EA, et al. **Pharm Acta Helv** 1997 Jun; 72(3):159-64

In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolysed glycerides. Vial-Bernasconi AC, et al. **Pharm Acta Helv** 1995 Dec;70(4):307-13

Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery. Jolliet P, et al. **Pharm Res** 1997 May;14(5):650-6

Isolation and characterization of major phase I and II metabolites of ibuprofen. Kepp DR, et al. **Pharm Res** 1997 May;14(5):676-80

Effect of sodium bicarbonate amount on in vitro indomethacin release from self-setting carbonated-apatite cement. Otsuka M, et al. **Pharm Res** 1997 Apr;14(4):444-9

Mefenamic acid bioequivalence assessment with a new statistical procedure. Rescigno A, et al. **Pharmacol Res** 1996 Sep-Oct;34(3-4):149-52

Interaction of ibuprofen and indomethacin with caffeine. Khalil RM. **Pharmazie** 1996 Dec;51(12):970-3

Effect of permeation enhancers on the release of ketoprofen through transdermal drug delivery systems. Singh SK, et al. **Pharmazie** 1996 Oct;51(10):741-4

Effect of various vehicles on ketoprofen permeation across artificial membranes and excised rat skin. Valenta C, et al. **Pharmazie** 1996 Aug;51(8):605-6

Effect of some anti-cancer drugs and combined chemotherapy on the pharmacokinetics of antipyrine in the rat. Skrętkowicz J. **Pol J Pharmacol** 1995 Nov-Dec; 47(6):519-24

Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. Landoni MF, et al. **Res Vet Sci** 1996 Jul; 61(1):26-32

Influence of severity of chronic inflammatory joint disease on the pharmacokinetics of indomethacin and etodolac. Pawlotsky Y, et al. **Rev Rhum Engl Ed** 1996 Mar; 63(3):179-87

Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. Ionac M, et al. **Rom J Intern Med** 1996 Jul-Dec;34(3-4):239-51

Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles. Fenner H. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):28-33 (14 ref.)

No effect of albumin on the dermal absorption rate of hydrocortisone 21-butyrate, permethrin or diflunisal in the isolated, single-pass perfused rabbit ear. Bast GE, et al. **Skin Pharmacol** 1996;9(5):327-33

Choline esters and biogenic amines in the hypobranchial gland of 55 molluscan species of the neogastropod Muricoidea superfamily. Roseghini M, et al. **Toxicon** 1996 Jan;34(1):33-55

Intramuscular bioavailability of ketoprofen lysine salt in horses. Anfossi P, et al. **Vet Q** 1997 Jun;19(2):65-8

Pharmacokinetic and pharmacodynamic studies on phenylbutazone and oxyphenbutazone in goats. Cheng Z, et al. **Vet Rec** 1997 Jan 11;140(2):40-3

Preliminary pharmacokinetic and pharmacodynamic studies on flunixin meglumine in donkeys. Cheng Z, et al. **Vet Res Commun** 1996;20(5):469-72

Pharmacokinetics of ketoprofen in the donkey (Equus asinus). Oukessou M, et al. **Zentralbl Veterinarmed A** 1996 Sep; 43(7):423-6

[Evaluation of drug concentration in tissues after percutaneous administration of non-steroidal antirheumatics] Wagener HH, et al. **Arzneimittelforschung** 1996 Mar;46(3):299-301 (Eng. Abstr.) **(Ger)**

[The concentration changes of different phenylbutazone formulations in horse plasma] Keller H, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Jun;103(6):224-30 (Eng. Abstr.) **(Ger)**

[The tissue cage in dogs--a pharmacologic model for the representation of plasma and tissue kinetics] Scherkl R, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 May; 103(5):174-7 (Eng. Abstr.) **(Ger)**

[Pharmacokinetic and pharmacodynamic profile of the trioxyethylene ester of indomethacin in a new oral prodrug] Palagiano F, et al. **Boll Chim Farm** 1996 Feb;135(2):89-91 **(Ita)**

[The modification of the pharmacokinetics and analgesic effect of naproxen by cimetidine, phenobarbital and thiamine diphosphate] Vovk OG, et al. **Eksp Klin Farmakol** 1996 Mar-Apr;59(2):35-7 (Eng. Abstr.) **(Rus)**

[The pharmacokinetic determinants of the analgesic effect of benzofurocaine in patients with burns and wounds of the joints] Stanislavchuk MA, et al. **Lik Sprava** 1996 Jul-Sep;(7-9):154-7 (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

Spinal actions of nonsteroidal anti-inflammatory drugs [see comments] Cherng CH, et al. **Acta Anaesthesiol Sin** 1996 Jun;34(2):81-8 (55 ref.). Comment in: Acta Anaesthesiol Sin 1996 Jun;34(2):i-ii.

Aspirin-like drugs, besides a cyclooxygenase inhibitor, what's more in the mode of analgesic action? [editorial; comment] Lui PW. **Acta Anaesthesiol Sin** 1996 Jun;34(2):i-ii. Comment on: Acta Anaesthesiol Sin 1996 Jun;34(2):81-8.

Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis. In vitro and in vivo studies. Gilhar A, et al. **Acta Derm Venereol** 1996 Nov;76(6):437-41

Stimulation of newborn-like hemoglobin synthesis in adult rats by recombinant human erythropoietin and suppression by aspirin. Abdelrahman HG, et al. **Acta Haematol** 1996; 96(4):214-20

Vitamins and analgesics in the prevention of collagen ageing. Malik NS, et al. **Age Ageing** 1996 Jul;25(4):279-84

Review article: beta 3-adrenoceptor agonists--future anti-inflammatory drugs for the gastrointestinal tract? Anthony A. **Aliment Pharmacol Ther** 1996 Dec; 10(6):859-63 (45 ref.)

Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. Collins CE, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):315-20

NSAIDs upregulate beta 2-integrin expression on human neutrophils through a calcium-dependent pathway. Fiorucci S, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):619-30

Nimesulide reduces skin-test reactivity. Senna GE, et al. **Allergy** 1997 May;52(5):596

Doppler echocardiographic evaluation of ventricular diastolic filling in fetuses with ductal constriction. Harada K, et al. **Am J Cardiol** 1997 Feb 15;79(4):442-6

Induction of cytochrome P-450-linked monooxygenase system in rat liver microsomes by xiao-chaihu-tang. Obnishi T, et al. **Am J Chin Med** 1996;24(2):143-51

Aspirin induces increased expression of both prostaglandin H synthase-1 and prostaglandin H synthase-2 in cultured human placental trophoblast. Johnson RD, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):78-85

Closure of the human fetal ductus arteriosus [letter; comment] Mielke G, et al. **Am J Obstet Gynecol** 1997 Feb; 176(2):495-6. Comment on: Am J Obstet Gynecol 1996 Mar;174(3):879-83.

Two comparative endoscopic evaluations of Naprelan. Hawkey C, et al. **Am J Orthop** 1996 Sep;25(9 Suppl):30-6

Nonsteroidal anti-inflammatory drugs alter chloride and fluid transport in bovine retinal pigment epithelium. Bialek S, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):C1175-89

Microvascular dysfunction induced by nonsteroidal anti-inflammatory drugs: role of leukocytes. Kurose I, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G363-9

Effect of carprofen on sulfated glycosaminoglycan metabolism, protein synthesis, and prostaglandin release by cultured osteoarthritic canine chondrocytes. Benton HP, et al. **Am J Vet Res** 1997 Mar;58(3):286-92

Effects of flunixin meglumine on short circuit current in equine colonic mucosa in vitro. Freeman DE, et al. **Am J Vet Res** 1997 Aug;58(8):915-9

The effects of a nonsteroidal antiinflammatory drug (ketoprofen) on morphine respiratory depression: a double-blind, randomized study in volunteers. Moren J, et al. **Anesth Analg** 1997 Aug;85(2):400-5

The effect of acetaminophen, ibuprofen, and misoprostol on prostaglandin E2 synthesis and the degree and rate of orthodontic tooth movement. Kehoe MJ, et al. **Angle Orthod** 1996;66(5):339-49

Long-term tolerability of nimesulide and acetaminophen in nonsteroidal antiinflammatory drug-intolerant patients. Quaratino D, et al. **Ann Allergy Asthma Immunol** 1997 Jul; 79(1):47-50

Comparison of the effect of different inhibitors of the non-enzymatic glycation of rat tail tendons and bovine serum albumin. Menzel EJ, et al. **Ann Clin Biochem** 1996 May;33 (Pt 3):241-8

Relation of prescription nonsteroidal antiinflammatory drug use to cognitive function among community-dwelling elderly. Hanlon JT, et al. **Ann Epidemiol** 1997 Feb; 7(2):87-94

Cyclo-oxygenase and colon cancer: clues to the aspirin effect? Gustafson-Svärd C, et al. **Ann Med** 1997 Jun; 29(3):247-52 (68 ref.)

Effects of indomethacin, dexamethasone, and erythromycin on endotoxin-induced intraepithelial mucus production of rat nasal epithelium. Takahashi Y, et al. **Ann Otol Rhinol Laryngol** 1997 Aug;106(8):683-7

Assay interaction between oxaprozin and phenytoin [letter] Patel T, et al. **Ann Pharmacother** 1997 Feb;31(2):254

The effects of chronic ketorolac tromethamine (toradol) on wound healing. Haws MJ, et al. **Ann Plast Surg** 1996 Aug; 37(2):147-51

Polyamine levels in various tissues of rats treated with 3-hydroxy-4-methoxycinnamic acid and 3,4-dimethoxycinnamic acid. Watanabe S, et al. **Anticancer Drugs** 1996 Nov;7(8):866-72

Effects of ibuprofen on the in vitro invasiveness of a human transitional cell carcinoma. Cook GP, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):365-8

In vitro interaction of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation of rat kidney mitochondria: respiration and ATP synthesis. Mingatto FE, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):303-8

Diclofenac sodium and mefenamic acid: potent inducers of the membrane permeability transition in renal cortex mitochondria. Uyemura SA, et al. **Arch Biochem Biophys** 1997 Jun 15;342(2):231-5

Effect of diclofenac, ketorolac, and fluorometholone on arachidonic acid metabolites following excimer laser corneal surgery. Phillips AF, et al. **Arch Ophthalmol** 1996 Dec;114(12):1495-8

Non-steroidal anti-inflammatory agents, Part 20. Method for testing non-steroidal anti-inflammatories: the modified hen's egg chorioallantoic membrane test (HET-CAM test) compared to other procedures. Dannhardt G, et al. **Arch Pharm (Weinheim)** 1996 Jun;329(6):301-10

Scavenging of free radicals by tenoxicam: a participating mechanism in the antirheumatic/antiinflammatory efficacy of the drug. Maffei Facino RM, et al. **Arch Pharm (Weinheim)** 1996 Oct;329(10):457-63

Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. de Paulis A, et al. **Arthritis Rheum** 1997 Mar;40(3):469-78

Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. Fernandes JC, et al. **Arthritis Rheum** 1997 Feb;40(2):284-94

Prevention of cytokine-induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family. García-Vicuña R, et al. **Arthritis Rheum** 1997 Jan;40(1):143-53

Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Mahmud T, et al. **Arthritis Rheum** 1996 Dec;39(12):1998-2003

In vitro studies of some 2,4-disubstituted thiazolyl-aminoketones with anti-inflammatory activity. Correlation with lipophilicity and structural characteristics. Geronikaki AA, et al. **Arzneimittelforschung** 1996 Dec; 46(12):1134-7

Anti-inflammatory activity of some novel 1-[3-(aroylo)] and one 1-[3-(aryloxy)]-propyl aminothiazole in correlation with structure and lipophilicity. Hadjipavlou-Litina DJ, et al. **Arzneimittelforschung** 1996 Aug;46(8):805-8

Influence of non-steroidal anti-inflammatory drugs on the binding kinetics of dansylsarcosine to human serum albumin. Stereoselectivity, steric and inductive effects. Keita Y, et al. **Arzneimittelforschung** 1996 Feb;46(2):164-8

Tetrandrine inhibits signal-induced NF-kappa B activation in rat alveolar macrophages. Chen F, et al. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):99-102

Reciprocal effects of pro-inflammatory stimuli and anti-inflammatory drugs on the activity of heat shock factor-1 in human monocytes. Soncin F, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):479-84

Ca2+ binding and translocating properties of diflunisal. Neigh GS, et al. **Biochem Mol Biol Int** 1996 May; 39(1):53-61

Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays. Cromlish WA, et al. **Biochem Pharmacol** 1996 Dec 13;52(11):1777-85

Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Kargman S, et al. **Biochem Pharmacol** 1996 Oct 11;52(7):1113-25

The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B4-stimulated skin by a specific leukotriene B4 receptor antagonist (LY293111). van Pelt JP, et al. **Biochem Pharmacol** 1997 Apr 4;53(7):1005-12

The effect of non-steroidal anti-inflammatory drugs on volume-activated amino acid transport. Hawkins P, et al. **Biochem Soc Trans** 1996 May;24(2):334S

Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. Petrescu I, et al. **Biochim Biophys Acta** 1997 Feb 15;1318(3):385-94

Inhibitory effect of magnosalin derived from Flos magnoliae on tube formation of rat vascular endothelial cells during the angiogenic process. Kobayashi S, et al. **Biol Pharm Bull** 1996 Oct;19(10):1304-6

Anti-inflammatory activities of 70% methanolic extract from Cinnamomi Cortex. Kubo M, et al. **Biol Pharm Bull** 1996 Aug;19(8):1041-5

Antiinflammatory effect of Trichosanthes kirilowii Maxim, and its effective parts. Ozaki Y, et al. **Biol Pharm Bull** 1996 Aug;19(8):1046-8

Relationship between pharmacokinetics and the analgesic effect of indomethacin in the rat. Suzuki T, et al. **Biol Pharm Bull** 1997 Apr;20(4):438-42

A polysaccharide fraction of Zizyphi fructus in augmenting natural killer activity by oral administration. Yamaoka Y, et al. **Biol Pharm Bull** 1996 Jul;19(7):936-9

Anti-inflammatory and analgesic activities of 3-imino-1-oxoisoindolines in CF1 mice. Butner L, et al. **Biomed Pharmacother** 1996;50(6-7):290-6

Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Park CT, et al. **Blood** 1997 Jun 15; 89(12):4268-74

Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Draper MP, et al. **Br J Cancer** 1997;75(6):810-5

Stereoselective interaction between piroxicam and acenocoumarol. Bonnabry P, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):525-30

Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients? Pritchard G, et al. **Br J Clin Pharmacol** 1997 Aug; 44(2):145-9

The effect of topical indomethacin on ultraviolet-radiation-induced erythema. Ibbotson SH, et al. **Br J Dermatol** 1996 Oct;135(4):523-7

Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim. Cortijo J, et al. **Br J Pharmacol** 1996 Sep;119(1):99-106

Inhibition of neutrophil and monocyte recruitment by endogenous and exogenous lipocortin 1. Getting SJ, et al. **Br J Pharmacol** 1997 Mar;120(6):1075-82

Cellular localization of the inhibitory action of abruquinone A against respiratory burst in rat neutrophils. Hsu MF, et al. **Br J Pharmacol** 1997 Mar;120(5):917-25

Inhibition by fenamates of calcium influx and proliferation of human lymphocytes. Kankaanranta H, et al. **Br J Pharmacol** 1996 Oct;119(3):487-94

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Riendeau D, et al. **Br J Pharmacol** 1997 May;121(1):105-17

Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation. Teixeira MM, et al. **Br J Pharmacol** 1996 Aug;118(8):2099-106

The effect of alpha-trinositol (D-myo-inositol 1,2,6-trisphosphate) on formalin-evoked spinal amino acid and prostaglandin E2 levels. Malmberg AB, et al. **Brain Res** 1997 Jan 30;747(1):160-4

PAG-microinjected dipyrone (metamizol) inhibits responses of spinal dorsal horn neurons to natural noxious stimulation in rats. Vanegas H, et al. **Brain Res** 1997 Jun 6;759(1):171-4

Anti-inflammatory and analgesic activity of a water-soluble fraction from shark cartilage. Fontenele JB, et al. **Braz J Med Biol Res** 1996 May;29(5):643-6

An international evaluation of the cancer-preventive potential of nonsteroidal anti-inflammatory drugs. Vainio H, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Sep; 6(9):749-53

Chemopreventive agents-induced regression of azoxymethane-induced aberrant crypt foci with the recovery of hexosaminidase activity. Tao L, et al. **Carcinogenesis** 1997 Jul;18(7):1415-8

Effects of nonsteroidal anti-inflammatory drugs on glutathione S-transferases of the rat digestive tract. van Lieshout EM, et al. **Carcinogenesis** 1997 Mar;18(3):485-90

Mechanism of action of the non-steroidal anti-inflammatory drug flufenamate on [Ca2+]i and Ca(2+)-activated currents in neurons. Lee RJ, et al. **Cell Calcium** 1996 May; 19(5):431-8

Simultaneous activation of granulocytes and extrathymic T cells in number and function by excessive administration of nonsteroidal anti-inflammatory drugs. Yamamura S, et al. **Cell Immunol** 1996 Nov 1;173(2):303-11

Potentiation of heat stress-induced hsp70 expression in vivo by aspirin. Fawcett TW, et al. **Cell Stress Chaperones** 1997 Jun;2(2):104-9

Potent inhibition of interleukin-6 expression in a human astrocytoma cell line by tenidap. Lieb K, et al. **Cell Tissue Res** 1997 May;288(2):251-7

Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors. Banner KH, et al. **Clin Exp Allergy** 1996 Mar;26 Suppl 2:2-9 (99 ref.)

Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts. Pelletier JP, et al. **Clin Exp Rheumatol** 1997 Jul-Aug;15(4):393-8

Differential influences of gold sodium thiomalate and bucillamine on the generation of CD14+ monocyte-lineage cells from bone marrow of rheumatoid arthritis patients. Hirohata S, et al. **Clin Immunol Immunopathol** 1997 Sep;84(3):290-5

Ibuprofen elevates immunoreactive beta-endorphin levels in humans during surgical stress. Troullos E, et al. **Clin Pharmacol Ther** 1997 Jul;62(1):74-81

The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cells. Schmidt C, et al. **Curr Med Res Opin** 1996;13(7):417-25

Biologic effects of nonsteroidal anti-inflammatory drugs. Simon LS. **Curr Opin Rheumatol** 1997 May;9(3):178-82 (31 ref.)

Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Sironi M, et al. **Cytokine** 1996 Sep;8(9):710-6

Effects of indomethacin and local prostaglandin E2 on fracture healing in rabbits. Keller J. **Dan Med Bull** 1996 Sep;43(4):317-29 (177 ref.)

Aspirin, but not sodium salicylate, indomethacin, or nabumetone, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats. Barnes CJ, et al. **Dig Dis Sci** 1997 May;42(5):920-6

Changes in sulfated macromolecules produced in vivo during normal and indomethacin-delayed ulcer healing in rats. Lyons KC, et al. **Dig Dis Sci** 1997 Aug;42(8):1755-64

Characterization of the effects of tebufelone on hepatic cytochromes P450 in the beagle dog. Smith BJ, et al. **Drug Metab Dispos** 1996 May;24(5):523-8

Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Brogden RN, et al. **Drugs** 1997 Mar;53(3):511-9 (29 ref.)

The mechanisms of action of NSAIDs in analgesia. Cashman JN. **Drugs** 1996;52 Suppl 5:13-23 (84 ref.)

Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Jouzeau JY, et al. **Drugs** 1997 Apr;53(4):563-82 (238 ref.)

Prime suspect [news] Manuel J. **Environ Health Perspect** 1997 Jan;105(1):28-9

Effects of flunixin, tolfenamic acid, R(-) and S(+) ketoprofen on the response of equine synoviocytes to lipopolysaccharide stimulation. Landoni MF, et al. **Equine Vet J** 1996 Nov;28(6):468-75

Antagonism of endotoxin-induced disruption of equine bowel motility by flunixin and phenylbutazone. King JN, et al. **Equine Vet J Suppl** 1989 Jun;(7):38-42

Mechanisms of actions of opioids and non-steroidal anti-inflammatory drugs. Bovill JG. **Eur J Anaesthesiol Suppl** 1997 May;15:9-15 (42 ref.)

In vitro activity of nonsteroidal anti-inflammatory agents, phenotiazines, and antidepressants against Brucella species. Muñoz-Criado S, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):418-20

The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Awni WM, et al. **Eur J Clin Pharmacol** 1997;52(1):49-54

Analgesic effects of propyphenazone in comparison to its combination with caffeine. Kraetsch HG, et al. **Eur J Clin Pharmacol** 1996;49(5):377-82

The negative mucosal potential: separating central and peripheral effects of NSAIDs in man. Lötsch J, et al. **Eur J Clin Pharmacol** 1997;52(5):359-64

Effects of ketoprofen and ibuprofen on platelet aggregation and prostanoid formation in man. Stichtenoth DO, et al. **Eur J Clin Pharmacol** 1996;51(3-4):231-4

Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients [letter] Taniyama M, et al. **Eur J Clin Pharmacol** 1997;52(1):77-8

Lack of interaction between meloxicam and warfarin in healthy volunteers. Türck D, et al. **Eur J Clin Pharmacol** 1997;51(5):421-5

Antioxidant action of a new flavonic derivative in acute carbon tetrachloride intoxication. Paduraru I, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jan-Mar;21(1):1-6

Effects of acetysal, dexamethasone and their combination on drug metabolizing enzyme systems in rat liver microsomes. Tantcheva LP, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct-Dec;20(4):281-6

Up-regulation of cyclooxygenase-2 expression in cultured microglia by prostaglandin E2, cyclic AMP and non-steroidal anti-inflammatory drugs. Minghetti L, et al. **Eur J Neurosci** 1997 May;9(5):934-40

Interactions between NMDA- and prostaglandin receptor-mediated events in a model of inflammatory nociception. Buritova J, et al. **Eur J Pharmacol** 1996 May 6;303(1-2):91-100

Effect of propionyl-L-carnitine on oscillatory potentials in electroretinogram in streptozotocin-diabetic rats. Hotta N, et al. **Eur J Pharmacol** 1996 Sep 12;311(2-3):199-206

Stimulus dependence of non-steroidal antiinflammatory drug potency in a cellular assay of prostaglandin H synthase-2. Hulkower KI, et al. **Eur J Pharmacol** 1997 Jul 16; 331(1):79-85

Dipyrone into the nucleus raphe magnus inhibits the rat nociceptive tail-flick reflex. Jones SL. **Eur J Pharmacol** 1996 Dec 27;318(1):37-40

Modulation of membrane currents and mechanical activity by niflumic acid in rat vascular smooth muscle. Kirkup AJ, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):165-74

Differential effects of sulindac on renal hemodynamics and function in the rat. Kramp RA, et al. **Eur J Pharmacol** 1997 Jul 9;330(2-3):165-76

N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Mazzari S, et al. **Eur J Pharmacol** 1996 Apr 11;300(3):227-36

Antiflammin-2, a nonapeptide of lipocortin-1, inhibits leukocyte chemotaxis but not arachidonic acid mobilization. Moreno JJ. **Eur J Pharmacol** 1996 Oct 24; 314(1-2):129-35

Inhibition of inflammatory responses by a series of novel dolabrane derivatives. Payá M, et al. **Eur J Pharmacol** 1996 Sep 19;312(1):97-105

Neutrophil-associated inflammatory responses in rats are inhibited by phenylarsine oxide. Roussin A, et al. **Eur J Pharmacol** 1997 Mar 12;322(1):91-6

Piroxicam modifies the effects of ethanol on isolated rat hepatocytes. Saldaña-Balmori Y, et al. **Eur J Pharmacol** 1996 Dec 19;317(2-3):225-9

Effects of flurbiprofen and flurbinitroxybutylester on prostaglandin endoperoxide synthases. Santini G, et al. **Eur J Pharmacol** 1996 Nov 28;316(1):65-72

Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide. Taniguchi Y, et al. **Eur J Pharmacol** 1997 Jul 9;330(2-3):221-9

Inhibition by abruquinone A of phosphoinositide-specific phospholipase C activation in rat neutrophils. Wang JP, et al. **Eur J Pharmacol** 1997 Jan 14;319(1):131-6

Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Yamazaki R, et al. **Eur J Pharmacol** 1997 Jun 25; 329(2-3):181-7

The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils. Tool AT, et al. **Eur Respir J Suppl** 1996 Aug;22:141s-145s

Curcumin, a compound with anti-inflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells. Xu YX, et al. **Exp Hematol** 1997 May;25(5):413-22

Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Suga H, et al. **Exp Toxicol Pathol** 1995 Sep;47(4):287-91

Aspirin inhibits expression of the interleukin-1beta-inducible group II phospholipase A2. Vervoordeldonk MJ, et al. **FEBS Lett** 1996 Nov 11;397(1):108-12

Effect of antioxidants, anti-inflammatory drugs, and histamine antagonists on sparfloxacin-induced phototoxicity in mice. Shimoda K, et al. **Fundam Appl Toxicol** 1996 May;31(1):133-40

Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Pairet M, et al. **Fundam Clin Pharmacol** 1996;10(1):1-17 (165 ref.)

NSAIDS and the microcirculation of the stomach. Kawano S, et al. **Gastroenterol Clin North Am** 1996 Jun; 25(2):299-315 (33 ref.)

Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Masferrer JL, et al. **Gastroenterol Clin North Am** 1996 Jun;25(2):363-72 (35 ref.)

Deranged hydrophobic barrier of the rat gastroduodenal mucosa after parenteral nonsteroidal anti-inflammatory drugs. Lugea A, et al. **Gastroenterology** 1997 Jun; 112(6):1931-9

Bromelain prevents secretion caused by Vibrio cholerae and Escherichia coli enterotoxins in rabbit ileum in vitro. Mynott TL, et al. **Gastroenterology** 1997 Jul;113(1):175-84

Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Reuter BK, et al. **Gastroenterology** 1997 Jan;112(1):109-17

General pharmacology of meloxicam--Part I: Effects on CNS, gastric emptying, intestinal transport, water, electrolyte and creatinine excretion. Engelhardt G, et al. **Gen Pharmacol** 1996 Jun;27(4):673-7

General pharmacology of meloxicam--Part II: Effects on blood pressure, blood flow, heart rate, ECG, respiratory minute volume and interactions with paracetamol, pirenzepine, chlorthalidone, phenprocoumon and tolbutamide. Engelhardt G, et al. **Gen Pharmacol** 1996 Jun; 27(4):679-88

Morphological and biochemical action of dipyrone on rat placenta. Espiridião S, et al. **Gen Pharmacol** 1996 Apr; 27(3):505-7

Effects of TYB-2285 on the accumulation of eosinophils in the airway induced by antigen exposure in actively sensitized brown Norway rats. Tominaga T, et al. **Gen Pharmacol** 1997 Feb;28(2):301-3

Effect of TYB-2285 on antigen-induced accumulation of eosinophils into the peritoneal cavity of rats sensitized with Ascaris suum extract. Tominaga T, et al. **Gen Pharmacol** 1997 Mar;28(3):411-4

Effect of the milk extract of Semecarpus anacardium nut on adjuvant arthritis--a dose-dependent study in Wistar albino rats. Vijayalakshmi T, et al. **Gen Pharmacol** 1996 Oct;27(7):1223-6

Effect of TYB-2285 on lung anaphylaxis in actively sensitized rats. Watanabe A, et al. **Gen Pharmacol** 1997 Feb; 28(2):305-9

Effect of TYB-2285 on passive cutaneous anaphylaxis in rats. Watanabe A, et al. **Gen Pharmacol** 1997 Feb;28(2):311-5

Gastric mucosal contraction and vascular injury induced by indomethacin precede neutrophil infiltration in the rat. Anthony A, et al. **Gut** 1996 Sep;39(3):363-8

Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Somasundaram S, et al. **Gut** 1997 May;40(5):608-13

Luminal non-selective cation and outwardly rectifying chloride channels in cultured strial marginal cells from gerbil. Yeh T, et al. **Hear Res** 1995 Oct;90(1-2):79-88

The anti-inflammatory drug sodium salicylate inhibits nitric oxide formation induced by interleukin-1beta at a translational step, but not at a transcriptional step, in hepatocytes. Sakitani K, et al. **Hepatology** 1997 Feb; 25(2):416-20

Generation of reactive oxygen species is required for bucillamine, a novel anti-rheumatic drug, to induce apoptosis in concert with copper. Sawada T, et al. **Immunopharmacology** 1997 Jan;35(3):195-202

IDPH-8261--a new nonsteroidal antiinflammatory agent. Rao CS, et al. **Indian J Exp Biol** 1995 Jan;33(1):28-33

Protective activity of ketoprofen lysine salt against the pulmonary effects induced by bradykinin in guinea-pigs. Daffonchio L, et al. **Inflamm Res** 1996 May;45(5):259-64

Anti-inflammatory activity of topical nimesulide gel in various experimental models. Gupta SK, et al. **Inflamm Res** 1996 Dec;45(12):590-2

Analgesic activity of the novel COX-2 preferring NSAID, meloxicam in mono-arthritic rats: central and peripheral components. Laird JM, et al. **Inflamm Res** 1997 Jun; 46(6):203-10

Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties. Moore PF, et al. **Inflamm Res** 1996 Feb;45(2):54-61

Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats. Mukherjee A, et al. **Inflamm Res** 1996 Nov;45(11):531-40

The inhibitory effect of pentamidine on the production of chemotactic cytokines by in vitro stimulated human blood cells. Van Wauwe J, et al. **Inflamm Res** 1996 Jul; 45(7):357-63

Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Young JM, et al. **Inflamm Res** 1996 May; 45(5):246-53

Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Anderson R, et al. **Inflammation** 1996 Dec;20(6):693-705

Assessment of the antiexudative and antiproliferative activities of non-steroidal anti-inflammatory drugs in inflammatory models developed in rats by subcutaneous implantation of bacterial cell walls from the dental plaque. Guimarães SA, et al. **Inflammation** 1996 Dec;20(6):623-36

Modulation of nitric oxide synthase activity by ibuprofen. Menzel JE, et al. **Inflammation** 1997 Aug;21(4):451-61

Bruceine B, a potent inhibitor of leukocyte-endothelial cell adhesion. Utoguchi N, et al. **Inflammation** 1997 Apr; 21(2):223-33

The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats. Zarif A, et al. **Inflammation** 1996 Jun;20(3):217-27

Mechanisms of active oxygen species reduction by non-steroidal anti-inflammatory drugs. Kimura K. **Int J Biochem Cell Biol** 1997 Mar;29(3):437-46

Benzydamine inhibits the release of tumor necrosis factor-alpha and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells. Sironi M, et al. **Int J Clin Lab Res** 1997;27(2):118-22

Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man. Depré M, et al. **Int J Clin Pharmacol Res** 1996; 16(1):1-8

Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. Suri A, et al. **Int J Clin Pharmacol Ther** 1997 Jan;35(1):1-8

Amelioration of rat experimental arthritides by treatment with the alkaloid sinomenine. Liu L, et al.

Int J Immunopharmacol 1996 Oct;18(10):529–43

Anti-inflammatory activity of 2,3-dihydrophthalazine-1,4-diones in CF1 mice. Butner L, et al. **Int J Tissue React** 1996;18(2-3):47–55

Reduction by antiinflammatory drugs of the response of corneal sensory nerve fibers to chemical irritation. Chen X, et al. **Invest Ophthalmol Vis Sci** 1997 Sep;38(10):1944–53

The effect of oral ibuprofen on patch test reactivity in subjects allergic to poison ivy/oak. Sherertz EF. **J Am Acad Dermatol** 1997 Apr;36(4):647–9

Pharmacology and chemistry of adapalene. Shroot B, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 2):S96–103 (14 ref.)

Morphometric analysis of the small intestinal epithelium in the indomethacin-treated mouse. Ettarh RR, et al. **J Anat** 1996 Aug;189 (Pt 1):51–6

Efficacy of ibuprofen and pentoxifylline in the treatment of phosgene-induced acute lung injury. Sciuto AM, et al. **J Appl Toxicol** 1996 Sep-Oct;16(5):381–4

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. Lehmann JM, et al. **J Biol Chem** 1997 Feb 7;272(6):3406–10

Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. Maddox JF, et al. **J Biol Chem** 1997 Mar 14;272(11):6972–8

Activation of phosphatidylinositol 3-kinase by interleukin-13. An inhibitory signal for inducible nitric-oxide synthase expression in epithelial cell line HT-29. Wright K, et al. **J Biol Chem** 1997 May 9; 272(19):12626–33

Anti-inflammatory medication after muscle injury. A treatment resulting in short-term improvement but subsequent loss of muscle function [letter; comment] Swaak AJ. **J Bone Joint Surg Am** 1997 Aug;79(8):1270–1. Comment on: J Bone Joint Surg Am 1995 Oct;77(10):1510–9.

Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. Bauer DC, et al. **J Bone Miner Res** 1996 Jan;11(1):29–35

Propofol at conscious sedation doses produces mild analgesia to cold pressor-induced pain in healthy volunteers. Zacny JP, et al. **J Clin Anesth** 1996 Sep;8(6):469–74

Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions? [editorial] Serhan CN, et al. **J Clin Invest** 1997 Mar 15; 99(6):1147–8

Nonsteroidal antiinflammatory drug modulation of behavioral responses to intrathecal N-methyl-D-aspartate, but not to substance P and amino-methyl-isoxazole-propionic acid in the rat. Björkman R, et al. **J Clin Pharmacol** 1996 Dec;36(12 Suppl):20S–26S

Inhibition of cyclooxygenase-1 and -2 by R(-)- and S(+)-ibuprofen. Boneberg EM, et al. **J Clin Pharmacol** 1996 Dec;36(12 Suppl):16S–19S

Interaction of meloxicam with cimetidine, Maalox, or aspirin. Busch U, et al. **J Clin Pharmacol** 1996 Jan;36(1):79–84

Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs. Carabaza A, et al. **J Clin Pharmacol** 1996 Jun;36(6):505–12

Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen. Evans AM. **J Clin Pharmacol** 1996 Dec;36(12 Suppl):7S–15S (54 ref.)

New insights into the site and mode of antinociceptive action of flurbiprofen enantiomers. Geisslinger G, et al. **J Clin Pharmacol** 1996 Jun;36(6):513–20 (85 ref.)

Antiproliferative effects of the enantiomers of flurbiprofen. McCracken JD, et al. **J Clin Pharmacol** 1996 Jun; 36(6):540–5

Understanding the chiral pharmacology of nonsteroidal antiinflammatory drugs in the aryl propionic acid class: S(+) ibuprofen. Overview of the symposium "update on S(+) ibuprofen" (Going/Kitzbuehl, Austria, February 2–4, 1996) [editorial] Wechter WJ. **J Clin Pharmacol** 1996 Dec; 36(12 Suppl):1S–2S

Inhibitory effect of drugs with a ketone group on reduction of acetohexamide catalyzed by carbonyl reductase from rabbit kidney. Imamura Y, et al. **J Enzyme Inhib** 1997 Feb; 11(4):285–92

Evaluation of some Samoan and Peruvian medicinal plants by prostaglandin biosynthesis and rat ear oedema assays. Dunstan CA, et al. **J Ethnopharmacol** 1997 Jun;57(1):35–56

Phytochemical and biological study of radal Lomatia hirsuta (Proteaceae). Erazo S, et al. **J Ethnopharmacol** 1997 Jul; 57(2):81–3

Effect of licorice roots on carrageenan-induced decrease in immune complexes clearance in mice. Matsumoto T, et al. **J Ethnopharmacol** 1996 Jul 26;53(1):1–4

Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. Takano T, et al. **J Exp Med** 1997 May 5;185(9):1693–704

Suppression of TNF-alpha secretion by azelastine in a rat mast (RBL-2H3) cell line: evidence for differential regulation of TNF-alpha release, transcription, and degranulation. Hide I, et al. **J Immunol** 1997 Sep 15; 159(6):2932–40

Use of the acute phase serum amyloid A2 (SAA2) gene promoter in the analysis of pro- and anti-inflammatory mediators: differential kinetics of SAA2 promoter induction by IL-1 beta and TNF-alpha compared to IL-6. Uhlar CM, et al. **J Immunol Methods** 1997 Apr 25;203(2):123–30

Influence of anti-inflammatory and antioxidant agents on endothelial permeability alterations induced by bradykinin. Deng X, et al. **J Invest Surg** 1996 Sep-Oct;9(5):337–49

Reduction of adhesion formation by intraperitoneal administration of anti-inflammatory peptide 2. Rodgers KE, et al. **J Invest Surg** 1997 Jan-Apr;10(1-2):31–6

Effects of anti-inflammatory agents on hydrochloric acid-induced pulmonary injury. Westervelt CL, et al. **J Invest Surg** 1996 Jul-Aug;9(4):283–91

Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. Stichtenoth DO, et al. **J Investig Med** 1997 Feb;45(2):44–9

Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. Lazer ES, et al. **J Med Chem** 1997 Mar 14; 40(6):980–9

Stabilized analogs of thymopentin. 3. Evaluation of ketomethylene pseudopeptides for antiarthritic properties. Smith RL, et al. **J Med Chem** 1997 Jul 18;40(15):2407–11

Recovery from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced immunosuppression in A/J mice by treatment with nonsteroidal anti-inflammatory drugs. Rioux N, et al. **J Natl Cancer Inst** 1997 Jun 18;89(12):874–80

The effect of rolipram on the production of cytokines in HTLV-I infected cell lines and peripheral blood mononuclear cells of patients with HTLV-I-associated myelopathy (HAM). Hatae T, et al. **J Neurol Sci** 1997 May 1;148(1):87–94

The responses of rat trigeminal ganglion neurons to capsaicin and two nonpungent vanilloid receptor agonists, olvanil and glyceryl nonamide. Liu L, et al. **J Neurosci** 1997 Jun 1;17(11):4101–11

Absorption, retention and urinary excretion of chromium-51 in rats pretreated with indomethacin and dosed with dimethylprostaglandin E2, misoprostol or prostacyclin. Kamath SM, et al. **J Nutr** 1997 Mar;127(3):478–82

Pharmacological evaluation of anti-inflammatory pyrrole-acetic acid derivative eye drops. Bucolo C, et al. **J Ocul Pharmacol Ther** 1997 Aug;13(4):353–61

Inhibitory effects of interleukin-1 blockers on corneal fibroblast proliferation. Chen Z, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):169–82

Tetrandrine inhibits breakdown of blood-aqueous barrier induced by endotoxin and interleukin-1 alpha in rats. Xiao JG, et al. **J Ocul Pharmacol Ther** 1996 Fall;12(3):323–9

Inhibitory effects of tetrandrine on intracellular free Ca2+ increase induced by glutamate, serotonin and histamine in dissociated retina cells. Xuan B, et al. **J Ocul Pharmacol Ther** 1996 Fall;12(3):331–6

The effects of a triterpene fraction isolated from Crataegus monogyna Jacq. on different acute inflammation models in rats and mice. Leucocyte migration and phospholipase A2 inhibition. Ahumada C, et al. **J Pharm Pharmacol** 1997 Mar;49(3):329–31

Anti-inflammatory, analgesic and ulcerogenic properties of S-(+)-ibuproxam, racemic ibuproxam-beta-cyclodextrin and S-(+)-ibuproxam-beta-cyclodextrin. Bole-Vunduk B, et al. **J Pharm Pharmacol** 1996 Nov;48(11):1153–7

hP, the component of log P controlling structure-activity relationships amongst non-steroidal anti-inflammatory drugs. Dean FM. **J Pharm Pharmacol** 1996 Mar;48(3):233–9

Effect of bakuchiol on leukocyte functions and some inflammatory responses in mice. Ferrándiz ML, et al. **J Pharm Pharmacol** 1996 Sep;48(9):975–80

In-vitro evaluation of biphenylyl acetic acid-beta-cyclodextrin conjugates as colon-targeting prodrugs: drug release behaviour in rat biological media. Hirayama F, et al. **J Pharm Pharmacol** 1996 Jan;48(1):27–31

2',5'-Dihydroxychalcone as a potent chemical mediator and cyclooxygenase inhibitor. Lin CN, et al. **J Pharm Pharmacol** 1997 May;49(5):530–6

Comparative evaluation of Butea frondosa and flurbiprofen for ocular anti-inflammatory activity in rabbits. Mengi SA, et al. **J Pharm Pharmacol** 1995 Dec;47(12A):997–1001

Effects of oren-gedoku-to and unsei-in, Chinese traditional medicines, on interleukin-8 and superoxide dismutase in rats. Wang LM, et al. **J Pharm Pharmacol** 1997 Jan; 49(1):102–4

Rationale for the development of stereochemically pure enantiomers: are the R enantiomers of chiral nonsteroidal anti-inflammatory drugs inactive? [letter] Wright MR, et al. **J Pharm Sci** 1994 Jun;83(6):911–2

Effects of intrathecal or intracerebroventricular administration of nonsteroidal anti-inflammatory drugs on a C-fiber reflex in rats. Bustamante D, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1381–91

Inhibition of DNA synthesis by aspirin in Swiss 3T3 fibroblasts. Castaño E, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):366–72

Differential inhibition of murine prostaglandin synthase-1 and -2 by nonsteroidal anti-inflammatory drugs using exogenous and endogenous sources of arachidonic acid. Chulada PC, et al. **J Pharmacol Exp Ther** 1997 Feb; 280(2):606–13

In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. Cohan VL, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1356–61

Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs. Curnock AP, et al. **J Pharmacol Exp Ther** 1997 Jul; 282(1):339–47

Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. Kirchner T, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):1094–101

Antiinflammatory and analgesic activity of an inhibitor of neuropeptide amidation. Ogonowski AA, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):846–53

Inhibition by boswellic acids of human leukocyte elastase. Safayhi H, et al. **J Pharmacol Exp Ther** 1997 Apr; 281(1):460–3

Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of diclofenac in the rat. Torres-López JE, et al. **J Pharmacol Exp Ther** 1997 Aug; 282(2):685–90

The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4. Turner CR, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1349–55

Prostaglandin E2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. Yamada M, et al. **J Pharmacol Exp Ther** 1997 May;281(2):1005–12

Effect of topical tranilast and corticosteroids on subepithelial haze after photorefractive keratectomy in rabbits. Furukawa H, et al. **J Refract Surg** 1997 Aug;13(5 Suppl):S457–8

Effects of topical ketorolac and diclofenac on normal corneal sensation. Sun R, et al. **J Refract Surg** 1997 Mar-Apr; 13(2):158–61

Effect of diclofenac on prostaglandin liberation in the rabbit after photorefractive keratectomy. Tomas-Barberan S, et al. **J Refract Surg** 1997 Mar-Apr;13(2):154–7

Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine. Aono H, et al. **J Rheumatol** 1996 Jan;23(1):65–70

Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. Cook ME, et al. **J Rheumatol** 1997 Jun; 24(6):1137–44

New perspectives for nonsteroidal antiinflammatory therapy [editorial] de Brum-Fernandes AJ. **J Rheumatol** 1997 Feb; 24(2):246–8 (29 ref.)

Effects of tenidap and nonsteroidal antiinflammatory drugs on the response of cultured human T cells to interleukin 2 in rheumatoid arthritis. Hall VC, et al. **J Rheumatol** 1997 Aug;24(8):1467–70

Aspirin and nonsteroidal antiinflammatory drug use in elderly women: effects on a marker of bone resorption. The Study of Osteoporotic Fractures Research Group. Lane NE, et al. **J Rheumatol** 1997 Jun;24(6):1132–6

Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts. Martel-Pelletier J, et al. **J Rheumatol** 1996 Jan; 23(1):24–31

In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis. Ounissi-Benkalha H, et al. **J Rheumatol** 1996 Jan; 23(1):16–23

Effect of a nonsteroidal antiinflammatory drug on synovial fluid in osteoarthritis. Schumacher HR Jr, et al. **J Rheumatol** 1996 Oct;23(10):1774–7

Tissue selective inhibition of prostaglandin biosynthesis by etodolac. Dvornik DM. **J Rheumatol Suppl** 1997 Feb; 47:40–7 (54 ref.)

Differential effects of IL-1 beta and ibuprofen after endotoxic challenge in mice. Mansilla-Roselló A, et al. **J Surg Res** 1997 Feb 1;67(2):199–204

Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts [published erratum appears in J Urol 1997 Sep;158(3 Pt 1):889] Yablonsky F, et al. **J Urol** 1997 Jun;157(6):2381–7

Influence of carprofen on minimum alveolar concentration of halothane in dogs. Alibhai HI, et al. **J Vet Pharmacol Ther** 1996 Aug;19(4):320–1

Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment. Okajima E, et al. **Jpn J Cancer Res** 1997 Jun;88(6):543–52

Enhancement of interleukin-1 alpha mediated autocrine growth of cultured human keratinocytes by sho-saiko-to. Matsumoto Y, et al. **Jpn J Pharmacol** 1997 Apr;73(4):333–6

Antinociceptive activity of a novel non-steroidal anti-inflammatory drug (M-5011) with low ulcerogenic effects in mice. Murakami N, et al. **Jpn J Pharmacol** 1996 Sep;72(1):29–37

Suppression of ischemic edema in mice by manganese-hyaluronate conjugate. Sakurai K, et al. **Jpn J Pharmacol** 1997 May;74(1):117–20

The novel anti-rheumatic drug TA-383 has a macrophage migration enhancing activity. Ueno M, et al. **Jpn J Pharmacol** 1997 Jun;74(2):221–4

Drug interactions with zileuton [letter] Lau R. **Lancet** 1997 May 17;349(9063):1479–80

Alterations in methotrexate pharmacokinetics by naproxen in the rat as measured by microdialysis. Ekstrøm PO, et al. **Life Sci** 1997;60(24):PL 359–64

Co-regulation of mucosal prostanoids and substance P by

indomethacin in rat stomachs. Ko JK, et al. **Life Sci** 1997; 60(19):PL 277-81

Anti-inflammatory action of Pluchea sagittalis: involvement of an antioxidant mechanism. Pérez-García F, et al. **Life Sci** 1996;59(24):2033-40

Pharmacologic inhibition of transglutaminase-induced cross-linking of Alzheimer's amyloid beta-peptide. Zhang W, et al. **Life Sci** 1997;60(25):2323-32

Lymphocyte subset responses to exercise and glucocorticoid suppression in healthy men. Singh A, et al. **Med Sci Sports Exerc** 1996 Jul;28(7):822-8

Presence of an acidic glycoprotein in the serum of arthritic rats: modulation by capsaicin and curcumin. Joe B, et al. **Mol Cell Biochem** 1997 Apr;169(1-2):125-34

Bee-glue reveals anti-inflammatory properties plus... [news] Jack DB. **Mol Med Today** 1996 Jul;2(7):271

Effects of aspirin on nitric oxide formation and de novo protein synthesis by RINm5F cells and rat islets. Kwon G, et al. **Mol Pharmacol** 1997 Sep;52(3):398-405

Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs. Mancini JA, et al. **Mol Pharmacol** 1997 Jan; 51(1):52-60

Aspirin inhibits tumor necrosis factoralpha gene expression in murine tissue macrophages. Shackelford RE, et al. **Mol Pharmacol** 1997 Sep;52(3):421-9

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents [published erratum appears in Nature 1997 Feb 6;385(6616):555] Kurumbail RG, et al. **Nature** 1996 Dec 19-26;384(6610):644-8

Investigations on the mechanism of action of the antiproliferant and ion channel antagonist flufenamic acid. Weiser T, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Mar;353(4):452-60

Nonsteroidal anti-inflammatory drugs (NSAIDs) and the kidney [editorial] Pugliese F, et al. **Nephrol Dial Transplant** 1997 Mar;12(3):386-8 (17 ref.)

Anti-inflammatory and antinociceptive effect of different somatostatin-analogs. Helyes Z, et al. **Neurobiology (Bp)** 1996;4(1-2):115-7

Effects of NSAIDs on IL-1 beta-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Fiebich BL, et al. **Neuroreport** 1996 Apr 26;7(6):1209-13

beta-Amyloid induction of gelatinase B secretion in cultured microglia: inhibition by dexamethasone and indomethacin. Gottschall PE. **Neuroreport** 1996 Nov 25;7(18):3077-80

Ulcerogenic cinchophen induces c-Fos expression in CRH-secreting cells in the PVH of rat brain. Jingu H, et al. **Neuroreport** 1996 Nov 4;7(15-17):2649-53

Ketoprofen, a non-steroidal anti-inflammatory drug prevents the late-onset reduction of muscarinic receptors in gerbil hippocampus after transient forebrain ischemia. Asanuma M, et al. **Neurosci Lett** 1997 Apr 4;225(2):109-12

Effect of TJ-960 (a Japanese herbal medicine) on free radical changes within an iron-induced focal epileptogenic region in rat brain measured by in vivo L-band electron spin resonance. Komatsu M, et al. **Neurosci Lett** 1996 Mar 1; 205(3):189-92

Effects of non-steroidal antiallergic eyedrops on the complement-mediated histamine release from human cells. Goldschmidt P, et al. **Ocul Immunol Inflamm** 1997 Mar; 5(1):11-7

New evidence that NSAIDs reduce breast cancer risk [news] **Oncology (Huntingt)** 1997 Jul;11(7):1046

Enhanced effects of co-administered dexamethasone and diclofenac on inflammatory pain processing and associated spinal c-Fos expression in the rat. Buritova J, et al. **Pain** 1996 Mar;64(3):559-68

Ketoprofen produces profound inhibition of spinal c-Fos protein expression resulting from an inflammatory stimulus but not from noxious heat. Buritova J, et al. **Pain** 1996 Oct;67(2-3):379-89

Changes in formalin-evoked spinal Fos expression and nociceptive behaviour after oral administration of Bufferin A (aspirin) and L-5409709 (ibuprofen + caffeine + paracetamol). Carrive P, et al. **Pain** 1997 Apr; 70(2-3):253-66

Stimulus properties and antinociceptive effects of selective bradykinin B1 and B2 receptor antagonists in rats. Sufka KJ, et al. **Pain** 1996 Jul;66(1):99-103

Additional comments on non-steroidal anti-inflammatory drugs and topical analgesia (PAIN, 61 (1995) 494-495). Willoughby DA, et al. **Pain** 1996 Jan;64(1):205

Intimal injury in a transiently occluded coronary artery increases myocardial necrosis. Effect of aspirin. Barrabés JA, et al. **Pflugers Arch** 1996 Aug;432(4):663-70

TSG-6, a glycoprotein associated with arthritis, and its ligand hyaluronan exert opposite effects in a murine model of inflammation. Wisniewski HG, et al. **Pflugers Arch** 1996; 431(6 Suppl 2):R225-6

Synthesis, antiinflammatory, and cytotoxic activities of 2-alkyl and 2-benzyl-2-dimethylaminomethyl-5-(E)-arylidene cyclopentanone hydrochlorides. Chen H, et al. **Pharm Res** 1996 Oct;13(10):1482-7

Vasodilating properties of a new non-steroidal anti-inflammatory drug, nitroflurbiprofen, on rat aortic rings. Adami A, et al. **Pharmacol Res** 1996 Apr-May; 33(4-5):239-44

Lipid peroxidation and lysosomal integrity in different inflammatory models in rats: the effects of indomethacin and naftazone. Agha AM, et al. **Pharmacol Res** 1995 Nov; 32(5):279-85

Ketoprofen lysine salt inhibits disuse-induced osteopenia in a new non-traumatic immobilization model in the rat. Fiorentino S, et al. **Pharmacol Res** 1996 Apr-May; 33(4-5):277-81

Does ibuprofen affect bilirubin-albumin binding in newborn infant serum? Cooper-Peel C, et al. **Pharmacol Toxicol** 1996 Dec;79(6):297-9

Ibuprofen inhibits the metabolism of the endogenous cannabimimetic agent anandamide. Fowler CJ, et al. **Pharmacol Toxicol** 1997 Feb;80(2):103-7

The effect of alpha-trinositol on cholera toxin-induced hypersecretion and morphological changes in pig jejunum. Hansen MB, et al. **Pharmacol Toxicol** 1996 Feb; 78(2):104-10

No effect of diclofenac on the pharmacokinetics of cloxacillin. Nergelius G, et al. **Pharmacol Toxicol** 1997 Jul; 81(1):26-30

Differential effects of increasing doses of alpha-trinositol on cerebral blood flow autoregulation. Vraamark T, et al. **Pharmacol Toxicol** 1997 Jan;80(1):38-43

A possible central antinociceptive effect of dipyrone in mice. Akman H, et al. **Pharmacology** 1996 Aug;53(2):71-8

Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. Bassleer C, et al. **Pharmacology** 1997 Jan;54(1):49-56

The effect of nitric oxide synthase blockade and indomethacin on gastric emptying and gastric contractility. Corak A, et al. **Pharmacology** 1997 Jun;54(6):298-304

Pretreatment with an inhibitor of mac-1 alters regional and systemic platelet function during ischemia-reperfusion in swine. Gurbel PA, et al. **Pharmacology** 1996 Aug; 53(2):79-86

The effect of flurbiprofen on steady-state plasma lithium levels. Hughes BM, et al. **Pharmacotherapy** 1997 Jan-Feb; 17(1):113-20

Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait. after oral and cutaneous application. Blazsó G, et al. **Pharmazie** 1997 May; 52(5):380-2

Molecular mechanism of drug photosensitization. IX. Effect of inorganic ions on DNA cleavage photosensitized by naproxen. De Guidi G, et al. **Photochem Photobiol** 1996 Apr;63(4):455-62

Interaction of ultraviolet-B-rich and ultraviolet-A-rich radiation in ketoprofen-induced photohemolysis. Eberlein-König B, et al. **Photodermatol Photoimmunol Photomed** 1996 Jun; 12(3):109-13

Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: suppression by glucocorticoids and NSAIDs. Imseis HM, et al. **Placenta** 1997 Sep;18(7):521-6

An analytical study, anti-inflammatory and analgesic effects of Harpagophytum procumbens and Harpagophytum zeyheri. Baghdikian B, et al. **Planta Med** 1997 Apr; 63(2):171-6

Investigation of anti-inflammatory and antinociceptive activities of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara. Part 1. Carvalho JC, et al. **Planta Med** 1996 Oct;62(5):402-4

Analgesic, anti-inflammatory, antipyretic and haematological effects of aethiopinone, an o-naphthoquinone diterpenoid from Salvia aethiopis roots and two hemisynthetic derivatives. Hernández-Pérez M, et al. **Planta Med** 1995 Dec;61(6):505-9

Anti-inflammatory and anti-nociceptive activity of disodium glycyrrhetinic acid hemiphthalate. Khaksa G, et al. **Planta Med** 1996 Aug;62(4):326-8

Studies on the anti-inflammatory activity of rhizomes of Nelumbo nucifera [letter] Mukherjee PK, et al. **Planta Med** 1997 Aug;63(4):367-9

Inhibitory effects of bisbenzylisoquinoline alkaloids on induction of proinflammatory cytokines, interleukin-1 and tumor necrosis factor-alpha. Onai N, et al. **Planta Med** 1995 Dec;61(6):497-501

Gastric cytoprotection of the non-steroidal anti-inflammatory sesquiterpene, beta-caryophyllene [letter] Tambe Y, et al. **Planta Med** 1996 Oct;62(5):469-70

Inhibition of prolidase activity by non-steroid antiinflammatory drugs in cultured human skin fibroblasts. Miltyk W, et al. **Pol J Pharmacol** 1996 Nov-Dec; 48(6):609-13

Inhibition of human platelet cathepsin A by non-steroidal anti-inflammatory drugs--in vitro study. Ostrowska H. **Pol J Pharmacol** 1996 Jan-Feb;48(1):113-6

Bioactivity of flavonoids. Robak J, et al. **Pol J Pharmacol** 1996 Nov-Dec;48(6):555-64 (65 ref.)

NSAIDs revisited: selection, monitoring, and safe use. Amadio P Jr, et al. **Postgrad Med** 1997 Feb;101(2):257-60, 263-7, 270-1 (20 ref.)

Gastrointestinal effects of NSAIDs. Difficulties in detection and management. Pearson SP, et al. **Postgrad Med** 1996 Nov;100(5):131-2, 135-6, 141-3 (20 ref.)

Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase-independent inhibition by aspirin. Bozza PT, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1; 93(20):11091-6

Piroxicam and tenoxicam effects on ethanol-induced lipid peroxidation in brains of CD-1 male mice. Pérez-Tapia E, et al. **Proc West Pharmacol Soc** 1996;39:77-9

Piroxicam inhibits epinephrine-induced stimulation of glycerol production in isolated rat adipocytes. Pimentel-Velazquez L, et al. **Proc West Pharmacol Soc** 1996;39:31-2

Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Serhan CN. **Prostaglandins** 1997 Feb; 53(2):107-37 (119 ref.)

The in vitro effects of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone, on rat gastric mucosal eicosanoid synthesis and metabolism. Melarange R, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Sep; 55(3):195-200

Effects of non-steroidal anti-inflammatory drugs on prostaglandin E2 production by cyclooxygenase-2 from endogenous and exogenous arachidonic acid in rat peritoneal macrophages stimulated with lipopolysaccharide. Nakatsugi S, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Dec; 55(6):451-7

1-[3-(Aryloxy) propyl]-diamines: a new class of non-steroidal basic antiinflammatory agents. Structure-activity studies: Part II. Hadjipavlou-Litina D. **Res Commun Mol Pathol Pharmacol** 1997 Mar;95(3):319-29

Effect of 2,4-disubstituted thiazol-5yl-aminoketones on inflammation. In vitro and in vivo biological studies: a structure-activity approach. Hadjipavlou-Litina DJ, et al. **Res Commun Mol Pathol Pharmacol** 1997 Jun;96(3):307-18

Ketorolac causes the release of methionine-enkephalin in rats. Michel RE, et al. **Res Commun Mol Pathol Pharmacol** 1996 Feb;91(2):249-52

Glycogenolysis stimulation by non-steroidal anti-inflammatories in the perfused rat liver is not accompanied by Ca2+ release. Nascimento EA, et al. **Res Commun Mol Pathol Pharmacol** 1997 May; 96(2):193-201

Investigation of the effect of chamazulene on lipid peroxidation and free radical processes. Rekka EA, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jun;92(3):361-4

Protein binding and in vitro serum thromboxane B2 inhibition by flunixin meglumine and meclofenamic acid in dog, goat and horse blood. Galbraith EA, et al. **Res Vet Sci** 1996 Jul;61(1):78-81

Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. Landoni MF, et al. **Res Vet Sci** 1996 Jul; 61(1):26-32

Diclofenac and indomethacin influence the healing of normal and ischaemic incisional wounds in skin. Quirinia A, et al. **Scand J Plast Reconstr Surg Hand Surg** 1997 Sep; 31(3):213-9

Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles. Fenner H. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):28-33 (14 ref.)

Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Spangler RS. **Semin Arthritis Rheum** 1996 Aug;26(1):435-46 (79 ref.)

Mechanism of action of aspirin-like drugs. Vane JR, et al. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):2-10 (78 ref.)

Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-kappa B/c-Rel nuclear translocation, and synthesis of tissue factor (TF) and tumor necrosis factor alfa (TNF-alpha) in human monocytes. Osnes LT, et al. **Thromb Haemost** 1996 Dec;76(6):970-6

The effect of indomethacin administration on the splenic changes induced by estradiol supplementation in ovariectomized New Zealand white rabbits. Thurmond TS, et al. **Toxicol Pathol** 1996 Mar-Apr;24(2):153-9

The effect and pharmacokinetics of nafamostat mesilate adjunct to cold nondepolarizing cardioplegia in a canine model of cardiac preservation. Sunamori M, et al. **Transpl Int** 1996;9(4):364-9

Cyclosporine nephrotoxicity evaluated by tissue calcium deposition and tubular enzymes is prevented by L-propionylcarnitine in isolated perfused rat kidney. Giovannini L, et al. **Transplant Proc** 1996 Dec;28(6):3122-5

Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Teixeira MM, et al. **Trends Pharmacol Sci** 1997 May;18(5):164-71 (101 ref.)

Preliminary pharmacokinetic and pharmacodynamic studies on flunixin meglumine in donkeys. Cheng Z, et al. **Vet Res Commun** 1996;20(5):469-72

Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin. Bitko V, et al. **Virology** 1997 Jun 9;232(2):369-78

Inhibition of tolbutamide 4-methylhydroxylation by a series of non-steroidal anti-inflammatory drugs in V79-NH cells expressing human cytochrome P4502C10. Kappers WA, et al. **Xenobiotica** 1996 Dec;26(12):1231-9

Clofibric acid increases the undirectional chiral inversion of ibuprofen in rat liver preparations. Roy-de Vos M, et al. **Xenobiotica** 1996 Jun;26(6):571-82

The influence of food, beverages and NSAIDs on gastric acid secretion and mucosal integrity. Peterson WL. **Yale J Biol Med** 1996 Jan-Feb;69(1):81-4 (22 ref.)

Chondroneutrality of meloxicam in rats with spontaneous osteoarthrosis of the ankle joint. Mohr W, et al. **Z Rheumatol** 1997 Jan-Feb;56(1):21-30

Combined effect of Web 2086 (Paf antagonist) and ketoprofen (Nsaid) on Paf-induced ex vivo platelet aggregation in bovine. Bastos da Silva M, et al. **Zentralbl Veterinarmed A** 1997 Apr;44(2):65-71

[The relationship between resorption and the morphological changes in the gastric mucosa of rats after acute and chronic exposures to acetylsalicylic acid] Tsaneva M, et al. **Eksp Med Morfol** 1994;32(3–4):69–79 (Eng. Abstr.) **(Bul)**

[Recent progresses in pharmacological and clinical studies of paeonol] Zhang LH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Mar; 16(3):187–90 (24 ref.) **(Chi)**

[Pharmacological action of siwei shaoyao decoction] Fang Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Apr; 21(4):238–40 inside backcover (Eng. Abstr.) **(Chi)**

[Antitussive, expectorant and anti-inflammatory effects of rhizoma Cynanchi stauntonii] Liang A, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Mar;21(3):173–5, 191–2 (Eng. Abstr.) **(Chi)**

[The effects of a single active ingredient (T4) of Tripterygium Wilfordii Hook on the production of tumor necrosis factor by the peripheral blood mononuclear cells and synovium cells of rheumatoid arthritis patients] Zeng X, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Apr; 18(2):138–42 (Eng. Abstr.) **(Chi)**

[Progress in the study of lipoxin and leukotriene] Wu SH. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):79–81 (10 ref.) **(Chi)**

[Indomethacin reduces cerebral blood flow and the intracranial pressure (editorial)] Lassen NA, et al. **Ugeskr Laeger** 1997 Jun 30;159(27):4249 **(Dan)**

[Biological rhythm, inflammation and non-steroidal anti-inflammatory agents] Bureau JP, et al. **Pathol Biol (Paris)** 1996 Sep;44(7):610–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Mechanism of action of anti-inflammatory agents] Scheen AJ. **Rev Med Liege** 1996 Sep;51(9):610–1 **(Fre)**

[Non-steroidal anti-inflammatory agents and cyclooxygenases] Vergne P, et al. **Therapie** 1996 Nov–Dec; 51(6):639–46 (57 ref.) **(Fre)**

[Anti-inflammatory effect of Urtica dioica folia extract in comparison to caffeic malic acid] Obertreis B, et al. **Arzneimittelforschung** 1996 Jan;46(1):52–6 (Eng. Abstr.) **(Ger)**

[2-Aryl-pyrrolo[2,1-b]benzothiazoles as a selective or dual inhibitors of cyclo-oxygenases and 5-lipoxygenases. 21. Non-steroidal anti-inflammatory agents] Dannhardt G, et al. **Pharmazie** 1997 Jun;52(6):428–36 (Eng. Abstr.) **(Ger)**

[Effect of non-steroidal antirheumatic agents on the gastrointestinal tract: clinical aspects and pathophysiology] Bertschinger P, et al. **Schweiz Med Wochenschr** 1996 Sep 14;126(37):1566–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[COX-2 inhibition: latest on NSAID (news)] **Z Orthop Ihre Grenzgeb** 1997 Jan–Feb;135(1):Oa20–1 **(Ger)**

[A comparison of the pharmacological actions between DSCG (disodium cromoglycate) and BDP (beclomethasone dipropionate) in the treatment of bronchial asthma] Shida T. **Nippon Rinsho** 1996 Nov; 54(11):3011–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Reduction of the antihypertensive effects of enalapril by indomethacin. Its independence from renal sodium retention] Polónia J, et al. **Rev Port Cardiol** 1996 Jun; 15(6):485–92, 460 (Eng. Abstr.) **(Por)**

[Nabumetone, a new nonsteroidal antiinflammatory agent: clinical prospects] Nasonov EL, et al. **Klin Med (Mosk)** 1996;74(8):13–6 (63 ref.) **(Rus)**

[Pharmacological bases of non-steroidal anti-inflammatory analgesics] Beltrán B, et al. **Gastroenterol Hepatol** 1996 Nov;19(9):478–88 **(Spa)**

[Effect of indomethacin on the secretion of pepsinogen in isolated human cells in vitro] Serrano Aulló MT, et al. **Rev Esp Enferm Dig** 1996 Apr;88(4):253–7 (Eng. Abstr.) **(Spa)**

[Meloxicam] Escolar M, et al. **Rev Med Univ Navarra** 1997 Apr–Jun;41(2):51–5 **(Spa)**

POISONING

Hypocalcemia and hypomagnesemia after ibuprofen overdose. al-Harbi NN, et al. **Ann Pharmacother** 1997 Apr; 31(4):432–4

Acute renal failure after binge drinking and NSAID use [letter] Spital A. **J Am Soc Nephrol** 1995 Dec;6(6):1682–5

An overdose fatality in a child involving disopyramide and sulindac. Singer P, et al. **J Anal Toxicol** 1995 Oct; 19(6):529–30

Fatal perforating intestinal ulceration attributable to flunixin meglumine overdose in rats. King CS, et al. **Lab Anim Sci** 1997 Apr;47(2):205–8

Naproxen toxicosis in a puppy. Dye TL. **Vet Hum Toxicol** 1997 Jun;39(3):157–9

SUPPLY & DISTRIBUTION

Acetylsalicylic-acid-containing drugs and nonsteroidal anti-inflammatory drugs available in Canada. Brigden M, et al. **Can Med Assoc J** 1997 Apr 1;156(7):1025–8 (30 ref.)

THERAPEUTIC USE

Evaluation of ketorolac in children with forearm fractures. Pierce MC, et al. **Acad Emerg Med** 1997 Jan;4(1):22–6

Efficacy of nonsteroidal antiinflammatory drugs in postoperative pain. Joris J. **Acta Anaesthesiol Belg** 1996; 47(3):115–23 (72 ref.)

Risk/benefit evaluation of NSAIDs in postoperative pain therapy. Nuutinen LS. **Acta Anaesthesiol Belg** 1996; 47(3):129–33

The use of Voltaren (diclofenac sodium, Ciba) in acute renal colic. Tankó A, et al. **Acta Chir Hung** 1995–96; 35(3–4):285–90

Diclofenac sodium as an alternative treatment of temporomandibular joint pain. Ekberg EC, et al. **Acta Odontol Scand** 1996 Jun;54(3):154–9

Ketorolac tromethamine in cancer pain. Yalçin S, et al. **Acta Oncol** 1997;36(2):231–2

Vitreous fluorophotometry and changes in blood–retinal barrier permeability induced by bendazac lysine. Nuzzi G, et al. **Acta Ophthalmol Scand** 1997 Feb;75(1):41–3

Colorectal cancer and nonsteroidal anti-inflammatory drugs. Smalley WE, et al. **Adv Pharmacol** 1997;39:1–20 (70 ref.)

Review article: COX-II inhibitors—a new generation of safer NSAIDs? Donnelly MT, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):227–36 (92 ref.)

The long-term management of patients with bleeding duodenal ulcers. McAlindon ME, et al. **Aliment Pharmacol Ther** 1997 Jun;11(3):505–10

5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Stretch GL, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):941–7

Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome. Tebano MT, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):659–63

Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Thomson AB, et al. **Aliment Pharmacol Ther** 1995 Dec; 9(6):673–83

Local treatment of nasal polyposis with capsaicin: preliminary findings. Filiaci F, et al. **Allergol Immunopathol (Madr)** 1996 Jan–Feb;24(1):13–8

Is decreased use of analgesics in Alzheimer disease due to a change in the affective component of pain? Scherder EJ, et al. **Alzheimer Dis Assoc Disord** 1997 Sep;11(3):171–4

Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Nguyen KN, et al. **Am J Cardiol** 1997 Jan 15;79(2):115–9

Measurement methods of drug consumption as a secondary judgment criterion for clinical trials in chronic rheumatic diseases. Constant F, et al. **Am J Epidemiol** 1997 May 1; 145(9):826–33

Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. d'Albasio G, et al. **Am J Gastroenterol** 1997 Jul;92(7):1143–7

Cyclic vomiting: association with multiple homeostatic abnormalities and response to ketorolac. Pasricha PJ, et al. **Am J Gastroenterol** 1996 Oct;91(10):2228–32

Medical amnioreduction with sulindac to reduce cord complications in monoamniotic twins. Peek MJ, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):334–6

Clinical efficacy and safety of Naprelan versus Naprosyn in the treatment of rheumatoid arthritis. Lisse JR. **Am J Orthop** 1996 Sep;25(9 Suppl):21–9

The appropriate use of NSAIDs in arthritic conditions. Moskowitz RW. **Am J Orthop** 1996 Sep;25(9 Suppl):4–6

A comparison of Naprelan and Naprosyn in the treatment of osteoarthritis of the knee. Schiff MH. **Am J Orthop** 1996 Sep;25(9 Suppl):14–20

Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinflammatory drugs. Scioscia KA, et al. **Am J Otolaryngol** 1997 Jan–Feb;18(1):1–8

A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits. The Kapooka Ankle Sprain Study. Slatyer MA, et al. **Am J Sports Med** 1997 Jul–Aug;25(4):544–53

Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. Cross AR, et al. **Am J Vet Res** 1997 Jun;58(6):626–31

Determination of an effective dose of eltenac and its comparison with that of flunixin meglumine in horses after experimentally induced carpitis. Hamm D, et al. **Am J Vet Res** 1997 Mar;58(3):298–302

A comparison of the efficacy of ketorolac and indomethacin for postoperative analgesia following laparoscopic surgery in day patients. Murrell GC, et al. **Anaesth Intensive Care** 1996 Apr;24(2):237–40

Peri-operative use of nonsteroidal anti-inflammatory drugs in children: analgesic efficacy and bleeding. Rømsing J, et al. **Anaesthesia** 1997 Jul;52(7):673–83 (40 ref.)

The analgesic efficacy of tenoxicam versus placebo in day case laparoscopy: a randomised parallel double-blind trial. Windsor A, et al. **Anaesthesia** 1996 Nov;51(11):1066–9

The impact of prostanoids on pulmonary gas exchange during abdominal surgery with mesenteric traction. Brinkmann A, et al. **Anesth Analg** 1997 Aug;85(2):274–80

Comparison of tenoxicam by intramuscular injection or wound infiltration for analgesia after inguinal herniorrhaphy [see comments] Mikkelsen SS, et al. **Anesth Analg** 1996 Dec;83(6):1239–43. Comment in: Anesth Analg 1997 May;84(5):1168–9.

Treatment of intracranial hypertension with indomethacin [letter; comment] Cold GE, et al. **Anesthesiology** 1996 Dec; 85(6):1499–501. Comment on: Anesthesiology 1995 Dec;83(6):1283–92.

Reducing pain after inguinal hernia repair in children: caudal anesthesia versus ketorolac tromethamine. Splinter WM, et al. **Anesthesiology** 1997 Sep;87(3):542–6

Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs. Giuseppe P, et al. **Ann Allergy Asthma Immunol** 1997 Jan; 78(1):74–8

Aspirin after myocardial infarction in the elderly [letter; comment] Ring BL. **Ann Intern Med** 1996 Dec 1; 125(11):938. Comment on: Ann Intern Med 1996 Feb 1;124(3):292–8.

Emergency department use of aspirin in patients with possible acute myocardial infarction. Saketkhou BB, et al. **Ann Intern Med** 1997 Jul 15;127(2):126–9

The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease. Bonapace CR, et al. **Ann Pharmacother** 1997 Jul–Aug;31(7–8):907–13 (32 ref.)

Zileuton: a new therapy for asthma or just the first of a new class of drugs [comment] Hendeles L, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):873–5. Comment on: Ann Pharmacother 1996 Jul–Aug;30(7–8):858–64.

Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma [see comments] Wenzel SE, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):858–64 (34 ref.). Comment in: Ann Pharmacother 1996 Jul–Aug;30(7–8):873–5.

Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomised clinical trials. Koes BW, et al. **Ann Rheum Dis** 1997 Apr;56(4):214–23 (53 ref.)

Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy. Baranda L, et al. **Arch Dermatol** 1997 Mar;133(3):325–9

Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells. Bruynzeel I, et al. **Arch Dermatol Res** 1997 Mar;289(4):189–93

Treatment of patent ductus arteriosus with ibuprofen. Van Overmeire B, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 May;76(3):F179–84

Efficacy of diclofenac in lateral epicondylitis of the elbow also treated with immobilization. The University of Montreal Orthopaedic Research Group [see comments] Labelle H, et al. **Arch Fam Med** 1997 May–Jun;6(3):257–62 . Comment in: Arch Fam Med 1997 May–Jun;6(3):263–4.

Treatment of an acute bacterial infection with a combination of acetylsalicylic acid/ibuprofen and interferon gamma. Hockertz S, et al. **Arzneimittelforschung** 1996 Oct; 46(10):1012–5

Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Panajotova V, et al. **Arzneimittelforschung** 1997 May; 47(5):648–52

Clinical incidents in general practice. Prescription errors. Britt H, et al. **Aust Fam Physician** 1996 Oct;25(10):1609–10

Rectal diclofenac analgesia after abdominal hysterectomy. Scott RM, et al. **Aust N Z J Obstet Gynaecol** 1997 Feb; 37(1):112–4

Evaluation of the effect of ketoprofen on experimentally induced ephemeral fever in dairy heifers [published erratum appears in Aust Vet J 1996 Aug;74(2):161] [see comments] Fenwick DC, et al. **Aust Vet J** 1996 Jul;74(1):37–41. Comment in: Aust Vet J 1997 Mar;75(3):221–3.

Effective treatment of bovine ephemeral fever [letter; comment] St George TD. **Aust Vet J** 1997 Mar;75(3):221–3 . Comment on: Aust Vet J 1996 Jul;74(1):37–41.

Use of anti-inflammatory and analgesic drugs in dogs and cats. Watson AD, et al. **Aust Vet J** 1996 Sep;74(3):203–10

Inhibitory effects of traditional Chinese medicine Shimotsu-to and its included crude fractions on adjuvant-induced chronic inflammation of mice. Kojima S, et al. **Biol Pharm Bull** 1996 Jan;19(1):47–52

Treatment of chronic graft-versus-host disease with clofazimine. Lee SJ, et al. **Blood** 1997 Apr 1;89(7):2298–302

Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. van der Poll T, et al. **Blood** 1997 May 15;89(10):3727–34

Tetracycline/flurbiprofen combination therapy modulates bone remodeling in ovariectomized rats: preliminary observations. Aoyagi M, et al. **Bone** 1996 Dec;19(6):629–35

Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease. Levi-Schaffer F, et al. **Bone Marrow Transplant** 1997 Apr; 19(8):823–8

Analgesia after day-case knee arthroscopy: double-blind study of intra-articular tenoxicam, intra-articular bupivacaine and placebo. Cook TM, et al. **Br J Anaesth** 1997 Feb;78(2):163–8

Morphine consumption in patients receiving rectal paracetamol and diclofenac alone and in combination. Montgomery JE, et al. **Br J Anaesth** 1996 Oct;77(4):445–7

IV perioperative ketoprofen in small children during adenoidectomy. Nikanne E, et al. **Br J Anaesth** 1997 Jan; 78(1):24–7

Metabolic effects of i.v. propacetamol, metamizol or external cooling in critically ill febrile sedated patients [see comments] Poblete B, et al. **Br J Anaesth** 1997 Feb; 78(2):123–7. Comment in: Br J Anaesth 1997 Feb;78(2):121–3.

A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients.

McMillan DC, et al. **Br J Cancer** 1997;76(6):788–90

Cancers related to contraceptive use [letter; comment] Rettig BA, et al. **Br J Cancer** 1996 Nov;74(9):1509–10. Comment on: Br J Cancer 1996 Mar;73(5):692–7.

A randomized, double-blind, placebo-controlled trial comparing pethidine to metamizol for treatment of post-anaesthetic shivering. Monsó A, et al. **Br J Clin Pharmacol** 1996 Sep;42(3):307–11

The efficacy of ketoprofen and paracetamol (acetaminophen) in postoperative pain after third molar surgery. Seymour RA, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):581–5

Self-medication of a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary. van Gerven JM, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):475–81

A post-marketing surveillance study of Voltarol 75 mg SR in the primary care setting. Jones CW. **Br J Clin Pract** 1996 Oct–Nov;50(7):390–5

Successful treatment of epidermolysis bullosa acquisita with mesalazine [letter] Robinowitz BN, et al. **Br J Dermatol** 1997 Jul;137(1):154–5

Randomised placebo controlled trial of mefenamic acid for premedication at outpatient hysteroscopy: a pilot study. Nagele F, et al. **Br J Obstet Gynaecol** 1997 Jul;104(7):842–4

Emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology [letter; comment] Trinquand C. **Br J Ophthalmol** 1996 Dec;80(12):1117. Comment on: Br J Ophthalmol 1996 May;80(5):480–5.

Comparison of the efficacy of diclofenac and betamethasone following strabismus surgery. Wright M, et al. **Br J Ophthalmol** 1997 Apr;81(4):299–301

The absence of any pre-emptive analgesic effect for non-steroidal anti-inflammatory drugs. Birdgman JB, et al. **Br J Oral Maxillofac Surg** 1996 Oct;34(5):428–31

Are rheumatoid arthritis patients more willing to accept non-steroidal anti-inflammatory drug treatment risks than osteoarthritis patients? Bagge E, et al. **Br J Rheumatol** 1997 Apr;36(4):470–2

Safety of meloxicam: a global analysis of clinical trials [British Journal of Rheumatology, 1996;35(suppl. 1):68–77] [letter] Fenn GC, et al. **Br J Rheumatol** 1997 Jul;36(7):817–9

High prevalence of Helicobacter pylori infection in duodenal ulcer perforations not caused by non-steroidal anti-inflammatory drugs [see comments] Ng EK, et al. **Br J Surg** 1996 Dec;83(12):1779–81. Comment in: Br J Surg 1997 Jul;84(7):1029–30.

Nervous diseases and Kampo (Japanese herbal) medicine: a new paradigm of therapy against intractable nervous diseases. Sugaya E, et al. **Brain Dev** 1997 Mar;19(2):93–103 (59 ref.)

Effect of dipyrone, L-NAME and L-arginine on endotoxin-induced rat paw edema. Fracasso JF, et al. **Braz J Med Biol Res** 1996 Nov;29(11):1543–8

Boy with peripheral joint pain [letter; comment] Baum J. **Bull Rheum Dis** 1997 Apr;46(2):1. Comment on: Bull Rheum Dis 1996 Aug;45(5):1–2.

Effects of allopurinol, ibuprofen and cyclosporin A on local microcirculatory disturbance due to burn injuries. Cetinkale O, et al. **Burns** 1997 Feb;23(1):43–9

Action of trypsin:chymotrypsin (Chymoral forte DS) preparation on acute-phase proteins following burn injury in humans. Latha B, et al. **Burns** 1997 Mar;23 Suppl 1:S3–7

Increased dermal perfusion after skin burn injury by D-myo-inositol-1,2,6-trisphosphate. Tarnow P, et al. **Burns** 1996 Aug;22(5):363–8

Preventive not pre-emptive analgesia with piroxicam [letter; comment] Futter M. **Can J Anaesth** 1997 Jan;44(1):101–2 . Comment on: Can J Anaesth 1996 Feb;43(2):97–101.

Dose-response of flurbiprofen on postoperative pain and emesis after paediatric strabismus surgery. Mikawa K, et al. **Can J Anaesth** 1997 Jan;44(1):95–8

Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C. Anderson FH, et al. **Can J Gastroenterol** 1997 May–Jun;11(4):294–7

Keratitis associated with presumed polyendocrinopathy syndrome: treatment with fluorometholone and diclofenac sodium. Des Marchais B, et al. **Can J Ophthalmol** 1995 Dec;30(7):380–4

Utilization of the serosal scarification model of postoperative intestinal adhesion formation to investigate potential adhesion-preventing substances in the rabbit. Singer ER, et al. **Can J Vet Res** 1996 Oct;60(4):305–11

Nonsteroidal anti-inflammatory analgesics in pain management in dogs and cats [published erratum appears in Can Vet J 1997 Mar;38(3):133] Mathews KA. **Can Vet J** 1996 Sep;37(9):539–45 (17 ref.)

A comparison of ketorolac with flunixin, butorphanol, and oxymorphone in controlling postoperative pain in dogs. Mathews KA, et al. **Can Vet J** 1996 Sep;37(9):557–67

Biologic characteristics of esophageal epithelial dysplasia assessed by proliferating cell nuclear antigen [letter; comment] Morgan G. **Cancer** 1996 Oct 1;78(7):1514–5. Comment on: Cancer 1996 Jan 15;77(2):237–44.

Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Reeves MJ, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Dec;5(12):955–60

Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Castonguay A, et al. **Carcinogenesis** 1997 Mar;18(3):491–6

Use of aspirin in ischaemic heart disease [letter] Constantine GR, et al. **Ceylon Med J** 1996 Dec;41(4):167–8

Premedication with diclofenac and prednisolone to prevent postoperative pain and swelling after third molar removal. Lin TC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jul;58(1):40–4

Contact lens induced conjunctivitis: a model of human ocular inflammation. Friedlaender MH. **CLAO J** 1996 Jul; 22(3):205–8

Actin polymerisation in neutrophils of rheumatoid arthritis patients in relation to treatment with non-steroidal anti-inflammatory drugs. De Clerck LS, et al. **Clin Chim Acta** 1997 May 6;261(1):19–25

Choice of therapy in porphyria cutanea tarda [letter] Adjarov D, et al. **Clin Exp Dermatol** 1996 Nov;21(6):461–2

Limited efficacy of pentoxifylline as anti-inflammatory agent in experimental pneumococcal meningitis. Zysk G, et al. **Clin Exp Immunol** 1997 Mar;107(3):458–61

Suppressive effects of a herbal formula, TBL-1, on type II collagen-induced arthritis in DBA/1J mice. Li SH, et al. **Clin Exp Pharmacol Physiol** 1996 Mar;23(3):236–40

Low incidence of colorectal cancer in patients with rheumatoid arthritis. Kauppi M, et al. **Clin Exp Rheumatol** 1996 Sep–Oct;14(5):551–3

Comparison of the effects of tenoxicam and mid-laser irradiation on chronic adjuvant arthritis in rats. Ulugöl A, et al. **Clin Exp Rheumatol** 1997 Jan–Feb;15(1):83–6

Increased use of cardiovascular medications in seniors prescribed non-ASA non-steroidal anti-inflammatory drugs. Hogan DB, et al. **Clin Invest Med** 1996 Feb; 19(1):46–54

Efficacy of naproxen sodium for exercise-induced dysfunction muscle injury and soreness. Dudley GA, et al. **Clin J Sport Med** 1997 Jan;7(1):3–10

Successful management of steroid-resistant nephrotic syndrome using ibuprofen. Low CL, et al. **Clin Nephrol** 1997 Jan;47(1):60–2

Aceclofenac in rheumatoid arthritis: a useful and novel anti-inflammatory. Hunter JA, et al. **Clin Rheumatol** 1996 Jul;15(4):329–34

Peri-articular injection of tenoxicam for painful shoulders: a double-blind, placebo controlled trial. Itzkowitch D, et al. **Clin Rheumatol** 1996 Nov;15(6):604–9

Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. Kornasoff D, et al. **Clin Rheumatol** 1997 Jan;16(1):32–8

Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Peréz Busquier M, et al. **Clin Rheumatol** 1997 Mar;16(2):154–9

Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. Perez-Ruiz F, et al. **Clin Rheumatol** 1996 Sep;15(5):473–7

Nonsteroidal anti-inflammatory drugs, traditional opioids, and tramadol: contrasting therapies for the treatment of chronic pain. Aronson MD. **Clin Ther** 1997 May–Jun; 19(3):420–32; discussion 367–8 (38 ref.)

Piroxicam fast-dissolving dosage form in the treatment of patients with acute low back pain. Englert R, et al. **Clin Ther** 1996 Sep–Oct;18(5):843–52

The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee. Makarowski W, et al. **Clin Ther** 1996 Jan–Feb;18(1):114–24

Ketorolac, prednisolone, and dexamethasone for postoperative inflammation. Ostrov CS, et al. **Clin Ther** 1997 Mar–Apr;19(2):259–72

Comparison of ketoprofen, piroxicam, and diclofenac gels in the treatment of acute soft-tissue injury in general practice. General Practice Study Group. Patel RK, et al. **Clin Ther** 1996 May–Jun;18(3):497–507

Evaluation of the safety, tolerability, and efficacy of meloxicam tablets in patients with osteoarthritis. Prouse PJ, et al. **Clin Ther** 1996 May–Jun;18(3):429–39

Chronic arthritis in children. Szer IS. **Compr Ther** 1997 Feb; 23(2):124–9 (12 ref.)

Effect of antiproteinuric treatment on the lipid profile in nondiabetic renal disease. Navis G, et al. **Contrib Nephrol** 1997;120:88–96 (50 ref.)

Treatment of inflamed pterygium and pinguecula with topical indomethacin 0.1% solution. Frucht-Pery J, et al. **Cornea** 1997 Jan;16(1):42–7

Evaluation of diclofenac sodium 0.1% ophthalmic solution in the treatment of ocular symptoms after bilateral radial keratotomy. Hettinger ME, et al. **Cornea** 1997 Jul; 16(4):406–13

Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations. Baumgartner H, et al. **Curr Med Res Opin** 1996;13(8):435–44

The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. Colberg K, et al. **Curr Med Res Opin** 1996;13(7):363–77

Actions and toxicity of nonsteroidal anti-inflammatory drugs. Simon LS. **Curr Opin Rheumatol** 1996 May;8(3):169–75 (48 ref.)

Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal antiinflammatory agents. A prospective study. Billingsley EM, et al. **Dermatol Surg** 1997 May;23(5):381–3; discussion 384–5

Evening primrose oil (Epogam) in the treatment of chronic hand dermatitis: disappointing therapeutic results. Whitaker DK, et al. **Dermatology** 1996;193(2):115–20

Effect of long-acting somatostatin analog (Somatulin) on renal hyperfiltration in patients with IDDM. Jacobs ML, et al. **Diabetes Care** 1997 Apr;20(4):632–6

Ketorolac for postoperative pain management in children. Forrest JB, et al. **Drug Saf** 1997 May;16(5):309–29 (113 ref.)

Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs. Senna GE, et al. **Drug Saf** 1996 Feb; 14(2):94–103 (73 ref.)

Systemic lupus erythematosus. **Drug Ther Bull** 1996 Mar; 34(3):20–3 (23 ref.)

Recognition and optimum management of myocarditis. Caforio AL, et al. **Drugs** 1996 Oct;52(4):515–25 (98 ref.)

Preclinical and clinical development of dexketoprofen. Mauleón D, et al. **Drugs** 1996;52 Suppl 5:24–45; discussion 45–6 (163 ref.)

Meloxicam. Noble S, et al. **Drugs** 1996 Mar;51(3):424–30; discussion 431–32 (43 ref.)

Diacerein. Spencer CM, et al. **Drugs** 1997 Jan;53(1):98–106; discussion 107–8 (45 ref.)

Current pharmacological treatment of osteoarthritis. Wollheim FA. **Drugs** 1996;52 Suppl 3:27–38 (97 ref.)

Selective inhibitors of cyclooxygenase-2. Potential in elderly patients. Davies NM, et al. **Drugs Aging** 1996 Dec; 9(6):406–17 (124 ref.)

Do nonsteroidal anti-inflammatory drugs have a protective effect against dementia? Van Muiswinkel FL, et al. **Drugs Aging** 1996 Jul;9(1):1–7

The anti-inflammatory effects of ketoprofen in animal experiments. Wang LM, et al. **Drugs Exp Clin Res** 1997; 23(1):1–6

Lichen planus esophagitis with secondary candidiasis: successful combination treatment with ketoconazole and a corticosteroid. Ali A, et al. **Endoscopy** 1996 Jun;28(5):460

Nonsteroidal antiinflammatory drugs and colorectal cancer. Berkel H, et al. **Epidemiol Rev** 1996;18(2):205–17 (123 ref.)

The effect of drugs used in the treatment of osteoarthrosis on stromelysin (proteoglycanase) of equine synovial cell origin. May SA, et al. **Equine Vet J Suppl** 1988 Sep; (6):28–32

Left ventricular myxoma presenting with constitutional symptoms and raised serum interleukin-6 both suppressed by naproxen [letter] Vaughan CJ, et al. **Eur Heart J** 1997 Apr;18(4):703

Post-operative pain relief in children following extraction of carious deciduous teeth under general anaesthesia: a comparison of nalbuphine and diclofenac. Littlejohn IH, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):359–63

A comparison of the effect of intramuscular diclofenac, ketorolac or piroxicam on post-operative pain following laparoscopy. O'Hanlon JJ, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):404–7

The value of continuous blockade of the lumbar plexus as an adjunct to acetylsalicyclic acid for pain relief after surgery for femoral neck fractures. Spansberg NL, et al. **Eur J Anaesthesiol** 1996 Jul;13(4):410–2

Non-steroidal anti-inflammatory drugs in the treatment of colorectal cancer [letter] Morgan G. **Eur J Cancer** 1997 Jul;33(8):1335–6

Aspirin, NSAIDS and human cancer [editorial; comment] Hill MJ. **Eur J Cancer Prev** 1996 Aug;5(4):219–20. Comment on: Eur J Cancer Prev 1996 Aug;5(4):221–31.

NSAIDs, Barrett's oesophagus and adenocarcinoma prevention [letter] Vainio H, et al. **Eur J Cancer Prev** 1997 Apr;6(2):200

Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever. Autret E, et al. **Eur J Clin Pharmacol** 1997;51(5):367–71

Comparative study of the efficacy of lysine acetylsalicylate, indomethacin and pethidine in acute renal colic. al-Sahlawi KS, et al. **Eur J Emerg Med** 1996 Sep;3(3):183–6

Lanreotide in the treatment of patients with thyroid eye disease. Krassas GE, et al. **Eur J Endocrinol** 1997 Apr; 136(4):416–22

Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. Karamanolis DG, et al. **Eur J Gastroenterol Hepatol** 1996 Nov;8(11):1083–8

Previous use of non-steroidal anti-inflammatory drugs and anticoagulants: the influence on clinical outcome of bleeding gastroduodenal ulcers. Vreeburg EM, et al. **Eur J Gastroenterol Hepatol** 1997 Jan;9(1):41–4

Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium. Schiffl H, et al. **Eur J Med Res** 1997 Mar 24;2(3):97–100

Pain relief during and following outpatient curettage and hysterosalpingography: a double blind study to compare the efficacy and safety of tramadol versus naproxen. Cobra Research Group. Peters AA, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 May;66(1):51–6

Antinociceptive effects of oral clonidine and S12813-4 in acute colon inflammation in rats. Miampamba M, et al. **Eur J Pharmacol** 1996 Jul 25;308(3):251–9

Pharmacological modulation of eosinophil influx into the lungs of Brown Norway rats. Namovic MT, et al. **Eur J Pharmacol** 1996 Nov 7;315(1):81–8

The potential of NSAIDs in the prevention and treatment of colorectal carcinoma [letter; comment] Morgan G. **Eur J Surg Oncol** 1996 Oct;22(5):560. Comment on: Eur J Surg Oncol 1996 Jun;22(3):217–9.

Topical diclofenac relieves pain from corneal rust ring.

Haynes RJ, et al. **Eye** 1996;10 (Pt 4):443–6

The effectiveness of topical diclofenac in relieving discomfort following traumatic corneal abrasions. Jayamanne DG, et al. **Eye** 1997;11 (Pt 1):79–83

Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. Levy GN. **FASEB J** 1997 Mar; 11(4):234–47 (109 ref.)

Effect of naklofen, alcohol and naklofen administered simultaneously with alcohol on transaminase levels. Łąkowska H, et al. **Folia Morphol (Warsz)** 1996;55(4):380–1

A randomized, double-blind, multicentre controlled trial of ibuprofen versus acetaminophen and placebo for symptoms of acute otitis media in children. Bertin L, et al. **Fundam Clin Pharmacol** 1996;10(4):387–92

Antipyretic efficacy of tiaprofenic acid in febrile children. Vauzelle-Kervroëdan F, et al. **Fundam Clin Pharmacol** 1996;10(1):56–9

Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. DuBois RN, et al. **Gastroenterol Clin North Am** 1996 Dec;25(4):773–91 (87 ref.)

NSAID-induced polyp regression in familial adenomatous polyposis patients. Giardiello FM. **Gastroenterol Clin North Am** 1996 Jun;25(2):349–62 (63 ref.)

NSAID use and decreased risk of gastrointestinal cancers. Thun MJ. **Gastroenterol Clin North Am** 1996 Jun; 25(2):333–48 (71 ref.)

Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study. Akriviadis EA, et al. **Gastroenterology** 1997 Jul;113(1):225–31

A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Hawkey CJ, et al. **Gastroenterology** 1997 Mar;112(3):718–24

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Sutherland LR, et al. **Gastroenterology** 1997 Apr;112(4):1069–77

Effects of sulindac on sporadic colorectal adenomatous polyps [see comments] Matsuhashi N, et al. **Gut** 1997 Mar; 40(3):344–9. Comment in: Gut 1997 Mar;40(3):430.

Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution? Sahmoud T, et al. **Gut** 1997 Feb;40(2):284–5

Discouraging colonic polyps [comment] Williams CB. **Gut** 1997 Mar;40(3):430. Comment on: Gut 1997 Mar;40(3):344–9.

Ketoprofen versus paracetamol in the treatment of acute migraine. Karabetsos A, et al. **Headache** 1997 Jan; 37(1):12–4

Incomplete analgesic effect of lanreotide in acromegaly [letter] Maffei P, et al. **Headache** 1997 May;37(5):299–300

Therapeutic approaches to osteoarthritis. Block JA, et al. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):159–64 (6 ref.)

Keys to managing systemic lupus erythematosus. Roberts WN. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):113–6, 119–22, 125–6 (5 ref.)

Management of irregular uterine bleeding and spotting associated with Norplant. Archer DF, et al. **Hum Reprod** 1996 Oct;11 Suppl 2:24–30

Aspirin and other nonsteroid anti-inflammatory drugs as cancer-preventive agents. Greenberg ER, et al. **IARC Sci Publ** 1996;(139):91–8 (29 ref.)

Inflammatory and immunological parameters of disease activity in rheumatoid arthritis patients treated with minocycline. Kloppenburg M, et al. **Immunopharmacology** 1996 Mar;31(2–3):163–9

Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer. Sandler RS. **Important Adv Oncol** 1996;:123–37 (77 ref.)

Gastrointestinal protection by NO from NSAIDs induced injury. Rishi RK, et al. **Indian J Physiol Pharmacol** 1996 Oct;40(4):377–9 (22 ref.)

Serum from NSAID-treated patients attenuates the capacity of rat leukocytes to synthesize leukotriene B4. Gutheil H, et al. **Inflamm Res** 1996 Jan;45(1):31–4

Effect of bucillamine on the rat trinitrobenzene sulfonic acid induced model of colitis. Kitano A, et al. **Inflamm Res** 1996 Oct;45(10):491–3

Activation of the arginine-nitric oxide pathway in primary sensory neurons contributes to dipyrone-induced spinal and peripheral analgesia. Lorenzetti BB, et al. **Inflamm Res** 1996 Jun;45(6):308–11

A comparison of clodronate and indomethacin in the treatment of adjuvant arthritis. Osterman T, et al. **Inflamm Res** 1997 Mar;46(3):79–85

Inhibition by hydroxyachillin, sesquiterpene lactone from Tanacetum microphyllum, of PMA-induced mouse ear oedema. Silván AM, et al. **Inflamm Res** 1996 Jun; 45(6):289–92

Surgery for left main spasm. Is it indicated? Ng WL, et al. **Int J Cardiol** 1996 Jun;54(3):213–6

Tolerability of mofebutazone in asthmatic patients. Khayyal MT, et al. **Int J Clin Pharmacol Res** 1995;15(4):145–51

Comparison of the analgesic effects of diflunisal and paracetamol in the treatment of postoperative dental pain. Selçuk E, et al. **Int J Clin Pharmacol Res** 1996; 16(2–3):57–65

Effect of inhaled heparin on adenosine-induced bronchial hyperreactivity. Ceyhan BB, et al. **Int J Clin Pharmacol Ther** 1997 May;35(5):208–13

Use of tolfenamic acid in febrile children with and without glucose-6-phosphate dehydrogenase deficiency. Haliotis FA, et al. **Int J Clin Pharmacol Ther** 1997 Mar;35(3):103–6

Sulindac for periampullary polyps in FAP patients. Richard CS, et al. **Int J Colorectal Dis** 1997;12(1):14–8

Colchicine as a novel therapeutic agent in chronic bullous dermatosis of childhood. Banodkar DD, et al. **Int J Dermatol** 1997 Mar;36(3):213–6

Malignant pyoderma responding to clofazimine [letter] Pari T, et al. **Int J Dermatol** 1996 Oct;35(10):757–8

Regarding Martenson et al., IJROBP 35:299–303; 1996 [letter] Michalowski AS. **Int J Radiat Oncol Biol Phys** 1996 Dec 1;36(5):1285–6

A controlled clinical investigation of 3% diclofenac/2.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with osteoarthritis. Roth SH. **Int J Tissue React** 1995; 17(4):129–32

Galactosaminoglycuronglycan sulfate in erosive osteoarthritis of the hands: early diagnosis, early treatment. Rovetta G, et al. **Int J Tissue React** 1996;18(1):43–6

Topical nonsteroidal antiinflammatory drugs for ophthalmic use. Flach AJ. **Int Ophthalmol Clin** 1996 Spring;36(2):77–83 (20 ref.)

The opiate-sparing effect of dipyrone in post-operative pain therapy with morphine using a patient-controlled analgesic system. Tempel G, et al. **Intensive Care Med** 1996 Oct; 22(10):1043–7

The choleretic effect of nonsteroidal anti-inflammatory drugs in total parenteral nutrition-associated cholestasis. Nussinovitch M, et al. **Isr J Med Sci** 1996 Dec; 32(12):1262–4

Gastroduodenal tolerability of highly specific cyclo-oxygenase-2 inhibitor. Hayllar J, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:30–2

Topical analgesia for superficial corneal injuries. Brahma AK, et al. **J Accid Emerg Med** 1996 May;13(3):186–8

Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. Caron D, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 2):S110–2

Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. Clucas A, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 2):S116–8

Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. Cunliffe WJ, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 2):S126–34

Indomethacin treatment of eighteen patients with Sweet's syndrome. Jeanfils S, et al. **J Am Acad Dermatol** 1997 Mar; 36(3 Pt 1):436–9

Factors affecting hypertrophic scar development in median sternotomy incisions for congenital cardiac surgery. Nakamura K, et al. **J Am Coll Surg** 1997 Sep;185(3):218–23

Use of carprofen for the treatment of pain and inflammation in dogs. Fox SM, et al. **J Am Vet Med Assoc** 1997 May 15;210(10):1493–8 (60 ref.)

Mechanisms of action of anti-inflammatory medications used for the treatment of osteoarthritis [see comments] Johnston SA, et al. **J Am Vet Med Assoc** 1997 May 15; 210(10):1486–92 (102 ref.). Comment in: J Am Vet Med Assoc 1997 May 15;210(10):1417–8.

Efficacy of hyaluronic acid/nonsteroidal anti-inflammatory drug systems in preventing postsurgical tendon adhesions. Miller JA, et al. **J Biomed Mater Res** 1997 Spring; 38(1):25–33

A sequential trial of pain killers in arthritis: issues of multiple comparisons with control and of interval-censored survival data. Whitehead J, et al. **J Biopharm Stat** 1997 Jul; 7(3):333–53

Prevention of heterotopic ossification after total hip replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. Knelles D, et al. **J Bone Joint Surg Br** 1997 Jul;79(4):596–602

Reduced albumin extravasation in experimental rat skin and muscle burn injury by D-myo-inositol-1,2,6-trisphosphate treatment. Tarnow P, et al. **J Burn Care Rehabil** 1996 May–Jun;17(3):207–12

Comparison of diclofenac sodium and flurbiprofen for inhibition of surgically induced miosis. Roberts CW. **J Cataract Refract Surg** 1996;22 Suppl 1:780–7

Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Rossetti L, et al. **J Cataract Refract Surg** 1996;22 Suppl 1:794–9

Efficacy and safety of combined diclofenac 0.1% and gentamicin 0.3% eyedrops after phacoemulsification. Rossetti L, et al. **J Cataract Refract Surg** 1997 Jun; 23(5):745–9

Efficacy and safety of topical diclofenac in reducing ocular pain after excimer photorefractive keratectomy. Tutton MK, et al. **J Cataract Refract Surg** 1996 Jun;22(5):536–41

Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. Fourrier A, et al. **J Clin Epidemiol** 1996 Oct;49(10):1201

A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation. McMahon AD, et al. **J Clin Epidemiol** 1997 Mar; 50(3):351–6

Assessing the relative sensitivity to change of rheumatoid arthritis activity measures: is the type of treatment an important third variable? Ward MM. **J Clin Epidemiol** 1996 Oct;49(10):1161–9

Some effects of mouthrinses containing salifluor on de novo plaque formation and developing gingivitis. Furuichi Y, et al. **J Clin Periodontol** 1996 Aug;23(8):795–802

Enantiospecific inhibition of ligature-induced periodontitis in beagles with topical (S)-ketoprofen. Paquette DW, et al. **J Clin Periodontol** 1997 Aug;24(8):521–8

Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU). Skaare AB, et al. **J Clin Periodontol** 1996 Aug;23(8):778–81

Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis. Kovarik JM, et al. **J Clin Pharmacol** 1997 Apr;37(4):336–43

Reevaluation of some double-blind, randomized studies of dexibuprofen (Seractil): a state-of-the-art overview. Studies in patients with lumbar vertebral column syndrome, rheumatoid arthritis, distortion of the ankle joint, gonarthrosis, ankylosing spondylitis, and activated coxarthrosis. Rahlfs VW, et al. **J Clin Pharmacol** 1996 Dec; 36(12 Suppl):33S–40S

Effectiveness of herbal medicine (shakuyaku-kanzo-to) for neuroleptic-induced hyperprolactinemia [letter] Yamada K, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):234–5

Comparative effect of tiaprofenic acid and piroxicam alone and as adjuvants to praziquantel in Schistosoma mansoni infected mice. Hegazy IH, et al. **J Egypt Soc Parasitol** 1997 Aug;27(2):397–404

Anti-inflammatory and antiulcer activity of Teucrium buxifolium. Fernández Puntero B, et al. **J Ethnopharmacol** 1997 Jan;55(2):93–8

Pain relief for renal colic. Bergus GR. **J Fam Pract** 1996 Nov;43(5):438–40

Propionyl-L-carnitine for intermittent claudication. Deckert J. **J Fam Pract** 1997 Jun;44(6):533–4

Cyclooxygenase, NSAIDs, and colorectal cancer. DuBois RN, et al. **J Gastroenterol** 1996 Dec;31(6):898–906 (85 ref.)

The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels. Dezube BJ, et al. **J Infect Dis** 1997 Sep;176(3):807–10

Prescribing rationale and budgetary outcomes associated with the introduction of a combined formulation of diclofenac sodium and misoprostol in Canada. Sclar DA, et al. **J Int Med Res** 1995 Nov–Dec;23(6):439–48

Efficacy of tenoxicam on intra-abdominal adhesion prevention in a rat model. Yilmazlar T, et al. **J Int Med Res** 1996 Jul–Aug;24(4):352–7

Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. Miguélez R, et al. **J Lipid Mediat Cell Signal** 1996 Jan; 13(1):35–49

Trunk exercise combined with spinal manipulative or NSAID therapy for chronic low back pain: a randomized, observer-blinded clinical trial. Bronfort G, et al. **J Manipulative Physiol Ther** 1996 Nov–Dec;19(9):570–82

Conservative management of spinal osteoarthritis with glucosamine sulfate and chiropractic treatment. Gottlieb MS. **J Manipulative Physiol Ther** 1997 Jul–Aug; 20(6):400–14 (157 ref.)

A risk assessment of cervical manipulation vs. NSAIDs for the treatment of neck pain [letter] Myler L. **J Manipulative Physiol Ther** 1996 Jun;19(5):357

Effects of perioperative indomethacin on intracranial pressure, cerebral blood flow, and cerebral metabolism in patients subjected to craniotomy for cerebral tumors. Bundgaard H, et al. **J Neurosurg Anesthesiol** 1996 Oct; 8(4):273–9

Postoperative pain management. d'Amours RH, et al. **J Orthop Sports Phys Ther** 1996 Oct;24(4):227–36 (65 ref.)

Opioid-sparing effect of diclofenac in cancer pain. Mercadante S, et al. **J Pain Symptom Manage** 1997 Jul; 14(1):15–20

Ibuprofen and/or acetaminophen: what price for "euthermia"? [letter] Block S. **J Pediatr** 1997 Aug;131(2):332–3

Ibuprofen and/or acetaminophen: what price for "euthermia"? [letter] Melis R. **J Pediatr** 1997 Aug;131(2):332; discussion 333

The effect of ketoprofen creams on periodontal disease in rhesus monkeys. Li KL, et al. **J Periodontal Res** 1996 Nov; 31(8):525–32

Effect of a non-steroidal anti-inflammatory drug on tissue levels of immunoreactive prostaglandin E2, immunoreactive leukotriene, and pain after periodontal surgery. O'Brien TP, et al. **J Periodontol** 1996 Dec; 67(12):1307–16

Back to the future: the pyramids of rheumatoid arthritis [editorial] [see comments] Bensen WG, et al. **J Rheumatol** 1997 Jun;24(6):1023–7. Comment in: J Rheumatol 1997 Jun;24(6):1028–30.

Prescribing nonsteroidal antiinflammatory drugs—what's new? [editorial] Hawker G. **J Rheumatol** 1997 Feb; 24(2):243–5 (15 ref.)

Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis. Huskisson EC, et al. **J Rheumatol** 1995 Oct;22(10):1941–6

A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. Kidd B, et al. **J Rheumatol** 1996 Sep;23(9):1605–11

Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Morreale P, et al. **J Rheumatol** 1996 Aug; 23(8):1385–91

An open, randomized study of ketoprofen in patients in surgery for Achilles or patellar tendinopathy. Rolf C, et al. **J Rheumatol** 1997 Aug;24(8):1595–8

A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip. Towheed TE, et al. **J Rheumatol** 1997 Feb;24(2):349–57

Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs. Tugwell P, et al. **J Rheumatol** 1997 Jun;24(6):1122–5

Low dose etodolac in rheumatoid arthritis: a review of early studies. Spencer-Green G. **J Rheumatol Suppl** 1997 Feb; 47:3–9; discussion 48–50

The pathophysiology and medical management of canine osteoarthritis. Vaughan-Scott T, et al. **J S Afr Vet Assoc** 1997 Mar;68(1):21–5 (40 ref.)

Carprofen as an analgesic for postoperative pain in cats: dose titration and assessment of efficacy in comparison to pethidine hydrochloride. Lascelles BD, et al. **J Small Anim Pract** 1995 Dec;36(12):535–41

Tolfenamic acid in the control of ocular inflammation in the dog: pharmacokinetics and clinical results obtained in an experimental model. Roze M, et al. **J Small Anim Pract** 1996 Aug;37(8):371–5

Effects of tadenan pretreatment on bladder physiology and biochemistry following partial outlet obstruction. Levin RM, et al. **J Urol** 1996 Dec;156(6):2084–8

A crossover comparison of bromfenac sodium, naproxen sodium, and placebo for relief of pain from primary dysmenorrhea. Mehlisch DR, et al. **J Womens Health** 1997 Feb;6(1):83–92

Comparative study of diclofenac sodium and flurbiprofen in osteoarthritis. Shaikh KA, et al. **JPMA J Pak Med Assoc** 1996 Dec;46(12):270–2

Effects of a combined use of steroidal and nonsteroidal anti-inflammatory drugs on E. coli endotoxin-induced uveitis in pigmented rabbits. Ogawa T, et al. **Jpn J Ophthalmol** 1995;39(4):353–9

CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. **Lancet** 1997 Jun 7;349(9066):1641–9

Aspirin for bowel cancer: an old friend finds a new role [news] Featherstone C. **Lancet** 1997 Aug 9;350(9075):418

Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery [letter] Sawdy R, et al. **Lancet** 1997 Jul 26;350(9073):265–6

Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial [letter] Tan LB. **Lancet** 1997 Aug 9;350(9075):443; discussion 443–4

Interferon-alpha and its effects on the cytokine cascade: a pro- and anti-inflammatory cytokine. Tilg H, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):55–60 (73 ref.)

Curcumin protects bleomycin-induced lung injury in rats. Venkatesan N, et al. **Life Sci** 1997;61(6):PL51–8

Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Meinão IM, et al. **Lupus** 1996 Jun; 5(3):237–41

The place of thalidomide in the treatment of inflammatory disease [editorial] Stevens RJ. **Lupus** 1996 Aug;5(4):257–8

The many uses of ibuprofen [see comments] Burke SM. **MCN Am J Matern Child Nurs** 1996 Jan-Feb;21(1):56. Comment in: MCN Am J Matern Child Nurs 1996 May-Jun;21(3):122. Comment in: MCN Am J Matern Child Nurs 1996 May-Jun;21(3):122, 161.

Ketorolac: an alternative for the management of acute pain. Burke SM. **MCN Am J Matern Child Nurs** 1997 Jan-Feb; 22(1):56 (6 ref.)

Leukotriene receptor antagonists: the newest in asthma drugs. Stevenson AM. **MCN Am J Matern Child Nurs** 1997 May-Jun;22(3):170, 169

Primary systemic amyloidoses: possible new directions in prophylaxis and therapy. Oken RJ. **Med Hypotheses** 1996 Jun;46(6):505–6

Adapalene for acne. **Med Lett Drugs Ther** 1997 Feb 28; 39(995):19–20

Pentosan for interstitial cystitis. **Med Lett Drugs Ther** 1997 Jun 6;39(1002):56

Ineffectiveness of a four week treatment with the thromboxane synthetase inhibitor, imidazole salycilate, in reducing airway hyperresponsiveness to methacholine in asthmatics. Peccini F, et al. **Monaldi Arch Chest Dis** 1997 Apr;52(2):130–7

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [see comments] [published erratum appears in N Engl J Med 1997 Jul 31;337(5):356] Ridker PM, et al. **N Engl J Med** 1997 Apr 3;336(14):973–9 . Comment in: N Engl J Med 1997 Apr 3;336(14):1014–6. Comment in: N Engl J Med 1997 Aug 7;337(6):422; discussion 423–4. Comment in: N Engl J Med 1997 Aug 7;337(6):422–3; discussion 423–4. Comment in: N Engl J Med 1997 Aug 7;337(6):423; discussion 423–4.

Ibuprofen in patients with sepsis [letter; comment] Zimmerli W, et al. **N Engl J Med** 1997 Sep 4;337(10):710. Comment on: N Engl J Med 1997 Mar 27;336(13):912–8.

Is it possible to prevent recurrent Crohn's disease with medical or surgical interventions? Mcleod RS. **Neth J Med** 1996 Feb;48(2):68–70 (15 ref.)

Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Breitner JC. **Neurobiol Aging** 1996 Sep-Oct;17(5):789–94 (93 ref.)

Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches. Chen S, et al. **Neurobiol Aging** 1996 Sep-Oct; 17(5):781–7

Inflammatory mechanisms and anti-inflammatory therapy in Alzheimer's disease [editorial] O'Banion MK, et al. **Neurobiol Aging** 1996 Sep-Oct;17(5):669–71 (38 ref.)

NSAIDs and cognition in Alzheimer's disease [letter] Doraiswamy PM, et al. **Neurology** 1996 Apr;46(4):1194

Effects of exogenous transforming growth factor-beta 1 on spinal cord injury in rats. Hamada Y, et al. **Neurosci Lett** 1996 Jan 19;203(2):97–100

Inhibition of prostaglandins may be mechanism by which aspirin protects against certain cancers [news] **Oncology (Huntingt)** 1996 Jan;10(1):85

Sulindac slows growth of colon polyps, may prevent colon cancer [news] **Oncology (Huntingt)** 1996 Feb;10(2):218

Combined non-steroidal therapy in experimental corneal injury. Laria C, et al. **Ophthalmic Res** 1997;29(3):145–53

Decrease of postoperative inflammation with diclofenac sodium [letter; comment] Ply JJ. **Ophthalmology** 1996 Sep; 103(9):1331. Comment on: Ophthalmology 1996 Apr;103(4):636–9.

A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient. St. Charles CS, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):76–82

Ketorolac does not depress ventilation in children [letter] Hamunen K, et al. **Paediatr Anaesth** 1996;6(1):79

Comparison of diclofenac and tenoxicam for postoperative analgesia with and without fentanyl in children undergoing adenotonsillectomy or tonsillectomy. Mendham JE, et al. **Paediatr Anaesth** 1996;6(6):467–73

Topical aspirin/diethyl ether mixture versus indomethacin and diclofenac/diethyl ether mixtures for acute herpetic neuralgia and postherpetic neuralgia: a double-blind crossover placebo-controlled study [see comments] De Benedittis G, et al. **Pain** 1996 Apr;65(1):45–51. Comment in: Pain 1997 Apr;70(2–3):287–9.

Ibuprofen compared with ibuprofen plus caffeine after third molar surgery. McQuay HJ, et al. **Pain** 1996 Aug; 66(2–3):247–51

Pain control after dental surgery: a double-blind, randomised trial of lornoxicam versus morphine. Nørholt SE, et al. **Pain** 1996 Oct;67(2–3):335–43

Experimental evaluation of the analgesic effect of ibuprofen on primary and secondary hyperalgesia. Petersen KL, et al. **Pain** 1997 Apr;70(2–3):167–74 (50 ref.)

Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats. Price DD, et al. **Pain** 1996 Nov; 68(1):119–27

Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a ramdomized, double-blind, placebo-controlled trial. Quijada-Carrera J, et al. **Pain** 1996 May-Jun;65(2–3):221–5

Postoperative pain management. Tobias JD. **Pediatr Ann** 1997 Aug;26(8):490–500 (23 ref.)

Varicella and necrotizing fasciitis [letter; comment] Rosefsky JB. **Pediatr Infect Dis J** 1996 Jun;15(6):556–7. Comment on: Pediatr Infect Dis J 1995 Jul;14(7):588–94.

Health-related quality of life assessments in osteoarthritis during NSAID treatment. de Bock GH, et al. **Pharm World Sci** 1996 Aug;18(4):130–6

Oxaceprol, an atypical inhibitor of inflammation and joint damage. Ionac M, et al. **Pharmacol Res** 1996 Jun; 33(6):367–73

Biochemical aspects of chronic pain and its relationship to treatment. Pleuvry BJ, et al. **Pharmacol Ther** 1996; 71(3):313–24 (128 ref.)

Inhibitory effect of TMK688 on skin tumor initiation caused by 7,12-dimethylbenz[a]anthracene in relation to inhibition of aryl hydrocarbon hydroxylase activity and Cyp1a1 mRNA induction. Jiang H, et al. **Pharmacology** 1996 Aug; 53(2):123–32

Mac-1 inhibitor affects certain hemostatic parameters during myocardial stunning in swine. Serebruany VL, et al. **Pharmacology** 1996 Aug;53(2):87–97

Anti-inflammatory activity of flavonol glycosides from Erythrospermum monticolum depending on single or repeated local TPA administration. del Carmen Recio M, et al. **Planta Med** 1995 Dec;61(6):502–4

Protective effect of boldine in experimental colitis. Gotteland M, et al. **Planta Med** 1997 Aug;63(4):311–5

NSAIDs revisited: selection, monitoring, and safe use. Amadio P Jr, et al. **Postgrad Med** 1997 Feb;101(2):257–60, 263–7, 270–1 (20 ref.)

Cox 2: the next stage in the NSAID story. Averns H. **Practitioner** 1996 Sep;240(1566):532–4

An oil rig worker presenting with acute gout. Hynes D, et al. **Practitioner** 1997 May;241(1574):239–41, 243–5

Anti-inflammatory drugs and myorelaxants. Pharmacology and clinical use in musculoskeletal disease. Balano KB. **Prim Care** 1996 Jun;23(2):329–34 (11 ref.)

Antiedematous effects of combination therapies with the leukotriene synthesis inhibitor BAY X 1005 in the archidonic acid-induced mouse ear inflammation test. Burchardt ER, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Apr; 56(4):301–6

Effectiveness of shakuyaku-kanzo-to in neuroleptic-induced hyperprolactinemia: a preliminary report. Yamada K, et al. **Psychiatry Clin Neurosci** 1996 Dec;50(6):341–2

A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Resbeut M, et al. **Radiother Oncol** 1997 Jul; 44(1):59–63

Use of preincisional ketorolac in hernia patients: intravenous versus surgical site. Connelly NR, et al. **Reg Anesth** 1997 May-Jun;22(3):229–32

Ketorolac as an adjunct to patient-controlled morphine in postoperative spine surgery patients. Reuben SS, et al. **Reg Anesth** 1997 Jul-Aug;22(4):343–6

Emergency treatment of lithium-induced diabetes insipidus with nonsteroidal anti-inflammatory drugs. Lam SS, et al. **Ren Fail** 1997 Jan;19(1):183–8 (29 ref.)

Floctafenin versus acetaminophen for pain control in patients with osteoarthritis in the lower limbs. Franco-Belgian Task Force. Lequesne M, et al. **Rev Rhum Engl Ed** 1997 May; 64(5):327–33

Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists. Rozenberg S, et al. **Rev Rhum Engl Ed** 1996 Apr;63(4):255–61

The course of pain and the restriction of mobility in patients with shoulder complaints in general practice. Winters JC, et al. **Rheumatol Int** 1997;16(6):219–25

Are prostaglandins major mediators in perennial allergic rhinitis? Lee WC, et al. **Rhinology** 1996 Sep;34(3):130–5

Effective treatment of osteoarthritis with a 150 mg prolonged-release of diclofenac sodium. Arcangeli P, et al. **Riv Eur Sci Med Farmacol** 1996 Sep-Dec;18(5–6):217–23

Piroxicam and poststeroidal damage of articular cartilage. Lewandowski B, et al. **Rocz Akad Med Bialymst** 1995; 40(2):396–407

NSAID treatment of gastrointestinal abnormalities: a challenge to 'cytoprotection' [letter] Morgan G. **Scand J Gastroenterol** 1997 Mar;32(3):288

Therapeutic potential of NSAIDs and omeprazole in the oesophagus [letter; comment] Morgan GP. **Scand J Gastroenterol** 1997 Jan;32(1):95. Comment on: Scand J Gastroenterol 1996 Aug;31(8):753–8.

Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease. Brynskov J, et al. **Scand J Gastroenterol Suppl** 1996; 216:175–80 (48 ref.)

Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence. Weiss HA, et al. **Scand J Gastroenterol Suppl** 1996;220:137–41 (29 ref.)

Growth retardation in non-steroid treated juvenile rheumatoid arthritis. Polito C, et al. **Scand J Rheumatol** 1997;26(2):99–103

Tenidap in patients with rheumatoid arthritis. A 4-week, placebo-controlled study. Prupas HM, et al. **Scand J Rheumatol** 1996;25(6):345–51

Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. Sandelin J, et al. **Scand J Rheumatol** 1997;26(4):287–92

Considerations for nonsteroidal anti-inflammatory drug therapy: benefits. Emery P. **Scand J Rheumatol Suppl** 1996; 105:5–9; discussion 10–2 (15 ref.)

Strategies and practice for use of nonsteroidal anti-inflammatory drugs. Peloso PM. **Scand J Rheumatol Suppl** 1996;105:29–43; discussion 44–6 (32 ref.)

Meloxicam: selective COX-2 inhibition in clinical practice. Furst DE. **Semin Arthritis Rheum** 1997 Jun;26(6 Suppl 1):21–7 (24 ref.)

A potential new treatment for rheumatoid arthritis: thunder god vine. Lipsky PE, et al. **Semin Arthritis Rheum** 1997 Apr;26(5):713–23 (81 ref.)

Management of acute and surgical pain. Hellyer PW. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):106–14 (55 ref.)

Principles of analgesic drug therapy. Papich MG. **Semin Vet Med Surg (Small Anim)** 1997 May;12(2):80–93 (111 ref.)

Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects. Rodwell LT, et al. **Thorax** 1997 Jan;52(1):59–66

Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Bartlett RR, et al. **Transplant Proc** 1996 Dec;28(6):3074–8 (28 ref.)

Analgesia for severe postoperative pain: a comparison of two methods. Amata AO, et al. **Trop Doct** 1997 Jul;27(3):133–4

Diclofenac sodium for pain relief following laparoscopic sterilization [letter] Somwanshi M, et al. **Trop Doct** 1997 Apr;27(2):124–5

Analysis of long-term Elmiron therapy for interstitial cystitis. Hanno PM. **Urology** 1997 May;49(5A Suppl):93–9

Epithelial coating techniques in the treatment of interstitial cystitis. Parsons CL. **Urology** 1997 May;49(5A Suppl):100–4

Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis. Johnston SA, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul; 27(4):841–62 (135 ref.)

Preliminary investigations of pain and analgesia assessment

in horses administered phenylbutazone or placebo after arthroscopic surgery. Raekallio M, et al. **Vet Surg** 1997 Mar-Apr;26(2):150-5

The anti-inflammatory drugs phenylbutazone and dipyrone in the treatment of field cases of bovine mastitis. Shpigel NY, et al. **Zentralbl Veterinarmed A** 1996 Aug;43(6):331-6

[Using ligustrazini and angelica sinensis treat the bleomycin-induced pulmonary fibrosis in rats] Dai L, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1996 Feb; 19(1):26-8 (Eng. Abstr.) **(Chi)**

[The effect of indolacin in rat periapical lesion and radioimmunoassay determination of prostaglandin E2] Li Y, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Sep; 30(5):295-7 **(Chi)**

[Clinical and experimental study on sustained release tablet of Tripterygium wilfordii in treating rheumatoid arthritis] Li RL, et al.
Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1996 Jan; 16(1):10-3 (Eng. Abstr.) **(Chi)**

[Favorable results of early 2nd-stage medication in rheumatoid arthritis] van Jaarsveld CH, et al.
Ned Tijdschr Geneeskd 1997 Apr 12;141(15):732-6 (Eng. Abstr.) **(Dut)**

[Strategy for preventing upper respiratory tract infections. Consensus of the Consulting Committee]
Allerg Immunol (Paris) 1997 Mar;29(3):80-2 (Eng. Abstr.) **(Fre)**

[Pleuropericarditis complicated of tamponade disclosing mixed connective tissue disease. Remission with non-steroidal anti-inflammatory agents. Apropos of a case] Richard P, et al. **Ann Cardiol Angeiol (Paris)** 1996 Nov; 45(9):513-5 (Eng. Abstr.) **(Fre)**

[Preventive analgesic effect of intraoperative administration of ibuprofen-arginine on postmastectomy pain syndrome] Lakdja F, et al. **Bull Cancer** 1997 Mar;84(3):259-63 (Eng. Abstr.) **(Fre)**

[Aspirin, non-steroidal anti-inflammatory agents and colonic carcinogenesis] Benamouzig R, et al.
Gastroenterol Clin Biol 1997;21(3):188-96 (129 ref.) **(Fre)**

[Could delayed action flanreotide be used as substitute for octreotide in the treatment of dumping syndrome? (letter)] Bouché O, et al. **Gastroenterol Clin Biol** 1997;21(1):84-5 **(Fre)**

[Pain in cancer patients. Practical attitude] Pichard-Léandri E. **J Chir (Paris)** 1997 May;134(1):14-21 (29 ref.) (Eng. Abstr.) **(Fre)**

[Double-blind study on 3 parallel groups of 2 formulations of 0.1% indomethacin and 0.1% diclofenac in preventing and controlling inflammation after cataract surgery] Arnaud B, et al. **J Fr Ophtalmol** 1997;20(3):183-8 (Eng. Abstr.) **(Fre)**

[Efficacy and tolerability of a combination of indomethacin and gentamicin for preventing inflammation after cataract surgery] Renard G, et al. **J Fr Ophtalmol** 1996; 19(11):689-95 (Eng. Abstr.) **(Fre)**

[Pregnancy in primary antiphospholipid syndrome. Proposal for a common management protocol] el Kouri D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):828-31 (Eng. Abstr.) **(Fre)**

[Pharma-Clinics. The drug of the month. Meloxicam (Mobic)] Scheen AJ. **Rev Med Liege** 1997 Apr;52(4):309-11 (5 ref.) **(Fre)**

[Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis] Bertin P, et al.
Therapie 1997 Mar-Apr;52(2):133-7 (20 ref.) (Eng. Abstr.) **(Fre)**

[Ketoprofen--a first-class nonsteroidal antirheumatic agent] Rass H. **Dtsch Med Wochenschr** 1997 Feb 28;122(9 Suppl):1-8 **(Ger)**

[Widespread arthrosis among the population. Degenerative joint diseases--conservative, minor invasive and surgical therapy] Gradinger R. **Fortschr Med** 1997 Jun 30;115(18):25 **(Ger)**

[Curcuma xanthorrhiza (Java tumeric) in clinical use] Hentschel C, et al. **Fortschr Med** 1996 Sep 30; 114(27):349-50 (Eng. Abstr.) **(Ger)**

[Gonarthrosis--assessment and conservative therapy] Häuselmann HJ, et al. **Ther Umsch** 1996 Oct;53(10):732-7 (Eng. Abstr.) **(Ger)**

[Ketoprofen--a first class nonsteroidal anti-arrhythmia agent] **Z Orthop Ihre Grenzgeb** 1997 Jan-Feb;135(1 Suppl):1-8 **(Ger)**

[Use of sodium diclofenac in acute renal colic] Tankó A, et al. **Orv Hetil** 1996 Nov 10;137(45):2523-5 (Eng. Abstr.) **(Hun)**

[Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase] Bracale G, et al.
Minerva Cardioangiol 1996 Oct;44(10):515-24 (Eng. Abstr.) **(Ita)**

[Mechanism of action of a new anti-inflammatory analgesic drug in some eye disorders] Manusia M.
Minerva Oftalmol 1967 Jul-Aug;9(4):137-9 (Eng. Abstr.) **(Ita)**

[The efficacy of and tolerance for ketoprofen lysine salt in solution for oropharyngeal use in inflammatory lesions of the oral cavity] Natale F, et al. **Minerva Stomatol** 1997 May;46(5):273-8 (Eng. Abstr.) **(Ita)**

[Flurbiprofen collutory in oral surgical pathology] Procaccini M, et al. **Minerva Stomatol** 1996 Sep;45(9):421-5 (Eng. Abstr.) **(Ita)**

[Use of the NSAID ketoprofen lysine salt in glucose-6-phosphate dehydrogenase (G6PD) deficiency in inflammatory disease in children] Corda R, et al.
Pediatr Med Chir 1996 Jul-Aug;18(4):391-4 (Eng. Abstr.) **(Ita)**

[Chemoprevention of familial cancer] Ishikawa H.
Gan To Kagaku Ryoho 1997 Jun;24(8):951-7 (38 ref.) (Eng. Abstr.) **(Jpn)**

[A case of colonic Crohn's disease possibly managed with tranilast] Kikuchi T, et al.
Nippon Shokakibyo Gakkai Zasshi 1997 Mar;94(3):195-9 **(Jpn)**

[A biochemiluminescent analysis of the pharmacotherapeutic activity of acetylsalicylic acid in combination with quercetin in a hypoxic syndrome] Luk'ianchuk VD, et al.
Eksp Klin Farmakol 1997 Jan-Feb;60(1):62-4 (Eng. Abstr.) **(Rus)**

[The antinociceptive effect of tramal when combined with nonsteroidal anti-inflammatory preparations] Stanislavchuk NA, et al. **Eksp Klin Farmakol** 1997 Jan-Feb;60(1):22-4 (Eng. Abstr.) **(Rus)**

[The modification of the pharmacokinetics and analgesic effect of naproxen by cimetidine, phenobarbital and thiamine diphosphate] Vovk OG, et al.
Eksp Klin Farmakol 1996 Mar-Apr;59(2):35-7 (Eng. Abstr.) **(Rus)**

[Use of dalargin in the treatment of acute cholecystopancreatitis complicated by obstructive jaundice] Skomarovskiĭ ATs, et al. **Klin Khir** 1996;(8):13-4 **(Rus)**

[New aspects of anti-inflammatory therapy of rheumatic diseases: preclinical validation and clinical trial of meloxicam] Nasonov EL, et al. **Klin Med (Mosk)** 1996; 74(4):4-8 (48 ref.) **(Rus)**

[The new nonsteroidal anti-inflammatory preparation meloxicam in the treatment of rheumatoid arthritis] Grishina EI. **Lik Sprava** 1997 Mar-Apr;(2):19-25 (27 ref.) **(Rus)**

[The combined pharmacological correction of oxidative homeostasis in a hypoxic syndrome] Savchenkova LV.
Lik Sprava 1996 Mar-Apr;(3-4):117-20 (Eng. Abstr.) **(Rus)**

[Primary osteoarthrosis: role of local immunologic responses, ways of correction] Bakaloiuk OI, et al.
Patol Fiziol Eksp Ter 1997 Jan-Mar;(1):24-6 (Eng. Abstr.) **(Rus)**

[Analgesic action of ketorol in clinical maxillofacial surgery] Beliaeva EI, et al. **Stomatologiia (Mosk)** 1995;74(6):35 **(Rus)**

[The use of rumalon in gonarthrosis] Alekseeva LI, et al. **Ter Arkh** 1997;69(5):64-6 (Eng. Abstr.) **(Rus)**

[The treatment of inflammatory intestinal diseases with preparations of 5-aminosalicylic acid] Frol'kis AV.
Ter Arkh 1996;68(2):75-7 (49 ref.) **(Rus)**

[An evaluation of the results of the long-term treatment of rheumatoid arthritis patients with gold salts, aminoquinoline preparations and nonsteroidal anti-inflammatory preparations] Ivanova MM, et al.
Ter Arkh 1997;69(5):27-32 **(Rus)**

[Principles of drug therapy of inflammatory eye diseases] Nesterov AP. **Vestn Oftalmol** 1997 Jan-Feb;113(1):3-5 (Eng. Abstr.) **(Rus)**

[Efficacy of combined treatment of sensorineural hearing loss with electrostimulation and polycatan] Lobzov MS.
Vestn Otorinolaringol 1997;(1):40-1 **(Rus)**

[Clinical experience with the use of Tantum Rosa in cancer patients] Chulkova OV, et al. **Vopr Onkol** 1997; 43(3):339-40 **(Rus)**

[Caffetin in the treatment of neck pain and lumbago-sciatica] Vornovskaia OV, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1997;97(4):48-9 (Eng. Abstr.) **(Rus)**

[Comparative, randomized, parallel clinical study of the effectiveness and safety of aceclofenac vs. paracetamol in the treatment of viral pharyngoamygdalitis] Conti M.
Acta Otorrinolaringol Esp 1997 Mar;48(2):133-7 (Eng. Abstr.) **(Spa)**

[Perennial rhinitis: antihistaminic and anti-inflammatory treatment] Eseverri JL, et al.
Allergol Immunopathol (Madr) 1997 Jan-Feb;25(1):1-9 (Eng. Abstr.) **(Spa)**

[A 100 years of aspirin: a drug with a future?] Sánchez García P. **An R Acad Nac Med (Madr)** 1997;114(1):157-63; discussion 164-7 **(Spa)**

[Non-steroid anti-inflammatory agents and gastrointestinal protection: adequate prescription in primary care?] Burrull M, et al. **Aten Primaria** 1996 Nov 30;18(9):507-10 (Eng. Abstr.) **(Spa)**

[The knowledge and attitude of consumers in relation to the use of NSAIDs. An intervention study] Montaño Alonso A, et al. **Aten Primaria** 1997 Jul-Aug;20(3):114, 116-20 (Eng. Abstr.) **(Spa)**

[The prescription of nonsteroidal anti-inflammatory and stomach-protector agents. Its adaptation to quality criteria in primary care] Sánchez Casado JI, et al.
Aten Primaria 1997 Jul-Aug;20(3):127-32 (Eng. Abstr.) **(Spa)**

[Pharmacological bases of therapy with 5-ASA] Beltrán B, et al. **Gastroenterol Hepatol** 1997 Jun-Jul;20(6):322-34 (107 ref.) **(Spa)**

[Aspirin: can it prevent colorectal cancer?] Cabeza E, et al.
Gastroenterol Hepatol 1996 Aug-Sep;19(7):366-73 (37 ref.) **(Spa)**

[Efficacy and safety of nabumetone in the treatment of knee osteoarthritis: a comparative clinical trial versus aceclofenac. Study Group of Nabumetone for Osteoarthritis of the Knee] Gijón Baños J.
Med Clin (Barc) 1997 Jun 21;109(4):130-4 (Eng. Abstr.) **(Spa)**

[Colonic cancer: is prophylaxis with NSAIDs justified?] Casillas Romo A. **Rev Gastroenterol Mex** 1996 Oct-Dec; 61(4 Suppl 2):S48-50 **(Spa)**

TOXICITY

Protective effect of taurine on indomethacin-induced gastric mucosal injury. Son M, et al. **Adv Exp Med Biol** 1996; 403:147-55

Pre-ulcerative villous contraction and microvascular occlusion induced by indomethacin in the rat jejunum: a detailed morphological study. Anthony A, et al.
Aliment Pharmacol Ther 1995 Dec;9(6):605-13

The role of acid in the pathogenesis of indomethacin-induced gastric antral ulcers in the rat. Clayton NM, et al.
Aliment Pharmacol Ther 1996 Jun;10(3):339-45

NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Davies NM, et al.
Aliment Pharmacol Ther 1997 Feb;11(1):69-79

Omeprazole prevents indomethacin-induced gastric ulcers in rabbits. Lee M, et al. **Aliment Pharmacol Ther** 1996 Aug; 10(4):571-6

Indomethacin-induced morphological changes in the rat gastric mucosa, with or without prior treatment with two proton pump inhibitors. Morini G, et al.
Aliment Pharmacol Ther 1995 Dec;9(6):615-23

Urinary gamma-glutamyl transferase activity in rats with nonsteroidal anti-inflammatory drug-induced nephrotoxicity. Kocaoğlu S, et al.
Arch Immunol Ther Exp (Warsz) 1997;45(1):73-7

Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Mahmud T, et al. **Arthritis Rheum** 1996 Dec;39(12):1998-2003

Lack of potentiation with felbinac patch on the convulsive toxicity of enoxacin in rats. Ohtani H, et al.
Biol Pharm Bull 1996 Jul;19(7):995-7

Lipid peroxidation in gastric mucosal lesions induced by indomethacin in rat. Tanaka J, et al. **Biol Pharm Bull** 1996 May;19(5):716-20

Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. González-Martin G, et al.
Biomed Pharmacother 1997;51(4):170-5

Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats. al Gohary OM, et al. **Boll Chim Farm** 1996 Jul-Aug; 135(7):421-8

Combined flurbiprofen and cyclosporin-A does not attenuate bone loss and exaggerates renal impairment. Sass DA, et al. **Bone** 1996 Oct;19(4):381-6

Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Elliott SL, et al.
Clin Exp Pharmacol Physiol 1996 May;23(5):432-4

Actions and toxicity of nonsteroidal anti-inflammatory drugs. Simon LS. **Curr Opin Rheumatol** 1996 May;8(3):169-75 (48 ref.)

Indomethacin treatment during initial period of acetic acid-induced rat gastric ulcer healing promotes persistent polymorphonuclear cell-infiltration and increases future ulcer recurrence. Possible mediation of prostaglandins. Arakawa T, et al. **Dig Dis Sci** 1996 Oct;41(10):2055-61

Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Murakami K, et al. **Dig Dis Sci** 1997 Feb;42(2):319-25

A knock-out for NSAIDs [news]
Environ Health Perspect 1996 Jun;104(6):598-600

Subacute and chronic oral toxicity of lornoxicam in cynomolgus monkeys. Atzpodien E, et al.
Food Chem Toxicol 1997 May;35(5):465-74

Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Knight EV, et al.
Fundam Appl Toxicol 1996 Sep;33(1):38-48

Influence of hydrocortisone on the analgesic effect, toxicity and metabolism of aspirin in mice. Tantcheva L, et al.
Gen Pharmacol 1997 Jan;28(1):123-8

Effects of salicylate on neural activity in cat primary auditory cortex. Ochi K, et al. **Hear Res** 1996 May;95(1-2):63-76

Pharmacological protection of NSAID-induced intestinal permeability in the rat: effect of tempo and metronidazole as potential free radical scavengers. Davies NM, et al.
Hum Exp Toxicol 1997 Jul;16(7):345-9

Interaction of ciprofloxacin with diclofenac and paracetamol in relation to it's epileptogenic effect. Shrivastava MP, et al. **Indian J Physiol Pharmacol** 1997 Apr;41(2):164-6

Role of endogenous sulphydryls and neutrophil infiltration in the pathogenesis of gastric mucosal injury induced by piroxicam in rats. Avila JR, et al. **Inflamm Res** 1996 Feb; 45(2):83-8

Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models. Carty TJ, et al. **Inflamm Res** 1997 May;46(5):168-79

Interaction between enoxacin, a new antimicrobial, and nimesulide, a new non-steroidal anti-inflammatory agent in mice. Taniguchi Y, et al. **Inflamm Res** 1996 Aug; 45(8):376-9

The role of extracellular matrix in injury to gastric mucosa

by indomethacin. Irwin FL Jr, et al.
J Clin Gastroenterol 1995;21 Suppl 1:S18–23

Effect of NG–nitro–L–arginine methyl ester, the nitric oxide synthase inhibitor, on duodenal alkaline secretion and mepirizole–induced duodenal lesions in rats. Takeuchi K, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S66–72

Role of neutrophil–endothelial cell interactions in gastric mucosal injury induced by aspirin. Yoshida N, et al.
J Clin Gastroenterol 1995;21 Suppl 1:S73–7

Comparative evaluation of the severity of gastric ulceration by solid dispersions and coprecipitates of indomethacin. Karnachi AA, et al. **J Drug Target** 1997;4(5):297–301

Nephrotoxicities of nonsteroidal anti–inflammatory drugs. Wen SF. **J Formos Med Assoc** 1997 Mar;96(3):157–71 (155 ref.)

Analysis of pathogenic elements involved in gastric lesions induced by non–steroidal anti–inflammatory drugs in rats. Takeuchi K, et al. **J Gastroenterol Hepatol** 1997 May; 12(5):360–7

Susceptibility of mice to bacterial and fungal infections after intragastric administration of ebselen. Nozawa R, et al.
J Pharm Pharmacol 1996 Jan;48(1):64–7

The cytoprotective effect of leminoprazole on indomethacin–induced damage to rabbit gastric mucosal cells. Takahashi S, et al. **J Pharmacol Exp Ther** 1996 Nov; 279(2):975–82

Isoenzyme–specific cyclooxygenase inhibitors: a whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line Mono Mac 6. Berg J, et al. **J Pharmacol Toxicol Methods** 1997 Jun; 37(4):179–86

Apoptosis induced by NS–398, a selective cyclooxygenase–2 inhibitor, in human colorectal cancer cell lines. Hara A, et al. **Jpn J Cancer Res** 1997 Jun;88(6):600–4

Circadian variation in enoxacin–induced convulsions in mice coadministered with fenbufen. Masukawa T, et al.
Jpn J Pharmacol 1997 Feb;73(2):175–7

Prevention of gastric ulcer relapse induced by indomethacin in rats by a mutein of basic fibroblast growth factor. Satoh H, et al. **Jpn J Pharmacol** 1997 Mar;73(3):229–41

Effects of dietary restriction on experimental gastric mucosal injury in Fischer 344 rats. Lee M, et al.
Mech Ageing Dev 1996 Jul 31;89(1):11–20

Preventive effect of atropine on indomethacin–induced gastrointestinal mucosal and vascular damage in rats. Karádi O, et al. **Pharmacology** 1996 Jan;52(1):46–55

Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5–lipoxygenase, on events associated with NSAID–induced gastrointestinal inflammation. Kirchner T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jun;56(6):417–23

Pathological and biochemical modifications of renal function in ibuprofen–induced interstitial nephritis. Chen CY, et al.
Ren Fail 1996 Jan;18(1):31–40

Induction of tumor necrosis factor–alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine. Slomiany BL, et al.
Scand J Gastroenterol 1997 Jul;32(7):638–42

Effect of ursodeoxycholic acid on the inflammatory activity of indomethacin–induced intestinal inflammation in rats. Kullmann F, et al. **Z Gastroenterol** 1997 Mar;35(3):171–8

[Acute toxicity and anti–inflammatory effect of processed products of gamboge] Kong L, et al.
Chung Kuo Chung Yao Tsa Chih 1996 Apr;21(4):214–6, 255 (Eng. Abstr.) **(Chi)**

[Effects of blastocyst deficiencies induced by aspirin treatment during preimplantation period in rats on development of embryos after implantation] Ying Y, et al.
Yao Hsueh Hsueh Pao 1996;31(6):416–9 (Eng. Abstr.) **(Chi)**

[Comparative endoscopic study of gastroduodenal tolerance of piroxicam–beta–cyclodextrin vs piroxicam] Müller P, et al. **Z Rheumatol** 1997 Mar–Apr;56(2):76–9 (Eng. Abstr.) **(Ger)**

[The toxicological characteristics of ammonium glycyrrhizinate (glycyram). A study of its acute and subacute toxicity] Antov G, et al. **Eksp Klin Farmakol** 1997 Mar–Apr;60(2):65–7 (Eng. Abstr.) **(Rus)**

[An evaluation of the chronic toxicity of the new preparation val'kofen for children] Shapovalova VA, et al.
Eksp Klin Farmakol 1996 Jul–Aug;59(4):47–50 (Eng. Abstr.) **(Rus)**

URINE

Direct characterization of drug glucuronide isomers in human urine by HPLC–NMR spectroscopy: application to the positional isomers of 6,11–dihydro–11–oxodibenz[b,e]oxepin–2–acetic acid glucuronide. Lenz EM, et al. **Anal Chem** 1996 Sep 1; 68(17):2832–7

Urinary excretion of mefenamic acid and its metabolites including their esterglucuronides in preterm infants undergoing mefenamic acid therapy. Sato J, et al.
Biol Pharm Bull 1997 Apr;20(4):443–5

Simultaneous analysis of tiaramide metabolites in horse urine and plasma by solid–phase extraction and reversed–phase ion–pair liquid chromatography. Takeda A, et al.
J Anal Toxicol 1995 Oct;19(6):435–42

Determination of phase II drug metabolites in equine urine by micellar electrokinetic capillary chromatography. Taylor MR, et al. **J Chromatogr A** 1996 Sep 20; 745(1–2):155–63

Characterization of a novel diclofenac metabolite in human urine by capillary gas chromatography–negative chemical ionization mass spectrometry. Blum W, et al.
J Chromatogr B Biomed Appl 1996 Oct 25;685(2):251–63

Determination of flunixin in equine urine and serum by capillary electrophoresis. Gu X, et al.
J Chromatogr B Biomed Appl 1997 Apr 25;692(1):187–98

Simultaneous analysis of several non–steroidal anti–inflammatory drugs in human urine by high–performance liquid chromatography with normal solid–phase extraction. Hirai T, et al.
J Chromatogr B Biomed Appl 1997 May 9;692(2):375–88

Rapid screening for acidic non–steroidal anti–inflammatory drugs in urine by gas chromatography–mass spectrometry in the selected–ion monitoring mode. Kim KR, et al.
J Chromatogr B Biomed Appl 1996 Jun 28;682(1):55–66

The detection and characterization of analgesics and anti–inflammatory drugs on high performance thin–layer chromatography plates using tandem mass spectrometry: application to drugs and metabolites in urine. Morden W, et al. **Rapid Commun Mass Spectrom** 1996;10(15):1951–5

[Enantioselectivity in the excretion of glucuronides of carprofen in man, dogs and horses] Delatour P, et al.
Bull Acad Natl Med 1996 Oct;180(7):1565–72 (Eng. Abstr.) **(Fre)**

ANTI-INFLAMMATORY AGENTS, STEROIDAL

Asthma: an important disease to Otolaryngologists—part III: anti–inflammatory therapy. Gordon BR.
Ear Nose Throat J 1996 Apr;75(4):216–24 (49 ref.)

ADMINISTRATION & DOSAGE

Magnetic resonance imaging of Crohn disease: early recognition of treatment response and relapse. Madsen SM, et al. **Abdom Imaging** 1997 Mar–Apr;22(2):164–6

The effects of combined intravenous and inhaled steroids (beclomethasone dipropionate) for the emergency treatment of acute asthma. The Asthma ED Study Group. Guttman A, et al. **Acad Emerg Med** 1997 Feb;4(2):100–6

Simple bone cysts treated by multiple drill–holes [letter; comment] Burgers AM, et al. **Acta Orthop Scand** 1997 Feb; 68(1):86. Comment on: Acta Orthop Scand 1996 Jun;67(3):288–90.

Effects of topical nasal steroids on human respiratory mucosa and human granulocytes in vitro. Steinsvåg SK, et al.
Acta Otolaryngol (Stockh) 1996 Nov;116(6):868–75

Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis—a randomized single–blind comparative study. Ardizzone S, et al.
Aliment Pharmacol Ther 1996 Dec;10(6):957–60

Colonic delivery of dexamethasone: a pharmacoscintigraphic evaluation. Kenyon CJ, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):205–13

Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis. Lucidarme D, et al.
Aliment Pharmacol Ther 1997 Apr;11(2):335–40

Rectal steroids suppress bone formation in patients with colitis. Robinson RJ, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):201–4

Aggressive treatment of childhood asthma with local steroids. Good or bad? Foucard T. **Allergy** 1996 Jun; 51(6):367–71 (52 ref.)

New formulation of aqueous flunisolide nasal spray in the treatment of allergic rhinitis: comparative assessment of safety, tolerability, and efficacy. Ratner P, et al.
Allergy Asthma Proc 1996 May–Jun;17(3):149–56

Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Bullard MJ, et al.
Am J Emerg Med 1996 Mar;14(2):139–43

Beclomethasone dipropionate administration via cecostomy in ulcerative colitis. Matake H, et al.
Am J Gastroenterol 1997 Aug;92(8):1384–5

The painful hemiplegic shoulder: effects of intra–articular triamcinolone acetonide. Dekker JH, et al.
Am J Phys Med Rehabil 1997 Jan–Feb;76(1):43–8

Effect of short–term treatment with low–dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo–controlled study. Olivieri D, et al. **Am J Respir Crit Care Med** 1997 Jun; 155(6):1864–71

Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Weersink EJ, et al. **Am J Respir Crit Care Med** 1997 Apr; 155(4):1241–6

Effect of systemic corticoid and antihistamine alone or in combination on elements of the response to a two dose nasal allergen challenge. Brooks CD, et al.
Am J Rhinol 1997 Mar–Apr;11(2):117–22

Treatment of plantar fasciitis by iontophoresis of 0.4% dexamethasone. A randomized, double–blind, placebo–controlled study. Gudeman SD, et al.
Am J Sports Med 1997 May–Jun;25(3):312–6

Epidural dexamethasone reduces the incidence of backache after lumbar epidural anesthesia. Wang YL, et al.
Anesth Analg 1997 Feb;84(2):376–8

Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Barlan IB, et al.
Ann Allergy Asthma Immunol 1997 Jun;78(6):598–601

Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Bronsky EA, et al.
Ann Allergy Asthma Immunol 1997 Jul;79(1):51–6

Response to intranasal fluticasone propionate in perennial allergic rhinitis not associated with glucocorticoid receptor characteristics. Garrelds IM, et al.
Ann Allergy Asthma Immunol 1997 Mar;78(3):319–24

Intravenous versus oral corticosteroids in the management of acute asthma in children. Barnett PL, et al.
Ann Emerg Med 1997 Feb;29(2):212–7

Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin–4 production and associated eosinophilia. Smith DR, et al. **Ann Neurol** 1997 Sep;42(3):313–8

Single dose of betamethasone in combined medical treatment of secretory otitis media. Hemlin C, et al.
Ann Otol Rhinol Laryngol 1997 May;106(5):359–63

Comparison of the accuracy of steroid placement with clinical outcome in patients with shoulder symptoms. Eustace JA, et al. **Ann Rheum Dis** 1997 Jan;56(1):59–63

Radiographic patterns and response to corticosteroid hip injection. Plant MJ, et al. **Ann Rheum Dis** 1997 Aug; 56(8):476–80

Management of chronic pain with epidural steroids. Markey BT, et al. **AORN J** 1997 Apr;65(4):791–2, 795–8

Pulse glucocorticoid therapy. The 'big shot' revisited [comment] Roujeau JC. **Arch Dermatol** 1996 Dec; 132(12):1499–502. Comment on: Arch Dermatol 1996 Dec;132(12):1435–9.

Augmented betamethasone: efficacy in psoriasis with different dosing frequencies [letter] Singh S.
Arch Dermatol 1996 Dec;132(12):1525–6

Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Balfour–Lynn IM, et al. **Arch Dis Child** 1997 Aug;77(2):124–30

The effect of peritonsillar corticosteroid infiltration in tonsillectomy. Egeli E, et al. **Auris Nasus Larynx** 1997 Apr; 24(2):179–83

A comparison of the effects of oral prednisone and inhaled beclomethasone dipropionate on circulating leukocytes. Cameron RG, et al. **Aust N Z J Med** 1996 Dec;26(6):800–5

A clinical comparison of intranasal budesonide with beclomethasone dipropionate for perennial non–allergic rhinitis: a 12 month study. Synnerstad B, et al.
Br J Clin Pract 1996 Oct–Nov;50(7):363–6

Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Reitter B. **Brain Dev** 1995;17 Suppl:39–43

Sustained local drug delivery to the arterial wall via biodegradable microspheres. Dev V, et al.
Cathet Cardiovasc Diagn 1997 Jul;41(3):324–32

Asthma therapy: what's new and is it necessarily better? [editorial; comment] Georgitis JW. **Chest** 1997 Jul; 112(1):3–5. Comment on: Chest 1997 Jul;112(1):34–9.

A comparison of double–strength beclomethasone dipropionate (84 microg) MDI with beclomethasone dipropionate (42 microg) MDI in the treatment of asthma [see comments] Nathan RA, et al. **Chest** 1997 Jul; 112(1):34–9. Comment in: Chest 1997 Jul;112(1):3–5.

Dose–ranging study of the clinical efficacy of twice–daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. Welch MJ, et al. **Chest** 1997 Sep; 112(3):597–606

An assessment of optimal hydrocortisone replacement therapy [see comments] Howlett TA.
Clin Endocrinol (Oxf) 1997 Mar;46(3):263–8. Comment in: Clin Endocrinol (Oxf) 1997 Mar;46(3):269–70.

The assessment of glucocorticoid replacement therapy [comment] Monson JP. **Clin Endocrinol (Oxf)** 1997 Mar; 46(3):269–70. Comment on: Clin Endocrinol (Oxf) 1997 Mar;46(3):255–61. Comment on: Clin Endocrinol (Oxf) 1997 Mar;46(3):263–8.

Glucocorticoid replacement therapy: are patients over treated and does it matter? [see comments] Peacey SR, et al. **Clin Endocrinol (Oxf)** 1997 Mar;46(3):255–61. Comment in: Clin Endocrinol (Oxf) 1997 Mar;46(3):269–70.

Granulocyte function in the airways of allergen–challenged pigs: effects of inhaled and systemic budesonide. Fornhem C, et al. **Clin Exp Allergy** 1996 Dec;26(12):1436–48

Allergic rhinitis in children: effects of flunisolide and disodium cromoglycate on nasal eosinophil cationic protein. Sensi LG, et al. **Clin Exp Allergy** 1997 Mar; 27(3):270–6

Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. Nesher G, et al. **Clin Exp Rheumatol** 1997 May–Jun;15(3):303–6

Renal parenchymal malakoplakia in a four–week–old infant. Honjo K, et al. **Clin Nephrol** 1997 May;47(5):341–4

Controlled–release budesonide in Crohn's disease.
Drug Ther Bull 1997 Apr;35(4):30–1 (13 ref.)

A dose–response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Grahnén A, et al.
Eur J Clin Pharmacol 1997;52(4):261–7

Successful treatment of syndrome of inappropriate antidiuretic secretion (SIADH) in 2 patients with CNS involvement of chronic lymphocytic leukaemia [letter] Hagberg H, et al. **Eur J Haematol** 1997 Mar;58(3):207–8

High–dose methylprednisolone for children with acute lymphoblastic leukemia and unfavorable presenting features. Hiçsönmez G, et al. **Eur J Haematol** 1997 Jan; 58(1):26–31

Inhaled versus systemic steroids in chronic oxygen dependency of preterm infants. Dimitriou G, et al. **Eur J Pediatr** 1997 Jan;156(1):51–5

Treatment of recurrent acute wheezing episodes in infancy with oral salbutamol and prednisolone. Fox GF, et al. **Eur J Pediatr** 1996 Jun;155(6):512–6

Megadose methylprednisolone for Kasabach–Merritt syndrome [letter; comment] Ozsoylu S. **Eur J Pediatr** 1996 Feb;155(2):149–50. Comment on: Eur J Pediatr 1995 May;154(5):365–8.

Regression of a conservatively treated gigantic fusiform aneurysm of the middle cerebral artery. Mull M, et al. **Eur Neurol** 1997;37(4):255–7

Accuracy of asthma treatment in schoolchildren in NSW, Australia. Paterson NA, et al. **Eur Respir J** 1997 Mar; 10(3):658–64

Compliance with inhaled medication and self-treatment guidelines following a self-management programme in adult asthmatics. van der Palen J, et al. **Eur Respir J** 1997 Mar;10(3):652–7

Low-dose prednisolone does not improve the outcome of in-vitro fertilization in male immunological infertility. Lähteenmäki A, et al. **Hum Reprod** 1995 Dec;10(12):3124–9

Effects of subconjunctival methylprednisolone on the blood aqueous barrier following cataract surgery. Nicolás T, et al. **Int Ophthalmol** 1995–96;19(4):235–8

Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. BenEzra D, et al. **Invest Ophthalmol Vis Sci** 1997 Sep;38(10):1954–62

Interferon and steroid treatment in patients with chronic hepatitis C and antinuclear or anti-liver–kidney microsomal antibodies. Provenzano G, et al. **Ital J Gastroenterol** 1996 Sep;28(7):377–80

Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler. Toogood JH, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):186–93

The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. ZuWallack RL, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):278–85

Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. Assil KK, et al. **J Cataract Refract Surg** 1997 Jun;23(5):750–7

Steroid versus placebo injection for trigger finger [letter; comment] Robinson JH. **J Hand Surg [Am]** 1996 May; 21(3):530. Comment on: J Hand Surg [Am] 1995 Jul;20(4):628–31.

Post-operative pain control with topical steroid injection after hot dissection tonsillectomy. Liu CM, et al. **J Laryngol Otol** 1996 Nov;110(11):1038–40

The use of epidural steroid injection and manipulation on patients with chronic low back pain. Nelson L, et al. **J Manipulative Physiol Ther** 1997 May;20(4):263–6

Pulsed high-dose dexamethasone treatment of polyneuropathy associated with monoclonal gammopathy [letter] Notermans NC, et al. **J Neurol** 1997 Jul;244(7):462–3

Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. Molenaar DS, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):388–90

Methylprednisolone delivery by Hyalobend corneal shields and its effects on rabbit ocular inflammation. Bucolo C, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):141–9

Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. Lang B, et al. **J Pediatr** 1996 Mar;128(3):429–32

A trial of the safety of inhaled beclomethasone in ventilator-treated neonates. Liu EA, et al. **J Pediatr** 1996 Jul;129(1):154–6

Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. Newman SP, et al. **J Pharm Sci** 1996 Sep;85(9):960–4

In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. Leopold CS, et al. **J Pharmacokinet Biopharm** 1995 Aug;23(4):397–406

Chronic steroid-eluting lead performance: a comparison of atrial and ventricular pacing. Hua W, et al. **Pacing Clin Electrophysiol** 1997 Jan;20(1 Pt 1):17–24

Acne fulminans treated with isotretinoin and "pulse" corticosteroids. Allison MA, et al. **Pediatr Dermatol** 1997 Jan–Feb;14(1):39–42

Nebulized flunisolide in infants and young children with asthma: a pilot study. de Benedictis FM, et al. **Pediatr Pulmonol** 1996 May;21(5):310–5

Differential inhibitory effect of regular inhaled corticosteroid on airway responsiveness to adenosine 5' monophosphate, methacholine, and bradykinin in symptomatic children with recurrent wheeze. Doull IJ, et al. **Pediatr Pulmonol** 1997 Jun;23(6):404–11

Eosinophilic peritonitis in CAPD: treatment with prednisone and diphenhydramine [letter] Thakur SS, et al. **Perit Dial Int** 1997 Jul–Aug;17(4):402–3

Effect of a chemical delivery system for dexamethasone (Dex-CDS) on peritumoral edema in an experimental brain tumor model. Siegal T, et al. **Pharm Res** 1997 May; 14(5):672–5

Symptomatic relief for patients with osseous metastasis treated with radiation and methylprednisolone: a prospective randomized study. Teshima T, et al. **Radiat Med** 1996 Jul–Aug;14(4):185–8

Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr. Lorentzen KA, et al. **Respir Med** 1996 Nov;90(10):609–17

Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye [letter] Machemer R. **Retina** 1996;16(2):166–7

What is the optimal treatment for acute crystal-induced arthritis? [editorial; comment] Pawlotsky Y. **Rev Rhum Engl Ed** 1996 Apr;63(4):231–3. Comment on: Rev Rhum Engl Ed 1996 Apr;63(4):248–54.

Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs [see comments] Werlen D, et al. **Rev Rhum Engl Ed** 1996 Apr;63(4):248–54 . Comment in: Rev Rhum Engl Ed 1996 Apr;63(4):231–3.

Serum concentrations of orosomucoid: improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease? Kjeldsen J, et al. **Scand J Gastroenterol** 1997 Sep;32(9):933–41

Reactivation of inactive systemic lupus erythematosus. Aranow C, et al. **Scand J Rheumatol** 1996;25(5):282–6

Adult idiopathic thrombocytopenic purpura (ITP)--a prospective tracking of its natural history [see comments] Kueh YK. **Singapore Med J** 1995 Aug;36(4):367–70. Comment in: Singapore Med J 1995 Aug;36(4):355–6.

Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Clark DJ, et al. **Thorax** 1996 Sep;51(9):941–3

Steroids in exacerbations of asthma: tablets or inhalers? [editorial] Griffiths C. **Thorax** 1996 Nov;51(11):1071–2

Comparison of topical silver nitrate and flunisolide treatment in patients with idiopathic non-allergic rhinitis. Erhan E, et al. **Tokai J Exp Clin Med** 1996 Jun;21(2):103–11

Modulation of peripheral blood lymphocyte subsets during methylprednisolone pulse therapy. Fukuda R, et al. **Tokai J Exp Clin Med** 1996 Jun;21(2):77–88

Modulation of silica-induced pulmonary toxicity by dexamethasone-containing liposomes. DiMatteo M, et al. **Toxicol Appl Pharmacol** 1997 Feb;142(2):411–21

Serum erythropoietin and granulocyte-macrophage-colony stimulating factor levels with megadose methylprednisolone treatment. Sayli TR, et al. **Turk J Pediatr** 1996 Oct–Dec;38(4):491–5

[Bone loss during low dose glucocorticoid treatment in patients with polymyalgia rheumatica. A double-blind, prospective comparison between prednisolone and deflazacort] Krogsgaard MR, et al. **Ugeskr Laeger** 1997 Jul 21;159(30):4641–4 (Eng. Abstr.) **(Dan)**

[Improved outcome by preoperative administration of methylprednisolone before large abdominal surgery interventions--a prospective double-blind study] Fu ZX, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997; 114:663–6 (Eng. Abstr.) **(Ger)**

[Regression of retroperitoneal fibrosis by combination therapy with tamoxifen and steroids] Allendorff J, et al. **Med Klin** 1997 Jul 15;92(7):439–43 (Eng. Abstr.) **(Ger)**

[Recommendations for treatment of asthma in pregnancy] Worth H, et al. **Med Klin** 1996 Jul 15;91(7):435–7 **(Ger)**

[Controlled clinical comparative evaluation of fluticasone powder inhalation versus flunisolide dose aerosol in patients with mild to moderate asthma] Bergmann KC. **Pneumologie** 1997 Jan;51(1):27–32 (Eng. Abstr.) **(Ger)**

[Differentiation and modification of compliance with reference to topical corticoid medication in patients with bronchial asthma] Müller C, et al. **Pneumologie** 1996 Mar; 50(3):257–9 (Eng. Abstr.) **(Ger)**

[Long-term therapeutic effect of different intra-articular injection treatments of the painful shoulder--effect on pain, mobility and work capacity] Ströbel G. **Rehabilitation (Stuttg)** 1996 Aug;35(3):176–8 (Eng. Abstr.) **(Ger)**

[Results of CT-guided periradicular pain therapy] Uhlenbrock D, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Jun;166(6):528–34 (Eng. Abstr.) **(Ger)**

[The topical treatment of atrophic-erosive oral lichen planus with fluocinonide in a bioadhesive gel, chlorhexidine and miconazole gel. A totally open trial] Carbone M, et al. **Minerva Stomatol** 1996 Mar;45(3):61–8 (Eng. Abstr.) **(Ita)**

[Preoperative flurbiprofen provides pain relief after laparoscopic cholecystectomy] Tanaka S, et al. **Masui** 1997 May;46(5):679–83 (Eng. Abstr.) **(Jpn)**

[A case of the "shrinking lung syndrome" in SLE--improvement with corticosteroid therapy] Kitamura Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun; 19(3):217–22 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Long-term renal prognosis in patients with lupus nephritis treated with pulse methylprednisolone] Ohno I, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun;19(3):185–92 (Eng. Abstr.) **(Jpn)**

[Effects of pre-operative administration of steroids on the serum interleukin (IL)-6, IL-8 and organ injuries in replacement of thoracic aorta] Nitta Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):825–30 (Eng. Abstr.) **(Jpn)**

[Interstitial pneumonia with Sjögren's syndrome: successful treatment with steroids and an immunosuppressant] Hirata Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Mar; 35(3):317–21 (Eng. Abstr.) **(Jpn)**

[Bronchoscopy in the diagnosis of diffuse pulmonary infiltrates, and corticosteroid treatment in patients with acute respiratory failure] Katakami N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:145–54 (Eng. Abstr.) **(Jpn)**

[High-dose inhaled beclomethasone in long-term management of chronic severe asthma--usefulness and dose-dependence] Kudo K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 May; 34(5):536–44 (Eng. Abstr.) **(Jpn)**

[Acute bronchiolitis due to Mycoplasma pneumoniae and successfully treated with steroids] Mashimoto H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Nov; 34(11):1277–82 (Eng. Abstr.) **(Jpn)**

[Classification of bronchial asthma according to steroid and immunosuppressive treatment] Nagasaka Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:134–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Pharmacologic therapy for patients with stable chronic obstructive pulmonary disease--emphasis on inhaled agents] Nishimura K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:75–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Anti-inflammatory drugs for the treatment of bronchial hyperresponsiveness] Sano Y. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:48–53 (Eng. Abstr.) **(Jpn)**

[High-dose inhaled beclomethasone dipropionate and maximal improvements in patients with stable chronic obstructive pulmonary disease] Zhang M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec; 33(12):1386–1391 (Eng. Abstr.) **(Jpn)**

[Inhaled corticosteroid therapy in long-term management of adult asthma] Imai T, et al. **Nippon Rinsho** 1996 Nov; 54(11):2969–75 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Problems of inhaled steroid therapy in children with asthma] Inoue T, et al. **Nippon Rinsho** 1996 Nov;54(11):2987–92 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Inhaled corticosteroid in out-patient management of asthma] Ishihara K. **Nippon Rinsho** 1996 Nov;54(11):2976–81 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Bronchial asthma as an inflammation and the use of inhaled steroid] Kaneko F, et al. **Nippon Rinsho** 1996 Nov; 54(11):2962–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

[High dose inhaled steroid therapy--usefulness and limitation] Kudo K. **Nippon Rinsho** 1996 Nov;54(11):2993–7 (6 ref.) (Eng. Abstr.) **(Jpn)**

[A new trend of inhaled corticosteroid therapy in Japan] Sano Y. **Nippon Rinsho** 1996 Nov;54(11):3004–10 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of reducing or stopping inhaled beclomethasone dipropionate on airway hyperresponsiveness in stable chronic asthma] Tsukino M, et al. **Nippon Rinsho** 1996 Nov; 54(11):2982–6 (Eng. Abstr.) **(Jpn)**

[The clinical usefulness of the combined use of inhaled beta 2-agonist and inhaled steroid in asthma] Yamamoto C, et al. **Nippon Rinsho** 1996 Nov;54(11):3087–92 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Primary biliary cirrhosis with polymyositis successfully treated with prednisolone and ursodeoxycholic acid] Ono M, et al. **Nippon Ronen Igakkai Zasshi** 1996 Oct; 33(10):779–82 (Eng. Abstr.) **(Jpn)**

[A successful treatment for mucosal prolapse syndrome by the steroid enema therapy in a postoperative patient of mesenteric panniculitis] Kato K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):565–8 **(Jpn)**

[Successful treatment in a case of type-C fulminant hepatitis with interferon and steroid-pulse therapy, and review of its virological aspects] Marusawa H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):583–7 **(Jpn)**

[Successful treatment of toe gangrene with moderate-dose steroid therapy in a patient with systemic sclerosis (CREST syndrome)] Yamada S, et al. **Ryumachi** 1997 Jun; 37(3):499–503 (Eng. Abstr.) **(Jpn)**

[Necrotizing scleritis--case report of a patient effectively treated with high doses of corticosteroids] Chorabik E. **Klin Oczna** 1996 Feb;98(2):133–5 (Eng. Abstr.) **(Pol)**

[The epidural administration of steroids and local anesthetics as the basis for the pathogenetic therapy of a radicular pain syndrome in the stages of its development] Gnezdilov AV, et al. **Anesteziol Reanimatol** 1996 May–Jun;(3):28–32 (Eng. Abstr.) **(Rus)**

[A comparative evaluation of local therapy methods in treating osteoarthrosis deformans] Khitrov NA, et al. **Ter Arkh** 1997;69(2):53–4 (Eng. Abstr.) **(Rus)**

[The intra-articular therapy with triamcinolone acetonide and betamethasone of rheumatoid arthritis patients: a double-blind study] Murav'ev IuV, et al. **Ter Arkh** 1997; 69(5):32–3 **(Rus)**

[Comparative treatment of acute optic neuritis with "boluses" of intravenous methylprednisolone or oral prednisone] Alejandro PM, et al. **Gac Med Mex** 1994 Jul–Aug; 130(4):227–30 (Eng. Abstr.) **(Spa)**

[Lupus myelitis: value of magnetic resonance and treatment with bolus of methylprednisolone and intravenous cyclophosphamide (letter)] Hernández Hernández JA, et al. **Med Clin (Barc)** 1996 Nov 30;107(19):757–8 **(Spa)**

[How often do we use the cortisone injection? Risk of overconsumption in musculoskeletal pain conditions] Dahlberg L. **Lakartidningen** 1997 Jun 4;94(23):2202–4 **(Swe)**

[Severe asthma was found to be an asthma-like condition.

Consider reduced doses of cortisone (see comments)] Löwhagen O, et al. **Lakartidningen** 1996 Oct 16; 93(42):3711–3 (Eng. Abstr.). Comment in: Lakartidningen 1997 Jan 29;94(5):317. **(Swe)**

[Successful treatment of recurrent esophageal stricture. Steroids and dilatation resulted in permanent cure] Toth E, et al. **Lakartidningen** 1997 Aug 6;94(32–33):2751–3 **(Swe)**

ADVERSE EFFECTS

Delayed hypersensitivity to deflazacort. Navarro Pulido AM, et al. **Allergy** 1996 Jun;51(6):441–2

Corticosteroid–associated complications in elderly Crohn's disease patients. Akerkar GA, et al. **Am J Gastroenterol** 1997 Mar;92(3):461–4

Repeated courses of steroids in preterm membrane rupture do not increase the risk of histologic chorioamnionitis. Ghidini A, et al. **Am J Perinatol** 1997 Jul;14(6):309–13

Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents. Fischer JR, et al. **Ann Pharmacother** 1996 Dec;30(12):1437–45 (52 ref.)

Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Bachelez H, et al. **Arch Intern Med** 1997 Jul 14;157(13):1501–3

A comparison of the effects of oral prednisone and inhaled beclomethasone dipropionate on circulating leukocytes. Cameron RG, et al. **Aust N Z J Med** 1996 Dec;26(6):800–5

Effects of lithium on steroid–induced depression. Terao T, et al. **Biol Psychiatry** 1997 Jun 15;41(12):1225–6

Delayed hypersensitivity reactions to corticosteroids applied to mucous membranes. Bircher AJ, et al. **Br J Dermatol** 1996 Aug;135(2):310–3

Corticosteroid usage and binding to arginine: determinants of corticosteroid hypersensitivity. Wilkinson SM, et al. **Br J Dermatol** 1996 Aug;135(2):225–30

Steroid–induced prepartum psychosis [letter] [see comments] Johnson I. **Br J Psychiatry** 1996 Oct;169(4):522. Comment in: Br J Psychiatry 1997 Jan;170:90.

The kinetics of skin thinning induced by topical fluticasone propionate 0.05% cream in volunteer subjects. Dykes PJ, et al. **Clin Exp Dermatol** 1996 May;21(3):180–4

Steroid induced avascular necrosis of the patella in an ulcerative colitis patient [letter] Elkayam O, et al. **Clin Exp Rheumatol** 1996 Jul–Aug;14(4):447–8

Posterior subcapsular cataracts associated with deflazacort therapy [letter] Krmar RT, et al. **Clin Nephrol** 1997 Mar; 47(3):205

Patch testing to detect corticosteroid allergy: is it adequate? Seukeran DC, et al. **Contact Dermatitis** 1997 Mar; 36(3):127–30

Nasal steroid sprays and septal perforations. Ferguson BJ. **Ear Nose Throat J** 1997 Feb;76(2):75–6

Acute laryngeal obstruction--reaction to intravenous hydrocortisone? [letter] Srinivasan V, et al. **Eur J Anaesthesiol** 1997 May;14(3):342

Dexamethasone associated systemic hypertension in low birth weight babies with chronic lung disease. Smets K, et al. **Eur J Pediatr** 1996 Jul;155(7):573–5

Avascular necrosis following extensive chemotherapy and dexamethasone treatment in a patient with advanced ovarian cancer: case report and review of the literature. Gogas H, et al. **Gynecol Oncol** 1996 Dec;63(3):379–81 (19 ref.)

Anorexia nervosa and steroid withdrawal. Morgan J, et al. **Int J Eat Disord** 1996 Mar;19(2):213–5

Postinfarction ventricular septal defect associated with long–term steroid therapy. Coakley F, et al. **Ir Med J** 1997 Mar;90(2):58, 60

Necrotising fasciitis as a complication of steroid injection. Birkinshaw R, et al. **J Accid Emerg Med** 1997 Jan; 14(1):52–4

Opportunistic infections in patients with temporal arteritis treated with corticosteroids. Hedderwick SA, et al. **J Am Geriatr Soc** 1997 Mar;45(3):334–7

Dexamethasone therapy worsens the neuropathology of human immunodeficiency virus type 1 encephalitis in SCID mice. Limoges J, et al. **J Infect Dis** 1997 Jun;175(6):1368–81

Steroid psychosis after orthognathic surgery: a case report. Galen DM, et al. **J Oral Maxillofac Surg** 1997 Mar; 55(3):294–7

Disseminated varicella and staphylococcal pericarditis after topical steroids [letter; comment] Brumund MR, et al. **J Pediatr** 1997 Jul;131(1 Pt 1):162–3. Comment on: J Pediatr 1997 Jul;131(1 Pt 1):10–2.

Severe hypokalemia after budesonide treatment for Crohn's disease. Rosenbach Y, et al. **J Pediatr Gastroenterol Nutr** 1997 Mar;24(3):352–5

Cytomegalovirus infection of the colon in ulcerative colitis: a pediatric case. Sebastián–Planas M, et al. **J Pediatr Gastroenterol Nutr** 1996 Aug;23(2):186–90

Managing corticosteroid induced osteoporosis in medical outpatients. Bell R, et al. **J R Coll Physicians Lond** 1997 Mar–Apr;31(2):158–61

Testosterone concentrations in men on chronic glucocorticosteroid therapy. Fitzgerald RC, et al. **J R Coll Physicians Lond** 1997 Mar–Apr;31(2):168–70

Visual hallucinations induced by intraarticular injection of steroids [letter] Daragon A, et al. **J Rheumatol** 1997 Feb; 24(2):411

Anaphylactic shock induced by intraarticular injection of methylprednisolone acetate. Mace S, et al. **J Rheumatol** 1997 Jun;24(6):1191–4 (37 ref.)

Warfarin—topical salicylate interactions: case reports. Ramanathan M. **Med J Malaysia** 1995 Sep;50(3):278–9

Lipoprotein derangement during steroid treatment in minimal–change nephrotic syndrome. Tsukamoto Y, et al. **Nephron** 1996;73(4):606–12

Comment on Ortler et al. (Pain 62 (1995) 357–361) [letter; comment] Arruda WO, et al. **Pain** 1996 Sep;67(1):225–6. Comment on: Pain 1995 Sep;62(3):357–61.

Lower gastrointestinal tract perforation in preterm infants treated with dexamethasone for bronchopulmonary dysplasia. Ng PC, et al. **Pediatr Surg Int** 1997 Feb; 12(2–3):211–2

Clinical varicella following varicella vaccination: don't be fooled. Feder HM Jr, et al. **Pediatrics** 1997 Jun;99(6):897–9

Recurrent ocular toxoplasmosis in patients treated with systemic corticosteroids. Morhun PJ, et al. **Retina** 1996; 16(5):383–7

[Toxicoderma caused by prednisone and prednisolone. Value of skin tests in the screening of cross sensitivity] Mathelier–Fusade P, et al. **Ann Dermatol Venereol** 1996; 123(8):453–5 (Eng. Abstr.) **(Fre)**

[Diplopia after peridural and intradural infiltrations of prednisolone. 2 cases (letter)] Brocq O, et al. **Presse Med** 1997 Mar 1;26(6):271 **(Fre)**

[Suppurative mediastinitis secondary to acute thyroiditis in a patient under corticotherapy (letter)] Dordain ML, et al. **Presse Med** 1997 Mar 8;26(7):319–20 **(Fre)**

[Acute cervical necrotizing fasciitis of pharyngeal origin: possible role of steroidal and non–steroidal anti–inflammatory agents. Apropos of 5 cases] Chaplain A, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996; 117(5):377–80 (20 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic alternatives to systemic corticotherapy in severe and chronic dermatologic disorders in the elderly patient] de la Brassinne M. **Rev Med Liege** 1997 Apr;52(4):296–8 (0 ref.) **(Fre)**

[Neurologic side–effects of pharmacologic corticoid therapy] Rösener M, et al. **Nervenarzt** 1996 Dec;67(12):983–6 (36 ref.) (Eng. Abstr.) **(Ger)**

[Influence of methylprednisolone and transforming growth factor–beta on wound healing] Osaka Y. **Hokkaido Igaku Zasshi** 1997 Mar;72(2):181–94 (Eng. Abstr.) **(Jpn)**

[Pneumonitis induced by the herbal medicine Sho–saiko–to in Japan] Sato A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Apr;35(4):391–5 (Eng. Abstr.) **(Jpn)**

[Coping with intractable femur head necrosis in patients with collagen diseases] Harada Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1882–8 **(Jpn)**

[Concerns about adverse effects of inhaled corticosteroids] Matsumoto H, et al. **Nippon Rinsho** 1996 Nov; 54(11):2998–3003 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Growth hormone prevents the steroid myopathy in rats] Matsushita T, et al. **Rinsho Shinkeigaku** 1996 Jun; 36(6):752–6 (Eng. Abstr.) **(Jpn)**

[The prevention of stress–related postoperative and drug–induced erosive–ulcerative lesions of the upper digestive tract] Degtiareva II, et al. **Lik Sprava** 1995 Mar–Apr;(3–4):61–4 (Eng. Abstr.) **(Rus)**

[Epidural abscess: a complication of the use of corticoids in the treatment for back pain] de Andrés J, et al. **Rev Esp Anestesiol Reanim** 1997 Apr;44(4):164–5 **(Spa)**

ANALYSIS

Determination of dexamethasone in tears by capillary electrophoresis. Baeyens V, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):222–6

BLOOD

Transepidermal water loss predicts systemic absorption of topical hydrocortisone in atopic dermatitis [letter] Aalto–Korte K, et al. **Br J Dermatol** 1996 Sep;135(3):497–8

Simultaneous determination of triamcinolone acetonide and hydrocortisone in human plasma by high–performance liquid chromatography. Döppenschmitt SA, et al. **J Chromatogr B Biomed Appl** 1996 Jun 28;682(1):79–88

Determination of epimers 22R and 22S of budesonide in human plasma by high–performance liquid chromatography–atmospheric pressure chemical ionization mass spectrometry. Li YN, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30;683(2):259–68

CEREBROSPINAL FLUID

Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. Bannwarth B, et al. **Rev Rhum Engl Ed** 1997 May;64(5):301–4

CHEMICAL SYNTHESIS

New steroidal anti–inflammatory antedrugs: methyl 3,20–dioxo–9 alpha–fluoro–11 beta,17 alpha,21–trihydroxy–1,4–pregnadiene–16 alpha–carboxylate and methyl 21–acetyloxy–3,20–dioxo–11 beta, 17 alpha–dihydroxy–9 alpha–fluoro–1,4–pregnadiene–16 alpha–carboxylate. Heiman AS, et al. **Steroids** 1997 Jun;62(6):491–9

CHEMISTRY

Bacterial adhesins as a drug carrier: covalent attachment of K99 fimbriae to 6–methylprednisolone. Bernkop–Schnürch A, et al. **Pharmazie** 1997 Jan;52(1):41–4

DIAGNOSTIC USE

Growth hormone response to clonidine and the cortisol response to dexamethasone in depressive patients. Valdivieso S, et al. **Psychiatry Res** 1996 Feb 28;60(1):23–32

HISTORY

Cortisone therapy: a challenge to academic medicine in 1949–1952. Hetenyi G Jr, et al. **Perspect Biol Med** 1997 Spring;40(3):426–39

An historical review of rheumatoid arthritis treatment: 1948 to 1952. Karsh J, et al. **Semin Arthritis Rheum** 1997 Aug; 27(1):57–65

IMMUNOLOGY

Anaphylaxis to dexamethasone. Figueredo E, et al. **Allergy** 1997 Aug;52(8):877

METABOLISM

Metered–dose inhalers, I: Drug content and particle size distribution of beclomethasone dipropionate. LeBelle M, et al. **J Pharm Biomed Anal** 1996 May;14(7):793–800

An in–vitro study of the effect of hydrocolloid patch occlusion on the penetration of triamcinolone acetonide through skin in man. Ladenheim D, et al. **J Pharm Pharmacol** 1996 Aug;48(8):806–11

PHARMACOKINETICS

Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Weijtens O, et al. **Am J Ophthalmol** 1997 Mar; 123(3):358–63

Pharmaceutical properties of freeze–dried formulations of egg albumin, several drugs and olive oil. Tsuji Y, et al. **Biol Pharm Bull** 1996 Apr;19(4):636–40

An investigation of the dose proportionality of deflazacort pharmacokinetics. Rao N, et al. **Biopharm Drug Dispos** 1996 Dec;17(9):753–60

The effect of food on the relative bioavailability of deflazacort. Rao N, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jui–Sep;21(3):241–5

Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. Jusko WJ, et al. **J Clin Pharmacol** 1996 Dec;36(12):1100–6

Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. Rohatagi S, et al. **J Clin Pharmacol** 1995 Dec;35(12):1187–93

Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. Reddy IK, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):159–67

The pharmacokinetics of dexamethasone in the thoroughbred racehorse. Cunningham FE, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):68–71

[Determination of flunisolide and its principal hydrolytic metabolite in urine and plasma by LC–NICI–MS with a particle beam interface] Rauli S, et al. **Boll Chim Farm** 1997 Apr;136(4):308–15 **(Ita)**

PHARMACOLOGY

Dexamethasone and colchicine reduce inflammation and delayed oedema following experimental brain contusion. Holmin S, et al. **Acta Neurochir (Wien)** 1996;138(4):418–24

Effects of topical nasal steroids on human respiratory mucosa and human granulocytes in vitro. Steinsvåg SK, et al. **Acta Otolaryngol (Stockh)** 1996 Nov;116(6):868–75

Review article: older systemic and newer topical glucocorticosteroids and the gastrointestinal tract. Thiesen A, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):487–96 (111 ref.)

Suppression of intestinal mucosal natural killer cells by corticosteroids. Van Ierssel AJ, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):347–53

Hepatic release of interleukin–10 during cardiopulmonary bypass in steroid–pretreated patients. Wan S, et al. **Am Heart J** 1997 Mar;133(3):335–9

Corticosteroid Action and Resistance in Asthma. Proceedings of a meeting. Buckinghamshire, United Kingdom, October 1995. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S1–79

Molecular mechanisms of immunosuppression and anti–inflammatory activities by glucocorticoids. Didonato JA, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S11–5 (35 ref.)

Prednisone increases PGH–synthase 2 in atopic humans in vivo. Dworski RT, et al. **Am J Respir Crit Care Med** 1997 Jan;155(1):351–7

Effects of dexamethasone on cell–mediated immune responses in cattle sensitized to Mycobacterium bovis. Doherty ML, et al. **Am J Vet Res** 1995 Oct;56(10):1300–6

Effects of prolactin and cortisol on the Harderian gland of the terrapin, Pseudemys scripta, adapted to different salinities. Baccari GC, et al. **Anat Rec** 1996 Feb; 244(2):225–34

Effects of indomethacin, dexamethasone, and erythromycin

on endotoxin-induced intraepithelial mucus production of rat nasal epithelium. Takahashi Y, et al. **Ann Otol Rhinol Laryngol** 1997 Aug;106(8):683-7

Retinoic acids and dexamethasone alter cell-surface density of beta 2-integrins and ICAM-1 on human leukemic (HMC-1) mast cells. Babina M, et al. **Arch Dermatol Res** 1997 Jan;289(2):111-5

Effect of diclofenac, ketorolac, and fluorometholone on arachidonic acid metabolites following excimer laser corneal surgery. Phillips AF, et al. **Arch Ophthalmol** 1996 Dec;114(12):1495-8

Glucocorticoid regulation of in vitro astrocyte phagocytosis. Roldán A, et al. **Biocell** 1997 Apr;21(1):83-9

Inhibitory effect of peritoneal macrophages on progesterone release from cocultured rat granulosa cells is reversed by dexamethasone: evidence for an action independent of nitric oxide and distal to cyclic adenosine 3',5'-monophosphate generation. Whitehead S, et al. **Biol Reprod** 1996 Jun;54(6):1317-25

Protection by dexamethasone of the functional desensitization to beta 2-adrenoceptor-mediated responses in human lung mast cells. Chong LK, et al. **Br J Pharmacol** 1997 Jun; 121(4):717-22

A novel murine model of allergic inflammation to study the effect of dexamethasone on eosinophil recruitment. Das AM, et al. **Br J Pharmacol** 1997 May;121(1):97-104

Effect of dexamethasone and endogenous corticosterone on airway hyperresponsiveness and eosinophilia in the mouse. De Bie JJ, et al. **Br J Pharmacol** 1996 Dec;119(7):1484-90

Inhibition of neutrophil and monocyte recruitment by endogenous and exogenous lipocortin 1. Getting SJ, et al. **Br J Pharmacol** 1997 Mar;120(6):1075-82

Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits. Gozzard N, et al. **Br J Pharmacol** 1996 Jul; 118(5):1201-8

Regulation of histamine H1 receptor coupling by dexamethasone in human cultured airway smooth muscle. Hardy E, et al. **Br J Pharmacol** 1996 Jun;118(4):1079-84

Differential effects of angiostatic steroids and dexamethasone on angiogenesis and cytokine levels in rat sponge implants. Hori Y, et al. **Br J Pharmacol** 1996 Aug;118(7):1584-91

Translocation of lipocortin (annexin) 1 to the membrane of U937 cells induced by phorbol ester, but not by dexamethasone. Kang SA, et al. **Br J Pharmacol** 1996 Apr; 117(8):1780-4

Involvement of secretory phospholipase A2 activity in the zymosan rat air pouch model of inflammation. Payá M, et al. **Br J Pharmacol** 1996 Apr;117(8):1773-9

Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone. Saunders MA, et al. **Br J Pharmacol** 1997 Feb;120(4):545-6

Conservation of apoptosis as an immune regulatory mechanism: effects of cortisol and cortisone on carp lymphocytes. Weyts FAA, et al. **Brain Behav Immun** 1997 Jun;11(2):95-105

A new mechanism of methylprednisolone and other corticosteroids action demonstrated in vitro: inhibition of a proteinase (calpain) prevents myelin and cytoskeletal protein degradation. Banik NL, et al. **Brain Res** 1997 Feb 14;748(1-2):205-10

Dexamethasone prevents apoptosis in a neonatal rat model of hypoxic-ischemic encephalopathy (HIE) by a reactive oxygen species-independent mechanism. Ekert P, et al. **Brain Res** 1997 Jan 30;747(1):9-17

Microglia-astrocyte interactions after cortisone treatment in a neonatal hypoxia-ischemia model. McRae A, et al. **Brain Res Dev Brain Res** 1996 Jun 14;94(1):44-51

Interactions of corticosterone and embryonic light deprivation on memory retention in day-old chicks. Sui N, et al. **Brain Res Dev Brain Res** 1997 Jul 18; 101(1-2):269-72

Glucocorticoid regulation of natural cytotoxicity: effects of cortisol on the phenotype and function of a cloned human natural killer cell line. Zhou J, et al. **Cell Immunol** 1997 Jun 15;178(2):108-16

Eosinophil locomotion and the release of IL-3 and IL-5 by allergen-stimulated mononuclear cells are effectively downregulated in vitro by budesonide. Lantero S, et al. **Clin Exp Allergy** 1996 Jun;26(6):656-64

The effect of dexamethasone on the expression of activated NF-kappa B in adjuvant arthritis. Tsao PW, et al. **Clin Immunol Immunopathol** 1997 May;83(2):173-8

Histopathologic study of veins in steroid treated rabbits. Nishimura T, et al. **Clin Orthop** 1997 Jan;(334):37-42

Sensitization studies with mometasone furoate, tixocortol pivalate, and budesonide in the guinea pig. Bruze M, et al. **Contact Dermatitis** 1996 Mar;34(3):161-4

Comparison of in vitro antiproliferative effects of steroids and nonsteroidal antiinflammatory drugs on human keratocytes. Lu KL, et al. **Cornea** 1996 Mar;15(2):185-90

Arginine, glutamine, and dehydroepiandrosterone reverse the immunosuppressive effect of prednisone during gut-derived sepsis [see comments] Gennari R, et al. **Crit Care Med** 1997 Jul;25(7):1207-14. Comment in: Crit Care Med 1997 Jul;25(7):1110-1.

Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Jeal W, et al. **Drugs** 1997 Feb;53(2):257-80 (73 ref.)

Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Silverstein H, et al. **Ear Nose Throat J** 1996 Aug;75(8):468-71, 474, 476 passim

Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects. Babadjanova G, et al. **Eur J Clin Pharmacol** 1996;51(1):53-7

In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia. Morabito F, et al. **Eur J Haematol** 1997 May;58(5):301-6

Uterine activity after betamethasone administration for the enhancement of fetal lung maturation. Yeshaya A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug;67(2):139-41

In vitro measurement of orthodontic tooth movement in rats given beta-aminopropionitrile or hydrocortisone using a time-lapse videotape recorder. Yamane A, et al. **Eur J Orthod** 1997 Feb;19(1):21-8

Effect of dexamethasone therapy on cerebral and ocular blood flow velocity in premature infants studied by colour Doppler flow imaging. Cabañas F, et al. **Eur J Pediatr** 1997 Jan;156(1):41-6

Effects of different treatment regimens of methylprednisolone on rat diaphragm contractility, immunohistochemistry and biochemistry. van Balkom RH, et al. **Eur Respir J** 1996 Jun;9(6):1217-23

Dexamethasone treatment decreases hyaluronan-formation by primate trabecular meshwork cells in vitro. Engelbrecht-Schnür S, et al. **Exp Eye Res** 1997 Apr; 64(4):539-43

Comparison of lens biochemistry and structure between BSO-treated and glucocorticoid-treated developing chick embryos. Murakami I, et al. **Exp Eye Res** 1996 Dec; 63(6):673-81

Prednisone alters the histopathology of chronic cyclosporine nephropathy. Stillman IE, et al. **Exp Nephrol** 1997 Jan-Feb; 5(1):61-8

Glucocorticoid-mediated inhibition of RANTES expression in human T lymphocytes. Wingett D, et al. **FEBS Lett** 1996 Dec 2;398(2-3):308-11

Influence of hydrocortisone on the analgesic effect, toxicity and metabolism of aspirin in mice. Tantcheva L, et al. **Gen Pharmacol** 1997 Jan;28(1):123-8

Exposure to chronic psychosocial stress and corticosterone in the rat: effects on spatial discrimination learning and hippocampal protein kinase Cgamma immunoreactivity. Krugers HJ, et al. **Hippocampus** 1997;7(4):427-36

Effects of pneumadin (PNM) on the adrenal glands. 5. Potent stimulating action of PNM on adrenocortical growth of dexamethasone-administered rats. Markowska A, et al. **Histol Histopathol** 1996 Jul;11(3):583-5

The mutual effect of dehydroepiandrosterone and dexamethasone on interleukin-8 release from human peripheral blood mononuclear cells cultured in vitro. Komorowski J, et al. **Horm Metab Res** 1996 Oct; 28(10):570-1

Dexamethasone or cyclosporin A inhibits stem cell factor-dependent secretory responses of rat peritoneal mast cells in vitro. Taylor AM, et al. **Immunopharmacology** 1996 Aug;34(1):63-70

16 beta-Methyl-17 alpha,21-diesterified glucocorticoids as partial agonists of glucocorticoid in rat endotoxin-induced inflammation. Tsuji F, et al. **Inflamm Res** 1997 Jun; 46(6):193-8

The intratracheal administration of endotoxin: X. Dexamethasone downregulates neutrophil emigration and cytokine expression in vivo. Yi ES, et al. **Inflammation** 1996 Apr;20(2):165-75

Anti-inflammatory properties of docosahexaenoic and eicosapentaenoic acids in phorbol-ester-induced mouse ear inflammation. Raederstorff D, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):284-90

Goodpasture's syndrome superimposed on membranous nephropathy. A case report. Thitiarchakul S, et al. **Int J Artif Organs** 1995 Dec;18(12):763-5

Dexamethasone and cyclosporin A modulation of human retinal pigment epithelial cell monocyte chemotactic protein-1 and interleukin-8. Kurtz RM, et al. **Invest Ophthalmol Vis Sci** 1997 Feb;38(2):436-45

Dexamethasone inhibits prolonged survival and autocrine granulocyte-macrophage colony-stimulating factor production by human eosinophils cultured on laminin or tissue fibronectin. Walsh GM, et al. **J Allergy Clin Immunol** 1997 Aug;100(2):208-15

The influence of cortisol on spontaneous and 5HT stimulated prolactin release in man. Dinan TG, et al. **J Basic Clin Physiol Pharmacol** 1996;7(1):45-56

Differential regulation of cytochrome P450 3A1 and P450 3A2 in rat liver following dexamethasone treatment. Choudhuri S, et al. **J Biochem Toxicol** 1995 Dec; 10(6):299-307

Steroid-induced adipogenesis in a pluripotential cell line from bone marrow. Cui Q, et al. **J Bone Joint Surg Am** 1997 Jul;79(7):1054-63

Effect of methylprednisolone on complement activation during heparin neutralization. Loubser PG. **J Cardiovasc Pharmacol** 1997 Jan;29(1):23-7

Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. Tornatore KM, et al. **J Clin Pharmacol** 1997 Apr;37(4):304-11

Effects of long-term corticosterone implants on growth and immune function in juvenile alligators, Alligator mississippiensis. Morici LA, et al. **J Exp Zool** 1997 Oct 1;279(2):156-62

Neutrophil-activating protein ENA-78 and IL-8 exhibit different patterns of expression in lipopolysaccharide- and cytokine-stimulated human monocytes. Schnyder-Candrian S, et al. **J Immunol** 1997 Apr 15; 158(8):3888-94

Dexamethasone potently enhances phorbol ester-induced IL-1beta gene expression and nuclear factor NF-kappaB activation. Wang Y, et al. **J Immunol** 1997 Jul 15; 159(2):534-7

Multifunctional cytokine expression by human mast cells: regulation by T cell membrane contact and glucocorticoids. Krishnaswamy G, et al. **J Interferon Cytokine Res** 1997 Mar;17(3):167-76

Induction of tumor necrosis factor-alpha in vivo by a skin irritant, tributyltin, through activation of transcription factors: its pharmacological modulation by anti-inflammatory drugs. Corsini E, et al. **J Invest Dermatol** 1997 Jun;108(6):892-6

High dose intravenous immunoglobulin does not improve abnormalities in the blood-brain barrier during acute relapse of multiple sclerosis [letter] Nos C, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):418

Increased apoptosis of T lymphocytes and macrophages in the central and peripheral nervous systems of Lewis rats with experimental autoimmune encephalomyelitis treated with dexamethasone. Nguyen KB, et al. **J Neuropathol Exp Neurol** 1997 Jan;56(1):58-69

Immunological detection of type II collagen degradation: use in the evaluation of anti-arthritic therapies. Chichester CO, et al. **J Pharm Pharmacol** 1996 Jul;48(7):694-8

Cytokine-mediated inhibition of erythropoietin synthesis by dexamethasone. Leng HM, et al. **J Pharm Pharmacol** 1996 Sep;48(9):971-4

16-epiestriol: an anti-inflammatory steroid without glycogenic activity. Latman NS, et al. **J Pharm Sci** 1994 Jun;83(6):874-7

The heat-stable enterotoxin-guanylin receptor is expressed in rat hepatocytes and in a rat hepatoma (H-35) cell line. Balint JP, et al. **J Recept Signal Transduct Res** 1997 Jul; 17(4):609-30

Effect of topical tranilast and corticosteroids on subepithelial haze after photorefractive keratectomy in rabbits. Furukawa H, et al. **J Refract Surg** 1997 Aug;13(5 Suppl):S457-8

Changes in synovial membrane and joint effusion volumes after intraarticular methylprednisolone. Quantitative assessment of inflammatory and destructive changes in arthritis by MRI. Ostergaard M, et al. **J Rheumatol** 1996 Jul;23(7):1151-61

Deflazacort versus methylprednisolone in polymyalgia rheumatica [letter; comment] Sáez Barcelona JA, et al. **J Rheumatol** 1996 Jul;23(7):1306-7. Comment on: J Rheumatol 1995 Aug;22(8):1492-8.

Effect of methylprednisolone acetate on proteoglycan and collagen metabolism of articular cartilage explants. Todhunter RJ, et al. **J Rheumatol** 1996 Jul;23(7):1207-13

Experimental vesicular stomatitis in swine: effects of route of inoculation and steroid treatment. Howerth EW, et al. **J Vet Diagn Invest** 1997 Apr;9(2):136-42

Beneficial effect of steroid on myocardial preservation in isolated rat hearts. Hisatomi K, et al. **Jpn Circ J** 1995 Dec; 59(12):815-23

The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Murgia MG, et al. **Kidney Int** 1996 Jan; 49(1):209-16

Effect of cortisporin otic suspension on cochlear function and efferent activity in the guinea pig. Perry BP, et al. **Laryngoscope** 1996 Dec;106(12 Pt 1):1557-61

Methylprednisolone inhibits neutrophil-endothelial cell interactions induced by interleukin-1beta under flow conditions. Yoshida N, et al. **Life Sci** 1997;60(25):2341-7

Effects of long-term low-dose methylprednisolone on rat diaphragm function and structure. van Balkom RH, et al. **Muscle Nerve** 1997 Aug;20(8):983-90

Inhibition of phospholipase A2 activities and some inflammatory responses by the marine product ircinin. Cholbi R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov;354(5):677-83

Inhibition of microglial superoxide anion production by isoproterenol and dexamethasone. Colton CA, et al. **Neurochem Int** 1996 Jul;29(1):43-53

Effect of a single huge dose of methylprednisolone on blood flow, evoked potentials, and histology after acute spinal cord injury in the rat. Koyanagi I, et al. **Neurol Res** 1997 Jun;19(3):289-99 (49 ref.)

beta-Amyloid induction of gelatinase B secretion in cultured microglia: inhibition by dexamethasone and indomethacin. Gottschall PE. **Neuroreport** 1996 Nov 25;7(18):3077-80

Corticosterone modifies the murine muscle acetylcholine receptor channel kinetics. Nurowska E, et al. **Neuroreport** 1996 Dec 20;8(1):77-80

Effects of adrenalectomy and corticosterone replacement on diurnal [3H]citalopram binding in rat midbrain. Kulikov A, et al. **Neurosci Lett** 1997 Jan 31;222(2):127-31

Chronic corticosterone treatment induces parallel changes in N-methyl-D-aspartate receptor subunit messenger RNA levels and antagonist binding sites in the hippocampus. Weiland NG, et al. **Neuroscience** 1997 Jun;78(3):653-62

The protective effect of dexamethasone against radiation damage induced by interstitial irradiation in normal monkey

brain. Tada E, et al. **Neurosurgery** 1997 Jul;41(1):209–17; discussion 217–9

Protein changes during aging and the effects of long-term cortisol treatment in macaque monkey lens. Matsushima H, et al. **Optom Vis Sci** 1997 Apr;74(4):190–7

Enhanced effects of co-administered dexamethasone and diclofenac on inflammatory pain processing and associated spinal c-Fos expression in the rat. Buritova J, et al. **Pain** 1996 Mar;64(3):559–68

The effects of chronic corticosterone on memory performance in the platform maze task. Bardgett ME, et al. **Physiol Behav** 1996 Jun;59(6):1111–5

Anti-inflammatory activity of aqueous extracts and steroidal sapogenins of Agave americana. Peana AT, et al. **Planta Med** 1997 Jun;63(3):199–202

Modulation of the forskolin-induced cyclic AMP accumulation by corticosterone. Czyrak A. **Pol J Pharmacol** 1996 Nov–Dec;48(6):595–9

Metabolism of tacrolimus (FK 506) in rat liver microsomes. Effect of rifampin and dexamethasone. Prasad, et al. **Res Commun Mol Pathol Pharmacol** 1997 Apr;96(1):107–10

Comparative studies concerning the effects of hydrocortisone and of some synthetic glucocorticoids upon the thymocytes of the Wistar rats. Giurgea R, et al. **Rom J Physiol** 1995 Jan–Dec;32(1–4):83–6

Antioxidant effects of hyaluronan and its alpha-methyl-prednisolone derivative in chondrocyte and cartilage cultures. Cortivo R, et al. **Semin Arthritis Rheum** 1996 Aug;26(1):492–501

Histologic changes in the intervertebral disc after intradiscal injections of methylprednisolone acetate in rabbits. Aoki M, et al. **Spine** 1997 Jan 15;22(2):127–31; discussion 132

The pathologic effects of intrathecal betamethasone. Latham JM, et al. **Spine** 1997 Jul 15;22(14):1558–62

The effects of taxol, methylprednisolone, and 4-aminopyridine in compressive spinal cord injury: a qualitative experimental study. Perez-Espejo MA, et al. **Surg Neurol** 1996 Oct;46(4):350–7

Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Takayanagui OM, et al. **Ther Drug Monit** 1997 Feb;19(1):51–5

[Effects of steroids on hepatic ATP and L/P ratio in rats subjected to acute hemorrhage] Ikeya K, et al. **Masui** 1997 May;46(5):613–7 (Eng. Abstr.) **(Jpn)**

[Production of inflammatory markers by HepG 2 cells stimulated with monocyte conditioned media: the effects of corticosteroid and other immunosuppressants] Shimetani N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Jun; 20(3):166–77 (Eng. Abstr.) **(Jpn)**

[Effects of disease modifying antirheumatic drugs (DMARDs) and DEX on IL-1 beta and IL-6 production by IL-1 beta stimulated synovial culture cells] Koda M, et al. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):419–23 (Eng. Abstr.) **(Jpn)**

[A comparison of the pharmacological actions between DSCG (disodium cromoglycate) and BDP (beclomethasone dipropionate) in the treatment of bronchial asthma] Shida T. **Nippon Rinsho** 1996 Nov; 54(11):3011–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The effect of age, sex and prenatal exposure to glucocorticoids on the corticosterone level of the blood in rats] Dygalo NN, et al. **Fiziol Zh Im I M Sechenova** 1995 Oct;81(10):83–8 (Eng. Abstr.) **(Rus)**

[New glucocorticoids are more selective. Current knowledge can eliminate serious adverse effects] Nilsson S, et al. **Lakartidningen** 1997 Jun 25;94(26–27):2465–71 (20 ref.) (Eng. Abstr.) **(Swe)**

THERAPEUTIC USE

Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone. Franciotta D, et al. **Acta Neurol Scand** 1997 May;95(5):275–9

Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants [see comments] Suske G, et al. **Acta Paediatr** 1996 Jun;85(6):713–8. Comment in: Acta Paediatr 1996 Jun;85(6):641. Comment in: Acta Paediatr 1996 Jun;85(6):757.

High-dose dexamethasone therapy for a 14-month-old boy with refractory idiopathic thrombocytopenic purpura. Watanabe A, et al. **Acta Paediatr Jpn** 1997 Jun;39(3):368–70

Globe tenting as a result of head trauma. Hrach CJ, et al. **AJNR Am J Neuroradiol** 1997 May;18(5):980–2

Anti-inflammatory drugs do not alleviate bronchial hyperreactivity in Sjögren's syndrome. Stålenheim G, et al. **Allergy** 1997 Apr;52(4):423–7

Immunologic effects of intranasal corticosteroids [editorial] Levenson T, et al. **Allergy Asthma Proc** 1996 May–Jun; 17(3):157–9

Onychomycosis and keratomycosis caused by Alternaria sp. A bipolar opportunistic infection in a wood-pulp worker on chronic steroid therapy. Arrese JE, et al. **Am J Dermatopathol** 1996 Dec;18(6):611–3

Treatment of idiopathic lymphocytic enterocolitis with oral beclomethasone dipropionate. Rai RM, et al. **Am J Gastroenterol** 1997 Jan;92(1):147–9

AIDS-associated membranous nephropathy with advanced renal failure: response to prednisone. Mattana J, et al. **Am J Kidney Dis** 1997 Jul;30(1):116–9

Prednisone, renal function, and proteinuria in immunodeficiency virus-associated nephropathy. Rao TK. **Am J Kidney Dis** 1997 Jul;30(1):156–9

A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Friedlaender MH, et al. **Am J Ophthalmol** 1997 Apr;123(4):455–64

Effect of topical anti-inflammatory treatment on the outcome of laser trabeculoplasty [letter; comment] Hollö G. **Am J Ophthalmol** 1997 Apr;123(4):570–1. Comment on: Am J Ophthalmol 1996 Sep;122(3):349–54.

Steroid resistance in asthma. Molecular mechanisms. Adcock IM. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S58–61 (30 ref.)

Mechanisms of action of glucocorticoids in asthma. Barnes PJ. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S21–6; discussion S26–7 (36 ref.)

Current management of asthma patients with corticosteroid resistance. Busse WW, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S70–2; discussion S72–3 (16 ref.)

Glucocorticoid-resistant asthma. T-lymphocyte defects. Corrigan CJ. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S53–5; discussion S55–7 (20 ref.)

The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Djukanović R, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):826–32

Corticosteroid resistance in other disease states and tissues. Lane SJ, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S62–5 (15 ref.)

Mononuclear cells in corticosteroid-resistant asthma. Lane SJ, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S49–51; discussion S52 (17 ref.)

Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Pizzichini MM, et al. **Am J Respir Crit Care Med** 1997 May; 155(5):1501–8

The epithelium as a target of glucocorticoid action in the treatment of asthma. Schwiebert LM, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S16–9; discussion S19–20 (35 ref.)

Corticosteroid-resistant asthma. Definitions. Woolcock AJ. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 2):S45–8

Budesonide aqueous nasal spray and pressurized metered dose inhaler in the treatment of adult patients with seasonal allergic rhinitis. Day J, et al. **Am J Rhinol** 1997 Jan–Feb; 11(1):77–83

High-dose hydrocortisone hemisuccinate in scorpion envenomation. Abroug F, et al. **Ann Emerg Med** 1997 Jul; 30(1):23–7

Single dose of betamethasone in combined medical treatment of secretory otitis media. Hemlin C, et al. **Ann Otol Rhinol Laryngol** 1997 May;106(5):359–63

Reversal of erythema multiforme major with cyclophosphamide and prednisone. Eastham JH, et al. **Ann Pharmacother** 1996 Jun;30(6):606–7

Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: a survey. Jackevicius CA, et al. **Ann Pharmacother** 1997 Feb; 31(2):160–4

Quantitative magnetic resonance imaging of the knee: a method of measuring response to intra-articular treatments. Creamer P, et al. **Ann Rheum Dis** 1997 Jun;56(6):378–81

Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response. Jones A, et al. **Ann Rheum Dis** 1996 Nov;55(11):829–32

Dexamethasone in laryngeal diphtheritic croup. Havaldar PV. **Ann Trop Paediatr** 1997 Mar;17(1):21–3

Dexamethasone adjunctive therapy for bacterial meningitis in children: a retrospective study in Brazil. Macaluso A, et al. **Ann Trop Paediatr** 1996 Sep;16(3):193–8

Prednisolone at anti-inflammatory or immunosuppressive dosages in conjunction with doxycycline does not potentiate the severity of Rickettsia rickettsii infection in dogs. Breitschwerdt EB, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):141–7

Curative treatment for pemphigus [letter; comment] Pasricha JS, et al. **Arch Dermatol** 1996 Dec;132(12):1518–9. Comment on: Arch Dermatol 1996 Feb;132(2):203–12.

Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids [see comments] Werth VP. **Arch Dermatol** 1996 Dec;132(12):1435–9. Comment in: Arch Dermatol 1996 Dec;132(12):1499–502.

Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone. Cohen IJ, et al. **Arch Dis Child** 1996 Sep;75(3):218–22

Corticosteroids in the management of central nervous system tumours. Kids Neuro-Oncology Workshop (KNOWS). Glaser AW, et al. **Arch Dis Child** 1997 Jan;76(1):76–8

Dexamethasone and bacterial meningitis in Pakistan. Qazi SA, et al. **Arch Dis Child** 1996 Dec;75(6):482–8

Effects of inhaled steroid treatment on serum eosinophilic cationic protein (ECP) and low affinity receptor for IgE (Fc epsilon RII/sCD23) in childhood bronchial asthma. Türktaş I, et al. **Arch Dis Child** 1996 Oct;75(4):314–8

Randomised trial of dopamine compared with hydrocortisone for the treatment of hypotensive very low birthweight infants. Bourchier D, et al. **Arch Dis Child Fetal Neonatal Ed** 1997 May;76(3):F174–8

Guidelines and realities of asthma management. The Philadelphia story. Lang DM, et al. **Arch Intern Med** 1997 Jun 9;157(11):1193–200

Fluticasone [letter; comment] Birchall MA. **Arch Otolaryngol Head Neck Surg** 1997 Apr;123(4):449–50 . Comment on: Arch Otolaryngol Head Neck Surg 1996 Jul;122(7):729–31.

Topical corticosteroid treatment of anosmia associated with nasal and sinus disease. Mott AE, et al. **Arch Otolaryngol Head Neck Surg** 1997 Apr;123(4):367–72

Splinting and local steroid injection for the treatment of ulnar neuropathy at the elbow: clinical and electrophysiological evaluation. Hong CZ, et al. **Arch Phys Med Rehabil** 1996 Jun;77(6):573–7

Management of traumatic optic neuropathy with coexistent spinal cord injury: a case report. Sherman AL, et al. **Arch Phys Med Rehabil** 1997 Sep;78(9):1012–4

Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Saag KG, et al. **Arthritis Rheum** 1996 Nov;39(11):1818–25

Diagnosing and managing polymyalgia rheumatica and temporal arteritis. Oral prednisolone 40 mg daily is not adequate for temporal arteritis once vision is affected [letter] Finlay R. **BMJ** 1997 Aug 30;315(7107):549

Seventy-two hour comparison of methylprednisolone suleptanate and methylprednisolone sodium succinate in patients with acute asthma. Muir JF, et al. **Br J Clin Pract** 1996 Dec;50(8):440–5

Comparative effects of calcipotriol ointment (50 micrograms/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis. Pinheiro N. **Br J Clin Pract** 1997 Jan–Feb;51(1):16–9

Corticosteroids in rheumatoid arthritis [letter; comment] Haslock I. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):50. Comment on: Br J Hosp Med 1996 Mar 6–19;55(5):235–6.

Churg-Strauss disease: deterioration in a twin pregnancy. Successful outcome following treatment with corticosteroids and cyclophosphamide. Barry C, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):746–7

Late treatment of methanol blindness [letter] Rotenstreich Y, et al. **Br J Ophthalmol** 1997 May;81(5):416–7

Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Ferreira SH, et al. **Br J Pharmacol** 1997 Jul;121(5):883–8

Ultrasonographic assessment of local steroid injection in Tietze's syndrome. Kamel M, et al. **Br J Rheumatol** 1997 May;36(5):547–50

The conservative treatment of phimosis in boys. Golubovic Z, et al. **Br J Urol** 1996 Nov;78(5):786–8

Management of skin disease in lupus. Callen JP. **Bull Rheum Dis** 1997 Apr;46(2):4–7 (11 ref.)

Budesonide in the management of patients with Crohn's disease. Thomson AB, et al. **Can J Gastroenterol** 1997 Apr; 11(3):255–60 (30 ref.)

Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma. Figg WD, et al. **Cancer** 1997 May 15;79(10):1964–8

Dexamethasone treatment does not ameliorate subglottic ischemic injury in rabbits. Kil HK, et al. **Chest** 1997 May; 111(5):1356–60

Steroid-responsive interstitial pneumonitis after fludarabine therapy [letter] Levin M, et al. **Chest** 1997 May; 111(5):1472–3

Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Mapel DW, et al. **Chest** 1996 Oct;110(4):1058–67 (67 ref.)

Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis [see comments] Marin MG. **Chest** 1997 Jul;112(1):29–33. Comment in: Chest 1997 Jul;112(1):1–3.

Systemic corticosteroids in COPD. An unresolved clinical dilemma [editorial] Niewoehner DE, et al. **Chest** 1996 Oct; 110(4):867–9

A clinical study on severe hydroa vacciniforme. Gu H, et al. **Chin Med J (Engl)** 1996 Aug;109(8):645–7

Premedication with diclofenac and prednisolone to prevent postoperative pain and swelling after third molar removal. Lin TC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jul;58(1):40–4

A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Asbell P, et al. **CLAO J** 1997 Jan;23(1):31–6

Hydrocortisone replacement therapy in children and adolescents with hypopituitarism. DeVile CJ, et al. **Clin Endocrinol (Oxf)** 1997 Jul;47(1):37–41

Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medicamentosa. Hallén H, et al. **Clin Exp Allergy** 1997 May; 27(5):552–8

The in vitro and in vivo effect of corticosteroids on basophil releasability in patients with mild and severe bronchial asthma. Kivity S, et al. **Clin Exp Allergy** 1997 Aug; 27(8):909–14

The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone [see comments] Macanovic M, et al. **Clin Exp Immunol** 1996 Nov;106(2):243–52. Comment in: Clin Exp Immunol 1996 Nov;106(2):187–9.

Once-daily fluocinonide-bifonazole combination for the treatment of vulvar itching and vulvovaginal candidiasis. Preliminary study. Kaplan B, et al. **Clin Exp Obstet Gynecol** 1996;23(3):173–6

Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response

and rheumatoid factor synthesis. Nesher G, et al. **Clin Exp Rheumatol** 1997 Jul–Aug;15(4):343–7

Experimental septic arthritis in rabbits treated by a combination of antibiotic and steroid drugs. Wysenbeek AJ, et al. **Clin Exp Rheumatol** 1996 Sep–Oct;14(5):507–12

Achilles tendonitis: are corticosteroid injections useful or harmful? [see comments] Shrier I, et al. **Clin J Sport Med** 1996 Oct;6(4):245–50. Comment in: Clin J Sport Med 1996 Oct;6(4):218–9.

Relative sensitivity of Tc–99m WBC versus In–111 WBC in a patient with Crohn's disease on steroids. Lyons KP, et al. **Clin Nucl Med** 1997 Jun;22(6):359–62

A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Morice AH, et al. **Clin Pharmacol Ther** 1996 Dec;60(6):675–8

Timing of administration of dexamethasone or the nitric oxide synthase inhibitor, nitro–L–arginine methyl ester, is critical for effective treatment of ischaemia–reperfusion injury to rat skeletal muscle. Zhang B, et al. **Clin Sci (Colch)** 1997 Aug;93(2):167–74

Placebo–controlled, double–blind study of the efficacy and safety of triamcinolone acetonide aerosol nasal inhaler in pediatric patients with seasonal allergic rhinitis. Banov CH, et al. **Clin Ther** 1996 Mar–Apr;18(2):265–72

Ketorolac, prednisolone, and dexamethasone for postoperative inflammation. Ostrov CS, et al. **Clin Ther** 1997 Mar–Apr;19(2):259–72

Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double–blind, placebo–controlled trial [see comments] Anene O, et al. **Crit Care Med** 1996 Oct;24(10):1666–9. Comment in: Crit Care Med 1996 Oct;24(10):1613–4.

Avoiding the rush [editorial; comment] Deutschman CS. **Crit Care Med** 1997 Jul;25(7):1110–1. Comment on: Crit Care Med 1997 Jul;25(7):1207–14.

Steroids for anything that swells: dexamethasone and postextubation airway obstruction [editorial; comment] Shemie S. **Crit Care Med** 1996 Oct;24(10):1613–4. Comment on: Crit Care Med 1996 Oct;24(10):1666–9.

A pilot study of prednisone in Alzheimer's disease. Aisen PS, et al. **Dementia** 1996 Jul–Aug;7(4):201–6

Pseudoxanthomatous lesions with membranocystic changes of collagen fibers in an SLE patient receiving long–term steroid treatment. Yasaka N, et al. **Dermatology** 1997; 194(2):162–5

Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy. Ito T, et al. **Dig Dis Sci** 1997 Jul;42(7):1458–68

Drug treatment of asthma in the elderly. Braman SS. **Drugs** 1996 Mar;51(3):415–23 (41 ref.)

Intra–articular corticosteroids. Guide to selection and indications for use. Caldwell JR. **Drugs** 1996 Oct; 52(4):507–14 (29 ref.)

Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Jeal W, et al. **Drugs** 1997 Feb;53(2):257–80 (73 ref.)

Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Wiseman LR, et al. **Drugs** 1997 May;53(5):885–907 (114 ref.)

Meniere's disease of syphilitic etiology. Pulec JL. **Ear Nose Throat J** 1997 Aug;76(8):508–10, 512 514, passim

Clinical evaluation and treatment of immune–mediated inner ear disease. Welling DB. **Ear Nose Throat J** 1996 May; 75(5):301–5

Subglottic stenosis in Wegener's granulomatosis limited to the head and neck region. Yumoto E, et al. **Ear Nose Throat J** 1997 Aug;76(8):571–4 (15 ref.)

Childhood nephrotic syndrome in Africa: the steroid question [editorial; comment] Luta M. **East Afr Med J** 1997 Apr; 74(4):205–6 (9 ref.). Comment on: East Afr Med J 1997 Apr;74(4):207–9.

Selective protein index and clinical features of childhood nephrotic syndrome in Kampala [see comments] Odiit A, et al. **East Afr Med J** 1997 Apr;74(4):207–9. Comment in: East Afr Med J 1997 Apr;74(4):205–6.

Dexamethasone inhibits virus production and the secretory IgA response in oesophageal–pharyngeal fluid in cattle persistently infected with foot–and–mouth disease virus. Ilott MC, et al. **Epidemiol Infect** 1997 Apr;118(2):181–7

Clinical remission of granulomatous enteritis in a standardbred gelding following long–term dexamethasone administration. Duryea JH, et al. **Equine Vet J** 1997 Mar; 29(2):164–7

The effect of drugs used in the treatment of osteoarthrosis on stromelysin (proteoglycanase) of equine synovial cell origin. May SA, et al. **Equine Vet J Suppl** 1988 Sep; (6):28–32

Controlled trial of methotrexate in patients with severe chronic asthma. Hedman J, et al. **Eur J Clin Pharmacol** 1996;49(5):347–9

Bile acid therapy and markers of immune–mediated damage in primary biliary cirrhosis [comment] de Caestecker JS. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):145–7. Comment on: Eur J Gastroenterol Hepatol 1997 Feb;9(2):155–61.

Oral pH–modified release budesonide versus 6–methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Gross V, et al. **Eur J Gastroenterol Hepatol** 1996 Sep;8(9):905–9

Soluble intercellular adhesion molecule–1 in primary biliary cirrhosis: effect of ursodeoxycholic acid and immunosuppressive therapy [see comments] Lim AG, et al. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):155–61. Comment in: Eur J Gastroenterol Hepatol 1997 Feb;9(2):145–7.

Beclomethasone dipropionate (3 mg) versus 5–aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Mulder CJ, et al. **Eur J Gastroenterol Hepatol** 1996 Jun;8(6):549–53

Antenatal steroid administration is associated with an improved chance of intact survival in preterm infants. Rennie JM, et al. **Eur J Pediatr** 1996 Jul;155(7):576–9

Effects of prednisolone and dexamethasone in children with alkali burns of the oesophagus. Bautista A, et al. **Eur J Pediatr Surg** 1996 Aug;6(4):198–203

A controlled assessment of an asthma self–management plan involving a budesonide dose regimen. OPTIONS Research Group. Ayres JG, et al. **Eur Respir J** 1996 May;9(5):886–92

Do patients with COPD benefit from treatment with inhaled corticosteroids? [editorial] van Schayck CP, et al. **Eur Respir J** 1996 Oct;9(10):1969–72

The effects of betamethasone derivatives on endotoxin–induced uveitis in rats. Tsuji F, et al. **Exp Eye Res** 1997 Jan;64(1):31–6

Treatment of hemorrhagic periodontitis using neopredin. Botushanov P, et al. **Folia Med (Plovdiv)** 1997;39(1):59–64

Elevated L–kynurenine level and its normalization by prednisolone in a patient with eosinophilia–myalgia syndrome. Hisatomi A, et al. **Fukuoka Igaku Zasshi** 1997 Jan;88(1):11–7

Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Azcue M, et al. **Gut** 1997 Aug; 41(2):203–8

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease [see comments] Bauditz J, et al. **Gut** 1997 Apr;40(4):470–4. Comment in: Gut 1997 Apr;40(4):559.

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Campieri M, et al. **Gut** 1997 Aug;41(2):209–14

Treatment of autoimmune hepatitis. Johnson PJ. **Gut** 1997 Jul;41(1):3–4

Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta–analysis. Marshall JK, et al. **Gut** 1997 Jun;40(6):775–81

Masking of the symptoms of esophageal and bowel perforation by combination treatment of sepsis with polyvalent immunoglobulins and low–dose hydrocortisone. Böhrer H, et al. **Hepatogastroenterology** 1996 May–Jun; 43(9):515–8

Treatment of active and postactive ileal and colonic Crohn's disease with oral pH–modified–release budesonide. German Budesonide Study Group. Caesar I, et al. **Hepatogastroenterology** 1997 Mar–Apr;44(14):445–51

Treatment of aplastic anemia in children with high dose methyl prednisolone. Agarwal BR, et al. **Indian Pediatr** 1995 Oct;32(10):1061–5

Usefulness of immunoadsorption therapy for systemic lupus erythematosus associated with transverse myelitis. A case report. Taniguchi Y, et al. **Int J Artif Organs** 1995 Dec; 18(12):799–801

Dexamethasone in adenotonsillectomy. Tom LW, et al. **Int J Pediatr Otorhinolaryngol** 1996 Oct;37(2):115–20

Methylprednisolone attenuates hypoxic pulmonary vasoconstriction in man [letter] Bjertnaes LJ, et al. **Intensive Care Med** 1996 Jul;22(7):715–7

Postextubation laryngeal edema in adults. Risk factor evaluation and prevention by hydrocortisone. Ho LI, et al. **Intensive Care Med** 1996 Sep;22(9):933–6

Bilateral acoustic neurofibromatosis camouflaged by corticosteroid treatment of sudden sensorineural hearing loss. Gaffney RJ, et al. **Ir J Med Sci** 1996 Jul–Sep; 165(3):151–2

Two atypical presentations of giant cell arteries. Reardon M, et al. **Ir J Med Sci** 1996 Jan–Mar;165(1):55–6

Treatment of chronic hepatitis B (HBeAg–HBV DNA–positive) with lymphoblastoid alpha interferon with or without corticosteroids: short– and long–term follow–up. Zavaglia C, et al. **Ital J Gastroenterol** 1996 Jul–Aug;28(6):324–31

Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma. Booms P, et al. **J Allergy Clin Immunol** 1997 Mar; 99(3):330–7

Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler. Toogood JH, et al. **J Allergy Clin Immunol** 1997 Feb;99(2):186–93

The effectiveness of once–daily dosing of inhaled flunisolide in maintaining asthma control. ZuWallack RL, et al. **J Allergy Clin Immunol** 1997 Mar;99(3):278–85

Impact of fluticasone propionate powder on health–related quality of life in patients with moderate asthma. Mahajan P, et al. **J Asthma** 1997;34(3):227–34

Topical steroid therapy in oral lichen planus: review of a novel delivery method in 24 patients. Aleinikov A, et al. **J Can Dent Assoc** 1996 Apr;62(4):324–7

Neuromyelitis optica in childhood: case report with sequential MRI findings. Davis R, et al. **J Child Neurol** 1996 Mar;11(2):164–7

Acyclovir or prednisone for treating herpes zoster. Becker LA, et al. **J Fam Pract** 1996 Dec;43(6):539–40

Perioperative steroids for secondary adrenal insufficiency. Blavin LR, et al. **J Fam Pract** 1997 Jun;44(6):532–3

Injection versus surgery in the treatment of trigger finger. Benson LS, et al. **J Hand Surg [Am]** 1997 Jan;22(1):138–44

Reflex sympathetic dystrophy: treatment with long–acting intramuscular corticosteroids. Grundberg AB. **J Hand Surg [Am]** 1996 Jul;21(4):667–70

Percutaneous release of trigger digit with and without cortisone injection. Patel MR, et al. **J Hand Surg [Am]** 1997 Jan;22(1):150–5

Treatment of experimental methicillin–resistant Staphylococcus epidermidis endophthalmitis with intravitreal vancomycin and intravitreal dexamethasone. Smith MA, et al. **J Infect Dis** 1997 Feb;175(2):462–6

Corticosteroid in tuberculous meningitis. Chotmongkol V, et al. **J Med Assoc Thai** 1996 Feb;79(2):83–90

CD4 subsets (CD45RA/RO) exhibit differences in proliferative responses, IL–2 and gamma–interferon production during intravenous methylprednisolone treatment of multiple sclerosis. Crockard AD, et al. **J Neurol** 1996 Jun;243(6):475–81

High dose intravenous immunoglobulin does not improve abnormalities in the blood–brain barrier during acute relapse of multiple sclerosis [letter] Nos C, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):418

Edema, thrombin, and dexamethasone [letter; comment] Abdou S. **J Neurosurg** 1997 Mar;86(3):575. Comment on: J Neurosurg 1996 Aug;85(2):335–9.

IL–4 and IL–13 expression in chronic sinusitis: relationship with cellular infiltrate and effect of topical corticosteroid treatment. al Ghamdi K, et al. **J Otolaryngol** 1997 Jun; 26(3):160–6

Safety of topical ear drops containing ototoxic antibiotics. Rakover Y, et al. **J Otolaryngol** 1997 Jun;26(3):194–6

Nasal inflammation and chronic ear disease in Australian Aboriginal children. Gibson PG, et al. **J Paediatr Child Health** 1996 Apr;32(2):143–7

Prednisolone and cellulose phosphate treatment in idiopathic infantile hypercalcaemia with nephrocalcinosis. Mizusawa Y, et al. **J Paediatr Child Health** 1996 Aug;32(4):350–2

Monitoring the effects of prednisone in Duchenne dystrophy [letter] Stern LM, et al. **J Paediatr Child Health** 1996 Apr; 32(2):196

Persistent hypercholesterolaemia in frequently relapsing steroid–responsive nephrotic syndrome. Tsukahara H, et al. **J Paediatr Child Health** 1997 Jun;33(3):253–5

Treatment of rheumatoid joint inflammation with intrasynovial triamcinolone [letter] Alarcón GS. **J Rheumatol** 1997 Sep;24(9):1849–50

Transient suppression of endogenous cortisol production after intraarticular steroid therapy for chronic arthritis in children. Huppertz HI, et al. **J Rheumatol** 1997 Sep; 24(9):1833–7

Prospective use of intramuscular triamcinolone acetonide in pseudogout. Roane DW, et al. **J Rheumatol** 1997 Jun; 24(6):1168–70

Evaluation of glucocorticosteroid injection for the treatment of trochanteric bursitis. Shbeeb MI, et al. **J Rheumatol** 1996 Dec;23(12):2104–6

The pathophysiology and medical management of canine osteoarthritis. Vaughan–Scott T, et al. **J S Afr Vet Assoc** 1997 Mar;68(1):21–5 (40 ref.)

Analysis of hepatitis B virus precore variants in hepatitis B e antibody–positive patients treated with prednisone plus interferon. Lopez–Alcorocho JM, et al. **J Viral Hepat** 1995; 2(6):279–84

Inhaled steroids and the risk of hospitalization for asthma. Donahue JG, et al. **JAMA** 1997 Mar 19;277(11):887–91

Dexamethasone as adjunctive therapy in bacterial meningitis. A meta–analysis of randomized clinical trials since 1988. McIntyre PB, et al. **JAMA** 1997 Sep 17;278(11):925–31

A case of amiodarone–induced thyrotoxicosis successfully treated with prednisolone. Hayashi K, et al. **Jpn Circ J** 1997 Apr;61(4):361–6

Clinical features of ulcerative colitis in Korea. Park SM, et al. **Korean J Intern Med** 1996 Jan;11(1):9–17

Treatment of pemphigus vulgaris with mycophenolate mofetil [letter] Enk AH, et al. **Lancet** 1997 Aug 16; 350(9076):494

Dexamethasone for bacterial meningitis: we need the answer. Dutch Bacterial Meningitis Study Group [letter] Enting R. **Lancet** 1997 Apr 19;349(9059):1179–80

Colchicine versus prednisone as treatment of usual interstitial pneumonia [see comments] Douglas WW, et al. **Mayo Clin Proc** 1997 Mar;72(3):201–9. Comment in: Mayo Clin Proc 1997 Mar;72(3):285–7.

Inhaled beclomethasone dipropionate (BDP) prevents seasonal changes in atopic asthmatics. Ponticiello A, et al. **Monaldi Arch Chest Dis** 1997 Apr;52(2):112–7

Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus. Carette S, et al. **N Engl J Med** 1997 Jun 5;336(23):1634–40

A case of unilateral bronchiolitis obliterans organizing pneumonia (BOOP). Kanwar BA, et al. **Nebr Med J** 1996 May;81(5):149–51

Budesonide in inflammatory bowel disease. Lamers CB, et al. **Neth J Med** 1996 Feb;48(2):60–3 (16 ref.)

How high is high in steroid treatment of Vogt–Koyanagi–Harada syndrome? Ikeda K, et al.

Neurology 1997 Feb;48(2):537

Ophthalmic fluorometholone-gentamicin versus ophthalmic betamethasone-gentamicin following cataract surgery. Steinbach PD, et al. **Ocul Immunol Inflamm** 1997 Mar; 5(1):51-4

What we have learned from the Optic Neuritis Treatment Trial [see comments] Beck RW, et al. **Ophthalmology** 1995 Oct;102(10):1504-8. Comment in: Ophthalmology 1995 Oct;102(10):1504-8.

Orbital pseudotumors treated with systemic corticosteroids [letter; comment] Jordan DR. **Ophthalmology** 1996 Oct; 103(10):1519; discussion 1520. Comment on: Ophthalmology 1996 Mar;103(3):521-8.

Orbital pseudotumors treated with systemic corticosteroids [letter; comment] Wirostko BM, et al. **Ophthalmology** 1996 Oct;103(10):1519-20. Comment on: Ophthalmology 1996 Mar;103(3):521-8.

Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Ménière's disease. Shea JJ Jr, et al. **Otolaryngol Clin North Am** 1996 Apr;29(2):353-8 (24 ref.)

Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Lucky AW, et al. **Pediatr Dermatol** 1997 Jul-Aug;14(4):321-4

The use of pulse corticosteroid therapy for juvenile dermatomyositis [see comments] Paller AS. **Pediatr Dermatol** 1996 Jul-Aug;13(4):347-8. Comment in: Pediatr Dermatol 1997 May-Jun;14(3):246-7.

Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis. Slusher T, et al. **Pediatr Infect Dis J** 1996 Jul;15(7):579-83

The effect of alternate-day low-dose prednisolone on bone age in children with steroid-dependent nephrotic syndrome [letter; comment] Bircan Z, et al. **Pediatr Nephrol** 1996 Jun;10(3):397-8. Comment on: Pediatr Nephrol 1994 Aug;8(4):480-2.

Does deflazacort therapy offer any advantages over conventional corticosteroids in children with renal disease? Clark G. **Pediatr Nephrol** 1997 Jun;11(3):394

An 8-year-old girl with nephrotic syndrome, delayed response to prednisolone, and fatty liver. Huttunen NP, et al. **Pediatr Nephrol** 1997 Apr;11(2):258-60; discussion 261-2

Croup. Geelhoed GC. **Pediatr Pulmonol** 1997 May; 23(5):370-4 (42 ref.)

Effect of asthma treatment on urinary growth hormone excretion in children [letter; comment] Nikolaizik WH. **Pediatr Pulmonol** 1997 Feb;23(2):126-7. Comment on: Pediatr Pulmonol 1996 Jun;21(6):361-6.

Effect of asthma treatment on urinary growth hormone excretion in children [see comments] O'Leary PC, et al. **Pediatr Pulmonol** 1996 Jun;21(6):361-6. Comment in: Pediatr Pulmonol 1997 Feb;23(2):126-7.

Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation. Wang JY, et al. **Pediatr Pulmonol** 1997 Mar;23(3):193-7

Methylprednisolone attenuates the pulmonary hypertensive response in porcine meconium aspiration. Soukka H, et al. **Pediatr Res** 1997 Aug;42(2):145-50

Effect of a chemical delivery system for dexamethasone (Dex-CDS) on peritumoral edema in an experimental brain tumor model. Siegal T, et al. **Pharm Res** 1997 May; 14(5):672-5

ANCA-associated vasculitis: diagnosis and treatment in the elderly. Parry R, et al. **Postgrad Med J** 1996 Jul; 72(849):423-6 (16 ref.)

Cyclophosphamide in severe steroid-resistant bronchiolitis obliterans organizing pneumonia. Purcell IF, et al. **Respir Med** 1997 Mar;91(3):175-7

Visual recovery following treatment with very high dose corticosteroid in traumatic optic neuropathy. Chan TK, et al. **Singapore Med J** 1996 Apr;37(2):216-7

Neurophysiologic changes in lumbar nerve root inflammation in the rat after treatment with cytokine inhibitors. Evidence for a role of interleukin-1. Wehling P, et al. **Spine** 1996 Apr 15;21(8):931-5

Effect of contact avoidance or treatment with oral prednisolone on bronchoalveolar lavage surfactant protein A levels in subjects with farmer's lung. Cormier Y, et al. **Thorax** 1996 Dec;51(12):1210-5

BTS sarcoidosis study [letter; comment] Israel H, et al. **Thorax** 1997 Jan;52(1):102. Comment on: Thorax 1996 Mar;51(3):238-47.

Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to severe paraquat poisoning: a preliminary report [see comments] Lin JL, et al. **Thorax** 1996 Jul;51(7):661-3. Comment in: Thorax 1996 Jul;51(7):659-60. Comment in: Thorax 1997 Jun;52(6):588.

How general practitioners manage acute asthma attacks. Neville RG, et al. **Thorax** 1997 Feb;52(2):153-6

BTS sarcoidosis study [letter; comment] Reich JM. **Thorax** 1997 Jan;52(1):102. Comment on: Thorax 1996 Mar;51(3):238-47.

The effect of corticosteroids on visual loss in Cryptococcus neoformans var. gattii meningitis. Seaton RA, et al. **Trans R Soc Trop Med Hyg** 1997 Jan-Feb;91(1):50-2

A case of steroid refractory ulcerative colitis treated with cyclosporin. Sreenivas DV, et al. **Trop Gastroenterol** 1997 Jan-Mar;18(1):26

High-dose methylprednisolone-induced dramatic maturation of granulocytes in idiopathic chronic neutropenia. Yetgin S, et al. **Turk J Pediatr** 1997 Apr-Jun;39(2):259-63

Hyperbaric oxygen as a therapy of Bell's palsy. Racic G, et al. **Undersea Hyperb Med** 1997;24(1):35-8

New drugs for improving injury outcome in spinal cord injuries. Werner PC. **West J Med** 1997 Apr;166(4):271-2

Efficacy of the combination sodium ceftiofur-flumethasone in the treatment of experimental Pasteurella haemolytica bronchopneumonia in calves. Sustronck B, et al. **Zentralbl Veterinarmed A** 1997 May;44(3):179-87

[Do corticotherapy and hemodilution decrease postoperative inflammation after maxillofacial surgery?] Peillon D, et al. **Ann Fr Anesth Reanim** 1996;15(2):157-61 (Eng. Abstr.) **(Fre)**

[Role of corticoids in purulent meningitis in children: analysis of literature studies] Jacqz-Aigrain E, et al. **Arch Pediatr** 1997 Jan;4(1):52-60 (46 ref.) (Eng. Abstr.) **(Fre)**

[Pain in cancer patients. Practical attitude] Pichard-Léandri E. **J Chir (Paris)** 1997 May;134(1):14-21 (29 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of aplastic anemia with cyclosporine, prednisolone and androgens (primary results apropos of 10 cases] Frikha M, et al. **Therapie** 1996 Nov-Dec; 51(6):627-9 (Eng. Abstr.) **(Fre)**

[Anti-inflammatory and immunosuppressive effect of glucocorticoids. What are the basic molecular mechanisms?] Petzoldt D, et al. **Hautarzt** 1996 Feb; 47(2):166-8 **(Ger)**

[A case of pancreatitis with transient eosinophilia improved by steroid therapy] Takahashi H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Apr;94(4):304-9 **(Jpn)**

[A new approach to assessing rheumatoid arthritis (RA) disease activity using the American College of Rheumatology core set of disease activity measures for RA trials--a multi-center study] Okano Y, et al. **Ryumachi** 1997 Jun;37(3):467-75 (Eng. Abstr.) **(Jpn)**

[Verification of indications for kidney biopsy in children with steroid-dependent nephrotic syndrome] Idczak-Nowicka E, et al. **Pediatr Pol** 1996 Aug;71(8):679-83 (Eng. Abstr.) **(Pol)**

[Clinical course and treatment results of IgA nephropathy in children] Sieniawska M, et al. **Pediatr Pol** 1996 Apr; 71(4):313-20 (Eng. Abstr.) **(Pol)**

[Impairment of antiviral cellular resistance and possibilities of its correction during acute altitude hypoxia] Sinopal'nikov DO, et al. **Aviakosm Ekolog Med** 1997; 31(2):28-32 (Eng. Abstr.) **(Rus)**

[Infantile peripheral facial paralysis] Carbonell J, et al. **Acta Otorrinolaringol Esp** 1996 Nov-Dec;47(6):429-33 (Eng. Abstr.) **(Spa)**

[Early corticoid treatment of idiopathic facial palsy (Bell)] Hurtado García JF, et al. **Acta Otorrinolaringol Esp** 1997 Apr;48(3):177-81 (Eng. Abstr.) **(Spa)**

[Treatment of nasal polyposis with systemic and local corticoids] Rasp G, et al. **Acta Otorrinolaringol Esp** 1997 Jan-Feb;48(1):37-40 (Eng. Abstr.) **(Spa)**

[Pneumocystis carinii pneumonia. Complications of cytotoxic treatment in a systemic vasculitis] Gamboa F, et al. **An Med Interna** 1995 Nov;12(11):555-6 (Eng. Abstr.) **(Spa)**

[Subcutaneous nodules as the initial manifestation of systemic sarcoidosis: response to treatment with oral corticoids (Letter)] Navarro Moreno L, et al. **An Med Interna** 1996 Jun;13(6):308-9 **(Spa)**

[Patients with rheumatoid arthritis: study of the correlation between density of glucocorticoid receptors in synovial cells and clinical response to steroidal treatment] Cuchacovich M, et al. **Rev Med Chil** 1996 Feb;124(2):160-9 (Eng. Abstr.) **(Spa)**

TOXICITY

Purification and characterization of dexamethasone inducible hepatic cytochrome P450 isozymes from rhesus monkey. Puri V, et al. **Drug Chem Toxicol** 1997 Feb-May; 20(1-2):11-9

Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone. Conaway HH, et al. **J Bone Miner Res** 1996 Oct; 11(10):1419-29

Proliferative bone lesions in rats fed a diet containing glucocorticoid for up to two years. Zwicker GM, et al. **Toxicol Pathol** 1996 Mar-Apr;24(2):246-50

URINE

Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11 beta-hydroxysteroid dehydrogenase in vivo. Best R, et al. **Clin Endocrinol (Oxf)** 1997 Aug;47(2):231-6

ANTI-INFLAMMATORY AGENTS, TOPICAL

Topical anti-inflammatory properties of flutrimazole, a new imidazole antifungal agent. Merlos M, et al. **Inflamm Res** 1996 Jan;45(1):20-5

ADMINISTRATION & DOSAGE

Comparison of topical silver nitrate and flunisolide treatment in patients with idiopathic non-allergic rhinitis. Erhan E, et al. **Tokai J Exp Clin Med** 1996 Jun;21(2):103-11

Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis--a practical approach. Parkin J, et al. **Urology** 1997 May;49(5A Suppl):105-7

[Local DMSO treatment of macular and papular amyloidosis] Ozkaya-Bayazit E, et al. **Hautarzt** 1997 Jan;48(1):31-7 (Eng. Abstr.) **(Ger)**

[Minor effect of anti-inflammatory therapy on intraocular inflammation after minimally invasive phacoemulsification] Hessemer V, et al. **Ophthalmologe** 1997 Jan;94(1):30-2 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Contact sensitization to 6 alpha-methylprednisolone aceponate. Balato N, et al. **Am J Contact Dermat** 1997 Mar; 8(1):24-5

Reactivity of tixocortol pivalate-positive patients in intradermal and oral provocation tests. Räsänen L, et al. **Br J Dermatol** 1996 Dec;135(6):931-4

Bufexamac is a frequent contact sensitizer. Kränke B, et al. **Contact Dermatitis** 1996 Jan;34(1):63-4

Epidemiological significance of bufexamac as a frequent and relevant contact sensitizer. Kränke B, et al. **Contact Dermatitis** 1997 Apr;36(4):212-5

Tolerability of topical NSAIDs in the elderly: do they really convey a safety advantage? Evans JM, et al. **Drugs Aging** 1996 Aug;9(2):101-8 (70 ref.)

ANTAGONISTS & INHIBITORS

Inhibitory effect of glycyrrhetinic acid derivatives on capsaicin-induced ear edema in mice. Inoue H, et al. **Jpn J Pharmacol** 1996 Aug;71(4):281-9

CHEMICAL SYNTHESIS

Synthesis of some 2-arylpropionic acid amides as prodrugs. Akgün H, et al. **Arzneimittelforschung** 1996 Sep;46(9):891-4

ISOLATION & PURIFICATION

Topical anti-inflammatory lignans from Haplophyllum hispanicum. Prieto JM, et al. **Z Naturforsch [C]** 1996 Sep-Oct;51(9-10):618-22

PHARMACOKINETICS

5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: II. Pharmacokinetics and demonstration of clinical safety. Khandwala A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):231-8

No effect of albumin on the dermal absorption rate of hydrocortisone 21-butyrate, permethrin or diflunisal in the isolated, single-pass perfused rabbit ear. Bast GE, et al. **Skin Pharmacol** 1996;9(5):327-33

PHARMACOLOGY

Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. Mrowietz U, et al. **Br J Dermatol** 1997 Apr;136(4):542-7

Sensitization studies with mometasone furoate, tixocortol pivalate, and budesonide in the guinea pig. Bruze M, et al. **Contact Dermatitis** 1996 Mar;34(3):161-4

Effect of topical anti-inflammatory drugs on epithelial cell-induced eosinophil survival and GM-CSF secretion. Roca-Ferrer J, et al. **Eur Respir J** 1997 Jul;10(7):1489-95

Inhibition of human complement by beta-glycyrrhetinic acid. Kroes BH, et al. **Immunology** 1997 Jan;90(1):115-20

Stem cell factor in nasal polyposis and allergic rhinitis: increased expression by structural cells is suppressed by in vivo topical corticosteroids. Kim YK, et al. **J Allergy Clin Immunol** 1997 Sep;100(3):389-99

Differential effects of dimethyl sulfoxide on nicotinic acetylcholine receptors from mouse muscle and Torpedo electrocytes. Eaton MJ, et al. **Neurosci Lett** 1997 Jul 25; 230(3):163-6

Inhibition of NF-kappa B activation by dimethyl sulfoxide correlates with suppression of TNF-alpha formation, reduced ICAM-1 gene transcription, and protection against endotoxin-induced liver injury [see comments] Essani NA, et al. **Shock** 1997 Feb;7(2):90-6. Comment in: Shock 1997 Feb;7(2):97.

[The effect of pinocadinene on the clinico-immunological status of patients in the combined treatment of periodontitis] Maksimovskii YuM, et al. **Stomatologiia (Mosk)** 1995;74(6):20-2 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

The effect of fumaric acid esters and dithranol on acanthosis and hyperproliferation in psoriasis vulgaris. Bacharach-Buhles M, et al. **Acta Derm Venereol** 1996 May; 76(3):190-3

Treatment of extravasation of both doxorubicin and vincristine administration in a Y-site infusion. Comas D, et al. **Ann Pharmacother** 1996 Mar;30(3):244-6

Topical corticosteroid treatment of anosmia associated with nasal and sinus disease. Mott AE, et al. **Arch Otolaryngol Head Neck Surg** 1997 Apr;123(4):367-72

The conservative treatment of phimosis in boys. Golubovic Z, et al. **Br J Urol** 1996 Nov;78(5):786-8

5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: II. Pharmacokinetics and

demonstration of clinical safety. Khandwala A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):231–8

5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: I. Clinical demonstration of acceleration of healing and resolution of pain. Khandwala A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):222–30

Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. Sandelin J, et al. **Scand J Rheumatol** 1997;26(4):287–92

[The antimicrobial activity of a new wound-healing compound ointment] Iakushchenko VA, et al. **Mikrobiol Z** 1996 May–Jun;58(3):78–82 (Eng. Abstr.) **(Rus)**

[The development and creation of a new generation of superoxide dismutase-based antioxidant preparations] Demchenko TV, et al. **Stomatologiia (Mosk)** 1996;Spec No:51–2 **(Rus)**

[The use of the preparation Tantum Verde in treating diseases of the oral mucosa] Rabinovich IM, et al. **Stomatologiia (Mosk)** 1996;75(4):20–2 (Eng. Abstr.) **(Rus)**

TOXICITY

The effects of topical nasal steroids on rat respiratory mucosa in vivo, with special reference to benzalkonium chloride. Berg OH, et al. **Allergy** 1997 Jun;52(6):627–32

ANTILEPROTIC AGENTS see LEPROSTATIC AGENTS

ANTILIPEMIC AGENTS

Clofibrate. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:391–426 (136 ref.)

Gemfibrozil. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:427–44 (75 ref.)

Garlic: the key to sophisticated lowering of hepatocellular lipid [editorial] Gebhardt R. **Nutrition** 1997 Apr; 13(4):379–80

ADMINISTRATION & DOSAGE

Colestipol tablets in adolescents with familial hypercholesterolaemia. Tonstad S, et al. **Acta Paediatr** 1996 Sep;85(9):1080–2

Hypolipidemic drugs in coronary artery disease [letter; comment] Isley WL. **Ann Intern Med** 1997 Jun 1; 126(11):916; discussion 917. Comment on: Ann Intern Med 1996 Oct 1;125(7):529–40.

Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs. Wiklund O, et al. **Atherosclerosis** 1996 Jan 5;119(1):57–67

Chemiluminescence and antioxidant levels during peroxisome proliferation by fenofibrate. Lores Arnaiz S, et al. **Biochim Biophys Acta** 1997 May 24;1360(3):222–8

Effect of a combination of gemfibrozil and niacin on lipid levels. Spencer GA, et al. **J Clin Pharmacol** 1996 Aug; 36(8):696–700

Effect of acute acipimox administration on the rates of lipid and glycogen synthesis in cachectic tumor-bearing rats. Obeid OA, et al. **Nutr Cancer** 1997;28(1):100–6

Effect of L-glutamine supplementation on impaired glucose regulation during intravenous lipid administration [see comments] Ballard TC, et al. **Nutrition** 1996 May; 12(5):349–54. Comment in: Nutrition 1996 May;12(5):375.

A drug utilisation study investigating prescribed daily doses of hypolipidaemic agents. Truter I, et al. **S Afr Med J** 1996 Nov;86(11):1397–401

Management of hyperlipidaemia. Sum CF, et al. **Singapore Med J** 1995 Aug;36(4):410–6 (61 ref.)

Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia. de Maat MP, et al. **Thromb Haemost** 1997 Jan;77(1):75–9

Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results. Parnetti L, et al. **Thromb Res** 1997 Jul 15;87(2):225–33

[The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia] Ceška R, et al. **Cas Lek Cesk** 1996 Jul 26;135(13):413–6 (Eng. Abstr.) **(Cze)**

[Goals and practical implementation of lipid therapy in coronary heart disease] Beil FU, et al. **Herz** 1997 Jun; 22(3):134–40 (40 ref.) (Eng. Abstr.) **(Ger)**

[Primary prevention of cardiovascular diseases by lowering lipids] Klose G. **Internist (Berl)** 1997 Jun;38(6):615–6 **(Ger)**

[Long term treatment of moderate to severe hypercholesterolemia with low dose statin. Comparison of simvastatin and pravastatin] Spagnolli W, et al. **Recenti Prog Med** 1996 Nov;87(11):538–42 (Eng. Abstr.) **(Ita)**

[Prevention—are we not good enough?] Kjekshus J. **Tidsskr Nor Laegeforen** 1997 Jun 20;117(16):2293 **(Nor)**

[Drug therapy of hyperlipidemia—unanswered questions (letter; comment)] Osmundsen K. **Tidsskr Nor Laegeforen** 1997 Apr 10;117(9):1334. Comment on: Tidsskr Nor Laegeforen 1997 Feb 20;117(5):674–7. **(Nor)**

[Drug therapy of hyperlipidemia—unanswered questions (see comments)] Tonstad S. **Tidsskr Nor Laegeforen** 1997 Feb 20;117(5):674–7 (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1997 Apr 10;117(9):1334. **(Nor)**

[The effects of eiconol in elderly patients with non-insulin-dependent diabetes mellitus] Malichenko SB, et al. **Ter Arkh** 1996;68(10):15–8 (Eng. Abstr.) **(Rus)**

[A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia] Zambrana García JL, et al. **Rev Esp Cardiol** 1996 Dec; 49(12):892–8 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens. Williams GM, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:554–72 (69 ref.)

Elevated blood concentrations of cyclosporine and kidney failure after bezafibrate in renal graft recipient [letter] Hirai M, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):883–4

Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals [letter] Horn M. **Arch Dermatol** 1996 Oct;132(10):1254

Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia. Nakai A, et al. **Biol Pharm Bull** 1997 Jan;20(1):104–6

Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment. Ramachandran S, et al. **BMJ** 1997 May 31;314(7094):1593

Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. De Pinieux G, et al. **Br J Clin Pharmacol** 1996 Sep;42(3):333–7

Bone scintigraphy of drug-induced rhabdomyolysis: antihyperlipidemia agent. Takayama T, et al. **Clin Nucl Med** 1996 Dec;21(12):988–9

Hyperlipidaemia and cardiovascular disease [editorial] Blum C. **Curr Opin Lipidol** 1996 Apr;7(2):U57–64

Diagnostic pitfalls during therapy for extreme hypertriglyceridaemia. Orth M, et al. **Eur J Clin Chem Clin Biochem** 1997 Feb;35(2):101–3

Fenofibrate-induced photosensitivity. Leenutaphong V, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):775–7

Evaluation of the phototoxic properties of some hypolipidemics in vitro: fenofibrate exhibits a prominent phototoxic potential in the UVA and UVB region. Diemer S, et al. **J Dermatol Sci** 1996 Nov;13(2):172–7

Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. van Puijenbroek EP, et al. **J Intern Med** 1996 Dec;240(6):403–4

Morphometry of abnormal peroxisomes induced by withdrawal of bezafibrate, a hypolipidemic drug in male rat hepatocytes. Kondo K, et al. **J Vet Med Sci** 1997 Apr; 59(4):297–9

Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone [letter] Jacobson RH, et al. **JAMA** 1997 Jan 22–29;277(4):296–7

Rhabdomyolysis and acute renal failure associated with bezafibrate treatment [letter] Górriz JL, et al. **Nephrol Dial Transplant** 1995 Dec;10(12):2371–2

Renal function changes in diabetic nephropathy induced by bezafibrate [letter] Bruce R, et al. **Nephron** 1996;73(3):490

Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy [letter] Górriz JL, et al. **Nephron** 1996; 74(2):437–8

Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient [letter] Panuccio V, et al. **Nephron** 1996;73(4):736

Prospective case control study to determine the effect of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure. Segarra A, et al. **Nephron** 1996;73(2):186–90

Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. Tal A, et al. **South Med J** 1997 May;90(5):546–7

[Painful acute liver involvement related to ingestion of fenofibrate (letter)] Rouhier ML, et al. **Gastroenterol Clin Biol** 1996;20(12):1137–8 **(Fre)**

[Rhabdomyolysis and unexplained malaise. Role of combination of ciprofibrate and norfloxacin (letter)] Blain H, et al. **Rev Med Interne** 1996;17(10):859–60 **(Fre)**

[Thyroid myopathy disclosed by a fibrate (letter)] Schlienger JL, et al. **Rev Med Interne** 1997;18(2):169–70 **(Fre)**

BLOOD

Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography. Masnatta LD, et al. **J Chromatogr B Biomed Appl** 1996 Dec 13;687(2):437–42

Microsample determination of lovastatin and its hydroxy acid metabolite in mouse and rat plasma by liquid chromatography/ionspray tandem mass spectrometry. Wu Y, et al. **J Mass Spectrom** 1997 Apr;32(4):379–87

Blood monitoring of bezafibrate in a chronic hemodialysis patient [letter] Takeda K, et al. **Nephron** 1997;76(4):487–8

CHEMICAL SYNTHESIS

Synthesis and antihyperlipaemic activity of some 2-aminomethyl-3-aryl-5,6,7,8-tetrahydrobenzo(b)/5,6-dimethylthieno++ +(2,3- d) -pyrimidin-4-ones. Gadad AK, et al. **Arzneimittelforschung** 1996 Oct;46(10):981–5

Synthesis and quantitative structure-activity relationships of antihyperlipaemic 2-substituted thieno[3,2-d]pyrimidin-4(3H)-ones. Shishoo CJ, et al. **Arzneimittelforschung** 1996 Mar;46(3):273–6

Synthesis and antihyperlipaemic activity of some novel N-cyanovinylformamidines. Shishoo CJ, et al. **Arzneimittelforschung** 1997 Jan;47(1):35–8

Synthesis and hypolipidemic activity of diesters of arylnaphthalene lignan and their heteroaromatic analogs. Kuroda T, et al. **Chem Pharm Bull (Tokyo)** 1997 Apr; 45(4):678–84

CHEMISTRY

Common structural requirements for peroxisome proliferation by tetrazole and carboxylic acid-containing compounds. Eacho PI, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:387–402

Photodegradation of bezafibrate in aqueous media. Studies of its in vitro phototoxicity. Canudas N, et al. **Arzneimittelforschung** 1996 Jul;46(7):694–7

Plasma triglyceride-decreasing components of pine needles. Iwata H, et al. **Biol Pharm Bull** 1997 Jun;20(6):656–61

Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity. Hawke RL, et al. **J Lipid Res** 1997 Jun;38(6):1189–203

Steroidal glycoside cholesterol absorption inhibitors. DeNinno MP, et al. **J Med Chem** 1997 Aug 1; 40(16):2547–54

Correlation of pharmacological properties of a group of hypolipaemic drugs by molecular topology. Cercós-del-Pozo RA, et al. **J Pharm Pharmacol** 1996 Mar; 48(3):240–4

ECONOMICS

Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada [see comments] Rivière M, et al. **Can Med Assoc J** 1997 Apr 1;156(7):991–7 . Comment in: Can Med Assoc J 1997 Apr 1;156(7):1005–7.

Cost-benefit analysis of lipid lowering therapy [editorial; comment] [see comments] Davie AP, et al. **Eur Heart J** 1996 Jul;17(7):974–5. Comment on: Eur Heart J 1996 Jul;17(7):1001–7. Comment in: Eur Heart J 1997 Jan;18(1):165–6.

Cost-benefit analysis of lipid lowering therapy [letter; comment] Jönsson B, et al. **Eur Heart J** 1997 Jan; 18(1):165–6. Comment on: Eur Heart J 1996 Jul;17(7):974–5.

[Cost-benefit analysis of the therapy of lipid metabolism disorders (letter)] Karádi I. **Orv Hetil** 1996 May 26; 137(21):1164 **(Hun)**

ISOLATION & PURIFICATION

Studies on the constituents of Cimicifuga species. XIX. Eight new glycosides from Cimicifuga simplex Wormsk. Kusano A, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov; 44(11):2078–85

METABOLISM

Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. Sallustio BC, et al. **Drug Metab Dispos** 1996 Sep;24(9):984–9

Evidence of metal binding activities of pentadecapeptide from Panax ginseng. Kajiwara H, et al. **J Chromatogr B Biomed Appl** 1996 Dec 13;687(2):443–8

Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Krey G, et al. **Mol Endocrinol** 1997 Jun;11(6):779–91

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Forman BM, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29; 94(9):4312–7

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Kliewer SA, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4318–23

PHARMACOKINETICS

Pharmacokinetic and bioequivalence study of two gemfibrozil preparations. Benkö S, et al. **Arzneimittelforschung** 1997 Aug;47(8):913–6

Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Desager JP, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S65–73

Comparative steady state study with 2 fenofibrate 250 mg slow release capsules. An example of bioequivalence assessment with a highly variable drug. Doser K, et al. **Int J Clin Pharmacol Ther** 1996 Aug;34(8):345–8

[Bioanalysis of gemfibrozil. Comparative human pharmacokinetics of 300 mg of gemfibrozil-containing Innogem and Lopid capsules] Benkóné Márkus S, et al. **Acta Pharm Hung** 1996 Sep;66(5):203–12 (Eng. Abstr.) **(Hun)**

[The kinetics of the excretion of a choline-containing polymer from the body of rats and its effect on the activity of intestinal enzymes] Poriadkov LF, et al.

Eksp Klin Farmakol 1996 Jul–Aug;59(4):43–6 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Effect of simvastatin on ejection fraction in cardiac transplant recipients. Jenkins GH, et al. **Am J Cardiol** 1996 Dec 15; 78(12):1453–6

Peroxisome proliferators induce high levels of DNA synthesis in primary cultures of rat hepatocytes. Bell DR, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:745–6

Peroxisome proliferators and signal transduction. Bronfman M, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:403–12

Structural diversity of peroxisome proliferators and their effects on mammalian liver cells in vivo. de la Iglesia F, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:310–27

Peroxisome proliferators: species differences in response of primary hepatocyte cultures. Elcombe CR, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:628–35

Zonal heterogeneity of peroxisome proliferation in rat liver. Fahimi HD, et al. **Ann N Y Acad Sci** 1996 Dec 27; 804:341–61

Role of eicosanoid metabolism in carcinogenesis by peroxisome proliferators. Glauert HP, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:719–21

Hypolipidemic effect of peroxisome proliferators. Transcriptional suppression of apolipoprotein C-III. Hertz R, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:731–3

Studies on the role of PPAR in the fibrate–modulated gene expression of apolipoprotein A–I, plasminogen activator inhibitor 1, and fibrinogen in primary hepatocyte cultures from cynomolgus monkey. Kockx M, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:711–2

Protein phosphorylation by peroxisome proliferators: species–specific stimulation of protein kinases and its role in PP–induced transcriptional activation. Motojima K, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:413–23

Pretreatment with peroxisome proliferators protects mice against some but not all hepatotoxins. Nicholls–Grzemski FA, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:742–4

The beneficial effect of tamoxifen on serum lipoprotein–A levels: an additional anti–atherogenic property. Elisaf M, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2725–8

Early effects of CI–924 on hepatic peroxisome proliferation, microsomal enzyme induction, PCNA, and apoptosis in B6C3F1 mice and Wistar rats. Hofstra AH, et al. **Arch Toxicol** 1997;71(4):250–7

Studies on the mechanism of fibrate–inhibited expression of plasminogen activator inhibitor–1 in cultured hepatocytes from cynomolgus monkey. Arts J, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):26–32

Hypolipidemic effect of Curcuma comosa in mice. Piyachaturawat P, et al. **Artery** 1997;22(5):233–41

Synthesis and quantitative structure–activity relationships of antihyperlipaemic 2–substituted thieno[3,2–d]pyrimidin–4(3H)–ones. Shishoo CJ, et al. **Arzneimittelforschung** 1996 Mar;46(3):273–6

Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Desager JP, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S65–73

Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats. Krause BR, et al. **Atherosclerosis** 1996 Nov 15;127(1):91–101

Effects of gemfibrozil administration on very low density lipoprotein receptor mRNA levels in rabbits. Matsuoka N, et al. **Atherosclerosis** 1996 Oct 25;126(2):221–6

Demonstration of potent lipid–lowering activity by a thyromimetic agent devoid of cardiovascular and thermogenic effects. Stephan ZF, et al. **Atherosclerosis** 1996 Sep 27;126(1):53–63

Effects of gemfibrozil on very–low–density lipoprotein composition and low–density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia. Yang CY, et al. **Atherosclerosis** 1996 Sep 27;126(1):105–16

Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl–diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol. Riddell D, et al. **Biochem Pharmacol** 1996 Oct 25;52(8):1177–86

Effects of gemfibrozil and clofibric acid on the uptake of taurocholate by isolated rat hepatocytes. Sabordo L, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):215–8

The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Staels B, et al. **Biochimie** 1997 Feb–Mar;79(2–3):95–9 (39 ref.)

Effect of gemfibrozil on centrifugal behavior of rat peroxisomes and activities of peroxisomal enzymes involved in lipid metabolism. Hashimoto F, et al. **Biol Pharm Bull** 1997 Apr;20(4):315–21

Effects of gonadectomy and sex hormones on the induction of hepatic CYP4A by clofibrate in rats. Hiratsuka M, et al. **Biol Pharm Bull** 1996 Jan;19(1):34–8

Shosaikoto (kampo medicine) protects macrophage function from suppression by hypercholesterolemia. Inoue M, et al. **Biol Pharm Bull** 1996 Apr;19(4):652–4

Plasma triglyceride–decreasing components of pine needles. Iwata H, et al. **Biol Pharm Bull** 1997 Jun;20(6):656–61

Intraperitoneal administration of Senegae Radix extract and its main component, senegin–II, affects lipid metabolism in normal and hyperlipidemic mice. Masuda H, et al. **Biol Pharm Bull** 1996 Feb;19(2):315–7

Anti–hyperlipidemic and anti–atherosclerotic actions of shosaikoto (kampo medicine). Shen YR, et al. **Biol Pharm Bull** 1996 Sep;19(9):1160–5

The effects of combined treatment with beta 1–selective receptor antagonists and lipid–lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo–controlled study in healthy subjects. Eagles CJ, et al. **Br J Clin Pharmacol** 1997 Mar; 43(3):291–300

Differences in hypolipidaemic effects of two statins on Hep G2 cells or human hepatocytes in primary culture. Clerc T, et al. **Br J Pharmacol** 1996 Aug;118(7):1862–8

Decreased susceptibility to copper–induced oxidation of rat–lipoproteins after fibrate treatment: influence of fatty acid composition. Vázquez M, et al. **Br J Pharmacol** 1996 Mar;117(6):1155–62

Effects of benfluorex on serum triacylglycerols and insulin sensitivity in the corpulent rat. Russell JC, et al. **Can J Physiol Pharmacol** 1996 Aug;74(8):879–86

Induction of cellular DNA synthesis in the pancreas and kidneys of rats by peroxisome proliferators, 9–cis retinoic acid, and 3,3',5–triiodo–L–thyronine. Ohmura T, et al. **Cancer Res** 1997 Mar 1;57(5):795–8

Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF–kappaB activity. Li Y, et al. **Carcinogenesis** 1996 Nov;17(11):2305–9

Peroxisome proliferator nafenopin potentiated cytotoxicity and genotoxicity of cyclophosphamide in the liver and bone marrow cells. Voskoboinik I, et al. **Chem Biol Interact** 1997 Jul 11;105(2):81–97

Stereoselective effects of chiral clofibric acid analogs on rat peroxisome proliferator–activated receptor alpha (rPPAR alpha) activation and peroxisomal fatty acid beta–oxidation. Rangwala SM, et al. **Chirality** 1997;9(1):37–47

Lipid–regulating action of gemfibrozil in the stroke–prone spontaneously hypertensive rat. Ogawa H, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S313–5

Elevation of intracellular Ca2+ concentration in rabbit nonpigmented ciliary epithelial cells by allicin. Chu TC, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Sep;115(1):89–94

Interactions between glucose and FFA metabolism in man. Saloranta C, et al. **Diabetes Metab Rev** 1996 Apr; 12(1):15–36 (187 ref.)

Effects of simvastatin on the number and composition of apoproteinB–containing lipoproteins in hypercholesterolemia: analysis of apoproteinB in each lipoprotein fraction by highly sensitive latex method. Ikeda Ryomoto K, et al. **Endocr J** 1996 Oct;43(5):469–75

Differences in the response of serum lipoproteins to fenofibrate between women and men with primary hypercholesterolaemia. Sudhop T, et al. **Eur J Clin Pharmacol** 1996;50(5):365–9

Differential eudismic ratios in the antagonism of human platelet function by phenoxy– and thiophenoxyacetic acids. Romstedt KJ, et al. **Farmaco** 1996 Feb;51(2):107–14

The direct effect of hepatic peroxisome proliferators on rat Leydig cell function in vitro. Liu RC, et al. **Fundam Appl Toxicol** 1996 Mar;30(1):102–8

Effect of dexamethasone on ciprofibrate–induced cell proliferation and peroxisome proliferation. Rao MS, et al. **Fundam Appl Toxicol** 1997 Jan;35(1):78–83

Hypolipidemic effects of synthetic gugulsterones in normal rats and assessment of its long–term toxicity at cellular levels in various organs. Far SR, et al. **Indian J Med Sci** 1996 Mar;50(3):63–7

Effect of bezafibrate on HDL with APO A–I and APO A–II and on HDL with APO A–I without APO A–II in hyperlipidaemic patients. Branchi A, et al. **Int J Clin Pharmacol Res** 1995;15(4):153–8

The effect of simvastatin on HDL cholesterol in hyperlipidemic patients. Evidence of a relationship with the changes in serum triglyceride level. Branchi A, et al. **Int J Clin Pharmacol Ther** 1996 Sep;34(9):384–9

The effect of substrate utilization, manipulated by nicotinic acid, on excess postexercise oxygen consumption. Trost S, et al. **Int J Sports Med** 1997 Feb;18(2):83–8

Cardioprotective and hypolipidemic effects of nisoldipine in the JCR:LA–cp rat. Russell JC, et al. **J Cardiovasc Pharmacol** 1997 May;29(5):586–92

Impaired growth hormone secretion in obese subjects is partially reversed by acipimox–mediated plasma free fatty acid depression. Cordido F, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):914–8

Inhibition of lipolysis stimulates whole body glucose production and disposal in normal postabsorptive subjects. Fery F, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):825–30

Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)–releasing hormone–mediated GH secretion in patients with Cushing's syndrome. Leal–Cerro A, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3165–8

Acipimox–mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH–releasing stimuli. Peino R, et al. **J Clin Endocrinol Metab** 1996 Mar; 81(3):909–13

Restoration of growth hormone (GH) response to GH–releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids. Pontiroli AE, et al. **J Clin Endocrinol Metab** 1996 Nov; 81(11):3998–4001

Research prospects with benfluorex. Ravel D, et al. **J Diabetes Complications** 1996 Sep–Oct;10(5):246–54 (56 ref.)

Hypolipidaemic effect of Myristica fragrans fruit extract in rabbits. Ram A, et al. **J Ethnopharmacol** 1996 Dec; 55(1):49–53

Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. Oberti F, et al. **J Hepatol** 1997 Jun; 26(6):1363–71

Malic enzyme gene in chick embryo hepatocytes in culture: clofibrate regulates responsiveness to triiodothyronine. Carlisle TL, et al. **J Lipid Res** 1996 Oct;37(10):2088–97

Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity. Hawke RL, et al. **J Lipid Res** 1997 Jun;38(6):1189–203

Role of the peroxisome proliferator–activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. Schoonjans K, et al. **J Lipid Res** 1996 May;37(5):907–25 (193 ref.)

In vitro efficacy of a compound derived from garlic against Pneumocystis carinii [letter] Abdullah TH. **J Natl Med Assoc** 1996 Nov;88(11):694, 704

Effects of cabbage leaf protein concentrate on the serum and liver lipid concentrations in rats. Igarashi K, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Apr;43(2):261–70

Correlation of pharmacological properties of a group of hypolipaemic drugs by molecular topology. Cercós–del–Pozo RA, et al. **J Pharm Pharmacol** 1996 Mar; 48(3):240–4

ACTH lowers serum lipids in steroid–treated hyperlipemic patients with kidney disease. Berg AL, et al. **Kidney Int** 1996 Aug;50(2):538–42

Differential inhibitory effects of garlic–derived organosulfur compounds on cholesterol biosynthesis in primary rat hepatocyte cultures. Gebhardt R, et al. **Lipids** 1996 Dec; 31(12):1269–76

Differential alterations of ethanolamine and choline phosphoglyceride metabolism by clofibrate and retinoic acid in human fibroblasts are not mediated by phorbol ester–sensitive protein kinase C. Mandla SG, et al. **Lipids** 1996 Jul;31(7):747–55

Effects of clofibrate on lipids and fatty acids of mouse liver. Pennacchiotti GL, et al. **Lipids** 1996 Feb;31(2):179–85

Effect of decreasing plasma free fatty acids by acipimox on hepatic glucose metabolism in normal rats. Lee KU, et al. **Metabolism** 1996 Nov;45(11):1408–14

Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels. Tanaka K, et al. **Metabolism** 1997 Apr; 46(4):355–8

Effects of clofibrate on flow cytometric populations in rat liver. Tomioka Y, et al. **Methods Find Exp Clin Pharmacol** 1996 Apr;18(3):189–95

Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats. Babu PS, et al. **Mol Cell Biochem** 1997 Jan; 166(1–2):169–75

Effect of high–fat cholesterol enriched diets on hypolipemic action of Oenothera paradoxa oil in rats. Part 1. Blood serum and liver lipids. Biernat J, et al. **Nahrung** 1997 Feb; 41(1):46–9

Effect of high–fat cholesterol enriched diets on hypolipemic action of Oenothera paradoxa oil in rats. Part 2. Blood serum and liver fatty acids. Grajeta H, et al. **Nahrung** 1997 Feb;41(1):50–2

Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation [letter] Fehrman–Ekholm I, et al. **Nephron** 1996;72(3):483

Altered hepatic metabolism of fatty acids in rats fed a hypolipidaemic drug, fenofibrate. Yamamoto K, et al. **Pharmacol Res** 1996 Jun;33(6):337–42

Studies on pyrazinoylguanidine. 2. Comparative drug and dose effects on glucose and lipid metabolism in streptozotocin–induced diabetic rats. A–Rahim YI, et al. **Pharmacology** 1996 Mar;52(3):145–52

Studies on pyrazinoylguanidine. 1. Characterization of metabolic effects in diabetic rats. A–Rahim YI, et al. **Pharmacology** 1996 Mar;52(3):135–44

Hypolipidemic effect of taurine in stroke–prone spontaneously hypertensive rats. Murakami S, et al. **Pharmacology** 1996 May;52(5):303–13

Stimulation of decreased lipoprotein lipase activity in the tumor–bearing state by the antihyperlipidemic drug bezafibrate. Nomura K, et al. **Surg Today** 1996;26(2):89–94

Effect of bezafibrate on hypercoagulability assessed by fluorogenic prothrombin time in hyperlipidemic patients with non–insulin–dependent diabetes mellitus. Yoshinari M, et al. **Thromb Res** 1997 Jun 15;86(6):443–51

Potent peroxisome proliferators inhibit beta–oxidation in the isolated perfused rat liver. Bojes HK, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):322–7

Differential effects of ciprofibrate on renal and hepatic cytochrome P450 2E1 expression. Zangar RC, et al. **Toxicol Appl Pharmacol** 1996 Nov;141(1):110–6

Comparative hypolipidaemic and peroxisomal effects of ciprofibrate, clofibric acid, and their respective difluorocyclopropyl and 4–fluoro–substituted analogues in

rat. Graham MJ, et al. **Xenobiotica** 1996 Jul;26(7):695–707
Clofibric acid increases the undirectional chiral inversion of ibuprofen in rat liver preparations. Roy–de Vos M, et al. **Xenobiotica** 1996 Jun;26(6):571–82
[Pharmacology of hypolipidemic agents] Féry F, et al. **Rev Med Brux** 1997 Feb;18(1):26–31 (28 ref.) (Eng. Abstr.) **(Fre)**
[The mechanism of action of hypolipidemic drugs] Scheen AJ. **Rev Med Liege** 1997 Jun;52(6):445–6 **(Fre)**
[Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate] Fonseca FA, et al. **Arq Bras Cardiol** 1996 Jan;66(1):33–5 (Eng. Abstr.) **(Por)**
[Steryl cellosolves—regulators of cholesterol metabolism in isolated rabbit hepatocytes] Maliugin AV, et al. **Bioorg Khim** 1996 Aug;22(8):606–10 (Eng. Abstr.) **(Rus)**
[Mechanisms of pyrimidine derivatives systemic immunomodulating effect] Slabnov IuD, et al. **Eksp Klin Farmakol** 1997 May–Jun;60(3):65–7 (Eng. Abstr.) **(Rus)**
[Effects of eifitol on lipid metabolism in patients with clinically different ischemic heart diseases] Panchenko VM, et al. **Klin Med (Mosk)** 1997;75(3):39–41 **(Rus)**
[The effect of a new hypolipemic preparation fluvastatin (Lescol) on rheological indices and hemostatic parameters] Filippova VG, et al. **Ter Arkh** 1997;69(4):43–5 (Eng. Abstr.) **(Rus)**
[The clinical pharmacology and efficacy of statins] Sidorenko BA, et al. **Ter Arkh** 1996;68(9):80–4 (30 ref.) **(Rus)**
[Effect of docanol on the status of hemostasis and fibrinolysis systems, as well as lipid spectrum in patients with ischemic heart disease depending on the initial level of fibrinolytic activity] Liutova LV, et al. **Vopr Med Khim** 1996 Jan–Mar; 42(1):64–70 (Eng. Abstr.) **(Rus)**
[Hypolipidemic effect of sulfated polysaccharides] Ryzhenkov VE, et al. **Vopr Med Khim** 1996 Apr–Jun; 42(2):115–9 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Photodegradation of bezafibrate in aqueous media. Studies of its in vitro phototoxicity. Canudas N, et al. **Arzneimittelforschung** 1996 Jul;46(7):694–7

THERAPEUTIC USE

Aggressive medical therapy for the prevention and treatment of coronary artery disease. Malloy MJ, et al. **Adv Intern Med** 1997;42:1–38 (113 ref.)
Lipid–lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross–over study. Akçiçek F, et al. **Adv Perit Dial** 1996;12:261–5
Current and future therapeutic approaches to hyperlipidemia. Farmer JA, et al. **Adv Pharmacol** 1996;35:79–114 (125 ref.)
Safety and efficacy of long–term statin–fibrate combinations in patients with refractory familial combined hyperlipidemia. Athyros VG, et al. **Am J Cardiol** 1997 Sep 1;80(5):608–13
Effects of intensive diet and exercise intervention in patients taking cholesterol–lowering drugs. Barnard RJ, et al. **Am J Cardiol** 1997 Apr 15;79(8):1112–4
Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Davidson MH, et al. **Am J Cardiol** 1997 Sep 15;80(6):797–8
Use of lipid–lowering medication in patients with acute myocardial infarction (Worcester Heart Attack Study). Goldberg RJ, et al. **Am J Cardiol** 1997 Apr 15;79(8):1095–7
Effect of simvastatin on ejection fraction in cardiac transplant recipients. Jenkins GH, et al. **Am J Cardiol** 1996 Dec 15; 78(12):1453–6
Lipid–lowering therapy and long–term survival in heart transplantation. Stapleton DD, et al. **Am J Cardiol** 1997 Sep 15;80(6):802–5
Pathogenic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis. Ganz P, et al. **Am J Med** 1996 Oct 8;101(4A):4A10S–16S (87 ref.)
Fibrates and HDL cholesterol [letter; comment] Murphy MJ, et al. **Ann Clin Biochem** 1997 Jan;34 (Pt 1):114. Comment on: Ann Clin Biochem 1996 Mar;33 (Pt 2):159–61.
Hypolipidemic drugs in coronary artery disease [letter; comment] Bittar GB. **Ann Intern Med** 1997 Jun 1; 126(11):916–7. Comment on: Ann Intern Med 1996 Oct 1;125(7):529–40.
Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non–insulin–dependent diabetes? Need for trial evidence. Pyörälä K, et al. **Ann Med** 1996 Aug;28(4):357–62 (35 ref.)
Lipoprotein disorders in women: which women are the best candidates for hormone replacement therapy? Plushner SL. **Ann Pharmacother** 1997 Jan;31(1):98–107 (32 ref.)
Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacy practitioners. Shibley MC, et al. **Ann Pharmacother** 1997 Jun;31(6):713–9
Role of Lp A–I and Lp A–I/A–II in cholesteryl ester transfer protein–mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy. McPherson R, et al. **Arterioscler Thromb Vasc Biol** 1996 Nov;16(11):1340–6
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease. Parhofer KG, et al. **Artif Organs** 1996 Apr;20(4):286–91 (40 ref.)
Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non–human primates which model human lesion types I–VII. Fincham JE, et al. **Arzneimittelforschung** 1996 May;46(5):519–25
Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia. Hailer S, et al. **Arzneimittelforschung** 1996 Sep;46(9):879–83
The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy. Chapman MJ, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S21–8 (33 ref.)
Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia. Knipscheer HC, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S75–81
A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Nestel P, et al. **Atherosclerosis** 1997 Mar 21;129(2):231–9
Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. Raal FJ, et al. **Atherosclerosis** 1997 Feb 28;129(1):97–102
Antiatherogenic effects of long–term benfluorex treatment in male insulin resistant JCR:LA–cp rats. Russell JC, et al. **Atherosclerosis** 1997 Jul 25;132(2):187–97
Effects of regular and extended–release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels. Schaefer EJ, et al. **Atherosclerosis** 1996 Nov 15;127(1):113–22
What targets should lipid–modulating therapy achieve to optimise the prevention of coronary heart disease? Thompson GR. **Atherosclerosis** 1997 May;131(1):1–5 (26 ref.)
Efficacy and safety of ciprofibrate in hyperlipoproteinaemias. Turpin G, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S83–7 (29 ref.)
Controversies in hyperlipidaemia: issues resolved? [editorial] Cramb R. **Br J Hosp Med** 1996 Dec 11–1997 Jan 14; 56(11):566–7 (8 ref.)
Lipid–lowering drugs and mortality [letter] Corrigan F. **Br J Psychiatry** 1997 Mar;170:289
Lipid–lowering therapy after myocardial infarction: is it worth it? [editorial; comment] Warnica JW. **Can Med Assoc J** 1997 Apr 1;156(7):1005–7 (13 ref.). Comment on: Can Med Assoc J 1997 Apr 1;156(7):991–7.
Chemoprevention of radiation–induced mammary tumors in rats by bezafibrate administered together with diethylstilbestrol as a promoter. Inano H, et al. **Carcinogenesis** 1996 Dec;17(12):2641–6
Lipid lowering: the case for identifying and treating the high–risk patient. Pearson TA, et al. **Cardiol Clin** 1996 Feb; 14(1):117–30 (71 ref.)
Drugs that delay the progression of coronary atherosclerosis. Ferraro–Borgida M, et al. **Cardiologia** 1997 Feb; 42(2):149–61 (67 ref.)
Targeted prevention of coronary artery disease: pharmacological considerations in multimodality treatment. Shviro I, et al. **Cardiology** 1996 Nov–Dec;87(6):469–75 (38 ref.)
Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. de Faire U, et al. **Cardiovasc Drugs Ther** 1997 May;11 Suppl 1:257–63 (44 ref.)
A head–to–head comparison of the cost effectiveness of HMG–CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Perreault S, et al. **Cardiovasc Drugs Ther** 1997 Jan;10(6):787–94
Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single–blind, randomized, and cross–over study. Jen SL, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Apr; 59(4):217–24
Phytochemicals and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Howard BV, et al. **Circulation** 1997 Jun 3; 95(11):2591–3 (25 ref.)
Improved glucose tolerance after effective lipid–lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis? Panz VR, et al. **Clin Endocrinol (Oxf)** 1997 Mar;46(3):365–8
Lipid modifying agents: mechanisms of action and reduction of cardiovascular disease. Scott R. **Clin Exp Pharmacol Physiol** 1997 May;24(5):A26–8 (27 ref.)
Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure. Thompson CH, et al. **Clin Nephrol** 1996 Jun;45(6):386–9
Lipid–lowering for prevention of coronary heart disease: what policy now? [published erratum appears in Clin Sci (Colch) 1996 Dec;91(6):773–4] [see comments] Ul Haq I, et al. **Clin Sci (Colch)** 1996 Oct;91(4):399–413. Comment in: Clin Sci (Colch) 1997 Apr;92(4):431–2.
Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia. Dujovne CA, et al. **Clin Ther** 1996 May–Jun;18(3):392–410; discussion 391 (58 ref.)
Effects of antihyperlipidemic drugs and diet plus exercise therapy in the treatment of patients with moderate hypercholesterolemia. Nomura H, et al. **Clin Ther** 1996 May–Jun;18(3):477–82
A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric–acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT Study. Lopid Coronary Angiography Trial. Syvänne M, et al. **Control Clin Trials** 1997 Feb;18(1):93–119
New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Crouse JR 3rd. **Coron Artery Dis** 1996 Apr;7(4):321–6 (47 ref.)
Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Kontopoulos AG, et al. **Coron Artery Dis** 1996 Nov;7(11):843–50
Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease. Suefuji H, et al. **Coron Artery Dis** 1996 Feb;7(2):167–72
Therapy and clinical trials. **Curr Opin Lipidol** 1995 Dec; 6(6):B77–82
Reduction of coronary events: evidence from clinical trials [editorial] Gotto AM Jr. **Curr Opin Lipidol** 1995 Dec; 6(6):345–7
Effects of lipid–lowering therapy on total and coronary mortality. Holme I. **Curr Opin Lipidol** 1995 Dec;6(6):374–8 (30 ref.)
Trials of lipid–lowering therapy in primary prevention of coronary heart disease. Jones PH. **Curr Opin Lipidol** 1995 Dec;6(6):365–8 (12 ref.)
Angiographic trials of lipid–lowering therapy: an update. Mancini GB. **Curr Opin Lipidol** 1995 Dec;6(6):379–85 (13 ref.)
Trials of the effects of drugs and hormones on lipids and lipoproteins. Mann WA, et al. **Curr Opin Lipidol** 1995 Dec; 6(6):354–9 (52 ref.)
Trials of lipid–lowering therapy in secondary prevention of coronary heart disease. Olsson AG, et al. **Curr Opin Lipidol** 1995 Dec;6(6):369–73 (20 ref.)
Lipid–lowering treatment: effects on endothelial dysfunction. Rubba P, et al. **Curr Opin Lipidol** 1995 Dec;6(6):348–53 (61 ref.)
Therapy and clinical trials. Seed M. **Curr Opin Lipidol** 1996 Oct;7(5):U168–72
Selection of appropriate type and intensity of lipid–lowering therapy. Tikkanen MJ. **Curr Opin Lipidol** 1995 Dec; 6(6):360–4 (39 ref.)
Statins and fibrates in the management of diabetic dyslipidemia [editorial; comment] Durrington P. **Diabet Med** 1997 Jul;14(7):513–6 (26 ref.). Comment on: Diabet Med 1997 Jul;14(7):564–70.
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM [see comments] Jeck T, et al. **Diabet Med** 1997 Jul;14(7):564–70. Comment in: Diabet Med 1997 Jul;14(7):513–6.
The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease [editorial; comment] Haffner SM. **Diabetes Care** 1997 Apr;20(4):469–71. Comment on: Diabetes Care 1997 Apr;20(4):614–20.
Glycosaminoglycans delay the progression of nephropathy in NIDDM. Solini A, et al. **Diabetes Care** 1997 May; 20(5):819–23
Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control. Shih KC, et al. **Diabetes Res Clin Pract** 1997 May; 36(2):113–9
The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. Steiner G. **Diabetologia** 1996 Dec;39(12):1655–61
Choosing the right lipid–regulating agent. A guide to selection. Farmer JA, et al. **Drugs** 1996 Nov;52(5):649–61 (59 ref.)
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia [published erratum appears in Drugs 1997 Jan;53(1):188] Goa KL, et al. **Drugs** 1996 Nov;52(5):725–53 (187 ref.)
Secondary preventive potential of lipid–lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). de Faire U, et al. **Eur Heart J** 1996 Dec;17 Suppl F:37–42 (28 ref.)
Randomized placebo–controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Mitropoulos KA, et al. **Eur Heart J** 1997 Feb;18(2):235–41
Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low–density–lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia. Rašlová K, et al. **Eur J Clin Pharmacol** 1997;52(2):101–6
Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia. Feussner G, et al. **Eur J Med Res** 1997 Apr 21;2(4):165–8
Drug therapy of severe hypercholesterolemia. Weizel A, et al. **Eur J Med Res** 1997 Jun 16;2(6):265–9 (40 ref.)
Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study. Fasching P, et al. **Horm Metab Res** 1996 May;28(5):230–6
The case for aggressive lipid regulation. Gotto AM Jr.

Hosp Pract (Off Ed) 1997 Feb 15;32(2):145–9, 155–6 (17 ref.)

A study of effect of guggulsterone on hyperlipidemia of secondary glomerulopathy. Beg M, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):237–40

Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL–apheresis. Schiel R, et al. **Int J Artif Organs** 1995 Dec;18(12):786–93

Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia. Fogari R, et al. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):61–4

Women with heart disease may need aggressive treatment for high cholesterol [news] **Int J Fertil Womens Med** 1997 May–Jun;42(3):182

Effects of initial BMI and on–treatment weight change on the lipid–lowering efficacy of fibrates. Muls E, et al. **Int J Obes Relat Metab Disord** 1997 Feb;21(2):155–8

The impact of thiazide diuretics on the initiation of lipid–reducing agents in older people: a population–based analysis. Monane M, et al. **J Am Geriatr Soc** 1997 Jan; 45(1):71–5

Lipid management: an opportunity for pharmacy service. Schoen MD. **J Am Pharm Assoc (Wash)** 1996 Oct; NS36(10):609–19; quiz 619–21 (21 ref.)

Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study. Hodis HN. **J Cardiovasc Pharmacol** 1995;25 Suppl 4:S25–31

Editorial on CHD. Riesen WF. **J Cardiovasc Pharmacol** 1995; 25 Suppl 4:S1–2 (30 ref.)

Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia. Asplund–Carlson A. **J Cardiovasc Risk** 1996 Aug;3(4):385–90

Recent trends in the consumption of lipid–lowering drugs in Finland. Martikainen J, et al. **J Clin Epidemiol** 1996 Dec; 49(12):1453–57

Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. Bruckert E, et al. **J Clin Pharm Ther** 1996 Apr;21(2):89–94

Insulin resistance and diabetes mellitus. DeFronzo RA, et al. **J Diabetes Complications** 1996 Sep–Oct;10(5):243–5 (28 ref.)

Therapeutic benefit of benfluorex in type II diabetic patients treated with sulfonylureas. Stucci N, et al. **J Diabetes Complications** 1996 Sep–Oct;10(5):267–73

Therapeutic effect of benfluorex in type II diabetic patients on diet regimen alone. Velussi M, et al. **J Diabetes Complications** 1996 Sep–Oct;10(5):261–6

Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization [see comments] O'Connor PJ, et al. **J Fam Pract** 1997 May; 44(5):462–7. Comment in: J Fam Pract 1997 May;44(5):449–50.

Endothelial function as an end–point in interventional trials: concepts, methods and current data. Lüscher TF, et al. **J Hypertens Suppl** 1996 Sep;14(2):S111–9; discussion S119–21 (82 ref.)

Primary prevention of cardiovascular disease: implications of lipid–lowering trials. Pedersen TR. **J Hypertens Suppl** 1996 Dec;14(5):S195–200 (47 ref.)

Meta–analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. Gaddi A, et al. **J Int Med Res** 1996 Sep–Oct;24(5):389–406

Glycosaminoglycans as a possible tool for micro– and macroalbuminuria in diabetic patients. A pilot study. Sorrenti G, et al. **J Int Med Res** 1997 Mar–Apr;25(2):81–6

Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease [see comments] Carlsen SM, et al. **J Intern Med** 1996 Mar;239(3):227–33 . Comment in: J Intern Med 1996 Jul;240(1):46–7.

The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. Hoogerbrugge N, et al. **J Intern Med** 1997 Feb;241(2):151–5

Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects. Jones PH, et al. **J Lipid Res** 1996 Jun;37(6):1298–308

Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. Sanjad SA, et al. **J Pediatr** 1997 Mar;130(3):470–4

Treatment of hypercholesterolemia in women: equality, effectiveness, and extrapolation of evidence [editorial; comment] Pearson TA, et al. **JAMA** 1997 Apr 23–30; 277(16):1320–1. Comment on: JAMA 1997 Apr 23–30;277(16):1281–6.

Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group [see comments] Schrott HG, et al. **JAMA** 1997 Apr 23–30; 277(16):1281–6. Comment in: JAMA 1997 Apr 23–30;277(16):1320–1. Comment in: JAMA 1997 Aug 27;278(8):633–4.

Familial hyperchylomicronaemia [letter; comment] Wierzbicki AS, et al. **Lancet** 1996 Nov 30;348(9040):1524–5 . Comment on: Lancet 1996 Sep 21;348(9030):794.

Antioxidant and triglyceride–lowering effects of vitamin E associated with the prevention of abnormalities in the reactivity and morphology of aorta from streptozotocin–diabetic rats. Antioxidants in Diabetes–Induced Complications (ADIC) Study Group. Karasu C, et al. **Metabolism** 1997 Aug;46(8):872–9

NHF guidelines on the management of dyslipidaemia [letter] Mann J, et al. **N Z Med J** 1996 Sep 13;109(1029):345

The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure. Irish AB, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2223–8

Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients [letter] Ok E, et al. **Nephron** 1996;73(3):491–2

Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. Samuelsson O, et al. **Nephron** 1997; 75(3):286–94

Effects of gemfibrozil or simvastatin on apolipoprotein–B–containing lipoproteins, apolipoprotein–CIII and lipoprotein(a) in familial combined hyperlipidaemia. Bredie SJ, et al. **Neth J Med** 1996 Aug; 49(2):59–67

Effect of pharmaceutical care on optimum colestipol treatment in elderly hypercholesterolemic veterans. Konzem SL, et al. **Pharmacotherapy** 1997 May–Jun; 17(3):576–83

Comparative efficacy and safety of ciprofibrate and sustained–release bezafibrate in patients with type II hyperlipidaemia. Betteridge DJ, et al. **Postgrad Med J** 1996 Dec;72(854):739–43

Current approaches to stable angina. Jackson G. **Practitioner** 1996 Nov;240(1568):642–4, 647–8

Dose–dependent effect of niceritrol on plasma lipoprotein–a. Teramoto T, et al. **Scand J Clin Lab Invest** 1996 Jul; 56(4):359–65

Management of hyperlipidaemia: postscript. Sum CF, et al. **Singapore Med J** 1995 Oct;36(5):538

Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Bröijersén A, et al. **Thromb Haemost** 1996 Aug;76(2):171–6

Novel lipid–lowering properties of Vaccinium myrtillus L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate. Cignarella A, et al. **Thromb Res** 1996 Dec 1;84(5):311–22

Protection by clofibrate against acetaminophen hepatotoxicity in male CD–1 mice is associated with an early increase in biliary concentration of acetaminophen–glutathione adducts. Manautou JE, et al. **Toxicol Appl Pharmacol** 1996 Sep;140(1):30–8

[Clinical study on the effect of shuxuening tablet in treatment of coronary heart disease] Chen K, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Jan; 16(1):24–6 (Eng. Abstr.) **(Chi)**

[Hypolipemic agents and prevention of coronary disease] Chadarevian R, et al. **Ann Cardiol Angeiol (Paris)** 1997 Feb; 46(2):89–98 (30 ref.) (Eng. Abstr.) **(Fre)**

[Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents] Aumont MC, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89 Spec No 3:39–41 (Eng. Abstr.) **(Fre)**

[Benfluorex (Mediator) and non–insulin–dependent diabetes] Ravel D. **Journ Annu Diabetol Hotel Dieu** 1997;:335–44 (19 ref.) **(Fre)**

[Nutrition in patients treated with antilipemic agents. Survey of 337 patients] Bernard MC, et al. **Presse Med** 1997 Apr 19;26(13):598–602 (13 ref.) (Eng. Abstr.) **(Fre)**

[Dyslipidemia and thrombosis: what role for therapeutics?] Ambrosi P, et al. **Rev Med Interne** 1997;18 Suppl 2:94s–95s **(Fre)**

[Hypolipidemic agents. Groupe de Travail et Groupe de Lecture de la Conférence de Consensus Hypolipidémiants] **Therapie** 1996 Nov–Dec;51(6):623–6 (0 ref.) **(Fre)**

[Gemfibrozil in the elderly. Effects on lipid metabolism] Brosche T, et al. **Fortschr Med** 1996 May 10;114(13):157–60 (Eng. Abstr.) **(Ger)**

[Cholesterol and statins (letter)] Ferrari M. **G Ital Cardiol** 1997 May;27(5):499–500 **(Ita)**

[Lipid factors and evolution of the atherosclerotic plaque: review of recent trials] Scardi S. **G Ital Cardiol** 1996 Dec; 26(12):1481–93 (Eng. Abstr.) **(Ita)**

[Effectiveness and tolerability of heparan sulfate in the treatment of superficial thrombophlebitis. Controlled clinical study vs sulodexide] Messa G, et al. **Minerva Cardioangiol** 1997 Apr;45(4):147–53 (Eng. Abstr.) **(Ita)**

[Pharmacologic treatment of lipid metabolism disorders] Gmiński J. **Wiad Lek** 1996;49(7–12):173–81 (0 ref.) (Eng. Abstr.) **(Pol)**

[Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study] dos Santos JE, et al. **Arq Bras Cardiol** 1996 Dec;67(6):419–22 (Eng. Abstr.) **(Por)**

[The possible means for the pharmacological correction of lipid metabolic disorders in atherosclerosis] Piskun RP, et al. **Eksp Klin Farmakol** 1997 Mar–Apr;60(2):78–85 (128 ref.) (Eng. Abstr.) **(Rus)**

[The hypolipidemic and antiatherosclerotic properties of the ammonium salt of glycyrrhetic acid and of 18–dehydroglycyrrhetic acid] Zakirov UB, et al. **Eksp Klin Farmakol** 1996 Sep–Oct;59(5):53–5 (Eng. Abstr.) **(Rus)**

[Experience in the use of eiconol (a complex of unsaturated fatty acids) in non–insulin–dependent diabetes mellitus] Lazebnik LB, et al. **Klin Med (Mosk)** 1996;74(3):29–33 (Eng. Abstr.) **(Rus)**

[The possible hypolipidemic action of the dietary fiber from barley meal] Iatskovskaia NIa, et al. **Lik Sprava** 1995 Sep–Dec;(9–12):106–9 (Eng. Abstr.) **(Rus)**

[A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia] Kukharchuk VV, et al. **Ter Arkh** 1996;68(6):58–61 (Eng. Abstr.) **(Rus)**

[The characteristics of the hypolipidemic effect of Mevacor with its permanent multiyear use] Lipovetskiĭ BM. **Ter Arkh** 1996;68(12):72–5 (Eng. Abstr.) **(Rus)**

[The clinical pharmacology and efficacy of statins] Sidorenko BA, et al. **Ter Arkh** 1996;68(9):80–4 (30 ref.) **(Rus)**

[Comparative evaluation of hypolipidemic effects of omega–3 polyunsaturated acids and lipostabil] Pogozheva AV, et al. **Vopr Pitan** 1996;(4):31–3 (Eng. Abstr.) **(Rus)**

[The validity of 6 indirect methods for assessing compliance with pharmacological treatment in dyslipidemias] Piñeiro F, et al. **Aten Primaria** 1997 May 31;19(9):465–8 (Eng. Abstr.) **(Spa)**

[Do the patients we treat with hypolipemic drugs have a coronary risk?] Vilaseca Canais J, et al. **Aten Primaria** 1997 Jun 15;20(1):49–53 (Eng. Abstr.) **(Spa)**

[Should lipid–lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments against] Brotons Cuixart C, et al. **Rev Esp Cardiol** 1996 Jul;49(7):486–91 **(Spa)**

[Should lipid–lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments for] de Teresa Galván E, et al. **Rev Esp Cardiol** 1996 Jul;49(7):483–5 **(Spa)**

TOXICITY

Oxysterols and human endothelial cell function. Taylor AC, et al. **Biochem Soc Trans** 1996 May;24(2):178S

Modulation of cholestane–3 beta,5 alpha,6 beta–triol toxicity by butylated hydroxytoluene, alpha–tocopherol and beta–carotene in newborn rat kidney cells in vitro. Wilson AM, et al. **Br J Nutr** 1997 Sep;78(3):479–92

Method for determining whether the number of hepatocytes in rat liver is increased after treatment with the peroxisome proliferator gemfibrozil. Carthew P, et al. **J Appl Toxicol** 1997 Jan–Feb;17(1):47–51

Of rodents, humankind, and cholesterol. Lindenmayer JM. **Med Health R I** 1996 Apr;79(4):148–50

Effects of propionic acid and pravastatin on HMG–CoA reductase activity in relation to forestomach lesions in the rat. Bueld JE, et al. **Pharmacol Toxicol** 1996 Apr; 78(4):229–34

[Pleiotrophic peroxisome induction by hypolipidemic agents in primates and rodents] Stangl H, et al. **Wien Klin Wochenschr** 1996;108(2):40–4 (56 ref.) (Eng. Abstr.) **(Ger)**

[Investigation of diabetogenic action of xanthurenic acid] Meĭramov GG, et al. **Biull Eksp Biol Med** 1997 Jun; 123(6):669–72 **(Rus)**

ANTILYMPHOBLAST GLOBULINS see **ANTILYMPHOCYTE SERUM**

ANTILYMPHOCYTE ANTIBODIES see **ANTILYMPHOCYTE SERUM**

ANTILYMPHOCYTE GLOBULIN see **ANTILYMPHOCYTE SERUM**

ANTILYMPHOCYTE SERUM

Long–term follow–up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin [letter] Storb R, et al. **Blood** 1997 May 15;89(10):3890–1

Trapidil modifies mesangial cell proliferation and collagen accumulation in anti–thymocyte serum (ATS)–induced glomerulonephritis. Razzaque MS, et al. **J Comp Pathol** 1996 Feb;114(2):175–82

Suppression of mesangial–cell proliferation by trapidil in glomerulonephritis induced by anti–thymocyte serum in rats. Razzaque MS, et al. **J Int Med Res** 1995 Nov–Dec; 23(6):458–66

Effect of anti–thymocyte serum on acquisition of resistance to infestation by Rhipicephalus appendiculatus larvae in rabbits. Binta MG, et al. **Onderstepoort J Vet Res** 1996 Sep;63(3):213–6

ADMINISTRATION & DOSAGE

Treatment of aplastic anemia with antithymocyte globulin, cyclosporin A, methylprednisolone, danazol and recombinant human granulocyte–colony stimulating factor. Shichino H, et al. **Acta Paediatr Jpn** 1996 Dec;38(6):644–7

Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA–matched siblings in children with severe aplastic anemia. Azuma E, et al. **Bone Marrow Transplant** 1997 Jun; 19(11):1085–7

Dose titration during anti–thymocyte globulin therapy: monitoring by CD3 count or total lymphocyte count? Gorrie M, et al. **Clin Lab Haematol** 1997 Mar;19(1):53–6

Treatment of recurrent rejection in heart transplantation: cytolytic therapy or bolus steroids? Hausen B, et al.

Eur J Cardiothorac Surg 1996;10(10):905–10; discussion 910–1

Early hemopoietic progenitors in the peripheral blood of patients with severe aplastic anemia (SAA) after treatment with antilymphocyte globulin (ALG), cyclosporin-A and G-CSF. Bacigalupo A, et al. **Haematologica** 1997 Mar-Apr;82(2):133–7

One course versus two courses of antithymocyte globulin for the treatment of severe aplastic anemia in children. Matloub YH, et al. **J Pediatr Hematol Oncol** 1997 Mar-Apr;19(2):110–4

Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Sykes M, et al. **Nat Med** 1997 Jul;3(7):783–7

Clinical significance of T cell monitoring during antithymocyte globulin induction in renal transplantation. Thervet E, et al. **Transplant Proc** 1997 Aug;29(5):2330–1

Prevention of graft-versus-host disease by intrathymic injection of recipient-type splenocytes into donor. Vaidya S, et al. **Transplantation** 1996 Nov 15;62(9):1366–8

[Mycophenolate mofetil (MMF)/tacrolinus/single shot ATG versus azathioprine/cyclosporine (CsA)/ATG in immunosuppression after pancreas-/kidney transplantation--results of a prospective randomized study] Büsing M, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:157–61 **(Ger)**

[Quadruple induction therapy after liver transplantation with ATG or interleukin-2 receptor antibody BT563. A prospective randomized study] Langrehr JM, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:673–6 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Liver function abnormality following treatment with antithymocyte globulin for aplastic anaemia. Killick SB, et al. **Bone Marrow Transplant** 1997 Feb;19(3):249–51

De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Jonas S, et al. **Cancer** 1997 Sep 15;80(6):1141–50

ATGAM associated coagulopathy in renal transplant patients: a report of two unusual cases. Trivedi HS, et al. **Int J Artif Organs** 1996 Aug;19(8):448–50

ANALYSIS

Anti-ribosomal and 'P-peptide'-specific autoantibodies bind to T lymphocytes [see comments] Stafford HA, et al. **Clin Exp Immunol** 1997 Jul;109(1):12–9. Comment in: Clin Exp Immunol 1997 Jul;109(1):1–3.

BIOSYNTHESIS

Humoral mechanisms in T cell vaccination: induction and functional characterization of anti-lymphocytic autoantibodies. Herkel J, et al. **J Autoimmun** 1997 Apr; 10(2):137–46

BLOOD

Donor-specific HLA antibodies after transplantation are associated with deterioration in cardiac function. Leech SH, et al. **Clin Transplant** 1996 Dec;10(6 Pt 2):639–45

Effect of human recombinant erythropoietin therapy on panel reactive antibodies in chronic dialysis patients. Friedlaender MM, et al. **Isr J Med Sci** 1996 Sep;32(9):730–6

Donor-specific anti-human leukocyte antigen class I antibodies after implantation of cardiac valve allografts. Hoekstra F, et al. **J Heart Lung Transplant** 1997 May; 16(5):570–2

CHEMISTRY

Unexpected reaction of anti-H-2d serum with thymic lymphoma cells derived from transgenic B6-H-2b TCR anti-HY/Db mice. Matuszyk J, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(2-3):103–7

Humoral mechanisms in T cell vaccination: induction and functional characterization of anti-lymphocytic autoantibodies. Herkel J, et al. **J Autoimmun** 1997 Apr; 10(2):137–46

A new murine lymphocytotoxic monoclonal antibody recognizing HLA-A2, -A28 and -A9. Mizuno S, et al. **Tissue Antigens** 1996 Sep;48(3):224–7

In vitro comparison of cytokine release from antithymocyte serum and OKT3. Inhibition with soluble and microencapsulated neutralizing antibodies. Oettinger CW, et al. **Transplantation** 1996 Dec 15;62(11):1690–3

IMMUNOLOGY

Anti-ribosomal and 'P-peptide'-specific autoantibodies bind to T lymphocytes [see comments] Stafford HA, et al. **Clin Exp Immunol** 1997 Jul;109(1):12–9. Comment in: Clin Exp Immunol 1997 Jul;109(1):1–3.

Are anti-ribosomal P protein antibodies a type of anti-lymphocyte antibody? [editorial; comment] Winfield JB. **Clin Exp Immunol** 1997 Jul;109(1):1–3. Comment on: Clin Exp Immunol 1997 Jul;109(1):12–9.

Lymphocytotoxic antibodies in Israeli patients with rheumatoid arthritis. Livneh A, et al. **Isr J Med Sci** 1997 Jan;33(1):30–5

CD44 in glomerulonephritis: expression in human renal biopsies, the Thy 1.1 model, and by cultured mesangial cells. Roy-Chaudhury P, et al. **Kidney Int** 1996 Jul; 50(1):272–81

Prostaglandin E1 inhibits collagen expression in anti-thymocyte antibody-induced glomerulonephritis: possible role of TGF beta. Schneider A, et al. **Kidney Int** 1996 Jul;50(1):190–9

Characterization of anti-thymoglobulin, anti-Atgam and anti-OKT3 IgG antibodies in human serum with an 11-min ELISA. Regan J, et al. **Transpl Immunol** 1997 Mar; 5(1):49–56

METABOLISM

Anti-lymphocyte autoantibodies in systemic lupus erythematosus. Winfield JB, et al. **Trans Am Clin Climatol Assoc** 1996;108:127–35 (35 ref.)

PHARMACOLOGY

Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Guérette B, et al. **Hum Gene Ther** 1996 Aug 1;7(12):1455–63

Redirecting circulating antibodies via ligand-hapten conjugates eliminates target cells in vivo. Lussow AR, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):257–65

Morphine modulates mesangial immunoglobulin G uptake in rats with antithymocyte serum-induced mesangial cell injury. Singhal PC, et al. **Nephron** 1996;74(1):197–203

Effect of variable doses of antilymphocyte serum on T cell depletion and cardiac allograft survival. Hylkema MN, et al. **Transplant Proc** 1997 May;29(3):1719–20

Bromocriptine prevents the immunosuppression induced in mice by anti-lymphocytic antiserum. Rosso di San Secondo VE, et al. **Transplant Proc** 1996 Dec;28(6):3193–5

PHYSIOLOGY

Human pregnancy serum suppresses the proliferative response of lymphocytes to autologous PHA-activated T lymphoblasts [see comments] Wolf-Levin R, et al. **Am J Reprod Immunol** 1996 Feb;35(2):63–9. Comment in: Am J Reprod Immunol 1997 Feb;37(2):212.

THERAPEUTIC USE

Dramatic efficacy of antithymocyte globulins in childhood EBV-associated haemophagocytic syndrome [letter] Perel Y, et al. **Acta Paediatr** 1997 Aug;86(8):911

Antithymocyte immunoglobulin in severe aplastic anemia and bone marrow transplantation. Colby C, et al. **Ann Pharmacother** 1996 Oct;30(10):1164–74 (76 ref.)

Monitoring antithymocyte globulin in renal transplantation. Clark K. **Ann R Coll Surg Engl** 1996 Nov;78(6):536–40 (22 ref.)

Rejection of the second allogeneic graft in a patient with severe aplastic anemia reversed by antilymphocyte globulin and donor lymphocyte infusions. Ljungman P, et al. **Bone Marrow Transplant** 1996 Dec;18(6):1179–81

Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria. Paquette RL, et al. **Br J Haematol** 1997 Jan;96(1):92–7

Mechanism of action of antithymocyte globulin in the treatment of aplastic anaemia: in vitro evidence for the presence of immunosuppressive mechanism. Teramura M, et al. **Br J Haematol** 1997 Jan;96(1):80–4

Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Biesma DH, et al. **Cancer** 1997 Apr 15; 79(8):1548–51

Dose titration during anti-thymocyte globulin therapy: monitoring by CD3 count or total lymphocyte count? Gorrie M, et al. **Clin Lab Haematol** 1997 Mar;19(1):53–6

The influence of the immunosuppressants OKT3 and ATG on immunological parameters. Neumann MC, et al. **Clin Nephrol** 1996 May;45(5):345–8

Single-center analysis of 468 first cadaveric kidney allografts with a uniform ATG-CsA sequential therapy. Giral M, et al. **Clin Transpl** 1996;:257–64

Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Cantarovich M, et al. **Clin Transplant** 1997 Aug; 11(4):316–21

Comparison of two antilymphocyte globulins replacing cyclosporin A after first kidney allotransplantation and prolonged graft ischemia. Gantenbein H, et al. **Clin Transplant** 1996 Aug;10(4):384–5

Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin. Guttmann RD, et al. **Clin Transplant** 1997 Jun;11(3):185–92

Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation. McVicar JP, et al. **Clin Transplant** 1997 Aug;11(4):328–33

Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience. Malinow L, et al. **Clin Transplant** 1996 Jun;10(3):237–42

Anti-thymocyte globulin treatment of a patient for paroxysmal nocturnal haemoglobinuria-aplastic anaemia syndrome: complement activation and transient decrease of the PNH clone. Ebenbichler CF, et al. **Immunobiology** 1996-97;196(5):513–21

Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction. Tsamandas AC, et al. **J Heart Lung Transplant** 1997 Jul;16(7):723–34

Antithymocyte globulin for a patient with systemic lupus erythematosus complicated by severe pancytopenia. Morishita Y, et al. **J Int Med Res** 1997 Jul-Aug; 25(4):219–23

Prevention and treatment of experimental autoimmune myasthenia gravis with anti-rabbit thymocyte serum and gammaglobulin in rabbits. Scelsa S, et al. **Pathobiology** 1995;63(3):168–74

Plasma exchange in steroid and anti-thymocyte globulin resistant allograft rejection in children. Nijsten EW, et al. **Pediatr Nephrol** 1996 Oct;10(5):613–5

Late adjunctive therapy with single doses of rapamycin in skin-allografted mice treated with antilymphocyte serum and donor bone marrow cells. De Fazio SR, et al. **Transpl Immunol** 1996 Jun;4(2):105–12

Strain-dependent differences in prolongation of rat cardiac allograft survival after intrathymic injection of donor bone marrow and ALS treatment. Walker KG, et al. **Transpl Immunol** 1996 Jun;4(2):177–9

No tolerance induction with cryopreserved bone marrow cells after allogeneic kidney transplantation and antilymphocyte globulin in rhesus monkeys [letter] Hollander AA, et al. **Transpl Int** 1997;10(3):249–50

Steroid-resistant rejection in kidney-transplanted patients: is ATG treatment for three or ten days preferable? Olausson M, et al. **Transpl Int** 1996;9 Suppl 1:S38–40

Monitoring of ATG therapy by flow cytometry and lymphocyte counts in renal transplantation. Buchler M, et al. **Transplant Proc** 1996 Oct;28(5):2817–8

Reduction in the incidence of early rejection in cadaveric renal allograft recipients treated with ATGAM induction and sequential mycophenolate mofetil. Florence LS, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):313–4

Prospective randomized study of quadruple versus triple therapy in long-term kidney allografts. Fruchaud G, et al. **Transplant Proc** 1996 Oct;28(5):2819

Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients. Fukuuchi F, et al. **Transplant Proc** 1996 Oct;28(5):2808–9

A unique mechanism of tolerance by perioperative intrathymic injection of bone marrow cells with a short course of ALS and FK506 in the rat cardiac allograft model. Ito A, et al. **Transplant Proc** 1997 Feb-Mar; 29(1-2):1137–8

Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation. Kaden J, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):344–7

Serum erythropoietin and parathyroid hormone concentrations in kidney transplant patients during acute graft rejection. Kokot F, et al. **Transplant Proc** 1996 Dec; 28(6):3477–9

Interleukin-2 receptor antibody versus antithymocyte globulin as part of quadruple induction therapy after orthotopic liver transplantation: a randomized study. Langrehr JM, et al. **Transplant Proc** 1996 Dec;28(6):3204

Expression of dendritic cell markers on bone marrow cells in a fraction enriched for the ability to prolong skin allograft survival in ALS-treated murine recipients. Masli S, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1147–8

A prospective study on efficacy and tolerance of antithymocyte globulin Fresenius versus thymoglobuline Merieux after renal transplantation. Ourahma S, et al. **Transplant Proc** 1997 Aug;29(5):2427

Reduction of early rejection in adult liver transplantation with ATG induction therapy. Schulak J, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):555–6

Intrathymic spleen cell inoculation and ALS fails to induce tolerance to rat pancreas allografts. Schulak JA, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1070–1

Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants. Shaffer D, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):342–3

Effects of intrathymic tolerance on mouse heart and skin allograft acceptance. Tu Y, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1063–4

Tolerance for graft-versus-host disease by intrathymic injection of recipient-type splenocytes into donor. Vaidya S, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1073–5

Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow. Hale DA, et al. **Transplantation** 1997 Feb 15; 63(3):359–64

A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Hourmant M, et al. **Transplantation** 1996 Dec 15;62(11):1565–70

A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy

ANTILYMPHOCYTE SERUM

following orthotopic liver transplantation. Langrehr JM, et al. **Transplantation** 1997 Jun 27;63(12):1772–81

Antilymphocyte induction therapy in cadaver renal transplantation: a retrospective, multicenter United Network for Organ Sharing Study. Shield CF, et al. **Transplantation** 1997 May 15;63(9):1257–63

ANTIMALARIALS

Pyrimethamine–resistant Plasmodium falciparum parasites among Tanzanian children: a facility–based study using the polymerase chain reaction. Edoh D, et al. **Am J Trop Med Hyg** 1997 Sep;57(3):342–7

Antimalarial activity of nitric oxide: cytostasis and cytotoxicity towards Plasmodium falciparum. Taylor–Robinson AW. **Biochem Soc Trans** 1997 May; 25(2):262S

Malaria in Mvumi, central Tanzania and the in vivo response of Plasmodium falciparum to chloroquine and sulphadoxine pyrimethamine. Wakibara JV, et al. **East Afr Med J** 1997 Feb;74(2):69–71

Malaria as a reemerging disease. Krogstad DJ. **Epidemiol Rev** 1996;18(1):77–89 (143 ref.)

Chloroquine resistant falciparum malaria in the Andamans. Uppal SS, et al. **J Assoc Physicians India** 1995 Feb; 43(2):103–5

Response of Plasmodium Falciparum to chloroquine in Digboi area of Assam, India. Dutta P, et al. **J Commun Dis** 1996 Sep;28(3):212–4

Status of Plasmodium falciparum resistance to chloroquine in Orissa. Satpathy SK, et al. **J Commun Dis** 1997 Jun; 29(2):145–51

Antimalarial workshop. **J Rheumatol** 1997 Jul;24(7):1393–5 (13 ref.)

Clonal diversity in single isolates of Malaysian Plasmodium falciparum. Ang HH, et al. **Med Trop (Mars)** 1996; 56(4):349–51

Malaria initiative needs drug industry's backing [editorial] **Nature** 1997 Aug 21;388(6644):699

The dog did nothing in the night–time [letter] Marriott MS. **Nature** 1997 May 8;387(6629):119

State of the art of the production of the antimalarial compound artemisinin in plants. Van Geldre E, et al. **Plant Mol Biol** 1997 Jan;33(2):199–209 (101 ref.)

Intensive therapy for chloroquine poisoning. A review of 29 cases. McKenzie AG. **S Afr Med J** 1996 May;86(5 Suppl):597–9

Guinea Bissau: association of chloroquine resistance of Plasmodium falciparum with the Tyr86 allele of the multiple drug–resistance gene Pfmdr1 [letter; comment] Adagu IS, et al. **Trans R Soc Trop Med Hyg** 1996 Jan–Feb; 90(1):90–1. Comment on: Trans R Soc Trop Med Hyg 1995 Jul–Aug;89(4):436–7.

[Evaluation of the Ivory Coast sentinel surveillance system for antimalarial drug sensitivity] Diawara B, et al. **Med Trop (Mars)** 1996;56(4):352–6 (Eng. Abstr.) **(Fre)**

[Plasmodium falciparum type R1 resistance to quinine after returning from Ivory Coast (letter)] Carles M, et al. **Presse Med** 1996 Sep 28;25(28):1303 **(Fre)**

ADMINISTRATION & DOSAGE

Ex vivo antimalarial activity of proguanil combined with dapsone against cycloguanil–resistant Plasmodium falciparum isolates. Edstein MD, et al. **Acta Trop** 1997 Sep 10;66(3):127–35

Monotherapy with sodium artesunate for uncomplicated falciparum malaria in Thailand: a comparison of 5– and 7–day regimens. Looareesuwan S, et al. **Acta Trop** 1997 Sep 30;67(3):197–205

Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria. Looareesuwan S, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):613–7

A comparative clinical trial of sequential treatments of severe malaria with artesunate suppository followed by mefloquine in Thailand. Looareesuwan S, et al. **Am J Trop Med Hyg** 1997 Sep;57(3):348–53

Malaria in pregnancy: efficacy of a low dose of mefloquine in an area holoendemic for multi–drug resistant Plasmodium falciparum. Okeyeh JN, et al. **Ann Trop Med Parasitol** 1996 Jun;90(3):265–8

Atovaquone and proguanil for the treatment of malaria in Brazil. de Alencar FE, et al. **J Infect Dis** 1997 Jun; 175(6):1544–7

Lymphatic transport of halofantrine in the triple–cannulated anesthetized rat model: effect of lipid vehicle dispersion. Porter CJ, et al. **J Pharm Sci** 1996 Apr;85(4):351–6

Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. Porter CJ, et al. **J Pharm Sci** 1996 Apr; 85(4):357–61

Dosage for malaria treatment [letter; comment] Abramowicz. **Lancet** 1996 Nov 9;348(9037):1311; discussion 1311–2. Comment on: Lancet 1996 Aug 31;348(9027):621–2.

Dosage for malaria treatment [letter; comment] Krogstad DJ, et al. **Lancet** 1996 Nov 9;348(9037):1311; discussion 1311–2. Comment on: Lancet 1996 Aug 31;348(9027):621–2.

Dosage for malaria treatment [letter; comment] Sanford JP. **Lancet** 1996 Nov 9;348(9037):1311; discussion 1311–2. Comment on: Lancet 1996 Aug 31;348(9027):621–2.

Dosage for malaria treatment [letter; comment] White NJ, et al. **Lancet** 1996 Nov 9;348(9037):1312. Comment on: Lancet 1996 Aug 31;348(9027):621–2.

The use of antimalarials in combination with other disease modifying agents in RA—the British experience. Duncan MR, et al. **Lupus** 1996 Jun;5 Suppl 1:S50–8 (53 ref.)

The use of antimalarials in combination with other disease modifying agents in rheumatoid arthritis—the French experience. Kahan A, et al. **Lupus** 1996 Jun;5 Suppl 1:S45–9 (27 ref.)

The treatment of malaria [letter; comment] Bailey CL. **N Engl J Med** 1997 Mar 6;336(10):733; discussion 733–4 . Comment on: N Engl J Med 1996 Sep 12;335(11):800–6.

Adaptive changes in Plasmodium transmission strategies following chloroquine chemotherapy. Buckling AG, et al. **Proc R Soc Lond B Biol Sci** 1997 Apr 22;264(1381):553–9

Quinine–tetracycline for multidrug resistant falciparum malaria. Bunnag D, et al. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):15–8

Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malaria. Cao XT, et al. **Trans R Soc Trop Med Hyg** 1997 May–Jun;91(3):335–42

[Malaria prevention (letter)] Bech B. **Ugeskr Laeger** 1997 Apr 14;159(16):2404–5 **(Dan)**

[Malaria prophylaxis (letter; comment)] Leutscher PD. **Ugeskr Laeger** 1997 Aug 4;159(32):4866–8. Comment on: Ugeskr Laeger 1997 Apr 28;159(18):2723–30. **(Dan)**

[Proguanil (letter)] Skjelbo EF. **Ugeskr Laeger** 1997 Jul 21; 159(30):4660–1 **(Dan)**

[Evaluation of the treatment of malaria using a 3–day regimen of quinine in Dakar] Gaye O, et al. **Med Trop (Mars)** 1997; 57(1):47–8 (Eng. Abstr.) **(Fre)**

[Imported malaria: about 1,000 cases per year. Studies of prevention and epidemiology—insufficient drug prevention, emergency medication correctly administered] Nothdurft HD. **Fortschr Med** 1996 Dec 20; 114(35–36):492–3 **(Ger)**

[Malaria prophylaxis—correct information is important (letter)] Hoel T, et al. **Tidsskr Nor Laegeforen** 1997 Mar 10;117(7):1001–2 **(Nor)**

[The clinical evaluation of quinine for the treatment of Plasmodium falciparum malaria] Boulos M, et al. **Rev Soc Bras Med Trop** 1997 May–Jun;30(3):211–3 (Eng. Abstr.) **(Por)**

[Chloroquine resistance and prophylaxis (letter)] Cronberg S. **Lakartidningen** 1997 May 7;94(19):1782 **(Swe)**

[Severe falciparum malaria among travellers to Thailand. Blood exchange and artemisinine treatment are therapeutic alternatives] Ekvall H, et al. **Lakartidningen** 1997 Apr 30; 94(18):1713–5 (15 ref.) **(Swe)**

[Chloroquine phosphate dosage in malaria prophylaxis should be based on body weight! (letter)] Mårtensson A. **Lakartidningen** 1997 Jan 15;94(3):114 **(Swe)**

ADVERSE EFFECTS

Chloroquine–induced vitiligo. A case report and review of the literature [letter] Selvaag E. **Acta Derm Venereol** 1996 Mar;76(2):166–7 (6 ref.)

Tolerance of mefloquine by SwissAir trainee pilots. Schlagenhauf P, et al. **Am J Trop Med Hyg** 1997 Feb; 56(2):235–40

Chloroquine–induced vitiligo–like depigmentation. Selvaag E. **Ann Trop Paediatr** 1997 Mar;17(1):45–8

Ototoxic reactions of quinine in healthy persons and patients with Plasmodium falciparum infection. Tange RA, et al. **Auris Nasus Larynx** 1997 Apr;24(2):131–6

An antimalarial malady. Baker PG. **Aust Fam Physician** 1996 May;25(5):791

Mefloquine prophylaxis—revisited. Cohen J. **Aust Fam Physician** 1997 Aug;26(8):909

Mefloquine—a brief review. Ruff T. **Aust Fam Physician** 1996 May;25(5):793 (0 ref.)

Adverse events associated with mefloquine. Explaining about possible adverse events may reduce problems [letter; comment] Behrens R. **BMJ** 1996 Dec 14;313(7071):1553–4 . Comment on: BMJ 1996 Aug 31;313(7056):525–9.

Adverse events associated with mefloquine. Study in returned travellers confirms authors' findings [letter; comment] Corbett EL, et al. **BMJ** 1996 Dec 14;313(7071):1552. Comment on: BMJ 1996 Aug 31;313(7056):525–8.

Adverse events associated with mefloquine. Risk–benefit ratio must be taken into account [letter; comment] Dollow S. **BMJ** 1996 Dec 14;313(7071):1553; discussion 1554. Comment on: BMJ 1996 Aug 31;313(7056):525–8.

Adverse events associated with mefloquine. Patients may start to take cheaper over the counter regimens [letter; comment] Evans MR. **BMJ** 1996 Dec 14;313(7071):1554. Comment on: BMJ 1996 Mar 30;312(7034):835–7.

Interaction of thyroxine sodium with antimalarial drugs. Munera Y, et al. **BMJ** 1997 May 31;314(7094):1593

Adverse events associated with mefloquine. Women may be more susceptible to adverse events [letter; comment] Phillips M. **BMJ** 1996 Dec 14;313(7071):1552–3. Comment on: BMJ 1996 Aug 31;313(7056):525–8.

Adverse events associated with mefloquine. Manufacturer should also give incidence of "severe" adverse events [letter; comment] Traer–Clark L. **BMJ** 1996 Dec 14; 313(7071):1553; discussion 1554. Comment on: BMJ 1996 Aug 31;313(7056):525–8.

Adverse events associated with mefloquine. Advice to warn patients about rare side effects overturns accepted practice [letter] Warner J. **BMJ** 1996 Dec 14;313(7071):1554

Antimalarial drugs and glucose metabolism. Davis TM. **Br J Clin Pharmacol** 1997 Jul;44(1):1–7 (45 ref.)

Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double–blind, placebo–controlled trial [see comments] Davis TM, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):415–21. Comment in: Br J Clin Pharmacol 1997 Jun;43(6):665.

Spontaneous reports of psychiatric adverse effects to mefloquine in the Netherlands [letter] van Riemsdijk MM, et al. **Br J Clin Pharmacol** 1997 Jul;44(1):105–6

Mefloquine: the benefits outweigh the risks. Winstanley P. **Br J Clin Pharmacol** 1996 Oct;42(4):411–3

Atrial flutter with 1:1 conduction after administration of the antimalarial drug mefloquine. Fonteyne W, et al. **Clin Cardiol** 1996 Dec;19(12):967–8

Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Hoebe C, et al. **Eur J Clin Pharmacol** 1997;52(4):269–75

Neuro–psychiatric effects of antimalarials. van Riemsdijk MM, et al. **Eur J Clin Pharmacol** 1997;52(1):1–6

Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Vnurman EF, et al. **Eur J Clin Pharmacol** 1996;50(6):475–82

Chloroquine—induced recurrent psychosis (brief report). Bhatia MS. **Indian J Med Sci** 1996 Nov;50(11):302–4

Is transglutaminase the mediator between antimalarial drugs and psoriasis? Wolf R, et al. **Int J Dermatol** 1997 Jan; 36(1):10–3 (36 ref.)

Mefloquine induced grand mal seizure in a case of uncomplicated falciparum malaria. Garg MR, et al. **J Assoc Physicians India** 1996 Oct;44(10):750

A rare presentation of falciparum malaria [letter; comment] Mishra SK, et al. **J Assoc Physicians India** 1996 Jun; 44(6):432. Comment on: J Assoc Physicians India 1995 Aug;43(8):582.

Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. Kollaritsch H, et al. **J Infect Dis** 1997 Apr; 175(4):871–5

The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen. Smoak BL, et al. **J Infect Dis** 1997 Sep;176(3):831–3

Ophthalmological monitoring of patients taking antimalarials: preferred practice patterns. Easterbrook M, et al. **J Rheumatol** 1997 Jul;24(7):1390–2 (21 ref.)

Fatal toxic epidermal necrolysis associated with mefloquine antimalarial prophylaxis. McBride SR, et al. **Lancet** 1997 Jan 11;349(9045):101

Post–malaria neurological syndrome [see comments] Nguyen TH, et al. **Lancet** 1996 Oct 5;348(9032):917–21. Comment in: Lancet 1996 Dec 14;348(9042):1658–9.

Aberrant atrioventricular conduction triggered by antimalarial prophylaxis with mefloquine. Richter J, et al. **Lancet** 1997 Jan 11;349(9045):101–2

Ophthalmologic considerations in using antimalarials in the United States. Rynes RI. **Lupus** 1996 Jun;5 Suppl 1:S73–4 (14 ref.)

Retinopathy and antimalarial drugs—the British experience. Spalton DJ. **Lupus** 1996 Jun;5 Suppl 1:S70–2 (17 ref.)

Doxycycline vs mefloquine [letter; comment] [see comments] Bohnker BK. **Mil Med** 1997 Apr;162(4):i, iv. Comment on: Mil Med 1997 Jan;162(1):viii. Comment in: Mil Med 1997 Jun;162(6):iii.

Response to doxycycline vs. mefloquine [letter; comment] Conrad KA, et al. **Mil Med** 1997 Jun;162(6):iii. Comment on: Mil Med 1997 Apr;162(4):i, iv.

Doxycycline vs. mefloquine [letter] [see comments] Conrad KA, et al. **Mil Med** 1997 Jan;162(1):viii. Comment in: Mil Med 1997 Apr;162(4):i, iv.

Artesunate and cerebellar dysfunction in falciparum malaria [letter] Davis TM, et al. **N Engl J Med** 1997 Sep 11; 337(11):792; discussion 793

Artesunate and cerebellar dysfunction in falciparum malaria [letter] Gachot B, et al. **N Engl J Med** 1997 Sep 11; 337(11):792–3

Ataxia and slurred speech after artesunate treatment for falciparum malaria [letter] Miller LG, et al. **N Engl J Med** 1997 May 1;336(18):1328

Malaria, mefloquine and the mind. Ingram RJ, et al. **N Z Med J** 1997 Apr 25;110(1042):137–8

Haematological complications of proguanil in a patient with chronic renal failure [letter] Sirsat RA, et al. **Nephron** 1997; 75(1):108

Halofantrine–associated ventricular fibrillation in a young woman with no predisposing QTc prolongation. Gundersen SG, et al. **Scand J Infect Dis** 1997;29(2):207–8

Fatal quinine cardiotoxicity in the treatment of falciparum malaria. Bonington A, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):305–7

Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Croft AM, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):199–203

Skin depigmentation due to antimalarial prophylaxis with chloroquine. Selvaag E. **Trans R Soc Trop Med Hyg** 1996 Nov–Dec;90(6):683

Blindness from quinine as an antimalarial [letter; comment] Waddell K. **Trans R Soc Trop Med Hyg** 1996 May–Jun; 90(3):331–2. Comment on: Trans R Soc Trop Med Hyg 1995 Jul–Aug;89(4):462–4.

Chloroquine retinopathy [editorial] Felton JM. **Trop Doct** 1997 Jan;27(1):2–4

Eye damage from chloroquine as an antimalarial: misuse makes safe medicines unsafe. Waddell KM. **Trop Doct** 1997 Jan;27(1):10–2

[There is no evidence of more symptoms with mefloquine than with other drugs in malaria prophylaxis (letter; comment)] Cobelens FG, et al. **Ned Tijdschr Geneeskd** 1997 Apr 19;141(16):794–5; discussion 796. Comment on: Ned Tijdschr Geneeskd 1997 Feb 15;141(7):331–4. **(Dut)**

[There is no evidence of more symptoms with mefloquine than with other drugs in malaria prophylaxis (letter)] de Beer PA. **Ned Tijdschr Geneeskd** 1997 Apr 19;141(16):795 **(Dut)**

[Not more symptoms with mefloquine use than with other drugs in malaria prophylaxis (letter; comment)] Kok PW, et al. **Ned Tijdschr Geneeskd** 1997 May 3;141(18):898. Comment on: Ned Tijdschr Geneeskd 1997 Feb 15;141(7):331–4. **(Dut)**

[Chloroquine maculopathy and prevention of malaria] Balo KP, et al. **J Fr Ophtalmol** 1996;19(12):770–6 (15 ref.) (Eng. Abstr.) **(Fre)**

[Anaphylactic shock related to the treatment of malaria with halofantrine (letter)] Fourcade L, et al. **Presse Med** 1997 Apr 12;26(12):559 **(Fre)**

[Psychopathological phenomena in long-term follow-up of acute psychosis after preventive mefloquinine (Lariam) administration] Meszaros K, et al. **Nervenarzt** 1996 May; 67(5):404–6 (Eng. Abstr.) **(Ger)**

[A case of hypersensitivity type of liver injury induced by pyrimetamine and sulfadoxin (Fansidar)] Okazaki Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Feb;94(2):129–32 **(Jpn)**

[Adverse effects associated with antimalarial chemoprophylaxis] Corominas N, et al. **Med Clin (Barc)** 1997 May 24;108(20):772–5 (Eng. Abstr.) **(Spa)**

ANALYSIS

High-performance liquid chromatographic determination of quinine in rat biological fluids. Chmurzyński L.
J Chromatogr B Biomed Appl 1997 Jun 6;693(2):423–9

Optimisation of the reversed phase liquid chromatographic separation of atovaquone, proguanil and related substances. de Aguiar PF, et al. **J Pharm Biomed Anal** 1997 Jul; 15(11):1781–7

Assessment of the incidence of substandard drugs in developing countries. Shakoor O, et al.
Trop Med Int Health 1997 Sep;2(9):839–45

BLOOD

Plasma chloroquine concentrations in young and older malaria patients treated with chloroquine. Maitland K, et al. **Acta Trop** 1997 Sep 10;66(3):155–61

Whole blood chloroquine concentrations with Plasmodium vivax infection in Irian Jaya, Indonesia. Baird JK, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):618–20

Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Baird JK, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):621–6 (34 ref.)

Chloroquine bioassay of plasma specimens obtained from soldiers on chloroquine plus doxycycline for malaria prophylaxis. Kotecka BM, et al. **Int J Parasitol** 1996 Nov; 26(11):1325–9

Determination of pyronaridine in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies. Jayaraman SD, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):253–7

Determination of artemether and its major metabolite, dihydroartemisinin, in plasma using high-performance liquid chromatography with electrochemical detection. Karbwang J, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):259–65

Determination of proguanil and metabolites in small sample volumes of whole blood stored on filter paper by high-performance liquid chromatography. Kolawole JA, et al. **J Chromatogr B Biomed Appl** 1995 Dec 1; 674(1):149–54

Determination of a new antimalarial drug, benflumetol, in blood plasma by high-performance liquid chromatography. Mansor SM, et al. **J Chromatogr B Biomed Appl** 1996 Jul 12;682(2):321–5

Simultaneous determination of artesunic acid and dihydroartemisinin in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies. Navaratnam V, et al.
J Chromatogr B Biomed Appl 1997 Apr 25;692(1):157–62

Determination of artemether and its metabolite, dihydroartemisinin, in plasma by high-performance liquid chromatography and electrochemical detection in the reductive mode. Sandrenan N, et al.
J Chromatogr B Biomed Appl 1997 Mar 28;691(1):145–53

Determination of benflumetol in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Zeng MY, et al.
J Chromatogr B Biomed Appl 1996 Jun 7;681(2):299–306

Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. Naisbitt DJ, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):884–93

Preliminary evaluation of primaquine activity on rodent malaria model after transdermal administration. Mayorga P, et al. **Parasite** 1997 Mar;4(1):87–90

A high-performance liquid chromatography analysis of plasma artemisinin using a glassy carbon electrode for reductive electrochemical detection. Chan KL, et al.
Planta Med 1997 Feb;63(1):66–9

The disposition of intramuscular artemether in children with cerebral malaria; a preliminary study. Murphy SA, et al.
Trans R Soc Trop Med Hyg 1997 May–Jun;91(3):331–4

CHEMICAL SYNTHESIS

Antimalarial activity of 1,4-epidioxy-bisabola-2,12-diene derivatives. Rücker G, et al. **Arch Pharm (Weinheim)** 1997 Jan–Feb;330(1–2):12–6

Synthesis of pyridopyrimidone derivatives and their activity against P. falciparum in vitro. Domínguez J, et al.
Farmaco 1996 Dec;51(12):781–4

Inhibition of Plasmodium falciparum proliferation in vitro by ribozymes. Flores MV, et al. **J Biol Chem** 1997 Jul 4; 272(27):16940–5

Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease. Domínguez JN, et al. **J Med Chem** 1997 Aug 15;40(17):2726–32

Toward a novel metal-based chemotherapy against tropical diseases. 3. Synthesis and antimalarial activity in vitro and in vivo of the new gold-chloroquine complex [Au(PPh3)(CQ)]PF6. Navarro M, et al. **J Med Chem** 1997 Jun 6;40(12):1937–9

Correlation of antimalarial activity of artemisinin derivatives with binding affinity with ferroprotoporphyrin IX. Paitayatat S, et al. **J Med Chem** 1997 Feb 28;40(5):633–8

Reaction between ferriprotoporphyrin IX and the antimalarial endoperoxide artesunate gives an intermediate species with enhanced redox catalytic activity. Adams PA, et al. **J Pharm Pharmacol** 1996 Feb;48(2):183–7

A model of Plasmodium falciparum lactate dehydrogenase and its implications for the design of improved antimalarials and the enhanced detection of parasitaemia. Sessions RB, et al. **Protein Eng** 1997 Apr;10(4):301–6

[Reaction of 3-hydroxy-dihydrosantonin with TsOH. A formal synthesis of dihydrocotunolide] Kawamata T, et al. **Yakugaku Zasshi** 1996 Sep;116(9):748–52 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

X-ray crystal structure of the antimalarial agent (-)-halofantrine hydrochloride supports stereospecificity for cardiotoxicity. Karle JM.
Antimicrob Agents Chemother 1997 Apr;41(4):791–4

Chemical Determinants of antimalarial activity of reversed siderophores. Tsafack A, et al.
Antimicrob Agents Chemother 1996 Sep;40(9):2160–6

Conformational analysis of the antimalarial agent quinidine. Silva TH, et al. **Bioorg Med Chem** 1997 Feb;5(2):353–61

Indonesian medicinal plants. XVII. Characterization of quassinoids from the stems of Quassia indica. Kitagawa I, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2009–14

A QSAR study of the antimalarial activity of some synthetic 1,2,4-trioxanes. Grigorov M, et al.
J Chem Inf Comput Sci 1997 Jan–Feb;37(1):124–30

Molecular electronic properties of a series of 4-quinolinecarbinolamines define antimalarial activity profile. Bhattacharjee AK, et al. **J Med Chem** 1996 Nov 8;39(23):4622–9

Mechanism-based design of parasite-targeted artemisinin derivatives: synthesis and antimalarial activity of benzylamino and alkylamino ether analogues of artemisinin. O'Neill PM, et al. **J Med Chem** 1996 Oct 25;39(22):4511–4

Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues. O'Neill PM, et al. **J Med Chem** 1997 Feb 14;40(4):437–48

Effect of temperature on chlorproguanil and proguanil hydrochloride solutions: a chemical stability study. Kolawole JA, et al. **J Pharm Biomed Anal** 1996 Apr; 14(6):685–93

Design and evaluation of two-phase partition-dissolution method and its use in evaluating artemisinin tablets. Hoa NT, et al. **J Pharm Sci** 1996 Oct;85(10):1060–3

Composition and antimalarial activity in vitro of the essential oil of Tetradenia riparia [letter] Campbell WE, et al.
Planta Med 1997 Jun;63(3):270–2

Steroidal geminal dihydroperoxides and 1,2,4,5-tetraoxanes: structure determination and their antimalarial activity. Todorović NM, et al. **Steroids** 1996 Dec;61(12):688–96

Triosephosphate isomerase from Plasmodium falciparum: the crystal structure provides insights into antimalarial drug design. Velanker SS, et al. **Structure** 1997 Jun 15; 5(6):751–61

CONTRAINDICATIONS

The safety of antimalarial drugs in pregnancy. Phillips-Howard PA, et al. **Drug Saf** 1996 Mar;14(3):131–45 (101 ref.)

HISTORY

The possibility of an "X" factor. The first documented drug resistance of human malaria. Sweeney AW.
Int J Parasitol 1996 Oct;26(10):1035–61

The history of antimalarials. Wallace DJ. **Lupus** 1996 Jun; 5 Suppl 1:S2–3

ISOLATION & PURIFICATION

Structural and antimalarial studies of saponins from Nauclea diderrichii bark. Lamidi M, et al. **Adv Exp Med Biol** 1996; 404:383–99

(+)-Angchibangkine, a new type of bisbenzylisoquinoline alkaloid, and other dimers from Pachygone dasycarpa. Guinaudeau H, et al. **J Nat Prod** 1997 Mar;60(3):258–60

Michellamines D–F, new HIV-inhibitory dimeric naphthylisoquinoline alkaloids, and korupensamine E, a new antimalarial monomer, from Ancistrocladus korupensis. Hallock YF, et al. **J Nat Prod** 1997 Jul; 60(7):677–83

New anti-HIV-1, antimalarial, and antifungal compounds from Terminalia bellerica. Valsaraj R, et al. **J Nat Prod** 1997 Jul;60(7):739–42

Betulinic acid: isolation from Triphyophyllum peltatum and Ancistrocladus heyneanus, antimalarial activity, and crystal structure of the benzyl ester. Bringmann G, et al.
Planta Med 1997 Jun;63(3):255–7

Medicinal plants and the control of protozoal disease, with particular reference to malaria. Kirby GC.
Trans R Soc Trop Med Hyg 1996 Nov–Dec;90(6):605–9 (41 ref.)

Antimalarial plants used by Hausa in northern Nigeria. Etkin NL. **Trop Doct** 1997;27 Suppl 1:12–6

METABOLISM

Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine. Zhang H, et al.
Br J Clin Pharmacol 1997 Mar;43(3):245–52

Hairy root culture of Artemisia annua L. by Ri plasmid transformation and biosynthesis of artemisinin. Cai G, et al. **Chin J Biotechnol** 1995;11(4):227–35

Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Ducharme J, et al.
Clin Pharmacokinet 1996 Oct;31(4):257–74 (148 ref.)

Correlation between proguanil and metabolites in plasma and saliva [letter] Alexander C, et al.
J Antimicrob Chemother 1995 Dec;36(6):1113–5

Uptake and transport characteristics of chloroquine in an in-vitro cell culture system of the intestinal mucosa, Caco-2. Augustijns PF. **J Pharm Pharmacol** 1996 Mar; 48(3):277–80

In-vitro interaction of artemisinin with intact human erythrocytes, erythrocyte ghosts, haemoglobin and carbonic anhydrase. Bakhshi HB, et al.
J Pharm Pharmacol 1997 Feb;49(2):223–6

High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu [letter] Kaneko A, et al. **Lancet** 1997 Mar 29;349(9056):921–2

Photoaffinity labeling of mefloquine-binding proteins in human serum, uninfected erythrocytes and Plasmodium falciparum-infected erythrocytes. Desneves J, et al.
Mol Biochem Parasitol 1996 Nov 25;82(2):181–94

Amodiaquine accumulation in Plasmodium falciparum as a possible explanation for its superior antimalarial activity over chloroquine. Hawley SR, et al.
Mol Biochem Parasitol 1996 Sep;80(1):15–25

Metabolism of quinine in children with global malnutrition. Tréluyer JM, et al. **Pediatr Res** 1996 Oct;40(4):558–63

PHARMACOKINETICS

Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Benakis A, et al.
Am J Trop Med Hyg 1997 Jan;56(1):17–23

The pharmacokinetics of a single dose of artemisinin in patients with uncomplicated falciparum malaria. De Vries PJ, et al. **Am J Trop Med Hyg** 1997 May;56(5):503–7

Disposition of proguanil in Thai patients with uncomplicated falciparum malaria. Edstein MD, et al.
Am J Trop Med Hyg 1997 May;56(5):498–502

Single-dose, comparative study of venous, capillary and salivary artemisinin concentrations in healthy, male adults. Sidhu JS, et al. **Am J Trop Med Hyg** 1997 Jan;56(1):13–6

Effect of food intake on pharmacokinetics of oral artemisinin in healthy Vietnamese subjects. Dien TK, et al.
Antimicrob Agents Chemother 1997 May;41(5):1069–72

Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. Basci NE, et al.
Br J Clin Pharmacol 1996 Dec;42(6):771–3

Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. Hellgren U, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):119–24

Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. Hussein Z, et al. **Br J Clin Pharmacol** 1996 Nov;42(5):589–97

Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers. Mordi MN, et al.
Br J Clin Pharmacol 1997 Apr;43(4):363–5

Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Teja-Isavadharm P, et al.
Br J Clin Pharmacol 1996 Nov;42(5):599–604

Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Ducharme J, et al.
Clin Pharmacokinet 1996 Oct;31(4):257–74 (148 ref.)

Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Krishna S, et al.
Clin Pharmacokinet 1996 Apr;30(4):263–99 (267 ref.)

ANTIMALARIALS

Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Hussein Z, et al. **Clin Pharmacol Ther** 1997 May;61(5):518–30

Uptake of mefloquine enantiomers into uninfected and malaria-infected erythrocytes. Vidrequin S, et al. **Drug Metab Dispos** 1996 Jun;24(6):689–91

Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria. Sowunmi A. **East Afr Med J** 1996 Aug;73(8):519–23

Stereoselective pharmacokinetics of mefloquine in young children. Bourahla A, et al. **Eur J Clin Pharmacol** 1996; 50(3):241–4

Pharmacokinetics and bioavailability of oral and intramuscular artemether. Karbwang J, et al. **Eur J Clin Pharmacol** 1997;52(4):307–10

Effect of dose size on the pharmacokinetics of orally administered quinine. Sowunmi A, et al. **Eur J Clin Pharmacol** 1996;49(5):383–6

Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. Na-Bangchang K, et al. **Fundam Clin Pharmacol** 1995;9(6):576–82

Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. Na-Bangchang K, et al. **Int J Clin Pharmacol Res** 1995;15(5–6):215–20

Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. Batty KT, et al. **J Pharm Pharmacol** 1996 Jan;48(1):22–6

Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. Gimenez F, et al. **J Pharm Sci** 1994 Jun;83(6):824–7

Identification of the glucuronides of the hydroxylated metabolites of the antimalarial arteether in rat plasma and urine by thermospray high-performance liquid chromatography/mass spectrometry. Ramu K, et al. **J Pharm Sci** 1997 Aug;86(8):915–20

The pharmacokinetics of chloroquine in healthy and Plasmodium chabaudi-infected mice: implications for chronotherapy. Cambie G, et al. **Parasite** 1994 Sep; 1(3):219–26

Time-dependent variability of chloroquine secretion into human saliva [see comments] Onyeji CO, et al. **Pharm World Sci** 1996 Dec;18(6):211–6. Comment in: Pharm World Sci 1996 Dec;18(6):193–4.

Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. Edstein MD, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):216–20

Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria. Bethell DB, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr; 91(2):195–8

Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Hassan Alin M, et al. **Trans R Soc Trop Med Hyg** 1996 Jan–Feb;90(1):61–5

[Pharmacokinetics of rectal absorption of amodiaquine in rabbits] Blum Z, et al. **Acta Pharm Hung** 1997 Jan;67(1):3–8 (Eng. Abstr.) **(Hun)**

PHARMACOLOGY

Repetitive dosing of artemisinin and quinine against Plasmodium falciparum in vitro: a simulation of the in vivo pharmacokinetics. Bwijo B, et al. **Acta Trop** 1997 Apr 30; 65(1):11–22

In vitro susceptibility of Plasmodium falciparum isolates in Vietnam to artemisinin derivatives and other antimalarials. Wongsrichanalai C, et al. **Acta Trop** 1997 Feb;63(2–3):151–8

Antimalaria activity of the triple combination of proguanil, atovaquone and dapsone. Yeo AE, et al. **Acta Trop** 1997 Sep 30;67(3):207–14

Molecular approaches to the spreading problem of drug resistant malaria. Plowe CV, et al. **Adv Exp Med Biol** 1995; 390:197–209 (48 ref.)

Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Cumming JN, et al. **Adv Pharmacol** 1997;37:253–97 (257 ref.)

Primaquine resistance in Plasmodium vivax. Collins WE, et al. **Am J Trop Med Hyg** 1996 Sep;55(3):243–9 (65 ref.)

Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro. De D, et al. **Am J Trop Med Hyg** 1996 Dec;55(6):579–83

In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. Gay F, et al. **Am J Trop Med Hyg** 1997 Mar;56(3):315–7

Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. Plowe CV, et al. **Am J Trop Med Hyg** 1996 Nov;55(5):467–71

In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Ringwald P, et al. **Am J Trop Med Hyg** 1996 Sep;55(3):254–8

The chemotherapy of rodent malaria. LIII. 'Fenozan B07' (Fenozan-50F), a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane: comparison with some compounds of the artemisinin series. Fleck SL, et al. **Ann Trop Med Parasitol** 1997 Jan;91(1):25–32

Naphthylisoquinoline alkaloids exhibit strong growth-inhibiting activities against Plasmodium falciparum and P. berghei in vitro--structure-activity relationships of dioncophylline C. François G, et al. **Ann Trop Med Parasitol** 1996 Apr;90(2):115–23

Is haemozoin a target for antimalarial drugs? Meshnick SR. **Ann Trop Med Parasitol** 1996 Aug;90(4):367–72 (40 ref.)

The activity of triple combinations of antifolate biguanides, with and without folinic acid, against plasmodium falciparum in vitro. Yeo AE, et al. **Ann Trop Med Parasitol** 1997 Apr;91(3):247–51

Influence of antimalarials chloroquine, quinine, primaquine and mepacrine on the evolution of Ehrlich ascites tumour. Castelli M, et al. **Anticancer Res** 1996 Sep–Oct; 16(5A):2673–5

Bisbenzylisoquinolines as modulators of chloroquine resistance in Plasmodium falciparum and multidrug resistance in tumor cells. Frappier F, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1476–81

Characterization of the potent in vitro and in vivo antimalarial activities of ionophore compounds. Gumila C, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):523–9

Manipulation of the N-alkyl substituent in amodiaquine to overcome the verapamil-sensitive chloroquine resistance component. Hawley SR, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2345–9

Kinetics of Plasmodium falciparum thymidylate synthase: interactions with high-affinity metabolites of 5-fluoroorotate and D1694. Hekmat-Nejad M, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1628–32

New quinoline di-Mannich base compounds with greater antimalarial activity than chloroquine, amodiaquine, or pyronaridine. Kotecka BM, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1369–74

In vitro activities of novel catecholate siderophores against Plasmodium falciparum. Pradines B, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2094–8

Antimalarial activity of the bisquinoline trans-N1,N2-bis (7-chloroquinolin-4-yl)cyclohexane-1,2-diamine: comparison of two stereoisomers and detailed evaluation of the S,S enantiomer, Ro 47-7737. Ridley RG, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):677–86

4-aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum. Ridley RG, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1846–54

Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Rosenthal PJ, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1600–3

In vitro and in vivo inhibition of erythrocytic development of malarial parasites by docetaxel. Sinou V, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):358–61

Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice. Smeijsters LJ, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1584–8

Chemical Determinants of antimalarial activity of reversed siderophores. Tsafack A, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2160–6

Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. White NJ. **Antimicrob Agents Chemother** 1997 Jul;41(7):1413–22 (74 ref.)

Potentiation of the antimalarial agent rufigallol. Winter RW, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1408–11

Effects of mefloquine on Ca2+ uptake and release by dog brain microsomes. Lee HS, et al. **Arch Int Pharmacodyn Ther** 1996 May–Jun;331(3):221–31

Antimalarial activity of 1,4-epidioxy-bisabola-2,12-diene derivatives. Rücker G, et al. **Arch Pharm (Weinheim)** 1997 Jan–Feb;330(1–2):12–6

Studies on the mechanism of antimalarial action of a novel arylene bis(methylketone). Berger BJ, et al. **Biochem Pharmacol** 1997 Sep 15;54(6):739–42

Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Riffkin CD, et al. **Biochem Pharmacol** 1996 Nov 22;52(10):1545–52

pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine. Sorensen M, et al. **Biochem Pharmacol** 1997 Aug 1;54(3):373–80

Effects of dual combinations of antifolates with atovaquone or dapsone on nucleotide levels in Plasmodium falciparum. Yeo AE, et al. **Biochem Pharmacol** 1997 Apr 4;53(7):943–50

Chloroquine therapy reduces oestrogen production in females. Nicola WG. **Boll Chim Farm** 1997 May; 136(5):447–9

Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial [letter; comment] Evans SJ, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):665. Comment on: Br J Clin Pharmacol 1996 Oct;42(4):415–21.

Potent block of volume-activated chloride currents in endothelial cells by the uncharged form of quinine and quinidine. Voets T, et al. **Br J Pharmacol** 1996 Aug; 118(7):1869–71

Pyronaridine: yet another promising antimalarial substance from China [news] **Ceylon Med J** 1996 Sep;41(3):123–4

Multi-drug resistant malaria in Sri Lanka [letter] Gunasekera DP, et al. **Ceylon Med J** 1996 Dec;41(4):170–1

Variability in schizonticidal drug susceptibility amongst clones and isolates of Plasmodium falciparum. Ang HH, et al. **Chemotherapy** 1997 Mar–Apr;43(2):142–7

In vitro susceptibility studies of Plasmodium falciparum isolates and clones against type II antifolate drugs. Ang HH, et al. **Chemotherapy** 1996 Sep–Oct;42(5):318–23

Chloroquine-induced venodilation in human hand veins. Abiose AK, et al. **Clin Pharmacol Ther** 1997 Jun; 61(6):677–83

Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Chiang G, et al. **Clin Ther** 1996 Nov–Dec;18(6):1080–92

Flow cytometric assessment of hydroxypyridinone iron chelators on in vitro growth of drug-resistant malaria. Pattanapanyasat K, et al. **Cytometry** 1997 Jan 1;27(1):84–91

Clearance of young parasite forms following treatment of falciparum malaria in humans: comparison of three simple mathematical models. Davis TM, et al. **Epidemiol Infect** 1997 Aug;119(1):61–9

Quinine in the treatment of Babesia divergens infections in humans [letter] Brasseur P, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):840–1

Plasmodium falciparum: direct cloning and expression of pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase domains. Hekmat-Nejad M, et al. **Exp Parasitol** 1997 Mar;85(3):303–5

Plasmodium vivax: in vitro antiparasitic effect of cyclosporins. Kocken CH, et al. **Exp Parasitol** 1996 Dec; 84(3):439–43

Plasmodium falciparum: chloroquine selection of a cloned line and DNA rearrangements. Lim AS, et al. **Exp Parasitol** 1996 Aug;83(3):283–94

Plasmodium falciparum: amplification and overexpression of pfmdr1 is not necessary for increased mefloquine resistance. Lim AS, et al. **Exp Parasitol** 1996 Aug;83(3):295–303

Xanthones as antimalarial agents; studies of a possible mode of action. Ignatushchenko MV, et al. **FEBS Lett** 1997 Jun 2;409(1):67–73

Depolymerization of malarial hemozoin: a novel reaction initiated by blood schizontocidal antimalarials. Pandey AV, et al. **FEBS Lett** 1997 Feb 3;402(2–3):236–40

Artemisinin enhances heme-catalysed oxidation of lipid membranes. Berman PA, et al. **Free Radic Biol Med** 1997; 22(7):1283–8

Effects of chloroquine treatment on antioxidant enzymes in rat liver and kidney. Magwere T, et al. **Free Radic Biol Med** 1997;22(1–2):321–7

Free radical production by azomethine H: effects on pancreatic and hepatic tissues. Novelli EL, et al. **Free Radic Res** 1997 Apr;26(4):319–24

The mode of action of the antimalarial artemisinin and its derivatives. Kamchonwongpaisan S, et al. **Gen Pharmacol** 1996 Jun;27(4):587–92 (85 ref.)

Detection of RAPD markers correlated with chloroquine resistance in Plasmodium falciparum. Lescuyer P, et al. **Genome Res** 1997 Jul;7(7):747–53

In-vivo and in-vitro sensitivity of Plasmodium falciparum to chloroquine in Chennai (Tamil Nadu), India. Dua VK, et al. **Indian J Malariol** 1997 Mar;34(1):1–7

Quinoline antimalarials: mechanisms of action and resistance. Foley M, et al. **Int J Parasitol** 1997 Feb;27(2):231–40 (60 ref.)

Retarded development of exoerythrocytic stages of the rodent malaria parasite Plasmodium berghei in human hepatoma cells by extracts from Dioncophyllaceae and Ancistrocladaceae species. François G, et al. **Int J Parasitol** 1997 Jan;27(1):29–32

In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Skinner TS, et al. **Int J Parasitol** 1996 May;26(5):519–25

Effect of chloroquine on the formation of tight junctions in cultured immature rat Sertoli cells. Okanlawon A, et al. **J Androl** 1996 May–Jun;17(3):249–55

Activity of pyronaridine and mepacrine against twelve strains of Plasmodium falciparum in vitro. Elueze EI, et al. **J Antimicrob Chemother** 1996 Mar;37(3):511–8

The effect of artemisinin on granulocyte function assessed by flow cytometry. Wenisch C, et al. **J Antimicrob Chemother** 1997 Jan;39(1):99–101

The hypoglycemic effect of chloroquine. Goyal V, et al. **J Assoc Physicians India** 1995 Jan;43(1):17–8

Probing the chloroquine resistance locus of Plasmodium falciparum with a novel class of multidentate metal(III) coordination complexes. Goldberg DE, et al. **J Biol Chem** 1997 Mar 7;272(10):6567–72

Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. Srivastava IK, et al. **J Biol Chem** 1997 Feb 14;272(7):3961–6

A QSAR study of the antimalarial activity of some synthetic 1,2,4-trioxanes. Grigorov M, et al. **J Chem Inf Comput Sci** 1997 Jan–Feb;37(1):124–30

Effect of 7-day daily replacement of culture medium containing Eurycoma longifolia Jack constituents on the Malaysian Plasmodium falciparum isolates. Ang HH, et al. **J Ethnopharmacol** 1995 Dec 15;49(3):171–5

Antimalarial activity of extracts and fractions from Bidens pilosa and other Bidens species (Asteraceae) correlated with the presence of acetylene and flavonoid compounds. Brandão MG, et al. **J Ethnopharmacol** 1997 Jul;57(2):131–8

Constituents of Picralima nitida display pronounced inhibitory activities against asexual erythrocytic forms of Plasmodium falciparum in vitro. François G, et al. **J Ethnopharmacol** 1996 Nov;54(2–3):113–7

Antiplasmodial activity of four Kenyan medicinal plants. Omulokoli E, et al. **J Ethnopharmacol** 1997 Apr;56(2):133–7

Combined action of inhibitors of S-adenosylmethionine decarboxylase with an antimalarial drug, chloroquine, on

Plasmodium falciparum. Das B, et al.
J Eukaryot Microbiol 1997 Jan–Feb;44(1):12–7

Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. Potvin F, et al. **J Immunol** 1997 Feb 15;158(4):1872–9

The interaction of the heme–octapeptide, N–acetylmicroperoxidase–8 with antimalarial drugs: solution studies and modeling by molecular mechanics methods. Marques HM, et al. **J Inorg Biochem** 1996 Oct; 64(1):7–23

Structure–activity relationships of the antimalarial agent artemisinin. 5. Analogs of 10–deoxoartemisinin substituted at C–3 and C–9. Avery MA, et al. **J Med Chem** 1996 Oct 11;39(21):4149–55

Antimalarial activity of new dihydroartemisinin derivatives. 7. 4–(p–substituted phenyl)–4(R or S)–[10(alpha or beta)–dihydroartemisininoxy]butyric acids. Lin AJ, et al. **J Med Chem** 1997 Apr 25;40(9):1396–400

Correlation of antimalarial activity of artemisinin derivatives with binding affinity with ferroprotoporphyrin IX. Paitayatat S, et al. **J Med Chem** 1997 Feb 28;40(5):633–8

In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta. Cimanga K, et al. **J Nat Prod** 1997 Jul;60(7):688–91

Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives. MacKinnon S, et al. **J Nat Prod** 1997 Apr;60(4):336–41

Antimalarial activity: the search for marine–derived natural products with selective antimalarial activity. Wright AD, et al. **J Nat Prod** 1996 Jul;59(7):710–6 (24 ref.)

Susceptibility studies of Plasmodium falciparum isolates and clones against cycloguanil and pyrimethamine using the modified in vitro microtechnique. Ang HH, et al.
J Parasitol 1996 Dec;82(6):1029–31

Studies on a primaquine–tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys. Nayar JK, et al. **J Parasitol** 1997 Aug;83(4):739–45

Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. Leo KU, et al. **J Pharm Pharmacol** 1996 Jul;48(7):723–8

Heme polymerase activity and the stage specificity of antimalarial action of chloroquine. Orjih AU.
J Pharmacol Exp Ther 1997 Jul;282(1):108–12

Anti–malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Fox R. **Lupus** 1996 Jun;5 Suppl 1:S4–10 (41 ref.)

Recombinant Plasmodium falciparum dihydrofolate reductase–based in vitro screen for antifolate antimalarials. Brobey RK, et al. **Mol Biochem Parasitol** 1996 Oct 30; 81(2):225–37

The antimalarial drug, chloroquine, interacts with lactate dehydrogenase from Plasmodium falciparum. Menting JG, et al. **Mol Biochem Parasitol** 1997 Sep;88(1–2):215–24

In vitro selection of halofantrine resistance in Plasmodium falciparum is not associated with increased expression of Pgh1. Ritchie GY, et al. **Mol Biochem Parasitol** 1996 Dec 2;83(1):35–46

Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum. Wooden JM, et al. **Mol Biochem Parasitol** 1997 Mar; 85(1):25–40

Effects of gramicidin and tryptophan–N–formylated gramicidin on the sodium and potassium content of human erythrocytes. Otten–Kuipers MA, et al.
Mol Membr Biol 1996 Oct–Dec;13(4):225–32

Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Wang P, et al.
Mol Microbiol 1997 Mar;23(5):979–86

4–Aminoquinoline resistance of Plasmodium falciparum: insights from the study of amodiaquine uptake. Bray PG, et al. **Mol Pharmacol** 1996 Dec;50(6):1551–8

Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum. Bray PG, et al. **Mol Pharmacol** 1996 Dec; 50(6):1559–66

Chloroquine administration in mice increases beta–amyloid immunoreactivity and attenuates kainate–induced blood–brain barrier dysfunction. Mielke JG, et al.
Neurosci Lett 1997 May 23;227(3):169–72

Chloroquine specifically impairs Merkel cell mechanoreceptor function in isolated rat sinus hairs. Senok SS, et al. **Neurosci Lett** 1996 Aug 23;214(2–3):167–70

Interaction of artemisinin and tetracycline or erythromycin against Plasmodium falciparum in vitro. Ye Z, et al.
Parasite 1994 Sep;1(3):211–8

GM–CSF–induced priming of human neutrophils for enhanced phagocytosis and killing of asexual blood stages of Plasmodium falciparum: synergistic effects of GM–CSF and TNF. Kumaratilake LM, et al. **Parasite Immunol** 1996 Mar;18(3):115–23

Modifications in the rhythm of schizogony in Plasmodium chabaudi chabaudi associated with the selection of chloroquine resistance. Coquelin F, et al. **Parasitol Res** 1997;83(5):504–9

In vitro inhibition of liver forms of the rodent malaria parasite Plasmodium berghei by naphthylisoquinoline alkaloids—structure–activity relationships of dioncophyllines A and C and ancistrocladine. François G, et al. **Parasitol Res** 1997;83(7):673–9

Potentiation of the antimalarial activity of atovaquone by doxycycline against Plasmodium falciparum in vitro. Yeo AE, et al. **Parasitol Res** 1997;83(5):489–91

In vitro susceptibility of Tanzanian wild isolates of Plasmodium falciparum to artemisinin, chloroquine, sulfadoxine/pyrimethamine and mefloquine. Alin MH.
Parasitology 1997 Jun;114 (Pt 6):503–6

Chloroquine is a potent inhibitor of glutamate dehydrogenase in liver and kidney–cortex of rabbit. Jarzyna R, et al.
Pharmacol Res 1997 Jan;35(1):79–84

The effect of mefloquine and quinine on the relaxation times of water protons in human erythrocytes, as revealed by NMR. Nishina M, et al. **Physiol Chem Phys Med NMR** 1996;28(1):35–9

Antifolate–resistant mutants of Plasmodium falciparum dihydrofolate reductase. Sirawaraporn W, et al.
Proc Natl Acad Sci U S A 1997 Feb 18;94(4):1124–9

On the molecular mechanism of chloroquine's antimalarial action. Sullivan DJ Jr, et al.
Proc Natl Acad Sci U S A 1996 Oct 15;93(21):11865–70

In vitro susceptibilities of field isolates of Plasmodium falciparum to chloroquine in Mpumalanga [letter] van Nierop WH, et al. **S Afr Med J** 1996 Aug;86(8):984–5

Malaria research. How the parasite gets its food [news; comment] Vogel G. **Science** 1997 May 16;276(5315):1031 . Comment on: Science 1997 May 16;276(5315):1122–5.

Steroidal geminal dihydroperoxides and 1,2,4,5–tetraoxanes: structure determination and their antimalarial activity. Todorović NM, et al. **Steroids** 1996 Dec;61(12):688–96

Plasmodium falciparum: adaptation in vitro of isolates from symptomatic individuals in Gabon: polymerase chain reaction typing and evaluation of chloroquine susceptibility. Domarle O, et al.
Trans R Soc Trop Med Hyg 1997 Mar–Apr;91(2):208–9

Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro. Edstein MD, et al. **Trans R Soc Trop Med Hyg** 1996 Jul–Aug;90(4):418–21

The effect of atovaquone (566C80) on the maturation and viability of Plasmodium falciparum gametocytes in vitro. Fleck SL, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun; 90(3):309–12

Features of recrudescent chloroquine–resistant Plasmodium falciparum infections confer a survival advantage on parasites and have implications for disease control. Handunnetti SM, et al. **Trans R Soc Trop Med Hyg** 1996 Sep–Oct;90(5):563–7

Antimalarial activity and interactions between quinine, dihydroquinine and 3–hydroxyquinine against Plasmodium falciparum in vitro. Nontprasert A, et al.
Trans R Soc Trop Med Hyg 1996 Sep–Oct;90(5):553–5

Activity of PS–15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo–in vitro model. Rieckmann KH, et al. **Trans R Soc Trop Med Hyg** 1996 Sep–Oct;90(5):568–71

Antimalarial drugs inhibit the phagocytosis of erythrocytes infected with Plasmodium falciparum. Shalmiev G, et al. **Trans R Soc Trop Med Hyg** 1996 Sep–Oct;90(5):558–62

Plasmodium falciparum chloroquine and quinine sensitivity in asymptomatic and symptomatic children in São Tomé Island. Baptista JL, et al. **Trop Med Int Health** 1997 Jun; 2(6):582–8

Efficacy of artemisinin and mefloquine combinations against Plasmodium falciparum. In vitro simulation of in vivo pharmacokinetics. Bwijo B, et al. **Trop Med Int Health** 1997 May;2(5):461–7

In vitro susceptibility of Plasmodium falciparum to quinine: relation to parasite density and drug distribution in culture fractions. Mapaba E, et al. **Trop Med Int Health** 1996 Dec; 1(6):802–9

[Malaria prophylaxis. Effects and side–effects of drugs used for prevention of malaria (see comments)] Petersen E.
Ugeskr Laeger 1997 Apr 28;159(18):2723–30 (39 ref.). Comment in: Ugeskr Laeger 1997 Aug 4;159(32):4866–8. **(Dan)**

In vitro sensitivity of Plasmodium falciparum to anti–folinic agents (trimethoprim, pyrimethamine, cycloguanil): a study of 29 African strains] Basco LK, et al.
Bull Soc Pathol Exot 1997;90(2):90–3 (Eng. Abstr.) **(Fre)**

[Mechanisms and epidemiology of resistances to antimalarials] Le Bras J, et al.
C R Seances Soc Biol Fil 1996;190(4):471–85 (Eng. Abstr.) **(Fre)**

[In vitro sensitivity of 85 Plasmodium falciparum isolates in the Fatick region, Senegal] Pradines B, et al.
Med Trop (Mars) 1996;56(2):141–5 (Eng. Abstr.) **(Fre)**

POISONING

Effects of catecholamines and diazepam in chloroquine poisoning in barbiturate anaesthetised rats. Buckley NA, et al. **Hum Exp Toxicol** 1996 Nov;15(11):909–14

Therapeutic trial of diazepam versus placebo in acute chloroquine intoxications of moderate gravity. Clemessy JL, et al. **Intensive Care Med** 1996 Dec;22(12):1400–5

Relevance of toxicological screening for chloroquine in nonmalarious areas [letter] Lambert W, et al.
J Anal Toxicol 1997 Jul–Aug;21(4):321–2

Toxic effects of antimalarial drugs in Paramecium: role of calcium channels. Nori VS, et al. **J Comp Physiol [A]** 1997 May;180(5):473–80

Chloroquine poisoning in a child. McCarthy VP, et al.
Pediatr Emerg Care 1996 Jun;12(3):207–9 (31 ref.)

Acute dapsone intoxication: a pediatric case report. MacDonald RD, et al. **Pediatr Emerg Care** 1997 Apr; 13(2):127–9

[A case of acute pyrimethamine poisoning] Aguemon AR, et al. **Bull Soc Pathol Exot** 1997;90(2):117–9 (7 ref.) (Eng. Abstr.) **(Fre)**

[Acute chloroquine poisoning] Altrock G, et al.
Dtsch Med Wochenschr 1997 Feb 21;122(8):225–8 (Eng. Abstr.) **(Ger)**

STANDARDS

Substandard primaquine phosphate for US Peace Corps personnel [letter] Kron MA. **Lancet** 1996 Nov 23; 348(9039):1453–4

SUPPLY & DISTRIBUTION

Evaluation of invermectin distribution in Benin, Côte d'Ivoire, Ghana and Togo: estimation of coverage of treatment and operational aspects of the distribution system. Biritwum RB, et al. **Ann Trop Med Parasitol** 1997 Apr; 91(3):297–305

Role of shops and shopkeepers in malaria control. Ongore D, et al. **East Afr Med J** 1996 Jun;73(6):390–4

THERAPEUTIC USE

Risk factors of chloroquine resistance in Plasmodium falciparum malaria. Hess FI, et al. **Acta Trop** 1996 Aug; 61(4):293–306

In vivo sensitivity of Plasmodium falciparum to chloroquine and sulfadoxine–pyrimethamine in school children in Hoima district, western Uganda. Ndyomugyenyi R, et al. **Acta Trop** 1997 Sep 10;66(3):137–43

Sensitivity of Plasmodium falciparum to reduced dose of mefloquine in pregnant women in Nigeria. Okoyeh JN, et al. **Acta Trop** 1996 Mar;61(1):1–8

High prevalence of chloroquine resistant Plasmodium falciparum infection in Rajasthan epidemic. Sharma YD, et al. **Acta Trop** 1996 Dec 16;62(3):135–41

Efficacy of artemether in severe falciparum malaria in African children. Sowunmi A, et al. **Acta Trop** 1996 Mar; 61(1):57–63

Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. Trigg JK, et al. **Acta Trop** 1997 Feb;63(2–3):185–9

Molecular approaches to the spreading problem of drug resistant malaria. Plowe CV, et al. **Adv Exp Med Biol** 1995; 390:197–209 (48 ref.)

In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Baird JK, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):627–31

Efficacy and tolerance of artemisinin in short combination regimens for the treatment of uncomplicated falciparum malaria. Bich NN, et al. **Am J Trop Med Hyg** 1996 Oct; 55(4):438–43

Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis. Fryauff DJ, et al.
Am J Trop Med Hyg 1997 Feb;56(2):137–40

Survey of in vivo sensitivity to chloroquine by Plasmodium falciparum and P. vivax in Lombok, Indonesia. Fryauff DJ, et al. **Am J Trop Med Hyg** 1997 Feb;56(2):241–4

Chloroquine–resistant Plasmodium falciparum malaria: report of two locally acquired infections in Saudi Arabia. Kinsara AJ, et al. **Am J Trop Med Hyg** 1997 May;56(5):573–5

WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine–resistant strain of Plasmodium vivax in Aotus monkeys. Obaldia N 3rd, et al. **Am J Trop Med Hyg** 1997 May;56(5):508–10

Arteflene compared with mefloquine for treating Plasmodium falciparum malaria in children. Radloff PD, et al. **Am J Trop Med Hyg** 1996 Sep;55(3):259–62

Short report: gametocytes, chloroquine pressure, and the relative parasite survival advantage of resistant strains of falciparum malaria in west Africa. Robert V, et al.
Am J Trop Med Hyg 1996 Sep;55(3):350–1

Short report: primaquine–tolerant Plasmodium vivax in an Italian traveler from Guatemala. Signorini L, et al.
Am J Trop Med Hyg 1996 Nov;55(5):472–3

Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia. Smoak BL, et al. **Am J Trop Med Hyg** 1997 Feb;56(2):231–4

Childhood mortality during and after hospitalization in western Kenya: effect of malaria treatment regimens [published erratum appears in Am J Trop Med Hyg 1997 Mar;56(3):358] Zucker JR, et al. **Am J Trop Med Hyg** 1996 Dec;55(6):655–60

Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double–blind, placebo–controlled trial. Ohrt C, et al.
Ann Intern Med 1997 Jun 15;126(12):963–72

The chemotherapy of rodent malaria. LIV. Combinations of 'Fenozan B07' (Fenozan–50F), a difluorinated 3,3'–spirocyclopentane 1,2,4–trioxane, with other drugs against drug–sensitive and drug–resistant parasites. Fleck SL, et al. **Ann Trop Med Parasitol** 1997 Jan;91(1):33–9

Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. Fryauff DJ, et al.
Ann Trop Med Parasitol 1997 Jan;91(1):7–16

Treatment of acute, uncomplicated, falciparum malaria with oral dihydroartemisinin. Looareesuwan S, et al.
Ann Trop Med Parasitol 1996 Feb;90(1):21–28

ANTIMALARIALS

Co-administration of desferrioxamine B with artesunate in malaria: an assessment of safety and tolerance. Looareesuwan S, et al. **Ann Trop Med Parasitol** 1996 Oct; 90(5):551–4

The effect of oral iron therapy during treatment for Plasmodium falciparum malaria with sulphadoxine–pyrimethamine on Malawian children under 5 years of age. Nwanyanwu OC, et al. **Ann Trop Med Parasitol** 1996 Dec;90(6):589–95

Evaluation of the safety and efficacy of micronized halofantrine in the treatment of semi-immune patients with acute, Plasmodium falciparum malaria. Ramsay AR, et al. **Ann Trop Med Parasitol** 1996 Oct;90(5):461–6

Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria. Vanijanonta S, et al. **Ann Trop Med Parasitol** 1996 Jun;90(3):269–75

Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulphadoxine–pyrimethamine in southern Malawi. Verhoeff FH, et al. **Ann Trop Med Parasitol** 1997 Mar;91(2):133–40

Poor efficacy of antimalarial biguanide–dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. Wilairatana P, et al. **Ann Trop Med Parasitol** 1997 Mar;91(2):125–32

Lymphocyte proliferative response and subset profiles during extended periods of chloroquine or primaquine prophylaxis. Fryauff DJ, et al. **Antimicrob Agents Chemother** 1996 Dec; 40(12):2737–42

Characterization of the potent in vitro and in vivo antimalarial activities of ionophore compounds. Gumila C, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):523–9

In vitro and in vivo inhibition of erythrocytic development of malarial parasites by docetaxel. Sinou V, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):358–61

Potentiation of an antimalarial oxidant drug. Winter RW, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1449–54

Your're the flight surgeon. Malaria chemoprophylaxis. Jex TT. **Aviat Space Environ Med** 1996 Jun;67(6):592–3

Mefloquine versus doxycycline for malaria prophylaxis in intermittent exposure of Israeli Air Force aircrew in Rwanda. Shamiss A, et al. **Aviat Space Environ Med** 1996 Sep;67(9):872–3

Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. Alin MH, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):587–92

Compliance with a 2 day course of artemether–mefloquine in an area of highly multi-drug resistant Plasmodium falciparum malaria. Na-Bangchang K, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):639–42

Mefloquine: the benefits outweigh the risks. Winstanley P. **Br J Clin Pharmacol** 1996 Oct;42(4):411–3

Antimalarial drugs in the treatment of rheumatological diseases. Rynes RI. **Br J Rheumatol** 1997 Jul;36(7):799–805 (64 ref.)

Using community health workers for malaria control: experience in Zaire. Delacollette C, et al. **Bull World Health Organ** 1996;74(4):423–30

A clinical trial with halofantrine on patients with falciparum malaria in Colombia. Restrepo M, et al. **Bull World Health Organ** 1996;74(6):591–7

Does an antimalarial drug history mean anything? Mahomva AI, et al. **Cent Afr J Med** 1996 Dec;42(12):345–6

Cotrifazid—an agent against malaria. Freerksen E, et al. **Chemotherapy** 1996 Nov–Dec;42(6):391–401

15-Deoxyspergualin, an immunosuppressive agent, used in organ transplantation showed suppressive effects on malarial parasites. Midorikawa Y, et al. **Chemotherapy** 1997 Jan–Feb;43(1):31–5

Chemotherapy of parasitic diseases. Current status and new directions. Liu Y. **Chin Med J (Engl)** 1996 Aug; 109(8):579–82 (28 ref.)

Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia. Barber BA, et al. **Clin Infect Dis** 1996 Oct;23(4):718–22

Treatment regimens for patients with toxoplasmic encephalitis. Fung HB, et al. **Clin Ther** 1996 Nov–Dec; 18(6):1037–56; discussion 1036 (67 ref.)

Mitotic effects of the aqueous leaf extract of Cymbopogon citratus in Allium cepa root tips. Williams GO, et al. **Cytobios** 1996;87(350):161–8

The safety of antimalarial drugs in pregnancy. Phillips-Howard PA, et al. **Drug Saf** 1996 Mar;14(3):131–45 (101 ref.)

Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. de Vries PJ, et al. **Drugs** 1996 Dec;52(6):818–36 (116 ref.)

Induction of chloroquine resistance in Plasmodium yoelii nigeriensis. Kimbi HK, et al. **East Afr Med J** 1996 Oct; 73(10):634–5

Utilisation of antimalarial drugs by pregnant women attending the antenatal clinic at Muhimbili Medical Centre, Dar es Salaam. Massele AY, et al. **East Afr Med J** 1997 Jan;74(1):28–30

East meets west for improved antimalarials [news] **Environ Health Perspect** 1996 Mar;104(3):252–3

Quinine in the treatment of Babesia divergens infections in humans [letter] Brasseur P, et al. **Eur J Clin Microbiol Infect Dis** 1996 Oct;15(10):840–1

A study of sensitivity of P. falciparum to chloroquine in a rural area of Bharuch district, Gujarat. SEWA-Rural Research Team. Society for Education, Welfare and Action. **Indian J Malariol** 1996 Sep;33(3):126–30

Drug resistant Plasmodium falciparum in Mandla District, Madhya Pradesh. Singh N, et al. **Indian J Malariol** 1995 Dec;32(4):174–7

Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat. Srivastava HC, et al. **Indian J Malariol** 1996 Dec;33(4):173–9

Effect of arteether alpha/beta on uncomplicated falciparum malaria cases in Upper Assam. Mohapatra PK, et al. **Indian J Med Res** 1996 Nov;104:284–7

"Ayush –64"—a new anti malarial herbal compound. Ali H. **Indian J Pathol Microbiol** 1996 Dec;39(5):499–500

Chemotherapy for cerebral malaria. Garg RK. **Indian Pediatr** 1996 Dec;33(12):1067–9

A standard regimen for treatment of plasmodium vivax malaria. Patwari AK. **Indian Pediatr** 1996 Sep;33(9):792–4

Intralesional chloroquine for the treatment of cutaneous sarcoidosis [letter] Liedtka JE. **Int J Dermatol** 1996 Sep; 35(9):682–3

Resistance to chloroquine therapy in pregnant women with malaria parasitemia. Rukaria-Kaumbutho RM, et al. **Int J Gynaecol Obstet** 1996 Jun;53(3):235–41

Chloroquine bioassay of plasma specimens obtained from soldiers on chloroquine plus doxycycline for malaria prophylaxis. Kotecka BM, et al. **Int J Parasitol** 1996 Nov; 26(11):1325–9

Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. Chiodini PL, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1073–8

A comparative clinical trial of artemether and the sequential regimen of artemether-mefloquine in multidrug resistant falciparum malaria. Karbwang J, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1079–83

Upregulation of reactive oxygen and nitrogen intermediates in Plasmodium berghei infected mice after rescue therapy with chloroquine or artemether. Prada J, et al. **J Antimicrob Chemother** 1996 Jul;38(1):95–102

Rajasthan malaria epidemic—1994—practical problems in prevention, diagnosis and treatment on the field [letter] Antony R, et al. **J Assoc Physicians India** 1996 Jul;44(7):508

Chloroquine resistant falciparum malaria—the Indian scene [editorial; comment] Chogle AR. **J Assoc Physicians India** 1996 Oct;44(10):677–8. Comment on: J Assoc Physicians India 1996 Oct;44(10):683–5.

Efficacy of sulfadoxine-pyrimethamine in chloroquine resistant falciparum malaria in Bombay [see comments] Garg MR, et al. **J Assoc Physicians India** 1996 Oct; 44(10):683–5. Comment in: J Assoc Physicians India 1996 Oct;44(10):677–8.

Resurgence of malaria and drug resistance in plasmodium falciparum and plasmodium vivax species in Bombay [see comments] Potkar CN, et al. **J Assoc Physicians India** 1995 May;43(5):336–8. Comment in: J Assoc Physicians India 1996 Jan;44(1):71.

Modified antimalarial treatment for chloroquin resistant plasmodium falciparum infection [letter] Singh PS. **J Assoc Physicians India** 1995 Jan;43(1):72–3

The role of different antimalarial drugs in the treatment of imported malaria. Pavlovic M, et al. **J Chemother** 1995 Nov;7 Suppl 4:196–8

Serum laminin and basic fibroblast growth factor concentrations in patients with complicated Plasmodium falciparum malaria. Burgmann H, et al. **J Clin Immunol** 1996 Sep;16(5):278–82

A quantification methodology of conversion rate based on field detected RI cases to RII-RIII cases—an approach for an alternative anti-malaria drug strategy. Pandya AP. **J Commun Dis** 1996 Jun;28(2):111–6

Poly ICLC enhances the antimalarial activity of chloroquine against multidrug-resistant Plasmodium yoelii nigeriensis in mice. Awasthi A, et al. **J Interferon Cytokine Res** 1997 Jul;17(7):419–23

Direct comparison of antimalarial activity among PS-15 combination therapies by bioassay of serum samples from treated Saimiri sciureus. Yeo AE. **J Parasitol** 1997 Jun; 83(3):515–8

An exploration of the structure-activity relationships of 4-aminoquinolines: novel antimalarials with activity in-vivo. Ismail FM, et al. **J Pharm Pharmacol** 1996 Aug; 48(8):841–50

Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. Parke A, et al. **J Rheumatol** 1996 Oct; 23(10):1715–8

The new antimalarials [editorial] Ebrahim GJ. **J Trop Pediatr** 1997 Apr;43(2):62–4

False chloroquine resistance in Africa [letter] Basco LK, et al. **Lancet** 1997 Jul 19;350(9072):224

Amodiaquine [letter; comment] Bloland PB, et al. **Lancet** 1996 Dec 14;348(9042):1659–60. Comment on: Lancet 1996 Nov 2;348(9036):1196–201.

Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Menendez C, et al. **Lancet** 1997 Sep 20;350(9081):844–50

Systematic review of amodiaquine treatment in uncomplicated malaria [see comments] Olliaro P, et al. **Lancet** 1996 Nov 2;348(9036):1196–201 (15 ref.). Comment in: Lancet 1996 Nov 2;348(9036):1184–5. Comment in: Lancet 1996 Dec 14;348(9042):1659–60.

Efficacy of low-dose halofantrine for second treatment of uncomplicated falciparum malaria [letter] Touze JE, et al. **Lancet** 1997 Jan 25;349(9047):255–6

Can amodiaquine be resurrected? [comment] White NJ. **Lancet** 1996 Nov 2;348(9036):1184–5. Comment on: Lancet 1996 Nov 2;348(9036):1196–201.

Management of antimalarial-refractory cutaneous lupus erythematosus. Callen JP. **Lupus** 1997;6(2):203–8 (37 ref.)

Role of antimalarials in rheumatoid arthritis—the British experience. Davis MJ, et al. **Lupus** 1996 Jun;5 Suppl 1:S37–40 (22 ref.)

Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Fox RI, et al. **Lupus** 1996 Jun;5 Suppl 1:S31–6

The use of hydroxychloroquine in lupus pregnancy: the British experience. Khamashta MA, et al. **Lupus** 1996 Jun; 5 Suppl 1:S65–6

The role of anti-malarials in rheumatoid arthritis—the American experience. Khraishi MM, et al. **Lupus** 1996 Jun; 5 Suppl 1:S41–4 (37 ref.)

Antimalarials in Sjögren's syndrome—the Greek experience. Manoussakis MN, et al. **Lupus** 1996 Jun;5 Suppl 1:S28–30 (15 ref.)

Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Meinão IM, et al. **Lupus** 1996 Jun; 5(3):237–41

The efficacy of antimalarials in systemic lupus erythematosus. Nayak V, et al. **Lupus** 1996 Jun;5 Suppl 1:S23–7 (26 ref.)

Antimalarial drugs in pregnancy—the North American experience. Parke AL, et al. **Lupus** 1996 Jun;5 Suppl 1:S67–9 (21 ref.)

The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Wallace DJ. **Lupus** 1996 Jun; 5 Suppl 1:S59–64 (86 ref.)

Severe falciparum malaria with hyperparasitaemia treated with intravenous artesunate. Davis TM, et al. **Med J Aust** 1997 Apr 21;166(8):416–8

Artemether in severe malaria [letter; comment] Fruchter O. **N Engl J Med** 1996 Dec 19;335(25):1922–3; discussion 1923–4. Comment on: N Engl J Med 1996 Jul 11;335(2):69–75.

Artemether in severe malaria [letter; comment] Gachot B, et al. **N Engl J Med** 1996 Dec 19;335(25):1922; discussion 1923–4. Comment on: N Engl J Med 1996 Jul 11;335(2):69–75. Comment on: N Engl J Med 1996 Jul 11;335(2):76–83.

Artemether in severe malaria [letter] Newmark A. **N Engl J Med** 1996 Dec 19;335(25):1923; discussion 1923–4

Sarcoidosis [letter] Than N, et al. **N Engl J Med** 1997 Sep 11;337(11):790–1

Recrudescence of Plasmodium falciparum malaria contracted in Lombok, Indonesia after quinine/doxycycline and mefloquine: case report. Tish KN, et al. **N Z Med J** 1997 Jul 11;110(1047):255–6

Making malaria research bite. MacLean M, et al. **Nat Med** 1997 Jan;3(1):14–6

Acute glomerulonephritis without fever: an unusual presentation of malaria on mefloquine prophylaxis [letter] Martínez-Ocana JC, et al. **Nephron** 1996;73(2):372

Plasmodium yoelii nigeriensis: biological mechanisms of resistance to chloroquine. Beauté-Lafitte A, et al. **Parasite** 1994 Sep;1(3):227–33

Malaria fighters gather at site of early victory [news] Bagla P. **Science** 1997 Sep 5;277(5331):1437–8

Information about antimalarial chemoprophylaxis in hospitalised patients—is it adequate? Nathwani D, et al. **Scott Med J** 1997 Feb;42(1):13–5

Identifying malaria control issues: a district hospital-based evaluation. Kimerling ME, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):611–9

Artemether-pyrimethamine in the treatment of pyrimethamine-resistant falciparum malaria. Na-Bangchang K, et al. **Southeast Asian J Trop Med Public Health** 1996 Mar; 27(1):19–23

Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant falciparum malaria. Na-Bangchang K, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):522–5

Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning. Deshpande SS, et al. **Toxicon** 1997 Mar;35(3):433–45

Chloroquine sensitive Plasmodium falciparum and P. vivax in central Java, Indonesia. Baird JK, et al. **Trans R Soc Trop Med Hyg** 1996 Jul–Aug;90(4):412–3

Survey of resistance to chloroquine of falciparum and vivax malaria in Palawan, The Philippines. Baird JK, et al. **Trans R Soc Trop Med Hyg** 1996 Jul–Aug;90(4):413–4

Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Baird JK, et al. **Trans R Soc Trop Med Hyg** 1996 Jul–Aug;90(4):409–11

pfmdr1 gene mutation and clinical response to chloroquine in Yaoundé, Cameroon. Basco LK, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):210–1

Artemether or artesunate followed by mefloquine as a possible treatment for multidrug resistant falciparum malaria. Bunnag D, et al. **Trans R Soc Trop Med Hyg** 1996 Jul–Aug;90(4):415–7

Treatment of Plasmodium vivax malaria—time for a change? Doherty JF, et al. **Trans R Soc Trop Med Hyg** 1997 Jan–Feb;91(1):76

Comparative efficacy of halofantrine, chloroquine and

sulfadoxine–pyrimethamine for treatment of acute uncomplicated falciparum malaria in Nigerian children. Falade CO, et al. **Trans R Soc Trop Med Hyg** 1997 Jan–Feb; 91(1):58–62

Possible prognostic significance of a brief rise in parasitaemia following quinine treatment of severe Plasmodium falciparum malaria. Gachot B, et al. **Trans R Soc Trop Med Hyg** 1996 Jul–Aug;90(4):388–90

Single dose artemisinin–mefloquine versus mefloquine alone for uncomplicated falciparum malaria. Le NN, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):191–4

Plasmodium falciparum: increased proportion of severe resistance (RII and RIII) to chloroquine and high rate of resistance to sulfadoxine–pyrimethamine in Peninsular Malaysia after two decades. Lokman Hakim S, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):294–7

Hyperreactive malarial splenomegaly and AIDS: proguanil prevents recurrent pneumonia. Lowenthal MN, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):313–4

alpha, beta–Arteether for the treatment of complicated falciparum malaria. Mohanty S, et al. **Trans R Soc Trop Med Hyg** 1997 May–Jun;91(3):328–30

An open randomized trial of artemether versus quinine in the treatment of cerebral malaria in African children. Murphy S, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun; 90(3):298–301

Validity of mother's history regarding antimalarial drug use in Malawian children under five years old. Nwanyanwu OC, et al. **Trans R Soc Trop Med Hyg** 1996 Jan–Feb; 90(1):66–8

Early clinical failures after pyrimethamine–sulfadoxine treatment of uncomplicated falciparum malaria. Onyiorah E, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun; 90(3):307–8

Prevention and morbidity of malaria in non–immune subjects; a case–control study among Italian troops in Somalia and Mozambique, 1992–1994. Peragallo MS, et al. **Trans R Soc Trop Med Hyg** 1997 May–Jun;91(3):343–6

Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria. Radloff PD, et al. **Trans R Soc Trop Med Hyg** 1996 Nov–Dec;90(6):682

Response of babesiosis to a combined regimen of quinine and azithromycin. Shaio MF, et al. **Trans R Soc Trop Med Hyg** 1997 Mar–Apr;91(2):214–5

Enhanced efficacy of chloroquine–chlorpheniramine combination in acute uncomplicated falciparum malaria in children. Sowunmi A, et al. **Trans R Soc Trop Med Hyg** 1997 Jan–Feb;91(1):63–7

Failure of chloroquine treatment for malaria in the highlands of Ethiopia. Tulu AN, et al. **Trans R Soc Trop Med Hyg** 1996 Sep–Oct;90(5):556–7

Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. Winstanley P, et al. **Trans R Soc Trop Med Hyg** 1997 May–Jun;91(3):322–7

Chloroquine–resistant Plasmodium falciparum among children in Calabar, south eastern Nigeria. Antia–Obong OE, et al. **Trop Doct** 1997 Jul;27(3):146–9

Sensitivities of malaria in Zaire [letter] Hodes RM, et al. **Trop Doct** 1997 Jul;27(3):190

Plants as a source of antimalarial drugs. Kirby GC. **Trop Doct** 1997;27 Suppl 1:7–11 (34 ref.)

Chloroquine resistance of Plasmodium falciparum malaria in Ethiopia and Eritrea. Alene GD, et al. **Trop Med Int Health** 1996 Dec;1(6):810–5

Compliance with malaria chemoprophylaxis and preventative measures against mosquito bites among Dutch travellers. Cobelens FG, et al. **Trop Med Int Health** 1997 Jul; 2(7):705–13

Chloroquine resistant Plasmodium vivax malaria in India. Dua VK, et al. **Trop Med Int Health** 1996 Dec;1(6):816–9

Severe falciparum malaria with hyperparasitaemia: management without exchange blood transfusion. Fontes CJ, et al. **Trop Med Int Health** 1996 Dec;1(6):820–3

Response of childhood malaria to chloroquine and Fansidar in an area of intermediate chloroquine resistance in Côte d'Ivoire. Henry MC, et al. **Trop Med Int Health** 1996 Oct; 1(5):610–5

Anti–malarial drug resistance, malnutrition and socio–economic status. Hess FI, et al. **Trop Med Int Health** 1997 Aug;2(8):721–8

A comparative study of the efficacies of chloroquine and a pyrimethamine–dapsone combination in clearing Plasmodium falciparum parasitaemia in school children in Tanzania. Mshinda H, et al. **Trop Med Int Health** 1996 Dec;1(6):797–801

Responses of multidrug–resistant Plasmodium falciparum parasites to mefloquine in Nigerian children. Okoyeh JN, et al. **Trop Med Int Health** 1997 Apr;2(4):319–24

Artemether treatment of recrudescent Plasmodium falciparum malaria in children. Sowunmi A, et al. **Trop Med Int Health** 1997 Jul;2(7):631–4

Therapeutic efficacy of clindamycin in combination with quinine for treating uncomplicated malaria in a village dispensary in Gabon. Vaillant M, et al. **Trop Med Int Health** 1997 Sep;2(9):917–9

[Not more symptoms with mefloquine use than with other drugs in malaria prophylaxis (see comments)] Wolters BA, et al. **Ned Tijdschr Geneeskd** 1997 Feb 15;141(7):331–4 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1997 Apr 19;141(16):794–5; discussion 796. Comment in: Ned Tijdschr Geneeskd 1997 May 3;141(18):898. **(Dut)**

[In vivo chemosensitivity tests of Plasmodium falciparum to chloroquine in Senegal: the development of resistance and the assessment of therapeutic efficacy] Sokhna CS, et al. **Bull Soc Pathol Exot** 1997;90(2):83–9 (Eng. Abstr.) **(Fre)**

[In vivo drug sensitivity of Plasmodium falciparum in the Tabou region of Ivory Coast] Villadary I, et al. **Bull Soc Pathol Exot** 1997;90(1):10–3 (Eng. Abstr.) **(Fre)**

[Malaria and marketing policy (letter)] Louis FJ, et al. **Med Trop (Mars)** 1996;56(4):414 **(Fre)**

[Will a gametocytocide combined with an antimalarial schizonticide soon be necessary in areas of drug resistance? (letter)] Molez JF, et al. **Med Trop (Mars)** 1997;57(1):97 **(Fre)**

[Use of artemether in the treatment of severe malaria, an alternative in an unusual situation (letter)] Nicolas X, et al. **Med Trop (Mars)** 1997;57(1):96–7 **(Fre)**

[2 cases of malarial flare–up with fatal outcome inspite of treatment with halofantrine (letter)] Angel G, et al. **Presse Med** 1996 Nov 2;25(33):1604 **(Fre)**

[Malaria: what treatment today? (editorial)] Bourée P. **Presse Med** 1997 Feb 15;26(4):156–7 (Eng. Abstr.) **(Fre)**

[Antimalarial agents in rheumatic diseases. New therapeutic aspects of an old medication] Barthel HR, et al. **Dtsch Med Wochenschr** 1996 Dec 13;121(50):1576–82 (48 ref.) **(Ger)**

[Malaria] Nickel P. **Pharm Unserer Zeit** 1997 Mar;26(2):84–5 **(Ger)**

[A study of relapsed cases of vivax malaria after the standard primaquine therapy] Kimura M, et al. **Kansenshogaku Zasshi** 1996 Oct;70(10):1086–91 (Eng. Abstr.) **(Jpn)**

[The evaluation of the efficacy of artesunate combined with tetracycline in the therapy of falciparum malaria] Salcedo JM, et al. **Rev Soc Bras Med Trop** 1997 May–Jun; 30(3):215–22 (Eng. Abstr.) **(Por)**

[Effect of Momordica charantia L. in mice infected with Plasmodium berghei] Ueno HM, et al. **Rev Soc Bras Med Trop** 1996 Sep–Oct;29(5):455–60 (Eng. Abstr.) **(Por)**

TOXICITY

Artemisinin neurotoxicity: neuropathology in rats and mechanistic studies in vitro. Kamchonwongpaisan S, et al. **Am J Trop Med Hyg** 1997 Jan;56(1):7–12

Arteether: risks of two–week administration in Macaca mulatta. Petras JM, et al. **Am J Trop Med Hyg** 1997 Apr; 56(4):390–6

X–ray crystal structure of the antimalarial agent (–)–halofantrine hydrochloride supports stereospecificity for cardiotoxicity. Karle JM. **Antimicrob Agents Chemother** 1997 Apr;41(4):791–4

Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)–9–(3–hydroxy–2–phosphonylmethoxypropyl)adenine in Plasmodium berghei–infected mice. Smeijsters LJ, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1584–8

Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Levy GD, et al. **Arthritis Rheum** 1997 Aug;40(8):1482–6

Enhanced in vitro neurotoxicity of artemisinin derivatives in the presence of haemin. Smith SL, et al. **Biochem Pharmacol** 1997 Jan 10;53(1):5–10

Effect of azadirachtin A on the fine structure of the midgut of Rhodnius prolixus. Nogueira NF, et al. **J Invertebr Pathol** 1997 Jan;69(1):58–63

Composition and antimalarial activity in vitro of the essential oil of Tetradenia riparia [letter] Campbell WE, et al. **Planta Med** 1997 Jun;63(3):270–2

Detection of fragile sites induced by pyrimethamine. Egeli U, et al. **Teratog Carcinog Mutagen** 1997;17(2):59–69

ANTIMANIC AGENTS

ADMINISTRATION & DOSAGE

Cerebellar ataxia in upper limbs triggered by addition of carbamazepine to lithium treatment. Manto MU, et al. **Acta Neurol Belg** 1996 Dec;96(4):316–7

Course of illness and pattern of recurrences in patients with affective disorders during long–term lithium prophylaxis: a retrospective analysis over 15 years. Berghöfer A, et al. **Acta Psychiatr Scand** 1996 May;93(5):349–54

Clonazepam in acute mania: time–blind evaluation of clinical response and concentrations in plasma. Bottaï T, et al. **J Affect Disord** 1995 Dec 24;36(1–2):21–7

Late non–response to lithium prophylaxis in bipolar patients: prevalence and predictors. Maj M, et al. **J Affect Disord** 1996 Jun 20;39(1):39–42

Renal reactions to changes of lithium dosage. Kusalic M, et al. **Neuropsychobiology** 1996;34(3):113–6

Chronic lithium attenuates dopamine D1–receptor mediated increases in acetylcholine release in rat frontal cortex. Acquas E, et al. **Psychopharmacology (Berl)** 1996 May; 125(2):162–7

Twelve–hour brain lithium concentration in lithium maintenance treatment of manic–depressive disorder: daily versus alternate–day dosing schedule. Jensen HV, et al. **Psychopharmacology (Berl)** 1996 Apr;124(3):275–8

[Acute inpatient treatment of manias. Effects of independent variables on neuroleptic dosage and length of stay] Adler L, et al. **Nervenarzt** 1996 Mar;67(3):235–43 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Lithium neurotoxicity at low therapeutic doses Hypotheses for causes and mechanism of action following a retrospective analysis of published case reports. Emilien G, et al. **Acta Neurol Belg** 1996 Dec;96(4):281–93 (76 ref.)

Irreversible sinus node dysfunction induced by resumption of lithium therapy. Terao T, et al. **Acta Psychiatr Scand** 1996 May;93(5):407–8

Lithium toxicity. Vipond AJ, et al. **Anaesthesia** 1996 Dec; 51(12):1156–8

Alopecia and mood stabilizer therapy. McKinney PA, et al. **Ann Clin Psychiatry** 1996 Sep;8(3):183–5 (12 ref.)

Photophobia and lithium. Pridmore S, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):287–9

Effects of chronic lithium treatment on retinal electrophysiologic function. Lam RW, et al. **Biol Psychiatry** 1997 Mar 15;41(6):737–42

Lithium decreases retinal sensitivity, but this is not cumulative with years of treatment. Wirz–Justice A, et al. **Biol Psychiatry** 1997 Mar 15;41(6):743–6

Lithium–induced follicular hyperkeratosis. Wakelin SH, et al. **Clin Exp Dermatol** 1996 Jul;21(4):296–8

Irreversible lithium neurotoxicity: an overview. Kores B, et al. **Clin Neuropharmacol** 1997 Aug;20(4):283–99 (84 ref.)

Central pontine myelinolysis related to lithium toxicity [letter] Khan AU, et al. **Gen Hosp Psychiatry** 1997 Mar; 19(2):150–2

Extrapyramidal syndrome due to valproate administration as an adjunct to lithium in an elderly manic patient [letter] Wils V, et al. **Int J Geriatr Psychiatry** 1997 Feb;12(2):272

Double–blind comparison of the side–effect profiles of daily versus alternate–day dosing schedules in lithium maintenance treatment of manic–depressive disorder. Jensen HV, et al. **J Affect Disord** 1996 Jan 22;36(3–4):89–93

Hormonal effects of valproic acid? [letter] Garland EJ, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Nov; 35(11):1424–5

Lithium and neuroleptics in combination: is there enhancement of neurotoxicity leading to permanent sequelae? Goldman SA. **J Clin Pharmacol** 1996 Oct; 36(10):951–62

Transient aphasia associated with lithium intoxication [letter] Gordon PH, et al. **J Clin Psychopharmacol** 1997 Feb; 17(1):55–6

Effect of lithium maintenance treatment on hypothalamic pituitary gonadal axis in bipolar men. Kusalic M, et al. **J Psychiatry Neurosci** 1996 May;21(3):181–6

Renal reactions to changes of lithium dosage. Kusalic M, et al. **Neuropsychobiology** 1996;34(3):113–6

Serotonin syndrome after lithium add–on medication to paroxetine. Sobanski T, et al. **Pharmacopsychiatry** 1997 May;30(3):106–7

[Is lithium a teratogen?] Kučera V. **Cas Lek Cesk** 1996 Nov 20;135(22):726–8 (20 ref.) (Eng. Abstr.) **(Cze)**

[Reversible neuropsychiatric side effects of lithium with normal serum levels. A case report] Fallgatter AJ, et al. **Nervenarzt** 1997 Jul;68(7):586–90 (Eng. Abstr.) **(Ger)**

BLOOD

An attempt to predict daily erythrocyte lithium fluctuations. Sögüt O, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct–Dec;20(4):271–4

The effect of flurbiprofen on steady–state plasma lithium levels. Hughes BM, et al. **Pharmacotherapy** 1997 Jan–Feb; 17(1):113–20

PHARMACOKINETICS

Duration of lithium treatment and brain lithium concentration in patients with unipolar and schizoaffective disorder—a study with magnetic resonance spectroscopy. Riedl U, et al. **Biol Psychiatry** 1997 Apr 15;41(8):844–50

Lithium pharmacokinetics in Chinese manic–depressive patients. Wing YK, et al. **J Clin Psychopharmacol** 1997 Jun; 17(3):179–84

[A comparative clinico–pharmacokinetic study of the use of equivalent daily doses of lithium carbonate and Contemnol] Mosolov SN, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(5):30–3 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Combined valproate or carbamazepine and electroconvulsive therapy. Zarate CA Jr, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):19–25

On the functions of lithium: the mood stabilizer. Shastry BS. **Bioessays** 1997 Mar;19(3):199–200 (25 ref.)

Inositol monophosphatase, the putative therapeutic target for lithium. Atack JR. **Brain Res Brain Res Rev** 1996 Aug; 22(2):183–90 (60 ref.)

The actions of ouabain and lithium chloride on cytosolic Ca2+ in single chromaffin cells. De la Fuente MT, et al. **Eur J Pharmacol** 1996 Jun 13;306(1–3):219–26

Altered protein phosphorylation in the rat brain following chronic lithium and carbamazepine treatments. Jensen JB, et al. **Eur Neuropsychopharmacol** 1997 Aug;7(3):173–9

Lithium prevents ouabain–induced behavioral changes. Toward an animal model for manic depression. Li R, et

al. **Mol Chem Neuropathol** 1997 May;31(1):65–72

Effects of lithium and carbamazepine on thyroid hormone metabolism in rat brain. Baumgartner A, et al. **Neuropsychopharmacology** 1997 Jan;16(1):25–41

Acute or chronic lithium does not affect agonist-stimulated inositol trisphosphate formation in rat brain in vivo. Gur E, et al. **Neuroreport** 1996 Jan 31;7(2):393–6

The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5–trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates. Dixon JF, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4757–60

Differential effects of lithium on platelet protein phosphorylation in bipolar patients and healthy subjects. Zanardi R, et al. **Psychopharmacology (Berl)** 1997 Jan; 129(1):44–7

POISONING

Hemodynamic, electrocardiographic, metabolic, and hematologic abnormalities resulting from lithium intoxication. A case report. Hussain KM, et al. **Angiology** 1997 Apr;48(4):351–4

Pathologic assessment of cerebellar atrophy following acute lithium intoxication. Mangano WE, et al. **Clin Neuropathol** 1997 Jan–Feb;16(1):30–3 (19 ref.)

THERAPEUTIC USE

Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Group for the Study of Lithium–treated patients (IGSLI). Müller–Oerlinghausen B, et al. **Acta Psychiatr Scand** 1996 Nov;94(5):344–7

Criteria for use of valproate in adult psychiatric inpatients and outpatients. Puzantian T. **Am J Health Syst Pharm** 1996 May 15;53(10):1187–8 (24 ref.)

Response of kleptomania and mixed mania to valproate [letter] Kmetz GF, et al. **Am J Psychiatry** 1997 Apr; 154(4):580–1

Treatment of bipolar depression with carbamazepine: results of an open study. Dilsaver SC, et al. **Biol Psychiatry** 1996 Nov 1;40(9):935–7

Relationship between prophylactic effect of lithium therapy and family history of affective disorders. Engström C, et al. **Biol Psychiatry** 1997 Sep 15;42(6):425–33

Duration of lithium treatment and brain lithium concentration in patients with unipolar and schizoaffective disorder—a study with magnetic resonance spectroscopy. Riedl U, et al. **Biol Psychiatry** 1997 Apr 15;41(8):844–50

Lack of advantage for imipramine combined with lithium versus imipramine alone in the treatment of major depression—a double–blind controlled study. Shahal B, et al. **Biol Psychiatry** 1996 Dec 1;40(11):1181–3

Choline in the treatment of rapid–cycling bipolar disorder: clinical and neurochemical findings in lithium–treated patients. Stoll AL, et al. **Biol Psychiatry** 1996 Sep 1; 40(5):382–8

Platelet endogenous adenosine 5'–diphosphate ribosylation in drug–free and lithium–treated subjects with bipolar disorder. Young LT, et al. **Biol Psychiatry** 1997 Sep 1; 42(5):413–5

Uptake of 99mTc–exametazime shown by single photon emission computed tomography before and after lithium withdrawal in bipolar patients: associations with mania. Goodwin GM, et al. **Br J Psychiatry** 1997 May;170:426–30

Generalisability of results from randomised drug trials. A trial on antimanic treatment. Licht RW, et al. **Br J Psychiatry** 1997 Mar;170:264–7

Lithium revisited [letter; comment] Moncrieff J. **Br J Psychiatry** 1996 Jun;168(6):789. Comment on: Br J Psychiatry 1996 Mar;168(3):381–3.

Valproate and neuroleptic medication [letter] Reutens S, et al. **Br J Psychiatry** 1997 May;170:484–5

Bipolar depression: an underestimated treatment challenge. Hlastala SA, et al. **Depress Anxiety** 1997;5(2):73–83

Decision model for the acute treatment of mania. Steffens DC, et al. **Depress Anxiety** 1996–97;4(6):289–93

Long term treatment of bipolar disorder [see comments] Silverstone T, et al. **Drugs** 1996 Mar;51(3):367–82 (105 ref.) . Comment in: Drugs 1997 Apr;53(4):726.

Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study. Greil W, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(1):42–50

Fluvoxamine and lithium in long–term treatment of unipolar subjects with high recurrence rate. Franchini L, et al. **J Affect Disord** 1996 Apr 26;38(1):67–9

Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. Greil W, et al. **J Affect Disord** 1996 Oct 14;40(3):179–90

Algorithms for the treatment of affective illness, primary disorder of vigilance, and task–dependent attention disorders (learning disabilities) in children and adolescents. Weinberg WA, et al. **J Child Neurol** 1996 May;11(3):220–7

Extreme mood lability associated with systemic lupus erythematosus and stroke successfully treated with valproic acid [letter] Himelhoch S, et al. **J Clin Psychopharmacol** 1996 Dec;16(6):469–70

Mania [letter; comment] Longhurst JG. **Lancet** 1997 Jul 26; 350(9073):292. Comment on: Lancet 1997 Apr 19;349(9059):1157–60.

Biological treatment of rapid–cycling bipolar disorder. Krüger S, et al. **Pharmacopsychiatry** 1996 Sep;29(5):167–75 (129 ref.)

Treating older adults with psychotic symptoms. Kim KY, et al. **Psychiatr Serv** 1997 Sep;48(9):1123–6 (34 ref.)

Association between mood–stabilizing medication and mental health resource use in the management of acute mania. Sajatovic M, et al. **Psychiatr Serv** 1997 Aug;48(8):1037–41

Lithium and recurrence in a long–term follow–up of bipolar affective disorder. Coryell W, et al. **Psychol Med** 1997 Mar; 27(2):281–9

Compliance with maintenance treatment in bipolar disorder. Keck PE Jr, et al. **Psychopharmacol Bull** 1997;33(1):87–91

Lithium, a multi–edged sword: the past, present, and future. Jefferson JW. **Wis Med J** 1996 Apr;95(4):231–5 (27 ref.)

[Administration of high dose levothyroxine in treatment of rapid cycling bipolar disorders. Review of the literature and initial therapeutic application apropos of 6 cases] Afflelou S, et al. **Encephale** 1997 May–Jun;23(3):209–17 (20 ref.) (Eng. Abstr.) **(Fre)**

[20 years unsuccessful prevention of bipolar affective psychosis recurrence] Godemann F, et al. **Nervenarzt** 1997 Jul;68(7):582–5 (21 ref.) (Eng. Abstr.) **(Ger)**

[Has drug treatment of manic disorders changed in clinical routine practice? Retrospective analysis of treatment modalities and results in a university psychiatric clinic] Reetz–Kokott U, et al. **Nervenarzt** 1996 Mar;67(3):229–34 (Eng. Abstr.) **(Ger)**

[The effect of lithium chloride on the desynchronization of "reserpine–induced depression"] Zamoshchina TA, et al. **Eksp Klin Farmakol** 1997 Jan–Feb;60(1):3–6 (Eng. Abstr.) **(Rus)**

[The treatment of atypical manias with finlepsin–retard] Dziub HK, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):146–8 (Eng. Abstr.) **(Ukr)**

TOXICITY

Irreversible lithium neurotoxicity: an overview. Kores B, et al. **Clin Neuropharmacol** 1997 Aug;20(4):283–99 (84 ref.)

ANTIMETABOLITES

2–Aminopurine labelled RNA bulge loops. Synthesis and thermodynamics. Zagórowska I, et al. **Biochimie** 1996; 78(2):123–30

ADMINISTRATION & DOSAGE

Five–year follow–up of the Fluorouracil Filtering Surgery Study [letter; comment] Van Buskirk EM. **Am J Ophthalmol** 1996 Nov;122(5):751–2. Comment on: Am J Ophthalmol 1996 Apr;121(4):349–66.

Computer–supported analysis (MegaBlot) of allopurinol–induced changes in the autoantibody repertoires of rats suffering from experimental lens–induced uveitis. Grus FH, et al. **Electrophoresis** 1997 Mar–Apr; 18(3–4):516–9

Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates. Kucharczuk JC, et al. **Hum Gene Ther** 1996 Dec 1;7(18):2225–33

Local injection of methotrexate dissolved in saline versus methotrexate suspensions for the conservative treatment of ectopic pregnancy. Fujishita A, et al. **Hum Reprod** 1995 Dec;10(12):3280–83

Short–term results of initial trabeculectomy with intraoperative or postoperative 5–fluorouracil for primary glaucomas. Lamba PA, et al. **Indian J Ophthalmol** 1996 Sep;44(3):157–60

Results of intraoperative 5–fluorouracil in patients undergoing trabeculectomy—pilot trial. Shelat B, et al. **Indian J Ophthalmol** 1996 Jun;44(2):91–4

Intravitreal sustained release corticosteroid–5–fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Berger AS, et al. **Invest Ophthalmol Vis Sci** 1996 Oct;37(11):2318–25

Results of intraoperative 5–fluorouracil or lower dose mitomycin–C administration on initial trabeculectomy surgery. Smith MF, et al. **J Glaucoma** 1997 Apr;6(2):104–10

Acute effects of propylthiouracil on hemodynamics and oxygen content in patients with alcoholic cirrhosis. Sogni P, et al. **J Hepatol** 1997 Mar;26(3):628–33

Low–dose perioperative 5–fluorouracil in trabeculectomy. Hugkulstone CE, et al. **Ophthalmic Surg Lasers** 1996 Nov; 27(11):910–6

Sustained–release subconjunctival 5–fluorouracil. Smith TJ, et al. **Ophthalmic Surg Lasers** 1996 Sep;27(9):763–7

Topical cyclosporine as a possible new antimetabolite in trabeculectomy. Turaçli ME, et al. **Ophthalmic Surg Lasers** 1996 Jun;27(6):438–44

5–fluorouracil in combined trabeculectomy and clear–cornea phacoemulsification with posterior chamber intraocular lens implantation. A one–year randomized, controlled clinical trial. Gandolfi SA, et al. **Ophthalmology** 1997 Feb; 104(2):181–6

Single exposures to 5–fluorouracil: a possible mode of targeted therapy to reduce contractile scarring in the injured tendon. Khan U, et al. **Plast Reconstr Surg** 1997 Feb;99(2):465–71

[Does the dosage of mitomycin–C applied during filtering surgery of glaucoma vary with the individual surgeon?] Mehel E, et al. **J Fr Ophtalmol** 1997;20(3):195–9 (Eng. Abstr.) **(Fre)**

[Antiproliferative therapy with 5–fluorouracil in erbium:YAG laser sclerostomy ab externo] Schmidbauer JM, et al. **Ophthalmologe** 1996 Oct;93(5):569–75 (Eng. Abstr.) **(Ger)**

[Single dose intraoperative administration of 5–fluorouracil (5–FU) in trabeculectomy. Long–term results of a pilot study] Spiegel D, et al. **Ophthalmologe** 1996 Oct;93(5):561–6 (Eng. Abstr.) **(Ger)**

[A study of serum oxipurinol concentration and renal function in patients administered allopurinol] Saji M. **Nippon Jinzo Gakkai Shi** 1996 Dec;38(12):640–50 (Eng. Abstr.) **(Jpn)**

[The effect of antioxidants on lipid metabolism in myocardium in experimental hyperthyroxinemic conditions] Grabowska–Maślanka H, et al. **Folia Med Cracov** 1996;37(1–2):61–6 (Eng. Abstr.) **(Pol)**

[Use of 5–fluorouracil shortly after trabeculectomy] Lewandowska–Furmanik M, et al. **Klin Oczna** 1996; 98(6):427–8 (Eng. Abstr.) **(Pol)**

[Experimental use of a cytostatic and a corticosteroid on a collagen implant in surgery for glaucoma] Batmanov IE, et al. **Vestn Oftalmol** 1996 Sep–Oct;112(4):14–16 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Antimetabolites and an optic neuropathy epidemic in Cuba [letter; comment] Ascherio A. **Am J Clin Nutr** 1997 Apr; 65(4):1092–3. Comment on: Am J Clin Nutr 1996 Sep;64(3):347–53. Comment on: Am J Clin Nutr 1996 Sep;64(3):383–4.

Late onset of sequential multifocal bleb leaks after glaucoma filtration surgery with 5–fluorouracil and mitomycin C. Belyea DA, et al. **Am J Ophthalmol** 1997 Jul;124(1):40–5

Cystitis associated with allopurinol. Bramble FJ, et al. **Br J Urol** 1997 May;79(5):817

Azathioprine–induced pericarditis in a patient with ulcerative colitis. Simpson CD. **Can J Gastroenterol** 1997 Apr; 11(3):217–9

Corneal ectasia secondary to excessive ocular massage following trabeculectomy with 5–fluorouracil. Baldassare RD, et al. **Can J Ophthalmol** 1996 Aug;31(5):252–4

[Xanthine urinary calculus in a patient with Lesch–Nyhan syndrome. Apropos of a case] Volpe P, et al. **Prog Urol** 1997 Feb;7(1):74–7 (Eng. Abstr.) **(Fre)**

[Granuloma annulare disseminatum as a rare side effect of allopurinol (letter; comment)] Brechtel B, et al. **Hautarzt** 1996 Feb;47(2):143. Comment on: Hautarzt 1995 May;46(5):343–5. **(Ger)**

[Allopurinol induced pancytopenia in a patient with myeloproliferative disorder] Shinagawa A, et al. **Rinsho Ketsueki** 1997 Jan;38(1):64–71 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Association between CYP2C19 genotype and proguanil oxidative polymorphism. Coller JK, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):659–60

CHEMISTRY

Stability of fluorouracil in polypropylene syringes and ethylene vinyl acetate infusion–pump reservoirs [letter] Baud–Camus F, et al. **Am J Health Syst Pharm** 1996 Jun 15;53(12):1457, 1461

Precipitation of fluorouracil in elastomeric infusers with a polyisoprene reservoir and in polypropylene syringes with an elastomeric joint. Corbrion V, et al. **Am J Health Syst Pharm** 1997 Aug 15;54(16):1845–8

DIAGNOSTIC USE

Reproducibility of the measurement of colonic proliferation using bromodeoxyuridine across laboratories. Roe DJ, et al. **Cancer Epidemiol Biomarkers Prev** 1996 May; 5(5):349–53

A combined cobalt and C–14 2–deoxyglucose approach to antiepileptic drug assessment. Krenz NR, et al. **Int J Neurosci** 1996 Jul;86(1–2):55–66

METABOLISM

Structure–activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases. Johansson NG, et al. **Acta Biochim Pol** 1996; 43(1):143–60 (77 ref.)

Protein–tyrosine phosphatase activity of Coxiella burnetii that inhibits human neutrophils. Li YP, et al. **Acta Virol** 1996 Nov–Dec;40(5–6):263–72

Association between CYP2C19 genotype and proguanil oxidative polymorphism. Coller JK, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):659–60

Substrate autoregulation of glucose transport: hexose 6–phosphate mediates the cellular distribution of glucose transporters. Sasson S, et al. **Diabetologia** 1997 Jan; 40(1):30–9

Dietary goitrogen–induced changes in the transport of 2–deoxy–D–glucose and amino acids across the rat blood–brain barrier. Bala TS, et al. **Int J Dev Neurosci** 1996 Aug;14(5):575–83

Dephosphorylation of 2–deoxyglucose 6–phosphate and 2–deoxyglucose export from cultured astrocytes. Forsyth RJ, et al. **Neurochem Int** 1996 Mar;28(3):243–50

Characterization of [2–3H]deoxy–D–glucose uptake in retina

and retinal pigment epithelium of normal and diabetic rats. Vilchis C, et al. **Neurochem Int** 1996 Feb;28(2):213–9

PHARMACOKINETICS

Intravitreal concentrations of some drugs administered with microdialysis. Waga J, et al. **Acta Ophthalmol Scand** 1997 Feb;75(1):36–40

Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters. Neshasteh-Riz A, et al. **Br J Cancer** 1997;75(4):493–9

The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nelson CA, et al. **Nucl Med Biol** 1996 May;23(4):533–41

PHARMACOLOGY

Metabolic inhibitors affect the conductance of low voltage-activated calcium channels in brain capillary endothelial cells. Delpiano MA. **Adv Exp Med Biol** 1996; 410:109–13

Discriminative stimulus effects of ethanol: lack of antagonism with N-methyl-D-aspartate and D-cycloserine. Bienkowski P, et al. **Alcohol** 1997 Jul–Aug;14(4):345–50

Effects of buthionine sulfoximine on the outcome of the in utero administration of alcohol on fetal development. Reyes E, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1243–51

Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Sanglard D, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2300–5

Effect of 2',3'-dideoxycytidine on oxidative phosphorylation in the PC12 cell, a neuronal model. Keilbaugh SA, et al. **Biochem Pharmacol** 1997 May 15;53(10):1485–92

Insensitivity of cultured rat cortical neurons to mitochondrial DNA synthesis inhibitors: evidence for a slow turnover of mitochondrial DNA. Wang GJ, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):181–7

Central nervous system depressant effects of N3-substituted derivatives of deoxyuridine in mice. Kimura T, et al. **Biol Pharm Bull** 1996 Jan;19(1):142–5

Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Randall TD, et al. **Blood** 1997 May 15;89(10):3596–606

Effect of allopurinol on lipid peroxidation induced in corporeal tissue by veno-occlusive priapism in a rat model. Evliyaoglu Y, et al. **Br J Urol** 1997 Sep;80(3):476–9

Evidence for the involvement of catecholamines in the 2-DG-induced immunomodulatory effects in spleen. Chou SH, et al. **Brain Behav Immun** 1997 Jun;11(2):79–93

Chronic, post-injury administration of D-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury. Temple MD, et al. **Brain Res** 1996 Nov 25;741(1–2):246–51

Modulation of the expression on constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil. Afsar A, et al. **Can J Physiol Pharmacol** 1996 Feb;74(2):150–6

2-Deoxy-D-glucose-induced changes in membrane potential, input resistance, and excitatory postsynaptic potentials of CA1 hippocampal neurons. Zhao YT, et al. **Can J Physiol Pharmacol** 1997 May;75(5):368–74

Aging effects on the organic base transporter and stereoselective renal clearance. Ujhelyi MR, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):117–28

Effect of electric pulses and antiproliferative drugs on cultured bovine retinal pigment epithelial cells. Oshima Y, et al. **Curr Eye Res** 1997 Jan;16(1):64–70

Dexamethasone prevents interleukin-1beta-mediated inhibition of rat islet insulin secretion without decreasing nitric oxide production. Mauricio D, et al. **Cytokine** 1997 Aug;9(8):563–9

Blockade of the estrogen induced increase in progesterone receptor caused by propylthiouracil, an anti-thyroid drug, in a transplantable pituitary tumor in rats. Fujimoto N, et al. **Endocr J** 1996 Jun;43(3):329–34

Glucoprivation by insulin leads to trans-synaptic increase in rat adrenal tyrosine hydroxylase mRNA levels. Vietor I, et al. **Eur J Pharmacol** 1996 Oct 10;313(1–2):119–27

The effects of D-cycloserine and MK-801 on the performance of rats in two spatial learning and memory tasks. Pitkänen M, et al. **Eur Neuropsychopharmacol** 1995 Dec;5(4):457–63

D-Cycloserine biases enrichment for auxotrophic mutants of Zymomonas mobilis. Pencreac'h G, et al. **FEMS Microbiol Lett** 1996 Sep 1;142(2–3):167–71

Modulation by alcohol and methadone of 2-deoxyglucose-stimulated pancreatic secretion in the rat. Nagain-Domaine C, et al. **Fundam Clin Pharmacol** 1996; 10(6):538–46

Immunomodulating activity of allopurinol in experimental lens-induced uveitis. Grus FH, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Feb;235(2):118–23

Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Benedetti S, et al. **Hum Gene Ther** 1997 Jul 20;8(11):1345–53

Enhancement of frequencies of restriction endonuclease-induced chromatid breaks by arabinoside adenine in normal human and ataxia telangiectasia cells. Liu N, et al. **Int J Radiat Biol** 1997 Sep;72(3):285–92

Single exposures to antiproliferatives: long-term effects on ocular fibroblast wound-healing behavior. Occleston NL, et al. **Invest Ophthalmol Vis Sci** 1997 Sep;38(10):1998–2007

The effect of acyclovir on the proliferative capacity of mononuclear cells from patients with chronic lymphocytic leukemia. Bessler H, et al. **Isr J Med Sci** 1996 Dec; 32(12):1228–31

Potential chemoprotectant activity of 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC) against ricin toxicity in Chinese hamster ovary and macrophage J774A.1 cell cultures. Hassoun EA, et al. **J Appl Toxicol** 1996 Jan–Feb; 16(1):43–8

Risk of microbial contamination with multiple use of 5-fluorouracil vials. Mora JS, et al. **J Glaucoma** 1996 Dec; 5(6):371–4

Effect of metabolic inhibition on K+ channels in pyramidal cells of the hippocampal CA1 region in rat brain slices. Hyllienmark L, et al. **J Physiol (Lond)** 1996 Oct 1;496 (Pt 1):155–64

Effect of high doses of 2-CdA on Schwann cells of mouse peripheral nerve. Djaldetti R, et al. **J Submicrosc Cytol Pathol** 1996 Jul;28(3):319–23

L-canaline: a potent antimetabolite and anti-cancer agent from leguminous plants. Rosenthal GA. **Life Sci** 1997; 60(19):1635–41 (40 ref.)

Stimulation of glutathione synthesis of in vitro matured bovine oocytes and its effect on embryo development and freezability. de Matos DG, et al. **Mol Reprod Dev** 1996 Dec;45(4):451–7

Effects of metabolic inhibitors on mouse preimplantation embryo development and the energy metabolism of isolated inner cell masses. Hewitson LC, et al. **Mol Reprod Dev** 1996 Mar;43(3):323–30

Chromosome painting analysis of spontaneous and methyl methanesulfonate-induced trifluorothymidine-resistant L5178Y cell colonies. Zhang LS, et al. **Mutat Res** 1996 Oct 1;370(3–4):181–90

Further investigation of allopurinol effects on MPTP-induced oxidative stress in the striatum and brain stem of the rat. Desole MS, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):377–83

Salbutamol antagonizes insulin- and sodium mercaptoacetate-induced but not 2-deoxy-D-glucose-induced hyperphagia. Nisoli E, et al. **Pharmacol Biochem Behav** 1996 Jun;54(2):409–13

Effects of D-cycloserine and aniracetam on spatial learning in rats with entorhinal cortex lesions. Zajaczkowski W, et al. **Pharmacol Biochem Behav** 1997 Jan;56(1):21–9

Nontasters, tasters, and supertasters of 6-n-propylthiouracil (PROP) and hedonic response to sweet. Drewnowski A, et al. **Physiol Behav** 1997 Sep;62(3):649–55

The effects of low-, medium-, and high-fat diets on 2-deoxy-D-glucose- and mercaptoacetate-induced feeding. Singer-Koegler LK, et al. **Physiol Behav** 1996 Jul; 60(1):321–3

Recombinant human immunodeficiency virus type 1 (HIV-1) Tat protein inhibits phagolysosomal fusion in human peripheral blood monocytes. Pittis MG, et al. **Viral Immunol** 1996;9(3):169–74

Effect of various potential inhibitors, activators and inducers on the N-oxidation of isomeric aromatic diazines in vitro using rabbit liver microsomal preparations. Altuntas TG, et al. **Xenobiotica** 1996 Jan;26(1):9–15

Lachnellins A, B, C, D, and naphthalene-1,3,8-triol, biologically active compounds from a Lachnellula species (ascomycetes). Semar M, et al. **Z Naturforsch [C]** 1996 Jul–Aug;51(7–8):500–12

[Inactivity of imipramine in the forced swimming test on old mice or on young mice undergone chronic glycinergic treatment] Vamvakides A. **Ann Pharm Fr** 1996;54(6):260–2 (Eng. Abstr.) **(Fre)**

[The effect of some antioxidants on the response of selected lipid compounds in myocardium of rats] Janik A, et al. **Folia Med Cracov** 1996;37(3–4):29–34 (Eng. Abstr.) **(Pol)**

[Derivatives of 2-mercaptobenzimidazole--a new group of specific bradycardic drugs] Chichkanov GG, et al. **Eksp Klin Farmakol** 1997 May–Jun;60(3):23–6 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Allopurinol therapy in post-kala-azar dermal leishmaniasis [letter] Ramesh V. **Acta Derm Venereol** 1996 Jul; 76(4):328–9

Methotrexate for the treatment of refractory Crohn's disease. Lémann M, et al. **Aliment Pharmacol Ther** 1996 Jun; 10(3):309–14

Cold agglutinin hemolysis responding to fludarabine therapy [letter] Jacobs A. **Am J Hematol** 1996 Dec;53(4):279–80

Trabeculectomy with intraoperative 5-fluorouracil vs mitomycin C. Singh K, et al. **Am J Ophthalmol** 1997 Jan; 123(1):48–53

Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Velez I, et al. **Ann Intern Med** 1997 Feb 1;126(3):232–6

Profile of non-compliance in lymphoblastic leukaemia. Lancaster D, et al. **Arch Dis Child** 1997 Apr;76(4):365–6

Trabeculectomy with intraoperative sponge 5-fluorouracil in Afro-Caribbeans. Lachkar Y, et al. **Br J Ophthalmol** 1997 Jul;81(7):555–8 (28 ref.)

A comparative clinical trial of mitomycin C and cyclosporin A in trabeculectomy. Turaçli E, et al. **Eur J Ophthalmol** 1996 Oct–Dec;6(4):398–401

Purine analogues and Crohn's disease: learning more about the long-term. Bernstein CN, et al. **Gastroenterology** 1996 Dec;111(6):1774–6

Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Crystal RG, et al. **Hum Gene Ther** 1997 May 20;8(8):985–1001

Transduction of the herpes thymidine kinase gene into premalignant murine mammary epithelial cells renders subsequent breast cancers responsive to ganciclovir therapy. Moolten FL, et al. **Hum Gene Ther** 1996 Jun 20; 7(10):1197–204

Evaluating treatment for visceral leishmaniosis [letter; comment] Vercammen F. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1379. Comment on: J Am Vet Med Assoc 1996 Aug 1;209(3):615–7.

Allopurinol in the treatment of zoonotic cutaneous leishmaniasis. Ghanem BM, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):619–28

Progression of X-linked adrenoleukodystrophy under interferon-beta therapy. Korenke GC, et al. **J Inherit Metab Dis** 1997 Mar;20(1):59–66

Gene therapy for glioblastoma [correction of gliobestome] multiform: in vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. Stockhammer G, et al. **J Mol Med** 1997 Apr;75(4):300–4

5-Fluorouracil reduces scarring after strabismus surgery. Andreo LK, et al. **J Pediatr Ophthalmol Strabismus** 1997 Mar–Apr;34(2):107–10

The role of initial 5-fluorouracil trabeculectomy in primary glaucoma. Dastur YK, et al. **J Postgrad Med** 1994 Oct–Dec; 40(4):197–201

Epstein-Barr virus-driven gene therapy for EBV-related lymphomas. Franken M, et al. **Nat Med** 1996 Dec; 2(12):1379–82

Glaucoma filtration surgery and antimetabolites. Mattox C. **Ophthalmic Surg Lasers** 1995 Sep–Oct;26(5):473–80 (22 ref.)

5-Fluorouracil in primary combined glaucoma surgery [letter] Khouri AS, et al. **Ophthalmology** 1997 Oct; 104(10):1527–8

Prolongation of canine renal allograft survival by combining tacrolimus with antimetabolic agents. Zhu Y, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):308–9

A case of autochthonous canine leishmaniasis in The Netherlands. Díaz-Espiñeira MM, et al. **Vet Q** 1997 Jun; 19(2):69–71

Effect of four therapeutic agents on Trichomonas phasiani carriage in pheasants [see comments] Pennycott TW. **Vet Rec** 1996 Aug 31;139(9):214–5. Comment in: Vet Rec 1996 Oct 19;139(16):399.

[Leishmaniasis in dogs in Germany: epidemiological case analysis and alternatives to conventional causal therapy] Gothe R, et al. **Tierarztl Prax** 1997 Jan;25(1):68–73 (Eng. Abstr.) **(Ger)**

[Retrovir in the treatment of acute viral hepatitis B] Rakhmanova AG, et al. **Klin Med (Mosk)** 1996;74(5):53–5 **(Rus)**

[5-fluorouracil in the treatment of postoperative glaucoma] Kuljača Z, et al. **Srp Arh Celok Lek** 1996 Jul–Aug; 124(7–8):190–2 (Eng. Abstr.) **(Scc)**

TOXICITY

AZT incorporation into mitochondria: study in a human myeloid cell line. Nusbaum NJ, et al. **DNA Cell Biol** 1996 May;15(5):363–6

Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies. Goodman JC, et al. **Hum Gene Ther** 1996 Jun 20;7(10):1241–50

Effects of prenatal exposure to 5-bromo-2'-deoxyuridine on reproductive function in male mouse offspring. Nagao T, et al. **Reprod Toxicol** 1997 Sep–Oct;11(5):663–73

Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time. Potten CS. **Stem Cells** 1996 Jul;14(4):452–9

Buthionine sulfoximine (BSO) and N-(3,5-dichlorophenyl)succinimide nephrotoxicity: temporal aspects of BSO administration and BSO effects on renal transport systems. Rankin GO, et al. **Toxicology** 1997 Feb 28;117(2–3):207–17

[The anxiolytic effect of the new 2-mercaptobenzimidazole derivative in MR and MNRA rats] Seredinin SB, et al. **Eksp Klin Farmakol** 1997 May–Jun;60(3):3–5 (Eng. Abstr.) **(Rus)**

ANTIMETABOLITES, ANTINEOPLASTIC

Effect of ethyldeoxyuridine on 5-fluorouracil-induced neutropenia. Megyeri A, et al. **Acta Physiol Hung** 1996; 84(3):309–10

A report of infusional 5-fluorouracil and subcutaneous alpha-2A-interferon in the treatment of advanced colorectal carcinoma. Koo WH, et al. **Ann Acad Med Singapore** 1996 Mar;25(2):210–4

5-Fluorouracil continuous infusion in metastatic colorectal cancer. Tan EH, et al. **Ann Acad Med Singapore** 1996 Sep; 25(5):748–51

Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer [see comments] Regazzoni S, et al. **Ann Oncol** 1996 Oct;7(8):807-13. Comment in: Ann Oncol 1996 Oct;7(8):771.

Continuous infusional 5-fluorouracil in breast cancer or the revival of an old drug? [editorial; comment] Smith IE. **Ann Oncol** 1996 Oct;7(8):771-2 (13 ref.). Comment on: Ann Oncol 1996 Oct;7(8):807-13.

Improvement of intestinal toxicity of 5-fluorouracil by conagenin, a low molecular immunomodulator. Kawatsu M, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2937-41

Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Kinsella AR, et al. **Br J Cancer** 1997; 75(7):935-45 (128 ref.)

Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. Bajetta E, et al. **Eur J Cancer** 1997 Apr;33(4):687-90

Modulation of 5-FU and its related compounds. Taguchi T. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:195-205 (40 ref.)

Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Mineishi S, et al. **Gene Ther** 1997 Jun;4(6):570-6

Implementing a formal cytotoxic agent program at an overseas medical treatment facility. Huntzinger PE. **Mil Med** 1997 Jan;162(1):71-3

[Recent development of antitumor antimetabolites in Japan--cytosine arabinoside analogues] Tsukagoshi S. **Gan To Kagaku Ryoho** 1997 May;24(7):761-70 (16 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain. Feliu J, et al. **Am J Clin Oncol** 1996 Dec;19(6):577-80

Phase I-II study of combined 5-fluorouracil and cisplatin chemotherapy and altered fractionation radiotherapy for advanced squamous cell carcinoma of the cervix. Fishman A, et al. **Am J Clin Oncol** 1997 Aug;20(4):342-7

Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial. Kish JA, et al. **Am J Clin Oncol** 1997 Aug;20(4):327-30

A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Look KY, et al. **Am J Clin Oncol** 1996 Oct;19(5):439-41

Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer. The Ottawa experience. Maroun JA, et al. **Am J Clin Oncol** 1997 Aug; 20(4):387-92

Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Sparano JA, et al. **Am J Clin Oncol** 1996 Dec;19(6):546-51

Hepatic arterial infusion for metastatic colorectal cancer: the price of "success". Ruffin WK. **Am J Gastroenterol** 1996 Nov;91(11):2444-5

Infusion pumps for systemic and intra-arterial chemotherapy of colorectal liver metastases. Howell JD, et al. **Ann R Coll Surg Engl** 1997 Jul;79(4):257-8

A phase II study of oral fluorouracil for gastrointestinal cancer. Cartei F, et al. **Anticancer Drugs** 1996 Jan; 7(1):48-53

Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. Martin C, et al. **Anticancer Drugs** 1996 May;7(3):351-7 (28 ref.)

Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. Punt CJ, et al. **Anticancer Drugs** 1997 Jun;8(5):454-8

A pharmacological pilot study: application of an intermittent schedule of oral uracil and ftorafur (UFT) for hepatocellular carcinoma patients. Une Y, et al. **Anticancer Drugs** 1996 Nov;7(8):881-4

High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia. Cole N, et al. **Blood Rev** 1997 Mar; 11(1):39-45 (27 ref.)

Complete remission following donor PBSC after low-dose cytarabine chemotherapy for early relapse of acute myelogenous leukemia after allogeneic stem cell transplantation. Trenschel R, et al. **Bone Marrow Transplant** 1997 Feb;19(4):381-3

Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients. Wingard JR, et al. **Bone Marrow Transplant** 1997 Jul; 20(1):49-51

Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution. Kerr DJ, et al. **Br J Cancer** 1996 Dec;74(12):2032-5

A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Munn SE, et al. **Br J Dermatol** 1996 Dec;135(6):969-71

A randomised controlled trial evaluating a novel cytotoxic drug delivery system for the treatment of cervical intraepithelial neoplasia. Sidhu HK, et al. **Br J Obstet Gynaecol** 1997 Feb;104(2):145-9

Role of portal vein chemotherapy following failure of previous treatment for advanced colorectal hepatic metastases. Fenton-Lee D, et al. **Br J Surg** 1997 Feb; 84(2):205-6

Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literature [letter; comment] Bielack SS, et al. **Cancer** 1997 Aug 1;80(3):516-8. Comment on: Cancer 1996 Nov 15;78(10):2127-35.

Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Feliu J, et al. **Cancer** 1997 May 15;79(10):1884-9

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Gebbia V, et al. **Cancer** 1996 Sep 15;78(6):1300-7

Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Tschmelitsch J, et al. **Cancer Res** 1997 Jun 1;57(11):2181-6

Continuous intrathecal perfusion of methotrexate for carcinomatous meningitis with pharmacokinetic studies: two case studies. Petit T, et al. **Clin Oncol (R Coll Radiol)** 1997;9(3):189-90

Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Nitti D, et al. **Eur J Cancer** 1997 Jul;33(8):1209-15

Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents. Schmoll HJ. **Eur J Cancer** 1996;32A Suppl 5:S18-22 (30 ref.)

Successful treatment of syndrome of inappropriate antidiuretic secretion (SIADH) in 2 patients with CNS involvement of chronic lymphocytic leukaemia [letter] Hagberg H, et al. **Eur J Haematol** 1997 Mar;58(3):207-8

Chemotherapy for lymphatic metastatic gynecologic cancer via pelvic retroperitoneal cannulation: a preliminary report. Zeyi C, et al. **Gynecol Oncol** 1996 Dec;63(3):358-63

Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type. Fandi A, et al. **Head Neck** 1997 Jan;19(1):41-7

Influence of stage classification, tumor differentiation and mode of invasion against clinical and histopathological effects on low dose sequential methotrexate and 5-fluorouracil administration as neo-adjuvant chemotherapy for oral squamous cell carcinoma. Asaumi J. **In Vivo** 1997 Mar-Apr;11(2):147-51

Gemcitabine: safety profile unaffected by starting dose. Martin C, et al. **Int J Clin Pharmacol Res** 1996;16(1):9-18

Primary resection and synchronous regional hepatic chemotherapy or cryotherapy for colorectal cancer with liver metastases. Dasappa V, et al. **Int J Colorectal Dis** 1996;11(1):38-41

Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. Skarlatos J, et al. **Int J Colorectal Dis** 1996;11(5):206-10

Dermatography with bleomycin as a new treatment for verrucae vulgaris. van der Velden EM, et al. **Int J Dermatol** 1997 Feb;36(2):145-50

A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer. Robertson JM, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):331-5

Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group. Naito S, et al. **Int J Urol** 1997 Jul; 4(4):352-7

Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels. Pollera CF, et al. **Invest New Drugs** 1997;15(2):115-21

5-fluorouracil iontophoretic therapy for Bowen's disease. Welch ML, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):956-8

Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. Smith GK, et al. **J Biol Chem** 1997 Jun 20;272(25):15804-16

The effect of methotrexate-loaded bone cement on local destruction by the VX2 tumour. Wang HM, et al. **J Bone Joint Surg Br** 1996 Jan;78(1):14-7

Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. Schwendener RA, et al. **J Cancer Res Clin Oncol** 1996; 122(12):723-6

Adjuvant therapy for resectable colorectal carcinoma with 5-fluorouracil portal vein infusion. Cremona F, et al. **J Chemother** 1997 Apr;9(2):140-1

Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients. Chéradame S, et al. **J Clin Oncol** 1997 Jul; 15(7):2604-10

Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. Farrow AC, et al. **J Clin Oncol** 1997 Apr;15(4):1560-6

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. Fossella FV, et al. **J Clin Oncol** 1997 Jan;15(1):310-6

Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy [letter] O'Connell MJ, et al. **J Clin Oncol** 1996 Oct;14(10):2887

More is better but ... how is best: are milligrams over hours better than grams over minutes? The case of gemcitabine [letter; comment] Pollera CF. **J Clin Oncol** 1997 May; 15(5):2172-4. Comment on: J Clin Oncol 1996 May;14(5):1656-62.

High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. Smith GA, et al. **J Clin Oncol** 1997 Feb; 15(2):833-9

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. Sobrero AF, et al. **J Clin Oncol** 1997 Jan;15(1):368-81 (163 ref.)

The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer. Köhne CH, et al. **J Infus Chemother** 1996 Fall;6(4):206-10 (31 ref.)

To modulate or not to modulate; to infuse or to bolus; the enigma of 5-fluorouracil is still alive after all these years [editorial] Lokich J, et al. **J Infus Chemother** 1996 Spring; 6(2):82-3

Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia. Insiripong S, et al. **J Med Assoc Thai** 1996 Sep;79(9):568-71

Preparation and release properties of biodegradable chitin microcapsules: II. Sustained release of 6-mercaptopurine from chitin microcapsules. Mi FL, et al. **J Microencapsul** 1997 Mar-Apr;14(2):211-23

Preparation and release properties of biodegradable chitin microcapsules: I. Preparation of 6-mercaptopurine microcapsules by phase separation methods. Mi FL, et al. **J Microencapsul** 1997 Jan-Feb;14(1):15-25

Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. Durand-Zaleski I, et al. **J Natl Cancer Inst** 1997 Jun 4; 89(11):790-5

Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). Schmiegelow K, et al. **J Pediatr Hematol Oncol** 1997 Mar-Apr;19(2):102-9

Appendiceal carcinoma: patterns of failure following surgery and implications for adjuvant therapy. Proulx GM, et al. **J Surg Oncol** 1997 Sep;66(1):51-3

Factors predictive of response and survival in patients with metastatic colorectal cancer in Taiwan. Wang WS, et al. **Jpn J Clin Oncol** 1997 Jun;27(3):174-9

2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Robak T, et al. **Leuk Lymphoma** 1996 Jun; 22(1-2):107-11

Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia. Momparler RL, et al. **Leukemia** 1997 Feb;11(2):175-80 (57 ref.)

Successful treatment of relapsed infant acute lymphoblastic leukemia with intensive antimetabolite-based chemotherapy. Barredo JC, et al. **Med Pediatr Oncol** 1997 Oct;29(4):256-9

Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies. Lennard L, et al. **Med Pediatr Oncol** 1997 Oct; 29(4):252-5

Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Menei P, et al. **Neurosurgery** 1996 Jul; 39(1):117-23; discussion 123-4

Gemcitabine shows promise as combination agent in NSCLC. **Oncology (Huntingt)** 1996 Sep;10(9):1311

Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Katz GJ, et al. **Ophthalmology** 1995 Sep;102(9):1263-9

Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma. Abratt RP, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-18-S8-23

Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study. Einhorn LH. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-24-S8-26

A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer. Gatzemeier U, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-36-S8-38

Gemcitabine plus radiotherapy for non-small cell lung cancer. Gregor A. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-39-S8-41

Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Klaassen U, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):32-7

Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Shepherd FA, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-27-S8-30

Rationale of a phase III study comparing a standard cisplatin

regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer. Tonato M, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-31-S8-35

New approaches to the management and treatment of malignant pericardial effusion. Tomkowski W, et al. **Support Care Cancer** 1997 Jan;5(1):64-6

A pilot study of adjuvant hepatic arterial infusion chemotherapy, associating 5-fluorouracil and leucovorin, after resection of colorectal cancer liver metastases. Porte H, et al. **Surg Oncol** 1995;4(6):317-22

Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma. Windsor AC, et al. **Surg Oncol** 1995;4(5):277-9

Histopathological response to preoperative chemotherapy including 5-fluorouracil additionally assessed by immunocytochemical and pharmacologic parameters in patients with advanced gastric cancer. Nakano H, et al. **Surg Today** 1996;26(7):482-8

Intermittent continuous infusion of fluorouracil and low-dose oral leucovorin in pretreated breast cancer: a pilot study. Colleoni M, et al. **Tumori** 1997 May-Jun;83(3):665-8

Hepatic metastases from colorectal cancer. Kemeny MM. **Tumori** 1997 Jan-Feb;83(1 Suppl):S26-7

The value of weekly high dose infusional 5-fluorouracil in the treatment of advanced colorectal cancer. Köhne CH, et al. **Tumori** 1997 Jan-Feb;83(1 Suppl):S56-60

Protracted infusional 5-fluorouracil for colorectal cancer. Lokich J. **Tumori** 1997 Jan-Feb;83(1 Suppl):S53-5 (13 ref.)

Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU. Göhring B, et al. **Urol Res** 1996;24(5):297-303

Enhancing effect of essential oils on the penetration of 5-fluorouracil through rat skin. Abdullah D, et al. **Yao Hsueh Hsueh Pao** 1996;31(3):214-21

[The influence on prognosis of intraoperative chemotherapy for adenocarcinoma of gastric cardia] Li Q, et al. **Chung Hua Chung Liu Tsa Chih** 1996 Mar;18(2):137-9 (Eng. Abstr.) **(Chi)**

[Preoperative intraluminal 5-FU osmosis chemotherapy as an adjuvant to radical resection for rectal cancer] Lu J, et al. **Chung Hua Wai Ko Tsa Chih** 1996 Jan;34(1):54-6 (Eng. Abstr.) **(Chi)**

[Low dose cytarabine in the treatment of acute myeloid leukemia. Apropos of 41 cases] Frikha M, et al. **Bull Cancer** 1996 Dec;83(12):996-1001 (22 ref.) (Eng. Abstr.) **(Fre)**

[Individual dose adjustment of high-dose methotrexate in clinical practice] Bagarry-Liégey D, et al. **Rev Med Interne** 1996;17(8):689-98 (Eng. Abstr.) **(Fre)**

[Drug targeting with liposome encapsulated 5-FU. Pharmacokinetics of i.v. and locoregional therapy--an animal experiment study with VX-2 liver tumor] Berger G, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997; 114:127-30 (Eng. Abstr.) **(Ger)**

[Concentration of intra-aortic 5-FU administration in hypoxia--an animal experiment study of abdominal stop-flow perfusion in the rabbit] Pohlen U, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:137-40 (Eng. Abstr.) **(Ger)**

[Filtering glaucoma operations. Can growth factor blockers replace antimetabolites?] Mietz H. **Ophthalmologe** 1997 Mar;94(3):242-7 (64 ref.) **(Ger)**

[Immunochemotherapy of metastatic renal cell carcinoma with interleukin 2, interferon-alpha and 5-fluorouracil] Hofmockel G, et al. **Urologe A** 1997 Jan;36(1):45-9 (Eng. Abstr.) **(Ger)**

[Adjuvant combined radiochemotherapy of rectum carcinoma with long-term 5-fluorouracil infusion] Fischbach W. **Z Gastroenterol** 1997 Mar;35(3):227-8 **(Ger)**

[Function and complications of diverse totally implantable systems for continuous intra-arterial infusion of FUdR in colorectal hepatic metastases] Civalleri D, et al. **G Chir** 1996 Jun-Jul;17(6-7):309-13 (Eng. Abstr.) **(Ita)**

[Preoperative adjuvant chemotherapy with oral anticancer agents for stomach cancer] Honda I, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1109-17 (Eng. Abstr.) **(Jpn)**

[Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas] Ishikawa O, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1635-41 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Methotrexate in gynecologic oncology] Isonishi S, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1896-900 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Moderately differentiated adenocarcinoma of the rectum: a case report of remarkable response to preoperative administration of FT suppository] Izumi M, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1321-5 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical study of home hepatic arterial infusion chemotherapy for liver metastasis from colorectal cancer] Sato K, et al. **Gan To Kagaku Ryoho** 1996 Dec;23 Suppl 3:252-5 (Eng. Abstr.) **(Jpn)**

[Successful treatment of acute non-lymphoblastic leukemia from myelodysplastic syndrome by combination of human macrophage colony-stimulating factor (M-CSF) and low dose cytosine arabinoside: M-CSF-induced proliferation and tyrosine phosphorylation in leukemic blasts] Hagiwara S, et al. **Rinsho Ketsueki** 1996 Nov;37(11):1259-64 (Eng. Abstr.) **(Jpn)**

[Randomized controlled study of very low-dose Ara-C versus low-dose aclarubicin for the treatment of myelodysplastic syndrome] Shibuya T, et al. **Rinsho Ketsueki** 1996 Sep;37(9):782-4 **(Jpn)**

[The combined treatment of locally disseminated stomach cancer with intra-arterial regional chemotherapy] Zyrianov BN, et al. **Khirurgiia (Mosk)** 1996;(6):13-6 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Chemotherapy-induced acral erythema due to Tegafur [letter] Bastida J, et al. **Acta Derm Venereol** 1997 Jan; 77(1):72-3

Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur [letter] Rios-Buceta L, et al. **Acta Derm Venereol** 1997 Jan; 77(1):80-1

Intrathecal methotrexate overdose. Lee AC, et al. **Acta Paediatr** 1997 Apr;86(4):434-7 (15 ref.)

Intelligence quotient in childhood acute lymphoblastic leukemia after prophylactic treatment in central nervous system with 18 Gy cranial irradiation and intrathecal methotrexate. Liu HC, et al. **Acta Paediatr Sin** 1996 Mar-Apr;37(2):107-10

Halogenoderma of the forearm caused by 2-chlorodeoxyadenosine treatment [letter] Zevin S, et al. **Am J Hematol** 1996 Nov;53(3):209-10

The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Cwikiel M, et al. **Ann Oncol** 1996 Sep; 7(7):731-7

Toxicity associated with high-dose cytosine arabinoside and total body irradiation as conditioning for allogeneic bone marrow transplantation. Kumar M, et al. **Bone Marrow Transplant** 1997 Jun;19(11):1061-4

High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy [letter] Yeh KH, et al. **Br J Cancer** 1997; 75(3):464-5

Inflammation of solar keratoses following systemic 5-fluorouracil. Bataille V, et al. **Br J Dermatol** 1996 Sep; 135(3):478-80

Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report. Kronawitter U, et al. **Cancer** 1997 Aug 15;80(4):656-60

Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Openshaw H, et al. **Cancer** 1996 Nov 1;78(9):1899-905

Fatal pulmonary toxicity resulting from treatment with gemcitabine. Pavlakis N, et al. **Cancer** 1997 Jul 15; 80(2):286-91

Gastric mucosal blood flow and gastric secretion following intravenous administration of 5-fluorouracil in anesthetized rats. Kakinuma S, et al. **Cancer Chemother Pharmacol** 1997; 39(4):357-60

Amelioration of methotrexate-induced malabsorption by vitamin A. Yamamoto J, et al. **Cancer Chemother Pharmacol** 1997;39(3):239-44

Transgenic mice expressing the Sh ble bleomycin resistance gene are protected against bleomycin-induced pulmonary fibrosis. Weinbach J, et al. **Cancer Res** 1996 Dec 15; 56(24):5659-65

Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Saxman SB, et al. **Chest** 1997 Mar;111(3):657-60

Systemic contact dermatitis from 5-fluorouracil. Nadal C, et al. **Contact Dermatitis** 1996 Aug;35(2):124-5

Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Chiara S, et al. **Eur J Cancer** 1997 May;33(6):967-9

Continuous plasma resin perfusion for detoxification of methotrexate. Greil J, et al. **Eur J Pediatr** 1997 Jul; 156(7):533-6

Colitis associated to chemotherapy with 5-fluorouracil. Trevisani F, et al. **Hepatogastroenterology** 1997 May-Jun; 44(15):710-2

B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells. Hayakawa M, et al. **Int J Cancer** 1997 Jun 11; 71(6):1091-102

Allergic contact dermatitis and reactivation phenomenon from iontophoresis of 5-fluorouracil. Anderson LL, et al. **J Am Acad Dermatol** 1997 Mar;36(3 Pt 1):478-9

Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. Kelsen DP, et al. **J Clin Oncol** 1997 Apr;15(4):1511-7

Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. Loprinzi CL, et al. **J Clin Oncol** 1997 Mar; 15(3):1235-8

Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. Widemann BC, et al. **J Clin Oncol** 1997 May; 15(5):2125-34

5-fluorouracil modulates the toxicity of high dose methotrexate. White RM. **J Clin Pharmacol** 1995 Dec; 35(12):1156-65

"Rescue" agent may circumvent rare but deadly complication from chemotherapy [news] Jenks S. **J Natl Cancer Inst** 1997 Jun 18;89(12):840-1

Delayed anemia and thrombocytopenia after treatment with gemcitabine [letter] Malayeri R, et al. **J Natl Cancer Inst** 1997 Aug 6;89(15):1164

Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol [letter] Muggia FM, et al. **J Natl Cancer Inst** 1996 Oct 16; 88(20):1495-6

Intravenous immunoglobulin as prophylaxis of chemotherapy-induced oral mucositis [letter] Plevová P, et al. **J Natl Cancer Inst** 1997 Feb 19;89(4):326-7

Intrathecal leukovorin after intrathecal methotrexate overdose [letter; comment] Trinkle R, et al. **J Pediatr Hematol Oncol** 1997 May-Jun;19(3):267-9. Comment on: J Pediatr Hematol Oncol 1996 Aug;18(3):302-4.

Acute tumor lysis syndrome following intrathecal methotrexate. Benekli M, et al. **Leuk Lymphoma** 1996 Jul; 22(3-4):361-3

Chemotherapy for acute lymphoblastic leukemia may cause subtle changes of the spinal cord detectable by somatosensory evoked potentials. Vainionpää L, et al. **Med Pediatr Oncol** 1997 Jan;28(1):41-7

P300 abnormalities in long-time survivors of acute lymphoblastic leukemia in childhood--side effects of CNS prophylaxis? Uberall MA, et al. **Neuropediatrics** 1996 Jun; 27(3):130-5

Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Morrison GB, et al. **Oncol Nurs Forum** 1997 Jan-Feb;24(1):83-8 (22 ref.)

Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Sonis ST, et al. **Oral Oncol** 1997 Jan;33(1):47-54

Methotrexate and oral mucositis [editorial; comment] Moe PJ. **Pediatr Hematol Oncol** 1996 Jul-Aug;13(4):313-4 (6 ref.). Comment on: Pediatr Hematol Oncol 1996 Jul-Aug;13(4):359-73.

Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate [see comments] Rask C, et al. **Pediatr Hematol Oncol** 1996 Jul-Aug;13(4):359-67. Comment in: Pediatr Hematol Oncol 1996 Jul-Aug;13(4):313-4.

Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil. Brown MC. **Pharmacotherapy** 1997 May-Jun;17(3):631-3

Acute encephalopathy attributed to 5-FU. Langer CJ, et al. **Pharmacotherapy** 1996 Mar-Apr;16(2):311-3

Symptomatic cardiotoxicity associated with 5-fluorouracil. Meyer CC, et al. **Pharmacotherapy** 1997 Jul-Aug; 17(4):729-36

Dihydropyrimidine dehydrogenase deficiency: a potential etiology for 5-fluorouracil-induced neurotoxicity. Risso ME, et al. **Pharmacotherapy** 1997 Jul-Aug;17(4):847-8; discussion 849

Acute renal failure with chronic lymphocytic leukaemia. Martinez-Vea A, et al. **Postgrad Med J** 1996 Dec; 72(854):763-5

Iatrogenic chest pain--5-fluorouracil cardiotoxicity [letter] Cassidy J. **QJM** 1997 Apr;90(4):305-6

Iatrogenic chest pain: a case of 5-fluorouracil cardiotoxicity [letter] Farooqi IS, et al. **QJM** 1996 Dec;89(12):953-5

Methotrexate osteopathy in patients with osteosarcoma. Ecklund K, et al. **Radiology** 1997 Feb;202(2):543-7

Gemcitabine safety overview. Green MR. **Semin Oncol** 1996 Oct;23(5 Suppl 10):32-5 (20 ref.)

Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. Cascinu S, et al. **Support Care Cancer** 1997 Jul;5(4):314-7

5-Fluorouracil-induced severe but reversible cardiogenic shock: a case report. Akhtar SS, et al. **Tumori** 1996 Sep-Oct;82(5):505-7

Sucralfate prophylaxis of fluorouracil-induced stomatitis. Giorgi F, et al. **Tumori** 1996 Nov-Dec;82(6):585-7

[Cardiotoxicity of 5-fluorouracil] Pan L, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb;31(2):86-9 (Eng. Abstr.) **(Chi)**

[The injury of liver sinusoidal endothelial cells in a rat's isolated liver perfusion (ILP) model for regional chemotherapy] Xing X, et al. **Chung Hua Wai Ko Tsa Chih** 1996 Jan;34(1):47-9 (Eng. Abstr.) **(Chi)**

[Reversible liver steatosis in patients treated with 5-fluorouracil and interferon-alpha] Sørensen P, et al. **Ugeskr Laeger** 1997 Feb 3;159(6):765-7 (Eng. Abstr.) **(Dan)**

[High-dose methotrexate and cerebral neurotoxicity. Apropos of a case of arachnoiditis] Brain E, et al. **Presse Med** 1997 Mar 1;26(6):265-8 (Eng. Abstr.) **(Fre)**

[Necrotizing myelopathy after intrathecal methotrexate (letter)] Sanhes L, et al. **Presse Med** 1997 May 3-10; 26(15):719 **(Fre)**

BLOOD

Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion

with or without interferon-alpha. Findlay MP, et al. **Ann Oncol** 1996 Jan;7(1):47-53

On-line precolumn derivatization for HPLC determination of methotrexate using a column packed oxidant. Emara S, et al. **Biomed Chromatogr** 1997 Jan-Feb;11(1):42-6

Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Cuffari C, et al. **Can J Physiol Pharmacol** 1996 May;74(5):580-5

Variability in the rate of 6-mercaptopurine methylation in the erythrocytes, liver and kidney in an Italian population. Ferroni MA, et al. **Eur J Clin Pharmacol** 1996;51(1):23-9

Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs. Bacci G, et al. **J Chemother** 1996 Dec;8(6):472-8

Determination of methotrexate in serum by high-performance liquid chromatography. Aboleneen H, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7; 681(2):317-22

Simultaneous gas chromatographic-mass spectrophotometric determination of alpha-fluoro-beta-alanine and 5-fluorouracil in plasma. Anderson D, et al. **J Chromatogr B Biomed Appl** 1997 Jan 10;688(1):87-93

High-performance liquid chromatographic determination of 5-fluorouracil and its prodrugs, tegafur and 4-deoxy-5-fluorouracil, in rat plasma. Jarugula VR, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23;677(1):199-203

Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study. Joulia JM, et al. **J Chromatogr B Biomed Appl** 1997 May 9;692(2):427-35

Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection. Synold TW, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30; 683(2):245-9

High-performance liquid chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood. Wattanatorn W, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):233-7

Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma. Gamelin E, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1;695(2):409-16

Determination of 5-fluorouracil in human plasma by a simple and sensitive reversed-phase HPLC method. Coe RA, et al. **J Pharm Biomed Anal** 1996 Sep;14(12):1733-41

Methotrexate elimination in a patient with an orthotopic neobladder with and without a urethral catheter. Wire PD, et al. **Pharmacotherapy** 1996 Sep-Oct;16(5):961-4

Determination of fludarabine phosphate in human plasma using reversed phase high-performance liquid chromatography. Misztal G, et al. **Pharmazie** 1996 Oct; 51(10):733-4

Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents. Boudoulas S, et al. **Ther Drug Monit** 1996 Dec;18(6):714-20

External quality assessment of Syva Emit and Abbott TDx II assays for methotrexate in serum. Wilson JF, et al. **Ther Drug Monit** 1996 Dec;18(6):721-3

CHEMICAL SYNTHESIS

NAD-analogues as potential anticancer agents: conformational restrictions as basis for selectivity. Pankiewicz KW, et al. **Acta Biochim Pol** 1996;43(1):183-93 (72 ref.)

A simplified and efficient synthesis of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF). Taylor EC, et al. **Invest New Drugs** 1996;14(3):281-5

Synthesis of nonhydrolyzable analogues of thiazole-4-carboxamide and benzamide adenine dinucleotide containing fluorine atom at the C2' of adenine nucleoside: induction of K562 differentiation and inosine monophosphate dehydrogenase inhibitory activity. Lesiak K, et al. **J Med Chem** 1997 Aug 1;40(16):2533-8

The practical synthesis of a methylenebisphosphonate analogue of benzamide adenine dinucleotide: inhibition of human inosine monophosphate dehydrogenase (type I and II). Pankiewicz KW, et al. **J Med Chem** 1997 Apr 11; 40(8):1287-91

Synthesis and properties of 5-fluorouracil oligonucleotides. Koga M, et al. **Nucleic Acids Symp Ser** 1995;(34):27-8

CHEMISTRY

Stability of 14 drugs in the latex reservoir of an elastomeric infusion device. Allen LV Jr, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2740-3

Gemcitabine concentration lower than cited in package insert [letter] O'Brien TE. **Am J Health Syst Pharm** 1996 Dec 1;53(23):2882

Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride. Xu QA, et al. **Ann Pharmacother** 1996 Jul-Aug;30(7-8):756-61

Rapid loss of fentanyl citrate admixed with fluorouracil in polyvinyl chloride containers. Xu QA, et al. **Ann Pharmacother** 1997 Mar;31(3):297-302

Solution structures of 5-fluorouracil-substituted RNA duplexes containing G-U wobble base pairs. Sahasrabudhe PV, et al. **Biochemistry** 1997 May 20;36(20):5981-91

Enzymatic formation of potential anticancer and antiviral inosine analogues. Sheid B, et al. **Experientia** 1996 Sep 15; 52(9):878-81

Solid-state characterization of AG337 (Thymitaq), a novel antitumor drug. Dash AK, et al. **J Pharm Sci** 1996 Oct; 85(10):1123-7

Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: assessing specificity and affinity. Rutenber EE, et al. **Structure** 1996 Nov 15;4(11):1317-24

DIAGNOSTIC USE

[Determination of the proliferative activity of breast cancer cells using 5-bromo-2'-deoxyuridine in vivo] Uporov AV, et al. **Vopr Onkol** 1997;43(2):176-82 (Eng. Abstr.) **(Rus)**

ECONOMICS

Clinical and financial analyses of ectopic pregnancy management at a large health plan. Hidlebaugh D, et al. **J Am Assoc Gynecol Laparosc** 1997 Feb;4(2):207-13

Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module. Evans WK. **Semin Oncol** 1997 Apr; 24(2 Suppl 7):S7-56-S7-63

IMMUNOLOGY

[Antigenicity tests of a new antineoplastic agent S-1] Maeda Y, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:661-73 (Eng. Abstr.) **(Jpn)**

METABOLISM

An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Ghoshal K, et al. **Biochem Pharmacol** 1997 Jun 1;53(11):1569-75 (50 ref.)

Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes. Fraternale A, et al. **Biochim Biophys Acta** 1996 Oct 24;1291(2):149-54

Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Longo GS, et al. **Blood** 1997 Aug 1;90(3):1241-5

Opiate effects on 5-fluorouracil disposition in mice. Li Y, et al. **Cancer Chemother Pharmacol** 1997;39(3):273-7

Tiazofurin enhances the anabolism and toxicity of 5-fluorouracil. Cysyk RL, et al. **Cancer Lett** 1996 Dec 3; 109(1-2):49-55

Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Gandhi V, et al. **Cancer Res** 1996 Oct 1;56(19):4453-9

Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Masuda M, et al. **Cancer Res** 1997 Aug 15;57(16):3506-10

Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia. Buchholz B, et al. **Eur J Cancer** 1996 Nov;32A(12):2101-7

Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. van der Wilt CL, et al. **Eur J Cancer** 1997 Mar;33(3):471-8

6-MP metabolite levels: a potential guide to Crohn's disease therapy. Sandborn WJ. **Gastroenterology** 1997 Aug; 113(2):690-2

Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells. Davey MW, et al. **Leuk Res** 1996 Aug; 20(8):657-64

Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts. Reuter C, et al. **Leukemia** 1997 Apr;11(4):561-71

Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Galpin AJ, et al. **Mol Pharmacol** 1997 Jul; 52(1):155-63

gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Longo GS, et al. **Oncol Res** 1997;9(5):259-63

Resistance mechanisms to methotrexate in tumors. Bertino JR, et al. **Stem Cells** 1996 Jan;14(1):5-9 (27 ref.)

Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era. Schilsky RL. **Stem Cells** 1996 Jan;14(1):29-32 (10 ref.)

Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Lennard L, et al. **Ther Drug Monit** 1996 Aug;18(4):328-34

PHARMACOKINETICS

Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Qin D, et al. **Am J Clin Oncol** 1997 Jun;20(3):263-5

Effective clearance of methotrexate using high-flux hemodialysis membranes. Wall SM, et al. **Am J Kidney Dis** 1996 Dec;28(6):846-54

Drug retention following intravesical delivery of fluorouracil therapeutic adhesive in C3H mouse bladder. Singh SS, et al. **Anticancer Drugs** 1996 Jul;7(5):507-13

Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2). Joulia JM, et al. **Anticancer Res** 1997 Jul-Aug; 17(4A):2727-30

Dose-dependent gastrointestinal absorption of 5-fluorouracil in rats in vivo. Yuasa H, et al. **Biol Pharm Bull** 1996 Nov; 19(11):1494-8

Intestinal brush border transport mechanism of 5-fluorouracil in rats. Yuasa H, et al. **Biol Pharm Bull** 1996 Jan;19(1):94-9

Percutaneous absorption and disposition studies of methotrexate in rabbits and rats. Lu G, et al. **Biopharm Drug Dispos** 1997 Jul;18(5):409-22

Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Versantvoort CH, et al. **Br J Cancer** 1996 Dec;74(12):1949-54

In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Devineni D, et al. **Cancer Chemother Pharmacol** 1996;38(6):499-507

Continuous intratumoral microdialysis during high-dose methotrexate therapy in a patient with malignant fibrous histiocytoma of the femur: a case report. Ekstrøm PO, et al. **Cancer Chemother Pharmacol** 1997;39(3):267-72

Pharmacokinetics of intrapericardial administration of 5-fluorouracil. Lerner-Tung MB, et al. **Cancer Chemother Pharmacol** 1997;40(4):318-20

Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma. Thomson AH, et al. **Cancer Chemother Pharmacol** 1996;38(6):566-70

Flow cytometry evaluation of the multidrug-resistant phenotype with functional tests involving uptake of daunorubicin, Hoechst 33342, or rhodamine 123: a comparative study. Lizard G, et al. **Cancer Detect Prev** 1995;19(6):527-34

Methotrexate plasma pharmacokinetics: importance of assay method. Eksborg S, et al. **Cancer Lett** 1996 Nov 29; 108(2):163-9

The activity of dihydropyrimidine dehydrogenase from rat liver was not affected by any of five 5-hydroxytryptamine antagonists. Tateishi T, et al. **Cancer Lett** 1996 Nov 12; 108(1):1-5

Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Kissel J, et al. **Cancer Res** 1997 Aug 15;57(16):3415-23

Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions. Kuan HY, et al. **Cancer Res** 1996 Oct 15; 56(20):4724-7

Effect of regional angiotensin II infusion on the relationship between tumour blood flow and fluorouracil uptake in a liver metastasis animal model. Dworkin MJ, et al. **Eur J Cancer** 1996 Aug;32A(9):1580-4

First-pass uptake of methotrexate after intra-arterial bolus injection in human head and neck cancers. Blöchl-Daum B, et al. **Eur J Clin Invest** 1996 May;26(5):371-5

A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. Bressolle F, et al. **Eur J Clin Pharmacol** 1996;49(4):285-92

Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy. Ikeda H, et al. **Hiroshima J Med Sci** 1996 Jun; 45(2):57-62

Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy. Blackstock AW, et al. **Int J Radiat Oncol Biol Phys** 1996 Oct 1;36(3):641-8

Controlled release of cytarabine from poly(2-hydroxyethyl methacrylate-co-N-vinyl-2-pyrrolidone) hydrogels. Blanco MD, et al. **J Biomater Sci Polym Ed** 1997; 8(9):709-19

Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. Balthasar JP, et al. **J Pharm Sci** 1996 Oct;85(10):1035-43

Nonlinear pharmacokinetics of 5-fluorouracil in rats. Jarugula VR, et al. **J Pharm Sci** 1997 Jun;86(6):756-8

Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Matherly LH, et al. **Leuk Lymphoma** 1996 May;21(5-6):359-68 (70 ref.)

Role of folylpolyglutamate synthetase (FPGS) in antifolate chemotherapy; a biochemical and clinical update. Synold TW, et al. **Leuk Lymphoma** 1996 Mar;21(1-2):9-15 (56 ref.)

Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies? [comment] Evans WE, et al. **Leuk Res** 1997 May;21(5):435-7 (13 ref.). Comment on: Leuk Res 1997 May;21(5):429-34.

On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemia [see comments] Seidel H, et al. **Leuk Res** 1997 May;21(5):429-34. Comment in: Leuk Res 1997 May;21(5):435-7.

Alterations in methotrexate pharmacokinetics by naproxen in the rat as measured by microdialysis. Ekstrøm PO, et al. **Life Sci** 1997;60(24):PL 359-64

Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate [see comments] Rask C, et al. **Pediatr Hematol Oncol** 1996 Jul-Aug;13(4):359-67. Comment in: Pediatr Hematol Oncol 1996

Jul-Aug;13(4):313-4.
The enhancer effect of several phenyl alcohols on percutaneous penetration of 5-fluorouracil. López A, et al. **Pharm Res** 1997 May;14(5):681-5
Mechanisms of 5-fluorouracil (5-FU) transport in isolated rabbit choroid plexus tissue slices. Washington CB, et al. **Pharm Res** 1996 Aug;13(8):1276-8
Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. Park JM, et al. **Res Commun Mol Pathol Pharmacol** 1996 Sep;93(3):353-62
Gemcitabine: preclinical pharmacology and mechanisms of action. Plunkett W, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 10):3-15 (50 ref.)
Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. Hiddemann W, et al. **Ther Drug Monit** 1996 Aug;18(4):341-9
Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Milano G, et al. **Ther Drug Monit** 1996 Aug;18(4):335-40 (41 ref.)
Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose. Welch J, et al. **Ther Drug Monit** 1997 Aug;19(4):382-5

PHARMACOLOGY

Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates. Schott H, et al. **Anticancer Drug Des** 1996 Sep; 11(6):451-62
Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells. Côté S, et al. **Anticancer Drugs** 1997 Jan;8(1):56-61
Phenylacetic acid halides inhibit estrogen receptor (ER)-positive MCF-7 cells, but not ER-negative human breast cancer cells or normal breast epithelial cells. Johnson DE, et al. **Anticancer Drugs** 1996 May;7(3):288-92
Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside. Momparler RL, et al. **Anticancer Drugs** 1996 May;7(3):266-74
Irreversible cytotoxic effect of a novel lowly immunosuppressive antitumor fluoruridine derivative, UK-21. Mori H, et al. **Anticancer Drugs** 1997 Jun; 8(5):482-8
Dual effects of folinic acid in 5-fluorouracil induced killing of human tumor cell lines in vitro. Blomgren H, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2713-7
Apoptosis in androgen-independent mouse mammary tumor cells induced by 5-fluorodeoxyuridine but not by androgen withdrawal. Furuya Y, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2613-8
Antiinvasive effects of Tiazofurin on liver-metastatic human colon carcinoma xenografts. Lapis KY, et al. **Anticancer Res** 1996 Nov-Dec;16(6A):3323-31
Cytotoxic interactions of 5-fluorouracil and nucleoside analogues in vitro. Li YX, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):21-7
Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Nishio K, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3387-95
5-Fluorouracil induces apoptotic cell death with G2 phase arrest in human breast cancer grafted in nude mice. Okamoto S, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2699-704
Tiazofurin: molecular and clinical action. Weber G, et al. **Anticancer Res** 1996 Nov-Dec;16(6A):3313-22
Increased levels of alpha V-associated integrins in association with growth inhibition of cultured tumor cells by bromodeoxyuridine. Yoshihara T, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):833-8
Interaction of 2-chlorodeoxyadenosine in combination either with interferons or recombinant human tumor necrosis factor alpha on myeloid progenitor cells in vitro. Korycka A, et al. **Arch Immunol Ther Exp (Warsz)** 1996;44(4):259-64
Induction of pgp3 expression and reversion of the multidrug resistance phenotype in 9-OH-ellipticine-resistant Chinese hamster lung fibroblasts transfected with the MYC oncogene. Delaporte C, et al. **Biochem Pharmacol** 1997 Jan 10;53(1):59-66
Mechanisms of acquired resistance to modulation of 5-fluorouracil by leucovorin in HCT-8 human ileocecal carcinoma cells. Lu K, et al. **Biochem Pharmacol** 1997 Mar 7;53(5):689-96
Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line. Gong M, et al. **Blood** 1997 Apr 1;89(7):2494-9
Expression of transcription factors during sodium phenylacetate induced erythroid differentiation in K562 cells. Rath AV, et al. **Blood Cells Mol Dis** 1997;23(1):27-38
Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application. McIvor RS. **Bone Marrow Transplant** 1996 Dec;18 Suppl 3:S50-4 (19 ref.)
Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals. Hagiwara A, et al. **Br J Cancer** 1996 Nov;74(9):1392-6
Murine marrow stromal response to myelotoxic agents in vitro. Hauser SP, et al. **Br J Haematol** 1996 Dec; 95(4):596-604
Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans. Khor SP, et al. **Cancer Chemother Pharmacol** 1997;39(3):233-8
Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Tonkinson JL, et al. **Cancer Chemother Pharmacol** 1997;39(6):521-31
Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats. Sakamoto S, et al. **Cancer Detect Prev** 1997;21(4):340-5
Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562: a comparison of methotrexate resistance. Braun SE, et al. **Cancer Gene Ther** 1997 Jan-Feb;4(1):26-32
Tiazofurin enhances the anabolism and toxicity of 5-fluorouracil. Cysyk RL, et al. **Cancer Lett** 1996 Dec 3; 109(1-2):49-55
Anti-tumor mechanisms of 3'-ethynyluridine and 3'-ethynylcytidine as RNA synthesis inhibitors: development and characterization of 3'-ethynyluridine-resistant cells. Tabata S, et al. **Cancer Lett** 1997 Jun 24;116(2):225-31
Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination. Adam L, et al. **Cancer Res** 1997 Mar 15;57(6):1023-9
Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Hori H, et al. **Cancer Res** 1996 Dec 15;56(24):5653-8
Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Koo HM, et al. **Cancer Res** 1996 Nov 15;56(22):5211-6
DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Matsui SI, et al. **Cancer Res** 1996 Oct 15; 56(20):4715-23
Evidence that cutaneous carcinogen-initiated epithelial cells from mice are quiescent rather than actively cycling. Morris RJ, et al. **Cancer Res** 1997 Aug 15;57(16):3436-43
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Shih C, et al. **Cancer Res** 1997 Mar 15;57(6):1116-23
Mechanisms of clinical resistance to 5-fluorouracil chemotherapy. Chu E, et al. **Cancer Treat Res** 1996; 87:175-95 (130 ref.)
Antifolates: current developments. Rayl EA, et al. **Cancer Treat Res** 1996;87:197-223 (220 ref.)
Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Gorospe M, et al. **Cell Growth Differ** 1996 Dec;7(12):1609-15
Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67). Grant S, et al. **Cell Growth Differ** 1996 May;7(5):603-13
Bleomycin-induced differentiation of bcl-2-transfected U937 leukemia cells. Guedez L, et al. **Cell Growth Differ** 1996 Dec;7(12):1625-31
Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Ray S, et al. **Cell Growth Differ** 1996 Dec;7(12):1617-23
Preferential induction of chromosome 1 multibranched figures and whole-arm deletions in a human pro-B cell line treated with 5-azacytidine or 5-azadeoxycytidine. Hernandez R, et al. **Cytogenet Cell Genet** 1997; 76(3-4):196-201
Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Noble S, et al. **Drugs** 1997 Sep;54(3):447-72 (119 ref.)
Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl-2. Guedez L, et al. **Eur J Haematol** 1996 Aug;57(2):149-56
Glucose transporter 2 expression: prevention of streptozotocin-induced reduction in beta-cells with 5-thio-D-glucose. Wang Z, et al. **Exp Clin Endocrinol Diabetes** 1995;103 Suppl 2:83-97
Hematopoietic precursor cell exhaustion is a cause of proliferative defect in primitive hematopoietic stem cells (PHSC) after chemotherapy. Gardner RV, et al. **Exp Hematol** 1997 Jun;25(6):495-501
Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Neff T, et al. **Exp Hematol** 1996 Sep;24(11):1340-6
5-Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler's virus. Lucchinetti CF, et al. **Exp Neurol** 1997 Sep;147(1):123-9
Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Ring CJ, et al. **Gene Ther** 1996 Dec;3(12):1094-103
The use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors. Szala S, et al. **Gene Ther** 1996 Nov;3(11):1026-31
Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Morabito F, et al. **Haematologica** 1997 Jan-Feb;82(1):16-20
Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders. Santini V, et al. **Haematologica** 1997 Jan-Feb;82(1):11-5
Hepatocytic phenotypes induced in sarcomatous cholangiocarcinoma cells treated with 5-azacytidine. Enjoji M, et al. **Hepatology** 1997 Aug;26(2):288-94
5-Azacytidine (5Az) induces apoptosis in PC12 cells: a model for 5Az-induced apoptosis in developing neuronal cells. Hossain MM, et al. **Histol Histopathol** 1997 Apr; 12(2):439-45
Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. Bolognesi A, et al. **Int J Cancer** 1996 Nov 4;68(3):349-55
Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine. Ge K, et al. **Int J Cancer** 1997 May 16;71(4):675-9
Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil. Ueda M, et al. **Int J Cancer** 1997 May 16;71(4):668-74
Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate. Miller AC, et al. **Int J Radiat Biol** 1997 Aug;72(2):211-8
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer. Hageboutros A, et al. **Invest New Drugs** 1997;15(2):139-45
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. Müller M, et al. **J Clin Invest** 1997 Feb 1;99(3):403-13
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. Sobrero AF, et al. **J Clin Oncol** 1997 Jan;15(1):368-81 (163 ref.)
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group. Thyss A, et al. **J Clin Oncol** 1997 May; 15(5):1824-30
Induction of the multidrug-transporter P-glycoprotein by 3'-azido-3'-deoxythymidine (AZT) treatment in tumor cell lines. Signoretti C, et al. **J Exp Clin Cancer Res** 1997 Mar; 16(1):29-32
Effect of glutathione depletion on cisplatin resistance in cancer cells transfected with the gamma-glutamylcysteine synthetase gene. Kurokawa H, et al. **Jpn J Cancer Res** 1997 Feb;88(2):108-10
Kinetics for camel (Camelus dromedarius) retina acetylcholinesterase inhibition by methotrexate in vitro. al-Jafari A, et al. **Jpn J Pharmacol** 1996 Sep;72(1):49-55
Haemopoietic growth factors, the cell cycle of acute myeloblastic leukaemia progenitors and sensitivity to cytosine arabinoside. Smith MA, et al. **Leuk Lymphoma** 1996 Nov;23(5-6):467-72 (36 ref.)
Effect of stem cell factor on leukemic progenitor cell growth and sensitivity to cytosine-arabinoside. Viallard JF, et al. **Leuk Res** 1996 Nov-Dec;20(11-12):915-23
Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein. Bullock G, et al. **Leukemia** 1996 Nov;10(11):1731-40
Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia. Momparler RL, et al. **Leukemia** 1997 Mar;11 Suppl 1:S1-6 (57 ref.)
Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Schröder JK, et al. **Leukemia** 1996 Dec;10(12):1919-24
Effects on interstitial glutathione, cysteine and 5-S-cysteinyldopa of buthionine sulphoximine in human melanoma transplants. Dizdar N, et al. **Melanoma Res** 1997 Aug;7(4):322-8
In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate. Kamal MA, et al. **Mol Cell Biochem** 1996 Jun 7;159(1):47-53
Seeking the nucleoside transporter [news; comment] Wiley JS. **Nat Med** 1997 Jan;3(1):25-6. Comment on: Nat Med 1997 Jan;3(1):89-93.
Stimulation of 1-(beta-D-arabinofuranosyl)cytosine (AraC)-induced apoptosis in the multidrug resistant human promyelocytic leukemia cell lines with protein kinase inhibitors. Hunáková L, et al. **Neoplasma** 1996;43(5):291-5
Modulatory effect of tempol on toxicity and antitumor activity of 6-mercaptopurine and on P450 cytochrome level. Konovalova NP, et al. **Neoplasma** 1996;43(5):341-6
The DNA methyltransferase inhibitor 5-azacytidine specifically alters the expression of helix-loop-helix proteins Id1, Id2 and Id3 during neuronal differentiation. Persengiev SP, et al. **Neuroreport** 1997 Jul 7;8(9-10):2091-5
Cytosine arabinoside is neurotoxic to chick embryo spinal cord motoneurons in culture. Sanz-Rodriguez C, et al. **Neurosci Lett** 1997 Feb 28;223(3):141-4
Activation of quiescent ABL-transduced hemopoietic stem cells. Chung SW, et al. **Oncogene** 1996 Dec 5;

13(11):2397–405

Antiproliferative effects of cyclopentenyl cytosine (NSC 375575) in human glioblastoma cells. Agbaria R, et al. **Oncol Res** 1997;9(3):111–8

Modulation of 5–fluorouracil resistance in human colon tumor cell lines by azidothymidine. Findenig G, et al. **Oncol Res** 1996;8(5):189–96

Inhibition by 5–fluorouracil of ERCC1 and gamma–glutamylcysteine synthetase messenger RNA expression in a cisplatin–resistant HST–1 human squamous carcinoma cell line. Fujishima H, et al. **Oncol Res** 1997; 9(4):167–72

Evolution of drug resistance in CCRF–CEM human leukemia cells selected by intermittent methotrexate exposure. McGuire JJ, et al. **Oncol Res** 1995;7(10–11):535–43

In vitro characterization of methotrexate loaded poly(lactic–co–glycolic) acid microspheres and antitumor efficacy in Sarcoma–180 mice bearing tumor. Singh UV, et al. **Pharm Acta Helv** 1997 Jun;72(3):165–73

Selective and synergistic activity of L–S,R–buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione–S–transferase. Fruehauf JP, et al. **Pigment Cell Res** 1997 Aug;10(4):236–49

Mutagenicity of 5–aza–2'–deoxycytidine is mediated by the mammalian DNA methyltransferase. Jackson–Grusby L, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4681–5

The emerging role of gemcitabine in lung cancer: part I [editorial] Bunn PA Jr. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7–1

Preclinical, pharmacologic, and phase I studies of gemcitabine. Storniolo AM, et al. **Semin Oncol** 1997 Apr; 24(2 Suppl 7):S7–2–S7–7 (16 ref.)

Resistance mechanisms to methotrexate in tumors. Bertino JR, et al. **Stem Cells** 1996 Jan;14(1):5–9 (27 ref.)

2',2'–Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2–chlorodeoxyadenosine (2–CdA). Gruber J, et al. **Stem Cells** 1996 May;14(3):351–62

Inhibition of thymidylate synthase: biochemical pharmacology of drugs with activity in colorectal cancer. Jackman AL. **Tumori** 1997 Jan–Feb;83(1 Suppl):S65–6 (11 ref.)

[The effects of histamine H2 receptor agonist, antagonist and antineoplastic agent on the in vitro growth of PB CFU–GM from normal individuals and HL–60 leukemia cells] He Q, et al. **Yao Hsueh Hsueh Pao** 1996;31(5):340–5 (Eng. Abstr.) **(Chi)**

[Morphological changes in human colon carcinoma after chemotherapy with 5–fluorouracil—a study in the nude mouse model] Lohwasser S, et al. **Z Gastroenterol** 1997 May;35(5):319–26 (Eng. Abstr.) **(Ger)**

[Nucleoside kinases and new types of antitumor nucleosides] Matsuda A. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1594–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[The correlation between thymidylate synthase expression and cytotoxicity of 5–fluorouracil in human cancer cell lines: study using polyclonal antibody against recombinant human thymidylate synthase] Okabe H, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):705–12 (Eng. Abstr.) **(Jpn)**

[Acquisition of resistance to anticancer agents by overproduction of target enzymes] Inaba M. **Nippon Rinsho** 1997 May;55(5):1030–7 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Ultroser–G and 5–azacytidine prolong the development of parthenogenetic mouse embryos] Penkov LI, et al. **Ontogenez** 1997 Mar–Apr;28(2):138–43 (Eng. Abstr.) **(Rus)**

POISONING

Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5–fluorouracil prodrugs [corrected and republished with original paging, article originally printed in Drug Metab Dispos 1997 Feb;25(2):270–3] Okuda H, et al. **Drug Metab Dispos** 1997 May;25(5):270–3

[Acute methotrexate poisoning: apropos of 16 cases reported to the Paris Poison Control Center and review of the literature] Maignen F, et al. **Therapie** 1996 Sep–Oct; 51(5):527–31 (35 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Three–day standard dose cytarabine could induce an M4Eo patient into complete remission. Higuchi T, et al. **Acta Haematol** 1997;97(3):189–90

Biochemical modulation by 5–fluorouracil and 1–folinic acid of tumor uptake of intra–arterial 5–[123I]iodo–2'deoxyuridine in patients with liver metastases from colorectal cancer. Mariani G, et al. **Acta Oncol** 1996;35(7):941–5

HIV–associated lymphoma. Kaplan LD. **AIDS Clin Rev** 1997–98;:349–73 (80 ref.)

Evaluation of intravenous 6–thioguanine as first–line chemotherapy in women with metastatic breast cancer. Ingle JN, et al. **Am J Clin Oncol** 1997 Feb;20(1):69–72

Phase II study of ZD1694 in patients with advanced gastric cancer. Meropol NJ, et al. **Am J Clin Oncol** 1996 Dec; 19(6):628–30

Docetaxel and gemcitabine released for cancer chemotherapy [news] **Am J Health Syst Pharm** 1996 Jul 15;53(14):1643, 1649

Gemcitabine: a cytidine analogue active against solid tumors. Hui YF, et al. **Am J Health Syst Pharm** 1997 Jan 15; 54(2):162–70; quiz 197–8 (69 ref.)

Prognostic significance of computed tomography in tumors of the oral cavity and oropharynx treated with neoadjuvant chemotherapy. Verschuur HP, et al. **Am J Otolaryngol** 1997 May–Jun;18(3):190–6

Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone. Braess J, et al. **Ann Hematol** 1996 Oct;73(4):201–4

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5–fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group [published erratum appears in Ann Oncol 1997 Apr;8(4):407] Cunningham D, et al. **Ann Oncol** 1996 Nov;7(9):961–5

5–Fluorouracil versus 5–fluorouracil plus alpha–interferon as treatment of metastatic colorectal carcinoma. A randomized study [see comments] Dufour P, et al. **Ann Oncol** 1996 Aug;7(6):575–9. Comment in: Ann Oncol 1996 Aug;7(6):551–2.

Post–remission therapy of adult acute myeloid leukaemia: one cycle of high–dose versus standard–dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK). Fopp M, et al. **Ann Oncol** 1997 Mar;8(3):251–7

Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective [editorial; comment] Gelber RD. **Ann Oncol** 1996 Apr;7(4):335–7. Comment on: Ann Oncol 1996 Apr;7(4):347–53.

5–Fluorouracil in colorectal cancer, a never ending story [editorial; comment] [see comments] Herrmann R. **Ann Oncol** 1996 Aug;7(6):575–9. Comment in: Ann Oncol 1996 Aug;7(6):551–2. Comment on: Ann Oncol 1997 Feb;8(2):139–40; discussion 141. Comment in: Ann Oncol 1997 Feb;8(2):203. Comment in: Ann Oncol 1997 Feb;8(2):203–4.

5–fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago–gastric junction area. Rotterdam Esophageal Tumor Study Group. Kok TC, et al. **Ann Oncol** 1996 Jul;7(5):533–4

Single–agent gemcitabine versus cisplatin–etoposide: early results of a randomised phase II study in locally advanced or metastatic non–small–cell lung cancer [see comments] Manegold C, et al. **Ann Oncol** 1997 Jun;8(6):525–9. Comment in: Ann Oncol 1997 Jun;8(6):513–4.

Infusional 5–fluorouracil in the treatment of gastrointestinal cancers: the Royal Marsden Hospital experience. Ross PJ, et al. **Ann Oncol** 1997 Feb;8(2):111–5 (24 ref.)

A phase II trial of gemcitabine in patients with 5–FU–refractory pancreas cancer [see comments] Rothenberg ML, et al. **Ann Oncol** 1996 Apr;7(4):347–53. Comment in: Ann Oncol 1996 Apr;7(4):333–4. Comment in: Ann Oncol 1996 Apr;7(4):335–7.

A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma. Rougier P, et al. **Ann Oncol** 1997 May;8(5):500–2

The role of 5–fluorouracil dose in the adjuvant therapy of colorectal cancer. Zalcberg JR, et al. **Ann Oncol** 1996 Jan; 7(1):42–6

Chemotherapy with FUDR in the management of metastatic renal cell carcinoma. Aveta P, et al. **Ann Urol (Paris)** 1997; 31(3):159–63

Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates. Kairemo KJ, et al. **Anticancer Drug Des** 1996 Sep;11(6):439–49

Safety profile of gemcitabine, a novel anticancer agent, in non–small cell lung cancer. Cortes–Funes H, et al. **Anticancer Drugs** 1997 Jul;8(6):582–7

Pilot phase I–II study on 5–aza–2'–deoxycytidine (Decitabine) in patients with metastatic lung cancer. Momparler RL, et al. **Anticancer Drugs** 1997 Apr; 8(4):358–68

Weekly chronomodulated 48 h infusion of high–dose 5–fluorouracil modulated by methotrexate and (6S)–leucovorin in advanced colorectal cancer: a phase IB study. Punt CJ, et al. **Anticancer Drugs** 1997 Jun;8(5):454–8

1–(2–Tetrahydrofuryl)–5–fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12–dimethylbenz[a]anthracene in rats. Sakamoto S, et al. **Anticancer Drugs** 1996 Feb; 7(2):199–203

Electrochemotherapy with bleomycin in SA–1 tumor–bearing mice—natural resistance and immune responsiveness. Serša G, et al. **Anticancer Drugs** 1996 Sep; 7(7):785–91

Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5–fluorouracil. Strumberg D, et al. **Anticancer Drugs** 1997 Mar;8(3):293–5

A pharmacological pilot study: application of an intermittent schedule of oral uracil and ftorafur (UFT) for hepatocellular carcinoma patients. Une Y, et al. **Anticancer Drugs** 1996 Nov;7(8):881–4

Activity of gemcitabine in the treatment of patients with non–small cell lung cancer: a multicenter phase II study. Yokoyama A, et al. **Anticancer Drugs** 1997 Jul;8(6):574–81

Methionine depletion modulates the antitumor and antimetastatic efficacy of ethionine. Guo H, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2719–23

Anticancer efficacy of methioninase in vivo. Tan Y, et al. **Anticancer Res** 1996 Nov–Dec;16(6C):3931–6

Serum methionine depletion without side effects by methioninase in metastatic breast cancer patients. Tan Y, et al. **Anticancer Res** 1996 Nov–Dec;16(6C):3937–42

Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'–phosphate dehydrogenase activity. Tricot G, et al. **Anticancer Res** 1996 Nov–Dec;16(6A):3341–7

Tiazofurin effects on IMP–dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. Wright DG, et al. **Anticancer Res** 1996 Nov–Dec; 16(6A):3349–51

Bleomycin–mediated electrochemotherapy of metastatic melanoma. Glass LF, et al. **Arch Dermatol** 1996 Nov; 132(11):1353–7

Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminata. A phase 3 clinical study. Swinehart JM, et al. **Arch Dermatol** 1997 Jan; 133(1):67–73

Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Fishburne BC, et al. **Arch Ophthalmol** 1997 Sep;115(9):1152–6

Combined chemotherapy in the medical management of tubal pregnancy. Anandakumar C, et al. **Aust N Z J Obstet Gynaecol** 1995 Nov;35(4):437–40

Pre–operative radiotherapy and chemotherapy for non–resectable rectal cancer. Leong T, et al. **Aust N Z J Surg** 1997 Sep;67(9):603–6

Case–control study suggests a favorable impact of TEL rearrangement in patients with B–lineage acute lymphoblastic leukemia treated with antimetabolite–based therapy: a Pediatric Oncology Group study. Rubnitz JE, et al. **Blood** 1997 Feb 15;89(4):1143–6

2–Chlorodeoxyadenosine treatment in the Sezary syndrome [letter; comment] Zaucha JM, et al. **Blood** 1997 Feb 15; 89(4):1462–4. Comment on: Blood 1996 Feb 1;87(3):906–11.

A phase III study of radiotherapy with and without continuous–infusion fluorouracil as palliation for non–small–cell lung cancer. Ball D, et al. **Br J Cancer** 1997; 75(5):690–7

Interleukin 2 and interferon alpha–2a do not improve anti–tumour activity of 5–fluorouracil in advanced colorectal cancer. Goey SH, et al. **Br J Cancer** 1996 Dec; 74(12):2018–23

A phase II study of recombinant interferon–beta (r–hIFN–beta 1a) in combination with 5–fluorouracil (5–FU) in the treatment of patients with advanced colorectal carcinoma. Joffe JK, et al. **Br J Cancer** 1997; 75(3):423–6

Bcl–2 expression and response to chemotherapy in colorectal adenocarcinomas. Schneider HJ, et al. **Br J Cancer** 1997; 75(3):427–31

Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites. Lennard L, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):525–7

Gemcitabine. Prendiville J, et al. **Br J Hosp Med** 1997 Apr 16–May 6;57(8):405–9

Randomized controlled trial of postoperative radiotherapy and short–term time–scheduled 5–fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Tveit KM, et al. **Br J Surg** 1997 Aug;84(8):1130–5

Protracted 5–fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Ishii H, et al. **Cancer** 1997 Apr 15;79(8):1516–20

Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5–fluorouracil. Sugamura K, et al. **Cancer** 1997 Jan 1;79(1):12–7

Dihydro–5–azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Yogelzang NJ, et al. **Cancer** 1997 Jun 1;79(11):2237–42

A phase I study of 5–fluorouracil, leucovorin and levamisole. Cleary JF, et al. **Cancer Chemother Pharmacol** 1997; 39(4):300–6

Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Sugimachi K, et al. **Cancer Chemother Pharmacol** 1997;40(3):233–8

Antitumor activity and low intestinal toxicity of S–1, a new formulation of oral tegafur, in experimental tumor models in rats. Takechi T, et al. **Cancer Chemother Pharmacol** 1997; 39(3):205–11

Synergistic effects of Actinobacillus suis cells in combination with 5–fluorouracil on mice bearing murine L1210 leukemia cells. Watanabe T, et al. **Cancer Immunol Immunother** 1997 Jun;44(4):216–20

AcSDKP plasma concentrations in patients with solid tumours: comparison of two chemotherapeutic regimens. Comte L, et al. **Cancer Lett** 1997 Jan 15;112(1):1–4

Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Kornmann M, et al. **Cancer Lett** 1997 Sep 16;118(1):29–35

Fludarabine phosphate in lymphoma: an important new therapeutic agent. McLaughlin P, et al. **Cancer Treat Res** 1996;85:3–14 (56 ref.)

A durable response to cytarabine in advanced breast cancer. Czaykowski PM, et al. **Clin Oncol (R Coll Radiol)** 1997; 9(3):181–3

Piperacillin–induced seizures. Malanga CJ, et al. **Clin Pediatr (Phila)** 1997 Aug;36(8):475–8

Intraoperative electron and external beam irradiation with

or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer. Gunderson LL, et al. **Dis Colon Rectum** 1996 Dec; 39(12):1379–95

Use of intraperitoneal 5-fluorouracil and chlorhexidine for prevention of recurrence of perforated colorectal carcinoma in a rat model. Stuntz M, et al. **Dis Colon Rectum** 1997 Sep;40(9):1085–8

Gemcitabine for lung cancer. **Drug Ther Bull** 1996 Sep; 34(9):71–2

Raltitrexed in colorectal cancer. **Drug Ther Bull** 1996 Oct; 34(10):78–80 (11 ref.)

Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. Susak YM, et al. **Drugs Exp Clin Res** 1996;22(3–5):115–22

Colorectal cancer—is there an alternative to 5-FU? Bleiberg H. **Eur J Cancer** 1997 Apr;33(4):536–41 (32 ref.)

Colorectal cancer: the challenge. Bleiberg H. **Eur J Cancer** 1996;32A Suppl 5:S2–6 (58 ref.)

Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Burris H, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S18–22

Advanced breast cancer: investigational role of gemcitabine. Carmichael J, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S27–30 (37 ref.)

Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data. Chéradame S, et al. **Eur J Cancer** 1997 May;33(6):950–9

Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. Comella P, et al. **Eur J Cancer** 1996 Sep;32A(10):1719–26

Oral tegafur and folinic acid for the treatment of advanced colorectal cancer [letter] Isla MD, et al. **Eur J Cancer** 1997 Jan;33(1):166–7

Gemcitabine in ovarian cancer: an overview of safety and efficacy. Kaufmann M, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S31–3 (14 ref.)

Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies. Labianca R, et al. **Eur J Cancer** 1996;32A Suppl 5:S7–12 (55 ref.)

Activity of gemcitabine in platinum-resistant ovarian germ cell cancer [letter] Maas K, et al. **Eur J Cancer** 1996 Jul; 32A(8):1437–8

Metastatic bladder cancer: advances in treatment. Stadler WM, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S23–6 (55 ref.)

Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Thatcher N, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S8–13 (33 ref.)

Treatment of men with flat (FC) or acuminata (CA) condylomata with interferon alpha-2a. Relakis K, et al. **Eur J Gynaecol Oncol** 1996;17(6):529–33

Treatment with 5-fluorouracil of 35 patients with clinical or subclinical HPV infection of the vagina. Stefanon B, et al. **Eur J Gynaecol Oncol** 1996;17(6):534

Locally recurrent colorectal cancer: IOERT and EBRT +/-5-FU and maximal resection. Gunderson LL, et al. **Front Radiat Ther Oncol** 1997;31:224–8

Locally advanced primary colorectal cancer: IOERT and EBRT +/-5-FU. Gunderson LL, et al. **Front Radiat Ther Oncol** 1997;31:204–8

6-MP metabolite levels: a potential guide to Crohn's disease therapy. Sandborn WJ. **Gastroenterology** 1997 Aug; 113(2):690–2

Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Shapiro JD, et al. **Gynecol Oncol** 1996 Oct;63(1):89–93

Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA. Zhao SC, et al. **Hum Gene Ther** 1997 May 20;8(8):903–9

Low incidence of CNS relapse with cranial radiotherapy and intrathecal methotrexate in acute lymphoblastic leukemia. Raje NS, et al. **Indian Pediatr** 1996 Jul;33(7):556–60

Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Hall SJ, et al. **Int J Cancer** 1997 Jan 17;70(2):183–7

Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Minsky BD, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):289–95

Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. Robertson JM, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):325–30

Biochemical modulation of 5-fluorouracil with murine interferon-alpha/beta against murine renal cell carcinoma. Marumo K, et al. **Int J Urol** 1997 Mar;4(2):163–8

Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group. Naito S, et al. **Int J Urol** 1997 Jan;4(1):8–12

Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. Capizzi RL. **Invest New Drugs** 1996;14(3):249–56 (34 ref.)

Phase II trial of trimetrexate in advanced esophageal cancer: a southwest oncology group study. Fleming TR, et al. **Invest New Drugs** 1996;13(4):363–5

Folate, antifolates, and folate analogs in pediatric oncology. Hum MC, et al. **Invest New Drugs** 1996;14(1):101–11 (59 ref.)

Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Jackman AL, et al. **Invest New Drugs** 1996;14(3):305–16 (83 ref.)

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Khorsand M, et al. **Invest New Drugs** 1997;15(2):157–63

Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Merriman RL, et al. **Invest New Drugs** 1996;14(3):243–7

Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Pazdur R, et al. **Invest New Drugs** 1996;13(4):355–8

Gemcitabine and radiosensitization in human tumor cells. Shewach DS, et al. **Invest New Drugs** 1996;14(3):257–63 (52 ref.)

Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team. Von Hoff DD. **Invest New Drugs** 1996;14(3):265–70

Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. Miller BH, et al. **J Am Acad Dermatol** 1997 Jan;36(1):72–7

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Burris HA 3rd, et al. **J Clin Oncol** 1997 Jun;15(6):2403–13

Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer [see comments] [published erratum appears in J Clin Oncol 1996 Dec;14(12):3175] Crawford J, et al. **J Clin Oncol** 1996 Oct;14(10):2774–84. Comment in: J Clin Oncol 1996 Oct;14(10):2627–30.

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. O'Connell MJ, et al. **J Clin Oncol** 1997 Jan; 15(1):246–50

Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. Quinn CT, et al. **J Clin Oncol** 1997 Aug;15(8):2800–6

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. Rustum YM, et al. **J Clin Oncol** 1997 Jan;15(1):389–400 (77 ref.)

Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. Scheithauer W, et al. **J Clin Oncol** 1997 Mar;15(3):908–14

Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. Sorensen JM, et al. **J Clin Oncol** 1997 Feb; 15(2):458–65

Comparing an apple to a fruit salad [letter; comment] Spector N, et al. **J Clin Oncol** 1997 Aug;15(8):3021–2. Comment on: J Clin Oncol 1997 Feb;15(2):483–90.

Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. Tepper JE, et al. **J Clin Oncol** 1997 May;15(5):2030–9

Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. Zaniboni A. **J Clin Oncol** 1997 Jun; 15(6):2432–41 (59 ref.)

Unusual multiple keratoacanthoma in a child successfully treated with 5-fluorouracil. Singal A, et al. **J Dermatol** 1997 Aug;24(8):546–8

Intra-hepatic arterial drug delivery. Blesing CH, et al. **J Drug Target** 1996;3(5):341–7 (63 ref.)

The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). Aranda E, et al. **J Infus Chemother** 1996 Summer; 6(3):118–22

The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer. Blijham GH. **J Infus Chemother** 1996 Summer;6(3):114–7

Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. Chu L, et al. **J Infus Chemother** 1996 Fall;6(4):211–6

The French experience with infusional 5-fluorouracil in advanced colorectal cancer. de Gramont A, et al. **J Infus Chemother** 1996 Summer;6(3):133–6 (26 ref.)

Clinical trial of low dose cytosine arabinoside in the treatment of acute promyelocytic leukemia. Sung KW, et al. **J Korean Med Sci** 1997 Aug;12(4):298–304

Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. Cascino TL, et al. **J Neurooncol** 1996 Dec;30(3):243–6

PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. Haberkorn U, et al. **J Nucl Med** 1997 Aug;38(8):1215–21

Studies of cerebral blood flow in children with acute lymphoblastic leukemia: case reports of six children treated with methotrexate examined by single photon emission computed tomography. Osterlundh G, et al. **J Pediatr Hematol Oncol** 1997 Jan–Feb;19(1):28–34

Effect of preoperative 5-fluorouracil on apoptosis of advanced gastric cancer. Inada T, et al. **J Surg Oncol** 1997 Jun;65(2):106–10

2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas. Canfield VA, et al. **Leuk Lymphoma** 1997 Jan;24(3–4):335–9

Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Montserrat E, et al. **Leuk Lymphoma** 1996 May; 21(5–6):467–72

Why do drugs work in CLL? Plunkett W, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:1–11 (75 ref.)

High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia. Schiller G, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):427–34

Role of folylpolygutamate synthetase (FPGS) in antifolate chemotherapy; a biochemical and clinical update. Synold TW, et al. **Leuk Lymphoma** 1996 Mar;21(1–2):9–15 (56 ref.)

Panuveitis responsive to 2-CdA: an unusual ocular presentation of hairy cell leukemia. Zeidman A, et al. **Leuk Lymphoma** 1996 Feb;20(5–6):501–3

Studies of decitabine with allogeneic progenitor cell transplantation. Giralt S, et al. **Leukemia** 1997 Mar;11 Suppl 1:S32–4

Decitabine studies in chronic and acute myelogenous leukemia. Kantarjian HM, et al. **Leukemia** 1997 Mar;11 Suppl 1:S35–6

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Kantarjian HM, et al. **Leukemia** 1997 Oct;11(10):1617–20

Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. Lauria F, et al. **Leukemia** 1997 May;11(5):629–32

Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia. Momparler RL, et al. **Leukemia** 1997 Mar;11 Suppl 1:S1–6 (57 ref.)

Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Schwartsmann G, et al. **Leukemia** 1997 Mar;11 Suppl 1:S28–31

Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Wijermans PW, et al. **Leukemia** 1997 Mar;11 Suppl 1:S19–23

A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Willemze R, et al. **Leukemia** 1997 Mar;11 Suppl 1:S24–7

Simultaneous 3D NMR spectroscopy of proton-decoupled fluorine and phosphorus in human liver during 5-fluorouracil chemotherapy. Gonen O, et al. **Magn Reson Med** 1997 Feb;37(2):164–9

Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG). O'Brien PC, et al. **Med J Aust** 1996 Oct 21;165(8):424–7

How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer. Ragnhammar P, et al. **Med Oncol** 1995 Sep;12(3):187–201 (137 ref.)

Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up. Freeman AI, et al. **Med Pediatr Oncol** 1997 Feb;28(2):98–107

Gemcitabine: a ray of hope for pancreatic cancer? Gupta P. **Natl Med J India** 1997 Mar–Apr;10(2):72–3

Biochemical modulation: its pharmacological basis and clinical applications. Proceedings of a meeting. Singapore, October 19, 1995. **Oncology** 1997;54 Suppl 1:1–39

Month-long postoperative radiotherapy and 5-FU improve survival in rectal cancer [news] **Oncology (Huntingt)** 1996 Sep;10(9):1311

Objective outcome measures of quality of life. Burris HA 3rd. **Oncology (Huntingt)** 1996 Nov;10(11 Suppl):131–5

Clinical trials referral resource. Clinical trials using compound 506U78. Ho PT, et al. **Oncology (Huntingt)** 1996 Dec;10(12):1831–2

New developments in chemotherapy for patients with advanced pancreatic cancer. Rothenberg ML. **Oncology (Huntingt)** 1996 Sep;10(9 Suppl):18–22 (25 ref.)

Clinical trials referral resource. Clinical trials with tomudex. Sorensen JM, et al. **Oncology (Huntingt)** 1996 Jul; 10(7):1041–2

Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctiva and cornea. Yeatts RP, et al. **Ophthalmology** 1995 Sep;102(9):1338–44

Efficacy of bleomycin treatment for symptomatic hemangiomas in children. Kullendorff CM. **Pediatr Surg Int** 1997 Sep;12(7):526–8

Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy. Tan Y, et al. **Protein Expr Purif** 1997 Mar;9(2):233–45

Combined preoperative irradiation and direct postoperative 5-fluorouracil without negative effects on early anastomotic healing in the rat colon. Biert J, et al.

Radiother Oncol 1996 Dec;41(3):257–62

Pilot study in locally advanced unresectable pancreas carcinoma using a combination of accelerated radiotherapy and continuous infusion of 5–fluorouracil. Luderhoff EC, et al. **Radiother Oncol** 1996 Sep;40(3):241–3

Phase II study of weekly gemcitabine in advanced non–small cell lung cancer. Halme M, et al. **Respir Med** 1997 Aug; 91(7):423–6

Fludarabine monophosphate as salvage for refractory chronic lymphocytic leukaemia. Pillay GS, et al. **S Afr Med J** 1996 Aug;86(8):949–51

Phase I studies with the novel nucleoside analog gemcitabine. Abbruzzese JL. **Semin Oncol** 1996 Oct;23(5 Suppl 10):25–31 (30 ref.)

The emerging role of gemcitabine in lung cancer. Bunn PA Jr. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8–1

Phase II activity of gemcitabine in advanced breast cancer. Carmichael J, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 10):77–81

Economic value of gemcitabine in non–small cell lung cancer. Copley–Merriman C, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 10):90–8 (15 ref.)

An estimate of the cost effectiveness of gemcitabine in stage IV non–small cell lung cancer. Evans WK. **Semin Oncol** 1996 Oct;23(5 Suppl 10):82–9

Phase II studies of gemcitabine for non–small cell lung cancer in Japan. Fukuoka M, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7–42–S7–46

Gemcitabine: we've reached the end of the beginning. Green MR. **Semin Oncol** 1996 Oct;23(5 Suppl 10):99–100

Efficacy of single–agent gemcitabine in advanced non–small cell lung cancer: a review. Hansen HH, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7–38–S7–41 (15 ref.)

Single–agent gemcitabine in non–small cell lung cancer: the French experience. Le Chevalier T, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7–47–S7–49

Single–agent activity of gemcitabine in advanced non–small cell lung cancer. Le Chevalier T. **Semin Oncol** 1996 Oct; 23(5 Suppl 10):36–42 (23 ref.)

A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non–small cell lung cancer. Manegold C, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8–13–S8–17

Gemcitabine in the treatment of elderly patients with advanced non–small cell lung cancer. Shepherd FA, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7–50–S7–55

Radiosensitization of human solid tumor cell lines with gemcitabine. Shewach DS, et al. **Semin Oncol** 1996 Oct; 23(5 Suppl 10):65–71 (42 ref.)

Gemcitabine: symptomatic benefit in advanced non–small cell lung cancer. Thatcher N, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8–6–S8–12 (37 ref.)

Gemcitabine: a case study for clinical benefit. Von Hoff DD. **Semin Oncol** 1996 Oct;23(5 Suppl 10):1–2

The use of cytotoxic agents in the treatment of immune–mediated diseases of dogs and cats. Miller E. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):157–60 (22 ref.)

Comparison by carcinoembryonic antigen doubling time of hepatic injection and infusion for unresectable hepatic metastasis from colorectal cancer. Ichikawa W, et al. **Surg Oncol** 1995;4(5):271–6

Increased apoptosis rate by hyperthermochemoradiotherapy for advanced rectal cancers. Sakakura C, et al. **Surg Today** 1997;27(8):773–6

Electrochemotherapy significantly inhibits the growth of colon 26 tumors in mice. Tada T, et al. **Surg Today** 1997; 27(6):506–10

5–Fluorouracil prodrug, ftorafur, modulated by uracil (UFT): preclinical and clinical prospective. Cao S, et al. **Tumori** 1997 Jan–Feb;83(1 Suppl):S90–3

The potential role of Tomudex in the treatment of advanced colorectal cancer. Sobrero AF. **Tumori** 1997 Mar–Apr; 83(2):576–80 (42 ref.)

[Fludarabine monophosphate in the treatment of patients with advanced stages of chronic B–cell lymphatic leukemia resistant to conventional chemotherapy] Papajik T, et al. **Vnitr Lek** 1997 Jan;43(1):25–8 (Eng. Abstr.) **(Cze)**

[A phase II multicenter study of gemcitabine in non small cell lung cancers] Le Chevalier T, et al. **Bull Cancer** 1997 Mar;84(3):282–8 (Eng. Abstr.) **(Fre)**

[Colorectal carcinoma: therapeutic approach in patients already treated with metastasis resection] Bajetta E, et al. **Ann Ital Chir** 1996 Nov–Dec;67(6):827–30 (Eng. Abstr.) **(Ita)**

[Methotrexate–leucovorin rescue therapy: pharmacological characteristics and clinical effective use] Fujimoto T. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1901–6 (6 ref.) (Eng. Abstr.) **(Jpn)**

[An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II] Fukuoka M, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1813–24 (Eng. Abstr.) **(Jpn)**

[Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non–small–cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)] Fukuoka M, et al. **Gan To Kagaku Ryoho** 1996 Nov; 23(13):1825–32 (Eng. Abstr.) **(Jpn)**

[A late phase II study of LY188011 (Gemcitabine hydrochloride) in patients with non–small–cell lung cancer. Gemcitabine Cooperative Study Group B for Late Phase II] Yokoyama A, et al. **Gan To Kagaku Ryoho** 1996 Oct; 23(12):1681–8 (Eng. Abstr.) **(Jpn)**

[Immunological monitoring of patients with disseminated colorectal cancer under thermochemotherapy] Iaremchuk AIa, et al. **Klin Khir** 1997;(1):35–7 (Eng. Abstr.) **(Rus)**

TOXICITY

Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Nomura A, et al. **Am J Pathol** 1997 Aug;151(2):539–47

New formulation of 5–fluorouracil in microspheres reduces toxicity in mice. Hagiwara A, et al. **Anticancer Drugs** 1996 Sep;7(7):780–4

Modulation by conagenin of inflammatory mediator productions in mice given 5–fluorouracil. Kawatsu M, et al. **Anticancer Res** 1997 Mar–Apr;17(2A):917–22

Effect of nordihydroguaiaretic acid and ibuprofen on bleomycin and hyperoxia–induced changes in lung superoxide dismutase, prostaglandins and lethality. Giri SN, et al. **Arch Toxicol** 1996;70(5):271–6

Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA–fluorescein. Gati WP, et al. **Blood** 1997 Jul 1;90(1):346–53

Differences in sensitivity to developmental toxicants as seen in Xenopus and Pimephales embryos. DeYoung DJ, et al. **Bull Environ Contam Toxicol** 1996 Jan;56(1):143–50

Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6–thioxanthine or 6–thioguanine. Tamiya T, et al. **Cancer Gene Ther** 1996 May–Jun;3(3):155–62

Involvement of stress–activated protein kinase in the cellular response to 1–beta–D–arabinofuranosylcytosine and other DNA–damaging agents. Saleem A, et al. **Cell Growth Differ** 1995 Dec;6(12):1651–8

Myelosuppression in the pig (Sus scrofa): uteroferrin reduces the myelosuppressive effects of 5–fluorouracil in young pigs. Laurenz JC, et al. **Comp Biochem Physiol A Physiol** 1997 Apr;116(4):369–77

Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5–fluorouracil prodrugs [corrected and republished in Drug Metab Dispos 1997 May;25(5):270–3] Okuda H, et al. **Drug Metab Dispos** 1997 Feb;25(2):270–3

Reduced renal medullary water channel expression in puromycin aminonucleoside–induced nephrotic syndrome. Apostol E, et al. **J Am Soc Nephrol** 1997 Jan; 8(1):15–24

Drug–induced apoptosis in hepatoma cells is mediated by the CD95 (APO–1/Fas) receptor/ligand system and involves activation of wild–type p53. Müller M, et al. **J Clin Invest** 1997 Feb 1;99(3):403–13

O6–(alkyl/aralkyl)guanosine and 2'–deoxyguanosine derivatives: synthesis and ability to enhance chloroethylnitrosourea antitumor action. Mounetou E, et al. **J Med Chem** 1997 Aug 29;40(18):2902–9

Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. Howarth GS, et al. **J Nutr** 1996 Oct; 126(10):2519–30

Vitamin A deficiency exacerbates methotrexate–induced jejunal injury in rats. Warden RA, et al. **J Nutr** 1997 May; 127(5):770–6

5–fluorouracil induced cardiotoxicity in albino rats. Kumar S, et al. **Mater Med Pol** 1995 Apr–Jun;27(2):63–6

Nephrotoxicity of low–dose methotrexate in guinea pigs: an ultrastructural study. el–Badawi MG, et al. **Nephron** 1996; 73(3):462–6

Cytotoxicity of sera from rats with puromycin aminonucleoside nephrosis. Natori Y, et al. **Nephron** 1996; 73(2):258–63

Ubiquitous, heritable damage in cell populations that survive treatment with methotrexate. Chow M, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8773–8

Potentiation of testicular cytotoxicity by the alkyltransferase inhibitor O6 benzylguanine and the 5–fluorouracil/N–(2–chloroethyl)–N–nitrosourea molecular combination, B.4152. Thompson MJ, et al. **Reprod Toxicol** 1996 Jan–Feb;10(1):71–7

In vitro interaction between gemcitabine and other anticancer drugs using a novel three–dimensional model. Kanzawa F, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7–8–S7–16

Combination chemotherapy studies with gemcitabine. van Moorsel CJ, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7–17–S7–23 (40 ref.)

Dose–response relationship of teratogenicity and prenatal–toxic risk estimation of 6–mercaptopurine riboside in mice. Platzek T, et al. **Teratog Carcinog Mutagen** 1996; 16(3):169–81

Cyclophosphamide–induced teratogenesis in ICR mice: the role of apoptosis. Torchinsky A, et al. **Teratog Carcinog Mutagen** 1995;15(4):179–90

Nucleoside–mediated mitigation of 5–fluorouracil–induced toxicity in synchronized murine erythroleukemic cells. Elstein KH, et al. **Toxicol Appl Pharmacol** 1997 Sep; 146(1):29–39

[Determination of dihydropyrimidine dehydrogenase in the prediction of toxic side effects of 5–fluorouracil] Katona C, et al. **Orv Hetil** 1997 Jul 20;138(29):1843–7 (Eng. Abstr.) **(Hun)**

[Reproductive and developmental toxicity study of a new antineoplastic agent, S–1 (IV)—Perinatal and postnatal study in rats by oral administration] Furuhashi T, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:643–59 (Eng. Abstr.) **(Jpn)**

[A 26–week oral repeated dose toxicity study of a new antineoplastic agent S–1 in rats] Hakoi K, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:545–60 (Eng. Abstr.) **(Jpn)**

[An oral repeated dose toxicity study of a new antineoplastic agent S–1 in dogs. I. A 13–week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study] Hayashi T, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:527–44 (Eng. Abstr.) **(Jpn)**

[Oral single–dose toxicity study of a new antineoplastic agent S–1, and its components, CDHP, and Oxo] Hayashi T, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:495–504 (Eng. Abstr.) **(Jpn)**

[A 13–week oral repeated dose toxicity study of a new antineoplastic agent S–1 in rats] Hayashi T, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:505–26 (Eng. Abstr.) **(Jpn)**

[A 52–week oral toxicity study of a new antineoplastic agent S–1 in dogs] Kitajima S, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:561–88 (Eng. Abstr.) **(Jpn)**

[Immunotoxic effects of a new antineoplastic agent S–1 in mice—comparison with S–1, UFT and 5–FU] Kouchi Y, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:691–701 (Eng. Abstr.) **(Jpn)**

[Mutagenicity study of a new antineoplastic agent S–1, and its components, CDHP, and Oxo] Ohuchida A, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:675–89 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity study of a new antineoplastic agent, S–1 (I)—Fertility study in rats by oral administration] Shinomiya M, et al. **J Toxicol Sci** 1996 Nov; 21 Suppl 3:589–602 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity study of a new antineoplastic agent, S–1 (III)—Teratological study in rabbits by oral administration] Shinomiya M, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:619–41 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity study of a new antineoplastic agent, S–1 (II)—Teratological study in rats by oral administration] Yukiyama S, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:603–18 (Eng. Abstr.) **(Jpn)**

[Reaction of the adrenal medulla to the effect of various extreme factors] Khlusov IA, et al. **Biull Eksp Biol Med** 1997 Mar;123(3):293–5 **(Rus)**

URINE

Determination of methotrexate and its main metabolite 7–hydroxymethotrexate in human urine by high–performance liquid chromatography with normal solid–phase extraction. Hirai T, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):267–73

ANTIMITOTIC AGENTS see **ANTINEOPLASTIC AGENTS**

ANTIMONY

New approach for elucidating the oxygen sensitivity and calibration of the antimony electrode. Sjöberg F, et al. **Med Biol Eng Comput** 1997 May;35(3):207–10

ADMINISTRATION & DOSAGE

High and low doses of antimony (Sbv) in American cutaneous leishmaniasis. A five years follow–up study of 15 patients. Oliveira Neto MP, et al. **Mem Inst Oswaldo Cruz** 1996 Mar–Apr;91(2):207–9

The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial. Slappendel RJ, et al. **Vet Q** 1997 Mar;19(1):10–3

ADVERSE EFFECTS

Pentavalent antimonial–induced torsade de pointes. Ortega–Carnicer J, et al. **J Electrocardiol** 1997 Apr; 30(2):143–5

Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis. Hantson P, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):869–71

[Pancreatitis during treatment of leishmaniasis with n–methylglucamine antimoniate in a subject infected with HIV] Trinchieri V, et al. **Riv Eur Sci Med Farmacol** 1996 Mar–Apr;18(2):49–51 (Eng. Abstr.) **(Ita)**

ANALYSIS

Sensing antimonite and arsenite at the subattomole level with genetically engineered bioluminescent bacteria. Ramanathan S, et al. **Anal Chem** 1997 Aug 15;69(16):3380–4

Genetically engineered bacteria: electrochemical sensing systems for antimonite and arsenite. Scott DL, et al. **Anal Chem** 1997 Jan 1;69(1):16–20

Antimony in drinking water, red blood cells, and serum: development of analytical methodology using transversely heated graphite furnace atomization–atomic absorption spectrometry. Subramanian KS, et al. **Arch Environ Contam Toxicol** 1997 May;32(4):431–5

Nondestructive determination of lead, cadmium, tin, antimony, and barium in ceramic glazes by radioisotope X–ray fluorescence spectrometry. Anderson DL, et al. **J AOAC Int** 1996 Sep–Oct;79(5):1141–57

METABOLISM

Antimonite is accumulated by the glycerol facilitator GlpF in Escherichia coli. Sanders OI, et al. **J Bacteriol** 1997 May; 179(10):3365–7

Resistance mechanisms to arsenicals and antimonials. Rosen BP. **J Basic Clin Physiol Pharmacol** 1995;6(3–4):251–63 (50 ref.)

PHARMACOLOGY

In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Faraut–Gambarelli F, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):827–30

THERAPEUTIC USE

Antimony/interferon–gamma combination in the treatment of visceral leishmaniasis in AIDS [letter] Kaplanski G, et al. **AIDS** 1996 Sep;10(10):1172–4

In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Faraut–Gambarelli F, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):827–30

Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis. Murray HW, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):586–7

Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil—an area of Leishmania (V.) braziliensis transmission. Oliveira–Neto MP, et al. **Int J Dermatol** 1997 Jun; 36(6):463–8

Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Oliveira–Neto MP, et al. **Pathol Biol (Paris)** 1997 Jun;45(6):496–9

TOXICITY

Comparative and environmental genotoxicity of antimony and arsenic. Gebel T, et al. **Anticancer Res** 1997 Jul–Aug; 17(4A):2603–7

Mutagenicity, carcinogenicity and teratogenicity of antimony compounds. Léonard A, et al. **Mutat Res** 1996 Oct; 366(1):1–8 (61 ref.)

Altered Ca2+ mobilization during excitation–contraction in cultured cardiac myocytes exposed to antimony. Toraason M, et al. **Toxicol Appl Pharmacol** 1997 Sep;146(1):104–15

URINE

Urinary antimony in infancy. Dezateux C, et al. **Arch Dis Child** 1997 May;76(5):432–6

ANTIMONY GLUCONATE SODIUM see **ANTIMONY SODIUM GLUCONATE**

ANTIMONY POTASSIUM TARTRATE

TOXICITY

The role of intracellular calcium in antimony–induced toxicity in cultured cardiac myocytes. Wey HE, et al. **Toxicol Appl Pharmacol** 1997 Jul;145(1):202–10

Antimony–induced alterations in thiol homeostasis and adenine nucleotide status in cultured cardiac myocytes. Tirmenstein MA, et al. **Toxicology** 1997 May 16; 119(3):203–11

ANTIMONY SODIUM GLUCONATE

ADMINISTRATION & DOSAGE

Synergism of IL–2–stimulated splenocytes and Pentostam enhances the killing of Leishmania donovani in vitro. Eslami Z, et al. **Clin Immunol Immunopathol** 1996 Oct; 81(1):74–81

Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Martinez S, et al. **Clin Infect Dis** 1997 Feb; 24(2):165–9

Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin–12 production. Li J, et al. **Infect Immun** 1997 Aug;65(8):3225–30

Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Tallab TM, et al. **Int J Dermatol** 1996 Aug;35(8):594–7

ADVERSE EFFECTS

Conduction defect following pentavalent antimony therapy in visceral leishmaniasis [letter] Ahasan HA, et al. **Trop Doct** 1997 Jan;27(1):59–61

PHARMACOLOGY

Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Ephros M, et al. **Antimicrob Agents Chemother** 1997 May; 41(5):1064–8

THERAPEUTIC USE

Pentavalent antimony–mannan conjugate therapy of experimental visceral leishmaniasis. Roberts WL, et al. **Am J Trop Med Hyg** 1996 Oct;55(4):444–6

Ketoconazole in antimonial unresponsive cases of Kala–azar. Jha TK, et al. **J Assoc Physicians India** 1995 May;43(5):347

Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis. Poli A, et al. **Vet Parasitol** 1997 Aug;71(4):263–71

[Facial cutaneous leishmaniasis from a vacation to the south] Király C. **Duodecim** 1995;111(12):1104–6 **(Fin)**

TOXICITY

Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Mukhopadhyay R, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10383–7

ANTIMUSCARINIC AGENTS see **MUSCARINIC ANTAGONISTS**

ANTIMUTAGENIC AGENTS

see related
ANTICARCINOGENIC AGENTS

Dietary phenolics as anti–mutagens and inhibitors of tobacco–related DNA adduction in the urothelium of smokers. Malaveille C, et al. **Carcinogenesis** 1996 Oct; 17(10):2193–200

Lactobacillus– and bifidobacterium–mediated antigenotoxicity in the colon of rats. Pool–Zobel BL, et al. **Nutr Cancer** 1996;26(3):365–80

ADMINISTRATION & DOSAGE

Cobalt but not hypoxia stimulates PDGF gene expression in rats. Bucher M, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E451–7

Suppressive effects of chlorophyllin on mutagen–induced umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002) and tumor promoter–dependent ornithine decarboxylase induction in BALB/c 3T3 fibroblast cells. Okai Y, et al. **Mutat Res** 1996 Aug;370(1):11–7

ANALYSIS

Chemiluminescence–high–performance liquid chromatographic determination of tea catechin, (–)–epigallocatechin 3–gallate, at picomole levels in rat and human plasma. Nakagawa K, et al. **Anal Biochem** 1997 May 15;248(1):41–9

[Mutagens and antimutagens in food products] Durnev AD. **Genetika** 1997 Feb;33(2):165–76 (123 ref.) (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

[Studies of chemopreventive agents against neoplasma: synthesis of 3–acetyl coumarin derivatives and relationship between antimutagenic activity and structure] Huang XL, et al. **Yao Hsueh Hsueh Pao** 1996;31(6):431–6 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Bio–antimutagenic activity of green tea catechins in cultured Chinese hamster V79 cells. Kuroda Y. **Mutat Res** 1996 Dec 12;361(2–3):179–86

Antimutagenicity of Tochu tea (an aqueous extract of Eucommia ulmoides leaves): 2. Suppressing effect of Tochu tea on the urine mutagenicity after ingestion of raw fish and cooked beef. Sasaki YF, et al. **Mutat Res** 1996 Dec 20;371(3–4):203–14

Complex formation of heterocyclic amines with porphyrins: its use in detection and prevention. Hayatsu H. **Princess Takamatsu Symp** 1995;23:172–80 (14 ref.)

ISOLATION & PURIFICATION

Two new nitrogenous sesquiterpenes from the sponge Axinyssa aplysinoides. Patil AD, et al. **J Nat Prod** 1997 May;60(5):507–10

A bioactive seco–rosane diterpenoid from Vellozia candida. Valente LM, et al. **J Nat Prod** 1997 May;60(5):478–81

Esculetin in Alchemilla speciosa: identification and antimutagenic properties. Schimmer O, et al. **Pharmazie** 1997 Jun;52(6):476–8

Polymethoxylated xanthones from the herb of Centaurium erythraea with strong antimutagenic properties in Salmonella typhimurium. Schimmer O, et al. **Planta Med** 1996 Dec;62(6):561–4

METABOLISM

Antimutagenic activity of casein against MNNG in the E. coli DNA repair host–mediated assay. van Boekel MA, et al. **Cancer Lett** 1997 Mar 19;114(1–2):85–7

PHARMACOLOGY

Epigallocatechin gallate–induced histamine release in patients with green tea–induced asthma. Shirai T, et al. **Ann Allergy Asthma Immunol** 1997 Jul;79(1):65–9

Differences in the apoptosis–inducing properties of Viscum album L. extracts. Büssing A, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S9–14 (30 ref.)

Antimutagenicity of benzo[a]phenothiazines in chemically induced mutagenesis. Tanaka M, et al. **Anticancer Res** 1997 Mar–Apr;17(2A):839–42

Antimutagenicity of phenothiazine–metal co–ordination complexes in chemically induced mutagenesis. Tanaka M, et al. **Anticancer Res** 1997 Jan–Feb;17(1A):381–5

Antimutagenicity of benzo[a]phenothiazines in chemically induced mutagenesis. Tanaka M, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3625–8

Some effects of 1,4–dihydroisonicotinic acid derivatives on repair pathways involved in chemical mutagenesis. Kuzhir TD, et al. **Biochem Soc Trans** 1997 Feb;25(1):139S

Chemopreventive effect of chlorophyllin on mutagenicity and cytotoxicity of 6–sulfooxymethylbenzo[a]pyrene. Cho YS, et al. **Cancer Lett** 1996 Oct 22;107(2):223–8

Antimutagenic activity of alkylresorcinols from cereal grains. Gąsiorowski K, et al. **Cancer Lett** 1996 Aug 23; 106(1):109–15

Screening of anticarcinogenic ingredients in tea polyphenols. Han C. **Cancer Lett** 1997 Mar 19;114(1–2):153–8

In vivo antigenotoxic effects of dietary allyl sulfides in the rat. Le Bon AM, et al. **Cancer Lett** 1997 Mar 19; 114(1–2):131–4

Reduction of urinary mutagen excretion in rats fed garlic. Polasa K, et al. **Cancer Lett** 1997 Mar 19;114(1–2):185–6

Effects of n–tritriacontane–16,18–dione, curcumin, chlorphyllin, dihydroguaiaretic acid, tannic acid and phytic acid on the initiation stage in a rat multi–organ carcinogenesis model. Takaba K, et al. **Cancer Lett** 1997 Feb 26;113(1–2):39–46

Hprt mutations in human T–lymphocytes reflect radioprotective effects of the aminothiol, WR–1065. Clark LS, et al. **Carcinogenesis** 1996 Dec;17(12):2647–53

Re: Barcelo, S., Gardiner, J.M., and Gescher, A. and Chipman, J.K. (1996) CYP2E1–mediated mechanism of anti–genotoxicity of the broccoli constituent sulforaphane. Carcinogenesis, 17, 277–282 [letter; comment] Paolini M, et al. **Carcinogenesis** 1997 Jul;18(7):1435–6. Comment on: Carcinogenesis 1996 Feb;17(2):277–82. Comment on: Carcinogenesis 1996 Apr;17(4):793–9.

Inhibitory effects of lemon grass (Cymbopogon citratus Stapf) on formation of azoxymethane–induced DNA adducts and aberrant crypt foci in the rat colon. Suaeyun R, et al. **Carcinogenesis** 1997 May;18(5):949–55

Clastogenic activity of pure chlorophyll and anticlastogenic effects of equivalent amounts of crude extract of Indian spinach leaf and chlorophyllin following dietary supplementation to mice. Sarkar D, et al. **Environ Mol Mutagen** 1996;28(2):121–6

The modulatory effect of aminothiols on the clastogenic activity of X–rays assayed by the vivo mouse micronucleus test. Mazur L. **Folia Biol (Krakow)** 1996;44(1–2):55–9

Inhibition of the mutagenicity of 2–nitrofluorene, 3–nitrofluoranthene and 1–nitropyrene by flavonoids, coumarins, quinones and other phenolic compounds. Edenharder R, et al. **Food Chem Toxicol** 1997 Mar–Apr; 35(3–4):357–72

Inhibition of the mutagenicity of 2–nitrofluorene, 3–nitrofluoranthene and 1–nitropyrene by vitamins, porphyrins and related compounds, and vegetable and fruit juices and solvent extracts. Tang X, et al. **Food Chem Toxicol** 1997 Mar–Apr;35(3–4):373–8

Anticlastogenicity of vitamin C in vivo against the cytogenetic toxicity of muriate of potash in murine bone marrow cells. Sinha AK, et al. **In Vivo** 1996 Jan–Feb; 10(1):111–2

Effect of different vitamin A status on carcinogen–induced DNA damage and repair enzymes in rats. Webster RP, et al. **In Vivo** 1996 Jan–Feb;10(1):113–8

In vivo effects of chlorophyllin on the antitumour agent cyclophosphamide. Te C, et al. **Int J Cancer** 1997 Jan 6; 70(1):84–9

Bacterial mutagenicity of terasi and antimutagenicity of Indonesian jasmine tea against terasi. Surono IS, et al. **Int J Food Microbiol** 1996 Sep;32(1–2):49–58

Antimutagenesis and anticancer effects. Bronzetti G, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):59–64 (28 ref.)

Inhibitory effect of chlorophyllin on diethylnitrosamine and phenobarbital–induced hepatocarcinogenesis in male F344 rats. Sugie S, et al. **Jpn J Cancer Res** 1996 Oct; 87(10):1045–51

Lipopolysaccharide–induced DNA damage is greatly reduced in rats treated with the pineal hormone melatonin. Sewerynek E, et al. **Mol Cell Endocrinol** 1996 Mar 25; 117(2):183–8

Inhibition of the genotoxic effects of heterocyclic amines in human derived hepatoma cells by dietary bioantimutagens. Sanyal R, et al. **Mutagenesis** 1997 Jul;12(4):297–303

Antimutagenic and anticarcinogenic activity of natural and synthetic curcuminoids. Anto RJ, et al. **Mutat Res** 1996 Sep 13;370(2):127–31

Inhibition of PhIP mutagenicity by catechins, and by theaflavins and gallate esters. Apostolides Z, et al. **Mutat Res** 1997 Mar 17;389(2–3):167–72

Hydrogen peroxide induces protection against N–methyl–N'–nitro–N–nitrosoguanidine (MNNG) effects in Escherichia coli. Asad LM, et al. **Mutat Res** 1997 Mar 12;383(2):137–42

Inhibition of clastogenic effects of arsenic through continued oral administration of garlic extract in mice in vivo. Choudhury AR, et al. **Mutat Res** 1997 Aug 14; 392(3):237–42

Antimutagenicity of xanthophylls present in Aztec Marigold (Tagetes erecta) against 1–nitropyrene. González de Mejía E, et al. **Mutat Res** 1997 Mar 17;389(2–3):219–26

ANTIMUTAGENIC AGENTS

Antimutagens from Plumeria acuminata Ait. Guevara AP, et al. **Mutat Res** 1996 Dec 12;361(2–3):67–72

Chemoprotection against the formation of colon DNA adducts from the food–borne carcinogen 2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine (PhIP) in the rat. Huber WW, et al. **Mutat Res** 1997 May 12; 376(1–2):115–22

Mixed disulfides from disulfiram inhibit the benzo[a]pyrene induced mutagenesis. Lee BH, et al. **Mutat Res** 1996 Dec 20;371(3–4):215–20

Chemopreventive effects of S–(N,N–diethyldithiocarbamoyl)–N–acetyl–L–cysteine against benzo[a]pyrene. Lee BH, et al. **Mutat Res** 1997 Jul 3;377(2):167–75

Inhibitory effect of chlorophyllin on the frequency of sister chromatid exchanges produced by benzo[a]pyrene in vivo. Madrigal–Bujaidar E, et al. **Mutat Res** 1997 Jan 15; 388(1):79–83

Antimutagenic effects of dehydrozingerone and its analogs on UV–induced mutagenesis in Escherichia coli. Motohashi N, et al. **Mutat Res** 1997 Jun 9;377(1):17–25

Antimutagenicity of Tochu tea (an aqueous extract of Eucommia ulmoides leaves): 1. The clastogen–suppressing effects of Tochu tea in CHO cells and mice. Nakamura T, et al. **Mutat Res** 1997 Jan 15;388(1):7–20

Vitamins as antimutagens: advantages and some possible mechanisms of antimutagenic action. Odin AP. **Mutat Res** 1997 Mar;386(1):39–67 (180 ref.)

Antimutagenicity of the porphyrins and non–enzyme porphyrin–containing proteins. Odin AP. **Mutat Res** 1997 Aug;387(1):55–68 (100 ref.)

Persistence of cadmium–induced adaptive response to genotoxicity of maleic hydrazide and methyl mercuric chloride in root meristem cells of Allium cepa L.: differential inhibition by cycloheximide and buthionine sulfoximine. Panda KK, et al. **Mutat Res** 1997 Mar 17; 389(2–3):129–39

Polyamines and their potential to be antimutagens. Pillai SP, et al. **Mutat Res** 1997 Jul 3;377(2):217–24

Phenethyl isothiocyanate modulates clastogenicity of mitomycin C and cyclophosphamide in vivo. Sen S, et al. **Mutat Res** 1996 Dec 20;371(3–4):159–64

Mechanism of antimutagenic action of (+)–catechin against the plant–activated aromatic amine 4–nitro–o–phenylenediamine. Toering SJ, et al. **Mutat Res** 1996 Dec 12;361(2–3):81–7

Antimutagenic effect of resveratrol against Trp–P–1. Uenobe F, et al. **Mutat Res** 1997 Feb 3;373(2):197–200

Tea polyphenols as inhibitors of mutagenicity of major classes of carcinogens. Weisburger JH, et al. **Mutat Res** 1996 Nov 4;371(1–2):57–63

Antimutagenic activity of extracts from Japanese eggplant. Yoshikawa K, et al. **Mutat Res** 1996 Nov 4;371(1–2):65–71

Antimutagenic activity of vitamin mixtures. Miadoková E, et al. **Pharmazie** 1997 Feb;52(2):168–9

Esculetin in Alchemilla speciosa: identification and antimutagenic properties. Schimmer O, et al. **Pharmazie** 1997 Jun;52(6):476–8

Anticlastogenic effect of S–2–(3–aminopropylamino) ethylphosphorothioic acid against X–rays in mice. Mazur L. **Physiol Res** 1996;45(1):59–63

In vitro antimutagenic effects of anthraquinone aglycones and naphthopyrone glycosides from Cassia tora. Choi JS, et al. **Planta Med** 1997 Feb;63(1):11–4

Protective properties of chlorophylls against the covalent binding of heterocyclic amines to DNA in vitro and in vivo. Dashwood R, et al. **Princess Takamatsu Symp** 1995; 23:181–9

Superoxide–mediated clastogenesis and anticlastogenic effects of exogenous superoxide dismutase. Emerit I, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):12799–804

Antigenotoxic activities of chitin and chitosan as assayed by sister chromatid exchange. Ohe T. **Sci Total Environ** 1996 Mar 1;181(1):1–5

[Mutagen–modifying effects of beta–carotene in vivo] Durnev AD, et al. **Genetika** 1997 May;33(5):717–20 (Eng. Abstr.) **(Rus)**

[The antimutagenic action of apiculture products] Bariliak IR, et al. **Tsitol Genet** 1996 Nov–Dec;30(6):48–55 (Eng. Abstr.) **(Rus)**

[Mutagenic and antimutagenic activities of human whole blood, plasma and albumin] Semenov VV, et al. **Vestn Ross Akad Med Nauk** 1997;(7):33–5 (Eng. Abstr.) **(Rus)**

[Receptor regulatory mechanisms of antimutagenic action] Semenov VV. **Vestn Ross Akad Med Nauk** 1997;(7):28–33 (53 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Protective effect of food additives on aflatoxin–induced mutagenicity and hepatocarcinogenicity. Soni KB, et al. **Cancer Lett** 1997 May 19;115(2):129–33

natural antimutagenic agents may prolong efficacy of human immunodeficiency virus drug therapy. McCarty MF. **Med Hypotheses** 1997 Mar;48(3):215–20 (77 ref.)

ANTIMYCIN A

ANALOGS & DERIVATIVES

Antimycin resistance and ubiquinol cytochrome c reductase instability associated with a human cytochrome b mutation. Bouzidi MF, et al. **Biochim Biophys Acta** 1996 Dec 16; 1317(3):199–209

ANTAGONISTS & INHIBITORS

Cytoprotective effect of ulinastatin on LLC–PK1 cells treated with antimycin A, gentamicin, and cisplatin. Ishibashi M, et al. **Nephron** 1997;76(3):300–6

ANTINEMATODAL AGENTS

The effect of cooking on veterinary drug residues in food; 5. Oxfendazole. Rose MD, et al. **Food Addit Contam** 1997 Jan;14(1):15–26

Solid–phase extraction and HPLC determination of levamisole hydrochloride in sheep plasma. Du Preez JL, et al. **Onderstepoort J Vet Res** 1996 Sep;63(3):209–11

ADMINISTRATION & DOSAGE

Intracystic application of mebendazole solution in the treatment of liver hydatid disease. Preliminary report of two cases. Erzurumlu K, et al. **Eur Surg Res** 1996; 28(6):466–70

Controlled dose confirmation study of a 2% moxidectin equine gel against equine internal parasites in The Netherlands. Eysker M, et al. **Vet Parasitol** 1997 Jun; 70(1–3):165–73

Effect of simulated rain, coat length and exposure to natural climatic conditions on the efficacy of a topical formulation of eprinomectin against endoparasites of cattle. Gogolewski RP, et al. **Vet Parasitol** 1997 Apr;69(1–2):95–102

ADVERSE EFFECTS

[Severe secondary reactions related to ivermectin treatment in patients with loiasis (letter)] Chippaux JP, et al. **Med Trop (Mars)** 1996;56(3):312 **(Fre)**

[Thiabendazole hypersensitivity (letter)] Moro Moro MM, et al. **Med Clin (Barc)** 1997 Apr 5;108(13):519 **(Spa)**

ANALYSIS

Thin–layer chromatographic detection of ivermectin in cattle dung. Floate KD, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20;694(1):246–51

BLOOD

Drug residues in milk from cows administered fenbendazole as a paste, drench, or feed top–dressing. Barker SA, et al. **J Vet Pharmacol Ther** 1997 Apr;20(2):160–2

Plasma protein binding of levamisole in several species. Sahagún A, et al. **Methods Find Exp Clin Pharmacol** 1997 Apr;19(3):185–7

CHEMICAL SYNTHESIS

Synthesis and nematocidal activity of aralkyl– and aralkenylamides related to piperamide on second–stage larvae of Toxocara canis. Kiuchi F, et al. **Chem Pharm Bull (Tokyo)** 1997 Apr;45(4):685–96

[The technology for manufacturing antiparasitic preparations. 7. Preparation G–1460 and its use for the treatment of monieziasis and intestinal nematodiases] Petrov IuF, et al. **Med Parazitol (Mosk)** 1996 Oct–Dec;(4):40–2 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Structure of the ascarosides from Ascaris suum. Bartley JP, et al. **J Nat Prod** 1996 Oct;59(10):921–6

METABOLISM

Fenbendazole–related drug residues in milk from treated dairy cows. Kappel LC, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):416–22

Major involvement of rabbit liver cytochrome P4501A in thiabendazole 5–hydroxylation. Rey–Grobellet X, et al. **Xenobiotica** 1996 Jul;26(7):765–78

PHARMACOKINETICS

Residue study of mebendazole and its metabolites hydroxy–mebendazole and amino–mebendazole in eel (Anguilla anguilla) after bath treatment. Iosifidou EG, et al. **Drug Metab Dispos** 1997 Mar;25(3):317–20

Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Baraka OZ, et al. **Eur J Clin Pharmacol** 1996;50(5):407–10

The kinetic disposition of pyrantel citrate and pamoate and their efficacy against pyrantel–resistant Oesophagostomum dentatum in pigs. Bjørn H, et al. **Int J Parasitol** 1996 Dec; 26(12):1375–80

Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications. Benchaoui HA, et al. **J Pharm Pharmacol** 1996 Jul; 48(7):753–9

Effects of diet and species on the pharmacokinetics of fenbendazole in cattle. Knox MR, et al. **Vet Res Commun** 1997 Jan;21(1):37–43

PHARMACOLOGY

The utility of strains of morphological group II Bacillus. Singer S. **Adv Appl Microbiol** 1996;42:219–61 (65 ref.)

Studies on the effect of fenbendazole and mebendazole on some enzymes of swine kidney worm Stephanurus dentatus. Singh K, et al. **Appl Parasitol** 1996 Sep;37(3):217–23

Bioreactor cultivation of the nematode Caenorhabditis elegans: large scale production of biologically active drug receptors for pharmaceutical research. Gbewonyo K, et al. **Biotechnol Genet Eng Rev** 1997;14:37–49 (35 ref.)

Regulation of cholinomimetic action of pyrantel pamoate by calcium channels in Setaria cervi. Ganguly B, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):245–8

Evaluation of immune dependence of anthelmintic treatment of Heligmosomoides polygyrus in CBA/Ca mice. Fallon PG, et al. **Int J Parasitol** 1996 May;26(5):557–60

The efficacy of ivermectin against laboratory strains of Heligmosomoides polygyrus (Nematoda). Njoroge JM, et al. **Int J Parasitol** 1997 Apr;27(4):439–42

In vitro characterization of anthelmintic susceptibility of field isolates of the pig nodular worm Oesophagostomum spp., susceptible or resistant to various anthelmintics. Várady M, et al. **Int J Parasitol** 1996 Jul;26(7):733–40

In vivo effect of a natural Aedes aegypti defensin on Brugia pahangi development. Albuquerque CM, et al. **Med Vet Entomol** 1996 Oct;10(4):397–9

Characterization of an acetylcholine receptor gene of Haemonchus contortus in relation to levamisole resistance. Hoekstra R, et al. **Mol Biochem Parasitol** 1997 Feb; 84(2):179–87

Reserpine–induced sulphomucin production by goblet cells in the jejunum of rats and its significance in the establishment of intestinal helminths. Ishikawa N, et al. **Parasite Immunol** 1995 Nov;17(11):581–6

Effect of haloallylamines on polyamine oxidase activity and spermine levels in Ascaris suum. Müller S, et al. **Parasitol Res** 1996;82(6):571–3

Electrophysiology of Ascaris muscle and anti–nematodal drug action. Martin RJ, et al. **Parasitology** 1996;113 Suppl:S137–56 (76 ref.)

How long before resistance makes it impossible to control some field strains of Haemonchus contortus in South Africa with any of the modern anthelmintics? van Wyk JA, et al. **Vet Parasitol** 1997 Jun;70(1–3):111–22

Nematode control practices and anthelmintic resistance on British sheep farms. Coles GC. **Vet Rec** 1997 Jul 26; 141(4):91–3

Evaluation of the effect of the fenbendazole sustained–release intraruminal device on the immunity of calves to lungworm. Jacobs DE, et al. **Vet Rec** 1996 Jul 20; 139(3):60–3

[An analysis of the results of histological and histochemical research on the integumental tissues and the digestive system of nematodes of the suborder Strongylata after the use of anthelmintics] Bogoiavlenskiĭ IuK. **Med Parazitol (Mosk)** 1996 Oct–Dec;(4):54–8 (17 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Intraductal administration of albendazole for biliary ascariasis. van den Bogaerde JB, et al. **Am J Gastroenterol** 1997 Sep;92(9):1531–3

Failure of mebendazole in treatment of human hookworm infections in the southern region of Mali. De Clercq D, et al. **Am J Trop Med Hyg** 1997 Jul;57(1):25–30

Efficacy of doramectin for treatment of experimentally induced infection with gastrointestinal nematodes in calves. Couvillion CE, et al. **Am J Vet Res** 1997 Mar;58(3):282–5

Efficacy of fenbendazole for treatment of giardiasis in calves. O'Handley RM, et al. **Am J Vet Res** 1997 Apr;58(4):384–8

Nematocidal efficacy of eprinomectin, delivered topically, in naturally infected cattle. Yazwinski TA, et al. **Am J Vet Res** 1997 Jun;58(6):612–4

Naphthalophos combinations with benzimidazoles or levamisole as effective anthelmintics for sheep. Cooper NA, et al. **Aust Vet J** 1996 Sep;74(3):221–4

The role of mebendazole in the surgical treatment of central nervous system hydatid disease. Erdinçler P, et al. **Br J Neurosurg** 1997 Apr;11(2):116–20

Impact of annual dosing with ivermectin on progression of onchocercal visual field loss. Cousens SN, et al. **Bull World Health Organ** 1997;75(3):229–36

Required duration of combined annual ivermectin treatment and vector control in the Onchocerciasis Control Programme in west Africa. Plaisier AP, et al. **Bull World Health Organ** 1997;75(3):237–45

Routine use of mebendazole in pregnancy. de Silva NR, et al. **Ceylon Med J** 1996 Sep;41(3):99–101

Treatment of onchocerciasis. Van Laethem Y, et al. **Drugs** 1996 Dec;52(6):861–9 (51 ref.)

Effect of ivermectin on the migration of Baylisascaris transfuga larvae into the brain of mice. Papini R, et al. **Folia Parasitol (Praha)** 1996;43(2):157–8

Physiology, pharmacology and parasitology. Hennessy DR. **Int J Parasitol** 1997 Feb;27(2):145–52

An in vivo dose–response study of fenbendazole against Oesophagostomum dentatum and Oesophagostomum quadrispinulatum in pigs. Praslička J, et al. **Int J Parasitol** 1997 Apr;27(4):403–9

Systemic strongyloidiasis complicating HIV: a promising response to ivermectin. Heath T, et al. **Int J STD AIDS** 1996 Jul;7(4):294–6

Treatment of Oslerus osleri infestation in a dog: case report and literature review. Levitan DM, et al. **J Am Anim Hosp Assoc** 1996 Sep–Oct;32(5):435–8 (24 ref.)

Genetic control of acquired resistance to Heligmosomoides

polygyrus: overcoming genetically determined weak responder status by strategic immunization with ivermectin-abbreviated infections. Wahid FN, et al. **J Helminthol** 1996 Jun;70(2):159–68

From the Food and Drug Administration. Nightingale SL. **JAMA** 1997 Mar 5;277(9):703

Efficacy and safety of mebendazole in children with worm infestation. Rafi S, et al. **JPMA J Pak Med Assoc** 1997 May;47(5):140–1

Effects of the synergistic action of febantel and pyrantel on the nematode Heterakis spumosa: a light and transmission electron microscopy study. Mehlhorn H, et al. **Parasitol Res** 1997;83(5):419–34

Alternative treatment protocols in giardiasis: a pilot study. Bulut BU, et al. **Scand J Infect Dis** 1996;28(5):493–5

A randomized comparative study of albendazole and thiabendazole in chronic strongyloidiasis. Pitisuttithum P, et al. **Southeast Asian J Trop Med Public Health** 1995 Dec; 26(4):735–8

Ivermectin-based control of onchocerciasis in northern Cameroon: individual factors influencing participation in community treatment. Gardon J, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):218–22

Parasite-specific serum IgG following successful treatment of endemic strongyloidiasis using ivermectin. Lindo JF, et al. **Trans R Soc Trop Med Hyg** 1996 Nov–Dec; 90(6):702–3

Effect of mass treatments with ivermectin, with only partial compliance, on prevalence and intensity of O. volvulus infection in adults and in untreated 4 and 5 year-old children in Burundi. Newell ED. **Trop Med Int Health** 1997 Sep;2(9):912–6

Clinical and parasitological responses after up to 6.5 years of ivermectin treatment for onchocerciasis. Whitworth JA, et al. **Trop Med Int Health** 1996 Dec;1(6):786–93

Benzimidazole resistance in cyathostomes in horses in the Ukraine. Borgsteede FH, et al. **Vet Parasitol** 1997 Jan; 68(1–2):113–7

Identification and characterization of a pyrantel pamoate resistant cyathostome population. Chapman MR, et al. **Vet Parasitol** 1996 Nov 15;66(3–4):205–12

The presence of an early L4 population in relation to the acquired resistance of calves naturally infected with Ostertagia ostertagi. Claerebout E, et al. **Vet Parasitol** 1997 Mar;68(4):337–46

Comparison between fenbendazole and moxidectin applied in a dose and move system for the control of Dictyocaulus viviparus infections in calves. Eysker M, et al. **Vet Parasitol** 1996 Sep 2;64(3):187–96

Effects of three nematode anthelmintic treatment regimes on flock performance of sheep and goats under extensive management in semi-arid Kenya. Gatongi PM, et al. **Vet Parasitol** 1997 Mar;68(4):323–36

Prophylaxis of bovine trichostrongylidosis and dictyocaulosis in the alpine region: comparison of an early and late administration of the oxfendazole pulse release bolus to first year grazing calves. Hertzberg H, et al. **Vet Parasitol** 1996 Nov 15;66(3–4):181–92

Comparison of the persistent activity of ivermectin, abamectin, doramectin and moxidectin in cattle in Zambia. Meeus PF, et al. **Vet Parasitol** 1997 Jul 1;70(4):219–24

Gastrointestinal nematode infections of first-season grazing calves in Belgium: general patterns and the effect of chemoprophylaxis. Shaw DJ, et al. **Vet Parasitol** 1997 Apr; 69(1–2):103–16

Immunisation of sheep by drug-abbreviated infections of Ostertagia circumcincta and Trichostrongylus colubriformis against field challenge of gastro-intestinal nematodes. Stankiewicz M, et al. **Vet Parasitol** 1996 Dec 2;67(1–2):121–32

Production responses following strategic parasite control in a beef cow/calf herd. Stromberg BE, et al. **Vet Parasitol** 1997 Mar;68(4):315–22

Endectocidal efficacies of doramectin in naturally parasitized pigs. Yazwinski TA, et al. **Vet Parasitol** 1997 Jun; 70(1–3):123–8

Comparison of the reappearance of strongyle eggs on foals, yearlings and adult horses after treatment with ivermectin or pyrantel. Boersema JH, et al. **Vet Q** 1996 Mar;18(1):7–9

An attempt to control lungworm disease and parasitic gastroenteritis on commercial dairy farms by the use of an adaptation of Michel's dose-and-move system. Eysker M, et al. **Vet Q** 1997 Jun;19(2):61–4

Evaluation of the persistence of the effect of ivermectin and abamectin against gastrointestinal and pulmonary nematodes in cattle. Barth D, et al. **Vet Rec** 1997 Mar 15; 140(11):278–9

Field evaluation of a fenbendazole slow release bolus in the control of nematode infections in first-season cattle. Bauer C, et al. **Vet Rec** 1997 Apr 12;140(15):395–9

Triple resistant Ostertagia from angora goats [letter] Coles GC, et al. **Vet Rec** 1996 Sep 21;139(12):299–300

Resistance to levamisole [letter] Coles GC, et al. **Vet Rec** 1996 Aug 3;139(5):124

Hypobiosis in the ostertagids of red deer and the efficacy of ivermectin and fenbendazole against them. Connan RM. **Vet Rec** 1997 Feb 22;140(8):203–5

Transmission electron microscope studies on the oncospheral envelopes of Taenia saginata after niclosamide treatment. Chomicz L, et al. **Wiad Parazytol** 1995;41(4):391–4

Ivermectin-based onchocerciasis control in Cameroon. Ngoumou P, et al. **World Health Forum** 1996;17(1):25–8

[Effect of flubendazole on Muellerius capillaris in mouflon] Lamka J, et al. **Vet Med (Praha)** 1996 Nov;41(11):347–50 (Eng. Abstr.) **(Cze)**

[Ivermectin and tropical dermatoses] Caumes E. **Bull Soc Pathol Exot** 1997;90(1):37–8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Efficacy of pyrantel pamoate in ascaridiasis in Vietnamese children (letter)] Bui XV, et al. **Med Trop (Mars)** 1997; 57(1):99–100 **(Fre)**

TOXICITY

Subchronic toxicity of thiabendazole (TBZ) in ICR mice. Tada Y, et al. **Food Chem Toxicol** 1996 Aug;34(8):709–16

Use of free living stages to study the effects of thiabendazole, levamisole, pyrantel and ivermectin on the fine structure of Haemonchus contortus and Heligmosomoides polygyrus. Beugnet F, et al. **Vet Parasitol** 1996 May;63(1–2):83–94

ANTINEOPLASTIC AGENTS

see related
ANTICARCINOGENIC AGENTS
CHEMOEMBOLIZATION, THERAPEUTIC
INFUSIONS, INTRA-ARTERIAL
PERFUSION, REGIONAL
TUMOR LYSIS SYNDROME

A report of infusional 5-fluorouracil and subcutaneous alpha-2A-interferon in the treatment of advanced colorectal carcinoma. Koo WH, et al. **Ann Acad Med Singapore** 1996 Mar;25(2):210–4

Interleukin-12: murine models of a potent antitumor agent. Brunda MJ, et al. **Ann N Y Acad Sci** 1996 Oct 31; 795:266–74

European drug agency: not yet ready for oncology [news] **Ann Oncol** 1996 Jan;7(1):2–3

9th NCI-EORTC Symposium on new drugs in cancer therapy. Amsterdam, the Netherlands, March 12–15, 1996. Abstracts. **Ann Oncol** 1996;7 Suppl 1:1–141

The nuclear matrix as a target for cancer therapy. Catapano CV, et al. **Ann Oncol** 1996 Sep;7(7):659–66 (90 ref.)

A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). Pavlidis N, et al. **Ann Oncol** 1996 Jul;7(5):529–31

Antiproliferative effects of an organic extract from the marine diatom Skeletonema costatum (Grev.) Cleve. Against a non-small-cell bronchopulmonary carcinoma line (NSCLC-N6). Bergé JP, et al. **Anticancer Res** 1997 May–Jun;17(3C):2115–20

Antitumor mechanism of intradermal administration of lipopolysaccharide. Inagawa H, et al. **Anticancer Res** 1997 May–Jun;17(3C):1961–4

Binding of non-homologous series of anticancer drugs to cytosine. Cserháti T, et al. **Biochem Mol Biol Int** 1996 Oct; 40(2):395–401

British Association for Cancer Research 38th annual meeting. New Targets in Cancer Chemotherapy Southampton, United Kingdom, 1–4 April 1997. Abstracts. **Br J Cancer** 1997;75 Suppl 1:1–53

From serendipity to design: the evolution of drug development in oncology. Markman M, et al. **Cleve Clin J Med** 1997 Mar;64(3):155–63

Promising new agents in oncologic treatment. Mani S, et al. **Curr Opin Oncol** 1996 Nov;8(6):525–34 (97 ref.)

A protein expression database for the molecular pharmacology of cancer. Myers TG, et al. **Electrophoresis** 1997 Mar–Apr;18(3–4):647–53

A monoclonal antibody against rat calcitonin inhibits the growth of a rat medullary thyroid carcinoma cell line in vitro. Zhang R, et al. **Endocrinology** 1997 Apr; 138(4):1697–703

The actions of ondansetron and dexamethasone to antagonise cisplatin-induced emesis in the ferret. Rudd JA, et al. **Eur J Pharmacol** 1997 Mar 12;322(1):79–82

New anticancer drugs in Europe. Armand JP. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:70–93 (120 ref.)

Pharmacology of purine nucleoside analogues. Plunkett W, et al. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S67–74 (77 ref.)

Droloxifene. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:241–51 (33 ref.)

Heat-shock protein expression in cisplatin-sensitive and -resistant human tumor cells. Hettinga JV, et al. **Int J Cancer** 1996 Sep 17;67(6):800–7

Gas chromatographic-mass spectrometric assay for N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in rat plasma. Lu H, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):219–25

Detection of N7-(2-hydroxyethyl)guanine adducts in DNA and 9L cells treated with 1-(2-chloroethyl)-1-nitrosourea. Ye Q, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20; 694(1):65–70

Pharmacologic bone marrow purging: is there any place for etoposide? In vitro comparison with mafosfamide. Olivieri A, et al. **J Hematother** 1997 Apr;6(2):137–44

Synthesis, structure, and antiproliferative activity of selenophenfurin, an inosine 5'-monophosphate dehydrogenase inhibitor analogue of selenazofurin. Franchetti P, et al. **J Med Chem** 1997 May 23;40(11):1731–7

Progress in the discovery of biosynthetic anticancer drugs. Pettit GR. **J Nat Prod** 1996 Aug;59(8):812–21 (127 ref.)

Green tea, mistletoe, and more: Canadians test alternative cancer therapies [news] Holzman D. **J Natl Cancer Inst** 1997 May 21;89(10):683–4

Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. Shichinohe T, et al. **J Surg Res** 1996 Dec;66(2):125–30

In vivo antitumor effect of cationic liposomes containing diphtheria toxin A-chain gene on cells infected with bovine leukemia virus. Tana, et al. **J Vet Med Sci** 1997 Jul; 59(7):617–9

Neuropharmacological mechanisms of emesis. II. Effects of antiemetic drugs on cisplatin-induced pica in rats. Takeda N, et al. **Methods Find Exp Clin Pharmacol** 1995 Dec; 17(10):647–52

Tailor-made chemotherapy for cancer patients. van Warmerdam LJ. **Neth J Med** 1997 Jul;51(1):30–5 (25 ref.)

Dietary retinoic acid inhibits mouse skin carcinogenesis irrespective of age at initiation. De Luca LM, et al. **Nutr Cancer** 1996;25(3):249–57

Garlic: its anticarcinogenic and antitumorigenic properties. Milner JA. **Nutr Rev** 1996 Nov;54(11 Pt 2):S82–6 (36 ref.)

NCI's anticancer drug screening program may not be selecting for clinically active compounds. Brown JM. **Oncol Res** 1997;9(5):213–5 (26 ref.)

New antifolates in clinical development. Takimoto CH, et al. **Oncology (Huntingt)** 1995 Jul;9(7):649–56, 659 DISC 660, 662, 665 (87 ref.)

Characterization of the plant homologue of prohibitin, a gene associated with antiproliferative activity in mammalian cells. Snedden WA, et al. **Plant Mol Biol** 1997 Mar; 33(4):753–6

Obstacles at the FDA? [letter; comment] Delap RJ. **Sci Am** 1997 Jan;276(1):8. Comment on: Sci Am 1996 Sep;275(3):166.

Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Christian MC, et al. **Semin Oncol** 1997 Apr;24(2):219–40 (152 ref.)

Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Cragg GM, et al. **Semin Oncol** 1997 Apr;24(2):156–63 (22 ref.)

Etoposide phosphate: what, why, where, and how? Schacter L. **Semin Oncol** 1996 Dec;23(6 Suppl 13):1–7 (27 ref.)

Antigen-specific agents in development. Sznol M, et al. **Semin Oncol** 1997 Apr;24(2):173–86 (120 ref.)

Intravesical chemotherapy for superficial bladder tumors category Ta/T1: who should be treated and how? Kurth KH. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):30–5 (7 ref.)

Advances in Cancer Treatment: The Chabner Symposium. Tribute to Dr. Bruce A. Chabner. April 7, 1995. **Stem Cells** 1996 Jan;14(1):i, 1–150

[Studies of chemopreventive agents against neoplasma: synthesis of 3-acetyl coumarin derivatives and relationship between antimutagenic activity and structure] Huang XL, et al. **Yao Hsueh Hsueh Pao** 1996;31(6):431–6 (Eng. Abstr.) **(Chi)**

[Dose expression of antineoplastic drugs] Favre R, et al. **Rev Med Interne** 1996;17(7):586–96 (Eng. Abstr.) **(Fre)**

[Topoisomerase I inhibitor with potential radiosensitizing effect] Sauer R, et al. **Strahlenther Onkol** 1997 Mar; 173(3):125–30 (39 ref.) (Eng. Abstr.) **(Ger)**

[Our policy and future tasks related to ICH in anti-cancer drug development—a discussion from the viewpoint of an enterprise] Ekimoto H. **Gan To Kagaku Ryoho** 1997 Jan; 24(2):229–37 (Eng. Abstr.) **(Jpn)**

[What has been done for international harmonization and what remains to be solved?] Mitsuhashi H. **Gan To Kagaku Ryoho** 1997 Jan;24(2):238–45 (Eng. Abstr.) **(Jpn)**

[Development of anti tumor agents targeting angiogenesis] Ono M, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):178–86 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Introduction of anticancer agents to phase I clinical trials] Shimoyama M. **Gan To Kagaku Ryoho** 1997 Jan; 24(2):246–55 (Eng. Abstr.) **(Jpn)**

[Recent advances in development of antitumor tyrosine kinase inhibitors] Uehara Y. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1536–40 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Evaluation of the stability of lipiodol-CDDP: suspension (LCS) by the pumping method] Yamamoto K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Aug; 56(9):674–5 (Eng. Abstr.) **(Jpn)**

[Antineoplastic drug development: some results and perspectives] Filov VA. **Vopr Onkol** 1997;43(1):120–3 (15 ref.) **(Rus)**

[alpha-Lipoic acid—a natural disulfide cofactor and antioxidant with anticarcinogenic effects] Dovinová I. **Ceska Slov Farm** 1996 Sep;45(5):237–41 (49 ref.) (Eng. Abstr.) **(Slo)**

ADMINISTRATION & DOSAGE

Regional chemotherapy with blood filtration for non resectable liver metastases. Taton G. **Acta Chir Belg** 1997 Apr;97(2):60–4 (26 ref.)

Polymeric controlled-release amsacrine chemotherapy in an experimental glioma model. Wahlberg LU, et al. **Acta Neurochir (Wien)** 1996;138(11):1323–9; discussion 1329–30

F wave studies after intrathecal methotrexate administration. Grzelec H, et al. **Acta Neurol Scand** 1996 Oct;94(4):276–8

On the importance of sensitivity to the dose-effect relationship in chemotherapy. Jakobsen A, et al.

Acta Oncol 1997;36(4):375–81

Hepatic arteriography in patients with hepatocellular carcinoma under balloon occlusion of a hepatic vein draining the tumor–bearing liver parenchyma: useful for arterial infusion treatment? [letter; comment] Murata S, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):1063–4. Comment on: **AJR** Am J Roentgenol 1995 Dec;165(6):1415–9.

Phase II trial with BCNU plus alpha–interferon in patients with recurrent high–grade gliomas. Brandes AA, et al. **Am J Clin Oncol** 1997 Aug;20(4):364–7

Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III–B non–small–cell lung cancer patients. Felip E, et al. **Am J Clin Oncol** 1997 Aug; 20(4):404–6

Phase II study of cisplatin, 5–fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain. Feliu J, et al. **Am J Clin Oncol** 1996 Dec;19(6):577–80

Phase I–II study of combined 5–fluorouracil and cisplatin chemotherapy and altered fractionation radiotherapy for advanced squamous cell carcinoma of the cervix. Fishman A, et al. **Am J Clin Oncol** 1997 Aug;20(4):342–7

Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP–16 with G–CSF support in extensive small cell lung cancer. Gridelli C, et al. **Am J Clin Oncol** 1996 Dec;19(6):589–91

Successful treatment with ranimustine and carboplatin for recurrent intraocular retinoblastoma with vitreous seeding. Ishii E, et al. **Am J Clin Oncol** 1996 Dec;19(6):562–5

Continuous–infusion 5–fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial. Kish JA, et al. **Am J Clin Oncol** 1997 Aug;20(4):327–30

Gonadal function following ABVD therapy for Hodgkin's disease. Kulkarni SS, et al. **Am J Clin Oncol** 1997 Aug; 20(4):354–7

Retrospective comparative analysis of 5FU + low–dose folinic acid vs. 5FU + high–dose folinic acid in the treatment of metastatic colorectal cancer. The Ottawa experience. Maroun JA, et al. **Am J Clin Oncol** 1997 Aug; 20(4):387–92

Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non–small cell lung cancer. Nakanishi Y, et al. **Am J Clin Oncol** 1997 Aug;20(4):393–7

Dose reduction of chemotherapeutic agents after weight loss. O'Marcaigh AS, et al. **Am J Clin Oncol** 1997 Apr; 20(2):193–5

Intravenous carboplatin for recurrent gliomas. A dose–escalating phase II trial. Prados MD, et al. **Am J Clin Oncol** 1996 Dec;19(6):609–12

Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Ramnath N, et al. **Am J Clin Oncol** 1997 Aug;20(4):368–72

Phase II trial of prolonged continuous infusion of 5–fluorouracil and interferon–alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Sparano JA, et al. **Am J Clin Oncol** 1996 Dec;19(6):546–51

Anaesthesia for intra–peritoneal perfusion of hyperthermic chemotherapy. Haemodynamic changes, oxygen consumption and delivery. Kanakoudis F, et al. **Anaesthesia** 1996 Nov;51(11):1033–6

High–dose chemotherapy for breast cancer [letter; comment] de Vries EG, et al. **Ann Intern Med** 1997 Jun 1; 126(11):917–8. Comment on: Ann Intern Med 1996 Oct 1;125(7):599–604.

High–dose chemotherapy for breast cancer [letter; comment] Rushing DA. **Ann Intern Med** 1997 Jun 1;126(11):917; discussion 918. Comment on: Ann Intern Med 1996 Oct 1;125(7):599–604.

Murine models of cancer cytokine gene therapy using interleukin–12. Tahara H, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:275–83

Dose intensification and breast cancer: current results and future perspectives. Antoine EC, et al. **Ann Oncol** 1996;7 Suppl 2:31–40 (52 ref.)

Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Chollet P, et al. **Ann Oncol** 1996 Dec;7(10):1065–70

Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti–neoplastic agents. Lokich J, et al. **Ann Oncol** 1997 Jan;8(1):15–25 (65 ref.)

A comparison of locoregional depot and systemic preparations of 9–aminocamptothecin for treatment of liver metastases in a rat tumor model: superior antitumor activity of sustained–release preparation. Dookeran KA, et al. **Ann Surg Oncol** 1997 Jun;4(4):355–60

Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: a study of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg. Wils JA, et al. **Anticancer Drugs** 1997 Jun;8(5):432–5

Antitumor mechanism of intradermal administration of lipopolysaccharide. Inagawa H, et al. **Anticancer Res** 1997 May–Jun;17(3C):1961–4

Effects of thermochemotherapy [1–hexylcarbamoyl–5–fluorouracil (HCFU) combined with hyperthermia]: a basic study on the most effective timing and sequence in vivo. Sakurai K, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2729–33

Frequency and duration of remission after isolated limb perfusion for melanoma. Thompson JF, et al. **Arch Surg** 1997 Aug;132(8):903–7 (23 ref.)

Carboplatin dosing based on measurement of renal function—experience at the Peter MacCallum Cancer Institute. Millward MJ, et al. **Aust N Z J Med** 1996 Jun; 26(3):372–9

Cell–specific, multidrug delivery system using streptavidin–protein A fusion protein. Ohno K, et al. **Biochem Mol Med** 1996 Aug;58(2):227–33

Antitumor effects of human recombinant interleukin–1 alpha and etoposide against human tumor cells: mechanism for synergism in vitro and activity in vivo. Usui N, et al. **Biotherapy** 1996;9(4):199–208

Weekly administration of 2–chlorodeoxyadenosine in patients with hairy–cell leukemia: a new treatment schedule effective and safer in preventing infectious complications [letter] Lauria F, et al. **Blood** 1997 Mar 1;89(5):1838–9

Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? [editorial] Rowe JM, et al. **Blood** 1997 Sep 15;90(6):2121–6 (76 ref.)

Low–dose interferon–alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia. The Benelux CML Study Group. **Bone Marrow Transplant** 1996 May;17 Suppl 3:S19–20

A phase I trial of recombinant human interleukin–1 beta (OCT–43) following high–dose chemotherapy and autologous bone marrow transplantation. Elkordy M, et al. **Bone Marrow Transplant** 1997 Feb;19(4):315–22

Phase I study of high–dose etoposide phosphate in man. Fields SZ, et al. **Bone Marrow Transplant** 1996 Nov; 18(5):851–6

The treatment of chronic myelogenous leukemia by interferon and cytosine–arabinoside: rational and design of the French trials. French CML Study Group. Guilhot F, et al. **Bone Marrow Transplant** 1996 May;17 Suppl 3:S29–31

Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. Hehlmann R, et al. **Bone Marrow Transplant** 1996 May;17 Suppl 3:S21–4

Results with high–dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Khouri IF, et al. **Bone Marrow Transplant** 1996 May;17(5):775–9

Cyclosporin A/alpha interferon–induced autologous graft–versus–host disease following peripheral blood stem cell transplant for chronic myeloid leukaemia: a clinico–pathological study. Lim SH, et al. **Bone Marrow Transplant** 1997 Jul;20(1):83–5

Comparative analysis of two consecutive phase II studies with IFN–alpha and IFN–alpha + ara–C in untreated chronic–phase CML patients. Austrian CML Study Group. Thaler J, et al. **Bone Marrow Transplant** 1996 May;17 Suppl 3:S25–8

High–dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule. Ballestrero A, et al. **Br J Cancer** 1997; 76(6):797–804

Hepatic arterial cannulation for regional chemotherapy is safe in patients with a liver metastasis volume of less than 1 litre. Burke D, et al. **Br J Cancer** 1997;75(8):1213–6

5–Hydroxyindoleacetic acid (5–HIAA) and cortisol excretion as predictors of chemotherapy–induced emesis. du Bois A, et al. **Br J Cancer** 1996 Oct;74(7):1137–40

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Gerrits CJ, et al. **Br J Cancer** 1997;76(7):952–62 (135 ref.)

A polymer–based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice. Jackson JK, et al. **Br J Cancer** 1997;75(7):1014–20

Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder. Moltó L, et al. **Br J Cancer** 1997;75(12):1849–53

Plateau–phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours. Phillips RM, et al. **Br J Cancer** 1997; 75(2):196–201

Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Rentsch KM, et al. **Br J Cancer** 1997;75(7):986–92

Combined effect of clinically relevant doses of emitefur, a new 5–fluorouracil derivative, and radiation in murine tumours. Shibamoto Y, et al. **Br J Cancer** 1996 Dec; 74(11):1709–13

Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Ahlke E, et al. **Br J Haematol** 1997 Mar;96(4):675–81

High response rates with short infusional 2–chlorodeoxyadenosine in de novo and relapsed low–grade lymphoma. Australian and New Zealand Lymphoma Study Group. Morton J, et al. **Br J Haematol** 1996 Oct;95(1):110–5

Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Judge IS, et al. **Br J Urol** 1997 Jan;79(1):40–2

Drug delivery to brain tumors. Walker WL, et al. **Bull Math Biol** 1996 Nov;58(6):1047–74

Controversy over high–dose chemotherapy [letter] Glück S. **Can Fam Physician** 1996 Jan;42:28, 30

Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo–leucovorin in untreated patients with advanced colorectal carcinoma. Bajetta E, et al. **Cancer** 1996 Nov 15;78(10):2087–93

Mode of chemotherapy does not affect complications with an implantable venous access device. Brown DF, et al. **Cancer** 1997 Sep 1;80(5):966–72

A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Dunphy FR, et al. **Cancer** 1997 May 15; 79(10):2016–23

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5–fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Gebbia V, et al. **Cancer** 1996 Sep 15;78(6):1300–7

Methotrexate bound to carbon particles used for treating cancers with lymph node metastases in animal experiments and a clinical pilot study. Hagiwara A, et al. **Cancer** 1996 Nov 15;78(10):2199–209

A phase I/II study of continuous infusion suramin in patients with hormone–refractory prostate cancer: toxicity and response. Bowden CJ, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):1–8

Phase I clinical trial of all–trans–retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Conley BA, et al. **Cancer Chemother Pharmacol** 1997; 39(4):291–9

A sequential Bayesian algorithm for dose individualisation of carboplatin. Duffull SB, et al. **Cancer Chemother Pharmacol** 1997;39(4):317–26

A Bayesian dosing method for carboplatin given by continuous infusion for 120 h. Guillet P, et al. **Cancer Chemother Pharmacol** 1997;40(2):143–9

Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Olivi A, et al. **Cancer Chemother Pharmacol** 1996; 39(1–2):90–6

A phase II study of weekly high–dose cisplatin combined with oral etoposide in advanced non–small–cell lung cancer. Planting A, et al. **Cancer Chemother Pharmacol** 1997;40(4):347–52

Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Loprinzi CL, et al. **Cancer Epidemiol Biomarkers Prev** 1996 May;5(5):371–4

Phase IB trial of picibanil (OK–432) as an immunomodulator in patients with resected high–risk melanoma. Kirkwood JM, et al. **Cancer Immunol Immunother** 1997 May; 44(3):137–49

Case study of quality assurance in the administration of chemotherapy. Tanghe A, et al. **Cancer Nurs** 1996 Dec; 19(6):447–54

Effect of attitudes and subjective norms on intention to provide oral care to patients receiving antineoplastic chemotherapy. Wallace KG, et al. **Cancer Nurs** 1997 Feb; 20(1):34–41

Enhanced therapeutic effects of liposome–associated 1–O–octadecyl–2–O–methyl–sn–glycero–3–phosphocholine. Ahmad I, et al. **Cancer Res** 1997 May 15; 57(10):1915–21

Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Ewend MG, et al. **Cancer Res** 1996 Nov 15;56(22):5217–23

Increased platinum–DNA damage tolerance is associated with cisplatin resistance and cross–resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Johnson SW, et al. **Cancer Res** 1997 Mar 1;57(5):850–6

Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin. Alexander HR, et al. **Cancer Treat Res** 1996;81:41–50 (34 ref.)

Peritoneal access devices for intraperitoneal chemotherapy. Ash SR. **Cancer Treat Res** 1996;82:387–413 (80 ref.)

Methodologic considerations in treatment using intraperitoneal chemotherapy. Averbach AM, et al. **Cancer Treat Res** 1996;82:289–309 (64 ref.)

High–dose chemotherapy in non–Hodgkin's lymphoma. Blay JY, et al. **Cancer Treat Res** 1996;85:87–103 (85 ref.)

Adjuvant hyperthermic intraperitoneal chemotherapy for adenocarcinoma of the pancreas. Ettinghausen SE, et al. **Cancer Treat Res** 1996;81:227–37 (69 ref.)

PCR monitoring of response in patients treated with high–dose chemotherapy for low–grade lymphoma. Gribben JG. **Cancer Treat Res** 1996;85:141–60 (58 ref.)

Effects of postoperative intraperitoneal chemotherapy on peritoneal wound healing and adhesion formation. Jacquet P, et al. **Cancer Treat Res** 1996;82:327–35 (39 ref.)

Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion. Kober F, et al. **Cancer Treat Res** 1996;82:211–9

Intraperitoneal regional chemotherapy with mitroxantrone. Link KH, et al. **Cancer Treat Res** 1996;81:31–40

Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis. Stephens AD, et al. **Cancer Treat Res** 1996;81:15–30 (35 ref.)

Peritoneal carcinomatosis: natural history and rational therapeutic interventions using intraperitoneal

chemotherapy. Sugarbaker PH. **Cancer Treat Res** 1996; 81:149–68 (42 ref.)

Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. Sugarbaker PH. **Cancer Treat Res** 1996; 82:317–25

A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor. Sugarbaker PH, et al. **Cancer Treat Res** 1996; 82:415–21

Liposomal drug delivery. Ranson M, et al. **Cancer Treat Rev** 1996 Sep;22(5):365–79 (137 ref.)

Characterization of biotinylated liposomes sensitive to temperature and pH: new tools for anti–cancer drug delivery. Ferraretto A, et al. **Chem Phys Lipids** 1996 Aug 19;82(2):133–9

Objective response to epirubicin and lonidamine. A case of advanced thymoma previously treated with the ADOC scheme and unresponsive to paclitaxel plus cyclophosphamide [letter] Berruti A, et al. **Chest** 1997 May; 111(5):1473–4

Recombinant interferon alpha–2b in the management of malignant pleural effusions. Wilkins HE 3rd, et al. **Chest** 1997 Jun;111(6):1597–9

Transient liver accumulation of Tc–99m phytate in hepatocellular carcinoma after percutaneous ethanol injection. Shiomi S, et al. **Clin Nucl Med** 1997 Aug; 22(8):550–2

Cardiac perforation associated with continuous infusional chemotherapy. Cooper RA, et al. **Clin Oncol (R Coll Radiol)** 1996;8(6):404–5

Pharmacokinetic rationale for chemotherapeutic drugs combined with intra–arterial degradable starch microspheres (Spherex). Johansson CJ. **Clin Pharmacokinet** 1996 Sep;31(3):231–40 (44 ref.)

Targeting of drugs to cell surface receptors. Říhová B. **Crit Rev Biotechnol** 1997;17(2):149–69 (147 ref.)

Chronotherapy for gastrointestinal cancers. Lévi F. **Curr Opin Oncol** 1996 Jul;8(4):334–41 (61 ref.)

Submucosal anal injection in the treatment of pelvic malignancies [letter] Shafik A. **Dis Colon Rectum** 1997 May; 40(5):629–30

Electroretinographic findings in subjects after administration of fenretinide. Krzeminski R, et al. **Doc Ophthalmol** 1995–96;91(4):299–309

A comparative study of undifferentiated nasopharyngeal carcinoma treated with radiotherapy or combined treatment with zorubicin–cisplatin and radiotherapy. Pendjer I, et al. **Eur Arch Otorhinolaryngol Suppl** 1997; 1:S127–9

The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Bajetta E, et al. **Eur J Cancer** 1997 Apr;33(4):587–91

Doxifluridine in colorectal cancer patients resistant to 5–fluorouracil (5–FU) containing regimens. Bajetta E, et al. **Eur J Cancer** 1997 Apr;33(4):687–90

Long–term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device [see comments] Biffi R, et al. **Eur J Cancer** 1997 Jul;33(8):1190–4. Comment in: Eur J Cancer 1997 Jul;33(8):1171–2.

Is intra–arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? Cohen AM, et al. **Eur J Cancer** 1996 Dec; 32A(13):2195–205 (74 ref.)

Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. Desoize B, et al. **Eur J Cancer** 1996 Sep;32A(10):1734–8

A prospective analysis of 949 long–term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. Nightingale CE, et al. **Eur J Cancer** 1997 Mar;33(3):398–403

Phase II study of weekly high–dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck. Planting AS, et al. **Eur J Cancer** 1997 Jan;33(1):61–5

Complications of an implantable venous access device (Port–a–Cath) during intermittent continuous infusion of chemotherapy. Poorter RL, et al. **Eur J Cancer** 1996 Dec; 32A(13):2262–6

Transaxillary access to perform hepatic artery infusion (HAI) for secondary or primitive hepatic tumours [letter] Zanon C, et al. **Eur J Cancer** 1996 Sep;32A(10):1824–5

Weekly cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer: a well–tolerated alternative. Giardina G, et al. **Eur J Gynaecol Oncol** 1997;18(3):173–6

Phase I and pharmacokinetic study of the P–glycoprotein modulator dexniguldipine–HCL. Nuessler V, et al. **Eur J Med Res** 1997 Feb 21;2(2):55–61

OK–432 therapy of lymphangiomas in children. Schmidt B, et al. **Eur J Pediatr** 1996 Aug;155(8):649–52

Superselective cisplatin (CDDP)–carboplatin (CBDCA) combined infusion for head and neck cancers. Imai S, et al. **Eur J Radiol** 1995 Dec 15;21(2):94–9

The case for high–dose adjuvant chemotherapy in breast cancer: (I) theoretical considerations. Cameron DA, et al. **Eur J Surg Oncol** 1996 Oct;22(5):540–2

Subcutaneous ports in the radiology suite: an effective and safe procedure for care in cancer patients. de Gregorio MA, et al. **Eur Radiol** 1996;6(5):748–52

Oral bropirimine immunotherapy of rodent prostate cancer. Sarosdy MF. **Eur Urol** 1997;31 Suppl 1:5–9

Ultrastructural study of the noninvolved urothelium of tumor–bearing patients after two years of intravesical interferon therapy. Stravoravdi P, et al. **Eur Urol** 1996; 29(4):477–82

Targeted delivery of diphtheria toxin via immunoliposomes: efficient antitumor activity in the presence of inactivating anti–diphtheria toxin antibodies. Vingerhoeds MH, et al. **FEBS Lett** 1996 Oct 21;395(2–3):245–50

Interventional radiology for hepatic arterial infusion chemotherapy. Arai Y. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1385–9 (8 ref.)

The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Connors TA. **Gene Ther** 1995 Dec; 2(10):702–9 (64 ref.)

Intraperitoneal carboplatin with or without interferon–alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. Bruzzone M, et al. **Gynecol Oncol** 1997 Jun;65(3):499–505

A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study. Reisinger SA, et al. **Gynecol Oncol** 1996 Dec;63(3):299–303

Re: Meta–analysis comparing cisplatin total dose intensity and survival: a critical reappraisal [letter; comment] Sauerbrei W, et al. **Gynecol Oncol** 1996 Sep;62(3):427–9. Comment on: Gynecol Oncol 1995 Oct;59(1):93–101.

Therapeutic value of neoadjuvant intra–arterial chemotherapy (cisplatin) and irradiation for locally advanced uterine cervical cancer. Toita T, et al. **Gynecol Oncol** 1997 Jun;65(3):421–4

Thyroid function is not affected by second exposure to erwinia asparaginase for childhood acute lymphoblastic leukemia [letter] Bossi G, et al. **Haematologica** 1997 Jul–Aug;82(4):507–8

Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma. Izumi R, et al. **Hepatogastroenterology** 1996 Nov–Dec;43(12):1415–20

Postoperative adjuvant arterial infusion chemotherapy for patients with hepatocellular carcinoma. Nakashima K, et al. **Hepatogastroenterology** 1996 Nov–Dec;43(12):1410–4

Chemoembolization and percutaneous ethanol injection for intrahepatic recurrence of hepatocellular carcinoma after hepatic resection. Sato M, et al. **Hepatogastroenterology** 1996 Nov–Dec;43(12):1421–6

Colloidal systems for tumor targeting. Storm G, et al. **Hybridoma** 1997 Feb;16(1):119–25 (58 ref.)

Targeting peptides for pleural cavity tumor radiotherapy: specificity and dosimetry of Re–188–RC–160. Zamora PO, et al. **Hybridoma** 1997 Feb;16(1):85–91

Adjuvant chemotherapy using cisplatin by subcutaneous administration. Dernell WS, et al. **In Vivo** 1997 Jul–Aug; 11(4):345–50

Circadian rhythm in toxic effects of cystemustine in mice: relevance for chronomodulated delivery. Martineau–Pivoteau N, et al. **Int J Cancer** 1996 Nov 27; 68(5):669–74

Dosage individualization of carboplatin and etoposide based on pharmacokinetic investigations. Jaehde U. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):76–8 (19 ref.)

Cancer therapy with liposomal formulations of anticancer drugs. Massing U. **Int J Clin Pharmacol Ther** 1997 Feb; 35(2):87–90 (19 ref.)

Conditions of drug delivery within solid tumors, and noninvasive methods for studies in humans. Port RE. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):78–9 (11 ref.)

Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony–stimulating factor. Okumura H, et al. **Int J Hematol** 1997 Apr;65(3):263–8

Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer. Graham MV, et al. **Int J Radiat Oncol Biol Phys** 1996 Dec 1;36(5):1215–20

A phase I pilot study of pelvic radiation and alpha–2A interferon in patients with locally advanced or recurrent rectal cancer. Perera F, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):297–303

Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Robbins KT, et al. **Int J Radiat Oncol Biol Phys** 1997 May 1;38(2):263–71

Tumor treatment by sustained intratumoral release of cisplatin: effects of drug alone and combined with radiation. Yapp DT, et al. **Int J Radiat Oncol Biol Phys** 1997 Sep 1;39(2):497–504

Phase II study of mitonafide in non–small cell lung cancer (NSCLC). Casado A, et al. **Invest New Drugs** 1996; 14(4):415–7

Early clinical investigation of sulofenur with a daily schedule in advanced solid tumours. Krarup–Hansen A, et al. **Invest New Drugs** 1997;15(2):147–51

Preclinical antitumor activity of CI–994. LoRusso PM, et al. **Invest New Drugs** 1996;14(4):349–56

Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days. Rassmann I, et al. **Invest New Drugs** 1996; 14(4):379–86

Active vs. passive resistance, dose–response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Stewart DJ, et al. **Invest New Drugs** 1996; 14(2):115–30 (94 ref.)

Comparison of chemotherapy safety procedures used in veterinary teaching hospitals and human oncology centers. Henry CJ, et al. **J Am Vet Med Assoc** 1996 Sep 1; 209(5):974–6

Soluble E–selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor–inhibiting anti–neovascularization agent, evaluated in phase I clinical trail. Wamil BD, et al. **J Cancer Res Clin Oncol** 1997; 123(3):173–9

Correction—malignant glioma [letter] Atiba JO, et al. **J Clin Oncol** 1997 Mar;15(3):1286–7

Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. Chambers SK, et al. **J Clin Oncol** 1997 May; 15(5):1945–52

Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. Coppin CM, et al. **J Clin Oncol** 1996 Nov; 14(11):2901–7

Phase II and pharmacologic study of topotecan administered as a 21–day continuous infusion to patients with colorectal cancer. Creemers GJ, et al. **J Clin Oncol** 1996 Sep; 14(9):2540–5

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. Creemers GJ, et al. **J Clin Oncol** 1997 Mar; 15(3):1087–93

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. Gurney H. **J Clin Oncol** 1996 Sep;14(9):2590–611 (186 ref.)

Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose [letter] Kobayashi K, et al. **J Clin Oncol** 1996 Sep; 14(9):2622–3

Data modifications to phase I study of suramin [letter] Kobayashi K, et al. **J Clin Oncol** 1996 Sep;14(9):2623–4

Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. Kohn EC, et al. **J Clin Oncol** 1997 May;15(5):1985–93

Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. Leyvraz S, et al. **J Clin Oncol** 1997 Jul;15(7):2589–95

Patient preferences for oral versus intravenous palliative chemotherapy. Liu G, et al. **J Clin Oncol** 1997 Jan; 15(1):110–5

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. McKeage MJ, et al. **J Clin Oncol** 1997 Jul;15(7):2691–700

Selecting patients with cisplatin–resistant germ cell tumors for high–dose chemotherapy [editorial; comment] Motzer RJ. **J Clin Oncol** 1996 Oct;14(10):2625–6. Comment on: J Clin Oncol 1996 Oct;14(10):2631–7. Comment on: J Clin Oncol 1996 Oct;14(10):2638–45.

Phase II trial of 9–aminocamptothecin administered as a 72–hour continuous infusion in metastatic colorectal carcinoma. Pazdur R, et al. **J Clin Oncol** 1997 Aug; 15(8):2905–9

Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors [see comments] Savarese DM, et al. **J Clin Oncol** 1997 Aug; 15(8):2981–95 (84 ref.). Comment in: J Clin Oncol 1997 Aug;15(8):2765–8.

Chemotherapy dose escalation: case unproven [editorial; comment] Siu LL, et al. **J Clin Oncol** 1997 Aug; 15(8):2765–8. Comment on: J Clin Oncol 1997 Aug;15(8):2981–95.

Successful treatment of molluscum contagiosum in the immunosuppressed adult with topical injection of streptococcal preparation OK–432. Inui S, et al. **J Dermatol** 1996 Sep;23(9):628–30 (19 ref.)

Evaluation of the efficiency of targeting of antitumor drugs: simulation analysis based on pharmacokinetic/pharmacodynamic considerations. Nakai D, et al. **J Drug Target** 1996;3(6):443–53

Endoscopic local injection of a new drug delivery formulation, anticancer drug bound to carbon particles, for digestive cancers: pilot study. Hagiwara A, et al. **J Gastroenterol** 1997 Apr;32(2):141–7

Infusional chemotherapy. Symposium proceedings. Paris, France, September 14–15, 1995. **J Infus Chemother** 1995 Fall;5(4):173–230

Infusional chemotherapy with new drugs: taxanes, vinorelbine and topoisomerase I inhibitors. Dieras V, et al. **J Infus Chemother** 1995 Fall;5(4):191–2 (15 ref.)

Options for venous access in ambulatory care: issues in selection and management. Herbst SL. **J Infus Chemother** 1996 Fall;6(4):186–94 (36 ref.)

Platinum dose–intensity. Los G. **J Infus Chemother** 1996 Spring;6(2):64–8 (47 ref.)

Application of ambulatory infusion devices in infusional cancer chemotherapy: a model for nursing management. Moore C, et al. **J Infus Chemother** 1996 Fall;6(4):181–5 (9 ref.)

Ambulatory infusional cancer chemotherapy: nursing role in patient management. The Cancer Center of Boston. Moore C, et al. **J Infus Chemother** 1996 Fall;6(4):164–70 (22 ref.)

Surveillance of the patient receiving infusional cancer chemotherapy: nursing role in recognition and management

of catheter-related complications. The Cancer Center of Boston. Moore C, et al. **J Infus Chemother** 1996 Fall; 6(4):171-80 (44 ref.)

Infusional cancer chemotherapy: the critical role for nurses [editorial] Moore C. **J Infus Chemother** 1996 Fall; 6(4):159-60

Administrative and technical support of ambulatory infusional cancer chemotherapy (ICC). Moore C, et al. **J Infus Chemother** 1996 Fall;6(4):161-3 (6 ref.)

Dose intensity: not the only path to clinical dose optimization [editorial] Muggia FM. **J Infus Chemother** 1996 Spring; 6(2):57-8

Biological perspectives on circadian cancer therapy. Wood PA, et al. **J Infus Chemother** 1995 Fall;5(4):182-90 (122 ref.)

Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group. **J Natl Cancer Inst** 1997 Apr 2; 89(7):497-505

Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. Dedrick RL, et al. **J Natl Cancer Inst** 1997 Apr 2;89(7):480-7 (61 ref.)

Modifying risks of secondary leukemias: is drug scheduling important? [editorial; comment] Karp JE, et al. **J Natl Cancer Inst** 1996 Dec 18;88(24):1787-9. Comment on: J Natl Cancer Inst 1996 Dec 18;88(24):1840-7.

Genetic therapy for breast cancer reaches the drawing board. McBride G. **J Natl Cancer Inst** 1996 Dec 4;88(23):1710

Accelerated titration designs for phase I clinical trials in oncology. Simon R, et al. **J Natl Cancer Inst** 1997 Aug 6;89(15):1138-47

Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis. Bongioanni MR, et al. **J Neurol Sci** 1996 Nov; 143(1-2):91-9

The effect of prolonged cycles of chemotherapy on quality of life in gynaecologic cancer patients. Carter JR, et al. **J Obstet Gynaecol Res** 1997 Apr;23(2):197-203

Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex-vivo model. Maignen F, et al. **J Ocul Pharmacol Ther** 1996 Fall;12(3):289-98

The difficulties and risks of surgical treatment of lymphangiomas in the cervicofacial region [letter; comment] Ng JW, et al. **J Pediatr Surg** 1996 Oct; 31(10):1463-4. Comment on: J Pediatr Surg 1995 Aug;30(8):1159-60.

Oral sustained-release cisplatin capsule. Houjou T, et al. **J Pharm Pharmacol** 1996 May;48(5):474-8

Antitumour activity of mitoxantrone-loaded chitosan microspheres against Ehrlich ascites carcinoma. Jameela SR, et al. **J Pharm Pharmacol** 1996 Jul;48(7):685-8

Oral sustained-release cisplatin preparation for rats and mice. Nakano K, et al. **J Pharm Pharmacol** 1997 May; 49(5):485-90

Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. Lim HJ, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):566-73

Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma. Didolkar MS, et al. **J Surg Oncol** 1996 Nov;63(3):148-58

Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors. Vrouenraets BC, et al. **J Surg Oncol** 1997 Jun;65(2):88-94

Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma: four-year follow-up. Ngan H, et al. **J Vasc Interv Radiol** 1996 May-Jun;7(3):419-25

Arterial infusion chemotherapy for uterine cervical carcinoma: embolization of the ovarian artery for improved drug distribution [letter] Tanaka N, et al. **J Vasc Interv Radiol** 1997 Sep-Oct;8(5):900

Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule. Ando Y, et al. **Jpn J Cancer Res** 1997 May;88(5):517-21

Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. Tobinai K, et al. **Jpn J Clin Oncol** 1997 Jun;27(3):146-53

Intrathecal chemotherapy and bone marrow [letter] Barişta I, et al. **Leukemia** 1997 Aug;11(8):1392-3

Intra-arterial chemotherapy with concomitant hemofiltration (chemofiltration) for treatment of loco-regional or pelvic metastases from malignant melanoma. Gutman M, et al. **Melanoma Res** 1996 Apr;6(2):167-71

Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Rensen PCN, et al. **Mol Pharmacol** 1997 Sep;52(3):445-55

Intrapleural administration of recombinant interleukin-2 in non-small cell lung cancer with neoplastic pleural effusion. Masotti A, et al. **Monaldi Arch Chest Dis** 1997 Jun; 52(3):225-8

Intrapericardial administration of cisplatin in treatment of metastatic pericardial involvement in adenocarcinoma of the lung. Tomkowski WZ, et al. **Monaldi Arch Chest Dis** 1997 Jun;52(3):221-4

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group [see comments] Guilhot F, et al. **N Engl J Med** 1997 Jul 24;337(4):223-9 . Comment in: N Engl J Med 1997 Jul 24;337(4):270-1.

Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report. Zhang W, et al. **Neurosurgery** 1996 Mar;38(3):587-90; discussion 590-1

Distribution of intraperitoneal chemotherapy into the pleural cavity. Vaccarello L, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):714-7 (14 ref.)

Triple check procedure prevents chemotherapy errors. Davis L, et al. **Oncol Nurs Forum** 1997 May;24(4):641-2

Order sheets help prevent chemotherapy administration errors. Olsen M. **Oncol Nurs Forum** 1997 Jun;24(5):802-3

Dacarbazine and interferon alpha for stage IV malignant melanoma. Tamm I, et al. **Oncology** 1997 Jul-Aug; 54(4):270-4

New approach allows high-dose chemotherapy to be given entirely on an outpatient basis [news] **Oncology (Huntingt)** 1996 Feb;10(2):221-2

DaunoXome data presented at international cancer meeting [news] **Oncology (Huntingt)** 1996 Jun;10(6):830

Update on hepatic intra-arterial chemotherapy. Venook AP. **Oncology (Huntingt)** 1997 Jul;11(7):947-57; discussion 961-2, 964, 970 (51 ref.)

Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits. Tilleul P, et al. **Ophthalmic Res** 1997;29(4):218-26

Profound hearing loss from intravertebral artery cisplatin. Wetmore SJ, et al. **Otolaryngol Head Neck Surg** 1997 Feb; 116(2):234-7

Marigenol-concentrates comprising Taxol and/or Taxan esters as active substances. Eugster C, et al. **Panminerva Med** 1996 Dec;38(4):234-42

Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur. Jonkman-de Vries JD, et al. **PDA J Pharm Sci Technol** 1997 Mar-Apr; 51(2):89-95

Reversible occlusion shunt for intraventricular chemotherapy in shunt-dependent brain tumor patients. Czech T, et al. **Pediatr Hematol Oncol** 1997 Jul-Aug;14(4):375-80

Clinical and hematological remission after a single dose of mitoxantrone in a child with Philadelphia chromosome-positive chronic myeloid leukemia. Oner AF, et al. **Pediatr Hematol Oncol** 1997 Sep-Oct;14(5):483-6

Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Merisko-Liversidge E, et al. **Pharm Res** 1996 Feb; 13(2):272-8

Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Molema G, et al. **Pharm Res** 1997 Jan;14(1):2-10 (68 ref.)

Liposome-mediated therapy of intracranial brain tumors in a rat model. Sharma US, et al. **Pharm Res** 1997 Aug; 14(8):992-8

Regional isolated perfusion of extremities for melanoma: a 20-year experience with drugs other than L-phenylalanine mustard. Ariyan S, et al. **Plast Reconstr Surg** 1997 Apr; 99(4):1023-9

Direct injection of anti-cancer drugs into endobronchial tumours for palliation of major airway obstruction. Celikoğlu SI, et al. **Postgrad Med J** 1997 Mar; 73(857):159-62

An information system to improve the safety and efficiency of chemotherapy ordering. Teich JM, et al. **Proc AMIA Annu Fall Symp** 1996;:498-502

Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine. Grégoire V, et al. **Radiat Res** 1996 Nov;146(5):548-53

Irradiation involving an implantable drug delivery system [letter] Beckham WA. **Radiother Oncol** 1997 Jan;42(1):92-3

Spherex (degradable starch microspheres) chemo-occlusion--enhancement of tumor drug concentration and therapeutic efficacy: an overview. Håkansson L, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6-100-S6-109 (64 ref.)

Total necrosis of hepatocellular carcinoma with a combination therapy of arterial infusion of chemotherapeutic lipiodol and transcatheter arterial embolization: report of 14 cases. Kenji J, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6-71-S6-80

Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Klaassen U, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):32-7

Conceptual basis for advances in the systemic drug therapy of breast cancer. Norton L. **Semin Oncol** 1997 Aug;24(4 Suppl 11):S11-2-S11-12 (50 ref.)

Paclitaxel and carboplatin for advanced breast cancer. Perez EA, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):41-5 (38 ref.)

The effect of YNK-01 (an oral prodrug of cytarabine) on hepatocellular carcinoma. Suto T, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6-122-S6-129

Does high-dose chemotherapy have a defined role in the treatment of solid tumors in 1997? Weaver CH, et al. **Semin Oncol** 1997 Aug;24(4):xxxi, xxxvii-xxxviii

Home infusion therapy. Gorski LA, et al. **Semin Oncol Nurs** 1996 Aug;12(3):193-201 (30 ref.)

Nursing implications in the management of superficial bladder cancer. Games J. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):36-40 (27 ref.)

High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow. Brockstein BE, et al. **Stem Cells** 1996 Jan;14(1):79-89 (71 ref.)

Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan. Hohenberger P, et al. **Strahlenther Onkol** 1996 Nov;172 Suppl 2:14-5

New approaches to the management and treatment of malignant pericardial effusion. Tomkowski W, et al. **Support Care Cancer** 1997 Jan;5(1):64-6

Haematoporphyrin derivative--photodynamic therapy of colorectal carcinoma, sensitized using verapamil and adriamycin. Purkiss SF, et al. **Surg Oncol** 1996 Aug; 5(4):169-75

Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma. Windsor AC, et al. **Surg Oncol** 1995;4(5):277-9

Hepatic arterial infusion (HAI) for unresectable liver metastases (ULM) from colorectal carcinoma. Nitti D, et al. **Tumori** 1997 Jan-Feb;83(1 Suppl):S61

Long-term infusion in cancer chemotherapy with the Groshong catheter via the inferior vena cava. Tavecchio L, et al. **Tumori** 1996 Jul-Aug;82(4):372-5

Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Portillo J, et al. **Urology** 1997 Feb;49(2):187-90

[Studies on preparation and characteristics of cisplatin chitosan microspheres] Wang YM, et al. **Yao Hsueh Hsueh Pao** 1996;31(4):300-5 (Eng. Abstr.) **(Chi)**

[Dose individualization for carboplatin in cancer chemotherapy] Oudard S, et al. **Bull Cancer** 1997 Jun; 84(6):675-7 (Eng. Abstr.) **(Fre)**

[Chronopharmacology and chronotherapy of cancers] Lévi F. **Pathol Biol (Paris)** 1996 Sep;44(7):631-44 (68 ref.) (Eng. Abstr.) **(Fre)**

[Hepatic metastases of colorectal cancers: intra-arterial chemotherapy. Value and indications] Rougier P, et al. **Presse Med** 1996 Nov 16;25(35):1683-8 (32 ref.) (Eng. Abstr.) **(Fre)**

[Individual dose adjustment in anticancer chemotherapy (editorial)] Gamelin E, et al. **Rev Med Interne** 1996; 17(7):529-33 **(Fre)**

[Insertion of permanent perfusion systems for chemotherapy. A ray of hope for the patients] Würsten HU, et al. **Rev Med Suisse Romande** 1997 Feb;117(2):155-8 (Eng. Abstr.) **(Fre)**

[Treatment of osteoid osteoma with CT-guided drilling and ethanol instillation] Duda SH, et al. **Dtsch Med Wochenschr** 1997 Apr 18;122(16):507-10 (Eng. Abstr.) **(Ger)**

[Intraoperative (hyperthermic) intraperitoneal chemotherapy--considerations and aspects of safe intra- and postoperative treatment with cytostatic drugs] Jähne J, et al. **Langenbecks Arch Chir** 1997;382(1):8-14 (Eng. Abstr.) **(Ger)**

[Value of regional lymph node excision for prognosis of advanced malignant melanoma treated by perfusion of the extremity] Huber R, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:118-21 (Eng. Abstr.) **(Ger)**

[Intra-arterial cisplatin and sequential radiotherapy. Long-term follow-up] Scheel JV, et al. **Laryngorhinootologie** 1996 Jan;75(1):38-42 (Eng. Abstr.) **(Ger)**

[Optimizing the dosage (editorial)] Heinzl S. **Med Monatsschr Pharm** 1997 Jan;20(1):1 **(Ger)**

[Image-guided therapy planning for interventional stereotactic therapy of brain tumors] Leemüller R, et al. **Radiologe** 1996 Sep;36(9):737-43 (Eng. Abstr.) **(Ger)**

[Guidelines for the handling of antineoplastic drugs] Neiger R. **Schweiz Arch Tierheilkd** 1996;138(8):383-6 (Eng. Abstr.) **(Ger)**

[Immunochemotherapy of metastatic renal cell carcinoma with interleukin 2, interferon-alpha and 5-fluorouracil] Hofmockel G, et al. **Urologe A** 1997 Jan;36(1):45-9 (Eng. Abstr.) **(Ger)**

[Prolonged oral etoposide therapy in advanced stage lung cancer] Bozóky G, et al. **Orv Hetil** 1997 Jul 13; 138(28):1791-5 (31 ref.) (Eng. Abstr.) **(Hun)**

[Locoregional chemotherapy of liver metastasis from colorectal carcinoma] Zamparelli G, et al. **Ann Ital Chir** 1996 Nov-Dec;67(6):793-7 (30 ref.) (Eng. Abstr.) **(Ita)**

[Performance and complications of totally implantable port device in bolus hepatic intra-arterial chemotherapy] Civalleri D, et al. **G Chir** 1997 Mar;18(3):127-30 (Eng. Abstr.) **(Ita)**

[Effects of adjuvant hyaluronidase in tumors refractory to chemotherapy. Review of the literature and pharmacokinetics of cisplatin after regional administration in animals and humans] Civalleri D, et al. **G Chir** 1997 Apr;18(4):175-81 (Eng. Abstr.) **(Ita)**

[A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)] Ferrari S, et al. **Minerva Pediatr** 1997 Jan-Feb; 49(1-2):29-37 (Eng. Abstr.) **(Ita)**

[The alteration of PyNPase activity in breast cancers due to preoperative oral administration of 5'-DFUR] Akao S, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):685-90 (Eng.

Abstr.) **(Jpn)**
[Chronochemotherapy for cancer] Akazawa S. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1191–202 (49 ref.) (Eng. Abstr.) **(Jpn)**
[Bropirimine (U-54461S) phase I clinical studies] Furue H. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1941–9 (Eng. Abstr.) **(Jpn)**
[Study of anti-cancer drug delivery into the organs during resection of esophagus—an experimental study] Hamabe Y, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):115–7 **(Jpn)**
[Effects of intra-hepatic arterial injection of mitoxantrone for hepatocellular carcinoma] Hiraki S, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1415–8 (Eng. Abstr.) **(Jpn)**
[Trial of radiation and cisplatin, carboplatin combination chemotherapy for advanced cancer (W-platinum chemoradiotherapy] Kato M, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):723–7 (Eng. Abstr.) **(Jpn)**
[Targeted chemotherapy of hepatocellular carcinoma using Lipiodol as a carrier] Konno T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1392–9 (Eng. Abstr.) **(Jpn)**
[Efficiency of segmental SMANCS/Lip-TAE for hepatocellular carcinoma—comparative studies in the efficacy of segmental SMANCS/Lip-TAI] Matoba M, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):37–42 (Eng. Abstr.) **(Jpn)**
[Significance of 5'-deoxy-5-fluorouridine (5'-DFUR) administration before surgery for advanced gastric and colonic cancers—activity of pyrimidine nucleoside phosphorylase (PyNPase) and serum immunosuppressive acidic protein (IAP)] Murakami N, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1959–66 (Eng. Abstr.) **(Jpn)**
[Immunomodulatory effect of daily low-dose cisplatin treatment] Nakagomi H, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):323–7 (Eng. Abstr.) **(Jpn)**
[Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate] Nishi T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1331–4 (Eng. Abstr.) **(Jpn)**
[Progress in the treatment of adult acute myeloid leukemia] Ohno R. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1053–8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine] Tomoda H, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):971–4 (Eng. Abstr.) **(Jpn)**
[Intraperitoneal administration of carboplatin loaded alpha-tricalcium phosphate (alpha-TCP) particles in rats bearing abdominal carcinomatosis] Ueda T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1512–5 (Eng. Abstr.) **(Jpn)**
[Report of nationwide questionnaire: intraperitoneal chemotherapy for advanced ovarian cancer based on clinical results—reports of 5th "Gynecologic Intraperitoneal Chemotherapy Study Group" meeting] Umezawa S, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(10):1305–11 (Eng. Abstr.) **(Jpn)**
[Recent progress in therapy for chronic myelogenous leukemia] Urabe A. **Gan To Kagaku Ryoho** 1997 Jul; 24(9):1066–73 (30 ref.) (Eng. Abstr.) **(Jpn)**
[A case of giant hepatocellular carcinoma successfully treated by arterial administration of SMANCS] Yajima Y, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1325–9 (Eng. Abstr.) **(Jpn)**
[Locoregional injection of OK-432/fibrinogen/thrombin for unresectable metastatic liver tumors] Yoshida T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1575–7 (Eng. Abstr.) **(Jpn)**
[Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma] Kise H, et al. **Hinyokika Kiyo** 1996 Nov; 42(11):879–81 (Eng. Abstr.) **(Jpn)**
[Combined hormone-chemotherapy for stage D2 prostatic cancer: starting time of chemotherapy in relation to hormone therapy] Tsukamoto T, et al. **Hinyokika Kiyo** 1996 May;42(5):351–6 (Eng. Abstr.) **(Jpn)**
[Analysis of contributing factors with high renal uptake of 99mTc-MDP after anti-cancer chemotherapy including cisplatin] Sato T, et al. **Kaku Igaku** 1996 Nov;33(11):1221–6 (Eng. Abstr.) **(Jpn)**
[Preoperative intra tumor biological response modifier injection therapy for patients with stomach neoplasms] Tanaka N, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):626 **(Jpn)**
[The efficacy of ATP sensitivity assay on intravesical prophylactic instillation for superficial bladder cancer] Inoue K, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Dec; 87(12):1281–8 (Eng. Abstr.) **(Jpn)**
[Histological effects of short term endocrine therapy on prostatic cancer] Irisawa C, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jul;87(7):977–85 (Eng. Abstr.) **(Jpn)**
[Combined hormone/chemotherapy for advanced prostatic cancer] Komatsu H. **Nippon Hinyokika Gakkai Zasshi** 1997 Mar;88(3):375–85 (86 ref.) **(Jpn)**
[Treatment results of brain metastasis from breast cancer: course of the disease and radiation therapy] Yamada K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Jan; 57(1):34–40 (Eng. Abstr.) **(Jpn)**
[Balloon-occluded intraarterial infusion therapy for advanced uterine cervical cancer: usefulness of four-lumen double balloon catheter] Yamamoto K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 May; 57(6):341–3 (Eng. Abstr.) **(Jpn)**
[Combined effect of adoptive immunotherapy (AIT) with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) and chemotherapy in tumor-bearing mice] Yamano Y, et al. **Nippon Ika Daigaku Zasshi** 1997 Jun;64(3):211–9 (Eng. Abstr.) **(Jpn)**
[Chemotherapy with low-dose consecutive cisplatin (CDDP) for patients with recurrent and distant metastasis of head and neck cancer] Nishino H, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Sep;99(9):1218–22 (Eng. Abstr.) **(Jpn)**
[A case of peritoneum malignant mesothelioma responding to arterial infusion chemotherapy] Tohda G, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jun;94(6):445–9 (10 ref.) **(Jpn)**
[A long surviving case of carcinoma of the common hepatic duct treated by chemotherapy with CDDP in the percutaneous external biliary tube and endoprosthesis] Yamashina T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Dec;93(12):927–31 **(Jpn)**
[Antileukemic agents—new drugs and attempts of rational administration] Ueda T. **Rinsho Ketsueki** 1996 Aug; 37(8):635–9 (16 ref.) **(Jpn)**
[Evaluation of intrapericardial cisplatin administration in cases of recurrent malignant pericardial effusion and cardiac tamponade] Tomkowski W, et al. **Pneumonol Alergol Pol** 1996;64 Suppl 2:180–6 (Eng. Abstr.) **(Pol)**
[Local use of polymer-based cytostatic agents in surgical treatment of patients with laryngeal cancer] Klochikhin AL, et al. **Vestn Otorinolaringol** 1997;(3):42–5 (Eng. Abstr.) **(Rus)**
[Experience in the use of viferon suppositories in young children with juvenile respiratory papillomatosis (preliminary report)] Onufrieva EK, et al. **Vestn Otorinolaringol** 1996 Jul–Aug;(4):32–3 (Eng. Abstr.) **(Rus)**
[In search of Eldorado. Breast cancer and intensification therapy] Murillo Capitán E. **Med Clin (Barc)** 1996 Jun 15; 107(3):95–8 **(Spa)**
[The initial experience of using the preparation Ukrain in treating cancer patients in Ukraine] Zemskov VS, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):158–61 (Eng. Abstr.) **(Ukr)**

ADVERSE EFFECTS

Cutaneous reactions after treatment with 2-chlorodeoxyadenosine. Meunier P, et al. **Acta Derm Venereol** 1996 Sep;76(5):385–6
Flare-up of squamous cell carcinoma of the skin following fludarabine therapy for chronic lymphocytic leukemia. Davidovitz Y, et al. **Acta Haematol** 1997;98(1):44–6
Therapy-related chronic myelomonocytic leukaemia with bone marrow eosinophilia associated with der(11)t(1;11)(q21;q14). Muroi K, et al. **Acta Haematol** 1996;96(4):251–4
Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy. Pogliani EM, et al. **Acta Haematol** 1997;97(4):228–30
Third space sequestration increases toxicity of fludarabine—a case report. Mahadevan A, et al. **Acta Oncol** 1997;36(4):441
Pantothenic acid and coenzyme A in experimental cisplatin-induced ototoxia. Ciges M, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):263–8
Radiotherapy enhanced ototoxicity of cisplatin in children. Miettinen S, et al. **Acta Otolaryngol Suppl (Stockh)** 1997; 529:90–4
Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles. Ciesielski-Carlucci C, et al. **Am J Clin Oncol** 1997 Aug; 20(4):373–5 (14 ref.)
Dose reduction of chemotherapeutic agents after weight loss. O'Marcaigh AS, et al. **Am J Clin Oncol** 1997 Apr; 20(2):193–5
Acute renal failure in a patient receiving treatment with suramin. Smith A, et al. **Am J Clin Oncol** 1997 Aug; 20(4):433–4
Tumor lysis syndrome in invasive thymoma with peripheral blood T-cell lymphocytosis. Yokoi K, et al. **Am J Clin Oncol** 1997 Feb;20(1):86–9
Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. Brehler R, et al. **Am J Dermatopathol** 1997 Feb;19(1):73–8
Coumarin-induced hepatic necrosis. Ghosh P, et al. **Am J Gastroenterol** 1997 Feb;92(2):348–9 (5 ref.)
Monitoring occupational exposure to cancer chemotherapy drugs. Baker ES, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2713–23 (146 ref.)
Amifostine for protection from antineoplastic drug toxicity. Foster-Nora JA, et al. **Am J Health Syst Pharm** 1997 Apr 1;54(7):787–800 (101 ref.)
Mitoxantrone extravasation and tissue necrosis [letter] Levin M, et al. **Am J Health Syst Pharm** 1996 May 15;53(10):1192, 1194
Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? [letter] Juliusson G. **Am J Hematol** 1996 Sep;53(1):49
All-trans retinoic acid-induced labor in a pregnant patient with acute promyelocytic leukemia [letter] Sham RL. **Am J Hematol** 1996 Oct;53(2):145
Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia [letter] Tsiara S, et al. **Am J Hematol** 1997 Apr;54(4):342
Work environment influence on cytostatics-induced genotoxicity in oncologic nurses. Brumen V, et al. **Am J Ind Med** 1996 Jul;30(1):67–71
Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia. Honda K, et al. **Am J Kidney Dis** 1997 Jul;30(1):123–30
Mitoxantrone-induced bradycardia [letter; comment] Benekli M, et al. **Ann Intern Med** 1997 Mar 1;126(5):409. Comment on: Ann Intern Med 1996 Jul 1;125(1):47–58.
Anthracycline-induced cardiotoxicity [letter; comment] Klein HO. **Ann Intern Med** 1997 May 15;126(10):827; discussion 827–8. Comment on: Ann Intern Med 1996 Jul 1;125(1):47–58.
Anthracycline-induced cardiotoxicity [letter; comment] Steinherz LJ. **Ann Intern Med** 1997 May 15;126(10):827; discussion 827–8. Comment on: Ann Intern Med 1996 Jul 1;125(1):47–58.
Prevention of gonadal damage during cytotoxic therapy. Blumenfeld Z, et al. **Ann Med** 1997 Jun;29(3):199–206 (76 ref.)
Incidence and prevention of nonhaematological toxicity of high-dose chemotherapy. Hoekman K, et al. **Ann Med** 1996 Apr;28(2):175–82 (66 ref.)
Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. Dimery IW, et al. **Ann Oncol** 1997 Jan; 8(1):85–9
Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Grandi AM, et al. **Ann Oncol** 1997 Jul;8(7):705–8
Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females? Lund MB, et al. **Ann Oncol** 1996 Mar;7(3):257–64
A phase I study of pentosan polysulfate sodium in patients with advanced malignancies. Lush RM, et al. **Ann Oncol** 1996 Nov;7(9):939–44
A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group [see comments] Olver I, et al. **Ann Oncol** 1996 Nov;7(9):945–52. Comment in: Ann Oncol 1997 Jun;8(6):615–6.
Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Smyth JF, et al. **Ann Oncol** 1997 Jun;8(6):569–73
Intra-abdominal abscess and tumor-enteric fistula formation: an unusual complication of chemotherapy for advanced testicular choriocarcinoma [letter] Stein ME, et al. **Ann Oncol** 1996 Jul;7(5):536–7
Comment: cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia [letter] Finkelstein SN, et al. **Ann Pharmacother** 1997 Sep;31(9):1094–5
Severe hypotension following inadvertent intravenous administration of interferon alfa-2a [letter] Hanson DS, et al. **Ann Pharmacother** 1997 Mar;31(3):371–2
Propofol in chemotherapy-associated nausea and vomiting. Phelps KC, et al. **Ann Pharmacother** 1996 Mar;30(3):290–2 (22 ref.)
Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Sheffield R, et al. **Ann Pharmacother** 1997 Jan;31(1):15–22 (58 ref.)
Cisplatin nephrotoxicity in a patient with a single kidney. Udeani GO, et al. **Ann Pharmacother** 1996 Jul–Aug; 30(7–8):782–6
Myoclonus due to chlorambucil in two adults with lymphoma. Wyllie AR, et al. **Ann Pharmacother** 1997 Feb; 31(2):171–4
Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis. Yarboro CH, et al. **Ann Pharmacother** 1996 Jul–Aug; 30(7–8):752–5
Octreotide in the management of treatment-related diarrhoea. Baillie-Johnson HR. **Anticancer Drugs** 1996 Jan; 7 Suppl 1:11–5 (43 ref.)
Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin. Borsi JD, et al. **Anticancer Drugs** 1996 Jan;7(1):121–6
Cytogenetic analysis in peripheral lymphocytes of cancer patients treated with cytostatic drugs: results from an EC Collaborative Study. Carbonell E, et al. **Anticancer Drugs** 1996 Jul;7(5):514–9
Treatment of prolonged chemotherapy induced severe thrombocytopenia with recombinant human interleukin-3—a report on four cases. Färber L, et al. **Anticancer Drugs** 1997 Mar;8(3):288–92
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. Gebbia V, et al. **Anticancer Drugs** 1996 Sep; 7(7):734–7
Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in

chemotherapy-naive patients receiving moderately emetogenic chemotherapy. Goldschmidt H, et al. **Anticancer Drugs** 1997 Jun;8(5):436–44

Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. Neri B, et al. **Anticancer Drugs** 1997 Jun;8(5):459–65

Neuroprotectant drugs in cisplatin neurotoxicity. Cavaletti G, et al. **Anticancer Res** 1996 Sep–Oct;16(5B):3149–59 (84 ref.)

The combination of metoclopramide, methylprednisolone and ondansetron against antiblastic-delayed emesis: a randomised phase II study. Mustacchi G, et al. **Anticancer Res** 1997 Mar–Apr;17(2B):1345–8

Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Sessink PJ, et al. **Arch Environ Health** 1997 May–Jun;52(3):240–4

Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Madasu R, et al. **Arch Otolaryngol Head Neck Surg** 1997 Sep;123(9):978–81

Birth defects and childhood cancer in offspring of survivors of childhood cancer. Green DM, et al. **Arch Pediatr Adolesc Med** 1997 Apr;151(4):379–83

Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions. Ozturan O, et al. **Auris Nasus Larynx** 1996;23:147–51

Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Ben-Yehuda D, et al. **Blood** 1996 Dec 1;88(11):4296–303

Development of paroxysmal nocturnal hemoglobinuria after chemotherapy [letter] Hakim F, et al. **Blood** 1996 Dec 15; 88(12):4725–6

All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Rowley JD, et al. **Blood** 1997 Jul 15;90(2):535–41

Hypoglycaemia associated with formestane treatment. Brankin E, et al. **BMJ** 1997 Mar 22;314(7084):869

Previous conventional chemotherapy is the principal risk factor for immunoglobulin deficiency during the early post-ABMT period in children. Grill J, et al. **Bone Marrow Transplant** 1996 Aug;18(2):325–32

T cell-depleted allogeneic bone marrow transplantation from a partially HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure. Mehta J, et al. **Bone Marrow Transplant** 1996 May;17(5):881–3

P. carinii pneumonia (PCP) following tandem cycles of high-dose chemotherapy and autologous PBPC support [letter] Meisenberg B, et al. **Bone Marrow Transplant** 1996 Oct;18(4):823

Topical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis [letter] Rymes N, et al. **Bone Marrow Transplant** 1996 Aug;18(2):484

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Saarto T, et al. **Br J Cancer** 1997;75(2):301–5

Raynaud's phenomenon and digital necrosis induced by interferon-alpha. Bachmeyer C, et al. **Br J Dermatol** 1996 Sep;135(3):481–3

Alpha interferon-induced hair discolouration [letter] Fleming CJ, et al. **Br J Dermatol** 1996 Aug;135(2):337–8

Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Akahori H, et al. **Br J Haematol** 1996 Sep;94(4):722–8

Fludarabine, as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies. Lärfars G, et al. **Br J Haematol** 1996 Sep;94(4):709–12

The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Rudd JA, et al. **Br J Pharmacol** 1996 Nov;119(5):931–6

Thirty-five years of isolated limb perfusion for melanoma: indications and results. Vrouenraets BC, et al. **Br J Surg** 1996 Oct;83(10):1319–28 (131 ref.)

A prospective study of suramin-induced peripheral neuropathy. Chaudhry V, et al. **Brain** 1996 Dec;119 (Pt 6):2039–52

Chemotherapeutic treatments: a study of the interplay among drug resistance, toxicity and recuperation from side effects. Costa MI, et al. **Bull Math Biol** 1997 Mar;59(2):205–32

Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Balducci L, et al. **Cancer** 1997 Oct 1;80(7):1317–22 (51 ref.)

Mineralocorticoid insufficiency due to suramin therapy. Kobayashi K, et al. **Cancer** 1996 Dec 1;78(11):2411–20

Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Kris MG, et al. **Cancer** 1996 Nov 15;78(10):2193–8

Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Nakamura Y, et al. **Cancer** 1996 Nov 15; 78(10):2210–5

Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy. Rahman Z, et al. **Cancer** 1997 Mar 15; 79(6):1150–7

Logistic regression model of fotemustine toxicity combining independent phase II studies. Raymond E, et al. **Cancer** 1996 Nov 1;78(9):1980–7

Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. Rubenstein EB, et al. **Cancer** 1997 Mar 15;79(6):1216–24

Ocular toxicity and cancer chemotherapy. A review. al-Tweigeri T, et al. **Cancer** 1996 Oct 1;78(7):1359–73 (170 ref.)

Metabolic support of the gastrointestinal tract: potential gut protection during intensive cytotoxic therapy. Wilmore DW. **Cancer** 1997 May 1;79(9):1794–803 (72 ref.)

Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity. Aamdal S, et al. **Cancer Chemother Pharmacol** 1997; 40(5):439–43

A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Bowden CJ, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):1–8

Arterial occlusion in patients with peripheral vascular disease treated with platinum-based regimens for lung cancer. Mathews J, et al. **Cancer Chemother Pharmacol** 1997; 40(1):19–22

Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy. Shlebak AA, et al. **Cancer Chemother Pharmacol** 1997;39(5):462–6

Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Stewart DJ, et al. **Cancer Chemother Pharmacol** 1997; 40(4):293–308

Autoimmune phenomena in patients receiving alpha-interferon therapy [letter] I nanç SE, et al. **Cancer Invest** 1996;14(6):642–3

A double-blind, randomized study of two different dosage regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapy. Kasimis BS, et al. **Cancer Invest** 1997;15(4):304–10

Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone. Hesketh PJ, et al. **Cancer J Sci Am** 1997 May–Jun;3(3):180–3

Chemoprotection of normal tissues by transfer of drug resistance genes. Rafferty JA, et al. **Cancer Metastasis Rev** 1996 Sep;15(3):365–83 (110 ref.)

Programmed instruction: cancer therapy. Associated late effects (III). Rodriguez CS, et al. **Cancer Nurs** 1996 Oct; 19(5):392–400; quiz 401–2 (26 ref.)

Programmed instruction: cancer therapy. Associated late effects (IV). Rodriguez CS, et al. **Cancer Nurs** 1996 Dec; 19(6):455–64; quiz 465–8

Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. Cimino G, et al. **Cancer Res** 1997 Jul 15; 57(14):2879–83

Safety constiderations in the use of intraoperative intraperitoneal chemotherapy. White SK, et al. **Cancer Treat Res** 1996;82:311–6

Reducing chemotherapy-associated toxicity in elderly cancer patients. Zagonel V, et al. **Cancer Treat Rev** 1996 May; 22(3):223–44 (135 ref.)

Steroid-responsive interstitial pneumonitis after fludarabine therapy [letter] Levin M, et al. **Chest** 1997 May; 111(5):1472–3

What primary care physicians should know about the toxicity of cancer chemotherapy. Markman M. **Cleve Clin J Med** 1997 Jun;64(6):331–3 (3 ref.)

Mitozantrone-induced onycholysis. A series of five cases. Creamer JD, et al. **Clin Exp Dermatol** 1995 Nov; 20(6):459–61

Fatal thromboembolism in acute promyelocytic leukaemia treated with a combination of all-trans retinoic acid and aprotonin. Mahendra P, et al. **Clin Lab Haematol** 1996 Mar; 18(1):51–2

Nephrotic syndrome associated with alpha interferon therapy in chronic myeloid leukemia [letter] Budak-Alpdoğan T, et al. **Clin Nephrol** 1997 Jul;48(1):59–60

Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Lehmann DF, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):225–9

Occupational contact urticaria due to cisplatin. Schena D, et al. **Contact Dermatitis** 1996 Mar;34(3):220–1

Mucosal protectants and their application for head and neck chemoirradiation. Marks JE. **Curr Opin Oncol** 1997 May; 9(3):267–73 (35 ref.)

Antiemetics revisited. Roila F, et al. **Curr Opin Oncol** 1997 Jul;9(4):321–6 (31 ref.)

Late effects of antineoplastic therapy in childhood on growth and endocrine function. Wallace WH, et al. **Drug Saf** 1996 Nov;15(5):325–32 (35 ref.)

Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations. de Lalla F. **Drugs** 1997 May;53(5):789–804 (103 ref.)

Drug treatment of chemotherapy-induced delayed emesis. Tavorath R, et al. **Drugs** 1996 Nov;52(5):639–48 (43 ref.)

Cancer chemotherapy in older adults. A tolerability perspective. Kimmick GG, et al. **Drugs Aging** 1997 Jan; 10(1):34–49 (100 ref.)

The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells. Legallicier B, et al. **Drugs Exp Clin Res** 1996;22(2):41–50

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Audhuy B, et al. **Eur J Cancer** 1996 May; 32A(5):807–13

Severe cutaneous reactions following interferon injections [letter] Azagury M, et al. **Eur J Cancer** 1996 Sep; 32A(10):1821

An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2. Brock P, et al. **Eur J Cancer** 1996 Sep;32A(10):1744–8

Clinical effects of amifostine (Ethyol) in patients treated with carboplatin. Budd GT, et al. **Eur J Cancer** 1996;32A Suppl 4:S43–5 (8 ref.)

Amifostine (Ethyol): dosing, administration and patient management guidelines. Bukowski RM. **Eur J Cancer** 1996; 32A Suppl 4:S46–9 (11 ref.)

Current approaches in cytoprotection: the role of amifostine (Ethyol) in altering and ameliorating toxicities in cancer therapy. Bukowski RM. **Eur J Cancer** 1996;32A Suppl 4:S1

The need for cytoprotection. Bukowski RM. **Eur J Cancer** 1996;32A Suppl 4:S2–4 (27 ref.)

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Capizzi RL. **Eur J Cancer** 1996;32A Suppl 4:S5–16 (88 ref.)

Suramin-induced neutropenia. Dawson NA, et al. **Eur J Cancer** 1996 Aug;32A(9):1534–9

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group [see comments] Dirix LY, et al. **Eur J Cancer** 1996 Oct;32A(11):2019–22. Comment in: Eur J Cancer 1996 Oct;32A(11):1833–4.

An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Jantunen IT, et al. **Eur J Cancer** 1997 Jan;33(1):66–74

Bile duct stents: is there an increased rate of complications in patients receiving chemotherapy? Lofts FJ, et al. **Eur J Cancer** 1997 Feb;33(2):209–13

Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol). Schuchter LM. **Eur J Cancer** 1996;32A Suppl 4:S40–2 (19 ref.)

Myocardial infarction associated with vinorelbine (Navelbine) [letter] Zabernigg A, et al. **Eur J Cancer** 1996 Aug;32A(9):1618–9

Chemotherapy-associated oral mucosal lesions in patients with leukaemia or lymphoma. Ramírez-Amador V, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):322–7

Modifications of the microflora of the oral cavity arising during immunosuppressive chemotherapy. Sixou JL, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):306–10 (35 ref.)

Second primary tumours (SPTs) after chemotherapy. Cartei G, et al. **Eur J Cancer Prev** 1996 Oct;5(5):400–2 (53 ref.)

Endocrine sequelae of cancer therapy. Shalet SM. **Eur J Endocrinol** 1996 Aug;135(2):135–43 (46 ref.)

Hepatitis B and C virus infection in Polish children with malignancies. Januszkiewicz D, et al. **Eur J Pediatr** 1997 Jun;156(6):454–6

Gonadal function of young adults after therapy of malignancies during childhood or adolescence. Müller HL, et al. **Eur J Pediatr** 1996 Sep;155(9):763–9

Development of chorea with lupus anticoagulant after interferon therapy. Neau JP, et al. **Eur Neurol** 1996; 36(4):235–6

Fertility after chemotherapy for testicular germ cell cancer. Pont J, et al. **Fertil Steril** 1997 Jul;68(1):1–5 (45 ref.)

Mitochondrial damage following exposure of organotypic cultures of human malignant gliomas to 2-chloro- and 2-bromo-2'-deoxyadenosine. Matyja E, et al. **Folia Neuropathol** 1996;34(1):31–9

Hepatotoxicity of chemotherapeutic and oncologic agents. King PD, et al. **Gastroenterol Clin North Am** 1995 Dec; 24(4):969–90 (194 ref.)

Combination effect of granisetron and methylprednisolone for preventing emesis induced by cytotoxic agents. Kigawa J, et al. **Gynecol Obstet Invest** 1997;43(3):195–9

Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. Martino R, et al. **Haematologica** 1997 May–Jun;82(3):297–304 (38 ref.)

Occurrence of cerebellar thrombohemorrhage during all-trans retinoic acid (ATRA) therapy in a case of acute promyelocytic leukemia [letter] Parma M, et al. **Haematologica** 1996 Jul–Aug;81(4):379–80

Listeriosis after fludarabine treatment for chronic lymphocytic leukemia. Hequet O, et al. **Hematol Cell Ther** 1997 Apr;39(2):89–91

Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Tertian G, et al. **Hematol Cell Ther** 1996 Aug;38(4):359–60

Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Blumenfeld Z, et al. **Hum Reprod** 1996 Aug; 11(8):1620–6

Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity. Dana R, et al. **Indian J Cancer** 1996 Dec;33(4):168–70

Occupational exposure to antineoplastic agents and

parameters for renal dysfunction. Sessink PJ, et al. **Int Arch Occup Environ Health** 1997;69(3):215–8

Longitudinal pigmented nail bands during hydroxyurea therapy [letter] Cakir B, et al. **Int J Dermatol** 1997 Mar; 36(3):236–7

Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management. Hatake K, et al. **Int J Hematol** 1997 Jul;66(1):13–9 (46 ref.)

Self-care behaviours initiated by chemotherapy patients in response to fatigue. Richardson A, et al. **Int J Nurs Stud** 1997 Feb;34(1):35–43

A study of patients' experiences of side-effects associated with chemotherapy: pilot stage report. Sitzia J, et al. **Int J Nurs Stud** 1995 Dec;32(6):580–600

Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment [see comments] Kwong DL, et al. **Int J Radiat Oncol Biol Phys** 1996 Sep 1; 36(2):281–9. Comment in: Int J Radiat Oncol Biol Phys 1996 Sep 1;36(2):515–7.

Psychometric evaluation of a questionnaire to document side-effects of chemotherapy. Sitzia J, et al. **J Adv Nurs** 1997 May;25(5):999–1007

More on cutaneous reactions to recombinant cytokine therapy [letter; comment] Le Gal FA, et al. **J Am Acad Dermatol** 1996 Oct;35(4):650–1. Comment on: J Am Acad Dermatol 1995 Sep;33(3):393–410; quiz 410–2.

Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis. Markman M, et al. **J Cancer Res Clin Oncol** 1997;123(4):224–6

Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy. Massidda B, et al. **J Chemother** 1996 Jun;8(3):237–42

Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. **J Clin Oncol** 1997 Jan;15(1):124–30

Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. Bow EJ, et al. **J Clin Oncol** 1997 Jun;15(6):2254–61

Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. Herrstedt J, et al. **J Clin Oncol** 1997 Apr; 15(4):1690–6

Proposal for classifying the acute emetogenicity of cancer chemotherapy. Hesketh PJ, et al. **J Clin Oncol** 1997 Jan; 15(1):103–9 (69 ref.)

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. Kris MG, et al. **J Clin Oncol** 1997 May;15(5):2135–8

Coumarin-induced hepatotoxicity [letter] Loprinzi CL, et al. **J Clin Oncol** 1997 Sep;15(9):3167–8

Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Osoba D, et al. **J Clin Oncol** 1997 Jan;15(1):116–23

Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer. Passalacqua R, et al. **J Clin Oncol** 1997 Jun;15(6):2467–73

G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. Messori A, et al. **J Clin Pharm Ther** 1996 Apr;21(2):57–63

Antiemetic efficacy of ginger (Zingiber officinale) against cisplatin-induced emesis in dogs. Sharma SS, et al. **J Ethnopharmacol** 1997 Jul;57(2):93–6

Clinical trial of low-dose rHuG-CSF in neutropenic cancer patients following anti-cancer chemotherapy. Chang MC, et al. **J Formos Med Assoc** 1996 Nov;95(11):845–50

Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB(486)interleukin-2). Cohen R, et al. **J Immunother** 1994 Oct;16(3):229–33

Generation of the complement activation product C5a precedes interleukin-2-induced capillary leakage syndrome. Nurnberger W, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jan; 19(1):45–9

Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy. Olencki T, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jan; 19(1):69–80

Defective polymorphonuclear leukocyte functions in children receiving chemotherapy for cancer are partially restored by recombinant human granulocyte colony-stimulating factor in vitro. Lejeune M, et al. **J Infect Dis** 1996 Oct;174(4):800–5

Chemotherapeutic purine analogs alter the level of interferon-beta mRNA induced by poly I-poly C in cultured osteosarcoma cells. Slomiany DJ, et al. **J Interferon Cytokine Res** 1997 May;17(5):245–54

Interferon-alpha-induced human lupus inclusions and p36 protein in cancer and AIDS. Vakharia DD, et al. **J Interferon Cytokine Res** 1996 Sep;16(9):709–15

Itraconazole for treatment of oral candidosis in pediatric cancer patients. Aanpreung P, et al. **J Med Assoc Thai** 1997 Jun;80(6):358–62

Severe tissue necrosis after cisplatin extravasation at low concentration: possible "immediate recall phenomenon" [letter] Bairey O, et al. **J Natl Cancer Inst** 1997 Aug 20; 89(16):1233–4

Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin [letter] Kris MG, et al. **J Natl Cancer Inst** 1997 Jun 4;89(11):817–8

Fighting nausea in the '90s: more and better anti-emetics can help [news] Saphir A. **J Natl Cancer Inst** 1997 Sep 3;89(17):1252–5

Accelerated titration designs for phase I clinical trials in oncology. Simon R, et al. **J Natl Cancer Inst** 1997 Aug 6;89(15):1138–47

Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. Pace A, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):409–11

Focal dystonia after chemotherapy: a case series. Brashear A, et al. **J Neurooncol** 1997 Sep;34(2):163–7

Parenchymal damage in the territory of the anterior choroidal artery following supraophthalmic intracarotid administration of CDDP for treatment of malignant gliomas. Tamaki M, et al. **J Neurooncol** 1997 Oct; 35(1):65–72

Ocular and orbital complications of intraarterial cisplatin. A case report. Wu HM, et al. **J Neuroophthalmol** 1997 Sep; 17(3):195–8

The effect of prolonged cycles of chemotherapy on quality of life in gynaecologic cancer patients. Carter JR, et al. **J Obstet Gynaecol Res** 1997 Apr;23(2):197–203

Adenomyosis in the broad ligament and tamoxifen: report of a case. Chung YP, et al. **J Obstet Gynaecol Res** 1997 Feb;23(1):69–73

Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. Valanis B, et al. **J Occup Environ Med** 1997 Jun; 39(6):574–80

A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlorodecaoxide in the management of chemotherapy-induced oral mucositis. Malik IA, et al. **J Pain Symptom Manage** 1997 Aug; 14(2):82–7

Bone density in survivors of childhood malignancies. Henderson RC, et al. **J Pediatr Hematol Oncol** 1996 Nov; 18(4):367–71

Assessment and management of chemotherapy-induced mucositis in children. Kennedy L, et al. **J Pediatr Oncol Nurs** 1997 Jul;14(3):164–74; quiz 175–7 (19 ref.)

Surgical pancreatic complications induced by L-asparaginase. Sadoff J, et al. **J Pediatr Surg** 1997 Jun; 32(6):860–3

Cytotoxic endocrinopathy: a legacy of insults. Shalet SM. **J R Soc Med** 1997 Apr;90(4):192–9 (36 ref.)

Alpha-interferon induced severe pneumonitis [letter] Wolf Y, et al. **J Toxicol Clin Toxicol** 1997;35(1):113–4 (5 ref.)

Immunotoxic effect of low dose cisplatin in mice. Kouchi Y, et al. **J Toxicol Sci** 1996 Nov;21(4):227–33

End stage renal disease and prophylactic intracavitary interferon. Pascual J, et al. **J Urol** 1997 Sep;158(3 Pt 1):881

Acute tumor lysis syndrome in a cat with lymphoma. Calia CM, et al. **J Vet Intern Med** 1996 Nov-Dec;10(6):409–11

Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy. Chang CS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Feb; 13(2):97–102

Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Merouani A, et al. **Kidney Int** 1996 Sep;50(3):1026–31

Ifosfamide nephrotoxicity: deleterious effect of previous cisplatin administration [letter; comment] Martinez F, et al. **Lancet** 1996 Oct 19;348(9034):1100–1. Comment on: Lancet 1996 Aug 31;348(9027):578–80.

Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alfa in malignant melanoma [letter] Reinhold U, et al. **Lancet** 1997 Feb 22; 349(9051):540–1

Ototoxicity resulting from combined administration of cisplatin and gentamicin [letter; comment] Kohn S, et al. **Laryngoscope** 1997 Mar;107(3):407–8. Comment on: Laryngoscope 1996 Apr;106(4):401–6.

Retinoic acid syndrome: pulmonary computed tomography (CT) findings. Davis BA, et al. **Leuk Lymphoma** 1996 Sep; 23(1-2):113–7

Occurrence of myeloma in a chronic lymphocytic leukemia patients after response to differentiation therapy with interleukin-4. Makower D, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):617–9

Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Tang SC, et al. **Leuk Lymphoma** 1996 Dec;24(1-2):93–101

Translocation t(7;11)(P15;P15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis. Xue Y, et al. **Leuk Res** 1997 Feb;21(2):107–9

Serum levels of soluble ICAM-1 in acute leukemia patients with chemotherapy-induced neutr- penia [letter] Bruserud O. **Leukemia** 1997 Sep;11(9):1596–7

Dental abnormalities in children treated for acute lymphoblastic leukemia. Kaste SC, et al. **Leukemia** 1997 Jun;11(6):792–6

Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA) [letter] Kroft SH, et al. **Leukemia** 1997 Jan;11(1):170

Prophylactic strategies to meet infectious complications in fludarabine-treated CLL. Südhoff T, et al. **Leukemia** 1997 Apr;11 Suppl 2:S38–41 (38 ref.)

Postchemotherapy connective tissue diseases--more than just rheumatism? [editorial] Amft N, et al. **Lupus** 1996 Aug; 5(4):255–6

Effect of recombinant human granulocyte colony stimulating factor on granulocytopenia induced by cytotoxic chemotherapy in patients with multiple myeloma. Pogłód R, et al. **Mater Med Pol** 1995 Jul-Sep;27(3):83–9

A woman with a balanced autosomal translocation who received chemotherapy while pregnant. Kim WY, et al. **Med Health R I** 1996 Nov;79(11):396–9

Prevention of risks from occupational exposure to antineoplastic drugs. Consensus document. Alessio L, et al. **Med Lav** 1996 May-Jun;87(3):194–206 (0 ref.) **(Eng, Ita)**

Infections in neutropenic patients. II: Management. Engervall P, et al. **Med Oncol** 1996 Mar;13(1):63–9 (74 ref.)

Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients. Ibrahim EM, et al. **Med Oncol** 1997 Mar;14(1):47–51

Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Ariceta G, et al. **Med Pediatr Oncol** 1997 Jan;28(1):35–40

Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy [letter; comment] Berberoglu S. **Med Pediatr Oncol** 1997 Mar; 28(3):241. Comment on: Med Pediatr Oncol 1995 Dec;25(6):457–62.

Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Hilliard LM, et al. **Med Pediatr Oncol** 1997 Apr;28(4):310–3

Improvement of Langerhans' cell histiocytosis and pancreatitis by alpha-interferon [letter] Hirose M. **Med Pediatr Oncol** 1997 Jun;28(6):462–3

Haematologic toxicity during craniospinal irradiation--the impact of prior chemotherapy [letter] Plowman PN. **Med Pediatr Oncol** 1997 Mar;28(3):238–9

Brain atrophy in children undergoing systemic chemotherapy for extracranial solid tumors. Prassopoulos P, et al. **Med Pediatr Oncol** 1997 Mar;28(3):228–33

Micronucleated erythrocytes in splenectomized patients with and without chemotherapy. Zúñiga G, et al. **Mutat Res** 1996 Dec 12;361(2–3):107–12

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-1997. A 39-year-old man with diarrhea and abdominal pain after chemotherapy for acute leukemia [clinical conference] **N Engl J Med** 1997 Jan 23;336(4):277–84

Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Robbins WA, et al. **Nat Genet** 1997 May;16(1):74–8

Minimization of cisplatin nephrotoxicity in high-risk patients [letter] Donadio C, et al. **Nephron** 1996;73(2):325–6

Vitamin D3 and chemotherapy-induced alopecia [editorial] Jimenez JJ, et al. **Nutrition** 1996 Jun;12(6):448–9

Growing teratoma syndrome after chemotherapy for germ cell tumors of the ovary. Geisler JP, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):719–21 (9 ref.)

Development of a comprehensive nursing/toxicity assessment form. Allaster RM, et al. **Oncol Nurs Forum** 1996 Sep; 23(8):1317–24

Outpatient chemotherapy: telephone triage for symptom management. Anastasia PJ, et al. **Oncol Nurs Forum** 1997 Jan-Feb;24(1 Suppl):13–22 (42 ref.)

Neurologic, pulmonary, and cutaneous toxicities of high-dose chemotherapy. Armstrong T, et al. **Oncol Nurs Forum** 1997 Jan-Feb;24(1 Suppl):23–33 (41 ref.)

Safe handling of cytotoxic drugs in the physician's office: a procedure manual model. Carmignani SS, et al. **Oncol Nurs Forum** 1997 Jan-Feb;24(1 Suppl):41–8 (31 ref.)

Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Dodd MJ, et al. **Oncol Nurs Forum** 1996 Jul;23(6):921–7

Intravenous drug compatibility: a challenge for the oncology nurse. Eisenberg S. **Oncol Nurs Forum** 1997 Jun; 24(5):859–69 (54 ref.)

Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. Goodman M. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):20–32 (39 ref.)

Nausea and vomiting, quality of life, and the oncology nurse. Grant M. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):5–7

Relieving nausea and vomiting in patients with cancer: a treatment algorithm. Johnson MH, et al. **Oncol Nurs Forum** 1997 Jan-Feb;24(1):51–7

Nonpharmacologic management of chemotherapy-induced nausea and vomiting. King CR. **Oncol Nurs Forum** 1997 Aug;24(7 Suppl):41–8 (59 ref.)

Oral complications from cancer therapy: Part 1--Pathophysiology and secondary complications. Madeya ML. **Oncol Nurs Forum** 1996 Jun;23(5):801–7 (28 ref.)

ANTINEOPLASTIC AGENTS

Oral complications from cancer therapy: Part 2--Nursing implications for assessment and treatment. Madeya ML. **Oncol Nurs Forum** 1996 Jun;23(5):808–19 (63 ref.)

Patients' perspectives of fatigue while undergoing chemotherapy. Messias DK, et al. **Oncol Nurs Forum** 1997 Jan–Feb;24(1):43–8

Detection of early ototoxic effect in testicular–cancer patients treated with cisplatin by transiently evoked otoacoustic emission: a pilot study. Biró K, et al. **Oncology** 1997 Sep–Oct;54(5):387–90

Ondansetron suppository: a randomised, double–blind, double–dummy, parallel–group comparison with oral ondansetron for the prevention of cyclophosphamide–induced emesis and nausea. The Ondansetron Suppository emesis study group. Davidson NG, et al. **Oncology** 1997 Sep–Oct;54(5):380–6

A randomised, double–blind, parallel–group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. du Bois A, et al. **Oncology** 1997 Jan–Feb;54(1):7–14

Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin–induced emesis. Pectasides D, et al. **Oncology** 1997 Jan–Feb; 54(1):1–6

Current role of protective agents in cancer treatment. Schuchter LM. **Oncology (Huntingt)** 1997 Apr; 11(4):505–12, 515–6; discussion 517–8 (87 ref.)

Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Lane L, et al. **Ophthalmology** 1995 Oct;102(10):1530–5

Oral pathoses caused by Candida albicans during chemotherapy: update on development mechanisms. Bunetel L, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Aug;82(2):161–5 (59 ref.)

Profound hearing loss from intravertebral artery cisplatin. Wetmore SJ, et al. **Otolaryngol Head Neck Surg** 1997 Feb; 116(2):234–7

Non–infectious interstitial alveolitis and foreign body pulmonary vasculitis in a child treated for acute lymphoblastic leukemia. Loriette Y, et al. **Pediatr Pulmonol** 1997 May;23(5):382–5

Successful combination of amphotericin therapy and surgical resection for fungal necrotizing pneumoniae in a child receiving chemotherapy for leukemia. Suc A, et al. **Pediatr Pulmonol** 1997 May;23(5):386–8

A prospective, open–label study of single–dose ciprofloxacin absorption after chemotherapy in patients with malignancy. Gattis WA, et al. **Pharmacotherapy** 1997 Jul–Aug; 17(4):836–40

Protective effect of oral administration of a pectic polysaccharide fraction from a Kampo (Japanese herbal) medicine "Juzen–Taiho–To" on adverse effects of cis–diaminedichloroplatinum. Kiyohara H, et al. **Planta Med** 1995 Dec;61(6):531–34

Side effects of adjuvant chemotherapy: perceptions of node–negative breast cancer patients. Beisecker A, et al. **Psychooncology** 1997 Jun;6(2):85–93

A modular questionnaire for the assessment of longterm quality of life in leukaemia patients: the MRC/EORTC QLQ–LEU. Watson M, et al. **Qual Life Res** 1996 Feb; 5(1):15–9

Prevention of cis–platinum nephrotoxicity in a high–risk patient. Donadio C, et al. **Ren Fail** 1996 Jul;18(4):691–5 (9 ref.)

Biomonitoring of occupational exposures to cytostatic anticancer drugs. Bos RP, et al. **Rev Environ Health** 1997 Jan–Mar;12(1):43–58 (104 ref.)

Benzydamine hydrochloride (Andolex) improves oral mucosal health in the immunocompromised patient [letter] [published erratum appears in S Afr Med J 1996 Dec;86(12):1566] Solomon C, et al. **S Afr Med J** 1996 Sep; 86(9):1136–7

Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy. Prussick R. **Semin Cutan Med Surg** 1996 Dec;15(4):267–76 (68 ref.)

Therapy–related myelodysplastic syndromes. Park DJ, et al. **Semin Hematol** 1996 Jul;33(3):256–73 (160 ref.)

Recombinant human erythropoietin in combination with other hematopoietic cytokines in attenuating chemotherapy–induced multilineage myelosuppression: brief communication. Vadhan–Raj S. **Semin Hematol** 1996 Jan;33(1 Suppl 1):16–8 (14 ref.)

Renal toxicities of antineoplastic drugs and bone marrow transplantation. Berns JS, et al. **Semin Nephrol** 1997 Jan; 17(1):54–66 (167 ref.)

A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients. Kaul S, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 13):15–22

A double–blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high–dose cisplatin chemotherapy. Chevallier B, et al. **Support Care Cancer** 1997 Jan;5(1):22–30

Antiemetic support: a continuous challenge [editorial] Dicato M. **Support Care Cancer** 1996 Jul;4(4):261–2

Treatment of cancer chemotherapy–induced toxicity with the pineal hormone melatonin. Lissoni P, et al. **Support Care Cancer** 1997 Mar;5(2):126–9

Changes in self–concept and body image during alopecia induced cancer chemotherapy. Münstedt K, et al. **Support Care Cancer** 1997 Mar;5(2):139–43

Effect of postchemotherapy nausea and vomiting on health–related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Osoba D, et al. **Support Care Cancer** 1997 Jul;5(4):307–13

Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin–induced emesis [see comments] Perez EA, et al. **Support Care Cancer** 1997 Jan;5(1):31–7 . Comment in: Support Care Cancer 1997 Jan;5(1):1–2.

Comparative studies of various antiemetic regimens. Roila F, et al. **Support Care Cancer** 1996 Jul;4(4):270–80 (57 ref.)

Scalp cooling in the prevention of alopecia in patients receiving depilating chemotherapy. Ron IG, et al. **Support Care Cancer** 1997 Mar;5(2):136–8

Orphan topics in supportive care: how about xerostomia? [editorial; comment] Senn HJ. **Support Care Cancer** 1997 Jul;5(4):261–2. Comment on: Support Care Cancer 1997 Jul;5(4):281–8.

Soft–tissue reconstruction following extravasation of chemotherapeutic agents. Shenaq SM, et al. **Surg Oncol Clin N Am** 1996 Oct;5(4):825–45 (35 ref.)

Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Levine MN. **Thromb Haemost** 1997 Jul;78(1):133–6 (22 ref.)

Carboplatin–induced immune hemolytic anemia. Marani TM, et al. **Transfusion** 1996 Nov–Dec;36(11–12):1016–8

A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Bajetta E, et al. **Tumori** 1996 Sep–Oct;82(5):450–2

Urinary 28–kD calbindin–D as a new marker for damage to distal renal tubules caused by cisplatin–based chemotherapy. Takashi M, et al. **Urol Int** 1996;56(3):174–9

Gynecomastia as a complication of chemotherapy for testicular germ cell tumors. Aki FT, et al. **Urology** 1996 Dec;48(6):944–6

Retinoic acid syndrome in acute promyelocytic leukemia. Sentero D, et al. **Wis Med J** 1997 Apr;96(4):35–8

[A randomized trial of tropisetron in the prophylaxis of nausea and vomiting induced by chemotherapy] Zhang P, et al. **Chung Hua Chung Liu Tsa Chih** 1996 Mar;18(2):154–6 (Eng. Abstr.) **(Chi)**

[Will transfer of cytostatic drug resistance genes increase hematopoiesis resistance in the treatment of malignant tumors?] Jelínek J, et al. **Cas Lek Cesk** 1997 Jan 8; 136(1):22–6 (Eng. Abstr.) **(Cze)**

[Nephrotoxicity of cytostatic drugs. Pathogenesis, prevention, therapy] Tesař V, et al. **Cas Lek Cesk** 1997 Apr 2;136(7):205–9 (63 ref.) (Eng. Abstr.) **(Cze)**

[Angiotensin–converting enzyme inhibitor in the treatment of epirubicin–induced dilated cardiomyopathy] Jensen BV, et al. **Ugeskr Laeger** 1997 Mar 24;159(13):1945–9 (Eng. Abstr.) **(Dan)**

[Reversible liver steatosis in patients treated with 5–fluorouracil and interferon–alpha] Sørensen P, et al. **Ugeskr Laeger** 1997 Feb 3;159(6):765–7 (Eng. Abstr.) **(Dan)**

[Toxiderma induced by fosfestrol (ST52)] Fradet G, et al. **Ann Med Interne (Paris)** 1997;148(3):290–2 **(Fre)**

[Psoriasis induced by interferon–alpha. Apropos of a case (letter)] Nguyen C, et al. **Ann Med Interne (Paris)** 1996; 147(7):519–21 (15 ref.) **(Fre)**

[Amifostine: current and future applications in cytoprotection] Lenoble M. **Bull Cancer** 1996 Sep; 83(9):773–87 (48 ref.) (Eng. Abstr.) **(Fre)**

[Chemotherapy–induced nausea and vomiting: from experimentation to experience] Marty M. **Bull Cancer** 1996 Dec;83(12):1014–8 (22 ref.) (Eng. Abstr.) **(Fre)**

[Fatal sub–fulminant hepatitis caused by cyproterone acetate. A new case (letter)] Castellani P, et al. **Gastroenterol Clin Biol** 1996;20(10):915–6 **(Fre)**

[Hepatic encephalopathy after injection of lanreotide, a somatostatin analog] Robin E, et al. **Gastroenterol Clin Biol** 1996;20(11):1014–6 (Eng. Abstr.) **(Fre)**

[Antiemetics in oncology] Longueville J. **J Pharm Belg** 1996 Jul–Aug;51(4):220–5 (13 ref.) **(Fre)**

[Hypoglycemia during a treatment with interferon–alpha (letter)] Isambert N, et al. **Presse Med** 1997 May 31; 26(18):855 **(Fre)**

[Nocardia nova pulmonary infection under treatment with fludarabine (letter)] Lasoudris J, et al. **Presse Med** 1997 Jul 5;26(23):1098 **(Fre)**

[Fludarabine and severe autoimmune hemolytic anemia: a new case (letter)] Crozat–Grosleron S, et al. **Rev Med Interne** 1996;17(8):701–2 **(Fre)**

[A nidulans bronchial aspergillosis after treatment of low–grade lymphoma with fludarabine] Peyrade F, et al. **Rev Med Interne** 1997;18(3):235–6 (Eng. Abstr.) **(Fre)**

[Hepatic complications of chemotherapy. From trivial cytolysis to hepatic veno–occlusive disease] Baron F, et al. **Rev Med Liege** 1997 Feb;52(2):93–7 **(Fre)**

[The kidney in children under chemotherapy] Cachat F, et al. **Rev Med Suisse Romande** 1996 Dec;116(12):985–93 (33 ref.) (Eng. Abstr.) **(Fre)**

[Impact of antimitotic chemotherapy on the dentition. Apropos of 71 cases] Salagnac JM, et al. **Rev Stomatol Chir Maxillofac** 1996;97(4):229–40 (Eng. Abstr.) **(Fre)**

[Acute depressive syndrome possibly due to nilutamide (Anandron) treatment (letter)] Maroy B, et al. **Therapie** 1997 Jan–Feb;52(1):79–81 **(Fre)**

[Life threatening anaphylaxis after repeated cisplatin administration: case report and neu therapy concepts] Berg K, et al. **Zentralbl Gynakol** 1996;118(12):684–8 (Eng. Abstr.) **(Ger)**

[Criteria and methods for the study of occupational exposure to antineoplastic agents] Apostoli P, et al. **Med Lav** 1996 May–Jun;87(3):230–54 (60 ref.) (Eng. Abstr.) **(Ita)**

[The health surveillance of personnel who handle antineoplastic agents] Forni A, et al. **Med Lav** 1996 May–Jun;87(3):265–7 (Eng. Abstr.) **(Ita)**

[Cytogenetic indicators of genotoxicity in subjects occupationally exposed to antineoplastic drugs] Forni A, et al. **Med Lav** 1996 May–Jun;87(3):222–9 (34 ref.) (Eng. Abstr.) **(Ita)**

[Pathological effects due to antineoplastic drugs in workers engaged in their production, preparation or administration] Merler E, et al. **Med Lav** 1996 May–Jun;87(3):207–21 (42 ref.) (Eng. Abstr.) **(Ita)**

[Guidelines for the health protection and safety of workers exposed to antineoplastic drugs] Palazzo S, et al. **Med Lav** 1996 May–Jun;87(3):255–64 (Eng. Abstr.) **(Ita)**

[Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma] Ridolfi L, et al. **Minerva Pediatr** 1996 May; 48(5):193–200 (Eng. Abstr.) **(Ita)**

[Occurrence of primary hypothyroidism in alpha–interferon treatment] Saglietti G, et al. **Recenti Prog Med** 1996 Jul–Aug;87(7–8):342–5 (Eng. Abstr.) **(Ita)**

[Prevention and treatment of febrile neutropenia] Montemurro F, et al. **Tumori** 1997;83(2 Suppl):S15–9 (30 ref.) (Eng. Abstr.) **(Ita)**

[Recent improvements in antiemetic therapy] Roila F, et al. **Tumori** 1997;83(2 Suppl):S3–14 (63 ref.) (Eng. Abstr.) **(Ita)**

[Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin–induced nausea and emesis] Ariyoshi Y, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):995–1011 (Eng. Abstr.) **(Jpn)**

[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP] Kimura E, et al. **Gan To Kagaku Ryoho** 1997 May; 24(7):855–9 (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of 2 mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin] Takada M, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):987–94 (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of 2–mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin] Yoshiya N, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1141–7 (Eng. Abstr.) **(Jpn)**

[Terminal care. II. Easing of symptoms of cancer patients. 5. Management of adverse effects of antineoplastic agents] Kurihara M, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2032–8 (5 ref.) **(Jpn)**

[Alteration of metastatic potential of ovarian cancer in clinical course] Kamura T. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):607–17 (Eng. Abstr.) **(Jpn)**

[The role of cytokines on hyperleukocytosis associated with acute promyelocytic leukemia induced by all–trans retinoic acid therapy] Hino K, et al. **Rinsho Ketsueki** 1996 Sep; 37(9):770–6 (Eng. Abstr.) **(Jpn)**

[High fever during the treatment of acute promyelocytic leukemia with all–trans retinoic acid] Shirono K, et al. **Rinsho Ketsueki** 1997 Jul;38(7):622–4 (Eng. Abstr.) **(Jpn)**

[Intracranial hypertension in a patient with acute promyelocytic leukemia treated with all–trans retinoic acid] Tanaka T, et al. **Rinsho Ketsueki** 1997 Jan;38(1):47–51 (Eng. Abstr.) **(Jpn)**

[Bilateral leg ulcers with pathologic evidence of small vessel vasculitis by skin biopsy during hydroxyurea therapy of chronic myelogenous leukemia] Tomiyama J, et al. **Rinsho Ketsueki** 1997 Mar;38(3):231–3 (Eng. Abstr.) **(Jpn)**

[Nephrotoxicity of antineoplastic drugs] Suzuki T, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):542–6 (26 ref.) **(Jpn)**

[The cardiotoxicity of anticancer agents] Wakasugi S. **Ryoikibetsu Shokogun Shirizu** 1996;(14):83–7 (14 ref.) **(Jpn)**

[Mechanisms of cytotoxic drug–induced emesis and its prevention] Matsuki N. **Yakugaku Zasshi** 1996 Sep; 116(9):710–8 (32 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical use of Amifostine (WR–2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy] Wrembel–Wargocka J, et al. **Przegl Lek** 1996;53(11):820–5 (15 ref.) (Eng. Abstr.) **(Pol)**

[Makmiror–complex in the treatment of post–radiation infectious vulvovaginitis in cancer patients] Borovtsova TM, et al. **Vopr Onkol** 1996;42(6):69–71 (Eng. Abstr.) **(Rus)**

[Use of Navoban in pediatric oncology] Safonova SA, et al. **Vopr Onkol** 1996;42(6):72–3 (Eng. Abstr.) **(Rus)**

[Tropisetron for the prevention of nausea and vomiting during chemotherapy: multicenter clinical study] Gutiérrez J, et al. **Rev Med Chil** 1996 Aug;124(8):967–74 (Eng. Abstr.) **(Spa)**

[Extravasation of cytostatic agents. A severe complication

in cancer therapy] Palmblad J, et al. **Lakartidningen** 1996 Oct 30;93(44):3889–91 **(Swe)**

[Patients compensated for local injuries caused by infusion of cytostatic agents] Räf L. **Lakartidningen** 1996 Oct 30; 93(44):3926 **(Swe)**

ANALYSIS

Analysis of gamma–(cholesteryloxy)butyric acid in biologic samples by derivatization with 5–(bromomethyl)fluorescein followed by high–performance liquid chromatography with laser–induced fluorescence detection. Mukherjee PS, et al. **Anal Chem** 1996 Jan 15;68(2):327–32

A physiological role of interferon (IFN)–beta derived from tumor: tumor growth of a mouse bladder carcinoma line MBT–2 is partially suppressed by autocrine IFN–beta. Kawabata K, et al. **Cancer Lett** 1997 Feb 26; 113(1–2):159–64

Sensitive isocratic liquid chromatographic assay for the determination of 5,10,15,20–tetra(m–hydroxyphenyl)chlorin in plasma and tissue with electrochemical detection. Barberi–Heyob M, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):331–8

Analysis of the imidazoacridinone C1311 by high–performance liquid chromatography. Calabrese CR, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7; 690(1–2):275–81

Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high–performance liquid chromatography. Cummings J, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):159–64

Derivatization and high–performance liquid chromatographic analysis of pentaazapentacosane pentahydrochloride. Heimbecher S, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):173–8

High–performance liquid chromatographic determination of cisplatin as platinum(II) in a pharmaceutical preparation and blood samples of cancer patients. Khuhawar MY, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):175–9

Determination of the anticancer drug prospidin in human tissue by high–performance capillary electrophoresis using derivatization. Okun VM, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26;675(2):313–9

Determination of mitoxantrone in mouse whole blood and different tissues by high–performance liquid chromatography. Rentsch KM, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1–2):185–92

Simultaneous determination of a new anticancer agent (NB–506) and its active metabolite in human plasma and urine by high–performance liquid chromatography with ultraviolet detection. Takenaga N, et al. **J Chromatogr B Biomed Appl** 1995 Dec 1;674(1):111–7

Simultaneous determination of cytotoxic (adriamycin, vincristine) and modulator of resistance (verapamil, S 9788) drugs in human cells by high–performance liquid chromatography and ultraviolet detection. Tassin JP, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):449–56

High–performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracine. Wsól V, et al. **J Chromatogr B Biomed Appl** 1996 May 31;681(1):169–75

Liquid chromatography—mass spectrometry for the detection of platinum antineoplastic complexes. Burns RB, et al. **J Pharm Biomed Anal** 1996 Jan;14(3):367–72

Dual–electrode amperometric detection for the determination of SR4233 and its metabolites with microbore liquid chromatography. Liang XZ, et al. **J Pharm Biomed Anal** 1995 Dec;14(1–2):113–9

Use of micellar media for the fluorimetric determination of ellipticine in aqueous solutions. Sbai M, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):959–65

The use of capillary electrophoresis as part of a specificity testing strategy for mitoguazone dihydrochloride HPLC methods. Thomson CE, et al. **J Pharm Biomed Anal** 1997 May;15(8):1103–11

Changes in prolactin bioactivity of milk following isolation from litter and oxytocin administration in rats. Yamamuro Y, et al. **Life Sci** 1997;60(11):809–15

Variability in anticancer lignan levels in flaxseed. Thompson LU, et al. **Nutr Cancer** 1997;27(1):26–30

Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur. Jonkman–de Vries JD, et al. **PDA J Pharm Sci Technol** 1997 Mar–Apr; 51(2):89–95

ANTAGONISTS & INHIBITORS

Antagonistic effect of amphotericin B on carboplatin antitumor activity in human osteosarcoma xenografts. Crnalic S, et al. **Anticancer Drugs** 1996 Jun;7(4):489–92

Amifostine does not alter the antitumor activity of cisplatin in a pre–clinical model of testicular cancer. Dunn TA, et al. **Anticancer Drugs** 1996 Sep;7(7):795–9

Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Aeschlimann C, et al. **Drug Metab Dispos** 1996 Dec; 24(12):1336–9

WR–1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. Alberts DS, et al. **Eur J Cancer** 1996;32A Suppl 4:S17–20

Serum can inhibit reversal of multidrug resistance by chemosensitisers. Lehnert M, et al. **Eur J Cancer** 1996 May; 32A(5):862–7

Inhibition of cytarabine–induced MDR1 (P–glycoprotein) gene activation in human tumor cells by fatty acid–polyethylene glycol–fatty acid diesters, novel inhibitors of P–glycoprotein function. Komarov PG, et al. **Int J Cancer** 1996 Oct 9;68(2):245–50

Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Tattersall FD, et al. **Neuropharmacology** 1996; 35(8):1121–9

BLOOD

Aldehyde dehydrogenase–mediated metabolism of acetaldehyde and mafosfamide in blood of healthy subjects and patients with malignant lymphoma. Metzenthin M, et al. **Adv Exp Med Biol** 1997;414:147–53

Fluorescence detection of the anticancer drug topotecan in plasma and whole blood by two–photon excitation. Burke TG, et al. **Anal Biochem** 1996 Nov 15;242(2):266–70

Stability and analysis of 2–chloro–2'–deoxyadenosine, 2–chloro–2'–arabino–fluoro–2'–deoxyadenosine and 2–chloroadenine in human blood plasma. Lindemalm S, et al. **Anticancer Drugs** 1997 Jun;8(5):445–53

Correlation between HPLC–determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer. Bottalico C, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3865–9

Carbon–11 labelling of the antitumour agent N–[2–(dimethylamino)ethyl]acridine–4–carboxamide (DACA) and determination of plasma metabolites in man. Brady F, et al. **Appl Radiat Isot** 1997 Apr;48(4):487–92

The in vitro binding kinetics of cisplatin to human plasma proteins is not affected by glutathione. Torti L, et al. **Boll Chim Farm** 1997 Apr;136(4):301–3

Certain biophysical properties of Ukrain. Susak YM, et al. **Drugs Exp Clin Res** 1996;22(3–5):185–7

Soluble E–selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor–inhibiting anti–neovascularization agent, evaluated in phase I clinical trail. Wamil BD, et al. **J Cancer Res Clin Oncol** 1997; 123(3):173–9

Determination of FCE 26644, a new polysulphonated derivative of distamycin A, in monkey plasma by reversed–phase ion–pair high–performance liquid chromatography with ultraviolet detection. Frigerio E, et al. **J Chromatogr A** 1996 Apr 5;729(1–2):237–42

Determination of the arotinoid mofarotene in human, rat and dog plasma by high–performance liquid chromatography with automated column switching and ultraviolet detection. Wyss R, et al. **J Chromatogr A** 1996 Apr 5;729(1–2):315–22

Simultaneous determination of a novel anticancer drug, TAS–103, and its N–demethylated metabolite in monkey plasma by high–performance liquid chromatography using solid–phase extraction. Azuma R, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):179–85

High–performance liquid chromatographic determination of the enantiomers of cyclophosphamide in serum. Corlett SA, et al. **J Chromatogr B Biomed Appl** 1996 Jul 12; 682(2):337–42

Simultaneous determination of all–trans–, 13–cis–, 9–cis–retinoic acid and their 4–oxo–metabolites in plasma by high–performance liquid chromatography. Disdier B, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30; 683(2):143–54

Reversed–phase high–performance liquid chromatographic determination of the new antitumor agent cyclopentenyl cytosine in biological fluids. Hegedus L, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):169–79

Analysis of perillic acid in plasma by reversed–phase high–performance liquid chromatography with ultraviolet detection. Ikechukwu Ezennia E, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):354–8

Determination of the antileukemic drug mitoguazone and seven other closely related bis(amidinohydrazones) in human blood serum by high–performance liquid chromatography. Koskinen M, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):141–9

Determination of the lactone and lactone plus carboxylate forms of 9–aminocamptothecin in human plasma by sensitive high–performance liquid chromatography with fluorescence detection. Loos WJ, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):435–41

Determination of the anticancer agent CI–980 in plasma by achiral liquid chromatography on a Pirkle–type stationary phase. Markoglou N, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):493–7

Determination of tallimustine in human plasma by high–performance liquid chromatography. Marrari P, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23;677(1):133–9

Determination of hydroxyurea in plasma and peritoneal fluid by high–performance liquid chromatography using electrochemical detection. Pujari MP, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20;694(1):185–91

High–performance capillary electrophoresis measurement of dolastatin–10. Reeves Huie W, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):451–61

Determination of O6–benzylguanine in human plasma by reversed–phase high–performance liquid chromatography. Stefan TL, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):331–8

Novel high–performance liquid chromatographic assay using fluorescence detection for the quantitation of plasma gamma–methylene–10–deazaaminopterin and its major metabolite, 7–hydroxy–gamma–methylene–10–deazaaminopterin, in patients with solid cancers in a phase I trial. Su H, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1;695(2):401–8

Radioimmunoassay for the measurement of S9788 in serum and microdialysis samples. Mackie CE, et al. **J Pharm Biomed Anal** 1997 Apr;15(7):917–28

Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates. Poon GK, et al. **J Pharm Biomed Anal** 1995 Nov;13(12):1493–8

The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma. Rosing H, et al. **J Pharm Biomed Anal** 1996 Nov;15(2):279–86

Determination of GI147211 in human blood by HPLC with fluorescence detection. Selinger K, et al. **J Pharm Biomed Anal** 1995 Nov;13(12):1521–30

High–performance liquid chromatographic analysis of the new antitumour drug N–benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro–volumes of plasma. van Gijn R, et al. **J Pharm Biomed Anal** 1995 Dec; 14(1–2):165–74

CHEMICAL SYNTHESIS

Aza and diaza bioisosteric anthracene–9,10–diones as antitumor agents. Krapcho AP, et al. **Acta Biochim Pol** 1995;42(4):427–32 (8 ref.)

Synthesis and X–ray structure of 2–(3–methyl–2–butenyl)–3,4,5–trimethoxyphenol: a potent anti–invasive agent against solid tumours. Parmar VS, et al. **Acta Chem Scand** 1996 Jun;50(6):558–60

2–Mercapto–N–(azolyl)benzenesulphonamides. II. Syntheses, anti–HIV–1 and anticancer activity of some S–substituted 4–chloro–2–mercapto–5–methyl–N–(5–amino–1,2,4–triazol–3–yl) benzenesulphonamides. Brzozowski Z. **Acta Pol Pharm** 1995 Jul–Aug;52(4):287–92

2–Mercapto–N–(azolyl)benzenesulphonamides. I. Synthesis of N–(1,1–dioxo–1,4,2–benzodithiazin–3–yl)guanidines and their transformations into 2–mercapto–N–(5–amino–1,2,4–triazol–3–yl) benzenesulphonamide derivatives with potential anti–HIV or anticancer activity. Brzozowski Z. **Acta Pol Pharm** 1995 Mar–Apr;52(2):91–101

Synthesis, antiviral and antiproliferative activity of a new class of 5–(alkyl or arylthio)–6–vinyl uracils. Baraldi PG, et al. **Anticancer Drug Des** 1996 Dec;11(8):597–609

Synthesis and in vivo antitumor activity of new heterocyclic derivatives of the 1,3,4–thiadiazolium–2–aminide class. Grynberg N, et al. **Anticancer Drugs** 1997 Jan;8(1):88–91

Synthesis and cytotoxic activity of indolyl thiazoles. Moody CJ, et al. **Anticancer Drugs** 1997 Jun;8(5):489–99

5–substituted–2–thiohydantoin analogs as a novel class of antitumor agents. al–Obaid AM, et al. **Anticancer Drugs** 1996 Nov;7(8):873–80

Potential antitumor agents. 25 [1]. Synthesis and cytotoxic activity of 3–(2–chloro–3–indolylmethylene)1,3–dihydroindol–2–ones. Andreani A, et al. **Anticancer Res** 1996 Nov–Dec; 16(6B):3585–8

5–benzyloxy–2–thiocyanatomethyl–4–pyranone, a novel heterocyclic compound: synthesis, structure determination and effects on neoplastic cell growth. Bransová J, et al. **Anticancer Res** 1997 Mar–Apr;17(2A):1175–8

Synthesis and antitumor activity of 1–[2–(chloroethyl)–3–(2–substituted–10H–phenothiazin–10–yl)alkyl– 1–urea s as potent anticancer agents. Motohashi N, et al. **Anticancer Res** 1996 Sep–Oct; 16(5A):2525–32

Antitumor activity of novel tricyclic pyrone analogs in murine leukemia cells in vitro. Perchellet JP, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2427–34

The synthesis of 191Pt labelled JM216, an orally active platinum anti–tumour agent. Bates PI, et al. **Appl Radiat Isot** 1997 Apr;48(4):469–76

Carbon–11 labelling of the antitumour agent N–[2–(dimethylamino)ethyl]acridine–4–carboxamide (DACA) and determination of plasma metabolites in man. Brady F, et al. **Appl Radiat Isot** 1997 Apr;48(4):487–92

Synthesis and antitumour activity of new derivatives of flavone–8–acetic acid (FAA). Part 1: 6–Methyl derivatives. Aitken RA, et al. **Arch Pharm (Weinheim)** 1996 Nov; 329(11):489–97

Synthesis and antitumour activity of new derivatives of flavone–8–acetic acid (FAA). Part 2: Ring–substituted derivatives. Aitken RA, et al. **Arch Pharm (Weinheim)** 1997 Jul;330(7):215–24

Synthesis and cytotoxic action of 3,5–isoxazolidinediones and 2–isoxazolin–5–ones in murine and human tumors. Hall IH, et al. **Arch Pharm (Weinheim)** 1997 Mar;330(3):67–73

Bioorganometallic chemistry––synthesis and antitumor activity of cobalt carbonyl complexes. Jung M, et al. **Arch Pharm (Weinheim)** 1997 Jun;330(6):173–6

Synthesis and characterization of the new cytostatic complex cis–diammineplatinum(II)–chlorocholylglycinate. Criado JJ, et al. **Bioconjug Chem** 1997 Jul–Aug;8(4):453–8

Amino acids and peptides. XXIX. Synthesis and antimetastatic effects of peptides and peptide–poly(ethylene glycol) hybrids related to the core sequence of the type III connecting segment domain of fibronectin. Kawasaki

K, et al. **Biol Pharm Bull** 1996 Dec;19(12):1574–9

Design, synthesis, and biological activity of anti–angiogenic hypoxic cell radiosensitizer haloacetylcarbamoyl–2–nitroimidazoles. Hori H, et al. **Bioorg Med Chem** 1997 Mar;5(3):591–9

Synthesis and biological evaluation of 1,1–dichloro–2,3–diarylcyclopropanes as antitubulin and anti–breast cancer agents. Jonnalagadda SS, et al. **Bioorg Med Chem** 1997 Apr;5(4):715–22

Molecular design of hybrid tumour necrosis factor–alpha. II: The molecular size of polyethylene glycol–modified tumour necrosis factor–alpha affects its anti–tumour potency. Tsutsumi Y, et al. **Br J Cancer** 1996 Oct; 74(7):1090–5

Synthesis and bioassay of 4–ipomeanol analogs as potential chemopreventive agents against 4–(methylnitrosamino)–1–(3–pyridyl)–1–butanone (NNK)–induced tumorigenicity in A/J mice. Desai D, et al. **Cancer Lett** 1996 Nov 29;108(2):263–70

Synthesis of inositol 2–phosphate–quercetin conjugates. Calias P, et al. **Carbohydr Res** 1996 Oct 4;292:83–90

A practical synthesis from siastatin B of (3S,4S,5R,6R)–4,5–dihydroxy–6–(trifluoroacetamido)piperidine–3–carboxylic acid having antimetastatic activity in mice. Satoh T, et al. **Carbohydr Res** 1996 Jun 5;286:173–8

Synthesis of tetrasaccharides as possible metastatic inhibitors. Zhu XX, et al. **Carbohydr Res** 1996 Dec 24;296:229–35

Fluorescent taxoids. Guy R, et al. **Chem Biol** 1996 Dec; 3(12):1021–31

Synthesis of furonaphth[1,3]oxazine and furo[1,3]oxazinoquinoline derivatives as precursors for an o–quinonemethide structure and potential antitumor agents. Benameur L, et al. **Chem Pharm Bull (Tokyo)** 1996 Mar; 44(3):605–8

Synthesis and cytotoxic activity of acronycine derivatives modified at the pyran ring. Elomri A, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2165–8

Synthesis and antitumor activity of 9–acyloxyellipticines. Harada N, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul; 45(7):1156–62

Synthesis and antitumor activity of quaternary salts of 2–(2'–oxoalkoxy)–9–hydroxyellipticines. Harada N, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan;45(1):134–7

Synthesis and biological evaluation of 7–hydroxy–3,4–diphenyl–1,2–dihydroisoquinolines as new 4–hydroxytamoxifen analogues. Kihara M, et al. **Chem Pharm Bull (Tokyo)** 1997 May;45(5):939–43

Synthesis and biological evaluation of 6–(9–hydroxy–5–methyl (and 5,6–dimethyl)–6H–pyrido[4,3–b]carbazol–1–yl)picolinic amides as new olivacine derivatives. Landras C, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2169–72

Synthesis of a new potent anti–angiogenic agent, 17 alpha–acetoxy–9 alpha–fluoro–6 alpha–methylprogesterone (9 alpha–fluoromedroxyprogesterone acetate [FMPA]). Sugino E, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb; 45(2):421–3

Synthesis and antitumor activity of fused quinoline derivatives. IV. Novel 11–aminoindolo[3,2–b]quinolines. Takeuchi Y, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb; 45(2):406–11

Synthesis and antiproliferative activity of cytidine–5'–alkylphosphonophosphates and structurally related compounds. Brachwitz H, et al. **Chem Phys Lipids** 1996 Sep 16;83(1):77–85

Cytotoxic quinolines (Part 3). Synthesis of 1–azolylalkyl–4(1H)–quinolones as cytotoxic agents. Abel MD, et al. **Drug Des Discov** 1996 Oct;14(2):115–27

Synthesis and biological evaluation of novel pyrrolidine–2,5–dione inhibitors as potential anti–tumour agents. Ahmed S, et al. **Drug Des Discov** 1995 Apr; 12(4):275–87

Synthesis and cytotoxic activities of the amine–exchange products of 2–dimethylaminomethyl–5–(E)–substituted arylidene cyclopentanones with anilines: 2–arylaminomethyl–5–(E)–arylidene cyclopentanones. Chen H, et al. **Drug Des Discov** 1996 Mar;14(1):43–52

Design, synthesis and biological evaluation of benzoic acid mustard derivatives of imidazole–containing and C–terminal carboxamide analogues of distamycin. Hartley JA, et al. **Drug Des Discov** 1995 Apr;12(4):323–35

Synthesis and biological evaluation of mono– and bis–[(alkylamino)alkylamino] substituted thienopyridopyridazines, a new class of potential antitumor agents. Antonini I, et al. **Farmaco** 1996 Jan;51(1):41–7

Diheterocyclanes as synthons for the preparation of novel series of nucleoside and acyclonucleoside analogues. Campos J, et al. **Farmaco** 1997 May;52(5):263–9

Synthesis and antitumor activity evaluation of Delta2–1,2,4–oxadiazoline derivatives. Chimirri A, et al. **Farmaco** 1996 Feb;51(2):125–9

IMP dehydrogenase as a target of antitumor and antiviral chemotherapy. Franchetti P, et al. **Farmaco** 1996 Jul; 51(7):457–69 (141 ref.)

Quinoxaline chemistry. Part 5. 2–(R)–benzylaminoquinoxalines as nonclassical antifolate agents. Synthesis and evaluation of in vitro anticancer activity. Loriga M, et al. **Farmaco** 1996 Aug–Sep; 51(8–9):559–68

Novel bioreductive anticancer agents based on indolequinones. Moody CJ, et al. **Farmaco** 1997 May; 52(5):271–9

Synthesis and biological properties of some 2H–1–benzopyrano[7,8–b][1,4]benzodioxin–2–ones. Rodighiero P, et al. **Farmaco** 1997 Jan;52(1):7–12

Synthesis and cytostatic properties of 5–substituted derivatives of 3–methylisoxazolo[5,4–d]1,2,3–triazine–4–ones and 3–methyl–5–triazene 4–isoxazolecarboxylic acid ethyl esters. Ryng S, et al. **Farmaco** 1997 Feb;52(2):105–8

Synthesis, antimicrobial and cytostatic activity of 1,2:5,6–di–O–isopropylidene–alpha–D–glucofuranosyl (–)–(S)–propanesulfinate. Saenz MT, et al. **Farmaco** 1996 Aug–Sep;51(8–9):613–5

Synthesis of a series of Homopterocarpane derivatives with potential antitumor and anti–AIDS activity. Valenti P, et al. **Farmaco** 1997 Jan;52(1):13–9

Synthesis and biological activities of higher homologues of retinoic acid. Winum JY, et al. **Farmaco** 1997 Jan; 52(1):39–42

Pre–clinical development of the anti–tumour agent CB 7646, bis N–(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol. Coley HM, et al. **Int J Cancer** 1996 Nov 4;68(3):356–63

Selection of potent inhibitors of farnesyl–protein transferase from a synthetic tetrapeptide combinatorial library. Wallace A, et al. **J Biol Chem** 1996 Dec 6;271(49):31306–11

Synthesis and cytotoxic activity of dextran carrying cis–dichloro(cyclohexane–trans–l–1,2–diamine)platinum(II) complex. Ohya Y, et al. **J Biomater Sci Polym Ed** 1996; 7(12):1085–96

Biological activities of new poly(N–1–adamantylmaleimide) and poly(N–1–diamantylmaleimide). Wang JJ, et al. **J Biomater Sci Polym Ed** 1996;7(10):905–15

Synthesis, structure, and spectroscopic properties of acetato(dimethyl)(pyridine–2–carbaldehydethiosemicarbazonato)tin(IV) acetic acid solvate, [SnMe2(PyTSC)(OAc)].HOAc. Comparison of its biological activity with that of some structurally related diorganotin(IV) bis(thiosemicarbazonates). Casas JS, et al. **J Inorg Biochem** 1996 Apr;62(1):41–55

Synthesis, characterization, cytotoxic, and DNA binding studies of some platinum (II) complexes of 1,2–diamine and alpha–diimine with 2–pyridinecarboxylate anion. Paul AK, et al. **J Inorg Biochem** 1996 Feb 15;61(3):179–96

Synthesis and antitumor activity of platinum(II) complexes with trans–3,4–diamino–2,2,6,6–tetramethylpiperidine–1–oxyl. Sen' VD, et al. **J Inorg Biochem** 1996 Oct;64(1):69–77

Synthesis, characterization, and antitumor activity of a series of novel cisplatin analogs with cis–1,4–diaminocyclohexane as nonleaving amine group. Shamsuddin S, et al. **J Inorg Biochem** 1996 Mar;61(4):291–301

Synthesis and characterization of a new bile acid and platinum(II) complex with cytostatic activity. Criado JJ, et al. **J Lipid Res** 1997 May;38(5):1022–32

Design and synthesis of potent antitumor 5,4'–diaminoflavone derivatives based on metabolic considerations. Akama T, et al. **J Med Chem** 1997 Jun 6;40(12):1894–900

Butitaxel analogues: synthesis and structure–activity relationships. Ali SM, et al. **J Med Chem** 1997 Jan 17; 40(2):236–41

Synthesis and antitumor evaluation of new thiazolo[5,4–b]quinoline derivatives. Alvarez–Ibarra C, et al. **J Med Chem** 1997 Feb 28;40(5):668–76

Folate–based inhibitors of thymidylate synthase: synthesis and antitumor activity of gamma–linked sterically hindered dipeptide analogues of 2–desamino–2–methyl–N10–propargyl–5,8–dideazafolic acid (ICI 198583). Bavetsias V, et al. **J Med Chem** 1997 May 9;40(10):1495–510

Enantioselective synthesis and antiproliferative properties of an ilmofosine analog, 2'–(trimethylammonio)ethyl 3–(hexadecyloxy)–2–(methoxymethyl)propyl phosphate, on epithelial cancer cell growth. Bittman R, et al. **J Med Chem** 1997 Apr 25;40(9):1391–5

Chromophore–modified bis–naphthalimides: synthesis and antitumor activity of bis–dibenz[de,h]isoquinoline–1,3–diones. Braña MF, et al. **J Med Chem** 1997 Feb 14;40(4):449–54

Antitumor agents. 178. Synthesis and biological evaluation of substituted 2–aryl–1,8–naphthyridin–4(1H)–ones as antitumor agents that inhibit tubulin polymerization. Chen K, et al. **J Med Chem** 1997 Sep 12;40(19):3049–56

Antitumor agents. 174. 2',3',4',5,6,7–Substituted 2–phenyl–1,8–naphthyridin–4–ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. Chen K, et al. **J Med Chem** 1997 Jul 4;40(14):2266–75

Synthesis and cytotoxic evaluation of substituted sulfonyl–N–hydroxyguanidine derivatives as potential antitumor agents. Chern JW, et al. **J Med Chem** 1997 Jul 4;40(14):2276–86

Synthesis and antitumor properties of N–[2–(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. Deady LW, et al. **J Med Chem** 1997 Jun 20;40(13):2040–6

New purines and purine analogs as modulators of multidrug resistance. Dhainaut A, et al. **J Med Chem** 1996 Sep 27; 39(20):4099–108

Synthesis and cytotoxic and antitumor activity of esters in the 1,2–dihydroxy–1,2–dihydroacronycine series. Elomri A, et al. **J Med Chem** 1996 Nov 22;39(24):4762–6

Preparation, DNA binding, and in vitro cytotoxicity of a pair of enantiomeric platinum(II) complexes, [(R)– and (S)–3–aminohexahydroazepine]dichloroplatinum(II). Crystal structure of the S enantiomer. Fenton RR, et al. **J Med Chem** 1997 Mar 28;40(7):1090–8

Synthesis and antiproliferative and antiviral activity of carbohydrate–modified pyrrolo[2,3–d]pyridazin–7–one nucleosides. Meade EA, et al. **J Med Chem** 1997 Feb 28; 40(5):794–801

Synthesis of carboranes containing an azulene framework and in vitro evaluation as boron carriers. Nakamura H, et al. **J Med Chem** 1997 Aug 29;40(18):2825–30

Synthesis and antimetastatic activity of L–iduronic acid–type 1–N–iminosugars. Nishimura Y, et al. **J Med Chem** 1997 Aug 1;40(16):2626–33

Nonclassical 2,4–diamino–5–aryl–6–ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents. Robson C, et al. **J Med Chem** 1997 Sep 12;40(19):3040–8

2–[2'–(Dimethylamino)ethyl]–1,2–dihydro–3H–dibenz[de,h]isoquinoline–1,3–diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure–activity relationships. Sami SM, et al. **J Med Chem** 1996 Dec 6;39(25):4978–87

Antitumor agents. 172. Synthesis and biological evaluation of novel deacetamidothiocolchicin–7–ols and ester analogs as antitubulin agents. Shi Q, et al. **J Med Chem** 1997 Mar 14;40(6):961–6

Hypoxia–selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4–(alkylamino)–5–nitroquinoline bioreductive drugs. Siim BG, et al. **J Med Chem** 1997 Apr 25;40(9):1381–90

Structure–activity relationships for acridine–substituted analogues of the mixed topoisomerase I/II inhibitor N–[2–(dimethylamino)ethyl]acridine–4–carboxamide. Spicer JA, et al. **J Med Chem** 1997 Jun 6;40(12):1919–29

Synthesis, antiproliferative and antiviral activity of imidazo[4,5–d]isothiazole nucleosides as 5:5 fused analogs of nebularine and 6–methylpurine ribonucleoside. Swayze EE, et al. **J Med Chem** 1997 Feb 28;40(5):771–84

Protein structure–based design, synthesis, and biological evaluation of 5–thia–2,6–diamino–4(3H)–oxopyrimidines: potent inhibitors of glycinamide ribonucleotide transformylase with potent cell growth inhibition. Varney MD, et al. **J Med Chem** 1997 Aug 1;40(16):2502–24

Anticancer and antiviral effects and inactivation of S–adenosyl–L–homocysteine hydrolase with 5'–carboxaldehydes and oximes synthesized from adenosine and sugar–modified analogues. Wnuk SF, et al. **J Med Chem** 1997 May 23;40(11):1608–18

Synthesis and activity of partial retro–inverso analogs of the antimetastatic laminin–derived peptide, YIGSR–NH2. Zhao M, et al. **J Pept Res** 1997 Mar;49(3):240–53

Xanthone derivatives as potential anti–cancer drugs. Lin CN, et al. **J Pharm Pharmacol** 1996 May;48(5):539–44

New spin labeled analogues of podophyllotoxin as potential antitumor agents. Wang Y, et al. **Life Sci** 1997;61(5):537–42

Synthesis of novel, aminoalkanolic derivatives of 5,7–dihydroxy–2–phenylbenzopyran–4–on as the potential cytostatic agents. Mazur A, et al. **Mater Med Pol** 1995 Oct–Dec;27(4):157–9

Selection of a histidine–containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries. Ferry G, et al. **Mol Divers** 1997 Mar;2(3):135–46

Synthetic chemistry. Cancer drugs better than taxol? [news; comment] Cowden CJ, et al. **Nature** 1997 May 15; 387(6630):238–9. Comment on: Nature 1997 May 15;387(6630):268–72.

Myxobacterial bounty [news] Mann J. **Nature** 1997 Jan 9; 385(6612):117

Synthesis of epothilones A and B in solid and solution phase [see comments] Nicolaou KC, et al. **Nature** 1997 May 15; 387(6630):268–72. Comment in: Nature 1997 May 15;387(6630):238–9.

A novel synthesis of antineoplastic 4'–thionucleosides using D–glucose as a chiral synthon. Yoshimura Y, et al. **Nucleic Acids Symp Ser** 1995;(34):161–2

Synthesis and cytotoxic evaluation of some carbohydrazones and thiocarbohydrazones of various unsaturated ketones and related Mannich bases. Dimmock JR, et al. **Pharmazie** 1997 Mar;52(3):182–6

Synthesis and tumor inhibiting activity of lanthanum (III) complexes with some 1–aminocycloalkancarboxylic acids. Kovachev TB, et al. **Pharmazie** 1996 Jan;51(1):25–7

Biological active acridine derivatives. Part 3: acridinylamino acids and their esters; synthesis and cytostatic activity. Lyakhov SA, et al. **Pharmazie** 1997 Jul;52(7):560–1

Synthesis of novel thiazolo[4,5–d]pyrimidine derivatives for antimicrobial, anti–HIV and anticancer investigation. Rida SM, et al. **Pharmazie** 1996 Dec;51(12):927–31

Potential antimelanomic drugs. I. Synthesis and antimelanomic effect of a spin labelled D,L–amino acid containing a 2–chloroethylnitrosocarbamoyl group. Zheleva A, et al. **Pharmazie** 1996 Aug;51(8):602–4

Synthetic C–nucleosides. I. Synthesis and the anomeric configuration of 1,2,3–triazole analogues of C–nucleosides. Różański A, et al. **Rocz Akad Med Bialymst** 1996; 41(2):321–33

Synthetic C–nucleosides. II. Synthesis of a 3–pyrrolecarboxamide analogue of the C–nucleoside. Różański A, et al. **Rocz Akad Med Bialymst** 1996;

41(2):429–40
Tumor–killer made; how does it work? [news] Service RF. **Science** 1996 Dec 20;274(5295):2009
[3–(1H–indol–3–yl)–4–(1–glykozylindol–3–yl)–1H–pyrrole–2,5–diones: synthesis and study of antiproliferative properties] Mel'nik SIa, et al. **Bioorg Khim** 1996 Oct–Nov; 22(10–11):832–7 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Molecular modeling of singlet–oxygen binding to anthraquinones in relation to the peroxidating activity of antitumor anthraquinone drugs. Liwo A, et al. **Acta Biochim Pol** 1995;42(4):445–56 (47 ref.)
Synthesis and conformational preference of novel 8–fluoroanthracyclines. Lombardi P, et al. **Acta Biochim Pol** 1995;42(4):433–44
(E,Z)–2–(2–chloro–5–nitrostyryl)–1–(1–propenyl) benzimidazole. Bacelo DE, et al. **Acta Crystallogr C** 1997 Jul 15;53 (Pt 7):907–9
Anticancer and antifertility agents. II. N,N'–hexamethylenebis(3–pyridinecarboxamide). Liu Q, et al. **Acta Crystallogr C** 1996 Sep 15;52 (Pt 9):2260–1
Electronic balance as quality assurance for cytotoxic drug admixtures. Ritter H, et al. **Am J Health Syst Pharm** 1996 Oct 1;53(19):2318–20
Stability of ondansetron hydrochloride and five antineoplastic medications. Stewart JT, et al. **Am J Health Syst Pharm** 1996 Jun 1;53(11):1297–300
Amido analogs of mitoxantrone: physico–chemical properties, molecular modeling, cellular effects and antineoplastic potential. Zagotto G, et al. **Anticancer Drug Des** 1997 Mar;12(2):99–112
Wool grease–derived alpha–monohydric fatty alcohols are carcinostatic depending on their branched alkyl moiety bulkiness. Miwa N, et al. **Anticancer Res** 1996 Sep–Oct; 16(5A):2479–84
Preparation of 188Re–RC–160 somatostatin analog: a peptide for local/regional radiotherapy. Zamora PO, et al. **Appl Radiat Isot** 1997 Mar;48(3):305–9
Interaction of 4–tert–butyl–[3–(2–chloroethyl) ureido] benzene with phosphatidylcholine bilayers: a differential scanning calorimetry and infrared spectroscopy study. Gicquad C, et al. **Arch Biochem Biophys** 1996 Oct 15; 334(2):193–9
Molecular interaction of DNA with bisplatinum(II) complexes having bis(vicinal 1,2–diamines) as ligand. Büning H, et al. **Biochemistry** 1997 Sep 23;36(38):11408–18
NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase. Johnson JM, et al. **Biochemistry** 1997 Apr 15;36(15):4399–411
Site–specific d(GpG) intrastrand cross–links formed by dinuclear platinum complexes. Bending and NMR studies. Kašpárková J, et al. **Biochemistry** 1996 Dec 24; 35(51):16705–13
NMR studies of the paramagnetic complex Fe(II)–bleomycin. Lehmann TE, et al. **Biochemistry** 1997 Mar 11; 36(10):2807–16
Mitosene–DNA adducts. Characterization of two major DNA monoadducts formed by 1,10–bis(acetoxy)–7–methoxymitosene upon reductive activation. Maliepaard M, et al. **Biochemistry** 1997 Jul 29; 36(30):9211–20
Structure–activity relation in camptothecin antitumor drugs: why a detailed molecular characterisation of their lactone and carboxylate forms by Raman and SERS spectroscopies? Chourpa I, et al. **Biochim Biophys Acta** 1997 Mar 15;1334(2–3):349–60
Combination of antitumor ether lipid with lipids of complementary molecular shape reduces its hemolytic activity. Perkins WR, et al. **Biochim Biophys Acta** 1997 Jul 5;1327(1):61–8
Novel acid labile COL1 trityl–linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity. Patel VF, et al. **Bioconjug Chem** 1996 Jul–Aug;7(4):497–510
Structural determination of the conjugate of human serum albumin with a mitomycin C derivative, KW–2149, by matrix–assisted laser desorption/ionization mass spectrometry. Yasuzawa T, et al. **Bioconjug Chem** 1997 May–Jun;8(3):391–9
Characterization of monoclonal antibodies against (1R,2R)–cyclohexanediamine platinum(II)–DNA adduct. Hirose J, et al. **Biol Pharm Bull** 1996 Sep;19(9):1220–2
Synthesis of transferrin–mitomycin C conjugate as a receptor–mediated drug targeting system. Tanaka T, et al. **Biol Pharm Bull** 1996 May;19(5):774–7
Inhibitors of farnesyl:protein transferase--a possible cancer chemotherapeutic. Scholten JD, et al. **Bioorg Med Chem** 1996 Sep;4(9):1537–43 (26 ref.)
Antiviral and tumor cell antiproliferative SAR studies on tetracyclic eudistomins. II. van Maarseveen JH, et al. **Bioorg Med Chem** 1997 May;5(5):955–70
Structure determination and synthesis of lysine isopeptides influencing on cell proliferation. Szökán G, et al. **Biopolymers** 1997 Sep;42(3):305–18
Loss of in vitro cytotoxicity of cisplatin after storage as stock solution in cell culture medium at various temperatures. Schuldes H, et al. **Cancer** 1997 May 1;79(9):1723–8
Intraliposomal conversion of lipophilic cis–bis–carboxylato–trans–R,R–1,2–diaminocyclohexane–platinum (II) complexes into cis–bis–dichloro–trans–R,R–1,2–diaminocyclohexane–platinum (II). Han I, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):17–24
Chemical characterization and comparative cellular effects of meta–iodobenzyl guanidine and benzyl guanidine. Van den Berg JD, et al. **Cancer Chemother Pharmacol** 1997; 40(2):131–7
An in vivo quantitative structure–activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Henderson BW, et al. **Cancer Res** 1997 Sep 15;57(18):4000–7
4–Demethylpenclomedine, an antitumor–active, potentially nonneurotoxic metabolite of penclomedine. Waud WR, et al. **Cancer Res** 1997 Mar 1;57(5):815–7
The structure of a coumarin derivative related to the carcinogen benz[a]anthracene. Flocco MM, et al. **Carcinogenesis** 1996 Oct;17(10):2245–8
Effects of grinding and tableting on physicochemical stability of an anticancer drug, TAT–59. Matsunaga Y, et al. **Chem Pharm Bull (Tokyo)** 1996 Oct;44(10):1931–4
Synthetic studies of vitamin D analogs. XXII. Synthesis and antiproliferation activity of putative metabolites of 1 alpha, 25–dihydroxy–22–oxavitamin D3. Watanabe H, et al. **Chem Pharm Bull (Tokyo)** 1996 Dec;44(12):2280–6
The conformational properties of the antineoplastic ether lipid 1–thiohexadecyl–2–O–methyl–S–glycero–3–phosphocholine. Mavromoustakos T, et al. **Chem Phys Lipids** 1996 Nov 1;84(1):21–34
Further insights into the influence of L–cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Shen XM, et al. **Chem Res Toxicol** 1996 Jun;9(4):751–63
Agents that target telomerase and telomeres. Raymond E, et al. **Curr Opin Biotechnol** 1996 Dec;7(6):583–91 (91 ref.)
New TNF–alpha analogues: a powerful but less toxic biological tool against tumours. Novaković S, et al. **Cytokine** 1997 Aug;9(8):597–604
Cytotoxic quinolines (part 1). Azolylalkyloxy quinolines and 1–azolylalkyl–4(1H)–quinolones. Abel MD, et al. **Drug Des Discov** 1996 Mar;14(1):15–30
Cytotoxic quinolines (part 2). Azolylalkylamino and–thio quinolines. Abel MD, et al. **Drug Des Discov** 1996 Mar; 14(1):31–42
Certain biophysical properties of Ukrain. Susak YM, et al. **Drugs Exp Clin Res** 1996;22(3–5):185–7
Sequence–selective intercalation of antitumour bis–naphthalimides into DNA. Evidence for an approach via the major groove. Bailly C, et al. **Eur J Biochem** 1996 Aug 15;240(1):195–208
DNA interactions of bifunctional dinuclear platinum(II) antitumor agents. Zaludová R, et al. **Eur J Biochem** 1997 Jun 1;246(2):508–17
The dolastatins. Pettit GR. **Fortschr Chem Org Naturst** 1997; 70:1–79 (175 ref.)
The autoxidation of the reduced forms of EO9. Butler J, et al. **Free Radic Res** 1996 Aug;25(2):141–8
Synthesis of glycosides in which the aglycon is an N–(hydroxymethyl)amino–1,3,5–triazine derivative [letter] Bagga K, et al. **Glycoconj J** 1997 Jun;14(4):519–21
NMR solution structure of a DNA decamer containing an interstrand cross–link of the antitumor drug cis–diamminedichloroplatinum (II). Paquet F, et al. **J Biomol Struct Dyn** 1996 Aug;14(1):67–77
Hydrophobic chromatography of the HL–60 cellular fraction co–binding with hexamethylene bisacetamide. Xie D, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):359–63
Comparative molecular field analysis and molecular modeling studies of 20–(S)–camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents. Carrigan SW, et al. **J Comput Aided Mol Des** 1997 Jan; 11(1):71–8
Inhibitors of the Ras signal transduction pathway as potential antitumour agents. Perrin D, et al. **J Enzyme Inhib** 1996 Oct;11(2):77–95 (103 ref.)
Drug stability and compatibility in oncology care. Williams DA. **J Infus Chemother** 1996 Fall;6(4):195–202 (54 ref.)
Cytotoxicity, DNA binding, and reactivity against nucleosides of platinum (II) and (IV) spermine compounds. Amo–Ochoa P, et al. **J Inorg Biochem** 1996 Dec; 64(4):287–99
Cis–Dichloro(diaminosuccinate diethyl ester)palladium (II) as Pd(II)/Pt(II) model compound for DNA–binding and antitumor properties: solution equilibria of their aqua–, hydroxo–, and/or chloro–species. González S, et al. **J Inorg Biochem** 1996 Mar;61(4):261–72
A comparison of structure–activity relationships between spermidine and spermine analogue antineoplastics. Bergeron RJ, et al. **J Med Chem** 1997 May 9;40(10):1475–94
Organometallic anticancer agents. 2. Aqueous chemistry and interaction of niobocene dichloride with nucleic acid constituents and amino acids. Harding MM, et al. **J Med Chem** 1996 Dec 6;39(25):5012–6
12,13–isotaxanes: synthesis of new potent analogs and X–ray crystallographic confirmation of structure. Johnson RA, et al. **J Med Chem** 1997 Aug 29;40(18):2810–2
Chemical and biological studies on a series of novel (trans–(1R,2R)–, trans–(1S,2S)–, and cis–1,2–diaminocyclohexane)platinum(IV) carboxylate complexes. Khokhar AR, et al. **J Med Chem** 1997 Jan 3; 40(1):112–6
Terbenzimidazoles: influence of 2"–, 4–, and 5–substituents on cytotoxicity and relative potency as topoisomerase I poisons. Kim JS, et al. **J Med Chem** 1997 Aug 29; 40(18):2818–24
Structure–activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. Pereira ER, et al. **J Med Chem** 1996 Oct 25;39(22):4471–7
Chemistry of the pyrrolo[1,2–alpha]benzimidazole antitumor agents: influence of the 7–substituent on the ability to alkylate DNA and inhibit topoisomerase II. Zhou R, et al. **J Med Chem** 1996 Oct 11;39(21):4321–31
In vitro reactivity of the antineoplastic drug carmustin and acrolein with model peptides. Carbone V, et al. **J Pept Res** 1997 Jun;49(6):586–95
Decomposition kinetics of cisplatin in human biological fluids. Nagai N, et al. **J Pharm Pharmacol** 1996 Sep; 48(9):918–24
Optimizing the lyophilization cycle and the consequences of collapse on the pharmaceutical acceptability of Erwinia L–asparaginase. Adams GD, et al. **J Pharm Sci** 1996 Dec; 85(12):1301–5
Determination of the acid dissociation constant for cis–diammineaquachloroplatinum(II) ion. A hydrolysis product of cisplatin. Andersson A, et al. **J Pharm Sci** 1994 Jun;83(6):859–62
Comments on 'Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U–80,244)' [letter] Bergon M. **J Pharm Sci** 1997 Sep;86(9):1070–1
Correlations between n–octanol/water partition coefficients and RP–HPLC capacity factors of 1,2–dithiole–3–thiones and 1,2–dithiol–3–ones. Boudeville P, et al. **J Pharm Sci** 1996 Sep;85(9):990–8
Decomposition of cisplatin in aqueous solutions containing chlorides by ultrasonic energy and light. Macka M, et al. **J Pharm Sci** 1994 Jun;83(6):815–8
3–[(Phenylacetyl)amino]–2,6–piperidinedione hydrolysis studies with improved synthesis and characterization of hydrolysates. Revelle LK, et al. **J Pharm Sci** 1996 Oct; 85(10):1049–52
In vitro cytotoxic effect of difluoromethylomithine increased nonspecifically by peptide coupling. Süli–Vargha H, et al. **J Pharm Sci** 1997 Sep;86(9):997–1000
Presence in Pieris rapae of cytotoxic activity against human carcinoma cells. Koyama K, et al. **Jpn J Cancer Res** 1996 Dec;87(12):1259–62
Differential scanning calorimetry and small angle x–ray diffraction study of the interaction of (R)–PAF, (R)–ET–18–OME and (R)–Lyso–PAF with model membranes. Xie XQ, et al. **Life Sci** 1997;61(9):909–23
Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents. Wang HK, et al. **Med Res Rev** 1997 Jul;17(4):367–425 (232 ref.)
High–volume cellular screening for anticancer agents with combinatorial chemical libraries: a new methodology. Salmon SE, et al. **Mol Divers** 1996 Oct;2(1–2):57–63
Effect of geometric isomerism in dinuclear platinum antitumour complexes on the rate of formation and structure of intrastrand adducts with oligonucleotides. Mellish KJ, et al. **Nucleic Acids Res** 1997 Mar 15; 25(6):1265–71
Coralyne has a preference for intercalation between TA.T triples in intramolecular DNA triple helices. Moraru–Allen AA, et al. **Nucleic Acids Res** 1997 May 15;25(10):1890–6
Hydrogen bond geometry in DNA–minor groove binding drug complexes. Tabernero L, et al. **Nucleic Acids Res** 1996 Sep 1;24(17):3458–66
Marigenol–concentrates comprising Taxol and/or Taxan esters as active substances. Eugster C, et al. **Panminerva Med** 1996 Dec;38(4):234–42
Dynamic compatibility testing of DMP 840, an experimental antitumor agent. Rubino JT, et al. **PDA J Pharm Sci Technol** 1997 May–Jun;51(3):130–6
Identification and characterization of the sulfate precipitate in GI147211C IV formulation. Tong WQ, et al. **PDA J Pharm Sci Technol** 1996 Sep–Oct;50(5):326–9
Biophysical characterization and formulation of TP40: A chimeric protein that requires a pH–dependent conformational change for its biological activity. Sanyal G, et al. **Pharm Biotechnol** 1996;9:365–92 (30 ref.)
Homodimerization of tumor–reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Ghetie MA, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7509–14
Estimation of the DNA sequence discriminatory ability of hairpin–linked lexitropsins. Walker WL, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5634–9
X–ray structure determination of antineoplastic agent 2–chloromethyl–1,2,4–triazolo [5,1–b] [1.3]–benzothiazin–9–one. Lu TH. **Proc Natl Sci Counc Repub China B** 1996 Apr;20(2):39–43
Structural studies of interactions between anticancer platinum drugs and DNA. Yang D, et al. **Prog Biophys Mol Biol** 1996;66(1):81–111 (65 ref.)
The structure of a complex of human 17beta–hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors. Breton R, et al. **Structure** 1996 Aug 15;4(8):905–15
Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy. Rowsell S, et al. **Structure** 1997 Mar 15;5(3):337–47
[Features of melting of DNA complexes with mitoxantrone at low concentrations] Babaian IuS, et al. **Biofizika** 1997 Mar–Apr;42(2):367–71 (Eng. Abstr.) **(Rus)**

ANTINEOPLASTIC AGENTS

[Modified nucleoside phosphates as precursors of antineoplastic and antiviral compounds in a cell] Arzumanov AA, et al. **Bioorg Khim** 1996 Oct–Nov; 22(10–11):777–94 (127 ref.) (Eng. Abstr.) **(Rus)**

[Protein drugs can be designed now. Targeting and cancer destroying drugs soon available] Josephson S, et al. **Lakartidningen** 1997 Jul 23;94(30–31):2650–3 **(Swe)**

CLASSIFICATION

Proposal for classifying the acute emetogenicity of cancer chemotherapy. Hesketh PJ, et al. **J Clin Oncol** 1997 Jan; 15(1):103–9 (69 ref.)

Inhibitors of the Ras signal transduction pathway as potential antitumour agents. Perrin D, et al. **J Enzyme Inhib** 1996 Oct;11(2):77–95 (103 ref.)

CONTRAINDICATIONS

Clinical decision making based on radionuclide determined ejection fraction in oncology patients. Peng NJ, et al. **J Nucl Med** 1997 May;38(5):702–5

ECONOMICS

Cost–effectiveness of interferon–alpha as maintenance therapy in chronic myelogenous leukemia [letter; comment] Messori A, et al. **Ann Intern Med** 1997 Apr 15;126(8):664–5 . Comment on: Ann Intern Med 1996 Oct 1;125(7):541–8.

Dutch agree budget for expensive anticancer drugs [news] Sheldon T. **BMJ** 1997 Mar 22;314(7084):848

Pharmacoeconomic profile of paclitaxel as a first–line treatment for patients with advanced ovarian carcinoma. A lifetime cost–effectiveness analysis. Messori A, et al. **Cancer** 1996 Dec 1;78(11):2366–73

Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Ross P, et al. **Eur J Cancer** 1996;32A Suppl 5:S13–7

Marketing and commercial challenges for anticancer products. Stevens DM. **In Vivo** 1996 Mar–Apr;10(2):261–4

Resource implications of palliative chemotherapy for ovarian cancer. Doyle C, et al. **J Clin Oncol** 1997 Mar;15(3):1000–7

HISTORY

Beyond DNA cross–linking: history and prospects of DNA–targeted cancer treatment—fifteenth Bruce F. Cain Memorial Award Lecture. Kohn KW. **Cancer Res** 1996 Dec 15;56(24):5533–46

IMMUNOLOGY

Preparation and specificity of antibodies to an anti–tumor beta–glucan, lentinan. Mizono M, et al. **Biochem Mol Biol Int** 1996 Jul;39(4):679–85

IgE–mediated allergic reaction to hyaluronidase in paediatric oncological patients. Szépfalusi Z, et al. **Eur J Pediatr** 1997 Mar;156(3):199–203

Interleukin–12, an emerging anti–tumour cytokine. Hiscox S, et al. **In Vivo** 1997 Mar–Apr;11(2):125–32 (97 ref.)

Peptides derived from a wild–type murine proto–oncogene c–erbB–2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. Nagata Y, et al. **J Immunol** 1997 Aug 1;159(3):1336–43

Differential in vitro and in vivo antitumor effects mediated by anti–CD40 and anti–CD20 monoclonal antibodies against human B–cell lymphomas. Funakoshi S, et al. **J Immunother Emphasis Tumor Immunol** 1996 Mar; 19(2):93–101

[The role of anti L–asparaginase antibody in childhood acute lymphoblastic leukemia] Akazai A, et al. **Rinsho Ketsueki** 1996 Feb;37(2):95–100 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Antimitotic activity of aqueous extracts of Inonotus obliquus. Burczyk J, et al. **Boll Chim Farm** 1996 May;135(5):306–9

A new bioactive metabolite from Xanthoria steineri . el–Fattah HA. **Boll Chim Farm** 1997 Mar;136(3):257–61

Cytotoxicity to tumors by alpha, beta–dihydric long–chain fatty alcohols isolated from esterolysates of uncytotoxic sheep cutaneous wax: the dependence on the molecular hydrophobicity balance of N– or iso–alkyl moiety bulkiness and two hydroxyl groups. Miwa N, et al. **Cancer Biochem Biophys** 1997 Jun;15(4):221–33

Immunomodulation and antitumor activity of polysaccharide–protein complex from the culture filtrates of a local edible mushroom, Tricholoma lobayense. Liu F, et al. **Gen Pharmacol** 1996 Jun;27(4):621–4

The isolation and characterization of an immunomodulatory and anti–tumor polysaccharide preparation from Flammulina velutipes. Leung MY, et al. **Immunopharmacology** 1997 Jan;35(3):255–63

Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9. Jonkman–de Vries JD, et al. **Invest New Drugs** 1996;14(2):181–91

A new anthracycline antibiotic, IT–62–B, converts the morphology of ras–transformed cells back to normal: taxonomy, fermentation, isolation, structure elucidation and biological characterization. Kawauchi T, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):297–303

Cytotoxic acylated Spermidine from a soft coral, Sinularia sp. Choi YH, et al. **J Nat Prod** 1997 May;60(5):495–6

Vasculyne, a new cytotoxic acetylenic alcohol from the marine sponge Cribrochalina vasculum. Dai JR, et al. **J Nat Prod** 1996 Jan;59(1):88–9

Triangulynes A–H and trangulynic acid, new cytotxic polyacetylenes from the marine sponge Pellina triangulata. Dai JR, et al. **J Nat Prod** 1996 Sep;59(9):860–5

Makaluvic acids A and B: novel alkaloids from the marine sponge Zyzzya fuliginosus. Fu X, et al. **J Nat Prod** 1996 Nov;59(11):1104–6

A new cytotoxic sterol methoxymethyl ether from a deep water marine sponge Scleritoderma sp. cf. paccardi. Gunasekera SP, et al. **J Nat Prod** 1996 Feb;59(2):161–2

Brasilidine A, a new cytotoxic isonitrile–containing indole alkaloid from the actinomycete Nocardia brasiliensis. Kobayashi J, et al. **J Nat Prod** 1997 Jul;60(7):719–20

Cytotoxic amides from the octocoral Telesto riisei. Liyanage GK, et al. **J Nat Prod** 1996 Feb;59(2):148–51

Granulosin, a new chromone from Galjpea granulosa. Lpez JA, et al. **J Nat Prod** 1997 Jan;60(1):24–6

Fusaricide, a new cytotoxic N–hydroxypyridone from Fusarium sp. McBrien KD, et al. **J Nat Prod** 1996 Dec; 59(12):1151–3

Cytotoxic triterpenes from a marine sponge, Stelletta sp. McCormick JL, et al. **J Nat Prod** 1996 Nov;59(11):1047–50

Isolation and characterization of new anti–HIV and cytotoxic leads from plants, marine, and microbial organisms. McKee TC, et al. **J Nat Prod** 1997 May;60(5):431–8

(Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties. McMorris TC, et al. **J Nat Prod** 1996 Sep;59(9):896–9

Isolation and characterization of 1,3–dimethylisoguanine from the Bermudian sponge Amphimedon viridis. Mitchell SS, et al. **J Nat Prod** 1997 Jul;60(7):727–8

New polyhalogenated monoterpenes from the sea hare Aplysia punctata. Ortega MJ, et al. **J Nat Prod** 1997 May; 60(5):482–4

3–Epi–aplykurodinone B, a new degraded sterol from Aplysia fasciata. Ortega MJ, et al. **J Nat Prod** 1997 May; 60(5):488–9

Antineoplastic agents. 362. Isolation and X–ray crystal structure of dibromophakellstatin from the Indian ocean sponge Phakellia mauritiana. Pettit GR, et al. **J Nat Prod** 1997 Feb;60(2):180–3

Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16–18. Pettit GR, et al. **J Nat Prod** 1996 Mar;59(3):286–9

Isolation and structure of the human cancer cell growth inhibitory cyclodepsipeptide dolastatin 16. Pettit GR, et al. **J Nat Prod** 1997 Aug;60(8):752–4

(2E,9E)–pyronaamidine 9–(N–methylimine), a new imidazole alkaloid from the northern Mariana islands sponge Leucetta sp. cf. chagosensis. Plubrukarn A, et al. **J Nat Prod** 1997 Jul;60(7):712–5

Sodwanones K, L, and M; new triterpenes from the marine sponge Axinella weltneri. Rudi A, et al. **J Nat Prod** 1997 Jul;60(7):700–3

A new norcembranoid dimer from the red sea soft coral Sinularia gardineri. el Sayed KA, et al. **J Nat Prod** 1996 Jul;59(7):687–9

New cytotoxic briaran diterpenes from the Formosan gorgonian Briareum sp. Sheu JH, et al. **J Nat Prod** 1996 Oct;59(10):935–8

Cytotoxic oxygenated desmosterols of the red alga Galaxaura marginata. Sheu JH, et al. **J Nat Prod** 1996 Jan;59(1):23–6

Makaluvamine N: a new pyrroloiminoquinone from Zyzzya fuliginosa. Venables DA, et al. **J Nat Prod** 1997 Apr; 60(4):408–10

Expression of a synthetic gene encoding the anticoagulant–antimetastatic protein ghilanten by the methylotropic yeast Pichia pastoris. Brankamp RG, et al. **Protein Expr Purif** 1995 Dec;6(6):813–20

Isolation of two cytotoxic diterpenes from the fern Pteris multifida. Woerdenbag HJ, et al. **Z Naturforsch [C]** 1996 Sep–Oct;51(9–10):635–8

[Antineoplastic glycoproteins in marine invertebrates] Yamazaki M, et al. **Gan To Kagaku Ryoho** 1997 Sep; 24(11):1477–85 (19 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Pantothenic acid and coenzyme A in experimental cisplatin–induced ototoxia. Ciges M, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):263–8

Synthesis, DNA–binding and cytotoxic properties of a bis(netropsin)–anthracenedione conjugate. Boitte N, et al. **Anticancer Drug Des** 1997 Sep;12(6):481–501

Biochemical and chemical characterization of phenylglyoxal bis(guanylhydrazone), an aromatic analogue of mitoguazone. Elo H, et al. **Anticancer Drug Des** 1996 Oct; 11(7):493–508

The novel use of Rh(I) complexes with naphthyridine ligands and poly(oxyethylene) as antitumorals. Sartori R, et al. **Anticancer Drugs** 1996 Jan;7(1):87–92

Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug–resistant human MCF–7 breast cancer cells. Chen G, et al. **Anticancer Res** 1996 Nov–Dec; 16(6B):3499–505

Biochemical characterization of cisplatin–resistance in MKN–45 human stomach adenocarcinoma cell line. Hong WS, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):3031–6

Dihydro–1,4–benzothiazine–6,7–dione, the ultimate toxic metabolite of 4–S–cysteaminylphenol and 4–S–cysteaminylcatechol. Hasegawa K, et al. **Biochem Pharmacol** 1997 May 15;53(10):1435–44

KW–2149 (7–N–[2–[gamma–L–glutamylamino]ethyldithioethyl]mitomycin C). A new mitomycin C analogue activated by serum. Masters JR, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):279–85

Bioreductive activation of a series of analogues of 5–aziridinyl–3–hydroxymethyl–1–methyl–2–[1H–indole–4, 7–dione] prop–beta–en–alpha–ol (EO9) by human DT–diaphorase. Phillips RM. **Biochem Pharmacol** 1996 Dec 13;52(11):1711–8

Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side–chain [published erratum appears in Biochem Pharmacol 1997 Jun 15;53(12):1946] Shankar VN, et al. **Biochem Pharmacol** 1997 Mar 21;53(6):783–93

Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage–enhancing antineoplastic drugs. Elsea SH, et al. **Biochemistry** 1997 Mar 11;36(10):2919–24

Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA–reactive intermediates contributing to cytotoxicity. Hayes MT, et al. **Biochemistry** 1997 Sep 2;36(35):10646–54

Structure and in vitro substrate specificity of the murine multidrug resistance–associated protein. Paul S, et al. **Biochemistry** 1996 Oct 22;35(42):13647–55

A new method for permeabilization of the plasma membrane of cultured mammalian cells. V. A standard procedure recommended for permeabilization by vortex–stirring with high molecular weight polyacrylic acid. Shimizu N, et al. **Biol Pharm Bull** 1996 Oct;19(10):1279–84

Selectivity of F8–actinomycin D for RNA:DNA hybrids and its anti–leukemia activity. Takusagawa F, et al. **Bioorg Med Chem** 1997 Jun;5(6):1197–207

Differential incorporation of ara–C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Iwasaki H, et al. **Blood** 1997 Jul 1;90(1):270–8

Retinoid metabolism and all–trans retinoic acid–induced growth inhibition in head and neck squamous cell carcinoma cell lines. Braakhuis BJ, et al. **Br J Cancer** 1997; 76(2):189–97

Metabolism and pharmacokinetics of the anti–tumour agent 2,3,5–trimethyl–6–(3–pyridylmethyl)1,4–benzoquinone (CV–6504). Hussey HJ, et al. **Br J Cancer** 1996 Nov; 74(9):1349–53

Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti–cancer chemotherapy. Kelsey KT, et al. **Br J Cancer** 1997;76(7):852–4

All–trans–retinoic acid 4–hydroxylation in human liver microsomes: in vitro modulation by therapeutic retinoids. Nadin L, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):609–12

Biodegradation and toxicity of the antineoplastics mitoxantron hydrochloride and treosulfane in the Closed Bottle Test (OECD 301 D). al–Ahmad A, et al. **Bull Environ Contam Toxicol** 1997 May;58(5):704–11

Multidrug resistance: molecular mechanisms and clinical relevance. Ling V. **Cancer Chemother Pharmacol** 1997;40 Suppl:S3–8 (36 ref.)

The effects of terbium on the cellular accumulation of cisplatin in MDA–MB–231 human breast tumor cells. Mack KM, et al. **Cancer Chemother Pharmacol** 1997;39(3):217–22

Isolation and structural confirmation of N–desmethyl topotecan, a metabolite of topotecan. Rosing H, et al. **Cancer Chemother Pharmacol** 1997;39(6):498–504

Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Lyne JC, et al. **Cancer J Sci Am** 1997 Jan–Feb;3(1):21–30

Woodchuck p–glycoprotein found in virus–induced hepatocellular carcinomas binds anticancer drugs. Dunn SE, et al. **Cancer Lett** 1996 Dec 20;110(1–2):177–80

Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site. Mooberry SL, et al. **Cancer Lett** 1996 Oct 1;107(1):53–7

Neutrophil–mediated activation of mitoxantrone to metabolites which form adducts with DNA. Panousis C, et al. **Cancer Lett** 1997 Feb 26;113(1–2):173–8

Rat and human maspins: structures, metastatic suppressor activity and mutation in prostate cancer cells. Umekita Y, et al. **Cancer Lett** 1997 Feb 26;113(1–2):87–93

Preclinical prediction of factors influencing the elimination of 5,6–dimethylxanthenone–4–acetic acid, a new anticancer drug. Miners JO, et al. **Cancer Res** 1997 Jan 15;57(2):284–9

The role of metabolism in mammary epithelial cell growth inhibition by the isoflavones genistein and biochanin A. Peterson TG, et al. **Carcinogenesis** 1996 Sep;17(9):1861–9

In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Saris CP, et al. **Carcinogenesis** 1996 Dec;17(12):2763–9

Macrophage–derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Dong Z, et al. **Cell** 1997 Mar 21;88(6):801–10

Induction of ductal morphogenesis and lobular hyperplasia by amphiregulin in the mouse mammary gland. Kenney NJ, et al. **Cell Growth Differ** 1996 Dec;7(12):1769–81

Phosphatidylinositol 3–kinase recruitment by p185erbB–2 and erbB–3 is potently induced by neu differentiation

factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Ram TG, et al. **Cell Growth Differ** 1996 May;7(5):551-61

The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Mello JA, et al. **Chem Biol** 1996 Jul;3(7):579-89

32P-post-labelling analysis of nucleobases involved in the formation of DNA adducts by antitumor 1-nitroacridines. Bartoszek A, et al. **Chem Biol Interact** 1997 Feb 28; 103(2):131-9

The role of beta-glucuronidase in drug disposition and drug targeting in humans. Sperker B, et al. **Clin Pharmacokinet** 1997 Jul;33(1):18-31 (123 ref.)

Pharmacokinetics and metabolism of lonidamine in rats: evidence of enterohepatic recycling. Besner JG, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):219-34

Modulation of cis-diamminedichloroplatinum (II) accumulation and cytotoxicity by spermine in sensitive and resistant human ovarian carcinoma cells. Marverti G, et al. **Eur J Cancer** 1997 Apr;33(4):669-75

Cross-resistance to cis-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair. Chao CC. **Eur J Pharmacol** 1996 Jun 3;305(1-3):213-22

Intracellular molecular interactions of antitumor drug amsacrine (m-AMSA) as revealed by surface-enhanced Raman spectroscopy. Chourpa I, et al. **FEBS Lett** 1996 Nov 11;397(1):61-4

Kupffer cells play important roles in the metabolic degradation of a soluble anti-tumor (1-->3)-beta-D-glucan, SSG, in mice. Suda M, et al. **FEMS Immunol Med Microbiol** 1996 Sep;15(2-3):93-100

Nitroreductase activation of CB1954--an alternative 'suicide' gene system [editorial; comment] Bailey SM, et al. **Gene Ther** 1997 Feb;4(2):80-1. Comment on: Gene Ther 1997 Feb;4(2):93-100. Comment on: Gene Ther 1997 Feb;4(2):101-10.

The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Bridgewater JA, et al. **Hum Gene Ther** 1997 Apr 10;8(6):709-17

FT-Raman studies on the transformation of G-actin to F-actin, the binding of cisplatin and transplatin to F-actin and the effects of the conformation of F-actin. Zeng HH, et al. **Int J Biol Macromol** 1997 Apr;20(2):107-13

In vivo effects of chlorophyllin on the antitumour agent cyclophosphamide. Te C, et al. **Int J Cancer** 1997 Jan 6; 70(1):84-9

Effect of hyperthermia on cisplatin sensitivity in human glioma and ovarian carcinoma cell lines resistant and sensitive to cisplatin treatment. Raaphorst GP, et al. **Int J Hyperthermia** 1996 Mar-Apr;12(2):211-22

Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. Burden DA, et al. **J Biol Chem** 1996 Nov 15; 271(46):29238-44

Anticancer drugs, ionophoric peptides, and steroids as substrates of the yeast multidrug transporter Pdr5p. Kolaczkowski M, et al. **J Biol Chem** 1996 Dec 6; 271(49):31543-8

Induction of p21 mediated by reactive oxygen species formed during the metabolism of aziridinylbenzoquinones by HCT116 cells. Qiu X, et al. **J Biol Chem** 1996 Dec 13; 271(50):31915-21

Determination of 2-chloro-2'-deoxyadenosine nucleotides in leukemic cells by ion-pair high-performance liquid chromatography. Reichelova V, et al. **J Chromatogr B Biomed Appl** 1996 Jun 28;682(1):115-23

High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracine. Wsól V, et al. **J Chromatogr B Biomed Appl** 1996 May 31;681(1):169-75

Kinetic analysis of the cis-diamminedichloroplatinum(II)--cysteine reaction: implications to the extent of platinum--DNA binding. Bose RN, et al. **J Inorg Biochem** 1997 Feb 15;65(3):199-205

Diorganotin(IV) antitumor agent. (C2H5)2SnCl2 (phen)/nucleotides aqueous and solid-state coordination chemistry and its DNA binding studies. Li Q, et al. **J Inorg Biochem** 1996 Nov 15;64(3):181-95

Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. Taatjes DJ, et al. **J Med Chem** 1997 Apr 11; 40(8):1276-86

Gas chromatography-mass spectrometry identification of a novel N3-methylated metabolite of 5'-deoxy-5-fluorouridine in plasma of cancer patients undergoing chemotherapy. Zambonin CG, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1521-8

Indocyanine green: intracellular uptake and phototherapeutic effects in vitro. Fickweiler S, et al. **J Photochem Photobiol B** 1997 Apr;38(2-3):178-83

Interactions of alpha-melanotropin and agouti on B16 melanoma cells: evidence for inverse agonism of agouti. Siegrist W, et al. **J Recept Signal Transduct Res** 1997 Jan-May;17(1-3):75-98

Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells. Kikuchi Y, et al. **Jpn J Cancer Res** 1997 Feb; 88(2):213-7

Effect of glutathione depletion on cisplatin resistance in cancer cells transfected with the gamma-glutamylcysteine synthetase gene. Kurokawa H, et al. **Jpn J Cancer Res** 1997 Feb;88(2):108-10

Distinct retinoid X receptor-retinoic acid receptor heterodimers are differentially involved in the control of expression of retinoid target genes in F9 embryonal carcinoma cells. Chiba H, et al. **Mol Cell Biol** 1997 Jun; 17(6):3013-20

Cross-linking CTX, a novel thymocyte-specific molecule, inhibits the growth of lymphoid tumor cells in Xenopus. Robert J, et al. **Mol Immunol** 1997 Feb;34(2):133-43

Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents. Verri A, et al. **Mol Pharmacol** 1997 Jan;51(1):132-8

Inhibition of mitosis and microtubule function through direct tubulin binding by a novel antiproliferative naphthopyran LY290181. Wood DL, et al. **Mol Pharmacol** 1997 Sep; 52(3):437-44

Increased delivery of a new cisplatin analogue (254-S) in a rat brain tumor by an intracarotid infusion of bradykinin. Koga H, et al. **Neurol Res** 1996 Jun;18(3):244-7

Superior cytotoxic potency of mitoxantrone in interaction with DNA: comparison with that of daunorubicin. Fukushima T, et al. **Oncol Res** 1996;8(2):95-100

Searching for new TNF-alpha analogs having potential application in cancer therapy. Menart V, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R233-4

Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. Tanaka K, et al. **Pharm Res** 1996 Jul; 13(7):1073-7

Formation of platinum-DNA adducts in pediatric patients receiving carboplatin. Tonda ME, et al. **Pharmacotherapy** 1996 Jul-Aug;16(4):631-7

Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: potential for cancer therapy. Newton DL, et al. **Protein Eng** 1997 Apr;10(4):463-70

Effect of substituents on the metabolism of nitracrine in rat. Robertson IG, et al. **Xenobiotica** 1996 May;26(5):559-69

[Inhibitors of farnesyl transferase in oncology: from basic research to pharmaceutical research] Lavelle F. **C R Seances Soc Biol Fil** 1997;191(2):211-9 (18 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Blood flow-independent accumulation of cisplatin in the guinea pig cochlea. Miettinen S, et al. **Acta Otolaryngol (Stockh)** 1997 Jan;117(1):55-60

Similar pharmacokinetics and differential ototoxicity after administration with cisplatin and transplatin in guinea pigs. Saito T, et al. **Acta Otolaryngol (Stockh)** 1997 Jan; 117(1):61-5

Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Kimura T, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:135-41

Studies of succinate dehydrogenase inhibition (SDI) test with cisplatin encapsulated liposome against cancer cells. Koketsu M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996; 525:120-4

Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part I. A double immunofluorescence analysis. Sinha AA, et al. **Anat Rec** 1996 Aug;245(4):652-61

How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients. Bénézet S, et al. **Ann Oncol** 1997 Jun;8(6):607-9

Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice. Cummings J, et al. **Ann Oncol** 1996 Mar;7(3):291-6

Antisense oligonucleotide inhibitors for the treatment of cancer: I. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Geary RS, et al. **Anticancer Drug Des** 1997 Jul;12(5):383-93 (23 ref.)

Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. Semb KA, et al. **Anticancer Drugs** 1997 Mar;8(3):296-303

Distribution of platinum in human gynecologic tissues and lymph nodes after intravenous and intraarterial neoadjuvant chemotherapy. Ishikawa H, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3849-53

HBO and the uptake and retention of [125I] MIBG in human platelets and two neuroendocrine cell lines. Tytgat GA, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):1209-12

Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits. Wilson TW, et al. **Arch Ophthalmol** 1996 Nov;114(11):1390-5

The chemical modification of E. coli L-asparaginase by N,O-carboxymethyl chitosan. Qian G, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1996 Nov; 24(6):567-77

Mammary excretion and placental transfer of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(II) in rats. Cho YB, et al. **Arzneimittelforschung** 1996 Sep;46(9):926-30

Pharmacokinetic behaviour and cardiovascular effects of intravenously administered hypoxoside and rooperol. Coetzee JF, et al. **Arzneimittelforschung** 1996 Oct; 46(10):997-1000

ATP-dependent transport of lipophilic cytotoxic drugs by membrane vesicles prepared from MRP-overexpressing HL60/ADR cells. Paul S, et al. **Biochemistry** 1996 Nov 5;35(44):14003-11

Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation. Siemers NO, et al. **Bioconjug Chem** 1997 Jul-Aug;8(4):510-9

Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine. Hamada A, et al. **Biol Pharm Bull** 1996 May;19(5):729-32

Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin. Figg WD, et al. **Biopharm Drug Dispos** 1997 May;18(4):347-59

The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Armour A, et al. **Br J Cancer** 1997;75(4):470-6

The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. Gerrits CJ, et al. **Br J Cancer** 1997;76(7):946-51

Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. Korst AE, et al. **Br J Cancer** 1997;75(10):1439-46

3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. Vaidyanathan G, et al. **Br J Cancer** 1997;76(2):226-33

Drug delivery to brain tumors. Walker WL, et al. **Bull Math Biol** 1996 Nov;58(6):1047-74

A new approach to cancer therapy due to appropriate uptake and retention kinetics of meta-tetrahydroxy-phenylchlorin in a human fibroblast cell line. Wierrani F, et al. **Cancer Biochem Biophys** 1996 Apr;15(3):171-6

The tissue distribution in BALB/c mice of C-14-labeled JM216, an orally active platinum antitumour compound. Bates PI, et al. **Cancer Chemother Pharmacol** 1996; 39(1-2):170-5

Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Conley BA, et al. **Cancer Chemother Pharmacol** 1997; 39(4):291-9

Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii. Egorin MJ, et al. **Cancer Chemother Pharmacol** 1996;39(1-2):51-60

Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Graham MA, et al. **Cancer Chemother Pharmacol** 1997;40(1):1-10

Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus. Johnsson A, et al. **Cancer Chemother Pharmacol** 1996;39(1-2):25-33

A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration. Liliemark J, et al. **Cancer Chemother Pharmacol** 1996;38(6):536-40

Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Martin J, et al. **Cancer Chemother Pharmacol** 1997;40(3):189-201

Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats. Moore LE, et al. **Cancer Chemother Pharmacol** 1997;39(6):532-6

Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Mosure KW, et al. **Cancer Chemother Pharmacol** 1997; 40(3):251-8

Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Nagai N, et al. **Cancer Chemother Pharmacol** 1996;39(1-2):131-7

Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo. Nagai N, et al. **Cancer Chemother Pharmacol** 1997;40(1):11-8

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. Newman EM, et al. **Cancer Chemother Pharmacol** 1997;39(3):254-8

Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Pagani O, et al. **Cancer Chemother Pharmacol** 1996;38(6):541-7

Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Sutton LM, et al. **Cancer Chemother Pharmacol** 1997;40(4):335-41

Biokinetics of indium-111-bleomycin complex in head and neck cancer--implementations for radiochemotherapy. Kairemo KJ, et al. **Cancer Detect Prev** 1997;21(1):83-90

Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs. Cheng TL, et al. **Cancer Immunol Immunother** 1997 Aug;

44(6):305–15

Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials. Osman S, et al. **Cancer Res** 1997 Jun 1;57(11):2172–80

Peritoneal-plasma barrier. Jacquet P, et al. **Cancer Treat Res** 1996;82:53–63 (29 ref.)

Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice. Freyer G, et al. **Cancer Treat Rev** 1997 May;23(3):153–69 (73 ref.)

Quantitative mapping of platinum and essential trace metal in cisplatin resistant and sensitive human ovarian adenocarcinoma cells. Ortega R, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Feb;42(1):77–88

Clinical pharmacokinetics of topotecan. Herben VM, et al. **Clin Pharmacokinet** 1996 Aug;31(2):85–102 (71 ref.)

The clinical pharmacokinetics of cladribine. Liliemark J. **Clin Pharmacokinet** 1997 Feb;32(2):120–31 (67 ref.)

Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Masson E, et al. **Clin Pharmacokinet** 1997 Apr;32(4):324–43 (135 ref.)

Clinical pharmacokinetics of tretinoin. Regazzi MB, et al. **Clin Pharmacokinet** 1997 May;32(5):382–402 (111 ref.)

Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation. Smith PJ, et al. **Cytometry** 1997 Jan 1;27(1):43–53

Metabolism and pharmacokinetics of N1,N14-diethylhomospermine. Bergeron RJ, et al. **Drug Metab Dispos** 1996 Mar;24(3):334–43

Disposition and metabolism of the sulfonylurea oncolytic agent LY295501 in mouse, rat, and monkey. Ehlhardt WJ, et al. **Drug Metab Dispos** 1997 Jun;25(6):701–8

Identification and characterization of human metabolites of CAI [5-amino-1-1(4'-chlorobenzoyl-3,5-dichlorobenzyl)-1,2,3-triazole- 4-carboxamide). Soltis MJ, et al. **Drug Metab Dispos** 1996 Jul;24(7):799–806

Metabolism and disposition of the antifolate LY231514 in mice and dogs. Woodland JM, et al. **Drug Metab Dispos** 1997 Jun;25(6):693–700

Pharmacokinetics and metabolism of lonidamine in rats: evidence of enterohepatic recycling. Besner JG, et al. **Drug Metab Rev** 1997 Feb-May;29(1-2):219–34

Modulation of P-glycoprotein mediated drug accumulation in multidrug resistant CCRF VCR-1000 cells by chemosensitisers. Boer R, et al. **Eur J Cancer** 1996 May; 32A(5):857–61

Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group. McLeod HL, et al. **Eur J Cancer** 1996 Aug;32A(9):1518–22

Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. van der Vijgh WJ, et al. **Eur J Cancer** 1996;32A Suppl 4:S26–30 (21 ref.)

Interspecies scaling: predicting clearance of anticancer drugs in humans. A comparative study of three different approaches using body weight or body surface area. Mahmood I. **Eur J Drug Metab Pharmacokinet** 1996 Jul-Sep;21(3):275–8

Reductive activation of nitroheterocyclic compounds. Tocher JH. **Gen Pharmacol** 1997 Apr;28(4):485–7 (27 ref.)

Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer. Lagrange JL, et al. **Int J Cancer** 1996 Nov 15;68(4):452–6

Pharmacokinetics and drug monitoring of L-asparaginase treatment. Boos J. **Int J Clin Pharmacol Ther** 1997 Mar; 35(3):96–8

Bioavailability and pharmacokinetic characteristics of dexniguldipine-HCl, a new anticancer drug. Goedhals L, et al. **Int J Clin Pharmacol Ther** 1995 Dec;33(12):664–9

Dosage individualization of carboplatin and etoposide based on pharmacokinetic investigations. Jaehde U. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):76–8 (19 ref.)

Pharmacokinetic interactions of antineoplastic agents. Rao-Schymanski RA, et al. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):84–7 (18 ref.)

Cellular transport of CI-980. Hook KE, et al. **Invest New Drugs** 1996;14(4):341–7

Pharmacokinetic profile of Mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma. Rizzo J, et al. **Invest New Drugs** 1996;14(2):227–34

Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane. Schilling T, et al. **Invest New Drugs** 1996;13(4):327–32

Study of the biotransformation of a potential benzo[c]fluorene antineoplastic using high-performance liquid chromatography with high-speed-scanning ultraviolet detection. Nobilis M, et al. **J Chromatogr B Biomed Appl** 1996 May 31;681(1):143–51

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. Berlin J, et al. **J Clin Oncol** 1997 Feb;15(2):781–9

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. McKeage MJ, et al. **J Clin Oncol** 1997 Jul;15(7):2691–700

Phase I and pharmacologic study of topotecan in patients with impaired renal function [see comments] O'Reilly S, et al. **J Clin Oncol** 1996 Dec;14(12):3062–73. Comment in: J Clin Oncol 1996 Dec;14(12):3053–5.

Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. Soni N, et al. **J Clin Oncol** 1997 Feb;15(2):766–72

Pharmacokinetics and pharmacodynamics of 9-cis-retinoic acid in healthy men. Weber C, et al. **J Clin Pharmacol** 1997 Jul;37(7):566–74

Evaluation of the efficiency of targeting of antitumor drugs: simulation analysis based on pharmacokinetic/pharmacodynamic considerations. Nakai D, et al. **J Drug Target** 1996;3(6):443–53

Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. Dedrick RL, et al. **J Natl Cancer Inst** 1997 Apr 2;89(7):480–7 (61 ref.)

Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics [letter; comment] [see comments] Fujiwara Y, et al. **J Natl Cancer Inst** 1997 Feb 5;89(3):260–2. Comment on: J Natl Cancer Inst 1995 Apr 19;87(8):573–80. Comment in: J Natl Cancer Inst 1997 Jul 2;89(13):968–70.

Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics [letter; comment] Minami H, et al. **J Natl Cancer Inst** 1997 Jul 2;89(13):968–70. Comment on: J Natl Cancer Inst 1997 Feb 5;89(3):260–2.

Menadione inhibits MIBG uptake in two neuroendocrine cell lines. Cornelissen J, et al. **J Neurooncol** 1997 Jan; 31(1-2):147–51

A human neuroblastoma xenograft model for 125-I-metaiodobenzylguanidine biodistribution studies. Lavitrano M, et al. **J Neurooncol** 1997 Jan;31(1-2):159–64

Steroids decrease uptake of carboplatin in rat gliomas--uptake improved by intracarotid infusion of bradykinin analog, RMP-7. Matsukado K, et al. **J Neurooncol** 1997 Sep;34(2):131–8

A strategy for selective anti-cancer drug concentration increase in rat glioma tissue with Ca(2+)-channel blocker co-administration: calcium kinetics in intra-glioma arteriolar smooth muscle cells. Zenke K, et al. **J Neurooncol** 1996 Oct;30(1):25–36

Quantification and pharmacokinetics of blood-brain barrier disruption in humans. Zünkeler B, et al. **J Neurosurg** 1996 Dec;85(6):1056–65

Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates. Poon GK, et al. **J Pharm Biomed Anal** 1995 Nov;13(12):1493–8

Terpene penetration enhancers in propylene glycol/water co-solvent systems: effectiveness and mechanism of action. Yamane MA, et al. **J Pharm Pharmacol** 1995 Dec; 47(12A):978–89

Pharmacokinetics of cisplatin and its monohydrated complex in humans. Andersson A, et al. **J Pharm Sci** 1996 Aug; 85(8):824–7

Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244). Vries JD, et al. **J Pharm Sci** 1996 Nov;85(11):1227–33

Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. Koller-Lucae SK, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1572–80

Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice. Reszka R, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):232–7

Role of membrane potential in the accumulation of quaternized ellipticines by human tumor cell lines. Vistica DT, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):1018–25

In vitro and in vivo spectrofluorometry of a water-soluble meta-(tetrahydroxyphenyl)chlorin (m-THPC) derivative. Morlet L, et al. **J Photochem Photobiol B** 1997 Jul; 39(3):249–57

Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma. Didolkar MS, et al. **J Surg Oncol** 1996 Nov;63(3):148–58

Kinetics and sodium independence of [3H]-tiazofurin blood to brain transport in the guinea pig. Redzic ZB, et al. **Methods Find Exp Clin Pharmacol** 1996 Jul-Aug; 18(6):413–8

Secondary ion mass spectrometry (SIMS) microscopy: a new tool for pharmacological studies in humans. Fragu P, et al. **Microsc Res Tech** 1997 Feb 15;36(4):296–300

Complementary advantages of fluorescence and SIMS microscopies in the study of cellular localization of two new antitumor drugs. Guerquin-Kern JL, et al. **Microsc Res Tech** 1997 Feb 15;36(4):287–95

Effect of tumor necrosis factor-alpha on the permeability of bovine brain microvessel endothelial cell monolayers. Anda T, et al. **Neurol Res** 1997 Aug;19(4):369–76

Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Matsukado K, et al. **Neurosurgery** 1996 Jul;39(1):125–33; discussion 133–4

Radiolabeled somatostatin analogs in prostate cancer. Thakur ML, et al. **Nucl Med Biol** 1997 Jan;24(1):105–13

Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. Vaidyanathan G, et al. **Nucl Med Biol** 1996 Aug; 23(6):851–6

9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Papadopoulou MV, et al. **Oncol Res** 1996; 8(10-11):425–34

Effect of bile acids on hepatobiliary transport of cisplatin by perfused rat liver. Villanueva GR, et al. **Pharmacol Toxicol** 1997 Mar;80(3):111–7

Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics. Piscitelli SC, et al. **Pharmacotherapy** 1997 May-Jun;17(3):431–7

Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients. Kaul S, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 13):23–9

Isolated liver perfusion for liver metastases: pharmacokinetic advantage? Ravikumar TS, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):443–9 (22 ref.)

IL-2 perfusion to the liver augments the hepatic extraction rate of accompanying anticancer drugs. Okuno K, et al. **Surg Today** 1996;26(8):662–4

Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Relling MV. **Ther Drug Monit** 1996 Aug;18(4):350–6

Pharmacokinetic monitoring of anticancer drugs at King Faisal Specialist Hospital, Riyadh, Saudi Arabia. el-Yazigi A, et al. **Ther Drug Monit** 1997 Aug;19(4):390–3

Comparative in vitro skin absorption and metabolism of coumarin (1,2-benzopyrone) in human, rat, and mouse. Beckley-Kartey SA, et al. **Toxicol Appl Pharmacol** 1997 Jul;145(1):34–42

[Multidrug-resistance by induction of inactivation for anti-cancer drugs] Ishii I, et al. **Nippon Rinsho** 1997 May; 55(5):1044–9 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Acquisition of resistance associated with impairment of metabolic activation of anticancer drugs] Tashiro T. **Nippon Rinsho** 1997 May;55(5):1038–43 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of the transport of novel nitrosoalkylurea derivative, nitrulline, into tumor and normal cells] Shulepova TS, et al. **Biull Eksp Biol Med** 1996 Dec; 122(12):648–50 **(Rus)**

PHARMACOLOGY

1H-magnetic resonance spectroscopic observation of cultured malignant cells pharmacologically induced to different phenotypes. Nakai T, et al. **Acad Radiol** 1996 Sep; 3(9):742–50

Time and dose dependency of radiation-induced changes in tumor microvascular characteristics using contrast-enhanced magnetic resonance imaging: impact on the delivery of chemotherapeutic agents. Schmidt HC, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S347–8

Topoisomerase II as a target for anticancer chemotherapy. Kaufmann SH, et al. **Acta Biochim Pol** 1995;42(4):381–93 (98 ref.)

Aza and diaza bioisosteric anthracene-9,10-diones as antitumor agents. Krapcho AP, et al. **Acta Biochim Pol** 1995;42(4):427–32 (8 ref.)

Advances with phospholipid signalling as a target for anticancer drug development. Powis G, et al. **Acta Biochim Pol** 1995;42(4):395–403 (51 ref.)

Protein kinase inhibitors--potential chemotherapeutic agents. Shugar D. **Acta Biochim Pol** 1995;42(4):405–18 (50 ref.)

Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis. In vitro and in vivo studies. Gilhar A, et al. **Acta Derm Venereol** 1996 Nov;76(6):437–41

Cyclosporin A down-regulates the LTA4 hydrolase level in human keratinocyte cultures. Iversen L, et al. **Acta Derm Venereol** 1996 Nov;76(6):424–8

Effect on human gamma interferon on mice testis: a quantitative analysis of the spermatogenic cells. Natwar RK, et al. **Acta Eur Fertil** 1995 Jan-Feb;26(1):45–9

Insulin-like growth factors in breast cancer. Helle SI, et al. **Acta Oncol** 1996;35 Suppl 5:19–22 (29 ref.)

A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour. Wood PJ, et al. **Acta Oncol** 1996;35(8):989–94

Human tonsillar lymphocytes as targets for immunosuppressive and anticancer drugs. Staub M, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:124–7

Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies. Konstantinov SM, et al. **Acta Trop** 1997 Apr 15;64(3-4):145–54

The role of thymidylate synthase in cellular regulation. Chu E, et al. **Adv Enzyme Regul** 1996;36:143–63

20-Epi-vitamin D3 analogs. Potent modulators of proliferation and differentiation of breast cancer cell lines in vitro. Elstner E, et al. **Adv Exp Med Biol** 1996;399:53–70

Phosphatidylcholine biosynthesis as a target for phospholipid analogues. Geilen CC, et al. **Adv Exp Med Biol** 1996; 416:333–6

Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine. Kaufmann-Kolle P, et al. **Adv Exp Med Biol** 1996;416:165–8

Influence of hexadecylphosphocholine (miltefosine) on cytokine synthesis and biological responses. Klenner T, et al. **Adv Exp Med Biol** 1996;416:181–7

The pH-dependent channels formed by cauloside C. Likhatskaya GN, et al. **Adv Exp Med Biol** 1996;404:239–49

Protein kinase C inhibition by ET-18-OCH3 and related analogs. A target for cancer chemotherapy. Pauig SB, et al. **Adv Exp Med Biol** 1996;416:173–80 (49 ref.)

Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Beck WT, et al. **Adv Pharmacol** 1994; 29B:145–69 (120 ref.)

Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs. D'Arpa P.

Adv Pharmacol 1994;29B:127–43 (100 ref.)

A bacteriophage model system for studying topoisomerase inhibitors. Kreuzer KN. **Adv Pharmacol** 1994;29B:171–86 (85 ref.)

Chemotherapy-induced apoptosis. Mesner PW Jr, et al. **Adv Pharmacol** 1997;41:461–99 (268 ref.)

Yeast as a genetic model system for studying topoisomerase inhibitors. Nitiss JL. **Adv Pharmacol** 1994;29B:201–26 (90 ref.)

Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Osheroff N, et al. **Adv Pharmacol** 1994;29B:105–26 (130 ref.)

Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Reed JC. **Adv Pharmacol** 1997; 41:501–32 (190 ref.)

The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. Albini A, et al. **AIDS** 1997 May;11(6):713–21

Induction of cytochrome P-450-linked monooxygenase system in rat liver microsomes by xiao-chaihu-tang. Obnishi T, et al. **Am J Chin Med** 1996;24(2):143–51

Enhancement of nitric oxide production from activated macrophages by glycyrrhizin. Yi H, et al. **Am J Chin Med** 1996;24(3–4):271–8

Computerized tomography assessment of women with weight changes associated with adjuvant treatment for breast cancer. Cheney CL, et al. **Am J Clin Nutr** 1997 Jul; 66(1):141–6

Tiazofurin-induced autosecretion of IL-6 and hemoglobin production in K562 human leukemia cells. Talley CJ, et al. **Am J Hematol** 1997 Apr;54(4):301–5

The effect of intermittent-release intraperitoneal chemotherapy on wound healing. Hopkins MP, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):819–23; discussion 823–5

Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer. Sevin BU, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):759–66; discussion 766–8

Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Watanabe M, et al. **Am J Pathol** 1997 May;150(5):1869–80

Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Hutson RG, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1691–9

Dephosphorylation of activated protein kinase C contributes to downregulation by bryostatin. Lee HW, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C304–11

Regulation of the secretory phenotype of human airway epithelium by retinoic acid, triiodothyronine, and extracellular matrix. Yoon JH, et al. **Am J Respir Cell Mol Biol** 1997 Jun;16(6):724–31

Treatment with the anti-tumor drugs, cis-platin and mafosfamide, does not affect the structure of prekinetochores in a human breast cancer cell line. An immunofluorescence study using human anti-centromere autoantibodies. Wolf KW, et al. **Anat Anz** 1996 Oct; 178(5):425–32

Induction of apoptosis in malignant and camptothecin-resistant human cells. Chatterjee D, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:143–56

Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells. Grabowski D, et al. **Ann N Y Acad Sci** 1996 Dec 13; 803:306–7

Pharmacokinetic and pharmacodynamic studies of 9-aminocamptothecin in vitro against human cancer cells. Li M, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:315–7

Using yeast to understand drugs that target topoisomerases. Nitiss JL, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:32–43 (62 ref.)

Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D. Dannecker C, et al. **Ann Oncol** 1996 Apr;7(4):391–5

Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells. Buell JF, et al. **Ann Surg Oncol** 1997 Mar;4(2):141–8

Molecular origins of selectivity in the interaction of amsacrine-4-carboxamide with GC-rich sequences in DNA. Bailly C, et al. **Anticancer Drug Des** 1996 Dec; 11(8):611–24

Targeting c-myc in leukemia. Calabretta B, et al. **Anticancer Drug Des** 1997 Jul;12(5):373–81 (31 ref.)

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Geary RS, et al. **Anticancer Drug Des** 1997 Jul;12(5):383–93 (23 ref.)

Application of combinatorial library methods in cancer research and drug discovery. Lam KS. **Anticancer Drug Des** 1997 Apr;12(3):145–67 (96 ref.)

A cell and mechanism-based approach for the selection of EGF receptor inhibitors. Lanzi C, et al. **Anticancer Drug Des** 1997 Sep;12(6):515–24

Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design. Lerner EC, et al. **Anticancer Drug Des** 1997 Jun;12(4):229–38 (55 ref.)

Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics. McGraw K, et al. **Anticancer Drug Des** 1997 Jul;12(5):315–26 (42 ref.)

The in vitro biological activities of synthetic 18-O-methyl mycalamide B, 10-epi-18-O-methyl mycalamide B and pederin. Richter A, et al. **Anticancer Drug Des** 1997 Apr; 12(3):217–27

Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT). Springer CJ, et al. **Anticancer Drug Des** 1996 Dec; 11(8):625–36

Mode of cytostatic action of mesoionic oxatriazole nitric oxide donors in proliferating human hematopoietic cells. Vilpo JA, et al. **Anticancer Drug Des** 1997 Mar;12(2):75–89

Amido analogs of mitoxantrone: physico-chemical properties, molecular modeling, cellular effects and antineoplastic potential. Zagotto G, et al. **Anticancer Drug Des** 1997 Mar;12(2):99–112

Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells. Asakura T, et al. **Anticancer Drugs** 1997 Feb;8(2):199–203

Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration. Bear HD, et al. **Anticancer Drugs** 1996 May;7(3):299–306

Protein kinase C: a worthwhile target for anticancer drugs? Caponigro F, et al. **Anticancer Drugs** 1997 Jan;8(1):26–33 (70 ref.)

Effects of diallyl sulfide and diallyl disulfide on cisplatin-induced changes in glutathione and glutathione-S-transferase activity. Dwivedi C, et al. **Anticancer Drugs** 1996 Sep;7(7):792–4

The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts. Egelmeers A, et al. **Anticancer Drugs** 1996 Jul; 7(5):586–90

Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Fichtner I, et al. **Anticancer Drugs** 1997 Feb;8(2):174–81

Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activjty of chemotherapeutic agents on neuroblastoma cells in vitro. Fulda S, et al. **Anticancer Drugs** 1997 Jan;8(1):34–41

Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Germann UA, et al. **Anticancer Drugs** 1997 Feb;8(2):125–40

Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Germann UA, et al. **Anticancer Drugs** 1997 Feb;8(2):141–55

Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs. Gornati D, et al. **Anticancer Drugs** 1997 Jun;8(5):509–16

Liarozole amplifies retinoid-induced apoptosis in human prostate cancer cells. Hall AK. **Anticancer Drugs** 1996 May; 7(3):312–20

The development of new chemotherapeutic agents. Hanauske AR. **Anticancer Drugs** 1996 Aug;7 Suppl 2:29–32 (39 ref.)

Assay of anticancer drugs in tissue culture: comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma. Haselsberger K, et al. **Anticancer Drugs** 1996 May; 7(3):331–8

The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Hasinoff BB, et al. **Anticancer Drugs** 1996 Jul;7(5):558–67

The effect of ethyldeshydroxy-sparsomycin and cisplatin on the intracellular glutathione level and glutathione S-transferase activity. Hofs HP, et al. **Anticancer Drugs** 1997 Apr;8(4):349–57

An orally active antitumor cyclohexanediamine-Pt(IV) complex: trans,cis,cis-bis(n-valerato)(oxalato)(1R,2R-cyclohexane diamine)Pt(IV). Kizu R, et al. **Anticancer Drugs** 1996 May; 7(3):248–56

A new synthetic lipid A analog, ONO-4007, stimulates the production of tumor necrosis factor-alpha in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells. Kuramitsu Y, et al. **Anticancer Drugs** 1997 Jun;8(5):500–8

Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines. Maki A, et al. **Anticancer Drugs** 1996 May; 7(3):344–50

Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Masanek U, et al. **Anticancer Drugs** 1997 Feb;8(2):189–98

Effect of S9788 on the efficiency of doxorubicin in vivo and in vitro in medullary thyroid carcinoma xenograft. Massart C, et al. **Anticancer Drugs** 1996 May;7(3):321–30

Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Mehta K, et al. **Anticancer Drugs** 1997 Jun;8(5):470–81

Enhanced immunostimulation by novel platinum anticancer agents. Muenchen HJ, et al. **Anticancer Drugs** 1997 Apr; 8(4):323–8

Cisplatin-induced changes in biological activity of blood platelets: thiol-related mechanisms. Olas B, et al. **Anticancer Drugs** 1996 Jun;7(4):476–82

In situ stimulation of topoisomerase II-induced cleavage sites in the c-myc protooncogene by antitumor agent pMC540 is associated with gene expression. Sharma R, et al. **Anticancer Drugs** 1996 May;7(3):293–8

Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Strumberg D, et al. **Anticancer Drugs** 1996 Jun;7(4):415–21

Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Tiberghien F, et al. **Anticancer Drugs** 1996 Jul;7(5):568–78

Terminally L-modified oligonucleotides: pairing, stability and biological properties. Tondelli L, et al. **Anticancer Drugs** 1996 Feb;7(2):189–94

The additive antiproliferative effect of all-trans retinoic acid and interferon-alpha2a on human cervical carcinoma cell lines is not associated with increased expression of retinoid receptors. Wahlberg P, et al. **Anticancer Drugs** 1997 Jun; 8(5):522–8

Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Watanabe T, et al. **Anticancer Drugs** 1996 Nov;7(8):825–32

Growth inhibition of cultured human leukemia cells by 3-aminothymidine and its analogue. Asano S, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):823–6

Antitumor activity and nephrotoxicity of a novel platinum complex, [1,3-bis(diphenylphosphino)propane](trans-1-dach) platinum(I I) dinitrate. Baek MS, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):955–9

In vitro effect of Pt and Pd mercaptopyridine complexes. Carrara M, et al. **Anticancer Res** 1997 Mar-Apr; 17(2A):975–80

Inhibition of N-methyl-N-nitrosourea-induced mammary tumors in rats by the soybean isoflavones. Constantinou AI, et al. **Anticancer Res** 1996 Nov-Dec;16(6A):3293–8

Hyperbaric oxygen enhances the effects of meta-iodobenzylguanidine (MIBG) on energy metabolism and lipid peroxidation in the human neuroblastoma cell line SK-N-BE(2C). Cornelissen J, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):259–64

Specification of the inhibitory action of MIBG on the respiratory chain by EPR scanning. Cornelissen J, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):265–8

Effects of microtubule inhibitors-taxol, vinblastine and estramustine on the growth and p53 gene expression in the hormone independent human prostatic JCA-1 cells. Darby E, et al. **Anticancer Res** 1996 Nov-Dec; 16(6B):3647–52

Expression of proteins correlated with the unique cisplatin-sensitivity of testicular cancer. de Graaf TW, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):369–75

The search for novel anticancer agents: a differentiation-based assay and analysis of a folklore product. Dinnen RD, et al. **Anticancer Res** 1997 Mar-Apr; 17(2A):1027–33

Activity of a mycobacterial antineoplastic glycan against human breast cancer. Donmez C, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):445–50

Enhancement of radiation response of prostatic carcinoma by lonidamine. Dudak SD, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3665–71

Reduced tissue ornithine increases the cytotoxicity of difluoromethylornithine. Grossie VB Jr, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3731–5

The cytotoxicity of adenosine 5'-[N,N-di-(gamma-o-carboranyl)propyl] phosphorodiamidate in human Tmolt3 leukemic cells. Hall IH, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):151–6

The cytotoxicity of 1-(phenylmethyl)-4,7,10-tris-[(4'methylphenyl) sulfonyl]-1,4,7,10-tetraazacyclododecane in human Tmolt3 T leukemic cells. Hall IH, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):1195–8

1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Higashimoto Y, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2653–9

Suppression of vincristine-mediated cytotoxic activity by mitoxantrone in human cell lines. Ho CK, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2645–51

Anticancer activities of 2,5,8,9-substituted 6-oxo-1,2,3,4,5,6-hexahydrophenanthridines on multi-drug-resistant phenotype cells. Hua DH, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2435–41

Cytotoxic properties of a phosphoglycoconjugated derivative of 7 beta-hydroxycholesterol upon normal and tumor cells in culture. Hyun JW, et al. **Anticancer Res** 1997 Jul-Aug; 17(4A):2621–6

Effects of verapamil and S9788 on MDR-1 mRNA expression studied by in situ hybridization. Joly P, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3609–14

Characterization of human erythrocyte membrane-bound acetylcholinesterase inhibition by cisplatin at reversible phase. Kamal MA. **Anticancer Res** 1996 Nov-Dec; 16(6B):3725–30

Mechanism of interferon action: in vivo activation of 91 kDa transcription factor. Korutla L, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2789–95

Cholesterol based antineoplastic strategies. Lenz M, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):1143–6

Antitumor effect of 2,6-di(2,3-epoxypropoxy)xanthone on tumor cell lines. Liu HS, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):1107–14

Effect of dehydrodidemnin B on human colon carcinoma

cell lines. Lobo C, et al. **Anticancer Res** 1997 Jan-Feb; 17(1A):333-6

Wool grease-derived alpha-monohydric fatty alcohols are carcinostatic depending on their branched alkyl moiety bulkiness. Miwa N, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2479-84

Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives. Moebus VJ, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):815-21

Effects of methylglyoxal bis (cyclopentylamidinohydrazone) (MGBCP) on cell cycle progression in three human osteosarcoma cell lines. Mori K, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2565-7

Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Nakamura S, et al. **Anticancer Res** 1997 Jan-Feb; 17(1A):173-9

Flat revertant inducers, styryl diphenylamine derivatives, inhibit growth and metastasis of murine tumor cells in vivo. Ohizumi I, et al. **Anticancer Res** 1997 Jan-Feb; 17(1A):393-400

Molecular mechanisms in the antiproliferative action of taxol and tiazofurin. Olah E, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2469-77

Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides. Olbina G, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3525-30

Antineoplastic and cytogenetic effects of complexes of Pd (II) with 4N-substituted derivatives of 2-acetyl-pyridine-thiosemicarbazone. Papageorgiou A, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):247-51

The effect of 5,6-dimethylxanthenone-4-acetic acid on tumour necrosis factor production by human immune cells. Patel S, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):141-50

Relationship between ascorbyl radical intensity and apoptosis-inducing activity. Sakagami H, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2635-44

Effect of ascorbate oxidase on radical intensity and cytotoxic activity of ascorbate. Sakagami H, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):1163-6

Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines. Santibáñez JF, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):1199-204

Paracetamol counteracts docosahexaenoic acid-induced growth inhibition of A-427 lung carcinoma cells and enhances tumor cell proliferation in vitro. Schønberg SA, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2443-8

Cytotoxic effect of sodium nitroprusside on cancer cells: involvement of apoptosis and suppression of c-myc and c-myb proto-oncogene expression. Sumitani K, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):865-71

Ca2+ mobilization during cell death induction by sodium 5, 6-benzylidene-L-ascorbate. Takahashi H, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2629-34

The antitumor effect of Tiazofurin (TR) consists of anti-proliferative and anti-invasive elements. Tóvári J, et al. **Anticancer Res** 1996 Nov-Dec;16(6A):3307-12

Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents. Villa R, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):961-8

Actions of lectins from the mushroom Tricholoma mongolicum on macrophages, splenocytes and life-span in sarcoma-bearing mice. Wang HX, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):419-24

L-histidinol reverses resistance to cisplatinum and other antineoplastics in a tumorigenic epithelial cell line. Warrington RC, et al. **Anticancer Res** 1996 Nov-Dec; 16(6B):3641-6

Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors. Watts ME, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):71-5

Effects in vitro of pachymatismin, a glycoprotein from the marine sponge Pachymatisma johnstonii, on a non-small-cell bronchopulmonary carcinoma line (NSCLC-N6). Zidane M, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2805-12

Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine. Rahn JJ, et al. **Antimicrob Agents Chemother** 1997 May;41(5):918-23

Antisense-protein kinase A: a single-gene-based therapeutic approach. Cho-Chung YS, et al. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):217-23 (20 ref.)

Protein kinase C as a target for cancer therapy. Glazer RI. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):235-8

Antisense oligonucleotides to p53 tumor suppressor suppress the induction of apoptosis by epidermal growth factor in NCI-H 596 human lung cancer cells. Murayama Y, et al. **Antisense Nucleic Acid Drug Dev** 1997 Apr;7(2):109-14

Retinoic acids and dexamethasone alter cell-surface density of beta 2-integrins and ICAM-1 on human leukemic (HMC-1) mast cells. Babina M, et al. **Arch Dermatol Res** 1997 Jan;289(2):111-5

Differential apoptotic pattern induced by photodynamic therapy and cisplatin in human squamous cell carcinoma cell line. Matsumoto Y, et al. **Arch Dermatol Res** 1996 Dec; 289(1):52-4

Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma. Shternfeld IS, et al. **Arch Ophthalmol** 1996 Nov;114(11):1396-401

Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 2: Ring-substituted derivatives. Aitken RA, et al. **Arch Pharm (Weinheim)** 1997 Jul;330(7):215-24

From chloroquine to antineoplastic drugs? the story of antibacterial quinolones. Rádl S. **Arch Pharm (Weinheim)** 1996 Mar;329(3):115-9 (31 ref.)

Pharmacokinetic behaviour and cardiovascular effects of intravenously administered hypoxoside and rooperol. Coetzee JF, et al. **Arzneimittelforschung** 1996 Oct; 46(10):997-1000

Electron-topological investigation of the structure-antitumor activity relationship of thiosemicarbazone derivatives. Dimoglo AS, et al. **Arzneimittelforschung** 1997 Apr; 47(4):415-9

Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Efferth T, et al. **Arzneimittelforschung** 1996 Feb;46(2):196-200

Antitumor activity of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on murine and human tumor models. Ikegami Y, et al. **Arzneimittelforschung** 1995 Nov;45(11):1225-30

Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions. Ozturan O, et al. **Auris Nasus Larynx** 1996;23:147-51

Deficient apoptotic process in cisplatin-resistant L1210 cells cannot account for the cellular response to various drug treatments. Canitrot Y, et al. **Biochem Biophys Res Commun** 1997 May 29;234(3):573-7

Activation of the p21(Waf1/Cip1) promoter by the ets oncogene family transcription factor E1AF. Funaoka K, et al. **Biochem Biophys Res Commun** 1997 Jul 9;236(1):79-82

Flavone acetic acid stimulates nitric oxide and peroxynitrite production in subcutaneous mouse tumors. Harris SR, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):509-14

Inhibitors of Ras farnesylation revert the increased resistance to oxidative stress in K-Ras transformed NIH 3T3 cells. Santillo M, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):739-45

DNA topoisomerase II as the cellular target of a novel antitumor agent ICRF-193, a bisdioxopiperazine derivative, in Xenopus egg extract. Sato M, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):571-5

Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Tamura T, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):21-6

Proximal 5'-flanking sequence of the human gamma-glutamylcysteine synthetase heavy subunit gene is involved in cisplatin-induced transcriptional up-regulation in a lung cancer cell line SBC-3. Tomonari A, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):616-21

Inhibition of DNA unwinding and ATPase activities of human DNA helicase II by chemotherapeutic agents. Tuteja N, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):636-40

Suppression of tumor growth with recombinant murine angiostatin. Wu Z, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):651-4

Enhancement of DNA repair activity in rat-liver cells exposed to cisplatin. Hibino Y, et al. **Biochem Mol Biol Int** 1996 Apr;38(5):973-9

Investigation of the effect of anti-neoplastic drugs, cyclophosphamide, cisplatin and methotrexate on the turnover kinetics of human erythrocyte acetylcholinesterase. Kamal MA, et al. **Biochem Mol Biol Int** 1996 May;39(2):293-302

Inhibition of DNA primase by sphingosine and its analogues parallels with their growth suppression of cultured human leukemic cells. Tamiya-Koizumi K, et al. **Biochem Mol Biol Int** 1997 May;41(6):1179-89

Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. Beltran PJ, et al. **Biochem Pharmacol** 1997 Jan 24;53(2):245-7

Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine. Berkovic D, et al. **Biochem Pharmacol** 1997 Jun 1;53(11):1725-33

Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones. de Isabella P, et al. **Biochem Pharmacol** 1997 Jan 24; 53(2):161-9

Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy. Dong Y, et al. **Biochem Pharmacol** 1997 Jun 1;53(11):1673-82

Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Duncan KL, et al. **Biochem Pharmacol** 1996 Nov 22;52(10):1553-60

Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Elwell JH, et al. **Biochem Pharmacol** 1997 Jul 15; 54(2):249-57

Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras. Fan J, et al. **Biochem Pharmacol** 1997 Apr 25;53(8):1203-9

Effects of nucleosomes and anti-tumor drugs on the catalytic activity of type II DNA topoisomerase from rat testis. Galande S, et al. **Biochem Pharmacol** 1997 May 9; 53(9):1229-38

Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation. Kawamura K, et al. **Biochem Pharmacol** 1996 Dec 24;52(12):1903-9

DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Köberle B, et al. **Biochem Pharmacol** 1996 Dec 13;52(11):1729-34

The antiproliferative effect of 8-chloro-adenosine, an active metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell cycle kinetics. Langeveld CH, et al. **Biochem Pharmacol** 1997 Jan 24;53(2):141-8

Chemical synthesis and biological activity of a novel fluorescent etoposide derivative. Lazo JS, et al. **Biochem Pharmacol** 1997 Mar 7;53(5):715-22

Transforming growth factor-beta3 protection of epithelial cells from cycle-selective chemotherapy in vitro. McCormack ES, et al. **Biochem Pharmacol** 1997 Apr 25; 53(8):1149-59

Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta. Marsh KL, et al. **Biochem Pharmacol** 1996 Dec 13; 52(11):1675-85

Cell kill kinetics of an antineoplastic nucleoside, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl) cytosine. Ono T, et al. **Biochem Pharmacol** 1996 Oct 25; 52(8):1279-85

Effect of penclomedine (NSC-338720) on telomere fusions, chromatin blebbing, and cell viability with and without telomerase activity and abrogated p53 function. Pandita TK, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):409-15

Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Parsons PG, et al. **Biochem Pharmacol** 1997 Jun 1;53(11):1719-24

Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Ren Z, et al. **Biochem Pharmacol** 1997 Jul 1; 54(1):113-20

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Rixe O, et al. **Biochem Pharmacol** 1996 Dec 24; 52(12):1855-65

Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone. Schrenk D, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1453-60

Effects of bifunctional netropsin-related minor groove-binding ligands on mammalian type I DNA topoisomerase. Wang Z, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):309-16

Comet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells [published erratum appears in Biochem Pharmacol 1997 Jun 15;53(12):1946] Ward TH, et al. **Biochem Pharmacol** 1997 Apr 25; 53(8):1115-21

Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein. Weiss G, et al. **Biochem Pharmacol** 1997 May 15;53(10):1419-24

Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics. Koblan KS, et al. **Biochem Soc Trans** 1996 Aug;24(3):688-92 (26 ref.)

IL-1 gene expression in human mammary tumour xenografts after treatment with hexadecylphosphocholine. Safa O, et al. **Biochem Soc Trans** 1997 May;25(2):265S

Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs. Sebti SM, et al. **Biochem Soc Trans** 1996 Aug;24(3):692-9 (45 ref.)

Inhibitory effects of platinum anticancer agents on rat brain protein kinase C. Sharma P, et al. **Biochem Soc Trans** 1997 Feb;25(1):73S

The dihydropyridine dexniguldipine hydrochloride inhibits cleavage and religation reactions of eukaryotic DNA topoisomerase I. Straub T, et al. **Biochemistry** 1997 Sep 2;36(35):10777-83

Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Cox AD, et al. **Biochim Biophys Acta** 1997 Aug 8;1333(1):F51-71 (139 ref.)

The antineoplastic drug lonidamine interferes with the acidification mechanism of cell organelles. Dell'Antone P, et al. **Biochim Biophys Acta** 1997 Aug 21;1358(1):46-52

4-Amidinoindan-1-one 2'-amidinohydrazone (CGP 48664A) exerts in vitro growth inhibitory effects that are not only related to S-adenosylmethionine decarboxylase (SAMdc) inhibition. Dorhout B, et al. **Biochim Biophys Acta** 1997 Apr 17;1335(1-2):144-52

Impermeant antitumor sulfonylurea conjugates that inhibit plasma membrane NADH oxidase and growth of HeLa cells in culture. Identification of binding proteins from sera of cancer patients. Kim C, et al. **Biochim Biophys Acta** 1997 Mar 13;1324(2):171-81

Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Kuo ML, et al. **Biochim Biophys Acta** 1996 Nov 15;1317(2):95-100

A protein disulfide-thiol interchange activity of HeLa plasma

membranes inhibited by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) Morré DJ, et al. **Biochim Biophys Acta** 1997 Apr 3;1325(1):117-25

Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Alakhov VYu, et al. **Bioconjug Chem** 1996 Mar-Apr;7(2):209-16

The antitumor agent cisplatin inhibits DNA gyrase and preferentially induces gyrB gene expression in Escherichia coli. Neumann S, et al. **Biol Chem** 1996 Nov;377(11):731-9

Anti-tumor effects of orally administered soft-shelled turtle powder in mice. Feng H, et al. **Biol Pharm Bull** 1996 Mar; 19(3):367-8

Inhibition of tumor cell invasion and matrix degradation by aminopeptidase inhibitors. Fujii H, et al. **Biol Pharm Bull** 1996 Jan;19(1):6-10

Selective antitumor activity in vitro from marine algae from Japan coasts. Harada H, et al. **Biol Pharm Bull** 1997 May; 20(5):541-6

In vitro and in vivo antitumor activity of a novel nucleoside, 4'-thio-2'-deoxy-2'-methylidenecytidine. Miura S, et al. **Biol Pharm Bull** 1996 Oct;19(10):1311-5

Effect of cisplatin on the disposition of endogenous serotonin and its main metabolite, 5-hydroxyindole-3-acetic acid, in rats and dogs. Nakajima Y, et al. **Biol Pharm Bull** 1996 Feb;19(2):318-22

Cytotoxic activities of solanum steroidal glycosides. Nakamura T, et al. **Biol Pharm Bull** 1996 Apr;19(4):564-6

A new method for permeabilization of the plasma membrane of cultured mammalian cells. VII. Permeabilization of growing and resting cells by vortex-stirring with high molecular weight polyacrylic acid. Noda Y, et al. **Biol Pharm Bull** 1996 Dec;19(12):1565-9

Effects of antitumor activity and protection of shock symptoms by a traditional Chinese medicine (sho-saiko-to) in recombinant human tumor necrosis factor administered mice. Sakaguchi S, et al. **Biol Pharm Bull** 1996 Nov; 19(11):1474-8

Cytotoxicity of fluoroethylating agents is potentiated by O6-benzylguanine. Terashima I, et al. **Biol Pharm Bull** 1996 Jul;19(7):956-61

In vitro cytotoxicity of imidazolyl-1,3,5-triazine derivatives. Yaguchi S, et al. **Biol Pharm Bull** 1997 Jun;20(6):698-700

Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Makhey D, et al. **Bioorg Med Chem** 1996 Jun;4(6):781-91

Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation. Mallams AK, et al. **Bioorg Med Chem** 1997 Jan;5(1):93-9

Antitumor activity studies of newly synthesized N-salicyloyl-N'-(p-hydroxybenzthioyl)hydrazine and its copper(II) complex both in vivo and in vitro. Singh NK, et al. **Bioorg Med Chem** 1997 Feb;5(2):245-51

Selectivity of F8-actinomycin D for RNA:DNA hybrids and its anti-leukemia activity. Takusagawa F, et al. **Bioorg Med Chem** 1997 Jun;5(6):1197-207

Antiviral and tumor cell antiproliferative SAR studies on tetracyclic eudistomins. II. van Maarseveen JH, et al. **Bioorg Med Chem** 1997 May;5(5):955-70

Farnesyltransferase as a target for anticancer drug design. Qian Y, et al. **Biopolymers** 1997;43(1):25-41 (122 ref.)

Interferons and the tumor cell. Strander H, et al. **Biotherapy** 1996;8(3-4):213-8 (54 ref.)

Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Banker DE, et al. **Blood** 1997 Jan 1;89(1):243-55

The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression. Bosco MC, et al. **Blood** 1997 May 1;89(9):3402-11

N-acetyl-L-cysteine exhibits antitumoral activity by increasing tumor necrosis factor alpha-dependent T-cell cytotoxicity. Delneste Y, et al. **Blood** 1997 Aug 1; 90(3):1124-32

CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Drénou B, et al. **Blood** 1997 Apr 15;89(8):2966-74

Role of nitric oxide in the anti-tumoral effect of retinoic acid and 1,25-dihydroxyvitamin D3 on human promonocytic leukemic cells. Dugas N, et al. **Blood** 1996 Nov 1;88(9):3528-34

Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Eischen CM, et al. **Blood** 1997 Aug 1;90(3):935-43

In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Hongo T, et al. **Blood** 1997 Apr 15;89(8):2959-65

Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Kaufmann SH, et al. **Blood** 1997 Mar 15;89(6):2098-104

The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Richardson DR, et al. **Blood** 1997 Apr 15;89(8):3025-38

A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Shao W, et al. **Blood** 1997 Jun 15;89(12):4282-9

Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Simonian PL, et al. **Blood** 1997 Aug 1;90(3):1208-16

Circulating immature cell counts on the harvest day predict the yields of CD34+ cells collected after granulocyte colony-stimulating factor plus chemotherapy-induced mobilization of peripheral blood stem cell [letter] Teshima T, et al. **Blood** 1997 Jun 15;89(12):4660-1

Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Urashima M, et al. **Blood** 1997 Jul 1;90(1):279-89

DNA interaction and electrochemical properties of bis-1-aminomethylnaphthalenes and related compounds. A correlation with their antineoplastic activity. Bruno AM, et al. **Boll Chim Farm** 1996 Jun;135(6):374-7

The alkyl-lysophospholipid, ET-18-OCH3 synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells [published erratum appears in Bone Marrow Transplant 1997 Jul;20(1):95] Yamazaki T, et al. **Bone Marrow Transplant** 1997 Jan;19(2):113-9

The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Armour A, et al. **Br J Cancer** 1997;75(4):470-6

DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase. Beith J, et al. **Br J Cancer** 1997;75(4):500-5

Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP. Bosanquet AG, et al. **Br J Cancer** 1997; 76(4):511-8

Retinoid metabolism and all-trans retinoic acid-induced growth inhibition in head and neck squamous cell carcinoma cell lines. Braakhuis BJ, et al. **Br J Cancer** 1997; 76(2):189-97

Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase. Butler SA, et al. **Br J Cancer** 1997;76(4):438-44

All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity. Chao TY, et al. **Br J Cancer** 1997;75(9):1284-90

Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells. Courage C, et al. **Br J Cancer** 1996 Oct;74(8):1199-205

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors. Davies SL, et al. **Br J Cancer** 1997;75(6):816-21

DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. De Feudis P, et al. **Br J Cancer** 1997;76(4):474-9

Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. Dewhurst LO, et al. **Br J Cancer** 1997; 75(6):860-8

Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Dhar S, et al. **Br J Cancer** 1996 Sep;74(6):888-96

Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Ghielmini M, et al. **Br J Cancer** 1997;75(6):878-83

Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440). Hofmann J, et al. **Br J Cancer** 1997; 76(7):862-9

Mechanism of the anti-tumour effect of 2,3,5-trimethyl-6-(3-pyridylmethyl) 1,4-benzoquinone (CV-6504). Hussey HJ, et al. **Br J Cancer** 1997;75(6):845-9

Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro. Jean-Claude BJ, et al. **Br J Cancer** 1997;76(4):467-73

Modulation of sensitivity to cis-diamminedichloroplatinum (II) by thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines. Kasahara K, et al. **Br J Cancer** 1996 Nov;74(10):1553-8

Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Kato Y, et al. **Br J Cancer** 1997;75(4):506-11

Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Kawa S, et al. **Br J Cancer** 1997;76(7):884-9

Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro. Lai PB, et al. **Br J Cancer** 1996 Nov;74(9):1375-83

Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation. Lamb J, et al. **Br J Cancer** 1996 Nov;74(9):1359-68

In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. McLeod HL, et al. **Br J Cancer** 1996 Dec;74(11):1714-8

Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice. Okutomi T, et al. **Br J Cancer** 1997;75(11):1613-6

Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex. O'Neill CF, et al. **Br J Cancer** 1996 Oct; 74(7):1037-45

The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study. Ormerod MG, et al. **Br J Cancer** 1996 Dec;74(12):1935-43

Inhibition of growth and induction of differentiation of metastatic melanoma cells in vitro by genistein: chemosensitivity is regulated by cellular p53. Rauth S, et al. **Br J Cancer** 1997;75(11):1559-66

Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours. Sargent JM, et al. **Br J Cancer** 1996 Dec;74(11):1730-3

Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor. Schmidt M, et al. **Br J Cancer** 1997;75(11):1575-84

Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Stein U, et al. **Br J Cancer** 1996 Nov; 74(9):1384-91

Cell-matrix interactions of normal and transformed human keratinocytes in vitro are modulated by the synthetic phospholipid analogue hexadecylphosphocholine. Schön M, et al. **Br J Dermatol** 1996 Nov;135(5):696-703

Dissociation of the effects of the antitumour ether lipid ET-18-OCH3 on cytosolic calcium and on apoptosis. Alonso MT, et al. **Br J Pharmacol** 1997 Aug;121(7):1364-8

Anti-insulin-like growth factor-I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines. de Cupis A, et al. **Br J Pharmacol** 1997 Feb;120(3):537-43

Future directions in the pharmacology of anti-cancer agents in children. Pearson AD. **Br Med Bull** 1996 Oct; 52(4):844-72 (95 ref.)

Effects of ether lipid 1-O-octadecyl-2-methoxy-rac-glycero-3-phosphocholine and its analogs PAF and CPAF on the release of nitric oxide in primary cultures of rat astrocytes. Cardile V, et al. **Brain Res** 1996 Apr 9;715(1-2):98-103

All-trans retinoic acid affects the expression of orphan receptors COUP-TF I and COUP-TF II in the developing neural tube. Brubaker K, et al. **Brain Res Dev Brain Res** 1996 May 31;93(1-2):198-202

Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Alonso DF, et al. **Breast Cancer Res Treat** 1996;40(3):209-23

CeReS-18, a novel cell surface sialoglycopeptide, induces cell cycle arrest and apoptosis in a calcium-sensitive manner. Betz NA, et al. **Breast Cancer Res Treat** 1997 Jan; 42(2):137-48

Anti-invasion drugs. Dickson RB, et al. **Breast Cancer Res Treat** 1996;38(1):121-32 (126 ref.)

Farnesyltransferase inhibitors and anti-Ras therapy. Gibbs JB, et al. **Breast Cancer Res Treat** 1996;38(1):75-83 (29 ref.)

Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay. Kurbacher CM, et al. **Breast Cancer Res Treat** 1996; 41(2):161-70

Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Simboli-Campbell M, et al. **Breast Cancer Res Treat** 1997 Jan;42(1):31-41

Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Small W Jr, et al. **Breast Cancer Res Treat** 1997 Jul;44(3):217-24

Structure-activity relations of S-adenosylmethionine decarboxylase inhibitors on the growth of MCF-7 breast cancer cells. Thomas T, et al. **Breast Cancer Res Treat** 1996;39(3):293-306

Comparison of action of the anti-neoplastic drug lonidamine on drug-sensitive and drug-resistant human breast cancer cells: 31P and 13C nuclear magnetic resonance studies. Vivi A, et al. **Breast Cancer Res Treat** 1997 Mar;43(1):15-25

Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Wakeling AE, et al. **Breast Cancer Res Treat** 1996;38(1):67-73 (25 ref.)

Cytotoxicity to tumors by alpha, beta-dihydric long-chain fatty alcohols isolated from esterolysates of uncytotoxic sheep cutaneous wax: the dependence on the molecular hydrophobicity balance of N- or iso-alkyl moiety bulkiness and two hydroxyl groups. Miwa N, et al. **Cancer Biochem Biophys** 1997 Jun;15(4):221-33

In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Alberts DS, et al. **Cancer Chemother Pharmacol** 1997; 39(6):493-7

In vitro antitumor activity of 3'-desamino-3'(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds. Alvino E, et al. **Cancer Chemother Pharmacol** 1997;40(2):180-4

Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Anderson HJ, et al. **Cancer Chemother Pharmacol** 1997;39(3):223-6

A comparison of a CB17 scid mouse model and the tetrazolium-dye assay using human haematological tumour cell lines. Cattan AR, et al.

Cancer Chemother Pharmacol 1996;38(6):548–52

DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Delmastro DA, et al. **Cancer Chemother Pharmacol** 1997;39(3):245–53

Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Dorie MJ, et al. **Cancer Chemother Pharmacol** 1997;39(4):361–6

In vivo antitumor activity of S 16020-2, a new olivacine derivative. Guilbaud N, et al.
Cancer Chemother Pharmacol 1996;38(6):513–21

Cisplatin-induced inhibition of the calcium–calmodulin complex, neuronal nitric oxide synthase activation and their role in stomach distention. Jarve RK, et al.
Cancer Chemother Pharmacol 1997;39(4):341–8

Effects of the polyamine analogues BE-4-4-4-4, BE-3-7-3, and BE-3-3-3 on the proliferation of three prostate cancer cell lines. Jeffers L, et al. **Cancer Chemother Pharmacol** 1997;40(2):172–9

New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Kitamura K, et al.
Cancer Chemother Pharmacol 1997;40 Suppl:S36–41

In vitro studies of the hyperthermic enhancement of activated ifosfamide (4-hydroperoxy-ifosfamide) and glucose isophosphoramide mustard. Kutz ME, et al.
Cancer Chemother Pharmacol 1997;40(2):167–71

Digitonin enhances the efficacy of carboplatin in liver tumour after intra-arterial administration. Lindnér PG, et al.
Cancer Chemother Pharmacol 1997;40(5):444–8

New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Naito M, et al.
Cancer Chemother Pharmacol 1997;40 Suppl:S20–4

A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene. Narasaki F, et al. **Cancer Chemother Pharmacol** 1997; 40(5):425–32

Establishment of a cisplatin-resistant gastric carcinoma cell line OCUM-2M/DDP. Nitta A, et al.
Cancer Chemother Pharmacol 1997;40(1):94–7

A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11. Onishi Y, et al.
Cancer Chemother Pharmacol 1997;39(6):473–8

Human tumor models in the severe combined immune deficient (scid) mouse. Paine-Murrieta GD, et al.
Cancer Chemother Pharmacol 1997;40(3):209–14

Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line. Pendyala L, et al. **Cancer Chemother Pharmacol** 1997;40(1):38–44

Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells. Poulain L, et al.
Cancer Chemother Pharmacol 1997;40(5):385–90

Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics. Rekha GK, et al. **Cancer Chemother Pharmacol** 1997; 40(3):215–24

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Sikic BI, et al.
Cancer Chemother Pharmacol 1997;40 Suppl:S13–9 (67 ref.)

Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells. Tolomeo M, et al.
Cancer Chemother Pharmacol 1996;39(1-2):157–61

Chemical characterization and comparative cellular effects of meta-iodobenzyl guanidine and benzyl guanidine. Van den Berg JD, et al. **Cancer Chemother Pharmacol** 1997; 40(2):131–7

Overexpression of thioredoxin does not confer resistance to cisplatin in transfected human ovarian and colon cancer cell lines. Yamada M, et al.
Cancer Chemother Pharmacol 1997;40(1):31–7

Antiblastic chemotherapy drugs up-modulate interferon-gamma receptor expression on human malignant T cells. Novelli F, et al. **Cancer Detect Prev** 1997; 21(2):191–5

Human retinoblastoma: in vitro differentiation and immunoglobulin superfamily antigen modulation by retinoic acid. Conway RM, et al.
Cancer Immunol Immunother 1997 Jun;44(4):189–96

Markedly induced asialoGM1+CD8+ T cell production and enhancement of antimetastatic activity by interferon beta with folic or folinic acid. Iigo M, et al.
Cancer Immunol Immunother 1997 Apr;44(2):65–9

The neutrophil as an information transmitter in tumor inhibition by a streptococcal biological response modifier, OK-432. Sato T, et al. **Cancer Immunol Immunother** 1996 Oct;43(2):77–86

Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: enhancement with interferon gamma. Takamuku K, et al.
Cancer Immunol Immunother 1996 Dec;43(4):220–5

Perspective: the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Martin DS, et al. **Cancer Invest** 1997; 15(4):372–81 (97 ref.)

Induction of iNOS mRNA by interferon-gamma in epithelial cells is associated with growth arrest and differentiation. Arany I, et al. **Cancer Lett** 1996 Dec 20;110(1-2):93–6

Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanism. Ercoli A, et al.
Cancer Lett 1996 Nov 12;108(1):7–14

Polyamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B. Gómez-Fabre PM, et al.
Cancer Lett 1997 Feb 26;113(1-2):141–4

H-ras transfection of the rat kidney cell line NRK-52E results in increased induction of c-fos, c-jun and hsp70 following sulofenur treatment. Gu H, et al. **Cancer Lett** 1996 Sep 10;106(2):199–205

Effects of green tea catechins on the progression or late promotion stage of mammary gland carcinogenesis in female Sprague-Dawley rats pretreated with 7,12-dimethylbenz(a)anthracene. Hirose M, et al.
Cancer Lett 1997 Jan 30;112(2):141–7

Synergistic effects of tamoxifen and cepharanthine for circumventing the multidrug resistance. Hotta T, et al.
Cancer Lett 1996 Oct 1;107(1):117–23

Nicotinamide-induced modification of hepatic MFO systems in tumour-bearing rats, treated with anti-cancer drugs. Kamat JP. **Cancer Lett** 1996 Dec 3;109(1-2):85–90

Apoptosis induced by retinoic acid in Hep 3B cells in vitro. Kim DG, et al. **Cancer Lett** 1996 Oct 1;107(1):149–59

Topical tretinoin enhances corticosteroid-induced inhibition of tumorigenesis in hairless mice previously exposed to solar simulating radiation. Kligman LH, et al.
Cancer Lett 1996 Oct 22;107(2):217–22

Effect of antiproliferative flavonoids on ascorbic acid accumulation in human colon adenocarcinoma cells. Kuo SM, et al. **Cancer Lett** 1997 Jun 24;116(2):131–7

Suppression of heat-induced hsp72 accumulation by cisplatin in human glioblastoma cells. Matsumoto H, et al.
Cancer Lett 1996 Dec 20;110(1-2):253–7

In vivo cisplatin resistance of rat ascites hepatoma AH66. Minamino T, et al. **Cancer Lett** 1996 Nov 29;108(2):153–6

Retinoic acid and N-(4-hydroxy-phenyl) retinamide suppress growth of esophageal squamous carcinoma cell lines. Muller A, et al. **Cancer Lett** 1997 Feb 26;113(1-2):95–101

Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts. Ohwada S, et al.
Cancer Lett 1996 Dec 20;110(1-2):149–54

Sulindac sulfide inhibits the proliferation of colon cancer cells: diminished expression of the proliferation markers PCNA and Ki-67. Qiao L, et al. **Cancer Lett** 1997 May 19;115(2):229–34

Emergence of osteoblast-like cells in a neoplastic human salivary cancer cell line after treatment with 22-oxa-1alpha, 25-dihydroxyvitamin D3. Sato M, et al.
Cancer Lett 1997 May 19;115(2):149–60

Induction of cyclin-dependent kinase inhibitor, p21WAF1, by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinoline (vesnarinone) in a human salivary cancer cell line with mutant p53 gene. Sato M, et al. **Cancer Lett** 1997 Jan 30;112(2):181–9

Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell. Singh AK, et al.
Cancer Lett 1996 Oct 1;107(1):109–15

Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. So FV, et al.
Cancer Lett 1997 Jan 30;112(2):127–33

Effects of n-tritriacontane-16,18-dione, curcumin, chlorphyllin, dihydroguaiaretic acid, tannic acid and phytic acid on the initiation stage in a rat multi-organ carcinogenesis model. Takaba K, et al. **Cancer Lett** 1997 Feb 26;113(1-2):39–46

Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Wang TT, et al. **Cancer Lett** 1996 Oct 1;107(1):65–71

Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice. Zagon IS, et al.
Cancer Lett 1997 Jan 30;112(2):167–75

Investigation of the effect of BB-94 (batimastat) on the colonization potential of human lymphoma cells in SCID mice. Zubair AC, et al. **Cancer Lett** 1996 Oct 1;107(1):91–5

Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Abbaszadegan MR, et al. **Cancer Res** 1996 Dec 1;56(23):5435–42

G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Akiyama T, et al. **Cancer Res** 1997 Apr 15;57(8):1495–501

Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Bible KC, et al. **Cancer Res** 1996 Nov 1;56(21):4856–61

p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Bonfanti M, et al. **Cancer Res** 1997 Apr 15;57(8):1442–6

Activation of actin-cleavable interleukin 1beta-converting enzyme (ICE) family protease CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells. Chen Z, et al. **Cancer Res** 1996 Nov 15; 56(22):5224–9

Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. Cuthbert JA, et al. **Cancer Res** 1997 Aug 15; 57(16):3498–505

Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Daly JM, et al. **Cancer Res** 1997 Sep 1;57(17):3804–11

Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Decaudin D, et al. **Cancer Res** 1997 Jan 1;57(1):62–7

Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Dunn SE, et al. **Cancer Res** 1997 Jul 1;57(13):2687–93

The role of DNA mismatch repair in platinum drug resistance. Fink D, et al. **Cancer Res** 1996 Nov 1; 56(21):4881–6

In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Fink D, et al. **Cancer Res** 1997 May 15;57(10):1841–5

High-dose selection with mafosfamide results in sensitivity to DNA cross-linking agents: characterization of hypersensitive cell lines. Fritz G, et al. **Cancer Res** 1997 Feb 1;57(3):454–60

The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Fulda S, et al.
Cancer Res 1997 Sep 1;57(17):3823–9

Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Glinsky GV, et al.
Cancer Res 1996 Dec 1;56(23):5319–24

Bcl2 is the guardian of microtubule integrity. Haldar S, et al. **Cancer Res** 1997 Jan 15;57(2):229–33

Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Ibrado AM, et al. **Cancer Res** 1996 Oct 15;56(20):4743–8

Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Jankun J, et al. **Cancer Res** 1997 Feb 15;57(4):559–63

A general role for c-Fos in cellular protection against DNA-damaging carcinogens and cytostatic drugs. Kaina B, et al. **Cancer Res** 1997 Jul 1;57(13):2721–31

Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Kawahara N, et al. **Cancer Res** 1996 Dec 1; 56(23):5330–3

Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin. Kirichenko AV, et al.
Cancer Res 1997 May 15;57(10):1929–33

Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Klauber N, et al. **Cancer Res** 1997 Jan 1;57(1):81–6

Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Li L, et al.
Cancer Res 1997 Apr 15;57(8):1487–94

Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Light BW, et al. **Cancer Res** 1997 Sep 1; 57(17):3759–64

Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Lorico A, et al. **Cancer Res** 1996 Dec 1;56(23):5351–5

Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Mollinedo F, et al. **Cancer Res** 1997 Apr 1; 57(7):1320–8

Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells. Richon VM, et al. **Cancer Res** 1997 Jul 1;57(13):2789–98

Bis(7-amino-4-azaheptyl)dimethylsilane and bis(7-ethylamino-4-azaheptyl)dimethylsilane: inhibition of tumor cell growth in vitro and in vivo. Seiler N, et al.
Cancer Res 1996 Dec 15;56(24):5624–30

Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Siim BG, et al. **Cancer Res** 1997 Jul 15;57(14):2922–8

A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Sim BK, et al. **Cancer Res** 1997 Apr 1;57(7):1329–34

Oncostatin M-mediated transcriptional suppression of the c-myc gene in breast cancer cells. Spence MJ, et al.
Cancer Res 1997 Jun 1;57(11):2223–8

Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, a novel inhibitor of ribonucleoside diphosphate reductase, on human colon carcinoma xenografts in nude mice. Sun LQ, et al. **Cancer Res** 1997 Sep 15;57(18):4023–8

Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Watabe M, et al.
Cancer Res 1997 Aug 1;57(15):3097–100

Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase. Whitacre CM, et al.
Cancer Res 1997 Jun 1;57(11):2157–63

Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Yoshimatsu K, et al.
Cancer Res 1997 Aug 1;57(15):3208–13

Microfilament depletion and circumvention of multiple drug resistance by sphinxolides. Zhang X, et al. **Cancer Res** 1997 Sep 1;57(17):3751–8

In vitro pharmalogic rationale for intraperitoneal regional chemotherapy. Link KH, et al. **Cancer Treat Res** 1996;

82:101–14
Cellular resistance to topoisomerase poisons. Rubin EH, et al. **Cancer Treat Res** 1996;87:243–60 (124 ref.)
Human immunodeficiency virus replication in the presence of antiretroviral drugs: analogies to antineoplastic drug resistance. Strair RK, et al. **Cancer Treat Res** 1996; 87:225–39 (63 ref.)
Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Huang MT, et al. **Carcinogenesis** 1997 Jan;18(1):83–8
Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one. Perkins SN, et al. **Carcinogenesis** 1997 May;18(5):989–94
Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Petersen LN, et al. **Carcinogenesis** 1996 Dec;17(12):2597–602
The role of metabolism in mammary epithelial cell growth inhibition by the isoflavones genistein and biochanin A. Peterson TG, et al. **Carcinogenesis** 1996 Sep;17(9):1861–9
Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Redman C, et al. **Carcinogenesis** 1997 Jun;18(6):1195–202
Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Stayrook KR, et al. **Carcinogenesis** 1997 Aug;18(8):1655–8
Anti-cancer effects of morphine through inhibition of tumour necrosis factor-alpha release and mRNA expression. Sueoka N, et al. **Carcinogenesis** 1996 Nov;17(11):2337–41
Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Tanaka T, et al. **Carcinogenesis** 1997 May;18(5):957–65
A xanthine oxidase inhibitor 1'-acetoxychavicol acetate inhibits azoxymethane-induced colonic aberrant crypt foci in rats. Tanaka T, et al. **Carcinogenesis** 1997 May; 18(5):1113–8
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. O'Reilly MS, et al. **Cell** 1997 Jan 24; 88(2):277–85
Cytotoxicity of two new ribosome-inactivating proteins, cinnamomin and camphorin, to carcinoma cells. Ling J, et al. **Cell Biochem Funct** 1996 Sep;14(3):157–61
Cisplatin inhibits pinocytosis in Dictyostelium discoideum. Reddy TB, et al. **Cell Biol Int** 1997 Apr;21(4):237–41
Synergistic antitumour activity of vitamins C and K3 against human prostate carcinoma cell lines. Venugopal M, et al. **Cell Biol Int** 1996 Dec;20(12):787–97
Synthetic hispidin, a PKC inhibitor, is more cytotoxic toward cancer cells than normal cells in vitro. Gonindard C, et al. **Cell Biol Toxicol** 1997 Mar;13(3):141–53
Ether lipid-induced cell damage of neuroblastoma cells is only weakly correlated with increased intracellular Ca2+ levels. Brinkmeier H, et al. **Cell Calcium** 1996 May; 19(5):383–90
Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells. Basu A, et al. **Cell Growth Differ** 1996 Nov;7(11):1507–12
7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Bunch RT, et al. **Cell Growth Differ** 1997 Jul; 8(7):779–88
Regulation of involucrin gene expression by retinoic acid and glucocorticoids. Monzon RI, et al. **Cell Growth Differ** 1996 Dec;7(12):1751–9
Changes in E2F DNA-binding activity during induced erythroid differentiation. Richon VM, et al. **Cell Growth Differ** 1996 Jan;7(1):31–42
Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Roberson KM, et al. **Cell Growth Differ** 1997 Jan; 8(1):101–11
Down-regulation of cyclin A gene expression upon genotoxic stress correlates with reduced binding of free E2F to the promoter. Spitkovsky D, et al. **Cell Growth Differ** 1997 Jun;8(6):699–710
Drug-related killings: a case of mistaken identity. Karran P, et al. **Chem Biol** 1996 Nov;3(11):875–9 (23 ref.)
32P-post-labelling analysis of nucleobases involved in the formation of DNA adducts by antitumor 1-nitroacridines. Bartoszek A, et al. **Chem Biol Interact** 1997 Feb 28; 103(2):131–9
In vitro DNA crosslinking by Ledakrin, an antitumor derivative of 1-nitro-9-aminoacridine. Bartoszek A, et al. **Chem Biol Interact** 1997 Feb 28;103(2):141–51
Palladium(II) compounds with potential antitumour properties and their platinum analogues: a comparative study of the reaction of some orotic acid derivatives with DNA in vitro. Butour JL, et al. **Chem Biol Interact** 1997 May 2;104(2-3):165–78
Effects of arenastatin A and its synthetic analogs on microtubule assembly. Koiso Y, et al. **Chem Biol Interact** 1996 Dec 20;102(3):183–91
Synthesis and antitumor activity of quaternary salts of 2-(2'-oxoalkoxy)-9-hydroxyellipticines. Harada N, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan;45(1):134–7
Synthesis and antitumor activity of 9-acyloxyellipticines. Harada N, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul; 45(7):1156–62
Characterization of the cytotoxic activity of nitric oxide generating N-nitroso compounds. Tanno M, et al. **Chem Pharm Bull (Tokyo)** 1997 Apr;45(4):595–8
Synthesis and antiproliferative activity of cytidine-5'-alkylphosphonophosphates and structurally related compounds. Brachwitz H, et al. **Chem Phys Lipids** 1996 Sep 16;83(1):77–85
New nucleoside-5'-alkylphosphonophosphates and related compounds containing 2'-deoxycytidine, thymidine and adenosine as nucleoside component. Syntheses and their effects on tumor cell growth in vitro. Brachwitz H, et al. **Chem Phys Lipids** 1997 May 30;87(1):31–9
Assessment of micronucleus induction in murine SCCVII cells treated with various anticancer agents. Jeremic B, et al. **Chemotherapy** 1996 Jul-Aug;42(4):266–72
In vitro effect of hyperthermia on chemoenhancement and uptake of cisplatin in human pharyngeal carcinoma KB cells. Ohtsubo T, et al. **Chemotherapy** 1997 Jan-Feb; 43(1):43–50
In vitro antitumor and antimicrobial activities of N-substituents of maleimide by adamantane and diamantane. Wang JJ, et al. **Chemotherapy** 1997 May-Jun; 43(3):182–9
Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Santos O, et al. **Clin Exp Metastasis** 1997 Sep;15(5):499–508
Pharmacology of cancer chemotherapy in the older person. Baker SD, et al. **Clin Geriatr Med** 1997 Feb;13(1):169–83 (62 ref.)
In vitro chemotherapy of steroid receptor positive human meningioma low-passage primary cultures with nitrosourea-methionine-steroid conjugates. Taut FJ, et al. **Clin Neuropharmacol** 1996 Dec;19(6):520–5
Duke researchers link brain tumor drug resistance to mismatch repair deficiency [news] **Compr Ther** 1997 Sep; 23(9):622–3
Riminophenazine compounds: pharmacology and anti-neoplastic potential. Van Rensburg CE, et al. **Crit Rev Oncol Hematol** 1997 Jan;25(1):55–67 (102 ref.)
Effect of pretreatment of germanium-132 on Na(+)-K(+)-ATPase and galactose cataracts. Unakar NJ, et al. **Curr Eye Res** 1997 Aug;16(8):832–7
Oncogene products as therapeutic targets for cancer. Huang PS, et al. **Curr Opin Oncol** 1997 Jan;9(1):94–100 (83 ref.)
Targets for cancer therapy in the cell cycle pathway. Rao RN. **Curr Opin Oncol** 1996 Nov;8(6):516–24 (75 ref.)
Barrier effect of gloves against cytostatic drugs. Mellström GA, et al. **Curr Probl Dermatol** 1996;25:163–9
Alterations in cell cycle control during tumor progression: effects on apoptosis and the response to therapeutic agents. Muschel RJ, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):197–213 (110 ref.)
Glucocorticoids inhibit oncostatin M-induced phospholipase A2 gene expression in human hepatoma cells. Haselmann J, et al. **Cytokine** 1997 Mar;9(3):199–205
Caffeine induces S-phase apoptosis in cis-diamminedichloroplatinum-treated cells, whereas cis-diamminedichloroplatinum induces a block in G2/M. Shinomiya N, et al. **Cytometry** 1997 Apr 1;27(4):365–73
Derivation and characterization of retinoid-resistant human embryonal carcinoma cells. Moasser MM, et al. **Differentiation** 1996 Jul;60(4):251–7
Suramin enhances ethanol-induced injury to gastric mucosa in rats. Blandizzi C, et al. **Dig Dis Sci** 1997 Jun; 42(6):1233–41
Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Weckbecker G, et al. **Digestion** 1996;57 Suppl 1:22–8
Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Akhter J, et al. **Dis Colon Rectum** 1997 Mar;40(3):317–21
Synthesis and biological evaluation of novel pyrrolidine-2,5-dione inhibitors as potential anti-tumour agents. Ahmed S, et al. **Drug Des Discov** 1995 Apr; 12(4):275–87
Design, synthesis and biological evaluation of benzoic acid mustard derivatives of imidazole-containing and C-terminal carboxamide analogues of distamycin. Hartley JA, et al. **Drug Des Discov** 1995 Apr;12(4):323–35
Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Adkins JC, et al. **Drugs** 1997 Jun;53(6):1005–37 (259 ref.)
Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Dunn CJ, et al. **Drugs Aging** 1996 Aug;9(2):122–47 (132 ref.)
Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Wiseman LR, et al. **Drugs Aging** 1996 Oct; 9(4):292–306 (71 ref.)
The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Amtmann E. **Drugs Exp Clin Res** 1996;22(6):287–94
Action of Ukrain, a cytostatic and immunomodulating drug, on effects of irradiation. Boyko VN, et al. **Drugs Exp Clin Res** 1996;22(3-5):167–71
Synergic influence of Ukrain and protoporphyrin amino acid conjugates on human malignant cell lines. Brzosko WJ, et al. **Drugs Exp Clin Res** 1996;22(3-5):193–4
Effect of six-month treatment with Ukrain on early osteoporosis induced by ovariectomy in rats. Part I: Preliminary studies of bone parameters. Jagiello-Wojtowicz E, et al. **Drugs Exp Clin Res** 1996; 22(3-5):173–6
Mitogenic properties of Ukrain (NSC-6315170) on human peripheral blood monocytes: clinical implications. Jin YM, et al. **Drugs Exp Clin Res** 1996;22(3-5):99–101
Induction of bimodal programmed cell death in malignant cells by the derivative Ukrain (NSC-631570). Liepins A, et al. **Drugs Exp Clin Res** 1996;22(3-5):73–9
Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570). Liepins A, et al. **Drugs Exp Clin Res** 1996;22(3-5):103–13
Influence of Ukrain on DNA, RNA and protein synthesis in malignant cells. Nowicky JW, et al. **Drugs Exp Clin Res** 1996;22(3-5):81–91
Influence of Ukrain on human xenografts in vitro. Nowicky JW, et al. **Drugs Exp Clin Res** 1996;22(3-5):93–7
Influence of Ukrain on immunological blood parameters in vitro and in vivo. Nowicky JW, et al. **Drugs Exp Clin Res** 1996;22(3-5):163–5
Inhibitory effect of thiophosphoric acid alkaloid derivatives from Chelidonium majus L. (Ukrain) on ovalbumin antigenicity and antiovalbumin IgE antibody response in mice. Wyczółkowska J, et al. **Drugs Exp Clin Res** 1996; 22(3-5):195–200
Influence of Ukrain on the redox processes of hepatocytes. Zhalilo LI, et al. **Drugs Exp Clin Res** 1996;22(3-5):189–91
Relationship among hormonal treatments, suppression of spermatogenesis, and testicular protection from chemotherapy-induced damage. Meistrich ML, et al. **Endocrinology** 1996 Sep;137(9):3823–31
New protein kinase inhibitors [news] **Environ Health Perspect** 1997 Jan;105(1):26
A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine. Baguley BC, et al. **Eur J Cancer** 1997 Feb;33(2):272–9
In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin. Belvedere G, et al. **Eur J Cancer** 1996 Oct;32A(11):2011–8
Effects of cisplatin and amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. Bergström P, et al. **Eur J Cancer** 1997 Jan; 33(1):153–9
Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Burger AM, et al. **Eur J Cancer** 1997 Apr;33(4):638–44
The effect of the neuroblastoma-seeking agent meta-iodobenzylguanidine (MIBG) on NADH-driven superoxide formation and NADH-driven lipid peroxidation in beef heart submitochondrial particles. Cornelissen J, et al. **Eur J Cancer** 1997 Mar;33(3):421–4
Long-term effects of fenretinide on retinal function. Decensi A, et al. **Eur J Cancer** 1997 Jan;33(1):80–4
Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line. Gonzalez Manzano R, et al. **Eur J Cancer** 1996 Nov;32A(12):2136–41
Tunicamycin potentiates drug cytotoxicity and vincristine retention in multidrug resistant cell lines. Hiss D, et al. **Eur J Cancer** 1996 Nov;32A(12):2164–72
Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours. Jonsson B, et al. **Eur J Cancer** 1996 May;32A(5):883–7
Effects of chronic administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eye. Lewis KC, et al. **Eur J Cancer** 1996 Sep;32A(10):1803–8
Evidence that cisplatin induces serotonin release from human peripheral blood mononuclear cells and that methylprednisolone inhibits this effect. Mantovani G, et al. **Eur J Cancer** 1996 Oct;32A(11):1983–5
Melanogenesis-targeted anti-melanoma pro-drug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Riley PA, et al. **Eur J Cancer** 1997 Jan;33(1):135–43
Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Scambia G, et al. **Eur J Cancer** 1996 May;32A(5):877–82
Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. Vink-van Wijngaarden T, et al. **Eur J Cancer** 1996 May;32A(5):842–8
2-Chlorodeoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukaemia [letter] Warzocha K, et al. **Eur J Cancer** 1997 Jan;33(1):170–3
Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines. Zaffaroni N, et al. **Eur J Cancer** 1996 Sep;32A(10):1766–73
Influence of N-methylformamide on the intracellular transport of doxorubicin. Calcabrini A, et al. **Eur J Cell Biol** 1997 Jan;72(1):61–9
Expression of PSA-N-CAM in human neuroblastoma cells induced to neuronal differentiation by retinoic acid. Cervello M, et al. **Eur J Cell Biol** 1997 Jul;73(3):270–5

ANTINEOPLASTIC AGENTS

Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects. Boege F. **Eur J Clin Chem Clin Biochem** 1996 Nov;34(11):873-88 (157 ref.)

Cytotoxic activity of cyclosporin A and [3-keto-Bmt1]-[Val2]-cyclosporin (SDZ PSC 833) on tumour cells from patients with haematological malignancies. Martinsson P, et al. **Eur J Clin Pharmacol** 1997;52(3):199-203

Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. Yeung JH, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct-Dec; 20(4):287-92

Recovery of drug sensitivity by MS-209, a new multidrug resistance-reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line. Wang YH, et al. **Eur J Haematol** 1997 Mar; 58(3):186-94

Competitive inhibition of photoaffinity labelling of P-glycoprotein by anticancer drugs and modulators including S9788. Demmer A, et al. **Eur J Pharmacol** 1996 Nov 21;315(3):339-43

Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents. Siegmund B, et al. **Eur J Pharmacol** 1997 Feb 26; 321(2):231-9

Chemotherapeutic profiles of human tumors implanted in SCID mice showing appreciable inconsistencies with those in nude mice. Yoshimura M, et al. **Exp Anim** 1997 Apr; 46(2):153-6

The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Smith ML, et al. **Exp Cell Res** 1997 Jan 10;230(1):61-8

All-trans-retinoic acid blocks cell cycle progression of human ovarian adenocarcinoma cells at late G1. Wu S, et al. **Exp Cell Res** 1997 May 1;232(2):277-86

A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets. Botzler C, et al. **Exp Hematol** 1997 Apr; 25(4):338-44

Glial cell reaction to cis-dichlorodiammine platinum treatment in the immature rat cerebellum. Necchi D, et al. **Exp Neurol** 1997 Mar;144(1):219-26

Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS. **EXS** 1997;79:273-94 (62 ref.)

In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody. Brusa P, et al. **Farmaco** 1997 Feb; 52(2):71-81

Quinoxaline chemistry. Part 7. 2-[aminobenzoates]- and 2-[aminobenzoylglutamate]-quinoxalines as classical antifolate agents. Synthesis and evaluation of in vitro anticancer, anti-HIV and antifungal activity. Loriga M, et al. **Farmaco** 1997 Mar;52(3):157-66

A simple ligation assay to detect effects of drugs on the curvature/flexibility of DNA. Bailly C, et al. **FEBS Lett** 1996 Nov 4;396(2-3):253-6

A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines. Cattaneo MG, et al. **FEBS Lett** 1996 Nov 18;397(2-3):164-8

Microtubule-active drugs suppress the closure of the permeability transition pore in tumour mitochondria. Evtodienko YV, et al. **FEBS Lett** 1996 Sep 9;393(1):86-8

Increased expression of T-plastin gene in cisplatin-resistant human cancer cells: identification by mRNA differential display. Hisano T, et al. **FEBS Lett** 1996 Nov 11; 397(1):101-7

G2 cell cycle arrest and apoptosis are induced in Burkitt's lymphoma cells by the anticancer agent oracin. Klucar J, et al. **FEBS Lett** 1997 Jan 2;400(1):127-30

Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). Taguchi Y, et al. **FEBS Lett** 1997 Jan 13;401(1):11-4

Apoptosis of WEHI-3B cells after Maphosphamide treatment. Kawiak J, et al. **Folia Histochem Cytobiol** 1996; 34 Suppl 1:39-40

Ultrastructural evaluation of Morris hepatoma metastases to the lungs after local administration of Mutein VI hrecTNF-alpha. Nowak HF, et al. **Folia Histochem Cytobiol** 1996;34 Suppl 1:21-2

Ultrastructural analysis of pulmonary capillaries after mutein VI rhTNF-alpha administration into Morris hepatoma. Sulkowska M, et al. **Folia Histochem Cytobiol** 1997; 35(2):83-4

Local reaction from eosinophils in the development of Morris hepatoma after hrecTNF-alpha administration. Terlikowski S, et al. **Folia Histochem Cytobiol** 1996;34 Suppl 1:101-2

New azidometalkojates and their biological activity. Hudecová D, et al. **Folia Microbiol (Praha)** 1996; 41(6):473-6

2-chloro- and 2-bromo-2'-deoxyadenosine have no effect on the morphology of rat neural and glial cells in organotypic culture. Matyja E, et al. **Folia Neuropathol** 1996;34(1):41-7

Mitochondrial damage following exposure of organotypic cultures of human malignant gliomas to 2-chloro- and 2-bromo-2'-deoxyadenosine. Matyja E, et al. **Folia Neuropathol** 1996;34(1):31-9

Inhibition of benzo[a]pyrene-induced mouse forestomach neoplasia and reduction of H2O2 concentration in human polymorphonuclear leucocytes by flavour components of Japanese-style fermented soy sauce. Kataoka S, et al. **Food Chem Toxicol** 1997 May;35(5):449-57

Taking chemotherapy from random to rational with the histoculture drug response assay. Hoffman RM. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:206-29 (215 ref.)

Development of new anticancer drugs in Japan--tubulin-interacting agents. Tsukagoshi S. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:94-9 (5 ref.)

Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion. Barrand MA, et al. **Gen Pharmacol** 1997 May;28(5):639-45 (44 ref.)

Preclinical studies on the broad-spectrum neuropeptide growth factor antagonist G. Jones DA, et al. **Gen Pharmacol** 1997 Feb;28(2):183-9 (22 ref.)

Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. Smitskamp-Wilms E, et al. **Gen Pharmacol** 1996 Apr;27(3):421-9 (88 ref.)

Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy. Thornalley PJ. **Gen Pharmacol** 1996 Jun;27(4):565-73 (77 ref.)

Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy. Bailey SM, et al. **Gene Ther** 1996 Dec; 3(12):1143-50

Gene transfer to augment the therapeutic index of anticancer chemotherapy [editorial] Baum C, et al. **Gene Ther** 1996 Jan;3(1):1-3

Selective cell ablation in transgenic mice expression E. coli nitroreductase [see comments] Clark AJ, et al. **Gene Ther** 1997 Feb;4(2):101-10. Comment in: Gene Ther 1997 Feb;4(2):80-1.

The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954 [see comments] Drabek D, et al. **Gene Ther** 1997 Feb; 4(2):93-100. Comment in: Gene Ther 1997 Feb;4(2):80-1.

Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V). Pavlovic J, et al. **Gene Ther** 1996 Jul; 3(7):635-43

Factors influencing the drug sensitization of human tumor cells for in situ lipofection. Son K, et al. **Gene Ther** 1996 Jul;3(7):630-4

Bacteriophage T4 mutants hypersensitive to an antitumor agent that induces topoisomerase-DNA cleavage complexes. Woodworth DL, et al. **Genetics** 1996 Jul; 143(3):1081-90

Decorin and suramin inhibit ocular fibroblast collagen production. Mietz H, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Jun;235(6):399-403

Induction of anchorage-independent growth by amphiregulin. Adam RM, et al. **Growth Factors** 1996; 13(3-4):193-203

Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gibb RK, et al. **Gynecol Oncol** 1997 Apr;65(1):13-22

Effect of fludarabine and arabinosylcytosine on multidrug resistant cells. Michelutti A, et al. **Haematologica** 1997 Mar-Apr;82(2):143-7

All-trans retinoic acid might also induce apoptosis in freshly isolated chronic myeloid leukemia cells [letter; comment] Stagno F, et al. **Haematologica** 1997 Jan-Feb;82(1):125. Comment on: Haematologica 1995 Jul-Aug;80(4):390-1. Comment on: Haematologica 1996 May-Jun;81(3):286-7.

Adhesion molecules as targets for cancer therapy. Huang YW, et al. **Histol Histopathol** 1997 Apr;12(2):467-77 (119 ref.)

Synergistic antitumor effects of human interferon-beta and interferon-gamma on human gastric adenocarcinoma cells. Nagao S, et al. **Hum Cell** 1997 Mar;10(1):95-104

Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Xu M, et al. **Hum Gene Ther** 1997 Jan 20;8(2):177-85

Anti-tumor activity of synthetic peptide fragments of the human interferon-alpha 2. Danilkovitch A, et al. **Hybridoma** 1997 Feb;16(1):69-75

Homologous complement activation on drug-induced apoptotic cells from a human lung adenocarcinoma cell line. Hara T, et al. **Immunobiology** 1996-97;196(5):491-503

The isolation and characterization of an immunomodulatory and anti-tumor polysaccharide preparation from Flammulina velutipes. Leung MY, et al. **Immunopharmacology** 1997 Jan;35(3):255-63

Restoration of immune responses in tumor-bearing mice by ONO-4007, an antitumor lipid A derivative. Matsumoto N, et al. **Immunopharmacology** 1997 Apr;36(1):69-78

The immunomodulatory and antitumor activities of lectins from the mushroom Tricholoma mongolicum. Wang HX, et al. **Immunopharmacology** 1996 Mar;31(2-3):205-11

p53 and response to chemotherapy and radiotherapy. Ruley HE. **Important Adv Oncol** 1996;:37-56 (269 ref.)

The cytotoxic interaction of inorganic trace elements with EDTA and cisplatin in sensitive and resistant human ovarian cancer cells. Maier RH, et al. **In Vitro Cell Dev Biol Anim** 1997 Mar;33(3):218-21

Immunomodulation by OK-432 and calcitonin gene-related peptide (CGRP) of nitric oxide synthase (NOS) and IL-1 beta gene expression and of HSV-1 pathogenicity in mouse skin Langerhans cells (LC). Berkowitz-Balshayi C, et al. **In Vivo** 1995 Sep-Oct;9(5):447-54

Clinical chronotolerance to anticancer drugs: relevance for dose-intensity. Bjarnason GA. **In Vivo** 1995 Nov-Dec; 9(6):557-64 (68 ref.)

Oncogene signal transduction inhibitors from medicinal plants. Chang CJ, et al. **In Vivo** 1996 Mar-Apr;10(2):185-90

Reversal of cisplatin resistance in vivo by an anti-fos ribozyme. Funato T, et al. **In Vivo** 1997 May-Jun; 11(3):217-20

Development of differential cytotoxic compounds containing nitrosourea and benzothiazine nucleus. Nyati MK, et al. **In Vivo** 1997 Jan-Feb;11(1):95-9

Antitumor activity of novel purine acyclic nucleotide analogs PMEA and PMEDAP. Otová B, et al. **In Vivo** 1997 Mar-Apr;11(2):163-7

PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy. Teicher BA, et al. **In Vivo** 1997 Jul-Aug;11(4):301-11

A review of the antineoplastic action of certain hydrazines and hydrazine-containing natural products. Toth B. **In Vivo** 1996 Jan-Feb;10(1):65-96 (172 ref.)

In vivo effect of pachymatismin, a new marine glycoprotein, on a human non-small-cell lung carcinoma. Zidane M, et al. **In Vivo** 1997 Mar-Apr;11(2):185-8

Synthetic peptides related to laminin pentapeptide (YIGSR) fragment. Sivanandaiah KM, et al. **Indian J Exp Biol** 1996 Jul;34(7):658-62

Anti-cancer agent OK432 induces manganese superoxide dismutase in human granulocytes. Akashi M, et al. **Int J Cancer** 1996 Nov 4;68(3):384-90

CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro OFF exhibits anti-tumor activity. Camoratto AM, et al. **Int J Cancer** 1997 Aug 7;72(4):673-9

Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol. Coley HM, et al. **Int J Cancer** 1996 Nov 4;68(3):356-63

MIBG causes oxidative stress and up-regulation of anti-oxidant enzymes in the human neuroblastoma cell line SK-N-BE(2c). Cornelissen J, et al. **Int J Cancer** 1997 Jul 29;72(3):486-90

Characterization of a cAMP-dependent protein kinase mutant resistant to cisplatin. Cvijic ME, et al. **Int J Cancer** 1997 Jul 17;72(2):345-50

Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. De Vincenzo R, et al. **Int J Cancer** 1996 Nov 4;68(3):340-8

Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Funatomi H, et al. **Int J Cancer** 1997 Jul 29;72(3):512-7

All-trans, 13-cis and 9-cis retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: implications for in vivo retinoic acid use. Giannini F, et al. **Int J Cancer** 1997 Jan 17;70(2):194-200

Intra-tumoral application of a heregulin-exotoxin-a fusion protein causes rapid tumor regression without adverse systemic or local effects. Groner B, et al. **Int J Cancer** 1997 Mar 17;70(6):682-7

DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Joto N, et al. **Int J Cancer** 1997 Aug 7;72(4):680-6

DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Köberle B, et al. **Int J Cancer** 1997 Mar 4; 70(5):551-5

Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Kondapaka SB, et al. **Int J Cancer** 1997 Mar 17;70(6):722-6

Local injection of OK432 can augment the TH1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential. Okamoto T, et al. **Int J Cancer** 1997 Mar 4;70(5):598-605

Transforming growth factor-beta1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Raynal S, et al. **Int J Cancer** 1997 Jul 17;72(2):356-61

Effect of all trans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. Taraboletti G, et al. **Int J Cancer** 1997 Jan 6; 70(1):72-7

Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Toma S, et al. **Int J Cancer** 1997 Mar 4; 70(5):619-27

Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Wagner M, et al. **Int J Cancer** 1996 Dec 11;68(6):782-7

The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Wang SY, et al. **Int J Cancer** 1997 Mar 17; 70(6):699-705

Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Wasilenko WJ, et al. **Int J Cancer** 1996 Oct 9;68(2):259-64

Prediction of growth sensitivity of acute promyelocytic leukemia cells to granulocyte colony-stimulating factor using 7AAD/PY during administration of all-trans retinoic acid. Toba K, et al. **Int J Hematol** 1997 Aug;66(2):203-12

Differential induction of apoptosis on human lymphoblastic leukemia Nalm-6 and Molt-4 cells by various antitumor drugs. Tsurusawa M, et al. **Int J Hematol** 1997 Jul; 66(1):79-88

In vitro effects of hyperthermia combined with cisplatin or peplomycin on the human maxillary carcinoma cell line IMC-2. Ohtsubo T, et al. **Int J Hyperthermia** 1997 Jan-Feb; 13(1):59-67

Mammalian cells adapted to growth at pH 6.7 have elevated HSP27 levels and are resistant to cisplatin. Wachsberger PR, et al. **Int J Hyperthermia** 1997 May-Jun;13(3):251-5; discussion 257-9

A retroviral peptide encoded by mutated env p15E gene is recognized by specific CD8+ T lymphocytes on drug-treated murine mastocytoma P815. Belladonna ML, et al. **Int J Immunopharmacol** 1996 Oct;18(10):563-76

Functional antagonism between IL-2 and PGA1 or PGJ2 in the control of proliferation of human cord blood-derived mononuclear cells. Franzese O, et al. **Int J Immunopharmacol** 1996 Nov;18(11):609-22

Comparison of antiproliferative effects of 1-histamine-2 receptor antagonists, cimetidine, ranitidine, and famotidine, in gastric cancer cells. Hahm KB, et al. **Int J Immunopharmacol** 1996 Jun-Jul;18(6-7):393-9

Human recombinant interferon alpha-2a inhibits angiogenesis of chick area vasculosa in shell-less culture. Ribatti D, et al. **Int J Microcirc Clin Exp** 1996 Jul-Aug;16(4):165-9

Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells. Larsen RH, et al. **Int J Radiat Biol** 1997 Jul;72(1):79-90

Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate. Miller AC, et al. **Int J Radiat Biol** 1997 Aug;72(2):211-8

An interaction of cisplatin and radiation in two rat yolk sac tumour cell lines with different radiosensitivities in vitro. Nakamoto S, et al. **Int J Radiat Biol** 1996 Dec;70(6):747-53

Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. Lamond JP, et al. **Int J Radiat Oncol Biol Phys** 1996 Sep 1;36(2):361-8

Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. Lamond JP, et al. **Int J Radiat Oncol Biol Phys** 1996 Sep 1; 36(2):369-76 (38 ref.)

Studies on pulmonary tissue after administration of mutein VI-HREC TNF-alpha into implantable experimental Morris hepatoma. Sulkowski S, et al. **Int J Tissue React** 1996;18(2-3):57-65

Effects of anti-intercellular adhesion molecule-1 and anti-lymphocyte-function-associated antigen-1 monoclonal antibodies on the metastasis of murine tumors. Sun R, et al. **Invasion Metastasis** 1996;16(1):39-48

AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Boritzki TJ, et al. **Invest New Drugs** 1996;14(3):295-303

Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Kelner MJ, et al. **Invest New Drugs** 1996; 14(2):161-7

Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Mendelsohn LG, et al. **Invest New Drugs** 1996; 14(3):287-94

Inhibition of B16 melanoma cell proliferation and alterations in p21 ras expression induced by interceptors of signal transduction pathways. Nordenberg J, et al. **Isr J Med Sci** 1996 Dec;32(12):1153-7

Esterase inhibitors diminish the modulation of gene expression by butyric acid derivative, pivaloyloxymethyl butyrate (AN-9). Rabizadeh E, et al. **Isr J Med Sci** 1996 Dec;32(12):1186-91

Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines. Delsite R, et al. **J Androl** 1996 Sep-Oct;17(5):481-90

A new anthracycline antibiotic, IT-62-B, converts the morphology of ras-transformed cells back to normal: taxonomy, fermentation, isolation, structure elucidation and biological characterization. Kawauchi T, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):297-303

A screening method for antimitotic and antifungal substances using conidia of Pyricularia oryzae, modification and application to tropical marine fungi. Kobayashi H, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):873-9

The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Croft SL, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1041-7

Effect of calcium channel blockers on the action of various antitumour agents in the yeast Saccharomyces cerevisiae. Tillgada E, et al. **J Appl Bacteriol** 1996 Nov;81(5):481-5

Effect of caulerpenyne, a toxin extracted from Caulerpa taxifolia on mechanisms regulating intracellular pH in sea urchin eggs and sea bream hepatocytes. Galgani I, et al. **J Biochem Toxicol** 1996;11(5):243-50

Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. Das KC, et al. **J Biol Chem** 1997 Jun 6;272(23):14914-20

Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. Dong Z, et al. **J Biol Chem** 1997 Apr 11;272(15):9962-70

4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. Fanjul AN, et al. **J Biol Chem** 1996 Sep 13;271(37):22441-6

Mitotic arrest with nocodazole induces selective changes in the level of O-linked N-acetylglucosamine and accumulation of incompletely processed N-glycans on proteins from HT29 cells. Haltiwanger RS, et al. **J Biol Chem** 1997 Mar 28;272(13):8752-8

All-trans-retinoic acid increases transforming growth factor-beta2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway. Han GR, et al. **J Biol Chem** 1997 May 23;272(21):13711-6

Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity. Lee CK, et al. **J Biol Chem** 1997 Aug 29;272(35):21872-7

The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action. Pfeffer LM, et al. **J Biol Chem** 1997 Apr 25;272(17):11002-5

The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. Potapova O, et al. **J Biol Chem** 1997 May 30;272(22):14041-4

c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. Seimiya H, et al. **J Biol Chem** 1997 Feb 14;272(7):4631-6

Bax can antagonize Bcl-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-XL. Simonian PL, et al. **J Biol Chem** 1996 Sep 13;271(37):22764-72

Biological activity of maleic anhydride copolymers. I. Biocompatibility and antitumoural effects of maleic anhydride-vinyl acetate, maleic anhydride-methyl methacrylate and maleic anhydride-styrene copolymers. Uglea CV, et al. **J Biomater Sci Polym Ed** 1996;8(4):269-80

Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells. Aviram A, et al. **J Cancer Res Clin Oncol** 1997;123(5):267-71

The development of alkylphosphocholines as signal transduction inhibitors: experimental and clinical challenges [letter] Hilgard P, et al. **J Cancer Res Clin Oncol** 1997; 123(5):286-7

Cytokinetic effects of cisplatin on diverse human head and neck carcinomas in vitro: dependence on the tumor sensitivity to cisplatin. Jäckel MC, et al. **J Cancer Res Clin Oncol** 1996;122(10):596-602

Enhancement of tumor cell susceptibility to tumor-infiltrating lymphocytes by cisplatin. Noguchi K, et al. **J Cancer Res Clin Oncol** 1997;123(6):345-51

Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. Otto AM, et al. **J Cancer Res Clin Oncol** 1996;122(10):603-12

Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. Zimra Y, et al. **J Cancer Res Clin Oncol** 1997;123(3):152-60

Evaluation of in vitro chemosensitivity using human lung cancer cell lines. Kratzke RA, et al. **J Cell Biochem Suppl** 1996;24:160-4 (31 ref.)

Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines. Lokshin A, et al. **J Cell Biochem Suppl** 1996;24:186-97

Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3. Vartanian T, et al. **J Cell Biol** 1997 Apr 7;137(1):211-20

Development of a novel in vitro chemosensitivity assay: telomerase as a possible marker of tumor cell survival. Faraoni I, et al. **J Chemother** 1996 Oct;8(5):394-8

Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. Del Bufalo D, et al. **J Clin Invest** 1996 Sep 1;98(5):1165-73

Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid. Elstner E, et al. **J Clin Invest** 1997 Jan 15;99(2):349-60

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. Gupta E, et al. **J Clin Oncol** 1997 Apr;15(4):1502-10

Fertility after chemotherapy for testicular germ cell cancers. Lampe H, et al. **J Clin Oncol** 1997 Jan;15(1):239-45

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. Takimoto CH, et al. **J Clin Oncol** 1997 Apr;15(4):1492-501

Pharmacokinetics and pharmacodynamics of 9-cis-retinoic acid in healthy men. Weber C, et al. **J Clin Pharmacol** 1997 Jul;37(7):566-74

DNA-damaging agents induce the 72-kD heat shock protein in SV40 transformed normal human fibroblasts. Muramatsu T, et al. **J Dermatol** 1996 Sep;23(9):589-93

Antitumour-promoting and antitumour activities of the crude extract from the leaves of Juniperus chinensis. Ali AM, et al. **J Ethnopharmacol** 1996 Sep;53(3):165-9

Antineoplastic agents 338. The cancer cell growth inhibitory. Constituents of Terminalia arjuna (Combretaceae). Pettit GR, et al. **J Ethnopharmacol** 1996 Aug;53(2):57-63

Dacarbazine-induced immunogenicity of a murine leukemia is attenuated in cells transfected with mutated K-ras gene. Testorelli C, et al. **J Exp Clin Cancer Res** 1997 Mar; 16(1):15-22

The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. Tsukada N, et al. **J Exp Clin Cancer Res** 1997 Jun;16(2):171-6

Improved retroviral vectors for hematopoietic stem cell protection and in vivo selection. Baum C, et al. **J Hematother** 1996 Aug;5(4):323-9 (40 ref.)

Inhibition of experimentally-induced liver cirrhosis in rats by a nonpeptidic mimetic of the extracellular matrix-associated Arg-Gly-Asp epitope. Bruck R, et al. **J Hepatol** 1996 Jun;24(6):731-8

Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. Fujimoto T, et al. **J Immunol** 1997 Jun 15;158(12):5619-26

Differential effect of the immunomodulator AS101 on B7-1 and B7-2 costimulatory molecules: role in the antitumoral effects of AS101. Kalechman Y, et al. **J Immunol** 1996 Jul 15;157(2):589-97

Water-soluble rhodium(II) carboxylate adducts: cytotoxicity of the new compounds. de Souza AR, et al. **J Inorg Biochem** 1996 Oct;64(1):1-5

Synthesis, antitumor activity and acute toxicity of diammine/diamino-cyclohexane platinum(II) complexes with oxygen-ligating leaving group. Zou J, et al. **J Inorg Biochem** 1997 Feb 1;65(2):145-9

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. Blatt LM, et al. **J Interferon Cytokine Res** 1996 Jul;16(7):489-99 (64 ref.)

Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production. Fujisawa H, et al. **J Interferon Cytokine Res** 1996 Jul; 16(7):555-9

A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons. Subramaniam PS, et al. **J Interferon Cytokine Res** 1997 Jan;17(1):11-5

Both human alpha/beta and gamma interferons upregulate the expression of CD48 cell surface molecules. Tissot C, et al. **J Interferon Cytokine Res** 1997 Jan;17(1):17-26

The roles of protein phosphorylation/dephosphorylation in tumor necrosis factor antitumor effects. Wang XY, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):1021-5

Pharmacological disruption of hair follicle pigmentation by cyclophosphamide as a model for studying the melanocyte response to and recovery from cytotoxic drug damage in situ. Slominski A, et al. **J Invest Dermatol** 1996 Jun; 106(6):1203-11

Upregulation of interferon-alpha receptor expression in hydroxyurea-treated leukemia cell lines. Tamura T, et al. **J Investig Med** 1997 Apr;45(4):160-7

Wherefore interferon? Gresser I. **J Leukoc Biol** 1997 May; 61(5):567-74 (109 ref.)

Macrophage and interleukin-1 induced nitric oxide production and cytostasis in hamster tumor cells varying in malignant potential. Lavnikova N, et al. **J Leukoc Biol** 1997 Apr;61(4):452-8

Butitaxel analogues: synthesis and structure-activity relationships. Ali SM, et al. **J Med Chem** 1997 Jan 17; 40(2):236-41

A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics. Bergeron RJ, et al. **J Med Chem** 1997 May 9;40(10):1475-94

Enantioselective synthesis and antiproliferative properties of an ilmofosine analog, 2'-(trimethylammonio)ethyl 3-(hexadecyloxy)-2-(methoxymethyl)propyl phosphate, on epithelial cancer cell growth. Bittman R, et al. **J Med Chem** 1997 Apr 25;40(9):1391-5

Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes. Buckley RG, et al. **J Med Chem** 1996 Dec 20; 39(26):5208-14

Cytotoxicity and antiestrogenicity of a novel series of basic diphenylethylenes. Gilbert J, et al. **J Med Chem** 1997 Mar 28;40(7):1104-11

Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. Hattori H, et al. **J Med Chem** 1996 Dec 6;39(25):5005-11

Structure-based design of substituted diphenyl sulfones and sulfoxides as lipophilic inhibitors of thymidylate synthase. Jones TR, et al. **J Med Chem** 1997 Feb 28;40(5):677-83

Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity. Kozikowski AP, et al. **J Med Chem** 1997 Apr 25; 40(9):1316-26

2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo. Naylor MA, et al. **J Med Chem** 1997 Jul 18;40(15):2335-46

Cytotoxicity of platinum (II) dinuclear complexes with 1-alkylthymine ligands against mouse sarcoma 180 cells. Rekonen P, et al. **J Med Chem** 1997 Feb 14;40(4):515-9

ANTINEOPLASTIC AGENTS

Antitumor agents. 172. Synthesis and biological evaluation of novel deacetamidothiocolchicin-7-ols and ester analogs as antitubulin agents. Shi Q, et al. **J Med Chem** 1997 Mar 14;40(6):961-6

Synthesis and evaluation of 6-(dibromomethyl)-5-nitropyrimidines as potential antitumor agents. Thompson MD, et al. **J Med Chem** 1997 Feb 28;40(5):766-70

Sulfonimidamide analogs of oncolytic sulfonylureas. Toth JE, et al. **J Med Chem** 1997 Mar 14;40(6):1018-25

Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. Campbell MJ, et al. **J Mol Endocrinol** 1997 Aug;19(1):15-27

RKS-1778, a new mammalian cell-cycle inhibitor and a key intermediate of the [11]cytochalasin group. Kakeya H, et al. **J Nat Prod** 1997 Jul;60(7):669-72

Cytotoxic oxygenated desmosterols of the red alga Galaxaura marginata. Sheu JH, et al. **J Nat Prod** 1996 Jan;59(1):23-6

Novel beta-methoxyacrylates of the 9-methoxystrobilurin and oudesmansin classes produced by the basidiomycete Favolaschia pustulosa. Wood KA, et al. **J Nat Prod** 1996 Jul;59(7):646-9

Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. Arcamone F, et al. **J Natl Cancer Inst** 1997 Aug 20;89(16):1217-23

Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. Ciardiello F, et al. **J Natl Cancer Inst** 1996 Dec 4;88(23):1770-6

Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play [editorial] Debatin KM. **J Natl Cancer Inst** 1997 Jun 4;89(11):750-1 (17 ref.)

Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA [see comments] Dixit M, et al. **J Natl Cancer Inst** 1997 Mar 5;89(5):365-73. Comment in: J Natl Cancer Inst 1997 Mar 5;89(5):341-3.

N-(4-hydroxyphenyl)retinamide activation of a distinct pathway signaling apoptosis [editorial; comment] Dmitrovsky E. **J Natl Cancer Inst** 1997 Aug 20; 89(16):1179-81. Comment on: J Natl Cancer Inst 1997 Aug 20;89(16):1191-8.

Multidrug resistance in breast cancer--is the jury in yet? [editorial; comment] Kaye SB. **J Natl Cancer Inst** 1997 Jul 2;89(13):902-3. Comment on: J Natl Cancer Inst 1997 Jul 2;89(13):917-31.

Apoptosis of N-type neuroblastoma cells after differentiation with 9-cis-retinoic acid and subsequent washout. Lovat PE, et al. **J Natl Cancer Inst** 1997 Mar 19;89(6):446-52

Epidermal growth factor receptor family and chemosensitization [editorial; comment] Mendelsohn J, et al. **J Natl Cancer Inst** 1997 Mar 5;89(5):341-3 (45 ref.). Comment on: J Natl Cancer Inst 1997 Mar 5;89(5):365-73.

Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. Micheau O, et al. **J Natl Cancer Inst** 1997 Jun 4;89(11):783-9

Baseline apoptosis of tumor cells as a response predictor to chemotherapy [letter; comment] Provinciali M, et al. **J Natl Cancer Inst** 1997 Jun 18;89(12):889-90. Comment on: J Natl Cancer Inst 1996 Sep 18;88(18):1308-14.

Promise and problems of Bcl-2 antisense therapy [editorial; comment] Reed JC. **J Natl Cancer Inst** 1997 Jul 16; 89(14):988-90 (36 ref.). Comment on: J Natl Cancer Inst 1997 Jul 16;89(14):1027-36.

Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. Rozen F, et al. **J Natl Cancer Inst** 1997 May 7;89(9):652-6

Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance [see comments] Trock BJ, et al. **J Natl Cancer Inst** 1997 Jul 2;89(13):917-31. Comment in: J Natl Cancer Inst 1997 Jul 2;89(13):902-3. Comment in: J Natl Cancer Inst 1997 Jul 2;89(13):904-5.

Synergistic induction of HL60 cell differentiation by ketoconazole and 1-desoxy analogues of vitamin D3. Wang X, et al. **J Natl Cancer Inst** 1997 Aug 20;89(16):1199-206

Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence [see comments] Ziegler A, et al. **J Natl Cancer Inst** 1997 Jul 16;89(14):1027-36. Comment in: J Natl Cancer Inst 1997 Jul 16;89(14):988-90.

"Sweet sixteen" drugs blur line between treatment, prevention [news] Ziegler J. **J Natl Cancer Inst** 1997 Jan 15;89(2):121-2

Retinoic acid induces apoptosis in PC12 cells independent of neurotrophic factors. Tong L, et al. **J Neurochem** 1997 Apr;68(4):1424-35

Modulation of the alpha 2 macroglobulin receptor/low density lipoprotein receptor related protein by interferon-gamma in human astroglial cells. Businaro R, et al. **J Neuroimmunol** 1997 Jan;72(1):75-81

The cell cycle and induction of apoptosis in a hamster fibrosarcoma cell line treated with anti-cancer drugs: its importance to solid tumour chemotherapy. el Alaoui S, et al. **J Neurooncol** 1997 Jan;31(1-2):195-207

Interferon-beta inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines. Garrison JI, et al. **J Neurooncol** 1996 Dec;30(3):213-23

Inhibitory effects of CAI in glioblastoma growth and invasion. Jacobs W, et al. **J Neurooncol** 1997 Apr; 32(2):93-101

Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors. Senkal M, et al. **J Neurooncol** 1997 May;32(3):203-8

Nerve terminal withdrawal from rat neuromuscular junctions induced by neuregulin and Schwann cells. Trachtenberg JT, et al. **J Neurosci** 1997 Aug 15;17(16):6243-55

N-(4-hydroxyphenyl)-retinamide increases lecithin:retinol acyltransferase activity in rat liver. Matsuura T, et al. **J Nutr** 1996 Oct;126(10):2474-80

The role of the agouti gene in the yellow obese syndrome. Miltenberger RJ, et al. **J Nutr** 1997 Sep;127(9):1902S-1907S (81 ref.)

Effects of all-trans retinoic acid on choriocarcinoma cells in vitro. Yamada S, et al. **J Obstet Gynaecol Res** 1997 Apr; 23(2):125-32

Cytochrome-P450 induction and antineoplastic action of fotemustine in mice. Isa M, et al. **J Pharm Belg** 1996 Jul-Aug;51(4):192-4

Detection of platinum in the brain of mice treated with cisplatin and subjected to short-term hypoxia. Minami T, et al. **J Pharm Pharmacol** 1996 May;48(5):505-9

Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. Crosasso P, et al. **J Pharm Sci** 1997 Jul;86(7):832-9

Synthesis and cytotoxic evaluation of some cyclic arylidene ketones and related oximes, oxime esters, and analogs. Dimmock JR, et al. **J Pharm Sci** 1994 Jun;83(6):852-8

Endogenous tumor necrosis factor enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines. Debernardis D, et al. **J Pharmacol Exp Ther** 1996 Oct; 279(1):84-90

Hydroxyurea induces the gene expression and synthesis of proinflammatory cytokines in vivo. Navarra P, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):477-82

Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells. Winkler JD, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):956-66

Determination of the mechanism of action of anticancer drugs by means of the computer-assisted microscope image analysis of Feulgen-stained nuclei. Pauwels O, et al. **J Pharmacol Toxicol Methods** 1997 Mar;37(2):105-15

Differential cytotoxic effects induced after photosensitization by hypericin. Vandenbogaerde AL, et al. **J Photochem Photobiol B** 1997 Apr;38(2-3):136-42

Sociosexual behaviour and paternity in procarbazine-exposed rats with or without regional testicular circulatory isolation. Farr SA, et al. **J Reprod Fertil** 1997 May; 110(1):29-34

Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. James SY, et al. **J Steroid Biochem Mol Biol** 1996 Jul;58(4):395-401

RU 58668: further in vitro and in vivo pharmacological data related to its antitumoral activity. Van de Velde P, et al. **J Steroid Biochem Mol Biol** 1996 Dec;59(5-6):449-57

Antiproliferative effect of suramin on primary cultures of human pheochromocytomas and rat PC12 pheochromocytoma cells. Zielke A, et al. **J Surg Oncol** 1997 Sep;66(1):11-8

Cucurbitacin E targets proliferating endothelia. Duncan MD, et al. **J Surg Res** 1997 Apr;69(1):55-60

Time course of induction of rat hepatic drug-metabolizing enzyme activities following dietary administration of flavonoids. Siess MH, et al. **J Toxicol Environ Health** 1996 Dec 6;49(5):481-96

The effect of Wilms tumor chemotherapy on contralateral renal growth after nephrectomy. Ferrer FA, et al. **J Urol** 1997 Sep;158(3 Pt 2):1086-9

Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. Kotoh S, et al. **J Urol** 1997 Mar;157(3):1054-8

Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C. Okamoto E, et al. **J Urol** 1996 Oct; 156(4):1492-5

Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule. Ando Y, et al. **Jpn J Cancer Res** 1997 May;88(5):517-21

Mechanisms of growth inhibition of human lung cancer cell line, PC-9, by tea polyphenols. Okabe S, et al. **Jpn J Cancer Res** 1997 Jul;88(7):639-43

In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors. Tsutsumi Y, et al. **Jpn J Cancer Res** 1996 Oct;87(10):1078-85

Establishment by adriamycin exposure of multidrug-resistant rat ascites hepatoma AH130 cells showing low DT-diaphorase activity and high cross resistance to mitomycins. Wakusawa S, et al. **Jpn J Cancer Res** 1997 Jan;88(1):88-96

Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Yoo YC, et al. **Jpn J Cancer Res** 1997 Feb;88(2):184-90

Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. Ikegami Y, et al. **Jpn J Pharmacol** 1996 Jan;70(1):65-72

Enhancement of interleukin-1 alpha mediated autocrine growth of cultured human keratinocytes by sho-saiko-to. Matsumoto Y, et al. **Jpn J Pharmacol** 1997 Apr;73(4):333-6

Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats. Miyauchi S, et al. **Jpn J Pharmacol** 1996 Feb; 70(2):139-48

Influence of time after the removal of nocodazole from nuclear donors on the development of reconstituted embryos in bovine nuclear transplantation. Tanaka H, et al. **Jpn J Vet Res** 1995 Dec;43(3-4):135-43

1,25-dihydroxyvitamin D3 and the synthetic vitamin D analogue, KH 1060, modulate the growth of mouse proximal tubular cells. Weinreich T, et al. **Kidney Blood Press Res** 1996;19(6):325-31

Apoptosis in mesangial cells induced by ionizing radiation and cytotoxic drugs. Cha DR, et al. **Kidney Int** 1996 Nov; 50(5):1565-71

Docosahexaenoic acid ethyl ester and its ultraviolet degradation products showed DNA-breaking activity in vitro and cytotoxic effects on the HSC-4 cell line. Liu W, et al. **Kobe J Med Sci** 1995 Dec;41(6):235-45

Practical role of genetic profiling and preservation stock of human tumour xenograft lines as a tool in animal experiments for antitumour drug evaluation. Ohnishi Y, et al. **Lab Anim** 1997 Apr;31(2):169-76

Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? [letter] Lallemand JY, et al. **Lancet** 1997 Sep 6; 350(9079):711-2

Starve the tumour, save the patient [news] Rowe PM. **Lancet** 1997 Jan 11;349(9045):108

The effects of 13-cis retinoic acid on squamous cell carcinoma proliferation and adhesion to extracellular matrix proteins. Speyer MT, et al. **Laryngoscope** 1997 Jan; 107(1):44-8

In vitro effects and localisation of the photosensitizers m-THPC and m-THPC MD on carcinoma cells of the human breast (MCF-7) and Chinese hamster fibroblasts (V-79). Hornung R, et al. **Lasers Surg Med** 1997; 20(4):443-50

N-(4-hydroxyphenyl)retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells. Chan LN, et al. **Leuk Lymphoma** 1997 Apr;25(3-4):271-80

Interferon-alpha, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia. Jewell AP. **Leuk Lymphoma** 1996 Mar;21(1-2):43-7 (48 ref.)

Retinoid resistance in leukemic cells. Kizaki M, et al. **Leuk Lymphoma** 1997 May;25(5-6):427-34 (42 ref.)

Effects of interferon-alpha and -gamma on B cell differentiation in macroglobulinemia. Levy Y, et al. **Leuk Lymphoma** 1996 Oct;23(3-4):347-51

In vitro and in vivo anti-leukemic efficacy of cyclic AMP modulating agents against human leukemic B-cell precursors. Myers DE, et al. **Leuk Lymphoma** 1996 Jul; 22(3-4):259-64

A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Newman A, et al. **Leuk Lymphoma** 1997 Feb;24(5-6):533-7

In vitro activity on myeloid progenitors of a combination of 2-chloro-2'-deoxyadenosine and interferon alpha: the effects of IL-1 and GM-CSF. Ballarino P, et al. **Leuk Res** 1996 Sep;20(9):777-80

Failure to induce resistance to cytotoxic drugs in normal lymphocytes. Bentley P, et al. **Leuk Res** 1996 Aug; 20(8):645-8

Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs. Doré BT, et al. **Leuk Res** 1996 Sep;20(9):761-9

Interleukin-4 is a pleotropic cytokine with effects on B-cell malignancies [comment] Dutcher JP, et al. **Leuk Res** 1997 Jan;21(1):17-9. Comment on: Leuk Res 1997 Jan;21(1):9-16.

Synergistic effects of interleukin-11 with other growth factors on the expansion of hematopoietic progenitors from normal individuals and chronic myeloid leukemia patients resistant to treatment with cytosine arabinoside or eilatin. Einat M, et al. **Leuk Res** 1996 Sep;20(9):751-9

Suppression of in vitro maintenance of non-promyelocytic myeloid leukemia clonogenic cells by all-trans retinoic acid: modulating effects of dihydroxylated vitamin D3, alpha interferon and 'stem cell factor'. Ferrero D, et al. **Leuk Res** 1997 Jan;21(1):51-8

Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients [see comments] Frankfurt OS, et al. **Leuk Res** 1997 Jan;21(1):9-16. Comment in: Leuk Res 1997 Jan;21(1):17-9.

Characterization of newly established human myeloid leukemia cell line (KF-19) and its drug resistant sublines. Fukuda T, et al. **Leuk Res** 1996 Nov-Dec;20(11-12):931-9

Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors [see comments] Li Y, et al. **Leuk Res** 1997 May;21(5):391-7. Comment in: Leuk Res 1997 May;21(5):399-401.

The in vitro effects of all-trans-retinoic acid and hematopoietic growth factors on the clonal growth and self-renewal of blast stem cells in acute promyelocytic leukemia [see comments] Miyauchi J, et al. **Leuk Res** 1997 Apr;21(4):285-94. Comment in: Leuk Res 1997 Apr;21(4):295-7.

All-trans and 9-cis retinoic acid enhance 1,25-dihydroxyvitamin D3-induced monocytic differentiation of U937 cells [see comments] Nakajima H, et al. **Leuk Res** 1996 Aug;20(8):665-76. Comment in: Leuk

Res 1997 Feb;21(2):173–6.
CB1093, a novel vitamin D analog; effects on differentiation and clonal growth on HL–60 and de novo leukemia cells. Pakkala I, et al. **Leuk Res** 1997 Apr;21(4):321–6
Bryostatin 1: differentiating agent from the depths [comment] Stone RM. **Leuk Res** 1997 May;21(5):399–401 (32 ref.). Comment on: Leuk Res 1997 May;21(5):391–7.
Heterogenous effects of bryostatin on human myeloid leukemia clonogenicity: dose and time scheduling dependency. van der Hem KG, et al. **Leuk Res** 1996 Sep; 20(9):743–50
Ether lipids are effective cytotoxic drugs against multidrug–resistant acute leukemia cells and can act by the induction of apoptosis. Verdonck LF, et al. **Leuk Res** 1997 Jan;21(1):37–43
Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells. Vial JP, et al. **Leuk Res** 1997 Feb; 21(2):163–72
The effect of edelfosine on CTP:cholinephosphate cytidylyltransferase activity in leukemic cell lines. Vogler WR, et al. **Leuk Res** 1996 Nov–Dec;20(11–12):947–51
Oncogenic RAS genes impair erythroid differentiation of erythroleukaemia cells. Zaker F, et al. **Leuk Res** 1997 Jul; 21(7):635–40
Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Antoku K, et al. **Leukemia** 1997 Oct;11(10):1665–72
Alterations of differentiation, clonal proliferation, cell cycle progression and bcl–2 expression in RAR alpha–altered sublines of HL–60. Grillier I, et al. **Leukemia** 1997 Mar; 11(3):393–400
The combined effects of all–trans retinoic acid and TGF–beta on the initial proliferation of normal human bone marrow progenitor cells. Lardon F, et al. **Leukemia** 1996 Dec; 10(12):1937–43
Effect of a vitamin D3 analog, EB1089, on hematopoietic stem cells from normal and myeloid leukemic blasts. Lee YY, et al. **Leukemia** 1996 Nov;10(11):1751–7
Inhibition of apoptotic cell death in B–CLL by interferon gamma correlates with clinical stage. Rojas R, et al. **Leukemia** 1996 Nov;10(11):1782–8
Topoisomerase II inhibitors induce DNA double–strand breaks at a specific site within the AML1 locus. Stanulla M, et al. **Leukemia** 1997 Apr;11(4):490–6
Effect of cisplatin on dopamine release from PC12 cells. Kasabdji D, et al. **Life Sci** 1996;59(21):1793–801
Free radical scavenging activities of mushroom polysaccharide extracts. Liu F, et al. **Life Sci** 1997; 60(10):763–71
Cisplatinum enhancement of myocardial Mg2+ transport. Murphy L, et al. **Life Sci** 1996;59(20):1739–44
Activation of P388D1 macrophage cell line by chemotherapeutic drugs. Pai K, et al. **Life Sci** 1997; 60(15):1239–48
Genetic control of biological rhythms: independent expression of each rhythm parameter. Peleg L, et al. **Life Sci** 1995 Feb 17;56(13):1143–9
IP6: a novel anti–cancer agent. Shamsuddin AM, et al. **Life Sci** 1997;61(4):343–54 (68 ref.)
Characterization of an HL–60 cell variant resistant to the antineoplastic ether lipid 1–O–octadecyl–2–O–methyl–rac–glycero–3–phosphocholine. Small GW, et al. **Lipids** 1997 Jul; 32(7):715–23
Comparison of mitoxantrone and tetracycline as pleural sclerosing agents in rabbits. Light RW, et al. **Lung** 1996; 174(6):373–81
Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents. Wang HK, et al. **Med Res Rev** 1997 Jul;17(4):367–425 (232 ref.)
Effect of retinoic acid on melanoma cell–derived factor stimulation of fibroblast glycosaminoglycan synthesis. Edward M, et al. **Melanoma Res** 1997 Jun;7(3):189–96
Regulation of interleukin–8 mRNA expression and protein secretion in a melanoma cell line by tumour necrosis factor–alpha and interferon–gamma. Möhler T, et al. **Melanoma Res** 1996 Aug;6(4):307–11
Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF–beta 1 in a rat orthotopic prostate adenocarcinoma. Lievano G, et al. **Methods Find Exp Clin Pharmacol** 1997 May; 19(4):261–7
Anaplasia and drug selection–independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor. Re GG, et al. **Mod Pathol** 1997 Feb;10(2):129–36
The anti–cancer agent distamycin A displaces essential transcription factors and selectively inhibits myogenic differentiation. Taylor A, et al. **Mol Cell Biochem** 1997 Apr; 169(1–2):61–72
Cell cycle parameters of Chinese hamster ovary cells during exponential, polyamine–limited growth. Harada JJ, et al. **Mol Cell Biol** 1981 Jul;1(7):594–9
E2F–1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53–independent apoptosis. Nip J, et al. **Mol Cell Biol** 1997 Mar;17(3):1049–56
DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher–order chromatin fragmentation during the initial stages of apoptosis. Stanulla M, et al. **Mol Cell Biol** 1997 Jul; 17(7):4070–9
The noncalcemic vitamin D analogues EB1089 and 22–oxacalcitriol interact with the vitamin D receptor and suppress parathyroid hormone–related peptide gene expression. Falzon M. **Mol Cell Endocrinol** 1997 Mar 14; 127(1):99–108
High–volume cellular screening for anticancer agents with combinatorial chemical libraries: a new methodology. Salmon SE, et al. **Mol Divers** 1996 Oct;2(1–2):57–63
Somatostatin acts by inhibiting the cyclic 3',5'–adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element–binding protein (CREB) phosphorylation, and CREB transcription potency. Tentler JJ, et al. **Mol Endocrinol** 1997 Jun;11(7):859–66
Proteolytic cleavage during chemotherapy–induced apoptosis. Kaufmann SH. **Mol Med Today** 1996 Jul; 2(7):298–303 (44 ref.)
Role of recombinational repair in sensitivity to an antitumour agent that inhibits bacteriophage T4 type II DNA topoisomerase. Neece SH, et al. **Mol Microbiol** 1996 Jun; 20(6):1145–54
Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180). Cornarotti M, et al. **Mol Pharmacol** 1996 Dec;50(6):1463–71
Evidence for distinction of the differentiation–inducing activities and cytostatic properties of 9–(2–phosphonylmethoxyethyl)adenine and a variety of differentiation–inducing agents in human erythroleukemia K562 cells. Hatse S, et al. **Mol Pharmacol** 1996 Nov; 50(5):1231–42
2–Chloro–2'–deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function. Hentosh P, et al. **Mol Pharmacol** 1997 Apr;51(4):613–9
Role of determinants of cadmium sensitivity in the tolerance of Schizosaccharomyces pombe to cisplatin. Perego P, et al. **Mol Pharmacol** 1997 Jan;51(1):12–8
Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication. Pisarev VM, et al. **Mol Pharmacol** 1997 Jul;52(1):63–8
Cisplatin, camptothecin, and taxol sensitivities of cells with p53–associated multidrug resistance. Vasey PA, et al. **Mol Pharmacol** 1996 Dec;50(6):1536–40
Inhibition of mitosis and microtubule function through direct tubulin binding by a novel antiproliferative naphthopyran LY290181. Wood DL, et al. **Mol Pharmacol** 1997 Sep; 52(3):437–44
DNA modifications by antitumor trans–[PtCl2(E–iminoether)2]. Zaludová R, et al. **Mol Pharmacol** 1997 Sep;52(3):354–61
Drug–induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy [see comments] Nyce JW. **Mutat Res** 1997 Apr; 386(2):153–61 (60 ref.). Comment in: Mutat Res 1997 Apr;386(2):103–5.
Bioactive murine and human interleukin–12 fusion proteins which retain antitumor activity in vivo. Lieschke GJ, et al. **Nat Biotechnol** 1997 Jan;15(1):35–40
Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs [see comments] Griffiths M, et al. **Nat Med** 1997 Jan; 3(1):89–93. Comment in: Nat Med 1997 Jan;3(1):25–6.
Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes [news; comment] Lamb JR, et al. **Nat Med** 1997 Sep;3(9):962–3. Comment on: Nat Med 1997 Sep;3(9):1034–6.
Evaluation of phthalmustine, a new anticancer compound. II. Tumor inhibitory effect in murine Ehrlich ascites carcinoma and sarcoma–180. Bhattacharya S, et al. **Neoplasma** 1996;43(3):209–13
Protective effects of cardioxane against anthracycline–induced cardiotoxicity in relapsed acute myeloid leukemias. Lemež P, et al. **Neoplasma** 1996; 43(6):417–9
Ascorbic acid and 6–deoxy–6–chloro–ascorbic acid: potential anticancer drugs. Osmak M, et al. **Neoplasma** 1997; 44(2):101–7
Retinoic acid–induced alteration of cell surface topography and other changes in an oral carcinoma cell line in culture. Sarkar R, et al. **Neoplasma** 1997;44(1):37–43
Antitumor action of bovine seminal ribonuclease. Souček J, et al. **Neoplasma** 1996;43(5):335–40
Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Weller M, et al. **Neurology** 1997 Jun;48(6):1704–9
Neuregulin and erbB receptors play a critical role in neuronal migration. Rio C, et al. **Neuron** 1997 Jul;19(1):39–50
Induction of trk receptors by retinoic acid in a human embryonal carcinoma cell line. Cheung WM, et al. **Neuroreport** 1996 Apr 26;7(6):1204–8
Induction of TrkA receptor by retinoic acid in leukaemia cell lines. Xie P, et al. **Neuroreport** 1997 Mar 24; 8(5):1067–70
Induction of tissue transglutaminase in rat superior cervical sympathetic ganglia following in vitro stimulation of retinoic acid. Ando M, et al. **Neurosci Res** 1996 Mar; 24(4):357–62
Prediction of drug cytotoxicity in 9L rat brain tumor by using flow cytometry with a deoxyribonucleic acid–binding dye. Iwadate Y, et al. **Neurosurgery** 1997 Apr;40(4):782–7; discussion 787–8
The effect of dacarbazine and vincristine sulfate on human melanoma cell lines. In vitro analysis of interaction on DNA synthesis, RNA synthesis and protein synthesis. Tachihara R. **Nippon Ika Daigaku Zasshi** 1997 Jun; 64(3):238–48
Determination of the target volume of HeLa cells treated with platinum–195 m radiolabeled cis–diammine(1, 1–cyclobutane–dicarboxylato)–platinum(II); comparison with cis– and trans–diamminedichloroplatinums(II). Akaboshi M, et al. **Nucl Med Biol** 1994 Oct;21(7):953–8
S–allyl cysteine inhibits nitrosomorpholine formation and bioactivation. Dion ME, et al. **Nutr Cancer** 1997;28(1):1–6
Effect of arecoline on the curcumin–modulated hepatic biotransformation system enzymes in lactating mice and translactationally exposed F1 pups. Singh A, et al. **Nutr Cancer** 1996;25(1):101–10
Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. So FV, et al. **Nutr Cancer** 1996;26(2):167–81
hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Brown R, et al. **Oncogene** 1997 Jul 3;15(1):45–52
Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Gallagher WM, et al. **Oncogene** 1997 Jan 16;14(2):185–93
IFNalpha induces the expression of the cyclin–dependent kinase inhibitor p21 in human prostate cancer cells. Hobeika AC, et al. **Oncogene** 1997 Mar 13;14(10):1165–70
WAF1/CIP1 increases the susceptibility of p53 non–functional malignant glioma cells to cisplatin–induced apoptosis. Kondo S, et al. **Oncogene** 1996 Sep 19; 13(6):1279–85
Geranylgeraniol potentiates lovastatin inhibition of oncogenic H–Ras processing and signaling while preventing cytotoxicity. McGuire TF, et al. **Oncogene** 1997 Jan 23;14(3):305–12
Induction of gamma–glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line. el–akawi Z, et al. **Oncol Res** 1996;8(10–11):415–23
Increased plasma serotonin following treatment with flavone–8–acetic acid, 5,6–dimethylxanthenone–4–acetic acid, vinblastine, and colchicine: relation to vascular effects. Baguley BC, et al. **Oncol Res** 1997;9(2):55–60
Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis. Bergnes G, et al. **Oncol Res** 1996; 8(3):121–30
Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4–methyl–5–amino–1–formylisoquinoline thiosemicarbazone. Cory AH, et al. **Oncol Res** 1996; 8(10–11):449–56
Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin–sensitive and –resistant human breast cancer cells. Fanciulli M, et al. **Oncol Res** 1996; 8(3):111–20
Systemic chemotherapy alters interleukin–1 beta and its receptor antagonist production by human alveolar macrophages in lung cancer patients. Haku T, et al. **Oncol Res** 1996;8(12):519–26
Resistance to inhibitors of S–adenosyl–L–homocysteine hydrolase in C1300 murine neuroblastoma tumor cells is associated with increased methionine adenosyltransferase activity. Hamre MR, et al. **Oncol Res** 1995;7(10–11):487–92
KRN7000, a novel immunomodulator, and its antitumor activities. Kobayashi E, et al. **Oncol Res** 1995; 7(10–11):529–34
Thymidylate synthase as a target for growth inhibition in methotrexate–sensitive and –resistant human head and neck cancer and leukemia cell lines. McGuire JJ, et al. **Oncol Res** 1997;9(3):139–47
9–[3–(2–Nitro–1–imidazolyl)propylamino]–cyclopenteno[b]quinoline hydrochloride (NLCPQ–1). A novel DNA–affinic bioreductive agent as cytotoxin and radiosensitizer. Papadopoulou MV, et al. **Oncol Res** 1996; 8(10–11):425–34
9–[3–(2–Nitro–1–imidazolyl)propylamino]–cyclopenteno[b]quinoline hydrochloride (NLCPQ–1): a novel DNA–affinic bioreductive agent as chemosensitizer. I. Papadopoulou MV, et al. **Oncol Res** 1997;9(5):249–57
The antiproliferative effect of trans–retinoic acid is associated with selective induction of interleukin–1 beta, a cytokine that directly inhibits growth of lung cancer cells. Ross HJ. **Oncol Res** 1996;8(4):171–8
Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. Subramanian D, et al. **Oncol Res** 1995;7(9):461–9
Enhancing effects of (2S,3S,4R)–1–O–(alpha–D–galactopyranosyl)–2–(N–hexacosanoylamino) –1,3,4–octadecanetriol (KRN7000) on antigen–presenting function of antigen–presenting cells and antimetastatic activity of KRN7000–pretreated antigen–presenting cells. Yamaguchi Y, et al. **Oncol Res** 1996;8(10–11):399–407
Effects of OK–432 (picibanil) on the estrogen receptors of MCF–7 cells and potentiation of antiproliferative effects of tamoxifen in combination with OK–432. Aoyagi H, et al. **Oncology** 1997 Sep–Oct;54(5):414–23
Topotecan's potency linked to presence of albumin [news] **Oncology (Huntingt)** 1996 Feb;10(2):254
Clinical Trials. Referral resource Clinical trials using CI–980 (mivobulin isethionate). Wright J, et al. **Oncology (Huntingt)** 1997 May;11(5):643–4
Prevention of secondary cataract by antimitotic drugs: experimental study. Ismail MM, et al. **Ophthalmic Res** 1996; 28(1):64–9

Tecogalan sodium inhibits corneal neovascularization induced by basic fibroblast growth factor. Murata T, et al. **Ophthalmic Res** 1995;27(6):330–4

Cytotoxic effects of TGF–alpha–Pseudomonas exotoxin A fusion protein in human pancreatic carcinoma cells. Baldwin RL, et al. **Pancreas** 1996 Jul;13(1):16–21

Biophysical characterization and formulation of TP40: A chimeric protein that requires a pH–dependent conformational change for its biological activity. Sanyal G, et al. **Pharm Biotechnol** 1996;9:365–92 (30 ref.)

Paclitaxel and nocodazole differentially alter endocytosis in cultured cells. Hamm–Alvarez SF, et al. **Pharm Res** 1996 Nov;13(11):1647–56

Cellular delivery of nucleoside diphosphates: a prodrug approach. Kang SH, et al. **Pharm Res** 1997 Jun; 14(6):706–12

Apoptosis: molecular mechanisms and implications for cancer chemotherapy. Guchelaar HJ, et al. **Pharm World Sci** 1997 Jun;19(3):119–25 (93 ref.)

Altered uterine sensitivity to oxytocin and prostaglandin F2 alpha in dimethylbenz(a)anthracene (DMBA)–induced rat mammary carcinoma: the effects of tamoxifen and/or recombinant human interferon alpha 2b therapy. Badary OA, et al. **Pharmacol Res** 1996 Sep–Oct;34(3–4):99–103

Induced differentiation, the cell cycle, and the treatment of cancer. Rifkind RA, et al. **Pharmacol Ther** 1996; 69(2):97–102 (59 ref.)

In vitro effect of avarone and avarol, a quinone/hydroquinone couple of marine origin, on platelet aggregation. Belisario MA, et al. **Pharmacol Toxicol** 1996 Dec;79(6):300–4

Polycyclic aromatic alkaloids. XII: In vitro– and in vivo–investigations of the cytotoxic marine alkaloid 2–bromoleptoclinidinone. Bracher F. **Pharmazie** 1997 Jan; 52(1):57–60

A comparison of the effects of cisplatin and cisplatinum (II)phosphonate complex on ADP–induced platelet aggregation in vitro. Kostka B, et al. **Pharmazie** 1996 Dec; 51(12):990–2

The photodynamic effect of Victoria blue BO on peripheral blood mononuclear and leukemic cells. Fiedorowicz M, et al. **Photochem Photobiol** 1997 May;65(5):855–61

Photodynamic therapy with a diode laser for implanted fibrosarcoma in mice employing mono–L–aspartyl chlorin E6. Katsumi TA, et al. **Photochem Photobiol** 1996 Oct; 64(4):671–5

Azelaic acid was sensitizing effect in the chemotherapeutic treatment of several melanoma cell lines. Rodriguez–Vicente J, et al. **Pigment Cell Res** 1996 Dec; 9(6):317–25

Antineoplastic agents; I. Three spirostanol glycosides from rhizomes of Dioscorea collettii var. hypoglauca. Hu K, et al. **Planta Med** 1996 Dec;62(6):573–5

Effect of quercetin on the growth of mouse fibroblast cells in vitro. Pawlikowska–Pawlęga B, et al. **Pol J Pharmacol** 1995 Nov–Dec;47(6):531–5

Effect of some anti–cancer drugs and combined chemotherapy on the pharmacokinetics of antipyrine in the rat. Skrętkowicz J. **Pol J Pharmacol** 1995 Nov–Dec; 47(6):519–24

Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small–cell lung cancer after treatment with bombesin antagonist RC–3095. Halmos G, et al. **Proc Natl Acad Sci U S A** 1997 Feb 4;94(3):956–60

Cisplatin increases meiotic crossing–over in mice. Hanneman WH, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5; 94(16):8681–5

A tumor–selective somatostatin analog (TT–232) with strong in vitro and in vivo antitumor activity. Kéri G, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12513–8

Sequence–specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C–raf kinase supports an antisense mechanism of action in vivo. Monia BP, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24; 93(26):15481–4

Cell–surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Rockwell P, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6523–8

Human lymphotoxin mutein lacks hypotensive activity but has higher in vivo antitumor activity than lymphotoxin or tumor necrosis factor. Taniyama M, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3324–9

Cloning of a gene (RIG–G) associated with retinoic acid–induced differentiation of acute promyelocytic leukemia cells and representing a new member of a family of interferon–stimulated genes. Yu M, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7406–11

Inhibition of growth in oral squamous carcinoma cells by cyclopentenone prostaglandins: comparison with chemotherapeutic agents. ElAttar TM, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jun; 56(6):461–5

Stimulation of tumor necrosis factor–alpha release from lipopolysaccharide–activated human blood monocytes by prostaglandin J2 and metabolites of prostaglandin J2. Vedin I, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Sep; 55(3):185–9

Effect of retinoic acid on prostatic development. Aboseif SR, et al. **Prostate** 1997 May 15;31(3):161–7

Effects of retinoid X receptor–selective ligands on proliferation of prostate cancer cells. de Vos S, et al. **Prostate** 1997 Jul 1;32(2):115–21

Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines. de Vos S, et al. **Prostate** 1997 May 1;31(2):77–83

Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability, and DNA synthesis. Maramag C, et al. **Prostate** 1997 Aug 1;32(3):188–95

Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin. Palayoor ST, et al. **Radiat Res** 1997 Aug; 148(2):105–14

Synergistic cytotoxic effects of ether phospholipid analogues and ionizing radiation in human carcinoma cells. Berkovic D, et al. **Radiother Oncol** 1997 Jun;43(3):293–301

Tumor–killer made; how does it work? [news] Service RF. **Science** 1996 Dec 20;274(5295):2009

An information–intensive approach to the molecular pharmacology of cancer. Weinstein JN, et al. **Science** 1997 Jan 17;275(5298):343–9

An overview of the clinical pharmacology of topotecan. Dennis MJ, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 5):S5–12–S5–18 (34 ref.)

Antisense oligonucleotides as therapeutics for malignant diseases. Ho PT, et al. **Semin Oncol** 1997 Apr;24(2):187–202 (103 ref.)

Contributions of protein structure–based drug design to cancer chemotherapy. Jackson RC. **Semin Oncol** 1997 Apr; 24(2):164–72 (46 ref.)

Tumor–associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Pluda JM. **Semin Oncol** 1997 Apr;24(2):203–18 (181 ref.)

Targeted therapy for prostate cancer: the Memorial Sloan–Kettering Cancer Center approach. Slovin SF, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 14):41–8 (61 ref.)

The effects of taxol, methylprednisolone, and 4–aminopyridine in compressive spinal cord injury: a qualitative experimental study. Perez–Espejo MA, et al. **Surg Neurol** 1996 Oct;46(4):350–7

Overexpression of bax sensitizes breast cancer MCF–7 cells to cisplatin and etoposide. Sakakura C, et al. **Surg Today** 1997;27(7):676–9

Cyclin–dependent kinase inhibitors block proliferation of human gastric cancer cells. Iseki H, et al. **Surgery** 1997 Aug;122(2):187–94; discussion 194–5

Dehydroepiandrosterone–sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo. Melvin WS, et al. **Surgery** 1997 Apr;121(4):392–7

TNF–alpha suppresses IL–6 upregulation of protein S in HepG–2 hepatoma cells. Hooper WC, et al. **Thromb Res** 1996 Feb 1;81(3):315–26

Oncostatin M: a new potent inhibitor of iodine metabolism inhibits thyroid peroxidase gene expression but not DNA synthesis in porcine thyroid cells in culture. Isozaki O, et al. **Thyroid** 1997 Feb;7(1):71–7

Detection of DNA damage in transcriptionally active genes by RT–PCR and assessment of repair of cisplatin–induced damage in the glutathione S–transferase–pi gene in human glioblastoma cells. Brandt TY, et al. **Toxicol Appl Pharmacol** 1997 Mar;143(1):22–9

Differential binding of HMG1, HMG2, and a single HMG box to cisplatin–damaged DNA. Farid RS, et al. **Toxicol Appl Pharmacol** 1996 Dec;141(2):532–9

Antimitotic intervention with colchicine alters the outcome of o–DCB–induced hepatotoxicity in Fischer 344 rats. Kulkarni SG, et al. **Toxicology** 1997 Jun 27;120(2):79–88

Novel non–steroidal aromatase inhibitors: are there new perspectives in the treatment of breast cancer? Bajetta E, et al. **Tumori** 1996 Sep–Oct;82(5):417–22 (44 ref.)

Comparative study of classical, colorimetric and immunologic staining methods for the assessment of tumor cell viability. Basha G, et al. **Tumour Biol** 1996;17(6):354–61

Influence of neoadjuvant chemotherapy on serum tumor markers CA 15–3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. Bottini A, et al. **Tumour Biol** 1997;18(5):301–10

Combined effect of tamoxifen or interferon–beta and 4–hydroxyphenylretinamide on the growth of breast cancer cell lines. Coradini D, et al. **Tumour Biol** 1997;18(1):22–9

Effect of carboplatin on rat spermatogenesis. Fuse H, et al. **Urol Int** 1996;56(4):219–23

Multidrug resistance in androgen–independent growing rat prostate carcinoma cells is mediated by P–glycoprotein. Siegsmund MJ, et al. **Urol Res** 1997;25(1):35–41

The influence of alkoxymethyl purine and pyrimidine acyclonucleosides on growth inhibition of Kirkman–Robbins hepatoma and possible mechanism of their cytostatic activity. Modrzejewska H, et al. **Z Naturforsch [C]** 1996 Jan–Feb;51(1–2):75–80

Fluorescence of chromatin DNA induced by antitumoral naphthalimides. Stockert JC, et al. **Z Naturforsch [C]** 1997 May–Jun;52(5–6):408–11

[Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer] Liang Z, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb;31(2):75–8 (Eng. Abstr.) **(Chi)**

[The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line] Shi W, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb;31(2):79–82 (Eng. Abstr.) **(Chi)**

[Human mucoepidermoid carcinoma MEC–1 cells induced differentiation by HMBA] Chen Y, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1996 Jan; 31(1):28–30 (Eng. Abstr.) **(Chi)**

[Effects of curcumin derivatives on the GJIC of normal and tumor cells] Li Y, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1996 Apr; 18(2):111–5 (Eng. Abstr.) **(Chi)**

[Protein kinase inhibitor staurosporine enhances cytotoxicity of antitumor drugs to cancer cells] Wang RH, et al. **Yao Hsueh Hsueh Pao** 1996;31(6):411–5 (Eng. Abstr.) **(Chi)**

[The effect of chemotherapy on energy and nitrogen balance in patients with hematologic neoplasms] Tomíška M, et al. **Vnitr Lek** 1997 Jan;43(1):18–24 (Eng. Abstr.) **(Cze)**

[Value and applications of pharmacogenetics in oncology and hematology] Albin N, et al. **Bull Cancer** 1997 Jun; 84(6):643–51 (79 ref.) (Eng. Abstr.) **(Fre)**

[Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry] Belhoussine R, et al. **Bull Cancer** 1997 Apr;84(4):343–9 (39 ref.) (Eng. Abstr.) **(Fre)**

[Inhibitors of Ras farnesylation: tomorrow's anticancer agents?] Perrin D, et al. **Bull Cancer** 1997 Jun;84(6):635–42 (56 ref.) (Eng. Abstr.) **(Fre)**

[Place of in vitro models in preclinical evaluation of anticancer drugs] Robert J. **Bull Cancer** 1996 Oct; 83(10):801–8 (Eng. Abstr.) **(Fre)**

[Anti–fibrotic effects of interferons. Mechanisms of action and therapeutic prospects] Pilette C, et al. **Gastroenterol Clin Biol** 1997;21(6–7):466–71 (40 ref.) **(Fre)**

[The "antisense" strategy: a new approach in the development of antineoplastic substances and gene therapy] Hélène C. **J Pharm Belg** 1997 Mar–Apr;52(2):79–85 (29 ref.) **(Fre)**

[Angiostatin. A biological inhibitor of tumor angiogenesis] Thimme R, et al. **Dtsch Med Wochenschr** 1997 Mar 27; 122(13):413–4 **(Ger)**

[In vitro studies of DNA synthesis inhibition by hyperthermia (42.5 degrees C, 120 min) and cytostatic drugs in embryonal tumors and sarcomas in childhood] Willnow U, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:1100–1 (Eng. Abstr.) **(Ger)**

[Morphological and functional features of cytostatic drug resistance and the effects of MDR modulators] Reymann A, et al. **Pharmazie** 1996 Mar;51(3):171–6 (Eng. Abstr.) **(Ger)**

[Theory and actual attempts to establish an effective cancer chemotherapy] Fujimoto S. **Gan To Kagaku Ryoho** 1997 Feb;24(4):501–10 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Antimitotic agents] Fukuoka K, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1519–25 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Reversal of drug resistance in human cancer cells by anti–oncogenes] Funato T. **Gan To Kagaku Ryoho** 1997 Feb;24(4):395–400 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Telomere and telomerase in human cancer] Hiyama K, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):196–201 (Eng. Abstr.) **(Jpn)**

[Effect of phospholipase C inhibitor peptides on cancer cell growth] Homma M, et al. **Gan To Kagaku Ryoho** 1997 Jan; 24(2):156–63 (Eng. Abstr.) **(Jpn)**

[Cell cycle and apoptosis in cancer induced by the artepillin C extracted from Brazilian propolis] Kimoto T, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1855–9 **(Jpn)**

[Chemosensitivity test for gastric carcinoma] Kubota T. **Gan To Kagaku Ryoho** 1997 Feb;24(4):495–500 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Involvement of ICE/CED 3 family proteases in antitumor agent–induced apoptosis] Mashima T, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):211–5 (Eng. Abstr.) **(Jpn)**

[Cell signaling and CDDP resistance] Masumoto N, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):424–30 (36 ref.) (Eng. Abstr.) **(Jpn)**

[gamma–Glutamylcysteine synthetase and chemosensitivity] Nishio K, et al. **Gan To Kagaku Ryoho** 1997 Feb; 24(4):418–23 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Apoptosis and chemosensitivity] Nishio K, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):216–21 (20 ref.) (Eng. Abstr.) **(Jpn)**

[CDK and MMP inhibitors] Okuyama A, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1547–62 (62 ref.) (Eng. Abstr.) **(Jpn)**

[Angiogenesis and its inhibitors] Ono M, et al. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1585–93 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Development of new antitumor reagents which block the cell cycle progression] Osada H. **Gan To Kagaku Ryoho** 1997 Sep;24(11):1541–6 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Screening for the inhibitors of tumor invasion into basement membranes] Saiki I. **Gan To Kagaku Ryoho** 1997 Jan; 24(2):187–95 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Glutathione levels in human colon cancer cell line M7609 following culture in a low sulfur amino acid medium and its sensitivity to various anticancer drugs] Saito T, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):823–7 (Eng. Abstr.) **(Jpn)**

[Development of anti cancer drugs targeted on Fas–mediated apoptosis signal] Takahashi M, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):222–8 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Antitumor effect and mechanism of a novel multifunctional

nucleoside, 3'-ethynylnucleoside, on human cancers] Tanaka M, et al. **Gan To Kagaku Ryoho** 1997 Feb; 24(4):476–82 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Anti tumor activity of farnesyl transferase inhibitor] Yoshimatsu K, et al. **Gan To Kagaku Ryoho** 1997 Jan; 24(2):145–55 (Eng. Abstr.) **(Jpn)**

[Chemosensitivity test on hepatocellular carcinoma (HCC) and drug resistance] Ishimura H. **Hokkaido Igaku Zasshi** 1996 Nov;71(6):689–98 (Eng. Abstr.) **(Jpn)**

[Inhibition of proliferation by retinoic acid on adult T cell leukemia cells] Miyatake J, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Oct;19(5):477–87 (Eng. Abstr.) **(Jpn)**

[Enhancement of cytotoxic effect of anticancer agents of renal cell carcinoma] Okano M, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Aug;87(8):1041–7 (Eng. Abstr.) **(Jpn)**

[Effects of anticancer drugs on vascular wall: histological and pharmacological studies] Sakai T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Oct; 56(12):818–21 (Eng. Abstr.) **(Jpn)**

[Biological behavior of hypopharyngeal carcinoma] Zhou LX. **Nippon Jibiinkoka Gakkai Kaiho** 1997 Jan;100(1):59–67 (Eng. Abstr.) **(Jpn)**

[Molecular mechanism of the stress induction of MDR1 gene] Kohno K. **Nippon Rinsho** 1997 May;55(5):1054–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical criteria of chemosensitivity test] Kubota T, et al. **Nippon Rinsho** 1997 May;55(5):1050–3 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Metallothionein] Naganuma A. **Nippon Rinsho** 1997 May; 55(5):1091–5 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Overcoming of multidrug resistance by a newly synthesized quinoline compound, MS-209] Naito M, et al. **Nippon Rinsho** 1997 May;55(5):1122–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Anticancer drugs and pharmacologic actions] Ogawa M. **Nippon Rinsho** 1997 May;55(5):1017–23 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Multidrug resistance of cancer cells mediated by ABC superfamily transporters] Ueda K. **Nippon Rinsho** 1997 May;55(5):1024–9 (16 ref.) (Eng. Abstr.) **(Jpn)**

[The mechanism of apoptosis induced by anticancer agents in human leukemia cells] Yoshida A, et al. **Nippon Rinsho** 1996 Jul;54(7):1822–7 (21 ref.) (Eng. Abstr.) **(Jpn)**

[The present of drug sensitivity test] Udagawa Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):751–60 (29 ref.) **(Jpn)**

[Study on potentiation of nitrosourea-cytotoxicity by DNA repair enzyme inhibitors in human brain tumor cells] Fukuchi M, et al. **No To Shinkei** 1997 Jun;49(6):521–8 (Eng. Abstr.) **(Jpn)**

[Mechanisms of retinoid resistance in leukemic cells] Kizaki M, et al. **Rinsho Ketsueki** 1996 Sep;37(9):766–9 (16 ref.) **(Jpn)**

[The mechanism of apoptosis induced by anticancer agents in human leukemia HL-60 cells] Yoshida A, et al. **Rinsho Ketsueki** 1996 Jul;37(7):552–7 (Eng. Abstr.) **(Jpn)**

[The effect of benzylpenicillin and doxycycline on toxicity and antineoplastic action of cyclophosphamide and methotrexate in mice] Pakulska W. **Acta Pol Pharm** 1992; 49(1-2):35–40 (Eng. Abstr.) **(Pol)**

[Inhibition of thymidylate synthase in chemotherapy] Rode W. **Postepy Biochem** 1996;42(2):133–40 (75 ref.) **(Pol)**

[L-MTP-PE--a potential antineoplastic agent] Dzierzbicka K, et al. **Postepy Hig Med Dosw** 1997;51(2):227–36 (37 ref.) (Eng. Abstr.) **(Pol)**

[Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes] Khabarov SV, et al. **Biokhimiia** 1996 Oct; 61(10):1866–73 (Eng. Abstr.) **(Rus)**

[A comparative study of the effect of chick embryo and cyclophosphamide hymogenate on the growth and metastasis of Pliss sarcoma in rats] Rodionov SIu, et al. **Biull Eksp Biol Med** 1995 Dec;120(12):610–2 **(Rus)**

[Comparison of blast cell sensitivity to low-intensity laser radiation and chemotherapeutic drugs] Karu TI, et al. **Dokl Akad Nauk** 1997 Mar;353(1):114–7 **(Rus)**

[Testicular morphology in rats in the early and late periods after platidiam administration] Borovskaia TG, et al. **Eksp Klin Farmakol** 1996 Mar-Apr;59(2):41–3 (Eng. Abstr.) **(Rus)**

[A quantitative description of the cytostatic effects of chelators of transition metal ions (exemplified by picolinic acid and Fe2+)] Poltorakov AP, et al. **Izv Akad Nauk Ser Biol** 1996 Nov-Dec;(6):645–52 (Eng. Abstr.) **(Rus)**

[Sanguinarine and ellipticine cytotoxic alkaloids isolated from well-known antitumor plants. Intracellular targets of their action] Faddeeva MD, et al. **Tsitologiia** 1997; 39(2-3):181–208 (156 ref.) (Eng. Abstr.) **(Rus)**

[The effect of trophoblast-specific beta 1-glycoprotein and oncoprecipitin A on the growth and morphology of HeLa-M tumor cells] Odintsova NA, et al. **Tsitologiia** 1997; 39(4-5):273–7 (Eng. Abstr.) **(Rus)**

[Comparative study of the action of antineoplastic platinum compounds with varying nephrotoxic effects] Bakhteeva VT, et al. **Vopr Med Khim** 1996 Oct-Dec;42(4):301–6 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

[Spectrographic studies on the radioresistance of Miltex and miltefosine] Bollmann G, et al. **Strahlenther Onkol** 1997 Apr;173(4):230–5 (Eng. Abstr.) **(Ger)**

STANDARDS

Evaluation of antineoplastic drug package inserts from different countries [letter] Jacobs JY, et al. **Ann Pharmacother** 1996 Dec;30(12):1496–8

Clinical trials of antitumor agents: experimental design and timeline considerations [editorial] Frei E 3rd. **Cancer J Sci Am** 1997 May-Jun;3(3):127–36 (61 ref.)

Development of angiogenesis inhibitors for cancer therapy. Eckhardt SG, et al. **Invest New Drugs** 1997;15(1):1–3 (10 ref.)

Tea and cancer prevention: an evaluation of the epidemiologic literature. Kohlmeier L, et al. **Nutr Cancer** 1997;27(1):1–13 (30 ref.)

Tea consumption and cancer. Katiyar SK, et al. **World Rev Nutr Diet** 1996;79:154–84 (141 ref.)

THERAPEUTIC USE

Recent avenues of chemotherapeutic research. Eckhardt S. **Acta Biochim Pol** 1996;43(2):301–4 (0 ref.)

Cabergoline treatment in a case of macroprolactinoma after delivery. Falsetti L. **Acta Eur Fertil** 1995 May-Jun; 26(3):105–7

T cells and natural killer cells after treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine. Schirmer M, et al. **Acta Haematol** 1997;97(3):180–3

Thrombotic microangiopathy in a patient with chronic myelogenous leukemia on hydroxyurea. Shammas F, et al. **Acta Haematol** 1997;97(3):184–6

F wave studies after intrathecal methotrexate administration. Grzelec H, et al. **Acta Neurol Scand** 1996 Oct;94(4):276–8

A possible correlation between growth-factor sensitivity and response to mitoxantrone treatment in a murine myeloid leukaemia (SA7HD) cell line. Abubakar AA, et al. **Acta Oncol** 1997;36(4):421–7

Bisphosphonate therapy in metastatic breast cancer. Blomqvist C, et al. **Acta Oncol** 1996;35 Suppl 5:81–3 (17 ref.)

The future of bisphosphonates in cancer. Coleman RE, et al. **Acta Oncol** 1996;35 Suppl 5:23–9 (51 ref.)

Aromatase inhibition for breast cancer treatment. Lønning PE. **Acta Oncol** 1996;35 Suppl 5:38–43 (31 ref.)

Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. Mirza MR, et al. **Acta Oncol** 1997;36(2):171–4

Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature. Moeholt K, et al. **Acta Oncol** 1996; 35(6):677–82 (33 ref.)

Predictive factors for response to cytotoxic treatment in advanced breast cancer: a review. Sjöström J, et al. **Acta Oncol** 1996;35 Suppl 5:84–90 (42 ref.)

Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. Trunet PF, et al. **Acta Oncol** 1996;35 Suppl 5:15–8 (27 ref.)

Somatostatin receptor scintigraphy and therapy of neuroendocrine (APUD) tumors of the head and neck. Kau R, et al. **Acta Otolaryngol (Stockh)** 1996 Mar;116(2):345–9

Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Kimura T, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:135–41

Histological effect of intranodal injection of the streptococcal preparation OK-432 for cervical lymph node metastases of malignant head and neck tumors. Suzuki K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;525:125–8

New cytostatic agents for the treatment of head and neck cancer. Devriendt D, et al. **Acta Otorhinolaryngol Belg** 1997;51(2):61–8 (39 ref.)

Hepatic haemangioendothelioma presenting with early heart failure in a newborn: treatment with hepatic artery embolization and interferon. Fok TF, et al. **Acta Paediatr** 1996 Nov;85(11):1373–5

Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies. Konstantinov SM, et al. **Acta Trop** 1997 Apr 15;64(3-4):145–54

Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo. Broitman SA, et al. **Adv Exp Med Biol** 1996;401:111–30

Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer. Crowell PL, et al. **Adv Exp Med Biol** 1996;401:131–6 (23 ref.)

A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. Vogler WR, et al. **Adv Exp Med Biol** 1996; 416:389–96

Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance. Chen AY, et al. **Adv Pharmacol** 1994;29B:245–56 (30 ref.)

Clinical development of topoisomerase-interactive drugs. Muggia FM, et al. **Adv Pharmacol** 1994;29B:1–31 (95 ref.)

Topoisomerases in human leukemia. Peereboom D, et al. **Adv Pharmacol** 1994;29B:33–50 (90 ref.)

HIV-associated lymphoma. Kaplan LD. **AIDS Clin Rev** 1997-98;:349–73 (80 ref.)

The effects of antineoplastic chemotherapy on HIV disease. Zanussi S, et al. **AIDS Res Hum Retroviruses** 1996 Dec 10;12(18):1703–7

Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: results of a phase I study. Bachaud JM, et al. **Am J Clin Oncol** 1997 Feb;20(1):1–5

Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer. Baldini E, et al. **Am J Clin Oncol** 1996 Dec;19(6):592–4

A phase II trial of edatrexate in previously treated squamous cell cervical cancer: a Gynecologic Oncology Group study. Broun ER, et al. **Am J Clin Oncol** 1997 Feb;20(1):78–80

A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Dreicer R, et al. **Am J Clin Oncol** 1997 Jun; 20(3):251–3

A prospective randomized administration of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Ikeda K, et al. **Am J Clin Oncol** 1997 Apr;20(2):202–8

Phase II trial of piroxantrone in advanced squamous cell carcinoma of the cervix: a Gynecological Oncology Group study. Lincoln S, et al. **Am J Clin Oncol** 1997 Feb; 20(1):84–5

A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. Robert F, et al. **Am J Clin Oncol** 1997 Jun;20(3):298–302

Mitoxantrone in the treatment of metastatic transitional cell carcinoma of the prostate. A case report. Stewart DJ, et al. **Am J Clin Oncol** 1997 Aug;20(4):381–2

Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Yeilding A, et al. **Am J Clin Oncol** 1996 Dec;19(6):619–23

Topotecan approved for cancer chemotherapy [news] **Am J Health Syst Pharm** 1996 Aug 1;53(15):1763–4

White House announces cancer-drug initiatives [news] **Am J Health Syst Pharm** 1996 May 15;53(10):1110

Nilutamide approved for metastatic prostate cancer [news] **Am J Health Syst Pharm** 1996 Dec 1;53(23):2784

Porfimer photodynamic therapy introduced for advanced esophageal cancer [news] **Am J Health Syst Pharm** 1996 Dec 15;53(24):2940

Special order forms for cancer chemotherapy [letter; comment] Carrera Hueso FJ. **Am J Health Syst Pharm** 1996 Oct 1;53(19):2343. Comment on: Am J Health Syst Pharm 1996 Apr 1;53(7):737–46.

Outpatient therapy with aldesleukin after autologous bone marrow transplantation [letter] Matos da Silva AC, et al. **Am J Health Syst Pharm** 1996 Jul 15;53(14):1722, 1724

Interferon alfa-2a tretinoin in patients with metastatic renal cell carcinoma: a pilot study. Paule B, et al. **Am J Health Syst Pharm** 1997 Jan 15;54(2):190–2

MALT non-Hodgkin's lymphoma associated with hepatitis C virus infection treated by interferon alpha [letter] Bauduer F. **Am J Hematol** 1996 Nov;53(3):209

Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. Edelman MJ, et al. **Am J Hematol** 1997 Apr;54(4):329–31

Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: clearance increases in relation to absolute neutrophil count with repeated dosing. Sturgill MG, et al. **Am J Hematol** 1997 Feb;54(2):124–30

Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy. Villa E, et al. **Am J Hypertens** 1997 Feb;10(2):202–8

A possible chemotherapeutic response by paclitaxel and other antineoplastic agents in treatment of choriocarcinoma in vitro [letter; comment] Farghaly SA. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1075–7. Comment on: Am J Obstet Gynecol 1995 Dec;173(6):1835–42.

Prognostic significance of computed tomography in tumors of the oral cavity and oropharynx treated with neoadjuvant chemotherapy. Verschuur HP, et al. **Am J Otolaryngol** 1997 May-Jun;18(3):190–6

Comparison of intratumoral administration of cisplatin versus bleomycin for treatment of periocular squamous cell carcinomas in horses. Théon AP, et al. **Am J Vet Res** 1997 Apr;58(4):431–6

Indications for and results of irradiation +/- chemotherapy for rectal cancer. Gunderson LL, et al. **Ann Acad Med Singapore** 1996 May;25(3):448–59 (32 ref.)

Hypoxic sensitizer and cytotoxin for head and neck cancer. Lee DJ, et al. **Ann Acad Med Singapore** 1996 May; 25(3):397–404 (42 ref.)

First-line treatment of Waldenström's disease with cladribine. Arbeitsgemeinschaft Medikamentöse Tumortherapie. Fridrik MA, et al. **Ann Hematol** 1997 Jan;74(1):7–10

Response of the extramedullary lung plasmacytoma with pleural effusion to chemotherapy. Nagai K, et al. **Ann Hematol** 1997 Jun;74(6):279–81

Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group. Thaler J, et al. **Ann Hematol** 1996 Jun;72(6):349–55

S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Verbeek W, et al. **Ann Hematol** 1997 May;74(5):205–8

ANTINEOPLASTIC AGENTS

Isotretinoin in metastatic thyroid cancer [letter] Börner AR, et al. **Ann Intern Med** 1997 Aug 1;127(3):246

Cost-effectiveness of interferon-alpha as maintenance therapy in chronic myelogenous leukemia [letter; comment] Messori A, et al. **Ann Intern Med** 1997 Apr 15;126(8):664-5 . Comment on: Ann Intern Med 1996 Oct 1;125(7):541-8.

Autologous stem cell transplantation in breast cancer. Joensuu H. **Ann Med** 1996 Apr;28(2):145-9 (35 ref.)

Clinical studies of topotecan. Broom C. **Ann N Y Acad Sci** 1996 Dec 13;803:264-71 (41 ref.)

Trials of 9-amino-20(S)-camptothecin in Boston. Eder JP, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:247-55

Factors affecting topotecan sensitivity in human leukemia samples. Kaufmann SH, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:128-42 (44 ref.)

The application of IL-12 to cytokine therapy and gene therapy for tumors. Nishimura T, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:375-8

9-Aminocamptothecin and beyond. Preclinical and clinical studies. Potmesil M, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:231-46 (48 ref.)

Clinical pharmacology of 9-aminocamptothecin. Takimoto CH, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:324-6

New drugs in non-Hodgkin's lymphoma. Arbuck SG, et al. **Ann Oncol** 1997;8 Suppl 1:119-28 (98 ref.)

A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. Bajetta E, et al. **Ann Oncol** 1997 Jul;8(7):649-54

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Bisagni G, et al. **Ann Oncol** 1996 Jan;7(1):99-102

Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Bokemeyer C, et al. **Ann Oncol** 1996 Jan;7(1):31-4

Purging of peripheral blood progenitor cells. Brugger W, et al. **Ann Oncol** 1996;7 Suppl 2:11-3 (23 ref.)

Phase II trial of 13-cis retinoic acid plus interferon-alpha in advanced squamous cell carcinoma of head and neck, refractory to chemotherapy [letter] Cascinu S, et al. **Ann Oncol** 1996 Jul;7(5):538

Is there a future for cancer chemotherapy? The Michel Clavel Lecture. Connors TA. **Ann Oncol** 1996 Jul; 7(5):445-52 (25 ref.)

A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium [see comments] Eckhardt SG, et al. **Ann Oncol** 1996 Jul;7(5):491-6. Comment in: Ann Oncol 1996 Jul;7(5):441-4.

Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? Edmonson JH, et al. **Ann Oncol** 1997 Jul;8(7):637-41

Are hematopoietic colony-stimulating factors useful in association with chemotherapy in the treatment of HIV-related non-Hodgkin's lymphomas? Errante D, et al. **Ann Oncol** 1996 Mar;7(3):233-7

Glutathione S-transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome [see comments] Ferrandina G, et al. **Ann Oncol** 1997 Apr;8(4):343-50. Comment in: Ann Oncol 1997 Apr;8(4):314-5.

Mantle-cell lymphoma: classification and therapeutic implications. Fisher RI. **Ann Oncol** 1996;7 Suppl 6:S35-9 (38 ref.)

Report of workshop 5: early high-dose chemotherapy. Fisher RI. **Ann Oncol** 1996;7 Suppl 4:131-3 (0 ref.)

Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation [editorial; comment] Gasparini G, et al. **Ann Oncol** 1996 Jul;7(5):441-4 (45 ref.). Comment on: Ann Oncol 1996 Jul;7(5):491-6.

L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase [see comments] Gentili D, et al. **Ann Oncol** 1996 Sep;7(7):725-30 . Comment in: Ann Oncol 1997 Feb;8(2):204-6.

Prolonged continuous hepatic artery infusion with interleukin-2 in unresectable liver metastases of colorectal cancer: a phase IA-B study. Goey SH, et al. **Ann Oncol** 1996 Mar;7(3):317-9

Experience with independent radiological review during a topotecan trial in ovarian cancer. Gwyther S, et al. **Ann Oncol** 1997 May;8(5):463-8

The role of high dose chemotherapy in adult solid tumours other than breast cancer. Hornedo J, et al. **Ann Oncol** 1996; 7 Suppl 2:23-30 (48 ref.)

Purine analogs in marginal-zone lymphomas. Horning SJ. **Ann Oncol** 1996;7 Suppl 6:S21-6 (34 ref.)

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Judson I, et al. **Ann Oncol** 1997 Jun;8(6):604-6

Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Juliusson G, et al. **Ann Oncol** 1996 Apr;7(4):373-9

Factors influencing response rates for advanced colorectal cancer chemotherapy. Labianca R, et al. **Ann Oncol** 1996 Nov;7(9):901-6 (39 ref.)

A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Lambert HE, et al. **Ann Oncol** 1997 Apr;8(4):327-33

A phase I study of pentosan polysulfate sodium in patients with advanced malignancies. Lush RM, et al. **Ann Oncol** 1996 Nov;7(9):939-44

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Machover D, et al. **Ann Oncol** 1996 Jan; 7(1):95-8

Interferon-alpha-2b in the management of patients with relapsed and/or refractory Hodgkin's disease [letter] Maloisel F, et al. **Ann Oncol** 1997 Apr;8(4):405-6

Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia. O'Brien S, et al. **Ann Oncol** 1996;7 Suppl 6:S27-33 (53 ref.)

Purine nucleoside therapy of low-grade follicular lymphoma. Piro LD. **Ann Oncol** 1996;7 Suppl 6:S41-7 (50 ref.)

5-Fluorouracil revisited: a new perspective for treatment planning [letter; comment] Presant CA, et al. **Ann Oncol** 1997 Feb;8(2):203-4. Comment on: Ann Oncol 1996 Aug;7(6):551-2.

Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Reni M, et al. **Ann Oncol** 1997 Mar;8(3):227-34

Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Smyth JF, et al. **Ann Oncol** 1997 Jun;8(6):569-73

Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC). Sternberg CN, et al. **Ann Oncol** 1997 Jul;8(7):695-6

5-Fluorouracil-based treatment of patients with advanced colorectal carcinoma outside clinical trials: importance of limited toxicity [letter; comment] van Halteren HK, et al. **Ann Oncol** 1997 Feb;8(2):203. Comment on: Ann Oncol 1996 Aug;7(6):551-2.

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. Verweij J, et al. **Ann Oncol** 1996 Oct; 7(8):867-9

The benefit of clinical benefit: a European perspective [editorial; comment] Verweij J. **Ann Oncol** 1996 Apr; 7(4):333-4. Comment on: Ann Oncol 1996 Apr;7(4):347-53.

Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease. Younes A, et al. **Ann Oncol** 1996 Dec;7(10):1083-5

Comment: vinorelbine and gemcitabine--new antineoplastic drugs [letter; comment] Guchelaar HJ. **Ann Pharmacother** 1996 Nov;30(11):1343. Comment on: Ann Pharmacother 1996 May;30(5):501-6.

Pegaspargase: an alternative? Holle LM. **Ann Pharmacother** 1997 May;31(5):616-24 (30 ref.)

Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Le AT, et al. **Ann Pharmacother** 1997 Sep;31(9):1006-8

Interferon alfa for macular degeneration. Williford SL, et al. **Ann Pharmacother** 1996 Jun;30(6):678-9

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Gibbs JB, et al. **Annu Rev Pharmacol Toxicol** 1997;37:143-66 (125 ref.)

Bis(7-amino-4-azaheptyl)dimethylsilane: a new tetramine with polyamine-like features. Effects on cell growth. Delcros JG, et al. **Anticancer Drug Des** 1997 Jan; 12(1):35-48

Treatment of residual metastases with Na[trans-RuCl4 (DMSO)Im] and ruthenium uptake by tumor cells. Bergamo A, et al. **Anticancer Drugs** 1996 Aug;7(6):697-702

Determination of the maximal tumor/normal skin ratio after HpD or m-THPC administration in hairless mouse (SKh-1) by fluorescence spectroscopy--a non-invasive method. Bossu E, et al. **Anticancer Drugs** 1997 Jan;8(1):67-72

Mistletoe: a story with an open end. Büssing A. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S1-2

Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors--an antiangiogenic effect? Dirix LY, et al. **Anticancer Drugs** 1996 Feb;7(2):175-81

New approaches to the treatment of advanced breast cancer. Eckardt JR. **Anticancer Drugs** 1996 Aug;7 Suppl 2:41-6 (23 ref.)

Antineoplastic activities of 2,3,4-chloro-substituted beta-alkylaminopropiophenone derivatives in CF1 mice and in murine and human tumor cells. Huang Y, et al. **Anticancer Drugs** 1996 Jul;7(5):613-20

Remission of advanced uterine leiomyosarcoma with pulmonary metastases with carboplatin and paclitaxel. Kudelka AP, et al. **Anticancer Drugs** 1996 Nov;7(8):885-9

A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group study 8918. Malviya VK, et al. **Anticancer Drugs** 1996 Jul;7(5):527-30

A phase II trial of topotecan in patients with previously untreated pancreatic cancer. O'Reilly S, et al. **Anticancer Drugs** 1996 Jun;7(4):410-4

Chemotherapy of gastric cancer. Schipper DL, et al. **Anticancer Drugs** 1996 Feb;7(2):137-49 (165 ref.)

Treatment of advanced seminoma: an update. Sleijfer DT, et al. **Anticancer Drugs** 1997 Feb;8(2):107-12 (56 ref.)

Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Takemura Y, et al. **Anticancer Drugs** 1997 Jan;8(1):3-16 (115 ref.)

Dose intensification of chemotherapy and the role of granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor in small cell lung cancer. Tjan-Heijnen VC, et al. **Anticancer Drugs** 1997 Jul; 8(6):549-64 (125 ref.)

Elimination of adult T cell leukemia cells by ultrasound in the presence of porfimer sodium. Uchida T, et al. **Anticancer Drugs** 1997 Apr;8(4):329-35

Interferon gamma is highly effective against orthotopically-implanted human pleural adenocarcinoma in nude mice. An Z, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2545-51

Efficacy of the platinum analog [Pt(cis-dach)(DPPE)-2NO3] on histocultured human patient bladder tumors and cancer cell lines. Chang SG, et al. **Anticancer Res** 1996 Nov-Dec; 16(6B):3423-8

Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Gutman M, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3673-7

Boron substituted deoxyribonucleosides as cytotoxic agents. Hall IH, et al. **Anticancer Res** 1996 Nov-Dec; 16(6B):3709-14

Methionine starvation modulates the efficacy of cisplatin on human breast cancer in nude mice. Hoshiya Y, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3515-7

Antineoplastic activities of alpha-methyl-beta-alkylaminopropiophenone derivatives in tissue culture cells. Huang Y, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3589-95

Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system. Inagawa H, et al. **Anticancer Res** 1997 May-Jun;17(3C):2153-8

Antitumor effects of a new polysaccharide-protein complex (ATOM) prepared from Agaricus blazei (Iwade strain 101) "Himematsutake" and its mechanisms in tumor-bearing mice. Ito H, et al. **Anticancer Res** 1997 Jan-Feb; 17(1A):277-84

Effects of 5'-DFUR and OK-432 on cytokines and thymidine phosphorylase in tumor tissue of gastric cancer patients. Ohwada S, et al. **Anticancer Res** 1997 May-Jun; 17(3C):2313-8

Antimetastatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with MCa mammary carcinoma. Pacor S, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2559-64

Inhibition of the progression of human and rat Wilms' tumor by Tiazofurin. Rásó E, et al. **Anticancer Res** 1996 Nov-Dec; 16(6A):3333-9

Morphological and immunological observations on the effects of hexadecylphosphocholine (HPC) in nude mice bearing MT-1 breast cancer xenografts. Safa O, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):37-43

Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters. Stathopoulos GP, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3855-60

A case of malignant schwannoma with overexpression of multidrug resistance gene (MDR1) after chemotherapy. Suto R, et al. **Anticancer Res** 1997 May-Jun;17(3C):2273-7

Keishi-ka-kei-to, a traditional Chinese herbal medicine, inhibits pulmonary metastasis of B16 melanoma. Suzuki F, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):873-8

Study of apoptosis in peripheral blood of patients with acute lymphoblastic leukemia during induction therapy. Tsangaris GT, et al. **Anticancer Res** 1996 Sep-Oct; 16(5B):3133-40

Antisense c-myc inhibition of lymphoma growth. Wickstrom E. **Antisense Nucleic Acid Drug Dev** 1997 Jun;7(3):225-8

Phosphorothioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisense mechanism. Jansen B, et al. **Antisense Res Dev** 1995 Winter;5(4):271-7

Treating patients with melanoma with interferon [letter] Cook J, et al. **Arch Dermatol** 1997 Mar;133(3):387-9

Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group [see comments] **Arch Ophthalmol** 1997 Jul;115(7):865-72. Comment in: Arch Ophthalmol 1997 Jul;115(7):915-6.

Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Murphree AL, et al. **Arch Ophthalmol** 1996 Nov;114(11):1348-56

Local carboplatin and radiation therapy in the treatment of murine transgenic retinoblastoma. Murray TG, et al. **Arch Ophthalmol** 1996 Nov;114(11):1385-9

Inhibition by streptococcal immunopotentiator OK432 of lymph-node metastasis in hamster cheek-pouch carcinoma with enhancement of tumour necrosis factor-alpha and interleukin-6 in serum. Nakajima J, et al. **Arch Oral Biol** 1996 May;41(5):513-6

The response of parotid hemangiomas to the use of systemic interferon alfa-2a or corticosteroids. Blei F, et al. **Arch Otolaryngol Head Neck Surg** 1997 Aug;123(8):841-4

Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-tetra (hydroxyphenyl) chlorin. Savary JF, et al. **Arch Otolaryngol Head Neck Surg** 1997 Feb;123(2):162-8

Observations with an S-adenosylmethionine decarboxylase inhibitor in rats with prostatic adenocarcinoma. Seiler N, et al. **Arzneimittelforschung** 1996 Mar;46(3):311-5

Breast cancer: current issues in diagnosis and treatment [see

comments] Furnival CM. **Aust N Z J Surg** 1997 Jan; 67(1):47–58 (55 ref.). Comment in: Aust N Z J Surg 1997 Jul;67(7):476.

Newer approaches to regional cancer therapy through tumour immunology: is there a 'breakthrough'? Stephens FO. **Aust N Z J Surg** 1997 Jan;67(1):2–4

Treatment of the elderly patient with acute myeloid leukaemia. Löwenberg B. **Baillieres Clin Haematol** 1996 Mar;9(1):147–59 (49 ref.)

Chemotherapy for malignant gliomas. Forsyth PA, et al. **Baillieres Clin Neurol** 1996 Jun;5(2):371–93 (112 ref.)

Apoptosis and cancer chemotherapy. Chresta CM, et al. **Behring Inst Mitt** 1996 Oct;(97):232–40 (35 ref.)

Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity. Engelhard H, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):400–5

A polysaccharide–peptide complex from cultured mycelia of the mushroom Tricholoma mongolicum with immunoenhancing and antitumor activities. Wang HX, et al. **Biochem Cell Biol** 1996;74(1):95–100

Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth. Omer CA, et al. **Biofactors** 1997;6(3):359–66 (37 ref.)

Pilot study for preoperative administration of l-OHP to patients with advanced scirrhous type gastric cancer. Eriguchi M, et al. **Biomed Pharmacother** 1997;51(5):217–20

Lymphangiographic study of pelvic adenopathy regression in a phase II trial of methyl-hydroxy-ellipticine in HIV1-AIDS complex [letter] Mathé G, et al. **Biomed Pharmacother** 1996;50(10):510–1

Enhanced biological activity of human recombinant interleukin 2 coupled to mouse red blood cells as evaluated using the mouse Meth A sarcoma model. Moyes RB, et al. **Biotechnol Appl Biochem** 1996 Feb;23 (Pt 1):29–36

Cytokines in animal models of cancer. Burke F, et al. **Biotherapy** 1996;8(3–4):229–41 (147 ref.)

Effect of Z-100, an immunomodulator extracted from human type tubercle bacilli, on the pulmonary metastases of Lewis lung carcinoma in attempt to regulate suppressor T cells and suppressor factor, IL-4. Emori Y, et al. **Biotherapy** 1996;9(4):249–56

Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: a pilot study. Prasad U, et al. **Biotherapy** 1996;9(1–3):109–15

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Beran M, et al. **Blood** 1996 Oct 1;88(7):2473–9

In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Francisco JA, et al. **Blood** 1997 Jun 15;89(12):4493–500

Delicious poison: arsenic trioxide for the treatment of leukemia [letter] Kwong YL, et al. **Blood** 1997 May 1; 89(9):3487–8

Neutrophil secondary-granule deficiency as a hallmark of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Miyauchi J, et al. **Blood** 1997 Jul 15;90(2):803–13

Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Puthier D, et al. **Blood** 1996 Dec 15;88(12):4659–66

Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Sgadari C, et al. **Blood** 1997 Apr 15;89(8):2635–43

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Shen ZX, et al. **Blood** 1997 May 1;89(9):3354–60

Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Tobita T, et al. **Blood** 1997 Aug 1;90(3):967–73

New drugs in essential thrombocythemia and polycythemia vera. Tefferi A, et al. **Blood Rev** 1997 Mar;11(1):1–7 (87 ref.)

Non-compliance with oral chemotherapy in childhood leukaemia [editorial] [see comments] Lilleyman JS, et al. **BMJ** 1996 Nov 16;313(7067):1219–20. Comment in: BMJ 1997 Mar 8;314(7082):755.

Very low rate of type I collagen synthesis and degradation in newly diagnosed children with acute lymphoblastic leukemia. Sorva R, et al. **Bone** 1997 Feb;20(2):139–43

Advances in CML–Therapy. Interferon and Autografting 4th International Workshop. Proceedings. Wachenburg/Weinheim, Germany, 23–24 June 1995. **Bone Marrow Transplant** 1996 May;17 Suppl 3:S1–74

High-dose chemotherapy and stem cell transplantation in solid tumors. Proceedings of a meeting. Berlin, Germany, 27–28 April 1996. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S1–74

4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement. Bird JM, et al. **Bone Marrow Transplant** 1996 Aug;18(2):309–13

Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation. de Kreuk M, et al. **Bone Marrow Transplant** 1996 Jun;17(6):963–71

Current controversies on the role of interferon-alpha for therapy of chronic myeloid leukemia. Heimpel H, et al. **Bone Marrow Transplant** 1996 May;17 Suppl 3:S39

Quantitative molecular methods to monitor the response of CML patients to interferon-alpha. Hochhaus A, et al. **Bone Marrow Transplant** 1996 May;17 Suppl 3:S41–4

High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients. Mahendra P, et al. **Bone Marrow Transplant** 1996 Jun;17(6):973–8

High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemia. Mahon FX, et al. **Bone Marrow Transplant** 1996 May;17 Suppl 3:S33–7

High-dose chemotherapy and autologous stem cell support for patients with malignant melanoma. Meisenberg B. **Bone Marrow Transplant** 1996 Jun;17(6):903–6 (25 ref.)

Interferon-alpha in the treatment of chronic myeloid leukemia. A summary and an update of the Italian studies. Rosti G, et al. **Bone Marrow Transplant** 1996 May;17 Suppl 3:S11–3

Progress with interferon in CML—results of the MRC UK CML III study. Shepherd PC, et al. **Bone Marrow Transplant** 1996 May;17 Suppl 3:S15–8

Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies. Vose JM, et al. **Bone Marrow Transplant** 1996 Jun;17(6):951–6

Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Burger AM, et al. **Br J Cancer** 1996 Nov;74(9):1369–74

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. Goey SH, et al. **Br J Cancer** 1996 Dec; 74(12):2018–23

Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. Hettinga JV, et al. **Br J Cancer** 1997;75(12):1735–43

Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung. Iigo M, et al. **Br J Cancer** 1997;75(5):650–5

Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations. Itoh K, et al. **Br J Cancer** 1997;76(1):107–13

A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. Joffe JK, et al. **Br J Cancer** 1997; 75(3):423–6

Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85—a synthetic agent binding at the colchicine site designed to overcome multidrug resistance. Judson I, et al. **Br J Cancer** 1997;75(4):608–13

An anti-cancer derivative of butyric acid (pivalyloxmethyl buterate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells. Kasukabe T, et al. **Br J Cancer** 1997;75(6):850–4

A mutation in exon 7 of the human cytochrome P-4501A1 gene as marker for sensitivity to anti-cancer drugs? [letter] Peters WH, et al. **Br J Cancer** 1997;75(9):1397

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. Punt CJ, et al. **Br J Cancer** 1997;76(2):266–9

Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Watson SA, et al. **Br J Cancer** 1996 Nov;74(9):1354–8

Interferons in oncology. Woll PJ, et al. **Br J Clin Pract** 1997 Mar;51(2):111–5

Non-HIV-related Kaposi's sarcoma suppressed by dapsone. de Haas ER, et al. **Br J Dermatol** 1996 Nov;135(5):813–4

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Bowen AL, et al. **Br J Haematol** 1997 Mar;96(3):617–9

Thymic function in adults: evidence derived from immune recovery patterns following myeloablative chemotherapy and stem cell infusion. Cavenagh JD, et al. **Br J Haematol** 1997 Jun;97(3):673–6

Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group. Hehlmann R, et al. **Br J Haematol** 1997 Apr;97(1):76–85

Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Khouri IF, et al. **Br J Haematol** 1997 May; 97(2):466–73

Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. Meng YG, et al. **Br J Haematol** 1996 Dec;95(3):535–41

Interferon-gamma+ and interleukin-2+ T cells in peripheral blood from multiple myeloma patients in relation to disease status and maintenance therapy with interferon-alpha2b (intron A). Millar BC, et al. **Br J Haematol** 1997 Jul; 98(1):119–25

Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation. Nowak-Göttl U, et al. **Br J Haematol** 1996 Oct;95(1):123–6

Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Uderzo C, et al. **Br J Haematol** 1997 Feb;96(2):387–94

Adjuvant treatment in high-risk breast cancer [letter; comment] Leonard RC. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):112. Comment on: Br J Hosp Med 1996 Feb 21–Mar 5;55(4):156–8.

Adjuvant treatment in high-risk breast cancer [letter; comment] Mansi JL. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):112. Comment on: Br J Hosp Med 1996 Feb 21–Mar 5;55(4):156–8.

Interferon alfa-2a. Williams CD, et al. **Br J Hosp Med** 1997 May 7–20;57(9):436–9 (10 ref.)

Clinical effect of meso-tetrahydroxyphenylchlorine based photodynamic therapy in recurrent carcinoma of the ovary: preliminary results. Wierrani F, et al. **Br J Obstet Gynaecol** 1997 Mar;104(3):376–8

Adjuvant intraoperative photodynamic therapy in experimental colorectal cancer using a new photosensitizer. Abulafi AM, et al. **Br J Surg** 1997 Mar;84(3):368–71

Primary metastatic bladder carcinoma during pregnancy. Danisman A, et al. **Br J Urol** 1997 Mar;79(3):489

Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine. Espin Jaime MT, et al. **Br J Urol** 1997 Jul;80(1):151–2

The management of superficial bladder cancer: an interactive seminar [see comments] McFarlane JP, et al. **Br J Urol** 1996 Sep;78(3):372–8 (36 ref.). Comment in: Br J Urol 1997 May;79(5):818.

Verrucous carcinoma of the penis: three cases treated with interferon-alpha. Maiche AG, et al. **Br J Urol** 1997 Mar; 79(3):481–3

Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment. Palmberg C, et al. **Br J Urol** 1997 May;79(5):808–9

The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3). Wang X, et al. **Br J Urol** 1997 Aug;80(2):260–2

Future directions in the pharmacology of anti-cancer agents in children. Pearson AD. **Br Med Bull** 1996 Oct; 52(4):844–72 (95 ref.)

Etiology of bacteraemia in patients with various malignancies: is there association between certain antineoplastic drugs and microorganism? Baláž M, et al. **Bratisl Lek Listy** 1996 Nov;97(11):675–9

Bacteremia in cancer patients with solid tumors undergoing chemotherapy versus surgery: risk factors, etiology and outcome in 276 patients. Grausová S, et al. **Bratisl Lek Listy** 1996 Nov;97(11):684–7

Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Bonetti A, et al. **Breast Cancer Res Treat** 1996;38(3):289–97

Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumors. Schneider MR, et al. **Breast Cancer Res Treat** 1996;38(1):133–41 (21 ref.)

Chemotherapeutic treatments: a study of the interplay among drug resistance, toxicity and recuperation from side effects. Costa MI, et al. **Bull Math Biol** 1997 Mar;59(2):205–32

Conflicting objectives in chemotherapy with drug resistance. Costa MI, et al. **Bull Math Biol** 1997 Jul;59(4):707–24

Pre-radiation chemotherapy for malignant glioma in adults. Kirby S, et al. **Can J Neurol Sci** 1996 May;23(2):123–7

Mobilization of peripheral blood progenitor cells by hematopoietic growth factors. Chao NJ. **Can J Oncol** 1995 Dec;5 Suppl 1:43–6

High-dose chemotherapy of breast cancer. Crown J, et al. **Can J Oncol** 1995 Dec;5 Suppl 1:80–2 (28 ref.)

Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. Paterson AH, et al. **Can J Oncol** 1995 Dec;5 Suppl 1:54–7

Intravitreal interferon alpha-2b for the treatment of neovascular age-related macular degeneration: a pilot study. Kertes PJ, et al. **Can J Ophthalmol** 1997 Apr; 32(3):185–8

The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Arase Y, et al. **Cancer** 1997 Apr 15; 79(8):1494–500

Extramedullary acute promyelocytic leukemia [letter; comment] Benekli M, et al. **Cancer** 1997 Aug 1;80(3):518–9 . Comment on: Cancer 1996 Dec 15;78(12):2510–4.

Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Budd GT, et al. **Cancer** 1997 Sep 15;80(6):1134–40

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Bukowski RM. **Cancer** 1997 Oct 1;80(7):1198–220 (222 ref.)

A phase II study of carboplatin as a treatment for children with acute leukemia recurring in bone marrow: a report of the Children's Cancer Group. Ettinger LJ, et al. **Cancer** 1997 Jul 15;80(2):311–6

The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia. Iwama H, et al. **Cancer** 1997 Apr 15;79(8):1552–60

A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined

with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Kimura H, et al. **Cancer** 1997 Jul 1;80(1):42–9

Interferon adjuvant therapy of melanoma [letter; comment] Kirkwood JM, et al. **Cancer** 1997 May 1;79(9):1843–6. Comment on: Cancer 1996 Sep 1;78(5):944–7.

Hormones, vitamins, and growth factors in cancer treatment and prevention. A critical appraisal. Lupulescu AP. **Cancer** 1996 Dec 1;78(11):2264–80 (131 ref.)

Extramedullary acute promyelocytic leukemia [letter; comment] Maloisel F, et al. **Cancer** 1997 Jun 1; 79(11):2263–4. Comment on: Cancer 1996 Dec 15;78(12):2510–4.

Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Pompili M, et al. **Cancer** 1997 Apr 15; 79(8):1501–8

Postsurgical adjuvant therapy for melanoma. Evaluation of a 3–year randomized trial with recombinant interferon–alpha after 3 and 5 years of follow–up. Rusciani L, et al. **Cancer** 1997 Jun 15;79(12):2354–60

Correlation between computed tomographic density of lymph node metastases and response to cisplatin–based chemotherapy in patients with head and neck squamous cell carcinoma in an area in which betel quid chewing is prevalent. Wang HM, et al. **Cancer** 1996 Nov 1; 78(9):1972–9

New therapeutic strategies for higher cure rates: high dose therapy and new therapeutic modalities. Proceedings of the 12th Bristol–Myers Squibb Nagoya International Cancer Treatment Symposium. Nagoya, Japan, 4–5 October 1996. **Cancer Chemother Pharmacol** 1997;40 Suppl:S1–118

Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Estey E, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S9–12 (08 ref.)

New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Kitamura K, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S36–41

Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non–small–cell lung cancer. Miller VA, et al. **Cancer Chemother Pharmacol** 1997; 40(5):415–8

Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Pagani O, et al. **Cancer Chemother Pharmacol** 1996;38(6):541–7

All–trans retinoic acid significantly increases 5–year survival in patients with acute promyelocytic leukemia: long–term follow–up of the New York study. Soignet S, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S25–9

A phase II trial of all–trans–retinoic acid in hormone–refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. Trump DL, et al. **Cancer Chemother Pharmacol** 1997;39(4):349–56

Tumor size and origin determine the antitumor activity of cisplatin or 5–fluorouracil and its modulation by leucovorin in murine colon carcinomas. Van Laar JA, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):79–89

Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Zalupski MM, et al. **Cancer Chemother Pharmacol** 1997;40(3):225–7

Inhibition of metastasis by cicaprost in rats with established SMT2A mammary carcinoma growth. Schirner M, et al. **Cancer Detect Prev** 1997;21(1):44–50

The frequency of micronuclei in lymphocytes of dogs with osteosarcoma: a predictive variable for tumor response during cisplatin chemotherapy. Hahn KA, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Aug;5(8):653–6

Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Wargovich MJ, et al. **Cancer Epidemiol Biomarkers Prev** 1996 May; 5(5):355–60

Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5–(aziridin–1–yl)–2,4–dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Green NK, et al. **Cancer Gene Ther** 1997 Jul–Aug;4(4):229–38

Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Roth W, et al. **Cancer Immunol Immunother** 1997 Mar;44(1):55–63

The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b. Tsavaris N, et al. **Cancer Immunol Immunother** 1996 Oct;43(2):94–102

Chemotherapy Foundation Symposium XIV, Innovative Cancer Chemotherapy for Tomorrow. New York City, New York, November 6–8, 1996. Abstracts. **Cancer Invest** 1997;15 Suppl 1:1–85

Lipid–laden macrophage infiltration of human adenocarcinoma in vivo associated with taxol and GCSF treatment. Abramson N, et al. **Cancer Invest** 1997; 15(1):18–22

The first clinical pilot study of roquinimex (Linomide) in cancer patients with special focus on immunological effects. Bergh JC, et al. **Cancer Invest** 1997;15(3):204–11

A phase II trial of deferoxamine in patients with hormone–refractory metastatic prostate cancer. Dreicer R, et al. **Cancer Invest** 1997;15(4):311–7

Phase II trial of topotecan in malignant melanoma. Kraut EH, et al. **Cancer Invest** 1997;15(4):318–20

Multiple myeloma: prognosis and standard treatment. Oken MM. **Cancer Invest** 1997;15(1):57–64 (60 ref.)

Clinical trials of antitumor agents: experimental design and timeline considerations [editorial] Frei E 3rd. **Cancer J Sci Am** 1997 May–Jun;3(3):127–36 (61 ref.)

Bicalutamide ('Casodex') development: from theory to therapy [see comments] Kolvenbag GJ, et al. **Cancer J Sci Am** 1997 Jul–Aug;3(4):192–203 (86 ref.). Comment in: Cancer J Sci Am 1997 Jul–Aug;3(4):204–8.

Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Ma GY, et al. **Cancer J Sci Am** 1997 May–Jun;3(3):174–9

'Casodex': defining the role of antiandrogens [comment] McCaffrey JA, et al. **Cancer J Sci Am** 1997 Jul–Aug; 3(4):204–8 (47 ref.). Comment on: Cancer J Sci Am 1997 Jul–Aug;3(4):192–203.

Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Hawk MA, et al. **Cancer Lett** 1996 Dec 3;109(1–2):217–22

Comparisons of geniposidic acid and geniposide on antitumor and radioprotection after sublethal irradiation. Hsu HY, et al. **Cancer Lett** 1997 Feb 26;113(1–2):31–7

Organic and inorganic selenium compounds inhibit mouse mammary cell growth in vitro by different cellular pathways. Sinha R, et al. **Cancer Lett** 1996 Oct 22; 107(2):277–84

Sonodynamically induced antitumor effect of gallium–porphyrin complex by focused ultrasound on experimental kidney tumor. Yumita N, et al. **Cancer Lett** 1997 Jan 15;112(1):79–86

Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third–generation aromatase inhibitor vorozole. de Jong PC, et al. **Cancer Res** 1997 Jun 1;57(11):2109–11

Gene–directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Marais R, et al. **Cancer Res** 1996 Oct 15;56(20):4735–42

Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Puri RK, et al. **Cancer Res** 1996 Dec 15; 56(24):5631–7

[D–Arg1,D–Trp5,7,9,Leu11]substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Seckl MJ, et al. **Cancer Res** 1997 Jan 1;57(1):51–4

A novel retinoic acid receptor–selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Shalinsky DR, et al. **Cancer Res** 1997 Jan 1;57(1):162–8

Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Thompson HJ, et al. **Cancer Res** 1997 Jan 15;57(2):267–71

Antiprogestin–progesterone interactions. Michna H, et al. **Cancer Treat Res** 1996;83:191–212 (99 ref.)

2–Chlorodeoxyadenosine treatment of lymphoma. Saven A, et al. **Cancer Treat Res** 1996;85:15–26 (52 ref.)

Chemotherapy for metastatic soft tissue sarcomas. Steward WP. **Cancer Treat Res** 1997;91:157–72 (71 ref.)

The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen. Bezwoda WR. **Cancer Treat Rev** 1997 Jan; 23(1):17–34 (144 ref.)

Antitumor, immunomodulatory and anti–HIV effect of mangiferin, a naturally occurring glucosylxanthone. Guha S, et al. **Chemotherapy** 1996 Nov–Dec;42(6):443–51

Primary pulmonary hypertension in a patient with CD8/T–cell large granulocyte leukemia: amelioration by cladribine therapy. Rossoff LJ, et al. **Chest** 1997 Aug; 112(2):551–3

The role of chemotherapy in the treatment of small cell lung cancer. Shepherd FA. **Chest Surg Clin N Am** 1997 Feb; 7(1):113–33 (82 ref.)

Exploration for drug therapy in endometrial carcinoma. Zhang X, et al. **Chin Med J (Engl)** 1996 May;109(5):356–60

What does tumor shrinkage mean to the patient receiving chemotherapy? Markman M. **Cleve Clin J Med** 1996 Sep; 63(5):301–2

Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Ferrari CI, et al. **Clin Endocrinol (Oxf)** 1997 Apr;46(4):409–13

The effect of a new slow–release, long–acting somatostatin analogue, lanreotide, in acromegaly. al–Maskari M, et al. **Clin Endocrinol (Oxf)** 1996 Oct;45(4):415–21

A case of recurrent (following surgery x2) invasive malignant melanoma with satellitosis (stage IIIA) successfully resolving after azelaic acid treatment administered by several routes [letter] Nazzaro–Porro M, et al. **Clin Exp Dermatol** 1996 Jul;21(4):321–3

Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. An Z, et al. **Clin Exp Metastasis** 1997 Mar;15(2):184–95

Inhibitory effects of fluorinated pyrimidines, 5'–DFUR, UFT and T–506, in a model of hepatic metastasis of mouse colon 26 adenocarcinoma–assessment of inhibitory activity and adverse reactions at the maximum tolerated dose. Tazawa K, et al. **Clin Exp Metastasis** 1997 May;15(3):266–71

Dose dependent in vivo inhibition of human colorectal cancer (LoVo) by the gastrin receptor antagonist, CI–988. Romani R, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):438–40

Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia. Frewin RJ, et al. **Clin Lab Haematol** 1997 Jun;19(2):151–2

Automated reticulocyte counting for monitoring patients on chemotherapy for acute leukaemias and malignant lymphomas. Kuse R, et al. **Clin Lab Haematol** 1996 Dec; 18 Suppl 1:39–43

A clinicopathological study of malignant glioma done after local administration of chemotherapeutic agents. Shimura T, et al. **Clin Neuropathol** 1996 Mar–Apr;15(2):119–24

Effect of gallium nitrate therapy on Ga–67 scintigraphic detection of lymphoma: case report. Akansel G, et al. **Clin Nucl Med** 1997 Jan;22(1):21–4

Comparison of mitozantrone and epirubicin in advanced breast cancer. Cook AM, et al. **Clin Oncol (R Coll Radiol)** 1996;8(6):363–6

Purine analogues in the management of lymphoproliferative diseases. Johnson SA. **Clin Oncol (R Coll Radiol)** 1996; 8(5):289–96 (107 ref.)

The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology. Petty RD. **Clin Oncol (R Coll Radiol)** 1996;8(3):186–9 (27 ref.)

Complete remission of extensive metastatic renal cancer following immunotherapy. Plowman PN, et al. **Clin Oncol (R Coll Radiol)** 1997;9(3):176–80

Imaging assessment of the response of bone tumors to preoperative chemotherapy. Kawai A, et al. **Clin Orthop** 1997 Apr;(337):216–25

Chemotherapy in adult germ cell tumors. Culine S, et al. **Crit Rev Oncol Hematol** 1996 Apr;22(3):229–63 (398 ref.)

Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Pieters R, et al. **Crit Rev Oncol Hematol** 1997 Jan; 25(1):11–26 (178 ref.)

Mechanism of action and clinical trials of Mpl ligand. Sheridan WP, et al. **Curr Opin Hematol** 1997 Sep;4(5):312–6 (35 ref.)

The treatment of metastatic melanoma with chemotherapy and biologics [see comments] Atkins MB. **Curr Opin Oncol** 1997 Mar;9(2):205–13 (71 ref.). Comment in: Curr Opin Oncol 1997 Mar;9(2):175–7.

High–dose chemotherapy for the treatment of breast and ovarian cancer [see comments] Cagnoni PJ, et al. **Curr Opin Oncol** 1997 Mar;9(2):122–5 (32 ref.). Comment in: Curr Opin Oncol 1997 Mar;9(2):115–6.

Radiotherapy and chemotherapy for gliomas. Delattre JY, et al. **Curr Opin Oncol** 1996 May;8(3):196–203 (76 ref.)

New drugs in gynecologic oncology. Eisenhauer EA, et al. **Curr Opin Oncol** 1996 Sep;8(5):408–14 (43 ref.)

The role of high–dose chemotherapy in the management of advanced ovarian cancer. Fennelly D. **Curr Opin Oncol** 1996 Sep;8(5):415–25 (69 ref.)

Preoperative chemotherapy for stage IIIa non–small cell lung cancer. Fossella FV, et al. **Curr Opin Oncol** 1996 Mar; 8(2):106–11 (41 ref.)

New drug therapy for squamous carcinoma of the head and neck. Murphy BA. **Curr Opin Oncol** 1996 May;8(3):221–6 (61 ref.)

Antiemetics revisited. Roila F, et al. **Curr Opin Oncol** 1997 Jul;9(4):321–6 (31 ref.)

Treatment of metastatic non–small cell lung cancer. van Zandwijk N, et al. **Curr Opin Oncol** 1996 Mar;8(2):120–5

Topical treatment of psoriasis with fludarabine. Nouri K, et al. **Cutis** 1997 May;59(5):284

Cancer chemotherapeutic agents. Terezhalmy GT, et al. **Dent Clin North Am** 1996 Jul;40(3):709–26 (104 ref.)

Photodynamic treatment of skin malignancies with aminolevulinic acid. Emphasis on anatomical observations and in vivo erythema visual assessment [see comments] Tosca AD, et al. **Dermatol Surg** 1996 Nov;22(11):929–34 . Comment in: Dermatol Surg 1997 Mar;23(3):161.

Combination of local PUVA–therapy and interferon alpha–2A in the treatment of tumoral stage mycosis fungoides [letter] Delpuget–Bertin N, et al. **Dermatology** 1996;193(1):74–5

Control of growth in neuroendocrine gastro–enteropancreatic tumours. Arnold R, et al. **Digestion** 1996;57 Suppl 1:69–71 (19 ref.)

The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro–intestinal tumours. Eriksson B, et al. **Digestion** 1996;57 Suppl 1:77–80

Interferon–alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours. Faiss S, et al. **Digestion** 1996;57 Suppl 1:84–5

Interferon–alpha versus somatostatin or the combination of both in gastro–enteropancreatic tumours. Oberg K. **Digestion** 1996;57 Suppl 1:81–3

Adjuvant chemotherapy in colorectal carcinoma: results of a meta–analysis. Dubé S, et al. **Dis Colon Rectum** 1997 Jan; 40(1):35–41

Improved surgical results after combining preoperative hyperthermia with chemotherapy and radiotherapy for patients with carcinoma of the rectum. Ohno S, et al. **Dis Colon Rectum** 1997 Apr;40(4):401–6

Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay. Yamaue H, et al. **Dis Colon Rectum** 1996 Apr;39(4):416–22

New aromatase inhibitors for breast cancer. **Drug Ther Bull** 1997 Jul;35(7):55–6 (11 ref.)

Emerging drug treatments for solid tumours. Schellens JH, et al. **Drugs** 1996 Jan;51(1):45–72 (321 ref.)

Current recommendations for the management of bladder

cancer. Drug therapy. Witjes JA. **Drugs** 1997 Mar; 53(3):404–14 (67 ref.)
Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Dunn CJ, et al. **Drugs Aging** 1996 Aug;9(2):122–47 (132 ref.)
Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Wiseman LR, et al. **Drugs Aging** 1997 Jun; 10(6):473–85 (52 ref.)
Influence of Ukrain on breast cancer. Brzosko WJ, et al. **Drugs Exp Clin Res** 1996;22(3–5):127–33
Influence of Ukrain on patients with surgically treated breast cancer. Part III. The immune system. Fomin KA, et al. **Drugs Exp Clin Res** 1996;22(3–5):143–5
Ukrain monotherapy in malignant melanoma (case report). Hamler F, et al. **Drugs Exp Clin Res** 1996;22(3–5):235–7
Ukrain therapy of recurrent breast cancer with lung metastases (case report). Kadan P, et al. **Drugs Exp Clin Res** 1996;22(3–5):243–5
Ukrain in the treatment of urethral recurrent carcinoma (case report). Kadan P, et al. **Drugs Exp Clin Res** 1996; 22(3–5):271–3
Ukrain treatment of rhabdomyosarcoma (case report). Kotsay B, et al. **Drugs Exp Clin Res** 1996;22(3–5):239–41
Ukrain treatment in carcinoma of the cervix (case report). Kroiss T, et al. **Drugs Exp Clin Res** 1996;22(3–5):255–7
Amino acids and their derivatives in blood plasma of patients with breast cancer treated with Ukrain. Part V. Nefyodov LI, et al. **Drugs Exp Clin Res** 1996;22(3–5):155–7
Amino acids and their derivatives in tumour tissue from patients with breast cancer treated with Ukrain. Part VI. Nefyodov LI, et al. **Drugs Exp Clin Res** 1996; 22(3–5):159–61
Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report). Sakalo VS, et al. **Drugs Exp Clin Res** 1996;22(3–5):263–5
Biophysiological effects of Ukrain therapy in a patient with breast cancer (case report). Schramm E, et al. **Drugs Exp Clin Res** 1996;22(3–5):247–54
Ukrain with chemotherapy in malignant melanoma (case report). Stabuc B, et al. **Drugs Exp Clin Res** 1996; 22(3–5):231–3
Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report). Steinacker J, et al. **Drugs Exp Clin Res** 1996; 22(3–5):275–7
Ukrain therapy of a recurrent astrocytoma of the optic nerve (case report). Steinacker J, et al. **Drugs Exp Clin Res** 1996; 22(3–5):279–81
Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. Susak YM, et al. **Drugs Exp Clin Res** 1996;22(3–5):115–22
Influence of Ukrain on patients with surgically treated breast cancer. Part IV. Electromicroscopic and cytochemical evaluation. Uglyanica KN, et al. **Drugs Exp Clin Res** 1996; 22(3–5):147–53
Influence of Ukrain on patients with surgically treated breast cancer (introductory remarks). Uglyanica KN, et al. **Drugs Exp Clin Res** 1996;22(3–5):123–5
Influence of Ukrain on patients with surgically treated breast cancer. Part I. Clinical and laboratory parameters. Uglyanica KN, et al. **Drugs Exp Clin Res** 1996; 22(3–5):135–8
Influence of Ukrain on patients with surgically treated breast cancer. Part II. Hormonal profile. Uglyanica KN, et al. **Drugs Exp Clin Res** 1996;22(3–5):139–41
Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma. Voltchek IV, et al. **Drugs Exp Clin Res** 1996;22(3–5):283–6
Ukrain treatment in carcinoma of the oesophagus (case report). Vyas JJ, et al. **Drugs Exp Clin Res** 1996; 22(3–5):267–9
A case of primary hyperparathyroidism accompanying multiple myeloma. Otsuka F, et al. **Endocr J** 1997 Feb; 44(1):105–9 (16 ref.)
EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer. Awada A, et al. **Eur J Cancer** 1997 Jul;33(8):1173–6
Lack of carboplatin activity in malignant lymphomas [letter] Balzarotti M, et al. **Eur J Cancer** 1996 Dec;32A(13):2370–1
Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Boos J, et al. **Eur J Cancer** 1996 Aug;32A(9):1544–50
Bioreductive agents, hypoxic cells and therapy [editorial; comment] Connors TA. **Eur J Cancer** 1996 Oct; 32A(11):1833–4. Comment on: Eur J Cancer 1996 Oct;32A(11):2019–22.
Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. Currow DC, et al. **Eur J Cancer** 1996 Dec; 32A(13):2357–9
A call for change in anticancer drug evaluation. Cvitkovic E. **Eur J Cancer** 1997 Jan;33 Suppl 2:S3–7 (11 ref.)
EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors. de Wit R, et al. **Eur J Cancer** 1997 Mar;33(3):493–5
Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits. Farrugia DC, et al. **Eur J Cancer** 1996 Dec;32A(13):2256–61
D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Hilgard P, et al. **Eur J Cancer** 1997 Mar;33(3):442–6
Improved efficacy of chemotherapy by parvovirus-mediated sensitisation of human tumour cells. Klein-Bauernschmitt P, et al. **Eur J Cancer** 1996 Sep;32A(10):1774–80
Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin. Kudoh K, et al. **Eur J Cancer** 1997 Jan;33(1):122–8
Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. Lissoni P, et al. **Eur J Cancer** 1997 Feb;33(2):304–6
A plea for improved use of the tools available for the evaluation of anticancer drugs. MacRae K. **Eur J Cancer** 1997 Jan;33 Suppl 2:S14–6 (10 ref.)
Non-steroidal anti-inflammatory drugs in the treatment of colorectal cancer [letter] Morgan G. **Eur J Cancer** 1997 Jul;33(8):1335–6
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Nichols J, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S34–6 (27 ref.)
An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma. Pawinski A, et al. **Eur J Cancer** 1997 Mar;33(3):496–9
Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Raghavan D, et al. **Eur J Cancer** 1997 Apr;33(4):566–74 (101 ref.)
The need for endpoints in anticancer drug trials that will simplify the clinical decision-making process. Redmond K. **Eur J Cancer** 1997 Jan;33 Suppl 2:S11–3 (6 ref.)
Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group). Rougier P, et al. **Eur J Cancer** 1996 Jul;32A(8):1432–3
Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. Seelig MH, et al. **Eur J Cancer** 1996 Oct;32A(11):1968–76
High-dose recombinant interleukin-2/verapamil combination in advanced cancer [letter] Tagliaferri P, et al. **Eur J Cancer** 1996 Jul;32A(8):1436–7
Anticancer drug evaluation: continuing progress from existing methodology. ten Bokkel Huinink W. **Eur J Cancer** 1997 Jan;33 Suppl 2:S8–10 (15 ref.)
Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck [letter] Degardin M, et al. **Eur J Cancer B Oral Oncol** 1996 Jul;32B(4):278–9
Hexamethylene bisacetamide as a chemopreventive agent in hamster cheek pouch tumorigenesis. Yura Y, et al. **Eur J Cancer B Oral Oncol** 1996 Jul;32B(4):246–50
Antiblastic chemotherapy for haematologic malignancies and second tumours. Barillari G, et al. **Eur J Cancer Prev** 1996 Oct;5(5):402–4 (14 ref.)
Importance of pyridoxal-5'-phosphate addition to the assay medium for the measurement of catalytic concentrations of plasma aspartate and alanine aminotransferases in patients undergoing antineoplastic chemotherapy. Mastroianni A, et al. **Eur J Clin Chem Clin Biochem** 1996 Jun;34(6):507–10
Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology [see comments] Plöckinger U, et al. **Eur J Endocrinol** 1997 Apr;136(4):369–76. Comment in: Eur J Endocrinol 1997 Apr;136(4):359–61.
Cis-platinum chemotherapy after surgical treatment for bilateral adenocarcinoid of the ovary. Case report. Azzena A, et al. **Eur J Gynaecol Oncol** 1997;18(2):130–2
Remission with carboplatin of paclitaxel resistant primary peritoneal papillary serous carcinoma: case report. Herrada J, et al. **Eur J Gynaecol Oncol** 1997;18(1):39–41
Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Osterborg A, et al. **Eur J Haematol** 1997 Jan; 58(1):5–13
Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). Robak T, et al. **Eur J Haematol** 1997 Feb;58(2):109–13
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. Rondelli D, et al. **Eur J Haematol** 1997 Jan;58(1):46–50
Fludarabine in the treatment of essential mixed cryoglobulinaemia [letter] Zaja F. **Eur J Haematol** 1996 Sep;57(3):259–60
A case of intrauterine medical treatment for cystic hygroma. Watari H, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec 27;70(2):201–3
Pretreatment with [131I] metaiodobenzylguanidine and surgical resection of advanced neuroblastoma. van Hasselt EJ, et al. **Eur J Pediatr Surg** 1996 Jun;6(3):155–8
Adenocarcinoma of the gastro-esophageal junction: CT for monitoring during neoadjuvant chemotherapy. Helmberger H 3rd, et al. **Eur J Radiol** 1996 Sep;23(2):107–10
Failed treatment of pseudomyxoma peritonei (PMP) with intraperitoneal interferon alpha. Maiche AG, et al. **Eur J Surg Oncol** 1996 Dec;22(6):640
Long-term complete remission of melanoma liver metastases after intermittent intra-arterial cisplatin chemotherapy and surgery. Metzger U, et al. **Eur J Surg Oncol** 1997 Jun; 23(3):270–4
The potential of NSAIDs in the prevention and treatment of colorectal carcinoma [letter; comment] Morgan G. **Eur J Surg Oncol** 1996 Oct;22(5):560. Comment on: Eur J Surg Oncol 1996 Jun;22(3):217–9.
Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone. van Ginkel RJ, et al. **Eur J Surg Oncol** 1996 Oct;22(5):528–31
High resolution computed tomography in patients referred for intraluminal bronchoscopic therapy with curative intent. Sutedja G, et al. **Eur Respir J** 1996 May;9(5):1020–3
Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Andriole GL. **Eur Urol** 1997;32 Suppl 3:65–9 (59 ref.)
Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Griffiths K, et al. **Eur Urol** 1997;32 Suppl 3:24–40 (82 ref.)
Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy. Hollender A, et al. **Eur Urol** 1997; 31(2):141–7
Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Krege S, et al. **Eur Urol** 1997;31(4):405–7
Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Roach M 3rd. **Eur Urol** 1997;32 Suppl 3:48–54 (34 ref.)
A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract. Sarosdy MF. **Eur Urol** 1997;31 Suppl 1:20–6 (36 ref.)
Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate. Smith JA Jr, et al. **Eur Urol** 1997;31 Suppl 3:25–9
Innovative approaches to the hormonal treatment of advanced prostate cancer. Trachtenberg J. **Eur Urol** 1997; 32 Suppl 3:78–80 (5 ref.)
Treatment of carcinoma in situ of the urinary bladder with bropirimine. Witjes JA. **Eur Urol** 1997;31 Suppl 1:27–30 (16 ref.)
Angiogenesis in human gliomas: prognostic and therapeutic implications. Johnson JP, et al. **EXS** 1997;79:29–46 (116 ref.)
Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. Levy GN. **FASEB J** 1997 Mar; 11(4):234–47 (109 ref.)
BAL-isolated cells after administration of mutein VI rhTNF-alpha into Morris hepatoma. Sulkowski S, et al. **Folia Histochem Cytobiol** 1997;35(2):81–2
Recent status of the antisense oligonucleotide approaches in oncology. Ma L, et al. **Fundam Clin Pharmacol** 1996; 10(2):97–115 (170 ref.)
Cytokine therapy for hematological malignancies. Ezaki K, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:182–94 (50 ref.)
New drugs for the treatment of lung cancer. The Tokyo Cooperative Oncology Group. Niitani H, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:117–9
N-(Hydroxymethyl) melamines. Coley HM. **Gen Pharmacol** 1997 Feb;28(2):177–82 (31 ref.)
Partial regression, yet incomplete eradication of mammary tumors in transgenic mice by retrovirally mediated HSVtk transfer 'in vivo'. Sacco MG, et al. **Gene Ther** 1996 Dec; 3(12):1151–6
Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Walther W, et al. **Gene Ther** 1997 Jun;4(6):544–52
Isochromosome for derivative 17q in acute promyelocytic leukemia: evidence for two copies of PML-RARA and favorable response to all-trans-retinoic acid therapy [letter; comment] Park JP, et al. **Genes Chromosomes Cancer** 1997 Feb;18(2):151–3. Comment on: Genes Chromosomes Cancer 1996 Mar;15(3):147–56.
Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction. Abu-Rustum NR, et al. **Gynecol Oncol** 1997 Mar;64(3):493–5
Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Markman M, et al. **Gynecol Oncol** 1997 Jun;65(3):434–6
Photodynamic therapy using topically applied dihematoporphyrin ether in the treatment of cervical intraepithelial neoplasia. Monk BJ, et al. **Gynecol Oncol** 1997 Jan;64(1):70–5
Carboplatin as a radiation sensitizer in locally advanced cervical cancer: a pilot study. Muderspach LI, et al. **Gynecol Oncol** 1997 May;65(2):336–42
Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Swisher EM, et al. **Gynecol Oncol** 1997 Sep; 66(3):480–6
Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Tanner B, et al. **Gynecol Oncol** 1997 Apr;65(1):54–62
Effects of electrochemotherapy on CaSki cells derived from a cervical squamous cell carcinoma. Yabushita H, et al. **Gynecol Oncol** 1997 May;65(2):297–303
Long-term survival in a case of high-risk type IgD myeloma; a possibility of effectiveness of interferon-alpha and erythropoietin. Hiyoshi M, et al. **Haematologia (Budap)** 1997;28(3):177–80

ANTINEOPLASTIC AGENTS

Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults. Bassan R, et al. **Haematologica** 1996 Jan-Feb;81(1):20-36 (172 ref.)

All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi). Sacchi S, et al. **Haematologica** 1997 Jan-Feb;82(1):106-21 (117 ref.)

Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine. Zaja F, et al. **Haematologica** 1997 Jul-Aug;82(4):468-70

Interferon-alpha therapy for multiple hemangiomas associated with coarctation of the aorta. Hijii T, et al. **Heart Vessels** 1996;11(4):211-4

Perspectives on purine analogues. Cheson BD. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S109-16 (104 ref.)

Adverse and beneficial immunological effects of purine nucleoside analogues. Dighiero G. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S75-81 (98 ref.)

Clinical experience with fludarabine in hemato-oncology. Keating MJ, et al. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S83-91 (61 ref.)

2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Saven A, et al. **Hematol Cell Ther** 1996 Dec;38 Suppl 2:S93-101 (73 ref.)

All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL). Chim CS, et al. **Hematol Oncol** 1996 Sep;14(3):147-54

Alpha-interferon and pregnancy in a patient with CML. Lipton JH, et al. **Hematol Oncol** 1996 Sep;14(3):119-22

Optimizing chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Arriagada R. **Hematol Oncol Clin North Am** 1997 Jun;11(3):461-72 (37 ref.)

Chemotherapy for advanced non-small cell lung cancer. Herbst RS, et al. **Hematol Oncol Clin North Am** 1997 Jun; 11(3):473-517 (204 ref.)

Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted? Mani S, et al. **Hematol Oncol Clin North Am** 1996 Jun;10(3):749-68 (106 ref.)

Experimental chemotherapeutic agents for the treatment of colorectal carcinoma. O'Reilly S, et al. **Hematol Oncol Clin North Am** 1997 Aug;11(4):721-58 (207 ref.)

Unresectable pancreatic cancer: is a multi-modality approach a promising therapeutical alternative? Lygidakis NJ, et al. **Hepatogastroenterology** 1997 Jul-Aug;44(16):1222-8

Simultaneous combination therapy of carboplatin and radiation for patients with carcinoma of the esophagus. Ohno S, et al. **Hepatogastroenterology** 1997 Jan-Feb; 44(13):181-6

Advances in the treatment of plasma cell diseases. Comenzo RL. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):67-70, 73-4, 79-84 passim (11 ref.)

Efficacy of intra-arterial norcantharidin in suppressing tumour 14C-labelled glucose oxidative metabolism in rat Morris hepatoma. Mack P, et al. **HPB Surg** 1996; 10(2):65-72

Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells. Tamura M, et al. **Hum Gene Ther** 1997 Mar 1;8(4):381-91

OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells. Madiyalakan R, et al. **Hybridoma** 1997 Feb;16(1):41-5

Locoregional IL-2 immunotherapy of bladder cancer. Santoni A, et al. **Immunopharmacol Immunotoxicol** 1997 Feb;19(1):1-13 (31 ref.)

Interleukin-12, an emerging anti-tumour cytokine. Hiscox S, et al. **In Vivo** 1997 Mar-Apr;11(2):125-32 (97 ref.)

Metabolism of proteins and glycoproteins in tumour bearing mice treated with Aeromonas L-asparaginase. Benny PJ, et al. **Indian J Biochem Biophys** 1996 Dec;33(6):527-30

Juvenile chronic myelogenous leukemia: therapeutic trial with interferon alpha 2B. Agarwal BR, et al. **Indian Pediatr** 1995 Sep;32(9):1002-4

OK-432 injection therapy for lymphangiomas. Motiwale SS, et al. **Indian Pediatr** 1996 Aug;33(8):686-8

Moving promising research findings to the clinic: methodological issues in the design and conduct of clinical trials of retinoids. Arnold A. **Int J Cancer** 1997 Feb 7; 70(4):467-9 (11 ref.)

Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Ellis PA, et al. **Int J Cancer** 1997 Aug 7;72(4):608-13

The anti-tumoral activity of human glycoprotein HGP.92: a study with the mouse Lewis-lung-tumor cell. Fontan E, et al. **Int J Cancer** 1997 Feb 7;70(4):416-22

Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. Ghetie MA, et al. **Int J Cancer** 1996 Sep 27;68(1):93-6

13-cis retinoic acid and interferon-alpha +/- irradiation in the treatment of squamous-cell carcinomas. Hoffmann W, et al. **Int J Cancer** 1997 Feb 7;70(4):475-7

Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Kellner U, et al. **Int J Cancer** 1997 May 29;71(5):817-24

Proteinase inhibition in invasive cancer therapy: four control levels of matrix degradation [letter] Opdenakker G, et al. **Int J Cancer** 1997 Mar 4;70(5):628-30

Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex. Sava G, et al. **Int J Cancer** 1996 Sep 27;68(1):60-6

Clinical and molecular aspects of retinoid therapy for acute promyelocytic leukemia. Warrell RP Jr. **Int J Cancer** 1997 Feb 7;70(4):496-7

Cancer therapy with liposomal formulations of anticancer drugs. Massing U. **Int J Clin Pharmacol Ther** 1997 Feb; 35(2):87-90 (19 ref.)

Retinoids for vulvar dysplasia in the HIV-infected patient. Del Priore G, et al. **Int J Gynaecol Obstet** 1996 Oct; 55(1):77-8

Quinacrine: sclerosing agent of the utero-tubal junction in women, with anticarcinogenic actions in transplanted tumors in mice. Zipper J, et al. **Int J Gynaecol Obstet** 1995 Dec;51 Suppl 1:S47-55 (73 ref.)

Administration of granulocyte colony-stimulating factor during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Usuki K, et al. **Int J Hematol** 1996 Oct;64(3-4):213-9

The in vivo interaction between flavone acetic acid and hyperthermia. Horsman MR, et al. **Int J Hyperthermia** 1996 Nov-Dec;12(6):779-89

Hyperthermia-enhanced effectiveness of mitoxantrone in an experimental rat tumour. Schopman EM, et al. **Int J Hyperthermia** 1996 Mar-Apr;12(2):241-54

Combination chemo-immunotherapy of murine solid tumor with OK-432, G-CSF, IL-2, and chemotherapeutics. Iida S, et al. **Int J Immunopharmacol** 1995 Dec;17(12):973-80

Retinoid actions and implications for prevention and therapy of oral cancer. Girod SC, et al. **Int J Oral Maxillofac Surg** 1996 Feb;25(1):69-73 (79 ref.)

Photofrin-mediated photodynamic therapy of chemically-induced premalignant lesions and squamous cell carcinoma of the palatal mucosa in rats. Nauta JM, et al. **Int J Oral Maxillofac Surg** 1997 Jun;26(3):223-31

Esthesioneuroblastoma in the pediatric age-group: the role of chemotherapy and autologous bone marrow transplantation. Nguyen QA, et al. **Int J Pediatr Otorhinolaryngol** 1996 Sep;37(1):45-52

Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Bachaud JM, et al. **Int J Radiat Oncol Biol Phys** 1996 Dec 1;36(5):999-1004

Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer. Kievit E, et al. **Int J Radiat Oncol Biol Phys** 1997 May 1;38(2):419-28

Concurrent daily carboplatin and accelerated hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer. Kunitoh H, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 1;37(1):103-9

Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study. Rhomberg W, et al. **Int J Radiat Oncol Biol Phys** 1996 Dec 1;36(5):1077-84

Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Al-Sarraf M, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 1;37(4):777-82

Phase I-II trial of concomitant continuous carboplatin (CBDCA) infusion and radiotherapy in advanced nonsmall cell lung cancer with evaluation for surgery: final report. Trodella L, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 1;37(1):93-101

Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi's sarcoma. Bower M, et al. **Int J STD AIDS** 1997 Aug;8(8):518-21

Phenotype frequency of human leukocyte antigens in Japanese patients with renal cell carcinoma who responded to interferon-alpha treatment. Onishi T, et al. **Int J Urol** 1996 Nov;3(6):435-40

"Web-like obstruction"--a sign of regional complete remission after concurrent chemoradiotherapy in small cell lung cancer. Hanada T, et al. **Intern Med** 1996 Sep; 35(9):732-5

Combination therapy with granulocyte colony-stimulating factor, all-trans retinoic acid, and low-dose cytotoxic drugs for acute myelogenous leukemia. Usuki K, et al. **Intern Med** 1995 Dec;34(12):1186-9

Suppression of metastatic potential of high-metastatic Lewis lung carcinoma cells by vanadate, an inhibitor of tyrosine phosphatase, through inhibiting cell-substrate adhesion. Takenaga K. **Invasion Metastasis** 1996;16(2):97-106

Phase II study of Mitonafide in advanced and relapsed colorectal cancer. Abad A, et al. **Invest New Drugs** 1996; 14(2):223-5

Pharmacologic strategies for the treatment of meningeal malignancy. Blaney SM, et al. **Invest New Drugs** 1996; 14(1):69-85 (85 ref.)

Phase II trial of edatrexate in patients with metastatic colorectal cancer. Clamon GH, et al. **Invest New Drugs** 1996;13(4):359-61

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Dunn TA, et al. **Invest New Drugs** 1997;15(2):109-14

Phase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group. Estlin EJ, et al. **Invest New Drugs** 1996;14(1):23-32 (31 ref.)

Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Fox SB, et al. **Invest New Drugs** 1997;15(1):15-28 (174 ref.)

An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Gradishar WJ. **Invest New Drugs** 1997;15(1):49-59 (103 ref.)

Antitumor diarylsulfonylureas: novel agents with unfulfilled promise. Houghton PJ, et al. **Invest New Drugs** 1996; 14(3):271-80 (34 ref.)

Multidrug resistance in pediatric oncology. Kuttesch JF Jr. **Invest New Drugs** 1996;14(1):55-67 (88 ref.)

An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group. Leaf AN, et al. **Invest New Drugs** 1997;15(2):165-72

The importance of phase I/II trials in pediatric oncology. MacArthur CA, et al. **Invest New Drugs** 1996;14(1):33-5 (11 ref.)

Exploitation of folate and antifolate polyglutamylation to achieve selective anticancer chemotherapy. McGuire JJ, et al. **Invest New Drugs** 1996;14(3):317-23 (28 ref.)

The preclinical evaluation of angiogenesis inhibitors. O'Reilly MS. **Invest New Drugs** 1997;15(1):5-13 (87 ref.)

Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Polin L, et al. **Invest New Drugs** 1997;15(2):99-108

Pharmacokinetic profile of Mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma. Rizzo J, et al. **Invest New Drugs** 1996;14(2):227-34

Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Scher RM, et al. **Invest New Drugs** 1996;13(4):347-54

Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane. Schilling T, et al. **Invest New Drugs** 1996;13(4):327-32

Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). Smith M, et al. **Invest New Drugs** 1996;14(1):11-22 (73 ref.)

Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study. Smith RE, et al. **Invest New Drugs** 1996;14(4):403-7

Topoisomerase I interactive drugs in children with cancer. Stewart CF, et al. **Invest New Drugs** 1996;14(1):37-47 (45 ref.)

New drug development for pediatric oncology. Weitman S, et al. **Invest New Drugs** 1996;14(1):1-10 (92 ref.)

Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Wojtowicz-Praga S, et al. **Invest New Drugs** 1996; 14(2):193-202

Matrix metalloproteinase inhibitors. Wojtowicz-Praga SM, et al. **Invest New Drugs** 1997;15(1):61-75 (94 ref.)

A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma. Woolley PV, et al. **Invest New Drugs** 1996; 14(2):219-22

Role of splenectomy in chronic lymphocytic leukemia. Cusack JC Jr, et al. **J Am Coll Surg** 1997 Sep;185(3):237-43

Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993). Chun R, et al. **J Am Vet Med Assoc** 1996 Nov 1;209(9):1588-91

Amputation and dexniguldipine as treatment for canine appendicular osteosarcoma. Hahn KA, et al. **J Cancer Res Clin Oncol** 1997;123(1):34-8

Regulation of the release of tumour necrosis factor (TNF)alpha and soluble TNF receptor by gamma irradiation and interferon gamma in Ewing's sarcoma/peripheral primitive neuroectodermal tumour cells. van Valen F, et al. **J Cancer Res Clin Oncol** 1997; 123(5):245-52

Clinical development plan: 9-cis-retinoic acid. **J Cell Biochem Suppl** 1996;26:158-67

Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study. Aasebø U, et al. **J Chemother** 1997 Apr;9(2):106-11

Bacteremia in cancer patients with solid tumors undergoing chemotherapy versus surgery: risk factors, etiology and outcome in 276 patients. Krcmery V Jr, et al. **J Chemother** 1997 Jun;9(3):232-7

Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide [see comments] Caron P, et al. **J Clin Endocrinol Metab** 1997 Jan; 82(1):18-22. Comment in: J Clin Endocrinol Metab 1997 Jan;82(1):15-7.

Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy [letter; comment] Colao A, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2756. Comment on: J Clin Endocrinol Metab 1997 Aug;82(8):2755-6.

Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy [letter; comment] [see comments] Delgrange E, et al. **J Clin Endocrinol Metab** 1997 Aug; 82(8):2755-6. Comment on: J Clin Endocrinol Metab 1997 Mar;82(3):876-83. Comment in: J Clin Endocrinol Metab 1997 Aug;82(8):2756.

Sandostatin LAR in acromegalic patients: long-term treatment [see comments] Fløgstad AK, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):23-8. Comment in: J Clin Endocrinol Metab 1997 Jan;82(1):15-7.

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. Antman KH, et al. **J Clin Oncol** 1997 May;15(5):1870-9

Topotecan, a new active drug in the second-line treatment

of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. Ardizzoni A, et al. **J Clin Oncol** 1997 May;15(5):2090–6

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. Bajetta E, et al. **J Clin Oncol** 1996 Sep; 14(9):2546–51

Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. Bergmann OJ, et al. **J Clin Oncol** 1997 Jun;15(6):2269–74

Interferons as biochemical modulators [editorial; comment] Borden EC, et al. **J Clin Oncol** 1996 Oct;14(10):2627–30 . Comment on: J Clin Oncol 1996 Oct;14(10):2653–65. Comment on: J Clin Oncol 1996 Oct;14(10):2774–84.

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Brice P, et al. **J Clin Oncol** 1997 Mar;15(3):1110–7

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study [see comments] Cole BF, et al. **J Clin Oncol** 1996 Oct; 14(10):2666–73. Comment in: J Clin Oncol 1997 May;15(5):2172.

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study [see comments] Creemers GJ, et al. **J Clin Oncol** 1996 Dec;14(12):3056–61. Comment in: J Clin Oncol 1996 Dec;14(12):3053–5.

Chemotherapy with mitoxantrone in hormone-refractory prostate cancer [letter; comment] Denes AE. **J Clin Oncol** 1997 Jan;15(1):410–1. Comment on: J Clin Oncol 1996 Jun;14(6):1753–5. Comment on: J Clin Oncol 1996 Jun;14(6):1756–64.

Improving the cancer chemotherapy use process. Fischer DS, et al. **J Clin Oncol** 1996 Dec;14(12):3148–55

Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. Hoffman MA, et al. **J Clin Oncol** 1997 Mar;15(3):1138–42

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Keilholz U, et al. **J Clin Oncol** 1997 Jul;15(7):2579–88

Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. Levine AM, et al. **J Clin Oncol** 1997 Mar; 15(3):1094–103

Patient preferences for interferon alfa in multiple myeloma. Ludwig H, et al. **J Clin Oncol** 1997 Apr;15(4):1672–9

Topotecan today [editorial; comment] Lynch T. **J Clin Oncol** 1996 Dec;14(12):3053–5. Comment on: J Clin Oncol 1996 Dec;14(12):3056–61. Comment on: J Clin Oncol 1996 Dec;14(12):3062–73. Comment on: J Clin Oncol 1996 Dec;14(12):3074–84.

Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. McQuaker IG, et al. **J Clin Oncol** 1997 Jun;15(6):2288–95

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Osterborg A, et al. **J Clin Oncol** 1997 Apr;15(4):1567–74

Treatment of recurrent ovarian cancer: increasing options—"recurrent" results [editorial; comment] Ozols RF. **J Clin Oncol** 1997 Jun;15(6):2177–80. Comment on: J Clin Oncol 1997 Jun;15(6):2183–93.

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. Pawson R, et al. **J Clin Oncol** 1997 Jul; 15(7):2667–72

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. Perez-Soler R, et al. **J Clin Oncol** 1996 Oct; 14(10):2785–90

Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. Perrault D, et al. **J Clin Oncol** 1996 Oct; 14(10):2709–12

Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. Saven A, et al. **J Clin Oncol** 1997 Jan;15(1):37–43

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Saxman SB, et al. **J Clin Oncol** 1997 Jul;15(7):2564–9

Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. Soni N, et al. **J Clin Oncol** 1997 Feb;15(2):766–72

Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. Steffens MG, et al. **J Clin Oncol** 1997 Apr;15(4):1529–37

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. Tempero M, et al. **J Clin Oncol** 1997 Apr; 15(4):1518–28

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [see comments] ten Bokkel Huinink W, et al. **J Clin Oncol** 1997 Jun;15(6):2183–93. Comment in: J Clin Oncol 1997 Jun;15(6):2177–80.

Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial. Vose JM, et al. **J Clin Oncol** 1997 Apr; 15(4):1617–23

Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. Warzocha K, et al. **J Clin Oncol** 1997 Feb;15(2):499–508

Survival benefit in melanoma [letter; comment] Williams MV, et al. **J Clin Oncol** 1997 May;15(5):2172. Comment on: J Clin Oncol 1996 Oct;14(10):2666–73.

Systemic cytokine administration alters the histology of the eruption of lymphocyte recovery. Horn T, et al. **J Cutan Pathol** 1996 Jun;23(3):242–6

OK-432 therapy for recalcitrant warts. Inui S, et al. **J Dermatol** 1997 May;24(5):301–5

Carotenoids in cancer, mastalgia, and AIDS: prevention and treatment—an overview. Santamaria L, et al. **J Environ Pathol Toxicol Oncol** 1996;15(2–4):89–95 (46 ref.)

The adjuvant treatment of malignant melanoma. Reintgen D, et al. **J Fla Med Assoc** 1997 Mar;84(3):147–52

Effect of arterial administration of a high molecular weight anti-tumor agent, styrene maleic acid neocarzinostatin, for multiple small liver cancer—a pilot study. Ikeda K, et al. **J Gastroenterol** 1997 Aug;32(4):513–20

Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. Chou YY, et al. **J Gastroenterol Hepatol** 1997 Aug;12(8):569–75

Case report: successful palliative treatment with intraperitoneal OK-432 injection for epithelioid haemangioendothelioma presenting with intractable ascites. Wei SC, et al. **J Gastroenterol Hepatol** 1997 Jan;12(1):39–43

L-arginine prevents heart transplant arteriosclerosis by modulating the vascular cell proliferative response to insulin-like growth factor-I and interleukin-6. Lou H, et al. **J Heart Lung Transplant** 1996 Dec;15(12):1248–57

Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery. Remes K, et al. **J Hematother** 1997 Feb;6(1):13–9

Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. Ferlazzo G, et al. **J Immunother** 1997 Mar; 20(2):158–63

Induction of tumor necrosis factor in a murine tumor by systemic administration of a novel synthetic lipid A analogue, ONO-4007. Ueda H, et al. **J Immunother** 1997 Jan;20(1):65–9

Combined infusional chemotherapy and radiation for esophageal carcinoma: a review. Chauveinc L, et al. **J Infus Chemother** 1995 Fall;5(4):215–7 (25 ref.)

Treatment strategies for early-stage chronic lymphocytic leukemia: can interferon-inducible MxA protein and tumor necrosis factor play a role as predictive markers for response to interferon therapy? Bezares F, et al. **J Interferon Cytokine Res** 1996 Jul;16(7):501–5

Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer. Byhardt RW, et al. **J Interferon Cytokine Res** 1996 Nov; 16(11):891–902

Circulating interleukin-2 receptors are a group of multimeric proteins with immunoreactivity for interleukin-2 receptor alpha, beta, and gamma chains. Dummer R, et al. **J Interferon Cytokine Res** 1996 Apr;16(4):315–20

Why do so many cancer patients fail to respond to interferon therapy? Einhorn S, et al. **J Interferon Cytokine Res** 1996 Apr;16(4):275–81 (83 ref.)

Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. Fleischmann CM, et al. **J Interferon Cytokine Res** 1996 Oct;16(10):805–12

B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16 alpha cells) as activators of tumor immunity in mice. Fleischmann CM, et al. **J Interferon Cytokine Res** 1997 Jan;17(1):37–43

Intranasal administration of IFN-alpha/beta inhibits the development of visceral tumor metastases. Kaido TJ. **J Interferon Cytokine Res** 1997 Jan;17(1):31–6

Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival. Mattson K, et al. **J Interferon Cytokine Res** 1997 Feb;17(2):103–5

Effects of interferon-alpha, beta, and gamma on the function of differentiated leukemic HL-60 cells induced by 1,25-dihydroxyvitamin D3. Watanabe M, et al. **J Interferon Cytokine Res** 1996 May;16(5):347–56

Phase I/IB study of polyadenylic-polyuridylic acid in patients with advanced malignancies: clinical and biologic effects. Witt PL, et al. **J Interferon Cytokine Res** 1996 Aug; 16(8):631–5

Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma. Yagi H, et al. **J Invest Dermatol** 1996 Dec;107(6):827–32

Use of interferon-alpha in laryngeal papillomatosis: eight years of the Cuban national programme. Deuñas L, et al. **J Laryngol Otol** 1997 Feb;111(2):134–40

Montiporic acids A and B, cytotoxic and antimicrobial polyacetylene carboxylic acids from eggs of the scleractinian coral Montipora digitata. Fusetani N, et al. **J Nat Prod** 1996 Aug;59(8):796–7

Treatment for rare brain tumors veers from traditional tack [news] McBride G. **J Natl Cancer Inst** 1997 Jul 2; 89(13):912–3

Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides [see comments] Skorski T, et al. **J Natl Cancer Inst** 1997 Jan 15;89(2):124–33. Comment in: J Natl Cancer Inst 1997 Jan 15;89(2):107–9.

Cancer problems lead list for potential medical marijuana research studies [news] Smigel K. **J Natl Cancer Inst** 1997 Sep 3;89(17):1255

Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b [letter] Vermeulen PB, et al. **J Natl Cancer Inst** 1997 Sep 3;89(17):1316–7

Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer. Bergan RC, et al. **J Natl Med Assoc** 1997 Sep;89(9):622–8

Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. Pace A, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):409–11

Heterogeneity of chemosensitivity in six clonal cell lines derived from a spontaneous murine astrocytoma and its relationship to genotypic and phenotypic characteristics. Bradford R, et al. **J Neurooncol** 1997 Sep;34(3):247–61

All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications. Defer GL, et al. **J Neurooncol** 1997 Sep;34(2):169–77

The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). Kaba SE, et al. **J Neurooncol** 1997 Sep;34(2):145–51

Resolution of recurrent malignant ganglioglioma after treatment with cis-retinoic acid. Kaba SE, et al. **J Neurooncol** 1996 Oct;30(1):55–60

The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. Lamond JP, et al. **J Neurooncol** 1996 Oct;30(1):1–6

All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. Phuphanich S, et al. **J Neurooncol** 1997 Sep;34(2):193–200

Clinical trial of external beam-radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme—a pilot study. Shinoda J, et al. **J Neurooncol** 1997 Oct;35(1):73–80

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. Schrell UM, et al. **J Neurosurg** 1997 May;86(5):840–4

Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. Schrell UM, et al. **J Neurosurg** 1997 May;86(5):845–52

Influence of chemotherapy on FDG uptake by human cancer xenografts in nude mice. Yoshioka T, et al. **J Nucl Med** 1997 May;38(5):714–7

Treatment of childhood lymphangiomas with interferon-alpha. Reinhardt MA, et al. **J Pediatr Hematol Oncol** 1997 May-Jun;19(3):232–6

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. Tubergen DG, et al. **J Pediatr Hematol Oncol** 1996 Nov;18(4):352–61

Pediatric phase II cancer chemotherapy trials: a Pediatric Oncology Group study. Weitman S, et al. **J Pediatr Hematol Oncol** 1997 May-Jun;19(3):187–91

Natural products derived from plants as potential drugs for the photodynamic destruction of tumor cells. Ebermann R, et al. **J Photochem Photobiol B** 1996 Nov;36(2):95–7 (15 ref.)

Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapy. Jori G. **J Photochem Photobiol B** 1996 Nov;36(2):87–93 (42 ref.)

The validity of melatonin as an oncostatic agent. Panzer A, et al. **J Pineal Res** 1997 May;22(4):184–202 (165 ref.)

Cutaneous lymphangitis carcinomatosa: a rare primary manifestation of malignancy. Keohane SG, et al. **J R Soc Med** 1996 Oct;89(10):582–3

Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group—third study on colorectal cancer. Ito K, et al. **J Surg Oncol** 1996 Oct;63(2):107–11

Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. Nguyen DM, et al. **J Thorac Cardiovasc Surg** 1996 Nov; 112(5):1372–6; discussion 1376–7

Concurrent cisplatin and radiotherapy for patients with

muscle invasive bladder cancer who are not candidates for radical cystectomy. Chauvet B, et al. **J Urol** 1996 Oct; 156(4):1258–62

Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. Hartley-Asp B, et al. **J Urol** 1997 Sep;158(3 Pt 1):902–7

Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions. Pfeffer LM, et al. **J Urol** 1996 Nov; 156(5):1867–71

A comparison of doxorubicin and COP for maintenance of remission in cats with lymphoma. Moore AS, et al. **J Vet Intern Med** 1996 Nov-Dec;10(6):372–5

Surgery and doxorubicin in dogs with hemangiosarcoma. Ogilvie GK, et al. **J Vet Intern Med** 1996 Nov-Dec; 10(6):379–84

Antitumor activity of natural-type human tumor necrosis factor on experimental brain tumors in rats. Nakaichi M, et al. **J Vet Med Sci** 1996 Sep;58(9):885–91

Researchers struggle with trials of stem-cell transplants for breast cancer [news] Stephenson J. **JAMA** 1997 Jun 18; 277(23):1827–9

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Kobayashi M, et al. **Jpn J Cancer Res** 1997 Mar;88(3):316–27

Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26. Midoro K, et al. **Jpn J Cancer Res** 1997 Mar;88(3):306–15

Cross sectional study of use of alternative medicines in Chinese cancer patients. Liu JM, et al. **Jpn J Clin Oncol** 1997 Feb;27(1):37–41

High dose chemotherapy with peripheral blood stem cells transplantation in patients with relapsed or refractory lymphomas preliminary reports. Chang CS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1997 Mar; 13(3):149–54

Synthetic lipid A produces antitumor effect in a hamster pancreatic carcinoma model through production of tumor necrosis factor from activated macrophages. Morita S, et al. **Kobe J Med Sci** 1996 Aug;42(4):219–31

Lessons from antineoplaston [editorial] [see comments] **Lancet** 1997 Mar 15;349(9054):741. Comment in: Lancet 1997 May 17;349(9063):1480. Comment in: Lancet 1997 May 17;349(9063):1481.

Miltefosine in recurrent cutaneous breast cancer [letter] Clive S, et al. **Lancet** 1997 Mar 1;349(9052):621–2

Multidrug resistance protein in recurrent breast cancer [letter] Nooter K, et al. **Lancet** 1997 Jun 28; 349(9069):1885–6

Chemotherapy. Pinedo HM, et al. **Lancet** 1997 May;349 Suppl 2:SII7–9 (24 ref.)

Multidrug-resistance gene employed to advantage [news] Rowe PM. **Lancet** 1997 Mar 22;349(9055):858

Hydroxyurea for treatment of unresectable meningiomas [letter] Schrell UM, et al. **Lancet** 1996 Sep 28; 348(9031):888–9

Lessons from antineoplaston [letter; comment] Silver H. **Lancet** 1997 May 17;349(9063):1480. Comment on: Lancet 1997 Mar 15;349(9054):741.

Keloid excision and recurrence prophylaxis via intradermal interferon-gamma injections: a pilot study. Broker BJ, et al. **Laryngoscope** 1996 Dec;106(12 Pt 1):1497–501

Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy. Braichotte DR, et al. **Lasers Surg Med** 1996; 19(3):340–6

Gold vapor laser versus tunable argon-dye laser for endobronchial photodynamic therapy. McCaughan JS Jr, et al. **Lasers Surg Med** 1996;19(3):347–50

Cooperative clinical trial of photodynamic therapy with photofrin II and excimer dye laser for early gastric cancer. Mimura S, et al. **Lasers Surg Med** 1996;19(2):168–72

Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies. Ris HB, et al. **Lasers Surg Med** 1996;18(1):39–45

Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukaemia and other haematological neoplasms but of neither marker with ex vivo chemosensitivity or patient survival. Bosanquet AG, et al. **Leuk Lymphoma** 1996 Dec;24(1-2):141–7

Prolonged survival in follicular non Hodgkins lymphoma is predicted by achievement of complete remission with initial treatment: results of a long-term study with multivariate analysis of prognostic factors. Davidge-Pitts M, et al. **Leuk Lymphoma** 1996 Dec;24(1-2):131–40

Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Escudier SM, et al. **Leuk Lymphoma** 1996 Feb;20(5-6):435–9

Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support. Johnsen HE, et al. **Leuk Lymphoma** 1996 Dec;24(1-2):81–91

2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders. Kong LR, et al. **Leuk Lymphoma** 1997 Jun;26(1-2):89–97

Quercetin and the growth of leukemic progenitors. Larocca LM, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):49–53 (51 ref.)

Improving the cytogenetic response to interferon alpha by zidovudine (AZT) in an HIV-positive chronic myelogenous leukemia patient. Mahon FX, et al. **Leuk Lymphoma** 1997 Jun;26(1-2):205–7

Tretinoin tocoferil as a possible differentiation-inducing agent against myelomonocytic leukemia. Makishima M, et al. **Leuk Lymphoma** 1997 Jun;26(1-2):43–8 (55 ref.)

Occurrence of myeloma in a chronic lymphocytic leukemia patients after response to differentiation therapy with interleukin-4. Makower D, et al. **Leuk Lymphoma** 1996 Nov;23(5-6):617–9

High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukemia: preliminary results. Mehta J, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):107–11

Screening for multidrug resistance in leukemia: cell reactivity to MRK-16 correlates with anthracycline retention and sensitivity of leukemic cells. Michieli M, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):99–105

Current strategies for the treatment of CLL. Montserrat E, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:65–8 (17 ref.)

Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. O'Brien S, et al. **Leuk Lymphoma** 1996 Oct;23(3-4):247–52 (24 ref.)

Why do drugs work in CLL? Plunkett W, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:1–11 (75 ref.)

Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma. Róbak T, et al. **Leuk Lymphoma** 1997 Jun;26(1-2):99–105

Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Robak T, et al. **Leuk Lymphoma** 1996 Aug;22(5-6):509–14

Rapid disappearance of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia following bone marrow transplantation and chemotherapy. Sakata N, et al. **Leuk Lymphoma** 1997 Jun;26(1-2):141–52

In vitro and in vivo biologic effects of interleukin-3 (IL-3) in follicular low-grade lymphoma. Shade RJ, et al. **Leuk Lymphoma** 1997 Jun;26(1-2):17–25

Interferon-alpha and its effects on the cytokine cascade: a pro- and anti-inflammatory cytokine. Tilg H, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):55–60 (73 ref.)

Potential use of recombinant human interleukin-6 in clinical oncology. Veldhuis GJ, et al. **Leuk Lymphoma** 1996 Feb; 20(5-6):373–9 (61 ref.)

A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Dutcher JP, et al. **Leuk Res** 1997 May;21(5):375–80

Achievement of a complete cytogenetic response with hydroxyurea in a patient with chronic myelogenous leukemia. Tanaka M, et al. **Leuk Res** 1997 May;21(5):465–8

Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Bergmann L. **Leukemia** 1997 Apr; 11 Suppl 2:S29–34 (77 ref.)

Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment. Chou WC, et al. **Leukemia** 1997 Jul;11(7):921–8

A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cortes J, et al. **Leukemia** 1997 Jul;11(7):929–32

Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Cortes J, et al. **Leukemia** 1997 Jun;11(6):788–91

Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia. Hochhaus A, et al. **Leukemia** 1997 Jul;11(7):933–9

Is there a place for 2-CDA in the treatment of B-CLL? Mitterbauer M, et al. **Leukemia** 1997 Apr;11 Suppl 2:S35–7 (27 ref.)

Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. O'Brien S, et al. **Leukemia** 1997 Oct;11(10):1631–5

Purine analogs in the treatment of chronic lymphocytic leukemia. Pott C, et al. **Leukemia** 1997 Apr;11 Suppl 2:S25–8 (52 ref.)

Chemical modification of L-asparaginase with comb-shaped copolymer of poly(ethylene glycol) derivative and maleic anhydride. Saito T, et al. **Leukemia** 1997 Apr;11 Suppl 3:408–9

Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Seymour JF, et al. **Leukemia** 1997 Jan;11(1):42–7

Application of myeloid growth factors in the treatment of acute myeloid leukemia. Terpstra W, et al. **Leukemia** 1997 Mar;11(3):315–27 (136 ref.)

An extremely delayed cytogenetic response to interferon-alpha in a patient with chronic myeloid leukaemia. Whiteway AJ, et al. **Leukemia** 1997 Apr; 11(4):614–6

Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Wijermans PW, et al. **Leukemia** 1997 Jan;11(1):1–5

First-line therapy of advanced chronic lymphocytic leukemia. Wilhelm M, et al. **Leukemia** 1997 Apr;11 Suppl 2:S14–8 (49 ref.)

Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Burke YD, et al. **Lipids** 1997 Feb;32(2):151–6

Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC). Borges M, et al. **Lung Cancer** 1996 Dec;16(1):21–33

Hyperfractionated radiotherapy and concomitant cisplatin in stage III non-small cell lung cancer: a phase II study by the AIRO-Lombardia Cooperative Group. Palazzi M, et al. **Lung Cancer** 1996 Aug;15(1):85–91

Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer. Tomkowski WZ, et al. **Lung Cancer** 1997 Mar; 16(2-3):215–22

Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group [published erratum appears in Lung Cancer 1997 May;17(1):179] Viallet J, et al. **Lung Cancer** 1996 Nov;15(3):367–73

In vivo and ex vivo study of metabolic and cellular effects of 5-fluorouracil chemotherapy in a mouse mammary carcinoma. Street JC, et al. **Magn Reson Imaging** 1997; 15(5):587–96

Acute leukemia and chemotherapy: a modeling viewpoint. Afenya E. **Math Biosci** 1996 Dec;138(2):79–100 (30 ref.)

Chemotherapy for soft tissue sarcomas. Clark JW. **Med Health R I** 1997 Jan;80(1):37–8 (23 ref.)

Haematopoietic growth factors and chemotherapy: new horizons [editorial] Clarke K, et al. **Med J Aust** 1996 Sep 16;165(6):303–4

Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer. Clarke SJ, et al. **Med J Aust** 1997 Jun 2;166 Suppl:S14–6

Drugs of choice for cancer chemotherapy. **Med Lett Drugs Ther** 1997 Mar 14;39(996):21–8

Topotecan hydrochloride for metastatic ovarian cancer. **Med Lett Drugs Ther** 1996 Oct 25;38(986):96–7

Acute promyelocytic leukaemia in the all trans retinoic acid era. DeLoughery TG, et al. **Med Oncol** 1996 Dec; 13(4):233–40 (107 ref.)

Mechanistic analysis of high antitumor effect of intradermal administration of lipopolysaccharide from Pantoea Agglomerans. Iwamoto I, et al. **Med Oncol** 1996 Jun; 13(2):103–9

Classical multidrug resistance in acute myeloid leukaemia. Paietta E. **Med Oncol** 1997 Mar;14(1):53–60 (63 ref.)

Curable and non-curable malignancies: lessons from paediatric cancer. Toren A, et al. **Med Oncol** 1996 Mar; 13(1):15–21 (45 ref.)

Spindle cell (Kaposiform) hemangioendothelioma with Kasabach-Merritt syndrome in an infant: successful treatment with alpha-2A interferon. Deb G, et al. **Med Pediatr Oncol** 1997 May;28(5):358–61

Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study. Bröcker EB, et al. **Melanoma Res** 1996 Oct;6(5):399–401

Chemosensitivity of human melanoma metastases in mouse subrenal capsule assay—can it predict tumour response to combined cytostatic plus interferon therapy in metastatic melanoma? Hahka-Kemppinen M, et al. **Melanoma Res** 1996 Jun;6(3):215–21

Effect of interferon-alpha on the expression of tumour necrosis factor-alpha by metastatic malignant melanoma in vivo. Håkansson A, et al. **Melanoma Res** 1997 Apr; 7(2):139–45

Signal transduction-based strategies for the treatment of chronic myelogenous leukemia. Senechal K, et al. **Mol Med Today** 1996 Dec;2(12):503–9 (43 ref.)

Multiple myeloma. Bataille R, et al. **N Engl J Med** 1997 Jun 5;336(23):1657–64 (100 ref.)

Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. Bosset JF, et al. **N Engl J Med** 1997 Jul 17;337(3):161–7

Polyprenoic acid in hepatocellular carcinoma [letter; comment] Decensi A, et al. **N Engl J Med** 1996 Nov 7; 335(19):1461; discussion 1461-2. Comment on: N Engl J Med 1996 Jun 13;334(24):1561–7.

Differentiation therapy for acute promyelocytic leukemia [editorial; comment] Fenaux P, et al. **N Engl J Med** 1997 Oct 9;337(15):1076–7. Comment on: N Engl J Med 1997 Oct 9;337(15):1021–8.

Pamidronate and metastatic breast cancer [letter; comment] Rubiales AS, et al. **N Engl J Med** 1997 May 29; 336(22):1609–10; discussion 1610. Comment on: N Engl J Med 1996 Dec 12;335(24):1785–91.

All-trans-retinoic acid in acute promyelocytic leukemia [see comments] Tallman MS, et al. **N Engl J Med** 1997 Oct 9;337(15):1021–8. Comment in: N Engl J Med 1997 Oct 9;337(15):1076–7.

Polyprenoic acid in hepatocellular carcinoma [letter; comment] Yang CH, et al. **N Engl J Med** 1996 Nov 7; 335(19):1460–61; discussion 1461-2. Comment on: N Engl J Med 1996 Jun 13;334(24):1561–7.

FDA launches "new use initiative" [news] **Nat Biotechnol** 1997 May;15(5):399

Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. Freije JM, et al. **Nat Med** 1997 Apr;3(4):395–401

Potent antitumour activity of a new class of tumour-specific killer cells. Chen SY, et al. **Nature** 1997 Jan 2; 385(6611):78–80

p53 and treatment of bladder cancer [letter; comment] Cote RJ, et al. **Nature** 1997 Jan 9;385(6612):123–5. Comment on: Nature 1996 Jun 20;381(6584):713–6.

DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma. Rudolf Z, et al. **Neoplasma** 1996;43(2):93-7

Crescentic glomerulonephritis associated with p-ANCA positivity in fludarabine-treated chronic lymphocytic leukaemia. Tisler A, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2306-8

Effects of interferon and PKC modulators on human glioma protein kinase C, cell proliferation, and cell cycle. Acevedo-Duncan M, et al. **Neurochem Res** 1997 Jul; 22(7):775-84

Phase II study of DTIC, ACNU, and vincristine combination chemotherapy for supratentorial malignant astrocytomas. Ikeda J, et al. **Neurol Med Chir (Tokyo)** 1996 Aug; 36(8):555-8; discussion 558-9

Intraoperative radiation therapy and chemotherapy for huge choroid plexus carcinoma in an infant--case report. Kumabe T, et al. **Neurol Med Chir (Tokyo)** 1996 Mar; 36(3):179-84

Chemotherapy of cerebral metastases from solid tumors. Lesser GJ. **Neurosurg Clin N Am** 1996 Jul;7(3):527-36 (73 ref.)

Evaluation of semiquantitative reverse transcriptase-polymerase chain reaction assay of PML/retinoic acid receptor alpha mRNA and in vitro differentiation assay as prognostic prediction in acute promyelocytic leukemia treated with all-trans retinoic acid. Iwakiri R, et al. **Nippon Ika Daigaku Zasshi** 1996 Aug; 63(4):259-67

Metabolic and transcriptional changes in osteosarcoma cells treated with chemotherapeutic drugs. Haberkorn U, et al. **Nucl Med Biol** 1994 Aug;21(6):835-45

Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea. Gensler HL, et al. **Nutr Cancer** 1996;26(3):325-35

Effects of the Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum. Kennedy CW, et al. **Nutr Cancer** 1996; 26(2):209-17

Suppression of aberrant colonic crypt foci by synthetic sphingomyelins with saturated or unsaturated sphingoid base backbones. Schmelz EM, et al. **Nutr Cancer** 1997; 28(1):81-5

Intervention of transplantable human mammary carcinoma MX-1 chemotherapy with dietary menhaden oil in athymic mice: increased therapeutic effects and decreased toxicity of cyclophosphamide. Shao Y, et al. **Nutr Cancer** 1997; 28(1):63-73

Dietary bioflavonoids, chalcones, and related alkenones in prevention and treatment of cancer [editorial] Varma RS. **Nutrition** 1996 Sep;12(9):643-5 (28 ref.)

All-trans retinoic acid for the treatment of acute promyelocytic leukemia in pregnancy. Incerpi MH, et al. **Obstet Gynecol** 1997 May;89(5 Pt 2):826-8

The use of chemotherapeutic agents during pregnancy. Sorosky JI, et al. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):591-9 (27 ref.)

New chemotherapy treatment options and implications for nursing care [published erratum appears in Oncol Nurs Forum 1997 Apr;24(3):442] Berg DT. **Oncol Nurs Forum** 1997 Jan-Feb;24(1 Suppl):5-12 (36 ref.)

Patients receiving chemotherapy at home require special considerations. Ryan KA. **Oncol Nurs Forum** 1996 Sep; 23(8):1336

A comprehensive interdisciplinary chemotherapy teaching documentation flowsheet. Steele S, et al. **Oncol Nurs Forum** 1997 Jun;24(5):907-11

Chemoprevention of cancer: review of the literature. Swan DK, et al. **Oncol Nurs Forum** 1997 May;24(4):719-27 (48 ref.)

Model allows nurses to prioritize patient teaching for chemotherapy. Wintermeyer-Pingle S, et al. **Oncol Nurs Forum** 1997 Apr;24(3):456-7

Combination of anti-cell adhesive synthetic Arg-Gly-Asp-Ser analogue and anticancer drug doxorubicin heightens their original antimetastatic activities. Komazawa H, et al. **Oncol Res** 1995; 7(7-8):341-51

Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Nakanishi O, et al. **Oncol Res** 1997;9(2):61-9

Ovarian cancer patients with high CA-125 but no symptoms--should antiangiogenic treatments be considered? Sharma A, et al. **Oncol Res** 1997;9(2):53-4 (13 ref.)

A phase II study of carboplatin in nasopharyngeal carcinoma. Chi KH, et al. **Oncology** 1997 May-Jun;54(3):203-7

Carboplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Yamashita F, et al. **Oncology** 1997 Jan-Feb; 54(1):28-33

Clinical trial to evaluate antitumor activity of epidermal growth factor in breast cancer [news] **Oncology (Huntingt)** 1996 May;10(5):709

Topotecan demonstrates significant activity in small-cell lung cancer [news] **Oncology (Huntingt)** 1996 Mar;10(3):422-3

Topotecan demonstrates significant activity in recurrent small-cell lung cancer [news] **Oncology (Huntingt)** 1996 Jan;10(1):111

Antiangiogenesis strategies proving valuable against breast and prostate cancer [news] **Oncology (Huntingt)** 1997 Sep; 11(9):1358

Clinical trials at the medicine branch of the NCI-part 2. Cheson BD, et al. **Oncology (Huntingt)** 1995 Jun;9(6):506, 509-10

Clinical trials referral resource. Clinical trials with pyrazoloacridine. Murgo AJ, et al. **Oncology (Huntingt)** 1997 Jul;11(7):991-4

Clinical trials referral resource. Clinical trials using bryostatin-1. Pluda JM, et al. **Oncology (Huntingt)** 1996 May;10(5):740-2

Use of transcription factors as agents and targets for drug development. Smith LM, et al. **Oncology (Huntingt)** 1996 Oct;10(10):1532-8; discussion 1541-2 (47 ref.)

Treatment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy. Greenwald MJ, et al. **Ophthalmology** 1996 Dec;103(12):1989-97

Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness. Kim RY, et al. **Ophthalmology** 1996 Dec;103(12):2029-36

Treatment of massive or life-threatening hemangiomas with recombinant alpha(2a)-interferon. Bauman NM, et al. **Otolaryngol Head Neck Surg** 1997 Jul;117(1):99-110

Inhibitory effect of sarcophytol A on pancreatic carcinogenesis after initiation by N-nitrosobis(2-oxypropyl)amine in Syrian hamsters. Yokomatsu H, et al. **Pancreas** 1996 Aug;13(2):154-9

Treatment of childhood cutaneous T-cell lymphoma with alpha-interferon plus PUVA. Tay YK, et al. **Pediatr Dermatol** 1996 Nov-Dec;13(6):496-500

Cutaneous infiltration by leukemic cells in acute promyelocytic leukemia of a child after treatment with all-trans retinoic acid. Kishimoto S, et al. **Pediatr Hematol Oncol** 1997 Mar-Apr;14(2):169-75

Contemporary chemotherapy issues for children with brainstem gliomas. Allen JC, et al. **Pediatr Neurosurg** 1996; 24(2):98-102

Errors evolution and analysis in antineoplastic drug preparation during one year. Escoms MC, et al. **Pharm World Sci** 1996 Oct;18(5):178-81

The DNA methylation machinery as a target for anticancer therapy. Szyf M. **Pharmacol Ther** 1996;70(1):1-37 (321 ref.)

The interaction of maintenance interferon with cytolytic cells in patients with multiple myeloma who responded to cytotoxic chemotherapy [published erratum appears in Pharmacotherapy 1997 May-Jun;17(3):634] Hall PD, et al. **Pharmacotherapy** 1997 Mar-Apr;17(2):248-55

Effect of platinum(II) choline complex on murine leukemias L1210 and P388. Ochocki J, et al. **Pharmazie** 1997 Jul; 52(7):567-9

Phthalocyanine photodynamic therapy: disparate effects of pharmacologic inhibitors on cutaneous photosensitivity and on tumor regression. Anderson C, et al. **Photochem Photobiol** 1997 May;65(5):895-901

Captopril augments antitumor activity of cyclophosphamide in mice. Kowalski J, et al. **Pol J Pharmacol** 1996 May-Jun; 48(3):281-5

Chemotherapy for advanced lung cancer. When to expect a response. Midthun DE, et al. **Postgrad Med** 1997 Mar; 101(3):187-8, 191-2, 194 passim (20 ref.)

Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone. Leese G, et al. **Postgrad Med J** 1997 Aug;73(862):507-8

Interferon-alpha in childhood haematological malignancies. Simkó R, et al. **Postgrad Med J** 1996 Dec;72(854):709-13 (58 ref.)

Prevention of cancer metastasis in mice with fibronectin-related substances. Azuma I, et al. **Princess Takamatsu Symp** 1994;24:125-41 (70 ref.)

Perspectives and progress in development of breast cancer chemopreventive drugs. Kelloff GJ, et al. **Prog Clin Biol Res** 1997;396:159-83 (159 ref.)

Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Jungwirth A, et al. **Prostate** 1997 Aug 1;32(3):164-72

Bone marrow transplantation vs. high-dose cytorabine-based consolidation chemotherapy for acute myelogenous leukemia. A long-term follow-up study of quality-of-life measures of survivors. Wellisch DK, et al. **Psychosomatics** 1996 Mar-Apr;37(2):144-54

Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma. Mastrangelo S, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):69-71

Factors influencing outcome following radio-chemotherapy for oesophageal cancer [letter; comment] Coia LR. **Radiother Oncol** 1997 Jan;42(1):91-2. Comment on: Radiother Oncol 1996 Jul;40(1):31-43.

Medical therapy of solid tumors in the elderly: an update. Balducci L. **Rays** 1997 Jan-Mar;22(1 Suppl):20-3

Role of IL12 as an anti-tumour agent: current status and future directions. Brunda MJ. **Res Immunol** 1995 Sep-Oct; 146(7-8):622-28 (29 ref.)

A sequence of cellular and molecular events involved in IL12-induced tumour regression. Fujiwara H, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):638-44 (25 ref.)

Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. Zitvogel L, et al. **Res Immunol** 1995 Sep-Oct;146(7-8):628-38 (29 ref.)

Histamine in cancer immunotherapy. Hellstrand K, et al. **Scand J Clin Lab Invest** 1997 May;57(3):193-202 (55 ref.)

Fungemia in cancer patients undergoing chemotherapy versus surgery: risk factors, etiology and outcome. Kralovicova K, et al. **Scand J Infect Dis** 1997;29(3):301-4

Designing therapies that target tumor blood vessels [news; comment] Barinaga M. **Science** 1997 Jan 24;275(5299):482-4 . Comment on: Science 1997 Jan 24;275(5299):547-50.

From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Fruchtman SM, et al. **Semin Hematol** 1997 Jan;34(1):17-23 (21 ref.)

Cladribine for the treatment of indolent non-Hodgkin's lymphomas. Hoffman MA. **Semin Hematol** 1996 Jan;33(1 Suppl 1):40-4 (23 ref.)

Cladribine in the treatment of low-grade non-Hodgkin's lymphoma. Piro LD. **Semin Hematol** 1996 Jan;33(1 Suppl 1):34-9 (37 ref.)

The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia. Saven A. **Semin Hematol** 1996 Jan;33(1 Suppl 1):28-33 (31 ref.)

Interferon alfa: effects of long-term treatment for polycythemia vera. Silver RT. **Semin Hematol** 1997 Jan; 34(1):40-50

Current results and prospective trials of cladribine in chronic lymphocytic leukemia. Tallman MS, et al. **Semin Hematol** 1996 Jan;33(1 Suppl 1):23-7 (27 ref.)

Management of polycythemia vera with hydroxyurea. Tatarsky I, et al. **Semin Hematol** 1997 Jan;34(1):24-8

Early studies of etoposide phosphate, a water-soluble prodrug. Budman DR. **Semin Oncol** 1996 Dec;23(6 Suppl 13):8-14 (40 ref.)

New options for the treatment of advanced ovarian cancer. Dunton CJ. **Semin Oncol** 1997 Feb;24(1 Suppl 5):S5-2-S5-11 (65 ref.)

Management strategies for recurrent non-small cell lung cancer. Fossella FV, et al. **Semin Oncol** 1997 Aug; 24(4):455-62 (54 ref.)

Current management of advanced breast cancer. Hortobagyi GN, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):1-5 (21 ref.)

Adjuvant application of interferons. el Kassas H, et al. **Semin Oncol** 1996 Dec;23(6):737-43 (35 ref.)

Gemcitabine in cisplatin-resistant ovarian cancer. Lund B, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 10):72-6 (20 ref.)

Systemic chemotherapy for the treatment of metastatic melanoma. Mc Clay EF, et al. **Semin Oncol** 1996 Dec; 23(6):744-53 (91 ref.)

Topotecan: an important new drug in the management of ovarian cancer. Markman M. **Semin Oncol** 1997 Feb;24(1 Suppl 5):S5-1

Overview of current and future chemotherapeutic agents in non-small cell lung cancer. Natale RB. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7-29-S7-37 (59 ref.)

Innovative approaches to the treatment of advanced breast cancer: introduction. Norton L, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 10):S10-1-S10-2

Evolving concepts in the systemic drug therapy of breast cancer. Norton L. **Semin Oncol** 1997 Aug;24(4 Suppl 10):S10-3-S10-10 (18 ref.)

Management of hormone-resistant prostate cancer: an Australian trial. Raghavan D, et al. **Semin Oncol** 1996 Dec; 23(6 Suppl 14):20-3

New therapeutic agents for hormone-refractory prostate cancer. Roth BJ. **Semin Oncol** 1996 Dec;23(6 Suppl 14):49-55 (56 ref.)

Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor? Saltz L, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 5):S5-26-S5-30 (24 ref.)

New treatments for breast cancer. Smith G, et al. **Semin Oncol** 1996 Aug;23(4):506-28 (161 ref.)

Patient benefits from new treatment options and schedules for breast cancer. Smith IE. **Semin Oncol** 1997 Aug;24(4 Suppl 10):S10-22-S10-26 (15 ref.)

Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. ten Bokkel Huinink W, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 5):S5-19-S5-25 (25 ref.)

The role of paclitaxel in the management of patients with carcinoma of the cervix. Thigpen T, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-41-S2-46 (46 ref.)

New sources and new antitumor drugs in development. Weiss RB. **Semin Oncol** 1997 Apr;24(2):153-5

Treatment of superficial bladder cancer with intravesical chemotherapy. Badalament RA, et al. **Semin Surg Oncol** 1997 Sep-Oct;13(5):335-41 (32 ref.)

Systemic chemotherapy of transitional cell carcinoma of the urothelium. Brinkley WM, et al. **Semin Surg Oncol** 1997 Sep-Oct;13(5):365-75 (112 ref.)

The role of chemotherapy in the treatment of non-small cell carcinoma of the lung. Treat J, et al. **Semin Thorac Cardiovasc Surg** 1997 Jan;9(1):90-100 (43 ref.)

Diagnosis and treatment of superficial bladder cancer: an update. Crawford ED. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):1-9 (70 ref.)

Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Franklin JR, et al. **Semin Urol Oncol** 1996 Nov;14(4):230-6

Intravesical chemotherapy versus immunotherapy for superficial bladder cancer. Huben RP. **Semin Urol Oncol** 1996 Feb;14(1 Suppl 1):17-22 (26 ref.)

Novel therapies for advanced prostate cancer. Konety BR, et al. **Semin Urol Oncol** 1997 Feb;15(1):33-42 (80 ref.)

Bayesian interim analysis of phase II cancer clinical trials. Heitjan DF. **Stat Med** 1997 Aug 30;16(16):1791-802

Interleukin 1 trials in cancer patients: a review of the toxicity,

antitumor and hematopoietic effects. Veltri S, et al. **Stem Cells** 1996 Mar;14(2):164–76 (58 ref.)

Treatment of recurrent stage IV neuroblastomas with 131I–MIBG and HBO Six years follow–up. van der Kleij AJ, et al. **Strahlenther Onkol** 1996 Nov;172 Suppl 2:28–9

Relief of jaundice by 5–fluorouracil and folinic acid in patients with recurrent gastric cancer. Kajiyama Y, et al. **Surg Oncol** 1996 Aug;5(4):177–81

Monocyte function associated with intermittent lentinan therapy after resection of gastric cancer. Takeshita K, et al. **Surg Oncol** 1996 Feb;5(1):23–8

Theoretic and experimental aspects of regional liver infusion. August DA. **Surg Oncol Clin N Am** 1996 Apr;5(2):399–409 (36 ref.)

Clinical and preclinical trials of isolated liver perfusion for advanced liver tumors: primary liver tumors. Lowy AM, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):429–41 (18 ref.)

Regional chemotherapy approaches for primary and metastatic liver tumors. Venook AP, et al. **Surg Oncol Clin N Am** 1996 Apr;5(2):411–427 (96 ref.)

Long–term follow–up of hemostatic molecular markers during remission induction therapy with all–trans retinoic acid for acute promyelocytic leukemia. Keio Hematology–Oncology Cooperative Study Group (KHOCS). Watanabe R, et al. **Thromb Haemost** 1997 Apr; 77(4):641–5

Conversion of non–iodine–concentrating differentiated thyroid carcinoma metastases into iodine–concentrating foci after anticancer chemotherapy. Morris JC, et al. **Thyroid** 1997 Feb;7(1):63–6

Enhancing the effect of anticancer drugs against the colorectal cancer cell line with electroporation. Kambe M, et al. **Tohoku J Exp Med** 1996 Oct;180(2):161–71

Comparison of carboplatin/etoposide/vincristine with cisplatin/etoposide as combination chemotherapy for small cell lung cancer. Kumagai M, et al. **Tokai J Exp Clin Med** 1995 Dec;20(4–6):209–14

Doxifluridine: previous experience and new developments in the treatment of colorectal cancer. Bajetta E, et al. **Tumori** 1997 Jan–Feb;83(1 Suppl):S87–9

Update on adjuvant therapy of colon cancer. Macdonald JS, et al. **Tumori** 1997 Jan–Feb;83(1 Suppl):S39–41 (17 ref.)

Radioimmunodetection and radioimmunotherapy of breast cancer. Riva P, et al. **Tumori** 1997 Mar–Apr;83(2):552–7

Phase II study of pentosan polysulfate (PPS) in patients with AIDS–related Kaposi's sarcoma. Schwartsmann G, et al. **Tumori** 1996 Jul–Aug;82(4):360–3

Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane. Martinetti A, et al. **Tumour Biol** 1997;18(4):197–205

Prognostic factors of peripheral blood lymphocyte subsets in patients with renal cell carcinoma. Arima K, et al. **Urol Int** 1996;57(1):5–10

Cyclic interferon alpha treatment in metastatic renal cell carcinoma: results of a phase II study and review of the literature. Hofmockel G, et al. **Urol Int** 1997;58(1):8–12 (34 ref.)

Modulation of platelet–activating factor synthesis by recombinant interferon–alpha in human renal cell carcinoma. Imagawa M, et al. **Urol Int** 1996;57(1):11–6

Bacillus Calmette–Guérin plus intravesical interferon alpha–2b in patients with superficial bladder cancer. Stricker P, et al. **Urology** 1996 Dec;48(6):957–61; discussion 961–2

Canine osteosarcoma: amputation and chemotherapy. Berg J. **Vet Clin North Am Small Anim Pract** 1996 Jan; 26(1):111–21 (29 ref.)

Intravesical suramin: a novel agent for the treatment of superficial transitional–cell carcinoma of the bladder. Walther MM, et al. **World J Urol** 1996;14 Suppl 1:S8–11 (31 ref.)

[The treatment of prostatic carcinoma with cyproterone acetate] Tsvetkov M, et al. **Khirurgiia (Sofiia)** 1996; 49(1):12–5 (Eng. Abstr.) **(Bul)**

[Summary of the National Conference on Chemotherapy of Gynecological Malignancies] Lang J, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb;31(2):71–4 **(Chi)**

[A new purine analog in the treatment of hematologic malignancy. I. Fludarabine] Vášová I, et al. **Vnitr Lek** 1997 Jan;43(1):45–50 (41 ref.) (Eng. Abstr.) **(Cze)**

[Campath–1H—a monoclonal antibody for treatment of non–Hodgkin's and chronic lymphatic leukemia] de Nully Brown P, et al. **Ugeskr Laeger** 1997 Jul 7;159(28):4389–93 (Eng. Abstr.) **(Dan)**

[Medical treatment of cancer] Dombernowsky, et al. **Ugeskr Laeger** 1997;159 Suppl 3:1–14 **(Dan)**

[Chronic lymphatic leukemia. Peroral cladribine as primary treatment] Gjedde SB, et al. **Ugeskr Laeger** 1996 Nov 4; 158(45):6432–4 (Eng. Abstr.) **(Dan)**

[Vascularization and perfusion of tumors as target in cancer therapy] Bernsen HJ, et al. **Ned Tijdschr Geneeskd** 1997 Feb 22;141(8):364–8 (25 ref.) (Eng. Abstr.) **(Dut)**

[Iodobenzylguanide–131 therapy as first choice in non–metastasized neuroblastoma] De Kraker J, et al. **Ned Tijdschr Geneeskd** 1996 Oct 5;140(40):1997–2000 (Eng. Abstr.) **(Dut)**

[Chemotherapy in animals: ethical or unethical? (letter)] Rutteman GR, et al. **Tijdschr Diergeneeskd** 1997 Feb 1; 122(3):77–9 **(Dut)**

[Chemotherapeutics] van Turnhout J. **Tijdschr Diergeneeskd** 1997 Mar 15;122(6):177 **(Dut)**

[Euthanasia or therapy? (letter)] Wijsmuller JM. **Tijdschr Diergeneeskd** 1997 Mar 15;122(6):171 **(Dut)**

[Chemotherapy of advanced colorectal cancers] Louvet C. **Ann Chir** 1997;51(4):361–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of macroprolactinomas with quinagolide (Norprolac)] Tabarin A, et al. **Ann Endocrinol (Paris)** 1997; 58(2):87–94 (30 ref.) (Eng. Abstr.) **(Fre)**

[Treatment with hydroxyurea of polycythemia vera in a 11 year–old child] Vodoff MV, et al. **Arch Pediatr** 1996 Sep; 3(9):870–3 (Eng. Abstr.) **(Fre)**

[Top–Forum: an interactive multimedia knowledge database to improve quality of care in pediatric oncology] Bernard J, et al. **Bull Cancer** 1996 Nov;83(11):901–9 (Eng. Abstr.) **(Fre)**

[Melanoma: a new interferon is coming ... handle with care!] Négrier S. **Bull Cancer** 1997 Apr;84(4):435–7 (22 ref.) **(Fre)**

[Oxaliplatin: the first DACH platinum in clinical practice] Soulié P, et al. **Bull Cancer** 1997 Jun;84(6):665–73 (Eng. Abstr.) **(Fre)**

[Concomitant radiotherapy and chemotherapy in the treatment of cancers of the upper respiratory and digestive tracts] Calais G, et al. **Bull Cancer Radiother** 1996; 83(4):321–9 **(Fre)**

[Theoretical justification of combined radio–chemotherapy in cancer of the cervix] Hennequin C, et al. **Bull Cancer Radiother** 1996;83(4):370–6 **(Fre)**

[Inoperable cancers of the cervix: therapeutic perspectives] Resbeut M. **Bull Cancer Radiother** 1996;83(4):385–7 (16 ref.) **(Fre)**

[Radiotherapy–chemotherapy combinations in locally advanced cancers of the cervix] Vincent P, et al. **Bull Cancer Radiother** 1996;83(4):377–84 **(Fre)**

[Inhibitors of farnesyl transferase in oncology: from basic research to pharmaceutical research] Lavelle F. **C R Seances Soc Biol Fil** 1997;191(2):211–9 (18 ref.) (Eng. Abstr.) **(Fre)**

[A combined radiochemotherapy trial for non–small cell lung cancers: initial results] Livartowski A, et al. **Cancer Radiother** 1997;1(2):170–3 (Eng. Abstr.) **(Fre)**

[Partial regression of a desmoid tumor after prolonged treatment with lanreotide (letter)] Mannant PR, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):1072–3 **(Fre)**

[Efficacy of interferon alpha in primary prevention of preneoplastic lesions in a transgenic murine model of hepatocellular carcinoma related to the interaction between woodchuck hepatitis viruses and c–myc oncogene] Merle P, et al. **Gastroenterol Clin Biol** 1997;21(6–7):459–65 (Eng. Abstr.) **(Fre)**

[Is there a place for arterial chemoembolization of the liver in the treatment for hepatocellular carcinoma? (editorial)] Trinchet JC, et al. **Gastroenterol Clin Biol** 1995 Dec; 19(12):967–9 (24 ref.) **(Fre)**

[Interperitoneal alpha–2b interferon for advanced ovarian cancer in complete remission or minimal residual disease (letter)] Cherchi PL, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(1):101–2 **(Fre)**

[Treatment of malignant adrenal cortex carcinoma] Andrès E, et al. **Presse Med** 1997 May 31;26(18):880–4 (47 ref.) (Eng. Abstr.) **(Fre)**

[Clinical value of interferon–alpha in the treatment of malignant hematologic diseases (editorial)] Harousseau JL. **Presse Med** 1997 May 31;26(18):857–9 (Eng. Abstr.) **(Fre)**

[Chemotherapy of non–small–cell lung cancers] Le Chevalier T. **Presse Med** 1996 Nov 16;25(35):1699–703 (16 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic intensification and autotransplantation of hematopoietic stem cells in metastatic breast cancers] Lotz JP, et al. **Presse Med** 1996 Nov 16;25(35):1737–43 (35 ref.) (Eng. Abstr.) **(Fre)**

[New wave of chemotherapeutic agents: update in pulmonary oncology] Sculier JP. **Rev Mal Respir** 1997 Apr;14(2):154–6 (24 ref.) **(Fre)**

[Up–to–date treatment of breast cancer. Myeloblastic chemotherapy and hematopoietic cell grafting] Jerusalem G. **Rev Med Liege** 1997 Feb;52(2):76–9 **(Fre)**

[Selective oral aromatase suppression and thymidilate synthase inhibition] **Chirurg** 1997 Feb;68(2 Suppl):1–16 **(Ger)**

[Topotecan—a new principle of effectiveness in oncology. 4th Salzburg Symposium on Quality of Life. 15–17 December 1995] **Geburtshilfe Frauenheilkd** 1996 Jun;56(6 Suppl):1–6 **(Ger)**

[Pro and contra adjuvant chemotherapy in colorectal carcinoma (letter; comment)] Mezger J, et al. **Med Klin** 1996 Sep 15;91(9):609–11. Comment on: Med Klin 1996 Apr 10;91(4):243–4; discussion 245–6. **(Ger)**

[Adjuvant systemic therapy of breast carcinoma] Wickramanayake PD, et al. **Med Klin** 1996 Oct 15; 91(10):646–53 (92 ref.) **(Ger)**

[New virostatic drugs, psychopharmaceuticals and cytostatic drugs (editorial)] **Med Monatsschr Pharm** 1996 Sep; 19(9):251 **(Ger)**

[Topoisomerase I inhibitors] Bornkessel B. **Med Monatsschr Pharm** 1997 May;20(5):114–6 **(Ger)**

[Cancer treatment—is there progress? (editorial)] Heinzl S. **Med Monatsschr Pharm** 1996 Mar;19(3):65 **(Ger)**

[Pleurodesis in malignant pleural effusion: bleomycin vs. mitoxantrone] Schmidt M, et al. **Pneumologie** 1997 Apr; 51(4):367–72 (Eng. Abstr.) **(Ger)**

[Oral All–transretinoic acid administration in intubated patients with acute promyelocytic leukemia] Bargetzi MJ, et al. **Schweiz Med Wochenschr** 1996 Nov 9;126(45):1944–5 (Eng. Abstr.) **(Ger)**

[Neytumorin as biomodular onco–therapy—allegations without documentation] Allewelt MC, et al. **Schweiz Rundsch Med Prax** 1997 Apr 30;86(18):750–61 (110 ref.) (Eng. Abstr.) **(Ger)**

[The value of adjuvant and neoadjuvant chemotherapy in treatment of stomach carcinoma] Ausch C, et al. **Wien Klin Wochenschr** 1996;108(16):496–504 (50 ref.) (Eng. Abstr.) **(Ger)**

[Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities] du Bois A, et al. **Zentralbl Gynakol** 1997;119(7):299–323 (330 ref.) (Eng. Abstr.) **(Ger)**

[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer] Edelman DZ, et al. **Harefuah** 1996 Jul;131(1–2):31–6 (48 ref.) **(Heb)**

[Photodynamic therapy of gastrointestinal malignant tumors] Haddad R, et al. **Harefuah** 1996 Jun 2;130(11):765–9 (43 ref.) **(Heb)**

[High–dose carboplatin superselective intraarterial chemotherapy in advanced head and neck cancer] Benazzo M, et al. **Acta Otorhinolaryngol Ital** 1996 Feb;16(1):30–4 (Eng. Abstr.) **(Ita)**

[Lipiodol with and without Gelfoam in primary liver tumors. Plasma levels of Mitoxantrone and clinical results] Civalleri D, et al. **G Chir** 1997 Jun–Jul;18(6–7):362–7 (36 ref.) (Eng. Abstr.) **(Ita)**

[A prospective study on nephrotoxicity induced by continuous infusion of high–dose ifosfamide (15/m2)] Ferrari S, et al. **Minerva Pediatr** 1997 Jan–Feb; 49(1–2):29–37 (Eng. Abstr.) **(Ita)**

[Mobilization of peripheral blood stem cells with conventional chemotherapy] Venturini M, et al. **Tumori** 1996 Mar–Apr;82(2 Suppl):S14–8 (25 ref.) (Eng. Abstr.) **(Ita)**

[(–)–Epigallocatechin gallate, the main constituent of Japanese green tea, inhibits tumor promotion of okadaic acid] Yoshizawa S. **Fukuoka Igaku Zasshi** 1996 Oct; 87(10):215–21 (Eng. Abstr.) **(Jpn)**

[Bropirimine (U–54461S) late phase II clinical study for carcinoma in situ of the bladder. Japan Bropirimine Study Group] Akaza H, et al. **Gan To Kagaku Ryoho** 1997 Jan; 24(1):77–85 (Eng. Abstr.) **(Jpn)**

[Bropirimine (U–54461S) early phase II clinical studies—to investigate the efficacy and safety of bropirimine treatment on various malignant tumors (urological, hematologic, and dermal cancers)] Furue H, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):67–75 (Eng. Abstr.) **(Jpn)**

[Phase I study on DMDC] Gemma A, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1799–811 (Eng. Abstr.) **(Jpn)**

[Clinical use of platinum compounds and fluorinated pyrimidines for lung cancer] Kobayashi K. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1747–56 (51 ref.) (Eng. Abstr.) **(Jpn)**

[Cancer chemotherapy and apoptosis] Mashima T, et al. **Nippon Rinsho** 1996 Jul;54(7):1935–42 (20 ref.) (Eng. Abstr.) **(Jpn)**

[A case of myelofibrosis that developed polycythemia vera following treatment with ranimustine and then acute myelogenous leukemia (M0)] Harashima S, et al. **Rinsho Ketsueki** 1996 Aug;37(8):713–8 (Eng. Abstr.) **(Jpn)**

[All–trans retinoic acid therapy in acute promyelocytic leukemia—current status and prospect] Kitamura K, et al. **Rinsho Ketsueki** 1996 Sep;37(9):760–5 (15 ref.) **(Jpn)**

[Mobilization and collection of peripheral blood stem cells] Shimazaki C, et al. **Rinsho Ketsueki** 1996 Jul;37(7):574–8 (10 ref.) **(Jpn)**

[Attitudes to treatment with cytostatic agents. Do cancer patients, physicians, nurses and healthy individuals vary in their views?] Bremnes RM, et al. **Tidsskr Nor Laegeforen** 1996 Sep 10;116(21):2583–7 (Eng. Abstr.) **(Nor)**

[Progress in the treatment of children with Wilms' tumor in the Department of Pediatric Oncology at the Institute of Mother and Child] Perek D, et al. **Pediatr Pol** 1996 Aug;71(8):659–65 (Eng. Abstr.) **(Pol)**

[Progress in the treatment of 155 children with rhabdomyosarcoma obtained in one center between 1962–1990] Perek D, et al. **Pediatr Pol** 1996 Aug; 71(8):667–72 (Eng. Abstr.) **(Pol)**

[Preliminary results of interferon alpha treatment for patients with chronic myelogenous leukemia] Popławska–Szczygłowska L, et al. **Pol Tyg Lek** 1996 May; 51(19–22):283–4 **(Pol)**

[Clinical pharmacology of 2–chlorodeoxyadenosine (Cladribine)] Góra–Tybor J, et al. **Przegl Lek** 1996; 53(8):614–8 (38 ref.) (Eng. Abstr.) **(Pol)**

[Clinical significance of multidrug resistance in acute leukemias] Maia RC, et al. **Rev Assoc Med Bras** 1996 Apr–Jun;42(2):101–8 (Eng. Abstr.) **(Por)**

[Chemotherapy of malignant tumors] Bychkov MB. **Arkh Patol** 1996 Jul–Aug;58(4):15–7 (Eng. Abstr.) **(Rus)**

[Therapeutic pathomorphism of Ewing's tumor] Makretsov NA, et al. **Arkh Patol** 1997 Jul–Aug;59(4):28–31 (Eng. Abstr.) **(Rus)**

[In vivo 31P–NMR spectroscopic study of changes in phosphate metabolism in Ehrlich carcinoma after treatment

with hydralazine and hyperthermia] Semenova NA, et al. **Dokl Akad Nauk** 1996 Nov;351(3):410–2 **(Rus)**

[Alpha–interferon in present–day treatment of myeloma] Demina EA, et al. **Gematol Transfuziol** 1996 Mar–Apr; 41(2):32–6 (70 ref.) **(Rus)**

[Treatment of acute promyelocytic leukemia in children with all–trans–retinoic acid] Maschan AA, et al. **Gematol Transfuziol** 1996 Mar–Apr;41(2):43–5 **(Rus)**

[The use of interferon–alfa (reaferon) in patients with chronic myeloleukemia] Machiulaĭtene ER, et al. **Ter Arkh** 1996; 68(10):44–7 (Eng. Abstr.) **(Rus)**

[Cycloplatam in the treatment of patients with disseminated prostatic cancer] Matveev BP, et al. **Urol Nefrol (Mosk)** 1996 May–Jun;(3):34–6 (Eng. Abstr.) **(Rus)**

[The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer] Sivko AV, et al. **Urol Nefrol (Mosk)** 1997 May–Jun;(3):49–52 (83 ref.) **(Rus)**

[Experience with the use of immunochemotherapy in stage–IV colorectal cancer] Grinev MV, et al. **Vestn Khir Im I I Grek** 1997;156(3):68–72 **(Rus)**

[Use of cytostatics in multimodal treatment of glaucoma] Potapova EA. **Vestn Oftalmol** 1996 Sep–Oct;112(5):38–40 (65 ref.) **(Rus)**

[Assessment of the formation of antibodies to interferon in patients with juvenile respiratory papillomatosis on interferon therapy] Kol'tsov VD, et al. **Vestn Otorinolaringol** 1996 Jul–Aug;(4):25–7 (Eng. Abstr.) **(Rus)**

[Use of immunomocorrection in the combined treatment of laryngeal papillomatosis in children] Savenko IV, et al. **Vestn Otorinolaringol** 1996 Jul–Aug;(4):12–4 (Eng. Abstr.) **(Rus)**

[Skeletal bone lesion and the effectiveness of Bonephos (clodronate) in the comprehensive therapy of multiple myeloma] Bessmel'tsev SS, et al. **Vopr Onkol** 1996; 42(4):12–8 (51 ref.) **(Rus)**

[Modulation of the antitumor effect of cyclophosphamide by the recombinant probiotic Subalin] Cherdyntseva NV, et al. **Vopr Onkol** 1997;43(3):313–6 (Eng. Abstr.) **(Rus)**

[Clinical experience with the use of Tantum Rosa in cancer patients] Chulkova OV, et al. **Vopr Onkol** 1997; 43(3):339–40 **(Rus)**

[A system of individual immunotherapy with leakadin in the combined therapy of acoustic neurinomas] Starchenko AA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct–Dec; (4):15–8 (Eng. Abstr.) **(Rus)**

[Changes in the nuclear morphometry in oropharyngeal epidermoid carcinoma after induction chemotherapy] Santa Cruz Ruiz S, et al. **Acta Otorrinolaringol Esp** 1997 Mar; 48(2):93–7 (Eng. Abstr.) **(Spa)**

[Perspectives of the use of informational drugs in cancer] Gutiérrez AA, et al. **Gac Med Mex** 1995 Jul–Aug; 131(4):481–4 **(Spa)**

[Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse] Briones J, et al. **Med Clin (Barc)** 1996 Jun 15;107(3):86–9 (Eng. Abstr.) **(Spa)**

[Fluctuating molecular remission in patients with chronic myeloid leukemia with long term complete cytogenetic response after alpha interferon treatment] Casado LF, et al. **Med Clin (Barc)** 1997 Sep 6;109(7):251–5 (Eng. Abstr.) **(Spa)**

[Lanreotide++: a new therapeutic option in acromegaly] Díez JJ. **Med Clin (Barc)** 1996 Sep 7;107(7):257–69 (200 ref.) **(Spa)**

[Clinical remission and reduction of malignant pheochromocytoma treated with iodine–131–meta–iodobenzylguanidine (letter)] Piñero A, et al. **Med Clin (Barc)** 1996 Nov 30;107(19):755–6 **(Spa)**

[Treatment of multiple myeloma with interferon] Bruno S. **Medicina (B Aires)** 1996;56 Suppl 1:92–4 **(Spa)**

[Acute promyelocytic leukemia: experience with trans–retinoic acid in Argentina] Nucifora E, et al. **Medicina (B Aires)** 1996;56(4):333–8 (Eng. Abstr.) **(Spa)**

[Primary cerebral tumors: the reality and the molecular basis of future treatment] Rosenfeld MR, et al. **Neurologia** 1997 May;12(5):185–96 (115 ref.) **(Spa)**

[Combined treatment in recurrent laryngeal papillomatosis with CO_2 laser microlaryngoscopic resection and interferon alpha 2b] Montero Mora P, et al. **Rev Alerg Mex** 1996 Sep–Oct;43(5):133–6 (Eng. Abstr.) **(Spa)**

[Busulfan versus busulfan–interferon as maintenance therapy in chronic myeloid leukemia] López Hernández MA, et al. **Rev Invest Clin** 1996 Jul–Aug;48(4):281–7 (Eng. Abstr.) **(Spa)**

[Effects, possibilities and limits. Cytostatic therapy of small cell and non–small cell lung cancer] Bergman B. **Lakartidningen** 1997 Apr 30;94(18):1702, 1707–10 (17 ref.) **(Swe)**

[Neoadjuvant (preoperative) chemotherapy in cancer of the breast] Shparik IaV. **Klin Khir** 1996;(8):38–42 (38 ref.) **(Ukr)**

[The efficacy of using prolonged–action L–asparaginase in a treatment program for acute lymphoblastic leukemia in adults] Tretiak NM, et al. **Lik Sprava** 1997 Jan–Feb;(1):81–3 **(Ukr)**

TOXICITY

Chronic cisplatin nephropathy, contrast media, and creatinine. Thomsen HS, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S444–6

Protection of both auditory hair cells and auditory neurons from cisplatin induced damage. Gabaizadeh R, et al. **Acta Otolaryngol (Stockh)** 1997 Mar;117(2):232–8

Similar pharmacokinetics and differential ototoxicity after administration with cisplatin and transplatin in guinea pigs. Saito T, et al. **Acta Otolaryngol (Stockh)** 1997 Jan; 117(1):61–5

Cisplatin metabolites and their toxicity on isolated cochlear outer hair cells in vitro. Saito T, et al. **Acta Otolaryngol (Stockh)** 1996 Jul;116(4):561–5

Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents. Sreerama L, et al. **Adv Exp Med Biol** 1997;414:81–94

Hematologic and systemic toxicoses associated with carboplatin administration in cats. Hahn KA, et al. **Am J Vet Res** 1997 Jun;58(6):677–9

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Henry SP, et al. **Anticancer Drug Des** 1997 Jul;12(5):395–408 (37 ref.)

In vitro cytotoxicity and DNA damage production in Chinese hamster ovary cells and topoisomerase II inhibition by 2–[2'–(dimethylamino)ethyl]–1, 2–dihydro–3H–dibenz[de,h]isoquinoline–1,3–diones with substitutions at the 6 and 7 positions (azonafides). Mayr CA, et al. **Anticancer Drugs** 1997 Mar;8(3):245–56

A quantitative morphometric study of the kinetics of tissue regeneration after administration of cisplatin. Sela J, et al. **Anticancer Drugs** 1996 Jul;7(5):579–85

Cisplatin microcrystals suspended in oil: pathological study of acute toxicity in mice. Tsujimoto H, et al. **Anticancer Drugs** 1996 May;7(3):240–7

State of differentiation affects the response of endometrial adenocarcinoma cells to retinoic acid. Carter CA, et al. **Anticancer Res** 1997 May–Jun;17(3C):1973–83

Suramin is synergistic with vinblastine in human colonic tumor cell lines: effect of cell density and timing of drug delivery. Frommel TO. **Anticancer Res** 1997 May–Jun; 17(3C):2065–71

Cytokinetic and morphologic differences in ovarian cancer cells treated with ET–18–OCH3 and the DNA–interacting agent, etoposide. Fujiwara K, et al. **Anticancer Res** 1997 May–Jun;17(3C):2159–67

Cytotoxicity of copper complexes of 2–furaldehyde oxime derivatives in murine and human tissue cultured cell lines. Hall IH, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2411–8

Transformation of human glioma cell lines with the p16 gene inhibits cell proliferation. Hama S, et al. **Anticancer Res** 1997 May–Jun;17(3C):1933–8

A newly synthesized bifunctional inhibitor, CKA1083, enhances adriamycin activity against human ovarian carcinoma cells. Maeda O, et al. **Anticancer Res** 1997 May–Jun;17(3C):1985–92

In vitro characterisation of soft tissue tumor chemosensitivity. Remmelink M, et al. **Anticancer Res** 1997 May–Jun; 17(3C):2009–17

Effect of copper and iron ions on cytotoxicity induced by ascorbate, gallate and caffeate. Satoh K, et al. **Anticancer Res** 1997 May–Jun;17(3C):2181–4

Cellular targets of the anti–breast cancer agent Z–1,1–dichloro–2,3–diphenylcyclopropane: type II estrogen binding sites and tubulin. ter Haar E, et al. **Anticancer Res** 1997 May–Jun;17(3C):1861–9

Inhibition of erbB–2–positive breast cancer cell growth by erbB–2 antisense oligonucleotides. Liu X, et al. **Antisense Nucleic Acid Drug Dev** 1996 Spring;6(1):9–16

Lack of cardiotoxicity of a new antineoplastic agent, a synthetic derivative of indenoisochinoline: comparison with daunorubicin in rabbits. Geršl V, et al. **Arch Toxicol** 1996; 70(10):645–51

Cisplatin–induced toxicity in immortalized renal cell lines established from transgenic mice harboring temperature sensitive SV40 large T–antigen gene. Hosoyamada M, et al. **Arch Toxicol** 1996;70(5):284–92

Evaluation of cardiac subacute toxicity of epirubicin, chlorambucil, cisplatin, methotrexate and a homo–aza–steroid ester with antitumor activity in rats using serum biochemical parameters. Pispirigos K, et al. **Arzneimittelforschung** 1997 Jan;47(1):92–6

Detection of DNA damage in stimulated human lymphocytes after adding cytostatic drugs in vitro. A model to demonstrate individual damage rates. Reitz M, et al. **Arzneimittelforschung** 1997 Jan;47(1):88–91

Elevated expression of DNA polymerase beta gene in glioma cell lines with acquired resistance to 1–(4–amino–2–methyl–5–pyrimidinyl)methyl–3–(2–chloroethyl)–3– nitrosourea. Gomi A, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):558–63

TNF–alpha mediates inducible nitric oxide synthase expression in human neuroblastoma cell line by cisplatin. Ogura T, et al. **Biochem Biophys Res Commun** 1997 Apr 28;233(3):788–91

Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA–reactive intermediates contributing to cytotoxicity. Hayes MT, et al. **Biochemistry** 1997 Sep 2;36(35):10646–54

Functional interactions between synthetic alkyl phospholipids and the ABC transporters P–glycoprotein, Ste–6, MRP, and Pgh 1. Ruetz S, et al. **Biochemistry** 1997 Jul 1;36(26):8180–8

Acyclothymidine alleviates intestinal toxicity of 5'–deoxy–5–fluorouridine without loss of antitumor activity in mice. Hamada A, et al. **Biol Pharm Bull** 1996 Oct; 19(10):1362–6

Effects of betamipron on cisplatin nephrotoxicity and its pharmacokinetics in rats. Tokunaga J, et al. **Biol Pharm Bull** 1997 Apr;20(4):386–91

Protective effects of N–benzoyl amino acids on cisplatin nephrotoxicity in rats. Tokunaga J, et al. **Biol Pharm Bull** 1996 Nov;19(11):1451–6

Discrepancy between cytotoxicity, platinum accumulation, and DNA platination in MCF–7 breast cancer cells treated with diaqua (1,2–diphenylethylenediamine) platinum (II) sulfates and cisplatin. Lux F, et al. **Biol Trace Elem Res** 1996 Summer;53(1–3):113–28

Use of arsenic trioxide (As_2O_3) in the treatment of acute promyelocytic leukemia (APL): I. As_2O_3 exerts dose–dependent dual effects on APL cells. Chen GQ, et al. **Blood** 1997 May 1;89(9):3345–53

O6–benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Chinnasamy N, et al. **Blood** 1997 Mar 1; 89(5):1566–73

Comparative activity of melarsoprol and arsenic trioxide in chronic B–cell leukemia lines. König A, et al. **Blood** 1997 Jul 15;90(2):562–70

Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all–trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Caliaro MJ, et al. **Br J Cancer** 1997;75(3):333–40

Anti–tumour activities of a new benzo[c]phenanthridine agent, 2,3–(methylenedioxy)–5–methyl–7–hydroxy–8–methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug–resistant human tumour cell lines. Kanzawa F, et al. **Br J Cancer** 1997; 76(5):571–81

Role of reactive oxygen species in cis–dichlorodiammineplatinum–induced cytotoxicity on bladder cancer cells. Miyajima A, et al. **Br J Cancer** 1997; 76(2):206–10

In vivo anti–tumour effect of 3'–sulphonoquinovosyl 1'–monoacylglyceride isolated from sea urchin (Strongylocentrotus intermedius) intestine. Sahara H, et al. **Br J Cancer** 1997;75(3):324–32

Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Screnci D, et al. **Br J Cancer** 1997;76(4):502–10

Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Vukovic V, et al. **Br J Cancer** 1997;75(8):1167–72

Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas. Arndt D, et al. **Breast Cancer Res Treat** 1997 May;43(3):237–46

Establishment and characterisation of new cell lines from human breast tumours initially established as tumour xenografts in NMRI nude mice. Hambly RJ, et al. **Breast Cancer Res Treat** 1997 May;43(3):247–58

Loss of in vitro cytotoxicity of cisplatin after storage as stock solution in cell culture medium at various temperatures. Schuldes H, et al. **Cancer** 1997 May 1;79(9):1723–8

The potential of N–[2–(dimethylamino)ethyl]acridine–4–carboxamide to circumvent three multidrug–resistance phenotypes in vitro. Davey RA, et al. **Cancer Chemother Pharmacol** 1997; 39(5):424–30

Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Olivi A, et al. **Cancer Chemother Pharmacol** 1996; 39(1–2):90–6

Protective role of metallothionein in renal toxicity of cisplatinum. Satoh M, et al. **Cancer Chemother Pharmacol** 1997;40(4):358–62

Cytotoxic effect of beta–carotene in vitro is dependent on serum concentration and source. Peram V, et al. **Cancer Lett** 1996 Aug 23;106(1):133–8

The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Coughlin CM, et al. **Cancer Res** 1997 Jun 15;57(12):2460–7

Transplacental mutagenicity of cisplatin: H–ras codon 12 and 13 mutations in skin tumors of SENCAR mice. Munoz EF, et al. **Carcinogenesis** 1996 Dec;17(12):2741–5

Dose response and time course of carboplatin–induced micronucleated polychromatic erythrocytes in the cat: implications for combination carboplatin chemotherapy. Hahn KA, et al. **Chemotherapy** 1997 Jul–Aug;43(4):282–7

Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia. Frewin RJ, et al. **Clin Lab Haematol** 1997 Jun;19(2):151–2

Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP–TF and their heterodimerization. Wu Q, et al. **EMBO J** 1997 Apr 1;16(7):1656–69

Effect of an antimitotic agent colchicine on thioacetamide hepatotoxicity. Mangipudy RS, et al. **Environ Health Perspect** 1996 Jul;104(7):744–9

Differentiating agents modulate topoisomerase I activity in U–937 promonocytic cells. Shayo CC, et al. **Eur J Pharmacol** 1997 Apr 11;324(1):129–33

ANTINEOPLASTIC AGENTS

The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. Singh L, et al. **Eur J Pharmacol** 1997 Feb 26;321(2):209-16

Apoptosis-resistant phenotype selected by alternating exposure to camptothecin and etoposide. Kubota M, et al. **Exp Cell Res** 1997 Aug 25;235(1):138-44

Induction of apoptosis and potentiation of TNF- and Fas-mediated apoptosis in U937 cells by the xanthogenate compound D609. Pörn-Ares MI, et al. **Exp Cell Res** 1997 Aug 25;235(1):48-54

Targeted delivery of diphtheria toxin via immunoliposomes: efficient antitumor activity in the presence of inactivating anti-diphtheria toxin antibodies. Vingerhoeds MH, et al. **FEBS Lett** 1996 Oct 21;395(2-3):245-50

Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats. Graziano MJ, et al. **Fundam Appl Toxicol** 1996 Jul;32(1):53-65

Subchronic intravenous toxicity of the antineoplastic drug, amsacrine, in male Wistar rats. Pegg DG, et al. **Fundam Appl Toxicol** 1996 Jul;32(1):45-52

D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Campbell KC, et al. **Hear Res** 1996 Dec 1;102(1-2):90-8

Co-administration of the neurotrophic ACTH(4-9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin. de Groot JC, et al. **Hear Res** 1997 Apr; 106(1-2):9-19

Evoked-potential thresholds and cubic distortion product otoacoustic emissions in the chinchilla following carboplatin treatment and noise exposure. Jock BM, et al. **Hear Res** 1996 Jul;96(1-2):179-90

Selective inner hair cell loss does not alter distortion product otoacoustic emissions. Trautwein P, et al. **Hear Res** 1996 Jul;96(1-2):71-82

Toxicity of chemotherapy. Lowenthal RM, et al. **Hematol Oncol Clin North Am** 1996 Aug;10(4):967-90 (156 ref.)

Modulation of cisplatin chronotoxicity related to reduced glutathione in mice. Boughattas NA, et al. **Hum Exp Toxicol** 1996 Jul;15(7):563-72

Comparative preclinical toxicology and pharmacology of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in vitro and in rodents and primates. Morgan LR, et al. **In Vivo** 1997 Jan-Feb;11(1):29-37

Effects of cisplatin on testicular functions in rats. Malarvizhi D, et al. **Indian J Exp Biol** 1996 Oct;34(10):995-8

Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3. Kanzawa F, et al. **Int J Cancer** 1997 May 2;71(3):311-9

Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Welters MJ, et al. **Int J Cancer** 1997 May 2;71(3):410-5

Effects of interleukin-11 on carboplatin-induced thrombocytopenia in rats and in combination with stem cell factor. Yonemura Y, et al. **Int J Hematol** 1997 Jun; 65(4):397-404

In vitro chemosensitivity of human pancreatic cancer cell lines. Sawabe Y, et al. **Int J Pancreatol** 1996 Dec; 20(3):185-90

Temporal induction of clusterin in cisplatin nephrotoxicity. Silkensen JR, et al. **J Am Soc Nephrol** 1997 Feb;8(2):302-5

Evaluation of the porphyrinogenic risk of antineoplastics. Cochón AC, et al. **J Appl Toxicol** 1997 May-Jun; 17(3):171-7

Effect of benomyl and carbendazim on steroid and molecular mechanisms in uterine decidual growth in rats. Spencer F, et al. **J Appl Toxicol** 1996 May-Jun;16(3):211-4

Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production. Chitambar CR, et al. **J Biol Chem** 1997 May 2;272(18):12151-7

Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm). Calamai P, et al. **J Inorg Biochem** 1997 May 1;66(2):103-9

Synthesis, antitumor activity and acute toxicity of diammine/diamino-cyclohexane platinum(II) complexes with oxygen-ligating leaving group. Zou J, et al. **J Inorg Biochem** 1997 Feb 1;65(2):145-9

Antitumor agents. 174. 2',3',4',5,6,7-Substituted 2-phenyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. Chen K, et al. **J Med Chem** 1997 Jul 4;40(14):2266-75

Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubulin polymerization. Chen K, et al. **J Med Chem** 1997 Sep 12;40(19):3049-56

Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents. Chern JW, et al. **J Med Chem** 1997 Jul 4;40(14):2276-86

A new cytotoxic sterol methoxymethyl ether from a deep water marine sponge Scleritoderma sp. cf. paccardi. Gunasekera SP, et al. **J Nat Prod** 1996 Feb;59(2):161-2

Cytotoxic amides from the octocoral Telesto riisei. Liyanage GK, et al. **J Nat Prod** 1996 Feb;59(2):148-51

Lazaroids inhibit proliferation of cultured human astrocytoma cells. Arora P, et al. **J Neurooncol** 1996 Aug; 29(2):143-8

Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. Liang BC. **J Neurooncol** 1996 Aug;29(2):149-55

In vitro cytotoxic effect of difluoromethylomithine increased nonspecifically by peptide coupling. Süli-Vargha H, et al. **J Pharm Sci** 1997 Sep;86(9):997-1000

Tissue specific toxicities of the anticancer drug 6-thioguanine is dependent on the Hprt status in transgenic mice. Aubrecht J, et al. **J Pharmacol Exp Ther** 1997 Aug; 282(2):1102-8

Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet. Grélot L, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):255-61

Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. Kruidering M, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):638-49

Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. Herman ME, et al. **J Steroid Biochem Mol Biol** 1996 Oct;59(2):121-34

Effects of cisplatin on erythropoietin production in rats. Unami A, et al. **J Toxicol Sci** 1996 Aug;21(3):157-65

High susceptibility of an Epstein-Barr virus-converted Burkitt's lymphoma cell line to cytotoxic drugs. Okano M. **Leuk Res** 1997 May;21(5):469-71

Antileukemic effect of interferon-alpha is mediated through down-modulation of E2F activity. Furukawa Y, et al. **Leukemia** 1997 Apr;11 Suppl 3:446-8

Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Nitiss JL, et al. **Mol Pharmacol** 1996 Nov;50(5):1095-102

Large deletions induced in the white gene of Drosophila melanogaster by the antitumoral drug cis-dichlorodiammineplatinum(II): influence of non-homologous recombination. Cizeau J, et al. **Mutat Res** 1996 Sep 23;356(2):197-202

Micronucleated cells during the growth of the Ehrlich ascites tumour on spontaneous and by titanocenedichloride-induced conditions. Tarillion P, et al. **Mutat Res** 1997 Mar 17;389(2-3):213-8

Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery. Remsen LG, et al. **Neurosurgery** 1997 May;40(5):1034-40; discussion 1040-2

Histological, histochemical and autoradiographic evidence of in vitro neurotoxic effects of the novel antitumor agent, 9-methoxy-N2-methylellipticinium acetate. Shankar L, et al. **Neurotoxicology** 1997;18(1):89-95

In vitro neurotoxicity of the antitumor agent 9-methoxy-N2-methylellipticinium acetate (MMEA): role of brain cytochrome P-450. Sriram K, et al. **Neurotoxicology** 1997;18(1):97-104

Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway. Yen L, et al. **Oncogene** 1997 Apr 17;14(15):1827-35

Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Nakanishi O, et al. **Oncol Res** 1997;9(2):61-9

Differential effects of cisplatin on the production of NADH-dependent superoxide and the activity of antioxidant enzymes in rat renal cortical slices in vitro. Zhang JG, et al. **Pharmacol Toxicol** 1996 Oct;79(4):191-8

Genotoxic properties of the newly synthesized antineoplastic agents amidox, didox and trimidox. Miadoková E, et al. **Pharmazie** 1997 Jul;52(7):540-4

Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Reese JS, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):14088-93

BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Strobel T, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):14094-9

Effect of glycine on cisplatin nephrotoxicity and heat-shock protein 70 expression in the rat kidney. Musio F, et al. **Ren Fail** 1997 Jan;19(1):33-46

Betamipron reduces cisplatin nephrotoxicity in rodents without modifying its antileukemic activity in mice. Tokunaga J, et al. **Ren Fail** 1997 May;19(3):425-38

Carpal and tarsal bone development is highly sensitive to three antiproliferative teratogens in mice. Rahman ME, et al. **Reprod Toxicol** 1996 Nov-Dec;10(6):485-9

Carboplatin-induced micronuclei formation in non-neuronal cells of rat foetal dorsal root ganglia cultured in vitro and comparison with another anticancer drug--cisplatin. Jirsová K, et al. **Sb Lek** 1996;97(3):331-42

Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines. Lambert PA, et al. **Surgery** 1997 Aug;122(2):372-8; discussion 378-9

Enhancing the effect of anticancer drugs against the colorectal cancer cell line with electroporation. Kambe M, et al. **Tohoku J Exp Med** 1996 Oct;180(2):161-71

Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II). Esposito M, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):370-7

Multiple factors contribute to the toxicity of the aromatic retinoid, TTNPB (Ro 13-7410): binding affinities and disposition. Pignatello MA, et al. **Toxicol Appl Pharmacol** 1997 Feb;142(2):319-27

Tiopronin protects against the nephrotoxicity of cisplatin in rat renal cortical slices in vitro. Zhang JG, et al. **Toxicol Appl Pharmacol** 1996 Dec;141(2):425-33

Disruptions of the hypothalamo-pituitary-adrenal axis increase anticancer drug lethality in the rat. Navarra P, et al. **Toxicol Lett** 1997 May 16;91(3):219-27

Cisplatin-induced nephrotoxicity in vitro: increases in cytosolic calcium concentration and the inhibition of cytosolic and mitochondrial protein kinase C. Zhang JG, et al. **Toxicol Lett** 1996 Dec;89(1):11-7

The synovial membrane, liver, and tongue: target organs for a ricin A-chain immunotoxin (ZD0490). Westwood FR, et al. **Toxicol Pathol** 1996 Jul-Aug;24(4):477-83

Immunohistochemical study of rat renal interstitial fibrosis induced by repeated injection of cisplatin, with special reference to the kinetics of macrophages and myofibroblasts. Yamate J, et al. **Toxicol Pathol** 1996 Mar-Apr;24(2):199-206

Renal insufficiency induced by cisplatin in rats is ameliorated by cyclosporin A. Campbell PI, et al. **Toxicology** 1996 Nov 15;114(1):11-7

Comparative effects of flavonoids and model inducers on drug-metabolizing enzymes in rat liver. Canivenc-Lavier MC, et al. **Toxicology** 1996 Nov 15;114(1):19-27

Cytotoxicity and antitumor activity of platinum (II) complexes of aromatic and cycloalkanecarboxylic acid hydrazides. Kushev DN, et al. **Z Naturforsch [C]** 1997 Jan-Feb;52(1-2):49-54

[Mutagenic effects of bimolane] Chen SQ, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Nov;16(6):531-3 (Eng. Abstr.) **(Chi)**

[Modulation of cisplatin cytotoxicity by amphotericin B in six human cell lines of medullary thyroid cancer] Massart C, et al. **Bull Cancer** 1996 Aug;83(8):619-25 (50 ref.) (Eng. Abstr.) **(Fre)**

[Selenium in the cytotoxicity of cisplatin] Olas B, et al. **Postepy Hig Med Dosw** 1997;51(1):95-108 (82 ref.) (Eng. Abstr.) **(Pol)**

[Morphofunctional state of rat ovaries after administration of platidiam] Gol'dberg ED, et al. **Biull Eksp Biol Med** 1996 Nov;122(11):571-3 **(Rus)**

[The role of binding activity of hematopoietic microenvironment cells in the recovery of various hematopoietic stems inhibited by cytostatics] Zhdanov VV, et al. **Biull Eksp Biol Med** 1996 Nov;122(11):490-4 **(Rus)**

[The late effects of the toxic action of platinum-containing cytostatic preparations on rat progeny] Borovskaia TG, et al. **Eksp Klin Farmakol** 1996 Jul-Aug;59(4):40-2 (Eng. Abstr.) **(Rus)**

[The toxicity and biological effects of organophosphorus epoxides] Studentsova IA, et al. **Eksp Klin Farmakol** 1996 Nov-Dec;59(6):31-3 (Eng. Abstr.) **(Rus)**

URINE

Urinary stability of carboxycyclophosphamide and carboxyifosfamide, two major metabolites of the anticancer drugs cyclophosphamide and ifosfamide. Joqueviel C, et al. **Cancer Chemother Pharmacol** 1997;40(5):391-9

Reversed-phase high-performance liquid chromatographic determination of the new antitumor agent cyclopentenyl cytosine in biological fluids. Hegedus L, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):169-79

Quantification of retinoyl-beta-glucuronides in rat urine by reversed-phase high-performance liquid chromatography with ultraviolet detection. Li S, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30;683(2):155-62

ANTINEOPLASTIC AGENTS, ALKYLATING

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Newlands ES, et al. **Cancer Treat Rev** 1997 Jan;23(1):35-61 (106 ref.)

[Mechanisms of resistance to melphalan in leukemia cell line and reversal by interferon alpha] Qian Q, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Jul;76(7):485-9 (Eng. Abstr.) **(Chi)**

ADMINISTRATION & DOSAGE

High-dose chemotherapy with autologous stem cell support for the treatment of advanced ovarian cancer--initial experience in Uppsala and Turku. Grenman S, et al. **Acta Obstet Gynecol Scand** 1997 Apr;76(4):363-8 (31 ref.)

Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. Brandes AA, et al. **Am J Clin Oncol** 1997 Aug;20(4):364-7

Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Colleoni M, et al. **Am J Clin Oncol** 1997 Aug;20(4):383-6

Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma. Vallejo C, et al. **Am J Clin Oncol** 1996 Dec;19(6):584-8

Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Taber SW, et al. **Ann Surg Oncol** 1997 Jul-Aug;4(5):440-5 (30 ref.)

Intermediate dose cyclophosphamide combined with a growth factor is a safe and effective regimen for

mobilisation of peripheral blood progenitor cells. Goss G, et al. **Aust N Z J Med** 1996 Jun;26(3):411–3

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high–dose cyclophosphamide plus GM–CSF vs G–CSF alone. Alegre A, et al. **Bone Marrow Transplant** 1997 Aug;20(3):211–7

High–dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Demirer T, et al. **Bone Marrow Transplant** 1996 May;17(5):769–74

Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high–dose cyclophosphamide and mesna. Fleming RA, et al. **Bone Marrow Transplant** 1996 Apr; 17(4):497–501

Mobilization of peripheral blood progenitor cells with high–dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony–stimulating factor in patients with multiple myeloma. Goldschmidt H, et al. **Bone Marrow Transplant** 1996 May;17(5):691–7

High–dose BCNU with ABMT followed by radiation therapy in the treatment of supratentorial glioblastoma multiforme. Linassier C, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S69–72

Role of CD34+ cells in engraftment after high–dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue. Millar BC, et al. **Bone Marrow Transplant** 1996 Nov;18(5):871–8

Unrelated allogeneic bone marrow transplantation using high–dose busulfan and cyclophosphamide (BU–CY) for the preparative regimen. Sahebi F, et al. **Bone Marrow Transplant** 1996 May;17(5):685–9

High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B–cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo–Immunotherapy, Vienna. Jaksic B, et al. **Cancer** 1997 Jun 1;79(11):2107–14

Feasibility trial of high–dose 7–day continuous–infusion ifosfamide given on an outpatient basis. Bellmunt J, et al. **Cancer Chemother Pharmacol** 1997;40(3):273–6

High–dose carmustine for high–grade gliomas in childhood. Bouffet E, et al. **Cancer Chemother Pharmacol** 1997; 39(4):376–9

Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Sipos EP, et al. **Cancer Chemother Pharmacol** 1997;39(5):383–9

2–Chloroethyl–3–sarcosinamide–1–nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Marcantonio D, et al. **Cancer Res** 1997 Sep 15;57(18):3895–8

Role of nitric oxide in recombinant tumor necrosis factor–alpha–induced circulatory shock: a study in patients treated for cancer with isolated limb perfusion. Zwaveling JH, et al. **Crit Care Med** 1996 Nov;24(11):1806–10

A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity. Byrne DS, et al. **Eur J Cancer** 1996 Nov; 32A(12):2082–7

A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor–prognosis primary melanoma of the lower limb. Fenn NJ, et al. **Eur J Surg Oncol** 1997 Feb;23(1):6–9

Induction thermochemotherapy increases therapeutic gain factor for the fractionated radiotherapy given to a mouse fibrosarcoma. Kuroda M, et al. **Int J Radiat Oncol Biol Phys** 1997 May 1;38(2):411–7

Comparison of hormonal therapy and chemohormonal therapy in patients with newly diagnosed clinical stage D prostatic cancer. Miyake H, et al. **Int J Urol** 1996 Nov; 3(6):472–7

6–Day continuous infusion of high–dose ifosfamide with bone marrow growth factors in advanced refractory malignancies. Brain EC, et al. **J Cancer Res Clin Oncol** 1997;123(4):227–31

Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. Busse D, et al. **J Clin Oncol** 1997 May; 15(5):1885–96

High–dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies—dose–response and schedule dependence. Patel SR, et al. **J Clin Oncol** 1997 Jun; 15(6):2378–84

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. Rustin GJ, et al. **J Clin Oncol** 1997 Jan;15(1):172–6

Infusional therapy with alkylating agents. Jones RB. **J Infus Chemother** 1996 Spring;6(2):74–81 (93 ref.)

Isolated lung perfusion with melphalan for the treatment of metastatic pulmonary sarcoma. Nawata S, et al. **J Thorac Cardiovasc Surg** 1996 Dec;112(6):1542–7; discussion 1547–8

Intra–arterial chemotherapy with concomitant hemofiltration (chemofiltration) for treatment of loco–regional or pelvic metastases from malignant melanoma. Gutman M, et al. **Melanoma Res** 1996 Apr;6(2):167–71

Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model. Wu Z, et al. **Melanoma Res** 1997 Feb;7(1):19–26

Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Wu ZY, et al. **Melanoma Res** 1997 Jun;7(3):252–64

Interstitial chemotherapy with carmustine–loaded polymers for high–grade gliomas: a randomized double–blind study. Valtonen S, et al. **Neurosurgery** 1997 Jul;41(1):44–8; discussion 48–9

Anaesthetic experience with isolated limb perfusion with melphalan for melanoma. Kam PC, et al. **Perfusion** 1996 Sep;11(5):395–9

A phase II trial of gemcitabine and ifosfamide in non–small cell lung cancer. Gatzemeier U, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8–36–S8–38

Isolated limb perfusion for malignant melanoma. Alexander HR Jr, et al. **Semin Surg Oncol** 1996 Nov–Dec;12(6):416–28 (85 ref.)

Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan. Hohenberger P, et al. **Strahlenther Onkol** 1996 Nov;172 Suppl 2:14–5

Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma. Würl P, et al. **Surg Today** 1997;27(8):719–25

Fibrinolytic and coagulant responses to regional limb perfusions of tumor necrosis factor, interferon–gamma, and/or melphalan. Merryman P, et al. **Thromb Haemost** 1997 Jan;77(1):53–6

[High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients] Baranzelli MC, et al. **Bull Cancer** 1997 Feb; 84(2):141–6 (Eng. Abstr.) **(Fre)**

[Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma] Kettelhack C, et al. **Dtsch Med Wochenschr** 1997 Feb 14;122(7):177–81 (Eng. Abstr.) **(Ger)**

[O2 utilization during hyperthermic extremity perfusion with rhTNF alpha and melphalan] Haier J, et al. **Langenbecks Arch Chir** 1997;382(3):128–33 (Eng. Abstr.) **(Ger)**

[Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor] Kettelhack C, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:127–9 (Eng. Abstr.) **(Ger)**

[Clinical results of extremity perfusion in malignant melanoma] Huber R, et al. **Zentralbl Chir** 1996; 121(3):234–42 (Eng. Abstr.) **(Ger)**

[Ifosfamide] Manegold C. **Zentralbl Gynakol** 1996; 118(10):580–1 **(Ger)**

[High–dose ifosfamide in the treatment of patients with soft tissue sarcoma] Tiuliandin SA, et al. **Vopr Onkol** 1996; 42(6):19–22 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Severe adverse skin reaction to chlorambucil in a patient with chronic lymphocytic leukemia. Aydogdu I, et al. **Anticancer Drugs** 1997 Jun;8(5):468–9

Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment. Lee CK, et al. **Bone Marrow Transplant** 1996 Sep;18(3):573–7

Headache, circumoral paresthesia, and facial flushing associated with high–dose carmustine infusion. Woo MH, et al. **Bone Marrow Transplant** 1997 Apr;19(8):845–7

Adenocarcinoma of the residual bladder following caecocystoplasty for cyclophosphamide–induced cystitis. Khawaja MA, et al. **Br J Urol** 1996 Sep;78(3):465–6

Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Del Mastro L, et al. **Breast Cancer Res Treat** 1997 Apr;43(2):183–90 (43 ref.)

Chlorambucil–induced seizures. Salloum E, et al. **Cancer** 1997 Mar 1;79(5):1009–13 (2 ref.)

Combined intravenous and oral mesna in outpatients treated with ifosfamide. Goren MP, et al. **Cancer Chemother Pharmacol** 1997;40(5):371–5

The DNA repair protein O6–methylguanine–DNA methyltransferase protects against skin tumor formation induced by antineoplastic chloroethylnitrosourea. Becker K, et al. **Cancer Res** 1997 Aug 15;57(16):3335–8

Interstitial pneumonitis as a late complication of high dose therapy with cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast. Mahendra P, et al. **Clin Oncol (R Coll Radiol)** 1996; 8(3):198–200

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide–based chemotherapy and maintenance of health–related quality of life [corrected and republished article originally printed in Clin Ther 1996 May–Jun;18(3):508–18] Crucitt MA, et al. **Clin Ther** 1996 Jul–Aug;18(4):778–88

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide–based chemotherapy and maintenance of health–related quality of life [corrected and republished in Clin Ther 1996 Jul–Aug;18(4):778–88] Crucitt MA, et al. **Clin Ther** 1996 May–Jun;18(3):508–18

Role of nitric oxide in recombinant tumor necrosis factor–alpha–induced circulatory shock: a study in patients treated for cancer with isolated limb perfusion. Zwaveling JH, et al. **Crit Care Med** 1996 Nov;24(11):1806–10

Bone marrow protection with amifostine in the treatment of high–risk malignant lymphoma. Avilés A, et al. **Eur J Cancer** 1997 Jul;33(8):1323–5

Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Küpfer A, et al. **Eur J Clin Pharmacol** 1996;50(4):249–52

Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Sonneveld EJ, et al. **Eur J Surg Oncol** 1996 Oct;22(5):521–7

Stevens–Johnson syndrome associated with topical nitrogen mustard therapy. Newman JM, et al. **J Am Acad Dermatol** 1997 Jan;36(1):112–4

Prospective randomized placebo–controlled study of granulocyte–macrophage colony–stimulating factor without stem–cell transplantation after high–dose melphalan in patients with multiple myeloma. Moreau P, et al. **J Clin Oncol** 1997 Feb;15(2):660–6

Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors. O'Reilly S, et al. **J Clin Oncol** 1997 May;15(5):1974–84

Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German–Austrian Pediatric Hodgkin's Disease Group. Schellong G, et al. **J Clin Oncol** 1997 Jun;15(6):2247–53

Renal dysfunctions secondary to ifosfamide treatment in children. Tokuc G, et al. **J Exp Clin Cancer Res** 1997 Jun; 16(2):227–30

A rare case of prednimustine–induced myoclonus [letter] Monnerat C, et al. **J Natl Cancer Inst** 1997 Jan 15; 89(2):173–4

Carmustine and the lungs . Schmitz N, et al. **Lancet** 1997 Jun 14;349(9067):1712–3

melphalan, single–fraction total–body irradiation and allogeneic bone marrow transplantation for acute leukemia: review of transplant–related mortality. Hjiyiannakis P, et al. **Leuk Lymphoma** 1997 May;25(5–6):565–72

Late reversibility of chronic ifosfamide–associated nephrotoxicity in a child. Ashraf MS, et al. **Med Pediatr Oncol** 1997 Jan;28(1):62–4

Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Thompson JF, et al. **Melanoma Res** 1996 Jun;6(3):267–71

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 25–1997. A 60–year–old man with pulmonary infiltrates after a bone marrow transplantation [clinical conference] **N Engl J Med** 1997 Aug 14;337(7):480–9

Nephrotoxicity of ifosfamide—moving towards understanding the molecular mechanisms [editorial] Rossi R. **Nephrol Dial Transplant** 1997 Jun;12(6):1091–2

The molecular pathogenesis of treatment–induced (secondary) leukemias: foundations for treatment and prevention. Karp JE, et al. **Semin Oncol** 1997 Feb; 24(1):103–13 (89 ref.)

[Methylene blue in ifosfamide–induced encephalopathy (letter)] Koschuth A, et al. **Dtsch Med Wochenschr** 1996 Sep 27;121(39):1210 **(Ger)**

[Sequential course and prospective management of ifosfamide–induced multi–organ toxicity] Mollenkopf A, et al. **Geburtshilfe Frauenheilkd** 1996 Oct;56(10):525–8 (Eng. Abstr.) **(Ger)**

[High–dose ifosfamide in the treatment of patients with soft tissue sarcoma] Tiuliandin SA, et al. **Vopr Onkol** 1996; 42(6):19–22 (Eng. Abstr.) **(Rus)**

BLOOD

Chromatographic analysis of the enantiomers of ifosfamide and some of its metabolites in plasma and urine. Kaijser GP, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7; 690(1–2):131–8

High–performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies. Pinguet F, et al. **J Chromatogr B Biomed Appl** 1996 Nov 8;686(1):43–9

Analysis of ifosfamide, 4–hydroxyifosfamide, N2–dechloroethylifosfamide, N3–dechloroethylifosfamide and iphosphoramide mustard in plasma by gas chromatography–mass spectrometry. Wang JJ, et al. **J Chromatogr B Biomed Appl** 1995 Dec 15;674(2):205–17

CHEMICAL SYNTHESIS

Synthesis, DNA binding and cytotoxicity of 1–[[omega–(9–acridinyl)amino]alkyl]carbonyl –3–(chloromethyl)–6–hydroxyindolines, a new class of DNA–targeted alkylating agents. Fan JY, et al. **Anticancer Drug Des** 1997 Jun;12(4):277–93

Synthesis and anti–cancer activity of 2,6–disubstituted N–methylpiperidine derivatives and their N–oxides. Henderson ND, et al. **Anticancer Drug Des** 1996 Sep; 11(6):421–38

Synthesis and evaluation of antitumor activity of arylamides and cyclohexylamides of isomeric 3–chloro–4–(2–chloroethylthio)butanoic– and 4–chloro–3–(2–chloroethylthio)butanoic acids. Vektariené A, et al. **Arzneimittelforschung** 1997 Feb;47(2):217–22

A new family of potential oncostatics: 2–chloroethylnitrososulfamides (CENS)—I. Synthesis, structure, and pharmacological evaluation (preliminary results). Abdaoui M, et al. **Bioorg Med Chem** 1996 Aug; 4(8):1227–35

Synthesis of O–methylsulfonyl derivatives of D–glucose as potential alkylating agents for targeted drug delivery to

the brain. Evaluation of their interaction with the human erythrocyte GLUT1 hexose transporter. Halmos T, et al. **Carbohydr Res** 1997 Mar 26;299(1-2):15-21

In vitro alkylating of alpha, beta-unsaturated amidoesters, diethyl pyridylmethylphosphonates and their cis-Pt(II)complexes. Najman-Bronzewska L, et al. **Pharmazie** 1997 Mar;52(3):198-202

Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Rink SM, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24; 93(26):15063-8

CHEMISTRY

Stability of thiotepa (lyophilized) in 5% dextrose injection at 4 and 23 degrees C. Xu QA, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2728-30

Antisense sequence-directed cross-linking of RNA oligonucleotides by mitomycin. Maruenda H, et al. **Anticancer Drug Des** 1997 Sep;12(6):473-9

Studies on duocarmycin SA and its derivatives. Nagamura S, et al. **Bioorg Med Chem** 1997 Mar;5(3):623-30

A quantitative structure-activity relationship study on DNA-directed alkylating agents. Gupta SP, et al. **Indian J Biochem Biophys** 1996 Jun;33(3):234-6

Chemical degradation of wastes of antineoplastic agents: cyclophosphamide, ifosfamide and melphalan. Hansel S, et al. **Int Arch Occup Environ Health** 1997;69(2):109-14

High resolution soiution structure of a DNA duplex alkylated by the antitumor agent duocarmycin SA. Eis PS, et al. **J Mol Biol** 1997 Sep 19;272(2):237-52

METABOLISM

Alkylation specificity for a series of distamycin analogues that tether chlorambucil. Wyatt MD, et al. **Anticancer Drug Des** 1997 Jan;12(1):49-60

Biodegradation and toxicity of the antineoplastics mitoxantron hydrochloride and treosulfane in the Closed Bottle Test (OECD 301 D). al-Ahmad A, et al. **Bull Environ Contam Toxicol** 1997 May;58(5):704-11

Quantification of 4-hydroxyifosfamide in plasma of ifosfamide-treated mice. Struck RF, et al. **Cancer Chemother Pharmacol** 1997;40(1):57-9

Binding of vinblastine and estramustine to isolated plasma membrane fractions from human prostate and prostatic tumors. Batra S, et al. **Cancer Lett** 1996 Sep 10; 106(2):217-20

Lack of glutathione conjugation of melphalan in the isolated in situ liver perfusion in humans. Vahrmeijer AL, et al. **Cancer Res** 1996 Oct 15;56(20):4709-14

Oxidative metabolism of 1-(2-chloroethyl)-3-alkyl-3-(methylcarbamoyl)triazenes: formation of chloroacetaldehyde and relevance to biological activity. Rouzer CA, et al. **Chem Res Toxicol** 1996 Jan-Feb; 9(1):172-8

Interactions of melphalan with glutathione and the role of glutathione S-transferase. Awasthi S, et al. **Drug Metab Dispos** 1996 Mar;24(3):371-4

Biological degradation of cyclophosphamide and its occurrence in sewage water. Steger-Hartmann T, et al. **Ecotoxicol Environ Saf** 1997 Mar;36(2):174-9

Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Bohnenstengel F, et al. **Eur J Clin Pharmacol** 1996; 51(3-4):297-301

Derivatives of melphalan designed to enhance drug accumulation in cancer cells. Kupczyk-Subotkowska L, et al. **J Drug Target** 1997;4(6):359-70

Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Chang TK, et al. **Pharmacogenetics** 1997 Jun;7(3):211-21

Nuclear magnetic resonance and high-performance liquid chromatography-nuclear magnetic resonance studies on the toxicity and metabolism of ifosfamide. Foxall PJ, et al. **Ther Drug Monit** 1996 Aug;18(4):498-505

PHARMACOKINETICS

Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. Lokiec F, et al. **Anticancer Drugs** 1996 Nov;7(8):893-6

Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. Wagner A, et al. **Anticancer Drugs** 1997 Jun;8(5):419-31 (51 ref.)

Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide. Kaijser GP, et al. **Anticancer Res** 1996 Sep-Oct; 16(5B):3247-57

Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Pinguet F, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):605-11

Pharmacokinetics of [14C] BBR 3053, an alkylating bisphosphonate, after single i.v. and multiple s.c. administration in rats. Bernareggi A, et al. **Boll Chim Farm** 1997 Apr;136(4):304-7

In vivo detection of ifosfamide by 31P-MRS in rat tumours: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas. Rodrigues LM, et al. **Br J Cancer** 1997;75(1):62-8

The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. Wu ZY, et al. **Br J Cancer** 1997; 75(8):1160-6

A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles. Lewis LD. **Br J Clin Pharmacol** 1996 Aug;42(2):179-86

Cyclophosphamide pharmacokinetics in children. Yule SM, et al. **Br J Clin Pharmacol** 1996 Jan;41(1):13-19

Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. Hare CB, et al. **Cancer Chemother Pharmacol** 1997;40(5):409-14

Pharmacokinetics of trofosfamide and its dechloroethylated metabolites. Hempel G, et al. **Cancer Chemother Pharmacol** 1997;40(1):45-50

L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. Moynihan K, et al. **Cancer Chemother Pharmacol** 1997;39(3):179-86

Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Chang TK, et al. **Cancer Res** 1997 May 15;57(10):1946-54

Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Dirven HA, et al. **Chem Res Toxicol** 1996 Mar;9(2):350-60 (92 ref.)

Dose-dependency of oxazaphosphorine pharmacokinetics. Busse D, et al. **Int J Clin Pharmacol Ther** 1997 Feb; 35(2):71-2

High-performance liquid chromatographic determination of acrolein as a marker for cyclophosphamide bioactivation in human liver microsomes. Bohnenstengel F, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):163-8

Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. Busse D, et al. **J Clin Oncol** 1997 May; 15(5):1885-96

Predicted and actual BCNU concentrations in normal rabbit brain during intraarterial and intravenous infusions. Hassenbusch SJ, et al. **J Neurooncol** 1996 Oct;30(1):7-18

Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. Wu ZY, et al. **J Pharmacol Exp Ther** 1997 Sep;282(3):1131-8

Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy. Dang W, et al. **Pharm Res** 1996 May;13(5):683-91

Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Fung LK, et al. **Pharm Res** 1996 May;13(5):671-82

[The biochemical mechanisms of the action of N-alkyl-N-nitrosoureas. The possible reasons for drug resistance to these compounds] Syrkin AB, et al. **Eksp Klin Farmakol** 1996 Mar-Apr;59(2):69-75 (110 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Influence of the antineoplastic agent cyclophosphamide on dental development in rat molars. Näsman M, et al. **Acta Odontol Scand** 1996 Oct;54(5):287-94

A scanning electron microscopy study of disturbances in the developing rat molar induced by cyclophosphamide. Näsman M, et al. **Acta Odontol Scand** 1997 Jun;55(3):186-91

Targeting microtubule-associated proteins in glioblastoma: a new strategy for selective therapy. Piepmeier JM, et al. **Ann Surg Oncol** 1996 Nov;3(6):543-9

Novel DNA-directed alkylating agents consisting of naphthalimide, nitrogen mustard and lexitropsin moieties: synthesis, DNA sequence specificity and biological evaluation. Gupta R, et al. **Anticancer Drug Des** 1996 Dec; 11(8):581-96

The 5'-GNC preference for mustard cross-linking is preserved in a restriction fragment. Millard JT, et al. **Anticancer Drug Des** 1996 Sep;11(6):485-92

Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs. Gornati D, et al. **Anticancer Drugs** 1997 Jun;8(5):509-16

Activity of TER286 against human tumor colony-forming units. Izbicka E, et al. **Anticancer Drugs** 1997 Apr; 8(4):345-8

Modulation of melphalan cytotoxic activity in human melanoma cell lines. Supino R, et al. **Anticancer Drugs** 1996 Jul;7(5):604-12

Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. Wagner A, et al. **Anticancer Drugs** 1997 Jun;8(5):419-31 (51 ref.)

The alkylating antitumor drug tallimustine does not induce DNA repair. Rossi R, et al. **Anticancer Res** 1996 Nov-Dec; 16(6B):3779-83

Involvement of gene-specific DNA damage and apoptosis in the differential toxicity of mitomycin C analogs towards B-lineage versus T-lineage lymphoma cells. Muscarella DE, et al. **Biochem Pharmacol** 1997 Mar 21;53(6):811-22

Immunomodulation and enhancement of antitumor activity by co-administration of 1,3-bis(2-chloroethyl)-1-nitrosourea and thymidine. Poo WJ, et al. **Biochem Pharmacol** 1997 Mar 7;53(5):705-13

Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Vanhoefer U, et al. **Biochem Pharmacol** 1997 Mar 21; 53(6):801-9

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Pommier Y, et al. **Biochemistry** 1996 Oct 15;35(41):13303-9

Effects of bizelesin (U-77,779), a bifunctional alkylating minor groove binder, on replication of genomic and simian virus 40 DNA in BSC-1 cells. Woynarowski JM, et al. **Biochim Biophys Acta** 1997 Jul 17;1353(1):50-60

Treatment with inhibitors of polyamine biosynthesis, which selectively lower intracellular spermine, does not affect the activity of alkylating agents but antagonizes the cytotoxicity of DNA topoisomerase II inhibitors. Desiderio MA, et al. **Br J Cancer** 1997;75(7):1028-34

Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide. Marshall E, et al. **Br J Cancer** 1997; 75(12):1715-20

Effect of melphalan and hyperthermia on p34cdc2 kinase activity in human melanoma cells. Orlandi L, et al. **Br J Cancer** 1996 Dec;74(12):1924-8

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Wedge SR, et al. **Br J Cancer** 1996 Oct;74(7):1030-6

Characterization of a BMS-181174-resistant human bladder cancer cell line. Xia H, et al. **Br J Cancer** 1997;76(4):461-6

Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants. Holden SA, et al. **Cancer Chemother Pharmacol** 1997; 40(1):87-93

Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Pruijn FB, et al. **Cancer Chemother Pharmacol** 1997;39(6):541-6

Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors. Teicher BA, et al. **Cancer Chemother Pharmacol** 1996;38(6):553-60

Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells. Volpe DA, et al. **Cancer Chemother Pharmacol** 1996; 39(1-2):143-9

Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Shamon LA, et al. **Cancer Lett** 1997 Jan 15;112(1):113-7

The relationship of a novel drug-resistant phenotype in C3H10T1/2 cells selected with alkylating agents to neoplastic transformation and ATP metabolism. Wroblewski-Giorgio D, et al. **Cancer Lett** 1997 Feb 26; 113(1-2):195-203

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Liu L, et al. **Cancer Res** 1996 Dec 1;56(23):5375-9

Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells. Walker A, et al. **Cancer Res** 1997 May 15;57(10):1939-45

Genomic instability and tolerance to alkylating agents. Karran P, et al. **Cancer Surv** 1996;28:69-85 (38 ref.)

Role of DNA repair in resistance to drugs that alkylate O6 of guanine. Koç ON, et al. **Cancer Treat Res** 1996;87:123-46 (138 ref.)

Mechanisms of resistance to alkylating agents. Penketh PG, et al. **Cancer Treat Res** 1996;87:65-81 (97 ref.)

Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Grombacher T, et al. **Carcinogenesis** 1996 Nov; 17(11):2329-36

Metabolic changes in the heme pathway driven by cyclophosphamide treatment in mice. Casas A, et al. **Cell Mol Biol (Noisy-le-grand)** 1997 Feb;43(1):95-101

Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells. Palomares T, et al. **Clin Exp Metastasis** 1997 May;15(3):329-37

Role of O6-methylguanine-DNA methyltransferase, glutathione transferase M3-3 and glutathione in resistance to carmustine in a human non-small cell lung cancer cell line. Egyházi S, et al. **Eur J Cancer** 1997 Mar;33(3):447-52

Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Halmos T, et al. **Eur J Pharmacol** 1996 Dec 30; 318(2-3):477-84

Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Morabito F, et al. **Haematologica** 1997 Jan-Feb;82(1):16-20

Ultrastructural alterations of the cortical epithelial cells of the rat thymus after cyclophosphamide treatment. Yoon S, et al. **Histol Histopathol** 1997 Apr;12(2):401-13

THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. Papadopoulou MV, et al. **In Vivo** 1996 Jan-Feb;10(1):49-57

Inducible protective processes in animal systems: adaptive

response to a low dose of methyl methanesulfonate in mouse bone marrow cells. Mahmood R, et al. **Indian J Exp Biol** 1996 Jun;34(6):502–7

Glucose–regulated stresses induce resistance to camptothecin in human cancer cells. Tomida A, et al. **Int J Cancer** 1996 Nov 4;68(3):391–6

Kinetics of serum granulocyte–colony stimulating factor (G–CSF) concentration and G–CSF receptor expression during G–CSF treatment of cyclophosphamide–treated mice. Matsuzaki G, et al. **Int J Immunopharmacol** 1996 Jun–Jul;18(6–7):363–9

Dynamics of tumor oxygenation, CD31 staining and transforming growth factor–beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Kakeji Y, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 15;37(5):1115–23

Faranoxi–a new antitumor agent. Breivis P, et al. **J Chemother** 1996 Feb;8(1):67–9

The effect of cyclophosphamide on Fas–mediated apoptosis. Lee JH, et al. **J Korean Med Sci** 1997 Jun;12(3):185–9

Cross–linking and sequence specific alkylation of DNA by aziridinyl quinones. 2. Structure requirements for sequence selectivity. Hargreaves RH, et al. **J Med Chem** 1997 Jan 31;40(3):357–61

Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand–melphalan conjugate. Kupczyk–Subotkowska L, et al. **J Med Chem** 1997 May 23;40(11):1726–30

Studies of pyrrolo[1,2–alpha]benzimidazolequinone DT–diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation. Skibo EB, et al. **J Med Chem** 1997 Apr 25;40(9):1327–39

Harnessing the power of antisense technology for combination chemotherapy [editorial; comment] Narayanan R. **J Natl Cancer Inst** 1997 Jan 15;89(2):107–8 . Comment on: J Natl Cancer Inst 1997 Jan 15;89(2):124–33.

In vitro inactivation of human O6–alkylguanine DNA alkyltransferase by antitumor triazene compounds. Lacal PM, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):416–22

Development of a canine chemotherapeutic model with ifosfamide. Ikeda K, et al. **Lab Anim Sci** 1996 Oct; 46(5):503–6

Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Begleiter A, et al. **Leuk Lymphoma** 1996 Oct; 23(3–4):187–201 (94 ref.)

Inhibition of O6–alkylguanine DNA–alkyltransferase or poly(ADP–ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Tentori L, et al. **Mol Pharmacol** 1997 Aug;52(2):249–58

Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. St. Croix B, et al. **Nat Med** 1996 Nov;2(11):1204–10

Tumor blood flow and the cytotoxic effects of estramustine and its constituents in a rat glioma model. Johansson M, et al. **Neurosurgery** 1997 Jul;41(1):237–43; discussion 243–4

In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate. Yoshida D, et al. **Neurosurgery** 1996 Aug;39(2):360–6

Pharmacodynamic evaluation of mitomycin C analog BMS–181174 for potential use in intravesical bladder cancer therapy. Yen WC, et al. **Pharm Res** 1997 Feb; 14(2):241–5

Biphasic emetic response of cyclophosphamide in the ferret. Wong RH, et al. **Pharmacol Biochem Behav** 1997 Sep; 58(1):179–82

Repair capacity of mouse lung after total body irradiation alone or combined with cyclophosphamide. Safwat A, et al. **Radiother Oncol** 1996 Sep;40(3):249–57

[Study on potentiation of nitrosourea–cytotoxicity by DNA repair enzyme inhibitors in human brain tumor cells] Fukuchi M, et al. **No To Shinkei** 1997 Jun;49(6):521–8 (Eng. Abstr.) **(Jpn)**

[Comparative study of three antineoplastic alkylating agents on DNA (letter)] Babaian IuS, et al. **Biofizika** 1997 Mar–Apr;42(2):542–3 (Eng. Abstr.) **(Rus)**

[Effect of imidazen in combination with RNA on the structure of DNA from sarcoma 45] Babaian IuS, et al. **Biofizika** 1997 Jan–Feb;42(1):125–8 (Eng. Abstr.) **(Rus)**

[Enhancement of antineoplastic activity of sarcolysin by the means of transforming it into lipid derivative and incorporating into liposomal membranes containing carbohydrate vector] Kozlov AM, et al. **Biull Eksp Biol Med** 1997 Apr;123(4):439–41 **(Rus)**

THERAPEUTIC USE

A prospective phase II trial to evaluate the efficacy and toxicity of hepatic arterial infusion of ifosfamide in patients with inoperable localized hepatocellular carcinoma. Malik IA, et al. **Am J Clin Oncol** 1997 Jun;20(3):289–92

A long–lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone. Mandigers CM, et al. **Ann Hematol** 1996 Jun;72(6):371–3

High–dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma [see comments] Goldschmidt H, et al. **Ann Oncol** 1997 Mar;8(3):243–6. Comment in: Ann Oncol 1997 Mar;8(3):219–21.

Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5–fluorouracil. Strumberg D, et al. **Anticancer Drugs** 1997 Mar;8(3):293–5

In vitro evaluation of temozolomide combined with X–irradiation. Wedge SR, et al. **Anticancer Drugs** 1997 Jan; 8(1):92–7

Augmentation of antitumor effect of endogenously induced tumor necrosis factor by cyclophosphamide. Inagawa H, et al. **Anticancer Res** 1997 Jan–Feb;17(1A):55–60

Maintenance chemotherapy with oral treosulfan following first–line treatment in patients with advanced ovarian cancer: feasibility and toxicity. Meden H, et al. **Anticancer Res** 1997 May–Jun;17(3C):2221–3

Adoptive transfer of anti–CD3–activated CD4+ T cells plus cyclophosphamide and liposome–encapsulated interleukin–2 cure murine MC–38 and 3LL tumors and establish tumor–specific immunity. Saxton ML, et al. **Blood** 1997 Apr 1;89(7):2529–36

High–dose melphalan +/– total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor. Stewart DA, et al. **Bone Marrow Transplant** 1996 Aug;18(2):315–8

Prognostic factors affecting leukemia relapse after allogeneic BMT conditioned with cyclophosphamide and fractionated TBI. Zapatero A, et al. **Bone Marrow Transplant** 1996 Sep; 18(3):591–6

The influence of ifosfamide scheduling on acute nephrotoxicity in children. English MW, et al. **Br J Cancer** 1997;75(9):1356–9

Cyclophosphamide therapy for pure red cell aplasia associated with granular lymphocyte–proliferative disorders. Yamada O, et al. **Br J Haematol** 1997 May; 97(2):392–9

Fibrogenesis imperfecta ossium: ineffectiveness of melphalan. Lafage–Proust M, et al. **Calcif Tissue Int** 1996 Oct; 59(4):240–4

Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. Rodriguez–Monge EJ, et al. **Cancer** 1997 Aug 1;80(3):396–400

Intraarterial O6–benzylguanine enables the specific therapy of nitrosourea–resistant intracranial human glioma xenografts in athymic rats with 1,3–bis(2–chloroethyl)–1–nitrosourea. Kurpad SN, et al. **Cancer Chemother Pharmacol** 1997;39(4):307–16

Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer. Malik IA, et al. **Cancer Chemother Pharmacol** 1997; 39(6):561–5

Complete remission of nephrotic syndrome after steroid–chlorambucil in a previous failed short–term steroidal treatment of a primary membranous nephropathy [letter] Ardiles LG, et al. **Clin Nephrol** 1996 Jun;45(6):423

Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study. Helsing MD. **Eur J Cancer** 1997 Mar;33(3):500–2

High–dose melphalan followed by autograft employing non–cryopreserved peripheral blood progenitor cells in children. Jones N, et al. **Eur J Cancer** 1996 Oct; 32A(11):1938–42

The Charing Cross Hospital experience with temozolomide in patients with gliomas. Newlands ES, et al. **Eur J Cancer** 1996 Dec;32A(13):2236–41

High–dose melphalan with re–infusion of unprocessed, G–CSF–primed whole blood is effective and non–toxic therapy in multiple myeloma. Ossenkoppele GJ, et al. **Eur J Cancer** 1996 Nov;32A(12):2058–63

In vitro improvement of chlorambucil–induced cytotoxicity by deflazacort and 6–methylprednisolone in B–cell chronic lymphocytic leukaemia. Morabito F, et al. **Eur J Haematol** 1997 May;58(5):301–6

Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation. Schmidt JD, et al. **Eur Urol** 1996;29(4):425–33

Phase II study of 96–hr continuous–infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer. Fleming GF, et al. **Gynecol Oncol** 1997 Apr;65(1):42–5

Hexamethylmelamine as a single second–line agent in ovarian cancer: follow–up report and review of the literature. Manetta A, et al. **Gynecol Oncol** 1997 Jul;66(1):20–6 (39 ref.)

Use of granulocyte–macrophage colony–stimulating factor (GM–CSF) in combination with hydroxyurea as post–transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. Carlo–Stella C, et al. **Haematologica** 1997 May–Jun; 82(3):291–6

Granulocyte colony–stimulating factor shortens the optimal interval of repetition of chemotherapy with cyclophosphamide in mice. Hattori K, et al. **In Vivo** 1996 May–Jun;10(3):361–8

Human brain tumor O(6)–methylguanine–DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. Mineura K, et al. **Int J Cancer** 1996 Oct 21;69(5):420–5

Thermal enhancement of the effect of ifosfamide against a spontaneous murine fibrosarcoma, FSa–II. Kuroda M, et al. **Int J Hyperthermia** 1997 Jan–Feb;13(1):125–31

Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks. Foster BJ, et al. **Invest New Drugs** 1996;13(4):321–6

A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study. Geyer JR, et al. **Invest New Drugs** 1996;13(4):337–42

Chlorambucil is an effective corticosteroid–sparing agent for recalcitrant pyoderma gangrenosum. Burruss JB, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):720–4

Faranoxi–a new antitumor agent. Breivis P, et al. **J Chemother** 1996 Feb;8(1):67–9

The use of recombinant human granulocyte colony–stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma. Erkisi M, et al. **J Chemother** 1996 Jun;8(3):224–8

Comparison in low–tumor–burden follicular lymphomas between an initial no–treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Brice P, et al. **J Clin Oncol** 1997 Mar;15(3):1110–7

Isolated limb perfusion with high–dose tumor necrosis factor–alpha in combination with interferon–gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial [see comments] Eggermont AM, et al. **J Clin Oncol** 1996 Oct;14(10):2653–65. Comment in: J Clin Oncol 1996 Oct;14(10):2627–30. Comment in: J Clin Oncol 1997 May;15(5):2174–5.

Phase I clinical trial of melphalan and 41.8 degrees C whole–body hyperthermia in cancer patients. Robins HI, et al. **J Clin Oncol** 1997 Jan;15(1):158–64

Progenitor–cell mobilization after low–dose cyclophosphamide and granulocyte colony–stimulating factor: an analysis of progenitor–cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. Watts MJ, et al. **J Clin Oncol** 1997 Feb;15(2):535–46

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. Witte RS, et al. **J Clin Oncol** 1997 Feb;15(2):589–93

Neoplastic chemotherapy and head and neck cancer [editorial] Jones AS. **J Laryngol Otol** 1997 Jul; 111(7):607–10 (29 ref.)

Treatment of recurrent malignant glioma with BCNU–fluosol and oxygen inhalation. A phase I–II study. Hochberg F, et al. **J Neurooncol** 1997 Mar;32(1):45–55

Apoptosis and proliferation (PCNA labelling) in CML—a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy. Thiele J, et al. **J Pathol** 1997 Mar;181(3):316–22

Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long–term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. Kurth K, et al. **J Urol** 1997 Aug;158(2):378–84

Salvage treatment after failure or relapse following initial chemotherapy for follicular non–Hodgkin's lymphoma. Davidge–Pitts M, et al. **Leuk Lymphoma** 1997 Jan; 24(3–4):341–7

Current aspects of drug therapy in Philadelphia–positive CML: correlation of tumor burden with survival. Hehlmann R, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:161–7 (42 ref.)

Why do drugs work in CLL? Plunkett W, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:1–11 (75 ref.)

Effect of radiotherapy and chemotherapy on composition of tumor membrane phospholipids. Street JC, et al. **Lipids** 1997 Jan;32(1):45–9

Two dose levels of ifosfamide in malignant mesothelioma [see comments] Içli F, et al. **Lung Cancer** 1996 Sep; 15(2):207–13. Comment in: Lung Cancer 1996 Dec;16(1):101–2.

Studies concerning high dose ifosfamide to patients suffering from malignant mesothelioma [letter; comment] Krarup–Hansen A. **Lung Cancer** 1996 Dec;16(1):101–2. Comment on: Lung Cancer 1996 Sep;15(2):207–13.

Renal function in cancer patients treated with hyperthermic isolated limb perfusion with recombinant tumor necrosis factor–alpha and melphalan. Zwaveling JH, et al. **Nephron** 1997;76(2):146–52

Palliative chemotherapy in non–Hodgkin's lymphoma. Salminen E, et al. **Oncology** 1997 Mar–Apr;54(2):108–11

The use of cytotoxic agents in the treatment of immune–mediated diseases of dogs and cats. Miller E. **Semin Vet Med Surg (Small Anim)** 1997 Aug;12(3):157–60 (22 ref.)

Oral dolasetron mesilate (MDL 73,147EF) for the control of emesis during fractionated total–body irradiation and high–dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation. Fauser AA, et al. **Support Care Cancer** 1997 May;5(3):219–22

Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte–colony–stimulating factor: an analysis of 497 patients. Weaver CH, et al. **Transfusion** 1997 Sep; 37(9):896–903

[Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs] Abu–Abid S, et al. **Harefuah** 1996 Oct;131(7–8):227–32, 296, 295 (Eng. Abstr.) **(Heb)**

[T–cell large granular lymphocytic leukemia associated with pure red cell aplasia, successfully treated with cyclophosphamide] Mátrai Z, et al. **Orv Hetil** 1997 Aug 17;138(33):2075–80 (45 ref.) (Eng. Abstr.) **(Hun)**

ANTINEOPLASTIC AGENTS, ALKYLATING

[Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma] Fujiki T, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):569–72 (Eng. Abstr.) **(Jpn)**

[Modulation of the antitumor effect of cyclophosphamide by the recombinant probiotic Subalin] Cherdyntseva NV, et al. **Vopr Onkol** 1997;43(3):313–6 (Eng. Abstr.) **(Rus)**

[Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan] Armenta D, et al. **Sangre (Barc)** 1996 Dec;41(6):465–7 (Eng. Abstr.) **(Spa)**

TOXICITY

Selective assay of the cytosolic forms of the aldehyde dehydrogenase in rat, with possible significance for the investigations of cyclophosphamide cytotoxicity. Wierzchowski J, et al. **Acta Pol Pharm** 1996 May–Jun; 53(3):203–8

Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol. Rekha GK, et al. **Adv Exp Med Biol** 1997;414:133–46

m-N-N-bis(2-chloroethyl)aminocinnamic acid and four new homo-aza-steroidal esters induce chromosomal abnormalities and affect protein synthesis in human lymphocytes in vitro. Psaraki K, et al. **Anticancer Drugs** 1997 Jan;8(1):73–9

Stimulation of neutropoiesis by a special standardized mistletoe preparation after cyclophosphamide chemotherapy in mice. Weber K, et al. **Arzneimittelforschung** 1996 Dec;46(12):1174–8

Induction of apoptosis in the germ cells of adult male rats after exposure to cyclophosphamide. Cai L, et al. **Biol Reprod** 1997 Jun;56(6):1490–7

Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. Borel Rinkes IH, et al. **Br J Cancer** 1997;75(10):1447–53

Interleukin-4 prevents spontaneous in-vitro apoptosis in chronic lymphatic leukaemia but sensitizes B-CLL cells to melphalan cytotoxicity. Pu QQ, et al. **Br J Haematol** 1997 Aug;98(2):413–7

Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells. Volpe DA, et al. **Cancer Chemother Pharmacol** 1996; 39(1-2):143–9

Keratinocyte growth factor ameliorates cyclophosphamide-induced ulcerative hemorrhagic cystitis. Ulich TR, et al. **Cancer Res** 1997 Feb 1;57(3):472–5

Teratogenic effects of chlormetine hydrochloride in rats. Anasiewicz A. **Folia Morphol (Warsz)** 1996;55(4):197–9

Protection of mammalian cells against chloroethylating agent toxicity by an O6-benzylguanine-resistant mutant of human O6-alkylguanine-DNA alkyltransferase. Hickson I, et al. **Gene Ther** 1996 Oct;3(10):868–77

A quantitative structure-activity relationship study on DNA-directed alkylating agents. Gupta SP, et al. **Indian J Biochem Biophys** 1996 Jun;33(3):234–6

O6-(alkyl/aralkyl)guanosine and 2'-deoxyguanosine derivatives: synthesis and ability to enhance chloroethylnitrosourea antitumor action. Mounetou E, et al. **J Med Chem** 1997 Aug 29;40(18):2902–9

Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice: reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning. Szebeni J, et al. **Leukemia** 1997 Oct; 11(10):1769–74

Chlorambucil-induced structural changes in the gpt gene of AS52 cells. Honma M, et al. **Mutat Res** 1997 Mar 17; 389(2-3):199–205

The inhibitory effect of cyclophosphamide on camel retina acetylcholinesterase activity. al-Khwyter F, et al. **Toxicol Lett** 1996 Oct;87(2-3):69–76

Character of structural disturbances caused by chloroalkylamines in the model and erythrocyte membranes. Lebed OI, et al. **Ukr Biokhim Zh** 1996 Nov-Dec;68(6):68–76

[Pathophysiological effects of combined exposure to emotional stress and cyclophosphamide] Ingel' FI, et al. **Biull Eksp Biol Med** 1997 May;123(5):506–9 **(Rus)**

URINE

Chromatographic analysis of the enantiomers of ifosfamide and some of its metabolites in plasma and urine. Kaijser GP, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7; 690(1-2):131–8

ANTINEOPLASTIC AGENTS, COMBINED

Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. Baldini E, et al. **Ann Oncol** 1996 Sep;7(7):747–9

Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.). Gridelli C, et al. **Ann Oncol** 1996 Oct;7(8):821–6

Combination chemotherapy for advanced bilharzial bladder carcinoma. Khaled HM, et al. **Ann Oncol** 1996 Sep; 7(7):751–4

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Legha SS, et al. **Ann Oncol** 1996 Oct; 7(8):827–35

A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. Wrigley E, et al. **Ann Oncol** 1996 Sep;7(7):705–11

The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma. Kawai A, et al. **Arch Orthop Trauma Surg** 1996;115(2):68–70

Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Stamatoullas A, et al. **Bone Marrow Transplant** 1997 Jan;19(1):31–5

A pilot study of cryochemotherapy for hepatic metastases from colorectal cancer. Rodríguez-Bigas MA, et al. **Cryobiology** 1996 Dec;33(6):600–6

Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. Mastrangelo R, et al. **J Neurooncol** 1997 Jan;31(1-2):153–8

Docetaxel in breast cancer and a rationale for combination therapy. Hortobágyi G. **Oncology (Huntingt)** 1997 Jun;11(6 Suppl 6):11–5 (21 ref.)

5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone. du Bois A, et al. **Support Care Cancer** 1996 Sep; 4(5):384–9

ADMINISTRATION & DOSAGE

First results of a clinical pilot study on intraarterial chemotherapy with haemofiltration of locally advanced gastrointestinal cancers. Taton G, et al. **Acta Chir Belg** 1996 Sep-Oct;96(5):206–10

High-dose chemotherapy with autologous stem cell support for the treatment of advanced ovarian cancer--initial experience in Uppsala and Turku. Grenman S, et al. **Acta Obstet Gynecol Scand** 1997 Apr;76(4):363–8 (31 ref.)

High-dose chemotherapy and autologous blood stem cell transplantation in children with metastatic neuroblastoma. Kai T, et al. **Acta Paediatr Jpn** 1997 Feb;39(1):54–60

Modulation of all-trans-retinoic acid administered on intermittent schedule by alpha-interferon 2a in a patient with AIDS-related Kaposi's sarcoma [letter] Toma S, et al. **AIDS** 1996 Aug;10(9):1049–50

Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: a novel approach. Manoharan A, et al. **Am J Hematol** 1997 Jun;55(2):115–7

Pure red-cell aplasia requiring cytotoxic chemotherapy: presence of clonal T-lymphocytes without characteristics of chronic lymphocytic leukemia [letter] Nezu M, et al. **Am J Hematol** 1996 Oct;53(2):145–7

Intraperitoneal chemotherapy in the treatment of ovarian cancer. Markman M. **Ann Med** 1996 Aug;28(4):293–6 (19 ref.)

Dose intensity in patients with metastatic breast cancer--time for novel thoughts? [editorial; comment] Bergh J. **Ann Oncol** 1997 Feb;8(2):109–10. Comment on: Ann Oncol 1997 Feb;8(2):155–62.

A better therapeutic profile for the combination of mitomycin-C, ifosfamide and cisplatin (MIC) in advanced non-small-cell lung cancer: a useful dose-schedule modification. Crinò L, et al. **Ann Oncol** 1997 Jul; 8(7):709–11

High-dose chemotherapy in germ-cell tumors. Droz JP, et al. **Ann Oncol** 1996 Dec;7(10):997–1003 (65 ref.)

Dose escalation of high-dose cyclophosphamide and etoposide with high-dose doxorubicin (CDE) and filgrastim for poor-risk non-Hodgkin's lymphoma. Juliusson G, et al. **Ann Oncol** 1996 Dec;7(10):1037–41

Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Pagani O, et al. **Ann Oncol** 1997 Jul;8(7):655–61

Economic impact with home delivery of chemotherapy to pediatric oncology patients. Holdsworth MT, et al. **Ann Pharmacother** 1997 Feb;31(2):140–8

Continuous infusional 5-fluorouracil chemotherapy [letter] Olthoff KM, et al. **Ann Surg** 1996 Nov;224(5):686

Antiemetic treatment with two different doses of methylprednisolone in breast cancer patients: a double-blind randomized cross-over study with evaluation of efficacy parameters. Havsteen H, et al. **Anticancer Drugs** 1996 Jul;7(5):535–42

Treatment of multiple lesions of Bowen disease with isotretinoin and interferon alfa. Efficacy of combination chemotherapy. Gordon KB, et al. **Arch Dermatol** 1997 Jun; 133(6):691–3

The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Hu YJ, et al. **Biol Trace Elem Res** 1997 Mar; 56(3):331–41

Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. Somlo G, et al. **Blood** 1997 Mar 1;89(5):1521–8

3'-Azido 3'-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas. Tosi P, et al. **Blood** 1997 Jan 15;89(2):419–25

Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Weaver A, et al. **Blood** 1996 Nov 1;88(9):3323–8

Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Zinzani PL, et al. **Blood** 1997 Jun 1; 89(11):3974–9

Prognosis after high-dose chemotherapy in patients with germ cell tumors. Beyer J, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S61–2

Mobilization of peripheral stem cells with intensive chemotherapy (ICE regimen) and G-CSF in chronic myeloid leukemia. Boqué C, et al. **Bone Marrow Transplant** 1996 Nov;18(5):879–84

High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results. Cagnoni PJ, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S26–9 (25 ref.)

Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia. Copelan EA, et al. **Bone Marrow Transplant** 1996 Nov;18(5):907–11

High-dose chemotherapy and autologous stem cell transplantation in advanced epithelial ovarian cancer. Cure H, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S34–5

Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. de Magalhaes-Silverman M, et al. **Bone Marrow Transplant** 1997 Apr;19(8):777–81

Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Engelhardt M, et al. **Bone Marrow Transplant** 1997 Mar; 19(6):529–37

High-dose therapy for the treatment of breast cancer: evaluation of effect of regimen on outcome. Fields KK, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S30–3

A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma. Fontelonga A, et al. **Bone Marrow Transplant** 1997 May;19(10):983–8

Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Gisselbrecht C, et al. **Bone Marrow Transplant** 1996 Nov;18(5):857–63

High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells. Humblet Y, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S36–9

The ICE regimen (ifosfamide, carboplatin, etoposide) for the treatment of germ-cell tumors and metastatic trophoblastic disease. Lotz JP, et al. **Bone Marrow Transplant** 1996 Sep; 18 Suppl 1:S55–9

High-dose chemotherapy for germ cell tumors (GCT): Memorial Sloan Kettering Cancer Center. Motzer RJ. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S53–4

Polychemotherapy combined with G-CSF-mobilized donor buffy coat transfusion for granulocytic sarcoma after allogeneic BMT for AML. Nachbaur D, et al. **Bone Marrow Transplant** 1997 May;19(9):947–9

Early utilization of high-dose chemotherapy in germ cell tumors. Nichols CR. **Bone Marrow Transplant** 1996 Sep; 18 Suppl 1:S50–2

Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. Palumbo A, et al. **Bone Marrow Transplant** 1997 Jan; 19(1):23–9

Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: an EBMT study. Perey L, et al. **Bone Marrow Transplant** 1996 Sep; 18 Suppl 1:S40–3

High-dose chemotherapy as salvage treatment for germ cell tumors. The ongoing IT94 study. Pico JL, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S63–6 (31 ref.)

Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure. Rebibou JM, et al. **Bone Marrow Transplant** 1997 Jul;20(1):63–5

High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland. Regazzoni S, et al. **Bone Marrow Transplant** 1997 Jan;19(1):3–7

Sequential intermediate high-dose chemotherapy in the primary treatment of poor risk testicular cancer. Schmoll HJ, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S48–9

High-dose chemotherapy and ASCR of patients with relapsed or refractory germ cell tumors: long-term follow-up. Siegert W, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S60

Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Stamatoullas A, et al. **Bone Marrow Transplant** 1997 Jan;19(1):31–5

Treatment intensification which includes high-dose induction improves survival of lung carcinoma patients treated by high-dose chemotherapy with hematopoietic progenitor cell rescue but does not prevent high rate of relapses. Tomeczko J, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S44-7

High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer. Viens P, et al. **Bone Marrow Transplant** 1997 Aug;20(3):199-203

Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Weaver CH, et al. **Bone Marrow Transplant** 1997 Apr;19(7):661-70

High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease. Weaver CH, et al. **Bone Marrow Transplant** 1996 May;17(5):715-21

High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study. Zander AR, et al. **Bone Marrow Transplant** 1996 Sep;18 Suppl 1:S24-5

Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer. Ardizzoni A, et al. **Br J Cancer** 1996 Oct;74(7):1141-7

High-dose chemotherapy of metastatic breast cancer: the end of the beginning? [editorial] Crown J. **Br J Cancer** 1997; 75(4):467-9

Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. Kuppen PJ, et al. **Br J Cancer** 1997; 75(10):1497-500

Anatomical basis of intra-arterial chemotherapy for patients with locally advanced breast cancer. Doughty JC, et al. **Br J Surg** 1996 Aug;83(8):1128-30

Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. Zambetti M, et al. **Breast Cancer Res Treat** 1997 Jul;44(3):255-60

Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Berg J, et al. **Cancer** 1997 Apr 1;79(7):1343-50

Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Beyer J, et al. **Cancer** 1997 Jan 1;79(1):161-8

Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Broun ER, et al. **Cancer** 1997 Apr 15; 79(8):1605-10

High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Kern W, et al. **Cancer** 1997 Jan 1;79(1):59-68

A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue. Schwartz GK, et al. **Cancer** 1996 Nov 1;78(9):1988-95

High-dose chemotherapy with hematopoietic rescue in breast cancer: from theory to practice. Bezwoda WR. **Cancer Chemother Pharmacol** 1997;40 Suppl:S79-87 (33 ref.)

Dose-intensive therapy in lung cancer. Elias A. **Cancer Chemother Pharmacol** 1997;40 Suppl:S64-9 (78 ref.)

A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer. Mori K, et al. **Cancer Chemother Pharmacol** 1997;39(4):327-32

Importance of dose and dose intensity in the treatment of small-cell lung cancer. Murray N. **Cancer Chemother Pharmacol** 1997;40 Suppl:S58-63 (18 ref.)

Dose-intensive chemotherapy in extensive-stage small-cell lung cancer. Negoro S, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S70-3

New concepts in the treatment of breast cancer using high-dose chemotherapy. Peters WP, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S88-93 (09 ref.)

Chemotherapy: the more the better? Overview. Saijo N. **Cancer Chemother Pharmacol** 1997;40 Suppl:S100-6 (46 ref.)

Chemotherapy for small-cell lung cancer: more is not better. Saka H, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S107-9 (21 ref.)

Chemotherapy: the more, the better in malignant lymphoma? Tobinai K. **Cancer Chemother Pharmacol** 1997;40 Suppl:S110-4 (25 ref.)

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in breast cancer. Tokuda Y, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S94-9

Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer. Venturini M, et al. **Cancer Chemother Pharmacol** 1996;38(6):487-94

Infusional chemotherapy for non-Hodgkin's lymphoma. Molldrem J, et al. **Cancer Invest** 1997;15(5):465-74 (65 ref.)

Intraperitoneal 5-fluorouracil and mitomycin C as adjuvants to resectable gastric cancer: a status report. Yu W. **Cancer Treat Res** 1996;81:177-83

Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Jaeger HJ, et al. **Cardiovasc Intervent Radiol** 1996 Nov-Dec;19(6):388-96 (32 ref.)

A phase I-II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Bolis G, et al. **Eur J Cancer** 1997 Apr;33(4):592-5

Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma. Colleoni M, et al. **Eur J Cancer** 1997 Jan; 33(1):56-60

Rhabdomyolysis and renal function impairment after isolated limb perfusion--comparison between the effects of perfusion with rhTNF alpha and a 'triple-drug' regimen. Hohenberger P, et al. **Eur J Cancer** 1997 Apr;33(4):596-601

Intraperitoneal cisplatin--mitoxantrone in ovarian cancer patients with minimal residual disease. Topuz E, et al. **Eur J Gynaecol Oncol** 1997;18(1):71-5

CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology). Montserrat E, et al. **Eur J Haematol** 1996 Nov;57(5):377-83

The case for high-dose adjuvant chemotherapy in breast cancer: (II) clinical experience. Cameron DA, et al. **Eur J Surg Oncol** 1996 Dec;22(6):634-7 (47 ref.)

Dose intensification and breast cancer. Khayat D, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:153-77 (130 ref.)

Combination of high-dose chemotherapy, autologous bone marrow/peripheral blood stem cell transplantation, and thoracoscopic surgery in refractory nongestational choriocarcinoma of a 45XO/46XY female: a case report. Chou HH, et al. **Gynecol Oncol** 1997 Mar;64(3):521-5

Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin). Muggia FM, et al. **Gynecol Oncol** 1997 Aug;66(2):290-4

A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group. Smith GM, et al. **Hematol Oncol** 1996 Dec;14(4):193-201

Multidisciplinary management of hepatocellular carcinoma. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 Nov-Dec;43(12):1611-9

Pancreatic head carcinoma: is pancreatic resection indicated for patients with stage III pancreatic duct cancer?. Lygidakis NJ, et al. **Hepatogastroenterology** 1995 Sep-Oct; 42(5):587-96

Histological analysis of hepatocellular carcinoma treated by intraarterial combined immunochemotherapy. Oka M, et al. **Hepatogastroenterology** 1995 Sep-Oct;42(5):561-6

Locoregional immuno-chemotherapy in liver carcinoma--present and future. Okuno K, et al. **Hepatogastroenterology** 1995 Sep-Oct;42(5):578-86 (38 ref.)

Optimal locoregional immunochemotherapy after tumor-mass reduction for advanced hepatocellular carcinoma. Yamamoto M, et al. **Hepatogastroenterology** 1995 Sep-Oct;42(5):567-77 (35 ref.)

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity. Hibi H, et al. **Hinyokika Kiyo** 1997 Feb;43(2):89-96

Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability. Caird LE, et al. **Hum Reprod** 1997 Mar; 12(3):436-40

Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells. Batra S, et al. **Int J Cancer** 1996 Nov 27;68(5):644-9

Recovery of leukocyte function after super-high-dose chemotherapy with peripheral blood stem cell transplantation in testicular cancer patients. Yamada Y, et al. **Int J Cancer** 1997 Jul 3;72(1):39-42

Advanced epidemic Kaposi's sarcoma: treatment with bleomycin or combination of doxorubicin, bleomycin, and vincristine. Hernández DE, et al. **Int J Dermatol** 1996 Nov; 35(11):831-3

Treatment outcome of AT-B88 regimen for B-cell non-Hodgkin's lymphoma and surface immunoglobulin-positive acute lymphoblastic leukemia in children. Horibe K, et al. **Int J Hematol** 1997 Jul; 66(1):89-98

Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children. Nagatoshi Y, et al. **Int J Hematol** 1997 Apr;65(3):269-75

Preliminary results of concurrent methotrexate, cisplatin and radiation treatment for locally advanced urothelial cancers. Igawa M, et al. **Int Urol Nephrol** 1996;28(2):189-94

Transurethral resection and intra-arterial chemotherapy for muscle-invasive bladder cancer. Kondás J, et al. **Int Urol Nephrol** 1996;28(2):181-7

Combination chemotherapy for malignant paraganglioma. Kimura S, et al. **Intern Med** 1997 Jan;36(1):35-9 (21 ref.)

Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. Bolis G, et al. **J Clin Oncol** 1997 May;15(5):1938-44

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. Conte PF, et al. **J Clin Oncol** 1997 Jul;15(7):2510-7

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. de Gramont A, et al. **J Clin Oncol** 1997 Feb;15(2):808-15

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. Holmes FA, et al. **J Clin Oncol** 1996 Oct; 14(10):2713-21

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. Huizing MT, et al. **J Clin Oncol** 1997 May;15(5):1953-64

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. Jakobsen A, et al. **J Clin Oncol** 1997 Jan;15(1):193-8

Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer. Lalisang RI, et al. **J Clin Oncol** 1997 Apr;15(4):1367-76

High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results [see comments] Legros M, et al. **J Clin Oncol** 1997 Apr;15(4):1302-8. Comment in: J Clin Oncol 1997 Apr;15(4):1291-3.

Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. Lemmers NW, et al. **J Clin Oncol** 1996 Nov;14(11):2916-22

Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. Meisenberg BR, et al. **J Clin Oncol** 1997 Jan; 15(1):11-7

Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Murren JR, et al. **J Clin Oncol** 1997 Jan;15(1):148-57

Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. Seiter K, et al. **J Clin Oncol** 1997 Jan;15(1):44-51

High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients [see comments] Stiff PJ, et al. **J Clin Oncol** 1997 Apr; 15(4):1309-17. Comment in: J Clin Oncol 1997 Apr;15(4):1291-3.

Dose-intensity in ovarian carcinoma: hold, enough? [editorial; comment] Thigpen JT. **J Clin Oncol** 1997 Apr; 15(4):1291-3. Comment on: J Clin Oncol 1997 Apr;15(4):1302-8. Comment on: J Clin Oncol 1997 Apr;15(4):1309-17.

Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. Tricot G, et al. **J Clin Oncol** 1997 Jul;15(7):2659-66

Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia [see comments] Winick N, et al. **J Clin Oncol** 1996 Oct;14(10):2803-11. Comment in: J Clin Oncol 1997 Aug;15(8):3024-6.

Continuous hyperthermic peritoneal perfusion for peritoneal carcinomatosis. Chung YC, et al. **J Formos Med Assoc** 1996 Feb;95(2):138-43

Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancer. Hebbar M, et al. **J Infus Chemother** 1995 Fall;5(4):201-5

Randomized trial comparing two different modalities of administration of the same cytotoxic drugs in metastatic breast cancer. Pierga JY, et al. **J Infus Chemother** 1995 Fall;5(4):197-200

Protracted infusional chemotherapy in breast cancer: the Royal Marsden Hospital experience. Smith IE. **J Infus Chemother** 1995 Fall;5(4):206-7

PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas. Dent S, et al. **J Neurooncol** 1996 Apr; 28(1):25-30

Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG Phase II study. Alvarado CS, et al. **J Pediatr Hematol Oncol** 1997 Jan-Feb;19(1):62-7

A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. Arndt C, et al. **J Pediatr Hematol Oncol** 1997 Mar-Apr;19(2):124-9

Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study. Bernstein ML, et al. **J Pediatr Hematol Oncol** 1997 Jan-Feb;19(1):68-72

Wilms' tumor treated with chemotherapy in a patient with a solitary kidney. Iñón AE, et al. **J Pediatr Surg** 1996 Sep; 31(9):1305-7

Mediastinal yolk sac tumor in a young girl: case report and

review of the literature. Uchiyama M, et al. **J Pediatr Surg** 1996 Sep;31(9):1318–21 (25 ref.)

Postsurgical sequential methotrexate, fluorouracil, and leucovorin for advanced colorectal carcinoma: a preliminary study. Tokunaga Y, et al. **J Surg Oncol** 1997 Sep;66(1):45–50

Dose–escalation study of oral etoposide and carboplatin in patients with advanced lung cancer. Atagi S, et al. **Jpn J Clin Oncol** 1996 Oct;26(5):316–21

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lévi F, et al. **Lancet** 1997 Sep 6; 350(9079):681–6

Philadelphia chromosome–positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts. Ribeiro RC, et al. **Leukemia** 1997 Sep;11(9):1493–6

Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Sonneveld P, et al. **Leukemia** 1996 Nov;10(11):1741–50

Home chemotherapy for cancer patients: cost analysis and safety [letter; comment] van Hazel G. **Med J Aust** 1997 Jan 20;166(2):110. Comment on: Med J Aust 1996 Aug 19;165(4):184–7.

Accidental intramuscular vincristine: lack of untoward effects and recommendations for management. Clark BS, et al. **Med Pediatr Oncol** 1997 Apr;28(4):314–5

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [see comments] Alberts DS, et al. **N Engl J Med** 1996 Dec 26;335(26):1950–5. Comment in: N Engl J Med 1997 Jun 5;336(23):1674; discussion 1675. Comment in: N Engl J Med 1997 Jun 5;336(23):1675.

High–dose chemotherapy in multiple myeloma [letter; comment] Atkins CD. **N Engl J Med** 1996 Dec 12; 335(24):1844; discussion 1845. Comment on: N Engl J Med 1996 Jul 11;335(2):91–7.

High–dose chemotherapy and autologous bone marrow transplantation compared with MACOP–B in aggressive B–cell lymphoma [see comments] Gianni AM, et al. **N Engl J Med** 1997 May 1;336(18):1290–7. Comment in: N Engl J Med 1997 Sep 4;337(10):711; discussion 711–2.

Low–dose compared with standard–dose m–BACOD chemotherapy for non–Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Kaplan LD, et al. **N Engl J Med** 1997 Jun 5;336(23):1641–8

Autologous bone marrow transplantation versus MACOP–B in B–cell lymphoma [letter; comment] Martins RG, et al. **N Engl J Med** 1997 Sep 4;337(10):711; discussion 711–2. Comment on: N Engl J Med 1997 May 1;336(18):1290–7.

Autologous bone marrow transplantation versus MACOP–B in B–cell lymphoma [letter; comment] Mok TS. **N Engl J Med** 1997 Sep 4;337(10):711; discussion 711–2. Comment on: N Engl J Med 1997 May 1;336(18):1290–7.

High–dose chemotherapy in multiple myeloma [letter; comment] Oivanen TM, et al. **N Engl J Med** 1996 Dec 12;335(24):1844–5; discussion 1845. Comment on: N Engl J Med 1996 Jul 11;335(2):91–7.

Chemotherapy for AIDS–related lymphomas [letter] Sparano J. **N Engl J Med** 1997 Oct 16;337(16):1173; discussion 1173–4

Chemotherapy for AIDS–related lymphomas [letter] Wilson WH. **N Engl J Med** 1997 Oct 16;337(16):1172–3; discussion 1173–4

Expression of 65–kDa oncofetal protein in experimental hepatoma after anticancer therapy. Mirowski M, et al. **Neoplasma** 1997;44(2):85–9

Phase I/II trial of carboplatin dose escalation in combination chemotherapy with etoposide, bleomycin and GM–CSF support for poor prognosis nonseminomatous germ cell tumors patients. Tjulandin SA, et al. **Neoplasma** 1996; 43(5):347–52

Magnetic resonance ventriculography with gadolinium DTPA: report of two cases. Siebner HR, et al. **Neuroradiology** 1997 Jun;39(6):418–22; discussion 422

A randomized phase II trial of two different schedules of mitomycin C and vinorelbine in pretreated breast cancer [letter] Colleoni M, et al. **Oncology** 1997 Sep–Oct; 54(5):438–9

Weekly CAF chemotherapy for advanced breast cancer patients. Hwang WS, et al. **Oncology** 1997 Jul–Aug; 54(4):293–7

Growth factor allows effective dose–intensive regimen in advanced breast cancer patients [news] **Oncology (Huntingt)** 1995 Jul;9(7):684

Docetaxel in combination with doxorubicin: a phase I dose–finding study. Diéras V. **Oncology (Huntingt)** 1997 Jun;11(6 Suppl 6):17–20

Docetaxel combined with vinorelbine: phase I results and new study designs. Fumoleau P, et al. **Oncology (Huntingt)** 1997 Jun;11(6 Suppl 6):29–31

Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer. Nabholtz JM, et al. **Oncology (Huntingt)** 1997 Jun;11(6 Suppl 6):25–7

Docetaxel in combination with fluorouracil: study design and preliminary results. Rowinsky E, et al. **Oncology (Huntingt)** 1997 Jun;11(6 Suppl 6):33–5

Docetaxel and cyclophosphamide in patients with advanced solid tumors. Valero V. **Oncology (Huntingt)** 1997 Jun;11(6 Suppl 6):21–3

Chemoradiotherapy in non–small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease. Belani CP, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):113–6

Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive–stage small cell lung cancer: a University of Colorado Cancer Center study. Bunn PA Jr, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):11–5

Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced–stage hepatocellular carcinoma: interim analysis. Carr BI, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6–97–S6–99

Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer. Greco FA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):7–10

Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer. Hortobagyi GN, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 3):S4–7 (20 ref.)

Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a phase I study. Keren–Rosenberg S, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 3):S26–9

Combination paclitaxel (1–hour) and carboplatin (AUC 7.5) in advanced non–small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network. Langer CJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):35–41

Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non–small cell lung cancer. Natale RB. **Semin Oncol** 1996 Dec;23(6 Suppl 16):51–4

Phase I studies of gemcitabine combined with carboplatin or paclitaxel. Pedersen AG. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7–64–S7–68

Gemcitabine and etoposide in small cell lung cancer: phase I and II trials. Rassmann I, et al. **Semin Oncol** 1997 Apr; 24(2 Suppl 7):S7–75–S7–78

Phase I dose–escalation trial of paclitaxel and ifosfamide in patients with advanced non–small cell lung cancer. Shepherd FA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):84–90

Hepatic arterial infusion chemotherapy combined with hyperthermia for metastatic liver tumors of colorectal cancer. Sugiyama A, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6–135–S6–138

High–dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow. Brockstein BE, et al. **Stem Cells** 1996 Jan;14(1):79–89 (71 ref.)

Fibrinolytic and coagulant responses to regional limb perfusions of tumor necrosis factor, interferon–gamma, and/or melphalan. Merryman P, et al. **Thromb Haemost** 1997 Jan;77(1):53–6

Augmented procoagulant activity in cancer patients, treated with recombinant interferon–gamma in addition to recombinant tumor necrosis factor–alpha and melphalan. Mulder AB, et al. **Thromb Haemost** 1996 Dec;76(6):897–901

Decrease in Thy–1 expression on peripheral CD34 positive cells induced by G–CSF mobilization. The Tohoku Children Leukemia Study Group. Tsuchiya S, et al. **Tohoku J Exp Med** 1997 Jun;182(2):157–62

Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer. Vaglini M, et al. **Tumori** 1996 Sep–Oct;82(5):459–62

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Higano CS, et al. **Urology** 1996 Nov;48(5):800–4

A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Pienta KJ, et al. **Urology** 1997 Sep;50(3):401–6; discussion 406–7

The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ–cell tumors. Bokemeyer C, et al. **World J Urol** 1996;14(6):354–9 (37 ref.)

[Regional chemotherapy of liver tumors] Zaloudík J, et al. **Vnitr Lek** 1997 Mar;43(3):171–2 (Eng. Abstr.) **(Cze)**

[Cytokines in regional immunochemotherapy of liver tumors] Zaloudík J, et al. **Vnitr Lek** 1997 Mar;43(3):173–6 (Eng. Abstr.) **(Cze)**

[Chemotherapy and immunotherapy of metastatic malignant melanomas] Benhammouda A, et al. **Presse Med** 1996 Nov 16;25(35):1690–7 (80 ref.) (Eng. Abstr.) **(Fre)**

[Chemotherapy of colorectal cancers with metastases] de Gramont A, et al. **Presse Med** 1996 Nov 16;25(35):1678–82 (33 ref.) (Eng. Abstr.) **(Fre)**

[Small–cell lung cancer: chemotherapy strategy] Lebeau B. **Presse Med** 1996 Nov 16;25(35):1705–8 (31 ref.) (Eng. Abstr.) **(Fre)**

[Results of isolated hyperthermic extremity perfusion in soft tissue sarcomas within the scope of a multimodality treatment concept (see comments)] Schwarzbach M, et al. **Chirurg** 1996 Dec;67(12):1237–43 (Eng. Abstr.). Comment in: Chirurg 1997 Jun;68(6):649. **(Ger)**

[Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma] Kettelhack C, et al. **Dtsch Med Wochenschr** 1997 Feb 14;122(7):177–81 (Eng. Abstr.) **(Ger)**

[Significance of cytostatic drug dose in adjuvant chemotherapy of breast carcinoma] Thomssen C. **Geburtshilfe Frauenheilkd** 1996 Jul;56(7):M102–5 (20 ref.) **(Ger)**

[Combined intra–arterial locoregional and systemic treatment of nonresectable hepatic metastases of colorectal carcinoma] Cantore M, et al. **G Chir** 1997 Apr;18(4):235–9 (Eng. Abstr.) **(Ita)**

[Intra–arterial chemotherapy in locally advanced or recurrent breast neoplasms] Morandi C, et al. **Radiol Med (Torino)** 1996 Jul–Aug;92(1–2):101–4 (Eng. Abstr.) **(Ita)**

[High–dose chemotherapy and peripheral hemtopoietic cells (PBPC) in solid tumors] Rosti G, et al. **Tumori** 1996 Mar–Apr;82(2 Suppl):S19–22 (27 ref.) (Eng. Abstr.) **(Ita)**

[Low–dose cisplatin added to continuous infusion of 5–fluorouracil or oral administration of UFT for inoperable advanced or recurrent colorectal cancer] Asano M, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):55–60 (Eng. Abstr.) **(Jpn)**

[Inhibition of prostate cancer growth in nude mice by hormone and chemotherapy] Fujita K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1335–8 (Eng. Abstr.) **(Jpn)**

[The usefulness of fibrin glue spraying combined with CDDP for lung cancer] Ishihama H, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):981–5 (Eng. Abstr.) **(Jpn)**

[Arterial infusion chemotherapy for advanced gastric cancer by sequential MTX/5–FU] Kitamura M, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1464–6 (Eng. Abstr.) **(Jpn)**

[Liver resection in a case of multiple liver metastases of gastric cancer following hepatic arterial infusion chemotherapy] Kobayashi T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1321–4 (Eng. Abstr.) **(Jpn)**

[Continuous hepatic arterial infusion chemotherapy with low–dose CDDP plus 5–FU for liver metastases from colorectal carcinoma] Kohnoe S, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1429–32 (Eng. Abstr.) **(Jpn)**

[Antitumor effect of S–1 and cisplatin treatment against human gastric cancer xenografted in nude mice] Kondo K, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1103–8 (Eng. Abstr.) **(Jpn)**

[A case of advanced esophageal cancer successfully treated by concurrent use of radiotherapy and low–dose CDDP and continuous infusion of 5–FU] Miyaji N, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):601–4 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer that responded to long–term administration of low–dose 5'–DFUR] Miyoshi K, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):101–3 (Eng. Abstr.) **(Jpn)**

[Trial of home anti–cancer chemotherapy with infusion of 5–FU and low–dose cisplatin] Muto A, et al. **Gan To Kagaku Ryoho** 1996 Dec;23 Suppl 3:245–50 (Eng. Abstr.) **(Jpn)**

[Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's] Nakamura T, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):579–83 (Eng. Abstr.) **(Jpn)**

[Consecutive low–dose cisplatin–based chemotherapy for gynecologic malignancies] Shimizu Y. **Gan To Kagaku Ryoho** 1997 Feb;24(4):431–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[An elderly case whose residual malignant lymphoma was completely remitted by oral etoposide treatment using unusual dosing schedule] Soga T, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):361–4 (Eng. Abstr.) **(Jpn)**

[A case of giant hepatocellular carcinoma successfully treated by arterial administration of SMANCS] Yajima Y, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1325–9 (Eng. Abstr.) **(Jpn)**

[A case of recurrent gallbladder cancer with marked response to arterial infusion chemotherapy and transarterial embolization] Yokoyama M, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):97–9 (Eng. Abstr.) **(Jpn)**

[A case study of metastatic renal cell carcinoma in lungs showing complete response to continuous subcutaneous injection of interferon alpha and gamma] Kawata N, et al. **Hinyokika Kiyo** 1996 Jul;42(7):509–12 (Eng. Abstr.) **(Jpn)**

[Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti–neoplastic agents] Morimoto Y, et al. **Masui** 1996 Sep;45(9):1096–9 (Eng. Abstr.) **(Jpn)**

[Significance and problem of post–operative adjuvant chemotherapy for colorectal cancer] Kato T, et al. **Nippon Geka Gakkai Zasshi** 1997 Mar;98(3):396–402 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Bronchial arterial infusion therapy for lung metastases of urogenital tumors] Imada S, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jun;87(6):942–5 (Eng. Abstr.) **(Jpn)**

[Characterization of tumor infiltrating lymphocytes from patients with renal cell carcinoma—influence of combination therapy with interferon alpha and gamma] Yanagiya H, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Jun;87(6):928–36 (Eng. Abstr.) **(Jpn)**

[Effects and efficacy of preoperative administration of

cisplatin and 5-fluorouracil in excision of cancer of the thoracic esophagus] Aoyama N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Mar;44(3):354–5 **(Jpn)**

[Improvement in the surgical outcome in esophageal cancer by multidisciplinary treatment—evaluation of pre-operative combined administration of CDDP and 5FU] Watabe N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Mar;44(3):356–7 **(Jpn)**

[Case of embryonal cell carcinoma treated with massive dosages of therapeutic agents together with transplantation of autologous peripheral stem cells] Gokuma T, et al. **Nippon Naika Gakkai Zasshi** 1997 Feb 10;86(2):307–9 **(Jpn)**

[Toxicity and efficacy of chemotherapy dependent on circadian time of cytostatic drug administration] Zuchowska-Vogelgesang B, et al. **Przegl Lek** 1996; 53(12):870–3 (Eng. Abstr.) **(Pol)**

[The optimization of the infusion therapy procedure in patients with acute leukemias] Moiseev SI, et al. **Ter Arkh** 1996;68(10):41–4 (Eng. Abstr.) **(Rus)**

[Stimulating and protective effect of recombinant interleukin-1-beta (beta-leukin) on leukopoiesis in chemotherapy of malignant tumors] Gershanovich ML, et al. **Vopr Onkol** 1996;42(6):13–8 (Eng. Abstr.) **(Rus)**

[High-dosage chemotherapy in breast cancer (letter; comment)] Sola C, et al. **Med Clin (Barc)** 1997 Mar 15; 108(10):398–9. Comment on: Med Clin (Barc) 1996 Jun 8;107(2):56–8. **(Spa)**

ADVERSE EFFECTS

Pneumatosis cystoides intestinalis with pneumoperitoneum and pneumoretroperitoneum following chemotherapy. Kopp AF, et al. **Abdom Imaging** 1997 Jul–Aug;22(4):395–7

The sarcoidosis-lymphoma syndrome: acceleration of the cutaneous sarcoidosis during chemotherapy of the lymphoma [letter] Keohane SG, et al. **Acta Derm Venereol** 1996 May;76(3):251–3

Severe anal condylomata acuminata following high-dose chemotherapy and autologous hematopoietic stem cell transplantation: a case report. D'Hondt L, et al. **Acta Gastroenterol Belg** 1996 Oct–Dec;59(4):254–5

Follicular cell carcinoma of the thyroid in a child after bone marrow transplantation for acute lymphoblastic leukemia. Rovelli A, et al. **Acta Haematol** 1997;97(4):225–7

Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study. Sundström GM, et al. **Acta Oncol** 1997;36(2):229–30

Chemotherapy for AIDS-related malignancies does not increase HIV viraemia [letter] Rutschmann OT, et al. **AIDS** 1997 Jun;11(7):944–5

Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Demark-Wahnefried W, et al. **Am J Clin Nutr** 1997 May; 65(5):1495–501

Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles. Ciesielski-Carlucci C, et al. **Am J Clin Oncol** 1997 Aug; 20(4):373–5 (14 ref.)

Rheumatic symptoms following adjuvant therapy for breast cancer. Warner E, et al. **Am J Clin Oncol** 1997 Jun; 20(3):322–6

Disseminated aspergillosis after mobilization with intensive chemotherapy prior to autologous stem-cell transplant in chronic myeloid leukemia [letter] Ferrer F, et al. **Am J Hematol** 1997 Feb;54(2):170–1

Avascular necrosis of bone after adult acute lymphocytic leukemia treatment with methotrexate, vincristine, L-asparaginase, and dexamethasone (MOAD). Hui L, et al. **Am J Hematol** 1996 Jul;52(3):184–8

Secondary acute myelogenous leukemia following treatment with oral etoposide [letter] Katato K, et al. **Am J Hematol** 1996 Sep;53(1):54–5

Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone. Merouani A, et al. **Am J Nephrol** 1997; 17(1):53–8

Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research. **Ann Oncol** 1997 Jun; 8(6):561–7

Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease. Bossi G, et al. **Ann Oncol** 1997;8 Suppl 1:19–24

Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Cremin P, et al. **Ann Oncol** 1996 Sep;7(7):745–6

Two secondary malignancies following the successful treatment of a patient with acute lymphoblastic leukemia [letter] Garcia-Boyero R, et al. **Ann Oncol** 1996 Mar; 7(3):322–3

Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Gehl J, et al. **Ann Oncol** 1996 Sep;7(7):687–93

Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Koo WH, et al. **Ann Oncol** 1996 Jan; 7(1):71–4

Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Kumagai K, et al. **Ann Oncol** 1997;8 Suppl 1:107–9

Tumor lysis syndrome, case report and review of the literature [letter] [published erratum appears in Ann Oncol 1997 Apr;8(4):407] Masera G, et al. **Ann Oncol** 1997 Jan; 8(1):97

Adjuvant therapy for breast cancer and psychological distress [letter] Montgomery GH, et al. **Ann Oncol** 1996 Nov; 7(9):977–8

Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C. Raderer M, et al. **Ann Oncol** 1996 Nov;7(9):973–5

A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy. Wymenga AN, et al. **Ann Oncol** 1996 Jul;7(5):505–10

Treatment of extravasation of both doxorubicin and vincristine administration in a Y-site infusion. Comas D, et al. **Ann Pharmacother** 1996 Mar;30(3):244–6

CNF combination as adjuvant treatment in breast cancer patients is well tolerated. Hirvikoski PP, et al. **Anticancer Drugs** 1997 Apr;8(4):376–8

Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities. Pazdur R, et al. **Anticancer Drugs** 1996 Sep;7(7):728–33

Liver function tests and lidocaine metabolism (MEGX test) during i.v. CMF therapy in breast cancer. Rizzi V, et al. **Anticancer Drugs** 1996 Nov;7(8):846–50

Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. Hidalgo M, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1175–7

Antineoplastic chemotherapy, sweat, and the skin [editorial; comment] Horn TD. **Arch Dermatol** 1997 Jul;133(7):905–6 . Comment on: Arch Dermatol 1997 Jul;133(7):873–8.

Acute and painful erythema of the hands and feet. Acral erythema induced by chemotherapy. Revenga Arranz F, et al. **Arch Dermatol** 1997 Apr;133(4):499–500, 502–3

Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells [see comments] Valks R, et al. **Arch Dermatol** 1997 Jul;133(7):873–8. Comment in: Arch Dermatol 1997 Jul;133(7):905–6.

Nutritional state alterations in children with acute lymphoblastic leukemia during induction and consolidation of chemotherapy. Mejía-Arangure JM, et al. **Arch Med Res** 1997 Summer;28(2):273–9

Rhabdomyolysis in patients with acute lymphoblastic leukemia. Morales-Polanco M, et al. **Arch Med Res** 1997 Autumn;28(3):377–81

Effect of chemotherapy on thyroid hormone concentration in patients with malignant hematologic diseases. Nellen Hummel H, et al. **Arch Med Res** 1997 Summer;28(2):215–7

Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. van Leeuwen FE. **Baillieres Clin Haematol** 1996 Mar;9(1):57–85 (115 ref.)

Apparent stimulation of thrombopoesis with interleukin-3 (IL-3) in chemotherapy induced myelosuppression. Schweiger C, et al. **Biofactors** 1995–96;5(2):73–4

Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Mackall CL, et al. **Blood** 1997 May 15;89(10):3700–7

Growth after bone marrow transplantation in young children conditioned with chemotherapy alone. Adan L, et al. **Bone Marrow Transplant** 1997 Feb;19(3):253–6

An acute cerebellar syndrome following high-dose chemotherapy and a blood cell autotransplant. Barnard K, et al. **Bone Marrow Transplant** 1997 Jul;20(1):87–8

Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Dueñas-Gonzalez A, et al. **Bone Marrow Transplant** 1996 May;17(5):809–12

Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Fisher DC, et al. **Bone Marrow Transplant** 1996 Jul;18(1):193–8

Predictive factors affecting mobilization and peripheral blood stem cell (PBSC) collection using single apheresis (SA) for rescuing patients after high-dose chemotherapy (HD.CHE) in various malignancies. Koumakis G, et al. **Bone Marrow Transplant** 1996 Dec;18(6):1065–72

A prospective study of the effects of high-dose chemotherapy and bone marrow transplantation on sexual function in the first year after transplant. Marks DI, et al. **Bone Marrow Transplant** 1997 Apr;19(8):819–22

Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC). Meisenberg BR, et al. **Bone Marrow Transplant** 1996 Dec;18(6):1087–93

Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. Peters BG, et al. **Bone Marrow Transplant** 1996 Jul;18(1):93–102 (60 ref.)

Ocular toxicity following high dose chemotherapy and autologous transplant. Rubin P, et al. **Bone Marrow Transplant** 1996 Jul;18(1):253–6

Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. de Graaf H, et al. **Br J Cancer** 1997;76(7):943–5

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Hilkens PH, et al. **Br J Cancer** 1997;75(3):417–22

Impact of tumour burden on chemotherapy-induced nausea and vomiting. Hursti TJ, et al. **Br J Cancer** 1996 Oct; 74(7):1114–9

Gonadal atrophy as a cause of thymic hyperplasia after chemotherapy [letter] Sperandio P, et al. **Br J Cancer** 1996 Sep;74(6):991–2

Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Govindarajan R, et al. **Br J Haematol** 1996 Nov;95(2):349–53

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Strum SB, et al. **Br J Urol** 1997 Jun;79(6):933–41

Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Del Mastro L, et al. **Breast Cancer Res Treat** 1997 Apr;43(2):183–90 (43 ref.)

Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. Hirvikoski PP, et al. **Breast Cancer Res Treat** 1997 Jul;44(3):269–74

A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Rella C, et al. **Breast Cancer Res Treat** 1996;40(2):151–9

Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: a consensus. Osoba D, et al. **Can J Oncol** 1995 Sep;5(3):381–400

Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Dunphy FR, et al. **Cancer** 1997 Apr 15;79(8):1623–8

Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma. Hecht JR, et al. **Cancer** 1997 May 1; 79(9):1698–702

Irreversible gonadal damage in male survivors of pediatric Hodgkin's disease. Heikens J, et al. **Cancer** 1996 Nov 1; 78(9):2020–4

Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas. Kido Y, et al. **Cancer** 1996 Oct 15;78(8):1794–7

Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center. Ortega JA, et al. **Cancer** 1997 Jun 15;79(12):2435–9

Second malignant neoplasms occuring in survivors of osteosarcoma. Pratt CB, et al. **Cancer** 1997 Sep 1; 80(5):960–5

Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study. Sartori S, et al. **Cancer** 1996 Oct 1;78(7):1477–82

High-dose chemotherapy with hematopoietic rescue in breast cancer: from theory to practice. Bezwoda WR. **Cancer Chemother Pharmacol** 1997;40 Suppl:S79–87 (33 ref.)

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in breast cancer. Tokuda Y, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S94–9

Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. Beck TM, et al. **Cancer Invest** 1997;15(4):297–303

GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study. Hicks LG, et al. **Cancer Invest** 1996; 14(6):507–12

Reduced systemic toxicity from superselective chemoembolization compared with systemic chemotherapy in patients with high-risk metastatic gestational trophoblastic disease. Lang EK. **Cardiovasc Intervent Radiol** 1997 Jul–Aug;20(4):280–4

Stent thrombosis in a patient receiving chemotherapy. Smith SC, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):383–6 (24 ref.)

Toxicity of chemotherapy for esophageal carcinoma. Ilson D. **Chest Surg Clin N Am** 1997 Aug;7(3):551–63; discussion 564 (49 ref.)

Reversal of CNS-prophylaxis-related leukoencephalopathy after CSF shunting: case histories of identical twins. Tekkök IH, et al. **Childs Nerv Syst** 1996 Jun;12(6):309–14

Partial seizures associated with cisplatin administration: a case report. Fuse-Nagase Y, et al. **Clin Electroencephalogr** 1997 Jan;28(1):55–6

Spontaneous recovery of chemotherapy-induced primary ovarian failure: implications for management. Nasir J, et al. **Clin Endocrinol (Oxf)** 1997 Feb;46(2):217–9

Acute mesenteric ischaemia associated with 5-FU, cisplatin and vincristine chemotherapy. Allerton R. **Clin Oncol (R Coll Radiol)** 1996;8(2):116–7 (15 ref.)

Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy. Bissett D, et al. **Clin Oncol (R Coll Radiol)** 1996;8(4):247–9

Citrobacter freundii and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer. Clemons MJ, et al. **Clin Oncol (R Coll Radiol)** 1997; 9(3):172–5

Haemolytic uraemic syndrome in a patient with lung cancer: further evidence for a toxic interaction between mitomycin-C and tamoxifen. Ellis PA, et al. **Clin Oncol (R Coll Radiol)** 1996;8(6):402–3

An acute toxicity study on the effects of synchronous chemotherapy and radiotherapy in early stage breast cancer after conservative surgery. Fernando IN, et al. **Clin Oncol (R Coll Radiol)** 1996;8(4):234–8

Large vessel effects of cytotoxic chemotherapy [editorial; comment] Madden FJ. **Clin Oncol (R Coll Radiol)** 1996; 8(2):75–6. Comment on: Clin Oncol (R Coll Radiol) 1996 ;8(2):116–7.

Interstitial pneumonitis as a late complication of high dose therapy with cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast. Mahendra P, et al. **Clin Oncol (R Coll Radiol)** 1996; 8(3):198–200

Case report: delayed radiation pneumonitis induced by chemotherapy. Soh LT, et al. **Clin Radiol** 1997 Sep; 52(9):720–3

Avascular necrosis of bone following an intensified chemotherapy regimen including high dose steroids. Thornton MJ, et al. **Clin Radiol** 1997 Aug;52(8):607–12

A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. Bates M, et al. **Clin Ther** 1997 Jan–Feb;19(1):167–84

Safety of concomitant use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor with cytotoxic chemotherapy agents. Petros WP, et al. **Curr Opin Hematol** 1997 May;4(3):213–6 (21 ref.)

Chemotherapy-induced myocardial infarction [letter] Law H. **Eur Heart J** 1996 Jun;17(6):966–7 (7 ref.)

Pneumothorax following induction chemotherapy for a germ cell tumour [letter] Laurencet FM, et al. **Eur J Cancer** 1997 Jan;33(1):169–70

A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Mori K, et al. **Eur J Cancer** 1997 Mar;33(3):503–5

Oral glutamine in the prevention of chemotherapy-induced gastrointestinal toxicity [letter] Muscaritoli M, et al. **Eur J Cancer** 1997 Feb;33(2):319–20

Symptomatic hypocalcemia and hypomagnesiemia in cisplatinum-based chemotherapy treated patients: case report. Maina A, et al. **Eur J Gynaecol Oncol** 1996; 17(4):281–2

Severe central nervous adverse effect of intrathecal chemotherapy in a 16-yr-old patient with Burkitt's type lymphoma [letter] Geissler RG, et al. **Eur J Haematol** 1997 Apr;58(4):286–8

Eclampsia after polychemotherapy for nodal-positive breast cancer during pregnancy. Müller T, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug;67(2):197–8

5-Fluorouracil- and levamisole-associated multifocal leukoencephalopathy. Galassi G, et al. **Eur Neurol** 1996; 36(4):244–6

Cervical spontaneous epidural hematoma as a complication of non-Hodgkin's lymphoma. Mastronardi L, et al. **Eur Spine J** 1996;5(4):268–71

Seizures associated with cisplatin administration. Brauers A, et al. **Eur Urol** 1997;32(1):118–20

Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma. Witjes JA, et al. **Eur Urol** 1997; 31(4):414–9

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Kurz Ch, et al. **Gynecol Oncol** 1997 Jun;65(3):461–6

Unexpected incidence of neurotoxicity [letter] Micha JP. **Gynecol Oncol** 1997 Aug;66(2):338–9

Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Faggioli P, et al. **Haematologica** 1997 Jan–Feb;82(1):38–42

High incidence of secondary myelodysplastic syndromes following PROMACE-MOPP and involved field radiotherapy for localized gastric non-Hodgkin's lymphomas. Corti C, et al. **Hematol Oncol** 1996 Dec; 14(4):159–63

Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis. Parikh PM, et al. **Indian J Cancer** 1996 Mar;33(1):17–20

False positive tumor markers: elevation in patients with breast cancer on FAC-type chemotherapy and correlation with the development of hand-foot syndrome. Tyshler LB, et al. **Int J Biol Markers** 1996 Oct–Dec;11(4):203–6

Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92–04. Komaki R, et al. **Int J Radiat Oncol Biol Phys** 1997 Apr 1;38(1):149–55

The protective effect of methylprednisolone against cisplatin-induced nephrotoxicity in patients with urothelial tumors. Uozumi J, et al. **Int J Urol** 1996 Sep;3(5):343–7

Quantitative assessment of cerebral atrophy during and after treatment in children with acute lymphoblastic leukemia. Prassopoulos P, et al. **Invest Radiol** 1996 Dec;31(12):749–54

A characteristic eruption associated with ifosfamide, carboplatin, and etoposide chemotherapy after pretreatment with recombinant interleukin-1 alpha. Prussick R, et al. **J Am Acad Dermatol** 1996 Nov;35(5 Pt 1):705–9

Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. Halton JM, et al. **J Bone Miner Res** 1996 Nov;11(11):1774–83

Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. Bosnjak SM, et al. **J Chemother** 1996 Aug;8(4):315–8

Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. Saarto T, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4453–7

Effects of chemotherapy-induced testicular damage on inhibin, gonadotropin, and testosterone secretion: a prospective longitudinal study. Wallace EM, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3111–5

Granulocyte-macrophage colony-stimulating factor with induction treatment of acute myelogenous leukemia [letter; comment] Adkins DR, et al. **J Clin Oncol** 1997 Feb; 15(2):862–3. Comment on: J Clin Oncol 1996 Jul;14(7):2150–9.

Evaluation of long-term toxicity after chemotherapy for testicular cancer. Bokemeyer C, et al. **J Clin Oncol** 1996 Nov;14(11):2923–32

Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. Brundage MD, et al. **J Clin Oncol** 1997 Jan;15(1):330–40

Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer [see comments] Cavaletti G, et al. **J Clin Oncol** 1997 Jan;15(1):199–206. Comment in: J Clin Oncol 1997 Jul;15(7):2761–2.

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. Del Mastro L, et al. **J Clin Oncol** 1997 Jul; 15(7):2715–21

Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. Diamandidou E, et al. **J Clin Oncol** 1996 Oct; 14(10):2722–30

Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. Dieras V, et al. **J Clin Oncol** 1996 Dec; 14(12):3097–104

Chemotherapy-induced insulin-dependent diabetes mellitus [letter] Dispenzieri A, et al. **J Clin Oncol** 1997 Mar; 15(3):1287

Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting. Gordon AN, et al. **J Clin Oncol** 1997 May;15(5):1965–73

Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer. Lalisang RI, et al. **J Clin Oncol** 1997 Apr;15(4):1367–76

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. Lofters WS, et al. **J Clin Oncol** 1997 Aug; 15(8):2966–73

Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. Ohno R, et al. **J Clin Oncol** 1997 Aug;15(8):2954–65

Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. Pritchard KI, et al. **J Clin Oncol** 1996 Oct;14(10):2731–7

Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. Rosner GL, et al. **J Clin Oncol** 1996 Nov;14(11):3000–8

Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. Rustin GJ, et al. **J Clin Oncol** 1996 Oct;14(10):2769–73

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. Saarto T, et al. **J Clin Oncol** 1997 Apr;15(4):1341–7

Diagnosis in oncology. Hand-foot syndrome. Skarin A. **J Clin Oncol** 1997 Sep;15(9):3164

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Swain SM, et al. **J Clin Oncol** 1997 Apr;15(4):1318–32

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. Swain SM, et al. **J Clin Oncol** 1997 Apr;15(4):1333–40

Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. Tannehill SP, et al. **J Clin Oncol** 1997 Aug;15(8):2850–7

Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy. van Basten JP, et al. **J Clin Oncol** 1997 Jun;15(6):2442–8 (55 ref.)

Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. Vandenberghe E, et al. **J Clin Oncol** 1997 Apr;15(4):1595–600

Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. von Tempelhoff GF, et al. **J Clin Oncol** 1996 Sep;14(9):2560–8

A 3-year follow-up of the intellectual and academic functioning of children receiving central nervous system prophylactic chemotherapy for leukemia. Brown RT, et al. **J Dev Behav Pediatr** 1996 Dec;17(6):392–8

Malignant lymphoma of the stomach after chemotherapy for hepatocellular carcinoma. Matsuo I, et al. **J Gastroenterol** 1997 Aug;32(4):533–7

Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it. Hassan HT, et al. **J Hematother** 1996 Aug;5(4):407–14 (57 ref.)

Re: Severe neurotoxicity in vinorelbine-paclitaxel combinations [letter; comment] Budman DR, et al. **J Natl Cancer Inst** 1997 Jan 1;89(1):87–8. Comment on: J Natl Cancer Inst 1996 Aug 7;88(15):1079–80.

Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support [letter; comment] Ribas A, et al. **J Natl Cancer Inst** 1997 Mar 5;89(5):395–6. Comment on: J Natl Cancer Inst 1996 Oct 2;88(19):1393–8.

Clinical trial of recombinant granulocyte colony-stimulating factor for chemotherapy-induced neutropenia patients with oral cancer. Iwase M, et al. **J Oral Maxillofac Surg** 1997 Aug;55(8):836–40; discussion 841

Outpatient treatment with ceftriaxone alone or in combination with teicoplanin in febrile neutropenic children and adolescents with cancer [letter; comment] Preis S, et al. **J Pediatr** 1997 Mar;130(3):500–1. Comment on: J Pediatr 1996 Jun;128(6):847–9.

Myelodysplasia in a child with Beckwith-Wiedemann syndrome previously treated for hepatoblastoma with multi-agent chemotherapy [letter] Koishi S, et al. **J Pediatr Hematol Oncol** 1996 Nov;18(4):419–20

Obstructive jaundice in patients receiving hepatic artery infusional chemotherapy: etiology, treatment implications, and complications after transhepatic biliary drainage. Brown KT, et al. **J Vasc Interv Radiol** 1997 Mar–Apr; 8(2):229–34

Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer. Yano S, et al. **Jpn Circ J** 1996 Mar;60(3):185–8

A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics. Boku N, et al. **Jpn J Clin Oncol** 1996 Oct;26(5):379–83

Colonoscopy for frank bloody stools associated with cancer chemotherapy. Yokoyama T, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):111–4

Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia [letter] Bseiso AW, et al. **Leukemia** 1997 Jan;11(1):168–9

High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Pedersen-Bjergaard J, et al. **Leukemia** 1997 Oct; 11(10):1654–60

Increases of sICAM-1 during neutropenic pneumonia in leukemic patients. Südhoff T, et al. **Leukemia** 1997 Mar; 11(3):346–51

Partial substitution of cisplatin with carboplatin in combination with etoposide in advanced non-small cell lung cancer (NSCLC): a multicentric randomised phase II trial. Comella P, et al. **Lung Cancer** 1996 Aug; 15(1):103–14

Rhabdomyolysis: an unusual complication of cytotoxic chemotherapy. Levy RJ, et al. **Med Oncol** 1995 Dec; 12(4):219–22

Therapeutic effect of cyclosporine A in thrombocytopenia after myeloablative chemotherapy in acute myeloid leukaemia. Novik Y, et al. **Med Oncol** 1997 Mar;14(1):43–6

Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors. Furman WL, et al. **Med Pediatr Oncol** 1997 Jun;28(6):444–50

Therapy-related acute myeloid leukemia with t(8;21) in a child with previous Ewing's sarcoma. Lesesve JF, et al. **Med Pediatr Oncol** 1997 Aug;29(2):132–4

Acute hepatic injury after discontinuation of chemotherapy in a patient with non-Hodgkin's lymphoma and chronic hepatitis B virus infection. Haanen JB, et al. **Neth J Med** 1996 Dec;49(6):239–43

Neuropsychologic late effects in children with malignant brain tumors treated with surgery, radiotherapy and "8 in 1" chemotherapy. Ilveskoski I, et al. **Neuropediatrics** 1996 Jun;27(3):124–9

Chemotherapy-induced spontaneous pneumothorax in a patient with bulky mediastinal lymphoma: a rare oncologic emergency. Stein ME, et al. **Oncology** 1997 Jan–Feb; 54(1):15–8 (18 ref.)

Intensive chemotherapy plus recombinant human granulocyte–colony stimulating factor support for distant metastatic nasopharyngeal carcinoma. A preliminary report. Wang CH, et al. **Oncology** 1997 Jan–Feb;54(1):34–7

Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer. Ben Arush MW, et al. **Pediatr Hematol Oncol** 1997 Jul–Aug; 14(4):381–6

Recurrent Clostridium difficile diarrhea associated with mitoxantrone and etoposide: a case report and review. Jarvis B, et al. **Pharmacotherapy** 1997 May–Jun; 17(3):606–11

Conditioned reactions to cancer chemotherapy: percent reinforcement predicts anticipatory nausea. Tomoyasu N, et al. **Physiol Behav** 1996 Feb;59(2):273–6

Treatment-related disseminated necrotizing leukoencephalopathy with characteristic contrast enhancement of the white matter. Laxmi SN, et al. **Radiat Med** 1996 Nov–Dec;14(6):303–7

Granulocyte–colony stimulating factor fails to prevent leucopenia caused by CEMP in elderly patients with aggressive lymphoma [letter] Nel JS, et al. **S Afr Med J** 1996 Dec;86(12):1564

Severe thrombosis after chemotherapy for metastatic choriocarcinoma of the testis maintaining complete remission for a long period. Lepidini G, et al. **Scand J Urol Nephrol** 1997 Apr;31(2):221–2

Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel–containing chemotherapy and concurrent radiation. Bonomi P, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–123–S12–129

Considerations regarding the less–than–expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Kearns CM, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–91–S2–96 (24 ref.)

Transverse leukonychia in patients receiving cancer chemotherapy. Chapman S, et al. **South Med J** 1997 Apr; 90(4):395–8 (26 ref.)

Parkinsonian syndrome in a dialysis–supported patient receiving high–dose chemotherapy for multiple myeloma [letter] Fleming DR, et al. **South Med J** 1997 Mar; 90(3):364–5

Hyponatremia related to medical anticancer treatment. Berghmans T. **Support Care Cancer** 1996 Sep;4(5):341–50 (81 ref.)

Acute and anticipatory emesis in breast cancer patients. Fernández–Marcos A, et al. **Support Care Cancer** 1996 Sep; 4(5):370–7

High incidence of infectious gastrointestinal complications observed in patients with acute myeloid leukemia receiving intensive chemotherapy for first induction of remission. Micozzi A, et al. **Support Care Cancer** 1996 Jul;4(4):294–7

Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy. Silva RR, et al. **Support Care Cancer** 1996 Jul;4(4):287–90

Postoperative adjuvant chemoradiotherapy for rectal cancer: analysis of acute and chronic toxicity. Bertuccelli M, et al. **Tumori** 1997 Mar–Apr;83(2):599–603

Advances in supportive therapy. Facchini T. **Zentralbl Gynakol** 1996;118(10):589–90

[Clinical study on treatment of chemo– or radiotherapy induced leukopenia with fuzheng compound] Zhang XQ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Jan;16(1):27–8 (Eng. Abstr.) **(Chi)**

[Antineoplastic chemotherapy and Wernicke's encephalopathy] Vanhulle C, et al. **Arch Pediatr** 1997 Mar; 4(3):243–6 (Eng. Abstr.) **(Fre)**

[Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin–fluorouracil on the 4th day of the therapeutic regimen] Cappelaere P, et al. **Bull Cancer** 1996 Jul;83(7):559–65 (36 ref.) (Eng. Abstr.) **(Fre)**

[Cell lysis syndrome after chemotherapy for cancer of the bladder (letter)] Suc E, et al. **Presse Med** 1996 Dec 21; 25(40):2044 **(Fre)**

[MRI diagnosis and follow–up of bilateral necrosis of the humeral head as a complication after chemotherapy] Morakkabati N, et al. **Aktuelle Radiol** 1997 Jan;7(1):41–4 (Eng. Abstr.) **(Ger)**

[Bleomycin–induced pneumonia] Berger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Nov; 31(9):577–81 (Eng. Abstr.) **(Ger)**

[Disseminated pneumoperitoneum during the therapy of lymphoma with methotrexate and cytosine arabinoside] Kirchner J, et al. **Dtsch Med Wochenschr** 1996 Oct 18; 121(42):1288–91 (15 ref.) (Eng. Abstr.) **(Ger)**

[Cicatricial small intestinal stenosis following chemotherapy for a gastrointestinal lymphoma] Libicher M, et al. **Dtsch Med Wochenschr** 1996 Nov 1;121(44):1359–62 (Eng. Abstr.) **(Ger)**

[Metastatic malignant melanoma in treated non–Hodgkin's lymphoma] Falk S, et al. **Hautarzt** 1996 Sep;47(9):716–8 (21 ref.) (Eng. Abstr.) **(Ger)**

[Induction of multiple melanocytic nevus cell nevi in 2 children with malignant hematologic systemic diseases and chemotherapy–induced immunosuppression] Jappe U, et al. **Hautarzt** 1996 Jul;47(7):537–40 (Eng. Abstr.) **(Ger)**

[SCE rate and lymphocyte differentiation in children with acute lymphoblastic leukemia and SCE rates of leukemia patients in long–term remission] Mertens R, et al. **Klin Padiatr** 1996 Mar–Apr;208(2):73–6 (Eng. Abstr.) **(Ger)**

[Hepatic veno–occlusive disease––simulating acute abdomen in chemotherapy of Wilms' tumors] Tröbs RB, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:1112–4 (Eng. Abstr.) **(Ger)**

[Effectiveness and tolerance of Navoban (5HT3–receptor antagonist tropisetron) in prevention of cytostatic drug–induced nausea and vomiting in patients with breast carcinomas and gynecological malignancies] Regidor PA, et al. **Zentralbl Gynakol** 1996;118(3):148–53 (Eng. Abstr.) **(Ger)**

[Silent myocardial infarction in a patient treated with radiation therapy and polychemotherapy for Hodgkin's lymphoma] Cordioli E, et al. **Cardiologia** 1997 Jun; 42(6):635–8 (Eng. Abstr.) **(Ita)**

[High–dose chemotherapy and peripheral hemtopoietic cells (PBPC) in solid tumors] Rosti G, et al. **Tumori** 1996 Mar–Apr;82(2 Suppl):S19–22 (27 ref.) (Eng. Abstr.) **(Ita)**

[Anticancer drug–induced colitis––case report and review of the literature] Abe H, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):619–24 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Comparison of effects between single vs five–day injection of granisetron for combination chemotherapy with cisplatin and 5–fluorouracil for head and neck cancer] Fujii M, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1095–101 (Eng. Abstr.) **(Jpn)**

[A case report of tongue cancer presenting with SSD type brain embolism induced by chemotherapy with CBDCA and 5–FU] Itoh H, et al. **Gan To Kagaku Ryoho** 1997 Mar; 24(5):597–9 (Eng. Abstr.) **(Jpn)**

[A case of postbulbar duodenal ulcer due to adjuvant chemotherapy after gastrectomy for gastric cancer] Saito A, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):1019–22 (Eng. Abstr.) **(Jpn)**

[A randomized cross–over comparative study of granisetron alone and combination of granisetron, methylprednisolone and droperidol as antiemetic prophilaxis in CDDP–based chemotherapy for gynecologic cancer] Wataba K, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):691–7 (Eng. Abstr.) **(Jpn)**

[Effective administration of recombinant granulocyte colony–stimulating factor to prevent granulocytopenia due to combination chemotherapy for testicular germ cell tumors] Nonomura K, et al. **Hinyokika Kiyo** 1996 Sep; 42(9):699–704 (Eng. Abstr.) **(Jpn)**

[Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti–neoplastic agents] Morimoto Y, et al. **Masui** 1996 Sep;45(9):1096–9 (Eng. Abstr.) **(Jpn)**

[Effect of timing of granulocyte–colony stimulating factor administration on leukopenia induced by systemic chemotherapy in patients with non–small–cell lung cancer––multi–center randomized crossover study] Katakami N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 May; 34(5):520–8 (Eng. Abstr.) **(Jpn)**

[Anxiety and depression during chemotherapy for lymphoproliferative diseases] Piusińska A, et al. **Pol Tyg Lek** 1996 May;51(19–22):278–80 (Eng. Abstr.) **(Pol)**

[Late complications of combined therapy of lymphogranulomatosis] Miasnikov AA, et al. **Klin Med (Mosk)** 1997;75(3):21–3 (Eng. Abstr.) **(Rus)**

[The 5HT3–receptor antagonist Zofran (ondansetron) as an agent for preventing nausea and vomiting during the cytostatic treatment of cancer patients] Perevodchikova NI, et al. **Ter Arkh** 1996;68(2):30–4 (Eng. Abstr.) **(Rus)**

[Effect of various chemotherapy regimens on survival and cause of death in patients with multiple myeloma (retrospective study)] Abdulkadyrov KM, et al. **Vopr Onkol** 1997;43(3):341–6 (Eng. Abstr.) **(Rus)**

[Stimulating and protective effect of recombinant interleukin–1–beta (beta–leukin) on leukopoiesis in chemotherapy of malignant tumors] Gershanovich ML, et al. **Vopr Onkol** 1996;42(6):13–8 (Eng. Abstr.) **(Rus)**

[Hemopoietic stem cell transplantation in lymphogranulomatosis] Uss AL, et al. **Vopr Onkol** 1997; 43(2):188–91 (Eng. Abstr.) **(Rus)**

[Colony–stimulating factors and HIV–related neoplasms] Valencia ME, et al. **An Med Interna** 1996 Jul;13(7):317–21 (Eng. Abstr.) **(Spa)**

[Chemotherapy schedules and bacteremia in adult patients with acute leukemia] Brodsky AL, et al. **Medicina (B Aires)** 1996;56(4):327–32 (Eng. Abstr.) **(Spa)**

ANALYSIS

Determination of S–1 (combined drug of tegafur, 5–chloro–2,4–dihydroxypyridine and potassium oxonate) and 5–fluorouracil in human plasma and urine using high–performance liquid chromatography and gas chromatography–negative ion chemical ionization mass spectrometry. Matsushima E, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):95–104

BLOOD

Measurement of plasma 5–fluorouracil by high–performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon–alpha. Findlay MP, et al. **Ann Oncol** 1996 Jan;7(1):47–53

CHEMISTRY

Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Stewart JT, et al. **Am J Health Syst Pharm** 1997 Apr 15;54(8):915–20

Argenteanones C–E and argenteanols B–E, cytotoxic cycloartanes from Aglaia argentea. Mohamad K, et al. **J Nat Prod** 1997 Feb;60(2):81–5

[Structural analysis of vinorelbine in solution determined by nuclear magnetic resonance spectrometry] Ribet JP, et al. **Ann Pharm Fr** 1997;55(1):20–34 (Eng. Abstr.) **(Fre)**

CONTRAINDICATIONS

Clinical decision making based on radionuclide determined ejection fraction in oncology patients. Peng NJ, et al. **J Nucl Med** 1997 May;38(5):702–5

ECONOMICS

Economic impact with home delivery of chemotherapy to pediatric oncology patients. Holdsworth MT, et al. **Ann Pharmacother** 1997 Feb;31(2):140–8

Advanced colorectal carcinoma: redefining the role of oral ftorafur. Ron IG, et al. **Anticancer Drugs** 1996 Aug; 7(6):649–54

The cost–effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non–small cell lung cancer. Evans WK, et al. **Eur J Cancer** 1996 Dec; 32A(13):2249–55

Cost–effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node–positive breast cancer [published erratum appears in Eur J Clin Pharmacol 1997;51(5):427] Messori A, et al. **Eur J Clin Pharmacol** 1996;51(2):111–6

Cost–utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Ortega A, et al. **Gynecol Oncol** 1997 Sep;66(3):454–63

Cost of combined modality interventions for stage III non–small–cell lung cancer [see comments] Evans WK, et al. **J Clin Oncol** 1997 Sep;15(9):3038–48. Comment in: J Clin Oncol 1997 Sep;15(9):3027–9.

The cost–effectiveness of four cisplatin–containing chemotherapy regimens in the treatment of stages III B and IV non–small cell lung cancer: an Italian perspective [see comments] Palmer AJ, et al. **Monaldi Arch Chest Dis** 1996 Aug;51(4):279–88. Comment in: Monaldi Arch Chest Dis 1997 Jun;52(3):305–6.

A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer. Doyle JJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 13):51–60

PHARMACOKINETICS

Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion. Lerza R, et al. **Ann Oncol** 1997 Apr;8(4):385–91

Urinary excretion of ifosfamide, 4–hydroxyifosfamide, 3– and 2–dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Kurowski V, et al. **Cancer Chemother Pharmacol** 1997;39(5):431–9

Disposition of 5–formyl– and 5–methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon–alpha–2b. Czejka MJ, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct–Dec; 20(4):255–62

Use of safety–modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial. Deisseroth AB, et al. **Hum Gene Ther** 1996 Feb 10;7(3):401–16

Dose–finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. Conte PF, et al. **J Clin Oncol** 1997 Jul;15(7):2510–7

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. Gianni L, et al. **J Clin Oncol** 1997 May;15(5):1906–15

Sequence–dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. Holmes FA, et al. **J Clin Oncol** 1996 Oct; 14(10):2713–21

Pharmacokinetics of paclitaxel and carboplatin in a dose–escalating and dose–sequencing study in patients with non–small–cell lung cancer. The European Cancer Centre. Huizing MT, et al. **J Clin Oncol** 1997 Jan;15(1):317–29

Phase I pharmacokinetic study of multicycle high–dose carboplatin followed by peripheral–blood stem–cell infusion in patients with cancer. Johansen MJ, et al. **J Clin Oncol** 1997 Apr;15(4):1481–91

Modulation of 5–FU/alpha–interferon with high–dose continuous infusion hydroxyurea. Horowitz R, et al. **J Infus Chemother** 1995 Fall;5(4):212–4 (33 ref.)

ANTINEOPLASTIC AGENTS, COMBINED

PHARMACOLOGY

Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells. Grabowski D, et al. **Ann N Y Acad Sci** 1996 Dec 13; 803:306-7

Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Olieman AF, et al. **Ann Surg Oncol** 1997 Jan;4(1):64-9

Saporin 6 and lonidamine in primary cell cultures from human breast carcinomas: a synergistic effect. Gasperi-Campani A, et al. **Anticancer Drug Des** 1997 Mar; 12(2):91-8

Effects of Dex-Verapamil on Doxorubicin cytotoxicity in P388 murine leukemia cells. Noviello E, et al. **Anticancer Drug Des** 1997 Jun;12(4):261-76

In vitro synergistic effects of some novel Cu(II) complexes in combination with epirubicin and mitomycin C against HeLa-S3 cervical cancer cell line. Geromichalos GD, et al. **Anticancer Drugs** 1996 Jun;7(4):469-75

The combination of paclitaxel with cisplatin exhibits antagonism in vitro against human melanoma. Mohith A, et al. **Anticancer Drugs** 1996 Jun;7(4):493-8

Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Pei XH, et al. **Anticancer Drugs** 1997 Mar;8(3):231-7

Enhanced antitumor activity of an adriamycin + 5-fluorouracil combination when preceded by biochemical modulation. Stolfi RL, et al. **Anticancer Drugs** 1996 Jan; 7(1):100-4

Retinoids increase idarubicin cytotoxicity in human myeloid leukemia cell lines. Tosi P, et al. **Anticancer Drugs** 1996 Sep;7(7):774-9

Therapeutic significance of the polyamine level in tissues of rats treated with adriamycin and cisplatin. Watanabe S, et al. **Anticancer Drugs** 1996 Jan;7(1):114-20

Effects of 1,4-phenylenebis(methylene)selenocyanate, phenethyl isothiocyanate, indole-3-carbinol, and d-limonene individually and in combination on the tumorigenicity of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. el-Bayoumy K, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2709-12

Etoposide enhances the antitumor effects of cisplatin in gastric cancer cells. Hotta T, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):885-9

The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule. Ishida R, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2735-40

Human recombinant interferon alpha-2a plus 3'-azido-3'-deoxythymidine. Synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells. Darnowski JW, et al. **Biochem Pharmacol** 1997 Feb 21;53(4):571-80

Peripheral blood stem cell (PBSC) collection in extremely low-weight infants. Nussbaumer W, et al. **Bone Marrow Transplant** 1996 Jul;18(1):15-7

Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Bokemeyer C, et al. **Br J Cancer** 1996 Dec; 74(12):2036-41

Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Ferlini C, et al. **Br J Cancer** 1997;75(6):884-91

In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Jensen PB, et al. **Br J Cancer** 1997;75(6):869-77

Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Nooijen PT, et al. **Br J Cancer** 1996 Dec;74(12):1908-15

The effects of cyclosporin A, tamoxifen, and medroxyprogesterone acetate on the enhancement of adriamycin cytotoxicity in primary cultures of human breast epithelial cells. Claudio JA, et al. **Breast Cancer Res Treat** 1996;41(2):111-22

Pharmacological considerations in high-dose chemotherapy. Sasaki Y. **Cancer Chemother Pharmacol** 1997;40 Suppl:S115-8 (18 ref.)

Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors. Teicher BA, et al. **Cancer Chemother Pharmacol** 1996;38(6):553-60

Effect of interferon on 5-fluorouracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaks. Wadler S, et al. **Cancer Chemother Pharmacol** 1996; 38(6):529-35

Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Wedge SR, et al. **Cancer Chemother Pharmacol** 1997;40(3):266-72

Interleukin-1alpha synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity. Yu WD, et al. **Cancer Immunol Immunother** 1997 Aug;44(6):316-22

Evaluation of chemotherapy and radiation enhancement and 31P NMR spectral changes induced by biochemical modulation. Koutcher JA, et al. **Cancer Invest** 1997; 15(2):111-20

In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3. Dixon SC, et al. **Cancer Lett** 1997 Feb 26;113(1-2):111-6

Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Bible KC, et al. **Cancer Res** 1997 Aug 15;57(16):3375-80

Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Whitacre CM, et al. **Cancer Res** 1997 Apr 15;57(8):1425-8

IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Evans R, et al. **Cell Immunol** 1997 Jul 10; 179(1):66-73

Effect of high-dose chemotherapy on intestinal permeability in humans. Keefe DM, et al. **Clin Sci (Colch)** 1997 Apr; 92(4):385-9

Synergic influence of Ukrain and protoporphyrin amino acid conjugates on human malignant cell lines. Brzosko WJ, et al. **Drugs Exp Clin Res** 1996;22(3-5):193-4

The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Johnston PG, et al. **Eur J Cancer** 1996 Nov;32A(12):2148-54

In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Photiou A, et al. **Eur J Cancer** 1997 Mar;33(3):463-70

Inversion of chromosome 11 inv(11)(p15q22), as a recurring chromosomal aberration associated with de novo and secondary myeloid malignancies: identification of a P1 clone spanning the 11q22 breakpoint. Kobayashi H, et al. **Genes Chromosomes Cancer** 1997 Jul;19(3):150-5

Synergism between N-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models. De Flora S, et al. **Int J Cancer** 1996 Sep 17; 67(6):842-8

Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils. García I, et al. **J Antimicrob Chemother** 1996 Nov;38(5):859-63

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. Baker SD, et al. **J Clin Oncol** 1996 Dec;14(12):3085-96

Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. Demirer T, et al. **J Clin Oncol** 1997 Feb; 15(2):684-90

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. Gianni L, et al. **J Clin Oncol** 1997 May;15(5):1906-15

Paradoxical effect of cytotoxic chemotherapy on anemia in cancer patients with beta-thalassemia minor [letter] Del Mastro L, et al. **J Natl Cancer Inst** 1997 Mar 19;89(6):455-6

Lentinan enhances sensitivity of mouse colon 26 tumor to cis-diamminedichloroplatinum (II) and decreases glutathione transferase expression. Murata T, et al. **Jpn J Cancer Res** 1996 Nov;87(11):1171-8

Experimental studies on potentiation of the antitumor activity of 5-fluorouracil with 3'-azido-3'-deoxythymidine for the gastric cancer cell line MKN28 in vivo. Yasuda C, et al. **Jpn J Cancer Res** 1997 Jan;88(1):97-102

The comparison of 2-chlorodeoxyadenosine (2-Cd A) in combination with interferon alpha (IFN alpha) or interferon gamma (IFN gamma) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts in (CFU-L) in vitro cultures. Robak T, et al. **Leuk Lymphoma** 1996 Mar;21(1-2):161-8

Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma. Takano H, et al. **Leuk Lymphoma** 1996 May;21(5-6):473-8

Vitamin D and 9-cis retinoic acid: an efficient partnership for the induction of myelomonocytic cell growth inhibition and differentiation [comment] Marti J, et al. **Leuk Res** 1997 Feb;21(2):173-6. Comment on: Leuk Res 1996 Aug;20(8):665-76.

In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Begleiter A, et al. **Leukemia** 1996 Dec;10(12):1959-65

Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines. Viallet J, et al. **Lung Cancer** 1996 Aug;15(1):93-101

Chemotherapy-induced expression of alpha B-crystallin in neuroblastoma. Ishiguro Y, et al. **Med Pediatr Oncol** 1997 Jul;29(1):11-5

In vivo detection by 31P NMR of pentose phosphate pathway block secondary to biochemical modulation. Mahmood U, et al. **NMR Biomed** 1996 May;9(3):114-20

Predictors of bone mineral loss in patients with ovarian cancer treated with anticancer agents. Douchi T, et al. **Obstet Gynecol** 1997 Jul;90(1):12-5

Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Jaffrézou JP, et al. **Oncol Res** 1995;7(10-11):517-27

Five-year follow-up of saliva in patients treated for lymphomas. Meurman JH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Apr;83(4):447-52

Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines. di Paolo A, et al. **Pharmacol Res** 1995 Sep;32(3):135-9

Effect of some anti-cancer drugs and combined chemotherapy on the pharmacokinetics of antipyrine in the rat. Skrętkowicz J. **Pol J Pharmacol** 1995 Nov-Dec; 47(6):519-24

A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Calvert AH. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-85-S2-90 (43 ref.)

Flow cytometric and ultrastructural aspects of the synergistic antitumor activity of vitamin C-vitamin K3 combinations against human prostatic carcinoma cells. Jamison M, et al. **Tissue Cell** 1996 Dec;28(6):687-701

[Adjuvant CMF chemotherapy in patients with breast cancer--results on blood coagulation and fibrinolysis] Oberhoff C, et al. **Zentralbl Gynakol** 1997;119(5):211-7 (Eng. Abstr.) **(Ger)**

POISONING

Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Vrouenraets BC, et al. **Ann Surg Oncol** 1997 Jan;4(1):88-94

RADIATION EFFECTS

In vitro mechanisms of chemopotentiation by tone-burst ultrasound. Harrison GH, et al. **Ultrasound Med Biol** 1996; 22(3):355-62

THERAPEUTIC USE

Bilateral primary renal non-Hodgkin's lymphoma presenting with acute renal failure: successful treatment with systemic chemotherapy. Choi JH, et al. **Acta Haematol** 1997; 97(4):231-5

Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy. Foa P, et al. **Acta Haematol** 1997; 97(3):187-8

Chemotherapy with MECOP-B for intermediate-grade and high-grade non-Hodgkin's lymphoma in Saudi Arabia: clinical results and analysis of prognostic factors. Ibrahim EM, et al. **Acta Haematol** 1996;96(3):126-34

Suspected malignant lymphoma presenting with widespread granulomatous lesions in bones and lymph nodes and responding to combination chemotherapy. Jensen MK, et al. **Acta Haematol** 1996;96(4):237-41

Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation. Hájek R, et al. **Acta Med Austriaca** 1996;23(3):85-91 (76 ref.)

Effect of low dose cyclophosphamide on the synthesis of acute phase protein and its significance for cancer chemotherapy. Iwagaki H, et al. **Acta Med Okayama** 1996 Oct;50(5):271-2

Transvaginal color Doppler ultrasound for monitoring the response to neoadjuvant chemotherapy in advanced cervical cancer. Greco P, et al. **Acta Obstet Gynecol Scand** 1997 Feb;76(2):169-72

Intra-arterial infusion chemotherapy in the treatment of locally advanced breast cancer. Cakmakli S, et al. **Acta Oncol** 1997;36(5):489-92

Ifosfamide-based chemotherapy for recurrent or metastatic hemangiopericytoma. Celik I, et al. **Acta Oncol** 1997; 36(3):348

Cisplatin-based chemotherapy in a renal transplant recipient with metastatic germ cell testicular cancer. Dahl O, et al. **Acta Oncol** 1996;35(6):759-61

Fluorouracil and high-dose leucovorin with radiotherapy as adjuvant therapy for rectal cancer. Results of a phase II study. Giralt J, et al. **Acta Oncol** 1997;36(1):51-4

G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease. Gustavsson A. **Acta Oncol** 1997; 36(5):483-8

ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease. Holte H, et al. **Acta Oncol** 1996;35 Suppl 8:73-80

Feasibility of non-cisplatin-based induction chemotherapy and concurrent chemoradiotherapy in advanced head and neck cancer. Kumar S, et al. **Acta Oncol** 1996;35(6):721-5

Local recurrence of basal cell carcinoma and cisplatinum containing chemotherapy. Moeholt K, et al. **Acta Oncol** 1997;36(1):87

Transarterial infusion of cisplatin and doxorubicin in bladder cancer. Mokarim A, et al. **Acta Oncol** 1997;36(2):175-81

Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG). Pfeiffer P, et al. **Acta Oncol** 1996;35 Suppl 5:57

Thyroid function following chemotherapy in testicular cancer. Salminen EK, et al. **Acta Oncol** 1997;36(1):85-6

Induction chemotherapy with versus without hormonal synchronisation in locally advanced breast cancer. Sjövall MP, et al. **Acta Oncol** 1997;36(2):207-12

Doxorubicin-melphalan with and without cisplatin in

advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group. Tropé C, et al. **Acta Oncol** 1996;35 Suppl 8:109–18

Intrathecal prophylaxis following autologous bone marrow transplantation for non-Hodgkin's lymphoma. Varadi G, et al. **Acta Oncol** 1997;36(3):349–50

Chemotherapy for osteosarcoma and Ewing's sarcoma. Saeter G, et al. **Acta Orthop Scand Suppl** 1997 Feb; 273:120–5 (51 ref.)

Chemotherapy for adult soft tissue sarcoma. Does it work? Saeter G. **Acta Orthop Scand Suppl** 1997 Feb;273:139–44 (35 ref.)

New cytostatic agents for the treatment of head and neck cancer. Devriendt D, et al. **Acta Otorhinolaryngol Belg** 1997;51(2):61–8 (39 ref.)

Testicular morphological changes in children with acute lymphoblastic leukemia following chemotherapy. Kobayashi H, et al. **Acta Paediatr Jpn** 1996 Dec;38(6):640–3

Treatment of multiple myeloma in elderly people: long-term results in 178 patients. Bladé J, et al. **Age Ageing** 1996 Sep; 25(5):357–61

Chemotherapy in the treatment of non-small cell lung cancer. Hainsworth JD. **Am Fam Physician** 1997 May 1; 55(6):2265–72 (31 ref.)

Cisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small cell lung cancer: final results of a phase II study. Aristu J, et al. **Am J Clin Oncol** 1997 Jun;20(3):276–81

Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Attivissimo LA, et al. **Am J Clin Oncol** 1996 Dec;19(6):581–3

Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients. Baldini E, et al. **Am J Clin Oncol** 1997 Apr;20(2):169–72

Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP). Ballestrero A, et al. **Am J Clin Oncol** 1997 Jun;20(3):266–71

A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors. Blanke C, et al. **Am J Clin Oncol** 1996 Oct;19(5):487–91

Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. Brandes AA, et al. **Am J Clin Oncol** 1997 Aug;20(4):364–7

Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. Chitambar CR, et al. **Am J Clin Oncol** 1997 Apr;20(2):173–8

Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Colleoni M, et al. **Am J Clin Oncol** 1997 Aug;20(4):383–6

Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma. Colleoni M, et al. **Am J Clin Oncol** 1997 Jun;20(3):303–7

Treatment of fallopian tube carcinoma with cyclophosphamide, adriamycin, and cisplatin. Cormio G, et al. **Am J Clin Oncol** 1997 Apr;20(2):143–5

Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. Culine S, et al. **Am J Clin Oncol** 1997 Apr; 20(2):184–8

Preoperative simultaneous chemoradiotherapy in locally advanced cancer of the oral cavity and oropharynx. del Campo JM, et al. **Am J Clin Oncol** 1997 Feb;20(1):97–100

A prospective study of VEC-POB and POCE chemotherapy in aggressive non-Hodgkin's lymphoma. Ezzat AA, et al. **Am J Clin Oncol** 1997 Apr;20(2):179–83

Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients. Felip E, et al. **Am J Clin Oncol** 1997 Aug; 20(4):404–6

Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain. Feliu J, et al. **Am J Clin Oncol** 1996 Dec;19(6):577–80

Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results. Ferrière JP, et al. **Am J Clin Oncol** 1997 Jun;20(3):219–25

Phase I-II study of combined 5-fluorouracil and cisplatin chemotherapy and altered fractionation radiotherapy for advanced squamous cell carcinoma of the cervix. Fishman A, et al. **Am J Clin Oncol** 1997 Aug;20(4):342–7

Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer. Gridelli C, et al. **Am J Clin Oncol** 1996 Dec;19(6):589–91

The addition of bleomycin and dose-escalated ifosfamide to the combination of cisplatin plus ifosfamide does not improve survival in advanced or recurrent cervical carcinoma. Hempling RE, et al. **Am J Clin Oncol** 1997 Jun;20(3):315–8

Successful treatment with ranimustine and carboplatin for recurrent intraocular retinoblastoma with vitreous seeding. Ishii E, et al. **Am J Clin Oncol** 1996 Dec;19(6):562–5

Treatment of squamous cell carcinoma of the esophagus with alternating radiotherapy and chemotherapy (cisplatin, methotrexate, and peplomycin). Kagami Y, et al. **Am J Clin Oncol** 1997 Feb;20(1):16–8

Commentary on "Adequacy of chemotherapy prior to cytoreductive surgery in testicular carcinoma" by B. J. Kennedy, Jane L. Torkelson, and Elwin E. Fraley in this issue pp. 541–545 [editorial; comment] Kagan AR. **Am J Clin Oncol** 1996 Dec;19(6):636. Comment on: Am J Clin Oncol 1996 Dec;19(6):541–5.

Adequacy of chemotherapy prior to cytoreductive surgery in testicular carcinoma [see comments] Kennedy BJ, et al. **Am J Clin Oncol** 1996 Dec;19(6):541–5. Comment in: Am J Clin Oncol 1996 Dec;19(6):636.

Effect of 13-cis-retinoic acid with neoadjuvant chemotherapy in patients with squamous cervical carcinoma. Kim JW, et al. **Am J Clin Oncol** 1996 Oct; 19(5):442–4

Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial. Kish JA, et al. **Am J Clin Oncol** 1997 Aug;20(4):327–30

Gonadal function following ABVD therapy for Hodgkin's disease. Kulkarni SS, et al. **Am J Clin Oncol** 1997 Aug; 20(4):354–7

Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyngeal carcinoma. Lin JC, et al. **Am J Clin Oncol** 1996 Dec;19(6):624–7

Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832). Luikart SD, et al. **Am J Clin Oncol** 1997 Feb;20(1):24–30

A phase II study of carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer. Makimoto T, et al. **Am J Clin Oncol** 1997 Feb;20(1):51–4

Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer. The Ottawa experience. Maroun JA, et al. **Am J Clin Oncol** 1997 Aug; 20(4):387–92

Primary non-Hodgkin's lymphoma of the maxillary sinus. Nakamura K, et al. **Am J Clin Oncol** 1997 Jun;20(3):272–5

Combined carboplatin and cisplatin therapy in patients with advanced non-small cell lung cancer. Nakanishi R, et al. **Am J Clin Oncol** 1997 Feb;20(1):31–5

Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer. Nakanishi Y, et al. **Am J Clin Oncol** 1997 Aug;20(4):393–7

A phase II trial of cisplatin and interferon alpha 2b in patients with advanced bladder cancer. Parnis FX, et al. **Am J Clin Oncol** 1997 Jun;20(3):319–21

A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate. Pienta KJ, et al. **Am J Clin Oncol** 1996 Oct;19(5):500–3

CODBLAM IV chemotherapy for large cell lymphoma: sequential use of infusional vincristine and bleomycin and "high dose" consolidation. Rafi S, et al. **Am J Clin Oncol** 1997 Feb;20(1):90–6

Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Ramnath N, et al. **Am J Clin Oncol** 1997 Aug;20(4):368–72

Activity of standard-dose carboplatin, cyclophosphamide, and etoposide in patients with metastatic breast cancer with previous exposure to anthracyclines. Recchia F, et al. **Am J Clin Oncol** 1997 Apr;20(2):166–8

Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study. Recchia F, et al. **Am J Clin Oncol** 1997 Apr;20(2):209–14

A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small-cell lung cancer. Rixe O, et al. **Am J Clin Oncol** 1997 Apr;20(2):128–31

Sequential chemotherapy and radiotherapy for squamous cell esophageal carcinoma. Sharma D, et al. **Am J Clin Oncol** 1997 Apr;20(2):151–3

Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Sparano JA, et al. **Am J Clin Oncol** 1996 Dec;19(6):546–51

Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin. Sporn JR, et al. **Am J Clin Oncol** 1997 Feb;20(1):81–3

Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703). Thomas CR Jr, et al. **Am J Clin Oncol** 1997 Apr;20(2):161–5

5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial. Tsavaris NB, et al. **Am J Clin Oncol** 1996 Oct;19(5):517–21

Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma. Vallejo C, et al. **Am J Clin Oncol** 1996 Dec;19(6):584–8

A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program Trial. Vaughn DJ, et al. **Am J Clin Oncol** 1997 Jun;20(3):242–6

Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations. Weiss AJ, et al. **Am J Clin Oncol** 1997 Feb; 20(1):63–8 (30 ref.)

A phase I study of methotrexate administration following 5-fluorouracil. White RM. **Am J Clin Oncol** 1996 Oct; 19(5):492–9

Chemotherapy versus best supportive care for advanced non-small-cell lung cancer. Abang AM. **Am J Health Syst Pharm** 1996 Dec 15;53(24):2980–4

Feasibility, toxicity, and activity of LNH84-derived chemotherapy in the management of aggressive lymphomas. Laurencet FM, et al. **Am J Hematol** 1997 Aug; 55(4):199–204

An "all-oral" combination therapy in chronic lymphocytic leukemia including the oral idarubicin [letter] Molica S, et al. **Am J Hematol** 1996 Jul;52(3):235–6

11q23 aberration is an additional chromosomal change in de novo acute leukemia after treatment with etoposide and mitoxantrone. Ohshima A, et al. **Am J Hematol** 1996 Dec; 53(4):264–6

Successful treatment of lymphomatoid granulomatosis using cyclosporin-A after failure of intensive chemotherapy. Raez LE, et al. **Am J Hematol** 1996 Nov;53(3):192–5

Malignant pheochromocytoma, still a therapeutic challenge. Tato A, et al. **Am J Hypertens** 1997 Apr;10(4 Pt 1):479–81

Identification of human papillomavirus types 16 and 18 deoxyribonucleic acid sequences in bulky cervical cancer after chemotherapy. Tseng CJ, et al. **Am J Obstet Gynecol** 1997 Apr;176(4):865–9

Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. Davidson BS, et al. **Am J Surg** 1996 Sep; 172(3):244–7

Anal canal cancer: current treatment and results. Cummings BJ. **Ann Acad Med Singapore** 1996 May;25(3):460–7 (45 ref.)

Primary cerebral lymphoma--a case report and review of the management. Li Q, et al. **Ann Acad Med Singapore** 1995 Nov;24(6):856–9 (25 ref.)

Treatment of small cell lung cancer: a single institutional experience. Soh LT, et al. **Ann Acad Med Singapore** 1996 Jul;25(4):531–5

Primary mediastinal germ cell tumour. Soh LT, et al. **Ann Acad Med Singapore** 1996 Mar;25(2):192–5

Chemotherapy in non-small cell lung cancer: a review. Tan EH, et al. **Ann Acad Med Singapore** 1996 Jul;25(4):570–83 (125 ref.)

Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Wong GC, et al. **Ann Acad Med Singapore** 1996 Jul;25(4):500–3

Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. Caballero MD, et al. **Ann Hematol** 1997 Feb;74(2):79–82

FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Huhmann IM, et al. **Ann Hematol** 1996 Dec;73(6):265–71

Intensive chemotherapy for adult acute lymphoblastic leukaemia given with or without granulocyte-macrophage colony stimulating factor. Papamichael D, et al. **Ann Hematol** 1996 Dec;73(6):259–63

S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Verbeek W, et al. **Ann Hematol** 1997 May;74(5):205–8

Induction of a hematological and cytogenetic remission in a patient with a myelodysplastic syndrome secondary to Fanconi's anemia employing the S-HAM regimen. Verbeek W, et al. **Ann Hematol** 1997 Jun;74(6):275–7

Autologous stem cell transplantation in solid tumours of childhood. Atra A, et al. **Ann Med** 1996 Apr;28(2):159–64 (43 ref.)

High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer. Grénman SE, et al. **Ann Med** 1996 Apr;28(2):151–8 (64 ref.)

Autologous stem cell transplants in lymphomas. Vandenberghe EA, et al. **Ann Med** 1996 Apr;28(2):137–43 (74 ref.)

Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan. Saijo N. **Ann N Y Acad Sci** 1996 Dec 13;803:292–305 (39 ref.)

Combined concomitant boost radiotherapy and chemotherapy in stage III–IV head and neck carcinomas: a comparison of toxicity and treatment results with those observed after radiotherapy alone. Allal AS, et al. **Ann Oncol** 1997 Jul;8(7):681–4

Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Aranda E, et al. **Ann Oncol** 1996 Aug;7(6):581–5

Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study. Auerbach M, et al. **Ann Oncol** 1997 May;8(5):439–44

Synchronous multifocal osteosarcoma: results in twelve patients treated with neoadjuvant chemotherapy and simultaneous resection of all involved bones. Bacci G, et al. **Ann Oncol** 1996 Oct;7(8):864–6

Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua [see comments] Baez F, et al. **Ann Oncol** 1997 Mar; 8(3):247–50. Comment in: Ann Oncol 1997 Mar;8(3):215–6.

Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer. Baumann I, et al. **Ann Oncol** 1996 Dec;7(10):1051-7

Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Bedikian AY, et al. **Ann Oncol** 1997 Apr;8(4):363-7

Chemotherapy for carcinoma of the esophagus: a comparison of evidence from meta-analyses of randomized trials and of historical control studies. Bhansali MS, et al. **Ann Oncol** 1996 Apr;7(4):355-9

A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Bokemeyer C, et al. **Ann Oncol** 1996 Dec;7(10):1015-21

Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Bower M, et al. **Ann Oncol** 1997 May;8(5):477-83

Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer. Boyer MJ, et al. **Ann Oncol** 1997 May;8(5):485-9

A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Braybrooke JP, et al. **Ann Oncol** 1997 Mar;8(3):294-6

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group [see comments] Brufman G, et al. **Ann Oncol** 1997 Feb;8(2):155-62. Comment in: Ann Oncol 1997 Feb;8(2):109-10.

Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation. Buser K, et al. **Ann Oncol** 1996 Jan;7(1):65-70

Is CHOP the standard of therapy for poor-prognosis large-cell lymphoma? Canellos GP. **Ann Oncol** 1997;8 Suppl 1:61-2 (7 ref.)

Chemotherapy for symptom control in recurrent squamous cell carcinoma of the head and neck [see comments] Constenla DO, et al. **Ann Oncol** 1997 May;8(5):445-9. Comment in: Ann Oncol 1997 May;8(5):417-8.

Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO). Conte PF, et al. **Ann Oncol** 1996 Jul;7(5):487-90

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group [published erratum appears in Ann Oncol 1997 Apr;8(4):407] Cunningham D, et al. **Ann Oncol** 1996 Nov;7(9):961-5

BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Diehl V, et al. **Ann Oncol** 1997 Feb;8(2):143-8

Ifosfamide and paclitaxel salvage chemotherapy for advanced epithelial ovarian cancer. Dimopoulos MA, et al. **Ann Oncol** 1997 Feb;8(2):195-7

Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Dreger P, et al. **Ann Oncol** 1997 Apr;8(4):401-3

Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. du Bois A, et al. **Ann Oncol** 1997 Apr;8(4):355-61

5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study [see comments] Dufour P, et al. **Ann Oncol** 1996 Aug;7(6):575-9. Comment in: Ann Oncol 1996 Aug;7(6):551-2.

Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy. Etienne MC, et al. **Ann Oncol** 1996 Mar;7(3):283-9 (66 ref.)

A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer. Ezzat A, et al. **Ann Oncol** 1997 Jul;8(7):663-7

Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. Falcone A, et al. **Ann Oncol** 1997 Jun;8(6):539-45

Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon. Falcone A, et al. **Ann Oncol** 1996 Aug; 7(6):601-5

Neo-adjuvant high-dose chemotherapy with autologous peripheral blood stem cell transplantation for inoperable relapse of nuchal liposarcoma resistant to standard-dose chemotherapy [letter] Fetscher S, et al. **Ann Oncol** 1996 Oct;7(8):871

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. Fetscher S, et al. **Ann Oncol** 1997 Jan;8(1):49-56

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer. Fetscher S, et al. **Ann Oncol** 1997 Jan;8(1):57-64

Randomized trial of neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil, with or without leucovorin, in locally advanced head and neck cancer [letter] Fonseca E, et al. **Ann Oncol** 1997 Jul;8(7):713-4

Long-term survival in an adult metastatic renal peripheral primitive neuroectodermal tumor (PPNET) with multimodality treatment including high-dose chemotherapy. Fontaine C, et al. **Ann Oncol** 1997 Jul; 8(7):691-4

Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Fountzilas G, et al. **Ann Oncol** 1997 May;8(5):451-5

Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Fox SB, et al. **Ann Oncol** 1997 Mar;8(3):271-5

Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study. Frasci G, et al. **Ann Oncol** 1997 Mar;8(3):291-3

Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate- to high-grade non-Hodgkin's lymphoma. Freilone R, et al. **Ann Oncol** 1996 Nov;7(9):919-24

Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Gehl J, et al. **Ann Oncol** 1996 Sep;7(7):687-93

Late relapse of germ cell tumors after cisplatin-based chemotherapy. Gerl A, et al. **Ann Oncol** 1997 Jan;8(1):41-7 (28 ref.)

Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Girouard C, et al. **Ann Oncol** 1997 Jul;8(7):675-80

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Glimelius B, et al. **Ann Oncol** 1996 Aug;7(6):593-600

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Glimelius B, et al. **Ann Oncol** 1997 Feb; 8(2):163-8

Treatment of mantle-cell lymphomas with the VAD +/- chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation. Gressin R, et al. **Ann Oncol** 1997;8 Suppl 1:103-6

Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte. Guerci A, et al. **Ann Oncol** 1996 Nov;7(9):966-9

Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Haraf DJ, et al. **Ann Oncol** 1996 Nov; 7(9):913-8

Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Hartmann JT, et al. **Ann Oncol** 1997 Jun;8(6):531-8

Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Hasenclever D, et al. **Ann Oncol** 1996;7 Suppl 4:95-8 (6 ref.)

5-Fluorouracil in colorectal cancer, a never ending story [editorial; comment] [see comments] Herrmann R. **Ann Oncol** 1996 Aug;7(6):551-2. Comment on: Ann Oncol 1996 Aug;7(6):575-9. Comment in: Ann Oncol 1997 Feb;8(2):139-40; discussion 141. Comment in: Ann Oncol 1997 Feb;8(2):203. Comment in: Ann Oncol 1997 Feb;8(2):203-4.

Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. Hidalgo M, et al. **Ann Oncol** 1997 Jun; 8(6):555-9

Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study. Hoffman PC, et al. **Ann Oncol** 1996 Mar;7(3):314-6

Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients. Honkoop AH, et al. **Ann Oncol** 1996 Jan;7(1):35-9

Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Horning SJ, et al. **Ann Oncol** 1996;7 Suppl 4:105-8 (27 ref.)

Carboplatin in the combination chemotherapy of non-seminomatous germ cell tumours [editorial] Horwich A, et al. **Ann Oncol** 1996 Dec;7(10):989-91

Residual mass following chemotherapy of seminoma. Horwich A, et al. **Ann Oncol** 1997 Jan;8(1):37-40

A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors. Huber MH, et al. **Ann Oncol** 1996 Jan; 7(1):59-63

Treatment of childhood Hodgkin's disease with chemotherapy alone [editorial; comment] Hudson MM. **Ann Oncol** 1997 Mar;8(3):215-6. Comment on: Ann Oncol 1997 Mar;8(3):247-50.

A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group. Kosmidis P, et al. **Ann Oncol** 1996 Jul;7(5):517-20

Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study. Kosmidis PA, et al. **Ann Oncol** 1997 Jul;8(7):697-9

5-Fluorouracil, interferon-alpha-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study. Hellenic Co-operative Oncology Group. Kosmidis PA, et al. **Ann Oncol** 1997 Apr;8(4):373-8

Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Kumagai K, et al. **Ann Oncol** 1997;8 Suppl 1:107-9

High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer. Labianca R, et al. **Ann Oncol** 1997 Feb; 8(2):169-74

Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Lassen U, et al. **Ann Oncol** 1996 Apr;7(4):365-71

Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Licitra L, et al. **Ann Oncol** 1996 Aug;7(6):640-2

Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials. Linch DC, et al. **Ann Oncol** 1997;8 Suppl 1:63-5

A pilot study of infusional CMF (CMF-inf): active and well tolerated in breast cancer. The Edinburgh Breast Group. Mackay J, et al. **Ann Oncol** 1996 Apr;7(4):409-11

The treatment of pediatric lymphomas: paradigms to plagiarize? Magrath IT. **Ann Oncol** 1997;8 Suppl 1:7-14 (36 ref.)

Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group. Manegold C, et al. **Ann Oncol** 1996 Aug;7(6):637-9

Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer [see comments] Manegold C, et al. **Ann Oncol** 1997 Jun;8(6):525-9. Comment in: Ann Oncol 1997 Jun;8(6):513-4.

The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group [see comments] Marini G, et al. **Ann Oncol** 1996 Mar;7(3):245-50. Comment in: Ann Oncol 1996 Aug;7(6):643.

Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. Marzola M, et al. **Ann Oncol** 1996 Apr;7(4):419-21

Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group. Meerwaldt JH, et al. **Ann Oncol** 1997;8 Suppl 1:67-70

Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study. Michelotti A, et al. **Ann Oncol** 1996 Oct;7(8):857-60

Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia. Montefusco E, et al. **Ann Oncol** 1997 Feb;8(2):175-9

Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non-Hodgkin's lymphomas: long-term results for 96 patients with tumors > 5 cm. Munck JN, et al. **Ann Oncol** 1996 Nov;7(9):925-31

Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma. Newell M, et al. **Ann Oncol** 1996 Dec;7(10):1029-36

Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. Norum J, et al. **Ann Oncol** 1997 Jan;8(1):65-70

Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. Peiffert D, et al. **Ann Oncol** 1997 Jun;8(6):575-81

Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma. Planting AS, et al. **Ann Oncol** 1996 Dec;7(10):1080-2

Chemotherapy of biliary tract cancer with mitomycin-C and 5-fluorouracil biologically modulated by folinic acid. A phase II study [letter] Polyzos A, et al. **Ann Oncol** 1996 Aug;7(6):644-5

Concurrent chemo- and radiotherapy in patients with locally advanced carcinoma of the cervix. Pras E, et al. **Ann Oncol** 1996 Jul;7(5):511-6

Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma. Prince HM, et al. **Ann Oncol** 1996 Dec;7(10):1043-9

The systemic treatment of non-small-cell lung cancer. Propper D, et al. **Ann Oncol** 1997 Mar;8(3):285-90

Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma

Cooperative Group and Groupe Pierre-et-Marie-Curie. Raemaekers J, et al. **Ann Oncol** 1997;8 Suppl 1:111-4

The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study-Group since 1978. German-Austrian Pediatric Hodgkin's Disease Study Group. Schellong G. **Ann Oncol** 1996;7 Suppl 4:67-72 (36 ref.)

Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. Shepherd FA, et al. **Ann Oncol** 1996 Mar;7(3):311-3

PACE BOM chemotherapy: a 12-week regimen for advanced Hodgkin's disease. Simmonds PD, et al. **Ann Oncol** 1997 Mar;8(3):259-66

A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. Swenerton K, et al. **Ann Oncol** 1996 Dec;7(10):1077-9

Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. ten Bokkel Huinink WW, et al. **Ann Oncol** 1997 Apr;8(4):351-4

Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Todeschini G, et al. **Ann Oncol** 1997; 8 Suppl 1:77-81

Initial chemotherapy for primary resectable large-cell lymphoma of the stomach [see comments] Tondini C, et al. **Ann Oncol** 1997 May;8(5):497-9. Comment in: Ann Oncol 1997 May;8(5):419-21.

Treatment of childhood Hodgkin's disease without radiotherapy. van den Berg H, et al. **Ann Oncol** 1997;8 Suppl 1:15-7

Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience. Vignetti M, et al. **Ann Oncol** 1996 Nov;7(9):933-8

Role of interferon as a modulator of fluoropyrimidines: reply to a recent editorial [comment] Wadler S, et al. **Ann Oncol** 1997 Feb;8(2):139-40; discussion 141. Comment on: Ann Oncol 1996 Aug;7(6):551-2.

Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Wilke H, et al. **Ann Oncol** 1996 Jan;7(1):55-8

Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Wolf M, et al. **Ann Oncol** 1997;8 Suppl 1:71-5

Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results. Zambetti M, et al. **Ann Oncol** 1996 Jul;7(5):481-5

Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Zinzani PL, et al. **Ann Oncol** 1997 Apr;8(4):379-83

Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Nakajima T, et al. **Ann Surg Oncol** 1997 Apr-May;4(3):203-8

Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer. van Basten JP, et al. **Ann Surg Oncol** 1997 Jun;4(4):342-8

A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Bokemeyer C, et al. **Anticancer Drugs** 1997 Apr;8(4):396-9

Different doses of granulocyte colony stimulating factor to support a weekly chemotherapeutic regimen in advanced gastric cancer: a randomized study. Cascinu S, et al. **Anticancer Drugs** 1996 Jan;7(1):43-7

A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. Cascinu S, et al. **Anticancer Drugs** 1996 Jul;7(5):520-4

Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group. Colucci G, et al. **Anticancer Drugs** 1997 Mar;8(3):257-64

Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Cree IA, et al. **Anticancer Drugs** 1996 Aug;7(6):630-5

In vivo effects of tumor necrosis factor-alpha or flavone acetic acid in combination with doxorubicin on multidrug-resistant B16 melanoma. D'Alessandro N, et al. **Anticancer Drugs** 1996 May;7(3):281-7

Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma. Gebbia V, et al. **Anticancer Drugs** 1996 Jun;7(4):386-91

Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin--a new, clinically active platinum analog in established human cancer cell lines. Harstrick A, et al. **Anticancer Drugs** 1997 Apr;8(4):391-5

CNF combination as adjuvant treatment in breast cancer patients is well tolerated. Hirvikoski PP, et al. **Anticancer Drugs** 1997 Apr;8(4):376-8

Colorectal cancer--an undertreated disease. Kemeny N. **Anticancer Drugs** 1996 Aug;7(6):623-9 (84 ref.)

Combining 5-fluorouracil with interferon-alpha in the treatment of advanced colorectal cancer: optimism followed by disappointment. Kjaer M. **Anticancer Drugs** 1996 Jan;7(1):35-42 (54 ref.)

Marked enhancement in vivo of paclitaxel's (taxol's) tumor-regressing activity by ATP-depleting modulation. Martin DS, et al. **Anticancer Drugs** 1996 Aug;7(6):655-9

Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-alpha and 13-cis-retinoic acid: report of two cases and review of the literature. Piamsomboon S, et al. **Anticancer Drugs** 1996 Sep; 7(7):800-4 (48 ref.)

Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells. Raymond E, et al. **Anticancer Drugs** 1996 Sep;7(7):752-7

Taxol and vinorelbine: a new active combination for disseminated malignant melanoma. Retsas S, et al. **Anticancer Drugs** 1996 Feb;7(2):161-5

Advanced colorectal carcinoma: redefining the role of oral ftorafur. Ron IG, et al. **Anticancer Drugs** 1996 Aug; 7(6):649-54

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Shirasaka T, et al. **Anticancer Drugs** 1996 Jul; 7(5):548-57

Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon. Werner A, et al. **Anticancer Drugs** 1996 May;7(3):307-11

Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: a study of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg. Wils JA, et al. **Anticancer Drugs** 1997 Jun;8(5):432-5

Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Asakawa H, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2757-62

Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours. Baars JW, et al. **Anticancer Res** 1996 Sep-Oct;16(5B):3089-95

Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Bottini A, et al. **Anticancer Res** 1996 Sep-Oct;16(5B):3105-10

Double modulation with methotrexate and L-leucovorin of weekly 24- hour fluorouracil infusion in fluorouracil-refractory colorectal cancer. Colleoni M, et al. **Anticancer Res** 1996 Sep-Oct;16(5B):3101-4

Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy. Garzetti GG, et al. **Anticancer Res** 1996 Sep-Oct;16(5B):3229-34

A phase II study of VM-26 plus lonidamine in pretreated small cell lung cancer. Gridelli C, et al. **Anticancer Res** 1997 Mar-Apr;17(2B):1277-9

Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin. Hsu CH, et al. **Anticancer Res** 1997 Mar-Apr;17(2B):1331-4

Interferons alpha-2a and beta increase the antitumor activity, detected by MTT assay, of 5-fluorouracil against experimental and clinical human gastrointestinal carcinomas. Kubota T, et al. **Anticancer Res** 1997 Jan-Feb; 17(1B):725-8

Effect of combination therapy with UFT plus cisplatin (UFTP) on the survival of mice in the experimental model for wide-spread metastasis in the peritoneal cavity of gastrointestinal cancer using colon 26 PMF-15 cells. Kurihara M, et al. **Anticancer Res** 1997 May-Jun; 17(3C):2217-20

Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up. Lee F, et al. **Anticancer Res** 1997 May-Jun; 17(3A):1511-5

Mitomycin C and lonidamine as second-line treatment of advanced colorectal cancer patients. Maiello E, et al. **Anticancer Res** 1996 Sep-Oct;16(5B):3177-9

Feasibility and toxicity of combination chemotherapy with ifosfamide, vinorelbine, cisplatin versus ifosfamide, vinorelbine in patients with advanced non small cell lung cancer. Mencoboni M, et al. **Anticancer Res** 1997 Jul-Aug; 17(4A):2795-8

Response to second line chemo-endocrine treatment may prolong the overall survival of advanced breast cancer patients. Nomura Y. **Anticancer Res** 1997 Mar-Apr; 17(2B):1425-30

Effects of 5'-DFUR and OK-432 on cytokines and thymidine phosphorylase in tumor tissue of gastric cancer patients. Ohwada S, et al. **Anticancer Res** 1997 May-Jun; 17(3C):2313-8

Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2-tetrahydrofuryl)-5-fluorouracil] with uracil, by oral l-leucovorin. Okabe H, et al. **Anticancer Res** 1997 Jan-Feb; 17(1A):157-64

Intensified M-VEC chemotherapy with G-CSF support as outpatient treatment for advanced bladder cancer. Pronzato P, et al. **Anticancer Res** 1997 May-Jun;17(3C):2325-7

A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer. Tibaldi C, et al. **Anticancer Res** 1996 Sep-Oct; 16(5B):3213-5

High-dose tamoxifen reverses drug resistance to cisplatin and etoposide in a patient with advanced large cell carcinoma of lung. Yeh KH, et al. **Anticancer Res** 1997 Mar-Apr; 17(2B):1341-3

Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukemia. Kerridge I, et al. **Arch Intern Med** 1997 Aug 11-25;157(15):1753-7 (26 ref.)

B-lineage acute lymphoblastic leukemia of childhood. An institutional experience. Rivera-Luna R, et al. **Arch Med Res** 1997 Summer;28(2):233-9

Dementia improvement with cytotoxic chemotherapy. A case of Alzheimer disease and multiple myeloma. Keimowitz RM. **Arch Neurol** 1997 Apr;54(4):485-8

Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Gallie BL, et al. **Arch Ophthalmol** 1996 Nov;114(11):1321-8

Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Kingston JE, et al. **Arch Ophthalmol** 1996 Nov;114(11):1339-43

Chemoreduction in the initial management of intraocular retinoblastoma. Shields CL, et al. **Arch Ophthalmol** 1996 Nov;114(11):1330-8

Bilateral macular retinoblastoma managed by chemoreduction and chemothermotherapy. Shields JA, et al. **Arch Ophthalmol** 1996 Nov;114(11):1426-7

The role of chemotherapy in malignant thymoma [letter] Coperchini ML, et al. **Aust N Z J Med** 1996 Jun;26(3):423

Multiple cycles of aggressive chemotherapy prior to autologous peripheral stem cell transplantation for lymphoma. Goss G, et al. **Aust N Z J Med** 1997 Jun; 27(3):323-9

Primary small-cell carcinoma of the oesophagus with spontaneous oesophageal perforation following chemotherapy. Clark T, et al. **Australas Radiol** 1996 Aug; 40(3):250-3

Concurrent chemoradiation for oesophageal cancer: factors influencing myelotoxicity. MacKean J, et al. **Australas Radiol** 1996 Nov;40(4):424-9

Treatment of acute promyelocytic leukaemia. Fenaux P, et al. **Baillieres Clin Haematol** 1996 Mar;9(1):107-28 (103 ref.)

Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice. Raghunathan K, et al. **Biochem Pharmacol** 1997 Apr 25; 53(8):1197-202

Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Stockerl-Goldstein KE, et al. **Biol Blood Marrow Transplant** 1996 May;2(2):76-85

The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Vredenburgh JJ, et al. **Biol Blood Marrow Transplant** 1997 Jun;3(2):91-7

Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer. Weaver CH, et al. **Biol Blood Marrow Transplant** 1997 Jun; 3(2):83-90

High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Wheeler C, et al. **Biol Blood Marrow Transplant** 1997 Jun;3(2):98-106

Treatment of small non-cleaved cell lymphoma in the adult. Hagemeister FB. **Biomed Pharmacother** 1996;50(9):433-41 (47 ref.)

Improved therapy for children with acute lymphoblastic leukemia. Komada Y, et al. **Biomed Pharmacother** 1996; 50(3-4):132-9

Treatment of Burkitt's lymphoma in HIV-positive patients. Straus DJ. **Biomed Pharmacother** 1996;50(9):447-50 (29 ref.)

Inhibitory effect of metastasis by combined administration with interleukin-2 and sizofiran, a single glucan--immunohistochemical study. Kano Y, et al. **Biotherapy** 1996;9(4):263-9

Augmentation of antitumor effect by combined administration with interleukin-2 and sizofiran, a single glucan, on murine EL-4 lymphoma. Kano Y, et al. **Biotherapy** 1996;9(4):241-7

Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study. Mantovani G, et al. **Biotherapy** 1994;8(2):91-8

Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Anderson JE, et al. **Blood** 1997 Apr 1;89(7):2578-85 (23 ref.)

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Barlogie B, et al. **Blood** 1997 Feb 1;89(3):789-93

Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Basser RL, et al. **Blood** 1997 May 1;89(9):3118-28

Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor

cell autografting. Corradini P, et al. **Blood** 1997 Jan 15; 89(2):724–31

High–dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Freedman AS, et al. **Blood** 1996 Oct 1; 88(7):2780–6

Granulocyte colony–stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia—a randomized phase–III study. Geissler K, et al. **Blood** 1997 Jul 15;90(2):590–6

Engraftment of allogeneic hematopoietic progenitor cells with purine analog–containing chemotherapy: harnessing graft–versus–leukemia without myeloablative therapy. Giralt S, et al. **Blood** 1997 Jun 15;89(12):4531–6

Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Hann IM, et al. **Blood** 1997 Apr 1; 89(7):2311–8

In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Hongo T, et al. **Blood** 1997 Apr 15;89(8):2959–65

High–dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Horning SJ, et al. **Blood** 1997 Feb 1; 89(3):801–13

Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte–macrophage colony–stimulating factor–based priming before and during TAD–9 induction therapy in acute myeloid leukemia. Jahns–Streubel G, et al. **Blood** 1997 Sep 1;90(5):1968–76

Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Kay NE, et al. **Blood** 1997 Jul 1;90(1):340–5

Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Leith CP, et al. **Blood** 1997 May 1;89(9):3323–9

Molecular remission in PML/RAR alpha–positive acute promyelocytic leukemia by combined all–trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano–Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Mandelli F, et al. **Blood** 1997 Aug 1;90(3):1014–21

Increased frequency of expression of elevated dihydrofolate reductase in T–cell versus B–precursor acute lymphoblastic leukemia in children. Matherly LH, et al. **Blood** 1997 Jul 15;90(2):578–89

Granulocyte–colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Moore JO, et al. **Blood** 1997 Feb 1;89(3):780–8

Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non–Hodgkin's lymphoma patients—results of a phase I/II trial. Moskowitz CH, et al. **Blood** 1997 May 1;89(9):3136–47

Case–control study suggests a favorable impact of TEL rearrangement in patients with B–lineage acute lymphoblastic leukemia treated with antimetabolite–based therapy: a Pediatric Oncology Group study. Rubnitz JE, et al. **Blood** 1997 Feb 15;89(4):1143–6

CD2 antigen expression on leukemic cells as a predictor of event–free survival after chemotherapy for T–lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Uckun FM, et al. **Blood** 1996 Dec 1;88(11):4288–95

Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Uckun FM, et al. **Blood** 1997 Jul 1;90(1):28–35

A randomized investigation of high–dose versus standard–dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Weick JK, et al. **Blood** 1996 Oct 15;88(8):2841–51

Comparison between conventional salvage therapy and high–dose therapy with autografting for recurrent or refractory Hodgkin's disease. Yuen AR, et al. **Blood** 1997 Feb 1;89(3):814–22

Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. Radford JA, et al. **BMJ** 1997 Feb 1; 314(7077):343–6

Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials. Ahmed T, et al. **Bone Marrow Transplant** 1997 Mar;19(5):449–54

Phase I–II study of high–dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. Ballester OF, et al. **Bone Marrow Transplant** 1996 Jul; 18(1):9–14

High–dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bensinger WI, et al. **Bone Marrow Transplant** 1997 Jun;19(12):1183–9

Prognostic factors for survival after high–dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Brice P, et al. **Bone Marrow Transplant** 1997 Jul;20(1):21–6

High–dose fractionated total–body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. Brunvand MW, et al. **Bone Marrow Transplant** 1996 Jul;18(1):131–41

Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. Carpenter PA, et al. **Bone Marrow Transplant** 1996 Sep;18(3):489–94

Granulocyte–macrophage colony–stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high–dose chemotherapy for lymphoma. Colombat P, et al. **Bone Marrow Transplant** 1996 Aug;18(2):293–9

High–dose BCNU and autologous progenitor cell transplantation given with intra–arterial cisplatinum and simultaneous radiotherapy in the treatment of high–grade gliomas: benefit for selected patients. Fernández–Hidalgo OA, et al. **Bone Marrow Transplant** 1996 Jul;18(1):143–9

Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy. Fielding AK, et al. **Bone Marrow Transplant** 1996 Sep; 18(3):507–11

The role of high–dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors. Finlay JL. **Bone Marrow Transplant** 1996 Dec;18 Suppl 3:S1–5 (20 ref.)

The treatment of relapsed or refractory intermediate grade non–Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Gryn J, et al. **Bone Marrow Transplant** 1997 Feb; 19(3):221–6

An incremental response to high–dose therapy in multiple myeloma. Hawkins T, et al. **Bone Marrow Transplant** 1996 Jun;17(6):929–35

Successful treatment of primary extramedullary leukemia (EML) of the uterus with radical surgery, chemotherapy, autologous bone marrow transplantation (BMT) and prophylactic local irradiation. Huter O, et al. **Bone Marrow Transplant** 1996 Sep;18(3):663–4

Autologous blood cell transplantation in B–CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Itälä M, et al. **Bone Marrow Transplant** 1997 Apr;19(7):647–51

A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. Kamani N, et al. **Bone Marrow Transplant** 1996 Jun;17(6):911–6

Phase II study of high–dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high–risk non–metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment. Klumpp TR, et al. **Bone Marrow Transplant** 1997 Aug; 20(4):273–81

Chemopurging of peripheral blood–derived progenitor cells by alkyl–lysophospholipid and its effect on haematopoietic rescue after high–dose therapy. Koenigsmann MP, et al. **Bone Marrow Transplant** 1996 Sep;18(3):549–57

Effective high–dose chemotherapy followed by autologous peripheral blood stem cell transplantation in a patient with the aggressive form of cytophagic histiocytic panniculitis. Koizumi K, et al. **Bone Marrow Transplant** 1997 Jul; 20(2):171–3

Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high–dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Koscielniak E, et al. **Bone Marrow Transplant** 1997 Feb; 19(3):227–31

Intensive combination chemotherapy in treatment of CML. Lengfelder E, et al. **Bone Marrow Transplant** 1996 May; 17 Suppl 3:S55–7 (19 ref.)

Sexual dysfunction prior to high–dose chemotherapy and bone marrow transplantation. Marks DI, et al. **Bone Marrow Transplant** 1996 Apr;17(4):595–9

Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma. Matthay KK. **Bone Marrow Transplant** 1996 Dec;18 Suppl 3:S21–4

High–dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Mehta J, et al. **Bone Marrow Transplant** 1997 Jul;20(2):113–6

BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Meloni G, et al. **Bone Marrow Transplant** 1996 Oct;18(4):693–8

Prolonged resolution of hemophagocytic lymphohistiocytosis following myeloablative chemotherapy and subsequent autologous peripheral blood stem cell transplantation. Ohga S, et al. **Bone Marrow Transplant** 1997 Mar;19(6):633–5

G–CSF (filgrastim)–stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM–like regimen in bad–risk lymphoma. Ossenkoppele GJ, et al. **Bone Marrow Transplant** 1996 Aug;18(2):427–31

Role of tumor cells contaminating the graft in breast cancer recurrence after high–dose chemotherapy. Pedrazzoli P, et al. **Bone Marrow Transplant** 1997 Jul;20(2):167–9

Phase II study of high–dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Schiffman KS, et al. **Bone Marrow Transplant** 1996 Jun;17(6):943–50

Allogeneic BMT vs. chemotherapy in late bone marrow relapsed childhood non–T/non–B ALL: results of BFM ALL relapse studies. BFM Relapse Study Group. Schmid H, et al. **Bone Marrow Transplant** 1996 Nov;18 Suppl 2:28–30

Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours. Shaw PJ, et al. **Bone Marrow Transplant** 1996 Dec;18(6):1043–7

Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Talmadge JE, et al. **Bone Marrow Transplant** 1997 Jan;19(2):161–72

Results of a pilot study of 40 patients using high–dose therapy with hematopoietic rescue after standard–dose adjuvant therapy for high–risk breast cancer. Tomás JF, et al. **Bone Marrow Transplant** 1997 Feb;19(4):331–6

Treatment of childhood acute lymphoblastic leukemia in first remission with allogeneic bone marrow transplantation or with intensive chemotherapy: a cooperative Italian study. The AIEOP (Associazione Italiana Ematologia ed Oncologia Pediatrica) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo), Italy. Uderzo C, et al. **Bone Marrow Transplant** 1996 Nov;18 Suppl 2:25–7

Phase I study of high–dose continuous intravenous infusion of VP–16 in combination with high–dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. Valteau–Couanet D, et al. **Bone Marrow Transplant** 1996 Apr;17(4):485–9

A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies. Vey N, et al. **Bone Marrow Transplant** 1996 Sep;18(3):495–9

Treatment–related mortality in 1000 consecutive patients receiving high–dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Weaver CH, et al. **Bone Marrow Transplant** 1997 Apr;19(7):671–8

High–dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high–risk cancer: non–haematological, haematological toxicities and role of growth factor administration. Benedetti Panici P, et al. **Br J Cancer** 1997; 75(8):1205–12

Initial prognostic factors in small–cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). Bernhard J, et al. **Br J Cancer** 1996 Nov;74(10):1660–7

Long–term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline–based neoadjuvant chemotherapy. Brain E, et al. **Br J Cancer** 1997;75(9):1360–7

High–dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer—phase I/II study. Edinburgh Breast Group. Cameron DA, et al. **Br J Cancer** 1996 Dec;74(12):2013–7

Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node–positive breast cancer: results at 8 years (Pronacam 85). Chacon R, et al. **Br J Cancer** 1997;76(4):545–50

Cisplatin/carboplatin + etoposide + vinorelbine in advanced non–small–cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Comella P, et al. **Br J Cancer** 1996 Dec;74(11):1805–11

Enhancement of paclitaxel activity against hormone–refractory prostate cancer cells in vitro and in vivo by quinacrine. de Souza PL, et al. **Br J Cancer** 1997; 75(11):1593–600

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half–life: a study in patients with disseminated non–seminomatous testicular cancer. de Wit R, et al. **Br J Cancer** 1997;75(3):432–5

Survival of patients with advanced urothelial cancer treated with cisplatin–based chemotherapy. Fosså SD, et al. **Br J Cancer** 1996 Nov;74(10):1655–9

A pilot study of concurrent whole–brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non–small–cell lung cancer with brain metastasis. Furuse K, et al. **Br J Cancer** 1997;75(4):614–8

Weekly doxorubicin and continuous infusional 5–fluorouracil for advanced breast cancer. Gabra H, et al. **Br J Cancer** 1996 Dec;74(12):2008–12

Advances in the management of metastatic non–seminomatous germ cell tumours during the cisplatin era: a single–institution experience. Gerl A, et al. **Br J Cancer** 1996 Oct;74(8):1280–5

Outpatient treatment with epirubicin and oral etoposide in patients with small–cell lung cancer. Gogas H, et al. **Br J Cancer** 1997;76(5):639–42

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study. Hernes EH, et al. **Br J Cancer** 1997;76(1):93–9

Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. Kok TC, et al. **Br J Cancer** 1996 Sep;74(6):980–4

Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. Kornek GV, et al. **Br J Cancer** 1996 Nov;74(10):1668–73

Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. Lee SM, et al. **Br J Cancer** 1997;75(1):110–5

A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. Lissoni P, et al. **Br J Cancer** 1996 Nov;74(9):1466–8

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. MacGrogan G, et al. **Br J Cancer** 1996 Nov; 74(9):1458–65

Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Melcher AA, et al. **Br J Cancer** 1996 Nov; 74(10):1651–4

Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer. Pedrazzoli P, et al. **Br J Cancer** 1997;75(9):1368–72

A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. Piga A, et al. **Br J Cancer** 1996 Sep;74(6):971–4

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. Punt CJ, et al. **Br J Cancer** 1997;76(2):266–9

A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. Rigg A, et al. **Br J Cancer** 1997;75(1):101–5

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer. Rustin GJ, et al. **Br J Cancer** 1996 Nov;74(9):1479–81

The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. British Columbia/Ontario Working Group. Sawka C, et al. **Br J Cancer** 1997;75(10):1534–42

Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis. Sleijfer S, et al. **Br J Cancer** 1996 Sep;74(6):947–50

Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Theyer G, et al. **Br J Cancer** 1997;75(10):1515–8

Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. Toffoli G, et al. **Br J Cancer** 1997;75(5):715–21

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. Veldhuis GJ, et al. **Br J Cancer** 1997;75(5):703–9

A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide. Weaver A, et al. **Br J Cancer** 1996 Dec; 74(11):1821–7

Calcium supplementation and ototoxicity in patients receiving cisplatin. Grau JJ, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):233–5

A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Abrahamson GM, et al. **Br J Haematol** 1996 Sep;94(4):659–64

Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma. Ballester OF, et al. **Br J Haematol** 1997 Mar;96(4):746–8

Conventional induction treatments do not influence overall survival in multiple myeloma. Boccadoro M, et al. **Br J Haematol** 1997 Feb;96(2):333–7

Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Borg A, et al. **Br J Haematol** 1996 Sep; 94(4):713–5

Long-term clinical outcome of B-cell chronic lymphocytic leukaemia patients in clinical remission phase evaluated at phenotypic level. Brugiatelli M, et al. **Br J Haematol** 1997 Apr;97(1):113–8

ICE, mini-ICE or high-dose hydroxyurea to mobilize Philadelphia (Ph1)-negative PBPC in chronic myelogenous leukaemia [letter; comment] Carella AM, et al. **Br J Haematol** 1996 Oct;95(1):213–5. Comment on: Br J Haematol 1996 Jun 2;93(4):863–8.

A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukaemia: preclinical cell culture studies. Curtis JE, et al. **Br J Haematol** 1996 Nov; 95(2):354–63

Combination of interferon-alpha and hydroxyurea in the treatment of idiopathic hypereosinophilic syndrome [letter; comment] Demiroglu H, et al. **Br J Haematol** 1997 Jun; 97(4):928–30. Comment on: Br J Haematol 1996 Jan;92(1):176–83.

Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol. Giona F, et al. **Br J Haematol** 1997 Jun; 97(4):896–903

Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. Joshua DE, et al. **Br J Haematol** 1997 Apr;97(1):38–45

Prognostic factors in elderly acute lymphoblastic leukaemia. Legrand O, et al. **Br J Haematol** 1997 Jun;97(3):596–602

A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Raje N, et al. **Br J Haematol** 1997 Apr;97(1):153–60

Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma. Rossi A, et al. **Br J Haematol** 1997 Mar;96(3):620–6

Combination chemotherapy with CHOP for recurrent thrombotic thrombocytopenic purpura. Spiekermann K, et al. **Br J Haematol** 1997 Jun;97(3):544–6

Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Wisløff F, et al. **Br J Haematol** 1997 Apr;97(1):29–37

High-dose therapy for aggressive non-Hodgkin's lymphoma. Pettengell R. **Br J Hosp Med** 1996 Nov 20–Dec 10; 56(10):521–4 (15 ref.)

Aggressive treatment in follicular non-Hodgkin's lymphoma. Schouten HC. **Br J Hosp Med** 1996 Nov 20–Dec 10; 56(10):525–8 (32 ref.)

The management of poor prognosis teratoma. Welch RS, et al. **Br J Hosp Med** 1996 Sep 4–17;56(5):222–4 (14 ref.)

Gestational trophoblastic disease with liver metastases: the Charing Cross experience. Crawford RA, et al. **Br J Obstet Gynaecol** 1997 Jan;104(1):105–9

Balloon-occluded arterial infusion as a useful neoadjuvant chemotherapy for bladder cancer. Arima K, et al. **Br J Urol** 1997 Sep;80(3):417–20

Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Cookson MS, et al. **Br J Urol** 1997 Mar;79(3):432–8

Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis. Culine S, et al. **Br J Urol** 1997 Feb;79(2):258–62

Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Fellin G, et al. **Br J Urol** 1997 Jul;80(1):44–9

Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Fleshner NE, et al. **Br J Urol** 1996 Dec;78(6):907–10

Complications of the post-chemotherapy resection of retroperitoneal residual tumour mass in patients with non-seminomatous testicular germ cell tumours. Gels ME, et al. **Br J Urol** 1997 Feb;79(2):263–8

Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer. Hellström M, et al. **Br J Urol** 1997 Mar;79(3):421–6

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Kreis W, et al. **Br J Urol** 1997 Feb; 79(2):196–202

Management of invasive squamous cell carcinoma of the bulbomembranous male urethra with co-ordinated chemo-radiotherapy and genital preservation. Oberfield RA, et al. **Br J Urol** 1996 Oct;78(4):573–8

Finasteride plus flutamide for prostatic carcinoma [letter] Sandhu SS, et al. **Br J Urol** 1997 Aug;80(2):360

Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer? A French Northern Oncology Group trial in 105 patients. French Northern Oncology Group. Adenis A, et al. **Breast Cancer Res Treat** 1996; 40(2):161–9

Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Amadori D, et al. **Breast Cancer Res Treat** 1997 Mar;43(1):7–14

P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Chung HC, et al. **Breast Cancer Res Treat** 1997 Jan;42(1):65–72

Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin. Colozza M, et al. **Breast Cancer Res Treat** 1996;38(3):277–82

Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer. de Vries EG, et al. **Breast Cancer Res Treat** 1996;39(3):307–13

High-dose chemotherapy with autologous stem cell rescue in breast cancer. Dillman RO, et al. **Breast Cancer Res Treat** 1996;37(3):277–89

Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Fehm T, et al. **Breast Cancer Res Treat** 1997 Mar; 43(1):87–95

Changes of biological features in breast cancer cells determined by primary chemotherapy. Frassoldati A, et al. **Breast Cancer Res Treat** 1997 Jul;44(3):185–92

Advanced breast cancer: a randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine. Green JA, et al. **Breast Cancer Res Treat** 1996;39(2):155–63

Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer. Ingle JN, et al. **Breast Cancer Res Treat** 1997 May;43(3):193–200

Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. Pronzato P, et al. **Breast Cancer Res Treat** 1997 Jan;42(2):183–6

Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells. Silvestrini R, et al. **Breast Cancer Res Treat** 1997 Jan; 42(2):103–12

Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Taylor CW, et al. **Breast Cancer Res Treat** 1997 Jan;42(1):7–14

Evaluation of long-term results of a modified VAB-6 chemotherapy regimen in a cohort of good-risk metastatic non seminomatous germ-cell tumors. Culine S, et al. **Bull Cancer** 1997 Apr;84(4):368–72

Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases. Purdy MH. **Can J Oncol** 1995 Dec;5 Suppl 1:63–8

Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma. Abitbol AA, et al. **Cancer** 1997 Jul 15;80(2):266–76

Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Adelstein DJ, et al. **Cancer** 1997 Sep 15; 80(6):1011–20

Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience. Akbulut H, et al. **Cancer** 1997 Jul 1;80(1):8–14 (19 ref.)

A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Ando E, et al. **Cancer** 1997 May 15; 79(10):1890–6

Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle. Arias F, et al. **Cancer** 1997 Jul 1;80(1):115–20

Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center. Athanasiadis I, et al. **Cancer** 1997 Feb 1;79(3):588–94

Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Bacci G, et al. **Cancer** 1997 Jan 15;79(2):245–54

A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi. Baldini L, et al. **Cancer** 1997 Mar 15; 79(6):1234–40

Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Étude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Beerblock K, et al. **Cancer** 1997 Mar 15;79(6):1100–5

Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen. Beguin Y, et al. **Cancer** 1997 Apr 1;79(7):1351–4

A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Bokemeyer C, et al. **Cancer** 1997 Oct 1; 80(7):1221–7

Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors. Brun B, et al. **Cancer** 1997 Jun 1;79(11):2137–46

A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group. Carpenter PA, et al. **Cancer** 1997 Aug 1;80(3):489–96

Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese Patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid. Chou WC, et al. **Cancer** 1996 Oct 15;78(8):1805–12

Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Chung YS, et al. **Cancer** 1997 Jul 1; 80(1):1–7

Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma.

Conzen SD, et al. **Cancer** 1996 Nov 1;78(9):1906–11

Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Crookes P, et al. **Cancer** 1997 May 1;79(9):1767–75

Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature [see comments] Delepine N, et al. **Cancer** 1996 Nov 15;78(10):2127–35. Comment in: Cancer 1997 Aug 1;80(3):516–8.

Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. Dimeo FC, et al. **Cancer** 1997 May 1;79(9):1717–22

Vinblastine, ifosfamide, and gallium nitrate--an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892). Dreicer R, et al. **Cancer** 1997 Jan 1;79(1):110–4

A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Dunphy FR, et al. **Cancer** 1997 May 15; 79(10):2016–23

Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. Feliu J, et al. **Cancer** 1997 May 15;79(10):1884–9

Phase I/II study of carboplatin and oral etoposide with granulocyte–colony stimulating factor in advanced nonsmall cell lung cancer. Frasci G, et al. **Cancer** 1995 Apr 1;75(7):1578–85

Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Geara FB, et al. **Cancer** 1997 Apr 1;79(7):1279–86

Vinorelbine, cisplatin, and 5–fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study. Gebbia V, et al. **Cancer** 1997 Apr 1; 79(7):1394–400

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5–fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Gebbia V, et al. **Cancer** 1996 Sep 15;78(6):1300–7

High dose tumor necrosis factor–alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Gutman M, et al. **Cancer** 1997 Mar 15; 79(6):1129–37

Mitoxantrone, 5–fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5–fluorouracil (CMF) in first–line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial. Hainsworth JD, et al. **Cancer** 1997 Feb 15;79(4):740–8

Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma. Hejna M, et al. **Cancer** 1996 Oct 15;78(8):1646–50

High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B–cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo–Immunotherapy, Vienna. Jaksic B, et al. **Cancer** 1997 Jun 1;79(11):2107–14

High dose etoposide–based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. Long GD, et al. **Cancer** 1996 Dec 15;78(12):2502–9

A comprehensive review of 5–fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Machover D. **Cancer** 1997 Oct 1;80(7):1179–87 (47 ref.)

Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Marina NM, et al. **Cancer** 1995 Apr 1;75(7):1706–11

Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC–91. Gesellschaft für Pädiatrische Onkologie und Hämatologie. Mertens R, et al. **Cancer** 1997 Sep 1; 80(5):951–9

Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Needle MN, et al. **Cancer** 1997 Jul 15;80(2):341–7

Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM, et al. **Cancer** 1997 Apr 15;79(8):1561–7

The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group [see comments] Olson JE, et al. **Cancer** 1997 Mar 15; 79(6):1138–49. Comment in: Cancer 1997 Mar 15;79(6):1061–6; discussion 1067–8.

Paclitaxel–based second–line therapy for patients with advanced chemotherapy–resistant bladder carcinoma (M1): a clinical Phase II study. Otto T, et al. **Cancer** 1997 Aug 1;80(3):465–70

Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial. Paccagnella A, et al. **Cancer** 1996 Oct 15;78(8):1701–7

A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Papadimitriou CA, et al. **Cancer** 1997 Jun 15;79(12):2391–5

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force. Pennucci MC, et al. **Cancer** 1997 May 15;79(10):1897–902

Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. Poplin EA, et al. **Cancer** 1996 Nov 1;78(9):1851–6

Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum–based chemotherapy. Recio FO, et al. **Cancer** 1996 Nov 15; 78(10):2157–63

Is primitive neuroectodermal tumor of the kidney a distinct entity? Rodriguez–Galindo C, et al. **Cancer** 1997 Jun 1; 79(11):2243–50

Phase II trials of 5–fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Rubin J, et al. **Cancer** 1996 Nov 1;78(9):1888–91

A carboplatin–based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Small EJ, et al. **Cancer** 1996 Oct 15; 78(8):1775–80

A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Spiridonidis CH, et al. **Cancer** 1996 Nov 15;78(10):2070–7

Bimonthly high dose leucovorin and 5–fluorouracil 48–hour infusion with interferon–alpha–2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Tournigand C, et al. **Cancer** 1997 Mar 15;79(6):1094–9

Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Uchida A, et al. **Cancer** 1997 Jan 15;79(2):411–5

Treatment of isolated testicular recurrence of acute lymphoblastic leukemia without radiotherapy. Report from the Dutch Late Effects Study Group. van den Berg H, et al. **Cancer** 1997 Jun 1;79(11):2257–62

All–trans retinoic acid and interferon–alpha–2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group. Wadler S, et al. **Cancer** 1997 Apr 15;79(8):1574–80

All–trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG). Asou N, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S30–5

Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study. Balmaceda C, et al. **Cancer Chemother Pharmacol** 1997;40(1):72–4

Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non–Hodgkin's lymphoma. Fisher RI. **Cancer Chemother Pharmacol** 1997; 40 Suppl:S42–6

Phase I study of treatment with oral 13–cis–retinoic acid, subcutaneous interferon alfa–2a, cisplatin, and 24–hour infusion 5–fluorouracil/leucovorin. Fleming GF, et al. **Cancer Chemother Pharmacol** 1997;39(3):227–32

Treatment for adult T–cell leukemia. Hanada S, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S47–50

Combination effects of cisplatin, vinorelbine and irinotecan in non–small–cell lung cancer cell lines in vitro. Mogi H, et al. **Cancer Chemother Pharmacol** 1997;39(3):199–204

A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma. Nagura E, et al. **Cancer Chemother Pharmacol** 1997;39(4):279–85

Apoptosis induced in advanced CD8F1–murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion. Nord LD, et al. **Cancer Chemother Pharmacol** 1997;40(5):376–84

Phase I/II trial of cure–oriented high–dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomagnetic bead method for refractory hematological malignancies. Nagoya CD34+ PBSCT Study Group. Ogura M, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S51–7

Combination chemotherapy involving orally administered etoposide and JM–216 in murine tumor models. Rose WC. **Cancer Chemother Pharmacol** 1997;40(1):51–6

Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony–stimulating factor and sequential radiotherapy in locally advanced, unresectable non–small–cell lung cancer. Scagliotti GV, et al. **Cancer Chemother Pharmacol** 1996;38(6):561–5

High–dose carboplatin plus paclitaxel with granulocyte colony–stimulating factor and peripheral blood stem–cell support in non–small–cell lung cancer. Shea TC. **Cancer Chemother Pharmacol** 1997;40 Suppl:S74–8

Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Sugimachi K, et al. **Cancer Chemother Pharmacol** 1997;40(3):233–8

Vinca alkaloids and macrolides in human immunodeficiency virus–related malignancies: a safe association [letter; comment] Torresin A, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):176–7. Comment on: Cancer Chemother Pharmacol 1995;35(3):188–90.

Value of autologous bone marrow transplantation (ABMT) in 42 patients with follicular lymphomas responsive to conventional chemotherapy: a "France Autogreffe" study. Linassier C, et al. **Cancer Detect Prev** 1996;20(1):11–9

A phase II study of interferon alpha and low–dose subcutaneous interleukin–2 in advanced renal cell carcinoma. Piga A, et al. **Cancer Immunol Immunother** 1997 Aug;44(6):348–51

High–dose mercaptopurine and intermediate–dose cytarabine during first remission of acute myeloid leukemia. Canpolat C, et al. **Cancer Invest** 1997;15(2):121–6

The role of high–dose chemotherapy with hematopoietic stem cell support in the treatment of patients with epithelial ovarian carcinoma. Hussein AM. **Cancer Invest** 1997; 15(3):288–95 (50 ref.)

Phase 1 trial of recombinant human interleukin–1 beta (rhIL–1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940. Rinehart J, et al. **Cancer Invest** 1997;15(5):403–10

Burkitt's lymphoma–leukemia in patients treated for Hodgkin's disease. Salloum E, et al. **Cancer Invest** 1996; 14(6):527–33 (47 ref.)

Concurrent chemoradiotherapy for salvage in relapsed squamous cell head and neck cancer. Tan EH, et al. **Cancer Invest** 1997;15(5):422–8

The role of chemotherapy in the management of celomic epithelial carcinoma of the ovary. Thigpen T, et al. **Cancer Invest** 1997;15(3):277–87 (36 ref.)

Carboplatin and short–infusion paclitaxel in high–risk and advanced–stage ovarian carcinoma. Coleman RL, et al. **Cancer J Sci Am** 1997 Jul–Aug;3(4):246–53

Outpatient subcutaneous interleukin–2 and interferon–alpha for metastatic renal cell cancer: five–year follow–up of the Cytokine Working Group Study [see comments] Dutcher JP, et al. **Cancer J Sci Am** 1997 May–Jun;3(3):157–62. Comment in: Cancer J Sci Am 1997 May–Jun;3(3):142–3.

Time for a change [comment] Hryniuk W. **Cancer J Sci Am** 1997 Jul–Aug;3(4):209–10. Comment on: Cancer J Sci Am 1997 Jul–Aug;3(4):213–23.

Cisplatin, fluorouracil, and L–leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience [see comments] Papadimitrakopoulou VA, et al. **Cancer J Sci Am** 1997 Mar–Apr;3(2):92–9. Comment in: Cancer J Sci Am 1997 Mar–Apr;3(2):73–5.

Predictive factors for outcome in invasive bladder cancer treated with alternating chemoradiotherapy [see comments] Sanguineti G, et al. **Cancer J Sci Am** 1997 Jul–Aug; 3(4):213–23. Comment in: Cancer J Sci Am 1997 Jul–Aug;3(4):209–10.

Combination of chemotherapy and recombinant interferon–alpha in advanced non–small cell lung cancer. Hastürk S, et al. **Cancer Lett** 1997 Jan 15;112(1):17–22

Optimization of chemotherapy administration for clinical 41.8 degrees C whole body hyperthermia. Katschinski DM, et al. **Cancer Lett** 1997 May 19;115(2):195–9

Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Kornmann M, et al. **Cancer Lett** 1997 Sep 16;118(1):29–35

Synergistic effect between doxorubicin and a low dose of all–trans–retinoic acid in MCF–7 breast cancer cell line. Toma S, et al. **Cancer Lett** 1997 Jun 3;116(1):103–10

A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction). Teicher BA. **Cancer Metastasis Rev** 1996 Jun;15(2):247–72 (316 ref.)

Tumor growth inhibition, apoptosis, and Bcl–2 down–regulation of MCF–7ras tumors by sodium phenylacetate and tamoxifen combination. Adam L, et al. **Cancer Res** 1997 Mar 15;57(6):1023–9

Effects of social housing condition on the response of the Shionogi mouse mammary carcinoma (SC115) to chemotherapy. Kerr LR, et al. **Cancer Res** 1997 Mar 15; 57(6):1124–8

Chemotherapy in oesophageal cancer. Kok TC. **Cancer Treat Rev** 1997 Mar;23(2):65–85 (188 ref.)

Dose response and time course of carboplatin–induced micronucleated polychromatic erythrocytes in the cat: implications for combination carboplatin chemotherapy. Hahn KA, et al. **Chemotherapy** 1997 Jul–Aug;43(4):282–7

Combined effects of S–1, a new form of oral tegafur, plus modulators on ovarian cancer in nude rats. Suzuki M, et al. **Chemotherapy** 1996 Nov–Dec;42(6):452–8

A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Tsavaris N, et al. **Chemotherapy** 1996 May–Jun;42(3):220–6

Objective response to epirubicin and lonidamine. A case of advanced thymoma previously treated with the ADOC scheme and unresponsive to paclitaxel plus cyclophosphamide [letter] Berruti A, et al. **Chest** 1997 May; 111(5):1473–4

Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide [see comments] Lara PN Jr, et al. **Chest** 1996 Oct;110(4):1115–7. Comment in: Chest 1997 Aug;112(2):572–3.

Salvage chemotherapy for recurrent invasive thymoma [letter; comment] Musi M, et al. **Chest** 1997 Aug; 112(2):572–3. Comment on: Chest 1996 Oct;110(4):1115–7.

Intraspinal high–grade astrocytoma in a child—rationale for chemotherapy and more intensive radiotherapy? Weiss E, et al. **Childs Nerv Syst** 1997 Feb;13(2):108–12 (42 ref.)

Effect of carboplatin based combination chemotherapy on ovarian cancer. Feng Y, et al. **Chin Med J (Engl)** 1996 May;109(5):349–52

Chemotherapy of ovarian carcinoma [editorial] Lian L. **Chin Med J (Engl)** 1996 May;109(5):339–43

Management of ovarian endodermal sinus tumor. Lian L, et al. **Chin Med J (Engl)** 1996 May;109(5):344–8

Neoadjuvant chemotherapy for malignant fibrous histiocytoma of bone and for osteosarcoma of the limbs: a comparison between the results obtained for 21 and 144 patients, respectively, treated during the same period with the same chemotherapy protocol. Bacci G, et al. **Chir Organi Mov** 1996 Apr–Jun;81(2):139–53 **(Eng, Ita)**

The VIP regimen effective treatment to refractory choriocarcinoma: a case report. Wang PH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 May;59(5):320–4

Malignant lymphomas in the elderly. O'Reilly SE, et al. **Clin Geriatr Med** 1997 May;13(2):251–63 (29 ref.)

Calcified gastric cancer—CT findings before and after chemotherapy. Case report and discussion of the pathogenesis of this type of calcification. Balestreri L, et al. **Clin Imaging** 1997 Mar–Apr;21(2):122–5

Chlorambucil and prednisolone therapy in a patient with T–cell chronic lymphocytic leukaemia [letter] Islam A, et al. **Clin Lab Haematol** 1996 Jun;18(2):125–6

The effect of GM–CSF on reticulocytes, haemoglobin and haematocrit in patients receiving chemotherapy for solid tumours. Paterakis GS, et al. **Clin Lab Haematol** 1996 Mar; 18(1):7–12

Chemotherapy as adjuvant and salvage treatment in women with endometrial carcinoma. Burke TW, et al. **Clin Obstet Gynecol** 1996 Sep;39(3):716–27 (40 ref.)

Fibrolamellar hepatocellular carcinoma responsive to platinum–based combination chemotherapy. Bower M, et al. **Clin Oncol (R Coll Radiol)** 1996;8(5):331–3

Carboplatin, 5–fluorouracil and folinic acid: a 48–hour chemotherapy regimen in advanced and recurrent squamous carcinoma of the head and neck. Hatton MQ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(6):380–3

Gestational choriocarcinoma metastatic to the brain treated successfully by stereotactic radiosurgery and chemotherapy. Leslie MD, et al. **Clin Oncol (R Coll Radiol)** 1996;8(4):259–60

Oral indomethacin and ranitidine in advanced melanoma: a phase II study. Mertens WC, et al. **Clin Oncol (R Coll Radiol)** 1996;8(2):112–5

Clinical efficacy of perceived 'CNS friendly' chemoradiotherapy for primary intracranial germ cell tumours. Plowman PN, et al. **Clin Oncol (R Coll Radiol)** 1997;9(1):48–53

A longitudinal study of quality of life in advanced non–small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931 [see comments] Herndon JE 2nd, et al. **Control Clin Trials** 1997 Aug;18(4):286–300. Comment in: Control Clin Trials 1997 Aug;18(4):306–10. Comment in: Control Clin Trials 1997 Aug;18(4):311–7.

Metastatic breast cancer. Kennedy MJ. **Curr Opin Oncol** 1996 Nov;8(6):485–90 (32 ref.)

Current status of larynx preservation trials. Lefebvre JL, et al. **Curr Opin Oncol** 1996 May;8(3):209–14 (55 ref.)

Adjuvant systemic therapy for breast cancer. Piccart MJ, et al. **Curr Opin Oncol** 1996 Nov;8(6):478–84 (52 ref.)

Adult acute leukemia. Cripe LD. **Curr Probl Cancer** 1997 Jan–Feb;21(1):1–64 (200 ref.)

Surgical approaches in special situations. Goldberg M. **Curr Probl Cancer** 1996 May–Jun;20(3):179–96 (96 ref.)

Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft. Noviello E, et al. **Cytokine** 1996 Apr;8(4):330–3

Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP–B) in the treatment of advanced cutaneous T–cell lymphoma. Fierro MT, et al. **Dermatology** 1997;194(3):268–72

Increased risk for opportunistic infections during chemotherapy in HIV–infected patients with Kaposi's sarcoma. Plettenberg A, et al. **Dermatology** 1997; 194(3):234–7

Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Farinati F, et al. **Dig Dis Sci** 1996 Dec;41(12):2332–9

Preliminary results of preoperative 5–fluorouracil, low–dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Grann A, et al. **Dis Colon Rectum** 1997 May;40(5):515–22

Chemotherapy for desmoid tumors in association with familial adenomatous polyposis. Schnitzler M, et al. **Dis Colon Rectum** 1997 Jul;40(7):798–801

Nonlinear pharmacokinetics of cyclophosphamide and 4–hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high–dose chemotherapy followed by autologous bone marrow transplantation. Chen TL, et al. **Drug Metab Dispos** 1997 May;25(5):544–51

Head and neck cancer: guidelines for chemotherapy. Catimel G. **Drugs** 1996 Jan;51(1):73–88 (114 ref.)

Current guidelines for the management of aggressive non–Hodgkin's lymphoma. Martelli M, et al. **Drugs** 1997 Jun;53(6):957–72 (72 ref.)

Treatment of multiple myeloma in elderly patients. New developments. Ossenkoppele GJ. **Drugs Aging** 1997 Aug; 11(2):152–64 (112 ref.)

Combined therapy with Ukrain and chemotherapy in ovarian cancer (case report). Lohninger A, et al. **Drugs Exp Clin Res** 1996;22(3–5):259–62

Ukrain with chemotherapy in malignant melanoma (case report). Stabuc B, et al. **Drugs Exp Clin Res** 1996; 22(3–5):231–3

Two cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine and dacarbazine in a combined chemotherapy. Noshiro T, et al. **Endocr J** 1996 Jun;43(3):279–84

A comparative study of undifferentiated nasopharyngeal carcinoma treated with radiotherapy or combined treatment with zorubicin–cisplatin and radiotherapy. Pendjer I, et al. **Eur Arch Otorhinolaryngol Suppl** 1997; 1:S127–9

Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma. Viens P, et al. **Eur Cytokine Netw** 1996 Sep;7(3):395–9

Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study. Barnadas A, et al. **Eur J Cancer** 1997 Feb;33(2):312–5

Granulocyte–macrophage colony–stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second–line chemotherapy: correlation with clinical responses. Baxevanis CN, et al. **Eur J Cancer** 1997 Jul;33(8):1202–8

Carboplatin and 5–fluorouracil in squamous cell carcinoma of the head and neck previously responding to cisplatin and 5–fluorouracil [letter] Benasso M, et al. **Eur J Cancer** 1997 Feb;33(2):318–9

Enhanced acute toxicity in oropharynx carcinoma treated with radiotherapy and concomitant cisplatin, 5–fluorouracil and mitomycin C. Berger C, et al. **Eur J Cancer** 1996 Sep; 32A(10):1707–11

Randomised phase II study of cisplatin and 5–fluorouracil (5–FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Bleiberg H, et al. **Eur J Cancer** 1997 Jul;33(8):1216–20

Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high–grade gliomas. Bouffet E, et al. **Eur J Cancer** 1997 Jan;33(1):91–5

POMB/ACE chemotherapy for mediastinal germ cell tumours [see comments] Bower M, et al. **Eur J Cancer** 1997 May;33(6):838–42. Comment in: Eur J Cancer 1997 May;33(6):809–11.

Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. The Swedish Lung Cancer Study Group. Brodin O, et al. **Eur J Cancer** 1996 Oct;32A(11):1893–900

CHOP–based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high–grade non–Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group. Cameron DA, et al. **Eur J Cancer** 1997 Jul;33(8):1195–201

A phase II study of continuous infusion 5–fluorouracil (5–FU) with epirubicin and cisplatin in metastatic, hormone–resistant prostate cancer: an active new regimen. Chao D, et al. **Eur J Cancer** 1997 Jul;33(8):1230–3

Clinical and pathological response to primary chemotherapy in operable breast cancer. Chollet P, et al. **Eur J Cancer** 1997 May;33(6):862–6

Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma. Comella P, et al. **Eur J Cancer** 1997 Jul;33(8):1326–9

Primary treatment in stage II non–seminomatous germ cell tumours of the testis: a matter of scalpel or drug infusion? Culine S, et al. **Eur J Cancer** 1996 Sep;32A(10):1641–4 (31 ref.)

Non–small cell lung cancer: an overview of current management. Dancey J, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S2–7 (88 ref.)

Oxaliplatin with high–dose leucovorin and 5–fluorouracil 48–hour continuous infusion in pretreated metastatic colorectal cancer. de Gramont A, et al. **Eur J Cancer** 1997 Feb;33(2):214–9

POMB/ACE chemotherapy for mediastinal germ–cell tumours [editorial; comment] Droz JP. **Eur J Cancer** 1997 May;33(6):809–11. Comment on: Eur J Cancer 1997 May;33(6):838–42.

Radiotherapy after chemotherapy for metastatic seminoma—a diminishing role. MRC Testicular Tumour Working Party. Duchesne GM, et al. **Eur J Cancer** 1997 May;33(6):829–35

Pre–operative chemoradiotherapy in non–small cell lung cancer stage III patients. Feasibility, toxicity and long–term results of a phase II study. Favaretto A, et al. **Eur J Cancer** 1996 Nov;32A(12):2064–9

Current status of chemotherapy in advanced seminoma [editorial] Fossa SD, et al. **Eur J Cancer** 1997 Feb; 33(2):181–3

Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin and vincristine. Frascella E, et al. **Eur J Cancer** 1996 May;32A(5):821–5

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects. Geisler J, et al. **Eur J Cancer** 1996 May;32A(5):789–92

Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Gentet JC, et al. **Eur J Cancer** 1997 Feb;33(2):232–7

Tandem high–dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high–risk primary breast cancer. Haas R, et al. **Eur J Cancer** 1997 Mar;33(3):372–8

Accelerated split–course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non–small cell lung cancer. Iaffaioli RV, et al. **Eur J Cancer** 1996 Oct;32A(11):1901–4

Randomised study of high–dose epirubicin versus high–dose epirubicin–cisplatin chemotherapy for advanced soft tissue sarcoma. Jelić S, et al. **Eur J Cancer** 1997 Feb;33(2):220–5

13–cis–retinoic acid and alpha–interferon in advanced squamous cell cancer of the oesophagus [letter] Kok TC, et al. **Eur J Cancer** 1997 Jan;33(1):165–6

Combination therapy with gemcitabine in non–small cell lung cancer. Mosconi AM, et al. **Eur J Cancer** 1997 Jan;33 Suppl 1:S14–7 (20 ref.)

Phase II study of a short course of weekly high–dose cisplatin combined with long–term oral etoposide in metastatic malignant melanoma. Planting AS, et al. **Eur J Cancer** 1996 Oct;32A(11):2026–8

Standard versus alternating non–cross–resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. Postmus PE, et al. **Eur J Cancer** 1996 Aug;32A(9):1498–503

A phase II study of dacarbazine, cisplatin, interferon–alpha and high–dose interleukin–2 in 'poor–risk' metastatic melanoma. Proebstle TM, et al. **Eur J Cancer** 1996 Aug; 32A(9):1530–3

A phase I/II trial of epirubicin and high dose tamoxifen as a potential modulator of multidrug resistance in advanced hepatocellular carcinoma [letter] Raderer M, et al. **Eur J Cancer** 1996 Dec;32A(13):2366–8

Clinical benefit with cisplatin, hydroxyurea and 5–fluorouracil/leucovorin in advanced pancreatic adenocarcinoma [letter] Raymond E, et al. **Eur J Cancer** 1997 Apr;33(4):696–7

Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer. Sagaster P, et al. **Eur J Cancer** 1996 Jul; 32A(8):1320–4

CPT–11 (irinotecan) and 5–fluorouracil: a promising combination for therapy of colorectal cancer. Saltz L, et al. **Eur J Cancer** 1996;32A Suppl 3:S24–31 (25 ref.)

Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Sanson M, et al. **Eur J Cancer** 1996 Dec;32A(13):2229–35

Combination of the new minor groove alkylator tallimustine and melphalan. Tagliabue G, et al. **Eur J Cancer** 1997 Feb; 33(2):284–7

Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Tomiak E, et al. **Eur J Cancer** 1996 Oct;32A(11):1876–87

The toxicity of radiotherapy following high–dose chemotherapy with peripheral blood stem cell support in high–risk breast cancer: a preliminary analysis. van der Wall E, et al. **Eur J Cancer** 1996 Aug;32A(9):1490–7

Cisplatin combined with the new cisplatin–procaine complex DPR: in vitro and in vivo studies. Viale M, et al. **Eur J Cancer** 1996 Dec;32A(13):2327–33

Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. von Schweinitz D, et al. **Eur J Cancer** 1997 Jul;33(8):1243–9

Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5–fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study. Wagener DJ, et al. **Eur J Cancer** 1996 Jul;32A(8):1310–3

Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma. Wiedemann GJ, et al. **Eur J Cancer** 1996 May;32A(5):888–92

The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience. Wiklund T, et al. **Eur J Cancer** 1997 Mar;33(3):357–61

A phase II study of 5–fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer. Ychou M, et al. **Eur J Cancer** 1996 Oct;32A(11):1933–7

Phase II trial of rhIL–6 (interleukin–6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma. Young RI, et al. **Eur J Cancer** 1997 Feb; 33(2):307–11

Marginal zone B cell lymphoma of the parotid glands: results of a randomised trial comparing radiotherapy to combined therapy. Avilés A, et al. **Eur J Cancer B Oral Oncol** 1996 Nov;32B(6):420–2

Neoadjuvant and adjuvant chemotherapy in the

multidisciplinary treatment of oral cancer stage III or IV. Grau JJ, et al. **Eur J Cancer B Oral Oncol** 1996 Jul; 32B(4):238–41

Cost–effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node–positive breast cancer [published erratum appears in Eur J Clin Pharmacol 1997;51(5):427] Messori A, et al. **Eur J Clin Pharmacol** 1996;51(2):111–6

Remission of recurrent mixed germ cell tumor of the ovary after treatment with vincristine, carboplatin, fluorouracil, and ifosfamide: a case report and review of the literature. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(5):342–4 (20 ref.)

Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease. Barakat RR, et al. **Eur J Gynaecol Oncol** 1997;18(3):161–3

Relapse of acute lymphoblastic leukemia during pregnancy. Camera A, et al. **Eur J Gynaecol Oncol** 1996;17(4):303–5

Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study. Deltetto F, et al. **Eur J Gynaecol Oncol** 1997;18(3):185–7

Neoadjuvant chemotherapy in advanced ovarian cancer. Onnis A, et al. **Eur J Gynaecol Oncol** 1996;17(5):393–6

Caecocystoplasty and bilateral oophorectomy followed by chemotherapy for diffuse, non–Hodgkins lymphoma of the ovary involving the bladder. Case report. Papadopoulos AJ, et al. **Eur J Gynaecol Oncol** 1997;18(2):101–3

The use of combined chemotherapy for the treatment of advanced sarcoma of the uterus. Psikakos G, et al. **Eur J Gynaecol Oncol** 1996;17(4):289–91

Remission of recurrent cervical cancer with paclitaxel and carboplatin: a case report and review of literature. Termrungruanglert W, et al. **Eur J Gynaecol Oncol** 1996; 17(6):493–6 (21 ref.)

Platinum based chemotherapy to treat recurrent Sertoli–Leydig cell ovarian carcinoma during pregnancy. Tomlinson MW, et al. **Eur J Gynaecol Oncol** 1997; 18(1):44–6 (18 ref.)

Maintenance therapy with alpha–interferon following first–line VAD in multiple myeloma. Kars A, et al. **Eur J Haematol** 1997 Aug;59(2):100–4

Salvage chemotherapy for relapsed or refractory non–Hodgkin's lymphoma with a combination of ACES (high–dose Ara C, carboplatin, etoposide and steroids) therapy. Niitsu N, et al. **Eur J Haematol** 1996 Oct; 57(4):320–4

A new strategy for treating patients with CD7+, CD4–, CD8– acute lymphoblastic leukaemia [letter] Ono K, et al. **Eur J Haematol** 1997 Feb;58(2):130–2

Changes in serum erythropoietin and the reticulocyte count during chemotherapy for leukemias. Sawabe Y, et al. **Eur J Haematol** 1996 Nov;57(5):384–8

Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia. Wahlin A, et al. **Eur J Haematol** 1997 Apr;58(4):233–40

Maintenance therapy with interferon–alpha (IFN–alpha) versus IFN–alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group. Zervas K, et al. **Eur J Haematol** 1996 Aug;57(2):142–8

Combination of chemotherapy and antiviral therapy for Epstein–Barr virus–associated non–Hodgkin's lymphoma of high grade malignancy in cases of HIV infection. Brockmeyer NH, et al. **Eur J Med Res** 1997 Mar 24; 2(3):133–5

Immunohistochemical analysis of glutathione S–transferase mu expression in ovarian tumors. Matsumoto T, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jun;73(2):171–6

Eclampsia after polychemotherapy for nodal–positive breast cancer during pregnancy. Müller T, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug;67(2):197–8

First line immunochemotherapy with cisplatin–based protocol by intraperitoneal and intravenous routes in ovarian cancer: technique and results of 82 cases. Zylberberg B, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 May;66(1):57–64

Randomized comparison of rotational chemotherapy in high–risk acute lymphoblastic leukaemia of childhood—follow up after 9 years. Coall Study Group. Janka–Schaub GE, et al. **Eur J Pediatr** 1996 Aug; 155(8):640–8

Markedly improved survival in malignant sacro–coccygeal teratomas—16 years, experience. Misra D, et al. **Eur J Pediatr Surg** 1997 Jun;7(3):152–5

Neoadjuvant intra–arterial polychemotherapy of locally advanced rectal cancer. Braun EM, et al. **Eur J Surg Oncol** 1997 Jun;23(3):228–32

Surgical complications related to peri–operative adjuvant chemotherapy in breast cancer. Results of a prospective, controlled, randomized clinical trial. Canavese G, et al. **Eur J Surg Oncol** 1997 Feb;23(1):10–2

Future trials in germ cell malignancy (GCM) of the testis. Oliver RT. **Eur J Surg Oncol** 1997 Apr;23(2):117–22 (29 ref.)

Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Lindén CJ, et al. **Eur Respir J** 1996 Dec;9(12):2565–72

Adjunctive interferon–alpha–2c in stage IIIB/IV small–cell lung cancer: a phase III trial [published erratum appears in Eur Respir J 1997 Apr;10(4):963] Prior C, et al. **Eur Respir J** 1997 Feb;10(2):392–6

The importance of continued endocrine treatment during chemotherapy of hormone–refractory prostate cancer. Chao D, et al. **Eur Urol** 1997;31(1):7–10

Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Imada S, et al. **Eur Urol** 1997;31(3):360–4

Up–to–date management of carcinoma of the penis. Pizzocaro G, et al. **Eur Urol** 1997;32(1):5–15 (49 ref.)

Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Pummer K, et al. **Eur Urol** 1997;32 Suppl 3:81–5

Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo–MVE) in transitional cell urothelial cancer. A Hellenic Co–Operative Oncology Group study. Skarlos DV, et al. **Eur Urol** 1997;31(4):420–7

A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Thorpe SC, et al. **Eur Urol** 1996;29(1):47–54

Multidrug chemotherapy in the treatment of non–elderly patients with hormone–refractory prostatic carcinoma. A phase II study. North–Eastern Italian Oncology Group (GOCCNE). Veronesi A, et al. **Eur Urol** 1996;29(4):434–8

Retinoblastoma after chemoreduction and irradiation: preliminary results. Freire J, et al. **Front Radiat Ther Oncol** 1997;30:88–92

Intraarterial infusion chemotherapy for unresectable hepatic metastases from colorectal cancer. Fujii M. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1381–4 (5 ref.)

Chemotherapy for gastric cancer in Japan. Furue H. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:120–5 (13 ref.)

The role of chemotherapy in the treatment of head and neck cancer. Inuyama Y, et al. **Gan To Kagaku Ryoho** 1997 May; 24 Suppl 1:52–9 (11 ref.)

Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer. Kitamura M, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:45–51 (14 ref.)

Mitoxantrone, 5–FU + folinic acid, mitomycin C for regional chemotherapy of malignant liver tumors. Link KH, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1380 (0 ref.)

Selection of adjuvant chemotherapy for gastric cancer using objective criteria. Nishiyama M, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:232–8 (10 ref.)

Clinical evaluation of anti–tumor effects of Lentinan combined with chemotherapy in the treatment of various malignancies. Qing ZJ, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:1–8

Pre– and/or post–operative immunochemotherapy for advanced digestive cancer. Saji S, et al. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:239–49 (14 ref.)

Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma. Shimizu Y. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:61–9 (14 ref.)

Molecular status of individual CFU–GM colonies derived from chemotherapy–mobilised peripheral blood stem cells in chronic myeloid leukaemia. Broughton CM, et al. **Genes Chromosomes Cancer** 1997 Apr;18(4):292–8

Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide. Hirota Y, et al. **Gynecol Obstet Invest** 1997;44(1):70–2

Adenocarcinoma arising from a mature cystic teratoma of the ovary: a case report of successful treatment with cisplatin–based chemotherapy. Nasu K, et al. **Gynecol Obstet Invest** 1996;41(2):143–6

Determinants of response to a cisplatin–based regimen as neoadjuvant chemotherapy in stage IB–IIB invasive cervical cancer. Bolis G, et al. **Gynecol Oncol** 1996 Oct; 63(1):62–5

Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Chambers JT, et al. **Gynecol Oncol** 1996 Mar;60(3):438–42

Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Codegoni AM, et al. **Gynecol Oncol** 1997 Apr; 65(1):130–7

Cisplatin–based chemotherapy in the management of germ cell tumors of the ovary: The Institut Gustave Roussy Experience. Culine S, et al. **Gynecol Oncol** 1997 Jan; 64(1):160–5

Primary radiation, cisplatin, and 5–fluorouracil for advanced squamous carcinoma of the vulva. Cunningham MJ, et al. **Gynecol Oncol** 1997 Aug;66(2):258–61 (19 ref.)

Primary ovarian non–Hodgkin's lymphoma: outcome after treatment with combination chemotherapy. Dimopoulos MA, et al. **Gynecol Oncol** 1997 Mar;64(3):446–50 (20 ref.)

Chemotherapy for metastatic melanoma during pregnancy. Dipaola RS, et al. **Gynecol Oncol** 1997 Sep;66(3):526–30 (21 ref.)

Prophylactic granulocyte colony–stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer. Fanning J, et al. **Gynecol Oncol** 1996 Dec;63(3):323–7

Decrease in tumor volume and histologic response to intraarterial neoadjuvant chemotherapy in patients with cervical and endometrial adenocarcinoma. Fujiwaki R, et al. **Gynecol Oncol** 1997 May;65(2):258–64

Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Goldberg JM, et al. **Gynecol Oncol** 1996 Dec;63(3):312–7

"MECCA": a developmental, dose–intensive, non–cross–resistant platinum–based chemotherapy for advanced ovarian cancer. Hoskins PJ, et al. **Gynecol Oncol** 1996 Dec;63(3):345–51

Cisplatin/5–fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long–term follow–up. Kaern J, et al. **Gynecol Oncol** 1996 Mar;60(3):387–92

Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy. Lai CH, et al. **Gynecol Oncol** 1997 Mar;64(3):456–62

Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first–line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA). Meerpohl HG, et al. **Gynecol Oncol** 1997 Jul;66(1):75–84

Cost–utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Ortega A, et al. **Gynecol Oncol** 1997 Sep;66(3):454–63

Phase II trial of doxorubicin, 5–fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma. Pierga JY, et al. **Gynecol Oncol** 1997 Aug;66(2):246–9

Cisplatin/etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma. Al–Saleh E, et al. **Gynecol Oncol** 1997 Mar;64(3):468–72

Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix. Serur E, et al. **Gynecol Oncol** 1997 May;65(2):348–56

A case of a patient diagnosed with malignant mixed Müllerian tumor of the ovary who conceived after conservative surgery and adjuvant chemotherapy. Shibahara H, et al. **Gynecol Oncol** 1997 May;65(2):363–5

The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D. Soto–Wright V, et al. **Gynecol Oncol** 1997 Jan;64(1):156–9

Hydroxyurea, 5–fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: a phase I–II trial of the Gynecologic Oncology Group. Stehman FB, et al. **Gynecol Oncol** 1997 Aug;66(2):262–7

Phase II trial of high–dose cisplatin plus ifosfamide as first–line followed by carboplatin as second–line treatment in epithelial ovarian carcinoma. Strauss G, et al. **Gynecol Oncol** 1997 Jul;66(1):66–70

Advanced–stage small cell carcinoma of the ovary in pregnancy: long–term survival after surgical debulking and multiagent chemotherapy. Tewari K, et al. **Gynecol Oncol** 1997 Sep;66(3):531–4

A randomized trial of concurrent chemoradiotherapy versus radiotherapy in advanced carcinoma of the uterine cervix. Tseng CJ, et al. **Gynecol Oncol** 1997 Jul;66(1):52–8

Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. van Besien K, et al. **Gynecol Oncol** 1997 May; 65(2):366–9

Treatment of stage IV "high–grade" endometrial stromal sarcoma with ifosfamide, adriamycin, and cisplatin. Yamawaki T, et al. **Gynecol Oncol** 1997 Feb;64(2):265–9

Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma. Zanetta G, et al. **Gynecol Oncol** 1997 Mar; 64(3):431–5

Leukaemia cutis preceding acute myelomonocytic leukaemia. Konstantopoulos K, et al. **Haematologia (Budap)** 1997; 28(3):169–72

Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP–B (A = doxorubicin) vs VICOP–B (I = idarubicin). Bertini M, et al. **Haematologica** 1997 May–Jun;82(3):309–13

Increased proportion of CD10–positive cells in a boy affected with common acute lymphoblastic leukemia in consolidation therapy [letter] Callea V, et al. **Haematologica** 1997 Jul–Aug;82(4):507

The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients. Celesti L, et al. **Haematologica** 1997 May–Jun;82(3):351–3

High efficacy of fludarabine–containing therapy (FLAG–FLANG) in poor risk acute myeloid leukemia. Clavio M, et al. **Haematologica** 1996 Nov–Dec;81(6):513–20

CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended–field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Gobbi PG, et al. **Haematologica** 1996 Nov–Dec; 81(6):503–12

The F–MACHOP regimen in the treatment of aggressive non–Hodgkin's lymphomas: a single center experience in 72 patients. Infanti L, et al. **Haematologica** 1996 Nov–Dec; 81(6):521–8

Therapeutic impact of adult–type acute lymphoblastic leukemia regimens in B–cell/L3 acute leukemia and advanced–stage Burkitt's lymphoma. Lerede T, et al. **Haematologica** 1996 Sep–Oct;81(5):442–9

Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Levis A, et al. **Haematologica** 1996 Sep–Oct;81(5):450–6

All–trans retinoic acid in combination with alpha–interferon and dexamethasone for advanced multiple myeloma. Musto P, et al. **Haematologica** 1997 May–Jun;82(3):354–6

EBVD and alternating MOPP/EBVD with or without localized field radiotherapy in advanced or unfavorably presenting Hodgkin's disease. Pogliani EM, et al. **Haematologica** 1996 Jan-Feb;81(1):8-14

Stomach preservation in low- and high-grade primary gastric lymphomas: preliminary results. Rabbi C, et al. **Haematologica** 1996 Jan-Feb;81(1):15-9

Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia. Scribano D, et al. **Haematologica** 1996 Jul-Aug;81(4):343-45

Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Zinzani PL, et al. **Haematologica** 1997 May-Jun;82(3):305-8 (27 ref.)

Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Zelefsky MJ, et al. **Head Neck** 1996 Sep-Oct;18(5):405-11

Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin's disease (stage I, II and IIIA). André M, et al. **Hematol Cell Ther** 1997 Apr;39(2):59-65

Timed sequential chemotherapy for advanced acute myeloid leukemia. Archimbaud E, et al. **Hematol Cell Ther** 1996 Apr;38(2):161-7

Treatment of acute myeloblastic leukemia in adults. The GOELAM experience. Harousseau JL, et al. **Hematol Cell Ther** 1996 Oct;38(5):381-91 (38 ref.)

Improved outcome in solitary bone plasmacytomata with combined therapy. Avilés A, et al. **Hematol Oncol** 1996 Sep;14(3):111-7

The role of adjuvant chemotherapy in the treatment of colorectal cancer. Vaughn DJ, et al. **Hematol Oncol Clin North Am** 1997 Aug;11(4):699-719 (92 ref.)

A comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma. Bayraktar Y, et al. **Hepatogastroenterology** 1996 May-Jun;43(9):681-7

Multidisciplinary management of hepatocellular carcinoma. Lygidakis NJ, et al. **Hepatogastroenterology** 1997 Jan-Feb; 44(13):268-73

Adjuvant hepatic arterial IL-2 and MMC, 5-FU after curative resection of colorectal liver metastases. Okuno K, et al. **Hepatogastroenterology** 1996 May-Jun;43(9):688-91

Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Yonemura Y, et al. **Hepatogastroenterology** 1996 Sep-Oct; 43(11):1260-72

Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin's disease. Crosbie OM, et al. **Hepatology** 1997 Jul;26(1):5-8

Factors related to the outcome of M-VAC in 101 patients with advanced urothelial cancer. Igawa M, et al. **Hiroshima J Med Sci** 1995 Dec;44(4):113-7

Cisplatin-based neoadjuvant chemotherapy for invasive bladder cancer. Kadena H, et al. **Hiroshima J Med Sci** 1995 Dec;44(4):129-32

Clinical evaluation of human granulocyte colony-stimulating factor in chemotherapy for ovarian cancer. Nagai N, et al. **Hiroshima J Med Sci** 1995 Dec;44(4):99-103

Chromosomal abnormalities in sperm from testicular cancer patients before and after chemotherapy. Martin RH, et al. **Hum Genet** 1997 Feb;99(2):214-8

Enhancement of chemotherapeutic effects with focused shock waves: extracorporeal shock wave chemotherapy (ESWC). Kambe M, et al. **In Vivo** 1996 May-Jun; 10(3):369-75

Spinal cord compression by primary non-Hodgkin's lymphoma. Lakshmaiah KC, et al. **Indian J Cancer** 1995 Jun;32(2):81-4

Modification of radio-thermo-chemotherapy by AK-2123 and hydralazine in tumor bearing mice. Kunugita N, et al. **Indian J Exp Biol** 1996 Sep;34(9):838-41

Chemotherapy in Hodgkin's disease. Kumari PK, et al. **Indian Pediatr** 1996 Jul;33(7):561-5

Retinoid-interferon therapy of solid tumors. Lippman SM, et al. **Int J Cancer** 1997 Feb 7;70(4):481-3 (27 ref.)

Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Pantel K, et al. **Int J Cancer** 1997 May 16;71(4):521-5

Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma. Teicher BA, et al. **Int J Cancer** 1996 Sep 17;67(6):864-70

Combination of alpha-interferon 2a (alpha-IFN 2a) and 13-cis-retinoic acid (13cRA) in recurrent, pre-treated squamous-cell carcinoma of head and neck (SCCHN). Toma S, et al. **Int J Cancer** 1997 Feb 7;70(4):491-3

Sensitization by interleukin-1alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo. Wang Z, et al. **Int J Cancer** 1996 Nov 27;68(5):583-7

Second-look operation in clear cell carcinoma of the ovary. Nishida T, et al. **Int J Gynaecol Obstet** 1997 Sep; 58(3):331-2

Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study Group. Kagami Y, et al. **Int J Hematol** 1996 Oct; 64(3-4):221-9

Treatment outcome and prognostic factors in childhood acute myeloblastic leukemia: a report from the Japanese Children's Cancer and Leukemia Study Group (CCLSG). Katano N, et al. **Int J Hematol** 1997 Jul;66(1):103-10

Radiation and chemotherapy improve outcome in oligodendroglioma. Allison RR, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):399-403

A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis. Bardet E, et al. **Int J Radiat Oncol Biol Phys** 1997 Apr 1;38(1):163-8

A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer. Blanke C, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 1;37(1):111-6

Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study. Calais G, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 1;38(4):769-75

"Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: impact of treatment intensity on local control and survival. Chan AK, et al. **Int J Radiat Oncol Biol Phys** 1997 Feb 1;37(3):629-37

Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. Garden AS, et al. **Int J Radiat Oncol Biol Phys** 1996 Dec 1;36(5):1005-12

Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study. Lau DH, et al. **Int J Radiat Oncol Biol Phys** 1997 Apr 1;38(1):157-61

Induction chemotherapy and radiotherapy of advanced cancer of the cervix: a pilot study and phase III randomized trial. Leborgne F, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):343-50

Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma. Lin JC, et al. **Int J Radiat Oncol Biol Phys** 1996 Dec 1;36(5):1127-36

Treatment for non-Hodgkin's lymphoma (stage I, II) of the elderly: usefulness of local and regional irradiation and reduced dose chemotherapy. Oguchi M, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 1;37(1):87-92

Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Peddada AV, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 15;37(5):1101-5

High-dose chemotherapy with peripheral blood stem-cell transplantation for hormone-refractory advanced carcinoma of the prostate: experience of two cases. Nishiyama T, et al. **Int J Urol** 1996 Jul;3(4):320-3

Cisplatin, vincristine, methotrexate, peplomycin, etoposide (COMPE) therapy for disseminated germ cell testicular tumors. Yoshimura K, et al. **Int J Urol** 1997 Jan;4(1):47-51

Chemotherapy in the treatment of retinoblastoma. O'Brien JM, et al. **Int Ophthalmol Clin** 1996 Spring;36(2):11-24 (58 ref.)

In vitro drug sensitivity testing of human testicular germ cell tumours with cytostatic drugs and interferon alpha-2b. Küpeli B, et al. **Int Urol Nephrol** 1997;29(1):79-84

Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin. Suga S, et al. **Intern Med** 1996 Dec;35(12):930-6

Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid. Tobita T, et al. **Intern Med** 1997 Jul;36(7):484-6

Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Stearns ME, et al. **Invasion Metastasis** 1996;16(3):116-31

Phase I trial of intravenous carboplatin added to oral etoposide and oral cyclophosphamide for stage IV non-small cell lung cancer. Grunberg SM, et al. **Invest New Drugs** 1996;13(4):333-5

Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Kakeji Y, et al. **Invest New Drugs** 1997;15(1):39-48

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Laohavinij S, et al. **Invest New Drugs** 1996;14(3):325-35

Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study. Martino RL, et al. **Invest New Drugs** 1996;14(4):419-21

A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma. Miller KD, et al. **Invest New Drugs** 1996;14(2):207-12

Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule. Pazdur R, et al. **Invest New Drugs** 1997; 15(2):123-8

13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial. Slabber CF, et al. **Invest New Drugs** 1996;14(4):391-4

A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer. Thiruvengadam R, et al. **Invest New Drugs** 1996;14(4):395-401

Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies. Wadler S, et al. **Invest New Drugs** 1996; 13(4):315-20

A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. Witte RS, et al. **Invest New Drugs** 1996;14(4):409-13

Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). Valerius KD, et al. **J Am Vet Med Assoc** 1997 Feb 15;210(4):512-6

Acute myeloblastic leukemia in adults. Kasthuri AS, et al. **J Assoc Physicians India** 1995 Feb;43(2):108-10

Immunocytochemical detection of P-glycoprotein in the management of malignant effusions. Athanassiadou P, et al. **J Cancer Res Clin Oncol** 1997;123(8):456-60

Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature. Fazeny B, et al. **J Cancer Res Clin Oncol** 1997;123(1):45-52 (39 ref.)

Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil. Weinländer G, et al. **J Cancer Res Clin Oncol** 1997;123(8):452-5

Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. Shaw GL, et al. **J Cell Biochem Suppl** 1996;24:173-85

Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Adamo V, et al. **J Chemother** 1997 Feb;9(1):72-6

A phase II trial of etoposide, leucovorin and 5-fluorouracil (ELF) in patients with advanced gastric cancer. Au E, et al. **J Chemother** 1996 Aug;8(4):300-3

Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs. Bacci G, et al. **J Chemother** 1996 Dec;8(6):472-8

Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study. Bacci G, et al. **J Chemother** 1996 Feb;8(1):70-81

Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen. Bacci G, et al. **J Chemother** 1997 Aug;9(4):293-9

Ovarian carcinoma: modification of T4 lymphocytes after surgery and during chemotherapy. Bogavac M, et al. **J Chemother** 1996 Jun;8(3):229-31

p53 overexpression and mutation, chemoresistance and patient survival in oral and maxillofacial squamous cell carcinoma. Cutilli T, et al. **J Chemother** 1997 Apr; 9(2):123-4

Preliminary observations on the interference of antiblastic agents in membrane fluidity and leukocyte potential. Florio S, et al. **J Chemother** 1996 Oct;8(5):399-402

Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer. Hastürk S, et al. **J Chemother** 1997 Feb;9(1):66-71

Neoadjuvant treatment of local recurrence of rectal cancer: our experience. Iannace C, et al. **J Chemother** 1997 Apr; 9(2):147-8

Modulation of cisplatin antitumor activity by short infusional high-dose cytosine arabinoside in advanced pretreated head and neck carcinoma: a phase II study. Jelic S, et al. **J Chemother** 1996 Aug;8(4):304-9

Ifosfamide, mesna and epirubicin as second-line chemotherapy in advanced breast cancer. Kiraz S, et al. **J Chemother** 1996 Aug;8(4):310-4

Experience with adriamycin, bleomycin, vincristine (ABV) palliative chemotherapy in advanced AIDS-related Kaposi's sarcoma. Paparizos VA, et al. **J Chemother** 1996 Oct;8(5):403-6

Surgery and polychemotherapy of non-functional endocrine pancreatic tumors: a case report with a dramatic clinical response. Piazza L, et al. **J Chemother** 1996 Aug; 8(4):319-24

Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine. Polyzos A, et al. **J Chemother** 1997 Apr;9(2):102-5

Cis/carboplatin + vinorelbine +/- radiotherapy in stage III and IV non small cell lung carcinoma. Tomirotti M, et al. **J Chemother** 1997 Feb;9(1):62-5

Sequential methotrexate and 5-fluorouracil as second-line chemotherapy for advanced colorectal cancer patients pretreated with 5-fluorouracil and leucovorin: a GISCAD study. Zaniboni A, et al. **J Chemother** 1996 Feb;8(1):82-4

Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. Hurel SJ, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):2962-5

Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer. Messori A, et al. **J Clin Gastroenterol** 1996 Dec;23(4):269-74

Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. International Breast Cancer Study Group.

J Clin Oncol 1997 Apr;15(4):1385–94

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non–small-cell lung cancer. Abratt RP, et al. **J Clin Oncol** 1997 Feb;15(2):744–9

Double dose–intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. Ayash LJ, et al. **J Clin Oncol** 1996 Nov;14(11):2984–92

Bleomycin in germ cell tumor therapy: not all regimens are created equal [editorial; comment] Bajorin DF, et al. **J Clin Oncol** 1997 May;15(5):1717–9. Comment on: J Clin Oncol 1997 May;15(5):1837–43.

Chemotherapy without irradiation—a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. Balmaceda C, et al. **J Clin Oncol** 1996 Nov;14(11):2908–15

Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. Bartelink H, et al. **J Clin Oncol** 1997 May; 15(5):2040–9

Elderly patients with aggressive non–Hodgkin's lymphoma: disease presentation, response to treatment, and survival—a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. Bastion Y, et al. **J Clin Oncol** 1997 Aug;15(8):2945–53

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. Bertheault-Cvitkovic F, et al. **J Clin Oncol** 1996 Nov; 14(11):2950–8

High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables [see comments] Beyer J, et al. **J Clin Oncol** 1996 Oct; 14(10):2638–45. Comment in: J Clin Oncol 1996 Oct;14(10):2625–6.

Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. Blanke CD, et al. **J Clin Oncol** 1997 Mar;15(3):915–20

Treatment of brain metastases in patients with testicular cancer. Bokemeyer C, et al. **J Clin Oncol** 1997 Apr; 15(4):1449–54

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD [see comments] Bonfante V, et al. **J Clin Oncol** 1997 Feb;15(2):528–34. Comment in: J Clin Oncol 1997 Aug;15(8):3022–3.

EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients [published erratum appears in J Clin Oncol 1997 Sep;15(9):3168] Bower M, et al. **J Clin Oncol** 1997 Jul;15(7):2636–43

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial [letter; comment] Brodowicz T, et al. **J Clin Oncol** 1997 May;15(5):2174–5. Comment on: J Clin Oncol 1996 Oct;14(10):2653–65.

Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. Byrd JC, et al. **J Clin Oncol** 1997 Feb; 15(2):466–75

Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. Byrne MJ, et al. **J Clin Oncol** 1997 Sep;15(9):3141–8

CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma [editorial; comment] Canellos GP. **J Clin Oncol** 1997 May;15(5):1713–6. Comment on: J Clin Oncol 1997 May;15(5):1722–9.

Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients. Chéradame S, et al. **J Clin Oncol** 1997 Jul; 15(7):2604–10

Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non–small-cell lung cancer. Choi NC, et al. **J Clin Oncol** 1997 Feb; 15(2):712–22

Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer. Clahsen PC, et al. **J Clin Oncol** 1997 Jul;15(7):2526–35

Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. Clark JR, et al. **J Clin Oncol** 1997 Sep;15(9):3100–10

Treatment of advanced Hodgkin's disease with chemotherapy—comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group [published erratum appears in J Clin Oncol 1997 Jul;15(7):2762] Connors JM, et al. **J Clin Oncol** 1997 Apr;15(4):1638–45

Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. Conter V, et al. **J Clin Oncol** 1997 Aug; 15(8):2786–91

Neuropsychologic effects of chemotherapy on children with cancer: a longitudinal study. Copeland DR, et al. **J Clin Oncol** 1996 Oct;14(10):2826–35

Cisplatin–gemcitabine combination in advanced non–small-cell lung cancer: a phase II study. Crinò L, et al. **J Clin Oncol** 1997 Jan;15(1):297–303

Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. Dawson NA, et al. **J Clin Oncol** 1997 Apr;15(4):1470–7

Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. Dekker AW, et al. **J Clin Oncol** 1997 Feb;15(2):476–82

Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group [see comments] de Wit R, et al. **J Clin Oncol** 1997 May;15(5):1837–43. Comment in: J Clin Oncol 1997 May;15(5):1717–9.

Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. Dieras V, et al. **J Clin Oncol** 1996 Dec; 14(12):3097–104

Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. Dinndorf PA, et al. **J Clin Oncol** 1997 Aug; 15(8):2780–5

Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. Doci R, et al. **J Clin Oncol** 1996 Dec;14(12):3121–5

Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. Earlam S, et al. **J Clin Oncol** 1997 May; 15(5):2022–9

Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine [see comments] Estey E, et al. **J Clin Oncol** 1997 Feb;15(2):483–90. Comment in: J Clin Oncol 1997 Aug;15(8):3021–2.

Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. Finlay JL, et al. **J Clin Oncol** 1996 Sep; 14(9):2495–503

Increased intensification and total dose of cyclophosphamide in a doxorubicin–cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B–22. Fisher B, et al. **J Clin Oncol** 1997 May;15(5):1858–69

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B–18 [see comments] Fisher B, et al. **J Clin Oncol** 1997 Jul;15(7):2483–93. Comment in: J Clin Oncol 1997 Jul;15(7):2479–82.

Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. Flam M, et al. **J Clin Oncol** 1996 Sep; 14(9):2527–39

Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non–small-cell lung cancer: a phase I study. Frasci G, et al. **J Clin Oncol** 1997 Apr; 15(4):1409–17

Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte–macrophage colony–stimulating factor in advanced soft tissue sarcomas: a pilot study. Frustaci S, et al. **J Clin Oncol** 1997 Apr;15(4):1418–26

Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus. Ganem G, et al. **J Clin Oncol** 1997 Feb;15(2):701–11

Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. Georgiadis MS, et al. **J Clin Oncol** 1997 Feb; 15(2):735–43

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. Gianni AM, et al. **J Clin Oncol** 1997 Jun; 15(6):2312–21

Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. Giralt S, et al. **J Clin Oncol** 1997 Feb; 15(2):667–73

High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. Graham ML, et al. **J Clin Oncol** 1997 May; 15(5):1814–23

Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. Greco FA, et al. **J Clin Oncol** 1996 Oct;14(10):2674–81

Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. Gregor A, et al. **J Clin Oncol** 1997 Aug;15(8):2840–9

Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. Grossman SA, et al. **J Clin Oncol** 1997 Jul;15(7):2596–603

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. Hainsworth JD, et al. **J Clin Oncol** 1997 Jun;15(6):2385–93

Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non–Hodgkin's lymphoma: updated results of the prospective study LNH87–2. Groupe d'Etude des Lymphomes de l'Adulte. Haioun C, et al. **J Clin Oncol** 1997 Mar;15(3):1131–7

Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? Harari PM. **J Clin Oncol** 1997 May; 15(5):2050–5

Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. Horning SJ, et al. **J Clin Oncol** 1997 May;15(5):1736–44

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. Horwich A, et al. **J Clin Oncol** 1997 May;15(5):1844–52

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. Hudes GR, et al. **J Clin Oncol** 1997 Sep; 15(9):3156–63

Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non–Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. Janicek M, et al. **J Clin Oncol** 1997 Apr;15(4):1631–7

Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. Jeremic B, et al. **J Clin Oncol** 1997 Mar;15(3):893–900

Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. Johnson CA, et al. **J Clin Oncol** 1997 Feb;15(2):773–80

Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. Jones SE, et al. **J Clin Oncol** 1996 Nov;14(11):2976–83

TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. Kaba SE, et al. **J Clin Oncol** 1997 Mar;15(3):1063–70

Bladder preservation by combined modality therapy for invasive bladder cancer. Kachnic LA, et al. **J Clin Oncol** 1997 Mar;15(3):1022–9

Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. Kornblau SM, et al. **J Clin Oncol** 1997 May;15(5):1796–802

Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. Kosmidis PA, et al. **J Clin Oncol** 1996 Oct;14(10):2682–7

Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. Kubota K, et al. **J Clin Oncol** 1997 Jan;15(1):292–6

Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. Lazzarino M, et al. **J Clin Oncol** 1997 Apr; 15(4):1646–53

Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B. Lee AY, et al. **J Clin Oncol** 1997 May;15(5):1745–53

Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. Leone BA, et al. **J Clin Oncol** 1996 Nov;14(11):2993–9

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. Loeffler M, et al. **J Clin Oncol** 1997 Jun;15(6):2275–87

Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. Loehrer PJ Sr, et al. **J Clin Oncol** 1997 Sep;15(9):3093–9

Topotecan today [editorial; comment] Lynch T. **J Clin Oncol** 1996 Dec;14(12):3053–5. Comment on: J Clin Oncol 1996 Dec;14(12):3056–61. Comment on: J Clin Oncol 1996 Dec;14(12):3062–73. Comment on: J Clin Oncol 1996 Dec;14(12):3074–84.

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. McCaffrey JA, et al. **J Clin Oncol** 1997 Jun;15(6):2449–55

Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. McCaffrey JA, et al. **J Clin Oncol** 1997 Jul; 15(7):2559–63

Mantle cell lymphoma: correlation of clinical outcome and

biologic features with three histologic variants. Majlis A, et al. **J Clin Oncol** 1997 Apr;15(4):1664–71

Treatment of germ cell cancer with two cycles of high–dose ifosfamide, carboplatin, and etoposide with autologous stem–cell support [see comments] Margolin BK, et al. **J Clin Oncol** 1996 Oct;14(10):2631–7. Comment in: J Clin Oncol 1996 Oct;14(10):2625–6.

Phase I study of vinorelbine and ifosfamide in advanced non–small–cell lung cancer. Masters GA, et al. **J Clin Oncol** 1997 Mar;15(3):884–92

Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. Merajver SD, et al. **J Clin Oncol** 1997 Aug; 15(8):2873–81

Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. Miller KD, et al. **J Clin Oncol** 1997 Apr;15(4):1427–31

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non–small–cell lung cancer. Millward MJ, et al. **J Clin Oncol** 1997 Feb;15(2):750–8

High–dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first–line therapy for patients with poor–risk germ cell tumors. Motzer RJ, et al. **J Clin Oncol** 1997 Jul;15(7):2546–52

Augmented Berlin–Frankfurt–Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. Nachman J, et al. **J Clin Oncol** 1997 Jun;15(6):2222–30

Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Omura GA, et al. **J Clin Oncol** 1997 Jan;15(1):165–71

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. O'Reilly S, et al. **J Clin Oncol** 1997 Jan;15(1):177–86

Phase II study of irinotecan and etoposide in patients with metastatic non–small–cell lung cancer. Oshita F, et al. **J Clin Oncol** 1997 Jan;15(1):304–9

Treatment of recurrent ovarian cancer: increasing options––"recurrent" results [editorial; comment] Ozols RF. **J Clin Oncol** 1997 Jun;15(6):2177–80. Comment on: J Clin Oncol 1997 Jun;15(6):2183–93.

Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa–2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. Patt YZ, et al. **J Clin Oncol** 1997 Apr; 15(4):1432–8

Randomized trial of CVPP for three versus six cycles in favorable–prognosis and CVPP versus AOPE plus radiotherapy in intermediate–prognosis untreated Hodgkin's disease. Pavlovsky S, et al. **J Clin Oncol** 1997 Jul;15(7):2652–8

Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non–small–cell lung cancer in a phase II randomized study. Perng RP, et al. **J Clin Oncol** 1997 May;15(5):2097–102

Chemotherapy–induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. Picci P, et al. **J Clin Oncol** 1997 Apr;15(4):1553–9

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node–positive estrogen and/or progesterone receptor–positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. Pritchard KI, et al. **J Clin Oncol** 1997 Jun;15(6):2302–11

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. Pronk LC, et al. **J Clin Oncol** 1997 Mar;15(3):1071–9

Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. Provisor AJ, et al. **J Clin Oncol** 1997 Jan;15(1):76–84

Dose–intensity of a four–drug chemotherapy regimen with or without recombinant human granulocyte–macrophage colony–stimulating factor in extensive–stage small–cell lung cancer: a multicenter randomized phase III study. Pujol JL, et al. **J Clin Oncol** 1997 May;15(5):2082–9

Preoperative chemotherapy and breast–conserving therapy: why not everyone? [editorial; comment] Recht A. **J Clin Oncol** 1997 Jul;15(7):2479–82. Comment on: J Clin Oncol 1997 Jul;15(7):2483–93.

Perioperative chemotherapy versus adjuvant hormonal therapy in breast cancer: claimed benefits [letter; comment] Rostom AY, et al. **J Clin Oncol** 1996 Oct;14(10):2885–6. Comment on: J Clin Oncol 1996 Mar;14(3):745–53.

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence [see comments] Rowinsky EK, et al. **J Clin Oncol** 1996 Dec; 14(12):3074–84. Comment in: J Clin Oncol 1996 Dec;14(12):3053–5.

Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study. Rueda A, et al. **J Clin Oncol** 1997 Mar;15(3):1118–22

Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second–line endocrine therapy of estrogen receptor–positive metastatic breast cancer: a Southwest Oncology Group phase III trial. Russell CA, et al. **J Clin Oncol** 1997 Jul;15(7):2494–501

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. Saltz LB, et al. **J Clin Oncol** 1996 Nov; 14(11):2959–67

Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study [published erratum appears in J Clin Oncol 1997 Feb;15(2):866] al–Sarraf M, et al. **J Clin Oncol** 1997 Jan;15(1):277–84

Prognostic factors in early–stage Hodgkin's disease [letter; comment] Sarris AH. **J Clin Oncol** 1997 Jan;15(1):411–2. Comment on: J Clin Oncol 1996 Jun;14(6):1928–35.

Long–term follow–up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Saxman SB, et al. **J Clin Oncol** 1997 Jul;15(7):2564–9

Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German–Austrian Pediatric Hodgkin's Disease Group. Schellong G, et al. **J Clin Oncol** 1997 Jun;15(6):2247–53

Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil––11–year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. Senn HJ, et al. **J Clin Oncol** 1997 Jul; 15(7):2502–9

Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral–blood progenitor cells and filgrastim in advanced breast cancer patients. Shapiro CL, et al. **J Clin Oncol** 1997 Feb; 15(2):674–83

Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early–stage testicular seminoma. Sharda NN, et al. **J Clin Oncol** 1996 Nov; 14(11):2933–9

Treatment of Kaposi's sarcoma after solid organ transplantation. Shepherd FA, et al. **J Clin Oncol** 1997 Jun; 15(6):2371–7

Phase I–II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. Shirao K, et al. **J Clin Oncol** 1997 Mar;15(3):921–7

Treatment of acute myelogenous leukemia [letter; comment] Slater S, et al. **J Clin Oncol** 1997 Apr;15(4):1710–1. Comment on: J Clin Oncol 1994 Apr;12(4):671–8.

High–dose chemotherapy and stem–cell rescue in the treatment of high–risk breast cancer: prognostic indicators of progression–free and overall survival. Somlo G, et al. **J Clin Oncol** 1997 Aug;15(8):2882–93

Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus–associated non–Hodgkin's lymphoma. Sparano JA, et al. **J Clin Oncol** 1996 Nov; 14(11):3026–35

Phase I trial of high–dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma [published erratum appears in J Clin Oncol 1996 Dec;14(12):3175] Sparano JA, et al. **J Clin Oncol** 1996 Sep;14(9):2576–83

Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study. Sparano JA, et al. **J Clin Oncol** 1997 May; 15(5):1880–4

Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high–dose chemotherapy and autologous bone marrow transplantation in high–risk lymphomas. Stahel RA, et al. **J Clin Oncol** 1997 May;15(5):1730–5

Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. Stewart DJ, et al. **J Clin Oncol** 1997 May;15(5):1897–905

Intensive sequential chemotherapy with repeated blood stem–cell support for untreated poor–prognosis non–Hodgkin's lymphoma [see comments] Stoppa AM, et al. **J Clin Oncol** 1997 May;15(5):1722–9. Comment in: J Clin Oncol 1997 May;15(5):1713–6.

Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies [see comments] Stram DO, et al. **J Clin Oncol** 1996 Sep;14(9):2417–26. Comment in: J Clin Oncol 1996 Sep;14(9):2413–4.

Adult Burkitt's and Burkitt–like non–Hodgkin's lymphoma––outcome for patients treated with high–dose therapy and autologous stem–cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. Sweetenham JW, et al. **J Clin Oncol** 1996 Sep;14(9):2465–72

Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children? Verrill MW, et al. **J Clin Oncol** 1997 Jul;15(7):2611–21

Intensified and high–dose chemotherapy with granulocyte colony–stimulating factor and autologous stem–cell transplantation support as first–line therapy in high–risk diffuse large–cell lymphoma. Vitolo U, et al. **J Clin Oncol** 1997 Feb;15(2):491–8

Single–photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high–dose chemotherapy and autologous stem–cell transplantation for non–Hodgkin's lymphoma. Vose JM, et al. **J Clin Oncol** 1996 Sep; 14(9):2473–9

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Webb A, et al. **J Clin Oncol** 1997 Jan;15(1):261–7

Randomized study of intensive MOPP–ABVD with or without low–dose total–nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. Weiner MA, et al. **J Clin Oncol** 1997 Aug; 15(8):2769–79

Cytarabine with high–dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. Weiss M, et al. **J Clin Oncol** 1996 Sep;14(9):2480–5

Follicular large–cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B–cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. Wendum D, et al. **J Clin Oncol** 1997 Apr; 15(4):1654–63

Randomized study of initial versus late chest irradiation combined with chemotherapy in limited–stage small–cell lung cancer. Aarhus Lung Cancer Group [see comments] Work E, et al. **J Clin Oncol** 1997 Sep;15(9):3030–7. Comment in: J Clin Oncol 1997 Sep;15(9):3027–9.

Long–term follow–up of patients with good–risk germ cell tumors treated with etoposide and cisplatin. Xiao H, et al. **J Clin Oncol** 1997 Jul;15(7):2553–8

Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. Colecchia M, et al. **J Clin Pathol** 1997 May;50(5):384–8

Initial pharmacokinetics and bioavailability of PSC 833, a P–glycoprotein antagonist. Lush RM, et al. **J Clin Pharmacol** 1997 Feb;37(2):123–8

5–fluorouracil modulates the toxicity of high dose methotrexate. White RM. **J Clin Pharmacol** 1995 Dec; 35(12):1156–65

Drug targeting in cancer therapy: the magic bullet, what next? [editorial] Duncan R, et al. **J Drug Target** 1996; 3(5):317–9

BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. Nathan FE, et al. **J Exp Clin Cancer Res** 1997 Jun;16(2):201–8

Intensified carboplatin regimen with GM–CSF support in non–small cell lung cancer (NSCLC). A Hellenic Co–operative Oncology Group Study (HeCOG). Nicolaides C, et al. **J Exp Clin Cancer Res** 1997 Mar; 16(1):91–4

MVP (mitomycin–C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer. Hsu C, et al. **J Formos Med Assoc** 1997 Mar; 96(3):185–8

Metastases to the hand from carcinoma of the lower alveolus. Viswanathan PN, et al. **J Hand Surg [Br]** 1996 Aug; 21(4):544–6

Impaired stem cell collection by consecutive courses of high–dose mobilizing chemotherapy using cyclophosphamide, etoposide, and G–CSF. Akard LP, et al. **J Hematother** 1996 Jun;5(3):271–7

Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced–stage breast cancer patients undergoing high–dose chemotherapy. Brockstein BE, et al. **J Hematother** 1996 Dec;5(6):617–24

Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high–dose chemotherapy and peripheral blood progenitor cell support. Papadopoulos KP, et al. **J Hematother** 1997 Feb;6(1):61–8

Recombinant interleukin–2 in combination with recombinant interferon–gamma in patients with advanced malignancy: a phase 1 study. Reddy SP, et al. **J Immunother** 1997 Jan; 20(1):79–87

Enhancing the effect of THERATOPE STn–KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low–dose intravenous cyclophosphamide. MacLean GD, et al. **J Immunother Emphasis Tumor Immunol** 1996 Jul; 19(4):309–16

Management of carcinoma anal canal with combination chemotherapy and concurrent radiotherapy. Mishra RC, et al. **J Indian Med Assoc** 1996 Feb;94(2):53–4, 57

Treatment of metastatic breast cancer by navelbine, mitoxantrone and continuous infusion 5–fluorouracil (FMN regimen): results of a pilot study. Azim HA. **J Infus Chemother** 1996 Spring;6(2):102–6

Combined chemotherapy and irradiation for transitional cell cancer of the bladder: a review. Beuzeboc P, et al. **J Infus Chemother** 1995 Fall;5(4):218–20 (22 ref.)

Continuous infusion cisplatin and 5–fluorouracil with bolus vinorelbine in the treatment of advanced nonsmall cell carcinoma of the lung. Beuzeboc P, et al. **J Infus Chemother** 1995 Fall;5(4):193–4

Combined infusional chemotherapy and radiation for esophageal carcinoma: a review. Chauveinc L, et al. **J Infus Chemother** 1995 Fall;5(4):215–7 (25 ref.)

Dual modulation of 5–fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. de Gramont A, et al. **J Infus Chemother** 1996 Spring;6(2):97–101

The French experience with infusional 5–FU in gastric and

pancreatic cancer. Ducreux M, et al. **J Infus Chemother** 1996 Fall;6(4):203–5

Neoadjuvant chemotherapy with continuous infusion of cisplatin and 5–fluorouracil, with or without leucovorin, for locally advanced nasopharyngeal carcinoma. Fonseca E, et al. **J Infus Chemother** 1996 Fall;6(4):217–20

A pilot trial of continuous infusion 5–fluorouracil with levamisole for adjuvant therapy of colon cancer. Leichman CG, et al. **J Infus Chemother** 1996 Spring;6(2):84–6

Intermittent continuous infusion of 5–fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity. Poorter RL, et al. **J Infus Chemother** 1996 Spring;6(2):87–91

The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices. Rowinsky EK. **J Infus Chemother** 1995 Fall;5(4):173–8 (60 ref.)

Interferon–alpha inhibits CFU–GM mobilization following chemotherapy and G–CSF administration. Ballarino P, et al. **J Interferon Cytokine Res** 1996 Nov;16(11):953–6

Dual modulation by l–leucovorin and recombinant human interferon alpha 2a of 5–fluorouracil antitumor activity against the human colon carcinoma xenograft Co–4. Kase S, et al. **J Interferon Cytokine Res** 1995 Dec;15(12):1089–93

Immunotherapy with low–dose interleukin–2 and interferon–gamma in a murine tumor model. Mao XW, et al. **J Interferon Cytokine Res** 1995 Dec;15(12):1017–27

Hodgkin's disease of middle ear and mastoid. Solanellas J, et al. **J Laryngol Otol** 1996 Sep;110(9):869–71

Randomized trial radiotherapy with and without concomitant 13–cis–retinoic acid plus interferon–alpha for locally advanced cervical cancer: a preliminary report. Veerasarn V, et al. **J Med Assoc Thai** 1996 Jul;79(7):439–47

Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. Bowman LC, et al. **J Natl Cancer Inst** 1997 Mar 5;89(5):373–80

Re: Response of aleukemic granulocytic sarcoma to all–trans–retinoic acid plus interferon alfa–2a [letter] Fleming GF, et al. **J Natl Cancer Inst** 1997 Jan 15; 89(2):172–3

Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. Johnston PG, et al. **J Natl Cancer Inst** 1997 Feb 19;89(4):308–13

Chemotherapy benefits nearly all early breast cancer patients [news] McNeil C. **J Natl Cancer Inst** 1997 Jun 18; 89(12):838–9

Five–day oral etoposide treatment for advanced small–cell lung cancer: randomized comparison with intravenous chemotherapy. Souhami RL, et al. **J Natl Cancer Inst** 1997 Apr 16;89(8):577–80

Opportunistic infection and immunologic function in patients with human immunodeficiency virus–associated non–Hodgkin's lymphoma treated with chemotherapy. Sparano JA, et al. **J Natl Cancer Inst** 1997 Feb 19; 89(4):301–7

Response of aleukemic granulocytic sarcoma to all–trans–retinoic acid plus interferon alfa–2a [letter] Toma S, et al. **J Natl Cancer Inst** 1996 Oct 16;88(20):1494–5

Neoadjuvant chemotherapy before surgery in cervical cancer. Eddy GL Sr. **J Natl Cancer Inst Monogr** 1996; (21):93–9 (45 ref.)

Concomitant and neoadjuvant chemotherapy in conjunction with radiotherapy in the management of locally advanced cervical cancer. Tattersall MH. **J Natl Cancer Inst Monogr** 1996;(21):101–3 (12 ref.)

Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study. Ameri A, et al. **J Neurooncol** 1997 Apr;32(2):155–60

MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. Ater JL, et al. **J Neurooncol** 1997 May; 32(3):243–52

Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy. Boiardi A, et al. **J Neurooncol** 1997 Sep;34(2):179–85

Early chemotherapy and concurrent radio–chemotherapy in high grade glioma. Brandes AA, et al. **J Neurooncol** 1996 Dec;30(3):247–55

All–trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications. Defer GL, et al. **J Neurooncol** 1997 Sep;34(2):169–77

Central neurocytoma: a clinical study of response to chemotherapy. Dodds D, et al. **J Neurooncol** 1997 Sep; 34(3):279–83

Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma. Elliott TE, et al. **J Neurooncol** 1997 Jul;33(3):239–50

Therapy of primary central nervous system lymphoma with pre–irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). Glass J, et al. **J Neurooncol** 1996 Dec;30(3):257–65

Chemotherapy for meningiomas. Kyritsis AP. **J Neurooncol** 1996 Sep;29(3):269–72 (19 ref.)

Chemotherapeutic induction of long–term remission in metastatic medulloblastoma. Leo E, et al. **J Neurooncol** 1997 Apr;32(2):149–54

The expanding role of chemotherapy for pediatric supratentorial malignant gliomas. Lyden DC, et al. **J Neurooncol** 1996 May–Jun;28(2–3):185–91 (65 ref.)

Treatment of pediatric low–grade gliomas with a nitrosourea–based multiagent chemotherapy regimen. Prados MD, et al. **J Neurooncol** 1997 May;32(3):235–41

Cranial radiation and concomitant cisplatin and mitomycin–C plus resistance modulators for malignant gliomas. Stewart DJ, et al. **J Neurooncol** 1997 Apr;32(2):161–8

Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low–grade gliomas. Packer RJ, et al. **J Neurosurg** 1997 May;86(5):747–54

Salvage chemotherapy for oligodendroglioma. Peterson K, et al. **J Neurosurg** 1996 Oct;85(4):597–601

Modulation of the multidrug resistance P–glycoprotein: detection with technetium–99m–sestamibi in vivo. Luker GD, et al. **J Nucl Med** 1997 Mar;38(3):369–72

Combination chemotherapy in the treatment of Kaposi sarcoma in a child infected with human immunodeficiency virus [letter] Mastroianni A, et al. **J Pediatr** 1997 Apr; 130(4):675

Growth and growth hormone secretion in children with cancer treated with chemotherapy. Roman J, et al. **J Pediatr** 1997 Jul;131(1 Pt 1):105–12

Preoperative chemotherapy for congenital hemangiopericytoma and a review of the literature. del Rosario ML, et al. **J Pediatr Hematol Oncol** 1997 May–Jun; 19(3):247–50 (26 ref.)

Disseminated Burkitt's lymphoma after kidney transplantation: a case report in a boy with Drash syndrome. Ferrari A, et al. **J Pediatr Hematol Oncol** 1997 Mar–Apr;19(2):151–5

Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). Frankel LS, et al. **J Pediatr Hematol Oncol** 1997 Jan–Feb; 19(1):35–42

Primary Burkitt's lymphoma of the liver: report of a case with long–term survival after surgical resection and combination chemotherapy. Huang CB, et al. **J Pediatr Hematol Oncol** 1997 Mar–Apr;19(2):135–8

High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. Kreissman SG, et al. **J Pediatr Hematol Oncol** 1997 Jul–Aug;19(4):309–12

A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F–ara–A) and cytarabine (ara–C) for refractory or recurrent pediatric acute myeloid leukemia (AML). Leahey A, et al. **J Pediatr Hematol Oncol** 1997 Jul–Aug;19(4):304–8

Successful treatment of metastatic poor risk extragonadal germ cell tumor in a 15–year–old boy [letter] Vetter V, et al. **J Pediatr Hematol Oncol** 1997 Mar–Apr;19(2):179–80

Improved long–term survival with preoperative chemotherapy for hepatoblastoma. Ehrlich PF, et al. **J Pediatr Surg** 1997 Jul;32(7):999–1002; discussion 1002–3

Enhanced anti–tumour effects of acriflavine in combination with guanosine in mice. Kim SG, et al. **J Pharm Pharmacol** 1997 Feb;49(2):216–22

Combination of antisense oligonucleotide and low–dose chemotherapy in hematological malignancies. Benner E, et al. **J Pharmacol Toxicol Methods** 1997 Jun;37(4):229–35 (34 ref.)

Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer. Içli F, et al. **J Surg Oncol** 1997 Apr; 64(4):318–23

Preoperative simultaneous cisplatin– or carboplatin–based chemotherapy and radiotherapy for squamous cell carcinoma of the oral cavity. Kirita T, et al. **J Surg Oncol** 1996 Dec;63(4):240–8

Tracheoesophageal fistula developing during chemotherapy for non–Hodgkins lymphoma. Lackner RP, et al. **J Surg Oncol** 1996 Dec;63(4):265–7

Advantage of surgery and adjuvant chemotherapy in the treatment of primary gastrointestinal lymphoma. Lin KM, et al. **J Surg Oncol** 1997 Mar;64(3):237–41

Adverse effects of intraportal chemotherapy on natural killer cell activity in colorectal cancer patients. Rafique M, et al. **J Surg Oncol** 1997 Apr;64(4):324–30

Malignant uterine smooth muscle tumors: role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy. Resnik E, et al. **J Surg Oncol** 1996 Nov;63(3):145–7

Cisplatin–based chemotherapy in advanced seminoma: experience of the Northern Israel Oncology Center: 1981–1994. Stein ME, et al. **J Surg Oncol** 1997 Apr; 64(4):331–5

Management of soft tissue sarcomas of the extremity in adults. Valle AA, et al. **J Surg Oncol** 1996 Dec;63(4):271–9 (80 ref.)

A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study [see comments] Ando N, et al. **J Thorac Cardiovasc Surg** 1997 Aug;114(2):205–9. Comment in: J Thorac Cardiovasc Surg 1997 Aug;114(2):203–4.

Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial [see comments] Law S, et al. **J Thorac Cardiovasc Surg** 1997 Aug;114(2):210–7. Comment in: J Thorac Cardiovasc Surg 1997 Aug;114(2):203–4.

Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. Brennemann W, et al. **J Urol** 1997 Sep;158(3 Pt 1):844–50

Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial. Culine S, et al. **J Urol** 1997 Mar;157(3):855–8; discussion 858–9

Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer. Kyriakakis Z, et al. **J Urol** 1997 Aug;158(2):408–11

A comparison of doxorubicin and COP for maintenance of remission in cats with lymphoma. Moore AS, et al. **J Vet Intern Med** 1996 Nov–Dec;10(6):372–5

Prognosis of malignant mammary tumor in 53 cats. Ito T, et al. **J Vet Med Sci** 1996 Aug;58(8):723–6

Phase II study of ifosfamide and etoposide chemotherapy for extensive–disease small–cell lung cancer. Chen YM, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):76–9

Second–line chemotherapy for relapsed small cell lung cancer. Ebi N, et al. **Jpn J Clin Oncol** 1997 Jun;27(3):166–9

Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: nine Japanese institutions trial. Ishida K, et al. **Jpn J Clin Oncol** 1996 Oct;26(5):310–5

Anaplastic Ki–1–positive large cell lymphoma of the pancreas: a case report and review of the literature. Maruyama H, et al. **Jpn J Clin Oncol** 1997 Feb;27(1):51–7 (25 ref.)

Small cell carcinoma of the esophagus: a case report. Ohmura Y, et al. **Jpn J Clin Oncol** 1997 Apr;27(2):95–100 (25 ref.)

Preoperative intra–arterial infusion chemotherapy for invasive thymoma: a case report. Otani Y, et al. **Jpn J Clin Oncol** 1996 Dec;26(6):476–9

Combination phase I/II study of irinotecan hydrochloride (CPT–11) and carboplatin in relapsed or refractory non–Hodgkin's lymphoma. CPT–11/Lymphoma Study Group. Tobinai K, et al. **Jpn J Clin Oncol** 1996 Dec; 26(6):455–60

High–dose cytarabine and mitoxantrone as salvage therapy for refractory non–Hodgkin's lymphoma. Wang WS, et al. **Jpn J Clin Oncol** 1997 Jun;27(3):154–7 (26 ref.)

Adjuvant cyclophosphamide, methotrexate and 5–fluorouracil versus cyclophosphamide plus futraful for premenopausal patients with stage I–II and one– to three–node–positive breast cancer: results of a prospective randomized study. Baba H, et al. **Keio J Med** 1996 Mar; 45(1):54–7

Preliminary results of primary chemotherapy in retinoblastoma. Bornfeld N, et al. **Klin Padiatr** 1997 Jul–Aug;209(4):216–21

High dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma initially treated according to the SIOP 9/GPOH trial and study. Hempel L, et al. **Klin Padiatr** 1996 Jul–Aug;208(4):186–9

The influence of maximum supportive care on dose compliance and survival. Single–center analysis of childhood acute lymphoblastic leukemia and non–Hodgkin's–lymphoma treated within 1984–1993. Urban C, et al. **Klin Padiatr** 1997 Jul–Aug;209(4):235–42

Treatment results in children and adolescents with loco–regional recurrences of abdominal germ cell tumors (GCTs): a pilot–study with PEI chemotherapy and regional deep hyperthermia (RHT) in comparison to a matched cohort. Wessalowski R, et al. **Klin Padiatr** 1997 Jul–Aug; 209(4):250–6

Second temporal remission in a malignant glioma with trofosfamide and etoposide: a case report. Wolff JE, et al. **Klin Padiatr** 1996 Jul–Aug;208(4):190–2

Combined cis–platinum and alpha interferon therapy of advanced hepatocellular carcinoma. Ji SK, et al. **Korean J Intern Med** 1996 Jan;11(1):58–68

Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5–fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co–ordinating Committee on Cancer Research [see comments] **Lancet** 1996 Oct 19; 348(9034):1049–54. Comment in: Lancet 1997 Jan 18;349(9046);205–6.

Simplified vs complex adjuvant chemotherapy schedule for osteosarcoma [comment] Blum RH. **Lancet** 1997 Sep 27; 350(9082):900–1. Comment on: Lancet 1997 Sep 27;350(9082):911–7.

Combined radiotherapy and chemotherapy for anal cancer. EORTC Radiotherapy and Gastrointestinal Cooperative Groups [letter; comment] Bosset JF, et al. **Lancet** 1997 Jan 18;349(9046):205–6. Comment on: Lancet 1996 Oct 19;348(9034):1049–54.

Preoperative chemotherapy induces apoptosis in early breast cancer [letter] Ellis PA, et al. **Lancet** 1997 Mar 22; 349(9055):849

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup [see comments] Souhami RL, et al. **Lancet** 1997 Sep 27;350(9082):911–7. Comment in: Lancet 1997 Sep 27;350(9082):900–1.

Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas. Beauvillain C, et al. **Laryngoscope** 1997 May;107(5):648–53

Planned early neck dissection before radiation for persistent neck nodes after induction chemotherapy. Thomas GR, et al. **Laryngoscope** 1997 Aug;107(8):1129–37

Granulocyte colony–stimulating factor (G–CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of

patient pretreatment characteristics, and costs. Bassan R, et al. **Leuk Lymphoma** 1997 Jun;26(1-2):153-61

Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. Bassan R, et al. **Leuk Lymphoma** 1996 Jul;22(3-4):295-301

A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly. Bellesi G, et al. **Leuk Lymphoma** 1996 Feb;20(5-6):475-80

The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. Bertini M, et al. **Leuk Lymphoma** 1996 Aug;22(5-6):483-93

High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group. Brown RA, et al. **Leuk Lymphoma** 1996 Jul;22(3-4):271-7

Consolidation therapy with idarubicin, cisplatin and prednisone (CIP) after P-VABEC regimen in the treatment of intermediate and high grade non-Hodgkin's lymphoma of the elderly. Caracciolo F, et al. **Leuk Lymphoma** 1997 Jan;24(3-4):355-61

Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. Carella AM, et al. **Leuk Lymphoma** 1996 Mar;21(1-2):63-70

Salvage treatment after failure or relapse following initial chemotherapy for follicular non-Hodgkin's lymphoma. Davidge-Pitts M, et al. **Leuk Lymphoma** 1997 Jan; 24(3-4):341-7

Vinorelbine: a new promising drug in Hodgkin's disease. Devizzi L, et al. **Leuk Lymphoma** 1996 Aug;22(5-6):409-14 (47 ref.)

Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma. Dufour P, et al. **Leuk Lymphoma** 1996 Jul;22(3-4):329-34

A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma. Engert A, et al. **Leuk Lymphoma** 1997 Feb;24(5-6):513-22

Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Escudier SM, et al. **Leuk Lymphoma** 1996 Feb;20(5-6):435-9

Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults. Fanin R, et al. **Leuk Lymphoma** 1997 Jan;24(3-4):369-77

Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Ghaddar HM, et al. **Leuk Lymphoma** 1996 Jun;22(1-2):71-6

Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Gisselbrecht C, et al. **Leuk Lymphoma** 1997 Apr; 25(3-4):289-300

Treatment of Hodgkin's disease: the Swedish National Care Programme experience. Glimelius B, et al. **Leuk Lymphoma** 1996 Mar;21(1-2):71-8

Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival. Hehlmann R, et al. **Leuk Lymphoma** 1996 Sep;22 Suppl 1:161-7 (42 ref.)

Heterogeneous effects of G-CSF and GM-CSF on cell growth and ara-C cytotoxicity in childhood leukemias which express myeloid markers. Higashigawa M, et al. **Leuk Lymphoma** 1996 Jul;22(3-4):279-85

Infradiaphragmatic Hodgkin's disease: long term results of combined modality therapy. Ifrah N, et al. **Leuk Lymphoma** 1996 Mar;21(1-2):79-84

The COP regimen is not a feasible treatment for advanced, refractory chronic lymphocytic leukemia. Itälä M, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):137-41

Effect of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) on chemotherapy-induced myelosuppression in patients with chronic lymphocytic leukemia: a crossover study. Itälä M, et al. **Leuk Lymphoma** 1997 May;25(5-6):503-8

Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Karakas T, et al. **Leuk Lymphoma** 1996 Dec; 24(1-2):121-9

Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: a combined clinical and laboratory study [published erratum appears in Leuk Lymphoma 1997 Feb;24(5-6):553] Kaufmann SH, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):71-83

Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas. Knauf WU, et al. **Leuk Lymphoma** 1996 Oct; 23(3-4):305-11

Treatment of patients with high grade non-Hodgkin's lymphomas and central nervous system involvement: is radiation an essential component of therapy? Magrath IT, et al. **Leuk Lymphoma** 1996 Mar;21(1-2):99-105

FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia. Martinelli G, et al. **Leuk Lymphoma** 1996 Jun;22(1-2):173-6

Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Montillo M, et al. **Leuk Lymphoma** 1997 May; 25(5-6):579-83

Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma. Oken MM, et al. **Leuk Lymphoma** 1996 Feb;20(5-6):447-52

A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Soussain C, et al. **Leuk Lymphoma** 1996 Oct;23(3-4):339-45

Etoposide and mitoxantrone as a second cycle of consolidation therapy following high dose cytosine arabinoside and daunorubicin in patients with acute non-lymphocytic leukemia in remission: a pilot study. Stein RS, et al. **Leuk Lymphoma** 1996 Sep;23(1-2):93-8

Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. Uckun FM, et al. **Leuk Lymphoma** 1996 Dec;24(1-2):57-70

Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Younes A, et al. **Leuk Lymphoma** 1997 Jun;26(1-2):77-82

Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Ferrero D, et al. **Leuk Res** 1996 Oct;20(10):867-76

Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Ruutu T, et al. **Leuk Res** 1997 Feb;21(2):133-8

Results of treatment with an intensive induction regimen using idarubicin in combination with cytarabine and etoposide in children with acute myeloblastic leukemia. Sackmann-Muriel F, et al. **Leuk Res** 1996 Nov-Dec; 20(11-12):973-81

Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study. Thaler J, et al. **Leuk Res** 1997 Jan; 21(1):75-80

Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia. Argiris A, et al. **Leukemia** 1997 Jun;11(6):886-9

Loss of the DEK-CAN fusion transcript in a child with t(6;9) acute myeloid leukemia following chemotherapy and allogeneic bone marrow transplantation. Boer J, et al. **Leukemia** 1997 Feb;11(2):299-300

Angioimmunoblastic lymphadenopathy with disseminated human herpesvirus 6 infection in a patient with acute myeloblastic leukemia. Daibata M, et al. **Leukemia** 1997 Jun;11(6):882-5

Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphoblastic Leukemia. Delannoy A, et al. **Leukemia** 1997 Sep;11(9):1429-34

Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML. de Nully Brown P, et al. **Leukemia** 1997 Jan;11(1):37-41

A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Feldman EJ, et al. **Leukemia** 1997 Apr; 11(4):485-9

Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie. Gardin C, et al. **Leukemia** 1997 Jan; 11(1):16-21

Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Haas R, et al. **Leukemia** 1996 Dec;10(12):1975-9

Outcome of patients with low-grade B cell non-Hodgkin lymphoma and initial bone marrow involvement: data of a single institution. Heinz R, et al. **Leukemia** 1997 Apr;11 Suppl 2:S52-4

Risk-adapted treatment of adult acute lymphoblastic leukemia (ALL). Linker CA. **Leukemia** 1997 May;11 Suppl 4:S24-7 (9 ref.)

High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Pedersen-Bjergaard J, et al. **Leukemia** 1997 Oct; 11(10):1654-60

Purine analogs in the treatment of chronic lymphocytic leukemia. Pott C, et al. **Leukemia** 1997 Apr;11 Suppl 2:S25-8 (52 ref.)

Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Reiffers J, et al. **Leukemia** 1996 Dec;10(12):1874-82

Drug resistance mechanisms in chronic lymphocytic leukemia. Ribrag V, et al. **Leukemia** 1996 Dec; 10(12):1944-9

Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Sacchi S, et al. **Leukemia** 1997 Oct; 11(10):1610-6

Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Schwartsmann G, et al. **Leukemia** 1997 Mar;11 Suppl 1:S28-31

A single course of remission reinduction chemotherapy for acute myelogenous leukemia relapsing after allogeneic bone marrow transplantation is complicated by graft-versus-host disease and followed by sustained complete remission. Vandenberghe P, et al. **Leukemia** 1997 Oct;11(10):1775-8

Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Weiss MA. **Leukemia** 1997 May;11 Suppl 4:S28-30 (20 ref.)

High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia. Whitlock JA, et al. **Leukemia** 1997 Feb;11(2):185-9

Pneumonia during remission induction chemotherapy in patients with AML or MDS. Wilhelm M, et al. **Leukemia** 1996 Dec;10(12):1870-3

First-line therapy of advanced chronic lymphocytic leukemia. Wilhelm M, et al. **Leukemia** 1997 Apr;11 Suppl 2:S14-8 (49 ref.)

A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Willemze R, et al. **Leukemia** 1997 Mar;11 Suppl 1:S24-7

Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients. Bretti S, et al. **Lung Cancer** 1996 Jun; 14(2-3):353-60

Efficacy of platinum-based regimens in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group. Buccheri G, et al. **Lung Cancer** 1997 Aug; 18(1):57-70

Partial substitution of cisplatin with carboplatin in combination with etoposide in advanced non-small cell lung cancer (NSCLC): a multicentric randomised phase II trial. Comella P, et al. **Lung Cancer** 1996 Aug; 15(1):103-14

Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer. Evans WK, et al. **Lung Cancer** 1997 Aug; 18(1):83-94

r-metHuG-CSF support to ifosfamide, cisplatin, etoposide chemotherapy in non-small cell lung cancer. Gautier V, et al. **Lung Cancer** 1996 Jun;14(2-3):343-51

A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Graziano SL, et al. **Lung Cancer** 1996 Jun;14(2-3):315-29

Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer. Kimura H, et al. **Lung Cancer** 1996 Jun;14(2-3):301-14

Histopathological grading of response to induction chemotherapy in non-small cell lung cancer: a preliminary study. Milano S, et al. **Lung Cancer** 1996 Sep;15(2):183-7

A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study. Mitchell EP, et al. **Lung Cancer** 1996 Sep;15(2):215-23

Vinorelbine and ifosfamide for unresectable non-small cell lung cancer. Morere JF, et al. **Lung Cancer** 1997 Aug; 18(1):95-100

Treatment of small cell lung cancer: the state of the art. Murray N. **Lung Cancer** 1997 Jun;17 Suppl 1:S75-89 (42 ref.)

Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. Muscato JJ, et al. **Lung Cancer** 1995 Dec; 13(3):285-94

Phase I/II study of combination chemotherapy with cisplatin, carboplatin and etoposide in small cell lung cancer. Sakurai M, et al. **Lung Cancer** 1996 Sep;15(2):225-32

Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer. Salomaa ER, et al. **Lung Cancer** 1996 Dec;16(1):75-80

Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer. Stewart DJ, et al. **Lung Cancer** 1996 Aug;15(1):115-23

Carboplatin as radiosensitizer in non-small cell lung cancer after cisplatin containing chemotherapy. A phase I study of a groupe francais de pneumo-cancerologie (G.F.P.C.). Thomas P, et al. **Lung Cancer** 1997 Aug;18(1):71-81

The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer. Trillet-Lenoir V, et al. **Lung Cancer** 1996 Jun;14(2-3):331-41

Advanced non-small cell lung cancer (ANSCLC): new chemotherapy phase II studies and old faults [letter] Tummarello D, et al. **Lung Cancer** 1996 Nov;15(3):375-6

Combination chemotherapy with vindesine–ifosfamide–cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non–small cell lung cancer: a phase II trial. Vansteenkiste J, et al. **Lung Cancer** 1995 Dec;13(3):295–303

Subacute encephalopathic toxicity of cisplatin. Verschraegen C, et al. **Lung Cancer** 1995 Dec;13(3):305–9 (13 ref.)

Phase II study of alternating doses of vinorelbine in combination with cisplatin for non–small cell lung cancer (NSCLC): a disappointing experience. Westeel V, et al. **Lung Cancer** 1996 Dec;16(1):61–73

Interferon alpha–2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. Zarogoulidis K, et al. **Lung Cancer** 1996 Sep;15(2):197–205

Angiosarcoma of the liver: MR imaging pre– and post–chemotherapy. Worawattanakul S, et al. **Magn Reson Imaging** 1997;15(5):613–7

Platinum–based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract. Lerner SE, et al. **Mayo Clin Proc** 1996 Oct;71(10):945–50

Preliminary results of combined chemotherapy and radiotherapy for non–AIDS primary central nervous system lymphoma. Trans–Tasman Radiation Oncology Group (TROG). O'Brien PC, et al. **Med J Aust** 1996 Oct 21;165(8):424–7

How to optimize the effect of 5–fluorouracil modulated therapy in advanced colorectal cancer. Ragnhammar P, et al. **Med Oncol** 1995 Sep;12(3):187–201 (137 ref.)

Modified BFM protocol for childhood acute lymphoblastic leukemia: a retrospective analysis. Aziz Z, et al. **Med Pediatr Oncol** 1997 Jan;28(1):48–53

Successful treatment of relapsed infant acute lymphoblastic leukemia with intensive antimetabolite–based chemotherapy. Barredo JC, et al. **Med Pediatr Oncol** 1997 Oct;29(4):256–9

Uncertain role of high dose chemotherapy with autologous stem cell support in pediatric pleuro–pulmonary blastoma (PPB) [letter; comment] Békássy AN, et al. **Med Pediatr Oncol** 1997 Jan;28(1):75–6. Comment on: Med Pediatr Oncol 1995 Dec;25(6):479–84.

Osteoblastoma response to radiotherapy and chemotherapy. Berberoglu S, et al. **Med Pediatr Oncol** 1997 Apr; 28(4):305–9

Treatment of standard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine. Bergman I, et al. **Med Pediatr Oncol** 1997 Dec;29(6):563–7

Chemotherapy for spinal cord astrocytoma. Bouffet E, et al. **Med Pediatr Oncol** 1997 Dec;29(6):560–2

Fractionated cylophosphamide and back to back high dose methotrexate and cytosine arabinoside improves outcome in patients with stage III high grade small non–cleaved cell lymphomas (SNCCL): a randomized trial of the Pediatric Oncology Group. Brecher ML, et al. **Med Pediatr Oncol** 1997 Dec;29(6):526–33

Acute lymphoblastic leukemia in children: nonrandomized comparison of conventional vs. intensive chemotherapy at the National Cancer Institute of Colombia. Buendia MT, et al. **Med Pediatr Oncol** 1997 Feb;28(2):108–16

Treatment of childhood post–irradiation sarcoma of bone in cancer survivors. Cefalo G, et al. **Med Pediatr Oncol** 1997 Dec;29(6):568–72

Results of a BFM–based protocol for the treatment of childhood B–non–Hodgkin's lymphoma and B–acute lymphoblastic leukemia in Argentina. Chantada GL, et al. **Med Pediatr Oncol** 1997 May;28(5):333–41

Bone marrow transplantation versus chemotherapy for maintenance of second remission of childhood acute lymphoblastic leukemia: a study of the Children's Cancer Group (CCG–1884). Feig SA, et al. **Med Pediatr Oncol** 1997 Dec;29(6):534–40

Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group. Feig SA, et al. **Med Pediatr Oncol** 1996 Dec;27(6):505–14

Long–term survival data and prognostic factors of a complete response to chemotherapy in patients with head and neck cancer treated with platinum–based induction chemotherapy: a Hellenic Co–operative oncology Group study. Fountzilas G, et al. **Med Pediatr Oncol** 1997 Jun; 28(6):401–10

Intermediate–dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten–year follow–up. Freeman AI, et al. **Med Pediatr Oncol** 1997 Feb;28(2):98–107

What is the best method of prevention of therapeutic failures in CNS in high risk retinoblastoma? [letter; comment] Grześkowiak–Melanowska J, et al. **Med Pediatr Oncol** 1997 Jan;28(1):79. Comment on: Med Pediatr Oncol 1994;22(2):125–8.

Hepatic angiosarcoma in a child: successful therapy with surgery and adjuvant chemotherapy. Gunawardena SW, et al. **Med Pediatr Oncol** 1997 Feb;28(2):139–43

HLH–94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Henter JI, et al. **Med Pediatr Oncol** 1997 May; 28(5):342–7

Evaluation of patients with advanced neuroblastoma surviving more than 5 years after initiation of an intensive Japanese protocol: a report from the Study Group of Japan for Treatment of Advanced Neuroblastoma. Iwafuchi M, et al. **Med Pediatr Oncol** 1996 Dec;27(6):515–20

Feasibility of sequential high–dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies. Jakacki RI, et al. **Med Pediatr Oncol** 1997 Dec;29(6):553–9

Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Kiltie AE, et al. **Med Pediatr Oncol** 1997 May;28(5):348–54

Successful treatment of orbital rhabdomyosarcoma in two infants using chemotherapy alone [letter; comment] Lackner H, et al. **Med Pediatr Oncol** 1997 Jun;28(6):463–4 . Comment on: Med Pediatr Oncol 1996 Mar;26(3):186–9.

Metastatic primitive neuroectodermal tumour of the ovary: successful treatment with mega–dose chemotherapy followed by peripheral blood progenitor cell rescue. Lawlor ER, et al. **Med Pediatr Oncol** 1997 Oct;29(4):308–12

"Response to Hord and Janco re chemotherapy for unresectable pancreatoblastoma" [letter; comment] Lee AC, et al. **Med Pediatr Oncol** 1997 Sep;29(3):237. Comment on: Med Pediatr Oncol 1996 Jun;26(6):432–3.

Prognostic significance of chemotherapy dosage characteristics in children with osteogenic sarcoma. Leung S, et al. **Med Pediatr Oncol** 1997 Mar;28(3):179–82

Granulocyte–macrophage colony–stimulating factor in association with high–dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group. McCowage GB, et al. **Med Pediatr Oncol** 1997 Aug;29(2):108–14

"Bad–risk childhood pleuropulmonary blastoma: does chemoradiotherapy help?" [letter; comment] Pistevou–Gompaki K, et al. **Med Pediatr Oncol** 1997 Sep; 29(3):236. Comment on: Med Pediatr Oncol 1995 Dec;25(6):479–84.

Hodgkin disease in children: results of a prospective randomized trial in a single institution in Argentina. Sackmann–Muriel F, et al. **Med Pediatr Oncol** 1997 Dec; 29(6):544–52

Organ–preserving management of rhabdomyosarcoma of the prostate and bladder in children. Silván AM, et al. **Med Pediatr Oncol** 1997 Dec;29(6):573–5

Combined radiation and chemotherapy for advanced undifferentiated nasopharyngeal carcinoma in children. Strojan P, et al. **Med Pediatr Oncol** 1997 May;28(5):366–9

Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy. van den Berg H, et al. **Med Pediatr Oncol** 1997 Jul;29(1):23–7

Hypercalcemia and carcinoma of the penis. Videtic GM, et al. **Med Pediatr Oncol** 1997 Dec;29(6):576–7

Chemosensitivity of human melanoma metastases in mouse subrenal capsule assay—can it predict tumour response to combined cytostatic plus interferon therapy in metastatic melanoma? Hahka–Kemppinen M, et al. **Melanoma Res** 1996 Jun;6(3):215–21

DNA flow cytometry and the outcome of chemoimmunotherapy in metastatic melanoma. Hahka–Kemppinen M, et al. **Melanoma Res** 1997 Aug; 7(4):329–34

A phase II study of interferon–alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. Schultz MZ, et al. **Melanoma Res** 1997 Apr;7(2):147–51

Complete responses and survival after polychemotherapy plus interferon–alpha for patients with metastatic melanoma. Vuoristo MS. **Melanoma Res** 1996 Aug; 6(4):331–6

The cost–effectiveness of four cisplatin–containing chemotherapy regimens in the treatment of stages III B and IV non–small cell lung cancer: an Italian perspective [letter; comment] Berdeaux G, et al. **Monaldi Arch Chest Dis** 1997 Jun;52(3):305–6. Comment on: Monaldi Arch Chest Dis 1996 Aug;51(4):279–88.

Hyperfractionated radiotherapy combined with simultaneous chemotherapy in inoperable non–small cell lung cancer: a pilot study. Ozkök S, et al. **Monaldi Arch Chest Dis** 1995 Dec;50(6):443–7

The cost–effectiveness of four cisplatin–containing chemotherapy regimens in the treatment of stages III B and IV non–small cell lung cancer: an Italian perspective [see comments] Palmer AJ, et al. **Monaldi Arch Chest Dis** 1996 Aug;51(4):279–88. Comment in: Monaldi Arch Chest Dis 1997 Jun;52(3):305–6.

Chemotherapy of non–small cell lung cancer. Scagliotti GV, et al. **Monaldi Arch Chest Dis** 1997 Jun;52(3):287–95 (75 ref.)

Chemotherapy helps patients with advanced non–small cell carcinoma of the lung. Socinski MA, et al. **N C Med J** 1996 Sep–Oct;57(5):281–6 (30 ref.)

Multimodal therapy for esophageal adenocarcinoma [letter; comment] Badwe RA, et al. **N Engl J Med** 1997 Jan 30; 336(5):374–5; discussion 375–6. Comment on: N Engl J Med 1996 Aug 15;335(7):462–7.

Differentiation therapy for acute promyelocytic leukemia [editorial; comment] Fenaux P, et al. **N Engl J Med** 1997 Oct 9;337(15):1076–7. Comment on: N Engl J Med 1997 Oct 9;337(15):1021–8.

Optimizing treatment for chronic myeloid leukemia [editorial; comment] Goldman JM. **N Engl J Med** 1997 Jul 24; 337(4):270–1. Comment on: N Engl J Med 1997 Jul 24;337(4):223–9.

Interferon alfa–2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group [see comments] Guilhot F, et al. **N Engl J Med** 1997 Jul 24;337(4):223–9 . Comment in: N Engl J Med 1997 Jul 24;337(4):270–1.

Postoperative radiotherapy in high–risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial [see comments] Overgaard M, et al. **N Engl J Med** 1997 Oct 2;337(14):949–55. Comment in: N Engl J Med 1997 Oct 2;337(14):996–7.

Human granulocyte colony–stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia [see comments] Pui CH, et al. **N Engl J Med** 1997 Jun 19;336(25):1781–7. Comment in: N Engl J Med 1997 Jun 19;336(25):1822–4.

All–trans–retinoic acid in acute promyelocytic leukemia [see comments] Tallman MS, et al. **N Engl J Med** 1997 Oct 9;337(15):1021–8. Comment in: N Engl J Med 1997 Oct 9;337(15):1076–7.

Thermochemotherapy for cancer of the tongue using magnetic induction hyperthermia (implant heating system: IHS). Tohnai I, et al. **Nagoya J Med Sci** 1996 Mar; 59(1–2):49–54

Adjuvant therapy for colon cancer—what's the FUFA? Gupta P. **Natl Med J India** 1996 Jul–Aug;9(4):174

Chemotherapy for advanced non–small cell lung cancer. Ichinose Y, et al. **Natl Med J India** 1996 Jan–Feb;9(1):24–5

Systemic adjuvant therapy for breast cancer. Reed EC. **Nebr Med J** 1996 Mar;81(3):48–50 (17 ref.)

Differential chemosensitivity of leukemic cells in the myeloid and lymphoid phases of stem cell leukemia (a case report). Mihál V, et al. **Neoplasma** 1997;44(2):133–6

A comparative study of preoperative B–V–M–M chemotherapy and irradiation in advanced squamous cell cancer of the oral cavity. Olasz L, et al. **Neoplasma** 1996; 43(1):51–6

Pilot study of enhancement of cisplatin activity by high dose cytarabine in advanced gastric and colorectal (G3/G4) cancer. Popov I, et al. **Neoplasma** 1996;43(4):221–4

DTIC vs. IFN–alpha plus DTIC in the treatment of patients with metastatic malignant melanoma. Rudolf Z, et al. **Neoplasma** 1996;43(2):93–7

Management of germ cell testicular cancer with pulmonary metastases. Schnorrer M, et al. **Neoplasma** 1996;43(1):47–50

Sequential combination of radio–chemotherapy (5–fluorouracil, cis–platinum and irradiation) in the management of locally advanced head and neck cancers. Suwiński R, et al. **Neoplasma** 1996;43(1):37–41

Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient. Gorschlüter M, et al. **Nephrol Dial Transplant** 1997 Mar; 12(3):593–5

Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy. Teruel JL, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1262–3

Combined chemotherapy and radiotherapy for esophageal carcinoma in a hemodialyzed patient. Long–term survival. Rebibou JM, et al. **Nephron** 1996;74(3):611–2

Successful treatment on an out–patient basis of a patient with Down's syndrome and disseminated testicular seminoma. Sleijfer S, et al. **Neth J Med** 1996 Mar;48(3):89–91

Combined irradiation and chemotherapy using ifosfamide, cisplatin, and etoposide for children with medulloblastoma/posterior fossa primitive neuroectodermal tumor—results of a pilot study. Sawamura Y, et al. **Neurol Med Chir (Tokyo)** 1996 Sep;36(9):632–8

Technetium–MIBI as a glioma imaging agent for the assessment of multi–drug resistance. Andrews DW, et al. **Neurosurgery** 1997 Jun;40(6):1323–32; discussion 1333–4

Combination of 6–thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. Kyritsis AP, et al. **Neurosurgery** 1996 Nov;39(5):921–6

In vivo 31P NMR spectroscopy of human musculoskeletal tumors as a measure of response to chemotherapy. Möller HE, et al. **NMR Biomed** 1996 Dec;9(8):347–58

Management of chemotherapy in a pregnancy complicated by a large neuroblastoma. Arango HA, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):665–8 (10 ref.)

Rhabdomyosarcoma treated with chemotherapy during the third trimester. Martin D, et al. **Obstet Gynecol** 1997 May; 89(5 Pt 2):828–31

Results of the cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) +/– bleomycin treatment and evaluation of prognostic factors in aggressive lymphomas in Turkey. Dinçol D, et al. **Oncology** 1997 Sep–Oct; 54(5):376–9

Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. Feliu J, et al. **Oncology** 1997;54 Suppl 1:30–7

UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. González Barón M, et al. **Oncology** 1997;54 Suppl 1:24–9

Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small–cell lung cancer. Hanauske AR, et al. **Oncology** 1997 Sep–Oct;54(5):363–70

Phase II evaluation of 5–fluourouracil plus folinic acid and alpha 2b–interferon in metastatic colorectal cancer. Köhne CH, et al. **Oncology** 1997 Mar–Apr;54(2):96–101

Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study. Miglietta L, et al. **Oncology** 1997 Mar–Apr;54(2):102–7

Granulocyte–macrophage–colony–stimulating factor support

in patients with acute non-lymphatic leukemia. Nel JS, et al. **Oncology** 1996 Nov-Dec;53(6):482-7

First-line chemotherapy of advanced breast cancer with a combination of mitoxantrone, methotrexate, and vincristine (MIMO). Samonis G, et al. **Oncology** 1997 Sep-Oct; 54(5):371-5

Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study. Schilling T, et al. **Oncology** 1997 Mar-Apr;54(2):89-95

Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU. Taguchi T. **Oncology** 1997;54 Suppl 1:12-8

A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital. Villalon AH, et al. **Oncology** 1997;54 Suppl 1:2-6

Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Wakahara Y, et al. **Oncology** 1997 Jan-Feb;54(1):48-54

Vinorelbine/paclitaxel combination studied in treatment of metastatic breast cancer patients. **Oncology (Huntingt)** 1995 Jun;9(6):518, 543

Hycamtin achieves promising results in study of patients with leukemia [news] **Oncology (Huntingt)** 1996 Dec;10(12):1860

Chemotherapy plus radiation improves prognosis of nasopharyngeal carcinoma [news] **Oncology (Huntingt)** 1996 Dec;10(12):1885

Trial of topotecan as first-line treatment for ovarian cancer announced [news] **Oncology (Huntingt)** 1996 Mar;10(3):416

Gemcitabine shows promise as combination agent in NSCLC. **Oncology (Huntingt)** 1996 Sep;10(9):1311

Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer. Amadori D, et al. **Oncology (Huntingt)** 1997 Apr;11(4 Suppl 3):30-3

Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Bonomi P, et al. **Oncology (Huntingt)** 1997 Apr;11(4 Suppl 3):9-10

Clinical trials at the medicine branch of the NCI-part 2. Cheson BD, et al. **Oncology (Huntingt)** 1995 Jun;9(6):506, 509-10

Clinical trials referral resource. Clinical trials in elderly patients. Cheson BD, et al. **Oncology (Huntingt)** 1997 Jun; 11(6):838, 844

Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer. Giaccone G, et al. **Oncology (Huntingt)** 1997 Apr;11(4 Suppl 3):11-4

Paclitaxel-based combination chemotherapy for breast cancer. Hortobagyi GN. **Oncology (Huntingt)** 1997 Mar; 11(3 Suppl 2):29-37 (54 ref.)

Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide. Hudis C. **Oncology (Huntingt)** 1997 Apr;11(4 Suppl 3):15-8 (25 ref.)

Management of esophageal cancer. Ilson DH, et al. **Oncology (Huntingt)** 1996 Sep;10(9):1385-96, 1401-2; discussion 1402-8 (79 ref.)

Strategies for identification and clinical evaluation of promising chemopreventive agents. Kelloff GJ, et al. **Oncology (Huntingt)** 1996 Oct;10(10):1471-84; discussion 1484-8 (102 ref.)

Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer. Klaassen U, et al. **Oncology (Huntingt)** 1997 Apr;11(4 Suppl 3):38-40

Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer. Lück HJ, et al. **Oncology (Huntingt)** 1997 Apr;11(4 Suppl 3):34-7

NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Mamounas EP. **Oncology (Huntingt)** 1997 Jun;11(6 Suppl 6):37-40

A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer. Schwartsmann G, et al. **Oncology (Huntingt)** 1997 Apr;11(4 Suppl 3):24-9

Integration of vinorelbine into chemotherapy strategies for non-small-cell lung cancer. Vokes EE. **Oncology (Huntingt)** 1995 Jun;9(6):565-74, 577; discussion 577-8, 581- (106 ref.)

Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Hill ME, et al. **Oral Oncol** 1997 Jul;33(4):275-8

Intensive chemotherapy using cisplatin and fluorouracil followed by radiotherapy in advanced head and neck cancer. Zidan J, et al. **Oral Oncol** 1997 Mar;33(2):129-35

Stage IV malignant intrapericardial germ cell tumor: a case report. Bath LE, et al. **Pediatr Hematol Oncol** 1997 Sep-Oct;14(5):451-5

Hodgkin's disease in 82 Turkish children diagnosed over a 10-year period: epidemiological, clinical, and histopathologic features and prognosis with prolonged chemotherapy. Ertem U, et al. **Pediatr Hematol Oncol** 1997 Jul-Aug;14(4):359-66

Primary malignant fibrous histiocytoma of the lung in a child: a case report and review of literature. Shah SJ, et al. **Pediatr Hematol Oncol** 1996 Nov-Dec;13(6):531-8

Understanding the psychosocial late effects of childhood cancer therapy. Simms S. **Pediatr Hematol Oncol** 1997 May-Jun;14(3):187-9 (7 ref.)

Malignant external otitis as the presentation of childhood acute lymphocytic leukemia. Pacini DL, et al. **Pediatr Infect Dis J** 1996 Dec;15(12):1132-4 (21 ref.)

A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study. Grill J, et al. **Pediatr Neurosurg** 1996 Jul;25(1):7-12

The pharmacologic effects of recombinant, human colony-stimulating factors and their modulation by theophylline. Petros WP, et al. **Pharmacotherapy** 1996 Sep-Oct;16(5):742-8

Kaposi's sarcoma: advances in tumor biology and pharmacotherapy. Sung JC, et al. **Pharmacotherapy** 1997 Jul-Aug;17(4):670-83 (103 ref.)

Pneumonitis complicating selective intra-arterial chemotherapy for locally advanced breast carcinoma. McLean AD, et al. **Postgrad Med J** 1996 Feb;72(844):117-8

Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment. Losa M, et al. **Prostate** 1997 Sep 1; 32(4):241-5

Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Zaccheo T, et al. **Prostate** 1997 Feb 1;30(2):85-91

CA and leukemia group B 9251 protocol. Zitter K, et al. **Radiol Technol** 1997 May-Jun;68(5):423-5

Locally advanced head and neck cancer: combined chemotherapy and radical radiation therapy for organ and function preservation (interim report). Cheung AY, et al. **Radiology** 1997 Jul;204(1):207-10

Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy. Shikama N, et al. **Radiology** 1997 Aug;204(2):467-70

Sequential quantitative MR analysis of bone marrow: differences during treatment of lymphoid versus myeloid leukemia. Vande Berg BC, et al. **Radiology** 1996 Nov; 201(2):519-23

Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG) [see comments] Denham JW, et al. **Radiother Oncol** 1996 Jul;40(1):31-43. Comment in: Radiother Oncol 1997 Jan;42(1):91-2.

Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Jeremic B, et al. **Radiother Oncol** 1997 Apr;43(1):29-37

Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Lewin F, et al. **Radiother Oncol** 1997 Apr;43(1):23-8

Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer. Touboul E, et al. **Radiother Oncol** 1997 Mar;42(3):219-29

Pulmonary sarcoid-like granulomata in a patient treated for extrapulmonary Hodgkin's disease. van den Berg, et al. **Respiration** 1997;64(1):114-7

Resolution of HIV-associated cystic benign lymphoepithelial lesion of the parotid gland in a patient undergoing chemotherapy for non-Hodgkin's lymphoma. Albrecht H, et al. **Scand J Infect Dis** 1996;28(6):621-3

Effects of intravesical instillation of 5-fluorouracil and interferon in patients with recurrent superficial urinary bladder carcinoma. A clinical and pharmacodynamic study. Hugosson J, et al. **Scand J Urol Nephrol** 1997 Aug; 31(4):343-7

Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience. Chen YC, et al. **Semin Hematol** 1996 Oct;33(4 Suppl 3):30-4

A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia. Masaoka T, et al. **Semin Hematol** 1996 Oct;33(4 Suppl 3):12-7

Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia. Mehta J, et al. **Semin Hematol** 1996 Oct;33(4 Suppl 3):18-23

Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study. Park HS, et al. **Semin Hematol** 1996 Oct;33(4 Suppl 3):24-9

The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 3: Gynecologic malignancies, head and neck cancer, and other tumor types. Marrakech, Morocco, January 18-20, 1996 and St Croix, Virgin Islands, March 13-16, 1996. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-1-S2-120; quiz S2-121-S2-123 (0 ref.)

The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 1: Lung Cancer. Puerto Rico, March 12-16, 1997. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-1-S12-162; quiz S12-163-S12-173 (0 ref.)

Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma. Abratt RP, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-18-S8-23

Paclitaxel in head and neck and other cancers: future prospects. Aisner J, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-113-S2-115 (21 ref.)

A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Amadori D, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):16-22

Paclitaxel and carboplatin in metastatic non-small cell lung cancer: preliminary results of a phase I study. Belani CP, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 12):19-21

A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer. Birch R, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-135-S12-137

The treatment of adult acute myeloid leukemia. Bishop JF. **Semin Oncol** 1997 Feb;24(1):57-69 (123 ref.)

A phase I trial with fixed-dose carboplatin and escalating doses of paclitaxel in advanced ovarian cancer. Bolis G, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-23-S2-25

Primary chemotherapy in operable breast cancer. Bonadonna G, et al. **Semin Oncol** 1996 Aug;23(4):464-74 (36 ref.)

Escalating paclitaxel doses combined with carboplatin/etoposide and thoracic radiotherapy as preoperative or definitive treatment for stage III non-small cell lung cancer. Bonomi P, et al. **Semin Oncol** 1996 Dec; 23(6 Suppl 16):102-7

A phase I study of etoposide phosphate plus paclitaxel. Brooks DJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 13):30-3

Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. Büchner T, et al. **Semin Oncol** 1997 Feb;24(1):124-31 (37 ref.)

A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer. Bunn PA Jr, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-144-S12-148

Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Bunn PA Jr. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-153-S12-162 (63 ref.)

Overview of chemotherapy for small cell lung cancer. Bunn PA Jr, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7-69-S7-74 (44 ref.)

Combination paclitaxel and platinum in the treatment of lung cancer: US experience. Bunn PA Jr. **Semin Oncol** 1996 Dec;23(6 Suppl 15):9-15 (29 ref.)

The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Bunn PA Jr. **Semin Oncol** 1996 Dec;23(6 Suppl 16):18-25 (34 ref.)

Future directions in therapeutic approaches for small cell lung cancer. Bunn PA Jr. **Semin Oncol** 1996 Dec;23(6 Suppl 16):136-8

Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience. Cagnoni PJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):43-8

Biology and treatment of acute lymphocytic leukemia in children. Camitta BM, et al. **Semin Oncol** 1997 Feb; 24(1):83-91

A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Carmichael J, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 10):55-9

Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience. Catimel G, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 3):S8-12

Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Choy H, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-21-S12-26

Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Choy H, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):117-9

Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results. Coeffic D, et al. **Semin Oncol** 1996 Dec; 23(6 Suppl 15):5-8

Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma. Coeffic D, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-38-S2-40

Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: a phase I study. Comella G, et al. **Semin Oncol** 1997 Aug; 24(4 Suppl 12):S12-113-S12-116

A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. Conley B, et al. **Semin Oncol** 1997 Feb; 24(1 Suppl 2):S2-78-S2-80

Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer. Conte PF, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):39-42 (10 ref.)

A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer. Conte PF, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):28-31

Paclitaxel in head and neck cancer and other tumor types: chairmen's introduction. Cortés-Funes H, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-51-S2-57 (48 ref.)

Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. Creaven PJ, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-138-S12-143

Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. Creaven PJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):26-31

Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase

II trials. DeVore RF 3rd, et al. **Semin Oncol** 1997 Aug; 24(4 Suppl 12):S12-27–S12-29

Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Dombernowsky P, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):23–7

The development of docetaxel (Taxotere) in non-small cell lung cancer—docetaxel in new combinations and new schedules: an overview of ongoing and future developments. Donnellan PP, et al. **Semin Oncol** 1997 Aug; 24(4 Suppl 14):S14-18–S14-21

A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer. Doyle JJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 13):51–60

Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie. du Bois A, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 11):S11-28–S11-33

Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study. Einhorn LH. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-24–S8-26

Acute promyelocytic leukemia: biology and treatment. Fenaux P, et al. **Semin Oncol** 1997 Feb;24(1):92–102 (114 ref.)

Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer. Fennelly DW, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-26–S2-30

Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study. Fountzilas G, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-65–S2-67

The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer. Frassineti GL, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 12):22–8

A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer. Gatzemeier U, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-36–S8-38

Paclitaxel, carboplatin, and oral etoposide: a phase II trial in limited-stage small cell lung cancer. Gatzemeier U, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-149–S12-152

Paclitaxel and doxorubicin in metastatic breast cancer. Gehl J, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):35–8 (17 ref.)

Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen. Georgoulias V, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-61–S12-66

Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results. Georgoulias V, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 14):S14-22–S14-25

Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer. Georgoulias V, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 14):S14-9–S14-14

Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer. Gianni L, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 3):S1–3

Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial. Greco FA, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-14–S12-17

Clinical studies with etoposide phosphate. Greco FA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 13):45–50

One-hour paclitaxel in the treatment of non-small cell lung cancer. Hainsworth JD, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):98–101

Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Haraf DJ, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-68–S2-71

The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer. Harper P. **Semin Oncol** 1997 Aug;24(4 Suppl 14):S14-30–S14-32

Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer. Hill M, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-34–S2-37

Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer. Hitt R, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-58–S2-64

Paclitaxel combination therapy in the treatment of metastatic breast cancer. Holmes FA. **Semin Oncol** 1996 Oct;23(5 Suppl 12):29–39 (56 ref.)

Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Holmes FA. **Semin Oncol** 1996 Oct;23(5 Suppl 11):46–56 (55 ref.)

Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. Hortobagyi GN, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 11):S11-13–S11-19

Adjuvant drug therapy for operable breast cancer. Hudis CA, et al. **Semin Oncol** 1996 Aug;23(4):475–93 (99 ref.)

Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. Johnson DH, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 3):S22–5

Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46). Johnson DH, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):42–6

Docetaxel in combination chemotherapy for metastatic breast cancer. Khayat D, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 13):S13-19–S13-26 (30 ref.)

Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Klaassen U, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):32–7

Paclitaxel and carboplatin in inoperable non-small cell lung cancer. Kosmidis P, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):68–70

Paclitaxel and carboplatin in nonoperable non-small cell lung cancer. Kosmidis P, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):16–8

Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study. Kosmidis P, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-30–S12-33

Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network. Langer CJ, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-81–S12-88

Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001. Langer CJ, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-89–S12-95

Treatment of adult acute lymphoblastic leukemia. Laport GF, et al. **Semin Oncol** 1997 Feb;24(1):70–82 (65 ref.)

Chemoradiotherapy for poor-risk stage III non-small cell lung cancer. Lau DH, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-110–S12-112

Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report. Lee JS, et al. **Semin Oncol** 1997 Aug; 24(4 Suppl 12):S12-52–S12-55

Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Legha SS. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S39-43 (25 ref.)

Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study. Lhommé C, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 12):48–54

Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer. Lück HJ, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 3):S13–6

Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. McGuire WP, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-13–S2-16

Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). McGuire WP, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 12):40–7

A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. Manegold C, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-13–S8-17

Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer. Markman M. **Semin Oncol** 1997 Aug;24(4 Suppl 11):S11-24–S11-27 (17 ref.)

Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer. Mattson K, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 14):S14-5–S14-8

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial. Meerpohl HG, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-17–S2-22

Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients. Michelotti A, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):38–40

Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial. Miller VA. **Semin Oncol** 1997 Aug; 24(4 Suppl 14):S14-15–S14-17

Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Natale RB. **Semin Oncol** 1996 Oct;23(5 Suppl 12):2–6

Paclitaxel with carboplatin for the treatment of ovarian cancer. Neijt JP, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):2–4 (12 ref.)

A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. Neill HB, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-130–S12-134

Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial. Nicholson B, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 11):S11-20–S11-23

Regional adjuvant chemotherapy after partial hepatectomy for metastatic colorectal carcinoma. Nonami T, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6-130–S6-134

Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Ono T, et al. **Semin Oncol** 1997 Apr; 24(2 Suppl 6):S6-18–S6-25

Chemotherapy of advanced ovarian cancer: current status and future directions. Ozols RF, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-1–S2-9 (49 ref.)

Gynecologic oncology group trials in ovarian carcinoma. Ozols RF. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-10–S2-12

Paclitaxel and carboplatin: a phase I study in advanced non-small cell lung cancer. Paccagnella A, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):76–9

Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. Palackdharry CS. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-108–S2-112

Preliminary results of neoadjuvant paclitaxel and carboplatin in the treatment of early stage non-small cell lung cancer. Palackdharry CS, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-34–S12-36

Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group. Panagos GE. **Semin Oncol** 1997 Feb;24(1 Suppl 3):S17–21

Paclitaxel and carboplatin for advanced breast cancer. Perez EA, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):41–5 (38 ref.)

Combinations of paclitaxel and etoposide in the treatment of lung cancer. Perez EA, et al. **Semin Oncol** 1996 Dec; 23(6 Suppl 15):21–5

Preclinical combination therapy with gemcitabine and mechanisms of resistance. Peters GJ, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 10):16–24 (35 ref.)

Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team. Pisters KM, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-41–S12-44

Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study. Porter D, et al. **Semin Oncol** 1996 Dec; 23(6 Suppl 13):34–44

Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group. Postmus PE, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 12):10–3

Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Ramanathan RK, et al. **Semin Oncol** 1997 Aug;24(4):440–54 (132 ref.)

A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer. Rosell R, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-56–S12-60

Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer. Roychowdhury DF, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-37–S12-40

Radiotherapy (RT) equipment technology in some developing countries is outdated [letter] Ruiz-Argüelles GJ, et al. **Semin Oncol** 1997 Jun;24(3):xlv

Preliminary results of a dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Scagliotti GV, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):80–3

Mobilization of peripheral blood progenitor cells with paclitaxel-based chemotherapy. Shea TC. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2-105–S2-107 (17 ref.)

Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer. Shepherd FA, et al. **Semin Oncol** 1996 Oct; 23(5 Suppl 10):48–54

Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Shepherd FA, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8-27–S8-30

Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies. Sledge GW Jr. **Semin Oncol** 1996 Oct;23(5 Suppl 11):57–9

High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. Socinski MA, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-45–S12-51 (51 ref.)

Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial. Socinski MA, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-117–S12-122

Preliminary results of a phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Sørensen JB, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-18–S12-20

Introduction to the treatment of lung cancer. Splinter TA. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-1–S12-5 (44 ref.)

Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer. Splinter TA. **Semin Oncol** 1996 Dec;23(6 Suppl 16):59–61

Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results. Steward WP, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 10):43–7

Ifosfamide/carboplatin/etoposide/paclitaxel in advanced

lung cancer: update and preliminary survival analysis. Strauss GM, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12-73–S12-80

Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose–finding study. ten Bokkel Huinink W, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–31–S2–33

Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Thompson JA, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 4):S44–8

Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non–small cell lung cancer. Tonato M, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8–31–S8–35

Clinical pharmacology of carboplatin administered in combination with paclitaxel. van Warmerdam LJ, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–97–S2–104

Phase I trial of paclitaxel/carboplatin in advanced carcinoma of the urothelium. Vaughn DJ, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–47–S2–50

Investigations of new drugs in combination with cisplatin in stage III non–small cell lung cancer. Vokes EE, et al. **Semin Oncol** 1997 Jun;24(3 Suppl 8):S8–42–S8–45 (24 ref.)

Paclitaxel/carboplatin plus ifosfamide in non–small cell lung cancer. Vokes EE, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–67–S12–69

Paclitaxel and cisplatin in patients with non–small cell lung cancer: results of a phase II trial. von Pawel J, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 12):7–9

Phase II study of paclitaxel and cisplatin in patients with non–small cell lung cancer. von Pawel J, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):47–50

Paclitaxel, ifosfamide, and carboplatin for the treatment of stages IIIB and IV non–small cell lung cancer: preliminary results. Zaniboni A, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–70–S12–72

Systemic chemotherapy of transitional cell carcinoma of the urothelium. Brinkley WM, et al. **Semin Surg Oncol** 1997 Sep–Oct;13(5):365–75 (112 ref.)

Neoadjuvant chemotherapy with cisplatinum/5–fluorouracil/low–dose leucovorin for advanced squamous cell carcinoma of the esophagus. Ide H, et al. **Semin Surg Oncol** 1997 Jul–Aug;13(4):263–9

Primary chemotherapy: how does it compare with surgery? Horwich A. **Semin Urol Oncol** 1996 Feb;14(1):34–5

Estramustine–based chemotherapy. Hudes G. **Semin Urol Oncol** 1997 Feb;15(1):13–9 (47 ref.)

Adjuvant chemotherapy for stage II nonseminomatous testicular cancer: what is its role? Motzer RJ. **Semin Urol Oncol** 1996 Feb;14(1):30–3 (28 ref.)

Other chemotherapy regimens including mitoxantrone and suramin. Siu LL, et al. **Semin Urol Oncol** 1997 Feb; 15(1):20–7 (38 ref.)

Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma. Tan EH, et al. **Singapore Med J** 1996 Apr;37(2):165–7

Chemo–immunotherapy for advanced–stage malignancies and its impact on quality of life: multidimensional evaluation in ten cancer patients. Curreli L, et al. **Support Care Cancer** 1996 Nov;4(6):462–4

The relationship between parameters of serotonin metabolism and emetogenic potential of platinum–based chemotherapy regimens. du Bois A, et al. **Support Care Cancer** 1997 May; 5(3):212–8

Complications associated with central venous catheters used for the collection of peripheral blood progenitor cells to support high–dose chemotherapy and autologous stem cell rescue. Meisenberg BR, et al. **Support Care Cancer** 1997 May;5(3):223–7

New approaches to the management and treatment of malignant pericardial effusion. Tomkowski W, et al. **Support Care Cancer** 1997 Jan;5(1):64–6

Medical treatment of metastatic melanoma. Houghton AN, et al. **Surg Clin North Am** 1996 Dec;76(6):1343–54 (113 ref.)

Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model. Tamura H, et al. **Surg Oncol** 1996 Jun;5(3):141–7

Paradoxical clinical deterioration despite near–complete pathological response to neoadjuvant chemotherapy for locally advanced gastro–oesophageal adenocarcinoma. Windsor AC, et al. **Surg Oncol** 1995;4(5):277–9

An effective chemotherapy regimen for liver metastasis from retroperitoneal fibrosarcoma: report of a case. Isobe H, et al. **Surg Today** 1997;27(5):463–5

Small intestinal cancer with extensive lymph node metastases showing complete remission by methotrexate/5–fluorouracil sequential therapy: report of a case. Onodera H, et al. **Surg Today** 1997;27(1):60–3

Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II–IV, M0 squamous cell carcinoma of the head and neck. Boni C, et al. **Tumori** 1996 Nov–Dec;82(6):567–72

A new regimen of cisplatin, epirubicin and methotrexate (PEM–3) as primary chemotherapy for locally advanced bladder cancer. Cacciari N, et al. **Tumori** 1996 Jul–Aug; 82(4):364–8

5–Fluorouracil prodrug, ftorafur, modulated by uracil (UFT): preclinical and clinical prospective. Cao S, et al. **Tumori** 1997 Jan–Feb;83(1 Suppl):S90–3

Results of a European multicentre trial of Tomudex versus 5–FU/high dose LV (Machover regimen). Cocconi G. **Tumori** 1997 Jan–Feb;83(1 Suppl):S72

Phase II study of oral L–leucovorin, 120–hour fluorouracil infusion and carboplatin in advanced pancreatic cancer. Colleoni M, et al. **Tumori** 1996 Nov–Dec;82(6):573–5

Response to chemotherapy of brain metastases from malignant pleural mesothelioma. Colleoni M, et al. **Tumori** 1996 Sep–Oct;82(5):456–8

Intermittent continuous infusion of fluorouracil and low–dose oral leucovorin in pretreated breast cancer: a pilot study. Colleoni M, et al. **Tumori** 1997 May–Jun;83(3):665–8

Do the conventional clinicopathologic parameters predict for response and survival in head and neck cancer patients undergoing neoadjuvant chemotherapy? Fonseca E, et al. **Tumori** 1996 Nov–Dec;82(6):560–6

Hydroxyurea did not enhance the clinical response to vinblastine in patients with anthracycline–resistant metastatic breast cancer. Huan SD, et al. **Tumori** 1996 Nov–Dec;82(6):576–8

Ifosfamide and etoposide in previously treated patients with advanced breast cancer. Kiraz S, et al. **Tumori** 1997 Mar–Apr;83(2):604–7

Therapies for advanced colorectal cancer: the role of interferon and leucovorin. Macdonald JS. **Tumori** 1997 Jan–Feb;83(1 Suppl):S67–9 (21 ref.)

Adjuvant chemotherapy for colon cancer: Italian studies. Marsoni S, et al. **Tumori** 1997 Jan–Feb;83(1 Suppl):S45–7 (11 ref.)

First–line chemotherapy with cisplatin, methotrexate and vinblastine in metastatic bladder cancer. Pajk B, et al. **Tumori** 1996 Sep–Oct;82(5):453–5

Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin–based regimen (M–CAVI). Ribas A, et al. **Tumori** 1996 Nov–Dec; 82(6):554–9

Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan. Santinami M, et al. **Tumori** 1996 Nov–Dec; 82(6):579–84

Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long–term results. Scattoni V, et al. **Tumori** 1996 Sep–Oct;82(5):463–9

Results of postchemotherapy adjunctive retroperitoneal lymph node dissection in non–seminomatous germ cell cancer patients. Goepel M, et al. **Urol Int** 1996;57(4):209–12

Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Hofmockel G, et al. **Urol Int** 1996;57(1):38–42

A modified BEP protocol: reduction of hospitalization without reducing the efficacy. Ozen H, et al. **Urol Int** 1997; 58(1):50–4

Health–related quality of life among patients with metastatic prostate cancer. Albertsen PC, et al. **Urology** 1997 Feb; 49(2):207–16; discussion 216–7

Combined finasteride and flutamide therapy in men with advanced prostate cancer. Ornstein DK, et al. **Urology** 1996 Dec;48(6):901–5

Late relapse of nonseminomatous germ cell tumor of the testis: successful treatment with salvage chemotherapy alone. Papadimitris C, et al. **Urology** 1997 Mar;49(3):469–70 (7 ref.)

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double–blind, randomized, multicenter trial. Casodex Combination Study Group. Schellhammer PF, et al. **Urology** 1997 Sep; 50(3):330–6

Radical cystectomy with or without adjuvant polychemotherapy for non–organ–confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Stöckle M, et al. **Urology** 1996 Dec;48(6):868–75

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2–3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Witjes WP, et al. **Urology** 1997 Mar; 49(3A Suppl):65–9

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone–releasing hormone analogue therapy, in patients with advanced prostate cancer [letter; comment] Zerbib M, et al. **Urology** 1996 Oct; 48(4):661–3. Comment on: Urology 1995 Dec;46(6):899–901.

Curing children with leukemia in West Virginia. Ritchey AK, et al. **W V Med J** 1997 Jul–Aug;93(4):179–81

Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. Dousset B, et al. **World J Surg** 1996 Sep;20(7):908–14; discussion 914–5

Primary chemotherapy in surgically resectable breast cancer: the experience of the Milan Cancer Institute. Valagussa P, et al. **Zentralbl Gynakol** 1996;118(10):571

[Regional and systemic neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri] Balchev G, et al. **Akush Ginekol (Sofiia)** 1996;35(4):17–8 (Eng. Abstr.) **(Bul)**

[The adjuvant chemotherapy of N(–) patients with breast cancer—when is it indicated?] Deliiski T, et al. **Akush Ginekol (Sofiia)** 1996;35(4):20–1 (Eng. Abstr.) **(Bul)**

[ACNU and methyl–CCNU in combination chemotherapy for advanced gastric cancer: a randomized comparative study. Shanghai ACNU Collaborative Study Group] Xiao S, et al. **Chung Hua Chung Liu Tsa Chih** 1996 Jan;18(1):30–3 (Eng. Abstr.) **(Chi)**

[Current status and trends in chemotherapy of ovarian cancer (editorial)] Lian L. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb;31(2):67–70 **(Chi)**

[A study on treatment of lung cancer by combined therapy of traditional Chinese medicine and chemotherapy] Li JH. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Mar; 16(3):136–8 (Eng. Abstr.) **(Chi)**

[Analysis of therapeutical effectiveness in 35 cases of acute leukemia with therapy of Chinese integrated medicine] Yan Y. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Nov; 15(11):643–5 (Eng. Abstr.) **(Chi)**

[Synergism of sobuzoxane in combination with doxorubicin against leukemia P388 in mice] Dai ZQ, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jan;17(1):69–71 (Eng. Abstr.) **(Chi)**

[Intensive chemotherapy with hematopoietic stem cell autograft in solid malignant tumors in children: current evaluation and prespectives (editorial)] Sommelet D. **Arch Pediatr** 1996 Jul;3(7):643–8 (17 ref.) **(Fre)**

["Limited" cancers of the glottic stage of the larynx and exclusive chemotherapy—15 years of experience] Laccourreye H. **Bull Acad Natl Med** 1997 Apr; 181(4):641–8; discussion 648–9 (Eng. Abstr.) **(Fre)**

[Laryngeal cancer and conservative treatment. Place of combined radiotherapy chemotherapy and modified fractionation radiotherapy] Brunin F, et al. **Bull Cancer** 1997 Feb;84(2):191–8 (43 ref.) (Eng. Abstr.) **(Fre)**

[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5–fluorouracil associated with cisplatin] Coudert B, et al. **Bull Cancer** 1996 Oct; 83(10):847–52 (Eng. Abstr.) **(Fre)**

[First–line chemotherapy in operable breast neoplasms: results of 3 protocols] Cure H, et al. **Bull Cancer** 1997 Jan; 84(1):31–4 (Eng. Abstr.) **(Fre)**

[Role of adjuvant chemotherapy in the treatment of soft tissue sarcoma] Debled M, et al. **Bull Cancer** 1997 Jun; 84(6):653–63 (Eng. Abstr.) **(Fre)**

[High–dose chemotherapy in relapse of medulloblastoma in young children] Dupuis–Girod S, et al. **Bull Cancer** 1997 Mar;84(3):264–72 (45 ref.) (Eng. Abstr.) **(Fre)**

[A comparative study of 4 sequential first–line chemotherapy protocols in locally advanced breast cancer] Ferrero JM, et al. **Bull Cancer** 1997 Jan;84(1):10–6 (Eng. Abstr.) **(Fre)**

[Primary mediastinal non–seminomatous germ–cell tumors: from clinics to biology] Fizazi K, et al. **Bull Cancer** 1997 Mar;84(3):313–27 (142 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of tumoral and lymph node response to neoadjuvant chemotherapy in undifferentiated nasopharyngeal carcinoma] Frikha M, et al. **Bull Cancer** 1997 Mar;84(3):273–6 (Eng. Abstr.) **(Fre)**

[Dose intensification of adjuvant chemotherapy in high–risk non–metastatic breast cancer: a critical review] Ganem G. **Bull Cancer** 1997 Jan;84(1):97–105 (84 ref.) (Eng. Abstr.) **(Fre)**

[Adjuvant chemotherapy with mitoxantrone, cyclophosphamide and 5–fluorouracil in breast neoplasms: therapeutic life] Genre D, et al. **Bull Cancer** 1997 Mar; 84(3):240–6 (Eng. Abstr.) **(Fre)**

[A phase II study with mitoxantrone–vinorelbine association in the treatment of advanced breast cancer in elderly women] Gladieff L, et al. **Bull Cancer** 1996 Sep;83(9):703–6 (Eng. Abstr.) **(Fre)**

[Treatment of aggressive non Hodgkin's lymphoma: the experience of a general hospital] Laurencet FM, et al. **Bull Cancer** 1996 Oct;83(10):864–9 (Eng. Abstr.) **(Fre)**

[New therapeutic strategies and current research in inoperable locally advanced non small–cell lung cancers (stage IIIB)] Le Cesne A, et al. **Bull Cancer** 1997 Apr; 84(4):413–9 (45 ref.) (Eng. Abstr.) **(Fre)**

[New therapeutic approaches in acute myeloblastic leukemia (AML) and chronic myeloid leukemia (CML)] Marie JP. **Bull Cancer** 1997 Apr;84(4):451–2 **(Fre)**

[Concomitant radiochemotherapy in invasive bladder tumors] Mottet N, et al. **Bull Cancer** 1997 Apr;84(4):405–11 (28 ref.) (Eng. Abstr.) **(Fre)**

[Carboplatin and cyclophosphamide in stage Ic–IV ovarian carcinoma: retrospective study of 101 cases] Petit T, et al. **Bull Cancer** 1996 Jul;83(7):566–72 (31 ref.) (Eng. Abstr.) **(Fre)**

[Adjuvant combined radiochemotherapy: a feasibility study of a new strategy in stages I and II] Serin D, et al. **Bull Cancer** 1997 Mar;84(3):247–53 (32 ref.) (Eng. Abstr.) **(Fre)**

[Lymphoma in the elderly] Coiffier B. **Bull Cancer Radiother** 1996;83(4):265–8 **(Fre)**

[Apropos of two recently published randomized trials of induction chemotherapy in nasopharyngeal and piriform sinus carcinoma] de Crevoisier R, et al. **Bull Cancer Radiother** 1996;83(3):174–6 **(Fre)**

[Non–Hodgkin's lymphoma in adults. Therapeutic strategy] Le Bourgeois JP, et al. **Bull Cancer Radiother** 1996; 83(4):258–64 **(Fre)**

[Induction chemotherapy followed by concomitant combined radiotherapy and chemotherapy in stage III non–small cell bronchial carcinoma] Bouillet T, et al. **Cancer Radiother** 1997;1(2):121–31 (39 ref.) (Eng. Abstr.) **(Fre)**

[Concomitant radiochemotherapy in inoperable non–small

cell lung cancer] Hennequin C, et al. **Cancer Radiother** 1997;1(2):143–7 (Eng. Abstr.) **(Fre)**

[Treatment of carcinoid tumors of the digestive tract] Votte A, et al. **Gastroenterol Clin Biol** 1995 Dec;19(12):1031–42 (122 ref.) **(Fre)**

[Mulleroblastoma of the uterus. Role of chemotherapy. A case report] Antoine JM, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(1):53–5 (Eng. Abstr.) **(Fre)**

[Management of hematologic malignancies during pregnancy] Maloisel F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(6):602–7 (49 ref.) (Eng. Abstr.) **(Fre)**

[Adjuvant chemotherapy of breast cancer] Rouëssé J, et al. **Presse Med** 1996 Nov 16;25(35):1731–6 (21 ref.) (Eng. Abstr.) **(Fre)**

[Adjuvant chemotherapy after cystectomy for bladder tumors staged as superior or equal to pT3] Schmid HP, et al. **Prog Urol** 1997 Feb;7(1):102–4 (9 ref.) **(Fre)**

[Second line chemotherapy in patients with refractory and resistant non small cell lung cancer] Jacoulet P, et al. **Rev Mal Respir** 1997 Jan;14(1):29–35 (Eng. Abstr.) **(Fre)**

[Primary granulocytic sarcoma of the pancreas: efficacy of early treatment with intensive chemotherapy] Moreau P, et al. **Rev Med Interne** 1996;17(8):677–9 (12 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of broncho-pulmonary cancer using carboplatin/etoposide: survival analysis] Skaventzos I, et al. **Rev Med Liege** 1996 Nov;51(11):718–20 **(Fre)**

[High dose therapy with transplantation of autologous peripheral hematopoietic stem cells. II. Indications and clinical results] Gunsilius E, et al. **Acta Med Austriaca** 1997; 24(3):102–7 (53 ref.) (Eng. Abstr.) **(Ger)**

[High dose therapy with transplantation of autologous peripheral hematopoietic stem cells. I. Basic principles and clinical development] Gunsilius E, et al. **Acta Med Austriaca** 1997;24(3):97–101 (53 ref.) (Eng. Abstr.) **(Ger)**

[Tumor targeting in colon cancer. Antibody therapy--a new adjuvant application] **Chirurg** 1995 Jul;66(7 Suppl):1–4 **(Ger)**

[Isolated hyperthermic extremity perfusion in soft tissue sarcoma (letter; comment)] Eigler FW, et al. **Chirurg** 1997 Jun;68(6):649. Comment on: Chirurg 1996 Dec;67(12):1237–43. **(Ger)**

[Therapy of metastatic endocrine tumors of the gastrointestinal tract (letter)] Arnold R, et al. **Dtsch Med Wochenschr** 1996 Oct 25;121(43):1346–7 **(Ger)**

[Ambulatory therapy of multiple myeloma with vincristine, adriamycin and dexamethasone] Egerer G, et al. **Dtsch Med Wochenschr** 1997 Apr 25;122(17):531–5 (Eng. Abstr.) **(Ger)**

[Neoadjuvant combined therapy in stage IIIA if non-small-cell bronchial cancer] Thomas M, et al. **Dtsch Med Wochenschr** 1997 Aug 15;122(33):993–8 (Eng. Abstr.) **(Ger)**

[High dose chemotherapy with autologous stem cell transplantation] Weissinger F, et al. **Fortschr Med** 1997 Mar 30;115(9):39–43 (20 ref.) (Eng. Abstr.) **(Ger)**

[Results of adjuvant chemotherapy of operated high risk cervix carcinoma] Dimpfl T, et al. **Geburtshilfe Frauenheilkd** 1996 Oct;56(10):517–9 (Eng. Abstr.) **(Ger)**

[Endocrinologic after-care of brain tumor patients: initial retrospective analysis of HIT-study documented auxologic and endocrine parameters] Dörr HG, et al. **Klin Padiatr** 1996 Jul-Aug;208(4):197–204 (Eng. Abstr.) **(Ger)**

[IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study] Fleischhack G, et al. **Klin Padiatr** 1996 Jul-Aug; 208(4):229–35 (Eng. Abstr.) **(Ger)**

[HIT-GBM: multicenter study of treatment of children with malignant glioma] Wolff JE, et al. **Klin Padiatr** 1996 Jul-Aug;208(4):193–6 (Eng. Abstr.) **(Ger)**

[Gastrointestinal lymphomas: results of multimodal therapy in 57 patients of one center] Kiene J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:244–6 (Eng. Abstr.) **(Ger)**

[Accelerated hyperfractionated simultaneous radiochemotherapy in advanced head-neck carcinomas in comparison: split course and concomitant boost concept] Dietz A, et al. **Laryngorhinootologie** 1996 Dec; 75(12):745–53 (Eng. Abstr.) **(Ger)**

[Tissue oxygen partial pressure in human head-neck carcinomas during primary radio-chemotherapy] Jund R, et al. **Laryngorhinootologie** 1996 Jan;75(1):43–7 (Eng. Abstr.) **(Ger)**

[High dose chemotherapy of solid tumors] Höffken K, et al. **Med Klin** 1997 Jul 15;92(7):410–4 (18 ref.) (Eng. Abstr.) **(Ger)**

[Pro and contra early systemic therapy of malignant tumors] Oldenkott B, et al. **Med Klin** 1996 Dec 15;91(12):780–90 (144 ref.) **(Ger)**

[Adjuvant systemic therapy of breast carcinoma] Wickramanayake PD, et al. **Med Klin** 1996 Oct 15; 91(10):646–53 (92 ref.) **(Ger)**

[Comparison of induction chemotherapy before radiotherapy and radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung] Heilmann HP. **Strahlenther Onkol** 1997 Jun;173(6):340–1 **(Ger)**

[G-CSF in radiochemotherapy] Riepl M, et al. **Strahlenther Onkol** 1997 Feb;173(2):76–82 (Eng. Abstr.) **(Ger)**

[The treatment of primary cutaneous B-cell small cleaved-cell lymphomas a clinical follow-up study of 55 patients who were treated with radio- and polychemotherapy] Sack H. **Strahlenther Onkol** 1996 Oct; 172(10):585–6 **(Ger)**

[Systemic neoadjuvant chemotherapy in advanced head and neck tumors: a randomized study of the combination of 5-FU/carboplatin versus 5-FU/cisplatin] Starr S. **Strahlenther Onkol** 1996 Mar;172(3):173–5 **(Ger)**

[Hormone therapy of metastasizing breast carcinoma] Hagen MF, et al. **Ther Umsch** 1996 Nov;53(11):820–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[Therapy with mitomycin C, folic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma--phase II study] Otto T, et al. **Urologe A** 1997 May;36(3):243–7 (Eng. Abstr.) **(Ger)**

[Drug therapy of ovarian carcinoma] Dittrich C. **Wien Med Wochenschr** 1996;146(1-2):23–34 (93 ref.) (Eng. Abstr.) **(Ger)**

[Intensification of chemotherapy dosage in metastatic breast carcinoma?] Brockmann B, et al. **Z Arztl Fortbild Qualitatssich** 1997 Mar;91(2):181–5 (Eng. Abstr.) **(Ger)**

[Adjuvant therapy of colon carcinoma: results of two Intergroup Studies (INT-0035 and INT-0089), a study by the German Cancer Aid 17-1A Study Group and the IMPACT Study] Petrasch S, et al. **Z Gastroenterol** 1997 Jan;35(1):49–52 **(Ger)**

[Should adjuvant chemotherapy be also used in Dukes stage B2 colon cancer?] Porschen R. **Z Gastroenterol** 1996 Sep; 34(9):549–51 **(Ger)**

[Outcome of simultaneous radiochemotherapy of anal carcinoma] Fraunholz IB, et al. **Zentralbl Chir** 1997; 122(1):39–43 (Eng. Abstr.) **(Ger)**

[Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities] du Bois A, et al. **Zentralbl Gynakol** 1997;119(7):299–323 (330 ref.) (Eng. Abstr.) **(Ger)**

[Principle and foundations of high dose therapy with stem cell transplantation] Haas R, et al. **Zentralbl Gynakol** 1996; 118(10):575–7 **(Ger)**

[Response evaluation with mammography and ultrasound] Junkermann H, et al. **Zentralbl Gynakol** 1996;118(10):572–3 **(Ger)**

[Ifosfamide] Manegold C. **Zentralbl Gynakol** 1996; 118(10):580–1 **(Ger)**

[High dose chemotherapy: an overview in ovarian carcinoma] Möbus VJ. **Zentralbl Gynakol** 1996; 118(10):573–4 **(Ger)**

[Adjuvant therapy of malignant ovarian tumors after organ preserving surgery] Schröder W. **Zentralbl Gynakol** 1996; 118(10):565–70 (Eng. Abstr.) **(Ger)**

[Results of ambulatory mono- and combined interferon therapy in advanced kidney tumors] Buzogány I, et al. **Orv Hetil** 1997 Jan 12;138(2):67–70 (Eng. Abstr.) **(Hun)**

[Metallothionein expression as a marker of therapeutic sensitivity in the early stages of testicular cancer] Eid H, et al. **Orv Hetil** 1997 Jan 19;138(3):135–9 (28 ref.) (Eng. Abstr.) **(Hun)**

[The type of local treatment conditions the prognosis in patients with nonmetastatic Ewing's sarcoma of the extremities treated with adjuvant chemotherapy] Bacci G, et al. **Minerva Chir** 1997 Apr;52(4):415–26 (Eng. Abstr.) **(Ita)**

[Transvaginal color-Doppler sonography for monitoring the response to neoadjuvant chemotherapy in patients with locally advanced cervical cancer] Di Vagno G, et al. **Minerva Ginecol** 1996 Nov;48(11):463–7 (Eng. Abstr.) **(Ita)**

[Gonadal function after chemotherapy for acute lymphoblastic leukemia] Loverro G, et al. **Minerva Ginecol** 1996 May;48(5):193–7 (Eng. Abstr.) **(Ita)**

[Analysis of clinical effects of a concurrent CDDP/5-FU therapy on inoperable colon cancer] Akazawa S, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1770–9 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Successful 5'-DFUR, CDDP and MMC combination therapy and 5'-DFUR and carboplatin combination therapy for a patient with inoperable advanced gastric cancer with peritonitis carcinomatosa] Ando S, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):869–73 (Eng. Abstr.) **(Jpn)**

[Hepatic intra-arterial 5-fluorouracil and CDDP administration in patients with colorectal cancer metastasis to the liver] Arai T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1447–50 (Eng. Abstr.) **(Jpn)**

[Investigation of chemotherapy combined with peripheral blood stem cell transplantation (PBSCT) both in elderly and in recurred patients with small cell lung cancer] Daido K, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):883–7 **(Jpn)**

[A study of combination chemotherapy using, 5-FU and CDDP in patients with advanced non-small cell lung cancer] Egusa Y, et al. **Gan To Kagaku Ryoho** 1996 Dec; 23(14):1997–2000 **(Jpn)**

[Efficacy of combination chemotherapy of cyclophosphamide and 5'-deoxy-5-fluorouridine in a mammary tumor xenograft model, MX-1] Endo M, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1295–301 (Eng. Abstr.) **(Jpn)**

[Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer] Fujii M, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1740–6 (Eng. Abstr.) **(Jpn)**

[Recent advances on the treatment of acute childhood leukemia] Fujimoto T. **Gan To Kagaku Ryoho** 1997 Jul; 24(9):1059–65 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Chemohyperthermic peritoneal perfusion and high-dose chemotherapy followed by peripheral blood stem cell transplantation in advanced colon cancer--a case report] Fujimura T, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1578–80 (Eng. Abstr.) **(Jpn)**

[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma] Fujinami K, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1689–91 (Eng. Abstr.) **(Jpn)**

[Phase I study of cisplatin, ifosfamide and CPT11 with granulocyte colony-stimulating factor support in advanced non-small cell lung cancer] Fujita A, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1285–90 (Eng. Abstr.) **(Jpn)**

[Three cases of resected primary mediastinal yolk sac tumor following six courses of bleomycin, etoposide and cisplatin (BEP) combination chemotherapy] Fujita A, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1981–4 (Eng. Abstr.) **(Jpn)**

[Study of hepatic arterial chemoinfusion with continuous CDDP, 5-FU low dose administration for advanced gallbladder cancer] Fukuda S, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1610–3 (Eng. Abstr.) **(Jpn)**

[A case of Borrmann type 4 gastric cancer successfully treated with MTX and 5-FU therapy through the hepatic artery] Gonda T, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1561–3 (Eng. Abstr.) **(Jpn)**

[Pathological evaluation of superselective one-shot intra-arterial infusion chemotherapy for head and neck tumors] Handa T, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1479–81 (Eng. Abstr.) **(Jpn)**

[Biweekly CHOP-E chemotherapy for aggressive non-Hodgkin's lymphoma] Hayashi T, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):889–91 **(Jpn)**

[A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist] Hisamatsu K, et al. **Gan To Kagaku Ryoho** 1997 Aug; 24(10):1327–30 (Eng. Abstr.) **(Jpn)**

[The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer] Honda S, et al. **Gan To Kagaku Ryoho** 1997 Apr; 24(6):679–83 (Eng. Abstr.) **(Jpn)**

[Characteristic and effective usage of adriamycin] Horiuchi K, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1916–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Unresectable gastric cancer followed by remarkably effective tumor disappearance and good quality of life for 10 months after CDDP/5'-DFUR combination chemotherapy--a case report] Hoshino K, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1841–5 (Eng. Abstr.) **(Jpn)**

[Effective combined injection method of fluoropyrimidine and platinum--application for advanced esophageal cancer] Ide H, et al. **Gan To Kagaku Ryoho** 1996 Nov; 23(13):1757–62 (Eng. Abstr.) **(Jpn)**

[Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer--phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration--Study Group of UFTM Therapy for Advanced Colorectal Cancer] Ikeda E, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(10):1291–8 (Eng. Abstr.) **(Jpn)**

[Concurrent radiotherapy and chemotherapy for non-small-cell lung cancer--continuous infusion of low dose cisplatin and 5-FU] Itoh Y, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1721–4 **(Jpn)**

[The effect of high-dose intraarterial chemotherapy with percutaneous hepatic venous isolation and charcoal hemoperfusion (HVI.CHP) for unresectable multiple hepatocellular carcinoma--comparison with other therapeutic modalities] Iwasaki T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1426–8 (Eng. Abstr.) **(Jpn)**

[Induced hypertensive chemotherapy with angiotensin-II for liver metastases from gastric cancer] Iwasaki Y, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1558–60 (Eng. Abstr.) **(Jpn)**

[Etoposide (VP-16) in gynecologic malignancy] Kanazawa K, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1925–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent pelvic tumors with or without radiotherapy] Kaneyasu Y, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1486–93 (Eng. Abstr.) **(Jpn)**

[Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer] Katsumata K, et al.

Gan To Kagaku Ryoho 1997 Feb;24(3):309–14 (Eng. Abstr.) **(Jpn)**

[A case of advanced hepatoma cured by repeated percutaneous isolated liver perfusion using hepatic venous isolation and charcoal hemoperfusion] Kitagawa T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1592–5 (Eng. Abstr.) **(Jpn)**

[Evaluation of clinical trials on adjuvant chemotherapy for curatively resected gastric cancer] Kitamura M, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1221–9 (Eng. Abstr.) **(Jpn)**

[A two-year asymptomatic case with postoperative lung metastasis of sigmoid colon cancer responding to sequential methotrexate and 5-fluorouracil] Kitao Y, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):613–7 (Eng. Abstr.) **(Jpn)**

[Treatment of refractory hematologic malignancies by combination of cytarabine ocfosfate and etoposide] Kiyama Y, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1717–20 (Eng. Abstr.) **(Jpn)**

[Two cases of relapse or refractory germ cell tumor who had been treated with combination chemotherapy of cisplatin and carboplatin] Kiyama Y, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1989–92 (Eng. Abstr.) **(Jpn)**

[A case of solitary metastatic splenic tumor of ovarian carcinoma] Kobayashi A, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1341–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of ondansetron suppository] Kobayashi F, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):625–7 **(Jpn)**

[The current status of postoperative adjuvant chemotherapy for colorectal cancer] Kodaira S. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1230–8 (Eng. Abstr.) **(Jpn)**

[A case of inoperable advanced gastric cancer remarkably responding to combined chemotherapy with UFT-E, MMC and PSK] Kogure A, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):875–8 (Eng. Abstr.) **(Jpn)**

[Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin] Kondo K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1299–303 (Eng. Abstr.) **(Jpn)**

[A study of arterial infusion chemotherapy for gastric cancer patients with peritoneal metastasis] Kosaka T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1467–71 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for peritoneal dissemination in gastric cancer under ureteral catheterization] Kubo Y, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1951–7 (Eng. Abstr.) **(Jpn)**

[Evaluation of neo-adjuvant chemotherapy for oral squamous cell carcinoma] Kurokawa H, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1273–8 (Eng. Abstr.) **(Jpn)**

[Successful UFT-E granule and 5-FUCDDP combination therapy for an unresectable advanced gastric cancer complicated with liver metastasis] Kushibiki K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1313–5 (Eng. Abstr.) **(Jpn)**

[A case of advanced cholangiocellular carcinoma treated successfully by percutaneous isolated liver perfusion with cisplatin] Maeda I, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1607–9 (Eng. Abstr.) **(Jpn)**

[Clinical study of primary central nervous system lymphoma: the role of chemotherapy] Maeda Y, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):807–13 (Eng. Abstr.) **(Jpn)**

[Optimal administration in combination chemotherapy with 5-fluorouracil and cisplatin for gastric cancer] Maeda Y, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1763–9 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Intra-arterial infusion chemotherapy for liver metastases from breast cancer] Masuda N, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1537–41 (Eng. Abstr.) **(Jpn)**

[A case of recurrent squamous cell carcinoma of cervix successfully treated with BOMP] Matsui R, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1985–8 (Eng. Abstr.) **(Jpn)**

[Quality of life and chemotherapy in terminal stage of gastrointestinal cancers] Matsukawa M, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):785–91 (Eng. Abstr.) **(Jpn)**

[A case resectable hepatic metastases of breast cancer following intrahepatic arterial chemotherapy] Matsumoto J, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1542–5 (Eng. Abstr.) **(Jpn)**

[Intra-arterial infusion chemotherapy for breast cancer] Matsumoto Y, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1526–8 (Eng. Abstr.) **(Jpn)**

[Clinical effects of postoperative immunochemotherapy with a combination of 5-FU, CDDP and lentinan for stage IVb gastric carcinoma and long-term pharmacokinetic studies on CDDP and 5-FU] Mio H, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):337–42 (Eng. Abstr.) **(Jpn)**

[Study of preoperative combination therapy with UFT + CDDP in patients with gastric and colorectal cancer—concomitant effects based on the thymidylate synthase inhibitory rat] Mitsuishi K, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1119–24 (Eng. Abstr.) **(Jpn)**

[Secondary hepatic resections in a case of sigmoid colon cancer with multiple liver metastasis (H3) after successful continuous hepatic artery infusion chemotherapy oriented by in vitro chemosensitivity test] Miura M, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):1031–4 (Eng. Abstr.) **(Jpn)**

[Effective clinical use of cyclophosphamide in hematological malignancies] Miyazaki H, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1891–5 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer] Mori K, et al. **Gan To Kagaku Ryoho** 1996 Sep; 23(11):1443–6 (Eng. Abstr.) **(Jpn)**

[Inoperable esophageal carcinoma managed by combined chemotherapy (CBDCA, 5-FU and VDS) and radiotherapy] Morishima Y, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):965–9 (Eng. Abstr.) **(Jpn)**

[Benefits of adjuvant chemotherapy for breast cancer] Motomura K, et al. **Gan To Kagaku Ryoho** 1997 Aug; 24(10):1239–44 (Eng. Abstr.) **(Jpn)**

[Preoperative chemoradiation therapy for lower rectal cancer] Murotani M, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1482–5 (Eng. Abstr.) **(Jpn)**

[Primary cutaneous lymphoma—mycosis fungoides] Nagatani T, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):23–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Efficacy of implantable injection port for advanced breast cancer patients] Nakamura S, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1529–32 (Eng. Abstr.) **(Jpn)**

[A case of FIGO stage IV A vulvar cancer successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)] Narimatsu A, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1161–5 (Eng. Abstr.) **(Jpn)**

[Usefulness of THP-COPBLM therapy in elderly patients with non-Hodgkin's lymphoma] Niitsu N, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):61–6 (Eng. Abstr.) **(Jpn)**

[A case of advanced breast cancer receiving combination therapy with 5'-DFUR and MPA with remarkable results] Nishibe M, et al. **Gan To Kagaku Ryoho** 1997 Jul; 24(9):1149–52 (Eng. Abstr.) **(Jpn)**

[Continuous infusion high-dose leucovorin with cisplatin and 5-fluorouracil for a recurrent oropharynx carcinoma] Nishino H, et al. **Gan To Kagaku Ryoho** 1997 Apr; 24(6):719–21 (Eng. Abstr.) **(Jpn)**

[Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus—a preliminary study for phase III clinical study] Noda K, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1285–93 (Eng. Abstr.) **(Jpn)**

[A case of gastric cancer with peritoneal dissemination and malignant biliary stenosis treated by loco-regional cancer therapy] Nonaka M, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1568–70 (Eng. Abstr.) **(Jpn)**

[Recent progress in the management of malignant lymphoma] Ohnishi K. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1074–8 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Progress in the treatment of adult acute myeloid leukemia] Ohno R. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1053–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[A randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP 5-FU and dl-leucovorin for colorectal cancer] Okabo S, et al. **Gan To Kagaku Ryoho** 1997 May; 24(7):849–54 (Eng. Abstr.) **(Jpn)**

[Efficacy of chemotherapy for clear cell adenocarcinoma of the ovary] Okubo T, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1279–83 (Eng. Abstr.) **(Jpn)**

[Diagnosis and therapy for metastatic liver cancer] Okuno K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1255–61 (17 ref.) (Eng. Abstr.) **(Jpn)**

[A case of gastric malignant lymphoma with perforation during chemotherapy] Ono K, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):105–8 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer with multiple liver metastasis successfully treated with combination chemotherapy using UFT, CDDP and etoposide] Ono T, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1709–12 (Eng. Abstr.) **(Jpn)**

[CMF or CAF combination chemotherapy for breast cancer] Ota J. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1886–90 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Adjuvant chemotherapy for non-small cell lung cancer] Otake Y, et al. **Gan To Kagaku Ryoho** 1997 Aug; 24(10):1245–51 (Eng. Abstr.) **(Jpn)**

[A comparative study of the effects of granisetron alone and a combination of granisetron plus steroids on CDDP-based combination chemotherapy-induced emesis—outcomes of a multicenter randomized comparative study using the central registration method. Nara Medical University Kytril Study Group] Ozono S, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):349–56 (Eng. Abstr.) **(Jpn)**

[Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation] Park Y, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):573–7 (Eng. Abstr.) **(Jpn)**

[Treatment of malignant melanoma: recent advances and perspectives] Saida T. **Gan To Kagaku Ryoho** 1997 Jan; 24(1):10–5 (20 ref.) (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer with carcinomatosa peritonitis effectively treated by 5-FU and low-dose CDDP therapy] Saito E, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1153–6 (Eng. Abstr.) **(Jpn)**

[Drug distribution of pelvic intraarterial infusion chemotherapy by bilateral internal iliac arterial catheter placement with coil occlusion of superior, inferior gluteal and obturator arteries] Sakaguchi S, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1495–8 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for pancreatic cancer] Sakata Y, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1647–50 (19 ref.) (Eng. Abstr.) **(Jpn)**

[A patient with pancreatic acinar cell carcinoma, effectively treated by the infusion chemotherapy through hepatic artery using 5-FU, CDDP and MMC] Sakon M, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1614–6 (Eng. Abstr.) **(Jpn)**

[Phase II study of combination chemotherapy with cisplatin, carboplatin and etoposide (CPVP) in unresectable non-small cell lung cancer: analysis of survival time and prognostic factors] Sakurai M, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):303–8 (Eng. Abstr.) **(Jpn)**

[Two cases of pseudomyxoma peritonei that responded to intraperitoneal administrations of a combined CDDP, 5-FU and MMC therapy] Sasaki A, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1571–4 (Eng. Abstr.) **(Jpn)**

[Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma] Sasaki K, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):959–64 (Eng. Abstr.) **(Jpn)**

[Sequential methotrexate and 5-fluorouracil] Sasaki T. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1907–10 (16 ref.) (Eng. Abstr.) **(Jpn)**

[A case of small cell lung carcinoma associated with pneumoconiosis who responded well to the over twenty chemotherapy treatments, resulting in prolonged survival] Sassa K, et al. **Gan To Kagaku Ryoho** 1997 Mar; 24(5):609–12 (Eng. Abstr.) **(Jpn)**

[Antimetastatic effects of UFT on murine liver metastasis model using L5178YHM lymphoma] Satake H, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):2001–4 **(Jpn)**

[A case of poorly differentiated ovarian serous adenocarcinoma responding favorably to etoposide and cisplatin] Sato Y, et al. **Gan To Kagaku Ryoho** 1996 Nov; 23(13):1847–9 (Eng. Abstr.) **(Jpn)**

[Two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil, cisplatin and cytarabine] Satoh T, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):879–82 (Eng. Abstr.) **(Jpn)**

[Combination chemotherapy with BH-AC, mitoxantrone, etoposide, and prednisolone to refractory or relapsed malignant lymphoma] Satoh T, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):733–6 **(Jpn)**

[A case of unresectable pancreatic cancer successfully treated with continuous venous daily infusion of 5-FU and low-dose CDDP] Seino K, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):1027–30 (Eng. Abstr.) **(Jpn)**

[Histopathological and autoradiographical studies of experimental brain tumors after continuous local chemotherapy—acute stage in rat models] Shimura T, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):713–8 (Eng. Abstr.) **(Jpn)**

[A case of pleural metastasis of invasive thymoma with pulmonary metastasis responding to chemotherapy with cyclophosphamide and prednisolone] Sugiyama S, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):605–8 (Eng. Abstr.) **(Jpn)**

[Locoregional therapy for liver metastases of colorectal cancer] Sugiyama Y, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1433–6 (Eng. Abstr.) **(Jpn)**

[Squamous cell carcinoma and basal cell carcinoma] Suzuki T, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):16–22 (10 ref.) (Eng. Abstr.) **(Jpn)**

[A case of recurrent gastric cancer with liver metastasis responding to combination chemotherapy with cisplatin and carmofur] Tadaoka N, et al. **Gan To Kagaku Ryoho** 1997 Apr;24(6):729–32 (Eng. Abstr.) **(Jpn)**

[A case of colon cancer with local recurrence successfully treated by systemic and local intra-arterial chemotherapy using a combination of 5-fluorouracil, interferon-alpha 2A, leucovorin and carboplatin] Takasaki S, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(1):109–13 (Eng. Abstr.) **(Jpn)**

[A case of advanced colon cancer with marked response to combination chemotherapy with 5-FU, low dose CDDP, and leucovorin] Takayanagi N, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(3):357–60 (Eng. Abstr.) **(Jpn)**

[Clinical effect of intra-arterial carboplatin-combined chemotherapy for advanced uterine cervical cancer and increased tissue platinum levels with Lipo PGE1

administration before chemotherapy] Takeda S, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1697–703 (Eng. Abstr.) **(Jpn)**

[Two cases of adenosquamous cell carcinoma of advanced cervical cancer treated by carboplatin-based chemotherapy with peripheral blood stem cell autotransplant] Takeda S, et al. **Gan To Kagaku Ryoho** 1997 Jun;24(8):1013–7 (Eng. Abstr.) **(Jpn)**

[Treatment of acute myelogenous leukemia in patients more than 80 years old] Takeyama H, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1089–93 (Eng. Abstr.) **(Jpn)**

[Intrahepatic arterial infusion chemotherapy for the colon cancer patients with liver metastases—a comparison of arterial embolization chemotherapy versus continuous arterial infusion chemotherapy] Tanada M, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1440–2 (Eng. Abstr.) **(Jpn)**

[Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer—a case report] Tanino H, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):861–4 (Eng. Abstr.) **(Jpn)**

[Combination therapy with 5'-DFUR, MMC and CDDP in patient with far advanced gastric cancer: report of a case] Tomita H, et al. **Gan To Kagaku Ryoho** 1997 Aug; 24(10):1311–4 (Eng. Abstr.) **(Jpn)**

[A case of non-resectable pancreatic cancer surviving more than 4 years by intra-arterial infusion chemotherapy with angiotensin-II] Tsuji Y, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1617–20 (Eng. Abstr.) **(Jpn)**

[Preoperative synchronized chemoradiation therapy for advanced esophageal cancer] Tsujinaka T, et al. **Gan To Kagaku Ryoho** 1997 Mar;24(5):557–61 (Eng. Abstr.) **(Jpn)**

[Fundamental studies on the surgical adjuvant chemotherapy to support the clinical efficacies] Tsukagoshi S. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1213–20 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A case of lung metastasis from breast cancer successfully treated by FLEP (5-FU leucovorin, etoposide CDDP) combined arterial infusion chemotherapy] Tsuneda Y, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1582–4 (Eng. Abstr.) **(Jpn)**

[A case of advanced gastric cancer showing complete disappearance of cancer cells in multiple liver metastases due to low-dose PMUE therapy] Ueda N, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1833–6 (Eng. Abstr.) **(Jpn)**

[Evaluation of hepatic arterial infusion chemotherapy for gastric cancer] Uemura T, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1787–91 (Eng. Abstr.) **(Jpn)**

[Progress in the treatment of multiple myeloma] Wada M, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1079–88 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Evaluation of combination chemotherapy with 5-FU and CDDP for human gastric carcinoma transplanted into nude mice] Yamada T, et al. **Gan To Kagaku Ryoho** 1997 Jan; 24(1):43–7 (Eng. Abstr.) **(Jpn)**

[Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment] Yamada Y, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1335–40 (Eng. Abstr.) **(Jpn)**

[CPE chemotherapy for tongue carcinoma—clinical effects and side effects] Yamamoto C, et al. **Gan To Kagaku Ryoho** 1997 May;24(7):843–7 (Eng. Abstr.) **(Jpn)**

[A case of far-advanced gastric cancer treated with neoadjuvant combination chemotherapy of UFT, low-dose CDDP and leucovorin, followed by subtotal gastrectomy with curative intent] Yamamoto S, et al. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1157–60 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature] Yamazaki N. **Gan To Kagaku Ryoho** 1997 Jan;24(1):30–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Usefulness of continuous arterial infusion chemotherapy for post operative multiple recurrence and residual hepatocellular carcinoma] Yanagi I, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1419–21 (Eng. Abstr.) **(Jpn)**

[An elderly patient with gastric cancer surviving long after chemotherapy using UFT alone] Yokoi K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1317–9 (Eng. Abstr.) **(Jpn)**

[Evaluation of endoscopic pirarubicin-Lipiodol emulsion injection therapy for gastric cancer] Yoshimura K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(11):1519–22 (Eng. Abstr.) **(Jpn)**

[Combination therapy with hormonal, radiation and chemotherapy for stage C prostate cancer] Iwasawa T, et al. **Hinyokika Kiyo** 1996 Nov;42(11):869–74 (Eng. Abstr.) **(Jpn)**

[A case of primary squamous cell carcinoma of the ureter: biochemical modulation with cisplatin and 5-fluorouracil] Kageyama S, et al. **Hinyokika Kiyo** 1997 Jan;43(1):41–4 (Eng. Abstr.) **(Jpn)**

[Tumor reduction in advanced renal cell carcinoma with tumor thrombus by renal embolization, interferon-alpha and UFT. A case report] Shiomi K, et al. **Hinyokika Kiyo** 1997 Mar;43(3):217–21 (Eng. Abstr.) **(Jpn)**

[Clinical study of testicular cancer] Tsumatani K, et al. **Hinyokika Kiyo** 1996 Dec;42(12):943–50 (Eng. Abstr.) **(Jpn)**

[Mechanism of cisplatin and peplomycin therapy on head and neck carcinoma] Kumazawa H, et al. **Hum Cell** 1996 Mar;9(1):69–74 (Eng. Abstr.) **(Jpn)**

[A case of embryonal carcinoma successfully treated by neoadjuvant chemotherapy: report of a case] Shibata S, et al. **Kyobu Geka** 1996 Oct;49(11):963–5 (Eng. Abstr.) **(Jpn)**

[A case of invasive thymoma made resectable by preoperative chemotherapy] Tanaka K, et al. **Kyobu Geka** 1996 Sep; 49(10):868–71 (Eng. Abstr.) **(Jpn)**

[Monoclonal rheumatoid factor in a patient with multiple myeloma after chemotherapy] Nishinarita M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Oct;19(5):519–23 (Eng. Abstr.) **(Jpn)**

[The effectiveness of neoadjuvant chemotherapy for invasive bladder cancer] Nishisaka N, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Nov;87(11):1250–7 (Eng. Abstr.) **(Jpn)**

[The efficacy of neoadjuvant chemotherapy and morphological classification of invasive bladder cancer according to chemoresponse] Tsutsumi M, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Sep;87(9):1105–13 (Eng. Abstr.) **(Jpn)**

[Usefulness of MR imaging in evaluating and predicting effect of neoadjuvant chemotherapy on uterine cervical carcinoma] Amano M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Mar; 57(4):176–81 (Eng. Abstr.) **(Jpn)**

[Experience in treatment of patients with locally advanced or recurrent breast cancer: intraarterial infusion chemotherapy combined with radiotherapy] Murakami M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Mar; 57(4):189–94 (Eng. Abstr.) **(Jpn)**

[Biochemical modulation applied to experimental cancer chemotherapy] Nakamura Y. **Nippon Jibiinkoka Gakkai Kaiho** 1996 Nov;99(11):1694–704 (Eng. Abstr.) **(Jpn)**

[A case of malignant mediastinal germ cell tumor benefited by multidisciplinary therapy] Kamiya I. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul;44(7):994–7 (Eng. Abstr.) **(Jpn)**

[Thymic carcinoma effectively treated by preoperative concurrent chemo-radiotherapy] Akiyama Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Sep; 34(9):1030–4 (Eng. Abstr.) **(Jpn)**

[Tumor lysis syndrome after treatment for mediastinal non-Hodgkin's lymphoma] Kaneki T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Apr;35(4):414–9 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for non-small cell lung cancer] Shinkai T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:92–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Small cell lung cancer with acute monocytic leukemia after combined chemotherapy including etoposide] Tamada T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 May; 35(5):577–82 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for small-cell lung cancer] Ueoka H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:87–91 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Case of malignant pheochromocytoma with successful control of systemic metastasis with CVD chemotherapy] Minami T, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2078–80 (10 ref.) **(Jpn)**

[Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer] Sugiyama T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Sep;48(9):827–34 (Eng. Abstr.) **(Jpn)**

[Quality of life in patients with advanced ovarian cancer who underwent cytoreductive surgery followed by chemotherapy] Tei S, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Oct;48(10):883–7 (Eng. Abstr.) **(Jpn)**

[Evaluation by dynamic MRI of the response of neoadjuvant chemotherapy in uterine cervical cancer] Yamamoto M, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Jul; 48(7):540–3 **(Jpn)**

[Treatment of metastatic brain tumors from lung cancer: analysis of performance status between treatment methods] Nakagawa H, et al. **No Shinkei Geka** 1997 Feb;25(2):117–22 (Eng. Abstr.) **(Jpn)**

[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer] Nakagawa H, et al. **No Shinkei Geka** 1997 Mar; 25(3):215–23 (39 ref.) (Eng. Abstr.) **(Jpn)**

[Successful treatment of combined interferon-alpha and hydroxycarbamide for chronic myelogenous leukemia following therapy for malignant lymphoma] Hasegawa A, et al. **Rinsho Ketsueki** 1996 Sep;37(9):853–7 (Eng. Abstr.) **(Jpn)**

[Low-grade non-Hodgkin's lymphoma: intensive combined chemotherapy] Hattori M, et al. **Rinsho Ketsueki** 1996 Feb; 37(2):101–8 (Eng. Abstr.) **(Jpn)**

[Short-term intensive treatment for acute myelogenous leukemia (excluding M3 subtype) in adults] Ino T, et al. **Rinsho Ketsueki** 1997 Mar;38(3):209–16 (Eng. Abstr.) **(Jpn)**

[Treatment results for unselected patients with acute myelogenous leukemia. During a 10-year period, August 1984 to July 1994] Ino T, et al. **Rinsho Ketsueki** 1996 Sep; 37(9):817–24 (Eng. Abstr.) **(Jpn)**

[Myelogenous leukemia in children. ANLL9205 study by Children's Cancer and Leukemia Study Group (CCLSG)] Mimaya J, et al. **Rinsho Ketsueki** 1997 Feb;38(2):100–7 (Eng. Abstr.) **(Jpn)**

[Successful high-dose chemotherapy combined with autologous bone marrow transplantation in a case of refractory follicular lymphoma] Nagai T, et al. **Rinsho Ketsueki** 1997 Jun;38(6):513–9 (Eng. Abstr.) **(Jpn)**

[8;21 translocation acute myelocytic leukemia developing in the second trimester of pregnancy with successful delivery] Nakayama M, et al. **Rinsho Ketsueki** 1996 Nov; 37(11):1265–70 (Eng. Abstr.) **(Jpn)**

[Prognostic factors of follicular lymphoma treated with combination chemotherapy] Niitsu N, et al. **Rinsho Ketsueki** 1997 Jun;38(6):496–504 (Eng. Abstr.) **(Jpn)**

[Chemotherapy of relapsed AML and ALL] Nishikawa K. **Rinsho Ketsueki** 1996 Aug;37(8):647–50 (6 ref.) **(Jpn)**

[Low-dose chemotherapy] Ogata K, et al. **Rinsho Ketsueki** 1996 Sep;37(9):777–81 (Eng. Abstr.) **(Jpn)**

[Early establishment of bone marrow hypoplasia by antileukemic chemotherapy with concurrent rhG-CSF in a case of acute myelogenous leukemia complicated with intestinal perforation] Ono Y, et al. **Rinsho Ketsueki** 1997 Jan;38(1):41–6 (Eng. Abstr.) **(Jpn)**

[Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia] Saito K. **Rinsho Ketsueki** 1996 Aug;37(8):651–3 (Eng. Abstr.) **(Jpn)**

[Chemotherapy for two patients with non-Hodgkin's lymphoma in hemodialysis] Sano F, et al. **Rinsho Ketsueki** 1996 Aug;37(8):688–93 (Eng. Abstr.) **(Jpn)**

[Comparison of long-term survival between bone marrow transplantation and maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission] Suzuki N, et al. **Rinsho Ketsueki** 1997 Feb;38(2):95–9 (Eng. Abstr.) **(Jpn)**

[Bone marrow transplantation versus maintenance chemotherapy for adult acute leukemia in first remission] Suzuki R, et al. **Rinsho Ketsueki** 1996 Dec;37(12):1362–70 (Eng. Abstr.) **(Jpn)**

[An intensive chemotherapy of adult T-cell leukemia/lymphoma] Taguchi H. **Rinsho Ketsueki** 1996 Aug;37(8):654–60 (Eng. Abstr.) **(Jpn)**

[High-clore chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT) for patients with malignant lymphoma—its role in the treatment strategy for non-Hodgkin's lymphoma, and ESHAP + PBSCT therapy] Tanosaki R, et al. **Rinsho Ketsueki** 1996 Jul;37(7):591–7 (24 ref.) **(Jpn)**

[Complete remission achieved by L-asparaginase, vincristine and prednisolone (LVP) therapy in secondary leukemia (M5a type) with an MLL gene rearrangement] Tomita N, et al. **Rinsho Ketsueki** 1997 Feb;38(2):135–41 (Eng. Abstr.) **(Jpn)**

[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation] Toyosawa M, et al. **Rinsho Ketsueki** 1997 Jan;38(1):33–40 (Eng. Abstr.) **(Jpn)**

[Treatment results in childhood acute myeloblastic leukemia—a report of clinical trials of a past decade from the Japanese children's Cancer and Leukemia Study Group (CCLSG)] Tsurusawa M, et al. **Rinsho Ketsueki** 1997 Jun; 38(6):505–12 (Eng. Abstr.) **(Jpn)**

[Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma] Kamieńska E. **Ann Acad Med Stetin** 1996;42:105–22 (Eng. Abstr.) **(Pol)**

[Chemotherapy versus chemoradiotherapy in patients with limited small cell lung carcinoma] Byszewska D, et al. **Pneumonol Alergol Pol** 1997;65(5-6):318–25 (Eng. Abstr.) **(Pol)**

[Early results of chemotherapy in patients with non-small cell lung cancer] Zukowska H, et al. **Pneumonol Alergol Pol** 1996;64(11-12):774–9 (Eng. Abstr.) **(Pol)**

[Preliminary results of conservative combination radiotherapy and chemotherapy in early stages of Hodgkin's disease] Gabryś K, et al. **Pol Arch Med Wewn** 1996 Nov;96(5):469–73 (Eng. Abstr.) **(Pol)**

[A case of Hodgkin's disease with an uncommon clinical course. Predominant localization in the liver] Marjańska-Radziszewska J, et al. **Przegl Lek** 1996; 53(11):830–2 (Eng. Abstr.) **(Pol)**

[A case of recurrent untreated non-hodgkin's lymphoma localized in the nasopharynx and maxillary sinuses after a 10-year remission] Braczkowski R, et al. **Wiad Lek** 1996; 49(7-12):112–5 (Eng. Abstr.) **(Pol)**

[Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives]

Bliumenberg AG, et al. **Biull Eksp Biol Med** 1996 Dec; 122(12):651–4 **(Rus)**

[The characteristics of the immunological indices in multiple myeloma during polychemotherapy] Abdulkadyrov KM, et al. **Lik Sprava** 1995 Mar–Apr;(3–4):75–80 (Eng. Abstr.) **(Rus)**

[Experience in treating peripheral T-cell lymphomas by a new program] Butenko AK. **Lik Sprava** 1996 Jul–Sep; (7–9):160–2 (Eng. Abstr.) **(Rus)**

[The treatment of non-Hodgkin's lymphomas taking into account individual sensitivity to the chemical preparations] Kindzel'skiĭ LP, et al. **Lik Sprava** 1996 Mar–Apr; (3–4):104–7 (Eng. Abstr.) **(Rus)**

[The treatment of Hodgkin's disease by taking into account individual sensitivity to antitumor preparations] Ponomareva OV, et al. **Lik Sprava** 1997 Jan–Feb;(1):103–6 (Eng. Abstr.) **(Rus)**

[The role of antitumor drugs in treating stomach cancer patients] Garin AM, et al. **Ter Arkh** 1997;69(2):16–8 (Eng. Abstr.) **(Rus)**

[Quality-of-life support for patients during antitumor chemotherapy (a lecture)] Perevodchikova NI. **Ter Arkh** 1996;68(10):37–41 **(Rus)**

[Experience in treating osseous sarcomas at the Research Institute of Pediatric Oncology, Cancer Research Center] Pashkov IV, et al. **Vestn Ross Akad Med Nauk** 1996; (10):10–3 (Eng. Abstr.) **(Rus)**

[Effectiveness of various chemotherapy regimens for patients with chronic myeloid leukemia in blast crisis] Abdulkadyrov KM, et al. **Vopr Onkol** 1997;43(3):284–9 (Eng. Abstr.) **(Rus)**

[Combination chemotherapy with total or subtotal lymphatic irradiation in the treatment of lymphogranulomatosis, stage IIIA or IIIB (based on five- and ten-year results)] Kanaev SV, et al. **Vopr Onkol** 1997;43(1):32–8 (Eng. Abstr.) **(Rus)**

[A case of the immediate efficacy of chemotherapy in a female patient with a glioblastoma] Kobiakov GL, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1996 Oct–Dec; (4):39–41 (22 ref.) **(Rus)**

[Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol] Marisavljević D, et al. **Srp Arh Celok Lek** 1996 Nov–Dec;124(11–12):292–6 (Eng. Abstr.) **(Scc)**

[Malignant mesothelioma—therapeutic response to various combinations of anthracyclines] Popov I, et al. **Srp Arh Celok Lek** 1996 Mar–Apr;124(3–4):77–81 (Eng. Abstr.) **(Scc)**

[The ANLL-NS 02 protocol for individualized therapy in acute nonlymphoblastic leukemia] Popović S. **Med Pregl** 1996;49(11–12):447–52 (Eng. Abstr.) **(Scr)**

[Systemic chemotherapy with cisplatin, methotrexate, and vinblastine, and bladder preservation in T2/T3a bladder cancer] Angulo Cuesta J, et al. **Actas Urol Esp** 1997 Jan; 21(1):28–33 (Eng. Abstr.) **(Spa)**

[A case of choroid metastasis of cancer of the breast with an excellent response to chemotherapy (letter)] Marcos Sánchez F, et al. **An Med Interna** 1996 Nov;13(11):567 **(Spa)**

[Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2–4 N0–1 M0)] Bellmunt Molins J, et al. **Arch Esp Urol** 1996 Jun;49(5):465–72 (Eng. Abstr.) **(Spa)**

[Preoperative and postoperative chemotherapy of osteogenic sarcoma of the limbs in children] Muñoz Villa A, et al. **Med Clin (Barc)** 1996 Jun 29;107(5):161–4 (Eng. Abstr.) **(Spa)**

[Effect of granulocyte colony-stimulating factor after chemotherapy with CHOP in patients with non-Hodgkin's lymphoma and HIV infection (letter)] Navarro JT, et al. **Med Clin (Barc)** 1996 Jun 15;107(3):118–9 **(Spa)**

[The intra-arterial chemotherapy of tumorous lesions of the stomach, rectum and liver] Hladkyĭ OV, et al. **Lik Sprava** 1997 Mar–Apr;(2):86–90 (Eng. Abstr.) **(Ukr)**

[The morphological aspects of a study of the efficacy of chemotherapy in ovarian cancer] Iakymova TP, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):103–6 (Eng. Abstr.) **(Ukr)**

[A combination of radiotherapy and chemotherapy with platidiam and fluorouracil in patients with head and neck cancer] Shparyk IaV, et al. **Lik Sprava** 1996 Mar–Apr; (3–4):153–7 **(Ukr)**

[The chemotherapy of metastases of unknown origin] Shparyk IaV, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):45–52 (51 ref.) **(Ukr)**

[The correlation of the hormonal and clinical effects in patients with prostatic cancer undergoing niftolid treatment in combination with low doses of synestrol] Vozianov OF, et al. **Lik Sprava** 1996 Jan–Feb;(1–2):107–10 (Eng. Abstr.) **(Ukr)**

TOXICITY

Cardiotoxicity of combined administration of adriamycin and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats-with special reference to 125I-MIBG cardioautoradiography and histopathological findings. Niitsu N, et al. **In Vivo** 1995 Sep–Oct;9(5):455–62

In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Kanzawa F, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7-8–S7-16

Combination chemotherapy studies with gemcitabine. van Moorsel CJ, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 7):S7-17–S7-23 (40 ref.)

[Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo] Hayashi T, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:495–504 (Eng. Abstr.) **(Jpn)**

[An oral repeated dose toxicity study of a new antineoplastic agent S-1 in dogs. I. A 13-week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study] Hayashi T, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:527–44 (Eng. Abstr.) **(Jpn)**

[A 13-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats] Hayashi T, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:505–26 (Eng. Abstr.) **(Jpn)**

[Immunotoxic effects of a new antineoplastic agent S-1 in mice—comparison with S-1, UFT and 5-FU] Kouchi Y, et al. **J Toxicol Sci** 1996 Nov;21 Suppl 3:691–701 (Eng. Abstr.) **(Jpn)**

ANTINEOPLASTIC AGENTS, HORMONAL

Endocrine resistance in advanced breast cancer. Dowsett M. **Acta Oncol** 1996;35 Suppl 5:91–5 (30 ref.)

Advertisement for toremifene. Playing on women's fears is unethical [letter] Twelves C, et al. **BMJ** 1996 Oct 12; 313(7062):944–5

Tamoxifen. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:253–365 (408 ref.)

Toremifene. **IARC Monogr Eval Carcinog Risks Hum** 1996; 66:367–87 (68 ref.)

ADMINISTRATION & DOSAGE

Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. Figg WD, et al. **Acta Oncol** 1996; 35(6):763–5

Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Attivissimo LA, et al. **Am J Clin Oncol** 1996 Dec;19(6):581–3

Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: standard-dose therapy followed by reduced-dose therapy. Broekmans FJ, et al. **Am J Obstet Gynecol** 1996 Nov;175(5):1208–16

Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma. Figg WD, et al. **Cancer** 1997 May 15;79(10):1964–8

Toremifene concentration and multidrug resistance in lung tumors. Liippo K, et al. **Cancer Chemother Pharmacol** 1997; 39(3):212–6

The antiandrogen withdrawal syndrome in relapsed prostate cancer. Scher HI, et al. **Eur Urol** 1997;31 Suppl 2:3–7; discussion 24–7

Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability. Caird LE, et al. **Hum Reprod** 1997 Mar; 12(3):436–40

Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer. Akaza H, et al. **Int J Urol** 1996 Nov;3(6):468–71

Comparison of hormonal therapy and chemohormonal therapy in patients with newly diagnosed clinical stage D prostatic cancer. Miyake H, et al. **Int J Urol** 1996 Nov; 3(6):472–7

Relationship of endometrial thickness with the menstrual timing of leuprolide acetate administration for preoperative preparation for hysteroscopic surgery. Nathanson HG, et al. **J Am Assoc Gynecol Laparosc** 1997 Feb;4(2):191–4

The myeloprotective effect of high dose medroxyprogesterone acetate (HD-MPA) in patients with carcinoma of the uterine cervix (stage II & III) treated by radiation. Sangruchi S. **J Med Assoc Thai** 1996 Sep; 79(9):604–7

Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group [see comments] [published erratum appears in J Natl Cancer Inst 1997 Apr 16;89(8):590] **J Natl Cancer Inst** 1996 Dec 18;88(24):1834–9. Comment in: J Natl Cancer Inst 1996 Dec 18;88(24):1791–3.

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group [see comments] **J Natl Cancer Inst** 1996 Nov 6;88(21):1543–9. Comment in: J Natl Cancer Inst 1996 Nov 6;88(21):1510–2. Comment in: J Natl Cancer Inst 1997 May 7;89(9):659–60.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [see comments] Fisher B, et al. **J Natl Cancer Inst** 1996 Nov 6;88(21):1529–42. Comment in: J Natl Cancer Inst 1996 Nov 6;88(21):1510–2.

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer [letter; comment] Machin D, et al. **J Natl Cancer Inst** 1997 May 7;89(9):659–60. Comment on: J Natl Cancer Inst 1996 Nov 6;88(21):1543–9.

Five years of tamoxifen—or more? [editorial; comment] Peto R. **J Natl Cancer Inst** 1996 Dec 18;88(24):1791–3. Comment on: J Natl Cancer Inst 1996 Nov 6;88(21):1571–9.

Tamoxifen: the long and short of it [editorial; comment] Swain SM. **J Natl Cancer Inst** 1996 Nov 6;88(21):1510–2. Comment on: J Natl Cancer Inst 1996 Nov 6;88(21):1529–43. Comment on: J Natl Cancer Inst 1996 Nov 6;88(21):1543–9.

Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group [see comments] Tormey DC, et al. **J Natl Cancer Inst** 1996 Dec 18; 88(24):1828–33. Comment in: J Natl Cancer Inst 1996 Dec 18;88(24):1791–3.

Persistent suppression of the pituitary-gonadal system in female rats by three-month depot injectable microspheres of leuprorelin acetate. Okada H, et al. **J Pharm Sci** 1996 Oct;85(10):1044–8

Systemic adjuvant therapy of breast cancer. Garrett TJ, et al. **J Surg Oncol** 1997 Feb;64(2):167–72 (35 ref.)

Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy. Teruel JL, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1262–3

Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report. Zhang W, et al. **Neurosurgery** 1996 Mar;38(3):587–90; discussion 590–1

In vitro evaluation of flutamide-carrier systems. Part 1: Preparation and evaluation of flutamide systems with polyvinyl pyrrolidone and polyethylene glycol 4000 and 6000. Adel MS, et al. **Pharmazie** 1997 May;52(5):373–5

Treatment of high-grade, high-stage prostate cancer with estramustine phosphate or diethylstilbestrol. A double-blind study. The SPCG-1 Study Group. Scandinavian Prostate Cancer Group. Hedlund PO, et al. **Scand J Urol Nephrol** 1997 Apr;31(2):167–72

The effectiveness of medroxyprogesterone in the treatment of multiple metastasizing leiomyosarcomas: report of a case. Uchida T, et al. **Surg Today** 1996;26(2):138–41

[Androgen test: comparison of a low test and a high test in the development of the penis in male pseudohermaphroditism] Wakim S, et al. **Arch Pediatr** 1996 Dec;3(12):1225–8 (Eng. Abstr.) **(Fre)**

[Value of premedication with gonadotropin releasing hormone agonists before transcervical resection of solitary submucous myoma] Römer T. **Gynakol Geburtshilfliche Rundsch** 1996;36(4):194–6 (Eng. Abstr.) **(Ger)**

[High dose oral prednisone for hemangiomas in infants] Sadan N, et al. **Harefuah** 1997 May 15;132(10):684–91, 744 (Eng. Abstr.) **(Heb)**

[Adjuvant tamoxifen duration: more large-scale randomized evidence is needed] Davies C, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1203–9 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Inhibition of prostate cancer growth in nude mice by hormone and chemotherapy] Fujita K, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1335–8 (Eng. Abstr.) **(Jpn)**

[Combined hormone-chemotherapy for stage D2 prostatic cancer: starting time of chemotherapy in relation to hormone therapy] Tsukamoto T, et al. **Hinyokika Kiyo** 1996 May;42(5):351–6 (Eng. Abstr.) **(Jpn)**

[A case of hormone-refractory prostate cancer responsive to low-dose prednisolone therapy] Enomoto Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 Jun;88(6):636–9 (Eng. Abstr.) **(Jpn)**

[Combined hormone/chemotherapy for advanced prostatic cancer] Komatsu H. **Nippon Hinyokika Gakkai Zasshi** 1997 Mar;88(3):375–85 (86 ref.) **(Jpn)**

[High-dose medroxyprogesterone acetate in the treatment of metastatic carcinoma of renal parenchyma] Popov I, et al. **Srp Arh Celok Lek** 1996 Mar–Apr;124(3–4):73–6 (Eng. Abstr.) **(Scc)**

ADVERSE EFFECTS

Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. Hann LE, et al. **AJR Am J Roentgenol** 1997 Mar;168(3):657–61

Acute liver injury and octreotide. González-Martín JA, et al. **Am J Gastroenterol** 1996 Nov;91(11):2434–5

Case report: systemic hypersensitivity reaction to goserelin acetate. Raj SG, et al. **Am J Med Sci** 1996 Oct; 312(4):187–90

Cushing's syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate. Malik KJ, et al. **Ann Clin Biochem** 1996 May;33 (Pt 3):187–9

Tamoxifen-induced female androgenetic alopecia in a patient with breast cancer [letter] Ayoub JP, et al. **Ann Intern Med** 1997 May 1;126(9):745–6

Low-dose prednisone and increased risk of development of bone metastases [letter; comment] Body JJ. **Ann Oncol** 1996 Aug;7(6):643. Comment on: Ann Oncol 1996 Mar;7(3):245–50.

Tamoxifen mediated human endometrial carcinogenesis may not involve estrogenic pathways: a preliminary note. Kuwashima Y, et al. **Anticancer Res** 1996 Sep–Oct; 16(5A):2993–6

Endometrial cancer after tamoxifen treatment: a descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer. Peters-Engl C, et al. **Anticancer Res** 1996 Sep–Oct;16(5B):3241–6

Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the

literature. Mann M, et al. **Arch Intern Med** 1997 Aug 11–25; 157(15):1651–6 (23 ref.)

Effect of tamoxifen on von Willebrand factor levels [letter; comment] Ounnoughène N, et al. **Arch Intern Med** 1997 Jul 28;157(14):1613. Comment on: Arch Intern Med 1996 Sep 9;156(16):1806–10.

Clinical adrenal insufficiency in patients receiving megestrol therapy. Subramanian S, et al. **Arch Intern Med** 1997 May 12;157(9):1008–11

Multiple polypoid endometriosis—a rare complication following withdrawal of gonadotrophin releasing hormone (GnRH) agonist for severe endometriosis: a case report. Othman NH, et al. **Aust N Z J Obstet Gynaecol** 1996 May; 36(2):216–8

Photosensitive dermatitis induced by flutamide [letter] Fujimoto M, et al. **Br J Dermatol** 1996 Sep;135(3):496–7

Uterine carcinosarcoma in association with tamoxifen therapy. McCluggage WG, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):748–50

Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Kristensen B, et al. **Breast Cancer Res Treat** 1996;39(3):321–6

Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Trendle MC, et al. **Cancer** 1997 Feb 15; 79(4):830–4

Tamoxifen–associated venous thrombosis and activated protein C resistance due to factor V Leiden. Weitz IC, et al. **Cancer** 1997 May 15;79(10):2024–7

Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy. Shlebak AA, et al. **Cancer Chemother Pharmacol** 1997;39(5):462–6

Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new? [letter; comment] Faustini–Fustini M. **Clin Endocrinol (Oxf)** 1997 Mar; 46(3):378. Comment on: Clin Endocrinol (Oxf) 1996 Jan;44(1):121–4.

Flutamide–induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. Cicognani C, et al. **Dig Dis Sci** 1996 Nov;41(11):2219–21

Tamoxifen and secondary tumours. An update. Wilking N, et al. **Drug Saf** 1997 Feb;16(2):104–17 (151 ref.)

IARC on tamoxifen [news] **Environ Health Perspect** 1996 Jul;104(7):688

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Assikis VJ, et al. **Eur J Cancer** 1996 Aug; 32A(9):1464–76 (75 ref.)

Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer. Borner MM, et al. **Eur J Cancer** 1996 Nov;32A(12):2173–6

Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patients treated with tamoxifen. Cohen I, et al. **Gynecol Obstet Invest** 1997;43(1):60–3

Endolymphatic stromal myosis associated with tamoxifen use. Eddy GL, et al. **Gynecol Oncol** 1997 Feb;64(2):262–4

Therapeutic approach to ovarian cysts in tamoxifen–treated women with breast cancer. Shushan A, et al. **Int J Gynaecol Obstet** 1996 Mar;52(3):249–53

Common endometrial decidual reaction in postmenopausal breast cancer patients treated with tamoxifen and progestogens. Cohen I, et al. **Int J Gynecol Pathol** 1996 Jan;15(1):17–22

Pseudotumour cerebri as a side effect of leuprorelin acetate [letter] Boot JH. **Ir J Med Sci** 1996 Jan–Mar;165(1):60

Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen. Marconi D, et al. **J Am Assoc Gynecol Laparosc** 1997 May;4(3):331–9

Long–term toxicity in adjuvant treatment with tamoxifen. Cobelli S, et al. **J Chemother** 1997 Aug;9(4):300–3

Re: second cancers after adjuvant tamoxifen therapy for breast cancer [letter; comment] Atkins CD. **J Natl Cancer Inst** 1996 Oct 16;88(20):1496–7; discussion, 1497–9. Comment on: J Natl Cancer Inst 1996 Jun 19;88(12):832–4.

Second cancers after adjuvant tamoxifen therapy for breast cancer [letter; comment] Cook LS, et al. **J Natl Cancer Inst** 1997 May 7;89(9):657–9. Comment on: J Natl Cancer Inst 1996 Jun 19;88(12):832–4.

Tamoxifen: the herald of a new era of preventive therapeutics [editorial; comment] Jordan VC. **J Natl Cancer Inst** 1997 Jun 4;89(11):747–9. Comment on: J Natl Cancer Inst 1997 Jun 4;89(11):776–82.

Re: second cancers after adjuvant tamoxifen therapy for breast cancer [letter; comment] Rutqvist LE. **J Natl Cancer Inst** 1996 Oct 16;88(20):1497–9; discussion, 1497–9. Comment on: J Natl Cancer Inst 1996 Jun 19;88(12):832–4.

Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Dijkhuizen FP, et al. **Maturitas** 1996 Aug;25(1):45–50

Tamoxifen induced endometrial abnormalities: evaluation by saline infusion sonohysterography. Jaeger BM, et al. **Md Med J** 1997 Sep;46(8):433–5

Acute leukaemia during tamoxifen therapy. Yalçin S, et al. **Med Oncol** 1997 Mar;14(1):61–2

Exacerbation of lupus nephritis in association with leuprorelin injection for uterine leiomyoma. Metcalfe W, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1699–700

Steroid myopathy in cancer patients. Batchelor TT, et al. **Neurology** 1997 May;48(5):1234–8

Iatrogenic endometrial megapolyps in women with breast carcinoma. Berezowsky J, et al. **Obstet Gynecol** 1994 Oct; 84(4 Pt 2):727–30

Granulosa cell tumor of the ovary associated with antecedent tamoxifen use. Gherman RB, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):717–9 (11 ref.)

Recurrent vulvovaginal candidiasis associated with long–term tamoxifen treatment in postmenopausal women. Sobel JD, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):704–6

Risk of endometrial cancer after tamoxifen treatment. Morgan RW. **Oncology (Huntingt)** 1997 Feb;11(2 Suppl 1):25–33 (46 ref.)

Management of hot flushes due to endocrine therapy for prostate carcinoma. Smith JA Jr. **Oncology (Huntingt)** 1996 Sep;10(9):1319–22; discussion 1324 (22 ref.)

Anxiety and mood disorders associated with gonadotropin–releasing hormone agonist therapy. Warnock JK, et al. **Psychopharmacol Bull** 1997;33(2):311–6

Brain irradiation and antioedematous dexamethasone treatment—risk factors for herpes simplex encephalitis? Dragoje S, et al. **Schweiz Arch Neurol Psychiatr** 1995; 146(6):277–80

Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. MacMahon B. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1–122–S1–39 (39 ref.)

Excessive sweating: unusual side effect of megestrol acetate therapy. Votaw ML. **Tenn Med** 1997 Feb;90(2):59

Tamoxifen and the uterus: an old drug tested by new modalities. Achiron R, et al. **Ultrasound Obstet Gynecol** 1996 May;7(5):374–8 (35 ref.)

Sonographic characteristics of adenofibroma of the endometrium following tamoxifen therapy for breast cancer: two case reports. Huang KT, et al. **Ultrasound Obstet Gynecol** 1996 May;7(5):363–6

Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Kelly WK, et al. **Urol Clin North Am** 1997 May;24(2):421–31

A study of the effects of tamoxifen in the frail elderly: difficulties encountered in nursing home research. Breuer B, et al. **Women Health** 1997;25(1):37–51

[Endometrial cancer and tamoxifen. Discussion apropos of a series of cases] Sasco AJ, et al. **Bull Cancer** 1997 Jan; 84(1):51–60 (81 ref.) (Eng. Abstr.) **(Fre)**

[Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer] Patel H, et al. **J Urol (Paris)** 1996;102(3):123–5 (12 ref.) (Eng. Abstr.) **(Fre)**

[The effective therapy of the hot flashes during hormone withdrawal treatment in patients with advanced prostatic carcinoma] Kliesch S, et al. **Dtsch Med Wochenschr** 1997 Jul 25;122(30):940–5 (64 ref.) **(Ger)**

[Occlusion of finger arteries and thrombotic angiopathy of the retina during adjuvant tamoxifen therapy of a mammary carcinoma] Schlich B, et al. **Dtsch Med Wochenschr** 1997 Jun 13;122(24):783–6 (Eng. Abstr.) **(Ger)**

[Does tamoxifen have a negative effect on survival chances of premenopausal women with locoregional recurrence of breast carcinoma?] Sauer H. **Strahlenther Onkol** 1997 Jul; 173(7):390 **(Ger)**

[Effects of ipriflavone on bone loss induced by GnRH analog] Pellicano M, et al. **Minerva Ginecol** 1996 Oct;48(10):435–9 (Eng. Abstr.) **(Ita)**

[Hepatoxicity caused by flutamide increased by hypotensive situation?] Serrano Hernández N, et al. **An Med Interna** 1996 Nov;13(11):552–4 (Eng. Abstr.) **(Spa)**

[Fulminant liver failure with a fatal outcome due to flutamide (letter)] Fernández Peña CM, et al. **Med Clin (Barc)** 1997 Feb 15;108(6):237–8 (8 ref.) **(Spa)**

ANALYSIS

Analysis of tamoxifen and its metabolites by on–line capillary electrophoresis–electrospray ionization mass spectrometry employing nonaqueous media containing surfactants. Lu W, et al. **Anal Chem** 1996 Feb 15;68(4):668–74

Tamoxifen–induced DNA adducts in leucocytes of breast cancer patients. Hemminki K, et al. **Carcinogenesis** 1997 Jan;18(1):9–13

ANTAGONISTS & INHIBITORS

Calcium reverses octreotide inhibition of insulin and glucagon levels in patients with insulinoma and glucagonoma. Thompson CS, et al. **Digestion** 1996;57 Suppl 1:62–8

BLOOD

Solid–phase extraction and high–performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma. MacCallum J, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12;678(2):317–23

Direct liquid chromatographic micro–measurement of tamoxifen in plasma of cancer patients. El–Yazigi A, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):457–62

DIAGNOSTIC USE

Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Kopf D, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):39–44

Somatostatin analogue in the localization and treatment of bronchial carcinoid tumours. Temeck BK, et al. **Surg Oncol** 1996 Oct–Dec;5(5–6):195–200 (27 ref.)

HISTORY

Summary of intermittent endocrine therapy for advanced prostate cancer (by Laurence H. Klotz, MD, Harry W. Herr, MD, Michael J. Morse, MD, and Willet F. Whitmore, Jr, MD). 1986. Klotz LH, et al. **Semin Urol Oncol** 1997 May;15(2):117–22

METABOLISM

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4–hydroxylation of tamoxifen by human liver microsomes. Crewe HK, et al. **Biochem Pharmacol** 1997 Jan 24;53(2):171–8

Adrenal proteins bound by a reactive intermediate of mitotane. Cai W, et al. **Cancer Chemother Pharmacol** 1997; 39(6):537–40

Short–term maintenance of phase I and II metabolism in precision–cut liver slices in dynamic organ culture. Ekins S. **Drug Metab Dispos** 1996 Mar;24(3):364–6

On–line high–performance liquid chromatographic–electrospray ionization mass spectrometric method for the study of tamoxifen metabolism. Jones RM, et al. **J Chromatogr A** 1996 Jan 26;722(1–2):249–55

Gas chromatographic–electron capture determination of 2,4'–dichlorodiphenylacetic acid from in–vitro adrenal transformations of mitotane and its analogs. Sinsheimer JE, et al. **J Pharm Biomed Anal** 1996 May;14(7):861–6

Tamoxifen metabolism by microsomal cytochrome P450 and flavin–containing monooxygenase. Kupfer D, et al. **Methods Enzymol** 1996;272:152–63

Radioiodinated estramustine phosphate and estramustine binding protein antibody accumulate in the prostate of a mouse. Ståhlberg K, et al. **Prostate** 1997 Jun 15;32(1):1–8

Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity. Tannenbaum SR. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1–81–S1–6 (38 ref.)

[Molecular aspects of different mechanisms of tamoxifen resistance] Bachmann–Moisson N, et al. **Bull Cancer** 1997 Jan;84(1):69–75 (62 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Tamoxifen metabolic patterns within a glioma patient population treated with high–dose tamoxifen. Ducharme J, et al. **Br J Clin Pharmacol** 1997 Feb;43(2):189–93

Frequent serum sampling in healthy men discloses testosterone peaks exacerbated by testosterone propionate administration. Brisson GR, et al. **Can J Appl Physiol** 1997 Feb;22(1):58–65

Influence of age on toremifene pharmacokinetics. Sotaniemi EA, et al. **Cancer Chemother Pharmacol** 1997;40(2):185–8

Internalisation of isotope–coupled somatostatin analogues. Hofland LJ, et al. **Digestion** 1996;57 Suppl 1:2–6 (32 ref.)

Disposition of 3H–labelled buserelin continuously infused into rats. Heinrich N, et al. **Eur J Drug Metab Pharmacokinet** 1996 Oct–Dec; 21(4):345–50

Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Luessen HL, et al. **Pharm Res** 1996 Nov;13(11):1668–72

PHARMACOLOGY

1H–magnetic resonance spectroscopic observation of cultured malignant cells pharmacologically induced to different phenotypes. Nakai T, et al. **Acad Radiol** 1996 Sep; 3(9):742–50

Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Lykkesfeldt AE. **Acta Oncol** 1996; 35 Suppl 5:9–14 (60 ref.)

Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Paulsen GH, et al. **Acta Oncol** 1996; 35(8):1011–9

Therapeutic potential of octreotide in the treatment of liver metastases. Davies N, et al. **Anticancer Drugs** 1996 Jan;7 Suppl 1:23–31 (41 ref.)

Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF–7 and T–47D mammary cancer cells. Chetrite G, et al. **Anticancer Res** 1997 Jan–Feb; 17(1A):135–40

Genomic effects of tamoxifen. Kellen JA. **Anticancer Res** 1996 Nov–Dec;16(6B):3537–41 (52 ref.)

High–dose tamoxifen reverses drug resistance to cisplatin and etoposide in a patient with advanced large cell carcinoma of lung. Yeh KH, et al. **Anticancer Res** 1997 Mar–Apr; 17(2B):1341–3

The effect of tamoxifen on established human colorectal cancer cell lines in vitro. Ziv Y, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3767–71

bcl–2 overexpression combined with p53 protein accumulation correlates with hormone–refractory prostate cancer. Apakama I, et al. **Br J Cancer** 1996 Oct; 74(8):1258–62

Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells [letter; comment] Benson JR, et al. **Br J Cancer** 1996 Sep;74(6):993–4.

Comment on: Br J Cancer 1995 Dec;72(6):1441–6.

Oestrogen increases S-phase fraction and oestrogen and progesterone receptors in human cervical cancer in vivo. Bhattacharya D, et al. **Br J Cancer** 1997;75(4):554–8

Ovarian status influences the skeletal effects of tamoxifen in adult rats. Sibonga JD, et al. **Breast Cancer Res Treat** 1996;41(1):71–9

Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors. Szepeshazi K, et al. **Breast Cancer Res Treat** 1996;40(2):129–39

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Witters LM, et al. **Breast Cancer Res Treat** 1997 Jan;42(1):1–5

Protecting spermatogenesis from damage induced by doxorubicin using the luteinizing hormone-releasing hormone agonist leuprorelin: an image analysis study of a rat experimental model. Manabe F, et al. **Cancer** 1997 Mar 1;79(5):1014–21

Tamoxifen-induced estrogen receptor up-regulation in mammary tumor cells is not related to growth inhibition. Legros N, et al. **Cancer Chemother Pharmacol** 1997; 39(4):380–2

Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination. Adam L, et al. **Cancer Res** 1997 Mar 15;57(6):1023–9

MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Brünner N, et al. **Cancer Res** 1997 Aug 15;57(16):3486–93

Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Hemminki K, et al. **Cancer Res** 1996 Oct 1;56(19):4374–7

Tamoxifen down-regulates CD36 messenger RNA levels in normal and neoplastic human breast tissues. Silva ID, et al. **Cancer Res** 1997 Feb 1;57(3):378–81

Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Xing RH, et al. **Cancer Res** 1997 Aug 15;57(16):3585–93

Transforming growth factor beta and dexamethasone cooperatively enhance c-jun gene expression and inhibit the growth of human monocytoid leukemia cells. Kanatani Y, et al. **Cell Growth Differ** 1996 Feb;7(2):187–96

Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Kanda N, et al. **Clin Exp Immunol** 1996 Nov;106(2):410–5

Mechanisms of action of endocrine treatment in breast cancer. Lønning E, et al. **Crit Rev Oncol Hematol** 1995 Nov;21(1-3):158–93 (510 ref.)

Effects of somatostatin analogues on human gastrointestinal motility. Camilleri M. **Digestion** 1996;57 Suppl 1:90–2 (10 ref.)

Somatostatin analogues and exocrine pancreatic secretion. Gullo L. **Digestion** 1996;57 Suppl 1:93

Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Pollak M. **Digestion** 1996;57 Suppl 1:29–33 (37 ref.)

Calcium reverses octreotide inhibition of insulin and glucagon levels in patients with insulinoma and glucagonoma. Thompson CS, et al. **Digestion** 1996;57 Suppl 1:62–8

Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Weckbecker G, et al. **Digestion** 1996;57 Suppl 1:22–8

Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Wiseman LR, et al. **Drugs** 1997 Jul;54(1):141–60 (117 ref.)

Liarozole. Bryson HM, et al. **Drugs Aging** 1996 Dec; 9(6):478–84; discussion 485

Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Mantovani G, et al. **Eur J Cancer** 1997 Apr; 33(4):602–7

Liarozole potentiates the all-trans-retinoic acid-induced structural remodelling in human breast carcinoma MCF-7 cells in vitro. Van heusden J, et al. **Eur J Cell Biol** 1996 Sep;71(1):89–98

Biological and clinical significance of in vitro prednisolone resistance in adult acute lymphoblastic leukaemia. Tosi P, et al. **Eur J Haematol** 1996 Aug;57(2):134–41

Sonographic evaluation of the uterus in postmenopausal women receiving tamoxifen: characterization of mid-uterine abnormalities. Anteby EY, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Nov;69(2):115–9

Enhancement of tamoxifen-induced E-cadherin function by Ca2+ channel antagonists in human breast cancer MCF7/6 cells. Charlier C, et al. **Eur J Pharmacol** 1996 Dec 19; 317(2-3):413–6

Tamoxifen retards glycosphingolipid metabolism in human cancer cells. Cabot MC, et al. **FEBS Lett** 1996 Sep 30; 394(2):129–31

Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Cheng WF, et al. **Gynecol Oncol** 1997 Aug;66(2):233–7

The effect of toremifene on the expression of genes in a rat mammary adenocarcinoma. Kellen JA, et al. **In Vivo** 1996 Sep-Oct;10(5):511–3

Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation. Cabot MC, et al. **Int J Cancer** 1997 Mar 4;70(5):567–74

Dexamethasone modulates CD2 expression. Migliorati G, et al. **Int J Immunopharmacol** 1996 Dec;18(12):677–84

Potentiating effect of buserelin acetate, an LHRH agonist, on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats. Maezawa H, et al. **Int J Urol** 1997 Jul;4(4):411–6

Hormone treatment after irradiation stimulates recovery of rat spermatogenesis from surviving spermatogonia. Meistrich ML, et al. **J Androl** 1997 Jan-Feb;18(1):80–7

Comparison of the response of rat testis and accessory sex organs to treatment with testosterone and the synthetic androgen methyltrienolone (R1881). van Roijen JH, et al. **J Androl** 1997 Jan-Feb;18(1):51–61

Clinical potential of new antiestrogens. Gradishar WJ, et al. **J Clin Oncol** 1997 Feb;15(2):840–52 (138 ref.)

Enhancement of gp130-mediated tyrosine phosphorylation of STAT3 and its DNA-binding activity in dexamethasone-treated AIDS-associated Kaposi's sarcoma cells: selective synergy between dexamethasone and gp130-related growth factors in Kaposi's sarcoma cell proliferation. Murakami-Mori K, et al. **J Immunol** 1997 Jun 1;158(11):5518–26

Angiogenic response of MCF7 human breast cancer to hormonal treatment: assessment by dynamic GdDTPA-enhanced MRI at high spatial resolution. Furman-Haran E, et al. **J Magn Reson Imaging** 1996 Jan-Feb;6(1):195–202

Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. Guthrie N, et al. **J Nutr** 1997 Mar; 127(3):544S–548S

Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Jordan VC. **J Womens Health** 1997 Aug;6(4):486–7

The adjuvant effect of oxytocin on GnRH analogue buserelin. Heberal A, et al. **JPMA J Pak Med Assoc** 1996 Jun;46(6):134–5

Dexamethasone inhibits glioma-induced formation of capillary like structures in vitro and angiogenesis in vivo. Wolff JE, et al. **Klin Padiatr** 1997 Jul-Aug;209(4):275–7

Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Weller M, et al. **Neurology** 1997 Jun;48(6):1704–9

Effects of OK-432 (picibanil) on the estrogen receptors of MCF-7 cells and potentiation of antiproliferative effects of tamoxifen in combination with OK-432. Aoyagi H, et al. **Oncology** 1997 Sep-Oct;54(5):414–23

Effect of tamoxifen on pS2 expression in human breast cancers. Motomura K, et al. **Oncology** 1997 Sep-Oct; 54(5):424–8

Tamoxifen's impact on the management of breast cancer: the oncologist's perspective. Glick JH, et al. **Oncology (Huntingt)** 1997 Feb;11(2 Suppl 1):49–54 (5 ref.)

Interaction of tamoxifen's impact on overall net mortality and quality of life. Ragaz J. **Oncology (Huntingt)** 1997 Feb; 11(2 Suppl 1):45–8 (22 ref.)

Clinical relevance of laboratory and animal data on tamoxifen. Swenberg JA. **Oncology (Huntingt)** 1997 Feb; 11(2 Suppl 1):39–44 (43 ref.)

Activation of signal transduction kinases by tamoxifen. Duh JL, et al. **Pharm Res** 1997 Feb;14(2):186–9

Tamoxifen prevents sulpiride-induced weight gain in female rats. Baptista T, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):215–22

Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Cohen CJ. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-55–S1-64 (61 ref.)

Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Gallo MA, et al. **Semin Oncol** 1997 Feb; 24(1 Suppl 1):S1-71–S1-80 (72 ref.)

Oestrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antioestrogens. de Cupis A, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):245–51 (69 ref.)

Testosterone release in intact male dogs following the injection of a GnRH analogue. Munro EA, et al. **Vet Rec** 1996 Jul 27;139(4):96

[Androgen test: comparison of a low test and a high test in the development of the penis in male pseudohermaphroditism] Wakim S, et al. **Arch Pediatr** 1996 Dec;3(12):1225–8 (Eng. Abstr.) **(Fre)**

[Does interferon-alpha enhance the effect of tamoxifen-medroxyprogesterone acetate and hydroxyflutamide on in vitro tumor cells? Werner A, et al. **Zentralbl Gynakol** 1996;118(11):616–21 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Proceedings of the Nordic Ciba Cancer Care Workshop on Advanced Breast Cancer. Stockholm, 18–19 January 1996. **Acta Oncol** 1996;35 Suppl 5:1–102

Endocrine treatment of advanced breast cancer. Dowsett M. **Acta Oncol** 1996;35 Suppl 5:68–72 (32 ref.)

Second-line endocrine treatment of advanced breast cancer--a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide. Hultborn R, et al. **Acta Oncol** 1996;35 Suppl 5:75

Novel endocrine therapies in breast cancer. Klijn JG, et al. **Acta Oncol** 1996;35 Suppl 5:30–7 (90 ref.)

Analysis of adjuvant treatment in postmenopausal patients with stage II invasive breast carcinoma--a pattern of care study and quality assurance of 431 consecutive patients in Oslo 1980–1989. Raabe NK, et al. **Acta Oncol** 1997; 36(3):255–60

Proper sequence of endocrine therapies in advanced breast cancer. Rose C. **Acta Oncol** 1996;35 Suppl 5:44–9 (14 ref.)

Induction chemotherapy with versus without hormonal synchronisation in locally advanced breast cancer. Sjövall MP, et al. **Acta Oncol** 1997;36(2):207–12

Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. Lundin P, et al. **AJNR Am J Neuroradiol** 1997 Apr;18(4):765–72

Phase II trial of decapeptyl (D-TRP-6), a potent luteinizing hormone-releasing hormone analogue in untreated advanced breast cancer. Garcia-Giralt E, et al. **Am J Clin Oncol** 1996 Oct;19(5):455–8

Treatment of metastatic carcinoma of the prostate. Goethuys H, et al. **Am J Clin Oncol** 1997 Feb;20(1):40–5 (47 ref.)

Megestrol acetate in the treatment of hormone refractory prostate cancer. Osborn JL, et al. **Am J Clin Oncol** 1997 Jun;20(3):308–10

Treatments with tamoxifen and an antiestradiol antibody have beneficial effects on experimental SLE via cytokine modulation. Sthoeger Z, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:367–8

Oral idarubicin and prednisone for advanced, previously untreated, multiple myeloma: a pilot study. Cooperative Group of Study and Treatment of Multiple Myeloma [letter] Brugnatelli S, et al. **Ann Oncol** 1996 Jul;7(5):537–8

The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study [see comments] Chang J, et al. **Ann Oncol** 1996 Sep;7(7):671–5 . Comment in: Ann Oncol 1996 Sep;7(7):655–6.

Aromatase inhibitors come of age [editorial] Dowsett M. **Ann Oncol** 1997 Jul;8(7):631–2

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer [see comments] Falkson CI, et al. **Ann Oncol** 1996 Jul;7(5):465–9. Comment in: Ann Oncol 1996 Jul;7(5):433–7.

The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group [see comments] Marini G, et al. **Ann Oncol** 1996 Mar;7(3):245–50. Comment in: Ann Oncol 1996 Aug;7(6):643.

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88 [see comments] Thürlimann B, et al. **Ann Oncol** 1996 Jul;7(5):471–9. Comment in: Ann Oncol 1996 Jul;7(5):433–7.

Octreotide in the management of treatment-related diarrhoea. Baillie-Johnson HR. **Anticancer Drugs** 1996 Jan; 7 Suppl 1:11–5 (43 ref.)

Octreotide therapy in carcinoid disease. Bax ND, et al. **Anticancer Drugs** 1996 Jan;7 Suppl 1:17–22 (35 ref.)

Therapeutic potential of octreotide in the treatment of liver metastases. Davies N, et al. **Anticancer Drugs** 1996 Jan;7 Suppl 1:23–31 (41 ref.)

Octreotide in malignant intestinal obstruction. Pandha HS, et al. **Anticancer Drugs** 1996 Jan;7 Suppl 1:5–10 (23 ref.)

Immunotherapy of the SL2-5 murine lymphoma with natural killer cells and tamoxifen or toremifene. Baral E, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):77–83

Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy. Behrakis P, et al. **Anticancer Res** 1997 May-Jun; 17(3A):1517–8

Antitumor and chemopreventive effects of a clomiphene analog, MDL 103,323, in mammary carcinoma. Bitonti AJ, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2553–7

Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up. Lee F, et al. **Anticancer Res** 1997 May-Jun; 17(3A):1511–5

Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy. Lee F, et al. **Anticancer Res** 1997 May-Jun; 17(3A):1507–10

Use of somatostatin analogue in management of a thyrotrophin secreting pituitary adenoma [letter] Stiles MK, et al. **Aust N Z J Med** 1996 Feb;26(1):122–3

Primary treatment of a combined somatotropin- and thyrotropin-secreting pituitary tumour with octreotide [letter] Walsh JP, et al. **Aust N Z J Med** 1996 Feb; 26(1):124–5

Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience. **Aust N Z J Obstet Gynaecol** 1996 Feb;36(1):55–60

Pregnancy during gonadotrophin-releasing hormone agonist therapy. Uncu G, et al. **Aust N Z J Obstet Gynaecol** 1996 Nov;36(4):484–5

Removal of fibromyomas by laparoscopic surgery after preoperative GnRH analogue--an alternative to abdominal hysterectomy or myomectomy. Wood C, et al. **Aust N Z J Obstet Gynaecol** 1996 Nov;36(4):464–8

Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Lien EA, et al. **Biochem Soc Trans** 1997 Feb;25(1):33–5 (19 ref.)

Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Puthier D, et al. **Blood** 1996 Dec 15;88(12):4659–66

Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy [letter; comment] Benson JR, et al. **Br J Cancer** 1997; 75(5):776–8. Comment on: Br J Cancer 1996 Aug;74(3):474–8.

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Geisler J, et al. **Br J Cancer** 1996 Oct; 74(8):1286–91

A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. Lissoni P, et al. **Br J Cancer** 1996 Nov;74(9):1466–8

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Saarto T, et al. **Br J Cancer** 1997; 75(4):602–5

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Soubeyran I, et al. **Br J Cancer** 1996 Oct; 74(7):1120–5

Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study [letter; comment] Ikomi AA, et al. **Br J Obstet Gynaecol** 1997 Mar;104(3):385–6. Comment on: Br J Obstet Gynaecol 1996 Sep;103(9):909–14.

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. **Br J Urol** 1997 Feb; 79(2):235–46

Prostatic carcinoma presenting as a huge intravesical mass after subcapsular prostatectomy for benign prostatic hyperplasia: an unusual manifestation. Enomoto Y, et al. **Br J Urol** 1996 Nov;78(5):798–9

The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate. Evans CP, et al. **Br J Urol** 1996 Sep;78(3):426–31

A 3-year follow-up of patients with localized prostate cancer operated on with or without pre-treatment with the GnRH-agonist triptorelin. Hellström M, et al. **Br J Urol** 1996 Sep;78(3):432–6

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Kreis W, et al. **Br J Urol** 1997 Feb; 79(2):196–202

Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. Schmeller N, et al. **Br J Urol** 1997 Feb; 79(2):226–34

An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Crump M, et al. **Breast Cancer Res Treat** 1997 Jul; 44(3):201–10

Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. Hirvikoski PP, et al. **Breast Cancer Res Treat** 1997 Jul;44(3):269–74

Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. Kuss JT, et al. **Breast Cancer Res Treat** 1997 Feb;42(3):265–74

Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. McClelland RA, et al. **Breast Cancer Res Treat** 1996;41(1):31–41

Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Morales M, et al. **Breast Cancer Res Treat** 1996;40(3):265–70

The rise of tamoxifen: temporal and geographical trends of tamoxifen use in Ontario. Palda VA, et al. **Breast Cancer Res Treat** 1997 Mar;43(1):33–41

A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Sawka CA, et al. **Breast Cancer Res Treat** 1997 Jul;44(3):211–5

Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results. Têtu B. **Can J Oncol** 1994 Nov;4 Suppl 1:33–4; discussion 35–6

Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Bu SZ, et al. **Cancer** 1997 May 15;79(10):1944–50

A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Buzdar AU, et al. **Cancer** 1997 Feb 15;79(4):730–9

Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Civantos F, et al. **Cancer** 1995 Apr 1;75(7):1634–41

Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Emons G, et al. **Cancer** 1996 Oct 1;78(7):1452–60

A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Ingle JN, et al. **Cancer** 1997 Jul 15; 80(2):218–24

Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Katsuki Y, et al. **Cancer** 1997 Jan 1;79(1):169–76

Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Kim YB, et al. **Cancer** 1997 Jan 15;79(2):320–7 (38 ref.)

Noncytotoxic drug therapy in children with unresectable desmoid tumors. Lackner H, et al. **Cancer** 1997 Jul 15; 80(2):334–40

Effects of endocrine therapy on the primary lesion in patients with prostate carcinoma as evaluated by endorectal magnetic resonance imaging. Nakashima J, et al. **Cancer** 1997 Jul 15;80(2):237–41

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Schellhammer PF, et al. **Cancer** 1996 Nov 15;78(10):2164–9

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Townsend MF, et al. **Cancer** 1997 Feb 1; 79(3):545–50

The effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in the conservatively treated breast. Wazer DE, et al. **Cancer** 1997 Aug 15;80(4):732–40

High-dose toremifene in advanced renal-cell carcinoma. Gershanovich MM, et al. **Cancer Chemother Pharmacol** 1997;39(6):547–51

A permanently charged tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents. Biegon A, et al. **Cancer Res** 1996 Oct 1; 56(19):4328–31

Therapy for hormone-resistant prostate cancer: no longer a myth. Petrylak DP, et al. **Cancer Treat Res** 1996;88:211–8 (41 ref.)

Aromatase inhibitors and breast cancer. Miller WR. **Cancer Treat Rev** 1997 May;23(3):171–87 (112 ref.)

Exploration for drug therapy in endometrial carcinoma. Zhang X, et al. **Chin Med J (Engl)** 1996 May;109(5):356–60

EGF/EGF-R system and benign breast disease during and following the treatment of gynaecological pathologies with an analogue of LH-RH. Di Lieto A, et al. **Clin Exp Obstet Gynecol** 1996;23(4):220–8

GnRH analogs in treating uterine leiomyomata and endometriosis. Szczurowicz A, et al. **Clin Exp Obstet Gynecol** 1996;23(4):214–9

The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom [editorial] Earl H, et al. **Clin Oncol (R Coll Radiol)** 1997; 9(3):141–3

Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Gibbs SJ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(6):346–52 (44 ref.)

Pulmonary metastases, an occult prostatic adenocarcinoma and delayed administration of antiandrogens. Harris SJ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(2):118–9

Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Vinorelbine: an update and review of activity [letter] Macbeth F. **Clin Oncol (R Coll Radiol)** 1997;9(3):197

Endocrine treatment of breast cancer. Fahey TJ Jr. **Curr Ther Endocrinol Metab** 1997;6:593–8 (7 ref.)

Pap smears of patients on tamoxifen [letter] Gu M, et al. **Diagn Cytopathol** 1997 Jan;16(1):96–7

The role of surgery in patients with advanced midgut carcinoid tumours. Ahlman H. **Digestion** 1996;57 Suppl 1:86–7

The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours. Bajetta E, et al. **Digestion** 1996;57 Suppl 1:72–6 (11 ref.)

The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. Eriksson B, et al. **Digestion** 1996;57 Suppl 1:77–80

Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours. Faiss S, et al. **Digestion** 1996;57 Suppl 1:84–5

Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disorders. Friess H, et al. **Digestion** 1996;57 Suppl 1:97–102

Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Wiseman LR, et al. **Drugs** 1997 Jul;54(1):141–60 (117 ref.)

Effects of chlormadinone acetate and ethinylestradiol treatment on epididymal 5 alpha-reductase activities in patients with prostate cancer. Nukui F. **Endocr J** 1997 Feb; 44(1):127–32

A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Stuart NS, et al. **Eur J Cancer** 1996 Oct;32A(11):1888–92

Locally advanced breast cancer: early results of a randomised trial of multimodal therapy versus initial hormone therapy. Willsher PC, et al. **Eur J Cancer** 1997 Jan;33(1):45–9

Remission of a chemotherapy resistant tumor of low malignant potential with tamoxifen. Llerena E, et al. **Eur J Gynaecol Oncol** 1997;18(1):23–5

Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer. Marinaccio M, et al. **Eur J Gynaecol Oncol** 1996;17(4):286–8

Metastatic breast carcinoma manifesting as postmenopausal uterine bleeding in a patient on tamoxifen therapy. Maymon R, et al. **Eur J Gynaecol Oncol** 1996;17(4):319–21

Treatment of idiopathic retroperitoneal fibrosis by tamoxifen. Tonietto G, et al. **Eur J Surg** 1997 Mar;163(3):231–5

Protective effect of leuprolide acetate on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis in rats. Inada K, et al. **Eur J Surg Oncol** 1996 Dec;22(6):583–7

Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Blackledge GR, et al. **Eur Urol** 1997;31 Suppl 2:30–9 (44 ref.)

The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer. Chao D, et al. **Eur Urol** 1997;31(1):7–10

DNA ploidy patterns in androgen-deprived localized prostate cancer. Hellström M, et al. **Eur Urol** 1996; 29(4):420–4

The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Hugosson J, et al. **Eur Urol** 1996;29(4):413–9

Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Imada S, et al. **Eur Urol** 1997;31(3):360–4

Antiandrogen monotherapy in the management of advanced prostate cancer. Kaisary AV. **Eur Urol** 1997;31 Suppl 2:14–9; discussion 24–7

Prognostic significance of prostate-specific antigen levels two months after hormonal manipulation of metastatic prostate cancer. Kawakami S, et al. **Eur Urol** 1997; 32(1):58–63

Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. Lissoni P, et al. **Eur Urol** 1997;31(2):178–81

Combined androgen blockade: the gold standard for metastatic prostate cancer. McLeod DG, et al. **Eur Urol** 1997;32 Suppl 3:70–7 (43 ref.)

A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Thorpe SC, et al. **Eur Urol** 1996;29(1):47–54

Progress in complete androgen blockade. Trachtenberg J. **Eur Urol** 1997;31 Suppl 2:8–10; discussion 24–7

Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Wechsel HW, et al. **Eur Urol** 1996;30 Suppl 1:7–14; discussion 19–21

Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia. Wheeler TM. **Eur Urol** 1996; 30(2):261–4 (20 ref.)

Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata. Deligdisch L, et al. **Fertil Steril** 1997 May;67(5):837–41

Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a large randomized, double-blind study. Donnez J, et al. **Fertil Steril** 1997 Jul; 68(1):29–36

Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. Cascinu S, et al. **Gastroenterology** 1997 Sep;113(3):767–72

Uterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy. Kuhlmann M, et al. **Gynecol Endocrinol** 1997 Jun;11(3):169–74

Ovarian volume in postmenopausal breast cancer patients treated with tamoxifen. Cohen I, et al. **Gynecol Oncol** 1997 Jan;64(1):105–8

Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens. Cohen I, et al. **Gynecol Oncol** 1997 Apr;65(1):83–8

A phase II study of leuprolide in advanced/recurrent endometrial cancer. Covens A, et al. **Gynecol Oncol** 1997 Jan;64(1):126–9

Leuprolide in the treatment of endometrial cancer [letter] Markman M, et al. **Gynecol Oncol** 1997 Sep;66(3):542

Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line. Shibata S, et al. **Gynecol Oncol** 1997 Aug;66(2):217–21

Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Tepper R, et al. **Gynecol Oncol** 1997 Mar;64(3):386–91

The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas. Horimi T, et al. **Hepatogastroenterology** 1996 Sep-Oct;43(11):1225–9

The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group. Gerris J, et al. **Horm Res** 1996;45(6):279–84

Sex hormones in postmenopausal women with breast cancer on tamoxifen. Kostoglou-Athanassiou I, et al. **Horm Res** 1997;47(3):116–20

GnRH agonists: an alternative to surgery? Maheux R. **Hum Reprod** 1996 Nov;11 Suppl 3:43–50

Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Ellis PA, et al. **Int J Cancer** 1997 Aug 7;72(4):608–13

Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Lindner DJ, et al. **Int J Cancer** 1997 May 2;71(3):456–61

Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Pantel K, et al. **Int J Cancer** 1997 May 16;71(4):521–5

Histology of leiomyomata in patients treated with leuprolide acetate. Demopoulos RI, et al. **Int J Gynecol Pathol** 1997 Apr;16(2):131–7

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer [see comments] Laverdière J, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):247–52. Comment in: Int J Radiat Oncol Biol Phys 1997 Jan 15;37(2):245–6.

Preoperative endocrine therapy for clinical stage A2, B, and C prostate cancer: an interim report on short-term effects. Prostate Cancer Study Group. Homma Y, et al. **Int J Urol** 1997 Mar;4(2):144–51

Role of steroid in childhood haemangioma: a 10 years review. Gangopadhyay AN, et al. **Int Surg** 1997 Jan–Mar; 82(1):49–51

A patient with acromegaly who showed remarkable improvement of hyperglycemia after treatment with octreotide [see comments] Hirose T, et al. **Intern Med** 1997 May;36(5):345–50. Comment in: Intern Med 1997 May;36(5):319–20.

Divergent effects of octreotide on glucose tolerance in patients with acromegaly [editorial; comment] Hizuka N. **Intern Med** 1997 May;36(5):319–20. Comment on: Intern Med 1997 May;36(5):345–50.

Octreotide as first-line treatment for women with metastatic breast cancer. Ingle JN, et al. **Invest New Drugs** 1996; 14(2):235–7

Patient treatment preference in metastatic prostate cancer [editorial] Creagh T. **Ir Med J** 1996 Jan–Feb;89(1):12

A pituitary mass and hypopituitarism: improvement after corticosteroid therapy. Shimon I, et al. **Isr J Med Sci** 1997 Jan;33(1):58–62 (28 ref.)

Treatment of submucous fibroids, and outcome of assisted conception. Narayan R, et al. **J Am Assoc Gynecol Laparosc** 1994 Aug;1(4 Pt 1):307–11

Octreotide and ketoconazole for persistent ectopic ACTH Cushing's disease due to mediastinal carcinoid. Parthiban A, et al. **J Assoc Physicians India** 1995 Feb;43(2):140

Octreotide combined with goserelin in the therapy of advanced pancreatic cancer—results of a pilot study and review of the literature. Fazeny B, et al. **J Cancer Res Clin Oncol** 1997;123(1):45–52 (39 ref.)

Long-term suppression of testosterone after treatment with a gonadotropin-releasing hormone agonist in a woman with a presumed testosterone secreting ovarian tumor. Barnes RB, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1746–8

Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. International Breast Cancer Study Group. **J Clin Oncol** 1997 Apr;15(4):1385–94

Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. Byrne MJ, et al. **J Clin Oncol** 1997 Sep;15(9):3141–8

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Carlomagno C, et al. **J Clin Oncol** 1996 Oct;14(10):2702–8

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. Elledge RM, et al. **J Clin Oncol** 1997 May;15(5):1916–22

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy [see comments] Kuukasjärvi T, et al. **J Clin Oncol** 1996 Sep; 14(9):2584–9. Comment in: J Clin Oncol 1997 Feb;15(2):862.

Response to commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients [letter; comment] Patterson JS, et al. **J Clin Oncol** 1996 Oct;14(10):2886–7 . Comment on: J Clin Oncol 1996 Mar;14(3):1027–39.

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. Pilepich MV, et al. **J Clin Oncol** 1997 Mar;15(3):1013–21

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Scher HI, et al. **J Clin Oncol** 1997 Aug;15(8):2928–38

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. Yamauchi H, et al. **J Clin Oncol** 1997 Jul;15(7):2518–25

Ultrastructural study of anti-tumor effects of tamoxifen in two malignant melanoma patients. Hirota T. **J Dermatol** 1997 Jul;24(7):441–50

The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma. Vainas G, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):119–26

Coronary heart disease mortality and adjuvant tamoxifen therapy [see comments] Costantino JP, et al. **J Natl Cancer Inst** 1997 Jun 4;89(11):776–82. Comment in: J Natl Cancer Inst 1997 Jun 4;89(11):747–9.

Tamoxifen: the herald of a new era of preventive therapeutics [editorial; comment] Jordan VC. **J Natl Cancer Inst** 1997 Jun 4;89(11):747–9. Comment on: J Natl Cancer Inst 1997 Jun 4;89(11):776–82.

Early changes in peritumorous oedema and contralateral white matter after dexamethasone: a study using proton magnetic resonance spectroscopy. Chumas P, et al. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):590–5

Estramustine in malignant glioma. Bergenheim AT, et al. **J Neurooncol** 1996 Oct;30(1):81–9 (79 ref.)

Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen. Cloughesy TF, et al. **J Neurooncol** 1997 Oct;35(1):39–45

The Breast Cancer Prevention Trial: evaluating tamoxifen's efficacy in preventing breast cancer. McKeon VA. **J Obstet Gynecol Neonatal Nurs** 1997 Jan–Feb;26(1):79–90 (62 ref.)

Palliative steroid therapy and serum interleukin-6 levels in a patient with lung cancer. Yanagawa H, et al. **J Pain Symptom Manage** 1996 Sep;12(3):195–8

Hepatic resection enhances growth of residual intrahepatic and subcutaneous hepatoma, which is inhibited by octreotide. Schindel DT, et al. **J Pediatr Surg** 1997 Jul; 32(7):995–7; discussion 997–8

Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer. Wasan KM, et al. **J Pharm Sci** 1997 Jul;86(7):876–9

GnRH agonists before surgery for uterine leiomyomas. A review [see comments] Crosignani PG, et al. **J Reprod Med** 1996 Jun;41(6):415–21 (38 ref.). Comment in: J Reprod Med 1997 Apr;42(4):253.

Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. Fishman A, et al. **J Reprod Med** 1996 Jun;41(6):393–6

Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens. Hansen LM, et al. **J Reprod Med** 1997 Apr;42(4):247–50

Decrease in the size of ovarian endometriomas during ovarian suppression in stage IV endometriosis. Role of preoperative medical treatment. Rana N, et al. **J Reprod Med** 1996 Jun; 41(6):384–92

Leuprolide acetate in advanced ovarian serous tumor of low malignant potential. A case report. Tresukosol D, et al. **J Reprod Med** 1996 May;41(5):363–6

Evaluation of somatostatin analogues for the detection and treatment of gastrinoma in a dog. Altschul M, et al. **J Small Anim Pract** 1997 Jul;38(7):286–91

Large Shionogi tumors lose their responsiveness to flutamide treatment. Chen C, et al. **J Steroid Biochem Mol Biol** 1996 Aug;58(5–6):489–94

Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate? [see comments] Datta SN, et al. **J Urol** 1997 Jul;158(1):175–7. Comment in: J Urol 1997 Jul;158(1):178.

Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not? Drew PA, et al. **J Urol** 1997 Jun;157(6):2201–5

Prostate specific antigen in black and white men after hormonal therapies for prostate cancer. Fowler JE, et al. **J Urol** 1997 Jul;158(1):150–4

Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. Iversen P, et al. **J Urol** 1997 Mar; 157(3):929–34

Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate [see comments] Smith JA Jr, et al. **J Urol** 1997 Apr;157(4):1329–34. Comment in: J Urol 1997 Apr;157(4):1335–6.

Quantitative MRI of uterine leiomyomas during triptorelin treatment: reproducibility of volume assessment and predictability of treatment response. Broekmans FJ, et al. **Magn Reson Imaging** 1996;14(10):1127–35

Pseudocarcinoid syndrome associated with hypogonadism and response to testosterone therapy. Shakir KM, et al. **Mayo Clin Proc** 1996 Dec;71(12):1145–9

Successful management with interferon alpha-2a after prednisone therapy failure in an infant with a giant cavernous hemangioma. Castello MA, et al. **Med Pediatr Oncol** 1997 Mar;28(3):213–5

Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma—a pilot study. Bernengo MG, et al. **Melanoma Res** 1996 Jun; 6(3):257–65

The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia. Levine AC, et al. **Mt Sinai J Med** 1997 Jan;64(1):20–5

Prostate cancer—the therapeutic challenge of locally advanced disease [editorial; comment] Blasko JC, et al. **N Engl J Med** 1997 Jul 31;337(5):340–1. Comment on: N Engl J Med 1997 Jul 31;337(5):295–300.

Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [see comments] Bolla M, et al. **N Engl J Med** 1997 Jul 31; 337(5):295–300. Comment in: N Engl J Med 1997 Jul 31;337(5):340–1.

Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone [published erratum appears in N Engl J Med 1997 Apr 3;336(14):1039] Palmieri G, et al. **N Engl J Med** 1997 Jan 23;336(4):263–5

Systemic adjuvant therapy for breast cancer. Reed EC. **Nebr Med J** 1996 Mar;81(3):48–50 (17 ref.)

Tamoxifen as primary treatment of breast cancer in elderly patients. Ciatto S, et al. **Neoplasma** 1996;43(1):43–5

Tamoxifen, balancing risks and benefits. Bergman L, et al. **Neth J Med** 1996 Dec;49(6):228–34 (33 ref.)

Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women [news] Hannaford M. **Nurse Pract** 1997 Mar;22(3):195–6, 201–2 (21 ref.)

A phase II study of flutamide in ovarian cancer. Vassilomanolakis M, et al. **Oncology** 1997 May–Jun; 54(3):199–202

Role for androgen withdrawal prior to radiation and surgery for prostate cancer? [news] **Oncology (Huntingt)** 1997 May; 11(5):738

Phase III trials of toremifene vs tamoxifen. Gams R. **Oncology (Huntingt)** 1997 May;11(5 Suppl 4):23–8 (0 ref.)

High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. Gershanovich M, et al. **Oncology (Huntingt)** 1997 May;11(5 Suppl 4):29–36

Phase I and II studies of toremifene. Hamm JT. **Oncology (Huntingt)** 1997 May;11(5 Suppl 4):19–22 (12 ref.)

Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer. Hietanen T, et al. **Oncology (Huntingt)** 1997 May;11(5 Suppl 4):37–40

Evolving role of toremifene in the adjuvant setting. Holli K. **Oncology (Huntingt)** 1997 May;11(5 Suppl 4):48–51

Tamoxifen treatment for breast cancer: concept to gold standard. Jordan VC. **Oncology (Huntingt)** 1997 Feb;11(2 Suppl 1):7–13 (51 ref.)

Hormonal therapy of breast cancer: state of the art. Murphy B, et al. **Oncology (Huntingt)** 1997 May;11(5 Suppl 4):7–13 (63 ref.)

Tamoxifen's impact on the management of breast cancer: patient perspectives. Reichman BS. **Oncology (Huntingt)** 1997 Feb;11(2 Suppl 1):55–8 (14 ref.)

Clinical efficacy of tamoxifen. Robert NJ. **Oncology (Huntingt)** 1997 Feb;11(2 Suppl 1):15–20 (41 ref.)

Reliability of estrogen receptors in predicting response to antiestrogens. Valavaara R. **Oncology (Huntingt)** 1997 May; 11(5 Suppl 4):14–8 (49 ref.)

Treatment of relapsed Langerhans cell histiocytosis by cyclosporin A combined with etoposide and prednisone. Körholz D, et al. **Pediatr Hematol Oncol** 1997 Sep–Oct; 14(5):443–9

Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer. Kylmälä T, et al. **Pharmacol Toxicol** 1996 Sep;79(3):157–60

Tamoxifen Breast Cancer Prevention Trial—an update. Ford LG, et al. **Prog Clin Biol Res** 1997;396:271–82

Targeted antiestrogens. Tonetti DA, et al. **Prog Clin Biol Res** 1997;396:245–55 (41 ref.)

Liarozole (R75251) in hormone-resistant prostate cancer patients. Dijkman GA, et al. **Prostate** 1997 Sep 15; 33(1):26–31

111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors. Ronga G, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):134–6

External radiation therapy of prostatic carcinoma and its relationship to hormonal therapy. Takada C, et al. **Radiat Med** 1995 Nov–Dec;13(6):297–300

Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies. Duchesne GM, et al. **Radiother Oncol** 1996 Jan;38(1):7–12

Chemohormonal therapy for malignant melanomas of the nasal and paranasal mucosa. Seo W, et al. **Rhinology** 1997 Mar;35(1):19–21

The effect of Buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The "Danish Buserelin Study Group". Bruun E, et al. **Scand J Urol Nephrol** 1996 Aug;30(4):291–7

Cellular changes in prostatic carcinoma after treatment with orchidectomy, estramustine phosphate and medroxyprogesterone acetate. Tomic R, et al. **Scand J Urol Nephrol** 1997 Jun;31(3):255–8

Aromatase inhibitors and breast cancer. Brodie AM, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 9):10–20 (118 ref.)

Aromatase inhibitors in metastatic breast cancer. Buzdar AU, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 9):28–32

Scientific review of tamoxifen. Overview from a medical oncologist. Carlson RW. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-151–S1-7 (19 ref.)

The control of breast cancer: the role of tamoxifen. Forbes JF. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-5–S1-19 (33 ref.)

Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Gelmann EP. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1-65–S1-70 (71 ref.)

Endocrine therapies of breast cancer. Goldhirsch A, et al. **Semin Oncol** 1996 Aug;23(4):494–505 (105 ref.)

Aromatase inhibitors in clinical practice: current status and a look to the future. Harvey HA. **Semin Oncol** 1996 Aug; 23(4 Suppl 9):33–8 (13 ref.)

Aromatase inhibitors in the treatment of advanced breast cancer. Introduction. Osborne CK. **Semin Oncol** 1996 Aug; 23(4 Suppl 9):1

Efficacy of tamoxifen as treatment of breast cancer. Powles TJ. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1–48–S1–54 (50 ref.)

Hormonal approaches to breast cancer treatment and prevention: an overview. Vogel CL. **Semin Oncol** 1996 Aug;23(4 Suppl 9):2–9 (41 ref.)

Aromatase inhibitors: rationale for use following antiestrogen therapy. Yue W, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 9):21–7

Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer? Bilimoria MM, et al. **Semin Surg Oncol** 1996 Sep–Oct;12(5):339–45 (44 ref.)

Endocrinology of melanoma. Neifeld JP. **Semin Surg Oncol** 1996 Nov–Dec;12(6):402–6 (37 ref.)

Estramustine–based chemotherapy. Hudes G. **Semin Urol Oncol** 1997 Feb;15(1):13–9 (47 ref.)

Secondary hormonal therapy. Smith DC. **Semin Urol Oncol** 1997 Feb;15(1):3–12 (95 ref.)

Abnormal vaginal bleeding from endometrial polyps in a woman receiving tamoxifen therapy for breast cancer: report of a case. Fujikawa T, et al. **Surg Today** 1997; 27(8):769–72

Current treatment of advanced prostate cancer. Ismail M, et al. **Tech Urol** 1997 Spring;3(1):16–24 (55 ref.)

Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review. Soderdahl DW, et al. **Tech Urol** 1996 Winter;2(4):194–206 (73 ref.)

Adjuvant hormone therapy after radical prostatectomy: indications and results. Ditonno P, et al. **Tumori** 1997 Mar–Apr;83(2):567–75 (64 ref.)

Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study. Exacoustos C, et al. **Ultrasound Obstet Gynecol** 1995 Dec;6(6):435–42

The use of prostate–specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer. Smith DC, et al. **Urol Clin North Am** 1997 May;24(2):433–7

Combination treatment versus LHRH alone in advanced prostatic cancer. Ferrari P, et al. **Urol Int** 1996;56 Suppl 1:13–7

Clinical study results of the new formulation leuprorelin acetate three–month depot for the treatment of advanced prostate carcinoma. Fornara P, et al. **Urol Int** 1996;56 Suppl 1:18–22

Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group. Kienle E, et al. **Urol Int** 1996;56 Suppl 1:23–30

Effects of androgen deprivation prior to radical prostatectomy in 375 patients. Tunn UW, et al. **Urol Int** 1996;56 Suppl 1:6–12

The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan–Kettering Cancer Center results. Fair WR, et al. **Urology** 1997 Mar;49(3A Suppl):46–55

Three–month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Fernandez del Moral P, et al. **Urology** 1996 Dec;48(6):894–900

Hormonal therapy in the management of prostate cancer: from Huggins to the present. Garnick MB. **Urology** 1997 Mar;49(3A Suppl):5–15 (35 ref.)

First International Conference on Neoadjuvant Hormonal Therapy of Prostate Cancer: overview consensus statement. Garnick MB, et al. **Urology** 1997 Mar;49(3A Suppl):1–4 (0 ref.)

PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group. McLeod DG, et al. **Urology** 1997 Mar;49(3A Suppl):70–3

Assessment of hormone refractory prostate cancer. Newling D, et al. **Urology** 1997 Apr;49(4A Suppl):46–53

Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Reuter VE. **Urology** 1997 Mar;49(3A Suppl):16–22 (31 ref.)

Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Zelefsky MJ, et al. **Urology** 1997 Mar;49(3A Suppl):38–45

Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Zietman AL, et al. **Urology** 1997 Mar;49(3A Suppl):74–83 (43 ref.)

Medical treatment of pituitary–dependent hyperadrenocorticism. Mitotane. Peterson ME, et al. **Vet Clin North Am Small Anim Pract** 1997 Mar; 27(2):255–72 (37 ref.)

Treatment of a dog with an insulinoma–related peripheral polyneuropathy with corticosteroids. Van Ham L, et al. **Vet Rec** 1997 Jul 26;141(4):98–100

[A comparative study of the effect of Zoladex treatment versus orchiectomy in patients with advanced prostatic cancer] Tsvetkov M, et al. **Khirurgiia (Sofiia)** 1996;49(1):5–8 (Eng. Abstr.) **(Bul)**

[The effect of long–term tamoxifen therapy on the occurrence of contralateral primary breast cancer] Xing B, et al. **Chung Hua Chung Liu Tsa Chih** 1996 Mar; 18(2):143–5 (Eng. Abstr.) **(Chi)**

[The roles of tamoxifen in the treatment of pre– and post–menopausal endometrial carcinoma patients] Sun H, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Feb;31(2):83–5 (Eng. Abstr.) **(Chi)**

[Hormonal therapy in the treatment of endometrial adenocarcinoma] Rob L. **Ceska Gynekol** 1996 Aug; 61(4):249–50 **(Cze)**

[Adjuvant tamoxifen treatment in breast cancer: is 5–year treatment sufficient?] Andersson M, et al. **Ugeskr Laeger** 1997 Jun 16;159(25):3968–9 **(Dan)**

[Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial] Delozier T, et al. **Bull Cancer** 1997 Jan;84(1):25–30 (Eng. Abstr.) **(Fre)**

[Tamoxifen and hepatocellular carcinoma: verdict after enthusiasm... (letter)] Barbare JC. **Gastroenterol Clin Biol** 1996;20(6–7):609–10 **(Fre)**

[Comparative effects of transurethral incision (TUIP) and the combination of TUIP and LHRH agonists in the treatment of benign prostatic hypertrophy] Di Silverio F, et al. **J Urol (Paris)** 1996;102(3):111–6 (Eng. Abstr.) **(Fre)**

[Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate] Boccon–Gibod L. **Prog Urol** 1997 Feb;7(1):97–8 (14 ref.) **(Fre)**

[Treatment of advanced kidney cancer using recombinant erythropoietin] Morere JF, et al. **Prog Urol** 1997 Jun; 7(3):399–402 (Eng. Abstr.) **(Fre)**

[Effectiveness and tolerance of three month sustained release leuprorelin in the treatment of metastatic prostatic cancer (comparative, randomized, multicentric study] Zerbib M, et al. **Prog Urol** 1997 Apr;7(2):246–53 (Eng. Abstr.) **(Fre)**

[Prediction of pharmacological effect of octreotide in acromegaly by means of 111In–pentetreotide scintigraphy and calculation of a pituitary uptake index] Görges R, et al. **Nuklearmedizin** 1997 Jun;36(4):117–24 (Eng. Abstr.) **(Ger)**

[Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities] du Bois A, et al. **Zentralbl Gynakol** 1997;119(7):299–323 (330 ref.) (Eng. Abstr.) **(Ger)**

[Echography and follow–up of prostate carcinoma: "follow up echography in the course of drug therapy"] Martino P, et al. **Arch Ital Urol Androl** 1996 Dec;68(5 Suppl):37–42 (10 ref.) (Eng. Abstr.) **(Ita)**

[Neoadjuvant combined hormonal therapy and radiotherapy with external beam irradiation in prostatic carcinoma] Cellini N, et al. **Radiol Med (Torino)** 1997 Apr;93(4):446–50 (Eng. Abstr.) **(Ita)**

[Combination therapy with hormonal, radiation and chemotherapy for stage C prostate cancer] Iwasawa T, et al. **Hinyokika Kiyo** 1996 Nov;42(11):869–74 (Eng. Abstr.) **(Jpn)**

[Luteinizing hormone–releasing hormone for prostate cancer in a hemodialysis patient: a case report] Mizusawa H, et al. **Hinyokika Kiyo** 1997 Jun;43(6):421–3 (Eng. Abstr.) **(Jpn)**

[Effect of estramustine phosphate on hormone refractory prostate cancer] Tanaka M, et al. **Hinyokika Kiyo** 1997 Mar;43(3):245–50 (Eng. Abstr.) **(Jpn)**

[A high CEA level in a case of Cronkhite–Canada syndrome, showing decrease by prednisolone treatment] Fukazawa M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Aug; 94(8):543–8 (18 ref.) **(Jpn)**

[Is there a basis for prevention of breast cancer with drugs?] Klemetsdal B. **Tidsskr Nor Laegeforen** 1997 Apr 20; 117(10):1493–5 (Eng. Abstr.) **(Nor)**

[GnRH analogs for treatment of ovarian cancer] Kośmider M. **Ginekol Pol** 1996 Oct;67(10):499–503 (Eng. Abstr.) **(Pol)**

[Results of tamoxifen treatment in patients with advanced breast cancer] Rolski J, et al. **Pol Merkuriusz Lek** 1996 Oct;1(4):271–3 (Eng. Abstr.) **(Pol)**

[Zoladex (ICI) in the therapy of prostatic cancer patients] Popko AS, et al. **Urol Nefrol (Mosk)** 1996 Nov–Dec; (6):53–5 (40 ref.) **(Rus)**

[Parameters of estrogen expression in patients with endometrial tumors as prognostic signs of the effectiveness of neoadjuvant antitumor hormone therapy] Ermakova NA, et al. **Vopr Onkol** 1996;42(5):56–60 (Eng. Abstr.) **(Rus)**

[Hormone therapy of advanced renal cancer with high–dose toremifene (Fareston)] Gershanovich ML, et al. **Vopr Onkol** 1996;42(5):105–9 (Eng. Abstr.) **(Rus)**

[Experimental study of the antitumor properties of acetomepregenol] Korkhov VV. **Vopr Onkol** 1997; 43(3):317–20 (Eng. Abstr.) **(Rus)**

[Current hormone therapy of prostate cancer] Perevodchikova NI, et al. **Vopr Onkol** 1996;42(4):7–11 (11 ref.) **(Rus)**

[New methods in the treatment of breast cancer] Semiglazov VF. **Vopr Onkol** 1997;43(1):22–6 (Eng. Abstr.) **(Rus)**

[Postoperative hormone therapy of breast cancer (analysis of overall survival)] Semiglazov VF, et al. **Vopr Onkol** 1996;42(6):37–42 (Eng. Abstr.) **(Rus)**

[Neovir, an interferon inductor, modifies expression of steroid hormone receptors in hormone–dependent tissues and restores sensitivity to tamoxifen in patients with inoperable breast cancer] Surkov KG, et al. **Vopr Onkol** 1996; 42(6):28–32 (Eng. Abstr.) **(Rus)**

[Tamoxifen: modern drug therapy of estrogen–dependent breast tumors] Jovanović–Mićić D, et al. **Med Pregl** 1996; 49(7–8):287–90 (20 ref.) (Eng. Abstr.) **(Scr)**

[Effect of complete androgen block before radical prostatectomy for cancer of the prostate] Gómez Veiga F, et al. **Arch Esp Urol** 1997 May;50(4):355–63 (Eng. Abstr.) **(Spa)**

[Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy] Villavicencio Mavrich H, et al. **Arch Esp Urol** 1996 Oct;49(8):797–806 (Eng. Abstr.) **(Spa)**

[The therapeutic applications of octreotide] Carrera–Hueso FJ, et al. **Med Clin (Barc)** 1996 Apr 6;106(13):505–16 (239 ref.) **(Spa)**

[Reduction of upper airway obstruction in a patient with acromegaly treated with octreotide (letter)] Rojas I, et al. **Med Clin (Barc)** 1996 Feb 3;106(4):158 **(Spa)**

TOXICITY

The role of cell death and cell proliferation in the promotion of rat liver tumours by tamoxifen. Carthew P, et al. **Cancer Lett** 1996 Sep 10;106(2):163–9

A two–year dietary carcinogenicity study of the antiestrogen toremifene in Sprague–Dawley rats. Karlsson S, et al. **Drug Chem Toxicol** 1996 Nov;19(4):245–66

Adducts and tamoxifen. Busch H. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1–98–S1–104 (37 ref.)

Relevance of rat liver tumors to human hepatic and endometrial cancer. Guzelian PS. **Semin Oncol** 1997 Feb; 24(1 Suppl 1):S1–105–S1–21 (130 ref.)

Review of the toxicology of tamoxifen. Wogan GN. **Semin Oncol** 1997 Feb;24(1 Suppl 1):S1–87–S1–97 (36 ref.)

[Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines] Bachmann–Moisson N, et al. **Bull Cancer** 1996 Oct;83(10):808–15 (37 ref.) (Eng. Abstr.) **(Fre)**

ANTINEOPLASTIC AGENTS, PHYTOGENIC

Camptothecin. Discovery to clinic. Wall ME, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:1–12 (28 ref.)

Rationale for the dosage and schedule of CPT–11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Armand JP, et al. **Ann Oncol** 1996 Oct; 7(8):837–42

Vinorelbine: an update and review of activity. Johnson SA. **Clin Oncol (R Coll Radiol)** 1996;8(6):353–7 (60 ref.)

Irinotecan (CPT–11): pharmacology and clinical applications. Masuda N, et al. **Crit Rev Oncol Hematol** 1996 Sep; 24(1):3–26 (114 ref.)

The clinical status of irinotecan (CPT–11), a novel water soluble camptothecin analogue: 1996. O'Reilly S, et al. **Crit Rev Oncol Hematol** 1996 Sep;24(1):47–70 (206 ref.)

Camptothecin and taxol: from discovery to clinic. Wall ME, et al. **J Ethnopharmacol** 1996 Apr;51(1–3):239–53; discussion 253–4

Effect of CPT–11 on lipid peroxide level in mouse tissues. Sadzuka Y, et al. **Jpn J Cancer Res** 1997 May;88(5):512–6

Taxanes from in vitro cultures of the Himalayan yew Taxus wallichiana. Banerjee S, et al. **Planta Med** 1996 Aug; 62(4):329–31

Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Cragg GM, et al. **Semin Oncol** 1997 Apr;24(2):156–63 (22 ref.)

The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute. Donehower RC. **Stem Cells** 1996 Jan; 14(1):25–8 (2 ref.)

[Development of a new tubulin–interacting agent, docetaxel (taxotere) in Japan] Tsukagoshi S. **Gan To Kagaku Ryoho** 1997 Jul;24(9):1167–74 (14 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Attivissimo LA, et al. **Am J Clin Oncol** 1996 Dec;19(6):581–3

Phase II study of estramustine, oral etoposide, and vinorelbine in hormone–refractory prostate cancer. Colleoni M, et al. **Am J Clin Oncol** 1997 Aug;20(4):383–6

Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III–B non–small–cell lung cancer patients. Felip E, et al. **Am J Clin Oncol** 1997 Aug; 20(4):404–6

Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP–16 with G–CSF support in extensive small cell lung cancer. Gridelli C, et al. **Am J Clin Oncol** 1996 Dec;19(6):589–91

Gonadal function following ABVD therapy for Hodgkin's disease. Kulkarni SS, et al. **Am J Clin Oncol** 1997 Aug; 20(4):354–7

Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non–small cell lung cancer. Nakanishi Y, et al. **Am J Clin Oncol** 1997 Aug;20(4):393–7

Prolonged infusion of etoposide in patients with advanced non-small cell lung cancer. Robert F, et al. **Am J Clin Oncol** 1996 Oct;19(5):483–6

Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma. Vallejo C, et al. **Am J Clin Oncol** 1996 Dec;19(6):584–8

Appropriateness of maximum-dose guidelines for vincristine. McCune JS, et al. **Am J Health Syst Pharm** 1997 Aug 1; 54(15):1755–8

The development of a novel intraperitoneal tumor-seeding prophylactic. Demetrick JS, et al. **Am J Surg** 1997 May; 173(5):403–6

Schedule-dependent efficacy of camptothecins in models of human cancer. Houghton PJ, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:188–201

Paclitaxel (Taxol) for the treatment of lymphoma. Younes A, et al. **Ann Oncol** 1997;8 Suppl 1:129–31

Paclitaxel formulation as a cause of ethanol intoxication. Wilson DB, et al. **Ann Pharmacother** 1997 Jul–Aug; 31(7–8):873–5

Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units. Raymond E, et al. **Anticancer Drugs** 1997 Apr;8(4):379–85

Pharmacokinetic study of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate after targeted delivery to the lung in mice. Sato H, et al. **Biol Pharm Bull** 1996 Dec; 19(12):1596–601

A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Dunphy FR, et al. **Cancer** 1997 May 15; 79(10):2016–23

Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Tester WJ, et al. **Cancer** 1997 Feb 15;79(4):724–9

Influence of route of administration on [3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies. Ahmed AE, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):122–30

The significance of the sequence of administration of topotecan and etoposide. Bonner JA, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):109–12

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer. Planting A, et al. **Cancer Chemother Pharmacol** 1997;40(4):347–52

The effects of food and divided dosing on the bioavailability of oral vinorelbine. Rowinsky EK, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):9–16

A feasibility study of 1-h paclitaxel infusion in patients with solid tumors. Tsavaris N, et al. **Cancer Chemother Pharmacol** 1997;40(4):353–7

Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Webster LK, et al. **Cancer Chemother Pharmacol** 1997;39(6):557–60

An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Zhang X, et al. **Cancer Chemother Pharmacol** 1997;40(1):81–6

Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Sharma A, et al. **Cancer Lett** 1996 Oct 22;107(2):265–72

Intraperitoneal taxol. Markman M. **Cancer Treat Res** 1996; 81:1–5 (20 ref.)

Alternative formulations of paclitaxel. Terwogt JM, et al. **Cancer Treat Rev** 1997 Mar;23(2):87–95 (32 ref.)

Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol. Wang YM, et al. **Chem Pharm Bull (Tokyo)** 1996 Oct;44(10):1935–40

Etoposide for the treatment of paediatric tumours: what is the best way to give it? Lowis SP, et al. **Eur J Cancer** 1996 Dec;32A(13):2291–7 (65 ref.)

Etoposide at different concentrations may open different apoptotic pathways in thymocytes. Pellicciari C, et al. **Eur J Histochem** 1996;40(4):289–98

Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer. de Jong RS, et al. **Gynecol Oncol** 1997 Aug;66(2):197–201

Prolonged low doses of oral etoposide may be effective in individual patients with advanced lymphoproliferative disorders refractory to aggressive chemotherapy [letter] Caruso R, et al. **Haematologica** 1997 Jan–Feb;82(1):126–7

Dosage individualization of carboplatin and etoposide based on pharmacokinetic investigations. Jaehde U. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):76–8 (19 ref.)

Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer—results from a Phase I trial. Hoffmann W, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 1;38(4):691–6

Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients. Schilling T, et al. **Invest New Drugs** 1996; 14(4):371–8

Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Smith KJ, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):239–42

Two doses of paclitaxel and statistical analysis: try, try, try again [letter; comment] Akerley W. **J Clin Oncol** 1997 Jan; 15(1):408–9. Comment on: J Clin Oncol 1996 Jun;14(6):1858–67.

Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. Blaney SM, et al. **J Clin Oncol** 1997 Apr;15(4):1538–43

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. Fennelly D, et al. **J Clin Oncol** 1997 Jan;15(1):187–92

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. Merrouche Y, et al. **J Clin Oncol** 1997 Mar;15(3):1080–6

Paclitaxel dose intensity. Reed E, et al. **J Infus Chemother** 1996 Spring;6(2):59–63 (33 ref.)

Continuous infusion etoposide in advanced AIDS-related kaposi sarcoma. Remick SC, et al. **J Infus Chemother** 1996 Spring;6(2):92–6

The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices. Rowinsky EK. **J Infus Chemother** 1995 Fall;5(4):173–8 (60 ref.)

A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). Lundberg BB. **J Pharm Pharmacol** 1997 Jan;49(1):16–21

Intravesical therapy with vinorelbine tartrate: antitumor activity in orthotopic murine cell carcinoma of the bladder. Bonfil RD, et al. **J Urol** 1997 Sep;158(3 Pt 1):912–5

Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. Carrato A, et al. **Lung Cancer** 1997 Jul;17(2–3):261–9

Errors involving pediatric patients receiving chemotherapy: a literature review [letter; comment] Walter AW. **Med Pediatr Oncol** 1997 Aug;29(2):155–6. Comment on: Med Pediatr Oncol 1996 May;26(5):344–51.

Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy. Sharma D, et al. **Oncol Res** 1996; 8(7–8):281–6

Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group. Furuse K, et al. **Oncology** 1997 Jul–Aug;54(4):298–303

Irinotecan shown to be effective against colorectal cancer [news] **Oncology (Huntingt)** 1996 Mar;10(3):417–21

Paclitaxel-based combination chemotherapy for breast cancer. Hortobagyi GN. **Oncology (Huntingt)** 1997 Mar; 11(3 Suppl 2):29–37 (54 ref.)

The taxanes: dosing and scheduling considerations. Rowinsky EK. **Oncology (Huntingt)** 1997 Mar;11(3 Suppl 2):7–19 (88 ref.)

Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide. Sato H, et al. **Pharm Res** 1996 Oct;13(10):1565–9

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. DeNardo SJ, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):4000–4

Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer. Akerley W. **Semin Oncol** 1996 Dec;23(6 Suppl 16):55–8

Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer. Akerley W 3rd, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 12):14–8

A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Amadori D, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):16–22

Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease. Belani CP, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):113–6

Escalating paclitaxel doses combined with carboplatin/etoposide and thoracic radiotherapy as preoperative or definitive treatment for stage III non-small cell lung cancer. Bonomi P, et al. **Semin Oncol** 1996 Dec; 23(6 Suppl 16):102–7

Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study. Bunn PA Jr, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):11–5

The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Bunn PA Jr. **Semin Oncol** 1996 Dec;23(6 Suppl 16):18–25 (34 ref.)

Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Choy H, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):117–9

A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer. Conte PF, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):28–31

Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. Creaven PJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):26–31

Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Dombernowsky P, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):23–7

Single-agent paclitaxel as a 3-hour infusion. Gatzemeier U, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):94–7

Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Glantz MJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):128–35

Paclitaxel via 1-hour infusion: clinical experience. Greco FA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):91–3 (7 ref.)

Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer. Greco FA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):7–10

Paclitaxel via 1-hour infusion: rationale and pharmacology. Greco FA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):19–20

One-hour paclitaxel in the treatment of non-small cell lung cancer. Hainsworth JD, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):98–101

Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Holmes FA. **Semin Oncol** 1996 Oct;23(5 Suppl 11):46–56 (55 ref.)

Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46). Johnson DH, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):42–6

Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Klaassen U, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):32–7

Paclitaxel and carboplatin in inoperable non-small cell lung cancer. Kosmidis P, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):68–70

Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network. Langer CJ, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):35–41

Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Löffler TM, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):32–4

Phase I/II study of paclitaxel and radiotherapy in non-small cell lung cancer. Marangolo M, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):124–7

Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer. Mattson K, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 14):S14-5–S14-8

Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients. Michelotti A, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):38–40

Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Natale RB. **Semin Oncol** 1996 Dec;23(6 Suppl 16):51–4

Paclitaxel and carboplatin: a phase I study in advanced non-small cell lung cancer. Paccagnella A, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):76–9

Paclitaxel and carboplatin for advanced breast cancer. Perez EA, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):41–5 (38 ref.)

Preoperative paclitaxel plus carboplatin for patients with intermediate-risk non-small cell lung cancer. Ruckdeschel JC. **Semin Oncol** 1996 Dec;23(6 Suppl 16):62–7 (65 ref.)

Preliminary results of a dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Scagliotti GV, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):80–3

Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer. Shepherd FA, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):84–90

Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies. Sledge GW Jr. **Semin Oncol** 1996 Oct;23(5 Suppl 11):57–9

Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer. Splinter TA. **Semin Oncol** 1996 Dec;23(6 Suppl 16):59–61

Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study. Vogt HG, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):120–3

Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. von Pawel J, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):47–50

Paclitaxel and simultaneous radiation in the treatment of stage IIIA/B non-small cell lung cancer. Wolf M, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 16):108–12

The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Hande KR. **Stem Cells** 1996 Jan; 14(1):18–24 (40 ref.)

Concurrent Taxol and split-course accelerated radiotherapy for advanced head and neck cancer. Plasswilm L, et al. **Strahlenther Onkol** 1996 Oct;172(10):573–9

The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors. Bokemeyer C, et al. **World J Urol** 1996;14(6):354–9 (37 ref.)

[Comparative study on the long-term effect of permanent embolization of hepatic artery with Bletilla striata in patients with primary liver cancer] Feng G, et al. **J Tongji Med Univ** 1996;16(2):111–6 (Eng. Abstr.) **(Ger)**

[Effectiveness and hematotoxicity of paclitaxel monotherapy in patients with advanced non-small cell bronchial carcinoma (NSCLC)] Leutz M, et al. **Pneumologie** 1997 Jan;51(1):62–5 (Eng. Abstr.) **(Ger)**

[Prolonged oral etoposide therapy in advanced stage lung cancer] Bozóky G, et al. **Orv Hetil** 1997 Jul 13; 138(28):1791–5 (31 ref.) (Eng. Abstr.) **(Hun)**

[Etoposide (VP-16) in gynecologic malignancy] Kanazawa K, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1925-8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[The role of etoposide therapy in urogenital cancer] Kawai K, et al. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1929-35 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Etoposide 21 therapy for malignant lymphoma] Masaoka T. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1936-40 (2 ref.) (Eng. Abstr.) **(Jpn)**

[Etoposide in the treatment of small-cell lung cancer] Ueoka H. **Gan To Kagaku Ryoho** 1996 Dec;23(14):1920-4 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of daily administration of oral etoposide for non-small cell lung cancer treated with concurrent radiation therapy] Ohnishi H, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Jul;57(8):510-4 (Eng. Abstr.) **(Jpn)**

[Early phase II study of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer] Hayasaka S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec; 33(12):1367-1371 (Eng. Abstr.) **(Jpn)**

[Small cell lung cancer with acute monocytic leukemia after combined chemotherapy including etoposide] Tamada T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 May; 35(5):577-82 (Eng. Abstr.) **(Jpn)**

[Effectiveness of prolonged oral therapy with low-dose etoposide in patients aged 85 years and over with non-Hodgkin's lymphoma] Niitsu N, et al. **Nippon Ronen Igakkai Zasshi** 1997 Apr;34(4):263-6 (Eng. Abstr.) **(Jpn)**

[The usefulness of high dose etoposide for peripheral blood stem cell harvest] Yamamuro O, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Nov; 48(11):1097-100 **(Jpn)**

[Long-term oral administration of etoposide in the treatment of patients with advanced non-small-cell carcinoma of the lung. The second phase of a clinical study] Jeremić B, et al. **Srp Arh Celok Lek** 1996 Mar-Apr;124(3-4):65-8 (Eng. Abstr.) **(Scc)**

ADVERSE EFFECTS

Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early breast cancer. Anderson CM, et al. **Am J Clin Oncol** 1996 Dec;19(6):566-8 (6 ref.)

Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles. Ciesielski-Carlucci C, et al. **Am J Clin Oncol** 1997 Aug; 20(4):373-5 (14 ref.)

Secondary acute myelogenous leukemia following treatment with oral etoposide [letter] Katato K, et al. **Am J Hematol** 1996 Sep;53(1):54-5

Therapy-related acute myeloid leukemia with minimal myeloid differentiation (AML-M0) associated with a t(11;19)(q23;p13.3) translocation [letter] Suehiro Y, et al. **Am J Hematol** 1997 Jul;55(3):165-6

Adynamic ileus in a patient with non-small-cell lung cancer after treatment with vinorelbine. Liebmann J, et al. **Am J Med** 1996 Dec;101(6):658-9

Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Bookman MA, et al. **Ann Oncol** 1997 Jun;8(6):611-4

Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel [letter] Gennari A, et al. **Ann Oncol** 1996 Nov;7(9):978-9

Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Hilkens PH, et al. **Ann Oncol** 1997 Feb;8(2):187-90

Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Lissoni A, et al. **Ann Oncol** 1996 Oct; 7(8):861-3

Docetaxel and interstitial pulmonary injury. Merad M, et al. **Ann Oncol** 1997 Feb;8(2):191-4

The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. Mross K, et al. **Ann Oncol** 1996 Jan;7(1):83-8

Is acute dyspnoea a rare side effect of vinorelbine? [letter] Tassinari D, et al. **Ann Oncol** 1997 May;8(5):503-4

Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions [letter] Westermann AM, et al. **Ann Oncol** 1996 Jan;7(1):104

Optimal use of docetaxel (Taxotere): maximizing its potential. Burris HA. **Anticancer Drugs** 1996 Aug;7 Suppl 2:25-8 (6 ref.)

Vinblastine toxicity to the ocular surface. Chowers I, et al. **Anticancer Drugs** 1996 Sep;7(7):805-8

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Hilkens PH, et al. **Br J Cancer** 1997;75(3):417-22

The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Béhar A, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):653-8

Skin ulceration potential of paclitaxel in a mouse skin model in vivo [letter; comment] Bertelli G, et al. **Cancer** 1997 Jun 1;79(11):2266-9. Comment on: Cancer 1996 Jul 1;78(1):152-6.

Pharmacodynamic modeling of prolonged administration of etoposide. Minami H, et al. **Cancer Chemother Pharmacol** 1996;39(1-2):61-6

Manufacturer's labeling for paclitaxel [letter; comment] Hill RJ Jr. **Cancer Invest** 1996;14(6):644. Comment on: Cancer Invest 1996;14(4):340-2.

Paclitaxel package insert [letter] Solimando DA. **Cancer Invest** 1997;15(5):503

Neurobiochemical changes from Taxol/Neupogen chemotherapy for metastatic breast carcinoma corresponds with suicidal depression. Cousins JP, et al. **Cancer Lett** 1996 Dec 20;110(1-2):163-7

Respiratory failure following vinorelbine tartrate infusion in a patient with non-small cell lung cancer. Kouroukis C, et al. **Chest** 1997 Sep;112(3):846-8

Acute mesenteric ischaemia associated with 5-FU, cisplatin and vincristine chemotherapy. Allerton R. **Clin Oncol (R Coll Radiol)** 1996;8(2):116-7 (15 ref.)

Thromboembolic events with paclitaxel [letter] [see comments] Chan AT, et al. **Clin Oncol (R Coll Radiol)** 1996; 8(2):133. Comment in: Clin Oncol (R Coll Radiol) 1996;8(5):341.

Accidental administration of vincristine into the brachial artery [letter] Jackson N, et al. **Clin Oncol (R Coll Radiol)** 1997;9(3):198

Thromboembolic events with paclitaxel [letter; comment] Jones KD. **Clin Oncol (R Coll Radiol)** 1996;8(5):341. Comment on: Clin Oncol (R Coll Radiol) 1996;8(2):133.

Acute myocardial infarction following paclitaxel administration for ovarian carcinoma. Laher S, et al. **Clin Oncol (R Coll Radiol)** 1997;9(2):124-6

Taxol-induced acral erythema. de Argila D, et al. **Dermatology** 1996;192(4):377-8

Docetaxel-induced subungual hemorrhage. Vanhooteghem O, et al. **Dermatology** 1997;194(4):419-20

Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Bleiberg H, et al. **Eur J Cancer** 1996;32A Suppl 3:S18-23 (11 ref.)

Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Lemenager M, et al. **Eur J Cancer** 1997 Feb;33(2):297-300

Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold [letter] Yeo W, et al. **Eur J Cancer** 1997 Apr;33(4):698-9

Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial. Carlson JW, et al. **Gynecol Oncol** 1997 May;65(2):325-9

Generalized pustular dermatosis following paclitaxel therapy [letter] Weinberg JM, et al. **Int J Dermatol** 1997 Jul; 36(7):559-60 (8 ref.)

Pulmonary changes in patients with lymphoma who receive paclitaxel [letter; comment] Ayoub JP, et al. **J Clin Oncol** 1997 Jun;15(6):2476. Comment on: J Clin Oncol 1996 Apr;14(4):1071-6.

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. Piccart MJ, et al. **J Clin Oncol** 1997 Sep;15(9):3149-55

Secondary acute myelogenous leukemia following safe exposure to etoposide. Stine KC, et al. **J Clin Oncol** 1997 Apr;15(4):1583-6

Re: Severe neurotoxicity in vinorelbine-paclitaxel combinations [letter; comment] Budman DR, et al. **J Natl Cancer Inst** 1997 Jan 1;89(1):87-8. Comment on: J Natl Cancer Inst 1996 Aug 7;88(15):1079-80.

Fatal hepatic coma attributed to paclitaxel [letter] Feenstra J, et al. **J Natl Cancer Inst** 1997 Apr 16;89(8):582-4

Paclitaxel-induced pancreatitis: a case report [letter] Hoff PM, et al. **J Natl Cancer Inst** 1997 Jan 1;89(1):91-3

Acute tumor pain in patients with head and neck cancer treated with vinorelbine [letter] Kornek GV, et al. **J Natl Cancer Inst** 1996 Nov 6;88(21):1593

Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. Forsyth PA, et al. **J Neurooncol** 1997 Oct;35(1):47-53

Anogenital warts [letter; comment] Blake RS. **Med J Aust** 1997 Jun 2;166(11):615. Comment on: Med J Aust 1996 Jun 3;164(11):669-71.

Images in clinical medicine. Nail changes after chemotherapy. Slee PH. **N Engl J Med** 1997 Jul 17; 337(3):168

Docetaxel neuropathy [letter] Pace A, et al. **Neurology** 1996 Aug;47(2):615

Nurses can learn to manage the unique side effects and adverse reactions associated with docetaxel. Pizzo B, et al. **Oncol Nurs Forum** 1997 Jan-Feb;24(1):22

Severe necrosis due to paclitaxel extravasation. Herrington JD, et al. **Pharmacotherapy** 1997 Jan-Feb;17(1):163-5

[Acute pulmonary edema induced by vinorelbine (letter)] Vaylet F, et al. **Presse Med** 1996 Sep 21;25(27):1259 **(Fre)**

[Small cell lung cancer with acute monocytic leukemia after combined chemotherapy including etoposide] Tamada T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 May; 35(5):577-82 (Eng. Abstr.) **(Jpn)**

[Three cases of secondary acute myeloid leukemia after long-term treatment with oral etoposide] Kikuta T, et al. **Rinsho Ketsueki** 1996 Nov;37(11):1276-82 (15 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Determination of paclitaxel and related taxanes in bulk drug and injectable dosage forms by reversed phase liquid chromatography. Shao LK, et al. **Anal Chem** 1997 Jun 1; 69(11):2008-16

A receptor protein-based bioassay for quantitative determination of paclitaxel. Suye S, et al. **Anal Chem** 1997 Sep 1;69(17):3633-5

Stability of vinblastine sulphate in 0.9% sodium chloride in polypropylene syringes. Girona V, et al. **Boll Chim Farm** 1996 Jul-Aug;135(7):413-4

Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography. Hempel G, et al. **J Chromatogr A** 1996 Sep 20;745(1-2):173-9

Miniaturized HPLC and ionspray mass spectrometry applied to the analysis of Paclitaxel and taxanes. Liu J, et al. **J Pharm Biomed Anal** 1997 Jul;15(11):1729-39

Taxol content of various Taxus species in Hungary. Németh-Kiss V, et al. **J Pharm Biomed Anal** 1996 Jun; 14(8-10):997-1001

BIOSYNTHESIS

Biosynthesis of taxol: enzymatic acetylation of 10-deacetylbaccatin-III to baccatin-III in crude extracts from roots of Taxus baccata. Zocher R, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):16-20

Sustained harvest of camptothecin from the leaves of Camptotheca acuminata. Vincent RM, et al. **J Nat Prod** 1997 Jun;60(6):618-9

Taxol from Pestalotiopsis microspora, an endophytic fungus of Taxus wallachiana. Strobel G, et al. **Microbiology** 1996 Feb;142 (Pt 2):435-40

Taxol biosynthesis: an update. Hezari M, et al. **Planta Med** 1997 Aug;63(4):291-5 (42 ref.)

BLOOD

Chemistry of the camptothecins in the bloodstream. Drug stabilization and optimization of activity. Burke TG. **Ann N Y Acad Sci** 1996 Dec 13;803:29-31

Effect of SDZ PSC 833 ([3'-keto-Bmt1]-[Val2]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide in vitro. Watanabe T, et al. **Anticancer Drugs** 1997 Apr;8(4):400-4

Higher in vivo protein binding of etoposide in children compared with adult cancer patients. Liliemark E, et al. **Cancer Lett** 1996 Aug 23;106(1):97-100

Considerable plasma levels of a cytotoxic etoposide metabolite in patients undergoing high-dose chemotherapy [letter] Stremetzne S, et al. **Eur J Cancer** 1997 May; 33(6):978-9

Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Urien S, et al. **Invest New Drugs** 1996; 14(2):147-51

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. Huizing MT, et al. **J Chromatogr B Biomed Appl** 1995 Dec 15;674(2):261-8

Determination of a new podophyllotoxin derivative, TOP-53, and its metabolite in rat plasma and urine by high-performance liquid chromatography with electrochemical detection. Kitamura R, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1-2):283-8

Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. Loos WJ, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):437-41

Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection. Robieux I, et al. **J Chromatogr B Biomed Appl** 1996 Nov 8;686(1):35-41

Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. Warner DL, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):161-71

Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. Ramaswamy M, et al. **J Pharm Sci** 1997 Apr;86(4):460-4

A simple and reliable reverse-phase high-performance liquid chromatographic procedure for determination of paclitaxel (taxol) in human serum. Andreeva M, et al. **Ther Drug Monit** 1997 Jun;19(3):327-32

CHEMICAL SYNTHESIS

Synthesis of CPT-11 (irinotecan hydrochloride trihydrate). Sawada S, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:13-28

Some geiparvarin bioisosteres and homologues: synthesis and biological evaluation against human colon carcinoma cells (LoVo). Valenti P, et al. **Anticancer Drug Des** 1997 Mar; 12(2):137-44

Synthesis, cytotoxicity and SAR of simple geiparvarin analogues. Valenti P, et al. **Anticancer Drug Des** 1997 Sep; 12(6):443-51

Synthesis and biological activity of A-nor-paclitaxel analogues. Chordia MD, et al. **Bioorg Med Chem** 1997 May; 5(5):941-7

Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT. de Bont DB, et al. **Bioorg Med Chem** 1997 Feb;5(2):405-14

Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. Ojima I, et al. **J Med Chem** 1996 Sep 27;39(20):3889-96

Synthesis and structure-activity relationships of nonaromatic

taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity. Ojima I, et al. **J Med Chem** 1997 Jan 31; 40(3):279–85

Syntheses and structure–activity relationships of taxoids derived from 14 beta–hydroxy–10–deacetylbaccatin III. Ojima I, et al. **J Med Chem** 1997 Jan 31;40(3):267–78

Camptothecin and minor–groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro. Zhao R, et al. **J Med Chem** 1997 Jan 17;40(2):216–25

Synthesis and antitumor activity of spin labeled derivatives of podophyllotoxin. Tian X, et al. **Life Sci** 1997;60(8):511–7

Synthesis and anti–proliferative activity of 2–hydroxy–1,2–dihydroacronycine glycosides. Mitaku S, et al. **Pharm Res** 1996 Jun;13(6):939–43

CHEMISTRY

Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Mazzo DJ, et al. **Am J Health Syst Pharm** 1997 Mar 1;54(5):566–9

Stability of doxorubicin hydrochloride and vincristine sulfate in two portable infusion–pump reservoirs. Nyhammar EK, et al. **Am J Health Syst Pharm** 1996 May 15;53(10):1171–3

4–deoxyannomontacin and (2,4–cis and trans)–annomontacinone, new bioactive mono–tetrahydrofuran annonaceous acetogenins from Goniothalamus giganteus. Alali F, et al. **Bioorg Med Chem** 1997 Mar;5(3):549–55

Key analogues of the tetrapeptide subunit of RA–VII and deoxybouvardin. Boger DL, et al. **Bioorg Med Chem** 1996 Oct;4(10):1597–603

Scutione, a new bioactive norquinonemethide triterpene from Maytenus scutioides (Celastraceae). González AG, et al. **Bioorg Med Chem** 1996 Jun;4(6):815–20

Helenanolide–type sesquiterpene lactones—III. Rates and stereochemistry in the reaction of helenalin and related helenanolides with sulfhydryl containing biomolecules. Schmidt TJ. **Bioorg Med Chem** 1997 Apr;5(4):645–53

Applying Mosher's method to acetogenins bearing vicinal diols. The absolute configurations of muricatetrocin C and rollidecins A and B, new bioactive acetogenins from Rollinia mucosa. Shi G, et al. **Bioorg Med Chem** 1996 Aug; 4(8):1281–6

cis–gigantrionenin and 4–acetyl gigantetrocin A, two new bioactive annonaceous acetogenins from Goniothalamus giganteus, and the stereochemistries of acetogenin 1,2,5–triols. Zeng L, et al. **Bioorg Med Chem** 1996 Aug; 4(8):1271–9

Alternative formulations of paclitaxel. Terwogt JM, et al. **Cancer Treat Rev** 1997 Mar;23(2):87–95 (32 ref.)

Antitumor agents. 169 Dysoxylum cumingianum. V. Cumingianosides P and Q, new cytotoxic triterpene glucosides with an apoturicallane–type skeleton from Dysoxylum cumingianum. Fujioka T, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan;45(1):202–6

Antitumor agents. 168. Dysoxylum cumingianum. IV. The structures of cumingianosides G–O, new triterpene glucosides with a 14,18–cycloapoturicallane–type skeleton from Dysoxylum cumingianum, and their cytotoxicity against human cancer cell lines. Fujioka T, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan;45(1):68–74

Indonesian medicinal plants. XVII. Characterization of quassinoids from the stems of Quassia indica. Kitagawa I, et al. **Chem Pharm Bull (Tokyo)** 1996 Nov;44(11):2009–14

Inhibitory effects of quassinoid derivatives on Epstein–Barr virus early antigen activation. Rahman S, et al. **Chem Pharm Bull (Tokyo)** 1997 Apr;45(4):675–7

Acetogenins from Annonaceae. Cavé A, et al. **Fortschr Chem Org Naturst** 1997;70:81–288 (245 ref.)

A simple algorithm for superimposing sets of NMR derived structures: its application to the conformational study of cephalomannine in lipophobic and lipophilic solution. Moyna G, et al. **J Chem Inf Comput Sci** 1996 Nov–Dec; 36(6):1224–7

Stereochemistry–dependent cytotoxicity of some artemisinin derivatives. Beekman AC, et al. **J Nat Prod** 1997 Apr; 60(4):325–30

Synthetic chemistry. Cancer drugs better than taxol? [news; comment] Cowden CJ, et al. **Nature** 1997 May 15; 387(6630):238–9. Comment on: Nature 1997 May 15;387(6630):268–72.

Physical stability of teniposide in bile salt–egg phosphatidylcholine mixed micelles and liposomes. Son K, et al. **PDA J Pharm Sci Technol** 1996 Mar–Apr;50(2):89–93

Bioactive polyacetylenes from Bidens pilosa [letter] Alvarez L, et al. **Planta Med** 1996 Aug;62(4):355–7

Konishiol, a new sesquiterpene, and bioactive components from Cunninghamia konishii. He K, et al. **Planta Med** 1997 Apr;63(2):158–60

Structural characterization of mono– and dihydroxylated metabolites of paclitaxel in rat bile using liquid chromatography/ion spray tandem mass spectrometry. Sottani C, et al. **Rapid Commun Mass Spectrom** 1997; 11(9):1025–32

Pulvinatal, a novel bioactive metabolite from the basidiomycete Nidularia pulvinata (Schw.) Fr. Becker U, et al. **Z Naturforsch [C]** 1997 May–Jun;52(5–6):313–8

(+)–10 alpha–Hydroxy–4–muurolen–3–one, a new inhibitor of leukotriene biosynthesis from a Favolaschia species. Comparison with other sesquiterpenes. Zapf S, et al. **Z Naturforsch [C]** 1996 Jul–Aug;51(7–8):487–91

[Structural analysis of vinorelbine in solution determined by nuclear magnetic resonance spectrometry] Ribet JP, et al. **Ann Pharm Fr** 1997;55(1):20–34 (Eng. Abstr.) **(Fre)**

ECONOMICS

Pharmacoeconomic profile of paclitaxel as a first–line treatment for patients with advanced ovarian carcinoma. A lifetime cost–effectiveness analysis [letter] Messori A, et al. **Cancer** 1997 Jun 1;79(11):2264–6

The cost–effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non–small cell lung cancer. Evans WK, et al. **Eur J Cancer** 1996 Dec; 32A(13):2249–55

Economic and policy implications of adopting paclitaxel as first–line therapy for advanced ovarian cancer: an Ontario perspective. Elit LM, et al. **J Clin Oncol** 1997 Feb; 15(2):632–9

Analysis of the cost–effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. McGuire W, et al. **J Clin Oncol** 1997 Feb;15(2):640–5

IMMUNOLOGY

Induction of anti–mistletoe lectin antibodies in relation to different mistletoe–extracts. Stein GM, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S57–9 (10 ref.)

ISOLATION & PURIFICATION

6'–0–apiosyl–verbascoside in the flowers of mullein (Verbascum species). Klimek B. **Acta Pol Pharm** 1996 Mar–Apr;53(2):137–40

Effects of a new clerodane diterpenoid isolated from propolis on chemically induced skin tumors in mice. Mitamura T, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2669–72

Cytotoxic trichilin–type limonoids from Melia azedarach. Takeya K, et al. **Bioorg Med Chem** 1996 Aug;4(8):1355–9

Cytotoxic cardenolides from woods of Euonymus alata. Kitanaka S, et al. **Chem Pharm Bull (Tokyo)** 1996 Mar; 44(3):615–7

Isolation, purification and biological activity of major docetaxel metabolites from human feces. Sparreboom A, et al. **Drug Metab Dispos** 1996 Jun;24(6):655–8

Withania somnifera Dunal (Ashwagandha): potential plant source of a promising drug for cancer chemotherapy and radiosensitization. Devi PU. **Indian J Exp Biol** 1996 Oct; 34(10):927–32 (41 ref.)

Structure–cytotoxicity relationships of some helenanolide–type sesquiterpene lactones. Beekman AC, et al. **J Nat Prod** 1997 Mar;60(3):252–7

Phytogrowth–inhibitory and antifungal constituents of Helianthella quinquenervis. Castañeda P, et al. **J Nat Prod** 1996 Mar;59(3):323–6

A new quassinoid from Castela texana. Dou J, et al. **J Nat Prod** 1996 Jan;59(1):73–6

Bioactive ent–kaurene diterpenoids from Annona senegalensis. Fatope MO, et al. **J Nat Prod** 1996 Mar; 59(3):301–3

Two new aromatic constitutents from the rootwood of Aeschynomene mimosifolia. Fullas F, et al. **J Nat Prod** 1996 Feb;59(2):190–2

Novel cytotoxic, alkylated hydroquinones from Lannea welwitschii. Groweiss A, et al. **J Nat Prod** 1997 Feb; 60(2):116–21

(+)–Angchibangkine, a new type of bisbenzylisoquinoline alkaloid, and other dimers from Pachygone dasycarpa. Guinaudeau H, et al. **J Nat Prod** 1997 Mar;60(3):258–60

Bioactive compounds from Taiwania cryptomerioides. He K, et al. **J Nat Prod** 1997 Jan;60(1):38–40

Squamotacin: an annonaceous acetogenin with cytotoxic selectivity for the human prostate tumor cell line (PC–3). Hopp DC, et al. **J Nat Prod** 1996 Feb;59(2):97–9

Novel mono–tetrahydrofuran ring acetogenins, from the bark of Annona squamosa, showing cytotoxic selectivities for the human pancreatic carcinoma cell line, PACA–2. Hopp DC, et al. **J Nat Prod** 1997 Jun;60(6):581–6

Isolation and structure elucidation of ardisenone: a new, cytotoxic alkenylphenol from Ardisia iwahigensis. Horgen FD, et al. **J Nat Prod** 1997 May;60(5):533–5

A new prenylated flavonol from the root of Petalostemon purpureus. Huang L, et al. **J Nat Prod** 1996 Mar; 59(3):290–2

Cytotoxic glycosides from Albizia julibrissin. Ikeda T, et al. **J Nat Prod** 1997 Feb;60(2):102–7

The secalosides, novel tumor cell growth inhibitory glycosides from a pollen extract. Jaton JC, et al. **J Nat Prod** 1997 Apr;60(4):356–60

New bioactive cerebrosides from Arisaema amurense. Jung JH, et al. **J Nat Prod** 1996 Mar;59(3):319–22

Bioactive steroidal alkaloids from Solanum umbelliferum. Kim YC, et al. **J Nat Prod** 1996 Mar;59(3):283–5

Spinonin, a novel glycoside from Ononis spinosa subsp. leiosperma. Kirmizigül S, et al. **J Nat Prod** 1997 Apr; 60(4):378–81

10–Epi–olguine from Rabdosia ternifolia. Lu GH, et al. **J Nat Prod** 1997 Apr;60(4):425–7

Isolation and characterization of new anti–HIV and cytotoxic leads from plants, marine, and microbial organisms. McKee TC, et al. **J Nat Prod** 1997 May;60(5):431–8

Taxuspinananes A and B, new taxoids from Taxus cuspidata var. nana. Morita H, et al. **J Nat Prod** 1997 Apr;60(4):390–2

Cyclic peptides from higher plants. 24.1 yunnanin C, a novel cyclic heptapeptide from Stellaria yunnanensis. Morita H, et al. **J Nat Prod** 1996 Mar;59(3):280–2

Caparratriene, an active sesquiterpene hydrocarbon from Ocotea caparrapi. Palomino E, et al. **J Nat Prod** 1996 Jan; 59(1):77–9

Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru. Perry NB, et al. **J Nat Prod** 1997 Jun;60(6):623–6

Five novel mono–tetrahydrofuran ring acetogenins from the seeds of Annona muricata. Rieser MJ, et al. **J Nat Prod** 1996 Feb;59(2):100–8

New taxane diterpenoids from the roots of Taxus mairei. Shen YC, et al. **J Nat Prod** 1996 Feb;59(2):173–6

Biologically active acylglycerides from the berries of saw–palmetto (Serenoa repens). Shimada H, et al. **J Nat Prod** 1997 Apr;60(4):417–8

Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia. Wu TS, et al. **J Nat Prod** 1997 Jun;60(6):606–8

Chlorinated annonaceous acetogenins and their bioactivities. Ye Q, et al. **J Nat Prod** 1996 Oct;59(10):994–6

DNA topoisomerase I inhibitors: cytotoxic flavones from Lethedon tannaensis. Zahir A, et al. **J Nat Prod** 1996 Jul; 59(7):701–3

Five new monotetrahydrofuran ring acetogenins from the leaves of Annona muricata. Zeng L, et al. **J Nat Prod** 1996 Nov;59(11):1035–42

Sample preparation for taxol and cephalomannine determination in various organs of Taxus sp. Glowniak K, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1215–20

A saporin–insulin conjugate: synthesis and biochemical characterization. Ippoliti R, et al. **Nat Toxins** 1996; 4(4):156–62

Erythroxan diterpenes from Fagonia glutinosa [letter] Abdel–Kader MS, et al. **Planta Med** 1997 Aug;63(4):374–6

New dimeric aporphine alkaloids and cytotoxic constituents of Hernandia nymphaeifolia. Chen JJ, et al. **Planta Med** 1996 Dec;62(6):528–33

Tonkinelin: a novel annonaceous acetogenin from Uvaria tonkinensis. Chen Y, et al. **Planta Med** 1996 Dec; 62(6):512–4

Isolation of paeonol from Arisaema erubescens. Ducki S, et al. **Planta Med** 1995 Dec;61(6):586–7

Cytotoxicity and immunosuppressive activity of withanolides from Discopodium penninervium. Habtemariam S. **Planta Med** 1997 Feb;63(1):15–7

Cytotoxic constituents from the stems of Diospyros maritima [letter] Kuo YH, et al. **Planta Med** 1997 Aug;63(4):363–5

A water–soluble antitumor glycoprotein from Chlorella vulgaris. Noda K, et al. **Planta Med** 1996 Oct;62(5):423–6

Cytotoxic components of Artemisia princeps. Ryu SY, et al. **Planta Med** 1997 Aug;63(4):384–5

The cytotoxicity of psoralidin from Psoralea corylifolia [letter] Yang YM, et al. **Planta Med** 1996 Aug;62(4):353–4

[Chemical constituents of Taxus yunnanensis Cheng et L. K. Fu.] Chen Z, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Apr;21(4):230–2, 256 (Eng. Abstr.) **(Chi)**

METABOLISM

The multidrug–resistant human lung tumour cell line, DLKP–A10, expresses novel drug accumulation and sequestration systems. Cleary I, et al. **Biochem Pharmacol** 1997 May 15;53(10):1493–502

Conversion of irinotecan (CPT–11) to its active metabolite, 7–ethyl–10–hydroxycamptothecin (SN–38), by human liver carboxylesterase. Rivory LP, et al. **Biochem Pharmacol** 1996 Oct 11;52(7):1103–11

Binding of vinblastine and estramustine to isolated plasma membrane fractions from human prostate and prostatic tumors. Batra S, et al. **Cancer Lett** 1996 Sep 10; 106(2):217–20

Identification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry. Poon GK, et al. **Drug Metab Dispos** 1996 May;24(5):565–71

DNA topoisomerase I changes the mode of interaction between camptothecin drugs and DNA as probed by UV–resonance Raman spectroscopy. Feofanov AV, et al. **FEBS Lett** 1996 Nov 4;396(2–3):289–92

Molecular mobility of nitroxyl–labelled taxol during tubulin assembly. Nicholov R, et al. **FEBS Lett** 1997 Mar 17; 405(1):73–6

The transport and binding of taxol. Parekh H, et al. **Gen Pharmacol** 1997 Aug;29(2):167–72 (47 ref.)

Mechanism of increased sensitivity to etoposide in a mitomycin C–resistant human bladder cancer cell line. Xia H, et al. **Int J Cancer** 1997 Mar 4;70(5):606–11

Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. Chu XY, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):304–14

Assays of CYP2C8– and CYP3A4–mediated metabolism of taxol in vivo and in vitro. Walle T. **Methods Enzymol** 1996; 272:145–51

Two–step hydrolysis of amygdalin in molds [letter] Brimer L, et al. **Riv Biol** 1996;89(3):493–6

PHARMACOKINETICS

Clinical pharmacology and pharmacodynamics of irinotecan. A review. Chabot GG. **Ann N Y Acad Sci** 1996 Dec 13; 803:164–72 (53 ref.)

Pharmacokinetics of camptothecins administered orally. Liehr JG, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:157–63

(19 ref.)
The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. Mross K, et al. **Ann Oncol** 1996 Jan;7(1):83-8
Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Bissery MC, et al. **Anticancer Drugs** 1996 Jun;7(4):437-60
Effect of modulators of the multidrug resistance pump on the distribution of vinblastine in tissues of the mouse. Lyubimov E, et al. **Anticancer Drugs** 1996 Jan;7(1):60-9
Tissue distribution, metabolism and excretion of paclitaxel in mice. Sparreboom A, et al. **Anticancer Drugs** 1996 Jan; 7(1):78-86
Chronopharmacology of etoposide given by low dose prolonged infusion in lung cancer patients. Yamamoto N, et al. **Anticancer Res** 1997 Jan-Feb;17(1B):669-72
Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP). Slapak CA, et al. **Biochem Pharmacol** 1996 Nov 22;52(10):1569-76
Pharmacokinetic study of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate after targeted delivery to the lung in mice. Sato H, et al. **Biol Pharm Bull** 1996 Dec; 19(12):1596-601
Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. de Jong RS, et al. **Br J Cancer** 1997;75(11):1660-6
Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Monsarrat B, et al. **Bull Cancer** 1997 Feb;84(2):125-33 (59 ref.)
Influence of route of administration on [3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies. Ahmed AE, et al. **Cancer Chemother Pharmacol** 1996;39(1-2):122-30
The effects of food and divided dosing on the bioavailability of oral vinorelbine. Rowinsky EK, et al. **Cancer Chemother Pharmacol** 1996;39(1-2):9-16
Bladder tissue pharmacokinetics of intravesical taxol. Song D, et al. **Cancer Chemother Pharmacol** 1997;40(4):285-92
Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Stewart CF, et al. **Cancer Chemother Pharmacol** 1997;40(3):259-65
Salivary drug monitoring of irinotecan and its active metabolite in cancer patients. Takahashi T, et al. **Cancer Chemother Pharmacol** 1997;40(5):449-52
The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue. van Tellingen O, et al. **Cancer Chemother Pharmacol** 1997; 40(4):330-4
The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity. Zhu G, et al. **Cancer Chemother Pharmacol** 1996; 39(1-2):138-42
Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Chu XY, et al. **Cancer Res** 1997 May 15;57(10):1934-8
Clinical pharmacokinetics of vinorelbine [published erratum appears in Clin Pharmacokinet 1997 Apr;32(4):323] Levêque D, et al. **Clin Pharmacokinet** 1996 Sep; 31(3):184-97 (89 ref.)
Natural anthracenone subcellular distribution and effects on NADPH-cytochrome P450 reductase microsomal activity. Guerrero-Olazarán M, et al. **Drug Chem Toxicol** 1996 Nov; 19(4):301-12
Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Sorio R, et al. **Eur J Cancer** 1997 Feb;33(2):301-3
Dosage individualization of carboplatin and etoposide based on pharmacokinetic investigations. Jaehde U. **Int J Clin Pharmacol Ther** 1997 Feb;35(2):76-8 (19 ref.)
Transmembranous transport of drugs: implications for kinetics and drug action. Stratmann G, et al. **Int J Clin Pharmacol Ther** 1997 Apr;35(4):151-4
Reversed-phase high-performance liquid chromatography method for the simultaneous quantitation of the lactone and carboxylate forms of the novel natural product anticancer agent 10-hydroxycamptothecin in biological fluids and tissues. Li YF, et al. **J Chromatogr B Biomed Appl** 1996 Nov 15;686(2):257-65
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. Canal P, et al. **J Clin Oncol** 1996 Oct; 14(10):2688-95
Synthesis, biodistribution and imaging properties of indium-111-DTPA-paclitaxel in mice bearing mammary tumors. Li C, et al. **J Nucl Med** 1997 Jul;38(7):1042-7
A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. Bruno R, et al. **J Pharmacokinet Biopharm** 1996 Apr;24(2):153-72
Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters. Mummaneni V, et al. **J Pharmacokinet Biopharm** 1996 Aug;24(4):313-25
Vincristine degradation by serum from leukemic patients: role of myeloperoxidase. Schlaifer D, et al. **Leuk Lymphoma** 1996 Feb;20(5-6):441-6
Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide. Sato H, et al. **Pharm Res** 1996 Oct;13(10):1565-9
Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Haaz MC, et al. **Pharmacol Toxicol** 1997 Feb;80(2):91-6
Structural characterization of mono- and dihydroxylated metabolites of paclitaxel in rat bile using liquid chromatography/ion spray tandem mass spectrometry. Sottani C, et al. **Rapid Commun Mass Spectrom** 1997; 11(9):1025-32
Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Panday VR, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 11):S11-34-S11-38 (37 ref.)

PHARMACOLOGY

"In vivo" and "in vitro" antitumoral action of Larrea divaricata Cav. Anesini C, et al. **Acta Physiol Pharmacol Ther Latinoam** 1996;46(1):33-40
Drug resistance mechanisms of topoisomerase I drugs. Andoh T, et al. **Adv Pharmacol** 1994;29B:93-103 (40 ref.)
Mechanisms of topoisomerase I inhibition by anticancer drugs. Pommier Y, et al. **Adv Pharmacol** 1994;29B:73-92 (120 ref.)
The Camptothecins: From Discovery to the Patient. Proceedings of a conference. Bethesda, Maryland, February 7-10, 1996. **Ann N Y Acad Sci** 1996 Dec 13; 803:1-335
Topoisomerase I inhibition by the camptothecin analog G1147211C. From the laboratory to the clinic. Besterman JM. **Ann N Y Acad Sci** 1996 Dec 13;803:202-9 (13 ref.)
Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice. Bissery MC, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:173-80 (35 ref.)
The effect of camptothecin on topoisomerase I catalysis. Christiansen K, et al. **Ann N Y Acad Sci** 1996 Dec 13; 803:50-9
The cell cycle effects of camptothecin. Darzynkiewicz Z, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:93-100 (30 ref.)
Mechanism of action of camptothecin. Liu LF, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:44-9 (14 ref.)
Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks. Murren JR, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:74-92 (64 ref.)
Cellular resistance to camptothecins. Pommier Y, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:60-73 (126 ref.)
Lowered phosphorylation of topoisomerase I is a direct reason for reduced sensitivity of L5178Y-S cells to camptothecin. Staron K, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:321-3
Induction of apoptosis by camptothecin and topotecan. Traganos F, et al. **Ann N Y Acad Sci** 1996 Dec 13; 803:101-10
Paclitaxel induces significant changes in epidoxorubicin distribution in mice [published erratum appears in Ann Oncol 1997 Feb;8(2):207] Colombo T, et al. **Ann Oncol** 1996 Oct;7(8):801-5
Ether lipids enhance the cytotoxic effect of teniposide and paclitaxel in liposomes against leukaemic cells in culture. Lundberg BB. **Anticancer Drug Des** 1997 Sep;12(6):503-13
Some geiparvarin bioisosteres and homologues: synthesis and biological evaluation against human colon carcinoma cells (LoVo). Valenti P, et al. **Anticancer Drug Des** 1997 Mar; 12(2):137-44
The scientific rationale for developing taxoids. Aapro M. **Anticancer Drugs** 1996 Aug;7 Suppl 2:33-6 (18 ref.)
Clinical relevance of immunoactive mistletoe lectin-I. Beuth J. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S53-5 (19 ref.)
Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Bissery MC, et al. **Anticancer Drugs** 1996 Jun;7(4):437-60
Mistletoe therapy and immunological research. Büssing A. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S65
Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro. Clements MK, et al. **Anticancer Drugs** 1996 Nov;7(8):851-7
Interactions between taxol and camptothecin. Debernardis D, et al. **Anticancer Drugs** 1996 Jul;7(5):531-4
Enhancement of etoposide (VP-16) cytotoxicity by enzymatic and photodynamically induced oxidative stress. Gantchev TG, et al. **Anticancer Drugs** 1997 Feb;8(2):164-73
Mitotic arrest and anaphase aberrations induced by vinorelbine in hamster cells in vitro. González-Cid M, et al. **Anticancer Drugs** 1997 Jun;8(5):529-32
Association of docetaxel/paclitaxel with irradiation in ovarian carcinoma cell lines in bidimensional (sulforhodamine B assay) and tridimensional (spheroids) cultures. Griffon-Etienne G, et al. **Anticancer Drugs** 1996 Aug;7(6):660-70
Immunomodulatory effects of Viscum album agglutinin-I on natural immunity. Hajto T, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S43-6
Differences in the topoisomerase I cleavage complexes formed by camptothecin and wakayin, a DNA-intercalating marine natural product. Kokoshka JM, et al. **Anticancer Drugs** 1996 Sep;7(7):758-65
Donor-dependent and dose-dependent variation in the induction of T lymphocyte locomotion in a three-dimensional collagen matrix system by a mistletoe preparation (Iscador). Nikolai G, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S61-4
Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Pei XH, et al. **Anticancer Drugs** 1997 Mar;8(3):231-7
Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins. Ribéreau-Gayon G, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S3-8 (20 ref.)
Mistletoe therapy for human cancer: the role of the natural killer cells. Schink M. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S47-51 (50 ref.)
Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha. Seong J, et al. **Anticancer Drugs** 1997 Jan;8(1):80-7
Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug-resistant cell lines. Stammler G, et al. **Anticancer Drugs** 1997 Mar; 8(3):265-8
Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Stein GM, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S39-42
Stimulation of antitumour immunity by intrapleural instillation of a Viscum album L. extract. Stumpf C, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S23-6
Efficacy of oral irinotecan against neuroblastoma xenografts. Thompson J, et al. **Anticancer Drugs** 1997 Apr;8(4):313-22
Concomitant decrease of resistance and modifications of the cytoskeleton after all-trans retinoic acid and phorbol ester treatments in a navelbine-resistant bladder carcinoma cell line. Debal V, et al. **Anticancer Res** 1997 Mar-Apr; 17(2A):1147-54
Docetaxel enhances the expression of E-cadherin and carcinoembryonic antigen (CEA) on human colon cancer cell lines in vitro. Eckert K, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):7-12
Taxane sensitivity of ovarian carcinoma in vitro. Engblom P, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2475-9
Induction of tumor necrosis factor by a camptothecin derivative, irinotecan, in mice and human mononuclear cells. Goto S, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2507-11
Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel in vitro. Jaakkola M, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):939-43
Interferon-alpha potentiates the antiproliferative activity of CPT-11 against human colon cancer xenografts in nude mice. Kobayashi I, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2677-80
Enhancement of UV-A-induced cytotoxicity to cancer cell lines by camptothecin. Kojima S, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):241-6
Activation of multiple effector pathways of immune system by the antineoplastic immunostimulator acidic polysaccharide ginsan isolated from Panax ginseng. Lee YS, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):323-31
Cytotoxicity of CPT-11 against a Taxol-resistant cell line. Matsuoka H, et al. **Anticancer Res** 1997 Jan-Feb; 17(1A):467-71
Effects of aristoloside, a component of guan-mu-tong (Caulis aristolochiae manshuriensis), on normal and preneoplastic mammary gland growth in mice. Nagasawa H, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):237-40
Paclitaxel and irradiation induce apoptosis in squamous cell carcinoma cell lines in an additive way. Pulkkinen JO, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2923-9
The effect of etoposide (VP-16) on mouse L fibroblasts: modulation of stress response, growth and apoptosis genes. Sacchi CM, et al. **Anticancer Res** 1996 Nov-Dec; 16(6B):3659-64
Notoginsenoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-induced lethality in mice in vivo. Zhang WJ, et al. **Arterioscler Thromb Vasc Biol** 1997 Mar;17(3):465-74
Paclitaxel selectively induces mitotic arrest and apoptosis in proliferating bovine synoviocytes. Hui A, et al. **Arthritis Rheum** 1997 Jun;40(6):1073-84
Taxol inhibits opioid binding on T47D human breast cancer cells. Bakogeorgou E, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):201-4
Pretreatment by tubulin agents decreases C-MYC induction in human colon carcinoma cell line HT29-D4. el Khyari S, et al. **Biochem Biophys Res Commun** 1997 Feb 24; 231(3):751-4
Molecular cloning of the genes suppressed in RVC lymphoma cells by topoisomerase inhibitors. Onishi Y, et al. **Biochem Biophys Res Commun** 1996 Nov 1;228(1):7-13
Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. Verma SP, et al. **Biochem Biophys Res Commun** 1997 Apr 28;233(3):692-6
Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Asano T, et al. **Biochem J** 1996 Oct 1;319 (Pt 1):307-13
Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Hsieh T, et al. **Biochem Mol Biol Int** 1997 Jul;42(3):535-44
Identification of a protein kinase C (PKC) activator,

daphnoretin, that suppresses hepatitis B virus gene expression in human hepatoma cells. Chen HC, et al. **Biochem Pharmacol** 1996 Oct 11;52(7):1025–32

Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. Li XG, et al. **Biochem Pharmacol** 1997 Apr 4; 53(7):1019–27

Dual cytotoxic mechanisms of submicromolar taxol on human leukemia HL–60 cells. Lieu CH, et al. **Biochem Pharmacol** 1997 Jun 1;53(11):1587–96

Acquisition of taxol resistance via P–glycoprotein– and non–P–glycoprotein–mediated mechanisms in human ovarian carcinoma cells. Parekh H, et al. **Biochem Pharmacol** 1997 Feb 21;53(4):461–70

Plant–derived anticancer agents. Pezzuto JM. **Biochem Pharmacol** 1997 Jan 24;53(2):121–33 (64 ref.)

Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta–tubulin isotypes. Derry WB, et al. **Biochemistry** 1997 Mar 25; 36(12):3554–62

Influence of OSW–1 [3 beta,16 beta,17 alpha–trihydroxycholest–5–en–22–one 16–O–(2–O–4–methoxybenzoyl–beta–D–xylopyranosyl)–(1––> 3)–(2–O–acetyl–alpha–L–arabinopyranoside)], a steroidal saponin, on endothelium dependent relaxation caused by acetylcholine in rat aorta. Honda H, et al. **Biol Pharm Bull** 1997 Apr;20(4):428–30

Anti–tumor–promoting activities of triterpenoids from ferns. I. Konoshima T, et al. **Biol Pharm Bull** 1996 Jul;19(7):962–5

Cytotoxic components of bardanae fructus (goboshi). Moritani S, et al. **Biol Pharm Bull** 1996 Nov;19(11):1515–7

Absence of lysosomal cleavage in the cytotoxicity mechanism of an immunoconjugate composed of anti–alpha–fetoprotein monoclonal antibody and vindesine analog. Nagata S, et al. **Biol Pharm Bull** 1996 Mar; 19(3):480–3

Synthesis and biological activity of A–nor–paclitaxel analogues. Chordia MD, et al. **Bioorg Med Chem** 1997 May; 5(5):941–7

Synthesis and biological activity of beta–glucuronyl carbamate–based prodrugs of paclitaxel as potential candidates for ADEPT. de Bont DB, et al. **Bioorg Med Chem** 1997 Feb;5(2):405–14

Scutione, a new bioactive norquinonemethide triterpene from Maytenus scutioides (Celastraceae). González AG, et al. **Bioorg Med Chem** 1996 Jun;4(6):815–20

Additional bioactive annonaceous acetogenins from Asimina triloba (Annonaceae). He K, et al. **Bioorg Med Chem** 1997 Mar;5(3):501–6

Effect of sizofiran on regional lymph nodes in patients with head and neck cancer. Kano Y, et al. **Biotherapy** 1996; 9(4):257–62

In vitro cytotoxic effect of some medicinal plants containing flavonoids. Trovato A, et al. **Boll Chim Farm** 1996 Apr; 135(4):263–6

Immunoconjugates made of an anti–EGF receptor monoclonal antibody and type 1 ribosome–inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata. Di Massimo AM, et al. **Br J Cancer** 1997; 75(6):822–8

Combination toxicity of etoposide (VP–16) and photosensitisation with a water–soluble aluminium phthalocyanine in K562 human leukaemic cells. Gantchev TG, et al. **Br J Cancer** 1996 Nov;74(10):1570–7

Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Terzis AJ, et al. **Br J Cancer** 1997;75(12):1744–52

Interaction of a new bis–indol derivative, KAR–2 with tubulin and its antimitotic activity. Orosz F, et al. **Br J Pharmacol** 1997 Jul;121(5):947–54

The interaction of a new anti–tumour drug, KAR–2 with calmodulin. Orosz F, et al. **Br J Pharmacol** 1997 Jul; 121(5):955–62

Estrogen increases intracellular p26Bcl–2 to p21Bax ratios and inhibits taxol–induced apoptosis of human breast cancer MCF–7 cells. Huang Y, et al. **Breast Cancer Res Treat** 1997 Jan;42(1):73–81

Docetaxel: a review of its pharmacology and clinical activity. Trudeau ME. **Can J Oncol** 1996 Jun;6(1):443–57 (110 ref.)

Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro. Csóka K, et al. **Cancer** 1997 Mar 15;79(6):1225–33

The human cell multiprotein DNA replication complex (MRC): the effect of camptothecin on its ability to support in vitro DNA synthesis. Coll JM, et al. **Cancer Chemother Pharmacol** 1996;39(1–2):97–102

Differential cytotoxicity of clinically important camptothecin derivatives in P–glycoprotein–overexpressing cell lines. Hoki Y, et al. **Cancer Chemother Pharmacol** 1997; 40(5):433–8

Preclinical antitumor activity of water–soluble paclitaxel derivatives. Rose WC, et al. **Cancer Chemother Pharmacol** 1997;39(6):486–92

Tubulin from paclitaxel–resistant cells as a probe for novel antimicrotubule agents. Sackett DL, et al. **Cancer Chemother Pharmacol** 1997;40(3):228–32

Augmentation of vincristine cytotoxicity by megestrol acetate. Tansan S, et al. **Cancer Chemother Pharmacol** 1997; 39(4):333–40

Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Yamazaki K, et al. **Cancer Chemother Pharmacol** 1997; 39(3):192–8

Resistance to paclitaxel mediated by P–glycoprotein can be modulated by changes in the schedule of administration. Zhan Z, et al. **Cancer Chemother Pharmacol** 1997; 40(3):245–50

Vinorelbine (Navelbine): a third–generation vinca alkaloid. Budman DR. **Cancer Invest** 1997;15(5):475–90 (140 ref.)

Inhibitory effect of ursolic acid on B16 proliferation through cell cycle arrest. Es–saady D, et al. **Cancer Lett** 1996 Sep 10;106(2):193–7

In vitro evaluation of Taxol combined with radiations in human squamous cell carcinoma spheroids. Griffon–Etienne G, et al. **Cancer Lett** 1996 Dec 3; 109(1–2):23–32

Effects of oleanolic acid and ursolic acid on inhibiting tumor growth and enhancing the recovery of hematopoietic system postirradiation in mice. Hsu HY, et al. **Cancer Lett** 1997 Jan 1;111(1–2):7–13

Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Huang TS, et al. **Cancer Lett** 1996 Dec 20;110(1–2):77–85

Quassinoids as inhibitors of Epstein–Barr virus early antigen activation. Kubota K, et al. **Cancer Lett** 1997 Feb 26; 113(1–2):165–8

Cytotoxic potential of the preparations from Solanum trilobatum and the effect of sobatum on tumour reduction in mice. Mohanan PV, et al. **Cancer Lett** 1996 Dec 20; 110(1–2):71–6

Interferon potentiates antiproliferative activity of CPT–11 against human colon cancer xenografts. Ohwada S, et al. **Cancer Lett** 1996 Dec 20;110(1–2):149–54

Raf–1/bcl–2 phosphorylation: a step from microtubule damage to cell death. Blagosklonny MV, et al. **Cancer Res** 1997 Jan 1;57(1):130–5

Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Chen AY, et al. **Cancer Res** 1997 Apr 15;57(8):1529–36

In vitro and in vivo reversal of multidrug resistance in a human leukemia–resistant cell line by mdr1 antisense oligodeoxynucleotides. Cucco C, et al. **Cancer Res** 1996 Oct 1;56(19):4332–7

Combretastatin A–4, an agent that displays potent and selective toxicity toward tumor vasculature. Dark GG, et al. **Cancer Res** 1997 May 15;57(10):1829–34

Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide. Eymin B, et al. **Cancer Res** 1997 Feb 15;57(4):686–95

Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent. Gerhauser C, et al. **Cancer Res** 1997 Aug 15;57(16):3429–35

Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Goldwasser F, et al. **Cancer Res** 1996 Oct 1;56(19):4430–7

Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331–induced apoptosis. Huang TS, et al. **Cancer Res** 1997 Jul 15;57(14):2974–8

Paclitaxel– and docetaxel–dependent activation of CA–125 expression in human ovarian carcinoma cells. Marth C, et al. **Cancer Res** 1997 Sep 1;57(17):3818–22

Adenovirus infection enhances killing of melanoma cells by a mitotoxin. Satyamoorthy K, et al. **Cancer Res** 1997 May 15;57(10):1873–6

Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Wang LF, et al. **Cancer Res** 1997 Apr 15;57(8):1516–22

Down–regulation of DNA replication in extracts of camptothecin–treated cells: activation of an S–phase checkpoint? Wang Y, et al. **Cancer Res** 1997 May 1; 57(9):1654–9

Paclitaxel (Taxol): mechanisms of Resistance. Casazza AM, et al. **Cancer Treat Res** 1996;87:149–71 (107 ref.)

The clinical pharmacology of etoposide: an update. Joel S. **Cancer Treat Rev** 1996 May;22(3):179–221 (317 ref.)

Effect of notoginsenoside R1 on the synthesis of components of the fibrinolytic system in cultured smooth muscle cells of human pulmonary artery. Zhang WJ, et al. **Cell Mol Biol (Noisy–le–grand)** 1997 Jun;43(4):581–7

Tubulin assembly in the presence of calcium ions and taxol: microtubule bundling and formation of macrotubule–ring complexes. Vater W, et al. **Cell Motil Cytoskeleton** 1997; 36(1):76–83

Process of dispersion and fragmentation of Golgi complex by microtubule bundles formed in taxol treated HeLa cells. Hoshino H, et al. **Cell Struct Funct** 1997 Jun;22(3):325–34

Antitumor agents. 168. Dysoxylum cumingianum. IV. The structures of cumingianosides G–O, new triterpene glucosides with a 14,18–cycloapotirucallane–type skeleton from Dysoxylum cumingianum, and their cytotoxicity against human cancer cell lines. Fujioka T, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan;45(1):68–74

Studies on traditional Chinese drugs. Zhang J. **Chin Med J (Engl)** 1996 Jan;109(1):54–8 (0 ref.)

Antitumor activity of thevetoside in vitro. Zhang X, et al. **Chin Med J (Engl)** 1996 Jun;109(6):478–81

Ovarian cancer cell invasion is inhibited by paclitaxel. Westerlund A, et al. **Clin Exp Metastasis** 1997 May; 15(3):318–28

Irinotecan (CPT–11): a brief overview. Rivory LP. **Clin Exp Pharmacol Physiol** 1996 Oct–Nov; 23(10–11):1000–4 (29 ref.)

Growth inhibition of K–ras–expressing tumours by a new vinca alkaloid, conophylline, in nude mice. Umezawa K, et al. **Drugs Exp Clin Res** 1996;22(2):35–40

Differential stabilization of topoisomerase–II–DNA cleavable complexes by doxorubicin and etoposide in doxorubicin–resistant rat glioblastoma cells. Montaudon D, et al. **Eur J Biochem** 1997 Apr 15;245(2):307–15

Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. Nicholson KM, et al. **Eur J Cancer** 1997 Jul;33(8):1291–8

Release of cytokines by a fermented lectin–1 (ML–1) free mistletoe extract reflects differences in the reactivity of PBMC in healthy and allergic individuals and tumour patients. Stein GM, et al. **Eur J Clin Pharmacol** 1996; 51(3–4):247–52

Megakaryocyte–like increase in ploidy of Friend's erythroleukemia cells induced to endoreplication by colcemid. Paoletti F, et al. **Exp Hematol** 1996 Oct; 24(12):1441–8

Cytostatic activity of some essential oils against HEp–2 cells. Saenz MT, et al. **Farmaco** 1996 Jul;51(7):539–40

DNA fragmentation and ultrastructural changes in the brain of rabbits treated with vincristine. Muzylak M, et al. **Folia Neuropathol** 1996;34(3):129–35

Murine intestinal crypt survival after combined taxol plus radiation exposure. Lojun SL, et al. **Gynecol Oncol** 1996 Nov;63(2):180–3

Calcium pyrophosphate dihydrate crystals activate MAP kinase in human neutrophils: inhibition of MAP kinase, oxidase activation and degranulation responses of neutrophils by taxol. Jackson JK, et al. **Immunology** 1997 Apr;90(4):502–10

Positive interaction of bisbenzylisoquinoline alkaloid, cepharanthin, with vinca alkaloid agents against human tumors. Ono M, et al. **In Vivo** 1997 May–Jun;11(3):233–41

Inhibition of HBsAg secretion from Alexander cell line by Phyllanthus amarus. Jayaram S, et al. **Indian J Pathol Microbiol** 1996 Jul;39(3):211–5

The antineoplastic drug vinorelbine activates non–immunological histamine release from rat mast cells. Estévez MD, et al. **Inflamm Res** 1997 Apr;46(4):119–24

Overcoming CPT–11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans–membrane potential. Aogi K, et al. **Int J Cancer** 1997 Jul 17;72(2):295–300

Induction of apoptosis by ribosome–inactivating proteins and related immunotoxins. Bolognesi A, et al. **Int J Cancer** 1996 Nov 4;68(3):349–55

CPT–11 in human colon–cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Jansen WJ, et al. **Int J Cancer** 1997 Jan 27;70(3):335–40

DX–8951f, a water–soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN–38–resistant variant. Joto N, et al. **Int J Cancer** 1997 Aug 7;72(4):680–6

Anti–neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Nativ O, et al. **Int J Cancer** 1997 Jan 27;70(3):297–301

Paclitaxel–induced apoptosis in MCF–7 breast–cancer cells. Saunders DE, et al. **Int J Cancer** 1997 Jan 17;70(2):214–20

New nortriterpenoid isolated from anti–rheumatoid arthritic plant, Tripterygium wilfordii, modulates tumor growth and neovascularization. Ushiro S, et al. **Int J Cancer** 1997 Aug 7;72(4):657–63

Highly potent CD22–recombinant ricin A results in complete cure of disseminated malignant B–cell xenografts in SCID mice but fails to cure solid xenografts in nude mice. Van Horssen PJ, et al. **Int J Cancer** 1996 Nov 4;68(3):378–83

Taxol induces tyrosine phosphorylation of Shc and its association with Grb2 in murine RAW 264.7 cells. Wolfson M, et al. **Int J Cancer** 1997 Jan 17;70(2):248–52

Reduction of etoposide induced cell killing by hyperthermia can occur without changes in etoposide transport or DNA topoisomerase II activity. Ng CE, et al. **Int J Hyperthermia** 1996 Jul–Aug;12(4):551–67

Cytotoxicity and cell–cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Gupta N, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 1;37(4):885–95

Subadditive interaction of radiation and Taxol in vitro. Ingram ML, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 15;37(5):1139–44

Effects of alendronate and taxol on PC–3 ML cell bone metastases in SCID mice. Stearns ME, et al. **Invasion Metastasis** 1996;16(3):116–31

Efficacy of 5'–nor–anhydrovinblastine (vinorelbine), against freshly explanted clonogenic human tumor cells in vitro. Djuanda I, et al. **Invest New Drugs** 1996;14(2):153–9

Antitumor activity of combretastatin–A4 phosphate, a natural product tubulin inhibitor. Dorr RT, et al. **Invest New Drugs** 1996;14(2):131–7

In vitro cytotoxicity of S16020–2, a new olivacine derivative. Léonce S, et al. **Invest New Drugs** 1996;14(2):169–80

Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils. García I, et al. **J Antimicrob Chemother** 1996 Nov;38(5):859–63

Ubiquitin–dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. Desai SD, et al. **J Biol Chem** 1997 Sep 26;272(39):24159–64

In vitro and in vivo modulation by rhizoxin of non–P–glycoprotein–mediated vindesine resistance. Arioka

H, et al. **J Cancer Res Clin Oncol** 1997;123(4):195–200
Cell cycle effects of thaliblastine. Seifert F, et al. **J Cancer Res Clin Oncol** 1996;122(11):707–10
Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. Trielli MO, et al. **J Cell Biol** 1996 Nov;135(3):689–700
Development and partial characterization of a human T-lymphoblastic leukemic (CCRF-CEM) cell line resistant to etoposide. Analysis of possible circumventing approaches. Flandina C, et al. **J Chemother** 1996 Dec; 8(6):465–71
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. Kavallaris M, et al. **J Clin Invest** 1997 Sep 1;100(5):1282–93
Mitochondrial damage by a new antitumour agent furanonaphthoquinone derivative in human cervical cancer HeLa cells. Pan J, et al. **J Electron Microsc (Tokyo)** 1997; 46(2):181–7
In vitro cytotoxicity and immunomodulating property of Rhaphidophora korthalsii. Wong KT, et al. **J Ethnopharmacol** 1996 May;52(1):53–7
Effect of viscum album in the inhibition of lung metastasis in mice induced by B16F10 melanoma cells. Antony S, et al. **J Exp Clin Cancer Res** 1997 Jun;16(2):159–62
Structure-activity relationships of diverse Annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF-7/Adr) cells. Oberlies NH, et al. **J Med Chem** 1997 Jun 20;40(13):2102–6
Synthesis and structure-activity relationships of nonaromatic taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity. Ojima I, et al. **J Med Chem** 1997 Jan 31; 40(3):279–85
Syntheses and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III. Ojima I, et al. **J Med Chem** 1997 Jan 31;40(3):267–78
Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro. Zhao R, et al. **J Med Chem** 1997 Jan 17;40(2):216–25
Two new aromatic constitutents from the rootwood of Aeschynomene mimosifolia. Fullas F, et al. **J Nat Prod** 1996 Feb;59(2):190–2
Squamotacin: an annonaceous acetogenin with cytotoxic selectivity for the human prostate tumor cell line (PC-3). Hopp DC, et al. **J Nat Prod** 1996 Feb;59(2):97–9
Asterlingulatosides C and D, cytotoxic triterpenoid saponins from Aster lingulatus. Shao Y, et al. **J Nat Prod** 1997 Jul; 60(7):743–6
Selective cytotoxicity of ginkgetin from Selaginella moellendorffii. Sun CM, et al. **J Nat Prod** 1997 Apr; 60(4):382–4
Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide [see comments] Chen CL, et al. **J Natl Cancer Inst** 1996 Dec 18;88(24):1840–7. Comment in: J Natl Cancer Inst 1996 Dec 18;88(24):1787–9.
Baseline apoptosis of tumor cells as a response predictor to chemotherapy [letter; comment] Provinciali M, et al. **J Natl Cancer Inst** 1997 Jun 18;89(12):889–90. Comment on: J Natl Cancer Inst 1996 Sep 18;88(18):1308–14.
Reversible blockade of retrograde axonal transport in the rat sciatic nerve by vincristine. Macfarlane BV, et al. **J Pharm Pharmacol** 1997 Jan;49(1):97–101
Effects of the anticancer agent vinorelbine on endothelial cell permeability and tissue-factor production in man. Mouchard-Delmas C, et al. **J Pharm Pharmacol** 1996 Sep; 48(9):951–4
Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. Kubota T, et al. **J Surg Oncol** 1997 Feb;64(2):115–21
No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. Ohashi N, et al. **Jpn J Cancer Res** 1996 Dec;87(12):1280–7
Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Visani G, et al. **Leukemia** 1997 May;11(5):624–8
Effect of Cordyceps sinensis on the proliferation and differentiation of human leukemic U937 cells. Chen YJ, et al. **Life Sci** 1997;60(25):2349–59
L-canaline: a potent antimetabolite and anti-cancer agent from leguminous plants. Rosenthal GA. **Life Sci** 1997; 60(19):1635–41 (40 ref.)
Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo. Lievano G, et al. **Methods Find Exp Clin Pharmacol** 1996 Dec; 18(10):659–62
Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Lee LF, et al. **Mol Cell Biol** 1997 Sep;17(9):5097–105
Ionizing radiation and teniposide increase p21(waf1/cip1) and promote Rb dephosphorylation but fail to suppress E2F activity in MCF-7 breast tumor cells. Orr MS, et al. **Mol Pharmacol** 1997 Sep;52(3):373–9
Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Valenti M, et al. **Mol Pharmacol** 1997 Jul;52(1):82–7
Protein tyrosine phosphatase-dependent activation of beta-globin and delta-aminolevulinic acid synthase genes in the camptothecin-induced IW32 erythroleukemia cell differentiation. Wang MC, et al. **Mol Pharmacol** 1997 Apr; 51(4):558–66
Cytotoxicity of neem leaf extract (Azadirachta indica, Juss): an antitumour activity! [letter] Gogate SS. **Natl Med J India** 1996 Nov-Dec;9(6):297
A novel K+ channel blocker isolated from 'hiccup nut' toxin. Guatteo E, et al. **Neuroreport** 1996 Nov 4;7(15–17):2575–9
Seizure-induced damage to the hippocampus is prevented by modulation of the GABAergic system. Jolkkonen J, et al. **Neuroreport** 1996 Aug 12;7(12):2031–5
Effects of neonatal lesions of the basal forebrain cholinergic system by 192 immunoglobulin G-saporin: biochemical, behavioural and morphological characterization. Leanza G, et al. **Neuroscience** 1996 Sep;74(1):119–41
Evaluation of lipid-coated microbubbles as a delivery vehicle for Taxol in brain tumor therapy. Ho SY, et al. **Neurosurgery** 1997 Jun;40(6):1260–6; discussion 1266–8
The effect of dacarbazine and vincristine sulfate on human melanoma cell lines. In vitro analysis of interaction on DNA synthesis, RNA synthesis and protein synthesis. Tachihara R. **Nippon Ika Daigaku Zasshi** 1997 Jun; 64(3):238–48
Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Ueno NT, et al. **Oncogene** 1997 Aug 18;15(8):953–60
Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Yu D, et al. **Oncogene** 1996 Sep 19;13(6):1359–65
Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Asano T, et al. **Oncol Res** 1996; 8(3):101–10
Differential effects of taxol on two human cancer cell lines. Banerjee S, et al. **Oncol Res** 1997;9(5):237–48
Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. Fujimori A, et al. **Oncol Res** 1996; 8(7–8):295–301
Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Goldwasser F, et al. **Oncol Res** 1996;8(7–8):317–23
Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth [published erratum appears in Oncol Res 1995;7(10–11):565] Hashimoto S, et al. **Oncol Res** 1995;7(7–8):407–16
Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin. Kawanami K, et al. **Oncol Res** 1996;8(5):197–206
Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells. Hotta T, et al. **Oncology** 1997 Mar-Apr;54(2):153–7
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Baselga J, et al. **Oncology (Huntingt)** 1997 Mar;11(3 Suppl 2):43–8 (47 ref.)
Docetaxel in breast cancer and a rationale for combination therapy. Hortobágyi G. **Oncology (Huntingt)** 1997 Jun;11(6 Suppl 6):11–5 (21 ref.)
EPR oximetry: reduction of cell respiration by vinblastine. Dolenc D, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R261–2
Paclitaxel and nocodazole differentially alter endocytosis in cultured cells. Hamm-Alvarez SF, et al. **Pharm Res** 1996 Nov;13(11):1647–56
Synthesis and anti-proliferative activity of 2-hydroxy-1,2-dihydroacronycine glycosides. Mitaku S, et al. **Pharm Res** 1996 Jun;13(6):939–43
Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics. Yen WC, et al. **Pharm Res** 1996 Sep;13(9):1305–12
Etoposide phosphate, the water soluble prodrug of etoposide. Witterland AH, et al. **Pharm World Sci** 1996 Oct; 18(5):163–70 (38 ref.)
Decursinol angelate: a cytotoxic and protein kinase C activating agent from the root of Angelica gigas [letter] Ahn KS, et al. **Planta Med** 1997 Aug;63(4):360–1
Cytotoxicity and electron microscopy of cell death induced by goniothalamin. Ali AM, et al. **Planta Med** 1997 Feb; 63(1):81–3
New aporphine alkaloids and cytotoxic constituents of Hernandia nymphaeifolia. Chen IS, et al. **Planta Med** 1997 Apr;63(2):154–7
Inhibition of 5 alpha-reductase and aromatase by the ellagitannins oenothein A and oenothein B from Epilobium species. Ducrey B, et al. **Planta Med** 1997 Apr;63(2):111–4
Cytotoxic and antibacterial activities of sesquiterpene lactones isolated from Tanacetum praeteritum subsp. praeteritum. Gören N, et al. **Planta Med** 1996 Oct; 62(5):419–22
Activity of extracts and alkaloids of thai Alstonia species against human lung cancer cell lines. Keawpradub N, et al. **Planta Med** 1997 Apr;63(2):97–101
Cytotoxic and antioxidative sesquiterpenoids from Heterotheca inuloides. Kubo I, et al. **Planta Med** 1996 Oct; 62(5):427–30
Antimitotic and cytotoxic constituents of Myodocarpus gracilis [letter] Montagnac A, et al. **Planta Med** 1997 Aug; 63(4):365–6
In vitro cytotoxicity of tanshinones from Salvia miltiorrhiza. Ryu SY, et al. **Planta Med** 1997 Aug;63(4):339–42
p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Lanni JS, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9679–83
Immunomodulation contributes to the anticancer activity of morinda citrifolia (noni) fruit juice. Hirazumi A, et al. **Proc West Pharmacol Soc** 1996;39:7–9
Modulation of the effect of camptothecin in x-irradiated L5178Y-R and L5178Y-S cells by benzamide. Grądzka I, et al. **Radiat Environ Biophys** 1996 Aug;35(3):185–91
Inhibitory effects of tetrandrine and hernandezine on Ca2+ mobilization in rat glioma C6 cells. Imoto K, et al. **Res Commun Mol Pathol Pharmacol** 1997 Feb;95(2):129–46
The effect of paclitaxel on the radiosensitivity of gynecological tumor cells. Rave-Fränk M, et al. **Strahlenther Onkol** 1997 May;173(5):281–6
CPT-11 (irinotecan) in the treatment of colorectal cancer: a new mechanism of action for additional activity. Bleiberg H. **Tumori** 1997 Jan-Feb;83(1 Suppl):S85–6 (13 ref.)
Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell lines. Bonfrer JM, et al. **Tumour Biol** 1997;18(4):232–40
Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer? Seckin B, et al. **World J Urol** 1996;14 Suppl 1:S26–9
[A multivariate analysis approach to antineoplastic and antiviral structure-activity relationships to a series of podophyllotoxins] Doré JC, et al. **J Pharm Belg** 1996 Jan-Feb;51(1):9–18 (Eng. Abstr.) **(Fre)**
[Camptothecin and derivatives: a new class of antitumor agents] Torck M, et al. **J Pharm Belg** 1996 Jul-Aug; 51(4):200–7 (82 ref.) (Eng. Abstr.) **(Fre)**
[DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance] Furukawa M, et al. **Nippon Rinsho** 1997 May;55(5):1096–102 (20 ref.) (Eng. Abstr.) **(Jpn)**
[The effect of topoisomerase II inhibitor, vepesid, on binding of doxorubicin with DNA in tumor cells sensitive to anthracycline] Bogush TA, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):87–90 **(Rus)**
[The effect of verapamil on the growth and sensitivity to vincristine of human tumor transplanted into kidney capsule of mice] Storozhenko IV, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):681–3 **(Rus)**

POISONING

Overdosage of vinorelbine in a woman with metastatic non-small-cell lung carcinoma [letter] Lotz JP, et al. **Ann Oncol** 1997 Jul;8(7):714–5
Accidental intraventricular vincristine administration: an avoidable iatrogenic death. Lau G. **Med Sci Law** 1996 Jul; 36(3):263–5

SUPPLY & DISTRIBUTION

Cancer treatments rationed by authority [news] Halle M. **BMJ** 1996 Sep 28;313(7060):774

THERAPEUTIC USE

Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy. Blom R, et al. **Acta Oncol** 1996;35(6):733–6
Soy isoflavonoids and cancer prevention. Underlying biochemical and pharmacological issues. Barnes S, et al. **Adv Exp Med Biol** 1996;401:87–100
Plant phenolics as potential cancer prevention agents. Newmark HL. **Adv Exp Med Biol** 1996;401:25–34 (42 ref.)
Preclinical and clinical development of camptothecins. Costin D, et al. **Adv Pharmacol** 1994;29B:51–72 (120 ref.)
Evidence of activity of vinorelbine in patients with previously treated AIDS-associated Kaposi's sarcoma [letter] Errante D, et al. **AIDS** 1996 Dec;10(14):1742–3
Docetaxel. A review of its role in breast cancer treatment. Antoine EC, et al. **Am J Clin Oncol** 1997 Aug;20(4):429–32 (38 ref.)
Phase II study of docetaxel in advanced soft tissue sarcomas. Edmonson JH, et al. **Am J Clin Oncol** 1996 Dec;19(6):574–6
Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Nardi M, et al. **Am J Clin Oncol** 1997 Jun;20(3):230–2
Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma. Niitsu N, et al. **Am J Clin Oncol** 1997 Jun;20(3):311–4
Docetaxel and gemcitabine released for cancer chemotherapy [news] **Am J Health Syst Pharm** 1996 Jul 15;53(14):1643, 1649
A possible chemotherapeutic response by paclitaxel and other antineoplastic agents in treatment of choriocarcinoma in vitro [letter; comment] Farghaly SA. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):1075–7. Comment on: Am J Obstet Gynecol 1995 Dec;173(6):1835–42.
CPT-11. The European experience. Armand JP, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:282–91 (34 ref.)
Treatment of central nervous system xenografts with camptothecins. Friedman HS, et al. **Ann N Y Acad Sci**

1996 Dec 13;803:210–2
Protocols for the treatment of human tumor xenografts with camptothecins. Giovanella BC, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:181–7 (15 ref.)
Camptothecin and its analogs. An overview of their potential in cancer therapeutics. Muggia FM, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:213–23 (71 ref.)
Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Natelson EA, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:224–30
The current status of irinotecan (CPT-11) in the United States. Rothenberg ML. **Ann N Y Acad Sci** 1996 Dec 13; 803:272–81 (18 ref.)
Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan. Saijo N. **Ann N Y Acad Sci** 1996 Dec 13;803:292–305 (39 ref.)
Topoisomerase-I inhibitors in the management of colon cancer. Willson JK. **Ann N Y Acad Sci** 1996 Dec 13; 803:256–63 (46 ref.)
Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. Balzarotti M, et al. **Ann Oncol** 1996 Nov;7(9):970–2
Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Bokemeyer C, et al. **Ann Oncol** 1996 Jan;7(1):31–4
Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group. Furuse K, et al. **Ann Oncol** 1996 Oct;7(8):815–20
Paclitaxel in the salvage treatment of Hodgkin's disease and non-Hodgkin's lymphoma [letter] Hopfinger G, et al. **Ann Oncol** 1996 Apr;7(4):423–4
Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Lissoni A, et al. **Ann Oncol** 1996 Oct; 7(8):861–3
c-erbB-2/p185-directed therapy in human lung adenocarcinoma. Snider JM, et al. **Ann Thorac Surg** 1996 Nov;62(5):1454–9
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Rowinsky EK. **Annu Rev Med** 1997;48:353–74 (117 ref.)
The clinical rationale for developing docetaxel (Taxotere). Armand JP. **Anticancer Drugs** 1996 Aug;7 Suppl 2:37–9 (13 ref.)
Taxoids in combination chemotherapy for metastatic breast cancer. Dieras V, et al. **Anticancer Drugs** 1996 Aug;7 Suppl 2:47–52 (33 ref.)
Treatment of patients with liver metastases. Fumoleau P. **Anticancer Drugs** 1996 Aug;7 Suppl 2:21–3 (24 ref.)
Antitumor activity of paclitaxel after failure of high-dose chemotherapy in a patient with late relapse of a non-seminomatous germ cell tumor. Gerl A, et al. **Anticancer Drugs** 1996 Aug;7(6):716–8
Evaluation of Taxol in head and neck squamous carcinoma multicellular tumor spheroids. Griffon-Etienne G, et al. **Anticancer Drugs** 1997 Jan;8(1):48–55
Antitumor activity of S 16020-2 in two orthotopic models of lung cancer. Guilbaud N, et al. **Anticancer Drugs** 1997 Mar;8(3):276–82
Viscum album L. preparation Isorel modifies the immune response in normal and in tumour-bearing mice. Jurin M, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S27–31
Conclusion: the place of docetaxel (Taxotere) in future therapy. Khayat D. **Anticancer Drugs** 1996 Aug;7 Suppl 2:53
Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Kudelka AP, et al. **Anticancer Drugs** 1996 Jun;7(4):398–401
Remission of advanced uterine leiomyosarcoma with pulmonary metastases with carboplatin and paclitaxel. Kudelka AP, et al. **Anticancer Drugs** 1996 Nov;7(8):885–9
Anticarcinogenic and antimetastatic activity of Iscador. Kuttan G, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S15–6
Marked enhancement in vivo of paclitaxel's (taxol's) tumor-regressing activity by ATP-depleting modulation. Martin DS, et al. **Anticancer Drugs** 1996 Aug;7(6):655–9
Daily oral etoposide in metastatic breast cancer. Nešković-Konstantinović ZB, et al. **Anticancer Drugs** 1996 Jul;7(5):543–7
Management of advanced breast cancer: patient needs, challenges and new treatment options. Introduction. Norton L. **Anticancer Drugs** 1996 Aug;7 Suppl 2:1–3
Treatment of advanced breast cancer: current status. Piccart M. **Anticancer Drugs** 1996 Aug;7 Suppl 2:5–7 (15 ref.)
Treatment of patients resistant to anthracycline therapy. Ravdin PM. **Anticancer Drugs** 1996 Aug;7 Suppl 2:13–6
A phase II trial of docetaxel in advanced non-small cell lung cancer. Saarinen A, et al. **Anticancer Drugs** 1996 Nov; 7(8):890–2
Remission of refractory gestational trophoblastic disease with high-dose paclitaxel. Termrungruanglert W, et al. **Anticancer Drugs** 1996 Jul;7(5):503–6
First-line treatment of metastatic breast cancer. Trudeau ME. **Anticancer Drugs** 1996 Aug;7 Suppl 2:9–12
Treatment of patients resistant to paclitaxel therapy. Valero V. **Anticancer Drugs** 1996 Aug;7 Suppl 2:17–9
A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer. Weiss GR, et al. **Anticancer Drugs** 1996 Jun;7(4):402–9
The Viscum album preparation Isorel inhibits the growth of melanoma B16F10 by influencing the tumour-host relationship. Zarkovic N, et al. **Anticancer Drugs** 1997 Apr; 8 Suppl 1:S17–22
Vinorelbine as palliative therapy in advanced breast cancer. Gasco M, et al. **Anticancer Res** 1997 Mar-Apr; 17(2B):1431–3
Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Chamberlain MC. **Arch Neurol** 1997 May;54(5):554–8
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer. Shapiro JD, et al. **Aust N Z J Med** 1997 Feb;27(1):40–4
Paclitaxel (Taxol) as salvage therapy for relapsed ovarian cancer. Planner RS, et al. **Aust N Z J Obstet Gynaecol** 1996 May;36(2):168–70
Enhancement of the antitumor effect of gamma-ray irradiation in combination with camptothecin against human colorectal adenocarcinoma. Wang DS, et al. **Biol Pharm Bull** 1996 Mar;19(3):354–9
Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups. Gore ME, et al. **Br J Cancer** 1997;75(5):710–4
Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Papamichael D, et al. **Br J Cancer** 1997;75(4):606–7
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. van Meerbeeck J, et al. **Br J Cancer** 1996 Sep;74(6):961–3
Docetaxel. Leahy M, et al. **Br J Hosp Med** 1997 Feb 19–Mar 4;57(4):141–4
Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Terenziani M, et al. **Breast Cancer Res Treat** 1996;39(3):285–91
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group. Grozea PN, et al. **Cancer** 1997 Sep 15;80(6):1029–33
Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis [letter] Messori A, et al. **Cancer** 1997 Jun 1;79(11):2264–6
p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Safran H, et al. **Cancer** 1996 Sep 15;78(6):1203–10
Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel—a phase II study. Fazeny B, et al. **Cancer Chemother Pharmacol** 1996; 39(1-2):150–6
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Hare CB, et al. **Cancer Chemother Pharmacol** 1997;39(3):187–91
Effects of lycopene-enriched tomato oleoresin on 7,12-dimethyl-benz[a]anthracene-induced rat mammary tumors. Sharoni Y, et al. **Cancer Detect Prev** 1997; 21(2):118–23
Vinorelbine (Navelbine): a third-generation vinca alkaloid. Budman DR. **Cancer Invest** 1997;15(5):475–90 (140 ref.)
Higher in vivo protein binding of etoposide in children compared with adult cancer patients. Liliemark E, et al. **Cancer Lett** 1996 Aug 23;106(1):97–100
Enhanced antitumour effect of photodynamic therapy by microtubule inhibitors. Ma LW, et al. **Cancer Lett** 1996 Dec 3;109(1-2):129–39
Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Leonard CE, et al. **Cancer Res** 1996 Nov 15;56(22):5198–204
Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Udeani GO, et al. **Cancer Res** 1997 Aug 15;57(16):3424–8
Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines. Grądzka I, et al. **Cell Biochem Funct** 1996 Sep;14(3):163–71
A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer. Davidson NG, et al. **Clin Oncol (R Coll Radiol)** 1996; 8(6):358–62
Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Vinorelbine: an update and review of activity [letter] Macbeth F. **Clin Oncol (R Coll Radiol)** 1997;9(3):197
Taxanes in ovarian cancer treatment. Seetalarom K, et al. **Curr Opin Obstet Gynecol** 1997 Feb;9(1):14–20 (46 ref.)
Metastatic breast cancer. Kennedy MJ. **Curr Opin Oncol** 1996 Nov;8(6):485–90 (32 ref.)
New systemic drugs in the treatment of gastrointestinal cancer. Ogawa M. **Curr Opin Oncol** 1996 Jul;8(4):317–20 (21 ref.)
Vinorelbine therapy for Kaposi's sarcoma in a kidney transplant patient. Brambilla L, et al. **Dermatology** 1997; 194(3):281–3
Paclitaxel and docetaxel in breast and ovarian cancer. **Drug Ther Bull** 1997 Jun;35(6):43–6 (34 ref.)
Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Wiseman LR, et al. **Drugs** 1996 Oct;52(4):606–23 (66 ref.)
A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study. Aravantinos G, et al. **Eur J Cancer** 1997 Jan;33(1):160–3
Feasibility of paclitaxel in a patient with anthracycline-induced congestive heart failure [letter] Colleoni M, et al. **Eur J Cancer** 1997 Feb;33(2):321–2
Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Cunningham D. **Eur J Cancer** 1996; 32A Suppl 3:S1–8 (39 ref.)
Vinorelbine in pregnancy [letter] Cuvier C, et al. **Eur J Cancer** 1997 Jan;33(1):168–9
Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum. du Bois A, et al. **Eur J Cancer** 1997 Mar; 33(3):379–84
Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma [letter] Gebbia N, et al. **Eur J Cancer** 1996 Sep;32A(10):1822–3
Single agent paclitaxel in advanced squamous cell head and neck carcinoma [letter] Gebbia V, et al. **Eur J Cancer** 1996 May;32A(5):901–2
Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Gridelli C, et al. **Eur J Cancer** 1997 Mar;33(3):392–7
A pilot study to evaluate paclitaxel (Taxol) as primary medical treatment for patients with inoperable stage III and IV breast carcinoma. Rees CN, et al. **Eur J Cancer** 1996 Dec;32A(13):2354–6
Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Shimada Y, et al. **Eur J Cancer** 1996;32A Suppl 3:S13–7 (27 ref.)
Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Veronesi A, et al. **Eur J Cancer** 1996 Sep;32A(10):1809–11
Future directions for clinical research with CPT-11 (irinotecan). von Hoff D. **Eur J Cancer** 1996;32A Suppl 3:S9–12 (20 ref.)
Prolonged stabilization of progressive platinum-refractory ovarian cancer with paclitaxel: brief report. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(4):264–6
Response of choriocarcinoma to paclitaxel. Case report and review of resistance. Gerson R, et al. **Eur J Gynaecol Oncol** 1997;18(2):108–10
Prolonged oral etoposide for advanced uterine leiomyosarcoma with pulmonary metastases: case report. Termrungruanglert W, et al. **Eur J Gynaecol Oncol** 1997; 18(2):97–100
Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice. Miki T, et al. **Eur Urol** 1997;31(1):92–6
Paclitaxel in advanced ovarian cancer: too much optimism? [letter] Bulusu VR, et al. **Gynecol Oncol** 1997 Aug; 66(2):335–6
Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer. Fleming GF, et al. **Gynecol Oncol** 1997 Apr;65(1):42–5
Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Mayerhofer K, et al. **Gynecol Oncol** 1997 Jan;64(1):109–13
Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Shapiro JD, et al. **Gynecol Oncol** 1996 Oct;63(1):89–93
Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Thigpen T, et al. **Gynecol Oncol** 1996 Oct;63(1):120–2
Reduced toxicity and enhanced antitumor efficacy of betacyclodextrin plumbagin inclusion complex in mice bearing Ehrlich ascites carcinoma. Singh UV, et al. **Indian J Physiol Pharmacol** 1997 Apr;41(2):171–5
Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Forsyth P, et al. **Invest New Drugs** 1996;14(2):203–6
A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study. Higano CS, et al. **Invest New Drugs** 1997;15(2):153–6
Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer. Latreille J, et al. **Invest New Drugs** 1996;13(4):343–5
New microtubular agents in pediatric oncology. Seibel NL, et al. **Invest New Drugs** 1996;14(1):49–54 (45 ref.)
Taxotere becomes first drug to outperform Adriamycin [news] **Ir Med J** 1997 Jun-Jul;90(4):156
The role of VP-16 in autologous bone marrow transplantation for acute myeloblastic leukemia. Parikh PM, et al. **J Assoc Physicians India** 1996 Apr;44(4):252–4
Identifying differential gene expression in monoterpene-treated mammary carcinomas using subtractive display. Ariazi EA, et al. **J Biol Chem** 1996 Nov 15;271(46):29286–94
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. Giannakakou P, et al. **J Biol Chem** 1997 Jul 4;272(27):17118–25
Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients. Tononi A, et al. **J Chemother** 1997 Aug;9(4):304–8
Recurrent cerebellar gliomas: salvage therapy with oral etoposide. Chamberlain MC. **J Child Neurol** 1997 Apr;

12(3):200–4
Mobilization of peripheral–blood progenitor cells with high–dose etoposide and granulocyte colony–stimulating factor in patients with breast cancer, non–Hodgkin's lymphoma, and Hodgkin's disease. Copelan EA, et al. **J Clin Oncol** 1997 Feb;15(2):759–65
Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non–small–cell lung cancer [see comments] [published erratum appears in J Clin Oncol 1996 Dec;14(12):3175] Crawford J, et al. **J Clin Oncol** 1996 Oct;14(10):2774–84. Comment in: J Clin Oncol 1996 Oct;14(10):2627–30.
Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. Fetell MR, et al. **J Clin Oncol** 1997 Sep; 15(9):3121–8
Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. Lacava JA, et al. **J Clin Oncol** 1997 Feb;15(2):604–9
Dose–intensive vinorelbine with concurrent granulocyte colony–stimulating factor support in paclitaxel–refractory metastatic breast cancer. Livingston RB, et al. **J Clin Oncol** 1997 Apr;15(4):1395–400
Phase II trial of docetaxel in patients with advanced or metastatic transitional–cell carcinoma. McCaffrey JA, et al. **J Clin Oncol** 1997 May;15(5):1853–7
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. Pitot HC, et al. **J Clin Oncol** 1997 Aug;15(8):2910–9
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy–naive patients and patients pretreated with fluorouracil–based chemotherapy. Rougier P, et al. **J Clin Oncol** 1997 Jan;15(1):251–60
Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. Safran H, et al. **J Clin Oncol** 1997 Mar;15(3):901–7
Clinical and pharmacokinetic study of oral etoposide in patients with AIDS–related Kaposi's sarcoma with no prior exposure to cytotoxic therapy. Schwartsmann G, et al. **J Clin Oncol** 1997 May;15(5):2118–24
Phase II study of irinotecan in prior chemotherapy–treated squamous cell carcinoma of the cervix. Verschraegen CF, et al. **J Clin Oncol** 1997 Feb;15(2):625–31
Phase II trial of paclitaxel and granulocyte colony–stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. Whitehead RP, et al. **J Clin Oncol** 1997 Jun;15(6):2414–9
CPT–11: the European clinical development. Terret C, et al. **J Infus Chemother** 1996 Summer;6(3):152–7 (44 ref.)
Five–day oral etoposide treatment for advanced small–cell lung cancer: randomized comparison with intravenous chemotherapy. Souhami RL, et al. **J Natl Cancer Inst** 1997 Apr 16;89(8):577–80
Allogeneic bone marrow transplant in pediatric patients with high–risk hematopoietic malignancies early in the course of their disease. Amylon MD, et al. **J Pediatr Hematol Oncol** 1997 Jan–Feb;19(1):54–61
Taxotere. Renick–Ettinger A. **J Pediatr Oncol Nurs** 1996 Jan;13(1):43–5 (10 ref.)
Niosomal plumbagin with reduced toxicity and improved anticancer activity in BALB/C mice. Naresh RA, et al. **J Pharm Pharmacol** 1996 Nov;48(11):1128–32
Reproductive status in GTD treated with etoposide. Matsui H, et al. **J Reprod Med** 1997 Feb;42(2):104–10
Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. Dreicer R, et al. **J Urol** 1996 Nov;156(5):1606–8. 1996 Nov;156(6):1609–10.
Enhancement of tumor radio–response by irinotecan in human lung tumor xenografts. Tamura K, et al. **Jpn J Cancer Res** 1997 Feb;88(2):218–23
Efficacy of camptothecin in progressive multifocal leucoencephalopathy [letter; comment] O'Reilly S. **Lancet** 1997 Jul 26;350(9073):291. Comment on: Lancet 1997 May 10;349(9062):1366.
Vinorelbine: a new promising drug in Hodgkin's disease. Devizzi L, et al. **Leuk Lymphoma** 1996 Aug;22(5–6):409–14 (47 ref.)
Evaluation of Taxol cytotoxicity on B–CLL cells in vitro. Di Raimondo F, et al. **Leuk Lymphoma** 1997 Jun; 26(1–2):115–9
Taxol pretreatment of tumor targets amplifies natural killer cell mediated lysis. Mehta S, et al. **Leuk Lymphoma** 1997 Jun;26(1–2):67–76
The taxanes: miracles for breast cancer treatment or just more chemotherapy? [editorial; comment] Claringbold PG. **Med J Aust** 1997 May 19;166(10):518–9. Comment on: Med J Aust 1997 May 19;166(10):520–3.
Recent advances in managing non–small–cell lung cancer: 4. Chemotherapy of metastatic cancer. Clarke SJ, et al. **Med J Aust** 1997 Jun 2;166 Suppl:S14–6
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy [see comments] Michael M, et al. **Med J Aust** 1997 May 19; 166(10):520–3. Comment in: Med J Aust 1997 May 19;166(10):518–9.
Irinotecan for metastatic colorectal cancer. **Med Lett Drugs Ther** 1997 Jan 17;39(992):8
Docetaxel (Taxotere) for advanced breast cancer. **Med Lett Drugs Ther** 1996 Sep 27;38(984):87–8 (0 ref.)
Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Einzig AI, et al. **Med Oncol** 1996 Jun; 13(2):111–7
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Einzig AI, et al. **Med Oncol** 1996 Jun; 13(2):87–93
Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Needle MN, et al. **Med Pediatr Oncol** 1997 Jul;29(1):28–32
Long–lasting complete remission after prolonged administration of etoposide in a child with a second recurrence of alveolar rhabdomyosarcoma. Schiavetti A, et al. **Med Pediatr Oncol** 1997 Feb;28(2):144–6
Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview. Hájek R, et al. **Neoplasma** 1996; 43(3):141–54 (158 ref.)
Oral vinorelbine promising and well tolerated in patients with advanced breast cancer [news] **Oncology (Huntingt)** 1997 Feb;11(2):255
Docetaxel said to be highly effective and well tolerated in advanced head and neck cancer [news] **Oncology (Huntingt)** 1996 Mar;10(3):422
Paclitaxel as first–line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand. Bishop JF, et al. **Oncology (Huntingt)** 1997 Apr; 11(4 Suppl 3):19–23 (43 ref.)
The international experience with docetaxel in the treatment of breast cancer. Ravdin PM. **Oncology (Huntingt)** 1997 Mar;11(3 Suppl 2):38–42 (30 ref.)
Paclitaxel for breast cancer: the Memorial Sloan–Kettering Cancer Center experience. Seidman AD, et al. **Oncology (Huntingt)** 1997 Mar;11(3 Suppl 2):20–8 (62 ref.)
Integration of vinorelbine into chemotherapy strategies for non–small–cell lung cancer. Vokes EE. **Oncology (Huntingt)** 1995 Jun;9(6):565–74, 577; discussion 577–8, 581– (106 ref.)
Treatment of relapsed Langerhans cell histiocytosis by cyclosporin A combined with etoposide and prednisone. Körholz D, et al. **Pediatr Hematol Oncol** 1997 Sep–Oct; 14(5):443–9
Etoposide phosphate, the water soluble prodrug of etoposide. Witterland AH, et al. **Pharm World Sci** 1996 Oct; 18(5):163–70 (38 ref.)
Therapeutic potential of paclitaxel–radiation treatment of a murine ovarian carcinoma. Milas L, et al. **Radiother Oncol** 1996 Aug;40(2):163–70
Phase II data on paclitaxel and docetaxel in gastrointestinal malignancies. Aapro MS. **Recent Results Cancer Res** 1996; 142:425–30
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 3: Gynecologic malignancies, head and neck cancer, and other tumor types. Marrakech, Morocco, January 18–20, 1996 and St Croix, Virgin Islands, March 13–16, 1996. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–1–S2–120; quiz S2–121–S2–123 (0 ref.)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 4: Breast Cancer II. Marrakech, Morocco, January 18–20, 1996 and St Croix, US Virgin Islands, March 13–16, 1996. **Semin Oncol** 1997 Feb;24(1 Suppl 3):S1–49, quiz S50–5 (0 ref.)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 1: Lung Cancer. Puerto Rico, March 12–16, 1997. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–1–S12–162; quiz S12–163–S12–173 (0 ref.)
Sarah Cannon Cancer Center Consensus Conference on Novel Developments with Podophyllotoxin Therapy. **Semin Oncol** 1996 Dec;23(6 Suppl 13):1–60 (0 ref.)
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 1: Breast Cancer I. **Semin Oncol** 1996 Oct; 23(5 Suppl 11):1–70 (0 ref.)
Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. Ajani JA, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 12):55–8
Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Bunn PA Jr. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–153–S12–162 (63 ref.)
Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. D'Andrea GM, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 13):S13–27–S13–44 (109 ref.)
Single–agent paclitaxel as first–line treatment of metastatic breast cancer: the British experience. Davidson NG. **Semin Oncol** 1996 Oct;23(5 Suppl 11):6–10
The development of docetaxel (Taxotere) in non–small cell lung cancer—docetaxel in new combinations and new schedules: an overview of ongoing and future developments. Donnellan PP, et al. **Semin Oncol** 1997 Aug; 24(4 Suppl 14):S14–18–S14–21
Single–agent paclitaxel in the treatment of small cell lung cancer. Ettinger DS. **Semin Oncol** 1996 Dec;23(6 Suppl 16):16–7
Docetaxel (Taxotere) and gemcitabine in the treatment of non–small cell lung cancer: preliminary results. Georgoulias V, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 14):S14–22–S14–25
Docetaxel (Taxotere) and vinorelbine in the treatment of non–small cell lung cancer. Georgoulias V, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 14):S14–9–S14–14
The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non–small cell lung cancer. Harper P. **Semin Oncol** 1997 Aug;24(4 Suppl 14):S14–30–S14–32
Paclitaxel in simultaneous radiochemotherapy of head and neck cancer: preclinical and clinical results. Hoffmann W, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–72–S2–77
Introduction: taxoids and the management of breast cancer. Hortobagyi GN. **Semin Oncol** 1997 Aug;24(4 Suppl 13):S13–1–S13–2
The development of docetaxel (Taxotere) in non–small cell lung cancer. Kris MG, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 14):S14–1–S14–4
Twice–weekly paclitaxel and radiation for stage III non–small cell lung cancer. Lau DH, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–106–S12–109
Paclitaxel and radiotherapy in the treatment of advanced non–small cell lung cancer. Marangolo M, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):31–4
Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non–small cell lung cancer: preliminary results of a phase I/II trial. Miller VA. **Semin Oncol** 1997 Aug; 24(4 Suppl 14):S14–15–S14–17
Future perspectives of docetaxel (Taxotere) in front–line therapy. Piccart MJ, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 10):S10–27–S10–33 (41 ref.)
An ongoing European organization for research and treatment of cancer crossover trial comparing single–agent paclitaxel and doxorubicin as first– and second–line treatment of advanced breast cancer. Piccart–Gebhart MJ, et al. **Semin Oncol** 1996 Oct;23(5 Suppl 11):11–5
Single–agent paclitaxel in advanced non–small cell lung cancer: single–center phase II study using a 3–hour administration schedule. Ranson MR, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–6–S12–9
Docetaxel (Taxotere) for the treatment of anthracycline–resistant breast cancer. Ravdin PM. **Semin Oncol** 1997 Aug;24(4 Suppl 10):S10–18–S10–21 (26 ref.)
Intensive radiation therapy concurrent with up to 7–week continuous–infusion paclitaxel for locally advanced solid tumors: phase I studies [published erratum appears in Semin Oncol 1997 Aug;24(4):499] Rosenthal DI, et al. **Semin Oncol** 1997 Feb;24(1 Suppl 2):S2–81–S2–84
Seven–week continuous–infusion paclitaxel plus concurrent radiation therapy for locally advanced non–small cell lung cancer: a phase I study. Rosenthal DI, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–96–S12–100
Docetaxel as single–agent therapy in metastatic breast cancer: clinical efficacy. Valero V. **Semin Oncol** 1997 Aug;24(4 Suppl 13):S13–11–S13–18 (39 ref.)
Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies. Vogt HG, et al. **Semin Oncol** 1997 Aug;24(4 Suppl 12):S12–101–S12–105 (15 ref.)
Simultaneous radiochemotherapy with paclitaxel in non–small cell lung cancer: a clinical phase I study. Vogt HG, et al. **Semin Oncol** 1996 Dec;23(6 Suppl 15):26–30
Clinical studies of docetaxel (Taxotere) and concomitant chest therapy. Vokes EE, et al. **Semin Oncol** 1997 Aug; 24(4 Suppl 14):S14–26–S14–29
The taxoids: same roots, different drugs. Von Hoff DD. **Semin Oncol** 1997 Aug;24(4 Suppl 13):S13–3–S13–10 (53 ref.)
Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte–colony–stimulating factor: an analysis of 497 patients. Weaver CH, et al. **Transfusion** 1997 Sep; 37(9):896–903
Paclitaxel activity in anthracycline refractory breast cancer patients. Vici P, et al. **Tumori** 1997 May–Jun;83(3):661–4
[The effect of topically garlic solution painting on experimental oral precancer and oral cancer in rats] Tang Z, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 Jul; 30(4):232–4 **(Chi)**
[Clinical study on effect of combined treatment of fuchunpian with radiotherapy on nasopharyngeal carcinoma] Han JQ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Dec;15(12):710–2 (Eng. Abstr.) **(Chi)**
[A phase II study with mitoxantrone–vinorelbine association in the treatment of advanced breast cancer in elderly women] Gladieff L, et al. **Bull Cancer** 1996 Sep;83(9):703–6 (Eng. Abstr.) **(Fre)**
[Navelbine (Vinorelbin)—current trends and results. Satellite symposium of the 22nd German Cancer Congress. Berlin, 20 February 1996] **Dtsch Med Wochenschr** 1996 Apr 12; 121(15 Suppl):1–8 **(Ger)**
[Chemotherapy of ovarian and breast cancer with Taxol] **Dtsch Med Wochenschr** 1996 Dec;121(50 Suppl):1–12 **(Ger)**
[Navelbine (Vinorelbin)—current trends and results. Satellite–Symposium on occasion of the 22nd German Cancer Congress. Berlin, 20 February 1996] **Geburtshilfe Frauenheilkd** 1996 Apr;56(4 Suppl):1–4 **(Ger)**
[Taxol in bronchial carcinoma] Gatzemeier U. **Med Klin** 1996 Dec 15;91 Suppl 2:1–6 (41 ref.) **(Ger)**
[Paclitaxel in therapy of breast carcinoma. Value and

perspectives] Klaassen U, et al. **Med Klin** 1996 Dec 15;91 Suppl 2:7–10 (31 ref.) **(Ger)**
[Docetaxel in lymphangiosis carcinomatosa] Pestalozzi BC. **Schweiz Med Wochenschr** 1997 May 10;127(19):839 **(Ger)**
[Regazell–Energen: bioactivator in tumor treatment? Documentation No. 26 D] Hauser SP, et al. **Schweiz Rundsch Med Prax** 1996 Dec 17;85(51–52):1652–5 (Eng. Abstr.) **(Ger)**
[Alzoon—antineoplastic remedy or medicinal syrup?] Hauser SP. **Schweiz Rundsch Med Prax** 1997 Jul 2; 86(27–28):1113–5 (Eng. Abstr.) **(Ger)**
[New drugs. Topoisomerase inhibitors] Gutzler F. **Zentralbl Gynakol** 1996;118(10):579 **(Ger)**
[Taxol] Kühnle H. **Zentralbl Gynakol** 1996;118(10):580 **(Ger)**
[A case of recurrent advanced colon cancer treated with CPT–11 for second–line chemotherapy] Kawabe S, et al. **Gan To Kagaku Ryoho** 1997 Aug;24(10):1315–9 (Eng. Abstr.) **(Jpn)**
[Effect of etoposide on a human pancreatic cancer cell line exposed to high dose X–ray irradiation] Mizumoto K, et al. **Gan To Kagaku Ryoho** 1996 Oct;23(12):1673–5 (3 ref.) (Eng. Abstr.) **(Jpn)**
[A new, more expensive agent against ovarian cancer. Worth its price?] Högberg T, et al. **Lakartidningen** 1997 Jan 8; 94(1–2):21–4 **(Swe)**

TOXICITY

Effects of taxol on isolated rat hepatocyte metabolism. Manzano A, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):C1957–62
Genotoxic effects of Karwinskia humboldtiana toxin T–514 in peripheral blood lymphocytes. Velazco MR, et al. **Anticancer Drugs** 1996 Aug;7(6):710–5
Formation of topoisomerase II alpha complexes with nascent DNA is related to VM–26–induced cytotoxicity. Qiu J, et al. **Biochemistry** 1996 Dec 17;35(50):16354–60
The effect of vincristine–polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity. Zhu G, et al. **Cancer Chemother Pharmacol** 1996; 39(1–2):138–42
Paclitaxel–induced apoptosis in HeLa cells is serum dependent. Maldonado V, et al. **J Biochem Toxicol** 1996; 11(4):183–8
Activation of multiple interleukin–1beta converting enzyme homologues in cytosol and nuclei of HL–60 cells during etoposide–induced apoptosis. Martins LM, et al. **J Biol Chem** 1997 Mar 14;272(11):7421–30
In vivo modulation of vincristine–induced neurotoxicity in Lymnaea stagnalis, by the ACTH(4–9) analogue Org 2766. Kiburg B, et al. **J Neurooncol** 1996 Dec;30(3):173–80
Glutamate ameliorates experimental vincristine neuropathy. Boyle FM, et al. **J Pharmacol Exp Ther** 1996 Oct; 279(1):410–5
Toxicity profile of the investigational new biotherapeutic agent, B43 (anti–CD19)–pokeweed antiviral protein immunotoxin. Gunther R, et al. **Leuk Lymphoma** 1996 Jun; 22(1–2):61–70, follow.186, color plate II–V
DNA–damaging agents induce both p53–dependent and p53–independent apoptosis in immature thymocytes. MacFarlane M, et al. **Mol Pharmacol** 1996 Oct;50(4):900–11
Enhancement of micronuclei frequency by vindesine in mouse bone marrow. Jagetia GC, et al. **Mutat Res** 1997 Jan 15;388(1):1–5
SARs of annonaceous acetogenins in rat liver mitochondria [published erratum appears in Nat Toxins 1996;4(6):295] Alfonso D, et al. **Nat Toxins** 1996;4(4):181–8
Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Aley KO, et al. **Neuroscience** 1996 Jul;73(1):259–65
Effect on the peripheral nervous system of the short–term intravenous administration of paclitaxel in the rat. Cavaletti G, et al. **Neurotoxicology** 1997;18(1):137–45
Cytotoxic triterpenoids from the leaves of Euphorbia pulcherrima. Smith–Kielland I, et al. **Planta Med** 1996 Aug; 62(4):322–5
Mouse embryonic development and tumor cell growth under the influence of recombinant trichosanthin (a ribosome inactivating protein) and its muteins. Chan WY, et al. **Teratog Carcinog Mutagen** 1995;15(5):259–68
Susceptibility to vinblastine–induced aneuploidy and preferential chromosome segregation during meiosis I in Robertsonian heterozygous mice. Pacchierotti F, et al. **Teratog Carcinog Mutagen** 1995;15(5):217–30
Experimental evidence for toxic damage induced by a dimeric anthracenone: diast T–514 (peroxisomicine A2). Martínez FJ, et al. **Toxicol Lett** 1997 Feb 7;90(2–3):155–62
Evaluation of cytotoxic effects of different doses of vinblastine on mouse spermatogenesis by flow cytometry. Jagetia GC, et al. **Toxicology** 1996 Sep 2;112(3):227–36
Metabolic activation of pyrrolizidine alkaloids by human, rat and avocado microsomes. Couet CE, et al. **Toxicon** 1996 Sep;34(9):1058–61
Extracts from Viscum and Crataegus are cytotoxic against larynx cancer cells. Sáenz MT, et al. **Z Naturforsch [C]** 1997 Jan–Feb;52(1–2):42–4
(+)–10 alpha–Hydroxy–4–muurolen–3–one, a new inhibitor of leukotriene biosynthesis from a Favolaschia species. Comparison with other sesquiterpenes. Zapf S, et al. **Z Naturforsch [C]** 1996 Jul–Aug;51(7–8):487–91

URINE

Determination of a new podophyllotoxin derivative, TOP–53, and its metabolite in rat plasma and urine by high–performance liquid chromatography with electrochemical detection. Kitamura R, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):283–8

ANTINEOPLASTIC ANTIBIOTICS see **ANTIBIOTICS, ANTINEOPLASTIC**

ANTINEOPLASTIC ANTIMETABOLITES see **ANTIMETABOLITES, ANTINEOPLASTIC**

ANTINEOPLASTIC DRUG COMBINATIONS see **ANTINEOPLASTIC AGENTS, COMBINED**

ANTINEOPLASTIC DRUG RESISTANCE see **DRUG RESISTANCE, NEOPLASM**

ANTINEOPLASTICS, BOTANICAL see **ANTINEOPLASTIC AGENTS, PHYTOGENIC**

ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES see **ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC**

ANTINOCICEPTIVE AGENTS see **ANALGESICS**

ANTINUCLEAR ANTIBODIES see **ANTIBODIES, ANTINUCLEAR**

ANTINUCLEAR ANTIBODY TEST, FLUORESCENT see **FLUORESCENT ANTIBODY TECHNIQUE**

ANTINUCLEAR FACTORS see **ANTIBODIES, ANTINUCLEAR**

ANTI–OBESITY AGENTS

Antiobesity drug, dexfenfluramine, cleared for marketing [news] **Am J Health Syst Pharm** 1996 Jun 1;53(11):1229
[A miracle cure and its solution (letter)] Borchgrevink CF. **Tidsskr Nor Laegeforen** 1997 Jan 30;117(3):410 **(Nor)**

ADVERSE EFFECTS

Chronic renal failure after ingestion of over–the–counter chromium picolinate [letter] Wasser WG, et al. **Ann Intern Med** 1997 Mar 1;126(5):410
Belgian (Chinese herb) nephropathy: why? Violon C. **J Pharm Belg** 1997 Jan–Feb;52(1):7–27
[Adverse reactions of anti–obesity master formulations (letter)] Lorenzo Riera A, et al. **Aten Primaria** 1996 Jun 30;18(2):98 **(Spa)**

PHARMACOLOGY

Anti–obesity and anti–diabetic effects of mazindol in yellow KK mice: its activating effect on brown adipose tissue thermogenesis. Yoshida T, et al. **Clin Exp Pharmacol Physiol** 1996 Jun–Jul;23(6–7):476–82
Sibutramine: a review of the pharmacology of a novel anti–obesity agent. Stock MJ. **Int J Obes Relat Metab Disord** 1997 Mar;21 Suppl 1:S25–9 (29 ref.)

THERAPEUTIC USE

High–frequency oscillatory ventilation with partial liquid ventilation in a model of acute respiratory failure. Baden HP, et al. **Crit Care Med** 1997 Feb;25(2):299–302
Pharmacological approaches to intervention. Guy–Grand B. **Int J Obes Relat Metab Disord** 1997 Mar;21 Suppl 1:S22–4 (7 ref.)
Sibutramine—a review of clinical efficacy. Lean ME. **Int J Obes Relat Metab Disord** 1997 Mar;21 Suppl 1:S30–6; discussion 37–9 (18 ref.)
Drug therapy for obesity: an update. Popovich NG, et al. **J Am Pharm Assoc (Wash)** 1997 Jan–Feb;NS37(1):31–9, 56 (34 ref.)
The pharmacologic management of obesity. Cerda JJ. **J Fla Med Assoc** 1997 Feb;84(2):89–92
["Anti–obesity master formulations" and "miraculous products" (reply) (letter)] Alonso Herreros JM. **Rev Clin Esp** 1997 Feb;197(2):136–7 **(Spa)**

ANTIONCOGENES see **GENES, SUPPRESSOR, TUMOR**

ANTIOXIDANTS

see related
OXIDATIVE STRESS
PHARMACEUTIC AIDS

Platelet serotonin acts as a locally releasable antioxidant. Huether G, et al. **Adv Exp Med Biol** 1996;398:299–306 (37 ref.)
Combined effects of lipid peroxidation and antioxidant status on carotid atherosclerosis in a population aged 59–71 y: The EVA Study. Etude sur le Vieillisement Artériel. Bonithon–Kopp C, et al. **Am J Clin Nutr** 1997 Jan; 65(1):121–7
Exercise, oxidative stress, and antioxidants. Ji LL. **Am J Sports Med** 1996;24(6 Suppl):S20–4 (42 ref.)
Antioxidants in human health and disease. Halliwell B. **Annu Rev Nutr** 1996;16:33–50 (124 ref.)
Direct evidence for antioxidant effect of Bcl–2 in PC12 rat pheochromocytoma cells. Tyurina YY, et al. **Arch Biochem Biophys** 1997 Aug 15;344(2):413–23
Glutathione transferases catalyse the detoxication of oxidized metabolites (o–quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Baez S, et al. **Biochem J** 1997 May 15;324 (Pt 1):25–8
Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES–FR30 ESR spectrometer system. Noda Y, et al. **Biochem Mol Biol Int** 1997 Jun;42(1):35–44
Protection against muscle damage exerted by oestrogen: hormonal or antioxidant action? Bär PR, et al. **Biochem Soc Trans** 1997 Feb;25(1):50–4 (39 ref.)
Phloridzin derivatives; food additives/chemopreventative drugs of the future. Ridgway T, et al. **Biochem Soc Trans** 1997 Feb;25(1):109S
Actions of oestrogen on vascular endothelial and smooth–muscle cells. Ruehlmann DO, et al. **Biochem Soc Trans** 1997 Feb;25(1):40–5 (79 ref.)
Oestrogens as antioxidant cardioprotectants. Wiseman H, et al. **Biochem Soc Trans** 1997 Feb;25(1):54–9 (48 ref.)
Thiopalmitic acid–mediated Fe(III)–nitrilotriacetate reduction and lipid peroxidation. Tanaka M, et al. **Biol Pharm Bull** 1996 May;19(5):678–82
Interaction between model membranes and a new class of surfactants with antioxidant function. Przestalski S, et al. **Biophys J** 1996 May;70(5):2203–11
Antioxidative enzyme activities in human erythrocytes. Andersen HR, et al. **Clin Chem** 1997 Apr;43(4):562–8
Antioxidant defense: vitamins E and C and carotenoids. Stahl W, et al. **Diabetes** 1997 Sep;46 Suppl 2:S14–8
Antioxidants and diabetes [news] Bloomgarden ZT. **Diabetes Care** 1997 Apr;20(4):670–3
Thiamine may indirectly act as an antioxidant [letter; comment] Bakker SJ, et al. **Diabetologia** 1997 Jun; 40(6):741–2. Comment on: Diabetologia 1996 Nov;39(11):1263–8.
Oxygen toxicity, free radicals and antioxidants in human disease: biochemical implications in atherosclerosis and the problems of premature neonates. Rice–Evans CA, et al. **Essays Biochem** 1995;29:39–63 (25 ref.)
Vitamins and minerals. Proceedings of a workshop. Milan, Italy, July 1996. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S1–83
Dietary profiles and anti–oxidants in a rural population of central Italy with a low frequency of cancer. Caperle M, et al. **Eur J Cancer Prev** 1996 Jun;5(3):197–206
A model membrane system to investigate antioxidants in bovine rod outer segments. Keys SA, et al. **Exp Eye Res** 1997 Mar;64(3):313–21
Antioxidant role of melatonin in lipid peroxidation of human LDL. Abuja PM, et al. **FEBS Lett** 1997 Aug 18; 413(2):289–93
Oxygen–induced embryopathy and the significance of glutathione–dependent antioxidant system in the rat embryo during early organogenesis. Ishibashi M, et al. **Free Radic Biol Med** 1997;22(3):447–54
A hydroxylated analog of the beta–adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Kramer JH, et al. **Free Radic Biol Med** 1996;21(6):813–25
Antioxidant and prooxidant role of beta–carotene in murine normal and tumor thymocytes: effects of oxygen partial pressure. Palozza P, et al. **Free Radic Biol Med** 1997; 22(6):1065–73
Effect of a water–soluble vitamin E analog, trolox C, on retinal vascular development in an animal model of retinopathy of prematurity. Penn JS, et al. **Free Radic Biol Med** 1997;22(6):977–84
Endogenous natural killer enhancing factor–B increases cellular resistance to oxidative stresses. Shau H, et al. **Free Radic Biol Med** 1997;22(3):497–507
Why do we expect carotenoids to be antioxidants in vivo? Rice–Evans CA, et al. **Free Radic Res** 1997 Apr; 26(4):381–98 (92 ref.)
Liposomes containing alpha–tocopherol and ascorbate are protected from an external oxidant stress. Waters RE 2nd, et al. **Free Radic Res** 1997 Apr;26(4):373–9
A comparison of the structure and function of the highly homologous maize antioxidant Cu/Zn superoxide dismutase genes, Sod4 and Sod4A. Kernodle SP, et al. **Genetics** 1996 Sep;144(1):317–28
LTW4 protein on mouse chromosome 1 is a member of a family of antioxidant proteins. Iakoubova OA, et al. **Genomics** 1997 Jun 15;42(3):474–8
Changes in the erythrocyte antioxidant enzyme system during transdermal estradiol therapy for secondary amenorrhea. Massafra C, et al. **Gynecol Endocrinol** 1996 Jun;10(3):155–8
Antioxidative capacity of preimplantation embryo culture medium declines following the incubation of poor quality embryos. Paszkowski T, et al. **Hum Reprod** 1996 Nov; 11(11):2493–5
Effects of activating and deactivating cytokines on the functionally linked tetrahydrobiopterin. No pathways in vascular smooth muscle cells. Walter R, et al. **Immunol Lett** 1996 Dec 1;54(1):25–9
Identification and characterization of antioxidant enzyme mRNAs in the rat epididymis. Zini A, et al. **Int J Androl** 1997 Apr;20(2):86–91

Melatonin as a hormone and an antioxidant: implications for organisms at high latitudes. Reiter RJ, et al. **Int J Circumpolar Health** 1997 Apr;56(1-2):4-11 (43 ref.)

Alcohol, fish, fibre and antioxidant vitamins intake do not explain population differences in coronary heart disease mortality. Kromhout D, et al. **Int J Epidemiol** 1996 Aug; 25(4):753-9

Plasma selenium in healthy man before and after nutratherapy. Karlsson J, et al. **Int J Vitam Nutr Res** 1997; 67(1):27-33

The relation between antioxidants and memory performance in the old and very old. Perrig WJ, et al. **J Am Geriatr Soc** 1997 Jun;45(6):718-24

Antioxidants and disease--current status. Daga MK, et al. **J Assoc Physicians India** 1996 Oct;44(10):703-10 (67 ref.)

Dietary antioxidant flavonoids and coronary heart disease. Nair S, et al. **J Assoc Physicians India** 1996 Oct; 44(10):699-702 (31 ref.)

Analysis of the decaprenyl diphosphate synthase (dps) gene in fission yeast suggests a role of ubiquinone as an antioxidant. Suzuki K, et al. **J Biochem (Tokyo)** 1997 Mar; 121(3):496-505

3-Hydroxyanthranilic acid is an efficient, cell-derived co-antioxidant for alpha-tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation. Thomas SR, et al. **J Biol Chem** 1996 Dec 20;271(51):32714-21

Antioxidants prevent the cellular deficit produced in response to burn injury. LaLonde C, et al. **J Burn Care Rehabil** 1996 Sep-Oct;17(5):379-83

Antioxidants and coronary heart disease: weighing the totality of the evidence. Buring JE, et al. **J Cardiovasc Risk** 1996 Aug;3(4):343-5

Basic research in antioxidant inhibition of steps in atherogenesis. Gokce N, et al. **J Cardiovasc Risk** 1996 Aug; 3(4):352-7 (65 ref.)

Neuroprotective action of cycloheximide involves induction of bcl-2 and antioxidant pathways. Furukawa K, et al. **J Cell Biol** 1997 Mar 10;136(5):1137-49

New antioxidant mixture for long term stability of serotonin, dopamine and their metabolites in automated microbore liquid chromatography with dual electrochemical detection. Thorré K, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):297-303

Impaired enzymatic antioxidant defense mechanism in cancerous human thyroid tissues. Durak I, et al. **J Endocrinol Invest** 1996 May;19(5):312-5

Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives. Portevin B, et al. **J Med Chem** 1997 Jun 6;40(12):1906-18

Oxidants and antioxidants in viral diseases: disease mechanisms and metabolic regulation. Peterhans E. **J Nutr** 1997 May;127(5 Suppl):962S-965S (41 ref.)

Effect of alpha-tocopherol and Trolox on the decomposition of methyl linoleate hydroperoxides. Hopia A, et al. **Lipids** 1996 Apr;31(4):357-65

Synthesis of a novel vitamin E derivative, 2-(alpha-D-glucopyranosyl) methyl-2,5,7,8-tetramethylchroman-6-ol, by alpha-glucosidase-catalyzed transglycosylation. Murase H, et al. **Lipids** 1997 Jan;32(1):73-8

Is beta-carotene an antioxidant? Crabtree DV, et al. **Med Hypotheses** 1997 Feb;48(2):183-7 (37 ref.)

Attenuation of rat ischemic brain damage by aged garlic extracts: a possible protecting mechanism as antioxidants. Numagami Y, et al. **Neurochem Int** 1996 Aug;29(2):135-43

Regulation of antioxidant enzyme expression by NGF. Sampath D, et al. **Neurochem Res** 1997 Apr;22(4):351-62

Reliability of a food frequency questionnaire to assess dietary antioxidant intake. McCarty CA, et al. **Ophthalmic Epidemiol** 1997 Mar;4(1):33-9

Cloning of peroxiredoxin, a novel antioxidant enzyme, from the helminth parasite Fasciola hepatica. McGonigle S, et al. **Parasitology** 1997 Jul;115 (Pt 1):101-4

A peroxiredoxin antioxidant is encoded by a dormancy-related gene, Per1, expressed during late development in the aleurone and embryo of barley grains. Stacy RA, et al. **Plant Mol Biol** 1996 Sep;31(6):1205-16

Protective effect of curcuminoids on epidermal skin cells under free oxygen radical stress [letter] Bonté F, et al. **Planta Med** 1997 Jun;63(3):265-6

Methionine residues as endogenous antioxidants in proteins. Levine RL, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15036-40

Lipid peroxidation and antioxidant enzymes in CAPD patients. Zima T, et al. **Ren Fail** 1996 Jan;18(1):113-9

Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Gillissen A, et al. **Respir Med** 1997 Mar;91(3):159-68

Antioxidant vitamins and human immune responses. Bendich A. **Vitam Horm** 1996;52:35-62 (104 ref.)

The 'Are' Sport Nutratherapy Program: the rationale for food supplements in sports medicine. Göransson U, et al. **World Rev Nutr Diet** 1997;82:101-21 (61 ref.)

Exercise, muscle metabolism and the antioxidant defense. Karlsson J. **World Rev Nutr Diet** 1997;82:81-100 (47 ref.)

[Natural substances with antioxidant activity] Spilková J, et al. **Ceska Slov Farm** 1996 Nov;45(6):296-301 (Eng. Abstr.) **(Cze)**

[Antioxidants in the diet of a general population] Roggi C, et al. **Ann Ig** 1996 Sep-Oct;8(5):547-57 (Eng. Abstr.) **(Ita)**

[Free radical scavengers] Kondo T, et al. **No To Shinkei** 1996 Dec;48(12):1099-113 (87 ref.) **(Jpn)**

[Effects of hyperbaric oxygenation on free radical oxidation and antioxidant system of blood in the newborn who had acute hypoxia at birth] Baĭborodov BD, et al. **Anesteziol Reanimatol** 1996 Nov-Dec;(6):56-8 (Eng. Abstr.) **(Rus)**

[Antioxidant properties of UV-irradiated blood plasma as determined by the photochemiluminescence method] Udilova N, et al. **Biofizika** 1997 Jan-Feb;42(1):187-90 (Eng. Abstr.) **(Rus)**

[The dynamics of stress inducers, of lipid peroxidation indices and of the antioxidant system components in children with acute surgical diseases of the abdominal cavity organs] Moskalenko VZ, et al. **Klin Khir** 1996;(7):29-32 **(Rus)**

[Lipid peroxidation and activity of the antioxidant system in patients with infective endocarditis] Vorob'eva AM, et al. **Klin Khir** 1996;(8):23-5 **(Rus)**

[Changes in indicators of the antioxidant defense system in patients with ischemic heart disease treated conventionally] Syrkin AL, et al. **Klin Med (Mosk)** 1996;74(3):24-7 (Eng. Abstr.) **(Rus)**

[Changes in the activity of the blood antioxidant enzymes during hemodialysis of patients with terminal kidney failure] Bogdan GM, et al. **Ter Arkh** 1995;67(12):37-9 (Eng. Abstr.) **(Rus)**

[Lipid peroxidation and the system of antioxidant protection in patients with chronic glomerulonephritis and normal kidney azoturic function] Riabov SI, et al. **Ter Arkh** 1995; 67(12):33-7 (Eng. Abstr.) **(Rus)**

[The correlations of lipid peroxidation, antioxidant protection and microrheological disorders in the development of IHD] Zakirova AN. **Ter Arkh** 1996;68(9):37-40 (Eng. Abstr.) **(Rus)**

[The participation of antioxidant systems in adaptive body reactions to the action of physical factors] Zubkova SM. **Vopr Kurortol Fizioter Lech Fiz Kult** 1997 Mar-Apr;(2):3-7 (Eng. Abstr.) **(Rus)**

[alpha-Lipoic acid--a natural disulfide cofactor and antioxidant with anticarcinogenic effects] Dovinová I. **Ceska Slov Farm** 1996 Sep;45(5):237-41 (49 ref.) (Eng. Abstr.) **(Slo)**

[Free radicals and antioxidant mechanisms. A general outline and its application in clinical practice] de la Peña Fernández A, et al. **Rev Clin Esp** 1997 Jun;197(6):434-46 (145 ref.) **(Spa)**

[The effect of lymphocytic chalone on lymphocyte functional activity in antioxidant deficiency and its correction with vitamin E] Harkava KH, et al. **Fiziol Zh** 1995 Sep-Dec; 41(5-6):27-32 (Eng. Abstr.) **(Ukr)**

[The age-related changes in the antioxidant system enzymes of the erythroid cells of swine at the early stages of postnatal development] Snityns'kyĭ VV, et al. **Fiziol Zh** 1996;42(5-6):19-25 (Eng. Abstr.) **(Ukr)**

[The effect of nicotinamide on the enzymatic activity of the antioxidant defense in experimental diabetes] Velykyĭ MM, et al. **Ukr Biokhim Zh** 1996 Mar-Apr;68(2):109-14 (Eng. Abstr.) **(Ukr)**

ADMINISTRATION & DOSAGE

Antioxidant drug targeting. Allison AC. **Adv Pharmacol** 1997; 38:273-91 (62 ref.)

Intake of antioxidants among American cardiologists. Mehta J. **Am J Cardiol** 1997 Jun 1;79(11):1558-60

Antioxidant flavonols and ischemic heart disease in a Welsh population of men: the Caerphilly Study. Hertog MG, et al. **Am J Clin Nutr** 1997 May;65(5):1489-94

beta-Carotene, malondialdehyde, and cystic fibrosis [letter; comment] Winklhofer-Roob BM. **Am J Clin Nutr** 1997 Feb;65(2):575-7. Comment on: Am J Clin Nutr 1996 Jul;64(1):87-93.

Diet and the risk of salivary gland cancer. Horn-Ross PL, et al. **Am J Epidemiol** 1997 Jul 15;146(2):171-6

Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Knekt P, et al. **Am J Epidemiol** 1997 Aug 1;146(3):223-30

Effect of caffeic acid dietary supplementation on the antioxidant defense system in rat: an in vivo study. Nardini M, et al. **Arch Biochem Biophys** 1997 Jun 1;342(1):157-60

Dietary antioxidants and Parkinson disease. The Rotterdam Study. de Rijk MC, et al. **Arch Neurol** 1997 Jun;54(6):762-5

The Inuit diet. Fatty acids and antioxidants, their role in ischemic heart disease, and exposure to organochlorines and heavy metals. An international study. Mulvad G, et al. **Arctic Med Res** 1996;55 Suppl 1:20-4

Effect of antioxidants alone and in combination with monounsaturated fatty acid-enriched diets on lipoprotein oxidation. Reaven P, et al. **Arterioscler Thromb Vasc Biol** 1996 Dec;16(12):1465-72

Vitamin E supplementation in elderly lowers the oxidation rate of linoleic acid in LDL. de Waart FG, et al. **Atherosclerosis** 1997 Sep;133(2):255-63

Effectiveness of alpha-tocopherol and selenium supplements in preventing lupinosis-associated myopathy in sheep. Smith GM, et al. **Aust Vet J** 1997 May;75(5):341-8

Effects of liposome size on penetration of dl-tocopherol acetate into skin. Natsuki R, et al. **Biol Pharm Bull** 1996 May;19(5):758-61

The effect of condensed tannins in Lotus pedunculatus on the solubilization and degradation of ribulose-1,5-bisphosphate carboxylase (EC 4.1.1.39; Rubisco) protein in the rumen and the sites of Rubisco digestion. McNabb WC, et al. **Br J Nutr** 1996 Oct; 76(4):535-49

The effects of condensed tannins from Desmodium intortum and Calliandra calothyrsus on protein and carbohydrate digestion in sheep and goats. Perez-Maldonado RA, et al. **Br J Nutr** 1996 Oct;76(4):515-33

Dietary antioxidants and cardioprotection--fact or fallacy? Steinbrecher UP. **Can J Physiol Pharmacol** 1997 Mar; 75(3):228-33 (66 ref.)

Combination oral antioxidant supplementation reduces blood pressure. Galley HF, et al. **Clin Sci (Colch)** 1997 Apr; 92(4):361-5

Antioxidant vitamins in the prevention of cardiovascular disease. The epidemiological evidence. Price JE, et al. **Eur Heart J** 1997 May;18(5):719-27 (59 ref.)

Effects of administration of antioxidants in acute intermittent porphyria. Thunell S, et al. **Eur J Clin Chem Clin Biochem** 1997 Jun;35(6):427-33

Enhanced plasma level of lipid peroxidation in Iranians could be improved by antioxidants supplementation. Meraji S, et al. **Eur J Clin Nutr** 1997 May;51(5):318-25

Effect of 6 month supplementation with different combinations of an association of antioxidant nutrients on biochemical parameters and markers of the antioxidant defence system in the elderly. The Geriatrie/Min.Vit.Aox Network. Monget AL, et al. **Eur J Clin Nutr** 1996 Jul; 50(7):443-9

Antioxidant vitamins in hospitalized elderly patients: analysed dietary intakes and biochemical status. Schmuck A, et al. **Eur J Clin Nutr** 1996 Jul;50(7):473-8

Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. Palomäki A, et al. **FEBS Lett** 1997 Jun 30;410(2-3):254-8

Conventional cell culture media do not adequately supply cells with antioxidants and thus facilitate peroxide-induced genotoxicity. Leist M, et al. **Free Radic Biol Med** 1996; 21(3):297-306

Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Halliwell B. **Free Radic Res** 1996 Jul;25(1):57-74 (210 ref.)

Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease. Mosca L, et al. **J Am Coll Cardiol** 1997 Aug;30(2):392-9

Effect of a two-year supplementation with low doses of antioxidant vitamins and/or minerals in elderly subjects on levels of nutrients and antioxidant defense parameters. Girodon F, et al. **J Am Coll Nutr** 1997 Aug;16(4):357-65

Blood antioxidants changes in young women following beta-carotene depletion and repletion. Omaye ST, et al. **J Am Coll Nutr** 1996 Oct;15(5):469-74

The effect of dietary fat, antioxidants, and pro-oxidants on blood lipids, lipoproteins, and atherosclerosis. Kwiterovich PO Jr. **J Am Diet Assoc** 1997 Jul;97(7 Suppl):S31-41 (75 ref.)

Antioxidants in health and disease [see comments] Cheraskin E. **J Am Optom Assoc** 1996 Jan;67(1):50-7 (50 ref.). Comment in: J Am Optom Assoc 1996 Jan;67(1):6-10.

Multicenter ophthalmic and nutritional age-related macular degeneration study--part 1: design, subjects and procedures. Richer S. **J Am Optom Assoc** 1996 Jan; 67(1):12-29

Multicenter ophthalmic and nutritional age-related macular degeneration study--part 2: antioxidant intervention and conclusions. Richer S. **J Am Optom Assoc** 1996 Jan; 67(1):30-49

Reproducibility of erythrocyte polyamine measurements and correlation with plasma micronutrients in an antioxidant vitamin intervention study [published erratum appears in J Cell Biochem 1996 Oct;63(1):123] Wang W, et al. **J Cell Biochem** 1996 Jul;62(1):19-26

Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial [see comments] Omenn GS, et al. **J Natl Cancer Inst** 1996 Nov 6;88(21):1550-9. Comment in: J Natl Cancer Inst 1996 Nov 6;88(21):1513-5. Comment in: J Natl Cancer Inst 1997 Feb 19;89(4):325-6.

Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. Vyth A, et al. **J Neurol Sci** 1996 Aug;139 Suppl:99-103

Flavinoids, vitamins and stroke [news] **J Neurosci Nurs** 1996 Aug;28(4):274

An enteral formula containing fish oil, indigestible oligosaccharides, gum arabic and antioxidants affects plasma and colonic phospholipid fatty acid and prostaglandin profiles in pigs. Campbell JM, et al. **J Nutr** 1997 Jan;127(1):137-45

Beta-carotene supplementation in cystic fibrosis [letter; comment] Winklhofer-Roob BM. **J Pediatr** 1996 Jul; 129(1):181-2. Comment on: J Pediatr 1995 Sep;127(3):491-4.

The relationship between the dietary provision of alpha-tocopherol and the concentration of this vitamin in the semen of chicken: effects on lipid composition and susceptibility to peroxidation. Surai PF, et al. **J Reprod Fertil** 1997 May;110(1):47-51

Oxidants, antioxidant nutrients and the athlete. Packer L. **J Sports Sci** 1997 Jun;15(3):353-63

Oxidative insult associated with hyperoxic cardiopulmonary bypass in the infantile heart and lung. Morita K, et al. **Jpn Circ J** 1996 Jun;60(6):355-63

Antioxidant flavonols and coronary heart disease risk [letter]

Hertog MG, et al. **Lancet** 1997 Mar 8;349(9053):699

Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infraction [see comments] Rapola JM, et al. **Lancet** 1997 Jun 14;349(9067):1715-20. Comment in: Lancet 1997 Jun 14;349(9067):1710.

Antioxidants and ischaemic heart disease [letter] Shahar E. **Lancet** 1997 Aug 30;350(9078):667; discussion 668

Antioxidants and ischaemic heart disease [letter] Violi F, et al. **Lancet** 1997 Aug 30;350(9078):667-8

The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. LeWitt P, et al. **Mov Disord** 1997 Mar;12(2):183-9

Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Scheider WL, et al. **Mov Disord** 1997 Mar;12(2):190-6

Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. **Neurology** 1997 Jul;49(1):142-6

Vitamins and related compounds: will increased intake provide greater protection against oxidative damage? [editorial] Chow CK. **Nutrition** 1996 Nov-Dec; 12(11-12):822-3

A pilot study of antioxidant intake in patients with cholesterol gallstones. Worthington HV, et al. **Nutrition** 1997 Feb; 13(2):118-27

Protective effect of acetaminophen against acute gastric mucosal lesions induced by ischemia-reperfusion in the rat. Nakamoto K, et al. **Pharmacology** 1997 Apr;54(4):203-10

A double-blind, placebo-controlled, crossover trial of oral vitamin C in erythropoietic protoporphyria. Boffa MJ, et al. **Photodermatol Photoimmunol Photomed** 1996 Feb; 12(1):27-30

Anti-oxidants and coronary heart disease [letter; comment] Walker AR, et al. **S Afr Med J** 1997 Jan;87(1 Suppl):103 . Comment on: S Afr Med J 1995 Dec;85(12):1279-81.

Bronchial reactivity and dietary antioxidants. Soutar A, et al. **Thorax** 1997 Feb;52(2):166-70

Antioxidant status in patients on chronic hemodialysis therapy: impact of parenteral selenium supplementation [see comments] Koenig JS, et al. **Wien Klin Wochenschr** 1997 Jan 17;109(1):13-9. Comment in: Wien Klin Wochenschr 1997 Jan 17;109(1):3-6.

[Progress in the treatment of coronary heart disease with antioxidant of integrated traditional Chinese medicine-Western medicine] Li AC, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Jan; 16(1):61-3 (21 ref.) **(Chi)**

[Coronary heart disease--a free radical associated disease? What is the value of antioxidant substances?] Döll M. **Med Monatsschr Pharm** 1997 Mar;20(3):66-70 (35 ref.) **(Ger)**

[Free radicals and antioxidants (editorial)] Heinzl S. **Med Monatsschr Pharm** 1997 Mar;20(3):57 **(Ger)**

[Selenium--an essential trace element (editorial; comment)] Tiran B. **Wien Klin Wochenschr** 1997 Jan 17;109(1):3-6. Comment on: Wien Klin Wochenschr 1997 Jan 17;109(1):13-9. **(Ger)**

[The significance of antioxidants] Kuhl H. **Zentralbl Gynakol** 1997;119(1):1-5 (11 ref.) **(Ger)**

[The effect of antioxidants on lipid metabolism in myocardium in experimental hyperthyroxinemic conditions] Grabowska-Maślanka H, et al. **Folia Med Cracov** 1996;37(1-2):61-6 (Eng. Abstr.) **(Pol)**

[Importance of toxicological studies in animals for elaboration of pathogenetic therapy of hydrazine intoxication] Baryshnikov II. **Med Tr Prom Ekol** 1997;(6):22-5 (Eng. Abstr.) **(Rus)**

[The use of the antioxidant trimetazidine (Preductal) in the combined therapy of acute myocardial infarct] Parkhomenko AE, et al. **Ter Arkh** 1996;68(9):47-52 (Eng. Abstr.) **(Rus)**

[Correction of alimentary methemoglobinemia in children of preschool age by inclusion in the diet of products rich in antioxidants, vitamins and dietary fiber] Krivitskaia EI. **Vopr Pitan** 1996;(2):26-8 (Eng. Abstr.) **(Rus)**

[The physiological characteristics of the antioxidant properties of Lipin in bronchial asthma in children] Tymchenko OH, et al. **Fiziol Zh** 1996;42(1-2):47-52 (Eng. Abstr.) **(Ukr)**

ADVERSE EFFECTS

Interventional therapy with megadose of antioxidant vitamins in patients with acute myocardial infarction: could we throw caution to the winds? [letter] Anand U, et al. **Am J Cardiol** 1997 Sep 15;80(6):823-4

Systemic contact dermatitis caused by ingestion of certain foods in propylene glycol-sensitive patients. Fisher AA. **Am J Contact Dermat** 1996 Dec;7(4):259

The safety of antioxidant vitamins [letter; comment] Koval GM. **Arch Intern Med** 1996 Dec 9-23;156(22):2626-7. Comment on: Arch Intern Med 1996 May 13;156(9):925-35.

Comments on the safety of antioxidant vitamin supplementation [letter; comment] Schulz LO. **Arch Intern Med** 1997 Aug 11-25;157(15):1776-7. Comment on: Arch Intern Med 1996 May 13;156(9):925-35.

Group allergy to tri- and ortho-diphenols (catechols) in a patient sensitized by propyl gallate. Hemmer W, et al. **Contact Dermatitis** 1996 Aug;35(2):110-2

Occupational contact dermatitis from tertiary-butylhydroquinone (TBHQ) in a cutting fluid. Meding B. **Contact Dermatitis** 1996 Mar;34(3):224

Contact dermatitis due to rubber boots worn by Japanese farmers, with special attention to 6-ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline (ETMDQ) sensitivity. Nishioka K, et al. **Contact Dermatitis** 1996 Oct; 35(4):241-5

Contact dermatitis due to ammonium bisulfite in a bleaching cream. Pambor M. **Contact Dermatitis** 1996 Jul;35(1):48-9

Pustular contact dermatitis from fluorine in an antirust solution. Stéciuk A, et al. **Contact Dermatitis** 1997 May; 36(5):276-7

Allergic contact dermatitis to propylene glycol in calcipotriene ointment. Fisher DA. **Cutis** 1997 Jul; 60(1):43-4

Beta-Carotene and lung cancer promotion in heavy smokers--a plausible relationship? [editorial; comment] Mayne ST, et al. **J Natl Cancer Inst** 1996 Nov 6; 88(21):1513-5. Comment on: J Natl Cancer Inst 1996 Nov 6;88(21):1550-9. Comment on: J Natl Cancer Inst 1996 Nov 6;88(21):1560-70.

Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. **Neurology** 1997 Jul;49(1):142-6

[Do antioxidants inhibit immune response?] Arends J. **Med Monatsschr Pharm** 1997 Feb;20(2):47-8 **(Ger)**

ANALYSIS

Lipofuscin product accumulation, insufficient antioxidant defence in erythrocytes and plasma and enhanced susceptibility to oxidative haemolysis after thermal trauma. Bekyarova G, et al. **Acta Chir Plast** 1997;39(2):60-4

Evaluation of antioxidant activity by chemiluminescence. Hirayama O, et al. **Anal Biochem** 1997 May 1;247(2):237-41

Enhanced chemiluminescent assay for measuring the total antioxidant capacity of serum, saliva and crevicular fluid. Chapple IL, et al. **Ann Clin Biochem** 1997 Jul;34 (Pt 4):412-21

Effect of anticoagulant choice on apparent antioxidant capacity [letter; comment] Doherty G, et al. **Ann Clin Biochem** 1996 Jan;33 (Pt 1):93-4. Comment on: Ann Clin Biochem 1995 Jul;32 (Pt 4):413-6.

Anticoagulants for total antioxidant activity assay [letter; comment] Miller NJ. **Ann Clin Biochem** 1996 Jan;33 (Pt 1):92-3. Comment on: Ann Clin Biochem 1995 Jul;32 (Pt 4):413-6.

Antioxidant enzymes response to endurance exercise training and dietary proteins in rat skeletal muscle and liver. Song Y, et al. **Appl Human Sci** 1996 Sep;15(5):219-25

Influence of vitamin C, vitamin E and beta-carotene on the osmotic fragility and the primary antioxidant system of erythrocytes in zinc-deficient rats. Kraus A, et al. **Arch Tierernahr** 1997;50(3):257-69

Increased oxidation resistance of atherogenic plasma lipoproteins at high vitamin E levels in non-vitamin E supplemented men. Porkkala-Sarataho E, et al. **Atherosclerosis** 1996 Jul;124(1):83-94

Endogenous superoxide-like species and antioxidant activity in ocular tissues detected by luminol luminescence. Trevithick JR, et al. **Biochem Mol Biol Int** 1997 Apr; 41(4):695-705

Changes in some pro- and antioxidants in rat cerebellum after chronic alcohol intake [published erratum appears in Biochem Pharmacol 1997 Jun 15;53(12):1945] Rouach H, et al. **Biochem Pharmacol** 1997 Feb 21;53(4):539-45

Chemiluminescence and antioxidant levels during peroxisome proliferation by fenofibrate. Lores Arnaiz S, et al. **Biochim Biophys Acta** 1997 May 24;1360(3):222-8

Tissue-specific differences in antioxidant distribution and susceptibility to lipid peroxidation during development of the chick embryo. Surai PF, et al. **Biochim Biophys Acta** 1996 Nov 11;1304(1):1-10

Human meconium has potent antioxidative properties. Kääpä P, et al. **Biol Neonate** 1997;72(2):71-5

Randomised controlled trial of effect of fruit and vegetable consumption on plasma concentrations of lipids and antioxidants. Zino S, et al. **BMJ** 1997 Jun 21; 314(7097):1787-91

cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Clinton SK, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Oct;5(10):823-33

Melatonin immunoreactivity in the photosynthetic prokaryote Rhodospirillum rubrum: implications for an ancient antioxidant system. Manchester LC, et al. **Cell Mol Biol Res** 1995;41(5):391-5

Measurement of individual vs total antioxidants [letter; comment] Lamont J, et al. **Clin Chem** 1997 May;43(5):852-4 . Comment on: Clin Chem 1996 Oct;42(10):1712-4.

Reduced serum antioxidant capacity in healthy centenarians [letter] Pinzani P, et al. **Clin Chem** 1997 May;43(5):855-6

Shortcomings of an automated assay for total antioxidant status in biological fluids [see comments] Schofield D, et al. **Clin Chem** 1996 Oct;42(10):1712-4. Comment in: Clin Chem 1997 May;43(5):852-4.

Antioxidant status in experimental hyperthyroidism: effect of vitamin E supplementation. Seven A, et al. **Clin Chim Acta** 1996 Dec 9;256(1):65-74

Abnormal antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Vijayalingam S, et al. **Diabet Med** 1996 Aug;13(8):715-9

Total radical-trapping antioxidant parameter in NIDDM patients. Ceriello A, et al. **Diabetes Care** 1997 Feb; 20(2):194-7

Total plasma antioxidants in first-degree relatives of patients with insulin-dependent diabetes. Ročić B, et al. **Exp Clin Endocrinol Diabetes** 1997;105(4):213-7

Comparison of individual antioxidants of sperm and seminal plasma in fertile and infertile men. Lewis SE, et al. **Fertil Steril** 1997 Jan;67(1):142-7

The effect of ascorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity. Lönnrot K, et al. **Free Radic Biol Med** 1996;21(2):211-7

Factors influencing the antioxidant activity determined by the ABTS.+ radical cation assay [published erratum appears in Free Radic Res 1997 Jun;26(6):594] Miller NJ, et al. **Free Radic Res** 1997 Mar;26(3):195-9

Serum total antioxidant activity in relative hypo- and hypercholesterolemia. Muldoon MF, et al. **Free Radic Res** 1996 Sep;25(3):239-45

Pitfalls in a method for assessment of total antioxidant capacity. Strube M, et al. **Free Radic Res** 1997 Jun; 26(6):515-21

Nutrient antioxidants in oregano. Lagouri V, et al. **Int J Food Sci Nutr** 1996 Nov;47(6):493-7

Blood glutathione status following distance running. Dufaux B, et al. **Int J Sports Med** 1997 Feb;18(2):89-93

Assessment of serum antioxidant micronutrients and biochemical indicators of nutritional status in children with cancer in search of prognostic factors. Malvy DJ, et al. **Int J Vitam Nutr Res** 1997;67(4):267-71

Antioxidant vitamins and immunodeficiency. Mastroiacovo P, et al. **Int J Vitam Nutr Res** 1996;66(2):141-5

Liquid chromatographic determination of tocopherols and tocotrienols in margarine, infant foods, and vegetables. Konings EJ, et al. **J AOAC Int** 1996 Jul-Aug;79(4):902-6

Photochemiluminescent detection of antiradical activity; IV: testing of lipid-soluble antioxidants. Popov IN, et al. **J Biochem Biophys Methods** 1996 Jan 11;31(1-2):1-8

Blood antioxidant status and urine sulfate and thiocyanate levels in smokers. Abou-Seif MA. **J Biochem Toxicol** 1996; 11(3):133-8

Supercritical fluid extraction and reversed-phase liquid chromatography methods for vitamin A and beta-carotene heterogeneous distribution of vitamin A in the liver. Burri BJ, et al. **J Chromatogr A** 1997 Feb 21;762(1-2):201-6

Simultaneous determination of alpha-tocopherol and alpha-tocopherolquinone by high-performance liquid chromatography and coulometric detection in the redox mode. Takeda H, et al. **J Chromatogr A** 1996 Jan 26; 722(1-2):287-94

Measurement of synthetic phenolic antioxidants in human tissues by high-performance liquid chromatography with coulometric electrochemical detection. Bianchi L, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4;694(2):359-65

Determination of naringin and naringenin in human plasma by high-performance liquid chromatography. Ishii K, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30;683(2):225-9

Simultaneous detection of carotenoids and vitamin E in human plasma. Sommerburg O, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1;695(2):209-15

Lack of correlation between the alpha-tocopherol content of plasma and LDL, but high correlations for gamma-tocopherol and carotenoids. Zlouzenkova O, et al. **J Lipid Res** 1996 Sep;37(9):1936-46

Plasma lipid peroxide and antioxidant levels in diabetic patients. Kajanachumpol S, et al. **J Med Assoc Thai** 1997 Jun;80(6):372-7

Oxidative stress and antioxidant status in mouse liver: effects of dietary lipid, vitamin E and iron. Ibrahim W, et al. **J Nutr** 1997 Jul;127(7):1401-6

Antioxidants in chocolate [letter] [see comments] Waterhouse AL, et al. **Lancet** 1996 Sep 21;348(9030):834. Comment in: Lancet 1996 Nov 30;348(9040):1514.

Decreased total antioxidant capacity but normal lipid hydroperoxide concentrations in sera of critically ill patients. Dasgupta A, et al. **Life Sci** 1997;60(4-5):335-40

Decreased total antioxidant capacity and elevated lipid hydroperoxide concentrations in sera of epileptic patients receiving phenytoin. Mahle C, et al. **Life Sci** 1997; 61(4):437-43

Magnesium and antioxidant vitamin status and risk of complications of ageing in an elderly urban population. Singh RB, et al. **Magnes Res** 1996 Dec;9(4):299-306

Antioxidant micronutrients and childhood malignancy during oncological treatment. Malvy DJ, et al. **Med Pediatr Oncol** 1997 Sep;29(3):213-7

alpha-Tocopherol in human spermatozoa and seminal plasma: relationships with motility, antioxidant enzymes and leukocytes. Thérond P, et al. **Mol Hum Reprod** 1996 Oct;2(10):739-44

Lipid and antioxidant blood levels in vegetarians. Krajčovičová-Kudláčková M, et al. **Nahrung** 1996 Feb; 40(1):17-20

Antioxidant status of elderly chronic renal patients treated by continuous ambulatory peritoneal dialysis. Bonnefont-Rousselot D, et al. **Nephrol Dial Transplant** 1997 Jul;12(7):1399-405

Bioactive ingredients: antioxidants and polyphenols in tea. Dreosti IE. **Nutr Rev** 1996 Nov;54(11 Pt 2):S51-8 (62 ref.)

Antioxidants in healthy elderly Parisians [editorial; comment] Thurnham DI. **Nutrition** 1997 Apr;13(4):377-8. Comment on: Nutrition 1997 Apr;13(4):319-26.

An apparatus for ultraviolet B irradiation of small volumes

of biological fluid under controlled oxygen tension. Richer SP, et al. **Optom Vis Sci** 1996 Nov;73(11):683–8

Inclusion of oxidized vegetable oil in broiler diets. Its influence on nutrient balance and on the antioxidative status of broilers. Engberg RM, et al. **Poult Sci** 1996 Aug; 75(8):1003–11

Oxidant stress and antioxidant protection in lupus nephropathy. Serban MG, et al. **Rom J Intern Med** 1996 Jan–Jun;34(1–2):105–9

Lipid peroxidation in workers exposed to manganese. Yiin SJ, et al. **Scand J Work Environ Health** 1996 Oct; 22(5):381–6

Antioxidative effectiveness of some natural antioxidants in sunflower oil. Yanishlieva NV, et al.
Z Lebensm Unters Forsch 1996 Sep;203(3):220–3

[Regeneration of endogenous antioxidants, ascorbic acid, alpha tocopherol, by the oligomeric procyanide fraction of Vitus vinifera L.:ESR study] Maffei Facino R, et al. **Boll Chim Farm** 1997 Apr;136(4):340–4 **(Ita)**

[Endogenous intoxication and its treatment with sodium hypochlorite in neurosurgical patients] Parfenov AL, et al. **Anesteziol Reanimatol** 1997 May–Jun;(3):62–5 (Eng. Abstr.) **(Rus)**

[Determination of the concentration of the cardioprotective drug cardiochrome in the plasma of patients] Ivanova MV, et al. **Biull Eksp Biol Med** 1996 Dec;122(12):662–4 **(Rus)**

[Erythremia: the activity of erythrocyte antioxidant enzymes and the association with iron deficiency] Petukhov VI, et al. **Ter Arkh** 1997;69(4):57–61 (Eng. Abstr.) **(Rus)**

CHEMICAL SYNTHESIS

Fused 2–thiohydantoin derivatives: evaluation as potential antioxidants. Kiec–Kononowicz K, et al.
Arch Pharm (Weinheim) 1997 Apr;330(4):85–90

Synthesis of GABA–valproic acid derivatives and evaluation of their anticonvulsant and antioxidant activity. Rekatas GV, et al. **Arch Pharm (Weinheim)** 1996 Aug–Sep; 329(8–9):393–8

Synthesis, antioxidant and anti–inflammatory activity of novel substituted ethylenediamines and ethanolamines. A preliminary quantitative structure–activity relationship study. Andreadou I, et al. **Arzneimittelforschung** 1997 May; 47(5):643–7

Novel bioconversions for the production of designer antioxidant and colourant flavonoids using polyphenol oxidases. Ridgway T, et al. **Biotechnol Genet Eng Rev** 1997; 14:165–90 (117 ref.)

Synthesis of novel vitamin C phosphodiesters: stability and antioxidant activity. Morisaki K, et al. **Carbohydr Res** 1996 Jun 5;286:123–38

In vivo biological activity of antioxidative aminothiazole derivatives. Uchikawa O, et al.
Chem Pharm Bull (Tokyo) 1996 Nov;44(11):2070–7

Evaluation of mercaptoalkyl derivatives of imidazolidine–4–one as potential antioxidants and free radical scavengers. Kieć–Kononowicz K, et al. **Farmaco** 1996 Dec;51(12):819–24

[Thionitrites as potent donors of nitric oxide: example of S–nitroso– and S,S'–dinitroso–dithiolipoic acids] Petit C, et al. **C R Seances Soc Biol Fil** 1996;190(5–6):641–50 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Modification of muscle protein functionality by antioxidants. Xiong YL, et al. **Adv Exp Med Biol** 1997;415:95–108

Evaluation of antioxidant capacity by chemiluminescence. Visioli F, et al. **Anal Biochem** 1997 Jul 1;249(2):244–6

Amphotericin B protects cis–parinaric acid against peroxyl radical–induced oxidation: amphotericin B as an antioxidant. Osaka K, et al.
Antimicrob Agents Chemother 1997 Apr;41(4):743–7

One–electron reduction of chromium(VI) by alpha–lipoic acid and related hydroxyl radical generation, dG hydroxylation and nuclear transcription factor–kappaB activation. Chen F, et al. **Arch Biochem Biophys** 1997 Feb 15;338(2):165–72

Antioxidant actions of beta–carotene in liposomal and microsomal membranes: role of carotenoid–membrane incorporation and alpha–tocopherol. Liebler DC, et al.
Arch Biochem Biophys 1997 Feb 15;338(2):244–50

Lycopene: a biologically important carotenoid for humans? Stahl W, et al. **Arch Biochem Biophys** 1996 Dec 1;336(1):1–9 (80 ref.)

Antioxidant reactions of all–trans retinol in phospholipid bilayers: effect of oxygen partial pressure, radical fluxes, and retinol concentration. Tesoriere L, et al.
Arch Biochem Biophys 1997 Jul 1;343(1):13–8

Comparative antioxidant and cardioprotective effects of ceruloplasmin, superoxide dismutase and albumin. Dumoulin MJ, et al. **Arzneimittelforschung** 1996 Sep; 46(9):855–61

Direct detection of the antioxidant activity of a new flavonic derivative using the chemiluminescence method. Saramet A, et al. **Arzneimittelforschung** 1996 May;46(5):501–4

In vitro comparative assessment of the antioxidant activity of nacystelyn against three reactive oxygen species. Vanderbist F, et al. **Arzneimittelforschung** 1996 Aug; 46(8):783–8

Quenching of singlet molecular oxygen by carnosine and related antioxidants. Monitoring 1270–nm phosphorescence in aqueous media. Egorov SYu, et al.
Biochem Mol Biol Int 1997 Apr;41(4):687–94

The efficiency of antioxidants delivered by liposomal transfer. Barclay LR, et al. **Biochim Biophys Acta** 1997 Aug 14; 1328(1):1–12

Antioxidant activity of polyphenolics in diets. Rate constants of reactions of chlorogenic acid and caffeic acid with reactive species of oxygen and nitrogen. Kono Y, et al. **Biochim Biophys Acta** 1997 Jun 6;1335(3):335–42

Formation of the mutagenic/carcinogenic imidazoquinoxaline–type heterocyclic amines through the unstable free radical Maillard intermediates and its inhibition by phenolic antioxidants. Kato T, et al.
Carcinogenesis 1996 Nov;17(11):2469–76

Remarkable enhancement of antioxidant activity of vitamin C in an artificial bilayer by making it lipo–soluble. Liu XY, et al. **Chem Phys Lipids** 1996 Sep 16;83(1):39–43

A quantum chemical explanation of the antioxidant activity of flavonoids. van Acker SA, et al. **Chem Res Toxicol** 1996 Dec;9(8):1305–12

N–allylsecoboldine as a novel antioxidant against peroxidative damage. Teng CM, et al. **Eur J Pharmacol** 1996 May 6;303(1–2):129–39

Influence of structure on the antioxidant activity of indolinic nitroxide radicals. Antosiewicz J, et al.
Free Radic Biol Med 1997;22(1–2):249–55

Antioxidant and prooxidant behavior of flavonoids: structure–activity relationships. Cao G, et al.
Free Radic Biol Med 1997;22(5):749–60

Evaluation of plasma low molecular weight antioxidant capacity by cyclic voltammetry. Chevion S, et al.
Free Radic Biol Med 1997;22(3):411–21

Reactivity of butylated hydroxytoluene. Lambert CR, et al.
Free Radic Biol Med 1996;21(3):395–400

Hydrogen bond formation as basis for radical scavenging activity: a structure–activity study of C–methylated dihydrochalcones from Myrica gale and structurally related acetophenones. Mathiesen L, et al.
Free Radic Biol Med 1997;22(1–2):307–11

Conversion of nitroxide radicals by phenolic and thiol antioxidants. Hiramoto K, et al. **Free Radic Res** 1997 Jul; 27(1):45–53

The antioxidant Trolox enhances the oxidation of 2',7'–dichlorofluorescin to 2',7'–dichlorofluorescein. Kalinich JF, et al. **Free Radic Res** 1997 Jan;26(1):37–47

Antioxidant activity of diethyldithiocarbamate. Liu J, et al.
Free Radic Res 1996 Jun;24(6):461–72

An investigation of the antioxidant activity of black tea using enhanced chemiluminescence. Robinson EE, et al.
Free Radic Res 1997 Mar;26(3):291–302

Antioxidant activity of phytoestrogenic isoflavones. Ruiz–Larrea MB, et al. **Free Radic Res** 1997 Jan;26(1):63–70

2D NMR of the metaboli.: antioxidant dihydrolipoic acid and its derivatives. Schepkin V, et al. **Free Radic Res** 1996 Sep;25(3):195–205

Antioxidant activities of some extracts of Thymus zygis. Soares JR, et al. **Free Radic Res** 1997 May;26(5):469–78

Comparative in vitro oxygen radical scavenging ability of zinc methionine and selected zinc salts and antioxidants. Bagchi D, et al. **Gen Pharmacol** 1997 Jan;28(1):85–91

Comparison of two antioxidants for poly(etherurethane urea) in an accelerated in vitro biodegradation system. Schubert MA, et al. **J Biomed Mater Res** 1997 Mar 15;34(4):493–505

Antioxidant and prooxidant properties of estrogens [editorial; comment] Liehr JG. **J Lab Clin Med** 1996 Oct;128(4):344–5 . Comment on: J Lab Clin Med 1996 Oct;128(4):367–75.

Spectrophotometric assay for total peroxyl radical–trapping antioxidant potential in human serum. Valkonen M, et al.
J Lipid Res 1997 Apr;38(4):823–33

Stability of curcumin in buffer solutions and characterization of its degradation products. Wang YJ, et al.
J Pharm Biomed Anal 1997 Aug;15(12):1867–76

Antioxidant herbal preparations [letter; comment] Anderton JG, et al. **J R Soc Med** 1996 Sep;89(9):540. Comment on: J R Soc Med 1996 May;89(5):241.

Inhibition of LDL oxidation by green tea extract [letter; comment] [see comments] Luo M, et al. **Lancet** 1997 Feb 1;349(9048):360–1. Comment on: Lancet 1996 Nov 30;348(9040):1514. Comment in: Lancet 1997 Mar 8;349(9053):735.

The chemistry and antioxidant properties of tocopherols and tocotrienols. Kamal–Eldin A, et al. **Lipids** 1996 Jul; 31(7):671–701 (324 ref.)

The antioxidant properties of captopril. Dobrucki R, et al.
Pharmazie 1996 Dec;51(12):992

Protective effect of plant flavonoids on the oxidation of lecithin liposomes. Gabrielska J, et al. **Pharmazie** 1997 Feb; 52(2):170–1

Antioxidant activities of polyphenolic extracts from flowers, in vitro callus and cell suspension cultures of Crataegus monogyna. Rakotoarison DA, et al. **Pharmazie** 1997 Jan; 52(1):60–4

Formation of 8–hydroxydeoxyguanosine in calf thymus DNA treated with tert–butylhydroquinone, a major metabolite of butylated hydroxyanisole. Nagai F, et al.
Toxicol Lett 1996 Dec 16;89(2):163–7

[Stabilization of roseofungin by antioxidants] Shenin IuD, et al. **Antibiot Khimioter** 1996 Apr;41(4):7–15 (Eng. Abstr.) **(Rus)**

[Relation between the conformation and antioxidant properties in a series of topochemical analogs of carnosine and carcinine with different N–acyl substitutes] Rozhkova EA, et al. **Bioorg Khim** 1996 Oct–Nov;22(10–11):838–45 (Eng. Abstr.) **(Rus)**

[Relationship between the nature of N–acyl substituent, molecular conformation and antioxidative properties of carnosine, carcinine, and their structural analogs] Evstigneeva RP, et al. **Dokl Akad Nauk** 1996 Aug; 349(5):694–7 **(Rus)**

CONTRAINDICATIONS

Melatonin as antioxidant––use or misuse? Löffler M.
Exp Clin Endocrinol Diabetes 1996;104(4):308–10

Contempo 1997: family medicine [letter] Solan SM.
JAMA 1997 Oct 8;278(14):1151–2

Beta–carotene and lung cancer? [letter] Lovas JG, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Sep;82(3):236–7

ISOLATION & PURIFICATION

Antioxidant properties of ethanolic and aqueous extracts of green tea compared to black tea. Wiseman H, et al.
Biochem Soc Trans 1996 Aug;24(3):390S

Procyanidins from tormentil: antioxidant properties towards lipoperoxidation and anti–elastase activity. Bos MA, et al.
Biol Pharm Bull 1996 Jan;19(1):146–8

Antioxidative constituents in Heterotheca inuloides. Haraguchi H, et al. **Bioorg Med Chem** 1997 May; 5(5):865–71

Properties of electrochemically active components in mammalian vitreous humor. Rose RC, et al.
Exp Eye Res 1997 May;64(5):807–12

Antioxidants in bronchoalveolar lavage fluid cells isolated from ozone––exposed normal and ascorbate–deficient guinea pigs. Kodavanti UP, et al. **Exp Lung Res** 1996 Jul–Aug;22(4):435–48

Green tea polyphenols inhibit oxidant–induced DNA strand breakage in cultured lung cells. Leanderson P, et al.
Free Radic Biol Med 1997;23(2):235–42

Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Vaya J, et al. **Free Radic Biol Med** 1997; 23(2):302–13

Cardioactive compounds from Eremophila species. Pennacchio M, et al. **J Ethnopharmacol** 1996 Jul 26; 53(1):21–7

Betulinans A and B, two benzoquinone compounds from Lenzites betulina. Lee IK, et al. **J Nat Prod** 1996 Nov; 59(11):1090–2

Faurine and O–methylfaurine, two novel benzyl–aporphine dimers from Thalictrum fauriei. Lee SS, et al.
J Nat Prod 1996 Aug;59(8):738–43

Lipoxygenase inhibition and antioxidant properties of bisbenzylisoquinoline alkaloids isolated from Mahonia aquifolium. Bezáková L, et al. **Pharmazie** 1996 Oct; 51(10):758–61

METABOLISM

Liver and serum antioxidant status after methanol intoxication in rats. Skrzydlewska E, et al.
Acta Biochim Pol 1997;44(1):139–45

Effects of diethyl–dithiocarbamate on antioxidant system in carp tissue. Hai DQ, et al. **Acta Biol Hung** 1997;48(1):1–8

Skeletal muscle and heart antioxidant defences in response to sprint training. Atalay M, et al. **Acta Physiol Scand** 1996 Oct;158(2):129–34

Nutritional metabolic diseases of poultry and disorders of the biological antioxidant defence system. Mézes M, et al.
Acta Vet Hung 1997;45(3):349–60 (55 ref.)

The indoleamine melatonin as a free radical scavenger, electron donor, and antioxidant. In vitro and in vivo studies. Reiter RJ. **Adv Exp Med Biol** 1996;398:307–13 (43 ref.)

4–oxo–retinoic acid is generated from its precursor canthaxanthin and enhances gap junctional communication in 10T1/2 cells. Stahl W, et al. **Adv Exp Med Biol** 1996; 387:121–8

Relationships among oxidation of low–density lipoprotein, antioxidant protection, and atherosclerosis. Esterbauer H, et al. **Adv Pharmacol** 1997;38:425–56 (150 ref.)

Antioxidant and chelating properties of flavonoids. Korkina LG, et al. **Adv Pharmacol** 1997;38:151–63 (80 ref.)

Antioxidative and metal–chelating effects of polyamines. Løvaas E. **Adv Pharmacol** 1997;38:119–49 (174 ref.)

Antioxidant nutrients and cancer incidence and mortality: an epidemiologic perspective. Mayne ST.
Adv Pharmacol 1997;38:657–75 (75 ref.)

Neurological disease. Muller DP. **Adv Pharmacol** 1997; 38:557–80 (147 ref.)

Alpha–lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Packer L, et al.
Adv Pharmacol 1997;38:79–101 (102 ref.)

Antioxidant actions of melatonin. Reiter RJ.
Adv Pharmacol 1997;38:103–17 (49 ref.)

Oxidative stress and antioxidant function in relation to risk for cataract. Taylor A, et al. **Adv Pharmacol** 1997;38:515–36 (91 ref.)

A new outlook for anti–oxidant defense system [editorial] Yu BP. **Aging (Milano)** 1995 Oct;7(5):338–9

beta–Carotene in breast milk and serum is increased after a single beta–carotene dose. Canfield LM, et al.
Am J Clin Nutr 1997 Jul;66(1):52–61

Circulating antioxidant concentrations in children with

inflammatory bowel disease. Hoffenberg EJ, et al. **Am J Clin Nutr** 1997 May;65(5):1482–8

Increased serum and low-density-lipoprotein antioxidant potential after antioxidant supplementation in endurance athletes. Vasankari TJ, et al. **Am J Clin Nutr** 1997 Apr; 65(4):1052–6

Enalapril and captopril enhance antioxidant defenses in mouse tissues. de Cavanagh EM, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R514–8

Air blast-induced pulmonary oxidative stress: interplay among hemoglobin, antioxidants, and lipid peroxidation. Gorbunov NV, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):L320–34

Relationship between anoxia exposure and antioxidant status in the frog Rana pipiens. Hermes-Lima M, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R918–25

Oxidative damage and antioxidants in Rana sylvatica, the freeze-tolerant wood frog. Joanisse DR, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R545–53

Hydrogen peroxide induces leukocyte rolling: modulation by endogenous antioxidant mechanisms including NO. Johnston B, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H614–21

Antioxidant status and lipid peroxidation after short-term maximal exercise in trained and untrained humans. Ortenblad N, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1258–63

Antioxidant expression in experimental hydronephrosis: role of mechanical stretch and growth factors. Ricardo SD, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):F789–98

Lack of antioxidant adaptation to short-term aerobic training in human muscle. Tiidus PM, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):R832–6

Higher lung antioxidant enzyme activity persists after single dose of corticosteroids in preterm lambs. Walther FJ, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):L187–91

Antioxidant kinetics in lung lavage fluid following exposure of humans to nitrogen dioxide. Kelly FJ, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1700–5

Antioxidant activity in bronchoalveolar lavage fluid from patients with lung cancer. Melloni B, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1706–11

Evaluation of ascorbate and urate antioxidant capacity in human semen. Gavella M, et al. **Andrologia** 1997 Jan–Feb; 29(1):29–35

Serum total antioxidant activity after myocardial infarction. Miller NJ, et al. **Ann Clin Biochem** 1997 Jan;34 (Pt 1):85–90

Responses to acute myocardial stress and prior drug therapy on plasma levels of antioxidants and oxidants and the proposed role of interventions on molecular adaptations. Singh RB, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:517–20

Late ischemic preconditioning is mediated in myocytes by enhanced endogenous antioxidant activity stimulated by oxygen-derived free radicals. Zhai X, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:156–66

Antioxidant enzymatic system and free radicals pathway in two different human cancer cell lines. Porta C, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2741–7

Changes in various antioxidant levels in human seminal plasma related to immunoinfertility. Palan P, et al. **Arch Androl** 1996 Mar–Apr;36(2):139–43

Antioxidant reactions of vitamin E in the perfused rat liver: product distribution and effect of dietary vitamin E supplementation. Ham AJ, et al. **Arch Biochem Biophys** 1997 Mar 1;339(1):157–64

Cell physiology of the pineal body. Marchiafava PL, et al. **Arch Ital Biol** 1997 Mar;135(2):183–94 (73 ref.)

Modifications of antioxidant capacity and heart electrical activity induced by hydroperoxide in normal and vitamin E-fed rats. Di Meo S, et al. **Arch Physiol Biochem** 1997 Apr;105(2):175–82

Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Goulinet S, et al. **Arterioscler Thromb Vasc Biol** 1997 Apr;17(4):786–96

Serum antioxidant status in hypobetalipoproteinaemia [letter] Crook MA, et al. **Atherosclerosis** 1997 May;131(1):135–6

Comparison of antioxidant activity in lipoprotein fractions from insulin-dependent diabetics and healthy controls. Maxwell S, et al. **Atherosclerosis** 1997 Feb 28;129(1):89–96

Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men. Nyyssönen K, et al. **Atherosclerosis** 1997 Apr;130(1–2):223–33

Bacterial scavengase p20 is structurally and functionally related to peroxiredoxins. Zhou Y, et al. **Biochem Biophys Res Commun** 1997 Apr 28;233(3):848–52

Delineation of the arginine- and tetrahydrobiopterin-binding sites of neuronal nitric oxide synthase. Boyhan A, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):131–9

Cysteine-200 of human inducible nitric oxide synthase is essential for dimerization of haem domains and for binding of haem, nitroarginine and tetrahydrobiopterin. Cubberley RR, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):141–6

Nitrogen dioxide depletes uric acid and ascorbic acid but not glutathione from lung lining fluid. Kelly FJ, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):95–9

Characterization of bovine endothelial nitric oxide synthase as a homodimer with down-regulated uncoupled NADPH oxidase activity: tetrahydrobiopterin binding kinetics and role of haem in dimerization. List BM, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):159–65

Gender specific alterations in antioxidant status of aging Zaprionus paravittiger fed on propyl gallate. Bains JS, et al. **Biochem Mol Biol Int** 1996 Nov;40(4):731–40

The antioxidant properties of thioctic acid: characterization by cyclic voltammetry. Chevion S, et al. **Biochem Mol Biol Int** 1997 Feb;41(2):317–27

Does the reduced form of neopterin serve as an antioxidant? Mori H, et al. **Biochem Mol Biol Int** 1996 Nov; 40(4):799–806

Proton-donative antioxidant activity of fucoxanthin with 1,1-diphenyl-2-picrylhydrazyl (DPPH). Nomura T, et al. **Biochem Mol Biol Int** 1997 Jun;42(2):361–70

Islet antioxidant and second phase enzyme levels following CYP1A, CYP2E, CYP2B and CYP4A induction. Clarke J, et al. **Biochem Soc Trans** 1997 Feb;25(1):133S

Free radical formation in non-photosynthetic plant tissue--an overview. Hendry GA, et al. **Biochem Soc Trans** 1996 May;24(2):484–8 (14 ref.)

Solubilisation of ferulic acid from plant cell wall materials in a model human gut system. Kroon PA, et al. **Biochem Soc Trans** 1996 Aug;24(3):384S

Antioxidant status, oxidative stress and DNA damage in the aetiology of malnutrition related diabetes mellitus. McDonagh M, et al. **Biochem Soc Trans** 1997 Feb; 25(1):146S

Opportunities for the genetic manipulation of antioxidants in plant foods. Mullineaux PM, et al. **Biochem Soc Trans** 1996 Aug;24(3):829–35 (22 ref.)

Tissue-specific development of antioxidant systems during avian embryogenesis. Speake BK, et al. **Biochem Soc Trans** 1996 May;24(2):182S

Identification of pro-oxidant or antioxidant characteristics of proteins and enzymes in membranes; use of liposome-entrapped proteins and other thiol-containing compounds. Straghan E, et al. **Biochem Soc Trans** 1996 Aug;24(3):375S

Influence of phenolics on protein binding to the antioxidant responsive element (ARE). Wang B, et al. **Biochem Soc Trans** 1996 Aug;24(3):461S

Kinetic study of the suicide inactivation of latent polyphenoloxidase from iceberg lettuce (Lactuca sativa) induced by 4-tert-butylcatechol in the presence of SDS. Chazarra S, et al. **Biochim Biophys Acta** 1997 May 23; 1339(2):297–303

Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat. Luo X, et al. **Biochim Biophys Acta** 1997 Feb 27;1360(1):45–52

A kinetic study of the one-electron oxidation of Trolox C by the hydroperoxidase activity of lipoxygenase. Núñez Delicado E, et al. **Biochim Biophys Acta** 1997 Apr 17; 1335(1–2):127–34

Endogenous and exogenous antioxidants and the generation of antigenic epitopes in oxidatively-modified LDL. Bellomo G, et al. **Biofactors** 1997;6(2):91–8 (31 ref.)

The influence of oxidized lipoproteins, oxidation products and antioxidants on the release of nitric oxide from the endothelium and the response of platelets to nitric oxide. Bruckdorfer KR, et al. **Biofactors** 1997;6(2):191–9 (49 ref.)

Breakdown of oxidized proteins as a part of secondary antioxidant defenses in mammalian cells. Grune T, et al. **Biofactors** 1997;6(2):165–72 (36 ref.)

Whole plasma oxidation assay as a measure of lipoprotein oxidizability. Kontush A, et al. **Biofactors** 1997;6(2):99–109

Influence of bilirubin on the antioxidant capacity of plasma in newborn infants. Bélanger S, et al. **Biol Neonate** 1997; 71(4):233–8

Possible role of uric acid as an antioxidant in premature infants. Schrod L, et al. **Biol Neonate** 1997;72(2):102–11

Cellular antioxidant defense by a ubiquinol-regenerating system coupled with cytosolic NADPH-dependent ubiquinone reductase: protective effect against carbon tetrachloride-induced hepatotoxicity in the rat. Takahashi T, et al. **Biol Pharm Bull** 1996 Aug;19(8):1005–12

Electronic and structural requirements for metabolic activation of butylated hydroxytoluene analogs to their quinone methides, intermediates responsible for lung toxicity in mice. Yamamoto K, et al. **Biol Pharm Bull** 1997 May;20(5):571–3

Selenium and antioxidant vitamin and lipidoperoxidation levels in preaging French population. EVA Study Group. Edude de vieillissement artériel. Coudray C, et al. **Biol Trace Elem Res** 1997 May;57(2):183–90

Effect of cadmium on antioxidant status in alloxane-induced diabetic rats. Gümüşlü S, et al. **Biol Trace Elem Res** 1997 May;57(2):105–14

Antioxidant status in persons with and without senile lens changes. Xue AN, et al. **Biomed Environ Sci** 1996 Sep; 9(2–3):144–8

Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Livrea MA, et al. **Blood** 1996 Nov 1; 88(9):3608–14

Antioxidant enzymes--superoxide dismutase and glutathione peroxidase--in haemodialyzed patients. Zima T, et al. **Blood Purif** 1996;14(3):257–61

Antioxidant state and mortality from coronary heart disease in Lithuanian and Swedish men: concomitant cross sectional study of men aged 50. Kristenson M, et al. **BMJ** 1997 Mar 1;314(7081):629–33

Digestion of 14C-labelled condensed tannins from Desmodium intortum in sheep and goats. Perez-Maldonado RA, et al. **Br J Nutr** 1996 Oct;76(4):501–13

Antioxidant deficiency following clam enterocystoplasty. Barrington JW, et al. **Br J Urol** 1997 Aug;80(2):238–42

Differential cellular distribution of glutathione--an endogenous antioxidant--in the guinea pig inner ear. Usami S, et al. **Brain Res** 1996 Dec 16;743(1–2):337–40

Fish antioxidant defenses--a comparative approach. Wilhelm Filho D. **Braz J Med Biol Res** 1996 Dec;29(12):1735–42

Evaluation of lipid peroxidation and total antioxidant status in plasma of rats following thermal injury. Cetinkale O, et al. **Burns** 1997 Mar;23(2):114–6

Heart and red blood cell antioxidant status and plasma lipid levels in the spontaneously hypertensive and normotensive Wistar-Kyoto rat. Yuan YV, et al. **Can J Physiol Pharmacol** 1996 Mar;74(3):290–7

Tissue antioxidants and postmenopausal breast cancer: the European Community Multicentre Study on Antioxidants, Myocardial Infarction, and Cancer of the Breast (EURAMIC). van 't Veer P, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Jun;5(6):441–7

Bioavailability of the dietary antioxidant flavonol quercetin in man. Hollman PC, et al. **Cancer Lett** 1997 Mar 19; 114(1–2):139–40

Cadmium-induced 8-hydroxydeoxyguanosine formation, DNA strand breaks and antioxidant enzyme activities in lymphoblastoid cells. Mikhailova MV, et al. **Cancer Lett** 1997 May 19;115(2):141–8

Loss and/or formation of antioxidants during food processing and storage. Nicoli MC, et al. **Cancer Lett** 1997 Mar 19; 114(1–2):71–4

Combined effects of complex mixtures of potentially anti-carcinogenic compounds on antioxidant enzymes and carcinogen metabolizing enzymes in the rat. Vang O, et al. **Cancer Lett** 1997 Mar 19;114(1–2):283–6 (12 ref.)

Plasma antioxidant vitamins, chronic hepatitis B virus infection and urinary aflatoxin B1-DNA adducts in healthy males. Yu MW, et al. **Carcinogenesis** 1997 Jun;18(6):1189–94

Antioxidant status of hypercholesterolemic patients treated with LDL apheresis. Lepage S, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):567–71

Erythrocyte lipid peroxidation and antioxidants in gastric cancer patients. Arivazhagan S, et al. **Cell Biochem Funct** 1997 Mar;15(1):15–8

Free radical scavenging and antioxidative properties of 'silibin' complexes on microsomal lipid peroxidation. Basaga H, et al. **Cell Biochem Funct** 1997 Mar;15(1):27–33

Comparison of oxidized low-density lipoprotein toxicity on EA.hy 926 cells and human vein endothelial cells: influence of antioxidant systems. Claise C, et al. **Cell Mol Life Sci** 1997 Feb;53(2):156–61

Respiratory tract lining fluid antioxidants: the first line of defence against gaseous pollutants. Kelly FJ, et al. **Cent Eur J Public Health** 1996;4 Suppl:11–4

Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. Jin L, et al. **Chem Res Toxicol** 1997 Mar;10(3):318–27

Metabolism of tert-butylhydroquinone to S-substituted conjugates in the male Fischer 344 rat. Peters MM, et al. **Chem Res Toxicol** 1996 Jan–Feb;9(1):133–9

The interdependence of lung antioxidants and antiprotease defense in ARDS. Gadek JE, et al. **Chest** 1996 Dec;110(6 Suppl):273S–277S (13 ref.)

Adaptation of lung antioxidants to cigarette smoking in humans. Hilbert J, et al. **Chest** 1996 Oct;110(4):916–20

Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Gambhir JK, et al. **Clin Biochem** 1997 Jun;30(4):351–5

HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. Yoshikawa M, et al. **Clin Biochem** 1997 Apr; 30(3):221–5

A pilot study of blood antioxidant and free radical marker profiles in patients awaiting coronary artery bypass grafting. Gu M, et al. **Clin Chim Acta** 1996 Aug 30; 252(2):181–95

The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Human JA, et al. **Clin Chim Acta** 1997 Jul 4;263(1):67–77

Diabetes mellitus, lipid peroxidation and antioxidant status in rural patients [letter] Srinivasan KN, et al. **Clin Chim Acta** 1997 Mar 18;259(1–2):183–6

Effects of different chromium compounds on blood pressure and lipid peroxidation in spontaneously hypertensive rats. Preuss HG, et al. **Clin Nephrol** 1997 May;47(5):325–30

Seasonal variation in the antioxidant defense system of the brain of the ground squirrel (Citellus citellus) and response to low temperature compared with rat. Buzadžić B, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jun;117(2):141–9

Organophosphate effects on antioxidant system of carp (Cyprinus carpio) and catfish (Ictalurus nebulosus). Hai DQ, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 May;117(1):83–8

Antioxidant enzymatic activity in embryos and placenta of rats chronically exposed to hypoxia and hyperoxia. Mover H, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jun;117(2):151–7

Chronic effect of insulin on monoamine oxidase and antioxidant enzyme activities in the rat brainstem. Radojičić R, et al.

Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1997 Jun;117(2):187–92

Activity of antioxidant defense enzymes and glutathione content in some tissues of the Belgrade (b/b) laboratory rat. Saičić ZS, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jun;117(2):173–9

Effect of cadmium and selenium on the antioxidant defense system in rat kidneys. Stajn A, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jun;117(2):167–72

Antioxidant defense mechanisms in parasitic protozoa. Mehlotra RK. **Crit Rev Microbiol** 1996;22(4):295–314 (144 ref.)

Eales' disease: accumulation of reactive oxygen intermediates and lipid peroxides and decrease of antioxidants causing inflammation, neovascularization and retinal damage. Bhooma V, et al. **Curr Eye Res** 1997 Feb;16(2):91–5

A comparison of antioxidant enzyme activities in organ-cultured rhesus monkey lenses following peroxide challenge. Tumminia SJ, et al. **Curr Eye Res** 1996 Aug; 15(8):845–51

Effects of nutritional antioxidants and other dietary constituents on coxsackievirus-induced myocarditis. Beck MA, et al. **Curr Top Microbiol Immunol** 1997;223:81–96 (50 ref.)

Erythrocyte and plasma antioxidant activity and subclinical complications in young diabetic patients [letter; comment] [see comments] Dorchy H, et al. **Diabetes Care** 1996 Oct; 19(10):1165. Comment on: Diabetes Care 1996 Mar;19(3):257–67. Comment in: Diabetes Care 1997 Aug;20(8):1338–9.

Lipids, lipoproteins, antioxidants and glomerular and tubular dysfunction in type 1 diabetes. O'Brien SF, et al. **Diabetes Res Clin Pract** 1996 Apr;32(1–2):81–90

Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Lih-Brody L, et al. **Dig Dis Sci** 1996 Oct;41(10):2078–86

Effect of exercise on tissue anti-oxidant capacity and heart electrical properties in male and female rats. Venditti P, et al. **Eur J Appl Physiol** 1996;74(4):322–9

Oxidative injury of synapse and alteration of antioxidative defense systems in rats, and its prevention by vitamin E. Urano S, et al. **Eur J Biochem** 1997 Apr 1;245(1):64–70

The antioxidant potential of the Mediterranean diet. Ghiselli A, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S15–9 (28 ref.)

Exercise, free radical generation and vitamins. Giuliani A, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S55–67 (163 ref.)

Free radicals, atherosclerosis, ageing, and related dysmetabolic pathologies: pathological and clinical aspects. Scarfiotti C, et al. **Eur J Cancer Prev** 1997 Mar;6 Suppl 1:S31–6 (31 ref.)

Lipid peroxidation, antioxidant status and troponin-T following cardiopulmonary bypass. A comparison between intermittent crossclamp with fibrillation and crystalloid cardioplegia. Cohen AS, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):248–53

Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Maxwell SR, et al. **Eur J Clin Invest** 1997 Jun; 27(6):484–90

Antioxidant vitamins in hospitalized elderly patients: analysed dietary intakes and biochemical status. Schmuck A, et al. **Eur J Clin Nutr** 1996 Jul;50(7):473–8

Lipoperoxidation and antioxidant enzymes activity in pregnancy complicated with hypertension. Loverro G, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec 27; 70(2):123–7

Antioxidant defenses of cultured colonic epithelial cells against reactive oxygen metabolites. Hata Y, et al. **Eur J Pharmacol** 1997 Feb 19;321(1):113–9

Oxidant-antioxidant imbalance in the experimental interstitial lung disease induced in sheep by visna-maedi virus. Cottin V, et al. **Eur Respir J** 1996 Oct;9(10):1983–8

Cellular glutathione turnover in vitro, with emphasis on type II pneumocytes. van Klaveren RJ, et al. **Eur Respir J** 1997 Jun;10(6):1392–400 (75 ref.)

Corneal aldehyde dehydrogenase displays antioxidant properties [letter] Uma L, et al. **Exp Eye Res** 1996 Jul; 63(1):117–20

Relationship between pituitary hormones, antioxidant enzymes, and histopathological changes in the mammary gland of senescent rats. Bolzán AD, et al. **Exp Gerontol** 1997 May-Jun;32(3):297–304

Oxidative stress: oxidants and antioxidants. Sies H. **Exp Physiol** 1997 Mar;82(2):291–5 (19 ref.)

The molecular basis of adaptation to ischemia in the heart: the role of stress proteins and anti-oxidants in the ischemic and reperfused heart. Heads RJ, et al. **EXS** 1996;76:383–407 (70 ref.)

Scavengase p20: a novel family of bacterial antioxidant enzymes. Wan XY, et al. **FEBS Lett** 1997 Apr 21; 407(1):32–6

Nonenzymatic antioxidant activity of human seminal plasma. Jóźwik M, et al. **Fertil Steril** 1997 Jul;68(1):154–7

Use of transgenic plants to study antioxidant defenses. Allen RD, et al. **Free Radic Biol Med** 1997;23(3):473–9 (39 ref.)

The effect of dietary treatment on lipid peroxidation and antioxidant status in newly diagnosed noninsulin dependent diabetes. Armstrong AM, et al. **Free Radic Biol Med** 1996; 21(5):719–26

Effects of exhaustive exercise and vitamin B6 deficiency on free radical oxidative process in male trained rats. Benderitter M, et al. **Free Radic Biol Med** 1996;21(4):541–9

Antioxidant defense system in differentially hydrogen peroxide sensitive L5178Y sublines. Boużyk E, et al. **Free Radic Biol Med** 1997;22(4):697–704

Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type—place of the extracellular glutathione peroxidase. Ceballos-Picot I, et al. **Free Radic Biol Med** 1996;20(4):579–87

Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Ceballos-Picot I, et al. **Free Radic Biol Med** 1996;21(6):845–53

Effects of anthracyclin-based chemotherapy on total plasma antioxidant capacity in small cell lung cancer patients. Erhola M, et al. **Free Radic Biol Med** 1996;21(3):383–90

5-Hydroxymethyluracil excretion, plasma TBARS and plasma antioxidant vitamins in adriamycin-treated patients. Faure H, et al. **Free Radic Biol Med** 1996;20(7):979–83

The effects of dialyzer reuse on plasma antioxidative mechanisms in patients on regular hemodialysis treatment. Gündüz Z, et al. **Free Radic Biol Med** 1996;21(2):225–31

Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells. Jung K, et al. **Free Radic Biol Med** 1997;23(1):127–33

Developmental changes of antioxidant enzymes in kidney and liver from rats. Jung K, et al. **Free Radic Biol Med** 1996; 20(4):613–7

Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system. Kowluru RA, et al. **Free Radic Biol Med** 1997;22(4):587–92

DT-Diaphorase maintains the reduced state of ubiquinones in lipid vesicles thereby promoting their antioxidant function. Landi L, et al. **Free Radic Biol Med** 1997; 22(1–2):329–35

Effects of chloroquine treatment on antioxidant enzymes in rat liver and kidney. Magwere T, et al. **Free Radic Biol Med** 1997;22(1–2):321–7

Complexes of iron with phenolic compounds from soybean nodules and other legume tissues: prooxidant and antioxidant properties. Moran JF, et al. **Free Radic Biol Med** 1997;22(5):861–70

Neutrophil antioxidant capacity during the respiratory burst: loss of glutathione induced by chloramines. Ogino T, et al. **Free Radic Biol Med** 1997;23(3):445–52

Role of oxidants/antioxidants in smoking-induced lung diseases. Rahman I, et al. **Free Radic Biol Med** 1996; 21(5):669–81 (155 ref.)

Antioxidants in peripheral nerve. Romero FJ. **Free Radic Biol Med** 1996;20(7):925–32 (112 ref.)

Oxidant/antioxidant balance in isolated glomeruli and cultured mesangial cells. Ruiz-Torres P, et al. **Free Radic Biol Med** 1997;22(1–2):49–56

Oxidative stress and defense mechanisms in plants: introduction. Scandalios JG. **Free Radic Biol Med** 1997; 23(3):471–2

The effects of ozone on antioxidant responses in plants. Sharma YK, et al. **Free Radic Biol Med** 1997;23(3):480–8 (53 ref.)

Oxidative stress and antioxidant defense mechanism in glomerular diseases. Túri S, et al. **Free Radic Biol Med** 1997;22(1–2):161–8

Exogenous reactive oxygen species deplete the isolated rat heart of antioxidants. Vaage J, et al. **Free Radic Biol Med** 1997;22(1–2):85–92

Effects of acute prolonged exercise on-serum and LDL oxidation and antioxidant defences. Vasankari TJ, et al. **Free Radic Biol Med** 1997;22(3):509–13

Role of lipid peroxidation and antioxidants in gastric mucosal injury induced by the hypoxanthine-xanthine oxidase system in rats. Yoshikawa T, et al. **Free Radic Biol Med** 1997;23(2):243–50

Unidentified antioxidant defences of human plasma in immobilized patients: a possible relation to basic metabolic rate. Aejmelaeus R, et al. **Free Radic Res** 1997 Apr; 26(4):335–41

Phospholipid hydroperoxides and lipid peroxidation in liver and plasma of ODS rats supplemented with alpha-tocopherol and ascorbic acid. Cadenas S, et al. **Free Radic Res** 1996 Jun;24(6):485–93

Effects of co-supplementation of iron with ascorbic acid on antioxidant—pro-oxidant balance in the guinea pig. Collis CS, et al. **Free Radic Res** 1997 Jul;27(1):113–21

Oxidative tissue response promoted by 5-aminolevulinic acid promptly induces the increase of plasma antioxidant capacity. Demasi M, et al. **Free Radic Res** 1997 Mar; 26(3):235–43

Will the 'good fairies' please prove to us that vitamin E lessens human degenerative disease? Diplock AT. **Free Radic Res** 1997 Jun;26(6):565–83 (85 ref.)

Antioxidant activity of reduced menadione in solvent solution and in model membranes. Fiorentini D, et al. **Free Radic Res** 1997 May;26(5):419–29

Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Halliwell B. **Free Radic Res** 1996 Jul;25(1):57–74 (210 ref.)

Factors influencing the antioxidant activity determined by the ABTS.+ radical cation assay [published erratum appears in Free Radic Res 1997 Jun;26(6):594] Miller NJ, et al. **Free Radic Res** 1997 Mar;26(3):195–9

Differential depletion of human respiratory tract antioxidants in response to ozone challenge. Mudway IS, et al. **Free Radic Res** 1996 Dec;25(6):499–513

The relationship between yield and the antioxidant defense system in tomatoes grown under heat stress. Rainwater DT, et al. **Free Radic Res** 1996 Nov;25(5):421–35

Cellular antioxidant properties of human natural killer enhancing factor B. Sarafian TA, et al. **Free Radic Res** 1997 Mar;26(3):281–9

Multiplicity of antioxidant enzyme catalase in mouse liver cells. Sun Y. **Free Radic Res** 1997 Apr;26(4):343–50

Antioxidant status and susceptibility of sickle erythrocytes to oxidative and osmotic stress. Tatum VL, et al. **Free Radic Res** 1996 Aug;25(2):133–9

Seasonal variation in low density lipoprotein oxidation and antioxidant status. Van de Vijver LP, et al. **Free Radic Res** 1997 Jul;27(1):89–96

Indoleamine 2,3-dioxygenase: antioxidant enzyme in the human eye. Malina HZ, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jul;234(7):457–62

Antioxidant enzyme levels in cancer. Oberley TD, et al. **Histol Histopathol** 1997 Apr;12(2):525–35 (82 ref.)

Endogenous and copper-induced lipid peroxidation and antioxidant activity of serum in hypercholesterolemic subjects. Mehmetçik G, et al. **Horm Metab Res** 1997 Feb; 29(2):63–5

Effect of anoxia and reoxygenation on antioxidant enzyme activities in immortalized brain endothelial cells. Rabin O, et al. **In Vitro Cell Dev Biol Anim** 1996 Apr;32(4):221–4

Effect of protein supplemented cassava diet in rats. Sreeja VG, et al. **Indian J Biochem Biophys** 1996 Apr;33(2):149–51

Antioxidant status of streptozotocin diabetic rats. Garg MC, et al. **Indian J Exp Biol** 1996 Mar;34(3):264–6

Superoxide anion scavenging capacity of human seminal plasma. Gavella M, et al. **Int J Androl** 1996 Apr;19(2):82–90

MIBG causes oxidative stress and up-regulation of anti-oxidant enzymes in the human neuroblastoma cell line SK-N-BE(2c). Cornelissen J, et al. **Int J Cancer** 1997 Jul 29;72(3):486–90

The role of antioxidants in the prevention of t-butyl hydroperoxide-induced chemiluminescence. Gümüşlü S, et al. **Int J Clin Lab Res** 1996;26(2):119–23

No evidence of oxidative stress after a triathlon race in highly trained competitors. Margaritis I, et al. **Int J Sports Med** 1997 Apr;18(3):186–90

Antioxidant-micronutrients and HIV infection. Lacey CJ, et al. **Int J STD AIDS** 1996 Nov-Dec;7(7):485–9

Changes in endogenous lipoperoxidation and antioxidant enzyme status induced by cysteine in the substantia Nigra. Calabrese V, et al. **Int J Tissue React** 1996;18(4–6):115–20

Nutritional implications in vascular endothelial cell metabolism. Hennig B, et al. **J Am Coll Nutr** 1996 Aug; 15(4):345–58 (138 ref.)

Blood antioxidants changes in young women following beta-carotene depletion and repletion. Omaye ST, et al. **J Am Coll Nutr** 1996 Oct;15(5):469–74

Favorable effect of hemodialysis on decreased serum antioxidant activity in hemodialysis patients demonstrated by electron spin resonance. Nagase S, et al. **J Am Soc Nephrol** 1997 Jul;8(7):1157–63

Effect of sprint cycle training on activities of antioxidant enzymes in human skeletal muscle. Hellsten Y, et al. **J Appl Physiol** 1996 Oct;81(4):1484–7

Interaction of exercise training and chronic ethanol ingestion on hepatic and plasma antioxidant system in rat. Husain K, et al. **J Appl Toxicol** 1997 May-Jun;17(3):189–94

Oxy radicals, anti-oxidants and diabetes mellitus [letter] Das UN. **J Assoc Physicians India** 1995 Jun;43(6):445–6

The role of free radicals in toxicity and disease. Stohs SJ. **J Basic Clin Physiol Pharmacol** 1995;6(3–4):205–28 (99 ref.)

Antioxidant activity of vitamin C in iron-overloaded human plasma. Berger TM, et al. **J Biol Chem** 1997 Jun 20; 272(25):15656–60

Do nitroxide antioxidants act as scavengers of O2-. or as SOD mimics? Krishna MC, et al. **J Biol Chem** 1996 Oct 18;271(42):26026–31

Carotenoids and antioxidant vitamins in patients after burn injury. Rock CL, et al. **J Burn Care Rehabil** 1997 May-Jun; 18(3):269–78; discussion 268

Changes of biological reducing activity in rat brain following closed head injury: a cyclic voltammetry study in normal and heat-acclimated rats. Beit-Yannai E, et al. **J Cereb Blood Flow Metab** 1997 Mar;17(3):273–9

High-performance liquid chromatographic methods for the quantification of tetrahydrobiopterin biosynthetic enzymes. Werner ER, et al. **J Chromatogr B Biomed Appl** 1996 Sep 20;684(1–2):51–8 (65 ref.)

Effects of estradiol and medroxyprogesterone-acetate treatment on erythrocyte antioxidant enzyme activities and malondialdehyde plasma levels in amenorrhoic women. Massafra C, et al. **J Clin Endocrinol Metab** 1997 Jan; 82(1):173–5

Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. Makino Y, et al. **J Clin Invest** 1996 Dec 1;98(11):2469–77

Reactive oxygen species and antioxidants in inflammatory diseases. Chapple IL. **J Clin Periodontol** 1997 May; 24(5):287–96 (103 ref.)

Mercuric chloride-induced reactive oxygen species and its effect on antioxidant enzymes in different regions of rat brain. Hussain S, et al. **J Environ Sci Health B** 1997 May;

32(3):395–409
Oxygen uptake and antioxidant responses of the free-living diplomonad Hexamita sp. Biagini GA, et al. **J Eukaryot Microbiol** 1997 Sep–Oct;44(5):447–53
Circulating antioxidants as determinants of the rate of biological aging in pigtailed macaques (Macaca nemestrina). Short R, et al. **J Gerontol A Biol Sci Med Sci** 1997 Jan;52(1):B26–38
Antioxidant defence system in a patient with cerebrovascular accident. Kocatürk S, et al. **J Int Med Res** 1996 Jul–Aug; 24(4):376–80
Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. Picardo M, et al. **J Invest Dermatol** 1996 Sep;107(3):322–6
Estradiol–17beta as an antioxidant: some distinct features when compared with common fat–soluble antioxidants [see comments] Ayres S, et al. **J Lab Clin Med** 1996 Oct; 128(4):367–75. Comment in: J Lab Clin Med 1996 Oct;128(4):344–5.
Tetrahydrobiopterin biosynthesis enhanced by lipopolysaccharide stimulation in murine neuroblastoma cell line N1E–115. Ota A, et al. **J Neurochem** 1996 Dec; 67(6):2540–8
The antioxidant enzymatic blood profile in Alzheimer's and vascular diseases. Their association and a possible assay to differentiate demented subjects and controls. Famulari AL, et al. **J Neurol Sci** 1996 Sep 15;141(1–2):69–78
Study of the antioxidant enzymes in human brain tumors. Pu PY, et al. **J Neurooncol** 1996 Aug;29(2):121–8
Increase in antioxidant capacity of plasma during propofol anesthesia. Hans P, et al. **J Neurosurg Anesthesiol** 1997 Jul; 9(3):234–6
Antioxidative activity of barley hordein and its loss by deamidation. Chiue H, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Feb;43(1):145–54
An assessment of docosahexaenoic acid (DHA) intake with special reference to lipid metabolism in rats. Saito M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1996 Jun;42(3):195–207
Prenatal dexamethasone administration to premature rats exposed to prolonged hyperoxia: a new rat model of pulmonary fibrosis (bronchopulmonary dysplasia). Chen Y, et al. **J Pediatr** 1997 Mar;130(3):409–16
Cocaine–induced peroxidative stress in rat liver: antioxidant enzymes and mitochondria. Devi BG, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):359–66
Antioxidant adaptive response in human blood mononuclear cells exposed to UVB. Alvarez S, et al. **J Photochem Photobiol B** 1997 Apr;38(2–3):152–7
Beta–carotene and disease: a suggested pro–oxidant and anti–oxidant mechanism and speculations concerning its role in cigarette smoking. Truscott TG. **J Photochem Photobiol B** 1996 Sep;35(3):233–5
Lipid and antioxidant changes in spermatozoa and seminal plasma throughout the reproductive period of bulls. Kelso KA, et al. **J Reprod Fertil** 1997 Jan;109(1):1–6
Micronutrients and exercise: anti–oxidants and minerals. Clarkson PM. **J Sports Sci** 1995 Summer;13 Spec No:S11–24 (161 ref.)
Pathological aspects of active oxygens/free radicals. Nakazawa H, et al. **Jpn J Physiol** 1996 Feb;46(1):15–32 (135 ref.)
Inhibition of LDL oxidation by cocoa [letter; comment] [see comments] Kondo K, et al. **Lancet** 1996 Nov 30; 348(9040):1514. Comment on: Lancet 1996 Sep 21;348(9030):834. Comment in: Lancet 1997 Feb 1;349(9048):360–1.
Antioxidant defense system in diabetic kidney: a time course study. Kakkar R, et al. **Life Sci** 1997;60(9):667–79
ESR imaging of the rat brain with a nitroxide radical perfused by in vivo microdialysis. Ueda Y, et al. **Magn Reson Imaging** 1997;15(3):355–60
Lipid peroxidation and activity of antioxidative enzymes in the rat model of ozone therapy. Laszczyca P, et al. **Mater Med Pol** 1996 Oct–Dec;28(4):155–60
Aging and detoxifying enzymes responses to hypoxic or hyperoxic treatment. Amicarelli F, et al. **Mech Ageing Dev** 1997 Sep;97(3):215–26
Effect of radiotherapy and chemoradiotherapy on circulating antioxidant system of human uterine cervical carcinoma. Bhuvarahamurthy V, et al. **Mol Cell Biochem** 1996 May 10;158(1):17–23
Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. Kaul N, et al. **Mol Cell Biochem** 1996 Jul–Aug;160–161:283–8
Alterations in tissue glutathione antioxidant system in streptozotocin–induced diabetic rats. Mak DH, et al. **Mol Cell Biochem** 1996 Sep 20;162(2):153–8
Gender–related regional antioxidant profiles in the gastrointestinal tract of the rat. Moghadasian MH, et al. **Mol Cell Biochem** 1996 Feb 9;155(1):43–9
Antioxidant systems and anoxia tolerance in a freshwater turtle Trachemys scripta elegans. Willmore WG, et al. **Mol Cell Biochem** 1997 May;170(1–2):177–85
The antioxidant function of the physiological content of vitamin C. Glascott PA Jr, et al. **Mol Pharmacol** 1996 Oct; 50(4):994–9
The reduction of alpha–tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha–tocopherolhydroquinone as a cellular antioxidant. Siegel D, et al. **Mol Pharmacol** 1997 Aug;52(2):300–5
In vivo antioxidant status, DNA damage, mutation and DNA repair capacity in cultured lymphocytes from healthy 75–to 80–year–old humans. King CM, et al. **Mutat Res** 1997 Jun 9;377(1):137–47
Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma. Zima T, et al. **Neoplasma** 1996; 43(2):69–73
Effect of parathyroid hormone on antioxidant enzyme activity and lipid peroxidation of erythrocytes in five–sixths nephrectomized rats. Chen SM, et al. **Nephron** 1996; 73(2):235–42
Decreased serum antioxidant activity of hemodialysis patients demonstrated by methylguanidine synthesis and microsomal lipid peroxidation. Nagase S, et al. **Nephron** 1996;74(3):555–60
Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes. Tang Z, et al. **Nephron** 1997;76(3):323–30
Effect of vitamin E on antioxidant enzymes, lipid peroxidation products and glomerulosclerosis in the rat remnant kidney. Van den Branden C, et al. **Nephron** 1997; 76(1):77–81
Expression of glomerular antioxidant enzymes in human glomerulonephritis. Wang JS, et al. **Nephron** 1997; 76(1):32–8
Role of antioxidants in the nitric oxide–elicited inhibition of dopamine uptake in cultured mesencephalic neurons. Insights into potential mechanisms of nitric oxide–mediated neurotoxicity. Cook JA, et al. **Neurochem Int** 1996 May–Jun;28(5–6):609–17
Role of metallothionein and other antioxidants in scavenging superoxide radicals and their possible role in neuroprotection. Hussain S, et al. **Neurochem Int** 1996 Aug; 29(2):145–52
Spermine partially normalizes in vivo antioxidant defense potential in certain brain regions in transiently hypoperfused rat brain. Farbiszewski R, et al. **Neurochem Res** 1996 Dec;21(12):1497–503
Nitric oxide and antioxidant status in glucose and oxygen deprived neonatal and adult rat brain synaptosomes. Keelan J, et al. **Neurochem Res** 1996 Aug;21(8):923–7
Lipid peroxidation and antioxidant systems in rat brain: effect of chronic alcohol consumption. Omodeo–Sale F, et al. **Neurochem Res** 1997 May;22(5):577–82
Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amiotrophic lateral sclerosis patients. Oteiza PI, et al. **Neurochem Res** 1997 Apr;22(4):535–9
Distribution of 6R–L–erythro–5,6,7,8–tetrahydrobiopterin in regional brain areas of inbred strains of rats and mice with different alcohol preferences. Yoshimoto K, et al. **Neuropsychobiology** 1996;33(2):85–9
beta Amyloid does not activate the antioxidant pentose phosphate pathway within the B12 neural cell line. Kopp A, et al. **Neuroreport** 1997 Mar 24;8(5):1197–201
Dissociated release of tetrahydrobiopterin and nitric oxide by lipopolysaccharide from mouse neuroblastoma cells. Yoshida S, et al. **Neurosci Lett** 1996 Jul 12;212(2):135–8
Effects of human diets of two different Japanese populations on cancer incidence in rat hepatic drug–metabolizing and antioxidant enzyme systems. Kanke Y, et al. **Nutr Cancer** 1996;26(1):63–71
Inflammation, free radicals, and antioxidants. Conner EM, et al. **Nutrition** 1996 Apr;12(4):274–7 (40 ref.)
Increased lipid peroxidation and antioxidant activity in methionine–induced hepatitis in rabbits. Toborek M, et al. **Nutrition** 1996 Jul–Aug;12(7–8):534–7
Role of catalase in retinal antioxidant defence system: its comparative study among rabbits, guinea pigs, and rats. Ohta Y, et al. **Ophthalmic Res** 1996;28(6):336–42
Glutathione as a cytoprotective antioxidant in erythrocytes of the newborn: the role of G6PD and zinc protoporphyrin: a hypothesis [letter] Malina L, et al. **Pediatr Hematol Oncol** 1997 Sep–Oct;14(5):495–7
Influence of long chain unsaturated fatty acids in formula feeds on lipid peroxidation and antioxidants in preterm infants. Jacobs NJ, et al. **Pediatr Res** 1996 Nov;40(5):680–6
Rat diaphragm oxidative capacity, antioxidant enzymes, and fatigue: newborn versus adult. Lattari A, et al. **Pediatr Res** 1997 Jul;42(1):60–5
Reduced levels of antioxidants in brains of apolipoprotein E–deficient mice following closed head injury. Lomnitski L, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):669–73
Oxidant, antioxidant status and photocarcinogenesis: the role of gene activation. Tyrrell RM. **Photochem Photobiol** 1996 Apr;63(4):380–3 (31 ref.)
Lipid peroxidation and antioxidants in normal and pre–eclamptic pregnancies. Poranen AK, et al. **Placenta** 1996 Sep;17(7):401–5
Activity of the antioxidant enzymes superoxide dismutase and glutathione peroxidase in fetal erythrocytes. Zima T, et al. **Prenat Diagn** 1996 Dec;16(12):1083–5
Tetrahydrobiopterin, nitric oxide and regulation of cerebral arterial tone. Kinoshita H, et al. **Prog Neurobiol** 1997 Jul; 52(4):295–302 (77 ref.)
Interrelationships between astrocyte function, oxidative stress and antioxidant status within the central nervous system. Peuchen S, et al. **Prog Neurobiol** 1997 Jul;52(4):261–81 (311 ref.)
Oxidant stress, anti–oxidants and essential fatty acids in systemic lupus erythematosus. Mohan IK, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Mar; 56(3):193–8
Antioxidants, atherosclerosis and thrombosis. Rao GH, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Mar; 54(3):155–66 (154 ref.)
Abnormal antioxidant vitamin and carotenoid status in chronic renal failure. Ha TK, et al. **QJM** 1996 Oct; 89(10):765–9
Lipid peroxidation and antioxidant defense mechanisms in rat renal tissue after daunorubicin administration. Dioudis C, et al. **Ren Fail** 1996 Jul;18(4):537–43
Effect of lung surfactant liposomes on the rabbit fetal lung type II cell antioxidant enzymes following prenatal dexamethasone treatment. Gupta A, et al. **Res Exp Med (Berl)** 1996;196(1):67–76
Lipid peroxidation and antioxidant activities in regenerating liver after partial hepatectomy in splenectomized rats. Imai T, et al. **Res Exp Med (Berl)** 1996;196(1):1–7
Effect of aluminum on regional brain antioxidant defense status in Wistar rats. Julka D, et al. **Res Exp Med (Berl)** 1996;196(3):187–94
The effect of acute ligation of the rabbit appendix on antioxidant enzymes. Turan C, et al. **Res Exp Med (Berl)** 1996;196(1):45–51
Effects of aging and/or training on antioxidant enzyme system in diaphragm of mice. Oh–ishi S, et al. **Respir Physiol** 1996 Sep;105(3):195–202
Decreased antioxidant status and increased lipid peroxidation in rats after methanol intoxication. Skrzydlewska E. **Rocz Akad Med Bialymst** 1996;41(2):397–404
Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene sulphonic acid–induced colitis rats. Protective effect of rebamipide. Zea–Iriarte WL, et al. **Scand J Gastroenterol** 1996 Oct;31(10):985–92
Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin. Cavdar C, et al. **Scand J Urol Nephrol** 1997 Aug;31(4):371–5
Free radical pathology and antioxidant defense in schizophrenia: a review. Mahadik SP, et al. **Schizophr Res** 1996 Mar;19(1):1–17 (165 ref.)
Impaired antioxidant defense at the onset of psychosis. Mukerjee S, et al. **Schizophr Res** 1996 Mar;19(1):19–26
Plasma antioxidant consumption associated with ischemia/reperfusion during carotid endarterectomy. Bacon PJ, et al. **Stroke** 1996 Oct;27(10):1808–11
Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. Schmidt R, et al. **Stroke** 1996 Nov;27(11):2043–7
Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease. Rahman I, et al. **Thorax** 1997 Jun; 52(6):565–8
Contribution of oxygen radicals to DNA cleavage by quinone compounds derived from phenolic antioxidants, tert–butylhydroquinone and 2,5–di–tert–butylhydroquinone. Okubo T, et al. **Toxicol Lett** 1997 Jan 15;90(1):11–8
Liposoluble antioxidants are not consumed in the pancreas after reperfusion in human simultaneous pancreas–kidney transplantation. Benz S, et al. **Transpl Int** 1996;9 Suppl 1:S258–60
Comparative metabolism and disposition of ethoxyquin in rat and mouse. II. Metabolism. Burka LT, et al. **Xenobiotica** 1996 Jun;26(6):597–611
[The effect of the factors of the working and living environment on oxidative/antioxidative balance (a review)] Vangelova K. **Probl Khig** 1996;21:27–36 (41 ref.) (Eng. Abstr.) **(Bul)**
[Antioxidants and malondialdehyde during hemodialysis with cellulose diacetate and polysulfone membranes] Eiselt J, et al. **Cas Lek Cesk** 1996 Nov 6;135(21):691–4 (Eng. Abstr.) **(Cze)**
[Does plasmapheresis affect the production of free radicals and the antioxidant system?] Eiselt J, et al. **Cas Lek Cesk** 1996 Sep 11;135(17):558–62 (Eng. Abstr.) **(Cze)**
[Evaluation of oxidative stress and antioxidant defences in malnourished Moroccan children] Squali Houssaini FZ, et al. **Ann Nutr Metab** 1997;41(3):149–59 (Eng. Abstr.) **(Fre)**
[Metabolism and antioxidant function of glutathione] Gérard–Monnier D, et al. **Pathol Biol (Paris)** 1996 Jan; 44(1):77–85 (65 ref.) (Eng. Abstr.) **(Fre)**
[Oxidant–antioxidant imbalance in the experimental interstitial lung disease induced in sheep by visna–maedi virus] Buhl R. **Pneumologie** 1997 Feb;51(2):150 **(Ger)**
[Prospective biochemical study of the antioxidant defense capacity in retinopathy of prematurity] Papp A, et al. **Orv Hetil** 1997 Jan 26;138(4):201–5 (47 ref.) (Eng. Abstr.) **(Hun)**
[Antioxidant defense capabilities of gastric mucosa induced by water immersion restraint stress of rat] Ohisa Y, et al. **Rinsho Byori** 1996 Feb;44(2):183–9 (Eng. Abstr.) **(Jpn)**
[The effect of diuretics on lipid peroxidation activity and antioxidant protective defense of plasma] Lan'shina OE, et al. **Biull Eksp Biol Med** 1994 May;117(5):478–9 **(Rus)**
[Effect of prenatal hypoxia on DNA synthesis in tracheal epithelium and lipid peroxidation–antioxidant defense system in lungs of newborn rats] Lebed'ko OA, et al. **Biull Eksp Biol Med** 1994 May;117(5):531–3 **(Rus)**
[Effect of melatonin and epithalamin on the antioxidant defense system activity in rats] Anisimov VM, et al. **Dokl Akad Nauk** 1997 Feb;352(6):831–3 **(Rus)**

ANTIOXIDANTS

[Lipid peroxidation and antioxidant defense system in myocardial ischemia] Barsel' VA, et al. **Dokl Akad Nauk** 1996 Dec;351(5):706–8 **(Rus)**

[Antioxidant defense of in vivo selected high- and low-malignant variants of tumor cells in the Syrian hamster] Kashkina LM, et al. **Dokl Akad Nauk** 1996 Dec; 351(5):702–5 **(Rus)**

[Lipid peroxidation and antioxidant defense in renal affections of exotoxic etiology] Seisembekov TZ, et al. **Klin Med (Mosk)** 1997;75(2):43–5 (Eng. Abstr.) **(Rus)**

[The antioxidant allowance of the body and lipid peroxidation in patients with gastric and duodenal peptic ulcers] Petrov EE. **Lik Sprava** 1996 Jul–Sep;(7–9):13–8 (50 ref.) **(Rus)**

[Role of the antioxidant system in the pathogenesis of toxic hepatitis] Gonskiĭ IaI, et al. **Patol Fiziol Eksp Ter** 1996 Apr–Jun;(2):43–5 (Eng. Abstr.) **(Rus)**

[Biochemical aspects of atherogenesis: the role of antioxidants] Dmitriev LF. **Ter Arkh** 1995;67(12):73–7 (67 ref.) **(Rus)**

[Structural–functional changes in erythrocyte membranes in bovine lympholeukemia] Riazantsev VV, et al. **Ukr Biokhim Zh** 1996 Jan–Feb;68(1):92–5 (Eng. Abstr.) **(Rus)**

[Interaction between lipid peroxides, the antioxidant system, and levels of cyclic AMP and cyclic GMP in hypoxic and hyperthermic animals] Savchenkova LV. **Ukr Biokhim Zh** 1995 Nov–Dec;67(6):102–5 (Eng. Abstr.) **(Rus)**

[The body's antioxidative systems in bronchopulmonary disease] Khyshiktuev BS. **Vestn Ross Akad Med Nauk** 1996; (9):23–7 (Eng. Abstr.) **(Rus)**

[Changes in the antioxidative activity of blood serum in inflammation] Volchegorskiĭ IA, et al. **Vopr Med Khim** 1997 Jul–Aug;43(4):233–8 (Eng. Abstr.) **(Rus)**

[Coenzyme Q10 and alpha-tocopherol in patients after heart transplantation] Kucharská J, et al. **Bratisl Lek Listy** 1996 Oct;97(10):603–6 (Eng. Abstr.) **(Slo)**

[Anti-oxidants, free radicals, and health. A chemical, organic, and physical approach] Ballester M. **Med Clin (Barc)** 1996 Oct 19;107(13):509–15 (64 ref.) **(Spa)**

[The antioxidative activity of homogenates and lipids obtained from intact and ischemic organs in rats] Paranich AV, et al. **Fiziol Zh** 1996;42(1–2):31–5 (Eng. Abstr.) **(Ukr)**

[Lipid peroxidation and the antioxidant activity of the blood serum in diabetic patients] Podil'chak MD, et al. **Lik Sprava** 1995 Sep–Dec;(9–12):110–1 **(Ukr)**

[Antioxidant system disorder in diabetic patients and the means for its normalization] Zelins'kyĭ BO, et al. **Lik Sprava** 1996 Jul–Sep;(7–9):99–102 (Eng. Abstr.) **(Ukr)**

[Role of phospholipids in functionally different cell membranes under conditions of antioxidant system disturbance] Datsenko ZM, et al. **Ukr Biokhim Zh** 1996 Jan–Feb;68(1):49–54 (Eng. Abstr.) **(Ukr)**

PHARMACOKINETICS

N alpha-acetylcarnosine is a prodrug of L-carnosine in ophthalmic application as antioxidant [published erratum appears in Clin Chim Acta 1997 Mar 18;259(1–2):199–201] Babizhayev MA, et al. **Clin Chim Acta** 1996 Oct 15; 254(1):1–21

Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis. Pearson LK, et al. **Eur J Clin Pharmacol** 1996; 50(4):299–304

Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Hollman PC, et al. **Free Radic Biol Med** 1996;21(5):703–7

Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day. Fleishaker JC, et al. **Int J Clin Pharmacol Ther** 1997 Jan;35(1):28–32

Preferential increase in chylomicron levels of the xanthophylls lutein and zeaxanthin compared to beta-carotene in the human. Gärtner C, et al. **Int J Vitam Nutr Res** 1996;66(2):119–25

The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. Zhi J, et al. **J Clin Pharmacol** 1996 Feb; 36(2):152–9

Ingestion by men of a combined dose of beta-carotene and lycopene does not affect the absorption of beta-carotene but improves that of lycopene. Johnson EJ, et al. **J Nutr** 1997 Sep;127(9):1833–7

Positron-labeled antioxidant 6-deoxy-6-[18F]fluoro-L-ascorbic acid: increased uptake in transient global ischemic rat brain. Yamamoto F, et al. **Nucl Med Biol** 1996 May;23(4):479–86

Comparative metabolism and disposition of ethoxyquin in rat and mouse. I. Disposition. Sanders JM, et al. **Xenobiotica** 1996 Jun;26(6):583–95

[The role of oxidative stress and the preventive effect of free radical scavengers in arteriosclerosis] Fehér J, et al. **Orv Hetil** 1997 Sep 7;138(36 Suppl 2):2283–7 (Eng. Abstr.) **(Hun)**

PHARMACOLOGY

Neuroprotective efficacy of microvascularly-localized versus brain-penetrating antioxidants. Hall ED, et al. **Acta Neurochir Suppl (Wien)** 1996;66:107–13 (23 ref.)

Modelling cortical cataractogenesis. XVIII. In vitro diabetic cataract reduction by venoruton. A flavonoid which prevents lens opacification. Kilic F, et al. **Acta Ophthalmol Scand** 1996 Aug;74(4):372–8

Effect of a new inhibitor of lipid peroxidation on kidney function after ischaemia-reperfusion. A study on rat and rabbit kidneys. Sørensen V, et al. **Acta Physiol Scand** 1996 Jun;157(2):289–97

Effect of antioxidants on hyperoxia-induced ICAM-1 expression in human endothelial cells. Aoki T, et al. **Adv Exp Med Biol** 1997;411:503–11

Some activities of the oxidant chromate. Park HS, et al. **Adv Exp Med Biol** 1996;387:85–96

Related mechanisms of action of growth factors and antioxidants in apoptosis: an overview. Oppenheim RW. **Adv Neurol** 1997;72:69–78 (40 ref.)

N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Cotgreave IA. **Adv Pharmacol** 1997;38:205–27 (122 ref.)

Antioxidants: the basics--what they are and how to evaluate them. Halliwell B. **Adv Pharmacol** 1997;38:3–20 (89 ref.)

Antioxidant-inducible genes. Primiano T, et al. **Adv Pharmacol** 1997;38:293–328 (216 ref.)

Antioxidants, redox-regulated transcription factors, and inflammation. Winyard PG, et al. **Adv Pharmacol** 1997; 38:403–21 (103 ref.)

Differences in the serum levels of acetaldehyde and cytotoxic acetaldehyde-albumin complexes after the consumption of red and white wine: in vitro effects of flavonoids, vitamin E, and other dietary antioxidants on cytotoxic complexes. Wickramasinghe SN, et al. **Alcohol Clin Exp Res** 1996 Aug; 20(5):799–803

Evaluation of the antioxidant and hepatoprotective activity of Terminalia catappa. Lin CC, et al. **Am J Chin Med** 1997; 25(2):153–61

Curcumin protects against 4-hydroxy-2-trans-nonenal-induced cataract formation in rat lenses. Awasthi S, et al. **Am J Clin Nutr** 1996 Nov; 64(5):761–6

Destroying immune homeostasis in normal adults with antioxidant supplements [letter; comment] Herbert V. **Am J Clin Nutr** 1997 Jun;65(6):1901–3. Comment on: Am J Clin Nutr 1996 Dec;64(6):960–5.

Increased serum and low-density-lipoprotein antioxidant potential after antioxidant supplementation in endurance athletes. Vasankari TJ, et al. **Am J Clin Nutr** 1997 Apr; 65(4):1052–6

Probucol suppresses oxidant stress in hypertensive arteries. Immunohistochemical evidence. Sharma RC, et al. **Am J Hypertens** 1996 Jun;9(6):577–90

Interaction between oxidative stress and gamma-linolenic acid in impaired neurovascular function of diabetic rats. Cameron NE, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E471–6

Cysteine S-conjugates activate transcription factor NF-kappa B in cultured renal epithelial cells. Otieno MA, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):F136–43

Oxidant stress-induced transendothelial migration of monocytes is linked to phosphorylation of PECAM-1. Rattan V, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E453–61

Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle. Streeper RS, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E185–91

Antioxidant PDTC induces stromelysin expression in mesangial cells via a tyrosine kinase-AP-1 pathway. Yokoo T, et al. **Am J Physiol** 1996 May;270(5 Pt 2):F806–11

Inhibition by L-ascorbic acid and other antioxidants of the 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) oxidation catalyzed by peroxidase: a new approach for determining total antioxidant status of foods. Arnao MB, et al. **Anal Biochem** 1996 May 1;236(2):255–61

Antioxidant effect of flavonoids. Catapano AL. **Angiology** 1997 Jan;48(1):39–44 (42 ref.)

Involvement of nitric oxide in the pathophysiology of acute heat stress in the rat. Influence of a new antioxidant compound H-290/51. Sharma HS, et al. **Ann N Y Acad Sci** 1997 Mar 15;813:581–90

Correlation of neutrophil activation and skin flap survival in pharmacologically altered pigs. Kosko JR, et al. **Ann Otol Rhinol Laryngol** 1997 Sep;106(9):790–4

Effects of diallyl sulfide and diallyl disulfide on cisplatin-induced changes in glutathione and glutathione-S-transferase activity. Dwivedi C, et al. **Anticancer Drugs** 1996 Sep;7(7):792–4

Inhibitory effect of crocetin on benzo(a)pyrene genotoxicity and neoplastic transformation in C3H10T1/2 cells. Chang WC, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3603–8

Methionine oxidation and apoptosis induction by ascorbate, gallate and hydrogen peroxide. Sakagami H, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2565–70

Prooxidant action of two antioxidants: ascorbic acid and gallic acid. Sakagami H, et al. **Anticancer Res** 1997 Jan–Feb; 17(1A):221–4

Copper, but not iron, enhances apoptosis-inducing activity of antioxidants. Satoh K, et al. **Anticancer Res** 1997 Jul–Aug;17(4A):2487–90

Effect of Trolox, a synthetic analog of alpha-tocopherol, on cytotoxicity induced by UV irradiation and antioxidants. Satoh K, et al. **Anticancer Res** 1997 Jul–Aug; 17(4A):2459–63

The mechanism of apolipoprotein B-100 thiol depletion during oxidative modification of low-density lipoprotein. Ferguson E, et al. **Arch Biochem Biophys** 1997 May 15; 341(2):287–94

Effect of butylhydroxytoluene and related compounds on permeability of the inner mitochondrial membrane. Gudz T, et al. **Arch Biochem Biophys** 1997 Jun 1;342(1):143–56

Marchantin H as a natural antioxidant and free radical scavenger. Hsiao G, et al. **Arch Biochem Biophys** 1996 Oct 1;334(1):18–26

2,3-Dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: design and evaluation as a novel radical-scavenging antioxidant against lipid peroxidation. Noguchi N, et al. **Arch Biochem Biophys** 1997 Jun 15; 342(2):236–43

Trolox inhibits peroxynitrite-mediated oxidative stress and apoptosis in rat thymocytes. Salgo MG, et al. **Arch Biochem Biophys** 1996 Sep 15;333(2):482–8

Enzymatic and molecular aspects of the antioxidant effect of menadione in hepatic microsomes. Tampo Y, et al. **Arch Biochem Biophys** 1996 Oct 1;334(1):163–74

A comparison of scavenging abilities of antioxidants against hydroxyl radicals. Ueda J, et al. **Arch Biochem Biophys** 1996 Sep 15;333(2):377–84

Comprehensive analysis of proteins which interact with the antioxidant responsive element: correlation of ARE-BP-1 with the chemoprotective induction response. Wasserman WW, et al. **Arch Biochem Biophys** 1997 Aug 15; 344(2):387–96

Effect of policosanol on in vitro and in vivo rat liver microsomal lipid peroxidation. Fraga V, et al. **Arch Med Res** 1997 Autumn;28(3):355–60

Histopathological evaluation on the effect of red propolis on liver damage induced by CCl4 in rats. Merino N, et al. **Arch Med Res** 1996 Autumn;27(3):285–9

Antioxidant activity of rat parotid saliva. Nagler RM, et al. **Arch Otolaryngol Head Neck Surg** 1997 Sep;123(9):989–93

Effect of guaiazulene on some cytochrome P450 activities. Implication in the metabolic activation and hepatotoxicity of paracetamol. Kourounakis AP, et al. **Arch Pharm (Weinheim)** 1997 Jan–Feb;330(1–2):7–11

Vitamin E protection of cell morphology under oxidative stress is related to cytoskeletal proteins in rat hepatocytes. Kuo JH, et al. **Arch Toxicol** 1997;71(4):231–7

Molecular modeling parameters predict antioxidant efficacy of 3-indolyl compounds. Shertzer HG, et al. **Arch Toxicol** 1996;70(12):830–4

Protective effect of vitamin E on chromium (VI)-induced cytotoxicity and lipid peroxidation in primary cultures of rat hepatocytes. Susa N, et al. **Arch Toxicol** 1996; 71(1–2):20–4

Comparative antioxidant and cardioprotective effects of ceruloplasmin, superoxide dismutase and albumin. Dumoulin MJ, et al. **Arzneimittelforschung** 1996 Sep; 46(9):855–61

Anti-inflammatory activity of some novel 1-[3-(aroylo)] and one 1-[3-(aryloxy)]-propyl aminothiazole in correlation with structure and lipophilicity. Hadjipavlou-Litina DJ, et al. **Arzneimittelforschung** 1996 Aug;46(8):805–8

The influence of antioxidant nutrients on platelet function in healthy volunteers. Calzada C, et al. **Atherosclerosis** 1997 Jan 3;128(1):97–105

Effect of ascorbate supplementation on low density lipoprotein oxidation in smokers. Fuller CJ, et al. **Atherosclerosis** 1996 Jan 26;119(2):139–50

Inhibition of oxidation of low density lipoprotein by troglitazone. Noguchi N, et al. **Atherosclerosis** 1996 Jun; 123(1–2):227–34

The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy. O'Leary VJ, et al. **Atherosclerosis** 1996 Jan 26; 119(2):169–79

Enhanced capacity of n-3 fatty acid-enriched macrophages to oxidize low density lipoprotein mechanisms and effects of antioxidant vitamins. Suzukawa M, et al. **Atherosclerosis** 1996 Aug 2;124(2):157–69

In vitro effects of a flavonoid-rich extract on LDL oxidation. Viana M, et al. **Atherosclerosis** 1996 Jun;123(1–2):83–91

Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Zuckerman SH, et al. **Atherosclerosis** 1996 Sep 27;126(1):65–75

Effect of beta-carotene, canthaxanthin, or lutein on lymphocyte proliferation (in vitro) of newly hatched chicks. Haq A, et al. **Avian Dis** 1996 Oct–Dec;40(4):823–7

Antioxidant action of ergothioneine: assessment of its ability to scavenge peroxynitrite. Aruoma OI, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):389–91

Spin trapping study of antioxidant properties of neopterin and 7,8-dihydroneopterin. Oettl K, et al. **Biochem Biophys Res Commun** 1997 May 29;234(3):774–8

Rapid Ca2+ influx induced by the action of dibutylhydroquinone and glucagon in the perfused rat liver. Applegate TL, et al. **Biochem J** 1997 Apr 15;323 (Pt 2):463–7

Substances in the aqueous fraction of cigarette smoke inhibit lipid peroxidation in synaptosomes of rat cerebral cortex. Kamisaki Y, et al. **Biochem Mol Biol Int** 1997 Jun; 42(1):1–10

Tempace and troxyl-novel synthesized 2,2,6,6-tetramethylpiperidine derivatives as antioxidants and radioprotectors. Metodiewa D, et al. **Biochem Mol Biol Int** 1996 Dec;40(6):1211–9

Evidence for antiradical and antioxidant properties of four biologically active N,N-diethylaminoethyl ethers of

flavanone oximes: a comparison with natural polyphenolic flavonoid (rutin) action. Metodiewa D, et al. **Biochem Mol Biol Int** 1997 Apr;41(5):1067–75

Antioxidant property of Fructus Momordicae extract. Shi H, et al. **Biochem Mol Biol Int** 1996 Dec;40(6):1111–21

Lung CuZn-superoxide dismutase and catalase gene expression in premature rabbits treated intratracheally with antioxidant-surfactant liposomes. Walther FJ, et al. **Biochem Mol Med** 1996 Dec;59(2):169–73

Adaptation to oxidative stress: quinone-mediated protection of signaling in rat lung epithelial L2 cells. Choi J, et al. **Biochem Pharmacol** 1997 Apr 4;53(7):987–93

Ebselen and cytokine-induced nitric oxide synthase expression in insulin-producing cells. de-Mello MA, et al. **Biochem Pharmacol** 1996 Dec 13;52(11):1703–9

Role of cellular thiol status in tocopheryl hemisuccinate cytoprotection against ethyl methanesulfonate-induced toxicity. Fariss MW, et al. **Biochem Pharmacol** 1997 Mar 7;53(5):651–61

Independent antioxidant action of vitamins E and C in cultured rat hepatocytes intoxicated with allyl alcohol. Glascott PA Jr, et al. **Biochem Pharmacol** 1996 Oct 25; 52(8):1245–52

The crucial antioxidant action of schisandrin B in protecting against carbon tetrachloride hepatotoxicity in mice: a comparative study with butylated hydroxytoluene. Ip SP, et al. **Biochem Pharmacol** 1996 Dec 13;52(11):1687–93

Molecular structure and antioxidant specificity of purpurogaliin in three types of human cardiovascular cells. Wu TW, et al. **Biochem Pharmacol** 1996 Oct 11; 52(7):1073–80

Effect of oral supplementation with micronutrient antioxidants on trans fatty acid content of lipoproteins in healthy humans. Chaloner C, et al. **Biochem Soc Trans** 1996 May;24(2):191S

Oxidative DNA damage in human cells: the influence of antioxidants and DNA repair. Collins AR, et al. **Biochem Soc Trans** 1997 Feb;25(1):326–31

An investigation of the radioprotective effect of dietary antioxidants on isolated murine lymphocytes. Galligan ES, et al. **Biochem Soc Trans** 1997 Feb;25(1):136S

The antioxidant activity of heparins. Grant D, et al. **Biochem Soc Trans** 1996 May;24(2):194S

Dietary beta-carotene supplementation modulates the production of tumour necrosis factor-alpha by human monocytes. Hughes DA, et al. **Biochem Soc Trans** 1996 Aug;24(3):387S

Beta-carotene supplementation enhances the expression of functionally associated molecules on human monocytes. Hughes DA, et al. **Biochem Soc Trans** 1996 Aug;24(3):388S

The effect of various dietary flavonoids on the susceptibility of low density lipoproteins to oxidation in vitro using both metallic and non-metallic oxidising agents. McAnlis GT, et al. **Biochem Soc Trans** 1997 Feb;25(1):142S

Reduced susceptibility of renal slices to oxidative damage. Obatomi DK, et al. **Biochem Soc Trans** 1997 Feb;25(1):36S

Effect of ethoxyquin on glutathione levels and peroxidisability of rat liver membranes. Plumb GW, et al. **Biochem Soc Trans** 1996 Aug;24(3):380S

Antioxidant activities of flavonoids as bioactive components of food. Rice-Evans CA, et al. **Biochem Soc Trans** 1996 Aug;24(3):790–5 (22 ref.)

Potent antioxidant properties of novel apple-derived flavonoids with commercial potential as food additives. Ridgway T, et al. **Biochem Soc Trans** 1996 Aug;24(3):391S

Antioxidant action of novel derivatives of the apple-derived flavonoid phloridzin compared to oestrogen: relevance to potential cardioprotective action. Ridgway T, et al. **Biochem Soc Trans** 1997 Feb;25(1):106S

Can carotenoids reduce oxidation-induced cataract? Sanderson J, et al. **Biochem Soc Trans** 1996 Aug;24(3):385S

Antioxidant properties of ethanolic and aqueous extracts of green tea compared to black tea. Wiseman H, et al. **Biochem Soc Trans** 1996 Aug;24(3):390S

The cardioprotective antioxidant activity of dietary phytoestrogens compared to oestrogen. Wiseman H, et al. **Biochem Soc Trans** 1997 Feb;25(1):107S

Influence of the dietary flavonoid quercetin on the cardioprotective antioxidant action of oestrogen and phytoestrogens. Wiseman H, et al. **Biochem Soc Trans** 1997 Feb;25(1):108S

Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin. Miller YI, et al. **Biochemistry** 1997 Oct 7; 36(40):12189–98

Effect of lipid peroxidation products and antioxidants on the formation of probucol radical in low density lipoproteins. Shumaev KB, et al. **Biochemistry (Mosc)** 1997 Jun; 62(6):657–60

Effect of in vivo iron supplementation on oxygen radical production by soybean roots. Caro A, et al. **Biochim Biophys Acta** 1996 Dec 6;1291(3):245–51

Fibronectin fragment mediated cartilage chondrolysis. I. Suppression by anti-oxidants. Homandberg GA, et al. **Biochim Biophys Acta** 1996 Nov 15;1317(2):134–42

Fibronectin fragment mediated cartilage chondrolysis. II. Reparative effects of anti-oxidants. Homandberg GA, et al. **Biochim Biophys Acta** 1996 Nov 15;1317(2):143–8

Antioxidant properties of isotorachrysone isolated from Rhamnus nakaharai. Hsiao G, et al. **Biochim Biophys Acta** 1996 Nov 14;1298(1):119–30

Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Kuo ML, et al. **Biochim Biophys Acta** 1996 Nov 15;1317(2):95–100

Inhibition of copper- and peroxyl radical-induced LDL lipid oxidation by ebselen: antioxidant actions in addition to hydroperoxide-reducing activity. Lass A, et al. **Biochim Biophys Acta** 1996 Sep 27;1303(2):111–8

Endogenous and exogenous antioxidants and the generation of antigenic epitopes in oxidatively-modified LDL. Bellomo G, et al. **Biofactors** 1997;6(2):91–8 (31 ref.)

The influence of oxidized lipoproteins, oxidation products and antioxidants on the release of nitric oxide from the endothelium and the response of platelets to nitric oxide. Bruckdorfer KR, et al. **Biofactors** 1997;6(2):191–9 (49 ref.)

Dynamics of oxidation of LDL and its inhibition by antioxidants. Niki E, et al. **Biofactors** 1997;6(2):201–8 (84 ref.)

Procyanidins from tormentil: antioxidant properties towards lipoperoxidation and anti-elastase activity. Bos MA, et al. **Biol Pharm Bull** 1996 Jan;19(1):146–8

Effect on free radical processes of some ascorbic acid analogues. Coudert P, et al. **Biol Pharm Bull** 1996 Feb; 19(2):220–3

Effects of methyl 9(or 10)-hydroxy-10(or 9)-mercaptostearate and hexadecanethioic S-acid on cupric ion- or 2,2-azo-bis(2-amidinopropane) dihydrochloride (AAPH)-induced oxidation of low density lipoprotein. Tanaka M, et al. **Biol Pharm Bull** 1996 May;19(5):692–6

Antioxidative effect of sesamol and related compounds on lipid peroxidation. Uchida M, et al. **Biol Pharm Bull** 1996 Apr;19(4):623–26

Antioxidative effects of phenylethanoids from Cistanche deserticola. Xiong Q, et al. **Biol Pharm Bull** 1996 Dec; 19(12):1580–5

Free radical scavengers suppress the accumulation of platinum in the cerebral cortex. Minami T, et al. **Biol Trace Elem Res** 1996 Oct-Nov;55(1-2):1–7

Black tea, green tea, and tea polyphenols. Effects on trace element status in weanling rats. Record IR, et al. **Biol Trace Elem Res** 1996 Summer;53(1-3):27–43

Antioxidant N-acetyl-cysteine increasing cell adhesion capability could facilitate the biocompatibility processes. Malorni W, et al. **Biomaterials** 1996 May;17(9):921–8

Antioxidants in food and chronic degenerative diseases. Candlish JK, et al. **Biomed Environ Sci** 1996 Sep; 9(2-3):117–23

Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-kappa B and AP-1 transcription factors activity. Muñoz C, et al. **Blood** 1996 Nov 1;88(9):3482–90

Antioxidant potential of i.v. fluids. Stratford N. **Br J Anaesth** 1997 Jun;78(6):757–9

Beta-carotene inhibits rat liver chromosomal aberrations and DNA chain break after a single injection of diethylnitrosamine. Sarkar A, et al. **Br J Cancer** 1997; 76(7):855–61

A method for simultaneous determination of plasma and erythrocyte antioxidant status. Evaluation of the antioxidant activity of vitamin E in healthy volunteers. Abella A, et al. **Br J Clin Pharmacol** 1996 Dec;42(6):737–41

Captopril has no significant scavenging antioxidant activity in human plasma in vitro or in vivo [letter] Benzie IF, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):209–10

Captopril has no significant scavenging antioxidant activity in human plasma in vitro or in vivo. Lapenna D, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):451–6

The effect of pharmacological supplementation with vitamin C on low-density lipoprotein oxidation. Wen Y, et al. **Br J Clin Pharmacol** 1997 Jul;44(1):94–7

Modulation of cholestane-3 beta,5 alpha,6 beta-triol toxicity by butylated hydroxytoluene, alpha-tocopherol and beta-carotene in newborn rat kidney cells in vitro. Wilson AM, et al. **Br J Nutr** 1997 Sep;78(3):479–92

Inhibition by antioxidants of nitric oxide synthase expression in murine macrophages: role of nuclear factor kappa B and interferon regulatory factor 1. Hecker M, et al. **Br J Pharmacol** 1996 Aug;118(8):2178–84

Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Iuliano L, et al. **Br J Pharmacol** 1996 Dec;119(7):1438–46

Antioxidant protection of NO-induced relaxations of the mouse anococcygeus against inhibition by superoxide anions, hydroquinone and carboxy-PTIO. Lilley E, et al. **Br J Pharmacol** 1996 Sep;119(2):432–8

Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition. Vázquez M, et al. **Br J Pharmacol** 1996 Mar;117(6):1155–62

Effect of vitamin A on the oxidative stability of broiler meat during storage: lack of interactions with vitamin E. Bartov I, et al. **Br Poult Sci** 1997 Jul;38(3):255–7

The antioxidant LY 231617 ameliorates functional and morphological sequelae induced by global ischemia in rats. Block F, et al. **Brain Res** 1995 Oct 2;694(1-2):308–11

Influence of cell culture conditions on the protective effect of antioxidants against beta-amyloid toxicity: studies with lazaroids. Lucca E, et al. **Brain Res** 1997 Aug 1; 764(1-2):293–8

Ascorbate attenuates the systemic kainate-induced neurotoxicity in the rat hippocampus. MacGregor DG, et al. **Brain Res** 1996 Jul 15;727(1-2):133–44

Antioxidants, mitochondrial hyperoxidation and electrical recovery after anoxia in hippocampal slices. Pérez-Pinzón MA, et al. **Brain Res** 1997 Apr 18;754(1-2):163–70

Effect of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin and infusion of L-tyrosine on the in vivo L-[beta-11C] DOPA disposition in the monkey brain. Tsukada H, et al. **Brain Res** 1996 Mar 25;713(1-2):92–8

Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats. Wright JW, et al. **Brain Res** 1996 Apr 22;717(1-2):1–11

The lazaroid U-83836E improves the survival of rat embryonic mesencephalic tissue stored at 4 degrees C and subsequently used for cultures or intracerebral transplantation. Grasbon-Frodl EM, et al. **Brain Res Bull** 1996;39(6):341–7

Inhibition of lipid peroxidation and iron (II)-dependent DNA damage by extracts of Pothomorphe peltata (L). Miq. Desmarchelier C, et al. **Braz J Med Biol Res** 1997 Jan; 30(1):85–91

The reaction between ABTS radical cation and antioxidants and its use to evaluate the antioxidant status of serum samples. Romay C, et al. **Braz J Med Biol Res** 1996 Feb; 29(2):175–83

The efficacy of retrograde infusion with LY231617 in a rat middle cerebral artery occlusion model. Inoue N, et al. **Can J Neurol Sci** 1996 Aug;23(3):175–83

Effects of doxorubicin, 4'-epirubicin, and antioxidant enzymes on the contractility of isolated cardiomyocytes. Chan EM, et al. **Can J Physiol Pharmacol** 1996 Aug; 74(8):904–10

Inhibitory effects of curcumin-free aqueous turmeric extract on benzo[a]pyrene-induced forestomach papillomas in mice. Deshpande SS, et al. **Cancer Lett** 1997 Sep 16; 118(1):79–85

Dose-related preventive and therapeutic effects of antioxidants-anticarcinogens on experimentally induced malignant tumors in Wistar rats. Evangelou A, et al. **Cancer Lett** 1997 May 1;115(1):105–11

Effects of n-tritriacontane-16,18-dione, curcumin, chlorphyllin, dihydroguaiaretic acid, tannic acid and phytic acid on the initiation stage in a rat multi-organ carcinogenesis model. Takaba K, et al. **Cancer Lett** 1997 Feb 26;113(1-2):39–46

Caffeic acid phenethyl ester stimulates human antioxidant response element-mediated expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene. Jaiswal AK, et al. **Cancer Res** 1997 Feb 1;57(3):440–6

Ascorbic acid and beta-carotene as modulators of oxidative damage. Cozzi R, et al. **Carcinogenesis** 1997 Jan;18(1):223–8

Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Delia D, et al. **Carcinogenesis** 1997 May;18(5):943–8

Biological activities of natural and synthetic carotenoids: induction of gap junctional communication and singlet oxygen quenching. Stahl W, et al. **Carcinogenesis** 1997 Jan; 18(1):89–92

Dietary quercetin glycosides: antioxidant activity and induction of the anticarcinogenic phase II marker enzyme quinone reductase in Hepalclc7 cells. Williamson G, et al. **Carcinogenesis** 1996 Nov;17(11):2385–7

Effects of beta mercaptoethanol on the proliferation and differentiation of human osteoprogenitor cells. Inui K, et al. **Cell Biol Int** 1997 Jul;21(7):419–25

Polyphenols in chocolate, which have antioxidant activity, modulate immune functions in humans in vitro. Sanbongi C, et al. **Cell Immunol** 1997 May 1;177(2):129–36

Antioxidant reactions of beta-carotene: identification of carotenoid-radical adducts. Liebler DC, et al. **Chem Res Toxicol** 1996 Jan-Feb;9(1):8–11

Purpurogallin inhibits DNA synthesis of murine fibrosarcoma L-929 and human U-87 MG glioblastoma cells in vitro. Fung KP, et al. **Chemotherapy** 1996 May-Jun;42(3):199–205

Effect of probucol on mRNA expression of glomerular antioxidant enzymes in rat with subtotal nephrectomy. Tang Z, et al. **Chin Med J (Engl)** 1996 Oct;109(10):780–6

Lazaroid (U74500A) prevents vascular and myocardial dysfunction after 24-hour heart preservation. A study based on cross-circulated blood-perfused rabbit hearts. Nishida T, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II326–31

Antioxidant protection of LDL by physiological concentrations of 17 beta-estradiol. Requirement for estradiol modification. Shwaery GT, et al. **Circulation** 1997 Mar 18;95(6):1378–85

Antioxidant activity of the stilbene astringin, newly extracted from Vitis vinifera cell cultures [letter] Mérillon JM, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):1092–3

The effects of tert-butyl hydroperoxide on human erythrocyte membrane ion transport and the protective actions of antioxidants. Dwight JF, et al. **Clin Chim Acta** 1996 May 30;249(1-2):167–81

A mechanism of antioxidant activity of calcium antagonist verapamil against LDL oxidation. Karmansky I, et al. **Clin Chim Acta** 1997 Mar 18;259(1-2):177–82

Phenolic content of various beverages determines the extent of inhibition of human serum and low-density lipoprotein oxidation in vitro: identification and mechanism of action of some cinnamic acid derivatives from red wine. Abu-Amsha R, et al. **Clin Sci (Colch)** 1996 Oct;91(4):449–58

Elevation of intracellular Ca2+ concentration in rabbit nonpigmented ciliary epithelial cells by allicin. Chu TC,

et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1996 Sep;115(1):89–94

Effect of Rooibos tea (Aspalathus linearis) on chick skeletal muscle cell growth in culture. Lamošová D, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1997 Jan;116(1):39–45

Antioxidant defense mechanisms in parasitic protozoa. Mehlotra RK. **Crit Rev Microbiol** 1996;22(4):295–314 (144 ref.)

The efficacy of antioxidants administered during low temperature storage of warm ischemic kidney tissue slices. McAnulty JF, et al. **Cryobiology** 1997 Jun;34(4):406–15

Evaluation of retinal susceptibility to light damage in pigmented rats supplemented with beta-carotene. Rapp LM, et al. **Curr Eye Res** 1996 Feb;15(2):219–23

Analytical and numerical techniques for the evaluation of free radical damage in cultured cells using scanning laser microscopy. Sawada GA, et al. **Cytometry** 1996 Nov 1; 25(3):254–62

Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Bierhaus A, et al. **Diabetes** 1997 Sep; 46(9):1481–90

The vitamin-E derivative U-83836-E in the low-dose streptozocin- treated mouse: effects on diabetes development. Papaccio G, et al.
Diabetes Res Clin Pract 1995 Dec;30(3):163–71

Effects of iron and vitamin E administration on some immunological parameters in pigs. Mudron P, et al.
DTW Dtsch Tierarztl Wochenschr 1996 Apr;103(4):131–3

Effects of beta-carotene, flavonoid quercitin and quinacrine on cell proliferation and lipid peroxidation breakdown products in BHK-21 cells. Alliangana DM.
East Afr Med J 1996 Nov;73(11):752–7

Promotion of glutathione-gamma-glutamyl transpeptidase-dependent lipid peroxidation by copper and ceruloplasmin: the requirement for iron and the effects of antioxidants and antioxidant enzymes. Glass GA, et al.
Environ Mol Mutagen 1997;29(1):73–80

The effects of sulfur dioxide inhalation and antioxidant vitamins on red blood cell lipoperoxidation. Etlik O, et al. **Environ Res** 1995 Oct;71(1):25–8

Propofol neuroprotection in a rat model of ischaemia reperfusion injury. Young Y, et al. **Eur J Anaesthesiol** 1997 May;14(3):320–6

Antioxidants as well as oxidants activate c-fos via Ras-dependent activation of extracellular-signal-regulated kinase 2 and Elk-1. Müller JM, et al. **Eur J Biochem** 1997 Feb 15;244(1):45–52

Bilirubin oxidation provoked by endotoxin treatment is suppressed by feeding ascorbic acid in a rat mutant unable to synthesize ascorbic acid. Yamaguchi T, et al.
Eur J Biochem 1997 Apr 15;245(2):233–40

Free radicals, oxidative damage and degenerative diseases [editorial] Giacosa A, et al. **Eur J Cancer Prev** 1996 Oct; 5(5):307–12 (35 ref.)

Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Aviram M.
Eur J Clin Chem Clin Biochem 1996 Aug;34(8):599–608 (95 ref.)

Beta-carotene as antioxidant. Bast A, et al.
Eur J Clin Nutr 1996 Jul;50 Suppl 3:S54–6

Effect of 6 month supplementation with different combinations of an association of antioxidant nutrients on biochemical parameters and markers of the antioxidant defence system in the elderly. The Geriatrie/Min.Vit.Aox Network. Monget AL, et al. **Eur J Clin Nutr** 1996 Jul; 50(7):443–9

Thiols prevent Fas (CD95)-mediated T cell apoptosis by down-regulating membrane Fas expression. Delneste Y, et al. **Eur J Immunol** 1996 Dec;26(12):2981–8

Amphiphilic alpha-tocopherol analogues as inhibitors of brain lipid peroxidation. Bolkenius FN, et al.
Eur J Pharmacol 1996 Feb 29;298(1):37–43

Endotoxin-induced changes of endothelial cell viability and permeability: protective effect of a 21-aminosteroid. Dimmeler S, et al. **Eur J Pharmacol** 1995 Dec 20; 287(3):257–61

Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives in mice. Ghezzi P, et al. **Eur J Pharmacol** 1996 Dec 19;317(2–3):369–76

Antioxidants prevent high-D-glucose-enhanced endothelial Ca2+/cGMP response by scavenging superoxide anions. Graier WF, et al. **Eur J Pharmacol** 1997 Mar 12; 322(1):113–22

Pyrrolidine dithiocarbamate inhibits immunostimulant-induced tetrahydrobiopterin synthesis in rat vascular smooth muscle. Hattori Y, et al.
Eur J Pharmacol 1996 Jan 18;296(1):107–12

N-allylsecoboldine as a novel antioxidant against peroxidative damage. Teng CM, et al. **Eur J Pharmacol** 1996 May 6;303(1–2):129–39

Epidermal localization and protective effects of topically applied superoxide dismutase. Filipe P, et al.
Exp Dermatol 1997 Jun;6(3):116–21

Effects of antioxidants on ischemic retinal dysfunction. Block F, et al. **Exp Eye Res** 1997 Apr;64(4):559–64

Curcumin, a compound with anti-inflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells. Xu YX, et al.
Exp Hematol 1997 May;25(5):413–22

Decrease in gamma-glutamyltransferase activity in rat type II cells exposed in vitro to hyperoxia: effects of the 21-aminosteroid U-74389G. van Klaveren RJ, et al.
Exp Lung Res 1997 Jul-Aug;23(4):347–59

Seizures and hippocampal damage produced by dendrotoxin-K in rats is prevented by the 21-aminosteroid U-74389G. Bagetta G, et al. **Exp Neurol** 1997 Sep; 147(1):204–10

Antioxidative effect of prostaglandin E2 in thioacetamide-induced liver cirrhosis. Buko V, et al.
Exp Toxicol Pathol 1997 Feb;49(1–2):141–6

(-)-Epigallocatechin gallate, a polyphenolic tea antioxidant, inhibits peroxynitrite-mediated formation of 8-oxodeoxyguanosine and 3-nitrotyrosine. Fiala ES, et al. **Experientia** 1996 Sep 15;52(9):922–6

The potential of antioxidants to prevent atherosclerosis development and its clinical manifestations. Pettersson KS, et al. **EXS** 1996;76:21–31 (47 ref.)

Impairment of excitatory amino acid transporter activity by oxidative stress conditions in retinal cells: effect of antioxidants. Agostinho P, et al. **FASEB J** 1997 Feb; 11(2):154–63

The carotenoids beta-carotene, canthaxanthin and zeaxanthin inhibit macrophage-mediated LDL oxidation. Carpenter KL, et al. **FEBS Lett** 1997 Jan 20;401(2–3):262–6

Peroxynitrite-induced hemolysis of human erythrocytes and its inhibition by antioxidants. Kondo H, et al.
FEBS Lett 1997 Aug 18;413(2):236–8

Antioxidant activity of allopurinol on copper-catalysed human lipoprotein oxidation. Lapenna D, et al.
FEBS Lett 1997 Jun 9;409(2):265–8

Prooxidant activity of caffeic acid, dietary non-flavonoid phenolic acid, on Cu2+-induced low density lipoprotein oxidation. Yamanaka N, et al. **FEBS Lett** 1997 Mar 24; 405(2):186–90

Inhibition of oxidative modification of proteins by RU486. Carpenter SE, et al. **Fertil Steril** 1996 Jul;66(1):90–4

Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Wilcox JG, et al. **Fertil Steril** 1997 Jan;67(1):57–62

Protective effects of diallyl sulfide on acetaminophen-induced toxicities. Hu JJ, et al.
Food Chem Toxicol 1996 Oct;34(10):963–9

Antioxidant and prooxidant properties of captopril and enalapril. Bartosz M, et al. **Free Radic Biol Med** 1997; 23(5):729–35

Protective effect of dehydroepiandrosterone against copper-induced lipid peroxidation in the rat. Boccuzzi G, et al. **Free Radic Biol Med** 1997;22(7):1289–94

Effect of natural antioxidant tanshinone II-A on DNA damage by lipid peroxidation in liver cells. Cao EH, et al. **Free Radic Biol Med** 1996;20(6):801–6

Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Cao G, et al.
Free Radic Biol Med 1997;22(5):749–60

Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Cominacini L, et al.
Free Radic Biol Med 1997;22(1–2):117–27

Antioxidant properties of hydroxy-flavones. Cotelle N, et al. **Free Radic Biol Med** 1996;20(1):35–43

Effects of lazaroids and a peroxynitrite scavenger in a cell model of peroxynitrite toxicity. Fici GJ, et al.
Free Radic Biol Med 1997;22(1–2):223–8

Effect of aromatic nitroxides on hemolysis of human erythrocytes entrapped with isolated hemoglobin chains. Gabbianelli R, et al. **Free Radic Biol Med** 1997;23(2):278–84

Regulation of nitric oxide synthase activity in cultured human endothelial cells: effect of antioxidants. Galley HF, et al. **Free Radic Biol Med** 1996;21(1):97–101

S-allyl cysteine inhibits activation of nuclear factor kappa B in human T cells. Geng Z, et al.
Free Radic Biol Med 1997;23(2):345–50

Efficacy of lipid soluble, membrane-protective agents against hydrogen peroxide cytotoxicity in cardiac myocytes. Horwitz LD, et al. **Free Radic Biol Med** 1996;21(6):743–53

Schisandrin B protects against carbon tetrachloride toxicity by enhancing the mitochondrial glutathione redox status in mouse liver. Ip SP, et al. **Free Radic Biol Med** 1996; 21(5):709–12

Allopurinol: discrimination of antioxidant from enzyme inhibitory activities. Klein AS, et al.
Free Radic Biol Med 1996;21(5):713–7

Protection of oxidative hemolysis by demethyldiisoeugenol in normal and beta-thalassemic red blood cells. Ko FN, et al. **Free Radic Biol Med** 1997;22(1–2):215–22

Boldine prevents human liver microsomal lipid peroxidation and inactivation of cytochrome P4502E1. Kringstein P, et al. **Free Radic Biol Med** 1995 Mar;18(3):559–63

alpha-tocopherol enrichment of high-density lipoproteins: stabilization of hydroperoxides produced during copper oxidation. Laureaux C, et al. **Free Radic Biol Med** 1997; 22(1–2):185–94

Green tea polyphenols inhibit oxidant-induced DNA strand breakage in cultured lung cells. Leanderson P, et al.
Free Radic Biol Med 1997;23(2):235–42

Effect of vitamin E on human glutathione peroxidase (GSH-PX1) expression in cardiomyocytes. Li RK, et al.
Free Radic Biol Med 1996;21(4):419–26

Contribution of vitamin A to the oxidation resistance of human low density lipoproteins. Livrea MA, et al.
Free Radic Biol Med 1995 Mar;18(3):401–9

Evaluation of the antioxidant activity of melatonin in vitro. Marshall KA, et al. **Free Radic Biol Med** 1996;21(3):307–15

Effect of vitamin E on human aortic endothelial cell responses to oxidative injury. Martin A, et al.
Free Radic Biol Med 1996;21(4):505–11

Spermine prevent iron accumulation and depress lipofuscin accumulation in cultured myocardial cells. Marzabadi MR, et al. **Free Radic Biol Med** 1996;21(3):375–81

Protective effect of the nitroxide tempol against the cardiotoxicity of adriamycin. Monti E, et al.
Free Radic Biol Med 1996;21(4):463–70

Two novel antioxidants, U74006F and U78517F, inhibit oxidant-stimulated calcium influx. Munns PL, et al.
Free Radic Biol Med 1995 Mar;18(3):467–78

Effects of a novel low-molecular weight antioxidant on cardiac injury induced by hydrogen peroxide. Nagy A, et al. **Free Radic Biol Med** 1996;20(4):567–72

Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Nickander KK, et al.
Free Radic Biol Med 1996;21(5):631–9

Measuring the oxidation of heme compounds in heart homogenates from rats supplemented with dietary antioxidants. North JA, et al. **Free Radic Biol Med** 1997; 22(1–2):175–84

Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Packer L, et al. **Free Radic Biol Med** 1997; 22(1–2):359–78 (215 ref.)

The anti-oxidant properties of 5-aminosalicylic acid. Pearson DC, et al. **Free Radic Biol Med** 1996;21(3):367–73

Antioxidant effects of a supplemented very low protein diet in chronic renal failure. Peuchant E, et al.
Free Radic Biol Med 1997;22(1–2):313–20

Antioxidant functions of inositol 1,2,3-trisphosphate and inositol 1,2,3,6-tetrakisphosphate. Phillippy BQ, et al.
Free Radic Biol Med 1997;22(6):939–46

Comparative study of the effect of 21-aminosteroid and alpha-tocopherol on models of acute oxidative renal injury. Salahudeen AK, et al. **Free Radic Biol Med** 1996; 21(5):691–7

Stable nitroxide radicals protect lipid acyl chains from radiation damage. Samuni AM, et al.
Free Radic Biol Med 1997;22(7):1165–74

Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Vaya J, et al. **Free Radic Biol Med** 1997; 23(2):302–13

Effects of metals, ligands and antioxidants on the reaction of oxygen with 1,2,4-benzenetriol. Zhang L, et al.
Free Radic Biol Med 1996;20(4):495–505

Inhibitory effect of ethanolamine plasmalogen on iron- and copper-dependent lipid peroxidation. Zommara M, et al.
Free Radic Biol Med 1995 Mar;18(3):599–602

The copper complex of captopril is not a superoxide dismutase mimic. Artefacts in DMPO spin trapping. Bartosz M, et al. **Free Radic Res** 1996 May;24(5):391–6

Vitamin C: antioxidant or pro-oxidant in vivo? Halliwell B.
Free Radic Res 1996 Nov;25(5):439–54 (182 ref.)

The superoxide dismutase-mimic copper-putrescine-pyridine suppresses lipid peroxidation in CHO cells. Implications for its prooxidative and antioxidative mechanisms of action. Nagele A, et al. **Free Radic Res** 1996 Aug;25(2):109–15

Are whole extracts and purified glucosinolates from cruciferous vegetables antioxidants? Plumb GW, et al.
Free Radic Res 1996 Jul;25(1):75–86

Protection against peroxynitrite-dependent tyrosine nitration and alpha 1-antiproteinase inactivation by ascorbic acid. A comparison with other biological antioxidants. Whiteman M, et al. **Free Radic Res** 1996 Sep;25(3):275–83

4-methylthiobenzoic acid protection against cisplatin nephrotoxicity: antioxidant system. Husain K, et al.
Fundam Appl Toxicol 1996 Aug;32(2):278–84

Effect of antioxidants, anti-inflammatory drugs, and histamine antagonists on sparfloxacin-induced phototoxicity in mice. Shimoda K, et al.
Fundam Appl Toxicol 1996 May;31(1):133–40

Oxidative degradation of cholesteryl esters in low-density lipoproteins: analysis by liquid chromatography-light scattering and protection by a new synthetic antioxidant, S20478. Arborati M, et al. **Fundam Clin Pharmacol** 1997; 11(1):68–77

Antioxidant action of Vaccinium myrtillus extract on human low density lipoproteins in vitro: initial observations. Laplaud PM, et al. **Fundam Clin Pharmacol** 1997; 11(1):35–40

Inhibition of ferrous-induced lipid peroxidation by dipyridamole, RA-642 and mopidamol in human lung tissue. De la Cruz JP, et al. **Gen Pharmacol** 1996 Jul; 27(5):855–9

Effect of multiple administration of calcium antagonists on lipid peroxidation in rat liver microsomes. Koleva M, et al. **Gen Pharmacol** 1996 Jul;27(5):891–3

Protection from acetaminophen-induced liver damage by the synergistic action of low doses of the poly(ADP-ribose) polymerase-inhibitor nicotinamide and the antioxidant N-acetylcysteine or the amino acid L-methionine. Kröger H, et al. **Gen Pharmacol** 1997 Feb;28(2):257–63

Hypochlorous acid and its pharmacological antagonism: an update picture. Lapenna D, et al. **Gen Pharmacol** 1996 Oct;

27(7):1145–7 (30 ref.)

Peroxidative damage in sickle-cell erythrocyte ghosts: protective effect of allopurinol. Sertac A, et al. **Gen Pharmacol** 1997 Mar;28(3):427–8

Effects of different antioxidants on lens-induced uveitis. Koch FH, et al. **Ger J Ophthalmol** 1996 Jul;5(4):185–8

Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Millar AD, et al. **Gut** 1996 Sep;39(3):407–15

Variable efficacy of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo. Song BB, et al. **Hear Res** 1996 May;94(1–2):87–93

Antioxidant effects of calcium antagonists on rat myocardial membrane lipid peroxidation. Sugawara H, et al. **Hypertens Res** 1996 Dec;19(4):223–8

7,8-Dihydroneopterin upregulates interferon-gamma promoter in T cells. Baier-Bitterlich G, et al. **Immunobiology** 1996;196(4):350–5

Beta-carotene enhances natural killer cell activity in athymic mice. Carlos TF, et al. **In Vivo** 1997 Jan–Feb;11(1):87–91

Oxidised low density lipoprotein, antioxidants and coronary atherosclerosis [editorial] Gambhir DS, et al. **Indian Heart J** 1997 Jan–Feb;49(1):19–22 (23 ref.)

Bacopa monniera Linn. as an antioxidant: mechanism of action. Tripathi YB, et al. **Indian J Exp Biol** 1996 Jun; 34(6):523–6

Interaction between beta-carotene and lipoxygenase in human skin. Bar-Natan R, et al. **Int J Biochem Cell Biol** 1996 Aug;28(8):935–41

Antioxidant effect of a Ginkgo biloba extract (EGb 761) on the retina. Droy-Lefaix MT, et al. **Int J Tissue React** 1995; 17(3):93–100

Inhibitory effects of a phosphate diester of alpha-tocopherol and ascorbic acid (EPC-K1) on myocardial infarction in rats. Kuribayashi Y, et al. **Int J Tissue React** 1996; 18(2–3):73–9

Effect of lipid peroxidation inhibition on retinal ganglion cell death. Levin LA, et al. **Invest Ophthalmol Vis Sci** 1996 Dec;37(13):2744–9

Antioxidant-sensitive regulation of inflammatory-response genes in Kaposi's sarcoma cells. Offermann MK, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep; 13(1):1–11

Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. Chen L, et al. **J Am Coll Cardiol** 1997 Aug; 30(2):569–75

Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant. Magil A. **J Am Soc Nephrol** 1996 Nov;7(11):2340–7

Role of oxidative stress and antioxidants in male infertility. Sikka SC, et al. **J Androl** 1995 Nov–Dec;16(6):464–81 (16 ref.)

N-tert-butyl-alpha-phenylnitrone: a free radical trap with unanticipated effects on diaphragm function. Andersen KA, et al. **J Appl Physiol** 1996 Mar;80(3):862–8

How can we protect our endothelium? [editorial] Hakim A, et al. **J Assoc Physicians India** 1995 Feb;43(2):85–7 (27 ref.)

Possible mechanisms for the protective action of alpha-tocopherol in vascular hypoxia. Kelly MJ, et al. **J Auton Pharmacol** 1996 Apr;16(2):87–95

Cadmium induced lipid peroxidation in kidney function. Sentürk UK, et al. **J Basic Clin Physiol Pharmacol** 1994 Jul–Dec;5(3–4):305–13

Photochemiluminescent detection of antiradical activity; IV: testing of lipid-soluble antioxidants. Popov IN, et al. **J Biochem Biophys Methods** 1996 Jan 11;31(1–2):1–8

Effect of unsaturated fatty acids and antioxidants on immunoglobulin production by mesenteric lymph node lymphocytes of Sprague-Dawley rats. Yamada K, et al. **J Biochem (Tokyo)** 1996 Jul;120(1):138–44

Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1. Chen Q, et al. **J Biol Chem** 1997 Jun 6;272(23):14532–41

Heme oxygenase-mediated resistance to oxygen toxicity in hamster fibroblasts. Dennery PA, et al. **J Biol Chem** 1997 Jun 6;272(23):14937–42

JNK (c-Jun NH2-terminal kinase) is a target for antioxidants in T lymphocytes. Gómez del Arco P, et al. **J Biol Chem** 1996 Oct 18;271(42):26335–40

Interleukin-1beta induction of mitogen-activated protein kinases in human mesangial cells. Role of oxidation. Wilmer WA, et al. **J Biol Chem** 1997 Apr 18;272(16):10877–81

Vitamin E as an antioxidant for poly(etherurethane urea): in vivo studies. Student Research Award in the Doctoral Degree Candidate Category, Fifth World Biomaterials Congress (22nd Annual Meeting of the Society for Biomaterials), Toronto, Canada, May 29–June 2, 1996. Schubert MA, et al. **J Biomed Mater Res** 1996 Dec; 32(4):493–504

Effect of antioxidants on lipopolysaccharide-stimulated induction of mangano superoxide dismutase mRNA in bovine pulmonary artery endothelial cells. Mitchell J, et al. **J Cell Physiol** 1996 Nov;169(2):333–40

Butylated hydroxyanisole blocks the inhibitory effects of tumor necrosis factor-alpha on collagen production in human dermal fibroblasts. Taniguchi S, et al. **J Dermatol Sci** 1996 Apr;12(1):44–9

The antioxidant activity of Chinese herbs for eczema and of placebo herbs—I. Kirby AJ, et al. **J Ethnopharmacol** 1997 Apr;56(2):103–8

Biological studies of Bolax gummifera, a plant of the Falkland Islands used as a treatment of wounds. Mongelli E, et al. **J Ethnopharmacol** 1997 Apr;56(2):117–21

Improvement of pulmonary graft after storage for twenty-four hours by in vivo administration of lazaroid U74389G: functional and morphologic analysis. Sasaki S, et al. **J Heart Lung Transplant** 1996 Jan;15(1 Pt 1):35–42

Successful twenty-four-hour canine lung preservation with lazaroid U74500A. Tanoue Y, et al. **J Heart Lung Transplant** 1996 Jan;15(1 Pt 1):43–50

Transcriptional up-regulation of intracellular adhesion molecule-1 in human endothelial cells by the antioxidant pyrrolidine dithiocarbamate involves the activation of activating protein-1. Muñoz C, et al. **J Immunol** 1996 Oct 15;157(8):3587–97

Antioxidant effect of alpha-tocopherol on fracture haematoma in rabbits. Durak K, et al. **J Int Med Res** 1996 Sep–Oct;24(5):419–24

Unoccluded retinol penetrates human skin in vivo more effectively than unoccluded retinyl palmitate or retinoic acid. Duell EA, et al. **J Invest Dermatol** 1997 Sep; 109(3):301–5

Influence of anti-inflammatory and antioxidant agents on endothelial permeability alterations induced by bradykinin. Deng X, et al. **J Invest Surg** 1996 Sep–Oct;9(5):337–49

Effects of hydroxyethyl starch-deferoxamine on arachidonic acid metabolism and small bowel wall perfusion in early sepsis. Schröppel B, et al. **J Invest Surg** 1997 Jul–Aug; 10(4):173–82

Mechanisms involved in sodium arsenite-induced apoptosis of human neutrophils. Watson RW, et al. **J Leukoc Biol** 1996 Nov;60(5):625–32

Antioxidant and prooxidant activity of alpha-tocopherol in human plasma and low density lipoprotein. Kontush A, et al. **J Lipid Res** 1996 Jul;37(7):1436–48

A rapid and simple screening test for potential inhibitors of tocopherol-mediated peroxidation of LDL lipids. Witting PK, et al. **J Lipid Res** 1996 Apr;37(4):853–67

Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). Pietri S, et al. **J Mol Cell Cardiol** 1997 Feb;29(2):733–42

Researchers seek the role of antioxidants in apoptosis [news] Holzman D. **J Natl Cancer Inst** 1997 Mar 19;89(6):413–4

Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. Michnovicz JJ, et al. **J Natl Cancer Inst** 1997 May 21;89(10):718–23

Tocopherols and the etiology of colon cancer. Stone WL, et al. **J Natl Cancer Inst** 1997 Jul 16;89(14):1006–14 (95 ref.)

Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism. Wesemann W, et al. **J Neural Transm Suppl** 1995;46:175–82

Oxidant injury in PC12 cells--a possible model of calcium "dysregulation" in aging: I. Selectivity of protection against oxidative stress. Joseph JA, et al. **J Neurochem** 1997 Sep; 69(3):1252–8

Inactivation of tryptophan hydroxylase by nitric oxide: enhancement by tetrahydrobiopterin. Kuhn DM, et al. **J Neurochem** 1997 Apr;68(4):1495–502

Actions of neurotoxic beta-amyloid on calcium homeostasis and viability of PC12 cells are blocked by antioxidants but not by calcium channel antagonists. Zhou Y, et al. **J Neurochem** 1996 Oct;67(4):1419–25

The effect of the 21-aminosteroid U74006F on the clinical course of acute experimental allergic encephalomyelitis. Uitdehaag BM, et al. **J Neurol Sci** 1996 Jan;135(1):18–20

Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. Pappolla MA, et al. **J Neurosci** 1997 Mar 1;17(5):1683–90

Neuroprotective effects of the novel brain-penetrating pyrrolopyrimidine antioxidants U-101033E and U-104067F against post-ischemic degeneration of nigrostriatal neurons. Andrus PK, et al. **J Neurosci Res** 1997 Mar 15;47(6):650–4

The protective effect of the olive oil polyphenol (3,4-dihydroxyphenyl)-ethanol counteracts reactive oxygen metabolite-induced cytotoxicity in Caco-2 cells. Manna C, et al. **J Nutr** 1997 Feb;127(2):286–92

Beta-carotene and lutein protect HepG2 human liver cells against oxidant-induced damage. Martin KR, et al. **J Nutr** 1996 Sep;126(9):2098–106

Antioxidative mechanism and apoptosis induction by 3-hydroxyanthranilic acid, an antioxidant in Indonesian food Tempeh, in the human hepatoma-derived cell line, HuH-7. Matsuo M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Apr;43(2):249–59

Effects of taurine on depletion of erythrocyte membrane Na-K ATPase activity due to ozone exposure or cholesterol enrichment. Qi B, et al. **J Nutr Sci Vitaminol (Tokyo)** 1995 Dec;41(6):627–34

Increase of ocular blood flow by some phytogenic compounds. Liu SX, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):95–101

Protective effect of 21-aminosteroid pretreatment in peripheral nerve low-load crush injury in mature and immature rats. Nasser RM, et al. **J Orthop Res** 1996 Sep; 14(5):823–9

The effect of allopurinol pretreatment on intestinal hypoperfusion encountered after correction of intestinal volvulus. Akgür FM, et al. **J Pediatr Surg** 1996 Sep; 31(9):1205–7

Antiperoxidative activity of neolignans from Magnolia obovata. Haraguchi H, et al. **J Pharm Pharmacol** 1997 Feb; 49(2):209–12

Inhibition of lipid peroxidation by sesquiterpenoid in Heterotheca inuloides. Haraguchi H, et al. **J Pharm Pharmacol** 1996 Apr;48(4):441–3

Modifications on antioxidant capacity and lipid peroxidation in mice under fraxetin treatment. Martín-Aragón S, et al. **J Pharm Pharmacol** 1997 Jan;49(1):49–52

Protective effect of butylated hydroxyanisole on adriamycin-induced cardiotoxicity. Vora J, et al. **J Pharm Pharmacol** 1996 Sep;48(9):940–4

Pharmacokinetic-toxicodynamic relationships of adriamycin in rat: prediction of butylated hydroxyanisole-mediated reduction in anthracycline cardiotoxicity. Vora J, et al. **J Pharm Pharmacol** 1996 Dec;48(12):1264–9

Pyrrolopyrimidines: novel brain-penetrating antioxidants with neuroprotective activity in brain injury and ischemia models. Hall ED, et al. **J Pharmacol Exp Ther** 1997 May; 281(2):895–904

Effects of preconditioning with ebselen on glutathione metabolism and stress protein expression. Hoshida S, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1471–5

Effects of silibinin and antioxidants on high glucose-induced alterations of fibronectin turnover in human mesangial cell cultures. Wenzel S, et al. **J Pharmacol Exp Ther** 1996 Dec; 279(3):1520–6

Thiols and selenium: protective effect on human skin fibroblasts exposed to UVA radiation. Emonet N, et al. **J Photochem Photobiol B** 1997 Aug;40(1):84–90

N-conjugates of 2,5-disubstituted pyrrole and glutathione. Evaluation of their potency as antioxidants against photosensitization of NCTC 2544 keratinocytes by excess endogenous protoporphyrin IX. Gaullier JM, et al. **J Photochem Photobiol B** 1997 May;39(1):24–9

Inhibiting effects of antioxidants on drug-induced phototoxicity in cell cultures. Investigations with sulphonamide-derived oral antidiabetics and diuretics. Selvaag E, et al. **J Photochem Photobiol B** 1997 Mar; 38(1):88–93

Characterization of the antioxidant effects of melatonin and related indoleamines in vitro. Chan TY, et al. **J Pineal Res** 1996 May;20(4):187–91

Melatonin inhibits vasospastic action of hydrogen peroxide in human umbilical artery. Okatani Y, et al. **J Pineal Res** 1997 Apr;22(3):163–8

Antioxidants inhibit tumor necrosis factor-alpha mediated stimulation of interleukin-8, monocyte chemoattractant protein-1, and collagenase expression in cultured human synovial cells. Sato M, et al. **J Rheumatol** 1996 Mar; 23(3):432–8

beta-Carotene attenuates peroxide-induced vasoconstriction in the human placenta. Cueto SM, et al. **J Soc Gynecol Investig** 1997 Mar–Apr;4(2):64–71

21-Aminosteroids block neutrophil infiltration and provide liver protection independent of NO2-/NO3- levels. Palma-Vargas JM, et al. **J Surg Res** 1996 Dec;66(2):131–7

Effect of selenium supplementation on biological constants and antioxidant status in rats. Coudray C, et al. **J Trace Elem Med Biol** 1996 Apr;10(1):12–9

Metallothionein and zinc as potential antioxidants in radical-induced lipid peroxidation in cultured hepatocytes. Markant A, et al. **J Trace Elem Med Biol** 1996 Jun; 10(2):88–95

Antioxidant-induced changes of the AP-1 transcription complex are paralleled by a selective suppression of human papillomavirus transcription. Rösl F, et al. **J Virol** 1997 Jan;71(1):362–70

Effect of 5,6,7,8-tetrahydroneopterin on oxidative modification of low-density lipoprotein, and its uptake in the macrophage-like cell line J774. Iizuka H, et al. **Jpn J Pharmacol** 1996 Dec;72(4):375–9

Reactive oxygen species-mediated tissue injury' in experimental ascending pyelonephritis. Gupta A, et al. **Kidney Int** 1996 Jan;49(1):26–33

Effects of antioxidant vitamins on renal and hepatic erythropoietin production. Jelkmann W, et al. **Kidney Int** 1997 Feb;51(2):497–501

Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Lee HS, et al. **Kidney Int** 1997 Apr;51(4):1151–9

Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-kappaB. Sokoloski JA, et al. **Leukemia** 1997 Sep;11(9):1546–53

The in vitro antioxidant activity of trilinolein and other lipid-related natural substances as measured by enhanced chemiluminescence. Chan P, et al. **Life Sci** 1996; 59(24):2067–73

The antioxidative activity of the mucoregulatory agents: ambroxol, bromhexine and N-acetyl-L-cysteine. A pulse radiolysis study. Felix K, et al. **Life Sci** 1996;59(14):1141–7

Melatonin is a scavenger of peroxynitrite. Gilad E, et al. **Life Sci** 1997;60(10):PL169–74

Anti-inflammatory action of Pluchea sagittalis: involvement of an antioxidant mechanism. Pérez-García F, et al. **Life Sci** 1996;59(24):2033–40

Pharmacological actions of melatonin in oxygen radical pathophysiology. Reiter R, et al. **Life Sci** 1997; 60(25):2255–71 (103 ref.)

Inhibitory effects of jasmine green tea epicatechin isomers on free radical-induced lysis of red blood cells. Zhang A, et al. **Life Sci** 1997;61(4):383–94

ANTIOXIDANTS

Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro. Gillissen A, et al. **Lung** 1997;175(4):235–42

Antioxidant dietary status and genetic cardiovascular risk, or how an adequate intake of a-tocopherol, selenium, taurine, magnesium and various other natural antioxidants may overcome the deleterious metabolic consequences related to the E4–4 type of apolipoprotein E [editorial] Durlach J, et al. **Magnes Res** 1996 Jun;9(2):139–41 (24 ref.)

Macrophage prostaglandin production contributes to the age–associated decrease in T cell function which is reversed by the dietary antioxidant vitamin E. Beharka AA, et al. **Mech Ageing Dev** 1997 Feb;93(1–3):59–77

The prolongation of survival in mice by dietary antioxidants depends on their age by the start of feeding this diet. Bezlepkin VG, et al. **Mech Ageing Dev** 1996 Dec 20; 92(2–3):227–34

Effects of cellular aging on the induction of c–fos by antioxidant treatments. Keogh BP, et al. **Mech Ageing Dev** 1996 Mar 29;86(3):151–60

Promotion of interleukin–2 activity as a strategy for 'rejuvenating' geriatric immune function. McCarty MF. **Med Hypotheses** 1997 Jan;48(1):47–54 (120 ref.)

Chemoprotection: a review of the potential therapeutic antioxidant properties of green tea (Camellia sinensis) and certain of its constituents. Mitscher LA, et al. **Med Res Rev** 1997 Jul;17(4):327–65 (160 ref.)

Autoradiographic localization of [3H]–pinoline binding sites in mouse tissues. Pähkla R, et al. **Methods Find Exp Clin Pharmacol** 1996 Jul–Aug; 18(6):359–66

Comparative antioxidant effects of beta–adrenoceptor blockers, calcium antagonists and U–74500A against iron–dependent lipid peroxidation in murine ventricular microsomal membranes. Reddy DS, et al. **Methods Find Exp Clin Pharmacol** 1996 Nov;18(9):559–67

Antioxidants attenuate postischemic endothelial cell swelling and luminal membrane blebbing in cardiac capillaries. Ward BJ, et al. **Microvasc Res** 1997 Mar;53(2):179–86

Tocotrienols from palm oil as effective inhibitors of protein oxidation and lipid peroxidation in rat liver microsomes. Kamat JP, et al. **Mol Cell Biochem** 1997 May; 170(1–2):131–7

Effects of Schisandrin B and alpha–tocopherol on lipid peroxidation, in vitro and in vivo. Mak DH, et al. **Mol Cell Biochem** 1996 Dec 20;165(2):161–5

Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Nirmala C, et al. **Mol Cell Biochem** 1996 Jun 21;159(2):85–93

Vitamin A inhibits lipoperoxidation ascorbate–Fe++ dependent of rat kidney microsomes and mitochondria. Piergiacomi VA, et al. **Mol Cell Biochem** 1996 Dec 20; 165(2):121–5

Regulation of p53 by metal ions and by antioxidants: dithiocarbamate down–regulates p53 DNA–binding activity by increasing the intracellular level of copper. Verhaegh GW, et al. **Mol Cell Biol** 1997 Oct; 17(10):5699–706

Neurodegenerative mechanisms in Alzheimer disease. A role for oxidative damage in amyloid beta protein precursor–mediated cell death. Sopher BL, et al. **Mol Chem Neuropathol** 1996 Oct–Dec;29(2–3):153–68

Synaptosomal iron–dependent lipid peroxidation inhibition after subarachnoid hemorrhage by lazaroid in vivo treatment. Torri C, et al. **Mol Chem Neuropathol** 1997 Jan–Feb;30(1–2):15–24

Inhibition of astrocyte glutamate uptake by reactive oxygen species: role of antioxidant enzymes. Sorg O, et al. **Mol Med** 1997 Jul;3(7):431–40

Neuroprotection against oxidative stress by estrogens: structure–activity relationship. Behl C, et al. **Mol Pharmacol** 1997 Apr;51(4):535–41

Improvement in bovine embryo production in vitro by glutathione–containing culture media. Luvoni GC, et al. **Mol Reprod Dev** 1996 Apr;43(4):437–43

A controlled trial of idebenone in Huntington's disease. Ranen NG, et al. **Mov Disord** 1996 Sep;11(5):549–54

Oxidative stress–related clastogenic factors in plasma from Chernobyl liquidators: protective effects of antioxidant plant phenols, vitamins and oligoelements. Emerit I, et al. **Mutat Res** 1997 Jul 3;377(2):239–46

Effects of antioxidants on streptonigrin–induced DNA damage and clastogenesis in CHO cells. Testoni MI, et al. **Mutat Res** 1997 Feb 3;373(2):201–6

Antioxidants and atherosclerotic heart disease. Diaz MN, et al. **N Engl J Med** 1997 Aug 7;337(6):408–16 (76 ref.)

Reversal of peripheral nerve conduction and perfusion deficits by the free radical scavenger, BM15.0639, in diabetic rats. Cameron NE, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Dec; 352(6):685–90

Effects of alpha–tocopherol on nerve conduction velocity and regeneration following a freeze lesion in immature diabetic rats. Love A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jan; 355(1):126–30

Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Dugan LL, et al. **Neurobiol Dis** 1996 Apr; 3(2):129–35

The antioxidant properties of zinc and metallothionein. Ebadi M, et al. **Neurochem Int** 1996 Aug;29(2):159–66

Sensitivity of ATPase–ADPase activities from synaptic plasma membranes of rat forebrain to lipid peroxidation in vitro and the protective effect of vitamin E. Vietta M, et al. **Neurochem Res** 1996 Mar;21(3):299–304

Effectiveness of retrograde perfusion of the cerebral vein for attenuating neuronal injury after transient ischemia following reperfusion in the rat brain. Inoue N, et al. **Neurol Med Chir (Tokyo)** 1997 Mar;37(3):243–9

Post–ischemic treatment with a lazaroid (U74389G) prevents transient global ischemic damage in rat hippocampus. Tseng MT, et al. **Neurol Res** 1997 Aug;19(4):431–4

Complexity of the regulation of Kir2.1 K+ channels. Ruppersberg JP, et al. **Neuropharmacology** 1996; 35(7):887–93

Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Chanvitayapongs S, et al. **Neuroreport** 1997 Apr 14;8(6):1499–502

Antioxidant drugs block in vitro the neurotoxicity of CSF from patients with amyotrophic lateral sclerosis. Terro F, et al. **Neuroreport** 1996 Aug 12;7(12):1970–2

Protective effect of the antioxidant N–acetyl–L–cysteine in pneumococcal meningitis in the rat. Koedel U, et al. **Neurosci Lett** 1997 Mar 28;225(1):33–6

Structural and functional analogs of CuZn superoxide dismutase inhibit rat brain nitric oxide synthase by interference with the reductase (diaphorase) domain. Mayer B, et al. **Neurosci Lett** 1996 May 17;209(3):169–72

Acute effects of tetrahydrobiopterin on the dynamic characteristics and adaptability of of vestibulo–ocular reflex in normal and flocculus lesioned rabbits. Nagao S, et al. **Neurosci Lett** 1997 Aug 1;231(1):41–4

Antioxidant treatment with phenyl–alpha–tert–butyl nitrone (PBN) improves the cognitive performance and survival of aging rats. Sack CA, et al. **Neurosci Lett** 1996 Mar 1; 205(3):181–4

Brain–derived neurotrophic factor, acidic and basic fibroblast growth factors, insulin–like growth factor–I, and various antioxidants do not prevent the apoptotic death of developing septal cholinergic neurons following nerve growth factor withdrawal in vitro. Kew JN, et al. **Neuroscience** 1997 Feb;76(3):809–20

Antioxidant treatment protects striatal neurons against excitotoxic insults. Nakao N, et al. **Neuroscience** 1996 Jul; 73(1):185–200

Brain attack. Acute therapeutic interventions. Free radical scavengers and antioxidants. Hall ED. **Neurosurg Clin N Am** 1997 Apr;8(2):195–206 (78 ref.)

Radioprotective effects of the 21–aminosteroid U–74389G for stereotactic radiosurgery. Kondziolka D, et al. **Neurosurgery** 1997 Jul;41(1):203–8

Methylmercury–induced neurotoxicity in cerebral neuron culture is blocked by antioxidants and NMDA receptor antagonists. Park ST, et al. **Neurotoxicology** 1996 Spring; 17(1):37–45

In vivo antiperoxidative effect of 9–cis beta–carotene compared with that of the all–trans isomer. Levin G, et al. **Nutr Cancer** 1997;27(3):293–7

Effect of individual and multiple antioxidant vitamins on growth and morphology of human nontumorigenic and tumorigenic parotid acinar cells in culture. Prasad KN, et al. **Nutr Cancer** 1996;26(1):11–9

Effect of antioxidant vitamin supplementation on DNA damage and repair in human lymphoblastoid cells. Sweetman SF, et al. **Nutr Cancer** 1997;27(2):122–30

Antioxidants and human disease: a general introduction. Halliwell B. **Nutr Rev** 1997 Jan;55(1 Pt 2):S44–9; discussion S49–52

Role of 7,8–dihydroneopterin in T–cell apoptosis and HTLV–1 transcription in vitro. Baier–Bitterlich G, et al. **Oncogene** 1996 Nov 21;13(10):2281–5

Preventive effect of natural and synthetic antioxidants on lipid peroxidation in the mammalian eye. Ueda T, et al. **Ophthalmic Res** 1996;28(3):184–92

Improved insulin secretion of cryopreserved human islets by antioxidant treatment. Janjic D, et al. **Pancreas** 1996 Aug; 13(2):166–72

Effects of the 21–amino steroid tirilazad mesylate (U–74006F) on brain damage and edema after perinatal hypoxia–ischemia in the rat. Bågenholm R, et al. **Pediatr Res** 1996 Sep;40(3):399–403

Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits. Bany–Mohammed FM, et al. **Pediatr Res** 1996 Sep;40(3):381–7

Maternal infusion of antioxidants (Trolox and ascorbic acid) protects the fetal heart in rabbit fetal hypoxia. Tan S, et al. **Pediatr Res** 1996 Mar;39(3):499–503

Bisaramil and antiarrhythmics as inhibitors of free radical generation. Paróczai M, et al. **Pharmacol Res** 1997 Apr; 35(4):279–85

Pharmacology of lazaroids and brain energy metabolism: a review. Villa RF, et al. **Pharmacol Rev** 1997 Mar; 49(1):99–136 (274 ref.)

Nitrofurantoin–induced hepatic and pulmonary biochemical changes in mice fed different vitamin E doses. Adam A, et al. **Pharmacol Toxicol** 1996 Dec;79(6):334–9

Chrysotile inhibits glutathione–dependent protection against the onset of lipid peroxidation in rat lung microsomes. Arif JM, et al. **Pharmacol Toxicol** 1996 Oct;79(4):205–10

Protective effects of antioxidants against uraemia–induced lipid peroxidation and glutathione depletion in humans. Hassan MQ, et al. **Pharmacol Toxicol** 1995 Dec; 77(6):407–11

Tetrandrine inhibits lipid peroxidation but lacks reactivity towards superoxide anion and hydrogen peroxide. Hui SC, et al. **Pharmacol Toxicol** 1996 Mar;78(3):200–1

Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. Luurila H, et al. **Pharmacol Toxicol** 1996 Feb;78(2):117–22

C–methylated dihydrochalcones from Myrica gale L: effects as antioxidants and as scavengers of 1,1–diphenyl–2–picrylhydrazyl. Malterud KE, et al. **Pharmacol Toxicol** 1996 Feb;78(2):111–6

Inhibition of low density lipoprotein oxidation by myrigalone B, a naturally occurring flavonoid. Mathiesen L, et al. **Pharmacol Toxicol** 1996 Mar;78(3):143–6

The pyridoindole antioxidant stobadine prevents alloxan–induced lipid peroxidation by inhibiting its propagation. Stefek M, et al. **Pharmacol Toxicol** 1996 Feb; 78(2):77–81

The prophylactic effects of U75412E pretreatment in a smoke–induced lung injury rabbit model. Wang S, et al. **Pharmacol Toxicol** 1996 Nov;79(5):231–7

Trilinolein preserves mitochondria ultrastructure in isolated rat heart subjected to global ischemia through antioxidant activity as measured by chemiluminescence. Chan P, et al. **Pharmacology** 1996 Apr;52(4):216–25

Effects of aloin and some structure–related anthracene, anthracenone, and anthraquinone derivatives on lipid peroxidation in rat brain cortex homogenates. Scheibler P. **Pharmazie** 1997 May;52(5):411–2

Inhibition of thiazide photohemolysis in vitro by antioxidants and a nitrogen atmosphere. Selvaag E. **Photodermatol Photoimmunol Photomed** 1996 Oct; 12(5):211–5

Photohemolytic potency of oral antidiabetic drugs in vitro: effects of antioxidants and a nitrogen atmosphere. Selvaag E. **Photodermatol Photoimmunol Photomed** 1996 Aug; 12(4):166–70

Antioxidant properties of the decarboxylated dimer of aminoethylcysteine ketimine. Pecci L, et al. **Physiol Chem Phys Med NMR** 1995;27(3):223–9

Scavenging effect of tetrandrine of active oxygen radicals. Cao ZF. **Planta Med** 1996 Oct;62(5):413–4

In vitro formation of crocetin glucosyl esters by Crocus sativus callus extract. Dufresne C, et al. **Planta Med** 1997 Apr;63(2):150–3

Antioxidative action of diterpenoids from Podocarpus nagi. Haraguchi H, et al. **Planta Med** 1997 Jun;63(3):213–5

Aged garlic extract and its constituents inhibit Cu(2+)–induced oxidative modification of low density lipoprotein [letter] Ide N, et al. **Planta Med** 1997 Jun; 63(3):263–4

Cytotoxic and antioxidative sesquiterpenoids from Heterotheca inuloides. Kubo I, et al. **Planta Med** 1996 Oct; 62(5):427–30

Procyanidines from Vitis vinifera seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Maffei Facinó R, et al. **Planta Med** 1996 Dec;62(6):495–502

Antioxidant activity of fruit exudate and C–methylated dihydrochalcones from Myrica gale. Mathiesen L, et al. **Planta Med** 1995 Dec;61(6):515–8

Bioactivity of flavonoids. Robak J, et al. **Pol J Pharmacol** 1996 Nov–Dec;48(6):555–64 (65 ref.)

The effect of ethoxyquin on tissue peroxidation and immune status of single comb White Leghorn cockerels. Bailey CA, et al. **Poult Sci** 1996 Sep;75(9):1109–12

Effect of beta–carotene, canthaxanthin, lutein, and vitamin E on neonatal immunity of chicks when supplemented in the broiler breeder diets. Haq AU, et al. **Poult Sci** 1996 Sep;75(9):1092–7

Effect of Santoquin and oxidized fat on liver and intestinal glutathione in broilers. Wang SY, et al. **Poult Sci** 1997 Jul; 76(7):961–7

Enhanced sensitivity of ubiquinone–deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids. Do TQ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7534–9

Reactive oxygen species are downstream mediators of p53–dependent apoptosis. Johnson TM, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11848–52

Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox–sensitive transcriptional events in human vascular endothelial cells. Khan BV, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9114–9

The yeast peptide–methionine sulfoxide reductase functions as an antioxidant in vivo. Moskovitz J, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9585–9

Nrf1 and Nrf2 positively and c–Fos and Fra1 negatively regulate the human antioxidant response element–mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Venugopal R, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14960–5

Functional antioxidant responsive elements. Wasserman WW, et al. **Proc Natl Acad Sci U S A** 1997 May 13;94(10):5361–6

Axotomy–induced retinal ganglion cell death in development: its time–course and its diminution by antioxidants. Castagné V, et al. **Proc R Soc Lond B Biol Sci** 1996 Sep 22;263(1374):1193–7

Prostanoids and free radicals in Cl4C–induced hepatotoxicity in rats: effect of astilbin. Closa D, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Apr; 56(4):331–4

Natural beta–carotene and whole body irradiation in rats.

Ben-Amotz A, et al. **Radiat Environ Biophys** 1996 Nov; 35(4):285-8

Liquid storage of ram semen in the absence or presence of some antioxidants. Maxwell WM, et al. **Reprod Fertil Dev** 1996;8(6):1013-20

Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract in vitro. Bagchi D, et al. **Res Commun Mol Pathol Pharmacol** 1997 Feb;95(2):179-89

Antioxidant effects of vitamin C in mice following X-irradiation. Harapanhalli RS, et al. **Res Commun Mol Pathol Pharmacol** 1996 Dec;94(3):271-87

Oxidant scavenger function of ambroxol in vitro: a comparison with N-acetylcysteine. Gillissen A, et al. **Res Exp Med (Berl)** 1997;196(6):389-98

Beta-2-agonists have antioxidant function in vitro. 1. Inhibition of superoxide anion, hydrogen peroxide, hypochlorous acid and hydroxyl radical. Gillissen A, et al. **Respiration** 1997;64(1):16-22

Beta-2-agonists have antioxidant function in vitro. 2. The effect of beta-2-agonists on oxidant-mediated cytotoxicity and on superoxide anion generated by human polymorphonuclear leukocytes. Gillissen A, et al. **Respiration** 1997;64(1):23-8

Antioxidant action of estrogens in rat hepatocytes. Ruiz-Larrea MB, et al. **Rev Esp Fisiol** 1997 Jun;53(2):225-9

Biochemical and cytogenetical study of the mycoplasmal antigen and of the cyclophosphamide action in mammalians, in vivo. The action of some immunomodulatory antioxidants. Dumitrescu M, et al. **Roum Arch Microbiol Immunol** 1996 Jul-Sep;55(3):225-39

Protective effects of trolox C, vitamin C, and catalase on bromobenzene-induced damage to rat hepatocytes. Wu J, et al. **Scand J Gastroenterol** 1996 Aug;31(8):797-803

Role of oxidative stress in the pathogenesis of acute pancreatitis. Sweiry JH, et al. **Scand J Gastroenterol Suppl** 1996;219:10-5 (47 ref.)

Inhibition of neutrophil apoptosis by antioxidants in culture medium. Oishi K, et al. **Scand J Immunol** 1997 Jan; 45(1):21-7

Antioxidant effects of hyaluronan and its alpha-methyl-prednisolone derivative in chondrocyte and cartilage cultures. Cortivo R, et al. **Semin Arthritis Rheum** 1996 Aug;26(1):492-501

Treatment of LPS-induced tissue injury: role of liposomal antioxidants. Suntres ZE, et al. **Shock** 1996;6 Suppl 1:S57-64

In vitro antioxidant effects of estrogens with a hindered 3-OH function on the copper-induced oxidation of low density lipoprotein. Miller CP, et al. **Steroids** 1996 May; 61(5):305-8

Novel "scavestrogens" and their radical scavenging effects, iron-chelating, and total antioxidative activities: delta 8,9-dehydro derivatives of 17 alpha-estradiol and 17 beta-estradiol. Römer W, et al. **Steroids** 1997 Mar; 62(3):304-10

Reperfusion injury of postischemic skeletal muscle is attenuated by the 21-aminosteroids U-74389F and U-74500A independent of iron binding. Fantini GA, et al. **Surgery** 1996 Nov;120(5):859-65

Free radical scavenging by lazaroids improves renal blood flow during sepsis. Krysztopik RJ, et al. **Surgery** 1996 Oct; 120(4):657-62

Effect of the 21-aminosteroid tirilazad mesylate on leukocyte adhesion and macromolecular leakage during endotoxemia. Schmidt H, et al. **Surgery** 1997 Mar;121(3):328-34

Potent peroxisome proliferators inhibit beta-oxidation in the isolated perfused rat liver. Bojes HK, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):322-7

R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells. Lai CT, et al. **Toxicol Appl Pharmacol** 1997 Jan; 142(1):186-91

Inhibition of bile-salt-induced hepatocyte apoptosis by the antioxidant lazaroid U83836E. Patel T, et al. **Toxicol Appl Pharmacol** 1997 Jan;142(1):116-22

Protective effects of antioxidants against benomyl-induced lipid peroxidation and glutathione depletion in rats. Banks D, et al. **Toxicology** 1997 Jan 15;116(1-3):177-81

Ebselen, a novel anti-oxidant compound, protects the rat liver from ischemia-reperfusion injury. Ozaki M, et al. **Transpl Int** 1997;10(2):96-102

Lazaroid U74006F for canine small bowel preservation. Hamada N, et al. **Transplant Proc** 1996 Oct;28(5):2607-8

Comparison of various lazaroid compounds for protection against ischemic liver injury. Ishizaki N, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1333-4

Reactive oxygen species mediate the effects of cyclosporine A on human cultured mesangial cells. Pérez de Lema G, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1241-3

Immunomodulation and anticytomegalovirus activity of antioxidant metal chelators. Scholz M, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1272-3

Hepatropic soluble vitamin E derivative EPC-K1 prevents warm ischemia/reperfusion injury of non-heart-beating donor liver transplantation in pigs. Yagi T, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1390-3

Renoprotective effects of the 21-aminosteroid U74389G in ischemia-reperfusion injury and cold storage preservation. Garvin PJ, et al. **Transplantation** 1997 Jan 27;63(2):194-201

Comparison of various lazaroid compounds for protection against ischemic liver injury. Ishizaki N, et al. **Transplantation** 1997 Jan 27;63(2):202-8

Antioxidant lazaroid U-74006F improves renal function and reduces the expression of cytokines, inducible nitric oxide synthase, and MHC antigens in a syngeneic renal transplant model. Partial support for the response-to-injury hypothesis. Salahudeen A, et al. **Transplantation** 1996 Dec 15;62(11):1628-33

Treatment with an antioxidant inhibits vascular changes caused by circulating lymphocytes during acute lung rejection in dogs. Wiklund L, et al. **Transplantation** 1997 Sep 27;64(6):807-11

Selective inhibition of I kappaB alpha phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidant compounds. Lee R, et al. **Virology** 1997 Aug 4; 234(2):277-90

beta-Apo-8'-carotenal, but not beta-carotene, is a strong inducer of liver cytochromes P4501A1 and 1A2 in rat. Gradelet S, et al. **Xenobiotica** 1996 Sep;26(9):909-19

Effects of fraxetin on glutathione redox status. Martín-Aragón S, et al. **Z Naturforsch [C]** 1997 Jan-Feb; 52(1-2):55-9

[Regulatory effect of lingqi anshen liquor on erythrocyte immune function and antioxidation in immunosuppressed mice] Tang B, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Mar; 16(3):167-9 (Eng. Abstr.) **(Chi)**

[Pharmacological modulation of alterations of endothelial cytoskeleton induced by hydrogen peroxyde and by TNF-alpha] d'Alessio P, et al. **C R Seances Soc Biol Fil** 1996;190(2-3):289-97 (Eng. Abstr.) **(Fre)**

[Effect of antioxidants on the relative risk of coronary heart disease] Stern F, et al. **Harefuah** 1996 Nov 15; 131(10):408-12 (41 ref.) **(Heb)**

[Antioxidant action of Foy in an experimental model of hypergeneration of oxygen free radicals] Novelli GP, et al. **Minerva Anestesiol** 1996 Dec;62(12):403-7 (Eng. Abstr.) **(Ita)**

[Inhibitory effect of vitamin E succinate on the proliferation of cultured bovine choroidal endothelial cells] Sakamoto T, et al. **Nippon Ganka Gakkai Zasshi** 1996 Oct; 100(10):777-82 (Eng. Abstr.) **(Jpn)**

[Role of oxidants in adhesion molecule expression and cytokine production] Ishii Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Dec;34 Suppl:126-30 (Eng. Abstr.) **(Jpn)**

[How do antioxidants work?] Bolann BJ, et al. **Tidsskr Nor Laegeforen** 1997 May 20;117(13):1928-32 (37 ref.) (Eng. Abstr.) **(Nor)**

[The effect of some antioxidants on the response of selected lipid compounds in myocardium of rats] Janik A, et al. **Folia Med Cracov** 1996;37(3-4):29-34 (Eng. Abstr.) **(Pol)**

[Immunomodulating, antioxidant and hepatoprotective action of the phytopreparation lochein] Konoplia EN, et al. **Antibiot Khimioter** 1997;42(7):12-5 (Eng. Abstr.) **(Rus)**

[Antioxidant properties of a series of extracts from medicinal plants] Bol'shakova IV, et al. **Biofizika** 1997 Mar-Apr; 42(2):480-3 (Eng. Abstr.) **(Rus)**

[Photosensitizing properties and antioxidant activity of furagin--an antimicrobial drug that is a derivative of nitrofuran] Makareeva EN, et al. **Biofizika** 1997 Mar-Apr; 42(2):472-9 (Eng. Abstr.) **(Rus)**

[Effect of an antioxidant (ubiquinone Q-9) and chronic low-dose irradiation on rat chromatin structure and T-lymphocyte proliferation] Novoselova EG, et al. **Biofizika** 1997 Mar-Apr;42(2):459-65 (Eng. Abstr.) **(Rus)**

[Antioxidant properties of dihydroquercetin] Teselkin IuO, et al. **Biofizika** 1996 May-Jun;41(3):620-4 (Eng. Abstr.) **(Rus)**

[The effect of antiandrogens cyproterone acetate and niftolide on free radical oxidation indices in model biological systems in vitro] Chukaev SA. **Biull Eksp Biol Med** 1996 Nov;122(11):524-6 **(Rus)**

[Astaxanthine-induced inhibition of oxidation of apolipoprotein B-containing lipoproteins in human blood] Kukharchuk VV, et al. **Biull Eksp Biol Med** 1997 Mar; 123(3):285-8 **(Rus)**

[Antihypoxic effect of succinate-containing derivative of oxypyridine on the EEG spectrum in rats with different resistance to oxygen deficiency] Luk'ianova LD, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):57-62 **(Rus)**

[Comparative study of the antioxidant properties of pharmacological agents blocking histamine receptors in an in vitro model system] Sergeev PV, et al. **Biull Eksp Biol Med** 1996 Dec;122(12):638-41 **(Rus)**

[Evaluation of the level of lipid peroxidation during acute poisoning with organophosphorus pesticide in cats and the effect of antioxidants on their survival] Tarakanov IA, et al. **Biull Eksp Biol Med** 1996 Dec;122(12):625-8 **(Rus)**

[Melatonin and epithalamin extinguishes the lipid peroxidation process in rats] Anisimov VN, et al. **Dokl Akad Nauk** 1996 May;348(2):265-7 **(Rus)**

[Disruption of phospholipid metabolism and intensity of free radical oxidation of lipids in rat splenic lymphocyte membranes exposed to the mycotoxin zearalenone and the role of sodium thiosulfate in their leveling and correction] Karagezian MK, et al. **Dokl Akad Nauk** 1997 Jun; 354(6):825-8 **(Rus)**

[Antioxidant protection of syrian hamster cells transformed in vitro by various agents] Kashkina LM, et al. **Dokl Akad Nauk** 1996 Oct;350(4):549-53 **(Rus)**

[Antiradical and antioxidant properties of probucol and its structural analogs during oxidation of unsaturated phospholipids in native and artificial membranes] Lankin VZ, et al. **Dokl Akad Nauk** 1996 Dec;351(4):554-7 **(Rus)**

[A clinico-pharmacological study of olifen in periodontal inflammation] Turgeneva LB, et al. **Eksp Klin Farmakol** 1997 Mar-Apr;60(2):75-7 (Eng. Abstr.) **(Rus)**

[Changes in the surface architectonics of erythrocytes under the influence of the synthetic antioxidant fenozan-1] Gendel' LIa, et al. **Izv Akad Nauk Ser Biol** 1996 Jul-Aug; (4):508-12 (Eng. Abstr.) **(Rus)**

[The effect of antioxidant on the growth and lipid composition of Saccharomyces cerevisiae yeasts at different phases of the development of a culture] Reshetnik OA, et al. **Izv Akad Nauk Ser Biol** 1997 Mar-Apr;(2):172-6 (Eng. Abstr.) **(Rus)**

[Role of membrane protectors and antioxidants in the process of perfusion and preservation of donor lungs] Khodzhimatov GM, et al. **Khirurgiia (Mosk)** 1997;(2):68-74 (Eng. Abstr.) **(Rus)**

[Pharmacological correction of lipid peroxidation during hypoxia and possibility to enhance human resistance to high altitude by using preparations of the metabolic type of action] Nagornev SN, et al. **Vestn Ross Akad Med Nauk** 1996;(7):53-60 (Eng. Abstr.) **(Rus)**

[Bio-antioxidant activity of 3,5-di-tert-butylpyrocatechol and its influence on hypoxia, inflammation, pain and burns] Shadyro OI, et al. **Vopr Med Khim** 1997 May-Jun; 43(3):153-7 (Eng. Abstr.) **(Rus)**

[Inhibiting effects of mixtures of alpha-tocopherol with beta-carotene or vitamin A during oxidation of polyunsaturated fatty acid esters] Storozhok NM, et al. **Vopr Med Khim** 1996 Jan-Mar;42(1):16-22 (Eng. Abstr.) **(Rus)**

[Natural flavonoids as dietary antioxidants and biologically active additives] Tiukavkina NA, et al. **Vopr Pitan** 1996; (2):33-8 (55 ref.) (Eng. Abstr.) **(Rus)**

[Tirilazad mesylate (Freedox)--an effective inhibitor of lipid membrane peroxidation] Sániová B. **Bratisl Lek Listy** 1997 Jun;98(6):339-42 (20 ref.) (Eng. Abstr.) **(Slo)**

[Oxygen free radicals and HIV infection. Can antioxidants be useful? (editorial)] Kilstein J, et al. **Medicina (B Aires)** 1996;56(1):105-7 **(Spa)**

RADIATION EFFECTS

Does small-dose gamma-ray radiation induce endogenous antioxidant potential in vivo? Kojima S, et al. **Biol Pharm Bull** 1997 Jun;20(6):601-4

THERAPEUTIC USE

Which changes in diet prevent coronary heart disease? A review of clinical trials of dietary fats and antioxidants. Oliver MF. **Acta Cardiol** 1996;51(6):467-90 (61 ref.)

Effectiveness of antioxidants (vitamin C and E) with and without sunscreens as topical photoprotectants. Darr D, et al. **Acta Derm Venereol** 1996 Jul;76(4):264-8

Reduced ischemia-reperfusion injury in muscle. Experiments in rats with EPC-K1, a new radical scavenger. Hirose J, et al. **Acta Orthop Scand** 1997 Aug;68(4):369-73

Antioxidant therapy for the prevention of type I diabetes. Heller B, et al. **Adv Pharmacol** 1997;38:629-38 (48 ref.)

Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Lieber CS. **Adv Pharmacol** 1997;38:601-28 (188 ref.)

Pharmacologic approaches to reperfusion injury. Willerson JT. **Adv Pharmacol** 1997;39:291-312 (120 ref.)

Is a randomized trial of antioxidants in the primary prevention of Alzheimer disease warranted? Evans DA, et al. **Alzheimer Dis Assoc Disord** 1996 Fall;10 Suppl 1:45-9

Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Kalmijn S, et al. **Am J Epidemiol** 1997 Jan 1;145(1):33-41

Study suggests antioxidants slow decline in Alzheimer's disease [news] **Am J Health Syst Pharm** 1997 Jul 1; 54(13):1478, 1481

Anti-oxidant treatment for shock: vitamin E but not vitamin C improves survival. Daughters K, et al. **Am Surg** 1996 Oct;62(10):789-92

Donor treatment with the lazeroid U74389G reduces ischemia-reperfusion injury in a rat lung transplant model. Hausen B, et al. **Ann Thorac Surg** 1997 Sep;64(3):814-20

Free radical-mediated tissue injury in acute lung allograft rejection and the effect of superoxide dismutase. Shiraishi T, et al. **Ann Thorac Surg** 1997 Sep;64(3):821-5

Effects of the new antioxidant nicanartine in an experimental model of atherosclerosis. Heinle H, et al. **Arzneimittelforschung** 1996 Oct;46(10):956-9

The lack of effect of beta-carotene on restenosis in cholesterol-fed rabbits. Burchenal JE, et al. **Atherosclerosis** 1996 Jun;123(1-2):157-67

Inhibitory effect of selenite and other antioxidants on complement-mediated tissue injury in patients with epidemic hemorrhagic fever. Hou JC. **Biol Trace Elem Res** 1997 Jan;56(1):125-30

Vitamin E and cardiovascular protection in diabetes [editorial] Gazis A, et al. **BMJ** 1997 Jun 28; 314(7098):1845-6

Modulation of paraquat toxicity by beta-carotene at low oxygen partial pressure in chicken embryo fibroblasts.

Lawlor SM, et al. **Br J Nutr** 1997 Jan;77(1):133–40

Antioxidants in the treatment of severe pre-eclampsia: an explanatory randomised controlled trial. Gülmezoğlu AM, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):689–96

Protective effect of ubiquinone (coenzyme Q9) on ascites in broiler chickens. Nakamura K, et al. **Br Poult Sci** 1996 Mar;37(1):189–95

Induction of sulfated glycoprotein-2 (clusterin) and glial fibrillary acidic protein (GFAP) RNA expression following transient global ischemia is differentially attenuated by LY231617. May PC, et al. **Brain Res Mol Brain Res** 1996 Nov;42(1):145–8

Lack of effect of daily N-acetylcysteine supplementation on mutagen sensitivity. Cloos J, et al.
Cancer Epidemiol Biomarkers Prev 1996 Nov;5(11):941–4

beta-Carotene treatment of cervical intraepithelial neoplasia: a phase II study. Manetta A, et al.
Cancer Epidemiol Biomarkers Prev 1996 Nov;5(11):929–32

Antioxidant vitamins and stomach cancer: the role of ecologic studies. Kromhout D, et al. **Cancer Lett** 1997 Mar 19;114(1-2):333–4

Protection against induction of mouse skin papillomas with low and high risk of conversion to malignancy by green tea polyphenols. Katiyar SK, et al. **Carcinogenesis** 1997 Mar;18(3):497–502

Diet and heart disease. The role of fat, alcohol, and antioxidants. Gaziano JM, et al. **Cardiol Clin** 1996 Feb; 14(1):69–83 (130 ref.)

Randomized, controlled trial of antioxidant vitamins and cardioprotective diet on hyperlipidemia, oxidative stress, and development of experimental atherosclerosis: the diet and antioxidant trial on atherosclerosis (DATA). Singh RB, et al. **Cardiovasc Drugs Ther** 1995 Dec;9(6):763–71

Oxidant-protease interaction in the lung. Prospects for antioxidant therapy. Buhl R, et al. **Chest** 1996 Dec;110(6 Suppl):267S–272S (57 ref.)

Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Heitzer T, et al. **Circulation** 1996 Jul 1; 94(1):6–9

Modulation of oxidant stress in vivo in chronic cigarette smokers. Reilly M, et al. **Circulation** 1996 Jul 1;94(1):19–25

Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Solzbach U, et al. **Circulation** 1997 Sep 2;96(5):1513–9

Antioxidants to treat coronary artery disease [editorial] Conti CR. **Clin Cardiol** 1997 Mar;20(3):185

One-year antioxidant supplementation with beta-carotene or selenium for patients infected with human immunodeficiency virus: a pilot study. Constans J, et al. **Clin Infect Dis** 1996 Sep;23(3):654–6

Abnormalities of antioxidant metabolism in a case of Friedreich's disease. Helveston W, et al.
Clin Neuropharmacol 1996 Jun;19(3):271–5

Reduction of bleomycin-induced acute DNA injury in the rat lung by the 21-aminosteroid, U-74389G. Dallessio JJ, et al. **Crit Care Med** 1997 Apr;25(4):652–6

The role of antioxidants in preventive cardiology. Rimm EB, et al. **Curr Opin Cardiol** 1997 Mar;12(2):188–94 (31 ref.)

Therapy and clinical trials [editorial] Dutta-Roy AK.
Curr Opin Lipidol 1996 Feb;7(1):U34–7

Antioxidants in the prevention of atherosclerosis. Olsson AG, et al. **Curr Opin Lipidol** 1996 Dec;7(6):374–80 (45 ref.)

Effect of N-acetylcysteine, an inhibitor of tumor necrosis factor, on irritant contact dermatitis in the human. Pasche-Koo F, et al. **Curr Probl Dermatol** 1995;23:198–206

Possible effects of tetrahydrobiopterin treatment in six children with autism--clinical and positron emission tomography data: a pilot study. Fernell E, et al.
Dev Med Child Neurol 1997 May;39(5):313–8

Pregnant diabetic rats fed the antioxidant butylated hydroxytoluene show decreased occurrence of malformations in offspring. Eriksson UJ, et al. **Diabetes** 1996 Nov;45(11):1497–502

The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Low PA, et al.
Diabetes 1997 Sep;46 Suppl 2:S38–42

Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Ziegler D, et al.
Diabetes 1997 Sep;46 Suppl 2:S62–6 (38 ref.)

Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Hammes HP, et al.
Diabetologia 1997 Jun;40(6):629–34

Antioxidant vitamins and cardiovascular disease: current perspectives and future directions [editorial] Hennekens CH. **Eur Heart J** 1997 Feb;18(2):177–9

Melatonin affords protection against gastric lesions induced by ischemia-reperfusion possibly due to its antioxidant and mucosal microcirculatory effects. Konturek PC, et al.
Eur J Pharmacol 1997 Mar 12;322(1):73–7

Nerve function and regeneration in diabetic and galactosaemic rats: antioxidant and metal chelator effects. Love A, et al. **Eur J Pharmacol** 1996 Oct 24;314(1-2):33–9

Effect of a novel histamine H2 receptor antagonist, IT-066, on acute gastric injury induced by ischemia-reperfusion in rats, and its antioxidative properties. Naito Y, et al.
Eur J Pharmacol 1995 Dec 27;294(1):47–54

Effect of the 21-aminosteroid U-74006F on antigen-induced bronchoconstriction and bronchoalveolar eosinophilia in allergic sheep. Fujimoto K, et al. **Eur Respir J** 1996 Oct; 9(10):2044–9

Lazaroid U-74389F attenuates phorbol ester-induced lung injury in rabbits. Miniati M, et al. **Eur Respir J** 1996 Apr; 9(4):758–64

Unilateral renal ischemia reperfusion in the rat: effect of blood volume trapped in the kidney, sucrose infusion, and antioxidant treatments. Zurovsky Y, et al.
Exp Toxicol Pathol 1995 Dec;47(6):471–8

The Leon Golberg Memorial Lecture. Antioxidants and disease prevention. Diplock AT. **Food Chem Toxicol** 1996 Oct;34(10):1013–20 (33 ref.)

The effects of intravenous antioxidants in patients with septic shock. Galley HF, et al. **Free Radic Biol Med** 1997; 23(5):768–74

Effect of MCI-186 on postischemic reperfusion injury in isolated rat heart. Minhaz U, et al. **Free Radic Res** 1996 May;24(5):361–7

Initiation and post-initiation chemopreventive effects of beta-carotene in toad liver carcinogenesis. Sadek IA, et al. **Histol Histopathol** 1996 Apr;11(2):357–60

Is it time to say yes to antioxidants? Kuritzky L.
Hosp Pract (Off Ed) 1996 Sep 15;31(9):96, 99–100 (12 ref.)

Why did antioxidants not protect against lung cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study? Huttunen JK. **IARC Sci Publ** 1996;(136):63–5

Chemoprevention trial on precancerous lesions of the stomach in Venezuela: summary of study design and baseline data. Muñoz N, et al. **IARC Sci Publ** 1996; (139):125–33

Inhibition of liver fibrosis by ellagic acid. Thresiamma KC, et al. **Indian J Physiol Pharmacol** 1996 Oct;40(4):363–6

beta-Carotene and alpha-tocopherol inhibit the development of atherosclerotic lesions in hypercholesterolemic rabbits. Sun J, et al. **Int J Vitam Nutr Res** 1997;67(3):155–63

Lazaroid U-74500A for warm ischemia and reperfusion injury of the canine small intestine. Tanaka H, et al.
J Am Coll Surg 1997 Apr;184(4):389–96

Atrophic armd--a nutrition responsive chronic disease [editorial; comment] Richer S. **J Am Optom Assoc** 1996 Jan;67(1):6–10 (24 ref.). Comment on: J Am Optom Assoc 1996 Jan;67(1):50–7.

DOs should be source of patients' education [editorial] Rosner HM. **J Am Osteopath Assoc** 1996 Feb;96(2):85

Lipid peroxidation and human sperm motility: protective role of vitamin E. Suleiman SA, et al. **J Androl** 1996 Sep-Oct; 17(5):530–7

Contraction-induced injury to the extensor digitorum longus muscles of rats: the role of vitamin E. Van Der Meulen JH, et al. **J Appl Physiol** 1997 Sep;83(3):817–23

Excessive liver oxidant stress causes mortality in response to burn injury combined with endotoxin and is prevented with antioxidants. LaLonde C, et al.
J Burn Care Rehabil 1997 May-Jun;18(3):187–92

Attenuation of myocardial stunning in isolated rat hearts by a 21-aminosteroid lazaroid (U74389G). Moreyra AE, et al. **J Cardiovasc Pharmacol** 1996 Nov;28(5):659–64

Animal studies on antioxidants. Afridi N, et al.
J Cardiovasc Risk 1996 Aug;3(4):358–62 (42 ref.)

Randomized trials of dietary antioxidants in cardiovascular disease prevention and treatment. Gaziano JM.
J Cardiovasc Risk 1996 Aug;3(4):368–71 (19 ref.)

The effect of antioxidant vitamin supplementation on traditional cardiovascular risk factors. Miller ER 3rd, et al. **J Cardiovasc Risk** 1997 Feb;4(1):19–24

Evidence for oxidative stress in essential hypertension: perspective for antioxidant therapy. Parik T, et al.
J Cardiovasc Risk 1996 Feb;3(1):49–54

Antioxidants and coronary heart disease: observational studies. Rexrode KM, et al. **J Cardiovasc Risk** 1996 Aug; 3(4):363–7 (22 ref.)

Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. Stroes E, et al. **J Clin Invest** 1997 Jan 1;99(1):41–6

Antioxidants, cholesterol, and ischaemic heart disease: CHAOS or confusion? Winder AF. **J Clin Pathol** 1997 Apr;50(4):269–70

Antioxidant vitamins and health. Gibaldi M.
J Clin Pharmacol 1996 Dec;36(12):1093–9 (36 ref.)

Anti-oxidative therapy with oral dapsone improved HCV antibody positive annular elastolytic giant cell granuloma. Igawa K, et al. **J Dermatol** 1997 May;24(5):328–31

Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. Velussi M, et al. **J Hepatol** 1997 Apr; 26(4):871–9

Inhibition of diabetes in non-obese diabetic mice by nicotinamide treatment for 5 weeks at the early age. Kim JY, et al. **J Korean Med Sci** 1997 Aug;12(4):293–7

Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance [see comments] Albanes D, et al. **J Natl Cancer Inst** 1996 Nov 6;88(21):1560–70. Comment in: J Natl Cancer Inst 1996 Nov 6;88(21):1513–5.

The effect of postinjury administration of polyethylene glycol-conjugated superoxide dismutase (pegorgotein, Dismutec) or lidocaine on behavioral function following fluid-percussion brain injury in rats. Hamm RJ, et al.
J Neurotrauma 1996 Jun;13(6):325–32

Protection by alpha G-rutin, a water-soluble antioxidant flavonoid, against renal damage in mice treated with ferric nitrilotriacetate. Shimoi K, et al. **Jpn J Cancer Res** 1997 May;88(5):453–60

Prevention by 2-mercaptoethane sulfonate and N-acetylcysteine of renal oxidative damage in rats treated with ferric nitrilotriacetate. Umemura T, et al.
Jpn J Cancer Res 1996 Sep;87(9):882–6

Antioxidants and dementia. Lethem R, et al. **Lancet** 1997 Apr 26;349(9060):1189–90

Anti-oxidant therapy for ischaemic heart disease: where do we stand? [comment] Stephens N. **Lancet** 1997 Jun 14; 349(9067):1710–1. Comment on: Lancet 1997 Jun 14;349(9067):1715–20.

Antioxidant and triglyceride-lowering effects of vitamin E associated with the prevention of abnormalities in the reactivity and morphology of aorta from streptozotocin-diabetic rats. Antioxidants in Diabetes-Induced Complications (ADIC) Study Group. Karasu C, et al. **Metabolism** 1997 Aug;46(8):872–9

High-performance antioxidants for a multitude of diseases [news] Veggeberg S. **Mol Med Today** 1996 Oct;2(10):406

A controlled trial of idebenone in Huntington's disease. Ranen NG, et al. **Mov Disord** 1996 Sep;11(5):549–54

Restenosis revisited--new targets, new therapies [editorial; comment] Libby P, et al. **N Engl J Med** 1997 Aug 7; 337(6):418–9. Comment on: N Engl J Med 1997 Aug 7;337(6):365–72.

Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group [see comments] Tardif JC, et al.
N Engl J Med 1997 Aug 7;337(6):365–72. Comment in: N Engl J Med 1997 Aug 7;337(6):418–9.

Therapeutic effect of a newly developed antioxidative agent (OPC-15161) on experimental immune complex nephritis. Sanaka T, et al. **Nephron** 1997;76(3):315–22

Mechanisms of hippocampal reoxygenation injury. Treatment with antioxidants. Horáková L, et al.
Neuropharmacology 1997 Feb;36(2):177–84

A novel antioxidant alleviates heat hyperalgesia in rats with an experimental painful peripheral neuropathy. Tal M.
Neuroreport 1996 May 31;7(8):1382–4

Therapeutic time window for the 21-aminosteroid, U-74389G, in global cerebral ischemia. Lee SH, et al.
Neurosurgery 1996 Mar;38(3):517–21; discussion 522

Glutathione inhibits experimental oral carcinogenesis, p53 expression, and angiogenesis. Schwartz JL, et al.
Nutr Cancer 1996;26(2):229–36

Antioxidant vitamins and cardiovascular disease. Buring JE, et al. **Nutr Rev** 1997 Jan;55(1 Pt 2):S53–8; discussion S58–60 (42 ref.)

Antioxidants in cardiovascular disease: randomized trials. Gaziano JM. **Nutr Rev** 1996 Jun;54(6):175–7 (6 ref.)

Antioxidants in cardiovascular disease: randomized trials. Gaziano JM. **Nutrition** 1996 Sep;12(9):583–8 (59 ref.)

Antioxidants, dietary fat saturation, lipoprotein oxidation and atherogenesis [editorial] Schwenke DC. **Nutrition** 1996 May;12(5):377–9

Visaline in the treatment of age-related macular degeneration: a pilot study. Kaiser HJ, et al.
Ophthalmologica 1995;209(6):302–5

Use of antioxidant supplements in the treatment of human oral leukoplakia. Kaugars GE, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Jan;81(1):5–14 (126 ref.)

Effect of antioxidants on postoperative hyperamylasemia in coronary bypass surgery. Paajanen H, et al. **Pancreas** 1996 Oct;13(3):236–40

Focal segmental glomerulosclerosis [letter; comment] Glassock RJ. **Pediatr Nephrol** 1997 Feb;11(1):129. Comment on: Pediatr Nephrol 1996 Jun;10(3):374–91.

Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation.
Winklhofer-Roob BM, et al. **Pediatr Res** 1996 Jul; 40(1):130–4

Oxidative stress in malaria; implications for prevention and therapy. Postma NS, et al. **Pharm World Sci** 1996 Aug; 18(4):121–9 (124 ref.)

Protection of rat heart from ischaemia-reperfusion injury by the 21-aminosteroid U-74389G. Perna AM, et al.
Pharmacol Res 1996 Jul-Aug;34(1-2):25–31

Protective effect of stobadine on isoproterenol premedicated rabbits. Guzy J, et al. **Pharmazie** 1997 May;52(5):408

The role of antioxidants in nutritional support. Fürst P.
Proc Nutr Soc 1996 Nov;55(3):945–61 (90 ref.)

Oxidative injury and potential use of antioxidants in schizophrenia. Mahadik SP, et al.
Prostaglandins Leukot Essent Fatty Acids 1996 Aug; 55(1-2):45–54 (117 ref.)

Antioxidant treatment of tardive dyskinesia. Rotrosen J, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1-2):77–81 (63 ref.)

Therapeutic strategies in the prevention of acute renal failure. García RE. **Ren Fail** 1997 Mar;19(2):231–5 (23 ref.)

Acceleration of corneal wound healing in diabetic rats by the antioxidant trolox. Hallberg CK, et al.
Res Commun Mol Pathol Pharmacol 1996 Jul;93(1):3–12

Effect of flavonoids on the outcome of myocardial mitochondrial ischemia/reperfusion injury. van Jaarsveld H, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jan; 91(1):65–75

Anti-oxidant supplementation in disease prevention--panacea or poison? [letter] Morris A.
S Afr Med J 1997 Jan;87(1 Suppl):103–4

The role of antioxidant vitamins and enzymes in the prevention of exercise-induced muscle damage. Dekkers

JC, et al. **Sports Med** 1996 Mar;21(3):213–38 (62 ref.)

A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). The RANTTAS Investigators. **Stroke** 1996 Sep;27(9):1453–8

Parallel antioxidant and antiexcitotoxic therapy improves outcome after incomplete global cerebral ischemia in dogs. Davis S, et al. **Stroke** 1997 Jan;28(1):198–204; discussion 204–5

Effects of vitamin E on monocyte acute stress response [letter] **Thromb Haemost** 1997 Mar;77(3):604–5

Lazaroids prevent acute cyclosporine-induced renal vasoconstriction. Krysztopik RJ, et al. **Transplantation** 1997 May 15;63(9):1215–20

Rationale for the use of antioxidant vitamins in clinical organ transplantation. Lehr HA, et al. **Transplantation** 1996 Nov 15;62(9):1197–9 (47 ref.)

[Vitamin E as a possible aid in the control of disease problems on pig farms: a field test] Lamberts FJ. **Tijdschr Diergeneeskd** 1997 Apr 1;122(7):190–2 (Eng. Abstr.) **(Dut)**

[Role of oxidation of lipoproteins in the pathogenesis of atherosclerosis] Picard S. **Pathol Biol (Paris)** 1996 Jan; 44(1):46–50 (35 ref.) (Eng. Abstr.) **(Fre)**

["Good" and "bad" beta-carotene? (letter)] Thiberville L, et al. **Rev Mal Respir** 1996 Oct;13(5):538 **(Fre)**

[Deferoxamine-conjugated hydroxyethyl starch reduces reperfusion injury to the liver following hemorrhagic shock] Bauer C, et al. **Anaesthesist** 1997 Jan;46(1):53–6 (Eng. Abstr.) **(Ger)**

[Pharmacotherapy of Alzheimer dementia: therapy of cognitive symptoms—new results of clinical studies] Heidrich A, et al. **Fortschr Neurol Psychiatr** 1997 Mar; 65(3):108–21 (180 ref.) (Eng. Abstr.) **(Ger)**

[Antioxidants in therapy of lung diseases. Concepts and reality] Buhl R, et al. **Med Monatsschr Pharm** 1996 Oct; 19(10):287–94 (45 ref.) **(Ger)**

[New perspectives of antioxidant therapy with thiols: nacystelyn] Gillissen A. **Pneumologie** 1996 Dec;50 Suppl 3:834–7 (31 ref.) **(Ger)**

[Value of antioxidants and vitamins in cardiovascular prevention and therapy] Wascher TC. **Wien Klin Wochenschr Suppl** 1997;2:33–7 (26 ref.) (Eng. Abstr.) **(Ger)**

[Protective effect on nephropathy and on cataract in the streptozotocin-diabetic rat of the vanadium-lazaroid combination] Bosia S, et al. **G Ital Med Lav** 1995 Jan–Nov; 17(1–6):71–5 (Eng. Abstr.) **(Ita)**

[Antioxidant action of gabexate mesilate (Foy) in an experimental model of endotoxic shock] Novelli GP, et al. **Minerva Anestesiol** 1995 Dec;61(12):509–13 (Eng. Abstr.) **(Ita)**

[An antioxidant in pediatrics] Gomirato G, et al. **Minerva Pediatr** 1996 Jul–Aug;48(7–8):321–4 (Eng. Abstr.) **(Ita)**

[Antioxidants for prophylaxis of eye diseases] Kałuzny J. **Klin Oczna** 1996 Feb;98(2):141–3 (29 ref.) (Eng. Abstr.) **(Pol)**

[Hypoxia and its pharmacological correction: a key problem of anesthesiology and intensive care] Smirnov AV, et al. **Anesteziol Reanimatol** 1997 May–Jun;(3):97–8 **(Rus)**

[Immunomodulating and hepatoprotective action of retinoids in toxic liver involvement induced by D-galactosamine] Konoplia EN, et al. **Antibiot Khimioter** 1996;41(7–8):22–5 (Eng. Abstr.) **(Rus)**

[Antioxidants and immunomodulating action of antibiotics and antibiotic-treated erythrocytes in staphylococcal infections] Prokopenko LG, et al. **Antibiot Khimioter** 1997; 42(3):15–9 (Eng. Abstr.) **(Rus)**

[Impairment of antiviral cellular resistance and possibilities of its correction during acute altitude hypoxia] Sinopal'nikov DO, et al. **Aviakosm Ekolog Med** 1997; 31(2):28–32 (Eng. Abstr.) **(Rus)**

[Use of an alpha-tocopherol emulsion for antioxidant protection of ischemic and conserved kidneys] Kirpatovskiĭ VI, et al. **Biull Eksp Biol Med** 1996 May;121(5):499–502 **(Rus)**

[The efficacy of using alpha-tocopherol during ftorotan anesthesia] Abidova SS, et al. **Eksp Klin Farmakol** 1996 Jul–Aug;59(4):3–4 (Eng. Abstr.) **(Rus)**

[The effect of phenol antioxidants on the development of alloxan diabetes in rats] Bobyreva LE. **Eksp Klin Farmakol** 1997 May–Jun;60(3):51–3 (Eng. Abstr.) **(Rus)**

[Changes in the morphofunctional status of the liver in rats with acute tetrachloromethane poisoning and their correction with antihypoxants, antioxidants and actoprotectors] Dubovaia TK, et al. **Eksp Klin Farmakol** 1996 Jul–Aug;59(4):51–4 (Eng. Abstr.) **(Rus)**

[The antioxidative properties of furosemide in renal ischemia] Lebedev AA, et al. **Eksp Klin Farmakol** 1996 Jul–Aug; 59(4):28–30 (Eng. Abstr.) **(Rus)**

[The effect of nicotinamide, methionine and alpha-tocopherol on the liver conjugating and mono-oxygenase systems and on lipid peroxidation in hepatosis-hepatitis in rats] Legon'kova LF, et al. **Eksp Klin Farmakol** 1997 Mar–Apr;60(2):68–71 (Eng. Abstr.) **(Rus)**

[The possible mechanisms of the antioxidant action of calcium channel blockers in the hypoxic syndrome] Savchenko LV, et al. **Eksp Klin Farmakol** 1996 Mar–Apr;59(2):53–5 (Eng. Abstr.) **(Rus)**

[The hypolipidemic and antiatherosclerotic properties of the ammonium salt of glycyrrhetic acid and of 18-dehydroglycyrrhetic acid] Zakirov UB, et al. **Eksp Klin Farmakol** 1996 Sep–Oct;59(5):53–5 (Eng. Abstr.) **(Rus)**

[Metabolic reactions of the liver in carbon tetrachloride intoxication and their correction by plant antioxidants] Rak manin IuV, et al. **Gig Sanit** 1997 Jan–Feb;(1):30–2 **(Rus)**

[Clinicoimmunological effects of piracetam and aevit in the course of duodenal ulcer patients' therapy] Balobanov VI, et al. **Klin Med (Mosk)** 1996;74(7):56–7 **(Rus)**

[The use of the antioxidant effect of parmidine in the combined therapy of patients with ischemic heart disease] Garmash VIa, et al. **Klin Med (Mosk)** 1996;74(2):67 **(Rus)**

[Essential phospholipids in combined therapy of chronic circulatory insufficiency] Golochevskaia VS, et al. **Klin Med (Mosk)** 1997;75(5):30–3 (Eng. Abstr.) **(Rus)**

[Olifen action on mutagenesis in human lymphocytes] Mazurov VI, et al. **Klin Med (Mosk)** 1996;74(9):58–61 (Eng. Abstr.) **(Rus)**

[Piracetam and tocopherol acetate ability to potentiate clinical effect of antianginal drugs in presenile and senile patients with ischemic heart disease (unstable angina)] Pimenov LT, et al. **Klin Med (Mosk)** 1997;75(1):32–5 (Eng. Abstr.) **(Rus)**

[Use of antihypoxants and antioxidants for pharmaco-correction of disorders of water metabolism in the liver and small intestine after vagotomy] Tsybulevskiĭ AIu, et al. **Patol Fiziol Eksp Ter** 1996 Oct–Dec;(4):33–6 (Eng. Abstr.) **(Rus)**

[The molecular, cellular and systemic mechanisms of the radioprotective action of multivitamin antioxidant complexes] Riabchenko NI, et al. **Radiats Biol Radioecol** 1996 Nov–Dec;36(6):895–9 (Eng. Abstr.) **(Rus)**

[The development and creation of a new generation of superoxide dismutase-based antioxidant preparations] Demchenko TV, et al. **Stomatologiia (Mosk)** 1996;Spec No:51–2 **(Rus)**

[The use of the antihypoxants olifen and amtizol for treating patients with chronic stage-IIB circulatory failure] Andrianov VP, et al. **Ter Arkh** 1996;68(5):74–8 (Eng. Abstr.) **(Rus)**

[The treatment of pneumonias in influenza using antioxidants] Nagibina MV, et al. **Ter Arkh** 1996;68(11):33–5 (Eng. Abstr.) **(Rus)**

[The clinico-endoscopic, psychological and physical characteristics of duodenal peptic ulcer patients using piracetam and aevit] Pimenov LT, et al. **Ter Arkh** 1997; 69(2):10–3 (Eng. Abstr.) **(Rus)**

[The antioxidant histochrome: its effect on lipid peroxidation and the blood rheological properties in patients with unstable stenocardia] Zakirova AN, et al. **Ter Arkh** 1996; 68(8):12–4 (Eng. Abstr.) **(Rus)**

[Antiradical and antioxidant activity of derivatives of 1,2,4-triazole and quinazoline in cerebral ischemia] Dunaev VV, et al. **Ukr Biokhim Zh** 1996 Jan–Feb;68(1):100–4 (Eng. Abstr.) **(Rus)**

[Chromatin-protective action of the biologically active preparation BTK-8L in tetrachloromethane and chlorophos poisoning] Levitskiĭ EL, et al. **Ukr Biokhim Zh** 1996 Sep–Oct;68(5):76–84 (Eng. Abstr.) **(Rus)**

[Antioxidants in the treatment of cholelithiasis patients] Vagner EA, et al. **Vestn Khir Im I I Grek** 1997;156(1):36–9 (Eng. Abstr.) **(Rus)**

[Pathogenetic validation of optimal antioxidant therapy in suppurative inflammatory otic diseases in children] Karabaev KE, et al. **Vestn Otorinolaringol** 1997;(1):5–7 (Eng. Abstr.) **(Rus)**

[Correction of disruption of oxidative processes by dimethyl sulfoxide and alpha-tocopherol in acute chemical injury to the liver] Gonskiĭ IaI, et al. **Vopr Med Khim** 1996 Jan–Mar;42(1):30–4 (Eng. Abstr.) **(Rus)**

[In vitro effect of BITO preparation, ceruloplasmin, transferrin, and essentiale on the intensity of lipid peroxidation during thermal injury] L'vovskaia EI, et al. **Vopr Med Khim** 1996 Apr–Jun;42(2):125–7 (Eng. Abstr.) **(Rus)**

[The effect of endovascular laser therapy and antioxidants on the immune status and energy metabolism of patients with treatment-resistant forms of schizophrenia] Kut'ko II, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(2):34–8 (Eng. Abstr.) **(Rus)**

[Antioxidants in the treatment of schizophrenia (the correction of lipid peroxidation processes)] Kut'ko II, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(6):32–4 (Eng. Abstr.) **(Rus)**

[Local immune defects—products of free oxygen radicals] Drobný M, et al. **Bratisl Lek Listy** 1997 Apr;98(4):204–8 (Eng. Abstr.) **(Slo)**

[The membrane-protective action of a new preparation of n-3 polyenic acids in the adrenaline-damaged myocardium] Kresiun VI, et al. **Lik Sprava** 1996 Mar–Apr;(3–4):49–52 (Eng. Abstr.) **(Ukr)**

[A comparative study of the hemodynamic and antioxidant effects of Capoten and prazosin in patients with refractory heart failure] Sabadyshyn RO, et al. **Lik Sprava** 1997 Mar–Apr;(2):72–6 (Eng. Abstr.) **(Ukr)**

[The antioxidant effects of emoxipin in patients with iron-deficiency anemia] Shved MI, et al. **Lik Sprava** 1995 Sep–Dec;(9–12):72–5 (Eng. Abstr.) **(Ukr)**

TOXICITY

Effect of alpha-tocopherol on cytotoxicity induced by UV irradiation and antioxidants. Sakagami H, et al. **Anticancer Res** 1997 May–Jun;17(3C):2079–82

Effect of copper and iron ions on cytotoxicity induced by ascorbate, gallate and caffeate. Satoh K, et al. **Anticancer Res** 1997 May–Jun;17(3C):2181–4

Effect of cysteine, N-acetyl-L-cysteine and glutathione on cytotoxic activity of antioxidants. Satoh K, et al. **Anticancer Res** 1997 May–Jun;17(3C):2175–9

Promoting activity of 3-tert-butyl-4-hydroxyanisole (BHA) in BALB/3T3 cell transformation. Sakai A, et al. **Cancer Lett** 1997 May 19;115(2):213–20

Assay of free-radical toxicity and antioxidant effect on the Hep 3B cell line: a test survey using lindane. Descampiaux B, et al. **Cell Biol Toxicol** 1996 Feb;12(1):19–28

Lipid peroxidation and DNA damage induced by morin and naringenin in isolated rat liver nuclei. Sahu SC, et al. **Food Chem Toxicol** 1997 May;35(5):443–7

Reproductive toxicity evaluation of methylethyl ketoxime by gavage in CD rats. Tyl RW, et al. **Fundam Appl Toxicol** 1996 Jun;31(2):149–61

Chronic oral toxicity of a synthetic antioxidant, 2,2'-methylenebis(4-ethyl- 6-tert-butylphenol), in rats. Takagi A, et al. **J Appl Toxicol** 1996 Jan–Feb;16(1):15–23

Lazaroids inhibit proliferation of cultured human astrocytoma cells. Arora P, et al. **J Neurooncol** 1996 Aug; 29(2):143–8

Selective suppression of in vitro T-dependent humoral immunity by synthetic food additive antioxidants. Kim HM, et al. **J Toxicol Sci** 1996 Feb;21(1):41–5

Single-dose toxicities of 2,5-di(tert-butyl)-1,4-hydroquinone in the rat: toxicants as of hydroquinone derivative or a microsomal Ca2+ ATPase inhibitor? [letter] Kitajima S, et al. **J Toxicol Sci** 1996 Aug;21(3):201–4

Evaluation of oral exposure to Polnoks R for female rats in developmental toxicity studies. Sitarek K, et al. **Teratog Carcinog Mutagen** 1996;16(2):75–80

Effect of butylated hydroxytoluene on alpha-tocopherol content in liver and adipose tissue of rats. Simán CM, et al. **Toxicol Lett** 1996 Oct;87(2–3):103–8

ANTIPAIN

PHARMACOLOGY

Inhibitors of Ca(2+)-dependent endopeptidases modulate morphine-induced effects in rats. Lyupina YV, et al. **Eur J Pharmacol** 1996 May 23;304(1–3):23–7

Hypomutable potential accompanying interferon-alpha resistance in a human cell line, IFr, derived from interferon-alpha-sensitive and hypermutable RSa cells. Suzuki N, et al. **J Interferon Cytokine Res** 1996 Sep; 16(9):733–8

[Transcription in nerve cells and hepatocytes of WAG and F344 rats of different ages] Iarygin VN, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):427–31 **(Rus)**

ANTIPARASITIC AGENTS

Antibiotics update. Southern PM Jr. **Compr Ther** 1997 Sep; 23(9):575–82 (29 ref.)

[The need to advance pharmaceutical innovation in tropical medicine: from incantations to reality (editorial)] Ambroise-Thomas P. **Med Trop (Mars)** 1997;57(1):33–4 **(Fre)**

ADMINISTRATION & DOSAGE

[Health and environmental risks after the use of anti-infective agents and antiparasitic agents in domestic animal husbandry—avoidance strategies and ways out] Blaha T. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul;103(7):278–80 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents. Reddy KR, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):923–36 (99 ref.)

Paranoid delusions caused by ketoconazole [letter] Finkelstein E, et al. **Int J Dermatol** 1996 Jan;35(1):75

[Parasite control and its effect on the environment] Liebisch A. **DTW Dtsch Tierarztl Wochenschr** 1996 Jul; 103(7):268–73 (20 ref.) (Eng. Abstr.) **(Ger)**

ANALYSIS

Effects of drug residues in the faeces of cattle treated with injectable formulations of ivermectin and moxidectin on larvae of the bush fly, Musca vetustissima and the house fly, Musca domestica. Wardhaugh KG, et al. **Aust Vet J** 1996 Nov;74(5):370–4

Confirmation of gentian violet and its metabolite leucogentian violet in catfish muscle using liquid chromatography combined with atmospheric pressure ionization mass spectrometry. Doerge DR, et al. **Rapid Commun Mass Spectrom** 1996;10(12):1479–84

BLOOD

High-performance liquid chromatographic determination of

ANTIPARASITIC AGENTS

licochalcone A and its metabolites in biological fluids. Nadelmann L, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1;695(2):389–400

CHEMISTRY

Molecular modeling of phosphofructokinase from Entamoeba histolytica for the prediction of new antiparasitic agents. Byington CL, et al. **Arch Med Res** 1997;28 Spec No:86–8

CONTRAINDICATIONS

Use of frontline spray on rabbits [letter] [see comments] Cooper PE, et al. **Vet Rec** 1997 May 17;140(20):535–6. Comment in: Vet Rec 1997 Jun 21;140(25):664.

DIAGNOSTIC USE

Workshop summary: antiparasitic testing guidelines. Theodorides VJ. **Vet Parasitol** 1996 Aug;64(1–2):159–61

PHARMACOKINETICS

Pharmacokinetic considerations in the camel (Camelus dromedarius): a review. Ali BH, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1996 Sep;115(1):1–9 (61 ref.)

Residue avoidance after topical application of veterinary drugs and parasiticides. Baynes RE, et al.
J Am Vet Med Assoc 1997 May 1;210(9):1288–9 (2 ref.)

PHARMACOLOGY

Effects of drug residues in the faeces of cattle treated with injectable formulations of ivermectin and moxidectin on larvae of the bush fly, Musca vetustissima and the house fly, Musca domestica. Wardhaugh KG, et al.
Aust Vet J 1996 Nov;74(5):370–4

The antiparasite effects of cyclosporin A: possible drug targets and clinical applications. Bell A, et al.
Gen Pharmacol 1996 Sep;27(6):963–71 (86 ref.)

[Development of resistance to antiparasitic agents in parasites pathogenic to animals] Daugschies A.
DTW Dtsch Tierarztl Wochenschr 1996 Jul;103(7):260–3 (52 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Workshop summary: antiparasitic testing guidelines. Theodorides VJ. **Vet Parasitol** 1996 Aug;64(1–2):159–61

THERAPEUTIC USE

Ivermectin–responsive crusted scabies in HTLV1 carrier. Cordoliani F, et al. **Dermatology** 1996;192(4):351–2

Hepatic echinococcus disease: our experience over 22 years. Di Matteo G, et al. **Hepatogastroenterology** 1996 Nov–Dec; 43(12):1562–5

Antiparasitic drugs in ophthalmology. Wilhelmus KR.
Int Ophthalmol Clin 1996 Spring;36(2):117–52 (162 ref.)

Current trends in the diagnosis and management of cystic hydatid disease of the liver. Dhar P, et al.
J Commun Dis 1996 Dec;28(4):221–30 (45 ref.)

Usage of antibacterial and antiparasitic drugs in animals in Sweden between 1988 and 1993 [published erratum appears in Vet Rec 1996 Oct 5;139(14):350] Björnerot L, et al.
Vet Rec 1996 Sep 21;139(12):282–6

Insecticide resistance and EU policy [letter; comment] Coles GC. **Vet Rec** 1996 Dec 7;139(23):576. Comment on: Vet Rec 1996 Nov 2;139(18):451.

[Scabies: a common infection nevertheless often misdiagnosed] Barthe L, et al. **Rev Med Liege** 1996 Aug; 51(8):522–6 (27 ref.) **(Fre)**

[Advances of medical treatment of human hydatidosis] De Rosa F, et al. **Recenti Prog Med** 1996 Jul–Aug; 87(7–8):346–52 (48 ref.) (Eng. Abstr.) **(Ita)**

[Dapsone in the prevention of HIV–related parasitosis] Garavelli PL. **Recenti Prog Med** 1996 Jun;87(6):279 **(Ita)**

TOXICITY

In vitro culture of Oestrus ovis (Linné 1761) first instar larvae: its application to antiparasitic drug screening. Duranton C, et al. **Int J Parasitol** 1997 Jan;27(1):125–8

URINE

High–performance liquid chromatographic determination of licochalcone A and its metabolites in biological fluids. Nadelmann L, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1;695(2):389–400

ANTIPARKINSON AGENTS

Trihexyphenidyl (Artane) abuse in schizophrenic patients. Zemishlany Z, et al. **Int Clin Psychopharmacol** 1996 Sep; 11(3):199–202

[Recent progress in development of psychotropic drugs (3)—Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals] Nomoto M.
Nihon Shinkei Seishin Yakurigaku Zasshi 1996 Aug; 16(4):113–22 (41 ref.) (Eng. Abstr.) **(Jpn)**

[New therapeutic strategy for Parkinson's disease based on pharmacological profiles] Ogawa N. **Nippon Rinsho** 1997 Jan;55(1):43–51 (19 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Sustained–release Madopar HBS compared with standard Madopar in the long–term treatment of de novo parkinsonian patients. Dupont E, et al.
Acta Neurol Scand 1996 Jan;93(1):14–20

(–)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment [letter] Knoll J.
Biomed Pharmacother 1996;50(6–7):315–7 (29 ref.)

Rapid stabilization at home [letter] [see comments] Reding KM, et al. **Can J Psychiatry** 1996 Nov;41(9):605–6. Comment in: Can J Psychiatry 1997 May;42(4):427.

Familial akathisia and depression treated with nefazodone [letter] Simpson JS. **Can J Psychiatry** 1996 Oct; 41(8):539–40

Comparison between percutaneous and subcutaneous routes of administration of apomorphine in rabbit. Durif F, et al.
Clin Neuropharmacol 1994 Oct;17(5):445–53

Clinical efficacy and tolerability of a new levodopa/benserazide dual–release formulation in parkinsonian patients. L–Dopa Dual–Release Study Group. Ghika J, et al. **Clin Neuropharmacol** 1997 Apr;20(2):130–9

Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. Hammerstad JP, et al.
Clin Neuropharmacol 1994 Oct;17(5):429–34

Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Stocchi F, et al. **Clin Neuropharmacol** 1997 Apr;20(2):95–115 (146 ref.)

Comparison of immediate–release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5–year study. The CR First Study Group. Block G, et al. **Eur Neurol** 1997;37(1):23–7

Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa. Schwarz J, et al. **Eur Neurol** 1997;37(4):236–8

Sustained–release of levodopa: single dose study of a new formulation. Gerlach M, et al.
J Neural Transm Gen Sect 1996;103(6):717–27

Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa–associated motor side effects. Long–term results of the PRADO study. Przuntek H, et al. **J Neural Transm Gen Sect** 1996;103(6):699–715

Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. Stocchi F, et al.
J Neurol 1996 May;243(5):377–80

Step initiation in Parkinson's disease: influence of levodopa and external sensory triggers. Burleigh–Jacobs A, et al. **Mov Disord** 1997 Mar;12(2):206–15

Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects. Eichhorn TE, et al. **Mov Disord** 1996 May;11(3):289–97

Hydrocephalic parkinsonism due to Paget's disease of bone: dramatic improvement following ventriculoperitoneal shunt and temporary levodopa/carbidopa therapy. Ikeda K, et al. **Mov Disord** 1997 Mar;12(2):241–2

The effects of early selegiline therapy on long–term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian—Danish 5–year study. Norwegian–Danish Study Group. Larsen JP, et al. **Mov Disord** 1997 Mar; 12(2):175–82

The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha–tocopherol. Parkinson Study Group. LeWitt P, et al. **Mov Disord** 1997 Mar;12(2):183–9

Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Tison F, et al. **Mov Disord** 1996 Nov;11(6):729–32

A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease. van Laar T, et al. **Mov Disord** 1996 Nov;11(6):633–8

[Parkinson disease—problems in long–term treatment. Dopamine agonists optimize L–dopa therapy] Fuchs G. **Fortschr Med** 1997 Feb 20;115(5):43–5 (Eng. Abstr.) **(Ger)**

[Current therapy of idiopathic Parkinson disease. 1: Diagnosis, therapeutic guidelines, standard pharmacotherapy and physical therapy] Müller T, et al. **Fortschr Med** 1997 May 10;115(13):28, 31–4 (0 ref.) (Eng. Abstr.) **(Ger)**

[Current therapy of idiopathic Parkinson disease. 2: Recent and alternative therapies] Müller T, et al. **Fortschr Med** 1997 May 10;115(13):37–41 (0 ref.) (Eng. Abstr.) **(Ger)**

[Treatment and prognosis of juvenile parkinsonism—L–dopa responsiveness] Takubo H. **Nippon Rinsho** 1997 Jan; 55(1):101–5 (23 ref.) (Eng. Abstr.) **(Jpn)**

[L–dopa/benserazide during pregnancy in a patient with juvenile parkinsonism] Arai H, et al.
Rinsho Shinkeigaku 1997 Mar;37(3):264–5 (Eng. Abstr.) **(Jpn)**

[Daily defined doses of parkinsonian drugs in Alcoi] Manzanares R, et al. **Rev Neurol** 1996 Apr;24(128):440–2 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Clozapine for the treatment of psychosis in Parkinson's disease: a review. Auzou P, et al. **Acta Neurol Scand** 1996 Nov;94(5):329–36 (76 ref.)

Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease. Wagner ML, et al. **Ann Clin Lab Sci** 1996 Sep–Oct; 26(5):389–95

Retrospective study of selegiline–antidepressant drug interactions and a review of the literature. Ritter JL, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):7–13 (37 ref.)

Unexpected findings of study of selegiline have not been treated with caution its authors advised [letter; comment] Silva MT, et al. **BMJ** 1997 Aug 9;315(7104):370. Comment on: BMJ 1995 Dec 16;311(7020):1583–4. Comment on: BMJ 1997 Dec 16;311(7020):1602–7.

Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease. Courty E, et al.
Clin Neuropharmacol 1997 Apr;20(2):140–7

Long–term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa–related motor fluctuations. Esteban Muñoz J, et al. **Clin Neuropharmacol** 1997 Jun;20(3):245–52

Deprenyl, excess mortality, and epidemiological traps. Riggs JE. **Clin Neuropharmacol** 1997 Jun;20(3):276–8

Safety of long–term levodopa therapy in malignant melanoma. Woofter MJ, et al. **Clin Neuropharmacol** 1994 Aug;17(4):315–9

Allergic contact dermatitis from apomorphine. Carboni GP, et al. **Contact Dermatitis** 1997 Mar;36(3):177–8

Methods of managing levodopa–induced dyskinesias. Giron LT Jr, et al. **Drug Saf** 1996 Jun;14(6):365–74 (35 ref.)

Mortality associated with selegiline in Parkinson's disease. What do the available data mean? Mizuno Y, et al.
Drug Saf 1997 May;16(5):289–94

Antiparkinsonian agents. Drug interactions of clinical significance. Pfeiffer RF. **Drug Saf** 1996 May;14(5):343–54 (124 ref.)

Potential of opioid antagonists in the treatment of levodopa–induced dyskinesias in Parkinson's disease. Henry B, et al. **Drugs Aging** 1996 Sep;9(3):149–58

Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Young BK, et al. **Drugs Aging** 1997 May;10(5):367–83 (153 ref.)

Comments and reply on Ikeguchi and Kuroda: Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs [letter] Friedman JH, et al.
Eur Arch Psychiatry Clin Neurosci 1996;246(2):106–7

Management of motor fluctuations in Parkinson's disease. Koller WC. **Eur Neurol** 1996;36 Suppl 1:43–8 (48 ref.)

Problems with current pharmacologic treatment of Parkinson's disease. Hurtig HI. **Exp Neurol** 1997 Mar; 144(1):10–6 (61 ref.)

Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Barbato L, et al. **Funct Neurol** 1996 Jul–Aug;11(4):201–7

Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. Pfützner W, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 2):332–6 (68 ref.)

Remoxipride in the treatment of levodopa–induced psychosis. Sandor P, et al. **J Clin Psychopharmacol** 1996 Oct; 16(5):395–9

Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: evidence from a double–blind crossover study [letter] Silver H, et al.
J Clin Psychopharmacol 1996 Dec;16(6):463–4

Use of clozapine to treat levodopa–induced psychosis in Parkinson's disease: retrospective review. Widman LP, et al. **J Geriatr Psychiatry Neurol** 1997 Apr;10(2):63–6

Dopaminergic effects on cognitive performance in patients with Parkinson's disease. Lange KW, et al.
J Neural Transm Suppl 1995;46:423–32

Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. Churchyard A, et al.
J Neurol Neurosurg Psychiatry 1997 Aug;63(2):228–34

Henoch–Schönlein syndrome induced by carbidopa/levodopa [letter] Niedermaier G, et al.
Lancet 1997 Apr 12;349(9058):1071–2

High–dose pergolide monotherapy in the treatment of severe levodopa–induced dyskinesias [letter] Facca A, et al.
Mov Disord 1996 May;11(3):327–9

Case 1, 1996: rapidly progressive parkinsonism, incontinence, impotency, and levodopa–induced moaning in a patient with multiple myeloma [clinical conference] Fahn S, et al.
Mov Disord 1996 May;11(3):298–310

Levodopa in pregnancy [letter; comment] Nomoto M, et al.
Mov Disord 1997 Mar;12(2):261. Comment on: Mov Disord 1995 Jan;10(1):115.

Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Nutt JG, et al.
Mov Disord 1997 May;12(3):285–92

Belly dystonia induced by levodopa and biperiden in a case of suspected multiple–system atrophy. Shan DE, et al.
Mov Disord 1996 Jul;11(4):455–7

Role of selegiline in combination therapy of Parkinson's disease. Myllylä VV, et al. **Neurology** 1996 Dec;47(6 Suppl 3):S200–9 (145 ref.)

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Richard IH, et al. **Neurology** 1997 Apr;48(4):1070–7

Modulation of levodopa–induced motor response complications by NMDA antagonists in Parkinson's disease. Blanchet PJ, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):447–53 (80 ref.)

Sodium benzoate differentially blocks circling induced by D–and L–dopa in the hemi–parkinsonian rat. Moses J, et

al. **Neurosci Lett** 1996 Nov 8;218(3):145–8

Incidence of and risk factors for delirium among psychiatric inpatients. Ritchie J, et al. **Psychiatr Serv** 1996 Jul; 47(7):727–30

[Pleural effusion and severe edema of the lower limbs induced by bromocriptine] Messiaen T, et al. **Rev Med Interne** 1996; 17(8):680–3 (14 ref.) (Eng. Abstr.) **(Fre)**

[Keratitis and corneal edema associated with levodopa use--a case report] Nakamagoe K, et al. **Rinsho Shinkeigaku** 1996 Jul;36(7):886–8 (Eng. Abstr.) **(Jpn)**

[Levodopa-induced dyskinesia in 176 patients with Parkinson's disease] Rocha MS, et al. **Arq Neuropsiquiatr** 1995 Dec;53(4):737–42 (Eng. Abstr.) **(Por)**

[Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa] Svetel MV, et al. **Srp Arh Celok Lek** 1997 Jul–Aug;125(7–8):203–6 (Eng. Abstr.) **(Scc)**

[Psychiatric complications of L-dopa: physiopathology and treatment] Castro-García A. **Rev Neurol** 1997 Aug;25 Suppl 2:S157–62 (70 ref.) (Eng. Abstr.) **(Spa)**

[Physiopathology of the dyskinesias induced by L-dopa] Grandas F, et al. **Rev Neurol** 1997 Aug;25 Suppl 2:S151–6 (93 ref.) (Eng. Abstr.) **(Spa)**

[Drug-related motor disorders in aged people] Martí-Massó JF. **Rev Neurol** 1997 Jul;25 Suppl 1:S37–43 (35 ref.) **(Spa)**

ANTAGONISTS & INHIBITORS

Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Papa SM, et al. **Brain Res** 1995 Dec 1;701(1–2):13–8

Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. Carvey PM, et al. **J Neural Transm** 1997;104(2–3):209–28

BLOOD

Concentrations of L-dopa in plasma and plasma ultrafiltrates. Rizzo V, et al. **J Pharm Biomed Anal** 1996 Jun; 14(8–10):1043–6

[The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients] García de Yébenes J, et al. **Neurologia** 1997 Apr;12(4):145–56 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association. Benetello P, et al. **Pharmacol Res** 1997 Apr;35(4):313–5

CHEMICAL SYNTHESIS

Oxazolidinones, dihydrofuranones, and pyrrolidinones as inactivators and substrates of monoamine oxidase B: approaches to the design of antiparkinsonian agents. Silverman RB. **Farmaco** 1997 May;52(5):343–52

CHEMISTRY

New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists. Goetz CG. **Exp Neurol** 1997 Mar;144(1):17–20 (45 ref.)

The stability of carbidopa in solution. Pappert EJ, et al. **Mov Disord** 1997 Jul;12(4):608–10

DIAGNOSTIC USE

Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. Zappia M, et al. **Mov Disord** 1997 Jan; 12(1):103–6

ECONOMICS

[Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy] Dodel RC, et al. **Med Klin** 1996 Jul 15;91(7):479–85 (64 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Shin HS. **Drug Metab Dispos** 1997 Jun;25(6):657–62

The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. Kornhuber J, et al. **J Neural Transm Suppl** 1995;46:131–7

The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients. Maruyama W, et al. **J Neurol Sci** 1996 Jul;139(1):141–8

PHARMACOKINETICS

In vivo microdialysis to determine the relative pharmacokinetics of drugs. Nakashima M, et al. **Biol Pharm Bull** 1996 Jul;19(7):988–94

Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Dingemanse J, et al. **Br J Clin Pharmacol** 1997 Jul; 44(1):41–8

Clinical drug monitoring by microdialysis: application to levodopa therapy in Parkinson's disease. O'Connell MT, et al. **Br J Clin Pharmacol** 1996 Dec;42(6):765–9

Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. Hammerstad JP, et al. **Clin Neuropharmacol** 1994 Oct;17(5):429–34

Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Ruottinen HM, et al. **Clin Neuropharmacol** 1996 Jun;19(3):222–33

Pharmacokinetic optimisation in the treatment of Parkinson's disease [published erratum appears in Clin Pharmacokinet 1996 Aug;31(2):110] Contin M, et al. **Clin Pharmacokinet** 1996 Jun;30(6):463–81 (196 ref.)

Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Triggs EJ, et al. **Eur J Clin Pharmacol** 1996;51(1):59–67

Levodopa biotransformation in hemi-Parkinson rats: effect of dopamine receptor agonists and antagonists. Sarre S, et al. **Eur J Pharmacol** 1996 Feb 5;296(3):247–60

Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). Waitzinger J, et al. **Int J Clin Pharmacol Ther** 1996 Oct; 34(10):427–32

Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. Djaldetti R, et al. **Isr J Med Sci** 1996 Dec;32(12):1224–7 (26 ref.)

Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. Wright CE, et al. **J Clin Pharmacol** 1997 Jun;37(6):520–5

Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. Murata M, et al. **J Neural Transm** 1996;103(10):1177–85

Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. Yamamoto M, et al. **J Neural Transm** 1997;104(2–3):229–36

Intravenous application of amantadine and antiparkinsonian efficacy in Parkinsonian patients. Müller T, et al. **J Neural Transm Suppl** 1995;46:407–13

Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. Pahwa R, et al. **Mov Disord** 1996 Jul;11(4):427–30

Effect of tolcapone on plasma and striatal apomorphine disposition in rats. Coudoré F, et al. **Neuroreport** 1997 Mar 3;8(4):877–80

[The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients] García de Yébenes J, et al. **Neurologia** 1997 Apr;12(4):145–56 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Antagonism of striatal muscarinic receptors inhibiting dopamine D1 receptor-stimulated adenylyl cyclase activity by cholinoceptor antagonist used to treat Parkinson's disease. Olianas MC, et al. **Br J Pharmacol** 1996 Jun; 118(4):827–8

Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Grondin R, et al. **Brain Res** 1996 Oct 7;735(2):298–306

L-deprenyl (selegiline) limits the repetitive firing of action potentials in rat hippocampal CA1 neurons via a dopaminergic mechanism. Huang CC, et al. **Brain Res** 1997 Apr 4;753(1):27–35

Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Kakkar R, et al. **Brain Res** 1997 Feb 28;749(2):290–4

MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Marin C, et al. **Brain Res** 1996 Oct 14;736(1–2):202–5

Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: implication for treatment of Parkinson's disease. Djaldetti R, et al. **Clin Neuropharmacol** 1996 Feb; 19(1):65–71

Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation. Loeffler DA, et al. **Clin Neuropharmacol** 1994 Aug;17(4):370–9

Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Guo Z, et al. **Drug Metab Dispos** 1997 Mar;25(3):390–3

Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. Cousins MS, et al. **Eur J Pharmacol** 1997 Mar 19;322(2–3):137–45

Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Klockgether T, et al. **Eur J Pharmacol** 1996 Apr 22;301(1–3):67–73

The behavioural effects of pramipexole, a novel dopamine receptor agonist. Maj J, et al. **Eur J Pharmacol** 1997 Apr 11;324(1):31–7

Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Piercey MF, et al. **Eur J Pharmacol** 1996 Sep 19;312(1):35–44

Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Schmidt WJ, et al. **Eur J Pharmacol** 1997 May 26;327(1):1–9

The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Jorga K, et al. **Eur Neurol** 1997;38(1):59–67

Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats. Lindner MD, et al. **Exp Neurol** 1997 May;145(1):130–40

Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Palfi S, et al. **Exp Neurol** 1997 Jul; 146(1):135–41

Effects of a dopaminergic agonist in the guinea pig cochlea. d'Aldin C, et al. **Hear Res** 1995 Oct;90(1–2):202–11

Inhibition of platelet monoamine oxidase type B by selegiline. Heinonen EH, et al. **J Clin Pharmacol** 1997 Jul; 37(7):597–601

Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. Heinonen EH, et al. **J Clin Pharmacol** 1997 Jul; 37(7):602–9

Effects of bromocriptine on dopamine turnover with or without levodopa. Ogawa N, et al. **J Int Med Res** 1996 May–Jun;24(3):271–7

Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys. Arai N, et al. **J Neural Transm** 1996;103(11):1307–16

Age-related decrease in responsiveness to L-DOPA is not due to changes in dopamine receptor mRNAs or G protein mRNAs. Murata M, et al. **J Neural Transm** 1996; 103(3):343–8

L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats. Xu K, et al. **J Neural Transm** 1996; 103(11):1295–305

Fluctuations in Parkinson's disease. Pathogenetic significance of levodopa's cerebral pharmacokinetics and pharmacodynamics. Baas H, et al. **J Neural Transm Suppl** 1995;46:367–79

In vivo studies on the effects of memantine on dopamine metabolism in the striatum and n. accumbens of the rat. Clement HW, et al. **J Neural Transm Suppl** 1995;46:107–15

Memantine prevents progressive functional neurodegeneration in rats. Heim C, et al. **J Neural Transm Suppl** 1995;46:117–30

Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. Quack G, et al. **J Neural Transm Suppl** 1995;46:97–105

The phonological loop in medicated patients with Parkinson's disease: presence of phonological similarity and word length effects. Moreaud O, et al. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):609–11

Trapping channel block of NMDA-activated responses by amantadine and memantine. Blanpied TA, et al. **J Neurophysiol** 1997 Jan;77(1):309–23

Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. Menzaghi F, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):393–401

[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. Newman-Tancredi A, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):181–91

D1 dopamine receptor activity of anti-parkinsonian drugs. Fici GJ, et al. **Life Sci** 1997;60(18):1597–603

Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. Kakkar R, et al. **Life Sci** 1996;59(21):PL337–41

Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. Morissette M, et al. **Mol Pharmacol** 1996 Nov;50(5):1073–9

A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity. Andreu N, et al. **Mov Disord** 1997 May;12(3):293–6

Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment. Benazzouz A, et al. **Mov Disord** 1996 Nov;11(6):627–32

Sleep benefit in Parkinson's disease. Merello M, et al. **Mov Disord** 1997 Jul;12(4):506–8

The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Rioux L, et al. **Mov Disord** 1997 Mar;12(2):148–58

Pharmacology of selegiline. Gerlach M, et al. **Neurology** 1996 Dec;47(6 Suppl 3):S137–45 (83 ref.)

Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies. Danysz W, et al. **Neurosci Biobehav Rev** 1997 Jul;21(4):455–68 (151 ref.)

Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Starr MS, et al. **Neurosci Biobehav Rev** 1997 Jul; 21(4):437–46 (69 ref.)

Enhancement of mRNA expression of tissue-type plasminogen activator by L-threo-3,4-dihydroxyphenylserine in association with ocular dominance plasticity. Mataga N, et al. **Neurosci Lett** 1996 Nov 8;218(3):149–52

Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Oh JD, et al. **Neurosci Lett** 1997 May 30;228(1):5–8

Effects of antimuscarinic antiparkinsonian drugs on

brightness discrimination performance in rats. Liu WF. **Pharmacol Biochem Behav** 1996 Jun;54(2):425–30

Levodopa induces AP-1 and CREB DNA-binding activities in the rat striatum. Kashihara K, et al. **Psychiatry Clin Neurosci** 1995 Dec;49(5–6):291–4

Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs. Mercuri NB, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):232–5 (34 ref.)

POISONING

Physostigmine temporarily and dramatically reversing acute mania [letter] Khouzam HR, et al. **Gen Hosp Psychiatry** 1996 May;18(3):203–4

Is levodopa toxic? Fahn S. **Neurology** 1996 Dec;47(6 Suppl 3):S184–95 (154 ref.)

A complication of self-poisoning. Gerrand CH, et al. **Postgrad Med J** 1997 Feb;73(856):113–4

STANDARDS

Stability of levodopa/carbidopa solutions [letter] Cedarbaum JM. **Mov Disord** 1997 Jul;12(4):625

THERAPEUTIC USE

Age at onset: the major determinant of outcome in Parkinson's disease. Hely MA, et al. **Acta Neurol Scand** 1995 Dec;92(6):455–63

Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study. Myllylä VV, et al. **Acta Neurol Scand** 1997 Apr;95(4):211–8

Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Olson WL, et al. **Am J Med** 1997 Jan;102(1):60–6

Short- and long-duration responses to levodopa during the first year of levodopa therapy. Nutt JG, et al. **Ann Neurol** 1997 Sep;42(3):349–55

Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Torstenson R, et al. **Ann Neurol** 1997 Mar;41(3):334–40

Carbidopa/levodopa in the treatment of neuroleptic malignant syndrome [letter] Shoop SA, et al. **Ann Pharmacother** 1997 Jan;31(1):119

Multi-centre trials: U-turns by bandwagons and the patient left by the wayside [editorial] Dobbs SM, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):143–5

Clinical drug monitoring by microdialysis: application to levodopa therapy in Parkinson's disease. O'Connell MT, et al. **Br J Clin Pharmacol** 1996 Dec;42(6):765–9

Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet. Lindner MD, et al. **Brain Res Bull** 1996;39(6):367–72

An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl. Shan DE, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Oct; 58(4):264–8

The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance. Tanaka H, et al. **Clin Auton Res** 1996 Aug;6(4):189–93

Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Ahlskog JE, et al. **Clin Neuropharmacol** 1996 Jun;19(3):202–12

Bromocriptine therapy in multiple sclerosis: an open label pilot study. Bissay V, et al. **Clin Neuropharmacol** 1994 Oct; 17(5):473–6

Intranasal apomorphine rescue therapy for parkinsonian "off" periods. Dewey RB Jr, et al. **Clin Neuropharmacol** 1996 Jun;19(3):193–201

Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations. Esteban Muñoz J, et al. **Clin Neuropharmacol** 1997 Jun;20(3):245–52

Apomorphine tolerance in Parkinson's disease: lack of a dose effect. Gancher ST, et al. **Clin Neuropharmacol** 1996 Feb; 19(1):59–64

Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Giménez-Roldán S, et al. **Clin Neuropharmacol** 1997 Feb; 20(1):67–76

Discontinuation of prolonged bromocriptine therapy in Parkinson's disease patients with uncontrolled motor oscillations. Giménez-Roldán S, et al. **Clin Neuropharmacol** 1994 Oct;17(5):435–44

Perceived exertion and muscle efficiency in Parkinson's disease: L-DOPA effects. LeWitt PA, et al. **Clin Neuropharmacol** 1994 Oct;17(5):454–9

A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients. Llau ME, et al. **Clin Neuropharmacol** 1996 Oct;19(5):420–7

Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo. Martignoni E, et al. **Clin Neuropharmacol** 1996 Feb;19(1):72–80

Drug-induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L-Dopa and apomorphine. Merello M, et al. **Clin Neuropharmacol** 1996 Oct;19(5):439–43

Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Merello M, et al. **Clin Neuropharmacol** 1997 Apr;20(2):165–7

Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Rabey JM, et al. **Clin Neuropharmacol** 1997 Aug;20(4):322–37

Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Rascol O, et al. **Clin Neuropharmacol** 1996 Jun;19(3):234–45

Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Stocchi F, et al. **Clin Neuropharmacol** 1997 Apr;20(2):95–115 (146 ref.)

Safety of long-term levodopa therapy in malignant melanoma. Woofter MJ, et al. **Clin Neuropharmacol** 1994 Aug;17(4):315–9

Result of long-term administration of L-threo-3,4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy. Yamamoto M, et al. **Clin Neuropharmacol** 1997 Aug; 20(4):371–3

Controversies in the treatment of Parkinson's disease. Hely MA, et al. **Curr Opin Neurol** 1996 Aug;9(4):308–13 (43 ref.)

Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Bryson HM, et al. **Drugs** 1996 Oct;52(4):549–63 (60 ref.)

Drug treatment of Parkinson's disease in the 1990s. Achievements and future possibilities. Hughes AJ. **Drugs** 1997 Feb;53(2):195–205 (65 ref.)

Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management. Jost WH. **Drugs Aging** 1997 Apr;10(4):249–58 (77 ref.)

Using liquid levodopa in the treatment of Parkinson's disease. A practical guide. Kurth MC. **Drugs Aging** 1997 May; 10(5):332–40 (40 ref.)

New directions in the drug treatment of Parkinson's disease. Montastruc JL, et al. **Drugs Aging** 1996 Sep;9(3):169–84 (82 ref.)

The effect of levodopa on the habituation of the acoustic-palpebral reflex in Parkinson's disease. Rey RD, et al. **Electromyogr Clin Neurophysiol** 1996 Sep; 36(6):357–60

Bromocriptine therapy in early-stage Parkinson's disease. Fukuyama H, et al. **Eur Neurol** 1996;36(3):164–70

Treatment of Parkinson's disease. Advances in the pharmacological therapy. Ghika J. **Eur Neurol** 1996; 36(6):396–9 (33 ref.)

Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy. Hasegawa K, et al. **Eur Neurol** 1997;38 Suppl 1:39–43

Nine-year follow-up study of bromocriptine monotherapy for Parkinson's disease. Kowa H, et al. **Eur Neurol** 1997; 38 Suppl 1:23–8

Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications. Kuno S. **Eur Neurol** 1997;38 Suppl 1:18–22

Analyzer workshop on the treatment of Parkinson's disease. Mizuno Y, et al. **Eur Neurol** 1997;38 Suppl 1:44–57

Dopamine neurotransmission and treatments for Parkinson's disease in the molecular biology era. Ogawa N. **Eur Neurol** 1997;38 Suppl 1:2–5 (39 ref.)

Motor fluctuations in levodopa treatment: clinical pharmacology. Stocchi F, et al. **Eur Neurol** 1996;36 Suppl 1:38–42 (38 ref.)

Eight-year follow-up study of bromocriptine monotherapy for Parkinson's disease. Tashiro K, et al. **Eur Neurol** 1996; 36 Suppl 1:32–7

Tremor and voluntary repetitive movement in Parkinson's disease: comparison before and after L-dopa with positron emission tomography. Duffau H, et al. **Exp Brain Res** 1996; 107(3):453–62

Lisuride and bromocryptine in L-Dopa stable-responder parkinsonian patients: a comparative, double-blind evaluation of cardiopressor and neurochemical effects. Micieli G, et al. **Funct Neurol** 1996 Nov-Dec;11(6):317–25

Current therapy of Parkinson's disease. Ajax T, et al. **Iowa Med** 1997 Feb;87(2):71–3

Current therapy of Parkinson's disease. Ajax T, et al. **Iowa Med** 1997 Jan;87(1):27–9

Segawa disease. Phanthumchinda K, et al. **J Med Assoc Thai** 1996 Jul;79(7):473–6

Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. Kuhn W, et al. **J Neural Transm** 1996;103(10):1187–93

Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. Yamamoto M, et al. **J Neural Transm** 1997;104(2–3):229–36

Antiparkinsonian effect of flupirtine in monoamine-depleted rats. Schwarz M, et al. **J Neural Transm Gen Sect** 1996; 103(5):581–90

Deprenyl--past and future. Proceedings of a symposium. Lake Starnberg, Bavaria, 1995. **J Neural Transm Suppl** 1996;48:1–112

Twenty-five years of amantadine therapy in Parkinson's disease. Danielczyk W. **J Neural Transm Suppl** 1995; 46:399–405 (34 ref.)

Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy. Fischer PA. **J Neural Transm Suppl** 1995;46:381–9 (29 ref.)

Amantadine in Parkinson's disease: pro and contra. Greulich W, et al. **J Neural Transm Suppl** 1995;46:415–21 (27 ref.)

DATATOP-study: significance of its results in the treatment of Parkinson's disease. Schneider E. **J Neural Transm Suppl** 1995;46:391–7

Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease? Ziv I, et al. **J Neural Transm Suppl** 1997;49:195–202 (21 ref.)

Amantadine in advanced Parkinson's disease: good use of an old drug [letter] Adler CH, et al. **J Neurol** 1997 May; 244(5):336–7

Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study [letter] Colosimo C, et al. **J Neurol** 1996 May;243(5):422–5

International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. Wolters EC, et al. **J Neurol** 1996 Mar;243(3):235–40

Management of parkinsonism and psychotic depression in a case of acute intermittent porphyria [letter] Chinnery PF, et al. **J Neurol Neurosurg Psychiatry** 1997 May;62(5):542

The phonological loop in medicated patients with Parkinson's disease: presence of phonological similarity and word length effects. Moreaud O, et al. **J Neurol Neurosurg Psychiatry** 1997 Jun;62(6):609–11

Comparison of utilization of Sinemet and Parkinson's disease mortality as surrogate indicators of Parkinson's disease in the United States. Lanska DJ. **J Neurol Sci** 1997 Jan; 145(1):105–8

Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa. Schwarz J, et al. **J Nucl Med** 1996 Jul;37(7):1112–5

The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease. Asin KE, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):454–9

New treatment for Parkinson's disease. **J R Soc Health** 1997 Jun;117(3):179

Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. **JAMA** 1997 Jul 9;278(2):125–30

Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group [letter] Agid Y, et al. **Lancet** 1997 Sep 6;350(9079):712–3

Zolpidem in Parkinson's disease [letter] [see comments] Daniele A, et al. **Lancet** 1997 Apr 26;349(9060):1222–3. Comment in: Lancet 1997 Jul 5;350(9070):74.

Zolpidem in Parkinson's disease [letter; comment] Lavoisy J, et al. **Lancet** 1997 Jul 5;350(9070):74. Comment on: Lancet 1997 Apr 26;349(9060):1222–3.

Gabapentin and motor fluctuations in Parkinson's disease. Chaná P, et al. **Mov Disord** 1997 Jul;12(4):608

The emerging role of clozapine in the treatment of movement disorders. Factor SA, et al. **Mov Disord** 1997 Jul; 12(4):483–96 (147 ref.)

Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. Gomez Arevalo G, et al. **Mov Disord** 1997 May;12(3):277–84

Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Lyytinen J, et al. **Mov Disord** 1997 Jul;12(4):497–505

Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease. Metman LV, et al. **Mov Disord** 1996 May;11(3):257–60

Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Nutt JG, et al. **Mov Disord** 1997 May;12(3):285–92

Dopa-responsive, nonprogressive juvenile parkinsonism: report of a case. Rajput A, et al. **Mov Disord** 1997 May; 12(3):453–6

Does levodopa therapy delay death in Parkinson's disease? [letter; comment] Uitti RJ, et al. **Mov Disord** 1996 May; 11(3):343–4. Comment on: Mov Disord 1995 May;10(3):250–6.

Newer therapies for Parkinson's disease. Korczyn AD, et al. **Neurol Neurochir Pol** 1996;30 Suppl 2:105–11 (22 ref.)

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Adler CH, et al. **Neurology** 1997 Aug;49(2):393–9

Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Ellis CM, et al. **Neurology** 1997 Aug;49(2):438–44

Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Friedman JH, et al. **Neurology** 1997 Apr;48(4):1077–81

Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Inzelberg R, et al. **Neurology** 1996 Sep;47(3):785–8

Selegiline monotherapy in the treatment of Parkinson's disease. Koller WC. **Neurology** 1996 Dec;47(6 Suppl 3):S196–9 (38 ref.)

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Kurth MC, et al. **Neurology** 1997 Jan;48(1):81–7

Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Lieberman A, et al. **Neurology** 1997 Jul;49(1):162–8

Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Metman LV, et al. **Neurology** 1997 Sep;49(3):711–3

Attempts to obtain neuroprotection in Parkinson's disease. Olanow CW. **Neurology** 1997 Jul;49(1 Suppl 1):S26–33 (87 ref.)

Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Rinne UK, et al. **Neurology** 1997 Feb;48(2):363–8

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Shannon KM, et al. **Neurology** 1997 Sep;49(3):724–8

Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study. Shinotoh H, et al. **Neurology** 1997 May;48(5):1282–5

Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Tulloch IF. **Neurology** 1997 Jul;49(1 Suppl 1):S58–62 (35 ref.)

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Waters CH, et al. **Neurology** 1997 Sep;49(3):665–71

The role of dopamine agonists in early Parkinson's disease. Watts RL. **Neurology** 1997 Jul;49(1 Suppl 1):S34–48 (87 ref.)

Gallium-transferrin binding in treated and untreated Parkinson's disease. Winsper SJ, et al. **Neuroreport** 1997 Feb 10;8(3):709–11

The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Schwarting RK, et al. **Prog Neurobiol** 1996 Oct;50(2-3):275–331 (395 ref.)

New dopamine agonists on the horizon. Heins JR. **S D J Med** 1997 Jul;50(7):239–40

Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Earley CJ, et al. **Sleep** 1996 Dec;19(10):801–10

Persistence of repetitive EEG arousals (K-alpha complexes) in RLS patients treated with L-DOPA. Montplaisir J, et al. **Sleep** 1996 Apr;19(3):196–9

Parkinson's disease: prospects for improved drug therapy. Hagan JJ, et al. **Trends Pharmacol Sci** 1997 May; 18(5):156–63 (76 ref.)

[Clinical trial of the first Polish levodopa preparation in the treatment of Parkinsonian patients] Kuran W, et al. **Neurol Neurochir Pol** 1996 Sep-Oct;30(5):745–50 (Eng. Abstr.) **(Pol)**

[Clinical experience in switching patients from standard levodopa to a controlled-release levodopa] Leiva Santana C, et al. **Neurologia** 1996 Jan;11(1):1–9 (Eng. Abstr.) **(Spa)**

[Pharmacological therapy of complicated Parkinson's disease] Jiménez-Jiménez FJ, et al. **Rev Neurol** 1997 Aug; 25 Suppl 2:S170–9 (249 ref.) (Eng. Abstr.) **(Spa)**

[Neuroprotective and neurorestorative therapy in Parkinson's disease] Jiménez-Jiménez FJ, et al. **Rev Neurol** 1997 Aug; 25 Suppl 2:S185–93 (207 ref.) (Eng. Abstr.) **(Spa)**

[Daily defined doses of parkinsonian drugs in Alcoi] Manzanares R, et al. **Rev Neurol** 1996 Apr;24(128):440–2 (Eng. Abstr.) **(Spa)**

[Treatment of parkinsonism. Views on the recommendations issued by the Medical Products Agency] Olsson JE. **Lakartidningen** 1997 Mar 5;94(10):819–22 (20 ref.) **(Swe)**

TOXICITY

Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Miyoshi Y, et al. **Ann Neurol** 1997 Aug; 42(2):208–14

Toxicokinetic evaluation of a selegiline transdermal system in the dog. Barrett JS, et al. **Biopharm Drug Dispos** 1997 Mar;18(2):165–84

Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. Cheng N, et al. **Brain Res** 1996 Dec 16;743(1-2):278–83

Levodopa induces apoptosis in cultured neuronal cells—a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Ziv I, et al. **Mov Disord** 1997 Jan; 12(1):17–23

Reproductive toxicity of cabergoline in mice, rats, and rabbits. Beltrame D, et al. **Reprod Toxicol** 1996 Nov-Dec; 10(6):471–83

Effect of a dopamine agonist on the development of Leydig cell hyperplasia in Sprague-Dawley rats. Dirami G, et al. **Toxicol Appl Pharmacol** 1996 Nov;141(1):169–77

URINE

Optimization of the hydrolysis of conjugated L-DOPA, dopamine and dihydroxyphenylacetic acid in human urine for assay by high-performance liquid chromatography with electrochemical detection. Tuomainen P, et al. **Eur J Clin Chem Clin Biochem** 1997 Mar;35(3):229–35

ANTIPERISTALTICS see **ANTIDIARRHEALS**

ANTIPHOSPHOLIPID ANTIBODIES see **ANTIBODIES, ANTIPHOSPHOLIPID**

ANTIPHOSPHOLIPID SYNDROME

The clinical significance of antiphospholipid antibodies. Martini A, et al. **Ann Med** 1997 Apr;29(2):159–63

Hemocoagulative pathology and immunological recurrent abortion. Borrelli AL, et al. **Clin Exp Obstet Gynecol** 1997; 24(1):39–40

Autoimmune disease in pregnancy. Systemic lupus erythematosus and antiphospholipid syndrome. Silver RM, et al. **Clin Perinatol** 1997 Jun;24(2):291–320 (240 ref.)

Antiphospholipid thrombosis syndromes: etiology, pathophysiology, diagnosis and management. Bick RL. **Int J Hematol** 1997 Apr;65(3):193–213 (145 ref.)

Antiphospholipid syndrome and pulmonary hypertension [editorial; comment] Kunieda T. **Intern Med** 1996 Nov; 35(11):842–3. Comment on: Intern Med 1996 Nov;35(11):912–5.

Primary antiphospholipid syndrome: indications for long-term anticoagulation. Sengstaken EA. **J Am Board Fam Pract** 1996 Jul-Aug;9(4):282–4

Antiphospholipid antibodies: a threat throughout pregnancy. Hewell SW, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Mar-Apr;26(2):162–8 (30 ref.)

Portal vein thrombosis associated with antiphospholipid antibodies in a child. Brady L, et al. **J Pediatr Gastroenterol Nutr** 1996 Nov;23(4):470–3

New Orleans 7th International Symposium on Antiphospholipid Antibodies. Proceedings and abstracts. **Lupus** 1996 Oct;5(5):343–558

Antiphospholipid antibody syndromes and the Internet. McCarty GA. **Lupus** 1996 Oct;5(5):418–24

Primary antiphospholipid syndrome evolving into systemic lupus erythematosus [letter; comment] Seisdedos L, et al. **Lupus** 1997;6(3):285–6. Comment on: Lupus 1996 Feb;5(1):4–5.

Antiphospholipid antibody syndrome in pediatric patients. Ravelli A, et al. **Rheum Dis Clin North Am** 1997 Aug; 23(3):657–76 (122 ref.)

Antiphospholipid syndrome in pregnancy. Obstetric concerns and treatment. Welsch S, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):71–84 (106 ref.)

Anticardiolipin antibody-associated stroke after liver transplantation. Bronster DJ, et al. **Transplantation** 1997 Mar 27;63(6):908–9

[Antiphospholipid antibodies and antiphospholipid syndrome and their relation with preqnancy-induced hypertension] Zhang X, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Aug;31(8):506–7 (10 ref.) **(Chi)**

[Antiphospholipid syndrome: a syndrome with re-recognition (editorial)] Dong Y. **Chung Hua Nei Ko Tsa Chih** 1996 Jan;35(1):7–8 **(Chi)**

[Catastrophic antiphospholipid syndrome] Le Loët X, et al. **Presse Med** 1997 Feb 8;26(3):131–4 (26 ref.) **(Fre)**

[Catastrophic antiphospholipid syndrome (letter)] Piette JC, et al. **Presse Med** 1997 Mar 22;26(9):421 **(Fre)**

[Clinical significance and predictive value of laboratory tests in thrombosis associated with antiphospolipid antibodies] Barbui T, et al. **Ann Ital Med Int** 1997 Apr-Jun;12(2):76–83 (60 ref.) (Eng. Abstr.) **(Ita)**

[Antiphospholipid antibody syndrome and thrombosis] Matsuda J. **Nippon Naika Gakkai Zasshi** 1997 Jun 10; 86(6):941–6 **(Jpn)**

[Antiphospholipid syndrome] Suzuki K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):432–5 (21 ref.) **(Jpn)**

[Antiphospholipid syndrome] Koniaev BV. **Klin Med (Mosk)** 1997;75(4):52–3 **(Rus)**

BLOOD

Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein s. Reverter JC, et al. **Arterioscler Thromb Vasc Biol** 1996 Nov;16(11):1319–26

Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Cuadrado MJ, et al. **Arthritis Rheum** 1997 May;40(5):834–41

The "lupus" circulating anticoagulant, AKA the primary antiphospholipid syndrome. Rothschild BM. **Compr Ther** 1996 Jul;22(7):420–3 (14 ref.)

Flow cytometric detection of circulating activated platelets in primary antiphospholipid syndrome. Correlation with thrombocytopenia and anticardiolipin antibodies. Fanelli A, et al. **Lupus** 1997;6(3):261–7

Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Branch DW, et al. **Obstet Gynecol** 1997 Apr; 89(4):549–55

Up-regulated tissue factor expression in antiphospholipid syndrome [letter] Atsumi T, et al. **Thromb Haemost** 1997 Jan;77(1):222–3

beta 2 glycoprotein-I inhibits factor XII activation on triglyceride rich lipoproteins: the effect of antibodies from plasma of patients with antiphospholipid syndrome. McNally T, et al. **Thromb Haemost** 1996 Aug;76(2):220–5

Increased plasma thrombomodulin in different subgroups of patients with antiphospholipid and anti beta(2) glycoprotein I antibodies [letter] Martinuzzo ME, et al. **Thromb Haemost** 1996 Jun;75(6):972–3

Nitrite and nitrate plasma levels, as markers of nitric oxide synthesis, in antiphospholipid antibodies-related conditions and in thrombotic thrombocytopenic purpura [letter] Porta C, et al. **Thromb Haemost** 1997 Aug;78(2):965–7

Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies. Zangari M, et al. **Thromb Res** 1997 Feb 1;85(3):177–83

CLASSIFICATION

The concept and classification of antiphospholipid/cofactor syndromes. Alarcón-Segovia D, et al. **Lupus** 1996 Oct; 5(5):364–7 (45 ref.)

1996 diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a "mission impossible"? Piette JC. **Lupus** 1996 Oct;5(5):354–63 (93 ref.)

COMPLICATIONS

Cardiac involvement in connective tissue diseases and primary antiphospholipid syndrome: echocardiographic assessment and correlation with antiphospholipid antibodies. Gabrielli F, et al. **Acta Cardiol** 1996;51(5):425–39

Atypical duodenal ulcer associated with the antiphospholipid antibody syndrome [letter; comment] Cappell MS. **Am J Gastroenterol** 1997 Apr;92(4):722. Comment on: Am J Gastroenterol 1996 Jun;91(6):1244–7.

Anti-phospholipid-antibody syndrome associated with peripheral T-cell lymphoma [letter] Onida P, et al. **Am J Hematol** 1997 Jul;55(3):167–8

Autoimmune hemolytic anemia, primary adrenal insufficiency, and the antiphospholipid syndrome. Hsu B, et al. **Am J Med Sci** 1997 Jul;314(1):41–3

Primary antiphospholipid syndrome and pulmonary hypertension with prolonged survival. A case report. Nagai H, et al. **Angiology** 1997 Feb;48(2):183–7

Successful control of refractory and life-threatening autoimmune hemolytic anemia with intravenous immunoglobulins in a man with the primary antiphospholipid syndrome. Vandenberghe P, et al. **Ann Hematol** 1996 Nov;73(5):253–6

Feasibility of a randomized clinical trial for the prevention of recurrent thrombosis in the antiphospholipid syndrome: the WAPS project. Provisional Steering Committee of the Warfarin in Antiphospholipid Syndrome (WAPS) Study. Finazzi G, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:38–41

Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment. Galli M, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:24–7 (44 ref.)

Antiphospholipid antibodies and the antiphospholipid syndrome. Clinical relevance in neuropsychiatric systemic lupus erythematosus. Alarcón-Segovia D, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:279–88

Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance, and therapeutic options. Feldmann E, et al. **Ann Neurol** 1995 May;37 Suppl 1:S114–30 (172 ref.)

Thrombocytopenia in the antiphospholipid syndrome. Cuadrado MJ, et al. **Ann Rheum Dis** 1997 Mar;56(3):194–6

Antiphospholipid syndrome presenting as episodic limb ischaemia. Evans RE, et al. **Arch Dis Child** 1996 Oct; 75(4):342–3

Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Cuadrado MJ, et al. **Arthritis Rheum** 1997 May;40(5):834–41

Spontaneous thrombosis of the internal jugular vein as the initial presentation of the primary antiphospholipid syndrome. Holland AJ, et al. **Aust N Z J Surg** 1996 Dec; 66(12):854–5

Treatment of pregnant women with recurrent miscarriage associated with phospholipid antibodies. General prognosis is favourable in untreated women [letter; comment] Christiansen OB. **BMJ** 1997 Aug 9;315(7104):372; discussion 373. Comment on: BMJ 1997 Jan 25;314(7076):253–7.

Systemic lupus erythematosus [clinical inference] [see comments] Cockwell P. **BMJ** 1997 Jan 25;314(7076):292–5 . Comment in: BMJ 1997 May 3;314(7090):1349; discussion 1350. Comment in: BMJ 1997 May 3;314(7090):1349–50.

Antiphospholipid (Hughes') syndrome [editorial; comment] Khamashta MA, et al. **BMJ** 1997 Jan 25;314(7076):244. Comment on: BMJ 1997 Jan 25;314(7076):253–7.

Treatment of pregnant women with recurrent miscarriage associated with phospholipid antibodies. No cytogenetic data were reported [letter; comment] Kingdom J, et al. **BMJ** 1997 Aug 9;315(7104):372. Comment on: BMJ 1997 Jan 25;314(7076):253–7.

Systemic lupus erythematosus complicated by antiphospholipid antibody syndrome. Young women should be referred to an obstetrician or gynaecologist [letter; comment] Llewelyn R. **BMJ** 1997 May 3; 314(7090):1349; discussion 1350. Comment on: BMJ 1997 Jan 25;314(7076):292–5.

Treatment of pregnant women with recurrent miscarriage associated with phospholipid antibodies. During pregnancy, heparin should be stopped during labour and then restarted soon after delivery [letter; comment] Piette JC, et al. **BMJ** 1997 Aug 9;315(7104):372–3; discussion 373 . Comment on: BMJ 1997 Jan 25;314(7076):253–7.

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage

associated with phospholipid antibodies (or antiphospholipid antibodies) [see comments] Rai R, et al. **BMJ** 1997 Jan 25;314(7076):253–7. Comment in: BMJ 1997 Jan 25;314(7076):244. Comment in: BMJ 1997 Aug 9;315(7104):372. Comment in: BMJ 1997 Aug 9;315(7104):372; discussion 373. Comment in: BMJ 1997 Aug 9;315(7104):372–3; discussion 373.

Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome. Ho YL, et al. **Cardiology** 1996 Jul–Aug;87(4):354–7

Chorea in primary antiphospholipid syndrome. Masala C, et al. **Clin Neurol Neurosurg** 1996 Aug;98(3):247–8

Widespread cutaneous necrosis associated with antiphospholipid syndrome. Jou IM, et al. **Clin Rheumatol** 1996 Jul;15(4):394–8

The "lupus" circulating anticoagulant, AKA the primary antiphospholipid syndrome. Rothschild BM. **Compr Ther** 1996 Jul;22(7):420–3 (14 ref.)

Antiphospholipid antibodies, infertility and recurrent miscarriage. Rai R, et al. **Curr Opin Obstet Gynecol** 1997 Aug;9(4):279–82

Budd–Chiari syndrome complicating severe preeclampsia in a parturient with primary antiphospholipid syndrome. Segal S, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Sep; 68(1–2):227–9

The lung physician and the antiphospholipid syndrome [editorial; comment] Hillerdal G. **Eur Respir J** 1997 Mar; 10(3):511–2. Comment on: Eur Respir J 1997 Mar;10(3):727–30.

Diffuse microvascular pulmonary thrombosis associated with primary antiphospholipid antibody syndrome [see comments] Maggiorini M, et al. **Eur Respir J** 1997 Mar; 10(3):727–30 (19 ref.). Comment in: Eur Respir J 1997 Mar;10(3):511–2.

Severe bleeding due to acquired hypoprothrombinemia–lupus anticoagulant syndrome. Case report and review of literature. Vivaldi P, et al. **Haematologica** 1997 May–Jun; 82(3):345–7 (26 ref.)

Hepatitis viruses and antiphospholipid autoantibodies [letter; comment] Cheng HM, et al. **Hepatology** 1997 Mar; 25(3):781–2. Comment on: Hepatology 1996 Feb;23(2):199–204.

Hepatitis C virus, antiphospholipid antibodies, and thrombosis [letter; comment] Violi F, et al. **Hepatology** 1997 Mar;25(3):782. Comment on: Hepatology 1996 Feb;23(2):199–204.

Case in point. Bilateral cerebellar infarcts in antiphospholipid syndrome. Ansari A, et al. **Hosp Pract (Off Ed)** 1997 Jul 15;32(7):36

Membranous nephropathy in primary antiphospholipid syndrome: description of a case and induction of renal injury in SCID mice. Levy Y, et al. **Hum Antibodies Hybridomas** 1996;7(3):91–6

Antiphospholipid syndrome complicated by thrombosis of the superior mesenteric artery, co–existence of smooth muscle hyperplasia. Kojima E, et al. **Intern Med** 1997 Jul; 36(7):528–31

Asymptomatic pulmonary hypertension complicated with antiphospholipid syndrome case [see comments] Miyashita Y, et al. **Intern Med** 1996 Nov;35(11):912–5. Comment in: Intern Med 1996 Nov;35(11):842–3.

Widespread cutaneous necrosis and antiphospholipid antibodies: two episodes related to surgical manipulation and urinary tract infection. Del Castillo LF, et al. **J Am Acad Dermatol** 1997 May;36(5 Pt 2):872–5 (15 ref.)

Antiphospholipid syndrome and the skin. Gibson GE, et al. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):970–82 (83 ref.)

A 90–year–old–woman with acute renal failure revealing an antiphospholipid syndrome. Rainfray M, et al. **J Am Geriatr Soc** 1997 Feb;45(2):200–1

Bone marrow necrosis in antiphospholipid syndrome. Paydas S, et al. **J Clin Pathol** 1997 Mar;50(3):261–2

Fulminant encephalopathy due to the catastrophic primary antiphospholipid syndrome [letter] Chinnery PF, et al. **J Neurol Neurosurg Psychiatry** 1997 Mar;62(3):300–1

Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy. Botet F, et al. **J Perinat Med** 1997;25(2):192–6

Cerebral infarction and antiphospholipid syndrome in children. Baca V, et al. **J Rheumatol** 1996 Aug; 23(8):1428–31

Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti–beta 2–glycoprotein–I than with antiphospholipid antibodies. Cabiedes J, et al. **J Rheumatol** 1995 Oct;22(10):1899–906

Catastrophic antiphospholipid antibody syndrome in pediatric systemic lupus erythematosus. Falcini F, et al. **J Rheumatol** 1997 Feb;24(2):389–92

Association of primary antiphospholipid syndrome with primary adrenal insufficiency. González G, et al. **J Rheumatol** 1996 Jul;23(7):1286–7

Graves' disease associated with the primary antiphospholipid syndrome. Hofbauer LC, et al. **J Rheumatol** 1996 Aug; 23(8):1435–7

Thrombolysis for acute ischemic stroke in the primary antiphospholipid syndrome. Julkunen H, et al. **J Rheumatol** 1997 Jan;24(1):181–3

Neonatal antiphospholipid syndrome [letter] Navarro F, et al. **J Rheumatol** 1997 Jun;24(6):1240–1 (17 ref.)

Arthritis in primary antiphospholipid syndrome? [letter; comment] [see comments] Queyrel V, et al. **J Rheumatol** 1996 Jul;23(7):1305–6. Comment on: J Rheumatol 1992 Dec;19(12):1835–7. Comment in: J Rheumatol 1997 Apr;24(4):808–9.

Bilateral adrenal hemorrhage and acute addisonian crisis—a complication of antiphospholipid syndrome. Garris GW, et al. **J Tenn Med Assoc** 1996 Apr;89(4):120

Post–partum dilated cardiomyopathy in anti–phospholipid positive woman. Airoldi ML, et al. **Lupus** 1996 Jun; 5(3):247–50 (14 ref.)

Central vein thrombosis in the antiphospholipid syndrome. Alcazar–Ramirez JD, et al. **Lupus** 1997;6(6):549–51

Thrombosis associated with antiphospholipid antibody in juvenile chronic arthritis. Andrews A, et al. **Lupus** 1997; 6(6):556–7

The catastrophic antiphospholipid syndrome 1996: acute multi–organ failure associated with antiphospholipid antibodies: a review of 31 patients. Asherson RA, et al. **Lupus** 1996 Oct;5(5):414–7

Treatment of neurologic complications of antiphospholipid antibody syndrome. Brey RL, et al. **Lupus** 1996 Oct; 5(5):473–6 (29 ref.)

Antiphospholipid antibodies and retinal vascular disease. Dunn JP, et al. **Lupus** 1996 Aug;5(4):313–22

Cutaneous manifestations of Hughes syndrome occurring in the context of lupus erythematosus. Francès C, et al. **Lupus** 1997;6(2):139–44 (57 ref.)

The syndrome of thrombosis, thrombocytopenia, and recurrent spontaneous abortions associated with antiphospholipid antibodies: Hughes syndrome. Gharavi AE, et al. **Lupus** 1996 Oct;5(5):343–4

Obstetric outcome in antiphospholipid syndrome. Granger KA, et al. **Lupus** 1997;6(6):509–13

Catastrophic haemorrhage in a case of paediatric primary antiphospholipid syndrome and factor II deficiency. Hudson N, et al. **Lupus** 1997;6(1):68–71

The antiphospholipid syndrome. Hughes GR. **Lupus** 1996 Oct;5(5):345–6

Neurological aspects of antiphospholipid antibody syndrome. Levine SR, et al. **Lupus** 1996 Oct;5(5):347–53 (65 ref.)

Clinical manifestations of the aPL syndrome. Levy RA. **Lupus** 1996 Oct;5(5):393–7 (42 ref.)

Vasculopathy of the antiphospholipid syndromes revisited: thrombosis is the culprit and vasculitis the consort. Lie JT. **Lupus** 1996 Oct;5(5):368–71 (40 ref.)

Factor V Arg506—>Gln mutation in patients with antiphospholipid antibodies. Montaruli B, et al. **Lupus** 1996 Aug;5(4):303–6

In vivo models of thrombosis for the antiphospholipid syndrome. Pierangeli SS, et al. **Lupus** 1996 Oct;5(5):451–5 (48 ref.)

Atherosclerosis in SLE and Hughes syndrome [editorial] Vaarala O. **Lupus** 1997;6(6):489–90

Libman–Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Ziporen L, et al. **Lupus** 1996 Jun;5(3):196–205

Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Cervera R, et al. **Medicine (Baltimore)** 1997 May;76(3):203–12 (50 ref.)

Valvular heart disease and systemic lupus erythematosus [letter; comment] McCarthy GM, et al. **N Engl J Med** 1997 May 1;336(18):1324; discussion 1324–5. Comment on: N Engl J Med 1996 Nov 7;335(19):1424–30.

Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. Alsulyman OM, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 2):644–6

Cerebral venous thrombosis and chronic active hepatitis as part of the antiphospholipid syndrome. Kesler A, et al. **Postgrad Med J** 1996 Nov;72(853):690–2

Antiphospholipid syndrome: patterns of life–threatening and severe recurrent vascular complications. Insko EK, et al. **Radiology** 1997 Feb;202(2):319–26

Primary antiphospholipid syndrome with retinal vein occlusion. Treatment with acetylsalicylic acid [letter] Etaouil N, et al. **Rev Rhum Engl Ed** 1997 Feb;64(2):139–40

Acquired protein S deficiency with primary antiphospholipid syndrome and recurrent thrombotic events: report of a case. Salazar–Paramo M, et al. **Rev Rhum Engl Ed** 1995 Dec; 62(11):810–11

Adrenal insufficiency in the antiphospholipid–antibody syndrome [letter; comment] Asherson RA. **Semin Arthritis Rheum** 1996 Aug;26(1):502–3. Comment on: Semin Arthritis Rheum 1995 Oct;25(2):109–16.

Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Nesher G, et al. **Semin Arthritis Rheum** 1997 Aug;27(1):27–35 (42 ref.)

Superior mesenteric artery occlusion and peripheral emboli caused by an aortic ulcer in a young patient with antiphospholipid syndrome. Vahl AC, et al. **Surgery** 1997 May;121(5):588–90

[Portal thrombosis disclosing antiphospholipid syndrome. 2 cases] Bouaniche M, et al. **Gastroenterol Clin Biol** 1996; 20(10):897–900 (Eng. Abstr.) **(Fre)**

[Nodular regenerative hyperplasia associated with primary antiphospholipid syndrome] Cadranel JF, et al. **Gastroenterol Clin Biol** 1996;20(10):901–4 (44 ref.) (Eng. Abstr.) **(Fre)**

[Antiphospholipid antibodies, lupus anticoagulant and thrombosis] Capel P. **Rev Med Brux** 1997 Jun;18(3):108–10 (18 ref.) (Eng. Abstr.) **(Fre)**

[Chondritis of the ears in a patient with primary antiphospholipid syndrome (letter)] Arlet P, et al. **Rev Med Interne** 1997;18(6):496 **(Fre)**

[Ischemic cerebrovascular complication disclosing primary antiphospholipid syndrome and an antithrombin III variant: a coagulation disorder (letter)] Borg JY, et al. **Rev Med Interne** 1996;17(12):1044–5 **(Fre)**

[Antiphospholipid syndrome and atrophic polychondritis (letter)] Piette JC, et al. **Rev Med Interne** 1997;18(2):172–3 **(Fre)**

[Obstetrical complications of antiphospholipid syndrome] Weber JC. **Rev Med Interne** 1997;18(3):240–9 (88 ref.) (Eng. Abstr.) **(Fre)**

[Chronic cor pulmonale after embolism, antiphospholipid syndrome, Horton disease: therapeutic approach apropos of a case] Beynel P, et al. **Rev Pneumol Clin** 1997; 53(3):162–6 (22 ref.) (Eng. Abstr.) **(Fre)**

[Coincident arterial and venous cerebral thrombosis in primary antiphospholipid syndrome] Keller E, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Sep;165(3):300–2 **(Ger)**

[Old, glorious traditional radiology ...] Cerri G, et al. **Radiol Med (Torino)** 1997 Mar;93(3):315–6 **(Ita)**

[A case report on mitral valve replacement associated with antiphospholipid syndrome in systemic lupus erythematosus] Araki Y, et al. **Kyobu Geka** 1997 Jun; 50(6):480–2 (Eng. Abstr.) **(Jpn)**

[A 10–year–old girl with anticardiolipin antibody, who showed bleeding tendency] Kawashima H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun;19(3):244–50 (Eng. Abstr.) **(Jpn)**

[A case of primary antiphospholipid antibody syndrome with severe nephrotic syndrome showing remarkable endothelial cell damage in the capillary lumen] Nakano H, et al. **Nippon Jinzo Gakkai Shi** 1997 May;39(4):431–7 (Eng. Abstr.) **(Jpn)**

[Coping with pathological changes in nerves and blood vessels in collagen disease—antiphospholipid syndrome and thrombosis] Ichikawa K, et al. **Nippon Naika Gakkai Zasshi** 1996 Nov 10;85(11):1828–32 (5 ref.) **(Jpn)**

[Transverse myelitis in a patient with primary antiphospholipid syndrome—a case report] Takamura Y, et al. **No To Shinkei** 1996 Sep;48(9):851–5 (Eng. Abstr.) **(Jpn)**

[Prevalence of thrombosis in secondary antiphospholipid–protein syndrome] Swadźba J, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):310–2 (Eng. Abstr.) **(Pol)**

[Antiphospholipid antibody syndrome in systemic lupus erythematosus] Zmonarski S, et al. **Pol Tyg Lek** 1996 May; 51(19–22):299–302 (35 ref.) (Eng. Abstr.) **(Pol)**

[Anti–endothelial antibodies and defects of heart valves in antiphospholipid syndrome: analysis of pathogenic mechanisms] Nasonov EL, et al. **Klin Med (Mosk)** 1997; 75(2):17–22 **(Rus)**

[Antiphospholipid syndrome in SLE males] Nasonov EL, et al. **Klin Med (Mosk)** 1996;74(4):18–22 **(Rus)**

[Involvement of cardiac valves in antiphospholipid syndrome] Sergakova LM, et al. **Klin Med (Mosk)** 1996; 74(9):39–42 (Eng. Abstr.) **(Rus)**

[Arterial hypertension and the antiphospholipid syndrome] Nasonov EL, et al. **Ter Arkh** 1996;68(2):37–40 (Eng. Abstr.) **(Rus)**

[Pulmonary thromboendarterectomy in a patient with primary antiphospholipid syndrome] Cucurull E, et al. **Med Clin (Barc)** 1996 Apr 6;106(13):498–500 (27 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Antiphospholipid syndrome: a case demonstrating diagnostic challenge [letter] Storek J, et al. **Am J Hematol** 1996 Jul; 52(3):235

The anaesthetist and the antiphospholipid syndrome [see comments] Madan R, et al. **Anaesthesia** 1997 Jan;52(1):72–6 (32 ref.). Comment in: Anaesthesia 1997 Jun;52(6):612.

Frequent difficulties encountered in the laboratory diagnosis of antiphospholipid–protein antibodies. Triplett DA. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:5–9 (29 ref.)

Recognizing antiphospholipid syndrome. Case report: misdiagnosis delayed treatment. Kirk P, et al. **Can Fam Physician** 1996 Feb;42:310–2

Antibodies to beta2–glycoprotein I—a specific marker for the antiphospholipid syndrome. Guerin J, et al. **Clin Exp Immunol** 1997 Aug;109(2):304–9

The neuroimaging features of the cardiolipin antibody syndrome. Weingarten K, et al. **Clin Imaging** 1997 Jan–Feb; 21(1):6–12

Shaded boundaries between antiphospholipid antibodies syndrome and lupus nephritis: low discriminating power of American Rheumatism Association criteria? [letter] Stratta P, et al. **Clin Nephrol** 1997 Feb;47(2):138–40

Polyarteritis nodosa and the antiphospholipid syndrome. Schoonjans R, et al. **Clin Rheumatol** 1996 Jul;15(4):410–3

Melanoderma revealing primary antiphospholipid syndrome. Guibal F, et al. **Dermatology** 1996;192(1):75–7

Antiphospholipid antibodies thrombotic syndrome misdiagnosed as Lucio's phenomenon. Bakos L, et al. **Int J Lepr Other Mycobact Dis** 1996 Sep;64(3):320–3

Antiphospholipid antibodies and the antiphospholipid antibody syndrome. Nahass GT. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):149–68; quiz 169–72 (302 ref.)

Prevention of recurrent fetal loss caused by antiphospholipid

syndrome. Black KD, et al. **J Perinatol** 1996 May–Jun;16(3 Pt 1):181–5 (25 ref.)

Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases [see comments] Berard M, et al. **J Rheumatol** 1996 Aug;23(8):1369–74. Comment in: J Rheumatol 1996 Aug;23(8):1319–22.

Arthritis and primary antiphospholipid syndrome [letter; comment] Hachulla E. **J Rheumatol** 1997 Apr;24(4):808–9 . Comment on: J Rheumatol 1996 Jul;23(7):1305–6.

Antiphospholipid antibody. Babies, blood clots, biology [clinical conference] Lockshin MD. **JAMA** 1997 May 21; 277(19):1549–51

Criteria for antiphospholipid syndrome: early pregnancy loss, fetal loss, or recurrent pregnancy loss? Branch DW, et al. **Lupus** 1996 Oct;5(5):409–13 (31 ref.)

1996 diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a "mission impossible"? Piette JC. **Lupus** 1996 Oct;5(5):354–63 (93 ref.)

Antigenic specificities of antiphospholipid autoantibodies: implications for clinical laboratory testing and diagnosis of the antiphospholipid syndrome. Roubey RA. **Lupus** 1996 Oct;5(5):425–30 (33 ref.)

Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. Angelini L, et al. **Neuropediatrics** 1996 Jun;27(3):149–53

Antiphospholipid syndromes with anti–human beta 2–glycoprotein I antibodies despite negative reactivity in conventional aPL and LA assays [letter] Guérin V, et al. **Thromb Haemost** 1997 May;77(5):1037–8

[Clinical spectrum of the antiphospholipid syndrome] Chábová V, et al. **Cas Lek Cesk** 1997 Apr 16;136(8):253–5 (Eng. Abstr.) **(Cze)**

[Antiphospholipid syndrome and psychosis] Clervoy P, et al. **Encephale** 1997 Mar–Apr;23(2):105–7 (14 ref.) (Eng. Abstr.) **(Fre)**

[Risk of thrombosis with increased anticardiolipin antibodies] Winckelmann G. **Dtsch Med Wochenschr** 1997 Apr 11; 122(15):492–3 **(Ger)**

[A 10–year–old girl with anticardiolipin antibody, who showed bleeding tendency] Kawashima H, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Jun;19(3):244–50 (Eng. Abstr.) **(Jpn)**

[Budd–Chiari syndrome as the presenting form of primary antiphospholipid syndrome (letter)] Garrido JA, et al. **An Med Interna** 1996 Jul;13(7):355–6 **(Spa)**

DRUG THERAPY

Do low–risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Cowchock S, et al. **Am J Obstet Gynecol** 1997 May;176(5):1099–100

Antiphospholipid antibody–associated recurrent pregnancy loss: treatment with heparin and low–dose aspirin is superior to low–dose aspirin alone. Kutteh WH. **Am J Obstet Gynecol** 1996 May;174(5):1584–9

Antiphospholipid syndrome and neurosurgery [letter; comment] Kiyama S. **Anaesthesia** 1997 Jun;52(6):612. Comment on: Anaesthesia 1997 Jan;52(1):72–6.

Randomized trial of aspirin versus aspirin and heparin in pregnant women with the antiphospholipid syndrome] Cohen H. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:44

Potential failure of the International Normalized Ratio (INR) System in the monitoring of oral anticoagulation in patients with lupus anticoagulants. Della Valle P, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:10–4

Systemic lupus erythematosus complicated by antiphospholipid antibody syndrome. Pulse treatment with cyclophosphamide would have been more appropriate [letter; comment] McDermott EM, et al. **BMJ** 1997 May 3;314(7090):1349–50. Comment on: **BMJ** 1997 Jan 25;314(7076):292–5.

Pregnancy outcome. Influence of antiphospholipid antibody titer, prior pregnancy losses and treatment. Reece EA, et al. **J Reprod Med** 1997 Jan;42(1):49–55

Hemorrhagic complications of long–term anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome. al–Sayegh FA, et al. **J Rheumatol** 1997 Sep;24(9):1716–8

Fibrinolytic treatment in primary antiphospholipid syndrome. Camps García MT, et al. **Lupus** 1996 Dec;5(6):627–9

Venous thromboembolism during pregnancy [letter; comment] Lockshin MD. **N Engl J Med** 1996 Dec 12; 335(24):1847. Comment on: N Engl J Med 1996 Jul 11;335(2):108–14.

[Pregnancy in primary antiphospholipid syndrome. Proposal for a common management protocol] el Kouri D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(8):828–31 (Eng. Abstr.) **(Fre)**

[A case of antiphospholipid antibody syndrome successfully treated with prednisolone and low–dose aspirin, with subsequent normal pregnancy] Yamamoto M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Feb;20(1):67–72 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

The association of antibodies to beta 2 glycoprotein I with the antiphospholipid syndrome: a meta–analysis. Najmey SS, et al. **Ann Clin Lab Sci** 1997 Jan–Feb;27(1):41–6

Hughes syndrome: a common problem in Kuwait hospitals. Malaviya AN, et al. **Br J Rheumatol** 1996 Nov; 35(11):1132–6

The antiphospholipid syndrome in childhood [editorial] Ravelli A, et al. **J Rheumatol** 1996 Jul;23(7):1121–2

Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—a meta–analysis. Wahl DG, et al. **Lupus** 1997;6(5):467–73

ETIOLOGY

Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI. García CO, et al. **Am J Reprod Immunol** 1997 Jan; 37(1):118–24

Update in allergy and immunology. Condemi JJ. **Ann Intern Med** 1996 Nov 1;125(9):744–50 (2 ref.)

Oxidized low–density lipoprotein (Ox–LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS). George J, et al. **Clin Exp Immunol** 1997 May;108(2):227–33

Antiphospholipid syndrome associated with cytomegalovirus infection: case report and review. Labarca JA, et al. **Clin Infect Dis** 1997 Feb;24(2):197–200

Thymectomy and autoimmunity [editorial; comment] Bach JF. **Lupus** 1997;6(5):419. Comment on: Lupus 1997 ;6(5):474–6.

Non beta 2–glycoprotein I cofactors for antiphospholipid antibodies. Galli M. **Lupus** 1996 Oct;5(5):388–92 (42 ref.)

beta 2–Glycoprotein I: target antigen for autoantibodies in the 'antiphospholipid syndrome'. Kandiah DA, et al. **Lupus** 1996 Oct;5(5):381–5 (40 ref.)

Pathogenesis of the antiphospholipid antibody syndrome. Lockshin MD. **Lupus** 1996 Oct;5(5):404–8 (43 ref.)

Primary antiphospholipid syndrome emerging following thymectomy for myasthenia gravis: additional evidence for the kaleidoscope of autoimmunity [see comments] Shoenfeld Y, et al. **Lupus** 1997;6(5):474–6. Comment in: Lupus 1997 ;6(5):419.

Genetic risk factors for aPL syndrome. Wilson WA, et al. **Lupus** 1996 Oct;5(5):398–403 (40 ref.)

Pathogenesis and treatment of the antiphospholipid antibody syndrome. Petri M. **Med Clin North Am** 1997 Jan; 81(1):151–77 (222 ref.)

The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin–induced thrombocytopenia [see comments] Arnout J. **Thromb Haemost** 1996 Apr;75(4):536–41 (93 ref.). Comment in: Thromb Haemost 1996 Nov;76(5):817–8.

[Biological autoimmune syndrome with antiphospholipid antibodies in occupational asbestosis (letter)] Vernhes JP, et al. **Rev Med Interne** 1997;18(4):342 **(Fre)**

[Development of deep vein thrombosis in an aplastic anemia patient with antiphospholipid antibodies] Okuda H, et al. **Rinsho Ketsueki** 1996 Nov;37(11):1283–8 (Eng. Abstr.) **(Jpn)**

GENETICS

Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome. Alarcón–Segovia D, et al. **J Rheumatol** 1996 Dec; 23(12):2162–5 (42 ref.)

Histocompatibility genes in antiphospholipid antibody syndrome. Wilson WA. **Lupus** 1996 Aug;5(4):259–62

The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Sebastiani GD, et al. **Semin Arthritis Rheum** 1996 Jun; 25(6):414–20 (38 ref.)

HISTORY

The antiphospholipid/cofactor syndromes [editorial; comment] Alarcón–Segovia D, et al. **J Rheumatol** 1996 Aug;23(8):1319–22. Comment on: J Rheumatol 1996 Aug;23(8):1369–74. Comment on: J Rheumatol 1996 Aug;23(8):1375–9.

IMMUNOLOGY

Prevalence and clinical significance of antiphospholipid antibodies in heart valve disease: a case–control study. Bouillanne O, et al. **Am Heart J** 1996 Oct;132(4):790–5

Antiphospholipid antibody–associated recurrent pregnancy loss: treatment with heparin and low–dose aspirin is superior to low–dose aspirin alone. Kutteh WH. **Am J Obstet Gynecol** 1996 May;174(5):1584–9

Pathogenic antibodies in women with obstetric features of antiphospholipid syndrome who have negative test results for lupus anticoagulant and anticardiolipin antibodies. Silver RM, et al. **Am J Obstet Gynecol** 1997 Mar; 176(3):628–33

Aspirin–interleukin–3 interrelationships in patients with anti–phospholipid syndrome. Fishman P, et al. **Am J Reprod Immunol** 1996 Feb;35(2):80–4

Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI. García CO, et al. **Am J Reprod Immunol** 1997 Jan; 37(1):118–24

Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome. Panzer S, et al. **Ann Hematol** 1997 May;74(5):239–42

Different target specificities of phospholipid–dependent antibodies. Amiral J, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:18–21

Questions–answers about antiphospholipid–protein antibodies and the "antiphospholipid antibody syndrome". Boffa MC, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:54–6

Immunology of the antiphospholipid antibody syndrome. Roubey RA. **Arthritis Rheum** 1996 Sep;39(9):1444–54 (116 ref.)

Comparison of an enzyme–linked immunosorbent assay for antibodies to beta 2–glycoprotein I and a conventional anticardiolipin immunoassay [see comments] Roubey RA, et al. **Arthritis Rheum** 1996 Sep;39(9):1606–7. Comment in: Arthritis Rheum 1996 Sep;39(9):1441–3. Comment in: Arthritis Rheum 1997 Jul;40(7):1366–8.

Tests for heparin–induced thrombocytopenia in primary antiphospholipid syndrome [letter] Lasne D, et al. **Br J Haematol** 1997 Jun;97(4):939

Anti–platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Macchi L, et al. **Br J Haematol** 1997 Aug;98(2):336–41

Lupus anticoagulants: strong association with the major histocompatibility complex class II and platelet antibodies. Panzer S, et al. **Br J Haematol** 1997 Aug;98(2):342–5

Specificity of ELISA for antibody to beta 2–glycoprotein I in patients with antiphospholipid syndrome. Amengual O, et al. **Br J Rheumatol** 1996 Dec;35(12):1239–43

Anti–beta 2–glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome. Teixidó M, et al. **Br J Rheumatol** 1997 Jan;36(1):113–6

Enrichment of antibodies against phospholipids in circulating immune complexes (CIC) in the anti–phospholipid syndrome (APLS). Arfors L, et al. **Clin Exp Immunol** 1997 Apr;108(1):47–51

Hemocoagulative pathology and immunological recurrent abortion. Borrelli AL, et al. **Clin Exp Obstet Gynecol** 1997; 24(1):39–40

Pathogenic role of antiprotein–phospholipid antibodies. Carreras LO, et al. **Haemostasis** 1996 Oct;26 Suppl 4:340–57 (91 ref.)

Antiphospholipid–protein antibodies: clinical use of laboratory test results (identification, predictive value, treatment). Triplett DA. **Haemostasis** 1996 Oct;26 Suppl 4:358–67 (44 ref.)

Defective maternal–fetal interaction in a murine autoimmune model. Tartakovsky B, et al. **Hum Reprod** 1996 Nov; 11(11):2408–11

Anti–beta2–glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant–like activity enhance the beta2GPI binding to phospholipids. Takeya H, et al. **J Clin Invest** 1997 May 1;99(9):2260–8

Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. Ziporen L, et al. **J Clin Invest** 1997 Aug 1; 100(3):613–9

The anti–beta2–glycoprotein I activity in human anti–phospholipid syndrome sera is due to monoreactive low–affinity autoantibodies directed to epitopes located on native beta2–glycoprotein I and preserved during species' evolution. Tincani A, et al. **J Immunol** 1996 Dec 15; 157(12):5732–8

Prevalence and clinical significance of IgG isotype anti–beta 2–glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. Sanmarco M, et al. **J Lab Clin Med** 1997 May; 129(5):499–506

The antiphospholipid/cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to beta 2–glycoprotein I but no antibodies detectable in standard antiphospholipid assays. Alarcon–Segovia D, et al. **J Rheumatol** 1997 Aug;24(8):1545–51

Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti–beta 2–glycoprotein–I than with antiphospholipid antibodies. Cabiedes J, et al. **J Rheumatol** 1995 Oct;22(10):1899–906

Antibodies to phospholipid–free beta 2–glycoprotein–I in patients with primary antiphospholipid syndrome. Cabral AR, et al. **J Rheumatol** 1995 Oct;22(10):1894–8

MHC studies of the primary antiphospholipid ant body syndrome and of antiphospholipid antibodies in systemic lupus erythematosus. Goldstein R, et al. **J Rheumatol** 1996 Jul;23(7):1173–9

Analytical and clinical relationships between human IgG autoantibodies to beta 2 glycoprotein I and anticardiolipin antibodies. El–Kadi HS, et al. **J Rheumatol** 1995 Dec; 22(12):2233–7

On the antiphospholipid/cofactor syndromes [letter] Mercado U. **J Rheumatol** 1997 Aug;24(8):1658–9

Non–Hodgkin's lymphoma presenting with coagulopathy due to anti–phospholipid antibody syndrome. McGuire D, et al. **Leuk Lymphoma** 1997 Jun;26(1–2):193–6

Epilepsy and antiphospholipid antibodies in systemic lupus erythematosus patients [letter; comment] Formiga F, et al. **Lupus** 1997;6(5):486. Comment on: Lupus 1996 Aug;5(4):307–12.

Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA–DR7 in Mexican patients with systemic lupus erythematosus (SLE). Granados J, et al. **Lupus** 1997;6(1):57–62

Association between IgM anticardiolipin antibodies and deep venous thrombosis in patients without systemic lupus erythematosus. Oger E, et al. **Lupus** 1997;6(5):455–61

ANTIPHOSPHOLIPID SYNDROME

Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism [see comments] Rand JH, et al. **N Engl J Med** 1997 Jul 17; 337(3):154–60. Comment in: N Engl J Med 1997 Jul 17;337(3):197–8.

Antibodies to beta 2 glycoprotein I: standardized immunoassay and a reference interval for healthy controls. Najmey SS, et al. **Proc Assoc Am Physicians** 1996 Nov; 108(6):467–72

Isolation and purification of anticardiolipin antibody from plasma of a patient with antiphospholipid syndrome: induced generation of platelet thromboxane A2 synthesis. Leung S, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Dec; 55(6):385–93

The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Sebastiani GD, et al. **Semin Arthritis Rheum** 1996 Jun; 25(6):414–20 (38 ref.)

Species specificity of anti-beta 2 glycoprotein I autoantibodies and its relevance to anticardiolipin antibody quantitation. Arvieux J, et al. **Thromb Haemost** 1996 May; 75(5):725–30

Relationship of lupus anticoagulant, anticardiolipin, anti-beta2-GPI and anti-prothrombin autoantibodies with history of thrombosis in patients with the clinical suspicion of APA-syndrome [letter] D'Angelo A, et al. **Thromb Haemost** 1997 Aug;78(2):967–8

Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Forastiero RR, et al. **Thromb Haemost** 1996 May;75(5):717–20

The pathogenesis of the antiphospholipid syndrome [letter; comment] Greaves M, et al. **Thromb Haemost** 1996 Nov; 76(5):817–8. Comment on: Thromb Haemost 1996 Apr;75(4):536–41.

Antiphospholipid syndromes with anti-human beta 2-glycoprotein I antibodies despite negative reactivity in conventional aPL and LA assays [letter] Guérin V, et al. **Thromb Haemost** 1997 May;77(5):1037–8

Antiphospholipid-protein antibodies are not an uncommon feature in retinal venous occlusions. Coniglio M, et al. **Thromb Res** 1996 Jul 15;83(2):183–8

[Autoimmune habitual abortion] Nouza K, et al. **Ceska Gynekol** 1996 Oct;61(5):310–6 **(Cze)**

[Antiphospholipid antibody/cofactors. What are they? Why, when and how to search for them? Is treatment justified?] Piette JC, et al. **Ann Med Interne (Paris)** 1996;147(7):492–7 (36 ref.) (Eng. Abstr.) **(Fre)**

[Risk of thrombosis with increased anticardiolipin antibodies] Winckelmann G. **Dtsch Med Wochenschr** 1997 Apr 11; 122(15):492–3 **(Ger)**

[Antiphospholipid antibodies syndrome: follow-up of patients with a high antiphospholipid antibodies titer] Urfer C, et al. **Schweiz Med Wochenschr** 1996 Dec 7; 126(49):2136–40 (17 ref.) (Eng. Abstr.) **(Ger)**

[Systemic lupus erythematosus and antiphospholipid syndrome] Gröne HJ. **Verh Dtsch Ges Pathol** 1996;80:21–37 (71 ref.) (Eng. Abstr.) **(Ger)**

[A study on antiprothrombin antibodies in antiphospholipid syndrome] Ieko M, et al. **Rinsho Ketsueki** 1997 May; 38(5):426–32 (Eng. Abstr.) **(Jpn)**

[Evan's syndrome with antiphospholipid-protein antibodies] Frołow M, et al. **Pol Merkuriusz Lek** 1996 Nov;1(5):344–5 (Eng. Abstr.) **(Pol)**

[Antiendothelial antibodies in systemic lupus erythematosus in men: the connection with kidney involvement and the antiphospholipid syndrome] Nasonov EL, et al. **Ter Arkh** 1996;68(6):46–9 **(Rus)**

[Antiphospholipid antibodies and neurological disorders. Types and mechanisms] Viñets C, et al. **Rev Neurol** 1996 Oct;24(134):1224–8 (42 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Ruiz-Argüelles GJ, et al. **Blood Coagul Fibrinolysis** 1996 Apr;7(3):344–8

Antiphospholipid antibody: functional specificity for inhibition of prothrombin activation by the prothrombinase complex. Pierangeli SS, et al. **Br J Haematol** 1997 Jun; 97(4):768–74

Influence of degraded phosphatidylserine on binding of antiphospholipid antibodies. Božič B, et al. **Int Arch Allergy Immunol** 1997 Jan;112(1):19–26

Activation of endothelial cells in thrombosis and vasculitis. Cockwell P, et al. **Scand J Rheumatol** 1997;26(3):145–50 (58 ref.)

Discordant effects on eicosanoids and fibrin degradation products in two murine models of antiphospholipid antibody. Schorer AE. **Thromb Res** 1997 Feb 15; 85(4):295–304

PATHOLOGY

Dramatic vasculopathy in a patient with antiphospholipid syndrome [letter] Lalova A, et al. **Acta Derm Venereol** 1996 Sep;76(5):406

Fatal cerebral venous thrombosis as the initial manifestation of the antiphospholipid syndrome. Agah R, et al. **Clin Neurol Neurosurg** 1996 May;98(2):189–91

Malignant hypertension and antiphospholipid syndrome [letter] Sirvent AE, et al. **Nephron** 1996;73(2):368–9

Abnormal cerebral blood flow associated with antiphospholipid antibody syndrome--four case reports. Oyama H, et al. **Neurol Med Chir (Tokyo)** 1997 Jan; 37(1):41–8

Placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome. Salafia CM, et al. **Rheum Dis Clin North Am** 1997 Feb;23(1):85–97 (72 ref.)

[Systemic lupus erythematosus and antiphospholipid syndrome] Gröne HJ. **Pathologe** 1996 Nov;17(6):405–16 (71 ref.) (Eng. Abstr.) **(Ger)**

[Systemic lupus erythematosus and antiphospholipid syndrome] Gröne HJ. **Verh Dtsch Ges Pathol** 1996;80:21–37 (71 ref.) (Eng. Abstr.) **(Ger)**

[Primary antiphospholipid antibody syndrome with left atrial intracardiac thombosis] Amato S, et al. **G Ital Cardiol** 1997 Apr;27(4):380–6 (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Case report: thoracic aorta thrombus with systemic embolization: a rare paraneoplastic antiphospholipid syndrome? Messiaen T, et al. **Am J Med Sci** 1996 Dec; 312(6):303–5

Possible pathogenetic role of activated platelets in the primary antiphospholipid syndrome involving the central nervous system. Emmi L, et al. **Ann N Y Acad Sci** 1997 Aug 14;823:188–200

A study of sixty pregnancies in patients with the antiphospholipid syndrome. Lima F, et al. **Clin Exp Rheumatol** 1996 Mar-Apr;14(2):131–6

Clinical features associated with a positive anticardiolipin antibody in Irish patients with systemic lupus erythematosus. Gourley IS, et al. **Clin Rheumatol** 1996 Sep; 15(5):457–60

Brain vascular changes in the case of primary antiphospholipid syndrome. Szpak GM, et al. **Folia Neuropathol** 1996;34(2):92–6

Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. Ziporen L, et al. **J Clin Invest** 1997 Aug 1; 100(3):613–9

Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome. Alarcón-Segovia D, et al. **J Rheumatol** 1996 Dec; 23(12):2162–5 (42 ref.)

PREVENTION & CONTROL

Immunosuppression and immunomodulation of experimental models of systemic lupus erythematosus and antiphospholipid syndrome. Shoenfeld Y, et al. **Transplant Proc** 1996 Dec;28(6):3096–8 (33 ref.)

RADIOGRAPHY

A patient with haemoptysis, rapidly changing pulmonary infiltrates and left flank pain. Lai YP, et al. **Eur Respir J** 1996 Oct;9(10):2184–7

Aortic occlusion in a patient with antiphospholipid antibody syndrome in systemic lupus erythematosus. Soubrier M, et al. **Int Angiol** 1995 Sep;14(3):233–5

THERAPY

The anaesthetist and the antiphospholipid syndrome [see comments] Madan R, et al. **Anaesthesia** 1997 Jan;52(1):72–6 (32 ref.). Comment in: Anaesthesia 1997 Jun;52(6):612.

Immunointerventions in experimental model for antiphospholipid syndrome. Krause I, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:50–3 (22 ref.)

Management of the antiphospholipid syndrome. Main trends, unsolved questions, practical and educational aspects. Piette JC, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:28–31 (32 ref.)

Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years. Neuwelt CM, et al. **Arthritis Rheum** 1997 Aug;40(8):1534–9

Management of the Hughes syndrome [editorial] Hunt BJ, et al. **Clin Exp Rheumatol** 1996 Mar-Apr;14(2):115–7 (30 ref.)

Management of immune thrombocytopenic purpura associated with the antiphospholipid antibody syndrome. Leuzzi RA, et al. **Clin Exp Rheumatol** 1997 Mar-Apr; 15(2):197–200

Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome. Pengo V, et al. **Clin Rheumatol** 1996 Sep;15(5):504–7

Treatment of systemic lupus erythematosus and antiphospholipid syndrome: from experimental models to patients' bedside. Krause I, et al. **Int Arch Allergy Immunol** 1996 Dec;111(4):355–61 (51 ref.)

Prevention of recurrent fetal loss caused by antiphospholipid syndrome. Black KD, et al. **J Perinatol** 1996 May-Jun;16(3 Pt 1):181–5 (25 ref.)

Prevention of fetal death in the antiphospholipid antibody syndrome. Cowchock S. **Lupus** 1996 Oct;5(5):467–72 (59 ref.)

Antiphospholipid antibody syndrome: treatment. Espinoza LR. **Lupus** 1996 Oct;5(5):456–7

Management of thrombosis in the antiphospholipid syndrome. Khamashta MA. **Lupus** 1996 Oct;5(5):463–6 (43 ref.)

Immunomodulation of experimental APS: lessons from murine models. Krause I, et al. **Lupus** 1996 Oct;5(5):458–62 (44 ref.)

Animal models for antiphospholipid syndrome in pregnancy. Ziporen L, et al. **Rheum Dis Clin North Am** 1997 Feb; 23(1):99–117 (90 ref.)

[Antiphospholipid syndrome. A better codified treatment (editorial)] Piette JC, et al. **Presse Med** 1997 Feb 8; 26(3):108–9 (Eng. Abstr.) **(Fre)**

[Primary antiphospholipid antibody syndrome in pregnancy--successful pregnancy outcome after intravenous immunoglobulin administration] Rosen AC, et al. **Geburtshilfe Frauenheilkd** 1996 Aug;56(8):410–3 (Eng. Abstr.) **(Ger)**

ANTIPLASMIN

Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets. Hevessy Z, et al. **Thromb Haemost** 1996 Jan;75(1):161–7

The influence of 6-AHA on the fibrin clot degradation initiated by streptokinase in normal and alpha 2-antiplasmin-deficient plasma. Andrianov SL, et al. **Ukr Biokhim Zh** 1996 Jul-Aug;68(4):26–7

ANALYSIS

Evaluation of chromogenic substrate assays for fibrinolytic analytes in dogs. Lanevschi A, et al. **Am J Vet Res** 1996 Aug;57(8):1124–30

[Changes in the activation markers of blood coagulation and fibrinolysis in the neonatal period] Ries M, et al. **Klin Padiatr** 1996 Nov-Dec;208(6):350–4 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Assignment of a single disulphide bridge in human alpha2-antiplasmin: implications for the structural and functional properties. Christensen S, et al. **Biochem J** 1997 May 1;323 (Pt 3):847–52

DEFICIENCY

Severe postadenoidectomy bleeding revealing congenital alpha 2 antiplasmin deficiency in a child. Paqueron X, et al. **Anesth Analg** 1997 May;84(5):1147–9

[Hemorrhagic syndrome and isolated alpha 2-antiplasmin deficiency. Apropos of a case] Guermazi S, et al. **Pathol Biol (Paris)** 1997 Jun;45(6):483–6 (Eng. Abstr.) **(Fre)**

[Mechanisms of impaired secretion in patients with the deficiency of alpha 2-plasmin inhibitor] Hirosawa S. **Rinsho Byori** 1997 Feb;Suppl 104:195–202 **(Jpn)**

IMMUNOLOGY

Functional characterization of monoclonal antibody inhibitors of alpha 2-antiplasmin that accelerate fibrinolysis in different animal plasmas. Reed GL. **Hybridoma** 1997 Jun; 16(3):281–6

ISOLATION & PURIFICATION

Presence in bovine milk of two protease inhibitors of the plasmin system. Precetti AS, et al. **J Dairy Sci** 1997 Aug; 80(8):1490–6

METABOLISM

alpha 2-Antiplasmin and plasminogen activator inhibitors in healing human skin wounds. Schaefer BM, et al. **Arch Dermatol Res** 1996 Mar;288(3):122–8

High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. Taguchi O, et al. **Clin Chim Acta** 1996 Jan 15;244(1):69–81

Determinants of substrate specificity for factor XIII. McDonagh J, et al. **Semin Thromb Hemost** 1996; 22(5):369–76 (47 ref.)

Experimental haemorrhage and blood component transfusion in humans: no change in plasma concentration of thrombin-antithrombin complex and plasmin-antiplasmin complex. Henriksson AE, et al. **Thromb Res** 1996 Jun 1; 82(5):409–15

PHARMACOLOGY

Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism. Butte AN, et al. **Circulation** 1997 Apr 1;95(7):1886–91

ANTIPLASMINS see **ANTIFIBRINOLYTIC AGENTS**

ANTIPLATELET AGENTS see **PLATELET AGGREGATION INHIBITORS**

ANTIPLATYHELMINTIC AGENTS

ADMINISTRATION & DOSAGE

Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. Guisse F, et al. **Am J Trop Med Hyg** 1997 May;56(5):511–4

A case of refractory schistosomiasis [letter] [see comments]

Murray-Smith SQ, et al. **Med J Aust** 1996 Oct 21; 165(8):458. Comment in: Med J Aust 1997 May 19;166(10):567; discussion 568. Comment in: Med J Aust 1997 May 19;166(10):568.
A case of refractory schistosomiasis [letter; comment] Prociv P. **Med J Aust** 1997 May 19;166(10):568. Comment on: Med J Aust 1996 Oct 21;165(8):458.

ADVERSE EFFECTS

Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. Jaoko WG, et al. **East Afr Med J** 1996 Aug;73(8):499-501
Large cerebral infarction during praziquantel therapy in neurocysticercosis [see comments] Bang OY, et al. **Stroke** 1997 Jan;28(1):211-3. Comment in: Stroke 1997 May;28(5):1088. Comment in: Stroke 1997 Aug;28(8):1648-9.
Clues to prevent cerebrovascular hazards of cysticidal drug therapy [letter; comment] Del Brutto OH. **Stroke** 1997 May;28(5):1088. Comment on: Stroke 1997 Jan;28(1):211-3.
Caution with praziquantel in neurocysticercosis [letter; comment] Fong GC, et al. **Stroke** 1997 Aug;28(8):1648-9 . Comment on: Stroke 1997 Jan;28(1):211-3.

BLOOD

High-performance liquid chromatography determination of praziquantel enantiomers in human serum using a reversed-phase cellulose-based chiral stationary phase and disc solid-phase extraction. Liu J, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):141-7

CHEMICAL SYNTHESIS

[The technology for manufacturing antiparasitic preparations. 6. The development of a technology for producing the anthelmintic Azinox (praziquantel) and the evaluation of its toxic and anthelmintic properties] Mikhallitsyn FS, et al. **Med Parazitol (Mosk)** 1996 Oct-Dec;(4):36-9 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Jung H, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1256-9

PHARMACOLOGY

Praziquantel has no direct effect on (Na(+)+K+)-ATPases and (Ca2(+)-Mg2+)ATPases of Schistosoma mansoni. Cunha VM, et al. **Life Sci** 1997;60(20):PL 289-94
The immunopathology of human Schistosomiasis-III. Immunoglobulin isotype profiles and response to praziquantel. Ramírez RM, et al. **Mem Inst Oswaldo Cruz** 1996 Sep-Oct;91(5):593-9
Effect of praziquantel and liposome-incorporated praziquantel on peritoneal macrophage activation in mice infected with Mesocestoides corti tetrathyridia (Cestoda). Hrčkova G, et al. **Parasitology** 1997 May;114 (Pt 5):475-82
Opisthorchis viverrini: effect of praziquantel on the adult tegument. Apinhasmit W, et al. **Southeast Asian J Trop Med Public Health** 1996 Jun; 27(2):304-11

POISONING

[How the Similia principle of homeopathy resolved an emergency. Case history of ivermectin poisoning in a Collie (see comments)] Opmeer RJ. **Tijdschr Diergeneeskd** 1997 Jan 15;122(2):36-9; discussion 40 (Eng. Abstr.). Comment in: Tijdschr Diergeneeskd 1997 Mar 1;122(5):133; discussion 134. Comment in: Tijdschr Diergeneeskd 1997 Mar 1;122(5):134. Comment in: Tijdschr Diergeneeskd 1997 Mar 15;122(6):164. Comment in: Tijdschr Diergeneeskd 1997 Mar 15;122(6):220. **(Dut)**

THERAPEUTIC USE

Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Horton RJ. **Acta Trop** 1997 Apr 1;64(1-2):79-93 (36 ref.)
Reversibility of lower reproductive tract abnormalities in women with Schistosoma haematobium infection after treatment with praziquantel--an interim report. Richter J, et al. **Acta Trop** 1996 Dec 30;62(4):289-301
Praziquantel in the treatment of Schistosoma mansoni infection: comparison of 40 and 60 mg/kg bodyweight regimens. Abu-Elyazeed RR, et al. **Am J Trop Med Hyg** 1997 Apr;56(4):404-7
Opisthorchis viverrini infection in Thailand: studies on the morbidity of the infection and resolution following praziquantel treatment. Pungpak S, et al. **Am J Trop Med Hyg** 1997 Mar;56(3):311-4
The impact of passive chemotherapy on Schistosoma mansoni prevalence and intensity of infection in the Egyptian Nile Delta. El Sayed MK, et al. **Am J Trop Med Hyg** 1997 Sep;57(3):266-71
Day-to-day variation of egg output and schistosome circulating antigens in urine of Schistosoma haematobium-infected school children from Gabon and follow-up after chemotherapy. Van Etten L, et al. **Am J Trop Med Hyg** 1997 Sep;57(3):337-41
Chemotherapy with praziquantel has the potential to reduce the prevalence of Echinococcus multilocularis in wild foxes (Vulpes vulpes). Schelling U, et al. **Ann Trop Med Parasitol** 1997 Mar;91(2):179-86
Acute cysticercal meningitis in children: response to praziquantel. Visudhiphan P, et al. **Ann Trop Paediatr** 1997 Mar;17(1):9-13
Evaluation of scolicidal agents in an experimental hydatid disease model. Landa García JI, et al. **Eur Surg Res** 1997; 29(3):202-8
Praziquantel therapy in neurocysticercosis. Aggarwal SP, et al. **J Assoc Physicians India** 1995 May;43(5):356-7
Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle. Proaño JV, et al. **J Neurosurg** 1997 Jul;87(1):29-33
A case of refractory schistosomiasis [letter; comment] Hipgrave DB. **Med J Aust** 1997 May 19;166(10):567; discussion 568. Comment on: Med J Aust 1996 Oct 21;165(8):458.
BCG and praziquantel for Schistosomiasis treatment. Viana L de G, et al. **Mem Inst Oswaldo Cruz** 1996 Sep-Oct; 91(5):637
Antigen detection assay to monitor the efficacy of praziquantel for treatment of Paragonimus westermani infections. Zhang Z, et al. **Trans R Soc Trop Med Hyg** 1996 Jan-Feb;90(1):43
Antibody and circulating antigen profiles before and after chemotherapy in goats infected with Fasciola gigantica. Mbuh JV, et al. **Vet Parasitol** 1996 Nov 15;66(3-4):171-9
Worming of dogs in mid-Wales for Echinococcus granulosus [letter] Llayd S, et al. **Vet Rec** 1997 May 3;140(18):487-8
[Pseudotumor form of hepatic distomatosis: successful treatment with praziquantel] Queneau PE, et al. **Gastroenterol Clin Biol** 1997;21(6-7):511-3 (Eng. Abstr.) **(Fre)**
[The results of an experimental study of an anti-Opisthorchis preparation made from plant raw material] Mefod'ev VV, et al. **Med Parazitol (Mosk)** 1996 Jul-Sep;(3):42-5 (Eng. Abstr.) **(Rus)**

TOXICITY

Experimental Schistosoma bovis infection in goats: pathological consequences of praziquantel treatment. Johansen MV, et al. **J Comp Pathol** 1996 Jul;115(1):1-11

ANTIPORT see **ION TRANSPORT**

ANTIPORTERS

A rapid anion exchange high-performance liquid chromatography method for the measurement of HbA2 in whole blood. Keevil BG, et al. **Ann Clin Biochem** 1996 May;33 (Pt 3):253-6
[Erythrocyte anion exchanger, band epsilon protein: structure and function] Hamasaki N. **Nippon Rinsho** 1996 Mar; 54(3):618-24 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Bacterial drug extruding antiporter] Yamaguchi A. **Tanpakushitsu Kakusan Koso** 1997 Jun;42(8):1253-62 (34 ref.) **(Jpn)**

ANALYSIS

Na+/Ca2+ exchanger in epithelial cells of the porcine cortical thick ascending limb. Dai LJ, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):F411-8
Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Medina JF, et al. **Hepatology** 1997 Jan;25(1):12-7
Angiotensin-converting enzyme (ACE) gene polymorphism and the erythrocyte sodium-lithium countertransporter (SLC) phenotype in hypertension [see comments] Hardman TC, et al. **J Hum Hypertens** 1996 Jun;10(6):429-30. Comment in: J Hum Hypertens 1997 Apr;11(4):251-2.
Erythrocyte Na(+)-Li+ countertransport in essential hypertension: correlation with membrane lipids levels. Villar J, et al. **J Hypertens** 1996 Aug;14(8):969-73

ANTAGONISTS & INHIBITORS

Protection of perfused lung from oxidant injury by inhibitors of anion exchange. Nozik-Grayck E, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):L296-304
A novel compound, 1,1-dimethyl-5(1-hydroxypropyl)-4,6,7-trimethylindan, is an effective inhibitor of the tet(K) gene-encoded metal-tetracycline/H+ antiporter of Staphylococcus aureus. Hirata T, et al. **FEBS Lett** 1997 Jul 28;412(2):337-40
Cross talk of bumetanide-sensitive and HCO3--dependent transporters activated by IBMX in renal epithelial A6 cells. Niisato N, et al. **J Membr Biol** 1997 May 1;157(1):53-61

BIOSYNTHESIS

Thyroid hormone stimulates Na(+)-Ca2+ exchanger expression in rat cardiac myocytes. Hojo Y, et al. **J Cardiovasc Pharmacol** 1997 Jan;29(1):75-80
The prostaglandin transporter is widely expressed in ocular tissues. Schuster VL, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S41-5

BLOOD

Membrane cation and anion transport activities in erythrocytes of hereditary spherocytosis: effects of different membrane protein defects. De Franceschi L, et al. **Am J Hematol** 1997 Jul;55(3):121-8
Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in subjects with coronary artery disease. Hardman TC, et al. **Am J Hypertens** 1996 Feb;9(2):184-7
A biometrical study of the relationship between sodium-lithium countertransport and triglycerides. Stengård JH, et al. **Ann Hum Genet** 1997 Mar;61 (Pt 2):121-36
Comparison of methods for measurement of Na+/U+ countertransport across the erythrocyte membrane [letter] van Norren K, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):1090-2
Genetic polymorphisms and erythrocyte sodium-lithium countertransport in essential hypertension. Tournoy KG, et al. **Clin Chim Acta** 1996 Nov 15;255(1):39-55
Catamenial variations in erythrocyte sodium-lithium countertransport and blood pressure. Adebayo GI, et al. **Clin Sci (Colch)** 1997 Jul;93(1):29-34
Nisoldipine blocks the increase of intracellular free calcium-ion concentration associated with elevated sodium-lithium countertransport activity in erythrocytes in patients with NIDDM. Fujita J, et al. **Diabet Med** 1997 Jun;14(6):499-502
Elevated erythrocyte sodium-lithium counter-transport in hypertensive patients with non-insulin-dependent diabetes mellitus. Senda T, et al. **Diabetes Res Clin Pract** 1996 Mar; 31(1-3):37-44
Elevated sodium-lithium countertransport activity in erythrocytes is predictive of the development of microalbuminuria in IDDM. Monciotti CG, et al. **Diabetologia** 1997 Jun;40(6):654-61
Controversies surrounding erythrocyte sodium-lithium countertransport [see comments] Hardman TC, et al. **J Hypertens** 1996 Jun;14(6):695-703 (81 ref.). Comment in: J Hypertens 1996 Sep;14(9):1153-4.
Risk factors for left ventricular hypertrophy: role of Na(+)-Li+ countertransport. Neves PL, et al. **Kidney Int Suppl** 1996 Jun;55:S160-2
Kinetic behavior of the erythrocyte sodium-lithium countertransporter in nonnephropathic diabetic twins. Hardman TC, et al. **Metabolism** 1996 Oct;45(10):1203-7

CHEMISTRY

Determination of a transmembrane segment using cysteine-scanning mutants of transposon Tn10-encoded metal-tetracycline/H+ antiporter. Kimura T, et al. **Biochemistry** 1996 Dec 10;35(49):15896-9
Implications of aging- and degeneration-related changes in anion exchange proteins for the maintenance of neuronal homeostasis. Bosman GJ, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Nov;42(7):905-18
Membrane topology of the metal-tetracycline/H+ antiporter TetA(K) from Staphylococcus aureus. Ginn SL, et al. **J Bacteriol** 1997 Jun;179(11):3786-9

DRUG EFFECTS

A study of the temporal effect of alcohol on human erythrocyte sodium-lithium countertransport in relation to membrane cholesterol and phospholipids. Adebayo GI, et al. **Alcohol** 1996 Nov-Dec;13(6):597-602
Thyroid hormone stimulates Na(+)-Ca2+ exchanger expression in rat cardiac myocytes. Hojo Y, et al. **J Cardiovasc Pharmacol** 1997 Jan;29(1):75-80

GENETICS

Variant chicken kidney AE1 anion exchanger transcripts are derived from a single promoter by alternative splicing. Cox KH, et al. **Gene** 1996 Sep 16;173(2):221-6
A Tn10 derivative (T-POP) for isolation of insertions with conditional (tetracycline-dependent) phenotypes. Rappleye CA, et al. **J Bacteriol** 1997 Sep;179(18):5827-34
Copper-specific transcriptional repression of yeast genes encoding critical components in the copper transport pathway. Labbé S, et al. **J Biol Chem** 1997 Jun 20; 272(25):15951-8
Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). Lu R, et al. **J Clin Invest** 1996 Sep 1;98(5):1142-9
Localized domains of DNA supercoiling: topological coupling between promoters. Mojica FJ, et al. **Mol Microbiol** 1996 Dec;22(5):919-28

ISOLATION & PURIFICATION

Functional identity of a purified proximal tubule anion exchanger protein: mediation of chloride/formate and chloride/bicarbonate exchange. Soleimani M, et al. **Kidney Int** 1996 Dec;50(6):1914-21
Purification of the Tn10-specified tetracycline efflux antiporter TetA in a native state as a polyhistidine fusion protein. Aldema ML, et al. **Mol Microbiol** 1996 Jan; 19(1):187-95

METABOLISM

Sodium lithium countertransport and blood pressure. Longitudinal findings. Trevisan M, et al. **Am J Hypertens** 1996 Nov;9(11):1132-5
Theoretical and experimental discrimination between Cl(-)-H+ symporters and Cl-/OH- antiporters. Alvarado F, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1612-28
Role of kinases and phosphatases in the regulation of fluid secretion and Cl-/HCO3- exchange in cholangiocytes.

ANTIPORTERS

Alvaro D, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):G303–13

Regulation of AE2 Cl–/HCO3– exchanger during intestinal development. Chow A, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G330–7

Anion exchanger AE1 as a candidate pathway for taurine transport in rat erythrocytes. Conejero C. **Am J Physiol** 1997 May;272(5 Pt 1):C1457–64

Different effect of cold storage and rewarming on three pH regulating transporters in isolated rat hepatocytes. Forestal DA, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):G638–45

Ion transport systems in human labial acinar cells. Paulais M, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):G213–9

Autosomal dominant polycystic kidney disease decreases anion exchanger activity. Perrone RD, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1748–56

An electroneutral anion exchange mechanism is present in brush-border membranes isolated from eel kidney. Vilella S, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1143–8

Modes of operation of an electroneutral Na+/Li+ countertransport in human skin fibroblasts. Zerbini G, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1373–9

Bicarbonate/chloride exchange and intracellular pH throughout preimplantation mouse embryo development. Zhao Y, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1512–20

K+/NH4+ antiporter: a unique ammonium carrying transporter in the kidney inner medulla. Amlal H, et al. **Biochim Biophys Acta** 1997 Jan 31;1323(2):319–33

Increase in force of contraction by activation of the Na+/Ca(2+)-exchanger in human myocardium. Müller-Ehmsen J, et al. **Br J Clin Pharmacol** 1997 Apr; 43(4):399–405

Erythrocyte Li-Na countertransport in uremic patients: effect of urea. Sun YF, et al. **Chin J Physiol** 1996; 39(3):177–81

Baseline sodium-lithium countertransport and 6-year incidence of hypertension. The Gubbio Population Study. Laurenzi M, et al. **Circulation** 1997 Feb 4;95(3):581–7

Raised affinity for extracellular sodium of the sodium–lithium countertransporter is associated with a family history of hypertension and uraemia in patients with renal disease. Carr SJ, et al. **Clin Sci (Colch)** 1997 May;92(5):497–503

Sodium–lithium countertransport, sodium–hydrogen exchange and membrane microviscosity in patients with hyperlipidaemia. MacLeod MJ, et al. **Clin Sci (Colch)** 1997 Mar;92(3):237–46

The mechanism of proline/glutamate antiport in rat kidney mitochondria. Energy dependence and glutamate–carrier involvement. Atlante A, et al. **Eur J Biochem** 1996 Oct 1;241(1):171–7

Assay of human erythrocyte sodium-dependent lithium efflux: the importance of timing of blood sampling. Adebayo GI, et al. **Eur J Clin Invest** 1996 Feb;26(2):131–5

The pH-dependent reciprocal changes in contributions of ADP/ATP antiporter and aspartate/glutamate antiporter to the fatty acid–induced uncoupling. Samartsev VN, et al. **FEBS Lett** 1997 Jul 21;412(1):179–82

Na(+)-dependent and -independent Cl–/HCO–3 exchange mediate cellular HCO3– transport in cultured human intrahepatic bile duct cells. Strazzabosco M, et al. **Hepatology** 1997 Apr;25(4):976–85

Survival during exposure to the electrophilic reagent N-ethylmaleimide in Escherichia coli: role of KefB and KefC potassium channels. Ferguson GP, et al. **J Bacteriol** 1997 Feb;179(4):1007–12

A Ni2+ binding motif is the basis of high affinity transport of the Alcaligenes eutrophus nickel permease. Eitinger T, et al. **J Biol Chem** 1997 Jul 4;272(27):17139–44

Excretion and uptake of putrescine by the PotE protein in Escherichia coli. Kashiwagi K, et al. **J Biol Chem** 1997 Mar 7;272(10):6318–23

Antiport-driven sulfate secretion in an invertebrate epithelium. Gerencser GA, et al. **J Exp Zool** 1996 Jul 1; 275(4):269–76 (58 ref.)

Electrogenic sulfate/chloride exchange in Xenopus oocytes mediated by murine AE1 E699Q. Chernova MN, et al. **J Gen Physiol** 1997 Mar;109(3):345–60

Angiotensin-I converting enzyme (ACE) gene polymorphism and the erythrocyte sodium–lithium countertransport in hypertension [letter; comment] Delanghe J, et al. **J Hum Hypertens** 1997 Apr;11(4):251–2 . Comment on: J Hum Hypertens 1996 Jun;10(6):429–30.

Kinetic properties of erythrocyte Na+–Li+ and Na+–H+ exchange in hypertensive patients. Semplicini A, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1566–70

Relationship between sodium–lithium countertransport and insulin sensitivity in mild hypertension. Herlitz H, et al. **J Intern Med** 1996 Mar;239(3):235–40

Renal cortical basolateral Na+/HCO3– cotransporter: IV. Characterization and localization with polyclonal antibodies. Bernardo AA, et al. **J Membr Biol** 1996 Nov; 154(2):155–62

Angiotensin II receptor type I–regulated anion secretion in cystic fibrosis pancreatic duct cells. Chan HC, et al. **J Membr Biol** 1997 Apr 1;156(3):241–9

Intracellular pH regulation in cultured microglial cells from mouse brain. Faff L, et al. **J Neurosci Res** 1996 Nov 1; 46(3):294–304

The neurotoxin 1-methyl-4-phenylpyridinium is a substrate for the canalicular organic cation/H+ exchanger. Moseley RH, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):34–40

Is resting state HCO3– secretion in frog gastric fundus mucosa mediated by apical Cl(–)-HCO3– exchange? Caroppo R, et al. **J Physiol (Lond)** 1997 Mar 15;499 (Pt 3):763–71

Regulation of AE1 anion exchanger and H(+)-ATPase in rat cortex by acute metabolic acidosis and alkalosis. Sabolić I, et al. **Kidney Int** 1997 Jan;51(1):125–37

The rate of transbilayer movement of erythrocyte membrane cholesterol is correlated with sodium–lithium countertransport. Muriana FJ, et al. **Life Sci** 1996; 59(23):1945–9

Structural determinants of substrates for the prostaglandin transporter PGT. Itoh S, et al. **Mol Pharmacol** 1996 Oct; 50(4):738–42

Measures of tubular function in normoalbuminuric insulin-dependent diabetic patients and their relationship with sodium lithium countertransport activity. Catalano C, et al. **Nephron** 1996;73(4):613–8

Nigericin-induced Na+/H+ and K+/H+ exchange in synaptosomes: effect on [3H]GABA release. Rodríguez R, et al. **Neurochem Res** 1996 Aug;21(8):889–95

Assessment of evidence for K+–H+ exchange in isolated type-1 cells of neonatal rat carotid body. Richmond PH, et al. **Pflugers Arch** 1997 Aug;434(4):429–37

A new class of plastidic phosphate translocators: a putative link between primary and secondary metabolism by the phosphoenolpyruvate/phosphate antiporter. Fischer K, et al. **Plant Cell** 1997 Mar;9(3):453–62

The purified Bacillus subtilis tetracycline efflux protein TetA(L) reconstitutes both tetracycline–cobalt/H+ and Na+(K+)/H+ exchange. Cheng J, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14446–51

A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Ortmann B, et al. **Science** 1997 Aug 29;277(5330):1306–9

Transporters of nucleotide sugars, nucleotide sulfate and ATP in the Golgi apparatus. Abeijon C, et al. **Trends Biochem Sci** 1997 Jun;22(6):203–7 (30 ref.)

PHARMACOLOGY

Anion exchange proteins and regulation of intracellular pH in cultured rat astrocytes and neurones. Bosman GJ, et al. **Neuroreport** 1997 Jan 20;8(2):427–30

PHYSIOLOGY

Regulation of GLUT1-mediated sugar transport by an antiport/uniport switch mechanism. Cloherty EK, et al. **Biochemistry** 1996 Oct 8;35(40):13231–9

Regulation of intracellular pH in rat lactotrophs: involvement of anionic exchangers. Garcia L, et al. **Endocrinology** 1997 Oct;138(10):4191–8

Role of the Na(+)-Ca2+ and Na(+)-H+ antiporters in prolactin release from anterior pituitary cells in primary culture. Di Renzo G, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):11–5

Involvement of neuronal anion exchange proteins in cell death in Alzheimer's disease. Bosman GJ, et al. **Gerontology** 1997;43(1-2):67–78

Influence of heat on Na(+)-dependent HCO3–/Cl– exchanger function in a thermoresistant cell line. Liu FF, et al. **Int J Radiat Biol** 1996 Oct;70(4):481–9

Sodium–lithium countertransport [letter; comment] Siffert W, et al. **J Hypertens** 1996 Sep;14(9):1153–4. Comment on: J Hypertens 1996 Jun;14(6):695–703.

Na–dependent regulation of intracellular free magnesium concentration in isolated rat ventricular myocytes. Handy RD, et al. **J Mol Cell Cardiol** 1996 Aug;28(8):1641–51

Intestinal brush-border membrane transport of monocarboxylic acids mediated by proton–coupled transport and anion antiport mechanisms. Tamai I, et al. **J Pharm Pharmacol** 1997 Jan;49(1):108–12

Reactive oxygen species involved in the glutamate toxicity of C6 glioma cells via xc antiporter system. Mawatari K, et al. **Neuroscience** 1996 Jul;73(1):201–8

Intracellular pH and heat sensitivity in two human cancer cell lines. Li JH, et al. **Radiother Oncol** 1997 Jan;42(1):69–76

[Na+ –Ca2+ exchanger] Matsuda T, et al. **Nippon Rinsho** 1996 Mar;54(3):612–7 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Bacterial resistance mechanisms for tetracyclines] Yamaguchi A. **Nippon Rinsho** 1997 May;55(5):1245–51 (15 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Membrane topology of the transposon 10–encoded metal–tetracycline/H+ antiporter as studied by site–directed chemical labeling. Kimura T, et al. **J Biol Chem** 1997 Jan 3;272(1):580–5

ANTIPROTOZOAL AGENTS

ADMINISTRATION & DOSAGE

Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Gangneux JP, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1214–8

Influence of foliage from African multipurpose trees on activity of rumen protozoa and bacteria. Newbold CJ, et al. **Br J Nutr** 1997 Aug;78(2):237–49

Synergism of IL–2–stimulated splenocytes and Pentostam enhances the killing of Leishmania donovani in vitro. Eslami Z, et al. **Clin Immunol Immunopathol** 1996 Oct; 81(1):74–81

Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Martinez S, et al. **Clin Infect Dis** 1997 Feb; 24(2):165–9

Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin–12 production. Li J, et al. **Infect Immun** 1997 Aug;65(8):3225–30

Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Tallab TM, et al. **Int J Dermatol** 1996 Aug;35(8):594–7

Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. Banerjee G, et al. **J Antimicrob Chemother** 1996 Jul;38(1):145–50

Treatment of visceral leishmaniasis with a 10 day course of L–ampB–LRC (Bombay), a liposomal amphotericin B. Bodhe PV, et al. **J Assoc Physicians India** 1996 Mar; 44(3):222

Liposomes as drug delivery system in leishmaniasis. Kshirsagar NA, et al. **J Assoc Physicians India** 1995 Jan; 43(1):46–8 (16 ref.)

Action of pentamidine–bound nanoparticles against Leishmania on an in vivo model. Fusai T, et al. **Parasite** 1994 Dec;1(4):319–24

Nebulisers for patients with HIV infection and AIDS. Miller RF, et al. **Thorax** 1997 Apr;52 Suppl 2:S60–3

Successful treatment of visceral leishmaniasis with high–dose amphotericin B diluted in fat emulsion: a case report. Herbrecht R, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):322–3

Glucantime dosage [letter; comment] Marsden PD, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):332. Comment on: Trans R Soc Trop Med Hyg 1995 Sep–Oct;89(5):476–7.

Topical chemotherapy for experimental murine African CNS–trypanosomiasis: the successful use of the arsenical, melarsoprol, combined with the 5–nitroimidazoles, fexinidazole or MK–436. Jennings FW, et al. **Trop Med Int Health** 1996 Oct;1(5):590–8

The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial. Slappendel RJ, et al. **Vet Q** 1997 Mar;19(1):10–3

[Lambliasis—a treatment responsive complication of Crohn disease] Scheurlen C. **Fortschr Med** 1996 Feb 20; 114(5):53–4 **(Ger)**

[Treatment of toxoplasmosis retinochoroiditis with atovaquone in an immunocompetent patient] Hudde T, et al. **Klin Monatsbl Augenheilkd** 1996 Oct;209(4):232–6 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Increased risk of toxoplasmic encephalitis in human immunodeficiency virus–infected patients with pyrimethamine–related rash. ANRS 005–ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS–INSERM) and the NIAID–AIDS Clinical Trials Group. Rousseau F, et al. **Clin Infect Dis** 1997 Mar; 24(3):396–402

Pentavalent antimonial–induced torsade de pointes. Ortega–Carnicer J, et al. **J Electrocardiol** 1997 Apr; 30(2):143–5

Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis. Hantson P, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):869–71

Conduction defect following pentavalent antimony therapy in visceral leishmaniasis [letter] Ahasan HA, et al. **Trop Doct** 1997 Jan;27(1):59–61

[Pancreatitis during treatment of leishmaniasis with n–methylglucamine antimoniate in a subject infected with HIV] Trinchieri V, et al. **Riv Eur Sci Med Farmacol** 1996 Mar–Apr;18(2):49–51 (Eng. Abstr.) **(Ita)**

ANALYSIS

Liquid chromatographic determination of monensin in premix and animal feeds: collaborative study. Coleman MR, et al. **J AOAC Int** 1997 Jul–Aug;80(4):693–702

Determination of pentamidine in serum and urine by micellar electrokinetic chromatography. Garzón MJ, et al. **J Chromatogr B Biomed Appl** 1997 Jan 10;688(1):135–42

High–performance liquid chromatographic assay detects pentamidine metabolism by Fisher rat liver microsomes. Tuttle RH, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):319–24

Stability studies and high–performance liquid chromatographic procedures for L–648,548 and its major degradates in an animal health formulation. Faulkner AJ, et al. **J Pharm Biomed Anal** 1997 Jan;15(4):523–36

Pentamidine aerosols and environmental contamination: health–care workers at risk. Ros JJ, et al. **Pharm World Sci** 1996 Aug;18(4):148–52

BLOOD

Determination of the potent antiprotozoal compound atovaquone in plasma using liquid–liquid extraction followed by reversed–phase high–performance liquid chromatography with ultraviolet detection. Hannan SL, et al. **J Chromatogr B Biomed Appl** 1996 Apr 12; 678(2):297–302

Rapid and selective analysis of secnidazole in human plasma

using high-performance liquid chromatography with ultraviolet detection. Ravi SK, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):208–11

Determination of sinefungin in rat plasma by high-performance liquid chromatography. Tharasse-Bloch C, et al. **J Chromatogr B Biomed Appl** 1995 Dec 15; 674(2):247–52

CHEMICAL SYNTHESIS

[Synthesis and antiparasitic activity of new N-alkyl derivatives of 1-(nitrophenyl)-3-(methyl-3-indolyl)-prop-2-ene-1-ones (nitroindolylchalcones)] Kirkiacharian S, et al. **Ann Pharm Fr** 1996;54(6):272–5 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Cephalosporin-pentamidine isethionate incompatibilities [letter] Lewis JD, et al. **Am J Health Syst Pharm** 1996 Jun 15;53(12):1461–2

Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines. Gamage SA, et al. **J Med Chem** 1997 Aug 1;40(16):2634–42

[Physico-chemical characteristics of meglumine antimoniate in different storage conditions] Romero GA, et al. **Rev Soc Bras Med Trop** 1996 Sep–Oct;29(5):461–5 (Eng. Abstr.) **(Por)**

ISOLATION & PURIFICATION

A new quassinoid from Castela texana. Dou J, et al. **J Nat Prod** 1996 Jan;59(1):73–6

New prenylated quinones from Peperomia galioides. Mahiou V, et al. **J Nat Prod** 1996 Jul;59(7):694–7

Two new antiprotozoal 5-methylcoumarins from Vernonia brachycalyx. Oketch-Rabah HA, et al. **J Nat Prod** 1997 May;60(5):458–61

METABOLISM

A cellular mechanism for imidocarb retention in edible bovine tissues. Moore AS, et al. **Toxicol Lett** 1996 Oct; 87(2–3):61–8

Evaluation of certain veterinary drug residues in food. Forty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives. **World Health Organ Tech Rep Ser** 1996;864:1–62 (118 ref.)

Synthesis, isolation and identification of glucuronides and mercapturic acids of a novel antiparasitic agent, licochalcone A. Nadelmann L, et al. **Xenobiotica** 1997 Jul; 27(7):667–80

PHARMACOKINETICS

Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Heinemann V, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1275–80

Disposition of atovaquone in humans. Rolan PE, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1319–21

Tissue concentration of dimetridazole in laying hens. Posyniak A, et al. **Food Addit Contam** 1996 Nov-Dec; 13(8):871–7

Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers. Stockis A, et al. **Int J Clin Pharmacol Ther** 1996 Aug;34(8):349–51

Pharmacokinetics and anti-trichomonal efficacy of a dimetridazole tablet and water-soluble powder in homing pigeons (Columba livia). Inghelbrecht S, et al. **J Vet Pharmacol Ther** 1996 Feb;19(1):62–7

Activation of tinidazole, an antiprotozoal drug to a mutagen by mammalian liver S9. Gupta RL, et al. **Mutat Res** 1996 Oct 1;370(3–4):195–201

Disposition of intravenous 123iodopentamidine in man. Thomas SH, et al. **Nucl Med Biol** 1997 May;24(4):327–32

PHARMACOLOGY

Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Lux H, et al. **Adv Exp Med Biol** 1996;416:201–11

Antileishmanial activity of rac-1-dodecyl-2-octanamido-2-deoxy-glycerophosphocholine, a new dialkylglycerophosphocholine, in vitro. Bourass J, et al. **Ann Trop Med Parasitol** 1996 Oct;90(5):559–61

The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Didier A, et al. **Anticancer Drugs** 1996 Sep;7(7):745–51

An axenic amastigote system for drug screening. Callahan HL, et al. **Antimicrob Agents Chemother** 1997 Apr; 41(4):818–22

Potential use of WR6026 as prophylaxis against transfusion-transmitted American trypanosomiasis. Chiari E, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):613–5

Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro. Didier ES. **Antimicrob Agents Chemother** 1997 Jul;41(7):1541–6

Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Ephros M, et al. **Antimicrob Agents Chemother** 1997 May; 41(5):1064–8

In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Faraut-Gambarelli F, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):827–30

Use of a fluorescent probe to assess the activities of candidate agents against intracellular forms of Encephalitozoon microsporidia. Leitch GJ, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):337–44

Activity and mode of action of acridine compounds against Leishmania donovani. Mesa-Valle CM, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):684–90

In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii. Romand S, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2015–20

In vitro activity and biochemical effectiveness of new organometallic complexes of osmium(III) against Leishmania donovani and Trypanosoma cruzi. Castilla JJ, et al. **Arzneimittelforschung** 1996 Oct;46(10):990–6

Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. Davis JD, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):246–8

In vivo quantification of muscle damage in dogs after intramuscular administration of drugs. Aktas M, et al. **Br Vet J** 1995 Mar-Apr;151(2):189–96

Leishmania (V.) guyanensis: isolation and characterization of glucantime-resistant cell lines. Ferreira-Pinto KC, et al. **Can J Microbiol** 1996 Sep;42(9):944–9

Assessment of amphotericin B susceptibility in Leishmania infantum promastigotes by flow cytometric membrane potential assay. Azas N, et al. **Cytometry** 1997 Jun 1; 28(2):165–9

Inhibition of complete development of Cryptosporidium parvum in Caco-2 cells [letter] Egraz-Bernard M, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):897–900

In vivo interference of paromomycin with mitochondrial activity of Leishmania. Maarouf M, et al. **Exp Cell Res** 1997 May 1;232(2):339–48

Leishmania infantum promastigotes: flow cytometry as a possible tool for assessing the effects of drugs on cellular functions. Azas N, et al. **Exp Parasitol** 1997 Sep;87(1):1–7

Synthesis and antiparasitic activities of amidinic azolated derivatives. Danan A, et al. **Farmaco** 1997 Apr;52(4):227–9

Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. Oliva G, et al. **J Antimicrob Chemother** 1995 Dec;36(6):1013–9

Polyamine metabolism as a therapeutic target for Microsporidia. Coyle C, et al. **J Eukaryot Microbiol** 1996 Sep-Oct;43(5):96S

Evolutionary origins of Microsporidia and basis for benzimidazole sensitivity: an update. Edlind T, et al. **J Eukaryot Microbiol** 1996 Sep-Oct;43(5):109S

Lovastatin inhibits interferon-gamma-induced Trypanosoma brucei brucei proliferation: evidence for mevalonate pathway involvement. Andersson M, et al. **J Interferon Cytokine Res** 1996 Jun;16(6):435–9

Therapeutic efficacy of atovaquone against the bovine intraerythrocytic parasite, Babesia divergens. Pudney M, et al. **J Parasitol** 1997 Apr;83(2):307–10

Induction of albendazole resistance in Giardia lamblia. Lindquist HD. **Microb Drug Resist** 1996 Winter;2(4):433–4

Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in beta-tubulin. Upcroft J, et al. **Microb Drug Resist** 1996 Fall;2(3):303–8

The potential effects of new synthetic drugs against Leishmania amazonensis and Trypanosoma cruzi. Canto-Cavalheiro MM, et al. **Microbios** 1997;90(362):51–60

Ultrastructural changes in parasites induced by nanoparticle-bound pentamidine in a Leishmania major/mouse model. Fusai T, et al. **Parasite** 1997 Jun; 4(2):133–9

Altered transport properties of pentamidine-resistant Leishmania donovani and L. amazonensis promastigotes. Basselin M, et al. **Parasitol Res** 1997;83(5):413–8

In vitro sensitivity of Leishmania donovani to organometallic derivatives of pentamidine. Mbongo N, et al. **Parasitol Res** 1997;83(5):515–7

Activity of IFN-gamma in experimental Leishmania infantum murine visceral leishmaniasis. Garin YJ, et al. **Pathol Biol (Paris)** 1997 Jan;45(1):48–51

Antileishmanial effect of a potent S-adenosylmethionine decarboxylase inhibitor: CGP 40215A. Mukhopadhyay R, et al. **Pharmacol Res** 1996 Jan;33(1):67–70

Biological activities of buddlejasaponin isolated from Buddleja madagascariensis and Scrophularia scorodonia. Emam AM, et al. **Pharmazie** 1997 Jan;52(1):76–7

Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Darkin-Rattray SJ, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13143–7

Jun NH2-terminal kinase is constitutively activated in T cells transformed by the intracellular parasite Theileria parva. Galley Y, et al. **Proc Natl Acad Sci U S A** 1997 May 13; 94(10):5119–24

Prophylactic activity of imidocarb against experimental infection with Babesia canis. Vercammen F, et al. **Vet Parasitol** 1996 Jun;63(3–4):195–8

[Synthesis and antiparasitic activity of new N-alkyl derivatives of 1-(nitrophenyl)-3-(methyl-3-indolyl)-prop-2-ene-1-ones (nitroindolylchalcones)] Kirkiacharian S, et al. **Ann Pharm Fr** 1996;54(6):272–5 (Eng. Abstr.) **(Fre)**

[Susceptibility to chemotherapeutic agents of Schistosoma mansoni isolates from patients treated with oxamniquine and praziquantel and not cured] Araújo N, et al. **Rev Soc Bras Med Trop** 1996 Sep–Oct;29(5):467–76 (Eng. Abstr.) **(Por)**

POISONING

Early antimoniate poisoning in a non-fatal visceral leishmaniasis kidney transplant recipient with renal failure [letter; comment] Esteban RJ, et al. **Nephrol Dial Transplant** 1996 Sep;11(9):1898. Comment on: Nephrol Dial Transplant 1991;6(10):736–8.

THERAPEUTIC USE

Allopurinol therapy in post-kala-azar dermal leishmaniasis [letter] Ramesh V. **Acta Derm Venereol** 1996 Jul; 76(4):328–9

Atovaquone is effective treatment for the symptoms of gastrointestinal microsporidiosis in HIV-1-infected patients. Anwar-Bruni DM, et al. **AIDS** 1996 Jun; 10(6):619–23

Treatment of isosporiasis with combined albendazole and ornidazole in patients with AIDS [letter] Dionisio D, et al. **AIDS** 1996 Sep;10(11):1301–2

Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. Katlama C, et al. **AIDS** 1996 Sep;10(10):1107–12

Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients [letter] Pérez-Molina JA, et al. **AIDS** 1996 Feb;10(2):237–8

Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals [letter; comment] Pérez-Molina JA, et al. **Am J Med** 1997 Jan;102(1):132. Comment on: Am J Med 1996 May;100(5):496–501.

Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Doumbo O, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):637–9

Migration of Leishmania donovani amastigotes in the cerebrospinal fluid. Prasad LS, et al. **Am J Trop Med Hyg** 1996 Dec;55(6):652–4

Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis. Roberts WL, et al. **Am J Trop Med Hyg** 1996 Oct;55(4):444–6

Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Velez I, et al. **Ann Intern Med** 1997 Feb 1;126(3):232–6

Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum. Buffet PA, et al. **Ann Trop Med Parasitol** 1996 Jun; 90(3):295–302

Albendazole as a treatment for Giardia infection. Pungpak S, et al. **Ann Trop Med Parasitol** 1996 Oct;90(5):563–5

Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis. Araujo FG, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):188–90

In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Faraut-Gambarelli F, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):827–30

Evaluation of selected antiprotozoal drugs in the Babesia microti-hamster model. Marley SE, et al. **Antimicrob Agents Chemother** 1997 Jan;41(1):91–4

Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis. Murray HW, et al. **Antimicrob Agents Chemother** 1996 Mar; 40(3):586–7

Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice. Sarciron ME, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1531–6

Antimicrobial therapy: toward the future [published erratum appears in Br J Hosp Med 1997 Feb 19-Mar 4;57(4):172] Ellis R, et al. **Br J Hosp Med** 1996 Aug 21-Sep 3; 56(4):145–50 (13 ref.)

Acanthamoeba keratitis: risk factors and outcome [letter; comment] Hay J, et al. **Br J Ophthalmol** 1996 Aug;80(8):773 . Comment on: Br J Ophthalmol 1995 Dec;79(12):1078–82.

Chemotherapy of parasitic diseases. Current status and new directions. Liu Y. **Chin Med J (Engl)** 1996 Aug; 109(8):579–82 (28 ref.)

Treatment of New World cutaneous and mucosal leishmaniases. Berman JD. **Clin Dermatol** 1996 Sep–Oct; 14(5):519–22

Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. Torres RA, et al. **Clin Infect Dis** 1997 Mar;24(3):422–9

Activity of compounds isolated from Chilean lichens against experimental cutaneous leishmaniasis. Fournet A, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jan;116(1):51–4

Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. Araujo FG, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):394–7

Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine. Seal D, et al. **Eye** 1996;10 (Pt 4):413–21

A clinical-parasitological monotherapy cure in the treatment

of experimental infection by a highly virulent strain of Toxoplasma gondii. de Diego JA, et al. **Folia Microbiol (Praha)** 1996;41(6):513–6

The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Frayha GJ, et al. **Gen Pharmacol** 1997 Feb; 28(2):273–99 (132 ref.)

Giardiasis and amebiasis in southern Iran [letter] Mirdehghan MM. **Indian Pediatr** 1996 May;33(5):431–2

Itraconazole and leishmaniasis: a randomised double–blind trial in cutaneous disease. Dogra J, et al. **Int J Parasitol** 1996 Dec;26(12):1413–5

Arsenical pessaries in the treatment of metronidazole–resistant Trichomonas vaginalis [letter] Walker PP, et al. **Int J STD AIDS** 1997 Jul;8(7):473

Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients [letter] Petit N, et al. **J Antimicrob Chemother** 1996 Jul; 38(1):154–7

Ketoconazole in antimonial unresponsive cases of Kala–azar. Jha TK, et al. **J Assoc Physicians India** 1995 May;43(5):347

Leishmania donovanib – knocking the door [editorial; comment] Kamath S, et al. **J Assoc Physicians India** 1995 May;43(5):315–6. Comment on: J Assoc Physicians India 1995 May;43(5):319–20.

Combination therapy in Kala–azar [see comments] Singh NK, et al. **J Assoc Physicians India** 1995 May;43(5):319–20. Comment in: J Assoc Physicians India 1995 May;43(5):315–6.

Gamma interferon in the treatment of Kala–azar and other forms of Leishmaniasis. Sundar S, et al. **J Assoc Physicians India** 1995 May;43(5):348–50 (31 ref.)

The efficacy of ivermectin in treating rabbits experimentally infected with Eimeria as indicated parasitologically and histologically. Arafa MA, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):773–80

Effect of ivermectin on combined intestinal protozoal infection (giardiasis and cryptosporidiosis). Youssef MY, et al. **J Egypt Soc Parasitol** 1996 Dec;26(3):543–53

Evaluation of the activities of rifabutin combined with atovaquone or low–dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model. Brun–Pascaud M, et al. **J Eukaryot Microbiol** 1996 Sep–Oct;43(5):14S–15S

Avermectins and milbemycins. McKellar QA, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):331–51 (223 ref.)

Occlusive paromomycin for cutaneous leishmaniasis [see comments] Bell SA, et al. **Lancet** 1997 Jan 4;349(9044):29 . Comment in: Lancet 1997 May 17;349(9063):1477.

Occlusive paromomycin for cutaneous leishmaniasis [letter; comment] Bryceson AD. **Lancet** 1997 May 17; 349(9063):1477. Comment on: Lancet 1997 Jan 4;349(9044):29.

Old–world leishmaniasis of the auricle. Skevas A, et al. **Lancet** 1997 Jan 4;349(9044):28–9

Outcome of acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. Duguid IG, et al. **Ophthalmology** 1997 Oct;104(10):1587–92

The control of ichthyophthiriasis by a medicated food containing quinine: efficacy tests and ultrastructure investigations. Schmahl G, et al. **Parasitol Res** 1996; 82(8):697–705

Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Oliveira–Neto MP, et al. **Pathol Biol (Paris)** 1997 Jun;45(6):496–9

Evaluation of aminosidine sulphate in mucosal leishmaniasis due to Leishmania (Viannia) braziliensis. Romero GA. **Rev Soc Bras Med Trop** 1996 Sep–Oct;29(5):509 **(Eng, Por)**

Onchocerca volvulus: striking decrease in transmission in the Vina valley (Cameroon) after eight annual large scale ivermectin treatments. Boussinesq M, et al. **Trans R Soc Trop Med Hyg** 1997 Jan–Feb;91(1):82–6

Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis. Castagnola E, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):317–8

Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Gangneux JP, et al. **Trans R Soc Trop Med Hyg** 1996 Sep–Oct;90(5):574–7

Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. Nonata R, et al. **Trans R Soc Trop Med Hyg** 1997 Jan–Feb;91(1):77

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose–finding study. Thakur CP, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):319–22

First report of invasive amebiasis in an organ transplant recipient. Palau LA, et al. **Transplantation** 1997 Sep 27; 64(6):936–7

Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis. Poli A, et al. **Vet Parasitol** 1997 Aug;71(4):263–71

Prophylactic treatment of experimental canine babesiosis (Babesia canis) with doxycycline. Vercammen F, et al. **Vet Parasitol** 1996 Nov 15;66(3–4):251–5

A general review on the prevention and treatment of Theileria annulata in China. Zhang ZH. **Vet Parasitol** 1997 Jun;70(1–3):77–81 (0 ref.)

Use of dimetridazole in gamebirds [letter; comment] Dalton P. **Vet Rec** 1996 Oct 19;139(16):399. Comment on: Vet Rec 1996 Aug 31;139(9):214–5.

Effect of four therapeutic agents on Trichomonas phasiani carriage in pheasants [see comments] Pennycott TW. **Vet Rec** 1996 Aug 31;139(9):214–5. Comment in: Vet Rec 1996 Oct 19;139(16):399.

Duration of persistence of injectable avermectins against sucking lice of cattle. Titchener RN, et al. **Vet Rec** 1996 Oct 5;139(14):345–6

[Facial cutaneous leishmaniasis from a vacation to the south] Király C. **Duodecim** 1995;111(12):1104–6 **(Fin)**

[Leishmaniasis in dogs in Germany: epidemiological case analysis and alternatives to conventional causal therapy] Gothe R, et al. **Tierarztl Prax** 1997 Jan;25(1):68–73 (Eng. Abstr.) **(Ger)**

[Treatment of american cutaneous leishmaniasis, with lesions in the mucosa, using pentamidine isethionate] Amato VS, et al. **Rev Soc Bras Med Trop** 1996 Sep–Oct;29(5):477–81 (Eng. Abstr.) **(Por)**

[Preliminary activities of the program for the control and treatment of onchocerciasis in the Yanomâmi territory, Roraima, Brazil] Coelho GE, et al. **Rev Soc Bras Med Trop** 1996 Jan–Feb;30(1):69–72 (Eng. Abstr.) **(Por)**

[Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis] Correia D, et al. **Rev Soc Bras Med Trop** 1996 Sep–Oct;29(5):447–53 (Eng. Abstr.) **(Por)**

[A therapeutic trial in Giardia muris infection in the mouse with metronidazole, tinidazole, secnidazole and furazolidone] Cruz CC, et al. **Rev Soc Bras Med Trop** 1997 May–Jun;30(3):223–8 (Eng. Abstr.) **(Por)**

[Open therapeutic study with aminosidine sulfate in mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis] Romero GA, et al. **Rev Soc Bras Med Trop** 1996 Nov–Dec; 29(6):557–65 (Eng. Abstr.) **(Por)**

[Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B] Sampaio RN, et al. **Rev Soc Bras Med Trop** 1997 Mar–Apr; 30(2):125–8 (Eng. Abstr.) **(Por)**

[Randomized study comparing the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children] Romero–Cabello R, et al. **Rev Latinoam Microbiol** 1995 Oct–Dec;37(4):315–23 (Eng. Abstr.) **(Spa)**

TOXICITY

Pentamidine–induced free radical toxicity to isolated islet cells [letter] Johansson AM, et al. **AIDS** 1996 Jun; 10(6):684–5

Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Sereno D, et al. **Antimicrob Agents Chemother** 1997 May;41(5):972–6

Safety pharmacology of a combination of tinidazole and oxyphenonium bromide. Joseph T, et al. **Arzneimittelforschung** 1997 Jul;47(7):869–72

Ecotoxicity of the avermectins: a reply to Forbes. Herd R. **Int J Parasitol** 1996 May;26(5):571–2

Simple detection of in vivo genotoxicity of pyrimethamine in rodents by the modified alkaline single–cell gel electrophoresis assay. Sasaki YF, et al. **Mutat Res** 1997 Aug 14;392(3):251–9

Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Mukhopadhyay R, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10383–7

URINE

Liquid chromatography–tandem mass spectrometry applied to a study of the metabolism of pentamidine. Discussion of possibilities and problems. Nordin J, et al. **J Chromatogr A** 1997 Aug 8;777(1):73–9

ANTIPRURITICS

ADVERSE EFFECTS

Systemic contact dermatitis to hydroxyzine [see comments] Ash S, et al. **Am J Contact Dermat** 1997 Mar;8(1):2–5. Comment in: Am J Contact Dermat 1997 Mar;8(1):1.

Allergic contact dermatitis from doxepin cream [letter; comment] Rapaport MJ. **Arch Dermatol** 1996 Dec; 132(12):1516–8. Comment on: Arch Dermatol 1996 May;132(5):515–8.

Allergic contact dermatitis due to 5% doxepin cream. Bilbao I, et al. **Contact Dermatitis** 1996 Oct;35(4):254–5

ANALYSIS

Chromatography of crotamiton and its application to the determination of active ingredients in ointments. Izumoto S, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1457–66

ISOLATION & PURIFICATION

[Studies on Kochiae Fructus. I. Antipruritogenic effect of 70% ethanol extract from kochiae fructus and its active component] Kubo M, et al. **Yakugaku Zasshi** 1997 Apr; 117(4):193–201 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

A model to assess the effectiveness of topical antipruritics. Drozdenko R, et al. **Skin Pharmacol** 1996;9(5):334–42

THERAPEUTIC USE

Rifampicin and the relief of pruritus of hepatic cholestatic origin [letter] Airede AK, et al. **Acta Paediatr** 1996 Jul; 85(7):887–8

Nalbuphine and pruritus [letter] Elias M. **Anaesthesia** 1997 Jun;52(6):613

Cholestyramine ointment to treat buttocks rash and anal excoriation in an infant. White CM, et al. **Ann Pharmacother** 1996 Sep;30(9):954–6

Effect of topical pramoxine on experimentally induced pruritus in humans. Yosipovitch G, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 1):278–80

[An animal model for screening of antiallergic and antipruritic drugs] Xu JH, et al. **Yao Hsueh Hsueh Pao** 1996;31(6):420–4 (Eng. Abstr.) **(Chi)**

ANTIPSYCHOTIC AGENTS

see related

DOPAMINE ANTAGONISTS

Images in psychiatry. Rauwolfia serpentina: the first herbal antipsychotic. Bhatara VS, et al. **Am J Psychiatry** 1997 Jul;154(7):894

New name for atypical antipsychotics? [letter] Copolov D. **Am J Psychiatry** 1997 Mar;154(3):439

Propofol sedation during awake craniotomy for seizures: patient–controlled administration versus neurolept analgesia. Herrick IA, et al. **Anesth Analg** 1997 Jun; 84(6):1285–91

Picogram determination of a novel dopamine D4 receptor antagonist in human plasma and urine by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. Chavez–Eng CM, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28; 691(1):77–85

Guidelines for the use of antipsychotic drug studies in healthy volunteers. The BAP Consensus Group. King DJ. **J Psychopharmacol (Oxf)** 1997;11(3):201–9

The high price of schizophrenia. Georgia restricts newer anti–psychotics for Medicaid members [news] **J Psychosoc Nurs Ment Health Serv** 1997 Feb;35(2):6–7

New antipsychotics: preclinical and clinical research [editorial] Gerlach J, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1–2):1

ADMINISTRATION & DOSAGE

Schizophrenia: a study comparing a family therapy group following a paradoxical model plus psychodrugs and a group treated by the conventional clinical approach. De Giacomo P, et al. **Acta Psychiatr Scand** 1997 Mar; 95(3):183–8

A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Pereira S, et al. **Acta Psychiatr Scand** 1997 Jun;95(6):464–8

An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Thakore JH, et al. **Acta Psychiatr Scand** 1996 Sep;94(3):194–7

Time to clozapine response in a standardized trial. Conley RR, et al. **Am J Psychiatry** 1997 Sep;154(9):1243–7

Replication. Liberman RP. **Am J Psychiatry** 1997 Mar; 154(3):440

A target–dose finding study of clozapine in patients with schizophrenia. Bennett JA, et al. **Ann Clin Psychiatry** 1996 Mar;8(1):19–21

Antipsychotic drug doses and adjunctive drugs in the outpatient treatment of schizophrenia. Galletly CA, et al. **Ann Clin Psychiatry** 1997 Jun;9(2):77–80

Risperidone: once–daily dosage [letter] Gupta S, et al. **Ann Clin Psychiatry** 1996 Dec;8(4):221

Adjunctive loxapine in a clozapine–resistant cohort of schizophrenic patients. Mowerman S, et al. **Ann Clin Psychiatry** 1996 Dec;8(4):193–7

Clozapine dosage and titration [letter] Taniguchi G, et al. **Ann Pharmacother** 1996 Jul–Aug;30(7–8):883

The successful treatment of a gender dysphoric patient with pimozide. Puri BK, et al. **Aust N Z J Psychiatry** 1996 Jun; 30(3):422–5

Chemical immobilisation of giraffe to facilitate short procedures. Vogelnest L, et al. **Aust Vet J** 1997 Mar; 75(3):180–2

Fluvoxamine augmentation in clozapine–resistant schizophrenia: an open pilot study. Silver H, et al. **Biol Psychiatry** 1996 Oct 1;40(7):671–4

Limitations of controlled augmentation trials in schizophrenia. Stern RG, et al. **Biol Psychiatry** 1997 Jul 15;42(2):138–43 (28 ref.)

Health beliefs and compliance with antipsychotic medication. Budd RJ, et al. **Br J Clin Psychol** 1996 Sep;35 (Pt 3):393–7

Double–blind, placebo–controlled, crossover trial of glycine adjuvant therapy for treatment–resistant schizophrenia. Heresco–Levy U, et al. **Br J Psychiatry** 1996 Nov; 169(5):610–7

Management of treatment resistant schizophrenia unresponsive to clozapine. Barnes TR, et al. **Br J Psychiatry Suppl** 1996 Dec;(31):31–40 (65 ref.)

Patients' attitudes toward having been forcibly medicated. Greenberg WM, et al. **Bull Am Acad Psychiatry Law** 1996; 24(4):513–24

Clozapine treatment of psychosis associated with multiple sclerosis [letter] Chong SA, et al. **Can J Psychiatry** 1997 Feb;42(1):90–1

Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Ghaemi SN, et al. **Can J Psychiatry** 1997 Mar;42(2):196–9

Neuroleptic dosing in chronic schizophrenia: a 10–year follow–up. Remington GJ, et al. **Can J Psychiatry** 1997 Feb;42(1):53–7

Bromocriptine as adjunctive therapy to clozapine in treatment–resistant schizophrenia [letter] al–Semaan Y. **Can J Psychiatry** 1996 Sep;41(7):484–5

Economic evaluation of zuclopenthixol acetate compared with injectable haloperidol in schizophrenic patients with acute psychosis. Laurier C, et al. **Clin Ther** 1997 Mar–Apr; 19(2):316–29

Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. Mattila MJ, et al. **Eur J Clin Pharmacol** 1996; 51(2):161–6

Antipsychotic dosing strategies in acute schizophrenia. Janicak PG, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:35–40 (29 ref.)

Clinical update on amisulpride in deficit schizophrenia. Rein W, et al. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S19–27 (27 ref.)

Lack of relationship of neuroleptic dose and blood serum levels to neuropsychological performance on the LNNB in chronic schizophrenia. Puente AE, et al. **Int J Neurosci** 1996 Oct;87(1–2):107–10

Drug treatment of schizophrenia and delusional disorder in late life. Howard R. **Int Psychogeriatr** 1996 Winter; 8(4):597–608 (60 ref.)

Case study: risperidone treatment of children and adolescents with developmental disorders. Hardan A, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Nov; 35(11):1551–6

Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education. Meador KG, et al. **J Am Geriatr Soc** 1997 Feb;45(2):207–10

A decision analysis approach to neuroleptic dosing: insights from a mathematical model. Mossman D. **J Clin Psychiatry** 1997 Feb;58(2):66–73

Dosing the antipsychotic medication olanzapine. Nemeroff CB. **J Clin Psychiatry** 1997;58 Suppl 10:45–9

The effects of clozapine on symptom clusters in treatment–refractory patients. Abraham G, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):49–53

Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia—a study group report. Delini–Stula A, et al. **J Psychiatr Res** 1996 Jul–Aug; 30(4):239–50

Neuroleptic dosing in Hispanic and Asian Inpatients with schizophrenia. Collazo Y, et al. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):310–3

Low–dose clozapine improves dyskinesias in Parkinson's disease. Durif F, et al. **Neurology** 1997 Mar;48(3):658–62

Effects of intermittent and continuous subchronic administration of raclopride on motor activity, dopamine turnover and receptor occupancy in the rat. Ericson H, et al. **Pharmacol Toxicol** 1996 Dec;79(6):277–86

Use of novel antipsychotic drugs. Raleigh F. **Pharmacotherapy** 1996 Nov–Dec;16(6 Pt 2):160S–165S; discussion 166S–168S (20 ref.)

Neuroleptic dosages [letter; comment] Dinakar HS, et al. **Psychiatr Serv** 1997 Jan;48(1):105. Comment on: Psychiatr Serv 1996 May;47(5):536.

Long–term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Grace J, et al. **Psychiatr Serv** 1996 Jan;47(1):41–5

Low– and standard–dose depot haloperidol combined with targeted oral neuroleptics. Huttunen MO, et al. **Psychiatr Serv** 1996 Jan;47(1):83–5

Neuroleptic dosage in psychiatric outpatients [letter] [see comments] Lin KM, et al. **Psychiatr Serv** 1996 May; 47(5):536. Comment in: Psychiatr Serv 1997 Jan;48(1):105.

Use of clozapine with nonresponsive patients [letter; comment] Markowitz JS, et al. **Psychiatr Serv** 1996 Dec; 47(12):1392. Comment on: Psychiatr Serv 1996 Aug;47(8):876.

Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients. Menditto AA, et al. **Psychiatr Serv** 1996 Jan;47(1):46–51

Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Segal SP, et al. **Psychiatr Serv** 1996 Mar;47(3):282–6

Effects of switching inpatients with treatment–resistant schizophrenia from clozapine to risperidone. Still DJ, et al. **Psychiatr Serv** 1996 Dec;47(12):1382–4

Long–term psychiatric patients' knowledge about their medication. Tempier R. **Psychiatr Serv** 1996 Dec; 47(12):1385–7

Does minimizing neuroleptic dosage influence hyponatremia? Canuso CM, et al. **Psychiatry Res** 1996 Jul 31;63(2–3):227–9

Utilization of depot neuroleptic medication in psychiatric inpatients. Citrome L, et al. **Psychopharmacol Bull** 1996; 32(3):321–6

The use of prn and stat medication in three child psychiatric inpatient settings. Kaplan SL, et al. **Psychopharmacol Bull** 1997;33(1):161–4

Risperidone: a novel antipsychotic with many "atypical" properties? Stathis P, et al. **Psychopharmacology (Berl)** 1996 Oct;127(3):181–6

Sulpiride (Eglonyl)—use to stimulate lactation [letter] [see comments] Gravenor M. S **Afr Med J** 1996 Jul;86(7):846 . Comment in: S Afr Med J 1997 Jun;87(6):774–5.

Placebo washout in trials of antipsychotic drugs. Volavka J, et al. **Schizophr Bull** 1996;22(4):567–76 (40 ref.)

Clozapine–reserpine combination for refractory psychosis [letter] Healy DJ, et al. **Schizophr Res** 1997 Jun 20; 25(3):259–60

Effect of smoking on neuroleptics in schizophrenia. Salokangas RK, et al. **Schizophr Res** 1997 Jan 17; 23(1):55–60

Risperidone–reserpine combination in refractory psychosis [letter] Solon EN. **Schizophr Res** 1996 Dec 15;22(3):265–6

Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects. Tugg LA, et al. **Schizophr Res** 1997 May 3; 25(1):71–8

Neuroleptic drug utilisation for acute schizophrenia. Razali MS, et al. **Singapore Med J** 1996 Dec;37(6):611–3

Surgical treatment of patients with psychiatric disorders: a review of 21 patients. Tsuji Y, et al. **Surg Today** 1997; 27(5):387–91

Thioridazine interferences with imipramine metabolism and measurement. Maynard GL, et al. **Ther Drug Monit** 1996 Dec;18(6):729–31

[Efficacy and tolerance of risperidone in various doses (report of a study)] Ceška E, et al. **Ceska Slov Psychiatr** 1996 Feb;92(1):50–6 (Eng. Abstr.) **(Cze)**

[Clinical effects of clozapine: effect on negative symptoms] Llorca PM, et al. **Encephale** 1996 Jul–Aug;22(4):287–92 (Eng. Abstr.) **(Fre)**

[Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study] Romain JL, et al. **Encephale** 1996 Jul–Aug;22(4):280–6 (Eng. Abstr.) **(Fre)**

[Acute inpatient treatment of manias. Effects of independent variables on neuroleptic dosage and length of stay] Adler L, et al. **Nervenarzt** 1996 Mar;67(3):235–43 (Eng. Abstr.) **(Ger)**

[Risperidone after clozapine in therapy refractory schizoaffective psychosis—a case report] Konrad C, et al. **Psychiatr Prax** 1997 Mar;24(2):88–9 (Eng. Abstr.) **(Ger)**

[Neuroleptic non–response due to self–induced hyperosmolar diarrhea] Metzger W, et al. **Psychiatr Prax** 1997 Jan; 24(1):45–6 **(Ger)**

ADVERSE EFFECTS

Caudate nucleus area in drug–induced parkinsonism. Brown KW, et al. **Acta Psychiatr Scand** 1996 Nov;94(5):348–51

Schizophrenic patients' experiences of neuroleptic medication: a Q–methodological investigation. Day JC, et al. **Acta Psychiatr Scand** 1996 May;93(5):397–402

Ketoacidosis as a side–effect of clozapine: a case report. Kostakoğlu AE, et al. **Acta Psychiatr Scand** 1996 Mar; 93(3):217–8

Tardive dyskinesia in older out–patients: a follow–up study. Labbate LA, et al. **Acta Psychiatr Scand** 1997 Sep; 96(3):195–8

Subjective experience of treatment, side–effects, mental state and quality of life in chronic schizophrenic out–patients treated with depot neuroleptics. Larsen EB, et al. **Acta Psychiatr Scand** 1996 May;93(5):381–8

Effect of pharmacotherapy on serum cholesterol levels in patients with panic disorder. Shioiri T, et al. **Acta Psychiatr Scand** 1996 Mar;93(3):164–7

Tardive dyskinesia: who is at risk? van Os J, et al. **Acta Psychiatr Scand** 1997 Sep;96(3):206–16

The role of cognition in the risk—benefit and safety analysis of antipsychotic medication. Borison RL. **Acta Psychiatr Scand Suppl** 1996;389:5–11 (57 ref.)

Minimizing the non–extrapyramidal side–effects of antipsychotics. Keks NA. **Acta Psychiatr Scand Suppl** 1996; 389:18–24 (49 ref.)

Spontaneous and drug–induced movement disorders in schizophrenia. Kopala LC. **Acta Psychiatr Scand Suppl** 1996;389:12–7 (32 ref.)

Serum triglyceride levels in patients treated with clozapine. Ghaeli P, et al. **Am J Health Syst Pharm** 1996 Sep 1; 53(17):2079–81

Additional information on using clozapine in adults [letter] Taniguchi G, et al. **Am J Health Syst Pharm** 1996 Aug 15;53(16):1965

Clozaril–induced lupus anticoagulant [letter] Kanjolia A, et al. **Am J Hematol** 1997 Apr;54(4):345–6

Akathisia in adults with mental retardation: development of the Akathisia Ratings of Movement Scale (ARMS). Bodfish JW, et al. **Am J Ment Retard** 1997 Jan;101(4):413–23

Dyskinetic movement disorder among adults with mental retardation: phenomenology and co–occurrence with stereotypy. Bodfish JW, et al. **Am J Ment Retard** 1996 Sep;101(2):118–29

Neuroleptics and bone mineral density [letter] al–Adwani A. **Am J Psychiatry** 1997 Aug;154(8):1173

Hypertension after initiation of clozapine [letter] George TP, et al. **Am J Psychiatry** 1996 Oct;153(10):1368–9

Propranolol treatment of olanzapine–induced akathisia [letter] Kurzthaler I, et al. **Am J Psychiatry** 1997 Sep; 154(9):1316

Diazepam–responsive neuroleptic malignant syndrome: a diagnostic subtype? [letter] Miyaoka H, et al. **Am J Psychiatry** 1997 Jun;154(6):882

Atypical neuroleptic malignant syndrome associated with risperidone treatment [letter] Newman M, et al. **Am J Psychiatry** 1997 Oct;154(10):1475

Blind, controlled, long–term study of the comparative incidence of treatment–emergent tardive dyskinesia with olanzapine or haloperidol. Tollefson GD, et al. **Am J Psychiatry** 1997 Sep;154(9):1248–54

Withdrawal–emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Anand VS, et al. **Ann Clin Psychiatry** 1996 Sep;8(3):179–82

Subjective muscle weakness and hypotonia during clozapine treatment. Galletly C. **Ann Clin Psychiatry** 1996 Dec; 8(4):189–92

Tardive dyskinesia and ethnicity: review of the literature. Swartz JR, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):53–9 (60 ref.)

Risk factors for hypothermia in psychiatric patients. Young DM. **Ann Clin Psychiatry** 1996 Jun;8(2):93–7

Suspected neuroleptic malignant syndrome in a patient receiving clozapine. Ganelin L, et al. **Ann Pharmacother** 1996 Mar;30(3):248–50

Delayed risperidone–induced neuroleptic malignant syndrome [letter] Kern JL, et al. **Ann Pharmacother** 1996 Mar;30(3):300

Lactic acidosis and fatal myocardial failure due to clozapine. Koren W, et al. **Ann Pharmacother** 1997 Feb;31(2):168–70

Cardiomyopathy associated with clozapine. Leo RJ, et al. **Ann Pharmacother** 1996 Jun;30(6):603–5

Fatal cardiac event following initiation of risperidone therapy. Ravin DS, et al. **Ann Pharmacother** 1997 Jul–Aug; 31(7–8):867–70

Risperidone–induced neuroleptic malignant syndrome. Sharma R, et al. **Ann Pharmacother** 1996 Jul–Aug; 30(7–8):775–8

Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Viguera AC, et al. **Arch Gen Psychiatry** 1997 Jan;54(1):49–55

Neuroleptic malignant syndrome and risperidone: a case report. Bonwick RJ, et al. **Aust N Z J Psychiatry** 1996 Jun;30(3):419–21

Neuroleptic malignant syndrome and clozapine monotherapy [see comments] Chatterton R, et al. **Aust N Z J Psychiatry** 1996 Oct;30(5):692–3. Comment in: Aust N Z J Psychiatry 1997 Jun;31(3):435–6.

Clozapine and constipation: a serious issue [letter] Drew L, et al. **Aust N Z J Psychiatry** 1997 Feb;31(1):149–50

Clozapine–induced agranulocytosis [letter] Fenner S, et al. **Aust N Z J Psychiatry** 1996 Dec;30(6):874–5

Hyponatremia, convulsions and neuroleptic malignant syndrome in a male with schizoaffective disorder. Looi JC, et al. **Aust N Z J Psychiatry** 1995 Dec;29(4):683–7

Bilateral ulnar nerve paralysis: an unreported complication of drug–induced extrapyramidal rigidity. Sampath G, et al. **Aust N Z J Psychiatry** 1997 Jun;31(3):427–8

Ocular abnormalities in chronic schizophrenia: clinical implications. Smith D, et al. **Aust N Z J Psychiatry** 1997 Apr;31(2):252–6

Neuroleptic malignant syndrome: two cases without muscle rigidity. Wong MM. **Aust N Z J Psychiatry** 1996 Jun; 30(3):415–8

Salivary flow–rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data. Ben–Aryeh H, et al. **Biol Psychiatry** 1996 Jun 1; 39(11):946–9

Beta 2–receptor density on mononuclear blood cells in patients suffering from neuroleptic–induced akathisia (NIA). Botschev C, et al. **Biol Psychiatry** 1996 Aug 1; 40(3):203–7

Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Chen CH, et al. **Biol Psychiatry** 1997 Apr 1;41(7):827–9

Treatment of long–term tardive dyskinesia with vitamin E. Dorevitch A, et al. **Biol Psychiatry** 1997 Jan 1;41(1):114–6

Clozapine–induced electroencephalogram changes as a function of clozapine serum levels. Freudenreich O, et al. **Biol Psychiatry** 1997 Jul 15;42(2):132–7

Handedness and the risk of tardive dyskinesia. Morgenstern H, et al. **Biol Psychiatry** 1996 Jul 1;40(1):35–42

Electroencephalography in schizophrenic patients: comparison between neuroleptic–naive state and after treatment. Nagase Y, et al. **Biol Psychiatry** 1996 Sep 15; 40(6):452–6

Neuroleptic malignant syndrome and catatonia: one entity or two? [letter; comment] Northoff G. **Biol Psychiatry** 1996 Sep 1;40(5):431–3. Comment on: Biol Psychiatry 1996 Jan 1;39(1):1–4.

Clozapine–chlorpromazine allergic cross–reactivity in a psychotic patient with asymptomatic AIDS [letter] Quintana J, et al. **Biol Psychiatry** 1996 Dec 1;40(11):1185–6

The effect of clozapine on saliva flow rate: a pilot study. Rabinowitz T, et al. **Biol Psychiatry** 1996 Dec 1; 40(11):1132–4

Tumor necrosis factor constellation polymorphism and clozapine–induced agranulocytosis in two different ethnic groups. Turbay D, et al. **Blood** 1997 Jun 1;89(11):4167–74

Do neuroleptic drugs hasten cognitive decline in dementia? Authors have not proved their argument [letter; comment] Bentham PW, et al. **BMJ** 1997 May 10;314(7091):1412. Comment on: BMJ 1997 Jan 25;314(7076):266–70.

Do neuroleptic drugs hasten cognitive decline in dementia? Carriers of apolipoprotein E epsilon 4 allele seem particularly susceptible to their effects [letter; comment] Holmes C, et al. **BMJ** 1997 May 10;314(7091):1411; discussion 1412. Comment on: BMJ 1997 Jan 25;314(7076):266–70.

Do neuroleptic drugs hasten cognitive decline in dementia?

Prospective study with necropsy follow up [see comments] McShane R, et al. **BMJ** 1997 Jan 25;314(7076):266–70. Comment in: BMJ 1997 May 10;314(7091):1411; discussion 1412. Comment in: BMJ 1997 May 10;314(7091):1412.

Do neuroleptic drugs hasten cognitive decline in dementia? Trials must determine which neuroleptics are best in dementia [letter; comment] Tobiansky R, et al. **BMJ** 1997 May 10;314(7091):1411; discussion 1412. Comment on: BMJ 1997 Jan 25;314(7076):266–70.

Coexistence of eosinophilia and agranulocytosis in a clozapine–treated patient [letter] Amital D, et al. **Br J Psychiatry** 1997 Feb;170:194

Antipsychotic drug–induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Armstrong M, et al. **Br J Psychiatry** 1997 Jan;170:23–6

Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Atkin K, et al. **Br J Psychiatry** 1996 Oct;169(4):483–8

Caudate nucleus morphology in tardive dyskinesia. Brown KW, et al. **Br J Psychiatry** 1996 Nov;169(5):631–6

Antipsychotic drug–induced dysphoria [letter] Hollistar LE. **Br J Psychiatry** 1997 Apr;170:387

A controlled study of education about drug treatment in schizophrenia. Macpherson R, et al. **Br J Psychiatry** 1996 Jun;168(6):709–17

Clozapine–induced hypersalivation and the alpha–2 adrenoceptor [letter; comment] Szabadi E. **Br J Psychiatry** 1996 Sep;169(3):380–1. Comment on: Br J Psychiatry 1995 Sep;167(3):412.

Paroxetine discontinuation syndrome in association with sertindole therapy [letter] Walker–Kinnear M, et al. **Br J Psychiatry** 1997 Apr;170:389

Continuing clozapine despite neutropenia. Wesson ML, et al. **Br J Psychiatry** 1996 Feb;168(2):217–20

Severe depression with risperidone–induced EPS in an elderly schizoaffective patient [letter] Benazzi F. **Can J Psychiatry** 1996 Apr;41(3):196–7

Spiramycin–associated acute dystonia during neuroleptic treatment [letter] Benazzi F. **Can J Psychiatry** 1997 Aug; 42(6):665–6

Severe extrapyramidal side effects when discontinuing clozapine and starting haloperidol [letter] Bobba R. **Can J Psychiatry** 1997 Jun;42(5):530

Extrapyramidal side effects with low–dose risperidone [letter] Brown ES. **Can J Psychiatry** 1997 Apr;42(3):325–6

Use of cytokines in clozapine–induced agranulocytosis [see comments] Chin–Yee I, et al. **Can J Psychiatry** 1996 Jun; 41(5):280–4 (42 ref.). Comment in: Can J Psychiatry 1996 Nov;41(9):603.

Hoarding and clozapine–risperidone combination [letter] Chong SA, et al. **Can J Psychiatry** 1996 Jun;41(5):315–6

Risperidone, weight gain, and bulimia nervosa [letter] Crockford DN, et al. **Can J Psychiatry** 1997 Apr; 42(3):326–7

Switching between clozapine and risperidone treatment [letter] Gardner DM, et al. **Can J Psychiatry** 1997 May; 42(4):430–1

Does combined neuroleptic–electroconvulsive therapy treatment increase the likelihood of creatine phosphokinase rise? [letter; comment] Geizer M, et al. **Can J Psychiatry** 1997 Feb;42(1):88. Comment on: Can J Psychiatry 1996 Mar;41(2):131.

Clozapine–induced neuroleptic malignant syndrome: clozapine monotherapy rechallenge in a case of previous NMS [letter] Illing M, et al. **Can J Psychiatry** 1996 May; 41(4):258

Clozapine–associated retrograde ejaculation [letter] Jeffries JJ, et al. **Can J Psychiatry** 1996 Feb;41(1):62–3

Re: Cytokines and agranulocytosis induced by clozapine [letter; comment] Malek–Ahmadi P. **Can J Psychiatry** 1996 Nov;41(9):603. Comment on: Can J Psychiatry 1996 Jun;41(5):280–4.

Risperidone–induced neuroleptic malignant syndrome: a case report and review. Meterissian GB. **Can J Psychiatry** 1996 Feb;41(1):52–4 (9 ref.)

Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy. Stip E. **Can J Psychiatry** 1996 Oct;41(8 Suppl 2):S27–34 (67 ref.)

Acute dystonic reaction with risperidone [letter] Takhar J, et al. **Can J Psychiatry** 1996 Feb;41(1):61–2

Swelling of salivary glands with clozapine treatment [letter] Troia M, et al. **Can J Psychiatry** 1996 Sep;41(7):485–6

Toxic delirium with low–dose clozapine [letter] Wilkins–Ho M, et al. **Can J Psychiatry** 1997 May;42(4):429–30

Bruxism secondary to antipsychotic drug exposure: a positive response to propranolol. Amir I, et al. **Clin Neuropharmacol** 1997 Feb;20(1):86–9

Clozapine induced polyserositis. Catalano G, et al. **Clin Neuropharmacol** 1997 Aug;20(4):352–6

Neuroleptic malignant syndrome while on tiapride treatment [letter] Duarte J, et al. **Clin Neuropharmscol** 1996 Dec; 19(6):539–40

Life–threatening dysphagia following prolonged neuroleptic therapy. Hayashi T, et al. **Clin Neuropharmacol** 1997 Feb; 20(1):77–81

Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change [see comments] Iwahashi K. **Clin Neuropharmacol** 1996 Jun;19(3):267–70. Comment in: Clin Neuropharmacol 1997 Apr;20(2):179.

Tardive akathisia due to sulpiride. López de Munain A, et al. **Clin Neuropharmacol** 1994 Oct;17(5):481–3

Electroencephalographic findings with low–dose clozapine treatment in psychotic Parkinsonian patients. Neufeld MY, et al. **Clin Neuropharmacol** 1996 Feb;19(1):81–6

Transient and intermittent oral dyskinesia appearing in a young woman ten days after neuroleptic treatment. Tawara Y, et al. **Clin Neuropharmacol** 1997 Apr;20(2):175–8

Spiking fevers with clozapine treatment. Trémeau F, et al. **Clin Neuropharmacol** 1997 Apr;20(2):168–70

Rationales, values, and DSM–IV: the case of "medication–induced movement disorders". Sadler JZ. **Compr Psychiatry** 1996 Nov–Dec;37(6):441–51 (59 ref.)

Dermatologic side effects of psychopharmacologic agents. Garnis–Jones S. **Dermatol Clin** 1996 Jul;14(3):503–8 (28 ref.)

Phototoxic properties of neuroleptic drugs. Eberlein–König B, et al. **Dermatology** 1997;194(2):131–5

Drug–induced movement disorders. Jiménez–Jiménez FJ, et al. **Drug Saf** 1997 Mar;16(3):180–204 (643 ref.)

Asthma mortality and antipsychotic or sedative use. What is the link? Joseph KS. **Drug Saf** 1997 Jun;16(6):351–4 (32 ref.)

A risk–benefit assessment of sulpiride in the treatment of schizophrenia. Mauri MC, et al. **Drug Saf** 1996 May; 14(5):288–98 (73 ref.)

Clinically significant interactions of psychotropic agents with antipsychotic drugs. Meyer MC, et al. **Drug Saf** 1996 Nov; 15(5):333–46 (200 ref.)

Antipsychotic use in pregnancy. What are the best treatment options? Trixler M, et al. **Drug Saf** 1997 Jun;16(6):403–10 (67 ref.)

Dysphagia in drug–induced parkinsonism: a case report. Leopold NA. **Dysphagia** 1996 Spring;11(2):151–3

Rebound insomnia after abrupt clozapine withdrawal. Staedt J, et al. **Eur Arch Psychiatry Clin Neurosci** 1996; 246(2):79–82

A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs. Bagheri H, et al. **Eur J Clin Pharmacol** 1997;52(5):339–42

Weight gain induced by clozapine. Hummer M, et al. **Eur Neuropsychopharmacol** 1995 Dec;5(4):437–40

Risk factors for the development of neuroleptic induced akathisia. Miller CH, et al. **Eur Neuropsychopharmacol** 1997 Feb;7(1):51–5

How to distinguish between the neuroleptic–induced deficit syndrome, depression and disease–related negative symptoms in schizophrenia. Barnes TR, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:115–21 (63 ref.)

Motor and mental aspects of extrapyramidal syndromes. Casey DE. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:105–14 (53 ref.)

Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? Casey DE. **Int Clin Psychopharmacol** 1997 Feb; 12 Suppl 1:S19–27 (60 ref.)

Aggressive behaviour and extrapyramidal side effects of neuroleptics in schizophrenia. Cheung P, et al. **Int Clin Psychopharmacol** 1996 Dec;11(4):237–40

Reflux oesophagitis and clozapine. Laker MK, et al. **Int Clin Psychopharmacol** 1997 Jan;12(1):37–9

Cocaine, Neuroleptics, and tardive dyskinesia as paleocortical escape. Howard JS 3rd. **Integr Physiol Behav Sci** 1996 Oct–Dec;31(4):306–14 (33 ref.)

Attentional dysfunctions in neuroleptic–naive and neuroleptic–withdrawn schizophrenic patients and their siblings. Finkelstein JR, et al. **J Abnorm Psychol** 1997 May; 106(2):203–12

TD from risperidone? [letter; comment] Edleman RJ. **J Am Acad Child Adolesc Psychiatry** 1997 Jul;36(7):867. Comment on: J Am Acad Child Adolesc Psychiatry 1996 Nov;35(11):1421–2.

Risperidone and tardive dyskinesia [letter] [see comments] Feeney DJ, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Nov;35(11):1421–2. Comment in: J Am Acad Child Adolesc Psychiatry 1997 Jul;36(7):867.

Case study: risperidone–induced hepatotoxicity in pediatric patients. Kumra S, et al. **J Am Acad Child Adolesc Psychiatry** 1997 May;36(5):701–5

Tics with risperidone withdrawal [letter] Rowan AB, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Feb;36(2):162–3

Gynecomastia with antipsychotics [letter] Storch DD. **J Am Acad Child Adolesc Psychiatry** 1997 Feb;36(2):161–2

Combined drug therapy debate (continued) [letter; comment] Zavodnick JM. **J Am Acad Child Adolesc Psychiatry** 1997 Jan;36(1):1–3. Comment on: J Am Acad Child Adolesc Psychiatry 1995 May;34(5):540. Comment on: J Am Acad Child Adolesc Psychiatry 1996 Jan;35(1):1–2.

Neuroleptic malignant syndrome: case report and review. Dykstra TJ, et al. **J Am Osteopath Assoc** 1997 Jun; 97(6):355–7 (10 ref.)

Managing dementia–related behavior in the community. Mort JR, et al. **J Am Pharm Assoc (Wash)** 1996 Apr; NS36(4):249–56

Attenuation of antipsychotic–induced hyperprolactinemia with clozapine. Bunker MT, et al. **J Child Adolesc Psychopharmacol** 1997 Spring;7(1):65–9

Lithium and neuroleptics in combination: is there enhancement of neurotoxicity leading to permanent sequelae? Goldman SA. **J Clin Pharmacol** 1996 Oct; 36(10):951–62

Safety of olanzapine. Beasley CM Jr, et al. **J Clin Psychiatry** 1997;58 Suppl 10:13–7

The relationship of pharmacology to side effects. Casey DE. **J Clin Psychiatry** 1997;58 Suppl 10:55–62 (32 ref.)

Side effect profiles of new antipsychotic agents. Casey DE. **J Clin Psychiatry** 1996;57 Suppl 11:40–5; discussion 46–52 (30 ref.)

Clozapine–induced urinary incontinence: incidence and treatment with ephedrine. Fuller MA, et al. **J Clin Psychiatry** 1996 Nov;57(11):514–8

Antipsychotic agents: minimizing side effects to maximize compliance. Kane JM, et al. **J Clin Psychiatry** 1996 Oct; 57(10):suppl 1–12

Clozapine–related speech disturbance [letter; comment] Knoll JL 4th. **J Clin Psychiatry** 1997 May;58(5):219–20. Comment on: J Clin Psychiatry 1995 Sep;56(9):418–22.

Parotid gland swelling with clozapine [letter] Patkar AA, et al. **J Clin Psychiatry** 1996 Oct;57(10):488

Clozapine treatment for neuroleptic–induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. Spivak B, et al. **J Clin Psychiatry** 1997 Jul;58(7):318–22

LSD–like panic from risperidone in post–LSD visual disorder [see comments] Abraham HD, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):238–41. Comment in: J Clin Psychopharmacol 1997 Aug;17(4):327–8.

A case report of risperidone–induced obsessive–compulsive symptoms [letter] Alzaid K, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):58–9

Clozapine–induced myoclonus: two case reports [letter] Barak Y, et al. **J Clin Psychopharmacol** 1996 Aug; 16(4):339–40

Induction of mania by risperidone resistant to mood stabilizers [letter] Barkin JS, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):57–8

Acute dystonia induced by rapid increase in risperidone dosage [letter] Brody AL. **J Clin Psychopharmacol** 1996 Dec;16(6):461–2

Cellulitis, eosinophilia, and unilateral pleural effusion associated with clozapine treatment [letter] Chatterjee A, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):232–3

Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports [letter] Chong SA, et al. **J Clin Psychopharmacol** 1997 Feb; 17(1):68–9

Effects of 'Seroquel' (quetiapine) on platelet serotonin–2 binding in schizophrenia [letter] Faustman WO, et al. **J Clin Psychopharmacol** 1996 Dec;16(6):464–6

Risperidone–associated hepatotoxicity [letter] Fuller MA, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):84–5

Risperidone–associated burning paraesthesia. Heimberg C, et al. **J Clin Psychopharmacol** 1996 Dec;16(6):446–8

Aspiration pneumonia possibly secondary to clozapine–induced sialorrhea [letter] Hinkes R, et al. **J Clin Psychopharmacol** 1996 Dec;16(6):462–3

Comments to "the evolution of the serotonin–dopamine antagonist concept" [letter] Howsepian AA. **J Clin Psychopharmacol** 1996 Feb;16(1):99

Hepatotoxicity of clozapine. Hummer M, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):314–7

Risperidone and obsessive–compulsive symptoms [letter] Iruela LM. **J Clin Psychopharmacol** 1996 Feb;16(1):85–6

Marked liver enzyme elevations with clozapine [letter] Markowitz JS, et al. **J Clin Psychopharmacol** 1997 Feb; 17(1):70–1

Exacerbation of hallucinogen–persisting perception disorder with risperidone [letter; comment] Morehead DB. **J Clin Psychopharmacol** 1997 Aug;17(4):327–8. Comment on: J Clin Psychopharmacol 1996 Jun;16(3):238–41.

Weight gain associated with risperidone [letter] Penn JV, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):259–60

Clozapine–induced necrotizing colitis [letter] Shammi CM, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):230–2

Extrapyramidal symptoms in patients treated with risperidone. Simpson GM, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):194–201

Dystonia while changing from clozapine to risperidone [letter; comment] Simpson GM, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):260–1. Comment on: J Clin Psychopharmacol 1995 Jun;15(3):225–6.

Hyponatremia during treatment with clomipramine, perphenazine, or clozapine: study of therapeutic drug monitoring samples [letter] Spigset O, et al. **J Clin Psychopharmacol** 1996 Oct;16(5):412–4

Unsuccessful reexposure to clozapine [letter] Szarek BL, et al. **J Clin Psychopharmacol** 1997 Feb;17(1):71–3

Effectiveness of herbal medicine (shakuyaku–kanzo–to) for neuroleptic–induced hyperprolactinemia [letter] Yamada K, et al. **J Clin Psychopharmacol** 1997 Jun;17(3):234–5

Recurrent mandibular dislocation under neuroleptic drug therapy, treated by bilateral eminectomy. Undt G, et al. **J Craniomaxillofac Surg** 1996 Jun;24(3):184–8

Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities. Branford D. **J Intellect Disabil Res** 1996 Aug;40 (Pt 4):322–9

Adverse effects of summer amongst people with learning disabilities: neuroleptic malignant syndrome. Fitzgerald B, et al. **J Intellect Disabil Res** 1997 Jun;41 (Pt 3):273–7

Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. Voruganti LN, et al. **J Nerv Ment Dis** 1997 Jul;185(7):463–5

Long–term antipsychotic medication of schizophrenics does not promote the development of Alzheimer's disease brain

pathology. Niizato K, et al. **J Neurol Sci** 1996 Jun; 138(1–2):165–7

Persistent spontaneous oral dyskinesias in haloperidol–withdrawn rats neonatally lesioned with 6–hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenates. Huang NY, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):268–76

Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. Awad AG, et al. **J Psychiatry Neurosci** 1997 Jul;22(4):244–8

Is the treatment worse than the cure? Attitudes toward medications among persons with severe mental illness. Van Dongen CJ. **J Psychosoc Nurs Ment Health Serv** 1997 Mar; 35(3):21–5

Low–dose imipramine for thioridazine–induced male orgasmic disorder. Aizenberg D, et al. **J Sex Marital Ther** 1996 Fall;22(3):225–9

Measurement of the validity of utility elicitations performed by computerized interview. Lenert LA, et al. **Med Care** 1997 Sep;35(9):915–20

Paradoxical hypertension associated with clozapine [letter] Ennis LM, et al. **Med J Aust** 1997 Mar 3;166(5):278

Severe tardive dystonia: treatment with continuous intrathecal baclofen administration. Dressler D, et al. **Mov Disord** 1997 Jul;12(4):585–7

Risperidone–induced tardive dyskinesia and parkinsonism. Gwinn KA, et al. **Mov Disord** 1997 Jan;12(1):119–21

Haematological side effects of clozapine: patient characteristics. Miller PR, et al. **N Z Med J** 1997 Apr 11; 110(1041):125–7

Human leukocyte antigen system in clozapine–induced agranulocytosis. Theodoropoulou S, et al. **Neuropsychobiology** 1997;36(1):5–7

Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Windgassen K, et al. **Neuropsychobiology** 1996;33(3):142–6

Olanzapine motor side effect [letter; comment] Daniel DG, et al. **Neuropsychopharmacology** 1997 Jan;16(1):88–90. Comment on: Neuropsychopharmacology 1996 Feb;14(2):111–23.

Extrapyramidal symptoms during long–term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Gerlach J, et al. **Neuropsychopharmacology** 1996 Mar;14(3 Suppl):35S–39S (24 ref.)

Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic–naive schizophrenic patients. Sweeney JA, et al. **Neuropsychopharmacology** 1997 Mar;16(3):217–28

Efficacy and side–effects of clozapine not associated with variation in the 5–HT2C receptor. Rietschel M, et al. **Neuroreport** 1997 May 27;8(8):1999–2003

Lymphocytopenia and thrombocytopenia during treatment with risperidone or clozapine. Assion HJ, et al. **Pharmacopsychiatry** 1996 Nov;29(6):227–8

Amantadine in the treatment of neuroleptic–induced obesity in rats: behavioral, endocrine and neurochemical correlates. Baptista T, et al. **Pharmacopsychiatry** 1997 Mar;30(2):43–54

Two cases of deep vein thrombosis associated with a combined paroxetine and zotepine therapy. Pantel J, et al. **Pharmacopsychiatry** 1997 May;30(3):109–11

Neuroleptic malignant syndrome with risperidone. Gleason PP, et al. **Pharmacotherapy** 1997 May–Jun;17(3):617–21

Neuroleptic malignant syndrome after neuroleptic discontinuation. Amore M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Dec; 19(8):1323–34

Side effects of low dose neuroleptics and their impact on clinical outcome in generalized anxiety disorder. Wurthmann C, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 May; 21(4):601–9

Restarting clozapine: a case report [letter] Barrons E, et al. **Psychiatr Serv** 1996 Jan;47(1):92

A centralized system for monitoring clozapine use in British Columbia. Black LL, et al. **Psychiatr Serv** 1996 Jan; 47(1):81–3

Absence of parkinsonism among patients in long–term neuroleptic therapy who abuse cocaine. Dhopesh V, et al. **Psychiatr Serv** 1997 Jan;48(1):95–7

Psychopharmacology. Clozapine and agranulocytosis. Feldman J. **Psychiatr Serv** 1996 Nov;47(11):1177–8

Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Honigfeld G. **Psychiatr Serv** 1996 Jan;47(1):52–6

Recurrent paroxysmal episodes characterized by perceptual alteration in three schizophrenic patients on neuroleptic medication. Higuchi H, et al. **Psychiatry Clin Neurosci** 1997 Jun;51(3):99–101

Current topics in tardive dyskinesia in Japan. Inada T, et al. **Psychiatry Clin Neurosci** 1995 Dec;49(5–6):239–44 (142 ref.)

Effectiveness of shakuyaku–kanzo–to in neuroleptic–induced hyperprolactinemia: a preliminary report. Yamada K, et al. **Psychiatry Clin Neurosci** 1996 Dec;50(6):341–2

Does minimizing neuroleptic dosage influence hyponatremia? Canuso CM, et al. **Psychiatry Res** 1996 Jul 31;63(2–3):227–9

Normal sustained effects of selective attention are absent in schizophrenic patients withdrawn from medication. Salo R, et al. **Psychiatry Res** 1996 May 17;62(2):121–30

Prediction of short–term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Sumiyoshi T, et al. **Psychiatry Res** 1997 Mar 24;69(2–3):113–21

Lithium and neuroleptics in combination: the spectrum of neurotoxicity [corrected] [published erratum appears in Psychopharmacol Bull 1996;32(4):544] Goldman SA. **Psychopharmacol Bull** 1996;32(3):299–309

Non–functional CYP2D6 alleles and risk for neuroleptic–induced movement disorders in schizophrenic patients. Andreassen OA, et al. **Psychopharmacology (Berl)** 1997 May;131(2):174–9

Does eosinophilia predict clozapine induced neutropenia? Hummer M, et al. **Psychopharmacology (Berl)** 1996 Mar; 124(1–2):201–4

5–HT2 antagonism and EPS benefits: is there a causal connection? Kapur S. **Psychopharmacology (Berl)** 1996 Mar; 124(1–2):35–9 (50 ref.)

Clozapine versus typical antipsychotics. A retro– and prospective study of extrapyramidal side effects. Peacock L, et al. **Psychopharmacology (Berl)** 1996 Mar; 124(1–2):188–96

Risperidone–induced galactorrhea [letter] Schreiber S, et al. **Psychopharmacology (Berl)** 1997 Apr;130(3):300–1

A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Awad AG, et al. **Qual Life Res** 1997 Jan;6(1):21–6

The risk of medication–free research. Carpenter WT Jr. **Schizophr Bull** 1997;23(1):11–8 (84 ref.)

Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Shiovitz TM, et al. **Schizophr Bull** 1996;22(4):591–5

Medical complications of new antipsychotic drugs. Umbricht D, et al. **Schizophr Bull** 1996;22(3):475–83 (70 ref.)

Research in schizophrenia and the discontinuation of antipsychotic medications. Wyatt RJ. **Schizophr Bull** 1997; 23(1):3–9 (40 ref.)

Cerebral perfusion correlates of negative symptomatology and parkinsonism in a sample of treatment–refractory schizophrenics: an exploratory 99mTc–HMPAO SPET study. Molina Rodríguez V, et al. **Schizophr Res** 1997 May 3;25(1):11–20

Age of illness onset and schizophrenic symptomatology during an inpatient washout period. Sharma RP, et al. **Schizophr Res** 1996 Jul 5;20(3):295–300

Schizophrenia, tardive dyskinesia and essential fatty acids. Vaddadi KS, et al. **Schizophr Res** 1996 Jul 5;20(3):287–94

The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curaçao Extrapyramidal Syndromes Study: I. van Harten PN, et al. **Schizophr Res** 1996 May;19(2–3):195–203

Effect of clozapine on motor function in schizophrenic patients [published erratum appears in Schizophr Res 1996 Dec 15;22(3):269] Vrtunski PB, et al. **Schizophr Res** 1996 May;20(1–2):187–98

[Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride] Liu KL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Dec; 12(12):685–90 (Eng. Abstr.) **(Chi)**

[Serious drug interaction between clozapine–Leponex and fluvoxamine–Fevarin] Olesen OV, et al. **Ugeskr Laeger** 1996 Nov 25;158(48):6931–2 (Eng. Abstr.) **(Dan)**

[Weight gain and clozapine] Jalenques I, et al. **Encephale** 1996 Oct;22 Spec No 3:77–9 **(Fre)**

[A new study of secondary effects in prescribing practices of neuroleptics] Lachaux B, et al. **Encephale** 1997 Apr;23 Spec No 2:25–34 (56 ref.) (Eng. Abstr.) **(Fre)**

[Hematologic effects of clozapine: a review of the international experience] Lamarque V. **Encephale** 1996 Dec;22 Spec No 6:35–6 (Eng. Abstr.) **(Fre)**

[Neuroleptic–induced supersensitivity] Börner I, et al. **Fortschr Neurol Psychiatr** 1997 May;65(5):214–20 (45 ref.) (Eng. Abstr.) **(Ger)**

[Chorea–like motor restlessness in clozapine] Garcí a C, et al. **Fortschr Neurol Psychiatr** 1996 Oct;64(10):418–21 (26 ref.) (Eng. Abstr.) **(Ger)**

[Neuroleptic malignant syndrome and acute life–threatening catatonia—two contrasting disease entities?] Heils A, et al. **Fortschr Neurol Psychiatr** 1997 Jan;65(1):8–15 (75 ref.) (Eng. Abstr.) **(Ger)**

[Neuroleptic malignant syndrome—sequela of an individually relatively high neuroleptic dosage? (letter)] Bechter K. **Nervenarzt** 1997 Jul;68(7):601 **(Ger)**

[Priapism with clozapine therapy] Hövermann P, et al. **Nervenarzt** 1997 Jan;68(1):74–6 (Eng. Abstr.) **(Ger)**

[Depressive stupor—malignant neuroleptic syndrome—serotonin syndrome. A case contribution to a difficult differential diagnosis] König F, et al. **Nervenarzt** 1996 May;67(5):407–12 (Eng. Abstr.) **(Ger)**

[Fluspirilene—safe weekly tranquilizer?] Kuhn W, et al. **Nervenarzt** 1997 Jun;68(6):528 **(Ger)**

[A case of malignant neuroleptic syndrome. Case report] Martius P, et al. **Nervenarzt** 1996 May;67(5):418–21 (Eng. Abstr.) **(Ger)**

[Catatonia, malignant neuroleptic syndrome and myositis ossificans] Topka H, et al. **Nervenarzt** 1996 May;67(5):413–7 (Eng. Abstr.) **(Ger)**

[Body weight increase: a side effect of zotepin (Nipolept)?] Wetterling T, et al. **Nervenarzt** 1996 Mar;67(3):256–61 (Eng. Abstr.) **(Ger)**

[Peri–/myocarditis with clozapine (Leponex)] Khalil N. **Psychiatr Prax** 1997 Jan;24(1):46 **(Ger)**

[Urinary retention with risperidone] Siepmann M, et al. **Psychiatr Prax** 1997 Jul;24(4):209 **(Ger)**

[Risperidone–induced priapism] Maizel S, et al. **Harefuah** 1996 Jun 2;130(11):744–5, 799 (Eng. Abstr.) **(Heb)**

[A case of malignant syndrome triggered by the use of haloperidol and chrorpromazine] Konishi K, et al. **Masui** 1997 Apr;46(4):547–8 (Eng. Abstr.) **(Jpn)**

[Recent research trends in diagnosis, treatment, and prevention of drug–induced extrapyramidal symptoms seen in psychiatric patients] Inada T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Oct; 16(5):181–5 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical investigation of 10 cases with acute renal failure induced by neuroleptics] Soejima A, et al. **Nippon Jinzo Gakkai Shi** 1996 Aug;38(8):335–41 (Eng. Abstr.) **(Jpn)**

[Tardive dyskinesia with special emphasis on tardive dyskinesia caused by neuroleptics] Preradović M, et al. **Vojnosanit Pregl** 1996 Nov–Dec;53(6):519–26 (63 ref.) **(Scr)**

[Drug–induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs] Martí Massó JF, et al. **Neurologia** 1996 Jan;11(1):10–5 (Eng. Abstr.) **(Spa)**

[Respiratory dyskinesia induced by verapiride] Marta–Moreno E, et al. **Rev Neurol** 1997 Feb;25(138):245–7 (Eng. Abstr.) **(Spa)**

[Drug–related motor disorders in aged people] Martí–Massó JF. **Rev Neurol** 1997 Jul;25 Suppl 1:S37–43 (35 ref.) **(Spa)**

ANALYSIS

Prothipendyl: detection and elimination in the horse—a case report. Hagedorn HW, et al. **DTW Dtsch Tierarztl Wochenschr** 1996 Apr;103(4):125–7

Stereospecific determination of amisulpride, a new benzamide derivative, in human plasma and urine by automated solid–phase extraction and liquid chromatography on a chiral column. application to pharmacokinetics. Ascalone V, et al. **J Chromatogr B Biomed Appl** 1996 Feb 9; 676(1):95–105

Determination of two CI–1007 sulfate metabolites in monkey plasma and urine. Feng MR, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):159–66

Determination of amisulpride, a new benzamide derivative, in human plasma and urine by liquid–liquid extraction or solid–phase extraction in combination with high–performance liquid chromatography and fluorescence detection. application to pharmacokinetics. Malavasi B, et al. **J Chromatogr B Biomed Appl** 1996 Feb 9;676(1):107–15

BLOOD

Beta 2–receptor density on mononuclear blood cells in patients suffering from neuroleptic–induced akathisia (NIA). Botschev C, et al. **Biol Psychiatry** 1996 Aug 1; 40(3):203–7

Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Nyberg S, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:81–5

Lack of relationship of neuroleptic dose and blood serum levels to neuropsychological performance on the LNNB in chronic schizophrenia. Puente AE, et al. **Int J Neurosci** 1996 Oct;87(1–2):107–10

Potential for overestimation of clozapine concentrations [letter; comment] Patrick KS, et al. **J Anal Toxicol** 1997 Jan–Feb;21(1):73–5. Comment on: J Anal Toxicol 1995 Nov–Dec;19(7):537–41.

Determination of clozapine and its major metabolites in human plasma and red blood cells by high–performance liquid chromatography with ultraviolet absorbance detection. Guitton C, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):211–22

Selective determination of sultopride in human plasma using high–performance liquid chromatography with ultraviolet detection and particle beam mass spectrometry. Jitsufuchi N, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7; 690(1–2):153–9

Automated on–line dialysis, trace enrichment and high–performance liquid chromatography. Inhibition of interaction with the dialysis membrane and disruption of protein binding in the determination of clozapine in human plasma. Johansen K, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1–2):223–31

Sensitive assay for pimozide in human plasma using high–performance liquid chromatography with fluorescence detection: application to pharmacokinetic studies. Kerbusch T, et al. **J Chromatogr B Biomed Appl** 1997 Jun 20;694(1):163–8

Sensitive high–performance liquid chromatographic method for the determination of a benzonaphthazepine antipsychotic agent, SCH 39166, and its active metabolite, SCH 40853, in human plasma and its cross–validation with a gas chromatographic method. Lin CC, et al. **J Chromatogr B Biomed Appl** 1996 Jul 12;682(2):309–13

Sensitive determination of sulpiride in human plasma by high–performance liquid chromatography. Tokunaga H, et al. **J Chromatogr B Biomed Appl** 1997 Mar 28;691(1):203–7

Determination of clozapine in serum by radioreceptor assay versus high–performance liquid chromatography: possible detection of hydroxy–metabolites. Odou P, et al.

J Clin Pharm Ther 1996 Oct;21(5):337–42

Plasma level measurement in a patient with clozapine intoxication [letter] Stevens I, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):86–7

Clozapine dosages and plasma drug concentrations. Chang WH, et al. **J Formos Med Assoc** 1997 Aug;96(8):599–605

Direct microtitre plate radioimmunoassay of savoxepine in unextracted plasma. Lefèvre G, et al. **J Immunoassay** 1996 Feb;17(1):29–46

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. Syvälahti EK, et al. **J Int Med Res** 1997 Jan–Feb;25(1):24–32

Determination of a novel anti-psychotic agent AD–5423 and its metabolites in plasma by high-performance liquid chromatography with fluorescence detection. Matsuda M, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1449–56

Screening of antipsychotic drugs by wide-bore capillary gas chromatography with nitrogen phosphorus detection--detection levels in plasma. Tokunaga H, et al. **Nippon Hoigaku Zasshi** 1996 Jun;50(3):196–202

Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Aravagiri M, et al. **Ther Drug Monit** 1997 Jun;19(3):307–13

Solid-phase extraction and high-performance liquid chromatographic analysis of clozapine and norclozapine in human plasma. Freeman DJ, et al. **Ther Drug Monit** 1996 Dec;18(6):688–92

Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Linnet K, et al. **Ther Drug Monit** 1996 Dec; 18(6):629–34

Therapeutic drug monitoring of risperidone and 9-hydroxyrisperidone in serum with solid-phase extraction and high-performance liquid chromatography. Price MC, et al. **Ther Drug Monit** 1997 Jun;19(3):333–7

A method for rapid determination of zotepine by gas chromatography-mass spectrometry. Tanaka O, et al. **Ther Drug Monit** 1996 Jun;18(3):294–6

Automated determination of clozapine and major metabolites in serum and urine. Weigmann H, et al. **Ther Drug Monit** 1997 Aug;19(4):480–8

CHEMICAL SYNTHESIS

Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole. Andersen K, et al. **J Med Chem** 1996 Sep 13;39(19):3723–38

Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate. Hrib NJ, et al. **J Med Chem** 1996 Sep 27; 39(20):4044–57

Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D4 receptor antagonists as potential antipsychotic agents. Unangst PC, et al. **J Med Chem** 1997 Aug 15; 40(17):2688–93

CHEMISTRY

Dopamine D2 receptor model explains binding affinity of neuroleptics: piquindone and its structure activity relationships. Teeter MM, et al. **Drug Des Discov** 1996 Apr; 13(3–4):49–62

(E)-(methyloxyimino)acetamides as analogues of neuroleptic benzamides: synthesis and D2-dopaminergic binding affinity. Lapucci A, et al. **Farmaco** 1996 Jan;51(1):33–9

2-Phenyl-4(5)-[[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]imidazole. A highly selective antagonist at cloned human D4 receptors. Thurkauf A, et al. **J Med Chem** 1997 Jan 3;40(1):1–3

Anodic voltammetry of fluphenazine at different solid electrodes. Sentürk Z, et al. **J Pharm Biomed Anal** 1996 Dec;15(3):365–70

CONTRAINDICATIONS

Additional information on using clozapine in adults [letter] Taniguchi G, et al. **Am J Health Syst Pharm** 1996 Aug 15;53(16):1965

Treatment with clozapine. Black patients' low white cell counts currently mean that they cannot be treated [letter] Fisher N, et al. **BMJ** 1996 Nov 16;313(7067):1262

ECONOMICS

Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Aronson SM. **Clin Ther** 1997 Jan–Feb;19(1):139–47; discussion 126–7

Impact of newer antipsychotics on outcomes in schizophrenia. Keks NA. **Clin Ther** 1997 Jan–Feb; 19(1):148–58; discussion 126–7

Economic evaluation of zuclopenthixol acetate compared with injectable haloperidol in schizophrenic patients with acute psychosis. Laurier C, et al. **Clin Ther** 1997 Mar–Apr; 19(2):316–29

Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Chouinard G, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):298–307

Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. Revicki DA. **J Psychiatry Neurosci** 1997 Jul;22(4):256–66 (55 ref.)

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia [see comments] Rosenheck R, et al. **N Engl J Med** 1997 Sep 18;337(12):809–15. Comment in: N Engl J Med 1997 Sep 18;337(12):851–2.

Cost-benefits of risperidone [letter] [see comments] Bilsker D. **Psychiatr Serv** 1996 Mar;47(3):309–10. Comment in: Psychiatr Serv 1996 Aug;47(8):877–8.

Assessing a drug's cost-benefits [letter; comment] Raleigh F. **Psychiatr Serv** 1996 Aug;47(8):877–8. Comment on: Psychiatr Serv 1996 Mar;47(3):309–10.

Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Carter CS, et al. **Psychopharmacol Bull** 1995;31(4):719–25

[Neuroleptics, drug benefits and cost savings (letter)] Pedersen K, et al. **Lakartidningen** 1996 Dec 18; 93(51–52):4711 **(Swe)**

HISTORY

The history of the psychopharmacology of schizophrenia [see comments] Lehmann HE, et al. **Can J Psychiatry** 1997 Mar; 42(2):152–62. Comment in: Can J Psychiatry 1997 Mar;42(2):131–2.

From chlorpromazine to olanzapine: a brief history of antipsychotics. Meyer JM, et al. **Psychiatr Serv** 1997 Sep; 48(9):1137–9

METABOLISM

Binding of clozapine metabolites and analogues to the histamine H3 receptor in rat brain cortex. Alves-Rodrigues A, et al. **Arch Pharm (Weinheim)** 1996 Aug–Sep; 329(8–9):413–6

JL 13, a potential successor to clozapine, is less sensitive to oxidative phenomena. Liégeois JF, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):252–5

Quantitative electroencephalographic frequencies and relative neuroleptic receptor affinities in schizophrenia. Small JG, et al. **Biol Psychiatry** 1996 Jun 1;39(11):986–8

In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Ring BJ, et al. **Br J Clin Pharmacol** 1996 Mar;41(3):181–6

Structural features associated with reactive metabolite formation in clozapine analogues. Uetrecht J, et al. **Chem Biol Interact** 1997 May 2;104(2–3):117–29

Biotransformation of clozapine in humans. Dain JG, et al. **Drug Metab Dispos** 1997 May;25(5):603–9

Metabolism of an atypical antipsychotic agent, 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2, 5,5-trimethyl-4-thiazolidinone (HP236). Mutlib AE, et al. **Drug Metab Dispos** 1996 Oct; 24(10):1139–50

Iloperidone binding to human and rat dopamine and 5-HT receptors. Kongsamut S, et al. **Eur J Pharmacol** 1996 Dec 19;317(2–3):417–23

Metabolism of clozapine by human neutrophils: evidence for a specific oxidation of clozapine by the myeloperoxidase system with inhibition of enzymatic chlorination cycle. Frimat B, et al. **Fundam Clin Pharmacol** 1997;11(3):267–74

Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Schotte A, et al. **Histochem J** 1996 Nov;28(11):791–9

Nitric oxide synthesis inhibition attenuates haloperidol-induced supersensitivity. Pudiak CM, et al. **J Psychiatry Neurosci** 1997 Jan;22(1):61–4

A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs. Roemer RA, et al. **J Psychiatry Neurosci** 1996 Nov;21(5):325–33

Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Eyles DW, et al. **Life Sci** 1997;60(8):529–34

Preclinical neurochemical and electrophysiological profile of 1192U90, a potential antipsychotic. Jones-Humble SA, et al. **Neuropsychopharmacology** 1996 Sep;15(3):217–30

The D2 receptor occupancy profile of loxapine determined using PET. Kapur S, et al. **Neuropsychopharmacology** 1996 Dec;15(6):562–6

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Bench CJ, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1-2):141–7

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study. Pilowsky LS, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1-2):148–53

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Schotte A, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1-2):57–73

Application of electrospray mass spectrometry in the identification of intact glucuronide and suplate conjugates of clozapine in rat. Zhang GO, et al. **Xenobiotica** 1996 May; 26(5):541–50

PHARMACOKINETICS

The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Miller DD. **Ann Clin Psychiatry** 1996 Jun;8(2):99–109 (47 ref.)

Pharmacokinetics of chlorprothixene after single intravenous and oral administration of three galenic preparations. Bagli M, et al. **Arzneimittelforschung** 1996 Mar;46(3):247–50

Increased manganese-superoxide dismutase activity in postmortem brain from neuroleptic-treated psychotic patients. Loven DP, et al. **Biol Psychiatry** 1996 Aug 1; 40(3):230–2

Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. Wong SL, et al. **Biopharm Drug Dispos** 1997 Aug;18(6):533–41

Large variations of plasma levels during maintenance treatment with depot neuroleptics. Tuninger E, et al. **Br J Psychiatry** 1996 Nov;169(5):618–21

Clozapine-fluroxamine interaction [letter; comment] Markowitz JS. **Clin Neuropharmacol** 1997 Jun;20(3):281–2. Comment on: Clin Neuropharmacol 1996 Aug;19(4):305–13.

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Wong SL, et al. **Clin Pharmacol Ther** 1997 Aug;62(2):157–64

Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Kassahun K, et al. **Drug Metab Dispos** 1997 Jan;25(1):81–93

Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Mattiuz E, et al. **Drug Metab Dispos** 1997 May;25(5):573–83

Characterization of the novel benzisothiazole ring-cleaved products of the antipsychotic drug ziprasidone. Prakash C, et al. **Drug Metab Dispos** 1997 Jul;25(7):897–901

Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Prakash C, et al. **Drug Metab Dispos** 1997 Jul;25(7):863–72

Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone. Prakash C, et al. **Drug Metab Dispos** 1997 Feb;25(2):206–18

An evaluation of linearity of kinetics for the neuroleptics perphenazine and zuclopenthixol [letter] Linnet K. **Eur J Clin Pharmacol** 1997;52(4):317–8

Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Wong SL, et al. **Eur J Clin Pharmacol** 1997;52(3):223–7

Effect of pigmentation on the drug deposition in hair of grey-haired subjects. Rothe M, et al. **Forensic Sci Int** 1997 Jan 17;84(1-3):53–60

The D3 receptor and its relevance in psychiatry. Schwartz JC, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:15–20 (43 ref.)

Therapeutic receptor-blocking concentrations of neuroleptics. Seeman P. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:5–13 (40 ref.)

Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients. Sommers DK, et al. **Int Clin Psychopharmacol** 1997 May;12(3):141–5

Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. Bagli M, et al. **Int J Clin Pharmacol Ther** 1995 Dec;33(12):646–52

Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. Silver AA, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Dec; 35(12):1631–6

Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. Huang HF, et al. **J Clin Pharmacol** 1996 Oct;36(10):963–9

Pharmacokinetics and drug interactions: update for new antipsychotics. Ereshefsky L. **J Clin Psychiatry** 1996;57 Suppl 11:12–25 (68 ref.)

Serum and urine risperidone concentrations in an acute overdose [letter] Lee HS, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):325–6

Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Creese I, et al. **J Neuropsychiatry Clin Neurosci** 1996 Spring;8(2):223–6

Improving the oral bioavailability of sulpiride by a gastric-retained form in rabbits. Kohri N, et al. **J Pharm Pharmacol** 1996 Apr;48(4):371–4

Disposition of remoxipride in plasma and cerebrospinal fluid in sheep. Main DC, et al. **J Vet Pharmacol Ther** 1996 Oct; 19(5):402–4

Radioreceptor binding profile of the atypical antipsychotic olanzapine. Bymaster FP, et al. **Neuropsychopharmacology** 1996 Feb;14(2):87–96

A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Nyberg S, et al. **Neuropsychopharmacology** 1997 Jan; 16(1):1–7

Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2'-ISP in nonhuman primates. Baldwin RM, et al. **Nucl Med Biol** 1994 Oct;21(7):969–76

Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. Feng MR, et al. **Pharm Res** 1997 Mar; 14(3):329–36

Risperidone: effects of formulations on oral bioavailability. Gutierrez R, et al. **Pharmacotherapy** 1997 May–Jun; 17(3):599–605

Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in

haloperidol-treated patients. Nyberg S, et al. **Psychiatry Res** 1996 Oct 7;67(3):163-71

Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug. Kondo T, et al. **Psychopharmacology (Berl)** 1996 Oct;127(4):311-4

[Pharmacokinetics of zotepine and various factors affecting that of zotepine] Tanaka O. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Apr; 16(2):49-52 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Mode of action of antipsychotic drugs: lessons from simpler models. Baker MW, et al. **Acta Biol Hung** 1995; 46(2-4):221-7

Molecular attributes of dopamine receptors: new potential for antipsychotic drug development. Hartman DS, et al. **Ann Med** 1996 Jun;28(3):211-9 (77 ref.)

Ethopharmacology of aggression: impact on autonomic and mesocorticolimbic activity. Miczek KA, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:60-77 (108 ref.)

Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Gurevich EV, et al. **Arch Gen Psychiatry** 1997 Mar; 54(3):225-32

Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study. Oliver DW, et al. **Arzneimittelforschung** 1997 Jun;47(6):692-9

Discriminative stimulus properties of CGS 10746B: similarity to dopamine D1 receptor antagonists. Meehan SM, et al. **Behav Brain Res** 1996 Jan;74(1-2):199-205

Effects of clozapine and haloperidol on baseline levels of vacuous jaw movements in aged rats. Steinpreis RE, et al. **Behav Brain Res** 1997 Jul;86(2):165-9

The antipsychotic potential of subtype-selective 5-HT receptor ligands based on interactions with mesolimbic dopamine systems. Tricklebank MD. **Behav Brain Res** 1996; 73(1-2):15-7 (25 ref.)

Differential effects of antipsychotics on nitric oxide synthase activity. Khan NS, et al. **Biochem Soc Trans** 1997 Feb; 25(1):50S

Effect of haloperidol on the sarcoplasmic reticulum Ca-dependent adenosine triphosphatase. Takara D, et al. **Biochim Biophys Acta** 1996 Nov 8;1314(1-2):57-65

Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Epstein JI, et al. **Biol Psychiatry** 1996 May 15;39(10):902-5

Increased manganese-superoxide dismutase activity in postmortem brain from neuroleptic-treated psychotic patients. Loven DP, et al. **Biol Psychiatry** 1996 Aug 1; 40(3):230-2

Gating of auditory P50 in schizophrenics: unique effects of clozapine. Nagamoto HT, et al. **Biol Psychiatry** 1996 Aug 1;40(3):181-8

Antipsychotic regulation of hippocampal dopamine receptor messenger RNA expression. Ritter LM, et al. **Biol Psychiatry** 1997 Aug 1;42(3):155-64

Antipsychotic drugs block IP3-dependent Ca(2+)-release from rat brain microsomes. Sczekan SR, et al. **Biol Psychiatry** 1996 Sep 15;40(6):497-502

High plasma prolactin levels after long-term neuroleptic treatment. Zelaschi NM, et al. **Biol Psychiatry** 1996 May 15;39(10):900-1

Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Hall DA, et al. **Br J Pharmacol** 1997 Jun;121(4):731-6

The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats. Okuyama S, et al. **Br J Pharmacol** 1997 Jun;121(3):515-25

The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Suessbrich H, et al. **Br J Pharmacol** 1997 Mar; 120(5):968-74

The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions. Zivin M, et al. **Br J Pharmacol** 1996 Nov; 119(6):1187-96

The sigma ligand rimcazole activates noradrenergic neurons projecting to the paraventricular nucleus and increases corticosterone secretion in rats. Eaton MJ, et al. **Brain Res** 1996 Sep 16;733(2):162-6

Effect of chronic clozapine administration on [3H]MK801-binding sites in the rat brain: a side-preference action in cortical areas. Giardino L, et al. **Brain Res** 1997 Jul 11;762(1-2):216-8

Inhibition of protein phosphatase-2B (calcineurin) activity towards Alzheimer abnormally phosphorylated tau by neuroleptics. Gong CX, et al. **Brain Res** 1996 Nov 25; 741(1-2):95-102

Antipsychotic drug effects on glutamatergic activity. Lidsky TI, et al. **Brain Res** 1997 Aug 1;764(1-2):46-52

Stable expression and characterization of the human brain potassium channel Kv2.1: blockade by antipsychotic agents. Wible B, et al. **Brain Res** 1997 Jun 27;761(1):42-50

Effects of sigma ligands on the ability of rimcazole to inhibit PCP hsp70 induction. Sharp JW, et al. **Brain Res Bull** 1996; 39(6):359-66

Effect of chronic antipsychotic drug treatment on preprosomatostatin and preprotachykinin A mRNA levels in the medial prefrontal cortex, the nucleus accumbens and the caudate putamen of the rat. Marcus MM, et al. **Brain Res Mol Brain Res** 1997 May;45(2):275-82

Effects of remoxipride, an atypical antipsychotic, on cocaine self-administration in the rat using fixed- and progressive-ratio schedules of reinforcement. Bourland JA, et al. **Drug Alcohol Depend** 1995 Dec;40(2):111-4

Clinically significant interactions of psychotropic agents with antipsychotic drugs. Meyer MC, et al. **Drug Saf** 1996 Nov; 15(5):333-46 (200 ref.)

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Fulton B, et al. **Drugs** 1997 Feb; 53(2):281-98 (71 ref.)

The importance of dopamine D4 receptors in the action and development of antipsychotic agents [published erratum appears in Drugs 1996 Mar;51(3):505] Reynolds GP. **Drugs** 1996 Jan;51(1):7-11 (35 ref.)

Contrasting effects of chronic clozapine, Seroquel(TM) (ICI 204,636) and haloperidol administration of deltaFosB-like immunoreactivity in the rodent forebrain. Vahid-Ansari F, et al. **Eur J Neurosci** 1996 May;8(5):927-36

7-OH-DPAT differentially reverses clozapine- and haloperidol-induced increases in Fos-like immunoreactivity in the rodent forebrain. Vahid-Ansari F, et al. **Eur J Neurosci** 1996 Dec;8(12):2605-11

Effects of risperidone, clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons of the rat brain. Bruggeman R, et al. **Eur J Pharmacol** 1997 Apr 11;324(1):49-56

The sigma receptor ligand rimcazole alters secretion of prolactin and alpha-melanocyte stimulating hormone by dopaminergic and non-dopaminergic mechanisms. Eaton MJ, et al. **Eur J Pharmacol** 1996 Mar 28;299(1-3):171-7

Dopamine D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of the dopamine D3 receptor antagonist GR103691 with typical and atypical neuroleptics. Hurley MJ, et al. **Eur J Pharmacol** 1996 Dec 30;318(2-3):283-93

Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Inoue A, et al. **Eur J Pharmacol** 1997 Feb 19;321(1):105-11

Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum. Ishibashi T, et al. **Eur J Pharmacol** 1996 May 15;303(3):247-51

Inhibition by antipsychotic drugs of L-type Ca2+ channel current in PC12 cells. Ito K, et al. **Eur J Pharmacol** 1996 Oct 24;314(1-2):143-50

(+)-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress through the activation of phenytoin-regulated sigma 1 sites. Kamei H, et al. **Eur J Pharmacol** 1996 Mar 28;299(1-3):21-8

Role of (+)-SKF-10,047-sensitive sub-population of sigma 1 receptors in amelioration of conditioned fear stress in rats: association with mesolimbic dopaminergic systems. Kamei H, et al. **Eur J Pharmacol** 1997 Jan 29; 319(2-3):165-72

Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain. Karolewicz B, et al. **Eur J Pharmacol** 1996 Oct 17; 313(3):181-6

Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain. McCoy L, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):41-5

Behavioural analysis of changes in nociceptive thresholds produced by remoxipride in sheep and rats. Main DC, et al. **Eur J Pharmacol** 1995 Dec 20;287(3):221-31

Neuropharmacological profile of EMD 57445, a sigma receptor ligand with potential antipsychotic activity. Maj J, et al. **Eur J Pharmacol** 1996 Nov 21;315(3):235-43

Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Momiyama T, et al. **Eur J Pharmacol** 1996 Aug 22;310(1):1-8

sigma Receptor antagonists block the development of sensitization to cocaine. Ujike H, et al. **Eur J Pharmacol** 1996 Jan 25;296(2):123-8

Effects of clozapine metabolites and chronic clozapine treatment on rat brain GABAA receptors. Wong G, et al. **Eur J Pharmacol** 1996 Oct 31;314(3):319-23

Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Zeng XP, et al. **Eur J Pharmacol** 1997 Mar 5;321(3):349-54

Induction of c-fos gene expression by the selective sigma receptor ligand EMD 57445 in rat brain. Dahmen N, et al. **Eur Neuropsychopharmacol** 1996 Aug;6(3):237-43

Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Marcus MM, et al. **Eur Neuropsychopharmacol** 1996 Mar;6(1):29-38

The effects of sulpiride on psychomotor performance and subjective tolerance. Meyer-Lindenberg A, et al. **Eur Neuropsychopharmacol** 1997 Aug;7(3):219-23

Enhancement of antipsychotic-like properties of the dopamine D2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat. Wadenberg ML, et al. **Eur Neuropsychopharmacol** 1996 Nov;6(4):305-10

Effects of SM-9018, a novel 5-HT2 and D2 receptor antagonist, on electrically-evoked [3H]acetylcholine release from rat striatal slices. Ishida K, et al. **Gen Pharmacol** 1996 Oct;27(7):1203-7

Effects of haloperidol and chlorpromazine on smooth muscle contractility, platelet aggregation and neuronal calcium current. Prokopenko RA, et al. **Gen Physiol Biophys** 1995 Aug;14(4):349-57

Differentiation of classical and novel antipsychotics using animal models. Arnt J, et al. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S9-17 (68 ref.)

D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. Farde L, et al. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S3-7

New antipsychotics: the present status. Gerlach J, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:39-48 (57 ref.)

Thought disorder, working memory and attention: interrelationships and the effects of neuroleptic medications. Goldberg TE, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:99-104 (46 ref.)

Neurobiological correlates of acute neuroleptic treatment. Sedvall GC. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:41-6 (20 ref.)

In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. Bymaster FP, et al. **J Clin Psychiatry** 1997;58 Suppl 10:28-36 (59 ref.)

The relationship of pharmacology to side effects. Casey DE. **J Clin Psychiatry** 1997;58 Suppl 10:55-62 (32 ref.)

Behavioral pharmacology of olanzapine: a novel antipsychotic drug. Moore NA, et al. **J Clin Psychiatry** 1997;58 Suppl 10:37-44 (28 ref.)

Preclinical pharmacology of neuroleptics: focus on new generation compounds. Richelson E. **J Clin Psychiatry** 1996;57 Suppl 11:4-11 (50 ref.)

Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatum. Hiroi N, et al. **J Comp Neurol** 1996 Oct 7;374(1):70-83

Antipsychotics with inverse agonist activity at the dopamine D3 receptor. Griffon N, et al. **J Neural Transm** 1996; 103(10):1163-75

Effects of chronic neuroleptic treatment on dopamine release: insights from studies using 3-methoxytyramine. Egan MF, et al. **J Neural Transm Gen Sect** 1996;103(7):777-805 (161 ref.)

BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. Volonté M, et al. **J Neurochem** 1997 Jul;69(1):182-90

Pathophysiology of schizophrenia: dopamine hypothesis. Neylan TC. **J Neuropsychiatry Clin Neurosci** 1996 Spring; 8(2):222

Modulation by neurosteroids of the in vivo (+)-[3H]SKF-10,047 binding to sigma 1 receptors in the mouse forebrain. Maurice T, et al. **J Neurosci Res** 1996 Dec 15;46(6):734-43

Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. Sabri O, et al. **J Nucl Med** 1997 Feb;38(2):181-8

Antagonistic effects of OPC-14597, a novel antipsychotic drug, on quinpirole- and (-)-sulpiride-induced changes in evoked dopamine release in rat striatal slices. Yamada S, et al. **J Pharm Pharmacol** 1997 Feb;49(2):206-8

Genetics, neuroleptic response and the organization of cholinergic neurons in the mouse striatum. Dains K, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1430-8

Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. Fischman AJ, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):939-47

Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. Florijn WJ, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):561-9

Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. Lidow MS, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):597-603

[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. Newman-Tancredi A, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):181-91

Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. Parada MA, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):582-8

Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Perrault G, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):73-82

Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. Prince JA, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):261-7

Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. Schoemaker H, et al. **J Pharmacol Exp Ther** 1997 Jan;280(1):83-97

Seroquel restores sensorimotor gating in phencyclidine-treated rats. Swerdlow NR, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1290–9

PNU–96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. Tang AH, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):440–7

Nitric oxide synthesis inhibition attenuates haloperidol-induced supersensitivity. Pudiak CM, et al. **J Psychiatry Neurosci** 1997 Jan;22(1):61–4

Noradrenergic mechanisms in the prefrontal cortex. Nutt DJ, et al. **J Psychopharmacol (Oxf)** 1997;11(2):163–8 (45 ref.)

5–HT receptors, genes and antipsychotic mechanisms. Reynolds GP. **J Psychopharmacol (Oxf)** 1997;11(1):26–7

Role of dopamine D2, D4 and serotonin(2A) receptors in antipsychotic and anticataleptic action. Seeman P, et al. **J Psychopharmacol (Oxf)** 1997;11(1):15–7

Atypical antipsychotics—serotonergic mechanisms but don't forget dopamine. Vile JM, et al. **J Psychopharmacol (Oxf)** 1997;11(1):24–5

Evaluation of perospirone (SM–9018), a novel serotonin–2 and dopamine–2 receptor antagonist, and other antipsychotics in the conditioned fear stress–induced freezing behavior model in rats. Ishida–Tokuda K, et al. **Jpn J Pharmacol** 1996 Oct;72(2):119–26

Limbic selectivity of clozapine [letter] Pilowsky LS, et al. **Lancet** 1997 Aug 16;350(9076):490–1

Olanzapine: a novel atypical neuroleptic agent [see comments] [published erratum appears in Lancet 1997 Aug 2;350(9074):372] Reus VI. **Lancet** 1997 May 3; 349(9061):1264–5. Comment in: Lancet 1997 Aug 23;350(9077):594.

The subiculum: a potential site of action for novel antipsychotic drugs? Greene JR. **Mol Psychiatry** 1996 Nov; 1(5):380–7 (69 ref.)

Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine [see comments] Meador–Woodruff JH, et al. **Mol Psychiatry** 1996 Mar;1(1):41–53. Comment in: Mol Psychiatry 1996 Mar;1(1):16–7.

Gender differences in psychotropic medications. Lewis–Hall F. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):326–9 (36 ref.)

Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Ruiz S, et al. **Mt Sinai J Med** 1996 Oct–Nov; 63(5–6):306–9

Chronic clozapine versus chronic haloperidol treatment: differential effects on electrically evoked dopamine efflux in the rat caudate putamen, but not in the nucleus accumbens. Feasey–Truger KJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Dec; 354(6):725–30

Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Kalkman HO, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Mar; 355(3):361–4

Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies. Huang N, et al. **Neurochem Int** 1997 Mar;30(3):277–90

Long–term neuroleptic treatments counteract dopamine D2 agonist inhibition of adenylate cyclase but do not affect pertussis toxin ADP–ribosylation in the rat brain. Okada F, et al. **Neurochem Int** 1996 Feb;28(2):161–8

Differential expression of c–fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study. Semba J, et al. **Neurochem Int** 1996 Oct;29(4):435–42

Clozapine and some other antipsychotic drugs may preferentially block the same subset of GABA(A) receptors. Squires RF, et al. **Neurochem Res** 1997 Feb; 22(2):151–62

Effect of antipsychotic drugs on the gene expression of NMDA receptor subunits in rats. Toyoda H, et al. **Neurochem Res** 1997 Mar;22(3):249–52

Long–term treatment with chlorpromazine and haloperidol but not with sulpiride and clozapine markedly elevates neuropeptide Y–like immunoreactivity in the rat hypothalamus. Obuchowicz E. **Neuropeptides** 1996 Oct; 30(5):471–8

5–HT1A receptors are not involved in clozapine's lack of cataleptogenic potential. Bartoszyk GD, et al. **Neuropharmacology** 1996;35(11):1645–6

Effects of chronic treatment with haloperidol on [3H]PK 11195 binding in the rat brain and peripheral tissues. Kurumaji A, et al. **Neuropharmacology** 1996;35(8):1075–9

Chronic treatment with antipsychotic drugs does not alter G protein alpha or beta subunit levels in rat brain. Meller E, et al. **Neuropharmacology** 1996;35(12):1785–91

Activity of "seroquel" (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Ellenbroek BA, et al. **Neuropsychopharmacology** 1996 Oct;15(4):406–16

Risperidone dose–dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2–adrenoceptor antagonism. Hertel P, et al. **Neuropsychopharmacology** 1997 Jul;17(1):44–55

Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Meltzer HY, et al. **Neuropsychopharmacology** 1996 Oct;15(4):395–405

Clozapine reverses the spatial working memory deficits induced by FG7142 in monkeys. Murphy BL, et al. **Neuropsychopharmacology** 1997 Jun;16(6):433–7

1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects. Rigdon GC, et al. **Neuropsychopharmacology** 1996 Sep;15(3):231–42

Adenosine A2A agonists: a potential new type of atypical antipsychotic. Rimondini R, et al. **Neuropsychopharmacology** 1997 Aug;17(2):82–91

Effects of olanzapine on regional C–Fos expression in rat forebrain. Robertson GS, et al. **Neuropsychopharmacology** 1996 Feb;14(2):105–110

Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Seeman P, et al. **Neuropsychopharmacology** 1997 Feb;16(2):93–110; discussion 111–35 (136 ref.)

Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Stockton ME, et al. **Neuropsychopharmacology** 1996 Feb; 14(2):97–105

Haloperidol– and clozapine–induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs. Weiner I, et al. **Neuropsychopharmacology** 1997 Jan;16(1):42–50

Analysis of a structural polymorphism in the 5–HT2A receptor and clinical response to clozapine. Arranz MJ, et al. **Neurosci Lett** 1996 Oct 18;217(2–3):177–8

Inhibition of synaptosomal veratridine–induced sodium influx by antidepressants and neuroleptics used in chronic pain. Deffois A, et al. **Neurosci Lett** 1996 Dec 13;220(2):117–20

Clozapine–induced potentiation of synaptic responses in the perforant path–dentate gyrus pathway in chronically prepared rabbits. Kubota T, et al. **Neurosci Lett** 1996 Jun 14;211(1):21–4

Chronic antipsychotic treatment alters glycine–stimulated NMDA receptor binding in rat brain. McCoy L, et al. **Neurosci Lett** 1996 Aug 2;213(2):137–41

Prolonged treatment with haloperidol and clozapine in the rat: differential effects on spontaneous and theophylline–induced motor activity. Ogren SO, et al. **Neurosci Lett** 1997 Aug 22;232(1):21–4

The novel atypical antipsychotic olanzapine, but not the CCK–B antagonist LY288513, blocks apomorphine–induced disruption of pre–pulse inhibition. Rasmussen K, et al. **Neurosci Lett** 1997 Jan 24;222(1):61–4

Regionally specific effects of haloperidol and clozapine on dopamine reuptake in the striatum. Rothblat DS, et al. **Neurosci Lett** 1997 Jun 6;228(2):119–22

Augmentation of opioid induced antinociception by the atypical antipsychotic drug risperidone in mice. Schreiber S, et al. **Neurosci Lett** 1997 May 30;228(1):25–8

Phenotypic characterization of neurotensin messenger RNA–expressing cells in the neuroleptic–treated rat striatum: a detailed cellular co–expression study. Augood SJ, et al. **Neuroscience** 1997 Feb;76(3):763–74

Atypical antipsychotics block the excitatory effects of serotonin in septohippocampal neurons in the rat. Liu W, et al. **Neuroscience** 1997 Jul;79(2):369–82

Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Tarazi FI, et al. **Neuroscience** 1997 Jun;78(4):985–96

Tamoxifen prevents sulpiride–induced weight gain in female rats. Baptista T, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):215–22

Effects of rating parameters on assessment of neuroleptic–induced vacuous chewing movements. Egan MF, et al. **Pharmacol Biochem Behav** 1996 Feb;53(2):401–10

Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear. Inoue T, et al. **Pharmacol Biochem Behav** 1996 Oct;55(2):195–201

The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Kelley BM, et al. **Pharmacol Biochem Behav** 1997 Aug; 57(4):707–19

Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride. Trimble KM, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):809–16

Effects of acute or chronic administration of risperidone on motor and sexual behavior of male rats. Drago F, et al. **Pharmacol Res** 1997 Jan;35(1):17–25

Prolonged treatment with the atypical antipsychotic agent remoxipride reduces extracellular glutamate levels in the striatum of freely moving rats. Magnusson O, et al. **Pharmacol Toxicol** 1997 Jul;81(1):53–6

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double–blind study. Meyer–Lindenberg A, et al. **Pharmacopsychiatry** 1997 Mar;30(2):35–42

The effects of raclopride on vacuous jaw movements in rats following acute administration. Steinpreis RE, et al. **Physiol Behav** 1996 Jul;60(1):253–6

Cellular responses to psychomotor stimulant and neuroleptic drugs are abnormal in mice lacking the D1 dopamine receptor. Moratalla R, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14928–33

Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission. Piazza PV, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15445–50

Typical and atypical antipsychotic drugs are potent antagonists of the relaxant 5–hydroxytryptamine receptor in the smooth muscle of canine coronary artery. Terrón JA. **Proc West Pharmacol Soc** 1996;39:23–5

Simultaneous monitoring of dopamine, its metabolites and trans–isomer of atypical neuroleptic drug carbidine concentrations in striatal dialysates of conscious rats. Gainetdinov RR, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Feb; 20(2):291–305

Improvement of schizophrenic symptoms and changes in plasma HVA concentrations, plasma anti–D2 and anti–5–HT2 receptor activities with clozapine. Yamada K, et al. **Psychiatry Clin Neurosci** 1996 Oct;50(5):291–4

Multilead quantitative EEG profile of clozapine in resting and vigilance–controlled conditions. Galderisi S, et al. **Psychiatry Res** 1996 Jul 31;67(2):113–22

Typical and atypical neuroleptic drugs decrease platelet 3H–dopamine uptake in the rat. Sundram S, et al. **Psychiatry Res** 1996 Jun 1;62(3):259–63

Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Needham PL, et al. **Psychopharmacol Bull** 1996;32(1):123–8

Inhibitory effects on the discriminative stimulus properties of D–amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system? Arnt J. **Psychopharmacology (Berl)** 1996 Mar;124(1–2):117–25

Discriminative–stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Carey GJ, et al. **Psychopharmacology (Berl)** 1997 Aug;132(3):261–9

Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys. Casey DE. **Psychopharmacology (Berl)** 1996 Mar;124(1–2):134–40

Similarity of clozapine's and olanzapine's acute effects on rats' lapping behavior. Das S, et al. **Psychopharmacology (Berl)** 1996 Feb;123(4):374–8

Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1–like" dopamine receptor agonist A 68930 and selective "D2–like" agonist RU 24213. Deveney AM, et al. **Psychopharmacology (Berl)** 1996 Mar; 124(1–2):40–9

Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Hertel P, et al. **Psychopharmacology (Berl)** 1996 Mar; 124(1–2):74–86

Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D2 and D3 receptors in rat brain. Hurley MJ, et al. **Psychopharmacology (Berl)** 1996 Dec;128(4):362–70

The attenuating effect of carteolol hydrochloride, a beta–adrenoceptor antagonist, on neuroleptic–induced catalepsy in rats. Kikuchi T, et al. **Psychopharmacology (Berl)** 1997 May;131(2):108–14

Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Kinon BJ, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1–2):2–34 (517 ref.)

High frequency oral movements induced by long–term administration of amperozide but not FG5803 in rats. Liminga U, et al. **Psychopharmacology (Berl)** 1996 Feb; 123(3):223–3O

NNC–19–1228 and NNC 22–0031, novel neuroleptics with a "mesolimbic–selective" behavioral profile. Nielsen EB, et al. **Psychopharmacology (Berl)** 1997 Jan;129(2):168–78

Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers. Peretti CS, et al. **Psychopharmacology (Berl)** 1997 Jun;131(4):329–38

In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole—a 123I IBZM single photon emission tomography (SPET) study. Pilowsky LS, et al. **Psychopharmacology (Berl)** 1997 Mar; 130(2):152–8

Discriminative stimulus control with olanzapine: generalization to the atypical antipsychotic clozapine. Porter JH, et al. **Psychopharmacology (Berl)** 1996 Nov; 128(2):216–9

Different behavioral effects of haloperidol, clozapine and thioridazine in a concurrent lever pressing and feeding procedure. Salamone JD, et al. **Psychopharmacology (Berl)** 1996 May;125(2):105–12

Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Sams–Dodd F, et al. **Psychopharmacology (Berl)** 1997 Aug;132(3):303–10

Effects of haloperidol on sensory processing in the hippocampus during classical eyeblink conditioning. Sears LL, et al. **Psychopharmacology (Berl)** 1997 Apr; 130(3):254–60

Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Skarsfeldt T. **Psychopharmacology (Berl)** 1996 Mar;124(1–2):126–33

Subchronic effects of clozapine and haloperidol on rats' forelimb force and duration during a press–while–licking task. Stanford JA, et al. **Psychopharmacology (Berl)** 1997 Apr;130(3):249–53

Olanzapine, a novel atypical antipsychotic, reverses d–amphetamine–induced inhibition of midbrain dopamine cells. Stockton ME, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1–2):50–6

Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Tarazi FI, et al. **Psychopharmacology (Berl)** 1996 Dec;128(4):371–9

Effects of clozapine, thioridazine, risperidone and haloperidol

on behavioral tests related to extrapyramidal motor function. Trevitt JT, et al. **Psychopharmacology (Berl)** 1997 Jul;132(1):74–81

(-)Alprenolol potentiates the disrupting effects of dizocilpine on sensorimotor function in the rat. Zhang J, et al. **Psychopharmacology (Berl)** 1997 Aug;132(3):281–8

Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats. Kosten TA. **Schizophr Bull** 1997;23(2):203–13

Olanzapine and fluperlapine mimic clozapine in preventing MK–801 neurotoxicity. Farber NB, et al. **Schizophr Res** 1996 Jul;21(1):33–7

Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1. Jones–Brando LV, et al. **Schizophr Res** 1997 May 3; 25(1):63–70

Lower plasma CC16, a natural anti–inflammatory protein, and increased plasma interleukin–1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Maes M, et al. **Schizophr Res** 1996 Jul;21(1):39–50

Naloxone–sensitive, haloperidol–sensitive, [3H](+)SKF–10047–binding protein partially purified from rat liver and rat brain membranes: an opioid/sigma receptor? Tsao LI, et al. **Synapse** 1997 Feb;25(2):117–24

Up–regulation of D3 dopamine receptor mRNA by neuroleptics. Wang W, et al. **Synapse** 1996 Jul;23(3):232–5

The experimental antipsychotic agent 1192U90 targets tapetum lucidum in canine eyes. Dillberger JE, et al. **Toxicol Pathol** 1996 Sep–Oct;24(5):595–601

The advantage of using positron emission tomography in drug research. Farde L. **Trends Neurosci** 1996 Jun; 19(6):211–4

Dopamine–cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Grace AA, et al. **Trends Neurosci** 1997 Jan;20(1):31–7 (71 ref.)

Risperidone—a new antipsychotic agent. Simpson GM. **West J Med** 1996 Mar;164(3):257

[New antipsychotic agents: new paths of research on the notion of atypical agents] Gosselin O, et al. **Encephale** 1996 Dec;22 Spec No 6:3–6 (Eng. Abstr.) **(Fre)**

[New drugs in the last year. Part 2. Antipsychotics] Eiden F, et al. **Pharm Unserer Zeit** 1996 Sep;25(5):250–9 (46 ref.) **(Ger)**

[In review: medicinal chemistry. Drug development in the last year. Antipsychotics. 1] Eiden F, et al. **Pharm Unserer Zeit** 1996 Jan;25(1):28–38 (35 ref.) **(Ger)**

[Neuropharmacological effects of sigma receptor ligands: anxiolytic, anti–amnesic and neuroprotective effects] Amano M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):73–84 (103 ref.) (Eng. Abstr.) **(Jpn)**

POISONING

Acute clozapine overdosage [letter] Piccini G, et al. **Br J Psychiatry** 1997 Mar;170:290 (4 ref.)

Acute risperidone overdose. Catalano G, et al. **Clin Neuropharmacol** 1997 Feb;20(1):82–5

Combined intoxication with a tricyclic antidepressive agent and a neuroleptic. Diltoer MW, et al. **Eur J Emerg Med** 1996 Mar;3(1):52–5

Fatal overdose of clozapine. Keller T, et al. **Forensic Sci Int** 1997 Apr 18;86(1–2):119–25

HPLC–DAD and HPLC–MS findings in fatality involving (Z)–cis–clopenthixol (zuclopenthixol). Tracqui A, et al. **J Anal Toxicol** 1997 Jul–Aug;21(4):314–8

Serum and urine risperidone concentrations in an acute overdose [letter] Lee HS, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):325–6

Plasma level measurement in a patient with clozapine intoxication [letter] Stevens I, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):86–7

A complication of self–poisoning. Gerrand CH, et al. **Postgrad Med J** 1997 Feb;73(856):113–4

[Methylphenidate (Ritalin) in the treatment of acute drug poisoning (discussion)] Baštecký J. **Ceska Slov Psychiatr** 1996 May;92 Suppl 1:68–9 (Eng. Abstr.) **(Cze)**

[Acute poisoning by risperidone and ionic and electrocardiographic changes (letter)] Laroussinie G, et al. **Therapie** 1997 Mar–Apr;52(2):155–6 **(Fre)**

THERAPEUTIC USE

Pharmacological approaches other than opioids in chronic non–cancer pain management. Merskey H. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 2):187–90

Clozapine for the treatment of psychosis in Parkinson's disease: a review. Auzou P, et al. **Acta Neurol Scand** 1996 Nov;94(5):329–36 (76 ref.)

Six–year follow–up of thyroid function during lithium treatment. Bocchetta A, et al. **Acta Psychiatr Scand** 1996 Jul;94(1):45–8

Psychopathological and SPECT findings in never–treated schizophrenia. Erkwoh R, et al. **Acta Psychiatr Scand** 1997 Jul;96(1):51–7

Observations on switching patients with schizophrenia to risperidone treatment. Risperidone Switching Study Group. Kirov GK, et al. **Acta Psychiatr Scand** 1997 May; 95(5):439–43

Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs. Maes M, et al. **Acta Psychiatr Scand** 1996 Jan;93(1):1–8

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Rossi A, et al. **Acta Psychiatr Scand** 1997 Jan;95(1):40–3

A prospective 1–5 year outcome study in first–admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment. Wieselgren IM, et al. **Acta Psychiatr Scand** 1996 Jan; 93(1):9–19

New drugs for schizophrenia: an update for family physicians. Amadio PB, et al. **Am Fam Physician** 1997 Sep 15; 56(4):1149–56, 1159–60 (19 ref.)

Antipsychotic drug choices now include olanzapine [news] **Am J Health Syst Pharm** 1996 Dec 1;53(23):2784

Meta–analysis of postmortem studies of Alzheimer's disease–like neuropathology in schizophrenia. Baldessarini RJ, et al. **Am J Psychiatry** 1997 Jun;154(6):861–3

Prospective study of patients' refusal of antipsychotic medication under a physician discretion review procedure. Kasper JA, et al. **Am J Psychiatry** 1997 Apr;154(4):483–9

Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Meltzer HY, et al. **Am J Psychiatry** 1997 Apr;154(4):475–82

SPECT study of regional cerebral perfusion in neuroleptic–resistant schizophrenic patients who responded or did not respond to clozapine. Molina Rodriguez V, et al. **Am J Psychiatry** 1996 Oct;153(10):1343–6

Low use of neuroleptic drugs in the treatment of psychotic major depression. Mulsant BH, et al. **Am J Psychiatry** 1997 Apr;154(4):559–61

Nemonapride for the treatment of schizophrenia [letter] Satoh K, et al. **Am J Psychiatry** 1997 Feb;154(2):292

CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Sharma RP, et al. **Am J Psychiatry** 1997 Jul;154(7):1019–21

Risperidone for treatment of childhood schizophrenia [letter] Sourander A. **Am J Psychiatry** 1997 Oct;154(10):1476

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Tollefson GD, et al. **Am J Psychiatry** 1997 Apr; 154(4):457–65

Negative symptoms: a path analytic approach to a double–blind, placebo– and haloperidol–controlled clinical trial with olanzapine. Tollefson GD, et al. **Am J Psychiatry** 1997 Apr;154(4):466–74

Controlled, dose–response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Zimbroff DL, et al. **Am J Psychiatry** 1997 Jun; 154(6):782–91

EEG abnormalities before clozapine therapy predict a good clinical response to clozapine. Pillay SS, et al. **Ann Clin Psychiatry** 1996 Mar;8(1):1–5

Improvement of debilitating tardive dyskinesia with risperidone. Rangwani SR, et al. **Ann Clin Psychiatry** 1996 Mar;8(1):27–9

Use of risperidone in delirium: case reports. Sipahimalani A, et al. **Ann Clin Psychiatry** 1997 Jun;9(2):105–7

Neuroleptics in acute mania: a pharmacoepidemiologic study. Chou JC, et al. **Ann Pharmacother** 1996 Dec;30(12):1396–8

Pharmacotherapy of aggressive behavior. Pabis DJ, et al. **Ann Pharmacother** 1996 Mar;30(3):278–87 (106 ref.)

The rationale and ethics of medication–free research in schizophrenia [see comments] Carpenter WT Jr, et al. **Arch Gen Psychiatry** 1997 May;54(5):401–7 (58 ref.). Comment in: Arch Gen Psychiatry 1997 May;54(5):412–3. Comment in: Arch Gen Psychiatry 1997 May;54(5):415–6.

The call of the sirens. Navigating the ethics of medication–free research in schizophrenia [comment] Fins JJ, et al. **Arch Gen Psychiatry** 1997 May;54(5):415–6. Comment on: Arch Gen Psychiatry 1997 May;54(5):401–7.

Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Gurevich EV, et al. **Arch Gen Psychiatry** 1997 Mar; 54(3):225–32

Medication–free research with schizophrenic patients. A European perspective [comment] Henn FA, et al. **Arch Gen Psychiatry** 1997 May;54(5):412–3. Comment on: Arch Gen Psychiatry 1997 May;54(5):401–7.

The effects of a selective D4 dopamine receptor antagonist (L–745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Kramer MS, et al. **Arch Gen Psychiatry** 1997 Jun;54(6):567–72

Quetiapine in patients with schizophrenia. A high– and low–dose double–blind comparison with placebo. Seroquel Study Group. Small JG, et al. **Arch Gen Psychiatry** 1997 Jun;54(6):549–57

Recent antipsychotic regulations in long–term care [letter; comment] Lisi DM. **Arch Intern Med** 1996 Oct 14; 156(18):2148. Comment on: Arch Intern Med 1996 Feb 12;156(3):249–56.

It is possible to use clozapine to treat Parkinson's disease [letter] Drew L, et al. **Aust N Z J Med** 1997 Apr;27(2):197

Is clozapine safe in the elderly? Herst L, et al. **Aust N Z J Psychiatry** 1997 Jun;31(3):411–7 (33 ref.)

A treatment–relevant classification of psychotic disorders. McGorry P. **Aust N Z J Psychiatry** 1995 Dec;29(4):555–8 (27 ref.)

Clozapine in the management of bipolar and schizoaffective manic episodes resistant to standard treatment. Mahmood T, et al. **Aust N Z J Psychiatry** 1997 Jun;31(3):424–6

Drug strategies and treatment–resistant schizophrenia. Pantelis C, et al. **Aust N Z J Psychiatry** 1996 Feb; 30(1):20–37 (184 ref.)

Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use. Abraham JT, et al. **Biol Psychiatry** 1997 Jul 15; 42(2):144–6

Successful treatment of tardive dystonia with clozapine [letter] Adityanjee, et al. **Biol Psychiatry** 1996 Jun 15; 39(12):1064–5

Serum cholesterol and treatment–resistance in schizophrenia. Boston PF, et al. **Biol Psychiatry** 1996 Sep 15;40(6):542–3

Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Friedman J, et al. **Biol Psychiatry** 1997 Sep 15;42(6):522–3

Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Harvey PD, et al. **Biol Psychiatry** 1996 Oct 15;40(8):755–60

Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes. Himelhoch S, et al. **Biol Psychiatry** 1996 Feb 1;39(3):227–9

Heterogeneity of serotonergic response in treatment–refractory schizophrenia patients. Lindenmayer JP, et al. **Biol Psychiatry** 1997 Jul 1;42(1):6–12

The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: assessment with technetium–99m hexamethyl–propyleneamine oxime single photon emission computed tomography. Miller DD, et al. **Biol Psychiatry** 1997 Mar 1;41(5):550–9

Gating of auditory P50 in schizophrenics: unique effects of clozapine. Nagamoto HT, et al. **Biol Psychiatry** 1996 Aug 1;40(3):181–8

Electroencephalography in schizophrenic patients: comparison between neuroleptic–naive state and after treatment. Nagase Y, et al. **Biol Psychiatry** 1996 Sep 15; 40(6):452–6

Neurological soft signs and response to risperidone in chronic schizophrenia. Smith RC, et al. **Biol Psychiatry** 1996 Nov 15;40(10):1056–9

Auditory event–related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication. Stefánsson SB, et al. **Biol Psychiatry** 1996 Jul 1;40(1):19–27

Seroquel and cognitive improvement in patients with schizophrenia [letter] Stip E, et al. **Biol Psychiatry** 1996 Sep 1;40(5):434–5

Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance. Sumiyoshi T, et al. **Biol Psychiatry** 1997 Mar 1;41(5):560–6

Efficacy and tolerance of D–cycloserine in drug–free schizophrenic patients. van Berckel BN, et al. **Biol Psychiatry** 1996 Dec 15;40(12):1298–300

The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine. Weiner I, et al. **Biol Psychiatry** 1996 Nov 1;40(9):834–43

Advances in the treatment of schizophrenia. Kuperberg GR, et al. **Br J Clin Pract** 1996 Sep;50(6):315–23 (190 ref.)

Treatment of schizophrenia: advances during the decade of the brain. Buckley PF. **Br J Hosp Med** 1996 Dec 11–1997 Jan 14;56(11):574–80 (31 ref.)

Should the administration of ECT during clozapine therapy be contraindicated? [letter; comment] Bloch Y, et al. **Br J Psychiatry** 1996 Aug;169(2):253–4. Comment on: Br J Psychiatry 1996 Nov;169(5):671.

Likelihood of hospital discharge [letter; comment] Duffett R, et al. **Br J Psychiatry** 1996 Jun;168(6):791. Comment on: Br J Psychiatry 1995 Dec;167(6):760–4.

Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Franz M, et al. **Br J Psychiatry** 1997 May;170:422–5

Consent to treatment [letter; comment] Jackson GA, et al. **Br J Psychiatry** 1996 Sep;169(3):382–3. Comment on: Br J Psychiatry 1996 May;168(5):540–4.

Consent to treatment [letter; comment] Laugharne J, et al. **Br J Psychiatry** 1996 Sep;169(3):382. Comment on: Br J Psychiatry 1996 May;168(5):540–4.

Long–term treatment with clozapine in schizophrenia [letter] Launer MA. **Br J Psychiatry** 1996 Mar;168(3):383

Amisulpride versus placebo in the medium–term treatment of the negative symptoms of schizophrenia. Loo H, et al. **Br J Psychiatry** 1997 Jan;170:18–22

Use of clozapine in a child with treatment–resistant schizophrenia. MacEwan TH, et al. **Br J Psychiatry** 1996 Mar;168(3):376–8

Valproate and neuroleptic medication [letter] Reutens S, et al. **Br J Psychiatry** 1997 May;170:484–5

ECT with clozapine: efficacy and safety [letter; comment] Trezise K. **Br J Psychiatry** 1996 Nov;169(5):671. Comment on: Br J Psychiatry 1996 Aug;169(2):253–4.

Schizophrenia, violence, clozapine and risperidone: a review. The Special Hospitals Treatment Resistant Schizophrenia Research Group. **Br J Psychiatry Suppl** 1996 Dec; (31):21–30 (60 ref.)

Factors which can make patients difficult to treat. Kane JM. **Br J Psychiatry Suppl** 1996 Dec;(31):10–4 (28 ref.)

Management of treatment refractory schizophrenia. Morrison DP. **Br J Psychiatry Suppl** 1996 Dec;(31):15–20 (40 ref.)

Biological determinants of difficult to treat patients with schizophrenia. Sharma T, et al. **Br J Psychiatry Suppl** 1996 Dec;(31):5–9 (45 ref.)

Advances in psychopharmacology--schizophrenia. Owens DG. **Br Med Bull** 1996 Jul;52(3):556–74 (90 ref.)
Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Stanislav SW. **Brain Inj** 1997 May; 11(5):335–41
Role of serotonin in forensic psychiatry [letter; comment] Buckley P, et al. **Bull Am Acad Psychiatry Law** 1996; 24(3):419–22. Comment on: Bull Am Acad Psychiatry Law 1996;24(1):57–72.
Clozapine and dopamine [letter] Aschheim E, et al. **Can J Psychiatry** 1997 Mar;42(2):212
Differential effects of D2- and D4-blocking neuroleptics on the procedural learning of schizophrenic patients. Bédard MA, et al. **Can J Psychiatry** 1996 Sep;41(7 Suppl 1):S21–4
Neurocognitive impairment in schizophrenia and how it affects treatment options [see comments] Bilder RM. **Can J Psychiatry** 1997 Apr;42(3):255–64 (58 ref.). Comment in: Can J Psychiatry 1997 Apr;42(3):247–8.
Risperidone treatment of bipolar disorder [letter] McIntyre R, et al. **Can J Psychiatry** 1997 Feb;42(1):88–90
Self-induced water intoxication treated with risperidone. Millson RC, et al. **Can J Psychiatry** 1996 Dec;41(10):648–50
Zuclopenthixol acetate in a demented elderly patient with agitation [letter] Myronuk L, et al. **Can J Psychiatry** 1997 Apr;42(3):325
Treatment of factitious disorder with pimozide [letter] Prior TI, et al. **Can J Psychiatry** 1997 Jun;42(5):532
Clozapine: current status and role in the pharmacotherapy of schizophrenia [see comments] Remington GJ, et al. **Can J Psychiatry** 1996 Apr;41(3):161–6. Comment in: Can J Psychiatry 1996 Sep;41(7):483.
Re: clozapine--current status and role in the pharmacotherapy of schizophrenia [letter; comment] Sharma V. **Can J Psychiatry** 1996 Sep;41(7):483. Comment on: Can J Psychiatry 1996 Apr;41(3):161–6.
Risperidone and neuropsychological test performance in cocaine-withdrawn patients [letter] Smelson DA, et al. **Can J Psychiatry** 1997 May;42(4):431
The effect of risperidone on cognition in patients with schizophrenia. Stip E, et al. **Can J Psychiatry** 1996 Oct; 41(8 Suppl 2):S35–40
The promise of new drugs for schizophrenia treatment [see comments] Tamminga CA. **Can J Psychiatry** 1997 Apr; 42(3):265–73 (76 ref.). Comment in: Can J Psychiatry 1997 Apr;42(3):247–8.
The treatment of psychotic disorders in late life. Thorpe L. **Can J Psychiatry** 1997 Jun;42 Suppl 1:19S–27S (116 ref.)
Clozapine for the control of hemiballismus. Bashir K, et al. **Clin Neuropharmacol** 1994 Oct;17(5):477–80
Smooth pursuit eye movements in the evaluation of famotidine adjunctive therapy of schizophrenia: a preliminary report. Rosenberg PB, et al. **Clin Neuropharmacol** 1996 Jun;19(3):276–81
D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Rosse RB, et al. **Clin Neuropharmacol** 1996 Oct;19(5):444–50
Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Ruggieri S, et al. **Clin Neuropharmacol** 1997 Jun;20(3):204–9
Clozapine in hemiballismus: report of two cases. Stojanovic M, et al. **Clin Neuropharmacol** 1997 Apr;20(2):171–4
Response to Iwashashi: "significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change" [letter; comment] Zuiderwijk PB, et al. **Clin Neuropharmacol** 1997 Apr;20(2):179. Comment on: Clin Neuropharmacol 1996 Jun;19(3):267–70.
Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Aronson SM. **Clin Ther** 1997 Jan–Feb;19(1):139–47; discussion 126–7
Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing. Borison RL. **Clin Ther** 1996 Jul–Aug;18(4):592–607; discussion 591 (42 ref.)
Impact of newer antipsychotics on outcomes in schizophrenia. Keks NA. **Clin Ther** 1997 Jan–Feb; 19(1):148–58; discussion 126–7
Neuroleptic-resistant schizophrenia treated with clozapine and ECT. Benatov R, et al. **Convuls Ther** 1996 Jun; 12(2):117–21
Risperidone and ECT combination therapy: a case series. Farah A, et al. **Convuls Ther** 1995 Dec;11(4):280–2.
An atypical neuroleptic drug in the treatment of behavioural disturbances and psychotic symptoms in elderly people. Robertsson B, et al. **Dementia** 1996 May–Jun;7(3):142–6
Psychopharmacology for dermatologic patients. Koo J, et al. **Dermatol Clin** 1996 Jul;14(3):509–23 (53 ref.)
A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Mauri MC, et al. **Drug Saf** 1996 May; 14(5):288–98 (73 ref.)
Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Fulton B, et al. **Drugs** 1997 Feb; 53(2):281–98 (71 ref.)
Optimal management of behavioural disorders associated with dementia. Class CA, et al. **Drugs Aging** 1997 Feb; 10(2):95–106 (70 ref.)
Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms. Möller HJ, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(1):1–5
Review: treatment of schizophrenia. State of the art. Möller HJ. **Eur Arch Psychiatry Clin Neurosci** 1996;246(5):229–34 (62 ref.)
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Beasley CM Jr, et al. **Eur Neuropsychopharmacol** 1997 May;7(2):125–37
Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. Kasper S, et al. **Eur Neuropsychopharmacol** 1997 Feb;7(1):65–70
Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Kohn Y, et al. **Eur Neuropsychopharmacol** 1997 Feb;7(1):39–43
The expanding indications for clozapine. Young CR, et al. **Exp Clin Psychopharmacol** 1997 Aug;5(3):216–34 (235 ref.)
Quantitative opioid withdrawal signs in rats: effects exerted by clothiapine administration. Pinelli A, et al. **Fundam Clin Pharmacol** 1997;11(4):346–55
Psychosis in medical conditions: response to risperidone. Furmaga KM, et al. **Gen Hosp Psychiatry** 1997 May; 19(3):223–8
Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they "stabilizer" rather than typical compounds? Altamura AC. **Int Clin Psychopharmacol** 1996 Sep;11(3):153–5 (24 ref.)
Improvement of negative symptoms: Concepts, definition and assessment. Andreasen NC. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S7–10 (17 ref.)
Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Awad AG, et al. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:123–32 (46 ref.)
Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Awad AG, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:55–9 (28 ref.)
Response to clozapine in acute mania is more rapid than that of chlorpromazine. Barbini B, et al. **Int Clin Psychopharmacol** 1997 Mar;12(2):109–12
Pharmacological treatment strategies in the non-responsive schizophrenic patient. Barnes TR, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:67–71 (50 ref.)
Negative symptoms: diagnosis, treatment and prognosis. Buchanan RW, et al. **Int Clin Psychopharmacol** 1996 May; 11 Suppl 2:3–11 (90 ref.)
Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Freeman HL. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S11–7 (22 ref.)
Prediction of response to acute neuroleptic treatment in schizophrenia. Gaebel W. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:47–54 (31 ref.)
Conclusions and treatment recommendations for the acute episode in schizophrenia. Gaebel W, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:93–100 (75 ref.)
Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. Gaebel W. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S37–42 (48 ref.)
A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Hong CJ, et al. **Int Clin Psychopharmacol** 1997 May;12(3):123–30
What are the therapeutic needs in schizophrenia and how are they satisfied by new antipsychotics? Kane JM. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S3–6 (28 ref.)
Dosing issues and depot medication in the maintenance treatment of schizophrenia. Kane JM. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:65–71 (46 ref.)
What can we achieve by implementing a compliance-improvement program? Kane JM. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S43–6 (21 ref.)
Antipsychotic drug--a study of the prescription pattern in a total sample of patients with a schizophrenic syndrome in one catchment area in the county of Uppland, Sweden, in 1991. Lindström E, et al. **Int Clin Psychopharmacol** 1996 Dec;11(4):241–6
Pharmacological treatment strategies in acute schizophrenia. Marder SR. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:29–34 (24 ref.)
A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Naber D. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:133–8
Severe withdrawal akathisia following neuroleptic discontinuation successfully controlled by clozapine. Poyurovsky M, et al. **Int Clin Psychopharmacol** 1996 Dec; 11(4):283–6
Effects of nemonapride on positive and negative symptoms of schizophrenia. Satoh K, et al. **Int Clin Psychopharmacol** 1996 Dec;11(4):279–81
Amisulpride: from animal pharmacology to therapeutic action. Scatton B, et al. **Int Clin Psychopharmacol** 1997 May;12 Suppl 2:S29–36 (45 ref.)
Integration of family and drug treatment strategies in the treatment of schizophrenia: a selective review. Schooler NR. **Int Clin Psychopharmacol** 1995 Sep;10 Suppl 3:73–80 (31 ref.)
The role of antipsychotic agents in the treatment of bipolar disorder patients. Soares JC, et al. **Int Clin Psychopharmacol** 1997 Mar;12(2):65–76 (155 ref.)
The new generation of antipsychotic drugs. Tamminga CA, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:73–6 (15 ref.)
Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Tamminga CA, et al. **Int Clin Psychopharmacol** 1997 Feb;12 Suppl 1:S29–35 (7 ref.)
The use of risperidone in severely demented patients with persistent vocalizations. Kopala LC, et al. **Int J Geriatr Psychiatry** 1997 Jan;12(1):73–7
Risperidone in the treatment of psychosis and concomitant buccolinguomasticatory dyskinesia in the elderly [letter] Koponen HJ. **Int J Geriatr Psychiatry** 1997 Mar; 12(3):412–3
Methodological issues in characterizing treatment response in demented patients with behavioral disturbances. Mulsant BH, et al. **Int J Geriatr Psychiatry** 1997 May;12(5):537–47
Outcome of clozapine therapy for elderly patients with refractory primary psychosis. Sajatovic M, et al. **Int J Geriatr Psychiatry** 1997 May;12(5):553–8
Neuroleptic prescribing to the community elderly in Nottingham. Thacker S, et al. **Int J Geriatr Psychiatry** 1997 Aug;12(8):833–7
Somatic treatment of catatonia. Hawkins JM, et al. **Int J Psychiatry Med** 1995;25(4):345–69 (109 ref.)
Clozapine therapy in patients with neurologic illness. Sajatovic M, et al. **Int J Psychiatry Med** 1995;25(4):331–44 (60 ref.)
Outcome of risperidone therapy in elderly patients with chronic psychosis. Sajatovic M, et al. **Int J Psychiatry Med** 1996;26(3):309–17
Schizophrenia and antipsychotic somatic treatment. Lindström LH, et al. **Int J Technol Assess Health Care** 1996 Fall;12(4):573–84 (94 ref.)
Behavioral symptoms in dementia: community-based research. Auer SR, et al. **Int Psychogeriatr** 1996;8 Suppl 3:363–6; discussion 381–2
Nursing home research from industry's perspective. Brecher M. **Int Psychogeriatr** 1996;8 Suppl 3:367–70
Neuroleptic use and behavioral disturbance in nursing homes: a 1-year study. Burton LC, et al. **Int Psychogeriatr** 1995 Winter;7(4):535–45
Antipsychotic treatment in outpatients with dementia. Devanand DP. **Int Psychogeriatr** 1996;8 Suppl 3:355–61; discussion 381–2
Nursing home research from investigators' perspective. Finkel SI, et al. **Int Psychogeriatr** 1996;8 Suppl 3:371–3; discussion 381–2
Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Goldberg RJ, et al. **Int Psychogeriatr** 1997 Mar;9(1):65–8
Meta-analysis of controlled pharmacologic trials. Schneider LS. **Int Psychogeriatr** 1996;8 Suppl 3:375–9; discussion 381–2
Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Choe BY, et al. **Invest Radiol** 1996 Jun;31(6):345–52
New drug seen as breakthrough in treatment of schizophrenia [news] **Ir Med J** 1996 Jul–Aug;89(4):136
A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients. Verdoux H, et al. **J Affect Disord** 1996 Jun 5;38(2–3):81–7
Risperidone in adolescents with schizophrenia: an open pilot study. Armenteros JL, et al. **J Am Acad Child Adolesc Psychiatry** 1997 May; 36(5):694–700
Drug therapy in autism [letter] Frischauf E. **J Am Acad Child Adolesc Psychiatry** 1997 May;36(5):577
Olanzapine in PDD [letter] Horrigan JP, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Sep;36(9):1166–7
Risperidone in children with schizophrenia -letter- Lykes WC, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Apr; 35(4):405–6
Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle [see comments] Spencer T, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Apr;35(4):409–32 (202 ref.). Comment in: J Am Acad Child Adolesc Psychiatry 1996 Dec;35(12):1569–70. Comment in: J Am Acad Child Adolesc Psychiatry 1997 Mar;36(3):301–2.
Aggression and schizophrenia: efficacy of risperidone. Buckley PF, et al. **J Am Acad Psychiatry Law** 1997; 25(2):173–81
Charles Bonnet syndrome [letter; comment] Nevins M. **J Am Geriatr Soc** 1997 Jul;45(7):894–5. Comment on: J Am Geriatr Soc 1996 Sep;44(9):1128–9.
The effect of clozapine on self-injurious behavior. Hammock RG, et al. **J Autism Dev Disord** 1995 Dec;25(6):611–26
Risperidone and explosive aggressive autism. Horrigan JP, et al. **J Autism Dev Disord** 1997 Jun;27(3):313–23
Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. Khan BU. **J Autism Dev Disord** 1997 Aug;27(4):479–89
Brief report: reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardation. Schroeder SR, et al. **J Autism Dev Disord** 1997 Feb;27(1):89–102
Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. Dryden-Edwards RC, et al. **J Child Adolesc Psychopharmacol** 1996 Summer;

6(2):139–45
Use of risperidone in pervasive developmental disorders: a case series. Fisman S, et al.
J Child Adolesc Psychopharmacol 1996 Fall;6(3):177–90
Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. Grcevich SJ, et al.
J Child Adolesc Psychopharmacol 1996 Winter;6(4):251–7
Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. Schulz E, et al.
J Child Adolesc Psychopharmacol 1996 Summer;6(2):119–31
Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. de Oliveira IR, et al. **J Clin Pharm Ther** 1996 Oct; 21(5):349–58
New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. Buckley PF.
J Clin Pharmacol 1997 May;37(5):363–78 (121 ref.)
The Expert Consensus Guideline Series. Treatment of schizophrenia. Steering Committee. American Psychiatric Association. **J Clin Psychiatry** 1996;57 Suppl 12b:3–58
Practical Issues in Using Olanzapine. Proceedings of a symposium. Boston, Massachusetts, August 1–3, 1996.
J Clin Psychiatry 1997;58 Suppl 10:3–73
New strategies for treating psychosis. **J Clin Psychiatry** 1996; 57 Suppl 11:1–93
Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. Allan ER, et al.
J Clin Psychiatry 1996 Oct;57(10):455–9
Efficacy of olanzapine: an overview of pivotal clinical trials. Beasley CM Jr, et al. **J Clin Psychiatry** 1997;58 Suppl 10:7–12
Olanzapine and the new generation of antipsychotic agents: patterns of use. Glazer WM. **J Clin Psychiatry** 1997;58 Suppl 10:18–21 (30 ref.)
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. Glazer WM, et al. **J Clin Psychiatry** 1997; 58 Suppl 10:50–4 (29 ref.)
Dopamine D2 receptor imaging and neuroleptic drug response. Heinz A, et al. **J Clin Psychiatry** 1996;57 Suppl 11:84–8; discussion 89–93
Antipsychotic agents: minimizing side effects to maximize compliance. Kane JM, et al. **J Clin Psychiatry** 1996 Oct; 57(10):suppl 1–12
Evaluating outcomes of treatments for persons with psychotic disorders. Lehman AF. **J Clin Psychiatry** 1996; 57 Suppl 11:61–7 (18 ref.)
Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. Lieberman JA.
J Clin Psychiatry 1996;57 Suppl 11:68–71 (28 ref.)
Management of treatment-resistant patients with schizophrenia. Marder SR. **J Clin Psychiatry** 1996;57 Suppl 11:26–30 (40 ref.)
Chronic neuroleptic exposure in bipolar outpatients [published erratum appears in J Clin Psychiatry 1997 Jun;58(6):275] Sernyak MJ, et al. **J Clin Psychiatry** 1997 May;58(5):193–5
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia [published erratum appears in J Clin Psychiatry 1997 Jun;58(6):275] Tran PV, et al. **J Clin Psychiatry** 1997 May; 58(5):205–11
Atypical antipsychotic drugs and long-term outcome in schizophrenia. Weiden P, et al. **J Clin Psychiatry** 1996;57 Suppl 11:53–60 (36 ref.)
Switching antipsychotic medications. Weiden PJ, et al.
J Clin Psychiatry 1997;58 Suppl 10:63–72
Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Blin O, et al. **J Clin Psychopharmacol** 1996 Feb; 16(1):38–44
Risperidone and fluoxetine in the treatment of pedophilia with comorbid dysthymia [letter] Bourgeois JA, et al.
J Clin Psychopharmacol 1996 Jun;16(3):257–8
Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Chouinard G, et al.
J Clin Psychopharmacol 1997 Aug;17(4):298–307
Clozapine in rapid cycling bipolar disorder [letter] Frye MA, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):87–90
Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsia. Fuller MA, et al.
J Clin Psychopharmacol 1996 Aug;16(4):329–32
Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. Kopala LC, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):308–13
Comments on "Clozapine treatment after agranulocytosis induced by classic neuroleptics" [letter; comment] Mahmood T, et al. **J Clin Psychopharmacol** 1996 Jun; 16(3):262–3. Comment on: J Clin Psychopharmacol 1994 Feb;14(1):71–3.
Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. Pollmächer T, et al.
J Clin Psychopharmacol 1996 Oct;16(5):403–9
Remoxipride in the treatment of levodopa-induced psychosis. Sandor P, et al. **J Clin Psychopharmacol** 1996 Oct; 16(5):395–9
Risperidone in comorbid borderline personality disorder and dysthymia [letter] Szigethy EM, et al.
J Clin Psychopharmacol 1997 Aug;17(4):326–7
Clozapine and neuroleptic malignant syndrome: a never-ending story [letter; comment] Weller M, et al.
J Clin Psychopharmacol 1997 Jun;17(3):233–4. Comment on: J Clin Psychopharmacol 1995 Oct;15(5):365–71.
Risperidone plus a monoamine oxidase inhibitor for agitated depression crisis [letter] Welner M.
J Clin Psychopharmacol 1996 Dec;16(6):460–1
Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: retrospective review. Widman LP, et al. **J Geriatr Psychiatry Neurol** 1997 Apr;10(2):63–6
Efficacy and safety of risperidone in psychotic patients: an open study. Daradkeh TK, et al. **J Int Med Res** 1996 May–Jun;24(3):291–5
A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicestershire. Branford D. **J Intellect Disabil Res** 1996 Aug;40 (Pt 4):358–68
Depot neuroleptic usage in adults with learning disabilities. Gravestock S. **J Intellect Disabil Res** 1996 Feb;40 (Pt 1):17–23
Informed consent and tardive dyskinesia. Long-term follow-up. Kleinman I, et al. **J Nerv Ment Dis** 1996 Sep; 184(9):517–22
BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats. Okumura K, et al.
J Neural Transm 1996;103(10):1153–61
Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? Kornhuber J, et al.
J Neural Transm Suppl 1995;46:315–23 (34 ref.)
Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. van Vugt JP, et al.
J Neurol Neurosurg Psychiatry 1997 Jul;63(1):35–9
The role of serotonin in the pathophysiology and treatment of schizophrenia. Abi-Dargham A, et al.
J Neuropsychiatry Clin Neurosci 1997 Winter;9(1):1–17 (243 ref.)
Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Creese I, et al. **J Neuropsychiatry Clin Neurosci** 1996 Spring;8(2):223–6
The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. Fujii DE, et al.
J Neuropsychiatry Clin Neurosci 1997 Spring;9(2):240–5
Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. Wagner ML, et al.
J Neuropsychiatry Clin Neurosci 1996 Summer;8(3):276–80
PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. Goyer PF, et al. **J Nucl Med** 1996 Jul;37(7):1122–7
Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. Joyce JN, et al. **J Psychiatr Res** 1997 Mar–Apr;31(2):197–217 (70 ref.)
Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. Sanyal S, et al.
J Psychiatr Res 1997 Mar–Apr;31(2):219–32 (85 ref.)
The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs. Wetter TC, et al. **J Psychiatr Res** 1996 Nov–Dec; 30(6):411–9
Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. Awad AG, et al. **J Psychiatry Neurosci** 1997 Jul;22(4):244–8
Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. Revicki DA. **J Psychiatry Neurosci** 1997 Jul;22(4):256–66 (55 ref.)
Quality of life measurement during antipsychotic drug therapy of schizophrenia. Voruganti LN, et al.
J Psychiatry Neurosci 1997 Jul;22(4):267–74 (37 ref.)
What is an atypical antipsychotic? Reynolds GP.
J Psychopharmacol (Oxf) 1997;11(3):195–9 (45 ref.)
Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia [letter] Seibyl JP.
J Psychopharmacol (Oxf) 1997;11(2):188–9
Integration and synthesis. Cognitive behavioral therapies within the biological paradigm. Blair DT.
J Psychosoc Nurs Ment Health Serv 1996 Dec;34(12):26–31
Olanzapine: a new atypical antipsychotic. Littrell K, et al.
J Psychosoc Nurs Ment Health Serv 1996 Aug;34(8):41–6 (16 ref.)
Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. Singh AN, et al.
J Psychosom Res 1997 May;42(5):489–93
Olanzapine [letter; comment] Kerwin R. **Lancet** 1997 Aug 23;350(9077):594. Comment on: Lancet 1997 May 3;349(9061):1264–5.
Olanzapine for schizophrenia. **Med Lett Drugs Ther** 1997 Jan 17;39(992):5–6
Substituting traditional antipsychotics with risperidone for individuals with mental retardation. Simon EW, et al.
Ment Retard 1996 Dec;34(6):359–66
The emerging role of clozapine in the treatment of movement disorders. Factor SA, et al. **Mov Disord** 1997 Jul; 12(4):483–96 (147 ref.)
Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Meco G, et al. **Mov Disord** 1997 Jul;12(4):610–2
Tardive lingual dystonia treated with clozapine. Raja M, et al. **Mov Disord** 1996 Sep;11(5):585–6
Pharmacologic advances in the treatment of schizophrenia [editorial; comment] Keith SJ. **N Engl J Med** 1997 Sep 18;337(12):851–2. Comment on: N Engl J Med 1997 Sep 18;337(12):809–15.
A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia [see comments] Rosenheck R, et al. **N Engl J Med** 1997 Sep 18;337(12):809–15. Comment in: N Engl J Med 1997 Sep 18;337(12):851–2.
Tourette syndrome. Treatment of tics. Kurlan R.
Neurol Clin 1997 May;15(2):403–9 (53 ref.)
Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Friedman JH, et al. **Neurology** 1997 Apr;48(4):1077–81
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Wolters EC, et al.
Neurology 1996 Oct;47(4):1085–7
Practical issues in clinical research of schizophrenia. Brunello N, et al. **Neuropsychobiology** 1997;35(2):57–60
Medicated chronic schizophrenic patients do not demonstrate left turning asymmetry. Levine J, et al.
Neuropsychobiology 1997;36(1):22–4
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial [see comments] Beasley CM Jr, et al.
Neuropsychopharmacology 1996 Feb;14(2):111–23. Comment in: Neuropsychopharmacology 1997 Jan;16(1):88–90.
Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Levin ED, et al.
Neuropsychopharmacology 1996 Nov;15(5):429–36
Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Meltzer HY, et al. **Neuropsychopharmacology** 1996 Mar; 14(3 Suppl):27S–33S (61 ref.)
Olanzapine: a new typical antipsychotic drug. Meltzer HY, et al. **Neuropsychopharmacology** 1996 Feb;14(2):83–5 (21 ref.)
Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Rietschel M, et al. **Neuropsychopharmacology** 1996 Nov; 15(5):491–6
Clozapine response and the 5HT2C Cys23Ser polymorphism. Malhotra AK, et al. **Neuroreport** 1996 Sep 2;7(13):2100–2
Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Rietschel M, et al.
Neuroreport 1997 May 27;8(8):1999–2003
Psychotropic drug use in a group of Dutch nursing home patients with dementia: many users, long-term use, but low doses. Koopmans RT, et al. **Pharm World Sci** 1996 Jan; 18(1):42–7
Cognitive function in schizophrenia--do neuroleptics make a difference? Mortimer AM. **Pharmacol Biochem Behav** 1997 Apr;56(4):789–95 (74 ref.)
Measuring the efficacy of psychopharmacological treatment of psychomotoric restlessness in dementia: clinical evaluation of tiapride. Gutzmann H, et al.
Pharmacopsychiatry 1997 Jan;30(1):6–11
The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels. Pollmächer T, et al.
Pharmacopsychiatry 1997 Jul;30(4):118–21
Risperidone in treatment-refractory chronic alcohol hallucinosis [letter] Soyka M, et al. **Pharmacopsychiatry** 1997 Jul;30(4):135–6
Considerable improvement in a case of obsessive-compulsive disorder in an emotionally unstable personality disorder, borderline type under treatment with clozapine. Steinert T, et al. **Pharmacopsychiatry** 1996 May;29(3):111–4
Reemergence of positive symptoms after initial response to risperidone. Cung DD, et al. **Pharmacotherapy** 1997 Mar–Apr;17(2):383–6
Sedation in acute and chronic agitation. Levy RH.
Pharmacotherapy 1996 Nov–Dec;16(6 Pt 2):152S–159S; discussion 166S–168S (33 ref.)
Sedation--therapeutic or side effect in psychoses. Introduction. Miller DD. **Pharmacotherapy** 1996 Nov–Dec; 16(6 Pt 2):141S–142S
New antipsychotic medications: what advantages do they offer? Citrome L. **Postgrad Med** 1997 Feb;101(2):207–10, 213–4 (19 ref.)
Platelet [3H]dopamine uptake is differentially affected by neuroleptic drug treatment in schizophrenia and schizophreniform disorder. Dean B, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1996 Jan; 20(1):45–55
Clozapine eligibility: the effect of stringent criteria on ethnic, gender and age subgroups of schizophrenic patients. Juarez-Reyes MG, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1996 Nov; 20(8):1341–52
A longitudinal study of cerebrospinal fluid angiotensin-converting enzyme in neuroleptic-treated schizophrenia. Wahlbeck K, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1997 May; 21(4):591–9
Psychopharmacologic treatment of pathologic aggression. Fava M. **Psychiatr Clin North Am** 1997 Jun;20(2):427–51 (176 ref.)
Clozapine plasma level monitoring: current status. Cooper TB. **Psychiatr Q** 1996 Winter;67(4):297–311 (73 ref.)
Geriatric psychosis. Lacro JP, et al. **Psychiatr Q** 1997 Fall; 68(3):247–60 (45 ref.)
Cost-benefits of risperidone [letter] [see comments] Bilsker D. **Psychiatr Serv** 1996 Mar;47(3):309–10. Comment in:

Psychiatr Serv 1996 Aug;47(8):877–8.
Clozapine and excessive psychotropic drug use [letter] [see comments] Drew LR, et al. **Psychiatr Serv** 1996 Aug; 47(8):876. Comment in: Psychiatr Serv 1996 Dec;47(12):1392.
Treating older adults with psychotic symptoms. Kim KY, et al. **Psychiatr Serv** 1997 Sep;48(9):1123–6 (34 ref.)
Documenting informed consent for treatment with neuroleptics: an alternative to the consent form. Munetz MR, et al. **Psychiatr Serv** 1996 Mar;47(3):302–3
A naturalistic outcome study of risperidone treatment among hospital patients. Negrón AE, et al. **Psychiatr Serv** 1996 Oct;47(10):1118–20
Medication noncompliance and substance abuse among patients with schizophrenia. Owen RR, et al. **Psychiatr Serv** 1996 Aug;47(8):853–8
Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Segal SP, et al. **Psychiatr Serv** 1996 Mar;47(3):282–6
Utilization of neuroleptic drugs in Italian mental health services: a survey in Piedmont. Tibaldi G, et al. **Psychiatr Serv** 1997 Feb;48(2):213–7
Impact of risperidone on the use of mental health care resources. Viale G, et al. **Psychiatr Serv** 1997 Sep; 48(9):1153–9
New directions in the prevention and treatment of schizophrenia: a biological perspective. Wyatt RJ, et al. **Psychiatry** 1996 Winter;59(4):357–70 (90 ref.)
Improvement of schizophrenic symptoms and changes in plasma HVA concentrations, plasma anti-D2 and anti-5-HT2 receptor activities with clozapine. Yamada K, et al. **Psychiatry Clin Neurosci** 1996 Oct;50(5):291–4
Residual symptoms and P300 in schizophrenic outpatients. Juckel G, et al. **Psychiatry Res** 1996 Nov 1;65(1):23–32
Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Krakowski M, et al. **Psychiatry Res** 1997 Jun 16;71(1):19–26
Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. Küfferle B, et al. **Psychiatry Res** 1996 Nov 25;68(1):23–30
Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Monteleone P, et al. **Psychiatry Res** 1997 Jun 16;71(1):11–7
Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. Yao JK, et al. **Psychiatry Res** 1996 Feb 28;60(1):11–21
Pre-morbid asociality in neuroleptic-resistant and neuroleptic-responsive schizophrenia. Findling RL, et al. **Psychol Med** 1996 Sep;26(5):1033–41
Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Wyatt RJ, et al. **Psychol Med** 1997 Mar;27(2):261–8
Attitude toward medication and perceived competence among chronically psychotic patients. Todman M Jr, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):809–10
Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Baker RW, et al. **Psychopharmacol Bull** 1996;32(1):89–93
Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Carter CS, et al. **Psychopharmacol Bull** 1995;31(4):719–25
Issues in polypharmacotherapy: focus on depression in schizophrenia. Dufresne RL. **Psychopharmacol Bull** 1995; 31(4):789–96 (31 ref.)
An open clinical trial of risperidone monotherapy in young children with autistic disorder. Findling RL, et al. **Psychopharmacol Bull** 1997;33(1):155–9
Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Hamner MB, et al. **Psychopharmacol Bull** 1996;32(1):107–10
Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Jeste DV, et al. **Psychopharmacol Bull** 1996;32(2):243–51
A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Petit M, et al. **Psychopharmacol Bull** 1996;32(1):81–7
Treatment of elderly institutionalized bipolar patients with clozapine. Shulman RW, et al. **Psychopharmacol Bull** 1997; 33(1):113–8
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Beasley CM Jr, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1-2):159–67
Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women. Fabrazzo M, et al. **Psychopharmacology (Berl)** 1996 Mar; 124(1-2):197–200
Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Frieboes RM, et al. **Psychopharmacology (Berl)** 1997 Jul;132(1):82–8
Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Meltzer HY, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1-2):176–87
A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. van Kammen DP, et al. **Psychopharmacology (Berl)** 1996 Mar;124(1-2):168–75
Outcome of first-episode schizophrenia and the new antipsychotics. A literature review. Emsley R. **S Afr Med J** 1996 Jun;86(6 Suppl):729–30, 734 (35 ref.)
Risperidone: how good is the evidence for efficacy? Mattes JA. **Schizophr Bull** 1997;23(1):155–61 (36 ref.)
Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Wilkins JN. **Schizophr Bull** 1997; 23(2):215–28
Change in quantified electroencephalography (QEEG) with medication and altered clinical state in the same subjects with schizophrenia [letter] Harris A, et al. **Schizophr Res** 1997 Jan 17;23(1):87–9
Lack of gender differences in neuroleptic response in patients with schizophrenia. Pinals DA, et al. **Schizophr Res** 1996 Dec 15;22(3):215–22 (38 ref.)
Effect of clozapine on physical and verbal aggression. Rabinowitz J, et al. **Schizophr Res** 1996 Dec 15; 22(3):249–55
Psychotropic drug prescription in rehabilitation. A survey in Hong Kong. Ungvari GS, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Sep;31(5):288–91
Sertindole hydrochloride: a novel antipsychotic medication with a favorable side effect profile. Brown GR, et al. **South Med J** 1997 Jul;90(7):691–3
Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Bristow LJ, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):186–8 (11 ref.)
["Polydipsia, intermittent hyponatremia and psychoses" syndrome: a diagnosis and therapeutic management of a case] Assouly-Besse F, et al. **Ann Med Psychol (Paris)** 1996 Jun;154(4):259–63 (Eng. Abstr.) **(Fre)**
[Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine] Göbel H, et al. **Drugs** 1997;53 Suppl 2:34–9 (Eng. Abstr.) **(Fre)**
[Patient education about neuroleptic treatment, can it reduce costs? A pilot study] Favrod J, et al. **Encephale** 1996 Sep-Oct;22(5):331–6 (Eng. Abstr.) **(Fre)**
[4 years using clozapine in community psychiatry] Fremont P, et al. **Encephale** 1996 Dec;22 Spec No 6:24–7 (Eng. Abstr.) **(Fre)**
[Indications for clozapine] Gaussarès C. **Encephale** 1996 Dec; 22 Spec No 6:12–5 (22 ref.) (Eng. Abstr.) **(Fre)**
[Clinical follow-up — EEG — serum determinations: therapeutic experience with clozapine] Gekiere F, et al. **Encephale** 1996 Dec;22 Spec No 6:16–23 (Eng. Abstr.) **(Fre)**
[Leponex: experience of the hospital pharmacist] Gury C, et al. **Encephale** 1996 Dec;22 Spec No 6:28–32 (Eng. Abstr.) **(Fre)**
[Clozapine in the treatment of schizophrenia] Kane JM. **Encephale** 1996 Dec;22 Spec No 6:7–11 **(Fre)**
[Clozapine and schizophrenias: 1991-1996] Lôo H, et al. **Encephale** 1996 Dec;22 Spec No 6:1–2 **(Fre)**
[New chemotherapy approaches to psychoses] Olié JP, et al. **Encephale** 1997 Apr;23 Spec No 2:2–9 (53 ref.) (Eng. Abstr.) **(Fre)**
[Schizophrenia and neural transmission: an excess of analogical treatment?] Tassin JP. **Encephale** 1996 Oct;22 Spec No 3:91–8 (55 ref.) **(Fre)**
[Prescribing clozapine to that patient: between anarchistic empiricism and arbitrary classification] Uhl R. **Encephale** 1996 Dec;22 Spec No 6:33–4 (Eng. Abstr.) **(Fre)**
[Pharma-clinics. Drug of the month. Risperidone (Risperdal)] Ansseau M. **Rev Med Liege** 1996 Oct;51(10):665–7 **(Fre)**
[Practical experiences in the therapy of postweaning edema disease in piglets] Papp I, et al. **Berl Munch Tierarztl Wochenschr** 1996 Oct;109(10):385–7 (Eng. Abstr.) **(Ger)**
[Remission of schizophrenic psychosis with negative symptoms with risperidone] Lübbe R. **Fortschr Med** 1996 Feb 28;114(6):35–6 (Eng. Abstr.) **(Ger)**
[Schizophrenia: prophylaxis prevents recurrence. Low dose depot neuroleptics--an exit from the "revolving door" psychiatry] **Fortschr Med Suppl** 1993;147:1–15 **(Ger)**
[Risperidon--contribution to an integrated therapy of schizophrenia. Yearly session of the German Society for Psychiatry, Psychotherapy and Neurology. Düsseldorf, 17 September 1996] **Fortschr Neurol Psychiatr** 1996 Dec;64(12 Suppl):1–4 **(Ger)**
[Olanzapin: a new perspective in the management of schizophrenia. X. Congress of the World Psychiatric Association, Madrid, August 1996] **Fortschr Neurol Psychiatr** 1996 Nov;64(11 Suppl Olanzapin):1–4 **(Ger)**
[Manneristic catatonia. A psychotropic drug refractory chronic progressive course] Stöber G, et al. **Fortschr Neurol Psychiatr** 1996 Jul;64(7):250–60 (Eng. Abstr.) **(Ger)**
[Treatment of sleep disorders] Holsboer-Trachsler E. **Internist (Berl)** 1997 Jul;38(7):704 **(Ger)**
[Risperidon: an advance for schizophrenic patients. Why new neuroleptics?] **Nervenarzt** 1994 May;65(5 Suppl [risperid]):1–4 **(Ger)**
[Zotepin--its value and potentials for further development] **Nervenarzt** 1994 Jul;65(7 Suppl):1–8 **(Ger)**
[Compulsory psychiatric drug therapy in Switzerland--legislation and reality exemplified by a few clinical cases] Caduff F. **Schweiz Med Wochenschr** 1997 Apr 5;127(14):585–96 (44 ref.) (Eng. Abstr.) **(Ger)**
[Clozapine, cytokines, fever and sleep] Hinze-Selch D, et al. **Wien Med Wochenschr** 1996;146(13-14):311–3 (Eng. Abstr.) **(Ger)**
[Seroquel in a resistant schizophrenic with negative and positive symptoms] Reznik I, et al. **Harefuah** 1996 May 15;130(10):675–7, 727 (Eng. Abstr.) **(Heb)**
[Pharmacological treatment of delusional depression] Amore M, et al. **Minerva Psichiatr** 1996 Mar;37(1):29–33 (28 ref.) (Eng. Abstr.) **(Ita)**
[Bromperidol decanoate in the residual phase of schizophrenia] Smeraldi E, et al. **Minerva Psichiatr** 1996 Mar;37(1):39–44 (Eng. Abstr.) **(Ita)**
[Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa] Svetel MV, et al. **Srp Arh Celok Lek** 1997 Jul-Aug;125(7-8):203–6 (Eng. Abstr.) **(Scc)**
[Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol] López Ibor JJ, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Jul-Aug;24(4):165–72 (Eng. Abstr.) **(Spa)**
[A preliminary study of low dosage zuclopenthixol depot in Alzheimer's disease] Robles A, et al. **Rev Neurol** 1996 Mar;24(127):273–5 (Eng. Abstr.) **(Spa)**
[An approach to the pharmacological treatment of autism] Ruggieri VL. **Rev Neurol** 1996 Nov;24(135):1451–5 (58 ref.) (Eng. Abstr.) **(Spa)**
[A new report from the SBU on treatment with neuroleptics. Over 2000 scientific articles critically scrutinized] **Lakartidningen** 1997 May 28;94(22):2108, 2111–2 **(Swe)**
[Brighter prospects for patients with psychoses? New neuroleptics may improve the long-term prognosis] Lindström L. **Lakartidningen** 1996 Nov 6;93(45):3989–90 (11 ref.) **(Swe)**
[Promising effects of the new antipsychotic agents in schizophrenia. But recommendations of the Medical Products Agency are conservative] Sedvall GC. **Lakartidningen** 1997 May 14;94(20):1873–6 (19 ref.) **(Swe)**

TOXICITY

Neuroleptic binding to sigma receptors: possible involvement in neuroleptic-induced acute dystonia. Jeanjean AP, et al. **Biol Psychiatry** 1997 May 15;41(10):1010–9
Test methods for predicting tardive toxicity of therapeutic drugs using laboratory animals. Ando K. **J Toxicol Sci** 1996 Feb;21(1):105–7 (5 ref.)
Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism. Seeman P, et al. **Jpn J Pharmacol** 1996 Jul;71(3):187–204 (140 ref.)
Clozapine-induced cognitive dysfunction in mice. Ninan I, et al. **Methods Find Exp Clin Pharmacol** 1996 Jul-Aug; 18(6):367–72
Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the "super-off" phenomenon. Dziewczapolski G, et al. **Mov Disord** 1997 Mar;12(2):159–66
Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Wadenberg ML. **Neurosci Biobehav Rev** 1996 Summer;20(2):325–39 (135 ref.)
Effects of perospirone (SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated vacuous chewing movement in rats: a role of 5-HT2 receptor blocking activity. Ohno Y, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):889–95
Effect of clozapine on dopamine-induced inhibition of prolactin release from cultured rat pituitary cells. Braghiroli L, et al. **Pharmacol Res** 1997 Mar;35(3):173–5
Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Egan MF, et al. **Psychopharmacology (Berl)** 1996 Oct;127(4):337–45

URINE

Automated determination of clozapine and major metabolites in serum and urine. Weigmann H, et al. **Ther Drug Monit** 1997 Aug;19(4):480–8

ANTIPSYCHOTIC AGENTS, BUTYROPHENONE

A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Janicak PG, et al. **Acta Psychiatr Scand** 1997 Apr;95(4):343–50

ADMINISTRATION & DOSAGE

A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Sultzer DL, et al. **Am J Geriatr Psychiatry** 1997 Winter;5(1):60–9
Evaluation of inpatient depot antipsychotic prescribing. Pabis DJ, et al. **Ann Pharmacother** 1996 Dec;30(12):1381–6
Re: Rapid stabilization at home [letter; comment] Jeffries JJ. **Can J Psychiatry** 1997 May;42(4):427. Comment on: Can J Psychiatry 1996 Nov;41(9):605–6.
Rapid stabilization at home [letter] [see comments] Reding KM, et al. **Can J Psychiatry** 1996 Nov;41(9):605–6. Comment in: Can J Psychiatry 1997 May;42(4):427.
Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients. Vallabhajosula S, et al. **J Nucl Med** 1997 Feb;38(2):203–7
Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate. Jann MW, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Jan; 20(1):73–86

Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics. Huttunen MO, et al. **Psychiatr Serv** 1996 Jan;47(1):83-5

Chronic haloperidol treatment does not affect structure of attention in schizophrenia. Allen DN, et al. **Schizophr Res** 1997 May 3;25(1):53-61

The Dose Reduction in Schizophrenia (DORIS) Study: a final report. Hirschowitz J, et al. **Schizophr Res** 1997 Jan 17;23(1):31-43

[Administration of high dose haloperidol in a patient refractory to treatment with traditional and atypical neuroleptics] Stip E, et al. **Encephale** 1996 Jul-Aug; 22(4):298-300 **(Fre)**

[Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation] Vanelle JM, et al. **Encephale** 1996 Oct;22 Spec No 3:82-4 **(Fre)**

ADVERSE EFFECTS

Extrapyramidal symptoms from intravenous haloperidol in the treatment of delirium [letter] Blitzstein SM, et al. **Am J Psychiatry** 1997 Oct;154(10):1474-5

Rhabdomyolysis associated with haloperidol without evidence of NMS [letter] Marinella MA. **Ann Pharmacother** 1997 Jul-Aug;31(7-8):927-8

Possible toxic encephalopathy following high-dose intravenous haloperidol. Maxa JL, et al. **Ann Pharmacother** 1997 Jun;31(6):736-7

Torsade de pointes and low-dose oral haloperidol. Jackson T, et al. **Arch Intern Med** 1997 Sep 22;157(17):2013-5 (7 ref.)

Antipsychotic drug-induced dysphoria [letter; comment] Lynch G, et al. **Br J Psychiatry** 1996 Oct;169(4):524. Comment on: Br J Psychiatry 1995 Oct;167(4):480-2. Comment on: Br J Psychiatry 1996 May;168(5):655-6.

Urinary retention with fluoxetine-haloperidol combination in a young patient [letter] Benazzi F. **Can J Psychiatry** 1996 Nov;41(9):606-7

Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jun;36(6):835-43

Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Jauss M, et al. **Mov Disord** 1996 Nov;11(6):726-8

Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal. Aloe L, et al. **Neuropsychobiology** 1997;36(2):65-8

Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients. Meszaros K, et al. **Neuropsychobiology** 1997;36(2):69-72

Urinary retention with venlafaxine-haloperidol combination [letter] Benazzi F. **Pharmacopsychiatry** 1997 Jan;30(1):27

Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Lawrence KR, et al. **Pharmacotherapy** 1997 May-Jun;17(3):531-7 (45 ref.)

Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics. Weisbard JJ, et al. **Psychopharmacol Bull** 1997;33(1):119-22

[Hypothermia during use of pipamperone] Eikenboom HC, et al. **Ned Tijdschr Geneeskd** 1997 Feb 8;141(6):301-3 (Eng. Abstr.) **(Dut)**

[Cytolytic hepatitis during treatment with phenothiazines: apropos of a case] Mesure G, et al. **Encephale** 1996 Sep-Oct;22(5):388-90 (Eng. Abstr.) **(Fre)**

[Depressive stupor--malignant neuroleptic syndrome--serotonin syndrome. A case contribution to a difficult differential diagnosis] König F, et al. **Nervenarzt** 1996 May;67(5):407-12 (Eng. Abstr.) **(Ger)**

Accidental intravenous administration of haloperidol decanoate] Heinz P. **Psychiatr Prax** 1996 Jan;23(1):42 **(Ger)**

Rhabdomyolysis and acute renal failure caused by haloperidol-decanoate (neuroleptic malignant syndrome)] Lazzarin M, et al. **Recenti Prog Med** 1996 Sep;87(9):422-4 (Eng. Abstr.) **(Ita)**

Acute recurrent dystonia secondary to neuroleptic suppression (letter)] Modrego Pardo P, et al. **Rev Clin Esp** 1997 Mar;197(3):211-2 **(Spa)**

ANALYSIS

Voltammetric determination of droperidol and benperidol. Biryol I, et al. **J Pharm Biomed Anal** 1997 Jul; 15(11):1695-701

ANTAGONISTS & INHIBITORS

The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats. McAllister KH. **Eur J Pharmacol** 1996 Oct 31;314(3):307-11

BLOOD

Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol. Odou P, et al. **Eur J Clin Pharmacol** 1996;50(5):357-63

Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization. Hoja H, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):275-80

Determination of timiperone in rat plasma by high-performance liquid chromatography with electrochemical detection. Takayasu T, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1-2):161-5

Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. de Oliveira IR, et al. **J Clin Pharm Ther** 1996 Aug;21(4):229-36

Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients. Meszaros K, et al. **Neuropsychobiology** 1997;36(2):69-72

CHEMICAL SYNTHESIS

Synthesis and affinities for dopamine (D2) and 5-hydroxytryptamine (5-HT2A) receptors of 1-(benzoylpropyl)-4-(1-oxocycloalkyl-2-ethyl)-piperazines as cyclic butyrophenone derivatives. Raviña E, et al. **Chem Pharm Bull (Tokyo)** 1996 Mar;44(3):534-41

ECONOMICS

Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Chouinard G, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):298-307

METABOLISM

Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Usuki E, et al. **Chem Res Toxicol** 1996 Jun; 9(4):800-6

[The binding of 3H-spiperone to lymphocytes in patients with schizophrenia and first-degree relatives: in search of a genetic marker] Heinze G, et al. **Gac Med Mex** 1994 Jul-Aug;130(4):241-5 (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Effect of d-limonene, alpha-pinene and cineole on in vitro transdermal human skin penetration of chlorpromazine and haloperidol. Almirall M, et al. **Arzneimittelforschung** 1996 Jul;46(7):676-80

Interaction between carbamazepine and bromperidol. Otani K, et al. **Eur J Clin Pharmacol** 1997;52(3):219-22

Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. Barbhaiya RH, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):26-34

Prediction of haloperidol steady-state levels in plasma after a single test dose. Javaid JI, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):45-50

Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients. Kim YH, et al. **J Clin Psychopharmacol** 1996 Jun;16(3):247-52

Plasma haloperidol and reduced haloperidol concentrations in a geriatric population. Chang WH, et al. **Neuropsychobiology** 1996;33(1):12-6

Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients. Jann MW, et al. **Neuropsychobiology** 1997;36(1):32-6

Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Avenoso A, et al. **Pharmacol Res** 1997 Apr;35(4):335-9

No interaction between desipramine and bromperidol. Suzuki A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Oct;20(7):1265-71

PHARMACOLOGY

Effects of clozapine and haloperidol on baseline levels of vacuous jaw movements in aged rats. Steinpreis RE, et al. **Behav Brain Res** 1997 Jul;86(2):165-9

Antipsychotic regulation of hippocampal dopamine receptor messenger RNA expression. Ritter LM, et al. **Biol Psychiatry** 1997 Aug 1;42(3):155-64

Haloperidol affects guinea pig chewing burst durations. Gerstner GE. **Brain Behav Evol** 1996;48(2):94-102

Bcl-2 prevents hippocampal cell death induced by the neuroleptic drug haloperidol. Lezoualc'h F, et al. **Brain Res** 1996 Oct 28;738(1):176-9

Temporal dissociation of neurotensin/neuromedin N mRNA expression in topographically separate subsets of rat striatal neurons following administration of haloperidol. Zahm DS, et al. **Brain Res Mol Brain Res** 1996 Nov;42(1):71-8

Evidence that the NH2-terminus of substance P modulates N-methyl-D-aspartate-induced activity by an action involving sigma receptors. Hornfeldt CS, et al. **Eur J Pharmacol** 1996 Jun 13;306(1-3):15-22

Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain. Karolewicz B, et al. **Eur J Pharmacol** 1996 Oct 17; 313(3):181-6

Subchronic haloperidol administration decreases aminopeptidase N activity and [Met5]enkephalin metabolism in rat striatum and cortex. Konkoy CS, et al. **Eur J Pharmacol** 1996 Feb 15;297(1-2):47-51

Effect of haloperidol on the behavioral stimulation by N-cyanomethylmethamphetamine, a main product of smoking methamphetamine mixed with tobacco. Kuribara H, et al. **Eur J Pharmacol** 1996 Jun 3;305(1-3):1-6

The effect of chlorpromazine and haloperidol on DNA transcription. Barak Y, et al. **Int Clin Psychopharmacol** 1996 Sep;11(3):193-7

Effect of ethanol, haloperidol, and lorazepam on cardiac conduction and contraction. Medlin RP Jr, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):792-8

Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. Barbhaiya RH, et al. **J Clin Psychopharmacol** 1996 Feb;16(1):26-34

Changes in EEG order in neuroleptically treated normal volunteers during a voluntary movement task. Diekmann V, et al. **J Neural Transm** 1996;103(8-9):1127-39

Inhibition of N-methyl-D-aspartate receptors by haloperidol: developmental and pharmacological characterization in native and recombinant receptors. Lynch DR, et al. **J Pharmacol Exp Ther** 1996 Oct; 279(1):154-61

Intravenous administration of haloperidol to healthy volunteers: lack of subjective effects but clear objective effects. Williams JH, et al. **J Psychopharmacol (Oxf)** 1997; 11(3):247-52

Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes. Eastwood SL, et al. **Mol Psychiatry** 1997 Jul; 2(4):322-9

Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine [see comments] Meador-Woodruff JH, et al. **Mol Psychiatry** 1996 Mar;1(1):41-53. Comment in: Mol Psychiatry 1996 Mar;1(1):16-7.

Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs. Weiner I, et al. **Neuropsychopharmacology** 1997 Jan;16(1):42-50

EEDQ reduces the striatal neurotensin mRNA response to haloperidol. Adams MR, et al. **Peptides** 1997;18(4):527-35

Typical and atypical neuroleptic drugs decrease platelet 3H-dopamine uptake in the rat. Sundram S, et al. **Psychiatry Res** 1996 Jun 1;62(3):259-63

Evidence for dissociable mechanisms of amphetamine- and stress-induced behavioral sensitization: effects of MK-801 and haloperidol pretreatment. Tolliver BK, et al. **Psychopharmacology (Berl)** 1996 Aug;126(3):191-8

Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol. Mihara K, et al. **Ther Drug Monit** 1997 Feb;19(1):43-5

POISONING

[Acute encephalomyopathy and persistent cerebellar syndrome after lithium salt and haloperidol poisoning] Gille M, et al. **Rev Neurol (Paris)** 1997 May;153(4):268-70 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Battaglia J, et al. **Am J Emerg Med** 1997 Jul;15(4):335-40

Treatment of a paradoxical reaction to midazolam with haloperidol. Khan LC, et al. **Anesth Analg** 1997 Jul; 85(1):213-5

Acute effects of haloperidol on cerebral cortex blood flow in normal and schizophrenic subjects. Goldman RG, et al. **Biol Psychiatry** 1996 Oct 1;40(7):604-8

First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Nagaoka S, et al. **Biol Psychiatry** 1997 Apr 15; 41(8):857-64

Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people. Williams JH, et al. **Biol Psychiatry** 1996 Dec 1; 40(11):1135-43

Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment. Czobor P, et al. **Compr Psychiatry** 1996 May-Jun; 37(3):205-15

Combination midazolam and droperidol for severe post-ECT agitation [letter] Hines AH, et al. **Convuls Ther** 1997 Jun; 13(2):113-4

D2-dopamine-receptor occupancy during treatment with haloperidol decanoate. Scherer J, et al. **Eur Arch Psychiatry Clin Neurosci** 1997;247(2):104-6

Melperone treatment in an organic delusional syndrome induced by hyperprolactinemia: a case report. Soygür H, et al. **Eur Neuropsychopharmacol** 1997 May;7(2):161-3

Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Barbato L, et al. **Funct Neurol** 1996 Jul-Aug;11(4):201-7

Droperidol treatment of status migrainosus and refractory migraine. Wang SJ, et al. **Headache** 1997 Jun;37(6):377-82

Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Foster S, et al. **Int Clin Psychopharmacol** 1997 May; 12(3):175-9

Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium. Nakamura J, et

al. **Int Clin Psychopharmacol** 1997 May;12(3):147–52
The use of haloperidol in the agitated, critically ill pediatric patient with burns. Brown RL, et al. **J Burn Care Rehabil** 1996 Jan–Feb;17(1):34–8
Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Chouinard G, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):298–307
The efficacy of intravenous droperidol in the prehospital setting. Rosen CL, et al. **J Emerg Med** 1997 Jan–Feb; 15(1):13–7
Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations. Suzuki E, et al. **J Psychiatry Neurosci** 1996 May;21(3):167–71
Effect of haloperidol on the development of the solid Ehrlich tumor in mice. Kleeb SR, et al. **Life Sci** 1997; 60(4–5):PL69–74
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial [see comments] Beasley CM Jr, et al. **Neuropsychopharmacology** 1996 Feb;14(2):111–23. Comment in: Neuropsychopharmacology 1997 Jan;16(1):88–90.
Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Avenoso A, et al. **Pharmacol Res** 1997 Apr;35(4):335–9
Predicting haloperidol treatment response in chronic schizophrenia. van Kammen DP, et al. **Psychiatry Res** 1996 Aug 30;64(1):47–58
Symptom change and extrapyramidal side effects during acute haloperidol treatment in chronic geriatric schizophrenics. Weisbard JJ, et al. **Psychopharmacol Bull** 1997;33(1):119–22
Positive and negative symptoms: is their change related? Czobor P, et al. **Schizophr Bull** 1996;22(4):577–90
A retrospective study of the psychiatric management and outcome of delirium in the cancer patient [see comments] Olofsson SM, et al. **Support Care Cancer** 1996 Sep; 4(5):351–7. Comment in: Support Care Cancer 1996 Sep;4(5):325.

TOXICITY

Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level. Tanii H, et al. **Brain Res** 1996 Dec 16;743(1–2):263–70
The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Millan MJ, et al. **Eur J Pharmacol** 1997 Mar 5;321(3):R7–9
Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Meshul CK, et al. **Psychopharmacology (Berl)** 1996 Jun;125(3):238–47
Autoradiographic mapping of mu opioid receptor changes in rat brain after long-term haloperidol treatment: relationship to the development of vacuous chewing movements. Sasaki T, et al. **Psychopharmacology (Berl)** 1996 Nov;128(1):97–104

ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE

ADMINISTRATION & DOSAGE

Suggestions to improve conversion of fluphenazine dosage forms [letter; comment] Raleigh F. **Am J Health Syst Pharm** 1996 Jul 15;53(14):1727, 1732. Comment on: Am J Health Syst Pharm 1995 Dec 15;52(24):2826–7.
Evaluation of inpatient depot antipsychotic prescribing. Pabis DJ, et al. **Ann Pharmacother** 1996 Dec;30(12):1381–6

ADVERSE EFFECTS

Acute dystonic reaction to methotrimeprazine in hypoparathyroidism. Gur H, et al. **Ann Pharmacother** 1996 Sep;30(9):957–9
Clozapine-chlorpromazine allergic cross-reactivity in a psychotic patient with asymptomatic AIDS [letter] Quintana J, et al. **Biol Psychiatry** 1996 Dec 1;40(11):1185–6
Dysarthria: lonely symptom of tardive dystonia [letter] Ananth J, et al. **Can J Psychiatry** 1997 May;42(4):428–9
Persistent chlorpromazine deposits in donor corneal tissue after corneal transplantation. Cahane M, et al. **Cornea** 1997 Sep;16(5):588–9
Phototoxic properties of neuroleptic drugs. Eberlein-König B, et al. **Dermatology** 1997;194(2):131–5
Fluphenazine decanoate causing atrioventricular block. Rao AV. **Indian Heart J** 1996 Nov–Dec;48(6):713–4
Rare, idiosyncratic reaction to acepromazine in dogs. Meyer EK. **J Am Vet Med Assoc** 1997 Apr 15;210(8):1114–5
Chlorpromazine induced diabetes mellitus [letter; comment] Aruna, et al. **J Assoc Physicians India** 1995 Feb;43(2):146 . Comment on: J Assoc Physicians India 1994 Oct;42(10):795–804, 809.
The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. Mulsant BH, et al. **J Clin Psychopharmacol** 1997 Aug; 17(4):318–21
Intracorporeal phenylephrine reduces thioridazine (Mellaril) induced priapism in a child [see comments] Siegel JF, et al. **J Urol** 1997 Feb;157(2):648. Comment in: J Urol 1997 Sep;158(3 Pt 1):888–9.
Neuroleptic induced incontinence--case report. Alvi T, et al. **JPMA J Pak Med Assoc** 1997 Jul;47(7):195–6
Anticholinergic overdose induced torsade de pointes successfully treated with verapamil. Liao WB, et al. **Jpn Heart J** 1996 Nov;37(6):925–31
Sudden unexplained death in a psychiatric patient--a case report: the role of phenothiazines and physical restraint. Kumar A. **Med Sci Law** 1997 Apr;37(2):170–5
Acute hepatitis, rhabdomyolisis and pancytopenia associated with perazine therapy [letter] Pantel J, et al. **Pharmacopsychiatry** 1996 Jan;29(1):43
[Cytolytic hepatitis during treatment with phenothiazines: apropos of a case] Mesure G, et al. **Encephale** 1996 Sep–Oct;22(5):388–90 (Eng. Abstr.) **(Fre)**
[Drug-induced laryngospasm] Nishikawa T, et al. **Masui** 1997 Feb;46(2):276–8 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Photostability-indicating HPLC method for determination of trifluoperazine in bulk form and pharmaceutical formulations. Abdel-Moety EM, et al. **J Pharm Biomed Anal** 1996 Aug;14(11):1639–44

BLOOD

Sensitive method for the simultaneous measurement of fluphenazine decanoate and fluphenazine in plasma by high-performance liquid chromatography with coulometric detection. Luo JP, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):303–8
[A double column double pH solid phase extraction and capillary GC/FID method for rapid simultaneous determination of acidic and basic drugs in human plasma] Qiu FH, et al. **Yao Hsueh Hsueh Pao** 1996;31(3):205–8 (Eng. Abstr.) **(Chi)**
[Systematic analysis of basic drugs in plasma using X-5 solid-phase extraction GC-FID and GC-MS] Qiu FH, et al. **Yao Hsueh Hsueh Pao** 1996;31(4):296–9 (Eng. Abstr.) **(Chi)**

ISOLATION & PURIFICATION

Effect of organic modifiers on retention and enantiomeric separations by capillary electrophoresis with human serum albumin as a chiral selector in solution. Ahmed A, et al. **J Chromatogr A** 1997 Apr 4;766(1–2):237–44

METABOLISM

Biotransformation of chlorpromazine and methdilazine by Cunninghamella elegans. Zhang D, et al. **Appl Environ Microbiol** 1996 Mar;62(3):798–803
Identification of lactams as in vitro metabolites of piperidine-type phenothiazine antipsychotic drugs [published erratum appears in J Pharm Biomed Anal 1997 Mar;15(6):855] Lin G, et al. **J Pharm Biomed Anal** 1996 Apr;14(6):727–38

PHARMACOKINETICS

Effect of d-limonene, alpha-pinene and cineole on in vitro transdermal human skin penetration of chlorpromazine and haloperidol. Almirall M, et al. **Arzneimittelforschung** 1996 Jul;46(7):676–80
Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Hartigan-Go K, et al. **Clin Pharmacol Ther** 1996 Nov;60(5):543–53
Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil. Luo JP, et al. **Pharm Res** 1997 Aug;14(8):1079–84
Effect of carbamazepine on the pharmacokinetics of promazine. Syrek M, et al. **Pol J Pharmacol** 1996 Nov–Dec; 48(6):601–8

PHARMACOLOGY

Antimutagenicity of benzo[a]phenothiazines in chemically induced mutagenesis. Tanaka M, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3625–8
Activation of sodium transport and intracellular sodium lowering by the neuroleptic drug chlorpromazine. Else PL, et al. **Biochem Pharmacol** 1997 Jul 15;54(2):275–81
Role of membrane lipid distribution in chlorpromazine-induced shape change of human erythrocytes. Chen JY, et al. **Biochim Biophys Acta** 1997 Jan 31;1323(2):299–309
Chlorpromazine activates chloride currents in Xenopus oocytes. Quamme GA. **Biochim Biophys Acta** 1997 Feb 21;1324(1):18–26
Chlorpromazine reduces toxicity and Ca2+ uptake induced by amyloid beta protein (25–35) in vitro. Ueda K, et al. **Brain Res** 1997 Feb 14;748(1–2):184–8
Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats. See RE, et al. **Eur J Pharmacol** 1996 Jul 25;308(3):279–82
Successive negative contrast in one-way avoidance: effect of thiopental sodium and chlorpromazine. Torres C, et al. **Eur J Pharmacol** 1996 Oct 31;314(3):269–75
Phenothiazines are potent inhibitors of osteoclastic bone resorption. Hall TJ, et al. **Gen Pharmacol** 1996 Jul; 27(5):845–8
Influence of trifluoperazine and verapamil on the isolated perfused rat kidney. Weinschelbaum-Jairala S, et al. **Gen Pharmacol** 1996 Jul;27(5):911–5
The effect of chlorpromazine and haloperidol on DNA transcription. Barak Y, et al. **Int Clin Psychopharmacol** 1996 Sep;11(3):193–7
Time resolved study of effect of chlorpromazine on mobility of cytochrome P-450 and phospholipids in the inner membrane of adrenocortical mitochondria. Homma R, et al. **J Pharm Biomed Anal** 1997 Jun;15(9–10):1215–22
Trifluoperazine is more effective than chlorpromazine in releasing oxygen from haemoglobin and myoglobin. Bhattacharyya J, et al. **J Pharm Pharmacol** 1996 Sep; 48(9):965–7
Tranquillization of cane rats (Thryonomys swinderianus) with a depot neuroleptic (pipothiazine palmitate). McCoy J, et al. **J Vet Pharmacol Ther** 1997 Jun;20(3):233–9
Effects of chlorpromazine on rats' acquisition of lever-press responding with immediate and delayed reinforcement. Byrne T, et al. **Pharmacol Biochem Behav** 1997 Sep; 58(1):31–5
Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Suzuki A, et al. **Ther Drug Monit** 1997 Jun; 19(3):261–4
[Plasma renin activity in tachistin-stimulated hypercalcemia and under the effect of chlorazine] Ilieva G, et al. **Eksp Med Morfol** 1994;32(3–4):1–8 (Eng. Abstr.) **(Bul)**

POISONING

Near fatal case of self-poisoning with thioridazine [letter] Annane D, et al. **Intensive Care Med** 1996 Dec; 22(12):1463–4

THERAPEUTIC USE

Response in chronic schizophrenia correlated with chlorpromazine, 7-OH-chlorpromazine and chlorpromazine sulfoxide levels. Chetty M, et al. **Eur Neuropsychopharmacol** 1996 May;6(2):85–91
Response to clozapine in acute mania is more rapid than that of chlorpromazine. Barbini B, et al. **Int Clin Psychopharmacol** 1997 Mar;12(2):109–12
A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Hong CJ, et al. **Int Clin Psychopharmacol** 1997 May;12(3):123–30
Transition from acute to maintenance treatment: prediction of stabilization. Schooler NR, et al. **Int Clin Psychopharmacol** 1996 May;11 Suppl 2:85–91
Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients. Ramchand CN, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1–2):27–31
[Study of the protective effects of phenothiazine derivatives on a stochastic model of brain compression edema-swelling] Platonov IA. **Patol Fiziol Eksp Ter** 1997 Jan–Mar;(1):12–5 (Eng. Abstr.) **(Rus)**

ANTIPYRETICS see **ANALGESICS, NON-NARCOTIC**

ANTIPYRINE

ADVERSE EFFECTS

Topical and systemic provocation of fixed drug eruption due to phenazone. Schick E, et al. **Contact Dermatitis** 1996 Jul; 35(1):58–9

ANALOGS & DERIVATIVES

Pulmonary distribution of iodoantipyrine: temperature and lipid solubility effects. Chinard FP, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2250–63
Use of [3H]methylglucose and [14C]iodoantipyrine to determine kinetic parameters of glucose transport in rat brain. Mori K, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R163–71
Oligosaccharide characterization and quantitation using 1-phenyl-3-methyl-5-pyrazolone derivatization and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Pitt JJ, et al. **Anal Biochem** 1997 May 15;248(1):63–75
Clean method for the simultaneous determination of propyphenazone and caffeine in pharmaceuticals by flow injection Fourier transform infrared spectrometry. Bouhsain Z, et al. **Analyst** 1997 May;122(5):441–5
Protein kinase C in focal ischemic rat brain: dual autoradiographic analysis of [14C]iodoantipyrine (IAP) and [3H]phorbol-12,13-dibutyrate (PDBu). Tohyama Y, et al. **Brain Res** 1997 Mar 7;750(1–2):155–60
Analgesic effects of propyphenazone in comparison to its combination with caffeine. Kraetsch HG, et al. **Eur J Clin Pharmacol** 1996;49(5):377–82
Effect of MCI-186 on postischemic reperfusion injury in isolated rat heart. Minhaz U, et al. **Free Radic Res** 1996 May;24(5):361–7
Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. Kawai H, et al. **J Pharmacol Exp Ther** 1997 May;281(2):921–7
Effects of ischemia-reperfusion injury on myocardial single

pass extraction and retention of Cu-PTSM in perfused rat hearts: comparison with 201T1 and 14C-iodoantipyrine. Wada K, et al. **Nucl Med Biol** 1994 May;21(4):613-7

Aluminum citrate is transported from brain into blood via the monocarboxylic acid transporter located at the blood-brain barrier. Ackley DC, et al. **Toxicology** 1997 Jun 27;120(2):89-97

[Caffetin in the treatment of neck pain and lumbago-sciatica] Vornovskaia OV, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1997;97(4):48-9 (Eng. Abstr.) **(Rus)**

BLOOD

Lack of effect of zinc supplementation on antipyrine clearance in alcoholic liver disease. Grønbaek K, et al. **Eur J Clin Pharmacol** 1996;49(5):397-9

[The effect of ovariectomy in women on metabolism of phenazone] Konieczny M. **Ginekol Pol** 1996 Sep; 67(9):451-6 (Eng. Abstr.) **(Pol)**

[Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer] Orzechowska-Juzwenko K, et al. **Przegl Lek** 1997; 54(2):103-6 (Eng. Abstr.) **(Pol)**

DIAGNOSTIC USE

Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitantly. Krejcie TC, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1050-7

METABOLISM

Antipyrine clearance and response to interferon therapy in chronic hepatitis [letter; comment] Fabbri A, et al. **Hepatology** 1997 Feb;25(2):500-2. Comment on: Hepatology 1995 Oct;22(4 Pt 1):1065-71.

Antipyrine, theophylline, and hexobarbital as in vivo P450 probe drugs. Groen K, et al. **Methods Enzymol** 1996; 272:169-77

Effect of spironolactone on antipyrine metabolism in calves. Janus K, et al. **Res Vet Sci** 1996 Jul;61(1):87-8

Effect of alcohol abuse and glutathione administration on the circulating levels of glutathione and on antipyrine metabolism in patients with alcoholic liver cirrhosis. Loguercio C, et al. **Scand J Clin Lab Invest** 1996 Aug; 56(5):441-7

[Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms] Wiela-Hojeńska A, et al. **Przegl Lek** 1997;54(3):163-6 (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Pharmacokinetics of antipyrine in calves at neonatal period fed with casein supplemented food. Janus K. **Arch Vet Pol** 1994;34(3-4):287-96

Assessment of total body water in hemodialysis patients by a single oral dose of antipyrine. Odar-Cederlöf I, et al. **ASAIO J** 1996 Jul-Aug;42(4):271-4

Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Shedlofsky SI, et al. **Br J Clin Pharmacol** 1997 Jun;43(6):627-32

Pharmacokinetics of phenazone (antipyrine) in rabbits with experimental common bile duct obstruction. Wójcicki J, et al. **Br J Pharmacol** 1996 Jan;117(1):1-4

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Sotaniemi EA, et al. **Clin Pharmacol Ther** 1997 Mar;61(3):331-9

Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. De Mey C, et al. **Int J Clin Pharmacol Ther** 1996 May;34(1 Suppl):S58-66

Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. Scavone JM, et al. **J Clin Pharmacol** 1997 May;37(5):437-41

Accuracy of the one-sample method for determination of antipyrine clearance in elderly subjects. Jorquera F, et al. **J Pharm Biomed Anal** 1996 Oct;15(1):7-11

Factors that influence microdialysis recovery. Comparison of experimental and theoretical microdialysis recoveries in rat liver. Stenken JA, et al. **J Pharm Sci** 1997 Aug; 86(8):958-66

The effect of experimental fascioliasis on the pharmacokinetics of antipyrine and sulphadimidine in desert sheep. Elsheikh HA, et al. **J Vet Pharmacol Ther** 1997 Jun;20(3):167-72

Pharmacokinetics of antipyrine in calves after intravenous and oral administration. Janus K, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):408-10

The effect of cimetidine on antipyrine metabolism in calves. Janus K, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):73-6

Extrahepatic ischemia-reperfusion injury reduces hepatic oxidative drug metabolism as determined by serial antipyrine clearance. Gurley BJ, et al. **Pharm Res** 1997 Jan;14(1):67-72

Effect of some anti-cancer drugs and combined chemotherapy on the pharmacokinetics of antipyrine in the rat. Skrętkowicz J. **Pol J Pharmacol** 1995 Nov-Dec; 47(6):519-24

Effect of age on the pharmacokinetics of antipyrine in calves. Janus K, et al. **Res Vet Sci** 1996 May;60(3):234-7

Choline esters and biogenic amines in the hypobranchial gland of 55 molluscan species of the neogastropod Muricoidea superfamily. Roseghini M, et al. **Toxicon** 1996 Jan;34(1):33-55

PHARMACOLOGY

Antipyrine and aminopyrine induce acetaldehyde accumulation from ethanol in isolated hepatocytes. Efthivoulou MA, et al. **Alcohol Clin Exp Res** 1997 Apr; 21(2):267-74

[The effect of sedatin--a synthetic analog of dermorphin--on cell division in cornea and tongue epithelium of albino rats] Fleishman MIu, et al. **Biull Eksp Biol Med** 1996 Jun; 121(6):641-4 **(Rus)**

THERAPEUTIC USE

Efficacy of Auralgan for treating ear pain in children with acute otitis media. Hoberman A, et al. **Arch Pediatr Adolesc Med** 1997 Jul;151(7):675-8

ANTIREJECTION THERAPY see **IMMUNOSUPPRESSION**

ANTIRHEUMATIC AGENTS

see related
ANTIMALARIALS
IMMUNOSUPPRESSIVE AGENTS

Methotrexate in the treatment of children with chronic arthritis—long-term observations of efficacy and safety. Huang JL. **Br J Clin Pract** 1996 Sep;50(6):311-4

Membranous glomerulonephritis in rheumatoid arthritis unrelated to gold, D-penicillamine or other connective tissue disease. Zarza LP, et al. **Clin Rheumatol** 1996 Jul; 15(4):385-8

Cytokines in juvenile arthritis [editorial; comment] Guerne PA. **Rev Rhum Engl Ed** 1996 Mar;63(3):153-8 (20 ref.). Comment on: Rev Rhum Engl Ed 1996 Mar;63(3):171-7.

ADMINISTRATION & DOSAGE

The safety of weekly low dose oral methotrexate in an Oriental population with rheumatoid arthritis. Thumboo J, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):205-9

Combination DMARD therapy for rheumatoid arthritis. Full or low DMARD doses? [letter; comment] Ferraccioli GF, et al. **Ann Rheum Dis** 1997 May;56(5):336-7. Comment on: Ann Rheum Dis 1996 Nov;55(11):781-3.

Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. ten Wolde S, et al. **Ann Rheum Dis** 1997 Apr;56(4):235-9

Methotrexate treatment every other week in patients with juvenile chronic arthritis [letter] Cimaz R, et al. **Br J Rheumatol** 1996 Oct;35(10):1030-1

Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Hamilton RA, et al. **Br J Rheumatol** 1997 Jan;36(1):86-90

Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. Jones G, et al. **Br J Rheumatol** 1997 Jan;36(1):95-9

N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment. Wiland P, et al. **Br J Rheumatol** 1997 Jan;36(1):59-63

Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Ramos PC, et al. **Clin Exp Rheumatol** 1996 May-Jun;14(3):295-9

Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Bannwarth B, et al. **Clin Pharmacokinet** 1996 Mar;30(3):194-210 (105 ref.)

Persistence of CD4+ T cells in the arthritic joint after CAMPATH-1H treatment [letter] Finnegan A, et al. **J Rheumatol** 1997 Jul;24(7):1448-9

Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy. Fries JF, et al. **J Rheumatol** 1997 May;24(5):838-44

Oral administration of an easily prepared solution of injectable methotrexate diluted in water: A comparison of serum concentrations vs methotrexate tablets and clinical utility. Marshall PS, et al. **J Rheumatol** 1996 Mar; 23(3):455-8

Pneumocystis carinii pneumonia after discontinuation of hydroxychloroquine in 2 patients with systemic lupus erythematosus [letter] Podrebarac TA, et al. **J Rheumatol** 1996 Jan;23(1):199-200

The use of antimalarials in combination with other disease modifying agents in RA—the British experience. Duncan MR, et al. **Lupus** 1996 Jun;5 Suppl 1:S50-8 (53 ref.)

The use of antimalarials in combination with other disease modifying agents in rheumatoid arthritis—the French experience. Kahan A, et al. **Lupus** 1996 Jun;5 Suppl 1:S45-9 (27 ref.)

Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis. Spadaro A, et al. **Rev Rhum Engl Ed** 1997 Feb;64(2):89-94

Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients. Elkayam O, et al. **Rheumatol Int** 1997;17(2):49-53

A comparison between bucillamine and D-penicillamine in the treatment of rheumatoid arthritis. Kim HA, et al. **Rheumatol Int** 1997;17(1):5-9

The effect of intravenous cyclophosphamide pulse on peripheral blood lymphocytes in lupus erythematosus patients. Lacki JK, et al. **Rheumatol Int** 1997;17(2):55-60

Low dose cyclosporine in early rheumatoid arthritis: effective and safe after two years of therapy when compared with chloroquine. van den Borne BE, et al. **Scand J Rheumatol** 1996;25(5):307-16

[Low dose methotrexate therapy in chronic polyarthritis--an update] Leeb BF, et al. **Acta Med Austriaca** 1996; 23(4):114-9 (63 ref.) (Eng. Abstr.) **(Ger)**

[D-penicillamine in treatment of scleroderma "en coup de sabre"] van Bergen BH, et al. **Hautarzt** 1997 Jan;48(1):42-4 (Eng. Abstr.) **(Ger)**

[Combination therapy with remission-inducing drugs in chronic polyarthritis: 1996 update] Wollin D, et al. **Z Rheumatol** 1997 May-Jun;56(3):114-26 (47 ref.) (Eng. Abstr.) **(Ger)**

[Nonconventional therapy in a case of systemic juvenile rheumatoid arthritis] Cocchi P, et al. **Pediatr Med Chir** 1996 May-Jun;18(3):319-20 (9 ref.) (Eng. Abstr.) **(Ita)**

[Prospective clinical study of the combination therapy of auranofin and methotrexate for rheumatoid arthritis--a multi-center study] Kashiwazaki S, et al. **Ryumachi** 1996 Jun;36(3):528-44 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. Rosenthal NS, et al. **Am J Clin Pathol** 1996 Nov; 106(5):676-9

Liver toxicity does not have to follow methotrexate therapy of patients with rheumatoid arthritis [editorial] [see comments] Kremer JM. **Am J Gastroenterol** 1997 Feb; 92(2):194-6 (29 ref.). Comment in: Am J Gastroenterol 1997 Aug;92(8):1402-3.

Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Kamel OW, et al. **Am J Surg Pathol** 1996 Oct;20(10):1279-87

The safety of weekly low dose oral methotrexate in an Oriental population with rheumatoid arthritis. Thumboo J, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):205-9

Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Alarcón GS, et al. **Ann Intern Med** 1997 Sep 1;127(5):356-64

Treatment of cyclosporine-induced gingival hypertrophy [letter] Cecchin E, et al. **Ann Intern Med** 1997 Mar 1; 126(5):409-10

Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate. Bologna C, et al. **Ann Rheum Dis** 1997 Feb;56(2):97-102 (33 ref.)

Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Grierson DJ. **Ann Rheum Dis** 1997 Mar; 56(3):188-90

Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ureña et al [letter; comment] Berthelot JM, et al. **Arthritis Rheum** 1997 Jan;40(1):193-4; discussion 195-6 (27 ref.). Comment on: Arthritis Rheum 1996 Feb;39(2):272-6.

Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis. Falcini F, et al. **Arthritis Rheum** 1997 Jan;40(1):175-8 (22 ref.)

Incidence of pancytopenia with methotrexate treatment of rheumatoid arthritis in Germany: comment on the article by Gutierrez-Ureña et al [letter; comment] Kassai A, et al. **Arthritis Rheum** 1997 Jan;40(1):195-6. Comment on: Arthritis Rheum 1996 Feb;39(2):272-6.

Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Merrill JT, et al. **Arthritis Rheum** 1997 Jul;40(7):1308-15

Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ureña et al [letter; comment] Nygaard H. **Arthritis Rheum** 1997 Jan;40(1):194-5; discussion 195-6. Comment on: Arthritis Rheum 1996 Feb;39(2):272-6.

Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry. Rodriguez F, et al. **Arthritis Rheum** 1996 Sep;39(9):1491-8

Penicillamine-induced type II bullous systemic lupus erythematosus [letter] Condon C, et al. **Br J Dermatol** 1997 Mar;136(3):474-5

Management of oral complications of disease-modifying drugs in rheumatoid arthritis. Carpenter EH, et al. **Br J Rheumatol** 1997 Apr;36(4):473-8

Should patients on hydroxychloroquine have their eyes examined regularly? [editorial; comment] Shipley M, et al. **Br J Rheumatol** 1997 May;36(5):514-5. Comment on: Br J Rheumatol 1997 May;36(5):599-601.

Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data [see comments] Silman A, et al. **Br J Rheumatol** 1997 May;36(5):599-601 (15 ref.). Comment in: Br J Rheumatol 1997 May;36(5):514-5.

Atypical methotrexate dermatitis in a patient with rheumatoid arthritis [letter] Giordano N, et al. **Clin Exp Rheumatol**

1996 Jul-Aug;14(4):450

Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis. Wolfe F. **Clin Exp Rheumatol** 1997 May-Jun;15 Suppl 17:S75-81 (77 ref.)

D-penicillamine-induced myositis in rheumatoid arthritis. Chappel R, et al. **Clin Rheumatol** 1996 Jan;15(1):86-7

Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Franck H, et al. **Clin Rheumatol** 1996 May;15(3):266-70

The frequency and clinical characteristics of methotrexate (MTX) oral toxicity in rheumatoid arthritis (RA): a masked and controlled study. Ince A, et al. **Clin Rheumatol** 1996 Sep;15(5):491-4

Isolated thrombocytopenia associated with low dose methotrexate therapy [letter; comment] Lapadula G, et al. **Clin Rheumatol** 1997 Jun;16(4):429-30. Comment on: Clin Rheumatol 1996 Mar;15(2):163-7.

Clinical characteristics related to methotrexate-induced pancytopenia [letter] Ohosone Y, et al. **Clin Rheumatol** 1997 May;16(3):321-3

Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Salaffi F, et al. **Clin Rheumatol** 1997 May;16(3):296-304 (53 ref.)

Sustained cough in methotrexate therapy for rheumatoid arthritis. Schnabel A, et al. **Clin Rheumatol** 1996 May; 15(3):277-82

Methotrexate related cutaneous vasculitis [letter] Torner O, et al. **Clin Rheumatol** 1997 Jan;16(1):108-9 (7 ref.)

Acute generalized exanthematous pustulosis induced by hydroxychloroquine [letter] Assier-Bonnet H, et al. **Dermatology** 1996;193(1):70-1 (9 ref.)

Use of methotrexate in older patients. A risk-benefit assessment. Tett SE, et al. **Drugs Aging** 1996 Dec; 9(6):458-71

Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine. Boehler A, et al. **Eur Respir J** 1996 Jun;9(6):1317-9 (28 ref.)

Clinical immunotoxicity of antirheumatic drugs. Bálint G, et al. **Inflamm Res** 1996 Dec;45 Suppl 2:S91-5 (70 ref.)

Transient acantholytic dermatosis (Grover's disease) in a patient with progressive systemic sclerosis treated with D-penicillamine [letter] Zvulunov A, et al. **Int J Dermatol** 1997 Jun;36(6):476-7

Benefit of simultaneous rhG-CSF and methylprednisolone 'pulse' therapy for methotrexate-induced bone marrow failure in rheumatoid arthritis. Kondo H, et al. **Int J Hematol** 1997 Feb;65(2):159-63

An unusual cause for collapse in a patient with arthritis. Heath KJ, et al. **Intensive Care Med** 1996 Oct;22(10):1096-7

D-penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1 in a patient with mixed connective tissue disease. Peñas PF, et al. **J Am Acad Dermatol** 1997 Jul;37(1):121-3

Cyclophosphamide-induced acute liver failure requiring transplantation in a patient with genetically deficient debrisoquine metabolism: a causal relationship? Gustafsson LL, et al. **J Intern Med** 1996 Nov;240(5):311-4

Chronic internuclear ophthalmoplegia. A manifestation of D-penicillamine cerebral vasculitis. Pless M, et al. **J Neuroophthalmol** 1997 Mar;17(1):44-6

Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: relation to withdrawal and side effects. Andersen LS, et al. **J Rheumatol** 1997 May;24(5):830-7

Accelerated nodulosis in a patient with psoriasis and arthritis during treatment with methotrexate [see comments] Berris B, et al. **J Rheumatol** 1995 Dec;22(12):2359-60. Comment in: J Rheumatol 1996 Nov;23(11):2004.

Effects on fibrogenesis markers of rheumatoid arthritis therapy with methotrexate. Biasi D, et al. **J Rheumatol** 1996 Mar;23(3):453-4

Ophthalmological monitoring of patients taking antimalarials: preferred practice patterns. Easterbrook M, et al. **J Rheumatol** 1997 Jul;24(7):1390-2 (21 ref.)

Association of methotrexate, rheumatoid arthritis, and melanoma in 2 patients [letter] Jeannou J, et al. **J Rheumatol** 1997 Jul;24(7):1444-5

Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis [see comments] Kremer JM, et al. **J Rheumatol** 1996 Mar; 23(3):459-61. Comment in: J Rheumatol 1996 Mar;23(3):413-5.

Longterm low dose cyclosporine in patients with rheumatoid arthritis: renal function loss without structural nephropathy [see comments] Landewé RB, et al. **J Rheumatol** 1996 Jan; 23(1):61-4. Comment in: J Rheumatol 1996 Jan;23(1):4.

Monitoring for methotrexate hepatotoxicity in patients with rheumatoid arthritis: another hepatologist's perspective [editorial] Lewis JH. **J Rheumatol** 1997 Aug;24(8):1459-60

Methotrexate osteopathy, does it exist? Maenaut K, et al. **J Rheumatol** 1996 Dec;23(12):2156-9

More on pericardial tamponade during methotrexate therapy [letter; comment] Marchesoni A, et al. **J Rheumatol** 1996 Dec;23(12):2182-4. Comment on: J Rheumatol 1994 May;21(5):934-7. Comment on: J Rheumatol 1995 Jul;22(7):1439.

Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died [see comments] Myllykangas-Luosujärvi R, et al. **J Rheumatol** 1995 Dec;22(12):2214-7. Comment in: J Rheumatol 1995 Dec;22(12):2200-2.

Chronic cyclosporine nephrotoxicity in rheumatoid arthritis [editorial; comment] Pei Y. **J Rheumatol** 1996 Jan;23(1):4-5. Comment on: J Rheumatol 1996 Jan;23(1):61-4.

Excess mortality in rheumatoid arthritis--is it the disease or the drugs? [editorial; comment] Symmons D. **J Rheumatol** 1995 Dec;22(12):2200-2. Comment on: J Rheumatol 1995 Dec;22(12):2214-7.

Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. Fries JF. **J Rheumatol Suppl** 1996 Mar;44:102-6 (22 ref.)

Azathioprine-induced lymphoma manifesting as fulminant hepatic failure. Aguilar HI, et al. **Mayo Clin Proc** 1997 Jul;72(7):643-5

Toxicity of antirheumatic drugs. Lehmann T, et al. **Med J Aust** 1997 Apr 7;166(7):378-83 (30 ref.)

Antiglomerular basement membrane glomerulonephritis following D-penicillamine-associated nephrotic syndrome. Bindi P, et al. **Nephrol Dial Transplant** 1997 Feb;12(2):325-7

Delay of corneal wound healing in patients treated with colchicine. Alster Y, et al. **Ophthalmology** 1997 Jan; 104(1):118-9

What's the right patient management for early diagnosis of hydroxychloroquine retinal toxicity? [letter] Giorgi D, et al. **Recenti Prog Med** 1996 Jun;87(6):308

A cause of acute urinary retention: chloroquine-induced neuromyopathy [letter] Dhote R, et al. **Rev Rhum Engl Ed** 1996 Jan;63(1):69

Severe drug-induced blistering disorders. Roujeau JC. **Rev Rhum Engl Ed** 1997 Jan;64(1):5-9 (41 ref.)

Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases. Roux N, et al. **Rev Rhum Engl Ed** 1996 Jun;63(6):453-6 (30 ref.)

Diplopia in a patient under hydroxychloroquine for systemic lupus erythematosus [letter] Sabbagh M. **Rev Rhum Engl Ed** 1997 Jan;64(1):65

Agranulocytosis and bone marrow aplasia induced by second-line drugs for rheumatoid arthritis. Treatment with granulocyte colony-stimulating factor [letter; comment] Sayag-Boukris V, et al. **Rev Rhum Engl Ed** 1997 Jan; 64(1):66. Comment on: Rev Rhum Engl Ed 1995 Jul-Sep;62(7-8):477-86.

Hematologic complications of rheumatic disease therapies. George CS, et al. **Rheum Dis Clin North Am** 1997 May; 23(2):425-37 (82 ref.)

Seizures and hepatotoxicity following sulphasalazine administration. Sentürk T, et al. **Rheumatol Int** 1997; 17(2):75-7

Methotrexate update [editorial] Kremer JM. **Scand J Rheumatol** 1996;25(6):341-4 (31 ref.)

Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment [see comments] Georgescu L, et al. **Semin Arthritis Rheum** 1997 Jun;26(6):794-804 (98 ref.). Comment in: Semin Arthritis Rheum 1997 Jun;26(6):785-7.

Is methotrexate oncogenic in patients with rheumatoid arthritis? [editorial; comment] Kremer JM. **Semin Arthritis Rheum** 1997 Jun;26(6):785-7. Comment on: Semin Arthritis Rheum 1997 Jun;26(6):794-804.

Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Schnabel A, et al. **Thorax** 1997 Apr; 52(4):377-9

[Medical treatment in rheumatoid arthritis and mortality (editorial)] Isomäki H, et al. **Duodecim** 1995;111(13):1185-6 **(Fin)**

[Acute cytolytic hepatitis in azathioprine hypersensitivity (letter)] Dubost JJ, et al. **Gastroenterol Clin Biol** 1996; 20(10):912-3 **(Fre)**

[Neuropsychiatric disorders induced by chloroquine (letter)] Bachmeyer C, et al. **Presse Med** 1997 Mar 1;26(6):271 **(Fre)**

[Respiratory function surveillance during prolonged treatment with low-dose methotrexate (editorial)] Cottin V, et al. **Presse Med** 1997 Mar 22;26(9):404-6 (Eng. Abstr.) **(Fre)**

[Treatment with low dose methotrexate in rheumatoid arthritis: risk factors for severe complications] Berthelot JM, et al. **Therapie** 1997 Mar-Apr;52(2):111-6 (40 ref.) (Eng. Abstr.) **(Fre)**

[Chloroquine-induced bull's eye maculopathy without electrophysiologic changes] Cursiefen C, et al. **Klin Monatsbl Augenheilkd** 1997 Jun;210(6):400-1 (Eng. Abstr.) **(Ger)**

[Adverse reaction of drugs in the field of orthopaedic surgery] Azuma T. **Nippon Seikeigeka Gakkai Zasshi** 1997 Feb;71(2):106-11 (13 ref.) **(Jpn)**

[D-penicillamine nephropathy] Ohno I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):523-5 (17 ref.) **(Jpn)**

[Gold nephropathy] Ujiie K, et al. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):529-30 (4 ref.) **(Jpn)**

[Adverse effects of low-dose methotrexate therapy in rheumatoid arthritis] Furuya T, et al. **Ryumachi** 1996 Oct; 36(5):746-52 (Eng. Abstr.) **(Jpn)**

[Untoward effects of low dose methotrexate therapy in rheumatoid arthritis] Kawabe Y, et al. **Ryumachi** 1996 Jun; 36(3):514-21 (Eng. Abstr.) **(Jpn)**

[Pancytopenia and Pneumocystis carinii pneumonia associated with low dose methotrexate pulse therapy for rheumatoid arthritis--case report and review of literature] Kitsuwa S, et al. **Ryumachi** 1996 Jun;36(3):551-8 (43 ref.) (Eng. Abstr.) **(Jpn)**

[Drug-induced renal disorders in patients with rheumatoid arthritis] Nakano M, et al. **Ryumachi** 1996 Oct;36(5):775-82 (40 ref.) **(Jpn)**

[Toxicity of low-dose methotrexate in rheumatoid arthritis--clinical characteristics in patients with MTX-induced pancytopenia and interstitial pneumonitis] Ohosone Y, et al. **Ryumachi** 1997 Feb;37(1):16-23 (Eng. Abstr.) **(Jpn)**

[myotoxicity by chloroquine: report of a case (letter)] Rabuñal Rey R, et al. **Med Clin (Barc)** 1997 Sep 6; 109(7):277-8 **(Spa)**

[Severe adverse effect of methotrexate in rheumatoid arthritis. Don't forget security routines in intercurrent disease!] Gülfe A, et al. **Lakartidningen** 1997 May 7; 94(19):1811-2 **(Swe)**

BLOOD

Simultaneous determination of azathioprine and 6-mercaptopurine by high-performance liquid chromatography. Van Os EC, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1-2):147-54

Determination of methotrexate and its metabolite 7-hydroxymethotrexate by direct injection of human plasma into a column-switching liquid chromatographic system using post-column photochemical reaction with fluorimetric detection. Yu Z, et al. **J Chromatogr B Biomed Appl** 1997 Feb 21;689(2):379-86

CHEMICAL SYNTHESIS

Preparation and antirheumatic activity of optically active 2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298). Kameo K, et al. **Chem Pharm Bull (Tokyo)** 1996 Mar;44(3):602-4

Antirheumatic agents. III. Novel methotrexate derivatives bearing an indoline ring and a modified ornithine or glutamic acid. Matsuoka H, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1146-50

Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect. Baba A, et al. **J Med Chem** 1996 Dec 20;39(26):5176-82

CHEMISTRY

Relationship between the metabolic chiral inversion and chemical structure of 4-phenyl-4-oxobutanoic acids, derivatives of anti-rheumatic agent KE-298. Yoshida H, et al. **Biol Pharm Bull** 1997 Jan;20(1):94-6

Antirheumatic agents. II. Novel methotrexate derivatives bearing an alkyl-substituted benzene ring. Matsuoka H, et al. **Chem Pharm Bull (Tokyo)** 1996 Dec;44(12):2287-93

Antirheumatic agents: novel methotrexate derivatives bearing a benzoxazine or benzothiazine moiety. Matsuoka H, et al. **J Med Chem** 1997 Jan 3;40(1):105-11

Ketoprofen sodium: preparation and its formation of mixed crystals with ketoprofen. Hildebrand GE, et al. **J Pharm Sci** 1997 Jul;86(7):854-7

ECONOMICS

Cost effectiveness analysis of drug therapies for rheumatoid arthritis. Criswell LA, et al. **J Rheumatol Suppl** 1996 Mar; 44:52-5

HISTORY

The treatment of rheumatoid arthritis in this century: from spas to monoclonal antibodies. Pasero G. **Clin Exp Rheumatol** 1997 May-Jun;15 Suppl 17:S67-70

History of combination therapy of rheumatoid arthritis. Paulus HE. **J Rheumatol Suppl** 1996 Mar;44:38-42

METABOLISM

Mechanistic studies on metabolic chiral inversion of 4-(4-methylphenyl)-2-methylthiomethyl-4-oxobutanoic acid (KE-748), an active metabolite of the new anti-rheumatic agent 2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298), in rats. Yoshida H, et al. **Biochem Pharmacol** 1997 Jan 24;53(2):179-87

Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Chatterjee DJ, et al. **Pharm Res** 1997 Aug;14(8):1058-65

Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Omar G, et al. **Ther Drug Monit** 1997 Aug;19(4):436-45

PHARMACOKINETICS

Identification of metabolites of KE-298, a new antirheumatic drug, and its physiological properties in rats. Yoshida H, et al. **Biol Pharm Bull** 1996 Mar;19(3):424-9

Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. Haagsma CJ, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):195-200

Stereoselective disposition and chiral inversion of KE-298, a new antirheumatic drug, in rats. Yoshida H, et al. **Chirality** 1997;9(1):22-8

Clinical pharmacokinetics of low-dose pulse methotrexate

in rheumatoid arthritis. Bannwarth B, et al. **Clin Pharmacokinet** 1996 Mar;30(3):194–210 (105 ref.)

Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods. Mehvar R, et al. **Clin Pharmacokinet** 1997 Aug;33(2):122–41 (88 ref.)

Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. Hübner G, et al. **J Rheumatol** 1997 May;24(5):845–51

Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Furst DE. **Lupus** 1996 Jun;5 Suppl 1:S11–5 (48 ref.)

[Evaluation of drug concentration in tissues after percutaneous administration of non-steroidal antirheumatics] Wagener HH, et al. **Arzneimittelforschung** 1996 Mar;46(3):299–301 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis [see comments] Munro R, et al. **Ann Rheum Dis** 1997 Jun;56(6):374–7. Comment in: Ann Rheum Dis 1997 Jun;56(6):341–2.

Scavenging of free radicals by tenoxicam: a participating mechanism in the antirheumatic/antiinflammatory efficacy of the drug. Maffei Facino RM, et al. **Arch Pharm (Weinheim)** 1996 Oct;329(10):457–63

Pharmacological influence of antirheumatic drugs on proteoglycans from interleukin-1 treated articular cartilage. Steinmeyer J, et al. **Biochem Pharmacol** 1997 Jun 1; 53(11):1627–35

Z-100, extracted from Mycobacterium tuberculosis strain Aoyama B, inhibits the development of collagen-induced arthritis in mice. Omata T, et al. **Biol Pharm Bull** 1997 Jun;20(6):694–7

The effect of keishi-bushi-to on collagen-induced arthritis. Wakabayashi K, et al. **Biol Pharm Bull** 1997 Apr; 20(4):376–80

Plasma testosterone level and the male genital system after chloroquine therapy. Nicola WG, et al. **Boll Chim Farm** 1997 Jan;136(1):39–43

Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Nakamura M, et al. **Br J Pharmacol** 1996 Sep; 119(2):205–12

The effect of sulphasalazine on neutrophil superoxide generation in rheumatoid arthritis. Bradley SM, et al. **Br J Rheumatol** 1997 May;36(5):530–4

Effect of methotrexate and sulphasalazine on UMR 106 rat osteosarcoma cells. Preston SJ, et al. **Br J Rheumatol** 1997 Feb;36(2):178–84

Preparation and antirheumatic activity of optically active 2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298). Kameo K, et al. **Chem Pharm Bull (Tokyo)** 1996 Mar;44(3):602–4

Antirheumatic agents. III. Novel methotrexate derivatives bearing an indoline ring and a modified ornithine or glutamic acid. Matsuoka H, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1146–50

In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Nesher G, et al. **Clin Exp Rheumatol** 1996 Jul–Aug;14(4):395–9

Chloroquine-induced venodilation in human hand veins. Abiose AK, et al. **Clin Pharmacol Ther** 1997 Jun; 61(6):677–83

Human gelatinase B, a marker enzyme in rheumatoid arthritis, is inhibited by D-penicillamine: anti-rheumatic activity by protease inhibition. Norga K, et al. **Clin Rheumatol** 1996 Jan;15(1):31–4

Pharmacological profile of KE-758, the main metabolite of the antirheumatic agent KE-298. Yasuda Y, et al. **Drugs Exp Clin Res** 1996;22(1):1–8

Pathological evaluation of effect of anti-rheumatic drugs on type II collagen-induced arthritis in Lewis rats. Takeshita M, et al. **Exp Anim** 1997 Apr;46(2):165–9

The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Bondeson J. **Gen Pharmacol** 1997 Aug;29(2):127–50 (287 ref.)

Effects of tenidap on intracellular signal transduction and the induction of proinflammatory cytokines: a review. Bondeson J. **Gen Pharmacol** 1996 Sep;27(6):943–56 (68 ref.)

Immunomodulating and articular protecting activities of a new anti-rheumatic drug, TAK-603. Ohta Y, et al. **Immunopharmacology** 1996 Aug;34(1):17–26

The inhibitory effects of antirheumatic drugs on the activity of human leukocyte elastase and cathepsin G. Steinmeyer J, et al. **Inflamm Res** 1996 Jul;45(7):324–9

In vitro effect of gold sodium thiomalate and methotrexate on tumor necrosis factor production in normal healthy individuals and patients with rheumatoid arthritis. Yadav R, et al. **Int J Immunopharmacol** 1997 Feb;19(2):111–4

7th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators. Geneva, Switzerland, 19–21 May 1997. Abstracts. **Int J Tissue React** 1997;19(1–2):17–128

Inhibition of neutrophil-dependent cytotoxicity for human endothelial cells by antirheumatic drugs. Bratt J, et al. **J Lab Clin Med** 1996 Dec;128(6):552–60

Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine. Aono H, et al. **J Rheumatol** 1996 Jan;23(1):65–70

Regulation of tumor necrosis factor-alpha production: basic aspects and pharmacological modulation [editorial] Huizinga TW, et al. **J Rheumatol** 1996 Mar;23(3):416–8

Sulfasalazine has a better efficacy/toxicity profile than auranofin—evidence from a 5 year prospective, randomized trial. McEntegart A, et al. **J Rheumatol** 1996 Nov; 23(11):1887–90

In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis. Ounissi-Benkalha H, et al. **J Rheumatol** 1996 Jan; 23(1):16–23

In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs. Seitz M, et al. **J Rheumatol** 1997 Aug;24(8):1471–6

Effects of antirheumatic agents on cytokines. Barrera P, et al. **Semin Arthritis Rheum** 1996 Feb;25(4):234–53 (187 ref.)

[Effect of non-steroidal antirheumatic agents on the gastrointestinal tract: clinical aspects and pathophysiology] Bertschinger P, et al. **Schweiz Med Wochenschr** 1996 Sep 14;126(37):1566–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Effects of disease modifying antirheumatic drugs (DMARDs) and DEX on IL-1 beta and IL-6 production by IL-1 beta stimulated synovial culture cells] Koda M, et al. **Nippon Ika Daigaku Zasshi** 1996 Oct;63(5):419–23 (Eng. Abstr.) **(Jpn)**

[The mechanisms of action of antirheumatic preparations] Nasonov EL. **Ter Arkh** 1996;68(5):8–13 (41 ref.) **(Rus)**

THERAPEUTIC USE

Re: J.M. Kremer—editorial [letter; comment] Levin DM. **Am J Gastroenterol** 1997 Aug;92(8):1402–3. Comment on: Am J Gastroenterol 1997 Feb;92(2):194–6.

Emerging treatments for rheumatoid arthritis. Schiff M. **Am J Med** 1997 Jan 27;102(1A):11S–15S (38 ref.)

Combination of second-line antirheumatic drugs. Haagsma CJ, et al. **Ann Med** 1997 Apr;29(2):169–73 (40 ref.)

Methotrexate treatment in patients with adult onset Still's disease—retrospective study of 13 Japanese cases. Fujii T, et al. **Ann Rheum Dis** 1997 Feb;56(2):144–8

Combination DMARD therapy for rheumatoid arthritis: a step closer to the goal [editorial] [see comments] O'Dell JR. **Ann Rheum Dis** 1996 Nov;55(11):781–3. Comment in: Ann Rheum Dis 1997 May;56(5):336–7.

Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A or methotrexate: comment on the article by Pasero et al [letter; comment] Alarcón GS. **Arthritis Rheum** 1997 Apr;40(4):791–2. Comment on: Arthritis Rheum 1996 Jun;39(6):1006–15.

Could the cytomegalovirus be an innocent bystander in methotrexate-treated rheumatoid arthritis patients? [letter; comment] Gangji V, et al. **Arthritis Rheum** 1996 Sep; 39(9):1608–9. Comment on: Arthritis Rheum 1995 Feb;38(2):291–2. Comment on: Arthritis Rheum 1995 Dec;38(12):1861–2.

Biologic agents for treating rheumatoid arthritis. Concepts and progress. Moreland LW, et al. **Arthritis Rheum** 1997 Mar;40(3):397–409 (123 ref.)

Effect of combination therapy with cyclosporine and methotrexate on liver function test results in rheumatoid arthritis. Stein CM, et al. **Arthritis Rheum** 1997 Sep; 40(9):1721–3

Treatment of collagenous colitis with methotrexate [letter] Bhullar DS, et al. **Aust N Z J Med** 1996 Feb;26(1):114

Early rheumatoid arthritis. Future treatment. Breedveld FC. **Baillieres Clin Rheumatol** 1997 Feb;11(1):83–96 (42 ref.)

Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs). van Gestel AM, et al. **Baillieres Clin Rheumatol** 1997 Feb;11(1):65–82 (33 ref.)

Cyclosporin can be used in early rheumatoid arthritis [letter; comment] Dawson JK, et al. **BMJ** 1997 Jun 21; 314(7097):1828. Comment on: BMJ 1997 Mar 15;314(7083):766–7.

Disease modifying drugs in rheumatoid arthritis [editorial] [see comments] Wollheim FA. **BMJ** 1997 Mar 15; 314(7083):766–7. Comment in: BMJ 1997 Jun 21;314(7097):1828.

Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. Haagsma CJ, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):195–200

Corticosteroids in rheumatoid arthritis [letter; comment] Haslock I. **Br J Hosp Med** 1996 Jun 19–Jul 9;56(1):50. Comment on: Br J Hosp Med 1996 Mar 6–19;55(5):235–6.

Successful treatment of optic neuropathy in association with systemic lupus erythematosus using intravenous cyclophosphamide. Rosenbaum JT, et al. **Br J Ophthalmol** 1997 Feb;81(2):130–2

Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Bologna C, et al. **Br J Rheumatol** 1997 May;36(5):535–40

Effective treatment of anti Jo-1 antibody-positive polymyositis with cyclosporin [letter; comment] Dawson JK, et al. **Br J Rheumatol** 1997 Jan;36(1):144–5. Comment on: Br J Rheumatol 1995 Dec;34(12):1187–8.

Shared DMARD monitoring [letter] Helliwell P, et al. **Br J Rheumatol** 1997 Aug;36(8):926–7

Rheumatoid arthritis: a possible sex bias in commencing second-line treatment [letter] Larkin JG, et al. **Br J Rheumatol** 1997 May;36(5):613–4

Penicillamine. Munro R, et al. **Br J Rheumatol** 1997 Jan; 36(1):104–9 (54 ref.)

Cyclosporin A in the long-term treatment of psoriatic arthritis [letter] Porzio F, et al. **Br J Rheumatol** 1996 Dec; 35(12):1331

Comparison of intramuscular methotrexate and goid sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Rau R, et al. **Br J Rheumatol** 1997 Mar; 36(3):345–52

Management of skin disease in lupus. Callen JP. **Bull Rheum Dis** 1997 Apr;46(2):4–7 (11 ref.)

Antirheumatic drug therapy during pregnancy. Soscia PN, et al. **Bull Rheum Dis** 1997 Apr;46(2):2–4 (11 ref.)

Association of methotrexate and corticosteroids in the treatment of patients with rheumatoid arthritis. Bologna C, et al. **Clin Exp Rheumatol** 1996 Jul–Aug;14(4):401–6

Statistical considerations concerning clinical studies designed to assess DC-ARTs. Della Casa-Alberighi O, et al. **Clin Exp Rheumatol** 1997 May–Jun;15 Suppl 17:S45–52 (48 ref.)

Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. Drosos AA, et al. **Clin Exp Rheumatol** 1997 May–Jun; 15(3):263–7

D-penicillamine in early rheumatoid arthritis: experience from a 2-year double blind placebo controlled study. Eberhardt K, et al. **Clin Exp Rheumatol** 1996 Nov–Dec; 14(6):625–31

Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Ferraccioli GF, et al. **Clin Exp Rheumatol** 1996 Jul–Aug;14(4):367–71

Effects of cyclosporin on joint damage in rheumatoid arthritis. The Italian Rheumatologists Study Group on Rheumatoid Arthritis. Ferraccioli GF, et al. **Clin Exp Rheumatol** 1997 May–Jun;15 Suppl 17:S83–9 (32 ref.)

Contrast enhanced Gd-DTPA magnetic resonance imaging in the evaluation of rheumatoid arthritis during a clinical trial with DMARDs. A prospective two-year follow-up study on hand joints in 31 patients. Jevtic V, et al. **Clin Exp Rheumatol** 1997 Mar–Apr;15(2):151–6

Prognostic criteria in rheumatoid arthritis: can we predict which patients will require specific anti-rheumatoid treatment? Kirwan JR, et al. **Clin Exp Rheumatol** 1997 May–Jun;15 Suppl 17:S15–25 (31 ref.)

Oxidative burst of neutrophils in patients with rheumatoid arthritis: influence of various cytokines and medication. Mur E, et al. **Clin Exp Rheumatol** 1997 May–Jun; 15(3):233–7

Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis. Nesher G, et al. **Clin Exp Rheumatol** 1997 Jul–Aug;15(4):343–7

The design of clinical trials aimed at assessing the DC-ART properties of new molecules in rheumatoid arthritis. Ortiz Z, et al. **Clin Exp Rheumatol** 1997 May–Jun;15 Suppl 17:S39–44 (33 ref.)

Juvenile onset of primary Sjögren's syndrome: report of 10 cases. Ostuni PA, et al. **Clin Exp Rheumatol** 1996 Nov–Dec; 14(6):689–93

Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Pincus T, et al. **Clin Exp Rheumatol** 1997 May–Jun;15 Suppl 17:S27–38 (59 ref.)

Three-year prospective study on methotrexate in rheumatoid arthritis. Analysis of radiological progression and comparison with a retrospective study [letter] Salaffi F, et al. **Clin Exp Rheumatol** 1996 May–Jun;14(3):350–1

Methotrexate in primary Sjögren's syndrome. Skopouli FN, et al. **Clin Exp Rheumatol** 1996 Sep–Oct;14(5):555–8

Currently used second-line agents: do they control the disease course? van de Putte LB, et al. **Clin Exp Rheumatol** 1997 May–Jun;15 Suppl 17:S71–4 (25 ref.)

International survey on the management of patients with SLE. I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement. Vitali C, et al. **Clin Exp Rheumatol** 1996 Nov–Dec;14 Suppl 16:S17–22

An atypical psoriatic spondylitis case, successfully treated with methotrexate. Tüzün C, et al. **Clin Rheumatol** 1996 Jul;15(4):403–9

Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Rothschild B, et al. **Compr Ther** 1997 May;23(5):327–31

Chronic arthritis in children. Szer IS. **Compr Ther** 1997 Feb; 23(2):124–9 (12 ref.)

Alternative treatments in the patient with intractable asthma. Spector SL. **Curr Opin Pulm Med** 1997 Jan;3(1):23–9 (64 ref.)

Clinical therapeutics. **Curr Opin Rheumatol** 1996 May; 8(3):B71–87

Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine. Conaghan PG, et al. **Curr Opin Rheumatol** 1996 May;8(3):176–82 (58 ref.)

ANTIRHEUMATIC AGENTS

Disease-modifying antirheumatic drugs. Conaghan PG, et al. **Curr Opin Rheumatol** 1997 May;9(3):183–90 (65 ref.)
Ulcerating necrobiosis lipoidica resolving in response to cyclosporine-A. Smith K. **Dermatol Online J** 1997 Mar; 3(1):2
Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments. Choy EH, et al. **Drugs** 1997 Mar;53(3):337–48 (91 ref.)
Characterization of a SV40-transformed rheumatoid synovial fibroblast cell line which retains genotypic expression patterns: a model for evaluation of anti-arthritic agents. Zhang HG, et al. **In Vitro Cell Dev Biol Anim** 1997 Jan; 33(1):37–41
Rheumatoid arthritis: changing concepts of treatment [editorial] O'Connell PG. **Ir Med J** 1996 Nov–Dec; 89(6):206
Juvenile rheumatoid arthritis. Pertusi RM, et al. **J Am Osteopath Assoc** 1996 May;96(5):298–302 (7 ref.)
Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis. van der Lubbe PA, et al. **J Autoimmun** 1997 Feb;10(1):87–97
Assessing the relative sensitivity to change of rheumatoid arthritis activity measures: is the type of treatment an important third variable? Ward MM. **J Clin Epidemiol** 1996 Oct;49(10):1161–9
Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis. Kovarik JM, et al. **J Clin Pharmacol** 1997 Apr;37(4):336–43
DNA hypomethylation in inflammatory arthritis: reversal with methotrexate. Kim YI, et al. **J Lab Clin Med** 1996 Aug;128(2):165–72
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice. DeGraw JI, et al. **J Med Chem** 1997 Jan 31;40(3):370–6
Analogues of methotrexate in rheumatoid arthritis. 2. Effects of 5-deazaaminopterin, 5,10-dideazaaminopterin, and analogues on type II collagen-induced arthritis in mice. Piper JR, et al. **J Med Chem** 1997 Jan 31;40(3):377–84
Macrophage activation syndrome in systemic juvenile rheumatoid arthritis [editorial; comment] [see comments] Grom AA, et al. **J Pediatr** 1996 Nov;129(5):630–2. Comment on: J Pediatr 1996 Nov;129(5):750–4. Comment in: J Pediatr 1997 Jun;130(6):1012.
Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases [see comments] Mouy R, et al. **J Pediatr** 1996 Nov; 129(5):750–4 (22 ref.). Comment in: J Pediatr 1996 Nov;129(5):630–2. Comment in: J Pediatr 1997 Jun;130(6):1012.
Low-dose pulse methotrexate inhibits articular destruction of adjuvant arthritis in rats. Kawai S, et al. **J Pharm Pharmacol** 1997 Feb;49(2):213–5
Back to the future: the pyramids of rheumatoid arthritis [editorial] [see comments] Bensen WG, et al. **J Rheumatol** 1997 Jun;24(6):1023–7. Comment in: J Rheumatol 1997 Jun;24(6):1028–30.
Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. Buckley LM, et al. **J Rheumatol** 1997 Aug;24(8):1489–94
The effects of traditional antirheumatic herbal medicines on immune response cells. Chang DM, et al. **J Rheumatol** 1997 Mar;24(3):436–41
Longterm effect of methotrexate in Felty's syndrome: a 12 year followup [letter] Gerster JC. **J Rheumatol** 1996 Jan; 23(1):200
The significance of AST changes in patients with rheumatoid arthritis treated with methotrexate [editorial; comment] Heathcote J. **J Rheumatol** 1996 Mar;23(3):413–5. Comment on: J Rheumatol 1996 Mar;23(3):459–61.
Multidrug resistance in rheumatoid arthritis [letter] Maillefert JF, et al. **J Rheumatol** 1996 Dec;23(12):2182
Cyclosporin A in the treatment of adult onset Still's disease. Marchesoni A, et al. **J Rheumatol** 1997 Aug;24(8):1582–7
Validity, reliability, and sensitivity to change of a French version of the arthritis impact measurement scales 2 (AIMS2) in patients with rheumatoid arthritis treated with methotrexate. Pouchot J, et al. **J Rheumatol** 1996 Jan; 23(1):52–60
Exacerbation of rheumatoid arthritis after termination of chemotherapy for breast carcinoma. Rosenstein ED, et al. **J Rheumatol** 1996 Nov;23(11):1988–90
Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes. Schnitzer TJ, et al. **J Rheumatol** 1997 Jun;24(6):1031–6
Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs. Tugwell P, et al. **J Rheumatol** 1997 Jun;24(6):1122–5
Rheumatoid Arthritis: The Status and Future of Combination Therapy. Proceedings of a meeting. Chatham, Massachusetts, USA, July 13–15, 1995. **J Rheumatol Suppl** 1996 Mar;44:1–110
Cost effectiveness analysis of drug therapies for rheumatoid arthritis. Criswell LA, et al. **J Rheumatol Suppl** 1996 Mar; 44:52–5
Chloroquine combined with cyclosporine in rheumatoid arthritis: more than the addition of 2 drugs alone. Dijkmans BA, et al. **J Rheumatol Suppl** 1996 Mar;44:61–3 (14 ref.)
Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. Fries JF. **J Rheumatol Suppl** 1996 Mar;44:102–6 (22 ref.)
Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis. Furst DE. **J Rheumatol Suppl** 1996 Mar;44:86–90 (16 ref.)
Efficacy assessment in trials of combination therapy for rheumatoid arthritis. Johnson K. **J Rheumatol Suppl** 1996 Mar;44:107–9
Historical overview of the treatment of rheumatoid arthritis with an emphasis on methotrexate. Kremer JM. **J Rheumatol Suppl** 1996 Mar;44:34–7
Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis. Moreland LW. **J Rheumatol Suppl** 1996 Mar;44:78–83 (74 ref.)
Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. O'Dell JR, et al. **J Rheumatol Suppl** 1996 Mar;44:72–4
Combination therapy in rheumatoid arthritis: the animal model perspective. Oliver SJ, et al. **J Rheumatol Suppl** 1996 Mar;44:56–60 (27 ref.)
Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis. Shiroky JB. **J Rheumatol Suppl** 1996 Mar;44:69–71 (31 ref.)
Combination therapy in rheumatoid arthritis: metaanalysis. Tugwell P. **J Rheumatol Suppl** 1996 Mar;44:43–6
Combination treatment of rheumatoid arthritis using azathioprine and methotrexate: a 48 week controlled clinical trial. Willkens RF, et al. **J Rheumatol Suppl** 1996 Mar;44:64–8
Combination therapy with cyclosporine in rheumatoid arthritis. Yocum DE. **J Rheumatol Suppl** 1996 Mar;44:75–7 (21 ref.)
New treatments and azathioprine in multiple sclerosis [letter] Palace J, et al. **Lancet** 1997 Jul 26;350(9073):261
Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Fox RI, et al. **Lupus** 1996 Jun;5 Suppl 1:S31–6
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Petri M. **Lupus** 1996 Jun;5 Suppl 1:S16–22 (59 ref.)
Treatment of rheumatoid arthritis. Jain R, et al. **Med Clin North Am** 1997 Jan;81(1):57–84 (174 ref.)
May colchicine therapy be of value in the prevention of dialysis amyloidosis? [letter] Arik N, et al. **Nephron** 1996; 73(2):365–6
Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Carpenter MT, et al. **Orthopedics** 1996 Mar;19(3):207–10
Effect of KE-298 on experimental arthritis in mice. Nagai H, et al. **Pharmacology** 1996 Sep;53(3):190–6
Predictors of flares and long-term outcome of systemic lupus erythematosus during combined treatment with azathioprine and low-dose prednisolone. Oelzner P, et al. **Rheumatol Int** 1996;16(4):133–9
Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases. Vatti R, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1997 Mar;14(1):73–6
Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Gøtzsche PC, et al. **Scand J Rheumatol** 1996;25(4):194–9
Therapy with cyclosporine in psoriatic arthritis. Olivieri I, et al. **Semin Arthritis Rheum** 1997 Aug;27(1):36–43 (69 ref.)
Slow-acting, disease-modifying osteoarthritis agents. McNamara PS, et al. **Vet Clin North Am Small Anim Pract** 1997 Jul;27(4):863–81 (109 ref.)
[Rheumatoid arthritis. Drug therapy (editorial)] Lorenzen I. **Ugeskr Laeger** 1997 Jul 21;159(30):4618–20 **(Dan)**
[A new approach to rheumatoid arthritis] Breedveld FC. **Ned Tijdschr Geneeskd** 1997 Apr 12;141(15):717–9 (17 ref.) (Eng. Abstr.) **(Dut)**
[Favorable results of early 2nd-stage medication in rheumatoid arthritis] van Jaarsveld CH, et al. **Ned Tijdschr Geneeskd** 1997 Apr 12;141(15):732–6 (Eng. Abstr.) **(Dut)**
[Non-cancer uses of methotrexate] Brion N, et al. **Presse Med** 1996 Dec 14;25(39):1929–34 (37 ref.) (Eng. Abstr.) **(Fre)**
[Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications] Bannwarth B, et al. **Therapie** 1997 Mar–Apr;52(2):129–32 (19 ref.) (Eng. Abstr.) **(Fre)**
[Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis] Bertin P, et al. **Therapie** 1997 Mar–Apr;52(2):133–7 (20 ref.) (Eng. Abstr.) **(Fre)**
[Selective cyclooxygenase-2 (COX-2) inhibitor. Progress in rheumatoid therapy?] Reuss-Borst M. **Internist (Berl)** 1997 Mar;38(3):266–71 (35 ref.) **(Ger)**
[Therapy of rheumatoid arthritis (chronic polyarthritis)] Villiger PM, et al. **Schweiz Rundsch Med Prax** 1996 Sep 10;85(37):1102–7 (Eng. Abstr.) **(Ger)**
[Radiologic healing phenomena in chronic polyarthritis treated with methotrexate or sodium aurothiomalate (published erratum appears in Z Rheumatol 1996 Sep-Oct;55(5):361)] Menninger H, et al. **Z Rheumatol** 1996 Jul-Aug;55(4):241–8 (Eng. Abstr.) **(Ger)**
[Alprostadil (PGE 1) and cyclosporin A in treatment of vasculitis in rheumatoid arthritis] Peichl P, et al. **Z Rheumatol** 1997 Mar–Apr;56(2):89–91 (Eng. Abstr.) **(Ger)**
[A refractory case of adult-onset Still's disease] Nishio J, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Jun; 20(3):191–8 (28 ref.) (Eng. Abstr.) **(Jpn)**
[Sulphasalazine: a promising drug in rheumatology] Nasonov EL. **Klin Med (Mosk)** 1997;75(6):39–44 (71 ref.) **(Rus)**
[The use of methotrexate in rheumatology: results and prospects] Nasonov EL. **Klin Med (Mosk)** 1996;74(5):10–5 (74 ref.) **(Rus)**
[Comparison of myocardial effects of various antirheumatic modalities in patients with rheumatoid arthritis (prospective clinico-echocardiographic study)] Nemchinov EN, et al. **Klin Med (Mosk)** 1997;75(8):36–40 (Eng. Abstr.) **(Rus)**
[The basic therapy of rheumatoid arthritis at an early stage (editorial)] Nasonova VA, et al. **Ter Arkh** 1996;68(5):5–8 (28 ref.) **(Rus)**
[New therapeutic methods against rheumatoid arthritisp6. Antibodies against TNFalpha significant for the progress] Bondeson J. **Lakartidningen** 1997 Jan 8;94(1–2):42–5 (30 ref.) (Eng. Abstr.) **(Swe)**
[New therapeutic methods against rheumatoid arthritis--1. Potent pharmaceuticals already at the debute of the disease] Bondeson J. **Lakartidningen** 1997 Jan 8;94(1–2):37–40 (16 ref.) **(Swe)**

TOXICITY

Folate supplementation and methotrexate [letter; comment] Houtman PM. **Br J Rheumatol** 1996 Oct;35(10):1031–2. Comment on: Br J Rheumatol 1995 Dec;34(12):1172–4.
Pulmonary toxicity, methotrexate and X-rays [letter; comment] Jobanputra P. **Br J Rheumatol** 1997 Jan; 36(1):148–9. Comment on: Br J Rheumatol 1996 May;35(5):446–52.
The significance of AST changes in patients with rheumatoid arthritis treated with methotrexate [editorial; comment] Heathcote J. **J Rheumatol** 1996 Mar;23(3):413–5. Comment on: J Rheumatol 1996 Mar;23(3):459–61.
The effects of antirheumatic drugs on reproductive function. Brent LH, et al. **Reprod Toxicol** 1997 Jul–Aug;11(4):561–77 (324 ref.)

ANTIRHEUMATIC AGENTS, GOLD

Auranofin. Kean WF, et al. **Br J Rheumatol** 1997 May; 36(5):560–72 (111 ref.)

ADMINISTRATION & DOSAGE

Injectable gold compounds: an overview. Jones G, et al. **Br J Rheumatol** 1996 Nov;35(11):1154–8 (55 ref.)
A stepwise increased dose of auranofin does not influence gastrointestinal side-effects [letter] Johannsen F, et al. **Clin Exp Rheumatol** 1997 Jul–Aug;15(4):454–5
Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. Egsmose C, et al. **J Rheumatol** 1995 Dec;22(12):2208–13
[The use of low doses of sodium aurothiomalate in the treatment of rheumatoid arthritis. Current trends in basic therapy] Bianucci G, et al. **Clin Ter** 1996 Dec; 147(12):609–20 (Eng. Abstr.) **(Ita)**
[Prospective clinical study of the combination therapy of auranofin and methotrexate for rheumatoid arthritis--a multi-center study] Kashiwazaki S, et al. **Ryumachi** 1996 Jun;36(3):528–44 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Nitritoid reaction in a patient on ACE inhibitor and Myocrisin treatments [letter] Ching DW, et al. **Aust N Z J Med** 1997 Jun;27(3):343
Bilateral tympanic membrane perforation--a result of gold toxicity? [letter] Raza SA, et al. **Br J Dermatol** 1997 Mar; 136(3):479–80
Vasomotor reactions with gold [editorial] Ho M, et al. **Br J Rheumatol** 1997 Feb;36(2):154–6 (15 ref.)
Chrysiasis [editorial] Smith RW, et al. **Br J Rheumatol** 1997 Jan;36(1):3–5
A case of chrysiasis. Miller ML, et al. **Cutis** 1997 May; 59(5):256–8
Adverse reactions to parenteral gold salts [letter] Tilelli JA, et al. **Lancet** 1997 Mar 22;349(9055):853
Obstructive sialadenitis caused by intraparotid deposits of gold salts: a case report. Zuazua JS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jun;81(6):649–51
[Cutaneous reactions to gold salts] Bonnetblanc JM. **Presse Med** 1996 Oct 26;25(32):1555–8 (27 ref.) (Eng. Abstr.) **(Fre)**
[A case of interstitial pneumonitis associated with auranofin occurring only in one side lung] Katoh H, et al. **Arerugi** 1996 Jul;45(7):678–80 **(Jpn)**

PHARMACOLOGY

Differential influences of gold sodium thiomalate and bucillamine on the generation of CD14+ monocyte-lineage cells from bone marrow of rheumatoid arthritis patients. Hirohata S, et al. **Clin Immunol Immunopathol** 1997 Sep;84(3):290–5
Abnormal Tl-201 myocardial scintigraphy associated with administration of sodium aurothiomalate. Allman KC, et al. **Clin Nucl Med** 1997 Jul;22(7):479–80
Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages. Yamashita M, et al. **Eur J Pharmacol** 1997 May 1;325(2–3):221–7

Gold salts inhibit osteoclastic bone resorption in vitro. Hall TJ, et al. **Inflamm Res** 1996 May;45(5):230–3
In vitro effect of gold sodium thiomalate and methotrexate on tumor necrosis factor production in normal healthy individuals and patients with rheumatoid arthritis. Yadav R, et al. **Int J Immunopharmacol** 1997 Feb;19(2):111–4
Sulfasalazine has a better efficacy/toxicity profile than auranofin—evidence from a 5 year prospective, randomized trial. McEntegart A, et al. **J Rheumatol** 1996 Nov; 23(11):1887–90

THERAPEUTIC USE

Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Rau R, et al. **Br J Rheumatol** 1997 Mar; 36(3):345–52
Alternative treatments in the patient with intractable asthma. Spector SL. **Curr Opin Pulm Med** 1997 Jan;3(1):23–9 (64 ref.)
Treatment of HIV associated psoriatic arthritis with oral gold. Shapiro DL, et al. **J Rheumatol** 1996 Oct; 23(10):1818–20
[Yellow nail syndrome associated with rheumatoid arthritis. Regression under chrysotherapy (letter)] Launay D, et al. **Rev Med Interne** 1997;18(6):494–6 **(Fre)**
[Mechanism of action of gold in treatment of rheumatoid arthritis] Burmester GR, et al. **Z Rheumatol** 1996 Sep–Oct; 55(5):299–306 (21 ref.) (Eng. Abstr.) **(Ger)**
[Gold antirheumatic drug: desired and adverse effects of Au(I) and Au(III) [corrected] on the immune system (published erratum appears in Z Rheumatol 1996 Nov–Dec;55(6):430)] Griem P, et al. **Z Rheumatol** 1996 Sep–Oct;55(5):348–58 (56 ref.) (Eng. Abstr.) **(Ger)**
[Does parenteral gold inhibit roentgen progression of chronic polyarthritis?] Rau R. **Z Rheumatol** 1996 Sep–Oct; 55(5):307–18 (34 ref.) (Eng. Abstr.) **(Ger)**
[The time for gold therapy has not yet expired (editorial)] Schattenkirchner M. **Z Rheumatol** 1996 Sep–Oct; 55(5):297–8 **(Ger)**
[A refractory case of adult-onset Still's disease] Nishio J, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1997 Jun; 20(3):191–8 (28 ref.) (Eng. Abstr.) **(Jpn)**
[An evaluation of the results of the long-term treatment of rheumatoid arthritis patients with gold salts, aminoquinoline preparations and nonsteroidal anti-inflammatory preparations] Ivanova MM, et al. **Ter Arkh** 1997;69(5):27–32 **(Rus)**
[The Tauredon treatment of rheumatoid arthritis patients: its efficacy and tolerance when used long term] Murav'ev IuV, et al. **Ter Arkh** 1996;68(5):16–8 **(Rus)**

TOXICITY

Species differences in the renal toxicity of the antiarthritic drug, gold sodium thiomalate. Cheriathundam E, et al. **J Biochem Toxicol** 1996;11(4):175–81
Genetic study of gold-salt-induced immune disorders in the rat. Kermarrec N, et al. **Nephrol Dial Transplant** 1995 Dec; 10(12):2187–91

ANTI-RHEUMATIC AGENTS, NON-STEROIDAL see **ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL**

ANTI-RHEUMATIC AGENTS, STEROIDAL see **ANTI-INFLAMMATORY AGENTS, STEROIDAL**

ANTISCHISTOSOMAL AGENTS see **SCHISTOSOMICIDES**

ANTISENSE DNA see **DNA, ANTISENSE**

ANTISENSE ELEMENTS (GENETICS)

see related
TRANSCRIPTION, GENETIC
Antisense targeting in behavioural neuroendocrinology. Landgraf R. **J Endocrinol** 1996 Dec;151(3):333–40
Strategy for designing specific antisense oligonucleotide sequences. Mitsuhashi M. **J Gastroenterol** 1997 Apr; 32(2):282–7 (37 ref.)
Gene silencing mediated by promoter homology occurs at the level of transcription and results in meiotically heritable alterations in methylation and gene activity. Park YD, et al. **Plant J** 1996 Feb;9(2):183–94
Antisense gene knockdown in the nervous system revisited: optimism for the future. Leslie R, et al. **Trends Neurosci** 1997 Aug;20(8):321–2

DIAGNOSTIC USE

Multiprimed cDNA synthesis followed by PCR is the most suitable method for Epstein-Barr virus transcript analysis in small lymphoma biopsies. Brink AA, et al. **Mol Cell Probes** 1997 Feb;11(1):39–47

GENETICS

Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. Hanna AK, et al. **J Vasc Surg** 1997 Feb;25(2):320–5
Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Gallagher WM, et al. **Oncogene** 1997 Jan 16;14(2):185–93
Modification of fatty acid composition by over- and antisense-expression of a microsomal omega-3 fatty acid desaturase gene in transgenic tobacco. Hamada T, et al. **Transgenic Res** 1996 Mar;5(2):115–21
A system for tissue-specific copper-controllable gene expression in transgenic plants: nodule-specific antisense of aspartate aminotransferase-P2. Mett VL, et al. **Transgenic Res** 1996 Mar;5(2):105–113
Antisense and ribozyme constructs in transgenic animals. Sokol DL, et al. **Transgenic Res** 1996 Nov;5(6):363–71 (89 ref.)

IMMUNOLOGY

Antisense homology boxes in C5a receptor and C5a anaphylatoxin: a new method for identification of potentially active peptides. Baranyi L, et al. **J Immunol** 1996 Nov 15;157(10):4591–601

PHARMACOKINETICS

Internalization of oligodeoxynucleotide antisense to type-1 plasminogen activator inhibitor mRNA in endothelial cells: a three-dimensional reconstruction by confocal microscopy. Wyroba E, et al. **Biol Cell** 1996;87(1–2):37–43
Uptake and distribution of fluorescein-labeled D2 dopamine receptor antisense oligodeoxynucleotide in mouse brain. Zhang SP, et al. **J Mol Neurosci** 1996 Spring;7(1):13–28
Immunofluorescence analysis of antisense oligodeoxynucleotide-mediated 'knock-down' of the mouse delta opioid receptor in vitro and in vivo. Lai J, et al. **Neurosci Lett** 1996 Aug 9;213(3):205–8

PHARMACOLOGY

Antisense inhibition of 85-kDa cPLA2 blocks arachidonic acid release from airway epithelial cells. Wu T, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):L331–8
Evaluation of antisense inhibition in a B cell model. McCall MN, et al. **Biochem Mol Biol Int** 1997 Jun;42(1):45–56
Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Go Y, et al. **Clin Exp Metastasis** 1997 Jul; 15(4):440–6
Human serum reactivity to porcine endothelial cells after antisense-mediated down-regulation of GpIIIa expression. Kearns-Jonker MK, et al. **Transplantation** 1997 Feb 27; 63(4):588–93

STANDARDS

Use of internal controls to increase quantitative capabilities of the ribonuclease protection assay. Davis MJ, et al. **Biotechniques** 1997 Aug;23(2):280–5

THERAPEUTIC USE

Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Morgan RA, et al. **Hum Gene Ther** 1996 Jun 20;7(10):1281–306
Osteogenesis imperfecta. Rehabilitation and prospects for gene therapy [clinical conference] Marini JC, et al. **JAMA** 1997 Mar 5;277(9):746–50
Application of antisense ribonucleic acid complementary to O6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas. Nagane M, et al. **Neurosurgery** 1997 Aug;41(2):434–40; discussion 440–1

ANTISENSE OLIGODEOXYRIBONUCLEOTIDES see **OLIGONUCLEOTIDES, ANTISENSE**

ANTISENSE OLIGONUCLEOTIDES see **OLIGONUCLEOTIDES, ANTISENSE**

ANTISENSE OLIGORIBONUCLEOTIDES see **OLIGONUCLEOTIDES, ANTISENSE**

ANTISENSE PROBES see **ANTISENSE ELEMENTS (GENETICS)**

ANTISENSE RNA see **RNA, ANTISENSE**

ANTISEPSIS

[The effect of changing some patient care practices on the incidence of surgical wound infections following "clean" interventions. PRINOS group of study] Moro ML, et al. **Minerva Chir** 1997 Jan–Feb;52(1–2):61–7 (Eng. Abstr.) **(Ita)**

HISTORY

Joseph Lister: pioneer of safe surgery. Kirkup J. **Ann R Coll Surg Engl** 1997 Mar;79(2 Suppl):82–4
[The introduction of antisepsis to the American continent in Mexico, 1872] Quijano-Pitman F. **Gac Med Mex** 1997 May–Jun;133(3):250–1 **(Spa)**

ANTISEPTICS see **ANTI-INFECTIVE AGENTS, LOCAL**

ANTISEPTICS, URINARY see **ANTI-INFECTIVE AGENTS, URINARY**

ANTISERA see **IMMUNE SERA**

ANTISEROTONERGIC AGENTS see **SEROTONIN ANTAGONISTS**

ANTI-SHOCK TROUSERS see **G SUITS**

ANTISICKLING AGENTS

ADVERSE EFFECTS

Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Liozon E, et al. **Hematol Cell Ther** 1997 Feb;39(1):11–8
Hydroxyurea-induced denaturation of normal and sickle cell hemoglobins in vitro. Roa D, et al. **J Clin Lab Anal** 1997; 11(4):208–13

PHARMACOLOGY

The effects of cetiedil and its congeners on levcromakalim-stimulated 86Rb efflux from smooth and skeletal muscle. Benton DC. **Eur J Pharmacol** 1996 Dec 19;317(2–3):329–33
The synthesis and some pharmacological actions of the enantiomers of the K(+)-channel blocker cetiedil. Roxburgh CJ, et al. **J Pharm Pharmacol** 1996 Aug; 48(8):851–7

THERAPEUTIC USE

Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Styles LA, et al. **Blood** 1997 Apr 1; 89(7):2554–9
Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Hackney AC, et al. **Clin Sci (Colch)** 1997 May;92(5):481–6
Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. Charache S, et al. **Control Clin Trials** 1995 Dec;16(6):432–46
Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. Jayabose S, et al. **J Pediatr** 1996 Oct;129(4):559–65
Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. de Montalembert M, et al. **J Pediatr Hematol Oncol** 1997 Jul–Aug;19(4):313–8
Treatment of thalassaemia major with phenylbutyrate and hydroxyurea [letter] Olivieri NF, et al. **Lancet** 1997 Aug 16;350(9076):491–2
Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Charache S, et al. **Medicine (Baltimore)** 1996 Nov;75(6):300–26
Hydroxyurea, sickle cell disease and renal transplantation [letter] Allen A, et al. **Nephron** 1997;75(1):106–7

ANTISOCIAL PERSONALITY DISORDER

Predisposition to criminality: Swedish adoption studies in retrospect. Bohman M. **Ciba Found Symp** 1996;194:99–109; discussion 109–14 (21 ref.) (Eng. Abstr.)
Antisocial and borderline personality disorders: two separate diagnoses or two aspects of the same psychopathology? Paris J. **Compr Psychiatry** 1997 Jul–Aug;38(4):237–42 (64 ref.)

CLASSIFICATION

Alcoholism and subtypes of antisocial personality disorder. Hesselbrock VM, et al. **Alcohol Alcohol Suppl** 1994; 2:479–84
Pursuing the psychopath: capturing the fledgling psychopath in a nomological net. Lynam DR. **J Abnorm Psychol** 1997 Aug;106(3):425–38
A Rorschach comparison of psychopathic and nonpsychopathic conduct disordered adolescents. Smith AM, et al. **J Clin Psychol** 1997 Jun;53(4):289–300

COMPLICATIONS

Alcoholism and subtypes of antisocial personality disorder. Hesselbrock VM, et al. **Alcohol Alcohol Suppl** 1994; 2:479–84
Alcohol abuse and psychopathic deviance in noncustodial parents as predictors of child-support payment and visitation. Dion MR, et al. **Am J Orthopsychiatry** 1997 Jan; 67(1):70–9
Heterogeneity in the families of sons of alcoholics: the impact of familial vulnerability type on offspring characteristics. Finn PR, et al. **J Abnorm Psychol** 1997 Feb;106(1):26–36
Psychopathy and conduct problems in children: II. Implications for subtyping children with conduct problems. Christian RE, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Feb;36(2):233–41
Overview: antisocial personality and treatment response in substance abusers. **NIDA Res Monogr** 1994;140:74–8
Relationship between solvent inhalation and antisocial behavior: special emphasis on two types of violence seen

in solvent abusers. Morita N, et al.
Psychiatry Clin Neurosci 1996 Feb;50(1):21–30

DIAGNOSIS

Clinical study of the relation of borderline personality disorder to Briquet's syndrome (hysteria), somatization disorder, antisocial personality disorder, and substance abuse disorders [published erratum appears in Am J Psychiatry 1997 Jan;154(1):139] Hudziak JJ, et al.
Am J Psychiatry 1996 Dec;153(12):1598–606

Violent offender research and implications for the criminal justice system. Rice ME. **Am Psychol** 1997 Apr; 52(4):414–23 (70 ref.)

Pathological gambling: forensic issues. Blaszczynski A, et al.
Aust N Z J Psychiatry 1996 Jun;30(3):358–69 (70 ref.)

Studies of violent and nonviolent male parolees: I. Laboratory and psychometric measurements of aggression. Cherek DR, et al. **Biol Psychiatry** 1997 Mar 1;41(5):514–22

Sex-role attitudes and clinical appraisal in psychiatry residents. Belitsky CA, et al. **Can J Psychiatry** 1996 Oct; 41(8):503–8

Severe conduct disorder—some key issues [see comments] Werry JS. **Can J Psychiatry** 1997 Aug;42(6):577–83 (37 ref.) . Comment in: Can J Psychiatry 1997 Aug;42(6):561–2.

Nonpsychotic thought disorder: objective clinical identification of somatization and antisocial personality in language patterns. North CS, et al. **Compr Psychiatry** 1997 May–Jun;38(3):171–8

Antisocial personality disorder and aggression in recently abstinent cocaine dependent subjects. Moeller FG, et al.
Drug Alcohol Depend 1997 Mar 14;44(2–3):175–82

Validity of the psychopathy checklist-revised in male methadone patients. Rutherford MJ, et al.
Drug Alcohol Depend 1997 Mar 14;44(2–3):143–9

Symptoms and personality characteristics of patients in a maximum security psychiatric unit. Rasmussen K, et al.
Int J Law Psychiatry 1996 Winter;19(1):27–37

Adult outcomes of child conduct problems: a cohort study. Kratzer L, et al. **J Abnorm Child Psychol** 1997 Feb; 25(1):65–81

Combat exposure and adult psychosocial adjustment among U.S. Army veterans serving in Vietnam, 1965–1971. Barrett DH, et al. **J Abnorm Psychol** 1996 Nov;105(4):575–81

Pursuing the psychopath: capturing the fledgling psychopath in a nomological net. Lynam DR. **J Abnorm Psychol** 1997 Aug;106(3):425–38

Antisocial personality disorder, conduct disorder, and substance abuse in schizophrenia. Mueser KT, et al.
J Abnorm Psychol 1997 Aug;106(3):473–7

Parent-reported problems in 211 adopted children: some risk and protective factors. Howe D.
J Child Psychol Psychiatry 1997 May;38(4):401–11

A new instrument to assess sibling relationships in antisocial youth: the social interaction between siblings (SIBS) interview: a research note. Slomkowski C, et al.
J Child Psychol Psychiatry 1997 Feb;38(2):253–6

Discriminating borderline from antisocial personality disorder in male patients based on psychopathology patterns and type of hostility. Hatzitaskos PK, et al.
J Nerv Ment Dis 1997 Jul;185(7):442–6

Relationship between solvent inhalation and antisocial behavior: special emphasis on two types of violence seen in solvent abusers. Morita N, et al.
Psychiatry Clin Neurosci 1996 Feb;50(1):21–30

Antisocial personality traits and patients' satisfaction with treatment for addiction. Cernovsky ZZ, et al.
Psychol Rep 1997 Feb;80(1):275–82

[Joy riding and dyssocial behavior. A comparative study based on 84 members of a delinquent group] Knecht T.
Arch Kriminol 1996 Sep–Oct;198(3–4):110–6 (Eng. Abstr.) **(Ger)**

["Serious crimes during treatment in legal psychiatric commitment (section 63 StGB)."Comment on the contribution by R. Freese et a. (letter; comment)] Leygraf N. **Nervenarzt** 1997 May;68(5):434–7. Comment on: Nervenarzt 1995 Jul;66(7):542–9. **(Ger)**

[Disintegrative psychosis with main symptoms of dysfunctional social behavior] Albert R, et al.
Psychiatr Prax 1997 Jul;24(4):207–8 **(Ger)**

DRUG THERAPY

Acute disturbed or violent behaviour: principles of treatment. Kerr IB, et al. **J Psychopharmacol (Oxf)** 1997;11(3):271–7 (40 ref.)

Sudden unexplained death in a psychiatric patient—a case report: the role of phenothiazines and physical restraint. Kumar A. **Med Sci Law** 1997 Apr;37(2):170–5

EPIDEMIOLOGY

Psychopathy and Axis I and Axis II psychiatric disorders in a forensic psychiatric population in Sweden. Stålenheim EG, et al. **Acta Psychiatr Scand** 1996 Oct;94(4):217–23

Effects of early drinking and an antisocial orientation on the alcohol use of young Russians. Parker DA, et al.
Alcohol Clin Exp Res 1996 Oct;20(7):1179–83

Early risk factors for serious antisocial behavior at age 21: a longitudinal community study. Pakiz B, et al.
Am J Orthopsychiatry 1997 Jan;67(1):92–101

Reading problems and antisocial behaviour: developmental trends in comorbidity. Maughan B, et al.
J Child Psychol Psychiatry 1996 May;37(4):405–18

Conduct disorder and antisocial personality in adult primary care patients. Barry KL, et al. **J Fam Pract** 1997 Aug; 45(2):151–8

The association of antisocial personality symptoms with marijuana abuse/dependence. A monozygotic co–twin control study. Scherrer JF, et al. **J Nerv Ment Dis** 1996 Oct;184(10):611–5

Psychiatric symptoms, risky behavior, and HIV infection. Woody GE, et al. **NIDA Res Monogr** 1997;172:156–70

Severe aggression and related conduct problems among runaway and homeless adolescents. Booth RE, et al.
Psychiatr Serv 1996 Jan;47(1):75–80

Antisocial traits in psychiatrically ill veterans without antisocial personality disorder: relationship to Axis I disorders and effects on functioning. Reich J.
Psychiatry Res 1997 Jul 4;71(2):77–82

ETIOLOGY

Autonomic nervous system factors underlying disinhibited, antisocial, and violent behavior. Biosocial perspectives and treatment implications. Raine A. **Ann N Y Acad Sci** 1996 Sep 20;794:46–59 (53 ref.)

Cognitive imbalance and antisocial personality characteristics. Snow M, et al. **J Clin Psychol** 1997 Jun; 53(4):351–4

A twin study of antisocial and neurotic symptoms in childhood. Thapar A, et al. **Psychol Med** 1996 Nov; 26(6):1111–8

GENETICS

The familial aggregation of depressive symptoms, antisocial behavior, and alcohol abuse. Stallings MC, et al.
Am J Med Genet 1997 Apr 18;74(2):183–91

The neurobehavioral genetics of aggression. Crusio WE.
Behav Genet 1996 Sep;26(5):459–61

Genetics, antisocial personality, and criminal responsibility. Dinwiddie SH. **Bull Am Acad Psychiatry Law** 1996; 24(1):95–108 (76 ref.)

Introduction: concepts of antisocial behaviour, of cause, and of genetic influences. Rutter M. **Ciba Found Symp** 1996; 194:1–15; discussion 15–20 (63 ref.)

Heterogeneity among juvenile antisocial behaviours: findings from the Virginia Twin Study of Adolescent Behavioural Development. Silberg J, et al. **Ciba Found Symp** 1996; 194:76–86; discussion 86–92 (36 ref.)

Associations of beta-endorphin with HVA and MHPG in the plasma of prepubertal boys: effects of familial drug abuse and antisocial personality disorder liability. Moss HB, et al. **Psychiatry Res** 1996 Jun 1;62(3):203–11

Analysis of a functional catechol–O–methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Strous RD, et al.
Psychiatry Res 1997 Mar 24;69(2–3):71–7

Cardiac profile and disruptive behavior in boys at risk for delinquency. Pine DS, et al. **Psychosom Med** 1996 Jul–Aug; 58(4):342–53

MORTALITY

Death rates in 71 men with antisocial personality disorder. A comparison with general population mortality. Black DW, et al. **Psychosomatics** 1996 Mar–Apr;37(2):131–6

PHYSIOPATHOLOGY

Criminality and psychopathy as related to thyroid activity in former juvenile delinquents. Alm PO, et al.
Acta Psychiatr Scand 1996 Aug;94(2):112–7

Salutary change after frontal brain trauma. Labbate LA, et al. **Ann Clin Psychiatry** 1997 Mar;9(1):27–30

Neuropsychological and cognitive psychophysiological substrates of impulsive aggression. Barratt ES, et al.
Biol Psychiatry 1997 May 15;41(10):1045–61

Anxiety, antisocial behavior, and heart rate regulation in adolescent males. Mezzacappa E, et al.
J Child Psychol Psychiatry 1997 May;38(4):457–69

Antisocial personality disorder, childhood delinquency, and frontal brain functioning: EEG and neuropsychological findings. Deckel AW, et al. **J Clin Psychol** 1996 Nov; 52(6):639–50

The psychopathic individual: a lack of responsiveness to distress cues? Blair RJ, et al. **Psychophysiology** 1997 Mar; 34(2):192–8

PREVENTION & CONTROL

Neither too sweet nor too sour: problem peers, maternal control, and problem behavior in African American adolescents. Mason CA, et al. **Child Dev** 1996 Oct; 67(5):2115–30

PSYCHOLOGY

Referred adolescents as young adults: the relationship between psychosocial functioning and personality disorder. Rey JM, et al. **Aust N Z J Psychiatry** 1997 Apr; 31(2):219–26

Studies of violent and nonviolent male parolees: II. Laboratory and psychometric measurements of impulsivity. Cherek DR, et al. **Biol Psychiatry** 1997 Mar 1;41(5):523–9

Aggressive, socially disruptive and antisocial behaviour associated with fronto-temporal dementia. Miller BL, et al. **Br J Psychiatry** 1997 Feb;170:150–4

Evolutionary adaptationism: another biological approach to criminal and antisocial behaviour. Daly M.
Ciba Found Symp 1996;194:183–91; discussion 192–5 (30 ref.)

Psychopathology and HIV risk behaviors among injection drug users in and out of treatment. Dinwiddie SH, et al.
Drug Alcohol Depend 1996 Dec 2;43(1–2):1–11

The psychopathic personality in a longitudinal perspective. Klinteberg B. **Eur Child Adolesc Psychiatry** 1996;5 Suppl 1:57–63 (66 ref.)

Deviant children grown up. Robins LN.
Eur Child Adolesc Psychiatry 1996;5 Suppl 1:44–6

Jacob—the case of a serial killer. Kallian M, et al.
Isr J Psychiatry Relat Sci 1996;33(4):221–7

Anomalous perceptual asymmetries for negative emotional stimuli in the psychopath. Day R, et al.
J Abnorm Psychol 1996 Nov;105(4):648–52

Predicting aggressive and socially disruptive behavior in a maximum security forensic psychiatric hospital. Hill CD, et al. **J Forensic Sci** 1996 Jan;41(1):56–9

Approach and avoidance motivation in psychopathic criminal offenders during passive avoidance. Arnett PA, et al. **J Pers Soc Psychol** 1997 Jun;72(6):1413–28

Antisocial personality by proxy: the Norton–Sims syndrome. Stawar TL. **J Psychol** 1997 Jan;131(1):5–19 (46 ref.)

Risk appraisal and management of violent behavior. Harris GT, et al. **Psychiatr Serv** 1997 Sep;48(9):1168–76 (132 ref.)

Early identification of chronic offenders: who is the fledgling psychopath? Lynam DR. **Psychol Bull** 1996 Sep; 120(2):209–34 (240 ref.)

The effects of unemployment on psychiatric illness during young adulthood. Fergusson DM, et al. **Psychol Med** 1997 Mar;27(2):371–81

Psychological perspective for a theory of behavior during riots. Lachman SJ. **Psychol Rep** 1996 Dec;79(3 Pt 1):739–44

[Criminal acts leading to commitment according to psychiatric jurisprudence] Jöckel D, et al. **Nervenarzt** 1997 May;68(5):390–4 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

A brain imaging (single photon emission computerized tomography) study of semantic and affective processing in psychopaths. Intrator J, et al. **Biol Psychiatry** 1997 Jul 15;42(2):96–103

Single photon emission computerised tomography in chronic alcoholism. Antisocial personality disorder may be associated with decreased frontal perfusion. Kuruoğlu AC, et al. **Br J Psychiatry** 1996 Sep;169(3):348–54

REHABILITATION

Pharmacological treatment for antisocial personality disorder alcoholics: a preliminary study. Penick EC, et al.
Alcohol Clin Exp Res 1996 May;20(3):477–84

Gender differences in manifestations of antisocial personality disorder among residential drug abuse treatment clients. Goldstein RB, et al. **Drug Alcohol Depend** 1996 May; 41(1):35–45

Short-term child psychiatric inpatient treatment. Place of residence as one-year outcome measure. Sourander A, et al. **Eur Child Adolesc Psychiatry** 1996 Apr;5(1):38–43

The treatment of dangerous patients in managed care. Psychiatric hospital utilization and outcome. Lansing AE, et al. **Gen Hosp Psychiatry** 1997 Mar;19(2):112–8

Total quality management and the reduction of inpatient violence and costs in a forensic psychiatric hospital. Hunter ME, et al. **Psychiatr Serv** 1996 Jul;47(7):751–4

FIRO-B scores and success in a positive peer–culture residential treatment program. Lee RE. **Psychol Rep** 1996 Feb;78(1):215–20

[Systemic counseling in dyssocial behavior, delinquency and violence] Schweitzer J.
Prax Kinderpsychol Kinderpsychiatr 1997 Mar;46(3):215–21 (Eng. Abstr.) **(Ger)**

[Dangerousness prognosis in the clinical context of fulfillment of psychiatric criminal commitment] Weber F, et al.
Psychother Psychosom Med Psychol 1996 Aug;46(8):312–7 (Eng. Abstr.) **(Ger)**

THERAPY

Cognitive therapy for antisocial and borderline personality disorders: single case study series. Davidson KM, et al.
Br J Clin Psychol 1996 Sep;35 (Pt 3):413–29

Can psychopaths be treated? [editorial] O'Malley P.
Ir Med J 1996 Jul–Aug;89(4):124–6

Response to methadone maintenance and counseling in antisocial patients with and without major depression. Alterman AI, et al. **J Nerv Ment Dis** 1996 Nov; 184(11):695–702

[Differentiation and therapy of delinquent behavior in borderline disorders. Psychodynamic approach] Dulz B.
Nervenarzt 1997 May;68(5):395–400 (31 ref.) (Eng. Abstr.) **(Ger)**

[Inpatient social therapy in adolescents with social behavior disorders] Hirschberg W.
Prax Kinderpsychol Kinderpsychiatr 1996 Dec; 45(10):374–82 (Eng. Abstr.) **(Ger)**

ANTISPASMODICS see **PARASYMPATHOLYTICS**

ANTISPERMATOGENIC AGENTS

PHARMACOLOGY

Estrogen receptor messenger ribonucleic acid changes during Leydig cell development. Zhai J, et al. **Biol Reprod** 1996 Oct;55(4):782–8

Measurement and modulation of nonoxynol–9 diffusion and bioactivity against spermatozoa in human cervical mucus. Dunmire EN, et al. **Contraception** 1997 Feb;55(2):115–22

TOXICITY

The value of spermatology in male reproductive toxicology: do spermatologic examinations in fertility studies provide new and additional information relevant for safety assessment? [editorial] Jahn AI, et al. **Reprod Toxicol** 1997 Mar–Jun;11(2–3):171–8

ANTISTREPTOLYSIN

IMMUNOLOGY

Gemella haemolysans endocarditis associated with a raised anti–streptolysin–O titre [letter] Breathnach AS, et al. **J Infect** 1997 Jan;34(1):87–8

ANTISYPHALILITIC AGENTS see **ANTITREPONEMAL AGENTS**

ANTITHROMBIN II see **ANTITHROMBIN III**

ANTITHROMBIN III

see related
ANTICOAGULANTS

ADMINISTRATION & DOSAGE

High dose of intravenous antithrombin III without heparin in the treatment of disseminated intravascular coagulation and organ failure in four children. Fuse S, et al. **Am J Hematol** 1996 Sep;53(1):18–21

Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine. Ali MN, et al. **Coron Artery Dis** 1996 Nov;7(11):851–61

AGONISTS

Pharmacokinetic properties of LMW–heparin–tyramine fractions with high or low affinity to antithrombin III in the rat. Stehle G, et al. **Semin Thromb Hemost** 1997; 23(1):31–7

ANALYSIS

Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Despotis GJ, et al. **Anesth Analg** 1997 Sep;85(3):498–506

The effect of dextran infusion on antithrombin III concentrations and on platelet function during minor surgery. Randell T, et al. **Ann Chir Gynaecol** 1996; 85(1):17–21

Laboratory studies on the reliability of a commercial immunoassay for thrombin–antithrombin complexes [letter] [see comments] Weltermann A, et al. **Blood Coagul Fibrinolysis** 1996 Jul;7(5):580–1. Comment in: Blood Coagul Fibrinolysis 1997 Jan;8(1):72.

Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Lowe GD, et al. **Br J Haematol** 1997 Jun;97(4):775–84

Biological variation in protein C, protein S and antithrombin concentrations in plasma of healthy subjects. Melzi d'Eril G, et al. **Eur J Clin Chem Clin Biochem** 1997 Apr; 35(4):257–60

Fibronectin and antithrombin as markers of pre–eclampsia in pregnancy. Paternoster DM, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Dec;70(1):33–9

A study of polymorphism of antithrombin III at the level of both protein and DNA in a Chinese population. Gou Q, et al. **Exp Clin Immunogenet** 1996;13(2):112–6

Thrombin–antithrombin III complexes and antithrombin III in amniotic fluid. Uszyński M, et al. **Gynecol Obstet Invest** 1997;43(1):29–33

Coagulation inhibitors and fibrinolytic parameters in patients on peritoneal dialysis and haemodialysis. Alwakeel J, et al. **Int Urol Nephrol** 1996;28(2):255–61

The effects of varying dietary n–6 to n–3 fatty acid ratios on platelet reactivity, coagulation screening assays, and antithrombin III activity in dogs. Boudreaux MK, et al. **J Am Anim Hosp Assoc** 1997 May–Jun;33(3):235–43

The effect of levenogesterol (Norplant) contraception on coagulation as measured by antithrombin–III levels. Pryor JA, et al. **J Miss State Med Assoc** 1996 Oct;37(10):777–9

Diagnostic significance of thrombin–antithrombin III complex (TAT) and D–dimer in patients with deep venous thrombosis. Sassa H, et al. **Jpn Circ J** 1996 Apr;60(4):201–6

Evaluation of thrombin–antithrombin complexes and fibrin fragment D in carbohydrate–induced acute laminitis. Weiss DJ, et al. **Res Vet Sci** 1996 Sep;61(2):157–9

TAT, F1 + 2, and D–dimer levels in patients after coronary angiography with nonionic or ionic contrast media or after cardiac catheterization. Biancardi M, et al. **Semin Thromb Hemost** 1996;22 Suppl 1:61–5

The coagulofibrinolytic state of patients with primary varicose veins of the lower legs. Ikeda M, et al. **Surg Today** 1996;26(12):985–9

Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery. Cofrancesco E, et al. **Thromb Haemost** 1997 Feb;77(2):267–9

Abnormally high level of antithrombin in a case with hepatocellular carcinoma. Iguchi K, et al. **Thromb Res** 1996 Oct 15;84(2):137–41

[Changes in the activation markers of blood coagulation and fibrinolysis in the neonatal period] Ries M, et al. **Klin Padiatr** 1996 Nov–Dec;208(6):350–4 (Eng. Abstr.) **(Ger)**

[Antithrombin III dosage using the chromogenic substrate Tos–Gly–Pro–Arg–NAN, in several pathological situations] Lourenço DM, et al. **Rev Assoc Med Bras** 1995 Nov–Dec;41(6):373–8 (Eng. Abstr.) **(Por)**

[Comparative measurement of antithrombin III by latex agglutination and radial immunodiffusion in patients with peritonitis] Miagkova MA, et al. **Klin Lab Diagn** 1997 Jan; (1):15–6 (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

The effect of immunodepletion of antithrombin III on the response of rabbits to Russell's viper venom–induced activation of factor X. Rapaport SI, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):409–16

A peptide derivative (1–70 fragment) of protein SV–IV accelerates human blood coagulation in vitro by selective inhibition of the heparin–induced antithrombin III activation process. Di Micco B, et al. **J Pept Res** 1997 Feb;49(2):174–82

CEREBROSPINAL FLUID

Cerebrospinal fluid tissue factor and thrombin–antithrombin III complex as indicators of tissue injury after subarachnoid hemorrhage. Hirashima Y, et al. **Stroke** 1997 Sep; 28(9):1666–70

CHEMISTRY

Structure–function relations of antithrombin III–heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide–pentasaccharide–docked complexes. Tyler–Cross R, et al. **Arch Biochem Biophys** 1996 Oct 15;334(2):206–13

The oligosaccharide side chain on Asn–135 of alpha–antithrombin, absent in beta–antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin–induced conformational change. Turk B, et al. **Biochemistry** 1997 Jun 3;36(22):6682–91

Intrinsic specificity of the reactive site loop of alpha1–antitrypsin, alpha1–antichymotrypsin, antithrombin III, and protease nexin I. Djie MZ, et al. **J Biol Chem** 1997 Jun 27;272(26):16268–73

Identification of the antithrombin III heparin binding site. Ersdal–Badju E, et al. **J Biol Chem** 1997 Aug 1; 272(31):19393–400

The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. Skinner R, et al. **J Mol Biol** 1997 Feb 28;266(3):601–9

Structural mobility of antithrombin and its modulation by heparin. Carrell R, et al. **Thromb Haemost** 1997 Jul; 78(1):516–9

Inactivation of factor Xia in vivo: studies in chimpanzees and in humans. Wuillemin WA, et al. **Thromb Haemost** 1996 Oct;76(4):549–55

DEFICIENCY

Recurrent small bowel infarction associated with antithrombin deficiency. Golino A, et al. **Am J Gastroenterol** 1997 Feb;92(2):323–5 (14 ref.)

Frequency of pregnancy–related venous thromboembolism in anticoagulant factor–deficient women: implications for prophylaxis [see comments] [published erratum appears in Ann Intern Med 1997 May 15;126(10):835] Friederich PW, et al. **Ann Intern Med** 1996 Dec 15;125(12):955–60. Comment in: Ann Intern Med 1996 Dec 15;125(12):1001–3. Comment in: Ann Intern Med 1997 Jul 15;127(2):163–4. Comment in: Ann Intern Med 1997 Jul 15;127(2):164. Comment in: Ann Intern Med 1997 Jul 15;127(2):164–5.

Type I antithrombin deficiency: five novel mutations associated with thrombosis. Daly M, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7(2):139–43

Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia. He S, et al. **Blood Coagul Fibrinolysis** 1997 Jun;8(4):232–8

Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C: correlation with type of defect, family history, and absence of the factor V Leiden mutation. McColl M, et al. **Blood Coagul Fibrinolysis** 1996 Oct;7(7):689–94

Molecular genetics of antithrombin deficiency. Lane DA, et al. **Blood Rev** 1996 Jun;10(2):59–74 (167 ref.)

Factors predicting morbidity following hematopoietic stem cell transplantation. Gordon B, et al. **Bone Marrow Transplant** 1997 Mar;19(5):497–501

Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting. **Bull World Health Organ** 1997; 75(3):177–89 (69 ref.)

Mesenteric venous thrombosis due to coagulation deficiencies – a case report [published erratum appears in Int Angiol 1996 Mar;15(1):following 85] Papalambros E, et al. **Int Angiol** 1995 Sep;14(3):236–8

Protein C, protein S and antithrombin III in children with portal vein obstruction. Dubuisson C, et al. **J Hepatol** 1997 Jul;27(1):132–5

Acquired protein S and antithrombin III deficiency caused by nephrotic syndrome: an unusual cause of graft thrombosis. Siddiqi FA, et al. **J Vasc Surg** 1997 Mar; 25(3):576–80

Index of suspicion. Antithrombin III deficiency. Nussbaum D 2nd. **Pediatr Rev** 1997 Aug;18(8):283, 285–6

National Antithrombin Investigators Program. Antithrombin Deficiency—Basis for Therapy. Proceedings of a symposium. Phoenix, Arizona, October 21–23, 1995. **Semin Hematol** 1995 Oct;32(4 Suppl 2):1–74

Antithrombin deficiency in special clinical syndromes—Part I: panel discussion. **Semin Hematol** 1995 Oct;32(4 Suppl 2):37–41

Thrombophilia and complex acquired deficiencies of antithrombin, protein C, and protein S. Humphries JE. **Semin Hematol** 1995 Oct;32(4 Suppl 2):8–16; discussion 17–8 (16 ref.)

Antithrombin deficiency in special clinical syndromes—Part II: cardiovascular surgery. Levy JH. **Semin Hematol** 1995 Oct;32(4 Suppl 2):49–55 (14 ref.)

Clinical relevance of antithrombin deficiencies. Mammen EF. **Semin Hematol** 1995 Oct;32(4 Suppl 2):2–6; discussion 7 (29 ref.)

Antithrombin deficiency in special clinical syndromes—Part II: trauma/burns. Penner J. **Semin Hematol** 1995 Oct;32(4 Suppl 2):42–7; discussion 48 (23 ref.)

Antithrombin deficiency in special clinical syndromes—Part II: panel discussion #2. Sacher R. **Semin Hematol** 1995 Oct;32(4 Suppl 2):67–71

Antithrombin deficiency in special clinical syndromes—Part I: neonatal and pediatric/physiologic deficiency: extracorporeal membrane oxygenation. Shapiro A. **Semin Hematol** 1995 Oct;32(4 Suppl 2):33–6 (10 ref.)

Antithrombin and its inherited deficiency states. van Boven HH, et al. **Semin Hematol** 1997 Jul;34(3):188–204 (155 ref.)

Acquired antithrombin deficiency following severe traumatic injury: rationale for study of antithrombin supplementation. Owings JT, et al. **Semin Thromb Hemost** 1997;23 Suppl 1:17–24

Isolated deep cerebral venous thrombosis treated by direct endovascular thrombolysis. Gerszten PC, et al. **Surg Neurol** 1997 Sep;48(3):261–6

Antithrombin: molecular basis of deficiency. Bayston TA, et al. **Thromb Haemost** 1997 Jul;78(1):339–43 (35 ref.)

Prevalence of mutant factor V in Italian patients with hereditary deficiencies of antithrombin, protein C or protein S [letter] Martinelli I, et al. **Thromb Haemost** 1996 Apr;75(4):694–5

Genetic analysis in Japanese kindreds of congenital type I antithrombin deficiency causing thrombosis. Nakahara Y, et al. **Thromb Haemost** 1997 Apr;77(4):616–9

Antithrombin Morioka (Cys 95–Arg): a novel missense mutation causing type I antithrombin deficiency [letter] Ozawa T, et al. **Thromb Haemost** 1997 Feb;77(2):403

Mortality and causes of death in inherited antithrombin deficiency. van Boven HH, et al. **Thromb Haemost** 1997 Mar;77(3):452–5

High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. Shen MC, et al. **Thromb Res** 1997 Aug 15;87(4):377–85

[Inherited thrombophilia] Jia X, et al. **Chung Hua Nei Ko Tsa Chih** 1996 Feb;35(2):133–6 (18 ref.) **(Chi)**

[Mesenteric infarction secondary to antithrombin III deficiency] Miguil M, et al. **Cah Anesthesiol** 1996; 44(4):357–9 (Eng. Abstr.) **(Fre)**

[Genetic analysis of congenital antithrombin deficiencies] Masuda H, et al. **Rinsho Byori** 1997 Feb;Suppl 104:187–94 (25 ref.) **(Jpn)**

[The application of molecular biology to thrombosis and hemostasis] Niiya K, et al. **Rinsho Byori** 1997 Apr; 45(4):305–9 (15 ref.) **(Jpn)**

[Congenital antithrombin III deficiency] Ohke M. **Ryoikibetsu Shokogun Shirizu** 1996;(15):460–3 (18 ref.) **(Jpn)**

[Coagulation–inhibiting proteins; implications for cerebrovascular disorders] Cáceres Sansaloni A, et al. **Rev Clin Esp** 1996 Nov;196(11):737–40 (Eng. Abstr.) **(Spa)**

[Cesarean section in a patient with a congenital deficit of antithrombin III: apropos of a case (see comments)] Benito MC, et al. **Rev Esp Anestesiol Reanim** 1996 Aug–Sep; 43(7):258–60 (Eng. Abstr.). Comment in: Rev Esp Anestesiol Reanim 1997 Feb;44(2):88–9. **(Spa)**

[Use of low molecular weight heparins (letter; comment)] Llau JV, et al. **Rev Esp Anestesiol Reanim** 1997 Feb; 44(2):88–9. Comment on: Rev Esp Anestesiol Reanim 1996 Aug–Sep;43(7):258–60 **(Spa)**

DRUG EFFECTS

[Activity of endogenous anticoagulants (antithrombin III, protein C and protein S) in women after menopause treated

with hormone replacement therapy (transdermal 17 beta-OH estradiol and oral medroxyprogesterone acetate)] Ciepluch R, et al. **Ginekol Pol** 1996 Aug;67(8):407-10 (Eng. Abstr.) **(Pol)**

GENETICS

Interstitial deletion of chromosome 1q [del(1)(q24q25.3)] identified by fluorescence in situ hybridization and gene dosage analysis of apolipoprotein A-II, coagulation factor V, and antithrombin III. Takano T, et al. **Am J Med Genet** 1997 Jan 20;68(2):207-10

Homozygous variant of antithrombin with lack of affinity for heparin: management of severe thrombotic complications associated with intrauterine fetal demise. Bauters A, et al. **Blood Coagul Fibrinolysis** 1996 Oct; 7(7):705-10

A novel nonsense mutation in the antithrombin III gene (Cys-4-->stop) causing recurrent venous thrombosis. Saleun S, et al. **Blood Coagul Fibrinolysis** 1996 Jul; 7(5):578-9

A study of polymorphism of antithrombin III at the level of both protein and DNA in a Chinese population. Gou Q, et al. **Exp Clin Immunogenet** 1996;13(2):112-6

Intracellular degradation of secretion defect-type mutants of antithrombin is inhibited by proteasomal inhibitors. Tokunaga F, et al. **FEBS Lett** 1997 Jul 21;412(1):65-9

Regions flanking exon 1 regulate constitutive expression of the human antithrombin gene. Fernandez-Rachubinski FA, et al. **J Biol Chem** 1996 Nov 15;271(46):29502-12

A novel antithrombin gene mutation: slippage and mispairing as a mechanism of genetic disease. Fitches AC, et al. **Pathology** 1996 Nov;28(4):339-42

A 5-nucleotide insertion in the antithrombin gene causing a quantitative antithrombin deficiency [letter] Jeong H, et al. **Thromb Haemost** 1997 Jan;77(1):212-3

Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Lane DA, et al. **Thromb Haemost** 1997 Jan;77(1):197-211 (131 ref.)

A novel 4 base pair deletion mutation inducing type I antithrombin deficiency. Ozawa T, et al. **Thromb Res** 1997 Mar 15;85(6):515-7

Analysis for antithrombin gene polymorphisms in Japanese subjects and cosegregation studies in families with hereditary antithrombin deficiency. Yamazaki T, et al. **Thromb Res** 1996 May 1;82(3):275-80

[Ischemic cerebrovascular complication disclosing primary antiphospholipid syndrome and an antithrombin III variant: a coagulation disorder (letter)] Borg JY, et al. **Rev Med Interne** 1996;17(12):1044-5 **(Fre)**

ISOLATION & PURIFICATION

Hamster antithrombin III: purification, characterization and acute phase response. Mak P, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Sep; 115(1):135-41

Commercial antithrombin concentrate contains inactive L-forms of antithrombin. Chang WS, et al. **Thromb Haemost** 1997 Feb;77(2):323-8

METABOLISM

Plasma levels of protein C, protein S, and antithrombin III in patients with subarachnoid haemorrhage. Kanamaru K, et al. **Acta Neurochir (Wien)** 1997;139(2):134-40

Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits. Hatton MW, et al. **Am J Physiol** 1997 May;272(5 Pt 1):E824-31

The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study [see comments] Chang J, et al. **Ann Oncol** 1996 Sep;7(7):671-5 . Comment in: Ann Oncol 1996 Sep;7(7):655-6.

Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity. Olson ST, et al. **Arch Biochem Biophys** 1997 May 15;341(2):212-21

Cardiopulmonary bypass using lomoparan: monitoring of anticoagulation using anti-Xa levels and thromboelastography. Sharma S, et al. **Aust N Z J Surg** 1997 Jun;67(6):392-4

Effect of 15-hydroperoxyeicosatetraenoic acid on the fibrinolytic factor release and the antithrombin binding of vascular endothelial cells. Soeda S, et al. **Biol Pharm Bull** 1997 Jan;20(1):15-9

The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs. Dahl OE, et al. **Blood Coagul Fibrinolysis** 1995 Dec;6(8):709-17

Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans. Hérault JP, et al. **Blood Coagul Fibrinolysis** 1997 Apr;8(3):161-7

Probable regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo. Gouin-Thibault I, et al. **Br J Haematol** 1996 Dec; 95(4):738-46

Coagulation and fibrinolytic responses of human peritoneal fluid and plasma to bacterial peritonitis. van Goor H, et al. **Br J Surg** 1996 Aug;83(8):1133-5

Coagulation and fibrinolysis activation markers in prostatic carcinoma patients. Geenen RW, et al. **Eur J Clin Chem Clin Biochem** 1997 Feb;35(2):69-72

Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Chamouard P, et al. **Eur J Gastroenterol Hepatol** 1995 Dec;7(12):1183-8

Intracellular degradation of secretion defect-type mutants of antithrombin is inhibited by proteasomal inhibitors. Tokunaga F, et al. **FEBS Lett** 1997 Jul 21;412(1):65-9

A unique trisaccharide sequence in heparin mediates the early step of antithrombin III activation. Petitou M, et al. **Glycobiology** 1997 Apr;7(3):323-7

Pregnancy induced hypertension and antithrombin-III. Srivastava M, et al. **Indian J Pathol Microbiol** 1995 Jul; 38(3):257-60

Are prothrombin fragment 1 + 2 and thrombin-antithrombin complexes useful in the management of oral anticoagulant therapy? Barcellona D, et al. **Int J Clin Lab Res** 1997; 27(1):76-8

Haemostatic parameters in childhood nephrotic syndrome. (Is there any difference in protein C levels between steroid sensitive and resistant groups?) Yalçinkaya F, et al. **Int Urol Nephrol** 1995;27(5):643-7

Inactivation of thrombin by antithrombin is accompanied by inactivation of regulatory exosite I. Bock PE, et al. **J Biol Chem** 1997 Aug 8;272(32):19837-45

Lysine residue 114 in human antithrombin III is required for heparin pentasaccharide-mediated activation. Kridel SJ, et al. **J Biol Chem** 1997 Mar 21;272(12):7656-60

Role of arginine 132 and lysine 133 in heparin binding to and activation of antithrombin. Meagher JL, et al. **J Biol Chem** 1996 Nov 15;271(46):29353-8

Heparin-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity. Pike RN, et al. **J Biol Chem** 1997 Aug 8;272(32):19652-5

Enzymatic preparation of heparin oligosaccharides containing antithrombin III binding sites. Toida T, et al. **J Biol Chem** 1996 Dec 13;271(50):32040-7

The mechanism of anticoagulant activity of a novel heparinoid sulfated glucoside-bearing polymer. Sakamoto N, et al. **J Biomater Sci Polym Ed** 1997;8(7):545-53

The interactions between antithrombin III, thrombin and surface immobilized heparin. van Delden CJ, et al. **J Biomater Sci Polym Ed** 1996;7(11):989-1004

Effect of fibronectin on the binding of antithrombin III to immobilized heparin. Byun Y, et al. **J Biomed Mater Res** 1996 Jan;30(1):95-100

The thrombin-antithrombin complex in rheumatoid arthritis [letter] Cella G, et al. **J Rheumatol** 1997 Feb;24(2):410

Prothrombin activation fragment 1 + 2 and thrombin-antithrombin-III complexes in plasma of patients with essential arterial hypertension. Kłoczko J, et al. **Pol J Pharmacol** 1996 Mar-Apr;48(2):233-5

Hemostatic balance during the acute inflammatory reaction; with special reference to antithrombin III. Pleşca LA, et al. **Rom J Physiol** 1995 Jan-Dec;32(1-4):71-6

Long-term persistence of biological activity following administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments--comparison with unfractionated heparin. Brieger D, et al. **Thromb Haemost** 1996 May; 75(5):740-6

Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Lormeau JC, et al. **Thromb Haemost** 1996 Jul;76(1):5-8

The VITA Project: population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen--relationship with physiological variables and establishment of reference ranges. Rodeghiero F, et al. **Thromb Haemost** 1996 Aug;76(2):226-33

Thrombin-inhibitor complexes in the blood during and after delivery. Andersson T, et al. **Thromb Res** 1996 Apr 15; 82(2):109-17

Determination of the kinetic constants of tissue factor/factor VII/factor VIIA and antithrombin/heparin using surface plasmon resonance. Björquist P, et al. **Thromb Res** 1997 Feb 1;85(3):225-36

Experimental haemorrhage and blood component transfusion in humans: no change in plasma concentration of thrombin-antithrombin complex and plasmin-antiplasmin complex. Henriksson AE, et al. **Thromb Res** 1996 Jun 1; 82(5):409-15

Short-time stability of markers of coagulation and fibrinolysis in frozen plasma [published erratum appears in Thromb Res 1996 Apr 15;82(2):199] Iversen LH, et al. **Thromb Res** 1996 Jan 15;81(2):253-61

Relationship between changes in F1+2 and TAT levels and blood coagulation early after prosthetic valve replacement. Nakamura K, et al. **Thromb Res** 1997 Apr 15;86(2):161-71

Antithrombin-III activity in plasma of healthy and sick cattle. Pusterla N, et al. **Vet Rec** 1997 Jan 4;140(1):17-8

[Investigation on the causes of pregnancy induced hypertension] Zhang Z, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Aug;31(8):458-60 (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

Covalent antithrombin-heparin complexes with high anticoagulant activity. Intravenous, subcutaneous, and intratracheal administration. Chan A, et al. **J Biol Chem** 1997 Aug 29;272(35):22111-7

PHARMACOLOGY

Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT beta. Frebelius S, et al. **Arterioscler Thromb Vasc Biol** 1996 Oct; 16(10):1292-7

Antithrombin III prevents blood pressure elevation and proteinuria induced by high salt intake in pregnant stroke-prone spontaneously hypertensive rats. Shinyama H, et al. **Biol Pharm Bull** 1996 Jun;19(6):819-23

Antithrombin III inhibits mesangial cell proliferation. Pahl MV, et al. **J Am Soc Nephrol** 1996 Oct;7(10):2249-53

Functional requirements for inhibition of thrombin by antithrombin III in the presence and absence of heparin. Tsiang M, et al. **J Biol Chem** 1997 May 2;272(18):12024-9

Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. van 't Veer C, et al. **J Biol Chem** 1997 Feb 14;272(7):4367-77

Inhibition of thrombin by hirudin genetically fused to wild-type or mutant antithrombin. Syed S, et al. **Thromb Res** 1996 Dec 15;84(6):419-29

Soluble complement receptor type 1 and antithrombin-III combination therapy prolongs xenograft survival: the role of thrombin and prostacyclin in hyperacute rejection. Fujiwara I, et al. **Transplant Proc** 1997 Feb-Mar; 29(1-2):935-7

Protective effects of antithrombin III supplementation on warm ischemia and reperfusion injury in rat liver. Okano K, et al. **World J Surg** 1996 Oct;20(8):1069-75

PHYSIOLOGY

Plasma thrombin-antithrombin complexes, latent coagulation disorders and metastatic spread in lung cancer: a longitudinal study. Tricerri A, et al. **Oncology** 1996 Nov-Dec;53(6):455-60

Antithrombin determinants of coronary artery disease in transplanted human hearts. Labarrere CA, et al. **Semin Hematol** 1995 Oct;32(4 Suppl 2):61-6 (38 ref.)

Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice. Nagase H, et al. **Thromb Haemost** 1997 Feb;77(2):399-402

Thrombin-inhibitor complexes in the blood during and after delivery. Andersson T, et al. **Thromb Res** 1996 Apr 15; 82(2):109-17

THERAPEUTIC USE

Antithrombin-III substitution in preterm infants--effect on intracranial hemorrhage and coagulation parameters. Brangenberg R, et al. **Biol Neonate** 1997;72(2):76-83

The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Kessler CM, et al. **Blood** 1997 Jun 15;89(12):4393-401

Is there a need for antithrombin III substitution early after burn injury? Danielsson P, et al. **Burns** 1997 Jun;23(4):300-5

Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study [see comments] Grip L, et al. **Eur Heart J** 1997 Mar;18(3):443-9. Comment in: Eur Heart J 1997 Mar;18(3):362-3.

Adjunctive infusion of antithrombin III during percutaneous transluminal coronary angioplasty [editorial; comment] Huber K, et al. **Eur Heart J** 1997 Mar;18(3):362-3. Comment on: Eur Heart J 1997 Mar;18(3):443-9.

Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis. Yamaguchi H, et al. **Gut** 1997 Apr;40(4):531-5

Antithrombin III prevents renal dysfunction and hypertension induced by enhanced intravascular coagulation in pregnant rats: pharmacological confirmation of the benefits of treatment with antithrombin III in preeclampsia. Shinyama H, et al. **J Cardiovasc Pharmacol** 1996 May;27(5):702-11

Antithrombotic and antifibrinolytic effects of antithrombin III replacement in liver cirrhosis [letter] Carmassi F, et al. **Lancet** 1997 Apr 12;349(9058):1069

National Antithrombin Investigators Program. Antithrombin Deficiency--Basis for Therapy. Proceedings of a symposium. Phoenix, Arizona, October 21-23, 1995. **Semin Hematol** 1995 Oct;32(4 Suppl 2):1-74

Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Jochum M. **Semin Hematol** 1995 Oct;32(4 Suppl 2):19-32 (8 ref.)

Experience with antithrombin concentrates in neurotrauma patients. Hoots WK. **Semin Thromb Hemost** 1997;23 Suppl 1:3-16

Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: concerted effect with antithrombin. Kamikubo Y, et al. **Thromb Haemost** 1996 Oct;76(4):621-6

Antithrombin III and antivenom reversal of coagulopathy in rats envenomated with Malayan pit viper venom. Pukrittayakamee S, et al. **Toxicon** 1994 Jan;32(1):97-103

A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Harper PL, et al. **Transfus Med** 1991 Jun; 1(2):121–8

[Antithrombin III in the treatment of disseminated intravascular coagulation (see comments)] Nordgaard–Andersen I, et al. **Ugeskr Laeger** 1997 Feb 3; 159(6):730–1. Comment in: Ugeskr Laeger 1997 May 19;159(21):3189–90. **(Dan)**

[Evidence–based medicine and disseminated intravascular coagulation (DIC) (letter; comment)] Skadborg MK. **Ugeskr Laeger** 1997 May 19;159(21):3189–90. Comment on: Ugeskr Laeger 1997 Feb 3;159(6):730–1. **(Dan)**

[Antithrombin III concentrate seeks its therapeutic role. Be careful and wait for the results of the studies!] Astermark J, et al. **Lakartidningen** 1996 Oct 23;93(43):3773–6, 3778 (55 ref.) **(Swe)**

ANTITHROMBIN VI see FIBRIN FIBRINOGEN DEGRADATION PRODUCTS

ANTITHROMBINS

see related
ANTICOAGULANTS

Use of thrombin inhibitors ex vivo allows critical care clinical chemistry and hematology testing on common specimens. Lyon AW, et al. **Clin Biochem** 1997 Mar;30(2):121–7

Anti–thrombogenic effects of 2–hydroxyethylmethacrylate–styrene block copolymer and argatroban in synthetic small–caliber vascular grafts in a rabbit inferior vena cava model. Terada S, et al. **J Reconstr Microsurg** 1997 Jan;13(1):9–16

ADMINISTRATION & DOSAGE

Comparison of the effects of the thrombin inhibitor r–hirudin in four animal models of neointima formation after arterial injury. Gerdes C, et al. **Arterioscler Thromb Vasc Biol** 1996 Oct;16(10):1306–11

Orally effective CVS–1123 prevents coronary artery thrombosis in the conscious dog. Cousins GR, et al. **Circulation** 1996 Oct 1;94(7):1705–12

Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short–term treatment. Andersen K, et al. **Coron Artery Dis** 1996 Sep;7(9):673–81

Subcutaneous infusion of r–hirudin does not inhibit neointimal proliferation after angioplasty of the subclavian artery in cholesterol–fed rabbits. Hadoke PW, et al. **Coron Artery Dis** 1996 Aug;7(8):599–608

Induction of thrombolysis and prevention of thrombus formation by local drug delivery with a double–occlusion balloon catheter. Tomaru T, et al. **Heart Vessels** 1996; 11(3):123–32

Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries. Tomaru T, et al. **Heart Vessels** 1996;11(3):133–44

Effects of locally administration of argatroban using a hydrogel–coated balloon catheter on intimal thickening induced by balloon injury. Imanishi T, et al. **Jpn Circ J** 1997 Mar;61(3):256–62

Heparin versus hirudin for acute coronary syndromes [letter; comment] Schmaier AH. **N Engl J Med** 1997 Mar 6; 336(10):730; discussion 730–1. Comment on: N Engl J Med 1996 Sep 12;335(11):775–82.

Active site–directed thrombin inhibitors: alpha–hydroxyacyl–prolyl–arginals, new orally active stable analogues of D–Phe–Pro–Arg–H. Bajusz S, et al. **Semin Thromb Hemost** 1996;22(3):243–6

Antithrombotic activity of argatroban in experimental thrombosis in the rabbit. Berry CN, et al. **Semin Thromb Hemost** 1996;22(3):233–41

New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors. Lenfors S, et al. **Semin Thromb Hemost** 1996;22(4):335–42

High and constant plasma levels of tissue plasminogen activator and PEG–hirudin can be achieved by subcutaneous delivery. Humphries J, et al. **Thromb Res** 1997 Jul 1;87(1):123–9

Adjuvant effect of argatroban on staphylokinase induced thrombolysis of platelet rich thrombi in rat mesenteric venules in vivo. Kawano M, et al. **Thromb Res** 1997 Apr 15;86(2):115–26

ADVERSE EFFECTS

Type IV allergy to natural hirudin confirmed by in vitro stimulation with recombinant hirudin. Zollner TM, et al. **Contact Dermatitis** 1996 Jul;35(1):59–60

Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb–IIIa receptor blockers. Armstrong PW, et al. **Eur Heart J** 1995 Nov;16 Suppl L:75–80 (28 ref.)

Pharmacodynamic and safety results of PEG–Hirudin in healthy volunteers. Esslinger HU, et al. **Thromb Haemost** 1997 May;77(5):911–9

ANALYSIS

Investigation on minor degraded derivatives of the recombinant hirudin variant HM2 from Hirudinaria manillensis isolated by isoelectric focusing in multicompartment electrolyzers. Bossi A, et al. **Electrophoresis** 1996 May;17(5):932–7

Increase in both pro–thrombotic and anti–thrombotic factors in obese premenopausal women: relationship with body fat distribution. De Pergola G, et al. **Int J Obes Relat Metab Disord** 1997 Jul;21(7):527–535

Quantitation of an orally available thrombin inhibitor in rat, monkey and human plasma and in human urine by high–performance liquid chromatography and fluorescent post–column derivatization of arginine. Mendoza CB, et al. **J Chromatogr A** 1997 Feb 21;762(1–2):299–310

The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma—the need for using absolute anti–factor Xa and antithrombin activities. Peyrou V, et al. **Thromb Haemost** 1997 Feb;77(2):312–6

CHEMICAL SYNTHESIS

Molecular recognition at the thrombin active site: structure–based design and synthesis of potent and selective thrombin inhibitors and the X–ray crystal structures of two thrombin–inhibitor complexes. Obst U, et al. **Chem Biol** 1997 Apr;4(4):287–95

Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1–argininal derivatives incorporating P3–P4 lactam sulfonamide moieties. Semple JE, et al. **J Med Chem** 1996 Nov 8;39(23):4531–6

Synthesis and structure–activity relationships of potent thrombin inhibitors: piperazides of 3–amidinophenylalanine. Stürzebecher J, et al. **J Med Chem** 1997 Sep 12;40(19):3091–9

Synthesis and study on a novel inhibitor of thrombin containing no side chain at the P1 position of the polypeptide chain. Gershkovich AA, et al. **Semin Thromb Hemost** 1996;22(4):343–5

CHEMISTRY

Covalent linkage of recombinant hirudin to poly(ethylene terephthalate) (Dacron): creation of a novel antithrombin surface. Phaneuf MD, et al. **Biomaterials** 1997 May; 18(10):755–65

Biochemistry and biology of hirudin. Toschi V, et al. **Coron Artery Dis** 1996 Jun;7(6):420–8 (95 ref.)

Characterization of a beta–Asp33 isoform of recombinant hirudin sequence variant 1 by low–energy collision–induced dissociation. Schindler P, et al. **J Mass Spectrom** 1996 Sep;31(9):967–74

Molecular modeling and 3D–QSAR studies on the interaction mechanism of tripeptidyl thrombin inhibitors with human alpha–thrombin. Jiang H, et al. **J Med Chem** 1997 Sep 12; 40(19):3085–90

Potent and selective thrombin inhibitors incorporating the constrained arginine mimic 1–3–piperidyl(N–guanidino)alanine at P1. Levy OE, et al. **J Med Chem** 1996 Nov 8;39(23):4527–30

Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha–thrombin. Féthière J, et al. **Protein Sci** 1996 Jun; 5(6):1174–83

Synthesis, structure, and structure–activity relationships of divalent thrombin inhibitors containing an alpha–keto–amide transition–state mimetic. Krishnan R, et al. **Protein Sci** 1996 Mar;5(3):422–33

Direct measurement of angles between bond vectors in high–resolution NMR. Reif B, et al. **Science** 1997 May 23; 276(5316):1230–3

Enzyme flexibility, solvent and 'weak' interactions characterize thrombin–ligand interactions: implications for drug design. Engh RA, et al. **Structure** 1996 Nov 15; 4(11):1353–62

Reevaluating the effects of tyrosine iodination of recombinant hirudin on its thrombin inhibition kinetics. Komatsu Y, et al. **Thromb Res** 1997 Aug 15;87(4):343–52

CLASSIFICATION

[Peptides: multiple source of antithrombotic agents (editorial)] Thurieau C. **Pathol Biol (Paris)** 1997 Apr; 45(4):264–7 (28 ref.) **(Fre)**

DEFICIENCY

Prenatal diagnosis in combined antithrombin and factor V gene mutation. Lane DA, et al. **Br J Haematol** 1996 Sep; 94(4):753–5

Anticoagulant effect of unfractionated heparin in antithrombin–depleted plasma in vitro. Krulder JW, et al. **Haemostasis** 1996 Mar–Apr;26(2):85–9

GENETICS

Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion. Hodgkins PR, et al. **Eye** 1995;9 (Pt 6):760–2

Inherited thrombophilias [editorial] Laffan MA, et al. **QJM** 1997 Jun;90(6):375–8

Antithrombin Morioka (Cys 95–Arg): a novel missense mutation causing type I antithrombin deficiency [letter] Ozawa T, et al. **Thromb Haemost** 1997 Feb;77(2):403

A novel 4 base pair deletion mutation inducing type I antithrombin deficiency. Ozawa T, et al. **Thromb Res** 1997 Mar 15;85(6):515–7

ISOLATION & PURIFICATION

Fumaric acid, anti–thrombin substance from Rhizopus javanicus. Okamura T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Apr;43(2):241–7

METABOLISM

Nonpolar interactions of thrombin and its inhibitors at the fibrinogen recognition exosite: thermodynamic analysis. Cheng Y, et al. **Biochemistry** 1996 Oct 8;35(40):13021–9

Serial changes of natural antithrombotics during myocardial ischemia–reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac–1 inhibitor. Serebruany VL, et al. **Blood Coagul Fibrinolysis** 1996 Sep;7(6):632–40

Binding affinities for sulfonamide inhibitors with human thrombin using Monte Carlo simulations with a linear response method. Jones–Hertzog DK, et al. **J Med Chem** 1997 May 9;40(10):1539–49

Thrombin inhibitors of bloodsucking animals. Dodt J, et al. **Semin Thromb Hemost** 1996;22(2):203–8 (44 ref.)

A family of arginal thrombin inhibitors related to efegatran. Smith GF, et al. **Semin Thromb Hemost** 1996;22(2):173–83

Monitoring of recombinant hirudin: assessment of a plasma–based ecarin clotting time assay. Pötzsch B, et al. **Thromb Res** 1997 Jun 1;86(5):373–83

Interaction between Yersinia pestis YopM protein and human alpha–thrombin. Skrzypek E, et al. **Thromb Res** 1996 Oct 1;84(1):33–43

PHARMACOKINETICS

Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Syed S, et al. **Blood** 1997 May 1; 89(9):3243–52

Effects of permeation enhancers on the transport of a peptidomimetic thrombin inhibitor (CRC 220) in a human intestinal cell line (Caco–2). Werner U, et al. **Pharm Res** 1996 Aug;13(8):1219–27

Pharmacodynamic and safety results of PEG–Hirudin in healthy volunteers. Esslinger HU, et al. **Thromb Haemost** 1997 May;77(5):911–9

PHARMACOLOGY

Identification of glycyrrhizin as a thrombin inhibitor [published erratum appears in Biochem Biophys Res Commun 1997 Aug 8;237(1):203] Francischetti IM, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):259–63

Mechanism of thrombin inhibition by antithrombin and heparin cofactor II in the presence of heparin. Maaroufi RM, et al. **Biomaterials** 1997 Feb;18(3):203–11

Heparin cofactor II–dependent antithrombin activity of calcium spirulan. Hayakawa Y, et al. **Blood Coagul Fibrinolysis** 1996 Jul;7(5):554–60

Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin. Duval N, et al. **Br J Pharmacol** 1996 Jun; 118(3):727–33

The human pharmacology of thrombin inhibition [published erratum appears in Coron Artery Dis 1997 Jan;8(1):A4] FitzGerald GA. **Coron Artery Dis** 1996 Dec;7(12):911–8 (108 ref.)

A recombinant hirudin (IK–HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time. Schenk JF, et al. **Haemostasis** 1996 May–Jun;26(3):140–9

Modulating platelet function with selective thrombin inhibitors. Verstraete M. **Haemostasis** 1996 Oct;26 Suppl 4:70–7 (28 ref.)

Inhibition of neointimal proliferation after coronary angioplasty by low–molecular–weight heparin (clivarine) and polyethyleneglycol–hirudin. Buchwald AB, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):481–7

CVS–1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. Rebello SS, et al. **J Cardiovasc Pharmacol** 1997 Feb;29(2):240–9

Inhibition by hirulog–1 of generation of plasminogen activator inhibitor–1 from vascular smooth–muscle cells induced by thrombin. Ren S, et al. **J Cardiovasc Pharmacol** 1997 Mar;29(3):337–42

Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis. Pratico D, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1178–85

Local delivery of antithrombotic drug prevents restenosis after balloon angioplasty in atherosclerotic rabbit artery. Tomaru T, et al. **Jpn Circ J** 1996 Dec;60(12):981–92

Effects of thiofedrine on platelet aggregation, thromboxane B2 and 6–keto–PGF1 alpha in rats. Qu YZ, et al. **Methods Find Exp Clin Pharmacol** 1996 Jun;18(5):297–300

Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery. Mittra RA, et al. **Ophthalmology** 1997 Mar;104(3):558–61

Comparison of the structures of the cyclotheonamide A complexes of human alpha–thrombin and bovine beta–trypsin. Ganesh V, et al. **Protein Sci** 1996 May; 5(5):825–35

Effect of 13–hydroperoxyoctadecadienoic acid on the glucosamine synthetase activity in rabbit gastric mucosa. Fujita T, et al. **Res Commun Mol Pathol Pharmacol** 1997 May;96(2):209–18

ANTITHROMBINS

Comparison of the anticoagulant activities of thrombin inhibitors as assessed by thromboelastographic analysis. Callas D, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:76–9

Hirudins: from leeches to man. Wallis RB. **Semin Thromb Hemost** 1996;22(2):185–96 (95 ref.)

Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot–associated thrombin. Lunven C, et al. **Thromb Haemost** 1996 Jan;75(1):154–60

The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Prasa D, et al. **Thromb Haemost** 1997 Mar; 77(3):498–503

Comparative studies on the antithrombin potency of various thrombin inhibitors, as determined by using an amidolytic method. Callas DD, et al. **Thromb Res** 1996 Jul 1; 83(1):97–102

Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. Callas DD, et al. **Thromb Res** 1996 Sep 15;83(6):463–8

Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model. Hayes JM, et al. **Thromb Res** 1996 Apr 15;82(2):187–91

In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. Teger-Nilsson AC, et al. **Thromb Res** 1997 Jan 15;85(2):133–45

PHYSIOLOGY

Biochemistry and biology of hirudin. Toschi V, et al. **Coron Artery Dis** 1996 Jun;7(6):420–8 (95 ref.)

THERAPEUTIC USE

The role of the leech in medical therapeutics. Eldor A, et al. **Blood Rev** 1996 Dec;10(4):201–9 (108 ref.)

Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugs. Hoppensteadt DA, et al. **Clin Chem** 1997 Sep;43(9):1786–8

Clinical trials of Hirulog in patients undergoing high-risk percutaneous transluminal coronary angioplasty. Bittl JA. **Coron Artery Dis** 1996 Jun;7(6):449–54 (64 ref.)

Direct thrombin inhibitors in cardiovascular disease. Catella-Lawson F. **Coron Artery Dis** 1997 Feb;8(2):105–11 (34 ref.)

Clinical trials of recombinant hirudin in acute coronary syndromes. Challapalli R, et al. **Coron Artery Dis** 1996 Jun; 7(6):429–37 (49 ref.)

Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Fitzgerald D, et al. **Coron Artery Dis** 1996 Jun;7(6):455–8 (33 ref.)

Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model. Kornowski R, et al. **Coron Artery Dis** 1996 Dec;7(12):903–9

Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Maraganore JM, et al. **Coron Artery Dis** 1996 Jun;7(6):438–48 (38 ref.)

Biological rationale for the therapeutic role of specific antithrombins. Weitz JI. **Coron Artery Dis** 1996 Jun; 7(6):409–19 (56 ref.)

Antiplatelet and antithrombin therapies in the acute coronary syndromes. Alexander JH, et al. **Curr Opin Cardiol** 1997 Jul;12(4):427–37 (44 ref.)

Clinical management of unstable angina: the place of antithrombins and platelet GP IIb/IIIa receptor blockers. Knudtson ML. **Eur Heart J** 1995 Nov;16 Suppl L:68–74 (105 ref.)

T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemostasis in rats. Ohtani A, et al. **Eur J Pharmacol** 1997 Jul 9; 330(2–3):151–6

Medicinal leeches: ancient therapy is a source of biotech drugs. Piascik P. **J Am Pharm Assoc (Wash)** 1997 May–Jun; NS37(3):285–6 (0 ref.)

Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. Schumacher WA, et al. **J Cardiovasc Pharmacol** 1996 Jul; 28(1):19–25

Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins. Zhang B, et al. **Microsurgery** 1996;17(2):89–96

Fifty years of experience with antithrombotic therapy in cardiac disease. A 1996 approach based on pathogenesis and risk. Freudenrerger RS, et al. **Mt Sinai J Med** 1996 Oct–Nov;63(5–6):342–58 (69 ref.)

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Lewis BE, et al. **Semin Thromb Hemost** 1997;23(2):197–202 (35 ref.)

Clinical trials of direct thrombin inhibitors during invasive procedures. Hermann JP, et al. **Thromb Haemost** 1997 Jul; 78(1):367–76 (85 ref.)

A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs. Schneider J, et al. **Thromb Haemost** 1997 Mar;77(3):535–9

Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance. Verstraete M. **Thromb Haemost** 1997 Jul;78(1):357–63 (34 ref.)

Clinical trials of direct thrombin inhibitors in acute ischaemic syndromes. White HD. **Thromb Haemost** 1997 Jul; 78(1):364–6 (17 ref.)

[Hirudin: the relative failure of a very promising molecule] Aiach M. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1485–90 (Eng. Abstr.) **(Fre)**

[Search for the "optimal" dose of antithrombotic agents] Mismetti P, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11 Suppl):1473–7 (Eng. Abstr.) **(Fre)**

[Direct thrombin inhibitors] Bornkessel B. **Med Monatsschr Pharm** 1997 Apr;20(4):86–9 (3 ref.) **(Ger)**

[A case of Fournier's gangrene with healing accelerated by argatroban] Soda T, et al. **Hinyokika Kiyo** 1996 Dec; 42(12):981–2 (Eng. Abstr.) **(Jpn)**

[Argatroban, a selective thrombin inhibitor, for anticoagulant therapy during and following vascular surgery] Fuji H, et al. **Masui** 1996 Oct;45(10):1289–92 (Eng. Abstr.) **(Jpn)**

ANTITHROMBOTIC AGENTS see **FIBRINOLYTIC AGENTS**

ANTITHYROID AGENTS

Longitudinal study on goiter prevalence and goitrogen factors in northeastern Sicily. Regalbuto C, et al. **J Endocrinol Invest** 1996 Oct;19(9):638–45

Behavioral and autonomic thermoregulation in the rat following propylthiouracil-induced hypothyroidism. Gordon CJ. **Pharmacol Biochem Behav** 1997 Sep; 58(1):231–6

ADMINISTRATION & DOSAGE

Antithyroid drug treatment. Lazarus JH. **Clin Endocrinol (Oxf)** 1996 Nov;45(5):517–8

A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism [published erratum appears in Clin Endocrinol (Oxf) 1997 Feb;46(2):240] Page SR, et al. **Clin Endocrinol (Oxf)** 1996 Nov;45(5):511–6

Evans' syndrome associated with Graves' disease. Yashiro M, et al. **Intern Med** 1996 Dec;35(12):987–90 (13 ref.)

In-vivo evaluation in man of a hydrophilic matrix containing propylthiouracil. Kabanda L, et al. **J Pharm Pharmacol** 1996 Oct;48(10):1023–6

Decreased growth rate and tumour formation of human anaplastic thyroid carcinoma cells transfected with a human thyrotropin receptor cDNA in NMRI nude mice treated with propylthiouracil. Gustavsson B, et al. **Mol Cell Endocrinol** 1996 Aug 9;121(2):143–51

Comparison of ultrastructural changes in thyrotrophs of the rat pituitary between intermittent and continuous treatments with sulfadimethoxine. Shimo T, et al. **Toxicol Pathol** 1997 Mar–Apr;25(2):177–85

[Effect of methimazole and dexamethasone on leucocyte glucocorticoid receptor, plasma ACTH, and cortisol levels in Graves' disease] Gao Y, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1996 Mar;27(1):75–8 (Eng. Abstr.) **(Chi)**

[Basedow disease hyperthyroidism—is there a therapeutic standard? Conservative therapy] Schumm-Draeger PM. **Zentralbl Chir** 1997;122(4):224–6 (7 ref.) (Eng. Abstr.) **(Ger)**

[Preparation and "in vitro" and "in vivo" evaluation of a transdermal formulation containing methimazole] Monti D, et al. **Boll Chim Farm** 1996 Feb;135(2):139–41 **(Ita)**

ADVERSE EFFECTS

Treatment of drug-induced bone marrow suppression with recombinant human granulocyte/monocyte colony stimulating factor. Somogyi A, et al. **Adverse Drug React Toxicol Rev** 1996 Jun;15(2):119–24

Methimazole-induced aplastic anemia? [letter] Bishara J, et al. **Ann Pharmacother** 1996 Jun;30(6):684

Propylthiouracil-induced hepatic damage. Ozenírler S, et al. **Ann Pharmacother** 1996 Sep;30(9):960–3

Elevation of serum creatine kinase during treatment with antithyroid drugs in patients with hyperthyroidism due to Graves disease. A novel side effect of antithyroid drugs. Suzuki S, et al. **Arch Intern Med** 1997 Mar 24;157(6):693–6

Propylthiouracil-induced rapidly progressive glomerulonephritis associated with antineutrophil cytoplasmic autoantibodies. Kudoh Y, et al. **Clin Nephrol** 1997 Jul;48(1):41–3

Severe pancytopenia associated with antithyroid drugs in a patient with Graves' disease and chronic renal failure [letter]. Macia M, et al. **Clin Nephrol** 1997 Feb;47(2):129

Severe pancitopenia associated with antithyroid drugs in a patient with Graves' disease and chronic renal failure [letter] Macia M, et al. **Clin Nephrol** 1997 Jan;47(1):69–70

Adverse effects of thyroid hormone preparations and antithyroid drugs. Bartalena L, et al. **Drug Saf** 1996 Jul; 15(1):53–63 (98 ref.)

Propylthiouracil-induced alveolar haemorrhage associated with antineutrophil cytoplasmic antibody. Ohtsuka M, et al. **Eur Respir J** 1997 Jun;10(6):1405–7

Propylthiouracil-induced cutaneous vasculitis. Yarman S, et al. **Int J Clin Pharmacol Ther** 1997 Jul;35(7):282–6

Cryofibrinogenemia with polyarthralgia, Raynaud's phenomenon and acral ulcer in a patient with Graves' disease treated with methimazole. Hosoi K, et al. **Intern Med** 1997 Jun;36(6):439–42

Propylthiouracil-induced diffuse proliferative lupus nephritis: review of immunological complications. Prasad GV, et al. **J Am Soc Nephrol** 1997 Jul;8(7):1205–10 (18 ref.)

Liver tests in hyperthyroidism: effect of antithyroid therapy. Gürlek A, et al. **J Clin Gastroenterol** 1997 Apr;24(3):180–3

Severe hepatotoxicity on beginning propylthiouracil therapy. Lock DR, et al. **J Clin Gastroenterol** 1997 Jun;24(4):267–9

Methimazole-induced cholestatic liver injury, mimicking sclerosing cholangitis. Schwab GP, et al. **Langenbecks Arch Chir** 1996;381(4):225–7

Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis associated with thiamazole therapy [letter] Hori Y, et al. **Nephron** 1996;74(4):734–5

Antineutrophil cytoplasmic antibodies (ANCA)-associated crescentic glomerulonephritis and propylthiouracil therapy. Yuasa S, et al. **Nephron** 1996;73(4):701–3

Thyrotoxicosis and antithyroid drugs. Monakier D, et al. **Postgrad Med J** 1997 Jun;73(860):335–6

Methimazole-induced severe aplastic anemia: unsuccessful treatment with recombinant human granulocyte-monocyte colony-stimulating factor. Escobar-Morreale HF, et al. **Thyroid** 1997 Feb;7(1):67–70

Successful treatment of a patient with Graves' disease on hemodialysis complicated by antithyroid drug-induced granulocytopenia and angina pectoris. Miyasaka Y, et al. **Thyroid** 1997 Aug;7(4):621–4

Usefulness of granulocyte count measurement four hours after injection of granulocyte colony-stimulating factor for detecting recovery from antithyroid drug-induced granulocytopenia. Tajiri J, et al. **Thyroid** 1997 Aug; 7(4):575–8

Propylthiouracil-induced hepatotoxicity. Hardee JT, et al. **West J Med** 1996 Sep;165(3):144–7

[Sialadenitis caused by carbimazole (letter)] Gaudouen Y, et al. **Ann Med Interne (Paris)** 1996;147(6):462–4 **(Fre)**

[A case of Grave's disease with MPO-ANCA-associated glomerulonephritis during propylthiouracil (PTU) therapy following interstitial pneumonitis] Saeki T, et al. **Nippon Jinzo Gakkai Shi** 1997 Mar;39(2):167–71 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Severe aplastic anemia as a complication of treatment with metizol] Swider G, et al. **Wiad Lek** 1996;49(7–12):136–9 (Eng. Abstr.) **(Pol)**

ANALYSIS

Potentiometric and coulometric titration of 6-propyl-2-thiouracil. Ciesielski W, et al. **Analyst** 1997 May;122(5):491–4

CHEMISTRY

Spectroscopic analysis of charge transfer complex formation and peroxidase inhibition with tricyclic antidepressant drugs: potential anti-thyroid action. Rousseau A, et al. **Biol Pharm Bull** 1996 May;19(5):726–8

PHARMACOKINETICS

Methimazole and propylthiouracil equally cross the perfused human term placental lobule. Mortimer RH, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3099–102

PHARMACOLOGY

Anti-thyroid drugs decrease mucosal damage in a rat model of experimental colitis. Oren R, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):341–5

Effects of transient prepubertal 6-N-propyl-2-thiouracil treatment on testis development and function in the domestic fowl. Kirby JD, et al. **Biol Reprod** 1996 Oct; 55(4):910–6

Myelin basic protein immunoreactivity in the internal capsule of neonates from rats on a low iodine intake or on methylmercaptoimidazole (MMI). Martinez-Galan JR, et al. **Brain Res Dev Brain Res** 1997 Jul 18;101(1–2):249–56

Methimazole slows hepatocyte streaming in rats. Oren R, et al. **Dig Dis Sci** 1997 Jul;42(7):1433–7

Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Guo Z, et al. **Drug Metab Dispos** 1997 Mar;25(3):390–3

Blockade of the estrogen induced increase in progesterone receptor caused by propylthiouracil, an anti-thyroid drug, in a transplantable pituitary tumor in rats. Fujimoto N, et al. **Endocr J** 1996 Jun;43(3):329–34

Effect of rearing temperature on perirenal adipose tissue development and thermoregulation following methimazole treatment of postnatal lambs. Symonds ME, et al. **Exp Physiol** 1996 Nov;81(6):995–1006

The effect of methimazole on the growth of the developing brushtail possum, Trichosurus vulpecula. Buaboocha W, et al. **Growth Dev Aging** 1996 Autumn-Winter; 60(3–4):163–9

Dietary goitrogen-induced changes in the transport of 2-deoxy-D-glucose and amino acids across the rat blood-brain barrier. Bala TS, et al. **Int J Dev Neurosci** 1996 Aug;14(5):575–83

Identification and characterization of novel genes modulated in the thyroid of dogs treated with methimazole and propylthiouracil. Wilkin F, et al. **J Biol Chem** 1996 Nov 8;271(45):28451–7

Inhibition of thyroid hormone uptake by calcium antagonists of the dihydropyridine class. Scholz GH, et al. **J Med Chem** 1997 May 9;40(10):1530–8

Inhibitory effects of (+/-)-tetrahydropalmatine on thyrotropin-stimulating hormone concentration in hyperthyroid rats. Hsieh MT, et al. **J Pharm Pharmacol** 1996 Sep;48(9):959–61

Propylthiouracil treatment reduces long-term potentiation in area CA1 of neonatal rat hippocampus. Niemi WD, et al. **Neurosci Lett** 1996 May 31;210(2):127–9

Effects of consecutive thiouracil exposures in the juvenile and adult single comb White Leghorn chicken on body weight and reproductive performance. Peebles ED, et al. **Poult Sci** 1997 Feb;76(2):236–43

[The effect of mercazolyl on the activity of the main hemostatic blood systems under the action of immobilization stress] Lunina NV, et al. **Lik Sprava** 1995 Sep-Dec;(9–12):160–3 (Eng. Abstr.) **(Ukr)**

THERAPEUTIC USE

Experience with carbimazole in the treatment of the hyperthyroidism of Graves' disease in Nigerian patients. Modebe O. **Afr J Med Med Sci** 1995 Dec;24(4):347–51

Lithium treatment in amiodarone-induced thyrotoxicosis. Dickstein G, et al. **Am J Med** 1997 May;102(5):454–8

Graves disease associated with autoimmune thrombocytopenic purpura. Hofbauer LC, et al. **Arch Intern Med** 1997 May 12;157(9):1033–6

Outcome of Graves' thyrotoxicosis after antithyroid drug treatment. Chiou SC, et al. **Chang Keng I Hsueh** 1995 Dec; 18(4):305–14

Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis. Nagasaka S, et al. **Clin Endocrinol (Oxf)** 1997 Aug; 47(2):215–21

Hyperthyroidism. Hashizume K, et al. **Curr Ther Endocrinol Metab** 1997;6:71–6 (4 ref.)

Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators. Prakash R. **Eur J Nucl Med** 1996 Feb;23(2):118–22

Propranolol as an adjunct therapy for hyperthyroid tremor. Henderson JM, et al. **Eur Neurol** 1997;37(3):182–5

Effects of propylthiouracil on intestinal transit time and symptoms in hyperthyroid patients. Papa A, et al. **Hepatogastroenterology** 1997 Mar-Apr;44(14):426–9

Dyspnoea, lung function & respiratory muscle pressures in patients with Graves' disease. Guleria R, et al. **Indian J Med Res** 1996 Nov;104:299–303

Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine—a prospective, randomized study. Thyroid Study Group. Törring O, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2986–93

Serial analysis of the effects of methimazole therapy on circulating B cell subsets in Graves' disease. Corrales JJ, et al. **J Endocrinol** 1996 Nov;151(2):231–40

Sodium ipodate (oragrafin) in the preoperative preparation of Graves' hyperthyroidism. Tomaski SM, et al. **Laryngoscope** 1997 Aug;107(8):1066–70

Changes in liver biochemical tests at diagnosis and after propylthiouracil therapy for hyperthyroidism. Gürlek A, et al. **Mater Med Pol** 1996 Jul-Sep;28(3):103–6

Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease. Kawakami-Tani T, et al. **Metabolism** 1997 Oct;46(10):1184–8

Treatment of thyroid disease in pregnancy. Ecker JL, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):575–89 (40 ref.)

A protocol for thyrotoxicosis. Press M. **Practitioner** 1997 May;241(1574):272–4, 276, 278

Controversies related to the medical and surgical management of hyperthyroidism in children. Waldhausen JH. **Semin Pediatr Surg** 1997 Aug;6(3):121–7 (37 ref.)

Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Vitti P, et al. **Thyroid** 1997 Jun;7(3):369–75

[Treatment of amiodarone-induced hyperthyroidism by carbimazole with maintenance of amiodarone] Talard P, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89(10):1301–3 (Eng. Abstr.) **(Fre)**

[Space occupying lesion in the anterior mediastinum in a patient with Basedow disease and previously diagnosed osteosarcoma] Lohwasser S, et al. **Dtsch Med Wochenschr** 1997 Sep 5;122(36):1070–4 (Eng. Abstr.) **(Ger)**

[Effect of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy] Moka D, et al. **Nuklearmedizin** 1997 Apr;36(3):87–92 (Eng. Abstr.) **(Ger)**

[Pre-surgical medical therapy of hyperthyroidism] Cesareo R, et al. **Recenti Prog Med** 1997 Jun;88(6):277–80 (20 ref.) (Eng. Abstr.) **(Ita)**

TOXICITY

Pituitary GH and prolactin deficiency and testis enlargement in hypothyroid rats caused by goitrogen methimazole. Kimura T, et al. **Exp Anim** 1996 Oct;45(4):369–75

Prevalence of endometriosis in rhesus (Macaca mulatta) monkeys ingesting PCB (Aroclor 1254): review and evaluation. Arnold DL, et al. **Fundam Appl Toxicol** 1996 May;31(1):42–55 (108 ref.)

Persistent alterations in regional brain glial fibrillary acidic protein and synaptophysin levels following pre- and postnatal polychlorinated biphenyl exposure. Morse DC, et al. **Toxicol Appl Pharmacol** 1996 Aug;139(2):252–61

[Modifying effects of goitrogens on the tumor development in the liver and lung of rats] Takegawa K, et al. **Eisei Shikenjo Hokoku** 1996;(114):33–7 (Eng. Abstr.) **(Jpn)**

URINE

Application of capillary zone electrophoresis for analysis of thyreostatics. Křivánková L, et al. **Electrophoresis** 1996 Dec;17(12):1959–63

Rapid and high-performance analysis of thyreostatic drug residues in urine using gas chromatography-mass spectrometry. Batjoens P, et al. **J Chromatogr A** 1996 Oct 25;750(1–2):127–32

ANTITOXINS

ADMINISTRATION & DOSAGE

[Brain lesions in rabbits given an intravenous injection of verotoxin 2 and protection by anti-VT2 antibody] Fujii J, et al. **Nippon Rinsho** 1997 Mar;55(3):736–40 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Hibbs RG, et al. **Clin Infect Dis** 1996 Aug;23(2):337–40

ANALYSIS

Mass spectrometric investigations on proteinaceous toxins and antibodies. Krishnamurthy T, et al. **Adv Exp Med Biol** 1996;391:439–63 (53 ref.)

BIOSYNTHESIS

Antibodies to maitotoxin elicited by immunization with toxin-fragment conjugates. Bignami GS, et al. **Toxicon** 1996 Nov-Dec;34(11–12):1393–7

CHEMISTRY

A conserved sequence region of scorpion toxins rendered immunogenic induces broadly cross-reactive, neutralizing antibodies. Devaux C, et al. **Eur J Biochem** 1996 Dec 15; 242(3):727–35

IMMUNOLOGY

Comparative studies of antisera against different toxins. Nascimento N, et al. **Adv Exp Med Biol** 1996;391:509–14

Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855–1296 with antitoxin antibodies from three host species. Atassi MZ, et al. **J Protein Chem** 1996 Oct;15(7):691–700

Immunoreactivity of a new generation of horse F(ab')2 preparations against European viper venoms and the tetanus toxin. Pépin-Covatta S, et al. **Toxicon** 1997 Mar; 35(3):411–22

PHARMACOLOGY

Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Kelly CP, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):373–9

Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Kelly CP, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):236–41

THERAPEUTIC USE

[Changes of circulating Lps and cytokines in burned patients after anti-endotoxin therapy] Fu W, et al. **Chung Hua I Hsueh Tsa Chih** 1996 May;76(5):355–8 (Eng. Abstr.) **(Chi)**

ANTITREPONEMAL AGENTS

HISTORY

The introduction of "606" in New Jersey. Wallhauser HT. **N J Med** 1997 Jul;94(7):43–6

[History of healing; early reception of the anti-syphilitic agent Salvarsan in The Netherlands (1910–1911)] Verhoef P. **Ned Tijdschr Geneeskd** 1996 Dec 14;140(50):2519–23 **(Dut)**

[First results of treatment with salvarsan in Krakow] Maciejasz B. **Przegl Lek** 1996;53(10):763–4 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

What's in a (compound) name? [letter; comment] Feuer AL. **N C Med J** 1997 Jan-Feb;58(1):7. Comment on: N C Med J 1996 Nov-Dec;57(6):342.

ANTITRICHOMONAL AGENTS

ADMINISTRATION & DOSAGE

Crystal dissolution-controlled release systems. II. Metronidazole release from semicrystalline poly(vinyl alcohol) systems. Mallapragada SK, et al. **J Biomed Mater Res** 1997 Jul;36(1):125–30

The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study. Spence MR, et al. **Obstet Gynecol** 1997 May;89(5 Pt 1):699–703

Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. duBouchet L, et al. **Sex Transm Dis** 1997 Mar;24(3):156–60

ADVERSE EFFECTS

Sudden death due to metronidazole/ethanol interaction. Cina SJ, et al. **Am J Forensic Med Pathol** 1996 Dec;17(4):343–6

Immediate rhinoconjunctivitis induced by metamizole and metronidazole. Añíbarro B, et al. **Ann Allergy Asthma Immunol** 1997 Apr;78(4):345–6

Metronidazole hypersensitivity in a patient with bacterial vaginosis. Bhaduri S, et al. **Int J STD AIDS** 1997 Jan; 8(1):57–8

ANALYSIS

High performance thin layer chromatographic analysis of hydrolyzed tinidazole solutions. I. Development and validation method. Salo JP, et al. **J Pharm Biomed Anal** 1996 Jun;14(8–10):1261–6

High performance thin layer chromatographic analysis of hydrolyzed tinidazole solutions. II. Hydrolysis kinetics of tinidazole. Salo JP, et al. **J Pharm Biomed Anal** 1996 Jun; 14(8–10):1267–70

A liquid chromatography assay for the study of serum and gastric juice metronidazole concentrations in the treatment of Helicobacter pylori. Pollak PT. **Ther Drug Monit** 1996 Dec;18(6):678–87

BLOOD

Direct assay of tinidazole in human serum by micellar liquid chromatography. Habel D, et al. **Biomed Chromatogr** 1997 Jan-Feb;11(1):16–8

CHEMISTRY

Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Allen LV Jr, et al. **Am J Health Syst Pharm** 1996 Sep 1;53(17):2073–8

Stability of ceftriaxone sodium and metronidazole hydrochloride. Bailey LC, et al. **Am J Health Syst Pharm** 1997 Feb 15;54(4):424–7

PHARMACOKINETICS

Accidental metronidazole overdose in a preterm newborn [letter] Lentelink MB, et al. **Clin Pharmacokinet** 1997 Jun; 32(6):496–7

Short-term sucralfate administration does not alter the absorption of metronidazole in healthy male volunteers. Moraes ME, et al. **Int J Clin Pharmacol Ther** 1996 Oct; 34(10):433–7

Crystal dissolution-controlled release systems. II. Metronidazole release from semicrystalline poly(vinyl alcohol) systems. Mallapragada SK, et al. **J Biomed Mater Res** 1997 Jul;36(1):125–30

Disposition of metronidazole in hens (Gallus gallus) and quails (Coturnix coturnix japonica): pharmacokinetics and whole-body autoradiography. Cybulski W, et al. **J Vet Pharmacol Ther** 1996 Oct;19(5):352–8

PHARMACOLOGY

Effects of nifedipine, metronidazole, and nitric oxide donors on spore germination and cell culture infection of the microsporidia Encephalitozoon hellem and Encephalitozoon intestinalis. He Q, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):179–85

In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Narcisi EM, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1121–5

Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers. Pitkin DH, et al. **Clin Infect Dis** 1997 Feb;24 Suppl 2:S238–48

Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Hachem CY, et al. **Diagn Microbiol Infect Dis** 1996 Jan; 24(1):37–41

Activity of amoxicillin, metronidazole, bismuth salicylate and six aminoglycosides against Helicobacter pylori. Brenciaglia MI, et al. **J Chemother** 1996 Feb;8(1):52–4

Breath hydrogen excretion by healthy cats after oral administration of oxytetracycline and metronidazole. Muir P, et al. **Vet Rec** 1996 Jun 29;138(26):635–9

POISONING

Accidental metronidazole overdose in a preterm newborn [letter] Lentelink MB, et al. **Clin Pharmacokinet** 1997 Jun; 32(6):496–7

ANTITRICHOMONAL AGENTS

THERAPEUTIC USE

Efficacy of antimicrobial treatment in non-dysenteric persistent diarrhoea in a community setting. Bahl R, et al. **Acta Paediatr** 1996 Nov;85(11):1290-4

Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). Yousfi MM, et al. **Aliment Pharmacol Ther** 1996 Feb;10(1):119-22

Bacterial vaginosis. Priestley CJ, et al. **Br J Clin Pract** 1996 Sep;50(6):331-4 (26 ref.)

Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. Avsar E, et al. **Eur J Gastroenterol Hepatol** 1996 May;8(5):449-52

Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. **Gut** 1997 Jul;41(1):8-13 (50 ref.)

Additive effect of diloxanide furoate and metronidazole (Entamizole) in experimental mouse caecal amoebiasis. Bhopale KK, et al. **Indian J Exp Biol** 1995 Jan;33(1):73-4

Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. Kempf P, et al. **Infection** 1996 Nov-Dec;24(6):473-9

Arsenical pessaries in the treatment of metronidazole-resistant Trichomonas vaginalis [letter] Walker PP, et al. **Int J STD AIDS** 1997 Jul;8(7):473

Efficacy of a combined diloxanide furoate-metronidazole preparation in the treatment of amoebiasis and giardiasis. Qureshi H, et al. **J Int Med Res** 1997 May-Jun;25(3):167-70

Concentrations of tinidazole in gingival crevicular fluid and plasma in dogs after multiple dose administration. Sarkiala-Kessel EM, et al. **J Vet Pharmacol Ther** 1996 Jun; 19(3):171-5

Alternative treatment protocols in giardiasis: a pilot study. Bulut BU, et al. **Scand J Infect Dis** 1996;28(5):493-5

First case of Lagochilascaris minor infection in Bolivia. Ollé-Goig JE, et al. **Trop Med Int Health** 1996 Dec; 1(6):851-3

Effect of four therapeutic agents on Trichomonas phasiani carriage in pheasants [see comments] Pennycott TW. **Vet Rec** 1996 Aug 31;139(9):214-5. Comment in: Vet Rec 1996 Oct 19;139(16):399.

[Metronidazole (Flagyl)] Simon F, et al. **Med Trop (Mars)** 1997;57(2):136 **(Fre)**

[The treatment of children with Helicobarter pylory by triple therapy can be shortened without the risk of losing it eradicating efficacy. Letter] Cilleruelo ML, et al. **An Esp Pediatr** 1996 Nov;45(5):550 **(Spa)**

TOXICITY

An improved method for in vitro susceptibility testing of Trichomonas vaginalis. Bromke BJ, et al. **Adv Exp Med Biol** 1995;390:211-6

Genotoxic effects of metronidazole. Elizondo G, et al. **Mutat Res** 1996 Sep 13;370(2):75-80

ANTITRUST LAWS

Reducing the number of radiology residents: antitrust and action by the Accreditation Council for Graduate Medical Education. Smith JJ, et al. **Acad Radiol** 1996 Sep;3(9):766-9

The fraud and abuse statute in an evolving health care marketplace: life in the health care speakeasy. Blumstein JF. **Am J Law Med** 1996;22(2-3):205-31 (0 ref.)

Night landings on an aircraft carrier: hospital mergers and antitrust law. Greaney TL. **Am J Law Med** 1997; 23(2-3):191-220

Antitrust. American Board of Emergency Physicians. **Ann Emerg Med** 1996 Dec;28(6):740

Physician-run health plans and antitrust [letter; comment] Duvall CP. **Ann Intern Med** 1997 Feb 1;126(3):252-3. Comment on: Ann Intern Med 1996 Jul 1;125(1):59-65.

How much should physicians worry about antitrust? Murphy LS. **Del Med J** 1997 Jun;69(6):305-9

Tacit collusion among hospitals in price competitive markets. Mobley LR. **Health Econ** 1996 May-Jun;5(3):183-93 (43 ref.)

Guiding light. Will the Justice Department's new antitrust guidelines really make a difference to physicians? [news] Hudson T. **Hosp Health Netw** 1996 Oct 5;70(19):24, 26

Physicians. Look for the union label. Meyer H. **Hosp Health Netw** 1996 Dec 5;70(23):69-70

Peer review and antitrust. Sfikas PM. **J Am Dent Assoc** 1997 Apr;128(4):496-8

Important changes in antitrust enforcement policy for physician networks [news] **J Ark Med Soc** 1996 Nov; 93(6):272-5

Health care and the federal antitrust laws: the likelihood of a harmonious coexistence. Remis RE. **J Contemp Health Law Policy** 1996 Fall;13(1):113-35

1995 Le Tourneau Award. An antitrust analysis of physician specialty networks under changing market conditions. Woodhall AL. **J Leg Med** 1996 Sep;17(3):383-425

New antitrust rules ease restrictions on physician networks. Cook DA. **J Med Assoc Ga** 1996 Nov;85(4):257-9

We will prevail [editorial] England LE. **J Miss State Med Assoc** 1996 Dec;37(12):911

Antitrust evaluation of physician networks [news] Rosen BF, et al. **Md Med J** 1996 Aug;45(8):611-3

Government loosens anti-trust laws. Weber RD. **Mich Med** 1997 Feb;96(2):8, 45

Peer review: federal and state protection. Kennedy KE. **Minn Med** 1996 Mar;79(3):52-4

Making sense of antitrust policy: its application to physician directed networks. Bennett T, et al. **Mo Med** 1997 Apr; 94(4):180-4

Physician-operated networks and the new antitrust guidelines [see comments] Kuttner R. **N Engl J Med** 1997 Jan 30; 336(5):386-91. Comment in: N Engl J Med 1997 Jul 3;337(1):55; discussion 56.

Physician-operated networks and antitrust regulations [letter; comment] Lance MP, et al. **N Engl J Med** 1997 Jul 3; 337(1):55; discussion 56. Comment on: N Engl J Med 1997 Jan 30;336(5):386-91.

Pandering to the enemy [letter] Gittleman VA. **N Y State Dent J** 1996 Oct;62(8):17-8

Progress in the new health care environment: be aggressive, not timid [editorial] D'Ambrosia R. **Orthopedics** 1997 Jan; 20(1):13

Revised antitrust guidelines: good news for physicians. Miles J. **Pa Med** 1996 Oct;99(10):22-5

Department of Justice and FTC redefine antitrust rules. Sewell T. **Tenn Med** 1996 Dec;89(12):442-4

Loosening up antitrust. Jones TL. **Tex Med** 1996 Dec; 92(12):36-7; quiz 37-9

ECONOMICS

Who carries the risk? Networks, antitrust, and carve-outs. Mason C. **Acad Radiol** 1996 Apr;3 Suppl 1:S150-3

ANTITRUST LIABILITY see **ANTITRUST LAWS**

ANTITUBERCULAR AGENTS

see related

TUBERCULOSIS, MULTIDRUG-RESISTANT

New antimycobacterial agents. Yew WW, et al. **Monaldi Arch Chest Dis** 1996 Oct;51(5):394-404 (143 ref.)

Tuberculosis control programme guidelines--treatment regimens [letter; comment] Durrheim DN, et al. **S Afr Med J** 1996 Oct;86(10):1293-4. Comment on: S Afr Med J 1996 May;86(5):560, 562.

ADMINISTRATION & DOSAGE

Multiple intracranial tuberculomas with atypical response to tuberculostatic chemotherapy. Review of the literature and own experience. Hejazi N, et al. **Acta Neurochir (Wien)** 1997;139(3):194-202 (29 ref.)

Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Moore RD, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):1013-9

The ultimate decision analysis: the confirmation of reality through theory [editorial; comment] Sbarbaro JA. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):835-6. Comment on: Am J Respir Crit Care Med 1996 Oct;154(4 Pt 1):1013-9.

Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Deol P, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1211-4

A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Burman WJ, et al. **Chest** 1997 Jul;112(1):63-70

Short-course chemoprophylaxis for tuberculosis. Bishai WR, et al. **Clin Chest Med** 1997 Mar;18(1):115-22 (56 ref.)

Using therapeutic drug monitoring to dose the antimycobacterial drugs. Peloquin CA. **Clin Chest Med** 1997 Mar;18(1):79-87 (26 ref.)

Therapeutic drug monitoring of the antimycobacterial drugs. Peloquin CA. **Clin Lab Med** 1996 Sep;16(3):717-29 (20 ref.)

Effect of polymer foam morphology and density on kinetics of in vitro controlled release of isoniazid from compressed foam matrices. Hsu YY, et al. **J Biomed Mater Res** 1997 Apr;35(1):107-16

Mechanisms of isoniazid release from poly(d,l-lactide-co-glycolide) matrices prepared by dry-mixing and low density polymeric foam methods. Hsu YY, et al. **J Pharm Sci** 1996 Jul;85(7):706-13

'Kits' of anti-tubercular drugs [letter] Aggarwal ID. **Natl Med J India** 1996 Nov-Dec;9(6):300

Directly observed therapy improves tuberculosis care. Ruben FL, et al. **Pa Med** 1996 Apr;99(4):26-7

A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation. **S Afr Med J** 1996 Aug; 86(8):960-5

Directly observed therapy (DOT) for tuberculosis in South Africa--a reality? [editorial; comment] Weyer K. **S Afr Med J** 1997 Aug;87(8 Suppl):1039-40. Comment on: S Afr Med J 1997 Aug;87(8 Suppl):1042-7.

Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance. Caminero JA, et al. **Thorax** 1996 Nov;51(11):1130-3

Administration of anti-tuberculosis drugs through patient empowerment. Banerjee A, et al. **Trop Doct** 1997 Oct; 27(4):240

Relapse after short-course chemotherapy of patients with sputum smear-positive pulmonary tuberculosis under routine conditions with additional information on side effects and contact tracing. Martinez FD, et al. **Tuber Lung Dis** 1996 Oct;77(5):425-8

Time to initiation of anti-tuberculosis treatment [see comments] Pirkis JE, et al. **Tuber Lung Dis** 1996 Oct; 77(5):401-6. Comment in: Tuber Lung Dis 1996 Oct;77(5):389-90.

A flawed strategy for controlling tuberculosis? [letter] Pool HM. **Tuber Lung Dis** 1996 Oct;77(5):483

[The treatment of pulmonary tuberculosis: shorter and with more potency] Broekmans JF, et al. **Ned Tijdschr Geneeskd** 1996 Nov 2;140(44):2160-3 **(Dut)**

[Shortening of therapy duration in patients with pulmonary tuberculosis from 9 to 6 months only justifiable on the basis of published data] van Loenhout-Rooyackers JH, et al. **Ned Tijdschr Geneeskd** 1996 Nov 2;140(44):2181-7 (36 ref.) (Eng. Abstr.) **(Dut)**

[Shorter treatment of pulmonary tuberculosis is only acceptable with at least 4 drugs in the initial combination of tuberculostatic agents] Veen J. **Ned Tijdschr Geneeskd** 1996 Nov 2;140(44):2164-7 (25 ref.) **(Dut)**

[Oral desensitization to antitubercular agents] Drira I, et al. **Rev Pneumol Clin** 1997;53(2):104-6 (Eng. Abstr.) **(Fre)**

[Infectiology of the urogenital tract. 7: Therapy of urogenital tuberculosis--side-effects--drugs--interactions--dose adjustment in decreased kidney function] Brühl P. **Fortschr Med** 1997 Jun 30;115(18):44-6 **(Ger)**

[Infectiology of the urogenital tract. 6: Therapy of urogenital tuberculosis] Brühl P. **Fortschr Med** 1997 Jun 20; 115(17):43-5 **(Ger)**

[Tuberculosis therapy in canton Zurich 1991-1993: what are the causes for recurrence and therapy failure?] Rose N, et al. **Schweiz Med Wochenschr** 1996 Nov 30; 126(48):2059-67 (Eng. Abstr.) **(Ger)**

[Therapy of tuberculosis today: to prescribe is not enough. A case report] Rogasi PG, et al. **Ann Ital Med Int** 1996 Jul-Sep;11(3):211-5 (Eng. Abstr.) **(Ita)**

[The present status of treatment of Mycobacterium avium complex infection] Harada S. **Kekkaku** 1996 Sep; 71(9):540-4 **(Jpn)**

[The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis] Iwanaga T, et al. **Kekkaku** 1997 Jan;72(1):9-13 (Eng. Abstr.) **(Jpn)**

[Pilot studies on the treatment of Mycobacterium avium complex lung disease--new macrolides and new quinolones. (2) Multi-drug chemotherapy for initial cases on trial] Tanaka E. **Kekkaku** 1996 Sep;71(9):547-9 **(Jpn)**

[Evaluation of treatment outcome for pulmonary tuberculosis with early introduction of intermittent methods, two years after the conclusion of treatment] Sedlaczek AM, et al. **Pneumonol Alergol Pol** 1996;64(11-12):729-32 (Eng. Abstr.) **(Pol)**

Morphological reactions in the subcutaneous fat after lymphotropic administration of isoniazid: experimental study] Gedymin LE, et al. **Probl Tuberk** 1997;(2):51-4 (Eng. Abstr.) **(Rus)**

[Effectiveness of regional lymphotropic therapy in combined treatment of tuberculosis in adolescents] Gubkina MF. **Probl Tuberk** 1996;(3):34-7 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Hepatotoxicity after a short course of low-dose pyrazinamide. al Sarraf KA, et al. **Acta Gastroenterol Belg** 1996 Oct-Dec;59(4):251-3

Lack of clinical evidence for potential interaction between isoniazid and selective serotonin-reuptake inhibitors [letter; comment] Stockley IH. **Am J Health Syst Pharm** 1996 Sep 15;53(18):2217. Comment on: Am J Health Syst Pharm 1995 Oct 1;52(19):2135-6.

Prophylaxis of anaphylactoid reaction to antituberculous drugs [letter] [see comments] Kévorkian JP, et al. **Ann Pharmacother** 1997 Mar;31(3):373-4. Comment in: Ann Pharmacother 1997 Jul-Aug;31(7-8):928-9.

Pancreatic insufficiency due to antituberculous therapy. Liu BA, et al. **Ann Pharmacother** 1997 Jun;31(6):724-6

Drug-food interaction with isoniazid resembling anaphylaxis [letter; comment] O'Sullivan TL. **Ann Pharmacother** 1997 Jul-Aug;31(7-8):928-9. Comment on: Ann Pharmacother 1997 Mar;31(3):373-4.

Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma. Watkins WM, et al. **Br J Clin Pharmacol** 1996 Feb; 41(2):160-2

Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Ridzon R, et al. **Clin Infect Dis** 1997 Jun;24(6):1264-5

Systemic paradoxical response to antituberculous drugs: resolution with corticosteroid therapy. Rodriguez-Bano J, et al. **Clin Infect Dis** 1997 Mar;24(3):517-9

Isoniazid hepatotoxicity in renal transplant recipients. Antony SJ, et al. **Clin Transplant** 1997 Feb;11(1):34-7

Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Durand F, et al. **Drug Saf** 1996 Dec;15(6):394-405 (62 ref.)

Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Schaberg T, et al. **Eur Respir J** 1996 Oct; 9(10):2026-30

Paradoxical worsening in tuberculosis during therapy in an HIV-infected patient [letter] Mofredj A, et al. **Infection**

1996 Sep–Oct;24(5):390–1
Osteomalacia during rifampicin and isoniazid therapy is rare in Hong Kong. Chan TY. **Int J Clin Pharmacol Ther** 1996 Dec;34(12):533–4
Metabolic complications in tuberculosis patients: the disease or the treatment? [letter] Albrand G, et al. **J Am Geriatr Soc** 1997 May;45(5):658–9
Pyrazinamide–induced granulomatous hepatitis. Knobel B, et al. **J Clin Gastroenterol** 1997 Jun;24(4):264–6
Isoniazid–induced fever. Lee CH, et al. **J Formos Med Assoc** 1996 Aug;95(8):632–4
A prospective clinical study of isoniazid–rifampicin–pyrazinamide–induced liver injury in an area endemic for hepatitis B. Hwang SJ, et al. **J Gastroenterol Hepatol** 1997 Jan;12(1):87–91
Severe acute hepatitis associated with morphazinamide therapy [letter] Zavaglia C, et al. **J Hepatol** 1996 Dec; 25(6):1001
Faulty prescription—an avoidable cause of multidrug resistance tuberculosis. Jain RF. **J Indian Med Assoc** 1996 Oct;94(10):385–8
A new epidemic [editorial] Pradhan MC. **J Indian Med Assoc** 1996 Sep;94(9):326–7, 333
Alcoholic hepatic impairment complicating treatment with hepatotoxic antituberculosis drugs. Tiwari VK. **J Indian Med Assoc** 1996 Sep;94(9):347–8
Demonstration of slow acetylator genotype of N–acetyltransferase in isoniazid neuropathy using an archival hematoxylin and eosin section of a sural nerve biopsy specimen. Yamamoto M, et al. **J Neurol Sci** 1996 Jan;135(1):51–4
Acute hypertension as an adverse effect of pyrazinamide [letter] Goldberg J, et al. **JAMA** 1997 May 7;277(17):1356
From the Food and Drug Administration. Nightingale SL. **JAMA** 1997 Jun 4;277(21):1664
Psychotic disorder associated with isoniazid. Bourgeois JA, et al. **Mil Med** 1996 Nov;161(11):707
Periodontal indices of patients taking isoniazid and rifampin: a pilot study. Zuehlke RK, et al. **Mil Med** 1997 Jan; 162(1):59–61
Acute toxic myopathy due to pyrazinamide in a patient with renal transplantation and cyclosporine therapy. Fernández–Solà J, et al. **Nephrol Dial Transplant** 1996 Sep; 11(9):1850–2
A case of acute deterioration in asthma symptoms induced by isoniazid prophylaxis. Polosa R, et al. **Respir Med** 1997 Aug;91(7):438–40
Ototoxicity of aminoglycoside drugs in tuberculosis treatment. Voogt GR, et al. **S Afr J Commun Disord** 1996; 43:3–6
Hepatotoxicity of antituberculosis drugs [letter; comment] Devlin J, et al. **Thorax** 1996 Nov;51(11):1168–9. Comment on: Thorax 1996 Feb;51(2):111–3.
Pseudomembranous colitis in a patient treated with ofloxacin for tuberculosis [letter] Yew WW, et al. **Tuber Lung Dis** 1996 Oct;77(5):484
Methazid–induced vitamin B2 deficiency in rats and its prevention. Kodentsova VM, et al. **Ukr Biokhim Zh** 1995 Nov–Dec;67(6):86–8
Isoniazid–related fatal hepatitis [letter; comment] Salpeter SR. **West J Med** 1996 Nov;165(5):323. Comment on: West J Med 1996 Jun;164(6):486–91.
[Four cases of similar Hexheimer's reaction during the initial chemotherapy for tuberculosis bacillus] Lu H, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Dec; 18(6):348–50, 382–3 (10 ref.) (Eng. Abstr.) **(Chi)**
[Paradoxical hypertrophy of cervical lymph nodes in the treatment for lymph node tuberculosis (letter)] Bani–Sadr F, et al. **Presse Med** 1997 Feb 8;26(3):118 **(Fre)**
[Lymph node hypertrophy during antitubercular treatment. A paradoxic phenomenon (letter)] Doco–Lecompte T, et al. **Presse Med** 1997 Apr 19;26(13):615 **(Fre)**
[Adverse effects related to the use of antitubercular drugs in psychiatric centers: retrospective study at the Philippe Pinel CH in Amiens 1994] Decocq G, et al. **Therapie** 1996 Sep–Oct;51(5):543–9 (Eng. Abstr.) **(Fre)**
[Liver injury under tuberculostatic treatment] Fattinger K, et al. **Schweiz Rundsch Med Prax** 1997 Apr 9;86(15):626–9 (Eng. Abstr.) **(Ger)**
[Fulminant hepatitis during the therapy for tuberculous meningitis] Garavelli PL. **Recenti Prog Med** 1996 Dec; 87(12):597 (8 ref.) **(Ita)**
[Vitamin K deficiency syndrome caused by antituberculous agents] Ishii F, et al. **Nippon Shokakibyo Gakkai Zasshi** 1997 Jun;94(6):389–97 (Eng. Abstr.) **(Jpn)**
[Effect of phytotherapy on the prevention and elimination of hepatotoxic responses in patients with pulmonary tuberculosis, carriers of hepatitis B virus markers] Galitskiĭ LA, et al. **Probl Tuberk** 1997;(4):35–8 (Eng. Abstr.) **(Rus)**
[Clinical and bacteriological features of intestinal dysbacteriosis in patients with pulmonary tuberculosis] Lineva ZE. **Probl Tuberk** 1997;(2):27–8 (Eng. Abstr.) **(Rus)**
[Use of maxaquin in the treatment of progressive pulmonary tuberculosis occurring with standard chemotherapy regimens] Mar'iandyshev AO, et al. **Probl Tuberk** 1997; (4):19–21 (Eng. Abstr.) **(Rus)**
[Correction of bronchial obstructive syndrome and antituberculous drugs–induced eosinophilia in patients with pulmonary tuberculosis by using plasmapheresis] Shmelev EI, et al. **Probl Tuberk** 1996;(6):57–60 (Eng. Abstr.) **(Rus)**
[Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence] Moitinho E, et al. **Gastroenterol Hepatol** 1996 Nov;19(9):448–51 (Eng. Abstr.) **(Spa)**

ANALYSIS

Determination of ethambutol in human plasma and urine by high–performance liquid chromatography with fluorescence detection. Breda M, et al. **J Chromatogr A** 1996 Apr 5;729(1–2):301–7
High–performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. Seifart HI, et al. **J Chromatogr B Biomed Appl** 1995 Dec 15;674(2):269–75

ANTAGONISTS & INHIBITORS

[The re–emergence of tuberculosis: the endemia of multiple–antibiotic–resistant strains (editorial)] Rossi G. **Recenti Prog Med** 1996 Oct;87(10):487–8 (16 ref.) **(Ita)**

BLOOD

Low antituberculosis drug concentrations in patients with AIDS. Peloquin CA, et al. **Ann Pharmacother** 1996 Sep; 30(9):919–25
Determination of rifabutin by high–performance liquid chromatography using on–line concentration and column switching. Bartels H, et al. **J Chromatogr B Biomed Appl** 1996 Nov 15;686(2):235–40
High–performance liquid chromatography assay of rifapentine in human serum. He X, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):412–5
Isocratic high–performance liquid chromatographic determination of thiacetazone by direct injection of plasma into an internal surface reversed–phase column. Song D, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7; 690(1–2):289–94
Correlation between steady–state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters. Woo J, et al. **J Med** 1995; 26(5–6):279–94
[The blood concentration of flurenizid in patients with destructive pulmonary tuberculosis] Panasiuk VO, et al. **Lik Sprava** 1997 Mar–Apr;(2):37–9 (Eng. Abstr.) **(Ukr)**

CHEMICAL SYNTHESIS

N1–Hetaryl substituted pyridine– and pyrazinecarboxamidrazones with antimycobacterial activity. Ranft D, et al. **Arch Pharm (Weinheim)** 1997 Jun; 330(6):169–72
Synthesis and antimycobacterial activity of some indole derivatives of pyridine–2–carboxamidrazone and quinoline–2–carboxamidrazone. Mamolo MG, et al. **Farmaco** 1996 Jan;51(1):65–70
1–Methyl–1H–2–imidazo[4,5–b]pyridinecarboxylic acid and some of its derivatives with suspected antituberculotic activity. Bukowski L, et al. **Pharmazie** 1996 Jan;51(1):27–30

CHEMISTRY

Electron–topological investigation of structure–antitubercular activity relationship of thiosemicarbazone derivatives. Saripinar E, et al. **Arzneimittelforschung** 1996 Aug;46(8):824–8
Quantitative structure–activity relationship (QSAR) study of polyhydroxyxanthones. Ungwitayatorn J, et al. **Pharm Acta Helv** 1997 Feb;72(1):23–9
QSAR analysis of a set of benzimidazole derivatives based on their tuberculostatic activities. Geban O, et al. **Pharmazie** 1996 Jan;51(1):34–6

ECONOMICS

Cost–effectiveness of directly observed versus self–administered therapy for tuberculosis. Moore RD, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):1013–9
The ultimate decision analysis: the confirmation of reality through theory [editorial; comment] Sbarbaro JA. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):835–6. Comment on: Am J Respir Crit Care Med 1996 Oct;154(4 Pt 1):1013–9.
Tuberculosis treatment is expensive for patients in developing countries [letter; comment] Bevan E. **BMJ** 1997 Jul 19; 315(7101):187–8. Comment on: BMJ 1997 Mar 29;314(7085):921.

ISOLATION & PURIFICATION

Antimycobacterial cycloartanes from Borrichia frutescens. Cantrell CL, et al. **J Nat Prod** 1996 Dec;59(12):1131–6

METABOLISM

The role of Mn(II)–peroxidase activity of mycobacterial catalase–peroxidase in activation of the antibiotic isoniazid. Magliozzo RS, et al. **J Biol Chem** 1997 Apr 4; 272(14):8867–70

PHARMACOKINETICS

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Parkin DP, et al. **Am J Respir Crit Care Med** 1997 May;155(5):1717–22
Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Sahai J, et al. **Ann Intern Med** 1997 Aug 15;127(4):289–93
Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol. Schall R, et al. **Arzneimittelforschung** 1995 Nov;45(11):1236–9
Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Choudhri SH, et al. **Clin Infect Dis** 1997 Jul;25(1):104–11
Pharmacokinetics of isoniazid in pulmonary tuberculosis—a comparative study at two dose levels. Roy V, et al. **Indian Pediatr** 1996 Apr;33(4):287–91
In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. Koudriakova T, et al. **J Pharmacol Exp Ther** 1996 Dec; 279(3):1300–9
Pharmacokinetic evaluation of thiacetazone. Peloquin CA, et al. **Pharmacotherapy** 1996 Sep–Oct;16(5):735–41
[Changes of isoniazid concentrations in guinea pig blood and organs after various routes of drug administration] Kaminskaia GO, et al. **Probl Tuberk** 1997;(2):45–7 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Laboratory diagnosis of antibiotic resistant Mycobacterium bovis within 48 h: a qualitative change in the approach to mycobacterial diseases in AIDS patients [letter] Espinosa de los Monteros LE, et al. **AIDS** 1997 May;11(6):827–8
Initial screening for antituberculous drug resistance at an inpatient facility in Leon, Nicaragua. de la Hoz RE, et al. **Am J Trop Med Hyg** 1997 Jan;56(1):24–6
Bioluminescence screening in vitro (Bio–Siv) assays for high–volume antimycobacterial drug discovery. Arain TM, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1536–41
Effects of isoniazid on ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on production of secreted proteins. Bardou F, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2459–67
Detection of rifampin– and ciprofloxacin–resistant Mycobacterium tuberculosis by using species–specific assays for precursor rRNA. Cangelosi GA, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1790–5
Isoniazid induces expression of the antigen 85 complex in Mycobacterium tuberculosis. Garbe TR, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1754–6
Bactericidal action of ofloxacin, sulbactam–ampicillin, rifampin, and isoniazid on logarithmic– and stationary–phase cultures of Mycobacterium tuberculosis. Herbert D, et al. **Antimicrob Agents Chemother** 1996 Oct; 40(10):2296–9
Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. Klemens SP, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):14–6
Gyrase mutations in laboratory–selected, fluoroquinolone–resistant mutants of Mycobacterium tuberculosis H37Ra. Kocagöz T, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1768–74
katG mutations in isoniazid–resistant Mycobacterium tuberculosis isolates recovered from Finnish patients. Marttila HJ, et al. **Antimicrob Agents Chemother** 1996 Sep; 40(9):2187–9
In vitro activities of levofloxacin used alone and in combination with first– and second–line antituberculous drugs against Mycobacterium tuberculosis. Rastogi N, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1610–6
Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Rastogi N, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2483–7
Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Reddy VM, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):633–36
Characterization of pncA mutations in pyrazinamide–resistant Mycobacterium tuberculosis. Scorpio A, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):540–3
Analysis of the oxyR–ahpC region in isoniazid–resistant and –susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Sreevatsan S, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):600–6
Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Sreevatsan S, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):636–40
Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Sreevatsan S, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1677–81
katG mutations in isoniazid–resistant strains of Mycobacterium tuberculosis are not infrequent [letter] Victor TC, et al. **Antimicrob Agents Chemother** 1996 Jun; 40(6):1572
Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies. Wright EL, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2206–8
A continuing survey of drug–resistant tuberculosis, New York City, April 1994. Fujiwara PI, et al. **Arch Intern Med** 1997 Mar 10;157(5):531–6

beta-Galactosidase reporter system in mycobacteria and its application in rapid antimycobacterial drug screening. Srivastava R, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):602-5

Determination of the primary target for isoniazid in mycobacterial mycolic acid biosynthesis with Mycobacterium aurum A+. Wheeler PR, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):451-7

Quantitative-competitive polymerase chain reaction for rapid susceptibility testing of Mycobacterium tuberculosis to isoniazid. Afghani B, et al. **Biochem Mol Med** 1997 Apr; 60(2):182-6

Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. O'Shea D, et al. **Br J Clin Pharmacol** 1997 Jan;43(1):99-103

Effects of isoniazid on the proliferation and cytokine production of bladder cancer cells in vitro induced by bacille Calmette-Guérin. Bevers RF, et al. **Br J Urol** 1997 Jul;80(1):35-9

Detection of resistance to isoniazid, rifampin, and streptomycin in clinical isolates of Mycobacterium tuberculosis by molecular methods. Nachamkin I, et al. **Clin Infect Dis** 1997 May;24(5):894-900

Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Chien JY, et al. **Clin Pharmacol Ther** 1997 Jan;61(1):24-34

Synergistic antimycobacterial activity between ethambutol and the beta-lactam drug cefepime. Abate G, et al. **Diagn Microbiol Infect Dis** 1997 Jul;28(3):119-22

Mycobacterial growth indicator tube for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin. Bergmann JS, et al. **Diagn Microbiol Infect Dis** 1997 Jul; 28(3):153-6

Synthesis and antimycobacterial activity of some new 3-heterocyclic substituted chromones. Gašparová R, et al. **Farmaco** 1997 Apr;52(4):251-3

On the catalase-peroxidase gene, katG, of Mycobacterium leprae and the implications for treatment of leprosy with isoniazid. Eiglmeier K, et al. **FEMS Microbiol Lett** 1997 Apr 15;149(2):273-8

Probenecid, sulfinpyrazone and pyrazinamide do not inhibit urinary excretion of the beta 2-adrenoceptor agonist clenbuterol in cattle. Gleixner A, et al. **Food Addit Contam** 1996 Aug-Sep;13(6):603-8

Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells. Nicod L, et al. **Hum Exp Toxicol** 1997 Jan;16(1):28-34

Effect of anti-tuberculosis drugs on the iron-sequestration mechanisms of mycobacteria. Raghu B, et al. **Indian J Pathol Microbiol** 1995 Jul;38(3):287-92

Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Heym B, et al. **Infect Immun** 1997 Apr;65(4):1395-401

The effects of therapy with rifampicin and isoniazid on basic investigations for Cushing's syndrome. Zawawi TH, et al. **Ir J Med Sci** 1996 Oct-Dec;165(4):300-2

Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. Amaral L, et al. **J Antimicrob Chemother** 1996 Dec;38(6):1049-53

Evaluation of the post-antibiotic effect of six anti-mycobacterial agents against Mycobacterium avium by the Bactec radiometric method. Fuursted K. **J Antimicrob Chemother** 1997 Jul;40(1):33-8

Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages. Pellegrin I, et al. **J Antimicrob Chemother** 1996 Mar;37(3):501-10

Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. Telenti A, et al. **J Clin Microbiol** 1997 Mar;35(3):719-23

Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by mycobacterium growth indicator tube method. Walters SB, et al. **J Clin Microbiol** 1996 Jun; 34(6):1565-7

Presence of katG gene in resistant Mycobacterium tuberculosis. Jaber M, et al. **J Clin Pathol** 1996 Nov; 49(11):945-7

Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. Mdluli K, et al. **J Infect Dis** 1996 Nov; 174(5):1085-90

Isoniazid resistance and the point mutation of codon 463 of katG gene of Mycobacterium tuberculosis. Shim TS, et al. **J Korean Med Sci** 1997 Apr;12(2):92-8

To treat or not to treat: the case of tuberculosis. Castillo-Chavez C, et al. **J Math Biol** 1997 Jun;35(6):629-56

Antimycobacterial cycloartanes from Borrichia frutescens. Cantrell CL, et al. **J Nat Prod** 1996 Dec;59(12):1131-6

Cytochrome P4502E in vivo and in vitro in the dwarf goat: effects of enzyme induction and the applicability of chlorzoxazone as marker substrate. Zweers-Zeilmaker WM, et al. **J Vet Pharmacol Ther** 1996 Jun;19(3):245-50

The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Telenti A, et al. **Nat Med** 1997 May;3(5):567-70

Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Mycobacterium tuberculosis. Wilson SM, et al. **Nat Med** 1997 Apr; 3(4):465-8

Quantitative structure-activity relationship (QSAR) study of polyhydroxyxanthones. Ungwitayatorn J, et al. **Pharm Acta Helv** 1997 Feb;72(1):23-9

1-Methyl-1H-2-imidazo[4,5-b]pyridinecarboxylic acid and some of its derivatives with suspected antituberculotic activity. Bukowski L, et al. **Pharmazie** 1996 Jan;51(1):27-30

The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Belanger AE, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11919-24

Molecular basis for the exquisite sensitivity of Mycobacterium tuberculosis to isoniazid. Zhang Y, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13212-6

Metabolism of tacrolimus (FK 506) in rat liver microsomes. Effect of rifampin and dexamethasone. Prasad, et al. **Res Commun Mol Pathol Pharmacol** 1997 Apr;96(1):107-10

High proportion of multi-drug resistant Mycobacterium tuberculosis in Saudi Arabia [see comments] Ellis ME, et al. **Scand J Infect Dis** 1996;28(6):591-5. Comment in: Scand J Infect Dis 1997;29(3):323.

Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics. Wilkinson D, et al. **Trans R Soc Trop Med Hyg** 1996 Nov-Dec; 90(6):692-5

Life without KatG. Zhang Y. **Trends Microbiol** 1996 Nov; 4(11):415-6 (15 ref.)

Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso. Ledru S, et al. **Tuber Lung Dis** 1996 Oct;77(5):429-36

Tuberculosis. The WHO/IUATLD Global Project on Antituberculosis Drug-Resistance Surveillance. **Wkly Epidemiol Rec** 1996 Sep 20;71(38):281-5 **(Eng, Fre)**

[From the immunological aspect--interleukin-10 production by human blood mononuclear cells stimulated with multidrug-resistant Mycobacterium tuberculosis] Fujiwara H, et al. **Kekkaku** 1996 Jan;71(1):43-6 (Eng. Abstr.) **(Jpn)**

[In vitro anti-MAC activities of new quinolones in focus (2)] Kawahara S, et al. **Kekkaku** 1996 Sep;71(9):537-9 **(Jpn)**

[A study on prevalence of resistance to antituberculosis drugs in Japan: comparison of results in the local facilities and in the reference laboratory] Kazumi Y, et al. **Kekkaku** 1996 Mar;71(3):267-76 (Eng. Abstr.) **(Jpn)**

[From the views of bacteriology--focusing on drug susceptibility test] Ogata H. **Kekkaku** 1996 Jan;71(1):37-41 (Eng. Abstr.) **(Jpn)**

[Preclinical study of therapeutic agents used against Mycobacterium avium complex infections--with special reference to new macrolides and new quinolones] Tomioka H, et al. **Kekkaku** 1996 Sep;71(9):531-5 **(Jpn)**

[In vitro anti-MAC activities of new quinolones in focus (1)] Tsuyuguchi K. **Kekkaku** 1996 Sep;71(9):536-7 **(Jpn)**

[In vitro antimycobacterial activities of pyrazinamide analogs: results of screening tests] Yamamoto S, et al. **Kekkaku** 1996 Mar;71(3):253-8 (Eng. Abstr.) **(Jpn)**

[Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media] Yamane N, et al. **Kekkaku** 1996 Aug;71(8):453-8 (Eng. Abstr.) **(Jpn)**

[Effect of lomefloxacin on the functional activity of the phagocytic system] Mozhokina GN, et al. **Antibiot Khimioter** 1996 Mar;41(3):25-8 (Eng. Abstr.) **(Rus)**

[Effect of a complex preparation of isoniazide on mononuclear cells in tuberculous granuloma] Shkurupiĭ VA, et al. **Biull Eksp Biol Med** 1996 May;121(5):559-61 **(Rus)**

[Immunological indicators in patients with pulmonary tuberculosis in the presence of drug-resistant Mycobacteria] Kuz'mina NV. **Probl Tuberk** 1996;(3):38-9 (Eng. Abstr.) **(Rus)**

[Drug resistance of Mycobacterium tuberculosis and its significance in the hospital practice] Rudoĭ NM. **Probl Tuberk** 1996;(3):6-8 (Eng. Abstr.) **(Rus)**

[Antibacterial effectiveness of long-acting isoniazid in the experiment] Shkurupiĭ VA, et al. **Probl Tuberk** 1997; (2):54-6 (Eng. Abstr.) **(Rus)**

[Sensitivity of Mycobacterium tuberculosis in our environment (letter)] Unzaga MJ, et al. **Enferm Infecc Microbiol Clin** 1996 Jun-Jul;14(6):399-400 **(Spa)**

[In vitro comparative activity (E test) of sparfloxacin and other 8 antimicrobial agents against bacteria isolated from patients with respiratory infections acquired in the community] Prado V, et al. **Rev Med Chil** 1995 Nov; 123(11):1394-1401 (Eng. Abstr.) **(Spa)**

[Usefulness of studies on antitubercular drug resistance] Valenzuela P. **Rev Panam Salud Publica** 1997 Jan;1(1):62-7 **(Spa)**

POISONING

Management of isoniazid poisoning--case report. Sood AK, et al. **Indian J Med Sci** 1996 Jul;50(7):247-9

Pyridoxine in acute isoniazid overdose. Langdana A, et al. **Indian Pediatr** 1996 Feb;33(2):132-4

Intentional overdosage with isoniazid: case report and review of literature. Tai DY, et al. **Singapore Med J** 1996 Apr; 37(2):222-5 (44 ref.)

STANDARDS

Future directions in the development of new antitubercular drugs. Where do we go from here? Yew WW, et al. **Drugs Aging** 1997 Jun;10(6):405-10 (66 ref.)

Quality control and essential drugs [editorial] **Lancet** 1997 Aug 30;350(9078):601

THERAPEUTIC USE

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. Chaisson RE, et al. **AIDS** 1997 Mar;11(3):311-7

Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. Foster S, et al. **AIDS** 1997 Jun;11(7):919-25

Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. Hawken MP, et al. **AIDS** 1997 Jun;11(7):875-82

Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand. Ngamvithayapong J, et al. **AIDS** 1997 Jan;11(1):107-12

Prevention and treatment of drug-resistant tuberculosis. Humma LM. **Am J Health Syst Pharm** 1996 Oct 1; 53(19):2291-8; quiz 2335-6

Advice on treatment of Mycobacterium avium complex infection [letter; comment] Peloquin CA, et al. **Am J Health Syst Pharm** 1997 May 15;54(10):1208-9. Comment on: Am J Health Syst Pharm 1996 Nov 1;53(21):2585-90.

Optimal treatment and long-term outcome of tuberculous peritonitis complicating continuous ambulatory peritoneal dialysis. Lui SL, et al. **Am J Kidney Dis** 1996 Nov; 28(5):747-51

Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Chaisson RE, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):1034-8

The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Gordin FM, et al. **Am J Respir Crit Care Med** 1996 Nov;154(5):1478-83

Directly observed isoniazid preventive therapy for released jail inmates. Nolan CM, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):583-6

Tuberculous anterior neck mass simulating goitre. Abdullah MA, et al. **Ann Trop Paediatr** 1996 Dec;16(4):369-71

Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Dhillon J, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):552-5

Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Hickey MJ, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):400-7

Inmate access to postrelease medical care: public health implications [letter; comment] Macher AM, et al. **Arch Fam Med** 1997 Jul-Aug;6(4):318. Comment on: Arch Fam Med 1994 Oct;3(10):894-8.

Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival. Moreno S, et al. **Arch Intern Med** 1997 Aug 11-25;157(15):1729-34

Management guidelines for M. tuberculosis in pregnancy. Casper GR, et al. **Aust N Z J Obstet Gynaecol** 1995 Nov; 35(4):401-5 (22 ref.)

Grand rounds--Hammersmith Hospital. Persistent fever in pulmonary tuberculosis [clinical conference] Barakat MT, et al. **BMJ** 1996 Dec 14;313(7071):1543-5

Cutaneous tuberculous abscess: a management problem. Harris A, et al. **Br J Dermatol** 1996 Sep;135(3):457-9

Science for combatting tuberculosis. Jacobs WR Jr. **Bull N Y Acad Med** 1996 Summer;73(1):46-52

Mantoux (tuberculosis) testing. Evaluation of guidelines for testing in Canadian institutions. Thomas RE. **Can Fam Physician** 1997 May;43:933-8 (40 ref.)

Antituberculosis drug resistance in Keelung area-1993 to 1994. Hua CC, et al. **Chang Keng I Hsueh** 1996 Jun; 19(2):107-14

Present situation of multidrug-resistant tuberculosis in Asian countries and the possibility of MDR-TB treatment by new quinolones. Proceedings of a satellite symposium for the 14th Asia Pacific Congress on Diseases of the Chest. Bali, June 26, 1996. **Chemotherapy** 1996;42 Suppl 3:1-35

Multidrug resistance in the world: the present situation. Reichman LB. **Chemotherapy** 1996;42 Suppl 3:2-9; discussion 30-3 (18 ref.)

Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment [see comments] Burman WJ, et al. **Chest** 1997 May;111(5):1168-73. Comment in: Chest 1997 May;111(5):1151-3.

Short-term incarceration for the management of noncompliance with tuberculosis treatment [see comments] Burman WJ, et al. **Chest** 1997 Jul;112(1):57-62. Comment in: Chest 1997 Jul;112(1):5-6.

Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes [see comments] Kritski

AL, et al. **Chest** 1997 May;111(5):1162–7. Comment in: Chest 1997 May;111(5):1149–51.

Beyond directly observed therapy for tuberculosis [editorial; comment] Nolan CM. **Chest** 1997 May;111(5):1151–3. Comment on: Chest 1997 May;111(5):1168–73.

'Multidrug'-resistant tuberculosis. It is time to focus on the private sector of medicine [editorial; comment] Sbarbaro JA. **Chest** 1997 May;111(5):1149–51. Comment on: Chest 1997 May;111(5):1162–7.

Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Cohn DL, et al. **Clin Infect Dis** 1997 Jan; 24 Suppl 1:S121–30 (97 ref.)

Concurrent mucosal leishmaniasis and pulmonary tuberculosis. Escobar MA, et al. **Clin Infect Dis** 1996 Oct; 23(4):836–7

Use of adjunctive treatment with interferon-gamma in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. Raad I, et al. **Clin Infect Dis** 1996 Mar;22(3):572–4

Disseminated infection due to multidrug-resistant Mycobacterium bovis in a patient who was seropositive for human immunodeficiency virus. Schultsz C, et al. **Clin Infect Dis** 1996 Oct;23(4):841–3

Anterior and posterior fusion for children with tuberculosis of the spine. Altman GT, et al. **Clin Orthop** 1996 Apr; (325):225–31

Tuberculosis of the long bone in children. Shih HN, et al. **Clin Orthop** 1997 Feb;(335):246–52

Diagnosis and outcome of isolated rectal tuberculosis. Puri AS, et al. **Dis Colon Rectum** 1996 Oct;39(10):1126–9

Tuberculosis. Part II. LoBue PA, et al. **Dis Mon** 1997 Apr; 43(4):181–274 (346 ref.)

Tuberculosis. Part I. McDermott LJ, et al. **Dis Mon** 1997 Mar;43(3):113–80 (172 ref.)

Epidemiology, control and treatment of multidrug-resistant tuberculosis. Chaulet P, et al. **Drugs** 1996;52 Suppl 2:103–7; discussion 107–8 (17 ref.)

Primary nasopharyngeal tuberculosis: case report and review of the literature. al Serhani AM, et al. **Ear Nose Throat J** 1997 Jan;76(1):41–2 (8 ref.)

Changes in the size of adrenal glands in acute pulmonary tuberculosis with therapy. Gülmez I, et al. **Endocr J** 1996 Oct;43(5):573–6

Tuberculin test after therapy. Seth V. **Indian Pediatr** 1996 Nov;33(11):984

Chemotherapy for tuberculosis [letter; comment] Seth V. **Indian Pediatr** 1996 Feb;33(2):146–8. Comment on: Indian Pediatr 1995 Aug;32(8):943–4.

Effect of treatment on contagiousness of patients with active pulmonary tuberculosis. Menzies D. **Infect Control Hosp Epidemiol** 1997 Aug;18(8):582–6 (54 ref.)

Paradoxical worsening in tuberculosis during therapy in an HIV-infected patient [letter] Mofredj A, et al. **Infection** 1996 Sep–Oct;24(5):390–1

Tuberculous meningitis [letter; comment] Pozniak A. **Int J STD AIDS** 1997 Feb;8(2):139–40. Comment on: Int J STD AIDS 1996 Jul;7(4):244–9; quiz 249–51.

Human immunodeficiency virus infection in children with tuberculosis in Santo Domingo, Dominican Republic: prevalence, clinical findings, and response to antituberculosis treatment. Espinal MA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Oct 1;13(2):155–9

Amplification of rRNA for assessment of treatment response of pulmonary tuberculosis patients during antimicrobial therapy. Moore DF, et al. **J Clin Microbiol** 1996 Jul; 34(7):1745–9

Multiple drug resistant tuberculosis [editorial] Drobniewski FA, et al. **J Clin Pathol** 1997 Feb;50(2):89–90

Treatment of tuberculosis. Sobti JC. **J Indian Med Assoc** 1996 Sep;94(9):349–50

Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model. Bermudez LE, et al. **J Infect Dis** 1996 Dec;174(6):1218–22

Multidrug-resistant tuberculosis: response to treatment. Saenghirunvattana S, et al. **J Med Assoc Thai** 1996 Sep; 79(9):601–3

Antituberculosis drug resistance: practical solutions to practical problems [editorial] Tayler E. **J Med Microbiol** 1997 Jul;46(7):531–3

Multiple small bowel perforations in a patient on treatment of tuberculosis. Scriven JM, et al. **J R Coll Surg Edinb** 1996 Oct;41(5):353

Tuberculous perianal ulcers. Sarela AI, et al. **J R Soc Med** 1996 Oct;89(10):584

Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. Vegt PD, et al. **J Urol** 1997 Apr;157(4):1246–9

Tuberculosis: old lessons unlearnt? [letter] Bloom B, et al. **Lancet** 1997 Jul 12;350(9071):149

Directly observed therapy [letter] Chaulk CP, et al. **Lancet** 1997 Aug 30;350(9078):666–7

Control of tuberculosis by community health workers in Bangladesh [see comments] Chowdhury AM, et al. **Lancet** 1997 Jul 19;350(9072):169–72. Comment in: Lancet 1997 Jul 19;350(9072):157.

Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Condos R, et al. **Lancet** 1997 May 24;349(9064):1513–5

Directly observed therapy [letter] Volmink J, et al. **Lancet** 1997 May 10;349(9062):1399–400

Impact on USAF tuberculosis detection and control program given a low facility tuberculosis prevalence rate. Popper SE, et al. **Mil Med** 1996 Jul;161(7):432–5

Rapid healing of endobronchial tuberculosis by local endoscopic injection of corticosteroids. Verhaeghe W, et al. **Monaldi Arch Chest Dis** 1996 Oct;51(5):391–3

Isoniazid hepatotoxicity after orthotopic liver transplantation. Schluger LK, et al. **Mt Sinai J Med** 1996 Oct–Nov; 63(5–6):364–9

A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. Gordin FM, et al. **N Engl J Med** 1997 Jul 31;337(5):315–20

A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda–Case Western Reserve University Research Collaboration [see comments] Whalen CC, et al. **N Engl J Med** 1997 Sep 18;337(12):801–8. Comment in: N Engl J Med 1997 Sep 18;337(12):847–9. Comment in: N Engl J Med 1997 Sep 18;337(12):849–51.

Resolution of a brainstem abscess through antituberculous therapy. García-Moncó JC, et al. **Neurology** 1997 Jul; 49(1):265–7

The maternal and fetal effects of tuberculosis therapy. Brost BC, et al. **Obstet Gynecol Clin North Am** 1997 Sep; 24(3):659–73 (80 ref.)

New treatments for new TB strains. Brennan PJ, et al. **Pa Med** 1996 Jul;99(7):26–7

Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children. Sánchez-Albisua I, et al. **Pediatr Infect Dis J** 1997 Aug;16(8):760–3

Multidrug-resistant tuberculosis in children: two cases and a review of the literature. Schluger NW, et al. **Pediatr Pulmonol** 1996 Feb;21(2):138–42 (28 ref.)

Tuberculosis in Africa: clinical presentation and management. Harries AD. **Pharmacol Ther** 1997;73(1):1–50 (455 ref.)

Tuberculosis. Recommendations for screening, prevention, and treatment. Moffitt MP, et al. **Postgrad Med** 1996 Oct; 100(4):201–4, 209, 212 passim (17 ref.)

Drug resistance of M. tuberculosis isolated from patients with HIV infection seen at an AIDS Reference Center in São Paulo, Brazil. Pinto WP, et al. **Rev Inst Med Trop Sao Paulo** 1996 Jan–Feb;38(1):15–21

Tailor make the TB message [news] van der Linde I. **S Afr Med J** 1996 Aug;86(8):900, 902

Drug-resistant mycobacterium tuberculosis; some data from Sweden, Estonia and Ethiopia. Hoffner SE. **Scand J Infect Dis Suppl** 1995;98:17–8

Clinical manifestations and treatment of mycobacterium avium-intracellulare complex infection in HIV-infected patients. Julander I. **Scand J Infect Dis Suppl** 1995;98:19–20

Mycobacterial infections in Sweden. Romanus V. **Scand J Infect Dis Suppl** 1995;98:15–6

Mortality of patients while on treatment for active tuberculosis. Tan KL, et al. **Singapore Med J** 1996 Jun; 37(3):258–60

Duration of antituberculosis chemotherapy in conjunction with radical surgery in the management of spinal tuberculosis. Upadhyay SS, et al. **Spine** 1996 Aug 15; 21(16):1898–903

Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis. Evans SA, et al. **Thorax** 1996 Dec; 51(12):1248–52

Efficacy of twice weekly treatment for tuberculosis given under direct observation in Africa. Wilkinson D, et al. **Trans R Soc Trop Med Hyg** 1997 Jan–Feb;91(1):87–9

Tuberculosis and renal transplantation. Zaragoza RM, et al. **Transplant Proc** 1996 Dec;28(6):3309

Autoimmune haemolytic anaemia responding to anti-tuberculous treatment. Siribaddana SH, et al. **Trop Doct** 1997 Oct;27(4):243–4

Coping with Africa's increasing tuberculosis burden: are community supervisors an essential component of the DOT strategy? Directly observed therapy. Wilkinson D, et al. **Trop Med Int Health** 1997 Jul;2(7):700–4

Treatment of clinical paratuberculosis in cattle. St Jean G. **Vet Clin North Am Food Anim Pract** 1996 Jul;12(2):417–30 (51 ref.)

Directly observed therapy for tuberculosis. Mannino E, et al. **West J Med** 1996 Oct;165(4):224–5

[The results of retreatment of pulmonary tuberculosis using a short 6-month protocol 1985–1991 in the pneumo-phthisiology department of the Point G hospital in Bamako] Kayantao D, et al. **Bull Soc Pathol Exot** 1997; 90(2):124–7 (Eng. Abstr.) **(Fre)**

[Mycobacterium ulcerans: in vitro sensitivity of a strain isolated in Ivory Coast (letter)] Darie H, et al. **Med Trop (Mars)** 1996;56(4):410 **(Fre)**

[Tuberculin test, antitubercular chemoprophylaxis and incidence of tuberculosis in a Swiss HIV cohort study (news)] Sudre P, et al. **Rev Epidemiol Sante Publique** 1997 Apr;45(2):171–3 **(Fre)**

[Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries] Anglaret X, et al. **Sante** 1997 Mar–Apr;7(2):89–94 (38 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and therapy of skin tuberculosis] Weibach C, et al. **Dtsch Med Wochenschr** 1996 Oct 4;121(40):1231–5 (29 ref.) **(Ger)**

[Preclinical study of therapeutic agents used against Mycobacterium avium complex infections--with special reference to new macrolides and new quinolones] Tomioka H, et al. **Kekkaku** 1996 Sep;71(9):531–5 **(Jpn)**

[Antituberculous drug-resistance among homeless peoples] Toyota E, et al. **Kekkaku** 1996 Jan;71(1):13–7 (Eng. Abstr.) **(Jpn)**

[The clinical study of clarithromycin for pulmonary Mycobacterium avium-intracellulare complex infection] Yamamoto M, et al. **Kekkaku** 1997 Jan;72(1):1–7 (Eng. Abstr.) **(Jpn)**

[Drug resistance among patients with tuberculosis] Szczuka I. **Pneumonol Alergol Pol** 1996;64(11–12):740–9 (Eng. Abstr.) **(Pol)**

[Results of anti-tuberculosis treatment of patients with tuberculosis--children and adolescents treated in Poland in 1993] Szczuka I, et al. **Pneumonol Alergol Pol** 1996; 64(7–8):403–12 (Eng. Abstr.) **(Pol)**

[Antitubercular activity of lomefloxacin in an experiment] Mozhokina GN, et al. **Antibiot Khimioter** 1996;41(7–8):31–3 (Eng. Abstr.) **(Rus)**

[The characteristics of the treatment of newly detected pulmonary tuberculosis in miners] Fomicheva NI, et al. **Lik Sprava** 1996 Mar–Apr;(3–4):130–4 (Eng. Abstr.) **(Rus)**

[Problems in the treatment of patients with pulmonary tuberculosis] Chukanov VI. **Probl Tuberk** 1997;(4):17–9 (19 ref.) (Eng. Abstr.) **(Rus)**

[Integral factorial assessment of preventive measure system in tuberculosis] Deviatkov MI, et al. **Probl Tuberk** 1997; (4):8–9 (Eng. Abstr.) **(Rus)**

[Rationale for the use of regional lymphotropic therapy in the management of tuberculosis in adolescents] Firsova VA, et al. **Probl Tuberk** 1996;(6):47–50 (Eng. Abstr.) **(Rus)**

[Treatment of tuberculosis patients with massive bacterial excretion] Gavril'ev SS, et al. **Probl Tuberk** 1997;(2):17–8 (Eng. Abstr.) **(Rus)**

[Changes and patterns of drug resistance of mycobacterium tuberculosis in patients with pulmonary tuberculosis (by data of the microbiological laboratory of research production association "Phthysiology")] Gorokhova TV. **Probl Tuberk** 1997;(2):33–5 (Eng. Abstr.) **(Rus)**

[Exacerbation of pulmonary tuberculosis during chemotherapy] Karachunskii MA. **Probl Tuberk** 1996; (5):23–5 (Eng. Abstr.) **(Rus)**

[Detection of patients with tuberculosis and current methods of chemotherapy] Khomenko AG. **Probl Tuberk** 1996; (5):2–5 **(Rus)**

[Diagnosis and treatment of acute progressive tuberculosis types] Khomenko AG, et al. **Probl Tuberk** 1996;(5):21–3 (Eng. Abstr.) **(Rus)**

[Chemotherapy effectiveness of tuberculosis patients in intensive phase (2–3 months)] Khomenko AG, et al. **Probl Tuberk** 1996;(5):13–6 **(Rus)**

[Efficacy of chemotherapy of pulmonary tuberculosis drug-resistant m.tuberculosis] Khomenko AG, et al. **Probl Tuberk** 1996;(6):42–4 (Eng. Abstr.) **(Rus)**

[Dynamics of isolation of mycobacterium tuberculosis during 2-stage standard chemotherapy] Khomenko AG, et al. **Probl Tuberk** 1996;(6):52–4 (Eng. Abstr.) **(Rus)**

[Drug therapy of tuberculosis: history and present-day status (editorial)] Khomenko AG. **Probl Tuberk** 1996;(3):2–6 (Eng. Abstr.) **(Rus)**

[Efficacy of clinical follow-up of patients with tuberculosis of the respiratory organs in terms of their cure under present-day epidemiological conditions] Kovaleva SI, et al. **Probl Tuberk** 1996;(6):25–7 (Eng. Abstr.) **(Rus)**

[Detection of tuberculosis in children of new risk groups and efficacy of chemoprophylaxis] Mitinskaia LA, et al. **Probl Tuberk** 1996;(6):33–5 (Eng. Abstr.) **(Rus)**

[Tuberculosis risk groups among children and principles of approach to chemoprophylaxis] Mitinskaia LA, et al. **Probl Tuberk** 1996;(3):10–12 (Eng. Abstr.) **(Rus)**

[Chemotherapy-induced lung functional changes in patients with destructive pulmonary tuberculosis] Nefedov VB, et al. **Probl Tuberk** 1996;(6):60–3 (Eng. Abstr.) **(Rus)**

[Treatment and outcomes of disseminated pulmonary tuberculosis] Rzhavskov IV, et al. **Probl Tuberk** 1997; (1):40–1 (Eng. Abstr.) **(Rus)**

[Use of immunochemical studies to predict the course of fibrous cavernous tuberculosis of lung and postoperative complications in patients on chemo and laser therapy] Sergeeva LV, et al. **Probl Tuberk** 1997;(4):23–6 (Eng. Abstr.) **(Rus)**

[Laser and chemotherapy and the immune status of patients with fibrous-cavernous tuberculosis] Sergeeva LV, et al. **Probl Tuberk** 1996;(1):22–4 (Eng. Abstr.) **(Rus)**

[Can we improve the prevention of tuberculosis? Analysis of the application of chemoprophylaxis] Franco Serrano J, et al. **Arch Bronconeumol** 1996 Dec;32(10):505–9 (Eng. Abstr.) **(Spa)**

[Treatment and retreatment of tuberculosis] Vidal R, et al. **Arch Bronconeumol** 1996 Nov;32(9):463–74 (60 ref.) **(Spa)**

[Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis] Colmenero JD, et al. **Enferm Infecc Microbiol Clin** 1997 Mar;15(3):129–33 (Eng.

ANTITUBERCULAR AGENTS

Abstr.) **(Spa)**

[Coinfection by mycobacteria in HIV-positive patients] von Wichmann MA, et al. **Enferm Infecc Microbiol Clin** 1996 Oct;14(8):466–9 (Eng. Abstr.) **(Spa)**

[Patterns of resistance to antitubercular agents in Girona. Diagnostic and therapeutic implications (letter; comment)] Camafort Babkowski M, et al. **Med Clin (Barc)** 1997 Mar 22;108(11):438–9. Comment on: Med Clin (Barc) 1996 Jan 13;106(1):1–6. **(Spa)**

[Paradoxal growth of cerebral tuberculomas during antituberculosis treatment (letter)] Iranzo A, et al. **Med Clin (Barc)** 1997 Feb 8;108(5):198–9 **(Spa)**

[The results of a clinical trial of flurenizid in phthisiopulmonology practice] Il'nyts'kyi IH, et al. **Lik Sprava** 1995 Sep–Dec;(9–12):67–9 (Eng. Abstr.) **(Ukr)**

TOXICITY

Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Sarich TC, et al. **Arch Toxicol** 1996;70(12):835–40

Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Deol P, et al. **Biochim Biophys Acta** 1997 Mar 15; 1334(2–3):161–72

URINE

Determination of pyrazinamide and its main metabolites in rat urine by high-performance liquid chromatography. Mehmedagic A, et al. **J Chromatogr B Biomed Sci Appl** 1997 Aug 1;695(2):365–72

ANTITUMOR DRUG SCREENING ASSAYS see **DRUG SCREENING ASSAYS, ANTITUMOR**

ANTITUSSIVE AGENTS

see related

EXPECTORANTS

Cough mixture misuse in Hong Kong—an emerging psychiatric problem? Lam LC, et al. **Addiction** 1996 Sep; 91(9):1375–8

Abuse of dextromethorphan-based cough syrup as a substitute for licit and illicit drugs: a theoretical framework. Darboe MN. **Adolescence** 1996 Spring;31(121):239–45

The abuse of dextromethorphan-based cough syrup: a pilot study of the community of Waynesboro, Pennsylvania. Darboe MN, et al. **Adolescence** 1996 Fall;31(123):633–44

Use of codeine- and dextromethorphan-containing cough remedies in children. American Academy of Pediatrics. Committee on Drugs. **Pediatrics** 1997 Jun;99(6):918–20

What you need to know: addiction—cough mixture. Perera I. **Singapore Med J** 1997 Mar;38(3):136–7

ADVERSE EFFECTS

Adverse reaction to potassium iodide from a cough syrup. Muñoz FJ, et al. **Allergy** 1997 Jan;52(1):111–2

Cough mixture induced psychosis. Lee DT, et al. **Br J Clin Pract** 1996 Oct–Nov;50(7):400–1

Bullous mastocytosis in an infant associated with the use of a nonprescription cough suppressant. Cook J, et al. **Pediatr Dermatol** 1996 Sep–Oct;13(5):410–4

Dextromethorphan-induced manic symptoms in a bipolar patient on lithium [letter; comment] Bostwick JM. **Psychosomatics** 1996 Nov–Dec;37(6):571–3. Comment on: Psychosomatics 1996 Jan–Feb;37(1):71–4.

Antiallergic and antitussive medications: extent of use and relationship to asthma exacerbations. Van Ganse E, et al. **Therapie** 1996 Jul–Aug;51(4):373–7

ANALYSIS

Determination of noscapine, hexylresorcinol and anethole in cough lozenges by liquid chromatography. Lucangioli S, et al. **Boll Chim Farm** 1996 Jun;135(6):387–90

Simultaneous determination of bromhexine hydrochloride and methyl and propyl p-hydroxybenzoate and determination of dextromethorphan hydrobromide in cough-cold syrup by high-performance liquid chromatography. Rauha JP, et al. **J Pharm Biomed Anal** 1996 Nov;15(2):287–93

[Determination of genkwanin in flos Genkwa by HPLC] Zhang B, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Apr; 21(4):237, 253, 256 (Eng. Abstr.) **(Chi)**

[Experimental studies on the quality control of xiaoluo pills] Zhen H, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Apr; 21(4):222–5, 255–6 (Eng. Abstr.) **(Chi)**

BLOOD

High-performance liquid chromatographic determination of levodropropizine in human plasma with fluorometric detection. Tagliaro F, et al. **J Chromatogr B Biomed Appl** 1996 Oct 11;685(1):165–70

Automated determination of dextromethorphan and its main metabolites in human plasma by high-performance liquid chromatography and column switching. Härtter S, et al. **Ther Drug Monit** 1996 Jun;18(3):297–303

ISOLATION & PURIFICATION

Analysis and identification of zipeprol and its metabolites during drug abuse screening. Athanaselis S, et al. **J Anal Toxicol** 1996 Nov–Dec;20(7):564–7

[Isolation and structure flucidation of alkaloids from the bulb of Fritillaria Wabuensis S.Y. Tang et S.C. Yueh] Wang H, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1996 Mar; 27(1):100–5 (Eng. Abstr.) **(Chi)**

METABOLISM

Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Schmider J, et al. **Biopharm Drug Dispos** 1997 Apr; 18(3):227–40

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Jones DR, et al. **Clin Pharmacol Ther** 1996 Oct;60(4):374–84

Metabolism of dextromethorphan in human liver microsomes: a rapid HPCL assay to monitor cytochrome P450 2D6 activity. Vielnascher E, et al. **Pharmazie** 1996 Aug; 51(8):586–8

PHARMACOKINETICS

Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population. Nagai N, et al. **Biopharm Drug Dispos** 1996 Jul;17(5):421–33

The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Capon DA, et al. **Clin Pharmacol Ther** 1996 Sep;60(3):295–307

Stereoselective pharmacokinetics of moguisteine metabolites in healthy subjects. Bernareggi A, et al. **Eur J Drug Metab Pharmacokinet** 1995 Oct–Dec; 20(4):263–70

Relative bioavailability of different butamirate citrate preparations after single dose oral administration to 18 healthy volunteers. Bohner H, et al. **Int J Clin Pharmacol Ther** 1997 Mar;35(3):117–22

Lack of pharmacokinetic interaction between dextromethorphan, coumarin and mephenytoin in man after simultaneous administration. Endres HG, et al. **Pharmazie** 1996 Jan;51(1):46–51

Effect of activated charcoal on the pharmacokinetics of pholcodine, with special reference to delayed charcoal ingestion. Laine K, et al. **Ther Drug Monit** 1997 Feb; 19(1):46–50

PHARMACOLOGY

Antitussive effect of herbal medicine bakumondo-to: a case report. Mizushima Y, et al. **Am J Chin Med** 1996; 24(3–4):321–5

Pharmacological profile of dextrorphan. Fossati A, et al. **Arzneimittelforschung** 1995 Nov;45(11):1188–93

Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl) methyl]. Ist communication: in vivo demonstration of the effects on animal models of cough and of mucociliary clearance. Mikus EG, et al. **Arzneimittelforschung** 1997 Apr;47(4):395–400

Possible involvement of ATP-dependent K-channel related mechanisms in the antihypertensive and cough suppressant effects of the novel ACE inhibitor (2S, 3aS, 7aS)-1-(N2-nicotinoyl-L-lysyl-gamma-D-glutamyl) octahydro-1H- indole-2-carboxylic acid. Nagata S, et al. **Arzneimittelforschung** 1997 Jun;47(6):726–30

Central antitussive activity of the NK1 and NK2 tachykinin receptor antagonists, CP-99,994 and SR 48968, in the guinea-pig and cat. Bolser DC, et al. **Br J Pharmacol** 1997 May;121(2):165–70

Effects of levodropropizine on vagal afferent C-fibres in the cat. Shams H, et al. **Br J Pharmacol** 1996 Mar;117(5):853–8

Inhibition of glycine currents by dextromethorphan in neurones dissociated from the guinea-pig nucleus tractus solitarii. Takahama K, et al. **Br J Pharmacol** 1997 Feb; 120(4):690–4

Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Mikus G, et al. **Clin Pharmacol Ther** 1997 Apr;61(4):459–66

The nonnarcotic antitussive drug dimemorfan: a review. Ida H. **Clin Ther** 1997 Mar–Apr;19(2):215–31 (26 ref.)

Zipeprol: preclinical assessment of abuse potential. Acteo MD, et al. **Drug Alcohol Depend** 1996 Oct;42(2):93–104

Antitussive effect of moguisteine on the enhanced coughing associated with enalapril in guinea-pig. Kamei J, et al. **Eur J Pharmacol** 1996 Sep 26;312(2):235–9

Dextromethorphan affects ventilation differently in male and female rats. Schlenker EH. **J Appl Physiol** 1996 Nov; 81(5):1911–6

Studies on antitussive activity of Drymaria cordata Willd. (Caryophyllaceae). Mukherjee PK, et al. **J Ethnopharmacol** 1997 Mar;56(1):77–80

Effects of methylnaltrexone on morphine-induced cough suppression in guinea pigs. Foss JF, et al. **Life Sci** 1996; 59(15):PL235–8

Dextromethorphan potentiates morphine antinociception, but does not reverse tolerance in rats. Hoffmann O, et al. **Neuroreport** 1996 Feb 29;7(3):838–40

Actions of moguisteine on cough and pulmonary rapidly adapting receptor activity in the guinea pig. Morikawa T, et al. **Pharmacol Res** 1997 Feb;35(2):113–8

Tachykinin receptor antagonists and cough. Advenier C, et al. **Pulm Pharmacol** 1996 Oct-Dec;9(5-6):329–33

Mechanisms of action of central and peripheral antitussive drugs. Bolser DC. **Pulm Pharmacol** 1996 Oct–Dec; 9(5–6):357–64 (78 ref.)

Role of opioidergic and serotonergic mechanisms in cough and antitussives. Kamei J. **Pulm Pharmacol** 1996 Oct–Dec; 9(5–6):349–56 (67 ref.)

Inhalation cough challenge in the investigation of the cough reflex and antitussives. Morice AH. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):281–4 (25 ref.)

[Antitussive, expectorant and anti-inflammatory effects of rhizoma Cynanchi stauntonii] Liang A, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Mar;21(3):173–5, 191–2 (Eng. Abstr.) **(Chi)**

POISONING

Dystonic reaction associated with dextromethorphan ingestion in a toddler. Warden CR, et al. **Pediatr Emerg Care** 1997 Jun;13(3):214–5

THERAPEUTIC USE

Dextrorphan, but not dextromethorphan, exerts weak antidystonic effects in mutant dystonic hamsters. Richter A, et al. **Brain Res** 1997 Jan 16;745(1–2):336–8

Antitussive effect of the GABA-agonist baclofen. Dicpinigaitis PV, et al. **Chest** 1997 Apr;111(4):996–9

The nonnarcotic antitussive drug dimemorfan: a review. Ida H. **Clin Ther** 1997 Mar–Apr;19(2):215–31 (26 ref.)

Differential effect of codeine on coughs caused by mechanical stimulation of two different sites in the airway of guinea pigs. Takahama K, et al. **Eur J Pharmacol** 1997 Jun 18;329(1):93–7

Oral doxophylline in patients with chronic obstructive pulmonary disease. Villani F, et al. **Int J Clin Pharmacol Ther** 1997 Mar;35(3):107–11

Studies on in vivo antitussive activity of Leucas lavandulaefolia using a cough model induced by sulfur dioxide gas in mice. Saha K, et al. **J Ethnopharmacol** 1997 Jul;57(2):89–92

Antitussive activity of moguisteine enantiomers in guinea-pigs and rats. Gallico L, et al. **J Pharm Pharmacol** 1996 Jan;48(1):112–4

Dextromethorphan-induced manic symptoms in a bipolar patient on lithium [letter; comment] Bostwick JM. **Psychosomatics** 1996 Nov–Dec;37(6):571–3. Comment on: Psychosomatics 1996 Jan–Feb;37(1):71–4.

Methods of assessing cough and antitussives in man. Chung KF. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):373–7 (44 ref.)

Codeine, cough and upper respiratory infection. Eccles R. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):293–7 (17 ref.)

Evaluation of antitussive agents in man. Parvez L, et al. **Pulm Pharmacol** 1996 Oct–Dec;9(5–6):299–308

[Controlled clinical study of doxophylline versus aminophylline in the treatment of acute cardiorespiratory insufficiency syndromes] Checchini M, et al. **Minerva Cardioangiol** 1997 Apr;45(4):185–90 (Eng. Abstr.) **(Ita)**

[A case of postinfectious chronic cough improved with bakumondo-to not with antihistamine and dextromethorphan hydrobromide] Fujimori K, et al. **Arerugi** 1995 Dec;44(12):1418–21 **(Jpn)**

TOXICITY

Comparative toxicology of two enantiomers of the peripherally acting non-narcotic antitussive drug moguisteine. Cavalletti E, et al. **Arzneimittelforschung** 1996 Dec;46(12):1114–9

ANTI-ULCER AGENTS

see related

HISTAMINE H2 ANTAGONISTS

Cisapride. Mangal N, et al. **Indian Pediatr** 1995 Oct; 32(10):1124–6 (9 ref.)

Effect of sucralfate on gastric intramucosal pH in critically ill patients. Calvet X, et al. **Intensive Care Med** 1997 Jul; 23(7):738–42

Hepatocyte growth factor as a key to modulate anti-ulcer action of prostaglandins in stomach. Takahashi M, et al. **J Clin Invest** 1996 Dec 1;98(11):2604–11

Physiology of gastric acid secretion [letter; comment] Zermansky A. **Lancet** 1997 Aug 9;350(9075):447. Comment on: Lancet 1997 Jun 7;349(9066):1637–8.

[Cell biology in gastric-acid secretion—drug design] Okabe S, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):113–5 (0 ref.) **(Jpn)**

[Crystal forms, improvements of dissolution and absorption of poorly water-soluble (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1, 4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022)] Yano K, et al. **Yakugaku Zasshi** 1996 Aug;116(8):639–46 (Eng. Abstr.) **(Jpn)**

[A powerful story. A TV documentary on Losec] Werkö L. **Lakartidningen** 1997 Jan 29;94(5):348–9 **(Swe)**

ADMINISTRATION & DOSAGE

Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis—a randomized single-blind comparative study. Ardizzone S, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):957–60

Enhanced eradication of Helicobacter pylori by pre- versus post-prandial amoxycillin suspension with omeprazole: implications for antibiotic delivery. Atherton JC, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):631-5

Factors affecting dose selection and outcome of cisapride treatment for dyspepsia in primary care. The Austro-Cis Study Group. Brunner H. **Aliment Pharmacol Ther** 1996 Aug;10(4):587-94

One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. de Boer WA, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):109-12

Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Hatlebakk JG, et al. **Aliment Pharmacol Ther** 1997 Apr; 11(2):365-72

Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease? [see comments] Hendel J, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):693-7. Comment in: Aliment Pharmacol Ther 1996 Jun;10(3):447-8.

One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. Labenz J, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):89-93

Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. Labenz J, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):95-100

Ranitidine 300 mg twice daily and 150 mg four-times daily are effective in healing erosive oesophagitis. Silver MT, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):373-80

A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Termanini B, et al. **Aliment Pharmacol Ther** 1996 Feb;10(1):61-71

A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. Vautier G, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):107-8

Nasogastric omeprazole: effects on gastric pH in critically Ill patients. Balaban DH, et al. **Am J Gastroenterol** 1997 Jan;92(1):79-83

Proton pump inhibitors and the urea breath test: how long is long enough? [letter; comment] Chey WD. **Am J Gastroenterol** 1997 Apr;92(4):720-1. Comment on: Am J Gastroenterol 1996 Oct;91(10):2120-4.

Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy. Kung NN, et al. **Am J Gastroenterol** 1997 Mar;92(3):438-41

Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus [see comments] Sharma P, et al. **Am J Gastroenterol** 1997 Apr;92(4):582-5. Comment in: Am J Gastroenterol 1997 Apr;92(4):556-8.

Nonencapsulated, intact omeprazole granules effectively suppress intragastric acidity when administered via a gastrostomy. Sharma VK, et al. **Am J Gastroenterol** 1997 May;92(5):848-51

H. pylori treatment recognized by FDA [news] **Am J Health Syst Pharm** 1996 Jun 1;53(11):1229

Which proton pump inhibitor should we use? Williams CN. **Can J Gastroenterol** 1997 Jan-Feb;11(1):29

Helicobacter pylori: new developments and treatments. Veldhuyzen van Zanten SJ, et al. **Can Med Assoc J** 1997 Jun 1;156(11):1565-74 (112 ref.)

Omeprazole plus amoxicillin versus triple therapy eradicates Helicobacter pylori in the Chinese with peptic ulcer disease. Wang K, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Mar; 57(3):184-90

A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Phillips JO, et al. **Crit Care Med** 1996 Nov;24(11):1793-800

Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer. Brummer RJ, et al. **Dig Dis Sci** 1996 Oct;41(10):2048-54

Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients. Tari A, et al. **Dig Dis Sci** 1997 Aug;42(8):1741-6

Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Markham A, et al. **Drugs** 1996 Jan; 51(1):161-78 (67 ref.)

Eradication of Helicobacter pylori in peptic ulcer disease with amoxycillin, 2.0 g, and omeprazole, 80 or 120 mg: a prospective randomized trial. Fleischmann R, et al. **Eur J Gastroenterol Hepatol** 1997 Jun;9(6):593-8

Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Koop H, et al. **Eur J Gastroenterol Hepatol** 1996 Sep;8(9):915-8

Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Yamada M, et al. **Eur J Pediatr** 1997 Mar;156(3):182-5

Prescribing nonsteroidal anti-inflammatory drugs together with antisecretory agents is safe but may be useless [editorial; comment] Guarner F. **Gastroenterology** 1996 Oct;111(4):1145-6. Comment on: Gastroenterology 1996 Oct;111(4):990-5.

Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats [see comments] Lichtenberger LM, et al. **Gastroenterology** 1996 Oct;111(4):990-5. Comment in: Gastroenterology 1996 Oct;111(4):1145-7.

Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. Labenz J, et al. **Gut** 1997 Jan;40(1):36-41

Effect of gastric mucosal protection in nonrheumatoid patients with short-term nonsteroidal anti-inflammatory drug therapy: a prospective randomized multicenter study. Miller K. **Hepatogastroenterology** 1997 May-Jun; 44(15):872-9

Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial. Svoboda P, et al. **Hepatogastroenterology** 1997 May-Jun;44(15):886-90

Concurrent use of antiulcerative agents. Monette J, et al. **J Clin Gastroenterol** 1997 Jun;24(4):207-13

One-week therapy for Helicobacter pylori. A randomized trial of two treatment regimens. Scheiman JM, et al. **J Clin Gastroenterol** 1996 Oct;23(3):170-3

Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease. Thomson AB, et al. **J Gastroenterol Hepatol** 1996 Dec;11(12):1171-6

"Infantile colic" as the sole manifestation of gastroesophageal reflux. Berkowitz D, et al. **J Pediatr Gastroenterol Nutr** 1997 Feb;24(2):231-3

Epigastric pain unrelieved by omeprazole. Weber L. **J Tenn Med Assoc** 1996 Mar;89(3):84-5

Triple therapy in duodenal ulcer healing--a follow up study. Qureshi H, et al. **JPMA J Pak Med Assoc** 1996 Sep; 46(9):194-5

Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study [see comments] Hasselgren G, et al. **Scand J Gastroenterol** 1997 Apr; 32(4):328-33. Comment in: Scand J Gastroenterol 1997 Apr;32(4):396-8.

Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Venables TL, et al. **Scand J Gastroenterol** 1997 Jul;32(7):627-32

[Dyspepsia in general practice. A study among users of anti-ulcer agents] Ahnfeldt-Mollerup I, et al. **Ugeskr Laeger** 1997 Jun 9;159(24):3772-6 (Eng. Abstr.) **(Dan)**

[Helicobacter pylori eradication: triple therapy versus dual therapy] Dammann HG. **Fortschr Med** 1996 Feb 10; 114(4):34-8 (34 ref.) (Eng. Abstr.) **(Ger)**

[Anti-Helicobacter pylori therapy. Who should be treated, how, how long?] Lux G. **Fortschr Med** 1996 Aug 20; 114(22-23):273-5 **(Ger)**

[Triple ranitidine therapy in Helicobacter pylori infection. Recommendation for effective, safe and cost effective combination for Helicobacter pylori eradication] Miederer S. **Fortschr Med** 1996 Nov 30;114(33):460-2 (Eng. Abstr.) **(Ger)**

[Good results with Helicobacter pylori eradication for treatment of non-ulcer dyspepsia (letter)] Bock H, et al. **Leber Magen Darm** 1996 Sep;26(5):268 **(Ger)**

[Helicobacter pylori eradication therapy with bismuth citrate/amoxycillin combination therapy] Stanescu A, et al. **Leber Magen Darm** 1996 Jan;26(1):32-6 (Eng. Abstr.) **(Ger)**

[Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease] Kobler E, et al. **Schweiz Med Wochenschr Suppl** 1997;89:14S-16S (Eng. Abstr.) **(Ger)**

[Maintenance therapy in reflux esophagitis] Katsoulis S, et al. **Z Gastroenterol** 1997 Feb;35(2):159-61 **(Ger)**

[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment] Tokushima H, et al. **Nippon Jinzo Gakkai Shi** 1996 Aug;38(8):349-55 (Eng. Abstr.) **(Jpn)**

[Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion] Inatomi N, et al. **Nippon Yakurigaku Zasshi** 1996 Dec;108(6):333-43 (Eng. Abstr.) **(Jpn)**

[Effects of histamine H2-receptor blockers and dalargin on reparative processes gastroduodenal mucosa in patients with duodenal ulcer] Alekseenko SA, et al. **Klin Med (Mosk)** 1996;74(9):52-4 (Eng. Abstr.) **(Rus)**

[The dynamic cytochemical properties of the protective barrier of the stomach during dalargin administration] Mogil'naia GM, et al. **Morfologiia** 1996;109(3):72-5 (Eng. Abstr.) **(Rus)**

[One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer] Gisbert JP, et al. **Med Clin (Barc)** 1997 Apr 12;108(14):524-9 (Eng. Abstr.) **(Spa)**

[The efficacy of using a short course of 6-day duration (OCA-6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin (letter)] Rodrigo Sáez L, et al. **Rev Esp Enferm Dig** 1997 Feb; 89(2):146-7 **(Spa)**

[Eradication of Helicobacter pylori in patients with recurrent abdominal pain using a triple drug treatment] Ramírez Mayans J, et al. **Rev Gastroenterol Mex** 1996 Oct-Dec; 61(4):310-3 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Severe nontyphoidal salmonellosis probably in relation with omeprazole treatment: report of 2 cases. Schapira M, et al. **Acta Gastroenterol Belg** 1996 Apr-Jun;59(2):168-9

The effect of long-term omeprazole on the glucose-hydrogen breath test in elderly patients. Hutchinson S, et al. **Age Ageing** 1997 Mar;26(2):87-9

The safety of ranitidine in over a decade of use. Mills JG, et al. **Aliment Pharmacol Ther** 1997 Feb;11(1):129-37 (58 ref.)

Cutaneous delayed reaction to ranitidine. Gonzalo-Garijo MA, et al. **Allergy** 1996 Sep;51(9):659-60

Diffuse alopecia associated with omeprazole [letter] Borum ML, et al. **Am J Gastroenterol** 1997 Sep;92(9):1576

Leukocytoclastic vasculitis associated with nizatidine therapy. Suh JG, et al. **Am J Med** 1997 Feb;102(2):216-7

Gait ataxia during omeprazole therapy [letter] Varona L, et al. **Ann Pharmacother** 1996 Feb;30(2):192

Ocular damage associated with proton pump inhibitors. Schönhöfer PS, et al. **BMJ** 1997 Jun 21;314(7097):1805

The risk of acute liver injury associated with cimetidine and other acid-suppressing anti-ulcer drugs. García Rodríguez LA, et al. **Br J Clin Pharmacol** 1997 Feb;43(2):183-8

A cohort study of the ocular safety of anti-ulcer drugs [see comments] García Rodríguez LA, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):213-6. Comment in: Br J Clin Pharmacol 1997 Apr;43(4):449.

Omeprazole, other antiulcer drugs and newly diagnosed gout [see comments] Meier CR, et al. **Br J Clin Pharmacol** 1997 Aug;44(2):175-8. Comment in: Br J Clin Pharmacol 1997 Aug;44(2):109-10.

Ocular safety of anti-ulcer drugs [letter; comment] Merlo J, et al. **Br J Clin Pharmacol** 1997 Apr;43(4):449. Comment on: Br J Clin Pharmacol 1996 Aug;42(2):213-6.

Pityriasis rosea-like eruption in a patient receiving omeprazole [letter] Buckley C. **Br J Dermatol** 1996 Oct; 135(4):660-1

Erythema nodosum caused by omeprazole. Ricci RM, et al. **Cutis** 1996 Jun;57(6):434

Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Garcia Rodríguez LA, et al. **Epidemiology** 1997 Sep;8(5):571-4

Confounding by indication and past clinical trials [letter; comment] Porta M. **Epidemiology** 1997 Mar;8(2):219-20. Comment on: Epidemiology 1996 Jul;7(4):335-6.

A comparison of two cohort studies evaluating the safety of cisapride: Prescription-Event Monitoring and a large phase IV study. Wager E, et al. **Eur J Clin Pharmacol** 1997; 52(2):87-94

Misoprostol-associated platelet aggregation dysfunction and increased gastrointestinal blood loss. Beales IL, et al. **Eur J Gastroenterol Hepatol** 1997 Jan;9(1):91-2

Reflux oesophagitis and acid exposure [letter; comment] Ransford R. **Gut** 1996 Dec;39(96):889. Comment on: Gut 1996 May;38(5):649-54.

Clostridium difficile and sucralfate [letter] Jensen G, et al. **Infect Control Hosp Epidemiol** 1996 Nov;17(11):712-3

Henoch-Schonlein purpura associated with ranitidine. Prajapati C, et al. **Int J Clin Pract** 1997 Jun;51(4):251

Generalized exanthematous pustulosis induced by medications. Sawhney RA, et al. **Int J Dermatol** 1996 Nov; 35(11):826-7

Quality problems that result in adverse outcomes provide opportunities for quality improvement. **Int J Qual Health Care** 1996 Dec;8(6):597-8

Esophageal obstruction by solidification of the enteral feed: a complication to be prevented. García-Luna PP, et al. **Intensive Care Med** 1997 Jul;23(7):790-2

Proton-pump inhibition and gastric giardiasis: a causal or casual association? Reynaert H, et al. **J Gastroenterol** 1995 Dec;30(6):775-8

An acute dystonic reaction with long-term use of ranitidine in an intensive care unit patient. Wilson LB, et al. **J La State Med Soc** 1997 Jan;149(1):36-8

Cisapride-induced long QT interval: what is the role of ranitidine? [letter; comment] Gunasekaran TS, et al. **J Pediatr** 1997 Apr;130(4):679-80. Comment on: J Pediatr 1996 Feb;128(2):279-81.

A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. García Rodríguez LA, et al. **Pharmacotherapy** 1997 Jul-Aug;17(4):721-8

Omeprazole-induced acute interstitial nephritis. d'Adamo G, et al. **Ren Fail** 1997 Jan;19(1):171-5

Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa. Arroyo Villarino MT, et al. **Rev Esp Enferm Dig** 1997 May; 89(5):347-56 **(Eng, Spa)**

Side effects of omeprazole [letter; comment] Markitziu A, et al. **Scand J Gastroenterol** 1996 Jun;31(6):624. Comment on: Scand J Gastroenterol 1995 Mar;30(3):216-8.

Lobular carcinoma of the male breast associated with the use of cimetidine. San Miguel P, et al. **Virchows Arch** 1997 Mar;430(3):261-3 (26 ref.)

[Long QT syndrome under cisapride in neonates and infants] Lupoglazoff JM, et al. **Arch Pediatr** 1997 Jun;4(6):509-14 (Eng. Abstr.) **(Fre)**

[Esophageal bezoar in a child treated with sucralfate] Razafimahefa H, et al. **Arch Pediatr** 1997 Jul;4(7):659-61 (Eng. Abstr.) **(Fre)**

[Syncope with long QT interval in a 39 day-old infant treated with cisapride] Valdes L, et al. **Arch Pediatr** 1997 Jun;

4(6):535-7 (Eng. Abstr.) **(Fre)**

[Toxic megacolon after Helicobacter pylori eradication therapy] Schweigart U, et al. **Internist (Berl)** 1997 Apr; 38(4):352-4 **(Ger)**

[Ulcer drugs: profile of side effects of proton-pump blockers in comparison to H2 blockers in the spontaneous reporting system] Hartmann K, et al. **Schweiz Med Wochenschr** 1996 Dec 7;126(49):2114-8 (Eng. Abstr.) **(Ger)**

[A case of hemolysis induced by lansoprazole] Suzuki T, et al. **Rinsho Ketsueki** 1996 Dec;37(12):1389-94 (Eng. Abstr.) **(Jpn)**

[Hemolytic anemia and thrombocytopenia induced by cimetidine: recurrence with ranitidine administration] Takimoto R, et al. **Rinsho Ketsueki** 1997 Feb;38(2):124-8 (Eng. Abstr.) **(Jpn)**

[Lansoprazole-induced hepatitis (letter)] Viana de Miguel C, et al. **Med Clin (Barc)** 1997 Apr 19;108(15):599 **(Spa)**

[Hepatic encephalopathy related to omeprazole (letter)] del Río Fernández M, et al. **Rev Esp Enferm Dig** 1997 Jul; 89(7):574-5 **(Spa)**

ANALYSIS

Use of post-column fluorescence derivatization to develop a liquid chromatographic assay for ranitidine and its metabolites in biological fluids. Viñas P, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):443-9

Estimation of impurity profiles of drugs and related materials Part 15. Identification of minor impurities in cimetidine. Halmos Z, et al. **J Pharm Biomed Anal** 1996 Oct;15(1):1-5

Detection and tissue distribution of anti-ulcer pectic polysaccharides from Bupleurum falcatum by polyclonal antibody. Sakurai MH, et al. **Planta Med** 1996 Aug; 62(4):341-6

BLOOD

Solid-phase extraction and determination of ranitidine in human plasma by a high-performance liquid chromatographic method utilizing midbore chromatography. Farthing D, et al. **J Chromatogr B Biomed Appl** 1997 Jan 24;688(2):350-3

Simple and robust high-performance liquid chromatographic method for the determination of ranitidine in microvolumes of human serum. López-Calull C, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):228-32

High-performance thin-layer chromatographic method for the detection and determination of lansoprazole in human plasma and its use in pharmacokinetic studies. Pandya KK, et al. **J Chromatogr B Biomed Appl** 1997 May 23; 693(1):199-204

Enantioselective high-performance liquid chromatographic assay for determination of the enantiomers of a new anti-ulcer agent, E3810, in beagle dog plasma and rat plasma. Takakuwa S, et al. **J Chromatogr B Biomed Appl** 1995 Nov 3;673(1):113-22

Plasma direct injection high-performance liquid chromatographic method for simultaneously determining E3810 enantiomers and their metabolites by using flavoprotein-conjugated column. Mano N, et al. **J Pharm Sci** 1996 Sep;85(9):903-7

Determination of a new antiulcer agent, YJA-20379-2, in human plasma and urine by high-performance liquid chromatography. Yoon WH, et al. **Res Commun Mol Pathol Pharmacol** 1996 Dec;94(3):317-22

CHEMICAL SYNTHESIS

Efficient and beta-stereoselective synthesis of 4(5)-methyl-5(4)-(5-amino-5-deoxy-beta-D-ribofuranosyl)imidazole and related compounds exhibiting antiulcer activity. Harusawa S, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan;45(1):53-61

Synthesis and cytoprotective antiulcer activity of 2- or 4-(1H-pyrazol-1-yl)pyrimidine derivatives related to mepirizole and dulcerozine. Ikeda M, et al. **Chem Pharm Bull (Tokyo)** 1996 Sep;44(9):1700-6

Synthesis and biological evaluation of a new reversely linked type of dual histamine H2 and gastrin receptor antagonist. Kawanishi Y, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan; 45(1):116-24

Quinoxaline chemistry. Part 6--Synthesis and evaluation of antiulcer and gastroprotective activity of 2-[arylmethylmercapto-, arylmethylsulfinyl-, piperazinyl-3-R-substituted]quinoxalines. Piras S, et al. **Farmaco** 1996 Aug-Sep;51(8-9):569-77

Synthesis, gastroprotective, antisecretory and anti-Helicobacter effect of N-[3-(3-(1-piperidinylmethyl) phenoxy)propyl]-hydroxyacetamide 2-hydroxypropane-1,2,3-tricarboxylate bismuth (3+) complex (MX1)-MX1. Ivanov C, et al. **J Pharm Pharmacol** 1996 Mar;48(3):297-301

[Synthesis of stable solvates of monosodium 2-[R*s,9S*)-(4-methoxy-6,7,8, 9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)sulfinyl]-1H-benzimidazole] Yamada S, et al. **Yakugaku Zasshi** 1996 Aug;116(8):657-70 (Eng. Abstr.) **(Jpn)**

[Synthesis of triterpene 2-deoxy-alpha-D-hexopyranosides on the basis of glycals and their effect on reparative processes] Baltina LA, et al. **Bioorg Khim** 1997 Jun; 23(6):512-8 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Stability of ranitidine hydrochloride in water for injection in glass vials and plastic syringes. Nahata MC, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1588-90

Stability of omeprazole in an extemporaneously prepared oral liquid. Quercia RA, et al. **Am J Health Syst Pharm** 1997 Aug 15;54(16):1833-6

Computer design and syntheses of antiulcer compounds. 1st communication: N-[3-[3-(1-piperidinomethyl)phenoxy]propyl]amines and benzamides. Kamenska V, et al. **Arzneimittelforschung** 1996 Nov;46(11):1090-5

Computer design and syntheses of antiulcer compounds. 2nd Communication: N-substituted N'-[3-[3-(1-piperidinomethyl)phenoxy]propyl]ureas. Kamenska V, et al. **Arzneimittelforschung** 1996 Dec; 46(12):1144-8

Structure-cytoprotective activity relationship of simple molecules containing an alpha,beta-unsaturated carbonyl system. Rodríguez AM, et al. **J Med Chem** 1997 Jun 6; 40(12):1827-34

CONTRAINDICATIONS

[Long-term inhibition of gastric acid secretion. Evaluation and healing of Helicobacter pylori infection? (editorial)] Labenz J, et al. **Leber Magen Darm** 1996 Sep;26(5):241-2 **(Ger)**

ECONOMICS

Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Harris RA, et al. **Am J Med** 1997 Jan; 102(1):78-88

Cost of acid peptic disorders in a managed-care organization. Segal R, et al. **Clin Ther** 1996 Mar-Apr;18(2):319-33; discussion 302

Concurrent use of antiulcerative agents. Monette J, et al. **J Clin Gastroenterol** 1997 Jun;24(4):207-13

Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands. Van Den Boom G, et al. **Scand J Gastroenterol** 1996 Jan;31(1):1-9

ISOLATION & PURIFICATION

Chiral resolution of pantoprazole sodium and related sulfoxides by complex formation with bovine serum albumin in capillary electrophoresis. Eberle D, et al. **J Chromatogr A** 1997 Jan 24;759(1-2):185-92

METABOLISM

Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. Zomorodi K, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):157-62

Identification of major biliary and urinary metabolites of ecabapide in rats. Nakaoka M, et al. **Xenobiotica** 1996 Sep; 26(9):983-94

[Enzyme kinetic studies on the in vitro metabolism of omeprazole by Chinese human liver microsomes] Zhao L, et al. **Yao Hsueh Hsueh Pao** 1996;31(5):352-7 (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Bell NJ, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):897-904

Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects. Pommerien W, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):295-301

Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. Naito Y, et al. **Arzneimittelforschung** 1996 Jul; 46(7):698-700

Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine. Shyu WC, et al. **Br J Clin Pharmacol** 1996 Oct;42(4):513-7

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Andersson T. **Clin Pharmacokinet** 1996 Jul; 31(1):9-28 (170 ref.)

Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. James LP, et al. **Clin Pharmacokinet** 1996 Aug;31(2):103-10 (21 ref.)

Pharmacokinetics and absolute bioavailability of lansoprazole. Gerloff J, et al. **Eur J Clin Pharmacol** 1996; 50(4):293-7

Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Katsuki H, et al. **Eur J Clin Pharmacol** 1997;52(5):391-6

Higher AUCs on oral administration of omeprazole and felodipine in Indian volunteers--are they clinically important? Joseph T, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):253-6

Pharmacokinetics of pantoprazole in man. Huber R, et al. **Int J Clin Pharmacol Ther** 1996 May;34(5):185-94

Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. Tanaka M, et al. **Int J Clin Pharmacol Ther** 1996 Oct;34(10):415-9

The effects of oral doses of lansoprazole and omeprazole on gastric pH. Tolman KG, et al. **J Clin Gastroenterol** 1997 Mar;24(2):65-70

Evaluation of sex differences in the pharmacokinetics of ranitidine in humans. Abad-Santos F, et al. **J Clin Pharmacol** 1996 Aug;36(8):748-51

Hepatic and cerebrospinal fluid accumulation of aluminium and bismuth in volunteers taking short course anti-ulcer therapy. Gane E, et al. **J Gastroenterol Hepatol** 1996 Oct; 11(10):911-5

Effect of salicylic acid on the plasma protein binding and pharmacokinetics of misoprostol acid. Cook CS, et al. **J Pharm Sci** 1994 Jun;83(6):883-6

Determination of analytical form of system weighting function. Durisová M, et al. **Methods Find Exp Clin Pharmacol** 1996 Jul-Aug; 18(6):407-12

Applications and simulations of a discontinuous oral absorption pharmacokinetic model. Witcher JW, et al. **Pharm Res** 1996 Nov;13(11):1720-4

Current status of acid pump antagonists (reversible PPIs). Wurst W, et al. **Yale J Biol Med** 1996 May-Jun; 69(3):233-43

PHARMACOLOGY

The effect of cimetidine versus ranitidine on the gastric emptying rate of intensive care unit patients sustained on artificial respiration. Pelfrene E, et al. **Acta Gastroenterol Belg** 1996 Oct-Dec;59(4):229-33

Effect of inhibition of pentagastrin-stimulated acid secretion on gastric mucosal gland luminal pressure. Synnerstad I, et al. **Acta Physiol Scand** 1997 May;160(1):103-11

Effect of the oral anti-ulcer agent, cimetidine, on HIV type 1 replication [letter] Bourinbaiar AS, et al. **AIDS Res Hum Retroviruses** 1997 Mar 1;13(4):281-2

In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity. Arnestad JS, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):355-8

Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Bell NJ, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):897-904

The role of acid in the pathogenesis of indomethacin-induced gastric antral ulcers in the rat. Clayton NM, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):339-45

The effect of omeprazole on gastric juice viscosity, pH and bacterial counts [see comments] Goddard AF, et al. **Aliment Pharmacol Ther** 1996 Feb;10(1):105-9. Comment in: Aliment Pharmacol Ther 1996 Aug;10(4):669-70.

Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man. Grimley CE, et al. **Aliment Pharmacol Ther** 1996 Oct;10(5):743-7

Twenty-four-hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo. Houben GM, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):649-54

Suppressive effect of tetraprenylacetone on gastric atrophy induced by short-term administration of N-methyl-N'-nitro-N-nitrosoguanidine in rats. Miwa H, et al. **Aliment Pharmacol Ther** 1997 Jun;11(3):613-8

Indomethacin-induced morphological changes in the rat gastric mucosa, with or without prior treatment with two proton pump inhibitors. Morini G, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):615-23

Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects. Pommerien W, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):295-301

Low-dose famotidine and ranitidine as single post-prandial doses: a three-period placebo-controlled comparative trial. Reilly TG, et al. **Aliment Pharmacol Ther** 1996 Oct; 10(5):749-55

The effects of cisapride on the topography of oesophageal peristalsis. Staiano A, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):875-82

Prevention of water immersion stress-induced gastric lesions through the enhancement of nitric oxide synthase activity in rats. Tachi K, et al. **Aliment Pharmacol Ther** 1996 Feb; 10(1):97-103

Effects of rebamipide on bile acid-induced inhibition of gastric epithelial repair in a rabbit cell culture model. Watanabe S, et al. **Aliment Pharmacol Ther** 1996 Dec; 10(6):927-32

The effects of omeprazole and famotidine on mucin and PGE2 release in the rat stomach [see comments] Yoshimura K, et al. **Aliment Pharmacol Ther** 1996 Feb;10(1):111-7. Comment in: Aliment Pharmacol Ther 1996 Aug;10(4):669-70.

Preventive effect of oren-gedoku-to (huanglian-jie-du-tang) extract on progression of carbon tetrachloride-induced acute liver injury in rats. Ohta Y, et al. **Am J Chin Med** 1997;25(1):57-68

Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? Annibale B, et al. **Am J Gastroenterol** 1997 May;92(5):790-4

Minimum inhibitory concentration of various single agents and the effect of their combinations against Helicobacter pylori, as estimated by a fast and simple in vitro assay method. Bamba H, et al. **Am J Gastroenterol** 1997 Apr; 92(4):659-62

Lansoprazole and omeprazole in the treatment of acid peptic disorders [see comments] Blum RA.

Am J Health Syst Pharm 1996 Jun 15;53(12):1401–15 (174 ref.). Comment in: Am J Health Syst Pharm 1996 Dec 1;53(23):2882, 2884.

Hypoprothrombinemia induced by warfarin sodium and cisapride [letter] Raburn M. **Am J Health Syst Pharm** 1997 Feb 1;54(3):320–1

ME-3407, a new antiulcer agent, inhibits acid secretion by interfering with redistribution of H(+)-K(+)-ATPase. Urushidani T, et al. **Am J Physiol** 1997 May;272(5 Pt 1):G1122–34

Effect of omeprazole on sodium and potassium output in pentagastrin-stimulated equine gastric contents. Merritt AM, et al. **Am J Vet Res** 1996 Nov;57(11):1640–4

Lansoprazole: a proton pump inhibitor. Garnett WR. **Ann Pharmacother** 1996 Dec;30(12):1425–36 (108 ref.)

Potentiation of nephrotoxicity by H2-antagonists in patients receiving cyclosporine. Lewis SM, et al. **Ann Pharmacother** 1997 Mar;31(3):363–5 (20 ref.)

Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Jung H, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1256–9

In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions. Sjöström JE, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):621–6

Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Zix JA, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1668–72

Pharmacological characteristics of DQ-2511 as a prokinetic agent. Hatanaka S, et al. **Arch Int Pharmacodyn Ther** 1995 Nov-Dec;330(3):332–44

Enhancement of alcohol-induced hypoglycaemia by H2-receptor antagonists. Czyżyk A, et al. **Arzneimittelforschung** 1997 Jun;47(6):746–9

Anti-gastric acid secretory mechanism of 1,6-dihydro-2-[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidinecarboxylic acid. Effect on mucosal mast cell. Ishizuka Y, et al. **Arzneimittelforschung** 1996 Sep; 46(9):919–22

Effect of 1,6-dihydro-2[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidineca rboxyli c acid on ethanol-induced microvascular injury in rats. Ishizuka Y, et al. **Arzneimittelforschung** 1996 Aug;46(8):779–83

Effect of the histamine H2-receptor antagonist (+/-)-(E)-1-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3'-[2-[[[5-methylamino) methyl-2-furyl] methyl]thio]ethyl]-2"-(methylsulfonyl)guanidine on acute gastric mucosal injury in rats and its free-radical scavenging activities. Naito Y, et al. **Arzneimittelforschung** 1997 Jul;47(7):845–8

Gastroprotective properties of ebrotidine. A review. Slomiany BL, et al. **Arzneimittelforschung** 1997 Apr; 47(4A):459–67 (49 ref.)

Mixed antisecretory and gastroprotective activities of a new H2-antagonist containing a nitric oxide-donor furoxan moiety. Sorba G, et al. **Arzneimittelforschung** 1997 Jul; 47(7):849–54

Prostaglandin E2 derivative, enprostil, reduces hepatic triacylglycerol content in Japanese quail. Murai A, et al. **Biochem Mol Biol Int** 1996 May;39(2):329–34

Gastric mucosal apoptosis induced by ethanol: effect of antiulcer agents. Piotrowski J, et al. **Biochem Mol Biol Int** 1997 Jun;42(2):247–54

Helicobacter pylori lipopolysaccharide inhibition of gastric somatostatin receptor: effect of sucralfate. Piotrowski J, et al. **Biochem Mol Biol Int** 1997 Jul;42(3):545–51

Suppression of Helicobacter pylori urease activity by sucralfate and sulglycotide. Slomiany BL, et al. **Biochem Mol Biol Int** 1997 Jun;42(1):155–61

Pharmacological profiles of a new antiulcer agent, SWR-215. Kataoka H, et al. **Biol Pharm Bull** 1997 Jan;20(1):28–35

Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Dueñas-Gonzalez A, et al. **Bone Marrow Transplant** 1996 May;17(5):809–12

Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Tjandrawinata RR, et al. **Br J Cancer** 1997;75(8):1111–8

Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Gugler R, et al. **Br J Clin Pharmacol** 1996 Aug;42(2):249–52

Lack of inhibitory effect of cimetidine on caffeine metabolism in children using the caffeine breath test. Parker AC, et al. **Br J Clin Pharmacol** 1997 May;43(5):467–70

Comparison of the profiles of agonists as stimulants of the beta 3-adrenoceptor in vitro with their gastroprotective effects in the conscious rat. Bahl AK, et al. **Br J Pharmacol** 1996 Feb;117(3):580–586

Time-course of deactivation of rat stomach ECL cells following cholecystokinin B/gastrin receptor blockade. Ding XQ, et al. **Br J Pharmacol** 1997 Sep;122(1):1–6

A cyclic GMP-dependent housekeeping Cl- channel in rabbit gastric parietal cells activated by a vasodilator ecabapide. Sakai H, et al. **Br J Pharmacol** 1996 Dec; 119(8):1591–9

Effects of a xanthine derivative, propentofylline, on local cerebral blood flow and glucose utilization in the rat. Grome JJ, et al. **Brain Res** 1996 Nov 18;740(1-2):41–6

Amelioration of ischemic brain damage by the preischemic administration of propentofylline (HWA285) in a rat focal ischemia. Matsumoto K, et al. **Brain Res** 1996 Jun 3; 723(1-2):228–30

Gastric mucosal blood flow and gastric secretion following intravenous administration of 5-fluorouracil in anesthetized rats. Kakinuma S, et al. **Cancer Chemother Pharmacol** 1997; 39(4):357–60

Antiulcer effect of diltiazem in rats. Yong DG, et al. **Chung Kuo Yao Li Hsueh Pao** 1995 Nov;16(6):517–20

The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Sarich T, et al. **Clin Pharmacol Ther** 1997 Jul;62(1):21–8

Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Driman DK, et al. **Dig Dis Sci** 1996 Oct;41(10):2039–47

Possible mechanism of increase in gastric mucosal PGE2 and PGI2 generation induced by ecabet sodium, a novel gastroprotective agent. Kinoshita M, et al. **Dig Dis Sci** 1997 Jan;42(1):83–90

Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Murakami K, et al. **Dig Dis Sci** 1997 Feb;42(2):319–25

Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats: a model for cytoprotective studies. Sikirić P, et al. **Dig Dis Sci** 1997 May;42(5):1029–37

Sucralfate impedes intestinal epithelial sheet migration in a Caco-2 cell culture model. Emenaker NJ, et al. **Digestion** 1997;58(1):34–42

Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors. Masubuchi N, et al. **Drug Metab Dispos** 1997 May;25(5):584–9

NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus. Champion GD, et al. **Drugs** 1997 Jan;53(1):6–19 (112 ref.)

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders [published errata appear in Drugs 1996 Jun;51(6):1074 and 1996 Jul;52(1):92] Fitton A, et al. **Drugs** 1996 Mar;51(3):460–82 (132 ref.)

Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Langtry HD, et al. **Drugs** 1997 Sep;54(3):473–500 (205 ref.)

The effects of famotidine, ranitidine and magnesium hydroxide/aluminium hydroxide on gastric fluid pH in adult horses. Murray MJ, et al. **Equine Vet J Suppl** 1992 Feb;(11):52–5

Are intragastric N-nitroso compounds elevated after short-term acid suppression? Houben GM, et al. **Eur J Cancer Prev** 1996 Sep;5 Suppl 1:83–7

In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori. Alarcón T, et al. **Eur J Clin Microbiol Infect Dis** 1996 Dec;15(12):937–40

Statistical interpretation of the antisecretory effect of famotidine measured by intragastric pH-metry. Hunyady B, et al. **Eur J Clin Pharmacol** 1996;50(6):449–56

Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg. Florent C, et al. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):195–200

Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Meyer UA. **Eur J Gastroenterol Hepatol** 1996 Oct; 8 Suppl 1:S21–5

Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats. Kinoshita M, et al. **Eur J Pharmacol** 1997 Mar 5;321(3):325–32

Effect of pentacaine and its derivatives on the contractile responses of smooth muscle in the guinea-pig stomach. Mai MP, et al. **Eur J Pharmacol** 1996 Nov 21;315(3):305–12

Gastrointestinal motor activity in conscious ferrets. Nagakura Y, et al. **Eur J Pharmacol** 1997 Feb 19;321(1):53–7

Actions of Daiichi DQ-2511 on electrical and synaptic behavior of enteric neurons in the guinea-pig small intestine. Zafirov D, et al. **Eur J Pharmacol** 1996 Sep 5; 311(1):61–6

Propentofylline inhibits polymorphonuclear leukocyte recruitment in vivo by a mechanism involving adenosine A2A receptors. Zhang Y, et al. **Eur J Pharmacol** 1996 Oct 17;313(3):237–42

The effect of rebamipide on gastric xanthine oxidase activity and type conversion in ethanol-treated rats. Huh K, et al. **Free Radic Biol Med** 1996;20(7):967–71

Effect on gastric secretion, gastrin and histamine release during and after long-term treatment by pirenzepine in dogs. Vatier J, et al. **Fundam Clin Pharmacol** 1996; 10(2):144–50

Omeprazole induces high intraglandular pressure in the rat gastric mucosa. Synnerstad I, et al. **Gastroenterology** 1997 Apr;112(4):1221–30

Reversal of gastric somatostatin receptor inhibition by Helicobacter pylori lipopolysaccharide with ebrotidine and sulglycotide. Piotrowski J, et al. **Gen Pharmacol** 1997 May; 28(5):705–8

Reappraisal of bicarbonate secretion by the human oesophagus [see comments] Mertz-Nielsen A, et al. **Gut** 1997 May;40(5):582–6. Comment in: Gut 1997 May;40(5):693–4.

Gastroprotective effect of ranitidine bismuth citrate is associated with increased mucus bismuth concentration in rats. Tanaka S, et al. **Gut** 1996 Aug;39(2):164–71

The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes. Widomski D, et al. **Immunopharmacol Immunotoxicol** 1997 May;19(2):165–74

A study of the antiulcer mechanisms of propranolol in rats. Kaan SK, et al. **Inflamm Res** 1996 Aug;45(8):370–5

Effect of cimetidine on the pharmacokinetics of the metabolites of metamizol. Bacracheva N, et al. **Int J Clin Pharmacol Ther** 1997 Jul;35(7):275–81

Pantoprazole does not interact with nifedipine in man under steady-state conditions. Bliesath H, et al. **Int J Clin Pharmacol Ther** 1996 Feb;34(2):51–5

Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Bliesath H, et al. **Int J Clin Pharmacol Ther** 1996 May;34(1 Suppl):S76–80

Pantoprazole does not interact with nifedipine in man under steady-state conditions. Bliesath H, et al. **Int J Clin Pharmacol Ther** 1996 May;34(1 Suppl):S81–5

Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers. Koch HJ, et al. **Int J Clin Pharmacol Ther** 1996 Oct;34(10):420–3

Short-term sucralfate administration does not alter the absorption of metronidazole in healthy male volunteers. Moraes ME, et al. **Int J Clin Pharmacol Ther** 1996 Oct; 34(10):433–7

Effects of omeprazole and amoxycillin on the human oral and gastrointestinal microflora in patients with Helicobacter pylori infection. Stark CA, et al. **J Antimicrob Chemother** 1996 Dec;38(6):927–39

Effects of sucralfate on vacuolating cytotoxin activity and adherence of Helicobacter pylori to human gastric epithelial cells. Smoot DT, et al. **J Assoc Acad Minor Phys** 1996;7(4):88–92

Interaction of meloxicam with cimetidine, Maalox, or aspirin. Busch U, et al. **J Clin Pharmacol** 1996 Jan;36(1):79–84

Therapeutic effect of egualen sodium (KT1-32), a new antiulcer agent, on chronic gastritis induced by sodium taurocholate in rats. Mochizuki S, et al. **J Gastroenterol** 1996 Dec;31(6):785–92

Can misoprostol and omeprazole reduce nicotine and ethanol induced gastric mucosal injury? A quantitative macroscopic and microscopic analysis in rats. Hui WM, et al. **J Gastroenterol Hepatol** 1997 Jan;12(1):7–12

Increase in hepatic tissue blood flow by teprenone. Kurihara T, et al. **J Gastroenterol Hepatol** 1996 Oct;11(10):978–84

Antiulcer agents. 6. Analysis of the in vitro biochemical and in vivo gastric antisecretory activity of substituted imidazo[1,2-a]pyridines and related analogues using comparative molecular field analysis and hypothetical active site lattice methodologies. Kaminski JJ, et al. **J Med Chem** 1997 Feb 14;40(4):427–36

Synthesis, gastroprotective, antisecretory and anti-Helicobacter effect of N-[3-(3-(1-piperidinylmethyl) phenoxy)propyl]-hydroxyacetamide 2-hydroxypropane-1,2,3-tricarboxylate bismuth (3+) complex (MX1)-MX1. Ivanov C, et al. **J Pharm Pharmacol** 1996 Mar;48(3):297–301

The role of gastric mucosal sulphydryls in the ulcer-protecting effects of cisapride. López A, et al. **J Pharm Pharmacol** 1996 Jan;48(1):37–40

Preventive effect of rebamipide on gastric mucosal cell damage evoked by activation of formyl-methionyl-leucyl-phenylalanine receptors of rabbit neutrophils. Kim CD, et al. **J Pharmacol Exp Ther** 1997 Apr;281(1):478–83

Effect of cisapride and renzapride on gastrointestinal motility and plasma motilin concentration in dogs. Song CW, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1312–6

The cytoprotective effect of leminoprazole on indomethacin-induced damage to rabbit gastric mucosal cells. Takahashi S, et al. **J Pharmacol Exp Ther** 1996 Nov; 279(2):975–82

Effects of heat shock and teprenone on ethanol-induced damage to cultured rabbit gastric mucosal cells. Takahashi S, et al. **J Physiol Pharmacol** 1996 Sep;47(3):433–41

The effect of cimetidine on antipyrine metabolism in calves. Janus K, et al. **J Vet Pharmacol Ther** 1997 Feb;20(1):73–6

Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori. Shibata K, et al. **Jpn J Antibiot** 1997 Jun; 50(6):525–31

Possible mechanisms underlying the suppression of gastric vagal afferents due to ecabapide (DQ-2511), a gastroprokinetic agent, in rats. Hatanaka S, et al. **Jpn J Pharmacol** 1997 May;74(1):105–8

Differential effect of benexate hydrochloride betadex on prostaglandin levels in stomach and inflammatory site in rats. Hori Y, et al. **Jpn J Pharmacol** 1996 Oct;72(2):183–90

Intracisternal injection of basic fibroblast growth factor reduces the severity of gastric mucosal lesions evoked by ethanol in rats. Watanabe Y, et al. **Jpn J Physiol** 1997 Apr; 47(2):231–3

Effect of propentofylline on [3H]-leucine incorporation into protein of postischemic rat brain. Faberová V, et al. **Methods Find Exp Clin Pharmacol** 1996 Sep;18(7):449–52

Comparative evaluation of DQ-2511, a novel gastroprokinetic agent, with cisapride in ameliorative action on experimentally induced delayed gastric emptying.

Hatanaka S, et al. **Neurogastroenterol Motil** 1996 Sep; 8(3):227–33

The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Benedetti F. **Pain** 1996 Mar;64(3):535–43

Demonstration of sucralfate-mediated preservation of growth factor bioactivity in the presence of low pH with a human gastric epithelial cell line (AGS). Sheng H, et al. **Pharm Res** 1996 Jul;13(7):1122–6

Effects of rebamipide on gastric cell damage by Helicobacter pylori–stimulated human neutrophils. Han BG, et al. **Pharmacol Res** 1995 Oct;32(4):201–7

Effect of cholecystokinin-B/gastrin receptor blockade on gastric acid secretion in conscious rats. Ding XQ, et al. **Pharmacol Toxicol** 1996 Dec;79(6):324–30

Cholecystokinin-B/gastrin receptor blockade suppresses the activity of rat stomach ECL cells. Ding XQ, et al. **Pharmacol Toxicol** 1997 Jul;81(1):19–25

Evaluation of the specificity and potency of a series of cholecystokinin-B/gastrin receptor antagonists in vivo. Ding XQ, et al. **Pharmacol Toxicol** 1996 Sep;79(3):124–30

Leminoprazole protects cultured gastric mucosal cells against damage caused by ethanol, indometacin and taurocholate. Takahashi S, et al. **Pharmacology** 1997 Mar;54(3):118–26

Effects of sucralfate on acute gastric mucosal injury and gastric ulcer induced by ischemia–reperfusion in rats. Wada K, et al. **Pharmacology** 1997 Feb;54(2):57–63

Gastroprotective effect of malotilate in indomethacin– and ethanol–induced gastric mucosal damage. Mirossay L, et al. **Physiol Res** 1996;45(5):405–11

Effect of stobadine on gastric mucosal injury after ischaemia/reperfusion. Mojžiš J, et al. **Physiol Res** 1996; 45(5):399–403

Investigations on the gastroprotective and antidiarrhoeal properties of ternatin, a tetramethoxyflavone from Egletes viscosa. Rao VS, et al. **Planta Med** 1997 Apr;63(2):146–9

Cytoprotective activity of cisapride on experimental gastric mucosal lesions induced by ethanol. Role of endogenous prostaglandins. Motilva V, et al. **Prostaglandins** 1996 Jul; 52(1):63–74

Depletion of enterochromaffin-like cell histamine increases histidine decarboxylase and chromogranin A mRNA levels in rat stomach by a gastrin–independent mechanism. Andersson K, et al. **Scand J Gastroenterol** 1996 Oct; 31(10):959–65

A double–blind placebo–controlled study on the effects of omeprazole on gut hormone secretion and gastric emptying rate. Rasmussen L, et al. **Scand J Gastroenterol** 1997 Sep; 32(9):900–5

Induction of tumor necrosis factor–alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine. Slomiany BL, et al. **Scand J Gastroenterol** 1997 Jul;32(7):638–42

Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene sulphonic acid–induced colitis rats. Protective effect of rebamipide. Zea–Iriarte WL, et al. **Scand J Gastroenterol** 1996 Oct;31(10):985–92

In- vivo and in vitro effects of carbenoxolone on glucocorticoid receptor binding and glucocorticoid activity. Soro A, et al. **Steroids** 1997 Apr;62(4):388–94

Current status of acid pump antagonists (reversible PPIs). Wurst W, et al. **Yale J Biol Med** 1996 May–Jun; 69(3):233–43

Healing process induced by a flavonic fraction of Bidens aurea on chronic gastric lesion in rat. Role of angiogenesis and neutrophil inhibition. Martín Calero M, et al. **Z Naturforsch [C]** 1996 Jul–Aug;51(7–8):570–7

Antiulcerogenicity of the flavonoid fraction from Erica andevalensis Cabezudo–Rivera. Reyes M, et al. **Z Naturforsch [C]** 1996 Jul–Aug;51(7–8):563–9

[Studies on the protective effect of lansoprazole on human gastric mucosa against low–dose acetylsalicylic acid. An endoscopic controlled double–blind study] Müller P, et al. **Arzneimittelforschung** 1997 Jun;47(6):758–60 (Eng. Abstr.) **(Ger)**

[Protection of cultured mammalian cells by rebamipide] Antoku S, et al. **Fukuoka Igaku Zasshi** 1997 Jun; 88(6):247–52 (Eng. Abstr.) **(Jpn)**

[A basic study on gastric emptying test using barium grains and effect of drugs on gastric emptying in rats] Sakurai T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Feb; 93(2):75–82 (Eng. Abstr.) **(Jpn)**

[The effect of selected cytoprotective drugs on alcohol–induced injury of isolated gastric mucosa cells] Mach T. **Folia Med Cracov** 1995;36(1–4):76–95 (Eng. Abstr.) **(Pol)**

[Oxyferriscorbone: anti–ulcer effect and its possible mechanisms] Rasulov MM, et al. **Biull Eksp Biol Med** 1994 May;117(5):490–3 **(Rus)**

[Comparison of anti–ulcer properties of OF–900, OF–743 and their combination in various models of stomach ulcer induction in rats] Zhulkova SV, et al. **Biull Eksp Biol Med** 1997 Jul;124(7):13–5 **(Rus)**

[The effect of phenobarbital and cimetidine on the elimination kinetics and distribution in the heart and liver of propranolol in rats with acute and chronic inflammations] Lutsevich AN, et al. **Eksp Klin Farmakol** 1996 May–Jun; 59(3):47–52 (Eng. Abstr.) **(Rus)**

[The modification of the pharmacokinetics and analgesic effect of naproxen by cimetidine, phenobarbital and thiamine diphosphate] Vovk OG, et al. **Eksp Klin Farmakol** 1996 Mar–Apr;59(2):35–7 (Eng. Abstr.) **(Rus)**

[The search for new antiulcer agents using a computer system for predicting the antiulcer activity] Trapkov VA, et al. **Vopr Med Khim** 1997 Jan–Feb;43(1):41–57 (Eng. Abstr.) **(Rus)**

[Gastric protection in the treatment with NSAIDs (see comments)] Gené Badía J, et al. **Aten Primaria** 1997 Mar 15;19(4):207–10 (23 ref.). Comment in: Aten Primaria 1997 Jun 15;20(1):1–2. **(Spa)**

[Eradication of Helicobacter pylori and chronic abdominal pain (editorial)] Madrazo de la Garza JA. **Rev Gastroenterol Mex** 1996 Oct–Dec;61(4):398–9 **(Spa)**

POISONING

Bromide intoxication due to propantheline bromide. Heckerling PS, et al. **Am J Nephrol** 1996;16(6):537–9

[Cardiac poisoning of cisapride (Prepulsid) must be considered in its prescription, specially in premature infants (editorial)] Autret E, et al. **Arch Pediatr** 1997 Jun;4(6):507–8 **(Fre)**

THERAPEUTIC USE

Prophylaxis against acid aspiration in regional anesthesia for elective cesarean section: a comparison between oral single–dose ranitidine, famotidine and omeprazole assessed with fiberoptic gastric aspiration. Lin CJ, et al. **Acta Anaesthesiol Sin** 1996 Dec;34(4):179–84

Lansoprazole versus omeprazole in the treatment of reflux esophagitis. Včev A, et al. **Acta Med Croatica** 1997; 51(3):171–4

A prospective trial of thalidomide for the treatment of HIV–associated idiopathic esophageal ulcers. Alexander LN, et al. **AIDS Res Hum Retroviruses** 1997 Mar 1; 13(4):301–4

Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. Bell GD, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):637–44

Successful low–dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole–resistant Helicobacter pylori. Breuer T, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):523–7

Symptomatic improvement with one–year cisapride treatment in neuropathic chronic intestinal dysmotility. Camilleri M, et al. **Aliment Pharmacol Ther** 1996 Jun; 10(3):403–9

Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta–analysis of long–term omeprazole trials. Carlsson R, et al. **Aliment Pharmacol Ther** 1997 Jun;11(3):473–82

Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Corinaldesi R, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):667–71

Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. De Boer WA, et al. **Aliment Pharmacol Ther** 1995 Dec;9(6):633–8

Cisapride in functional dyspepsia in general practice. A placebo–controlled, randomized, double–blind study. de Groot GH, et al. **Aliment Pharmacol Ther** 1997 Feb; 11(1):193–9

Omeprazole–amoxycillin versus omeprazole–amoxycillin–clarithromycin in the eradication of Helicobacter pylori. Delchier JC, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):263–8

Effects of misoprostol on healing and prevention of biopsy–induced gastroduodenal lesions occurring during the administration of diclofenac to volunteers [published erratum appears in Aliment Pharmacol Ther 1996 Oct;10(5):833] Dorta G, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):563–9

Helicobacter pylori eradication in clinical practice: one–week low–dose triple therapy is preferable to classical bismuth based triple therapy. Goddard AF, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):1009–13

Ranitidine bismuth citrate therapy [letter; comment] Harris A, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):1035. Comment on: Aliment Pharmacol Ther 1996 Jun;10(3):251–61.

Long–term treatment with lansoprazole for patients with Zollinger–Ellison syndrome. Hirschowitz BI, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):507–22

Long–term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. Hirschowitz BI, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):497–506

Implication of nitric oxide synthase activity in the genesis of water immersion stress–induced gastric lesions in rats: the protective effects of FK506. Hisanaga Y, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):933–40

Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid–related dyspepsia in general practice. Jones RH, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):541–6

Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients. Kato M, et al. **Aliment Pharmacol Ther** 1996 Oct; 10(5):821–7

Comparison of ranitidine and lansoprazole in short–term low–dose triple therapy for Helicobacter pylori infection. Kihira K, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):511–4

Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. Labenz J, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):515–22

Long–term follow–up after cure of Helicobacter pylori infection with 4 days of quadruple therapy. Lai JY, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):645–50

Randomized comparison of differing periods of twice–a–day triple therapy for the eradication of Helicobacter pylori. Laine L, et al. **Aliment Pharmacol Ther** 1996 Dec; 10(6):1029–33

Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Lewis SJ, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):557–61

Ranitidine bismuth citrate: a novel anti–ulcer agent with different physico–chemical characteristics and improved biological activity to a bismuth citrate–ranitidine admixture. McColm AA, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):241–50

Maintenance therapy with cisapride after healing of erosive oesophagitis: a double–blind placebo–controlled trial. McDougall NI, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):487–95

High–dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection. Malaty H, et al. **Aliment Pharmacol Ther** 1996 Dec; 10(6):1001–4

Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Mee AS, et al. **Aliment Pharmacol Ther** 1996 Oct;10(5):757–63

An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Miehlke S, et al. **Aliment Pharmacol Ther** 1997 Apr; 11(2):323–9

One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. Moshkowitz M, et al. **Aliment Pharmacol Ther** 1996 Dec;10(6):1015–9

Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Penston JG. **Aliment Pharmacol Ther** 1996 Aug;10(4):469–86 (200 ref.)

Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group [see comments] Peterson WL, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):251–61. Comment in: Aliment Pharmacol Ther 1996 Dec;10(6):1035.

The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Peterson WL. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:21–5 (36 ref.)

Dose–response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. Pommerien W, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):303–8

A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis. Pouderoux P, et al. **Aliment Pharmacol Ther** 1995 Dec; 9(6):661–6

The treatment of Helicobacter pylori infection. Pounder RE, et al. **Aliment Pharmacol Ther** 1997 Apr;11 Suppl 1:35–41 (35 ref.)

Effect of short– and long–term treatment with omeprazole on the absorption and serum levels of cobalamin. Schenk BE, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):541–5

Comparison of two dosing regimens of cisapride in the treatment of reflux oesophagitis. Schütze K, et al. **Aliment Pharmacol Ther** 1997 Jun;11(3):497–503

Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Segura AM, et al. **Aliment Pharmacol Ther** 1997 Jun;11(3):529–32

Ranitidine 300 mg twice daily and 150 mg four–times daily are effective in healing erosive oesophagitis. Silver MT, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):373–80

Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi–centre double–blind study. Sontag SJ, et al. **Aliment Pharmacol Ther** 1997 Apr; 11(2):373–80

Omeprazole versus ranitidine: short–term triple–therapy in patients with Helicobacter pylori–positive duodenal ulcers. Spadaccini A, et al. **Aliment Pharmacol Ther** 1996 Oct; 10(5):829–31

Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. Spinzi G, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):317–22

Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori. Ström M, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):311–6

High–dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. ten Wolde S, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):347–51

One–week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance. Thijs JC, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):305–9

Low–dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. Tursi A, et al. **Aliment Pharmacol Ther** 1996 Jun;

10(3):285–8
A trial of lansoprazole in refractory gastric ulcer. van Rensburg CJ, et al. **Aliment Pharmacol Ther** 1996 Jun; 10(3):381–6
Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week. Van Zwet AA, et al. **Aliment Pharmacol Ther** 1997 Jun; 11(3):533–5
A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate. Weldon MJ, et al. **Aliment Pharmacol Ther** 1996 Jun;10(3):279–83
Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). Yousfi MM, et al. **Aliment Pharmacol Ther** 1996 Feb;10(1):119–22
One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. Yousfi MM, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):617–21
Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy. Bohmer CJ, et al. **Am J Gastroenterol** 1997 Sep; 92(9):1475–9
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. Chey WD, et al. **Am J Gastroenterol** 1997 Sep;92(9):1483–6
Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. Chey WD, et al. **Am J Gastroenterol** 1997 Mar;92(3):446–50
Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. Chiba N. **Am J Gastroenterol** 1996 Oct;91(10):2139–43
Re: short-term treatment with lansoprazole [letter; comment] Dhar A, et al. **Am J Gastroenterol** 1996 Oct;91(10):2251. Comment on: Am J Gastroenterol 1995 Oct;90(10):1824–8.
Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Freston JW. **Am J Gastroenterol** 1997 Apr;92(4 Suppl):51S–55S; discussion 55S–57S (28 ref.)
Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole [see comments] Graham DY, et al. **Am J Gastroenterol** 1996 Oct;91(10):2120–4. Comment in: Am J Gastroenterol 1997 Apr;92(4):720–1.
Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study. Gupta VK, et al. **Am J Gastroenterol** 1997 Jul;92(7):1140–2
Omeprazole to treat asthma? Kahrilas PJ, et al. **Am J Gastroenterol** 1996 Oct;91(10):2245–6
Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients [see comments] Labenz J, et al. **Am J Gastroenterol** 1997 Apr;92(4):576–81 . Comment in: Am J Gastroenterol 1997 Apr;92(4):555–6.
Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. Lazzaroni M, et al. **Am J Gastroenterol** 1997 Apr; 92(4):649–52
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study. Lerang F, et al. **Am J Gastroenterol** 1997 Apr;92(4):653–8
Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients. Miglioli M, et al. **Am J Gastroenterol** 1996 Nov;91(11):2367–71
The effect of cisapride in patients with reflux esophagitis: an ambulatory esophageal manometry/pH-metry study. Paterson WG, et al. **Am J Gastroenterol** 1997 Feb; 92(2):226–30
Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients. Porro GB, et al. **Am J Gastroenterol** 1997 Apr;92(4):663–7
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Sontag SJ, et al. **Am J Gastroenterol** 1997 Mar;92(3):429–37
Lanzoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism [letter] Stermer E, et al. **Am J Gastroenterol** 1997 Sep;92(9):1575–6
Acid secretion, response to omeprazole, and Helicobacter pylori status [editorial; comment] Treiber G, et al. **Am J Gastroenterol** 1997 Apr;92(4):555–6. Comment on: Am J Gastroenterol 1997 Apr;92(4):576–81.
Patients failing moderately high doses of omeprazole [letter; comment] Waring JP, et al. **Am J Gastroenterol** 1997 May; 92(5):907–9. Comment on: Am J Gastroenterol 1996 Oct;91(10):2110–3.
Two products released for H. pylori treatment [news] **Am J Health Syst Pharm** 1996 Nov 1;53(21):2556
Cisapride improves gastric emptying in mechanically ventilated, critically ill patients. A randomized, double-blind trial. Heyland DK, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1678–83
Effects of intermittent feed deprivation, intermittent feed deprivation with ranitidine administration, and stall confinement with ad libitum access to hay on gastric ulceration in horses. Murray MJ, et al. **Am J Vet Res** 1996 Nov;57(11):1599–603
Acoustic measurement of change in voice quality with treatment for chronic posterior laryngitis. Hanson DG, et al. **Ann Otol Rhinol Laryngol** 1997 Apr;106(4):279–85
Extent and variation of omeprazole prescribing in an elderly population of Ontario. McBride JE, et al. **Ann Pharmacother** 1997 Apr;31(4):411–6
Antimicrobial management of Helicobacter pylori-associated gastrointestinal tract disease. Guay DR, et al. **Arch Fam Med** 1997 Mar–Apr;6(2):173–80 (00 ref.)
Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials [see comments] Koch M, et al. **Arch Intern Med** 1996 Nov 11;156(20):2321–32. Comment in: ACP J Club 1997 Mar–Apr;126(2):36.
Effect of fish oil on indometacin-induced gastric lesions in rats. Güzel C, et al. **Arzneimittelforschung** 1995 Nov; 45(11):1172–3
Omeprazole, amoxicillin and bismuth for peptic ulcer healing and Helicobacter pylori eradication. Treiber G, et al. **Arzneimittelforschung** 1997 Jan;47(1):47–50
Protective effect of fish oil against stress-induced gastric injury in rats. Ulak G, et al. **Arzneimittelforschung** 1995 Nov;45(11):1174–5
Adult asthma and gastro-oesophageal reflux: the effects of omeprazole therapy on asthma. Teichtahl H, et al. **Aust N Z J Med** 1996 Oct;26(5):671–6
Predictors of duodenal ulcer healing in sucralfate treated patients. Haq SA, et al. **Bangladesh Med Res Counc Bull** 1996 Aug;22(2):65–9
Simultaneous evaluation of gastric and duodenal ulcers-healing activities of anti-ulcer agents in rats. Segami T, et al. **Biol Pharm Bull** 1996 Jan;19(1):53–6
Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. Axon AT, et al. **BMJ** 1997 Feb 22; 314(7080):565–8
H2 blockers in the intensive care unit: ignoring the evidence? Telephone survey [see comments] Wyncoll DL, et al. **BMJ** 1997 Apr 5;314(7086):1013. Comment in: BMJ 1997 Aug 9;315(7104):371–2.
An evaluation of the use of cisapride in horses with chronic grass sickness (equine dysautonomia) [see comments] Milne EM, et al. **Br Vet J** 1996 Sep;152(5):537–49. Comment in: Br Vet J 1996 Sep;152(5):497–9.
Omeprazole before emergency caesarean section [letter; comment] Gin T. **Can J Anaesth** 1996 Aug;43(8):878–9. Comment on: Can J Anaesth 1995 Sep;42(9):797–800.
Clinical trials in nonulcer dyspepsia (NUD): a cautionary note. A closer look at "a double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia" [editorial; comment] Champion MC. **Can J Gastroenterol** 1997 Mar;11(2):125–6. Comment on: Can J Gastroenterol 1997 Mar;11(2):127–34.
A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group [see comments] Champion MC, et al. **Can J Gastroenterol** 1997 Mar;11(2):127–34. Comment in: Can J Gastroenterol 1997 Mar;11(2):125–6.
Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer. O'Brien B, et al. **Can J Gastroenterol** 1997 May-Jun; 11(4):323–31
Maintenance therapy for inflammatory bowel disease: what really works. Sutherland LR. **Can J Gastroenterol** 1997 Apr;11(3):261–4 (40 ref.)
New drug to prevent NSAID-related ulcers [letter; comment] Liss GM. **Can Med Assoc J** 1996 Oct 15; 155(8):1043. Comment on: Can Med Assoc J 1996 Jul 1;155(1):77–88.
Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study. Sartori S, et al. **Cancer** 1996 Oct 1;78(7):1477–82
Cytoprotective effects of 4,6-bis(1H-pyrazol-1-yl)pyrimidine and related compounds on HCl.ethanol-induced gastric lesions in rats. Ikeda M, et al. **Chem Pharm Bull (Tokyo)** 1997 Mar; 45(3):549–51
Synthesis and cytoprotective antiulcer activity of 2- or 4-(1H-pyrazol-1-yl)pyrimidine derivatives related to mepirizole and dulcerozine. Ikeda M, et al. **Chem Pharm Bull (Tokyo)** 1996 Sep;44(9):1700–6
The effect of cimetidine on serum acidic markers and Helicobacter pylori in gastric ulcer subjects. Lee CT, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Jan; 57(1):28–33
Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. James LP, et al. **Clin Pharmacokinet** 1996 Aug;31(2):103–10 (21 ref.)
The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Van Groenendael JH, et al. **Clin Rheumatol** 1996 Sep; 15(5):450–6
Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Sanders SW. **Clin Ther** 1996 Jan–Feb;18(1):2–34; discussion 1 (178 ref.)
Effectiveness of ranitidine 150 mg at bedtime as maintenance therapy for healed gastric ulcers. Sue SO, et al. **Clin Ther** 1996 Nov–Dec;18(6):1175–83
Omeprazole, a specific gastric secretion inhibitor on oxyntic opeptic cells, reduces gizzard erosion in broiler chicks fed with toxic fish meals. Hinrichsen JP, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jul;117(3):267–73
Repair of rat gastric mucosa: effect of 16,16-dimethyl prostaglandin E2. Cook GA, et al. **Dig Dis Sci** 1997 Mar; 42(3):654–60
Effects of omeprazole on mechanisms of gastroesophageal reflux in childhood. Cucchiara S, et al. **Dig Dis Sci** 1997 Feb;42(2):293–9
Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Levy MJ, et al. **Dig Dis Sci** 1997 Jun; 42(6):1255–9
Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Sikirić P, et al. **Dig Dis Sci** 1997 Mar;42(3):661–71
Clinical application of gastric histology to monitor treatment of dual therapy in H. pylori eradication. Yang HB, et al. **Dig Dis Sci** 1997 Sep;42(9):1835–40
Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders [published errata appear in Drugs 1996 Jun;51(6):1074 and 1996 Jul;52(1):92] Fitton A, et al. **Drugs** 1996 Mar;51(3):460–82 (132 ref.)
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Langtry HD, et al. **Drugs** 1997 Sep;54(3):473–500 (205 ref.)
Zollinger-Ellison syndrome. Recognition and management of acid hypersecretion. Maton PN. **Drugs** 1996 Jul; 52(1):33–44 (59 ref.)
Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists. Lazzaroni M, et al. **Drugs Aging** 1996 Oct;9(4):251–61 (72 ref.)
Idiopathic esophageal ulceration associated with human immunodeficiency virus infection: efficacy of thalidomide treatment. Louvel D, et al. **Endoscopy** 1996 Jun;28(5):471–2
A comparison of two cohort studies evaluating the safety of cisapride: Prescription-Event Monitoring and a large phase IV study. Wager E, et al. **Eur J Clin Pharmacol** 1997; 52(2):87–94
Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. Avsar E, et al. **Eur J Gastroenterol Hepatol** 1996 May;8(5):449–52
Triple therapy as a cure for Helicobacter pylori infection. Bardhan KD. **Eur J Gastroenterol Hepatol** 1996 Oct;8 Suppl 1:S27–30 (36 ref.)
Cure of gastric ulcer disease after cure of Helicobacter pylori infection—German Gastric Ulcer Study [see comments] Bayerdörffer E, et al. **Eur J Gastroenterol Hepatol** 1996 Apr;8(4):343–9. Comment in: Eur J Gastroenterol Hepatol 1996 Apr;8(4):333–4.
Proton-pump inhibitors are the treatment of choice in acid-related disease. Brunner G. **Eur J Gastroenterol Hepatol** 1996 Oct;8 Suppl 1:S9–13 (42 ref.)
Omeprazole works best when used properly [comment] Castell DO. **Eur J Gastroenterol Hepatol** 1996 May; 8(5):413–4. Comment on: Eur J Gastroenterol Hepatol 1996 May;8(5):417–20.
Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study [see comments] de Boer WA, et al. **Eur J Gastroenterol Hepatol** 1995 Dec;7(12):1189–94. Comment in: ACP J Club 1996 May–Jun;124(3):64–5.
Ranitidine in a twice daily triple-therapy regimen for the eradication of Helicobacter pylori [see comments] Drake IM, et al. **Eur J Gastroenterol Hepatol** 1996 Dec; 8(12):1169–73. Comment in: Eur J Gastroenterol Hepatol 1997 May;9(5):544.
Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy [see comments] Goh KL, et al. **Eur J Gastroenterol Hepatol** 1996 May;8(5):421–3 . Comment in: Eur J Gastroenterol Hepatol 1996 May;8(5):415–6.
Monitoring of omeprazole treatment in gastro-oesophageal reflux disease [see comments] Hendel J, et al. **Eur J Gastroenterol Hepatol** 1996 May;8(5):417–20. Comment in: Eur J Gastroenterol Hepatol 1996 May;8(5):413–4.
The changing role of H2-receptor antagonists in acid-related diseases. Lamers CB. **Eur J Gastroenterol Hepatol** 1996 Oct;8 Suppl 1:S3–7 (38 ref.)
Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Parsons ME. **Eur J Gastroenterol Hepatol** 1996 Oct;8 Suppl 1:S15–20 (45 ref.)
Clarithromycin or amoxycillin plus high-dose ranitidine in the treatment of Helicobacter pylori-positive functional dyspepsia. Schütze K, et al. **Eur J Gastroenterol Hepatol** 1996 Jan;8(1):41–6
Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. Swarbrick ET, et al. **Eur J Gastroenterol Hepatol** 1996 May;8(5):431–8
The use of omeprazole for resistant oesophagitis in children. Martin PB, et al. **Eur J Pediatr Surg** 1996 Aug;6(4):195–7
Effect of a novel histamine H2 receptor antagonist, IT-066, on acute gastric injury induced by ischemia-reperfusion in rats, and its antioxidative properties. Naito Y, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):47–54
Propentofylline prevents neuronal dysfunction induced by

infusion of anti-nerve growth factor antibody into the rat septum. Nitta A, et al. **Eur J Pharmacol** 1996 Jun 20; 307(1):1-6

Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Simon LS, et al. **Fam Med** 1996 Mar;28(3):204-10

How do you spell relief in reflux esophagitis? PPI! Fennerty MB. **Gastroenterology** 1996 Sep;111(3):826-7

Is the only good H. pylori a dead H. pylori? Fennerty MB. **Gastroenterology** 1996 Dec;111(6):1773-4

Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Sackmann M, et al. **Gastroenterology** 1997 Oct;113(4):1087-90

Helicobacter pylori infection and omeprazole efficacy [letter; comment] Verdú EF, et al. **Gastroenterology** 1996 Nov; 111(5):1401-2. Comment on: Gastroenterology 1996 Mar;110(3):947-50.

Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy. Weber HC, et al. **Gastroenterology** 1997 Jan; 112(1):84-91

Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Malesci A, et al. **Gastrointest Endosc** 1996 Dec;44(6):700-5

Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Sampliner RE, et al. **Gastrointest Endosc** 1996 Nov; 44(5):532-5

A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic esophagitis. Silvis SE, et al. **Gastrointest Endosc** 1996 Mar;43(3):216-21

Investigations on the protective action of Condonopsis pilosula (Dangshen) extract on experimentally-induced gastric ulcer in rats. Wang ZT, et al. **Gen Pharmacol** 1997 Mar;28(3):469-73

Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. Bardhan KD, et al. **Gut** 1997 Aug;41(2):181-6

Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy [see comments] Bianchi Porro G, et al. **Gut** 1996 Jul;39(1):22-6. Comment in: Gut 1997 Apr;40(4):560-1.

1976 and all that!—20 years of antisecretory therapy. Garner A, et al. **Gut** 1996 Dec;39(96):784-6

Treating Helicobacter pylori—the best is yet to come? Harris A, et al. **Gut** 1996 Dec;39(96):781-3

Inhibiting acid and Helicobacter pylori? [comment] Healey Z, et al. **Gut** 1997 Jul;41(1):125-6. Comment on: Gut 1997 Jul;41(1):33-6.

Effect of sucralfate on aspirin induced mucosal injury and impaired haemostasis in humans. Hudson N, et al. **Gut** 1997 Jul;41(1):19-23

Effect of capsaicin and cimetidine on the healing of acetic acid induced gastric ulceration in the rat. Kang JY, et al. **Gut** 1996 Jun;38(6):832-6

Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer [see comments] Labenz J, et al. **Gut** 1997 Jul;41(1):33-6. Comment in: Gut 1997 Jul;41(1):125-6.

Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Thorens J, et al. **Gut** 1996 Jul;39(1):54-9

Marked increase in gastric acid secretory capacity after omeprazole treatment. Waldum HL, et al. **Gut** 1996 Nov; 39(5):649-53

Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux—the "sensitive oesophagus". Watson RG, et al. **Gut** 1997 May; 40(5):587-90

Omeprazole versus histamine H2 receptor antagonists in the treatment of acute upper non-variceal bleeding. Mohamed SA, et al. **Hepatogastroenterology** 1996 Jul-Aug; 43(10):863-5

Managing the patient with atypical chest pain. Snape WJ Jr. **Hosp Pract (Off Ed)** 1997 Apr 15;32(4):159-73; discussion 173-4 passim

Gastric antiulcer activity of UL-409 in rats. Kulkarni SK, et al. **Indian J Exp Biol** 1996 Jul;34(7):683-8

Triple-drug therapy of Helicobacter pylori infection in duodenal ulcer disease. Dayal VM, et al. **Indian J Gastroenterol** 1997 Apr;16(2):46-8

Helicobacter pylori eradication—evaluation of triple therapy containing omeprazole. Goenka MK, et al. **Indian J Gastroenterol** 1996 Jan;15(1):1-3

Healing of chronic antral gastritis: effect of sucralfate and colloidal bismuth subcitrate. Kumar M, et al. **Indian J Gastroenterol** 1996 Jul;15(3):90-3

Gastric bacterial overgrowth accompanies profound acid suppression. Patel TA, et al. **Indian J Gastroenterol** 1995 Oct;14(4):134-6

Sucralfate for radiation mucositis: results of a double-blind randomized trial. Meredith R, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):275-9

Prevention of NSAID-gastropathy. Ardizzone S, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:33-6 (19 ref.)

Therapy of NSAIDs-induced gastropathy. La Corte R, et al. **Ital J Gastroenterol** 1996 Dec;28 Suppl 4:37-41 (34 ref.)

The impact of omeprazole and laparoscopy upon hiatal hernia and reflux esophagitis. McKenzie D, et al. **J Am Coll Surg** 1996 Oct;183(4):413-8 (46 ref.)

Determinants of initiation and suboptimal use of anti-ulcer medication: a study of the Quebec older population. Moride Y, et al. **J Am Geriatr Soc** 1997 Jul;45(7):853-6

Oral cimetidine and the treatment of verrucae [letter] Mahoney JM. **J Am Podiatr Med Assoc** 1996 Apr; 86(4):183-6

Suppression of gastric acidity in horses. Murray MJ. **J Am Vet Med Assoc** 1997 Jul 1;211(1):37-40 (33 ref.)

One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy. Phull PS, et al. **J Antimicrob Chemother** 1995 Dec; 36(6):1085-8

Comparison of colloidal bismuth subcitrate and metronidazole, both in combination with an H2-antagonist as therapy for Helicobacter pylori. Baffone W, et al. **J Chemother** 1997 Jun;9(3):208-12

Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole. Goenka MK, et al. **J Clin Gastroenterol** 1996 Jul;23(1):7-10

Increased immunoreactivity and concentration of basic fibroblast growth factor in lansoprazole-treated gastric mucosa. Nakamura M, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S24-9

Helicobacter pylori eradication helps resolve pyloric and duodenal stenosis. Tursi A, et al. **J Clin Gastroenterol** 1996 Sep;23(2):157-8

Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. Loprinzi CL, et al. **J Clin Oncol** 1997 Mar; 15(3):1235-8

Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. McGinnis WL, et al. **J Clin Oncol** 1997 Mar;15(3):1239-43

Anti-inflammatory and antiulcer activity of Teucrium buxifolium. Fernández Puntero B, et al. **J Ethnopharmacol** 1997 Jan;55(2):93-8

Gastric antiulcer and cytoprotective effect of Commiphora molmol in rats. al-Harbi MM, et al. **J Ethnopharmacol** 1997 Jan;55(2):141-50

Eremomastax speciosa: effects of leaf aqueous extract on ulcer formation and gastric secretion in rats. Tan PV, et al. **J Ethnopharmacol** 1996 Nov;54(2-3):139-42

Effects of Cistus laurifolius L. flowers on gastric and duodenal lesions. Yeşilada E, et al. **J Ethnopharmacol** 1997 Feb;55(3):201-11

Prevention of NSAID-induced GI mucosal injury. Gerritz S, et al. **J Fam Pract** 1997 Feb;44(2):130-1

Prevention of NSAID-induced ulcers. Lawless C, et al. **J Fam Pract** 1996 Sep;43(3):239-40

Treatment of bleeding peptic ulcers with omeprazole. Munkel L, et al. **J Fam Pract** 1997 Jul;45(1):20-1

Sofalcone for treatment of Helicobacter pylori infection. Fujioka T, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:56-8

Effect of omeprazole on the course of associated esophagitis and laryngitis. Jaspersen D, et al. **J Gastroenterol** 1996 Dec; 31(6):765-7

Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. Kawano S, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:41-3

Control of gastric pH with ranitidine in patients with Crohn's disease receiving total parenteral nutrition. Comparison of two intravenous regimens. Matsui T, et al. **J Gastroenterol** 1996 Feb;31(1):6-11

Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. Moayyedi P, et al. **J Gastroenterol** 1997 Feb; 32(1):24-7

Significant increase in eradication rates of Helicobacter pylori infection with two consecutive dual therapies (omeprazole and amoxycillin or omeprazole and clarithromycin). A randomized study in 450 Spanish patients. Moreno JA, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:48-52

Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients. Shimoyama T, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:59-62

Sucralfate and Helicobacter pylori. Terano A, et al. **J Gastroenterol** 1996 Nov;31 Suppl 9:63-5 (10 ref.)

Omeprazole in the treatment of patients with complicated gastro-oesophageal reflux disease [see comments] Jaspersen D, et al. **J Gastroenterol Hepatol** 1996 Oct;11(10):900-2. Comment in: J Gastroenterol Hepatol 1996 Oct;11(10):897-9.

A method of evaluating drug efficacy by statistical analysis of healing speed of peptic ulcer. Kimura K, et al. **J Gastroenterol Hepatol** 1996 Oct;11(10):916-21

Towards an increased efficacy of acid inhibition in the treatment of erosive oesophagitis [editorial; comment] Lambert R. **J Gastroenterol Hepatol** 1996 Oct;11(10):897-9 . Comment on: J Gastroenterol Hepatol 1996 Oct;11(10):900-2.

Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo-controlled trial. Yeoh KG, et al. **J Gastroenterol Hepatol** 1997 Jan;12(1):13-8

Efficacy of lansoprazole against peptic ulcers induced by non-steroidal anti-inflammatory drugs: endoscopic evaluation of ulcer healing. Matsukawa Y, et al. **J Int Med Res** 1997 Jul-Aug;25(4):190-5

Prescribing rationale and budgetary outcomes associated with the introduction of a combined formulation of diclofenac sodium and misoprostol in Canada. Sclar DA, et al. **J Int Med Res** 1995 Nov-Dec;23(6):439-48

Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia. Mielke R, et al. **J Neurol Sci** 1996 Sep 15; 141(1-2):59-64

Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twenty-four-hour intragastric acidity. Kato S, et al. **J Pediatr** 1996 Mar;128(3):415-21

Omeprazole for severe reflux esophagitis in children. De Giacomo C, et al. **J Pediatr Gastroenterol Nutr** 1997 May; 24(5):528-32

Possible cytoprotective mechanism in rats of D-002, an anti-ulcerogenic product isolated from beeswax. Carbajal D, et al. **J Pharm Pharmacol** 1996 Aug;48(8):858-60

Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride. Halter F, et al. **J Physiol Pharmacol** 1997 Jun;48(2):185-92

Subjective, laryngoscopic, and acoustic measurements of laryngeal reflux before and after treatment with omeprazole. Shaw GY, et al. **J Voice** 1996 Dec;10(4):410-8

Practice guidelines for treatment of peptic ulcer disease [letter; comment] Fennerty MB. **JAMA** 1996 Oct 9; 276(14):1135; discussion 1136-7. Comment on: JAMA 1996 Feb 28;275(8):622-9.

Practice guidelines for treatment of peptic ulcer disease [letter; comment] Olson CA. **JAMA** 1996 Oct 9; 276(14):1135-6; discussion 1136-7. Comment on: JAMA 1996 Feb 28;275(8):622-9.

Prevention of gastric ulcer relapse induced by indomethacin in rats by a mutein of basic fibroblast growth factor. Satoh H, et al. **Jpn J Pharmacol** 1997 Mar;73(3):229-41

Proton-pump inhibitors: three of a kind? [see comments] Bateman DN. **Lancet** 1997 Jun 7;349(9066):1637-8. Comment in: Lancet 1997 Aug 9;350(9075):446; discussion 447. Comment in: Lancet 1997 Aug 9;350(9075):447.

Regression of mucosa-associated lymphoid-tissue lymphoma after eradication of Helicobacter pylori [letter] Wright DH. **Lancet** 1997 Sep 27;350(9082):960-1

Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility. Wetscher GJ, et al. **Langenbecks Arch Chir** 1997;382(2):95-9

Drugs for treatment of peptic ulcers. **Med Lett Drugs Ther** 1997 Jan 3;39(991):1-4

Famotidine to prevent peptic ulcer caused by NSAIDs [letter] Graham DY. **N Engl J Med** 1996 Oct 24; 335(17):1322; discussion 1322-3

A comparison of omeprazole and placebo for bleeding peptic ulcer [see comments] Khuroo MS, et al. **N Engl J Med** 1997 Apr 10;336(15):1054-8. Comment in: N Engl J Med 1997 Apr 10;336(15):1091-3.

Therapy for bleeding peptic ulcers [editorial; comment] Saltzman JR, et al. **N Engl J Med** 1997 Apr 10; 336(15):1091-3. Comment on: N Engl J Med 1997 Apr 10;336(15):1054-8.

Famotidine to prevent peptic ulcer caused by NSAIDs [letter; comment] Singh G, et al. **N Engl J Med** 1996 Oct 24;335(17):1322; discussion 1322-3. Comment on: N Engl J Med 1996 May 30;334(22):1435-9.

Prevention of posttransplant peptic ulcer by misoprostol. Yang CW, et al. **Nephron** 1996;74(1):131-5

A twelve-month follow-up after Helicobacter pylori eradication. A clinical and histological evaluation. Bruno M, et al. **Panminerva Med** 1996 Sep;38(3):139-44

Treatment of Helicobacter pylori infection: a review. Blecker U, et al. **Pediatr Infect Dis J** 1997 Apr;16(4):391-9 (105 ref.)

The effect of the combination therapy with sucralfate and famotidine on experimentally induced duodenal ulcers in rats. Zupančič P. **Pflugers Arch** 1996;431(6 Suppl 2):R215-6

A protective role for calcitonin gene-related peptide in water-immersion stress-induced gastric ulcers in rats. Evangelista S, et al. **Pharmacol Res** 1997 Apr;35(4):347-50

Proton pump inhibitors and acid-related diseases. Sachs G. **Pharmacotherapy** 1997 Jan-Feb;17(1):22-37 (112 ref.)

Lansoprazole: a comprehensive review. Zimmermann AE, et al. **Pharmacotherapy** 1997 Mar-Apr;17(2):308-26 (184 ref.)

Short-term eradication therapy for Helicobacter pylori does not reduce the incidence of gastric metaplasia in duodenal ulcer patients. Rudnicka L, et al. **Pol J Pathol** 1997; 48(2):103-6

Gastroesophageal reflux disease. The long and the short of therapeutic options. Brady WM, et al. **Postgrad Med** 1996 Nov;100(5):76-80, 85-6, 89 (21 ref.)

Does profound acid inhibition improve haemostasis in peptic ulcer bleeding? [comment] Berstad A. **Scand J Gastroenterol** 1997 Apr;32(4):396-8. Comment on: Scand J Gastroenterol 1997 Apr;32(4):320-7. Comment on: Scand J Gastroenterol 1997 Apr;32(4):328-33.

Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study [see comments] Ekström P, et al. **Scand J Gastroenterol** 1996 Aug;31(8):753-8. Comment in: Scand J Gastroenterol 1997 Jan;32(1):95.

Peptic ulcer perforation before and after the introduction of H2-receptor blockers and proton pump inhibitors. Hermansson M, et al. **Scand J Gastroenterol** 1997 Jun; 32(6):523-9

Therapeutic potential of NSAIDs and omeprazole in the oesophagus [letter; comment] Morgan GP.
Scand J Gastroenterol 1997 Jan;32(1):95. Comment on: Scand J Gastroenterol 1996 Aug;31(8):753–8.
Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study [see comments] Schaffalitzky de Muckadell OB, et al.
Scand J Gastroenterol 1997 Apr;32(4):320–7. Comment in: Scand J Gastroenterol 1997 Apr;32(4):396–8.
Gastric mucosal cell cycle regulation with ulcer healing by sulglycotide. Slomiany BL, et al. **Scand J Gastroenterol** 1997 Sep;32(9):873–7
Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands. Van Den Boom G, et al.
Scand J Gastroenterol 1996 Jan;31(1):1–9
Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Verdú EF, et al. **Scand J Gastroenterol** 1996 Dec; 31(12):1151–6
Eradication of Helicobacter pylori: omeprazole in combination with antibiotics. Axon AT, et al.
Scand J Gastroenterol Suppl 1996;215:82–9 (58 ref.)
Italian omeprazole triple therapy—a 1-week regimen. Bazzoli F. **Scand J Gastroenterol Suppl** 1996;215:118
Helicobacter pylori reinfection after apparent eradication—the Ipswich experience. Bell GD, et al.
Scand J Gastroenterol Suppl 1996;215:96–104
Dual and triple therapy regimens of antisecretory agents and antibiotics for the eradication of Helicobacter pylori: an overview. Ciociola AA, et al.
Scand J Gastroenterol Suppl 1996;218:3–9 (119 ref.)
Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Jönsson B.
Scand J Gastroenterol Suppl 1996;215:90–5
Helicobacter pylori eradication: therapy other than with bismuth or proton-pump inhibitors. Korman MG.
Scand J Gastroenterol Suppl 1996;220:41–3 (25 ref.)
Management of Helicobacter pylori-positive peptic ulcer disease. Malfertheiner P. **Scand J Gastroenterol Suppl** 1996; 215:69
Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics. Solcia E, et al.
Scand J Gastroenterol Suppl 1996;215:105–10
Pooled analysis of anti-Helicobacter pylori treatment regimens. Unge P, et al. **Scand J Gastroenterol Suppl** 1996; 220:27–40 (307 ref.)
Acute erosions of the gastric mucosa in burned rats: effect of sucralfate. Samdal F, et al.
Scand J Plast Reconstr Surg Hand Surg 1997 Sep; 31(3):221–7
Sucralfate prophylaxis of fluorouracil-induced stomatitis. Giorgi F, et al. **Tumori** 1996 Nov–Dec;82(6):585–7
Randomised controlled trial of ranitidine versus omeprazole in combination with antibiotics for eradication of Helicobacter pylori. Tham TC, et al. **Ulster Med J** 1996 Nov;65(2):131–6
pH, healing rate and symptom relief in acid-related diseases. Huang JQ, et al. **Yale J Biol Med** 1996 Mar–Apr; 69(2):159–74 (123 ref.)
Proton pump inhibitory therapy: then and now. Schepp W.
Yale J Biol Med 1996 Mar–Apr;69(2):175–86 (99 ref.)
Pharmacotherapy for acid/peptic disorders. Schubert ML.
Yale J Biol Med 1996 Mar–Apr;69(2):197–201 (23 ref.)
Evaluation of therapeutic regimens for the treatment of Helicobacter pylori infection. Lee DH, et al.
Yonsei Med J 1996 Aug;37(4):270–7
Development of duodenal ulcer concomitant with successful Helicobacter pylori eradication. Pohle T, et al.
Z Gastroenterol 1997 Jul;35(7):563–5
[Teprenone in the treatment of chronic superficial gastritis, a multicentre study] Liu X, et al.
Chung Hua Nei Ko Tsa Chih 1996 Jan;35(1):12–4 (Eng. Abstr.) **(Chi)**
[Analogy method for the extended use and mechanism research of xilei powder] Ou BN.
Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1996 Feb; 16(2):115–6 **(Chi)**
[Clinical and experimental studies of yuyang powder in treatment of peptic ulcer] Wan QX, et al.
Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1996 Feb; 16(2):78–80 (Eng. Abstr.) **(Chi)**
[Treatment of duodenal ulcer with pantoprazole. A multicenter study] Frič P, et al. **Cas Lek Cesk** 1996 Dec 4;135(23):758–61 (Eng. Abstr.) **(Cze)**
[Intravenous omeprazole versus ranitidine in the treatment of hemorrhagic duodenal ulcer: a prospective randomized study] Cardi M, et al. **Ann Chir** 1997;51(2):136–9 (32 ref.) (Eng. Abstr.) **(Fre)**
[Anti-ulcer agents. Recommendations and medical references. Agence Nationale pour le Développement de l'Evaluation Médicale] **Gastroenterol Clin Biol** 1996; 20(11):991–1008 (211 ref.) **(Fre)**
[Medico-economic aspects of the treatment of duodenal ulcer: from antisecretory treatment to eradication of Helicobacter pylori] Carrère MO, et al.
Gastroenterol Clin Biol 1995 Dec;19(12):1023–30 (Eng. Abstr.) **(Fre)**
[Anti-ulcer drugs] Horsmans Y. **J Pharm Belg** 1996 Nov–Dec;51(6):300–4 (0 ref.) **(Fre)**
[Is gastric acid secretion inhibition necessary for successful eradication of Helicobacter pylori?] Müller P, et al.
Fortschr Med 1996 Aug 20;114(22–23):275–6 **(Ger)**
[Helicobacter pylori eradication: modified triple therapy with lansoprazole] Müller P, et al. **Fortschr Med** 1996 Dec 20; 114(35–36):497–9 (17 ref.) (Eng. Abstr.) **(Ger)**
[Eradication of Helicobacter pylori infection. A new therapy standard for duodenal ulcer] Caspary WF, et al.
Internist (Berl) 1996 Dec;37(12):1204–11 (41 ref.) **(Ger)**
[Do other proton pump blockers have advantages over Antra (omeprazole)?] Creutzfeldt W. **Internist (Berl)** 1996 Sep; 37(9):936–7 **(Ger)**
[What is the role of H2 receptor blockers today in ulcer therapy?] Creutzfeldt W. **Internist (Berl)** 1996 Sep; 37(9):937–8 **(Ger)**
[2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole] Leonhardt U, et al. **Internist (Berl)** 1996 Sep;37(9):944–9; discussion 949 **(Ger)**
[Prevention and therapy of NSAID-induced ulcers: fact versus myth] Fried M, et al. **Schweiz Med Wochenschr** 1996 Sep 14;126(37):1569–72 (15 ref.) (Eng. Abstr.) **(Ger)**
[Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer] Kayser S, et al.
Schweiz Med Wochenschr 1997 Apr 26;127(17):722–7 (Eng. Abstr.) **(Ger)**
[Is misoprostol effective in NSAID-induced gastrointestinal complications?] Stucki G, et al.
Schweiz Med Wochenschr 1996 Sep 14;126(37):1573–8 (26 ref.) (Eng. Abstr.) **(Ger)**
[Morphological variations of the human gastric mucosa after omeprazole treatment: a scanning electron microscopic study] Magaudda L, et al. **Minerva Gastroenterol Dietol** 1996 Jun;42(2):61–9 (Eng. Abstr.) **(Ita)**
[Sucralfate in odontostomatology. Clinical experience] Campisi G, et al. **Minerva Stomatol** 1997 Jun;46(6):297–305 (42 ref.) (Eng. Abstr.) **(Ita)**
[Pharmacological studies of BX661A. 5-[4-(2-carboxyethylcarbamoyl)-phenylazo]-salicylic acid disodium salt dihydrate (1). Therapeutic effects on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) model in rats] Kimura I, et al.
Nippon Yakurigaku Zasshi 1997 Feb;109(2):85–94 (Eng. Abstr.) **(Jpn)**
[Effects of lansoprazole on indomethacin-induced gastric bleeding and mucosal lesions in rats] Murakami I, et al.
Nippon Yakurigaku Zasshi 1996 Dec;108(6):323–32 (Eng. Abstr.) **(Jpn)**
[Effect of a novel antiulcer drug, lafutidine, on experimental chronic gastritis in rats] Onodera S, et al.
Nippon Yakurigaku Zasshi 1997 Jan;109(1):31–40 (Eng. Abstr.) **(Jpn)**
[Morphology of the gastric mucosa in patients with duodenal ulcer treated with bismuth-containing drugs] Mach T.
Folia Med Cracov 1995;36(1–4):53–75 (Eng. Abstr.) **(Pol)**
[The anti-ulcer action of zinc sulfate in models of acute and chronic ulcerogenesis in the rat duodenum] Trapkov VA, et al. **Eksp Klin Farmakol** 1996 Nov–Dec;59(6):26–8 (Eng. Abstr.) **(Rus)**
[Peptic ulcer and reparants] Maiorov VM, et al.
Klin Med (Mosk) 1996;74(4):71–2 (9 ref.) **(Rus)**
[Disturbance of regional blood flow and activity of lipid peroxidation in recurrent ulcer and their drug correction] Tsimmerman IS, et al. **Klin Med (Mosk)** 1996;74(4):31–4 (Eng. Abstr.) **(Rus)**
[The validation and effect of the prophylactic (antirelapse) treatment of peptic ulcer patients with chlorozil and metronidazole] Tsimmerman IaS, et al.
Klin Med (Mosk) 1996;74(2):58–60 **(Rus)**
[New data on clinical response to therapeutic effects of gastrozepin] Zaĭtseva EI, et al. **Klin Med (Mosk)** 1996; 74(3):49–50 **(Rus)**
[Ethonium in the treatment of patients with gastric and duodenal peptic ulcers] Babak OIa, et al. **Lik Sprava** 1996 Mar–Apr;(3–4):123–5 (Eng. Abstr.) **(Rus)**
[The approach to prescribing pharmacological preparations in peptic ulcer] Dudar' LV. **Lik Sprava** 1995 Mar–Apr; (3–4):145–6 **(Rus)**
[The endoscopic assessment of the effect of ranitidine and pirenzepine on the manifestations of the gastropathy induced by nonsteroidal anti-inflammatory preparations] Karateev AE, et al. **Ter Arkh** 1997;69(5):67–9 (Eng. Abstr.) **(Rus)**
[Ulfamid in the combined therapy of gastric and duodenal peptic ulcer] Pal'tsev AI, et al. **Ter Arkh** 1997;69(2):62–3 **(Rus)**
[The clinico-endoscopic, psychological and physical characteristics of duodenal peptic ulcer patients using piracetam and aevit] Pimenov LT, et al. **Ter Arkh** 1997; 69(2):10–3 (Eng. Abstr.) **(Rus)**
[Ebrotidine] Elizalde JI. **Gastroenterol Hepatol** 1997 Feb; 20(2):65–7 (30 ref.) **(Spa)**
[Ebrotidine: an new alternative in peptic acid diseases (editorial)] Piqué JM. **Med Clin (Barc)** 1997 Mar 1; 108(8):301–3 **(Spa)**
[Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients] Gisbert JP, et al. **Rev Clin Esp** 1996 Sep;196(9):588–93 (Eng. Abstr.) **(Spa)**
[A multicenter clinical trial. Zinc acexamate versus famotidine in the treatment of acute duodenal ulcer. Study Group of Zinc acexamate (new UP doses)] García-Plaza A, et al. **Rev Esp Enferm Dig** 1996 Nov;88(11):757–62 (Eng. Abstr.) **(Spa)**
[What is the current therapeutic role of omeprazole in gastroduodenal ulcer disease?] Gisbert JP, et al.
Rev Esp Enferm Dig 1997 Feb;89(2):116–23 (131 ref.) **(Spa)**
[Reflux esophagitis: a comparative study of lansoprazole and omeprazole as short-term therapy. Preliminary report] Córdova-Villalobos JA, et al. **Rev Gastroenterol Mex** 1996 Oct–Dec;61(4):306–9 (Eng. Abstr.) **(Spa)**
[Superiority of pantoprazole over ranitidine in the treatment of duodenal ulcer. Mexican clinical experience. Mexican Study Group of Pantoprazole++ in Duodenal Ulcer] Dibildox M, et al. **Rev Gastroenterol Mex** 1996 Jul–Sep; 61(3):193–8 (Eng. Abstr.) **(Spa)**
[Effectiveness and safety of lansoprazole in the treatment of peptic ulcer] Ramón Nogueira J, et al.
Rev Gastroenterol Mex 1996 Oct–Dec;61(4):314–9 (Eng. Abstr.) **(Spa)**

TOXICITY

A possible mechanism of heinz body hemolytic anemia induced by DQ-2511, a new gastroprokinetic drug, in dogs. Ohno H, et al. **Fundam Appl Toxicol** 1996 Aug;32(2):269–77
Changes in tissue contents of zinc, copper and iron in rats and beagle dogs treated with polaprezinc. Yamaguchi I, et al. **J Toxicol Sci** 1996 Aug;21(3):177–87
[The toxicological characteristics of Gastrofenzin. III. Its chronic oral toxicity] Antov G, et al. **Probl Khig** 1996; 21:96–102 (Eng. Abstr.) **(Bul)**
[The toxicological characteristics of Gastrofenzin. IV. Its gonadotropic action] Ilieva P, et al. **Probl Khig** 1996; 21:102–6 (Eng. Abstr.) **(Bul)**
[The toxicological characteristics of Gastrofenzin. I. Its acute toxicity (oral, subcutaneous and intravenous)] Khalkova Zh, et al. **Probl Khig** 1996;21:81–8 (Eng. Abstr.) **(Bul)**
[The toxicological characteristics of Gastrofenzin. II. Its subacute oral toxicity] Mikhailova A, et al. **Probl Khig** 1996; 21:88–96 (Eng. Abstr.) **(Bul)**

URINE

Determination of ebrotidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography. Rozman E, et al.
J Chromatogr B Biomed Appl 1997 Jan 10;688(1):107–15
Saturable urinary excretion kinetics of famotidine in the dog. Boom SP, et al. **J Pharm Pharmacol** 1997 Mar;49(3):288–92
Determination of a new antiulcer agent, YJA-20379-2, in human plasma and urine by high-performance liquid chromatography. Yoon WH, et al.
Res Commun Mol Pathol Pharmacol 1996 Dec;94(3):317–22

ANTIVENINS

Exotic envenomation [letter; comment] Bey TA, et al.
Ann Emerg Med 1997 Jan;29(1):195. Comment on: Ann Emerg Med 1996 Jul;28(1):87–9.
Successful treatment of crotalid-induced neurotoxicity with a new polyspecific crotalid Fab antivenom. Clark RF, et al. **Ann Emerg Med** 1997 Jul;30(1):54–7

ADMINISTRATION & DOSAGE

New approaches in antivenom therapy. Choumet V, et al.
Adv Exp Med Biol 1996;391:515–20
A red-back spider bite in a lymphoedematous arm. Couser GA, et al. **Med J Aust** 1997 Jun 2;166(11):587–8
Clinical trial of intramuscular anti-snake venom administration as a first aid measure in the field in the management of Russell's viper bite patients. Win-Aung, et al. **Southeast Asian J Trop Med Public Health** 1996 Sep; 27(3):494–7
[Antivenom serum doses in the treatment of poisoning by a venomous snake of the genus Bothrops] Jorge MT, et al. **Rev Assoc Med Bras** 1997 Jan–Mar;43(1):74–6 (18 ref.) **(Por)**

BIOSYNTHESIS

Clinical and laboratory alterations in horses during immunization with snake venoms for the production of polyvalent (Crotalinae) antivenom. Angulo Y, et al.
Toxicon 1997 Jan;35(1):81–90
Assessment of an ovine antivenom raised against venom from the desert black cobra (Walterinnesia aegyptia). al-Asmari AK, et al. **Toxicon** 1997 Jan;35(1):141–5
Encapsulation of native crotoxin in liposomes: a safe approach for the production of antivenom and vaccination against Crotalus durissus terrificus venom. Freitas TV, et al. **Toxicon** 1997 Jan;35(1):91–100

BLOOD

Efficacy and potency of antivenoms in neutralizing the procoagulant effects of Australian snake venoms in dog and human plasma. Sprivulis P, et al.
Anaesth Intensive Care 1996 Jun;24(3):379–81

IMMUNOLOGY

A comparison of in vitro methods for assessing the potency of therapeutic antisera against the venom of the coral snake Micrurus nigrocinctus. Alape-Girón A, et al. **Toxicon** 1997 Apr;35(4):573–81

ANTIVENINS

Antigenic cross-reactivity of venoms from medically important Loxosceles (Araneae) species in Brazil. Barbaro KC, et al. **Toxicon** 1994 Jan;32(1):113-20

An enzyme-linked immunosorbent assay (ELISA) that discriminates between the venoms of Brazilian Bothrops species and Crotalus durissus. Chávez-Olórtegui C, et al. **Toxicon** 1997 Feb;35(2):253-60

In vivo protection against Androctonus australis hector scorpion toxin and venom by immunization with a synthetic analog of toxin II. Zenouaki I, et al. **Vaccine** 1997 Feb; 15(2):187-94

ISOLATION & PURIFICATION

A new triterpenoid saponin, bredemeyeroside B. from the roots of Bredemeyera floribunda. Daros M do D, et al. **Planta Med** 1996 Dec;62(6):523-7

Erinacin, an antihaemorrhagic factor from the European hedgehog, Erinaceus europaeus. Mebs D, et al. **Toxicon** 1996 Nov-Dec;34(11-12):1313-6

PHARMACOLOGY

Efficacy and potency of antivenoms in neutralizing the procoagulant effects of Australian snake venoms in dog and human plasma. Sprivulis P, et al.
Anaesth Intensive Care 1996 Jun;24(3):379-81

Screening of the venoms of two Parabuthus scorpion species on isolated cardiomyocytes. Van Aarde MN, et al.
Onderstepoort J Vet Res 1996 Jun;63(2):127-30

Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions. Pépin-Covatta S, et al. **Toxicol Appl Pharmacol** 1996 Nov; 141(1):272-7

Development of an antivenom against toxins of Lonomia obliqua caterpillars. Da Silva WD, et al. **Toxicon** 1996 Sep; 34(9):1045-9

Isolation of protein factors from opossum (Didelphis albiventris) serum which protect against Bothrops jararaca venom. Farah MF, et al. **Toxicon** 1996 Sep;34(9):1067-71

Alpha 2-macroglobulin of rabbits inhibits the habutobin activity. Oka U, et al. **Toxicon** 1996 Aug;34(8):903-12

Body distribution of Tityus serrulatus scorpion venom in mice and effects of scorpion antivenom. Revelo MP, et al. **Toxicon** 1996 Oct;34(10):1119-25

Effect of Habu (Trimeresurus flavoviridis) antivenom on changes of hemostatic parameters following administration of crude venom from T. flavoviridis in rabbits. Yamashita S, et al. **Toxicon** 1996 Aug;34(8):893-902

THERAPEUTIC USE

First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom. Meyer WP, et al.
Am J Trop Med Hyg 1997 Mar;56(3):291-300

Relationship of venom effects to venom antigen and antivenom serum concentrations in a patient with Crotalus atrox envenomation treated with a Fab antivenom. Seifert SA, et al. **Ann Emerg Med** 1997 Jul;30(1):49-53

Lessons from four studies on the management of snake bite in Sri Lanka. Sellahewa K. **Ceylon Med J** 1997 Mar; 42(1):8-15

Snake and spider antivenin: risks and benefits of therapy. Weisman RS, et al. **J Fla Med Assoc** 1996 Mar;83(3):192-5

First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming. Karlson-Stiber C, et al. **J Intern Med** 1997 Jan;241(1):53-8

Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy. Rivière G, et al.
J Pharmacol Exp Ther 1997 Apr;281(1):1-8

Delayed administration of Vipera xanthina palaestinae antivenin. Bentur Y, et al. **J Toxicol Clin Toxicol** 1997; 35(3):257-61

Severe envenomation by the taipan (Oxyuranus scutellatus) [letter; comment] Lalloo DG, et al. **Med J Aust** 1997 Jul 7;167(1):54-5. Comment on: Med J Aust 1996 Dec 2-16;165(11-12):662-4.

A comparison of in vitro methods for assessing the potency of therapeutic antisera against the venom of the coral snake Micrurus nigrocinctus. Alape-Girón A, et al. **Toxicon** 1997 Apr;35(4):573-81

Time factor in the detection of circulating whole venom and crotoxin and efficacy of antivenom therapy in patients envenomed by Crotalus durissus. Amaral CF, et al.
Toxicon 1997 May;35(5):699-704

Inhibition of the hemorrhagic activity of Bothrops asper venom by a novel neutralizing mixture. Borkow G, et al. **Toxicon** 1997 Jun;35(6):865-77

Anticholinesterases as antidotes to envenomation of rats by the death adder (Acanthophis antarcticus). Flachsenberger W, et al. **Toxicon** 1994 Jan;32(1):35-9

Snakebite by the bushmaster (Lachesis muta) in Brazil: case report and review of the literature. Jorge MT, et al.
Toxicon 1997 Apr;35(4):545-54 (33 ref.)

Similar effectiveness of Fab and F(ab')2 antivenoms in the neutralization of hemorrhagic activity of Vipera berus snake venom in mice. Lomonte B, et al. **Toxicon** 1996 Oct; 34(10):1197-202

Inhibitory properties of the antibothropic complex from the South American opossum (Didelphis marsupialis) serum. Neves-Ferreira AG, et al. **Toxicon** 1997 Jun;35(6):849-63

Antithrombin III and antivenom reversal of coagulopathy in rats envenomated with Malayan pit viper venom. Pukrittayakamee S, et al. **Toxicon** 1994 Jan;32(1):97-103

Development and clinical application of immunoassays for European adder (Vipera berus berus) venom and antivenom. Sjostrom L, et al. **Toxicon** 1996 Jan;34(1):91-8

A randomized double-blind clinical trial of two antivenoms in patients bitten by Bothrops atrox in Colombia. The Regional Group on Antivenom Therapy Research (REGATHER). Otero R, et al.
Trans R Soc Trop Med Hyg 1996 Nov-Dec;90(6):696-700

ANTIVIRAL AGENTS

see related

REVERSE TRANSCRIPTASE INHIBITORS

First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands [letter] de Ronde A, et al. **AIDS** 1996 Feb;10(2):231-2

The 10th International Conference on Antiviral Research. Atlanta, Georgia, USA, April 6-11, 1997. Abstracts.
Antiviral Res 1997 Apr;34(2):A1-95

9th International Conference on Antiviral Research. Urabandi, Fukushima, Japan, May 19-24, 1996. Abstracts.
Antiviral Res 1996 Apr;30(1):A1-60

Phosprenyl: a novel drug with antiviral and immunomodulatory activity. Danilov LL, et al.
Arch Immunol Ther Exp (Warsz) 1996;44(5-6):395-400 (13 ref.)

Recent advances in the uses and applications of ribosome-inactivating proteins from plants. Girbés T, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Jun;42(4):461-71 (122 ref.)

Antibiotics update. Southern PM Jr. **Compr Ther** 1997 Sep; 23(9):575-82 (29 ref.)

Adeno-associated virus based vectors as antivirals. Wong KK Jr, et al. **Curr Top Microbiol Immunol** 1996;218:145-70 (157 ref.)

Potent anti-feline immunodeficiency virus and anti-human immunodeficiency virus effect of IFN-tau. Pontzer CH, et al. **J Immunol** 1997 May 1;158(9):4351-7

Proline-rich tandem repeats of antibody complementarity-determining regions bind and neutralize human immunodeficiency virus type 1 particles. Fontenot JD, et al. **J Virol** 1996 Oct;70(10):6557-62

RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE). Schols D, et al. **J Virol** 1997 Oct;71(10):7300-4

Antiretroviral drugs for AIDS. Lipsky JJ. **Lancet** 1996 Sep 21;348(9030):800-3 (45 ref.)

Human chorionic gonadotropin hormone is antiviral. Harris PJ. **Med Hypotheses** 1996 Aug;47(2):71-2

Cytokines released by human peripheral blood mononuclear cells inhibit the production of early and late cytomegalovirus proteins. Torigoe S, et al.
Microbiol Immunol 1997;41(5):403-13

New approach for inhibiting Rev function and HIV-1 production using the influenza virus NS1 protein. Qian XY, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):8873-7

The antiviral role of nitric oxide. Mannick JB.
Res Immunol 1995 Nov-Dec;146(9):693-7 (41 ref.)

Transactivation of dianthin transgene expression by African cassava mosaic virus AC2. Hong Y, et al. **Virology** 1997 Feb 17;228(2):383-7

Novobiocin inhibits vaccinia virus replication by blocking virus assembly. Sekiguchi J, et al. **Virology** 1997 Aug 18; 235(1):129-37

[Development of an anti-HIV gene therapy based on the antiviral properties of beta interferon] De Maeyer E, et al. **Transfus Clin Biol** 1997;4(3):281-6 (13 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

n-Docosanol 10% cream in the treatment of recurrent herpes labialis: a randomised, double-blind, placebo-controlled study. Habbema L, et al. **Acta Derm Venereol** 1996 Nov; 76(6):479-81

Comparison of specific immunities to varicella-zoster virus following post-exposure prophylaxis of varicella by oral acyclovir observed in a family. Asano Y, et al.
Acta Paediatr Jpn 1996 Dec;38(6):692-4

Methionine enkephalin used in combination with azidothymidine in murine retrovirus infection. Specter S, et al. **Adv Exp Med Biol** 1996;402:59-62

Therapy in chronic hepatitis C: say goodbye to the 6-month interferon regimen [editorial] Koff RS.
Am J Gastroenterol 1996 Oct;91(10):2072-4

Gilead issues new warnings about cidofovir nephrotoxicity [news] **Am J Health Syst Pharm** 1997 Jan 1;54(1):12, 15

Consensus panel advocates prolonged interferon treatment for chronic hepatitis C [news]
Am J Health Syst Pharm 1997 May 15;54(10):1140, 1145

Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group.
Ann Intern Med 1997 Feb 15;126(4):264-74

Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Lalezari JP, et al. **Ann Intern Med** 1997 Feb 15; 126(4):257-63

Combination antiviral therapy for cytomegalovirus disease in patients with AIDS. Cline JJ, et al.
Ann Pharmacother 1997 Sep;31(9):1080-2 (14 ref.)

Intravitreal ganciclovir for cytomegalovirus retinitis in patients with AIDS. Montero MC, et al.
Ann Pharmacother 1996 Jul-Aug;30(7-8):717-23

Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Yang L, et al. **Ann Surg** 1996 Sep; 224(3):405-14; discussion 414-7

Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Bender AR, et al.
Antimicrob Agents Chemother 1996 Jun;40(6):1467-71

Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation. Drusano GL, et al.
Antimicrob Agents Chemother 1996 May;40(5):1143-7

Treatment of acyclovir-resistant perianal herpetic ulceration with intramuscular interferon alfa. Borrego L, et al.
Arch Dermatol 1996 Oct;132(10):1157-8

A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. The Epithelial Keratitis Trial. The Herpetic Eye Disease Study Group. **Arch Ophthalmol** 1997 Jun;115(6):703-12

Hypotony and visual loss with intravenous cidofovir treatment of cytomegalovirus retinitis [letter] [see comments] Friedberg DN. **Arch Ophthalmol** 1997 Jun; 115(6):801-2. Comment in: Arch Ophthalmol 1997 Jun;115(6):785-6.

Cyclodialysis complicating intravitreal ganciclovir implantation [letter] Gentile RC, et al. **Arch Ophthalmol** 1997 Sep;115(9):1204-5

Triple therapy reduces HIV virus to undetected levels [news]
Aust Fam Physician 1996 Dec;25(12):1816

Management issues in herpes zoster. Dwyer DE.
Aust Fam Physician 1996 Mar;25(3):299-307 (14 ref.)

Ribavirin conjugated with lactosaminated poly-L-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis. Di Stefano G, et al.
Biochem Pharmacol 1997 Aug 1;54(3):357-63

Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up. Zaia JA, et al.
Biol Blood Marrow Transplant 1995 Dec;1(2):88-93

Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy? [editorial] Mathé G, et al.
Biomed Pharmacother 1996;50(10):473-9 (41 ref.)

Oral application of cytokines. Georgiades JA, et al.
Biotherapy 1996;8(3-4):205-12 (44 ref.)

Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis. Nicholson VA, et al.
Bone Marrow Transplant 1997 Jan;19(1):37-41

Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Sparrelid E, et al.
Bone Marrow Transplant 1997 May;19(9):905-8

Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Ljungman P, et al. **Clin Infect Dis** 1996 Jul;23(1):167-9

Cytomegalovirus retinitis: decreased risk of bilaterality with increased use of systemic treatment. Swiss HIV Cohort Study Group. Stalder N, et al. **Clin Infect Dis** 1997 Apr; 24(4):620-4

A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Verdonck LF, et al. **Clin Infect Dis** 1997 May; 24(5):901-7

Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations. Rensen PC, et al.
Clin Pharmacokinet 1996 Aug;31(2):131-55 (190 ref.)

Oral ganciclovir: role in maintenance therapy for CMV retinitis in AIDS patients. Owens RC Jr, et al.
Conn Med 1996 Nov;60(11):663-5

Preliminary results of beta-interferon treatment in the elderly. Terranova R, et al. **Control Clin Trials** 1996 Apr; 17(2):123-9

Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Cundy KC, et al.
Curr Eye Res 1996 May;15(5):569-76

Interferon-ribavirin combination therapy for chronic hepatitis C. Schalm SW, et al. **Dig Dis Sci** 1996 Dec;41(12 Suppl):131S-134S

Alpha-Interferon for the treatment of idiopathic sudden sensorineural hearing loss. Kanemaru S, et al.
Eur Arch Otorhinolaryngol 1997;254(3):158-62

Resolution of anorectal incontinence in herpes proctitis confirmed by anorectal manometry. Joseph D, et al.
Gastrointest Endosc 1997 May;45(5):429-32 (14 ref.)

Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind

clinical trial. International Valaciclovir HSV Study Group. Bodsworth NJ, et al. **Genitourin Med** 1997 Apr;73(2):110–6

Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group [see comments] Patel R, et al. **Genitourin Med** 1997 Apr; 73(2):105–9. Comment in: Genitourin Med 1997 Apr;73(2):83–4.

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation [see comments] Bizollon T, et al. **Hepatology** 1997 Aug;26(2):500–4. Comment in: Hepatology 1997 Aug;26(2):505–6.

Ribavirin and interferon for recurrent posttransplantation HCV infection: to treat or not to treat? [editorial; comment] McHutchison JG. **Hepatology** 1997 Aug;26(2):505–6. Comment on: Hepatology 1997 Aug;26(2):500–4.

N-acetylcysteine infusion in viral myocarditis: a case report. Rowbotham DS, et al. **Int J Cardiol** 1997 Aug 8;60(3):315–6

Sustained remission and viraemia in chronic hepatitis C treated with recombinant alpha-interferon (rIFN-alpha). Bresci G, et al. **Int J Clin Pharmacol Res** 1995; 15(5–6):175–9

Antiviral efficacies of famciclovir, valaciclovir, and brivudin in disseminated herpes simplex virus type 1 infection in mice. Wutzler P, et al. **Intervirology** 1997;40(1):15–21

Prolonged treatment of chronic C hepatitis by means of medium-high doses of recombinant alpha-2b interferon: an open study to evaluate response and long-term relapse. Benetti GP, et al. **Ital J Gastroenterol** 1996 Apr; 28(3):127–35

Interferon and steroid treatment in patients with chronic hepatitis C and antinuclear or anti-liver-kidney microsomal antibodies. Provenzano G, et al. **Ital J Gastroenterol** 1996 Sep;28(7):377–80

Is long-term continuous therapy for recurrent herpes simplex safe? [letter] Wolf R, et al. **J Am Acad Dermatol** 1997 Sep; 37(3 Pt 1):508–10

Nutrition support for children with HIV/AIDS [news] Heller LS, et al. **J Am Diet Assoc** 1997 May;97(5):473–4

Predictive factors of a response to interferon therapy in chronic hepatitis C. Nomura H, et al. **J Clin Gastroenterol** 1996 Oct;23(3):185–90

Oral famciclovir for recurrent genital herpes. Brown D. **J Fam Pract** 1996 Oct;43(4):341–2

Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial. Tanaka K, et al. **J Gastroenterol Hepatol** 1996 Dec;11(12):1155–60

Prevalence of breakthrough in chronic hepatitis C patients undergoing antiviral therapy: role of type and schedule of alpha interferon C.H.S.G [letter] Bellati G, et al. **J Hepatol** 1997 Feb;26(2):449–50

Hepatotropic conjugate of adenine arabinoside monophosphate with lactosaminated poly-L-lysine. Synthesis of the carrier and pharmacological properties of the conjugate. Fiume L, et al. **J Hepatol** 1997 Feb; 26(2):253–9

Timing of IFN therapy initiation for acute hepatitis C after accidental needlestick [letter] Sata M, et al. **J Hepatol** 1997 Aug;27(2):425–6

Inhibition of graft-versus-host disease. Use of a T cell-controlled suicide gene. Helene M, et al. **J Immunol** 1997 Jun 1;158(11):5079–82

Central venous line infections in AIDS. Moore DA, et al. **J Infect** 1997 Jan;34(1):35–40

Topical undecylenic acid for herpes simplex labialis: a multicenter, placebo-controlled trial. Shafran SD, et al. **J Infect Dis** 1997 Jul;176(1):78–83

Targeting antiviral nucleotide analogues to macrophages. Magnani M, et al. **J Leukoc Biol** 1997 Jul;62(1):133–7 (32 ref.)

Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. Gordon M, et al. **J Med** 1997;28(1–2):108–28

Release kinetics of liposome-encapsulated ganciclovir after intravitreal injection in rabbits. Le Bourlais C, et al. **J Microencapsul** 1996 Jul–Aug;13(4):473–80

Alternative delivery systems for antiviral nucleosides and antisense oligonucleotides to the brain. Levy RM, et al. **J Neurovirol** 1997 May;3 Suppl 1:S74–5

Intravenous ribavirin therapy in a neonate with disseminated adenovirus infection undergoing extracorporeal membrane oxygenation: pharmacokinetics and clearance by hemofiltration. Aebi C, et al. **J Pediatr** 1997 Apr; 130(4):612–5

Ribavirin potentiates the efficacy and toxicity of 2',3'-dideoxyinosine in the murine acquired immunodeficiency syndrome model. Harvie P, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):1009–17

Prolonged therapy of chronic hepatitis C with ribavirin. Hoofnagle JH, et al. **J Viral Hepat** 1996 Sep;3(5):247–52

The Delta trial [letter; comment] Bucher HC. **Lancet** 1996 Nov 2;348(9036):1237; discussion 1237–8. Comment on: Lancet 1996 Aug 3;348(9023):278–9.

Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Honkoop P, et al. **Liver** 1997 Apr;17(2):103–6

Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study. Imai Y, et al. **Liver** 1997 Apr;17(2):88–92

More on continuous-infusion acyclovir for severe varicella [letter; comment] Krolewiecki AJ, et al. **N Engl J Med** 1997 Jul 17;337(3):203–4. Comment on: N Engl J Med 1997 Mar 6;336(10):732–3.

Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. Musch DC, et al. **N Engl J Med** 1997 Jul 10;337(2):83–90

Zidovudine in HIV-positive pregnant women and their babies [letter] Samuel NM, et al. **Natl Med J India** 1996 Jul-Aug;9(4):200–1

Impact of ganciclovir prophylaxis on cytomegalovirus infection in recipients of cadaveric renal allografts. Ram Peddi V, et al. **Nephron** 1997;76(1):49–55

Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon. Anlar B, et al. **Neurology** 1997 Feb; 48(2):526–8

Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Plioplys AV, et al. **Neuropsychobiology** 1997; 35(1):16–23

Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Randolph AG, et al. **Obstet Gynecol** 1996 Oct;88(4 Pt 1):603–10

Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Baudouin C, et al. **Ophthalmologica** 1996; 210(6):329–35

Ganciclovir intraocular implant [letter; comment] Morley MG, et al. **Ophthalmology** 1996 Oct;103(10):1517. Comment on: Ophthalmology 1996 Mar;103(3):416–21.

Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Taskintuna I, et al. **Ophthalmology** 1997 Jun;104(6):1049–57

Marigenol-concentrates comprising Taxol and/or Taxan esters as active substances. Eugster C, et al. **Panminerva Med** 1996 Dec;38(4):234–42

Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review. Zaknun D, et al. **Pediatr Infect Dis J** 1997 Aug; 16(8):807–11

Early ribavirin treatment did not prevent severe disease in high-risk bronchopulmonary dysplasia patients with respiratory syncytial virus infection [letter] De Boeck K, et al. **Pediatr Pulmonol** 1996 May;21(5):343

Central venous catheter infections in AIDS patients receiving daily home therapy for cytomegalovirus disease. Casado JL, et al. **QJM** 1996 Sep;89(9):695–9

Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection. Grimaldi S, et al. **Res Virol** 1997 Mar-Apr;148(2):177–80

Use of herpes simplex virus thymidine kinase to improve the antiviral activity of zidovudine. Guettari N, et al. **Virology** 1997 Sep 1;235(2):398–405

A new mode of treatment of human papilloma virus associated anogenital lesions using a nonsteroid estrogen analogue. Schön HJ, et al. **Wien Klin Wochenschr** 1996; 108(2):45–7

[Systemic antiviral chemotherapy] Gerstoft J. **Ugeskr Laeger** 1997 Apr 7;159(15):2197–200 **(Dan)**

[Acyclovir freely obtainable (letter; comment)] Lekkerkerker JF, et al. **Ned Tijdschr Geneeskd** 1996 Sep 7;140(36):1832 . Comment on: Ned Tijdschr Geneeskd 1996 Jul 6;140(27):1412–3. **(Dut)**

[How should hepatitis C be treated? Treatment of hepatitis C with interferon] Marcellin P. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S81–8 (44 ref.) **(Fre)**

[Technique of implantation of A ganciclovir-containing intravitreal device] Lehoang P, et al. **J Fr Ophtalmol** 1997; 20(2):163–5 **(Fre)**

[Infectious complications of implantable infusion ports in patients with HIV infection] Benharrats I, et al. **Rev Med Interne** 1997;18(6):443–9 (Eng. Abstr.) **(Fre)**

[Herpes neonatorum—prevention and therapy. Which newborn infants are at risk? When cesarean section, when acyclovir?] Gabler-Sandberger E. **Fortschr Med** 1996 Oct 30;114(30):393–4 **(Ger)**

[What should be done after needlestick injuries with possible HIV exposure?] Marcus U. **Fortschr Med** 1996 Feb 10; 114(4):23–4 **(Ger)**

[The same procedure as every year] Schaberg T. **Pneumologie** 1996 Feb;50(2):220–2 **(Ger)**

[Intravitreal injection of ganciclovir in AIDS patients with cytomegalovirus retinitis] Fujino Y, et al. **Nippon Ganka Gakkai Zasshi** 1996 Aug;100(8):634–40 (Eng. Abstr.) **(Jpn)**

[Use of intravitreal ganciclovir for cytomegalovirus retinitis in a patient with systemic lupus erythematosus] Kaji Y, et al. **Nippon Ganka Gakkai Zasshi** 1997 Jun;101(6):525–31 (Eng. Abstr.) **(Jpn)**

[Successful treatment in a case of type-C fulminant hepatitis with interferon and steroid-pulse therapy, and review of its virological aspects] Marusawa H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):583–7 **(Jpn)**

[Clinical effectiveness of aprotinin aerosol in influenza and parainfluenza] Zhirnov OP, et al. **Vestn Ross Akad Med Nauk** 1996;(5):26–31 (Eng. Abstr.) **(Rus)**

[Prediction of the epidemiological efficiency rate of preventive antiviral drugs from laboratory findings] Zhukov VA, et al. **Vestn Ross Akad Med Nauk** 1996; (10):36–40 (Eng. Abstr.) **(Rus)**

[Interferon alfa in the treatment of chronic hepatitis C: course of 24 versus 48 weeks. Results of a randomized trial] Fassio E, et al. **Acta Gastroenterol Latinoam** 1996;26(3):149–53 (Eng. Abstr.) **(Spa)**

[Famciclovir plus interferon in the treatment of a patient with chronic hepatitis B and severe liver failure] Piqueras B, et al. **Rev Esp Enferm Dig** 1997 Mar;89(3):217–21 (Eng. Abstr.) **(Spa)**

[Severe falciparum malaria among travellers to Thailand. Blood exchange and artemisinine treatment are therapeutic alternatives] Ekvall H, et al. **Lakartidningen** 1997 Apr 30; 94(18):1713–5 (15 ref.) **(Swe)**

ADVERSE EFFECTS

Foscarnet-induced hypercalcaemia in AIDS [letter] Gayet S, et al. **AIDS** 1997 Jul;11(8):1068–70

Acyclovir-induced colitis. Wardle TD, et al. **Aliment Pharmacol Ther** 1997 Apr;11(2):415–7

Allergic contact dermatitis to Zovirax cream. Bourezane Y, et al. **Allergy** 1996 Oct;51(10):755–6 (10 ref.)

Gilead issues new warnings about cidofovir nephrotoxicity [news] **Am J Health Syst Pharm** 1997 Jan 1;54(1):12, 15

Confusion and bradykinesia associated with famciclovir therapy for herpes zoster [letter] Gales BJ, et al. **Am J Health Syst Pharm** 1996 Jun 15;53(12):1454, 1456

Gancyclovir-induced megakaryocyte loss in chronic myelogenous leukemia post bone-marrow transplant [letter] Gardner L, et al. **Am J Hematol** 1996 Nov; 53(3):204–5

In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Dornsife RE, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):514–9

Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Wang LH, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):80–5

Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis [see comments] Davis JL, et al. **Arch Ophthalmol** 1997 Jun;115(6):733–7. Comment in: Arch Ophthalmol 1997 Jun;115(6):785–6.

Lack of beta-oxidation defects in human immunodeficiency virus-positive subjects with and without chronic zidovudine exposure [letter; comment] Wachsman M, et al. **Blood** 1996 Oct 15;88(8):3243–4. Comment on: Blood 1995 Oct 1;86(7):2481–7.

Reversible brain MRI changes in acyclovir neurotoxicity. Blohm ME, et al. **Bone Marrow Transplant** 1997 May; 19(10):1049–51

Eye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir. Openshaw H, et al. **Bone Marrow Transplant** 1997 Mar;19(5):503–5

The topical application of resorcinol can provoke a systemic allergic reaction [letter] Barbaud A, et al. **Br J Dermatol** 1996 Dec;135(6):1014–5

Development of arthritis and hypothyroidism during alpha-interferon therapy for chronic hepatitis C. Pittau E, et al. **Clin Exp Rheumatol** 1997 Jul-Aug;15(4):415–9 (25 ref.)

Fixed drug eruption due to acyclovir. Montoro J, et al. **Contact Dermatitis** 1997 Apr;36(4):225

Nephrotoxicity of antiviral therapies. Becker BN, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):375–9 (44 ref.)

Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis. Shiba T, et al. **Diabetes Res Clin Pract** 1995 Dec;30(3):237–41

Granulomatous hepatitis in a patient with chronic hepatitis C treated with interferon-alpha. Veerabagu MP, et al. **Dig Dis Sci** 1997 Jul;42(7):1445–8

Mitochondrial injury. Lessons from the fialuridine trial. Honkoop P, et al. **Drug Saf** 1997 Jul;17(1):1–7 (37 ref.)

Minimising the dosage-limiting toxicities of foscarnet induction therapy. Jayaweera DT. **Drug Saf** 1997 Apr; 16(4):258–66 (40 ref.)

Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. Areias J, et al. **Eur J Gastroenterol Hepatol** 1996 Aug;8(8):825–8

Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Ishizaki T, et al. **Eur Respir J** 1996 Dec;9(12):2691–6

Hepatotoxicity of antiviral agents. Styrt B, et al. **Gastroenterol Clin North Am** 1995 Dec;24(4):839–52 (84 ref.)

Side effects of alpha interferon in chronic hepatitis C. Dusheiko G. **Hepatology** 1997 Sep;26(3 Suppl 1):112S–121S (112 ref.)

Unusual course of herpes simplex virus encephalitis after acyclovir therapy. Preiser W, et al. **Infection** 1996 Sep–Oct; 24(5):384–9

Anticholinergic syndrome with severe rhabdomyolysis—an unusual feature of amantadine toxicity [letter] Yang CC, et al. **Intensive Care Med** 1997 Mar;23(3):355–6

Occurrence of lymphomas during ddC or ddC/zidovudine combination therapy in persons infected with HIV type 1 [letter] Moyle GJ. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 15;13(5):464–5

Interferon alfa-associated retinopathy. Chambers RB, et al. **J Am Osteopath Assoc** 1997 Jan;97(1):43-5 (12 ref.)

Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor: the effects of zidovudine. Aweeka FT, et al. **J Clin Pharmacol** 1996 Dec;36(12):1107-13

Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B. Sata M, et al. **J Gastroenterol** 1997 Apr;32(2):206-10

Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C. Tada H, et al. **J Gastroenterol** 1996 Aug;31(4):582-4

Hemolytic anemia provoked by recombinant alpha-interferon. Takase K, et al. **J Gastroenterol** 1995 Dec; 30(6):795-7

Case report: agranulocytosis induced by interferon-alpha therapy for chronic hepatitis C. Higashi Y, et al. **J Gastroenterol Hepatol** 1996 Nov;11(11):1012-5

Immune thrombocytopenia and alpha-interferon therapy. Dourakis SP, et al. **J Hepatol** 1996 Dec;25(6):972-5

Interferon-associated thyroid dysfunction in anti-D-related chronic hepatitis C. Sachithanandan S, et al. **J Interferon Cytokine Res** 1997 Jul;17(7):409-11

Interferon-alpha-induced human lupus inclusions and p36 protein in cancer and AIDS. Vakharia DD, et al. **J Interferon Cytokine Res** 1996 Sep;16(9):709-15

Mitochondrial DNA levels in the brain of HIV-positive patients after zidovudine therapy. Davison FD, et al. **J Neurol** 1996 Sep;243(9):648-51

Changes in results of Gallium-67-citrate scanning after interferon therapy for chronic hepatitis C. Shiomi S, et al. **J Nucl Med** 1997 Feb;38(2):216-9

Health care worker exposure to aerosolized ribavirin: biological and air monitoring. Shults RA, et al. **J Occup Environ Med** 1996 Mar;38(3):257-63

Interferon-alpha associated arthritis. Chung A, et al. **J Rheumatol** 1997 Sep;24(9):1844-5

Axonal neuropathy in a patient receiving interferon-alpha therapy for chronic hepatitis C [letter] Tambini R, et al. **J Rheumatol** 1997 Aug;24(8):1656-7

Strategic proposals for predicting drug-drug interactions during new drug development: based on sixteen deaths caused by interactions of the new antiviral sorivudine with 5-fluorouracil prodrugs. Watabe T. **J Toxicol Sci** 1996 Dec; 21(5):299-300

Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. Thevenot T, et al. **J Viral Hepat** 1997 Jul; 4(4):243-53

From the Food and Drug Administration. Nightingale SL. **JAMA** 1996 Dec 4;276(21):1710

The Delta trial [letter; comment] Blackmore T, et al. **Lancet** 1996 Nov 2;348(9036):1238-9. Comment on: Lancet 1996 Aug 3;348(9023):283-91.

Nephrogenic diabetes insipidus in a patient taking cidofovir [letter] Schliefer K, et al. **Lancet** 1997 Aug 9; 350(9075):413-4

The Delta trial [letter; comment] Scott WF. **Lancet** 1996 Nov 2;348(9036):1238; discussion 1239. Comment on: Lancet 1996 Aug 3;348(9023):283-91.

Interferon-alpha does not cause significant cardiac dysfunction in patients with chronic active hepatitis. Kadayifci A, et al. **Liver** 1997 Apr;17(2):99-102

Histopathologic changes associated with fialuridine hepatotoxicity. Kleiner DE, et al. **Mod Pathol** 1997 Mar; 10(3):192-9

Neurotoxicity associated with acyclovir in end stage renal failure. Kitching AR, et al. **N Z Med J** 1997 May 9; 110(1043):167-9 (19 ref.)

Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Rostaing L, et al. **Nephron** 1996;74(3):512-6

Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention [published erratum appears in Ophthalmology 1997 Jul;104(7):1063] Chavez-de la Paz E, et al. **Ophthalmology** 1997 Mar;104(3):539-44

Delayed gastric emptying during interferon-alpha therapy in patients with chronic hepatitis C: relief by cisapride. Nishibayashi H, et al. **Scand J Gastroenterol** 1997 Jun; 32(6):547-51

Rapid growth of hepatocellular carcinoma after or during interferon treatment of chronic hepatitis C: report of three cases. Onitsuka A, et al. **Surg Today** 1996;26(2):126-30

Indinavir-induced nephropathy. Weber L, et al. **Tenn Med** 1997 Jul;90(7):286-8

[Natural history of dysthyroidism during interferon treatment of chronic hepatitis C] Mekkakia-Benhabib C, et al. **Ann Endocrinol (Paris)** 1996;57(5):419-27 (Eng. Abstr.) **(Fre)**

[Persecution syndrome after the use of interferon: a case report] Lemonnier E, et al. **Ann Med Psychol (Paris)** 1996 Jun;154(4):246-8; discussion 248-9 (Eng. Abstr.) **(Fre)**

[Sudden deafness induced by interferon-alpha in viral hepatitis C (letter)] Bailly F, et al. **Gastroenterol Clin Biol** 1997;21(2):157-8 **(Fre)**

[Severe local cutaneous necrosis during treatment with interferon-alpha and ribavirin for chronic viral hepatitis C (letter)] de Ledinghen V, et al. **Gastroenterol Clin Biol** 1997;21(6-7):523-4 **(Fre)**

[How should hepatitis C be monitored? Monitoring of treated hepatitis C] Larrey D. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S99-110 (124 ref.) **(Fre)**

[Sugar diabetes in AIDS patients treated with antiretroviral nucleoside analogs] Mauvais-Jarvis F, et al. **Journ Annu Diabetol Hotel Dieu** 1997;:43-8 (29 ref.) **(Fre)**

[Coma induced by intravenous acyclovir in a hemodialyzed patient (letter)] Abad S, et al. **Presse Med** 1997 Jun 28; 26(22):1050 **(Fre)**

[Raynaud syndrome complicated by digital gangrene during treatment with interferon-alpha] Liozon E, et al. **Rev Med Interne** 1997;18(4):316-9 (Eng. Abstr.) **(Fre)**

[A case of chronic hepatitis complicated by subacute thyroiditis during beta-interferon treatment] Tanabashi S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jul; 93(7):496-500 **(Jpn)**

[A patient with thyroid carcinoma who developed consciousness disturbance during acyclovir administration for herpes zoster] Matsumoto R, et al. **Rinsho Shinkeigaku** 1996 Apr;36(4):590-3 (Eng. Abstr.) **(Jpn)**

[Ciprofloxacin nephropathy, acyclovir nephropathy] Ohno I. **Ryoikibetsu Shokogun Shirizu** 1997;(16 Pt 1):556-9 (18 ref.) **(Jpn)**

[Hypothyroidism as a complication of the treatment of hepatitis C with interferon] Gomollón García F, et al. **An Med Interna** 1996 Sep;13(9):438-40 (Eng. Abstr.) **(Spa)**

[Management of acyclovir-induced renal insufficiency (letter; comment)] Rodríguez González A, et al. **An Med Interna** 1996 Sep;13(9):459-60. Comment on: An Med Interna 1995 Oct;12(10):501-2. **(Spa)**

[Genital ulcers from foscarnet: three cases (letter)] Luelmo J, et al. **Med Clin (Barc)** 1996 Sep 14;107(8):318 **(Spa)**

[Thyroid dysfunction in patients with chronic hepatitis C pre and post treatment with interferon] Martín-Vivaldi R, et al. **Rev Esp Enferm Dig** 1996 Jul;88(7):480-4 (Eng. Abstr.) **(Spa)**

ANALYSIS

Didanosine measurement by radioimmunoassay. DeRemer M, et al. **Antimicrob Agents Chemother** 1996 Jun; 40(6):1331-4

Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology. Robbins BL, et al. **Antimicrob Agents Chemother** 1996 Nov; 40(11):2651-4

Comparison of high performance capillary electrophoresis and liquid chromatography for the determination of acyclovir and guanine in pharmaceuticals and urine. Zhang SS, et al. **Biomed Chromatogr** 1996 Sep-Oct;10(5):256-7

Identification of a biological inactive complex form of pokeweed antiviral protein. Desvoyes B, et al. **FEBS Lett** 1997 Jun 30;410(2-3):303-8

High-performance liquid chromatographic determination of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane, and their metabolite (-)-beta-D-dioxolane guanine in monkey serum, urine and cerebrospinal fluid. Chen H, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11;691(2):425-32

High-performance liquid chromatographic determination of cytosine-containing compounds by precolumn fluorescence derivatization with phenacyl bromide: application to antiviral nucleosides and nucleotides. Eisenberg EJ, et al. **J Chromatogr B Biomed Appl** 1996 Apr 26;679(1-2):119-27

ANTAGONISTS & INHIBITORS

Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model. Romanowski EG, et al. **Invest Ophthalmol Vis Sci** 1997 Jan;38(1):253-7

BLOOD

Radioimmunoassay for quantitation of 2',3'-didehydro-3'-deoxythymidine (D4T) in human plasma. Zhou XJ, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1472-5

A simple high performance liquid chromatography (HPLC) assay for aciclovir and ganciclovir in serum [letter] McMullin CM, et al. **J Antimicrob Chemother** 1996 Oct; 38(4):739-40

Determination of FCE 26644, a new polysulphonated derivative of distamycin A, in monkey plasma by reversed-phase ion-pair high-performance liquid chromatography with ultraviolet detection. Frigerio E, et al. **J Chromatogr A** 1996 Apr 5;729(1-2):237-42

Determination of acyclovir in human plasma by high-performance liquid chromatography. Boulieu R, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):233-6

Validation of a high-performance liquid chromatographic-mass spectrometric method for the measurement of 5-chloro-2',3'-dideoxy-3' -fluorouridine (935U83) in human plasma. Dunn JA, et al. **J Chromatogr B Biomed Appl** 1996 Nov 15;686(2):241-8

High-performance liquid chromatographic method for the determination of an HIV-1 non-nucleoside reverse transcriptase inhibitor (L-696,229) in plasma samples from animals. Lee LL, et al. **J Chromatogr B Biomed Appl** 1996 Oct 25;685(2):323-8

Simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma using fluorescence detection. Peh KK, et al. **J Chromatogr B Biomed Appl** 1997 May 23;693(1):241-4

Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanine in serum and urine using solid-phase extraction and high-performance liquid chromatography. Svensson JO, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1-2):363-6

Determination of amiprilose in human plasma by high-performance liquid chromatography with fluorimetric detection. Wu ST, et al. **J Chromatogr B Biomed Appl** 1997 Apr 25;692(1):149-56

Scintillation proximity radioimmunoassay for the measurement of acyclovir. Tadepalli SM, et al. **J Pharm Biomed Anal** 1996 Nov;15(2):157-63

Variability in zidovudine serum concentrations. Fletcher CV, et al. **Pharmacotherapy** 1996 Nov-Dec;16(6):1154-8

CEREBROSPINAL FLUID

Sensitive reversed-phase high-performance liquid chromatographic method for the determination of atevirdine and its N-desethyl metabolite in human saliva or cerebrospinal fluid using solid-phase extraction. Howard GM, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6; 693(2):431-6

CHEMICAL SYNTHESIS

Synthetic and biological applications of tricyclic analogues of guanosine. Golankiewicz B. **Acta Biochim Pol** 1996; 43(1):53-64 (47 ref.)

New insights regarding the potential of the pronucleotide approach in antiviral chemotherapy. Gosselin G, et al. **Acta Biochim Pol** 1996;43(1):196-208 (31 ref.)

Modified substrates of DNA polymerases and design of antivirals. Krayevsky AA, et al. **Acta Biochim Pol** 1996; 43(1):125-32 (43 ref.)

Synthesis and antiviral activity of 5-substituted (2'S)-2'-deoxy-2'-C-methylcytidines and -uridines. Awano H, et al. **Arch Pharm (Weinheim)** 1996 Feb; 329(2):66-72

Pyridazines 79. Novel oxazolo[3',2':1,2]pyrrolo[3,4-d]pyridazines and imidazolo[1'2':1,2]pyrrolo[3,4-d]pyridazines: synthesis and biological evaluation. Barth B, et al. **Arch Pharm (Weinheim)** 1996 Aug-Sep;329(8-9):403-7

Carbohydrate natural products as a scaffolding for the preparation of potential neuraminidase inhibitors. Maione AM, et al. **Arch Pharm (Weinheim)** 1997 Jan-Feb; 330(1-2):17-20

2',3'-dideoxynucleoside triphosphates (ddNTP) and di-2',3'-dideoxynucleoside tetraphosphates (ddNp4ddN) behave differently to the corresponding NTP and Np4N counterparts as substrates of firefly luciferase, dinucleoside tetraphosphatase and phosphodiesterases. Sillero MA, et al. **Biochim Biophys Acta** 1997 Mar 15;1334(2-3):191-9

Synthesis and antiviral activity of peptide-oligonucleotide conjugates prepared by using N alpha-(bromoacetyl)peptides. Arar K, et al. **Bioconjug Chem** 1995 Sep-Oct;6(5):573-7

Synthesis and antiviral activity of 3'-C-branched-3'-deoxy analogues of adenosine. Mikhailopulo IA, et al. **Carbohydr Res** 1996 May 14;285:17-28

Synthesis and antiviral activity of 6-chloropurine arabinoside and its 2'-deoxy-2'-fluoro derivative. Maruyama T, et al. **Chem Pharm Bull (Tokyo)** 1996 Dec;44(12):2331-4

New neplanocin analogues. IX. A practical preparation of (6'R)-6'-C-methylneplanocin A (RMNPA), a potent antiviral agent, and the determination of its 6'-configuration. Diastereoselective deamination by adenosine deaminase. Shuto S, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan;45(1):138-42

New neplanocin analogues. VIII. Synthesis and biological activity of 6'-C-ethyl, -ethenyl, and -ethynyl derivatives of neplanocin A. Shuto S, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1163-8

Halogenated isoniazid derivatives VI. Evaluation of anti-HSV-1 and anti-HIV-1 in vitro activities of fluorinated analogues. Arena A, et al. **Farmaco** 1996 Jul; 51(7):517-23

New naphthyloxyalkyl beta-diketone and 3,5-dimethylisoxazole derivatives as potential antiviral agents. Balkan A, et al. **Farmaco** 1996 Aug-Sep; 51(8-9):589-94

Acyclic glycosidopyrroles analogues of ganciclovir: synthesis and biological activity. Diana P, et al. **Farmaco** 1997 May; 52(5):281-2

IMP dehydrogenase as a target of antitumor and antiviral chemotherapy. Franchetti P, et al. **Farmaco** 1996 Jul; 51(7):457-69 (141 ref.)

3,6-Disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles: synthesis and evaluation for antimicrobial and antiviral activity. III. Invidiata FP, et al. **Farmaco** 1997 Apr; 52(4):259-61

Design of aromatic inhibitors of influenza virus neuraminidase. Luo M, et al. **J Infect Dis** 1997 Aug;176 Suppl 1:S62-5

Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides. Du J, et al. **J Med Chem** 1997 Sep 12; 40(19):2991-3

Synthesis and antiviral activity of certain 5'-modified analogs of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole. Gudmundsson KS, et al. **J Med Chem** 1997 Feb 28;

40(5):785–93
Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity. Holý A, et al. **J Med Chem** 1996 Sep 27;39(20):4073–88
Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. Hultén J, et al. **J Med Chem** 1997 Mar 14;40(6):885–97
Synthesis and anti-hepatitis B virus activity of 9-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl) purine nucleosides. Ma T, et al. **J Med Chem** 1997 Aug 15; 40(17):2750–4
Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides? Marquez VE, et al. **J Med Chem** 1996 Sep 13;39(19):3739–47
Synthesis and antiproliferative and antiviral activity of carbohydrate-modified pyrrolo[2,3-d]pyridazin-7-one nucleosides. Meade EA, et al. **J Med Chem** 1997 Feb 28; 40(5):794–801
New neplanocin analogues. 7. Synthesis and antiviral activity of 2-halo derivatives of neplanocin A. Obara T, et al. **J Med Chem** 1996 Sep 13;39(19):3847–52
Synthesis and anti-HIV activity of novel N-1 side chain-modified analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). Pontikis R, et al. **J Med Chem** 1997 Jun 6; 40(12):1845–54
Synthesis, antiproliferative and antiviral activity of imidazo[4,5-d]isothiazole nucleosides as 5:5 fused analogs of nebularine and 6-methylpurine ribonucleoside. Swayze EE, et al. **J Med Chem** 1997 Feb 28;40(5):771–84
Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues. Wnuk SF, et al. **J Med Chem** 1997 May 23;40(11):1608–18
A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities. Yoshimura Y, et al. **J Med Chem** 1997 Jul 4;40(14):2177–83
Design, synthesis, and antiviral evaluation of 2-substituted 4,5-dichloro- and 4,6-dichloro-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections. Zou R, et al. **J Med Chem** 1997 Feb 28;40(5):802–10
Design, synthesis, and antiviral evaluation of 2-chloro-5,6-dihalo-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections. Zou R, et al. **J Med Chem** 1997 Feb 28;40(5):811–8
Synthesis of alpha-glucosidase I inhibitors showing antiviral (HIV-1) and immunosuppressive activity. van den Broek LA, et al. **J Pharm Pharmacol** 1996 Feb;48(2):172–8
Synthesis and antiviral activities of 9-cyclopentylpurine derivatives. Kojima E, et al. **Nucleic Acids Symp Ser** 1995; (34):107–8
Synthesis of carbocyclic oxetanocin analogs bearing fluorine and their antiviral activities. Sato, et al. **Nucleic Acids Symp Ser** 1995;(34):159–60
A facile synthesis of 4'-thio-arabinonucleosides as potential antiviral agents from D-glucose. Yoshimura Y, et al. **Nucleic Acids Symp Ser** 1995;(34):21–2
QSAR of thiosemicarbazones derived from formyl- and acyl-diazines designed as antiviral agents. Hadjipavlou-Litina D. **Pharmazie** 1996 Jul;51(7):468–70
Synthetic analogues of netropsin and distamycin. II. Synthesis of a carbocyclic analogue of the pyrrolecarboxamide antitumour antibiotics. Bartulewicz D, et al. **Rocz Akad Med Bialymst** 1995;40(2):364–75
Synthetic C-nucleosides. I. Synthesis and the anomeric configuration of 1,2,3-triazole analogues of C-nucleosides. Różański A, et al. **Rocz Akad Med Bialymst** 1996; 41(2):321–33
[Synthesis and biological activity of hydrophosphoryl derivatives of amphotericin B] Belakhov VV, et al. **Antibiot Khimioter** 1996;41(7-8):4–8 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Crystal structures of some acyclonucleosides with antiviral activity and related compounds. Birnbaum KB. **Acta Biochim Pol** 1996;43(1):65–76 (33 ref.)
Stability of 14 drugs in the latex reservoir of an elastomeric infusion device. Allen LV Jr, et al. **Am J Health Syst Pharm** 1996 Nov 15;53(22):2740–3
Stability of cidofovir in 0.9% sodium chloride injection and in 5% dextrose injection. Yuan LC, et al. **Am J Health Syst Pharm** 1996 Aug 15;53(16):1939–43
Synthesis and properties of new antisense oligodeoxynucleotides containing benzylphosphonate linkages. Samstag W, et al. **Antisense Nucleic Acid Drug Dev** 1996 Fall;6(3):153–6
Relationship between structural properties and affinity for herpes simplex virus type 1 thymidine kinase of bromine substituted 5-heteroaromatic 2'-deoxyuridines. Creuven I, et al. **Antiviral Res** 1996 May;30(2-3):63–74
The formation of crystals in ganciclovir used for intraocular injection [letter] Fiscella RG, et al. **Arch Ophthalmol** 1997 Jul;115(7):945–6
Analysis of the disulfide linkage pattern in circulin A and B, HIV-inhibitory macrocyclic peptides. Derua R, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):632–8
Hairpin antisense oligonucleotides containing 2'-methoxynucleosides with base-pairing in the stem region at the 3'-end: penetration, localization, and Anti-HIV activity. Kuwasaki T, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):623–31
Solution structure of a DNA decamer containing the antiviral drug ganciclovir: combined use of NMR, restrained molecular dynamics, and full relaxation matrix refinement. Foti M, et al. **Biochemistry** 1997 May 6;36(18):5336–45
Differential contribution of metal complexation and dimerization to the chemotherapeutic potential of bicyclen-Zn2II complex against human immunodeficiency virus. Inouye Y, et al. **Biol Pharm Bull** 1996 Mar; 19(3):456–8
Exploration of the effects of linker chain modifications on anti-HIV activities in a series of cosalane analogues. Golebiewski WM, et al. **Bioorg Med Chem** 1996 Oct; 4(10):1637–48
Antiviral and tumor cell antiproliferative SAR studies on tetracyclic eudistomins. II. van Maarseveen JH, et al. **Bioorg Med Chem** 1997 May;5(5):955–70
Imidazo[1,2-a]pyridine derivatives as antiviral agents: biological assays and NMR study of their interactions with membranes and oligonucleotides. Debouzy JC, et al. **Boll Chim Farm** 1996 Mar;135(3):192–8
New neplanocin analogues. IX. A practical preparation of (6'R)-6'-C-methylneplanocin A (RMNPA), a potent antiviral agent, and the determination of its 6'-configuration. Diastereoselective deamination by adenosine deaminase. Shuto S, et al. **Chem Pharm Bull (Tokyo)** 1997 Jan;45(1):138–42
Evidence of a butterfly-like configuration of structurally diverse allosteric inhibitors of the HIV-1 reverse transcriptase. Mager PP. **Drug Des Discov** 1996 Dec; 14(3):241–57
Enzymatic formation of potential anticancer and antiviral inosine analogues. Sheid B, et al. **Experientia** 1996 Sep 15; 52(9):878–81
Molecular electrostatic potential mapping and structure-activity relationship for 3-methoxy flavones. Santhosh C, et al. **Indian J Biochem Biophys** 1996 Dec; 33(6):458–64
Antiherpetic and anticoagulant properties of carrageenans from the red seaweed Gigartina skottsbergii and their cyclized derivatives: correlation between structure and biological activity. Carlucci MJ, et al. **Int J Biol Macromol** 1997 Apr;20(2):97–105
Crystal and molecular structure of didemnin A, an antiviral depsipeptide. Hossain MB, et al. **Int J Pept Protein Res** 1996 Jan-Feb;47(1-2):20–7
Hypericin site specific interactions within polynucleotides used as DNA model compounds. Miskovsky P, et al. **J Biomol Struct Dyn** 1995 Dec;13(3):547–52
Copper(II) interactions with an experimental antiviral agent, I-deoxynojirimycin, and oxygen activation by resulting complexes. Jezowska-Bojczuk M, et al. **J Inorg Biochem** 1996 Dec;64(4):231–46
Structural requirements for agonist activity of a murine interferon-gamma peptide. Szente BE, et al. **J Interferon Cytokine Res** 1996 Oct;16(10):813–7
Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties. Fedorov II, et al. **J Med Chem** 1997 Feb 14;40(4):486–94
Structure-activity modifications of the HIV-1 inhibitors (+)-calanolide A and (-)-calanolide B. Galinis DL, et al. **J Med Chem** 1996 Oct 25;39(22):4507–10
(+)-7-Deaza-5'-norariste romycin as an anti-trypanosomal agent. Seley KL, et al. **J Med Chem** 1997 Feb 14; 40(4):622–4
An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex. Smith AB 3rd, et al. **J Med Chem** 1997 Aug 1;40(16):2440–4
Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime. Victor F, et al. **J Med Chem** 1997 May 9;40(10):1511–8
Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. Das K, et al. **J Mol Biol** 1996 Dec 20;264(5):1085–100
Design and analysis of RNA structure-specific agents as potential antivirals. Wilson WD, et al. **J Mol Recognit** 1996 Mar-Apr;9(2):187–96
New pyranocoumarins isolated from Calophyllum lanigerum and Calophyllum teysmannii [published erratum appears in J Nat Prod 1996 Nov;59(11):1108] McKee TC, et al. **J Nat Prod** 1996 Aug;59(8):754–8
The preparation, characterisation and solubility characteristics of a hydrogen-bonded complex between acyclovir and cytosine. Newby CS, et al. **J Pharm Biomed Anal** 1996 Oct;15(1):39–47
9-[(3-[18F]-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG): a potential imaging agent of viral infection and gene therapy using PET. Alauddin MM, et al. **Nucl Med Biol** 1996 Aug;23(6):787–92
Hydrogen bond geometry in DNA-minor groove binding drug complexes. Tabernero L, et al. **Nucleic Acids Res** 1996 Sep 1;24(17):3458–66
Marigenol-concentrates comprising Taxol and/or Taxan esters as active substances. Eugster C, et al. **Panminerva Med** 1996 Dec;38(4):234–42
Characterization of metal-ion-nucleotide based particulate matter in solutions of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Yuan LC, et al. **PDA J Pharm Sci Technol** 1997 Jan-Feb; 51(1):30–5
Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 GP41 sequence. Jiang S, et al. **Pept Res** 1995 Nov-Dec;8(6):345–8
Antiviral activities of photoactive perylenequinones. Hudson JB, et al. **Photochem Photobiol** 1997 Feb;65(2):352–4
The pentamer channel stiffening model for drug action on human rhinovirus HRV-1A. Vaidehi N, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2466–71
Use of the multiple copy simultaneous search (MCSS) method to design a new class of picornavirus capsid binding drugs. Joseph-McCarthy D, et al. **Proteins** 1997 Sep; 29(1):32–58
Synthetic analogues of netropsin and distamycin. I. Pyridine-containing analogues of distamycin—a molecular modelling study. Bielawski K, et al. **Rocz Akad Med Bialymst** 1995;40(2):352–63
[Modified nucleoside phosphates as precursors of antineoplastic and antiviral compounds in a cell] Arzumanov AA, et al. **Bioorg Khim** 1996 Oct-Nov; 22(10-11):777-94 (127 ref.) (Eng. Abstr.) **(Rus)**
[Conjugates of oligodeoxyribonucleotides with lexitropsins, forming a DNA-ligand complex with a 1:2 ratio] Siniakov AN, et al. **Dokl Akad Nauk** 1997 Jan;352(2):262–4 **(Rus)**

CONTRAINDICATIONS

Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet. Zaman MM, et al. **Clin Infect Dis** 1996 Feb; 22(2):378

ECONOMICS

Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. Huse DM, et al. **Am J Health Syst Pharm** 1997 May 15;54(10):1180–4
International expenditure projections for pharmacotherapeutic advances in the treatment of HIV/AIDS. Sclar DA, et al. **Clin Ther** 1997 Jan-Feb; 19(1):86–95; discussion 84–5
An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Sullivan SD, et al. **Clin Ther** 1996 May-Jun;18(3):546–58
An economic exploration of oral and intravenous ganciclovir in the induction and maintenance treatment of AIDS-related cytomegalovirus retinitis. Davies L, et al. **Int J STD AIDS** 1996 Oct;7(6):415–21
Evaluation of drug use and cost of hospital care for AIDS patients between 1990 and 1994. Peyron F, et al. **Pharm World Sci** 1997 Aug;19(4):202–7
Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Grant DM, et al. **Pharmacotherapy** 1997 Mar-Apr;17(2):333–41
[Cost-effectiveness analysis of the treatment of chronic hepatitis C (see comments)] Joliot E, et al. **Gastroenterol Clin Biol** 1996;20(11):958–67 (Eng. Abstr.). Comment in: Gastroenterol Clin Biol 1997;21(4):336–8. **(Fre)**

IMMUNOLOGY

Soluble HIV suppressive factors: more than one Holy Grail? Clerici M, et al. **Immunol Today** 1996 Jul;17(7):297–8

ISOLATION & PURIFICATION

Antiviral substance from silkworm faeces: purification and its chemical characterization. Hiraki A, et al. **Biol Pharm Bull** 1997 May;20(5):547–55
Effect of temperature on the high-performance liquid chromatographic separation of the anti-HIV agents, didanosine and stavudine. Stancato FA, et al. **Biomed Chromatogr** 1996 Jan-Feb;10(1):29–31
A new bioactive metabolite from Xanthoria steineri . el-Fattah HA. **Boll Chim Farm** 1997 Mar;136(3):257–61
Resolution of enantiomers of uridine analogs, potential antiviral agents. Levin S, et al. **J Chromatogr A** 1996 Nov 1;752(1-2):131–46
Application of spherical and other polymers in capillary zone electrophoresis: separation of antiviral drugs and deoxyribonucleoside phosphates by different principles. Singhal R, et al. **J Chromatogr A** 1996 Dec 20; 756(1-2):263–77
Calcium spirulan, an inhibitor of enveloped virus replication, from a blue-green alga Spirulina platensis. Hayashi T, et al. **J Nat Prod** 1996 Jan;59(1):83–7
Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus. Kernan MR, et al. **J Nat Prod** 1997 Jun;60(6):635–7
Niruriside, a new HIV REV/RRE binding inhibitor from Phyllanthus niruri. Qian-Cutrone J, et al. **J Nat Prod** 1996 Feb;59(2):196–9
Two new naphthoquinones with antiviral activity from Rhinacanthus nasutus. Sendl A, et al. **J Nat Prod** 1996 Aug; 59(8):808–11
Isolation and characterization of a monomethioninesulfoxide

variant of interferon alpha-2b. Gitlin G, et al. **Pharm Res** 1996 May;13(5):762-9

Antiviral activity of Porphyridium cruentum polysaccharide. Minkova K, et al. **Pharmazie** 1996 Mar;51(3):194

Antiviral flavonoids from Alkanna orientalis. elsohly HN, et al. **Planta Med** 1997 Aug;63(4):384

Antiviral activity of some hydroxycoumarin derivatives. Galabov AS, et al. **Z Naturforsch [C]** 1996 Jul-Aug; 51(7-8):558-62

METABOLISM

The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. Barry MG, et al. **AIDS** 1996 Oct;10(12):1361-7

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Faletto MB, et al. **Antimicrob Agents Chemother** 1997 May;41(5):1099-107

Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl) methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase. Mendel DB, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):641-6

Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Wang J, et al. **Antimicrob Agents Chemother** 1996 Jun; 40(6):1555-7

Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Xiong X, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):594-9

Relationship between structural properties and affinity for herpes simplex virus type 1 thymidine kinase of bromine substituted 5-heteroaromatic 2'-deoxyuridines. Creuven I, et al. **Antiviral Res** 1996 May;30(2-3):63-74

Fialuridine is phosphorylated and inhibits DNA synthesis in isolated rat hepatic mitochondria. Horn DM, et al. **Antiviral Res** 1997 Mar;34(1):71-4

Metabolism of ganciclovir and cidofovir in cells infected with drug-resistant and wild-type strains of murine cytomegalovirus. Okleberry KM, et al. **Antiviral Res** 1997 Jul;35(2):83-90

The potential of aspirin in prodrug synthesis: a new potential delivery system of AZT and FLT. Zahran MA, et al. **Arch Pharm (Weinheim)** 1996 Aug-Sep;329(8-9):417-20

Effect of stereoisomerism on the cellular pharmacology of beta-enantiomers of cytidine analogs in Hep-G2 cells. Martin LT, et al. **Biochem Pharmacol** 1997 Jan 10; 53(1):75-87

Targeting the Tat-binding site of bovine immunodeficiency virus TAR RNA with a shape-selective rhodium complex. Lim AC, et al. **Bioorg Med Chem** 1997 Jun;5(6):1131-6

Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Shaw JP, et al. **Drug Metab Dispos** 1997 Mar;25(3):362-6

Zidovudine glucuronidation in human liver: interindividual variability. Pacifici GM, et al. **Int J Clin Pharmacol Ther** 1996 Aug;34(8):329-34

Gamma-phosphate-substituted 2'-deoxynucleoside 5'-triphosphates as substrates for DNA polymerases. Arzumanov AA, et al. **J Biol Chem** 1996 Oct 4; 271(40):24389-94

C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. Scala E, et al. **J Immunol** 1997 May 1;158(9):4485-92

Neutralization of endogenous interferon-beta increases the efficiency of adenoviral vector-mediated gene transduction. Dong Z, et al. **J Interferon Cytokine Res** 1997 Jul;17(7):401-7

Human interferon-alpha receptor: identification of the region involved in binding to interferon-alpha B. Hirata MH, et al. **J Interferon Cytokine Res** 1996 Oct;16(10):845-52

Regulated expression of the interferon-induced protein kinase p68 (PKR) by vaccinia virus recombinants inhibits the replication of vesicular stomatitis virus but not that of poliovirus. Lee SB, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):1073-8

The intracellular domain of the second chain of the interferon-gamma receptor is interchangeable between species. Muthukumaran G, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):1039-45

Expression of intracellular interferon constitutively activates ISGF3 and confers resistance to EMC viral infection. Rutherford MN, et al. **J Interferon Cytokine Res** 1996 Jul; 16(7):507-10

Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120. Neurath AR, et al. **J Mol Recognit** 1995 Nov-Dec; 8(6):345-57

Design and analysis of RNA structure-specific agents as potential antivirals. Wilson WD, et al. **J Mol Recognit** 1996 Mar-Apr;9(2):187-96

Comparison of the DNA incorporation in human MOLT-4 cells of two 2'-beta-fluoronucleosides, 2'-beta-fluoro-2',3'-dideoxyadenosine and fialuridine. Ahluwalia GS, et al. **J Pharm Sci** 1996 Apr;85(4):454-5

Relationship of skin target site free drug concentration (C*) to the in vivo efficacy: an extensive evaluation of the predictive value of the C* concept using acyclovir as a model drug. Mehta SC, et al. **J Pharm Sci** 1997 Jul; 86(7):797-801

A recombinant vaccinia virus encoding inducible nitric oxide synthase is attenuated in vivo. Rolph MS, et al. **J Virol** 1996 Nov;70(11):7678-85

Antiretrovirus specificity and intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324. Balzarini J, et al. **Mol Pharmacol** 1996 Nov;50(5):1207-13

Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Cihlar T, et al. **Mol Pharmacol** 1996 Dec;50(6):1502-10

Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents. Verri A, et al. **Mol Pharmacol** 1997 Jan;51(1):132-8

In vivo evaluation of acyclovir prodrug penetration and metabolism through rat skin using a diffusion/bioconversion model. Bando H, et al. **Pharm Res** 1997 Jan;14(1):56-62

Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Nakayama H, et al. **Pharmacogenetics** 1997 Feb;7(1):35-43

Use of herpes simplex virus thymidine kinase to improve the antiviral activity of zidovudine. Guettari N, et al. **Virology** 1997 Sep 1;235(2):398-405

PHARMACOKINETICS

Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons. Griffy KG. **AIDS** 1996 Dec;10 Suppl 4:S3-6

Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. Buckheit RW Jr, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10; 13(9):789-96

Famciclovir for treatment of herpesvirus infections. Luber AD, et al. **Ann Pharmacother** 1996 Sep;30(9):978-85 (42 ref.)

Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Cañas E, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):230-3

Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys. Chen H, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2332-6

Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. Dieterich DT, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1226-30

In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Dornsife RE, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):514-9

Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation. Drusano GL, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1143-7

Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine. Harvie P, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):225-9

Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Heald AE, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1514-9

Effective ribavirin concentration in hamster brains for antiviral chemotherapy for subacute sclerosing panencephalitis. Ishii T, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):241-3

Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Kerb R, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2087-93

Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl) adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Naesens L, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):22-8

Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks. Rajagopalan P, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):642-5

Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults. Riddler SA, et al. **Antimicrob Agents Chemother** 1996 Dec; 40(12):2842-7

Cellular uptake and biological effects of antisense oligodeoxynucleotide analogs targeted to herpes simplex virus. Shoji Y, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1670-5

Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Wang LH, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):80-5

Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Zhou XJ, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2202-5

Bioavailability and metabolism of cidofovir following topical administration to rabbits. Cundy KC, et al. **Antiviral Res** 1997 Jul;35(2):113-22

Effect of 9-(4-hydroxybutyl)-N2-phenylguanine (HBPG), a thymidine kinase inhibitor, on clinical recurrences of ocular herpetic keratitis in squirrel monkeys. Kaufman HE, et al. **Antiviral Res** 1996 Dec;33(1):65-72

Cellular localization of antiviral polyoxometalates in J774 macrophages. Ni L, et al. **Antiviral Res** 1996 Nov; 32(3):141-8

Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Wachsman M, et al. **Antiviral Res** 1996 Mar; 29(2-3):153-61

The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats [letter; comment] Soria I, et al. **Biopharm Drug Dispos** 1996 Dec;17(9):817-8. Comment on: Biopharm Drug Dispos 1995 Jan;16(1):71-5.

Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil (L-FMAU) in rats. Wright JD, et al. **Biopharm Drug Dispos** 1996 Apr;17(3):197-207

Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. Noormohamed FH, et al. **Br J Clin Pharmacol** 1997 Jan; 43(1):112-5

Effect of isoprinosine on 3'-Azido-3'-deoxythymidine uptake and phosphorylation in human peripheral blood mononuclear cells. Riva C, et al. **Chemotherapy** 1996 May-Jun;42(3):192-8

Clinical pharmacokinetics of zidovudine. An update. Acosta EP, et al. **Clin Pharmacokinet** 1996 Apr;30(4):251-62 (56 ref.)

The clinical pharmacokinetics of famciclovir. Gill KS, et al. **Clin Pharmacokinet** 1996 Jul;31(1):1-8 (25 ref.)

Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships. Hoetelmans RM, et al. **Clin Pharmacokinet** 1996 Apr;30(4):314-27 (98 ref.)

The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Yan J, et al. **Clin Pharmacol Ther** 1997 May;61(5):563-73

Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Cundy KC, et al. **Curr Eye Res** 1996 May;15(5):569-76

Cidofovir transport in the pigmented rabbit conjunctiva. Hosoya K, et al. **Curr Eye Res** 1997 Jul;16(7):693-7

Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Lam NP, et al. **Dig Dis Sci** 1997 Jan;42(1):178-85

Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Cundy KC, et al. **Drug Metab Dispos** 1996 Jul; 24(7):738-44

Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Cundy KC, et al. **Drug Metab Dispos** 1996 Jul; 24(7):745-52

Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. Cundy KC, et al. **Drug Metab Dispos** 1996 Mar;24(3):315-21

Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Leeds JM, et al. **Drug Metab Dispos** 1997 Aug;25(8):921-6

In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Rashidi MR, et al. **Drug Metab Dispos** 1997 Jul; 25(7):805-13

Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Shaw JP, et al. **Drug Metab Dispos** 1997 Mar;25(3):362-6

Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse [see comments] Rees WA, et al. **Equine Vet J** 1997 Mar; 29(2):104-10. Comment in: Equine Vet J 1997 Mar;29(2):89-91.

Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis. Castelli F, et al. **Eur J Clin Pharmacol** 1997;52(5):397-401

Weibull function fits to pharmacokinetic data of ribavirin in man. Liu XD, et al. **Eur J Drug Metab Pharmacokinet** 1996 Jul-Sep; 21(3):227-31

In vivo bioavailability predictions from perfused intestine studies [letter; comment] Soria I, et al. **Int J Clin Pharmacol Ther** 1996 Feb;34(2):90-1. Comment on: Int J Clin Pharmacol Ther 1994 Sep;32(9):474-82.

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. Japour AJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Nov 1;13(3):235-46

Pharmacology of new antiherpes agents: famciclovir and valacyclovir. Stein GE. **J Am Pharm Assoc (Wash)** 1997

Mar-Apr;NS37(2):157-63 (39 ref.)
Pharmacokinetics of netivudine, a potent anti-varicella zoster virus drug, in patients with renal impairment. Fillastre JP, et al. **J Antimicrob Chemother** 1996 May;37(5):965-74
Pharmacokinetics of netivudine in haemodialysis patients [letter] Le Roy F, et al. **J Antimicrob Chemother** 1996 Nov; 38(5):913-5
Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. Bisogno T, et al. **J Biol Chem** 1997 Feb 7;272(6):3315-23
Binding measurements of indolocarbazole derivatives to immobilised human serum albumin by high-performance liquid chromatography. Ashton DS, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23;677(1):194-8
Simple reversed-phase high-performance liquid chromatography quantitation of ganciclovir in human serum and urine. Page T, et al. **J Chromatogr B Biomed Appl** 1996 Jan 26;675(2):342-6
Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. Villani P, et al. **J Clin Pharmacol** 1996 Feb;36(2):117-21
Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine [published erratum appears in J Clin Pharmacol 1996 Apr;36(4):373] Yuen GJ, et al. **J Clin Pharmacol** 1995 Dec;35(12):1174-80
Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. Swart PJ, et al. **J Drug Target** 1996;4(2):109-16
Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. Benzaria S, et al. **J Med Chem** 1996 Dec 6;39(25):4958-65
Synthesis, biotransformation, and pharmacokinetic studies of 9-(beta-D-arabinofuranosyl)-6-azidopurine: a prodrug for ara-A designed to utilize the azide reduction pathway. Kotra LP, et al. **J Med Chem** 1996 Dec 20;39(26):5202-7
Synthesis and cellular uptake of 2'-substituted analogues of (E)-5-(2-[125I]iodovinyl)-2'-deoxyuridine in tumor cells transduced with the herpes simplex type-1 thymidine kinase gene. Evaluation as probes for monitoring gene therapy. Morin KW, et al. **J Med Chem** 1997 Jul 4; 40(14):2184-90
Release kinetics of liposome-encapsulated ganciclovir after intravitreal injection in rabbits. Le Bourlais C, et al. **J Microencapsul** 1996 Jul-Aug;13(4):473-80
Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. Hughes PM, et al. **J Ocul Pharmacol Ther** 1996 Summer;12(2):209-24
Pharmacokinetics of acyclovir in the cat. Owens JG, et al. **J Vet Pharmacol Ther** 1996 Dec;19(6):488-90
Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. Stathoulopoulou F, et al. **Nephron** 1996;74(2):337-41
In vitro evaluation of polymeric matrix and porous biodegradable reservoir devices for slow-release drug delivery. Peyman GA, et al. **Ophthalmic Surg Lasers** 1996 May;27(5):384-91
Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Annaert P, et al. **Pharm Res** 1997 Apr;14(4):492-6
Intravenous infusion of RMP-7 increases ocular uptake of ganciclovir. Elliot PJ, et al. **Pharm Res** 1997 Jan;14(1):80-5
Lack of effect of catheterization on the pharmacokinetics of (-)-carbovir in rats. Zimmerman CL, et al. **Pharm Res** 1996 Sep;13(9):1417-8
Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. Wolfe EJ, et al. **Pharmacotherapy** 1997 May-Jun;17(3):591-8
Ganciclovir use during mild renal failure in heart transplantation. Bastien O, et al. **Transplant Proc** 1996 Oct; 28(5):2876-7
[Design of topically resorptive interferon drugs] Shchekanova SM, et al. **Vestn Ross Akad Med Nauk** 1996; (9):30-3 (48 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Interferon-omega suppresses hepatitis B surface antigen production in human hepatoma cell line. Hajnická V, et al. **Acta Virol** 1996 Sep;40(4):221-2
Partial inhibition of yellow fever virus replication in vitro with different phosphorothioate oligodeoxyribonucleotides. Tolou H, et al. **Acta Virol** 1996 Apr;40(2):73-9
Inhibition of hepatitis B virus in vitro by antisense oligonucleotides. Yao ZQ, et al. **Acta Virol** 1996 Feb; 40(1):35-9
Resistance to anti-human immunodeficiency virus therapeutic agents. Emini EA. **Adv Exp Med Biol** 1995; 390:187-95 (50 ref.)
Antiviral activity of tomatoside from Lycopersicon esculentum Mill. Spinu K, et al. **Adv Exp Med Biol** 1996; 404:505-9
In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. Medveczky MM, et al. **AIDS** 1997 Sep;11(11):1327-32
Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. Buckheit RW Jr, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10; 13(9):789-96
Inhibition of human immunodeficiency virus infection by heparin derivatives. Clayette P, et al. **AIDS Res Hum Retroviruses** 1996 Jan 1;12(1):63-9
Inhibition of HIV activation in latently infected cells by flavonoid compounds. Critchfield JW, et al. **AIDS Res Hum Retroviruses** 1996 Jan 1;12(1):39-46
A natural sulfated polysaccharide, calcium spirulan, isolated from Spirulina platensis: in vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. Hayashi K, et al. **AIDS Res Hum Retroviruses** 1996 Oct 10;12(15):1463-71
Early treatment with 9-(2-phosphonylmethoxyethyl)adenine reduces virus burdens for a prolonged period in SIV-infected rhesus macaques. Joag SV, et al. **AIDS Res Hum Retroviruses** 1997 Feb 10;13(3):241-6
n-Docosanol inhibits in vitro replication of HIV and other retroviruses. Marcelletti JF, et al. **AIDS Res Hum Retroviruses** 1996 Jan 1;12(1):71-4
Inhibition of human immunodeficiency virus infection of CD4+ cells by CD4-free glycopeptides from monocytic U937 cells. Mbemba E, et al. **AIDS Res Hum Retroviruses** 1996 Jan 1;12(1):47-53
Clonal selection of HIV type 1 variants associated with resistance to foscarnet in vitro: confirmation by molecular evolutionary analysis. Nakano T, et al. **AIDS Res Hum Retroviruses** 1997 May 1;13(7):563-73
Further insights on the inhibition of HIV type 1 infection in vitro by CD4-modified synthetic peptides containing phenylalanine. Prieto I, et al. **AIDS Res Hum Retroviruses** 1996 Jul 20;12(11):1023-30
Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. Swart PJ, et al. **AIDS Res Hum Retroviruses** 1996 Jun 10;12(9):769-75
The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. Yamaguchi K, et al. **AIDS Res Hum Retroviruses** 1997 May 1;13(7):545-54
Valacyclovir. Acosta EP, et al. **Ann Pharmacother** 1997 Feb; 31(2):185-91 (36 ref.)
Pharmacologic considerations for antiviral drug development [see comments] Fletcher CV. **Ann Pharmacother** 1996 Sep; 30(9):972-7 (36 ref.). Comment in: Ann Pharmacother 1996 Sep;30(9):964-6.
Famciclovir for treatment of herpesvirus infections. Luber AD, et al. **Ann Pharmacother** 1996 Sep;30(9):978-85 (42 ref.)
Combination antiretroviral chemotherapy: a potential strategy in AIDS-related malignancy. Nusbaum NJ, et al. **Anticancer Drugs** 1996 Jan;7(1):109-14
Evaluation of prodrugs ability to induce effective ablation of cells transduced with viral thymidine kinase gene. Kuriyama S, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2623-8
Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPV 16 E7 oncogene. Lappalainen K, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2485-92
Activities of various compounds against murine and primate polyomaviruses. Andrei G, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):587-93
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Arts EJ, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):527-40 (182 ref.)
Inhibition of murine leukemia virus with poly-2'-O-(2,4-dinitrophenyl)poly[A] Ashun MA, et al. **Antimicrob Agents Chemother** 1996 Oct;40(10):2311-7
Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Balakrishna Pai S, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):380-6
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Balfour HH Jr, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2721-6
Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice. Balzarini J, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):611-6
Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Balzarini J, et al. **Antimicrob Agents Chemother** 1996 Jun;40(6):1454-66
MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection. Bridges CG, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1072-7
SCH 48973: a potent, broad-spectrum, antienterovirus compound. Buontempo PJ, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1220-5
Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases. Cherrington JM, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1270-3
Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Cherrington JM, et al. **Antimicrob Agents Chemother** 1996 Sep;40(9):2212-6
Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro. Civitico G, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1180-5
(-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes. Condreay LD, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):520-3
Inhibition of poliovirus replication by prostaglandins A and J in human cells. Conti C, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):367-72
Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Datema R, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):750-4
Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro. Fischer KP, et al. **Antimicrob Agents Chemother** 1996 Aug;40(8):1957-60
Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate. Fujiwara M, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):271-3
Potentiation of the stavudine anti-human immunodeficiency virus activity by 5-fluorouracil [letter] Gong YF, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1329
Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo. Hafkemeyer P, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):792-4
Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Hastings JC, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1304-7
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Innaimo SF, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1444-8
In vivo anti-influenza virus activity of a zinc finger peptide. Judd AK, et al. **Antimicrob Agents Chemother** 1997 Mar; 41(3):687-92
Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Korba BE, et al. **Antimicrob Agents Chemother** 1996 May; 40(5):1282-4
Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Lamarre D, et al. **Antimicrob Agents Chemother** 1997 May; 41(5):965-71
Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor. Lin PF, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):133-8
Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. McKimm-Breschkin JL, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):40-6
Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. Morse GD, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):767-71
Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl) adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Naesens L, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):22-8
Assessment of antiviral activity, efficacy, and toxicity of prostaglandin A2 in a rabbit model of herpetic keratitis. O'Brien WJ, et al. **Antimicrob Agents Chemother** 1996 Oct; 40(10):2327-31
Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine. Palmer S, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1285-8
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Patick AK, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):292-7
Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha. Pawlotsky JM, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):320-4
Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines. Piscitelli SC, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):161-5
Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Rabin L, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):755-62
Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Rusconi S, et al. **Antimicrob Agents Chemother** 1996 Jan; 40(1):234-6

Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Shafer RW, et al. **Antimicrob Agents Chemother** 1996 Dec;40(12):2887-90

Cellular uptake and biological effects of antisense oligodeoxynucleotide analogs targeted to herpes simplex virus. Shoji Y, et al. **Antimicrob Agents Chemother** 1996 Jul;40(7):1670-5

Potent anti-murine cytomegalovirus activity and reduced nephrotoxicity of ganciclovir cyclic phosphonate. Smee DF, et al. **Antimicrob Agents Chemother** 1996 Aug; 40(8):1964-6

A novel antiviral agent which inhibits the endonuclease of influenza viruses. Tomassini JE, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1189-93

Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells. Wachsman M, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):433-6

Inhibition of replication of hepatitis B virus by cytallene in vitro. Zhu YL, et al. **Antimicrob Agents Chemother** 1997 Aug;41(8):1755-60

Comparison of the antiviral efficacy of ribozymes and antisense RNA directed against bovine leukemia virus rex/tax. Cantor GH, et al. **Antisense Nucleic Acid Drug Dev** 1996 Winter;6(4):301-4

Herpes simplex virus-mediated activation of human immunodeficiency virus is inhibited by oligonucleoside methylphosphonates that target immediate-early mRNAs 1 and 3. Feng CP, et al. **Antisense Nucleic Acid Drug Dev** 1996 Spring;6(1):25-35

Use of a nonviral vector to express a chimeric tRNA-ribozyme against lymphocytic choriomeningitis virus: cytoplasmic accumulation of a catalytically competent transcript but minimal antiviral effect. Gebhard JR, et al. **Antisense Nucleic Acid Drug Dev** 1997 Feb; 7(1):3-11

Antiviral activity of an oligo(nucleoside methylphosphonate) that targets HSV-1 immediate-early pre-mRNA 4,5 is augmented by cotreatment with replication-defective adenovirus. Kulka M, et al. **Antisense Res Dev** 1995 Winter; 5(4):243-9

Antiviral properties of extract of Opuntia streptacantha. Ahmad A, et al. **Antiviral Res** 1996 May;30(2-3):75-85

SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2. Albin R, et al. **Antiviral Res** 1997 Aug;35(3):139-46

Structure-activity relationship of the affinity of 5-substituted uracil nucleoside analogues for varicella-zoster virus thymidine kinase and their activity against varicella-zoster virus. Ashida N, et al. **Antiviral Res** 1997 Aug;35(3):167-75

Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Barnard DL, et al. **Antiviral Res** 1997 Mar;34(1):27-37

New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Bellarosa D, et al. **Antiviral Res** 1996 May;30(2-3):109-24

Inhibition of arenavirus multiplication in vitro by phenotiazines. Candurra NA, et al. **Antiviral Res** 1996 Jul; 31(3):149-58

Suppressive effects of destruxin B on hepatitis B virus surface antigen gene expression in human hepatoma cells. Chen HC, et al. **Antiviral Res** 1997 May;34(3):137-44

Antiviral effects of 6-diazo-5-oxo-L-norleucin on replication of herpes simplex virus type 1. Cinatl J, et al. **Antiviral Res** 1997 Feb;33(3):165-75

In vitro inhibition of human cytomegalovirus replication by calcium trinatrium diethylenetriaminepentaacetic acid. Cinatl J Jr, et al. **Antiviral Res** 1996 Jun;31(1-2):23-34

Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU). Colacino JM. **Antiviral Res** 1996 Mar;29(2-3):125-39 (66 ref.)

Antipicornavirus activity of SCH 47802 and analogs: in vitro and in vivo studies. Cox S, et al. **Antiviral Res** 1996 Oct; 32(2):71-9

The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. De Vreese K, et al. **Antiviral Res** 1996 Mar; 29(2-3):209-19

Antisense oligodeoxynucleotides against the BZLF1 transcript inhibit induction of productive Epstein-Barr virus replication [published erratum appears in Antiviral Res 1996 Oct;32(2):117] Diabata M, et al. **Antiviral Res** 1996 Mar;29(2-3):243-60

Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Esté JA, et al. **Antiviral Res** 1996 Mar; 29(2-3):297-307

Inhibition of replication of rinderpest virus by 5-fluorouracil. Ghosh A, et al. **Antiviral Res** 1996 Jun;31(1-2):35-44

Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon-alpha. Heim A, et al. **Antiviral Res** 1997 May;34(3):101-11

A rapid assay for determination of antiviral activity against human cytomegalovirus. Hippenmeyer PJ, et al. **Antiviral Res** 1996 Aug;32(1):35-42

Herpesvirus proteases: targets for novel antiviral drugs. Holwerda BC. **Antiviral Res** 1997 Jun;35(1):1-21 (89 ref.)

Fialuridine is phosphorylated and inhibits DNA synthesis in isolated rat hepatic mitochondria. Horn DM, et al. **Antiviral Res** 1997 Mar;34(1):71-4

Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro. Hostetler KY, et al. **Antiviral Res** 1996 Jun;31(1-2):59-67

Inhibition of human immunodeficiency virus type 1 infectivity by a new amine bellenamine. Ikeda R, et al. **Antiviral Res** 1996 Mar;29(2-3):163-73

Inhibition of herpes simplex virus replication by retinoic acid. Isaacs CE, et al. **Antiviral Res** 1997 Jan;33(2):117-27

Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Jairath S, et al. **Antiviral Res** 1997 Feb;33(3):201-13

Inhibitors of infectious pancreatic necrosis virus (IPNV) replication. Jashés M, et al. **Antiviral Res** 1996 Mar; 29(2-3):309-12

Photodynamic inactivation of enveloped viruses by buckminsterfullerene. Käsermann F, et al. **Antiviral Res** 1997 Mar;34(1):65-70

Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method. Kodama E, et al. **Antiviral Res** 1996 Jul;31(3):159-64

Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Marchetti M, et al. **Antiviral Res** 1996 Mar; 29(2-3):221-31

Inhibitory activity of 3'-fluoro-2' deoxythymidine and related nucleoside analogues against adenoviruses in vitro. Mentel R, et al. **Antiviral Res** 1997 May;34(3):113-9

In vitro inactivation of herpes simplex virus by a biological response modifier, PSK. Monma Y, et al. **Antiviral Res** 1997 Aug;35(3):131-8

Sulfated pentagalloyl glucose (Y-ART-3) inhibits HIV replication and cytopathic effects in vitro, and reduces HIV infection in hu-PBL-SCID mice. Nakashima H, et al. **Antiviral Res** 1996 May;30(2-3):95-108

Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Neyts J, et al. **Antiviral Res** 1996 May; 30(2-3):125-32

In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses. Parang K, et al. **Antiviral Res** 1997 May;34(3):75-90

Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: efficiency metabolism and activity against human immunodeficiency virus or herpes simplex virus. Perno CF, et al. **Antiviral Res** 1997 Feb;33(3):153-64

Nuclease stability as dominant factor in the antiviral activity of oligonucleotides directed against HSV-1 IE110. Peyman A, et al. **Antiviral Res** 1997 Jan;33(2):135-9

Effect of combined alpha IFN and prostaglandin A1 treatment on vesicular stomatitis virus replication and heat shock protein synthesis in epithelial cells. Pica F, et al. **Antiviral Res** 1996 Mar;29(2-3):187-98

Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-gamma 1. Saravolac EG, et al. **Antiviral Res** 1996 Mar;29(2-3):199-207

Therapeutic basis of glycyrrhizin on chronic hepatitis B. Sato H, et al. **Antiviral Res** 1996 May;30(2-3):171-7

The inhibition of human immunodeficiency virus proteases by 'interface peptides'. Schramm HJ, et al. **Antiviral Res** 1996 May;30(2-3):155-70

Inhibition of adenovirus infection with protease inhibitors. Sircar S, et al. **Antiviral Res** 1996 May;30(2-3):147-53

Combination of antiviral immunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections. Smee DF, et al. **Antiviral Res** 1996 Nov; 32(3):165-71

Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. Sudo K, et al. **Antiviral Res** 1996 Aug;32(1):9-18

Neuramide inhibits Epstein-Barr virus-induced transformation activity and proliferation of transformed B lymphocytes. Venanzoni MC, et al. **Antiviral Res** 1997 Feb; 33(3):177-85

Anti-hepatitis B virus activity of N-acetyl-L-cysteine (NAC): new aspects of a well-established drug. Weiss L, et al. **Antiviral Res** 1996 Aug;32(1):43-53

Recombinant superoxide dismutase (SOD) administered by aerosol inhibits respiratory syncytial virus infection in cotton rats. Wyde PR, et al. **Antiviral Res** 1996 Jul; 31(3):173-84

Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice. Yang H, et al. **Antiviral Res** 1996 Mar;29(2-3):233-41

Effect of exogenous tumor necrosis factor alpha, interleukin 6 and interferons on vesicular stomatitis virus replication in human placenta and amniotic membrane organ cultures. Paradowska E, et al. **Arch Immunol Ther Exp (Warsz)** 1996; 44(1):57-62

Antiviral activity of 2-chloro-2'-deoxyadenosine (2-CdA). Zahorska R, et al. **Arch Immunol Ther Exp (Warsz)** 1996; 44(2-3):137-41

Inhibition of three alphaherpesviruses (herpes simplex 1 and 2 and pseudorabies virus) by heparin, heparan and other sulfated polyelectrolytes [published erratum appears in Arch Med Res 1996 Summer;27(2):following 255] Ramos-Kuri M, et al. **Arch Med Res** 1996 Spring;27(1):43-8

A novel synthetic reversible inhibitor of sialidase efficiently blocks secondary but not primary influenza virus infection of MDCK cells in culture. Barrère B, et al. **Arch Virol** 1997;142(7):1365-80

Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir. Harada K, et al. **Arch Virol** 1997; 142(2):215-25

Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Krusat T, et al. **Arch Virol** 1997; 142(6):1247-54

Evidence that neomycin inhibits human cytomegalovirus infection of fibroblasts. Lobert PE, et al. **Arch Virol** 1996; 141(8):1453-62

Toxicity and enzyme-inducing effect of the antiviral compound mopyridone in mice. Tantcheva LP, et al. **Arzneimittelforschung** 1996 Sep;46(9):931-3

Stimulation of antiviral activities of interferon by a liver extract preparation. Yokochi S, et al. **Arzneimittelforschung** 1997 Aug;47(8):968-74

An antiviral effect of nitric oxide: inhibition of reovirus replication. Pertile TL, et al. **Avian Dis** 1996 Apr-Jun; 40(2):342-8

Analysis of the disulfide linkage pattern in circulin A and B, HIV-inhibitory macrocyclic peptides. Derua R, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):632-8

Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells. Hatta T, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):545-9

Hairpin antisense oligonucleotides containing 2'-methoxynucleosides with base-pairing in the stem region at the 3'-end: penetration, localization, and Anti-HIV activity. Kuwasaki T, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):623-31

Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system. Lavigne C, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):566-71

Study of structure-activity correlation in destruxins, a class of cyclodepsipeptides possessing suppressive effect on the generation of hepatitis B virus surface antigen in human hepatoma cells. Yeh SF, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):65-72

Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro. Hostetler KY, et al. **Biochem Pharmacol** 1997 Jun 15; 53(12):1815-22

Linked lexitropsins and the in vitro inhibition of HIV-1 reverse transcriptase RNA-directed DNA polymerization: a novel induced-fit of 3,5 m-pyridyl bisdistamycin to enzyme-associated template-primer. Filipowsky ME, et al. **Biochemistry** 1996 Dec 3;35(48):15397-410

Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Ueno T, et al. **Biochemistry** 1997 Feb 4;36(5):1092-9

Lack of stereospecificity of some cellular and viral enzymes involved in the synthesis of deoxyribonucleotides and DNA: molecular basis for the antiviral activity of unnatural L-beta-nucleosides. Spadari S, et al. **Biochimie** 1995; 77(11):861-67

Synthesis and antiviral activity of peptide-oligonucleotide conjugates prepared by using N alpha-(bromoacetyl)peptides. Arar K, et al. **Bioconjug Chem** 1995 Sep-Oct;6(5):573-7

Characterization of cystatin C from bovine parotid glands: cysteine proteinase inhibition and antiviral properties. Cimerman N, et al. **Biol Chem Hoppe Seyler** 1996 Jan; 377(1):19-23

Antiviral substance from silkworm faeces: purification and its chemical characterization. Hiraki A, et al. **Biol Pharm Bull** 1997 May;20(5):547-55

Differential contribution of metal complexation and dimerization to the chemotherapeutic potential of bicyclen-Zn2II complex against human immunodeficiency virus. Inouye Y, et al. **Biol Pharm Bull** 1996 Mar; 19(3):456-8

Inhibition of theophylline metabolism by aciclovir. Maeda Y, et al. **Biol Pharm Bull** 1996 Dec;19(12):1591-5

FR901724, a novel anti-human immunodeficiency virus (HIV) peptide produced by Streptomyces, shows synergistic antiviral activities with HIV protease inhibitor and 2',3'-dideoxynucleosides. Nakashima H, et al. **Biol Pharm Bull** 1996 Mar;19(3):405-12

Pharmacokinetics of glycyrrhizin in rats with D-galactosamine-induced hepatic disease. Wang Z, et al. **Biol Pharm Bull** 1996 Jun;19(6):901-4

Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle. De Clercq E. **Biomed Pharmacother** 1996;50(5):207-15 (76 ref.)

In vitro and ex vivo inhibition of hepatitis A virus 3C proteinase by a peptidyl monofluoromethyl ketone. Morris TS, et al. **Bioorg Med Chem** 1997 May;5(5):797-807

Antiviral and tumor cell antiproliferative SAR studies on tetracyclic eudistomins. II. van Maarseveen JH, et al. **Bioorg Med Chem** 1997 May;5(5):955-70

Oral application of cytokines. Georgiades JA, et al. **Biotherapy** 1996;8(3-4):205-12 (44 ref.)

Rationale and clinical results of using leucocyte-derived immunosupportive therapies in HIV disease. Gottlieb AA, et al. **Biotherapy** 1996;9(1-3):27-31

Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Munshi NC, et al. **Blood** 1997 Feb 15;89(4):1334-40

Differential effects of zidovudine and zidovudine triphosphate on mitochondrial permeability transition and oxidative phosphorylation. Elimadi A, et al. **Br J Pharmacol** 1997 Aug;121(7):1295-300

Antiviral activity of crude extracts of Guarea guidona. Simoni IC, et al. **Braz J Med Biol Res** 1996 May; 29(5):647-50

Human immunodeficiency virus replication in the presence of antiretroviral drugs: analogies to antineoplastic drug resistance. Strair RK, et al. **Cancer Treat Res** 1996; 87:225-39 (63 ref.)

Melatonin protects mice infected with Venezuelan equine encephalomyelitis virus. Bonilla E, et al. **Cell Mol Life Sci** 1997 May;53(5):430-4

New neplanocin analogues. VIII. Synthesis and biological activity of 6'-C-ethyl, -ethenyl, and -ethynyl derivatives of neplanocin A. Shuto S, et al. **Chem Pharm Bull (Tokyo)** 1997 Jul;45(7):1163-8

New hydrolyzable tannins, shephagenins A and B, from Shepherdia argentea as HIV-1 reverse transcriptase inhibitors. Yoshida T, et al. **Chem Pharm Bull (Tokyo)** 1996 Aug;44(8):1436-9

The role of recombinant human fusion protein IL-6/IL-2 (CH925) in hepadna virus infection treatment. Mi Z, et al. **Chin Med Sci J** 1995 Dec;10(4):210-3

Antiviral treatment with WIN 54 954 reduces mortality in murine coxsackievirus B3 myocarditis. Fohlman J, et al. **Circulation** 1996 Nov 1;94(9):2254-9

Preclinical development of antiviral drugs. Szczech GM. **Clin Infect Dis** 1996 Feb;22(2):355-60 (25 ref.)

Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients. Martin J, et al. **Cytokine** 1996 Apr;8(4):313-7

Antiviral susceptibility testing-flow cytometric analysis (AST-FCA) for the detection of cytomegalovirus drug resistance. Lipson SM, et al. **Diagn Microbiol Infect Dis** 1997 Jul;28(3):123-9

Effect of interferon-alpha on MHC expression and influx of inflammatory cells on the rat eye. van Klink E, et al. **Doc Ophthalmol** 1996-97;92(1):17-28

The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Amtmann E. **Drugs Exp Clin Res** 1996;22(6):287-94

Estimation of direct influence of Ukrain preparation on influenza viruses and the bacteria E. coli and S. aureus. Ciebiada I, et al. **Drugs Exp Clin Res** 1996;22(3-5):219-23

Biological activity of some thiophosphamide derivatives of alkaloids with respect to influenza virus. Lisnyak OI, et al. **Drugs Exp Clin Res** 1996;22(3-5):225-8

Theoretical grounds and experimental confirmation of the antiviral effect of the preparation Ukrain. Lozjuk RM, et al. **Drugs Exp Clin Res** 1996;22(3-5):213-7

Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno. Ayisi NK. **East Afr Med J** 1995 Oct;72(10):654-7

Effect of interferon-beta on thyroid function in patients of chronic hepatitis C without preexisting autoimmune thyroid disease. Nagai Y, et al. **Endocr J** 1996 Oct; 43(5):545-9

Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse [see comments] Rees WA, et al. **Equine Vet J** 1997 Mar; 29(2):104-10. Comment in: Equine Vet J 1997 Mar;29(2):89-91.

Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication. Lee CD, et al. **Eur J Clin Invest** 1996 Dec;26(12):1069-76

Protective effect of recombinant interferon (IFN)-alpha/beta on MHV-2cc-induced chronic hepatitis in athymic nude mice. Uetsuka K, et al. **Exp Anim** 1996 Jul;45(3):293-7

Dose-related effects of Ampligen (poly(I).poly(C12U)), a mismatched double-stranded RNA, in a bleomycin-mouse model of pulmonary fibrosis. Wild JS, et al. **Exp Lung Res** 1996 May-Jun;22(3):375-91

Synthesis and microbiological evaluations of (N-heteroaryl) arylmethanamines and their Schiff bases. Fioravanti R, et al. **Farmaco** 1996 Oct;51(10):643-52

Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. Balzarini J, et al. **FEBS Lett** 1997 Jun 30;410(2-3):324-8

AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation. Lucarelli M, et al. **FEBS Lett** 1996 Nov 4;396(2-3):323-6

A systemic antiviral resistance-inducing protein isolated from Clerodendrum inerme Gaertn. is a polynucleotide:adenosine glycosidase (ribosome-inactivating protein). Olivieri F, et al. **FEBS Lett** 1996 Nov 4;396(2-3):132-4

Interferon gamma and interleukin 1, but not interferon alfa, inhibit rotavirus entry into human intestinal cell lines. Bass DM. **Gastroenterology** 1997 Jul;113(1):81-9

NovoSeven--virus safety. Lund-Hansen T. **Haemostasis** 1996;26 Suppl 1:96-7

Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Marinos G, et al. **Hepatology** 1996 Nov; 24(5):991-5

Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Scaglioni P, et al. **Hepatology** 1996 Nov;24(5):1010-7

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Shaw T, et al. **Hepatology** 1996 Nov;24(5):996-1002

Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Kramm CM, et al. **Hum Gene Ther** 1996 Oct 20;7(16):1989-94

Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274). Treat J, et al. **Hum Gene Ther** 1996 Oct 20;7(16):2047-57

Soluble HIV suppressive factors: more than one Holy Grail? Clerici M, et al. **Immunol Today** 1996 Jul;17(7):297-8

Antitumor activity of novel purine acyclic nucleotide analogs PMEA and PMEDAP. Otová B, et al. **In Vivo** 1997 Mar-Apr;11(2):163-7

Inhibition of HBsAg secretion from Alexander cell line by Phyllanthus amarus. Jayaram S, et al. **Indian J Pathol Microbiol** 1996 Jul;39(3):211-5

Barrier and antiviral effect of a new cream formulation [letter] Spencer B, et al. **Infect Control Hosp Epidemiol** 1997 Mar;18(3):159-60

Antiherpetic and anticoagulant properties of carrageenans from the red seaweed Gigartina skottsbergii and their cyclized derivatives: correlation between structure and biological activity. Carlucci MJ, et al. **Int J Biol Macromol** 1997 Apr;20(2):97-105

Anti-retroviral activity of methionine enkephalin and AZT in a murine cell culture. Sin JI, et al. **Int J Immunopharmacol** 1996 May;18(5):305-9

Effects of protein tyrosine kinase inhibitors on the replication of herpes simplex virus and the phosphorylation of viral proteins. Yura Y, et al. **Intervirology** 1997;40(1):7-14

Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir. Gordon YJ, et al. **Invest Ophthalmol Vis Sci** 1996 Dec;37(13):2774-8

Chemically modified bovine beta-lactoglobulin blocks uptake of HIV-1 by colon- and cervix-derived epithelial cell lines [letter] Jiang S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 15;13(5):461-2

Therapeutic options for resistant cytomegalovirus retinitis. Kuppermann BD. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S13-21 (40 ref.)

A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: a novel potential intravaginal virucide. Stafford MK, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Mar 1;14(3):213-8

Antiviral activity of local anaesthetic agents [letter] De Amici D, et al. **J Antimicrob Chemother** 1996 Mar;37(3):635

Antiviral activity of 5,6,7-trimethoxyflavone and its potentiation of the antiherpes activity of acyclovir. Hayashi K, et al. **J Antimicrob Chemother** 1997 Jun;39(6):821-4

Antiviral resistance: mechanisms, clinical significance, and future implications. Kimberlin DW, et al. **J Antimicrob Chemother** 1996 Mar;37(3):403-21 (144 ref.)

Damage to Pseudomonas aeruginosa PAO1 bacteriophage F116 DNA by biocides. Maillard JY, et al. **J Appl Bacteriol** 1996 May;80(5):540-4

Modulation of E2F activity is linked to interferon-induced growth suppression of hematopoietic cells. Iwase S, et al. **J Biol Chem** 1997 May 9;272(19):12406-14

The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action. Pfeffer LM, et al. **J Biol Chem** 1997 Apr 25;272(17):11002-5

Effects of serotonin and melanin on in vitro HIV-1 infection. Sidibe S, et al. **J Biol Regul Homeost Agents** 1996 Jan-Mar; 10(1):19-24

Studies on the pharmacological properties of novel arylene bis(methylketone) compounds using solid-phase extraction and high-performance liquid chromatography. Berger BJ, et al. **J Chromatogr B Biomed Appl** 1997 Apr 11; 691(2):433-40

Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. Kedes DH, et al. **J Clin Invest** 1997 May 1; 99(9):2082-6

In vitro antiviral activity of indigenous glycyrrhizin, licorice and glycyrrhizic acid (Sigma) on Japanese encephalitis virus. Badam L. **J Commun Dis** 1997 Jun;29(2):91-9

Efficacy of Cafon gel on cutaneous infection with herpes simplex virus (HSV)-2 and acyclovir-resistant HSV in mice. Yoshida Y, et al. **J Dermatol Sci** 1996 Dec; 13(3):237-41

Antiviral activity of galangin isolated from the aerial parts of Helichrysum aureonitens. Meyer JJ, et al. **J Ethnopharmacol** 1997 Apr;56(2):165-9

Inhibition of herpes simplex virus type 1 by aqueous extracts from shoots of Helichrysum aureonitens (Asteraceae). Meyer JJ, et al. **J Ethnopharmacol** 1996 May;52(1):41-3

Antiviral activities of medicinal plants of southern Nepal. Taylor RS, et al. **J Ethnopharmacol** 1996 Aug;53(2):97-104

The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells. Mlynar E, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):825-35

Lobular--but not periovular--inhibition of collagen deposition in the liver of S. mansoni infected mice using interferon-gamma. Lortat-Jacob H, et al. **J Hepatol** 1997 Apr;26(4):894-903

Thymosin-alpha 1, but not interferon-alpha, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells. Moshier JA, et al. **J Hepatol** 1996 Dec;25(6):814-20

Evidence for a deficiency of interferon response in mononuclear cells from hepatitis C viremic patients. Podevin P, et al. **J Hepatol** 1997 Aug;27(2):265-71

Evaluation of the disinfectant effect of Solprogel against human immunodeficiency virus type 1 (HIV-1). Hernández A, et al. **J Hosp Infect** 1996 Nov;34(3):223-8

Inactivation of hepatitis B virus: evaluation of the efficacy of the disinfectant 'Solprogel' using a DNA-polymerase activity assay. Hernández A, et al. **J Hosp Infect** 1997 Aug; 36(4):305-12

Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. Reusser P. **J Hosp Infect** 1996 Aug;33(4):235-48 (89 ref.)

The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25- quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus. Borvak J, et al. **J Infect Dis** 1996 Oct;174(4):850-3

Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture. Colacino JM, et al. **J Infect Dis** 1997 Aug;176 Suppl 1:S66-8

Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. Erice A, et al. **J Infect Dis** 1997 May;175(5):1087-92

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. Schmit JC, et al. **J Infect Dis** 1996 Nov; 174(5):962-8

High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. Smith IL, et al. **J Infect Dis** 1997 Jul; 176(1):69-77

The interleukin-2 fusion protein, DAB389IL-2, inhibits the development of infectious virus in human immunodeficiency virus type 1-infected human peripheral blood mononuclear cells. Zhang LJ, et al. **J Infect Dis** 1997 Apr;175(4):790-4

Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. Zhang ZX, et al. **J Infect Dis** 1997 Jun;175(6):1294-301

Synthesis and characterization in solid and solution of trans-dichloro-1-(2', 6'-difluorophenyl)-1H,3H-thiazolo [3,4-a]-benzimidazole(tri-n-propyl-phosphine)-palladium (II)": a palladium(II) complex of a ligand with anti-HIV properties. Bruno G, et al. **J Inorg Biochem** 1997 Feb 1; 65(2):97-102

Partial inhibition of vesicular stomatitis virus by the interferon-induced human 9-27 protein. Alber D, et al. **J Interferon Cytokine Res** 1996 May;16(5):375-80

Obstruction of HIV-1 particle release by interferon-alpha occurs before viral protease processing and is independent of envelope glycoprotein. Babé LM, et al. **J Interferon Cytokine Res** 1997 May;17(5):287-93

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. Blatt LM, et al. **J Interferon Cytokine Res** 1996 Jul;16(7):489-99 (64 ref.)

IFN-gamma enhances production of IFN-alpha in human macrophages but not in monocytes. Cantell K, et al. **J Interferon Cytokine Res** 1996 Jun;16(6):461-3

Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. Foster GR, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):1027-33

Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production. Fujisawa H, et al. **J Interferon Cytokine Res** 1996 Jul; 16(7):555-9

Human interferon reduces surface expression but not total production of herpes simplex virus type 1 glycoproteins gC and gE in heterologous hamster cells. Holberg-Petersen M, et al. **J Interferon Cytokine Res** 1996 Sep;16(9):717-24

Effects of recombinant interferon-tau on ovine lentivirus replication. Juste RA, et al. **J Interferon Cytokine Res** 1996 Dec;16(12):989-94

Role of interferon-stimulated gene ISG-15 in the interferon-omega-mediated inhibition of human immunodeficiency virus replication. Künzi MS, et al. **J Interferon Cytokine Res** 1996 Nov;16(11):919-27

Mechanism of enhancement of the antiviral action of interferon against herpes simplex virus-1 by chloroquine. Singh AK, et al. **J Interferon Cytokine Res** 1996 Sep; 16(9):725-31

Hypomutable potential accompanying interferon-alpha resistance in a human cell line, IFr, derived from

interferon-alpha-sensitive and hypermutable RSa cells. Suzuki N, et al. **J Interferon Cytokine Res** 1996 Sep; 16(9):733–8

Impact of prophylactic ganciclovir on bronchoalveolar lavage lymphocyte numbers and phenotypes in murine cytomegalovirus-induced reactivation of Toxoplasma pneumonia. Goetz L, et al. **J Lab Clin Med** 1996 Oct; 128(4):384–91

Wherefore interferon? Gresser I. **J Leukoc Biol** 1997 May; 61(5):567–74 (109 ref.)

Targeting antiviral nucleotide analogues to macrophages. Magnani M, et al. **J Leukoc Biol** 1997 Jul;62(1):133–7 (32 ref.)

N-acetyl-L-cysteine-induced up-regulation of HIV-1 gene expression in monocyte-derived macrophages correlates with increased NF-kappaB DNA binding activity. Nottet HS, et al. **J Leukoc Biol** 1997 Jan;61(1):33–9

Anti-herpes simplex virus activity of n-docosanol correlates with intracellular metabolic conversion of the drug. Pope LE, et al. **J Lipid Res** 1996 Oct;37(10):2167–78

Synthesis and antiviral activity of certain 5'-modified analogs of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole. Gudmundsson KS, et al. **J Med Chem** 1997 Feb 28; 40(5):785–93

Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. Hultén J, et al. **J Med Chem** 1997 Mar 14;40(6):885–97

Polyanion inhibitors of human immunodeficiency virus and other viruses. 5. Telomerized anionic surfactants derived from amino acids. Leydet A, et al. **J Med Chem** 1997 Jan 31;40(3):342–9

Polyanion inhibitors of human immunodeficiency virus and other viruses. 6. Micelle-like anti-HIV polyanionic compounds based on a carbohydrate core. Leydet A, et al. **J Med Chem** 1997 Jan 31;40(3):350–6

Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity. Moss N, et al. **J Med Chem** 1996 Oct 11; 39(21):4173–80

New neplanocin analogues. 7. Synthesis and antiviral activity of 2-halo derivatives of neplanocin A. Obara T, et al. **J Med Chem** 1996 Sep 13;39(19):3847–52

Synthesis and evaluation of 6-(dibromomethyl)-5-nitropyrimidines as potential antitumor agents. Thompson MD, et al. **J Med Chem** 1997 Feb 28;40(5):766–70

Carbocyclic oxetanocins lacking the C-3' methylene. Wu J, et al. **J Med Chem** 1997 Apr 25;40(9):1401–6

Studies to show that with podophyllotoxin the early replicative stages of herpes simplex virus type 1 depend upon functional cytoplasmic microtubules. Hammonds TR, et al. **J Med Microbiol** 1996 Sep;45(3):167–72

Inhibition of herpes simplex virus reactivation by dipyridamole in a mouse model. Hay KA, et al. **J Med Virol** 1996 Oct;50(2):198–203

Inhibition of hepatitis B surface antigen secretion on human hepatoma cells. Components from Rubia cordifolia. Ho LK, et al. **J Nat Prod** 1996 Mar;59(3):330–3

Niruriside, a new HIV REV/RRE binding inhibitor from Phyllanthus niruri. Qian-Cutrone J, et al. **J Nat Prod** 1996 Feb;59(2):196–9

Anti-HIV triterpene acids from Geum japonicum. Xu HX, et al. **J Nat Prod** 1996 Jul;59(7):643–5

Multitracer studies during gene therapy of hepatoma cells with herpes simplex virus thymidine kinase and ganciclovir. Haberkorn U, et al. **J Nucl Med** 1997 Jul;38(7):1048–54

QSAR studies of some sulphonamidobenzophenone oximes with antiviral activity. Hadjipavlou-Litina DJ. **J Pharm Pharmacol** 1996 Dec;48(12):1215–7

The role of interferon-gamma in antiretroviral activity of methionine enkephalin and AZT in a murine cell culture. Sin JI, et al. **J Pharmacol Exp Ther** 1996 Dec; 279(3):1268–73

Virucidal activity of pure singlet oxygen generated by thermolysis of a water-soluble naphthalene endoperoxide. Dewilde A, et al. **J Photochem Photobiol B** 1996 Oct; 36(1):23–9

Discovery, development and characterization of agents active against the AIDS virus. Pauwels R, et al. **J Recept Signal Transduct Res** 1995 Jan-Mar; 15(1-4):609–16 (12 ref.)

Effect of brefeldin A on influenza A virus-induced apoptosis in vitro. Saito T, et al. **J Vet Med Sci** 1996 Nov; 58(11):1137–9

Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA. Ji W, et al. **J Viral Hepat** 1997 May; 4(3):167–73

Inhibition of viral replication reverses respiratory syncytial virus-induced NF-kappaB activation and interleukin-8 gene expression in A549 cells. Fiedler MA, et al. **J Virol** 1996 Dec;70(12):9079–82

N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. Fischer PB, et al. **J Virol** 1996 Oct;70(10):7143–52

N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure. Fischer PB, et al. **J Virol** 1996 Oct;70(10):7153–60

Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. Gubareva LV, et al. **J Virol** 1997 May;71(5):3385–90

The antiretrovirus drug 3'-azido-3'-deoxythymidine increases the retrovirus mutation rate. Julias JG, et al. **J Virol** 1997 Jun;71(6):4254–63

Restoration of interferon responses of adenovirus E1A-expressing HT1080 cell lines by overexpression of p48 protein. Leonard GT, et al. **J Virol** 1997 Jul; 71(7):5095–101

Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. Luo G, et al. **J Virol** 1997 May;71(5):4062–70

Antiviral activity of influenza virus M1 zinc finger peptides. Nasser EH, et al. **J Virol** 1996 Dec;70(12):8639–44

Inactivation of murine leukemia virus by compounds that react with the zinc finger in the viral nucleocapsid protein. Rein A, et al. **J Virol** 1996 Aug;70(8):4966–72

Poliovirus infection and expression of the poliovirus protein 2B provoke the disassembly of the Golgi complex, the organelle target for the antipoliovirus drug Ro-090179. Sandoval IV, et al. **J Virol** 1997 Jun;71(6):4679–93

Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. Sasadeusz JJ, et al. **J Virol** 1997 May;71(5):3872–8

A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. Smith RA, et al. **J Virol** 1997 Mar;71(3):2357–62

Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. Tachedjian G, et al. **J Virol** 1996 Oct; 70(10):7171–81

A simplified technique for determining the sensitivity of cytomegalovirus strains to ganciclovir. Calicó I, et al. **J Virol Methods** 1996 Jun;60(1):59–64

Assessment of a cytoprotection assay for the discovery and evaluation of anti-human immunodeficiency virus compounds utilizing a genetically-impaired virus. Kiser R, et al. **J Virol Methods** 1996 Apr 26;58(1-2):99–109

Fluorescent focus reduction assay for the screening of antiadenoviral agents. Mentel R, et al. **J Virol Methods** 1996 May;59(1-2):99–104

A method for detection of HHV-6 antigens and its use for evaluating antiviral drugs. Yoshida M, et al. **J Virol Methods** 1996 Apr 26;58(1-2):137–43

Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats. Miyauchi S, et al. **Jpn J Pharmacol** 1996 Feb; 70(2):139–48

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [see comments] Bartholomew MM, et al. **Lancet** 1997 Jan 4;349(9044):20–2. Comment in: Lancet 1997 Jan 4;349(9044):3–4.

Suppression of retrovirial replication: inactivation of murine leukemia virus by compounds reacting with the zinc finger in the viral nucleocapsid protein. Rein A, et al. **Leukemia** 1997 Apr;11 Suppl 3:106–8

The human immunodeficiency virus. Hardy WD Jr. **Med Clin North Am** 1996 Nov;80(6):1239–61 (131 ref.)

Analysis of resistance mutants of viral polymerases. Oxford JS, et al. **Methods Enzymol** 1996;275:555–600 (179 ref.)

Design of nucleoside analog inhibitors of herpesvirus polymerases. Prisbe EJ, et al. **Methods Enzymol** 1996; 275:425–40

Different properties of wild type and drug-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase in vitro. Ijichi K, et al. **Microbiol Immunol** 1996;40(5):353–8

Evaluation of antiherpetic compounds using a gastric cancer cell line: pronounced activity of BVDU against herpes simplex virus replication. Kodama E, et al. **Microbiol Immunol** 1996;40(5):359–63

Colorimetric assay system for screening antiviral compounds against hepatitis B virus. Sudo K, et al. **Microbiol Immunol** 1996;40(2):153–9

Antiseptic myramistin possesses the strong anti-HIV properties. Kryvorutchenko IuL, et al. **Mikrobiol Z** 1996 Sep-Oct;58(5):90–2

Acyclic nucleosides as antiviral compounds. Freeman S, et al. **Mol Biotechnol** 1996 Apr;5(2):125–37 (94 ref.)

Differences that show up in translation [news] O'Brien C. **Mol Med Today** 1996 Feb;2(2):49

Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO). Arion D, et al. **Mol Pharmacol** 1996 Nov;50(5):1057–64

Antiretrovirus specificity and intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324. Balzarini J, et al. **Mol Pharmacol** 1996 Nov;50(5):1207–13

Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Este JA, et al. **Mol Pharmacol** 1997 Jul;52(1):98–104

Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Robinson WE Jr, et al. **Mol Pharmacol** 1996 Oct;50(4):846–55

Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Rice WG, et al. **Nat Med** 1997 Mar;3(3):341–5

Ammonium salt of glycyrrhizic acid as an antiviral [letter] Badam L. **Natl Med J India** 1997 Mar-Apr;10(2):98

Expression of herpes virus thymidine kinase in Neurospora crassa. Sachs MS, et al. **Nucleic Acids Res** 1997 Jun 15; 25(12):2389–95

Differential effects of the incorporation of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) on the binding of the transcription factors, AP-1 and TFIID, to their cognate target DNA sequences. Staschke KA, et al. **Nucleic Acids Res** 1996 Nov 1;24(21):4111–6

Design and anti-HIV-1 activity of ribozymes that cleave HIV-1 LTR. Koizumi M, et al. **Nucleic Acids Symp Ser** 1995;(34):125–6

Synthesis and antiviral activities of 9-cyclopentylpurine derivatives. Kojima E, et al. **Nucleic Acids Symp Ser** 1995; (34):107–8

Synthesis of carbocyclic oxetanocin analogs bearing fluorine and their antiviral activities. Sato, et al. **Nucleic Acids Symp Ser** 1995;(34):159–60

Phytosterol compounds having antiviral efficacy. Eugster C, et al. **Panminerva Med** 1997 Mar;39(1):12–20

A macrophage-like cell model for testing anti-CMV drugs. Delannoy AS, et al. **Pathol Biol (Paris)** 1997 May; 45(5):394–9

Acyclovir. Abadi J. **Pediatr Rev** 1997 Feb;18(2):70–1

Liver targeting of interferon through pullulan conjugation. Xi K, et al. **Pharm Res** 1996 Dec;13(12):1846–50

Neuramide stimulates adrenocorticotropin but not prolactin release from rat pituitary. Brunetti L, et al. **Pharmacol Res** 1996 Nov-Dec;34(5-6):269–73

Antiviral activity of Porphyridium cruentum polysaccharide. Minkova K, et al. **Pharmazie** 1996 Mar;51(3):194

Effect of Oxadin on phagocytosis and hydrogen peroxide production. Stefanova Z, et al. **Pharmazie** 1997 May; 52(5):409–10

Factors affecting M13 bacteriophage inactivation by methylene blue photosensitization. Abe H, et al. **Photochem Photobiol** 1997 May;65(5):873–6

Antiviral activities of photoactive perylenequinones. Hudson JB, et al. **Photochem Photobiol** 1997 Feb;65(2):352–4

Cloning and characterisation of a gene encoding an antiviral protein from Clerodendrum aculeatum L. Kumar D, et al. **Plant Mol Biol** 1997 Mar;33(4):745–51

Inhibitory activity of soyasaponin II on virus replication in vitro. Hayashi K, et al. **Planta Med** 1997 Apr;63(2):102–5

Antiviral effect of a polysaccharide from Sclerotium glucanicum towards herpes simplex virus type 1 infection. Marchetti M, et al. **Planta Med** 1996 Aug;62(4):303–7

The potential of acyclic nucleoside phosphonates as broad-spectrum antiviral agents. Naesens L, et al. **Postepy Biochem** 1995;41(5 Suppl):347–51 (44 ref.)

Herpesvirus-encoded thymidine kinase in chemotherapy. Ostrowski T, et al. **Postepy Biochem** 1995;41(5 Suppl):342–7 (67 ref.)

Inhibition of human immunodeficiency virus-1 reverse transcriptase by heme and synthetic heme analogs. Staudinger R, et al. **Proc Assoc Am Physicians** 1996 Jan; 108(1):47–54

Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells. Cirino NM, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1937–42

Casein kinase II is a selective target of HIV-1 transcriptional inhibitors. Critchfield JW, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6110–5

Peptidyl-transferase inhibitors have antiviral properties by altering programmed -1 ribosomal frameshifting efficiencies: development of model systems. Dinman JD, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6606–11

Critical role of reverse transcriptase in the inhibitory mechanism of CNI-H0294 on HIV-1 nuclear translocation. Popov S, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11859–64

Conditional reduction of human immunodeficiency virus type 1 replication by a gain-of-herpes simplex virus 1 thymidine kinase function. Smith SM, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7955–60

Novel and unusual nucleosides as drugs. Kolb VM. **Prog Drug Res** 1997;48:195–232 (118 ref.)

The effect of AZT on dendritic cell number and provirus load in the peripheral blood of AIDS patients: a preliminary study. Patterson S, et al. **Res Virol** 1996 Mar-Jun; 147(2-3):109–14

Anti-human immunodeficiency virus type 1 activities of dideoxynucleoside phosphotriester derivatives in primary monocytes/macrophages. Thumann-Schweitzer C, et al. **Res Virol** 1996 Mar-Jun;147(2-3):155–63

Testing of some pharmacological characteristics of the autochthonous product Acyclovir. Mutiu A, et al. **Rom J Virol** 1995 Jan-Jun;46(1-2):9–19

Study of the antiviral activity of some new classes of AS-triazine derivatives (preliminary note). Tomas E, et al. **Rom J Virol** 1995 Jan-Jun;46(1-2):51–6

Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1. Jones-Brando LV, et al. **Schizophr Res** 1997 May 3; 25(1):63–70

The pharmacological profile of famciclovir. Crumpacker C. **Semin Dermatol** 1996 Jun;15(2 Suppl 1):14–26 (44 ref.)

Contributions of protein structure-based drug design to cancer chemotherapy. Jackson RC. **Semin Oncol** 1997 Apr; 24(2):164–72 (46 ref.)

Antiviral and immunomodulatory activities of ascorbic acid. Jariwalla RJ, et al. **Subcell Biochem** 1996;25:213–31 (92 ref.)

A colorimetric LDH assay for the titration of infectivity and the evaluation of anti-viral activity against ortho- and paramyxoviruses. Mori S, et al. **Tohoku J Exp Med** 1995 Dec;177(4):315–25

Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin. Crooke RM, et al. **Toxicol Appl Pharmacol** 1996 Sep;140(1):85–93

Antiviral efficacy and toxicity of ribavirin and foscarnet each given alone or in combination in the murine AIDS model. Omar RF, et al. **Toxicol Appl Pharmacol** 1997 Mar; 143(1):140–51

Effects of ganciclovir and acyclovir on vascular cell proliferation of cytomegalovirus-positive and negative donors. Mohacsi PJ, et al. **Transplant Proc** 1996 Dec; 28(6):3234–5

Immunomodulation and anticytomegalovirus activity of antioxidant metal chelators. Scholz M, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1272–3

Antiviral activity of cyclopentenone prostanoids. Santoro MG. **Trends Microbiol** 1997 Jul;5(7):276–81 (41 ref.)

The effect of interferon-gamma on genetic immunization. Xiang ZQ, et al. **Vaccine** 1997 Jun;15(8):896–8

Recombinant HIV envelope expressed in an alpha-glucosidase I-deficient CHO cell line and its parental cell line in the presence of 1-deoxynojirimycin is functional. Fenouillet E, et al. **Virology** 1997 Apr 28; 231(1):89–95

Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Franke EK, et al. **Virology** 1996 Aug 1;222(1):279–82

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Gale MJ Jr, et al. **Virology** 1997 Apr 14;230(2):217–27

Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity. Hahm B, et al. **Virology** 1996 Dec 15;226(2):318–26

Entry of Semliki forest virus into cells: effects of concanamycin A and nigericin on viral membrane fusion and infection. Irurzun A, et al. **Virology** 1997 Jan 20; 227(2):488–92

Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes. Jagodzinski PP, et al. **Virology** 1996 Dec 15;226(2):217–27

Inhibition of vaccinia virus replication by N-(phosphonoacetyl)-L-aspartate: differential effects on viral gene expression result from a reduced pyrimidine nucleotide pool. Katsafanas GC, et al. **Virology** 1997 Sep 15;236(1):177–87

In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Kleim JP, et al. **Virology** 1997 Apr 28;231(1):112–8

In vitro mutational and inhibitory analysis of the cis-acting translational elements within the 5' untranslated region of coxsackievirus B3: potential targets for antiviral action of antisense oligomers. Yang D, et al. **Virology** 1997 Feb 3; 228(1):63–73

Inhibition of HIV-1, HIV-2 and SIV envelope glycoprotein-mediated cell fusion by calmodulin. Malvoisin E, et al. **Virus Res** 1997 Aug;50(2):119–27

[Experimental study on the effect of qing-wen granule on epidemic hemorrhagic fever virus] Guo WF, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Dec; 15(12):735–6 **(Chi)**

[Effects of qiwei baizhu san in inhibiting replication of human rotavirus in vitro] He ST, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Nov; 15(11):669–71 (Eng. Abstr.) **(Chi)**

[Antiviral activity of hydroalcoholic extract from Haemanthus albiflos on the Moloney murine leukemia virus and the human immunodeficiency virus] Husson GP, et al. **C R Seances Soc Biol Fil** 1997;191(3):473–85 (Eng. Abstr.) **(Fre)**

[A multivariate analysis approach to antineoplastic and antiviral structure-activity relationships to a series of podophyllotoxins] Doré JC, et al. **J Pharm Belg** 1996 Jan-Feb;51(1):9–18 (Eng. Abstr.) **(Fre)**

[Prevalence of transmission of zidovudine-resistant viruses in Switzerland. l'Etude suisse de cohorte VIH] Yerly S, et al. **Schweiz Med Wochenschr** 1996 Oct 26;126(43):1845–8 (Eng. Abstr.) **(Fre)**

[Viral attenuation of labile blood products] Folléa G, et al. **Transfus Clin Biol** 1996;3(2):113–23 (84 ref.) (Eng. Abstr.) **(Fre)**

[Preliminary screening for antiviral AIDS drugs. IV. Report on fiscal year 1992] Sekine H, et al. **Eisei Shikenjo Hokoku** 1994;(112):131–3 (Eng. Abstr.) **(Jpn)**

[The HIV proteinase—a target for antiviral agents] Grinde B, et al. **Tidsskr Nor Laegeforen** 1996 Oct 10; 116(24):2908–11 (20 ref.) (Eng. Abstr.) **(Nor)**

[Comparative study of the mechanism of inhibition of Sindbis virus reproduction by adamantane derivatives: remantadine and amide of 1-adamantane carboxylic acid] Andronova VL. **Antibiot Khimioter** 1996;41(7-8):26–30 (Eng. Abstr.) **(Rus)**

[Antiviral activity of several vasodilator agents] Zhilinskaia IN, et al. **Biull Eksp Biol Med** 1996 Feb;121(2):167–9 **(Rus)**

[Features of the antiviral effect of carbocyclic compounds depending on their concentration] Boreko EI, et al. **Vopr Virusol** 1996 May-Jun;41(3):129–33 (Eng. Abstr.) **(Rus)**

[Features of formation of antiviral resistance upon local application of the interferon inducer ridostin] Masycheva VI, et al. **Vopr Virusol** 1997 May-Jun;42(3):126–8 (Eng. Abstr.) **(Rus)**

[Suppression of the reproduction of the human immunodeficiency virus (HIV) with a cytokine-like antiviral factor] Gribkova NV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep-Oct;(5):27–9 (Eng. Abstr.) **(Rus)**

[Combined activity of meliacin and foscarnet against different strains of herpes simplex virus type 1 using a three-dimensional model] Barquero AA, et al. **Rev Argent Microbiol** 1997 Jan-Mar;29(1):32–7 (Eng. Abstr.) **(Spa)**

[Antiviral agents that act in the early phases of the viral cycle] Damonte EB. **Rev Argent Microbiol** 1996 Oct-Dec; 28(4):204–16 (67 ref.) (Eng. Abstr.) **(Spa)**

[Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection] Salomon HE, et al. **Rev Argent Microbiol** 1995 Oct-Dec;27(4):214–29 (100 ref.) **(Spa)**

[The course for a successor for acyclovir] Ramos JM, et al. **Rev Clin Esp** 1996 Nov;196(11):761–5 (66 ref.) **(Spa)**

POISONING

Progressive somnolence leading to coma in a 68-year-old man. Bradley J, et al. **Chest** 1997 Aug;112(2):538–40

Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs [corrected and republished with original paging, article originally printed in Drug Metab Dispos 1997 Feb;25(2):270–3] Okuda H, et al. **Drug Metab Dispos** 1997 May;25(5):270–3

Fialuridine toxicity [letter] Schmid R. **Hepatology** 1997 Jun; 25(6):1548

Nephrotoxicity of acyclovir and ganciclovir in rats: evaluation of glomerular hemodynamics. Dos Santos M de F, et al. **J Am Soc Nephrol** 1997 Mar;8(3):361–7

STANDARDS

Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines. Piscitelli SC, et al. **Antimicrob Agents Chemother** 1996 Jan;40(1):161–5

SUPPLY & DISTRIBUTION

Opening an electronic pharmacy to the world [news] Steele FR. **Nat Med** 1996 Oct;2(10):1064

THERAPEUTIC USE

Successful interferon treatment for lichen planus associated with chronic active hepatitis due to hepatitis C virus infection [letter] Lapidoth M, et al. **Acta Derm Venereol** 1997 Mar;77(2):171–2

Effect of alpha-interferon on natural killer cell activity and lymphocyte subsets in thalassemia patients with chronic hepatitis C. Malaponte G, et al. **Acta Haematol** 1997; 98(2):83–8

Herpetic stromal disease: response to acyclovir/steroid therapy. O'Brien WJ, et al. **Acta Ophthalmol Scand** 1996 Jun;74(3):265–70

Antisense inhibition of virus infections. Kilkuskie RE, et al. **Adv Pharmacol** 1997;40:437–83 (181 ref.)

Trifluorothymidine 0.5% ointment in the treatment of aciclovir-resistant mucocutaneous herpes simplex in AIDS [letter] Amin AR, et al. **AIDS** 1996 Aug;10(9):1051–3

A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS: longitudinal molecular analysis of the CMV viral load and viral mutations in blood compartments. Boivin G, et al. **AIDS** 1997 Jun;11(7):867–73

Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. Böttiger D, et al. **AIDS** 1997 Feb;11(2):157–62

Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex. Brew BJ, et al. **AIDS** 1996 Oct; 10(12):1357–60

Convenient twice daily foscarnet in induction therapy of AIDS-associated cytomegalovirus retinitis. The Foscarnet Italian Study Group [letter] Carosi G, et al. **AIDS** 1997 Feb;11(2):258–60

Cytomegalovirus retinitis in AIDS patients: a comparative study of intravenous and oral ganciclovir as maintenance therapy. Danner SA, et al. **AIDS** 1996 Dec;10 Suppl 4:S7–11

Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients. Drusano GL, et al. **AIDS** 1996 Sep;10(10):1113–9

Ganciclovir evaluation in AIDS patients with cytomegalovirus retinitis: a European study of treatment patterns and resource utilization. Hardens M. **AIDS** 1996 Dec;10 Suppl 4:S25–30

Famciclovir in AIDS-related acute retinal necrosis [letter; comment] Klein JL, et al. **AIDS** 1996 Sep;10(11):1300–1. Comment on: AIDS 1996 Jan;10(1):55–60.

Funduscopy versus photographic assessment of cytomegalovirus retinitis progression: a clinician's perspective. Migdal C. **AIDS** 1996 Dec;10 Suppl 4:S19–23 (4 ref.)

Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Mocroft A, et al. **AIDS** 1996 Sep;10(10):1101–5

Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovir [letter] Mueller AJ, et al. **AIDS** 1997 Mar;11(3):397–9

Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. Rose DN, et al. **AIDS** 1997 Jun;11(7):883–7

Early foscarnet failure in herpes simplex virus infection in a patient with AIDS [letter] Segal BH, et al. **AIDS** 1997 Mar 15;11(4):552–3

Topical foscarnet for aciclovir-resistant mucocutaneous herpes infections in AIDS [letter] Smith NA, et al. **AIDS** 1997 Feb;11(2):254–5

Oral ganciclovir for cytomegalovirus retinitis in patients with AIDS: results of two randomized studies. Squires KE. **AIDS** 1996 Dec;10 Suppl 4:S13–8

Cytomegalovirus retinitis: new developments in prophylaxis and therapy. Jacobson MA. **AIDS Clin Rev** 1997–98; :249–69 (44 ref.)

Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1. Scadden DT, et al. **AIDS Res Hum Retroviruses** 1996 Aug 10;12(12):1151–9

Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. Tsai CC, et al. **AIDS Res Hum Retroviruses** 1997 May 20; 13(8):707–12

Subcutaneously administered recombinant human beta-interferon in the treatment of chronic hepatitis B virus infection. Guan R, et al. **Aliment Pharmacol Ther** 1996 Oct; 10(5):807–14

Cidofovir for AIDS-related retinitis [news] **Am Fam Physician** 1996 Nov 1;54(6):2124

Interferon alfa-2b therapy for chronic hepatitis [letter; comment] Kirchner JT. **Am Fam Physician** 1997 May 15; 55(7):2434. Comment on: Am Fam Physician 1996 Oct;54(5):1598–605.

Treatment of chronic hepatitis B and hepatitis C with interferon alfa-2b [see comments] Molloy PJ, et al. **Am Fam Physician** 1996 Oct;54(5):1598–605. Comment in: Am Fam Physician 1997 May 15;55(7):2434.

Famciclovir: a new systemic antiviral agent for herpesvirus infections. Stott GA. **Am Fam Physician** 1997 May 15; 55(7):2501–4

Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels: a predictive marker for IFN therapy. Akiyoshi F, et al. **Am J Gastroenterol** 1997 Sep; 92(9):1463–6

Sustained response to interferon in a patient with common variable immunodeficiency and hepatitis C. Castro F, et al. **Am J Gastroenterol** 1997 Sep;92(9):1557–8

Long-term prognosis of chronic hepatitis C after treatment with interferon alpha 2b and characterization of incomplete responders. Hakozaki Y, et al. **Am J Gastroenterol** 1996 Oct;91(10):2144–9

Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B. Hayashi PH, et al. **Am J Gastroenterol** 1996 Nov;91(11):2323–8

Core promoter mutations of hepatitis B virus for the response to interferon in e antigen-positive chronic hepatitis B. Kanai K, et al. **Am J Gastroenterol** 1996 Oct;91(10):2150–6

Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Karino Y, et al. **Am J Gastroenterol** 1997 Jan;92(1):61–5

Breakthrough of interferon therapy [letter; comment] Scalori A, et al. **Am J Gastroenterol** 1996 Oct;91(10):2249–50. Comment on: Am J Gastroenterol 1995 Jun;90(6):951–4.

Patterns of hepatitis C viremia in patients receiving hemodialysis. Umlauft F, et al. **Am J Gastroenterol** 1997 Jan;92(1):73–8

Serial quantitation of serum core protein and viral RNA of hepatitis C virus after interferon therapy: increase in viral loads in biochemical responders. Yoshioka K, et al. **Am J Gastroenterol** 1997 Aug;92(8):1305–9

MALT non-Hodgkin's lymphoma associated with hepatitis C virus infection treated by interferon alpha [letter] Bauduer F. **Am J Hematol** 1996 Nov;53(3):209

Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection. Sarac E, et al. **Am J Kidney Dis** 1997 Jul; 30(1):113–5

Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Roti E, et al. **Am J Med** 1996 Nov; 101(5):482–7

Treatment of hepatitis B virus associated glomerulonephritis

with recombinant human alpha interferon. Chung DR, et al. **Am J Nephrol** 1997;17(2):112–7

Serological markers of autoimmunity in renal transplant patients before and after alpha-interferon therapy for chronic hepatitis C. Rostaing L, et al. **Am J Nephrol** 1996; 16(6):478–83

Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group [see comments] **Am J Ophthalmol** 1997 Aug;124(2):141–57. Comment in: Am J Ophthalmol 1997 Aug;124(2):227–33.

Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet–Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group (ACTG). **Am J Ophthalmol** 1997 Jul;124(1):61–70

Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis [see comments] Banker AS, et al. **Am J Ophthalmol** 1997 Aug;124(2):168–80. Comment in: Am J Ophthalmol 1997 Aug;124(2):227–33.

Antiviral chemoprophylaxis after occupational exposure to human immunodeficiency virus: why, when, where, and what [see comments] Landers MB 3rd, et al. **Am J Ophthalmol** 1997 Aug;124(2):234–9. Comment in: Am J Ophthalmol 1997 Aug;124(2):227–33.

Use of the ganciclovir implant for treating cytomegalovirus retinitis secondary to immunosuppression after bone marrow transplantation. McAuliffe PF, et al. **Am J Ophthalmol** 1997 May;123(5):702–3

Treatment of bilateral cytomegalovirus retinitis with sustained-release ganciclovir implants in a child. Malley DS, et al. **Am J Ophthalmol** 1996 Nov;122(5):731–2

The potential impact of the varicella vaccine and new antivirals on ocular disease related to varicella-zoster virus. Pepose JS. **Am J Ophthalmol** 1997 Feb;123(2):243–51 (75 ref.)

Varicella pneumonia in adults--clinical spectrum. Oh HM, et al. **Ann Acad Med Singapore** 1996 Nov;25(6):816–9

Acyclovir plus steroids for herpes zoster [letter; comment] Atkins CD. **Ann Intern Med** 1997 May 15;126(10):831; discussion 832. Comment on: Ann Intern Med 1996 Sep 1;125(5):376–83.

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Benhamou Y, et al. **Ann Intern Med** 1996 Nov 1;125(9):705–12

Acyclovir plus steroids for herpes zoster [letter; comment] Carson MP. **Ann Intern Med** 1997 May 15;126(10):831–2 . Comment on: Ann Intern Med 1996 Sep 1;125(5):376–83.

Acyclovir plus steroids for herpes zoster [letter; comment] Herbert DA. **Ann Intern Med** 1997 May 15;126(10):831; discussion 832. Comment on: Ann Intern Med 1996 Sep 1;125(5):376–83.

Cidofovir for cytomegalovirus retinitis [letter] Kravcik S. **Ann Intern Med** 1997 Sep 15;127(6):490–1

Interferon-alpha treatment and formation of factor VIII antibodies [letter; comment] Makris M, et al. **Ann Intern Med** 1997 May 15;126(10):829; discussion 829–30. Comment on: Ann Intern Med 1996 Aug 15;125(4):297–9.

Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C. Martinot M, et al. **Ann Intern Med** 1997 Jun 1;126(11):874–81

Acyclovir suppresses subclinical shedding of herpes simplex virus [letter; comment] Straus SE, et al. **Ann Intern Med** 1996 Nov 1;125(9):776–7. Comment on: Ann Intern Med 1996 Jan 1;124(1 Pt 1):8–15.

Interferon-alpha treatment and formation of factor VIII antibodies [letter; comment] Stricker RB. **Ann Intern Med** 1997 May 15;126(10):829; discussion 829–30. Comment on: Ann Intern Med 1996 Aug 15;125(4):297–9.

Hepatitis C virus genotype, hepatitis C virus RNA titers, and response to interferon [letter; comment] Taliani G, et al. **Ann Intern Med** 1997 Jul 1;127(1):89. Comment on: Ann Intern Med 1996 Oct 15;125(8):634–9.

Guidelines for prophylaxis of cytomegalovirus disease in bone marrow transplant patients. Badas A, et al. **Ann Pharmacother** 1996 Dec;30(12):1483–6

Antiviral drug development: the road less taken [comment] Balfour HH Jr. **Ann Pharmacother** 1996 Sep;30(9):964–6. Comment on: Ann Pharmacother 1996 Sep;30(9):967–71. Comment on: Ann Pharmacother 1996 Sep;30(9):972–7.

Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Dickinson BI, et al. **Ann Pharmacother** 1996 Dec;30(12):1452–64 (35 ref.)

Cytomegalovirus prophylaxis and treatment following bone marrow transplantation. Tsinontides AC, et al. **Ann Pharmacother** 1996 Nov;30(11):1277–90 (79 ref.)

The past as prelude to the future: history, status, and future of antiviral drugs [see comments] Whitley RJ. **Ann Pharmacother** 1996 Sep;30(9):967–71 (9 ref.). Comment in: Ann Pharmacother 1996 Sep;30(9):964–6.

Interferon alfa in the treatment of chronic viral hepatitis B and C. Woo MH, et al. **Ann Pharmacother** 1997 Mar; 31(3):330–7 (59 ref.)

Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice. Balzarini J, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):611–6

Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leukocytes of immunocompromised patients. Boivin G, et al. **Antimicrob Agents Chemother** 1997 Apr;41(4):860–2

Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease. Brandt CR, et al. **Antimicrob Agents Chemother** 1996 May;40(5):1078–84

Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. Dieterich DT, et al. **Antimicrob Agents Chemother** 1997 Jun;41(6):1226–30

Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Lewinsohn DM, et al. **Antimicrob Agents Chemother** 1996 Nov;40(11):2555–7

The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Lin E, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):413–18

Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo. Shigeta S, et al. **Antimicrob Agents Chemother** 1997 Jul;41(7):1423–7

Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Utsunomiya T, et al. **Antimicrob Agents Chemother** 1997 Mar;41(3):551–6

A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Van Rompay KK, et al. **Antimicrob Agents Chemother** 1997 Feb;41(2):278–83

Fanconi syndrome associated with cidofovir therapy [letter] Vittecoq D, et al. **Antimicrob Agents Chemother** 1997 Aug; 41(8):1846

2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Zoulim F, et al. **Antimicrob Agents Chemother** 1996 Feb; 40(2):448–53

Inhibition of rabies virus infection by an oligodeoxynucleotide complementary to rabies virus genomic RNA. Fu ZF, et al. **Antisense Nucleic Acid Drug Dev** 1996 Summer;6(2):87–93

Effects of SKF 108922, an HIV-1 protease inhibitor, on retrovirus replication in mice. Black PI, et al. **Antiviral Res** 1996 Mar;29(2-3):175–86

Famciclovir: review of clinical efficacy and safety. Cirelli R, et al. **Antiviral Res** 1996 Mar;29(2-3):141–51 (54 ref.)

Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies. de Jong MD, et al. **Antiviral Res** 1997 Jul; 35(2):65–82

Assessment of pain in herpes zoster: lessons learned from antiviral trials. Dworkin RH, et al. **Antiviral Res** 1997 Jan; 33(2):73–85 (43 ref.)

Quantitative systemic and local evaluation of the antiviral effect of ganciclovir and foscarnet induction treatment on human cytomegalovirus gastrointestinal disease of patients with AIDS. Italian Foscarnet GID Study Group. Gerna G, et al. **Antiviral Res** 1997 Mar;34(1):39–50

Effective treatment of experimental cytomegalovirus-induced encephalo-meningitis in immunocompromised rats with HPMPC. Kloover JS, et al. **Antiviral Res** 1997 Jul;35(2):105–12

Safety and efficacy of Virend for topical treatment of genital and anal herpes simplex lesions in patients with AIDS. Orozco-Topete R, et al. **Antiviral Res** 1997 Jul;35(2):91–103

Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice: an evaluation of the predictive value of the C* concept. Patel PJ, et al. **Antiviral Res** 1996 Mar;29(2-3):279–86

Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir [see comments] Meadows KP, et al. **Arch Dermatol** 1997 Aug;133(8):987–90. Comment in: Arch Dermatol 1997 Aug;133(8):1039–41.

Ribavirin and bronchiolitis: variation in use in the UK [letter] Allport TD, et al. **Arch Dis Child** 1997 Apr;76(4):385

The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Jackson JL, et al. **Arch Intern Med** 1997 Apr 28; 157(8):909–12

Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Kox WJ, et al. **Arch Intern Med** 1997 Feb 24;157(4):389–93

Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Mertz GJ, et al. **Arch Intern Med** 1997 Feb 10;157(3):343–9

Cidofovir [editorial; comment] Jabs DA. **Arch Ophthalmol** 1997 Jun;115(6):785–6 (19 ref.). Comment on: Arch Ophthalmol 1997 Jun;115(6):733–7. Comment on: Arch Ophthalmol 1997 Jun;115(6):801–2.

Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses. Lee MG, et al. **Arch Virol** 1996;141(10):1979–89

Interferon beta in the management of multiple sclerosis [editorial] Pender MP. **Aust N Z J Med** 1996 Jun;26(3):343

Interferon therapy for chronic hepatitis C. Davis GL. **Baillieres Clin Gastroenterol** 1996 Jul;10(2):289–98 (78 ref.)

New treatments for chronic viral hepatitis B and C. Dusheiko GM. **Baillieres Clin Gastroenterol** 1996 Jul;10(2):299–333 (154 ref.)

Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells. Vile RG, et al. **Biochem Soc Trans** 1997 May;25(2):717–22 (51 ref.)

Protective effect of Astragali Radix by intraperitoneal injection against Japanese encephalitis virus infection in mice. Kajimura K, et al. **Biol Pharm Bull** 1996 Jun; 19(6):855–9

AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue. Mathé G, et al. **Biomed Pharmacother** 1996;50(5):220–7

Use of anti HHV-6 transfer factor for the treatment of two patients with chronic fatigue syndrome (CFS). Two case reports. Ablashi DV, et al. **Biotherapy** 1996;9(1-3):81–6

Effect of anti-herpes specific transfer factor. Byston J, et al. **Biotherapy** 1996;9(1-3):73–5

Lessons from a pilot study of transfer factor in chronic fatigue syndrome. De Vinci C, et al. **Biotherapy** 1996;9(1-3):87–90

The use of transfer factors in chronic fatigue syndrome: prospects and problems. Levine PH. **Biotherapy** 1996; 9(1-3):77–9 (25 ref.)

Efficacy of transfer factor in treating patients with recurrent ocular herpes infections. Meduri R, et al. **Biotherapy** 1996; 9(1-3):61–6

Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: a pilot study. Prasad U, et al. **Biotherapy** 1996;9(1-3):109–15

Therapeutic effects of glycyrrhizin in mice infected with LP-BM5 murine retrovirus and mechanisms involved in the prevention of disease progression. Watanbe H, et al. **Biotherapy** 1996;9(4):209–20

Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Boeckh M, et al. **Blood** 1996 Nov 15; 88(10):4063–71

Downregulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy [letter; comment] Böhler T, et al. **Blood** 1997 Jul 15;90(2):886–8 . Comment on: Blood 1997 Jan 15;89(2):550–7.

Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Wang FZ, et al. **Blood** 1996 Nov 1; 88(9):3615–20

Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. Amir J, et al. **BMJ** 1997 Jun 21;314(7097):1800–3

Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. Foster GR, et al. **BMJ** 1997 Aug 23;315(7106):453–8

Advising patients with genital herpes [editorial] Patel R, et al. **BMJ** 1997 Jan 11;314(7074):85–6

New guidelines on hepatitis C [news] Tanne JH. **BMJ** 1997 Apr 12;314(7087):1070

Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct). Bacigalupo A, et al. **Bone Marrow Transplant** 1996 Nov;18 Suppl 2:110–4

Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Canpolat C, et al. **Bone Marrow Transplant** 1996 Apr; 17(4):589–93

Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation. Choi JH, et al. **Bone Marrow Transplant** 1997 Jan;19(2):187–90

Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation. Iino T, et al. **Bone Marrow Transplant** 1996 Dec;18(6):1185–8

Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Ljungman P, et al. **Bone Marrow Transplant** 1996 Apr;17(4):583–7

Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Ljungman P, et al. **Bone Marrow Transplant** 1996 Sep;18(3):565–8

Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Prentice HG, et al. **Bone Marrow Transplant** 1997 Jan;19(2):129–33

Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant. Prentice HG, et al. **Bone Marrow Transplant** 1997 Jan; 19(2):135–42 (27 ref.)

European survey of herpesvirus resistance to antiviral drugs

in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Reusser P, et al. **Bone Marrow Transplant** 1996 May;17(5):813–7

Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poor–prognosis myelodysplastic syndrome. Beguin Y, et al. **Br J Haematol** 1996 Sep; 94(3):507–9

Antimicrobial therapy: toward the future [published erratum appears in Br J Hosp Med 1997 Feb 19–Mar 4;57(4):172] Ellis R, et al. **Br J Hosp Med** 1996 Aug 21–Sep 3; 56(4):145–50 (13 ref.)

Interferon alfa–2a. Williams CD, et al. **Br J Hosp Med** 1997 May 7–20;57(9):436–9 (10 ref.)

Management of varicella zoster virus retinitis in AIDS. Moorthy RS, et al. **Br J Ophthalmol** 1997 Mar;81(3):189–94

RetroActive antivirals [editorial] MacInnis BJ. **Can J Ophthalmol** 1996 Oct;31(6):275–6 **(Eng, Fre)**

The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Arase Y, et al. **Cancer** 1997 Apr 15; 79(8):1494–500

Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Dilber MS, et al. **Cancer Res** 1997 Apr 15;57(8):1523–8

Antiviral activities of tragacanthin polysaccharides on Punta Toro virus infections in mice. Smee DF, et al. **Chemotherapy** 1996 Jul–Aug;42(4):286–93

Cytomegalovirus infection–enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Lemström K, et al. **Circulation** 1997 Jun 17; 95(12):2614–6

Treatment of HIV infection and its complications. Polsky B. **Clin Chest Med** 1996 Dec;17(4):647–63 (68 ref.)

alpha–Glutathione S–transferase levels in chronic hepatitis C infection and the effect of alpha–interferon therapy. Thorburn D, et al. **Clin Chim Acta** 1996 Sep 30; 253(1–2):171–80

Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study. Flichman D, et al. **Clin Diagn Virol** 1997 May;8(1):63–70

Amantadine susceptibility in influenza A virus isolates: determination methods and lack of resistance in a Canadian sample, 1991–94. Prud'homme IT, et al. **Clin Diagn Virol** 1997 May;8(1):41–51

Chronic sinusitis refractory to standard management in patients with humoral immunodeficiencies. Buehring I, et al. **Clin Exp Immunol** 1997 Sep;109(3):468–72

Naive and memory T cell infiltrates in chronic hepatitis C: phenotypic changes with interferon treatment. Imada K, et al. **Clin Exp Immunol** 1997 Jul;109(1):59–66

Interferon alpha–2 (IFN alpha 2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH–chloroquine. Ferraccioli GF, et al. **Clin Exp Rheumatol** 1996 Jul–Aug;14(4):367–71

Erosive arthritis and posterior uveitis in Behçet's disease: treatment with interferon alpha and interferon gamma. Kötter I, et al. **Clin Exp Rheumatol** 1996 May–Jun; 14(3):313–5

Immune complex mediated vasculitis in hepatitis B and C infections and the effect of antiviral therapy. Nityanand S, et al. **Clin Immunol Immunopathol** 1997 Mar;82(3):250–7

Supraglottitis due to herpes simplex virus type 1 in an adult. Bengualid V, et al. **Clin Infect Dis** 1996 Feb;22(2):382–3

Destructive mucocutaneous phagedenic herpes simplex virus infection in an HIV–infected patient who had a partial response to interferon and ultraviolet rays. Giani G, et al. **Clin Infect Dis** 1996 Feb;22(2):381–2

Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Kilgore PE, et al. **Clin Infect Dis** 1997 Apr; 24(4):718–22

Myelitis due to varicella–zoster virus in two patients with AIDS: successful treatment with acyclovir. Lionnet F, et al. **Clin Infect Dis** 1996 Jan;22(1):138–40

Diagnosis of cytomegalovirus meningoencephalitis by polymerase chain reaction in an immunocompetent infant who recovered after treatment with ganciclovir. Mahieu LM, et al. **Clin Infect Dis** 1997 Mar;24(3):520–1

Acyclovir therapy for immunocompetent children with chickenpox. Acyclovir–chickenpox Italian Study Group. Manfredi R, et al. **Clin Infect Dis** 1997 Jun;24(6):1261–2

Cytarabine therapy for progressive multifocal leukoencephalopathy in patients with AIDS. Moreno S, et al. **Clin Infect Dis** 1996 Nov;23(5):1066–8

Foscarnet therapy for acyclovir–resistant herpes simplex virus 1 infection in allogeneic bone marrow transplant recipients. Naik HR, et al. **Clin Infect Dis** 1995 Dec; 21(6):1514–5

Early therapy with interferon for acute hepatitis C acquired through a needlestick. Noguchi S, et al. **Clin Infect Dis** 1997 May;24(5):992–4

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis–HIV Spanish Study Group. Soriano V, et al. **Clin Infect Dis** 1996 Sep;23(3):585–91

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta–analysis of placebo–controlled trials. Wood MJ, et al. **Clin Infect Dis** 1996 Feb;22(2):341–7

Reassessment of indications for ribavirin therapy in respiratory syncytial virus infection. Steele RW. **Clin Pediatr (Phila)** 1996 Jul;35(7):377

Treatment of viral infections during pregnancy and the neonatal period. Whitley RJ, et al. **Clin Perinatol** 1997 Mar; 24(1):267–83 (51 ref.)

An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Sullivan SD, et al. **Clin Ther** 1996 May–Jun;18(3):546–58

Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Gotti E, et al. **Clin Transplant** 1996 Dec;10(6 Pt 1):550–5

Interferon–alpha therapy for hepatitis C virus recurrence after liver transplantation: long–term response with maintenance therapy. Singh N, et al. **Clin Transplant** 1996 Aug;10(4):348–51

Herpesvirus disease: an update. Nadler JP, et al. **Compr Ther** 1997 Feb;23(2):104–7 (15 ref.)

Treatment of chronic hepatitis C. Nelson DR, et al. **Compr Ther** 1997 Apr;23(4):269–76 (29 ref.)

Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Colin J, et al. **Cornea** 1997 Jul; 16(4):393–9

Treatment of adenoviral conjunctivitis with topical cidofovir [letter] Gordon YJ, et al. **Cornea** 1996 Sep;15(5):546

Advances in antiviral therapy. Dwyer DE, et al. **Curr Opin Pediatr** 1997 Feb;9(1):24–30 (36 ref.)

Antiviral chemotherapy. Mueller BU. **Curr Opin Pediatr** 1997 Apr;9(2):178–83 (52 ref.)

"Stat." single dose of acyclovir for prevention of herpes simplex. Shelley WB, et al. **Cutis** 1996 Jun;57(6):453

Acyclovir therapy for angioedema and chronic urticaria. Shelley WB, et al. **Cutis** 1997 Apr;59(4):185–8

Granulocyte–macrophage colony–stimulating factor as adjuvant therapy for factor as adjuvant therapy for interferon alpha treatment of chronic hepatitis C. Carreno V, et al. **Cytokine** 1996 Apr;8(4):318–22

Current clinical issues in the management of herpes simplex virus infections in patients with HIV. Conant M. **Dermatology** 1997;194(2):93–7

Antiviral therapy for recurrent herpes simplex reconsidered. Wolf R, et al. **Dermatology** 1997;194(3):205–7

Thymus–derived peptides in the treatment of viral chronic hepatitis [see comments] Naylor PH, et al. **Dig Dis** 1996 Nov–Dec;14(6):362–70 (41 ref.). Comment in: Dig Dis 1996 Nov–Dec;14(6):331–3.

Long–term efficacy of interferon–alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis. Senturk H, et al. **Dig Dis Sci** 1997 Jul;42(7):1438–44

Treatment of chronic hepatitis C with amantadine. Smith JP. **Dig Dis Sci** 1997 Aug;42(8):1681–7

Home intravenous anti–infective therapy (HIVAT): do the benefits outweigh the risks? Williams DN. **Drug Saf** 1996 Jan;14(1):1–7

New antiherpesvirus agents. Their targets and therapeutic potential. Alrabiah FA, et al. **Drugs** 1996 Jul;52(1):17–32 (131 ref.)

Cidofovir. Lea AP, et al. **Drugs** 1996 Aug;52(2):225–230; discussion 231 (8 ref.)

Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Perry CM, et al. **Drugs** 1996 Nov; 52(5):754–72 (70 ref.)

Severity of varicella infection in Saudis with diabetes mellitus: a possible role of acyclovir in treatment. Kubeyinje EP. **East Afr Med J** 1995 Nov;72(11):739–41

Inflammatory markers in bronchoalveolar lavage fluid of standardbred racehorses with inflammatory airway disease: response to interferon–alpha. Moore BR, et al. **Equine Vet J** 1997 Mar;29(2):142–7

Amantadine in man and horse––can we learn from each other? [editorial; comment] Oxford JS. **Equine Vet J** 1997 Mar;29(2):89–91. Comment on: Equine Vet J 1997 Mar;29(2):104–10.

Detection of hepatitis C virus RNA in serum and peripheral blood mononuclear cells in patients with chronic hepatitis C treated with interferon alpha. Basaras M, et al. **Eur J Clin Microbiol Infect Dis** 1996 Nov;15(11):887–90

Cytomegalovirus polyradiculopathy treated successfully with foscarnet [letter] Corral I, et al. **Eur J Clin Microbiol Infect Dis** 1996 May;15(5):428–9 (10 ref.)

Advances and controversies in the antiviral therapy of herpes zoster [editorial] Cunningham AL, et al. **Eur J Clin Microbiol Infect Dis** 1996 Apr;15(4):273–5

Results of a double–blind placebo–controlled study of the double–stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Thompson KA, et al. **Eur J Clin Microbiol Infect Dis** 1996 Jul;15(7):580–7

Effect of N–acetylcysteine(NAC) treatment on HIV–1 infection: a double–blind placebo–controlled trial. Akerlund B, et al. **Eur J Clin Pharmacol** 1996;50(6):457–61

Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon–alpha–2a therapy. Areias J, et al. **Eur J Gastroenterol Hepatol** 1996 Aug;8(8):825–8

Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Fargion S, et al. **Eur J Gastroenterol Hepatol** 1997 May;9(5):497–503

HCV–RNA levels play an important role independently of genotype in predicting response to interferon therapy. Picciotto A, et al. **Eur J Gastroenterol Hepatol** 1997 Jan; 9(1):67–9

Treatment of men with flat (FC) or acuminata (CA) condylomata with interferon alpha–2a. Relakis K, et al. **Eur J Gynaecol Oncol** 1996;17(6):529–33

A long–term follow–up study of interferon treatment for chronic hepatitis C in Japanese patients with congenital bleeding disorders. Yamada M, et al. **Eur J Haematol** 1996 Aug;57(2):165–70

Combination of chemotherapy and antiviral therapy for Epstein–Barr virus–associated non–Hodgkin's lymphoma of high grade malignancy in cases of HIV infection. Brockmeyer NH, et al. **Eur J Med Res** 1997 Mar 24; 2(3):133–5

Intravitreal and systemic foscarnet in the treatment of AIDS–related CMV retinitis. Tognon MS, et al. **Eur J Ophthalmol** 1996 Apr–Jun;6(2):179–82

Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Gottrand F, et al. **Eur J Pediatr** 1996 Dec; 155(12):1031–4

Attenuation of influenza–like symptomatology and improvement of cell–mediated immunity with long–term N–acetylcysteine treatment. De Flora S, et al. **Eur Respir J** 1997 Jul;10(7):1535–41

Efficacy of 6–chloro–2',3'–dideoxyguanosine (6–Cl–ddG) on an ARC/AIDS rhesus macaque (Macaca mulatta) infected with simian immunodeficiency virus. Fujii Y, et al. **Exp Anim** 1997 Jan;46(1):83–7

Alpha–interferon for chronic active hepatitis B in human immunodeficiency virus–infected patients. Zylberberg H, et al. **Gastroenterol Clin Biol** 1996;20(11):968–71

Lamivudine therapy for chronic hepatitis B: a six–month randomized dose–ranging study. Nevens F, et al. **Gastroenterology** 1997 Oct;113(4):1258–63

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo–Chiba Hepatitis Research Group. Shiratori Y, et al. **Gastroenterology** 1997 Aug;113(2):558–66

Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Squadrito G, et al. **Gastroenterology** 1997 Aug; 113(2):567–72

Disease stage of chronic hepatitis C assessed by both peritoneoscopic and histologic findings and its relationship with response to interferon therapy. Ohkawa K, et al. **Gastrointest Endosc** 1997 Feb;45(2):168–75

Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Izquierdo M, et al. **Gene Ther** 1996 Jun;3(6):491–5

Gene therapy against an experimental glioma using adeno–associated virus vectors. Okada H, et al. **Gene Ther** 1996 Nov;3(11):957–64

A continuous intracerebral gene delivery system for in vivo liposome–mediated gene therapy. Zhu J, et al. **Gene Ther** 1996 Jun;3(6):472–6

Sharing prescribing of continuous aciclovir treatment: effects of a new policy and general practitioner responses [letter] Vonau B, et al. **Genitourin Med** 1997 Jun;73(3):225–6

Beyond efficacy: new issues for HSV antiviral therapy [editorial; comment] Wald A. **Genitourin Med** 1997 Apr; 73(2):83–4. Comment on: Genitourin Med 1997 Apr;73(2):105–9.

Viral hepatitis: how to manage type C and D infections. Najm W. **Geriatrics** 1997 May;52(5):28–30, 33–4, 37 (20 ref.)

Use of antivirals in influenza in the elderly: prophylaxis and therapy. Nicholson KG. **Gerontology** 1996;42(5):280–9 (55 ref.)

Clinical characteristics of acyclovir–resistant herpetic keratitis and experimental studies of isolates. Yao YF, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234 Suppl 1:S126–32

Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment [see comments] Boucher E, et al. **Gut** 1997 Jul;41(1):115–20. Comment in: Gut 1997 Jul;41(1):127–8.

Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: an effective in vitro drug–sensitization system. Al–Hendy A, et al. **Gynecol Obstet Invest** 1997;43(4):268–75

Of magic bullets and social justice: emerging challenges of recent advances in AIDS treatment. Linsk NL, et al. **Health Soc Work** 1997 Feb;22(1):70–4

Parameters predicting response to alpha–interferon treatment in chronic hepatitis C. Glück T, et al. **Hepatogastroenterology** 1997 Mar–Apr;44(14):484–91

Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C. Laghi V, et al. **Hepatogastroenterology** 1997 Jul–Aug; 44(16):1182–6

Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Okano J, et al. **Hepatogastroenterology** 1997 Mar–Apr;44(14):525–8

Case of small hepatocellular carcinoma in the caudate lobe detected after interferon caused disappearance of hepatitis C virus. Tamori A, et al. **Hepatogastroenterology** 1996 Jul–Aug;43(10):1079–83

Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Van Thiel DH, et al. **Hepatogastroenterology** 1997 May–Jun;44(15):808–12

Therapy of hepatitis C: re–treatment with alpha interferon. Alberti A, et al. **Hepatology** 1997 Sep;26(3 Suppl 1):137S–142S (26 ref.)

ANTIVIRAL AGENTS

A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B. Andreone P, et al. **Hepatology** 1996 Oct;24(4):774–7

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Bodenheimer HC Jr, et al. **Hepatology** 1997 Aug;26(2):473–7

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Carithers RL Jr, et al. **Hepatology** 1997 Sep;26(3 Suppl 1):83S–88S

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection [see comments] Chayama K, et al. **Hepatology** 1997 Mar;25(3):745–9. Comment in: Hepatology 1997 Mar;25(3):769–71.

Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro [see comments] Colledge D, et al. **Hepatology** 1997 Jul; 26(1):216–25. Comment in: Hepatology 1997 Jul;26(1):234–7.

Antipyrine clearance and response to interferon therapy in chronic hepatitis [letter; comment] Fabbri A, et al. **Hepatology** 1997 Feb;25(2):500–2. Comment on: Hepatology 1995 Oct;22(4 Pt 1):1065–71.

Therapy of hepatitis C: interferon alfa-n1 trials. Farrell GC. **Hepatology** 1997 Sep;26(3 Suppl 1):96S–100S (24 ref.)

Combination therapy for chronic hepatitis B [editorial; comment] Fontana RJ, et al. **Hepatology** 1997 Jul; 26(1):234–7. Comment on: Hepatology 1997 Jul;26(1):216–25.

The interferon sensitivity determining region: all hepatitis C virus isolates are not the same [editorial; comment] Herion D, et al. **Hepatology** 1997 Mar;25(3):769–71. Comment on: Hepatology 1997 Mar;25(3):740–4. Comment on: Hepatology 1997 Mar;25(3):745–9. Comment on: Hepatology 1997 Mar;25(3):750–3.

Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Keeffe EB, et al. **Hepatology** 1997 Sep;26(3 Suppl 1):101S–107S (28 ref.)

Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy [see comments] Kurosaki M, et al. **Hepatology** 1997 Mar;25(3):750–3. Comment in: Hepatology 1997 Mar;25(3):769–71.

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Lai CL, et al. **Hepatology** 1997 Jan;25(1):241–4

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Lam NP, et al. **Hepatology** 1997 Jul;26(1):226–31

Therapy of hepatitis C: interferon alfa-2a trials. Lee WM. **Hepatology** 1997 Sep;26(3 Suppl 1):89S–95S

Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression. Luscombe C, et al. **Hepatology** 1996 Oct;24(4):766–73

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Poynard T, et al. **Hepatology** 1996 Oct;24(4):778–89

Therapy of hepatitis C: alpha interferon and ribavirin. Reichard O, et al. **Hepatology** 1997 Sep;26(3 Suppl 1):108S–111S (29 ref.)

Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Shinohara E, et al. **Hepatology** 1997 Jun;25(6):1502–6

Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial. Simon DM, et al. **Hepatology** 1997 Feb;25(2):445–8

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Tipples GA, et al. **Hepatology** 1996 Sep;24(3):714–7

Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa [see comments] Zeuzem S, et al. **Hepatology** 1997 Mar; 25(3):740–4. Comment in: Hepatology 1997 Mar;25(3):769–71.

A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Alvarez RD, et al. **Hum Gene Ther** 1997 Mar 20; 8(5):597–613

Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Eck SL, et al. **Hum Gene Ther** 1996 Aug 1;7(12):1465–82

Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response. Smith JG, et al. **Hum Gene Ther** 1997 May 20;8(8):943–54

Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells. Tamura M, et al. **Hum Gene Ther** 1997 Mar 1;8(4):381–91

In vivo anti-influenza virus activity of Kampo (Japanese herbal) medicine "Sho-seiryu-to"--effects on aged mice, against subtypes of a viruses and B virus, and therapeutic effect. Nagai T, et al. **Immunopharmacol Immunotoxicol** 1996 May;18(2):193–208

Potential in vitro activity of Kutapressin against Epstein-Barr virus. Rosenfeld E, et al. **In Vivo** 1996 May-Jun;10(3):313–8

Anti-HIV activity of some non-nucleoside s-triazine derivatives (Part-IV). Desai NC, et al. **Indian J Exp Biol** 1996 Jun;34(6):584–7

Acyclovir therapy in chickenpox. Aggarwal V, et al. **Indian Pediatr** 1996 Apr;33(4):313–7 (19 ref.)

Acyclovir in chickenpox [letter] Singh H. **Indian Pediatr** 1996 Dec;33(12):1061

The pathogenesis of AIDS: lessons learned from other medical conditions. Griffiths PD, et al. **Infect Agents Dis** 1996 Oct;5(4):231–9 (50 ref.)

Triple combination antiretroviral prophylaxis for needlestick exposure to HIV [letter] Rich JD, et al. **Infect Control Hosp Epidemiol** 1997 Mar;18(3):161

Parenteral ganciclovir treatment of acute CMV infection in the immunocompetent host. Laing RB, et al. **Infection** 1997 Jan-Feb;25(1):44–6

Management of herpes simplex virus type 1 pneumonia following liver transplantation. Liebau P, et al. **Infection** 1996 Mar-Apr;24(2):130–5

Unusual course of herpes simplex virus encephalitis after acyclovir therapy. Preiser W, et al. **Infection** 1996 Sep-Oct; 24(5):384–9

Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Hall SJ, et al. **Int J Cancer** 1997 Jan 17;70(2):183–7

Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy. Giustina G, et al. **Int J Clin Lab Res** 1996;26(1):33–6

Cost-benefit of oral acyclovir in the treatment of herpes zoster. Kubeyinje EP. **Int J Dermatol** 1997 Jun;36(6):457–9

Oral acyclovir therapy for varicella in pregnancy. Mutalik S, et al. **Int J Dermatol** 1997 Jan;36(1):49–51

Treatment of herpes zoster with interferon alpha-2A. Naoum C, et al. **Int J Dermatol** 1996 Oct;35(10):749–50

Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus. D'Agostini C, et al. **Int J Immunopharmacol** 1996 Feb;18(2):95–102

Vancouver: optimism, but at a cost [editorial] Churchill D, et al. **Int J STD AIDS** 1996 Oct;7(6):385–7

Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study. Tay SK. **Int J STD AIDS** 1996 Jul;7(4):276–80

Survey of the management of genital herpes in general practice. Woolley PD, et al. **Int J STD AIDS** 1996 May-Jun;7(3):206–11

Medical management of herpes simplex ocular infections. Lee SY, et al. **Int Ophthalmol Clin** 1996 Spring;36(2):85–97 (42 ref.)

New therapies for cytomegalovirus retinitis. Schwartz DM. **Int Ophthalmol Clin** 1996 Spring;36(2):1–9 (35 ref.)

Treatment of herpes simplex & varicella zoster infection [editorial] Barrg C, et al. **Ir Med J** 1996 Jul-Aug; 89(4):132–4 (8 ref.)

Long-term variations of serum laminin and procollagen III peptide in chronic HCV hepatitis after alpha-interferon therapy. Casaril M, et al. **Ital J Gastroenterol** 1996 Jan; 28(1):15–9

Treatment of "problematic" hepatitis C patients. Colombo M. **Ital J Gastroenterol** 1996 Sep;28(7):393–5 (24 ref.)

Resistance to alpha interferon therapy in HCV chronic liver disease: role of hepatic fibrosis. Di Costanzo GG, et al. **Ital J Gastroenterol** 1996 Apr;28(3):140–6

Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Scotto G, et al. **Ital J Gastroenterol** 1996 Dec;28(9):505–11

Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alpha interferon with or without corticosteroids: short- and long-term follow-up. Zavaglia C, et al. **Ital J Gastroenterol** 1996 Jul-Aug;28(6):324–31

New approaches to the treatment of cytomegalovirus retinitis. Proceedings of a roundtable meeting. Washington, D.C., January 26, 1996. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:vii, S1–38

Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. Bazarbachi A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;13 Suppl 1:S186–90 (16 ref.)

Successful use of cidofovir in treating AIDS-related cytomegalovirus retinitis, encephalitis, and esophagitis [letter] Blick G, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 May 1;15(1):84–5

Management strategies for patients with cytomegalovirus retinitis. Hardy WD. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S7–12 (19 ref.)

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. Japour AJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Nov 1;13(3):235–46

Cidofovir: a new therapy for cytomegalovirus retinitis. Lalezari JP. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S22–6 (25 ref.)

Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. Lalezari JP, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S27–31 (16 ref.)

Changes in HIV-1 RNA plasma level in patients treated with foscarnet [letter] Segondy M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Jan 1;14(1):79–80

Hydroxyurea treatment in HIV-infected patients [letter] Simonelli C, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Dec 15;13(5):462–4

Current therapeutic challenges in the treatment of cytomegalovirus retinitis. Spector SA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997;14 Suppl 1:S32–5 (13 ref.)

Clinical experience with stavudine as salvage therapy in patients with advanced HIV disease [letter] Wallace MR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Sep;13(1):96–7

Viral infection and tic exacerbation [letter] Budman CL, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Feb;36(2):162

Cimetidine therapy for warts in children [letter; comment] Fischer G, et al. **J Am Acad Dermatol** 1997 Aug;37(2 Pt 1):289–90. Comment on: J Am Acad Dermatol 1996 Aug;35(2 Pt 1):271–2.

Management of hepatitis C [letter; comment] Kirchner JT. **J Am Board Fam Pract** 1996 Sep-Oct;9(5):391. Comment on: J Am Board Fam Pract 1996 May-Jun;9(3):157–61.

Pharmacologic management of cytomegalovirus retinitis: review of current and future therapeutic modalities. Bright DC. **J Am Optom Assoc** 1997 Jan;68(1):11–30 (195 ref.)

Drug updates [news] **J Am Pharm Assoc (Wash)** 1996 Jan; NS36(1):7–8

Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. Brennan DC, et al. **J Am Soc Nephrol** 1997 Jan;8(1):118–25

Antiviral activity of natural and semisynthetic polysaccharides on the early steps of rubella virus infection. Mastromarino P, et al. **J Antimicrob Chemother** 1997 Mar; 39(3):339–45

Multiple dose netivudine, a potent anti-varicella zoster virus agent, in healthy elderly volunteers and patients with shingles. Peck RW, et al. **J Antimicrob Chemother** 1996 Mar;37(3):583–97

Antiretroviral therapy 1996. Beck JM 2nd. **J Ark Med Soc** 1996 Mar;92(10):499–500

Postexposure prophylaxis after an occupational exposure to HIV. Porche DJ. **J Assoc Nurses AIDS Care** 1997 Jan-Feb; 8(1):83–7

Cytovene-IV, Cytovene-Capsules. Porche DJ. **J Assoc Nurses AIDS Care** 1996 Jan-Feb;7(1):50–5 (7 ref.)

New horizons: antiretroviral therapy in 1997. Williams AB. **J Assoc Nurses AIDS Care** 1997 Jul-Aug;8(4):26–38 (17 ref.)

Zoster myelitis and its response to Acyclovir. Sharma R, et al. **J Assoc Physicians India** 1996 Mar;44(3):220–1

Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy. The Melbourne Excimer Laser Group. Gillies MC, et al. **J Cataract Refract Surg** 1996 Sep;22(7):891–900

Potential benefit of acyclovir for chickenpox acquired from household contacts. The Italian Acyclovir-Chickenpox Study Group. Manfredi R, et al. **J Chemother** 1997 Jun; 9(3):199–202

Combined therapy with zidovudine, recombinant granulocyte colony stimulating factors and erythropoietin in asymptomatic HIV patients. Perrella O, et al. **J Chemother** 1996 Feb;8(1):63–6

Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. Wald A, et al. **J Clin Invest** 1997 Mar 1;99(5):1092–7

Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes. Diaz-Mitoma F, et al. **J Clin Microbiol** 1996 Mar; 34(3):657–63

Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. Bergmann OJ, et al. **J Clin Oncol** 1997 Jun;15(6):2269–74

A case of herpes zoster associated with colitis. Okimura H, et al. **J Dermatol** 1996 Sep;23(9):631–4 (6 ref.)

Acyclovir or prednisone for treating herpes zoster. Becker LA, et al. **J Fam Pract** 1996 Dec;43(6):539–40

Penciclovir cream for herpes simplex labialis. Lawless C, et al. **J Fam Pract** 1997 Aug;45(2):105–6

Acyclovir in pregnancy for primary prevention of neonatal herpes. Stiffman MN, et al. **J Fam Pract** 1997 Jan; 44(1):29–30

Ribavirin for RSV lower respiratory tract infection. Zamorski M. **J Fam Pract** 1996 Dec;43(6):536–7

Influenza, influenza vaccine, and amantadine/rimantadine. Zimmerman RK, et al. **J Fam Pract** 1997 Aug;45(2):107–22; quiz 123–4 (44 ref.)

A randomized, double-blind, controlled trial of natural interferon-beta therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels.

Arase Y, et al. **J Gastroenterol** 1996 Aug;31(4):559–64

Effects of high–dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis. Berling R, et al. **J Gastroenterol** 1996 Oct;31(5):702–9

Effectiveness of glycyrrhizin for oral lichen planus in patients with chronic HCV infection. Da Nagao Y, et al. **J Gastroenterol** 1996 Oct;31(5):691–5

Expression of interferon–alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: relation to effectiveness of interferon therapy. Fukuda R, et al. **J Gastroenterol** 1996 Dec;31(6):806–11

Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon–alpha. Hirashima N, et al. **J Gastroenterol Hepatol** 1996 Oct;11(10):955–8

Interferon–alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment. Orito E, et al. **J Gastroenterol Hepatol** 1997 Jan;12(1):58–61

Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study. Tsutsumi M, et al. **J Gastroenterol Hepatol** 1996 Nov;11(11):1006–11

Impact of ganciclovir prophylaxis on heart–lung and lung transplant recipients. Soghikian MV, et al. **J Heart Lung Transplant** 1996 Sep;15(9):881–7

Permanent response to alpha–interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV–RNA from serum. Ampurdanés S, et al. **J Hepatol** 1996 Dec; 25(6):827–32

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. Aye TT, et al. **J Hepatol** 1997 May;26(5):1148–53

Responsiveness to interferon alpha treatment in patients with chronic hepatitis C coinfected with hepatitis G virus. Berg T, et al. **J Hepatol** 1996 Nov;25(5):763–8

Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin. Durand F, et al. **J Hepatol** 1997 Mar;26(3):722–6

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo–controlled study. Dusheiko G, et al. **J Hepatol** 1996 Nov;25(5):591–8

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). Fattovich G, et al. **J Hepatol** 1997 Jul; 27(1):201–5

Effectiveness of interferon–alpha therapy in chronic hepatitis C is associated with the amount of interferon–alpha receptor mRNA in the liver. Fukuda R, et al. **J Hepatol** 1997 Mar;26(3):455–61

Mutations of hepatitis C virus 1b NS5A 2209–2248 amino acid sequence do not predict the response to recombinant interferon–alfa therapy in French patients. Khorsi H, et al. **J Hepatol** 1997 Jul;27(1):72–7

Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep). Krogsgaard K, et al. **J Hepatol** 1996 Dec;25(6):795–802

Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. Krogsgaard K, et al. **J Hepatol** 1996 Dec;25(6):803–13

Treatment of hepatitis B–related polyarteritis nodosa with famciclovir and interferon alfa–2b. Kruger M, et al. **J Hepatol** 1997 Apr;26(4):935–9

HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy). Magrin S, et al. **J Hepatol** 1996 Nov;25(5):583–90

Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: clinical course and possible treatment with ganciclovir. Mertens T, et al. **J Hepatol** 1996 Dec;25(6):968–71

Long–term interferon alfa–2b retreatment of relapsing patients with chronic hepatitis C [letter] Picciotto A, et al. **J Hepatol** 1997 Feb;26(2):447–8

Interferon–alpha treatment of hepatitis C virus–associated mixed cryoglobulinemia. Polzien F, et al. **J Hepatol** 1997 Jul;27(1):63–71

Hepatitis G virus infection in chronic hepatitis C: frequency, features and response to interferon therapy. Sáiz JC, et al. **J Hepatol** 1997 Apr;26(4):787–93

Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha–2b for chronic hepatitis type C. Results of a multicenter randomized trial. Saracco G, et al. **J Hepatol** 1997 Jul;27(1):56–62

Outcome of liver disease and response to interferon treatment are not influenced by hepatitis B virus core gene variability in children with chronic type B hepatitis. Schepis F, et al. **J Hepatol** 1997 Apr;26(4):765–70

The clinical value of grading and staging scores for predicting a long–term response and evaluating the efficacy of interferon therapy in chronic hepatitis C. Shindo M, et al. **J Hepatol** 1997 Mar;26(3):492–7

Platelet–associated immunoglobulin G, thrombocytopenia and response to interferon treatment in chronic hepatitis C [letter; comment] Taliani G, et al. **J Hepatol** 1996 Dec; 25(6):999. Comment on: J Hepatol 1996 Feb;24(2):135–40.

Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. Toyoda H, et al. **J Hepatol** 1997 Jan; 26(1):6–13

Time course of histological changes in patients with a sustained biochemical and virological response to interferon–alpha therapy for chronic hepatitis C virus infection. Tsubota A, et al. **J Hepatol** 1997 Jul;27(1):49–55

Steroid and interferon therapy in liver/kidney microsomal antibody–positive patients with chronic hepatitis C [letter] Vento S, et al. **J Hepatol** 1997 Apr;26(4):955–6

A histopathological study of the effects of 6–month versus 12–month interferon alpha–2b therapy in chronic hepatitis C. Ziol M, et al. **J Hepatol** 1996 Dec;25(6):833–41

Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. **J Infect Dis** 1997 Jul; 176(1):50–8

Evaluation of sorivudine (BV–araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus–infected adults. The Multinational Sorivudine Study Group. Bodsworth NJ, et al. **J Infect Dis** 1997 Jul;176(1):103–11

Monitoring responses to antiretroviral treatment in human immunodeficiency virus type 1 (HIV–1)–infected patients by serial lymph node aspiration. Bürgisser P, et al. **J Infect Dis** 1997 May;175(5):1202–5

Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. Chou S, et al. **J Infect Dis** 1997 Sep;176(3):786–9

Pentoxifylline improves cell–mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV–seropositive persons. Clerici M, et al. **J Infect Dis** 1997 May;175(5):1210–5

High–dose nevirapine in previously untreated human immunodeficiency virus type 1–infected persons does not result in sustained suppression of viral replication. de Jong MD, et al. **J Infect Dis** 1997 Apr;175(4):966–70

Evaluation of retinal toxicity and efficacy of anti–cytomegalovirus and anti–herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. Flores–Aguilar M, et al. **J Infect Dis** 1997 Jun; 175(6):1308–16

Antivirals for pandemic influenza. Hayden FG. **J Infect Dis** 1997 Aug;176 Suppl 1:S56–61 (59 ref.)

Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. Lafeuillade A, et al. **J Infect Dis** 1997 May; 175(5):1051–5

Effect of interferon–alpha and ribavirin therapy on serum GB virus C/hepatitis G virus (GBV–C/HGV) RNA levels in patients chronically infected with hepatitis C virus and GBV–C/HGV. Lau JY, et al. **J Infect Dis** 1997 Aug; 176(2):421–6

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1–infected children. Luzuriaga K, et al. **J Infect Dis** 1996 Oct;174(4):713–21

A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. Montaner JS, et al. **J Infect Dis** 1997 Apr; 175(4):801–6

Prospects for pandemic influenza control with currently available vaccines and antivirals. Monto AS. **J Infect Dis** 1997 Aug;176 Suppl 1:S32–7 (25 ref.)

Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Whitley RJ, et al. **J Infect Dis** 1997 May;175(5):1080–6

Activation of local cell–mediated immunity in interferon–responsive patients with human papillomavirus–associated lesions. Arany I, et al. **J Interferon Cytokine Res** 1996 Jun;16(6):453–60

Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide. Bahr GM, et al. **J Interferon Cytokine Res** 1996 Apr;16(4):297–306

Tolerance and efficacy of subcutaneous interferon–beta administered for treatment of chronic hepatitis C. Castro A, et al. **J Interferon Cytokine Res** 1997 Feb;17(2):65–7

Multicenter randomized, controlled study of intramuscular administration of interferon–beta for the treatment of chronic hepatitis C. Castro A, et al. **J Interferon Cytokine Res** 1997 Jan;17(1):27–30

Modulation of human papillomavirus type 16 mRNA in cervical invasive carcinoma patients by interferon–alpha therapy. García–Milián R, et al. **J Interferon Cytokine Res** 1996 Sep;16(9):739–43

Recombinant Interferons beta and gamma have a higher antiviral activity than interferon–alpha in coxsackievirus B3–infected carrier state cultures of human myocardial fibroblasts. Heim A, et al. **J Interferon Cytokine Res** 1996 Apr;16(4):283–7

Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. Liaw YF, et al. **J Interferon Cytokine Res** 1997 Aug;17(8):449–52

Effect of acyclovir and prednisolone on the serological response in herpes zoster. Bates CJ, et al. **J Med Virol** 1996 Nov;50(3):244–8

A randomized controlled trial of high–dose maintenance interferon therapy in chronic hepatitis C. Di Marco V, et al. **J Med Virol** 1997 Jan;51(1):17–24

Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation. Lao WC, et al. **J Med Virol** 1997 Mar; 51(3):152–8

Changes in hepatitis C virus quasispecies and density populations in patients before and after interferon therapy. Nagasaka A, et al. **J Med Virol** 1996 Nov;50(3):214–20

Differential flotation centrifugation study of hepatitis C virus and response to interferon therapy. Nagasaka A, et al. **J Med Virol** 1997 Jun;52(2):190–4

Effect of interferon on GB virus C and hepatitis C virus in hepatitis patients with the co–infection. Nagayama R, et al. **J Med Virol** 1997 Jun;52(2):156–60

Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug–arrested intermediates of minus–strand viral DNA synthesis are enveloped and secreted from infected cells as virion–like particles. Tencza MG, et al. **J Med Virol** 1997 Jan;51(1):6–16

Relevance of inapparent coinfection by hepatitis B virus in alpha interferon–treated patients with hepatitis C virus chronic hepatitis. Zignego AL, et al. **J Med Virol** 1997 Apr;51(4):313–8

Treatment of ganciclovir–resistant human cytomegalovirus infection. Grossi P, et al. **J Nephrol** 1997 May–Jun; 10(3):146–51 (90 ref.)

Acyclovir treatment of relapsing–remitting multiple sclerosis. A randomized, placebo–controlled, double–blind study. Lycke J, et al. **J Neurol** 1996 Mar;243(3):214–24

Progressive multifocal leucoencephalopathy treated with cytosine arabinoside: 12 year follow up and postmortem findings [letter] O'Brien MD, et al. **J Neurol Neurosurg Psychiatry** 1997 Apr;62(4):427–8

Preferential radiosensitization of 9L glioma cells transduced with HSV–tk gene by acyclovir. Kim SH, et al. **J Neurooncol** 1997 Jul;33(3):189–94

Recurrence of chickenpox in an acyclovir–treated patient [letter] Ijichi N, et al. **J Paediatr Child Health** 1997 Jun; 33(3):272

Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy. Kesson AM, et al. **J Paediatr Child Health** 1996 Jun;32(3):211–7 (73 ref.)

Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. Aleixo LF, et al. **J Pediatr** 1997 Jun;130(6):906–14

Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus–associated respiratory failure. Pediatric Critical Study Group. Moler FW, et al. **J Pediatr** 1996 Mar;128(3):422–8

Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia–guided preemptive ganciclovir therapy. Koehler M, et al. **J Pediatr Hematol Oncol** 1997 Jan–Feb;19(1):43–7

Anti–viral drug treatment: dynamics of resistance in free virus and infected cell populations. Nowak MA, et al. **J Theor Biol** 1997 Jan 21;184(2):203–17

Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene–inducing and antiviral actions. Pfeffer LM, et al. **J Urol** 1996 Nov; 156(5):1867–71

The use of deferoxamine infusions to enhance the response rate to interferon–alpha treatment of chronic viral hepatitis B. Bayraktar Y, et al. **J Viral Hepat** 1996 May;3(3):129–35

Relationship between the serum alanine aminotransferase level at the end of interferon treatment and histologic changes in wild–type and precore mutant hepatitis B virus infections. Bayraktar Y, et al. **J Viral Hepat** 1996 May; 3(3):137–42

Ribavirin and interferon–alpha combination therapy vs interferon–alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. Bellobuono A, et al. **J Viral Hepat** 1997 May;4(3):185–91

Treatment of chronic hepatitis C with interferon–alpha by monitoring the response according to viraemia. Bonetti P, et al. **J Viral Hepat** 1997 Mar;4(2):107–12

Interferon treatment of chronic hepatitis C with cirrhosis. Cooksley WG. **J Viral Hepat** 1997;4 Suppl 1:85–8 (15 ref.)

Variables that influence response to different interferon schedules in chronic hepatitis C and predictive models. De Salvo GL, et al. **J Viral Hepat** 1997;4 Suppl 1:79–83

Long–term interferon–alpha treatment of children with chronic hepatitis delta: a multicentre study. Di Marco V, et al. **J Viral Hepat** 1996 May;3(3):123–8

Long–term effects of interferon–alpha in five HIV–positive patients with chronic hepatitis B. di Martino V, et al. **J Viral Hepat** 1996 Sep;3(5):253–60

Clinical relevance of hepatitis C virus quasispecies. Enomoto N, et al. **J Viral Hepat** 1995;2(6):267–72 (27 ref.)

A double–blind controlled trial of recombinant interferon–alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Fernández JL, et al. **J Viral Hepat** 1997 Mar; 4(2):113–9

Detectable levels of IgM antibodies to hepatitis C virus core protein predict breakthrough in patients with chronic hepatitis C treated with interferon–alpha. Fracassetti O, et al. **J Viral Hepat** 1996 Sep;3(5):265–6

Human leucocyte interferon–alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon–alpha: a randomized controlled trial. Gaeta GB, et al. **J Viral Hepat** 1997 May;4(3):209–14

Interleukin–12: potential clinical applications in the treatment

of chronic viral hepatitis. Gately MK. **J Viral Hepat** 1997; 4 Suppl 1:33–9 (48 ref.)

Modulation of hepatitis C virus quasispecies heterogeneity by interferon–alpha and ribavirin therapy. González–Peralta RP, et al. **J Viral Hepat** 1997 Mar; 4(2):99–106

Prolonged therapy of chronic hepatitis C with ribavirin. Hoofnagle JH, et al. **J Viral Hepat** 1996 Sep;3(5):247–52

Hepatitis G virus infection: clinical characteristics and response to interferon. Karayiannis P, et al. **J Viral Hepat** 1997 Jan;4(1):37–44

2',3'–dideoxy–3'–fluoroguanosine inhibits duck hepatitis B virus in vivo. Löfgren B, et al. **J Viral Hepat** 1996 Mar; 3(2):61–5

Efficacy of prolonged interferon–alpha treatment in chronic hepatitis B patients with HBeAb: comparison between 6 and 12 months of therapy. Lopez–Alcorocho JM, et al. **J Viral Hepat** 1997;4 Suppl 1:27–32

Analysis of hepatitis B virus precore variants in hepatitis B e antibody–positive patients treated with prednisone plus interferon. Lopez–Alcorocho JM, et al. **J Viral Hepat** 1995; 2(6):279–84

A double blind, placebo–controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. Main J, et al. **J Viral Hepat** 1996 Jul;3(4):211–5

Prolonged interferon–alpha therapy of hepatitis B virus–related decompensated cirrhosis. Marcellin P, et al. **J Viral Hepat** 1997;4 Suppl 1:21–6

Variations of hepatitis C virus NS5B sequence (nucleotides 8261–8566) do not correlate with response to interferon–alpha therapy. Nelson DR, et al. **J Viral Hepat** 1995;2(6):285–92

A model to predict long–term sustained response to interferon therapy in chronic hepatitis C. Noventa F, et al. **J Viral Hepat** 1997 May;4(3):193–7

Combination low–dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B. Rasi G, et al. **J Viral Hepat** 1996 Jul;3(4):191–6

Treatment of chronic hepatitis C with interferon: how long should a lasting response last if a lasting response could last? Ryff JC. **J Viral Hepat** 1997;4 Suppl 1:95–9

A preliminary experience with GM–CSF plus interferon in patients with HBV and HCV resistant to interferon therapy. Van Thiel DH, et al. **J Viral Hepat** 1997;4 Suppl 1:101–6

Response to interferon–alpha of Egyptian patients infected with hepatitis C virus genotype 4. el–Zayadi A, et al. **J Viral Hepat** 1996 Sep;3(5):261–4

Interleukin–12 exhibits potent antiviral activity in experimental herpesvirus infections. Carr JA, et al. **J Virol** 1997 Oct;71(10):7799–803

Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. Nowak MA, et al. **J Virol** 1997 Oct;71(10):7518–25

Human cytomegalovirus DNA kinetics using a novel HCMV DNA quantitative assay in white blood cells of immunocompromised patients under Ganciclovir therapy. Payan C, et al. **J Virol Methods** 1997 Apr;65(1):131–8

Famciclovir for genital herpes [letter; comment] Goldman BD. **JAMA** 1997 Jan 15;277(3):210–1. Comment on: JAMA 1996 Jul 3;276(1):44–9.

Contempo 1997: dermatology [letter] Marks L, et al. **JAMA** 1997 Oct 8;278(14):1148; discussion 1149

Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double–blind, placebo–controlled trial. Topical Penciclovir Collaborative Study Group. Spruance SL, et al. **JAMA** 1997 May 7; 277(17):1374–9

Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis [letter] Whitcup SM, et al. **JAMA** 1997 May 21;277(19):1519–20

Treatment of verruca vulgaris with topical cidofovir [letter] Zabawski EJ Jr, et al. **JAMA** 1997 Oct 15;278(15):1236

Acyclovir prophylaxis for cytomegalovirus disease in high–risk renal transplant recipients: is it effective? Goral S, et al. **Kidney Int Suppl** 1996 Dec;57:S62–5 (22 ref.)

Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression [letter] [see comments] Bode L, et al. **Lancet** 1997 Jan 18; 349(9046):178–9. Comment in: Lancet 1997 Mar 29;349(9056):958.

Azothymidine and interferon–alpha are active in AIDS–associated small non–cleaved cell lymphoma but not large–cell lymphoma [letter] Harrington WJ Jr, et al. **Lancet** 1996 Sep 21;348(9030):833

Some antivirals may lower Kaposi's sarcoma risk [news] Larkin M. **Lancet** 1996 Sep 21;348(9030):812

Depression, Borna disease, and amantadine [letter; comment] Lieb K, et al. **Lancet** 1997 Mar 29;349(9056):958. Comment on: Lancet 1997 Jan 18;349(9046):178–9.

Inclusion of women in clinical trials of antiretroviral agents for HIV/AIDS during pregnancy [letter] Mangino JE, et al. **Lancet** 1997 Jul 12;350(9071):150

Interferon therapy for hepatitis C. Preston H, et al. **Lancet** 1996 Oct 12;348(9033):973–4

Interferon for hepatitis C [letter] Puoti C, et al. **Lancet** 1997 Feb 8;349(9049):398–9

Second–generation non–nucleosidic reverse transcriptase inhibitor HBY097 and HIV–1 viral load [letter] Rübsamen–Waigmann H, et al. **Lancet** 1997 May 24; 349(9064):1517

Clinical implications of lamivudine resistance by HBV [comment] Schalm SW. **Lancet** 1997 Jan 4;349(9044):3–4. Comment on: Lancet 1997 Jan 4;349(9044):20–2.

The Delta trial [letter; comment] [see comments] Zaretsky MD. **Lancet** 1996 Nov 2;348(9036):1237; discussion 1237–8 . Comment on: Lancet 1996 Aug 3;348(9023):278–9. Comment in: Lancet 1997 Feb 1;349(9048):358–9.

Interferon–alpha and its effects on the cytokine cascade: a pro– and anti–inflammatory cytokine. Tilg H, et al. **Leuk Lymphoma** 1996 Sep;23(1–2):55–60 (73 ref.)

Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon–alpha 2a therapy in Japanese patients with chronic hepatitis C. Mizokami M, et al. **Liver** 1996 Feb;16(1):23–7

The diagnosis and management of HIV infection. Gold JW. **Med Clin North Am** 1996 Nov;80(6):1283–307 (118 ref.)

Neurologic manifestations of HIV infection. Simpson DM, et al. **Med Clin North Am** 1996 Nov;80(6):1363–94 (253 ref.)

Antiretroviral therapy. Threlkeld SC, et al. **Med Clin North Am** 1996 Nov;80(6):1263–82 (107 ref.)

Pediatric HIV infection. Wiznia AA, et al. **Med Clin North Am** 1996 Nov;80(6):1309–36 (206 ref.)

natural antimutagenic agents may prolong efficacy of human immunodeficiency virus drug therapy. McCarty MF. **Med Hypotheses** 1997 Mar;48(3):215–20 (77 ref.)

Topical penciclovir for herpes labialis. **Med Lett Drugs Ther** 1997 Jun 20;39(1003):57–8

More new drugs for HIV and associated infections. **Med Lett Drugs Ther** 1997 Feb 14;39(994):14–6

Drugs for non–HIV viral infections. **Med Lett Drugs Ther** 1997 Aug 1;39(1006):69–76

Long–term results regarding the use of recombinant interferon alpha–2b in the treatment of II type mixed essential cryoglobulinemia. Lauta VM, et al. **Med Oncol** 1995 Dec;12(4):223–30

Clinical use of interferons in hepatology. Civeira MP. **Methods Find Exp Clin Pharmacol** 1996;18 Suppl B:33–4

Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis. Clerici C, et al. **Minerva Med** 1997 May;88(5):219–25

Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). **MMWR Morb Mortal Wkly Rep** 1997 Apr 25; 46(RR–9):1–25

A new antiviral agent for influenza—is there a clinical niche? [editorial; comment] Couch RB. **N Engl J Med** 1997 Sep 25;337(13):927–8. Comment on: N Engl J Med 1997 Sep 25;337(13):874–80.

The treatment of chronic viral hepatitis. Hoofnagle JH, et al. **N Engl J Med** 1997 Jan 30;336(5):347–56 (106 ref.)

Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Jacobson MA. **N Engl J Med** 1997 Jul 10;337(2):105–14 (94 ref.)

A continuous infusion of acyclovir for severe hemorrhagic varicella [letter] [see comments] Kakinuma H, et al. **N Engl J Med** 1997 Mar 6;336(10):732–3. Comment in: N Engl J Med 1997 Jul 17;337(3):203–4.

Treatment of HCV liver disease by recombinant interferon alpha. Bailly F, et al. **Nephrol Dial Transplant** 1996;11 Suppl 4:56–7 (11 ref.)

Antiviral treatment for HCV patients pre–renal transplantation? [letter] McLaughlin K, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1770–1

Treatment of chronic hepatitis C: another therapeutic option. Trepo C, et al. **Nephrol Dial Transplant** 1996;11 Suppl 4:62–4 (9 ref.)

Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3. Gómez E, et al. **Nephron** 1996;74(2):367–72

Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Rostaing L, et al. **Nephron** 1996;74(3):512–6

In vivo 31P MRS evaluation of ganciclovir toxicity in C6 gliomas stably expressing the herpes simplex thymidine kinase gene. Stegman LD, et al. **NMR Biomed** 1996 Dec; 9(8):364–8

Viral resistance and CMV retinitis: design and methods of a prospective study. CRVR Research Groups. Cytomegalovirus Retinitis Viral Resistance Research Group. Enger C, et al. **Ophthalmic Epidemiol** 1997 Mar; 4(1):41–8

Treatment of herpetic keratitis with acyclovir: benefits and problems. Ohashi Y. **Ophthalmologica** 1997;211 Suppl 1:29–32 (26 ref.)

Cytomegalovirus papillitis in patients with acquired immune deficiency syndrome. Visual prognosis of patients treated with ganciclovir and/or foscarnet. Patel SS, et al. **Ophthalmology** 1996 Sep;103(9):1476–82

Long–term oral acyclovir therapy. Effect on recurrent infectious herpes simplex keratitis in patients with and without grafts [see comments] Simon AL, et al. **Ophthalmology** 1996 Sep;103(9):1399–404; discussion 1404–5. Comment in: Ophthalmology 1997 Mar;104(3):343.

Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis. Walton RC, et al. **Ophthalmology** 1995 Dec;102(12):1865–70

Long–term oral acyclovir therapy [letter; comment] Wessels HA. **Ophthalmology** 1997 Mar;104(3):343. Comment on: Ophthalmology 1996 Sep;103(9):1399–404; discussion 1404–5.

Case report of a monoclonal gammopathy in a patient with chronic hepatitis: effects of beta–IFN treatment. Gattoni A, et al. **Panminerva Med** 1996 Sep;38(3):175–8

Therapeutic approaches for severe Epstein–Barr virus infection. Okano M. **Pediatr Hematol Oncol** 1997 Mar–Apr; 14(2):109–19 (44 ref.)

Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Kimberlin D, et al. **Pediatr Infect Dis J** 1996 Mar;15(3):247–54

Follow–up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: potential effect of ribavirin on long term pulmonary function. The Bronchiolitis Study Group. Krilov LR, et al. **Pediatr Infect Dis J** 1997 Mar; 16(3):273–6

Interferon–alpha–2b treatment of chronic hepatitis C in children with hemophilia. Zwiener RJ, et al. **Pediatr Infect Dis J** 1996 Oct;15(10):906–8

Chickenpox complications among immunocompetent hospitalized children in Italy. Acyclovir–Chickenpox Italian Study Group. Manfredi R, et al. **Pediatr Med Chir** 1997 Mar–Apr;19(2):99–104

Study of interobserver reliability in clinical assessment of RSV lower respiratory illness: a Pediatric Investigators Collaborative Network for Infections in Canada (PICNIC) study. Wang EE, et al. **Pediatr Pulmonol** 1996 Jul; 22(1):23–7

Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. McJunkin JE, et al. **Pediatrics** 1997 Feb;99(2):261–7

Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answer [see comments] Prober CG, et al. **Pediatrics** 1997 Mar; 99(3):472–5. Comment in: Pediatrics 1997 Mar;99(3):454–61.

Evaluation of drug use and cost of hospital care for AIDS patients between 1990 and 1994. Peyron F, et al. **Pharm World Sci** 1997 Aug;19(4):202–7

Suppression of herpes simplex virus infections with oral lithium carbonate—a possible antiviral activity. Amsterdam JD, et al. **Pharmacotherapy** 1996 Nov–Dec;16(6):1070–5

A meta–analysis of interferon–alpha treatment of hepatitis D virus infection. Malaguarnera M, et al. **Pharmacotherapy** 1996 Jul–Aug;16(4):609–14

When to use the new antivirals. Dedicoat M, et al. **Practitioner** 1996 Nov;240(1568):634–7, 639–40

Pre–existence and emergence of drug resistance in HIV–1 infection. Bonhoeffer S, et al. **Proc R Soc Lond B Biol Sci** 1997 May 22;264(1382):631–7

Use of novel beta–L(–)–nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. Bridges EG, et al. **Prog Liver Dis** 1995;13:231–45 (70 ref.)

Update on antiretroviral therapy. Hicks CB. **Radiol Clin North Am** 1997 Sep;35(5):995–1005 (59 ref.)

The treatment of AIDS–related cytomegalovirus disease with ganciclovir and foscarnet association. Three case reports. Manfredi R, et al. **Recenti Prog Med** 1996 Nov;87(11):545–8

Differential effects of a new amphotericin B derivative, MS–8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Adjou KT, et al. **Res Virol** 1996 Jul–Aug;147(4):213–8

Successful treatment of progressive outer retinal necrosis syndrome. Spaide RF, et al. **Retina** 1996;16(6):479–87

Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus–1 retinitis. Taskintuna I, et al. **Retina** 1997;17(1):57–64

Hepatitis C: ribavirin and/or interferon? Heathcote J. **Rev Gastroenterol Mex** 1996 Oct–Dec;61(4 Suppl 2):S71–5

Clearance of hepatitis C viral RNA in cirrhotic patients with antiviral therapy. Ono SK, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Sep–Oct; 51(5):180–3

The influence of CD4+ T cells, HIV disease stage and zidovudine on HIV isolation in Bahia, Brazil. Brites C, et al. **Rev Soc Bras Med Trop** 1996 Jan–Feb;29(1):5–9

Interferon found helpful in herpes genitalis case [letter] Dungwa N. **S Afr Med J** 1997 Apr;87(4):475

Treatment options for human immunodeficiency virus. Heins JR. **S D J Med** 1996 Feb;49(2):51–2

Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection. Fernández I, et al. **Scand J Gastroenterol** 1997 Jan; 32(1):70–6

Factors influencing the response to interferon therapy in chronic hepatitis C. Studies on viral genotype and induction of 2',5'–oligoadenylate synthetase in the liver and peripheral blood cells. Grandér D, et al. **Scand J Gastroenterol** 1996 Jun;31(6):604–11

High levels of serum interleukin–10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Kuzushita N, et al. **Scand J Gastroenterol** 1997 Feb;32(2):169–74

Antiviral therapy of hepatitis C. Schalm SW, et al. **Scand J Gastroenterol Suppl** 1997;223:46–9

Genotype, viral load and age as independent predictors of treatment outcome of interferon–alpha 2a treatment in patients with chronic hepatitis C. Construct group. Bell H, et al. **Scand J Infect Dis** 1997;29(1):17–22

Serum polymerase chain reaction for cytomegalovirus DNA for monitoring ganciclovir treatment in AIDS patients.

Marenzi R, et al. **Scand J Infect Dis** 1996;28(4):347–51
Antiviral drugs in development for herpes zoster. Fiddian AP. **Scand J Infect Dis Suppl** 1996;100:51–4 (17 ref.)
How to measure and reduce the burden of zoster-associated pain. Wood MJ. **Scand J Infect Dis Suppl** 1996;100:55–8 (18 ref.)
Researchers seek new weapon against the flu [news] Service RF. **Science** 1997 Feb 7;275(5301):756–7
Genital herpes simplex virus and its treatment: focus on famciclovir. Sacks SL. **Semin Dermatol** 1996 Jun;15(2 Suppl 1):32–6 (43 ref.)
Efficacy of famciclovir in the treatment of herpes zoster. Tyring SK. **Semin Dermatol** 1996 Jun;15(2 Suppl 1):27–31 (23 ref.)
Reversal of feline leukemia virus infection by adoptive transfer of activated T lymphocytes, interferon alpha, and zidovudine. Zeidner NS, et al.
Semin Vet Med Surg (Small Anim) 1995 Nov;10(4):256–66
Over-the-counter acyclovir. An idea whose time has come [editorial] Fife KH. **Sex Transm Dis** 1996 May-Jun; 23(3):174–6
Acyclovir should not be approved for marketing without prescription [editorial] Handsfield HH. **Sex Transm Dis** 1996 May-Jun;23(3):171–3
Treatment of genital HPV infection with carbon dioxide laser and systemic interferon alpha-2b. Nieminen P, et al.
Sex Transm Dis 1994 Mar-Apr;21(2):65–9
Understanding HIV disease. Leo YS. **Singapore Med J** 1995 Oct;36(5):545–8 (11 ref.)
Outcomes among pediatric heart transplant recipients. Gajarski RJ, et al. **Tex Heart Inst J** 1997;24(2):97–104
Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation. Haller GW, et al. **Transpl Int** 1996;9 Suppl 1:S210–2
Role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for development of disease and should PCR be used to guide antiviral therapy? Abecassis MM, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):800–1
Long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Aljumah AA, et al.
Transplant Proc 1997 Feb-Mar;29(1-2):514
New approaches to treatment of recurrent hepatitis C virus following liver transplantation using ribavirin. Bizollon T, et al. **Transplant Proc** 1996 Oct;28(5):2842–3 (13 ref.)
Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients. Brennan DC, et al.
Transplant Proc 1997 Feb-Mar;29(1-2):809–11
Cytomegalovirus infection in kidney transplantation: prophylaxis and management. Bulinski P, et al.
Transplant Proc 1996 Dec;28(6):3310–1
Ganciclovir prophylaxis of cytomegalovirus disease. Conti DJ, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):804–6
Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Garnier JL, et al.
Transplant Proc 1997 Feb-Mar;29(1-2):783
Treatment of hepatitis B virus replication by ganciclovir in kidney transplant patients. Garnier JL, et al.
Transplant Proc 1997 Feb-Mar;29(1-2):817
Use of quantitative PCR to predict onset of Epstein-Barr viral infection and post-transplant lymphoproliferative disease after intestinal transplantation in children. Green M, et al. **Transplant Proc** 1996 Oct;28(5):2759–60
Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. Mazzaferro V, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):519–21
Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Pouteil-Noble C, et al. **Transplant Proc** 1996 Oct;28(5):2811
The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Abecassis MM, et al.
Transplantation 1997 Jan 27;63(2):275–9
Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection. Akposso K, et al. **Transplantation** 1997 Apr 15;63(7):974–6
Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Badley AD, et al. **Transplantation** 1997 Jul 15;64(1):66–73
Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Darenkov IA, et al.
Transplantation 1997 Sep 27;64(6):848–52
Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Al Faraidy K, et al.
Transplantation 1997 Sep 27;64(6):926–8
Conversion of recurrent delta-positive hepatitis B infection to seronegativity with famciclovir after liver transplantation. Klein M, et al. **Transplantation** 1997 Jul 15;64(1):162–3
Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation. Shen GK, et al. **Transplantation** 1997 Sep 27;64(6):931–3
Destroying retroviruses from within. Boeke JD, et al.
Trends Microbiol 1996 Nov;4(11):421–6 (27 ref.)
Wheel keeps turning for antiviral combination chemotherapy. Coen DM. **Trends Microbiol** 1996 Feb;4(2):51–2 (14 ref.)
Interferon alfa-2b for treatment of subclinical intraurethral human papilloma virus infection [letter; comment] Harrison RH 3rd. **Urology** 1997 Aug;50(2):317. Comment on: Urology 1996 Apr;47(4):553–7.
Zidovudine and interferon therapy for adult T-cell leukaemia/lymphoma. Results of a preliminary study at UHWI-Mona. Wharfe G, et al. **West Indian Med J** 1996 Dec;45(4):107–9
New therapies for cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Cunningham ET Jr. **West J Med** 1997 Feb;166(2):138–9
Protection and therapy of experimental herpesvirus infections in mice with immunomodulating Propionibacterium avidum KP-40 and/or acyclovir. Kobus M, et al.
Zentralbl Bakteriol 1997 Feb;285(3):445–9
[The effect of interferon in combination with ribavirin on the plus and minus strands of hepatitis C virus RNA in patients with hepatitis] He Y, et al.
Chung Hua Nei Ko Tsa Chih 1996 Jan;35(1):32–5 (Eng. Abstr.) **(Chi)**
[Curative effect of Interfon-Alpha in children with infectious mononucleosis] Wu Y, et al.
Hua Hsi I Ko Ta Hsueh Hsueh Pao 1996 Mar;27(1):82–4 (Eng. Abstr.) **(Chi)**
[Bell's palsy treated with acyclovir (see comments)] Jørgensen KE. **Ugeskr Laeger** 1996 Dec 9;158(50):7249–50 . Comment in: Ugeskr Laeger 1997 Mar 31;159(14):2105. **(Dan)**
[Bell's palsy treated with acyclovir (letter; comment)] Jørgensen KE. **Ugeskr Laeger** 1997 Jun 9;159(24):3799. Comment on: Ugeskr Laeger 1997 Mar 31;159(14):2105. **(Dan)**
[Bell's palsy treated with acyclovir (comment) (see comments)] Peitersen E. **Ugeskr Laeger** 1997 Mar 31; 159(14):2105. Comment on: Ugeskr Laeger 1996 Dec 9;158(50):7249–50. Comment in: Ugeskr Laeger 1997 Jun 9;159(24):3799. **(Dan)**
[Should recurrent Cytomegalovirus infections in patients with liver transplantation be treated?] Tarp BD, et al.
Ugeskr Laeger 1997 May 26;159(22):3413–6 (Eng. Abstr.) **(Dan)**
[Acyclovir freely obtainable (letter; comment)] Schippers HM. **Ned Tijdschr Geneeskd** 1996 Sep 7;140(36):1831–2. Comment on: Ned Tijdschr Geneeskd 1996 Jul 6;140(27):1412–3. **(Dut)**
[Strategy for preventing upper respiratory tract infections. Consensus of the Consulting Committee]
Allerg Immunol (Paris) 1997 Mar;29(3):80–2 (Eng. Abstr.) **(Fre)**
[Natural history of dysthyroidism during interferon treatment of chronic hepatitis C] Mekkakia-Benhabib C, et al.
Ann Endocrinol (Paris) 1996;57(5):419–27 (Eng. Abstr.) **(Fre)**
[Treatment with ganciclovir of congenital cytomegalovirus infections (letter)] Guimarães H, et al. **Arch Pediatr** 1996 Jun;3(6):609–10 **(Fre)**
[Viral load and antiretroviral treatments in children infected by human immunodeficiency virus (letter)] Monpoux F, et al. **Arch Pediatr** 1996 Oct;3(10):1046–7 **(Fre)**
[Prevention and treatment of hepatitis C] Poupon R, et al.
Bull Acad Natl Med 1996 Jun-Jul;180(6):1279–89; discussion 1289–92 (45 ref.) (Eng. Abstr.) **(Fre)**
[Chronic hepatitis C: therapeutic uncertainties (editorial)] Blondon H, et al. **Gastroenterol Clin Biol** 1996; 20(12):1043–6 **(Fre)**
[Should Hepatitis C be treated? Objectives of antiviral treatments in hepatitis C virus infection] Degos F.
Gastroenterol Clin Biol 1997;21(1 Pt 2):S57–65 (99 ref.) **(Fre)**
[Should hepatitis C be treated? Which biological tests are useful before deciding or refuting a treatment with interferon-alpha in patients with chronic hepatitis C?] Pawlotsky JM. **Gastroenterol Clin Biol** 1997;21(1 Pt 2):S41–50 (85 ref.) **(Fre)**
[Monitoring of treated or non-treated chronic viral hepatitis C. 2: Criteria of efficacy and monitoring of treatment with interferon-alpha] Payen JL. **Gastroenterol Clin Biol** 1997; 21(1 Pt 2):S175–89 (276 ref.) **(Fre)**
[Results of treatment of hepatitis C with interferon alone or combined with other drugs] Serfaty L.
Gastroenterol Clin Biol 1997;21(1 Pt 2):S154–66 (136 ref.) **(Fre)**
[New therapeutic strategies in HIV infection] Delfraissy JF.
Presse Med 1997 Apr 19;26(13):612–4 **(Fre)**
[Acquired cytomegalovirus infection in infants. A case successfully treated with ganciclovir] Dündaröz R, et al.
Presse Med 1997 Jun 21;26(21):1000–1 (Eng. Abstr.) **(Fre)**
[Future prospects of valacyclovir in treating and preventing herpesviridae infections in immunosuppressed patients] Raffi F. **Presse Med** 1997 Jan;26 Suppl 1:19–21 (13 ref.) **(Fre)**
[Anti-retrovirus agents in AIDS: therapeutic strategy and prospectives for the future] **Rev Med Interne** 1997; 18(2):100–5 (37 ref.) **(Fre)**
[Pathogenesis and alpha-2 interferon treatment of chronic hepatitis B] Pirotte J. **Rev Med Liege** 1996 Aug; 51(8):514–21 (38 ref.) **(Fre)**
[Early antiretroviral combination therapy--standard today and tomorrow] **Dtsch Med Wochenschr** 1997 Mar 14;122(11 Suppl):1–4 **(Ger)**
[The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation] Fricke L, et al. **Dtsch Med Wochenschr** 1997 May 2;122(18):565–71 (Eng. Abstr.) **(Ger)**
[AIDS: David Ho's concept of virus elimination (news)] Schattenfroh S. **Dtsch Med Wochenschr** 1997 Jun 13; 122(24):A7 **(Ger)**
[Therapy using virus-resistant immunoglobulins. First on the prevention front: immunoglobulins] **Internist (Berl)** 1995 Oct;36(10 Suppl):1–4 **(Ger)**
[Individualization of HIV-therapy] **Internist (Berl)** 1995 Jul; 36(7 Suppl [individu]):1–4 **(Ger)**
[Ganciclovir-resistant cytomegalovirus infection: 2 cases with different clinical impact] Reusser P, et al.
Schweiz Med Wochenschr 1996 Oct 19;126(42):1779–84 (Eng. Abstr.) **(Ger)**
[Antiretroviral drugs in the primary and secondary prevention of HIV infection (news)]
Schweiz Rundsch Med Prax 1997 Jan 21;86(4):101 **(Ger)**
[Therapy noncompliance in chronic viral hepatitis--standard therapy, prognostic parameters, treatment strategy] Hopf U. **Schweiz Rundsch Med Prax** 1997 Jan 21;86(4):83–5 **(Ger)**
[Disappointing response of chronic C hepatitis to interferon] Theodor E, et al. **Harefuah** 1997 Mar 16;132(6):402–3, 447 (Eng. Abstr.) **(Heb)**
[Optimal antiviral therapy of chronic hepatitis caused by hepatitis C virus] Cooreman MP, et al. **Orv Hetil** 1997 Jun 1;138(22 Suppl 1):1476–82 (51 ref.) (Eng. Abstr.) **(Hun)**
[Effect of interferon-alpha2b therapy in chronic hepatitis C] Fehér J, et al. **Orv Hetil** 1996 Jun 2;137(22):1179–85 (Eng. Abstr.) **(Hun)**
[Management of chronic hepatitis B] Telegdy L.
Orv Hetil 1997 Jun 1;138(22 Suppl 1):1462–5 (Eng. Abstr.) **(Hun)**
[Role of clinical pharmacology in the monitoring of therapy of HIV-infected subjects] Villani P, et al. **Clin Ter** 1996 Jun;147(6):279–93 (57 ref.) (Eng. Abstr.) **(Ita)**
[Combination of beta-interferon and laser-CO2 therapy in female HPV genitalis] Facchini C, et al.
Minerva Ginecol 1996 Sep;48(9):345–9 (Eng. Abstr.) **(Ita)**
[Interstitial pulmonitis due to the cytomegalovirus in an immunocompetent adolescent: treatment with ganciclovir] Pellegrini G, et al. **Pediatr Med Chir** 1996 May-Jun; 18(3):315–7 (19 ref.) (Eng. Abstr.) **(Ita)**
[Interferon treatment for hepatitis G virus infection in patients with chronic hepatitis C] Baba T, et al.
Nippon Rinsho 1997 Mar;55(3):625–30 (Eng. Abstr.) **(Jpn)**
[Successful diagnosis and treatment of a case of cytomegalovirus infection in a previously healthy adult by antigenemia assay] Nagata S, et al.
Nippon Shokakibyo Gakkai Zasshi 1997 Mar;94(3):225–8 (15 ref.) **(Jpn)**
[Intercalation monitoring PCR(IM-PCR), its principle and application: quantitative monitoring of HCV RNA in the course of IFN therapy] Ishiguro T, et al. **Rinsho Byori** 1997 Mar;45(3):213–7 (Eng. Abstr.) **(Jpn)**
[Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor] Fujisaki T, et al. **Rinsho Ketsueki** 1997 Feb;38(2):142–5 (Eng. Abstr.) **(Jpn)**
[Ribavirin for chronic hepatitis C: many doubts and some hope (editorial; comment)] Andrade Júnior DR, et al.
Arq Gastroenterol 1995 Jul-Sep;32(3):102–4. Comment on: Arq Gastroenterol 1996 Jul-Sep;32(3):105–9. **(Por)**
[Ribavirin in the treatment of hepatic cirrhosis due to hepatitis C virus. A non-controlled study (see comments)] Parise ER, et al. **Arq Gastroenterol** 1995 Jul-Sep; 32(3):105–9 (Eng. Abstr.). Comment in: Arq Gastroenterol 1996 Jul-Sep;32(3):102–4. **(Por)**
[Treatment of HIV infection (orientation--February 1996)] Amato Neto V, et al. **Rev Assoc Med Bras** 1996 Apr-Jun; 42(2):98–100 **(Por)**
[Orientations and present day possibilities for use of anti-HIV drugs] Amato Neto V, et al. **Rev Assoc Med Bras** 1996 Jan-Mar;42(1):16–8 **(Por)**
[Effect of the amide of 1-adamantanecarboxylic acid (AACA) and its combination with ribavirin on the course of experimental infection, caused by the sindbis virus in tissue culture and in mouse brain. Possible isolation of the virus mutant resistant to ribavirin and to a combination of the inhibitors] Andronova VL. **Antibiot Khimioter** 1997; 42(7):3–7 (Eng. Abstr.) **(Rus)**
[Activity of benzamide and it's derivatives against botulinum intoxication] Ugriumova GA, et al.
Biull Eksp Biol Med 1997 Jun;123(6):684–6 **(Rus)**
[Etiological structure of respiratory virus diseases and modern therapeutic opportunities] Kolomiets AG, et al.
Klin Med (Mosk) 1997;75(2):6–12 (41 ref.) **(Rus)**
[Retrovir in the treatment of acute viral hepatitis B] Rakhmanova AG, et al. **Klin Med (Mosk)** 1996;74(5):53–5 **(Rus)**
[The evolution of th theory of chronic hepatitis: classification, nomenclature, diagnosis and treatment] Tsimmerman IS.
Klin Med (Mosk) 1996;74(8):19–24 (33 ref.) **(Rus)**
[Laferon in the treatment of meningoencephalitis] Rudenko AA, et al. **Lik Sprava** 1995 Mar-Apr;(3-4):109–12 (Eng.

Abstr.) **(Rus)**

[The successful use of recombinant alfa-2 interferon in HBV-associated glomerulonephritis in a child] Fedorchenko SV, et al. **Ter Arkh** 1996;68(2):69-70 (9 ref.) **(Rus)**

[Para-aminobenzoic acid in therapy of experimental keratitis caused by herpes simplex virus in rabbits: the therapeutic effect and decrease of infectious titer] Akberova SI, et al. **Vestn Oftalmol** 1996 Sep-Oct;112(4):23-6 (Eng. Abstr.) **(Rus)**

[Arbidole--a new drug for prevention of influenza and acute viral respiratory infections in children] Beliaev AL, et al. **Vestn Ross Akad Med Nauk** 1996;(8):34-7 (Eng. Abstr.) **(Rus)**

[Recombinant probiotics: problems and prospects of their use for medicine and veterinary practice] Sorokulova IB, et al. **Vestn Ross Akad Med Nauk** 1997;(3):46-9 (15 ref.) (Eng. Abstr.) **(Rus)**

[Efficacy of herpetic vaccine, larifan, myelopid and their combinations during herpesvirus infection in irradiated animals] Alimbarova LM, et al. **Vopr Virusol** 1996 Nov-Dec;41(6):270-4 (Eng. Abstr.) **(Rus)**

[Experimental study of possible treatment of Marburg hemorrhagic fever with desferal, ribavirin, and homologous interferon] Ignat'ev GM, et al. **Vopr Virusol** 1996 Sep-Oct; 41(5):206-9 (Eng. Abstr.) **(Rus)**

[Bronchiolitis: revision of 153 cases and comparative study of ribavirin treatment] Colinas Herrero J, et al. **An Esp Pediatr** 1997 Feb;46(2):143-7 (Eng. Abstr.) **(Spa)**

[Long term survival in an HIV-immunosuppressed patient treated with foscarnet] Soriano V, et al. **An Med Interna** 1996 Aug;13(8):387-9 (Eng. Abstr.) **(Spa)**

[Prophylaxis secondary to retinitis by CMV in patients with AIDS: the efficacy of an intermittent schedule of 3 days/week] Mallolas J, et al. **Enferm Infecc Microbiol Clin** 1997 Feb;15(2):61-4 (Eng. Abstr.) **(Spa)**

[Retrospective multicenter study of the efficacy of interferon alpha in chronic hepatitis C] Salmerón J, et al. **Med Clin (Barc)** 1996 Nov 23;107(18):689-92 (Eng. Abstr.) **(Spa)**

[Interferon alpha 2b in pain caused by herpes zoster. Preliminary report] Montero Mora P, et al. **Rev Alerg Mex** 1996 Nov-Dec;43(6):148-51 (Eng. Abstr.) **(Spa)**

[Treatment with interferon alpha of hemophiliacs with chronic hepatitis C (letter)] Aguilar Franco C, et al. **Rev Clin Esp** 1996 Oct;196(10):727-8 **(Spa)**

[Treatment of chronic hepatitis C. Many interrogatives and some answers (editorial)] Ampurdanès S, et al. **Rev Clin Esp** 1996 Oct;196(10):667-9 **(Spa)**

[Treatment with recombinant interferon alfa-2b of a patient with chronic hepatitis C and concomitant ulcerative colitis] De Diego Lorenzo A, et al. **Rev Esp Enferm Dig** 1997 May;89(5):399-401 (Eng. Abstr.) **(Spa)**

[Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment] Pérez Roldán F, et al. **Rev Esp Enferm Dig** 1996 Sep;88(9):609-15 (23 ref.) (Eng. Abstr.) **(Spa)**

[Virology. The art of controlling the geniality which even the smallest contagions show] Norrby E. **Lakartidningen** 1997 Jun 18;94(25):2357-8, 2362-4 (0 ref.) **(Swe)**

[The efficacy of caleflone in treating patients with viral hepatitis] Nelko EM, et al. **Lik Sprava** 1995 Sep-Dec; (9-12):138-9 (Eng. Abstr.) **(Ukr)**

TOXICITY

In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Dornsife RE, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):514-9

The anti-human immunodeficiency virus agent 3'-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Sundseth R, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):331-5

Selective protection of toxicity of 2',3'-dideoxypyrimidine nucleoside analogs by beta-D-uridine in human granulocyte-macrophage progenitor cells. Faraj A, et al. **Antiviral Res** 1996 Mar;29(2-3):261-7

Clinical toxicity of antiretroviral nucleoside analogs. Styrt BA, et al. **Antiviral Res** 1996 Jul;31(3):121-35 (122 ref.)

The human immunodeficiency virus type 1 Tat protein potentiates zidovudine-induced cellular toxicity in transgenic mice. Prakash O, et al. **Arch Biochem Biophys** 1997 Jul 15;343(2):173-80

Toxic effect of concomitant administration of cyclosporin A and acyclovir on renal function and morphology in rats. Hannemann J, et al. **Arch Toxicol** 1997;71(9):556-62

Toxicity and enzyme-inducing effect of the antiviral compound mopyridone in mice. Tantcheva LP, et al. **Arzneimittelforschung** 1996 Sep;46(9):931-3

Preclinical development of antiviral drugs. Szczech GM. **Clin Infect Dis** 1996 Feb;22(2):355-60 (25 ref.)

Nephrotoxicity of antiviral therapies. Becker BN, et al. **Curr Opin Nephrol Hypertens** 1996 Jul;5(4):375-9 (44 ref.)

Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs [corrected and republished in Drug Metab Dispos 1997 May;25(5):270-3] Okuda H, et al. **Drug Metab Dispos** 1997 Feb;25(2):270-3

Gene transfer in hepatocarcinoma cell lines: in vitro optimization of a virus-free system. Ghoumari AM, et al. **Gene Ther** 1996 Jun;3(6):483-90

Differential toxicity of ganciclovir for rat neurons and astrocytes in primary culture following adenovirus-mediated transfer of the HSVtk gene. Maron A, et al. **Gene Ther** 1997 Jan;4(1):25-31

In vitro sensitization of the B16 murine melanoma cells to ganciclovir by different RNA and plasmid DNA constructions encoding HSVtk. Yarovoi SV, et al. **Gene Ther** 1996 Oct;3(10):913-8

Effect of combination interleukin-3 (IL-3) and granulocyte-macrophage colony stimulating factor (GM-CSF) on hematopoiesis administered to retrovirus-infected immunodeficient mice receiving dose-escalation zidovudine (AZT). Gallicchio VS, et al. **Int J Immunopharmacol** 1995 Nov;17(11):865-78

In vitro lymphotoxicity and selective T cell immunotoxicity of high doses of acyclovir and its derivatives in mice. Poluektova L, et al. **Int J Immunopharmacol** 1996 Jun-Jul; 18(6-7):429-38

Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lewis W, et al. **Lab Invest** 1997 Jan;76(1):77-87

Mitochondrial and cellular toxicity induced by fialuridine in human muscle in vitro. Semino-Mora C, et al. **Lab Invest** 1997 Apr;76(4):487-95

Intravitreal application of ganciclovir in rabbits: ERG and electron-microscopic findings. Moschos M, et al. **Ophthalmologica** 1996;210(4):215-22

In vivo toxicity of foscarnet and zidovudine given alone or in combination. Omar RF, et al. **Toxicol Appl Pharmacol** 1996 Aug;139(2):324-32

Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Khan KN, et al. **Toxicol Pathol** 1996 Sep-Oct;24(5):531-8

[Determination of the genotoxicity of fullerene C60 and fullerol using the method of somatic mosaics on cells of Drosophila melanogaster wing and SOS-chromotest] Zakharenko LP, et al. **Genetika** 1997 Mar;33(3):405-9 (Eng. Abstr.) **(Rus)**

[Neurotoxicity of acyclovir (letter)] Calvo Romero JM, et al. **Rev Clin Esp** 1997 Apr;197(4):297 **(Spa)**

URINE

Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanine in serum and urine using solid-phase extraction and high-performance liquid chromatography. Svensson JO, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7;690(1-2):363-6

Determination of the novel sialic acid analog GG167 (GR121167X) in human urine by liquid chromatography: direct injection with column switching. Morris DM, et al. **J Pharm Biomed Anal** 1995 Dec;14(1-2):191-201

Hplc-nmr identification of the human urinary metabolites of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analogue active against human immunodeficiency virus (HIV). Shockcor JP, et al. **Xenobiotica** 1996 Feb;26(2):189-99

ANTLERS

GROWTH & DEVELOPMENT

Seasonal levels of reproductive hormones and their relationship to the antler cycle of male and female reindeer (Rangifer tarandus). Bubenik GA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Feb; 116(2):269-77

Effect of testosterone on binding of insulin-like growth factor-I (IGF-I) and IGF-II in growing antlers of fallow deer (Dama dama). Elliott JL, et al. **Growth Regul** 1996 Dec;6(4):214-21

INNERVATION

Innervation and anesthesia of the antler pedicle in wapiti and fallow deer. Woodbury MR, et al. **Can Vet J** 1996 Aug;37(8):486-9

METABOLISM

Bone morphogenetic protein 2 transcripts in rapidly developing deer antler tissue contain an extended 5' non-coding region arising from a distal promoter. Feng JQ, et al. **Biochim Biophys Acta** 1997 Jan 3;1350(1):47-52

Chondrogenesis in the regenerating antler tip in red deer: expression of collagen types I, IIA, IIB, and X demonstrated by in situ nucleic acid hybridization and immunocytochemistry. Price JS, et al. **Dev Dyn** 1996 Mar; 205(3):332-47

Effect of testosterone on binding of insulin-like growth factor-I (IGF-I) and IGF-II in growing antlers of fallow deer (Dama dama). Elliott JL, et al. **Growth Regul** 1996 Dec;6(4):214-21

PHYSIOLOGY

Experimental and theoretical quantification of the development of damage in fatigue tests of bone and antler. Zioupos P, et al. **J Biomech** 1996 Aug;29(8):989-1002

ANTRUM OF HIGHMORE see **MAXILLARY SINUS**

ANTRUM, PYLORIC see **PYLORIC ANTRUM**

ANTS

Mandible muscle fibers in ants: fast or powerful? Gronenberg W, et al. **Cell Tissue Res** 1997 Aug;289(2):347-61

An unusual presentation of vulvar carcinoma: a traumatic aetiology? [letter] Weinberg JM, et al. **Genitourin Med** 1997 Apr;73(2):146

[Lice, fleas, ticks and ants: non-venomous apterous arthropods] **Med Trop (Mars)** 1996;56(3):238-40 **(Fre)**

ANATOMY & HISTOLOGY

Brains of ants and elephants [editorial] Gregory R. **Perception** 1997;26(3):249-52

CHEMISTRY

Inhibitory effects of Chinese ant extract (CAE) on nephrotoxicity induced by ferric-nitrilotriacetate (Fe-NTA) in Wistar rats. Ma Y, et al. **Res Commun Mol Pathol Pharmacol** 1997 May;96(2):169-78

CLASSIFICATION

Molecular phylogenetic study of a myrmecophyte symbiosis: did Leonardoxa/ ant associations diversify via cospeciation? Chenuil A, et al. **Mol Phylogenet Evol** 1996 Oct;6(2):270-86

ENZYMOLOGY

Proteinases from pollen and pests. Travis J, et al. **Acta Biochim Pol** 1996;43(3):411-7 (23 ref.)

GENETICS

Expression of jumper ant (Myrmecia pilosula) venom allergens: post-translational processing of allergen gene products. Donovan GR, et al. **Biochem Mol Biol Int** 1996 Aug;39(5):877-85

Isolation of DNA suitable for PCR for field and laboratory work. Altschmied J, et al. **Biotechniques** 1997 Aug; 23(2):228-9

Genomic dispersion of 28S rDNA during karyotypic evolution in the ant genus Myrmecia (Formicidae) [published erratum appears in Chromosoma 1997 Apr;105(6):380-1] Hirai H, et al. **Chromosoma** 1996 Sep; 105(3):190-6

Multilocus evolution in fire ants: effects of selection, gene flow and recombination. Ross KG. **Genetics** 1997 Apr; 145(4):961-74

Analysis of the nucleolar organizing regions in the ant Tapinoma nigerrimum (Hymenoptera, Formicidae). Lorite P, et al. **Heredity** 1997 Jun;78 (Pt 6):578-82

Population and colony structure of the carpenter ant Camponotus floridanus. Gadau J, et al. **Mol Ecol** 1996 Dec; 5(6):785-92

Microsatellite loci for Pseudomyrmex pallidus (Hymenoptera:formicidae). Peters JM. **Mol Ecol** 1997 Sep; 6(9):887-8

Parentage, reproductive skew and queen turnover in a multiple-queen ant analysed with microsatellites. Bourke AF, et al. **Proc R Soc Lond B Biol Sci** 1997 Feb 22; 264(1379):277-83

IMMUNOLOGY

Hymenoptera hypersensitivity in an imported fire ant endemic area. Freeman TM. **Ann Allergy Asthma Immunol** 1997 Apr;78(4):369-72

METABOLISM

Primary tetradecenyl amines from the ant Monomorium floricola. Jones TH, et al. **J Nat Prod** 1996 Aug;59(8):801-2

MICROBIOLOGY

Yeasts associated with nests of the leaf-cutting ant Atta sexdens rubropilosa Forel, 1908. Carreiro SC, et al. **Antonie Van Leeuwenhoek** 1997 Mar;71(3):243-8

Amplified fragment length polymorphism (AFLP) fingerprinting of symbiotic fungi cultured by the fungus-growing ant Cyphomyrmex minutus. Mueller UG, et al. **Mol Ecol** 1996 Feb;5(1):119-22

Intracellular endosymbiotic bacteria of Camponotus species (carpenter ants): systematics, evolution and ultrastructural characterization. Schröder D, et al. **Mol Microbiol** 1996 Aug;21(3):479-89

PARASITOLOGY

A cholesteryl ester transfer protein inhibitor from an insect-associated fungus. Lee JC, et al. **J Antibiot (Tokyo)** 1996 Jul;49(7):693-6

PHYSIOLOGY

Detection of magnetism in the red imported fire ant (Solenopsis invicta) using magnetic resonance imaging. Slowik TJ, et al. **Bioelectromagnetics** 1997;18(5):396-9

Ant colonies for the travelling salesman problem. Dorigo M, et al. **Biosystems** 1997;43(2):73–81
Active random walkers simulate trunk trail formation by ants. Schweitzer F, et al. **Biosystems** 1997;41(3):153–66
Transmission of information regarding the quantitative characteristics of an object in ants. Reznikova ZI, et al. **Neurosci Behav Physiol** 1996 Sep–Dec;26(5):397–405
Millipede defense: use of detachable bristles to entangle ants. Eisner T, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1; 93(20):10848–51

ANURA

The use of in vitro preparations of the isolated amphibian central nervous system in neuroanatomy and electrophysiology. Luksch H, et al. **J Neurosci Methods** 1996 Dec;70(1):91–102
Production and characterization of site-directed antibodies against dermorphin and dermorphin-related peptides. Cucumel K, et al. **Peptides** 1996;17(6):973–82
In vitro and in vivo biological activities of PG-KII, a novel kassinin-like peptide from the skin of the Australian frog, Pseudophryne guntheri. Improta G, et al. **Peptides** 1996; 17(6):1003–8
Absence of tetrodotoxins in a captive-raised riparian frog, Atelopus varius. Daly JW, et al. **Toxicon** 1997 May; 35(5):705–9
Corneal curvatures and refractions of central American frogs. Howland HC, et al. **Vision Res** 1997 Jan;37(2):169–74

ANATOMY & HISTOLOGY

Similarities and differences in the cytoarchitecture of the tectum of frogs and salamanders. Dicke U, et al. **Acta Biol Hung** 1996;47(1–4):41–59
The synaptic organization of the horizontal vestibulo-ocular reflex in the frog. Dieringer N, et al. **Acta Biol Hung** 1996; 47(1–4):61–72 (37 ref.)
Correlations between call characteristics and morphology in male cricket frogs (Acris crepitans). McClelland BE, et al. **J Exp Biol** 1996 Sep;199 (Pt 9):1907–19
Osteology and skeletal development of Discoglossus sardus (Anura:Discoglossidae). Analía Púgener L, et al. **J Morphol** 1997 Sep;233(3):267–86
Elastic structures in the vocalization apparatus of the Túngara frog Physalaemus pustulosus (Leptodactylidae). Jaramillo C, et al. **J Morphol** 1997 Sep;233(3):287–95
Description of the adult skeleton and developmental osteology of the hyperossified horned frog, Ceratophrys cornuta (Anura:Leptodactylidae). Wild ER. **J Morphol** 1997 May;232(2):169–206
Sperm–egg interaction in the painted frog (Discoglossus pictus): an ultrastructural study. Campanella C, et al. **Mol Reprod Dev** 1997 Jul;47(3):323–33

BLOOD

[Hematologic values and altitudinal distribution of Chilean amphibians] Ruiz G, et al. **Arch Biol Med Exp (Santiago)** 1987;20(1):79–84 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

A phylogeny for the African treefrog family Hyperoliidae based on mitochondrial rDNA. Richards CM, et al. **Mol Phylogenet Evol** 1996 Jun;5(3):522–32
Phylogenetic relationships among bufonoid frogs (Anura:Neobatrachia) inferred from mitochondrial DNA sequences. Ruvinsky I, et al. **Mol Phylogenet Evol** 1996 Jun;5(3):533–47

EMBRYOLOGY

Genesis of the frog retinal pigment epithelium. Beazley LD, et al. **Brain Res Dev Brain Res** 1996 Oct 23;96(1–2):290–4
An essay on the similarities and differences between inductive interactions in anuran and urodele embryos. Malacinski GM, et al. **Cell Mol Life Sci** 1997 Apr;53(4):410–7 (30 ref.)
Patterns of distal-less gene expression and inductive interactions in the head of the direct developing frog Eleutherodactylus coqui. Fang H, et al. **Dev Biol** 1996 Oct 10;179(1):160–72
What are the key advantages and disadvantages of urodele species compared to anurans as a model system for experimental analysis of early development? Nieuwkoop PD. **Int J Dev Biol** 1996 Aug;40(4):617–9 (16 ref.)

GENETICS

Heteromorphic sex chromosomes in Eupsophus insularis (Amphibia: Anura: Leptodactylidae). Cuevas CC, et al. **Chromosome Res** 1996 Sep;4(6):467–70
Phenotypic and genetic divergence in three species of dart-poison frogs with contrasting parental behavior. Summers K, et al. **J Hered** 1997 Jan–Feb;88(1):8–13
A phylogeny for the African treefrog family Hyperoliidae based on mitochondrial rDNA. Richards CM, et al. **Mol Phylogenet Evol** 1996 Jun;5(3):522–32
Phylogenetic relationships among bufonoid frogs (Anura:Neobatrachia) inferred from mitochondrial DNA sequences. Ruvinsky I, et al. **Mol Phylogenet Evol** 1996 Jun;5(3):533–47

GROWTH & DEVELOPMENT

Reproduction in the Mexican leaf frog, Pachymedusa dacnicolor. VI. Presence and distribution of multiple GnRH forms in the brain. Iela L, et al. **Gen Comp Endocrinol** 1996 Sep;103(3):235–43
The analysis of complex developmental programmes: amphibian metamorphosis. Kanamori A, et al. **Genes Cells** 1996 May;1(5):429–35 (59 ref.)
Osteology and skeletal development of Discoglossus sardus (Anura:Discoglossidae). Analía Púgener L, et al. **J Morphol** 1997 Sep;233(3):267–86
Early development of chondrocranium in the tailed frog Ascaphus truei (Amphibia: Anura): implications for anuran palatoquadrate homologies. Reiss JO. **J Morphol** 1997 Jan; 231(1):63–100

IMMUNOLOGY

Plasticity of thymuses of ectothermic vertebrates [letter; comment] Ptytycz B, et al. **Immunol Today** 1996 Sep; 17(9):442. Comment on: Immunol Today 1994 Apr;15(4):192–3.

METABOLISM

Soybean agglutinin binding by primary olfactory and primary accessory olfactory projections in different frogs. Meyer DL, et al. **Brain Res** 1996 May 25;722(1–2):222–6
Toxicity of chlorpyrifos, fenubucarb, monocrotophos, and methyl parathion to fish and frogs after a simulated overflow of paddy water. Calumpang SM, et al. **Bull Environ Contam Toxicol** 1997 Jun;58(6):909–14
Salt and water balance in the toad Bufo viridis during recovery from two different osmotically stressful conditions. Hoffman J, et al. **Comp Biochem Physiol A Physiol** 1997 May;117(1):147–54
Effects of urea on M4-lactate dehydrogenase from elasmobranchs and urea-accumulating Australian desert frogs. Fuery CJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):143–50
Alkaloid 223A: the first trisubstituted indolizidine from dendrobatid frogs. Garraffo HM, et al. **J Nat Prod** 1997 Jan;60(1):2–5
A 1,4-disubstituted quinolizidine from a Madagascan mantelline frog (Mantella). Jain P, et al. **J Nat Prod** 1996 Dec;59(12):1174–8
The structures of the frenatin peptides from the skin secretion of the giant tree frog Litoria infrafrenata. Raftery MJ, et al. **J Pept Sci** 1996 Mar–Apr;2(2):117–24
New caerin antibacterial peptides from the skin glands of the Australian tree frog Litoria xanthomera. Part 2. Sequence determination using mass spectrometry and associated techniques. Steinborner ST, et al. **Rapid Commun Mass Spectrom** 1997;11(9):997–1000
Immunoreactive mammalian and chicken-II GnRHs in Rana esculenta brain during development. Di Fiore MM, et al. **Regul Pept** 1996 Apr 23;62(2–3):119–24
Formation of varanic acid, 3 alpha, 7 alpha, 12 alpha, 24-tetrahydroxy-5 beta-cholestanoic acid from 3 alpha, 7 alpha, 12 alpha-trihydroxy-5 beta-cholestanoic acid in Bombina orientalis. Une M, et al. **Steroids** 1996 Nov; 61(11):639–41
Absence of skin alkaloids in captive-raised Madagascan mantelline frogs (Mantella) and sequestration of dietary alkaloids. Daly JW, et al. **Toxicon** 1997 Jul;35(7):1131–5

PARASITOLOGY

Comparisons of molecular karyotype and RAPD patterns of anuran trypanosome isolates during long-term in vitro cultivation. Lun ZR, et al. **Folia Parasitol (Praha)** 1996; 43(4):241–8
Helminth infracommunities in Litoria genimaculata (Amphibia:Anura) from Birthday Creek, an upland rainforest stream in northern Queensland, Australia. Barton DP, et al. **Int J Parasitol** 1996 Dec;26(12):1381–5
Helminths from three treefrogs Hyla arenicolor, Hyla wrightorum, and Pseudacris triseriata (Hylidae) from Arizona. Goldberg SR, et al. **J Parasitol** 1996 Oct; 82(5):833–5
Cryptosporidium parvum is not transmissible to fish, amphibians, or reptiles. Graczyk TK, et al. **J Parasitol** 1996 Oct;82(5):748–51
Intrahepatic larval nematode infection in the northern spring peeper, Pseudacris crucifer crucifer (Anura: Hylidae), in West Virginia. Joy JE, et al. **J Wildl Dis** 1996 Apr; 32(2):340–3
[A new host and taxonomic notes for Baerietta chilensis (Cestoda:Nematotaeniidae)] Puga S. **Bol Chil Parasitol** 1996 Jan–Jun;51(1–2):34–5 **(Spa)**

PHYSIOLOGY

The synaptic organization of the horizontal vestibulo-ocular reflex in the frog. Dieringer N, et al. **Acta Biol Hung** 1996; 47(1–4):61–72 (37 ref.)
Influence of pretectal lesions on tectal responses to visual stimulation in anurans: field potential, single neuron and behavior analyses. Ewert JP, et al. **Acta Biol Hung** 1996; 47(1–4):89–111
Frog experiment onboard space station Mir. Izumi-Kurotani A, et al. **Adv Space Biol Med** 1997;6:193–211
Role of pulmonary stretch receptor feedback in control of episodic breathing in the bullfrog. Kinkead R, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R497–508
The frog brainstem preparation as a model for studying the central control of breathing in tetrapods. Perry SF, et al. **Braz J Med Biol Res** 1995 Nov–Dec;28(11–12):1339–46 (24 ref.)
Immunocytochemical localization of prohormone convertases PC1 and PC2 in the anuran pituitary gland: subcellular localization in corticotrope and melanotrope cells. Kurabuchi S, et al. **Cell Tissue Res** 1997 Jun; 288(3):485–96
The role of androgens in opportunistic breeding, tropical frogs. Emerson SB, et al. **Gen Comp Endocrinol** 1996 Aug; 103(2):220–30
Reproductive endocrinology of the explosively breeding desert spadefoot toad, Scaphiopus couchii. Harvey LA, et al. **Gen Comp Endocrinol** 1997 Jan;105(1):102–13
Basal ganglia organization in amphibians: efferent connections of the striatum and the nucleus accumbens. Marín O, et al. **J Comp Neurol** 1997 Mar 31;380(1):23–50
Sensory modulation and behavioral choice during feeding in the Australian frog, Cyclorana novaehollandiae. Valdez CM, et al. **J Comp Physiol** [A] 1997 Mar;180(3):187–202
The key role of the H+ V-ATPase in acid-base balance and Na+ transport processes in frog skin. Ehrenfeld J, et al. **J Exp Biol** 1997 Jan;200 (Pt 2):247–56 (78 ref.)
Correlations between call characteristics and morphology in male cricket frogs (Acris crepitans). McClelland BE, et al. **J Exp Biol** 1996 Sep;199 (Pt 9):1907–19
Evolution of forelimb movement patterns for prey manipulation in anurans. Gray LA, et al. **J Exp Zool** 1997 Apr 15;277(6):417–24
Elastic structures in the vocalization apparatus of the Túngara frog Physalaemus pustulosus (Leptodactylidae). Jaramillo C, et al. **J Morphol** 1997 Sep;233(3):287–95
Culicidae (Diptera) in the diet of predatory stages of anurans (Amphibia) in humid biotopes of the Rhine Valley in Germany. Blum S, et al. **J Vector Ecol** 1997 Jun;22(1):23–9
[The chemical interaction of tadpoles of the common frog Rana temporaria L. with conspecific and heterospecific anuran tadpoles] Kiseleva EI. **Zh Obshch Biol** 1996 Nov–Dec;57(6):740–6 (Eng. Abstr.) **(Rus)**

ANURIA

CHEMICALLY INDUCED

Neonatal anuria by ACE inhibitors during pregnancy [letter] Lavoratti G, et al. **Nephron** 1997;76(2):235–6
Incidence of acute oligoanuric renal failure in dextran 40 treated patients with acute ischemic stroke stage III or IV. Biesenbach G, et al. **Ren Fail** 1997 Jan;19(1):69–75
Anuric acute renal failure caused by dextran 40 administration. Ferraboli R, et al. **Ren Fail** 1997 Mar; 19(2):303–6

CONGENITAL

Renal tubular dysgenesis: a report of two cases. Querfeld U, et al. **J Perinatol** 1996 Nov–Dec;16(6):498–500

ETIOLOGY

Postrenal anuria after appendectomy in childhood. Timm K, et al. **Eur J Pediatr Surg** 1997 Aug;7(4):237–8
Anuria and acute renal failure caused by multiple bladder calculi. Madjar S, et al. **Int Urol Nephrol** 1996;28(5):639–41
Postrenal anuria in pelvic or acetabular injury: a report of three cases. Hötker U, et al. **J Trauma** 1996 Nov; 41(5):916–9
Thrombotic occlusion of ureteric stent: an unusual cause of anuria after kidney transplantation. Doehn C, et al. **Nephrol Dial Transplant** 1997 Jun;12(6):1267–8
A case of reflex anuria and uremia related to a unilateral ureteral stone. Hayashi K, et al. **Nippon Jinzo Gakkai Shi** 1996 Oct;38(10):460–2 (5 ref.)
Vomiting and anuria after bicycle accident. Swischuk LE. **Pediatr Emerg Care** 1996 Apr;12(2):137–9
An unusual case of anuria: spontaneous perirenal hematoma in a solitary kidney. Beccari M, et al. **Ren Fail** 1996 Jan; 18(1):147–50
Obstructive anuria and dermatomyositis: a unique association. Parulkar BG, et al. **Urology** 1997 Jul;50(1):135–7
[Clinical thinking and decision making in practice. A patient with flank pain and anuria] Gans RO, et al. **Ned Tijdschr Geneeskd** 1997 May 10;141(19):931–7 (Eng. Abstr.) **(Dut)**

METABOLISM

Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. Joos B, et al. **Nephrol Dial Transplant** 1996 Aug;11(8):1582–5

PHYSIOPATHOLOGY

Spontaneous resolution of upper urinary tract obstruction in an anuric premature neonate [letter; comment] Gupta IR, et al. **Pediatr Nephrol** 1996 Aug;10(4):544–5. Comment on: Pediatr Nephrol 1995 Dec;9(6):718–22.

THERAPY

The removal index for evaluation of dialysis. Chen TW, et al. **Perit Dial Int** 1996 Mar–Apr;16(2):128–34

ANUS

consider also terms at PROCT-

see related

PROCTOSCOPY

A local sphincter-saving treatment of distal rectal cancer (editorial)] Viola G. **Ann Ital Chir** 1996 Sep-Oct; 67(5):603-6

Damaging effects of anal stretching on the external anal sphincter. Li L, et al. **Dis Colon Rectum** 1996 Nov; 39(11):1249-54

Treatment of puborectalis syndrome with progressive anal dilation. Maria G, et al. **Dis Colon Rectum** 1997 Jan; 40(1):89-92

A case of ectopic anus localized on the right gluteus. Aritürk E, et al. **J Pediatr Surg** 1996 Oct;31(10):1451-3

Anal dilatation in the management of painful defaecation in children. Johnstone JM, et al. **J R Coll Surg Edinb** 1997 Aug;42(4):269-71

What is new in the treatment of perianal fistulae in Crohn's disease? Delemarre JB. **Neth J Med** 1996 Feb;48(2):74-6

Endoscopic anal dilatation for fissure-in-ano: a new outpatient treatment modality. Pérez-Miranda M, et al. **Rev Esp Enferm Dig** 1996 Apr;88(4):265-72 **(Eng, Spa)**

Anal incontinence after vaginal delivery [letter; comment] Stewart CJ. **S Afr Med J** 1996 Oct;86(10):1300. Comment on: S Afr Med J 1996 Jun;86(6):694-6.

The role of nitric oxide in the acetylcholine-induced relaxation of the feline internal anal sphincter, in vitro. Buntzen S, et al. **Scand J Gastroenterol** 1996 Dec; 31(12):1189-94

[Severe anal incontinence: treatment by implantation of an artificial anal sphincter] Michot F, et al. **Contracept Fertil Sex** 1997 Jun;25(6):XII-XVII (18 ref.) **(Fre)**

[Perianal glands of Hermann and their pathology. Review of the literature. Apropos of a cyst case] Gullino D, et al. **J Chir (Paris)** 1996;133(9-10):422-6 (31 ref.) (Eng. Abstr.) **(Fre)**

[Functional results of sphincter-saving techniques in cancer of the low rectum] Santoro GA, et al. **G Chir** 1996 Oct; 17(10):547-50 (25 ref.) (Eng. Abstr.) **(Ita)**

[Sphincter saving procedure for low rectal carcinoma] Sugihara K, et al. **Nippon Geka Gakkai Zasshi** 1997 Mar; 98(3):391-5 (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Sacrococcygeal teratoma and anorectal malformation. Ng WT, et al. **Aust N Z J Surg** 1997 Apr;67(4):218-20 (28 ref.)

Partial monosomy 10q and partial trisomy 9q with anal atresia due to maternal translocation: t(9;10)(q32;q26). Tsukuda T, et al. **Clin Genet** 1996 Oct;50(4):220-2

Congenital psoriasiform erythrokeratodermia with cleidocranial dysplasia, urogenital anomalies and atresia ani. Watanabe K, et al. **Dermatology** 1996;192(4):368-72

An autosomal dominant syndrome of renal and anogenital malformations with syndactyly. Green AJ, et al. **J Med Genet** 1996 Jul;33(7):594-6

Anal anomalies: an uncommon feature of velocardiofacial (Shprintzen) syndrome? Worthington S, et al. **J Med Genet** 1997 Jan;34(1):79-82

Anatomy of the nerve supply of the rectum, bladder, and internal genitalia in anorectal dysgenesis in the male. Davies MR. **J Pediatr Surg** 1997 Apr;32(4):536-41

A comparison of anal endosonography with electromyography and manometry in high and intermediate anorectal anomalies. Fukata R, et al. **J Pediatr Surg** 1997 Jun;32(6):839-42

Anteriorly located anus: is constipation caused by abnormal location of the anus? Fukunaga K, et al. **J Pediatr Surg** 1996 Feb;31(2):245-6

Abnormal internal anal sphincter innervation in patients with Hirschsprung's disease and allied disorders. Kobayashi H, et al. **J Pediatr Surg** 1996 Jun;31(6):794-9

Currarino triad: anorectal malformation, sacral bony abnormality, and presacral mass--a review of 11 cases. Lee SC, et al. **J Pediatr Surg** 1997 Jan;32(1):58-61

The tethered spinal cord in patients with anorectal malformations. Levitt MA, et al. **J Pediatr Surg** 1997 Mar; 32(3):462-8

Congenital funnel anus. Rintala RJ, et al. **J Pediatr Surg** 1996 Sep;31(9):1308-10

Anterior sagittal anorectoplasty for anorectal malformations and perineal trauma in the female child. Wakhlu A, et al. **J Pediatr Surg** 1996 Sep;31(9):1236-40

Anorectal malformation: a new anatomic variant resembling an H-type fistula. Willems M, et al. **J Pediatr Surg** 1996 Dec;31(12):1682-4

Rectal ectasia associated with anorectal anomalies. Zia-ul-Miraj M, et al. **J Pediatr Surg** 1997 Apr;32(4):621-3

Accessory scrotum and anorectal malformation associated with "pseudo" prune belly in a neonate. Shoshany G, et al. **J Perinatol** 1996 May-Jun;16(3 Pt 1):224-6 (25 ref.)

Anorectal anomalies: anorectal manometric function and anal endosonography in relation to functional outcome. Emblem R, et al. **Pediatr Surg Int** 1997 Sep;12(7):516-9

Subfertility and atresias of the alimentary tract. Robert E, et al. **Reprod Toxicol** 1996 Mar-Apr;10(2):125-8

A report of 27 cases of congenital short colon with an imperforate anus: so-called 'pouch colon syndrome'. Budhiraja S, et al. **Trop Doct** 1997 Oct;27(4):217-20

[Currarino triad : a case report] Miyake S, et al. **No Shinkei Geka** 1996 Feb;24(2):189-93 (Eng. Abstr.) **(Jpn)**

[Relationship between adaptation mechanisms and the level of functioning of the cardiovascular system in children with abnormalities of the large intestine and anorectal region] Agzamkhodzhaev TS, et al. **Anesteziol Reanimatol** 1996 Nov-Dec;(6):27-31 (Eng. Abstr.) **(Rus)**

ANATOMY & HISTOLOGY

Anal sphincter structure and function in homosexual males engaging in anoreceptive intercourse. Chun AB, et al. **Am J Gastroenterol** 1997 Mar;92(3):465-8

Issues in anatomy: the external anal sphincter revisited. Bogduk N. **Aust N Z J Surg** 1996 Sep;66(9):626-9

Endoanal MRI of the anal sphincter complex: correlation with cross-sectional anatomy and histology. Hussain SM, et al. **J Anat** 1996 Dec;189 (Pt 3):677-82

BLOOD SUPPLY

Transjugular embolization of the inferior mesenteric vein for bleeding anorectal varices after unsuccessful transjugular intrahepatic portosystemic shunt. Demirel H, et al. **Am J Gastroenterol** 1997 Jul;92(7):1226-7

Intractable anal pain due to ischaemic proctitis caused by venous obstruction. Seow-Choen F, et al. **Aust N Z J Surg** 1997 Jun;67(6):390-2

Innovative indications for tips. Conn HO. **Hepatology** 1997 Jun;25(6):1543-5

CHEMISTRY

Immunohistochemical assessment of steroid hormone receptors in tissues of the anal canal. Implications for anal incontinence? Franz HB, et al. **Acta Obstet Gynecol Scand** 1996 Nov;75(10):892-5

CYTOLOGY

Location of external anal sphincter motoneurons in the sacral cord of the female domestic pig. Blok BF, et al. **Neurosci Lett** 1996 Oct 4;216(3):203-6

Ultrastructural studies on the anal canal epithelium in the mouse, with special reference to the keratinizing process. Nakano T. **Okajimas Folia Anat Jpn** 1996 Oct;73(4):211-7

DRUG EFFECTS

Influence of botulinum toxin injections on the sphincteric compound muscle action potential of the external anal sphincter [letter] Jost WH. **Dis Colon Rectum** 1997 Aug; 40(8):995-6

Pharmacology of the internal anal sphincter and abnormalities in faecal incontinence. Speakman CT. **Eur J Gastroenterol Hepatol** 1997 May;9(5):442-6 (56 ref.)

Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Sun WM, et al. **Scand J Gastroenterol** 1997 Jan;32(1):34-8

EMBRYOLOGY

Function of posterior HoxD genes in the morphogenesis of the anal sphincter. Kondo T, et al. **Development** 1996 Sep; 122(9):2651-9

ENZYMOLOGY

A unique myosin isoform transition in cat striated external anal sphincter muscle induced by denervation. Kustasz R, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):G698-704

Immunohistochemical localization of the pro-peptide processing enzymes PC1/PC3 and PC2 in the human anal canal. Hörsch D, et al. **Peptides** 1997;18(5):755-60

IMMUNOLOGY

Quantitative analysis of the immune cells in the anal mucosa. Gervaz E, et al. **Pathol Res Pract** 1995 Nov; 191(11):1067-71

INJURIES

Can women with intrapartum rupture of anal sphincter still suffer after-effects two decades later? Haadem K, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):601-3

Transvaginal versus anal endosonography for detecting damage to the anal sphincter. Frudinger A, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1435-8

Perineal examination as a predictor of underlying external anal sphincter damage. Frudinger A, et al. **Br J Obstet Gynaecol** 1997 Sep;104(9):1009-13

Anal and urinary incontinence in women with obstetric anal sphincter rupture [letter; comment] Malik A, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):753-4. Comment on: Br J Obstet Gynaecol 1996 Oct;103(10):1034-40.

Third degree obstetric perineal tears: risk factors and the preventive role of mediolateral episiotomy. Poen AC, et al. **Br J Obstet Gynaecol** 1997 May;104(5):563-6

Anal and urinary incontinence in women with obstetric anal sphincter rupture [letter; comment] Sultan AH, et al. **Br J Obstet Gynaecol** 1997 Jun;104(6):754-5. Comment on: Br J Obstet Gynaecol 1996 Oct;103(10):1034-40.

Anal and urinary incontinence in women with obstetric anal sphincter rupture [see comments] Tetzschner T, et al. **Br J Obstet Gynaecol** 1996 Oct;103(10):1034-40. Comment in: Br J Obstet Gynaecol 1997 Jun;104(6):753-4. Comment in: Br J Obstet Gynaecol 1997 Jun;104(6):754-5.

Surgical management of anorectal incontinence due to internal anal sphincter deficiency. Morgan R, et al. **Br J Surg** 1997 Feb;84(2):226-30

The anal sphincter in idiopathic megarectum: effects of manual disimpaction under general anesthetic. Gattuso JM, et al. **Dis Colon Rectum** 1996 Apr;39(4):435-9

Overlap repair of damaged anal sphincter. A single surgeon's series. Sitzler PJ, et al. **Dis Colon Rectum** 1996 Dec; 39(12):1356-60

Occult obstetric trauma and anal incontinence. Sultan AH, et al. **Eur J Gastroenterol Hepatol** 1997 May;9(5):423-7 (32 ref.)

Clinical consequences of anal sphincter rupture during vaginal delivery. Fornell EK, et al. **J Am Coll Surg** 1996 Dec;183(6):553-8

Anal incontinence after anal sphincter disruption: a 30-year retrospective cohort study. Nygaard IE, et al. **Obstet Gynecol** 1997 Jun;89(6):896-901

[Multiple ruptures of the internal sphincter after anal rape: an underknown cause of fecal incontinence (letter)] Rakotomalala L, et al. **Gastroenterol Clin Biol** 1996; 20(12):1142-3 **(Fre)**

[Ano-genital injuries in female victims of sexual assault] Kindermann G, et al. **Swiss Surg** 1996;(1):10-3 (Eng. Abstr.) **(Ger)**

[Surgical treatment concept in traumatic sphincter lesions] Ecker KW, et al. **Zentralbl Chir** 1996;121(8):681-7 (Eng. Abstr.) **(Ger)**

[Pelvic floor reconstruction after traumatic childbirth damage] Franz HB, et al. **Zentralbl Chir** 1996;121(8):688-91 (20 ref.) (Eng. Abstr.) **(Ger)**

[Blunt perineal injuries] Kluger Y, et al. **Harefuah** 1997 Feb 2;132(3):233-5, 239 (Eng. Abstr.) **(Heb)**

[Impalement injuries. A clinical case] De Rosa G, et al. **Minerva Chir** 1997 Jan-Feb;52(1-2):143-8 (19 ref.) (Eng. Abstr.) **(Ita)**

[Role of anal endosonography in inflammation and trauma of the anal canal] Brunese L, et al. **Radiol Med (Torino)** 1996 Dec;92(6):742-7 (Eng. Abstr.) **(Ita)**

INNERVATION

A unique myosin isoform transition in cat striated external anal sphincter muscle induced by denervation. Kustasz R, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):G698-704

Experimental model of pudendal nerve innervation of a skeletal muscle neosphincter for faecal incontinence. Congilosi SM, et al. **Br J Surg** 1997 Sep;84(9):1269-73

Preoperative increase in neuromuscular jitter and outcome following surgery for faecal incontinence. Gee AS, et al. **Br J Surg** 1997 Sep;84(9):1265-8

Anorectal sensitivity in patients with obstructed defaecation. Solana A, et al. **Int J Colorectal Dis** 1996;11(2):65-70

Pudendal nerve recovery after a non-instrumented vaginal delivery. Tetzschner T, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(2):102-4

Morphological and morphometric characterisation of Onuf's nucleus in the spinal cord in man. Pullen AH, et al. **J Anat** 1997 Aug;191 (Pt 2):201-13

Involvement of Onuf's nucleus in amyotrophic lateral sclerosis. Kihira T, et al. **J Neurol Sci** 1997 Mar 20; 147(1):81-8

L-arginine deficiency causes suppression of nonadrenergic noncholinergic nerve-mediated smooth muscle relaxation: role of L-citrulline recycling. Chakder S, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):378-84

Motoneuronal location of the external urethral and anal sphincters: a single and double labeling study in the male and female golden hamster. Gerrits PO, et al. **Neurosci Lett** 1997 May 2;226(3):191-4

Intraoperative recording of the bulbocavernosus reflex. Deletis V, et al. **Neurosurgery** 1997 Jan;40(1):88-92; discussion 92-3

Differential effects of intrathecal thyrotropin-releasing hormone (TRH) on perineal reflexes in male rats. Holmes GM, et al. **Physiol Behav** 1997 Jan;61(1):57-63

The hypertonic rectosigmoid junction: description of a new clinicopathologic entity causing constipation. Shafik A. **Surg Laparosc Endosc** 1997 Apr;7(2):116-20

Abnormalities in visceral evoked potentials from the anal canal in children with chronic constipation. Kubota M, et al. **Surg Today** 1997;27(7):632-7

Functional perineal colostomy with pudendal nerve anastomosis following anorectal resection: a cadaver operation study on a new procedure. Sato T, et al. **Surgery** 1997 May;121(5):569-74

[Anal sphincter electromyography, bulbocavernosus reflex and pudendal somatosensory evoked potentials in diagnosis of neurogenic lumbosacral lesions with disorders of bladder and large intestine emptying and erectile dysfunction] Ziemann U, et al. **Nervenarzt** 1996 Feb;67(2):140-6 (Eng. Abstr.) **(Ger)**

METABOLISM

L-citrulline recycling in opossum internal anal sphincter relaxation by nonadrenergic, noncholinergic nerve stimulation. Rattan S, et al. **Gastroenterology** 1997 Apr;

112(4):1250–9

PARASITOLOGY

Search for Trypanosoma cruzi in the anal glands of wild Didelphis albiventris from Santiago del Estero, Argentina. Conti O, et al. **Mem Inst Oswaldo Cruz** 1995 Nov–Dec; 90(6):687

Trypanosoma cruzi in the anal glands of urban opossums. I—Isolation and experimental infections. Urdaneta-Morales S, et al. **Mem Inst Oswaldo Cruz** 1996 Jul–Aug; 91(4):399–403

PATHOLOGY

Acute colonic obstruction caused by intussusception and extrusion of a sigmoid lipoma through the anus after barium enema. Kabaalioğlu A, et al. **Abdom Imaging** 1997 Jul–Aug; 22(4):389–91

High-resolution MR imaging of the anal sphincter in children: a pilot study using endoanal receiver coils. deSouza NM, et al. **AJR Am J Roentgenol** 1997 Jul; 169(1):201–6

MR imaging of the anal sphincter in multiparous women using an endoanal coil: correlation with in vitro anatomy and appearances in fecal incontinence. deSouza NM, et al. **AJR Am J Roentgenol** 1996 Dec;167(6):1465–71

Postmortem perianal findings in children. McCann J, et al. **Am J Forensic Med Pathol** 1996 Dec;17(4):289–98

Anal transitional zone and columnar cuff in restorative proctocolectomy. Thompson-Fawcett MW, et al. **Br J Surg** 1996 Aug;83(8):1047–55 (104 ref.)

Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Jay N, et al. **Dis Colon Rectum** 1997 Aug;40(8):919–28

Internal anal sphincter myopathy causing proctalgia fugax and constipation: further clinical and radiological characterization in a patient. Guy RJ, et al. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):221–4

Anal cytology as a screening tool for anal squamous intraepithelial lesions. Palefsky JM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 15;14(5):415–22

Idiopathic constipation in childhood is associated with thickening of the internal anal sphincter. Hosie GP, et al. **J Pediatr Surg** 1997 Jul;32(7):1041–3; discussion 1043–4

Primary degeneration of the internal anal sphincter as a cause of passive faecal incontinence. Vaizey CJ, et al. **Lancet** 1997 Mar 1;349(9052):612–5

Median raphe cyst of the perineum presenting as a perianal polyp. Scelwyn M. **Pathology** 1996 May;28(2):201–2

Perianal abscess and fistula in ano in infancy and childhood: a clinicopathological study. al-Salem AH, et al. **Pediatr Pathol Lab Med** 1996 Sep–Oct;16(5):755–64

Endoanal magnetic resonance imaging versus endosonography. Stoker J, et al. **Radiol Med (Torino)** 1996 Dec;92(6):738–41

[Clinical anatomy of the continence organ] Fritsch H. **Zentralbl Chir** 1996;121(8):613–6 (14 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Anorectal manometry in women with urinary stress incontinence. Kjølhede P, et al. **Acta Obstet Gynecol Scand** 1997 Mar;76(3):266–70

Effects of transmural field stimulation in isolated smooth muscle of human rectum and internal anal sphincter. Glavind EB, et al. **Am J Physiol** 1997 May;272(5 Pt 1):G1075–82

Bombesin-stimulated ceramide production and MAP kinase activation in rabbit rectosigmoid smooth muscle cells. Sbrissa D, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):G1615–25

Postestrus anogenital swelling in female barbary macaques. The larger, the better? Wallner B, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:590–2

Current techniques of assessing defecation dynamics. Rao SS, et al. **Dig Dis** 1997;15 Suppl 1:64–77 (62 ref.)

Anal sensitivity test: what does it measure and do we need it? Cause or derivative of anorectal complaints. Felt-Bersma RJ, et al. **Dis Colon Rectum** 1997 Jul; 40(7):811–6

Anorectal manometric examination in encopretic-constipated children. Sutphen J, et al. **Dis Colon Rectum** 1997 Sep; 40(9):1051–5

Influence of Parks' anal retractor on anal sphincter pressures. van Tets WF, et al. **Dis Colon Rectum** 1997 Sep; 40(9):1042–5

L-citrulline recycling in opossum internal anal sphincter relaxation by nonadrenergic, noncholinergic nerve stimulation. Rattan S, et al. **Gastroenterology** 1997 Apr; 112(4):1250–9

Effects of age on anal function in normal women. Ryhammer AM, et al. **Int J Colorectal Dis** 1997;12(4):225–9

Anorectal manometry before, during and after estrogen replacement therapy. Schellart RP, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(2):77–80

The effect of pelvic nerve stimulation on recto-anal motility in the cat. Buntzen S, et al. **J Auton Nerv Syst** 1996 Dec 14;61(3):243–7

Biomechanical evaluation of an artificial anal sphincter prosthesis. Hajivassiliou CA, et al. **J Med Eng Technol** 1997 May-Aug;21(3-4):89–95

Motor evoked potentials recorded from external anal sphincter by cortical and lumbo-sacral magnetic stimulation: normative data. Pelliccioni G, et al. **J Neurol Sci** 1997 Jul;149(1):69–72

Motor activity of refashioned colorectoanus in patients with total colonic aganglionosis. Endo M, et al. **J Pediatr Surg** 1996 Feb;31(2):283–90

Neuronal mediators of inhibitory junction potentials and relaxation in the guinea-pig internal anal sphincter. Rae MG, et al. **J Physiol (Lond)** 1996 Jun 1;493 (Pt 2):517–27

Age and anorectal sensibility in normal women. Ryhammer AM, et al. **Scand J Gastroenterol** 1997 Mar;32(3):278–84

Physiology and pathophysiology of anal function. Rasmussen OO, et al. **Scand J Gastroenterol Suppl** 1996;216:169–74 (46 ref.)

Influence of ileal pouch capacity and anal sphincteric function on the clinical outcome after ileal pouch-anal anastomosis. Takesue Y, et al. **Surg Today** 1997;27(5):392–7

[A new approach of functional recto-anal exploration: the compliance of the rectum and the anal canal] Arsac M, et al. **Bull Acad Natl Med** 1996 Apr;180(4):747–64; discussion 765–8 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Characterization of afferent mechanisms in ileoanal pouches [published erratum appears in Am J Gastroenterol 19997 Aug;92(8):1409] Bernstein CN, et al. **Am J Gastroenterol** 1997 Jan;92(1):103–8

Comparison of anal sonography with conventional needle electromyography in the evaluation of anal sphincter defects [see comments] Enck P, et al. **Am J Gastroenterol** 1996 Dec;91(12):2539–43. Comment in: Am J Gastroenterol 1997 May;92(5):907.

Can biofeedback therapy improve anorectal function in fecal incontinence? Rao SS, et al. **Am J Gastroenterol** 1996 Nov; 91(11):2360–6

How useful are manometric tests of anorectal function in the management of defecation disorders? [see comments] Rao SS, et al. **Am J Gastroenterol** 1997 Mar;92(3):469–75 . Comment in: Am J Gastroenterol 1997 Aug;92(8):1400.

Should ileoanal pouch surgery be denied to patients with low resting pressures? Takao Y, et al. **Am Surg** 1997 Aug; 63(8):726–31

The electrically stimulated gracilis neosphincter incorporated as part of total anorectal reconstruction after abdominoperineal excision of the rectum. Mander BJ, et al. **Ann Surg** 1996 Dec;224(6):702–9; discussion 709–11

Extent of smooth muscle resection during mucosectomy and ileal pouch-anal anastomosis affects anorectal physiology and functional outcome [published erratum appears in Dis Colon Rectum 1997 Jul;40(7):763] Becker JM, et al. **Dis Colon Rectum** 1997 Jun;40(6):653–60

Lack of correlation of anorectal manometry with symptoms of chronic childhood constipation and encopresis. Borowitz SM, et al. **Dis Colon Rectum** 1996 Apr;39(4):400–5

Restorative proctocolectomy for idiopathic megarectum: postoperative recovery of hypotonic anal sphincters. Report of two cases. Brown SR, et al. **Dis Colon Rectum** 1997 May;40(5):625–7

Prospective trial of pelvic floor retraining in patients with fecal incontinence. Rieger NA, et al. **Dis Colon Rectum** 1997 Jul;40(7):821–6

Disturbances in anorectal function in patients with diabetes mellitus and faecal incontinence. Sun WM, et al. **Eur J Gastroenterol Hepatol** 1996 Oct;8(10):1007–12

Prospective controlled trial of duplicated (J) versus quadruplicated (W) pelvic ileal reservoirs in restorative proctocolectomy for ulcerative colitis. Johnston D, et al. **Gut** 1996 Aug;39(2):242–7

Paroxysmal anal hyperkinesis: a characteristic feature of proctalgia fugax. Rao SS, et al. **Gut** 1996 Oct;39(4):609–12

Paradoxical sphincter contraction is rarely indicative of anismus. Voderholzer WA, et al. **Gut** 1997 Aug; 41(2):258–62

Post-operative faecal continence in patients with ulcerative colitis after ileo-anal anastomosis with preservation of the transitional zone: a report from a low-incidence region. Orsoni P, et al. **Int J Colorectal Dis** 1997;12(4):209–13

Anterior rectocele and anorectal dysfunction. Pucciani F, et al. **Int J Colorectal Dis** 1996;11(1):1–9

Who should care for anorectal dysfunction in women? [editorial] Sangalli MR, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1996;7(1):1–2

Continence and rectoanal sphincteric inhibitory reflex after posterior sagittal anorectoplasty. Lin CL, et al. **J Formos Med Assoc** 1996 Apr;95(4):303–7

Anorectal dysfunction in systemic sclerosis. Kim KC, et al. **J Korean Med Sci** 1996 Jun;11(3):244–9

Disturbances of ano-rectal function in multiple sclerosis. Nordenbo AM, et al. **J Neurol** 1996 Jun;243(6):445–51

External anal sphincter dysfunction and postoperative bowel habits of patients with Hirschsprung's disease. Kubota M, et al. **J Pediatr Surg** 1997 Jan;32(1):22–4

Electromyography of the external anal sphincter in patients with Parkinson's disease and multiple system atrophy: frequency of abnormal spontaneous activity and polyphasic motor unit potentials. Schwarz J, et al. **Muscle Nerve** 1997 Sep;20(9):1167–72

Anorectal anomalies: anorectal manometric function and anal endosonography in relation to functional outcome. Emblem R, et al. **Pediatr Surg Int** 1997 Sep;12(7):516–9

Primary and secondary disorders to gut muscle and nerve. Kamm MA. **Scand J Gastroenterol Suppl** 1996;220:91–3 (17 ref.)

[Initial experience with anorectal manometry with the PC Polygraf apparatus in surgery] Slauf P, et al. **Rozhl Chir** 1997 Mar;76(3):151–5 (Eng. Abstr.) **(Cze)**

[Reproducibility of conventional anorectal manometry] Freys SM, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997; 114:445–50 (Eng. Abstr.) **(Ger)**

[Anorectal physiological tests: indication and relevance (editorial)] von Flüe M. **Schweiz Rundsch Med Prax** 1996 Nov 12;85(46):1465–7 **(Ger)**

[The functional and morphological changes in the intestinal sphincter apparatus created by muscle flaps on a fixed vascular-neural pedicle] Tat'ianchenko VK, et al. **Morfologiia** 1995;108(3):67–71 (Eng. Abstr.) **(Rus)**

[Paraplegia with sphincter function. An unusual complication of mycoplasma infection] Lindholm AC, et al. **Lakartidningen** 1997 Feb 19;94(8):622, 627–8 **(Swe)**

RADIATION EFFECTS

Effect of radiotherapy on anorectal function in patients with cervical cancer. Iwamoto T, et al. **Dis Colon Rectum** 1997 Jun;40(6):693–7

Late effects of integrated therapies, including IORT, on lumbosacral plexus and anorectal physiology in patients treated for rectal cancer. Ratto C, et al. **Front Radiat Ther Oncol** 1997;31:41–4

RADIOGRAPHY

Dynamic MR imaging compared with evacuation proctography when evaluating anorectal configuration and pelvic floor movement. Healy JC, et al. **AJR Am J Roentgenol** 1997 Sep;169(3):775–9

RADIONUCLIDE IMAGING

Imaging of anorectal function [letter; comment] Notghi A, et al. **Br J Radiol** 1997 May;70(833):545–6. Comment on: Br J Radiol 1996 Nov;69(827):985–8.

SECRETION

Additional sulfur compounds from the anal glands of the striped polecat, Ictonyx striatus (Mustelidae, Mammalia). Wheeler JW, et al. **Z Naturforsch [C]** 1997 Mar–Apr; 52(3–4):283–5

SURGERY

Re: Reconstruction of anal and perianal defects [letter; comment] Peled IJ. **Ann Plast Surg** 1997 Mar;38(3):306. Comment on: Ann Plast Surg 1996 Sep;37(3):340–1.

V-Y advancement posterior thigh fasciocutaneous flaps for total anal canal and large perianal defects [letter] [see comments] Terashi H, et al. **Ann Plast Surg** 1996 Sep; 37(3):340–1. Comment in: Ann Plast Surg 1997 Mar;38(3):306.

Postanal repair for faecal incontinence: long-term follow-up. Rieger NA, et al. **Aust N Z J Surg** 1997 Aug;67(8):566–70 (19 ref.)

Surgical correction of anorectal atresia and rectovaginal fistula in an alpaca cria. Carraro DB, et al. **Aust Vet J** 1996 Nov;74(5):352–4

Removal of the anus during proctectomy. Frizelle FA, et al. **Br J Surg** 1997 Jan;84(1):68

Removal of the anus during proctectomy [letter] Windsor AC, et al. **Br J Surg** 1997 Aug;84(8):1176

Progressive release of the left colon for a tension-free colorectal or coloanal anastomosis. Sugarbaker PH. **Cancer Treat Res** 1996;82:255–61

Local nitroglycerin for treatment of anal fissures: an alternative to lateral sphincterotomy? Bacher H, et al. **Dis Colon Rectum** 1997 Jul;40(7):840–5

Prospective evaluation of local excision for small rectal cancers. Bleday R, et al. **Dis Colon Rectum** 1997 Apr; 40(4):388–92

Open vs. closed sphincteroplasty for chronic anal fissure: long-term results. Garcia-Aguilar J, et al. **Dis Colon Rectum** 1996 Apr;39(4):440–3

Total anorectal reconstruction with a double dynamic graciloplasty after abdominoperineal reconstruction for low rectal cancer. Geerdes BP, et al. **Dis Colon Rectum** 1997 Jun;40(6):698–705

Assessment of a novel implantable artificial anal sphincter. Hajivassiliou CA, et al. **Dis Colon Rectum** 1997 Jun; 40(6):711–7

Lateral internal sphincterotomy for fissure-in-ano—revisited. Hananel N, et al. **Dis Colon Rectum** 1997 May; 40(5):597–602

Biofeedback improves functional outcome after sphincteroplasty. Jensen LL, et al. **Dis Colon Rectum** 1997 Feb;40(2):197–200

Results of artificial sphincter in severe anal incontinence. Report of 14 consecutive implantations. Lehur PA, et al. **Dis Colon Rectum** 1996 Dec;39(12):1352–5

Technique of local anesthesia for anorectal surgery [letter] Nivatvongs S. **Dis Colon Rectum** 1997 Sep;40(9):1128–9

Artificial anal sphincter. Wong WD, et al. **Dis Colon Rectum** 1996 Dec;39(12):1345–51

Idiopathic non-familial rectal and colonic varices requiring sigmoidorectal resection and coloanal anastomosis. Detry RJ, et al. **Eur J Gastroenterol Hepatol** 1996 Oct; 8(10):1023–6 (32 ref.)

Transanal surgery with a new anal retractor and a stapler for tumours in the proximal rectum. Maeda K, et al. **Eur J Surg** 1997 Mar;163(3):219–21

Coloanal anastomosis for benign lesions: long term functional results in 11 patients. Panis Y, et al. **Eur J Surg** 1996 Jul; 162(7):555–9

Obturator internus muscle autotransfer: a new concept for the treatment of anismus. Clinical experience. Farag A. **Eur Surg Res** 1997;29(1):42–51

Surveillance of familial adenomatous polyposis patients after ileorectal anastomosis or ileoanal pouch anastomosis. Tytgat GNJ. **Gastrointest Endosc Clin N Am** 1997 Jan; 7(1):111–27 (55 ref.)

Vaginal repair of rectocele after dynamic graciloplasty for fecal incontinence due to imperforate anus. Altomare DF, et al. **Int J Colorectal Dis** 1996;11(5):243–5

Clinico-physiological results after sphincter-saving resection for rectal carcinoma. Ikeuchi H, et al. **Int J Colorectal Dis** 1996;11(4):172–6

Internal anal sphincter repair. Leroi AM, et al. **Int J Colorectal Dis** 1997;12(4):243–5

Functional outcome after coloanal versus low colorectal anastomosis for rectal carcinoma. Benoist S, et al. **J Am Coll Surg** 1997 Aug;185(2):114–9

Continence and rectoanal sphincteric inhibitory reflex after posterior sagittal anorectoplasty. Lin CL, et al. **J Formos Med Assoc** 1996 Apr;95(4):303–7

Internal sphincterotomy in post-pull-through Hirschsprung's disease. Blair GK, et al. **J Pediatr Surg** 1996 Jun;31(6):843–5

Anteriorly located anus: is constipation caused by abnormal location of the anus? Fukunaga K, et al. **J Pediatr Surg** 1996 Feb;31(2):245–6

The rectoanal relaxation reflex and continence in repaired anorectal malformations with and without an internal sphincter-saving procedure. Lin CL, et al. **J Pediatr Surg** 1996 May;31(5):630–3

Anal reeducation for postoperative fecal incontinence in congenital diseases of the rectum and anus. Ménard C, et al. **J Pediatr Surg** 1997 Jun;32(6):867–9

Anterior sagittal anorectoplasty for anorectal malformations and perineal trauma in the female child. Wakhlu A, et al. **J Pediatr Surg** 1996 Sep;31(9):1236–40

One-stage neonatal pull-through to treat Hirschsprung's disease. Wilcox DT, et al. **J Pediatr Surg** 1997 Feb; 32(2):243–5; discussion 245–7

Paediatric rectal prolapse in Rwanda. Chaloner EJ, et al. **J R Soc Med** 1996 Dec;89(12):688–9

Avoiding stomas with total anorectal reconstruction [news] Jack D. **Lancet** 1997 Jun 14;349(9067):1750

Current aspects of sphincter preservation in the surgical therapy of rectal cancer. Schlag PM. **Recent Results Cancer Res** 1996;142:249–56 (25 ref.)

Anal fissure: new concepts in pathogenesis and treatment. Schouten WR, et al. **Scand J Gastroenterol Suppl** 1996; 218:78–81 (34 ref.)

Functional results after "high" coloanal anastomosis and "low" coloanal anastomosis with a colonic J-pouch for rectal carcinoma. Ikeuchi H, et al. **Surg Today** 1997;27(8):702–5

Abdominopreanal proctocolectomy and ileal U-pouch in ulcerative colitis or familial adenomatous polyposis. Oh NG. **Surg Today** 1996;26(11):861–8

Functional perineal colostomy with pudendal nerve anastomosis following anorectal resection: a cadaver operation study on a new procedure. Sato T, et al. **Surgery** 1997 May;121(5):569–74

[Results of deep rectum resection and intersphincteric rectum excision] Bruch HP, et al. **Chirurg** 1997 Jul;68(7):689–92 (Eng. Abstr.) **(Ger)**

[Is sphincter-plasty for treatment of fecal incontinence in patients older than 60 justified?] Pfeifer J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:474–6 (Eng. Abstr.) **(Ger)**

[Indications and outcome of anal sphincter myectomy in childhood] Wessel L, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:1047–52 (Eng. Abstr.) **(Ger)**

[Results with a new therapy concept in anal fistula: suture of the anal sphincter] Gemsenjäger E. **Schweiz Med Wochenschr** 1996 Nov 23;126(47):2021–5 (Eng. Abstr.) **(Ger)**

[Ultra-low laparoscopic rectal resection and colo-anal anastomosis. Experimental study on swine] Rea R, et al. **Ann Ital Chir** 1996 May-Jun;67(3):425–33; discussion 433–4 (Eng. Abstr.) **(Ita)**

[Surgical therapy of chronic constipation in pediatric age] Ponticelli A, et al. **Minerva Pediatr** 1996 May;48(5):217–20 (Eng. Abstr.) **(Ita)**

[Peritoneo-anal resection with remucosation of the anal canal in the treatment of cancer of the middle ampullary section of the rectum] Bondar' GV, et al. **Klin Khir** 1996;(4):8–10 **(Rus)**

[Abdomino-anal resection of the rectum with the bringing down of the demesenterized colon into the anal canal] Bondar' GV, et al. **Klin Khir** 1997;(1):31–3 (Eng. Abstr.) **(Rus)**

[Use of peritoneo-anal resection with levator sphincteroplasty in the treatment of cancer of the lower ampullary part of the rectum] Bondar' GV, et al. **Klin Khir** 1996;(6):22–4 **(Rus)**

[The treatment of acute reflex urinary retention after operations in the area of the rectal sphincter] Iaitskiĭ NA, et al. **Vestn Khir Im I I Grek** 1996;155(6):80–1 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Transvaginal versus anal endosonography for detecting damage to the anal sphincter. Frudinger A, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1435–8

Comparison of anal sonography with conventional needle electromyography in the evaluation of anal sphincter defects [see comments] Enck P, et al. **Am J Gastroenterol** 1996 Dec;91(12):2539–43. Comment in: Am J Gastroenterol 1997 May;92(5):907.

How reproducible are measures of the anal sphincter muscle diameter by endoanal ultrasound? Enck P, et al. **Am J Gastroenterol** 1997 Feb;92(2):293–6

Exoanal ultrasound of the anal sphincter: normal anatomy and sphincter defects. Peschers UM, et al. **Br J Obstet Gynaecol** 1997 Sep;104(9):999–1003

Clinical, manometric and sonographic assessment of the anal sphincters. A comparative prospective study. Favetta U, et al. **Int J Colorectal Dis** 1996;11(4):163–6

A comparison of anal endosonography with electromyography and manometry in high and intermediate anorectal anomalies. Fukata R, et al. **J Pediatr Surg** 1997 Jun;32(6):839–42

Endoanal magnetic resonance imaging versus endosonography. Stoker J, et al. **Radiol Med (Torino)** 1996 Dec;92(6):738–41

[Role of anal endosonography in inflammation and trauma of the anal canal] Brunese L, et al. **Radiol Med (Torino)** 1996 Dec;92(6):742–7 (Eng. Abstr.) **(Ita)**

[A new test for the diagnosis of anismus: dynamic endoanal echography (letter)] Navarro A, et al. **Rev Esp Enferm Dig** 1996 Nov;88(11):814–5 **(Spa)**

ANUS, ARTIFICIAL see **COLOSTOMY**

ANUS DISEASES

Anogenital warts in children. Siegfried EC, et al. **Adv Dermatol** 1997;12:141–66; discussion 167

Anogenital warts in children. Obalek S, et al. **Clin Dermatol** 1997 May-Jun;15(3):369–76 (58 ref.)

Anogenital warts. von Krogh G, et al. **Clin Dermatol** 1997 May-Jun;15(3):355–68 (92 ref.)

Condyloma acuminata in infants and children. A survey of colon and rectal surgeons. Budayr M, et al. **Dis Colon Rectum** 1996 Oct;39(10):1112–5

Perianal Crohn's disease [comment] O'Donoghue DP, et al. **Eur J Gastroenterol Hepatol** 1997 Mar;9(3):235–6 (11 ref.) . Comment on: Eur J Gastroenterol Hepatol 1997 Mar;9(3):239–43.

CHEMICALLY INDUCED

[Perianal ergotismus gangraenosus] Brandt O, et al. **Hautarzt** 1997 Mar;48(3):199–202 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Severe complications of perianal sepsis in patients with human immunodeficiency virus [letter] Sarela AI. **Br J Surg** 1996 Nov;83(11):1655–6

Vesicular dermatitis of the hands secondary to perianal allergic contact dermatitis caused by preservatives in moistened toilet tissues. de Groot AC. **Contact Dermatitis** 1997 Mar;36(3):173–4

Anogenital lichen sclerosus in women. Thomas RH, et al. **J R Soc Med** 1996 Dec;89(12):694–8

[Perianal dermatitis] Mauss J. **Ther Umsch** 1997 Apr; 54(4):205–8 (Eng. Abstr.) **(Ger)**

[A pelvic and abdominal wall abscess secondary to a perianal abscess (letter)] Acea Nebril B, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):69–70 **(Spa)**

DIAGNOSIS

Perianal condylomata acuminata. Hoang P, et al. **Acta Gastroenterol Belg** 1996 Jul-Sep;59(3):214–6 (28 ref.)

Pediatric case of the day. Streptococcal myositis and perianal cellulitis. Berlin SC, et al. **AJR Am J Roentgenol** 1997 Jul; 169(1):303, 306–7

Comparison of anal sonography with conventional needle electromyography in the evaluation of anal sphincter defects [see comments] Enck P, et al. **Am J Gastroenterol** 1996 Dec;91(12):2539–43. Comment in: Am J Gastroenterol 1997 May;92(5):907.

Evaluation of anal sphincter defects [letter; comment] Wald A. **Am J Gastroenterol** 1997 May;92(5):907. Comment on: Am J Gastroenterol 1996 Dec;91(12):2539–43.

Clinical presentation and natural course of anogenital warts. Handsfield HH. **Am J Med** 1997 May 5;102(5A):16–20 (13 ref.)

Latent and subclinical HPV external anogenital infection. Barrasso R. **Clin Dermatol** 1997 May-Jun;15(3):349–53 (22 ref.)

Internal anal sphincter myopathy causing proctalgia fugax and constipation: further clinical and radiological characterization in a patient. Guy RJ, et al. **Eur J Gastroenterol Hepatol** 1997 Feb;9(2):221–4

Anal lesions: any significant prognosis in Crohn's disease? [see comments] Siproudhis L, et al. **Eur J Gastroenterol Hepatol** 1997 Mar;9(3):239–43. Comment in: Eur J Gastroenterol Hepatol 1997 Mar;9(3):235–6.

Imaging of the anorectal region. Hussain SM, et al. **Eur J Radiol** 1996 May;22(2):116–22 (19 ref.)

Perianal complications of Crohn disease: MR imaging findings. Laniado M, et al. **Eur Radiol** 1997;7(7):1035–42

Clinical diagnostic accuracy of faecal occult blood test for anal diseases. Nakama H, et al. **Int J Qual Health Care** 1997 Apr;9(2):139–41

MR imaging of anorectal Crohn disease: a pictorial essay. O'Donovan AN, et al. **Radiographics** 1997 Jan-Feb; 17(1):101–7

[Anorectal abscess and fistula] De Lorenzi D. **Ther Umsch** 1997 Apr;54(4):197–201 (Eng. Abstr.) **(Ger)**

DIET THERAPY

Red pepper effect [letter] Brooks MH, et al. **Br J Gen Pract** 1996 Dec;46(413):759

DRUG THERAPY

Safety and efficacy of Virend for topical treatment of genital and anal herpes simplex lesions in patients with AIDS. Orozco-Topete R, et al. **Antiviral Res** 1997 Jul;35(2):91–103

Treatment of acyclovir-resistant perianal herpetic ulceration with intramuscular interferon alfa. Borrego L, et al. **Arch Dermatol** 1996 Oct;132(10):1157–8

[Symptomatic efficacy of clotrimazole combined with surgery in the treatment of recurring anal and genital condylomatosis in seropositive and AIDS patients] Erenbourg L, et al. **Minerva Med** 1996 Sep;87(9):433–5 (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIV-seropositive women. Hillemanns P, et al. **AIDS** 1996 Dec;10(14):1641–7

Contact sensitivity in women with anogenital dermatoses. Goldsmith PC, et al. **Contact Dermatitis** 1997 Mar; 36(3):174–5

Anorectal disease: risk factors and delay in presentation in the United Arab Emirates [letter] Alathmani FK, et al. **J Public Health Med** 1996 Dec;18(4):486–7

Epidemiology of anogenital warts and cancer. Franco EL. **Obstet Gynecol Clin North Am** 1996 Sep;23(3):597–623 (114 ref.)

ETIOLOGY

Severe anal condylomata acuminata following high-dose chemotherapy and autologous hematopoietic stem cell transplantation: a case report. D'Hondt L, et al. **Acta Gastroenterol Belg** 1996 Oct-Dec;59(4):254–5

Can women with intrapartum rupture of anal sphincter still suffer after-effects two decades later? Haadem K, et al. **Acta Obstet Gynecol Scand** 1997 Jul;76(6):601–3

Skin disorders in organ transplant recipients. External anogenital lesions [editorial; comment] Penn I. **Arch Dermatol** 1997 Feb;133(2):221–3. Comment on: Arch Dermatol 1997 Feb;133(2):175–8.

Disruption of the internal anal sphincter can occur after transanal stapling. Farouk R, et al. **Br J Surg** 1996 Oct; 83(10):1400

Low malignant potential of the double-stapled ileal pouch-anal anastomosis. Haray PN, et al. **Br J Surg** 1996 Oct;83(10):1406

Double Y-V plasty for postsurgical anal stricture. Neelakandan B. **Br J Surg** 1996 Nov;83(11):1599

Perianal sepsis in children. Nix P, et al. **Br J Surg** 1997 Jun; 84(6):819–21

Perianal abscess in Crohn's disease. Makowiec F, et al. **Dis Colon Rectum** 1997 Apr;40(4):443–50

Outcome of the pelvic pouch procedure in patients with prior perianal disease. Richard CS, et al. **Dis Colon Rectum** 1997 Jun;40(6):647–52

Pudendal canal syndrome and proctalgia fugax [letter] Shafik A. **Dis Colon Rectum** 1997 Apr;40(4):504

Prevalence and factors influencing hemorrhoids, anorectal varices, and colopathy in patients with portal hypertension. Misra SP, et al. **Endoscopy** 1996 May;28(4):340–5

Anorectal diseases. Parè AA, et al. **Gastroenterol Clin North Am** 1997 Jun;26(2):367–76 (68 ref.)

Disturbed anal sphincter function following vaginal delivery. Wynne JM, et al. **Gut** 1996 Jul;39(1):120–4

Inflammatory cloacogenic polyp: an unrecognized cause of hematochezia and tenesmus in childhood. Poon KK, et al. **J Pediatr** 1997 Feb;130(2):327–9 (13 ref.)

Anal tenesmus caused by seminal vesicle cyst. Callewaert P, et al. **Urology** 1997 Jan;49(1):139–41

[Perianal manifestations in Crohn's disease] Teixeira MG, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Jul-Aug; 51(4):125–30 (Eng. Abstr.) **(Por)**

[Anorectal diseases in patients with human immunodeficiency virus (HIV) infection] Rius J, et al. **Rev Gastroenterol Mex** 1996 Apr-Jun;61(2):139–46 (18 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Abnormal internal anal sphincter innervation in patients with Hirschsprung's disease and allied disorders. Kobayashi H, et al. **J Pediatr Surg** 1996 Jun;31(6):794–9

MICROBIOLOGY

Perianal streptococcal dermatitis in adults. Neri I, et al. **Br J Dermatol** 1996 Nov;135(5):796–8

Anal and cervical abnormality in women--prediction by human papillomavirus tests. Melbye M, et al. **Int J Cancer** 1996 Nov 27;68(5):559–64

Anal and perianal tuberculosis: a report of three cases in 10 years. Chung CC, et al. **J R Coll Surg Edinb** 1997 Jun; 42(3):189–90 (6 ref.)

Outbreak of perianal Streptococcus pyogenes infection in a day-care center. Saxén H, et al. **Pediatr Infect Dis J** 1997 Feb;16(2):247–9

[Perianal streptococcal dermatitis in children] van Zeijl JH, et al. **Ned Tijdschr Geneeskd** 1996 Nov 2;140(44):2191–3 (Eng. Abstr.) **(Dut)**

[Streptococcal perianal disease] García Puga JM, et al. **An Esp Pediatr** 1996 Dec;45(6):647–8 (19 ref.) **(Spa)**

PARASITOLOGY

[Perianal abscess caused by Enterobius vermicularis (letter)] López-Vélez R, et al. **Enferm Infecc Microbiol Clin** 1997 Apr;15(4):228 **(Spa)**

PATHOLOGY

Comparison of conventional cytologic smears and ThinPrep preparations from the anal canal. Darragh TM, et al. **Acta Cytol** 1997 Jul-Aug;41(4):1167–70

Atypical localization of cutaneous leishmaniasis [letter] Aste N, et al. **Acta Derm Venereol** 1997 Jan;77(1):85–6

External anogenital lesions in organ transplant recipients. A clinicopathologic and virologic assessment [see comments] Euvrard S, et al. **Arch Dermatol** 1997 Feb;133(2):175–8. Comment in: Arch Dermatol 1997 Feb;133(2):221–3.

Infantile perianal pyramidal protrusion. Kayashima K, et al. **Arch Dermatol** 1996 Dec;132(12):1481–4

Unilateral perianogenital papulokeratotic lesion. Inflammatory linear verrucous epidermal nevus (ILVEN). Opršalova K, et al. **Arch Dermatol** 1996 Dec; 132(12):1508–9, 1511–2

Ulcerative perianal lichen planus [letter] Payne CM, et al. **Br J Dermatol** 1997 Mar;136(3):479

Perianal cytomegalovirus ulcer in an HIV-infected patient. Aloi F, et al. **Dermatology** 1996;192(1):81–3

Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease. Palefsky JM, et al. **Genitourin Med** 1997 Jun; 73(3):174–80

Anogenital skin diseases of childhood. Siegfried EC, et al. **Pediatr Ann** 1997 May;26(5):321–31

Biliary, anorectal and esophageal atresia: a new entity? Dessanti A, et al. **Tohoku J Exp Med** 1997 Jan;181(1):49–55

[Cutaneous malacoplakia in a patient with psoriasis vulgaris] Schaller J, et al. **Hautarzt** 1996 Oct;47(10):763–6 (Eng. Abstr.) **(Ger)**

[Case of the month] Buchmann P. **Ther Umsch** 1997 Apr; 54(4):209–10 **(Ger)**

PHYSIOPATHOLOGY

Anal sensitivity test: what does it measure and do we need it? Cause or derivative of anorectal complaints. Felt-Bersma RJ, et al. **Dis Colon Rectum** 1997 Jul; 40(7):811–6

Anorectal disorders. Janicke DM, et al. **Emerg Med Clin North Am** 1996 Nov;14(4):757–88 (83 ref.)

Paroxysmal anal hyperkinesis: a characteristic feature of proctalgia fugax. Rao SS, et al. **Gut** 1996 Oct;39(4):609–12

Paradoxical sphincter contraction is rarely indicative of anismus. Voderholzer WA, et al. **Gut** 1997 Aug; 41(2):258–62

Physiology and pathophysiology of anal function. Rasmussen OO, et al. **Scand J Gastroenterol Suppl** 1996;216:169–74 (46 ref.)

[A new approach of functional recto-anal exploration: the compliance of the rectum and the anal canal] Arsac M, et al. **Bull Acad Natl Med** 1996 Apr;180(4):747–64; discussion 765–8 (Eng. Abstr.) **(Fre)**

SURGERY

Anorectal surgery in patients infected with human immunodeficiency virus: factors associated with delayed wound healing. Lord RV. **Ann Surg** 1997 Jul;226(1):92–9

Randomized comparison of agents for caudal anaesthesia in anal surgery [letter; comment] Chan MT, et al. **Br J Surg** 1996 Sep;83(9):1300. Comment on: Br J Surg 1996 Mar;83(3):364–5.

Surgical management of anorectal incontinence due to internal anal sphincter deficiency. Morgan R, et al. **Br J Surg** 1997 Feb;84(2):226–30

Operative results of House advancement anoplasty. Sentovich SM, et al. **Br J Surg** 1996 Sep;83(9):1242–44

Anal transitional zone and columnar cuff in restorative proctocolectomy. Thompson-Fawcett MW, et al. **Br J Surg** 1996 Aug;83(8):1047–55 (104 ref.)

Anorectal abscesses: need for accurate anatomical localization of the disease. Nomikos IN. **Clin Anat** 1997; 10(4):239–44

Treatment of colorectal and ileoanal anastomotic sinuses. Whitlow CB, et al. **Dis Colon Rectum** 1997 Jul;40(7):760–3

IIIrd European Workshop on Digestive Surgery. Brussels, Belgium, 13–14 May 1997. **Int J Colorectal Dis** 1997; 12(2):97–105

Anorectal stenosis in a neonate: report of a case and review of the Japanese literature. Hamada Y, et al. **Surg Today** 1996;26(10):814–7 (20 ref.)

[Study of early postoperative lactitol versus paraffin following anal surgery in 110 adult patients] Copé R, et al. **Ann Chir** 1996;50(7):570–6 (Eng. Abstr.) **(Fre)**

[Ambulatory anal surgery: a feasibility study] Martel E, et al. **Ann Chir** 1996;50(8):589–92 (Eng. Abstr.) **(Fre)**

[Symptomatic efficacy of clotrimazole combined with surgery in the treatment of recurring anal and genital condylomatosis in seropositive and AIDS patients] Erenbourg L, et al. **Minerva Med** 1996 Sep;87(9):433–5 (Eng. Abstr.) **(Ita)**

[Simultaneous treatment of an anal abscess and fistula] Vrzgula A, et al. **Rozhl Chir** 1996 Apr;75(4):219–21 (Eng. Abstr.) **(Slo)**

THERAPY

Perianal condylomata acuminata. Hoang P, et al. **Acta Gastroenterol Belg** 1996 Jul-Sep;59(3):214–6 (28 ref.)

Aggressive giant condyloma acuminatum associated with oncogenic human papilloma virus: a case report. Kibrité A, et al. **Can J Surg** 1997 Apr;40(2):143–5 (10 ref.)

Biofeedback is effective treatment for levator ani syndrome. Heah SM, et al. **Dis Colon Rectum** 1997 Feb;40(2):187–9

Primary care office management of perianal and anal disease. Nagle D, et al. **Prim Care** 1996 Sep;23(3):609–20 (27 ref.)

ULTRASONOGRAPHY

Comparison of anal sonography with conventional needle electromyography in the evaluation of anal sphincter defects [see comments] Enck P, et al. **Am J Gastroenterol** 1996 Dec;91(12):2539–43. Comment in: Am J Gastroenterol 1997 May;92(5):907.

Exoanal ultrasound of the anal sphincter: normal anatomy and sphincter defects. Peschers UM, et al. **Br J Obstet Gynaecol** 1997 Sep;104(9):999–1003

Anal sphincter disorders. Bartram CI. **Gastrointest Endosc** 1996 Feb;43(2 Pt 2):S32–4

[Transanal ultrasonography in the study of fistulas of perianal abscess] Piccinini EE, et al. **Minerva Chir** 1996 Sep; 51(9):653–9 (Eng. Abstr.) **(Ita)**

VIROLOGY

Clinical presentation and natural course of anogenital warts. Handsfield HH. **Am J Med** 1997 May 5;102(5A):16–20 (13 ref.)

External anogenital lesions in organ transplant recipients. A clinicopathologic and virologic assessment [see comments] Euvrard S, et al. **Arch Dermatol** 1997 Feb;133(2):175–8. Comment in: Arch Dermatol 1997 Feb;133(2):221–3.

Asymptomatic perianal shedding of herpes simplex virus in patients with acquired immunodeficiency syndrome. Pannuti CS, et al. **Arch Dermatol** 1997 Feb;133(2):180–3

Perianal herpes zoster presenting as suspected child abuse. Christian CW, et al. **Pediatrics** 1997 Apr;99(4):608–10

ANUS, IMPERFORATE

Hirschsprung's disease, imperforate anus, and Down's syndrome: a case report. Flageole H, et al. **J Pediatr Surg** 1996 Jun;31(6):759–60

Imperforate anus (anal agenesis) with rectal and sigmoid atresias in a newborn. Ein SH. **Pediatr Surg Int** 1997 Jul; 12(5–6):449–51

[Townes-Brocks syndrome] Ishikiriyama S. **Ryoikibetsu Shokogun Shirizu** 1996;(15):305–6 (8 ref.) **(Jpn)**

COMPLICATIONS

Anorectal malformation with ileal atresia. Asabe K, et al. **Pediatr Surg Int** 1997 Apr;12(4):302–4 (9 ref.)

Imperforate anus (anal agenesis) with rectal and sigmoid atresias in a newborn. Ein SH. **Pediatr Surg Int** 1997 Jul; 12(5–6):449–51

DIAGNOSIS

Perinatal features of omphalocele-exstrophy-imperforate anus-spinal defects (OEIS complex) associated with large meningomyeloceles and severe limb defects. Chen CP, et al. **Am J Perinatol** 1997 May;14(5):275–9

Additional congenital defects in anorectal malformations. Hassink EA, et al. **Eur J Pediatr** 1996 Jun;155(6):477–82

Are congenital malformations in older people underdiagnosed? [letter] Fernández-Viadero C, et al. **J Am Geriatr Soc** 1997 Jul;45(7):895–7

EPIDEMIOLOGY

Genital malformations and coexistent urinary tract or spinal anomalies in patients with imperforate anus. Metts JC 3rd, et al. **J Urol** 1997 Sep;158(3 Pt 2):1298–300

ETIOLOGY

Anal atresia: effect of smoking and drinking habits during pregnancy. Yuan P, et al. **Jpn J Hum Genet** 1995 Dec; 40(4):327–32

GENETICS

Evidence for a critical region for penoscrotal inversion, hypospadias, and imperforate anus within chromosomal region 13q32.2q34. Bartsch O, et al. **Am J Med Genet** 1996 Oct 28;65(3):218–21

Identification of a cat eye syndrome using DNA sequence dosage analysis. Bulle F, et al. **Ann Genet** 1996;39(3):139–43

Antley-Bixler syndrome. Description of two new cases and a review of the literature. Bottero L, et al. **Childs Nerv Syst** 1997 May;13(5):275–80; discussion 281 (19 ref.)

Caudal developmental field defect with female pseudohermaphroditism and VACTERL anomalies. Lukusa T, et al. **Genet Couns** 1996;7(3):207–12

The Currarino triad: its importance in pediatric neurosurgery. Gaskill SJ, et al. **Pediatr Neurosurg** 1996 Sep;25(3):143–6

HISTORY

The journal 100 & 150 years ago. New Orleans Medical and Surgical Journal. July 1847 & 1897. Colon G. **J La State Med Soc** 1997 Jul;149(6):231–3

PHYSIOPATHOLOGY

Neurovesical dysfunction due to spinal dysraphism in anorectal anomalies. Capitanucci ML, et al. **Eur J Pediatr Surg** 1996 Jun;6(3):159–62

RADIOGRAPHY

The use of augmented-pressure colostography in imperforate anus. Wang C, et al. **Pediatr Surg Int** 1997 Jul;12(5–6):383–5

SURGERY

Simplified colorrhaphy and posterior sagittal anorectoplasty for the management of congenital short colon with imperforate anus. Sharma AK, et al. **Br J Surg** 1997 Mar; 84(3):389

Acetylcholinesterase (ACE) staining shows the abnormal innervation of a pulled-through rectum in a case of repaired anorectal malformation. Shono T, et al. **Eur J Pediatr Surg** 1997 Aug;7(4):248–51

Vaginal repair of rectocele after dynamic graciloplasty for fecal incontinence due to imperforate anus. Altomare DF, et al. **Int J Colorectal Dis** 1996;11(5):243–5

Postoperative MRI of anorectal malformation. Li YW, et al. **J Formos Med Assoc** 1997 Mar;96(3):199–204

Urologic problems in anorectal malformations. Part 2: functional urologic sequelae. Boemers TM, et al. **J Pediatr Surg** 1996 May;31(5):634–7

Somatic function, mental health, and psychosocial adjustment of adolescents with anorectal anomalies. Diseth TH, et al. **J Pediatr Surg** 1996 May;31(5):638–43

The rectoanal relaxation reflex and continence in repaired anorectal malformations with and without an internal sphincter-saving procedure. Lin CL, et al. **J Pediatr Surg** 1996 May;31(5):630–3

Do children with repaired low anorectal malformations have normal bowel function? Rintala RJ, et al. **J Pediatr Surg** 1997 Jun;32(6):823–6

The anterior sagittal approach for high imperforate anus: a simplification of the Mollard approach. Sigalet DL, et al. **J Pediatr Surg** 1996 May;31(5):625–9

Accessory scrotum with imperforate anus. Rattan KN, et al. **Pediatr Surg Int** 1997 Feb;12(2–3):217

[Recto-cutaneous penile fistula. A description of a clinical case and review of the literature] Brunero M, et al. **Minerva Pediatr** 1996 Sep;48(9):393–6 (Eng. Abstr.) **(Ita)**

ANUS NEOPLASMS

The National Cancer Data Base report on carcinoma of the anus. Myerson RJ, et al. **Cancer** 1997 Aug 15;80(4):805–15

Anorectal melanoma in The Netherlands: a report of 63 patients. Roumen RM. **Eur J Surg Oncol** 1996 Dec; 22(6):598–601

Perianal fetal rhabdomyoma: case report. Lapner PC, et al. **Pediatr Surg Int** 1997 Sep;12(7):544–7 (26 ref.)

Anal leiomyosarcoma. Porwal KK, et al. **Trop Gastroenterol** 1996 Jul-Sep;17(3):187

[Malignant melanoma of the esophagus and anorectum] Stremmel C, et al. **Dtsch Med Wochenschr** 1996 Dec 13; 121(50):1573–5 (16 ref.) **(Ger)**

CHEMISTRY

Perianal basal cell carcinoma: a comparative histologic, immunohistochemical, and flow cytometric study with basaloid carcinoma of the anus. Alvarez-Cañas MC, et al. **Am J Dermatopathol** 1996 Aug;18(4):371–9

COMPLICATIONS

EBV-associated anorectal lymphomas in patients with acquired immune deficiency syndrome. Ioachim HL, et al. **Am J Surg Pathol** 1997 Sep;21(9):997–1006 (56 ref.)

Epidermoid anal cancer in HIV infected patients. Bottomley DM, et al. **Clin Oncol (R Coll Radiol)** 1996;8(5):319–22

Perianal Bowen's disease: associated tumors, human papillomavirus, surgery, and other controversies. Sarmiento JM, et al. **Dis Colon Rectum** 1997 Aug; 40(8):912–8

Perianal extramammary Paget's disease associated with

primary linitis plastica of the rectum: report of a case. Ikoma A, et al. **Surg Today** 1996;26(9):711–4

Adenocarcinoma in the anal canal associated with a fistula: report of a case. Taniguchi S, et al. **Surg Today** 1996; 26(9):707–10

CONGENITAL

Limb ring constriction. Mutsuddi M, et al. **J Indian Med Assoc** 1996 Feb;94(2):82

Congenital anorectal teratoma: report of a case. Jona JZ. **J Pediatr Surg** 1996 May;31(5):709–10

DIAGNOSIS

Anal canal cancer diagnosis: usefulness of serum tumor markers. Indinnimeo M, et al. **J Chemother** 1997 Apr; 9(2):121–2

Anal carcinoma: a 14 year experience. Gallén M, et al. **Rev Esp Enferm Dig** 1997 Jan;89(1):23–8 **(Eng, Spa)**

[Malignant anorectal melanoma: description of a clinical case and review of the literature] Malaguarnera M, et al. **Bull Cancer** 1997 Apr;84(4):423–6 (35 ref.) (Eng. Abstr.) **(Fre)**

[Non-Hodgkin's lymphoma with perianal localization in patients with acquired immunodeficiency syndrome: a case report] Bianchi C, et al. **Ann Ital Chir** 1996 Mar–Apr; 67(2):277–80 (Eng. Abstr.) **(Ita)**

[Primary gastrointestinal localization of N-H lymphoma: authors' experience] Versaci A, et al. **G Chir** 1997 Jun–Jul; 18(6–7):340–3 (40 ref.) (Eng. Abstr.) **(Ita)**

[Anal epidermoid carcinoma: a rare incidence or a rare diagnosis?] Prieto Reyes M, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):128–32 (53 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. Peiffert D, et al. **Ann Oncol** 1997 Jun;8(6):575–81

Radiation therapy and chemotherapy in the conservative treatment of carcinoma of the anal canal: survival and late morbidity in a series of 25 patients. Gabriele AM, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):653–6

The impact of treatment factors on local control in T2–T3 anal carcinomas treated by radiotherapy with or without chemotherapy. Allal AS, et al. **Cancer** 1997 Jun 15; 79(12):2329–35

Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Peddada AV, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 15;37(5):1101–5

Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. Bartelink H, et al. **J Clin Oncol** 1997 May; 15(5):2040–9

Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. Doci R, et al. **J Clin Oncol** 1996 Dec;14(12):3121–5

Management of carcinoma anal canal with combination chemotherapy and concurrent radiotherapy. Mishra RC, et al. **J Indian Med Assoc** 1996 Feb;94(2):53–4, 57

Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research [see comments] **Lancet** 1996 Oct 19; 348(9034):1049–54. Comment in: Lancet 1997 Jan 18;349(9046);205–6.

Combined radiotherapy and chemotherapy for anal cancer. EORTC Radiotherapy and Gastrointestinal Cooperative Groups [letter; comment] Bosset JF, et al. **Lancet** 1997 Jan 18;349(9046):205–6. Comment on: Lancet 1996 Oct 19;348(9034):1049–54.

A new mode of treatment of human papilloma virus associated anogenital lesions using a nonsteroid estrogen analogue. Schön HJ, et al. **Wien Klin Wochenschr** 1996; 108(2):45–7

[Outcome of simultaneous radiochemotherapy of anal carcinoma] Fraunholz IB, et al. **Zentralbl Chir** 1997; 122(1):39–43 (Eng. Abstr.) **(Ger)**

[The anal canal: 2 cycles of radiochemotherapy and boost brachytherapy] Valentini V, et al. **Radiol Med (Torino)** 1997 Apr;93(4):451–6 (38 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Glutathione S-transferase M1 genotypes and the risk of anal cancer: a population-based case-control study. Chen C, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Dec; 5(12):985–91

Cumulative risk of second primary cancers in women with index primary cancers of uterine cervix and incidence of lower anogenital tract cancers, Michigan, 1985–1992. Fisher G, et al. **Gynecol Oncol** 1997 Feb;64(2):213–23

Epidemiology of anogenital warts and cancer. Franco EL. **Obstet Gynecol Clin North Am** 1996 Sep;23(3):597–623 (114 ref.)

Malignant anal tumours in the Chinese population in Hong Kong. Leow CK, et al. **Surg Oncol** 1996 Apr;5(2):65–8

[The epidemiology, risk factors and prevention of anal cancer] Balagué Corbella M, et al. **Gastroenterol Hepatol** 1997 May;20(5):283–9 (65 ref.) **(Spa)**

[Anal epidermoid carcinoma: a rare incidence or a rare diagnosis?] Prieto Reyes M, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):128–32 (53 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Basal cell carcinoma arising in a fistula-in-ano. Kulaylat MN, et al. **Am Surg** 1996 Dec;62(12):1000–2 (26 ref.)

Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Arends MJ, et al. **Br J Cancer** 1997;75(5):722–8

Anal neoplasia. Pathogenesis, diagnosis, and management. Northfelt DW, et al. **Hematol Oncol Clin North Am** 1996 Oct;10(5):1177–87 (43 ref.)

Sexual behaviour and increased anal cancer. Ablin RJ, et al. **Immunol Cell Biol** 1997 Apr;75(2):181–3

Cancer in the anal canal (transitional zone) after restorative proctocolectomy with stapled ileal pouch-anal anastomosis. Sequens R. **Int J Colorectal Dis** 1997; 12(4):254–5

Cervical intraepithelial neoplasia, anogenital cancer, and other cancer types in women after hospitalization for condylomata acuminata. Friis S, et al. **J Infect Dis** 1997 Apr;175(4):743–8

[Malignant neoplasms and AIDS. Review of the literature and critical considerations on a case of epidermoid carcinoma of the anus] Romito A, et al. **Recenti Prog Med** 1997 Jul–Aug;88(7–8):348–55 (48 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Amplification and expression of the cyclin D1 gene in anal and esophageal squamous cell carcinomas. Sheyn I, et al. **Hum Pathol** 1997 Mar;28(3):270–6

METABOLISM

Keratin expression in anal carcinoma: an immunohistochemical study. Williams GR, et al. **Histopathology** 1997 May;30(5):443–50

Evaluation of the prognostic significance of nm23/NDP kinase and cathepsin D in anal carcinomas. An immunohistochemical study. Holm R, et al. **Virchows Arch** 1996 May;428(2):85–9

PATHOLOGY

Comparison of conventional cytologic smears and ThinPrep preparations from the anal canal. Darragh TM, et al. **Acta Cytol** 1997 Jul–Aug;41(4):1167–70

Perianal basal cell carcinoma: a comparative histologic, immunohistochemical, and flow cystometric study with basaloid carcinoma of the anus. Alvarez-Cañas MC, et al. **Am J Dermatopathol** 1996 Aug;18(4):371–9

Adenoma of anogenital mammary-like glands. Donati P, et al. **Am J Dermatopathol** 1996 Feb;18(1):73–6

Skin appendage involvement in anal intraepithelial neoplasia. Skinner PP, et al. **Br J Surg** 1997 May;84(5):675–8

Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Jay N, et al. **Dis Colon Rectum** 1997 Aug;40(8):919–28

A case of malignant melanoma in the anorectal region: colonoscopic features [letter] Amano K, et al. **Gastrointest Endosc** 1997 Jun;45(6):536–7

Adenocarcinoma of the anal glands. Behan WM, et al. **J Clin Pathol** 1996 Dec;49(12):1009–11

Primary anorectal melanomas: an istitutional experience. Rossetti C, et al. **J Exp Clin Cancer Res** 1997 Mar; 16(1):81–5

Perianal ependymoma presenting in the neonatal period. Webber EM, et al. **Pediatr Pathol Lab Med** 1997 Mar–Apr; 17(2):283–91

HPV-16-positive anal and penile carcinomas in a young man--anogenital 'field effect' in the immunosuppressed male? Frisch M, et al. **Scand J Infect Dis** 1996;28(6):629–32

Anal squamous cell cancer nodal metastases: prognostic significance and therapeutic considerations. Cohen AM, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):203–10

[Development of squamous cell carcinoma in chronic anal eczema and therapeutic consequences] Sommer B, et al. **Hautarzt** 1996 Nov;47(11):850–3 (Eng. Abstr.) **(Ger)**

[Case of the month] Buchmann P. **Ther Umsch** 1997 Apr; 54(4):209–10 **(Ger)**

[Anal and perianal tumors] Heitland W. **Ther Umsch** 1997 Apr;54(4):202–4 (Eng. Abstr.) **(Ger)**

[Adenocarcinoma of the anal glands. Description of a clinical case and review of the literature] Larghero GC, et al. **Minerva Chir** 1996 Jul-Aug;51(7–8):573–6 (Eng. Abstr.) **(Ita)**

[A case of invasive bladder cancer with Pagetoid skin lesion of the vulva and anogenital Paget's disease] Koga F, et al. **Nippon Hinyokika Gakkai Zasshi** 1997 Apr;88(4):503–6 (Eng. Abstr.) **(Jpn)**

[Inguinal lymphadenectomy in malignant anal tumors] Timofeev IuM. **Vopr Onkol** 1997;43(3):327–9 (Eng. Abstr.) **(Rus)**

[Verrucous carcinoma of the anal margin. The Buschke-Loewenstein tumor] Arcos Navarro A, et al. **Rev Esp Enferm Dig** 1997 Feb;89(2):125–7 (10 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Anal cytology as a screening tool for anal squamous intraepithelial lesions. Palefsky JM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1997 Apr 15;14(5):415–22

[The epidemiology, risk factors and prevention of anal cancer] Balagué Corbella M, et al. **Gastroenterol Hepatol** 1997 May;20(5):283–9 (65 ref.) **(Spa)**

RADIOGRAPHY

Giant fibrous polyp of the anal canal [letter] Van Gossum A, et al. **Acta Gastroenterol Belg** 1997 Apr-Jun;60(2):184

RADIOTHERAPY

Anal canal cancer: current treatment and results. Cummings BJ. **Ann Acad Med Singapore** 1996 May;25(3):460–7 (45 ref.)

Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. Peiffert D, et al. **Ann Oncol** 1997 Jun;8(6):575–81

Radiation therapy and chemotherapy in the conservative treatment of carcinoma of the anal canal: survival and late morbidity in a series of 25 patients. Gabriele AM, et al. **Anticancer Res** 1997 Jan–Feb;17(1B):653–6

The impact of treatment factors on local control in T2–T3 anal carcinomas treated by radiotherapy with or without chemotherapy. Allal AS, et al. **Cancer** 1997 Jun 15; 79(12):2329–35

Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Peddada AV, et al. **Int J Radiat Oncol Biol Phys** 1997 Mar 15;37(5):1101–5

Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Peiffert D, et al. **Int J Radiat Oncol Biol Phys** 1997 Jan 15;37(2):313–24

Conservative treatment by irradiation of epidermoid carcinomas of the anal margin. Peiffert D, et al. **Int J Radiat Oncol Biol Phys** 1997 Aug 1;39(1):57–66

Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. Bartelink H, et al. **J Clin Oncol** 1997 May; 15(5):2040–9

Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. Doci R, et al. **J Clin Oncol** 1996 Dec;14(12):3121–5

Management of carcinoma anal canal with combination chemotherapy and concurrent radiotherapy. Mishra RC, et al. **J Indian Med Assoc** 1996 Feb;94(2):53–4, 57

Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research [see comments] **Lancet** 1996 Oct 19; 348(9034):1049–54. Comment in: Lancet 1997 Jan 18;349(9046);205–6.

Combined radiotherapy and chemotherapy for anal cancer. EORTC Radiotherapy and Gastrointestinal Cooperative Groups [letter; comment] Bosset JF, et al. **Lancet** 1997 Jan 18;349(9046):205–6. Comment on: Lancet 1996 Oct 19;348(9034):1049–54.

Pulsed dose rate (PDR) brachytherapy of anal carcinoma. Roed H, et al. **Radiother Oncol** 1996 Nov;41(2):131–4

Squamous cell carcinoma of the anal margin treated with radiotherapy. Mendenhall WM, et al. **Surg Oncol** 1996 Feb; 5(1):29–35 (20 ref.)

[Outcome of simultaneous radiochemotherapy of anal carcinoma] Fraunholz IB, et al. **Zentralbl Chir** 1997; 122(1):39–43 (Eng. Abstr.) **(Ger)**

[The anal canal: 2 cycles of radiochemotherapy and boost brachytherapy] Valentini V, et al. **Radiol Med (Torino)** 1997 Apr;93(4):451–6 (38 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Control of pre-sacral haemorrhage by drawing pin tamponade. Stewart BT, et al. **Aust N Z J Surg** 1996 Oct; 66(10):715–6

Vulvoperineal reconstruction after excision of anogenital multifocal intraepithelial neoplasia ("MIN"). Thomas SS, et al. **Br J Plast Surg** 1996 Dec;49(8):539–46

Transanal endoscopic microsurgery. Initial registry results. Smith LE, et al. **Dis Colon Rectum** 1996 Oct;39(10 Suppl):S79–84

Anorectal melanoma--an incurable disease? Thibault C, et al. **Dis Colon Rectum** 1997 Jun;40(6):661–8

Anorectal malignant melanoma. Luna-Perez P, et al. **Surg Oncol** 1996 Aug;5(4):165–8

Anorectal malignant melanoma: report of a case. Nyui S, et al. **Surg Today** 1997;27(8):753–6

[Primary anorectal melanoma. Apropos of 19 cases] Dubé P, et al. **J Chir (Paris)** 1997 May;134(1):3–8 (Eng. Abstr.) **(Fre)**

[11 cases of anal Bowen's disease] Kreyden OP, et al. **Schweiz Med Wochenschr** 1996 Sep 7;126(36):1536–40 (Eng. Abstr.) **(Ger)**

[Inguinal lymphadenectomy in malignant anal tumors] Timofeev IuM. **Vopr Onkol** 1997;43(3):327–9 (Eng. Abstr.) **(Rus)**

THERAPY

Epidermoid anal cancer in HIV infected patients. Bottomley DM, et al. **Clin Oncol (R Coll Radiol)** 1996;8(5):319–22

Organ preservation in anal and rectal cancers. Willett CG. **Curr Opin Oncol** 1996 Jul;8(4):329–33 (25 ref.)

Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. Flam M, et al. **J Clin Oncol** 1996 Sep; 14(9):2527–39

Squamous cell carcinoma of the anal margin [see comments] Mendenhall WM, et al. **Oncology (Huntingt)** 1996 Dec; 10(12):1843–8; discussion 1848, 1853–4 (7 ref.). Comment in: Oncology (Huntingt) 1997 May;11(5):629–30.

More on the treatment of anal margin carcinomas [letter; comment] Takanishi DM Jr, et al. **Oncology (Huntingt)** 1997 May;11(5):629–30. Comment on: Oncology (Huntingt) 1996 Dec;10(12):1843–8; discussion 1848, 1853–4.

Anal squamous cell cancer nodal metastases: prognostic significance and therapeutic considerations. Cohen AM, et al. **Surg Oncol Clin N Am** 1996 Jan;5(1):203–10

[Malignant anorectal melanoma: description of a clinical case and review of the literature] Malaguarnera M, et al. **Bull Cancer** 1997 Apr;84(4):423–6 (35 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Anal sphincter disorders. Bartram CI. **Gastrointest Endosc** 1996 Feb;43(2 Pt 2):S32–4

VETERINARY

Anal leiomyoma in a Holstein heifer. Lopez MJ, et al. **Can Vet J** 1997 Jun;38(6):377–8

VIROLOGY

Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. Gaidano G, et al. **AIDS** 1996 Aug;10(9):941–9

HPV 16 infection in a patient with two primary squamous cell carcinomas: of the uterine cervix and the anal mucosa. Berner A, et al. **APMIS** 1997 Mar;105(3):207–12

Human papillomavirus type in anal epithelial lesions is influenced by human immunodeficiency virus. Unger ER, et al. **Arch Pathol Lab Med** 1997 Aug;121(8):820–4

Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers [see comments] Bjørge T, et al. **BMJ** 1997 Sep 13; 315(7109):646–9. Comment in: BMJ 1997 Sep 13;315(7109):620–1.

Is human papillomavirus an infectious cause of non-cervical anogenital tract cancers? [editorial; comment] Strickler HD, et al. **BMJ** 1997 Sep 13;315(7109):620–1. Comment on: BMJ 1997 Sep 13;315(7109):646–9.

Anogenital premalignant and malignant tumors (including Buschke-Löwenstein tumors). Grussendorf-Conen EI. **Clin Dermatol** 1997 May-Jun;15(3):377–88 (95 ref.)

Human papillomavirus-associated tumors of the skin and mucosa. Majewski S, et al. **J Am Acad Dermatol** 1997 May; 36(5 Pt 1):659–85; quiz 686–8 (272 ref.)

Anal human papillomavirus and anal cancer. Tilston P. **J Clin Pathol** 1997 Aug;50(8):625–34 (108 ref.)

Properties of HPV-positive and HPV-negative anal carcinomas. Williams GR, et al. **J Pathol** 1996 Dec; 180(4):378–82

Frequent association of human papillomavirus 16 and 18 DNA with anal squamous cell and basaloid carcinoma. Vincent-Salomon A, et al. **Mod Pathol** 1996 Jun; 9(6):614–20

The role of human papillomavirus in anogenital cancer. Pfister H. **Obstet Gynecol Clin North Am** 1996 Sep; 23(3):579–95 (110 ref.)

ANUS PROLAPSE see **RECTAL PROLAPSE**

ANXIETY

Kynurenines and anxiety. Lapin IP. **Adv Exp Med Biol** 1996; 398:191–4 (18 ref.)

Re: anxiety in patients submitted to endoscopy [letter; comment] Dumitrascu DL, et al. **Am J Gastroenterol** 1997 Aug;92(8):1403–4. Comment on: Am J Gastroenterol 1996 Dec;91(12):2505–8.

Pre-operative parental anxiety [see comments] Thompson N, et al. **Anaesthesia** 1996 Nov;51(11):1008–12. Comment in: Anaesthesia 1997 Mar;52(3):284.

What looks good and is good for you? The Journal Depression and Anxiety [editorial] Uhde TW. **Anxiety** 1996;2(6):255

Intraoperative progress reports decrease family members' anxiety. Leske JS. **AORN J** 1996 Sep;64(3):424–5, 428–36

Patients' attitudes toward detection of heterozygous familial hypercholesterolemia. Andersen LK, et al. **Arch Intern Med** 1997 Mar 10;157(5):553–60

Fearing the worst—why do pregnant women feel 'at risk'? [see comments] Searle J. **Aust N Z J Obstet Gynaecol** 1996 Aug;36(3):279–86. Comment in: Aust N Z J Obstet Gynaecol 1997 May;37(2):247–8.

Re: Fearing the worst—why do pregnant women feel 'at risk'? [letter; comment] Svensson J, et al. **Aust N Z J Obstet Gynaecol** 1997 May;37(2):247–8. Comment on: Aust N Z J Obstet Gynaecol 1996 Aug;36(3):279–86.

ABC of mental health. Anxiety. Hale AS. **BMJ** 1997 Jun 28;314(7098):1886–9 (0 ref.)

The psychological impact of negative TV news bulletins: the catastrophizing of personal worries. Johnston WM, et al. **Br J Psychol** 1997 Feb;88 (Pt 1):85–91

5-HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Gonzalez LE, et al. **Brain Res** 1996 Sep 2;732(1–2):145–53

The CF carrier status is not associated with a diminished self-concept or increased anxiety: results of psychometric testing after at least 1 year. Denayer L, et al. **Clin Genet** 1996 May;49(5):232–6

Psychological long-term effects of sterilization on anxiety and depression. Luo L, et al. **Contraception** 1996 Dec; 54(6):345–57

A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Charney DS, et al. **Crit Rev Neurobiol** 1996;10(3–4):419–46 (237 ref.)

Development and evaluation of written patient information for endoscopic procedures. Aabakken L, et al. **Endoscopy** 1997 Jan;29(1):23–6

Goal difficulty, anxiety and performance. Jones G, et al. **Ergonomics** 1997 Mar;40(3):319–33

Anxiety and depression in adolescent cancer: findings in patients and parents at the time of diagnosis. Allen R, et al. **Eur J Cancer** 1997 Jul;33(8):1250–5

Anxiety during pregnancy and fetal attachment after in-vitro fertilization conception. McMahon CA, et al. **Hum Reprod** 1997 Jan;12(1):176–82

Anxiety-induced failure in erectile response to intracorporeal prostaglandin-E1 in non-organic male impotence: a new diagnostic approach [letter] Vicari E, et al. **Int J Androl** 1997 Apr;20(2):126

State anxiety following 20 minutes of bicycle ergometer exercise at selected intensities. Raglin JS, et al. **Int J Sports Med** 1996 Aug;17(6):467–71

Quality of life and anxiety before and after lung cancer chemotherapy: relationship to patient's personality. Nakada S, et al. **Intern Med** 1996 Aug;35(8):611–6

Relationship of hunger and food insecurity to food availability and consumption. Kendall A, et al. **J Am Diet Assoc** 1996 Oct;96(10):1019–24; quiz 1025–6

The role of perceived overprotectiveness in recovery 3 months after myocardial infarction. Clarke DE, et al. **J Cardiopulm Rehabil** 1996 Nov-Dec;16(6):372–7

Neurobiology of psychologic predictors of duodenal ulcer healing [letter; comment] Friedman EH. **J Clin Gastroenterol** 1996 Jul;23(1):81. Comment on: J Clin Gastroenterol 1996 Mar;22(2):84–9.

Patient reassurance when test results are normal. Levine MJ. **J Fam Pract** 1996 Nov;43(5):440–1

Factors related to stress in patients with non-insulin-dependent diabetes mellitus. Okada S, et al. **J Int Med Res** 1995 Nov-Dec;23(6):449–57

Patients wrestle with anxiety and fear in treatment choices affecting sexuality [news] McIntosh H. **J Natl Cancer Inst** 1996 Nov 20;88(22):1618–20

Relationship between prenatal anxiety and perinatal outcome in nulliparous women: a prospective study. Bhagwanani SG, et al. **J Natl Med Assoc** 1997 Feb;89(2):93–8

Ageing Jewish Holocaust survivors: anxieties in dealing with health professionals. Joffe HI, et al. **Med J Aust** 1996 Nov 4;165(9):517–20 (38 ref.)

Variability in precompetition anxiety and performance in college track and field athletes. Turner PE, et al. **Med Sci Sports Exerc** 1996 Mar;28(3):378–85

Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. König M, et al. **Nature** 1996 Oct 10; 383(6600):535–8

Fear, panic, anxiety, and disorders of emotion. Barlow DH, et al. **Nebr Symp Motiv** 1996;43:251–328 (100 ref.)

Diagnosis and treatment of panic disorder and generalized anxiety in primary care. Valente SM. **Nurse Pract** 1996 Aug;21(8):26, 32–4, 37–8, passim (30 ref.)

Impact of parental anxiety on child emotional adjustment when a parent has cancer. Heiney SP, et al. **Oncol Nurs Forum** 1997 May;24(4):655–61

Psychosocial factors and asthma. Bosley CM, et al. **Respir Med** 1996 Sep;90(8):453–7 (32 ref.)

Worry associated with screening for colorectal carcinomas. Lindholm E, et al. **Scand J Gastroenterol** 1997 Mar; 32(3):238–45

Optimal and predicted anxiety in 9–12-year-old track and field athletes. Wilson GS, et al. **Scand J Med Sci Sports** 1997 Aug;7(4):253–8

[Biological study of anxiety and depression and the application for the pharmacological study] Yamamoto T, et al. **Nippon Yakurigaku Zasshi** 1996 Sep;108(3):147–9 (6 ref.) **(Jpn)**

[Effects of a written consent for liver biopsy on information and anxiety of patients] Hernando Robles P, et al. **Rev Clin Esp** 1997 Aug;197(8):564–7 (Eng. Abstr.) **(Spa)**

BLOOD

Lack of effect of laboratory-provoked anxiety on plasma homovanillic acid concentration in normal subjects. Zemishlany Z, et al. **Biol Psychiatry** 1996 Aug 15; 40(4):247–52

CHEMICALLY INDUCED

The practical use of carbon dioxide-induced anxiety in the diagnosis and care of patients with panic disorder. Ware MR, et al. **Ann Clin Psychiatry** 1996 Dec;8(4):199–202

Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers. McCann UD, et al. **Anxiety** 1994–95;1(6):258–67

Behavioral measures of anxiety during opiate withdrawal. Grasing K, et al. **Behav Brain Res** 1996 Oct;80(1–2):195–201

Acute inositol induces anxiety in rats. Cohen H, et al. **Biol Psychiatry** 1996 Sep 1;40(5):426–7

Prospective study of FK506 side effects: anxiety or akathisia? DiMartini AF, et al. **Biol Psychiatry** 1996 Sep 1; 40(5):407–11

Pseudoephedrine toxicity in renal failure. Lyon CC, et al. **Br J Clin Pract** 1996 Oct-Nov;50(7):396–7

Effect of a pharmacological stressor on glutamate efflux in the prefrontal cortex. Karreman M, et al. **Brain Res** 1996 Apr 15;716(1–2):180–2

Distinct grooming patterns induced by intracerebroventricular injection of CRH, TRH and LHRH in male rats. Gargiulo PA, et al. **Braz J Med Biol Res** 1996 Mar;29(3):375–9

Marked decrease of plasma neuroactive steroids during alcohol withdrawal. Romeo E, et al. **Clin Neuropharmacol** 1996 Aug;19(4):366–9

Efficacy of buspirone in smoking cessation: a placebo-controlled trial. Schneider NG, et al. **Clin Pharmacol Ther** 1996 Nov;60(5):568–75

Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam. Kask A, et al. **Eur J Pharmacol** 1996 Dec 19;317(2–3):R3–4

Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Teixeira RM, et al. **Eur J Pharmacol** 1996 Sep 5;311(1):7–14

Effects of some anxiogenic agents on rat brain monoamine oxidase (MAO) A and B inhibitory (tribulin) activity. Bhattacharya SK, et al. **Indian J Exp Biol** 1996 Dec; 34(12):1190–3

Behavioural effects of prenatal diazepam administration on anxiety patterns in rats. Singh Y, et al. **Indian J Exp Biol** 1996 Nov;34(11):1095–9

A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium. Nisijima K, et al. **Int Clin Psychopharmacol** 1996 Dec;11(4):289–90

Convulsive effects of a benzodiazepine receptor inverse agonist: are they related to anxiogenic processes? Clément Y, et al. **J Physiol Paris** 1997 Feb;91(1):21–9

Anxiogenic action of caffeine: an experimental study in rats. Bhattacharya SK, et al. **J Psychopharmacol (Oxf)** 1997; 11(3):219–24

Ritanserin facilitates anxiety in a simulated public-speaking paradigm. Guimarães FS, et al. **J Psychopharmacol (Oxf)** 1997;11(3):225–31

Role of different neurotransmitter systems in the cholecystokinin octapeptide-induced anxiogenic response in rats. Biró E, et al. **Neuropeptides** 1997 Jun;31(3):281–5

Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Duxon MS, et al. **Neuropharmacology** 1997 Apr-May; 36(4–5):601–8

Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Navarro M, et al. **Neuroreport** 1997 Jan 20; 8(2):491–6

Concurrent positive and negative goalbox events produce runway behaviors comparable to those of cocaine-reinforced rats. Geist TD, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1–2):145–50

Stimulant activities of dimethocaine in mice: reinforcing and anxiogenic effects. Rigon AR, et al. **Psychopharmacology (Berl)** 1996 Oct;127(4):323–7

[Anxiety and depression during chemotherapy for lymphoproliferative diseases] Piusińska A, et al. **Pol Tyg Lek** 1996 May;51(19–22):278–80 (Eng. Abstr.) **(Pol)**

[The anxiolytic effect of the new 2-mercaptobenzimidazole derivative in MR and MNRA rats] Seredinin SB, et al. **Eksp Klin Farmakol** 1997 May-Jun;60(3):3–5 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Preoperative anxiety and fear: a comparison of assessments by patients and anesthesia and surgery residents. Shafer A, et al. **Anesth Analg** 1996 Dec;83(6):1285–91

ANXIETY

COMPLICATIONS

The tension in hypertension [editorial] Barringer TA 3rd. **Arch Fam Med** 1997 Jan–Feb;6(1):50–1

Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Jonas BS, et al. **Arch Fam Med** 1997 Jan–Feb;6(1):43–9

Anxiety–induced hyperventilation. A common cause of symptoms in patients with hypertension. Kaplan NM. **Arch Intern Med** 1997 May 12;157(9):945–8

Habits, tics, and stuttering. Prevalence and relation to anxiety and somatic awareness. Woods DW, et al. **Behav Modif** 1996 Apr;20(2):216–25

Anxiety as a possible predictor of acute GVHD. Gregurek R, et al. **Bone Marrow Transplant** 1996 Sep;18(3):585–9

Do anxiety or hypocapnia predispose to apnoea after induction of anaesthesia? Drummond GB, et al. **Br J Anaesth** 1997 Feb;78(2):153–6

Acute hyperventilation in the emergency department [letter; comment] Singer EF. **Chest** 1997 Jul;112(1):294–5. Comment on: Chest 1996 Oct;110(4):952–7.

Depression and anxiety in patients with systemic sclerosis [letter] Straszecka J, et al. **Clin Rheumatol** 1996 Nov; 15(6):621

Somatization and somatosensory amplification in psychiatric outpatients: an explorative study. Spinhoven P, et al. **Compr Psychiatry** 1997 Mar–Apr;38(2):93–7

Effect of demographic and clinical variables on time to antidepressant response in geriatric depression. Flint AJ, et al. **Depress Anxiety** 1997;5(2):103–7

Irritable bowel syndrome and food allergy: an association via anxiety–depression? [letter; comment] Addolorato G, et al. **Gastroenterology** 1996 Sep;111(3):833–4. Comment on: Gastroenterology 1995 Dec;109(6):1736–41. Comment on: Gastroenterology 1995 Dec;109(6):2029–31.

Correlates of psychologic distress in colorectal cancer patients undergoing genetic testing for hereditary colon cancer. Vernon SW, et al. **Health Psychol** 1997 Jan; 16(1):73–86

Anxiety and depression in adult untreated celiac subjects and in patients affected by inflammatory bowel disease: a personality "trait" or a reactive illness? Addolorato G, et al. **Hepatogastroenterology** 1996 Nov–Dec;43(12):1513–7

Personality characteristics of patients with "white coat" hypertension. Muneta S, et al. **Hypertens Res** 1997 Jun; 20(2):99–104

Anxiety–induced failure in erectile response to intracorporeal prostaglandin–E1 in non–organic male impotence: a new diagnostic approach. Aversa A, et al. **Int J Androl** 1996 Oct;19(5):307–13

Do emotional states influence binge eating in the obese? Telch CF, et al. **Int J Eat Disord** 1996 Nov;20(3):271–9

Children with alopecia areata: psychiatric symptomatology and life events. Liakopoulou M, et al. **J Am Acad Child Adolesc Psychiatry** 1997 May; 36(5):678–84

Accommodations for test anxiety under ADA? Zuriff GE. **J Am Acad Psychiatry Law** 1997;25(2):197–206

Anxiety, depression and psychosomatic symptoms in patients with atopic dermatitis: comparison with normal controls and among groups of different degrees of severity. Hashiro M, et al. **J Dermatol Sci** 1997 Jan;14(1):63–7

Association between self–reported stressful feeling by SACL and mortality in a Japanese community. Utoguchi K, et al. **J Epidemiol** 1997 Mar;7(1):9–16

A longitudinal study of alexithymia and psychological distress in inflammatory bowel disease. Porcelli P, et al. **J Psychosom Res** 1996 Dec;41(6):569–73

Is anxiety early after myocardial infarction associated with subsequent ischemic and arrhythmic events? [see comments] Moser DK, et al. **Psychosom Med** 1996 Sep–Oct;58(5):395–401. Comment in: Psychosom Med 1996 Sep–Oct;58(5):402–3. Comment in: Psychosom Med 1997 Mar–Apr;59(2):211.

Anxiety after myocardial infarction predicts in–hospital complications: important association highlights need for research on rapid psychosocial intervention after infarction [editorial; comment] Schneiderman N, et al. **Psychosom Med** 1996 Sep–Oct;58(5):402–3. Comment on: Psychosom Med 1996 Sep–Oct;58(5):395–401.

Psychological differences between young male and female survivors of myocardial infarction. Uusküla M. **Psychother Psychosom** 1996;65(6):327–30

Self–esteem and trait anxiety in relation to drug misuse in Kuwait. al–Najjar M, et al. **Subst Use Misuse** 1996 May; 31(7):937–43

Association of anxiety with perception of histamine induced bronchoconstriction in patients with asthma. Spinhoven P, et al. **Thorax** 1997 Feb;52(2):149–52

DIAGNOSIS

The Yale Preoperative Anxiety Scale: how does it compare with a "gold standard"? Kain ZN, et al. **Anesth Analg** 1997 Oct;85(4):783–8

Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol–dependent patients. Heinz A, et al. **Arch Gen Psychiatry** 1996 Dec; 53(12):1123–8

Assessment of worry in children and adolescents: an adaptation of the Penn State Worry Questionnaire. Chorpita BF, et al. **Behav Res Ther** 1997 Jun;35(6):569–81

Psychometric properties of four anxiety measures in older adults. Stanley MA, et al. **Behav Res Ther** 1996 Oct; 34(10):827–38

Anxiety and depression in elderly patients receiving treatment for cerebral tumours. Kaplan CP, et al. **Brain Inj** 1997 Feb;11(2):129–35

Computer attitude and computer anxiety in nursing. Validation of an instrument using an Australian sample. Jayasuriya R, et al. **Comput Nurs** 1996 Nov–Dec; 14(6):340–5

Validity studies of the filial anxiety scale. Murray PD, et al. **Gerontologist** 1996 Feb;36(1):110–2

Cognitive processing and trait anxiety in typically developing children: evidence for an interpretation bias. Hadwin J, et al. **J Abnorm Psychol** 1997 Aug;106(3):486–90

Patterns of regional brain activity differentiate types of anxiety. Heller W, et al. **J Abnorm Psychol** 1997 Aug; 106(3):376–85

The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. March JS, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Apr;36(4):554–65

Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? Yonkers KA. **J Clin Psychiatry** 1997;58 Suppl 3:62–7; discussion 68–9 (50 ref.)

Parent ratings of children's depression, anxiety, and aggression: a cross–sample analysis of agreement and differences with child and teacher ratings. Epkins CC. **J Clin Psychol** 1996 Nov;52(6):599–608

The Beck Anxiety Inventory: reexamination of factor structure and psychometric properties. Osman A, et al. **J Clin Psychol** 1997 Jan;53(1):7–14

Relation between symptoms of anxiety and depression in children: a multitrait–multimethod–multigroup assessment. Cole DA, et al. **J Consult Clin Psychol** 1997 Feb; 65(1):110–9

Self–statements of test–anxious children: thought–listing and questionnaire approaches. Prins PJ, et al. **J Consult Clin Psychol** 1997 Jun;65(3):440–7

Death anxiety and the paranormal: the primacy of belief over experience. Lange R, et al. **J Nerv Ment Dis** 1997 Sep; 185(9):584–6

International experiences with the Hospital Anxiety and Depression Scale—a review of validation data and clinical results. Herrmann C. **J Psychosom Res** 1997 Jan;42(1):17–41 (211 ref.)

Anxiety and depression in general practice patients: prevalence and management [letter; comment] Marosszeky NE, et al. **Med J Aust** 1996 Oct 21;165(8):456–7. Comment on: Med J Aust 1996 May 6;164(9):526–9. Comment on: Med J Aust 1996 May 20;164(10):585–8.

Antecedents of state anxiety in rugby. Lane AM, et al. **Percept Mot Skills** 1997 Apr;84(2):427–33

Measurement of depression and anxiety for hospitalized depressed patients. Fischer EH, et al. **Psychiatr Serv** 1997 May;48(5):705–7

On Clark–Watson's tripartite model of anxiety and depression. Bedford A. **Psychol Rep** 1997 Feb;80(1):125–6

Trait anxiety, coping with stress, and norharman. Verheij R, et al. **Psychol Rep** 1997 Feb;80(1):51–9

[Anxiety—medical aspects] Dosiak M. **Wiad Lek** 1997; 50(1–3):21–7 (19 ref.) (Eng. Abstr.) **(Pol)**

[Mood disorders among inpatients in ambulatory and validation of the anxiety and depression scale HAD] Botega NJ, et al. **Rev Saude Publica** 1995 Oct;29(5):355–63 (Eng. Abstr.) **(Por)**

[The assessment of anxiety in the surgical anteroom (letter)] Moix Queraltó J. **Med Clin (Barc)** 1997 Feb 1;108(4):157–8 **(Spa)**

DRUG THERAPY

Pharmacologic treatment of noncognitive symptoms of dementia. Karlsson I. **Acta Neurol Scand Suppl** 1996; 165:101–4 (31 ref.)

The pharmacologic treatment of anxiety and depression in African Americans. Considerations for the general practitioner. Strickland TL, et al. **Arch Fam Med** 1997 Jul–Aug;6(4):371–5 (43 ref.)

Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety. Sramek JJ, et al. **Clin Ther** 1997 May–Jun;19(3):498–506

Oral low–dose midazolam as premedication for intraocular surgery in retrobulbar anesthesia: cardiovascular effects and relief of perioperative anxiety. Kiefer RT, et al. **Eur J Ophthalmol** 1997 Apr–Jun;7(2):185–92

Acute inhibition of nitric oxide synthesis induces anxiolysis in the plus maze test. Faria MS, et al. **Eur J Pharmacol** 1997 Mar 26;323(1):37–43

Effects of central administration of tachykinin receptor agonists and antagonists on plus–maze behavior in mice. Teixeira RM, et al. **Eur J Pharmacol** 1996 Sep 5;311(1):7–14

Interactions between ifenprodil and dizocilpine on mouse behaviour in models of anxiety and working memory. Fraser CM, et al. **Eur Neuropsychopharmacol** 1996 Nov; 6(4):311–6

Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats. Jenck F, et al. **Eur Neuropsychopharmacol** 1996 Nov;6(4):291–8

The effects of repeated administration of diazepam, MK–801 and CGP 37849 on rat behavior in two models of anxiety. Jessa M, et al. **Eur Neuropsychopharmacol** 1996 Mar; 6(1):55–61

Overnight sedation with midazolam or propofol in the ICU: effects on sleep quality, anxiety and depression. Treggiari–Venzi M, et al. **Intensive Care Med** 1996 Nov; 22(11):1186–90

Drug–seeking patients. Eckstat S. **Iowa Med** 1997 Jan; 87(1):31

Sertraline treatment of transition–associated anxiety and agitation in children with autistic disorder. Steingard RJ, et al. **J Child Adolesc Psychopharmacol** 1997 Spring; 7(1):9–15

Gepirone and diazepam in generalized anxiety disorder: a placebo–controlled trial. Rickels K, et al. **J Clin Psychopharmacol** 1997 Aug;17(4):272–7

Experimental anxiety and antidepressant drugs: the effects of moclobemide, a selective reversible MAO–A inhibitor, fluoxetine and imipramine in mice. de Angelis L. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug–Sep; 354(3):379–83

MCPP–induced anxiety—a potential new method for screening anxiolytic activity. Bilkei–Gorzó A, et al. **Neurobiology (Bp)** 1996;4(3):253–5

Effects of anxiety and memory of systemic and intra–amygdala injection of 5–HT3 receptor antagonist BRL 46470A. Gargiulo PA, et al. **Neuropsychobiology** 1996;33(4):189–95

Anxiolytic activity of intraventricularly administered atrial natriuretic peptide in the rat. Bhattacharya SK, et al. **Neuropsychopharmacology** 1996 Aug;15(2):199–206

Pre– or postsynaptic activity of 5–HT1A compounds in mice depends on the anxiety paradigm. López–Rubalcava C. **Pharmacol Biochem Behav** 1996 Aug;54(4):677–86

Effect of chronic diazepam treatment on footshock–induced ultrasonic vocalization in adult male rats. Nielsen CK, et al. **Pharmacol Toxicol** 1995 Sep;77(3):177–81

Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Fichter MM, et al. **Pharmacopsychiatry** 1997 May;30(3):85–92

Short–term consumption of a diet rich in fat decreases anxiety response in adult male rats. Prasad A, et al. **Physiol Behav** 1996 Sep;60(3):1039–42

Anxiolytic and memory improving activity of fluoxetine. Nowakowska E, et al. **Pol J Pharmacol** 1996 May–Jun; 48(3):255–60

Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Mizuki Y, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 May; 21(4):573–90

Behavioural profiles of the reversible monoamine–oxidase–A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti–panic drugs. Griebel G, et al. **Psychopharmacology (Berl)** 1997 May; 131(2):180–6

Effect of d–fenfluramine on human experimental anxiety. Hetem LA, et al. **Psychopharmacology (Berl)** 1996 Oct; 127(3):276–82

The antidepressant drug phenelzine produces antianxiety effects in the plus–maze and increases in rat brain GABA. Paslawski T, et al. **Psychopharmacology (Berl)** 1996 Sep; 127(1):19–24

Effects of the selective angiotensin II receptor antagonists losartan and PD123177 in animal models of anxiety and memory. Shepherd J, et al. **Psychopharmacology (Berl)** 1996 Aug;126(3):206–18

[Antidepressants, anxiety and depression disorders] Lépine JP. **Encephale** 1996 Dec;22 Spec No 7:15–7 **(Fre)**

[Range of activity of anxiolytic and antidepressant drugs] Linkowski P. **Rev Med Brux** 1996 Sep;17(4):220–3 (Eng. Abstr.) **(Fre)**

[Anxiety and depression. Highlights from the 149th Session of the American Psychiatric Association, New York 4–9 May 1996] **Fortschr Neurol Psychiatr** 1997 Apr;65(4 Suppl Angst Und):1–4 **(Ger)**

[Neuropharmacological effects of sigma receptor ligands: anxiolytic, anti–amnesic and neuroprotective effects] Amano M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):73–84 (103 ref.) (Eng. Abstr.) **(Jpn)**

[The comparative effect of melatonin and diazepam on shifts in the anxiety–phobia status of rats evoked by damage to the amygdala] Arushanian EB, et al. **Eksp Klin Farmakol** 1997 Jan–Feb;60(1):7–9 (Eng. Abstr.) **(Rus)**

[The effect of calcium channel blockers on anxiety evoked by amputation of the vibrissae in rats] Kozlovskiĭ VL, et al. **Eksp Klin Farmakol** 1997 Jan–Feb;60(1):10–2 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Relationships between depressive symptoms, anxiety, alcohol consumption, and blood pressure: results from the CARDIA Study. Coronary Artery Risk Development in Young Adults Study. Jones–Webb R, et al. **Alcohol Clin Exp Res** 1996 May;20(3):420–7

Distress and coping among women with HIV infection: preliminary findings from a multiethnic sample. Kaplan MS, et al. **Am J Orthopsychiatry** 1997 Jan;67(1):80–91

Psychiatric disturbance and acute stress responses in surgical patients. Clarke DM, et al. **Aust N Z J Surg** 1997 Feb–Mar; 67(2–3):115–8

A dimensional model for common mental disorders.

Goldberg D. **Br J Psychiatry Suppl** 1996 Jun;(30):44–9

Psychiatric symptoms of Hawaiian adolescents. Makini GK Jr, et al. **Cult Divers Ment Health** 1996;2(3):183–91

Levels and risks of depression and anxiety symptomatology among diabetic adults. Peyrot M, et al. **Diabetes Care** 1997 Apr;20(4):585–90

The Zurich Study: XXII. Epidemiology of gastrointestinal complaints and comorbidity with anxiety and depression. Hochstrasser B, et al.
Eur Arch Psychiatry Clin Neurosci 1996;246(5):261–72

The course of aggression in first-grade children with and without comorbid anxious symptoms. Ialongo N, et al.
J Abnorm Child Psychol 1996 Aug;24(4):445–56

Discriminating depression and anxiety in youth: a role for diagnostic criteria. Gurley D, et al. **J Affect Disord** 1996 Jul 29;39(3):191–200

Comorbidity in ADHD: implications for research, practice, and DSM-V. Jensen PS, et al.
J Am Acad Child Adolesc Psychiatry 1997 Aug; 36(8):1065–79 (69 ref.)

Relation between symptoms of anxiety and depression in children: a multitrait-multimethod-multigroup assessment. Cole DA, et al. **J Consult Clin Psychol** 1997 Feb; 65(1):110–9

Gender differences in depressive symptoms in adolescence: comparison of national samples of clinically referred and nonreferred youths. Compas BE, et al.
J Consult Clin Psychol 1997 Aug;65(4):617–26

Covariation of the anxious-depressed syndrome during adolescence: separating fact from artifact. Hinden BR, et al. **J Consult Clin Psychol** 1997 Feb;65(1):6–14

Posttraumatic stress, family functioning, and social support in survivors of childhood leukemia and their mothers and fathers. Kazak AE, et al. **J Consult Clin Psychol** 1997 Feb; 65(1):120–9

Menarche and the onset of depression and anxiety in Victoria, Australia. Patton GC, et al.
J Epidemiol Community Health 1996 Dec;50(6):661–6

The overlap of attention deficit hyperactivity disorder with other common mental disorders. Hazell P.
J Paediatr Child Health 1997 Apr;33(2):131–7 (60 ref.)

Anxiety, economic growth and suicide and homicide. Lester D. **Percept Mot Skills** 1997 Aug;85(1):382

Depression and anxiety among women in an urban setting in Zimbabwe. Abas MA, et al. **Psychol Med** 1997 Jan; 27(1):59–71

Patients who somatize in primary care: a longitudinal study of cognitive and social characteristics. Kirmayer LJ, et al. **Psychol Med** 1996 Sep;26(5):937–51

Fifteen years on: evolving ideas in researching sex differences in depression. Wilhelm K, et al. **Psychol Med** 1997 Jul; 27(4):875–83

Mixed anxiety and depressive disorder. Sartorius N, et al. **Psychopathology** 1995;28 Suppl 1:21–5 (14 ref.)

[Level of anxiety in patients with lung cancer] Nalepa P. **Pneumonol Alergol Pol** 1996;64(5–6):315–22 (Eng. Abstr.) **(Pol)**

ETHNOLOGY

The pharmacologic treatment of anxiety and depression in African Americans. Considerations for the general practitioner. Strickland TL, et al. **Arch Fam Med** 1997 Jul-Aug;6(4):371–5 (43 ref.)

Sources of ethnic differences between Asian American and white American college students on measures of depression and social anxiety. Okazaki S. **J Abnorm Psychol** 1997 Feb; 106(1):52–60

Refugees' and immigrants' mental health: association of demographic and post-immigration factors. Pernice R, et al. **J Soc Psychol** 1996 Aug;136(4):511–9

Postpartum worries: an exploration of Taiwanese primiparas who participate in the Chinese ritual of tso-yueh-tzu. Liu-Chiang CY. **Matern Child Nurs J** 1995 Oct-Dec; 23(4):110–22

ETIOLOGY

Assessment of maternal anxiety following neonatal screening and investigation for occult spinal dysraphism. Gibson PJ, et al. **Acta Paediatr** 1997 Jan;86(1):72–6

Parent-child interactions predict anxiety in Mexican adolescents. Hernández-Guzmán L, et al. **Adolescence** 1996 Winter;31(124):955–63

The psychological condition of a cohort of Nigerian diabetic subjects. Akinlade KS, et al. **Afr J Med Med Sci** 1996 Mar; 25(1):61–7

An epidemic of apprehension: questions about HIV/AIDS to an east African newspaper health advice column. Asera R, et al. **AIDS Care** 1997 Feb;9(1):5–12

Effect of informed consent on anxiety in patients undergoing diagnostic electrophysiology studies. Goldberger JJ, et al. **Am Heart J** 1997 Jul;134(1):119–26

Anxiety in patients with symptomatic breast disease: effects of immediate versus delayed communication of results. Ubhi SS, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5):466–9

Perfectionism in obsessive-compulsive disorder patients. Frost RO, et al. **Behav Res Ther** 1997 Apr;35(4):291–6

The meta-chlorophenylpiperazine challenge test in cocaine addicts: hormonal and psychological responses.
Buydens-Branchey L, et al. **Biol Psychiatry** 1997 Jun 1; 41(11):1071–86

Terminations of pregnancy, not unplanned deliveries, increased as result of pill scare [letter] Child TJ, et al. **BMJ** 1996 Oct 19;313(7063):1005

"Phlebomania Hancocksia": prevalence of a previously undescribed psychomotor disturbance. John LC. **BMJ** 1996 Dec 21-28;313(7072):1620

What worries parents when their preschool children are acutely ill, and why: a qualitative study [see comments] Kai J. **BMJ** 1996 Oct 19;313(7063):983–6. Comment in: BMJ 1996 Oct 19;313(7063):954–5. Comment in: BMJ 1997 Feb 1;314(7077):373. Comment in: BMJ 1997 Feb 1;314(7077):373–4.

Student teacher anxieties related to class management, pedagogy, evaluation, and staff relations. Morton LL, et al. **Br J Educ Psychol** 1997 Mar;67 (Pt 1):69–89

Acute effects of beta blockade and exercise on mood and anxiety. Head A, et al. **Br J Sports Med** 1996 Sep; 30(3):238–42

Perceived risk, anxiety, mammogram uptake, and breast self-examination of women with a family history of breast cancer: the role of knowing to be at increased risk. Drossaert CC, et al. **Cancer Detect Prev** 1996;20(1):76–85

Exercise training decreases dyspnea and the distress and anxiety associated with it. Monitoring alone may be as effective as coaching. Carrieri-Kohlman V, et al. **Chest** 1996 Dec;110(6):1526–35

An information-processing perspective on childhood anxiety. Daleiden EL, et al. **Clin Psychol Rev** 1997;17(4):407–29 (81 ref.)

Potential role of childrearing practices in the development of anxiety and depression. Rapee RM. **Clin Psychol Rev** 1997;17(1):47–67 (127 ref.)

Combination midazolam and droperidol for severe post-ECT agitation [letter] Hines AH, et al. **Convuls Ther** 1997 Jun; 13(2):113–4

Psychological impact of screening for familial ovarian cancer: reactions to initial assessment [see comments] Erlick Robinson G, et al. **Gynecol Oncol** 1997 May;65(2):197–205 . Comment in: Gynecol Oncol 1997 May;65(2):195–6.

Precipitating and predisposing factors of acute confusional state among emergency department patients. Elmstahl S, et al. **Int Psychogeriatr** 1995 Winter;7(4):519–26

Relationship between dyspnea in daily life and psycho-physiologic state in patients with chronic obstructive pulmonary disease during long-term domiciliary oxygen therapy. Mishima M, et al.
Intern Med 1996 Jun;35(6):453–8

Psychosocial stress and anxiety in senile dementia. Orrell M, et al. **J Affect Disord** 1996 Jul 29;39(3):165–73

Case study: seizure disorder presenting as panic disorder with agoraphobia. Lee DO, et al.
J Am Acad Child Adolesc Psychiatry 1997 Sep;36(9):1295–8

Childhood asthma complicated by anxiety: an application of cognitive behavioural therapy. Park SJ, et al.
J Paediatr Child Health 1996 Apr;32(2):183–7

Psychiatric complications of hemodialysis at a kidney center in Nigeria. Aghanwa HS, et al. **J Psychosom Res** 1997 May; 42(5):445–51

Helping children relax during magnetic resonance imaging. Smart G. **MCN Am J Matern Child Nurs** 1997 Sep-Oct; 22(5):236–41

The neuropsychology of anxiety: reprise. Gray JA, et al. **Nebr Symp Motiv** 1996;43:61–134 (175 ref.)

The activation and regulation of fear and anxiety. Izard CE, et al. **Nebr Symp Motiv** 1996;43:1–59 (105 ref.)

Amygdala kindling in the rat: anxiogenic-like consequences. Helfer V, et al. **Neuroscience** 1996 Aug;73(4):971–8

An evaluation of preoperative anxiety in a population of parents of infants and children undergoing ambulatory surgery. Litman RS, et al. **Paediatr Anaesth** 1996;6(6):443–7

Cognitive dysfunction resulting from hippocampal hyperactivity--a possible cause of anxiety disorder? McNaughton N. **Pharmacol Biochem Behav** 1997 Apr; 56(4):603–11 (69 ref.)

Anxiety disorders in plastic surgery. Rankin M, et al.
Plast Reconstr Surg 1997 Aug;100(2):535–42

Anxiety levels of pregnant women during ultrasound examination: coping styles, amount of feedback and learned resourcefulness. Zlotogorski Z, et al.
Ultrasound Obstet Gynecol 1995 Dec;6(6):425–9

[Risperdal: a new hope for schizophrenic patients?]
Fortschr Neurol Psychiatr 1994 May;62(5 Suppl):1–4 **(Ger)**

[Intensive Care Unit stay. Variables that affect emotional reactions] Novaes MA, et al. **Arq Bras Cardiol** 1996 Aug; 67(2):99–102 (Eng. Abstr.) **(Por)**

[Reasons for anxiety in primary care professionals. A resident-tutor comparison] Saura Llamas J, et al.
Aten Primaria 1997 Jul-Aug;20(3):142–6 (Eng. Abstr.) **(Spa)**

GENETICS

Decreased measures of experimental anxiety in rats bred for high alcohol preference. Möller C, et al.
Alcohol Clin Exp Res 1997 Jun;21(4):656–60

Genetic and environmental contributions to the correlation between alcohol consumption and symptoms of anxiety and depression. Results from a bivariate analysis of Norwegian twin data. Tambs K, et al. **Behav Genet** 1997 May; 27(3):241–50

Anxiety behavior, exploratory behavior, and activity in NZB x NZW F1 hybrid mice: role of genotype and autoimmune disease progression. Schrott LM, et al.
Brain Behav Immun 1996 Sep;10(3):260–74

Genetic factors regulate processes related to anxiety in mice. Clément Y, et al. **Brain Res** 1997 Mar 28;752(1–2):127–35

An autoradiographic study of serotonergic receptors in a murine genetic model of anxiety-related behaviors. Clement Y, et al. **Brain Res** 1996 Feb 19;709(2):229–42

Genetic analyses of emotionality. Eley TC, et al.
Curr Opin Neurobiol 1997 Apr;7(2):279–84 (38 ref.)

Association of short alleles of a VNTR of the serotonin transporter gene with anxiety symptoms in patients presenting after deliberate self harm. Evans J, et al.
Neuropharmacology 1997 Apr-May;36(4–5):439–43

METABOLISM

An autoradiographic study of serotonergic receptors in a murine genetic model of anxiety-related behaviors. Clement Y, et al. **Brain Res** 1996 Feb 19;709(2):229–42

Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety. Duncan GE, et al.
Brain Res 1996 Mar 25;713(1–2):79–91

Selective dopamine depletion within the medial prefrontal cortex induces anxiogenic-like effects in rats placed on the elevated plus maze. Espejo EF. **Brain Res** 1997 Jul 11; 762(1–2):281–4

Effect of a pharmacological stressor on glutamate efflux in the prefrontal cortex. Karreman M, et al. **Brain Res** 1996 Apr 15;716(1–2):180–2

Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Windle RJ, et al. **Endocrinology** 1997 Jul;138(7):2829–34

Cholecystokinin in anxiety. van Megen HJ, et al.
Eur Neuropsychopharmacol 1996 Nov;6(4):263–80 (156 ref.)

Resting metabolic rate is influenced by anxiety in college men. Schmidt WD, et al. **J Appl Physiol** 1996 Feb; 80(2):638–42

Cerebral glucose utilization is reduced in second test session. Stapleton JM, et al. **J Cereb Blood Flow Metab** 1997 Jun; 17(6):704–12

Salivary cortisol and anxiety in recurrent aphthous stomatitis. McCartan BE, et al. **J Oral Pathol Med** 1996 Aug; 25(7):357–9

Cortical 5-HT-CCK interactions and anxiety-related behaviour of guinea-pigs: a microdialysis study. Rex A, et al. **Neurosci Lett** 1997 Jun 6;228(2):79–82

Consequences of selective blockade of septal noradrenergic afferents on anxiety and spatial working memory performance in mice. Belotti M, et al.
Pharmacol Biochem Behav 1996 Mar;53(3):541–7

Influence of early postnatal gonadal hormones on anxiety in adult male rats. Lucion AB, et al. **Physiol Behav** 1996 Dec;60(6):1419–23

Monoamines in the dorsomedial hypothalamus of rats following exposure to different tests of "anxiety". Sajdyk TJ, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Jan;21(1):193–209

Alterations of benzodiazepine receptor binding potential in anxiety and somatoform disorders measured by 123I-iomazenil SPECT. Tokunaga M, et al. **Radiat Med** 1997 May-Jun;15(3):163–9

[The characteristics of the brain serotonin system and anxiety in the C57BL and CBA mouse strains] Popova NK, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Mar-Apr; 46(2):348–54 (Eng. Abstr.) **(Rus)**

MORTALITY

Mortality of anxiety syndromes in a normal population. The Lundby Study. Gråsbeck A, et al. **Neuropsychobiology** 1996;33(3):118–26

NURSING

Centering: reducing rape trauma syndrome anxiety during a gynecologic examination. Dole PJ.
J Psychosoc Nurs Ment Health Serv 1996 Oct;34(10):32–7

Helping children relax during magnetic resonance imaging. Smart G. **MCN Am J Matern Child Nurs** 1997 Sep-Oct; 22(5):236–41

Three phases of research in validating nursing diagnoses. Whitley GG. **West J Nurs Res** 1997 Jun;19(3):379–99

PHYSIOPATHOLOGY

Effects of anxiety arousal and mental stress on the vestibulo-ocular reflex. Yardley L, et al.
Acta Otolaryngol (Stockh) 1995 Sep;115(5):597–602

Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Davis M, et al.
Ann N Y Acad Sci 1997 Jun 21;821:305–31 (76 ref.)

Short-term rebound anxiolytic effects and long-term changes in platelet benzodiazepine binding after pentylenetetrazole-kindling in two strains of rat. File SE, et al. **Anxiety** 1996;2(3):109–16

Blockade of CCK(B) but not CCK(A) receptors before and after the stress of predator exposure prevents lasting increases in anxiety-like behavior: implications for anxiety associated with posttraumatic stress disorder. Adamec RE, et al. **Behav Neurosci** 1997 Apr;111(2):435–49

Dissociations among the anxiolytic effects of septal, hippocampal, and amygdaloid lesions. Treit D, et al.
Behav Neurosci 1997 Jun;111(3):653–8

An information processing model of anxiety: automatic and

strategic processes. Beck AT, et al. **Behav Res Ther** 1997 Jan;35(1):49–58

Time course of attentional bias for threat information in non-clinical anxiety. Mogg K, et al. **Behav Res Ther** 1997 Apr;35(4):297–303

Cognitive content specificity in selective attention across four domains of maladjustment. Westra HA, et al. **Behav Res Ther** 1997 Apr;35(4):349–65

Behaviour of the transgenic (mREN2)27 rat. Wilson W, et al. **Brain Res** 1996 Aug 5;729(1):1–9

Is worrying bad for your heart? A prospective study of worry and coronary heart disease in the Normative Aging Study. Kubzansky LD, et al. **Circulation** 1997 Feb 18;95(4):818–24

Psychoneuroendocrinological indicators of stress and intellectual performance among older adults: an exploratory study. Kelly KS, et al. **Exp Aging Res** 1996 Oct–Dec;22(4):393–401

Intestinal transit in anxiety and depression. Gorard DA, et al. **Gut** 1996 Oct;39(4):551–5

Abnormal passive head-up tilt test in subjects with symptoms of anxiety power spectral analysis study of heart rate and blood pressure. Piccirillo G, et al. **Int J Cardiol** 1997 Jul 25;60(2):121–31

Cerebral correlates of anticipated fear: a PET study of specific phobia. Wik G, et al. **Int J Neurosci** 1996 Nov; 87(3–4):267–76

Behavioral activation sensitivity and resting frontal EEG asymmetry: covariation of putative indicators related to risk for mood disorders. Harmon-Jones E, et al. **J Abnorm Psychol** 1997 Feb;106(1):159–63

Behavioral and neurophysiological evidence for altered processing of anxiety-related words in panic disorder. Pauli P, et al. **J Abnorm Psychol** 1997 May;106(2):213–20

Somatic symptoms in anxious-depressed school refusers. Bernstein GA, et al. **J Am Acad Child Adolesc Psychiatry** 1997 May;36(5):661–8

Anxiety, antisocial behavior, and heart rate regulation in adolescent males. Mezzacappa E, et al. **J Child Psychol Psychiatry** 1997 May;38(4):457–69

Cognitive processing bias of children in a real life stress situation and a neutral situation. Kindt M, et al. **J Exp Child Psychol** 1997 Jan;64(1):79–97

Central serotonergic systems in the spontaneously hypertensive and Lewis rat strains that differ in the elevated plus-maze test of anxiety. Kulikov A, et al. **J Pharmacol Exp Ther** 1997 May;281(2):775–84

Symptoms of anxiety and depression as precursors to hypertension [editorial] Dimsdale JE. **JAMA** 1997 Feb 19; 277(7):574–5

Heterogeneity in the performance of outbred Sprague-Dawley rats in an elevated-plus maze test: a possible animal model for anxiety disorder. Prasad A, et al. **Life Sci** 1996;59(18):1499–506

Glucocorticoids and the hippocampus. Developmental interactions facilitating the expression of behavioral inhibition. Takahashi LK. **Mol Neurobiol** 1996 Dec; 13(3):213–26 (141 ref.)

A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Griebel G, et al. **Neuropharmacology** 1997 Jun;36(6):793–802

Urocortin, a novel neuropeptide with anxiogenic-like properties. Moreau JL, et al. **Neuroreport** 1997 May 6; 8(7):1697–701

Chlordiazepoxide discriminates between the neural circuits mediating neuroendocrine responses to fear- and anxiety-producing stimuli in the rat. Yagi K, et al. **Neurosci Res** 1996 Jan;24(2):151–8

Behavioral characterization of mice packing the 5-HT1B receptor. Ramboz S, et al. **NIDA Res Monogr** 1996; 161:39–57 (32 ref.)

Anxiety and pain: attentional and endorphinergic influences. Janssen SA, et al. **Pain** 1996 Aug;66(2–3):145–50

Hippocampal mineralocorticoid, but not glucocorticoid, receptors modulate anxiety-like behavior in rats. Smythe JW, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):507–13

Neurochemical mediators of anxiety have inconsistent effects on hypothalamic self-stimulation in rats. Borisenko SA, et al. **Pharmacol Toxicol** 1996 May;78(5):354–60

Lateral and medial septal lesions reduce anxiety in the plus-maze and probe-burying tests. Menard J, et al. **Physiol Behav** 1996 Sep;60(3):845–53

Effects of myocardial infarction and captopril therapy on anxiety-related behaviors in the rat. Prickaerts J, et al. **Physiol Behav** 1996 Jul;60(1):43–50

Variability in the effects of 5-HT-related compounds in experimental models of anxiety: evidence for multiple mechanisms of 5-HT in anxiety or never ending story? Griebel G. **Pol J Pharmacol** 1996 Mar–Apr;48(2):129–36 (40 ref.)

5-HT systems and anxiety: multiple mechanisms in the elevated X-maze. McCreary AC, et al. **Pol J Pharmacol** 1996 Jan–Feb;48(1):1–12 (87 ref.)

Midbrain and medullary regulation of defensive cardiovascular functions. Lovick TA. **Prog Brain Res** 1996; 107:301–13 (42 ref.)

Anxiety-like and depression-like behavior in Maudsley reactive (MR) and non-reactive (NMRA) rats. Commissaris RL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Apr; 20(3):491–501

A view on noradrenergic, hypothalamic-pituitary-adrenal axis and extrahypothalamic corticotrophin-releasing factor function in anxiety and affective disorders: the reduced growth hormone response to clonidine. Coplan JD, et al. **Psychopharmacol Bull** 1997;33(2):193–204 (93 ref.)

The cardiovascular startle response: anxiety and the benzodiazepine receptor complex. Berntson GG, et al. **Psychophysiology** 1997 May;34(3):348–57

Is anxiety early after myocardial infarction associated with subsequent ischemic and arrhythmic events? [see comments] Moser DK, et al. **Psychosom Med** 1996 Sep–Oct;58(5):395–401. Comment in: Psychosom Med 1996 Sep–Oct;58(5):402–3. Comment in: Psychosom Med 1997 Mar–Apr;59(2):211.

Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Bremner JD, et al. **Synapse** 1996 May; 23(1):28–38 (138 ref.)

Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Bremner JD, et al. **Synapse** 1996 May;23(1):39–51 (118 ref.)

Influence of wet suit wear on anxiety responses to underwater exercise. Koltyn KF, et al. **Undersea Hyperb Med** 1997; 24(1):23–8

[The neuropeptide cholecystokinin and anxiety states] Cohen H, et al. **Harefuah** 1996 May 15;130(10):707–10 (31 ref.) **(Heb)**

[The effect of melatonin on the anxiety-phobic behavioral characteristics of intact and epiphysectomized rats] Baturin VA, et al. **Fiziol Zh Im I M Sechenova** 1996 Apr; 82(4):126–8 **(Rus)**

[The effect of mammalian anxiety factors on insects. The action of the corticoliberin 2–4 fragment on the behavior of the mealworm beetle Tenebrio molitor] Gritsai OB, et al. **Zh Evol Biokhim Fiziol** 1996 Jul–Aug;32(4):440–7 (Eng. Abstr.) **(Rus)**

[The effect of stress in pregnant rats on the anxiety level in their offspring] Batuev AS, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 May–Jun; 46(3):558–63 (Eng. Abstr.) **(Rus)**

[The participation of serotonin S1A and S2 receptors in the formation of different levels of anxiety in male mice under the influence of the experience of social victories and defeats] Kudriavtseva NN, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Mar–Apr; 46(2):370–7 (Eng. Abstr.) **(Rus)**

[The genotypic correlations of the expression of anxiety and dopamine metabolism in the mouse brain] Popova NK, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Sep–Oct; 46(5):904–10 (Eng. Abstr.) **(Rus)**

[The effect of stress on the anxiety level in female white rats at different stages of the estrous cycle] Vinogradova EP, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jul–Aug;46(4):769–75 (Eng. Abstr.) **(Rus)**

[Relationship between psychosocial and cardiovascular variables in adolescents] Bretaña Casado ML, et al. **An Esp Pediatr** 1996 Dec;45(6):603–8 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Preoperative ICU tours: are they helpful? Lynn-McHale D, et al. **Am J Crit Care** 1997 Mar;6(2):106–15

Assertion training therapy in psychiatric milieus. Aschen SR. **Arch Psychiatr Nurs** 1997 Feb;11(1):46–51

Responses of consecutive patients to reassurance after gastroscopy: results of self administered questionnaire survey. Lucock MP, et al. **BMJ** 1997 Sep 6;315(7108):572–5

Student teacher anxieties related to class management, pedagogy, evaluation, and staff relations. Morton LL, et al. **Br J Educ Psychol** 1997 Mar;67 (Pt 1):69–89

Effects of psychotherapy in moderately severe COPD: a pilot study. Eiser N, et al. **Eur Respir J** 1997 Jul;10(7):1581–4

Magnetic resonance imaging of children without sedation: preparation with simulation. Rosenberg DR, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jun;36(6):853–9

A cognitive behavioural approach to preventing anxiety during magnetic resonance imaging. Lukins R, et al. **J Behav Ther Exp Psychiatry** 1997 Jun;28(2):97–104

Self-hypnosis reduces anxiety following coronary artery bypass surgery. A prospective, randomized trial. Ashton C Jr, et al. **J Cardiovasc Surg (Torino)** 1997 Feb;38(1):69–75

Prevention and early intervention for anxiety disorders: a controlled trial. Dadds MR, et al. **J Consult Clin Psychol** 1997 Aug;65(4):627–35

Strategies to assist students to be successful the next time around on the NCLEX-RN. Vance A, et al. **J Nurs Educ** 1997 Apr;36(4):190–2

Cognitive behavioral pain and anxiety interventions in pediatric oncology centers and bone marrow transplant units. McCarthy AM, et al. **J Pediatr Oncol Nurs** 1996 Jan;13(1):3–12; discussion 13–4

Adult claustrophobia, anxiety and sedation in MRI. Murphy KJ, et al. **Magn Reson Imaging** 1997;15(1):51–4

Flumazenil blockade of anxiety following ethanol withdrawal in rats. Moy SS, et al. **Psychopharmacology (Berl)** 1997 Jun; 131(4):354–60

[The Standard 'Threatened) Miscarriage' of the Dutch Society of Family Physicians (letter; comment)] Braken JB. **Ned Tijdschr Geneeskd** 1997 Jan 11;141(2):114–5. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1935–9. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1939–40. Comment on: Ned Tijdschr Geneeskd 1996 Sep 28;140(39):1956–9. **(Dut)**

[Management of anxious and painful manifestations in pediatric uroradiology] Schmit P, et al. **J Radiol** 1997 May; 78(5):367–72 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Psychological adjustment of infertile women entering IVF treatment: differentiating aspects and influencing factors. Bringhenti F, et al. **Acta Obstet Gynecol Scand** 1997 May; 76(5):431–7

Effects of alcohol and expectancy on self-disclosure and anxiety in male and female social drinkers. Schippers GM, et al. **Addict Behav** 1997 May–Jun;22(3):305–14

ESBRA-Nordmann 1996 Award Lecture: ethanol drinking behaviour in Sardinian alcohol-preferring rats. Colombo G. **Alcohol Alcohol** 1997 Jul–Aug;32(4):443–53

Aggression, attachment, and depression among school-age children at high social risk. Easterbrooks MA, et al. **Ann N Y Acad Sci** 1996 Sep 20;794:346–7

Relationship of aggression and anxiety to autonomic regulation of heart rate variability in adolescent males. Mezzacappa E, et al. **Ann N Y Acad Sci** 1996 Sep 20; 794:376–9

Development of anxiety symptoms during a deep diving experiment. Abraini JH, et al. **Anxiety** 1994–95;1(5):237–41

High-dose subchronic imipramine treatment: effects on anxiety-like (conflict) behavior in rats. Commissaris RL, et al. **Anxiety** 1994–95;1(3):109–13

Safety signals and human anxiety: a fear-potentiated startle study. Grillon C, et al. **Anxiety** 1994;1(1):13–21

Preoperative anxiety in children. Predictors and outcome [letter; comment] Agre F. **Arch Pediatr Adolesc Med** 1997 Jun;151(6):636–7. Comment on: Arch Pediatr Adolesc Med 1996 Dec;150(12):1238–45.

Preoperative anxiety in children. Predictors and outcomes [see comments] Kain ZN, et al. **Arch Pediatr Adolesc Med** 1996 Dec;150(12):1238–45. Comment in: Arch Pediatr Adolesc Med 1996 Dec;150(12):1234–5. Comment in: Arch Pediatr Adolesc Med 1997 Jun;151(6):636–7.

Psychophysiological stress in elite golfers during practice and competition. McKay JM, et al. **Aust J Sci Med Sport** 1997 Jun;29(2):55–61

Perceived uncertainty of outcome as a contributing factor in competitive state anxiety. Marchant DB, et al. **Aust J Sci Med Sport** 1997 Jun;29(2):41–6

Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light/dark and dark/light tests. Chaouloff F, et al. **Behav Brain Res** 1997 Apr;85(1):27–35

Ischemia-induced anxiety following cardiac arrest in the rat. Dhooper A, et al. **Behav Brain Res** 1997 Mar;84(1–2):57–62

Effects of an electrolytic lesion of the prelimbic area on anxiety-related and cognitive tasks in the rat. Maaswinkel H, et al. **Behav Brain Res** 1996 Sep;79(1–2):51–9

Lesion of the habenular efferent pathway produces anxiety and locomotor hyperactivity in rats: a comparison of the effects of neonatal and adult lesions. Murphy CA, et al. **Behav Brain Res** 1996 Nov;81(1–2):43–52

A multiple-test study of anxiety-related behaviours in six inbred rat strains. Ramos A, et al. **Behav Brain Res** 1997 Apr;85(1):57–69

Increased anxiety behaviors in autoimmune mice. Schrott LM, et al. **Behav Neurosci** 1996 Jun;110(3):492–502

Suppression of the emotional Stroop effect by increased anxiety in patients with social phobia. Amir N, et al. **Behav Res Ther** 1996 Nov–Dec;34(11–12):945–8

Cued UCS rehearsal and the impact of painful conditioned stimuli: UCS rehearsal increases SCRs but reduces experienced pain. Arntz A, et al. **Behav Res Ther** 1997 Jul; 35(7):591–605

Anxiety sensitivity: confirmatory evidence for a multidimensional construct. Cox BJ, et al. **Behav Res Ther** 1996 Jul;34(7):591–8

Information processing in anxiety and depression. Lang AJ, et al. **Behav Res Ther** 1997 May;35(5):451–5

Pessimistic attributional style: is it specific to depression versus anxiety versus negative affect? Luten AG, et al. **Behav Res Ther** 1997 Aug;35(8):703–19

The assessment of anxiety and fear in persons with chronic pain: a comparison of instruments. McCracken LM, et al. **Behav Res Ther** 1996 Nov–Dec;34(11–12):927–33

Chronic low back pain: predictions of pain and relationship to anxiety and avoidance. Murphy D, et al. **Behav Res Ther** 1997 Mar;35(3):231–8

How to remain neutral: an experimental analysis of neutralization. Rachman S, et al. **Behav Res Ther** 1996 Nov–Dec;34(11–12):889–98

A cognitive-behavioral model of anxiety in social phobia. Rapee RM, et al. **Behav Res Ther** 1997 Aug;35(8):741–56

Anxiety and memory: a recall bias for threatening words in high anxiety. Reidy J, et al. **Behav Res Ther** 1997 Jun; 35(6):531–42

Looming vulnerability to threat: a cognitive paradigm for anxiety. Riskind JH. **Behav Res Ther** 1997 Aug; 35(8):685–702

Looming vulnerability to spreading contamination in subclinical OCD. Riskind JH, et al. **Behav Res Ther** 1997 May;35(5):405–14

Anxiogenic effects of high illumination levels assessed with the acoustic startle response in rats. Walker DL, et al. **Biol Psychiatry** 1997 Sep 15;42(6):461–71

Dietary restraint and anxiety in adolescent girls. Bleau R. **Br J Clin Psychol** 1996 Nov;35 (Pt 4):573–83

Hypomania, anxiety and the emotional Stroop. French CC,

et al. **Br J Clin Psychol** 1996 Nov;35 (Pt 4):617–26

The risk society in an age of anxiety: situating fear of crime. Hollway W, et al. **Br J Sociol** 1997 Jun;48(2):255–66 (15 ref.)

Excitatory amino acid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Sajdyk TJ, et al. **Brain Res** 1997 Aug 1;764(1–2):262–4

The burn specific pain anxiety scale: introduction of a reliable and valid measure. Taal LA, et al. **Burns** 1997 Mar; 23(2):147–50

Anxiety and depression in hospitalized patients with cancer: agreement in patient–staff dyads. Lampic C, et al. **Cancer Nurs** 1996 Dec;19(6):419–28

Anxiety, needs, and coping in family members of the bone marrow transplant patient. Wochna V. **Cancer Nurs** 1997 Aug;20(4):244–50 (18 ref.)

Problems in differentiating sexually from nonsexually abused adolescent psychiatric inpatients by self–reported anxiety, depression, internalization, and externalization. Kumar G, et al. **Child Abuse Negl** 1996 Nov;20(11):1079–86

Detached concern and death anxiety of first–year medical students: before and after the gross anatomy course. Dickinson GE, et al. **Clin Anat** 1997;10(3):201–7

Parental presence during lumbar puncture: anxiety and attitude toward the procedure. Haimi–Cohen Y, et al. **Clin Pediatr (Phila)** 1996 Jan;35(1):2–4

Mediators of gender differences in mathematics college entrance test scores: a comparison of spatial skills with internalized beliefs and anxieties. Casey MB, et al. **Dev Psychol** 1997 Jul;33(4):669–80

Effects of site–selective NMDA receptor antagonists in an elevated plus–maze model of anxiety in mice. Wiley JL, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):101–7

Stress–induced hyperthermia as a putative anxiety model. Zethof TJ, et al. **Eur J Pharmacol** 1995 Dec 27; 294(1):125–35

Impaired exploratory behaviour after DSP–4 treatment in rats: implications for the increased anxiety after noradrenergic denervation. Harro J, et al. **Eur Neuropsychopharmacol** 1995 Dec;5(4):447–55

Psychotherapy and the ethics of attention. Lipson M, et al. **Hastings Cent Rep** 1996 Jan–Feb;26(1):17–22

Negative affect relates to cross–sectional but not longitudinal symptom reporting: data from elderly adults. Diefenbach MA, et al. **Health Psychol** 1996 Jul;15(4):282–8

Attentional mediation of cigarette smoking's effect on anxiety. Kassel JD, et al. **Health Psychol** 1997 Jul; 16(4):359–68

Assessing anxiety about retirement: the case of academicians. Hayslip B Jr, et al. **Int J Aging Hum Dev** 1997;44(1):15–36

The effects of hypnosis, context reinstatement, and anxiety on eyewitness memory. Ready DJ, et al. **Int J Clin Exp Hypn** 1997 Jan;45(1):55–68

But is Paris really burning? Uncertainty anxieties and the normal chaos of love. Barale F, et al. **Int J Psychoanal** 1997 Apr;78 (Pt 2):373–8

Pre– and post–stimulus processes in affective task and event–related desynchronization (ERD): do they discriminate anxiety coping styles? Aftanas LI, et al. **Int J Psychophysiol** 1996 Dec;24(3):197–212

Opposite asymmetries in blind locomotor orientation of patients with panic agoraphobia compared to those with generalized anxiety. Kállai J, et al. **Int J Psychophysiol** 1996 Oct;23(3):155–61

Influence of time of day on the anxiolytic effects of exercise. Trine MR, et al. **Int J Sports Med** 1997 Apr;18(3):161–8

Reported health concerns of Israeli high school students—differences by age and sex. Palti H, et al. **Isr J Med Sci** 1997 Feb;33(2):123–8

Parental anxiety in febrile convulsions. Shuper A, et al. **Isr J Med Sci** 1996 Dec;32(12):1282–5

Expectancy bias in trait anxiety. Chan CK, et al. **J Abnorm Psychol** 1996 Nov;105(4):637–47

The role of anxiety sensitivity in the pathogenesis of panic: prospective evaluation of spontaneous panic attacks during acute stress. Schmidt NB, et al. **J Abnorm Psychol** 1997 Aug;106(3):355–64

Abnormalities in weight status, eating attitudes, and eating behaviors among urban high school students: correlations with self–esteem and anxiety. Pastore DR, et al. **J Adolesc Health** 1996 May;18(5):312–9

The study of biology as a cause of anxiety in student nurses undertaking the common foundation programme. Nicoll L, et al. **J Adv Nurs** 1996 Sep;24(3):615–24

The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. March JS, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Apr;36(4):554–65

Primary femininity and female genital anxiety. Richards AK. **J Am Psychoanal Assoc** 1996;44 Suppl:261–81

Relationships between anxiety sensitivity, hyperventilation, and emotional reactivity to displays of facial emotions. Dowden SL, et al. **J Anxiety Disord** 1997 Jan–Feb; 11(1):63–75

Normative data for the personal report of confidence as a speaker. Phillips GC, et al. **J Anxiety Disord** 1997 Mar–Apr;11(2):215–20

Trait anxiety: it's not what you think it is. Reiss S. **J Anxiety Disord** 1997 Mar–Apr;11(2):201–14 (36 ref.)

Gender differences in dimensions of anxiety sensitivity. Stewart SH, et al. **J Anxiety Disord** 1997 Mar–Apr; 11(2):179–200

Cognitive correlates of anxious and depressive symptomatology: an examination of the Helplessness/Hopelessness model. Waikar SV, et al. **J Anxiety Disord** 1997 Jan–Feb;11(1):1–16

Role of anxiety sensitivity in pain–related fear and avoidance. Asmundson GJ, et al. **J Behav Med** 1996 Dec;19(6):577–86

The effects of anxiety on response times to disease detection and health promotion behaviors. Millar MG, et al. **J Behav Med** 1996 Aug;19(4):401–13

Parents' and children's appraisals of each other's anxiety while facing a common threat. Rosenbaum M, et al. **J Clin Child Psychol** 1997 Mar;26(1):43–52

Computerized assessment of sustained attention: interactive effects of task demand, noise, and anxiety. Ballard JC. **J Clin Exp Neuropsychol** 1996 Dec;18(6):864–82

Predictors of patient cooperation during gastrointestinal endoscopy. Mahajan RJ, et al. **J Clin Gastroenterol** 1997 Jun;24(4):220–3

Item factor analysis of the Italian version of the Death Anxiety Scale. Saggino A, et al. **J Clin Psychol** 1996 May; 52(3):329–33

Hey Bubba, what's the disease du jour? Sternbach G, et al. **J Emerg Med** 1997 May–Jun;15(3):407–8

Parental distress and children's problems among single–parent families in China. Cheung CK, et al. **J Genet Psychol** 1997 Sep;158(3):245–60

Parents' perceptions of children's worries in a changing world. Gottlieb D, et al. **J Genet Psychol** 1996 Mar; 157(1):104–18

An investigation of worry content among generally anxious individuals. Roemer L, et al. **J Nerv Ment Dis** 1997 May; 185(5):314–9

Informational coping styles: a validity study. Ross CJ, et al. **J Nurs Meas** 1995 Winter;3(2):145–58

Illness behaviour, personality traits, anxiety, and depression in patients with Menière's disease. Savastano M, et al. **J Otolaryngol** 1996 Oct;25(5):329–33 (12 ref.)

Mothers' knowledge of the risk factors and anxiety about SIDS. Cooper RM, et al. **J Paediatr Child Health** 1996 Aug;32(4):310–5

Anxiety responses of parents during and after the hospitalization of their 5– to 11–year–old children. Tiedeman ME. **J Pediatr Nurs** 1997 Apr;12(2):110–9

Prediction of children's postoperative pain: the role of presurgical expectations and anticipatory emotions. Palermo TM, et al. **J Pediatr Psychol** 1996 Oct;21(5):683–98

Detecting anxiety and defensiveness from visual and auditory cues. Harrigan JA, et al. **J Pers** 1996 Sep;64(3):675–709

Anxiety, alcohol, aphasia, and ums. Christenfeld N, et al. **J Pers Soc Psychol** 1996 Mar;70(3):451–60

Personality, punishment, and procedural learning: a test of J.A. Gray's anxiety theory. Corr PJ, et al. **J Pers Soc Psychol** 1997 Aug;73(2):337–44

Facilitating and debilitating trait anxiety, situational anxiety, and coping with an anticipated stressor: a process analysis. Raffety BD, et al. **J Pers Soc Psychol** 1997 Apr; 72(4):892–906

The effects of flumazenil, Ro 15–4513 and beta–CCM on the behaviour of control and stressed mice in the plus–maze test. Pokk P, et al. **J Physiol Pharmacol** 1997 Jun; 48(2):253–61

A preliminary analysis of the perceived risks of misusing multiple substances, trait anxiety, and approval motivation. Hittner JB. **J Psychol** 1997 Sep;131(5):501–11

A prospective study of changes in negative mood states of women undergoing surgical hysterectomy: the relationship to cognitive predisposition and familial support. Thornton EW, et al. **J Psychosom Obstet Gynaecol** 1997 Mar; 18(1):22–30

Word–association emotional indicators: associations with anxiety, psychoticism, neuroticism, extraversion, and creativity. Upmanyu VV, et al. **J Soc Psychol** 1996 Aug; 136(4):521–9

A study of the effects of patient anxiety, perceptions and equipment on motion artifacts in magnetic resonance imaging. Dantendorfer K, et al. **Magn Reson Imaging** 1997; 15(3):301–6

Perioperative knowledge and anxiety score of patients undergoing surgery. Kureshi J, et al. **Middle East J Anesthesiol** 1995 Oct;13(3):325–33

Some doubts about the basic concept of hole–board test. Bilkei–Gorzó A, et al. **Neurobiology (Bp)** 1996;4(4):405–15

Activation of 5–HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Duxon MS, et al. **Neuropharmacology** 1997 Apr–May; 36(4–5):601–8

Association of short alleles of a VNTR of the serotonin transporter gene with anxiety symptoms in patients presenting after deliberate self harm. Evans J, et al. **Neuropharmacology** 1997 Apr–May;36(4–5):439–43

Further evidence for differences between non–selective and BZ–1 (omega 1) selective, benzodiazepine receptor ligands in murine models of "state" and "trait" anxiety. Griebel G, et al. **Neuropharmacology** 1996;35(8):1081–91

Catecholaminergic, neuroendocrine and anxiety responses to acute psychological stress in healthy subjects: influence of alprazolam administration. Santagostino G, et al. **Neuropsychobiology** 1996;34(1):36–43

Septal vasopressin modulates anxiety–related behaviour in rats. Liebsch G, et al. **Neurosci Lett** 1996 Oct 18; 217(2–3):101–4

Amygdala kindling in the rat: anxiogenic–like consequences. Helfer V, et al. **Neuroscience** 1996 Aug;73(4):971–8

Adjustment responses of children and their mothers to cancer: self–care and anxiety. Moore JB, et al. **Oncol Nurs Forum** 1997 Apr;24(3):519–25

The influence of psychological variables on postoperative anxiety and physical complaints in patients undergoing lumbar surgery. de Groot KI, et al. **Pain** 1997 Jan; 69(1–2):19–25

Anxiety and pain: attentional and endorphinergic influences. Janssen SA, et al. **Pain** 1996 Aug;66(2–3):145–50

Exploratory factor analysis of the Pain Anxiety Symptoms Scale in patients with chronic pain complaints. Larsen DK, et al. **Pain** 1997 Jan;69(1–2):27–34

Effect of present pain and mood on the memory of past postoperative pain in women treated surgically for breast cancer. Tasmuth T, et al. **Pain** 1996 Dec;68(2–3):343–7

Psychological and clinical effects of renal biopsy performed using sedation. Blake KD, et al. **Pediatr Nephrol** 1996 Dec; 10(6):693–5

Two scales of death anxiety: their reliability and correlation among Kuwaiti samples. Abdel–Khalek AM. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):921–2

Psychology of computer use: XLIV. Computer anxiety and learning style. Bozionelos N. **Percept Mot Skills** 1997 Jun; 84(3 Pt 1):753–4

Home field advantage: does anxiety contribute? Duffy LJ, et al. **Percept Mot Skills** 1997 Feb;84(1):283–6

Psychology of computer use: XLII. Problem solving and humor as a function of computer anxiety. Emanuele S, et al. **Percept Mot Skills** 1997 Feb;84(1):147–56

Brief aikido training versus karate and golf training and university students' scores on self–esteem, anxiety, and expression of anger. Foster YA. **Percept Mot Skills** 1997 Apr;84(2):609–10

Social physique anxiety: personality constructs, motivations, exercise attitudes, and behaviors. Frederick CM, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):963–72

Effects of mental practice on performance are moderated by cognitive anxiety as measured by the Sport Competition Anxiety Test. Halvari H. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1375–83

Effects of subliminal symbiotic stimuli on anxiety reduction. Malik R, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):771–84

Measures of anxiety among tennis players in singles and doubles matches. Terry PC, et al. **Percept Mot Skills** 1996 Oct;83(2):595–603

Perception of anxiety and expectations of performance. Wiggins MS, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 1):1071–4

Comparison of apprehension about communication in China and the United States. Zhang Y, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 2):1168–70

Marmoset conspecific confrontation: an ethologically–based model of anxiety. Cilia J, et al. **Pharmacol Biochem Behav** 1997 Sep;58(1):85–91

Effects of L–NOARG on plus–maze performance in rats. De Oliveira CL, et al. **Pharmacol Biochem Behav** 1997 Jan; 56(1):55–9

Evaluation of perinatal flumazenil effects on the behavior of female RLA/Verh rats in anxiety tests and shuttle box avoidance. Ferré P, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):475–80

Comparative analysis of anxiety–like behavior in partition and plus–maze tests after agonistic interactions in mice. Avgustinovich DF, et al. **Physiol Behav** 1997 Jan; 61(1):37–43

Illumination has no effect on rats' behavior in the elevated plus–maze. Becker A, et al. **Physiol Behav** 1996 Jun; 59(6):1175–7

Understanding the anxious patient. Spurrell M. **Practitioner** 1996 Dec;240(1569):700–3

Quality of life and anxiety in pregnancies after late pregnancy loss: a case–control study. Hunfeld JA, et al. **Prenat Diagn** 1996 Sep;16(9):783–90

Differential effects of noradrenergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Mizuki Y, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov; 20(8):1353–67

A longitudinal study of the effects of pessimism, trait anxiety, and life stress on depressive symptoms in middle–aged women. Bromberger JT, et al. **Psychol Aging** 1996 Jun; 11(2):207–13

Mothers' trait anxiety and adaptation to an infant born subsequent to the loss of a late pregnancy. Agterberg G, et al. **Psychol Rep** 1997 Feb;80(1):216–8

Psychology of computer use: XLV. Cognitive spontaneity as a correlate of computer anxiety and attitudes toward computer use. Bozionelos N. **Psychol Rep** 1997 Apr; 80(2):395–402

Smoking and trait anxiety. Canals J, et al. **Psychol Rep** 1996 Dec;79(3 Pt 1):809–10

Reduction of anxiety about death: need for beliefs about immortality. Conn R, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1315–8

Depression and anxiety in young children of substance abusers. Drucker PM, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):723–32

Poststroke anxiety and its relationship to coping and stage of recovery. Gillespie DC. **Psychol Rep** 1997 Jun;80(3 Pt 2):1059–64

Preliminary study of death anxiety of believers versus

percipients of the paranormal. Houran J. **Psychol Rep** 1997 Feb;80(1):345–6
Clinical description of children's anxiety during the Gulf War. al-Khawaja JM. **Psychol Rep** 1997 Jun;80(3 Pt 1):733–4
Sex and mathematical background as predictors of anxiety and self-efficacy in mathematics. Lussier G. **Psychol Rep** 1996 Dec;79(3 Pt 1):827–33
Social support, need for support, and anxiety among women graduate students. Munir SS, et al. **Psychol Rep** 1997 Apr; 80(2):383–6
Coping strategies and anxiety in Italian adolescents. Nigro G. **Psychol Rep** 1996 Dec;79(3 Pt 1):835–9
Perceived family-of-origin health and current adjustment. O'Leary JA, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1326
A note on measuring apprehension about writing. Rechtien JG, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):907–13
Undertakers' death anxiety. Thorson JA, et al. **Psychol Rep** 1996 Jun;78(3 Pt 2):1228–30
Anxiety and hostility in written verbal samples of male and female subjects. A content analytic study. Sanfuentes MT, et al. **Psychopathology** 1996;29(3):169–73
7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. Volke V, et al. **Psychopharmacology (Berl)** 1997 Jun; 131(4):399–405
Anxiety and complications associated with acute myocardial infarction [letter; comment] Kornfeld DS. **Psychosom Med** 1997 Mar–Apr;59(2):211. Comment on: Psychosom Med 1996 Sep–Oct;58(5):395–401.
Effects of cynical hostility, anger out, anxiety, and defensiveness on ambulatory blood pressure in black and white college students. Shapiro D, et al. **Psychosom Med** 1996 Jul–Aug;58(4):354–64
Unemployment, coping and psychological distress. Smári J, et al. **Scand J Psychol** 1997 Jun;38(2):151–6
Prevalence and severity of anxiety, depression and Type A behaviors in angina pectoris. Smith DF, et al. **Scand J Psychol** 1996 Sep;37(3):249–58
Life events and anxiety in Chinese medical students. Liu XC, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Feb; 32(2):63–7
Predictors of family anxiety in the weeks before bereavement. Higginson I, et al. **Soc Sci Med** 1996 Dec;43(11):1621–5
Anxiety and patient participation in clinical decision-making: the case of patients with ureteral calculi. Margalith I, et al. **Soc Sci Med** 1997 Aug;45(3):419–27
Responses to underwater exercise in scuba divers differing in trait anxiety. Raglin JS, et al. **Undersea Hyperb Med** 1996 Jun;23(2):77–82
[Correlation between anxiety and pain in the first gynecological examination of children and adolescents] Bodden-Heidrich R, et al. **Geburtshilfe Frauenheilkd** 1996 Oct;56(10):M161–3 **(Ger)**
[Environmental concern of clients of an environmental medicine counseling center] Neuhann HF, et al. **Gesundheitswesen** 1996 Aug–Sep;58(8–9):477–81 (Eng. Abstr.) **(Ger)**
[ICD-10 (International Classification of Diseases): a new way with speed bumps? Discussed on the example of depression, anxiety and sleep disorders] **Psychiatr Prax** 1996 Jan;23(1 Suppl):1–8 **(Ger)**
[Anxiety-induced reactions in connection with magnetic resonance tomography (MRI) examinations] Goyen M, et al. **Rontgenpraxis** 1997 Mar;50(3):63–6 (32 ref.) **(Ger)**
[The anxious patient during magnetic resonance tomography (MRI) examination. Health care economic aspects of patient education] Goyen M, et al. **Z Arztl Fortbild Qualitatssich** 1997 Jul;91(4):319–22 (21 ref.) (Eng. Abstr.) **(Ger)**
[Environmental concerns—fear of the environment or concern for the environment?] Kappos AD. **Z Arztl Fortbild Qualitatssich** 1997 Feb;91(1):5–10 (Eng. Abstr.) **(Ger)**
[Relationship between psychosocial and cardiovascular variables in adolescents] Bretaña Casado ML, et al. **An Esp Pediatr** 1996 Dec;45(6):603–8 (Eng. Abstr.) **(Spa)**
[Parent's perception of vaccination] Díez-Delgado Rubio J, et al. **An Esp Pediatr** 1996 Aug;45(2):129–32 (Eng. Abstr.) **(Spa)**
[Factors associated with anxiety and taking psychotropic drugs in caregivers of incapacitated patients] García Lozano L, et al. **Aten Primaria** 1996 Oct 31;18(7):395–8 (Eng. Abstr.) **(Spa)**

THERAPY

Homeopathic treatment of depression and anxiety. Davidson JR, et al. **Altern Ther Health Med** 1997 Jan;3(1):46–9
Music therapy for patients undergoing regional anesthesia. Eisenman A, et al. **AORN J** 1995 Dec;62(6):947–50
A management approach to anxiety. Lampe LA. **Aust Fam Physician** 1996 Oct;25(10):1561–3, 1566–7 (17 ref.)
An information processing model of anxiety: automatic and strategic processes. Beck AT, et al. **Behav Res Ther** 1997 Jan;35(1):49–58
Massage therapy reduces anxiety and enhances EEG pattern of alertness and math computations. Field T, et al. **Int J Neurosci** 1996 Sep;86(3–4):197–205
Measuring effectiveness of eye movement desensitization and reprocessing (EMDR) in non-clinical anxiety: a multi-subject, yoked-control design. Dunn TM, et al. **J Behav Ther Exp Psychiatry** 1996 Sep;27(3):231–9
Evaluating the efficacy of a biofeedback intervention to reduce children's anxiety. Wenck LS, et al. **J Clin Psychol** 1996 Jul;52(4):469–73
Childhood asthma complicated by anxiety: an application of cognitive behavioural therapy. Park SJ, et al. **J Paediatr Child Health** 1996 Apr;32(2):183–7
Centering: reducing rape trauma syndrome anxiety during a gynecologic examination. Dole PJ. **J Psychosoc Nurs Ment Health Serv** 1996 Oct;34(10):32–7
Problem-solving therapy in palliative care. Wood BC, et al. **Palliat Med** 1997 Jan;11(1):49–54
Persisting improvement in complaint-related cognitions initiated during medical consultations in functional abdominal complaints. van Dulmen AM, et al. **Psychol Med** 1997 May;27(3):725–9

ANXIETY, CASTRATION

PSYCHOLOGY

The Oedipus complex, castration and the fetish: a revision of the psychoanalytic theory of sexuality. Marucco NC. **Int J Psychoanal** 1997 Apr;78 (Pt 2):351–5
Castration anxiety or feminine genital anxiety? Dorsey D. **J Am Psychoanal Assoc** 1996;44 Suppl:283–302

ANXIETY, DENTAL see **DENTAL ANXIETY**

ANXIETY DISORDERS

Compulsive washing in the absence of phobic and illness anxiety. Tallis F. **Behav Res Ther** 1996 Apr;34(4):361–2
Fear and anxiety in children and adolescents. Craske MG. **Bull Menninger Clin** 1997 Spring;61(2 Suppl A):A4–36 (145 ref.)
Anxiety disorders in primary care: a life-span perspective. Shear MK, et al. **Bull Menninger Clin** 1997 Spring;61(2 Suppl A):A37–53
Depression & anxiety in the primary care setting. Cunningham LA. **Compr Ther** 1997 Jun;23(6):400–6 (20 ref.)
Childhood anxiety disorders. Pine DS. **Curr Opin Pediatr** 1997 Aug;9(4):329–38 (119 ref.)
The mind-body connection--anxiety, panic, mood and compulsion [news] **Int J Fertil Menopausal Stud** 1996 Nov–Dec;41(6):498–505
The Impact of Anxiety. on the Health Care System. Proceedings of a symposium. Stowe, Vermont, March 15–16, 1996. **J Clin Psychiatry** 1997;58 Suppl 3:1–80; quiz 82–3
Fear, panic, anxiety, and disorders of emotion. Barlow DH, et al. **Nebr Symp Motiv** 1996;43:251–328 (100 ref.)

BLOOD

Serum cholesterol levels in patients with generalized anxiety disorder (GAD) and with GAD and comorbid major depression. Kuczmierczyk AR, et al. **Can J Psychiatry** 1996 Sep;41(7):465–8
Platelet I1-imidazoline binding sites are elevated in depression but not generalized anxiety disorder. Piletz JE, et al. **J Psychiatr Res** 1996 May–Jun;30(3):147–68
Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in non-psychotic depressed patients: a pilot study. Hamner MB, et al. **Psychiatry Res** 1996 Oct 16;64(3):209–11
Effect of benzodiazepines on plasma levels of homovanillic acid in anxious patients and control subjects. Wingerson DK, et al. **Psychiatry Res** 1996 Nov 1;65(1):53–9

CHEMICALLY INDUCED

Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Brawman-Mintzer O, et al. **Am J Psychiatry** 1997 May;154(5):700–2
Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy. Warnock JK, et al. **Psychopharmacol Bull** 1997;33(2):311–6

CLASSIFICATION

Major depression and generalised anxiety disorder. Same genes, (partly)different environments--revisited. Kendler KS. **Br J Psychiatry Suppl** 1996 Jun;(30):68–75
Subthreshold syndromes of depression and anxiety in the community. Angst J, et al. **J Clin Psychiatry** 1997;58 Suppl 8:6–10

COMPLICATIONS

Liaison psychiatry in an HIV/AIDS unit. Judd FK, et al. **Aust N Z J Psychiatry** 1997 Jun;31(3):391–7
Comorbidity and its effects on panic disorder. Marshall JR. **Bull Menninger Clin** 1996 Spring;60(2 Suppl A):A39–53 (63 ref.)
Lifetime anxiety disorders in women with bulimia nervosa. Bulik CM, et al. **Compr Psychiatry** 1996 Sep–Oct; 37(5):368–74
On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Manning JS, et al. **Compr Psychiatry** 1997 Mar–Apr; 38(2):102–8
Psychiatric symptoms in clients presenting for commercial weight reduction treatment. Goldstein LT, et al. **Int J Eat Disord** 1996 Sep;20(2):191–7
Course of depression in patients with comorbid anxiety disorders. Sherbourne CD, et al. **J Affect Disord** 1997 May; 43(3):245–50
Systematic assessment of 50 children with selective mutism. Dummit ES 3rd, et al. **J Am Acad Child Adolesc Psychiatry** 1997 May; 36(5):653–60
Anxious children in adulthood: a prospective study of adjustment. Last CG, et al. **J Am Acad Child Adolesc Psychiatry** 1997 May; 36(5):645–52
Management of blood-drawing fears in adolescents with comorbid anxiety and depressive disorders. Bernstein GA, et al. **J Child Adolesc Psychopharmacol** 1996 Spring; 6(1):53–61
Treating comorbid depression and anxiety. Kuzel RJ. **J Fam Pract** 1996 Dec;43(6 Suppl):S45–53 (75 ref.)
Anxiety and short stature [letter; comment] Cizza G, et al. **Pediatrics** 1997 Mar;99(3):500. Comment on: Pediatrics 1996 Jun;97(6 Pt 1):856–63.
Anxiety and short stature [letter; comment] Friedman EH. **Pediatrics** 1997 Mar;99(3):499–500; discussion 500. Comment on: Pediatrics 1996 Jun;97(6 Pt 1):856–63.
[Anxiety disorders and unexplained syncopes of presumed vaso-vagal origin] Kouakam C, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89(10):1247–54 (31 ref.) (Eng. Abstr.) **(Fre)**
[Psychopathological disorders and coronary diseases] Boisseau R, et al. **Rev Med Interne** 1997;18(4):303–10 (70 ref.) (Eng. Abstr.) **(Fre)**
[Coincidence of anxiety and sleep disorders. Overview and case reports] Hajak G, et al. **Fortschr Neurol Psychiatr** 1996 Jan;64(1):26–40 (Eng. Abstr.) **(Ger)**
[Clinical considerations regarding co-morbidity in childhood and adolescent anxiety disorders] Ballesteros Alcalde MC, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Nov–Dec;24(6):339–52 (45 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

What do anxiety scales measure? Keedwell P, et al. **Acta Psychiatr Scand** 1996 Mar;93(3):177–80
Determinants of self-rating and expert rating concordance in psychiatric out-patients, using the affective subscales of the CPRS. Mattila-Evenden M, et al. **Acta Psychiatr Scand** 1996 Dec;94(6):386–96
Generalized anxiety and depression. Assessment over 2 years after stroke. Schultz SK, et al. **Am J Geriatr Psychiatry** 1997 Summer;5(3):229–37
Complicated grief as a disorder distinct from bereavement-related depression and anxiety: a replication study. Prigerson HG, et al. **Am J Psychiatry** 1996 Nov; 153(11):1484–6
Panic disorder in Singapore: clinical features and comparisons with generalised anxiety disorder. Lim LE, et al. **Ann Acad Med Singapore** 1997 Mar;26(2):188–92
Phenomenology and severity of major depression and comorbid lifetime anxiety disorders in primary medical care practice. Brown C, et al. **Anxiety** 1996;2(5):210–8
Four-dimensional Anxiety and Depression Scale: a preliminary psychometric report. Bystritsky A, et al. **Anxiety** 1996;2(1):47–50
Pilot MRI study of brain size in nervous pointer dogs. George MS, et al. **Anxiety** 1994–95;1(3):129–33
Ambulatory monitoring of respiration in anxiety. Martinez JM, et al. **Anxiety** 1996;2(6):296–302
Anxiety among widowed elders: is it distinct from depression and grief? Prigerson HG, et al. **Anxiety** 1996;2(1):1–12
Comparison of descriptive variables for symptomatic volunteers and clinical patients with anxiety disorders. Rapaport MH, et al. **Anxiety** 1996;2(3):117–22
Comparison of RDC, DSM-III, DSM-III-R diagnostic criteria for generalized anxiety disorder. Wolk SI, et al. **Anxiety** 1996;2(2):71–9
Behavioral expressions of intolerance of uncertainty in worry. Experimental findings. Ladouceur R, et al. **Behav Modif** 1997 Jul;21(3):355–71
Characteristics of generalized anxiety disorder in older adults: a descriptive study. Beck JG, et al. **Behav Res Ther** 1996 Mar;34(3):225–34
Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Brown TA, et al. **Behav Res Ther** 1997 Jan;35(1):79–89
Does the Beck Anxiety Inventory measure anything beyond panic attack symptoms? Cox BJ, et al. **Behav Res Ther** 1996 Nov–Dec;34(11–12):949–54; discussion 955–61
Validation of the spanish version of the Anxiety Sensitivity Index in a clinical sample. Sandin B, et al. **Behav Res Ther** 1996 Mar;34(3):283–90
Regional brain asymmetries in major depression with or without an anxiety disorder: a quantitative electroencephalographic study. Bruder GE, et al. **Biol Psychiatry** 1997 May 1;41(9):939–48
Comorbid depression and anxiety spectrum disorders. Gorman JM. **Depress Anxiety** 1996–97;4(4):160–8 (80 ref.)
Preliminary investigation of the role of previous exposure to potentially traumatizing events in generalized anxiety disorder. Roemer L, et al. **Depress Anxiety** 1996–97; 4(3):134–8
Screening for anxiety and depression in primary care with

the Duke Anxiety-Depression Scale [see comments] Parkerson GR Jr, et al. **Fam Med** 1997 Mar;29(3):177–81 . Comment in: Fam Med 1997 Mar;29(3):182–3.

Recognition of mental health problems in primary care practices [editorial; comment] Volk RJ, et al. **Fam Med** 1997 Mar;29(3):182–3. Comment on: Fam Med 1997 Mar;29(3):172–6. Comment on: Fam Med 1997 Mar;29(3):177–81.

Chronic fatigue syndrome. A practical guide to assessment and management. Sharpe M, et al. **Gen Hosp Psychiatry** 1997 May;19(3):185–99 (128 ref.)

The relationship between social phobia and avoidant personality disorder: workshop report 3. Dahl AA. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:109–12

Depression, anxiety, and sleep disturbances. Reifler BV. **Int Psychogeriatr** 1996;8 Suppl 3:415–8; discussion 423–4

Stability of anxious symptomatology in children. Beidel DC, et al. **J Abnorm Child Psychol** 1996 Jun;24(3):257–69

What I Think and Feel: a revised measure of Children's Manifest Anxiety. Reynolds CR, et al. **J Abnorm Child Psychol** 1997 Feb;25(1):15–20

Predictors of the generation of episodic stress: a longitudinal study of late adolescent women. Daley SE, et al. **J Abnorm Psychol** 1997 May;106(2):251–9

Structure of anxiety symptoms among children: a confirmatory factor-analytic study. Spence SH. **J Abnorm Psychol** 1997 May;106(2):280–97

Prevalence and correlates of anger attacks: a two site study. Gould RA, et al. **J Affect Disord** 1996 Jun 20;39(1):31–8

Covariance in the measurement of depression/anxiety and three Cluster C personality disorders (avoidant, dependent, obsessive-compulsive). Rees A, et al. **J Affect Disord** 1997 Sep;45(3):143–53

The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics. Birmaher B, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Apr;36(4):545–53

Long-term impact of exposure to suicide: a three-year controlled follow-up. Brent DA, et al. **J Am Acad Child Adolesc Psychiatry** 1996 May; 35(5):646–53

A prospective study of childhood anxiety disorders. Last CG, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Nov; 35(11):1502–10

Psychometric properties and diagnostic utility of the Beck Anxiety Inventory and the State-Trait Anxiety Inventory with older adult psychiatric outpatients. Kabacoff RI, et al. **J Anxiety Disord** 1997 Jan-Feb;11(1):33–47

Temperament and psychopathology amongst siblings of probands with depressive and anxiety disorders. Kelvin RG, et al. **J Child Psychol Psychiatry** 1996 Jul;37(5):543–50

An investigation of negative affectivity in Australian adolescents. Boyd CP, et al. **J Clin Child Psychol** 1997 Jun;26(2):190–7

Variability in symptom expression among sexually abused girls: developing multivariate models. Spaccarelli S, et al. **J Clin Child Psychol** 1997 Mar;26(1):24–35

Subthreshold syndromes of depression and anxiety in the community. Angst J, et al. **J Clin Psychiatry** 1997;58 Suppl 8:6–10

Depression and anxiety: implications for nosology, course, and treatment. Angst J. **J Clin Psychiatry** 1997;58 Suppl 8:3–5 (34 ref.)

Mixed anxiety and depression: from theory to practice. Boulenger JP, et al. **J Clin Psychiatry** 1997;58 Suppl 8:27–34 (49 ref.)

Anxiety disorders and the syndrome of chest pain with normal coronary arteries: prevalence and pathophysiology. Carter CS, et al. **J Clin Psychiatry** 1997;58 Suppl 3:70–3; discussion 74–5 (21 ref.)

The offensive subtype of Taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder. Clarvit SR, et al. **J Clin Psychiatry** 1996 Nov; 57(11):523–7

The detection and consequences of anxiety in clinical depression. Fawcett J. **J Clin Psychiatry** 1997;58 Suppl 8:35–40

The infrequency of "pure culture" diagnoses among the anxiety disorders. Goldenberg IM, et al. **J Clin Psychiatry** 1996 Nov;57(11):528–33

Recognizing and treating anxiety in the elderly. Small GW. **J Clin Psychiatry** 1997;58 Suppl 3:41–7; discussion 48–50 (43 ref.)

Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? Yonkers KA. **J Clin Psychiatry** 1997;58 Suppl 3:62–7; discussion 68–9 (50 ref.)

Importance of establishing the diagnosis of persistent anxiety. Zajecka J. **J Clin Psychiatry** 1997;58 Suppl 3:9–13; discussion 14–5 (20 ref.)

Family treatment of childhood anxiety: a controlled trial. Barrett PM, et al. **J Consult Clin Psychol** 1996 Apr; 64(2):333–42

Decline in self-reported dysphoria after treatment entry in inner-city cocaine addicts. Husband SD, et al. **J Consult Clin Psychol** 1996 Feb;64(1):221–4

Cognitive bias in spider fear and control children: assessment of emotional interference by a card format and a single-trial format of the stroop task. Kindt M, et al. **J Exp Child Psychol** 1997 Aug;66(2):163–79

Dissociation contributes to anxiety and psychoticism on the Brief Symptom Inventory. Allen JG, et al. **J Nerv Ment Dis** 1996 Oct;184(10):639–41

Psychological distress and bereavement. Middleton W, et al. **J Nerv Ment Dis** 1997 Jul;185(7):447–53

Defense style in depressed and anxious psychiatric outpatients: an explorative study. Spinhoven P, et al. **J Nerv Ment Dis** 1997 Feb;185(2):87–94

Detection of feigned mental disorders on the personality assessment inventory: a discriminant analysis. Rogers R, et al. **J Pers Assess** 1996 Dec;67(3):629–40

Confirmatory factor analyses of the Anxiety and Depression content scales of the MMPI-2. Ward LC. **J Pers Assess** 1997 Jun;68(3):678–91

Anxiety, depression and management of medically unexplained symptoms in medical clinics. Hamilton J, et al. **J R Coll Physicians Lond** 1996 Jan-Feb;30(1):18–20

MJA practice essentials. 3. Assessment of anxiety and depression in primary care. Ellen SR, et al. **Med J Aust** 1997 Sep 15;167(6):328–33

Women's health. Anxiety disorders. Pennington A. **Prim Care** 1997 Mar;24(1):103–11 (34 ref.)

Distress reduction during the structured clinical interview for DSM-III-R. Scarvalone PA, et al. **Psychiatry Res** 1996 Jan 31;59(3):245–9

Discriminant validity of the Inventory to Diagnose Depression between patients with major depression and pure anxiety disorders. Uehara T, et al. **Psychiatry Res** 1997 Jun 16;71(1):57–61

Content validity of the Psychiatric Symptom Index, CES-depression Scale, and State-Trait Anxiety Inventory from the perspective of DSM-IV. Okun A, et al. **Psychol Rep** 1996 Dec;79(3 Pt 1):1059–69

Symptoms of neuroses: profile patterns and factor structure of clinic attenders with non-psychotic functional psychiatric disorders. Kitamura T, et al. **Psychopathology** 1997;30(4):191–9

Depressive, not anxiety, symptoms are associated with current cigarette smoking among university internal medical patients. Kick SD, et al. **Psychosomatics** 1997 Mar-Apr;38(2):132–9

Do anxiety disorders exist in persons with severe and profound mental retardation? Matson JL, et al. **Res Dev Disabil** 1997 Jan-Feb;18(1):39–44

Electrodermal lability in anxiety disorders. Jensen HH, et al. **Scand J Psychol** 1996 Mar;37(1):103–8

First-night-effects on generalized anxiety disorder (GAD)-based insomnia: laboratory versus home sleep recordings. Saletu B, et al. **Sleep** 1996 Nov;19(9):691–7

[Disorders of assertiveness and social anxiety] Azais F, et al. **Ann Med Psychol (Paris)** 1995 Dec;153(10):667–75 (33 ref.) (Eng. Abstr.) **(Fre)**

[Panic disorder and panic attack] Abbar M. **Encephale** 1996 Dec;22 Spec No 5:13–8 (32 ref.) (Eng. Abstr.) **(Fre)**

[Paroxysmal anxiety crisis, viewpoint of the general practitioner] Bourgeois M. **Encephale** 1996 Dec;22 Spec No 5:9–10 (Eng. Abstr.) **(Fre)**

[Panic attack and panic disorder in the child and adolescent] Braconnier A. **Encephale** 1996 Dec;22 Spec No 5:19–24 (16 ref.) (Eng. Abstr.) **(Fre)**

[Anxiety disorders. Diagnosis and therapy in family practice. 1: Anxiety reactions--psychiatric disorders and anxiety--anxiety disorders] Riemann D. **Fortschr Med** 1996 Nov 30;114(33):457–9 **(Ger)**

[Electroencephalography in psychiatry--current status and outlook] Herrmann WM, et al. **Nervenarzt** 1996 May; 67(5):348–59 (139 ref.) (Eng. Abstr.) **(Ger)**

[Panic attacks with cycloleptic course--differential diagnostic considerations in differentiating panic disorder from epileptic anxiety attacks] Heinemann F, et al. **Psychiatr Prax** 1996 Jul;23(4):192–3 (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of anxiety disorders] Wacker HR. **Ther Umsch** 1997 Jul;54(7):380–5 (Eng. Abstr.) **(Ger)**

[Validation of the hospital anxiety and depression scale in a gastro-intestinal clinic] Higashi A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Dec;93(12):884–92 (Eng. Abstr.) **(Jpn)**

[Use of Hospital Anxiety and Depression Scale in psychosomatic disorders] Karakula H, et al. **Psychiatr Pol** 1996 Jul-Aug;30(4):653–67 (Eng. Abstr.) **(Pol)**

[Physical manifestations of anxiety during group psychotherapy] Gregurek R, et al. **Lijec Vjesn** 1996 Mar-Apr;118(3-4):63–7 (Eng. Abstr.) **(Scr)**

DRUG THERAPY

Treatment of non-cognitive symptoms in dementia. Karlsson I. **Acta Neurol Scand Suppl** 1996;168:93–5 (20 ref.)

Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder. Klein E, et al. **Acta Psychiatr Scand** 1995 Dec;92(6):399–408

The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Razavi D, et al. **Acta Psychiatr Scand** 1996 Sep;94(3):205–10

Paroxetine efficacy in the treatment of generalized anxiety disorder. Rocca P, et al. **Acta Psychiatr Scand** 1997 May; 95(5):444–50

Anxious depression in elderly patients. Response to antidepressant treatment. Flint AJ, et al. **Am J Geriatr Psychiatry** 1997 Spring;5(2):107–15

Calcium channel blockers for anxiety disorders? Balon R, et al. **Ann Clin Psychiatry** 1996 Dec;8(4):215–20 (42 ref.)

Placebo response in anxiety disorders. Piercy MA, et al. **Ann Pharmacother** 1996 Sep;30(9):1013–9 (47 ref.)

Lactate-induced anxiety after imipramine and diazepam treatment. Pohl R, et al. **Anxiety** 1994;1(2):54–63

Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics. Sheehan DV, et al. **Anxiety** 1996;2(1):40–6

Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder [letter] Sramek JJ, et al. **Anxiety** 1994-95;1(5):242–3

Alprazolam-induced hypomania. Reddy J, et al. **Aust N Z J Psychiatry** 1996 Aug;30(4):550–2

Benzodiazepine use by students: risky business [letter] McSherry J. **Can Fam Physician** 1996 Feb;42:234, 236

Treatment of anxiety disorders in late life. Sadavoy J, et al. **Can J Psychiatry** 1997 Jun;42 Suppl 1:28S–34S (78 ref.)

Alprazolam-reinforced medication use in outpatients with anxiety. Roache JD, et al. **Drug Alcohol Depend** 1997 May 2;45(3):143–55

A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Pecknold JC. **Drug Saf** 1997 Feb; 16(2):118–32 (241 ref.)

Optimal management of anxiety in older patients. Weiss KJ. **Drugs Aging** 1996 Sep;9(3):191–201 (76 ref.)

A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Bourin M, et al. **Fundam Clin Pharmacol** 1997;11(2):127–32

Application of the Stages of Change Scale in a clinical drug trial. Wilson M, et al. **J Anxiety Disord** 1997 Jul-Aug; 11(4):395–408

Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. Fairbanks JM, et al. **J Child Adolesc Psychopharmacol** 1997 Spring;7(1):17–29

Cardiovascular effects of tricyclic antidepressants in childhood asthma: a case series and review. Wamboldt MZ, et al. **J Child Adolesc Psychopharmacol** 1997 Spring; 7(1):45–64 (63 ref.)

Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. Bodkin JA, et al. **J Clin Psychiatry** 1997 Apr;58(4):137–45

The offensive subtype of Taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder. Clarvit SR, et al. **J Clin Psychiatry** 1996 Nov; 57(11):523–7

A treatment algorithm for the management of anxiety in primary care practice. Hales RE, et al. **J Clin Psychiatry** 1997;58 Suppl 3:76–80 (24 ref.)

Management of patients with depression associated with anxiety symptoms. Nutt D. **J Clin Psychiatry** 1997;58 Suppl 8:11–6 (67 ref.)

A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. Ravindran AV, et al. **J Clin Psychiatry** 1997 Mar;58(3):112–8

Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link. Stahl SM. **J Clin Psychiatry** 1997;58 Suppl 8:20–6 (64 ref.)

Buspirone for the treatment of anxiety in patients with chronic obstructive airways disease [letter] Alderman CP, et al. **J Clin Psychopharmacol** 1996 Oct;16(5):410–1

Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder. Pourmotabbed T, et al. **J Clin Psychopharmacol** 1996 Jun; 16(3):202–7

Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study. Sramek JJ, et al. **J Clin Psychopharmacol** 1996 Dec; 16(6):454–8

Recent developments in the psychopharmacology of anxiety disorders. Lydiard RB, et al. **J Consult Clin Psychol** 1996 Aug;64(4):660–8 (85 ref.)

Treating comorbid depression and anxiety. Kuzel RJ. **J Fam Pract** 1996 Dec;43(6 Suppl):S45–53 (75 ref.)

Physicians' decisions to prescribe benzodiazepines for nervousness and insomnia. Brown RL, et al. **J Gen Intern Med** 1997 Jan;12(1):44–52

Management of the prescription-drug-dependent adult: case of meprobamate abuse and its treatment. Gonzales JJ, et al. **J Geriatr Psychiatry Neurol** 1996 Apr;9(2):91–6

Anxiety, depression and management of medically unexplained symptoms in medical clinics. Hamilton J, et al. **J R Coll Physicians Lond** 1996 Jan-Feb;30(1):18–20

Single-subject experiments to determine individually differential effects of anxiolytics in generalized anxiety disorder. Wurthmann C, et al. **Neuropsychobiology** 1996; 33(4):196–201

Anxiety and depression. Diagnosis and treatment during pregnancy. Diket AL, et al. **Obstet Gynecol Clin North Am** 1997 Sep;24(3):535–58 (50 ref.)

Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Michelini S, et al. **Pharmacopsychiatry** 1996 Jul; 29(4):127–34 (93 ref.)

Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. Volz HP, et al. **Pharmacopsychiatry** 1997 Jan;30(1):1–5

Side effects of low dose neuroleptics and their impact on clinical outcome in generalized anxiety disorder. Wurthmann C, et al.

Prog Neuropsychopharmacol Biol Psychiatry 1997 May; 21(4):601–9

The realities of clonazepam discontinuation. Freeman S. **Psychiatr Serv** 1997 Jul;48(7):881–2

Two–year outcome of elderly patients with anxious depression. Flint AJ, et al. **Psychiatry Res** 1997 Jan 15; 66(1):23–31

An open trial of nefazodone in adult patients with generalized anxiety disorder. Hedges DW, et al. **Psychopharmacol Bull** 1996;32(4):671–6

Tranquillizers are good for you. Hallström C. **Trans Med Soc Lond** 1994–95;111:59–62

[Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study] Romain JL, et al. **Encephale** 1996 Jul–Aug;22(4):280–6 (Eng. Abstr.) **(Fre)**

[The 5–HT1A receptor: a new effective principle in psychopharmacologic therapy?] Davids E, et al. **Fortschr Neurol Psychiatr** 1996 Nov;64(11):460–72 (135 ref.) (Eng. Abstr.) **(Ger)**

[Fluspirilene––safe weekly tranquilizer?] Kuhn W, et al. **Nervenarzt** 1997 Jun;68(6):528 **(Ger)**

[Benzodiazepine withdrawal syndrome in low dose dependency] Thomas H, et al. **Psychiatr Prax** 1996 Sep; 23(5):249–50 **(Ger)**

[Alprazolam in the treatment of anxiety disorders and mixed anxiety and depressive disorders. Results of multicenter clinical trial] Kiejna A, et al. **Psychiatr Pol** 1996 Nov–Dec; 30(6):973–92 (Eng. Abstr.) **(Pol)**

ECONOMICS

Economic costs of anxiety disorders. DuPont RL, et al. **Anxiety** 1996;2(4):167–72

EPIDEMIOLOGY

Generalized anxiety disorder in chronic fatigue syndrome. Fischler B, et al. **Acta Psychiatr Scand** 1997 May; 95(5):405–13

The primary care anxiety and depression (PCAD) scale: a culture–oriented screening scale. El–Rufaie OE, et al. **Acta Psychiatr Scand** 1997 Feb;95(2):119–24

Screening for anxiety and depression in elderly medical outpatients. Neal RM, et al. **Age Ageing** 1994 Nov; 23(6):461–4

Eating pathology among women with alcoholism and/or anxiety disorders. Sinha R, et al. **Alcohol Clin Exp Res** 1996 Oct;20(7):1184–91

Sleep and anxieties in Brazilian children: the role of cultural and environmental factors in child sleep disturbance. Dollinger SJ, et al. **Am J Orthopsychiatry** 1996 Apr; 66(2):252–61

Comorbid anxiety disorders in late–life depression. Mulsant BH, et al. **Anxiety** 1996;2(5):242–7

Treatment typically provided for comorbid anxiety disorders [see comments] Meredith LS, et al. **Arch Fam Med** 1997 May–Jun;6(3):231–7. Comment in: Arch Fam Med 1997 May–Jun;6(3):238–9.

Competing priorities and comorbidities. So much to do and so little time [editorial; comment] Schwenk TL. **Arch Fam Med** 1997 May–Jun;6(3):238–9. Comment on: Arch Fam Med 1997 May–Jun;6(3):231–7.

Comorbid anxiety disorder and the functioning and well–being of chronically ill patients of general medical providers. Sherbourne CD, et al. **Arch Gen Psychiatry** 1996 Oct;53(10):889–95

Prevalence of posttraumatic stress disorder, depression and anxiety in a community sample of New Zealand Vietnam War veterans. Long N, et al. **Aust N Z J Psychiatry** 1996 Apr;30(2):253–6

Do specific anxiety disorders show specific drug problems? Page AC, et al. **Aust N Z J Psychiatry** 1996 Jun;30(3):410–4

Psychological morbidity in obstetric–gynaecology patients: testing the need for expanded psychiatry services in obstetric–gynaecology facilities [published erratum appears in Aust N Z J Psychiatry 1996 Apr;30(2):308] Phillips N, et al. **Aust N Z J Psychiatry** 1996 Feb;30(1):74–81

Relationship of obsessive–compulsive symptomatology to anxiety, depression and schizotypy in a clinical population. Norman RM, et al. **Br J Clin Psychol** 1996 Nov;35 (Pt 4):553–66

Stress and psychiatric disorder in the Hindu Kush: a community survey of mountain villages in Chitral, Pakistan [see comments] Mumford DB, et al. **Br J Psychiatry** 1996 Mar;168(3):299–307. Comment in: Br J Psychiatry 1996 Jun;168(6):788–9.

Social factors and comorbidity of depressive and anxiety disorders. Brown GW, et al. **Br J Psychiatry Suppl** 1996 Jun;(30):50–7

Major depression and generalised anxiety disorder. Same genes, (partly)different environments––revisited. Kendler KS. **Br J Psychiatry Suppl** 1996 Jun;(30):68–75

Comorbidity and boundaries of affective disorders with anxiety disorders and substance misuse: results of an international task force. Merikangas KR, et al. **Br J Psychiatry Suppl** 1996 Jun;(30):58–67

Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Sartorius N, et al. **Br J Psychiatry Suppl** 1996 Jun; (30):38–43

Epidemiology and comorbidity of anxiety disorders in later life: implications for treatment. Flint AJ. **Clin Neurosci** 1997;4(1):31–6 (60 ref.)

Substance abuse, comorbidity, and sensation seeking: gender differences. Scourfield J, et al. **Compr Psychiatry** 1996 Nov–Dec;37(6):384–92

Childhood adversity and vulnerability to mood and anxiety disorders. Young EA, et al. **Depress Anxiety** 1997; 5(2):66–72

Psychiatric disturbances and the use of psychotropic drugs in a population of nonagenarians. Forsell Y, et al. **Int J Geriatr Psychiatry** 1997 May;12(5):533–6

Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. Pini S, et al. **J Affect Disord** 1997 Feb;42(2–3):145–53

The prevalence of affective and anxiety disorders in primary care practice in Hungary. Szádóczky E, et al. **J Affect Disord** 1997 May;43(3):239–44

Soft signs in children of parents with agoraphobia. Kaplan SL, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Apr; 35(4):516–22

Anxiety disorders in elderly patients. Banazak DA. **J Am Board Fam Pract** 1997 Jul–Aug;10(4):280–9 (46 ref.)

Mental health patient profile [letter; comment] Solomon GL. **J Am Board Fam Pract** 1997 Jan–Feb;10(1):77–8. Comment on: J Am Board Fam Pract 1996 Sep–Oct;9(5):336–45.

Lifetime comorbidity among anxiety disorders and between anxiety disorders and other mental disorders in adolescents. Lewinsohn PM, et al. **J Anxiety Disord** 1997 Jul–Aug; 11(4):377–94

Anxiety and the irritable bowel syndrome: psychiatric, medical, or both? Lydiard RB. **J Clin Psychiatry** 1997;58 Suppl 3:51–8; discussion 59–61 (51 ref.)

Generalized anxiety disorder in primary care: the precursor/modifier pathway to increased health care utilization. Roy–Byrne PP, et al. **J Clin Psychiatry** 1997; 58 Suppl 3:34–8; discussion 39–40 (37 ref.)

Trauma and chronic depression among patients with anxiety disorders. Zlotnick C, et al. **J Consult Clin Psychol** 1997 Apr;65(2):333–6

Anxiety disorders in non–demented and demented elderly patients: prevalence and correlates [letter] Forsell Y, et al. **J Neurol Neurosurg Psychiatry** 1997 Mar;62(3):294–5

Prevalence of mood and anxiety disorders in a working population in Japan. Kawakami N, et al. **J Occup Environ Med** 1996 Sep;38(9):899–905

The influence of SCUD missile attacks on the utilization of ambulatory services in a family practice. Nakar S, et al. **Med Confl Surviv** 1996 Apr–Jun;12(2):149–53

Anxiety disorders, comorbid substance abuse, and benzodiazepine discontinuation: implications for treatment. Barlow DH. **NIDA Res Monogr** 1997;172:33–51 (48 ref.)

Prevalence and predictors of depressive, anxiety and substance use disorders in HIV–infected and uninfected men: a longitudinal evaluation. Dew MA, et al. **Psychol Med** 1997 Mar;27(2):395–409

A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Spinhoven P, et al. **Psychol Med** 1997 Mar;27(2):363–70

Loneliness, perceived social support, and anxiety among Israeli adolescents. Ginter EJ, et al. **Psychol Rep** 1996 Aug; 79(1):335–41

Psychiatric disorder and outcome in irritable bowel syndrome. Blewett A, et al. **Psychosomatics** 1996 Mar–Apr; 37(2):155–60

Prevalence of anxiety disorders in a clinic–based sample of pediatric asthma patients. Bussing R, et al. **Psychosomatics** 1996 Mar–Apr;37(2):108–15

Utilization of medical specialists by anxiety disorder patients. Kennedy BL, et al. **Psychosomatics** 1997 Mar–Apr; 38(2):109–12

Early onset depression: the relevance of anxiety. Parker G, et al. **Soc Psychiatry Psychiatr Epidemiol** 1997 Jan; 32(1):30–7

[Incidence of comorbid anxiety disorders in outpatient primary care] Buddeberg C. **Schweiz Rundsch Med Prax** 1997 Jun 11;86(24):1034 **(Ger)**

ETIOLOGY

Psychological variables and cancer pain. Zimmerman L, et al. **Cancer Nurs** 1996 Feb;19(1):44–53

Psychological and cognitive status before and after heart transplantation. Deshields TL, et al. **Gen Hosp Psychiatry** 1996 Nov;18(6 Suppl):62S–69S

Prevalence and predictors of depression and anxiety–related disorders during the year after heart transplantation. Dew MA, et al. **Gen Hosp Psychiatry** 1996 Nov;18(6 Suppl):48S–61S

Tornado disasters and stress responses. Godleski LS. **J Ky Med Assoc** 1997 Apr;95(4):145–8

Anxiety and Parkinson's disease. Richard IH, et al. **J Neuropsychiatry Clin Neurosci** 1996 Fall;8(4):383–92 (81 ref.)

Conditioning and ethological models of anxiety disorders: stress–in–dynamic–context anxiety models. Mineka S, et al. **Nebr Symp Motiv** 1996;43:135–210 (235 ref.)

Anxiety disorders and insomnia in geriatric patients. Folks DG, et al. **Psychiatr Clin North Am** 1997 Mar;20(1):137–64 (109 ref.)

Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers. Aluoja A, et al. **Psychiatry Res** 1997 Jan 15;66(1):59–67

The influence of stress intrusion on immunodepression in generalized anxiety disorder patients and controls. La Via MF, et al. **Psychosom Med** 1996 Mar–Apr;58(2):138–42

Psychiatric morbidity in patients with sickle cell anaemia. Udofia O, et al. **West Afr J Med** 1996 Oct–Dec; 15(4):196–200

[Anxiety disorders. Diagnostic and therapeutic process. 2: Differential diagnosis and therapy in general practice] Riemann D. **Fortschr Med** 1996 Dec 10;114(34):479–81 **(Ger)**

GENETICS

Increased mRNA for corticotrophin releasing hormone in the amygdala of fawn–hooded rats: a potential animal model of anxiety. Altemus M, et al. **Anxiety** 1994–95; 1(6):251–7

Clinical characteristics of familial generalized anxiety disorder. Kendler KS, et al. **Anxiety** 1994–95;1(4):186–91

Genetic and environmental influences on child reports of manifest anxiety and symptoms of separation anxiety and overanxious disorders: a community–based twin study. Topolski TD, et al. **Behav Genet** 1997 Jan;27(1):15–28

Major depression and generalised anxiety disorder. Same genes, (partly)different environments––revisited. Kendler KS. **Br J Psychiatry Suppl** 1996 Jun;(30):68–75

Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. Manfro GG, et al. **J Affect Disord** 1996 Nov 25; 41(2):135–9

At risk for anxiety: I. Psychopathology in the offspring of anxious parents. Beidel DC, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jul;36(7):918–24

A prospective four–year follow–up study of children at risk for ADHD: psychiatric, neuropsychological, and psychosocial outcome. Faraone SV, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Nov; 35(11):1449–59

Startle modulation in children at risk for anxiety disorders and/or alcoholism. Grillon C, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jul;36(7):925–32

Psychiatric diagnoses in the child and adolescent members of extended families identified through adult bipolar affective disorder probands. Todd RD, et al. **J Am Acad Child Adolesc Psychiatry** 1996 May; 35(5):664–71

Sibling resemblance for psychiatric disorders in offspring at high and low risk for depression. Rende R, et al. **J Child Psychol Psychiatry** 1995 Nov;36(8):1353–63

Status report on molecular genetic studies of anxiety disorders. **Psychiatr Genet** 1996 Summer;6(2):39–40

Platelet alpha 2–adrenoreceptors, catecholamines, hemodynamic variables, and anxiety in panic patients and their asymptomatic relatives. Cameron OG, et al. **Psychosom Med** 1996 Jul–Aug;58(4):289–301

Association of anxiety–related traits with a polymorphism in the serotonin transporter gene regulatory region [see comments] Lesch KP, et al. **Science** 1996 Nov 29; 274(5292):1527–31. Comment in: Science 1996 Nov 29;274(5292):1483.

IMMUNOLOGY

The influence of stress intrusion on immunodepression in generalized anxiety disorder patients and controls. La Via MF, et al. **Psychosom Med** 1996 Mar–Apr;58(2):138–42

PATHOLOGY

The functional neuroanatomy of anxiety: a study of three disorders using positron emission tomography and symptom provocation. Rauch SL, et al. **Biol Psychiatry** 1997 Sep 15;42(6):446–52

PHYSIOPATHOLOGY

Growth hormone response to clonidine in the nervous pointer dog model of anxiety. Uhde TW, et al. **Anxiety** 1994; 1(2):45–9

Fearful responding to repeated CO2 inhalation: a preliminary investigation. Beck JG, et al. **Behav Res Ther** 1996 Aug; 34(8):609–20

Anxiety sensitivity, suffocation fear, trait anxiety, and breath–holding duration as predictors of response to carbon dioxide challenge. Eke M, et al. **Behav Res Ther** 1996 Aug; 34(8):603–7

Cerebral vasodilation and vasoconstriction associated with acute anxiety. Mathew RJ, et al. **Biol Psychiatry** 1997 Apr 1;41(7):782–95

Heterogeneity of information–processing alterations according to dimensions of depression: an event–related potentials study. Pierson A, et al. **Biol Psychiatry** 1996 Jul 15;40(2):98–115

A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Charney DS, et al. **Crit Rev Neurobiol** 1996;10(3–4):419–46 (237 ref.)

Role of GABA in memory and anxiety. Kalueff A, et al. **Depress Anxiety** 1996–97;4(3):100–10 (86 ref.)

Raised blood albumin levels are associated with trait anxiety [letter] Stones A, et al. **Depress Anxiety** 1996–97;4(3):151–2

Unsteadiness of breathing in patients with hyperventilation syndrome and anxiety disorders. Han JN, et al. **Eur Respir J** 1997 Jan;10(1):167–76

Two faces of cholecystokinin: anxiety and schizophrenia. Bourin M, et al. **Fundam Clin Pharmacol** 1996;10(2):116–26

(140 ref.)
Anxiety and autonomic regulation in major depressive disorder: an exploratory study. Tulen JH, et al. **J Affect Disord** 1996 Sep 9;40(1–2):61–71
Child and adolescent anxiety disorders and early attachment. Warren SL, et al. **J Am Acad Child Adolesc Psychiatry** 1997 May;36(5):637–44
A neuro–evolutionary approach to the anxiety disorders. Stein DJ, et al. **J Anxiety Disord** 1997 Jul–Aug;11(4):409–29 (110 ref.)
Biological basis of generalized anxiety disorder. Brawman–Mintzer O, et al. **J Clin Psychiatry** 1997;58 Suppl 3:16–25; discussion 26 (78 ref.)
Intracranial and extracranial blood flow during acute anxiety. Mathew RJ, et al. **Psychiatry Res** 1997 May 16;74(2):93–107
Respiratory psychophysiology and anxiety: cognitive intervention in the doxapram model of panic. Abelson JL, et al. **Psychosom Med** 1996 Jul–Aug;58(4):302–13
Anxiety disorders in women: gender–related modulation of neurobiology and behavior. Shear MK. **Semin Reprod Endocrinol** 1997 Feb;15(1):69–76
[Neurosteroids—basic principles, anxiolysis and clinical applications] Hartmann A, et al. **Fortschr Neurol Psychiatr** 1996 Nov;64(11):444–51 (98 ref.) (Eng. Abstr.) **(Ger)**
[The neuropeptide cholecystokinin and anxiety states] Cohen H, et al. **Harefuah** 1996 May 15;130(10):707–10 (31 ref.) **(Heb)**

PREVENTION & CONTROL

Screening for anxiety disorders in the primary care setting. Stoessel PW, et al. **Fam Pract** 1995 Dec;12(4):448–51
Occupational factors of anxiety and depressive disorders in the French National Electricity and Gas Company. The Anxiety–Depression Group. Chevalier A, et al. **J Occup Environ Med** 1996 Nov;38(11):1098–107

PSYCHOLOGY

Anxiety disorders: a result of long–term chronic fatigue—the psychiatric characteristics of the sufferers of Iceland disease. Lindal E, et al. **Acta Neurol Scand** 1997 Sep; 96(3):158–62
Origins of individual differences in anxiety proneness: a twin/adoption study of the anxiety–related scales from the Karolinska Scales of Personality (KSP). Gustavsson JP, et al. **Acta Psychiatr Scand** 1996 Jun;93(6):460–9
Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder. Klein E, et al. **Acta Psychiatr Scand** 1995 Dec;92(6):399–408
Family characteristics as mediators of the influence of problem drinking and multiple risk status on child mental health. Roosa MW, et al. **Am J Community Psychol** 1996 Oct;24(5):607–24
Sleep and anxieties in Brazilian children: the role of cultural and environmental factors in child sleep disturbance. Dollinger SJ, et al. **Am J Orthopsychiatry** 1996 Apr; 66(2):252–61
Parapsychological phenomena and anxiety disorders. Feder R. **Anxiety** 1994;1(2):103
Anxiety symptoms in panic disorder and social phobia: support for suffocation theory of panic? Hazen AL, et al. **Anxiety** 1996;2(2):102–5
Comparison of anxiety sensitivity in panic disorder and social phobia. Hazen AL, et al. **Anxiety** 1994–95;1(6):298–301
Cognitive differences between anxious, normal, and ADHD children on a dichotic listening task. Manassis K, et al. **Anxiety** 1996;2(6):279–85
Childhood adversity, attachment and personality styles as predictors of anxiety among elderly caregivers. Prigerson HG, et al. **Anxiety** 1996;2(5):234–41
Theme of current journal issue: anxiety disorders across the lifespan [editorial] Shear MK, et al. **Anxiety** 1996;2(5):205–9
Social rhythm in anxiety disorder patients. Shear MK, et al. **Anxiety** 1994;1(2):90–5
Etiological beliefs and treatment preferences in anxiety–disordered patients. Waikar SV, et al. **Anxiety** 1994–95;1(3):134–7
Liaison psychiatry in an HIV/AIDS unit. Judd FK, et al. **Aust N Z J Psychiatry** 1997 Jun;31(3):391–7
The role of parental fearfulness and modeling in children's fear. Muris P, et al. **Behav Res Ther** 1996 Mar;34(3):265–8
Stress and psychiatric disorder in the Hindu Kush: a community survey of mountain villages in Chitral, Pakistan [see comments] Mumford DB, et al. **Br J Psychiatry** 1996 Mar;168(3):299–307. Comment in: Br J Psychiatry 1996 Jun;168(6):788–9.
Phenomenology and course of generalised anxiety disorder. Yonkers KA, et al. **Br J Psychiatry** 1996 Mar;168(3):308–13
Misuse of loperamide in anxiety disorder patients [letter] Lavin MR. **Depress Anxiety** 1996–97;4(5):254–5
The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease [see comments] Walker EA, et al. **Gen Hosp Psychiatry** 1996 Jul;18(4):220–9. Comment in: Gen Hosp Psychiatry 1996 Jul;18(4):215–9.
Quality of life in anxiety and social phobia. Bech P, et al. **Int Clin Psychopharmacol** 1996 Jun;11 Suppl 3:97–100 (28 ref.)
Worry and intrinsic/extrinsic religious orientation among Buddhist (Thai) and Christian (Canadian) elderly persons. Tapanya S, et al. **Int J Aging Hum Dev** 1997;44(1):73–83
Lunar cycle and consultations for anxiety and depression in general practice. Wilkinson G, et al. **Int J Soc Psychiatry** 1997 Spring;43(1):29–34
Family enhancement of cognitive style in anxious and aggressive children. Barrett PM, et al. **J Abnorm Child Psychol** 1996 Apr;24(2):187–203
Discrepancies among mother, child, and teacher reports: examining the contributions of maternal depression and anxiety. Briggs–Gowan MJ, et al. **J Abnorm Child Psychol** 1996 Dec;24(6):749–65
Family process and child anxiety and aggression: an observational analysis. Dadds MR, et al. **J Abnorm Child Psychol** 1996 Dec;24(6):715–34
Reward dominance: associations with anxiety, conduct problems, and psychopathy in children. O'Brien BS, et al. **J Abnorm Child Psychol** 1996 Apr;24(2):223–40
Inhibition in ADHD, aggressive, and anxious children: a biologically based model of child psychopathology. Oosterlaan J, et al. **J Abnorm Child Psychol** 1996 Feb; 24(1):19–36
Relationship between perception of facial emotions and anxiety in clinical depression: does anxiety–related perception predict persistence of depression? Bouhuys AL, et al. **J Affect Disord** 1997 May;43(3):213–23
The functioning and well–being of patients with unrecognized anxiety disorders and major depressive disorder. Schonfeld WH, et al. **J Affect Disord** 1997 Apr; 43(2):105–19
Course of depression in patients with comorbid anxiety disorders. Sherbourne CD, et al. **J Affect Disord** 1997 May; 43(3):245–50
Anxiety disorders in children and adolescents: a review of the past 10 years. Bernstein GA, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Sep;35(9):1110–9 (72 ref.)
Expressed emotion toward children with behavioral inhibition: associations with maternal anxiety disorder. Hirshfeld DR, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jul;36(7):910–7
Nuclear anxiety revisited [letter] Jerome L, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Sep;35(9):1108–9
Premigratory expectations and postmigratory mental health symptoms in Vietnamese Amerasians. McKelvey RS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Feb; 35(2):240–5
State and trait anxiety in adolescent suicide attempters. Ohring R, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Feb;35(2):154–7
Selective mutism and social anxiety [letter; comment] Szabo CP. **J Am Acad Child Adolesc Psychiatry** 1996 May; 35(5):555. Comment on: J Am Acad Child Adolesc Psychiatry 1995 Jul;34(7):847–56.
Beliefs about worry and intrusions: the Meta–Cognitions Questionnaire and its correlates. Cartwright–Hatton S, et al. **J Anxiety Disord** 1997 May–Jun;11(3):279–96
Social expectancies and self–perceptions in anxiety–disordered children. Chansky TE, et al. **J Anxiety Disord** 1997 Jul–Aug;11(4):347–63
Maternal expectations and attributions about coping in anxious children. Kortlander E, et al. **J Anxiety Disord** 1997 May–Jun;11(3):297–315
Space and motion discomfort in Brazilian versus American patients with anxiety disorders. Romas RT, et al. **J Anxiety Disord** 1997 Mar–Apr;11(2):131–9
Fear, anxiety and perceived control in children of agoraphobic parents. Capps L, et al. **J Child Psychol Psychiatry** 1996 May;37(4):445–52
Information processing in clinically depressed and anxious children and adolescents. Dalgleish T, et al. **J Child Psychol Psychiatry** 1997 Jul;38(5):535–41
Worrisome thoughts in children clinically referred for anxiety disorder. Perrin S, et al. **J Clin Child Psychol** 1997 Jun; 26(2):181–9
Self–talk in youth with anxiety disorders: states of mind, content specificity, and treatment outcome. Treadwell KR, et al. **J Consult Clin Psychol** 1996 Oct;64(5):941–50
An investigation of worry content among generally anxious individuals. Roemer L, et al. **J Nerv Ment Dis** 1997 May; 185(5):314–9
Mood disorder and chronic hypercalcemia. White RE, et al. **J Psychosom Res** 1996 Oct;41(4):343–7
Cognitive bias in the anxiety disorders. McNally RJ. **Nebr Symp Motiv** 1996;43:211–50 (95 ref.)
The effects of unemployment on psychiatric illness during young adulthood. Fergusson DM, et al. **Psychol Med** 1997 Mar;27(2):371–81
Gender differences in risk factors for mood and anxiety disorders: implications for clinical treatment research. Blehar MC. **Psychopharmacol Bull** 1995;31(4):687–91 (30 ref.)
Anxiety disorders in pregnant and postpartum women. Shear MK, et al. **Psychopharmacol Bull** 1995;31(4):693–703 (71 ref.)
Human immunodeficiency virus (HIV) infection and quality of life: the potential impact of Axis I psychiatric disorders in a sample of 95 HIV seropositive men. Holmes WC, et al. **Psychosom Med** 1997 Mar–Apr;59(2):187–92
Short stature, growth hormone deficiency, and social anxiety. Nicholas LM, et al. **Psychosom Med** 1997 Jul–Aug; 59(4):372–5
Preinjury psychiatric illness and postinjury adjustment in adult burn survivors. Fauerbach JA, et al. **Psychosomatics** 1996 Nov–Dec;37(6):547–55
[Anxiety and the defibrillator: the Foreign Legion] Sirois F. **Can J Psychiatry** 1996 Apr;41(3):193–4 **(Fre)**
[Anxiety, aggression, agitation and depression: psychopathologic aspects] Braconnier A, et al. **Encephale** 1997 Jun;23 Spec No 3:43–7 (20 ref.) (Eng. Abstr.) **(Fre)**
[Fictional anxiety in detective literature and motion pictures] Mijolla–Mellor SD. **Encephale** 1996 Dec;22 Spec No 5:61–6 **(Fre)**
[Memory complaints and anxiety. Apropos of 40 patients attending a specialized memory consultation] Thomas–Anterion C, et al. **Encephale** 1997 Jan–Feb; 23(1):42–7 (Eng. Abstr.) **(Fre)**
[Alcohol abuse: ever earlier, ever more frequent. A study shows correlation with early childhood anxiety disorders] Schweiger A. **Fortschr Med** 1996 Oct 20;114(29):24 **(Ger)**
[Anxiety in alcohol–dependent patients] Baving L, et al. **Fortschr Neurol Psychiatr** 1996 Mar;64(3):83–9 (66 ref.) (Eng. Abstr.) **(Ger)**
[Vertigo and anxiety disorders—results of interdisciplinary evaluation] Eckhardt A, et al. **Laryngorhinootologie** 1996 Sep;75(9):517–22 (Eng. Abstr.) **(Ger)**
[Psychopathology and differential typology of depressive anxiety] Kick H. **Nervenarzt** 1997 Jan;68(1):48–54 (Eng. Abstr.) **(Ger)**
[Anxiety as an existential phenomenon. An existential analytic approach to understanding and therapy of anxieties] Längle A. **Psychother Psychosom Med Psychol** 1997 Jul; 47(7):227–33 (18 ref.) (Eng. Abstr.) **(Ger)**
[Stress, depression and anxiety in patients with headache. Considerations of literature and experimental data] Fulcheri M, et al. **Minerva Psichiatr** 1995 Dec;36(4):179–85 (48 ref.) (Eng. Abstr.) **(Ita)**
[Anxiety and vertigo] Pardal Refoyo JL, et al. **An Otorrinolaringol Ibero Am** 1997;24(1):85–95 (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

[Assessment of cerebral benzodiazepine receptor distribution in anxiety disorders by 123I–iomazenil–SPECT: comparison to cerebral perfusion scintigraphy by 123I–IMP] Uchiyama M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Jan;57(1):41–6 (Eng. Abstr.) **(Jpn)**

REHABILITATION

Education program targets anxiety disorders [news] **J Psychosoc Nurs Ment Health Serv** 1997 Jan;35(1):9
Influence of breathing therapy on complaints, anxiety and breathing pattern in patients with hyperventilation syndrome and anxiety disorders. Han JN, et al. **J Psychosom Res** 1996 Nov;41(5):481–93

SURGERY

Radiosurgical lesions in the normal human brain 17 years after gamma knife capsulotomy. Kihlström L, et al. **Neurosurgery** 1997 Aug;41(2):396–401; discussion 401–2

THERAPY

Cognitive therapy with elderly people. Wilkinson P. **Age Ageing** 1997 Jan;26(1):53–8
Our bodies, our selves: treating the somatic expressions of trauma with ego–state therapy. Phillips M. **Am J Clin Hypn** 1995 Oct;38(2):109–21
Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Brown C, et al. **Am J Psychiatry** 1996 Oct;153(10):1293–300
Management of post traumatic stress disorder using combat stress treatment principles—a case report. Lee JT. **Ann Acad Med Singapore** 1997 Jan;26(1):113–7 (24 ref.)
Psychologic treatment by EMS personnel in disasters [letter; comment] Reeves RR, et al. **Ann Emerg Med** 1997 Feb; 29(2):299–300. Comment on: Ann Emerg Med 1996 Aug;28(2):119–28.
Anxiety sensitivity and treatment outcome in panic disorder. Hazen AL, et al. **Anxiety** 1996;2(1):34–9
Treatment typically provided for comorbid anxiety disorders [see comments] Meredith LS, et al. **Arch Fam Med** 1997 May–Jun;6(3):231–7. Comment in: Arch Fam Med 1997 May–Jun;6(3):238–9.
Competing priorities and comorbidities. So much to do and so little time [editorial; comment] Schwenk TL. **Arch Fam Med** 1997 May–Jun;6(3):238–9. Comment on: Arch Fam Med 1997 May–Jun;6(3):231–7.
The effects of video feedback on the self–evaluation of performance in socially anxious subjects. Rapee RM, et al. **Behav Res Ther** 1996 Apr;34(4):315–22
On predicting improvement and relapse in generalized anxiety disorder following psychotherapy. Durham RC, et al. **Br J Clin Psychol** 1997 Feb;36 (Pt 1):101–19
Application of autogenic training for anxiety disorders: a clinical study in a psychiatric setting. Sakai M. **Fukuoka Igaku Zasshi** 1997 Mar;88(3):56–64
Effectiveness of group anxiety management with elderly clients of a community psychogeriatric team. Radley M, et al. **Int J Geriatr Psychiatry** 1997 Jan;12(1):79–84
Tailor–made and standardized therapy: complementary tasks

in behavior therapy. A contrarian view. Schulte D. **J Behav Ther Exp Psychiatry** 1996 Jun;27(2):119–26 (31 ref.)
Strategies for treatment of generalized anxiety in the primary care setting. Schweizer E, et al. **J Clin Psychiatry** 1997; 58 Suppl 3:27–31; discussion 32–3 (14 ref.)
Recognizing and treating anxiety in the elderly. Small GW. **J Clin Psychiatry** 1997;58 Suppl 3:41–7; discussion 48–50 (43 ref.)
Long–term follow–up of a cognitive–behavioral therapy for anxiety–disordered youth. Kendall PC, et al. **J Consult Clin Psychol** 1996 Aug;64(4):724–30
Therapy for youths with anxiety disorders: a second randomized clinical trial. Kendall PC, et al. **J Consult Clin Psychol** 1997 Jun;65(3):366–80
The undertreatment of anxiety: overcoming the confusion and stigma. Blair DT, et al. **J Psychosoc Nurs Ment Health Serv** 1996 Jun;34(6):9–18 (72 ref.)
The psychosocial treatments interview for anxiety disorders. A method for assessing psychotherapeutic procedures in anxiety disorders. Steketee G, et al. **J Psychother Pract Res** 1997 Summer;6(3):194–210
Anxiety disorders, comorbid substance abuse, and benzodiazepine discontinuation: implications for treatment. Barlow DH. **NIDA Res Monogr** 1997;172:33–51 (48 ref.)
A planning checklist for establishing time–limited psychotherapy groups. Crosby G, et al. **Psychiatr Serv** 1996 Jan;47(1):25–6
Morita therapy: 1919 to 1995. Kitanishi K, et al. **Psychiatry Clin Neurosci** 1995 Dec;49(5–6):245–54 (142 ref.)
[Group techniques and relaxation in the treatment of several subtypes of anxiety: a non–randomized controlled trial] Tello Bernabé ME, et al. **Aten Primaria** 1997 Feb 15; 19(2):67–71 (Eng. Abstr.) **(Spa)**

URINE

Urinary catecholamine excretion in childhood overanxious and posttraumatic stress disorders. De Bellis MD, et al. **Ann N Y Acad Sci** 1997 Jun 21;821:451–5

ANXIETY NEUROSES see **ANXIETY DISORDERS**

ANXIETY, SEPARATION

Brain systems for the mediation of social separation–distress and social–reward. Evolutionary antecedents and neuropeptide intermediaries. Panksepp J, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:78–100 (63 ref.)
Homesickness: a review of the literature. Van Tilburg MA, et al. **Psychol Med** 1996 Sep;26(5):899–912 (70 ref.)

COMPLICATIONS

Adolescent suicidality in urban minorities and its relationship to conduct disorders, depression, and separation anxiety. Feldman M, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jan;36(1):75–84

DIAGNOSIS

A short measure of social and separation anxiety. Gilbert P, et al. **Br J Med Psychol** 1996 Jun;69 (Pt 2):155–61
Is early separation anxiety a risk factor for adult panic disorder?: a critical review. Silove D, et al. **Compr Psychiatry** 1996 May–Jun;37(3):167–79

ETIOLOGY

Children of Holocaust survivors: separation obstacles, attachments, and anxiety. Zilberfein F. **Soc Work Health Care** 1996;23(3):35–55 (30 ref.)

GENETICS

Genetic and environmental influences on child reports of manifest anxiety and symptoms of separation anxiety and overanxious disorders: a community–based twin study. Topolski TD, et al. **Behav Genet** 1997 Jan;27(1):15–28

PSYCHOLOGY

"When I am lonely the mountains call me": the impact of sacred geography on Navajo psychological well being. Griffin–Pierce T. **Am Indian Alsk Native Ment Health Res** 1997;7(3):1–10
Is there an adult form of separation anxiety disorder? A brief clinical report. Manicavasagar V, et al. **Aust N Z J Psychiatry** 1997 Apr;31(2):299–303
Heart–focused and general illness fears in relation to parental medical history and separation experiences. Eifert GH, et al. **Behav Res Ther** 1996 Sep;34(9):735–9
Separation, termination process and long–term outcome in psychotherapy with severely disturbed patients. Werbart A. **Bull Menninger Clin** 1997 Winter;61(1):16–43
School phobia with separation anxiety disorder: a comparative 20– to 29–year follow–up study of 35 school refusers. Flakierska–Praquin N, et al. **Compr Psychiatry** 1997 Jan–Feb;38(1):17–22
"You can try or you can just give up": the impact of perceived control and coping style on childhood homesickness. Thurber CA, et al. **Dev Psychol** 1997 May;33(3):508–17
Prenatal alcohol exposure influences the effects of neuroactive steroids on separation–induced ultrasonic vocalizations in rat pups. Zimmerberg B, et al. **Pharmacol Biochem Behav** 1996 Dec;55(4):541–7
Retarded acquisition and reduced expression of conditioned locomotor activity in adult rats following repeated early maternal separation: effects of prefeeding, d–amphetamine, dopamine antagonists and clonidine. Matthews K, et al. **Psychopharmacology (Berl)** 1996 Jul;126(1):75–84

THERAPY

A systematic replication of the prescriptive treatment of school refusal behavior in a single subject. Chorpita BF, et al. **J Behav Ther Exp Psychiatry** 1996 Sep;27(3):281–90

ANXIETY STATES, NEUROTIC see **ANXIETY DISORDERS**

ANXIOLYTIC AGENTS see **ANTI–ANXIETY AGENTS**

ANXIOLYTICS, BENZODIAZEPINE see **ANTI–ANXIETY AGENTS, BENZODIAZEPINE**

AORTA

see related
AORTOGRAPHY
CORONARY ARTERY BYPASS
Vascular complications of lumbar disc surgery. Fruhwirth J, et al. **Acta Neurochir (Wien)** 1996;138(8):912–6
Linear reverberation in the ascending aorta: a cause of multiplane transesophageal echocardiographic artifact [letter] Ducart AR, et al. **Anesthesiology** 1996 Dec; 85(6):1497–8
Addition of calcium to Euro–Collins solution is essential for 24–hour preservation of the vasculature. Ingemansson R, et al. **Ann Thorac Surg** 1997 Feb;63(2):408–13
Transapical aortic cannulation in pediatric patients. Watanabe H, et al. **Ann Thorac Surg** 1997 Apr;63(4):1149–50
Aortic compression in massive postpartum haemorrhage––an old but lifesaving technique. Keogh J, et al. **Aust N Z J Obstet Gynaecol** 1997 May;37(2):237–8
Renal effects of concurrent E–24.11 and ACE inhibition in the aorto–venocaval fistula rat. Kirk JE, et al. **Br J Pharmacol** 1996 Nov;119(5):943–8
Delayed appearance of traumatic aorto–right ventricular fistula [letter; comment] Cheng TO. **Cathet Cardiovasc Diagn** 1995 Dec;36(4):375. Comment on: Cathet Cardiovasc Diagn 1995 Jun;35(2):136–8.
Continuous measurement of gut luminal PCO2 in the rat: responses to transient episodes of graded aortic hypotension [see comments] Morgan TJ, et al. **Crit Care Med** 1997 Sep; 25(9):1575–8. Comment in: Crit Care Med 1997 Sep;25(9):1458–9.
Dose–response relationship between aortic infusions of polymerized bovine hemoglobin and return of circulation in a canine model of ventricular fibrillation and advanced cardiac life support. Paradis NA. **Crit Care Med** 1997 Mar; 25(3):476–83
Risk factors for intestinal ischaemia after aortoiliac surgery: a combined cohort and case–control study of 2824 operations. Björck M, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):531–9
Aortic and iliac artery thrombosis in calves: nine cases (1974–1993). Morley PS, et al. **J Am Vet Med Assoc** 1996 Jul 1;209(1):130–6
Heart failure in a macaw with atherosclerosis of the aorta and brachiocephalic arteries. Phalen DN, et al. **J Am Vet Med Assoc** 1996 Oct 15;209(8):1435–40
Clinical implications of short–axis aortopulmonary rotation on juxtacommissural origin of the coronary artery in transposition of the great arteries and surgical strategy. Chiu IS, et al. **J Card Surg** 1997 Jan–Feb;12(1):23–31
Treatment of haemorrhage following rupture of aortic leiomyosarcoma. Survival for 4.2 years. Testini M, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):593–6 (16 ref.)
Magnetic resonance acquisition to determine the lumen length of a tortuous phantom aorta. Liu Y, et al. **J Endovasc Surg** 1995 Aug;2(3):272–7
Risk factors predictive of para–aortic lymph node metastasis in endometrial carcinomas. Yokoyama Y, et al. **J Obstet Gynaecol Res** 1997 Apr;23(2):179–87
Renal artery embolization after back massage in a patient with aortic occlusion. Mikhail A, et al. **Nephrol Dial Transplant** 1997 Apr;12(4):797–8
Breath–hold single–dose gadolinium–enhanced three–dimensional MR aortography: usefulness of a timing examination and MR power injector. Earls JP, et al. **Radiology** 1996 Dec;201(3):705–10
[Relationship between end–systolic aortic pressure and mean aortic pressure in adults] Hébert JL, et al. **Arch Mal Coeur Vaiss** 1996 Dec;89(12):1633–42 (31 ref.) (Eng. Abstr.) **(Fre)**
[Sonographic demonstration of an aortic thrombosis in the dog] Hörauf A, et al. **Tierarztl Prax** 1996 Aug;24(4):374–7 (Eng. Abstr.) **(Ger)**
[Antiblastic locoregional perfusion with control of the aorto–caval flow: technique of percutaneous access] Ricci S, et al. **Radiol Med (Torino)** 1997 Mar;93(3):246–52 (Eng. Abstr.) **(Ita)**
[The efficacy of myocardial protection with prolonged aortic cross–clamping] Fujioka Y, et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):170–3 (Eng. Abstr.) **(Jpn)**
[The prolonged aortic occlusion in valvular surgery and myocardial protection] Nakayama Y, et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):174–7 (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Sonographic detection of parallel great arteries in the fetus. Allan LD. **AJR Am J Roentgenol** 1997 May;168(5):1283–6
Magnetic resonance imaging of anomalous origin of the right pulmonary artery from the ascending aorta in association with ventricular septal defect. Lin MH, et al. **Am Heart J** 1996 Nov;132(5):1073–4
Isolated anomalous origin of left pulmonary artery from the ascending aorta. Tagliente MR, et al. **Am Heart J** 1996 Dec;132(6):1289–92 (6 ref.)
Aortocaval fistula associated with abdominal aortic aneurysm: a diagnostic challenge. Bednarkiewicz M, et al. **Ann Vasc Surg** 1997 Sep;11(5):464–6
Functional abnormalities of the aorta. Lehmann ED. **Atherosclerosis** 1996 Nov 15;127(1):139–42
The value of MRI in diagnosing vascular abnormalities causing stridor. Beekman RP, et al. **Eur J Pediatr** 1997 Jul;156(7):516–20
Right pulmonary artery from aorta with origin stenosis: a treatable hemitruncus in a 12–year child. Kothari SS, et al. **Indian Heart J** 1997 May–Jun;49(3):319–21
One–stage repair of pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries by a handmade trifurcated valved conduit. Yang YJ, et al. **J Card Surg** 1996 Mar–Apr;11(2):151–4
Effect of volume unloading surgery on coronary flow dynamics in patients with aortic atresia. Fogel MA, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):718–26; discussion 726–7
Repair of interrupted aortic arch: a ten–year experience. Serraf A, et al. **J Thorac Cardiovasc Surg** 1996 Nov; 112(5):1150–60
Cervical aortic arch associated with 22q11.2 deletion. Kazuma N, et al. **Pediatr Cardiol** 1997 Mar–Apr; 18(2):149–51
Dissection of an aneurysmic ascending aorta in a child with atresia of the aortic isthmus. Lindinger A, et al. **Pediatr Cardiol** 1997 Mar–Apr;18(2):146–8
[Origin of the right or left pulmonary artery from the ascending aorta] Hoshino S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):314–6 (8 ref.) **(Jpn)**
[Aortico–left ventricular tunnel] Saito A. **Ryoikibetsu Shokogun Shirizu** 1996;(13):249–51 (20 ref.) **(Jpn)**
[Severe respiratory failure secondary to vascular ring. Report of 2 cases] Furuya–Meguro ME, et al. **Arch Inst Cardiol Mex** 1995 Nov–Dec;65(6):520–7 (Eng. Abstr.) **(Spa)**
[Mediastinal enlargement with upper esophageal impression] Crespo Valadés E, et al. **Rev Clin Esp** 1996 Aug; 196(8):561–2 **(Spa)**

ANATOMY & HISTOLOGY

Structural and architectural changes during arterial development and the role of hemodynamics. Stehbens WE. **Acta Anat (Basel)** 1996;157(4):261–74 (95 ref.)
A 3D–LDA study of the relation between wall shear stress and intimal thickness in a human aortic bifurcation. Hayashi K, et al. **J Biomech Eng** 1996 Aug;118(3):273–9
Optimization of contrast timing for breath–hold three–dimensional MR angiography. Hany TF, et al. **J Magn Reson Imaging** 1997 May–Jun;7(3):551–6
Exponentially tapered T–tube model in the characterization of arterial non–uniformity. Chang KC, et al. **J Theor Biol** 1996 Nov 7;183(1):35–46
[The vasa vasorum of the arteries] Williams JK, et al. **J Mal Vasc** 1996;21 Suppl C:266–9 (25 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

VCAM–1 expression and network of VCAM–1 positive vascular dendritic cells in advanced atherosclerotic lesions of carotid arteries and aortas. Bobryshev YV, et al. **Acta Histochem** 1996 Apr;98(2):185–94
Effects of dietary gamma–linolenic acid on the tissue phospholipid fatty acid composition and the synthesis of eicosanoids in rats. Quoc KP, et al. **Ann Nutr Metab** 1996; 40(2):99–108
Presence of Ca(2+)–sensitive and –insensitive SM22 alpha isoproteins in bovine aorta. Shishibori T, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):225–30
Age–dependent aluminum accumulation in the human aorta and cerebral artery. Minami T, et al. **Biol Trace Elem Res** 1996 Oct–Nov;55(1–2):199–205
Hyperinsulinaemia accelerates accumulation of cholesterol ester in aorta of rats with transplanted pancreas. Abe H, et al. **Diabetologia** 1996 Nov;39(11):1276–83
Immunohistochemical detection of platelet derived growth factor (PDGF) in the aortic wall of atherosclerotic rabbits. Agapitos E, et al. **Int Angiol** 1996 Sep;15(3):249–51
Isolation and identification of myosin I from porcine aorta media smooth muscle. Hasegawa Y, et al. **J Biochem (Tokyo)** 1996 Nov;120(5):901–7
Human arterial proteoglycans increase the rate of proteolytic fusion of low density lipoprotein particles. Pentikäinen MO, et al. **J Biol Chem** 1997 Oct 3;272(40):25283–8

Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. Niwa T, et al. **J Clin Invest** 1997 Mar 15;99(6):1272–80

Expression of two novel recombinant proteins from aortic adventitia (kappafibs) sharing amino acid sequences with cytomegalovirus. Ozsvath KJ, et al. **J Surg Res** 1997 May; 69(2):277–82

Quantification of mRNAs for three alpha 1-adrenoceptor subtypes in rat aorta by solution hybridization. Xu K, et al. **Life Sci** 1996;59(21):PL343–7

Identification of [Met5]-enkephalin in developing, adult, and renewing tissues by reversed-phase high performance liquid chromatography and radioimmunoassay. Zagon IS, et al. **Life Sci** 1997;61(4):363–70

Platelet and aorta arachidonic and eicosapentaenoic acid levels and in vitro eicosanoid production in rats fed high-fat diets. Sanigorski AJ, et al. **Lipids** 1996 Jul; 31(7):729–35

Chemical characterization of peroxidized low-density lipoprotein in plasma and aortic atheroma. Kanazawa T, et al. **Pathobiology** 1996;64(1):18–26

CYTOLOGY

Inhibitory effects of hypercholesterolemia and ox-LDL on angiogenesis-like endothelial growth in rabbit aortic explants. Essential role of basic fibroblast growth factor. Chen CH, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul; 17(7):1303–12

The distribution of centrosomes in endothelial cells of the rat aorta and inferior vena cava. Kiosses WB, et al. **Artery** 1997;22(5):251–65

Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Gal alpha 1-3Gal), blood group H determinant and N-glycolylneuraminic acid. Bouhours D, et al. **Glycoconj J** 1996 Dec;13(6):947–53

Cell proliferation in aortic, mammary artery and saphenous vein biopsies in patients subjected to open heart surgery. Aaltomaa S, et al. **In Vivo** 1997 May-Jun;11(3):243–7

Cyclic changes in the organization of cell adhesions and the associated cytoskeleton, induced by stimulation of tyrosine phosphorylation in bovine aortic endothelial cells. Ayalon O, et al. **J Cell Sci** 1997 Mar;110 (Pt 5):547–56

Characteristics of vascular wall cells subjected to dynamic cyclic strain and fluid shear conditions in vitro. Benbrahim A, et al. **J Surg Res** 1996 Oct;65(2):119–27

Proliferation of smooth muscle cells in acute allograft vascular rejection. Amano J, et al. **J Thorac Cardiovasc Surg** 1997 Jan;113(1):19–25

Placement of endothelial cells on the luminal surface of denuded arteries in vitro and in vivo. Consigny PM. **J Vasc Interv Radiol** 1997 Jul-Aug;8(4):595–604

Human aortic endothelial cell migration onto stent surfaces under static and flow conditions. Sprague EA, et al. **J Vasc Interv Radiol** 1997 Jan-Feb;8(1 Pt 1):83–92

Effect of monoclonal antibody on the adhesion of platelets to aortic segments. Chiang TM. **Thromb Res** 1996 Dec 1; 84(5):345–9

[Proliferative behavior of cultured endothelial cells from human aorta and expression of adhesion molecules] Il'inskaia OP, et al. **Biull Eksp Biol Med** 1996 Aug; 122(8):214–7 **(Rus)**

DRUG EFFECTS

Drug-induced alteration of endothelial permeability in the rat aorta. Potential consequences on the vessel wall. Plante GE, et al. **Adv Exp Med Biol** 1996;416:249–53

Heterogeneous aortic response to acute beta-adrenergic blockade in Marfan syndrome. Haouzi A, et al. **Am Heart J** 1997 Jan;133(1):60–3

Effect of acute administration of estradiol 17 beta on aortic blood flow in menopausal women. Leonardo F, et al. **Am J Cardiol** 1997 Sep 15;80(6):791–3

Role of intracellular alkalinization in inhibition of acetylcholine-induced relaxation by FMLP in rat aorta. Ando K, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2405–10

In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity. Barra JG, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H859–68

Differential stimulation of Na+ pump activity by insulin and nitric oxide in rabbit aorta. Gupta S, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):H1287–93

Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells. López-Ongil S, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1072–8

Action of protein kinase C in endothelin-induced contractions in rat aortic rings. Oriji GK, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C398–404

Hypoxia-reoxygenation impairs endothelium-dependent relaxation in isolated rat aorta. Yokoyama S, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R1126–31

Isoflurane and halothane produce similar alterations in aortic distensibility and characteristic aortic impedance. Hettrick DA, et al. **Anesth Analg** 1996 Dec;83(6):1166–72

Effects of isoflurane and propofol on arterial mechanical properties [letter; comment] Hettrick DA, et al. **Anesth Analg** 1997 Apr;84(4):940–1. Comment on: Anesth Analg 1996 Nov;83(5):958–64.

Early mural reactions to fibrinogen injections into aortic wall of rabbits. Haust MD. **Ann N Y Acad Sci** 1997 Apr 15; 811:361–7; discussion 367–8

Vasorelaxation of noradrenaline-constricted guinea-pig and rabbit aorta by the adenosine analogue NECA: roles of intra-and extracellular calcium. Ford WR, et al. **Arch Int Pharmacodyn Ther** 1996 May-Jun;331(3):285–300

Reduced responsiveness of hypercholesterolemic rabbit aortic smooth muscle cells to nitric oxide. Weisbrod RM, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):394–402

Vascular responses to norepinephrine and bethanechol in isolated aortae from 2-month diabetic rabbits induced by alloxan. Wong KK. **Artery** 1996;22(1):49–54

Effect of endothelium on the aortic contraction induced by norepinephrine and KCl in isolated rat aorta. Wong KK. **Artery** 1996;22(1):55–60

Efficacy of the chitosan posttreatment in calcification prevention of the glutaraldehyde-treated porcine aortic noncoronary cusp implanted in the right ventricular outflow tract in dogs. Kuribayashi R, et al. **Artif Organs** 1996 Jul;20(7):761–6

Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture. Bishop-Bailey D, et al. **Br J Pharmacol** 1997 May; 121(1):125–33

Increase by adrenaline or angiotensin II of the accumulation of low density lipoprotein and fibrinogen by aortic walls in unrestrained conscious rats. Cardona-Sanclemente LE, et al. **Br J Pharmacol** 1996 Mar;117(6):1089–94

Endothelium-independent relaxation of aortic rings by the nitric oxide synthase inhibitor diphenyleneiodonium. Dodd-o JM, et al. **Br J Pharmacol** 1997 Mar;120(5):857–64

The mechanism of acidic pH-induced contraction in aortae from SHR and WKY rats enhanced by increasing blood pressure. Furukawa K, et al. **Br J Pharmacol** 1996 Jun; 118(3):485–92

Further investigations into the mechanism of the antihypertensive activity of the angiotensin AT1 receptor antagonist, GR138950. Hilditch A, et al. **Br J Pharmacol** 1996 Jun;118(3):711–9

Mechanotransduction through the endothelial cytoskeleton: mediation of flow- but not agonist-induced EDRF release. Hutcheson IR, et al. **Br J Pharmacol** 1996 Jun;118(3):720–6

A comparative study on the rat aorta and mesenteric arterial bed of the possible role of nitric oxide in the desensitization of the vasoconstrictor response to an alpha 1-adrenoceptor agonist. Kamata K, et al. **Br J Pharmacol** 1997 Apr; 120(7):1221–8

Dissociation of P2 purinoceptor-mediated increase in intracellular Ca2+ level from myosin light chain phosphorylation and contraction in rat aorta. Kitajima S, et al. **Br J Pharmacol** 1996 Jun;118(3):543–8

The effects of purine compounds on the isolated aorta of the frog Rana temporaria. Knight GE, et al. **Br J Pharmacol** 1996 Mar;117(5):873–8

Investigation of role for oxidant stress in vascular tolerance development to glyceryl trinitrate in vitro. Laight DW, et al. **Br J Pharmacol** 1997 Apr;120(8):1477–82

Mechanism of enhanced vasoconstrictor hormone action in vascular smooth muscle cells by cyclosporin A. Lo Russo A, et al. **Br J Pharmacol** 1997 May;121(2):248–52

Hydrogen peroxide-induced impairment of reactivity in rat isolated aorta: potentiation by 3-amino-1,2,4-triazole. Mian KB, et al. **Br J Pharmacol** 1997 Jun;121(4):813–9

Endothelium-dependent and NO-mediated desensitization to vasopressin in rat aorta. Millette E, et al. **Br J Pharmacol** 1996 Nov;119(5):899–904

Down-regulation of aortic and cardiac AT1 receptor gene expression in transgenic (mRen-2) 27 rats. Nickenig G, et al. **Br J Pharmacol** 1997 May;121(1):134–40

Adenosine inhibitory effect on enhanced growth of aortic smooth muscle cells from streptozotocin-induced diabetic rats. Parés-Herbuté N, et al. **Br J Pharmacol** 1996 Jun; 118(3):783–9

Ionic mechanisms contributing to the vasorelaxant properties of iodinated contrast media: a comparison of iohexol and iodixanol in the rabbit isolated aorta. Pitman MR, et al. **Br J Pharmacol** 1996 Oct;119(4):685–90

Effect of copper on nitric oxide synthase and guanylyl cyclase activity in the rat isolated aorta. Plane F, et al. **Br J Pharmacol** 1997 May;121(2):345–50

Effects of calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta. Ruiz E, et al. **Br J Pharmacol** 1997 Jun;121(4):711–6

The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells. Salameh A, et al. **Br J Pharmacol** 1996 Aug; 118(8):1899–904

The effect of ovariectomy on depressed contractions to phenylephrine and KCl and increased relaxation to acetylcholine in isolated aortic rings of female compared to male rabbits. Sánchez A, et al. **Br J Pharmacol** 1996 Aug;118(8):2017–22

Vasoconstrictor responses via P2X-receptors are selectively antagonized by NF023 in rabbit isolated aorta and saphenous artery. Ziyal R, et al. **Br J Pharmacol** 1997 Mar; 120(5):954–60

The influence of angiotensin II-induced increase in aortic wall mass on compliance in rats in vivo. Brouwers-Ceiler DL, et al. **Cardiovasc Res** 1997 Feb;33(2):478–84

Effects of 17 beta-estradiol and progesterone on growth-factor-induced proliferation and migration in human female aortic smooth muscle cells in vitro. Suzuki A, et al. **Cardiovasc Res** 1996 Sep;32(3):516–23

Separate activation of intracellular Ca2+ release, voltage-dependent and receptor-operated Ca2+ channels in the rat aorta. Huang Y, et al. **Chin J Physiol** 1996; 39(1):1–8

Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Deckert V, et al. **Circulation** 1997 Feb 4;95(3):723–31

Vascular reactivity to phenylephrine and angiotensin II in hypertensive rats associated with insulin resistance. Iyer SN, et al. **Clin Exp Hypertens** 1996 Feb;18(2):227–42

Comparison of effects of vasoactive agents on adenylate cyclase activity in endothelial and smooth muscle cells from the same specimen of fetal bovine aorta. Ashikaga T, et al. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):36–42

Antiproliferative effect in rat vascular smooth muscle cells by osthole, isolated from Angelica pubescens. Guh JH, et al. **Eur J Pharmacol** 1996 Mar 7;298(2):191–7

Tranilast inhibits contraction of rat aortic smooth muscle. Ihara T, et al. **Eur J Pharmacol** 1997 Jun 18;329(1):43–8

Oligodeoxynucleotides directed to early growth response gene-1 mRNA inhibit DNA synthesis in the smooth muscle cell. Sachinidis A, et al. **Eur J Pharmacol** 1996 Aug 1; 309(1):95–105

Direct vascular effects of plantain extract in rats. Orie NN. **Exp Physiol** 1997 May;82(3):501–6

alpha-Methylnoradrenaline-induced contractions in rat aorta are mediated via alpha 1D-adrenoceptors. Castillo EF, et al. **Fundam Clin Pharmacol** 1997;11(4):339–45

Altered growth and lack of responsiveness to angiotensin II in aortic vascular smooth muscle cells from cirrhotic rats. Tazi KA, et al. **Gastroenterology** 1997 Jun; 112(6):2065–72

Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Chen CK, et al. **Gen Pharmacol** 1996 Mar; 27(2):363–6

Effects of auro-detoxin treatment on vascular responses in mouse aorta. Güney HZ, et al. **Gen Pharmacol** 1997 Aug; 29(2):261–4

Tetrahydrobiopterin synthesis inhibitors induce nitric oxide synthesis in rat aorta. Joly GA, et al. **Gen Pharmacol** 1997 Mar;28(3):475–80

Mechanism of the potentiating effect of NH4Cl on vasoconstriction in rat aorta. Tanaka H, et al. **Gen Pharmacol** 1996 Apr;27(3):535–8

Effects of tumor necrosis factor and interleukin-1 on the constriction induced by angiotensin II in rat aorta. Vicaut E, et al. **J Appl Physiol** 1996 Jun;80(6):1891–7

Pentoxifylline-induced vasodilatation is not endothelium-dependent in rabbit aorta. Kaputlu I, et al. **J Basic Clin Physiol Pharmacol** 1994 Jul-Dec; 5(3–4):295–304

Thapsigargin inhibits the response to acetylcholine and substance P but does not interfere with the responses to endothelium-independent agents. Amerini S, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):82–8

Gender-related differences in androgen regulation of thromboxane A2 receptors in rat aortic smooth-muscle cells. Higashiura K, et al. **J Cardiovasc Pharmacol** 1997 Mar;29(3):311–5

Inhibition of endothelium-dependent relaxation by hemoglobin in rabbit aortic strips: comparison between acellular hemoglobin derivatives and cellular hemoglobins. Nakai K, et al. **J Cardiovasc Pharmacol** 1996 Jul; 28(1):115–23

Contribution of arachidonic acid metabolites to reduced norepinephrine-induced contractions in hypercholesterolemic rabbit aortas. Pfister SL, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):784–91

Mouse aorta: a preparation highly sensitive to the vasodilatory action of CGRP. Pomerleau F, et al. **J Cardiovasc Pharmacol** 1997 Sep;30(3):343–51

The contractile mechanism of sodium metavanadate in isolated rat aortae. Zhou Q, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):84–9

Effect of deoxycorticosterone acetate on blood pressure in relation to accumulation of low-density lipoprotein and fibrinogen by aorta and other tissues of normotensive Wistar rats. Medina RA, et al. **J Hypertens** 1997 May; 15(5):531–6

Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. Masuda O, et al. **J Nutr** 1996 Dec;126(12):3063–8

Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. Dahring TK, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1446–56

Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. Raiteri M, et al. **J Pharmacol Exp Ther** 1997 Jun;281(3):1144–53

Investigation of aortic CYP3A bioactivation of nitroglycerin in vivo. Yuan R, et al. **J Pharmacol Exp Ther** 1997 Jun; 281(3):1499–505

Vasodilatory effects of a salen-manganese complex with potent oxyradical scavenger activities. Barandier C, et al. **J Vasc Res** 1997 Jan-Feb;34(1):49–57

Preservation of endothelium-dependent vascular relaxation in cholesterol-fed mice by the chronic administration of

prazosin or pravastatin. Kamata K, et al. **Jpn J Pharmacol** 1996 Feb;70(2):149–56

Effects of dietary Spirulina maxima on endothelium dependent vasomotor responses of rat aortic rings. Paredes-Carbajal MC, et al. **Life Sci** 1997;61(15):PL 211–9

Blood lipoproteins and their effect on contractile function of vessels in rats of different age. Frolkis VV, et al. **Mech Ageing Dev** 1997 Sep;97(3):207–14

Antioxidant and triglyceride-lowering effects of vitamin E associated with the prevention of abnormalities in the reactivity and morphology of aorta from streptozotocin-diabetic rats. Antioxidants in Diabetes-Induced Complications (ADIC) Study Group. Karasu C, et al. **Metabolism** 1997 Aug;46(8):872–9

Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on contractile responses in isolated rat aorta. Aloamaka CP, et al. **Methods Find Exp Clin Pharmacol** 1997 Jan-Feb; 19(1):13–7

An experimental model to study the cytotoxic effects induced by beta-amyloid, histamine, LPS and serum from Alzheimer patients on cultured rat endothelial cells. Maneiro E, et al. **Methods Find Exp Clin Pharmacol** 1997 Jan-Feb;19(1):5–12

Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657. Aramori I, et al. **Mol Pharmacol** 1997 Feb;51(2):171–6

Intra-aortic injection of myoblasts in mdx mice: genetic and technetium-99m cell labeling and biodistribution. Bresolin N, et al. **Muscle Nerve** 1997 Jun;20(6):757–9

Pharmacological properties of cardiovascular histamine H1 receptor binding sites: characterisation with 2-phenylhistamines. Carman-Krzan M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Apr; 355(4):431–7

Binding and effects of P1075, an opener of ATP-sensitive K+ channels, in the aorta from streptozotocin-treated diabetic rats. Glocker S, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Aug; 356(2):210–5

Activators of protein kinase A induce a glibenclamide-sensitive 86Rb+ efflux in rat isolated aorta. Kessler C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Apr;355(4):483–90

Intracellular and extracellular Ca2+ regulate histamine-induced release of nitric oxide in vascular endothelial cells as shown with sensitive and selective nitric oxide electrodes. Kishi F, et al. **Pharmacol Res** 1996 Feb; 33(2):123–6

Effects of ergotamine and dihydroergotamine on 5-hydroxytryptamine-2A receptors in the isolated rat aorta. Kalkman HO, et al. **Pharmacology** 1996 Dec; 53(6):351–5

Responsiveness of aortic rings of cadmium-hypertensive rats to endothelin-1. Ozdem SS, et al. **Pharmacology** 1997 Jun; 54(6):328–32

Endothelium-dependent higenamine-induced aortic relaxation in isolated rat aorta. Wong KK, et al. **Planta Med** 1997 Apr;63(2):130–2

Prostacyclin and thromboxane production of rat and cat arterial tissue is altered independently by several vasoactive substances. Szekacs B, et al. **Prostaglandins** 1996 Sep; 52(3):221–35

Characteristics of contractile responses of aorta to norepinephrine in db/db mice. Kamata K, et al. **Res Commun Mol Pathol Pharmacol** 1997 Jun;96(3):319–28

Role of aortic chemoreceptors in the hypertensive response to cigarette smoke. Anand A. **Respir Physiol** 1996 Dec; 106(3):231–8

Cardiac and vascular responses of isolated rat tissues treated with diterpenes from Sinularia flexibilis (coelenterata: octocorallia). Aceret TL, et al. **Toxicon** 1996 Oct; 34(10):1165–71

A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Räisänen-Sokolowski AK, et al. **Transplantation** 1997 Apr 15;63(7):936–41

The effect of anti-hypertensive drugs on DNA synthesis and proliferation of cultured rat aortic smooth muscle cells. Kang SW, et al. **Yonsei Med J** 1997 Jun;38(3):160–6

[Endothelin-1 modulates acetylcholine-induces relaxation of isolated rat aorta] Grafov MA, et al. **Dokl Akad Nauk** 1996 Nov;351(1):128–30 **(Rus)**

EMBRYOLOGY

Dorsal aortic impedance in stage 24 chick embryo following acute changes in circulating blood volume. Yoshigi M, et al. **Am J Physiol** 1996 May;270(5 Pt 2):H1597–606

Development of the aortic vessel wall as defined by vascular smooth muscle and extracellular matrix markers. Hungerford JE, et al. **Dev Biol** 1996 Sep 15;178(2):375–92

Characterization of the first definitive hematopoietic stem cells in the AGM and liver of the mouse embryo. Sánchez MJ, et al. **Immunity** 1996 Dec;5(6):513–25

ENZYMOLOGY

Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts. Akyürek LM, et al. **Am J Pathol** 1996 Dec; 149(6):1981–90

Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells. López-Ongil S, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1072–8

A beta-adrenoceptor agonist evokes a nitric oxide-cGMP relaxation mechanism modulated by adenylyl cyclase in rat aorta. Halothane does not inhibit this mechanism. Iranami H, et al. **Anesthesiology** 1996 Nov;85(5):1129–38

Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Hoshida S, et al. **Atherosclerosis** 1997 Apr;130(1–2):53–9

Extracellular signal-regulated kinase and c-Jun NH2-terminal kinase activities are continuously and differentially increased in aorta of hypertensive rats. Kim S, et al. **Biochem Biophys Res Commun** 1997 Jul 9; 236(1):199–204

Purification of the blood vessel ATP diphosphohydrolase, identification and localisation by immunological techniques. Sévigny J, et al. **Biochim Biophys Acta** 1997 Feb 11;1334(1):73–88

Protein kinase C isoenzymes in rat and human cardiovascular tissues. Erdbrügger W, et al. **Br J Pharmacol** 1997 Jan; 120(2):177–86

Increased activity of guanylate cyclase in the atherosclerotic rabbit aorta: role of non-endothelial nitric oxide synthases. Rupin A, et al. **Br J Pharmacol** 1996 Nov;119(6):1233–8

Sustained increase in aortic endothelial nitric oxide synthase expression in vivo in a model of chronic high blood flow. Nadaud S, et al. **Circ Res** 1996 Oct;79(4):857–63

Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta. Ishizaka N, et al. **Circulation** 1997 Sep 16;96(6):1923–9

Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Knox JB, et al. **Circulation** 1997 Jan 7;95(1):205–12

Regulation of Na+,K(+)-ATPase activity by dopamine in cultured rat aortic smooth muscle cells. Rashed SM, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):223–30

Potent inhibition of inducible nitric oxide synthase by geldanamycin, a tyrosine kinase inhibitor, in endothelial, smooth muscle cells, and in rat aorta. Joly GA, et al. **FEBS Lett** 1997 Feb 10;403(1):40–4

The potentiation of nitroglycerin-induced relaxation by PKG inhibition in rat aortic rings. Satake N, et al. **Gen Pharmacol** 1996 Jun;27(4):701–5

The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hayakawa H, et al. **Hypertension** 1997 Jan; 29(1 Pt 2):235–41

Vascular relaxation probably mediates the antihypertensive effect of a high-potassium diet: a role for enhanced vascular Na,K-ATPase activity. Dolson GM, et al. **J Hypertens** 1995 Dec;13(12 Pt 1):1433–9

Aorta and skeletal muscle NO synthase expression in experimental heart failure. Comini L, et al. **J Mol Cell Cardiol** 1996 Nov;28(11):2241–8

Isoform-specific biotransformation of glyceryl trinitrate by rat aortic glutathione S-transferases. Nigam R, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1527–34

Cyclic strain is a weak inducer of prostacyclin synthase expression in bovine aortic endothelial cells. Segurola RJ Jr, et al. **J Surg Res** 1997 Apr;69(1):135–8

Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta. Shireman PK, et al. **J Vasc Surg** 1997 Jan;25(1):157–64

Effects of ovariectomy and estrogen replacement on aorta angiotensin-converting enzyme activity in rats. Tanaka M, et al. **Jpn J Pharmacol** 1997 Apr;73(4):361–3

Two different activities of phospholipase A2 in porcine aortic cytosol. Hao LY, et al. **Life Sci** 1996;59(17):1443–54

Effect of trifluoperazine on certain arterial wall lipid-metabolizing enzymes inducing atherosclerosis in rhesus monkeys. Mohindroo A, et al. **Lipids** 1997 Aug; 32(8):867–72

Lipopolysaccharide-responsive protein kinase C isotypes in the adult rat aorta. McKenna TM, et al. **Shock** 1997 Apr; 7(4):269–73

Rabbit aorta glutathione S-transferases and their role in bioactivation of trinitroglycerin. Singhal SS, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):378–86

IMMUNOLOGY

Autoantibodies against arterial antigens: characterization by ELISA and immunoblot analysis in the spontaneously hypertensive rat. Ofosu-Appiah W, et al. **Clin Exp Hypertens** 1996 Jan;18(1):21–35

Prothrombin-related antigens in human aortic intima. Smith EB, et al. **Semin Thromb Hemost** 1996;22(4):347–50

Comparison between aortic and sinusoidal liver endothelial cells as targets of hyperacute xenogeneic rejection in the pig to human combination. Cattan P, et al. **Transplantation** 1996 Sep 27;62(6):803–10

INJURIES

Dilation mechanism, causes of restenosis and stenting in balloon coarctation angioplasty. Ino T, et al. **Acta Paediatr** 1997 Apr;86(4):367–71 (55 ref.)

Torn ascending aorta missed by transesophageal echocardiography. Lick SD, et al. **Ann Thorac Surg** 1997 Jun;63(6):1768–70

Traumatic aortic transections: eight-year experience with the "clamp-sew" technique. Sweeney MS, et al. **Ann Thorac Surg** 1997 Aug;64(2):384–7; discussion 387–9

Injury produces early rise in lipoprotein lipase activity in rabbit aorta. Werba JP, et al. **Atherosclerosis** 1996 Sep 6; 125(2):257–66

The aorta. Aortic aneurysm, trauma, and dissection. Erbel R, et al. **Crit Care Clin** 1996 Jul;12(3):733–66 (135 ref.)

Intramural posttraumatic hematoma of the ascending aorta in a patient with a double aortic arch. Fattori R, et al. **Eur Radiol** 1997;7(1):51–3

Traumatic aortic ruptures diagnosed by transesophageal echocardiography. Berenfeld A, et al. **J Am Soc Echocardiogr** 1996 Sep–Oct;9(5):657–62

Penetrating injuries to the thoracic great vessels. Demetriades D. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):173–9; discussion 179–80 (15 ref.)

Chest trauma: the role of transesophageal echocardiography. O'Connor C. **J Clin Anesth** 1996 Nov;8(7):605–13 (53 ref.)

Penetration of the interatrial septum: a rare complication of percutaneous transluminal mitral commissurotomy. Tseng CD, et al. **J Formos Med Assoc** 1997 Apr;96(4):272–5

High resolution MR imaging and localization of laser-induced thermal injury in the vascular wall. Ahmad A, et al. **J Magn Reson Imaging** 1996 Nov-Dec;6(6):868–73

Assessment of blunt aortic-brachiocephalic trauma: should angiography be supplanted by transesophageal echocardiography? [comment] Ben-Menachem Y. **J Trauma** 1997 May;42(5):969–72 (42 ref.). Comment on: J Trauma 1996 Mar;40(3):422–7. Comment on: J Trauma 1997 May;42(5):960–3.

Aortic transection following air-bag deployment [letter] deGuzman BJ, et al. **N Engl J Med** 1997 Aug 21; 337(8):573–4

Blunt trauma to the heart and great vessels. Prêtre R, et al. **N Engl J Med** 1997 Feb 27;336(9):626–32 (49 ref.)

Potential large vessel injury during thoracolumbar pedicle screw removal. A case report. Vanichkachorn JS, et al. **Spine** 1997 Jan 1;22(1):110–3

[Aortic trauma] Ando M. **Ryoikibetsu Shokogun Shirizu** 1996; (14):356–9 (6 ref.) **(Jpn)**

[Traumatic dissecting aneurysm] Hayashi T. **Ryoikibetsu Shokogun Shirizu** 1996;(14):322–4 (9 ref.) **(Jpn)**

INNERVATION

Baroreflex frequency-response characteristics to aortic depressor and carotid sinus nerve stimulation in rats. Fan W, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2218–27

Stimulation of aortic nerve evokes three different response patterns in neurons of rostral VLM of the rat. Zagon A, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1720–8

Effects of combined carotid sinus and aortic depressor nerve denervations in neonatal rat pups. Shair HN, et al. **Biol Neonate** 1997;71(4):251–64

Effect of aortic baroreceptor deafferentation on plasma vasopressin and oxytocin in the conscious rat. Ciriello J. **Brain Res** 1996 Nov 11;739(1–2):52–6

Non-voltage-gated Ca2+ influx through mechanosensitive ion channels in aortic baroreceptor neurons. Sullivan MJ, et al. **Circ Res** 1997 Jun;80(6):861–7

Salt enhances responsiveness of terminal aortic vascular bed to sympathetic activity. Shimamoto H, et al. **Eur J Clin Pharmacol** 1997;52(5):343–9

Short-term aortic barodenervation diminishes alpha 1-adrenoceptor reactivity in rat aortic smooth muscle. el-Mas MM, et al. **Eur J Pharmacol** 1997 Mar 19; 322(2–3):201–10

A descriptive and quantitative light and electron microscopy study of the aortic depressor nerve in normotensive rats. Fazan VP, et al. **Hypertension** 1997 Sep;30(3 Pt 2):693–8

Dynamics of sensory afferent synaptic transmission in aortic baroreceptor regions on nucleus tractus solitarius. Andresen MC, et al. **J Neurophysiol** 1995 Oct;74(4):1518–28

Temporal processing of aortic nerve evoked activity in the nucleus of the solitary tract. Scheuer DA, et al. **J Neurophysiol** 1996 Dec;76(6):3750–7

Influences of excitatory amino acid receptor agonists on nucleus of the solitary tract neurons receiving aortic depressor nerve inputs. Zhang J, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):639–47

[The innervation of the vasa vasorum of the aorta, pulmonary trunk, venae cavae and portal vein in man and animals (dogs)] Dzhangirov MSh. **Arkh Anat Gistol Embriol** 1968 Nov;55(11):24–7 (Eng. Abstr.) **(Rus)**

METABOLISM

Effects of protein kinase C activation and inhibition on endothelin-1 release from human aortic and pulmonary artery endothelial cells: comparison with effects on bovine endothelin-1 and human prostaglandin I2 release. Yamada Y, et al. **Am J Hypertens** 1997 Jan;10(1):32–42

Production of C-type natriuretic peptide in human aortic endothelial cells induced by activation of protein kinase C. Yamada Y, et al. **Am J Hypertens** 1996 Sep;9(9):924–9

Case report: thoracic aorta thrombus with systemic embolization: a rare paraneoplastic antiphospholipid syndrome? Messiaen T, et al. **Am J Med Sci** 1996 Dec; 312(6):303–5

Pregnancy-induced elevation in aortic vascular smooth muscle actin in the Sprague-Dawley rat. Davidge ST, et al. **Am J Obstet Gynecol** 1997 Jan;176(1 Pt 1):212–3

Cellular retinol-binding protein-1 is expressed by distinct

subsets of rat arterial smooth muscle cells in vitro and in vivo. Neuville P, et al. **Am J Pathol** 1997 Feb;150(2):509–21

Dual inhibitory effects of dopamine on Na+ homeostasis in rat aorta smooth muscle cells. Borin ML. **Am J Physiol** 1997 Feb;272(2 Pt 1):C428–38

Changes in angiotensin II receptor density and calcium handling during proliferation in SHR aortic myocytes. Côrtes SF, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2330–8

Differential stimulation of Na+ pump activity by insulin and nitric oxide in rabbit aorta. Gupta S, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):H1287–93

Dual role of cGMP in modulation of macromolecule permeability of aortic endothelial cells. Hölschermann H, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H91–8

Oxidative stress increases glyceraldehyde-3-phosphate dehydrogenase mRNA levels in isolated rabbit aorta. Ito Y, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H81–7

Elemental composition of Na pump inhibited rabbit aorta VSM cells by electron probe X-ray microanalysis. Krep H, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H514–20

Dual modulation of Na/H antiport by atrial natriuretic factor in rat aortic smooth muscle cells. Ricci R, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C643–52

Dual regulation of PLA2 and PGI2 production by G proteins in bovine aortic endothelial cells. Rosenstock M, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C555–62

Annexin II inhibition of G protein-regulated inositol trisphosphate formation in rat aortic smooth muscle. Schelling JR, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):F682–90

Tyrosine phosphorylation of pp125FAK and paxillin in aortic endothelial cells induced by mechanical strain. Yano Y, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C635–49

Opioid growth factor-dependent DNA synthesis in the neonatal rat aorta. Zagon IS, et al. **Am J Physiol** 1996 Jan; 270(1 Pt 2):R22–32

Three putative integrin ligands identified in human aortic smooth muscle cells. Herren B, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:498–505

Changes with age in the influence of endogenous nitric oxide on transport properties of the rabbit aortic wall near branches. Forster BA, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1361–8

P-selectin and vascular cell adhesion molecule-1 are focally expressed in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and T lymphocytes. Sakai A, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb; 17(2):310–6

Involvement of phosphatidylcholine hydrolysis by phospholipase D in extracellular ATP-induced arachidonic acid release in aortic smooth muscle cells. Shinoda J, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):295–9

Effect of glucocorticoids on tumor necrosis factor induced suppression of protein synthesis in rat aortic smooth muscle: comparison with extensor digitorum longus. Cheema IR, et al. **Artery** 1994;21(5):243–55

Estrogen inhibits endothelin-1 production and c-fos gene expression in rat aorta. Akishita M, et al. **Atherosclerosis** 1996 Aug 23;125(1):27–38

Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Anber V, et al. **Atherosclerosis** 1996 Aug 2;124(2):261–71

Collagen-synthesizing cells in initial and advanced atherosclerotic lesions of human aorta. Andreeva ER, et al. **Atherosclerosis** 1997 Apr;130(1-2):133–42

Formation of Birbeck granule-like structures in vascular dendritic cells in human atherosclerotic aorta. Lag-antibody to epidermal Langerhans cells recognizes cells in the aortic wall. Bobryshev YV, et al. **Atherosclerosis** 1997 Sep;133(2):193–202

Vitamin E levels in human atherosclerotic plaque: the influence of risk factors. Killion SL, et al. **Atherosclerosis** 1996 Oct 25;126(2):289–97

Detection and localization of tumor necrosis factor-alpha in WHHL rabbit arteries. Lei X, et al. **Atherosclerosis** 1996 Aug 23;125(1):81–9

The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Sugano M, et al. **Atherosclerosis** 1996 Nov 15;127(1):123–9

Expression of vascular cell adhesion molecule-1 (VCAM-1) in the aortae of hypercholesterolemic rabbits with high (HAR) and low (LAR) atherosclerotic response. Teupser D, et al. **Atherosclerosis** 1997 Feb 10;128(2):157–64

Isolation and characterization of a proteoglycan variant from human aorta exhibiting a marked affinity for low density lipoprotein and demonstration of its enhanced expression in atherosclerotic plaques. Vijayagopal P, et al. **Atherosclerosis** 1996 Dec 20;127(2):195–203

Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective de-endothelialization. Wang H, et al. **Atherosclerosis** 1996 Sep 27;126(1):95–104

ICAM-1 expression on cardiac myocytes and aortic endothelial cells via their specific endothelin receptor subtype. Hayasaki Y, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):817–24

Glucose-induced down-regulation of NO production and inducible NOS expression in cultured rat aortic vascular smooth muscle cells: role of protein kinase C. Nishio E, et al. **Biochem Biophys Res Commun** 1996 Dec 24; 229(3):857–63

Activation of human prothrombin by porcine aortic endothelial cells--a potential barrier to pig to human xenotransplantation. Jurd KM, et al. **Blood Coagul Fibrinolysis** 1996 Apr;7(3):336–43

Endothelin receptors in human coronary artery and aorta. Bacon CR, et al. **Br J Pharmacol** 1996 Mar;117(5):986–92

Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. Saifeddine M, et al. **Br J Pharmacol** 1996 Jun;118(3):521–30

Aortic collagen, aortic stiffness, and AT1 receptors in experimental and human hypertension. Benetos A, et al. **Can J Physiol Pharmacol** 1996 Jul;74(7):862–6 (30 ref.)

Alpha 1-adrenoceptor subtypes in rat aorta and mesenteric small arteries are preserved during left ventricular dysfunction post-myocardial infarction. Stassen FR, et al. **Cardiovasc Res** 1997 Mar;33(3):706–13

Use of La3+ to distinguish activity of the plasmalemmal Ca2+ pump from Na+/Ca2+ exchange in arterial myocytes. Shimizu H, et al. **Cell Calcium** 1997 Jan; 21(1):31–41

Effects of hyperlipidemia on aortic endothelial cell turnover and transendothelial macromolecular transport in cholesterol-fed rats. Lin SJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 Oct; 58(4):235–40

Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Bacon CR, et al. **Circ Res** 1996 Oct;79(4):794–801

Vascular thrombin receptor regulation in hypertensive rats. Capers Q 4th, et al. **Circ Res** 1997 Jun;80(6):838–44

p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Fukui T, et al. **Circ Res** 1997 Jan;80(1):45–51

Heparin-binding epidermal growth factor-like growth factor regulates fibroblast growth factor-2 expression in aortic smooth muscle cells. Peifley KA, et al. **Circ Res** 1996 Aug; 79(2):263–70

Residence time of low-density lipoprotein in the normal and atherosclerotic rabbit aorta. Tozer EC, et al. **Circ Res** 1997 Feb;80(2):208–18

Prostacyclin formation elicited by endothelin-1 in rat aorta is mediated via phospholipase D activation and not phospholipase C or A2. Wright HM, et al. **Circ Res** 1996 Aug;79(2):271–6

Hypertension increases connexin43 in a tissue-specific manner. Haefliger JA, et al. **Circulation** 1997 Feb 18; 95(4):1007–14

Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Lubec B, et al. **Circulation** 1996 Nov 15; 94(10):2620–5

Intracellular free Ca2+ and basal Mn2+ influx in cultured aortic smooth muscle cells from spontaneously hypertensive and normotensive Wistar-Kyoto rats. Monteith GR, et al. **Clin Exp Hypertens** 1997 May; 19(4):431–43

Elevated epidermal growth factor receptor levels in hypertensive Lyon rat kidney and aorta. Swaminathan N, et al. **Clin Exp Pharmacol Physiol** 1996 Sep;23(9):793–6

Time course study of oxidative stress in aorta and heart of diabetic rat. Kakkar R, et al. **Clin Sci (Colch)** 1996 Oct; 91(4):441–8

Mechanism of angiotensin II-induced arachidonic acid metabolite release in aortic smooth muscle cells: involvement of phospholipase D. Shinoda J, et al. **Eur J Endocrinol** 1997 Feb;136(2):207–12

Evidence that most high-affinity ATP binding sites on aortic endothelial cells and membranes do not correspond to P2 receptors. Motte S, et al. **Eur J Pharmacol** 1996 Jun 27; 307(2):201–9

Accumulation of glycosphingolipids in human atherosclerotic plaque and unaffected aorta tissues. Chatterjee SB, et al. **Glycobiology** 1997 Feb;7(1):57–65

Vascular angiotensin-converting enzyme expression regulates local angiotensin II. Müller DN, et al. **Hypertension** 1997 Jan;29(1 Pt 1):98–104

Induction of growth hormone receptor and insulin-like growth factor-I mRNA in aorta and caval vein during hemodynamic challenge. Wickman A, et al. **Hypertension** 1997 Jan;29(1 Pt 1):123–30

Differential response of rat aortic and coronary smooth muscle cell DNA synthesis in response to mechanical stretch in vitro [letter] Lundberg MS, et al. **In Vitro Cell Dev Biol Anim** 1996 Jan;32(1):13–5

Bcl-2 and p53 protein expression in aortic, mammary artery and saphenous vein biopsies in patients subjected to open heart surgery. Aaltomaa S, et al. **In Vivo** 1997 Jul-Aug; 11(4):337–43

Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modification of the lysine residues. Oörni K, et al. **J Biol Chem** 1997 Aug 22;272(34):21303–11

Arterial versus venous metabolism of nitroglycerin to nitric oxide: a possible explanation of organic nitrate venoselectivity. Bauer JA, et al. **J Cardiovasc Pharmacol** 1996 Sep;28(3):371–4

Cefamandole and Ca2+ uptake by bovine aortic media. Kokkas B, et al. **J Chemother** 1995 Nov;7 Suppl 4:32–3

Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. Boonmark NW, et al. **J Clin Invest** 1997 Aug 1;100(3):558–64

Stimulation of activin A expression in rat aortic smooth muscle cells by thrombin and angiotensin II correlates with neointimal formation in vivo. Pawlowski JE, et al. **J Clin Invest** 1997 Aug 1;100(3):639–48

Effect of deoxycorticosterone acetate on blood pressure in relation to accumulation of low-density lipoprotein and fibrinogen by aorta and other tissues of normotensive Wistar rats. Medina RA, et al. **J Hypertens** 1997 May; 15(5):531–6

Effect of ageing and hypertension on endothelial modulation of ouabain-induced contraction and sodium pump activity in the rat aorta. Ponte A, et al. **J Hypertens** 1996 Jun; 14(6):705–12

Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. Liang JS, et al. **J Lipid Res** 1996 Oct; 37(10):2109–16

Vascular-derived myocardial contractile factor: positive myocardial inotropic substance released from medial layer of the canine aorta. Li K, et al. **J Mol Cell Cardiol** 1996 May;28(5):881–92

Aortic elastin and collagen content and synthesis in two strains of rats with different susceptibilities to rupture of the internal elastic lamina. Sauvage M, et al. **J Vasc Res** 1997 Mar-Apr;34(2):126–36

Multiple mechanisms of activating Ca2+ entry in freshly isolated rabbit aortic endothelial cells. Wang X, et al. **J Vasc Res** 1997 May-Jun;34(3):196–207

Platelet-derived growth factor production by cells from Dacron grafts implanted in a canine model. Pitsch RJ, et al. **J Vasc Surg** 1997 Jul;26(1):70–8

Impaired synthesis of elastin in walls of aorta and large conduit arteries during early development as an initiating event in pathogenesis of systemic hypertension. Martyn CN, et al. **Lancet** 1997 Sep 27;350(9082):953–5 (29 ref.)

Induction of ICE and inhibition of c-fos, jun D and zif 268 in 12-month old spontaneously hypertensive rats. Chen H, et al. **Life Sci** 1997;61(2):PL27–31

Oryzanol decreases cholesterol absorption and aortic fatty streaks in hamsters. Rong N, et al. **Lipids** 1997 Mar; 32(3):303–9

Expression of alpha 1 adrenergic receptor subtype mRNAs in the rat cardiovascular system with aging. Miller JW, et al. **Mech Ageing Dev** 1996 Jun 7;87(2):75–89

Dietary linolenic acid-mediated increase in vascular prostacyclin formation. Rupp H, et al. **Mol Cell Biochem** 1996 Sep 6;162(1):59–64

Alpha1D-adrenergic receptors and mitogen-activated protein kinase mediate increased protein synthesis by arterial smooth muscle. Xin X, et al. **Mol Pharmacol** 1997 May;51(5):764–75

Capacitative Ca2+ entry associated with alpha1-adrenoceptors in rat aorta. Noguera MA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jul; 356(1):83–9

Expression of platelet-derived growth factor ligands and receptors by rat aortic endothelium in vivo. Lindner V. **Pathobiology** 1995;63(5):257–64

Levels of taurine, amino acids and related compounds in plasma, vena cava, aorta and heart of rats after taurine administration. Korang K, et al. **Pharmacology** 1996 Apr; 52(4):263–70

Cold-induced heat shock protein expression in rat aorta and brown adipose tissue. Matz JM, et al. **Physiol Behav** 1996 Nov;60(5):1369–74

Prostacyclin and thromboxane production of rat and cat arterial tissue is altered independently by several vasoactive substances. Szekacs B, et al. **Prostaglandins** 1996 Sep; 52(3):221–35

Endothelin-induced prostacyclin production in rat aortic rings is mediated by protein kinase C. Oriji GK, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Nov; 55(5):309–13

Increased cyclic AMP in aortas of cholesterol fed rabbits. Langner RO, et al. **Res Commun Mol Pathol Pharmacol** 1996 Nov;94(2):193–202

Effects of dietary fluoride and magnesium supplements on cyclic adenosine monophosphate (cAMP), calcium and magnesium levels in aorta of genetically hypercholesterolaemic RICO rats. Luoma H, et al. **Scand J Clin Lab Invest** 1997 Aug;57(5):421–5

Hypoxic effects on cholesterol metabolism of cultured rat aortic and brain microvascular endothelial cells, and aortic vascular smooth muscle cells. Arai Y, et al. **Tohoku J Exp Med** 1996 Sep;180(1):17–25

Temporal relationship between insulin-like growth factor-I and platelet-derived growth factor-BB expression in the rat aorta allograft in the early phase following transplantation. Saito S, et al. **Transplant Proc** 1997 Sep; 29(6):2552–3

The effect of anti-hypertensive drugs on DNA synthesis and proliferation of cultured rat aortic smooth muscle cells. Kang SW, et al. **Yonsei Med J** 1997 Jun;38(3):160–6

[Localization of collagen-synthesizing cells in normal and atherosclerotic intima of human aorta] Andreeva ER, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):95–7 **(Rus)**

[An unusual pathway of export from the cell of synthesized protein] Klimov AN, et al. **Biull Eksp Biol Med** 1996 Sep; 122(9):268–70 **(Rus)**

AORTA

MICROBIOLOGY

Induction of nitric oxide production by polyosides from the cell walls of Streptococcus mutans OMZ 175, a gram-positive bacterium, in the rat aorta. Martin V, et al. **Infect Immun** 1997 Jun;65(6):2074-9

PATHOLOGY

Morphologic mural changes in the aorta revealed by CT in patients with nonspecific aortoarteritis (Takayasu's arteritis). Sharma S, et al. **AJR Am J Roentgenol** 1996 Nov; 167(5):1321-5

Respective role of humoral factors and blood pressure in aortic remodeling of DOCA hypertensive rats [see comments] Karam H, et al. **Am J Hypertens** 1996 Oct;9(10 Pt 1):991-8. Comment in: Am J Hypertens 1997 Jul;10(7 Pt 1):825-7.

Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Morikang E, et al. **Am J Hypertens** 1997 Apr;10(4 Pt 1):440-6

Monoclonality of smooth muscle cells in human atherosclerosis. Murry CE, et al. **Am J Pathol** 1997 Sep; 151(3):697-705

C-type natriuretic protein inhibits intimal thickening after vascular injury. Matsuo H, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:45-7 (10 ref.)

Endothelial activation potentiates neointimal lesion formation in the rabbit aorta after balloon injury. Tanaka H, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:448-58

Wild-type p53 gene transfer: a novel therapeutic strategy for neointimal hyperplasia after arterial injury. Yonemitsu Y, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:395-400 (13 ref.)

Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. Bastaki M, et al. **Arterioscler Thromb Vasc Biol** 1997 Mar;17(3):454-64

Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Felton CV, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1337-45

Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT beta. Frebelius S, et al. **Arterioscler Thromb Vasc Biol** 1996 Oct; 16(10):1292-7

Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. Jovinge S, et al. **Arterioscler Thromb Vasc Biol** 1997 Mar;17(3):490-7

The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Kenagy RD, et al. **Arterioscler Thromb Vasc Biol** 1996 Nov;16(11):1373-82

Vitamin E inhibits low-density lipoprotein-induced adhesion of monocytes to human aortic endothelial cells in vitro. Martin A, et al. **Arterioscler Thromb Vasc Biol** 1997 Mar; 17(3):429-36

P-selectin and vascular cell adhesion molecule-1 are focally expressed in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and T lymphocytes. Sakai A, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb; 17(2):310-6

Ischemia-induced transplant arteriosclerosis in the rat. Induction of peptide growth factor expression. Waltenberger J, et al. **Arterioscler Thromb Vasc Biol** 1996 Dec;16(12):1516-23

Combined treatment of probucol with diltiazem regresses atherosclerosis induced by 196 cholesterol diet in rabbit aorta. Kouzuma R, et al. **Artery** 1995;21(6):337-51

Different effects of hypertension and hypercholesterolemia on the natural history of aortic atherosclerosis by the stage of intimal lesions. Homma S, et al. **Atherosclerosis** 1997 Jan 3;128(1):85-95

Aortic medial necrosis with or without thrombosis in rabbits treated with Russell's viper venom and angiotensin II. Nakamura M, et al. **Atherosclerosis** 1997 Feb 10; 128(2):149-56

Aortic collagen, aortic stiffness, and AT1 receptors in experimental and human hypertension. Benetos A, et al. **Can J Physiol Pharmacol** 1996 Jul;74(7):862-6 (30 ref.)

Modified catheter shapes for engaging left coronary ostium in unusually wide ascending aortas [letter] Abhyankar AD. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):327

Elemental changes in atherosclerotic lesions using nuclear microscopy. Thong PS, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Feb;42(1):103-10

Aortic root dilatation in Marfan's syndrome: a contribution from obstructive sleep apnea? Cistulli PA, et al. **Chest** 1997 Jun;111(6):1763-6 (16 ref.)

Tumor neutrophil elastase is closely associated with the direct extension of non-small cell lung cancer into the aorta. Yamashita J, et al. **Chest** 1997 Apr;111(4):885-90

Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Steg PG, et al. **Circulation** 1997 Jul 15;96(2):408-11

Aortic stents [letter; comment] Adiseshiah M. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):423-4. Comment on: Eur J Vasc Endovasc Surg 1996 Oct;12(3):287-94.

Inflammatory aortic aneurysms: regression of fibrosis after aneurysm surgery. Bitsch M, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):371-4

Perforin-positive leukemic cell infiltration in the aortic tissue of a patient with T-cell prolymphocytic leukemia. Seko Y, et al. **Int Angiol** 1996 Sep;15(3):245-8

Malignant hemangioendothelioma of the aorta. Shijubo N, et al. **Intern Med** 1995 Nov;34(11):1126-9 (14 ref.)

Atherosclerotic plaque components in human aortas contrasted by ex vivo imaging using fast spin-echo magnetic resonance imaging and spiral computed tomography [published erratum appears in Invest Radiol 1997 Jan;32(1):65] Halliburton SS, et al. **Invest Radiol** 1996 Nov;31(11):724-8

The effect of age on residual strain in the rat aorta. Badreck-Amoudi A, et al. **J Biomech Eng** 1996 Nov; 118(4):440-4

Synergistic inhibition of calcification of porcine aortic root with preincubation in FeCl3 and alpha-amino oleic acid in a rat subdermal model. Chen W, et al. **J Biomed Mater Res** 1997 Spring;38(1):43-8

Effect of E5510 on anastomotic intimal hyperplasia and platelet aggregation in dogs. Fujioka K, et al. **J Cardiovasc Pharmacol** 1996 Jun;27(6):824-30

Coronary artery bypass grafting of Takayasu's disease with calcified aorta and subclavian artery obstruction. Goh K, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):415-7

Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. Cohen RD, et al. **J Clin Invest** 1997 Apr 15;99(8):1906-16

Stimulation of activin A expression in rat aortic smooth muscle cells by thrombin and angiotensin II correlates with neointimal formation in vivo. Pawlowski JE, et al. **J Clin Invest** 1997 Aug 1;100(3):639-48

The 20 mm Medtronic Hall prosthesis in the small aortic root. Aris A, et al. **J Heart Valve Dis** 1996 Jul;5(4):459-62

Smooth muscle cell types at different aortic levels and in microvasculature of rabbits with renovascular hypertension. Pauletto P, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1679-85

Early morphologic changes of atherosclerosis induced by ventromedial hypothalamic lesion in the spontaneously diabetic Goto-Kakizaki rat. Nishida M, et al. **J Lab Clin Med** 1997 Feb;129(2):200-7

High resolution MR imaging and localization of laser-induced thermal injury in the vascular wall. Ahmad A, et al. **J Magn Reson Imaging** 1996 Nov-Dec;6(6):868-73

The aortic root in supravalvular aortic stenosis: the potential surgical relevance of morphologic findings. Stamm C, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):16-24

High resolution intravascular MRI and MRS by using a catheter receiver coil. Atalar E, et al. **Magn Reson Med** 1996 Oct;36(4):596-605

Chemical characterization of peroxidized low-density lipoprotein in plasma and aortic atheroma. Kanazawa T, et al. **Pathobiology** 1996;64(1):18-26

Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Bourassa PA, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10022-7

Contrast-enhanced abdominal MR angiography: optimization of imaging delay time by automating the detection of contrast material arrival in the aorta. Prince MR, et al. **Radiology** 1997 Apr;203(1):109-14

Aneurysmal dilatation of ascending aorta and aortic insufficiency in juvenile spondyloarthropathy. Kim TH, et al. **Scand J Rheumatol** 1997;26(3):218-21

Sequential herniation of stomach, then colon through the aortic hiatus. Wagner RB, et al. **South Med J** 1997 Mar; 90(3):338-40

Leaking giant aneurysm of the aortic root due to cystic medial necrosis with pericardial tamponade mimicking type-A aortic dissection. Attenhofer CH, et al. **Thorac Cardiovasc Surg** 1996 Apr;44(2):103-4

Magnetic resonance imaging in the follow-up of patients after aortic root reconstruction. Lepore V, et al. **Thorac Cardiovasc Surg** 1996 Aug;44(4):188-92

Endothelium-derived nitric oxide decreases polymorphonuclear leukocyte interaction with the deeply injured arterial wall under intermediate and high shear conditions. Provost P, et al. **Thromb Haemost** 1997 Aug; 78(2):939-46

Ischemia induced upregulation of growth factor expression in experimental transplant arteriosclerosis. Fellström B, et al. **Transplant Proc** 1997 Sep;29(6):2558

Angiopeptin induces beneficial vascular remodeling after balloon injury. Foegh ML, et al. **Transplant Proc** 1997 Sep; 29(6):2605-8

The impact of acute rejection on the development of intimal hyperplasia associated with chronic rejection. Hullett DA, et al. **Transplantation** 1996 Dec 27;62(12):1842-6

Thrombosis of the aorta and the caudal arteries in the horse; additional diagnostics and a new surgical treatment. Brama PA, et al. **Vet Q** 1996;18 Suppl 2:S85-9

[Aortic inner surface morphology in aortic disease by three-dimensional transesophageal echocardiography] Matsumura M, et al. **J Cardiol** 1996 Mar;27(3):143-51 (Eng. Abstr.) **(Jpn)**

[Injury to ascending aorta by cross-clamp--histologic evaluation] Takano T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2130-7 (Eng. Abstr.) **(Jpn)**

[Cystic medial necrosis] Imakita M. **Ryoikibetsu Shokogun Shirizu** 1996;(14):405-7 (18 ref.) **(Jpn)**

[Aortic tumors (neoplasms of the aortal)] Iwabuchi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):383-6 (15 ref.) **(Jpn)**

[The reactive changes in the vascular intima under chronic infection] Molchanova VV. **Arkh Anat Gistol Embriol** 1968 Nov;55(11):52-9 (Eng. Abstr.) **(Rus)**

[Varying expression of atherosclerosis in the aortic regions with high and low density of the adrenergic nervous plexuses] Shvalev VN, et al. **Arkh Patol** 1996 Sep-Oct; 58(5):28-30 (Eng. Abstr.) **(Rus)**

[Virus-induced morphological changes in arterial vessels of rabbits with herpetic keratoconjunctivitis and in patients with generalized herpetic infection] Amvros'eva TV, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):702-6 **(Rus)**

[The phenomenon of focal sympathetic denervation of the major vessels in the development of atherosclerosis] Shvalev VN, et al. **Morfologiia** 1996;110(4):102-4 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Influence of sympathetic stimulation on the mechanical properties of the aorta in humans. Sonesson B, et al. **Acta Physiol Scand** 1997 Feb;159(2):139-45

Aortic and abdominal glomera. Howe A. **Adv Exp Med Biol** 1995;381:57-61

The relaxation responses to corticotropin-releasing factor in rat aorta are endothelium dependent and gestationally regulated. Jain V, et al. **Am J Obstet Gynecol** 1997 Jan; 176(1 Pt 1):234-40

In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity. Barra JG, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H859-68

Oxygen modulates alpha 1B-adrenergic receptor gene expression by arterial but not venous vascular smooth muscle. Eckhart AD, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1599-608

Comparison of linear and nonlinear formulations of the three-element windkessel model. Fogliardi R, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2661-8

Differential nitric oxide production by microvascular and macrovascular endothelial cells. Geiger M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):L275-81

Direct measurement of transverse residual strains in aorta. Han HC, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):H750-9

Effect of pioglitazone on vascular reactivity in vivo and in vitro. Kotchen TA, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):R660-6

Transfer function analysis of central arc of aortic baroreceptor reflex in rabbits. Kubo T, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):H1054-62

Thrombin-induced vascular reactivity is modulated by ETB receptor-coupled nitric oxide release in rat aorta. Magazine HI, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):C923-8

Differential activation of NF-kappa B in human aortic endothelial cells conditioned to specific flow environments. Mohan S, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C572-8

Action of protein kinase C in endothelin-induced contractions in rat aortic rings. Oriji GK, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C398-404

Vasorelaxation by an endothelium-derived metabolite of arachidonic acid. Pfister SL, et al. **Am J Physiol** 1996 Mar; 270(3 Pt 2):H1021-30

Desensitization of norepinephrine receptor function is associated with G protein uncoupling in the rat aorta. Seasholtz TM, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H279-85

In vivo adaptive responses of the aorta to hypertension and aging. Sumitani M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H96-103

A technique to assess aortic distensibility and compliance in anesthetized and awake rats. Van Gorp A, et al. **Am J Physiol** 1996 Feb;270(2 Pt 2):H780-6

Characterization of embryonic aortic impedance with lumped parameter models. Yoshigi M, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H19-27

Response to: possible contribution of transmembrane Ca2+ influx to adenylate cyclase-mediated NO-cGMP relaxation in rat aorta [letter] Wu SN. **Anesthesiology** 1997 Sep; 87(3):712-3

Hemodynamic and biochemical characteristics of the aorta in the WKY, SHR, WKHT, and WKHA rat strains. Ricci MA, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:121-30

Antegrade cardioplegia pressure monitoring [letter; comment] Fabri BM, et al. **Ann Thorac Surg** 1997 Jul; 64(1):292. Comment on: Ann Thorac Surg 1996 Oct;62(4):1213-4.

Aortic root pressure monitoring during antegrade cardioplegia administration [see comments] Young JN, et al. **Ann Thorac Surg** 1996 Oct;62(4):1213-4. Comment in: Ann Thorac Surg 1997 Jul;64(1):292.

Experimental study of extraaortic balloon counterpulsation as a bridge to other mechanical assists. Odaguchi H, et al. **ASAIO J** 1996 May-Jun;42(3):190-4

Protein kinase inhibition and the oestrogen-like relaxant effects of genistein on isolated rat aorta. Babaei H, et al. **Biochem Soc Trans** 1997 Feb;25(1):111S

Residual stresses in the human aorta and their influences by growth and remodelling. Valenta J, et al. **Biomed Mater Eng** 1997;7(3):159-69

The effect of aging and pressure on the specific hydraulic conductivity of the aortic wall. Whale MD, et al. **Biorheology** 1996 Jan-Feb;33(1):17-44

Effect of fasting on insulin signaling in the aorta of intact rats. Silva LA, et al. **Braz J Med Biol Res** 1996 Dec;

29(12):1611-5
Continuous oesophageal aortic blood flow echo-Doppler measurement during general anaesthesia in infants. Gueugniaud PY, et al. **Can J Anaesth** 1997 Jul;44(7):745-50
Spontaneous running increases aortic compliance in Wistar-Kyoto rats. Kingwell BA, et al. **Cardiovasc Res** 1997 Jul;35(1):132-7
Effect of a mechanical vs a pharmacologic increase in aortic pressure on coronary blood flow and thrombolysis induced by IV administration of a thrombolytic agent. Prewitt RM, et al. **Chest** 1997 Feb;111(2):449-53
Mechanism of vascular smooth muscle relaxation by estrogen in depolarized rat and mouse aorta. Role of nuclear estrogen receptor and Ca2+ uptake. Freay AD, et al. **Circ Res** 1997 Aug;81(2):242-8
Targeted ablation of the phospholamban gene is associated with a marked decrease in sensitivity in aortic smooth muscle. Lalli J, et al. **Circ Res** 1997 Apr;80(4):506-13
Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Chen CH, et al. **Circulation** 1997 Apr 1;95(7):1827-36
Dependence of aortic pulse wave assessments on behavioural state in normal term fetus. Hu J, et al. **Early Hum Dev** 1997 Apr 25;48(1-2):59-70
Pulmonary artery, aortic and oesophageal pressure changes during high intensity treadmill exercise in the horse: a possible relation to exercise-induced pulmonary haemorrhage [see comments] Erickson BK, et al. **Equine Vet J Suppl** 1990 Jun;(9):47-52. Comment in: Equine Vet J Suppl 1990 Jun;(9):5-6.
The modulus of elasticity of lobster aorta microfibrils. McConnell CJ, et al. **Experientia** 1996 Sep 15;52(9):918-21
Age dependency of nanosecond fluorescence characteristics in human arteries. Araki T, et al. **Front Med Biol Eng** 1996; 7(4):265-73
Aortic and peripheral blood pressure during isometric and dynamic exercise. Blum V, et al. **Int J Sports Med** 1997 Jan;18(1):30-4
Testosterone worsens endothelial dysfunction associated with hypercholesterolemia and environmental tobacco smoke exposure in male rabbit aorta. Hutchison SJ, et al. **J Am Coll Cardiol** 1997 Mar 15;29(4):800-7
Comparison of techniques for measuring pulse-wave velocity in the rat. Mitchell GF, et al. **J Appl Physiol** 1997 Jan; 82(1):203-10
Viscoelastic properties of cultured porcine aortic endothelial cells exposed to shear stress. Sato M, et al. **J Biomech** 1996 Apr;29(4):461-7
A 3D-LDA study of the relation between wall shear stress and intimal thickness in a human aortic bifurcation. Hayashi K, et al. **J Biomech Eng** 1996 Aug;118(3):273-9
Comparison of pulsatile versus nonpulsatile perfusion on the postcardiopulmonary bypass aortic-radial artery pressure gradient. Badner NH, et al. **J Cardiothorac Vasc Anesth** 1997 Jun;11(4):428-31
Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. Holm P, et al. **J Clin Invest** 1997 Aug 15;100(4):821-8
Potent inhibitory effects of steroids in an in vitro model of angiogenesis. Jaggers DC, et al. **J Endocrinol** 1996 Sep; 150(3):457-64
A method for repeated high-fidelity micromanometer measurement of intracardiac pressures. Fanton JW, et al. **J Invest Surg** 1996 May-Jun;9(3):167-73
Control of lymphocyte adhesion to brain and aortic endothelium: ICAM-1, VCAM-1 and negative charge. dos Santos WL, et al. **J Neuroimmunol** 1996 May; 66(1-2):125-34
Oxygen transport and utilization during feeding in the young lamb. Grant DA, et al. **J Physiol (Lond)** 1997 Aug 15;503 (Pt 1):195-202
Calcium-activated potassium channels in the endothelium of intact rat aorta. Marchenko SM, et al. **J Physiol (Lond)** 1996 Apr 1;492 (Pt 1):53-60
Role of ganglionic cotransmission in sympathetic control of the isolated bullfrog aorta. Thorne R, et al. **J Physiol (Lond)** 1997 Jan 1;498 (Pt 1):201-14
Measurement of flow rates through aortic branches in the anesthetized rabbit. Barakat AI, et al. **Lab Anim Sci** 1997 Apr;47(2):184-9
Acceleration mapping by Fourier acceleration-encoding: in vitro study and initial results in the great thoracic vessels. Tasu JP, et al. **Magn Reson Med** 1997 Jul;38(1):110-6
Dimensions and mechanical properties of porcine aortic segments determined by combined impedance planimetry and high-frequency ultrasound. Storkholm JH, et al. **Med Biol Eng Comput** 1997 Jan;35(1):21-6
Retinal artery and vein pressures in the dog and their relationship to aortic, intraocular, and cerebrospinal fluid pressures. Morgan WH, et al. **Microvasc Res** 1997 May; 53(3):211-21
Calcium channels and cation transport ATPases in cardiac hypertrophy induced by aortic constriction in newborn rats. Zheng L, et al. **Mol Cell Biochem** 1996 Oct-Nov; 163-164:23-9
Aortic barodenervation up-regulates alpha2-adrenoceptors in the nucleus tractus solitarius and rostral ventrolateral medulla: an autoradiographic study. El-Mas MM, et al. **Neuroscience** 1997 Jul;79(2):581-90
Bisferiens peaks in the radial artery pressure wave during patent ductus arteriosus in newborn infants: relationship with ascending aortic flow. Gevers M, et al. **Pediatr Res** 1996 Jul;40(1):163-8
Minor components with smooth muscle relaxing properties from scented myrrh (Commiphora guidotti). Andersson M, et al. **Planta Med** 1997 Jun;63(3):251-4
In vivo assessment of luminal cross-sectional areas and circumferential tension-strain relations of the porcine aorta. Frøbert O, et al. **Scand J Thorac Cardiovasc Surg** 1996; 30(1):11-9
Cardiac functional changes in the human fetus in the late first and early second trimesters. van Splunder IP, et al. **Ultrasound Obstet Gynecol** 1996 Jun;7(6):411-5
[Non-invasive test for aortic compliance in man.] Savin E, et al. **Arch Physiol Biochem** 1996;104(3):257-64 (Eng. Abstr.) **(Fre)**
[Structure of blood flow in the left ventricle and aorta using the analytical solutions of nonstationary hydrodynamics equations and morphometric study] Kiknadze GI, et al. **Dokl Akad Nauk** 1996 Nov;351(1):119-22 **(Rus)**

PHYSIOPATHOLOGY

Diabetes-induced changes in the contractility of the aorta and pA2 of nifedipine in the rat. Mahmoudian M, et al. **Acta Diabetol** 1996 Jul;33(2):114-7
Vascular reactivity and effect of serum in a rat model of hypertriglyceridemia and hypertension. Baños G, et al. **Am J Hypertens** 1997 Apr;10(4 Pt 1):379-88
Derivation of the ascending aortic-carotid pressure transfer function with an arterial model. Karamanoglu M, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):H2399-404
Cardiac function in a rat model of chronic aortic stiffness. Lartaud-Idjouadiene I, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2211-8
Macromolecular transport in the arterial intima: comparison of chronic and acute injuries. Penn MS, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1560-70
Viscoelastic mechanisms of aortic baroreceptor resetting to hypotension and to hypertension. Xavier-Neto J, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1407-15
Hypoxia-reoxygenation impairs endothelium-dependent relaxation in isolated rat aorta. Yokoyama S, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R1126-31
Effect of surgical reconstruction on flow profiles in the aorta using magnetic resonance blood tagging. Fogel MA, et al. **Ann Thorac Surg** 1997 Jun;63(6):1691-700
Effects of hypovolemia on aortic baroreflex control of heart rate in humans. Convertino VA, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):838-43
Stenting of aortopulmonary collaterals in complex pulmonary atresia. Redington AN, et al. **Circulation** 1996 Nov 15; 94(10):2479-84
Aortic function in arterial hypertension determined by pressure-diameter relation: effects of diltiazem. Stefanadis C, et al. **Circulation** 1997 Sep 16;96(6):1853-8
Aortic root dilatation in patients with spontaneous cervical artery dissection. Tzourio C, et al. **Circulation** 1997 May 20;95(10):2351-3
Increased arterial stiffness in IDDM women--methodological considerations [letter] Länne T, et al. **Diabetologia** 1996 Jul;39(7):871-2
Increased aortic stiffness in women with NIDDM [letter; comment] Lehmann ED, et al. **Diabetologia** 1996 Jul; 39(7):870-1. Comment on: Diabetologia 1995 Sep;38(9):1082-9.
In vitro alteration of aortic vascular reactivity in hypertension induced by chronic NG-nitro-L-arginine methyl ester. Henrion D, et al. **Hypertension** 1996 Sep; 28(3):361-6
Calcification of medial elastic fibers and aortic elasticity. Niederhoffer N, et al. **Hypertension** 1997 Apr; 29(4):999-1006
Direct magnetic resonance determination of aortic distensibility in essential hypertension: relation to age, abdominal visceral fat, and in situ intracellular free magnesium. Resnick LM, et al. **Hypertension** 1997 Sep;30(3 Pt 2):654-9
Lisinopril reverses left ventricular hypertrophy through improved aortic compliance. Shimamoto H, et al. **Hypertension** 1996 Sep;28(3):457-63
Distinct mechanisms of modulation of angiotensin II type I receptor gene expression in heart and aorta. Wang DH, et al. **Hypertension** 1997 May;29(5):1104-8
Effects of menopause on aortic root function in hypertensive women. Karpanou EA, et al. **J Am Coll Cardiol** 1996 Nov 15;28(6):1562-6
Improved measurement of pressure gradients in aortic coarctation by magnetic resonance imaging. Oshinski JN, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1818-26
Severe pulmonary hypertension as a cause of reverse aortic arch flow in the neonate: report of two cases. Khongphatthanayothin A, et al. **J Am Soc Echocardiogr** 1996 Nov-Dec;9(6):915-7
Aortic flow velocity patterns in chronic aortic regurgitation: implications for Doppler echocardiography. Reimold SC, et al. **J Am Soc Echocardiogr** 1996 Sep-Oct;9(5):675-83
Systemic arterial compliance is decreased in newly-diagnosed patients with coronary heart disease: implications for prediction of risk. Cameron JD, et al. **J Cardiovasc Risk** 1996 Dec;3(6):495-500
Effect of ageing and hypertension on endothelial modulation of ouabain-induced contraction and sodium pump activity in the rat aorta. Ponte A, et al. **J Hypertens** 1996 Jun; 14(6):705-12
Factors related to aortic pulse-wave velocity in patients with non-insulin-dependent diabetes mellitus. Tanokuchi S, et al. **J Int Med Res** 1995 Nov-Dec;23(6):423-30
Effect of proximal arterial perfusion pressure on function, spinal cord blood flow, and histopathologic changes after increasing intervals of aortic occlusion in the rat [letter; comment] Schepens MA. **Stroke** 1997 Apr;28(4):878-9. Comment on: Stroke 1996 Oct;27(10):1850-8.
[Evaluation of the degree of atherosclerosis by pulse wave velocity (PWV)] Hasegawa M. **Nippon Rinsho** 1997 Mar; 55 Suppl 1:688-90 (8 ref.) **(Jpn)**
[Effect of heat shock on the endothelium-mediated reactions in the isolated rat aorta] Manukhina EB, et al. **Biull Eksp Biol Med** 1996 Aug;122(8):148-51 **(Rus)**

RADIOGRAPHY see AORTOGRAPHY

SURGERY

Aortic valve sparing in aortic root disease. Cochran RP, et al. **Adv Card Surg** 1996;8:81-107
Severe intraoperative coagulopathy following routine aortobi-iliac bypass with knitted Dacron graft. Naslund TC, et al. **Am Surg** 1997 May;63(5):386-9
Retrospective review of 100 cases of endoluminal aortic stent-graft surgery from an anaesthetic perspective. Baker AB, et al. **Anaesth Intensive Care** 1997 Aug;25(4):378-84
Leriche syndrome. Surgical procedures and early and late results. Sugimoto T, et al. **Angiology** 1997 Jul;48(7):637-42
Hypertrophic osteoarthropathy following aortic surgery. Dellestable F, et al. **Ann Rheum Dis** 1996 Dec;55(12):863-7
"Incisura" of the ascending aorta and vascular pedicle width in the cardiac transplant patient. Chiou AC, et al. **Ann Thorac Surg** 1996 Oct;62(4):1141-5
Effect of surgical reconstruction on flow profiles in the aorta using magnetic resonance blood tagging. Fogel MA, et al. **Ann Thorac Surg** 1997 Jun;63(6):1691-700
Shawl lapel aortoplasty. Harrison LH Jr, et al. **Ann Thorac Surg** 1996 Dec;62(6):1867
Composite aortic root replacement with direct coronary artery implantation. Hilgenberg AD, et al. **Ann Thorac Surg** 1996 Oct;62(4):1090-5
Transaortic approach in double-outlet right ventricle with subaortic ventricular septal defect. Sakamoto K, et al. **Ann Thorac Surg** 1997 Sep;64(3):856-8
Traumatic aortic transections: eight-year experience with the "clamp-sew" technique. Sweeney MS, et al. **Ann Thorac Surg** 1997 Aug;64(2):384-7; discussion 387-9
Repair of aortoesophageal fistula after aortic grafting. Wickstrom PH, et al. **Ann Thorac Surg** 1997 Jul;64(1):253-5
Experimental laparoscopic aortobifemoral bypass for occlusive aortoiliac disease. Dion YM, et al. **Can J Surg** 1996 Dec;39(6):451-5
Composite graft replacement of the aortic root in patients with Marfan's syndrome. Sekine S, et al. **Cardiovasc Surg** 1996 Oct;4(5):635-8
Transluminal extraction atherectomy for aortosaphenous vein graft stent restenosis. Patel JJ, et al. **Cathet Cardiovasc Diagn** 1996 Jul;38(3):320-4
Late stenosis of an aortorenal bypass graft fashioned from pericardium. Ilyas M, et al. **Clin Nephrol** 1996 Aug; 46(2):139-40
Aortic valve-sparing operations in patients with ascending aortic aneurysms. David TE. **Curr Opin Cardiol** 1997 Jul; 12(4):391-5 (29 ref.)
Alternative techniques for surgical management of recoarctation. Caspi J, et al. **Eur J Cardiothorac Surg** 1997 Jul;12(1):116-9
Aortic root replacement with human tissue valves in aortic valve endocarditis. Dossche K, et al. **Eur J Cardiothorac Surg** 1997 Jul;12(1):47-55
Aortic root replacement in type A dissection [letter] Moriyama Y, et al. **Eur J Cardiothorac Surg** 1997 Aug; 12(2):325-6
The role of aortic, iliac and femoropopliteal endarterectomy in vascular surgery today. Van Sterkenburg SM, et al. **Eur J Surg** 1995 Nov;161(11):783-9 (68 ref.)
Aortic stents [letter; comment] Adiseshiah M. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):423-4. Comment on: Eur J Vasc Endovasc Surg 1996 Oct;12(3):287-94.
The myth of the second prophylactic antibiotic dose in aortoiliac reconstructions. van Dijk-van Dam MS, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):428-30
Transesophageal echocardiographic detection of complications after Cabrol's procedure. Davis G, et al. **J Am Soc Echocardiogr** 1997 May;10(4):375-6
Renal protection by a dual ETA/ETB endothelin antagonist, L-754,142, after aortic cross-clamping in the dog. Krause SM, et al. **J Am Soc Nephrol** 1997 Jul;8(7):1061-71
Dilative characteristics of Microvel and Vasculour-II aortic bifurcation grafts. Nunn DB, et al. **J Biomed Mater Res** 1996 Jan;30(1):41-6
The proper use of glue: a 20-year experience with the GRF glue in acute aortic dissection. Bachet J, et al. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):243-53; discussion 253-5 (30 ref.)
Utilization of the aortic flap above the facing commissure in arterial switch operations. Chiu IS, et al. **J Card Surg** 1996 May-Jun;11(3):187-91
Experience with retrograde cerebral perfusion during proximal aortic surgery in 290 patients. Coselli JS, et al.

J Card Surg 1997 Mar–Apr;12(2 Suppl):322–5

Use of hypothermic circulatory arrest for cerebral protection during aortic surgery. Griepp RB, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):312–21 (9 ref.)

Bentall operation for a child with Marfan syndrome: a case report. Miura M, et al. **J Card Surg** 1997 Mar–Apr; 12(2):116–9 (14 ref.)

The management of bleeding following surgery requiring hypothermic circulatory arrest. Rooney SJ, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):238–42

Hemostasis for aortic surgery. Svensson LG. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):229–31 (17 ref.)

Intraoperative transesophageal echocardiographic diagnosis of prosthetic conduit compression after valved conduit replacement of the ascending aorta. Bruefach M 3rd, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):778–80

Apico–aortic shunt: a support technique during surgery on the descending thoracic aorta. Kuribayashi R, et al. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):271–6

Angioscopic evaluation of an endoluminal aortic graft: the first clinical experience. Hill BB, et al. **J Endovasc Surg** 1995 Aug;2(3):248–54

Endovascular repair of an ascending aorta–to–left common femoral artery graft with aneurysmal degeneration. Jaff MR, et al. **J Endovasc Surg** 1995 May;2(2):189–95

Surgery for aortic root aneurysm with aortic insufficiency [editorial; comment] David TE. **J Heart Valve Dis** 1996 May;5(3):238–9. Comment on: J Heart Valve Dis 1996 May;5(3):240–6. Comment on: J Heart Valve Dis 1996 May;5(3):247–50.

Echocardiographic monitoring of minimally invasive mitral valve surgery using an endoaortic clamp. Falk V, et al. **J Heart Valve Dis** 1996 Nov;5(6):630–7

Replacement of the ascending aorta with composite valve grafts: long term results [see comments] Lepore V, et al. **J Heart Valve Dis** 1996 May;5(3):240–6. Comment in: J Heart Valve Dis 1996 May;5(3):238–9.

Functional results after aortic valve repair in aortic root ectasia [see comments] Pethig K, et al. **J Heart Valve Dis** 1996 May;5(3):247–50. Comment in: J Heart Valve Dis 1996 May;5(3):238–9.

Magnetic resonance imaging evaluation of the ascending aorta after graft–inclusion surgery: comparison between an ultrafast contrast–enhanced MR sequence and conventional cine–MRI. Loubeyre P, et al. **J Magn Reson Imaging** 1996 May–Jun;6(3):478–83

A mediastinal window approach to aortopexy. Bullard KM, et al. **J Pediatr Surg** 1997 May;32(5):680–1

Lower extremity hypertrophic osteoarthropathy associated with aortic graft infection [letter; comment] al Dalaan A, et al. **J Rheumatol** 1995 Oct;22(10):2008. Comment on: J Rheumatol 1995 Jan;22(1):183–5.

Intraoperative autologous transfusion during elective infrarenal aortic reconstruction. Huber TS, et al. **J Surg Res** 1997 Jan;67(1):14–20

Aortic root endoscopy in valve–sparing operations. Itoh T, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):141–2

Extended aortic replacement for acute type A dissection with the tear in the descending aorta. Kazui T, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):973–8

Repair of interrupted aortic arch: a ten–year experience. Serraf A, et al. **J Thorac Cardiovasc Surg** 1996 Nov; 112(5):1150–60

Stented elephant trunk procedure for an extensive aneurysm involving distal aortic arch and descending aorta. Suto Y, et al. **J Thorac Cardiovasc Surg** 1996 Nov;112(5):1389–90

Alternative approach for management of infected aortic grafts. Darling RC 3rd, et al. **J Vasc Surg** 1997 Jan; 25(1):106–12

Endothelium on the flow surface of human aortic Dacron vascular grafts. Shi Q, et al. **J Vasc Surg** 1997 Apr; 25(4):736–42

Tissue ablation and gas formation of two excimer laser systems: an in vitro evaluation on porcine aorta. Appelman YE, et al. **Lasers Surg Med** 1996;18(2):197–205

Comparative study of Nd:YAG laser angioplasty at 1.06 microns, 1.32 microns, and 1.44 microns wavelengths: decreased vascular spasm and early mortality with 1.44 microns laser ablation. Bauer J, et al. **Lasers Surg Med** 1996;19(3):299–310

Treatment of multiple cerebral emboli from an ulcerated, thrombogenic ascending aorta with aortectomy and graft replacement. Belden JR, et al. **Neurology** 1997 Aug; 49(2):621–2

Management of complex left ventricular outflow tract obstruction with pulmonary autografts. Daenen WJ. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):358–61

Extensive replacement of the aorta from the ascending aorta to the supraceliac abdominal aorta during a one–stage operation. Murashita T, et al. **Surg Today** 1997;27(4):368–72

Ascending aorta to supraceliac abdominal aorta bypass for coarctation of the aorta in an adult. Yamamoto S, et al. **Surg Today** 1997;27(3):288–90

Transthoracic reconstruction of the great vessels using minimally invasive technique. Takach TJ, et al. **Tex Heart Inst J** 1996;23(4):284–8

Early and late results of ascending aorta surgery: risk factors for early and late outcome. Biglioli P, et al. **World J Surg** 1997 Jul–Aug;21(6):590–8

[Gene expression of bFGF and intimal hyperplasia of autologous vein grafts in rats] Qian H, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Nov;76(11):826–8 (Eng. Abstr.) **(Chi)**

[Smooth intramural and kink–resistant polyester vascular prosthesis] Rao T, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Nov;76(11):841–4 (Eng. Abstr.) **(Chi)**

[Microsurgical sutures with non–transfixing staples. An experimental study of 15 rat aortas] Rampillon F, et al. **Ann Chir Plast Esthet** 1996 Aug;41(4):376–80; discussion 381–3 (Eng. Abstr.) **(Fre)**

[Forensic medical implications of vascular injuries and accidents related to the practice of conventional vascular surgery] Natali J. **J Mal Vasc** 1996 Nov;21(4):216–9 (Eng. Abstr.) **(Fre)**

[Surgery of the ascending aorta: the 1984–1995 experience of the cardiac surgery teaching unit in the University of Milan. Multivariate analysis of its risk factors for hospital mortality and reduced long–term survival] Spirito R, et al. **G Ital Cardiol** 1997 Aug;27(8):775–85 (Eng. Abstr.) **(Ita)**

[Surgery for acute type A aortic dissection associated with Marfan syndrome] Furukawa K, et al. **Kyobu Geka** 1996 Jul;49(7):548–51 (Eng. Abstr.) **(Jpn)**

[A case report of coronary artery bypass grafting (CABG) and graft replacement of the ascending aorta for coronary artery disease associated with dissection of the ascending aorta] Hanada T, et al. **Kyobu Geka** 1997 Jul;50(7):557–9 (Eng. Abstr.) **(Jpn)**

[Replacement of the aortic root with woven and knitted Dacron composite graft] Mashiko K, et al. **Kyobu Geka** 1997 Jul;50(7):540–3 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of T4 lung cancer: combined resection of lung and heart or great vessels] Yamato Y, et al. **Kyobu Geka** 1997 Feb;50(2):114–9 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of aorto–iliac occlusive disease] Okadome K, et al. **Nippon Geka Gakkai Zasshi** 1996 Jul;97(7):545–50 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical study of re–do surgery after Bentall–type operation] Ando M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):606–13 (Eng. Abstr.) **(Jpn)**

[Successful aortic root replacement with pulmonary autograft (Ross) in two cases of congenital aortic stenosis] Morita K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr; 45(4):594–600 (Eng. Abstr.) **(Jpn)**

[Extended aortoplasty for supravalvular aortic stenosis with Williams syndrome] Nagasaka S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):601–6 (Eng. Abstr.) **(Jpn)**

[David's operation for aortic regurgitation associated with annulo–aortic ectasia] Taketani S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):635–8 (Eng. Abstr.) **(Jpn)**

[An anterior longitudinal aortotomy with a distal aortic transection for the arterial switch operation] Sakamoto K, et al. **Rinsho Kyobu Geka** 1989 Oct;9(5):459–62 (Eng. Abstr.) **(Jpn)**

[Assisted circulation to the right ventricle through pulmonary counterpulsation using a biological method] Lacoste MO, et al. **Arq Bras Cardiol** 1995 Nov;65(5):409–12 (Eng. Abstr.) **(Por)**

[Initial experience with the surgical treatment of hypertrophic cardiopathy using an apico–aortic valved conduit] Poliakov VP, et al. **Vestn Khir Im I I Grek** 1996; (1):17–20 (Eng. Abstr.) **(Rus)**

[Retrograde cerebral perfusion during circulatory arrest with deep hypothermia. A new technique for brain protection in surgery of ascending aorta and aortic arch] Zalaquett R, et al. **Rev Med Chil** 1995 Dec;123(12):1489–98 (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts. Akyürek LM, et al. **Am J Pathol** 1996 Dec; 149(6):1981–90

Extracardiac right atrium–to–right ventricle homograft for uncorrectable tricuspid valve disease. Al–Halees Z, et al. **Ann Thorac Surg** 1997 Jun;63(6):1794–6

LVOT pseudoaneurysm: a late complication of extended aortic root replacement. Jaggers J, et al. **Ann Thorac Surg** 1996 Oct;62(4):1198–9

Homograft as a conduit for superior vena cava syndrome. Ohri SK, et al. **Ann Thorac Surg** 1997 Aug;64(2):531–3

Simultaneous aortorenal homograft transplantation: expanding the indications for renal and vascular replacement [letter; comment] Jamieson CW. **Br J Surg** 1996 Dec;83(12):1797. Comment on: Br J Surg 1996 Jul;83(7):918.

Homograft replacement of thoraco–abdominal aorta for a leaking mycotic aneurysm. Pagano D, et al. **Eur J Cardiothorac Surg** 1996;10(5):383–5

Repair of anomalous connection of the left coronary artery to the pulmonary artery using native aortic and pulmonary tissue flaps. van Son JA, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):322–4

Growth factors and myointimal hyperplasia in experimental aortic allografts. Randone B, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):66–71

Clinical and echocardiographical study of the aortic homograft implantations in patients with Marfan syndrome. Podolec P, et al. **Int J Cardiol** 1997 Jun 27;60(1):41–7

Ketanserin reduces graft arteriosclerosis after allogeneic aorta transplantation in rats. Geerling RA, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):307–11

Infected abdominal aortic aneurysm: in situ replacement with cryopreserved arterial homograft. Alonso M, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):371–5

Evaluation of cryopreserved homografts in the right ventricular outflow tract after the Ross procedure: intermediate–term follow up. Ward KE, et al. **J Heart Valve Dis** 1997 Mar;6(2):130–3

A new experimental model for simultaneous evaluation of aortic and pulmonary allograft performance in a composite graft. Shimokawa S, et al. **J Invest Surg** 1996 Nov–Dec; 9(6):487–93

In situ repair of aortobronchial, aortoesophageal, and aortoenteric fistulae with cryopreserved aortic homografts. Vogt PR, et al. **J Vasc Surg** 1997 Jul;26(1):11–7

Blockade of growth factor synthesis and growth factor action: two possible sites of interference in allograft vessel disease and coronary bypass or balloon injury. Häyry P, et al. **Metabolism** 1996 Aug;45(8 Suppl 1):101–3

Correlation between the intensity of cytomegalovirus infection and the amount of perivasculitis in aortic allografts. Li FL, et al. **Transpl Int** 1996;9 Suppl 1:S340–4

Genes upregulated in ischemia–induced arteriosclerosis in rat aortic transplants. Chen J, et al. **Transplant Proc** 1997 Sep; 29(6):2559–60

Ischemia induced upregulation of growth factor expression in experimental transplant arteriosclerosis. Fellström B, et al. **Transplant Proc** 1997 Sep;29(6):2558

The role of alloantigen–independent factors in transplant arteriosclerosis. Kouwenhoven EA, et al. **Transplant Proc** 1997 May;29(3):1721–2

Effect of cyclosporine and some derivatives on chronic rejection. Lu X, et al. **Transplant Proc** 1996 Dec; 28(6):3152–3

Effect of locally and systemically administered angiopeptin on growth factor expression in syngeneic deendothelialized heterotopic aorta grafts in the rat. Motomura N, et al. **Transplant Proc** 1997 Sep;29(6):2563–4

Progression of changes in arteries following cold storage preservation in UW and Collins solution in a syngeneic aortic transplant model. Neil DA, et al. **Transplant Proc** 1997 Sep;29(6):2561–2

ULTRASONOGRAPHY

Intravascular ultrasound assessment of regional aortic wall stiffness, distensibility, and compliance in patients with coarctation of the aorta. Xu J, et al. **Am Heart J** 1997 Jul;134(1):93–8

Torn ascending aorta missed by transesophageal echocardiography. Lick SD, et al. **Ann Thorac Surg** 1997 Jun;63(6):1768–70

Continuous oesophageal aortic blood flow echo–Doppler measurement during general anaesthesia in infants. Gueugniaud PY, et al. **Can J Anaesth** 1997 Jul;44(7):745–50

Importance of pressure recovery for the assessment of aortic stenosis by Doppler ultrasound. Role of aortic size, aortic valve area, and direction of the stenotic jet in vitro. Niederberger J, et al. **Circulation** 1996 Oct 15;94(8):1934–40

Effects of age on aortic blood velocity at rest and during exercise in patients with coronary artery disease. Salmasi AM, et al. **Clin Auton Res** 1996 Apr;6(2):99–106

Left atrial myxoma presenting with embolism to the aorta. Ponduri K, et al. **J Am Soc Echocardiogr** 1997 May; 10(4):381–3

Systolic and diastolic mitral regurgitation in a patient with annulo–aortic ectasia demonstrated by color Doppler flow imaging. Oki T, et al. **J Heart Valve Dis** 1996 May; 5(3):254–7

Cardiac tamponade during transesophageal echocardiography in the patient of circumferential aortic dissection. Kim CM, et al. **J Korean Med Sci** 1997 Jun; 12(3):266–8

Transthoracic and transesophageal echocardiographic evaluation of the aortic root and subvalvular structures in ankylosing spondylitis. Arnason JA, et al. **J Rheumatol** 1996 Jan;23(1):120–3

Measurement of aortic diameter [letter; comment] Anderson RH. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):146. Comment on: J Thorac Cardiovasc Surg 1996 Oct;112(4):954–61.

Feasibility of aortic diameter measurement by multiplane transesophageal echocardiography for preoperative selection and preparation of homograft aortic valves [see comments] Weinert L, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):954–61. Comment in: J Thorac Cardiovasc Surg 1997 Jul;114(1):146.

Doppler velocimetry of the aortic isthmus in human fetuses with abnormal velocity waveforms in the umbilical artery. Sonesson SE, et al. **Ultrasound Obstet Gynecol** 1997 Aug; 10(2):107–11

[Aortic inner surface morphology in aortic disease by three–dimensional transesophageal echocardiography] Matsumura M, et al. **J Cardiol** 1996 Mar;27(3):143–51 (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Aortic endothelial cell changes in the acute septicemic phase of experimental Trypanosoma cruzi infection in rats: scanning and transmission electron microscopic study. Rossi MA. **Am J Trop Med Hyg** 1997 Sep;57(3):321–7

Morphology of capillary–like structures in a three–dimensional aorta/collagen gel culture. Akita M, et

al. **Anat Anz** 1997 Apr;179(2):127–36
Formation of new capillary–like tubes in a three–dimensional in vitro model (aorta/collagen gel). Akita M, et al. **Anat Anz** 1997 Apr;179(2):137–47
Homocysteine induced arteriosclerosis–like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Matthias D, et al. **Atherosclerosis** 1996 May;122(2):201–16
Porcine aortic endothelial gap junctions: identification and permeation by caged InsP3. Carter TD, et al. **J Cell Sci** 1996 Jul;109 (Pt 7):1765–73

AORTA, ABDOMINAL

Effect of balloon–expandable and self–expanding stent fixation on endoluminal polytetrafluoroethylene graft healing. Ombrellaro MP, et al. **Am J Surg** 1997 Jun; 173(6):461–6
Combined acute aortic thrombosis and metastatic spinal cord compression causing paraplegia in a patient with small–cell lung carcinoma (SCLC) [letter] Mermershtain W, et al. **Ann Oncol** 1996 Mar;7(3):321–2
The effect of endovascular aortic stents placed across the renal arteries. Malina M, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):207–13
The effect of placing an aortic Wallstent across the renal artery origins in an animal model. Whitbread T, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):154–8
Aortic stents covering the renal arteries ostia: an animal study. Desgranges P, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):77–82
Percutaneous transluminal stent placement in the abdominal aorta. Sheeran SR, et al. **J Vasc Interv Radiol** 1997 Jan–Feb; 8(1 Pt 1):55–60
Ruptured aneurysms of the thoracoabdominal aorta: a case series. Rampoldi V, et al. **Panminerva Med** 1995 Sep; 37(3):123–8
Improved performances of the isolated rat liver when washed out via the aorta. Ben Abdennebi H, et al. **Transplant Proc** 1996 Oct;28(5):2917–9

ABNORMALITIES

Ileocolic artery arising directly from the aorta [letter; comment] Docktor B, et al. **J Vasc Interv Radiol** 1996 Jan–Feb;7(1):150–1. Comment on: J Vasc Interv Radiol 1995 May–Jun;6(3):493–5.

ANATOMY & HISTOLOGY

Wall strength and stiffness of aneurysmal and nonaneurysmal abdominal aorta. Vorp DA, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:274–6
Left subpancreatic transplexus exposure of the proximal abdominal aorta. Di Marino V, et al. **Surg Radiol Anat** 1996;18(3):167–72
[Ultrafast contrast–enhanced 3D MR angiography of the aorta and renal arteries in apnea] Hany TF, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 May;166(5):397–405 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Variability in the proliferative responsiveness of cultured human vascular smooth muscle cells to alpha–thrombin. Kanthou C, et al. **Blood Coagul Fibrinolysis** 1995 Dec; 6(8):753–60
Differential response of mesoderm– and neural crest–derived smooth muscle to TGF–beta1: regulation of c–myb and alpha1 (I) procollagen genes. Gadson PF Jr, et al. **Exp Cell Res** 1997 Feb 1;230(2):169–80
Segmental aortic differences in vascular responses during pregnancy. Bobadilla RA, et al. **Proc West Pharmacol Soc** 1996;39:37–8
Acceleration of arteriosclerosis of the rat aorta allograft by insulin growth factor–I. Motomura N, et al. **Transplantation** 1997 Apr 15;63(7):932–6

EMBRYOLOGY

Aortic vessel wall characteristics and blood pressure in children with intrauterine growth retardation and abnormal foetal aortic blood flow. Ley D, et al. **Acta Paediatr** 1997 Mar;86(3):299–305
Intraobserver variability of pulsatility index measurements in three fetal vessels in the first trimester. Alcázar JL. **J Clin Ultrasound** 1997 Sep;25(7):366–71
Hemodynamic alteration by fetal surgery accelerates myocyte proliferation in fetal guinea pig hearts. Saiki Y, et al. **Surgery** 1997 Aug;122(2):412–9

ENZYMOLOGY

Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Morales–Ruiz M, et al. **Hepatology** 1996 Dec;24(6):1481–6

GROWTH & DEVELOPMENT

Growth potential of aortic autografts and allografts: effects of cryopreservation and immunosuppression in an experimental model. Kreitmann B, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):943–52

INJURIES

Chronic post–traumatic pseudoaneurysm of the abdominal aorta diagnosed by duplex Doppler ultrasonography. A case report. González Llorente J, et al. **Acta Radiol** 1997 Jan;38(1):121–3 (12 ref.)
The ongoing challenge of retroperitoneal vascular injuries. Coimbra R, et al. **Am J Surg** 1996 Nov;172(5):541–4; discussion 545
Healing characteristics of intraarterial stent grafts in an injured artery model. Weatherford DA, et al. **Ann Vasc Surg** 1997 Jan;11(1):54–61
Penetrating trauma to the abdominal vessels. Khoury G, et al. **Cardiovasc Surg** 1996 Jun;4(3):405–7
Greenfield filter caval perforation causing an aortic mural thrombus and femoral artery occlusion. Chintalapudi UB, et al. **Cathet Cardiovasc Diagn** 1997 May;41(1):53–5
Phenotypic modification of arterial smooth muscle cells in response to medial dissection. Dufourcq P, et al. **Coron Artery Dis** 1997 Mar–Apr;8(3–4):163–70
Hyperextension injury causing abdominal aortic rupture. Almeida AA, et al. **Eur J Vasc Endovasc Surg** 1997 Feb; 13(2):247–8
Gunshot injuries of the abdominal aorta: a continuing challenge. Degiannis E, et al. **Injury** 1997 Apr;28(3):195–7
Rare traumatic aorto–iliac dissection injury in a child with pelvic fracture and urethral rupture: a case report. Namasivayam S, et al. **J Pediatr Surg** 1997 Apr; 32(4):638–40
Blunt abdominal aortic transection in a child: case report. Fox JT, et al. **J Trauma** 1996 Dec;41(6):1051–3
Red River anthology. Mattox KL. **J Trauma** 1997 Mar; 42(3):353–68 (44 ref.)
Blunt injury of the abdominal aorta: a review. Roth SM, et al. **J Trauma** 1997 Apr;42(4):748–55 (63 ref.)
Localisation of endothelin–1 in rat aortae, the relationship to flow and elastic tissue tears. Jones GT, et al. **J Vasc Res** 1996 Sep–Oct;33(5):425–31
Traumatic abdominal aortic pseudoaneurysm causing biliary obstruction: a case report and review of the literature. Chase CW, et al. **J Vasc Surg** 1997 May;25(5):936–40 (21 ref.)
Blunt disruption of the abdominal aorta: report of a case and review of the literature. Naude GP, et al. **J Vasc Surg** 1997 May;25(5):931–5 (21 ref.)
Upper abdominal aortic injury during spinal surgery. Smythe WR, et al. **J Vasc Surg** 1997 Apr;25(4):774–7
Vascular complications in lumbar disk surgery: report of four cases. Szolar DH, et al. **Neuroradiology** 1996 Aug; 38(6):521–5
Low–dose hypertonic saline (NaCl 8.0%) treatment of uncontrolled abdominal hemorrhage: effects on arterial versus venous injury. Elgjo GI, et al. **Shock** 1996 Jan; 5(1):52–8
Vascular complications in minimally invasive surgery. Fruhwirth J, et al. **Surg Laparosc Endosc** 1997 Jun; 7(3):251–4
Operative strategies for management of abdominal aortic gunshot wounds. Richardson JD, et al. **Surgery** 1996 Oct; 120(4):667–71
Vascular injury during lumbar disc surgery. Report of two cases; a review of the literature. Sağdiç K, et al. **Vasa** 1996; 25(4):378–81 (21 ref.)
[Internal hemorrhage in abdominal dermolipectomy. 2 reported cases, one of which needing emergency surgical repair of aortic fissure] Fogli A, et al. **Ann Chir Plast Esthet** 1996 Aug;41(4):385–8 (Eng. Abstr.) **(Fre)**
[Blunt abdominal trauma with lesion of the abdominal aorta--a case report] Leiser A, et al. **Swiss Surg** 1997; 3(4):181–4 (Eng. Abstr.) **(Ger)**
[Gunshot injury of the aorta] Guch OO, et al. **Klin Khir** 1996; (5):53–4 **(Ukr)**

METABOLISM

Different cholesterol deposition in aorta of Dahl salt–sensitive rats and spontaneously hypertensive rats fed a high–cholesterol diet. Yamaguchi Y, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S249–50
Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo. De Garavilla L, et al. **Eur J Pharmacol** 1996 Oct 10;313(1–2):89–96
Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Wagner JD, et al. **Metabolism** 1997 Jun; 46(6):698–705
Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Tamarina NA, et al. **Surgery** 1997 Aug;122(2):264–71; discussion 271–2
[Effect of erythropoietin on protein permeability of rats abdominal aortic wall] Timoshenko TE, et al. **Biull Eksp Biol Med** 1997 Jun;123(6):614–6 **(Rus)**

PARASITOLOGY

Arteriosclerosis in dialysis patients. Bommer J, et al. **Int J Artif Organs** 1996 Nov;19(11):638–44
Ultrasonographic identification of Dirofilaria immitis in the aorta and liver of a dog. Goggin JM, et al. **J Am Vet Med Assoc** 1997 Jun 1;210(11):1635–7

PATHOLOGY

Aortocaval fistula: diagnosis with MR angiography. Schott EE 3rd, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):59–61
New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25–year follow–up study. Kauppila LI, et al. **Atherosclerosis** 1997 Jul 25;132(2):245–50
Development of an avian model for restenosis. Lucas A, et al. **Atherosclerosis** 1996 Jan 5;119(1):17–41
Histological response to stent graft therapy. Eton D, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II182–7
Infrarenal aortic dimensions in siblings of patients with infrarenal abdominal aortic aneurysm or aortoiliac occlusive disease. Jaakkola P, et al. **Eur J Surg** 1995 Dec; 161(12):871–5
Are self–expanding stents superior to balloon–expanded in dilating aortas? An experimental study in pigs [see comments] Mangell P, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):287–94. Comment in: Eur J Vasc Endovasc Surg 1997 Apr;13(4):423–4.
Assessing atherosclerotic plaque morphology: comparison of optical coherence tomography and high frequency intravascular ultrasound. Brezinski ME, et al. **Heart** 1997 May;77(5):397–403
Arteriomegaly and inflammatory abdominal aortic aneurysm. Case report. Cavallini M, et al. **J Cardiovasc Surg (Torino)** 1997 Feb;38(1):37–41
Immediate postgadolinium spoiled gradient–echo MRI for evaluating the abdominal aorta in the setting of abdominal MR examination. Kelekis NL, et al. **J Magn Reson Imaging** 1997 Jul–Aug;7(4):652–6
Contrast–enhanced, K–space–centered, breath–hold MR angiography of the renal arteries and the abdominal aorta. Steffens JC, et al. **J Magn Reson Imaging** 1997 Jul–Aug; 7(4):617–22
Gadolinium–enhanced breath–hold three–dimensional time–of–flight MR angiography of the abdominal and pelvic vessels: the value of ultrafast MP–RAGE sequences. Yamashita Y, et al. **J Magn Reson Imaging** 1997 Jul–Aug; 7(4):623–8
MR microscopy of the arterial wall in an experimental model of atherosclerosis: preliminary results. Ford JC, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):93–9
Aortic corset syndrome. Hagino RT, et al. **J Vasc Surg** 1997 Jul;26(1):138–41
Nonporous silicone polymer coating of expanded polytetrafluoroethylene grafts reduces graft neointimal hyperplasia in dog and baboon models. Lumsden AB, et al. **J Vasc Surg** 1996 Nov;24(5):825–33
Beneficial effect of proteases on allograft arteriosclerosis in a rat aortic model. Gaciong Z, et al. **Nephrol Dial Transplant** 1996 Jun;11(6):987–9
Gadolinium–enhanced ultrafast three–dimensional spoiled gradient–echo MR imaging of the abdominal aorta and visceral and iliac vessels [published erratum appears in Radiographics 1997 May–Jun;17(3):804] Gilfeather M, et al. **Radiographics** 1997 Mar–Apr;17(2):423–32
Gadolinium–enhanced three–dimensional MR angiography of the thoracoabdominal aorta. Krinsky G, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):280–303 (19 ref.)
Disc degeneration/back pain and calcification of the abdominal aorta. A 25–year follow–up study in Framingham. Kauppila LI, et al. **Spine** 1997 Jul 15; 22(14):1642–7; discussion 1648–9
Protease therapy alleviates allograft arteriosclerosis in rats. Gaciong Z, et al. **Transplant Proc** 1996 Dec;28(6):3439–40
[Results of a contrast–medium supported 3D MR–angiography in respiratory arrest following optimization of contrast medium bolus] Kopka L, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Apr;166(4):290–5 (Eng. Abstr.) **(Ger)**
[Diameter decrement of abdominal aorta and redistribution of systemic blood flow in non–ambulant Duchenne muscular dystrophy patients] Shinoe T, et al. **Rinsho Shinkeigaku** 1996 Oct;36(10):1172–4 (Eng. Abstr.) **(Jpn)**
[Malignant paraganglioma with aortic infiltration cured by radical surgery (letter)] Tinahones FJ, et al. **An Med Interna** 1996 Jun;13(6):303 **(Spa)**

PHYSIOLOGY

Luminal diameter and vasa vasorum response to stent dilation in the rabbit aorta. Sahler LG, et al. **Acad Radiol** 1996 Jul;3(7):545–9
Effects of desflurane on systemic, preportal and renal circulatory responses to infra–renal aortic cross–clamping in the pig. Sundeman H, et al. **Acta Anaesthesiol Scand** 1996 Sep;40(8 Pt 1):876–82
Aortic vessel wall characteristics and blood pressure in children with intrauterine growth retardation and abnormal foetal aortic blood flow. Ley D, et al. **Acta Paediatr** 1997 Mar;86(3):299–305
Arterial expansive remodeling induced by high flow rates. Ben Driss A, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H851–8
Noninvasive determination of pulse–wave velocity in mice. Hartley CJ, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H494–500
Regional differentiation in the rat aorta: effects of cyclooxygenase inhibitors. Schachter D, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1478–83

Regional differentiation in the rat aorta for a novel signaling pathway: leucine to glutamate. Schachter D, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1484–92

In vivo/in vitro comparison of rat abdominal aorta wall viscosity. Influence of endothelial function. Boutouyrie P, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1346–55

Confirmation and initial documentation of thoracic and abdominal aortic helical flow. An ultrasound study. Frazin LJ, et al. **ASAIO J** 1996 Nov–Dec;42(6):951–6

In vivo wall shear stress measured by magnetic resonance velocity mapping in the normal human abdominal aorta. Oyre S, et al. **Eur J Vasc Endovasc Surg** 1997 Mar; 13(3):263–71

Static elastic wall properties of the abdominal porcine aorta in vitro and in vivo. Storkholm JH, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):31–6

Possible involvement of endothelium–derived hyperpolarizing factor in vascular responses of abdominal aorta from pregnant rats. Bobadilla RA, et al. **Hypertension** 1997 Sep;30(3 Pt 2):596–602

Computer simulation of convective diffusion processes in large arteries. Rappitsch G, et al. **J Biomech** 1996 Feb; 29(2):207–15

Wall shear rate distribution in an abdominal aortic bifurcation model: effects of vessel compliance and phase angle between pressure and flow waveforms. Lee CS, et al. **J Biomech Eng** 1997 Aug;119(3):333–42

Arterial input functions from MR phase imaging. Akbudak E, et al. **Magn Reson Med** 1996 Dec;36(6):809–15

Computation of vascular flow dynamics from intravascular ultrasound images. Chandran KB, et al. **Med Eng Phys** 1996 Jun;18(4):295–304

Immediate postnatal rat heart development modified by abdominal aortic banding: analysis of gene expression. Engelmann GL, et al. **Mol Cell Biochem** 1996 Oct–Nov; 163–164:47–56

PHYSIOPATHOLOGY

Low cardiac output abolishes cardiovascular responses to infra–renal aortic cross–clamping in the pig. Seeman–Lodding H, et al. **Acta Anaesthesiol Scand** 1997 Feb;41(2):232–8

Influence of aortic impedance on the development of pressure–overload left ventricular hypertrophy in rats. Kobayashi S, et al. **Circulation** 1996 Dec 15;94(12):3362–8

Thrombosis of the abdominal aorta secondary to Brucella spondylitis. Sanchez–Gonzalez J, et al. **Infection** 1996 May–Jun;24(3):261–2

Altered cardiac mechanism and sarcoplasmic reticulum function in pressure overload–induced cardiac hypertrophy in rats. Ohkusa T, et al. **J Mol Cell Cardiol** 1997 Jan; 29(1):45–54

Steady flow in models of abdominal aortic aneurysms. Part I: Investigation of the velocity patterns. Peattie RA, et al. **J Ultrasound Med** 1996 Oct;15(10):679–88

Steady flow in models of abdominal aortic aneurysms. Part II: Wall stresses and their implication for in vivo thrombosis and rupture. Peattie RA, et al. **J Ultrasound Med** 1996 Oct; 15(10):689–96

Combined exposure to cigarette smoke and hypercholesterolemia decreases vasorelaxation of the aorta. Mudaliar JH, et al. **J Vasc Surg** 1997 May;25(5):884–9

[Combined cardiac surgery and aneurysm of subrenal abdominal aorta] Saccani S, et al. **Acta Biomed Ateneo Parmense** 1995;66(5):209–15 (Eng. Abstr.) **(Ita)**

RADIATION EFFECTS

Determining light dose for photodynamic therapy of atherosclerotic lesions in the Yucatan miniswine. Hsiang YN, et al. **J Endovasc Surg** 1995 Nov;2(4):365–71

RADIOGRAPHY

Enhancement of hepatic parenchyma, aorta, and portal vein in helical CT: comparison of iodixanol and iopromide. Graf O, et al. **AJR Am J Roentgenol** 1997 Jan;168(1):213–7

CT angiography versus intraarterial digital subtraction angiography for assessment of aortoiliac occlusive disease. Rieker O, et al. **AJR Am J Roentgenol** 1997 Oct; 169(4):1133–8

Images in cardiovascular medicine. Takayusu's arteritis involving the abdominal aorta and renal arteries. Reddy SC, et al. **Circulation** 1997 Jan 21;95(2):529

The efficacy of transfemoral endovascular aneurysm management: a study on size changes of the abdominal aorta during mid–term follow–up. Broeders IA, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):84–90

Simultaneous manifestation of an aortocaval and aortoduodenal fistula. Bengisun U, et al. **Vasa** 1996; 25(1):81–3

[Chronic non–aneurysmal rupture of the infrarenal aorta. Report of a case] Cazaban–Mazerolles D, et al. **J Mal Vasc** 1997;22(1):40–2 (Eng. Abstr.) **(Fre)**

[Amyloidosis of a coral reef infrarenal aorta] Combe J, et al. **J Mal Vasc** 1997;22(1):43–7 (Eng. Abstr.) **(Fre)**

[Evaluation of normal thoracic and abdominal aortic diameters through computerized tomography] Lucarelli CL, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Nov–Dec;51(6):239–46 (Eng. Abstr.) **(Por)**

SURGERY

Does epidural sufentanil provide effective analgesia per– and postoperatively for abdominal aortic surgery? Broekema AA, et al. **Acta Anaesthesiol Scand** 1996 Jan;40(1):20–5

Anesthesia and surgery influences regional net release and uptake rates of tissue–type plasminogen activator. An experimental study in the intact pig. Seeman–Lodding H, et al. **Acta Anaesthesiol Scand Suppl** 1997;110:151–3

Superoxide dismutase (SOD) prevents hypotension after hemorrhagic shock and aortic cross clamping. Simon HM, et al. **Am J Med Sci** 1996 Oct;312(4):155–9

Hepatic resection with vascular isolation and routine supraceliac aortic clamping [letter] Leow CK, et al. **Am J Surg** 1997 Feb;173(2):149

Lumbar muscle rhabdomyolysis after abdominal aortic surgery. Bertrand M, et al. **Anesth Analg** 1997 Jul; 85(1):11–5

The impact of prostanoids on pulmonary gas exchange during abdominal surgery with mesenteric traction. Brinkmann A, et al. **Anesth Analg** 1997 Aug;85(2):274–80

Effects of a hemoglobin–based oxygen carrier (HBOC–201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Kasper SM, et al. **Anesth Analg** 1996 Nov;83(5):921–7

Management of abdominal aortic prosthetic graft infection requiring emergent treatment. Mingoli A, et al. **Angiology** 1997 Jun;48(6):491–5

Specificity of cardiac markers troponin I and T in excluding postoperative myocardial infarction. Ben Ayed S, et al. **Ann Clin Biochem** 1997 Sep;34 (Pt 5):559–60

Laparoscopic aortofemoral bypass in an animal model [letter; comment] Byrne J, et al. **Ann Surg** 1997 Jan;225(1):133, 135. Comment on: Ann Surg 1995 Nov;222(5):677–83.

Current status of the use of retroperitoneal approach for reconstructions of the aorta and its branches. Darling C 3rd, et al. **Ann Surg** 1996 Oct;224(4):501–6; discussion 506–8

Transperitoneal and retroperitoneal laparoscopic implantation of an aortofemoral prosthesis [letter; comment] Said S. **Ann Surg** 1997 Jan;225(1):134–5. Comment on: Ann Surg 1995 Nov;222(5):677–83.

Laparoscopic aortofemoral bypass surgery performed in an animal model [letter; comment] Weber G. **Ann Surg** 1997 Jan;225(1):133–4, discussion 135. Comment on: Ann Surg 1995 Nov;222(5):677–83.

Gerota's fascia flap: an alternative for aortic graft coverage. LaMuraglia GM, et al. **Ann Vasc Surg** 1996 Jul;10(4):405–8

Accelerated endothelialization model for the study of Dacron graft healing. Onuki Y, et al. **Ann Vasc Surg** 1997 Mar; 11(2):141–8

Aortic transgraft hemorrhage after systemic thrombolytic therapy. Pope M, et al. **Ann Vasc Surg** 1997 May; 11(3):292–4

Aortoiliac bypass in a renal transplant patient using a new technique [letter; comment] Schneider JR. **Ann Vasc Surg** 1996 May;10(3):324. Comment on: Ann Vasc Surg 1995 Jul;9(4):385–9.

Deployment and healing of an ePTFE encapsulated stent endograft in the canine aorta. Wilson EP, et al. **Ann Vasc Surg** 1997 Jul;11(4):354–8

Late disruption of Dacron aortic grafts. Wilson SE, et al. **Ann Vasc Surg** 1997 Jul;11(4):383–6 (19 ref.)

ACE inhibitors and renal protection [letter; comment] Colson P. **Br J Anaesth** 1997 Apr;78(4):477–8. Comment on: Br J Anaesth 1996 May;76(5):632–9.

Lack of specific renal haemodynamic effects of different doses of dopamine after infrarenal aortic surgery [see comments] Girbes AR, et al. **Br J Anaesth** 1996 Dec; 77(6):753–7. Comment in: Br J Anaesth 1997 Apr;78(4):350–1.

Conservative management of chylous ascites complicating aortic surgery: a case report. Petrasek AJ, et al. **Can J Surg** 1996 Dec;39(6):499–501

In situ arterial allografting for aortoiliac graft infection: a 6–year experience. Koskas F, et al. **Cardiovasc Surg** 1996 Aug;4(4):495–9

The Perth endoluminal bifurcated graft system—development and early experience. Lawrence–Brown MM, et al. **Cardiovasc Surg** 1996 Dec; 4(6):706–12

Comparison of transperitoneal and retroperitoneal approaches for infrarenal aortic surgery: early and late results. Sieunarine K, et al. **Cardiovasc Surg** 1997 Feb; 5(1):71–6

Sigmoid pH after aortoiliac surgery [letter; comment] Björck M, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):253–4 . Comment on: Eur J Vasc Endovasc Surg 1996 Apr;11(3):304–7.

Renal arteries covered by aortic stents: clinical experience from endovascular grafting of aortic aneurysms. Malina M, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):109–13

Growth factors and myointimal hyperplasia in experimental aortic allografts. Randone B, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):66–71

Bacterial and clinical criteria relating to the outcome of patients undergoing in situ replacement of infected abdominal aortic grafts. Speziale F, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):127–33

Replacement of the abdominal aorta in a young patient with neurofibromatosis and massive retroperitoneal haemorrhage. Wigger P, et al. **Eur J Vasc Endovasc Surg** 1997 Mar;13(3):337–9

Types of renal arteries in aspect of the reconstruction operation of the abdominal aorta. Kuczmik W, et al. **Folia Morphol (Warsz)** 1996;55(4):367–8

The role of profunda femoris revascularization in aortofemoral surgery. An analysis of factors affecting graft patency. Bastounis E, et al. **Int Angiol** 1997 Jun; 16(2):107–13

Inflammatory response to aorto–bifemoral graft surgery. Pärsson HN, et al. **Int Angiol** 1997 Mar;16(1):55–64

Abnormal glomerular response to atrial natriuretic peptide in rats with aortocaval fistulas. Norling LL, et al. **J Am Soc Nephrol** 1996 Jul;7(7):1038–44

Effects of anesthetic technique on myocardial wall motion abnormalities during abdominal aortic surgery [see comments] Dodds TM, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):129–36. Comment in: J Cardiothorac Vasc Anesth 1997 Apr;11(2):127–8.

Influence of prostaglandin E1 on tissue ischemia during surgical repair of the abdominal aorta. Gabriel A, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):201–6

Evaluation of the effects of mivacurium chloride on hemodynamics and left ventricular function in patients with coronary artery disease undergoing abdominal aortic surgery. Goossens S, et al. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):62–6

Prolonged oxygen debt after abdominal aortic surgery. Hess W, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):149–54

The epidural space: is it the place to be during vascular surgery? [editorial; comment] Kahn RA, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):127–8. Comment on: J Cardiothorac Vasc Anesth 1997 Apr;11(2):129–36. Comment on: J Cardiothorac Vasc Anesth 1997 Apr;11(2):137–40.

Blunt abdominal aortic transection in a child: case report. Fox JT, et al. **J Trauma** 1996 Dec;41(6):1051–3

Treatment of a failed bifurcated abdominal aortic stent graft with thrombolysis and Wallstent placement. Amesur NB, et al. **J Vasc Interv Radiol** 1997 Sep–Oct;8(5):795–8

Stent–graft repair of aorto–iliac occlusive disease coexisting with common femoral artery disease. Cynamon J, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):19–26

Prosthetic graft infection: diagnostic and therapeutic role of interventional radiology. Rossi P, et al. **J Vasc Interv Radiol** 1997 Mar–Apr;8(2):271–7

Laparoscopic aortobifemoral bypass. Ahn SS, et al. **J Vasc Surg** 1997 Jul;26(1):128–32

Autogenous aortoiliac/femoral reconstruction from superficial femoral–popliteal veins: feasibility and durability. Clagett GP, et al. **J Vasc Surg** 1997 Feb; 25(2):255–66; discussion 267–70

Supraceliac aortorenal bypass. Hagino RT, et al. **J Vasc Surg** 1997 Sep;26(3):482–9; discussion 490–1

Fate of the proximal aortic cuff: implications for endovascular aneurysm repair. Illig KA, et al. **J Vasc Surg** 1997 Sep;26(3):492–9; discussion 499–501

Simultaneous abdominal aortic replacement and thoracic stent–graft placement for multilevel aortic disease. Moon MR, et al. **J Vasc Surg** 1997 Feb;25(2):332–40

Staple occlusion of the infrarenal aorta: a videoscopic retroperitoneal approach. Murayama KM, et al. **J Vasc Surg** 1997 Apr;25(4):786–90

Technical complications of endovascular abdominal aortic aneurysm repair. Naslund TC, et al. **J Vasc Surg** 1997 Sep; 26(3):502–9; discussion 509–10

Endovascular aortounifemoral grafts and femorofemoral bypass for bilateral limb–threatening ischemia. Ohki T, et al. **J Vasc Surg** 1996 Dec;24(6):984–96; discussion 996–7

Abdominal aortic tailoring for renal, visceral, and lower extremity malperfusion resulting from acute aortic dissection. Webb TH, et al. **J Vasc Surg** 1997 Sep; 26(3):474–80; discussion 480–1

Laser assisted vascular welding with real time temperature control. Stewart RB, et al. **Lasers Surg Med** 1996;19(1):9–16

Suggested approach for end to side anastomosis to the abdominal aorta in aorto–femoral bypass grafting for aorto–iliac occlusive disease. Nazem N, et al. **Panminerva Med** 1996 Sep;38(3):199–200

Endovascular aortic stent–grafts: transcatheter embolization of persistent perigraft leaks. Golzarian J, et al. **Radiology** 1997 Mar;202(3):731–4

Ascending aorta to supraceliac abdominal aorta bypass for coarctation of the aorta in an adult. Yamamoto S, et al. **Surg Today** 1997;27(3):288–90

Aortoiliofemoral bypass graft in young adults: long–term results in a series of sixty–eight patients. Mingoli A, et al. **Surgery** 1997 Jun;121(6):646–53

Operative strategies for management of abdominal aortic gunshot wounds. Richardson JD, et al. **Surgery** 1996 Oct; 120(4):667–71

Hemodynamic alteration by fetal surgery accelerates myocyte proliferation in fetal guinea pig hearts. Saiki Y, et al. **Surgery** 1997 Aug;122(2):412–9

Embolization of a complete prosthetic aortic valve to the abdominal aorta. Long–term survival after surgery. Villani M, et al. **Tex Heart Inst J** 1996;23(3):236–7

[Marginal indications for revascularization in the aortoiliac region] Malý I, et al. **Rozhl Chir** 1997 Apr;76(4):181–2 (Eng. Abstr.) **(Cze)**

[Quantification of kidney cortex perfusion with thermodiffusion during experimental infrarenal aortic clamping] Kraus T, et al.

Langenbecks Arch Chir Suppl Kongressbd 1997;114:21–4 (Eng. Abstr.) **(Ger)**
[Video endoscopic vascular surgery at the pelvic level in the animal experiment: introduction of a new surgical method and development of laparoscopic vascular surgery instruments] Said S, et al.
Langenbecks Arch Chir Suppl Kongressbd 1996;113:882–4 (Eng. Abstr.) **(Ger)**
[Minimally invasive and direct approach for aorto-iliac reconstruction] Weber G, et al.
Langenbecks Arch Chir Suppl Kongressbd 1996;113:885–8 (Eng. Abstr.) **(Ger)**
[Bipolar radiofrequency energy in arteries—the experimental results with a new catheter system] Simon C, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997 Mar;166(3):248–53 (Eng. Abstr.) **(Ger)**
[Combined cardiac surgery and aneurysm of subrenal abdominal aorta] Saccani S, et al.
Acta Biomed Ateneo Parmense 1995;66(5):209–15 (Eng. Abstr.) **(Ita)**
[Surgery of the descending thoracic and thoraco-abdominal arteries. Report of 105 cases] Zanetti PP, et al.
G Ital Cardiol 1997 Jul;27(7):682–5 (Eng. Abstr.) **(Ita)**
[Bifurcated prosthesis in infrarenal aortic position in stenosing lesions. Functional results] Illuminati G, et al.
Minerva Chir 1997 Jun;52(6):789–94 (Eng. Abstr.) **(Ita)**
[Prevention and treatment of early and late postoperative complications of prosthetic surgery of the arterial aorto-iliac area] Tridico F, et al. **Minerva Chir** 1996 Sep; 51(9):675–80 (Eng. Abstr.) **(Ita)**
[A successful case of infrarenal abdominal aortic replacement against acute abdominal organ failures and ischemia of bilateral lower limbs following the operation of DeBakey IIIb-type dissecting aneurysm] Gu K, et al.
Kyobu Geka 1996 Dec;49(13):1100–3 (Eng. Abstr.) **(Jpn)**
[Repeated reconstructive operations in late complications of the aorto-iliofemoral segment surgery] Arekelian VS, et al. **Khirurgiia (Mosk)** 1996;(2):99–103 (Eng. Abstr.) **(Rus)**
[Successful x-ray endovascular prosthesis in abdominal aortic aneurysm] Nemytin IuV, et al. **Voen Med Zh** 1997 Jan; 318(1):62–4 **(Rus)**
[Dacron and polytetrafluoroethylene aorto-bifemoral grafts] Davidović LB, et al. **Srp Arh Celok Lek** 1997 Mar–Apr; 125(3–4):75–83 (Eng. Abstr.) **(Scc)**
[Report of a case. Late enteral graft erosion is a rare condition] Buntzen S, et al. **Lakartidningen** 1996 Oct 2; 93(40):3457–9 **(Swe)**

TRANSPLANTATION

Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection. Chow LH, et al. **Circulation** 1996 Dec 15; 94(12):3079–82
Growth potential of aortic autografts and allografts: effects of cryopreservation and immunosuppression in an experimental model. Kreitmann B, et al.
Eur J Cardiothorac Surg 1997 May;11(5):943–52
Adenovirus-mediated in vivo gene transfer in a rabbit model of allograft vasculopathy. Mehra MR, et al.
J Heart Lung Transplant 1996 Jan;15(1 Pt 1):51–7
Simultaneous aortic bifurcation graft and kidney transplantation from the same multi-organ donor: a new therapeutic tool in complex renal transplantation. Talbot-Wright R, et al. **J Urol** 1996 Dec;156(6):2000–1
Beneficial effect of proteases on allograft arteriosclerosis in a rat aortic model. Gaciong Z, et al.
Nephrol Dial Transplant 1996 Jun;11(6):987–9
Protease therapy alleviates allograft arteriosclerosis in rats. Gaciong Z, et al. **Transplant Proc** 1996 Dec;28(6):3439–40
Local administration of estrogen inhibits transplant arteriosclerosis in rat aorta accelerated by topical exposure to IGF-I. Motomura N, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):1118–20
Cell and extracellular matrix rejection in arterial concordant and discordant xenografts in the rat. Allaire E, et al.
Transplantation 1996 Sep 27;62(6):794–803
Presensitization accelerates allograft arteriosclerosis. Kolb F, et al. **Transplantation** 1996 Nov 27;62(10):1401–10

ULTRASONOGRAPHY

Infoson in vascular and renal sonography. Jakobsen JA, et al. **Acad Radiol** 1996 Aug;3 Suppl 2:S322–4
Chronic post-traumatic pseudoaneurysm of the abdominal aorta diagnosed by duplex Doppler ultrasonography. A case report. González Llorente J, et al. **Acta Radiol** 1997 Jan;38(1):121–3 (12 ref.)
The use of ultrasonic tomography to measure the calibers of the iliac arteries and veins and the caliber and length of the inferior vena cava and the abdominal aorta. Macchi C, et al. **Ital J Anat Embryol** 1994 Jul–Sep;99(3):181–6
Intraobserver variability of pulsatility index measurements in three fetal vessels in the first trimester. Alcázar JL.
J Clin Ultrasound 1997 Sep;25(7):366–71
Changes in diameter of the abdominal aorta with age: an epidemiological study. Grimshaw GM, et al.
J Clin Ultrasound 1997 Jan;25(1):7–13
Intravenous intravascular ultrasound for arterial visualization: a feasibility study [see comments] Kriegel AV, et al. **J Endovasc Surg** 1996 Nov;3(4):429–34. Comment in: J Endovasc Surg 1996 Nov;3(4):435.
Quality of the measurement of the infrarenal aortic diameter by ultrasound. Wilmink AB, et al. **J Med Screen** 1997; 4(1):49–53
Feasibility of transgastric ultrasonography of the abdominal aorta. Keen RR, et al. **J Vasc Surg** 1996 Nov;24(5):834–42
Computation of vascular flow dynamics from intravascular ultrasound images. Chandran KB, et al. **Med Eng Phys** 1996 Jun;18(4):295–304
Some considerations on the measurements of mean frequency shift and integrated backscatter following administration of Albunex. Wang SH, et al. **Ultrasound Med Biol** 1996; 22(4):441–51

AORTA, ASCENDING see **AORTA**

AORTA, DESCENDING see **AORTA, THORACIC**

AORTA, THORACIC

Selective aortic arch perfusion during cardiac arrest: enhanced resuscitation using oxygenated perflubron emulsion, with and without aortic arch epinephrine. Manning JE, et al. **Ann Emerg Med** 1997 May;29(5):580–7
Atheromatous disease of the thoracic aorta: pathologic and clinical implications. Kronzon I, et al. **Ann Intern Med** 1997 Apr 15;126(8):629–37 (41 ref.)
Images in cardiovascular medicine. Mycotic aneurysm of the descending thoracic aorta. Oxorn D, et al. **Circulation** 1997 Apr 1;95(7):1972–3
Dissociation of left ventricular hypertrophy, beta-myosin heavy chain gene expression, and myosin isoform switch in rats after ascending aortic stenosis. Wiesner RJ, et al. **Circulation** 1997 Mar 4;95(5):1253–9
Failure of left heart bypass to prevent acute left ventricular failure associated with proximal thoracic aortic cross-clamping. Gordon G, et al.
J Cardiothorac Vasc Anesth 1997 Feb;11(1):80–2
Endovascular stenting of an aortopulmonary fistula presenting with hemoptysis. A case report. Campagna AC, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):643–6
Aortic function. Boudoulas H, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S258–63 (26 ref.)
Effect of nitroglycerin and cerebrospinal fluid drainage on spinal cord perfusion pressure and paraplegia during aortic cross-clamping. Marini CP, et al. **J Surg Res** 1997 Jun; 70(1):61–5
Thoracic aortic rupture during vigorous exercise. Tinkoff GH, et al. **J Trauma** 1997 Jan;42(1):137–40
Ruptured aneurysms of the thoracoabdominal aorta: a case series. Rampoldi V, et al. **Panminerva Med** 1995 Sep; 37(3):123–8
Vascular events during follow-up in patients with aortic arch atherosclerosis. Mitusch R, et al. **Stroke** 1997 Jan;28(1):36–9
An updated report of a case of lung cancer resected using cardiopulmonary bypass. Horita K, et al.
Thorac Cardiovasc Surg 1997 Apr;45(2):100–1
[Penetrating atheromatous ulcer of the thoracic aorta. Apropos of a case] Habis M, et al.
Arch Mal Coeur Vaiss 1996 Jul;89(7):907–11 (Eng. Abstr.) **(Fre)**
[The aortic arch as the source of a peripheral arterial embolism] Rühlmann C, et al. **Dtsch Med Wochenschr** 1997 Mar 7;122(10):287–92 (Eng. Abstr.) **(Ger)**
[The aortic arch as an embolism source for cerebral infarcts] Kaps M, et al. **Fortschr Neurol Psychiatr** 1996 Sep; 64(9):367–74 (Eng. Abstr.) **(Ger)**
[Management of aortoesophageal fistula due to thoracic aortic aneurysm] Sakurai T, et al. **Kyobu Geka** 1996 Sep; 49(10):815–20 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Atypical coarctation. Repair with Dacron graft and aortic sarcoma] Caralps Riera JM, et al. **Rev Esp Cardiol** 1996 Sep;49(9):693–6 (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Interruption of aortic arch type A in two siblings. Nakada T, et al. **Acta Paediatr Jpn** 1996 Feb;38(1):63–5
The spectrum of extrinsic lower airway compression in children: MR imaging. Donnelly LF, et al.
AJR Am J Roentgenol 1997 Jan;168(1):59–62
Deletions in chromosome 22q11 region in cervical aortic arch. Kumar A, et al. **Am J Cardiol** 1997 Feb 1;79(3):388–90
A genetic etiology for interruption of the aortic arch type B. Lewin MB, et al. **Am J Cardiol** 1997 Aug 15;80(4):493–7
Cervical aortic arch with aneurysm formation. Pearson GD, et al. **Am J Cardiol** 1997 Jan 1;79(1):112–4
Operative mortality and frequency of coexistent anomalies in interruption of the aortic arch. Powell CB, et al.
Am J Cardiol 1997 Apr 15;79(8):1147–8
Cervical aortic arch. A case report. Açikel U, et al.
Angiology 1997 Jul;48(7):659–62
Diagnosis and management of left main stem bronchus compression. Goldman SA, et al.
Ann Otol Rhinol Laryngol 1997 Jun;106(6):461–5
Ross-Konno procedure with interrupted aortic arch repair in a premature neonate. Hirooka K, et al.
Ann Thorac Surg 1997 Jul;64(1):249–51
Isolated right subclavian artery, interrupted aortic arch, and ventricular septal defect. Mulay AV, et al.
Ann Thorac Surg 1997 Apr;63(4):1163–5
Radiological case of the month. Double aortic arch. Saslow JG, et al. **Arch Pediatr Adolesc Med** 1997 Mar;151(3):313–4
Dissection of retroesophageal aortic diverticulum and descending aorta in a patient with right aortic arch: magnetic resonance demonstration. Ko SF, et al.
Cardiovasc Intervent Radiol 1996 Nov-Dec;19(6):438–41
Case report: MR angiography of cervical aortic arch. Kumar S, et al. **Clin Radiol** 1997 Sep;52(9):717–9
Bicuspid aortic valve and associated aortic wall abnormalities [editorial] Braverman AC. **Curr Opin Cardiol** 1996 Sep; 11(5):501–3 (15 ref.)
Aneurysm of aberrant right subclavian [correction of subdavian] artery arising from diverticulum of Kommerell. Report of a case with tracheal compression. Aoyagi S, et al. **Eur J Cardiothorac Surg** 1997 Jul;12(1):138–40
Left main bronchus compression after aortic reconstruction for interruption of aortic arch. Sakai T, et al.
Eur J Cardiothorac Surg 1995;9(11):667–9
An alternative method for repair of aortico-left ventricular tunnel associated with severe aortic stenosis presenting in a newborn. Weldner P, et al. **Eur J Cardiothorac Surg** 1996; 10(5):380–2
Intramural posttraumatic hematoma of the ascending aorta in a patient with a double aortic arch. Fattori R, et al.
Eur Radiol 1997;7(1):51–3
Aortic arch interruption in association with Ebstein's anomaly of tricuspid valve and rheumatic mitral stenosis [see comments] Shah P, et al. **Indian Heart J** 1996 Jul–Aug; 48(4):398–400. Comment in: Indian Heart J 1996 Nov-Dec;48(6):735–6.
Vascular compression of the airway: indications for and results of surgical management. Erwin EA, et al.
Int J Pediatr Otorhinolaryngol 1997 Jun 20;40(2–3):155–62
Marked arteriosclerosis of the descending aorta in a teenager with interruption of the aorta. Kawai S, et al.
Intern Med 1996 May;35(5):383–7
Morphology of the ventricular septal defect in two types of interrupted aortic arch. Chin AJ, et al.
J Am Soc Echocardiogr 1996 Mar–Apr;9(2):199–201
Tortuosity of the descending thoracic aorta simulating dissection on transesophageal echocardiography. Katz ES, et al. **J Am Soc Echocardiogr** 1997 Jan–Feb;10(1):83–7
Primary repair of interrupted aortic arch and associated heart lesions in newborns. Tláskal T, et al.
J Cardiovasc Surg (Torino) 1997 Apr;38(2):113–8
Extensive facial strawberry mark associated with cerebellar hypoplasia and vascular abnormalities. Matsui T, et al.
J Dermatol 1997 Feb;24(2):113–6
Right aortic arch with mirror-image branching and coarctation of the aorta. Liang CD, et al.
J Formos Med Assoc 1997 Aug;96(8):657–9
A rare case of the right-sided aortic arch that has the right subclavian artery as the last branch. Tanaka H, et al.
Kurume Med J 1997;44(2):147–52
Variation of the right subclavian artery as the last branch of the aortic arch in two Japanese cadavers. Komiyama M, et al. **Okajimas Folia Anat Jpn** 1995 Dec;72(5):245–7
Congenital pulmonary steal phenomenon associated with tetralogy of Fallot, right aortic arch, and isolation of the left subclavian artery. Carano N, et al. **Pediatr Cardiol** 1997 Jan–Feb;18(1):57–60
Total one-stage repair of aortopulmonary window and interrupted aortic arch in a neonate. Davies MJ, et al.
Pediatr Cardiol 1996 Mar–Apr;17(2):122–4 (12 ref.)
Persistent left fifth aortic arch associated with tetralogy of Fallot. Donti A, et al. **Pediatr Cardiol** 1997 May–Jun; 18(3):229–31
Aortic arch complex anomalies: 20-year experience with symptoms, diagnosis, associated cardiac defects, and surgical repair. Kocis KC, et al. **Pediatr Cardiol** 1997 Mar–Apr;18(2):127–32
Percutaneous balloon aortoplasty for restenosis after extended aortic arch anastomosis for type B interrupted aortic arch. Sato S, et al. **Pediatr Cardiol** 1996 Jul–Aug; 17(4):275–7
Diagnostic dilemma: left aortic arch with right descending aorta—a rare vascular ring. Singh GK, et al.
Pediatr Cardiol 1997 Jan–Feb;18(1):45–8
Tracheoesophageal compression due to congenital vascular anomalies (vascular rings). Valletta EA, et al.
Pediatr Pulmonol 1997 Aug;24(2):93–105 (82 ref.)
Spiral CT angiography in an infant with severe hypoplasia of a long segment of the descending aorta. Brochhagen HG, et al. **Pediatr Radiol** 1997 Feb;27(2):181–3
Index of suspicion. Case 1. Diagnosis: vascular ring. Nuber SM. **Pediatr Rev** 1997 May;18(5):175–6
"Lumps" and "bumps" that mimic acute aortic and brachiocephalic vessel injury. Fisher RG, et al.
Radiographics 1997 Jul–Aug;17(4):825–34
Vascular rings in symptomatic children: frequency of chest radiographic findings. Pickhardt PJ, et al. **Radiology** 1997 May;203(2):423–6
Isolation of the left subclavian artery in tetralogy of Fallot and bronchial anomalies. Kalis NN, et al. **S Afr Med J** 1997 Feb;87 Suppl 1:C25–8
Bilateral persistent trigeminal arteries associated with cerebral aneurysms and aortic arch vessel anomaly. Alleyne CH Jr, et al. **South Med J** 1997 Apr;90(4):434–8 (49 ref.)
Transcatheter embolization of a pulmonary collateral vessel in a child with tricuspid atresia: case report. Karaaslan S, et al. **Turk J Pediatr** 1996 Jan–Mar;38(1):107–11
[Aortic-ventricular tunnel with right coronary artery atresia] Rauzier JM, et al. **Arch Mal Coeur Vaiss** 1997 May; 90(5):725–7 (Eng. Abstr.) **(Fre)**
[Fatal double tracheo-esophageal vascular compression and

neurofibromatosis] Fischberg C, et al. **Arch Pediatr** 1996 Dec;3(12):1253–7 (Eng. Abstr.) **(Fre)**

[A surgical case of vascular ring (Edwards IIIB) with dysphagia evaluated by esophageal scintigraphy] Hosono M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun; 45(6):909–12 (Eng. Abstr.) **(Jpn)**

[A successful surgical case of a dissecting aortic aneurysm with right-sided aortic arch and right-sided descending aorta] Osako M, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Aug;44(8):1145–50 (Eng. Abstr.) **(Jpn)**

[Repair of D-transposition of the great arteries associated with double aortic arch] Suetsugu F, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Jun;45(6):894–9 (Eng. Abstr.) **(Jpn)**

[Vascular ring associated with severe ventricular septal defect—report of a case with simultaneously surgical treatment] Kou T, et al. **Rinsho Kyobu Geka** 1989 Aug; 9(4):392–5 (Eng. Abstr.) **(Jpn)**

[Atresia of the fourth aortic arch] Ajiki H, et al.
Ryoïkibetsu Shokogun Shirizu 1996;(13):276–9 (21 ref.) **(Jpn)**

[Congenital anomalies of the aortic arch] Ikeda T, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):199–202 (11 ref.) **(Jpn)**

[Persistent fifth aortic arch] Ikeda T, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):232–5 (26 ref.) **(Jpn)**

[Double aortic arch] Ito T, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):133–5 (8 ref.) **(Jpn)**

[Vascular ring] Kato I, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):75–7 (13 ref.) **(Jpn)**

[Right-sided aortic arch (right aortic arch)] Matsui Y, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):55–8 (10 ref.) **(Jpn)**

[Interrupted aortic arch] Nomoto S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):273–5 (15 ref.) **(Jpn)**

[Aortic arch obstruction] Ohtani S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(13):239–41 (19 ref.) **(Jpn)**

[Anomalies of aortic arch arteries as a cause of dyspnea and dysphagia in adults] Holomáň M, et al.
Bratisl Lek Listy 1997 May;98(5):269–73 **(Slo)**

[Aortico-left ventricular tunnel associated with pulmonary valve stenosis] Martín Jiménez J, et al. **Rev Esp Cardiol** 1996 Dec;49(12):921–4 (9 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Alteration of ascending thoracic aorta compliance after treatment with menotropin. Chelsky R, et al.
Am J Obstet Gynecol 1997 Jun;176(6):1255–9; discussion 1260–1

In vitro and finite-element model investigation of the conductance technique for measurement of aortic segmental volume. Hettrick DA, et al. **Ann Biomed Eng** 1996 Nov-Dec;24(6):675–84

Morphologic features of the normal aortic arch in neonates, infants, and children pertinent to growth. Machii M, et al. **Ann Thorac Surg** 1997 Aug;64(2):511–5

Microanatomy of the vasa vasorum of the human thoracic aorta: a study utilizing a polyester resin casting technique. Tsikaras DP, et al. **Bull Assoc Anat (Nancy)** 1997 Mar; 81(252):21–2

Comparison of different methods for the determination of the true wave propagation coefficient, in rubber tubes and the canine thoracic aorta. Bertram CD, et al.
Med Eng Phys 1997 Apr;19(3):212–22

Identification and physiological relevance of an exponentially tapered tube model of canine descending aortic circulation. Fogliardi R, et al. **Med Eng Phys** 1997 Apr;19(3):201–11

Determination of the mean cross-sectional area of the thoracic aorta using a double indicator dilution technique. Kornet L, et al. **Pflugers Arch** 1996 Oct;432(6):1069–73

Cadaveric vascular anatomy for total en bloc spondylectomy in malignant vertebral tumors. Kawahara N, et al.
Spine 1996 Jun 15;21(12):1401–7

[Dimensions of the proximal thoracic aorta from childhood to adult age: reference values for two-dimensional echocardiography. Ligurian Group of SIEC (Italian Society of Echocardiography)] Cassottana P, et al.
G Ital Cardiol 1997 Jul;27(7):686–96 (43 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Couffinhal T, et al. **Am J Pathol** 1997 May; 150(5):1673–85

Cholesterol-dependent changes of glycosaminoglycan pattern in human aorta. Kruse R, et al.
Basic Res Cardiol 1996 Sep-Oct;91(5):344–52

The role of glycation cross-links in diabetic vascular stiffening. Sims TJ, et al. **Diabetologia** 1996 Aug; 39(8):946–51

The localization of tissue factor and apolipoprotein(a) in atherosclerotic lesions of the human aorta and their relation to fibrinogen-fibrin transition. Ichikawa K, et al.
Pathol Res Pract 1996 Mar;192(3):224–32

CYTOLOGY

Emergence and distribution of intimal smooth muscle cells in the postnatal rat aorta. Kobayashi N, et al.
Cell Tissue Res 1997 Sep;289(3):487–97

Human aortic endothelial cell aminopeptidase N. Papapetropoulos A, et al. **Immunopharmacology** 1996 May; 32(1–3):153–6

Local administration of estrogen inhibits transplant arteriosclerosis in rat aorta accelerated by topical exposure to IGF-I. Motomura N, et al. **Transplant Proc** 1997 Feb-Mar;29(1–2):1118–20

DRUG EFFECTS

Induction of nitric oxide synthase by endotoxin in rat isolated aorta but not in rat aortic smooth muscle cells grown in culture from explant. McKendrick JD, et al.
Arch Int Pharmacodyn Ther 1995 Sep-Oct;330(2):206–24

The effect of chronic treatment with NO donors during intimal thickening and fatty streak formation. De Meyer GR, et al. **Biofactors** 1997;6(2):209–15

Influence of OSW-1 [3 beta,16 beta,17 alpha-trihydroxycholest-5-en-22-one 16-O-(2-O-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1—> 3)-(2-O-acetyl-alpha-L-arabinopyranoside)], a steroidal saponin, on endothelium dependent relaxation caused by acetylcholine in rat aorta. Honda H, et al.
Biol Pharm Bull 1997 Apr;20(4):428–30

Role of endothelium in the modulation of isoflurane-induced vasodilatation in rat thoracic aorta. Kirstetter P, et al.
Br J Anaesth 1997 Jul;79(1):84–7

Functional effects of econazole on inducible nitric oxide synthase: production of a calmodulin-dependent enzyme. Bogle RG, et al. **Br J Pharmacol** 1996 Mar;117(6):1053–8

Effect of niflumic acid on noradrenaline-induced contractions of the rat aorta. Criddle DN, et al.
Br J Pharmacol 1996 Jun;118(4):1065–71

Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Kenny BA, et al. **Br J Pharmacol** 1996 Jun;118(4):871–8

Evidence for N-acetylcysteine-sensitive nitric oxide storage as dinitrosyl-iron complexes in lipopolysaccharide-treated rat aorta. Muller B, et al. **Br J Pharmacol** 1996 Nov; 119(6):1281–5

Activation of multiple sites by adenosine analogues in the rat isolated aorta. Prentice DJ, et al. **Br J Pharmacol** 1996 Jul;118(6):1509–17

Study of the mechanisms involved in adenosine-5'-O-(2-thiodiphosphate) induced relaxation of rat thoracic aorta and pancreatic vascular bed. Saïag B, et al. **Br J Pharmacol** 1996 Jun;118(3):804–10

Effect of angiotensin receptor blockade in the rabbit aorta: influence of the endothelium. le Tran Y, et al.
Can J Physiol Pharmacol 1996 Dec;74(12):1277–86

Twenty-four-hour variations in the sensitivity of rat aorta to vasoactive agents. Keskil Z, et al. **Chronobiol Int** 1996 Dec;13(6):465–75

Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Bjarnason NH, et al. **Circulation** 1997 Sep 16;96(6):1964–9

Unfavorable effect of smoking on the elastic properties of the human aorta. Stefanadis C, et al. **Circulation** 1997 Jan 7;95(1):31–8

Effects of dietary salt and angiotensin-converting enzyme inhibitor on ATP-driven Ca pump and Na/Ca exchange in aortic rings of Dahl rats. Ashida T, et al.
Clin Exp Hypertens 1996 Aug;18(6):851–71

Effects of 5HT2 receptor antagonists on responses to potassium depolarization in rat isolated aorta. Okoro EO, et al. **Clin Exp Pharmacol Physiol** 1997 Jan;24(1):34–9

Reversal of in vitro lipopolysaccharide-induced suppression of contraction in rat aorta by NG-nitro-arginine, diphenyleneiodonium and di-2-thienyliodonium. Palacios B, et al. **Eur J Pharmacol** 1996 Jan 18;296(1):75–9

Intracellular Ca2+ and contractile responses to alpha 1-adrenoceptor subtype activation in rat aortic vascular smooth muscle. Tognarini DP, et al. **Eur J Pharmacol** 1997 Mar 12;322(1):31–6

Effect of KMD-3213, an alpha 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Yamagishi R, et al. **Eur J Pharmacol** 1996 Nov 7;315(1):73–9

Differential response of mesoderm- and neural crest-derived smooth muscle to TGF-beta1: regulation of c-myb and alpha1 (I) procollagen genes. Gadson PF Jr, et al.
Exp Cell Res 1997 Feb 1;230(2):169–80

Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds. Arjona AA, et al. **Gen Pharmacol** 1997 Mar;28(3):387–92

Action of elgodipine on atherosclerosis development, cell growth, and oncogene expression in vascular smooth muscle cells. Del Rio M, et al. **Gen Pharmacol** 1997 Mar; 28(3):463–8

Interaction of calcium channel blockers with different agonists in aorta from normal and diseased rats. Bhugra P, et al. **Indian J Physiol Pharmacol** 1996 Apr;40(2):109–19

Effects of manipulation of dietary cholesterol on the function of the thoracic aorta from New Zealand white rabbits. Dowell FJ, et al. **J Cardiovasc Pharmacol** 1996 Feb; 27(2):235–9

Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. Pieper GM.
J Cardiovasc Pharmacol 1997 Jan;29(1):8–15

Vascular expression of inducible nitric oxide synthase is associated with activation of Ca(++)-dependent K+ channels. Taguchi H, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1514–9

Pharmacological evaluation of ocoteine, isolated from Cassytha filiformis, as an alpha 1-adrenoceptor antagonist in rat thoracic aorta. Chang CW, et al.
Jpn J Pharmacol 1997 Mar;73(3):207–14

Acetylcholine-induced relaxation of rat aorta is greatest during estrus in the sexual cycle. Honda H, et al.
Jpn J Pharmacol 1997 May;74(1):113–5

The vasorelaxant effects of amrinone on neonatal rabbit thoracic aortic strips. Hassan S, et al. **Kobe J Med Sci** 1996 Feb;42(1):73–91

Cyclic AMP and cyclic GMP relax phorbol ester-induced contractions of rat aorta by different mechanisms. Ahn HY, et al. **Life Sci** 1997;60(25):2333–40

Analysis of the action of idazoxan calls into question the reliability of the rat isolated small mesenteric artery assay as a predictor for alpha 1-adrenoceptor-mediated pressor activity. Van der Graaf PH, et al.
Naunyn Schmiedebergs Arch Pharmacol 1996 Aug-Sep; 354(3):389–92

Effect of divalent cations on the contractile response of rat aorta to depolarization before and after nifedipine treatment. Noguera MA, et al. **Pharmacology** 1996 Aug; 53(2):98–108

Segmental aortic differences in vascular responses during pregnancy. Bobadilla RA, et al.
Proc West Pharmacol Soc 1996;39:37–8

Alpha 1 adrenergic receptor activation of proto-oncogene expression in arterial smooth muscle: regulation by nitric oxide and vascular injury. Okazaki M, et al.
Recept Signal Transduct 1996;6(3–4):165–78

Decreased vascular sensitivity after acute exercise and chronic exercise training in rat thoracic aorta. Izawa T, et al. **Res Commun Mol Pathol Pharmacol** 1996 Sep; 93(3):331–42

Chronic treatment with cyclosporine A in New Zealand rabbit: aortic and erectile tissue alterations. Ragazzi E, et al. **Urol Res** 1996;24(6):323–8

[Effect of cyclosporin A dosage on the vascular tone of the thoracic aorta of rats] Cartier R, et al. **Ann Chir** 1996; 50(8):667–72 (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

Abnormal patterning of the aortic arch arteries does not evoke cardiac malformations. Kirby ML, et al.
Dev Dyn 1997 Jan;208(1):34–47

ENZYMOLOGY

Serum transcriptionally regulates Na(+)-K(+)-ATPase gene expression in vascular smooth muscle cells. Nemoto J, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C1088–99

An in vitro model of aneurysmal disease: effect of leukocyte infiltration and shear stress on MMP production within the arterial wall. Thompson MM, et al.
Ann N Y Acad Sci 1996 Nov 18;800:270–3

Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. Zaltsman AB, et al. **Atherosclerosis** 1997 Apr; 130(1–2):61–70

Endothelial nitric oxide synthase is downregulated during hyperdynamic sepsis. Zhou M, et al.
Biochim Biophys Acta 1997 Apr 17;1335(1–2):182–90

Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Morales-Ruiz M, et al.
Hepatology 1996 Dec;24(6):1481–6

Human aortic endothelial cell aminopeptidase N. Papapetropoulos A, et al. **Immunopharmacology** 1996 May; 32(1–3):153–6

Elevated vascular angiotensin converting enzyme mediates increased neointima formation after balloon injury in spontaneously hypertensive rats. Jandeleit-Dahm K, et al.
J Hypertens 1997 Jun;15(6):643–50

GROWTH & DEVELOPMENT

Postnatal regulation of fibroblast growth factor ligand and receptor gene expression in rat thoracic aorta. Winkles JA, et al. **Am J Pathol** 1996 Dec;149(6):2119–31

Arch growth after staged repair of interrupted aortic arch using carotid artery interposition. Hakimi M, et al.
Ann Thorac Surg 1997 Aug;64(2):503–7

Hypoplastic aortic arch morphology pertinent to growth after surgical correction of aortic coarctation. Machii M, et al. **Ann Thorac Surg** 1997 Aug;64(2):516–20

Cardiac neural crest is essential for the persistence rather than the formation of an arch artery. Waldo KL, et al.
Dev Dyn 1996 Mar;205(3):281–92

Developmental dynamics of endothelial and neurogenic control of canine thoracic aorta. Török J, et al.
Mech Ageing Dev 1997 Apr;95(1–2):143–52

Age-related alteration of cross-linking amino acids of elastin in human aorta. Watanabe M, et al.
Tohoku J Exp Med 1996 Oct;180(2):115–30

INJURIES

Traumatic rupture of the thoracic aorta: the diagnostic challenge. Casselman F, et al. **Acta Chir Belg** 1996 Nov-Dec;96(6):291-4 (13 ref.)

Traumatic type B aortic dissection. Goverde P, et al. **Acta Chir Belg** 1996 Sep-Oct;96(5):233-6

Transesophageal echocardiography in the evaluation of cardiothoracic trauma. Mollod M, et al. **Am Heart J** 1996 Oct;132(4):841-9

Ductus diverticulum interpreted as traumatic aortic injury. Ferrera PC, et al. **Am J Emerg Med** 1997 Jul;15(4):371-2

Cervical prevertebral soft-tissue measurements and chest radiographic findings in acute traumatic aortic injury. Plewa MC, et al. **Am J Emerg Med** 1997 May;15(3):256-9

Kommerell's diverticulum: a potential cause for false diagnosis of aortic disruption by transesophageal echocardiography. Swenson JD, et al. **Anesth Analg** 1997 Jan;84(1):220-2

Hyaluronan and hyaluronectin production in injured rat thoracic aorta. Chajara A, et al. **Atherosclerosis** 1996 Sep 6;125(2):193-207

Blunt injury to the supra-aortic arteries. Prêtre R, et al. **Br J Surg** 1997 May;84(5):603-9 (65 ref.)

Multiplane transesophageal echocardiography in traumatic aortic dissection: a case report. Liao WB, et al. **Chang Keng I Hsueh** 1995 Dec;18(4):383-6

Use of transesophageal echocardiography for diagnosis of traumatic aortic injury. Goarin JP, et al. **Chest** 1997 Jul; 112(1):71-80

Trauma to the aorta and major vessels. Feliciano DV. **Chest Surg Clin N Am** 1997 May;7(2):305-23 (68 ref.)

Successful surgery for perforation of the thoracic aorta caused by the tip of an intra-aortic balloon pump. Wolff T, et al. **Eur J Cardiothorac Surg** 1997 Jun;11(6):1176-9

Traumatic disruption of the thoracic aorta: a rational approach to imaging. Driscoll PA, et al. **Injury** 1996 Dec; 27(10):679-85 (43 ref.)

Laceration of the thoracic aorta from a .22 lr bullet. Karger B, et al. **Int J Legal Med** 1997;110(2):92-4

Rupture of thoracic aorta resulting from blunt trauma. Franchello A, et al. **Int Surg** 1997 Jan-Mar;82(1):79-84

The ductus diverticulum: false-positive angiographic diagnosis of traumatic aortic disruption. Oxorn D, et al. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):86-8

Elevated vascular angiotensin converting enzyme mediates increased neointima formation after balloon injury in spontaneously hypertensive rats. Jandeleit-Dahm K, et al. **J Hypertens** 1997 Jun;15(6):643-50

Disruption of the aortic arch convexity containing the innominate and left common carotid artery origins resulting from blunt trauma. Kalangos A, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):129-31

Angiography in blunt thoracic aortic injury. Ahrar K, et al. **J Trauma** 1997 Apr;42(4):665-9

Prospective study of blunt aortic injury: Multicenter Trial of the American Association for the Surgery of Trauma. Fabian TC, et al. **J Trauma** 1997 Mar;42(3):374-80; discussion 380-3

Lateral impact motor vehicle collisions: significant cause of blunt traumatic rupture of the thoracic aorta. Katyal D, et al. **J Trauma** 1997 May;42(5):769-72

Noncorrelation between thoracic skeletal injuries and acute traumatic aortic tear. Lee J, et al. **J Trauma** 1997 Sep; 43(3):400-4

Traumatic carotid artery dissection of restrained driver and thoracic aorta transection of unrestrained passenger in a motor vehicle accident: case report. Mason DP, et al. **J Trauma** 1997 Sep;43(3):537-40

Red River anthology. Mattox KL. **J Trauma** 1997 Mar; 42(3):353-68 (44 ref.)

Comparison of digital subtraction and cut film arteriography in the evaluation of suspected thoracic aortic injury. Johnson MS, et al. **J Vasc Interv Radiol** 1997 Sep-Oct; 8(5):799-807

Thoracic aortography in a motor vehicle accident victim [see comments] Redman HC. **J Vasc Interv Radiol** 1997 Mar-Apr;8(2):226-7. Comment in: J Vasc Interv Radiol 1997 Jul-Aug;8(4):720.

Overview of traumatic injury of the thoracic aorta. Creasy JD, et al. **Radiographics** 1997 Jan-Feb;17(1):27-45 (66 ref.)

"Lumps" and "bumps" that mimic acute aortic and brachiocephalic vessel injury. Fisher RG, et al. **Radiographics** 1997 Jul-Aug;17(4):825-34

Subtle or atypical injuries of the thoracic aorta and brachiocephalic vessels in blunt thoracic trauma. Fisher RG, et al. **Radiographics** 1997 Jul-Aug;17(4):835-49

Can helical CT replace aortography in blunt aortic trauma? [letter; comment] Bailey YD, et al. **Radiology** 1996 Nov; 201(2):579-80. Comment on: Radiology 1995 Oct;197(1):125-33.

[Effect of vitamin E on the endothelial function of the regenerated aorta in rats following direct arterial injury] Cartier R, et al. **Ann Chir** 1996;50(8):673-81 (36 ref.) (Eng. Abstr.) **(Fre)**

[Blunt thoracic trauma with aortic rupture and lung contusion caused by hoof kick in a 15-year-old girl. Diagnostic and therapeutic management] Brück E, et al. **Unfallchirurg** 1996 Nov;99(11):901-4 (Eng. Abstr.) **(Ger)**

[Diagnosis of traumatic aortic rupture. Transesophageal echocardiography versus computerized tomography] Ertel W, et al. **Unfallchirurg** 1997 Feb;100(2):168-9; discussion 169 **(Ger)**

[Results of surgical treatment of acute traumatic aortic rupture] Charpentier A, et al. **Zentralbl Chir** 1996; 121(9):744-9 (26 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of chronic traumatic aortic aneurysm] Fraedrich G, et al. **Zentralbl Chir** 1996;121(9):756-60 (Eng. Abstr.) **(Ger)**

[Delayed surgical therapy of acute aortic rupture] Kalmár P, et al. **Zentralbl Chir** 1996;121(9):750-5 (Eng. Abstr.) **(Ger)**

[Rupture of thoracic aorta due to blunt trauma: a report of three cases] Yuda A, et al. **Kyobu Geka** 1996 Oct; 49(11):883-7; discussion 887-91 (Eng. Abstr.) **(Jpn)**

[Prognostic factor and care of patients with traumatic rupture of thoracic aorta and respiratory insufficiency] Soma K, et al. **Masui** 1996 Dec;45 Suppl:S100-4 **(Jpn)**

[A case of total arch replacement for traumatic aortic arch rupture] Ikeda K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):878-81 (Eng. Abstr.) **(Jpn)**

[Traumatic thoracic aortic rupture--diagnosis and surgical repair] Kamata S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul;44(7):918-22 (Eng. Abstr.) **(Jpn)**

[Traumatic transection of the descending thoracic aorta with free open rupture in left pleural cavity--a case report] Kamohara K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):783-6 (Eng. Abstr.) **(Jpn)**

[Traumatic injuries of the thoracic aorta--report of five cases] Kanazawa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec; 44(12):2155-63 (Eng. Abstr.) **(Jpn)**

[Traumatic rupture of the thoracic aorta] Glock Y, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:100-6 (Eng. Abstr.) **(Spa)**

[Treatment with endoprosthesis of the pathology of the descending thoracic artery] Rousseau H, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:107-15 (50 ref.) (Eng. Abstr.) **(Spa)**

INNERVATION

Mechanical stimulation of neurites generates an inward current in putative aortic baroreceptor neurons in vitro. Cunningham JT, et al. **Brain Res** 1997 May 16; 757(1):149-54

Reflex vascular responses from aortic arch, carotid sinus and coronary baroreceptors in the anaesthetized dog. McMahon NC, et al. **Exp Physiol** 1996 May;81(3):397-408

METABOLISM

Comparison of K+ channel properties in freshly isolated myocytes from thoracic aorta of WKY and SHR. Cox RH. **Am J Hypertens** 1996 Sep;9(9):884-94

Postnatal regulation of fibroblast growth factor ligand and receptor gene expression in rat thoracic aorta. Winkles JA, et al. **Am J Pathol** 1996 Dec;149(6):2119-31

IGF-I regulation of Na(+)-K(+)-ATPase in rat arterial smooth muscle. Standley PR, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E113-21

Modified low density lipoprotein is a potent stimulus for smooth muscle cell outgrowth from rat aortic explant in vitro. Görög P. **Atherosclerosis** 1997 Feb 28;129(1):1-7

A novel aortic smooth muscle cell line obtained from p53 knock out mice expresses several differentiation characteristics. Ohmi K, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):154-8

Age-related change of mineral content in the human thoracic aorta and in the human cerebral artery. Tohno Y, et al. **Biol Trace Elem Res** 1996 Jul;54(1):23-31

Pharmacological characterization of the sulphonylurea receptor in rat isolated aorta. Löffler C, et al. **Br J Pharmacol** 1997 Feb;120(3):476-80

Sarcoplasmic reticulum Ca2+ uptake is not decreased in aorta from deoxycorticosterone acetate hypertensive rats: functional assessment with cyclopiazonic acid. Tostes RC, et al. **Can J Physiol Pharmacol** 1995 Nov;73(11):1536-45

Depression of endothelial nitric oxide synthase but increased expression of endothelin-1 immunoreactivity in rat thoracic aortic endothelium associated with long-term, but not short-term, sympathectomy. Aliev G, et al. **Circ Res** 1996 Aug;79(2):317-23

Comparison of aorta and pulmonary artery: I. Early cholesterol accumulation and relative susceptibility to atheromatous lesions. Schwenke DC. **Circ Res** 1997 Sep; 81(3):338-45

Comparison of aorta and pulmonary artery: II. LDL transport and metabolism correlate with susceptibility to atherosclerosis. Schwenke DC. **Circ Res** 1997 Sep; 81(3):346-54

Oxidation of plasma low-density lipoprotein accelerates its accumulation and degradation in the arterial wall in vivo. Juul K, et al. **Circulation** 1996 Oct 1;94(7):1698-704

Effects of dietary salt and angiotensin-converting enzyme inhibitor on ATP-driven Ca pump and Na/Ca exchange in aortic rings of Dahl rats. Ashida T, et al. **Clin Exp Hypertens** 1996 Aug;18(6):851-71

Arterial fatty lesions have increased uptake of chylomicron remnants but not low-density lipoproteins. Proctor SD, et al. **Coron Artery Dis** 1996 Mar;7(3):239-45

The effect of propofol and thiopentone on impairment by reactive oxygen species of endothelium-dependent relaxation in rat aortic rings. Kelicen P, et al. **Eur J Anaesthesiol** 1997 May;14(3):310-5

Pyrrolidine dithiocarbamate inhibits immunostimulant-induced tetrahydrobiopterin synthesis in rat vascular smooth muscle. Hattori Y, et al. **Eur J Pharmacol** 1996 Jan 18;296(1):107-12

Extracellular Mg2+ inhibits receptor-mediated Ca(2+)-permeable non-selective cation currents in aortic smooth muscle cells. Nakajima T, et al. **Eur J Pharmacol** 1997 Feb 5;320(1):81-6

Conversion of big-endothelin-1 elicits an endothelin ETA receptor-mediated response in endothelial cells. N'Diaye N, et al. **Eur J Pharmacol** 1997 Mar 5;321(3):387-96

Dynamic regulation of intracellular Ca2+ concentration in aortic endothelial cells. Oike M, et al. **Eur J Pharmacol** 1997 Jan 29;319(2-3):291-8

Characterization of thromboxane A2/prostaglandin endoperoxide receptors in aorta. Zhang R, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):91-6

Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. Takai S, et al. **FEBS Lett** 1997 Jul 21;412(1):86-90

Similarity between naturally occurring modified desialylated, electronegative and aortic low density lipoprotein. Tertov VV, et al. **Free Radic Res** 1996 Oct;25(4):313-9

Stimulation of angiotensin subtype 2 receptor reduces basal cGMP levels in the neointima of rat aorta after balloon injury. Moroi M, et al. **Gen Pharmacol** 1997 Jan;28(1):113-7

Selective induction of heparin-binding epidermal growth factor-like growth factor by methylglyoxal and 3-deoxyglucosone in rat aortic smooth muscle cells. The involvement of reactive oxygen species formation and a possible implication for atherogenesis in diabetes. Che W, et al. **J Biol Chem** 1997 Jul 18;272(29):18453-9

ATP-sensitive potassium channels in isolated rat aorta during physiologic, hypoxic, and low-glucose conditions. Hüsken BC, et al. **J Cardiovasc Pharmacol** 1997 Jan;29(1):130-5

Induction of nitric oxide synthase II does not account for excess vascular nitric oxide production in experimental cirrhosis. Sogni P, et al. **J Hepatol** 1997 May;26(5):1120-7

Gender differences in the generation of superoxide anions in the rat aorta. Brandes RP, et al. **Life Sci** 1997;60(6):391-6

Prejunctional modulation by prostaglandin E2 of noradrenaline release from sympathetic neurones in rabbit aorta. Jensen TJ, et al. **Pharmacol Toxicol** 1997 Jan; 80(1):18-23

Alpha 1 adrenergic receptor activation of proto-oncogene expression in arterial smooth muscle: regulation by nitric oxide and vascular injury. Okazaki M, et al. **Recept Signal Transduct** 1996;6(3-4):165-78

PATHOLOGY

Spontaneous rupture of thoracic aorta through an atheromatous plaque: case report and literature review. Ma TK, et al. **Am J Forensic Med Pathol** 1996 Mar;17(1):38-42 (15 ref.)

Endothelial injury in vivo: a technical and statistical approach to the study of aortic integrity. Skantze HB, et al. **Am J Physiol** 1996 May;270(5 Pt 2):H1841-9

Management of arch hypoplasia after successful coarctation repair. DeLeon MM, et al. **Ann Thorac Surg** 1997 Apr; 63(4):975-80

Postpneumonectomy syndrome with an ipsilateral aortic arch after left pneumonectomy. Shamji FM, et al. **Ann Thorac Surg** 1996 Dec;62(6):1627-31

Metastasizing sarcoma of the aorta. A case report. Ingeholm P, et al. **APMIS** 1997 Aug;105(8):609-11

Relation of C4b-binding protein to athero-sclerosis of the descending thoracic aorta. Kimoto K, et al. **Artery** 1996; 22(2):101-14

Atherosclerosis-prone branch regions in human aorta: microarchitecture and cell composition of intima. Kolpakov V, et al. **Atherosclerosis** 1996 May;122(2):173-89

Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. Zaltsman AB, et al. **Atherosclerosis** 1997 Apr; 130(1-2):61-70

Heterogeneity in morphological characteristics of coronary arteries and aortae in various models of hypertension. Hüsken BC, et al. **Blood Press** 1997 Jul;6(4):242-9

Case report: MR angiography of cervical aortic arch. Kumar S, et al. **Clin Radiol** 1997 Sep;52(9):717-9

Aortic wall structural strengthening by intraluminal net prosthesis to arrest aneurysm progression and to prevent dissection and rupture. Nazari S, et al. **Eur J Cardiothorac Surg** 1996;10(4):264-72

Three-dimensional contrast-enhanced magnetic resonance angiography of the thoracic vasculature. Leung DA, et al. **Eur Radiol** 1997;7(7):981-9 (28 ref.)

Metastasising sarcoma of the aorta. Ruijter ET, et al. **Histopathology** 1996 Sep;29(3):278-81

Marked arteriosclerosis of the descending aorta in a teenager with interruption of the aorta. Kawai S, et al. **Intern Med** 1996 May;35(5):383-7

Acute results of balloon angioplasty of native coarctation versus recurrent aortic obstruction are equivalent. Valvuloplasty and Angioplasty of Congenital Anomalies (VACA) Registry Investigators. McCrindle BW, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1810-7

Magnetic resonance angiography of the aortic arch. Carpenter JP, et al. **J Vasc Surg** 1997 Jan;25(1):145-51

The localization of tissue factor and apolipoprotein(a) in atherosclerotic lesions of the human aorta and their relation

to fibrinogen–fibrin transition. Ichikawa K, et al. **Pathol Res Pract** 1996 Mar;192(3):224–32

Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet–induced atherosclerosis. Hoeg JM, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15; 93(21):11448–53

Thoracic aorta: comparison of gadolinium–enhanced three–dimensional MR angiography with conventional MR imaging. Krinsky GA, et al. **Radiology** 1997 Jan; 202(1):183–93

Gadolinium–enhanced three–dimensional MR angiography of the thoracoabdominal aorta. Krinsky G, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):280–303 (19 ref.)

Histomorphological examination of endoluminal stent grafting in the descending aorta in a sheep model. Orend KH, et al. **Thorac Cardiovasc Surg** 1996 Jun;44(3):132–5

[Mediastinal spreading and aortic insufficiency] Manger B, et al. **Med Klin** 1997 Mar 15;92(3):144 **(Ger)**

[Results of a contrast–medium supported 3D MR–angiography in respiratory arrest following optimization of contrast medium bolus] Kopka L, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Apr;166(4):290–5 (Eng. Abstr.) **(Ger)**

[Bronchogenic carcinoma located in the aortic window] Saitoh Y, et al. **Kyobu Geka** 1997 Jan;50(1):59–62 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Modulation of Ca2+ and Na+ transport by taurine in heart and vascular smooth muscle. Bkaily G, et al. **Adv Exp Med Biol** 1996;403:263–73

Alteration of ascending thoracic aorta compliance after treatment with menotropin. Chelsky R, et al. **Am J Obstet Gynecol** 1997 Jun;176(6):1255–9; discussion 1260–1

Noninvasive determination of pulse–wave velocity in mice. Hartley CJ, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):H494–500

Characterization of ATP–sensitive potassium channels in freshly dissociated rabbit aortic endothelial cells. Katnik C, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2507–11

Change in intramural strain distribution in rat aorta due to smooth muscle contraction and relaxation. Matsumoto T, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1711–6

Regional differentiation in the rat aorta for a novel signaling pathway: leucine to glutamate. Schachter D, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1484–92

Regional differentiation in the rat aorta: effects of cyclooxygenase inhibitors. Schachter D, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1478–83

Aortic distensibility and compliance in conscious pregnant rats. Slangen BF, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1260–5

Confirmation and initial documentation of thoracic and abdominal aortic helical flow. An ultrasound study. Frazin LJ, et al. **ASAIO J** 1996 Nov–Dec;42(6):951–6

Changes in biomechanical properties, composition of collagen and elastin, and advanced glycation endproducts of the rat aorta in relation to age. Brüel A, et al. **Atherosclerosis** 1996 Dec 20;127(2):155–65

Evans' blue dye abolishes endothelium–dependent relaxation of rabbit aortic rings [letter] Forster BA, et al. **Atherosclerosis** 1997 Feb 28;129(1):129–31

In vivo determinants of arterial stiffness [letter; comment] Lehmann ED, et al. **Atherosclerosis** 1996 Aug 23; 125(1):139–48. Comment on: Atherosclerosis 1995 Oct;117(2):263–72.

Effect of aortic impedance on preload–afterload mismatch in canine hearts in situ. Yano M, et al. **Basic Res Cardiol** 1997 Apr;92(2):115–22

Effect of a cholesterol–rich diet on the excitability of rabbit aorta. Wong KK. **Biochem Mol Biol Int** 1996 Oct; 40(2):389–93

Continuous wavelet transform of aortic pressure oscillations in anesthetized dogs: effects of 45 degrees tilting. Jiménez RF, et al. **Biol Res** 1997;30(2):53–64

Influence of the estrous cycle on the norepinephrine–induced contraction of rat aorta: relationship to vascular prostanoids biosynthesis. Zamorano B, et al. **Biol Res** 1994; 27(3–4):209–15

Residual stresses in the human aorta and their influences by growth and remodelling. Valenta J, et al. **Biomed Mater Eng** 1997;7(3):159–69

Endothelium–dependent and –independent vasoactive actions of a Japanese kampo medicine, Saiko–ka–ryukotsu–borei–to. Wei MJ, et al. **Biomed Pharmacother** 1997;51(1):38–43

Impairment of endothelium–dependent but not of endothelium–independent dilatation in guinea–pig aorta rings incubated in the presence of elevated glucose. Dorigo P, et al. **Br J Pharmacol** 1997 Jul;121(5):972–6

Effect of treatment with cholecalciferol on the membrane potential and contractility of aortae from spontaneously hypertensive rats. Silva EG, et al. **Br J Pharmacol** 1996 Jul;118(6):1367–70

Twenty–four–hour variations in the sensitivity of rat aorta to vasoactive agents. Keskil Z, et al. **Chronobiol Int** 1996 Dec;13(6):465–75

Effects of intra–aortic balloon occlusion on hemodynamics during, and survival after cardiopulmonary resuscitation in dogs. Rubertsson S, et al. **Crit Care Med** 1997 Jun; 25(6):1003–9

Interactions of elastin and aorta with sugars in vitro and their effects on biochemical and physical properties. Winlove CP, et al. **Diabetologia** 1996 Oct;39(10):1131–9

Comparison of vasopressin and oxytocin receptors in the rat uterus and vascular tissue. Anouar A, et al. **Eur J Pharmacol** 1996 Jul 11;308(1):87–96

Effects of hypertension on hypercholesterolemia–induced changes in contraction of rabbit aorta and carotid artery. Moreland RS, et al. **Eur J Pharmacol** 1996 Jun 20; 307(1):55–64

Intracellular pH and H+ buffering capacity in guinea–pigs with left ventricular hypertrophy induced by constriction of the thoracic aorta. Wallis WR, et al. **Exp Physiol** 1997 Jan;82(1):227–30

The role of endothelium in the calcium–induced reduction of the contractile response of the rabbit aorta. Ortega A, et al. **Gen Pharmacol** 1997 May;28(5):745–52

Abnormal renal vascular reactivity to acetylcholine and nitroprusside in aging rats. Vargas F, et al. **Gen Pharmacol** 1997 Jan;28(1):133–7

Flow patterns in dog aortic arch under a steady flow condition simulating mid–systole. Endo S, et al. **Heart Vessels** 1996;11(4):180–91

KATP channel opening does not contribute significantly to the vasodilatory effect of SH–group–containing ACE inhibitors. Köppel H, et al. **Heart Vessels** 1996;11(4):192–6

Selective carotid angiography during cross–clamping of the descending thoracic aorta in pigs. Strømholm T, et al. **Int Angiol** 1996 Sep;15(3):263–7

Protease activated receptors modulate aortic vascular tone. Magazine HI, et al. **Int J Cardiol** 1996 Apr 26;53 Suppl:S75–80

Elastic area compressibility of the rabbit aorta. Yu Q, et al. **J Biomech** 1996 Aug;29(8):1033–7

Kallistatin is a potent new vasodilator. Chao J, et al. **J Clin Invest** 1997 Jul 1;100(1):11–7

A novel mechanosensitive cationic channel from the endothelium of rat aorta. Marchenko SM, et al. **J Physiol (Lond)** 1997 Jan 15;498 (Pt 2):419–25

Mechanical characteristics of fresh and frozen human descending thoracic aorta. Adham M, et al. **J Surg Res** 1996 Jul 15;64(1):32–4

Primary fibrinolysis during supraceliac aortic clamping. Illig KA, et al. **J Vasc Surg** 1997 Feb;25(2):244–51; discussion 252–4

Cine magnetic resonance imaging study of blood flow and wall motion of the aortic arch. Yoshii S, et al. **Jpn Circ J** 1996 Aug;60(8):553–9

Pulse wave velocity as a marker of vascular disease [letter] Cameron J, et al. **Lancet** 1996 Dec 7;348(9041):1586–7

Pulse wave velocity as a marker of vascular disease [letter] Martyn CN, et al. **Lancet** 1996 Dec 7;348(9041):1586; discussion 1587

In vivo validation of MR pulse pressure measurement in an aortic flow model: preliminary results. Urchuk SN, et al. **Magn Reson Med** 1997 Aug;38(2):215–23

Developmental dynamics of endothelial and neurogenic control of canine thoracic aorta. Török J, et al. **Mech Ageing Dev** 1997 Apr;95(1–2):143–52

Direct measurement of clamping forces in cardiovascular surgery. Trobec R, et al. **Med Biol Eng Comput** 1997 Jan; 35(1):17–20

Comparison of different methods for the determination of the true wave propagation coefficient, in rubber tubes and the canine thoracic aorta. Bertram CD, et al. **Med Eng Phys** 1997 Apr;19(3):212–22

Identification and physiological relevance of an exponentially tapered tube model of canine descending aortic circulation. Fogliardi R, et al. **Med Eng Phys** 1997 Apr;19(3):201–11

Endothelium–dependent vasodilator effect of extract prepared from the roots of Paeonia lactiflora on isolated rat aorta. Goto H, et al. **Planta Med** 1996 Oct;62(5):436–9

Decreased vascular sensitivity after acute exercise and chronic exercise training in rat thoracic aorta. Izawa T, et al. **Res Commun Mol Pathol Pharmacol** 1996 Sep; 93(3):331–42

Effects of cyclosporine A on the regenerating endothelium following direct arterial injury. Cartier R, et al. **Transplant Proc** 1997 May;29(3):1886–90

PHYSIOPATHOLOGY

Pathophysiology of aortic cross–clamping. Gelman S. **Acta Anaesthesiol Scand Suppl** 1997;110:41–2

A new technique for study of impact of arterial elasticity on left ventricular mass in rats. Amin F, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):H981–7

In vivo aortic wall characteristics at the early stage of atherosclerosis in rabbits. Hironaka K, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1142–7

bFGF restores endothelium–dependent responses of hypercholesterolemic rabbit thoracic aorta. Meurice T, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):H613–7

Effect of surgical reconstruction on flow profiles in the aorta using magnetic resonance blood tagging. Fogel MA, et al. **Ann Thorac Surg** 1997 Jun;63(6):1691–700

A significant increase of aortic response to a combination of norepinephrine and KCl in aorta isolated from 2–month diabetic rats induced by streptozocin. Wong KK. **Artery** 1996;22(3):164–71

Localization and activity of tissue factor in human aortic atherosclerotic lesions. Hatakeyama K, et al. **Atherosclerosis** 1997 Sep;133(2):213–9

Influence of aortic impedance on the development of pressure–overload left ventricular hypertrophy in rats. Kobayashi S, et al. **Circulation** 1996 Dec 15;94(12):3362–8

Attenuation of intrinsic active tone by endothelium–derived nitric oxide in aortae of spontaneously hypertensive rats with different levels of blood pressure. Sunano S, et al. **Clin Exp Hypertens** 1996 Aug;18(6):873–90

Vascular hyporesponsiveness in aortic rings from cirrhotic rats: role of nitric oxide and endothelium. Ortíz MC, et al. **Clin Sci (Colch)** 1996 Dec;91(6):733–8

Stress and strain distribution in hypertensive and normotensive rat aorta considering residual strain. Matsumoto T, et al. **J Biomech Eng** 1996 Feb;118(1):62–73

Prolonged inhibition of nitric oxide synthesis in Yoshida hyperlipidemic rat: aorta functional and structural properties. Chinellato A, et al. **Life Sci** 1997;60(15):1249–62

Aortic stiffness with the Williams–Beuren syndrome [letter] Wessel A, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):244

Effect of endotoxin–enhanced hepatic reperfusion injury on endothelium–dependent relaxation in rat aorta. McKenna R, et al. **Shock** 1996 Aug;6(2):106–11

Increased stiffness of the aorta in children and adolescents with insulin–dependent diabetes mellitus. Hu J, et al. **Ultrasound Med Biol** 1996;22(5):537–43

Abnormal fetal aortic velocity waveform and minor neurological dysfunction at 7 years of age. Ley D, et al. **Ultrasound Obstet Gynecol** 1996 Sep;8(3):152–9

Abnormal fetal aortic velocity waveform and intellectual function at 7 years of age. Ley D, et al. **Ultrasound Obstet Gynecol** 1996 Sep;8(3):160–5

RADIOGRAPHY

Ductus diverticulum interpreted as traumatic aortic injury. Ferrera PC, et al. **Am J Emerg Med** 1997 Jul;15(4):371–2

Cervical prevertebral soft–tissue measurements and chest radiographic findings in acute traumatic aortic injury. Plewa MC, et al. **Am J Emerg Med** 1997 May;15(3):256–9

Radiological case of the month. Double aortic arch. Saslow JG, et al. **Arch Pediatr Adolesc Med** 1997 Mar;151(3):313–4

Aortic arch angiography prior to carotid endarterectomy. Is its continued use justified? Kadwa AM, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):527–30

Helical CT angiography of the thoracic aorta. Rubin GD. **J Thorac Imaging** 1997 Apr;12(2):128–49 (38 ref.)

Use of intravenous digital subtraction angiography for imaging of the thoracic aorta [letter; comment] Haskal ZJ. **J Vasc Interv Radiol** 1997 Jul–Aug;8(4):720. Comment on: J Vasc Interv Radiol 1997 Mar–Apr;8(2):226–7.

Comparison of digital subtraction and cut film arteriography in the evaluation of suspected thoracic aortic injury. Johnson MS, et al. **J Vasc Interv Radiol** 1997 Sep–Oct; 8(5):799–807

Spiral CT angiography of the thoracic aorta. Chung JW, et al. **Radiographics** 1996 Jul;16(4):811–24

Subtle or atypical injuries of the thoracic aorta and brachiocephalic vessels in blunt thoracic trauma. Fisher RG, et al. **Radiographics** 1997 Jul–Aug;17(4):835–49

Evaluation of thoracic aortic disease with the use of helical CT and multiplanar reconstructions: comparison with surgical findings. Quint LE, et al. **Radiology** 1996 Oct; 201(1):37–41

[Imaging of acquired pathologies of the thoracic aorta] Golzarian J, et al. **J Belge Radiol** 1996 Nov;79(5):216–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of normal thoracic and abdominal aortic diameters through computerized tomography] Lucarelli CL, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 Nov–Dec;51(6):239–46 (Eng. Abstr.) **(Por)**

SECRETION

Diet–induced hypercholesterolemia increases endothelin–1 release by aortic endothelial cells. Uyama H, et al. **Pathobiology** 1996;64(6):328–32

SURGERY

Combined revascularization of coronary and femoral arteries, using the ascending aorta as inflow source. Daenens K, et al. **Acta Chir Belg** 1997 Jan–Feb;97(1):47–9

Operative mortality and frequency of coexistent anomalies in interruption of the aortic arch. Powell CB, et al. **Am J Cardiol** 1997 Apr 15;79(8):1147–8

Surgical management of traumatic aortic disruption. Sharma S, et al. **Am J Surg** 1997 May;173(5):416–8

Aortomyoplasty and muscle relaxants [letter] Pandit JJ. **Anesth Analg** 1997 Sep;85(3):708–9

Extension of the "elephant trunk" technique in complex aortic pathology: the "bidirectional" option. Carrel T, et al. **Ann Thorac Surg** 1997 Jun;63(6):1755–8

Effect of surgical reconstruction on flow profiles in the aorta using magnetic resonance blood tagging. Fogel MA, et al. **Ann Thorac Surg** 1997 Jun;63(6):1691–700

Arch growth after staged repair of interrupted aortic arch using carotid artery interposition. Hakimi M, et al. **Ann Thorac Surg** 1997 Aug;64(2):503–7

Long–term follow–up (8 to 17 years) after thromboexclusion operation for thoracic aortic aneurysms. Ku K, et al. **Ann Thorac Surg** 1997 Aug;64(2):399–403

Thoracic aortic operations: management of maldistribution of arterial flow during cardiopulmonary bypass. Najafi H, et al. **Ann Thorac Surg** 1997 Aug;64(2):565–7

Transpericardial inferior vena caval cannulation in thoracic

aorta operations. Neri E, et al. **Ann Thorac Surg** 1996 Oct; 62(4):1208–9

Anteroaxillary thoracotomy facilitates the use of retrograde cerebral perfusion in distal aortic arch reconstruction. Sasaguri S, et al. **Ann Thorac Surg** 1996 Dec;62(6):1861–2

Intraluminal shunt for the thoracic aorta: blood flow and function in chronic studies. Van Voorst SJ, et al. **Ann Thorac Surg** 1997 Feb;63(2):419–24

Descending thoracic aorta to femoral artery bypass: surgical technique. Criado E. **Ann Vasc Surg** 1997 Mar;11(2):206–15

Video-assisted aortofemoral bypass: results in seven cases. Fabiani JN, et al. **Ann Vasc Surg** 1997 May;11(3):273–7

Aortoiliac bypass in a renal transplant patient using a new technique [letter; comment] Mellière D. **Ann Vasc Surg** 1997 May;11(3):329. Comment on: Ann Vasc Surg 1995 Jul;9(4):385–9.

Myristoyl gelatin as a sealant for Dacron vascular prostheses. Sasajima T, et al. **Artif Organs** 1997 Apr;21(4):287–92

Distinctive microcirculation of the brain during cerebral perfusion by observation with a CCD microscope. Furuzawa Y, et al. **ASAIO J** 1996 Sep–Oct;42(5):M423–8

Aortic stent surgery [letter; comment] Wildsmith JA, et al. **Br J Anaesth** 1996 Nov;77(5):699. Comment on: Br J Anaesth 1996 Jun;76(6):882–3.

Temporary left external axillofemoral bypass during repair of a leaking type B aortic dissection. Taylor PR, et al. **Br J Surg** 1997 Mar;84(3):423

Surgical removal from the descending aorta of a floating thrombus caused by blunt chest trauma. Lukács L, et al. **Cardiovasc Surg** 1996 Dec;4(6):846–7

The use of profound hypothermia and circulatory arrest in operations on the thoracic aorta. Ehrlich M, et al. **Eur J Cardiothorac Surg** 1997 Jan;11(1):176–81

Late complications after surgical exclusion of the thoracic aorta. Gontijo B, et al. **Eur J Cardiothorac Surg** 1996; 10(7):590–2

Expandable prosthesis for sutureless anastomosis in thoracic aorta prosthetic substitution. Nazari S, et al. **Eur J Cardiothorac Surg** 1996;10(11):1003–9

Extensive resection with selective cerebral perfusion for a lung cancer invading the aortic arch. Okubo K, et al. **Eur J Cardiothorac Surg** 1996;10(5):389–91

Left main bronchus compression after aortic reconstruction for interruption of aortic arch. Sakai T, et al. **Eur J Cardiothorac Surg** 1995;9(11):667–9

Retrograde cerebral perfusion through antero-axillary thoracotomy in the aortic arch surgery. Sasaguri S, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):657–60

Type B dissection involving a right-sided aortic arch. Senthil V, et al. **Eur J Cardiothorac Surg** 1996;10(6):477–9

Successful surgery for perforation of the thoracic aorta caused by the tip of an intra-aortic balloon pump. Wolff T, et al. **Eur J Cardiothorac Surg** 1997 Jun;11(6):1176–9

How do we protect the brain? Antegrade selective cerebral perfusion with cold blood during aortic arch surgery. Bachet J, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):193–200

Individual strategies of hemostasis for thoracic aortic surgery. de Figueiredo LF, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):222–8 (47 ref.)

Brain protection. Svensson LG. **J Card Surg** 1997 Mar–Apr; 12(2 Suppl):326–9; discussion 329–30 (30 ref.)

Apico-aortic shunt: a support technique during surgery on the descending thoracic aorta. Kuribayashi R, et al. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):271–6

Management of coarctation with multiple calcified aneurysms of the intercostal arteries in adults. Sethi GK, et al. **J Thorac Cardiovasc Surg** 1975 Jun;69(6):909–11

Traumatic carotid artery dissection of restrained driver and thoracic aorta transection of unrestrained passenger in a motor vehicle accident: case report. Mason DP, et al. **J Trauma** 1997 Sep;43(3):537–40

Simultaneous abdominal aortic replacement and thoracic stent-graft placement for multilevel aortic disease. Moon MR, et al. **J Vasc Surg** 1997 Feb;25(2):332–40

Results of surgery for bronchogenic carcinoma located in the aortic window. Saitoh Y, et al. **Lung Cancer** 1997 Aug; 18(1):47–56

The reliability of evoked spinal cord potentials elicited by direct stimulation of the cord as a monitor of spinal cord ischemia during temporary occlusion of the thoracic aorta. Matsui Y, et al. **Panminerva Med** 1997 Jun;39(2):78–84

Total one-stage repair of aortopulmonary window and interrupted aortic arch in a neonate. Davies MJ, et al. **Pediatr Cardiol** 1996 Mar–Apr;17(2):122–4 (12 ref.)

Percutaneous balloon aortoplasty for restenosis after extended aortic arch anastomosis for type B interrupted aortic arch. Sato S, et al. **Pediatr Cardiol** 1996 Jul–Aug; 17(4):275–7

Congestive heart failure with tetralogy of Fallot relieved by an aortopulmonary shunt. Watson DG, et al. **Pediatr Cardiol** 1997 Sep–Oct;18(5):381–4

Endovascular treatment of aortic arch occlusive disease. Queral LA, et al. **Semin Vasc Surg** 1996 Jun;9(2):156–63

Exposure of the brachiocephalic vessels. Rutherford RB. **Semin Vasc Surg** 1996 Jun;9(2):77–83

Total aortic arch reconstruction for multiple great vessel occlusive disease. Takach TJ, et al. **Semin Vasc Surg** 1996 Jun;9(2):118–24

Neurological outcome in a porcine model of descending thoracic aortic surgery. Left atrial-femoral artery bypass versus clamp/repair. Maharajh GS, et al. **Stroke** 1996 Nov; 27(11):2095–100; discussion 2101

Modified Bentall operation with concomitant total aortic arch replacement for DeBakey type I aortic dissection: report of a case. Katoh T, et al. **Surg Today** 1997; 27(4):373–5

Hemodynamic effects of isovolemic hemodilution during descending thoracic aortic cross clamping and lower torso reperfusion. Poli de Figueiredo LF, et al. **Surgery** 1997 Jul;122(1):32–8

Successful sequential double lung transplantation and cardiac repair for aortopulmonary window: technical and functional advantages over heart-lung transplantation. Charpentier A, et al. **Transplant Proc** 1996 Oct;28(5):2878–9

[Obturator bypass--a method of extra-anatomic reconstruction in the region of the femoral trigone] Marušiak J, et al. **Rozhl Chir** 1997 Feb;76(2):56–8 (Eng. Abstr.) **(Cze)**

[Bipolar radiofrequency energy in arteries--the experimental results with a new catheter system] Simon C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):248–53 (Eng. Abstr.) **(Ger)**

[Total proximal reconstruction of chronic aortic dissection in patients with Marfan syndrome] Szabolcs Z, et al. **Orv Hetil** 1997 Mar 16;138(11):681–5 (Eng. Abstr.) **(Hun)**

[Our experience in the surgery of thoracic aorta] Fesani F, et al. **Acta Biomed Ateneo Parmense** 1995;66(5):217–22 (Eng. Abstr.) **(Ita)**

[Surgery of the descending thoracic and thoraco-abdominal arteries. Report of 105 cases] Zanetti PP, et al. **G Ital Cardiol** 1997 Jul;27(7):682–5 (Eng. Abstr.) **(Ita)**

[Surgical therapy for prosthetic infections of the thoracic aorta. Conservative approach] Spirito R, et al. **Minerva Cardioangiol** 1997 Mar;45(3):101–6 (Eng. Abstr.) **(Ita)**

[A case report on graft replacement of ruptured aneurysm of the arch and the descending thoracic aorta associated with dense pulmonary adhesion] Hirai M, et al. **Kyobu Geka** 1996 May;49(5):367–71 (16 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of total aortic arch replacement for distal aortic arch aneurysm in an octogenarian] Inaoka M, et al. **Kyobu Geka** 1997 Mar;50(3):226–9 (Eng. Abstr.) **(Jpn)**

[Concomitant composite graft replacement of the aortic root and the aortic arch for type A aortic dissection] Kikuchi Y, et al. **Kyobu Geka** 1997 Jun;50(6):469–74 (Eng. Abstr.) **(Jpn)**

[Postoperative evaluation of presealed vascular prostheses in surgical treatment of the thoracic aorta] Tsutsumi Y, et al. **Kyobu Geka** 1997 May;50(5):358–61 (Eng. Abstr.) **(Jpn)**

[A case of total arch graft replacement for distal aortic arch aneurysm developed around the site of graft patch aortoplasty] Hachiro Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2172–6 (Eng. Abstr.) **(Jpn)**

[Two cases of total arch replacement after coronary artery bypass surgery with internal mammary artery graft] Hasegawa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct;44(10):1935–40 (Eng. Abstr.) **(Jpn)**

[Extended total aortic arch replacement involving the proximal descending aorta through a median sternotomy] Kurimoto Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):661–5 (Eng. Abstr.) **(Jpn)**

[Effects of pre-operative administration of steroids on the serum interleukin (IL)-6, IL-8 and organ injuries in replacement of thoracic aorta] Nitta Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):825–30 (Eng. Abstr.) **(Jpn)**

[Rupture of the aortic arch due to bacterial aortitis--a case report of a patient undergoing successful surgical therapy] Sudo Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2221–4 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of diffuse supravalvular aortic stenosis with Williams syndrome] Sudoh Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):764–8 (Eng. Abstr.) **(Jpn)**

[Repair of D-transposition of the great arteries associated with double aortic arch] Suetsugu F, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):894–9 (Eng. Abstr.) **(Jpn)**

[A successful case report of composite graft and total aortic arch replacement in a patient with chronic idiopathic thrombocytopenic purpura (ITP)] Yanagiya A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug;44(8):1168–71 (Eng. Abstr.) **(Jpn)**

[A clinical study of retrograde cerebral perfusion in long duration] Yoshitaka H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):806–11 (Eng. Abstr.) **(Jpn)**

[Changes in bioelectric activity and metabolism of the brain during surgery of the aorta under deep hypothermic arrest of circulation] Mierbekov EM, et al. **Anesteziol Reanimatol** 1997 Mar–Apr;(2):45–9 (Eng. Abstr.) **(Rus)**

[Treatment with endoprosthesis of the pathology of the descending thoracic artery] Rousseau H, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:107–15 (50 ref.) (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

Nonvalved homografts of thoracic aorta in operation for complex congenital cardiac disease. Bové T, et al. **Ann Thorac Surg** 1996 Nov;62(5):1347–50

Effect of cyclosporine during initiation of transplant arteriosclerosis. An ultrastructural study in the aorta-transplanted rabbit. Andersen HO, et al. **Atherosclerosis** 1997 Sep;133(2):171–81

Accelerated aortic allograft fibrocalcification after right ventricular outflow tract reconstruction in pediatric patients: report of two cases. Santini F, et al. **Eur J Cardiothorac Surg** 1996;10(4):290–3

Chronic rejection of concordant aortic xenografts in the hamster-to-rat model. Scheringa M, et al. **Transpl Immunol** 1996 Sep;4(3):192–7

Cell and extracellular matrix rejection in arterial concordant and discordant xenografts in the rat. Allaire E, et al. **Transplantation** 1996 Sep 27;62(6):794–803

Abrogation of chronic rejection in a murine model of aortic allotransplantation by prior induction of donor-specific tolerance. Subbotin V, et al. **Transplantation** 1997 Sep 15; 64(5):690–5

ULTRASONOGRAPHY

Dynamic properties of the aorta and of the foot microcirculation in adolescents with diabetes mellitus. Hu J, et al. **Acta Paediatr** 1997 Jun;86(6):620–5

Opacification of the thoracic aorta after venous injection of sonicated albumin microbubbles. Implications for aortic dissection. Voci P. **Cardiologia** 1997 Mar;42(3):299–304

Spontaneous echocardiographic contrast in the descending thoracic aorta. Zainea MA, et al. **Cardiology** 1996 Sep–Oct; 87(5):379–83

Use of transesophageal echocardiography for diagnosis of traumatic aortic injury. Goarin JP, et al. **Chest** 1997 Jul; 112(1):71–80

Mobile thromboses of the aortic arch without aortic debris. A transesophageal echocardiographic finding associated with unexplained arterial embolism. The Filiale Echocardiographie de la Société Française de Cardiologie. Laperche T, et al. **Circulation** 1997 Jul 1;96(1):288–94

Three-dimensional echocardiography of the thoracic aorta [see comments] Kasprzak JD, et al. **Eur Heart J** 1996 Oct; 17(10):1584–92. Comment in: Eur Heart J 1996 Oct;17(10):1456–8.

Aortic arch interruption in association with Ebstein's anomaly of tricuspid valve and rheumatic mitral stenosis [letter; comment] Mahorkar UK, et al. **Indian Heart J** 1996 Nov-Dec;48(6):735–6. Comment on: Indian Heart J 1996 Jul-Aug;48(4):398–400.

Prognostic significance of spontaneous echo contrast in the thoracic aorta: relation with accelerated clinical progression of coronary artery disease. Steinberg EH, et al. **J Am Coll Cardiol** 1997 Jul;30(1):71–5

Morphology of the ventricular septal defect in two types of interrupted aortic arch. Chin AJ, et al. **J Am Soc Echocardiogr** 1996 Mar–Apr;9(2):199–201

Aortic elastic properties with transesophageal echocardiography with automated border detection: validation according to regional differences between proximal and distal descending thoracic aorta. Cholley BP, et al. **J Am Soc Echocardiogr** 1996 Jul–Aug;9(4):539–48

Tortuosity of the descending thoracic aorta simulating dissection on transesophageal echocardiography. Katz ES, et al. **J Am Soc Echocardiogr** 1997 Jan–Feb;10(1):83–7

Salmonella aortitis with pseudoaneurysm formation diagnosed by transesophageal echocardiography. Kures P, et al. **J Am Soc Echocardiogr** 1996 Nov–Dec;9(6):885–7

Transesophageal echocardiography of the thoracic aorta. Ailloni-Charas O, et al. **J Cardiothorac Vasc Anesth** 1996 Aug;10(5):683–5

Changes in umbilical artery, middle cerebral artery, and aorta blood flow Doppler waveform pulsatility indices after funisocentesis. Chitrit Y, et al. **J Ultrasound Med** 1997 May; 16(5):359–64

Intra-aortic ultrasonography in advanced esophageal cancer. Akiyama S, et al. **Semin Surg Oncol** 1997 Jul–Aug; 13(4):234–7

Parametric (integrated backscatter and attenuation) images constructed using backscattered radio frequency signals (25–56 MHz) from human aortae in vitro. Bridal SL, et al. **Ultrasound Med Biol** 1997;23(2):215–29

Correlation of ultrasonic attenuation (30 to 50 MHz and constituents of atherosclerotic plaque. Bridal SL, et al. **Ultrasound Med Biol** 1997;23(5):691–703

[Thrombus in the thoracic aorta as cause of peripheral embolism diagnosed using transesophageal echocardiography] Laraudogoitia E, et al. **Rev Esp Cardiol** 1997 Jan;50(1):62–4 (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

Characterization of alpha 1 D-adrenoceptor subtype in rat myocardium, aorta and other tissues. Deng XF, et al. **Br J Pharmacol** 1996 Sep;119(2):269–76

Connexin43 gap junction levels during development of the thoracic aorta are temporally correlated with elastic laminae deposition and increased blood pressure. Blackburn JP, et al. **Cell Biol Int** 1997 Feb;21(2):87–97

Structural heterogeneity and contacting interactions of vascular dendritic cells in early atherosclerotic lesions of the human aorta. Bobryshev YV, et al. **J Submicrosc Cytol Pathol** 1996 Jan;28(1):49–60

AORTIC ANEURYSM

Sinus of valsalva aneurysms [letter; comment] Cheng TO. **Am Heart J** 1996 Dec;132(6):1319. Comment on: Am Heart J 1995 Dec;130(6):1265–9.

Replicas of human aortic and iliac artery aneurysms for endovascular repair. Practice makes perfect. Wisselink W, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:258–9

Immunohistochemical abnormalities of fibrillin in cardiovascular tissues in Marfan's syndrome. Fleischer KJ, et al. **Ann Thorac Surg** 1997 Apr;63(4):1012–7

Images in cardiovascular medicine. Mycotic aneurysm of the descending thoracic aorta. Oxorn D, et al. **Circulation** 1997 Apr 1;95(7):1972–3

Nonneoplastic diseases of aorta and pulmonary trunk--Part I. Waller BF, et al. **Clin Cardiol** 1997 Aug;20(8):730–4 (21 ref.)

Aortic dissection. Braverman AC. **Curr Opin Cardiol** 1997 Jul;12(4):389–90 (4 ref.)

Progress report: evaluation and treatment of ascending and aortic arch aneurysm/dissection. Meadors FA. **J Ark Med Soc** 1997 Mar;93(10):481–3 (7 ref.)

Aortic dissection. Prêtre R, et al. **Lancet** 1997 May 17; 349(9063):1461–4 (65 ref.)

Aortic and other arterial dissections associated with pregnancy. Rutherford RB, et al. **Semin Vasc Surg** 1995 Dec;8(4):299–305 (29 ref.)

[Aortic dissection: new diagnostic and therapeutic trends] Marra L, et al. **Clin Ter** 1996 Jun;147(6):333–7 (Eng. Abstr.) **(Ita)**

[Triple-barrel(ed) or three channeled aortic dissection] Fujiwara K, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (14):375–7 (13 ref.) **(Jpn)**

[Aortic dissection, dissecting aortic aneurysm] Matsco H. **Ryoikibetsu Shokogun Shirizu** 1996;(14):303–6 (12 ref.) **(Jpn)**

[Aortic aneurysms] Yasuda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):387–90 (20 ref.) **(Jpn)**

[Aortic dissection: clinical evaluation, comparison of diagnostic techniques and treatment election] San Román JA, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:2–12 (84 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Cocaine-induced aortic dissection. Rashid J, et al. **Am Heart J** 1996 Dec;132(6):1301–4 (20 ref.)

Acute dissection of the aorta with amphetamine misuse. Dihmis WC, et al. **BMJ** 1997 Jun 7;314(7095):1665

COMPLICATIONS

Fatal myocardial ischemia caused by compression of the left coronary system by a large left sinus of Valsalva aneurysm. Bashour TT, et al. **Am Heart J** 1996 Nov;132(5):1050–2

Drawback of aortoplasty for aneurysm of the ascending aorta associated with aortic valve disease. Mueller XM, et al. **Ann Thorac Surg** 1997 Mar;63(3):762–6; discussion 766–7

Unruptured sinus of Valsalva aneurysm with right ventricular outflow tract obstruction associated with ventricular septal defect. Liang CD, et al. **Cathet Cardiovasc Diagn** 1996 Feb; 37(2):158–61

Aneurysms of all sinuses of Valsalva and aortic valve prolapse secondary to Behçet's disease [letter] Wakabayashi Y, et al. **Eur Heart J** 1996 Nov;17(11):1766

Unruptured aneurysms of the non-coronary and left sinuses of Valsalva accompanied by severe aortic valve regurgitation. Simic O, et al. **Eur J Cardiothorac Surg** 1996; 10(11):1030–2

Aortic insufficiency and stenosis in unruptured aneurysm of sinus of Valsalva [letter] Yuan SM. **Int J Cardiol** 1997 May 23;59(3):321–2

Spontaneous echocardiographic contrast within an unruptured sinus of Valsalva aneurysm: a potential embolic source diagnosed by transesophageal echocardiography. Steinberg E, et al. **J Am Soc Echocardiogr** 1996 Nov-Dec; 9(6):880–1

Ductus diverticulum aneurysm associated with bicuspid aortic valve and dilatation of ascending aorta. Sagic D, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):137–40

Atypical manifestations in a patient with systemic lupus erythematosus. Lam KY, et al. **J Clin Pathol** 1997 Feb; 50(2):174–6

Aortic dissection in puerperium: a case report. Scalia D, et al. **J Heart Valve Dis** 1996 May;5(3):251–3

Reoperation for aneurysmal disease of the ascending aorta in patients with concomitant aortic valve incompetence. Karck M, et al. **J Thorac Cardiovasc Surg** 1996 Nov; 112(5):1392–3

Platypnea and orthodeoxia: shunting associated with an aortic aneurysm. Laybourn KA, et al. **J Thorac Cardiovasc Surg** 1997 May;113(5):955–6

Rash in an elderly woman presenting with collapse. Prajapati C, et al. **Postgrad Med J** 1997 Mar;73(857):175–6

CT scanning as a helpful tool for decision-making during CPR [letter] Ladner E, et al. **Resuscitation** 1996 Apr; 31(2):171–3

Ascending aortic aneurysm with or without features of Marfan syndrome and other fibrillinopathies: new insights. Furthmayr H, et al. **Semin Thorac Cardiovasc Surg** 1997 Jul;9(3):191–205 (45 ref.)

Regression of ST segment elevation after thrombolysis in acute aortic dissection. Safi J Jr, et al. **South Med J** 1996 Nov;89(11):1091–3

[Arterial fibromuscular dysplasia and Bourneville's tuberous sclerosis] Paraf F, et al. **Ann Pathol** 1996;16(3):203–6 (Eng. Abstr.) **(Fre)**

[Stent implantation in severe tracheal and bronchial compression caused by aortic aneurysm] Ewert R, et al. **Pneumologie** 1997 Jan;51(1):19–23 (Eng. Abstr.) **(Ger)**

[A case report of closing aortic dissection with cardiac tamponade] Yoshimura N, et al. **Kyobu Geka** 1996 Oct; 49(11):943–6 (Eng. Abstr.) **(Jpn)**

[A case report of Stanford type A acute thrombosed aortic dissection complicating cardiac tamponade] Morimoto K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep; 44(9):1805–8 (Eng. Abstr.) **(Jpn)**

[A successful surgical case report of impending rupture of the true thoraco-abdominal aortic aneurysm induced by thrombosed-type acute aortic dissection (Stanford type A)] Ohnishi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):649–54 (Eng. Abstr.) **(Jpn)**

[A successful surgical case of a dissecting aortic aneurysm with right-sided aortic arch and right-sided descending aorta] Osako M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug;44(8):1145–50 (Eng. Abstr.) **(Jpn)**

[A case report of an infundibular ventricular septal defect with severe right ventricular outflow tract obstruction due to aneurysm of the aortic sinus of valsalva] Shuntoh K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec; 44(12):2183–6 (Eng. Abstr.) **(Jpn)**

[Successful surgical treatment for distal arch aneurysm involving an aberrant right subclavian artery] Wakiyama H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug; 44(8):1155–8 (Eng. Abstr.) **(Jpn)**

[Spinal cord ischemia caused by dissecting aortic aneurysm in a patient with acute exacerbation of pulmonary emphysema] Yanagisawa N, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Jan;35(1):77–81 (Eng. Abstr.) **(Jpn)**

[Case of aortic occlusion caused by aortic dissection: recanalization by multiple fenestrations] Kihira Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2081–2 **(Jpn)**

[Acute anterior myocardial wall infarct caused by aortic dissection] Panić G, et al. **Med Pregl** 1996;49(11–12):493–6 (Eng. Abstr.) **(Scr)**

[Brown-Sequard syndrome secondary to dissecting aortic aneurysm (letter)] Blanco Jiménez J, et al. **Rev Clin Esp** 1997 Apr;197(4):299–301 **(Spa)**

CONGENITAL

Clinicopathologic findings in congenital aneurysms of the great vessels. Adès LC, et al. **Am J Med Genet** 1996 Dec 18;66(3):289–99 (37 ref.)

Endoaneurysmal repair of a congenital right coronary sinus aneurysm. Olearchyk AS, et al. **J Card Surg** 1997 Mar-Apr; 12(2):81–5

Aneurysms of the sinus of Valsalva. Yilmaz AT, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):119–24

Unruptured congenital aneurysm of the right sinus of Valsalva. Dissecting into the interventricular septum. Kalimanovska-Oštrić D, et al. **Tex Heart Inst J** 1996; 23(3):217–21

[Aneurysm of the sinus of Valsalva] Sugama M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):323–5 (19 ref.) **(Jpn)**

DIAGNOSIS

Pharmacist with hypotension and altered mental status [clinical conference] Van Voorst T, et al. **Acad Emerg Med** 1996 Jun;3(6):634–40

Segmented K-space cine breath-hold cardiovascular MR imaging: Part 2. Evaluation of aortic vasculopathy. Bluemke DA, et al. **AJR Am J Roentgenol** 1997 Aug; 169(2):401–7

Thrombolytic therapy in aortic dissection [letter] Cheng TO. **Am Fam Physician** 1997 Sep 1;56(3):738, 741

Sinus of Valsalva aneurysm presenting as myocardial infarction during dobutamine stress test. Ferreira AC, et al. **Cathet Cardiovasc Diagn** 1996 Dec;39(4):400–2 (7 ref.)

Chronic aortic dissection presenting as a prolonged febrile disease and arterial embolization. Schattner A, et al. **Chest** 1996 Oct;110(4):1111–4 (13 ref.)

Ormond's disease or aortic aneurysm? Case reports. Debrand-Passard A, et al. **Int Urol Nephrol** 1996; 28(3):295–304

Aneurysm of the arch of aorta presenting as an opaque hemithorax. Avasthi G, et al. **J Assoc Physicians India** 1995 Jun;43(6):435–6

A young woman fainted. Avery JK. **J Tenn Med Assoc** 1996 Mar;89(3):87–8

Biochemical diagnosis of aortic dissection by raised concentrations of creatine kinase BB-isozyme [letter] Suzuki T, et al. **Lancet** 1997 Sep 13;350(9080):784–5

MRI postoperative monitoring in patients surgically treated for aortic dissection. Di Cesare E, et al. **Magn Reson Imaging** 1996;14(10):1149–56

Review of techniques used to image aortic dissection. Dowd SB, et al. **Radiol Technol** 1996 Jan-Feb;67(3):223–30; quiz 231–2 (34 ref.)

[Increased serum concentration of myosin heavy chain in aortic dissection: discussion of 2 cases] von Kodolitsch Y, et al. **Z Kardiol** 1997 Jun;86(6):469–73 (Eng. Abstr.) **(Ger)**

[Diagnostic techniques useful to surgical treatment] Monaca V, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):595–7 **(Ita)**

[Computerized tomography and magnetic resonance in the study of aortic dissection] Sardanelli F, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):583–94 **(Ita)**

[Role of noninvasive graphic diagnosis in acute type A aortic dissection and selection of the adjunct for cerebral protection] Sueda T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug;44(8):1130–5 (Eng. Abstr.) **(Jpn)**

[Superior cava vena syndrome, infrequent form of presentation of aortic dissecting aneurysm (letter)] Marcos Sánchez F, et al. **An Med Interna** 1996 Dec;13(12):612 **(Spa)**

DRUG THERAPY

Thrombolytic therapy in aortic dissection [letter] Cheng TO. **Am Fam Physician** 1997 Sep 1;56(3):738, 741

Results of long-term medical treatment of patients with arterial hypertension complicated by aortic dissection. Grajek S, et al. **J Hum Hypertens** 1995 Dec;9(12):987–92

[Natural history and prognosis of medical treatment for the patients with aortic dissections] Masuda Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):890–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

An in vitro model of aneurysmal disease: effect of leukocyte infiltration and shear stress on MMP production within the arterial wall. Thompson MM, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:270–3

ETHNOLOGY

Ethnic differences in aortic aneurysm and peripheral vascular disease. Authors' data are inadequate [letter; comment] Wilmshurst P. **BMJ** 1996 Oct 26;313(7064):1084. Comment on: BMJ 1996 Jul 20;313(7050):173.

ETIOLOGY

Aortic dissection extending from the left coronary artery during percutaneous coronary angioplasty. Ochi M, et al. **Ann Thorac Surg** 1996 Oct;62(4):1180–2

Marfanoid aneurysm in donor aorta after transplantation. Pathi VL, et al. **Ann Thorac Surg** 1997 Jun;63(6):1770–1

Enlarging mediastinal mass after cardiac transplantation. Weinstein S, et al. **Ann Thorac Surg** 1997 Sep;64(3):845–7

Dissection of the ascending aorta: a late complication of coronary artery bypass grafting. Yaku H, et al. **Ann Thorac Surg** 1996 Dec;62(6):1834–5

The risk of aortic dissection in women with Turner syndrome [letter] Birdsall M, et al. **Hum Reprod** 1996 Jul;11(7):1587

Aortic dissection during directional coronary atherectomy. Ohmoto Y, et al. **Int J Cardiol** 1996 Aug;55(3):289–91

Traumatic pseudoaneurysm of the left sinus of Valsalva: a case report. Gharzuddine WS, et al. **J Am Soc Echocardiogr** 1997 May;10(4):377–80

Huge aneurysm of the sinus of Valsalva following infective endocarditis in Behçet's disease. Okada K, et al. **J Heart Valve Dis** 1997 Mar;6(2):179–80

Aneurysmal dilatation of ascending aorta and aortic insufficiency in juvenile spondyloarthropathy. Kim TH, et al. **Scand J Rheumatol** 1997;26(3):218–21

Leaking giant aneurysm of the aortic root due to cystic medial necrosis with pericardial tamponade mimicking type-A aortic dissection. Attenhofer CH, et al. **Thorac Cardiovasc Surg** 1996 Apr;44(2):103–4

[Acute retrograde dissection of the aorta is a formidable complication in retrograde perfusion through the femoral artery] Matsuzaki K, et al. **Kyobu Geka** 1997 Jun; 50(6):463–5 (Eng. Abstr.) **(Jpn)**

[Aortic dissection after weaning from extracorporeal circulation] Ohashi Y, et al. **Masui** 1996 Oct;45(10):1281–4 (Eng. Abstr.) **(Jpn)**

[A case report of postcoarctation mycotic aneurysm after surgical treatment for cerebral arterial aneurysms] Kido M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul; 45(7):1006–10 (7 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The pathogenicity of the Pro1148Ala substitution in the FBN1 gene: causing or predisposing to Marfan syndrome and aortic aneurysm, or clinically innocent? Schrijver I, et al. **Hum Genet** 1997 May;99(5):607–11

[Is heterozygote alpha 1-antitrypsin deficiency a risk factor in the etiology of aortic aneurysm?] Hernandez-Richter T, et al. **Chirurg** 1997 May;68(5):513–6 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. Modur V, et al. **J Clin Invest** 1997 Jul 1;100(1):158–68

METABOLISM

Expression of two novel recombinant proteins from aortic adventitia (kappafibs) sharing amino acid sequences with cytomegalovirus. Ozsvath KJ, et al. **J Surg Res** 1997 May; 69(2):277–82

MICROBIOLOGY

Double mycotic aneurysms of the ascending aorta. Chen YF, et al. **Ann Thorac Surg** 1997 Feb;63(2):529–31

NURSING

Marfan's syndrome and surgical repair of ascending aortic aneurysms. Wieczorek P, et al. **AORN J** 1996 Dec; 64(6):895–913; quiz 916–8, 921–2 (46 ref.)

PATHOLOGY

Inflammatory aneurysm of the ascending aorta and aortic arch. Girardi LN, et al. **Ann Thorac Surg** 1997 Jul; 64(1):251–3

Rupture of dissecting aneurysm in a China Airlines co–pilot. Shaw KP, et al. **Forensic Sci Int** 1996 Aug 15; 81(2–3):157–64

Pathologic correlates of aortic plaques, thrombi and mobile "aortic debris" imaged in vivo with transesophageal echocardiography. Vaduganathan P, et al. **J Am Coll Cardiol** 1997 Aug;30(2):357–63

Elastase–induced matrix degradation in arterial organ cultures: an in vitro model of aneurysmal disease. Wills A, et al. **J Vasc Surg** 1996 Oct;24(4):667–79

[Cystic medial necrosis] Imakita M. **Ryoikibetsu Shokogun Shirizu** 1996;(14):405–7 (18 ref.) **(Jpn)**

[Mega aorta syndrome] Kosuga K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):307–10 (7 ref.) **(Jpn)**

PHYSIOPATHOLOGY

The pulsatile pain of acute aortic dissection: a neurosurgeon's personal experience. Hunt WE, et al. **Am Heart J** 1996 Dec;132(6):1267–8

Chronic intraaneurysmal pressure measurement: an experimental method for evaluating the effectiveness of endovascular aortic aneurysm exclusion. Sanchez LA, et al. **J Vasc Surg** 1997 Aug;26(2):222–30

RADIOGRAPHY

Fast CT for aortic dissection. Small JH, et al. **Br J Radiol** 1996 Oct;69(826):900–5

Ascending aortic pseudoaneurysm masquerading as pulmonary embolus: case report. Murphy JP, et al. **Can Assoc Radiol J** 1997 Aug;48(4):270–2

Prevalence of motion artifact simulating aortic dissection on spiral CT using a 180 degree linear interpolation algorithm for reconstruction of the images. Loubeyre P, et al. **Eur Radiol** 1997;7(3):320–2

Radiological case of the month. Motion artifact simulating aortic dissection. Nokes SR, et al. **J Ark Med Soc** 1997 Feb;93(9):459–60

Spiral CT artifact that simulates aortic dissection: image reconstruction with use of 180 degrees and 360 degrees linear–interpolation algorithms. Loubeyre P, et al. **Radiology** 1997 Oct;205(1):153–7

The "draped aorta" in leaking aneurysms: aneurysm size correlation should have been provided [letter; comment] Maclaurin WA, et al. **Radiology** 1997 May;203(2):578. Comment on: Radiology 1996 Apr;199(1):41–3.

The dissected aorta: part III. Anatomy and radiologic diagnosis of branch–vessel compromise. Williams DM, et al. **Radiology** 1997 Apr;203(1):37–44

CT scanning as a helpful tool for decision–making during CPR [letter] Ladner E, et al. **Resuscitation** 1996 Apr; 31(2):171–3

[Imaging techniques in aortic dissection. Diagnosis with angiography] Orzan F, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):579–82 **(Ita)**

[Variations in the origin of the artery of Adamkiewicz] Illuminati G, et al. **Riv Eur Sci Med Farmacol** 1996 Mar–Apr;18(2):61–6 (Eng. Abstr.) **(Ita)**

[A 71–year–old woman complaining of right arm and shoulder pain followed by fever] Hashimoto S, et al. **J Cardiol** 1997 Mar;29(3):177–8 **(Jpn)**

[Angiography of the aorta] Soto B, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:52–62 (31 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

High frequency jet ventilation for severe pulmonary hemorrhage during aortic dissection operation—a case report. Cheng KS, et al. **Acta Anaesthesiol Sin** 1997 Mar; 35(1):51–4

Endocaval suture of aortocaval fistula. Illuminati G, et al. **Am Surg** 1997 May;63(5):399–400

Double mycotic aneurysms of the ascending aorta. Chen YF, et al. **Ann Thorac Surg** 1997 Feb;63(2):529–31

Paraplegia after thoracoabdominal aortic aneurysm repair: is dissection a risk factor? Coselli JS, et al. **Ann Thorac Surg** 1997 Jan;63(1):28–35; discussion 35–6

Clinical application of transluminal endovascular graft placement for aortic aneurysms. Inoue K, et al. **Ann Thorac Surg** 1997 Feb;63(2):522–8

Successful surgical repair of aortic dissection presenting with complete heart block. Jessen ME, et al. **Ann Thorac Surg** 1996 Oct;62(4):1202–3

Elephant trunk reconstruction for aberrant right subclavian and aortic aneurysm. Lee R, et al. **Ann Thorac Surg** 1997 Aug;64(2):547–8

Drawback of aortoplasty for aneurysm of the ascending aorta associated with aortic valve disease. Mueller XM, et al. **Ann Thorac Surg** 1997 Mar;63(3):762–6; discussion 766–7

Open distal anastomosis in retrograde cerebral perfusion for repair of ascending aortic dissection. Yamashita C, et al. **Ann Thorac Surg** 1997 Sep;64(3):665–9

Marfan's syndrome and surgical repair of ascending aortic aneurysms. Wieczorek P, et al. **AORN J** 1996 Dec; 64(6):895–913; quiz 916–8, 921–2 (46 ref.)

Randomized controlled trial of the effect of mannitol on renal reperfusion injury during aortic aneurysm surgery [see comments] Nicholson ML, et al. **Br J Surg** 1996 Sep; 83(9):1230–3. Comment in: Br J Surg 1997 Apr;84(4):587.

'In vivo' size of knitted Dacron prostheses (Gelseal) used in the thoracic aorta: a computed tomography study. Goossens D, et al. **Cardiovasc Surg** 1996 Apr;4(2):205–6

Circulatory management with retrograde cerebral perfusion for acute type A aortic dissection. Bavaria JE, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II173–6

Is use of aprotinin safe with deep hypothermic circulatory arrest in aortic surgery? Investigations on blood coagulation. Okita Y, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II177–81

Aortic valve–sparing operations in patients with ascending aortic aneurysms. David TE. **Curr Opin Cardiol** 1997 Jul; 12(4):391–5 (29 ref.)

Protamine–induced fulminating non–cardiogenic pulmonary edema following cardiopulmonary bypass. Kindler C, et al. **Eur J Cardiothorac Surg** 1996;10(6):463–6

Successful surgical repair of a false aneurysm of the ascending aorta following orthotopic cardiac transplantation: a case report. Punjabi P, et al. **Eur J Cardiothorac Surg** 1997 Jun; 11(6):1174–5

Composite graft in annulo–aortic ectasia. Nineteen years' experience without graft inclusion. Savunen T, et al. **Eur J Cardiothorac Surg** 1996;10(6):428–32

Heparin during aneurysm repair [letter; comment] Vahl AC, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):425. Comment on: Eur J Vasc Endovasc Surg 1996 Jul;12(1):86–90.

Ambulatory follow–up of aortic dissection: comparison between computed tomography and biplane transesophageal echocardiography [editorial; comment] Erbel R. **Int J Card Imaging** 1996 Jun;12(2):137–8. Comment on: Int J Card Imaging 1996 Jun;12(2):105–11.

Ambulatory follow–up of aortic dissection: comparison between computed tomography and biplane transesophageal echocardiography [see comments] Maffei S, et al. **Int J Card Imaging** 1996 Jun;12(2):105–11. Comment in: Int J Card Imaging 1996 Jun;12(2):137–8.

Clinical and echocardiographical study of the aortic homograft implantations in patients with Marfan syndrome. Podolec P, et al. **Int J Cardiol** 1997 Jun 27;60(1):41–7

The proper use of glue: a 20–year experience with the GRF glue in acute aortic dissection. Bachet J, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):243–53; discussion 253–5 (30 ref.)

Current practice in Marfan's syndrome and annulo–aortic ectasia: aortic root replacement with a composite graft over a twenty–year period. Bachet J, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):157–66

Current practice in Marfan's aortic root surgery: reconstruction with aortic valve preservation or replacement? What to do with the mitral valve? David TE. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):147–50

Aortic root surgery in Marfan syndrome: current practice and evolving techniques. LeMaire SA, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):137–41 (38 ref.)

The Bentall procedure in patients with Marfan's syndrome. Nguyen KH, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):142–6

Endoaneurysmal repair of a congenital right coronary sinus aneurysm. Olearchyk AS, et al. **J Card Surg** 1997 Mar–Apr; 12(2):81–5

Valve conserving operation for aortic regurgitation. Pepper J, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):151–6 (5 ref.)

The infected aorta. von Segesser LK, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):256–60; discussion 260–1

Transesophageal echocardiography not without pitfalls [letter] Benedict PE, et al. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):123

High–dose intrathecal morphine for thoracoabdominal aneurysm repair [letter] Chaney MA. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):306–7

Failure of left heart bypass to prevent acute left ventricular failure associated with proximal thoracic aortic cross–clamping. Gordon G, et al. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):80–2

Disseminated intravascular coagulation associated with acute ischemic hepatitis after elective aortic aneurysm repair: comparative analysis of 10 cases. Levy PJ, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):141–8

A case of Turner's syndrome associated with partial anomalous pulmonary venous return complicated by dissecting aortic aneurysm and aortic regurgitation. Shiroma K, et al. **J Cardiovasc Surg (Torino)** 1997 Jun; 38(3):257–9

A new nonstented balloon–expandable graft for straight or bifurcated endoluminal bypass. White GH, et al. **J Endovasc Surg** 1994 Sep;1:16–24

Surgery for aortic root aneurysm with aortic insufficiency [editorial; comment] David TE. **J Heart Valve Dis** 1996 May;5(3):238–9. Comment on: J Heart Valve Dis 1996 May;5(3):240–6. Comment on: J Heart Valve Dis 1996 May;5(3):247–50.

Huge aneurysm of the sinus of Valsalva following infective endocarditis in Behçet's disease. Okada K, et al. **J Heart Valve Dis** 1997 Mar;6(2):179–80

Aortic root endoscopy in valve–sparing operations. Itoh T, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):141–2

Reoperation for aneurysmal disease of the ascending aorta in patients with concomitant aortic valve incompetence. Karck M, et al. **J Thorac Cardiovasc Surg** 1996 Nov; 112(5):1392–3

Intraoperative identification of spinal cord blood supply during repairs of descending aorta and thoracoabdominal aorta. Svensson LG. **J Thorac Cardiovasc Surg** 1996 Dec; 112(6):1455–60; discussion 1460–1

Surgical treatment of ascending aortic dissecting aneurysm—clinical application of modified Cabrol's operation. Yang C, et al. **J Tongji Med Univ** 1996;16(2):96–8

Clinical experience with epidural cooling for spinal cord protection during thoracic and thoracoabdominal aneurysm repair. Cambria RP, et al. **J Vasc Surg** 1997 Feb; 25(2):234–41; discussion 241–3

Simultaneous abdominal aortic replacement and thoracic stent–graft placement for multilevel aortic disease. Moon MR, et al. **J Vasc Surg** 1997 Feb;25(2):332–40

Regarding "Endoluminal repair of atypical dissecting aneurysm of descending thoracic aorta and fusiform aneurysm of the abdominal aorta" [letter; comment] Sandmann W. **J Vasc Surg** 1996 Oct;24(4):698–700. Comment on: J Vasc Surg 1995 Aug;22(2):167–72.

Retrograde cerebral perfusion with pharmacological cerebral protection in the repair of aortic arch aneurysm. Yamashita C, et al. **Kobe J Med Sci** 1997 Feb;43(1):25–35

Dissection of an aneurysmic ascending aorta in a child with atresia of the aortic isthmus. Lindinger A, et al. **Pediatr Cardiol** 1997 Mar–Apr;18(2):146–8

New and future approaches for spinal cord protection. Svensson LG. **Semin Thorac Cardiovasc Surg** 1997 Jul; 9(3):206–21 (104 ref.)

Coagulation disturbance in profound hypothermia: the influence of anti–fibrinolytic therapy. Westaby S. **Semin Thorac Cardiovasc Surg** 1997 Jul;9(3):246–56 (62 ref.)

Ascending aortic aneurysm and aortic valve disease: what is the most optimal surgical technique? Yun KL, et al. **Semin Thorac Cardiovasc Surg** 1997 Jul;9(3):233–45 (30 ref.)

Surgical implication of aortic dissection on long–term outcome in Marfan patients. Hayashi J, et al. **Surg Today** 1996;26(12):980–4 (19 ref.)

Extensive replacement of the aorta from the ascending aorta to the supraceliac abdominal aorta during a one–stage operation. Murashita T, et al. **Surg Today** 1997;27(4):368–72

Magnetic resonance imaging in the follow–up of patients after aortic root reconstruction. Lepore V, et al. **Thorac Cardiovasc Surg** 1996 Aug;44(4):188–92

A randomised trial of fibrin sealant in peripheral vascular surgery. Miine AA, et al. **Vox Sang** 1996;70(4):210–2

[Causes of failure in surgical treatment of acute dissection of the ascending aorta (type A)] Hejnal J, et al. **Vnitr Lek** 1996 Aug;42(8):524–7 (Eng. Abstr.) **(Cze)**

[Early results in the surgical treatment of type B aortic dissection] Genoni M, et al. **Schweiz Med Wochenschr** 1997 Feb 8;127(6):208–13 (Eng. Abstr.) **(Ger)**

[Acute type A dissection of the ascending aorta after aortocoronary bypass operation] Staubach P, et al. **Z Kardiol** 1996 Sep;85(9):668–72 (Eng. Abstr.) **(Ger)**

[Diagnostic techniques useful to surgical treatment] Monaca V, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):595–7 **(Ita)**

[Surgery of the ascending aorta: the 1984–1995 experience of the cardiac surgery teaching unit in the University of Milan. Multivariate analysis of its risk factors for hospital mortality and reduced long–term survival] Spirito R, et al. **G Ital Cardiol** 1997 Aug;27(8):775–85 (Eng. Abstr.) **(Ita)**

[Spinal cord protection in surgery of the thoracic, descending, and thoraco–abdominal aorta. Comparison of methods] Zanetti PP, et al. **Minerva Chir** 1996 Sep; 51(9):681–9 (Eng. Abstr.) **(Ita)**

[Surgically treated unruptured sinus of Valsalva aneurysm: a case report] Fukui T, et al. **J Cardiol** 1997;29 Suppl 2:67–71 (Eng. Abstr.) **(Jpn)**

[Surgery for acute type A aortic dissection associated with Marfan syndrome] Furukawa K, et al. **Kyobu Geka** 1996 Jul;49(7):548–51 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of aortic valve endocarditis associated with aortic root aneurysm and abscess] Kamata S, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):612–6 (Eng. Abstr.) **(Jpn)**

[Surgical treatment for recrudescent Stanford type A early closing dissection] Kuwabara M, et al. **Kyobu Geka** 1996 Jul;49(7):575–8 (Eng. Abstr.) **(Jpn)**

[A case report of type A dissection of the aorta presenting as a superior vena cava syndrome 10 years after aortic valve

replacement] Murai N, et al. **Kyobu Geka** 1997 Feb; 50(2):146–9 (Eng. Abstr.) **(Jpn)**

[A case of redo operation for ascending aortic aneurysm after modified Bentall operation for Marfan syndrome associated with type A acute dissecting aortic aneurysm] Murashita T, et al. **Kyobu Geka** 1996 Jul;49(7):579–82 (Eng. Abstr.) **(Jpn)**

[A case report of sudden death after Bentall's operation (Piehler's modification) due to left coronary occlusion] Nonoyama M, et al. **Kyobu Geka** 1997 Jul;50(7):569–72 (Eng. Abstr.) **(Jpn)**

[Constrictive pericarditis with dissecting aortic aneurysm (DeBakey type II)] Nosaka S, et al. **Kyobu Geka** 1996 Aug; 49(9):759–61 (Eng. Abstr.) **(Jpn)**

[A case of ruptured sinus of Valsalva aneurysm with bicuspid aortic valve] Ohkado A, et al. **Kyobu Geka** 1996 Jul; 49(7):567–9 (Eng. Abstr.) **(Jpn)**

[A case of successful surgical treatment of recurrent Stanford type A thrombosed aortic dissection] Sakurada T, et al. **Kyobu Geka** 1997 Mar;50(3):223–5 (Eng. Abstr.) **(Jpn)**

[Ascending aortic aneurysms operated through redo median sternotomy under selective cerebral perfusion] Yamazaki Y, et al. **Kyobu Geka** 1997 Mar;50(3):190–3 (Eng. Abstr.) **(Jpn)**

[Recent progress in adjunctive methods during surgery of aortic dissection] Takamoto S.
Nippon Geka Gakkai Zasshi 1996 Oct;97(10):894–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical outcome of aortic arch aneurysm in the institutes registered with Tokai Cardiovascular Surgeons Conference] Fuwa S, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Aug;44(8):1082–8 (Eng. Abstr.) **(Jpn)**

[A successful surgical case report of acute aortic dissection involving entire sinus of Valsalva] Jung E, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Jun;45(6):913–8 (Eng. Abstr.) **(Jpn)**

[An alternative technique for coronary reattachment in aortic root replacement—the "shell" button technique] Katsumata T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep; 44(9):1759–62 (Eng. Abstr.) **(Jpn)**

[A case of extracardiac noncoronary sinus Valsalva aneurysm associated with aortic regugitation] Kochi K, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Jan;45(1):84–7 (Eng. Abstr.) **(Jpn)**

[Two cases of annulo-aortic ectasia with type A aortic dissection reconstructed by reimplantation of the aortic valve] Konishi T, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Apr;45(4):611–4 (Eng. Abstr.) **(Jpn)**

[Surgical repair of a dissecting aortic aneurysm with entry at proximal descending aorta through left thoracotomy—a case report] Mitsumaru A, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Aug;44(8):1163–7 (Eng. Abstr.) **(Jpn)**

[Surgery for acute aortic dissection extending to the aortic root using gelatine-resorcine-formol biological glue--a case report] Uchida K, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Jul;45(7):1024–7 (Eng. Abstr.) **(Jpn)**

[Successful surgical treatment for distal arch aneurysm involving an aberrant right subclavian artery] Wakiyama H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug; 44(8):1155–8 (Eng. Abstr.) **(Jpn)**

[Two cases of ruptured aneurysm of sinus of Valsalva into right atrium (Konno's type IV)] Suesada H, et al.
Rinsho Kyobu Geka 1989 Jun;9(3):291–6 (Eng. Abstr.) **(Jpn)**

[Surgical experience in patients with Marfan's syndrome and cardiovascular disease] Tabayashi K, et al.
Rinsho Kyobu Geka 1989 Jun;9(3):283–7 (Eng. Abstr.) **(Jpn)**

[New coronary tube for Cabrol's technique] Yokoyama M, et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):160–2 (Eng. Abstr.) **(Jpn)**

[Immediate and late results of the surgical treatment of the aneurysms and dissections of the ascending aorta] Couto WJ, et al. **Arq Bras Cardiol** 1996 Jun;66(6):349–52 (Eng. Abstr.) **(Por)**

[A case of in vivo diagnosis of compound aortic aneurysm successfully treated surgically] Volkov GG, et al.
Klin Med (Mosk) 1996;74(3):61–2 **(Rus)**

[Aortic valve prosthesis and the plication of a dissecting aneurysm of the ascending aorta in a patient with infectious endocarditis against a background of chronic kidney failure and its management by regular hemodialysis] Uglov FG, et al. **Vestn Khir Im I I Grek** 1996;155(2):9–14 (28 ref.) (Eng. Abstr.) **(Rus)**

[Surgery of type A acute aortic dissection. Past, present and future] Canestri A, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:77–84 (Eng. Abstr.) **(Spa)**

THERAPY

Impact of retrograde cerebral perfusion on ascending aortic and arch aneurysm repair. Safi HJ, et al.
Ann Thorac Surg 1997 Jun;63(6):1601–7

[Intravascular ultrasound for monitoring percutaneous fenestration of a membrane from an aortic dissection] Görge G, et al. **Dtsch Med Wochenschr** 1996 Dec 20; 121(51–52):1598–602 (Eng. Abstr.) **(Ger)**

[Interventional coronary revascularization in a patient with chronic dissection of the ascending aorta] von Kodolitsch Y, et al. **Z Kardiol** 1996 Sep;85(9):673–6 (Eng. Abstr.) **(Ger)**

[Retrograde aortic dissection during cardiopulmonary bypass a case report successfully treated by contralateral femoral cannulation] Saito T, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Oct;44(10):1953–7 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

The aorta. Aortic aneurysm, trauma, and dissection. Erbel R, et al. **Crit Care Clin** 1996 Jul;12(3):733–66 (135 ref.)

Pathologic correlates of aortic plaques, thrombi and mobile "aortic debris" imaged in vivo with transesophageal echocardiography. Vaduganathan P, et al.
J Am Coll Cardiol 1997 Aug;30(2):357–63

Spectrum of acute dissection of the ascending aorta: a transesophageal echocardiographic study. Armstrong WF, et al. **J Am Soc Echocardiogr** 1996 Sep–Oct;9(5):646–56

Transesophageal echocardiographic detection of complications after Cabrol's procedure. Davis G, et al.
J Am Soc Echocardiogr 1997 May;10(4):375–6

Echocardiographic diagnosis of right and left sinus of Valsalva aneurysms dissecting into the ventricular septum. Silance PG, et al. **J Am Soc Echocardiogr** 1996 Mar–Apr; 9(2):190–4 (12 ref.)

Spontaneous echocardiographic contrast within an unruptured sinus of Valsalva aneurysm: a potential embolic source diagnosed by transesophageal echocardiography. Steinberg E, et al. **J Am Soc Echocardiogr** 1996 Nov–Dec; 9(6):880–1

Intraoperative usefulness of transesophageal echocardiography: detection of unsuspected rupture of an aneurysm of the sinus of Valsalva. Lobato EB, et al.
J Cardiothorac Vasc Anesth 1997 Aug;11(5):619–21

The role of echocardiography in the diagnosis of aortic dissection. Treasure T, et al. **J Heart Valve Dis** 1996 Nov; 5(6):623–9 (13 ref.)

The dissected aorta: part II. Differentiation of the true from the false lumen with intravascular US. Lee DY, et al.
Radiology 1997 Apr;203(1):32–6

The dissected aorta: part I. Early anatomic changes in an in vitro model. Williams DM, et al. **Radiology** 1997 Apr; 203(1):23–31

[Transesophageal and intravascular echocardiographic imaging in aortic dissection] Memmola C, et al.
Cardiologia 1995 Dec;40(12 Suppl 1):575–8 **(Ita)**

[Recent progress in adjunctive methods during surgery of aortic dissection] Takamoto S.
Nippon Geka Gakkai Zasshi 1996 Oct;97(10):894–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[The echocardiographic diagnosis of a rare complication of an aneurysm of the sinus of Valsalva] Cabral S, et al.
Rev Port Cardiol 1997 Apr;16(4):393–6, 352 (11 ref.) (Eng. Abstr.) **(Por)**

[Echocardiography and aortic dissection] Vilacosta I, et al.
Rev Esp Cardiol 1996;49 Suppl 4:13–26 (82 ref.) (Eng. Abstr.) **(Spa)**

AORTIC ANEURYSM, ABDOMINAL

Inflammatory abdominal aortic aneurysms. Mauro MA.
Abdom Imaging 1997 May–Jun;22(3):357–8

The Abdominal Aorta Aneurysm: Genetics, Pathophysiology, and Molecular Biology. Proceedings of a conference. New York City, March 79, 1996.
Ann N Y Acad Sci 1996 Nov 18;800:1–300

Inflammatory aortic aneurysms. A clinical review with new perspectives in pathogenesis. Rasmussen TE, et al.
Ann Surg 1997 Feb;225(2):155–64 (72 ref.)

Influence of hypercholesterolemia and adventitial inflammation on the development of aortic aneurysm in rabbits. Freestone T, et al.
Arterioscler Thromb Vasc Biol 1997 Jan;17(1):10–7

Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem. Thompson RW. **Curr Opin Cardiol** 1996 Sep;11(5):504–18 (113 ref.)

Candida albicans mycotic abdominal aortic aneurysm. Barry MC, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):237–9

Abdominal aortic aneurysms, what's changing? Shealy CB, et al. **J S C Med Assoc** 1997 Jan;93(1):13–6

Clinical analysis of abdominal aortic aneurysms associated with iliofemoral occlusive disease. Sugawara Y, et al.
Jpn Circ J 1997 Jan;61(1):14–8

Abdominal aortic aneurysm [see comments] van der Vliet JA, et al. **Lancet** 1997 Mar 22;349(9055):863–6 (31 ref.). Comment in: Lancet 1997 Jun 7;349(9066):1699.

Management of renal artery stenosis in conjunction with aortic aneurysm. Ballard JL. **Semin Vasc Surg** 1996 Sep; 9(3):221–30 (57 ref.)

[Thrombosed type aortic dissection] Matsuo H.
Ryoikibetsu Shokogun Shirizu 1996;(14):341–4 (16 ref.) **(Jpn)**

[Chronic contained rupture of abdominal aortic aneurysm] Murashita T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (14):348–50 (17 ref.) **(Jpn)**

[Spontaneous perforation of the atherosclerotic aorta] Origuchi N, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (14):399–402 (22 ref.) **(Jpn)**

[Vasculo-Behçet's disease] Yasuda K, et al.
Ryoikibetsu Shokogun Shirizu 1996;(14):338–40 (16 ref.) **(Jpn)**

BLOOD

Decrease of plasma vitamin E (alpha-tocopherol) levels in patients with abdominal aortic aneurysm. Sakalihasan N, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:278–82

Haemostatic factors, atherosclerosis and risk of abdominal aortic aneurysm. Lee AJ, et al.
Blood Coagul Fibrinolysis 1996 Oct;7(7):695–701

Plasma factors augment neutrophil and endothelial cell activation during aortic surgery. Barry MC, et al.
Eur J Vasc Endovasc Surg 1997 Apr;13(4):381–7

Changes in platelet count, coagulation and fibrinogen associated with elective repair of asymptomatic abdominal aortic aneurysm and aortic reconstruction for occlusive disease. Bradbury A, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):375–80

Serum-elastin-peptides as a predictor of expansion of small abdominal aortic aneurysms. Lindholt JS, et al.
Eur J Vasc Endovasc Surg 1997 Jul;14(1):12–6

Aminoterminal propeptide of type III procollagen in the follow-up of patients with abdominal aortic aneurysms. Satta J, et al. **J Vasc Surg** 1997 May;25(5):909–15

CEREBROSPINAL FLUID

Cerebral spinal fluid drainage and distal aortic perfusion decrease the incidence of neurological deficit: the results of 343 descending and thoracoabdominal aortic aneurysm repairs. Safi HJ, et al. **Eur J Vasc Endovasc Surg** 1997 Aug; 14(2):118–24

CHEMICALLY INDUCED

Formation and growth of aortic aneurysms induced by adventitial elastolysis. White JV, et al.
Ann N Y Acad Sci 1996 Nov 18;800:97–120 (14 ref.)

COMPLICATIONS

Infected abdominal aortic aneurysm associated with a psoas abscess, aorto-duodenal and sigmoid fistulas. Case report and review of the literature. Louagie YA, et al.
Acta Chir Belg 1997 Jan–Feb;97(1):39–43 (22 ref.)

Abdominal wall hernias with abdominal aortic aneurysmal versus aortoiliac occlusive disease [letter; comment] La Morte WW, et al. **Am J Surg** 1997 May;173(5):457–8. Comment on: Am J Surg 1995 Dec;170(6):572–5; discussion 575–6.

Clinical, electrocardiographic, and echocardiographic features in patients with asymptomatic aortic abdominal aneurysm. Bolognesi R, et al. **Angiology** 1996 Dec; 47(12):1139–44

A case of Behçet's disease with an abdominal aortic aneurysm and two aneurysms in the common carotid artery. A case report. Tuzuner A, et al. **Angiology** 1996 Dec; 47(12):1173–80

Variables that affect the expansion rate and rupture of abdominal aortic aneurysms. Cronenwett JL.
Ann N Y Acad Sci 1996 Nov 18;800:56–67 (31 ref.)

Neovascularization in the abdominal aortic aneurysm. Endothelial nitric oxide synthase, nitric oxide, and elastolysis. Paik D, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:277

Thoracoabdominal fenestration for aortic dissection with ischemic colonic perforation. Howell JF, et al.
Ann Thorac Surg 1997 Jul;64(1):242–4

Aortic aneurysm-induced disseminated intravascular coagulation. Aboulafia DM, et al. **Ann Vasc Surg** 1996 Jul; 10(4):396–405 (34 ref.)

Combined renal artery stenosis and aortic aneurysm: treatment options. Ballard JL, et al. **Ann Vasc Surg** 1996 Jul;10(4):361–4

Aortocaval fistula associated with abdominal aortic aneurysm: a diagnostic challenge. Bednarkiewicz M, et al. **Ann Vasc Surg** 1997 Sep;11(5):464–6

Sarcoma arising from an abdominal aortic aneurysm. Compagnoni G, et al. **Ann Vasc Surg** 1997 Mar;11(2):183–5

Infrarenal abdominal aortic aneurysm repair: detection and treatment of associated carotid and coronary lesions. Deville C, et al. **Ann Vasc Surg** 1997 Sep;11(5):467–72

Juxtarenal aortic aneurysm associated with a horseshoe kidney. Transfemoral endoluminal repair. Ferko A, et al.
Arch Surg 1997 Mar;132(3):316–7

Problems of abdominal aortic aneurysm associated with horseshoe kidney. Artioukh DY, et al.
Eur J Vasc Endovasc Surg 1997 Jul;14(1):75–8 (12 ref.)

Infrainguinal saphenous vein graft aneurysm and aortic aneurysm. Casha A, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):380–2

Abdominal aortic aneurysm with lumbar vertebral erosion in Behçet's disease. A case report and review of the literature. Roeyen G, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):242–6 (40 ref.)

Inferior vena cava thrombosis, aortocaval fistula and aortic aneurysm: a unique combination. van Keulen CJ, et al.
Eur J Vasc Endovasc Surg 1996 Nov;12(4):501–2

Cholesterol embolisation. A lethal complication of instrumentation of an aneurysmal aorta: a case report. Geroulakos G, et al. **Int Angiol** 1997 Mar;16(1):69–71 (17 ref.)

Atherosclerotic abdominal aorta saccular protrusion. Iwai T, et al. **Int Surg** 1996 Apr–Jun;81(2):189–94

Hematuria associated with ruptured abdominal aortic aneurysms. Pomper SR, et al. **Int Surg** 1995 Jul–Sep;

80(3):261–3
Risk factors and incidence of coronary artery lesions in patients with abdominal aortic aneurysms. Kishi K, et al. **Intern Med** 1997 Jun;36(6):384–8
Chest wall infarction following bilateral internal mammary to coronary arterial bypass in a patient with a thoracoabdominal aneurysm. Keyser EJ, et al. **J Card Surg** 1997 Mar–Apr;12(2):126–9
Aortocaval fistula in ruptured inflammatory abdominal aortic aneurysm. A report of two cases and literature review. Farid A, et al. **J Cardiovasc Surg (Torino)** 1996 Dec; 37(6):561–5 (24 ref.)
Ruptured aortic pseudo-aneurysm: a rare presentation as aortocaval fistula. Pagni S, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):165–8
Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. Blasi F, et al. **J Clin Microbiol** 1996 Nov;34(11):2766–9
Spontaneous rupture of abdominal aortic aneurysms in patients with non-related blunt traumatic injuries. Carrillo EH, et al. **J Ky Med Assoc** 1997 Feb;95(2):64–6
Technical complications of endovascular abdominal aortic aneurysm repair. Naslund TC, et al. **J Vasc Surg** 1997 Sep; 26(3):502–9; discussion 509–10
Abdominal aortic aneurysm [letter; comment] Emmerich J, et al. **Lancet** 1997 Jun 7;349(9066):1699. Comment on: Lancet 1997 Mar 22;349(9055):863–6.
Abdominal aortic aneurysm. A rare cause of destructive lesions of the spine. Vandecandelaere M, et al. **Rev Rhum Engl Ed** 1996 Apr;63(4):296–9
Flexible sigmoidoscopy. A reliable determinant of colonic ischemia following ruptured abdominal aortic aneurysm. Brandt CP, et al. **Surg Endosc** 1997 Feb;11(2):113–5
Risk factors associated with rapid growth of small abdominal aortic aneurysms. Chang JB, et al. **Surgery** 1997 Feb; 121(2):117–22
Aortic aneurysm rupture after extracorporeal shock wave lithotripsy. Lazarides MK, et al. **Surgery** 1997 Jul; 122(1):112–3
Abdominal aortic aneurysm combined with a second intraabdominal non vascular disease—a clinical study and surgical treatment. Dimakakos PB, et al. **Swiss Surg** 1996; 2(5):215–8
Abdominal aortic aneurysm and congenital pelvic kidney. A rare association. Glock Y, et al. **Tex Heart Inst J** 1997; 24(2):131–3 (5 ref.)
Global renal infarction secondary to a dissecting thoracic aneurysm. Frank RG, et al. **Urology** 1996 Dec;48(6):930–1
[Deep venous thrombosis of the right leg caused by compression by an abdominal aortic aneurysm] Schmitz PH, et al. **Ned Tijdschr Geneeskd** 1997 May 24; 141(21):1060–4 (Eng. Abstr.) **(Dut)**
[Extensive pseudotumoral lumbar spine lesions of vascular origin] Husson JL, et al. **Chirurgie** 1996;121(3):223–4 (Eng. Abstr.) **(Fre)**
[Rare complication of developmental aneurysm of the subrenal aorta: pulmonary embolism (letter)] Bernard F, et al. **Presse Med** 1997 Mar 1;26(6):269 **(Fre)**
[Aorto-iliac aneurysms and associated gastrointestinal neoplasms. Treatment problems] Cina G, et al. **Ann Ital Chir** 1996 Jul–Aug;67(4):507–13; discussion 513–4 (Eng. Abstr.) **(Ita)**
[Association of rupture abdominal aneurysm and intestinal infarct] Mattioli A, et al. **Minerva Chir** 1996 Jul–Aug; 51(7–8):597–601 (Eng. Abstr.) **(Ita)**
[A case of one stage operation for primary lung cancer and abdominal aortic aneurysm] Tanaka K, et al. **Kyobu Geka** 1996 Jul;49(7):599–601 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Diagnosis and treatment of abdominal aortic aneurysms. Santilli JD, et al. **Am Fam Physician** 1997 Sep 15; 56(4):1081–90 (37 ref.)
Ruptured abdominal aortic aneurysm masquerading as testicular pain [letter] Crausman RS, et al. **Am J Emerg Med** 1997 Jul;15(4):445
Abdominal aortic aneurysm screening in elderly males with atherosclerosis: the value of physical exam. Arnell TD, et al. **Am Surg** 1996 Oct;62(10):861–4
The case against a national screening programme for aortic aneurysms [letter] Shiralkar S, et al. **Ann R Coll Surg Engl** 1997 Sep;79(5):385–6
Rupture of the perivisceral aorta: atherosclerotic versus mycotic aneurysm. Quiñones-Baldrich WJ, et al. **Ann Vasc Surg** 1997 Jul;11(4):331–41
Infected aneurysms of the infrarenal abdominal aorta: diagnostic criteria and therapeutic strategy. Sessa C, et al. **Ann Vasc Surg** 1997 Sep;11(5):453–63
Abdominal aortic aneurysms. The old and the new. Myers K, et al. **Aust Fam Physician** 1997 Apr;26(4):418–21, 423, 425 (16 ref.)
Follow-up of aortic dissection: contribution of MR angiography for evaluation of the abdominal aorta and its branches. Bogaert J, et al. **Eur Radiol** 1997;7(5):695–702
Abdominal aortic aneurysm presenting as meralgia paraesthetica. Brett A, et al. **J Accid Emerg Med** 1997 Jan; 14(1):49–51
Abdominal aortic aneurysms and autosomal dominant polycystic kidney disease. Torra R, et al. **J Am Soc Nephrol** 1996 Nov;7(11):2483–6
Suitability of abdominal aortic aneurysms for endovascular repair: it's not the size....[comment] Allen RC, et al. **J Endovasc Surg** 1997 Aug;4(3):284–5. Comment on: J Endovasc Surg 1997 Aug;4(3):279–83.
Imaging modalities for aortic endografting. Beebe HG. **J Endovasc Surg** 1997 May;4(2):111–23 (28 ref.)
Immediate postgadolinium spoiled gradient-echo MRI for evaluating the abdominal aorta in the setting of abdominal MR examination. Kelekis NL, et al. **J Magn Reson Imaging** 1997 Jul–Aug;7(4):652–6
Mycotic aneurysm of the aorta: MRI and MRA features. Walsh DW, et al. **J Magn Reson Imaging** 1997 Mar–Apr; 7(2):312–5
Comparison of magnetic resonance imaging measurements of abdominal aortic aneurysms with measurements obtained by other imaging techniques and intraoperative measurements: possible implications for endovascular grafting. Fox AD, et al. **J Vasc Surg** 1996 Oct;24(4):632–8
A novel case of pediatric abdominal aortic aneurysm with visceral arterial stenoses. Kim LJ, et al. **J Vasc Surg** 1997 Apr;25(4):778–83
Unsuspected abdominal aortic aneurysm. Coy J, et al. **Mil Med** 1997 Jun;162(6):441–3
Vascular complications in lumbar disk surgery: report of four cases. Szolar DH, et al. **Neuroradiology** 1996 Aug; 38(6):521–5
Case of the season. Infected false aneurysm of the aorta with aorto-enteric fistula. Kew J, et al. **Semin Roentgenol** 1996 Jul;31(3):182–4
[Should the population be screened for abdominal aortic aneurysm? (editorial)] Schroeder TV. **Ugeskr Laeger** 1997 Mar 24;159(13):1907 **(Dan)**
[Left-sided flank pain in coincident infrarenal aortic aneurysm and left-sided nephropathy] Scherf FG, et al. **Urologe A** 1996 Jul;35(4):342–4 (Eng. Abstr.) **(Ger)**
[Aortitis and development of an aneurysm after PTA of distal aortic stenosis] Raschke R, et al. **Vasa** 1996;25(3):287–91 (Eng. Abstr.) **(Ger)**
[Clinical suspicion and instrumental diagnosis of ruptured aneurysm of the abdominal aorta. Analysis of our experience] Rubini P, et al. **Minerva Chir** 1996 Apr; 51(4):195–201 (Eng. Abstr.) **(Ita)**
[Localized abdominal aortic dissection] Iino M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):411–4 (14 ref.) **(Jpn)**

DRUG THERAPY

Suppression of experimental aneurysmal degeneration with chemically modified tetracycline derivatives. Petrinec D, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:263–5
Design of a trial to evaluate the effect of propranolol upon abdominal aortic aneurysm expansion. Ricci MA, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:252–3

ECONOMICS

Physician work effort and reimbursement for ruptured abdominal aortic aneurysms. Morehouse DL, et al. **Am J Surg** 1997 Aug;174(2):136–9
A modern series of ruptured infrarenal aortic aneurysms. Improved survival at a cost. Ascer E, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:231–3
Resource use and costs of elective surgery for asymptomatic abdominal aortic aneurysm. Jepson RG, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):143–8
Utility of clinical pathway and prospective case management to achieve cost and hospital stay reduction for aortic aneurysm surgery at a tertiary care hospital. Muluk SC, et al. **J Vasc Surg** 1997 Jan;25(1):84–93

ENZYMOLOGY

Aneurysmal smooth muscle cells exhibit increased matrix metalloproteinase-2 production in vitro. Crowther M, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:283–5
Role of serine proteases in aneurysm development. Rao SK, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:131–7 (35 ref.)
Role of matrix metalloproteinases in abdominal aortic aneurysms. Thompson RW, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:157–74 (93 ref.)
Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta. Shireman PK, et al. **J Vasc Surg** 1997 Jan;25(1):157–64

EPIDEMIOLOGY

Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Lederle FA, et al. **Ann Intern Med** 1997 Mar 15; 126(6):441–9
Incidence and prevalence of abdominal aortic aneurysms, estimated by necropsy studies and population screening by ultrasound. Bengtsson H, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:1–24 (144 ref.)
Incidence of cancer and abdominal aortic aneurysms. A logistic regression analysis. Chan EL, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:68–73
The Oxford Screening Program for aortic aneurysm and screening first-order male siblings of probands with abdominal aortic aneurysm. Collin J. **Ann N Y Acad Sci** 1996 Nov 18;800:36–43 (29 ref.)
Smoking as a risk factor for abdominal aortic aneurysm. Powell JT, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:246–8
Aortic aneurysmal disease in women. Is there a greater incidence of suprarenal involvement? Silane MF, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:256–7
Selective screening for abdominal aortic aneurysm. Cole CW, et al. **Chronic Dis Can** 1996 Spring;17(2):51–5
Increasing incidence of aneurysms of the abdominal aorta in The Netherlands. Reitsma JB, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):446–51
Co-morbidity in patients with abdominal aortic aneurysm. Kanagasabay R, et al. **J Med Screen** 1996;3(4):208–10
Prevalence of abdominal aortic aneurysms in men with diabetes [see comments] Mattes E, et al. **Med J Aust** 1997 Jun 16;166(12):630–3. Comment in: Med J Aust 1997 Jun 16;166(12):619–20.

ETHNOLOGY

Relationship of cardiovascular risk factors to racial differences in femoral bypass surgery and abdominal aortic aneurysmectomy in Massachusetts. LaMorte WW, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:25–35 (27 ref.)

ETIOLOGY

Infected abdominal aortic aneurysm caused by spinal brucellar infection [letter] Yee N, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):1068–9
Prevalence of abdominal aortic aneurysm in a hypertensive population. Williams IM, et al. **Ann R Coll Surg Engl** 1996 Nov;78(6):501–4
Persistent cauda equina syndrome following bilateral aortoiliac dissection as a complication of cardiac angiography. Verneuil A, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):377–9
Abdominal aortic aneurysms [editorial; comment] Bergqvist D. **Eur Heart J** 1997 Apr;18(4):545–6. Comment on: Eur Heart J 1997 Apr;18(4):671–6.
Smoking, atherosclerosis and risk of abdominal aortic aneurysm [see comments] Lee AJ, et al. **Eur Heart J** 1997 Apr;18(4):671–6. Comment in: Eur Heart J 1997 Apr;18(4):545–6.
Pathogenesis of abdominal aortic aneurysms—cellular and biochemical mechanisms. Wills A, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):391–400 (111 ref.)
Infected abdominal aortic aneurysm due to penicillin-, ceftriaxone-, and cefotaxime-resistant Streptococcus pneumoniae. Albrecht WE, et al. **J Clin Microbiol** 1997 Apr;35(4):985–7
Can the infusion of elastase in the abdominal aorta of the Yucatán miniature swine consistently produce experimental aneurysms? Marinov GR, et al. **J Invest Surg** 1997 May–Jun;10(3):129–50
Aortic dissection after trauma: case report and review of the literature. Rogers FB, et al. **J Trauma** 1996 Nov; 41(5):906–8 (16 ref.)
1997 SCVIR Gary J. Becker Young Investigator Award paper. A transluminally created abdominal aortic aneurysm model. Hallisey MJ. **J Vasc Interv Radiol** 1997 May–Jun; 8(3):305–12
Septic arteritis causing iliac artery rupture and aneurysmal transformation of the distal aorta after iliac artery stent placement. Hoffman AI, et al. **J Vasc Interv Radiol** 1997 Mar–Apr;8(2):215–9
Traumatic abdominal aortic pseudoaneurysm causing biliary obstruction: a case report and review of the literature. Chase CW, et al. **J Vasc Surg** 1997 May;25(5):936–40 (21 ref.)
Upper abdominal aortic injury during spinal surgery. Smythe WR, et al. **J Vasc Surg** 1997 Apr;25(4):774–7
Abdominal aortic aneurysm: a general defect in the vasculature with focal manifestations in the abdominal aorta? Sonesson B, et al. **J Vasc Surg** 1997 Aug;26(2):247–54
Klebsiella pneumoniae-induced mycotic aneurysm of the abdominal aorta complicated by bloody pleural effusion—a case report. Lai CP, et al. **Jpn Circ J** 1996 Sep;60(9):703–6
Inflammatory abdominal aortic aneurysms and atherosclerotic abdominal aortic aneurysms—comparisons of clinical features and long-term results. Sasaki S, et al. **Jpn Circ J** 1997 Mar;61(3):231–5
Seasonal variations in the rupture of abdominal aortic aneurysms. Manfredini R, et al. **Jpn Heart J** 1997 Jan; 38(1):67–72
Mineral-cholesterol concentrations of the aortic aneurysmatic wall. Pawlikowski M, et al. **Pol J Pathol** 1996; 47(4):225–32
Delayed presentation of false abdominal aortic aneurysm following umbilical artery catheterisation. Bapat VN, et al. **Thorac Cardiovasc Surg** 1997 Jun;45(3):154–7
[Inflammatory aortic aneurysm (non-mycotic)] Sasaki S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):318–21 (17 ref.) **(Jpn)**

GENETICS

Multiple defects in type III collagen synthesis are associated with the pathogenesis of abdominal aortic aneurysms. Anderson DW, et al. **Ann N Y Acad Sci** 1996 Nov 18; 800:216–28
Candidate genes for abdominal aortic aneurysms. Kuivaniemi H, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:186–97 (46 ref.)
Abdominal aortic aneurysm with left iliac aneurysm in identical twins. Ricci MA, et al. **Ann N Y Acad Sci** 1996

Nov 18;800:254–5

A genetic basis for autoimmune manifestations in the abdominal aortic aneurysm resides in the MHC class II locus DR-beta-1. Tilson MD, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:208–15

Genetic aspects of abdominal aortic aneurysm. Verloes A, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:44–55 (53 ref.)

The cholesteryl ester transfer protein (CETP) locus as a candidate gene in abdominal aortic aneurysm. Ramsbottom D, et al. **Clin Genet** 1997 Apr;51(4):241–5

Infrarenal aortic dimensions in siblings of patients with infrarenal abdominal aortic aneurysm or aortoiliac occlusive disease. Jaakkola P, et al. **Eur J Surg** 1995 Dec; 161(12):871–5

Familial abdominal aortic aneurysms: screening of 71 families. Jaakkola P, et al. **Eur J Surg** 1996 Aug;162(8):611–7

Molecular cloning of the complementary DNA for an additional member of the family of aortic aneurysm antigenic proteins. Hirose H, et al. **J Vasc Surg** 1997 Aug; 26(2):313–8

Genetic risk factors in inflammatory abdominal aortic aneurysms: polymorphic residue 70 in the HLA-DR B1 gene as a key genetic element. Rasmussen TE, et al. **J Vasc Surg** 1997 Feb;25(2):356–64

[Abdominal aortic aneurysms: contribution of genetics. From atheromatous theory to parietal theory] Cacoub P, et al. **Ann Med Interne (Paris)** 1997;148(1):25–8 (27 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Molecular mimicry in human aortic aneurysmal diseases. Ozsvath KJ, et al. **Ann N Y Acad Sci** 1996 Nov 18; 800:288–93

Cellular components and features of immune response in abdominal aortic aneurysms. Pearce WH, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:175–85 (45 ref.)

Intramucosal acidosis and systemic host responses in abdominal aortic aneurysm surgery. Soong CV, et al. **Crit Care Med** 1997 Sep;25(9):1472–9

Biological responses to endovascular treatment of abdominal aortic aneurysms. Norgren L, et al. **J Endovasc Surg** 1997 May;4(2):169–73 (8 ref.)

Complement activation and subclassification of tissue immunoglobulin G in the abdominal aortic aneurysm. Capella JF, et al. **J Surg Res** 1996 Sep;65(1):31–3

METABOLISM

Biochemistry and molecular regulation of matrix macromolecules in abdominal aortic aneurysms. Ghorpade A, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:138–50 (30 ref.)

Trace elements, atherosclerosis, and abdominal aneurysms. Klevay LM. **Ann N Y Acad Sci** 1996 Nov 18;800:239–42 (31 ref.)

Elastin degradation products induce adventitial angiogenesis in the Anidjar/Dobrin rat aneurysm model. Nackman GB, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:260–2

Identification of uric acid in aortic aneurysms and atherosclerotic artery. Patetsios P, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:243–5

Plasminogen activators in abdominal aortic aneurysmal disease. Reilly JM. **Ann N Y Acad Sci** 1996 Nov 18; 800:151–6 (29 ref.)

Vascular aneurysms: a side-splitting affair [see comments] Weber KT. **Cardiovasc Res** 1996 Feb;31(2):222–3. Comment in: Cardiovasc Res 1997 May;34(2):431–4.

Endovascular abdominal aortic aneurysm repair induces significant alterations in surface adhesion molecule expression on donor white blood cells exposed to patient plasma. Swartbol P, et al. **Eur J Vasc Endovasc Surg** 1997 Jul;14(1):48–59

Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. Holmes DR, et al. **J Vasc Surg** 1997 May;25(5):810–5

Elastin degradation products induce adventitial angiogenesis in the Anidjar/Dobrin rat aneurysm model. Nackman GB, et al. **Surgery** 1997 Jul;122(1):39–44

Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Tamarina NA, et al. **Surgery** 1997 Aug;122(2):264–71; discussion 271–2

MICROBIOLOGY

Immunohistochemical detection of Chlamydia pneumoniae in abdominal aortic aneurysms. Juvonen J, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:236–8

No evidence for the presence of Helicobacter pylori in atherosclerotic plaques in abdominal aortic aneurysm specimens [letter] Blasi F, et al. **Atherosclerosis** 1996 Oct 25;126(2):339–40

Aortic dissection due to Clostridium septicum infection. Monsen T, et al. **Eur J Vasc Endovasc Surg** 1997 May; 13(5):517–8

Evolution of salmonella aortitis towards the formation of abdominal aneurysm. Carreras M, et al. **Eur Radiol** 1997; 7(1):54–6

Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. Blasi F, et al. **J Clin Microbiol** 1996 Nov;34(11):2766–9

Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. Juvonen J, et al. **J Vasc Surg** 1997 Mar;25(3):499–505

[Aortic aneurysms due to Yersinia enterocolitica: three new cases and a review of the literature] Mercié P, et al. **J Mal Vasc** 1996;21(2):68–71 (21 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

How do surgeons' probability estimates of operative mortality compare with a decision analytic model? Timmermans D, et al. **Acta Psychol (Amst)** 1996 Sep; 93(1–3):107–20

Predicting survival from ruptured abdominal aortic aneurysm. Computer modeling with AIM versus clinical judgment. Cloutier L, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:234–5

Long-term survival after elective repair of infrarenal abdominal aortic aneurysm: results of a prospective multicentric study. Association for Academic Research in Vascular Surgery (AURC). Koskas F, et al. **Ann Vasc Surg** 1997 Sep;11(5):473–81

Surgery for ruptured abdominal aortic aneurysm: early and late results of a prospective study by the AURC in 1989. Koskas F, et al. **Ann Vasc Surg** 1997 Jan;11(1):90–9

POSSUM and APACHE II scores do not predict the outcome of ruptured infrarenal aortic aneurysms. Lazarides MK, et al. **Ann Vasc Surg** 1997 Mar;11(2):155–8

Outcome for patients with abdominal aortic aneurysms that are treated non-surgically. Englund R, et al. **Aust N Z J Surg** 1997 May;67(5):260–3

Mortality and experience in abdominal aortic aneurysm treatment: how do they relate? [editorial] Salenius JP. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):81–3 (11 ref.)

Predictors of death in nonruptured and ruptured abdominal aortic aneurysms. Chen JC, et al. **J Vasc Surg** 1996 Oct; 24(4):614–20; discussion 621–3

PATHOLOGY

Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. López-Candales A, et al. **Am J Pathol** 1997 Mar; 150(3):993–1007

Inflammatory aspects of experimental aneurysms. Effect of methylprednisolone and cyclosporine. Dobrin PB, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:74–88

Smooth muscle cell apoptosis and p53 expression in human abdominal aortic aneurysms. Holmes DR, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:286–7

Effects of hypertension and propranolol upon aneurysm expansion in the Anidjar/Dobrin aneurysm model. Ricci MA, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:89–96

Wall strength and stiffness of aneurysmal and nonaneurysmal abdominal aorta. Vorp DA, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:274–6

Analysis of renal artery geometry may assist in the design of new stents for endovascular aortic aneurysm repair. Wijesinghe LD, et al. **Br J Surg** 1997 Jun;84(6):797–9

Vascular aneurysms: a side-splitting affair. Herron GS. **Cardiovasc Res** 1996 Feb;31(2):224–30 (52 ref.)

The anatomy of abdominal aortic aneurysms: implications for sizing of endovascular grafts. Armon MP, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):398–402

Cytokine profiles in abdominal aortic aneurysms [letter; comment] Masood I. **Eur J Vasc Endovasc Surg** 1996 Nov; 12(4):509. Comment on: Eur J Vasc Endovasc Surg 1995 Oct;10(3):289–93.

The ileocolic artery as a separate aortic branch in a patient with an aortic aneurysm. Vahl AC, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):417–8

Expansion rates of abdominal aortic aneurysm: current limitations in evaluation. Wilson KA, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):521–6 (48 ref.)

The influence of shape on the stresses in model abdominal aortic aneurysms. Elger DF, et al. **J Biomech Eng** 1996 Aug;118(3):326–32

Arteriomegaly and inflammatory abdominal aortic aneurysm. Case report. Cavallini M, et al. **J Cardiovasc Surg (Torino)** 1997 Feb;38(1):37–41

Results of autopsy 7 months after successful endoluminal treatment of an infrarenal abdominal aortic aneurysm. McGahan TJ, et al. **J Endovasc Surg** 1995 Nov;2(4):348–55

Cellular content and permeability of intraluminal thrombus in abdominal aortic aneurysm. Adolph R, et al. **J Vasc Surg** 1997 May;25(5):916–26

Morphologic assessment of abdominal aortic aneurysms by spiral computed tomographic scanning. Bayle O, et al. **J Vasc Surg** 1997 Aug;26(2):238–46

Rupture of an abdominal aortic aneurysm causes priming of phagocytic oxidative burst. Lindsay TF, et al. **J Vasc Surg** 1997 Apr;25(4):599–610

Reduction in aortic aneurysm size: early results after endovascular graft placement. EVT Investigators. Matsumura JS, et al. **J Vasc Surg** 1997 Jan;25(1):113–23

[Helicoidal mode scanning of an aortic dissecting aneurysm] Andreassian B, et al. **Ann Cardiol Angeiol (Paris)** 1997 Mar; 46(3):171 **(Fre)**

[Morphology of abdominal aortic aneurysms with reference to endovascular blood vessel prosthesis] Marty B, et al. **Swiss Surg** 1996;2(5):219–22 (Eng. Abstr.) **(Ger)**

[Severe fatal shock after syncope in an old man (clinical conference)] Bar-Dayan Y, et al. **Harefuah** 1996 Nov 1; 131(9):360–2 **(Heb)**

[Three specific forms of aortic dilatation] Homma S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):360–6 (16 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Usefulness of transesophageal echocardiography in detecting changes in flow dynamics responsible for malperfusion phenomena observed during surgery of aortic dissection. Yamada E, et al. **Am J Cardiol** 1997 Apr 15;79(8):1149–52

Ex vivo biomechanical behavior of abdominal aortic aneurysm: assessment using a new mathematical model. Raghavan ML, et al. **Ann Biomed Eng** 1996 Sep–Oct; 24(5):573–82

Aneurysm pressure following endovascular exclusion. Chuter T, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):85–7

Steady flow in an aneurysm model: correlation between fluid dynamics and blood platelet deposition. Bluestein D, et al. **J Biomech Eng** 1996 Aug;118(3):280–6

An experimental model for the acute and chronic evaluation of intra-aneurysmal pressure [see comments] Faries PL, et al. **J Endovasc Surg** 1997 Aug;4(3):290–7. Comment in: J Endovasc Surg 1997 Aug;4(3):298.

Efficacy of transcranial motor-evoked myogenic potentials to detect spinal cord ischemia during operations for thoracoabdominal aneurysms. de Haan P, et al. **J Thorac Cardiovasc Surg** 1997 Jan;113(1):87–100; discussion 100–1

Steady flow in models of abdominal aortic aneurysms. Part I: Investigation of the velocity patterns. Peattie RA, et al. **J Ultrasound Med** 1996 Oct;15(10):679–88

Steady flow in models of abdominal aortic aneurysms. Part II: Wall stresses and their implication for in vivo thrombosis and rupture. Peattie RA, et al. **J Ultrasound Med** 1996 Oct; 15(10):689–96

Abdominal aortic aneurysm: a general defect in the vasculature with focal manifestations in the abdominal aorta? Sonesson B, et al. **J Vasc Surg** 1997 Aug;26(2):247–54

PREVENTION & CONTROL

The case against a national screening programme for aortic aneurysms [see comments] Cheatle TR. **Ann R Coll Surg Engl** 1997 Mar;79(2):90–5 (65 ref.). Comment in: Ann R Coll Surg Engl 1997 Jul;79(4):310.

Improving attendance rates for abdominal aortic aneurysm screening [letter] Gujral S, et al. **Ann R Coll Surg Engl** 1997 Jan;79(1):71

The case against a national screening programme for aortic aneurysms [letter; comment] Heather B, et al. **Ann R Coll Surg Engl** 1997 Jul;79(4):310. Comment on: Ann R Coll Surg Engl 1997 Mar;79(2):90–5.

Mass or high-risk screening for abdominal aortic aneurysm. Lindholt JS, et al. **Br J Surg** 1997 Jan;84(1):40–2

Screening study of abdominal aortic aneurysm in a general population: lipid parameters. Simoni G, et al. **Cardiovasc Surg** 1996 Aug;4(4):445–8

Opportunistic screening for abdominal aortic aneurysm. Derbyshire ND, et al. **J Med Screen** 1994 Oct;1(4):220–2

Prevalence of abdominal aortic aneurysm associated with hypertension in an urban population. Grimshaw GM, et al. **J Med Screen** 1994 Oct;1(4):226–8

Is screening once at age 65 an effective method for detection of abdominal aortic aneurysms? Khoo DE, et al. **J Med Screen** 1994 Oct;1(4):223–5

"Opportunistic" screening [editorial] Law M. **J Med Screen** 1994 Oct;1(4):208

Hospital based screening of 65–73 year old men for abdominal aortic aneurysms in the county of Viborg, Denmark. Lindholt JS, et al. **J Med Screen** 1996;3(1):43–6

Prospects for screening for abdominal aortic aneurysms. Cole CW. **Lancet** 1997 May 24;349(9064):1490–1

Abdominal aortic screening programme [letter] Guest MG, et al. **Lancet** 1997 Jan 18;349(9046):209–10

Aortic aneurysm screening in general practice [letter] Jones HJ, et al. **Lancet** 1996 Nov 9;348(9037):1320

Abdominal aortic aneurysms: who should we be screening? [editorial; comment] Myers KA. **Med J Aust** 1997 Jun 16; 166(12):619–20. Comment on: Med J Aust 1997 Jun 16;166(12):630–3.

The effect of spatial definition on the allocation of clients to screening clinics. Hyndman J, et al. **Soc Sci Med** 1997 Jul;45(2):331–40

[Screening for abdominal aortic aneurysm (see comments)] Lindholt JS, et al. **Ugeskr Laeger** 1997 Mar 24; 159(13):1915–9 (40 ref.) (Eng. Abstr.). Comment in: Ugeskr Laeger 1997 Aug 18;159(34):5108–10. **(Dan)**

[Preliminary results of screening for abdominal aortic aneurysm in the ounty of Viborg] Lindholt JS, et al. **Ugeskr Laeger** 1997 Mar 24;159(13):1920–3 (Eng. Abstr.) **(Dan)**

[Screening for abdominal aortic aneurysm (letter; comment)] Nybo Andersen AM. **Ugeskr Laeger** 1997 Aug 18; 159(34):5108–10. Comment on: Ugeskr Laeger 1997 Mar 24;159(13):1915–9. **(Dan)**

RADIOGRAPHY

Mycotic aneurysm of the abdominal aorta: CT finding in three patients. Parellada JA, et al. **Abdom Imaging** 1997 May–Jun;22(3):321–4

Evolution of the infected abdominal aortic aneurysm: CT observation of early aortitis. Rozenblit A, et al. **Abdom Imaging** 1996 Nov–Dec;21(6):512–4

Helical computed tomography in the assessment of abdominal

aortic pathology. Vicaretti M, et al. **Australas Radiol** 1997 May;41(2):125–31

Pre-operative classification of abdominal aortic aneurysms with spiral CT: the axial source images revisited. Albrecht T, et al. **Clin Radiol** 1997 Sep;52(9):659–65

Complete pre-operative imaging assessment of abdominal aortic aneurysm with spiral CT angiography. Errington ML, et al. **Clin Radiol** 1997 May;52(5):369–77

The efficacy of transfemoral endovascular aneurysm management: a study on size changes of the abdominal aorta during mid-term follow-up. Broeders IA, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):84–90

Importance of plain x-ray in endoluminal aortic graft surveillance. May J, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):202–6

Helical CT for the study of abdominal aortic aneurysms in patients undergoing conventional surgical repair. Simoni G, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):354–8

Abdominal aortic aneurysm and left sided inferior vena cava. A case report. Bastounis E, et al. **Int Angiol** 1995 Sep; 14(3):229–32

Spiral CT angiography in the assessment of abdominal aortic aneurysms after stent grafting: value of maximum intensity projections. Dorffner R, et al. **J Comput Assist Tomogr** 1997 May-Jun;21(3):472–7

Influence of abdominal aortic aneurysm size on the feasibility of endovascular repair [see comments] Armon MP, et al. **J Endovasc Surg** 1997 Aug;4(3):279–83. Comment in: J Endovasc Surg 1997 Aug;4(3):284–5.

Aortic aneurysm morphology for planning endovascular aortic grafts: limitations of conventional imaging methods [see comments] Beebe HG, et al. **J Endovasc Surg** 1995 May;2(2):139–48. Comment in: J Endovasc Surg 1995 May;2(2):149.

Preoperative sizing of grafts for transfemoral endovascular aneurysm management: a prospective comparative study of spiral CT angiography, arteriography, and conventional CT imaging. Broeders IA, et al. **J Endovasc Surg** 1997 Aug; 4(3):252–61

Moving beyond conventional [comment] Chuter TA. **J Endovasc Surg** 1995 May;2(2):149. Comment on: J Endovasc Surg 1995 May;2(2):139–48.

Will contrast aortography become obsolete in the preoperative evaluation of abdominal aortic aneurysm for endovascular exclusion? [editorial; comment] Diethrich EB. **J Endovasc Surg** 1997 Feb;4(1):5–12 (10 ref.). Comment on: J Endovasc Surg 1997 Feb;4(1):39–44.

A prospective study of changes in morphology and dimensions of abdominal aortic aneurysms following endoluminal repair: a preliminary report. May J, et al. **J Endovasc Surg** 1995 Nov;2(4):343–7

Morphometry and classification in abdominal aortic aneurysms: patient selection for endovascular and open surgery [see comments] Schumacher H, et al. **J Endovasc Surg** 1997 Feb;4(1):39–44. Comment in: J Endovasc Surg 1997 Feb;4(1):5–12.

Radiology case of the month. Calcified mass and indistinct retroperitoneal landmarks on abdominal radiograph. Ruptured abdominal aortic aneurysm. Romano CC, et al. **J La State Med Soc** 1997 Aug;149(8):267–8

Computed tomographic angiographic imaging of abdominal aortic aneurysms: implications for transfemoral endovascular aneurysm management. Balm R, et al. **J Vasc Surg** 1997 Aug;26(2):231–7

Morphologic assessment of abdominal aortic aneurysms by spiral computed tomographic scanning. Bayle O, et al. **J Vasc Surg** 1997 Aug;26(2):238–46

Mycotic aneurysm after aortic bifurcation prosthesis. Galema L, et al. **Neth J Med** 1996 Mar;48(3):105–8

Abdominal aortic aneurysm: rupture associated with the high-attenuating crescent sign. Arita T, et al. **Radiology** 1997 Sep;204(3):765–8

[Spiral computerized tomography of acute abdominal aortic aneurysm with optimal 3-D image reconstruction] Holland BR, et al. **Chirurg** 1996 Jan;67(1):44–52 (Eng. Abstr.) **(Ger)**

[Preoperative imaging of aneurysms of the abdominal aorta. Role of CT scan] Simoni G, et al. **Minerva Cardioangiol** 1996 Jun;44(6):275–9 (Eng. Abstr.) **(Ita)**

[The crescent and the periluminal halo: two computer tomography signs of aortic aneurysm with risk of rupture?] Catalano O, et al. **Radiol Med (Torino)** 1997 Apr; 93(4):392–5 (Eng. Abstr.) **(Ita)**

[Inflammatory aneurysm of the abdominal aorta: TC assessment of the postoperative course] Gigoni R, et al. **Radiol Med (Torino)** 1996 Sep;92(3):213–7 (Eng. Abstr.) **(Ita)**

[A case of DeBakey type IIIb acute aortic dissection extending through an atherosclerotic abdominal aortic aneurysm] Iino M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1996 Nov; 56(13):985–7 (Eng. Abstr.) **(Jpn)**

[Acute occlusion of aortic aneurysms] Yasuda K. **Ryoikibetsu Shokogun Shirizu** 1996;(14):395–8 (13 ref.) **(Jpn)**

[Computerized tomography in aortic pathology] Lecumberri Olaverri F, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:27–36 (54 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

A mural thrombus of an infrarenal aortic aneurysm demonstrated as photon deficiency in a radionuclide study. Shih WJ, et al. **Ann Nucl Med** 1996 May;10(2):241–5

Detection of a dissecting aortic aneurysm by renal transplant imaging. Andreas J, et al. **Clin Nucl Med** 1997 Mar; 22(3):182

SURGERY

Hyperosmotic-hyperoncotic solutions during abdominal aortic aneurysm (AAA) resection. Christ F, et al. **Acta Anaesthesiol Scand** 1997 Jan;41(1 Pt 1):62–70

Reduction of ischemia-reperfusion syndrome after abdominal aortic aneurysmectomy by N-acetylcysteine but not mannitol. Kretzschmar M, et al. **Acta Anaesthesiol Scand** 1996 Jul;40(6):657–64

The use of countercurrent heat exchangers diminishes accidental hypothermia during abdominal aortic aneurysm surgery. Muth CM, et al. **Acta Anaesthesiol Scand** 1996 Nov;40(10):1197–202

Spinal cord ischemia--use of spinal-evoked potentials for intraoperative monitoring in thoraco-abdominal aortic aneurysm (TAA) repair. Freye E, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:50–3

The management of patients with ruptured abdominal aortic aneurysms. Perler BA. **Adv Surg** 1996;30:21–38 (99 ref.)

Diagnosis and treatment of abdominal aortic aneurysms. Santilli JD, et al. **Am Fam Physician** 1997 Sep 15; 56(4):1081–90 (37 ref.)

A new generation endovascular graft for repair of abdominal aortic aneurysms. Gorin DR, et al. **Am J Surg** 1997 Mar; 173(3):159–64

Video-assisted, retroperitoneal approach for abdominal aortic aneurysm exclusion. Grune MT, et al. **Am J Surg** 1996 Oct;172(4):363–5

Delayed abdominal closure in the management of ruptured abdominal aortic aneurysms. Oelschlager BK, et al. **Am J Surg** 1997 May;173(5):411–5

A two-layer "telescoping" proximal anastomosis for repair of juxtarenal abdominal aortic aneurysms. Hans SS, et al. **Am Surg** 1997 Sep;63(9):839–41

Abdominal aortic aneurysectomy after kidney transplantation: case report and review of the literature. Ierardi RP, et al. **Am Surg** 1996 Nov;62(11):961–6 (30 ref.)

The effects of epidural anesthesia on the neuroendocrine response to major surgical stress: a randomized prospective trial. Norman JG, et al. **Am Surg** 1997 Jan;63(1):75–80

Current practice in the pre-operative assessment of patients for elective repair of abdominal aortic aneurysm. A survey of UK hospitals. Pullman MD, et al. **Anaesthesia** 1997 Apr; 52(4):367–73

Near-infrared spectroscopy changes during hypothermic circulatory arrest with retrograde cerebral perfusion. Rigg CD, et al. **Anaesthesia** 1997 Apr;52(4):356–9

Changes in cerebrospinal fluid pressure and lactate concentrations during thoracoabdominal aortic aneurysm surgery. Drenger B, et al. **Anesthesiology** 1997 Jan; 86(1):41–7

Reducing cross-clamping duration in aortoiliac reconstruction after renal transplantation. A case report. Albers M, et al. **Angiology** 1996 Dec;47(12):1181–5

Thoracoabdominal aortic aneurysm in an infant treated by thromboexclusion with thoracoabdominal aortic bypass. A case report. Hashimoto R, et al. **Angiology** 1996 Dec; 47(12):1157–62

Infrarenal aortofemoral bypass surgery: risk factors and mortality in 330 patients with abdominal aortic aneurysm or aortoiliac occlusive disease. Jaakkola P, et al. **Ann Chir Gynaecol** 1996;85(1):28–35

Outcome of elective infrarenal abdominal aortic aneurysm repair--an analysis of 174 consecutive patients. Satta J, et al. **Ann Chir Gynaecol** 1996;85(3):231–5

The rupture type determines the outcome for ruptured abdominal aortic aneurysm patients. Satta J, et al. **Ann Chir Gynaecol** 1997;86(1):24–9

The UK Small Aneurysm Trial. Powell JT, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:249–51

Gluteal infarction as a complication of aortofemoral bypass grafting. Ho PR, et al. **Ann Plast Surg** 1996 Dec;37(6):645–9

Impact of previous thoracic aneurysm repair on thoracoabdominal aortic aneurysm management. Coselli JS, et al. **Ann Thorac Surg** 1997 Sep;64(3):639–50

Treatment of aortic dissection and ruptured abdominal aneurysm with coronary bypass. Ghalili KC, et al. **Ann Thorac Surg** 1997 Jan;63(1):223–5

Operation for type B aortic dissection using hypothermic selective cerebral perfusion. Tayama K, et al. **Ann Thorac Surg** 1997 Feb;63(2):535–7

The validity of current vascular imaging methods in the evaluation of aortic anastomotic aneurysms developing after abdominal aortic aneurysm repair. Bastounis E, et al. **Ann Vasc Surg** 1996 Nov;10(6):537–45

Infrarenal abdominal aortic aneurysm repair: detection and treatment of associated carotid and coronary lesions. Deville C, et al. **Ann Vasc Surg** 1997 Sep;11(5):467–72

Successful treatment of early postoperative aortic graft infection by percutaneous catheter drainage. Glickerman DJ, et al. **Ann Vasc Surg** 1996 Sep;10(5):486–9

Single-stage management of abdominal aortic aneurysm and colon carcinoma. Gouny P, et al. **Ann Vasc Surg** 1996 May; 10(3):299–305

Successful treatment of an iatrogenic infrarenal aortic dissection with serial Wallstents. Johnson MS, et al. **Ann Vasc Surg** 1997 May;11(3):295–9

Surgery for ruptured abdominal aortic aneurysm: early and late results of a prospective study by the AURC in 1989. Koskas F, et al. **Ann Vasc Surg** 1997 Jan;11(1):90–9

Long-term survival after elective repair of infrarenal abdominal aortic aneurysm: results of a prospective multicentric study. Association for Academic Research in Vascular Surgery (AURC). Koskas F, et al. **Ann Vasc Surg** 1997 Sep;11(5):473–81

Gerota's fascia flap: an alternative for aortic graft coverage. LaMuraglia GM, et al. **Ann Vasc Surg** 1996 Jul;10(4):405–8

Results of endoluminal grafting of abdominal aortic aneurysms are dependent on aneurysm morphology. May J, et al. **Ann Vasc Surg** 1996 May;10(3):254–61

Infected aneurysms of the infrarenal abdominal aorta: diagnostic criteria and therapeutic strategy. Sessa C, et al. **Ann Vasc Surg** 1997 Sep;11(5):453–63

Juxtarenal aortic aneurysm associated with a horseshoe kidney. Transfemoral endoluminal repair. Ferko A, et al. **Arch Surg** 1997 Mar;132(3):316–7

A new supportive method of aortic aneurysm surgery: centrifugal left heart bypass combined with an oxygenator and a heat exchanger. Aomi S, et al. **Artif Organs** 1996 Jun;20(6):700–3

Our distal aortic perfusion system in descending thoracic and thoracoabdominal aortic aneurysm repairs. Morishita K, et al. **Artif Organs** 1997 Jul;21(7):822–4

Use of percutaneous cardiopulmonary support system with rotary blood pump in graft replacement of the descending thoracic and thoracoabdominal aorta. Watanabe S, et al. **Artif Organs** 1997 Jul;21(7):846–51

A self-expanding bifurcated endovascular graft for abdominal aortic aneurysm repair. An initial study in a canine model. Wilson GJ, et al. **ASAIO J** 1996 Sep-Oct; 42(5):M386–93

Abdominal aortic aneurysms. The old and the new. Myers K, et al. **Aust Fam Physician** 1997 Apr;26(4):418–21, 423, 425 (16 ref.)

'Trash foot' following operations involving the abdominal aorta. Kuhan G, et al. **Aust N Z J Surg** 1997 Jan;67(1):21–4 (14 ref.)

Treatment of abdominal aortic aneurysm disease in the 9th and 10th decades of life. Robinson D, et al. **Aust N Z J Surg** 1997 Sep;67(9):640–2

Endovascular aneurysm repair [editorial] Thompson MM, et al. **BMJ** 1997 Apr 19;314(7088):1139–40

Haemodynamic and metabolic response to endovascular repair of infra-renal aortic aneurysms. Baxendale BR, et al. **Br J Anaesth** 1996 Nov;77(5):581–5

Low-dose dopamine: will there ever be a scientific rationale? [editorial; comment] McCrory C, et al. **Br J Anaesth** 1997 Apr;78(4):350–1. Comment on: Br J Anaesth 1996 Dec;77(6):753–7.

Pictorial review: endovascular repair of abdominal aortic aneurysms. Dyet JF. **Br J Radiol** 1996 Nov;69(827):1069–74 (8 ref.)

Anatomical suitability of abdominal aortic aneurysms for endovascular repair. Armon MP, et al. **Br J Surg** 1997 Feb;84(2):178–80

Morphological classification of abdominal aortic aneurysm in selection of patients for endovascular grafting [letter] Armon MP, et al. **Br J Surg** 1996 Nov;83(11):1654–5

Immunological and physiological responses to aortic surgery: effect of reperfusion on neutrophil and monocyte activation and pulmonary function. Barry MC, et al. **Br J Surg** 1997 Apr;84(4):513–9

Rectus sheath bupivacaine analgesia after aortic surgery [see comments] Curley P, et al. **Br J Surg** 1996 Nov;83(11):1558 . Comment in: Br J Surg 1997 May;84(5):728. Comment in: Br J Surg 1997 Jul;84(7):1033–4.

Endotoxin related early neutrophil activation is associated with outcome after thoracoabdominal aortic aneurysm repair. Foulds S, et al. **Br J Surg** 1997 Feb;84(2):172–7

Surgical blood-ordering schedules for elective aortic aneurysm repair. The Scottish Vascular Audit Group. Milne AA, et al. **Br J Surg** 1997 Mar;84(3):331–2

A 4-year prospective audit of the cause of death after infrarenal aortic aneurysm surgery. Sandison AJ, et al. **Br J Surg** 1996 Oct;83(10):1386–9

Randomized controlled trial of the effect of mannitol on renal reperfusion injury during aortic aneurysm surgery [letter; comment] Tisi PV, et al. **Br J Surg** 1997 Apr;84(4):587. Comment on: Br J Surg 1996 Sep;83(9):1230–3.

Duodenal obstruction following elective abdominal aortic aneurysm repair. Campagnol M, et al. **Cardiovasc Surg** 1996 Dec;4(6):843–5 (8 ref.)

Progress in abdominal aortic aneurysm surgery: four decades of experience at a teaching center. Chen JC, et al. **Cardiovasc Surg** 1997 Apr;5(2):150–6

Surgical treatment of infected thoracic and abdominal aortic aneurysms. Chiba Y, et al. **Cardiovasc Surg** 1996 Aug; 4(4):476–9

Advances in the surgical repair of ruptured abdominal aortic aneurysms. Darling RC 3rd, et al. **Cardiovasc Surg** 1996 Dec;4(6):720–3

Surgical treatment of abdominal aortic aneurysms of octogenarians. Falk V, et al. **Cardiovasc Surg** 1996 Dec; 4(6):727–31

A prospective randomized study of abdominal aortic surgery without postoperative nasogastric decompression. Friedman SG, et al. **Cardiovasc Surg** 1996 Aug;4(4):492–4

'In vivo' size of knitted Dacron prostheses (Gelseal) used in the thoracic aorta: a computed tomography study.

Goossens D, et al. **Cardiovasc Surg** 1996 Apr;4(2):205–6

In situ arterial allografting for aortoiliac graft infection: a 6-year experience. Koskas F, et al. **Cardiovasc Surg** 1996 Aug;4(4):495–9

The Perth endoluminal bifurcated graft system—development and early experience. Lawrence-Brown MM, et al. **Cardiovasc Surg** 1996 Dec; 4(6):706–12

Results of 1000 consecutive elective abdominal aortic aneurysm repairs. Lloyd WE, et al. **Cardiovasc Surg** 1996 Dec;4(6):724–6

Bilateral splenorenal bypass and axillofemoral graft for management of juxtarenal mycotic aneurysm. Marty-Ané C, et al. **Cardiovasc Surg** 1996 Jun;4(3):331–4

Survival and aortic events after graft replacement for thoracoabdominal aortic aneurysm. Schepens MA, et al. **Cardiovasc Surg** 1996 Dec;4(6):713–9

Comparison of transperitoneal and retroperitoneal approaches for infrarenal aortic surgery: early and late results. Sieunarine K, et al. **Cardiovasc Surg** 1997 Feb; 5(1):71–6

Endoluminal pulse oximetry combined with tonometry to monitor the perfusion of the sigmoid during and after resection of abdominal aortic aneurysm. Vahl AC, et al. **Cardiovasc Surg** 1997 Feb;5(1):65–70

Sigmoidal ischaemia after aortic grafting, detected by endoluminal pulse oximetry. Vahl AC, et al. **Cardiovasc Surg** 1996 Jun;4(3):345–50

Embolization of iliac artery aneurysms following abdominal aortic aneurysm repair with a bifurcated graft. McLoughlin RF, et al. **Clin Radiol** 1997 Sep;52(9):680–3

Intramucosal acidosis and systemic host responses in abdominal aortic aneurysm surgery. Soong CV, et al. **Crit Care Med** 1997 Sep;25(9):1472–9

Endovascular stent graft repair of aortic aneurysms. Parodi JC. **Curr Opin Cardiol** 1997 Jul;12(4):396–405

Protection of the spinal cord during surgery of thoraco-abdominal aortic aneurysms. Bachet J, et al. **Eur J Cardiothorac Surg** 1996;10(10):817–25

Repair for aneurysms of the entire descending thoracic aorta or thoracoabdominal aorta using a deep hypothermia. Okita Y, et al. **Eur J Cardiothorac Surg** 1997 Jul;12(1):120–6

Surgery for ruptured thoracic and thoraco-abdominal aortic aneurysms. von Segesser LK, et al. **Eur J Cardiothorac Surg** 1996;10(11):996–1001; discussion 1002

The importance of transesophageal echocardiography during surgery of the thoracic aorta. Aadahl P, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):401–6

Aortic stents [letter; comment] Adiseshiah M. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):423–4. Comment on: Eur J Vasc Endovasc Surg 1996 Oct;12(3):287–94.

The anatomy of abdominal aortic aneurysms: implications for sizing of endovascular grafts. Armon MP, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):398–402

Problems of abdominal aortic aneurysm associated with horseshoe kidney. Artioukh DY, et al. **Eur J Vasc Endovasc Surg** 1997 Jul;14(1):75–8 (12 ref.)

Plasma factors augment neutrophil and endothelial cell activation during aortic surgery. Barry MC, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):381–7

Inflammatory aortic aneurysms: regression of fibrosis after aneurysm surgery. Bitsch M, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):371–4

Risk factors for intestinal ischaemia after aortoiliac surgery: a combined cohort and case-control study of 2824 operations. Björck M, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):531–9

Endovascular repair of an inflammatory aortic aneurysm. Boyle JR, et al. **Eur J Vasc Endovasc Surg** 1997 Mar; 13(3):328–9

Changes in platelet count, coagulation and fibrinogen associated with elective repair of asymptomatic abdominal aortic aneurysm and aortic reconstruction for occlusive disease. Bradbury A, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):375–80

A prototype simulator for endovascular repair of abdominal aortic aneurysms. Chong CK, et al. **Eur J Vasc Endovasc Surg** 1997 Mar;13(3):330–3

Aneurysm pressure following endovascular exclusion. Chuter T, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):85–7

Factors influencing the long-term results of abdominal aortic aneurysm repair. Geroulakos G, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):3–8 (49 ref.)

Surgical strategy of abdominal aortic aneurysm with preoperative renal failure. Komori K, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):105–8

The first 15 months of transluminal abdominal aortic aneurysm management: a single centre experience. Kretschmer G, et al. **Eur J Vasc Endovasc Surg** 1997 Jul; 14(1):24–32

A prospective survey of patients presenting with abdominal aortic aneurysm. Magee TR, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):403–6

Renal arteries covered by aortic stents: clinical experience from endovascular grafting of aortic aneurysms. Malina M, et al. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):109–13

Concurrent comparison of endoluminal repair vs. no treatment for small abdominal aortic aneurysms. May J, et al. **Eur J Vasc Endovasc Surg** 1997 May;13(5):472–6

Conversion from endoluminal to open repair of abdominal aortic aneurysms: a hazardous procedure. May J, et al. **Eur J Vasc Endovasc Surg** 1997 Jul;14(1):4–11

Endovascular repair of residual iliac artery aneurysms following surgery for ruptured abdominal aortic aneurysm. Panayiotopoulos YP, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):482–6

Midline extraperitoneal approach for elective abdominal aortic aneurysm repair. Quick CR, et al. **Eur J Vasc Endovasc Surg** 1997 Jul;14(1):63–8

Mortality and experience in abdominal aortic aneurysm treatment: how do they relate? [editorial] Salenius JP. **Eur J Vasc Endovasc Surg** 1997 Aug;14(2):81–3 (11 ref.)

Fatal colonic ischaemia after stent graft for aortic aneurysm. Sandison AJ, et al. **Eur J Vasc Endovasc Surg** 1997 Feb; 13(2):219–20

Surgical management of 671 abdominal aortic aneurysms: a 13 year review from a single centre. Sayers RD, et al. **Eur J Vasc Endovasc Surg** 1997 Mar;13(3):322–7

Helical CT for the study of abdominal aortic aneurysms in patients undergoing conventional surgical repair. Simoni G, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):354–8

Endovascular abdominal aortic aneurysm repair induces significant alterations in surface adhesion molecule expression on donor white blood cells exposed to patient plasma. Swartbol P, et al. **Eur J Vasc Endovasc Surg** 1997 Jul;14(1):48–59

Haemostasis during infrarenal aortic aneurysm surgery: effect of volume loading and cross-clamping. Vahl AC, et al. **Eur J Vasc Endovasc Surg** 1997 Jan;13(1):60–5

The use of intravascular ultrasound as control procedure for the deployment of endovascular stented grafts. Vogt KC, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):592–6

Juxtarenal aortic aneurysm: endoluminal transfemoral repair? Ferko A, et al. **Eur Radiol** 1997;7(5):703–7

Atherosclerotic abdominal aorta saccular protrusion. Iwai T, et al. **Int Surg** 1996 Apr-Jun;81(2):189–94

Intestinal ischemia after aortic surgery. Porcellini M, et al. **Int Surg** 1996 Apr-Jun;81(2):195–9

Infected abdominal aortic aneurysms. Experience with 14 consecutive cases. Sriussadaporn S. **Int Surg** 1996 Oct-Dec; 81(4):395–9

Diagnosis and management of cerebral malperfusion phenomena during aortic dissection repair by transesophageal Doppler echocardiographic monitoring. Coletti G, et al. **J Card Surg** 1996 Sep-Oct;11(5):355–8

Current status of thoracoabdominal aortic aneurysm repair in Marfan syndrome. Coselli JS, et al. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):167–72

Comparison of lumbar and thoracic epidural narcotics for postoperative analgesia in patients undergoing abdominal aortic aneurysm repair [see comments] Gold MS, et al. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2):137–40. Comment in: J Cardiothorac Vasc Anesth 1997 Apr;11(2):127–8.

Experience with the use of polytetrafluoroethylene pericardial membrane (preclude pericardial membrane) for retroperitoneal closure after abdominal aortic surgery. Abad C. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):283–6

Infected abdominal aortic aneurysm: in situ replacement with cryopreserved arterial homograft. Alonso M, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):371–5

Anomalous inferior vena cava complicating abdominal aortic aneurysmectomy. Bastounis E, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):367–9

Aortoduodenal fistula. Two case reports and a review of the literature. Capaldo GR, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):567–70

Operative results of thoracoabdominal repair for chronic type B aortic dissection. Dudra J, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):147–51

Temporary axillo-femoral bypass graft for renal transplant protection during aortic aneurysm repair. Giulini SM, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):575–8

Ruptured abdominal aortic aneurysm. A ten year experience. Martinez R, et al. **J Cardiovasc Surg (Torino)** 1997 Feb; 38(1):1–6

Postoperative inflammatory reactions to sealed Dracon prostheses: a comparison of Gelseal and Hemashield. Utoh J, et al. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):287–90

Gastric intramucosal pH changes after volume replacement with hydroxyethyl starch or crystalloid in patients undergoing elective abdominal aortic aneurysm repair. Marik PE, et al. **J Crit Care** 1997 Jun;12(2):51–5

Regional anesthesia for endovascular treatment of abdominal aortic aneurysms. Aadahl P, et al. **J Endovasc Surg** 1997 Feb;4(1):56–61

Endoluminal repair of large abdominal aortic aneurysms using PTFE: a feasibility study. Adiseshiah M, et al. **J Endovasc Surg** 1997 Aug;4(3):286–9

What are the characteristics of the ideal endovascular graft for abdominal aortic aneurysm exclusion? Allen RC, et al. **J Endovasc Surg** 1997 May;4(2):195–202 (0 ref.)

Two-center German experience with aortic endografting. Blum U, et al. **J Endovasc Surg** 1997 May;4(2):137–46

Improved respiratory function and analgesia control after endovascular AAA repair. Boyle JR, et al. **J Endovasc Surg** 1997 Feb;4(1):62–5

European experience with a system for bifurcated stent-graft insertion. Chuter TA, et al. **J Endovasc Surg** 1997 Feb; 4(1):13–22

Surgical reconstruction of the iliac arteries prior to endovascular aortic aneurysm repair. Chuter TA, et al. **J Endovasc Surg** 1997 Aug;4(3):307–11

The Italian trial of endovascular AAA exclusion using the Parodi endograft. Coppi G, et al. **J Endovasc Surg** 1997 Aug;4(3):299–306

Evaluation of endovascular abdominal aortic aneurysm repair: anatomical classification, procedural success, clinical assessment, and data collection. Dorros G, et al. **J Endovasc Surg** 1997 May;4(2):203–25 (8 ref.)

Efficacy determination of endovascular AAA exclusion [comment] Haji-Aghaii M, et al. **J Endovasc Surg** 1997 Aug;4(3):298 (2 ref.). Comment on: J Endovasc Surg 1997 Aug;4(3):290–7.

The need for clinical trials of endovascular abdominal aortic aneurysm stent-graft repair: The EUROSTAR Project. EUROpean collaborators on Stent-graft Techniques for abdominal aortic Aneurysm Repair. Harris PL, et al. **J Endovasc Surg** 1997 Feb;4(1):72–7; discussion 78–9 (15 ref.)

Abdominal aortic aneurysms: experience with the Ivancev-Malmö endovascular system for aortomonoiliac stent-grafts. Ivancev K, et al. **J Endovasc Surg** 1997 Aug; 4(3):242–51

Successful endoluminal repair of arterial aneurysms by Wallstent prosthesis and PTFE graft: preliminary results with a new technique. Krajcer Z, et al. **J Endovasc Surg** 1997 Feb;4(1):80–7

Ultrasound imaging during endovascular abdominal aortic aneurysm repair using the Stentor bifurcated endograft. Lie T, et al. **J Endovasc Surg** 1997 Aug;4(3):272–8

Changing aneurysmal morphology after endovascular grafting: relation to leakage or persistent perfusion [see comments] Malina M, et al. **J Endovasc Surg** 1997 Feb; 4(1):23–30. Comment in: J Endovasc Surg 1997 Feb;4(1):31–2.

The ins and outs of the excluded abdominal aortic aneurysm: decreasing diameters and dilating necks [comment] May J. **J Endovasc Surg** 1997 Feb;4(1):31–2 (6 ref.). Comment on: J Endovasc Surg 1997 Feb;4(1):23–30.

Endoluminal repair of abdominal aortic aneurysms: strengths and weaknesses of various prostheses observed in a 4.5-year experience. May J, et al. **J Endovasc Surg** 1997 May; 4(2):147–51

Endoluminal grafting of abdominal aortic aneurysms: causes of failure and their prevention. May J, et al. **J Endovasc Surg** 1994 Sep;1:44–52

Early experience with the Sydney and EVT prostheses for endoluminal treatment of abdominal aortic aneurysms. May J, et al. **J Endovasc Surg** 1995 Aug;2(3):240–7

A prospective study of changes in morphology and dimensions of abdominal aortic aneurysms following endoluminal repair: a preliminary report. May J, et al. **J Endovasc Surg** 1995 Nov;2(4):343–7

The EVT tube and bifurcated endograft systems: technical considerations and clinical summary. EVI Investigators. Moore WS. **J Endovasc Surg** 1997 May;4(2):182–94 (12 ref.)

Biological responses to endovascular treatment of abdominal aortic aneurysms. Norgren L, et al. **J Endovasc Surg** 1997 May;4(2):169–73 (8 ref.)

Endovascular treatment of abdominal aortic aneurysms: lessons learned. Parodi JC, et al. **J Endovasc Surg** 1997 May;4(2):102–10 (20 ref.)

Aortomonoiliac endovascular grafting: difficult solutions to difficult aneurysms. Thompson MM, et al. **J Endovasc Surg** 1997 May;4(2):174–81

Ultrasound-based quantification of emboli during conventional and endovascular aneurysm repair. Thompson MM, et al. **J Endovasc Surg** 1997 Feb;4(1):33–8

Three-year experience with the White-Yu Endovascular GAD Graft for transluminal repair of aortic and iliac aneurysms. White GH, et al. **J Endovasc Surg** 1997 May; 4(2):124–36

Endoleak as a complication of endoluminal grafting of abdominal aortic aneurysms: classification, incidence, diagnosis, and management. White GH, et al. **J Endovasc Surg** 1997 May;4(2):152–68 (20 ref.)

Operative repair for aortic aneurysms: the gold standard. Zarins CK, et al. **J Endovasc Surg** 1997 Aug;4(3):232–41 (57 ref.)

Surgical experience with Salmonella-infected aneurysms of the abdominal aorta. Luo CY, et al. **J Formos Med Assoc** 1997 May;96(5):346–52

Animal model for investigation of spinal cord injury caused by aortic cross-clamping. Qayumi AK, et al. **J Invest Surg** 1997 Jan-Apr;10(1-2):47–52

Retroperitoneal repair of an abdominal aortic aneurysm associated with a horseshoe kidney. Adoumie R, et al. **J Ky Med Assoc** 1997 Apr;95(4):143–4

The retroperitoneal approach for abdominal aortic aneurysms. Laohapensang K, et al. **J Med Assoc Thai** 1997 Aug;80(8):479–85

Abdominal aortic aneurysms in children. Millar AJ, et al. **J Pediatr Surg** 1996 Dec;31(12):1624–8

Looking for the artery of Adamkiewicz: a quest to minimize paraplegia after operations for aneurysms of the descending thoracic and thoracoabdominal aorta. Griepp RB, et al. **J Thorac Cardiovasc Surg** 1996 Nov;112(5):1202–13; discussion 1213–5

Treatment of a failed bifurcated abdominal aortic stent graft with thrombolysis and Wallstent placement. Amesur NB, et al. **J Vasc Interv Radiol** 1997 Sep-Oct;8(5):795–8

Inflammatory aneurysm treated by means of transfemoral endovascular graft insertion. Chuter T, et al. **J Vasc Interv Radiol** 1997 Jan-Feb;8(1 Pt 1):39–41

Embolization of perigraft leaks after endovascular stent-graft treatment of aortic aneurysms. Kato N, et al. **J Vasc Interv Radiol** 1996 Nov-Dec;7(6):805-11

Embolization of backbleeding lumbar arteries filling an aortic aneurysm sac after endovascular stent-graft placement. Khilnani NM, et al. **J Vasc Interv Radiol** 1996 Nov-Dec; 7(6):813-7

Repositioning of a malaligned aortic stent-graft [letter] Maclennan AC, et al. **J Vasc Interv Radiol** 1997 Jan-Feb; 8(1 Pt 1):151-2

Fenestrated stent-grafts for preserving visceral arterial branches in the treatment of abdominal aortic aneurysms: preliminary experience. Park JH, et al. **J Vasc Interv Radiol** 1996 Nov-Dec;7(6):819-23

Use of a stone basket as a target during fenestration of aortic dissection. Trerotola SO. **J Vasc Interv Radiol** 1996 Sep-Oct;7(5):687-90

Reporting standards for infrarenal endovascular abdominal aortic aneurysm repair. Ad Hoc Committee for Standardized Reporting Practices in Vascular Surgery of The Society for Vascular Surgery/International Society for Cardiovascular Surgery. Ahn SS, et al. **J Vasc Surg** 1997 Feb;25(2):405-10

Computed tomographic angiographic imaging of abdominal aortic aneurysms: implications for transfemoral endovascular aneurysm management. Balm R, et al. **J Vasc Surg** 1997 Aug;26(2):231-7

Predictors of death in nonruptured and ruptured abdominal aortic aneurysms. Chen JC, et al. **J Vasc Surg** 1996 Oct; 24(4):614-20; discussion 621-3

Clinical experience with a bifurcated endovascular graft for abdominal aortic aneurysm repair. Chuter TA, et al. **J Vasc Surg** 1996 Oct;24(4):655-66

Is preoperative cardiac evaluation for abdominal aortic aneurysm repair necessary? D'Angelo AJ, et al. **J Vasc Surg** 1997 Jan;25(1):152-6

Coagulation changes during thoracoabdominal aneurysm repair. Gertler JP, et al. **J Vasc Surg** 1996 Dec;24(6):936-43; discussion 943-5

Graft-related complications after abdominal aortic aneurysm repair: reassurance from a 36-year population-based experience. Hallett JW Jr, et al. **J Vasc Surg** 1997 Feb; 25(2):277-84; discussion 285-6

Multiple idiopathic arterial aneurysms in children: a case report and review of the literature. Halpern V, et al. **J Vasc Surg** 1997 May;25(5):949-56 (22 ref.)

Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model. Huber TS, et al. **J Vasc Surg** 1997 Jun;25(6):984-93; discussion 993-4

Primary fibrinolysis during supraceliac aortic clamping. Illig KA, et al. **J Vasc Surg** 1997 Feb;25(2):244-51; discussion 252-4

Fate of the proximal aortic cuff: implications for endovascular aneurysm repair. Illig KA, et al. **J Vasc Surg** 1997 Sep;26(3):492-9; discussion 499-501

Gender differences in abdominal aortic aneurysm prevalence, treatment, and outcome. Katz DJ, et al. **J Vasc Surg** 1997 Mar;25(3):561-8

Treatment for abdominal aortic aneurysm in a patient with hemophilia A: a case report and review of the literature. Kobayashi M, et al. **J Vasc Surg** 1997 May;25(5):945-8 (16 ref.)

Reduction in aortic aneurysm size: early results after endovascular graft placement. EVT Investigators. Matsumura JS, et al. **J Vasc Surg** 1997 Jan;25(1):113-23

Endovascular treatment of infrarenal abdominal aneurysms by the Stentor system: preliminary results of 79 cases. Stentor Retrospective Study Group. Mialhe C, et al. **J Vasc Surg** 1997 Aug;26(2):199-209

Utility of clinical pathway and prospective case management to achieve cost and hospital stay reduction for aortic aneurysm surgery at a tertiary care hospital. Muluk SC, et al. **J Vasc Surg** 1997 Jan;25(1):84-93

A prospective randomized study comparing exclusion technique and endoaneurysmorrhaphy for treatment of infrarenal aortic aneurysm. Paty PS, et al. **J Vasc Surg** 1997 Mar;25(3):442-5

Fate of the excluded abdominal aortic aneurysm sac: long-term follow-up of 831 patients. Resnikoff M, et al. **J Vasc Surg** 1996 Nov;24(5):851-5

Abdominal aortic tailoring for renal, visceral, and lower extremity malperfusion resulting from acute aortic dissection. Webb TH, et al. **J Vasc Surg** 1997 Sep; 26(3):474-80; discussion 480-1

Regression of an abdominal aortic aneurysm after endograft exclusion. White RA, et al. **J Vasc Surg** 1997 Jul; 26(1):133-7

Preliminary clinical outcome and imaging criterion for endovascular prosthesis development in high-risk patients who have aortoiliac and traumatic arterial lesions. White RA, et al. **J Vasc Surg** 1996 Oct;24(4):556-69; discussion 569-71

Evaluation of a modular endovascular bifurcation prosthesis in a canine aortic aneurysm model. White RA, et al. **J Vasc Surg** 1996 Dec;24(6):1034-42

Endovascular grafts for noninfected aortoiliac anastomotic aneurysms. Yuan JG, et al. **J Vasc Surg** 1997 Aug; 26(2):210-21

Early results of endovascular aortic aneurysm surgery with aortouniiliac graft, contralateral iliac occlusion, and femorofemoral bypass. Yusuf SW, et al. **J Vasc Surg** 1997 Jan;25(1):165-72

Surgical results of abdominal aortic aneurysm repair in patients with chronic renal dysfunction. Sugawara Y, et al. **Jpn Circ J** 1997 Sep;61(9):762-6

Surgical treatment of abdominal aortic aneurysms in octogenarians. Sugawara Y, et al. **Jpn Circ J** 1996 Jun; 60(6):328-33

Repair of abdominal aortic aneurysms by the endoluminal method: outcome in the first 100 patients. May J, et al. **Med J Aust** 1996 Nov 18;165(10):549-51

Endoluminal stent-grafts for infrarenal abdominal aortic aneurysms [see comments] Blum U, et al. **N Engl J Med** 1997 Jan 2;336(1):13-20. Comment in: N Engl J Med 1997 Jan 2;336(1):59-60. Comment in: N Engl J Med 1997 Jun 12;336(24):1756; discussion 1757.

Current therapy for infrarenal aortic aneurysms [editorial; comment] [see comments] Ernst CB. **N Engl J Med** 1997 Jan 2;336(1):59-60. Comment on: N Engl J Med 1997 Jan 2;336(1):13-20. Comment in: N Engl J Med 1997 Jan 12;336(24):1756; discussion 1757-8.

Infrarenal aortic aneurysms [letter; comment] Hoch RC. **N Engl J Med** 1997 Jun 12;336(24):1757; discussion 1757-8 . Comment on: N Engl J Med 1997 Jan 2;336(1):59-60.

Infrarenal aortic aneurysms [letter; comment] Matsumura JS, et al. **N Engl J Med** 1997 Jun 12;336(24):1756; discussion 1757. Comment on: N Engl J Med 1997 Jan 2;336(1):13-20.

Infrarenal aortic aneurysms [letter; comment] Yusuf SW, et al. **N Engl J Med** 1997 Jun 12;336(24):1756; discussion 1757-8. Comment on: N Engl J Med 1997 Jan 2;336(1):59-60.

Transfemoral placement of endoluminal grafts to repair abdominal aortic aneurysms [letter] Choong CK, et al. **N Z Med J** 1996 Sep 27;109(1030):368

Nifedipine can preserve renal function in patients undergoing aortic surgery with infrarenal crossclamping. Antonucci F, et al. **Nephron** 1996;74(4):668-73

The surgical treatment of vascular and gastrointestinal implications in Behçet disease. Report of four cases. Testini M, et al. **Panminerva Med** 1996 Sep;38(3):185-9

Treatment of abdominal aortic aneurysms with transfemoral placement of stent-grafts: complications and secondary radiologic intervention. Dorffner R, et al. **Radiology** 1997 Jul;204(1):79-86

Aortic reconstruction and concomitant renal artery revascularization using the retroperitoneal approach: techniques and results. Darling RC 3rd, et al. **Semin Vasc Surg** 1996 Sep;9(3):231-5

Abdominal aortic aneurysms. Katz DJ, et al. **Semin Vasc Surg** 1995 Dec;8(4):289-98 (42 ref.)

Mesenteric revascularization during aneurysmectomy. Donaldson MC, et al. **Surg Clin North Am** 1997 Apr; 77(2):443-59 (51 ref.)

Laparoscopically assisted abdominal aortic aneurysm repair. A report of 10 cases. Chen MHM, et al. **Surg Endosc** 1996 Dec;10(12):1136-9

Experimental laparoscopic aortic aneurysm resection and aortobifemoral bypass. Dion YM, et al. **Surg Laparosc Endosc** 1996 Jun;6(3):184-90

Utilization of a mass-infusion system in the management of ruptured abdominal aortic aneurysms: an alternative application for devices employed in cardiopulmonary bypass. Katsumata T, et al. **Surg Today** 1996;26(10):852-3

The retroperitoneal approach to aortoiliac surgery associated with a horseshoe kidney: report of a case. Moriyasu K, et al. **Surg Today** 1996;26(8):655-7

Two types of major venous anomalies associated with abdominal aneurysmectomy: a report of two cases. Nonami Y, et al. **Surg Today** 1996;26(11):940-4

Antiperistaltic transverse colostomy for massive bowel necrosis following surgery for an abdominal aortic aneurysm: report of a case. Yagi T, et al. **Surg Today** 1997; 27(6):554-8

Abdominal aortic aneurysm combined with a second intraabdominal non vascular disease--a clinical study and surgical treatment. Dimakakos PB, et al. **Swiss Surg** 1996; 2(5):215-8

Spinal cord protection in descending and thoracoabdominal aortic surgery--the role of distal perfusion. Bonatti J, et al. **Thorac Cardiovasc Surg** 1996 Jun;44(3):136-9

Does laser Doppler flowmetry aid the prevention of ischemic colitis in abdominal aortic aneurysm surgery? Sakakibara Y, et al. **Thorac Cardiovasc Surg** 1997 Feb;45(1):32-4

Infected aneurysms--clinical study of 5 cases. Fujimura T, et al. **Tokai J Exp Clin Med** 1996 Feb;21(1):25-31

[Ruptured abdominal aortic aneurysm] Sebesta P, et al. **Rozhl Chir** 1996 Sep;75(9):422-8 (Eng. Abstr.) **(Cze)**

[Aneurysms of the abdominal aorta] Třeška V, et al. **Rozhl Chir** 1997 Apr;76(4):176-80 (Eng. Abstr.) **(Cze)**

[Technical advances in the surgical management of thoracoabdominal aortic aneurysms] Kieffer E, et al. **Bull Acad Natl Med** 1996 Nov;180(8):1841-52; discussion 1852-3 (13 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of abdominal aortic aneurysm by application of a Corvita endoprosthesis. Medium-term results of a feasibility study] Dereume JP, et al. **Chirurgie** 1996; 121(6):428-31 (Eng. Abstr.) **(Fre)**

[Abdominal aortic aneurysm: surgery, indications, technique, outcome] Prager M, et al. **Acta Med Austriaca** 1997; 24(1):10-4 (Eng. Abstr.) **(Ger)**

[Infrarenal aortic aneurysm (letter; comment)] Bruijnen H, et al. **Chirurg** 1996 Dec;67(12):1287-8. Comment on: Chirurg 1996 Jul;67(7):697-702. **(Ger)**

[Infrarenal aortic aneurysm--10 year follow-up after bypass operation with cost analysis (see comments)] Cappeller WA, et al. **Chirurg** 1996 Jul;67(7):697-702 (Eng. Abstr.). Comment in: Chirurg 1996 Dec;67(12):1287-8. **(Ger)**

[The superficial femoral vein in aorto-iliac position--suitable as autogenous vascular replacement in deep prosthesis infection?] Franke S, et al. **Chirurg** 1996 Aug;67(8):843-9 (Eng. Abstr.) **(Ger)**

[Simultaneous retroperitoneal operation of juxtarenal abdominal aortic aneurysm and ischemic vertebral body necrosis] Kolvenbach R, et al. **Chirurg** 1997 Apr; 68(4):429-32 (Eng. Abstr.) **(Ger)**

[Aortic aneurysm in horseshoe kidney--special diagnosis and therapy] Luther B, et al. **Chirurg** 1997 Apr;68(4):403-9 (Eng. Abstr.) **(Ger)**

[Long-term outcome after reconstructive interventions of the aorto-iliac segment] Kirsch D, et al. **Langenbecks Arch Chir** 1997;382(1):49-54 (Eng. Abstr.) **(Ger)**

[Abdominal aortic aneurysm--is surgical therapy in over 80-year-old patients justified?] Ritter R, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:894-6 (Eng. Abstr.) **(Ger)**

[Prospective preoperative morphometry of abdominal aortic aneurysms: selective patient management for endovascular surgery] Schumacher H, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:875-7 (Eng. Abstr.) **(Ger)**

[Effect of endovascular surgery of infrarenal aortic aneurysms on circulating endothelial adhesion molecules, cytokines and proteinase inhibitors] Schumacher H, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:15-9 (Eng. Abstr.) **(Ger)**

[Early perioperative suppression of inducible leukocytic cytokine gene expression after electric abdominal aortic aneurysm repair] Ziegenfuss T, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:691-4 (Eng. Abstr.) **(Ger)**

[Periprosthetic urinoma after aorto-biiliac vascular prosthesis: a rare complication] Ernst S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Oct;165(4):406-8 **(Ger)**

[Morphology of abdominal aortic aneurysms with reference to endovascular blood vessel prosthesis] Marty B, et al. **Swiss Surg** 1996;2(5):219-22 (Eng. Abstr.) **(Ger)**

[Mycotic aortic aneurysm after appendectomy] Rhomberg M, et al. **Vasa** 1996;25(1):90-3 (Eng. Abstr.) **(Ger)**

[Infrarenal abdominal aortic aneurysm--indications for surgery and survival] Imig H, et al. **Zentralbl Chir** 1996; 121(3):223-7 (Eng. Abstr.) **(Ger)**

[Preoperative blood storage and intraoperative blood recovery in elective treatment of abdominal aorta aneurysm] Tedesco M, et al. **Ann Ital Chir** 1996 May-Jun; 67(3):399-403 (Eng. Abstr.) **(Ita)**

[Aorto-enteric fistula: current information on diagnostic and therapeutic procedures] Bianchi G, et al. **G Chir** 1997 Jun-Jul;18(6-7):378-81 (Eng. Abstr.) **(Ita)**

[Surgery of the descending thoracic and thoraco-abdominal arteries. Report of 105 cases] Zanetti PP, et al. **G Ital Cardiol** 1997 Jul;27(7):682-5 (Eng. Abstr.) **(Ita)**

[Evaluation of cerebral perfusion during aortic clamping and cross-clamping in patients undergoing resection for abdominal aortic aneurysm. A study with transcranial doppler] Pittella G, et al. **Minerva Anestesiol** 1997 Mar; 63(3):69-75 (Eng. Abstr.) **(Ita)**

[Intestinal infarction after ruptured aneurysm of the abdominal aorta. Clinical contribution] Giordanengo F, et al. **Minerva Cardioangiol** 1995 Oct;43(10):429-34 (Eng. Abstr.) **(Ita)**

[Endovascular treatment of abdominal aorta aneurysms using the Stentor device. Preliminary experience] Jausseran JM, et al. **Minerva Cardioangiol** 1996 Nov;44(11):563-79 (Eng. Abstr.) **(Ita)**

[Postoperative evaluation of vascular bifurcation prostheses by means of helical CT] Simoni G, et al. **Minerva Cardioangiol** 1996 May;44(5):223-7 (Eng. Abstr.) **(Ita)**

[Use of autotransfusion in prosthetic surgery of the abdominal aorta] Tridico F, et al. **Minerva Cardioangiol** 1996 Sep; 44(9):461-6 (Eng. Abstr.) **(Ita)**

[The indications for and limits of combined treatment of associated aortoiliac and digestive tract pathology] Battisti G, et al. **Minerva Chir** 1997 May;52(5):589-93 (Eng. Abstr.) **(Ita)**

[Clinical suspicion and instrumental diagnosis of ruptured aneurysm of the abdominal aorta. Analysis of our experience] Rubini P, et al. **Minerva Chir** 1996 Apr; 51(4):195-201 (Eng. Abstr.) **(Ita)**

[Colorectal ischemic necrosis following reconstructive surgery of the abdominal aorta. Report of 2 clinical cases] Tridico F, et al. **Minerva Chir** 1996 Sep;51(9):739-43 (Eng. Abstr.) **(Ita)**

[Prevention and treatment of early and late postoperative complications of prosthetic surgery of the arterial aorto-iliac area] Tridico F, et al. **Minerva Chir** 1996 Sep; 51(9):675-80 (Eng. Abstr.) **(Ita)**

[A multi-center study on medical and surgical management in patients with aortic aneurysm and dissection from 1988 through 1993] Hayashi J, et al. **J Cardiol** 1996 Jun; 27(6):335-8 **(Jpn)**

[A case report of a successful surgery for thoracoabdominal aortic aneurysm under partial cardiopulmonary bypass with

selective perfusion of major abdominal branches] Abe M, et al. **Kyobu Geka** 1996 Nov;49(12):1010–3 (Eng. Abstr.) **(Jpn)**

[Abdominal aortic aneurysm and annuloaortic ectasia in siblings with Marfan syndrome] Koga M, et al. **Kyobu Geka** 1997 Mar;50(3):239–42 (Eng. Abstr.) **(Jpn)**

[Redo operation after surgery for aortic aneurysm and dissection] Ohmi M, et al. **Kyobu Geka** 1997 Jul;50(7):523–8; discussion 528–30 (Eng. Abstr.) **(Jpn)**

[Case report of a thoracoabdominal aneurysm operation using profound hypothermia and circulatory arrest] Okada Y, et al. **Kyobu Geka** 1996 Dec;49(13):1105–9 (Eng. Abstr.) **(Jpn)**

[Abdominal aortic surgery in Stanford type B chronic dissecting aortic aneurysm] Sakurada T, et al. **Kyobu Geka** 1997 Apr;50(4):270–4 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of thoracoabdominal aortic aneurysm] Shiiya N, et al. **Kyobu Geka** 1997 Feb;50(2):133–43 (122 ref.) **(Jpn)**

[A case of one stage operation for primary lung cancer and abdominal aortic aneurysm] Tanaka K, et al. **Kyobu Geka** 1996 Jul;49(7):599–601 (Eng. Abstr.) **(Jpn)**

[A case of anastomotic aneurysm–enteric fistula] Takiguchi M, et al. **Nippon Geka Gakkai Zasshi** 1997 Jun;98(6):580–3 (Eng. Abstr.) **(Jpn)**

[A successful surgical treatment of dissecting thoracoabdominal aortic aneurysm using a heparin coated percutaneous cardiopulmonary support system] Tanaka H, et al. **Nippon Geka Gakkai Zasshi** 1997 May;98(5):524–8 (Eng. Abstr.) **(Jpn)**

[Operative results and long-term prognosis of aortic dissections] Ueda T, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):916–20 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Evolution and recent trends in patient selection and reconstruction method for chronic aortic dissection] Yasuda K, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct; 97(10):906–15 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Stent graft treatment for two cases of DeBakey IIIb dissecting aortic aneurysm] Kawaguchi S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):926–33 (Eng. Abstr.) **(Jpn)**

[A successful surgical case report of impending rupture of the true thoraco–abdominal aortic aneurysm induced by thrombosed–type acute aortic dissection (Stanford type A)] Ohnishi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):649–54 (Eng. Abstr.) **(Jpn)**

[Subtotal aortic replacement in a patient with Marfan's syndrome––replacement of the ascending aorta and entire aortic arch for acute type I aortic dissection 4 years after the thoracoabdominal replacement] Shiiya N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Nov;44(11):2095–9 (Eng. Abstr.) **(Jpn)**

[Successful surgical repair of acute DeBakey type I aortic dissection complicated by acute occlusion of the suprarenal abdominal aorta] Shiiya N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):682–6 (Eng. Abstr.) **(Jpn)**

[A case report of primary repair for thoracic and thoracoabdominal and iliac artery aneurysms associated with severe visceral artery occlusive diseases––a redo operation for thoracoabdominal aortic aneurysm after infrarenal abdominal aortic aneurysm repair] Takigami K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr; 45(4):577–81 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of thoracoabdominal aortic aneurysm] Goto H, et al. **Rinsho Kyobu Geka** 1989 Oct;9(5):447–51 (Eng. Abstr.) **(Jpn)**

[Surgical treatment for thoracoabdominal aortic aneurysm] Sakuma M, et al. **Rinsho Kyobu Geka** 1989 Oct;9(5):435–40 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of thoracoabdominal aortic aneurysms] Shin H, et al. **Rinsho Kyobu Geka** 1989 Oct;9(5):441–6 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of thoracoabdominal aortic aneurysm: detection and prevention of spinal cord injury] Yamashita K, et al. **Rinsho Kyobu Geka** 1989 Oct;9(5):452–5 (Eng. Abstr.) **(Jpn)**

[The surgical treatment of aneurysms of the abdominal aorta] Sedov VM, et al. **Vestn Khir Im I I Grek** 1996;155(6):44–8 (Eng. Abstr.) **(Rus)**

[Successful x–ray endovascular prosthesis in abdominal aortic aneurysm] Nemytin IuV, et al. **Voen Med Zh** 1997 Jan; 318(1):62–4 **(Rus)**

[Polyester–covered spiral Z stent. Initial clinical experience with endovascular treatment of aortic aneurysms] Ferko A, et al. **Rozhl Chir** 1996 Sep;75(9):450–60 (Eng. Abstr.) **(Slo)**

[Surgical treatment of the pathology of the descending aorta. Aneurysm and dissection] Lisbona Sabater C, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:85–91 (Eng. Abstr.) **(Spa)**

THERAPY

CD–18 monoclonal antibody blocks the early events of aneurysm expansion. Strindberg G, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:266–7

Role of the BioMedicus pump and distal aortic perfusion in thoracoabdominal aortic aneurysm repair. Safi HJ. **Artif Organs** 1996 Jun;20(6):694–9

A self–expanding endoluminal graft for treatment of aneurysms: results through the development phase. Gordon MK, et al. **Aust N Z J Surg** 1996 Sep;66(9):621–5

Percutaneous fenestration of aortic dissection: salvage of an ischemic solitary left kidney. Park JH, et al. **Cardiovasc Intervent Radiol** 1997 Mar–Apr;20(2):146–8

Leaks after endovascular therapy for aneurysm: detection and classification. Beebe HG, et al. **J Endovasc Surg** 1996 Nov;3(4):445–8

Proximal stent deployment without contrast during endovascular aneurysm repair: an improved technique. Boyle JR, et al. **J Endovasc Surg** 1996 Nov;3(4):380–1

Use of a self–expanding vascular occluder for embolization during endovascular aortic aneurysm repair. Kato N, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):27–33

Endovascular repair of abdominal aortic aneurysms: how should it evolve? Martin EC. **J Vasc Interv Radiol** 1996 Jul–Aug;7(4):477–8

Use of stents covered with polytetrafluoroethylene in experimental abdominal aortic aneurysm. Palmaz JC, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6):879–85

True lumen obliteration in complicated aortic dissection: endovascular treatment. Slonim SM, et al. **Radiology** 1996 Oct;201(1):161–6

Management of renal artery stenosis in conjunction with aortic aneurysm. Ballard JL. **Semin Vasc Surg** 1996 Sep; 9(3):221–30 (57 ref.)

[Current status of abdominal aortic aneurysm therapy (editorial)] Allenberg JR. **Langenbecks Arch Chir** 1997; 382(3):117–8 **(Ger)**

[Infrarenal abdominal aortic aneurysm: morphological classification as decision aid for therapeutic procedures] Allenberg JR, et al. **Zentralbl Chir** 1996;121(9):721–6 (Eng. Abstr.) **(Ger)**

[Vascular stents and development of endoluminal therapy of aortic aneurysm] Blum U, et al. **Zentralbl Chir** 1996; 121(9):714–20 (47 ref.) (Eng. Abstr.) **(Ger)**

[Initial clinical experiences with endovascular stent–grafts for treatment of infrarenal abdominal aortic aneurysm] Spillner G, et al. **Zentralbl Chir** 1996;121(9):727–33 (Eng. Abstr.) **(Ger)**

[Difficulties and complications in transfemoral implantation of stent prostheses in infrarenal abdominal aortic aneurysms] Stelter WJ, et al. **Zentralbl Chir** 1996; 121(9):734–43 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Chronic post–traumatic pseudoaneurysm of the abdominal aorta diagnosed by duplex Doppler ultrasonography. A case report. González Llorente J, et al. **Acta Radiol** 1997 Jan;38(1):121–3 (12 ref.)

Usefulness of transesophageal echocardiography in detecting changes in flow dynamics responsible for malperfusion phenomena observed during surgery of aortic dissection. Yamada E, et al. **Am J Cardiol** 1997 Apr 15;79(8):1149–52

The UK Small Aneurysm Trial. Powell JT, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:249–51

Screening for abdominal aortic aneurysms in a hypertensive patient population. Simon G, et al. **Arch Intern Med** 1996 Oct 14;156(18):2081–4

A prospective study to define the optimum rescreening interval for small abdominal aortic aneurysm. Cook TA, et al. **Cardiovasc Surg** 1996 Aug;4(4):441–4

Potential influence of intraluminal thrombus on abdominal aortic aneurysm as assessed by a new non–invasive method. Vorp DA, et al. **Cardiovasc Surg** 1996 Dec;4(6):732–9

Improved reliability of ultrasonic surveillance of abdominal aortic aneurysms. Länne T, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):149–53

The use of intravascular ultrasound as control procedure for the deployment of endovascular stented grafts. Vogt KC, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):592–6

Diagnosis of small infrarenal aortic aneurysms by ultrasonography. Pedersen OM, et al. **Int Angiol** 1996 Dec; 15(4):328–34

Postoperative color flow duplex scanning in aortic endografting. Heilberger P, et al. **J Endovasc Surg** 1997 Aug;4(3):262–71

Ultrasound imaging during endovascular abdominal aortic aneurysm repair using the Stentor bifurcated endograft. Lie T, et al. **J Endovasc Surg** 1997 Aug;4(3):272–8

Intravascular ultrasound: the ultimate tool for abdominal aortic aneurysm assessment and endovascular graft delivery. White RA, et al. **J Endovasc Surg** 1997 Feb; 4(1):45–55 (12 ref.)

Positive predictive value of clinical suspicion for abdominal aortic aneurysm. Implications for use of ultrasonography [see comments] Kahn CE Jr, et al. **J Gen Intern Med** 1996 Dec;11(12):756–8. Comment in: J Gen Intern Med 1996 Dec;11(12):774–5.

Looking for asymptomatic abdominal aortic aneurysms [editorial; comment] Lederle FA. **J Gen Intern Med** 1996 Dec;11(12):774–5. Comment on: J Gen Intern Med 1996 Dec;11(12):756–8.

Quality of the measurement of the infrarenal aortic diameter by ultrasound. Wilmink AB, et al. **J Med Screen** 1997; 4(1):49–53

Abdominal sonography in asymptomatic executives: prevalence of pathologic findings, potential benefits, and problems. Spouge AR, et al. **J Ultrasound Med** 1996 Nov; 15(11):763–7; quiz 769–70

Prenatal ultrasound diagnosis of abdominal aortic aneurysm with fibrotic occlusion in aortic branch vessels. Malee MP, et al. **Prenat Diagn** 1997 May;17(5):479–82

AORTIC ANEURYSM, RUPTURED see **AORTIC RUPTURE**

AORTIC ANEURYSM, THORACIC

Geriatrics photo quiz. Thoracic aortic aneurysm. Shua–Haim JR, et al. **Geriatrics** 1997 Sep;52(9):35, 90

Thoracic aortic dissection or aneurysm: clinical presentation, diagnostic imaging and initial management in a tertiary referral centre. Hennessy TG, et al. **Ir J Med Sci** 1996 Oct–Dec;165(4):259–62

Progress report: evaluation and treatment of ascending and aortic arch aneurysm/dissection. Meadors FA. **J Ark Med Soc** 1997 Mar;93(10):481–3 (7 ref.)

The natural history of thoracic aortic aneurysm disease: an overview. Pitt MP, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):270–8 (71 ref.)

Acute aortic dissection without intimal tear. Utoh J, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):419–20

[Vasculo–Behçet's disease] Yasuda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):338–40 (16 ref.) **(Jpn)**

CEREBROSPINAL FLUID

Cerebral spinal fluid drainage and distal aortic perfusion decrease the incidence of neurological deficit: the results of 343 descending and thoracoabdominal aortic aneurysm repairs. Safi HJ, et al. **Eur J Vasc Endovasc Surg** 1997 Aug; 14(2):118–24

CHEMICALLY INDUCED

Thoracic aortic dissection secondary to crack cocaine ingestion. Perron AD, et al. **Am J Emerg Med** 1997 Sep; 15(5):507–9

Aortic dissection and use of the nicotine patch: a case involving a temporal relationship. Ropchan GV, et al. **Can J Cardiol** 1997 May;13(5):525–8

CLASSIFICATION

[Aortic dissection] Mészáros I. **Orv Hetil** 1997 Apr 6; 138(14):843–9 (53 ref.) (Eng. Abstr.) **(Hun)**

COMPLICATIONS

Cervical aortic arch with aneurysm formation. Pearson GD, et al. **Am J Cardiol** 1997 Jan 1;79(1):112–4

Stent angioplasty for renovascular disease associated with acute aortic dissection. Hata M, et al. **Ann Thorac Surg** 1997 Jan;63(1):244–6

Thoracoabdominal fenestration for aortic dissection with ischemic colonic perforation. Howell JF, et al. **Ann Thorac Surg** 1997 Jul;64(1):242–4

Compression of a composite graft by a peri–aortic pseudoaneurysm in a postoperative Marfan patient. López–Candales A. **Can J Cardiol** 1997 Jun;13(6):611–4

Obstruction of the left pulmonary artery by aortic arch aneurysm. Miroult L, et al. **Clin Nucl Med** 1996 Dec; 21(12):984–6

Aorto–pulmonary fistula: a rare event in the evolution of a dissecting aneurysm of the thoracic aorta. Massetti M, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):994–6

Obstruction of the superior vena cava due to aortic dissection: CT findings of collateral venous flow via the bronchial veins. Schepers–Bok R, et al. **Eur Radiol** 1996;6(5):753–5

Chylothorax complicating a thoracic aortic aneurysm. Gil–Suay V, et al. **Eur Respir J** 1997 Mar;10(3):737–9

Back pain in a 43–year–old man. Archer TP, et al. **Hosp Pract (Off Ed)** 1996 Aug 15;31(8):104–6

Pseudoaneurysm of the gastrointestinal artery. Maes RM, et al. **J Belge Radiol** 1996 Dec;79(6):273

Chest wall infarction following bilateral internal mammary to coronary arterial bypass in a patient with a thoracoabdominal aneurysm. Keyser EJ, et al. **J Card Surg** 1997 Mar–Apr;12(2):126–9

Rupture of a dissecting aneurysm into the superior vena cava in Marfan's syndrome. Toyoda Y, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):411–3

Aortic diverticulum without vascular ring: a rare cause of dysphagia. Donatelli F, et al. **J Vasc Surg** 1997 Jul; 26(1):142–3

Paraparesis due to syphilitic aortic dissection. Kellett MW, et al. **Neurology** 1997 Jan;48(1):221–3

Breathlessness and a widened mediastinum. Bruce–Jones PN, et al. **Postgrad Med J** 1997 Mar;73(857):183–5

Aortobronchial fistula secondary to chronic post–traumatic thoracic aneurysm. Fernández González AL, et al. **Tex Heart Inst J** 1996;23(2):174–7

[Unusual case of pulmonary artery compression caused by aortic arch aneurysm] Midiri M, et al. **Radiol Med (Torino)** 1997 May;93(5):639–41 **(Ita)**

[Pathophysiology and complications of aortic dissection] Matsuo H. **Nippon Geka Gakkai Zasshi** 1996 Oct; 97(10):879–83 (11 ref.) (Eng. Abstr.) **(Jpn)**

[A case of ruptured aortic arch aneurysm with hemorrhagic cardiac tamponade] Ohtani N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):865–8 (Eng. Abstr.) **(Jpn)**

[Usefulness of Dumon–type endotracheal stent for left main bronchial obstruction caused by thoracic aortic aneurysm––a case report] Watanabe S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep;44(9):1776–80

(Eng. Abstr.) **(Jpn)**

[A case of acute thrombosed aortic dissection (Stanford type A) in association with a true aortic arch aneurysm] Yamamoto H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct;44(10):1945–8 (Eng. Abstr.) **(Jpn)**

[Massive hemoptysis in a patient with a tuberculous thoracic aneurysm] Hatakeyama S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Jan; 35(1):106–10 (Eng. Abstr.) **(Jpn)**

[Case of thrombotic–occlusive type dissecting aneurysm appeared during the course of thoracic aortic aneurysm] Fukushima S, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):118–20 **(Jpn)**

[Combined operation for patients with ischemic heart disease and thoracic aortic aneurysm] Kitamura S, et al. **Rinsho Kyobu Geka** 1989 Aug;9(4):329–32 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Right pleural effusion as first manifestation of dissecting aneurysm of the aorta (letter)] Marcos Sánchez F, et al. **An Med Interna** 1996 Nov;13(11):562–3 **(Spa)**

DIAGNOSIS

Dissection of retroesophageal aortic diverticulum and descending aorta in a patient with right aortic arch: magnetic resonance demonstration. Ko SF, et al. **Cardiovasc Intervent Radiol** 1996 Nov–Dec;19(6):438–41

Mycotic thoracic aneurysm due to Clostridium septicum and occult adenocarcinoma of the cecum. Montoya FJ, et al. **Clin Infect Dis** 1997 May;24(5):785, 1007

Diagnostic dilemmas in dysphagia aortica. Wilkinson JM, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):222–7

False aneurysm of the thyrocervical trunk [letter; comment] Chalmers RT. **Eur J Vasc Endovasc Surg** 1997 Apr; 13(4):424–5. Comment on: Eur J Vasc Endovasc Surg 1996 Apr;11(3):373–4.

Dyspnoea, anorexia and weight loss in a 74 year old man. Heaney LG, et al. **Eur Respir J** 1997 Jun;10(6):1412–4

Retrograde extension of a chronic type III aortic dissection. Leon M, et al. **J Ark Med Soc** 1997 Jul;94(2):78

Artifact in SE phase images can mimic aortic dissection. den Boer JA, et al. **J Magn Reson Imaging** 1996 Nov–Dec; 6(6):964–5

Evaluation of magnetic resonance imaging in coarctation of the aorta: the importance of multiple imaging planes. Greenberg SB, et al. **Pediatr Cardiol** 1997 Sep–Oct; 18(5):345–9

Definitive diagnosis of intramural hematoma of the thoracic aorta with MR imaging [editorial; comment] Bluemke DA. **Radiology** 1997 Aug;204(2):319–21. Comment on: Radiology 1997 Aug;204(2):349–55.

Intramural hematoma of the thoracic aorta: MR image findings and their prognostic implications [see comments] Murray JG, et al. **Radiology** 1997 Aug;204(2):349–55. Comment in: Radiology 1997 Aug;204(2):319–21.

[Acute respiratory distress revealing an aneurysm of the thoracic aorta. Report of a case (letter)] Ameur A, et al. **J Mal Vasc** 1997;22(1):62–3 **(Fre)**

[Clinical case of the month. Intramural aortic hematoma: an acute special aortic dissection] Radermecker MA, et al. **Rev Med Liege** 1996 May;51(5):332–5 **(Fre)**

[Acute thoracic aortic dissection with occlusion of the left coronary artery] Weber M, et al. **Herz** 1997 Apr; 22(2):104–10 (Eng. Abstr.) **(Ger)**

[Intramural hematoma of the thoracic aorta: diagnostic imaging and differential diagnosis] Sommer T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Sep;165(3):249–56 (Eng. Abstr.) **(Ger)**

[What is your diagnosis? Traumatic transsection (incomplete, non–transmural aortic rupture) of the thoracic aorta with post–traumatic aneurysm of the proximal descending aorta] Hauser M, et al. **Schweiz Rundsch Med Prax** 1997 Feb 18; 86(8):281–5 **(Ger)**

[Familial aortic dissection in a young woman. A clinical case and review of the literature] Cucchi G. **Cardiologia** 1997 Feb;42(2):211–3 (22 ref.) (Eng. Abstr.) **(Ita)**

[Recent progress of diagnostic imaging for aortic dissection] Takamiya M, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct; 97(10):884–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

[A difficult case for the intravital diagnosis of an aortic aneurysm (notes from practice)] Iakimova OG, et al. **Ter Arkh** 1996;68(12):75–6 **(Rus)**

DRUG THERAPY

Successful management of acute aortic dissection in a heart transplant recipient. Defraigne JO, et al. **Acta Chir Belg** 1997 Jun;97(3):141–4 (15 ref.)

ETIOLOGY

Dissection of the ascending aorta induced by coronary angiography. Birnbaum Y, et al. **Am J Cardiol** 1997 Aug 15;80(4):537

Late true aneurysm after bypass grafting for long aortic coarctation. Fujita T, et al. **Ann Thorac Surg** 1996 Nov; 62(5):1511–3 (10 ref.)

Tuberculous pseudoaneurysm of the thoracic aorta. Ohtsuka T, et al. **Ann Thorac Surg** 1996 Dec;62(6):1831–4 (8 ref.)

Marfan syndrome presenting as fatal ruptured dissecting aneurysm of aorta. Kale MM, et al. **J Assoc Physicians India** 1996 Oct;44(10):734–5

Mycotic aortic aneurysms after orthotopic heart transplantation: a three–case report and review of the literature. Knosalla C, et al. **J Heart Lung Transplant** 1996 Aug;15(8):827–39 (27 ref.)

Tuberculous pseudoaneurysm of the descending thoracic aorta: a case report and literature review of surgically treated cases. Ikezawa T, et al. **J Vasc Surg** 1996 Oct; 24(4):693–7 (32 ref.)

A female with aneurysm of aortic arch due to lung cancer [clinical conference] Kikuchi K, et al. **Keio J Med** 1997 Jun;46(2):90–3

Thoracic aortic dissection complicating autosomal dominant polycystic kidney disease. Paynter HE, et al. **Nephrol Dial Transplant** 1997 Aug;12(8):1711–3

Dissection of the descending aorta after balloon angioplasty of native coarctation. Beitzke A, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):222–5

Mineral–cholesterol concentrations of the aortic aneurysmatic wall. Pawlikowski M, et al. **Pol J Pathol** 1996; 47(4):225–32

[False hydatic aneurysm of the thoraco–abdominal aorta] El Mesnaoui A, et al. **J Chir (Paris)** 1996 Jul;133(5):227–5 (Eng. Abstr.) **(Fre)**

[A case report of Takayasu's arteritis with aortic pseudoaneurysm caused by aortic perforation] Hachiya T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct; 44(10):1921–4 (Eng. Abstr.) **(Jpn)**

[Traumatic injuries of the thoracic aorta—report of five cases] Kanazawa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec; 44(12):2155–63 (Eng. Abstr.) **(Jpn)**

[Ruptured descending thoracic aortic aneurysm due to aortitis syndrome—a case report] Masaki H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):655–60 (Eng. Abstr.) **(Jpn)**

GENETICS

Fibrillin–1 (FBN1) mutations in patients with thoracic aortic aneurysms. Milewicz DM, et al. **Circulation** 1996 Dec 1; 94(11):2708–11

Familial thoracic aortic dilatations and dissections: a case control study. Biddinger A, et al. **J Vasc Surg** 1997 Mar; 25(3):506–11

[Aortic aneurysms in Ullrich–Turner syndrome] Buheitel G, et al. **Klin Padiatr** 1996 Jan–Feb;208(1):42–5 (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Mycotic aneurysm of the thoracic aorta caused by Clostridium septicum. Murphy DP, et al. **Ann Thorac Surg** 1996 Dec;62(6):1835–7

Aortic dissection due to Clostridium septicum infection. Monsen T, et al. **Eur J Vasc Endovasc Surg** 1997 May; 13(5):517–8

MORTALITY

[Long–term survival after treatment of thoracic aneurysms by thromboexclusion operation] Gu K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep;44(9):1749–52 (Eng. Abstr.) **(Jpn)**

NURSING

Stent–graft placement procedures for descending thoracic aortic aneurysms. Liston SM. **AORN J** 1997 Sep; 66(3):433–8, 440, 442 passim

PARASITOLOGY

A rare case of hydatid cyst perceived as false aneurysm of thoracic aorta. Zakhariev T, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):792–3

PATHOLOGY

Histomorphological examination of endoluminal stent grafting in the descending aorta in a sheep model. Orend KH, et al. **Thorac Cardiovasc Surg** 1996 Jun;44(3):132–5

[Pathology of aortic dissection] Hosoda Y. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):873–8 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Three specific forms of aortic dilatation] Homma S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):360–6 (16 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Improved management of selective cerebral perfusion in aortic arch surgery. Matsuwaka R, et al. **ASAIO J** 1996 Sep–Oct;42(5):M794–6

Evaluation of blood flow patterns of true and false lumens in dissecting aneurysms using MR phase–contrast techniques. Inoue T, et al. **Clin Imaging** 1996 Oct–Dec; 20(4):262–8

Natural history of descending and thoracoabdominal aortic aneurysms. Coselli JS, et al. **J Card Surg** 1997 Mar–Apr; 12(2 Suppl):285–9; discussion 289–91 (24 ref.)

Efficacy of transcranial motor–evoked myogenic potentials to detect spinal cord ischemia during operations for thoracoabdominal aneurysms. de Haan P, et al. **J Thorac Cardiovasc Surg** 1997 Jan;113(1):87–100; discussion 100–1

Circadian rhythmicity in the occurrence of spontaneous acute dissection and rupture of thoracic aorta. Gallerani M, et al. **J Thorac Cardiovasc Surg** 1997 Mar;113(3):603–4

[Pathophysiology and complications of aortic dissection] Matsuo H. **Nippon Geka Gakkai Zasshi** 1996 Oct; 97(10):879–83 (11 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Ductus diverticulum interpreted as traumatic aortic injury. Ferrera PC, et al. **Am J Emerg Med** 1997 Jul;15(4):371–2

Prospective study of the natural history of thoracic aortic aneurysms [published erratum appears in Ann Thorac Surg 1997 Aug;64(2):594] Juvonen T, et al. **Ann Thorac Surg** 1997 Jun;63(6):1533–45

Intramural aortic dissection. Wambeek ND, et al. **Australas Radiol** 1996 Nov;40(4):442–6

Case in point. Chronic aortic dissection. Hariharan R, et al. **Hosp Pract (Off Ed)** 1997 Jul 15;32(7):24

A 52–year–old woman complaining of back pain. Hada Y. **J Cardiol** 1996 Feb;27(2):85–87

Case report. Aortic pseudoaneurysm with aortobronchial fistula: diagnosis with CT angiography. Ferretti GR, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):975–8 (8 ref.)

Chest pain in an elderly patient. Vilke GM. **J Emerg Med** 1997 Jul–Aug;15(4):523

Electron–beam CT angiography for thoracic aortic aneurysm and dissection: application of continuous volume scan and electrocardiographically triggered scan. Nakanishi T, et al. **Radiat Med** 1997 May–Jun;15(3):155–61

Evaluation of thoracic aortic disease with the use of helical CT and multiplanar reconstructions: comparison with surgical findings. Quint LE, et al. **Radiology** 1996 Oct; 201(1):37–41

Unilateral hypertranslucency of the left hemithorax due to aneurysm of the thoracic aorta. Loukides S, et al. **Thorax** 1997 Mar;52(3):299–300

[Dissecting hematoma of the thoracic aorta] Fossati P, et al. **J Radiol** 1997 Jul;78(7):517–8 **(Fre)**

[Routine thoracic image of an 86–year–old patient with tracheobronchitis. Scalloping—pressure–induced ventral vertebral erosions caused by a thoracic aortic aneurysm] Zenzius RP. **Radiologe** 1997 Jun;37(6):483–5 **(Ger)**

[Diagnostic imaging of aortic pseudoaneurysm: study of 4 clinical cases] Fedriga E, et al. **Cardiologia** 1996 Jul; 41(7):661–5 (Eng. Abstr.) **(Ita)**

[Chest radiographic diagnosis of dissecting thoracic descending aorta] Momiyama Y, et al. **J Cardiol** 1997 Mar; 29(3):157–62 (Eng. Abstr.) **(Jpn)**

[A 69–year–old woman with unconsciousness] Morimoto K, et al. **J Cardiol** 1996 Aug;28(2):113–4 **(Jpn)**

[Computerized tomography in aortic pathology] Lecumberri Olaverri F, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:27–36 (54 ref.) (Eng. Abstr.) **(Spa)**

[Asymptomatic aortic dissection in a patient with aortic valve prosthesis] Sánchez Calle JM, et al. **Rev Esp Cardiol** 1997 Apr;50(4):287–9 (Eng. Abstr.) **(Spa)**

SURGERY

Spinal cord ischemia—use of spinal–evoked potentials for intraoperative monitoring in thoraco–abdominal aortic aneurysm (TAA) repair. Freye E, et al. **Acta Anaesthesiol Scand Suppl** 1996;109:50–3

Near–infrared spectroscopy changes during hypothermic circulatory arrest with retrograde cerebral perfusion. Rigg CD, et al. **Anaesthesia** 1997 Apr;52(4):356–9

Changes in cerebrospinal fluid pressure and lactate concentrations during thoracoabdominal aortic aneurysm surgery. Drenger B, et al. **Anesthesiology** 1997 Jan; 86(1):41–7

Demonstration of false lumen perfusion during repair of type A aortic dissection. Voci P, et al. **Anesthesiology** 1996 Oct; 85(4):926–8

Thoracoabdominal aortic aneurysm in an infant treated by thromboexclusion with thoracoabdominal aortic bypass. A case report. Hashimoto R, et al. **Angiology** 1996 Dec; 47(12):1157–62

Impact of previous thoracic aneurysm repair on thoracoabdominal aortic aneurysm management. Coselli JS, et al. **Ann Thorac Surg** 1997 Sep;64(3):639–50

Selective approach to descending thoracic aortic aneurysm repair: a ten–year experience. Galloway AC, et al. **Ann Thorac Surg** 1996 Oct;62(4):1152–7

Treatment of aortic dissection and ruptured abdominal aneurysm with coronary bypass. Ghalili KC, et al. **Ann Thorac Surg** 1997 Jan;63(1):223–5

1989: New technique for repair of ascending thoracic aortic dissections. Updated in 1997. Hammond GL. **Ann Thorac Surg** 1997 Jan;63(1):287

Aortic arch operation using selective cerebral perfusion for nondissecting thoracic aneurysm [see comments] Hayashi J, et al. **Ann Thorac Surg** 1997 Jan;63(1):88–92. Comment in: Ann Thorac Surg 1997 Jan;63(1):9–11.

Operation for nondissecting aneurysm in the descending thoracic aorta [see comments] Hayashi J, et al. **Ann Thorac Surg** 1997 Jan;63(1):93–7. Comment in: Ann Thorac Surg 1997 Jan;63(1):9–11.

Prospective study of the natural history of thoracic aortic aneurysms [published erratum appears in Ann Thorac Surg 1997 Aug;64(2):594] Juvonen T, et al. **Ann Thorac Surg** 1997 Jun;63(6):1533–45

Long–term follow–up (8 to 17 years) after thromboexclusion operation for thoracic aortic aneurysms. Ku K, et al. **Ann Thorac Surg** 1997 Aug;64(2):399–403

Successful management of secondary aortoesophageal fistula. Luketich JD, et al. **Ann Thorac Surg** 1996 Dec;62(6):1852–4 (11 ref.)

Recurrent aortic dissection after orthotopic heart transplantation. Mullen JC, et al. **Ann Thorac Surg** 1996 Dec;62(6):1830–1

Thoracic aortic operations: management of maldistribution of arterial flow during cardiopulmonary bypass. Najafi H, et al. **Ann Thorac Surg** 1997 Aug;64(2):565–7

Surgical treatment of acute type B aortic dissection using an endoprosthesis (elephant trunk). Palma JH, et al. **Ann Thorac Surg** 1997 Apr;63(4):1081–4

Operation for type B aortic dissection using hypothermic selective cerebral perfusion. Tayama K, et al. **Ann Thorac Surg** 1997 Feb;63(2):535–7

Long-term results of flow reversal and thromboexclusion method for thoracic aortic aneurysm. Urayama H, et al. **Ann Thorac Surg** 1997 Mar;63(3):716–20

Total intercostal artery reimplantation for descending thoracic aortic replacement. Usui A, et al. **Ann Thorac Surg** 1996 Nov;62(5):1523–5

Stent-graft placement procedures for descending thoracic aortic aneurysms. Liston SM. **AORN J** 1997 Sep; 66(3):433–8, 440, 442 passim

Our distal aortic perfusion system in descending thoracic and thoracoabdominal aortic aneurysm repairs. Morishita K, et al. **Artif Organs** 1997 Jul;21(7):822–4

Use of percutaneous cardiopulmonary support system with rotary blood pump in graft replacement of the descending thoracic and thoracoabdominal aorta. Watanabe S, et al. **Artif Organs** 1997 Jul;21(7):846–51

Improved management of selective cerebral perfusion in aortic arch surgery. Matsuwaka R, et al. **ASAIO J** 1996 Sep–Oct;42(5):M794–6

Intentional asystole during endoluminal thoracic aortic surgery without cardiopulmonary bypass. Baker AB, et al. **Br J Anaesth** 1997 Apr;78(4):444–8

Endotoxin related early neutrophil activation is associated with outcome after thoracoabdominal aortic aneurysm repair. Foulds S, et al. **Br J Surg** 1997 Feb;84(2):172–7

Surgical management of type A aortic dissection: evaluation of predisposing factors for postoperative neurologic complication and late reoperation. Ahn H, et al. **Cardiovasc Surg** 1997 Feb;5(1):104–11

Surgery of descending thoracic aortic aneurysms with centrifugal pump support. Biglioli P, et al. **Cardiovasc Surg** 1997 Feb;5(1):99–103

Surgical treatment of infected thoracic and abdominal aortic aneurysms. Chiba Y, et al. **Cardiovasc Surg** 1996 Aug; 4(4):476–9

'In vivo' size of knitted Dacron prostheses (Gelseal) used in the thoracic aorta: a computed tomography study. Goossens D, et al. **Cardiovasc Surg** 1996 Apr;4(2):205–6

Survival and aortic events after graft replacement for thoracoabdominal aortic aneurysm. Schepens MA, et al. **Cardiovasc Surg** 1996 Dec;4(6):713–9

Surgical treatment for acute aortic arch dissection. Suda H, et al. **Cardiovasc Surg** 1996 Jun;4(3):315–9

New graft-implanting method for thoracic aortic aneurysm or dissection with a stented graft. Kato M, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II188–93

Endovascular stent graft repair of aortic aneurysms. Parodi JC. **Curr Opin Cardiol** 1997 Jul;12(4):396–405

A rare case of gastrointestinal hemorrhage: aortoesophageal fistula following repair of aortic dissection. Kirchgatterer A, et al. **Endoscopy** 1997 Feb;29(2):137–8

Pacemaker twiddler's syndrome: delayed transection of permanent ventricular lead [letter] Said SA, et al. **Eur Heart J** 1996 Dec;17(12):1914–5

Aneurysm of aberrant right subclavian [correction of subdavian] artery arising from diverticulum of Kommerell. Report of a case with tracheal compression. Aoyagi S, et al. **Eur J Cardiothorac Surg** 1997 Jul;12(1):138–40

Protection of the spinal cord during surgery of thoraco-abdominal aortic aneurysms. Bachet J, et al. **Eur J Cardiothorac Surg** 1996;10(10):817–25

Images in cardio-thoracic surgery. Mycotic aneurysms of the thoracic aorta caused by Streptococcus pneumoniae. Berdat PA, et al. **Eur J Cardiothorac Surg** 1997 Jul; 12(1):154–5

Repair of descending thoracic aneurysms through a left posterolateral thoracotomy using deep hypothermic circulatory arrest. Dossche K, et al. **Eur J Cardiothorac Surg** 1996;10(9):799–802

Radical replacement of the aortic root in acute type A dissection: indications and outcome. Ergin MA, et al. **Eur J Cardiothorac Surg** 1996;10(10):840–4; discussion 845

Syphilitic aortic aneurysm eroding through the sternum. Fulton JO, et al. **Eur J Cardiothorac Surg** 1996;10(10):922–4

Late complications after surgical exclusion of the thoracic aorta. Gontijo B, et al. **Eur J Cardiothorac Surg** 1996; 10(7):590–2

Reoperative aortic root surgery late after use of histo-acryl. Goossens D, et al. **Eur J Cardiothorac Surg** 1997 Jan; 11(1):194–5

Early and late outcome of operated and non-operated acute dissection of the descending aorta. Gysi J, et al. **Eur J Cardiothorac Surg** 1997 Jun;11(6):1163–9; discussion 1169–70

Extraanatomic thoracic aortic bypass grafts: indications, techniques, and results. Heinemann MK, et al. Eur J Cardiothorac Surg 1997 Jan;11(1):169–75

Percutaneous occlusion of the entry to a leaking false aneurysm after ascending aortic replacement for aortic dissection type A facilitating surgical repair. Henriques JP, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):381–3

Aortic root replacement in type A dissection [letter] Moriyama Y, et al. **Eur J Cardiothorac Surg** 1997 Aug; 12(2):325–6

Aortic wall structural strengthening by intraluminal net prosthesis to arrest aneurysm progression and to prevent dissection and rupture. Nazari S, et al. **Eur J Cardiothorac Surg** 1996;10(4):264–72

Repair for aneurysms of the entire descending thoracic aorta or thoracoabdominal aorta using a deep hypothermia. Okita Y, et al. **Eur J Cardiothorac Surg** 1997 Jul;12(1):120–6

Surgery for aortic dissection with intimal tear in the transverse aortic arch. Okita Y, et al. **Eur J Cardiothorac Surg** 1996;10(9):784–90

Long-term results of patch repair for saccular aneurysms of the transverse aortic arch. Okita Y, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):953–6

Homograft replacement of thoraco-abdominal aorta for a leaking mycotic aneurysm. Pagano D, et al. **Eur J Cardiothorac Surg** 1996;10(5):383–5

Surgery of the thoracic aorta with hypothermic circulatory arrest: experience with retrograde perfusion via the superior vena cava and demonstration of cerebral perfusion. Pagano D, et al. **Eur J Cardiothorac Surg** 1996;10(10):833–8; discussion 839

Aprotinin and deep hypothermic circulatory arrest: there are no benefits even when appropriate amounts of heparin are given. Parolari A, et al. **Eur J Cardiothorac Surg** 1997 Jan; 11(1):149–56

Reoperations after dacron patch aortoplasty with heparinized femoro-femoral bypass. Roth M, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):997–1000

Retrograde cerebral perfusion through antero-axillary thoracotomy in the aortic arch surgery. Sasaguri S, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):657–60

Type B dissection involving a right-sided aortic arch. Senthil V, et al. **Eur J Cardiothorac Surg** 1996;10(6):477–9

Upper and lower extremity somatosensory evoked potential recording during surgery for aneurysms of the descending thoracic aorta. Shahin GM, et al. **Eur J Cardiothorac Surg** 1996;10(5):299–304

Surgery for ruptured thoracic and thoraco-abdominal aortic aneurysms. von Segesser LK, et al. **Eur J Cardiothorac Surg** 1996;10(11):996–1001; discussion 1002

Aortobronchial and aortoesophageal fistulae as risk factors in surgery of descending thoracic aortic aneurysms. von Segesser LK, et al. **Eur J Cardiothorac Surg** 1997 Aug; 12(2):195–201

Surgery of the thoracic aorta using deep hypothermic total circulatory arrest. Are there neurological consequences other than frank cerebral defects? Welz A, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):650–6

Four-channeled aortic dissection and rupture. Yagyu K, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):315–8

The importance of transesophageal echocardiography during surgery of the thoracic aorta. Aadahl P, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):401–6

False aneurysm of the thyrocervical trunk [letter; comment] Chalmers RT. **Eur J Vasc Endovasc Surg** 1997 Apr; 13(4):424–5. Comment on: Eur J Vasc Endovasc Surg 1996 Apr;11(3):373–4.

A case of traumatic pseudoaneurysm of the ascending aorta occurring in a postoperative patient who underwent arch replacement and Bentall's operation. Kochi K, et al. **Hiroshima J Med Sci** 1995 Dec;44(4):145–7

How do we protect the brain? Antegrade selective cerebral perfusion with cold blood during aortic arch surgery. Bachet J, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):193–200

Diagnosis and management of cerebral malperfusion phenomena during aortic dissection repair by transesophageal Doppler echocardiographic monitoring. Coletti G, et al. **J Card Surg** 1996 Sep–Oct;11(5):355–8

Current status of thoracoabdominal aortic aneurysm repair in Marfan syndrome. Coselli JS, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):167–72

Individual strategies of hemostasis for thoracic aortic surgery. de Figueiredo LF, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):222–8 (47 ref.)

Identification of risk factors in patients undergoing thoracoabdominal aneurysm repair. Galla JD, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):292–9

Leftward deviation of the interatrial septum during left heart bypass for repair of a thoracic aortic aneurysm. Hanowell LH, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):251–2

Endovascular stenting of an aortopulmonary fistula presenting with hemoptysis. A case report. Campagna AC, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):643–6

Operative results of thoracoabdominal repair for chronic type B aortic dissection. Dudra J, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):147–51

Directly visualized cerebral circulation during retrograde cerebral perfusion. Yoshimura N, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):553–6

Animal model for investigation of spinal cord injury caused by aortic cross-clamping. Qayumi AK, et al. **J Invest Surg** 1997 Jan–Apr;10(1–2):47–52

What is the appropriate size criterion for resection of thoracic aortic aneurysms? Coady MA, et al. **J Thorac Cardiovasc Surg** 1997 Mar;113(3):476–91; discussion 489–91

Successful repair of thoracic aortic aneurysm in a child with Ehlers-Danlos syndrome. Conte S, et al. **J Thorac Cardiovasc Surg** 1997 Feb;113(2):410–1

Looking for the artery of Adamkiewicz: a quest to minimize paraplegia after operations for aneurysms of the descending thoracic and thoracoabdominal aorta. Griepp RB, et al. **J Thorac Cardiovasc Surg** 1996 Nov;112(5):1202–13; discussion 1213–5

Clinical endovascular placement of branched graft for type B aortic dissection. Inoue K, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):1111–3

Extended aortic replacement for acute type A dissection with the tear in the descending aorta. Kazui T, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):973–8

Stented elephant trunk procedure for an extensive aneurysm involving distal aortic arch and descending aorta. Suto Y, et al. **J Thorac Cardiovasc Surg** 1996 Nov;112(5):1389–90

Posterior circulation cerebral infarcts associated with repair of thoracic aortic disruption using partial left heart bypass. Duke BJ, et al. **J Trauma** 1997 Jun;42(6):1135–9

Alternate surgical approach for posttraumatic thoracic aortic pseudoaneurysm. Mull DH, et al. **J Trauma** 1997 Mar; 42(3):546–8

Embolization of perigraft leaks after endovascular stent-graft treatment of aortic aneurysms. Kato N, et al. **J Vasc Interv Radiol** 1996 Nov–Dec;7(6):805–11

Acute rupture of the descending thoracic aorta: repair with use of endovascular stent-grafts. Semba CP, et al. **J Vasc Interv Radiol** 1997 May–Jun;8(3):337–42

Saccular aneurysm in the right-sided aortic arch: a successfully corrected case. Imagawa H, et al. **J Vasc Surg** 1997 May;25(5):941–4 (7 ref.)

Non clamping anastomosis of the ascending and arch aneurysm using retrograde cerebral perfusion. Yamashita C, et al. **Kobe J Med Sci** 1996 Aug;42(4):261–70

Acute dissecting aortic aneurysm in an operational environment. Henning KS. **Mil Med** 1997 Aug;162(8):573–4 (5 ref.)

Intermittent antegrade/selective cerebral perfusion during circulatory arrest for repair of the aortic arch. Maas C, et al. **Perfusion** 1997 Mar;12(2):127–32 (12 ref.)

Evaluation of thoracic aortic disease with the use of helical CT and multiplanar reconstructions: comparison with surgical findings. Quint LE, et al. **Radiology** 1996 Oct; 201(1):37–41

Surgical and long-term outcome of graft replacement of aneurysms of the descending thoracic aorta. Analysis of 28 consecutive cases. Pokela R, et al. **Scand Cardiovasc J** 1997;31(3):141–5

Acute dissection of ascending aortic aneurysm in a patient with previous coronary artery bypass grafting. Savunen T, et al. **Scand Cardiovasc J** 1997;31(3):161–3

Retrograde cerebral perfusion (RCP) in aortic arch surgery: efficacy and possible mechanisms of brain protection. Bavaria JE, et al. **Semin Thorac Cardiovasc Surg** 1997 Jul; 9(3):222–32 (55 ref.)

Endovascular stent graft repair of thoracic aortic aneurysms. Mitchell RS. **Semin Thorac Cardiovasc Surg** 1997 Jul; 9(3):257–68

Modified Bentall operation with concomitant total aortic arch replacement for DeBakey type I aortic dissection: report of a case. Katoh T, et al. **Surg Today** 1997; 27(4):373–5

Emergency aortic arch replacement in a patient with idiopathic thrombocytopenic purpura. Usui A, et al. **Surg Today** 1996;26(10):828–30

Use of the retrograde "pull-through" technique. Vitali E, et al. **Tex Heart Inst J** 1997;24(2):114–7

Spinal cord protection in descending and thoracoabdominal aortic surgery—the role of distal perfusion. Bonatti J, et al. **Thorac Cardiovasc Surg** 1996 Jun;44(3):136–9

[Development of circulatory support during 420 aneurysm resections of the descending thoracic aorta] Verdant A, et al. **Ann Chir** 1996;50(8):619–25 (Eng. Abstr.) **(Fre)**

[Technical advances in the surgical management of thoracoabdominal aortic aneurysms] Kieffer E, et al. **Bull Acad Natl Med** 1996 Nov;180(8):1841–52; discussion 1852–3 (13 ref.) (Eng. Abstr.) **(Fre)**

[Anesthesia in endovascular treatment of aortic aneurysm. Results and perioperative risks] Eberle B, et al. **Anaesthesist** 1996 Oct;45(10):931–40 (Eng. Abstr.) **(Ger)**

[Prophylactic indications in thoracic aortic aneurysm] Sunder-Plassmann L, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:851–6 (18 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of chronic traumatic aortic aneurysm] Fraedrich G, et al. **Zentralbl Chir** 1996;121(9):756–60 (Eng. Abstr.) **(Ger)**

[Value of intraoperative transesophageal echocardiography during repair of thoracic aorta dissection] Nicosia A, et al. **Cardiologia** 1995 Dec;40(12):941–6 (Eng. Abstr.) **(Ita)**

[Surgery of the descending thoracic and thoraco-abdominal arteries. Report of 105 cases] Zanetti PP, et al. **G Ital Cardiol** 1997 Jul;27(7):682–5 (Eng. Abstr.) **(Ita)**

[A multi-center study on medical and surgical management in patients with aortic aneurysm and dissection from 1988 through 1993] Hayashi J, et al. **J Cardiol** 1996 Jun; 27(6):335–8 **(Jpn)**

[A case report of a successful surgery for thoracoabdominal

aortic aneurysm under partial cardiopulmonary bypass with selective perfusion of major abdominal branches] Abe M, et al. **Kyobu Geka** 1996 Nov;49(12):1010–3 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of aortic dissection (Stanford type A) using hypothermic retrograde cerebral perfusion in patients older than 70 years of age] Ataka K, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):641–4 (Eng. Abstr.) **(Jpn)**

[A successful case of infrarenal abdominal aortic replacement against acute abdominal organ failures and ischemia of bilateral lower limbs following the operation of DeBakey IIIb-type dissecting aneurysm] Gu K, et al. **Kyobu Geka** 1996 Dec;49(13):1100–3 (Eng. Abstr.) **(Jpn)**

[A case report on graft replacement of ruptured aneurysm of the arch and the descending thoracic aorta associated with dense pulmonary adhesion] Hirai M, et al. **Kyobu Geka** 1996 May;49(5):367–71 (16 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of total aortic arch replacement for distal aortic arch aneurysm in an octogenarian] Inaoka M, et al. **Kyobu Geka** 1997 Mar;50(3):226–9 (Eng. Abstr.) **(Jpn)**

[Concomitant composite graft replacement of the aortic root and the aortic arch for type A aortic dissection] Kikuchi Y, et al. **Kyobu Geka** 1997 Jun;50(6):469–74 (Eng. Abstr.) **(Jpn)**

[A case report of ruptured distal aortic arch aneurysm into pericardial space] Koshino T, et al. **Kyobu Geka** 1997 Mar; 50(3):205–8 (Eng. Abstr.) **(Jpn)**

[The surgical results of aged thoracic aortic aneurysm] Kunihara T, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):627–31 (Eng. Abstr.) **(Jpn)**

[An aged case of successful repair for the ruptured distal aortic arch aneurysm associated with aortic regurgitation: a case report] Kusuhara K, et al. **Kyobu Geka** 1996 Aug; 49(9):754–8 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of thoracic aorta for elderly patient] Nakai M, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):622–6 (Eng. Abstr.) **(Jpn)**

[Combined surgery for coronary artery disease and thoracic aortic disease] Ohashi H, et al. **Kyobu Geka** 1997 Apr; 50(4):263–7; discussion 267–9 (Eng. Abstr.) **(Jpn)**

[Redo operation after surgery for aortic aneurysm and dissection] Ohmi M, et al. **Kyobu Geka** 1997 Jul;50(7):523–8; discussion 528–30 (Eng. Abstr.) **(Jpn)**

[Case report of a thoracoabdominal aneurysm operation using profound hypothermia and circulatory arrest] Okada Y, et al. **Kyobu Geka** 1996 Dec;49(13):1105–9 (Eng. Abstr.) **(Jpn)**

[Management of aortoesophageal fistula due to thoracic aortic aneurysm] Sakurai T, et al. **Kyobu Geka** 1996 Sep; 49(10):815–20 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical treatment of thoracoabdominal aortic aneurysm] Shiiya N, et al. **Kyobu Geka** 1997 Feb;50(2):133–43 (122 ref.) **(Jpn)**

[Aortic arch surgery in the elderly] Tayama K, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):637–40 (Eng. Abstr.) **(Jpn)**

[Obstruction of the true lumen by retrograde perfusion during repair of DeBakey type I aortic dissection: a case report] Tsuda K, et al. **Kyobu Geka** 1996 May;49(5):372–5 (Eng. Abstr.) **(Jpn)**

[Application of heparin-coated percutaneous cardiopulmonary support system to elective cardiac and aortic operations] Watanabe SI, et al. **Kyobu Geka** 1997 May;50(5):362–7 (Eng. Abstr.) **(Jpn)**

[The surgical treatment for acute aortic dissection and changing concept of surgical procedures] Nakajima N. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):900–5 (9 ref.) (Eng. Abstr.) **(Jpn)**

[A successful surgical treatment of dissecting thoracoabdominal aortic aneurysm using a heparin coated percutaneous cardiopulmonary support system] Tanaka H, et al. **Nippon Geka Gakkai Zasshi** 1997 May;98(5):524–8 (Eng. Abstr.) **(Jpn)**

[Operative results and long-term prognosis of aortic dissections] Ueda T, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct;97(10):916–20 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Evolution and recent trends in patient selection and reconstruction method for chronic aortic dissection] Yasuda K, et al. **Nippon Geka Gakkai Zasshi** 1996 Oct; 97(10):906–15 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Keypoints in improving the results of emergency surgery of aneurysm of the thoracic aorta—evaluation of therapeutic results] Adachi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Mar;45(3):332–3 **(Jpn)**

[A case of extended surgery in acute aortic dissection by perfusion into extra anatomic bypass] Fujii H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul;44(7):1003–7 (Eng. Abstr.) **(Jpn)**

[Surgical strategy for Stanford type A aortic dissection with Marfan syndrome] Fukada J, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):724–8 (Eng. Abstr.) **(Jpn)**

[Surgical outcomes of transverse aortic arch replacement] Fukuda I, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):718–23 (Eng. Abstr.) **(Jpn)**

[Long-term survival after treatment of thoracic aneurysms by thromboexclusion operation] Gu K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep;44(9):1749–52 (Eng. Abstr.) **(Jpn)**

[A case of total arch graft replacement for distal aortic arch aneurysm developed around the site of graft patch aortoplasty] Hachiro Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2172–6 (Eng. Abstr.) **(Jpn)**

[Two cases of total arch replacement after coronary artery bypass surgery with internal mammary artery graft] Hasegawa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct;44(10):1935–40 (Eng. Abstr.) **(Jpn)**

[Urgent replacement of aortic arch and descending aorta following replacement of ascending aorta for Stanford a aortic dissection—a case report] Hata H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jan;45(1):102–7 (Eng. Abstr.) **(Jpn)**

[Debakey IIIb aortic dissection from a distal arch atherosclerotic aneurysm—a case report] Hayashi S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):569–71 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical treatment of type A acute aortic dissection—experience of hypothermic circulatory arrest associated with the cerebroplegia] Hirotani T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):556–62 (Eng. Abstr.) **(Jpn)**

[Result of surgery for aneurysms of distal aortic arch and proximal descending aorta] Inada H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep;44(9):1709–16 (Eng. Abstr.) **(Jpn)**

[Traumatic injuries of the thoracic aorta—report of five cases] Kanazawa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec; 44(12):2155–63 (Eng. Abstr.) **(Jpn)**

[Stent graft treatment for two cases of DeBakey IIIb dissecting aortic aneurysm] Kawaguchi S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):926–33 (Eng. Abstr.) **(Jpn)**

[Postoperative inflammatory responses to gelatin- and collagen-impregnated Dacron grafts and changes of endotoxin] Kawashima T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):531–5 (Eng. Abstr.) **(Jpn)**

[Extended total aortic arch replacement involving the proximal descending aorta through a median sternotomy] Kurimoto Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):661–5 (Eng. Abstr.) **(Jpn)**

[Surgical repair of a dissecting aortic aneurysm with entry at proximal descending aorta through left thoracotomy—a case report] Mitsumaru A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug;44(8):1163–7 (Eng. Abstr.) **(Jpn)**

[Clinical experience with the gelatin-resorcine-formol biological glue in acute type A aortic dissection] Moriyama Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May; 45(5):682–6 (Eng. Abstr.) **(Jpn)**

[Simultaneous surgical treatment for distal aortic arch aneurysm associated with innominate artery aneurysm and coronary artery disease] Nakashima S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):778–82 (Eng. Abstr.) **(Jpn)**

[Emergency surgery of aneurysm of the thoracic aorta: for prediction of surgical results based on preoperative factors and determination of therapeutic policies] Nishiuchi M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Mar;45(3):336–7 **(Jpn)**

[A simultaneous operation of aortic root, arch replacement, and sternal elevation for Marfan's syndrome—a case report] Ohhira M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):759–63 (Eng. Abstr.) **(Jpn)**

[Surgical treatment for acute dissection associated with thoracic aneurysm—a case report and a review of Japanese literatures] Ohki S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug;44(8):1151–4 (7 ref.) (Eng. Abstr.) **(Jpn)**

[A successful surgical case report of impending rupture of the true thoraco-abdominal aortic aneurysm induced by thrombosed-type acute aortic dissection (Stanford type A)] Ohnishi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):649–54 (Eng. Abstr.) **(Jpn)**

[Laser Doppler flowmetry of the bulbar conjunctiva as a monitor of the cerebral blood flow] Ohtani N. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Sep;44(9):1721–8 (Eng. Abstr.) **(Jpn)**

[Monitoring for spinal cord ischemia by the use of the motor evoked potentials, the evoked spinal cord potential and the segmental evoked spinal cord potential during thoracoabdominal aortic surgery—a case report] Okada K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul; 45(7):1003–5 (Eng. Abstr.) **(Jpn)**

[Results and keypoints in emergency surgery of true and dissecting aortic aneurysms] Omi M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Mar;45(3):339–41 **(Jpn)**

[Successful surgical treatment of intraoperative aortic dissection complicating aortic valve replacement] Ozaki S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul; 44(7):1022–6 (Eng. Abstr.) **(Jpn)**

[A case report of a left bronchial stump fistula from which the wrapped omentum was removed, because of rupture of the anastomotic aneurysm of the descending thoracic aorta—functions of the wrapped omentum in the early phase and extended phase after surgery] Ozaki S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):687–90 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of aortic dissection with ringed intraluminal graft—late results and fate of the false lumen] Sasaki K. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul; 44(7):923–35 (Eng. Abstr.) **(Jpn)**

[Subtotal aortic replacement in a patient with Marfan's syndrome—replacement of the ascending aorta and entire aortic arch for acute type I aortic dissection 4 years after the thoracoabdominal replacement] Shiiya N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Nov;44(11):2095–9 (Eng. Abstr.) **(Jpn)**

[Management of emergency surgery of aneurysm of the thoracic aorta and postoperative results—evaluation of the causes of death and surgical methods] Shimamoto M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Mar;45(3):341–3 **(Jpn)**

[Postoperative results of emergency surgery of aneurysm of the thoracic aorta based on the site of replacement and etiology] Suda H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Mar;45(3):337–9 **(Jpn)**

[Management of emergency surgery of aneurysm of thoracic aorta and postoperative results] Tamiya Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Mar;45(3):334–5 **(Jpn)**

[Acute aortic dissection complicated with acute myocardial infarction—a case report of successful operation for the case of DOA] Tayama K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul;44(7):965–9 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of thoracoabdominal aortic aneurysm] Goto H, et al. **Rinsho Kyobu Geka** 1989 Oct;9(5):447–51 (Eng. Abstr.) **(Jpn)**

[Combined operation for patients with ischemic heart disease and thoracic aortic aneurysm] Kitamura S, et al. **Rinsho Kyobu Geka** 1989 Aug;9(4):329–32 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical treatment for thoracoabdominal aortic aneurysm] Sakuma M, et al. **Rinsho Kyobu Geka** 1989 Oct;9(5):435–40 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of thoracoabdominal aortic aneurysms] Shin H, et al. **Rinsho Kyobu Geka** 1989 Oct;9(5):441–6 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of thoracoabdominal aortic aneurysm: detection and prevention of spinal cord injury] Yamashita K, et al. **Rinsho Kyobu Geka** 1989 Oct;9(5):452–5 (Eng. Abstr.) **(Jpn)**

[Clinical usefulness of intraoperative color Doppler sonography in the operation of the dissecting aortic aneurysm] Yozu R, et al. **Rinsho Kyobu Geka** 1989 Aug; 9(4):401–5 (Eng. Abstr.) **(Jpn)**

[Surgery for acute type-A aortic dissection] Brazão A, et al. **Rev Port Cardiol** 1997 Jun;16(6):525–32, 507 (40 ref.) (Eng. Abstr.) **(Por)**

[Surgical treatment of the pathology of the descending aorta. Aneurysm and dissection] Lisbona Sabater C, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:85–91 (Eng. Abstr.) **(Spa)**

THERAPY

Stent treatment of obstructing dissection after percutaneous transluminal angioplasty of aortic stenosis caused by nonspecific aortitis. Sharma S, et al. **Cardiovasc Intervent Radiol** 1997 Sep–Oct;20(5):377–9

Coronary stenting for aortocoronary dissection following balloon angioplasty. Seifein HB, et al. **Cathet Cardiovasc Diagn** 1996 Jun;38(2):222–5

Transcatheter Inoue endovascular graft for treatment of canine aortic dissection. Htay T, et al. **Heart Vessels** 1996; 11(2):80–5

Natural history of aneurysms of the descending and thoracoabdominal aorta. Svensson LG. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):279–84 (40 ref.)

Endovascular stent-graft exclusion of an aortobronchial fistula. Chuter TA, et al. **J Vasc Interv Radiol** 1996 May–Jun;7(3):357–9

Use of a self-expanding vascular occluder for embolization during endovascular aortic aneurysm repair. Kato N, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):27–33

True lumen obliteration in complicated aortic dissection: endovascular treatment. Slonim SM, et al. **Radiology** 1996 Oct;201(1):161–6

ULTRASONOGRAPHY

Acute aortic dissection: association with patent ductus arteriosus. Cusick DA, et al. **Am J Card Imaging** 1996 Jul; 10(3):200–3

Opacification of the thoracic aorta after venous injection of sonicated albumin microbubbles. Implications for aortic dissection. Voci P. **Cardiologia** 1997 Mar;42(3):299–304

Multiplane transesophageal echocardiography in traumatic aortic dissection: a case report. Liao WB, et al. **Chang Keng I Hsueh** 1995 Dec;18(4):383–6

Use of transesophageal echocardiography for diagnosis of traumatic aortic injury. Goarin JP, et al. **Chest** 1997 Jul; 112(1):71–80

Spontaneous echocardiographic contrast in the true lumen of a dissected aortic aneurysm. Allan JJ, et al. **J Am Soc Echocardiogr** 1997 Jul–Aug;10(6):673–6

Mycotic aneurysm of the descending thoracic aorta: the role of transesophageal echocardiography. Joffe II, et al. **J Am Soc Echocardiogr** 1996 Sep–Oct;9(5):663–7

AORTIC ANEURYSM, THORACIC

Tortuosity of the descending thoracic aorta simulating dissection on transesophageal echocardiography. Katz ES, et al. **J Am Soc Echocardiogr** 1997 Jan-Feb;10(1):83-7

False-positive diagnosis of ascending aorta dissection by single-plane transesophageal echocardiography. Neri E, et al. **J Thorac Cardiovasc Surg** 1996 Nov;112(5):1387-9

[Aortic intramural hematoma. A rare new clinical form of aortic dissection] Bolognesi R, et al. **Cardiologia** 1997 Aug; 42(8):789-94 (27 ref.) **(Ita)**

[Value of intraoperative transesophageal echocardiography during repair of thoracic aorta dissection] Nicosia A, et al. **Cardiologia** 1995 Dec;40(12):941-6 (Eng. Abstr.) **(Ita)**

[A case report of a pseudoaneurysm of the thoracic aorta (thrombotic closure type) showing like a mediastinal tumor--value of endoscopic ultrasonography in differential diagnosis] Muraki S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct; 44(10):1917-20 (Eng. Abstr.) **(Jpn)**

[Clinical usefulness of intraoperative color Doppler sonography in the operation of the dissecting aortic aneurysm] Yozu R, et al. **Rinsho Kyobu Geka** 1989 Aug; 9(4):401-5 (Eng. Abstr.) **(Jpn)**

[A case report of thoracic aortic and common carotid artery dissecting aneurysm diagnosed by duplex ultrasound examination] Kimura K, et al. **Rinsho Shinkeigaku** 1996 Feb;36(2):348-51 (Eng. Abstr.) **(Jpn)**

AORTIC ARCH see **AORTA, THORACIC**

AORTIC ARCH SYNDROMES

[Aortitis syndrome] Shimizu A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):351-5 (12 ref.) **(Jpn)**

COMPLICATIONS

Aortic arch interruption in association with Ebstein's anomaly of tricuspid valve and rheumatic mitral stenosis [see comments] Shah P, et al. **Indian Heart J** 1996 Jul-Aug; 48(4):398-400. Comment in: Indian Heart J 1996 Nov-Dec;48(6):735-6.

Growth hormone-secreting pituitary adenoma associated with multiple bone cysts, skin pigmentation and aortitis syndrome. Ihara C, et al. **J Endocrinol Invest** 1996 Dec; 19(11):753-7

[CABG performed for LMT orifice stenosis 15 years after AVR in a case of aortitis syndrome] Chikazawa G, et al. **Kyobu Geka** 1997 May;50(5):396-9 (Eng. Abstr.) **(Jpn)**

[Ruptured descending thoracic aortic aneurysm due to aortitis syndrome--a case report] Masaki H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):655-60 (Eng. Abstr.) **(Jpn)**

[Right eye blindness as the predominating clinical sign in a patient with aortic arch syndrome: a case report] Kopytek M, et al. **Neurol Neurochir Pol** 1996 Nov-Dec; 30(6):1065-71 (Eng. Abstr.) **(Pol)**

EMBRYOLOGY

Aortic arch thrombosis in a neonate with coarctation exposed to cocaine in utero. Wardle SP, et al. **J R Soc Med** 1996 Sep;89(9):524-5

SURGERY

Management of arch hypoplasia after successful coarctation repair. DeLeon MM, et al. **Ann Thorac Surg** 1997 Apr; 63(4):975-80

Gut mucosal perfusion in neonates undergoing cardiopulmonary bypass. Booker PD, et al. **Br J Anaesth** 1996 Nov;77(5):597-602

[A case of coronary artery bypass grafting using patch mounted graft technique for aortitis syndrome with left coronary ostial stenosis] Aida H, et al. **Kyobu Geka** 1996 Nov;49(12):1018-21 (Eng. Abstr.) **(Jpn)**

[Simultaneous operation of aortic valve replacement and renal artery reconstruction in a patient of aortitis syndrome: a case report] Ikeda M, et al. **Kyobu Geka** 1996 Nov; 49(12):1005-7 (Eng. Abstr.) **(Jpn)**

[Successful surgical repair of composite graft detachment occurred 5 months after combined Bentall's operation and graft replacement with active aortitis syndrome] Tanaka S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jan; 45(1):67-72 (Eng. Abstr.) **(Jpn)**

THERAPY

Percutaneous balloon aortoplasty for restenosis after extended aortic arch anastomosis for type B interrupted aortic arch. Sato S, et al. **Pediatr Cardiol** 1996 Jul-Aug; 17(4):275-7

ULTRASONOGRAPHY

[A case of aortitis syndrome, in which carotid ultrasonography was a useful approach for the diagnosis] Watanabe Y, et al. **Ryumachi** 1996 Oct;36(5):753-6 (Eng. Abstr.) **(Jpn)**

VETERINARY

Long-term results of surgical correction of persistent right aortic arch in dogs: 25 cases (1980-1995). Muldoon MM, et al. **J Am Vet Med Assoc** 1997 Jun 15;210(12):1761-3

AORTIC BODIES

[Pheochromocytoma as a cause of collapse and hypertension during a stay in the tropics] Maassen van den Brink KI, et al. **Ned Tijdschr Geneeskd** 1997 Jan 18;141(3):152-4 (Eng. Abstr.) **(Dut)**

PHYSIOLOGY

Modelling the peripheral chemosensory drive of ventilation on basis of homogenous sensory units. Eugenín J. **Adv Exp Med Biol** 1996;410:405-10

Peripheral chemoreflex in chronic heart failure: friend and foe [editorial] Chugh SS, et al. **Am Heart J** 1996 Oct; 132(4):900-4 (42 ref.)

Spatial relationships of enteric nerve fibers to vagal motor terminals and the sarcolemma in motor endplates of the rat esophagus: a confocal laser scanning and electron-microscopic study. Wörl J, et al. **Cell Tissue Res** 1997 Jan;287(1):113-8

Brain ischemia and gastric mucosal damage in spontaneously hypertensive rats: the role of arterial vagal adrenoceptors. Kawakubo K, et al. **Dig Dis Sci** 1996 Dec;41(12):2383-91

Reflex cardiac dromotropic responses to stimulation of the carotid and aortic chemoreceptors in the anaesthetized cat. Jones JF, et al. **J Physiol (Lond)** 1997 Jul 15;502 (Pt 2):461-7

AORTIC COARCTATION

[Atypical coarctation of the aorta] Miyamoto T. **Ryoikibetsu Shokogun Shirizu** 1996;(13):29-32 (6 ref.) **(Jpn)**

[Localized juxtaductal coarctation] Miyamoto T. **Ryoikibetsu Shokogun Shirizu** 1996;(13):78-81 (11 ref.) **(Jpn)**

[Coarctation of the aorta] Nomoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):252-6 (17 ref.) **(Jpn)**

[Pseudocoarctation of the aorta] Suehiro S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):329-31 (13 ref.) **(Jpn)**

COMPLICATIONS

Single therapeutic catheterization to treat coexisting coarctation of the aorta and patent ductus arteriosus. Ing FF, et al. **Am J Cardiol** 1997 Feb 15;79(4):535-7

Aortic coarctation: a rare and unexpected cause of secondary arterial hypertension in the elderly. Convens C, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):71-4 (26 ref.)

Retinal vascular abnormalities in aortic coarctation [letter] Tabandeh H. **Eye** 1996;10 (Pt 4):525-7

Thrombus in coarctation of the aorta masquerading as an interrupted aortic arch. Bonhoeffer P, et al. **Heart** 1997 Feb;77(2):183-4

Interferon-alpha therapy for multiple hemangiomas associated with coarctation of the aorta. Hijii T, et al. **Heart Vessels** 1996;11(4):211-4

Tetralogy of Fallot, absent pulmonary valve, partial anomalous pulmonary venous return and coarctation of the aorta [see comments] Elami A, et al. **Int J Cardiol** 1995 Dec;52(3):203-6. Comment in: Int J Cardiol 1996 Jun;54(3):287.

Tetralogy of Fallot, absent pulmonary valve and coarctation of the aorta [letter; comment] Momma K. **Int J Cardiol** 1996 Jun;54(3):287 (5 ref.). Comment on: Int J Cardiol 1995 Dec;52(3):203-6.

Extensive facial hemangioma associated with cardiac and abdominal anomalies. Patel SD, et al. **J Am Acad Dermatol** 1997 Apr;36(4):636-8

Coarctation of aorta and hereditary spherocytosis [letter; comment] Charan VD. **J Assoc Physicians India** 1996 Apr; 44(4):290. Comment on: J Assoc Physicians India 1995 Sep;43(9):649.

Aortic coarctation associated with an aberrant right subclavian artery. Celis I, et al. **J Belge Radiol** 1996 Aug; 79(4):170-1

Coarctation of the abdominal aorta with left renal artery and splenic artery aneurysms. Dogan R, et al. **J Cardiovasc Surg (Torino)** 1996 Oct;37(5):457-61

Renal autotransplantation for renovascular hypertension caused by midaortic syndrome. Bleacher J, et al. **J Pediatr Surg** 1997 Feb;32(2):248-50; discussion 250-1

Intracranial aneurysms [letter; comment] Navarrete P. **N Engl J Med** 1997 Jun 12;336(24):1759. Comment on: N Engl J Med 1997 Jan 2;336(1):28-40.

Acute renal failure following ACE inhibition in a patient with coarctation of the aorta. Sever MS, et al. **Nephrol Dial Transplant** 1996 Aug;11(8):1643-4

An unusual cause of chest pain in an adolescent presenting to the emergency department. Graneto JW, et al. **Pediatr Emerg Care** 1997 Feb;13(1):33-6

Necrotizing enterocolitis in a term infant with coarctation of the aorta complex. Hasegawa T, et al. **Pediatr Surg Int** 1997;12(1):57-8

[Rupture of cerebral aneurysm associated with aortic coarctation (letter)] Gire C, et al. **Rev Neurol (Paris)** 1997 Jun;153(5):357-8 **(Fre)**

[A case report of postcoarctation mycotic aneurysm after surgical treatment for cerebral arterial aneurysms] Kido M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul; 45(7):1006-10 (7 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Screening for coarctation of the aorta [letter] Schapera CH. **Am Fam Physician** 1997 Jun;55(8):2612

Nuchal translucency: a marker for the antenatal diagnosis of aortic coarctation. Moselhi M, et al. **Br J Obstet Gynaecol** 1996 Oct;103(10):1044-5

Is echocardiography or magnetic resonance imaging superior for precoarctation angioplasty evaluation? Mendelsohn AM, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):26-30

Pseudocoarctation of the aorta coexistent with coarctation [letter] Yamada M, et al. **Eur J Pediatr** 1996 Nov; 155(11):993

Right aortic arch with mirror-image branching and coarctation of the aorta. Liang CD, et al. **J Formos Med Assoc** 1997 Aug;96(8):657-9

Measurement of collateral blood flow in a porcine model of aortic coarctation by velocity-encoded cine MRI. Chernoff DM, et al. **J Magn Reson Imaging** 1997 May-Jun; 7(3):557-63

[What is your diagnosis? Pseudo-aortic coarctation. Congenital bicuspid aortic valve. Left anterior hemiblock] Hauser M, et al. **Schweiz Rundsch Med Prax** 1997 Jan 21; 86(4):79-82 **(Ger)**

[Aortic coarctation and the bicuspid aortic valve] Poliakova ND, et al. **Ter Arkh** 1996;68(4):48-50 (Eng. Abstr.) **(Rus)**

ECONOMICS

Comparison of hospital charges for balloon angioplasty and surgical repair in children with native coarctation of the aorta. Shim D, et al. **Am J Cardiol** 1997 Apr 15;79(8):1143-6

EMBRYOLOGY

Aortic arch thrombosis in a neonate with coarctation exposed to cocaine in utero. Wardle SP, et al. **J R Soc Med** 1996 Sep;89(9):524-5

ENZYMOLOGY

[Invertory mechanism of the changes in Na,K-ATPase activity in myocardium cytoplasmatic membranes during critical stage of compensatory hyperfunction of the heart in adult and aged rats] Frolkis VV, et al. **Biull Eksp Biol Med** 1996 Jun;121(6):631-3 **(Rus)**

ETIOLOGY

[Successful surgical management of cardiovascular thrombosis and aortic coarctation, caused by protein C deficiency, in a newborn infant] István H, et al. **Orv Hetil** 1996 Feb 4;137(5):251-3 (Eng. Abstr.) **(Hun)**

[Acquired aortic coarctation after surgical operation of ductus arteriosus in a preterm infant] Cabrera A, et al. **Rev Esp Cardiol** 1996 Aug;49(8):615-7 (Eng. Abstr.) **(Spa)**

GENETICS

Interruption of aortic arch type A in two siblings. Nakada T, et al. **Acta Paediatr Jpn** 1996 Feb;38(1):63-5

Noonan syndrome with cardiac left-sided obstructive lesions [letter; comment] [see comments] Digilio MC, et al. **Hum Genet** 1997 Feb;99(2):289. Comment on: Hum Genet 1996 May;97(5):564-7. Comment in: Hum Genet 1997 Feb;99(2):290-7.

Further clinical model for the possible impairment of a putative lymphogenic gene(s) for Turner stigmata [letter; comment] Ogata T, et al. **Hum Genet** 1997 Feb;99(2):290 . Comment on: Hum Genet 1997 Feb;99(2):289.

Middle aortic syndrome in a boy with arteriohepatic dysplasia (Alagille syndrome). Shefler AG, et al. **Pediatr Cardiol** 1997 May-Jun;18(3):232-4

METABOLISM

Multiple polyamine regulatory pathways control compensatory cardiovascular hypertrophy in coarctation hypertension. Lipke DW, et al. **Clin Exp Hypertens** 1997 Apr;19(3):269-95

Eflornithine alters changes in vascular responsiveness associated with coarctation hypertension. Lipke DW, et al. **Clin Exp Hypertens** 1997 Apr;19(3):297-312

MICROBIOLOGY

Endaortitis of coarctation of the aorta after invasive diagnostics. Böhm JO, et al. **Ann Thorac Surg** 1997 Mar; 63(3):829-30

PATHOLOGY

Evaluation of magnetic resonance imaging in coarctation of the aorta: the importance of multiple imaging planes. Greenberg SB, et al. **Pediatr Cardiol** 1997 Sep-Oct; 18(5):345-9

[Shone's syndrome] Muraki N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):311-3 (10 ref.) **(Jpn)**

[Status of the renal arterial system in experimental aortic coarctation and after its repair] Shormanov SV, et al. **Arkh Patol** 1996 Jan-Feb;58(1):37-41 (Eng. Abstr.) **(Rus)**

[Morpho-functional changes in renal blood vessels during experimental aortic coarctation and after its surgical

treatment] Shormanov SV, et al. **Biull Eksp Biol Med** 1997 May;123(5):591–3 **(Rus)**

[Structural changes in the walls of the intraorganic vessels of the kidney in experimental aortic coarctation] Ial'tsev AV, et al. **Morfologiia** 1996;109(3):41–6 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Influence of aortic impedance on the development of pressure–overload left ventricular hypertrophy in rats. Kobayashi S, et al. **Circulation** 1996 Dec 15;94(12):3362–8

Improved measurement of pressure gradients in aortic coarctation by magnetic resonance imaging. Oshinski JN, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1818–26

Measurement of collateral blood flow in a porcine model of aortic coarctation by velocity–encoded cine MRI. Chernoff DM, et al. **J Magn Reson Imaging** 1997 May–Jun; 7(3):557–63

Altered cardiac mechanism and sarcoplasmic reticulum function in pressure overload–induced cardiac hypertrophy in rats. Ohkusa T, et al. **J Mol Cell Cardiol** 1997 Jan; 29(1):45–54

Echocardiographic evaluation of systolic and diastolic function in postoperative coarctation patients. Sigurdardóttir LÝ, et al. **Pediatr Cardiol** 1997 Mar–Apr; 18(2):96–100

RADIOGRAPHY

[Severe calcifying atherosclerosis of the thoracic aorta with symptoms of aortic isthmus stenosis. Case report] Froelich JJ, et al. **Radiologe** 1997 Feb;37(2):173–6 (Eng. Abstr.) **(Ger)**

SURGERY

Dilation mechanism, causes of restenosis and stenting in balloon coarctation angioplasty. Ino T, et al. **Acta Paediatr** 1997 Apr;86(4):367–71 (55 ref.)

Effects of morphologic restenosis, defined by MRI after coarctation repair, on blood pressure and arm–leg and Doppler gradients. Günthard J, et al. **Angiology** 1996 Nov; 47(11):1073–80

Management of arch hypoplasia after successful coarctation repair. DeLeon MM, et al. **Ann Thorac Surg** 1997 Apr; 63(4):975–80

Late true aneurysm after bypass grafting for long aortic coarctation. Fujita T, et al. **Ann Thorac Surg** 1996 Nov; 62(5):1511–3 (10 ref.)

Repair of aortobronchial fistula using extraanatomic grafts and hypothermic arrest. Lawrence WA, et al. **Ann Thorac Surg** 1997 Apr;63(4):1158–60

Hypoplastic aortic arch morphology pertinent to growth after surgical correction of aortic coarctation. Machii M, et al. **Ann Thorac Surg** 1997 Aug;64(2):516–20

Long–term follow–up after repair of coarctation of the aorta in adults [letter; comment] Viganò M, et al. **Ann Thorac Surg** 1997 Jun;63(6):1827–8. Comment on: Ann Thorac Surg 1996 Apr;61(4):1168–71.

The usefulness of the spinal and subcortical components of the posterior tibial nerve SEPs for spinal cord monitoring during aortic coarctation repair. Guérit JM, et al. **Electroencephalogr Clin Neurophysiol** 1997 Mar; 104(2):115–21

Arm–leg pressure gradients on late follow–up after coarctation repair. Possible causes and implications. Guenthard J, et al. **Eur Heart J** 1996 Oct;17(10):1572–5

Repair of aortic arch interruption by direct anastomosis. Bogers AJ, et al. **Eur J Cardiothorac Surg** 1997 Jan; 11(1):100–4

Alternative techniques for surgical management of recoarctation. Caspi J, et al. **Eur J Cardiothorac Surg** 1997 Jul;12(1):116–9

Bilateral internal mammary artery atherosclerosis: a late complication of delayed repair of coarctation of the aorta. Dlingea M, et al. **Eur J Cardiothorac Surg** 1997 Apr; 11(4):788–9

Extraanatomic thoracic aortic bypass grafts: indications, techniques, and results. Heinemann MK, et al. **Eur J Cardiothorac Surg** 1997 Jan;11(1):169–75

Spinal cord protection using hypothermic cardiocirculatory arrest in extended repair of recoarctation and persistent hypoplastic aortic arch. Lange R, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):697–702

Early and moderate long–term results of a new surgical technique for repair of aortic coarctation. Sarioğlu T, et al. **Eur J Cardiothorac Surg** 1996;10(10):884–8; discussion 889

Primary repair of coarctation of the thoracic aorta by patch graft aortoplasty. A three–decade experience and follow–up in 60 patients. Venturini A, et al. **Eur J Cardiothorac Surg** 1996;10(10):890–6

Aortoaortic bypass: indications, techniques and results. Airan B, et al. **Indian Heart J** 1997 May–Jun;49(3):303–8

Coarctation in teenagers: two new surgical modifications. Sarsam MA. **J Card Surg** 1997 Jan–Feb;12(1):41–5

Onion skin and functionality in congenital heart disease [editorial; comment] Cyran SE. **J Pediatr** 1997 Aug; 131(2):178–9. Comment on: J Pediatr 1997 Aug;131(2):210–4.

Excessive anaerobic metabolism during exercise after repair of aortic coarctation [see comments] Rhodes J, et al. **J Pediatr** 1997 Aug;131(2):210–4. Comment in: J Pediatr 1997 Aug;131(2):178–9.

Management of coarctation with multiple calcified aneurysms of the intercostal arteries in adults. Sethi GK, et al. **J Thorac Cardiovasc Surg** 1975 Jun;69(6):909–11

Endovascular stent–graft exclusion of an aortobronchial fistula. Chuter TA, et al. **J Vasc Interv Radiol** 1996 May–Jun;7(3):357–9

Ascending aorta to supraceliac abdominal aorta bypass for coarctation of the aorta in an adult. Yamamoto S, et al. **Surg Today** 1997;27(3):288–90

Repair of a ruptured sinus of Valsalva aneurysm. Associated with annuloaortic ectasia and coarctation of the aorta in a patient with Marfan syndrome. Tesler UF, et al. **Tex Heart Inst J** 1997;24(2):134–8

Neurogenic lesions after posterolateral thoracotomy in young children. Emmel M, et al. **Thorac Cardiovasc Surg** 1996 Apr;44(2):86–91

Repair of coarctation of the aorta in adults with simultaneous aortic valve replacement and coronary artery bypass grafting. Thomka I, et al. **Thorac Cardiovasc Surg** 1997 Apr; 45(2):93–6

[Aortic coarctation––long–term follow–up in adults] Heger M, et al. **Z Kardiol** 1997 Jan;86(1):50–5 (Eng. Abstr.) **(Ger)**

[Management of aortic recoarctation by transluminal balloon angioplasty in childhood] Szatmári A, et al. **Orv Hetil** 1997 Aug 24;138(34):2127–31 (Eng. Abstr.) **(Hun)**

[Graft replacement for repair of coarctation of the aorta in adults: a case report] Aida H, et al. **Kyobu Geka** 1996 Sep; 49(10):859–61 (Eng. Abstr.) **(Jpn)**

[Single–stage correction of coarctation of the aorta with aortic regurgitation] Uchida N, et al. **Kyobu Geka** 1997 Apr;50(4):317–20 (Eng. Abstr.) **(Jpn)**

[Primary surgical repair of aorticopulmonary septal defect with coarctation of the aorta] Kashima I, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):615–8 (Eng. Abstr.) **(Jpn)**

[A case of extra anatomical bypass grafting for coarctation of aorta associated with Turner's syndrome] Kikuchi C, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug; 44(8):1175–8 (Eng. Abstr.) **(Jpn)**

[A successful staged complete repair in a neonate with coarctation of aorta, ventricular septal defect, and left ventricular outflow tract obstruction––a new palliative operation] Suzuki T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug;44(8):1179–84 (Eng. Abstr.) **(Jpn)**

[Atypical coarctation. Repair with Dacron graft and aortic sarcoma] Caralps Riera JM, et al. **Rev Esp Cardiol** 1996 Sep;49(9):693–6 (Eng. Abstr.) **(Spa)**

[The use of transesophageal echocardiography in the diagnosis of aortic hematoma after an aortic recoarctation angioplasty] Mercé J, et al. **Rev Esp Cardiol** 1997 May; 50(5):355–6 (Eng. Abstr.) **(Spa)**

THERAPY

Reopening of the ductal ampulla during balloon angioplasty of native aortic coarctation [letter] Wong JA, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):316–7

Long segment coarctation of the thoracic aorta: treatment with multiple balloon–expandable stent implantation. Thanopoulos BV, et al. **Am Heart J** 1997 Apr;133(4):470–3

Single therapeutic catheterization to treat coexisting coarctation of the aorta and patent ductus arteriosus. Ing FF, et al. **Am J Cardiol** 1997 Feb 15;79(4):535–7

Comparison of hospital charges for balloon angioplasty and surgical repair in children with native coarctation of the aorta. Shim D, et al. **Am J Cardiol** 1997 Apr 15;79(8):1143–6

Implantation of balloon–expandable stents for coarctation of the aorta: implantation data and short–term results [see comments] Bulbul ZR, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):36–42. Comment in: Cathet Cardiovasc Diagn 1996 Sep;39(1):43.

Successful balloon dilation of an abdominal coarctation of the aorta in patient with presumed Takayasu's aortitis. Kashani IA, et al. **Cathet Cardiovasc Diagn** 1996 Aug; 38(4):406–9

Stent redilation in canine models of congenital heart disease: pulmonary artery stenosis and coarctation of the aorta. Mendelsohn AM, et al. **Cathet Cardiovasc Diagn** 1996 Aug; 38(4):430–40

Endovascular stent implantation for severe recoarctation of the aorta: case report with angiographic and 18–month clinical follow–up. Pedulla DM, et al. **Cathet Cardiovasc Diagn** 1997 Mar;40(3):311–4

Stenting coarctation of the aorta: promising concept but primitive technology [editorial; comment] Ruiz CE, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):43. Comment on: Cathet Cardiovasc Diagn 1996 Sep;39(1):36–42.

Predictors of outcome of balloon angioplasty of native aortic coarctation [letter; comment] Rao PS, et al. **Circulation** 1997 Aug 5;96(3):1057–9. Comment on: Circulation 1996 Sep 1;94(5):1056–62.

Transballoon intravascular ultrasound imaging during balloon angioplasty in animal models with coarctation and branch pulmonary stenosis. Stock JH, et al. **Circulation** 1997 May 20;95(10):2354–7

Should balloon angioplasty be used instead of surgery for native aortic coarctation? [letter; comment] Qureshi SA, et al. **Heart** 1997 Jan;77(1):86–7. Comment on: Br Heart J 1995 Dec;74(6):578–9.

Self–expanding wallstent for management of severe abdominal coarctation due to non–specific aortoarteritis. Bahl VK, et al. **Indian Heart J** 1997 Mar–Apr;49(2):189–91

Follow–up results of balloon angioplasty for native coarctation of aorta. Biswas PK, et al. **Indian Heart J** 1996 Nov–Dec;48(6):673–6

Self–expanding Wallstent deployment in an adult with coarctation of the aorta. Gambhir DS, et al. **Indian Heart J** 1996 Jul–Aug;48(4):409–11

Balloon dilatation of native coarctation of aorta in infancy. Jagtap PM, et al. **Indian Pediatr** 1996 Jan;33(1):55–8

Acute results of balloon angioplasty of native coarctation versus recurrent aortic obstruction are equivalent. Valvuloplasty and Angioplasty of Congenital Anomalies (VACA) Registry Investigators. McCrindle BW, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1810–7

Balloon angioplasty of recurrent coarctation: a 12–year review. Yetman AT, et al. **J Am Coll Cardiol** 1997 Sep; 30(3):811–6

Endovascular techniques in adult aortic coarctation: the use of stents for native and recurrent coarctation repair. Diethrich EB, et al. **J Endovasc Surg** 1995 May;2(2):183–8

Balloon angioplasty for aortic coarctation––report of a questionnaire survey by the Japanese Pediatric Interventional Cardiology Committee. Ino T, et al. **Jpn Circ J** 1997 May;61(5):375–83

Dissection of the descending aorta after balloon angioplasty of native coarctation. Beitzke A, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):222–5

[Dilatation of congenital aortic stenosis] Carminati M. **Cardiologia** 1995 Dec;40(12 Suppl 1):409–11 **(Ita)**

[Experience in catheter balloon dilatation of the heart valves abd aorta in 1024 patients] Silin VA, et al. **Vestn Rentgenol Radiol** 1996 Sep–Oct;(5):10–2 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Intravascular ultrasound assessment of regional aortic wall stiffness, distensibility, and compliance in patients with coarctation of the aorta. Xu J, et al. **Am Heart J** 1997 Jul;134(1):93–8

Transballoon intravascular ultrasound imaging during balloon angioplasty in animal models with coarctation and branch pulmonary stenosis. Stock JH, et al. **Circulation** 1997 May 20;95(10):2354–7

Multiplane transoesophageal echocardiography in an adult with coarctation of aorta. Trehan VK, et al. **Indian Heart J** 1996 Nov–Dec;48(6):707–9

Ventricular discrepancy as a sonographic sign of coarctation of the fetal aorta: how reliable is it? Brown DL, et al. **J Ultrasound Med** 1997 Feb;16(2):95–9

Corrected transposition of the great arteries with isolated aortic coarctation: In utero echocardiographic diagnosis. Santoro G, et al. **Pediatr Cardiol** 1997 Sep–Oct;18(5):396–8

Echocardiographic evaluation of systolic and diastolic function in postoperative coarctation patients. Sigurdardóttir LÝ, et al. **Pediatr Cardiol** 1997 Mar–Apr; 18(2):96–100

[Disproportion in diameter of the cardiac chambers and great arteries in the fetus. Contribution to the prenatal diagnosis of coarctation of the aorta] David N, et al. **Arch Mal Coeur Vaiss** 1997 May;90(5):673–8 (Eng. Abstr.) **(Fre)**

[Intravascular ultrasound. Initial experience and review of the literature] Ledesma M, et al. **Arch Inst Cardiol Mex** 1996 Jul–Aug;66(4):313–21 (33 ref.) (Eng. Abstr.) **(Spa)**

AORTIC DISEASES

Young women with advanced aortoiliac occlusive disease: new insights. Gagne PJ, et al. **Ann Vasc Surg** 1996 Nov; 10(6):546–57

Nonneoplastic diseases of aorta and pulmonary trunk––Part I. Waller BF, et al. **Clin Cardiol** 1997 Aug;20(8):730–4 (21 ref.)

Nonneoplastic diseases of aorta and pulmonary trunk––Part II. Waller BF, et al. **Clin Cardiol** 1997 Sep;20(9):798–804 (15 ref.)

Diseases of the aorta, pulmonary, and peripheral vessels. **Curr Opin Cardiol** 1996 Sep;11(5):B143–52

Bone mineral density and aortic calcification: the Study of Osteoporotic Fractures. Vogt MT, et al. **J Am Geriatr Soc** 1997 Feb;45(2):140–5

[Aortic atherosclerosis, aortic atheroma] Fukui R, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):378–82 (18 ref.) **(Jpn)**

[Aortic thrombosis] Kamiya K. **Ryoikibetsu Shokogun Shirizu** 1996;(14):370–4 (30 ref.) **(Jpn)**

[Juxta renal aortic occlusion] Kosuga K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):345–7 (13 ref.) **(Jpn)**

[Aortic root dilatation] Tanaka Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(15):115–7 (13 ref.) **(Jpn)**

[Aortic intramural hematoma and penetrating aortic ulcer] Vilacosta I, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:63–76 (51 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Correlation between plasma homocyst(e)ine and aortic

atherosclerosis. Konecky N, et al. **Am Heart J** 1997 May; 133(5):534–40

Aortoiliac occlusion associated with the lupus anticoagulant. Report of two cases. Setoguchi M, et al. **Angiology** 1997 Apr;48(4):359–64

Changes in platelet count, coagulation and fibrinogen associated with elective repair of asymptomatic abdominal aortic aneurysm and aortic reconstruction for occlusive disease. Bradbury A, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):375–80

CHEMICALLY INDUCED

Aortic medial necrosis with or without thrombosis in rabbits treated with Russell's viper venom and angiotensin II. Nakamura M, et al. **Atherosclerosis** 1997 Feb 10; 128(2):149–56

Acceleration of arteriosclerosis of the rat aorta allograft by insulin growth factor–I. Motomura N, et al. **Transplantation** 1997 Apr 15;63(7):932–6

COMPLICATIONS

Splenic infarction: report of three cases of atherosclerotic embolization originating in the aorta and retrospective study of 64 cases. Frippiat F, et al. **Acta Clin Belg** 1996; 51(6):395–402

Massive aortic thrombus detected by transesophageal echocardiography as a cause of peripheral emboli in young patients. Wells KE, et al. **Am Heart J** 1996 Oct;132(4):882–3

Pancreatitis and aortic calcifications [letter] Boruchowicz A, et al. **Am J Gastroenterol** 1996 Dec;91(12):2650–1

Effect of renal insufficiency on outcome following infrarenal aortic surgery. Powell RJ, et al. **Am J Surg** 1997 Aug; 174(2):126–30

Aortic atheroma is related to outcome but not numbers of emboli during coronary bypass. Barbut D, et al. **Ann Thorac Surg** 1997 Aug;64(2):454–9

Diagnosis and management of patients with peripheral macroemboli from thoracic aortic pathology. Lau LS, et al. **Ann Vasc Surg** 1997 Jul;11(4):348–53

Haemoptysis: a rare cause. Hynes JE, et al. **Br J Radiol** 1997 Mar;70:317–8

Aorto–left atrial fistula associated with left coronary artery origin anomaly and bicuspid aortic valve and aortic regurgitation: a case report [letter] San M, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):330

Aorto–left atrial fistula. A reversible cause of acute refractory heart failure. Archer TP, et al. **Chest** 1997 Mar; 111(3):828–31 (17 ref.)

An update on aortic causes of ischemic stroke. Heinzlef O, et al. **Curr Opin Neurol** 1997 Feb;10(1):64–72 (42 ref.)

A rare case of gastrointestinal hemorrhage: aortoesophageal fistula following repair of aortic dissection. Kirchgatterer A, et al. **Endoscopy** 1997 Feb;29(2):137–8

Aortobronchial and aortoesophageal fistulae as risk factors in surgery of descending thoracic aortic aneurysms. von Segesser LK, et al. **Eur J Cardiothorac Surg** 1997 Aug; 12(2):195–201

Unilateral lower limb hypertrophic osteoarthropathy due to aortic graft infection and aortoenteric fistula. Martínez JI, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):497–500 (23 ref.)

Inferior vena cava thrombosis, aortocaval fistula and aortic aneurysm: a unique combination. van Keulen CJ, et al. **Eur J Vasc Endovasc Surg** 1996 Nov;12(4):501–2

Neoplastic angina: a case report. White HL, et al. **Int J Cardiol** 1997 Apr 18;59(2):209–11

Atherosclerotic abdominal aorta saccular protrusion. Iwai T, et al. **Int Surg** 1996 Apr–Jun;81(2):189–94

Ductus diverticulum aneurysm associated with bicuspid aortic valve and dilatation of ascending aorta. Sagic D, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):137–40

A rare case of hydatid cyst perceived as false aneurysm of thoracic aorta. Zakhariev T, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):792–3

Floating thrombus in the ascending aorta: a rare cause of peripheral emboli. Kalangos A, et al. **J Vasc Surg** 1997 Jul;26(1):150–4 (22 ref.)

Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke [letter; comment] Di Tullio MR, et al. **N Engl J Med** 1996 Nov 7;335(19):1464; discussion 1464–5. Comment on: N Engl J Med 1996 May 9;334(19):1216–21.

Treatment of multiple cerebral emboli from an ulcerated, thrombogenic ascending aorta with aortectomy and graft replacement. Belden JR, et al. **Neurology** 1997 Aug; 49(2):621–2

Aortic intimal sarcoma with acute myocardial infarction. Nanjo H, et al. **Pathol Int** 1996 Sep;46(9):673–81 (40 ref.)

Superior mesenteric artery occlusion and peripheral emboli caused by an aortic ulcer in a young patient with antiphospholipid syndrome. Vahl AC, et al. **Surgery** 1997 May;121(5):588–90

Simultaneous manifestation of an aortocaval and aortoduodenal fistula. Bengisun U, et al. **Vasa** 1996; 25(1):81–3

[Cerebrovascular complication caused by aortic atheroma] Malaterre HR, et al. **Ann Med Interne (Paris)** 1996; 147(5):347–51 (40 ref.) (Eng. Abstr.) **(Fre)**

[Acute upper limb ischemia in a young adult without cardiac disease. Value of transesophageal echocardiography] Sal R, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89(10):1317–21 (Eng. Abstr.) **(Fre)**

[The aortic arch as an embolism source for cerebral infarcts] Kaps M, et al. **Fortschr Neurol Psychiatr** 1996 Sep; 64(9):367–74 (Eng. Abstr.) **(Ger)**

[Aortoduodenal fistula as the cause of gastrointestinal hemorrhage] Adamek HE, et al. **Leber Magen Darm** 1996 Nov;26(6):317–9 (Eng. Abstr.) **(Ger)**

[Sympathetic reflex dystrophy in circumscribed stenosis of the abdominal aorta. Case report and discussion of pathophysiologic principles] Haarmeier T, et al. **Nervenarzt** 1997 Feb;68(2):147–9 (Eng. Abstr.) **(Ger)**

[Left thoracotomy for coronary artery bypass grafting without cardiopulmonary bypass in a patient with porcelain aorta] Mizumoto T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):161–4 (Eng. Abstr.) **(Jpn)**

[Coronary artery bypass in patients having lesions in the ascending aorta and cerebral arteries] Okabayashi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Mar;44(3):374–5 **(Jpn)**

[Multiple cerebral infarction following coronary artery bypass grafting for the patient with calcified aorta—a case report] Koike R, et al. **Rinsho Kyobu Geka** 1989 Aug; 9(4):396–9 (Eng. Abstr.) **(Jpn)**

[Primary aorto–enteric fistula associated with Takayasu disease (letter)] Pérez M, et al. **Med Clin (Barc)** 1996 Oct 19;107(13):516 **(Spa)**

CONGENITAL

Aorto–left atrial fistula with bicuspid aortic valve and coronary artery origin anomaly. Topcuoğlu MS, et al. **Ann Thorac Surg** 1997 Mar;63(3):854–6

[Valsalva fistula] Sugama M. **Ryoikibetsu Shokogun Shirizu** 1996;(13):326 (8 ref.) **(Jpn)**

[Congenital diseases of the aorta] McConnell ME, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:92–9 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Gadolinium–enhanced three–dimensional MR angiography of acquired arch vessel disease. Krinsky G, et al. **AJR Am J Roentgenol** 1996 Oct;167(4):981–7

Aortic wall sarcoma with tumor emboli and peripheral ischemia: case report with review of literature. Khan A, et al. **Am J Clin Oncol** 1997 Feb;20(1):73–7

Dissection of retroesophageal aortic diverticulum and descending aorta in a patient with right aortic arch: magnetic resonance demonstration. Ko SF, et al. **Cardiovasc Intervent Radiol** 1996 Nov–Dec;19(6):438–41

Aortic root abscess with fistula formation. Hwang SW, et al. **Chest** 1997 May;111(5):1436–8

Aortoesophageal fistula of unusual location. da Fonseca J, et al. **Endoscopy** 1997 Feb;29(2):138–9

Imaging the thoracic aorta [letter; comment] Banning AP. **Heart** 1997 Jan;77(1):87–8. Comment on: Heart 1996 Jul;76(1):3–5.

Paradoxical embolism and aortic occlusion: a case report. Paes EH, et al. **Int Angiol** 1997 Mar;16(1):72–5 (16 ref.)

Magnetic resonance imaging of thoracic vascular disease (congenital diseases excluded). Croisille P, et al. **J Belge Radiol** 1997 Jun;80(3):136–8 (8 ref.)

Dynamic breath–hold 3D gadolinium–enhanced MRI of intraarterial masses: findings in two patients. Krinsky G, et al. **J Comput Assist Tomogr** 1997 Jul–Aug;21(4):631–4 (9 ref.)

The diagnosis and treatment of acute aortic occlusions. Buth J, et al. **J Mal Vasc** 1996;21(3):133–5 (11 ref.)

Magnetic resonance angiography of the aortic arch. Carpenter JP, et al. **J Vasc Surg** 1997 Jan;25(1):145–51

Diagnosis and treatment of thoracic aortic intramural hematoma. Muluk SC, et al. **J Vasc Surg** 1996 Dec; 24(6):1022–9

Images in clinical medicine. Aortic intramural hematoma. Harris KM, et al. **N Engl J Med** 1997 Jun 26;336(26):1875

Malignant tumors of the heart and great vessels: MR imaging appearance. Mader MT, et al. **Radiographics** 1997 Jan–Feb; 17(1):145–53

Evaluation of the aortoiliac and renal arteries: comparison of breath–hold, contrast–enhanced, three–dimensional MR angiography with conventional catheter angiography. Hany TF, et al. **Radiology** 1997 Aug;204(2):357–62

Thoracoabdominal aorta in Marfan syndrome: MR imaging findings of progression of vasculopathy after surgical repair. Kawamoto S, et al. **Radiology** 1997 Jun; 203(3):727–32

Thoracic aorta: comparison of gadolinium–enhanced three–dimensional MR angiography with conventional MR imaging. Krinsky GA, et al. **Radiology** 1997 Jan; 202(1):183–93

Case of the season. Infected false aneurysm of the aorta with aorto–enteric fistula. Kew J, et al. **Semin Roentgenol** 1996 Jul;31(3):182–4

[Diagnosis of secondary aorto–intestinal fistula (letter; comment)] Schønheyder HC, et al. **Ugeskr Laeger** 1996 Dec 9;158(50):7256. Comment on: Ugeskr Laeger 1996 Aug 19;158(34):4771–2. **(Dan)**

[Clinical case of the month. Intramural aortic hematoma: an acute special aortic dissection] Radermecker MA, et al. **Rev Med Liege** 1996 May;51(5):332–5 **(Fre)**

[MR angiography of thoracic blood vessels] Bongartz G, et al. **Radiologe** 1997 Jul;37(7):529–38 (Eng. Abstr.) **(Ger)**

[Diagnostic imaging of aortic diseases] Nienaber CA, et al. **Radiologe** 1997 May;37(5):402–9 (61 ref.) (Eng. Abstr.) **(Ger)**

[Intramural hematoma of the thoracic aorta: diagnostic imaging and differential diagnosis] Sommer T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Sep;165(3):249–56 (Eng. Abstr.) **(Ger)**

[Aortic saddle embolus] Sugimura S. **Ryoikibetsu Shokogun Shirizu** 1996;(14):314–7 (7 ref.) **(Jpn)**

[Anatomo–clinical correlation. Case 4/96 (Instituto do Coração do Hospital das Clínicas—FMUSP] **Arq Bras Cardiol** 1996 Nov;67(5):359–64 **(Por)**

[Study of aortic pathology using magnetic resonance] Méndez Fernández R, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:37–51 (41 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

The effect of isradipine administration on existing fatty streaks in the cholesterol–fed rabbit: a morphometric study. Skepper JN, et al. **Atherosclerosis** 1996 Jan 26;119(2):247–60

Resolution of an aortic mobile mass with anticoagulation without evidence of arterial embolism. Pasierski T, et al. **Clin Cardiol** 1996 Feb;19(2):151–2

Successful use of recombinant tissue plasminogen activator in the treatment of aortic thrombosis in a premature neonate. Torkington J, et al. **Eur J Vasc Endovasc Surg** 1997 May;13(5):515–6

ECONOMICS

Same–day admissions and other cost–saving strategies for elective aortoiliac surgery. Calligaro KD, et al. **J Vasc Surg** 1997 Jan;25(1):141–4

ENZYMOLOGY

Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Knox JB, et al. **Circulation** 1997 Jan 7;95(1):205–12

Elevations of tissue–type plasminogen activator and differential expression of urokinase–type plasminogen activator in diseased aorta. Shireman PK, et al. **J Vasc Surg** 1997 Jan;25(1):157–64

ETIOLOGY

Allograft aortopathy: an in vivo study of donor aorta involvement in cardiac allograft vasculopathy. Mehra MR, et al. **Am Heart J** 1997 Jun;133(6):698–702

Aortoesophageal conduit due to a foreign body. Jiraki K. **Am J Forensic Med Pathol** 1996 Dec;17(4):347–8

Gastro–aortic fistula: an uncommon complication of Nissen fundoplication. Wasvary H, et al. **Am Surg** 1997 May; 63(5):455–8

Acute aortic thrombosis. A case report. Barrett LO, et al. **Angiology** 1996 Dec;47(12):1163–5

Successful management of secondary aortoesophageal fistula. Luketich JD, et al. **Ann Thorac Surg** 1996 Dec;62(6):1852–4 (11 ref.)

Aortic dissection in a neonate associated with arterial cannulation for extracorporeal life support. Paul JJ, et al. **ASAIO J** 1997 Jan–Feb;43(1):92–4

Effects of low–dose pravastatin sodium on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year. Harsch M, et al. **Atherosclerosis** 1997 Feb 10; 128(2):139–47

Massive hemorrhage caused by a perforating Gianturco–Z stent resulting in an aortoesophageal fistula. Siersema PD, et al. **Endoscopy** 1997 Jun;29(5):416–20 (44 ref.)

Aorto–pulmonary fistula: a rare event in the evolution of a dissecting aneurysm of the thoracic aorta. Massetti M, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):994–6

Aorto–colonic fistula as a late complication of colon interposition for oesophageal atresia. Debras B, et al. **Eur J Pediatr Surg** 1996 Oct;6(5):310–1

Marked arteriosclerosis of the descending aorta in a teenager with interruption of the aorta. Kawai S, et al. **Intern Med** 1996 May;35(5):383–7

Case 2—1997. Aorto–iliac occlusion and rhabdomyolysis after coronary artery revascularization [clinical conference] Menon G, et al. **J Cardiothorac Vasc Anesth** 1997 Apr; 11(2):242–5

Aortocaval fistula in ruptured inflammatory abdominal aortic aneurysm. A report of two cases and literature review. Farid A, et al. **J Cardiovasc Surg (Torino)** 1996 Dec; 37(6):561–5 (24 ref.)

Ruptured aortic pseudo–aneurysm: a rare presentation as aortocaval fistula. Pagni S, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):165–8

Left atrial myxoma with embolization presenting as an acute infrarenal aortic occlusion. Horn KD, et al. **J Vasc Surg** 1997 Aug;26(2):341–5

Aortoesophageal fistula. Report of one case complicating foreing body ingestion with considerations about pathogenesis. Sonzogni A, et al. **Pathologica** 1996 Oct; 88(5):447–8

Perforation of the aorta associated with Staphylococcus aureus endocarditis. Martínez–Roig A, et al. **Pediatr Infect Dis J** 1997 Aug;16(8):821–3

Primary aortoduodenal fistula caused by duodenal tuberculosis without an abdominal aortic aneurysm: report

of a case. Kodaira Y, et al. **Surg Today** 1997;27(8):745–8

Subintimal hematoma of the aorta after deceleration injury [letter; comment] Baciewicz FA Jr. **Tex Heart Inst J** 1996; 23(3):248–9. Comment on: Tex Heart Inst J 1995;22(3):268–70. Comment on: Tex Heart Inst J 1996;23(1):70–1.

Aortobronchial fistula secondary to chronic post–traumatic thoracic aneurysm. Fernández González AL, et al. **Tex Heart Inst J** 1996;23(2):174–7

Smoking, haemostatic factors and the severity of aorto–iliac and femoro–popliteal disease. Smith FB, et al. **Thromb Haemost** 1996 Jan;75(1):19–24

Embolism from the aortic arch in patients with cerebral ischemia. Kessler C, et al. **Thromb Res** 1996 Nov 1; 84(3):145–55

[Penetrating atheromatous ulcer of the thoracic aorta. Apropos of a case] Habis M, et al. **Arch Mal Coeur Vaiss** 1996 Jul;89(7):907–11 (Eng. Abstr.) **(Fre)**

[Secondary aorto–digestive fistula (letter)] Andreu MR, et al. **Presse Med** 1997 Feb 22;26(5):215 **(Fre)**

[Gases and damages] André M, et al. **Rev Med Interne** 1996; 17(8):699–700 **(Fre)**

[A study of aortic calcification uremia] Nakagawa K. **Nippon Jinzo Gakkai Shi** 1997 Mar;39(2):135–43 (Eng. Abstr.) **(Jpn)**

[Successful surgical repair of acute DeBakey type I aortic dissection complicated by acute occlusion of the suprarenal abdominal aorta] Shiiya N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):682–6 (Eng. Abstr.) **(Jpn)**

[Case of aortic occlusion caused by aortic dissection: recanalization by multiple fenestrations] Kihira Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2081–2 **(Jpn)**

[Report of a case. Late enteral graft erosion is a rare condition] Buntzen S, et al. **Lakartidningen** 1996 Oct 2; 93(40):3457–9 **(Swe)**

GENETICS

Deletions in chromosome 22q11 region in cervical aortic arch. Kumar A, et al. **Am J Cardiol** 1997 Feb 1;79(3):388–90

Infrarenal aortic dimensions in siblings of patients with infrarenal abdominal aortic aneurysm or aortoiliac occlusive disease. Jaakkola P, et al. **Eur J Surg** 1995 Dec; 161(12):871–5

IMMUNOLOGY

Participation of T lymphocytes and macrophages in atherogenesis. Shimokama T, et al. **J Atheroscler Thromb** 1994;1 Suppl 1:S14–20

METABOLISM

Immunohistochemical and quantitative analysis of cellular and extracellular components of aortic atherosclerosis in WHHL rabbits. Ito T, et al. **J Atheroscler Thromb** 1994; 1(1):45–52

[Localization of collagen–synthesizing cells in normal and atherosclerotic intima of human aorta] Andreeva ER, et al. **Biull Eksp Biol Med** 1997 Jan;123(1):95–7 **(Rus)**

PATHOLOGY

Aortic endothelium in HIV–1 infection: chronic injury, activation, and increased leukocyte adherence. Zietz C, et al. **Am J Pathol** 1996 Dec;149(6):1887–98

Atheromatous aortic plaque as a cause of resistance to needle passage during transaortic celiac plexus block. Naveira FA, et al. **Anesth Analg** 1996 Dec;83(6):1327–9

Aortic intimal sarcoma: a case report. Wills VL, et al. **Aust N Z J Surg** 1997 Jul;67(7):482–5

Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease. Caputo M, et al. **Eur Heart J** 1996 Sep;17(9):1329–36

Three–dimensional echocardiographic evaluation of aortic disorders with rotational multiplanar imaging: experimental and clinical studies. Sugeng L, et al. **J Am Soc Echocardiogr** 1997 Mar;10(2):120–32

Differential calcification of cusps and aortic wall of failed stented porcine bioprosthetic valves. Biedrzycki LM, et al. **J Biomed Mater Res** 1997 Mar 15;34(4):411–5

Structural heterogeneity and contacting interactions of vascular dendritic cells in early atherosclerotic lesions of the human aorta. Bobryshev YV, et al. **J Submicrosc Cytol Pathol** 1996 Jan;28(1):49–60

An atypical aortic atherosclerotic lesion in cynomolgus monkeys during hypercholesterolemia: a protection by smooth muscle cells against advanced lesions? Bouissou H, et al. **J Submicrosc Cytol Pathol** 1996 Jan;28(1):109–20

Images in clinical medicine. Aortoenteric fistula. Abernethy W, et al. **N Engl J Med** 1997 Jan 2;336(1):27

[Calciphylactic arteriopathy] Seifert G, et al. **Frankf Z Pathol** 1966;75(4):342–61 **(Ger)**

[Atherosclerosis regression in the elderly—correlation between centrally depressed lesions and risk factors] Ohni S, et al. **Nippon Ronen Igakkai Zasshi** 1996 Dec; 33(12):923–7 (Eng. Abstr.) **(Jpn)**

[The reactive changes in the vascular intima under chronic infection] Molchanova VV. **Arkh Anat Gistol Embriol** 1968 Nov;55(11):52–9 (Eng. Abstr.) **(Rus)**

[Two cases of fibromuscular dysplasia of the aorta (intimal hyperplasia)] Golosovskaia MA, et al. **Arkh Patol** 1996 Jan–Feb;58(1):62–6 (Eng. Abstr.) **(Rus)**

[Mediacalcinosis of the aorta (pathomorphology and pathogenesis of arterial calcification and its relationship to atherosclerosis)] Sokolova RI. **Arkh Patol** 1996 Sep–Oct; 58(5):31–5 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Anaesthesia for caesarean section in a Marfan patient with recurrent aortic dissection. Tritapepe L, et al. **Can J Anaesth** 1996 Nov;43(11):1153–5

Diminished postprandial hyperemia in patients with aortic and mesenteric arterial occlusive disease. Quantification by magnetic resonance flow imaging. Dalman RL, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II206–10

Wall shear stress and early atherosclerotic lesions in the abdominal aorta in young adults. Pedersen EM, et al. **Eur J Vasc Endovasc Surg** 1997 May;13(5):443–51

Spinal cord protection with the use of prostacyclin during aortic occlusion. Katircioğlu SF, et al. **J Surg Res** 1996 Sep;65(1):77–81

Antioxidant and triglyceride–lowering effects of vitamin E associated with the prevention of abnormalities in the reactivity and morphology of aorta from streptozotocin–diabetic rats. Antioxidants in Diabetes–Induced Complications (ADIC) Study Group. Karasu C, et al. **Metabolism** 1997 Aug;46(8):872–9

Effect of proximal arterial perfusion pressure on function, spinal cord blood flow, and histopathologic changes after increasing intervals of aortic occlusion in the rat [see comments] Taira Y, et al. **Stroke** 1996 Oct;27(10):1850–8 . Comment in: Stroke 1997 Apr;28(4):878–9.

[Intraoperative acute aortic obstructive embolism] Bendyk K, et al. **Anaesthesist** 1996 Nov;45(11):1089–92 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Dietary conjugated linoleic acid reduces plasma lipoproteins and early aortic atherosclerosis in hypercholesterolemic hamsters. Nicolosi RJ, et al. **Artery** 1997;22(5):266–77

Strategies to mitigate mineralization in the bioprosthetic or homograft cusp and aortic wall [editorial] Levy RJ. **J Heart Valve Dis** 1997 Jan;6(1):7–8

Antioxidant and triglyceride–lowering effects of vitamin E associated with the prevention of abnormalities in the reactivity and morphology of aorta from streptozotocin–diabetic rats. Antioxidants in Diabetes–Induced Complications (ADIC) Study Group. Karasu C, et al. **Metabolism** 1997 Aug;46(8):872–9

A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Räisänen–Sokolowski AK, et al. **Transplantation** 1997 Apr 15;63(7):936–41

RADIOGRAPHY

CT angiography of aortoiliac disease with volumetric rendering technique [letter; comment] Marcus CD, et al. **AJR Am J Roentgenol** 1997 Jun;168(6):1619–20. Comment on: AJR Am J Roentgenol 1996 Jun;166(6):1347–54.

CT angiography versus intraarterial digital subtraction angiography for assessment of aortoiliac occlusive disease. Rieker O, et al. **AJR Am J Roentgenol** 1997 Oct; 169(4):1133–8

Aortoduodenal fistula: appearances on computed tomography. Daly CA, et al. **Aust N Z J Surg** 1997 Oct; 67(10):745–6

Uncommon features of abdominal aortoiliac disease. Griffith JF, et al. **Br J Radiol** 1997 May;70(833):536–42 (8 ref.)

Primary sarcoma of the aortic wall. Hashimoto M, et al. **Cardiovasc Intervent Radiol** 1997 Jul–Aug;20(4):322–3

Quantitative assessment of abdominal aortic atherosclerosis observed in CT scans. Dougherty G. **Comput Med Imaging Graph** 1997 May–Jun;21(3):185–93

Aortic arch angiography prior to carotid endarterectomy. Is its continued use justified? Kadwa AM, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):527–30

Aortic occlusion in a patient with antiphospholipid antibody syndrome in systemic lupus erythematosus. Soubrier M, et al. **Int Angiol** 1995 Sep;14(3):233–5

The ductus diverticulum: false–positive angiographic diagnosis of traumatic aortic disruption. Oxorn D, et al. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):86–8

Case report. Aortic pseudoaneurysm with aortobronchial fistula: diagnosis with CT angiography. Ferretti GR, et al. **J Comput Assist Tomogr** 1996 Nov–Dec;20(6):975–8 (8 ref.)

Helical CT angiography of the thoracic aorta. Rubin GD. **J Thorac Imaging** 1997 Apr;12(2):128–49 (38 ref.)

Spiral CT angiography of the thoracic aorta. Chung JW, et al. **Radiographics** 1996 Jul;16(4):811–24

Evaluation of thoracic aortic disease with the use of helical CT and multiplanar reconstructions: comparison with surgical findings. Quint LE, et al. **Radiology** 1996 Oct; 201(1):37–41

Spiral CT angiography of the aorta. Kopecky KK, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):304–15 (15 ref.)

Stenting of stenosis of the abdominal aorta. Lim MC, et al. **Singapore Med J** 1995 Oct;36(5):562–5

Acute occlusion of the descending thoracic aorta: report of a case. Kawahito K, et al. **Surg Today** 1996;26(8):652–4

Aortotracheal fistula: demonstration by computerized tomography. Elmadbouh HM, et al. **Thorac Cardiovasc Surg** 1997 Jun;45(3):142–4

[Imaging of acquired pathologies of the thoracic aorta] Golzarian J, et al. **J Belge Radiol** 1996 Nov;79(5):216–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Severe calcifying atherosclerosis of the thoracic aorta with symptoms of aortic isthmus stenosis. Case report] Froelich JJ, et al. **Radiologe** 1997 Feb;37(2):173–6 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Acute proximal occlusion of a nonaneurysmal abdominal aorta and renal arteries detected by renal imaging. Gilbert LA, et al. **Clin Nucl Med** 1997 Apr;22(4):231–4

Gamma imaging of atherosclerotic lesions: the role of antibody affinity in in vivo target localization [see comments] Narula J, et al. **J Nucl Cardiol** 1996 May–Jun; 3(3):231–41. Comment in: J Nucl Cardiol 1996 May–Jun;3(3):278–80.

Imaging of atherosclerosis—a worthy challenge [editorial; comment] Strauss HW. **J Nucl Cardiol** 1996 May–Jun; 3(3):278–80. Comment on: J Nucl Cardiol 1996 May–Jun;3(3):231–41.

SURGERY

Clonidine for major vascular surgery in hypertensive patients: a double–blind, controlled, randomized study. Quintin L, et al. **Anesth Analg** 1996 Oct;83(4):687–95

Intraoperative diagnosis of torsion of the left lung after repair of a disruption of the descending thoracic aorta. Goskowicz R, et al. **Anesthesiology** 1997 Jul;87(1):164–6

Repair of aortobronchial fistula using extraanatomic grafts and hypothermic arrest. Lawrence WA, et al. **Ann Thorac Surg** 1997 Apr;63(4):1158–60

Central nervous system injury after aortic operations: profits of amending old ways [editorial; comment] Svensson LG. **Ann Thorac Surg** 1997 Jan;63(1):9–11. Comment on: Ann Thorac Surg 1997 Jan;63(1):88–92. Comment on: Ann Thorac Surg 1997 Jan;63(1):93–7.

Successful repair of primary concomitant aortobronchial and aortoesophageal fistulas. Tkebuchava T, et al. **Ann Thorac Surg** 1997 Jun;63(6):1779–81

Repair of aortoesophageal fistula after aortic grafting. Wickstrom PH, et al. **Ann Thorac Surg** 1997 Jul;64(1):253–5

Successful management of an aortoesophageal fistula using a cryopreserved arterial allograft. Debras B, et al. **Ann Vasc Surg** 1996 May;10(3):292–6 (24 ref.)

Published results of surgery for aortoiliac occlusive disease. McDaniel MD, et al. **Ann Vasc Surg** 1997 Jul;11(4):425–41

A randomized, prospective trial of deep venous thrombosis prophylaxis in aortic surgery. Killewich LA, et al. **Arch Surg** 1997 May;132(5):499–504

Bowel ischaemia after aortoiliac surgery. Bergqvist D, et al. **Br J Surg** 1997 May;84(5):593–4

Intraoperative pulse amplitude monitoring of distal perfusion after aortic cross–clamping. de Nie AJ, et al. **Br J Surg** 1996 Aug;83(8):1104

Prospective randomized placebo–controlled trial of aprotinin for elective aortic reconstruction. Ranaboldo CJ, et al. **Br J Surg** 1997 Aug;84(8):1110–3

Temporary left external axillofemoral bypass during repair of a leaking type B aortic dissection. Taylor PR, et al. **Br J Surg** 1997 Mar;84(3):423

Diagnosis and therapy of aortic prosthetic fistulas: trends over a 30–year experience. van Baalen JM, et al. **Br J Surg** 1996 Dec;83(12):1729–34

Changing patterns in aortoiliac reconstruction: a 7–year audit. Whiteley MS, et al. **Br J Surg** 1996 Oct;83(10):1367–9

Conservative surgery for aortic graft infection. Earnshaw JJ. **Cardiovasc Surg** 1996 Oct;4(5):570–2 (32 ref.)

Spontaneous perforation of a non–aneurysmal atherosclerotic abdominal aorta or femoral artery. Origuchi N, et al. **Cardiovasc Surg** 1996 Jun;4(3):351–5

Changing patterns of atheroembolism. Sharma PV, et al. **Cardiovasc Surg** 1996 Oct;4(5):573–9

The use of profound hypothermia and circulatory arrest in operations on the thoracic aorta. Ehrlich M, et al. **Eur J Cardiothorac Surg** 1997 Jan;11(1):176–81

Extraanatomic thoracic aortic bypass grafts: indications, techniques, and results. Heinemann MK, et al. **Eur J Cardiothorac Surg** 1997 Jan;11(1):169–75

Axillary artery cannulation for cardiopulmonary bypass in the presence of diseased ascending aorta [letter] Isomura T, et al. **Eur J Cardiothorac Surg** 1996;10(6):481

Aprotinin in aortic surgery requiring profound hypothermia and circulatory arrest. Rooney SJ, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):373–8

Simplified technique for antegrade cerebral perfusion. Scorsin M, et al. **Eur J Cardiothorac Surg** 1997 Apr; 11(4):776–8

Significantly reduced incidence of stroke during coronary artery bypass grafting using transesophageal echocardiography. Trehan N, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):234–42

Symptomatic unilateral hydronephrosis: a late complication of aortobifemoral bypass graft surgery. Barber NJ, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):419–20

Changes in platelet count, coagulation and fibrinogen associated with elective repair of asymptomatic abdominal aortic aneurysm and aortic reconstruction for occlusive

disease. Bradbury A, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):375–80

Albumin–impregnated polyester vascular prosthesis for abdominal aortic surgery: an improvement? Chakfe N, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):346–53

Aortoiliac occlusion treated by a combination of aortoiliac stent and femorofemoral crossover grafting. Wilkinson JM, et al. **Eur J Vasc Endovasc Surg** 1996 Oct;12(3):372–4

Aortoaortic bypass: indications, techniques and results. Airan B, et al. **Indian Heart J** 1997 May–Jun;49(3):303–8

Acalculous cholecystitis after aortic reconstruction. Hagino RT, et al. **J Am Coll Surg** 1997 Mar;184(3):245–8

Combined percutaneous transluminal angioplasty, iliac stent deployment, and femorofemoral bypass for bilateral aortoiliac occlusive disease. Lopez–Galarza LA, et al. **J Am Coll Surg** 1997 Mar;184(3):249–58

Accuracy of transesophageal echocardiography in preoperative determination of aortic anulus size during valve replacement. Abraham TP, et al. **J Am Soc Echocardiogr** 1997 Mar;10(2):149–54

Diagnosis of esophageal varices by transesophageal echocardiography: a mimicker of aortic disease. Chang GL, et al. **J Am Soc Echocardiogr** 1997 Apr;10(3):231–5

Proceedings of the Birmingham Aortic Surgery Symposium. November 1–2, 1996. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):131–330

Surgical management of aortic root abscess. David TE. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):262–6; discussion 266–9

Intraoperative epiaortic ultrasound during cardiac surgery. Nicolosi AC, et al. **J Card Surg** 1996 Jan–Feb;11(1):49–55

Case 6—1996, Traumatic aortocoronary saphenous vein graft occlusion [clinical conference] Jacobsohn E, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):950–6

Surgical management of endocarditis–induced aorto–atrial and aorto–ventricular fistula: a new technique. Gharagozloo F, et al. **J Cardiovasc Surg (Torino)** 1997 Apr; 38(2):131–5

Coronary artery bypass grafting of Takayasu's disease with calcified aorta and subclavian artery obstruction. Goh K, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):415–7

What is the safe time limit for retrograde cerebral perfusion with hypothermic circulatory arrest in aortic surgery? Sasaguri S, et al. **J Cardiovasc Surg (Torino)** 1996 Oct; 37(5):441–4

Replacement of the ascending aorta with composite valve grafts: long term results [see comments] Lepore V, et al. **J Heart Valve Dis** 1996 May;5(3):240–6. Comment in: J Heart Valve Dis 1996 May;5(3):238–9.

Functional results after aortic valve repair in aortic root ectasia [see comments] Pethig K, et al. **J Heart Valve Dis** 1996 May;5(3):247–50. Comment in: J Heart Valve Dis 1996 May;5(3):238–9.

Aortic valve replacement after repair of pulmonary atresia and ventricular septal defect or tetralogy of Fallot. Dodds GA 3rd, et al. **J Thorac Cardiovasc Surg** 1997 Apr; 113(4):736–41

Neurophysiologic monitoring to assure delivery of retrograde cerebral perfusion. Ganzel BL, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):748–55; discussion 755–7

Aortoesophageal fistula: repair with transluminal placement of a thoracic aortic stent–graft. Oliva VL, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):35–8

Same–day admissions and other cost–saving strategies for elective aortoiliac surgery. Calligaro KD, et al. **J Vasc Surg** 1997 Jan;25(1):141–4

Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model. Huber TS, et al. **J Vasc Surg** 1997 Jun;25(6):984–93; discussion 993–4

Secondary aortoesophageal fistula. Pipinos II, et al. **J Vasc Surg** 1997 Jul;26(1):144–9 (21 ref.)

In situ repair of aortobronchial, aortoesophageal, and aortoenteric fistulae with cryopreserved aortic homografts. Vogt PR, et al. **J Vasc Surg** 1997 Jul;26(1):11–7

Results of axillofemoral by–passes for aorto–iliac occlusive disease. Illuminati G, et al. **Langenbecks Arch Chir** 1996; 381(4):212–7

Occurrence and magnitude of pressure waves during Er:YAG laser ablation of atherosclerotic tissue: comparison to XeCl excimer laser ablation. Rose CH, et al. **Lasers Surg Med** 1996;19(3):273–83

Surgery of the thoracic aorta. Kouchoukos NT, et al. **N Engl J Med** 1997 Jun 26;336(26):1876–88 (144 ref.)

Evaluation of thoracic aortic disease with the use of helical CT and multiplanar reconstructions: comparison with surgical findings. Quint LE, et al. **Radiology** 1996 Oct; 201(1):37–41

Radical endarterectomy of severely calcified ascending aorta prevents stroke during open–heart surgery. Koul B, et al. **Scand Cardiovasc J** 1997;31(1):33–7

Endovascular treatment of aortic arch occlusive disease. Queral LA, et al. **Semin Vasc Surg** 1996 Jun;9(2):156–63

Aortoiliac occlusive disease. Schneider JR. **Semin Vasc Surg** 1995 Dec;8(4):277–83 (39 ref.)

Stenting of stenosis of the abdominal aorta. Lim MC, et al. **Singapore Med J** 1995 Oct;36(5):562–5

The surgical management of aortoenteric fistulas. Montgomery RS, et al. **Surg Clin North Am** 1996 Oct; 76(5):1147–57 (54 ref.)

Videoendoscopic vascular surgery on aortoiliac vessels. An experimental study. Said S, et al. **Surg Endosc** 1996 Dec; 10(12):1140–4

Prevention of postsurgical adhesions with N,O–carboxymethyl chitosan: examination of the most efficacious preparation and the effect of N,O–carboxymethyl chitosan on postsurgical healing. Costain DJ, et al. **Surgery** 1997 Mar;121(3):314–9

[Thoracic electric impedance and fluid balance during aortic surgery] Jónsson F, et al. **Ugeskr Laeger** 1996 Oct 28; 158(44):6256–9 (Eng. Abstr.) **(Dan)**

[Should aortic atheromatous plaques be excised?] Gandjbakhch I, et al. **Arch Mal Coeur Vaiss** 1997 May;90 Spec No 2:25–8 (Eng. Abstr.) **(Fre)**

[The superficial femoral vein in aorto–iliac position—suitable as autogenous vascular replacement in deep prosthesis infection?] Franke S, et al. **Chirurg** 1996 Aug;67(8):843–9 (Eng. Abstr.) **(Ger)**

[Laparoscopy–assisted aortoiliac reconstructions] Kolvenbach R, et al. **Langenbecks Arch Chir** 1997; 382(3):119–22 (Eng. Abstr.) **(Ger)**

[Primary malignant intraluminal tumor of the aorta] Settmacher U, et al. **Langenbecks Arch Chir** 1997; 382(3):138–40 (Eng. Abstr.) **(Ger)**

[Aorto–duodenal fistula—direct suture and pedicled omentum flap–plasty] Friedrich J, et al. **Zentralbl Chir** 1997;122(7):565–8; discussion 568 (Eng. Abstr.) **(Ger)**

[Surgery of the descending thoracic and thoraco–abdominal arteries. Report of 105 cases] Zanetti PP, et al. **G Ital Cardiol** 1997 Jul;27(7):682–5 (Eng. Abstr.) **(Ita)**

[A case of uretero–aortic fistula] Awakura Y, et al. **Hinyokika Kiyo** 1997 Apr;43(4):299–301 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Early and late results of cardiac and thoracic aortic surgery in patients older than 75 years from a quality of life point of view] Mitsumaru A, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):718–21 (Eng. Abstr.) **(Jpn)**

[Management of aortoesophageal fistula due to thoracic aortic aneurysm] Sakurai T, et al. **Kyobu Geka** 1996 Sep; 49(10):815–20 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Results of cardiac operation and thoracic aortic operation in patients aged 75 years or older] Shichijo T, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):714–7 (Eng. Abstr.) **(Jpn)**

[Aortic emergencies] Yasuda K. **Ryoikibetsu Shokogun Shirizu** 1996;(14):367–9 (18 ref.) **(Jpn)**

[Our experience in treating patients with embolisms of the aorta and major arteries of the extremities (on the centenary of the first embolectomy)] Barsukov AE, et al. **Vestn Khir Im I I Grek** 1996;(1):10–3 (Eng. Abstr.) **(Rus)**

[An alternative treatment in aortic reconstruction (letter)] Olofsson P, et al. **Lakartidningen** 1996 Dec 18; 93(51–52):4711–2 **(Swe)**

THERAPY

Technique for rapid control of bleeding from an aortoenteric fistula. Loftus IM, et al. **Br J Surg** 1997 Aug;84(8):1114

Intraaortic balloon pump insertion after percutaneous revascularization in patients with severe peripheral vascular disease [see comments] Colyer WR Jr, et al. **Cathet Cardiovasc Diagn** 1997 Sep;42(1):1–6. Comment in: Cathet Cardiovasc Diagn 1997 Sep;42(1):7.

Simultaneous use of a diagnostic catheter to facilitate stent deployment in aorto–ostial artery stenosis: a case report. Lambros J, et al. **Cathet Cardiovasc Diagn** 1997 Feb; 40(2):210–1

Percutaneous occlusion of an iatrogenic aortosaphenous vein—coronary vein fistula via retrograde coronary sinus approach. Lopez JJ, et al. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):339–41

Aortocaval fustulae: a percutaneous model and treatment with stent grafts in sheep. Boudghène F, et al. **Circulation** 1996 Jul 1;94(1):108–12

Endovascular stent–graft exclusion of an aortobronchial fistula. Chuter TA, et al. **J Vasc Interv Radiol** 1996 May–Jun;7(3):357–9

Percutaneous transluminal stent placement in the abdominal aorta. Sheeran SR, et al. **J Vasc Interv Radiol** 1997 Jan–Feb; 8(1 Pt 1):55–60

Current controversies in the management of aortoiliac occlusive disease. Brewster DC. **J Vasc Surg** 1997 Feb; 25(2):365–79 (152 ref.)

Diagnosis and treatment of thoracic aortic intramural hematoma. Muluk SC, et al. **J Vasc Surg** 1996 Dec; 24(6):1022–9

Meta–analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Bosch JL, et al. **Radiology** 1997 Jul;204(1):87–96

Stenting for abdominal aortic occlusive disease. Long–term results. Martinez R, et al. **Tex Heart Inst J** 1997;24(1):15–22

Blue toes due to floating plaque of the abdominal aorta: endovascular repair with stent. Do DD, et al. **Vasa** 1997 May;26(2):132–4

[Amyloidosis of a coral reef infrarenal aorta] Combe J, et al. **J Mal Vasc** 1997;22(1):43–7 (Eng. Abstr.) **(Fre)**

[Aortitis and development of an aneurysm after PTA of distal aortic stenosis] Raschke R, et al. **Vasa** 1996;25(3):287–91 (Eng. Abstr.) **(Ger)**

[Case of aortic occlusion caused by aortic dissection: recanalization by multiple fenestrations] Kihira Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Dec 10;85(12):2081–2 **(Jpn)**

ULTRASONOGRAPHY

Retrograde ascending aortic dissection diagnosed by intraoperative transesophageal echocardiography. Wang CH, et al. **Acta Anaesthesiol Sin** 1996 Sep;34(3):157–62

Massive aortic thrombus detected by transesophageal echocardiography as a cause of peripheral emboli in young patients. Wells KE, et al. **Am Heart J** 1996 Oct;132(4):882–3

Frequency and distribution of atherosclerotic plaques in the thoracic aorta as determined by transesophageal echocardiography in patients with coronary artery disease. Khoury Z, et al. **Am J Cardiol** 1997 Jan 1;79(1):23–7

Use of intravascular ultrasound in the endovascular management of atherosclerotic aortoiliac occlusive disease. Arko F, et al. **Am J Surg** 1996 Nov;172(5):546–9; discussion 549–50

The utility of dobutamine echocardiography in preoperative evaluation for elective aortic surgery. Shafritz R, et al. **Am J Surg** 1997 Aug;174(2):121–5

Severity of aortic atheromatous disease diagnosed by transesophageal echocardiography predicts stroke and other outcomes associated with coronary artery surgery: a prospective study. Hartman GS, et al. **Anesth Analg** 1996 Oct;83(4):701–8

Kommerell's diverticulum: a potential cause for false diagnosis of aortic disruption by transesophageal echocardiography. Swenson JD, et al. **Anesth Analg** 1997 Jan;84(1):220–2

Atherosclerotic aortic plaque detected by transesophageal echocardiography: its significance and limitation as a marker for coronary artery disease in the elderly. Matsumura Y, et al. **Chest** 1997 Jul;112(1):81–6

Transesophageal echocardiographic detection of cardiac embolic source in cor triatriatum complicated by aortic saddle emboli. Huang TY, et al. **Clin Cardiol** 1997 Mar; 20(3):294–6

Transesophageal echocardiographic assessment of embolic sources: intracardiac and extracardiac masses and aortic degenerative disease. DeRook FA, et al. **Crit Care Clin** 1996 Apr;12(2):273–94 (106 ref.)

Three–dimensional echocardiography of the thoracic aorta [see comments] Kasprzak JD, et al. **Eur Heart J** 1996 Oct; 17(10):1584–92. Comment in: Eur Heart J 1996 Oct;17(10):1456–8.

Aortic atherosclerosis and perioperative stroke in patients undergoing coronary artery bypass: role of intra–operative transesophageal echocardiography. Choudhary SK, et al. **Int J Cardiol** 1997 Aug 29;61(1):31–8

Intraoperative transesophageal echocardiography and epiaortic ultrasound for assessment of atherosclerosis of the thoracic aorta. Dávila–Román VG, et al. **J Am Coll Cardiol** 1996 Oct;28(4):942–7

Systemic embolization by a thrombus in a apparently normal aorta detected with transesophageal echocardiography. Crawford J, et al. **J Am Soc Echocardiogr** 1997 Jun; 10(5):569–72

Three–dimensional echocardiographic evaluation of aortic disorders with rotational multiplanar imaging: experimental and clinical studies. Sugeng L, et al. **J Am Soc Echocardiogr** 1997 Mar;10(2):120–32

Intraoperative epiaortic ultrasound during cardiac surgery. Nicolosi AC, et al. **J Card Surg** 1996 Jan–Feb;11(1):49–55

Preoperative cardiogenic shock related to dynamic obstruction of left ventricular outflow in a patient with acute aortic dissection: diagnosis by transesophageal echocardiography. Canivet JL, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):781–4

Systolic and diastolic mitral regurgitation in a patient with annulo–aortic ectasia demonstrated by color Doppler flow imaging. Oki T, et al. **J Heart Valve Dis** 1996 May; 5(3):254–7

[Transesophageal echographic demonstration of ulcerated atheromatous plaques of the thoracic aorta responsible for cholesterol emboli] Mirode A, et al. **Ann Cardiol Angeiol (Paris)** 1997 Mar;46(3):151–3 (Eng. Abstr.) **(Fre)**

[Evaluation of aortic atherosclerosis by transesophageal echocardiography. Prognostic implications] Cohen A, et al. **Arch Mal Coeur Vaiss** 1997 May;90 Spec No 2:11–23 (88 ref.) (Eng. Abstr.) **(Fre)**

[Aortic inner surface morphology in aortic disease by three–dimensional transesophageal echocardiography] Matsumura M, et al. **J Cardiol** 1996 Mar;27(3):143–51 (Eng. Abstr.) **(Jpn)**

[Protruding plaques of the thoracic aorta in the transesophageal echocardiogram: clinical and echographic characteristics] Cárdenas F. **Rev Med Chil** 1996 Sep; 124(9):1093–9 (Eng. Abstr.) **(Spa)**

VETERINARY

First–pass radionuclide angiography in the diagnosis of aortoiliac thromboembolism in a horse. Ross MW, et al. **Vet Radiol Ultrasound** 1997 May–Jun;38(3):226–30

AORTIC GLOMUS see **AORTIC BODIES**

AORTIC INCOMPETENCE see **AORTIC VALVE INSUFFICIENCY**

AORTIC REGURGITATION see **AORTIC VALVE**

INSUFFICIENCY

AORTIC RUPTURE

Trauma to the aorta and major vessels. Feliciano DV. **Chest Surg Clin N Am** 1997 May;7(2):305–23 (68 ref.)

Diagnosis and management of blunt great vessel trauma. von Segesser LK, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):181–6; discussion 186–92 (27 ref.)

Abdominal aortic aneurysm [see comments] van der Vliet JA, et al. **Lancet** 1997 Mar 22;349(9055):863–6 (31 ref.). Comment in: Lancet 1997 Jun 7;349(9066):1699.

[The crescent and the periluminal halo: two computer tomography signs of aortic aneurysm with risk of rupture?] Catalano O, et al. **Radiol Med (Torino)** 1997 Apr; 93(4):392–5 (Eng. Abstr.) **(Ita)**

[Spontaneous rupture of the aorta] Ando M. **Ryoikibetsu Shokogun Shirizu** 1996;(14):403–4 (5 ref.) **(Jpn)**

[Chronic contained rupture of abdominal aortic aneurysm] Murashita T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (14):348–50 (17 ref.) **(Jpn)**

[Spontaneous perforation of the atherosclerotic aorta] Origuchi N, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (14):399–402 (22 ref.) **(Jpn)**

[Ruptured aortic aneurysm] Shiiya N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):391–4 (23 ref.) **(Jpn)**

COMPLICATIONS

Spontaneous rupture of thoracic aorta through an atheromatous plaque: case report and literature review. Ma TK, et al. **Am J Forensic Med Pathol** 1996 Mar;17(1):38–42 (15 ref.)

Hematuria associated with ruptured abdominal aortic aneurysms. Pomper SR, et al. **Int Surg** 1995 Jul–Sep; 80(3):261–3

Aortocaval fistula in ruptured inflammatory abdominal aortic aneurysm. A report of two cases and literature review. Farid A, et al. **J Cardiovasc Surg (Torino)** 1996 Dec; 37(6):561–5 (24 ref.)

Ruptured aortic pseudo-aneurysm: a rare presentation as aortocaval fistula. Pagni S, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):165–8

Rupture of a dissecting aneurysm into the superior vena cava in Marfan's syndrome. Toyoda Y, et al. **J Cardiovasc Surg (Torino)** 1997 Aug;38(4):411–3

Spontaneous rupture of abdominal aortic aneurysms in patients with non-related blunt traumatic injuries. Carrillo EH, et al. **J Ky Med Assoc** 1997 Feb;95(2):64–6

Sealed rupture of an abdominal aortic aneurysm with chronic vertebral destruction as the first manifestation. Contribution of computed tomography to the diagnosis [letter] Jacquot JM, et al. **Rev Rhum Engl Ed** 1996 May;63(5):377–9

Abdominal aortic aneurysm. A rare cause of destructive lesions of the spine. Vandecandelaere M, et al. **Rev Rhum Engl Ed** 1996 Apr;63(4):296–9

Flexible sigmoidoscopy. A reliable determinant of colonic ischemia following ruptured abdominal aortic aneurysm. Brandt CP, et al. **Surg Endosc** 1997 Feb;11(2):113–5

Repair of acute dissection of the ascending aorta associated with aortic coarctation. Tesler UF, et al. **Tex Heart Inst J** 1996;23(2):170–3

[Extensive pseudotumoral lumbar spine lesions of vascular origin] Husson JL, et al. **Chirurgie** 1996;121(3):223–4 (Eng. Abstr.) **(Fre)**

[Association of rupture abdominal aneurysm and intestinal infarct] Mattioli A, et al. **Minerva Chir** 1996 Jul–Aug; 51(7–8):597–601 (Eng. Abstr.) **(Ita)**

[A case report of Takayasu's arteritis with aortic pseudoaneurysm caused by aortic perforation] Hachiya T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Oct; 44(10):1921–4 (Eng. Abstr.) **(Jpn)**

[A case of ruptured aortic arch aneurysm with hemorrhagic cardiac tamponade] Ohtani N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):865–8 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Pharmacist with hypotension and altered mental status [clinical conference] Van Voorst T, et al. **Acad Emerg Med** 1996 Jun;3(6):634–40

Rupture of the perivisceral aorta: atherosclerotic versus mycotic aneurysm. Quiñones-Baldrich WJ, et al. **Ann Vasc Surg** 1997 Jul;11(4):331–41

Ruptured aneurysm of the sinus of Valsalva. Islam MN, et al. **Bangladesh Med Res Counc Bull** 1996 Apr;22(1):19–26

Delayed surgery of traumatic aortic rupture. Role of magnetic resonance imaging. Fattori R, et al. **Circulation** 1996 Dec 1;94(11):2865–70

Intramural posttraumatic hematoma of the ascending aorta in a patient with a double aortic arch. Fattori R, et al. **Eur Radiol** 1997;7(1):51–3

Dyspnoea, anorexia and weight loss in a 74 year old man. Heaney LG, et al. **Eur Respir J** 1997 Jun;10(6):1412–4

An unusual case of testicular pain. De Marco R, et al. **Hosp Pract (Off Ed)** 1997 Feb 15;32(2):197, 201

Echocardiography and magnetic resonance imaging of sinus of Valsalva aneurysm with rupture into the ventricle. Kulan K, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):639–41

Blunt disruption of the abdominal aorta: report of a case and review of the literature. Naude GP, et al. **J Vasc Surg** 1997 May;25(5):931–5 (21 ref.)

Spontaneous aortic rupture in a 22-year-old. Memon MA, et al. **Postgrad Med J** 1996 May;72(847):311–3

Overview of traumatic injury of the thoracic aorta. Creasy JD, et al. **Radiographics** 1997 Jan–Feb;17(1):27–45 (66 ref.)

Definitive diagnosis of intramural hematoma of the thoracic aorta with MR imaging [editorial; comment] Bluemke DA. **Radiology** 1997 Aug;204(2):319–21. Comment on: Radiology 1997 Aug;204(2):349–55.

Intramural hematoma of the thoracic aorta: MR image findings and their prognostic implications [see comments] Murray JG, et al. **Radiology** 1997 Aug;204(2):349–55. Comment in: Radiology 1997 Aug;204(2):319–21.

Ruptured sinus of Valsalva aneurysm in a patient with autosomal dominant polycystic kidney disease. Sprung RF, et al. **West J Med** 1996 Dec;165(6):379–82

[Blunt abdominal trauma with lesion of the abdominal aorta—a case report] Leiser A, et al. **Swiss Surg** 1997; 3(4):181–4 (Eng. Abstr.) **(Ger)**

[Diagnosis of traumatic aortic rupture. Transesophageal echocardiography versus computerized tomography] Ertel W, et al. **Unfallchirurg** 1997 Feb;100(2):168–9; discussion 169 **(Ger)**

[Left-sided flank pain in coincident infrarenal aortic aneurysm and left-sided nephropathy] Scherf FG, et al. **Urologe A** 1996 Jul;35(4):342–4 (Eng. Abstr.) **(Ger)**

[Volume increase of the left leg and dyspnea as clinical manifestation of ruptured abdominal aorta aneurysm: problems of diagnostic assessment] Brancato A, et al. **Ann Ital Med Int** 1996 Apr–Jun;11(2):138–9 (Eng. Abstr.) **(Ita)**

[Aortic trauma] Ando M. **Ryoikibetsu Shokogun Shirizu** 1996; (14):356–9 (6 ref.) **(Jpn)**

[A difficult case for the intravital diagnosis of an aortic aneurysm (notes from practice)] Iakimova OG, et al. **Ter Arkh** 1996;68(12):75–6 **(Rus)**

ECONOMICS

Physician work effort and reimbursement for ruptured abdominal aortic aneurysms. Morehouse DL, et al. **Am J Surg** 1997 Aug;174(2):136–9

A modern series of ruptured infrarenal aortic aneurysms. Improved survival at a cost. Ascer E, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:231–3

ETIOLOGY

Traumatic type B aortic dissection. Goverde P, et al. **Acta Chir Belg** 1996 Sep–Oct;96(5):233–6

Variables that affect the expansion rate and rupture of abdominal aortic aneurysms. Cronenwett JL. **Ann N Y Acad Sci** 1996 Nov 18;800:56–67 (31 ref.)

Aortic laceration during laparoscopic cholecystectomy that required delayed emergency laparotomy. Modini C, et al. **Eur J Surg** 1996 Sep;162(9):739–41

Hyperextension injury causing abdominal aortic rupture. Almeida AA, et al. **Eur J Vasc Endovasc Surg** 1997 Feb; 13(2):247–8

Replacement of the abdominal aorta in a young patient with neurofibromatosis and massive retroperitoneal haemorrhage. Wigger P, et al. **Eur J Vasc Endovasc Surg** 1997 Mar;13(3):337–9

Cardiac tamponade during transesophageal echocardiography in the patient of circumferential aortic dissection. Kim CM, et al. **J Korean Med Sci** 1997 Jun; 12(3):266–8

Lateral impact motor vehicle collisions: significant cause of blunt traumatic rupture of the thoracic aorta. Katyal D, et al. **J Trauma** 1997 May;42(5):769–72

Posterior fracture of the left sixth rib causing late aortic laceration: case report. Marco JV, et al. **J Trauma** 1997 Apr;42(4):736–7

Thoracic aortic rupture during vigorous exercise. Tinkoff GH, et al. **J Trauma** 1997 Jan;42(1):137–40

Seasonal variations in the rupture of abdominal aortic aneurysms. Manfredini R, et al. **Jpn Heart J** 1997 Jan; 38(1):67–72

Spontaneous rupture of non-aneurysmal ascending aorta. Tomita M, et al. **Pathol Int** 1996 Sep;46(9):667–72

[Spontaneous rupture of the ascending aorta disclosing inflammatory arteritis] Bosson C, et al. **Arch Mal Coeur Vaiss** 1996 Dec;89(12):1683–6 (Eng. Abstr.) **(Fre)**

[What is your diagnosis? Traumatic transsection (incomplete, non-transmural aortic rupture) of the thoracic aorta with post-traumatic aneurysm of the proximal descending aorta] Hauser M, et al. **Schweiz Rundsch Med Prax** 1997 Feb 18; 86(8):281–5 **(Ger)**

[Ruptured descending thoracic aortic aneurysm due to aortitis syndrome—a case report] Masaki H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):655–60 (Eng. Abstr.) **(Jpn)**

[Rupture of the aortic arch due to bacterial aortitis—a case report of a patient undergoing successful surgical therapy] Sudo Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2221–4 (Eng. Abstr.) **(Jpn)**

[Inflammatory aneurysm of aortic arch with perforation to the right auricle as complication of endocarditis by Staphylococcus aureus (letter)] Rubio Barbón S, et al. **An Med Interna** 1996 Dec;13(12):612–3 **(Spa)**

GENETICS

[Aortic aneurysms in Ullrich-Turner syndrome] Buheitel G, et al. **Klin Padiatr** 1996 Jan–Feb;208(1):42–5 (Eng. Abstr.) **(Ger)**

METABOLISM

Aortic elastin and collagen content and synthesis in two strains of rats with different susceptibilities to rupture of the internal elastic lamina. Sauvage M, et al. **J Vasc Res** 1997 Mar–Apr;34(2):126–36

MORTALITY

Predicting survival from ruptured abdominal aortic aneurysm. Computer modeling with AIM versus clinical judgment. Cloutier L, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:234–5

Surgery for ruptured abdominal aortic aneurysm: early and late results of a prospective study by the AURC in 1989. Koskas F, et al. **Ann Vasc Surg** 1997 Jan;11(1):90–9

POSSUM and APACHE II scores do not predict the outcome of ruptured infrarenal aortic aneurysms. Lazarides MK, et al. **Ann Vasc Surg** 1997 Mar;11(2):155–8

Predictors of death in nonruptured and ruptured abdominal aortic aneurysms. Chen JC, et al. **J Vasc Surg** 1996 Oct; 24(4):614–20; discussion 621–3

Mortality from aortic aneurysm in migrants between counties of England and Wales: evidence for causes acting early in life. Coggon D, et al. **QJM** 1997 Feb;90(2):133–7

PATHOLOGY

Spontaneous rupture of thoracic aorta through an atheromatous plaque: case report and literature review. Ma TK, et al. **Am J Forensic Med Pathol** 1996 Mar;17(1):38–42 (15 ref.)

Thoracic aortic rupture during vigorous exercise. Tinkoff GH, et al. **J Trauma** 1997 Jan;42(1):137–40

Rupture of an abdominal aortic aneurysm causes priming of phagocytic oxidative burst. Lindsay TF, et al. **J Vasc Surg** 1997 Apr;25(4):599–610

[Severe fatal shock after syncope in an old man (clinical conference)] Bar-Dayan Y, et al. **Harefuah** 1996 Nov 1; 131(9):360–2 **(Heb)**

PHYSIOPATHOLOGY

Circadian rhythmicity in the occurrence of spontaneous acute dissection and rupture of thoracic aorta. Gallerani M, et al. **J Thorac Cardiovasc Surg** 1997 Mar;113(3):603–4

Steady flow in models of abdominal aortic aneurysms. Part II: Wall stresses and their implication for in vivo thrombosis and rupture. Peattie RA, et al. **J Ultrasound Med** 1996 Oct; 15(10):689–96

Localisation of endothelin-1 in rat aortae, the relationship to flow and elastic tissue tears. Jones GT, et al. **J Vasc Res** 1996 Sep–Oct;33(5):425–31

PREVENTION & CONTROL

The Oxford Screening Program for aortic aneurysm and screening first-order male siblings of probands with abdominal aortic aneurysm. Collin J. **Ann N Y Acad Sci** 1996 Nov 18;800:36–43 (29 ref.)

The UK Small Aneurysm Trial. Powell JT, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:249–51

Design of a trial to evaluate the effect of propranolol upon abdominal aortic aneurysm expansion. Ricci MA, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:252–3

The case against a national screening programme for aortic aneurysms [see comments] Cheatle TR. **Ann R Coll Surg Engl** 1997 Mar;79(2):90–5 (65 ref.). Comment in: Ann R Coll Surg Engl 1997 Jul;79(4):310.

Improving attendance rates for abdominal aortic aneurysm screening [letter] Gujral S, et al. **Ann R Coll Surg Engl** 1997 Jan;79(1):71

The case against a national screening programme for aortic aneurysms [letter; comment] Heather B, et al. **Ann R Coll Surg Engl** 1997 Jul;79(4):310. Comment on: Ann R Coll Surg Engl 1997 Mar;79(2):90–5.

The case against a national screening programme for aortic aneurysms [letter] Shiralkar S, et al. **Ann R Coll Surg Engl** 1997 Sep;79(5):385–6

Aortic wall structural strengthening by intraluminal net prosthesis to arrest aneurysm progression and to prevent dissection and rupture. Nazari S, et al. **Eur J Cardiothorac Surg** 1996;10(4):264–72

[Prophylactic indications in thoracic aortic aneurysm] Sunder-Plassmann L, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:851–6 (18 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Angiography in blunt thoracic aortic injury. Ahrar K, et al. **J Trauma** 1997 Apr;42(4):665–9

Abdominal aortic aneurysm: rupture associated with the high-attenuating crescent sign. Arita T, et al. **Radiology** 1997 Sep;204(3):765–8

[Chronic non-aneurysmal rupture of the infrarenal aorta. Report of a case] Cazaban-Mazerolles D, et al. **J Mal Vasc** 1997;22(1):40–2 (Eng. Abstr.) **(Fre)**

[Spiral computerized tomography of acute abdominal aortic aneurysm with optimal 3-D image reconstruction] Holland

BR, et al. **Chirurg** 1996 Jan;67(1):44–52 (Eng. Abstr.) **(Ger)**

[Traumatic rupture of thoracic aorta: review of a 10-year experience] Fedriga E, et al. **Radiol Med (Torino)** 1996 Sep; 92(3):206–12 (Eng. Abstr.) **(Ita)**

[Traumatic thoracic aortic rupture—diagnosis and surgical repair] Kamata S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul;44(7):918–22 (Eng. Abstr.) **(Jpn)**

[Traumatic dissecting aneurysm] Hayashi T. **Ryoikibetsu Shokogun Shirizu** 1996;(14):322–4 (9 ref.) **(Jpn)**

SURGERY

The management of patients with ruptured abdominal aortic aneurysms. Perler BA. **Adv Surg** 1996;30:21–38 (99 ref.)

Delayed abdominal closure in the management of ruptured abdominal aortic aneurysms. Oelschlager BK, et al. **Am J Surg** 1997 May;173(5):411–5

Surgical management of traumatic aortic disruption. Sharma S, et al. **Am J Surg** 1997 May;173(5):416–8

Endocaval suture of aortocaval fistula. Illuminati G, et al. **Am Surg** 1997 May;63(5):399–400

The rupture type determines the outcome for ruptured abdominal aortic aneurysm patients. Satta J, et al. **Ann Chir Gynaecol** 1997;86(1):24–9

Treatment of aortic dissection and ruptured abdominal aneurysm with coronary bypass. Ghalili KC, et al. **Ann Thorac Surg** 1997 Jan;63(1):223–5

Aortic arch operation using selective cerebral perfusion for nondissecting thoracic aneurysm [see comments] Hayashi J, et al. **Ann Thorac Surg** 1997 Jan;63(1):88–92. Comment in: Ann Thorac Surg 1997 Jan;63(1):9–11.

Operation for nondissecting aneurysm in the descending thoracic aorta [see comments] Hayashi J, et al. **Ann Thorac Surg** 1997 Jan;63(1):93–7. Comment in: Ann Thorac Surg 1997 Jan;63(1):9–11.

Successful treatment of early postoperative aortic graft infection by percutaneous catheter drainage. Glickerman DJ, et al. **Ann Vasc Surg** 1996 Sep;10(5):486–9

Surgery for ruptured abdominal aortic aneurysm: early and late results of a prospective study by the AURC in 1989. Koskas F, et al. **Ann Vasc Surg** 1997 Jan;11(1):90–9

Surgical repair of type-A aortic dissection: early and late results in 32 consecutive patients. La Hei E, et al. **Aust N Z J Surg** 1997 Oct;67(10):712–6

Full-thickness burn and venous thrombosis following intravenous infusion of microwave-heated crystalloid fluids. Sieunarine K, et al. **Burns** 1996 Nov;22(7):568–9

Progress in abdominal aortic aneurysm surgery: four decades of experience at a teaching center. Chen JC, et al. **Cardiovasc Surg** 1997 Apr;5(2):150–6

Advances in the surgical repair of ruptured abdominal aortic aneurysms. Darling RC 3rd, et al. **Cardiovasc Surg** 1996 Dec;4(6):720–3

Surgical treatment of abdominal aortic aneurysms of octogenarians. Falk V, et al. **Cardiovasc Surg** 1996 Dec; 4(6):727–31

Spontaneous perforation of a non-aneurysmal atherosclerotic abdominal aorta or femoral artery. Origuchi N, et al. **Cardiovasc Surg** 1996 Jun;4(3):351–5

Survival and aortic events after graft replacement for thoracoabdominal aortic aneurysm. Schepens MA, et al. **Cardiovasc Surg** 1996 Dec;4(6):713–9

Sigmoidal ischaemia after aortic grafting, detected by endoluminal pulse oximetry. Vahl AC, et al. **Cardiovasc Surg** 1996 Jun;4(3):345–50

Delayed surgery of traumatic aortic rupture. Role of magnetic resonance imaging. Fattori R, et al. **Circulation** 1996 Dec 1;94(11):2865–70

Aortic dissection type A versus type B: a different post-surgical death hazard? Rizzoli G, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):202–8

Surgery for ruptured thoracic and thoraco-abdominal aortic aneurysms. von Segesser LK, et al. **Eur J Cardiothorac Surg** 1996;10(11):996–1001; discussion 1002

Four-channeled aortic dissection and rupture. Yagyu K, et al. **Eur J Cardiothorac Surg** 1997 Aug;12(2):315–8

Aortic laceration during laparoscopic cholecystectomy that required delayed emergency laparotomy. Modini C, et al. **Eur J Surg** 1996 Sep;162(9):739–41

A prospective survey of patients presenting with abdominal aortic aneurysm. Magee TR, et al. **Eur J Vasc Endovasc Surg** 1997 Apr;13(4):403–6

Surgical management of 671 abdominal aortic aneurysms: a 13 year review from a single centre. Sayers RD, et al. **Eur J Vasc Endovasc Surg** 1997 Mar;13(3):322–7

Replacement of the abdominal aorta in a young patient with neurofibromatosis and massive retroperitoneal haemorrhage. Wigger P, et al. **Eur J Vasc Endovasc Surg** 1997 Mar;13(3):337–9

Deliberate hypotension and prophylactic cerebral protection in a case of combined severe neurotrauma and aortic rupture. Herlevsen P, et al. **J Cardiothorac Vasc Anesth** 1996 Jun;10(4):513–5

Aortoduodenal fistula. Two case reports and a review of the literature. Capaldo GR, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):567–70

Echocardiography and magnetic resonance imaging of sinus of Valsalva aneurysm with rupture into the ventricle. Kulan K, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):639–41

Ruptured abdominal aortic aneurysm. A ten year experience. Martinez R, et al. **J Cardiovasc Surg (Torino)** 1997 Feb; 38(1):1–6

Aneurysms of the sinus of Valsalva. Yilmaz AT, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):119–24

Cardiac tamponade due to a rupture of the coronary arteriovenous aneurysm—a case report. Ryu JC, et al. **J Korean Med Sci** 1997 Apr;12(2):143–5

Acute rupture of the descending thoracic aorta: repair with use of endovascular stent-grafts. Semba CP, et al. **J Vasc Interv Radiol** 1997 May-Jun;8(3):337–42

Predictors of death in nonruptured and ruptured abdominal aortic aneurysms. Chen JC, et al. **J Vasc Surg** 1996 Oct; 24(4):614–20; discussion 621–3

Repair of acute dissection of the ascending aorta associated with aortic coarctation. Tesler UF, et al. **Tex Heart Inst J** 1996;23(2):170–3

Repair of a ruptured sinus of Valsalva aneurysm. Associated with annuloaortic ectasia and coarctation of the aorta in a patient with Marfan syndrome. Tesler UF, et al. **Tex Heart Inst J** 1997;24(2):134–8

[Ruptured abdominal aortic aneurysm] Sebesta P, et al. **Rozhl Chir** 1996 Sep;75(9):422–8 (Eng. Abstr.) **(Cze)**

[Abdominal aortic aneurysm—is surgical therapy in over 80-year-old patients justified?] Ritter R, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:894–6 (Eng. Abstr.) **(Ger)**

[Blunt thoracic trauma with aortic rupture and lung contusion caused by hoof kick in a 15-year-old girl. Diagnostic and therapeutic management] Brück E, et al. **Unfallchirurg** 1996 Nov;99(11):901–4 (Eng. Abstr.) **(Ger)**

[Results of surgical treatment of acute traumatic aortic rupture] Charpentier A, et al. **Zentralbl Chir** 1996; 121(9):744–9 (26 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of chronic traumatic aortic aneurysm] Fraedrich G, et al. **Zentralbl Chir** 1996;121(9):756–60 (Eng. Abstr.) **(Ger)**

[Infrarenal abdominal aortic aneurysm—indications for surgery and survival] Imig H, et al. **Zentralbl Chir** 1996; 121(3):223–7 (Eng. Abstr.) **(Ger)**

[Delayed surgical therapy of acute aortic rupture] Kalmár P, et al. **Zentralbl Chir** 1996;121(9):750–5 (Eng. Abstr.) **(Ger)**

[Intestinal infarction after ruptured aneurysm of the abdominal aorta. Clinical contribution] Giordanengo F, et al. **Minerva Cardioangiol** 1995 Oct;43(10):429–34 (Eng. Abstr.) **(Ita)**

[Clinical suspicion and instrumental diagnosis of ruptured aneurysm of the abdominal aorta. Analysis of our experience] Rubini P, et al. **Minerva Chir** 1996 Apr; 51(4):195–201 (Eng. Abstr.) **(Ita)**

[A case report of ruptured distal aortic arch aneurysm into pericardial space] Koshino T, et al. **Kyobu Geka** 1997 Mar; 50(3):205–8 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of thoracic aorta for elderly patient] Nakai M, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):622–6 (Eng. Abstr.) **(Jpn)**

[Rupture of thoracic aorta due to blunt trauma: a report of three cases] Yuda A, et al. **Kyobu Geka** 1996 Oct; 49(11):883–7; discussion 887–91 (Eng. Abstr.) **(Jpn)**

[A case of total arch replacement for traumatic aortic arch rupture] Ikeda K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):878–81 (Eng. Abstr.) **(Jpn)**

[Traumatic thoracic aortic rupture—diagnosis and surgical repair] Kamata S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul;44(7):918–22 (Eng. Abstr.) **(Jpn)**

[Traumatic transection of the descending thoracic aorta with free open rupture in left pleural cavity—a case report] Kamohara K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):783–6 (Eng. Abstr.) **(Jpn)**

[A successful surgical case report of impending rupture of the true thoraco-abdominal aortic aneurysm induced by thrombosed-type acute aortic dissection (Stanford type A)] Ohnishi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):649–54 (Eng. Abstr.) **(Jpn)**

[A case report of a left bronchial stump fistula from which the wrapped omentum was removed, because of rupture of the anastomotic aneurysm of the descending thoracic aorta—functions of the wrapped omentum in the early phase and extended phase after surgery] Ozaki S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):687–90 (Eng. Abstr.) **(Jpn)**

[Rupture of the aortic arch due to bacterial aortitis—a case report of a patient undergoing successful surgical therapy] Sudo Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2221–4 (Eng. Abstr.) **(Jpn)**

[Two cases of ruptured aneurysm of sinus of Valsalva into right atrium (Konno's type IV)] Suesada H, et al. **Rinsho Kyobu Geka** 1989 Jun;9(3):291–6 (Eng. Abstr.) **(Jpn)**

[Aortic emergencies] Yasuda K. **Ryoikibetsu Shokogun Shirizu** 1996;(14):367–9 (18 ref.) **(Jpn)**

THERAPY

Interventional radiological treatments tested [news] Skolnick AA. **JAMA** 1997 May 14;277(18):1424–5

ULTRASONOGRAPHY

Transesophageal echocardiography in the evaluation of cardiothoracic trauma. Mollod M, et al. **Am Heart J** 1996 Oct;132(4):841–9

Kommerell's diverticulum: a potential cause for false diagnosis of aortic disruption by transesophageal echocardiography. Swenson JD, et al. **Anesth Analg** 1997 Jan;84(1):220–2

A prospective study to define the optimum rescreening interval for small abdominal aortic aneurysm. Cook TA, et al. **Cardiovasc Surg** 1996 Aug;4(4):441–4

Traumatic aortic ruptures diagnosed by transesophageal echocardiography. Berenfeld A, et al. **J Am Soc Echocardiogr** 1996 Sep-Oct;9(5):657–62

Intraoperative usefulness of transesophageal echocardiography: detection of unsuspected rupture of an aneurysm of the sinus of Valsalva. Lobato EB, et al. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):619–21

Non-invasive diagnostic approaches of the dissection of the aorta: transesophageal echocardiography vs computed tomography. Jootar P, et al. **J Med Assoc Thai** 1996 Jun; 79(6):353–7

An unusual case of ruptured aneurysm of sinus of Valsalva. Lim ST, et al. **Singapore Med J** 1996 Feb;37(1):115–6

AORTIC SINUS see **SINUS OF VALSALVA**

AORTIC STENOSIS see **AORTIC VALVE STENOSIS**

AORTIC STENOSIS, SUPRAVALVULAR see **AORTIC VALVE STENOSIS**

AORTIC SUBVALVULAR STENOSIS

[Idiopathic hypertrophic subaortic stenosis] Ikeda Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):297–300 (16 ref.) **(Jpn)**

[Discrete subaortic membranous stenosis] Kawai S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):334–6 (13 ref.) **(Jpn)**

[Subaortic stenosis] Kino K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):260–3 (17 ref.) **(Jpn)**

[Uncommon forms of subaortic stenosis] Nishimoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):73–4 (20 ref.) **(Jpn)**

[Discrete subaortic stenosis] Terada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):82–4 (19 ref.) **(Jpn)**

COMPLICATIONS

Subaortic stenosis due to accessory tissue of the mitral valve associated with Ebstein's anomaly in an adult. Isobe M, et al. **Int J Cardiol** 1996 Dec 13;57(3):286–8

Enoximone usage for experimental spinal cord protection during aortic cross-clamping. Katircioğlu SF, et al. **Thorac Cardiovasc Surg** 1996 Oct;44(5):245–7

CONGENITAL

[Congenital supravalvular aortic stenosis, congenital valvular aortic stenosis, congenital subaortic stenosis, aortic atresia, congenital aortic regurgitation] Okada R. **Ryoikibetsu Shokogun Shirizu** 1996;(13):242–5 (20 ref.) **(Jpn)**

ETIOLOGY

"Diverticula" of anterior mitral valve leaflet as a cause of subvalvular aortic stenosis. Agathos EA, et al. **J Heart Valve Dis** 1996 May;5(3):309–11

[Accessory mitral valve tissue as a rare cause of subaortic stenosis and valvular aortic insufficiency] Gamillscheg A, et al. **Z Kardiol** 1997 Jul;86(7):549–53 (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Bacterial endocarditis involving a subaortic membrane. Pentousis D, et al. **Heart** 1996 Oct;76(4):370–1

SURGERY

Safer approach to transthoracic intra-aortic balloon cannulation [letter; comment] Santini F, et al. **Eur J Cardiothorac Surg** 1996;10(10):928. Comment on: Eur J Cardiothorac Surg 1995;9(10):602–3.

[Secondary subaortic obstruction after correction of double outlet right ventricle. Echocardiographic aspects and surgical findings] Piot JD, et al. **Arch Mal Coeur Vaiss** 1997 May;90(5):639–43 (Eng. Abstr.) **(Fre)**

[Surgical treatment of diffuse supravalvular aortic stenosis with Williams syndrome] Sudoh Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):764–8 (Eng. Abstr.) **(Jpn)**

VETERINARY

Surgical management of subvalvular aortic stenosis and mitral dysplasia in a golden retriever. White RN, et al. **J Small Anim Pract** 1997 Jun;38(6):251–5

AORTIC VALVE

Aortic valve endocarditis with Whipple disease [letter] Jeserich M, et al. **Ann Intern Med** 1997 Jun 1;126(11):920

Active native valve endocarditis: determinants of operative death and late mortality. Jault F, et al. **Ann Thorac Surg** 1997 Jun;63(6):1737–41

Long-term follow-up of small (size 20 and 21) Medtronic-Hall aortic valve prostheses. Obadia JF, et al. **Ann Thorac Surg** 1997 Aug;64(2):421–5

Mitral-aortic intervalvular fibrosa pseudoaneurysm complicating aortic valve endocarditis [letter] Cheong YM, et al. **Aust N Z J Med** 1997 Apr;27(2):193–4

Comparison of human tissues and mechanical prostheses for aortic valve replacement in children. Lupinetti FM, et al. **Circulation** 1997 Jul 1;96(1):321–5

Successful treatment of fungal prosthetic valve endocarditis: case report and review [see comments] Gilbert HM, et al. **Clin Infect Dis** 1996 Feb;22(2):348–54 (52 ref.). Comment in: Clin Infect Dis 1996 Dec;23(6):1338–40.

Freeze drying of cardiac valves in preparation for cellular repopulation. Curtil A, et al. **Cryobiology** 1997 Feb; 34(1):13–22

Surgical treatment of acute endocarditis of the aortic valve with paravalvular abscess: considerations justifying the use of mechanical replacement devices. Bauernschmitt R, et al. **Eur J Cardiothorac Surg** 1996;10(9):741–7

Infective endocarditis due to Streptococcus suis serotype 2 [letter] Tayoro J, et al. **Eur J Clin Microbiol Infect Dis** 1996 Sep;15(9):765–6 (10 ref.)

Severe aortic stenosis without left ventricular hypertrophy: prevalence, predictors, and short-term follow up after aortic valve replacement. Seiler C, et al. **Heart** 1996 Sep; 76(3):250–5

Spectral characterization and classification of Carpentier-Edwards heart valves implanted in the aortic position. Sava HP, et al. **IEEE Trans Biomed Eng** 1996 Oct;43(10):1046–8

Bioprosthetic valve endocarditis caused by Neisseria elongata subspecies nitroreducens. Meuleman P, et al. **Infection** 1996 May-Jun;24(3):258–60

Recurrent aortic valve prosthesis dehiscence secondary to aortoarteritis: three case reports and literature review. Chau EM, et al. **Int J Cardiol** 1996 Oct 11;56(2):113–8 (12 ref.)

Ruptured aortic cusp aneurysm in infective endocarditis. Morelli S, et al. **Int J Cardiol** 1996 Nov 15;57(1):51–3

Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. Stewart BF, et al. **J Am Coll Cardiol** 1997 Mar 1;29(3):630–4

Papillary fibroelastoma of the aortic valve in a patient with an acute myocardial infarction. Pasteuning WH, et al. **J Am Soc Echocardiogr** 1996 Nov-Dec;9(6):897–900

Anatomy of the aortic root with particular emphasis on options for its surgical enlargement. Anderson RH, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S249–57 (20 ref.)

Anticoagulant related complications in elderly patients with St. Jude mechanical valve prostheses. Arom KV, et al. **J Heart Valve Dis** 1996 Sep;5(5):505–10

The use of mechanical prostheses in native aortic valve endocarditis. Gaudino M, et al. **J Heart Valve Dis** 1997 Jan;6(1):79–83 (24 ref.)

Aortic valve replacement in patients 50 years old or younger with the St. Jude Medical valve: 14-year experience. Tatoulis J, et al. **J Heart Valve Dis** 1996 Sep;5(5):491–7

Systolic hypertension in critical aortic stenosis and the effect of valve replacement. Ie E, et al. **J Hum Hypertens** 1996 Feb;10(2):65–7

A comparison of the hydrodynamical behaviour of three heart aortic prostheses by numerical methods. Cerrolaza M, et al. **J Med Eng Technol** 1996 Nov-Dec;20(6):219–28

Effect of cryopreservation and histocompatibility on type I procollagen gene expression in aortic valve grafts. Song YC, et al. **J Thorac Cardiovasc Surg** 1997 Sep;114(3):421–7

Medtronic-Hall prosthetic aortic valve. Akins CW. **Semin Thorac Cardiovasc Surg** 1996 Jul;8(3):242–8

Porcine valves: Hancock and Carpentier-Edwards aortic prostheses. Fann JI, et al. **Semin Thorac Cardiovasc Surg** 1996 Jul;8(3):259–68 (39 ref.)

Surgical treatment of infective endocarditis complicated by annular infection and cerebral infarction. Sugimoto T, et al. **Surg Today** 1996;26(9):679–82

Calcification of the mitral valve annulus and of the aortic valve in patients with transplanted kidneys. Krauz E, et al. **Transplant Proc** 1996 Dec;28(6):3483–4

[The Carpentier-Edwards porcine valve in the supra annular aortic position. Results after 12 years in a series of 1108 patients] Logeais Y, et al. **Arch Mal Coeur Vaiss** 1997 Jun; 90(6):779–88 (Eng. Abstr.) **(Fre)**

[Heart valve disease. Brain abscess in aortic valve endocarditis] Drochner U, et al. **Radiologe** 1996 Dec; 36(12):995–6 **(Ger)**

[Clinical analysis of infective endocarditis with aneurysmal formation of the mitral or aortic valve] Kinoshita N, et al. **J Cardiol** 1997 Aug;30(2):79–87 (Eng. Abstr.) **(Jpn)**

[Underlying cardiac disease in infective endocarditis] Fujiwara T, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):621–4 (Eng. Abstr.) **(Jpn)**

[A case report of papillary fibroelastoma of the aortic valve] Hirota J, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 May;44(5):705–8 (Eng. Abstr.) **(Jpn)**

[A case of infective endocarditis with the mycotic aortic valve aneurysm] Aokage K, et al. **Rinsho Kyobu Geka** 1989 Jun;9(3):305–8 (Eng. Abstr.) **(Jpn)**

[A case report of successful aortic and mitral balloon valvotomy in patient with acute renal failure] Kanehiro K, et al. **Rinsho Kyobu Geka** 1989 Apr;9(2):191–4 (Eng. Abstr.) **(Jpn)**

[Perivalvular abscess] Kondo T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):425–7 (20 ref.) **(Jpn)**

[Combined valvular heart disease] Ohashi H. **Ryoikibetsu Shokogun Shirizu** 1996;(13):448–50 (8 ref.) **(Jpn)**

[Aortic valve perforation] Shu T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):415–20 (16 ref.) **(Jpn)**

ABNORMALITIES

Quadricuspid aortic valve diagnosed by transesophageal echocardiography. Georgeson S, et al. **Am Heart J** 1996 Dec;132(6):1292–3

Aortic outflow obstruction in visceral heterotaxy: a study based on twenty postmortem cases. Van Praagh S, et al. **Am Heart J** 1997 May;133(5):558–69

Aorto-left atrial fistula with bicuspid aortic valve and coronary artery origin anomaly. Topcuoğlu MS, et al. **Ann Thorac Surg** 1997 Mar;63(3):854–6

Anomalous origin of the right coronary artery as a risk factor in aortic valve surgery [letter; comment] Utoh J, et al. **Ann Thorac Surg** 1996 Dec;62(6):1886–7. Comment on: Ann Thorac Surg 1996 Feb;61(2):706–7.

Thrombus formation on a calcific and severely stenotic bicuspid aortic valve. Wan S, et al. **Ann Thorac Surg** 1997 Aug;64(2):535–6

You're the flight surgeon: bicuspid aortic valve with mild aortic insufficiency and mild left ventricular enlargement. Ramsey CS. **Aviat Space Environ Med** 1996 Dec; 67(12):1204–5

Aorto-left atrial fistula associated with left coronary artery origin anomaly and bicuspid aortic valve and aortic regurgitation: a case report [letter] San M, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):330

Bicuspid aortic valve and associated aortic wall abnormalities [editorial] Braverman AC. **Curr Opin Cardiol** 1996 Sep; 11(5):501–3 (15 ref.)

Congenital quadricuspid aortic valve anomaly associated with hypertrophic non-obstructive cardiomyopathy: a case report and review of the literature. Janssens U, et al. **Heart** 1997 Jul;78(1):83–7 (45 ref.)

Images in cardiology. Non-invasive detection of quadricuspid aortic valve. Kajinami K, et al. **Heart** 1997 Jul;78(1):87

Detection of an abnormal aortic valve by intraoperative transesophageal echocardiography. Lazar JM, et al. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):673–4

Ductus diverticulum aneurysm associated with bicuspid aortic valve and dilatation of ascending aorta. Sagic D, et al. **J Cardiovasc Surg (Torino)** 1997 Apr;38(2):137–40

Small aortic root in neonates. Frescura C, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S272–5 (10 ref.)

Aortic root replacement for annuloaortic ectasia in Shprintzen-Goldberg syndrome: a case report. Fukunaga S, et al. **J Heart Valve Dis** 1997 Mar;6(2):181–3 (11 ref.)

Bicuspid aortic valve in an adult human cadaver: a case report. Ohtsuka A, et al. **Kaibogaku Zasshi** 1996 Apr; 71(2):122–5

[What is your diagnosis? Pseudo-aortic coarctation. Congenital bicuspid aortic valve. Left anterior hemiblock] Hauser M, et al. **Schweiz Rundsch Med Prax** 1997 Jan 21; 86(4):79–82 **(Ger)**

[Quadricuspid aortic valve: diagnosis by multiple transesophageal echocardiography] Erena C, et al. **Z Kardiol** 1996 Nov;85(11):889–92 (Eng. Abstr.) **(Ger)**

[The quadri-cusp aortic valve: a congenital defect, responsible for pathologic changes?] Vicol C, et al. **Z Kardiol** 1997 Jul;86(7):538–40 (Eng. Abstr.) **(Ger)**

[Aortic regurgitation caused by quadri-cuspid aortic valve] Kayser S, et al. **Orv Hetil** 1997 Jun 8;138(23):1511–3 (Eng. Abstr.) **(Hun)**

[Aortic regurgitation due to ruptured fibrous band in the noncoronary cusp: a case report] Kaneko T, et al. **J Cardiol** 1996;27 Suppl 2:79–82; discussion 83 (Eng. Abstr.) **(Jpn)**

[Valvuloplasty for aortic insufficiency in a patient with bicuspid aortic valve] Okada Y, et al. **J Cardiol** 1996;27 Suppl 2:85–9; discussion 90 (Eng. Abstr.) **(Jpn)**

[Nonrheumatic calcification of the mitral valve in patients with stenotic calcified bicuspid aortic valve] Sawada H, et al. **J Cardiol** 1996 Oct;28(4):221–6 (Eng. Abstr.) **(Jpn)**

[Aortic valve regurgitation due to quadricuspid valve: a report of complicated case] Kaminishi Y, et al. **Kyobu Geka** 1997 Jan;50(1):63–6 (Eng. Abstr.) **(Jpn)**

[Surgery for aortic valvular disease with congenital quadricuspid aortic valve] Komesu I, et al. **Kyobu Geka** 1996 Aug;49(9):775–9 (27 ref.) (Eng. Abstr.) **(Jpn)**

[A case of ruptured sinus of Valsalva aneurysm with bicuspid aortic valve] Ohkado A, et al. **Kyobu Geka** 1996 Jul; 49(7):567–9 (Eng. Abstr.) **(Jpn)**

[Quadricuspid aortic valve: report of a case associated with severe aortic regurgitation] Seki A, et al. **Kyobu Geka** 1996 Nov;49(12):1027–31 (31 ref.) (Eng. Abstr.) **(Jpn)**

[A case of bicuspid aortic valve stenosis with single coronary artery] Ichikawa Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):796–9 (Eng. Abstr.) **(Jpn)**

[Successful open commissurotomy and resection of dysplastic myxomatous tissue on the leaflet edges in a neonate and an early infant with critical aortic stenosis] Inoue M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):900–4 (Eng. Abstr.) **(Jpn)**

[A case of quadricuspid aortic valve associated with aortic steno-insufficiency] Sasahashi N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul;45(7):1055–60 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Congenital supravalvular aortic stenosis, congenital valvular aortic stenosis, congenital subaortic stenosis, aortic atresia, congenital aortic regurgitation] Okada R. **Ryoikibetsu Shokogun Shirizu** 1996;(13):242–5 (20 ref.) **(Jpn)**

[Congenital malformations of aortic valve] Sunayama S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):208–11 (12 ref.) **(Jpn)**

[Aortic coarctation and the bicuspid aortic valve] Poliakova ND, et al. **Ter Arkh** 1996;68(4):48–50 (Eng. Abstr.) **(Rus)**

[Acute myocardial infarction in a 5-year-old boy] Romero Ibarra C, et al. **Rev Esp Cardiol** 1996 Nov;49(11):855–7 (13 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Reconstruction of loads in the fibrosa and ventricularis of porcine aortic valves. Vesely I. **ASAIO J** 1996 Sep-Oct; 42(5):M739–46

Location of the coronary arterial orifices in the normal heart. Muriago M, et al. **Clin Anat** 1997;10(5):297–302

The positions of coronary arterial ostia. Turner K, et al. **Clin Anat** 1996;9(6):376–80

The formation of a discrete subvalvular outflow tract obstruction—at the interface between rheology and morphology [editorial; comment] Mertens L, et al. **Eur Heart J** 1996 Jun;17(6):809–10. Comment on: Eur Heart J 1996 Jun;17(6):935–9.

Relationships between the dimensions of the human aortic and pulmonary valve leaflets: implications on Ross' operation. Santiago MT, et al. **Eur J Cardiothorac Surg** 1996;10(8):599–602

Aortic valve structure-function correlations: role of elastic fibers no longer a stretch of the imagination [editorial] Schoen FJ. **J Heart Valve Dis** 1997 Jan;6(1):1–6

Measurement of aortic diameter [letter; comment] Anderson RH. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):146. Comment on: J Thorac Cardiovasc Surg 1996 Oct;112(4):954–61.

Morphology of the pulmonary and aortic roots with regard to the pulmonary autograft procedure. Hokken RB, et al. **J Thorac Cardiovasc Surg** 1997 Mar;113(3):453–61

[The morphometry of the leaflets of the aortic and pulmonary valves: the implications for homo- and autografts] Santiago T, et al. **Rev Port Cardiol** 1997 Jan;16(1):95–100 **(Por)**

DRUG EFFECTS

Effects of dobutamine on aortic valve indexes in asymptomatic patients with bileaflet mechanical prostheses in the aortic valve position. Tsai CH, et al. **Am J Cardiol** 1997 Jun 1;79(11):1546–9

Amide cross-linking: an alternative to glutaraldehyde fixation. Girardot JM, et al. **J Heart Valve Dis** 1996 Sep; 5(5):518–25

Effects of cryopreservation on contractile properties of porcine isolated aortic valve leaflets and aortic wall. Wassenaar C, et al. **J Thorac Cardiovasc Surg** 1997 Jan; 113(1):165–72

Palytoxin-induced increase in endothelial Ca2+ concentration in the rabbit aortic valve. Amano K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jun; 355(6):751–8

EMBRYOLOGY

Is there such a thing as the "tendon of the infundibulum" in the heart? Lal M, et al. **Clin Anat** 1997;10(5):307–12

ENZYMOLOGY

Reduced concentration of myocardial Na+,K(+)-ATPase in human aortic valve disease as well as of Na+,K(+)- and Ca(2+)-ATPase in rodents with hypertrophy. Larsen JS, et al. **Mol Cell Biochem** 1997 Apr;169(1-2):85–93

IMMUNOLOGY

Immunogenicity of human heart valve endothelial cells and fibroblasts. Johnson DL, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):984–5

INJURIES

Echocardiographic recognition of iatrogenic aortic valve leaflet perforation. Hill AC, et al. **Ann Thorac Surg** 1997 Sep;64(3):684–9

Surgical treatment of traumatic rupture of the normal aortic valve. Egoh Y, et al. **Eur J Cardiothorac Surg** 1997 Jun; 11(6):1180–2

Aortic valve rupture—an unsuspected cause of acute cardiac failure after chest trauma [letter] Loeb T, et al. **Intensive Care Med** 1996 Jul;22(7):714–5

Repair of aortic cusp traumatic laceration caused by cardiac catheterization. Fundarò P, et al. **J Heart Valve Dis** 1996 May;5(3):281–2

Diagnosis and management of acute aortic valvular disruption secondary to rapid–deceleration trauma. Munshi IA, et al. **J Trauma** 1996 Dec;41(6):1047–50

Airbags and trauma [letter; comment] Lee LH. **Tenn Med** 1997 Aug;90(8):332. Comment on: Tenn Med 1997 May;90(5):195–6.

[Valvular lesions in the course of nonpenetrating thoracic trauma: their diagnosis by transesophageal echocardiography] Ussia GP, et al. **Cardiologia** 1996 Nov; 41(11):1107–11 (39 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Agonist– and CPA–induced elevation of cytoplasmic free Ca2+ in intact valvular endothelium from rabbits. Li L, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):H837–48

A mechanism for the decrease in stiffness of bioprosthetic heart valve tissues after cross–linking. Vesely I. **ASAIO J** 1996 Nov–Dec;42(6):993–9

Novel anti–calcification treatment of biological tissues by grafting of sulphonated poly(ethylene oxide). Park KD, et al. **Biomaterials** 1997 Jan;18(1):47–51

MICROBIOLOGY

Penetration of the atrialventricular septum by spread of infection from aortic valve endocarditis: early diagnosis by transesophageal echocardiography and implications for surgical management. Barbour SI, et al. **Am Heart J** 1996 Dec;132(6):1287–9

Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. Wilson AP, et al. **J Antimicrob Chemother** 1996 Sep;38(3):507–21

[Successful surgical treatment for fungal endocarditis involving the aortic valve: report of a case] Fukui T, et al. **Kyobu Geka** 1996 Sep;49(10):855–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Correspondence of aortic valve area determination from transesophageal echocardiography, transthoracic echocardiography, and cardiac catheterization. Kim CJ, et al. **Am Heart J** 1996 Dec;132(6):1163–72

Detection of strands in native aortic valves by transesophageal echocardiography. Menzel T, et al. **Am J Cardiol** 1997 Jun 1;79(11):1549–52

Comparison of age, gender, number of aortic valve cusps, concomitant coronary artery bypass grafting, and magnitude of left ventricular–systemic arterial peak systolic gradient in adults having aortic valve replacement for isolated aortic valve stenosis. Stephan PJ, et al. **Am J Cardiol** 1997 Jan 15;79(2):166–72

Effects of warm ischemia on valve endothelium. Pompilio G, et al. **Ann Thorac Surg** 1997 Mar;63(3):656–62

Effects of increasing flow rate on aortic stenotic indices: evidence from percutaneous transvenous balloon dilatation of the mitral valve in patients with combined aortic and mitral stenosis [published erratum appears in Heart 1997 Mar;77(3):294] Lee TM, et al. **Heart** 1996 Dec;76(6):490–4

The use of pulmonary allografts for aortic valve replacement. Short term results and comparative morphometric analysis of the aortic and pulmonary valves. Pragliola C, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):603–7

The aortic root in supravalvular aortic stenosis: the potential surgical relevance of morphologic findings. Stamm C, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):16–24

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28–1997. A 67–year–old woman with increasing neurologic deficits and a history of breast and ovarian cancer [clinical conference] **N Engl J Med** 1997 Sep 11;337(11):770–7

[Fibrous aortic valve tumor (Lambl's excrescence) trapped in the right coronary artery. Apropos of a case] Quinson P, et al. **Arch Mal Coeur Vaiss** 1996 Nov;89(11):1419–23 (Eng. Abstr.) **(Fre)**

[Polypoid ulcerating endocarditis aortalis caused by Streptococcus viridans with perforation of the right atrium. Pathology and clinical aspects of 2 autopsy cases] Poremba C, et al. **Pathologe** 1996 Sep;17(5):391–5 (Eng. Abstr.) **(Ger)**

[MR diagnosis after a Ross operation] Steffens JC, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):466–9 (Eng. Abstr.) **(Ger)**

[Severe aortic regurgitation with marked thickening of the aortic annulus: a case report] Sugiyama Y, et al. **J Cardiol** 1997;29 Suppl 2:81–6 (Eng. Abstr.) **(Jpn)**

[A case of DVR with Nicks's procedure for active infective endocarditis with periannular abscess] Bonkohara Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Feb;45(2):174–80 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

A computer–controlled aortic and mitral valve occluder. Solomon SB, et al. **Ann Biomed Eng** 1997 Jan–Feb; 25(1):172–9

Performance assessment of prosthetic heart valves using the energy index method. Souza–Campos F, et al. **ASAIO J** 1996 May–Jun;42(3):170–6

Reconstruction of loads in the fibrosa and ventricularis of porcine aortic valves. Vesely I. **ASAIO J** 1996 Sep–Oct; 42(5):M739–46

An improved valve–spreading catheter for producing reversible graded acute aortic regurgitation. Ardehali A, et al. **Cardiology** 1996 Jul–Aug;87(4):276–8

Numerical analysis of three–dimensional Björk–Shiley valvular flow in an aorta. Shim EB, et al. **J Biomech Eng** 1997 Feb;119(1):45–51

Echocardiography and the small aortic root. Chambers J. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S264–8 (35 ref.)

Aortic valve structure–function correlations: role of elastic fibers no longer a stretch of the imagination [editorial] Schoen FJ. **J Heart Valve Dis** 1997 Jan;6(1):1–6

Effects of cryopreservation on contractile properties of porcine isolated aortic valve leaflets and aortic wall. Wassenaar C, et al. **J Thorac Cardiovasc Surg** 1997 Jan; 113(1):165–72

Hemodynamic assessment of carbomedics bileaflet heart valves by ultrasound: studies in the aortic and mitral positions. Cape EG, et al. **Ultrasound Med Biol** 1996; 22(4):421–30

PHYSIOPATHOLOGY

Influences of aortic pressure gradient and ventricular septal thickness with systolic coronary flow in aortic valve stenosis. Tamborini G, et al. **Am J Cardiol** 1996 Dec 1; 78(11):1303–6

Effects of dobutamine on aortic valve indexes in asymptomatic patients with bileaflet mechanical prostheses in the aortic valve position. Tsai CH, et al. **Am J Cardiol** 1997 Jun 1;79(11):1546–9

Usefulness of dobutamine echocardiography in the hemodynamic assessment of mechanical prostheses in the aortic valve position. Zabalgoitia M, et al. **Am J Cardiol** 1997 Aug 15;80(4):523–6

Detection of osteopontin in calcified human aortic valves. Mohler ER 3rd, et al. **Arterioscler Thromb Vasc Biol** 1997 Mar;17(3):547–52

Doppler echocardiographic study of three different mechanical valves in the aortic position: the use of external nominal diameter indexed to body surface area [see comments] Bailly P, et al. **J Heart Valve Dis** 1997 May; 6(3):236–48. Comment in: J Heart Valve Dis 1997 May;6(3):234.

Early diagnosis of obstructed aortic valve prostheses: a clinical challenge [editorial; comment] Shah PM. **J Heart Valve Dis** 1997 May;6(3):234–5. Comment on: J Heart Valve Dis 1997 May;6(3):236–48.

[Late ventricular potentials, ventricular arrhythmias and sudden death in patients with acquired heart defects] Kubyshkin VF, et al. **Ter Arkh** 1996;68(4):45–7 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Cineradiographic evaluation of ATS open pivot bileaflet valves. Aoyagi S, et al. **J Heart Valve Dis** 1997 May; 6(3):258–63

Radiographic detection of single strut leg separations as a putative basis for prophylactic explantation of Björk–Shiley convexo–concave heart valves. Chandler JG, et al. **World J Surg** 1996 Oct;20(8):953–9; discussion 959–60

SURGERY

Complete resolution of diastolic mitral regurgitation in chronic, but not acute aortic regurgitation after aortic valve replacement--a transesophageal echocardiography study. Wang CH, et al. **Acta Anaesthesiol Sin** 1996 Mar; 34(1):37–41

Aortic valve sparing in aortic root disease. Cochran RP, et al. **Adv Card Surg** 1996;8:81–107

Aortic valve reparative procedures. Fraser CD Jr, et al. **Adv Card Surg** 1996;7:65–86 (48 ref.)

Clinical and echocardiographic follow–up after aortic valve reconstruction with bovine or autologous pericardium. Bjørnstad K, et al. **Am Heart J** 1996 Dec;132(6):1173–8

Unusual presentation of late regional cardiac tamponade after aortic surgery. Jadhav P, et al. **Am J Card Imaging** 1996 Jul;10(3):204–6

Minimally invasive aortic valve surgery: anesthetic considerations. Hearn CJ, et al. **Anesth Analg** 1996 Dec; 83(6):1342–4

Severe isolated aortic stenosis with advanced left ventricular dysfunction. Results of aortic valve replacement. Tesler UF, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:437–8

Minimally invasive mitral operations [letter; comment] Arom KV, et al. **Ann Thorac Surg** 1997 Apr;63(4):1219–20. Comment on: Ann Thorac Surg 1996 Nov;62(5):1542–4.

Left ventricular mass regression early after aortic valve replacement. Christakis GT, et al. **Ann Thorac Surg** 1996 Oct;62(4):1084–9

Allograft aortic root replacement in prosthetic aortic valve endocarditis: a review of 32 patients. Dossche KM, et al. **Ann Thorac Surg** 1997 Jun;63(6):1644–9

Ross procedure with aortic root tailoring for aortic valve replacement in the pediatric population. Durham LA 3rd, et al. **Ann Thorac Surg** 1997 Aug;64(2):482–6

Pulmonary autograft implantation in the dilated aortic annulus. Eishi K, et al. **Ann Thorac Surg** 1997 Apr; 63(4):1155–8

Composite aortic root replacement with direct coronary artery implantation. Hilgenberg AD, et al. **Ann Thorac Surg** 1996 Oct;62(4):1090–5

Clinical outcome and left ventricular function after pulmonary autograft implantation in children. Hokken RB, et al. **Ann Thorac Surg** 1997 Jun;63(6):1713–7

Impact of size mismatch and left ventricular function on performance of the St. Jude disc valve after aortic valve replacement. Lund O, et al. **Ann Thorac Surg** 1997 May; 63(5):1227–34

Two–directional aortic annular enlargement for aortic valve replacement in the small aortic annulus. Otaki M, et al. **Ann Thorac Surg** 1997 Jan;63(1):261–3

Risk of bacteremia complicating valve replacement in the presence of colon cancer [letter] Prabhakar G, et al. **Ann Thorac Surg** 1997 Aug;64(2):587–8

Aortic valve replacement with patch enlargement of the aortic annulus. Sommers KE, et al. **Ann Thorac Surg** 1997 Jun;63(6):1608–12

Previous coronary artery bypass grafting is not a risk factor for aortic valve replacement. Sundt TM 3rd, et al. **Ann Thorac Surg** 1997 Sep;64(3):651–7; discussion 657–8

Anomalous origin of the right coronary artery as a risk factor in aortic valve surgery [letter; comment] Utoh J, et al. **Ann Thorac Surg** 1996 Dec;62(6):1886–7. Comment on: Ann Thorac Surg 1996 Feb;61(2):706–7.

The Ross procedure for replacement of diseased aortic valves. Bower JO. **AORN J** 1996 Dec;64(6):966, 969–72

Clinical use of CarboMedics and St. Jude Medical valves. Wang SS, et al. **Artif Organs** 1996 Dec;20(12):1299–303

Transluminal aortic valve placement. A feasibility study with a newly designed collapsible aortic valve. Moazami N, et al. **ASAIO J** 1996 Sep–Oct;42(5):M381–5

Effects of aprotinin on plasma levels of neutrophil elastase and postoperative blood loss in cardiac surgery. Dernek S, et al. **Cardiovasc Surg** 1996 Aug;4(4):515–9

What are the limits for the Ross operation? Melo JQ, et al. **Cardiovasc Surg** 1996 Aug;4(4):526–9

Effect of aortic valve replacement on coronary flow velocity during metabolic stress in a patient with aortic stenosis. Takeuchi M, et al. **Cathet Cardiovasc Diagn** 1997 Mar; 40(3):287–90

Echocardiography of the right ventricle–to–pulmonary artery homograft conduit of patients with transposition of the great arteries or double outlet right ventricle undergoing the Rastelli procedure. Yüan SM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Jun; 59(6):359–66

Changing pattern of valve surgery. Rao V, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II113–20

Obstruction of the left main coronary ostium due to an aortic vegetation: survival after early surgery. Millaire A, et al. **Clin Infect Dis** 1996 Jan;22(1):192–3

Aortic valve–sparing operations in patients with ascending aortic aneurysms. David TE. **Curr Opin Cardiol** 1997 Jul; 12(4):391–5 (29 ref.)

Mitral, tricuspid, and aortic valve repair or reconstruction. Hammond GL, et al. **Curr Opin Cardiol** 1997 Mar; 12(2):100–7 (47 ref.)

Allograft valves for aortic and mitral valve replacement. Reardon MJ, et al. **Curr Opin Cardiol** 1997 Mar; 12(2):114–22 (30 ref.)

Importance of the right ventricle in valvular heart disease. Nagel E, et al. **Eur Heart J** 1996 Jun;17(6):829–36 (75 ref.)

Aortic valve repair: still a dream? [editorial; comment] Antunes MJ. **Eur J Cardiothorac Surg** 1997 Feb;11(2):266–7 . Comment on: Eur J Cardiothorac Surg 1997 Feb;11(2):258–65.

Warm blood cardioplegia in high risk patients. Bel A, et al. **Eur J Cardiothorac Surg** 1997 Jun;11(6):1118–23; discussion 1124

Editorial comment on hemodynamic evaluation of the CarboMedics R, St Jude Medical HP and Sorin–Bicarbon valve in patients with small aortic anulus: Noera et al [editorial; comment] Chambers J. **Eur J Cardiothorac Surg** 1997 Mar;11(3):477–8. Comment on: Eur J Cardiothorac Surg 1997 Mar;11(3):473–5.

Mechanical valve in aortic position is a valid option in children and adolescents. Champsaur G, et al. **Eur J Cardiothorac Surg** 1997 Jan;11(1):117–22

Aortic root replacement with human tissue valves in aortic valve endocarditis. Dossche K, et al. **Eur J Cardiothorac Surg** 1997 Jul;12(1):47–55

Valve replacement in the small aortic annulus: prospective randomized trial of St. Jude with Medtronic Hall. Fiore AC, et al. **Eur J Cardiothorac Surg** 1997 Mar;11(3):485–91; discussion 491–2

Are pulmonary homografts subjected to pulmonary hypertension more appropriate for aortic valve replacement than normal pulmonary homografts? Results of echocardiography in a multicentric study. Gaudino M, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):676–81

Valve repair for aortic insufficiency: surgical classification and techniques [see comments] Haydar HS, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):258–65. Comment in: Eur J Cardiothorac Surg 1997 Feb;11(2):266–7.

Aortic valve debridement by ultrasonic surgical aspirator in degenerative, aortic valve stenosis: follow–up with Doppler echocardiography. Kellner HJ, et al. **Eur J Cardiothorac Surg** 1996;10(7):498–504

The pulmonary homograft as aortic valve substitute: 7 years' follow up. Mair R, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):910–6

Hemodynamic evaluation of the Carbomedics R, St Jude

Medical HP and Sorin-Bicarbon valve in patients with small aortic annulus [see comments] Noera G, et al. **Eur J Cardiothorac Surg** 1997 Mar;11(3):473-5; discussion 475-6. Comment in: Eur J Cardiothorac Surg 1997 Mar;11(3):477-8.

The influence of free hand suturing technique and zero pressure fixation on the hydrodynamic function of aortic root and aortic valve leaflets. Revanna P, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):280-6

Stentless porcine bioprostheses for all types of aortic root pathology. Sidiropoulos A, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):917-21

Hydrodynamic function of tilting disc prostheses and bileaflet valves in double valve replacement. Strüber M, et al. **Eur J Cardiothorac Surg** 1996;10(6):422-7

Allograft reconstruction of the right ventricular outflow tract. Willems TP, et al. **Eur J Cardiothorac Surg** 1996; 10(8):609-14; discussion 614-5

Early results of minimally invasive aortic valve replacement. Experience with the first 34 cases. Minale C, et al. **G Ital Cardiol** 1997 May;27(5):458-61

Regression of left ventricular dilatation and hypertrophy after aortic valve replacement. Waszyrowski T, et al. **Int J Cardiol** 1996 Dec 13;57(3):217-25

Surgical results in cardiac patients over the age of 80 years. Sahar G, et al. **Isr J Med Sci** 1996 Dec;32(12):1322-5

Intermittent antegrade warm blood cardioplegia in aortic valve replacement. Calafiore AM, et al. **J Card Surg** 1996 Sep-Oct;11(5):348-54

Surgical management of aortic root abscess. David TE. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):262-6; discussion 266-9

Bentall operation for a child with Marfan syndrome: a case report. Miura M, et al. **J Card Surg** 1997 Mar-Apr; 12(2):116-9 (14 ref.)

Valve conserving operation for aortic regurgitation. Pepper J, et al. **J Card Surg** 1997 Mar-Apr;12(2 Suppl):151-6 (5 ref.)

Regional increment in myocardial reflectivity after aortic valve replacement: early detection of air and assessment of treatment by transesophageal echocardiography. Ducart A, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):926-7

The use of pulmonary allografts for aortic valve replacement. Short term results and comparative morphometric analysis of the aortic and pulmonary valves. Pragliola C, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):603-7

Acute carpal tunnel syndrome as a complication of oral anticoagulant therapy. Black PR, et al. **J Hand Surg [Br]** 1997 Feb;22(1):50-1

Biceps rupture in a patient on long-term anticoagulation leading to compartment syndrome and nerve palsies. Richards AM, et al. **J Hand Surg [Br]** 1997 Jun;22(3):411-2

The influence of geometric mismatch between the native aortic, native pulmonary and homograft pulmonary valve on the results of the pulmonary autograft operation. Botha CA, et al. **J Heart Valve Dis** 1997 Jul;6(4):355-60

The Bicarbon heart valve prosthesis: short-term results. Casselman F, et al. **J Heart Valve Dis** 1997 Jul;6(4):410-5

Comparison of magnetic resonance imaging and Laser Doppler Anemometry velocity measurements downstream of replacement heart valves: implications for in vivo assessment of prosthetic valve function. Fontaine AA, et al. **J Heart Valve Dis** 1996 Jan;5(1):66-73

Anatomic and physiologic bases for the Ross procedure. Gonzalez-Lavin L, et al. **J Heart Valve Dis** 1996 Jul; 5(4):383-90; discussion 401-3 (87 ref.)

A systematic technical approach to the Ross operation. Joyce F, et al. **J Heart Valve Dis** 1996 Jul;5(4):391-401; discussion 401-3

Choice of replacement valve in the elderly. Kobayashi Y, et al. **J Heart Valve Dis** 1997 Jul;6(4):404-9

Hemodynamic performance of the Edwards Prima stentless valve [letter] Konertz W. **J Heart Valve Dis** 1997 Jul; 6(4):441-2

Ross operation and right ventricular outflow tract reconstruction with stentless xenografts. Konertz W, et al. **J Heart Valve Dis** 1996 Jul;5(4):418-20

Replacement of the ascending aorta with composite valve grafts: long term results [see comments] Lepore V, et al. **J Heart Valve Dis** 1996 May;5(3):240-6. Comment in: J Heart Valve Dis 1996 May;5(3):238-9.

Coronary translocation during aortic root replacement with the pulmonary autograft: complications and their management. Luciani GB, et al. **J Heart Valve Dis** 1997 Jul;6(4):361-9

Perioperative morbidity and mortality in combined aortic and mitral valve surgery. Mueller XM, et al. **J Heart Valve Dis** 1997 Jul;6(4):387-94

Aortic and mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 10-year results. Murakami T, et al. **J Heart Valve Dis** 1996 Jan; 5(1):45-9

The International Registry of the Ross procedure: 1996 results [editorial] Oury JH. **J Heart Valve Dis** 1997 Jul; 6(4):333-4

Functional results after aortic valve repair in aortic root ectasia [see comments] Pethig K, et al. **J Heart Valve Dis** 1996 May;5(3):247-50. Comment in: J Heart Valve Dis 1996 May;5(3):238-9.

Autograft failure after the Ross operation in a rheumatic population: pre- and postoperative echocardiographic observations. Pieters FA, et al. **J Heart Valve Dis** 1996 Jul;5(4):404-8; discussion 408-9

The influence of sizing and method of fixation on the hydrodynamic function of stentless, free-hand inserted porcine bioprosthesis: an in vitro study. Revanna P, et al. **J Heart Valve Dis** 1997 Jul;6(4):433-8

Pulmonary autografts: the unresolved issues. Ross DN. **J Heart Valve Dis** 1997 Jul;6(4):330-2

Current techniques to reduce blood loss after the Ross procedure. Santini F, et al. **J Heart Valve Dis** 1997 Jul; 6(4):343-6

The use of larger size pulmonary homografts for the Ross operation in children. Sardari F, et al. **J Heart Valve Dis** 1996 Jul;5(4):410-3

Hemodynamic assessment of replacement valves in the aortic position: is stress echocardiography necessary? [editorial] Takeda S, et al. **J Heart Valve Dis** 1997 Jul;6(4):380-2

Carpentier-Edwards supra-annular bioprosthesis in the aortic position. Has altered design affected performance? Wilson ES, et al. **J Heart Valve Dis** 1996 Jan;5(1):40-4

Freehand subcoronary aortic valve and aortic root replacement with cryopreserved homografts: intermediate term results. Yankah AC, et al. **J Heart Valve Dis** 1996 Sep;5(5):498-504

Transcatheter embolization of mycotic iliac aneurysm after aortic valve replacement because of bacterial endocarditis. Akomea-Agyin C, et al. **J Thorac Cardiovasc Surg** 1996 Dec;112(6):1671-2

Development of an intraluminal device for the treatment of aortic regurgitation: prototype and in vitro testing system. Ashton RC, et al. **J Thorac Cardiovasc Surg** 1996 Oct; 112(4):979-83

Geometric mismatch of the aortic and pulmonary roots causes aortic insufficiency after the Ross procedure. David TE, et al. **J Thorac Cardiovasc Surg** 1996 Nov; 112(5):1231-7; discussion 1237-9

Morphology of the pulmonary and aortic roots with regard to the pulmonary autograft procedure. Hokken RB, et al. **J Thorac Cardiovasc Surg** 1997 Mar;113(3):453-61

Pulmonary autograft versus homograft replacement of the aortic valve: a prospective randomized trial. Santini F, et al. **J Thorac Cardiovasc Surg** 1997 May;113(5):894-9; discussion 899-900

Valve detachment after aortic valve replacement--a successfully reoperated case with the Cabrol technique. Aoyagi S, et al. **Jpn Circ J** 1996 Jun;60(6):377-81

Bone mineral density in patients given oral vitamin K antagonists. Laffargue P, et al. **Rev Rhum Engl Ed** 1997 Apr;64(4):249-54

The Ross operation: applications to children. Elkins RC. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):345-9

Utilization of the St. Jude Medical prosthesis in the aortic position. Emery RW, et al. **Semin Thorac Cardiovasc Surg** 1996 Jul;8(3):231-6

Changing indications for the Ross operation. Joyce F, et al. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):336-44

Clinical aspects of the Ross procedure: indications and contraindications. Oury JH. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):328-35 (25 ref.)

The pulmonary autograft: history and basic techniques. Ross D. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):350-7

The pulmonary autograft: results and left ventricular function. Rubay JE, et al. **Semin Thorac Cardiovasc Surg** 1996 Oct;8(4):362-8

Ascending aortic aneurysm and aortic valve disease: what is the most optimal surgical technique? Yun KL, et al. **Semin Thorac Cardiovasc Surg** 1997 Jul;9(3):233-45 (30 ref.)

Ultrasonic decalcification of calcified valve and annulus during heart valve replacement. Unal M, et al. **Tex Heart Inst J** 1996;23(2):85-7

25 years follow-up of patients after replacement of the aortic valve with a Smeloff-Cutter prosthesis. Gödje O, et al. **Thorac Cardiovasc Surg** 1996 Oct;44(5):234-8

[Valve replacement in congenital aortic stenosis] Dominik J, et al. **Cas Lek Cesk** 1997 Jan 22;136(2):48-50 (Eng. Abstr.) **(Cze)**

[Results of open valvotomy in congenital stenosis of the aortic valve] Brzek V, et al. **Rozhl Chir** 1997 Apr; 76(4):173-5 (Eng. Abstr.) **(Cze)**

[Is heart surgery in over 80-year-old patients justified?] Brandt M, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:1015-7 (Eng. Abstr.) **(Ger)**

[MR diagnosis after a Ross operation] Steffens JC, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Nov;165(5):466-9 (Eng. Abstr.) **(Ger)**

[Research for the "ideal" aortic valve substitute] Colombo T. **G Ital Cardiol** 1997 Feb;27(2):146-51 (38 ref.) **(Ita)**

[Replacement of the aortic valve with a pulmonary autograft: experience at the University of Verona] Santini F, et al. **G Ital Cardiol** 1997 Feb;27(2):141-5 (Eng. Abstr.) **(Ita)**

[Adherence to valve repair surgery: from the mitral to the aortic valve] Kawazoe K. **J Cardiol** 1997;29 Suppl 2:3-9 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Aortic valve replacement with stentless porcine aortic valve] Nakano K, et al. **J Cardiol** 1997;29 Suppl 2:73-8 (Eng. Abstr.) **(Jpn)**

[Valvuloplasty for aortic insufficiency in a patient with bicuspid aortic valve] Okada Y, et al. **J Cardiol** 1996;27 Suppl 2:85-9; discussion 90 (Eng. Abstr.) **(Jpn)**

[Intraoperative and follow-up color Doppler echocardiography for evaluating the surgical results of aortic valvuloplasty in a patient with bicuspid aortic valve] Teranishi J, et al. **J Cardiol** 1997;29 Suppl 2:105-8 (Eng. Abstr.) **(Jpn)**

[Successful surgical treatment for fungal endocarditis involving the aortic valve: report of a case] Fukui T, et al. **Kyobu Geka** 1996 Sep;49(10):855-8 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical treatment of infective endocarditis : an analysis of the risk factor for operative mortality] Hata T, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):625-9 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of aortic valve endocarditis associated with aortic root aneurysm and abscess] Kamata S, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):612-6 (Eng. Abstr.) **(Jpn)**

[Surgery for aortic valvular disease with congenital quadricuspid aortic valve] Komesu I, et al. **Kyobu Geka** 1996 Aug;49(9):775-9 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Long-term clinical results with a new surgical method for the fragile valvular annulus] Moro H, et al. **Kyobu Geka** 1997 Mar;50(3):175-8; discussion 178-80 (Eng. Abstr.) **(Jpn)**

[Valve replacement concomitant with anulus reconstruction] Sawazaki M, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):617-20 (Eng. Abstr.) **(Jpn)**

[A case report of aortic valvuloplasty by rasping technique for aortic stenosis with small annulus simultaneously performed with mitral valve replacement] Taniyasu N, et al. **Kyobu Geka** 1997 Feb;50(2):155-7 (Eng. Abstr.) **(Jpn)**

[Trends in surgery of heart valve diseases and recommendation of valvoplasty in aortic and mitral valve insufficiencies] Kitahara H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Mar;45(3):414-7 **(Jpn)**

[The prolonged aortic occlusion in valvular surgery and myocardial protection] Nakayama Y, et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):174-7 (Eng. Abstr.) **(Jpn)**

[The effect of aortic valve translocation and a few problems] Sakamoto S, et al. **Rinsho Kyobu Geka** 1989 Apr; 9(2):157-61 (Eng. Abstr.) **(Jpn)**

[Aortic valve replacement with pulmonary autograft (Ross procedure). Initial experience] Affonso da Costa FD, et al. **Arq Bras Cardiol** 1996 Jan;66(1):15-9 (Eng. Abstr.) **(Por)**

[Clinical and echocardiographic assessment of surgical replacement of the aortic valve with lung autograft: results after 2 years] Parreira L, et al. **Rev Port Cardiol** 1996 Jun; 15(6):475-82, 459 (Eng. Abstr.) **(Por)**

[The morphometry of the leaflets of the aortic and pulmonary valves: the implications for homo- and autografts] Santiago T, et al. **Rev Port Cardiol** 1997 Jan;16(1):95-100 **(Por)**

TRANSPLANTATION

Persistence of human leukocyte antigen (HLA) antibodies after one year in children receiving cryopreserved valved allografts. Shaddy RE, et al. **Am J Cardiol** 1997 Aug 1; 80(3):358-9

Comparison of techniques for implantation of aortic valve allografts. Dearani JA, et al. **Ann Thorac Surg** 1996 Oct; 62(4):1069-75

Coronary artery problems during homograft aortic valve replacement: role of transesophageal echocardiography. Koh TW, et al. **Ann Thorac Surg** 1997 Aug;64(2):533-5

The aortic homograft: evolution of indications, techniques, and results in 107 patients. Prager RL, et al. **Ann Thorac Surg** 1997 Sep;64(3):659-63; discussion 663-4

Aortic valve replacement in a United States Air Force pilot: case report and literature review. Hardy JC, et al. **Aviat Space Environ Med** 1997 Mar;68(3):221-4

Echocardiographic characteristics of the cryopreserved allograft aortic valve replacement assessed by intraoperative transoesophageal echocardiography. Hasegawa J, et al. **Cardiovasc Surg** 1996 Jun;4(3):293-8

Semilunar valve switch in aortic insufficiency. Deleon SY, et al. **Eur J Cardiothorac Surg** 1995;9(11):631-5

Accuracy of transesophageal echocardiography in preoperative determination of aortic anulus size during valve replacement. Abraham TP, et al. **J Am Soc Echocardiogr** 1997 Mar;10(2):149-54

Valve replacement in aortic stenosis with preoperative mean gradient < 50 mmHg: hemodynamic outcome. Blackshear JL, et al. **J Heart Valve Dis** 1996 Nov;5(6):647-55

Factors influencing medium-term performance of right-sided cryopreserved homografts. Daenen W, et al. **J Heart Valve Dis** 1997 Jul;6(4):347-53; discussion 353-4

Strategies to mitigate mineralization in the bioprosthetic or homograft cusp and aortic wall [editorial] Levy RJ. **J Heart Valve Dis** 1997 Jan;6(1):7-8

Human aortic valve allografts elicit a donor-specific immune response. Hogan P, et al. **J Thorac Cardiovasc Surg** 1996 Nov;112(5):1260-6; discussion 1266-7

Procollagen production in fresh and cryopreserved aortic valve grafts. Lupinetti FM, et al. **J Thorac Cardiovasc Surg** 1997 Jan;113(1):102-7

Feasibility of aortic diameter measurement by multiplane transesophageal echocardiography for preoperative selection and preparation of homograft aortic valves [see comments] Weinert L, et al. **J Thorac Cardiovasc Surg** 1996 Oct;112(4):954-61. Comment in: J Thorac Cardiovasc Surg 1997 Jul;114(1):146.

From the Centers for Disease Control and Prevention. Candida albicans endocarditis with a contaminated aortic valve allograft—California, 1996. **JAMA** 1997 Apr 23–30; 277(16):1271–2

Candida albicans endocarditis associated with a contaminated aortic valve allograft—California, 1996. **MMWR Morb Mortal Wkly Rep** 1997 Mar 28;46(12):261–3

Aortic valve replacement with homograft and autograft. Doty DB. **Semin Thorac Cardiovasc Surg** 1996 Jul; 8(3):249–58 (27 ref.)

A new model for heterotopic aortic valve transplantation. Zhou ZY, et al. **Transplantation** 1997 Jul 27;64(2):228–32

[Use of aortic valve homografts in adults] Habib G, et al. **Ann Cardiol Angeiol (Paris)** 1997 Feb;46(2):99–105 (31 ref.) (Eng. Abstr.) **(Fre)**

[Transplantation of aortic and mitral valves: permanent valve replacement without anticoagulation?] Vetter HO, et al. **Herz** 1997 Apr;22(2):120–1 **(Ger)**

[Successful redo–AVR with cryopreserved allograft for prosthetic valve endocarditis : report of a case] Imanaka K, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):693–6 (Eng. Abstr.) **(Jpn)**

[A case report of aortic root replacement with fresh aortic homograft for valve detachment due infective endocarditis] Niwaya K, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):688–92 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Penetration of the atrialventricular septum by spread of infection from aortic valve endocarditis: early diagnosis by transesophageal echocardiography and implications for surgical management. Barbour SI, et al. **Am Heart J** 1996 Dec;132(6):1287–9

Quadricuspid aortic valve diagnosed by transesophageal echocardiography. Georgeson S, et al. **Am Heart J** 1996 Dec;132(6):1292–3

Correspondence of aortic valve area determination from transesophageal echocardiography, transthoracic echocardiography, and cardiac catheterization. Kim CJ, et al. **Am Heart J** 1996 Dec;132(6):1163–72

Doppler echocardiographic assessment of the new ATS medical prosthetic valve in the aortic position. Karpuz H, et al. **Am J Card Imaging** 1996 Oct;10(4):254–60

Changes in effective aortic valve area during ejection in adults with aortic stenosis. Badano L, et al. **Am J Cardiol** 1996 Nov 1;78(9):1023–8

Detection of strands in native aortic valves by transesophageal echocardiography. Menzel T, et al. **Am J Cardiol** 1997 Jun 1;79(11):1549–52

Usefulness of dobutamine echocardiography in the hemodynamic assessment of mechanical prostheses in the aortic valve position. Zabalgoitia M, et al. **Am J Cardiol** 1997 Aug 15;80(4):523–6

Importance of pressure recovery for the assessment of aortic stenosis by Doppler ultrasound. Role of aortic size, aortic valve area, and direction of the stenotic jet in vitro. Niederberger J, et al. **Circulation** 1996 Oct 15;94(8):1934–40

Multiplane transoesophageal echocardiography detection of papillary fibroelastomas of the aortic valve causing a stroke [letter] Shelh M. **Eur Heart J** 1997 Apr;18(4):702–3

Transoesophageal echocardiographic assessment of mitral and aortic valve function during cardiopulmonary resuscitation. Huemer G, et al. **Eur J Anaesthesiol** 1996 Nov;13(6):622–6

Planimetry of aortic valve area using multiplane transoesophageal echocardiography is not a reliable method for assessing severity of aortic stenosis. Bernard Y, et al. **Heart** 1997 Jul;78(1):68–73

Pseudoaneurysm of mitral–aortic intervalvular fibrosa in aortic valve endocarditis: transoesophageal echocardiographic diagnosis. Kothari SS, et al. **Indian Heart J** 1997 Jan–Feb;49(1):85–6

Doppler echocardiographic assessment of prosthetic aortic valve area: estimation with the continuity equation compared to the Gorlin formula. Mohan JC, et al. **Int J Cardiol** 1996 Jul 26;55(2):177–81

Planimetry and transthoracic two–dimensional echocardiography in noninvasive assessment of aortic valve area in patients with valvular aortic stenosis. Okura H, et al. **J Am Coll Cardiol** 1997 Sep;30(3):753–9

Simultaneous determination of aortic valve area by the Gorlin formula and by transesophageal echocardiography under different transvalvular flow conditions. Evidence that anatomic aortic valve area does not change with variations in flow in aortic stenosis. Tardif JC, et al. **J Am Coll Cardiol** 1997 May;29(6):1296–302

Accuracy of transesophageal echocardiography in preoperative determination of aortic anulus size during valve replacement. Abraham TP, et al. **J Am Soc Echocardiogr** 1997 Mar;10(2):149–54

Normal echocardiographic characteristics of the Sorin Bicarbon bileaflet prosthetic heart valve in the mitral and aortic positions. Badano L, et al. **J Am Soc Echocardiogr** 1997 Jul–Aug;10(6):632–43

A study of the human aortic valve orifice by transesophageal echocardiography. Darmon PL, et al. **J Am Soc Echocardiogr** 1996 Sep–Oct;9(5):668–74

Improved transvalvular continuous–wave Doppler signal intensity after intravenous Albunex injection in patients with prosthetic aortic valves. Okura H, et al. **J Am Soc Echocardiogr** 1997 Jul–Aug;10(6):608–12

Flow dependence of the aortic valve area in patients with aortic stenosis: assessment by application of the continuity equation. Rask LP, et al. **J Am Soc Echocardiogr** 1996 May–Jun;9(3):295–9

Unsuspected aortic valve vegetation detected during intraoperative transesophageal echocardiographic monitoring for coronary artery bypass grafting. London MJ, et al. **J Cardiothorac Vasc Anesth** 1996 Feb;10(2):253–7

Doppler echocardiographic study of three different mechanical valves in the aortic position: the use of external nominal diameter indexed to body surface area [see comments] Bailly P, et al. **J Heart Valve Dis** 1997 May; 6(3):236–48. Comment in: J Heart Valve Dis 1997 May;6(3):234.

Echocardiography and the small aortic root. Chambers J. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S264–8 (35 ref.)

Early diagnosis of obstructed aortic valve prostheses: a clinical challenge [editorial; comment] Shah PM. **J Heart Valve Dis** 1997 May;6(3):234–5. Comment on: J Heart Valve Dis 1997 May;6(3):236–48.

Hemodynamic assessment of replacement valves in the aortic position: is stress echocardiography necessary? [editorial] Takeda S, et al. **J Heart Valve Dis** 1997 Jul;6(4):380–2

Transthoracic and transesophageal echocardiographic evaluation of the aortic root and subvalvular structures in ankylosing spondylitis. Arnason JA, et al. **J Rheumatol** 1996 Jan;23(1):120–3

Effects of velocity distribution, diameter measurement and velocity tracing on the accuracy of cardiac output measurement by pulsed Doppler echocardiography in the aortic annulus of pigs. Zhou YQ, et al. **Ultrasound Med Biol** 1997;23(2):177–85

[Cardiovascular imaging in–a–month. A 56–year–old man complaining of dyspnea] Sugiyama Y, et al. **J Cardiol** 1996 Sep;28(3):171–4 **(Jpn)**

[Clinical and echocardiographic assessment of surgical replacement of the aortic valve with lung autograft: results after 2 years] Parreira L, et al. **Rev Port Cardiol** 1996 Jun; 15(6):475–82, 459 (Eng. Abstr.) **(Por)**

ULTRASTRUCTURE

Morphology of porcine aortic valve cusp elastin. Scott MJ, et al. **J Heart Valve Dis** 1996 Sep;5(5):464–71

The effect of ACE inhibitors on atheroma formation is potentiated by association with a calcium channel blocker. A biochemical and ultrastructural study. Raicu M, et al. **J Submicrosc Cytol Pathol** 1997 Jul;29(3):317–28

AORTIC VALVE INCOMPETENCE see **AORTIC VALVE INSUFFICIENCY**

AORTIC VALVE INSUFFICIENCY

Aortic regurgitation in women. Does the measuring stick need a change? [editorial; comment] Carabello BA. **Circulation** 1996 Nov 15;94(10):2355–7. Comment on: Circulation 1996 Nov 15;94(10):2472–8.

BLOOD

Twenty–four–hour ambulatory blood pressure and vasoactive hormones in valvular aortic disease. Jensen LW, et al. **Blood Press** 1996 Sep;5(5):292–9

COMPLICATIONS

Drawback of aortoplasty for aneurysm of the ascending aorta associated with aortic valve disease. Mueller XM, et al. **Ann Thorac Surg** 1997 Mar;63(3):762–6; discussion 766–7

Unruptured sinus of Valsalva aneurysm with right ventricular outflow tract obstruction associated with ventricular septal defect. Liang CD, et al. **Cathet Cardiovasc Diagn** 1996 Feb; 37(2):158–61

Aorto–left atrial fistula associated with left coronary artery origin anomaly and bicuspid aortic valve and aortic regurgitation: a case report [letter] San M, et al. **Cathet Cardiovasc Diagn** 1996 Nov;39(3):330

Estimating myocardial damage and the need for surgery in patients with valvular heart disease by Tl–201 SPECT. Yamazaki J, et al. **Clin Nucl Med** 1996 Nov;21(11):855–63

Unruptured aneurysms of the non–coronary and left sinuses of Valsalva accompanied by severe aortic valve regurgitation. Simic O, et al. **Eur J Cardiothorac Surg** 1996; 10(11):1030–2

Gerbode's defect associated with acute sinus node dysfunction as a complication of infective endocarditis. Michel C, et al. **Heart** 1996 Oct;76(4):379

A case of Q fever endocarditis treated medically: 9 years of follow–up [letter] Dalmau D, et al. **Infection** 1997 Mar–Apr;25(2):131–2

Aortic insufficiency and stenosis in unruptured aneurysm of sinus of Valsalva [letter] Yuan SM. **Int J Cardiol** 1997 May 23;59(3):321–2

Myocardial sympathetic denervation prevents chamber–specific alteration of beta–adrenergic transmembrane signaling in rabbits with heart failure. Anzai T, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1314–22

How to manage patients with severe left ventricular dysfunction and valvular regurgitation. Acar J, et al. **J Heart Valve Dis** 1996 Jul;5(4):421–9

Reoperation for aneurysmal disease of the ascending aorta in patients with concomitant aortic valve incompetence. Karck M, et al. **J Thorac Cardiovasc Surg** 1996 Nov; 112(5):1392–3

Spontaneous regression of left ventricular hypertrophy in a rabbit model of aortic insufficiency: possible clinical implications. Simko F. **Med Hypotheses** 1995 Dec; 45(6):556–8 (18 ref.)

Secular trends in coronary atherosclerosis [letter; comment] Ruygrok P, et al. **N Engl J Med** 1997 Jan 16;336(3):224; discussion 225. Comment on: N Engl J Med 1996 Aug 1;335(5):316–22.

Carcinoid heart disease with severe hypoxia due to interatrial shunt through patent foramen ovale. Boglioli LR, et al. **Tex Heart Inst J** 1997;24(2):125–8

Aortitis, aortic valve incompetence, and left coronary ostium stenosis in a patient with C–ANCA–associated necrotizing vasculitis. Morshuis WJ, et al. **Thorac Cardiovasc Surg** 1997 Apr;45(2):97–9

[Aortic valve abscess with perforation in the right atrium] Zuber M, et al. **Schweiz Med Wochenschr** 1996 Nov 2; 126(44):1900 **(Ger)**

[A 98–year–old woman with syphilitic aortic regurgitation combined with systolic murmur and calcification of the pulmonary artery] Ohkawa S, et al. **J Cardiol** 1997 Apr; 29(4):231–4 **(Jpn)**

[Three cases of coronary to pulmonary arterial fistulae combined with valvular disease] Iida H, et al. **Kyobu Geka** 1996 May;49(5):384–7 (Eng. Abstr.) **(Jpn)**

[A case of coronary artery embolism after double valve replacement] Taniyasu N, et al. **Kyobu Geka** 1996 Jul; 49(7):583–6 (Eng. Abstr.) **(Jpn)**

[A case of aortic valve replacement for active infectious endocarditis with multi–organ failure preoperatively] Togashi K, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):684–7 (Eng. Abstr.) **(Jpn)**

[A case of extracardiac noncoronary sinus Valsalva aneurysm associated with aortic regugitation] Kochi K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jan;45(1):84–7 (Eng. Abstr.) **(Jpn)**

[Hypertension secondary to cardiovascular disease] Nakamura Y. **Ryoikibetsu Shokogun Shirizu** 1996;(12):103–6 (9 ref.) **(Jpn)**

[Hypertrophic response to cardiac overload. Similarities and differences between left ventricular hypertrophy as response to pressure overload or to volumetric overload] Chagas AC, et al. **Arq Bras Cardiol** 1995 Dec;65(6):541–4 **(Por)**

CONGENITAL

The Ross procedure in children and young adults with congenital aortic valve disease. Walters HL 3rd, et al. **J Heart Valve Dis** 1997 Jul;6(4):335–42

[The quadri–cusp aortic valve: a congenital defect, responsible for pathologic changes?] Vicol C, et al. **Z Kardiol** 1997 Jul;86(7):538–40 (Eng. Abstr.) **(Ger)**

[Congenital supravalvular aortic stenosis, congenital valvular aortic stenosis, congenital subaortic stenosis, aortic atresia, congenital aortic regurgitation] Okada R. **Ryoikibetsu Shokogun Shirizu** 1996;(13):242–5 (20 ref.) **(Jpn)**

DIAGNOSIS

The importance of slice location on the accuracy of aortic regurgitation measurements with magnetic resonance phase velocity mapping. Chatzimavroudis GP, et al. **Ann Biomed Eng** 1997 Jul–Aug;25(4):644–52

You're the flight surgeon: bicuspid aortic valve with mild aortic insufficiency and mild left ventricular enlargement. Ramsey CS. **Aviat Space Environ Med** 1996 Dec; 67(12):1204–5

Hill's sign in aortic regurgitation: enhanced pressure wave transmission or artefact? Kutryk M, et al. **Can J Cardiol** 1997 Mar;13(3):237–40

Reappraisal of cardiac murmurs related to aortic regurgitation. Lee D, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1995 Sep;56(3):152–8

Diagnosis and management of acute aortic valvular disruption secondary to rapid–deceleration trauma. Munshi IA, et al. **J Trauma** 1996 Dec;41(6):1047–50

[Can Doppler echocardiography help to avoid cardiac catheterization in the surgical decision–making in isolated left heart valve diseases?] Tribouilloy C, et al. **Arch Mal Coeur Vaiss** 1996 Dec;89(12):1607–16 (28 ref.) (Eng. Abstr.) **(Fre)**

[Mediastinal spreading and aortic insufficiency] Manger B, et al. **Med Klin** 1997 Mar 15;92(3):144 **(Ger)**

[Aortic valve insufficiency in Crohn disease] Wäckerlin A, et al. **Schweiz Med Wochenschr** 1997 May 31;127(22):935–9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Aortic valve insufficiency caused by nonpenetrating chest trauma difficult to distinguish from infective endocarditis with transesophageal echocardiography: a case report] Hioki J, et al. **J Cardiol** 1997;29 Suppl 2:143–9 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. Levine HJ, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1083–91 (53 ref.)

ETIOLOGY

Follow–up results of balloon aortic valvuloplasty in children with special reference to causes of late aortic insufficiency.

Galal O, et al. **Am Heart J** 1997 Apr;133(4):418–27

Aortic valve prolapse and aortic regurgitation associated with subpulmonic ventricular septal defect. Tohyama K, et al. **Am J Cardiol** 1997 May 1;79(9):1285–9

An improved valve-spreading catheter for producing reversible graded acute aortic regurgitation. Ardehali A, et al. **Cardiology** 1996 Jul–Aug;87(4):276–8

Surgical treatment of traumatic rupture of the normal aortic valve. Egoh Y, et al. **Eur J Cardiothorac Surg** 1997 Jun; 11(6):1180–2

Acquired aortic regurgitation following occlusion of the persistent arterial duct: an echocardiographic assessment. Harrisberg JR, et al. **Heart** 1997 May;77(5):404–6

Repair of aortic cusp traumatic laceration caused by cardiac catheterization. Fundarò P, et al. **J Heart Valve Dis** 1996 May;5(3):281–2

Post-radiation valvular and coronary artery disease. Gonzaga AT, et al. **J Heart Valve Dis** 1997 Mar;6(2):219–21

Aortic dissection in puerperium: a case report. Scalia D, et al. **J Heart Valve Dis** 1996 May;5(3):251–3

Cardiac valve disease in Wegener's granulomatosis [letter] Greidinger EL, et al. **J Rheumatol** 1996 Aug;23(8):1485–7 (11 ref.)

Geometric mismatch of the aortic and pulmonary roots causes aortic insufficiency after the Ross procedure. David TE, et al. **J Thorac Cardiovasc Surg** 1996 Nov; 112(5):1231–7; discussion 1237–9

Aortic valve replacement in relapsing polychondritis. Lang-Lazdunski L, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):131–2

Aneurysmal dilatation of ascending aorta and aortic insufficiency in juvenile spondyloarthropathy. Kim TH, et al. **Scand J Rheumatol** 1997;26(3):218–21

Aortic valve injury secondary to blunt trauma from an air bag [see comments] Hanna KM, et al. **Tenn Med** 1997 May; 90(5):195–6. Comment in: Tenn Med 1997 Aug;90(8):332.

Coronary artery and aortic valve disease as a long-term sequel of mediastinal and thoracic irradiation. Kleikamp G, et al. **Thorac Cardiovasc Surg** 1997 Feb;45(1):27–31

A case of nonpenetrating traumatic aortic regurgitation detected by transesophageal echocardiography. Oda H, et al. **Tohoku J Exp Med** 1997 May;182(1):93–101

[Rheumatoid aortic insufficiency. Apropos of a case treated by mechanical valve replacement. Review of the literature] Moini C, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jun; 45(6):329–33 (20 ref.) (Eng. Abstr.) **(Fre)**

[Accessory mitral valve tissue as a rare cause of subaortic stenosis and valvular aortic insufficiency] Gamillscheg A, et al. **Z Kardiol** 1997 Jul;86(7):549–53 (Eng. Abstr.) **(Ger)**

[Aortic valve insufficiency caused by nonpenetrating chest trauma difficult to distinguish from infective endocarditis with transesophageal echocardiography: a case report] Hioki J, et al. **J Cardiol** 1997;29 Suppl 2:143–9 (Eng. Abstr.) **(Jpn)**

[Aortic regurgitation due to ruptured fibrous band in the noncoronary cusp: a case report] Kaneko T, et al. **J Cardiol** 1996;27 Suppl 2:79–82; discussion 83 (Eng. Abstr.) **(Jpn)**

[Successful surgical treatment of aortic regurgitation due to annuloaortic ectasia and mitral regurgitation caused by tendon rupture in a case of osteogenesis imperfecta] Maekawa Y, et al. **J Cardiol** 1997;29 Suppl 2:89–94 (Eng. Abstr.) **(Jpn)**

[Clinical significance of valvular regurgitation during long-term antihypertensive therapy in patients with mild to moderate essential hypertension] Takaoka N, et al. **J Cardiol** 1997 Apr;29(4):209–16 (Eng. Abstr.) **(Jpn)**

[Preventive concomitant aortic root replacement for annuloaortic ectasia in a patient with Marfan syndrome undergoing mitral valve replacement for mitral regurgitation] Takeda M, et al. **J Cardiol** 1997;29 Suppl 2:97–101 (Eng. Abstr.) **(Jpn)**

[Aortic valve regurgitation due to quadricuspid valve: a report of complicated case] Kaminishi Y, et al. **Kyobu Geka** 1997 Jan;50(1):63–6 (Eng. Abstr.) **(Jpn)**

[Surgery for aortic valvular disease with congenital quadricuspid aortic valve] Komesu I, et al. **Kyobu Geka** 1996 Aug;49(9):775–9 (27 ref.) (Eng. Abstr.) **(Jpn)**

[A case of report of traumatic aortic regurgitation accompanying cerebral embolism] Takaki Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec; 44(12):2225–30 (Eng. Abstr.) **(Jpn)**

[A case of Behçet's disease associated with aortic regurgitation and nephrotic syndrome] Akiyama Y, et al. **Ryumachi** 1995 Dec;35(6):910–4 (Eng. Abstr.) **(Jpn)**

METABOLISM

Beta adrenoceptor density in patients with left-sided valvular regurgitation. Dzimiri N, et al. **Fundam Clin Pharmacol** 1996;10(6):547–53

MICROBIOLOGY

A case of Q fever endocarditis treated medically: 9 years of follow-up [letter] Dalmau D, et al. **Infection** 1997 Mar–Apr;25(2):131–2

PATHOLOGY

[Severe aortic regurgitation with marked thickening of the aortic annulus: a case report] Sugiyama Y, et al. **J Cardiol** 1997;29 Suppl 2:81–6 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Transesophageal Doppler echocardiographic assessment of systolic and diastolic coronary blood flow velocities at baseline and during adenosine triphosphate-induced coronary vasodilation in chronic aortic regurgitation. Kisanuki A, et al. **Am Heart J** 1997 Jan;133(1):71–7

Relation of ultra-low frequency heart rate variability to the clinical course of chronic aortic regurgitation. Freed LA, et al. **Am J Cardiol** 1997 Jun 1;79(11):1482–7

Twenty-four-hour ambulatory blood pressure and vasoactive hormones in valvular aortic disease. Jensen LW, et al. **Blood Press** 1996 Sep;5(5):292–9

Hill's sign in aortic regurgitation: enhanced pressure wave transmission or artefact? Kutryk M, et al. **Can J Cardiol** 1997 Mar;13(3):237–40

An improved valve-spreading catheter for producing reversible graded acute aortic regurgitation. Ardehali A, et al. **Cardiology** 1996 Jul–Aug;87(4):276–8

Beta-blockade prevents ventricular failure following aortic regurgitation in rabbits. Suzuki M, et al. **Cardiology** 1997 Sep–Oct;88(5):418–24

Hemodynamic changes pre- and post-pacing with complete heart block and aortic valve stenosis and regurgitation. Karim MA, et al. **Cathet Cardiovasc Diagn** 1996 Feb; 37(2):178–83

Evaluation of left ventricular relaxation using the continuous-wave Doppler velocity profile of aortic regurgitation: noninvasive measurement of left ventricular negative dP/dt and time constant. Honda Y, et al. **Clin Cardiol** 1996 Sep;19(9):709–15

Factors influencing heart rate variability in patients with severe aortic valve disease. Jung J, et al. **Clin Cardiol** 1997 Apr;20(4):341–4

Retrograde atrial kick in acute aortic regurgitation. Study of mitral and pulmonary venous flow velocities by transthoracic and transesophageal echocardiography. Vilacosta I, et al. **Clin Cardiol** 1997 Jan;20(1):35–40

Giant T wave inversion associated with severe aortic regurgitation. Weston CF, et al. **Int J Cardiol** 1996 Jun; 54(3):277–82

Aortic flow velocity patterns in chronic aortic regurgitation: implications for Doppler echocardiography. Reimold SC, et al. **J Am Soc Echocardiogr** 1996 Sep–Oct;9(5):675–83

Effect of physiological factors on proximal flow convergence upstream of an incompetent valve: an in-vitro study. Guenet FS, et al. **J Biomech Eng** 1997 Feb;119(1):39–44

Peculiar patterns of aortic regurgitation and carotid pulse due to dysfunction of a Medtronic Hall prosthetic valve: a case report. Fukuda N, et al. **J Heart Valve Dis** 1996 May;5(3):283–5

A hemodynamic comparison of Omniscience and Medtronic Hall aortic prostheses [see comments] Plehn JF, et al. **J Heart Valve Dis** 1996 May;5(3):328–36. Comment in: J Heart Valve Dis 1996 Nov;5(6):675–7.

Relationship between exercise capacity and left ventricular function in aortic and mitral regurgitation. Jakrapanichakul D, et al. **J Med Assoc Thai** 1996 Feb;79(2):98–102

Hemodynamic benefits of the Toronto Stentless Valve. Del Rizzo DF, et al. **J Thorac Cardiovasc Surg** 1996 Dec; 112(6):1431–45; discussion 1445–6

Left ventricular adaptation to aortic regurgitation in conscious dogs. Gaynor JW, et al. **J Thorac Cardiovasc Surg** 1997 Jan;113(1):149–58

Stroke volume generation of the left ventricle and its relation to chamber shape in normal subjects and patients with mitral or aortic regurgitation. Hiro T, et al. **Jpn Circ J** 1996 Apr;60(4):216–27

Slice location dependence of aortic regurgitation measurements with MR phase velocity mapping. Chatzimavroudis GP, et al. **Magn Reson Med** 1997 Apr; 37(4):545–51

Automated blood pressure measurement in special situations: patients with chronic atrial fibrillation or chronic aortic regurgitation. Eckert S, et al. **Z Kardiol** 1996;85 Suppl 3:92–8

[Aortic insufficiency: physiopathology and the best timing for surgery] Mariani M, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):325–8 **(Ita)**

[Postoperative follow-up results of aortic valve diseases—the relationship between residual left ventricular hypertrophy and dysfunctions of contractile and dilative functions] Taniguchi K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Mar;44(3):324–6 **(Jpn)**

RADIONUCLIDE IMAGING

Antimyosin antibody imaging in experimental aortic regurgitation [see comments] Lu P, et al. **J Nucl Cardiol** 1997 Jan–Feb;4(1 Pt 1):25–32. Comment in: J Nucl Cardiol 1997 Jan–Feb;4(1 Pt 1):79–82.

SURGERY

Complete resolution of diastolic mitral regurgitation in chronic, but not acute aortic regurgitation after aortic valve replacement—a transesophageal echocardiography study. Wang CH, et al. **Acta Anaesthesiol Sin** 1996 Mar; 34(1):37–41

Congenital aortic valve disease. Improved survival and quality of life. Elkins RC, et al. **Ann Surg** 1997 May; 225(5):503–10; discussion 510–1

Pulmonary autograft implantation in the dilated aortic annulus. Eishi K, et al. **Ann Thorac Surg** 1997 Apr; 63(4):1155–8

An alternative airway in cardiac surgery? [letter] Ghosh S, et al. **Ann Thorac Surg** 1997 Mar;63(3):921–2

Thirty-year results of Starr-Edwards prostheses in the aortic and mitral position. Gödje OL, et al. **Ann Thorac Surg** 1997 Mar;63(3):613–9

Drawback of aortoplasty for aneurysm of the ascending aorta associated with aortic valve disease. Mueller XM, et al. **Ann Thorac Surg** 1997 Mar;63(3):762–6; discussion 766–7

Medtronic intact porcine bioprosthesis [letter; comment] Odell JA. **Ann Thorac Surg** 1997 Apr;63(4):1218–9. Comment on: Ann Thorac Surg 1996 Sep;62(3):940–1.

Heart valve operation in acromegaly. Ohtsuka G, et al. **Ann Thorac Surg** 1997 Aug;64(2):390–3

Event status of the Starr-Edwards aortic valve to 20 years: a benchmark for comparison. Orszulak TA, et al. **Ann Thorac Surg** 1997 Mar;63(3):620–6

Aortic valve replacement via left thoracotomy after an esophageal operation. Takahara Y, et al. **Ann Thorac Surg** 1997 Jan;63(1):225–7

Aortic valve replacement in a patient with cardiac amyloidosis [letter] Terada Y, et al. **Ann Thorac Surg** 1996 Nov;62(5):1571–2

Thirty years experience with heart valve surgery: isolated aortic valve replacement. Bessell JR, et al. **Aust N Z J Surg** 1996 Dec;66(12):799–805

Aortic valve replacement in a United States Air Force pilot: case report and literature review. Hardy JC, et al. **Aviat Space Environ Med** 1997 Mar;68(3):221–4

Echocardiographic characteristics of the cryopreserved allograft aortic valve replacement assessed by intraoperative transoesophageal echocardiography. Hasegawa J, et al. **Cardiovasc Surg** 1996 Jun;4(3):293–8

The stentless Bravo 300 aortic porcine xenograft: supra-annular versus annular implantation. Hvass U, et al. **Cardiovasc Surg** 1997 Apr;5(2):220–4

What are the limits for the Ross operation? Melo JQ, et al. **Cardiovasc Surg** 1996 Aug;4(4):526–9

Composite graft replacement of the aortic root in patients with Marfan's syndrome. Sekine S, et al. **Cardiovasc Surg** 1996 Oct;4(5):635–8

Stentless valve replacement in the small aortic root. Walther T, et al. **Cardiovasc Surg** 1997 Apr;5(2):229–34

The stentless Toronto SPV bioprosthesis for aortic valve replacement. Walther T, et al. **Cardiovasc Surg** 1996 Aug; 4(4):536–42

Diagnosis of left atrial thrombus with the aid of transesophageal echocardiography during aortic valve replacement: a case report. Wang CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Mar;59(3):186–9

Surgery for aortic regurgitation in Women. Contrasting indications and outcomes compared with men [see comments] Klodas E, et al. **Circulation** 1996 Nov 15; 94(10):2472–8. Comment in: Circulation 1996 Nov 15;94(10):2355–7.

Circulating microemboli in patients after aortic valve replacement with pulmonary autografts and mechanical valve prostheses. Nötzold A, et al. **Circulation** 1997 Sep 16;96(6):1843–6

Time-related changes in left ventricular function after double valve replacement for combined aortic and mitral regurgitation in a young rheumatic population. Predictors of postoperative left ventricular performance and role of chordal preservation. Skudicky D, et al. **Circulation** 1997 Feb 18;95(4):899–904

Aortic valve repair: still a dream? [editorial; comment] Antunes MJ. **Eur J Cardiothorac Surg** 1997 Feb;11(2):266–7 . Comment on: Eur J Cardiothorac Surg 1997 Feb;11(2):258–65.

Pericardial valves in small aortic annuli: ten years' results. Aupart M, et al. **Eur J Cardiothorac Surg** 1996; 10(10):879–83

Semilunar valve switch in aortic insufficiency. Deleon SY, et al. **Eur J Cardiothorac Surg** 1995;9(11):631–5

Surgical treatment of traumatic rupture of the normal aortic valve. Egoh Y, et al. **Eur J Cardiothorac Surg** 1997 Jun; 11(6):1180–2

Thirty years survival after double valve replacement with Starr-Edwards prostheses in aortic and mitral position. Gödje O, et al. **Eur J Cardiothorac Surg** 1997 Feb; 11(2):391–3

Valve repair for aortic insufficiency: surgical classification and techniques [see comments] Haydar HS, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):258–65. Comment in: Eur J Cardiothorac Surg 1997 Feb;11(2):266–7.

Aortic valve debridement by ultrasonic surgical aspirator in degenerative, aortic valve stenosis: follow-up with Doppler echocardiography. Kellner HJ, et al. **Eur J Cardiothorac Surg** 1996;10(7):498–504

Protamine-induced fulminating non-cardiogenic pulmonary edema following cardiopulmonary bypass. Kindler C, et al. **Eur J Cardiothorac Surg** 1996;10(6):463–6

The pulmonary homograft as aortic valve substitute: 7 years' follow up. Mair R, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):910–6

Ross procedure in congenital patients: results and left ventricular function. Rubay JE, et al. **Eur J Cardiothorac Surg** 1997 Jan;11(1):92–9

Composite graft in annulo-aortic ectasia. Nineteen years' experience without graft inclusion. Savunen T, et al. **Eur J Cardiothorac Surg** 1996;10(6):428–32

Stentless porcine bioprostheses for all types of aortic root

pathology. Sidiropoulos A, et al.
Eur J Cardiothorac Surg 1997 May;11(5):917–21

Emergency surgery for acute infective aortic valve endocarditis: performance of cryopreserved homografts and mode of failure. Vogt PR, et al.
Eur J Cardiothorac Surg 1997 Jan;11(1):53–61

Spontaneous bacterial endocarditis and aortic valve replacement complicating pregnancy. Hautman GD, et al.
Int J Gynaecol Obstet 1996 Aug;54(2):173–4

Repair for acquired aortic valve disease. Antunes MJ.
Isr J Med Sci 1996 Oct;32(10):817–20 (5 ref.)

Cardiologic aspects of aortic valve surgery—who? when? what? Barlow JB. **Isr J Med Sci** 1996 Oct;32(10):821–31 (37 ref.)

Aortic valve replacement with a stentless porcine bioprosthesis (TSPV). Goldman BS, et al.
Isr J Med Sci 1996 Oct;32(10):846–8

The Ross procedure in children. Reddy VM, et al.
Isr J Med Sci 1996 Oct;32(10):888–91

Optimizing timing of surgical correction in patients with severe aortic regurgitation: role of symptoms. Klodas E, et al. **J Am Coll Cardiol** 1997 Sep;30(3):746–52

Color Doppler and two-dimensional echocardiographic determination of the mechanism of aortic regurgitation with surgical correlation. Cohen GI, et al.
J Am Soc Echocardiogr 1996 Jul–Aug;9(4):508–15

In vitro evaluation of forward and reverse volumetric flow across a regurgitant aortic valve using Doppler power-weighted mean velocities. Minich LL, et al.
J Am Soc Echocardiogr 1997 Jul–Aug;10(6):623–31

Intravalvular implantation of aortic valve prosthesis. Ghosh PK, et al. **J Card Surg** 1996 Nov–Dec;11(6):432–3

Bentall operation for a child with Marfan syndrome: a case report. Miura M, et al. **J Card Surg** 1997 Mar–Apr; 12(2):116–9 (14 ref.)

Valve conserving operation for aortic regurgitation. Pupper J, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):151–6 (5 ref.)

Long-term results of heart valve replacement with bileaflet prostheses. Renzulli A, et al. **J Cardiovasc Surg (Torino)** 1997 Jun;38(3):241–7

Takayasu's arteritis complicating annuloaortic ectasia (AAE) treated with modified Bentall procedure. Sasaki S, et al.
J Cardiovasc Surg (Torino) 1997 Aug;38(4):381–4

A case of Turner's syndrome associated with partial anomalous pulmonary venous return complicated by dissecting aortic aneurysm and aortic regurgitation. Shiroma K, et al. **J Cardiovasc Surg (Torino)** 1997 Jun; 38(3):257–9

How to manage patients with severe left ventricular dysfunction and valvular regurgitation. Acar J, et al.
J Heart Valve Dis 1996 Jul;5(4):421–9

Double valve replacement with the Carpentier–Edwards pericardial valve: 10-year results. Aupart MR, et al.
J Heart Valve Dis 1996 May;5(3):312–6

Hemodynamic performance of the Edwards Prima stentless valve. Bortolotti U, et al. **J Heart Valve Dis** 1997 Mar; 6(2):134–7

Surgery for aortic root aneurysm with aortic insufficiency [editorial; comment] David TE. **J Heart Valve Dis** 1996 May;5(3):238–9. Comment on: J Heart Valve Dis 1996 May;5(3):240–6. Comment on: J Heart Valve Dis 1996 May;5(3):247–50.

Aortic root replacement for annuloaortic ectasia in Shprintzen–Goldberg syndrome: a case report. Fukunaga S, et al. **J Heart Valve Dis** 1997 Mar;6(2):181–3 (11 ref.)

Repair of aortic cusp traumatic laceration caused by cardiac catheterization. Fundarò P, et al. **J Heart Valve Dis** 1996 May;5(3):281–2

Surgical management of aortic regurgitation associated with ventricular septal defect. Ogino H, et al.
J Heart Valve Dis 1997 Mar;6(2):174–8

Functional results after aortic valve repair in aortic root ectasia [see comments] Pethig K, et al.
J Heart Valve Dis 1996 May;5(3):247–50. Comment in: J Heart Valve Dis 1996 May;5(3):238–9.

Autograft failure after the Ross operation in a rheumatic population: pre- and postoperative echocardiographic observations. Pieters FA, et al. **J Heart Valve Dis** 1996 Jul;5(4):404–8; discussion 408–9

The Ross procedure in children and young adults with congenital aortic valve disease. Walters HL 3rd, et al.
J Heart Valve Dis 1997 Jul;6(4):335–42

Guides to surgical intervention in chronic aortic regurgitation: myocytes file a claim [editorial; comment] Narula J, et al. **J Nucl Cardiol** 1997 Jan–Feb;4(1 Pt 1):79–82 . Comment on: J Nucl Cardiol 1997 Jan–Feb;4(1 Pt 1):25–32.

Development of an intraluminal device for the treatment of aortic regurgitation: prototype and in vitro testing system. Ashton RC, et al. **J Thorac Cardiovasc Surg** 1996 Oct; 112(4):979–83

Minimally invasive aortic valve replacement. Benetti FJ, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):806–7

Aortic valve replacement after repair of pulmonary atresia and ventricular septal defect or tetralogy of Fallot. Dodds GA 3rd, et al. **J Thorac Cardiovasc Surg** 1997 Apr; 113(4):736–41

Does the pulmonary autograft in the aortic position in adults increase in diameter? An echocardiographic study. Hokken RB, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):667–74

Complete intraoperative dislodgement of a St. Jude Medical Mechanical Heart Valve Hemodynamic Plus valve sewing cuff. Vitale N, et al. **J Thorac Cardiovasc Surg** 1996 Dec; 112(6):1669–71

Anatomic correction of the syndrome of prolapsing right coronary aortic cusp, dilatation of the sinus of Valsalva, and ventricular septal defect. Yacoub MH, et al.
J Thorac Cardiovasc Surg 1997 Feb;113(2):253–60; discussion 261

Evaluation of fetal and uterine hemodynamics during maternal cardiopulmonary bypass. Khandelwal M, et al.
Obstet Gynecol 1996 Oct;88(4 Pt 2):667–71

Ascending aortic aneurysm and aortic valve disease: what is the most optimal surgical technique? Yun KL, et al.
Semin Thorac Cardiovasc Surg 1997 Jul;9(3):233–45 (30 ref.)

Repair of a ruptured sinus of Valsalva aneurysm. Associated with annuloaortic ectasia and coarctation of the aorta in a patient with Marfan syndrome. Tesler UF, et al.
Tex Heart Inst J 1997;24(2):134–8

[The indication for surgery in aortic valve insufficiency] Herbon G. **Dtsch Med Wochenschr** 1996 Sep 13; 121(37):1141 **(Ger)**

[Ball variance and fracture of a Smeloff-Cutter prosthesis 24 years after aortic valve replacement] Hust MH, et al.
Z Kardiol 1997 Jul;86(7):541–4 (Eng. Abstr.) **(Ger)**

[Surgical treatment of aortic valve insufficiency] Spampinato N, et al. **Cardiologia** 1995 Dec;40(12 Suppl 1):329–32 **(Ita)**

[Severe aortic valve insufficiency in asymptomatic patients: when to consider surgical intervention] Domenicucci S, et al. **G Ital Cardiol** 1996 May;26(5):605–16 (80 ref.) **(Ita)**

[Valvuloplasty for aortic insufficiency in a patient with bicuspid aortic valve] Okada Y, et al. **J Cardiol** 1996;27 Suppl 2:85–9; discussion 90 (Eng. Abstr.) **(Jpn)**

[Preventive concomitant aortic root replacement for annuloaortic ectasia in a patient with Marfan syndrome undergoing mitral valve replacement for mitral regurgitation] Takeda M, et al. **J Cardiol** 1997;29 Suppl 2:97–101 (Eng. Abstr.) **(Jpn)**

[CABG performed for LMT orifice stenosis 15 years after AVR in a case of aortitis syndrome] Chikazawa G, et al.
Kyobu Geka 1997 May;50(5):396–9 (Eng. Abstr.) **(Jpn)**

[A clinical investigation of Bentall's operation for annuloaortic ectasia in the elderly] Harada H, et al.
Kyobu Geka 1997 Jul;50(8 Suppl):632–6 (Eng. Abstr.) **(Jpn)**

[Simultaneous operation of aortic valve replacement and renal artery reconstruction in a patient of aortitis syndrome: a case report] Ikeda M, et al. **Kyobu Geka** 1996 Nov; 49(12):1005–7 (Eng. Abstr.) **(Jpn)**

[Echocardiographic evaluation of hemodynamic function of CarboMedics heart valve in the aortic position in patients with small aortic annuli] Imanaka K, et al. **Kyobu Geka** 1996 Jul;49(7):529–33 (Eng. Abstr.) **(Jpn)**

[Aortic valve regurgitation due to quadricuspid valve: a report of complicated case] Kaminishi Y, et al.
Kyobu Geka 1997 Jan;50(1):63–6 (Eng. Abstr.) **(Jpn)**

[A case report of liaison psychiatry and open heart surgery in a patient with schizophrenia] Kawasaki H, et al.
Kyobu Geka 1997 Mar;50(3):209–11 (Eng. Abstr.) **(Jpn)**

[Abdominal aortic aneurysm and annuloaortic ectasia in siblings with Marfan syndrome] Koga M, et al.
Kyobu Geka 1997 Mar;50(3):239–42 (Eng. Abstr.) **(Jpn)**

[Surgery for aortic valvular disease with congenital quadricuspid aortic valve] Komesu I, et al. **Kyobu Geka** 1996 Aug;49(9):775–9 (27 ref.) (Eng. Abstr.) **(Jpn)**

[An aged case of successful repair for the ruptured distal aortic arch aneurysm associated with aortic regurgitation: a case report] Kusuhara K, et al. **Kyobu Geka** 1996 Aug; 49(9):754–8 (Eng. Abstr.) **(Jpn)**

[Long-term clinical results with a new surgical method for the fragile valvular annulus] Moro H, et al.
Kyobu Geka 1997 Mar;50(3):175–8; discussion 178–80 (Eng. Abstr.) **(Jpn)**

[Quadricuspid aortic valve: report of a case associated with severe aortic regurgitation] Seki A, et al. **Kyobu Geka** 1996 Nov;49(12):1027–31 (31 ref.) (Eng. Abstr.) **(Jpn)**

[A case of coronary artery embolism after double valve replacement] Taniyasu N, et al. **Kyobu Geka** 1996 Jul; 49(7):583–6 (Eng. Abstr.) **(Jpn)**

[A case report of aortic valvuloplasty by rasping technique for aortic stenosis with small annulus simultaneously performed with mitral valve replacement] Taniyasu N, et al. **Kyobu Geka** 1997 Feb;50(2):155–7 (Eng. Abstr.) **(Jpn)**

[A case of aortic valve replacement for active infectious endocarditis with multi-organ failure preoperatively] Togashi K, et al. **Kyobu Geka** 1996 Jul;49(8 Suppl):684–7 (Eng. Abstr.) **(Jpn)**

[Single-stage correction of coarctation of the aorta with aortic regurgitation] Uchida N, et al. **Kyobu Geka** 1997 Apr;50(4):317–20 (Eng. Abstr.) **(Jpn)**

[Perforation and localized dissection of the left common iliac artery during the modified Bentall procedure: a case report] Yuda T, et al. **Kyobu Geka** 1996 Nov;49(12):1033–5 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of aortic valve regurgitation due to nonpenetrating trauma of the chest—a case report and review of the literature in Japan] Ashida Y, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Feb;45(2):207–12 (24 ref.) (Eng. Abstr.) **(Jpn)**

[A case of DVR with Nicks's procedure for active infective endocarditis with periannular abscess] Bonkohara Y, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Feb;45(2):174–80 (Eng. Abstr.) **(Jpn)**

[Surgical treatment of traumatic rupture of the aortic valve] Imamaki M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Nov;44(11):2050–3 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Trends in surgery of heart valve diseases and recommendation of valvoplasty in aortic and mitral valve insufficiencies] Kitahara H, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Mar;45(3):414–7 **(Jpn)**

[Aortic valve injury due to blunt trauma—treatment in acute phase] Kohno M, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Oct;44(10):1882–6 (Eng. Abstr.) **(Jpn)**

[Two cases of annulo-aortic ectasia with type A aortic dissection reconstructed by reimplantation of the aortic valve] Konishi T, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Apr;45(4):611–4 (Eng. Abstr.) **(Jpn)**

[A case of primary tissue failure in aortic bioprosthesis due to pannus formation] Kumano H, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Jul;44(7):1012–4 (Eng. Abstr.) **(Jpn)**

[A case of quadricuspid aortic valve associated with aortic steno-insufficiency] Sasahashi N, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Jul;45(7):1055–60 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Hemobilia after percutaneous transhepatic gallbladder drainage for cholecystitis in a patient undergoing aortic valve replacement] Tago K, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Jul;45(7):1020–3 (Eng. Abstr.) **(Jpn)**

[David's operation for aortic regurgitation associated with annulo-aortic ectasia] Taketani S, et al.
Nippon Kyobu Geka Gakkai Zasshi 1997 Apr;45(4):635–8 (Eng. Abstr.) **(Jpn)**

[Surgical experience in patients with Marfan's syndrome and cardiovascular disease] Tabayashi K, et al.
Rinsho Kyobu Geka 1989 Jun;9(3):283–7 (Eng. Abstr.) **(Jpn)**

[New coronary tube for Cabrol's technique] Yokoyama M, et al. **Rinsho Kyobu Geka** 1988 Apr;8(2):160–2 (Eng. Abstr.) **(Jpn)**

[Cardiac manifestations in osteogenesis imperfecta. A case report and therapeutic implications] Myrmel T, et al.
Tidsskr Nor Laegeforen 1997 Feb 10;117(4):519–20 (Eng. Abstr.) **(Nor)**

THERAPY

Managing asymptomatic patients with chronic aortic regurgitation. Gaasch WH, et al. **Chest** 1997 Jun; 111(6):1702–9 (53 ref.)

Aortic valve disease. Leggett M, et al. **Curr Opin Cardiol** 1996 Mar;11(2):120–5 (22 ref.)

Diagnosis and management of acute aortic valvular disruption secondary to rapid-deceleration trauma. Munshi IA, et al. **J Trauma** 1996 Dec;41(6):1047–50

ULTRASONOGRAPHY

Evaluation of eccentric aortic regurgitation by color Doppler jet and color Doppler-imaged vena contracta measurements: an animal study of quantified aortic regurgitation. Ishii M, et al. **Am Heart J** 1996 Oct; 132(4):796–804

Transesophageal Doppler echocardiographic assessment of systolic and diastolic coronary blood flow velocities at baseline and during adenosine triphosphate-induced coronary vasodilation in chronic aortic regurgitation. Kisanuki A, et al. **Am Heart J** 1997 Jan;133(1):71–7

Doppler echocardiographic assessment of progression of aortic regurgitation. Padial LR, et al. **Am J Cardiol** 1997 Aug 1;80(3):306–14

Gender-associated differences in left ventricular geometry in patients with aortic valve disease and effect of distinct overload subsets. Rohde LE, et al. **Am J Cardiol** 1997 Aug 15;80(4):475–80

Is colour flow imaging needed to exclude clinically significant valvular regurgitation in adult patients undergoing transthoracic echocardiography? Cox JL, et al. **Can J Cardiol** 1997 Mar;13(3):261–9

Quantifying aortic regurgitation by using the color Doppler-imaged vena contracta: a chronic animal model study. Ishii M, et al. **Circulation** 1997 Sep 16;96(6):2009–15

Evaluation of left ventricular relaxation using the continuous-wave Doppler velocity profile of aortic regurgitation: noninvasive measurement of left ventricular negative dP/dt and time constant. Honda Y, et al.
Clin Cardiol 1996 Sep;19(9):709–15

The "proximal isovelocity surface area" method in assessing mitral valve area in patients with mitral stenosis and associated aortic regurgitation. Centamore G, et al.
G Ital Cardiol 1997 Feb;27(2):133–40

Four years follow-up study in patients with Takayasu arteritis and severe aortic regurgitation; assessment by echocardiography. Hashimoto Y, et al. **Int J Cardiol** 1997 Aug;54 Suppl:S173–6

Spontaneous bacterial endocarditis and aortic valve replacement complicating pregnancy. Hautman GD, et al.
Int J Gynaecol Obstet 1996 Aug;54(2):173–4

Calculation of aortic regurgitant volume by a new digital

Doppler color flow mapping method: an animal study with quantified chronic aortic regurgitation. Shiota T, et al. **J Am Coll Cardiol** 1997 Sep;30(3):834–42

Color Doppler and two-dimensional echocardiographic determination of the mechanism of aortic regurgitation with surgical correlation. Cohen GI, et al. **J Am Soc Echocardiogr** 1996 Jul–Aug;9(4):508–15

Increased myocardial echo density in left ventricular pressure and volume overload in human aortic valvular disease: an ultrasonic tissue characterization study. Di Bello V, et al. **J Am Soc Echocardiogr** 1997 May;10(4):320–9

The effect of heart rate on the slope and pressure half-time of the Doppler regurgitant velocity curve in aortic insufficiency. Gozzelino G, et al. **J Am Soc Echocardiogr** 1996 Jul–Aug;9(4):516–26

Usefulness of color Doppler proximal isovelocity surface area method in quantitating valvular regurgitation. Yamachika S, et al. **J Am Soc Echocardiogr** 1997 Mar;10(2):159–68

An unusual case of aortic insufficiency. Lazar JM, et al. **J Cardiothorac Vasc Anesth** 1996 Dec;10(7):963–4

Systolic and diastolic mitral regurgitation in a patient with annulo-aortic ectasia demonstrated by color Doppler flow imaging. Oki T, et al. **J Heart Valve Dis** 1996 May; 5(3):254–7

Chaotic musical murmur in aortic regurgitation. Miyahara K, et al. **Jpn Circ J** 1996 Dec;60(12):993–7

A case of nonpenetrating traumatic aortic regurgitation detected by transesophageal echocardiography. Oda H, et al. **Tohoku J Exp Med** 1997 May;182(1):93–101

[Quadricuspid aortic valve: diagnosis by multiple transesophageal echocardiography] Erena C, et al. **Z Kardiol** 1996 Nov;85(11):889–92 (Eng. Abstr.) **(Ger)**

[Cardiovascular imaging in-a-month. A 56-year-old man complaining of dyspnea] Sugiyama Y, et al. **J Cardiol** 1996 Sep;28(3):171–4 **(Jpn)**

[Annuloaortic ectasia (AAE)] Onodera K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):268–72 (7 ref.) **(Jpn)**

[The significance of subclinical forms of aortic regurgitation detected during Doppler echocardiography] Belenkov IuN, et al. **Ter Arkh** 1996;68(9):59–62 (Eng. Abstr.) **(Rus)**

[Extrinsic compression of the left atrium as an infrequent and fatal form of type B aortic dissection: value of ECG] Vicente T, et al. **Rev Esp Cardiol** 1997 Aug;50(8):590–2 (Eng. Abstr.) **(Spa)**

AORTIC VALVE PROLAPSE

[Aortic valve disease, aortic valve prolapse syndrome] Kawada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (13):421–4 (15 ref.) **(Jpn)**

COMPLICATIONS

Aneurysms of all sinuses of Valsalva and aortic valve prolapse secondary to Behçet's disease [letter] Wakabayashi Y, et al. **Eur Heart J** 1996 Nov;17(11):1766

ETIOLOGY

Aortic valve prolapse and aortic regurgitation associated with subpulmonic ventricular septal defect. Tohyama K, et al. **Am J Cardiol** 1997 May 1;79(9):1285–9

Inflammatory valvular prolapse produced by acute rheumatic carditis: echocardiographic analysis of 66 cases of acute rheumatic carditis. Zhou LY, et al. **Int J Cardiol** 1997 Jan 31;58(2):175–8

[Aortic cusp prolapse associated with ventricular septal defect] Morishita Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):155–7 (13 ref.) **(Jpn)**

ULTRASONOGRAPHY

[Cardiovascular imaging in-a-month. A 56-year-old man complaining of dyspnea] Sugiyama Y, et al. **J Cardiol** 1996 Sep;28(3):171–4 **(Jpn)**

AORTIC VALVE STENOSIS

see related
CARDIOMYOPATHY, HYPERTROPHIC

Is pressure recovery an important cause of "Doppler aortic stenosis" with no gradient at cardiac catheterisation? [editorial] Chambers J. **Heart** 1996 Nov;76(5):381–3

[Aortic valve disease, aortic valve prolapse syndrome] Kawada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (13):421–4 (15 ref.) **(Jpn)**

[Supravalvular aortic stenosis] Kino K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):264–7 (21 ref.) **(Jpn)**

BLOOD

Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Ikeda T, et al. **Am Heart J** 1997 Mar;133(3):307–14

Elevated levels of circulating soluble adhesion molecules in patients with nonrheumatic aortic stenosis. Shahi CN, et al. **Am J Cardiol** 1997 Apr 1;79(7):980–2

Twenty-four-hour ambulatory blood pressure and vasoactive hormones in valvular aortic disease. Jensen LW, et al. **Blood Press** 1996 Sep;5(5):292–9

COMPLICATIONS

Spontaneous cerebral embolus from a calcified aortic valve. Doiron A, et al. **AJR Am J Roentgenol** 1996 Oct; 167(4):955–6

Congenital absence of the pulmonary valve with tetralogy of Fallot with associated aortic stenosis and patent ductus arteriosus: a prenatal diagnosis. Rowland DG, et al. **Am Heart J** 1996 Nov;132(5):1075–7

Percutaneous transvenous mitral balloon valvuloplasty alone in patients with combined aortic and mitral stenosis. Lee TM, et al. **Angiology** 1997 May;48(5):445–50

Drawback of aortoplasty for aneurysm of the ascending aorta associated with aortic valve disease. Mueller XM, et al. **Ann Thorac Surg** 1997 Mar;63(3):762–6; discussion 766–7

Thrombus formation on a calcific and severely stenotic bicuspid aortic valve. Wan S, et al. **Ann Thorac Surg** 1997 Aug;64(2):535–6

Coronary artery aneurysm associated with adult supravalvular aortic stenosis. Yilmaz AT, et al. **Ann Thorac Surg** 1996 Oct;62(4):1205–7

Aortic valve replacement for aortic stenosis with severe left ventricular dysfunction. Prognostic indicators. Connolly HM, et al. **Circulation** 1997 May 20;95(10):2395–400

Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Weinberg EO, et al. **Circulation** 1997 Mar 18; 95(6):1592–600

Atherosclerosis, aortic stenosis and sudden onset central diabetes insipidus. Hensen J, et al. **Exp Clin Endocrinol Diabetes** 1997;105(4):227–33

Syncope in a man with a history of chest pain. Knox K, et al. **Hosp Pract (Off Ed)** 1997 Jun 15;32(6):71, 75–6

Diverticulum of the left ventricle associated with subvalvar aortic stenosis. Fernández AL, et al. **Int J Cardiol** 1996 Oct 25;56(3):223–6

Aortic insufficiency and stenosis in unruptured aneurysm of sinus of Valsalva [letter] Yuan SM. **Int J Cardiol** 1997 May 23;59(3):321–2

Abnormalities of the left ventricular outflow tract associated with discrete subaortic stenosis in children: an echocardiographic study. Sigfússon G, et al. **J Am Coll Cardiol** 1997 Jul;30(1):255–9

Valvular aortic stenosis: risk of syncope. Omran H, et al. **J Heart Valve Dis** 1996 Jan;5(1):31–4

Abnormal morphological patterns of the left ventricular myocardium in the critical stenosis of the aortic valve and the intact ventricular septum. Kim SH, et al. **J Korean Med Sci** 1997 Feb;12(1):49–54

Atrioventricular septal defect with subaortic stenosis: extended valvular detachment and leaflet augmentation [letter; comment] Macé L, et al. **J Thorac Cardiovasc Surg** 1997 Mar;113(3):615–6. Comment on: J Thorac Cardiovasc Surg 1995 Nov;110(5):1534–41; discussion 1541–2.

Development of severe aortic stenosis and left ventricular dysfunction with endocardial fibroelastosis in a second trimester fetus. Hornberger LK, et al. **J Ultrasound Med** 1996 Sep;15(9):651–4

Spontaneous calcific cerebral embolus. Shanmugam V, et al. **Neurology** 1997 Feb;48(2):538–9

Partial atrioventricular canal with left-sided obstruction in patients with Noonan syndrome [letter; comment] Marino B, et al. **Pediatr Cardiol** 1996 Jul–Aug;17(4):278. Comment on: Pediatr Cardiol 1995 Mar–Apr;16(2):95–9.

[Heyde syndrome] Larsen NH. **Ugeskr Laeger** 1997 Jul 21; 159(30):4628–30 (29 ref.) (Eng. Abstr.) **(Dan)**

[Percutaneous alcoholization of hepatocellular carcinoma complicated by acute endocarditis on aortic valvulopathy and cerebral abscess (letter)] Vuillemin E, et al. **Gastroenterol Clin Biol** 1997;21(5):441–2 **(Fre)**

[Nonrheumatic calcification of the mitral valve in patients with stenotic calcified bicuspid aortic valve] Sawada H, et al. **J Cardiol** 1996 Oct;28(4):221–6 (Eng. Abstr.) **(Jpn)**

[A problem with qualifying for heart surgery for a patient with severe congestive heart failure in both ventricles in the course of left aortic stenosis] Lukasik-Madej B, et al. **Pol Arch Med Wewn** 1995 Nov;94(5):447–50 (Eng. Abstr.) **(Pol)**

CONGENITAL

An alternative method for repair of aortico-left ventricular tunnel associated with severe aortic stenosis presenting in a newborn. Weldner P, et al. **Eur J Cardiothorac Surg** 1996; 10(5):380–2

The Ross procedure in children and young adults with congenital aortic valve disease. Walters HL 3rd, et al. **J Heart Valve Dis** 1997 Jul;6(4):335–42

Abnormal morphological patterns of the left ventricular myocardium in the critical stenosis of the aortic valve and the intact ventricular septum. Kim SH, et al. **J Korean Med Sci** 1997 Feb;12(1):49–54

Progressive congenital valvar aortic stenosis during infancy: five cases. Anand R, et al. **Pediatr Cardiol** 1997 Jan–Feb; 18(1):35–7

Open heart surgery in the pediatric Jehovah's Witness population: no longer "Russian roulette" [letter] Rosengart TK, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):245–6

Supravalvular aortic stenosis without Williams syndrome. Ozergin U, et al. **Thorac Cardiovasc Surg** 1996 Aug; 44(4):219–21

[Results of open valvotomy in congenital stenosis of the aortic valve] Brzek V, et al. **Rozhl Chir** 1997 Apr; 76(4):173–5 (Eng. Abstr.) **(Cze)**

[Dilatation of congenital aortic stenosis] Carminati M. **Cardiologia** 1995 Dec;40(12 Suppl 1):409–11 **(Ita)**

[Successful open commissurotomy and resection of dysplastic myxomatous tissue on the leaflet edges in a neonate and an early infant with critical aortic stenosis] Inoue M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):900–4 (Eng. Abstr.) **(Jpn)**

[Congenital aortic stenosis] Ino T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):203–7 (12 ref.) **(Jpn)**

[Surgical treatment of congenital aortic stenosis] Mizuhara H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):246–8 (13 ref.) **(Jpn)**

[Congenital supravalvular aortic stenosis, congenital valvular aortic stenosis, congenital subaortic stenosis, aortic atresia, congenital aortic regurgitation] Okada R. **Ryoikibetsu Shokogun Shirizu** 1996;(13):242–5 (20 ref.) **(Jpn)**

DIAGNOSIS

Brain natriuretic peptide concentrations in patients with aortic stenosis. Prasad N, et al. **Am Heart J** 1997 Apr; 133(4):477–9

Comparison of multiplane and biplane transesophageal echocardiography in the assessment of aortic stenosis. Kim KS, et al. **Am J Cardiol** 1997 Feb 15;79(4):436–41

Images in cardiovascular medicine. Hypertrophic cardiomyopathy. Stress induction of subaortic stenosis and mitral regurgitation. Kilner PJ, et al. **Circulation** 1997 Feb 18;95(4):1083–4

Exercise-induced syncope and Holter-documented asystole in an endurance runner with moderate aortic stenosis. Shapira Y, et al. **Clin Cardiol** 1996 Jan;19(1):71–3

Current concepts in aortic stenosis. Gill EA, et al. **Hosp Pract (Off Ed)** 1997 Aug 15;32(8):169–73, 177–8

Syncope and aortic valve stenosis: clues to diagnosis and pathophysiology. Thrasher JR, et al. **J Ark Med Soc** 1996 Sep;93(4):191–3

64-year-old woman with chronic epigastric pain. Miller AL, et al. **Mayo Clin Proc** 1997 Jan;72(1):73–6

Stroke normalized pressure: a useful parameter for the analysis of left ventricular outflow obstruction. Hay AS, et al. **Med Eng Phys** 1996 Dec;18(8):609–14

Changing concepts in the determination of valvular stenosis. Dangas G, et al. **Prog Cardiovasc Dis** 1997 Jul–Aug; 40(1):55–64 (29 ref.)

[Can Doppler echocardiography help to avoid cardiac catheterization in the surgical decision-making in isolated left heart valve diseases?] Tribouilloy C, et al. **Arch Mal Coeur Vaiss** 1996 Dec;89(12):1607–16 (28 ref.) (Eng. Abstr.) **(Fre)**

[Survived sudden cardiac death in aortic stenosis and Wolff-Parkinson-White syndrome: Differential diagnosis and therapy] Klöter Weber U, et al. **Schweiz Rundsch Med Prax** 1997 Jun 11;86(24):1017–20 (Eng. Abstr.) **(Ger)**

[Prenatal echocardiography of aortic stenosis] Respondek M, et al. **Pediatr Pol** 1996 Jun;71(6):505–10 (Eng. Abstr.) **(Pol)**

[Mitral insufficiency simulating aortic stenosis] Mena Martín FJ, et al. **Rev Esp Cardiol** 1997 Feb;50(2):140–1 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Unger SA, et al. **Aust N Z J Med** 1997 Feb;27(1):24–8

[Aortic stenosis] Figulla HR. **Internist (Berl)** 1997 May; 38(5):484 **(Ger)**

[Hemodynamic effects of oral captopril in patients with critical aortic stenosis] Martínez Sánchez C, et al. **Arch Inst Cardiol Mex** 1996 Jul–Aug;66(4):322–30 (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Natural history and outcome of aortic stenosis diagnosed prenatally. Simpson JM, et al. **Heart** 1997 Mar;77(3):205–10

EPIDEMIOLOGY

Aortic stenosis in children: 19-year experience. Liu CW, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Feb; 59(2):107–13

The significance of basal systolic murmurs in the elderly. Reardon M, et al. **Ir Med J** 1996 Nov–Dec;89(6):230–1

Calcific degeneration of the aortic valve in old age: is the development of flow obstruction predictable? [see comments] Iivanainen AM, et al. **J Intern Med** 1996 Mar; 239(3):269–73. Comment in: J Intern Med 1996 Jul;240(1):43–4.

ETIOLOGY

Autoimmune vasculitis and aortic stenosis in aspirin-induced asthma (AIA). Szczeklik A, et al. **Allergy** 1997 Mar; 52(3):352–4

Subaortic stenosis caused by anomalous papillary muscle of the mitral valve. Imoto Y, et al. **Ann Thorac Surg** 1996

Dec;62(6):1858–60

Medial arterial calcification, calcific aortic stenosis and mitral annular calcification in a diabetic patient with severe autonomic neuropathy. Cronin CC, et al. **Diabet Med** 1996 Aug;13(8):768–70

An atypical aortic valve non–bacterial thrombotic endocarditis in the course of multiple myeloma [letter] Kalangos A, et al. **Eur Heart J** 1997 Feb;18(2):351–2

Hypertrophic subaortic stenosis and hyperparathyroidism [letter] Macieira–Coelho E, et al. **Eur Heart J** 1996 Nov; 17(11):1763–4

Potential role of mechanical stress in the etiology of pediatric heart disease: septal shear stress in subaortic stenosis. Cape EG, et al. **J Am Coll Cardiol** 1997 Jul;30(1):247–54

Small aortic root: specific problems in the child. Vouhé PR. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S269–71 (9 ref.)

[Successful surgical management of cardiovascular thrombosis and aortic coarctation, caused by protein C deficiency, in a newborn infant] István H, et al. **Orv Hetil** 1996 Feb 4;137(5):251–3 (Eng. Abstr.) **(Hun)**

[Role of the atrioventricular septum and mitro–aortic separation in the pathogenesis of fixed subaortic stenosis] Miyague NI, et al. **Arq Bras Cardiol** 1996 Oct;67(4):231–5 (Eng. Abstr.) **(Por)**

GENETICS

Elastin point mutations cause an obstructive vascular disease, supravalvular aortic stenosis. Li DY, et al. **Hum Mol Genet** 1997 Jul;6(7):1021–8

Elastin: genomic structure and point mutations in patients with supravalvular aortic stenosis. Tassabehji M, et al. **Hum Mol Genet** 1997 Jul;6(7):1029–36

Fluorescent in situ hybridisation (FISH) for hemizygous deletion at the elastin locus in patients with isolated supravalvular aortic stenosis. Fryssira H, et al. **J Med Genet** 1997 Apr;34(4):306–8

[Familial supravalvular aortic stenosis. Investigation in a family and review of the literature] Burnel P, et al. **Arch Mal Coeur Vaiss** 1997 May;90(5):719–24 (12 ref.) (Eng. Abstr.) **(Fre)**

[Genetic diagnosis of Williams syndrome] Urbán Z, et al. **Orv Hetil** 1997 Jul 6;138(27):1749–52 (27 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Dissociation of left ventricular hypertrophy, beta–myosin heavy chain gene expression, and myosin isoform switch in rats after ascending aortic stenosis. Wiesner RJ, et al. **Circulation** 1997 Mar 4;95(5):1253–9

MICROBIOLOGY

Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. Juvonen J, et al. **J Am Coll Cardiol** 1997 Apr;29(5):1054–9

MORTALITY

Mortality and worsening of prognostic profile during waiting time for valve replacement in aortic stenosis. Lund O, et al. **Thorac Cardiovasc Surg** 1996 Dec;44(6):289–95

NURSING

Aortic stenosis in pregnancy: a case report. Comport KA, et al. **J Obstet Gynecol Neonatal Nurs** 1997 Jan–Feb; 26(1):67–77

PATHOLOGY

Correspondence of aortic valve area determination from transesophageal echocardiography, transthoracic echocardiography, and cardiac catheterization. Kim CJ, et al. **Am Heart J** 1996 Dec;132(6):1163–72

The aortic root in supravalvular aortic stenosis: the potential surgical relevance of morphologic findings. Stamm C, et al. **J Thorac Cardiovasc Surg** 1997 Jul;114(1):16–24

Delayed manifestation of aortic stenosis after blunt abdominal trauma: report of a case. Shindo S, et al. **Surg Today** 1997; 27(1):76–9

[Aortic ring supravalvular stenosis] Fulcheri E. **Pathologica** 1996 Dec;88(6):533–4 **(Ita)**

[Shone's syndrome] Muraki N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):311–3 (10 ref.) **(Jpn)**

[Influence of the degree of aortic valve calcification on the estimate of valvular area using planimetry with transesophageal echocardiography] de la Fuente Galán L, et al. **Rev Esp Cardiol** 1996 Sep;49(9):663–8 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Epidural anesthesia for emergency caesarean section in a patient with single ventricle and aortic stenosis. Peng TC, et al. **Acta Anaesthesiol Sin** 1997 Mar;35(1):39–44

Hemodynamic assessment of patients with low–flow, low–gradient valvular aortic stenosis. Blitz LR, et al. **Am J Cardiol** 1996 Sep 15;78(6):657–61

Tailored stent treatment for severe supravalvular aortic stenosis. Suárez de Lezo J, et al. **Am J Cardiol** 1996 Nov 1;78(9):1081–3

Influences of aortic pressure gradient and ventricular septal thickness with systolic coronary flow in aortic valve stenosis. Tamborini G, et al. **Am J Cardiol** 1996 Dec 1; 78(11):1303–6

Thrombogenesis in mitral regurgitation and aortic stenosis. Lip GY, et al. **Angiology** 1996 Dec;47(12):1117–25

Experimental analysis of fluid mechanical energy losses in aortic valve stenosis: importance of pressure recovery. Heinrich RS, et al. **Ann Biomed Eng** 1996 Nov–Dec; 24(6):685–94

Twenty–four–hour ambulatory blood pressure and vasoactive hormones in valvular aortic disease. Jensen LW, et al. **Blood Press** 1996 Sep;5(5):292–9

Effects of aortic valve replacement on exercise duration and functional status in adults with valvular aortic stenosis. Munt BI, et al. **Can J Cardiol** 1997 Apr;13(4):346–50

Doppler echocardiographic estimation of the pressure gradient in aortic stenosis. An updated assessment of the technique used in clinical practice in 249 patients. Schroeder AP, et al. **Cardiology** 1996 Nov–Dec; 87(6):545–51

Hemodynamic changes pre– and post–pacing with complete heart block and aortic valve stenosis and regurgitation. Karim MA, et al. **Cathet Cardiovasc Diagn** 1996 Feb; 37(2):178–83

Effect of aortic valve replacement on coronary flow velocity during metabolic stress in a patient with aortic stenosis. Takeuchi M, et al. **Cathet Cardiovasc Diagn** 1997 Mar; 40(3):287–90

Turbulent/viscous interactions control Doppler/catheter pressure discrepancies in aortic stenosis. The role of the Reynolds number. Cape EG, et al. **Circulation** 1996 Dec 1;94(11):2975–81

Why angina pectoris in aortic stenosis [editorial; comment] Gould KL. **Circulation** 1997 Feb 18;95(4):790–2 (14 ref.). Comment on: Circulation 1997 Feb 18;95(4):892–8.

Angina pectoris in patients with aortic stenosis and normal coronary arteries. Mechanisms and pathophysiological concepts [see comments] Julius BK, et al. **Circulation** 1997 Feb 18;95(4):892–8. Comment in: Circulation 1997 Feb 18;95(4):790–2.

Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome [see comments] Otto CM, et al. **Circulation** 1997 May 6;95(9):2262–70. Comment in: Circulation 1997 May 6;95(9):2241–3.

Factors influencing heart rate variability in patients with severe aortic valve disease. Jung J, et al. **Clin Cardiol** 1997 Apr;20(4):341–4

The formation of a discrete subvalvular outflow tract obstruction—at the interface between rheology and morphology [editorial; comment] Mertens L, et al. **Eur Heart J** 1996 Jun;17(6):809–10. Comment on: Eur Heart J 1996 Jun;17(6):935–9.

Effects of incoordination on left ventricular force–velocity relation in aortic stenosis. Jin XY, et al. **Heart** 1996 Dec; 76(6):495–501

Prevalence of late potentials in adult aortic stenosis. Sorgato A, et al. **Int J Cardiol** 1996 Jan;53(1):55–9

Simultaneous determination of aortic valve area by the Gorlin formula and by transesophageal echocardiography under different transvalvular flow conditions. Evidence that anatomic aortic valve area does not change with variations in flow in aortic stenosis. Tardif JC, et al. **J Am Coll Cardiol** 1997 May;29(6):1296–302

Age dependency of left ventricular diastolic function in pressure overload hypertrophy. Villari B, et al. **J Am Coll Cardiol** 1997 Jan;29(1):181–6

Valve replacement in aortic stenosis with preoperative mean gradient < 50 mmHg: hemodynamic outcome. Blackshear JL, et al. **J Heart Valve Dis** 1996 Nov;5(6):647–55

A hemodynamic comparison of Omniscience and Medtronic Hall aortic prostheses [see comments] Plehn JF, et al. **J Heart Valve Dis** 1996 May;5(3):328–36. Comment in: J Heart Valve Dis 1996 Nov;5(6):675–7.

[Postoperative follow–up results of aortic valve diseases—the relationship between residual left ventricular hypertrophy and dysfunctions of contractile and dilative functions] Taniguchi K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Mar;44(3):324–6 **(Jpn)**

[Correlation between aortic transvalvular gradient obtained with Doppler ultrasonography and with hemodynamics study. Role of the underlying etiology] Gonçalves LM, et al. **Rev Port Cardiol** 1996 Oct;15(10):717–22, 695 (Eng. Abstr.) **(Por)**

SURGERY

Improvement in mitral regurgitation after aortic valve replacement. Harris KM, et al. **Am J Cardiol** 1997 Sep 15;80(6):741–5

Prospective evaluation of a stiff shaft glide wire compared with the standard straight wire in crossing severely stenotic aortic valves. Sharma SK, et al. **Am J Cardiol** 1997 Jul 1;80(1):103–5

Comparison of age, gender, number of aortic valve cusps, concomitant coronary artery bypass grafting, and magnitude of left ventricular–systemic arterial peak systolic gradient in adults having aortic valve replacement for isolated aortic valve stenosis. Stephan PJ, et al. **Am J Cardiol** 1997 Jan 15;79(2):166–72

Tailored stent treatment for severe supravalvular aortic stenosis. Suárez de Lezo J, et al. **Am J Cardiol** 1996 Nov 1;78(9):1081–3

Severe isolated aortic stenosis with advanced left ventricular dysfunction. Results of aortic valve replacement. Tesler UF, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:437–8

Congenital aortic valve disease. Improved survival and quality of life. Elkins RC, et al. **Ann Surg** 1997 May; 225(5):503–10; discussion 510–1

Technique for reconstruction of the sinotubular junction. Bhatnagar G, et al. **Ann Thorac Surg** 1997 Feb;63(2):559–60

Calcified embolus of the left coronary ostia after aortic valve replacement. Folliguet TA, et al. **Ann Thorac Surg** 1997 Apr;63(4):1162–3

Thirty–year results of Starr–Edwards prostheses in the aortic and mitral position. Gödje OL, et al. **Ann Thorac Surg** 1997 Mar;63(3):613–9

Ross–Konno procedure with interrupted aortic arch repair in a premature neonate. Hirooka K, et al. **Ann Thorac Surg** 1997 Jul;64(1):249–51

Clinical outcome and left ventricular function after pulmonary autograft implantation in children. Hokken RB, et al. **Ann Thorac Surg** 1997 Jun;63(6):1713–7

Commissurotomy and bileaflet pericardial augmentation–resuspension for bicuspid aortic valve stenosis. Kadri MA, et al. **Ann Thorac Surg** 1997 Feb; 63(2):548–50

Impact of size mismatch and left ventricular function on performance of the St. Jude disc valve after aortic valve replacement. Lund O, et al. **Ann Thorac Surg** 1997 May; 63(5):1227–34

Drawback of aortoplasty for aneurysm of the ascending aorta associated with aortic valve disease. Mueller XM, et al. **Ann Thorac Surg** 1997 Mar;63(3):762–6; discussion 766–7

Aortic valve replacement after previous coronary artery bypass grafting. Odell JA, et al. **Ann Thorac Surg** 1996 Nov;62(5):1424–30 (24 ref.)

Event status of the Starr–Edwards aortic valve to 20 years: a benchmark for comparison. Orszulak TA, et al. **Ann Thorac Surg** 1997 Mar;63(3):620–6

Discrete membranous subaortic stenosis: improved results after resection and myectomy. Rayburn ST, et al. **Ann Thorac Surg** 1997 Jul;64(1):105–9

Aortic valve repair of congenital stenosis with bovine pericardium. Tolan MJ, et al. **Ann Thorac Surg** 1997 Feb; 63(2):465–9

Ross–Konno operation with resection of endocardial fibroelastosis for critical aortic stenosis with borderline–sized left ventricle in neonates [retracted by van Son JA. In: Ann Thorac Surg 1997 Jun;63(6):1834] van Son JA, et al. **Ann Thorac Surg** 1997 Jan;63(1):112–6

Thirty years experience with heart valve surgery: isolated aortic valve replacement. Bessell JR, et al. **Aust N Z J Surg** 1996 Dec;66(12):799–805

Effects of aortic valve replacement on exercise duration and functional status in adults with valvular aortic stenosis. Munt BI, et al. **Can J Cardiol** 1997 Apr;13(4):346–50

Long–term changes in left ventricular mass, chamber size and function after valve replacement in patients with severe aortic stenosis and depressed ejection fraction. Pelà G, et al. **Cardiology** 1997 Jul–Aug;88(4):315–22

Echocardiographic characteristics of the cryopreserved allograft aortic valve replacement assessed by intraoperative transoesophageal echocardiography. Hasegawa J, et al. **Cardiovasc Surg** 1996 Jun;4(3):293–8

The stentless Bravo 300 aortic porcine xenograft: supra–annular versus annular implantation. Hvass U, et al. **Cardiovasc Surg** 1997 Apr;5(2):220–4

An alternative procedure to intra–arterial aortoinfundibuloplasty. Katsumata T, et al. **Cardiovasc Surg** 1996 Jun;4(3):340–4

What are the limits for the Ross operation? Melo JQ, et al. **Cardiovasc Surg** 1996 Aug;4(4):526–9

The stentless Toronto SPV bioprosthesis for aortic valve replacement. Walther T, et al. **Cardiovasc Surg** 1996 Aug; 4(4):536–42

Stentless valve replacement in the small aortic root. Walther T, et al. **Cardiovasc Surg** 1997 Apr;5(2):229–34

Percutaneous transcatheter therapy of aorto–ostial stenoses. Kereiakes DJ. **Cathet Cardiovasc Diagn** 1996 Jul; 38(3):292–300 (38 ref.)

Effect of aortic valve replacement on coronary flow velocity during metabolic stress in a patient with aortic stenosis. Takeuchi M, et al. **Cathet Cardiovasc Diagn** 1997 Mar; 40(3):287–90

Timing of valve replacement in aortic stenosis. Moving closer to perfection [editorial; comment] Carabello BA. **Circulation** 1997 May 6;95(9):2241–3. Comment on: Circulation 1997 May 6;95(9):2262–70.

Aortic valve replacement for aortic stenosis with severe left ventricular dysfunction. Prognostic indicators. Connolly HM, et al. **Circulation** 1997 May 20;95(10):2395–400

Pericardial valves in small aortic annuli: ten years' results. Aupart M, et al. **Eur J Cardiothorac Surg** 1996; 10(10):879–83

Left ventricular remodelling and improvement in Freestyle stentless valve haemodynamics. Jin XY, et al. **Eur J Cardiothorac Surg** 1997 Jul;12(1):63–9

The pulmonary homograft as aortic valve substitute: 7 years' follow up. Mair R, et al. **Eur J Cardiothorac Surg** 1997 May;11(5):910–6

Ross procedure in congenital patients: results and left ventricular function. Rubay JE, et al. **Eur J Cardiothorac Surg** 1997 Jan;11(1):92–9

Stentless porcine bioprostheses for all types of aortic root pathology. Sidiropoulos A, et al.

Eur J Cardiothorac Surg 1997 May;11(5):917–21
Infant Ross procedure for recurrent aortic stenosis. Runciman M, et al. **Heart** 1996 Nov;76(5):449–50
Severe aortic stenosis without left ventricular hypertrophy: prevalence, predictors, and short-term follow up after aortic valve replacement. Seiler C, et al. **Heart** 1996 Sep; 76(3):250–5
Combined aortic and mitral valve replacement in an adult with mucopolysaccharidosis (Maroteaux–Lamy syndrome). Hachida M, et al. **Heart Vessels** 1996;11(4):215–7
Emergency aortic valve replacement for critical aortic stenosis. A lifesaving treatment for patients with cardiogenic shock and multiple organ failure. Christ G, et al. **Intensive Care Med** 1997 Mar;23(3):297–300
Repair for acquired aortic valve disease. Antunes MJ. **Isr J Med Sci** 1996 Oct;32(10):817–20 (5 ref.)
Aortic valve replacement with a stentless porcine bioprosthesis (TSPV). Goldman BS, et al. **Isr J Med Sci** 1996 Oct;32(10):846–8
The Ross procedure in children. Reddy VM, et al. **Isr J Med Sci** 1996 Oct;32(10):888–91
Cardiopulmonary bypass procedures in patients with cold-reactive hemagglutination. A case report and a literature review. Ko W, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6):623–6 (15 ref.)
Stentless aortic valve replacement with the biocor prosthesis: indications and outcome. Achtelik M, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S314–6
The small aortic root and the Medtronic Hall valve: ultrafast computed tomography assessment of left ventricular mass following aortic valve replacement. Anderson WA, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S329–35
Valve replacement in aortic stenosis with preoperative mean gradient < 50 mmHg: hemodynamic outcome. Blackshear JL, et al. **J Heart Valve Dis** 1996 Nov;5(6):647–55
Aortic valve replacement: better myocardial protection by cold or warm retrograde blood cardioplegia? Boening A, et al. **J Heart Valve Dis** 1996 May;5(3):273–.0
Doppler-echocardiographic assessment of the carbomedics supra-annular 'Top-Hat' prosthetic heart valve in the aortic position. de Brux JL, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S336–8
Hemodynamic performances of small diameter carbomedics and St. Jude valves. De Paulis R, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S339–43
Aortic valve replacement for aortic stenosis in patients with small aortic root. Franzen SF, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S284–8
Small aortic root in neonates. Frescura C, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S272–5 (10 ref.)
The influence of the design on the medium to long-term hemodynamic behavior of 19 mm pericardial aortic valve prostheses. Gonzalez-Juanatey JR, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S317–23
Hemodynamics of St. Jude Medical prostheses in the small aortic root: in vivo studies using dobutamine Doppler echocardiography. Kadir I, et al. **J Heart Valve Dis** 1997 Mar;6(2):123–9
Concomitant procedures in the small versus standard aortic root. Knez I, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S294–301
Suture loop restriction of the medtronic hall valve: late presentation of a rare complication. Kuo J, et al. **J Heart Valve Dis** 1996 Jan;5(1):117–9
The potential for normal long term survival and morbidity rates after valve replacement for aortic stenosis. Lund O, et al. **J Heart Valve Dis** 1996 May;5(3):258–67
Aortic valve replacement in elderly women with small aortic roots: comparing sorin pericardial and St.Jude Medical mechanical valves. Mahon BD, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S324–8
Small aortic root in the elderly: use of stentless bioprosthesis. Sintek CF, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S308–13
Valve replacement for aortic stenosis with severe congestive heart failure and pulmonary hypertension. Snopek G, et al. **J Heart Valve Dis** 1996 May;5(3):268–72
The Ross procedure in children and young adults with congenital aortic valve disease. Walters HL 3rd, et al. **J Heart Valve Dis** 1997 Jul;6(4):335–42
Stentless bioprostheses for the small aortic root. Walther T, et al. **J Heart Valve Dis** 1996 Nov;5 Suppl 3:S302–7
Systolic hypertension in critical aortic stenosis and the effect of valve replacement. Ie E, et al. **J Hum Hypertens** 1996 Feb;10(2):65–7
Late bioprosthetic valve endocarditis caused by Phialemonium aff. curvatum and Streptococcus sanguis: a case report. Schønheyder HC, et al. **J Med Vet Mycol** 1996 Jun–Jul;34(3):209–14
Medicine and elderly people: over-investigation or under-treatment [letter; comment] Jolobe OM. **J R Coll Physicians Lond** 1996 May–Jun;30(3):270–1. Comment on: J R Coll Physicians Lond 1996 Mar–Apr;30(2):170–3.
Surgical treatment of subaortic stenosis after biventricular repair of double-outlet right ventricle. Belli E, et al. **J Thorac Cardiovasc Surg** 1996 Dec;112(6):1570–78; discussion 1578–80
Minimally invasive aortic valve replacement. Benetti FJ, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):806–7
Extent and pattern of regression of left ventricular hypertrophy in patients with small size CarboMedics aortic valves. De Paulis R, et al. **J Thorac Cardiovasc Surg** 1997 May;113(5):901–9
Does the pulmonary autograft in the aortic position in adults increase in diameter? An echocardiographic study. Hokken RB, et al. **J Thorac Cardiovasc Surg** 1997 Apr;113(4):667–74
Early failure of freehand aortic stentless xenograft valves. Luciani GB, et al. **J Thorac Cardiovasc Surg** 1997 Jun; 113(6):1109–10
Comparison of aortic valve replacement and percutaneous aortic balloon valvuloplasty for elderly patients with aortic stenosis. Hashimoto H, et al. **Jpn Circ J** 1996 Mar; 60(3):142–8
64-year-old woman with chronic epigastric pain. Miller AL, et al. **Mayo Clin Proc** 1997 Jan;72(1):73–6
Repair of subaortic stenosis in atrioventricular canal with absent or restrictive interventricular communication by patch augmentation of ventricular septum, resuspension of atrioventricular valves, and septal myectomy. van Son JA, et al. **Mayo Clin Proc** 1997 Mar;72(3):220–4
Supravalvular aortic stenosis, pulmonary artery stenosis, and coronary artery stenosis in twins. Nakanishi T, et al. **Pediatr Cardiol** 1996 Mar–Apr;17(2):125–8 (12 ref.)
Results of cardiac operations in five kidney transplant patients. Christiansen S, et al. **Thorac Cardiovasc Surg** 1997 Apr;45(2):75–7
Mortality and worsening of prognostic profile during waiting time for valve replacement in aortic stenosis. Lund O, et al. **Thorac Cardiovasc Surg** 1996 Dec;44(6):289–95
Repair of coarctation of the aorta in adults with simultaneous aortic valve replacement and coronary artery bypass grafting. Thomka I, et al. **Thorac Cardiovasc Surg** 1997 Apr; 45(2):93–6
The omental flap with skin grafting for treatment of a difficult sternal closure. Yasuura K, et al. **Thorac Cardiovasc Surg** 1997 Jun;45(3):138–40
[Valve replacement in congenital aortic stenosis] Dominik J, et al. **Cas Lek Cesk** 1997 Jan 22;136(2):48–50 (Eng. Abstr.) **(Cze)**
[Results of open valvotomy in congenital stenosis of the aortic valve] Brzek V, et al. **Rozhl Chir** 1997 Apr; 76(4):173–5 (Eng. Abstr.) **(Cze)**
[What myocardial protection to select for isolated aortic valve replacement? A clinical prospective study of 3 cases of cardioplegia] Bouchart F, et al. **Arch Mal Coeur Vaiss** 1997 Mar;90(3):345–51 (Eng. Abstr.) **(Fre)**
[Ostium stenosis of the left coronary artery after aortic valve replacement—2 case reports] Roithinger FX, et al. **Wien Klin Wochenschr** 1996;108(17):552–4 (Eng. Abstr.) **(Ger)**
[Aortic isthmic stenosis: clinical study and postoperative follow-up by MRI. Report of a case] Hoffmann E, et al. **Minerva Cardioangiol** 1995 Oct;43(10):439–42 (Eng. Abstr.) **(Ita)**
[The leaflet fracture of a 19 mm SJM (HP) valve during valve insertion to the calcified small aortic annulus] Akiyama K, et al. **Kyobu Geka** 1997 Jul;50(7):562–4 (Eng. Abstr.) **(Jpn)**
[Echocardiographic evaluation of hemodynamic function of CarboMedics heart valve in the aortic position in patients with small aortic annuli] Imanaka K, et al. **Kyobu Geka** 1996 Jul;49(7):529–33 (Eng. Abstr.) **(Jpn)**
[Surgical treatment of aortic stenosis with polycythemia vera: a case report] Matsuyama N, et al. **Kyobu Geka** 1996 Dec; 49(13):1097–9 (15 ref.) (Eng. Abstr.) **(Jpn)**
[A case report of aortic valvuloplasty by rasping technique for aortic stenosis with small annulus simultaneously performed with mitral valve replacement] Taniyasu N, et al. **Kyobu Geka** 1997 Feb;50(2):155–7 (Eng. Abstr.) **(Jpn)**
[Aortic valve replacement with the Toronto stentless porcine valve in a patient with clipping for cerebral arterial aneurysm] Tsukui H, et al. **Kyobu Geka** 1997 Jul; 50(7):565–8 (Eng. Abstr.) **(Jpn)**
[Application of heparin-coated percutaneous cardiopulmonary support system to elective cardiac and aortic operations] Watanabe SI, et al. **Kyobu Geka** 1997 May;50(5):362–7 (Eng. Abstr.) **(Jpn)**
[Appropriate early open heart palliation of univentricular atrioventricular connection with subaortic stenosis] Yamagishi M, et al. **Kyobu Geka** 1997 Jun;50(6):437–43; discussion 443–6 (Eng. Abstr.) **(Jpn)**
[A case of bicuspid aortic valve stenosis with single coronary artery] Ichikawa Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 May;45(5):796–9 (Eng. Abstr.) **(Jpn)**
[Successful open commissurotomy and resection of dysplastic myxomatous tissue on the leaflet edges in a neonate and an early infant with critical aortic stenosis] Inoue M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):900–4 (Eng. Abstr.) **(Jpn)**
[A successful Konno's operation for subaortic stenosis progressed after total correction of partial atrioventricular septal defect associated with polysplenia] Matsuo K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul;45(7):1049–54 (Eng. Abstr.) **(Jpn)**
[Successful aortic root replacement with pulmonary autograft (Ross) in two cases of congenital aortic stenosis] Morita K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr; 45(4):594–600 (Eng. Abstr.) **(Jpn)**
[Extended aortoplasty for supravalvular aortic stenosis with Williams syndrome] Nagasaka S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):601–6 (Eng. Abstr.) **(Jpn)**
[A case of quadricuspid aortic valve associated with aortic steno-insufficiency] Sasahashi N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jul;45(7):1055–60 (35 ref.) (Eng. Abstr.) **(Jpn)**
[A surgical case of aortic valve stenosis associated with systemic lupus erythematosus] Toda R, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):919–22 (Eng. Abstr.) **(Jpn)**
[The problem of 19 mm St. Jude Medical valve prosthesis in the small aortic annuls—19 mm St. Jude Medical valve vs 23 mm St. Jude Medical valve] Yamanaka K, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jul;44(7):906–11 (Eng. Abstr.) **(Jpn)**
[Surgical treatment of congenital aortic stenosis] Mizuhara H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(13):246–8 (13 ref.) **(Jpn)**
[A problem with qualifying for heart surgery for a patient with severe congestive heart failure in both ventricles in the course of left aortic stenosis] Lukasik-Madej B, et al. **Pol Arch Med Wewn** 1995 Nov;94(5):447–50 (Eng. Abstr.) **(Pol)**
[Results of aortic stenosis surgery in patients with severe ventricular dysfunction] Pomerantzeff PM, et al. **Arq Bras Cardiol** 1996 Dec;67(6):375–8 (Eng. Abstr.) **(Por)**
[Aortic valve stenosis. Surgical treatment in children] Cabrera Duro A, et al. **An Esp Pediatr** 1997 Jun; 46(6):555–60 (Eng. Abstr.) **(Spa)**
[Extracorporeal circulation in pregnancy: report of a case. Update and review of the literature] Carrascal Hinojal Y, et al. **Rev Esp Cardiol** 1996 Oct;49(10):776–9 (8 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Follow-up results of balloon aortic valvuloplasty in children with special reference to causes of late aortic insufficiency. Galal O, et al. **Am Heart J** 1997 Apr;133(4):418–27
Percutaneous double-valve balloon valvotomy for multivalve stenosis: immediate results and intermediate-term follow-up. Sharma S, et al. **Am Heart J** 1997 Jan;133(1):64–70
Evaluation of the significance of a transvalvular catheter on aortic valve gradient in aortic stenosis: a direct hemodynamic and Doppler echocardiographic study. Adele C, et al. **Am J Cardiol** 1997 Feb 15;79(4):513–6
Usefulness of repeat balloon aortic valvuloplasty in children. Shim D, et al. **Am J Cardiol** 1997 Apr 15;79(8):1141–3
In utero management of hydrops fetalis caused by critical aortic stenosis. Bitar FF, et al. **Am J Perinatol** 1997 Aug; 14(7):389–91 (7 ref.)
Direct transaortic balloon valvuloplasty under cardiopulmonary bypass for neonatal critical aortic stenosis. Nogi S, et al. **Cardiovasc Intervent Radiol** 1996 Sep–Oct;19(5):374–6
Management of pediatric patients with isolated valvar aortic stenosis by balloon aortic valvuloplasty. Kuhn MA, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):55–61
Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty. Shea KW, et al. **Clin Infect Dis** 1996 Mar;22(3):601
Aortic valve disease. Leggett M, et al. **Curr Opin Cardiol** 1996 Mar;11(2):120–5 (22 ref.)
Aortic valve replacement after aortic valvuloplasty for calcified aortic stenosis. Soyer R, et al. **Eur J Cardiothorac Surg** 1996;10(11):977–82
Balloon dilatation of the aortic valve in the fetus. A case report. Lopes LM, et al. **Fetal Diagn Ther** 1996 Jul–Aug; 11(4):296–300
Percutaneous balloon aortic valvuloplasty with anterograde crossing of aortic valve. Shah C, et al. **Indian Heart J** 1995 Sep–Oct;47(5):495–6
Versatility of Inoue balloon catheter. Bahl VK, et al. **Int J Cardiol** 1997 Mar;59(1):75–83
Percutaneous balloon dilatation of subaortic membrane using an Inoue balloon. Bahl VK, et al. **Int J Cardiol** 1996 Apr 19;54(1):81–4
Cardiologic aspects of aortic valve surgery—who? when? what? Barlow JB. **Isr J Med Sci** 1996 Oct;32(10):821–31 (37 ref.)
Transvascular balloon dilation for neonatal critical aortic stenosis: early and midterm results. Egito ES, et al. **J Am Coll Cardiol** 1997 Feb;29(2):442–7
Carotid artery approach to balloon aortic valvuloplasty in infants with critical aortic valve stenosis. Maeno Y, et al. **Pediatr Cardiol** 1997 Jul–Aug;18(4):288–91
Balloon aortic valvuloplasty. Wang A, et al. **Prog Cardiovasc Dis** 1997 Jul–Aug;40(1):27–36 (39 ref.)
[Value of echocardiography-dobutamine in the study of reserve myocardial contractility in aortic stenosis with alteration of left ventricular function. Apropos of a case] Deluche L, et al. **Ann Cardiol Angeiol (Paris)** 1996 Nov; 45(9):523–6 (10 ref.) (Eng. Abstr.) **(Fre)**
[Percutaneous aortic valvuloplasty in the adult. When and why is now useful?] Piovaccari G, et al. **Ann Ital Med Int** 1996 Oct–Dec;11(4):258–62 (Eng. Abstr.) **(Ita)**
[Dilatation of congenital aortic stenosis] Carminati M. **Cardiologia** 1995 Dec;40(12 Suppl 1):409–11 **(Ita)**
[Papillary muscle rupture during subaortic membrane balloon dilatation] Frutos A, et al. **Rev Esp Cardiol** 1996 Feb;

49(2):146–8 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Correspondence of aortic valve area determination from transesophageal echocardiography, transthoracic echocardiography, and cardiac catheterization. Kim CJ, et al. **Am Heart J** 1996 Dec;132(6):1163–72

Sequential development of fetal aortic valve stenosis and endocardial fibroelastosis during the second trimester of pregnancy. Mielke G, et al. **Am Heart J** 1997 May; 133(5):607–10

Changes in effective aortic valve area during ejection in adults with aortic stenosis. Badano L, et al. **Am J Cardiol** 1996 Nov 1;78(9):1023–8

Transgastric Doppler echocardiographic assessment of the severity of aortic stenosis using multiplane transesophageal echocardiography. Blumberg FC, et al. **Am J Cardiol** 1997 May 1;79(9):1273–5

Gender–associated differences in left ventricular geometry in patients with aortic valve disease and effect of distinct overload subsets. Rohde LE, et al. **Am J Cardiol** 1997 Aug 15;80(4):475–80

Turbulent/viscous interactions control Doppler/catheter pressure discrepancies in aortic stenosis. The role of the Reynolds number. Cape EG, et al. **Circulation** 1996 Dec 1;94(11):2975–81

Importance of pressure recovery for the assessment of aortic stenosis by Doppler ultrasound. Role of aortic size, aortic valve area, and direction of the stenotic jet in vitro. Niederberger J, et al. **Circulation** 1996 Oct 15;94(8):1934–40

Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome [see comments] Otto CM, et al. **Circulation** 1997 May 6;95(9):2262–70. Comment in: Circulation 1997 May 6;95(9):2241–3.

Subpulmonary and subaortic ridges in doubly committed subarterial ventricular septal defect: an echocardiographic study [see comments] Ozkutlu S, et al. **Eur Heart J** 1996 Jun;17(6):935–9. Comment in: Eur Heart J 1996 Jun;17(6):809–10.

Planimetry of aortic valve area using multiplane transoesophageal echocardiography is not a reliable method for assessing severity of aortic stenosis. Bernard Y, et al. **Heart** 1997 Jul;78(1):68–73

Natural history and outcome of aortic stenosis diagnosed prenatally. Simpson JM, et al. **Heart** 1997 Mar;77(3):205–10

Multiplane transoesophageal echocardiography is the only definitive ultrasound approach in adult supravalvular aortic stenosis. Schürger D, et al. **Int J Cardiol** 1996 Mar; 53(3):305–9

Effects of dobutamine on Doppler echocardiographic indexes of aortic stenosis. Bermejo J, et al. **J Am Coll Cardiol** 1996 Nov 1;28(5):1206–13

Planimetry and transthoracic two–dimensional echocardiography in noninvasive assessment of aortic valve area in patients with valvular aortic stenosis. Okura H, et al. **J Am Coll Cardiol** 1997 Sep;30(3):753–9

Abnormalities of the left ventricular outflow tract associated with discrete subaortic stenosis in children: an echocardiographic study. Sigfússon G, et al. **J Am Coll Cardiol** 1997 Jul;30(1):255–9

An echocardiographic approach to the assessment of aortic stenosis. Bednarz JE, et al. **J Am Soc Echocardiogr** 1996 May–Jun;9(3):286–94 (18 ref.)

Increased myocardial echo density in left ventricular pressure and volume overload in human aortic valvular disease: an ultrasonic tissue characterization study. Di Bello V, et al. **J Am Soc Echocardiogr** 1997 May;10(4):320–9

Quantitative assessment of aortic stenosis by three–dimensional echocardiography. Menzel T, et al. **J Am Soc Echocardiogr** 1997 Apr;10(3):215–23

Flow dependence of the aortic valve area in patients with aortic stenosis: assessment by application of the continuity equation. Rask LP, et al. **J Am Soc Echocardiogr** 1996 May–Jun;9(3):295–9

An unusual echo–free space between the great vessels and left atrium. Shanewise JS. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):113–4

Prenatal diagnosis of severe aortic stenosis. McCaffrey FM, et al. **Pediatr Cardiol** 1997 Jul–Aug;18(4):276–81

M–mode echocardiography in aortic stenosis. Clinical correlates and prognostic significance after valve replacement. Lund O, et al. **Scand Cardiovasc J** 1997; 31(1):17–23

[Echocardiographic evaluation of hemodynamic function of CarboMedics heart valve in the aortic position in patients with small aortic annuli] Imanaka K, et al. **Kyobu Geka** 1996 Jul;49(7):529–33 (Eng. Abstr.) **(Jpn)**

[Combined calcified valvular disease] Ishimitsu T. **Ryoikibetsu Shokogun Shirizu** 1996;(13):385–8 (8 ref.) **(Jpn)**

[Correlation between aortic transvalvular gradient obtained with Doppler ultrasonography and with hemodynamics study. Role of the underlying etiology] Gonçalves LM, et al. **Rev Port Cardiol** 1996 Oct;15(10):717–22, 695 (Eng. Abstr.) **(Por)**

[Influence of the degree of aortic valve calcification on the estimate of valvular area using planimetry with transesophageal echocardiography] de la Fuente Galán L, et al. **Rev Esp Cardiol** 1996 Sep;49(9):663–8 (Eng. Abstr.) **(Spa)**

VETERINARY

Open resection for subvalvular aortic stenosis in dogs [published erratum appears in J Am Vet Med Assoc 1997 Jan 1;210(1):92] Monnet E, et al. **J Am Vet Med Assoc** 1996 Oct 1;209(7):1255–61

The problem of inherited diseases. 2: Subaortic stenosis in boxers [news] Swift S. **J Small Anim Pract** 1996 Jul; 37(7):351–2

AORTICOPULMONARY SEPTAL DEFECT see **AORTOPULMONARY SEPTAL DEFECT**

AORTITIS

Inflammatory aortic aneurysms. A clinical review with new perspectives in pathogenesis. Rasmussen TE, et al. **Ann Surg** 1997 Feb;225(2):155–64 (72 ref.)

[Rheumatoid aortitis] Nakamura H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):417–20 (11 ref.) **(Jpn)**

[Tuberculous aortitis] Yasuda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):335–7 (16 ref.) **(Jpn)**

[Mycotic aneurysm and mycotic aortitis] Yasuda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):325–8 (21 ref.) **(Jpn)**

BLOOD

Elastin degradation in systemic vasculitis. Bokarewa M, et al. **Pathol Biol (Paris)** 1996 Apr;44(4):254–8

[The clinical importance of determining protein C and protein S in patients with nonspecific aortoarteritis] Baranov AA, et al. **Ter Arkh** 1996;68(4):50–2 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Infectious aortitis due to penicillin–resistant Streptococcus pneumoniae. Maclennan AC, et al. **Ann Vasc Surg** 1997 Sep;11(5):533–5

Recurrent aortic valve prosthesis dehiscence secondary to aortoarteritis: three case reports and literature review. Chau EM, et al. **Int J Cardiol** 1996 Oct 11;56(2):113–8 (12 ref.)

Inflammatory abdominal aortic aneurysms and atherosclerotic abdominal aortic aneurysms—comparisons of clinical features and long–term results. Sasaki S, et al. **Jpn Circ J** 1997 Mar;61(3):231–5

Aortitis, aortic valve incompetence, and left coronary ostium stenosis in a patient with C–ANCA–associated necrotizing vasculitis. Morshuis WJ, et al. **Thorac Cardiovasc Surg** 1997 Apr;45(2):97–9

[Rupture of the aortic arch due to bacterial aortitis—a case report of a patient undergoing successful surgical therapy] Sudo Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2221–4 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Immediate postgadolinium spoiled gradient–echo MRI for evaluating the abdominal aorta in the setting of abdominal MR examination. Kelekis NL, et al. **J Magn Reson Imaging** 1997 Jul–Aug;7(4):652–6

[Aortic valve insufficiency in Crohn disease] Wäckerlin A, et al. **Schweiz Med Wochenschr** 1997 May 31;127(22):935–9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Aortitis and development of an aneurysm after PTA of distal aortic stenosis] Raschke R, et al. **Vasa** 1996;25(3):287–91 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Aortitis syndrome in children: clinical observation of 35 cases in Japan. Maeda M, et al. **Acta Paediatr Jpn** 1997 Apr; 39(2):280–4

ETIOLOGY

Endaortitis of coarctation of the aorta after invasive diagnostics. Böhm JO, et al. **Ann Thorac Surg** 1997 Mar; 63(3):829–30

[Aortitis in Horton disease. Review of the literature] Le Tourneau T, et al. **Ann Med Interne (Paris)** 1996; 147(5):361–8 (89 ref.) (Eng. Abstr.) **(Fre)**

[The biochemical and clinical aspects of the participation of granulocytes and their proteinases in a vascular wall lesion] Ogloblina OG, et al. **Ter Arkh** 1996;68(5):78–80 (Eng. Abstr.) **(Rus)**

–Prolonged fever syndrome and infection of abdominal aortic aneurysm due to Salmonella enteritidis] Winkel M, et al. **Medicina (B Aires)** 1995;55(4):341–4 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Cellular components and features of immune response in abdominal aortic aneurysms. Pearce WH, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:175–85 (45 ref.)

Lupus aortitis: a case report and review of the literature. Willett WF 3rd, et al. **J La State Med Soc** 1996 Feb; 148(2):55–9 (29 ref.)

MICROBIOLOGY

Immunohistochemical detection of Chlamydia pneumoniae in abdominal aortic aneurysms. Juvonen J, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:236–8

Evolution of salmonella aortitis towards the formation of abdominal aneurysm. Carreras M, et al. **Eur Radiol** 1997; 7(1):54–6

[Rupture of the aortic arch due to bacterial aortitis—a case report of a patient undergoing successful surgical therapy] Sudo Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Dec;44(12):2221–4 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Inflammatory aspects of experimental aneurysms. Effect of methylprednisolone and cyclosporine. Dobrin PB, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:74–88

Valve detachment after aortic valve replacement—a successfully reoperated case with the Cabrol technique. Aoyagi S, et al. **Jpn Circ J** 1996 Jun;60(6):377–81

[Giant cell granulomatous aortitis and pulmonary arteritis] Podhola M. **Cesk Patol** 1997 Feb;33(1):31–3 (Eng. Abstr.) **(Cze)**

RADIOGRAPHY

Evolution of the infected abdominal aortic aneurysm: CT observation of early aortitis. Rozenblit A, et al. **Abdom Imaging** 1996 Nov–Dec;21(6):512–4

[Inflammatory aneurysm of the abdominal aorta: TC assessment of the postoperative course] Gigoni R, et al. **Radiol Med (Torino)** 1996 Sep;92(3):213–7 (Eng. Abstr.) **(Ita)**

SURGERY

Cerebral revasculization in aortitis with occluded bilateral common carotid and left vertebral arteries. Takagi Y, et al. **Acta Neurochir (Wien)** 1997;139(4):375–6

Surgical management of Behçet's aortitis: a report of eight patients. Okada K, et al. **Ann Thorac Surg** 1997 Jul; 64(1):116–9

Endovascular repair of an inflammatory aortic aneurysm. Boyle JR, et al. **Eur J Vasc Endovasc Surg** 1997 Mar; 13(3):328–9

Aortoarteritis involving supra–aortic trunks: a profile of six cases. Bhattacharyya S, et al. **Indian Heart J** 1997 May–Jun; 49(3):292–6

Inflammatory aneurysm treated by means of transfemoral endovascular graft insertion. Chuter T, et al. **J Vasc Interv Radiol** 1997 Jan–Feb;8(1 Pt 1):39–41

[An alternative treatment in aortic reconstruction (letter)] Olofsson P, et al. **Lakartidningen** 1996 Dec 18; 93(51–52):4711–2 **(Swe)**

ULTRASONOGRAPHY

Transesophageal echocardiographic evaluation of aortitis. Harris KM, et al. **Clin Cardiol** 1997 Sep;20(9):813–5

Salmonella aortitis with pseudoaneurysm formation diagnosed by transesophageal echocardiography. Kures P, et al. **J Am Soc Echocardiogr** 1996 Nov–Dec;9(6):885–7

VETERINARY

Multiple congenital cardiac anomalies and idiopathic thoracic aortitis in a horse. Reppas GP, et al. **Vet Rec** 1996 Jan 6;138(1):14–6

AORTITIS SYNDROME see **AORTIC ARCH SYNDROMES**

AORTITIS, SYPHILITIC see **SYPHILIS, CARDIOVASCULAR**

AORTOCORONARY BYPASS see **CORONARY ARTERY BYPASS**

AORTOGRAPHY

Iodixanol and ioxaglate in adult aortography and peripheral arteriography: a phase III clinical trial. Rosenblum JD, et al. **Acad Radiol** 1996 Sep;3 Suppl 3:S514–8

Comparison of iodixanol and ioxaglate for adult aortography and renal/visceral angiography: a phase III clinical trial. Siegel EL, et al. **Acad Radiol** 1996 Sep;3 Suppl 3:S507–13

Morphologic mural changes in the aorta revealed by CT in patients with nonspecific aortoarteritis (Takayasu's arteritis). Sharma S, et al. **AJR Am J Roentgenol** 1996 Nov; 167(5):1321–5

"Incisura" of the ascending aorta and vascular pedicle width in the cardiac transplant patient. Chiou AC, et al. **Ann Thorac Surg** 1996 Oct;62(4):1141–5

Angiographic evidence of long–axis rotation in addition to short–axis aortopulmonary rotation: its implication in transposition of the great arteries. Chiu IS, et al. **Cathet Cardiovasc Diagn** 1996 Sep;39(1):21–30

Importance of plain x–ray in endoluminal aortic graft surveillance. May J, et al. **Eur J Vasc Endovasc Surg** 1997 Feb;13(2):202–6

Ultrafast computed tomography in infectious pseudoaneurysm of the left ventricular outflow tract. Berrizbeitia LD, et al. **J Thorac Cardiovasc Surg** 1997 Jul; 114(1):138–9

"Lumps" and "bumps" that mimic acute aortic and brachiocephalic vessel injury. Fisher RG, et al. **Radiographics** 1997 Jul–Aug;17(4):825–34

[Prospective preoperative morphometry of abdominal aortic aneurysms: selective patient management for endovascular surgery] Schumacher H, et al.

Langenbecks Arch Chir Suppl Kongressbd 1996;113:875–7 (Eng. Abstr.) **(Ger)**

[Severe calcifying atherosclerosis of the thoracic aorta with symptoms of aortic isthmus stenosis. Case report] Froelich JJ, et al. **Radiologe** 1997 Feb;37(2):173–6 (Eng. Abstr.) **(Ger)**

[Experiment in ultra-rapid injection of isotonic sodium chloride after injection of contrast medium: time-density analysis of the aorta and portal vein] Itou N, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1997 Jul;57(8):523–5 (Eng. Abstr.) **(Jpn)**

[Aortorenal angiography and other approaches in the diagnosis of arterial hypertension of renal origin] Savić SB. **Srp Arh Celok Lek** 1996;124 Suppl 1:202–4 (Eng. Abstr.) **(Scc)**

[Angiography of the aorta] Soto B, et al. **Rev Esp Cardiol** 1996;49 Suppl 4:52–62 (31 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Helical CT angiography of the thoracic aorta. Rubin GD. **J Thorac Imaging** 1997 Apr;12(2):128–49 (38 ref.)

METHODS

Two-dimensional aortographic coronary arteriography with above-K-edge monochromatic synchrotron radiation. Takeda T, et al. **Acad Radiol** 1997 Jun;4(6):438–45

Geometric risk factors for atherosclerosis in the aortic bifurcation: a digitized angiography study. Smedby O. **Ann Biomed Eng** 1996 Jul-Aug;24(4):481–8

Transseptal approach to aortography and carotid artery stenting in pulseless disease. Joseph G, et al. **Cathet Cardiovasc Diagn** 1997 Apr;40(4):416–20; discussion 421

Complete pre-operative imaging assessment of abdominal aortic aneurysm with spiral CT angiography. Errington ML, et al. **Clin Radiol** 1997 May;52(5):369–77

Influence of abdominal aortic aneurysm size on the feasibility of endovascular repair [see comments] Armon MP, et al. **J Endovasc Surg** 1997 Aug;4(3):279–83. Comment in: J Endovasc Surg 1997 Aug;4(3):284–5.

Will contrast aortography become obsolete in the preoperative evaluation of abdominal aortic aneurysm for endovascular exclusion? [editorial; comment] Diethrich EB. **J Endovasc Surg** 1997 Feb;4(1):5–12 (10 ref.). Comment on: J Endovasc Surg 1997 Feb;4(1):39–44.

Use of intravenous digital subtraction angiography for imaging of the thoracic aorta [letter; comment] Haskal ZJ. **J Vasc Interv Radiol** 1997 Jul-Aug;8(4):720. Comment on: J Vasc Interv Radiol 1997 Mar-Apr;8(2):226–7.

Thoracic aortography in a motor vehicle accident victim [see comments] Redman HC. **J Vasc Interv Radiol** 1997 Mar-Apr;8(2):226–7. Comment in: J Vasc Interv Radiol 1997 Jul-Aug;8(4):720.

Computed tomographic angiographic imaging of abdominal aortic aneurysms: implications for transfemoral endovascular aneurysm management. Balm R, et al. **J Vasc Surg** 1997 Aug;26(2):231–7

Spiral CT angiography of the aorta. Kopecky KK, et al. **Semin Ultrasound CT MR** 1996 Aug;17(4):304–15 (15 ref.)

STANDARDS

Aortic arch angiography prior to carotid endarterectomy. Is its continued use justified? Kadwa AM, et al. **Eur J Vasc Endovasc Surg** 1997 Jun;13(6):527–30

Angiography in blunt thoracic aortic injury. Ahrar K, et al. **J Trauma** 1997 Apr;42(4):665–9

UTILIZATION

Is aortography in lower limb ischaemia still abused? Andrew DR, et al. **J R Army Med Corps** 1994 Oct;140(3):135–6

AORTOPULMONARY SEPTAL DEFECT

[Aortopulmonary septal defect] Sese A. **Ryoikibetsu Shokogun Shirizu** 1996;(13):257–9 (14 ref.) **(Jpn)**

DIAGNOSIS

Images in cardiovascular medicine. Correlative imaging of aortopulmonary window: demonstration with echocardiography, angiography, and MRI. Garver KA, et al. **Circulation** 1997 Aug 5;96(3):1036–7

SURGERY

Repair of aortopulmonary window in an infant with extremely low birth weight. Kawata H, et al. **Ann Thorac Surg** 1996 Dec;62(6):1843–5

Congenital aortopulumonary window: diagnosis, surgical technique and long-term results. Tkebuchava T, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):293–7

Transcatheter umbrella closure of aorto-pulmonary window. Tulloh RM, et al. **Heart** 1997 May;77(5):479–80

Neonatal correction of interrupted aortic arch, aortopulmonary window and ascending aortic origin of right pulmonary artery. Sharma R, et al. **Indian Heart J** 1996 Nov-Dec;48(6):717–20

Total one-stage repair of aortopulmonary window and interrupted aortic arch in a neonate. Davies MJ, et al. **Pediatr Cardiol** 1996 Mar-Apr;17(2):122–4 (12 ref.)

[Aortopulmonary window: influence of associated cardiovascular lesions on surgical management] Elami A, et al. **Harefuah** 1996 Jul;131(1-2):1–3, 72 (Eng. Abstr.) **(Heb)**

[Primary surgical repair of aorticopulmonary septal defect with coarctation of the aorta] Kashima I, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Apr;45(4):615–8 (Eng. Abstr.) **(Jpn)**

AOTINAE

An EBV-transformed owl monkey B-lymphocyte cell line [letter] Scammell JG, et al. **In Vitro Cell Dev Biol Anim** 1997 Feb;33(2):88–91

ANATOMY & HISTOLOGY

In vivo and in vitro bone strain in the owl monkey circumorbital region and the function of the postorbital septum. Ross CF, et al. **Am J Phys Anthropol** 1996 Oct; 101(2):183–215

The distribution and morphology of LGN K pathway axons within the layers and CO blobs of owl monkey V1. Ding Y, et al. **Vis Neurosci** 1997 Jul-Aug;14(4):691–704

PARASITOLOGY

Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys. Nayar JK, et al. **J Parasitol** 1997 Aug;83(4):739–45

PHYSIOLOGY

Evidence for glutamate as a neurotransmitter in spinothalamic tract terminals in the posterior region of owl monkeys. Blomqvist A, et al. **Exp Brain Res** 1996 Feb; 108(1):33–44

VIROLOGY

Further observations on coronavirus infection of primate CNS. Murray RS, et al. **J Neurovirol** 1997 Feb;3(1):71–5

AOTUS TRIVIRGATUS

ANATOMY & HISTOLOGY

Distribution of M retinal ganglion cells in diurnal and nocturnal New World monkeys. Lima SM, et al. **J Comp Neurol** 1996 May 13;368(4):538–52

GENETICS

Reverse transcriptase-polymerase chain reaction amplification and partial sequence of T helper 1- and T helper 2-type lymphokine genes from the owl monkey (Aotus trivirgatus). Bost KL, et al. **Am J Trop Med Hyg** 1997 Mar;56(3):351–8

PARASITOLOGY

The Malayan IV strain of Plasmodium falciparum in Aotus monkeys. Collins WE, et al. **Am J Trop Med Hyg** 1997 Jan;56(1):49–56

PHYSIOLOGY

Movement representation in the dorsal and ventral premotor areas of owl monkeys: a microstimulation study [published erratum appears in J Comp Neurol 1997 Jan 27;377(4):611] Preuss TM, et al. **J Comp Neurol** 1996 Aug 5;371(4):649–76

PSYCHOLOGY

Use of olfactory cues in foraging by owl monkeys (Aotus nancymai) and capuchin monkeys (Cebus apella). Bolen RH, et al. **J Comp Psychol** 1997 Jun;111(2):152–8

VIROLOGY

Five new or recently discovered (GBV-A) virus species are indigenous to New World monkeys and may constitute a separate genus of the Flaviviridae. Bukh J, et al. **Virology** 1997 Mar 17;229(2):429–36

AP-1 ENHANCER-BINDING PROTEIN see **TRANSCRIPTION FACTOR AP-1**

APACHE

Mortality predicted by APACHE II. The effect of changes in physiological values on predicted hospital mortality [letter; comment] Tunnell RD, et al. **Anaesthesia** 1997 May; 52(5):503–4. Comment on: Anaesthesia 1996 Aug;51(8):719–23.

Prediction of the risk of death by APACHE II scoring in critically ill trauma patients without head injury. Muckart DJ, et al. **Br J Surg** 1996 Aug;83(8):1123–7

Prediction of outcome from intensive care: a prospective cohort study comparing Acute Physiology and Chronic Health Evaluation II and III prognostic systems in a United Kingdom intensive care unit. Beck DH, et al. **Crit Care Med** 1997 Jan;25(1):9–15

Sepsis and serum cytokine concentrations. Damas P, et al. **Crit Care Med** 1997 Mar;25(3):405–12

Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit [see comments] Friedland JS, et al. **Crit Care Med** 1996 Nov;24(11):1775–81. Comment in: Crit Care Med 1996 Nov;24(11):1769–71.

Assessing the impact of patient characteristics and process performance on rural intensive care unit hospital mortality rates [published erratum appears in Crit Care Med 1997 Aug;25(8):1440] Jiang HJ, et al. **Crit Care Med** 1997 May; 25(5):773–8

A comparison of the Acute Physiology and Chronic Health Evaluation (APACHE) II score and the Trauma-Injury Severity Score (TRISS) for outcome assessment in intensive care unit trauma patients. Wong DT, et al. **Crit Care Med** 1996 Oct;24(10):1642–8

Leakage of intrathoracic oesophagovisceral anastomoses in adenocarcinoma of the gastric cardia: changes in serial APACHE II scores and their prognostic significance. Fahn HJ, et al. **Eur J Surg** 1997 May;163(5):345–50

Use of severity of illness to evaluate quality of care. Mackenzie TA, et al. **Int J Qual Health Care** 1996 Apr; 8(2):125–30

The performance of SAPS II in a cohort of patients admitted to 99 Italian ICUs: results from GiViTI. Gruppo Italiano per la Valutazione degli interventi in Terapia Intensiva. Apolone G, et al. **Intensive Care Med** 1996 Dec; 22(12):1368–78

Application of the APACHE III prognostic system in Brazilian intensive care units: a prospective multicenter study. Bastos PG, et al. **Intensive Care Med** 1996 Jun; 22(6):564–70

Comparison of the APACHE III, APACHE II and Glasgow Coma Scale in acute head injury for prediction of mortality and functional outcome. Cho DY, et al. **Intensive Care Med** 1997 Jan;23(1):77–84

The effect of case mix adjustment on mortality as predicted by APACHE II [letter] Fidler V. **Intensive Care Med** 1997 Jun;23(6):711–2

The effect of casemix adjustment on mortality as predicted by APACHE II. Goldhill DR, et al. **Intensive Care Med** 1996 May;22(5):415–9

Outcome prediction in intensive care: results of a prospective, multicentre, Portuguese study. Moreno R, et al. **Intensive Care Med** 1997 Feb;23(2):177–86

Mortality discrimination in acute myocardial infarction: comparison between APACHE III and SAPS II prognosis systems. PAEEC Group. Reina A, et al. **Intensive Care Med** 1997 Mar;23(3):326–30

Heart rate variability correlates negatively with cardiac index in patients with sepsis [letter] Tang GJ, et al. **Intensive Care Med** 1996 May;22(5):514

Outcome prediction for patients with cirrhosis of the liver in a medical ICU: a comparison of the APACHE scores and liver-specific scoringsystems. Zauner CA, et al. **Intensive Care Med** 1996 Jun;22(6):559–63

Influence of the severity of illness measured by the Simplified Acute Physiology Score (SAPS) on occurrence of nosocomial infections in ICU patients. Girou E, et al. **J Hosp Infect** 1996 Oct;34(2):131–7

APACHE II in a postoperative intensive care unit in Thailand. Lertakyamanee J, et al. **J Med Assoc Thai** 1997 Mar;80(3):169–77

Application of a prognostic scoring system to critically ill patients in a small military facility. Messinger-Rapport BJ, et al. **Mil Med** 1997 Jun;162(6):407–11

Prognoses of seriously ill hospitalized patients on the days before death: implications for patient care and public policy. Lynn J, et al. **New Horiz** 1997 Feb;5(1):56–61 (10 ref.)

Patient outcome and intensive care resource allocation using APACHE II. Lim SC, et al. **Singapore Med J** 1996 Oct; 37(5):488–91

[Assessment of critical care costs of an intensive care unit with TISS (Therapeutic Intervention Scoring System)--an economic analysis of intensive care] Lefering R, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:318–20 (Eng. Abstr.) **(Ger)**

[Prediction of outcome in critically ill patients using haemodynamic and oxyphoretic parameters] Donati A, et al. **Minerva Anestesiol** 1996 Jul-Aug;62(7-8):243–8 (Eng. Abstr.) **(Ita)**

[Vital prognosis in severe acute hepatic failure. Value of the quantitative indexes of evaluation] Andresen M, et al. **Rev Med Chil** 1995 Nov;123(11):1373–8 (Eng. Abstr.) **(Spa)**

APAMIN

ADMINISTRATION & DOSAGE

Potentiation by apamin of histamine-stimulated catecholamine biosynthesis and tyrosine hydroxylase phosphorylation in cultured bovine adrenal chromaffin cells. Kitamura K, et al. **Tokushima J Exp Med** 1996 Jun; 43(1-2):17–23

ANTAGONISTS & INHIBITORS

Characterization of the apamin- and L-nitroarginine-resistant NANC inhibitory transmission to the circular muscle of guinea-pig colon. Maggi CA, et al. **J Auton Pharmacol** 1996 Jun;16(3):131–45

APAMIN

CHEMISTRY

Deletion of a single amino acid changes the folding of an apamin hybrid sequence peptide to that of endothelin. Volkman BF, et al. **Biopolymers** 1997 Apr 5;41(4):451–60

METABOLISM

Characterization of PO1, a new peptide ligand of the apamin-sensitive Ca2+ activated K+ channel. Zerrouk H, et al. **Int J Pept Protein Res** 1996 Dec;48(6):514–21

Apamin binding proteins and oligosaccharyltransferases [letter] Strong PN, et al. **Toxicon** 1996 May;34(5):507–9 (15 ref.)

PHARMACOLOGY

Relaxant effect of xenin on rat ileum is mediated by apamin-sensitive neurotensin-type receptors. Clemens A, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):G190–6

ATP-induced rise in apamin-sensitive Ca(2+)-dependent K+ conductance in adult rat hepatocytes. Yamashita Y, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G307–13

The L-name-resistant component of acetylcholine-induced relaxation of the rat superior mesenteric arterial bed is innervation-dependent. Scott TM, et al. **Artery** 1994; 21(5):271–86

Apamin-sensitive Ca2+-dependent K+ current and hyperpolarization in human endothelial cells. Muraki K, et al. **Biochem Biophys Res Commun** 1997 Jul 18; 236(2):340–3

Discrimination between subtypes of apamin-sensitive Ca(2+)-activated K+ channels by gallamine and a novel bis-quaternary quinolinium cyclophane, UCL 1530. Dunn PM, et al. **Br J Pharmacol** 1996 Jan;117(1):35–42

VIP- and PACAP-mediated nonadrenergic, noncholinergic inhibition in longitudinal muscle of rat distal colon: involvement of activation of charybdotoxin- and apamin-sensitive K+ channels. Kishi M, et al. **Br J Pharmacol** 1996 Oct;119(4):623–30

Properties of the inhibitory junction potential in smooth muscle of the guinea-pig gastric fundus. Ohno N, et al. **Br J Pharmacol** 1996 Mar;117(5):974–8

The possible role of ATP and PACAP as mediators of apaminsensitive NANC inhibitory junction potentials in circular muscle of guinea-pig colon. Zagorodnyuk V, et al. **Br J Pharmacol** 1996 Nov;119(5):779–86

Sleep cycle disturbances induced by apamin, a selective blocker of Ca(2+)-activated K+ channels. Gandolfo G, et al. **Brain Res** 1996 Oct 14;736(1–2):344–7

Effects of K+ channel blockers on K+ channels, membrane potential, and aldosterone secretion in rat adrenal zona glomerulosa cells. Lotshaw DP. **Endocrinology** 1997 Oct; 138(10):4167–75

A novel calcium-activated apamin-insensitive potassium current in pituitary gonadotrophs. Vergara L, et al. **Endocrinology** 1997 Jul;138(7):2658–64

Characterization of four toxins from Buthus martensi scorpion venom, which act on apamin-sensitive Ca2+-activated K+ channels. Romi-Lebrun R, et al. **Eur J Biochem** 1997 Apr 15;245(2):457–64

Apamin-sensitive SK(Ca) channels modulate adrenal catecholamine release in anesthetized dogs. Nagayama T, et al. **Eur J Pharmacol** 1997 May 30;327(2–3):135–41

Apamin-sensitive K+ channels involved in the inhibition of acetylcholine-induced contractions in lamb coronary small arteries. Simonsen U, et al. **Eur J Pharmacol** 1997 Jun 25;329(2–3):153–63

Characterization of the membrane conductance changes underlying the apamin-resistant NANC inhibitory junction potential in the guinea-pig proximal and distal colon. Watson MJ, et al. **J Auton Nerv Syst** 1996 Aug 27; 60(1–2):31–42

Apamin-sensitive and -insensitive components of inhibitory junction potentials in rat caecum: role of nitric oxide. Serio R, et al. **J Auton Pharmacol** 1996 Aug;16(4):183–9

Determinants of apamin and d-tubocurarine block in SK potassium channels. Ishii TM, et al. **J Biol Chem** 1997 Sep 12;272(37):23195–200

Properties of channels mediating the apamin-insensitive afterhyperpolarization in vagal motoneurons. Sah P. **J Neurophysiol** 1995 Oct;74(4):1772–6

Differential roles of apamin- and charybdotoxin-sensitive K+ conductances in the generation of inferior olive rhythmicity in vivo. Lang EJ, et al. **J Neurosci** 1997 Apr 15;17(8):2825–38

Characterization of apamin-sensitive Ca(2+)-activated potassium channels in human leukaemic T lymphocytes. Hanselmann C, et al. **J Physiol (Lond)** 1996 Nov 1;496 (Pt 3):627–37

Activity dependence and functional role of the apamin-sensitive K+ current in rat supraoptic neurones in vitro. Kirkpatrick K, et al. **J Physiol (Lond)** 1996 Jul 15;494 (Pt 2):389–98

Apamin blocks the direct relaxant effect of melatonin on rat ileal smooth muscle. Reyes-Vázquez C, et al. **J Pineal Res** 1997 Jan;22(1):1–8

Participation of nitric oxide in the relaxation of the rat gastric corpus. Holzer-Petsche U, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Aug-Sep; 354(3):348–54

Apamin-sensitive Ca(2+)-activated K+ channels regulate pacemaker activity in nigral dopamine neurons. Ping HX, et al. **Neuroreport** 1996 Feb 29;7(3):809–14

Effect of apamin, a selective blocker of Ca2+-activated K+-channel, on habituation and passive avoidance responses in rats. Deschaux O, et al. **Neurosci Lett** 1997 May 9;227(1):57–60

Apamin improves learning in an object recognition task in rats. Deschaux O, et al. **Neurosci Lett** 1997 Feb 7; 222(3):159–62

APATITES

Osteogenesis in extraskeletally implanted porous calcium phosphate ceramics: variability among different kinds of animals. Yang Z, et al. **Biomaterials** 1996 Nov; 17(22):2131–7

Effect of electrochemically deposited apatite coating on bonding of bone to the HA-G-Ti composite and titanium. Ban S, et al. **J Biomed Mater Res** 1997 Jul;36(1):9–15

Apatite as carrier for growth hormone: in vitro characterization of loading and release. Guicheux J, et al. **J Biomed Mater Res** 1997 Feb;34(2):165–70

Ectopic bone induction in porous apatite-wollastonite-containing glass ceramic combined with bone morphogenetic protein. Ijiri S, et al. **J Biomed Mater Res** 1997 Jun 15;35(4):421–32

Bonding strength of bonelike apatite layer to Ti metal substrate. Kim HM, et al. **J Biomed Mater Res** 1997 Summer;38(2):121–7

Quantitative assessment of apatite formation via a biomimetic method using quartz crystal microbalance. Tanahashi M, et al. **J Biomed Mater Res** 1996 Jun;31(2):243–9

Effect of high external pressures on the vibrational spectra of biomedical materials: calcium hydroxyapatite and calcium fluoroapatite. Xu J, et al. **J Biomed Mater Res** 1996 Feb;30(2):239–44

ANALYSIS

19F NMR spectroscopy of glass ceramics containing fluorapatites. Jana C, et al. **Biomaterials** 1996 Nov; 17(21):2065–9

Characterization of the apatite crystals of bone and their maturation in osteoblast cell culture: comparison with native bone crystals. Rey C, et al. **Connect Tissue Res** 1996; 35(1–4):343–9

ANTAGONISTS & INHIBITORS

Human histidine-rich glycoprotein expressed in SF9 insect cells inhibits apatite formation. Schinke T, et al. **FEBS Lett** 1997 Aug 4;412(3):559–62

CHEMICAL SYNTHESIS

Formation and characteristics of the apatite layer on plasma-sprayed hydroxyapatite coatings in simulated body fluid. Weng J, et al. **Biomaterials** 1997 Aug;18(15):1027–35

Transformation of hydroxyapatite to fluorapatite by irradiation with high-energy CO2 laser. Meurman JH, et al. **Caries Res** 1997;31(5):397–400

Apatite-forming ability of silicate ion dissolved from silica gels. Cho SB, et al. **J Biomed Mater Res** 1996 Nov; 32(3):375–81

CHEMISTRY

Atomic force microscopic study of the surface morphology of apatite films deposited by pulsed laser ablation. Antonov EN, et al. **Biomaterials** 1997 Aug;18(15):1043–9

Heterogeneous iron-containing fluoridated apatites. Okazaki M, et al. **Biomaterials** 1997 Jan;18(1):11–4

Ultrastructural study of an apatite layer formed by a biomimetic process and its bonding to bone. Tanahashi M, et al. **Biomaterials** 1996 Jan;17(1):47–51

Formation and characteristics of the apatite layer on plasma-sprayed hydroxyapatite coatings in simulated body fluid. Weng J, et al. **Biomaterials** 1997 Aug;18(15):1027–35

Ipriflavone does not alter bone apatite crystal structure in adult male rats. Ghezzo C, et al. **Calcif Tissue Int** 1996 Dec;59(6):496–9

Fluoride analysis of apatite crystals with a central planar OCP inclusion: concerning the role of F- ions on apatite/OCP/apatite structure formation. Iijima M, et al. **Calcif Tissue Int** 1996 Nov;59(5):377–84

Structure, crystal chemistry and density of enamel apatites. Elliott JC. **Ciba Found Symp** 1997;205:54–67; discussion 67–72 (59 ref.)

The effect of fluoride on apatite structure and growth. Aoba T. **Crit Rev Oral Biol Med** 1997;8(2):136–53 (148 ref.)

Apatite formation on silica gel in simulated body fluid: its dependence on structures of silica gels prepared in different media. Cho SB, et al. **J Biomed Mater Res** 1996 Fall; 33(3):145–51

Bone bonding ability of an apatite-coated polymer produced using a biomimetic method: a mechanical and histological study in vivo. Nagano M, et al. **J Biomed Mater Res** 1996 Aug;31(4):487–94

Dissolution of artificial (natural) stones in a standard model: first results. Heimbach D, et al. **J Endourol** 1997 Feb; 11(1):63–6

Production of artificial urinary stones from natural materials and their physical properties. First results. Heimbach D, et al. **Scand J Urol Nephrol** 1997 Feb;31(1):9–13

31P-19F rotational-echo, double-resonance nuclear magnetic resonance experiment on fluoridated hydroxyapatite. Pan Y. **Solid State Nucl Magn Reson** 1995 Dec;5(3):263–8

[Glass ceramic apatite-containing materials for medical use] Abdullaev ShIu. **Stomatologiia (Mosk)** 1996;75(5):57–8 **(Rus)**

METABOLISM

Apatite deposition on titanium surfaces—the role of albumin adsorption. Serro AP, et al. **Biomaterials** 1997 Jul; 18(14):963–8

Interactions of hydroxyapatite and fluorapatite particles on human osteoarthritis type B synoviocytes: effects on interleukin-1 alpha levels and lipoxygenase pathways. Liagre B, et al. **J Biomed Mater Res** 1997 Fall;38(3):243–56

Surface functional group dependence on apatite formation on self-assembled monolayers in a simulated body fluid. Tanahashi M, et al. **J Biomed Mater Res** 1997 Mar 5; 34(3):305–15

Resorption of hydroxyapatite and fluorapatite coatings in man. An experimental study in trabecular bone. Overgaard S, et al. **J Bone Joint Surg Br** 1997 Jul;79(4):654–9

Calcium carbonate apatite deposition in the cervical spine with associated vertebral destruction. Case report. Ojemann JG, et al. **J Neurosurg** 1997 Jun;86(6):1022–6

Apatite deposition in polymyositis subluxing arthropathy. Citera G, et al. **J Rheumatol** 1996 Mar;23(3):551–3

Intraarticular apatite crystal deposition as a predictor of erosive osteoarthritis of the fingers [letter; comment] Jones JG. **J Rheumatol** 1995 Oct;22(10):2007. Comment on: J Rheumatol 1994 Nov;21(11):2164–5.

THERAPEUTIC USE

Hydroxyapatite and fluorapatite coatings for fixation of weight loaded implants. Overgaard S, et al. **Clin Orthop** 1997 Mar;(336):286–96

APC VIRUSES see **ADENOVIRUSES, HUMAN**

APE, BARBARY see **MACACA**

APE, BLACK see **MACACA**

APE, CELEBES see **MACACA**

APE DISEASES

DIAGNOSIS

Polyclonal lymphoid tumor of the choroid plexus presenting as an intraventricular mass in a young gorilla. Thomas C, et al. **Acta Neuropathol (Berl)** 1996 Dec;92(6):621–4

Amoebic meningoencephalitis caused by Balamuthia mandrillaris in an orang utan. Canfield PJ, et al. **Aust Vet J** 1997 Feb;75(2):97–100

A clumsy 3-year-old who liked junk food [see comments] von Mühlendahl KE, et al. **Lancet** 1996 Dec 21–28; 348(9043):1705. Comment in: Lancet 1997 Mar 8;349(9053):728. Comment in: Lancet 1997 Mar 8;349(9053):728–9.

MICROBIOLOGY

Naturally acquired leprosy in two wild-born chimpanzees. Alford PL, et al. **Lab Anim Sci** 1996 Jun;46(3):341–6 (29 ref.)

VIROLOGY

Immune and hematopoietic parameters in HIV-1-infected chimpanzees during clinical progression toward AIDS. Villinger F, et al. **J Med Primatol** 1997 Feb–Apr; 26(1–2):11–8

APERT SYNDROME see **ACROCEPHALOSYNDACTYLIA**

APES see **PONGIDAE**

APEU VIRUS see **BUNYAVIRUS**

APEX CARDIOGRAPHY see **KINETOCARDIOGRAPHY**

APGAR SCORE

Neurological findings in neonates with low Apgar in Zimbabwe. Wolf MJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Jun;73(2):115–9

ACOG committee opinion. Use and abuse of the Apgar score. Number 174–July 1996 (replaces No. 49, November 1986). Committee on Obstetric Practice and American Academy of Pediatrics: Committee on Fetus and Newborn. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1996 Sep;54(3):303–5

Obstetric determinants of low Apgar scores in a Chinese population. Mongelli M, et al. **Int J Gynaecol Obstet** 1997 Apr;57(1):67–8

Apgar score [letter; comment] Hodgins C. **J Obstet Gynecol Neonatal Nurs** 1997 Jan–Feb;26(1):15–6 . Comment on: J Obstet Gynecol Neonatal Nurs 1996 May;25(4):299–303.

Virginia Apgar (1909–1974). Morishima HO. **J Pediatr** 1996 Nov;129(5):768–70

Virginia Apgar and the Apgar score: kudos and a correction

[letter; comment] Butterfield LJ. **JAMA** 1997 Jun 11; 277(22):1762. Comment on: JAMA 1996 Dec 25;276(24):1939–40.

Apgar quartet plays perinatologist's instruments [news] [see comments] [published erratum appears in JAMA 1997 Jun 11;277(22):1762] Skolnick AA. **JAMA** 1996 Dec 25; 276(24):1939–40. Comment in: JAMA 1997 Jun 11;277(22):1762.

The relationship between Apgar score and umbilical arterial blood gas values in newborns. Energin M, et al. **Turk J Pediatr** 1996 Oct–Dec;38(4):447–57

[Upright birthing position--more birth canal injuries? Results of a retrospective comparative study] Kleine-Tebbe A, et al. **Zentralbl Gynakol** 1996;118(8):448–52 (Eng. Abstr.) **(Ger)**

APHAKIA

COMPLICATIONS

[Trabeculo-intendation. A new surgical treatment of glaucoma of the aphakic eye] Saracco JB, et al. **J Fr Ophtalmol** 1996;19(6–7):410–4 (Eng. Abstr.) **(Fre)**

CONGENITAL

Congenital aphakia: a clinicopathologic report of three cases. Johnson BL, et al. **J Pediatr Ophthalmol Strabismus** 1997 Jan–Feb;34(1):35–9

Congenital aphakia [letter] Kashani AA. **J Pediatr Ophthalmol Strabismus** 1997 Jul–Aug;34(4):208–9

Corneal coloboma, aphakia and retinal neovascularization with anterior segment dysgenesis (Peters' anomaly). Gunderson CA, et al. **Ophthalmologica** 1996;210(6):361–6

PATHOLOGY

Congenital aphakia: a clinicopathologic report of three cases. Johnson BL, et al. **J Pediatr Ophthalmol Strabismus** 1997 Jan–Feb;34(1):35–9

REHABILITATION

Unilateral pseudophakia in children under 4 years. Awner S, et al. **J Pediatr Ophthalmol Strabismus** 1996 Jul–Aug; 33(4):230–6

SURGERY

Traumatic aphakia treated with an iris prosthesis/intraocular lens or epikeratophakia. Uusitalo RJ, et al. **J Refract Surg** 1997 Jul–Aug;13(4):382–7

THERAPY

Clinical assessment of Holo-Or trifocal diffractive contact lens. Fulga V, et al. **CLAO J** 1996 Oct;22(4):245–9

APHAKIA, POSTCATARACT

The efficacy of neodymium: YAG laser iridotomy in the treatment of closed peripheral iridotomies in silicone-oil-filled aphakic eyes. Reddy MA, et al. **Eye** 1995; 9 (Pt 6):757–9

COMPLICATIONS

Filtration surgery in a young, aphakic, high myope. II. Management of postoperative choroidal hemorrhage. Shabto U, et al. **J Glaucoma** 1996 Apr;5(2):120–6

Childhood aphakic glaucoma [letter] Schulz E. **J Pediatr Ophthalmol Strabismus** 1997 Jul–Aug;34(4):211

Pars plana vitrectomy in the treatment of combined rhegmatogenous retinal detachment and choroidal detachment in aphakic or pseudophakic patients. Yang CM. **Ophthalmic Surg Lasers** 1997 Apr;28(4):288–93

Iris cyst in aphakic patient: improvement of visual acuity after excision. Di Maria A, et al. **Ophthalmologica** 1997; 211(5):312–5

[Pseudophakic uveitis] Stefan C, et al. **Oftalmologia** 1996 Jul–Sep;40(3):289–92 (Eng. Abstr.) **(Rum)**

DRUG THERAPY

[The characteristics of the pathogenesis and immunomodulator treatment in the postoperative period in pseudophakia patients] Boiştean V, et al. **Oftalmologia** 1996 Jul–Sep;40(3):210–3 (Eng. Abstr.) **(Rum)**

ETIOLOGY

Review of aphakic glaucoma after surgery for congenital cataract. Russell-Eggitt I, et al. **J Cataract Refract Surg** 1997;23 Suppl 1:664–8 (14 ref.)

Corneal diameter in childhood aphakic glaucoma. Wallace DK, et al. **J Pediatr Ophthalmol Strabismus** 1996 Sep–Oct; 33(5):230–4

[The characteristics of the pathogenesis and immunomodulator treatment in the postoperative period in pseudophakia patients] Boiştean V, et al. **Oftalmologia** 1996 Jul–Sep;40(3):210–3 (Eng. Abstr.) **(Rum)**

PHYSIOPATHOLOGY

Myopic shift after cataract removal in childhood. McClatchey SK, et al. **J Pediatr Ophthalmol Strabismus** 1997 Mar–Apr;34(2):88–95

Extracapsular cataract surgery with and without intraocular lens implantation in Fuchs heterochromic cyclitis. O'Neill D, et al. **Ophthalmology** 1995 Sep;102(9):1362–8

Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Hoyng PF, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S83–8 (33 ref.)

SURGERY

Secondary implantation of open-loop, flexible, anterior chamber intraocular lenses. Ellerton CR, et al. **J Cataract Refract Surg** 1996 Sep;22(7):951–4

Secondary capsule-supported intraocular lens implantation in children. Sharma A, et al. **J Cataract Refract Surg** 1997; 23 Suppl 1:675–80

Comparison of fluorine-surface-modified and unmodified lenses for implantation in pediatric aphakia. Thouvenin D, et al. **J Cataract Refract Surg** 1996 Nov;22(9):1226–31

Primary posterior capsulorhexis with and without anterior vitrectomy in congenital cataracts. Vasavada A, et al. **J Cataract Refract Surg** 1997;23 Suppl 1:645–51

Long-term follow-up of pediatric epikeratophakia. Uusitalo RJ, et al. **J Refract Surg** 1997 Jan–Feb;13(1):45–54

Efficacy of argon laser trabeculoplasty in aphakic and pseudophakic eyes. Schwartz AL, et al. **Ophthalmic Surg Lasers** 1997 Mar;28(3):215–8

The trabeculum as a drain in aphakic glaucoma. Devin F, et al. **Ophthalmologica** 1997;211(1):21–4

Results following secondary intraocular lens implantation in children. Biglan AW, et al. **Trans Am Ophthalmol Soc** 1996; 94:353–73; discussion 374–9

[The results of correcting aphakia by an artificial lens implant] Nicula C. **Oftalmologia** 1996 Oct–Dec; 40(4):349–53 (Eng. Abstr.) **(Rum)**

THERAPY

Bausch & Lomb CW 79 aphakic extended wear contact lens: long-term follow-up. Jong KY, et al. **CLAO J** 1997 Jan; 23(1):78–80

Clinical evaluation of back optic radius and power determination by age in pediatric aphakia due to congenital cataract fitted with a Silicone Elaster contact lens [published erratum appears in Optom Vis Sci 1996 May;73(5):352] Lightman JM, et al. **Optom Vis Sci** 1996 Jan;73(1):22–7

VETERINARY

Effect of optical defocus on visual acuity in dogs. Murphy CJ, et al. **Am J Vet Res** 1997 Apr;58(4):414–8

Follow-up report of a case of surgical aphakia with an analysis of equine visual function. Farrall H, et al. **Equine Vet J Suppl** 1990 Sep;(10):91–3

APHANIPTERA see **FLEAS**

APHASIA

see related
LANDAU-KLEFFNER SYNDROME

Review of research on the clinical presentation of acquired childhood aphasia [letter; comment] Van Hout A. **Acta Neurol Scand** 1997 Apr;95(4):253–5. Comment on: Acta Neurol Scand 1996 Jun;93(6):428–36.

The Academy of Aphasia 34th annual meeting. London, England, November 3, 1996. Abstracts. **Brain Lang** 1996 Oct;55(1):1–197

Fractionating the articulatory loop: dissociations and associations in phonological recoding in aphasia. Nickels L, et al. **Brain Lang** 1997 Feb 1;56(2):161–82

"Echoing approval": a new speech disorder. Ghika J, et al. **J Neurol** 1996 Sep;243(9):633–7

Speech timing in apraxia of speech versus conduction aphasia. Seddoh SA, et al. **J Speech Hear Res** 1996 Jun; 39(3):590–603

[Developmental dysphasia] Billard C, et al. **Arch Pediatr** 1996 Jun;3(6):580–7 (41 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Transient aphasia associated with lithium intoxication [letter] Gordon PH, et al. **J Clin Psychopharmacol** 1997 Feb; 17(1):55–6

COMPLICATIONS

The effects of age-induced changes in communicative abilities on the type of aphasia. Ceccaldi M, et al. **Brain Lang** 1996 Jul;54(1):75–85

Remediation of sentence processing deficits in aphasia using a computer-based microworld. Crerar MA, et al. **Brain Lang** 1996 Jan;52(1):229–75

Assessing the elements contributing to a "mapping" deficit: a targeted treatment study. Haendiges AN, et al. **Brain Lang** 1996 Jan;52(1):276–302

Auditory comprehension problems in aphasia from the perspective of aphasic persons and their families and friends. Le Dorze G, et al. **Disabil Rehabil** 1996 Nov; 18(11):550–8

A case of concomitant impairment of operational signs and punctuation marks. Laiacona M, et al. **Neuropsychologia** 1997 Mar;35(3):325–32

[Language and aphasias] Porta-Etessam J, et al. **Rev Neurol** 1997 Aug;25(144):1269–77 (47 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Review of research on the clinical presentation of acquired childhood aphasia [see comments] Paquier PF, et al. **Acta Neurol Scand** 1996 Jun;93(6):428–36 (101 ref.). Comment in: Acta Neurol Scand 1997 Apr;95(4):253–5.

An examination of impaired acoustic-phonetic processing in aphasia. Gow DW Jr, et al. **Brain Lang** 1996 Feb; 52(2):386–407

The modality-specific organization of grammatical categories: evidence from impaired spoken and written sentence production. Rapp B, et al. **Brain Lang** 1997 Feb 1;56(2):248–86

Accounting for handicaps in aphasia: communicative assessment from an authentic social perspective. Simmons-Mackie NN, et al. **Disabil Rehabil** 1996 Nov; 18(11):540–9

Somatosensory evoked potentials in aphasic patients. Dickstein R, et al. **Int J Neurosci** 1996 Sep;86(3–4):169–77

1995 IPA/Bayer Research Awards in Psychogeriatrics. Bihemispheric language disorders in early-stage dementia of the Alzheimer type: evidence from a novel metalinguistic task. De Vreese LP, et al. **Int Psychogeriatr** 1996 Spring; 8(1):63–81

Test-retest reliability of three aphasia tests: performance of non-brain-damaged older adults. Flanagan JL, et al. **J Commun Disord** 1997 Jan–Feb;30(1):33–42; quiz 42–3

Determinants of sentence comprehension in aphasic patients in sentence-picture matching tasks. Caplan D, et al. **J Speech Lang Hear Res** 1997 Jun;40(3):542–55

Breakdown of cross-modal function in dementia. Freedman M, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr;10(2):102–6

Selective language aphasia from herpes simplex encephalitis. Ku A, et al. **Pediatr Neurol** 1996 Sep;15(2):169–71

A study on simplification of the Standard Language Test of Aphasia (SLTA). Tamura A, et al. **Tokushima J Exp Med** 1996 Jun;43(1–2):39–46

[Tests for aphasia, apraxia and agnosia] Hasegawa T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:318–21 (11 ref.) **(Jpn)**

[The effect of aphasia and organic brain damage on the variability of the results of "Token" test] Jarzębska E. **Neurol Neurochir Pol** 1996 Jul–Aug;30(4):581–8 (Eng. Abstr.) **(Pol)**

[Aphasia in a polyglot: description and neuropsychological course] Martinell-Gispert-Saúch M, et al. **Rev Neurol** 1997 Apr;25(140):562–5 (Eng. Abstr.) **(Spa)**

[Epileptic syndromes which show continuous spike and wake complexes during slow wave sleep] Nieto-Barrera M, et al. **Rev Neurol** 1997 Jul;25(143):1045–51 (Eng. Abstr.) **(Spa)**

[A study of bilingual Galician-Castillian aphasic patients] Vilariño I, et al. **Rev Neurol** 1997 Aug;25(144):1165–7 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study. Huber W, et al. **Arch Phys Med Rehabil** 1997 Mar; 78(3):245–50

Effects of increased cholinergic activity on naming in aphasia [letter] Tanaka Y, et al. **Lancet** 1997 Jul 12;350(9071):116–7

ETIOLOGY

Global aphasia due to thalamic hemorrhage: a case report and review of the literature. Kumar R, et al. **Arch Phys Med Rehabil** 1996 Dec;77(12):1312–5 (16 ref.)

Extreme altitude transient aphasia [see comments] Garrido E, et al. **Br J Sports Med** 1996 Dec;30(4):364. Comment in: Br J Sports Med 1996 Dec;30(4):275–6.

Morphological processing in Italian agrammatic speakers: eight experiments in lexical morphology. Luzzatti C, et al. **Brain Lang** 1996 Jul;54(1):26–74

Relations between the sides of linguistic cerebral dominance and manuality in Chinese aphasics. Wang Y. **Chin Med J (Engl)** 1996 Jul;109(7):572–5

Aphasia, apraxia, and agnosia in the diagnosis of dementia. Kramer JH, et al. **Dementia** 1996 Jan–Feb;7(1):23–6

Crossed mixed transcortical aphasia with hypernomia. Fujii T, et al. **Eur Neurol** 1997;37(3):193–4

Dysphasia accompanied by periodic lateralized epileptiform discharges. Ono S, et al. **Intern Med** 1997 Jan;36(1):59–61

Childhood systemic lupus erythematosus presenting with neuropsychiatric manifestations. Vyas SD, et al. **J Indian Med Assoc** 1996 Feb;94(2):71, 73

Feasibility of cognitive screening of patients with ischaemic stroke using the CAMCOG. A hospital-based study. Kwa VI, et al. **J Neurol** 1996 May;243(5):405–9

Transcortical mixed aphasia with left frontoparietal lesions. Maeshima S, et al. **Neuroradiology** 1996 May;38 Suppl 1:S78–9

[Aphasia in acute apoplexy. Incidence, background factors and course] Pedersen PM, et al. **Ugeskr Laeger** 1997 Feb 17;159(8):1109–13 (Eng. Abstr.) **(Dan)**

[Emergency medicine for the practitioner: neurological

emergencies] Stern D, et al. **Rev Med Suisse Romande** 1997 Apr;117(4):301–3 **(Fre)**

[Mixed transcortical aphasia due to multiple deep white matter infarction in the dominant cerebral hemisphere: a case report] Sato K, et al. **No To Shinkei** 1997 Aug; 49(8):765–9 (Eng. Abstr.) **(Jpn)**

[A case report of mixed transcortical aphasia due to three attacks of cerebral infarction] Ibayashi K, et al. **Rinsho Shinkeigaku** 1997 Apr;37(4):304–8 (Eng. Abstr.) **(Jpn)**

[Progressive degenerative aphasia: clinical and neuroradiological observations in 18 cases] Robles A, et al. **Rev Neurol** 1997 Apr;25(140):505–12 (18 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

A brief history of Russian aphasiology. Glozman JM. **Neuropsychol Rev** 1996 Mar;6(1):1–10

PATHOLOGY

Primary progressive aphasia: description of a clinical case with nine years of follow-up. Mazzoni M, et al. **Ital J Neurol Sci** 1996 Apr;17(2):161–5

Conduction aphasia in multiple sclerosis: a case report with MRI findings. Arnett PA, et al. **Neurology** 1996 Aug; 47(2):576–8

PHYSIOPATHOLOGY

Recovery of language after brain damage. Karbe H, et al. **Adv Neurol** 1997;73:347–58 (46 ref.)

Crossed aphasia. Functional brain imaging with PET or SPECT. Bakar M, et al. **Arch Neurol** 1996 Oct; 53(10):1026–32 (36 ref.)

Neurolinguistic and follow-up study of an unusual pattern of recovery from bilingual subcortical aphasia. Aglioti S, et al. **Brain** 1996 Oct;119 (Pt 5):1551–64

Focal cortical atrophy syndromes. Black SE. **Brain Cogn** 1996 Jul;31(2):188–229 (207 ref.)

Crossed aphasia and related anomalies of cerebral organization: case reports and a genetic hypothesis. Alexander MP, et al. **Brain Lang** 1996 Nov;55(2):213–39 (120 ref.)

Fricative production in aphasia: effects of speaking rate. Baum SR. **Brain Lang** 1996 Feb;52(2):328–41

Compensation for jaw fixation by aphasic patients. Baum SR, et al. **Brain Lang** 1997 Feb 15;56(3):354–76

Verb retrieval in aphasia. 2. Relationship to sentence processing. Berndt RS, et al. **Brain Lang** 1997 Jan; 56(1):107–37

Verb retrieval in aphasia. 1. Characterizing single word impairments. Berndt RS, et al. **Brain Lang** 1997 Jan; 56(1):68–106

The effects of right-hemisphere brain damage on patients' use of terms of personal reference. Brownell H, et al. **Brain Lang** 1997 Mar;57(1):60–79

Optic aphasia: a case with spared action naming and associated disorders. Campbell R, et al. **Brain Lang** 1996 May;53(2):183–221

A PET follow-up study of recovery after stroke in acute aphasics. Cappa SF, et al. **Brain Lang** 1997 Jan;56(1):55–67

On the status of object concepts in aphasia. Chertkow H, et al. **Brain Lang** 1997 Jun 15;58(2):203–32

Can the right hemisphere speak? Code C. **Brain Lang** 1997 Mar;57(1):38–59 (85 ref.)

Picture confrontation oral naming: performance differences between aphasics and normals. Deloche G, et al. **Brain Lang** 1996 Apr;53(1):105–20

Interaction between tone and intonation in Thai after unilateral brain damage. Gandour J, et al. **Brain Lang** 1997 Jun 1;58(1):174–96

Adynamic aphasia: a transcortical motor aphasia with defective semantic strategy formation. Gold M, et al. **Brain Lang** 1997 May;57(3):374–93

Judgments of concept similarity by normal and aphasic subjects: relation to naming and comprehension. Goodglass H, et al. **Brain Lang** 1997 Jan;56(1):138–58

Lateralization of affective prosody in brain and the callosal integration of hemispheric language functions. Ross ED, et al. **Brain Lang** 1997 Jan;56(1):27–54

Theory of mind and pragmatic understanding following right hemisphere damage. Siegal M, et al. **Brain Lang** 1996 Apr; 53(1):40–50

The gradual deterioration of syntax and semantics in a patient with progressive aphasia. Tyler LK, et al. **Brain Lang** 1997 Feb 15;56(3):426–76

Language processing in aphasia: changes in lateralization patterns during recovery reflect cerebral plasticity in adults. Thomas C, et al. **Electroencephalogr Clin Neurophysiol** 1997 Feb; 102(2):86–97

Left and right hemispheric contributions to discourse coherence and cohesion. Bloom RL, et al. **Int J Neurosci** 1996 Nov;88(1–2):125–40

Evolution of oral and written confrontation naming errors in aphasia. A retrospective study on vascular patients. Basso A, et al. **J Clin Exp Neuropsychol** 1996 Feb;18(1):77–87

Bedside screening for aphasia: a comparison of two methods. Al-Khawaja I, et al. **J Neurol** 1996 Feb;243(2):201–4

Speech-induced cerebral metabolic activation reflects recovery from aphasia. Heiss WD, et al. **J Neurol Sci** 1997 Feb 12;145(2):213–7

Spontaneous grammatical corrections in an anomic aphasic. Shuren JE, et al. **Neurology** 1996 Sep;47(3):845–6

Verbal memory function in mild aphasia. Ween JE, et al. **Neurology** 1996 Sep;47(3):795–801

Discrimination of speech sounds in a boy with Landau-Kleffner syndrome: an intraoperative event-related potential study. Boyd SG, et al. **Neuropediatrics** 1996 Aug;27(4):211–5

Memory and aphasia. Burgio F, et al. **Neuropsychologia** 1997 Jun;35(6):759–66

Use of the family to facilitate communicative changes in adults with neurological impairments. Burns MS. **Semin Speech Lang** 1996 May;17(2):115–21; quiz 121–2

Neurobiology of learning disabilities. Chase CH. **Semin Speech Lang** 1996 Aug;17(3):173–81 (32 ref.)

[Speech-specific cortical potentials--methodologic aspects and initial clinical results] Rosanowski F, et al. **Laryngorhinootologie** 1996 Jun;75(6):326–9 (Eng. Abstr.) **(Ger)**

[Progressive loss of speech output with festinating speech--a case report] Satoh S, et al. **No To Shinkei** 1997 Jul; 49(7):646–9 (Eng. Abstr.) **(Jpn)**

[The effect of aphasia and organic brain damage on the variability of the results of "Token" test] Jarzębska E. **Neurol Neurochir Pol** 1996 Jul-Aug;30(4):581–8 (Eng. Abstr.) **(Pol)**

[Aphasia in a polyglot: description and neuropsychological course] Martinell-Gispert-Saúch M, et al. **Rev Neurol** 1997 Apr;25(140):562–5 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Knowledge of scripts reflected in discourse of aphasics and right-brain-damaged patients. Lojek-Osiejuk E. **Brain Lang** 1996 Apr;53(1):58–80

Lexical-semantic organization: evidence from aphasia. Berndt RS, et al. **Clin Neurosci** 1997;4(2):57–63 (60 ref.)

Childhood aphasias. Martins IP. **Clin Neurosci** 1997;4(2):73–7 (65 ref.)

Associative agnosia and optic aphasia: qualitative or quantitative difference? De Renzi E, et al. **Cortex** 1997 Mar; 33(1):115–30

Interactions between recovery in aphasia, emotional and psychosocial factors in subjects with aphasia, their significant others and speech pathologists. Hemsley G, et al. **Disabil Rehabil** 1996 Nov;18(11):567–84

"La toccatina": polyglottal aphasia in Pirandello. Sghirlanzoni A, et al. **Ital J Neurol Sci** 1997 Feb;18(1):55–7

Performance consistency in picture naming: a study of the rehabilitation effect on two aphasic patients. Laiacona M, et al. **J Clin Exp Neuropsychol** 1996 Dec;18(6):923–33

Semantic and episodic memory in aphasia. Barba GD, et al. **Neuropsychologia** 1996 May;34(5):361–7

Two routes to naming: a case study. Manning L, et al. **Neuropsychologia** 1996 Aug;34(8):809–17

Factor structure and age effects with an aphasia test battery in normal Taiwanese adults. Hua MS, et al. **Neuropsychology** 1997 Jan;11(1):156–62

Acquired aphasia in children. Van Hout A. **Semin Pediatr Neurol** 1997 Jun;4(2):102–8 (31 ref.)

[Self-evaluation on the ability to retrieve Kanji words: a comparison between an aphasiac and normal subjects] Tanigami A, et al. **Shinrigaku Kenkyu** 1997 Apr;68(1):17–24 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Crossed aphasia. Functional brain imaging with PET or SPECT. Bakar M, et al. **Arch Neurol** 1996 Oct; 53(10):1026–32 (36 ref.)

Cerebellar induced aphasia: case report of cerebellar induced prefrontal aphasic language phenomena supported by SPECT findings. Mariën P, et al. **J Neurol Sci** 1996 Dec; 144(1–2):34–43

Recovery from nonfluent aphasia after melodic intonation therapy: a PET study. Belin P, et al. **Neurology** 1996 Dec; 47(6):1504–11

Right temporal compensatory mechanisms in a deep dysphasic patient: a case report with activation study by SPECT. Cardebat D, et al. **Neuropsychologia** 1994 Jan; 32(1):97–103

REHABILITATION

In-hospital patients with aphasia, dysarthria deserve our attention [letter] Del Torro JF. **ASHA** 1996 Spring;38(2):4

Cognitive approaches to recovery and rehabilitation in aphasia. Martin N. **Brain Lang** 1996 Jan;52(1):3–6

The utility of meta-analysis in the determination of efficacy of treatment in aphasia: a reply to Robey (1994). Nye C, et al. **Brain Lang** 1997 Apr;57(2):280–2

An evaluation of short-term group therapy for people with aphasia. Brumfitt SM, et al. **Disabil Rehabil** 1997 Jun; 19(6):221–30

Weightings of items on the Code-Müller Protocols: the effects of clinical experience of aphasia therapy. Herrmann M, et al. **Disabil Rehabil** 1996 Oct;18(10):509–14

Time to talk: counselling for people with dysphasia. Ireland C, et al. **Disabil Rehabil** 1996 Nov;18(11):585–91

The behaviour of stroke patients in unsupervised computer-administered aphasia therapy. Petheram B. **Disabil Rehabil** 1996 Jan;18(1):21–6

Performance consistency in picture naming: a study of the rehabilitation effect on two aphasic patients. Laiacona M, et al. **J Clin Exp Neuropsychol** 1996 Dec;18(6):923–33

Diversity of patterns of improvement in confrontation naming rehabilitation: some tentative hypotheses. Deloche G, et al. **J Commun Disord** 1997 Jan-Feb;30(1):11–21; quiz 21–2

Treatment efficacy: aphasia. Holland AL, et al. **J Speech Hear Res** 1996 Oct;39(5):S27–36

THERAPY

Computer rehabilitation in aphasia. Weinrich M. **Clin Neurosci** 1997;4(2):103–7 (43 ref.)

The efficacy of computer-provided reading treatment for chronic aphasic adults. Katz RC, et al. **J Speech Lang Hear Res** 1997 Jun;40(3):493–507

Recovery from nonfluent aphasia after melodic intonation therapy: a PET study. Belin P, et al. **Neurology** 1996 Dec; 47(6):1504–11

APHASIA, ACQUIRED see **APHASIA**

APHASIA, ACQUIRED EPILEPTIC see **LANDAU-KLEFFNER SYNDROME**

APHASIA, AMNESIC see **ANOMIA**

APHASIA, ANOMIC see **ANOMIA**

APHASIA, BROCA

COMPLICATIONS

Dissociated identity and semantic priming in Broca's aphasia: how controlled processing produces inhibitory semantic priming. Bushell CM. **Brain Lang** 1996 Nov;55(2):264–88

Training wh-question production in agrammatic aphasia: analysis of argument and adjunct movement. Thompson CK, et al. **Brain Lang** 1996 Jan;52(1):175–228

Surface dyslexia in nonfluent progressive aphasia. Watt S, et al. **Brain Lang** 1997 Feb 1;56(2):211–33

DIAGNOSIS

Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia. Turner RS, et al. **Ann Neurol** 1996 Feb;39(2):166–73 (49 ref.)

Trace deletion, theta-roles, and cognitive strategies. Grodzinsky Y. **Brain Lang** 1995 Dec;51(3):469–97

Semantic priming in Broca's aphasics at a short SOA: no support for an automatic access deficit. Hagoort P. **Brain Lang** 1997 Feb 1;56(2):287–300

ETIOLOGY

Motor aphasia due to prolonged hypoglycaemic coma in a patient with insulin-dependent diabetes mellitus. Kurabayashi H, et al. **J Int Med Res** 1996 Nov-Dec; 24(6):487–91 (17 ref.)

[A case of corticobasal degeneration presenting with primary progressive aphasia] Katai S, et al. **Rinsho Shinkeigaku** 1997 Mar;37(3):249–52 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Motor aphasia as the only manifestation of focal status epilepticus (letter)] Ramón Valiente MR, et al. **Med Clin (Barc)** 1996 Feb 3;106(4):154 **(Spa)**

PHYSIOPATHOLOGY

Auditory vigilance in aphasic individuals: detecting nonlinguistic stimuli with full or divided attention. Erickson RJ, et al. **Brain Cogn** 1996 Mar;30(2):244–53

Dual processing of open- and closed-class words. Biassou N, et al. **Brain Lang** 1997 May;57(3):360–73

Subcortical aphasia: still a useful concept? Cappa SF. **Brain Lang** 1997 Jul;58(3):424–6; discussion 436–58

Subcortical aphasia and the problem of attributing functional responsibility to parts of distributed brain processes. Carver CF, et al. **Brain Lang** 1997 Jul;58(3):427–35; discussion 436–58

Subcortical aphasia and the problem of attributing functional responsibility to parts of distributed brain processes. Craver CF, et al. **Brain Lang** 1997 Jul;58(3):427–35; discussion 436–58

Subcortical aphasia(s): a controversial and promising topic. Démonet JF. **Brain Lang** 1997 Jul;58(3):410–7; discussion 436–58

Tense and agreement in agrammatic production: pruning the syntactic tree. Friedmann N, et al. **Brain Lang** 1997 Feb 15;56(3):397–425

Comprehension of wh-questions in two Broca's aphasics. Hickok G, et al. **Brain Lang** 1996 Feb;52(2):314–27

Mechanisms of and misconceptions about subcortical aphasia [comment] Wallesch CW, et al. **Brain Lang** 1997 Jul; 58(3):403–9; discussion 436–58. Comment on: Brain Lang 1997 Jul;58(3):355–402.

Effects of left basal ganglia lesions on language production. Fabbro F, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 2):1291–8

PSYCHOLOGY

Agrammatism in aphasiology. Goodglass H. **Clin Neurosci** 1997;4(2):51–6 (41 ref.)

Grammaticality judgments and sentence comprehension in Parkinson's disease: a comparison with Broca's aphasia. McNamara P, et al. **Int J Neurosci** 1996 Jul;86(1–2):151–66

The importance of word-initial phonology: error patterns in prolonged naming efforts by aphasic patients. Goodglass H, et al. **J Int Neuropsychol Soc** 1997 Mar;3(2):128–38
Anxiety, alcohol, aphasia, and ums. Christenfeld N, et al. **J Pers Soc Psychol** 1996 Mar;70(3):451–60

REHABILITATION

Conversational rate of a non-vocal person with motor neurone disease using the 'TALK' system. Todman J, et al. **Int J Rehabil Res** 1996 Sep;19(3):285–7
Training and generalized production of wh- and NP-movement structures in agrammatic aphasia. Thompson CK, et al. **J Speech Lang Hear Res** 1997 Apr; 40(2):228–44

THERAPY

Remediating production of tense morphology improves verb retrieval in chronic aphasia. Weinrich M, et al. **Brain Lang** 1997 Jun 1;58(1):23–45
Generalization from single sentence to multisentence production in severely aphasic patients. Weinrich M, et al. **Brain Lang** 1997 Jun 15;58(2):327–52

APHASIA, CONDUCTION

PSYCHOLOGY

The importance of word-initial phonology: error patterns in prolonged naming efforts by aphasic patients. Goodglass H, et al. **J Int Neuropsychol Soc** 1997 Mar;3(2):128–38

APHASIA, EPILEPTIC, ACQUIRED see **LANDAU-KLEFFNER SYNDROME**

APHASIA, EXPRESSIVE see **APHASIA, BROCA**

APHASIA, FLUENT see **APHASIA, WERNICKE**

APHASIA, MOTOR see **APHASIA, BROCA**

APHASIA, NOMINAL see **ANOMIA**

APHASIA, NONFLUENT see **APHASIA, BROCA**

APHASIA, PRIMARY PROGRESSIVE

see related
ALZHEIMER'S DISEASE

COMPLICATIONS

Alzheimer disease and nonfluent progressive aphasia. Greene JD, et al. **Arch Neurol** 1996 Oct;53(10):1072–8 (51 ref.)

DIAGNOSIS

Imaging in primary progressive aphasia. Abe K, et al. **Neuroradiology** 1997 Aug;39(8):556–9

ETIOLOGY

A clinical profile of corticobasal degeneration presenting as primary progressive aphasia. Sakurai Y, et al. **Eur Neurol** 1996;36(3):134–7
[A case of corticobasal degeneration presenting with primary progressive aphasia] Katai S, et al. **Rinsho Shinkeigaku** 1997 Mar;37(3):249–52 (18 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Apolipoprotein E genotypes in primary progressive aphasia. Mesulam MM, et al. **Neurology** 1997 Jul;49(1):51–5

PATHOLOGY

Corticobasal degeneration with primary progressive aphasia and accentuated cortical lesion in superior temporal gyrus: case report and review. Ikeda K, et al. **Acta Neuropathol (Berl)** 1996 Nov;92(5):534–9
A case of primary progressive aphasia with abnormally ubiquitinated neurites in the cerebral cortex. Kinoshita A, et al. **Acta Neuropathol (Berl)** 1996 Nov;92(5):520–4
Clinical and pathological characteristics of primary progressive aphasia and frontal dementia. Kertesz A, et al. **J Neural Transm Suppl** 1996;47:133–41

PHYSIOPATHOLOGY

Clinical and pathological characteristics of primary progressive aphasia and frontal dementia. Kertesz A, et al. **J Neural Transm Suppl** 1996;47:133–41

PSYCHOLOGY

Primary progressive aphasia. Kertesz A, et al. **Clin Neurosci** 1997;4(2):95–102 (64 ref.)

APHASIA, RECEPTIVE see **APHASIA, WERNICKE**

APHASIA, SENSORY see **APHASIA, WERNICKE**

APHASIA TESTS see **NEUROPSYCHOLOGICAL TESTS**

APHASIA, WERNICKE

COMPLICATIONS

Recovery in deep dysphasia: evidence for a relation between auditory - verbal STM capacity and lexical errors in repetition. Martin N, et al. **Brain Lang** 1996 Jan; 52(1):83–113
[Crossed aphasia disclosed by central auditory disorder] Nedelec-Ciceri C, et al. **Rev Neurol (Paris)** 1996 Nov; 152(11):700–3 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Disconnected phonology: a linguistic analysis of phonemic jargon aphasia. Hanlon RE, et al. **Brain Lang** 1996 Nov; 55(2):199–212
Memory dysfunction in mild aphasics. Rönnberg J, et al. **Scand J Psychol** 1996 Mar;37(1):46–61
[Relation between defect in comprehension and frontal lobe lesion] Otsuki M, et al. **No To Shinkei** 1996 Feb; 49(2):122–30 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Subcortical aphasia: still a useful concept? Cappa SF. **Brain Lang** 1997 Jul;58(3):424–6; discussion 436–58
Subcortical aphasia and the problem of attributing functional responsibility to parts of distributed brain processes. Carver CF, et al. **Brain Lang** 1997 Jul;58(3):427–35; discussion 436–58
Subcortical aphasia and the problem of attributing functional responsibility to parts of distributed brain processes. Craver CF, et al. **Brain Lang** 1997 Jul;58(3):427–35; discussion 436–58
Subcortical aphasia(s): a controversial and promising topic. Démonet JF. **Brain Lang** 1997 Jul;58(3):410–7; discussion 436–58
Subcortical aphasia [see comments] Nadeau SE, et al. **Brain Lang** 1997 Jul;58(3):355–402; discussion 418–23 (215 ref.). Comment in: Brain Lang 1997 Jul;58(3):403–9; discussion 436–58.
Mechanisms of and misconceptions about subcortical aphasia [comment] Wallesch CW, et al. **Brain Lang** 1997 Jul; 58(3):403–9; discussion 436–58. Comment on: Brain Lang 1997 Jul;58(3):355–402.
Effects of left basal ganglia lesions on language production. Fabbro F, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 2):1291–8

PSYCHOLOGY

Evidence for multiple routes of speech production in a case of fluent aphasia. Ingles JL, et al. **Cortex** 1996 Jun; 32(2):199–219
The importance of word-initial phonology: error patterns in prolonged naming efforts by aphasic patients. Goodglass H, et al. **J Int Neuropsychol Soc** 1997 Mar;3(2):128–38
Anxiety, alcohol, aphasia, and ums. Christenfeld N, et al. **J Pers Soc Psychol** 1996 Mar;70(3):451–60
[Relation between defect in comprehension and frontal lobe lesion] Otsuki M, et al. **No To Shinkei** 1996 Feb; 49(2):122–30 (Eng. Abstr.) **(Jpn)**

APHERESIS see **BLOOD COMPONENT REMOVAL**

APHIDICOLIN

PHARMACOLOGY

Induction of apoptosis within T lymphoblastoid cells by a topoisomerase I inhibitor. Johnson N, et al. **Biochem Soc Trans** 1997 May;25(2):240S
Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours. Sargent JM, et al. **Br J Cancer** 1996 Dec;74(11):1730–3
Comparative study of chromosome aberrations induced with aphidicolin in women affected by breast cancer and cervix uterine cancer. Paz-y-Miño C, et al. **Cancer Genet Cytogenet** 1997 Apr;94(2):120–4
Microtubule dependence of chromosome cycles in Xenopus laevis blastomeres under the influence of a DNA synthesis inhibitor, aphidicolin. Clute P, et al. **Dev Biol** 1997 May 1;185(1):1–13
Aphidicolin-sensitive specific common fragile sites: a biomarker of exposure to pesticides. Musio A, et al. **Environ Mol Mutagen** 1997;29(3):250–5
Aphidicolin uncouples the chloroplast division cycle from the mitotic cycle in the unicellular red alga Cyanidioschyzon merolae. Itoh R, et al. **Eur J Cell Biol** 1996 Nov;71(3):303–10
Effects of aphidicolin and hydroxyurea on the cell cycle and differentiation of Trypanosoma brucei bloodstream forms. Mutomba MC, et al. **Mol Biochem Parasitol** 1996 Sep; 80(1):89–102
Increased efficacy of aphidicolin killing of human neuroblastoma cells in vitro by encapsulation in liposomes. Cinatl J Jr, et al. **Neoplasma** 1997;44(2):91–5
[The effect of aphidicolin on trochoblast differentiation in the early ontogeny of polychaetes] Dondua AK, et al. **Ontogenez** 1996 Nov-Dec;27(6):419–26 **(Rus)**

APHIDS

Aphicide persistence on spinach and mustard greens. Sweeden MB, et al. **J Econ Entomol** 1997 Feb;90(1):195–8
Expression and suppression of circulative aphid transmission in pea enation mosaic virus. Demler SA, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):511–23

CHEMISTRY

Psyllids as a potential source of heavy metals for predators. Glowacka E, et al. **Arch Environ Contam Toxicol** 1997 May; 32(4):376–82

EMBRYOLOGY

Ribosomal DNA is frequently concentrated on only one X chromosome in permanently apomictic aphids, but this does not inhibit male determination. Blackman RL, et al. **Chromosome Res** 1996 Jun;4(4):314–20

GENETICS

Chromosomal localization of a highly repeated EcoRI DNA fragment in Megoura viciae (Homoptera, Aphididae) by nick translation and fluorescence in situ hybridization. Bizzaro D, et al. **Chromosome Res** 1996 Aug;4(5):392–6
Microsatellite and chromosome evolution of parthenogenetic sitobion aphids in Australia. Sunnucks P, et al. **Genetics** 1996 Oct;144(2):747–56
Variation in the ribosomal RNA cistron among host-adapted races of an aphid (Schizaphis graminum). Black WC 4th. **Insect Mol Biol** 1993;2(2):59–69
Polymerase chain reaction-based identification of insecticide resistance genes and DNA methylation in the aphid Myzus persicae (Sulzer). Field LM, et al. **Insect Mol Biol** 1996 Aug;5(3):197–202
Nucleotide sequence and presumed secondary structure of the 28S rRNA of pea aphid: implication for diversification of insect rRNA. Amako D, et al. **J Mol Evol** 1996 Nov; 43(5):469–75
Evolution of the tryptophan biosynthetic pathway in Buchnera (aphid endosymbionts): studies of plasmid-associated trpEG within the genus Uroleucon. Rouhbakhsh D, et al. **Mol Phylogenet Evol** 1997 Oct; 8(2):167–76
Genotypic variation among different phenotypes within aphid clones. Lushai G, et al. **Proc R Soc Lond B Biol Sci** 1997 May 22;264(1382):725–30

METABOLISM

Two distinct mechanisms regulate luteovirus transmission efficiency and specificity at the aphid salivary gland. Peiffer ML, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):495–503
In vitro interactions of the aphid endosymbiotic SymL chaperonin with barley yellow dwarf virus. Filichkin SA, et al. **J Virol** 1997 Jan;71(1):569–77

MICROBIOLOGY

Structure of the dnaA region of the endosymbiont, Buchnera aphidicola, of aphid Schizaphis graminum. Hassan AK, et al. **DNA Res** 1996 Dec 31;3(6):415–9
Expression and control of an operon from an intracellular symbiont which is homologous to the groE operon. Sato S, et al. **J Bacteriol** 1997 Apr;179(7):2300–4
Structure and expression of the dnaKJ operon of Buchnera, an intracellular symbiotic bacteria of aphid. Sato S, et al. **J Biochem (Tokyo)** 1997 Jul;122(1):41–8
Evolution of the tryptophan biosynthetic pathway in Buchnera (aphid endosymbionts): studies of plasmid-associated trpEG within the genus Uroleucon. Rouhbakhsh D, et al. **Mol Phylogenet Evol** 1997 Oct; 8(2):167–76

PHYSIOLOGY

A comparison of acute mortality and population growth rate as endpoints of toxicological effect. Walthall WK, et al. **Ecotoxicol Environ Saf** 1997 Jun;37(1):45–52
Potyvirus transmission is not increased by pre-acquisition fasting of aphids reared on artificial diet. Wang RY, et al. **J Gen Virol** 1996 Dec;77 (Pt 12):3145–8

VIROLOGY

The N-terminal region of the luteovirus readthrough domain determines virus binding to Buchnera GroEL and is essential for virus persistence in the aphid. van den Heuvel JF, et al. **J Virol** 1997 Oct;71(10):7258–65
Improved detection of barley yellow dwarf virus in single aphids using RT-PCR. Canning ES, et al. **J Virol Methods** 1996 Feb;56(2):191–7
Detection of stylet-borne and circulative potato viruses in aphids by duplex reverse transcription polymerase chain reaction [published erratum appears in J Virol Methods 1996 Jul;60(2):183] Singh RP, et al. **J Virol Methods** 1996 May;59(1-2):189–96

APHONIA

DIAGNOSIS

Acute palsy of the recurrent laryngeal nerve complicating Epstein-Barr virus infection. Parano E, et al.

APHONIA

Neuropediatrics 1996 Jun;27(3):164–6

PHYSIOPATHOLOGY

Ictal speech arrest and parasagittal lesions. Wieshmann UC, et al. **Eur Neurol** 1997;38(2):123–7

PSYCHOLOGY

A comparative study of psychological aspects of recurring and non-recurring functional aphonias. Günther V, et al. **Eur Arch Otorhinolaryngol** 1996;253(4–5):240–4

APHORISMS AND PROVERBS

"Dichos" therapy group: a therapeutic use of Spanish language proverbs with hospitalized Spanish-speaking psychiatric patients. Aviera A. **Cult Divers Ment Health** 1996;2(2):73–87

Aphorisms [letter] Waldman M. **J Emerg Med** 1997 Jul–Aug; 15(4):535

Four laws of therapeutic dynamics [editorial] Hadler NM. **J Occup Environ Med** 1997 Apr;39(4):295–8

Proverb comprehension in youth: the role of concreteness and familiarity. Nippold MA, et al. **J Speech Hear Res** 1996 Feb;39(1):166–76

Proverb explanation through the lifespan: a developmental study of adolescents and adults. Nippold MA, et al. **J Speech Lang Hear Res** 1997 Apr;40(2):245–53

APHRODISIACS

Sexual behavior in male and female rats after a tryptophan-free amino acid mixture. Moja EA, et al. **Adv Exp Med Biol** 1996;398:89–91

ADVERSE EFFECTS

Yohimbine and sinusitis [letter] Wylie KR. **Br J Psychiatry** 1996 Sep;169(3):384–5

PHARMACOLOGY

Aphrodisiac property of Trichopus zeylanicus extract in male mice. Subramoniam A, et al. **J Ethnopharmacol** 1997 Jun; 57(1):21–7

POISONING

Treatment of toad venom poisoning with digoxin-specific Fab fragments [see comments] Brubacher JR, et al. **Chest** 1996 Nov;110(5):1282–8. Comment in: Chest 1996 Nov;110(5):1139–41.

GC/MS comparison of the West Indian aphrodisiac "Love Stone" to the Chinese medication "chan su": bufotenine and related bufadienolides. Barry TL, et al. **J Forensic Sci** 1996 Nov;41(6):1068–73

THERAPEUTIC USE

Sexual desire in men: effects of oral ingestion of a product derived from fertilized eggs. Eskeland B, et al. **J Int Med Res** 1997 Mar–Apr;25(2):62–70

APHTHAE see **STOMATITIS, APHTHOUS**

APHTHOVIRUS

Phenotypic features of BHK-21 cells used for production of foot-and-mouth disease vaccine. Amadori M, et al. **Biologicals** 1997 Mar;25(1):65–73

CHEMISTRY

Biochemical characterization of FMDV A10 and A22 subtypes by PAGE and IEF. Nandi S, et al. **Comp Immunol Microbiol Infect Dis** 1997 Jan;20(1):95–9

The solution structure of the immunodominant and cell receptor binding regions of foot-and-mouth disease virus serotype A, variant A. Pegna M, et al. **J Pept Sci** 1996 Mar–Apr;2(2):75–90

The solution conformational features of two highly homologous antigenic peptides of foot-and-mouth disease virus serotype A, variant A and USA, correlate with their serological properties. Pegna M, et al. **J Pept Sci** 1996 Mar–Apr;2(2):91–105

Perturbations in the surface structure of A22 Iraq foot-and-mouth disease virus accompanying coupled changes in host cell specificity and antigenicity. Curry S, et al. **Structure** 1996 Feb 15;4(2):135–45

CLASSIFICATION

Differentiation of the seven serotypes of foot-and-mouth disease virus by reverse transcriptase polymerase chain reaction. Callens M, et al. **J Virol Methods** 1997 Aug; 67(1):35–44

Antigenic features of foot-and-mouth disease virus serotype Asia1 as revealed by monoclonal antibodies and neutralization-escape mutants. Sanyal A, et al. **Virus Res** 1997 Aug;50(2):107–17

DRUG EFFECTS

Antiviral activity of crude extracts of Guarea guidona. Simoni IC, et al. **Braz J Med Biol Res** 1996 May; 29(5):647–50

ENZYMOLOGY

Antigenicity of a viral peptide displayed on beta-galactosidase fusion proteins is influenced by the presence of the homologous partner protein. Corchero JL, et al. **FEMS Microbiol Lett** 1996 Nov 15;145(1):77–82

Foot-and-mouth disease virus 2A protease mediates cleavage in attenuated Sabin 3 poliovirus vectors engineered for delivery of foreign antigens. Mattion NM, et al. **J Virol** 1996 Nov;70(11):8124–7

Crystallization and preliminary X-ray diffraction studies of the Lb proteinase from foot-and-mouth disease virus. Guarné A, et al. **Protein Sci** 1996 Sep;5(9):1931–3

Construction of a chimeric Theiler's murine encephalomyelitis virus containing the leader gene of foot-and-mouth disease virus. Piccone ME, et al. **Virology** 1996 Dec 1;226(1):135–9

[Use of protease 3c and foot-and-mouth disease virus RNA polymerase hybrid proteins, synthesized in Escherichia coli, for diagnosis] Aminev AG, et al. **Mol Biol (Mosk)** 1997 May–Jun;31(3):568–72 **(Rus)**

GENETICS

Stability of foot-and-mouth disease virus, its genome and proteins at 37 degrees C. Razdan R, et al. **Acta Virol** 1996 Feb;40(1):9–14

Genetic lesions associated with Muller's ratchet in an RNA virus. Escarmís C, et al. **J Mol Biol** 1996 Nov 29; 264(2):255–67

Conserved structural motifs located in distal loops of aphthovirus internal ribosome entry site domain 3 are required for internal initiation of translation. López de Quinto S, et al. **J Virol** 1997 May;71(5):4171–5

Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. Sa-Carvalho D, et al. **J Virol** 1997 Jul;71(7):5115–23

Evolution of a persistent aphthovirus in cytolytic infections: partial reversion of phenotypic traits accompanied by genetic diversification. Sevilla N, et al. **J Virol** 1996 Oct; 70(10):6617–24

Structural analysis of the interaction of the pyrimidine tract-binding protein with the internal ribosomal entry site of encephalomyocarditis virus and foot-and-mouth disease virus RNAs. Kolupaeva VG, et al. **RNA** 1996 Dec; 2(12):1199–212

Emerging foot-and-mouth disease virus variants with antigenically critical amino acid substitutions predicted by model studies using reference viruses. Feigelstock DA, et al. **Vaccine** 1996 Feb;14(2):97–102

Computer simulations to identify in polyproteins of FMDV OK1 and A12 strains putative nonapeptides with amino acid motifs for binding to BoLA class I A11 and A20 haplotype molecules. Becker Y. **Virus Genes** 1997; 14(2):123–9

Molecular evolution of aphthoviruses. Domingo E, et al. **Virus Genes** 1995;11(2–3):197–207 (80 ref.)

Characteristic in vitro evolution pattern of foot and mouth disease virus A81/Castellanos/Arg/87. Mbayed V, et al. **Virus Res** 1997 May;48(2):157–63

Antigenic features of foot-and-mouth disease virus serotype Asia1 as revealed by monoclonal antibodies and neutralization-escape mutants. Sanyal A, et al. **Virus Res** 1997 Aug;50(2):107–17

Serological and molecular analysis of serotype O foot-and-mouth disease virus isolated from disease outbreaks in India during 1987–91. Singh M, et al. **Virus Res** 1996 Jul;43(1):45–55

[Bacterial synthesis of immunogenic epitopes of foot-and-mouth disease virus fused either to human necrosis factor or to hepatitis B core antigen] Nekrasova OV, et al. **Bioorg Khim** 1997 Feb;23(2):118–26 (Eng. Abstr.) **(Rus)**

[Study of transcript translation of a DNA-copy of the translated region of the foot-and-mouth disease A22 virus genome] Aminev AG, et al. **Mol Biol (Mosk)** 1997 May–Jun;31(3):398–402 **(Rus)**

IMMUNOLOGY

Serological study of type A Indian foot-and-mouth disease virus isolates. Meer Azad H, et al. **Acta Virol** 1995 Sep; 39(4):193–6

Conformational preferences of a peptide corresponding to the major antigenic determinant of foot-and-mouth disease virus: implications for peptide-vaccine approaches. de Prat-Gay G. **Arch Biochem Biophys** 1997 May 15; 341(2):360–9

Antigenic analysis of type O foot-and-mouth disease virus in the persistently infected bovine. Salt JS, et al. **Arch Virol** 1996;141(8):1407–21

Cellular immune response to foot-and-mouth disease virus. Cedillo-Barron L, et al. **Biochem Soc Trans** 1997 May; 25(2):275S

Cellular and humoral immunity to foot-and-mouth disease virus and its non-structural proteins in infected swine. Cook A, et al. **Biochem Soc Trans** 1997 May;25(2):273S

Preparation and characterization of monoclonal antibodies to foot-and-mouth disease virus type Asia-1. Amineva SP, et al. **Biochemistry (Mosc)** 1997 May;62(5):469–73

Mimicry of viral epitopes with retro-inverso peptides of increased stability. Benkirane N, et al. **Dev Biol Stand** 1996; 87:283–91

Structure of the complex of an Fab fragment of a neutralizing antibody with foot-and-mouth disease virus: positioning of a highly mobile antigenic loop. Hewat EA, et al. **EMBO J** 1997 Apr 1;16(7):1492–500

Dexamethasone inhibits virus production and the secretory IgA response in oesophageal-pharyngeal fluid in cattle persistently infected with foot-and-mouth disease virus. Ilott MC, et al. **Epidemiol Infect** 1997 Apr;118(2):181–7

Converging antigenic structure of a recombinant viral peptide displayed on different frameworks of carrier proteins. Carbonell X, et al. **FEBS Lett** 1996 Nov 18;397(2–3):169–72

Differential restrictions on antigenic variation among antigenic sites of foot-and-mouth disease virus in the absence of antibody selection. Holguín A, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):601–9

A porcine CD8+ T cell clone with heterotypic specificity for foot-and-mouth disease virus. Rodríguez A, et al. **J Gen Virol** 1996 Sep;77 (Pt 9):2089–96

Duration of the foot-and-mouth disease virus antibody response in mice is closely related to the presence of antigen-specific presenting cells. Wigdorovitz A, et al. **J Gen Virol** 1997 May;78 (Pt 5):1025–32

Preparation of virus-infection-associated (VIA) antigen of foot-and-mouth disease (FMD) virus from inactivated vaccine. Sugimura T, et al. **J Vet Med Sci** 1996 Jun; 58(6):599–601

Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus. Grigera PR, et al. **J Virol** 1996 Dec;70(12):8492–501

Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. Ward G, et al. **J Virol** 1997 Oct;71(10):7442–7

Baculovirus expressed 2C of foot-and-mouth disease virus has the potential for differentiating convalescent from vaccinated animals. Meyer RF, et al. **J Virol Methods** 1997 Apr;65(1):33–43

Prevalence of foot-and-mouth disease antibodies in dairy herds in The Netherlands four years after vaccination. Dekker A, et al. **Res Vet Sci** 1996 Jul;61(1):89–91

Recent structural solutions for antibody neutralization of viruses. Stewart PL, et al. **Trends Microbiol** 1997 Jun; 5(6):229–33 (36 ref.)

International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants. Barnett PV, et al. **Vaccine** 1996 Sep;14(13):1187–98

Total and isotype humoral responses in cattle vaccinated with foot and mouth disease virus (FMDV) immunogen produced either in bovine tongue tissue or in BHK-21 cell suspension cultures. Capozzo AV, et al. **Vaccine** 1997 Apr–May;15(6–7):624–30

Emerging foot-and-mouth disease virus variants with antigenically critical amino acid substitutions predicted by model studies using reference viruses. Feigelstock DA, et al. **Vaccine** 1996 Feb;14(2):97–102

Implementation of internal laboratory quality control procedures for the monitoring of ELISA performance at a regional veterinary laboratory. Blacksell SD, et al. **Vet Microbiol** 1996 Jul;51(1–2):1–9

Role of a distinct population of bovine gamma delta T cells in the immune response to viral agents. Amadori M, et al. **Viral Immunol** 1995;8(2):81–91

Cloning and expression of a single-chain antibody fragment specific for foot-and-mouth disease virus. Mason P, et al. **Virology** 1996 Oct 15;224(2):548–54

Antigenically profound amino acid substitutions occur during large population passages of foot-and-mouth disease virus. Sevilla N, et al. **Virology** 1996 Nov 15;225(2):400–5

Computer simulations to identify in polyproteins of FMDV OK1 and A12 strains putative nonapeptides with amino acid motifs for binding to BoLA class I A11 and A20 haplotype molecules. Becker Y. **Virus Genes** 1997; 14(2):123–9

[The use of synthetic peptides for detection of antibodies against foot-and-mouth disease virus in the blood from convalescent animals] Petrov VN, et al. **Mol Gen Mikrobiol Virusol** 1996 Jul–Sep;(3):27–31 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Identification of foot-and-mouth disease virus-free regions by use of a standardized enzyme-linked immunoelectrotransfer blot assay. Bergmann IE, et al. **Am J Vet Res** 1996 Jul;57(7):972–4

Foot and mouth disease virus concentration and purification by affinity chromatography. Navarro del Cañizo AA, et al. **Appl Biochem Biotechnol** 1996 Dec;61(3):399–409

Development of tests for antibodies against foot-and-mouth disease virus in cattle milk. Armstrong RM. **J Virol Methods** 1997 Jan;63(1–2):175–80

A risk-assessment model for foot and mouth disease (FMD) virus introduction through deboned beef importation. Yu P, et al. **Prev Vet Med** 1997 Apr;30(1):49–59

[Mechanism of retaining stability of foot-and-mouth disease virus during manufacturing dried concentrated preparations] Ponomarev AP, et al. **Vopr Virusol** 1996 Sep–Oct;41(5):218–21 (Eng. Abstr.) **(Rus)**

METABOLISM

Stability of foot-and-mouth disease virus, its genome and proteins at 37 degrees C. Razdan R, et al. **Acta Virol** 1996 Feb;40(1):9–14

A recombinant, arginine-glycine-aspartic acid (RGD) motif from foot-and-mouth disease virus binds mammalian cells through vitronectin and, to a lower extent, fibronectin receptors. Villaverde A, et al. **Gene** 1996 Nov 21; 180(1-2):101-6

The cleavage activities of aphthovirus and cardiovirus 2A proteins. Donnelly ML, et al. **J Gen Virol** 1997 Jan;78 (Pt 1):13-21

Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. Sa-Carvalho D, et al. **J Virol** 1997 Jul;71(7):5115-23

Mengovirus leader is involved in the inhibition of host cell protein synthesis. Zoll J, et al. **J Virol** 1996 Aug; 70(8):4948-52

Intracellular membrane proliferation in E. coli induced by foot-and-mouth disease virus 3A gene products. Weber S, et al. **Virus Genes** 1996;12(1):5-14

PATHOGENICITY

Pathogenesis of wild-type and leaderless foot-and-mouth disease virus in cattle. Brown CC, et al. **J Virol** 1996 Aug; 70(8):5638-41

PHYSIOLOGY

Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. Jackson T, et al. **J Virol** 1996 Aug; 70(8):5282-7

Characterization of synthetic foot-and-mouth disease virus provirions separates acid-mediated disassembly from infectivity. Knipe T, et al. **J Virol** 1997 Apr;71(4):2851-6

Point mutations within the betaG-betaH loop of foot-and-mouth disease virus O1K affect virus attachment to target cells. Leippert M, et al. **J Virol** 1997 Feb; 71(2):1046-51

Foot-and-mouth disease virus and poliovirus particles contain proteins of the replication complex. Newman JF, et al. **J Virol** 1997 Oct;71(10):7657-62

Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. Ward G, et al. **J Virol** 1997 Oct;71(10):7442-7

Evolution subverting essentiality: dispensability of the cell attachment Arg-Gly-Asp motif in multiply passaged foot-and-mouth disease virus. Martínez MA, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6798-802

Propagation of an attenuated virus by design: engineering a novel receptor for a noninfectious foot-and-mouth disease virus. Rieder E, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10428-33

Natural adaption to pigs of a Taiwanese isolate of foot-and-mouth disease virus. Dunn CS, et al. **Vet Rec** 1997 Aug 16;141(7):174-5

Infectivity assays of foot-and-mouth disease virus: contact transmission between cattle and buffalo (Bubalus bubalis) in the early stages of infection. Gomes I, et al. **Vet Rec** 1997 Jan 11;140(2):43-7

Long-term, large-population passage of aphthovirus can generate and amplify defective noninterfering particles deleted in the leader protease gene. Charpentier N, et al. **Virology** 1996 Sep 1;223(1):10-8

APICOECTOMY

Are postoperative review appointments necessary following uncomplicated minor oral surgery? Worrall SF. **Br J Oral Maxillofac Surg** 1996 Dec;34(6):495-9

The resected root surface. The issue of canal isthmuses. Hsu YY, et al. **Dent Clin North Am** 1997 Jul;41(3):529-40 (30 ref.)

[Dens in dente: apicoectomy and retrograde obturation] Sakkal S, et al. **J Can Dent Assoc** 1997 Jan;63(1):48-51 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Relationship between apical and marginal healing in periradicular surgery. Jansson L, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 May;83(5):596-601

INSTRUMENTATION

Connective tissue response to root surfaces resected with Nd:YAG laser or burs. Maillet WA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Dec;82(6):681-90

[The operating microscope in root tip resection. I. The resection] Velvart P. **Schweiz Monatsschr Zahnmed** 1997; 107(6):506-21 (26 ref.) **(Ger, Fre)**

METHODS

[Clinical experience of the Er: YAG laser for apicoectomy] Komori T, et al. **Kokubyo Gakkai Zasshi** 1996 Sep; 63(3):516-20 (Eng. Abstr.) **(Jpn)**

APICOMPLEXA

Country-wide prevalence of Ascogregarina culicis (apicomplexa: lecudinidae), a protozoan parasite of Aedes aegypti in Trinidad, West Indies. Beier JC, et al. **J Am Mosq Control Assoc** 1995 Dec;11(4):419-23

CHEMISTRY

Contribution of Perkinsus marinus extracellular products in the infection of eastern oysters (Crassostrea virginica). La Peyre JF, et al. **J Invertebr Pathol** 1996 Nov;68(3):312-3

CLASSIFICATION

Gregarina triboliorum (Eugregarinida: Gregarinidae) n. sp. from Tribolium confusum and resolution of the confused taxonomic history of Gregarina minuta Ishii, 1914. Watwood S, et al. **J Parasitol** 1997 Jun;83(3):502-7

DRUG EFFECTS

Recombinant expression of the antimicrobial peptide polyphemusin and its activity against the protozoan oyster pathogen Perkinsus marinus. Pierce JC, et al. **Mol Mar Biol Biotechnol** 1997 Sep;6(3):248-59

GENETICS

The growing importance of the plastid-like DNAs of the Apicomplexa. Jeffries AC, et al. **Int J Parasitol** 1996 Nov; 26(11):1139-50 (77 ref.)

Phylogenetic analysis of Perkinsus based on actin gene sequences. Reece KS, et al. **J Parasitol** 1997 Jun; 83(3):417-23

Extrachromosomal DNA in the Apicomplexa. Wilson RJ, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):1-16 (127 ref.)

Effects of nucleotide sequence alignment on phylogeny estimation: a case study of 18S rDNAs of apicomplexa. Morrison DA, et al. **Mol Biol Evol** 1997 Apr;14(4):428-41

GROWTH & DEVELOPMENT

Developmental synchrony of Ascogregarina taiwanensis (Apicomplexa: Lecudinidae) within Aedes albopictus (Diptera: Cuclicidae). Chen WJ, et al. **J Med Entomol** 1996 Mar;33(2):212-5

Ultrastructure and cytochemistry study of Goussia sparis (Protozoa: Apicomplexa) stages from the intestine of the gilthead sea bream Sparus aurata L. (Pisces: Teleostei). Alvarez-Pellitero P, et al. **Parasitol Res** 1997;83(1):24-33

PATHOGENICITY

Contribution of Perkinsus marinus extracellular products in the infection of eastern oysters (Crassostrea virginica). La Peyre JF, et al. **J Invertebr Pathol** 1996 Nov;68(3):312-3

PHYSIOLOGY

Ultrastructure of infection, development and gametocyst formation of Ascogregarina taiwanensis (Apicomplexa: Lecudinidae) in its mosquito host, Aedes albopictus (Diptera: Culicidae). Chen WJ, et al. **J Eukaryot Microbiol** 1997 Mar-Apr;44(2):101-8

The distribution, prevalence, and morphological features of the cystic stage of an apicomplexan parasite of native littleneck clams (Protothaca staminea) in British Columbia. Desser SS, et al. **J Parasitol** 1997 Aug;83(4):642-6

Appearance and spread of diseases among bivalve molluscs in the northern hemisphere in relation to international trade. Renault T. **Rev Sci Tech** 1996 Jun;15(2):551-61 (40 ref.)

ULTRASTRUCTURE

Ultrastructure and cytochemistry study of Goussia sparis (Protozoa: Apicomplexa) stages from the intestine of the gilthead sea bream Sparus aurata L. (Pisces: Teleostei). Alvarez-Pellitero P, et al. **Parasitol Res** 1997;83(1):24-33

A plastid of probable green algal origin in Apicomplexan parasites [see comments] Köhler S, et al. **Science** 1997 Mar 7;275(5305):1485-9. Comment in: Science 1997 Mar 7;275(5305):1422.

APIS VENOMS see **BEE VENOMS**

APLASIA CUTIS CONGENITA see **ECTODERMAL DYSPLASIA**

APLYSIA

Reversal of relative thresholds for synaptic facilitation and increased excitability induced by serotonin and tail nerve stimulation in Aplysia sensory neurons. Bunge SA, et al. **Neurobiol Learn Mem** 1997 May;67(3):259-63

ANATOMY & HISTOLOGY

Ontogeny of serotonergic neurons in Aplysia californica. Marois R, et al. **J Comp Neurol** 1997 Sep 29;386(3):477-90

Partial anatomical and physiological characterization and dissociated cell culture of the nervous system of the marine mollusc Aplysia kurodai. Lim CS, et al. **Mol Cells** 1997 Jun 30;7(3):399-407

Putative neuroendocrine cells in the Aplysia cerebral ganglion. Soinila S, et al. **Neurosci Res** 1996 Jul; 25(3):209-16

CHEMISTRY

Annexin-immunoreactive proteins in the nervous system and eye of the gastropods, Aplysia and Helix. Kerschbaum HH, et al. **Brain Res** 1997 Jan 23;746(1-2):133-40

Refolding of myoglobins of nonhomologous sequences by the island model. Kobayashi Y, et al. **J Protein Chem** 1997 Feb;16(2):83-98

Purification, primary structure, and neuronal localization of cerebral peptide 1 from Aplysia. Phares GA, et al. **Peptides** 1996;17(5):753-61

CYTOLOGY

Projection patterns and target tissues of the serotonergic cells in larval Aplysia californica. Marois R, et al. **J Comp Neurol** 1997 Sep 29;386(3):491-506

EMBRYOLOGY

Early FMRFamide-like immunoreactive cells in gastropod neurogenesis. Croll RP, et al. **Acta Biol Hung** 1995; 46(2-4):295-303

ENZYMOLOGY

Molecular cloning of Aplysia neuronal cDNAs that encode carboxypeptidases related to mammalian prohormone processing enzymes. Fan X, et al. **DNA Cell Biol** 1996 Nov; 15(11):937-45

Characterization of Aplysia carboxypeptidase E. Juvvadi S, et al. **FEBS Lett** 1997 May 19;408(2):195-200

A mechanism of adaptation to hypergravity in the statocyst of Aplysia californica. Pedrozo HA, et al. **Hear Res** 1996 Dec 1;102(1-2):51-62

Identification of an 8-lipoxygenase pathway in nervous tissue of Aplysia californica. Steel DJ, et al. **J Biol Chem** 1997 Jul 25;272(30):18673-81

Large-scale purification of Aplysia ADP-ribosylcyclase and measurement of its activity by fluorimetric assay. Lee HC, et al. **Methods Enzymol** 1997;280:331-40

Crystal structure of Aplysia ADP ribosyl cyclase, a homologue of the bifunctional ectozyme CD38. Prasad GS, et al. **Nat Struct Biol** 1996 Nov;3(11):957-64

GENETICS

Cloning and tissue distribution of the Aplysia Na+ channel alpha-subunit cDNA. Dyer JR, et al. **DNA Cell Biol** 1997 Mar;16(3):347-56

Gene expression and regulation of Aplysia californica prohormone convertases aPC1B and aPC2. Ouimet T, et al. **J Neurochem** 1997 Mar;68(3):1031-40

GROWTH & DEVELOPMENT

Maturation effects on the NMR microimaging characteristics of single neurons. Aiken NR, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1295-302

Myosin drives retrograde F-actin flow in neuronal growth cones. Lin CH, et al. **Biol Bull** 1997 Feb;192(1):183-5 (29 ref.)

An Aplysia cell adhesion molecule associated with site-directed actin filament assembly in neuronal growth cones. Thompson C, et al. **J Cell Sci** 1996 Dec;109 (Pt 12):2843-54

Projection patterns and target tissues of the serotonergic cells in larval Aplysia californica. Marois R, et al. **J Comp Neurol** 1997 Sep 29;386(3):491-506

Ontogeny of serotonergic neurons in Aplysia californica. Marois R, et al. **J Comp Neurol** 1997 Sep 29;386(3):477-90

Developmental dissociation of excitability and secretory ability in Aplysia bag cell neurons. Nick TA, et al. **J Neurophysiol** 1996 Nov;76(5):3351-9

METABOLISM

The role of glutamate reuptake in regulation of glutamate responses in Aplysia neurons. Carpenter DO, et al. **Acta Biol Hung** 1995;46(2-4):363-73

Early FMRFamide-like immunoreactive cells in gastropod neurogenesis. Croll RP, et al. **Acta Biol Hung** 1995; 46(2-4):295-303

Annexins in the gastropod nervous system. Kerschbaum HH, et al. **Acta Biol Hung** 1995;46(2-4):413-6

Detection of radionuclides in capillary electrophoresis using a phosphor-imaging detector. Tracht SE, et al. **Anal Chem** 1996 Nov 15;68(22):3922-7

Chronic stimulation increases acetylcholinesterase activity in old Aplysia. Peretz B, et al. **Behav Brain Res** 1996 Oct; 80(1-2):203-10

Evidence for the involvement of carbonic anhydrase and urease in calcium carbonate formation in the gravity-sensing organ of Aplysia californica. Pedrozo HA, et al. **Calcif Tissue Int** 1997 Sep;61(3):247-55

Synapsin-like molecules in Aplysia punctata and Helix pomatia: identification and distribution in the nervous system and during the formation of synaptic contacts in vitro. Cibelli G, et al. **Eur J Neurosci** 1996 Dec; 8(12):2530-43

The fate of newly synthesized hormone from neuroendocrine cells of Aplysia. Lee W, et al. **Gen Comp Endocrinol** 1997 Aug;107(2):201-11

New polyhalogenated monoterpenes from the sea hare Aplysia punctata. Ortega MJ, et al. **J Nat Prod** 1997 May; 60(5):482-4

3-Epi-aplykurodinone B, a new degraded sterol from Aplysia fasciata. Ortega MJ, et al. **J Nat Prod** 1997 May; 60(5):488-9

Immunocytological and biochemical localization and biological activity of the newly sequenced cerebral peptide

2 in Aplysia. Phares GA, et al. **J Neurosci** 1996 Dec 15; 16(24):7841–52

Identification of a vesicular pool of calcium channels in the bag cell neurons of Aplysia californica. White BH, et al. **J Neurosci** 1997 Mar 1;17(5):1582–95

NO decreases evoked quantal ACh release at a synapse of Aplysia by a mechanism independent of Ca2+ influx and protein kinase G. Mothet JP, et al. **J Physiol (Lond)** 1996 Jun 15;493 (Pt 3):769–84

PHYSIOLOGY

Effect of acetylcholinesterase inhibition on behavior is age-dependent in freely moving Aplysia. Srivatsan M, et al. **Behav Brain Res** 1996 May;77(1–2):115–24

Phase sensitivity and entrainment in a modeled bursting neuron. Demir SS, et al. **Biophys J** 1997 Feb;72(2 Pt 1):579–94

Ubiquitin C-terminal hydrolase is an immediate-early gene essential for long-term facilitation in Aplysia. Hegde AN, et al. **Cell** 1997 Apr 4;89(1):115–26

A simple systems approach to neural-immune communication. Clatworthy AL. **Comp Biochem Physiol A Physiol** 1996 Sep;115(1):1–10 (77 ref.)

Regulation of statoconia mineralization in Aplysia californica in vitro. Pedrozo HA, et al. **Connect Tissue Res** 1996; 35(1–4):317–23

The synapse between LE sensory neurons and gill motoneurons makes only a small contribution to the Aplysia gill-withdrawal reflex. Hickie C, et al. **Eur J Neurosci** 1997 Apr;9(4):627–36

Characterization of buccal motor programs elicited by a cholinergic agonist applied to the cerebral ganglion of Aplysia californica. Susswein AJ, et al. **J Comp Physiol [A]** 1996 Oct;179(4):509–24

The kinematics of swallowing in the buccal mass of Aplysia californica. Drushel RF, et al. **J Exp Biol** 1997 Feb;200 (Pt 4):735–52

Rhythmic activities of isolated and clustered pacemaker neurons and photoreceptors of Aplysia retina in culture. Jacklet J, et al. **J Neurobiol** 1996 Sep;31(1):16–28

Tetanic stimulation and cyclic adenosine monophosphate regulate segregation of presynaptic inputs on a common postsynaptic target neuron in vitro. Sun ZY, et al. **J Neurobiol** 1996 Feb;29(2):183–201

Sign stimulus activates a peptidergic neural system controlling reproductive behavior in Aplysia. Begnoche VL, et al. **J Neurophysiol** 1996 May;75(5):2161–6

Identification and characterization of cerebral ganglion neurons that induce swimming and modulate swim-related pedal ganglion neurons in Aplysia brasiliana. Gamkrelidze GN, et al. **J Neurophysiol** 1995 Oct;74(4):1444–62

Serotonergic modulation of a voltage-gated calcium current in parapodial swim muscle from Aplysia brasiliana. Laurienti PJ, et al. **J Neurophysiol** 1997 Mar;77(3):1496–502

Parapodial swim muscle in Aplysia brasiliana. I. Voltage-gated membrane currents in isolated muscle fibers. Laurienti PJ, et al. **J Neurophysiol** 1996 Sep;76(3):1517–30

Parapodial swim muscle in Aplysia brasiliana. II. Ca(2+)-dependent K+ currents in isolated muscle fibers and their blockade by chloride substitutes. Laurienti PJ, et al. **J Neurophysiol** 1996 Sep;76(3):1531–9

Realistic simulation of the Aplysia siphon-withdrawal reflex circuit: roles of circuit elements in producing motor output. Lieb JR Jr, et al. **J Neurophysiol** 1997 Mar;77(3):1249–68

Long-term depression of Aplysia sensorimotor synapses in cell culture: inductive role of a rise in postsynaptic calcium. Lin XY, et al. **J Neurophysiol** 1996 Sep;76(3):2111–4

Differential effects of 4-aminopyridine, serotonin, and phorbol esters on facilitation of sensorimotor connections in Aplysia. Sugita S, et al. **J Neurophysiol** 1997 Jan; 77(1):177–85

Serotonin and the small cardioactive peptides differentially modulate two motor neurons that innervate the same muscle fibers in Aplysia. Fox LE, et al. **J Neurosci** 1997 Aug 15;17(16):6064–74

Mechanosensory neurons innervating Aplysia siphon encode noxious stimuli and display nociceptive sensitization. Illich PA, et al. **J Neurosci** 1997 Jan 1;17(1):459–69

Clustered voltage-gated Na+ channels in Aplysia axons. Johnston WL, et al. **J Neurosci** 1996 Mar 1;16(5):1730–9

The role of K+ currents in frequency-dependent spike broadening in Aplysia R20 neurons: a dynamic-clamp analysis. Ma M, et al. **J Neurosci** 1996 Jul 1;16(13):4089–101

A cerebral central pattern generator in Aplysia and its connections with buccal feeding circuitry. Perrins R, et al. **J Neurosci** 1996 Nov 1;16(21):7030–45

An NF-kappaB-like transcription factor in axoplasm is rapidly inactivated after nerve injury in Aplysia. Povelones M, et al. **J Neurosci** 1997 Jul 1;17(13):4915–20

Site specificity of short-term and long-term habituation in the tail-elicited siphon withdrawal reflex of Aplysia. Stopfer M, et al. **J Neurosci** 1996 Aug 15;16(16):4923–32

Heterosynaptic facilitation of tail sensory neuron synaptic transmission during habituation in tail-induced tail and siphon withdrawal reflexes of Aplysia. Stopfer M, et al. **J Neurosci** 1996 Aug 15;16(16):4933–48

Costorage and corelease of modulatory peptide cotransmitters with partially antagonistic actions on the accessory radula closer muscle of Aplysia californica. Vilim FS, et al. **J Neurosci** 1996 Dec 15;16(24):8092–104

Release of peptide cotransmitters in Aplysia: regulation and functional implications. Vilim FS, et al. **J Neurosci** 1996 Dec 15;16(24):8105–14

An identified interneuron contributes to aspects of six different behaviors in Aplysia. Xin Y, et al. **J Neurosci** 1996 Aug 15;16(16):5266–79

Site-specific and sensory neuron-dependent increases in postsynaptic glutamate sensitivity accompany serotonin-induced long-term facilitation at Aplysia sensorimotor synapses. Zhu H, et al. **J Neurosci** 1997 Jul 1;17(13):4976–86

Partial anatomical and physiological characterization and dissociated cell culture of the nervous system of the marine mollusc Aplysia kurodai. Lim CS, et al. **Mol Cells** 1997 Jun 30;7(3):399–407

Mutation in the phosphorylation sites of MAP kinase blocks learning-related internalization of apCAM in Aplysia sensory neurons [see comments] Bailey CH, et al. **Neuron** 1997 Jun;18(6):913–24. Comment in: Neuron 1997 Jun;18(6):839–42.

Evidence for transmitter similarity of two classes of mechanoreceptor neurons in the cerebral ganglion of Aplysia. Gapon S, et al. **Neurosci Lett** 1996 Mar 1; 205(3):157–60

Parameters influencing ectopic gene expression in Aplysia neurons. Kaang BK. **Neurosci Lett** 1996 Dec 27; 221(1):29–32

Role of transforming growth factor-beta in long-term synaptic facilitation in Aplysia [see comments] Zhang F, et al. **Science** 1997 Feb 28;275(5304):1318–20. Comment in: Science 1997 Feb 28;275(5304):1277–8.

ULTRASTRUCTURE

Fine structure of the apical ganglion and its serotonergic cells in the larva of Aplysia californica. Marois R, et al. **Biol Bull** 1997 Jun;192(3):388–98

APNEA

Breath holding spells in a neonate [letter] Nair PM. **Indian Pediatr** 1995 Oct;32(10):1129–30

Breath-holding spells. Evans OB. **Pediatr Ann** 1997 Jul; 26(7):410–4 (15 ref.)

The apnea/SIDS debate [letter; comment] Guntheroth W, et al. **Pediatrics** 1997 Jun;99(6):924–5. Comment on: Pediatrics 1997 Jan;99(1):119–21.

Apnea prolongation via short-term inhibition. Dempsey JA, et al. **Sleep** 1996 Dec;19(10 Suppl):S160–3

BLOOD

Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Lee TC, et al. **Clin Pharmacol Ther** 1997 Jun;61(6):628–40

Breath-holding spells in a patient with transient erythroblastopenia of childhood [see comments] Tam DA, et al. **J Pediatr** 1997 Apr;130(4):651–3. Comment in: J Pediatr 1997 Apr;130(4):510–2.

CHEMICALLY INDUCED

Tetrodotoxin infusion: nonventilatory effects and role in toxicity models. Mackenzie CF, et al. **Acad Emerg Med** 1996 Dec;3(12):1106–12

Transient apnea with intramuscular ketamine [letter; comment] Green SM, et al. **Am J Emerg Med** 1997 Jul; 15(4):440–1. Comment on: Am J Emerg Med 1993 Mar;22(3):613–5. Comment on: Am J Emerg Med 1996 Oct;14(6):580–1.

Apnea and oxyhemoglobin desaturation after intramuscular ketamine administration in a 2-year-old child [letter; comment] Litman RS. **Am J Emerg Med** 1997 Sep; 15(5):547–8. Comment on: Am J Emerg Med 1996 Oct;14(6):580–1.

Respiratory arrest after intramuscular ketamine in a 2-year-old child [see comments] Mitchell RK, et al. **Am J Emerg Med** 1996 Oct;14(6):580–1. Comment in: Am J Emerg Med 1997 Jul;15(4):440–1. Comment in: Am J Emerg Med 1997 Sep;15(5):547–8.

Mivacurium apnoea [letter] Ireland RM. **Anaesth Intensive Care** 1996 Jun;24(3):401

Midazolam co-induction and laryngeal mask insertion [letter; comment] Bellman MH. **Anaesthesia** 1997 Jan;52(1):92. Comment on: Anaesthesia 1996 Aug;51(8):782–4.

Three sudden postoperative respiratory arrests associated with epidural opioids in patients with sleep apnea. Ostermeier AM, et al. **Anesth Analg** 1997 Aug;85(2):452–60 (45 ref.)

Apnea after immunization of preterm infants. Sánchez PJ, et al. **J Pediatr** 1997 May;130(5):746–51

[Prolonged apnea after suxamethonium administration during staphylococcal toxic shock] Blanloeil Y, et al. **Ann Fr Anesth Reanim** 1996;15(2):189–91 (Eng. Abstr.) **(Fre)**

[Apnea and retarded awakening following oral premedication with midazolam (letter)] Rufino-Ruiz J, et al. **Rev Esp Anestesiol Reanim** 1997 Mar;44(3):129 **(Spa)**

CLASSIFICATION

Use of a magnified cardiac airflow oscillation to classify neonatal apnea. Lemke RP, et al. **Am J Respir Crit Care Med** 1996 Nov;154(5):1537–42

Impact of central, obstructive and mixed apnea on cerebral hemodynamics in preterm infants. Jenni OG, et al. **Biol Neonate** 1996;70(2):91–100

COMPLICATIONS

A 6-week-old girl with persistent apnea and worsening pulmonary disease. Vernacchio L, et al. **Curr Opin Pediatr** 1996 Oct;8(5):459–66 (67 ref.)

Laryngologic management of infants with the Chiari II syndrome. Linder A, et al. **Int J Pediatr Otorhinolaryngol** 1997 Apr 11;39(3):187–97

Symptoms, sweating and reactivity of infants who die of SIDS compared with community controls. New Zealand National Cot Death Study Group. Taylor BJ, et al. **J Paediatr Child Health** 1996 Aug;32(4):316–22

Role of apnea in nonaccidental head injury. Johnson DL, et al. **Pediatr Neurosurg** 1995;23(6):305–10

CONGENITAL

Brainstem tegmental necrosis and olivary hypoplasia: a lethal entity associated with congenital apnea. Cortez SC, et al. **J Neuropathol Exp Neurol** 1996 Jul;55(7):841–9

DIAGNOSIS

Ambulatory monitoring devices and the forensic autopsy. Weitzman JB, et al. **Am J Forensic Med Pathol** 1996 Sep; 17(3):210–6

Apnoea testing in children [letter; comment] Sharples A, et al. **Anaesthesia** 1997 May;52(5):503. Comment on: Anaesthesia 1997 Jan;52(1):87.

PaCO2 and apnoea testing for brain stem death [letter] [see comments] Visram A, et al. **Anaesthesia** 1997 Jan;52(1):87 . Comment in: Anaesthesia 1997 May;52(5):503.

Spectral analysis of an acoustic respiratory signal with a view to developing an apnoea monitor. Ajmani A, et al. **Australas Phys Eng Sci Med** 1996 Jun;19(2):46–52

Documented home apnea monitoring: effect on compliance, duration of monitoring, and validation of alarm reporting. Gibson E, et al. **Clin Pediatr (Phila)** 1996 Oct;35(10):505–13

An apnea monitor using a rapid-response hygrometer. Tatara T, et al. **J Clin Monit** 1997 Jan;13(1):5–9

Reduction of motion artefacts during paediatric/infant apnoea monitoring. Mayotte MJ, et al. **Med Biol Eng Comput** 1996 Jan;34(1):93–6

Apnea testing [letter; comment] Jeret JS. **Neurology** 1996 Apr;46(4):1192–3. Comment on: Neurology 1995 May;45(5):966–9.

Improved monitoring of preterm infants by Fuzzy Logic. Wolf M, et al. **Technol Health Care** 1996 Aug;4(2):193–201

Use and abuse of apnea monitors—1995. Position statement of the Texas Pediatric Society Committee on Fetus and Newborn. Speer ME. **Tex Med** 1996 Sep;92(9):54–5

DRUG THERAPY

Improved recovery from laryngeal-stimulation-induced apnea by alpha-adrenergic blockade in adult rabbits. Beyaert C, et al. **Biol Neonate** 1996;70(6):359–62

Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. Lee TC, et al. **Br J Clin Pharmacol** 1996 Mar;41(3):191–200

Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity. Lee TC, et al. **Ther Drug Monit** 1996 Jun;18(3):288–93

EMBRYOLOGY

Fetal breathing movements are associated with changes in compliance of the left ventricle. Miyague NI, et al. **Fetal Diagn Ther** 1997 Mar-Apr;12(2):72–5

ETIOLOGY

Respiratory syncytial virus infection enhances the response to laryngeal chemostimulation and inhibits arousal from sleep in young lambs. Lindgren C, et al. **Acta Paediatr** 1996 Jul;85(7):789–97

Effects of bottle feeding and two different methods of gavage feeding on oxygenation and breathing patterns in preterm infants. Poets CF, et al. **Acta Paediatr** 1997 Apr; 86(4):419–23

Prolonged apnea in the preterm infant is not a random event. al-Saedi SA, et al. **Am J Perinatol** 1997 Apr;14(4):195–200

Laryngeal reflex apnea is blunted during and after hindlimb muscle contraction in sheep. Haouzi P, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R586–92

End-tidal oxygraphy and safe duration of apnoea in young adults and elderly patients [letter; comment] Snowdon SL. **Anaesthesia** 1997 Jun;52(6):606–7. Comment on: Anaesthesia 1997 Feb;52(2):175–8.

Do anxiety or hypocapnia predispose to apnoea after induction of anaesthesia? Drummond GB, et al. **Br J Anaesth** 1997 Feb;78(2):153–6

A case of infantile spasms: epileptic apnea as partial seizures at onset. Kamei A, et al. **Brain Dev** 1996 May-Jun; 18(3):239–41

Debunking myths of chronic obstructive lung disease [editorial; comment] Hoyt JW. **Crit Care Med** 1997 Sep; 25(9):1450–1. Comment on: Crit Care Med 1997 Sep;25(9):1522–6.

Mesenchymal liver hamartoma in a newborn; case report. Balmer B, et al. **Eur J Pediatr Surg** 1996 Oct;6(5):303–5

Perils of the recovery position: neurapraxia of radial and

common peroneal nerve [letter] Kumar P, et al. **J Accid Emerg Med** 1996 Jan;13(1):69–70

Covert video surveillance and the principle of double effect: a response to criticism [comment] [see comments] Shinebourne EA. **J Med Ethics** 1996 Feb;22(1):26–31. Comment on: J Med Ethics 1996 Feb;22(1):22–5. Comment in: J Med Ethics 1996 Dec;22(6):349–50; discussion 351.

Guidelines for the multi-agency management of patients suspected or at risk of suffering from life-threatening abuse resulting in cyanotic-apnoeic episodes. North Staffordshire Hospital Trust, Staffordshire Social Services and Staffordshire Police. Southall DP, et al. **J Med Ethics** 1996 Feb;22(1):16–21

Brainstem tegmental necrosis and olivary hypoplasia: a lethal entity associated with congenital apnea. Cortez SC, et al. **J Neuropathol Exp Neurol** 1996 Jul;55(7):841–9

Breath-holding spells: waiting to inhale, waiting for systole, or waiting for iron therapy? [editorial; comment] Hannon DW. **J Pediatr** 1997 Apr;130(4):510–2. Comment on: J Pediatr 1997 Apr;130(4):547–50. Comment on: J Pediatr 1997 Apr;130(4):647–51. Comment on: J Pediatr 1997 Apr;130(4):651–3.

Anemia in children with breath-holding spells [letter; comment] Yilmaz S, et al. **J Pediatr** 1996 Mar;128(3):440–1 . Comment on: J Pediatr 1995 Mar;126(3):395–7.

Anaesthetic management of children with Joubert syndrome. Habre W, et al. **Paediatr Anaesth** 1997;7(3):251–3

Respiratory arrest in Treacher-Collins syndrome: implications for dental management: case report. Shapira J, et al. **Pediatr Dent** 1996 May-Jun;18(3):242–4

[Lungs and underwater diving] Héritier F. **Rev Med Suisse Romande** 1997 Jun;117(6):475–8 (28 ref.) **(Fre)**

[Respiratory arrest after a ventriculoscopic surgery in infants: two case reports] Enya S, et al. **Masui** 1997 Mar; 46(3):416–20 (Eng. Abstr.) **(Jpn)**

[Automatic movements of extremities induced in primary massive brain lesion with apneic coma] Nokura K, et al. **Rinsho Shinkeigaku** 1997 Mar;37(3):198–207 (Eng. Abstr.) **(Jpn)**

[The possibility of the occurrence of hyperventilation apnea and loss of consciousness] Potapov AV. **Voen Med Zh** 1996 Sep;317(9):46–8, 80 (Eng. Abstr.) **(Rus)**

[Clinical significance of episodes of apnea in babies] Martínez-Bermejo A, et al. **Rev Neurol** 1997 Apr; 25(140):545–7 (Eng. Abstr.) **(Spa)**

GENETICS

Family pedigree analysis of children with severe breath-holding spells [see comments] DiMario FJ Jr, et al. **J Pediatr** 1997 Apr;130(4):647–51. Comment in: J Pediatr 1997 Apr;130(4):510–2.

METABOLISM

Prospective evaluation of two dosing equations for theophylline in premature infants. Bhatt-Mehta V, et al. **Pharmacotherapy** 1996 Sep-Oct;16(5):769–76

Reflex reversal of apnoeic episodes by electrical stimulation of upper airway in cats. Tomori Z, et al. **Respir Physiol** 1995 Dec;102(2-3):175–85

PATHOLOGY

Contribution of Sinerem used as blood-pool contrast agent: detection of cerebral blood volume changes during apnea in the rabbit. Berry I, et al. **Magn Reson Med** 1996 Sep; 36(3):415–9

PHYSIOPATHOLOGY

Adrenalectomy reduces the ability of newborn rats to gasp and survive anoxia. Yuan SZ, et al. **Acta Physiol Scand** 1997 Apr;159(4):285–92

Prolonged hemodynamic effects of intermittent, brief chemoreceptor stimulation in humans. Trzebski A, et al. **Adv Exp Med Biol** 1996;410:421–9

Low baseline oxygenation predisposes preterm infants to mixed apneas during inhalation of 100% oxygen. Zia Haider A, et al. **Am J Perinatol** 1996 Aug;13(6):363–9

Laryngeal reflex apnea is blunted during and after hindlimb muscle contraction in sheep. Haouzi P, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R586–92

Heart rate variability during artificial ventilation and apnea in brain-damaged rabbits. Kawamoto M, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):H410–6

Lack of peripheral modulation of cardiovascular central oscillatory autonomic activity during apnea in humans. Passino C, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H123–9

Influence of apnea on cardiovascular responses to neck suction during exercise. Sundblad P, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1370–4

Reflex stimulation of renal sympathetic nerve activity and blood pressure in response to apnea. O'Donnell CP, et al. **Am J Respir Crit Care Med** 1996 Dec;154(6 Pt 1):1763–70

End-tidal oxygraphy and safe duration of apnoea in young adults and elderly patients [see comments] Bhatia PK, et al. **Anaesthesia** 1997 Feb;52(2):175–8. Comment in: Anaesthesia 1997 Jun;52(6):606–7.

Spectral analysis of an acoustic respiratory signal with a view to developing an apnoea monitor. Ajmani A, et al. **Australas Phys Eng Sci Med** 1996 Jun;19(2):46–52

Impact of central, obstructive and mixed apnea on cerebral hemodynamics in preterm infants. Jenni OG, et al. **Biol Neonate** 1996;70(2):91–100

The effects of induced apneic episodes on cerebral cortical oxygenation in newborn piglets. Tammela OK, et al. **Brain Res** 1996 Nov 25;741(1-2):160–5

Developmental patterns of heart rate and variability in prematurely-born infants with apnea of prematurity. Henslee JA, et al. **Early Hum Dev** 1997 Jan 3;47(1):35–50

Predominant role of peripheral chemoreceptors in the termination of apnea in maturing newborn lambs. Delacourt C, et al. **J Appl Physiol** 1996 Mar;80(3):892–8

PCO2 affects tracheal tone during apnea in anesthetized dogs. Dickstein J, et al. **J Appl Physiol** 1996 Sep;81(3):1184–9

Negative pressure-induced deformation of the upper airway causes central apnea in awake and sleeping dogs. Harms CA, et al. **J Appl Physiol** 1996 May;80(5):1528–39

Airway obstruction during sleep increases blood pressure without arousal. O'Donnell CP, et al. **J Appl Physiol** 1996 Mar;80(3):773–81

Temporal relationships of ventilatory failure, pump failure, and diaphragm fatigue. Sassoon CS, et al. **J Appl Physiol** 1996 Jul;81(1):238–45

Mechanisms of circulatory depression during simulated central apneas in the anesthetized dog. Tarasiuk A, et al. **J Basic Clin Physiol Pharmacol** 1994 Jul-Dec;5(3-4):253–68

Respiratory sinus arrhythmia in children with severe cyanotic breath-holding spells. DiMario FJ Jr, et al. **J Child Neurol** 1997 Jun;12(4):260–2

Study of the safe threshold of apneic period in children during anesthesia induction. Xue FS, et al. **J Clin Anesth** 1996 Nov;8(7):568–74

Transition times to oral feeding in premature infants with and without apnea. Mandich MB, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Nov-Dec; 25(9):771–6

Beta-endorphin immunoreactivity levels in CSF after laryngeal chemoreflex activation correlate with apnoea duration in piglets. Storm H, et al. **J Perinat Med** 1996; 24(4):363–72

The effect of maternal smoking during pregnancy on sleep respiratory and arousal patterns in neonates. Tirosh E, et al. **J Perinatol** 1996 Nov-Dec;16(6):435–8

Measurement of right ventricular performance during apnea in patients with acute lung injury. Jellinek H, et al. **J Trauma** 1997 Jun;42(6):1062–7

The Kölliker-Fuse nucleus mediates the trigeminally induced apnoea in the rat. Dutschmann M, et al. **Neuroreport** 1996 May 31;7(8):1432–6

Temporal relationship between pauses in nasal airflow and desaturation in preterm infants. Watkin SL, et al. **Pediatr Pulmonol** 1996 Mar;21(3):171–5

Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. Eichenwald EC, et al. **Pediatrics** 1997 Sep;100(3 Pt 1):354–9

Post-hyperventilation hypopnea in humans during NREM sleep. Badr MS, et al. **Respir Physiol** 1996 Feb; 103(2):137–45

Breathing pattern awake and asleep in myotonic dystrophy. Ververs CC, et al. **Respiration** 1996;63(1):1–7

[Measurement of carbon monoxide transfer factor using the apnea method] Roche N. **Rev Mal Respir** 1996 Dec; 13(6):607–8 **(Fre)**

[Acute, arterial hypoxia: a new method in diagnosis and O2 administration (editorial)] Mertzlufft F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Aug; 31(6):368–70 **(Ger)**

[The effect of CO2 and apnea on cochlear and middle ear blood flow in guinea pigs] Yamamoto J, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1997 Jan;100(1):36–44 (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Comparison of continuous infusion of fentanyl to bolus dosing in neonates after surgery. Vaughn PR, et al. **J Pediatr Surg** 1996 Dec;31(12):1616–23

Home documented monitoring of cardiorespiratory pattern and oxygen saturation in healthy infants. Hunt CE, et al. **Pediatr Res** 1996 Feb;39(2):216–22

PSYCHOLOGY

Anxiety sensitivity, suffocation fear, trait anxiety, and breath-holding duration as predictors of response to carbon dioxide challenge. Eke M, et al. **Behav Res Ther** 1996 Aug; 34(8):603–7

Voluntary breath holding: not a suitable probe of the suffocation alarm in panic disorder. Willem Van der Does AJ. **Behav Res Ther** 1997 Aug;35(8):779–84

SURGERY

Laryngologic management of infants with the Chiari II syndrome. Linder A, et al. **Int J Pediatr Otorhinolaryngol** 1997 Apr 11;39(3):187–97

THERAPY

Efficacy of cardiopulmonary resuscitation using intratracheal insufflation. Brochard L, et al. **Am J Respir Crit Care Med** 1996 Nov;154(5):1323–9

Effect of blood transfusion on apnoea, bradycardia and hypoxaemia in preterm infants. Poets CF, et al. **Eur J Pediatr** 1997 Apr;156(4):311–6

Effectiveness of iron therapy on breath-holding spells [see comments] Daoud AS, et al. **J Pediatr** 1997 Apr; 130(4):547–50. Comment in: J Pediatr 1997 Apr;130(4):510–2.

VETERINARY

Use of the respiratory stimulant doxapram in southern elephant seals (Mirounga leonina). Woods R, et al. **Vet Rec** 1996 May 25;138(21):514–7

APNEA, CENTRAL see **SLEEP APNEA SYNDROMES**

APNEA, OBSTRUCTIVE see **SLEEP APNEA SYNDROMES**

APNEA, SLEEP see **SLEEP APNEA SYNDROMES**

APO-A see **APOLIPOPROTEINS A**

APO A-I see **APOLIPOPROTEIN A-I**

APO A-II see **APOLIPOPROTEIN A-II**

APO-B see **APOLIPOPROTEINS B**

APO-C see **APOLIPOPROTEINS C**

APO-E see **APOLIPOPROTEINS E**

APO-1 ANTIGEN see **ANTIGENS, CD95**

APOCRINE GLANDS

see related

SWEATING

The hybrid epidermoid and apocrine cyst. A combination of apocrine hidrocystoma and epidermal inclusion cyst. Andersen WK, et al. **Am J Dermatopathol** 1996 Aug; 18(4):364–6

Apocrine adenocarcinoma presenting as a large ulcerated axillary mass. Zehr KJ, et al. **Dermatol Surg** 1997 Jul; 23(7):585–7

Apocrine gland adenocarcinoma and pheochromocytoma in a cat. Chun R, et al. **J Am Anim Hosp Assoc** 1997 Jan-Feb; 33(1):33–6

ABNORMALITIES

Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Bamshad M, et al. **Nat Genet** 1997 Jul;16(3):311–5

ANATOMY & HISTOLOGY

Infraorbital glands of a male Formosan serow (Capricornis crispus swinhoei). Atoji Y, et al. **Eur J Morphol** 1996; 34(2):87–94

METABOLISM

Sweat glands accumulate Tc-99m MIBI. Jonsson C, et al. **Clin Nucl Med** 1996 Aug;21(8):612–4

PATHOLOGY

Duct disruption, a new explanation of miliaria. Shuster S. **Acta Derm Venereol** 1997 Jan;77(1):1–3

Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. Brehler R, et al. **Am J Dermatopathol** 1997 Feb;19(1):73–8

Clear cell hidradenoma associated with the folliculo-sebaceous-apocrine unit. Histologic study of five cases. Gianotti R, et al. **Am J Dermatopathol** 1997 Aug; 19(4):351–7

Nevus sebaceus with apocrine and sebaceous differentiation. Ng WK. **Am J Dermatopathol** 1996 Aug;18(4):420–3

Apocrine hidrocystoma: report of a case. Armstrong AP, et al. **Br J Oral Maxillofac Surg** 1996 Aug;34(4):335–7

Apocrine cystadenoma, apocrine hidrocystoma, and eccrine hidrocystoma: three distinct tumors defined by expression of keratins and human milk fat globulin 1. de Viragh PA, et al. **J Cutan Pathol** 1997 Apr;24(4):249–55

Papillary apocrine fibroadenoma of the vulva. Higgins CM, et al. **J Cutan Pathol** 1997 Apr;24(4):256–60

Apocrine cystadenoma arising on the ear [letter] Mitsuishi T, et al. **J Dermatol** 1996 Aug;23(8):583–4 (9 ref.)

A unique case of squamous cell carcinoma showing adenocarcinomatous features with focal apocrine differentiation. Yamamoto O, et al. **J Dermatol** 1997 Apr; 24(4):249–54

Familial Lafora body disease of late onset: report of four cases in one family and a review of the literature. Footitt DR, et al. **J Neurol** 1997 Jan;244(1):40–4 (32 ref.)

Apocrine gland tumor of the eyelid in a dog. Hirai T, et al. **Vet Pathol** 1997 May;34(3):232–4

APODEMUS see **MURIDAE**

APOENZYMES

ANTAGONISTS & INHIBITORS

[Modification of cytochrome P-450 apoenzyme during its oxidative self-inactivation in a reconstituted

APOENZYMES

mono-oxygenase system] Zgoda VG, et al.
Vopr Med Khim 1996 Jul-Sep;42(3):203-10 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Production, characterization, and reconstitution of recombinant quinoprotein glucose dehydrogenase (soluble type; EC 1.1.99.17) apoenzyme of Acinetobacter calcoaceticus. Olsthoorn AJ, et al.
Arch Biochem Biophys 1996 Dec 1;336(1):42-8

Expression of CYP2B1 in freshly isolated and proliferating cultures of epithelial rat lung cells. Låg M, et al.
Exp Lung Res 1996 Nov-Dec;22(6):627-49

CHEMISTRY

Study of non-covalent enzyme-inhibitor complexes of aldose reductase by electrospray mass spectrometry. Potier N, et al. **Adv Exp Med Biol** 1997;414:453-4

Performance of the apoenzyme-membrane sensors for microdetermination of heavy metal ions. Satoh I.
Ann N Y Acad Sci 1996 Oct 12;799:514-8

Reconstitution of the quinoprotein methanol dehydrogenase from inactive Ca(2+)-free enzyme with Ca2+, Sr2+ or Ba2+. Goodwin MG, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):839-42

Gene cloning, purification, and characterization of NfsB, a minor oxygen-insensitive nitroreductase from Escherichia coli, similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri. Zenno S, et al.
J Biochem (Tokyo) 1996 Oct;120(4):736-44

Enantioseparation using apoenzymes immobilized in a porous polymeric membrane. Lakshmi BB, et al. **Nature** 1997 Aug 21;388(6644):758-60

GENETICS

PHR2 of Candida albicans encodes a functional homolog of the pH-regulated gene PHR1 with an inverted pattern of pH-dependent expression. Mühlschlegel FA, et al.
Mol Cell Biol 1997 Oct;17(10):5960-7

An enzyme similar to animal type II photolyases mediates photoreactivation in Arabidopsis. Ahmad M, et al.
Plant Cell 1997 Feb;9(2):199-207

An Arabidopsis photolyase mutant is hypersensitive to ultraviolet-B radiation. Landry LG, et al.
Proc Natl Acad Sci U S A 1997 Jan 7;94(1):328-32

METABOLISM

Reconstitution of the quinoprotein methanol dehydrogenase from inactive Ca(2+)-free enzyme with Ca2+, Sr2+ or Ba2+. Goodwin MG, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):839-42

Discovery of a novel mechanism for cofactor assembly by Escherichia coli porphobilinogen deaminase. Awan SJ, et al. **Biochem Soc Trans** 1997 Feb;25(1):79S

Reconstitution of the holoenzyme form of Escherichia coli porphobilinogen deaminase from apoenzyme with porphobilinogen and preuroporphyrinogen: a study using circular dichroism spectroscopy. Awan SJ, et al.
Biochemistry 1997 Jul 29;36(30):9273-82

Zn(II) dependence of the Aeromonas hydrophila AE036 metallo-beta-lactamase activity and stability. Hernandez Valladares M, et al. **Biochemistry** 1997 Sep 23; 36(38):11534-41

Enzymatic diagnosis of holocarboxylase synthetase deficiency using apo-carboxyl carrier protein as a substrate. Suzuki Y, et al. **Clin Chim Acta** 1996 Jul 15;251(1):41-52

APOFERRITIN

ANALOGS & DERIVATIVES

Immunomagnetic isolation of magnetoferritin-labeled cells in a modified ferrograph. Zborowski M, et al.
Cytometry 1996 Jul 1;24(3):251-9

CHEMISTRY

Two-dimensional crystals of apoferritin. Yoshimura H.
Adv Biophys 1997;34:93-107

ULTRASTRUCTURE

Single molecular functional assay of ferritin arrays. Yamaki M. **Adv Biophys** 1997;34:191-203

Two-dimensional crystals of apoferritin. Yoshimura H.
Adv Biophys 1997;34:93-107

APOLIPOPROTEIN A-I

Role of HDL phospholipid in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats. Fournier N, et al. **J Lipid Res** 1996 Aug;37(8):1704-11

ANALYSIS

Isotope dilution--mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Barr JR, et al. **Clin Chem** 1996 Oct;42(10):1676-82

Apolipoprotein AI isoforms in serum determined by isoelectric focusing and immunoblotting. Contiero E, et al. **Electrophoresis** 1997 Jan;18(1):122-6

Apolipoprotein AIV of human interstitial fluid is associated with apolipoprotein AI-containing but not with AII-containing particles. Ghalim N, et al.
Int J Clin Lab Res 1996;26(4):224-8

Comparison of haptoglobin and apolipoprotein A-I on biliary lipid particles involved in cholesterol crystallization. Yamashita G, et al. **J Gastroenterol Hepatol** 1996 Aug; 11(8):738-45

Structural relationships between nascent apoA-I-containing particles that are extracellularly assembled in cell culture. Forte TM, et al. **J Lipid Res** 1996 May;37(5):1076-85

The significance of renal tubular deposition of apolipoprotein A1 [letter; comment] Streather CP, et al. **Nephron** 1996; 74(1):235. Comment on: Nephron 1995;70(3):348-52.

BIOSYNTHESIS

Synthesis and messenger ribonucleic acid expression of apolipoproteins E and A-I by the bovine corpus luteum during the estrous cycle and pregnancy. Ndikum-Moffor FM, et al. **Biol Reprod** 1997 Mar;56(3):745-56

Rapid movement of newly synthesized chicken apolipoprotein AI to trans-Golgi network and its secretion in Madin-Darby canine kidney cells. Banerjee D, et al.
Exp Cell Res 1997 Sep 15;235(2):334-44

Expression of mRNA for ovarian steroid-stimulating factor (apolipoprotein A-I and apolipoprotein A-I-like protein) in human granulosa cells. Pascher E, et al.
Exp Clin Endocrinol Diabetes 1997;105(2):122-4

Regulation of human apolipoprotein A-I gene expression by gramoxone. Cuthbert C, et al. **J Biol Chem** 1997 Jun 6; 272(23):14954-60

Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene. Naganawa S, et al.
J Clin Invest 1997 Apr 15;99(8):1958-65

Effect of ethanol on the synthesis and secretion of apoA-I- and apoB-containing lipoproteins in HepG2 cells. Dashti N, et al. **J Lipid Res** 1996 Apr;37(4):810-24

Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. Francone OL, et al. **J Lipid Res** 1996 Jun;37(6):1268-77

Apolipoprotein A1 expression in young and aged rats is modulated by dietary carbohydrates. Mooradian AD, et al. **Metabolism** 1997 Oct;46(10):1132-6

Biosynthesis and compartmentalization of Po, apolipoprotein A-I, and lipids in the myelinating chick sciatic nerve. Lemieux MJ, et al. **Neurochem Res** 1995 Oct;20(10):1239-48

BLOOD

Serum apolipoproteins A-I and B in male and female full-term newborns of the Toledo study (Spain). Bastida S, et al. **Acta Paediatr** 1996 Jun;85(6):750-2

Alcohol feeding impedes early atherosclerosis in low-density lipoprotein receptor knockout mice: factors in addition to high-density lipoprotein-apolipoprotein A1 are involved. Dai J, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):11-8

Age-related changes in the responsiveness of apolipoprotein A1 to thyroid hormone. Mooradian AD, et al.
Am J Physiol 1996 Dec;271(6 Pt 2):R1602-7

Decreased serum apolipoprotein B-100 and A-I concentrations in cows with ketosis and left displacement of the abomasum. Oikawa S, et al. **Am J Vet Res** 1997 Feb;58(2):121-5

Optimized automated apolipoprotein A-I assays as markers for coronary artery disease. Levinson SS, et al.
Arch Pathol Lab Med 1997 Jul;121(7):678-84

Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy. McPherson R, et al.
Arterioscler Thromb Vasc Biol 1996 Nov;16(11):1340-6

Increased esterification of cholesterol and transfer of cholesteryl ester to apo B-containing lipoproteins in Type 2 diabetes: relationship to serum lipoproteins A-I and A-II. Jones RJ, et al. **Atherosclerosis** 1996 Jan 26;119(2):151-7

Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol. Kamboh MI, et al. **Atherosclerosis** 1996 Dec 20; 127(2):255-62

LpA-I levels do not reflect pre beta1-HDL levels in human plasma. Miida T, et al. **Atherosclerosis** 1997 Sep; 133(2):221-6

HDL subparticles and coronary artery disease in NIDDM. O'Brien T, et al. **Atherosclerosis** 1996 Apr 5;121(2):285-91

Abnormalities of serum apo A1 containing lipoprotein particles in patients with primary biliary cirrhosis. O'Kane MJ, et al. **Atherosclerosis** 1997 Jun;131(2):203-10

In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107-->0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency. Tilly-Kiesi M, et al. **Atherosclerosis** 1997 Feb 10;128(2):213-22

Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Castro G, et al. **Biochemistry** 1997 Feb 25; 36(8):2243-9

Decreased serum apolipoprotein A-I concentrations in cows infected with Salmonella typhimurium. Oikawa S, et al.
Can J Vet Res 1997 Jul;61(3):182-6

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. Lamarche B, et al.
Circulation 1996 Aug 1;94(3):273-8

Interaction of the cholesteryl ester transfer protein I405V polymorphism with alcohol consumption in smoking and non-smoking healthy men, and the effect on plasma HDL cholesterol and apoAI concentration. Gudnason V, et al.
Clin Genet 1997 Jan;51(1):15-21

High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Frénais R, et al.
Diabetologia 1997 May;40(5):578-83

Relationship between low-density lipoprotein size and apolipoprotein A-I-containing particles: the ECTIM study. Luc G, et al. **Eur J Clin Invest** 1997 Mar;27(3):242-7

Effect of bezafibrate on HDL with APO A-I and APO A-II and on HDL with APO A-I without APO A-II in hyperlipidaemic patients. Branchi A, et al.
Int J Clin Pharmacol Res 1995;15(4):153-8

ApoA-II/apoA-I molar ratio in the HDL particle influences phospholipid transfer protein-mediated HDL interconversion. Pussinen PJ, et al. **J Lipid Res** 1997 Jan; 38(1):12-21

Monomethylethanolamine reduces plasma triacylglycerols and apolipoprotein B and increases apolipoprotein A-I rats without induction of fatty liver. Rusiñol AE, et al.
J Lipid Res 1996 Nov;37(11):2296-304

Chromatographic methods for quantitation of apolipoprotein A-I. Anantharamaiah GM, et al. **Methods Enzymol** 1996; 263:267-82

Heterogeneity of high-density lipoproteins and apolipoprotein A-I as related to quantification of apolipoprotein A-I. Kunitake ST, et al.
Methods Enzymol 1996;263:260-7

Haptoglobin-related protein and apolipoprotein AI are components of the two trypanolytic factors in human serum. Tomlinson S, et al. **Mol Biochem Parasitol** 1997 May;86(1):117-20

Serum levels of carnitine, apolipoprotein A I, and apolipoprotein B in children with nephrotic proteinuria [letter] Bircan Z, et al. **Pediatr Nephrol** 1996 Oct;10(5):680

The role of apolipoprotein AI domains in lipid binding. Davidson WS, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13605-10

Apolipoprotein A and biological half-life of prostaglandin I2 in HIV-1 infection. Pirich C, et al. **Thromb Res** 1996 Jan 15;81(2):213-18

[HDL-cholesterol or apolipoprotein AI: which parameter to choose?] Bigot-Corbel E, et al.
Ann Biol Clin (Paris) 1996;54(10-11):349-52 (Eng. Abstr.) **(Fre)**

[Prognostic value of serum levels of cholesterol and apolipoprotein A1 in pulmonary cancer (letter)] Charet JC, et al. **Ann Biol Clin (Paris)** 1997 Jan-Feb;55(1):52 **(Fre)**

[Evaluation of atherogenic risk in homozygous sickle cell disease: study of lipid and apolipoprotein AI and B plasma levels] Monnet PD, et al. **Bull Soc Pathol Exot** 1996; 89(4):278-81 (Eng. Abstr.) **(Fre)**

[Subfractionation of serum high density lipoproteins and its clinical significance] Hua F, et al. **Rinsho Byori** 1996 Aug; 44(8):802-6 (Eng. Abstr.) **(Jpn)**

[Apolipoprotein A1 and biliary lithiasis in hepatic cirrhosis] Baranda J, et al. **Acta Med Port** 1996 Jul-Sep;9(7-9):203-6 (Eng. Abstr.) **(Por)**

CHEMISTRY

Activation of lecithin cholesterol acyltransferase by a disulfide-linked apolipoprotein A-I dimer. Calabresi L, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):345-9

Deletion of central alpha-helices in human apolipoprotein A-I: effect on phospholipid association. Frank PG, et al.
Biochemistry 1997 Feb 18;36(7):1798-806

Denaturation and self-association of apolipoprotein A-I investigated by electrophoretic techniques. Gianazza E, et al. **Biochemistry** 1997 Jun 24;36(25):7898-905

Structural analysis of apolipoprotein A-I: limited proteolysis of methionine-reduced and -oxidized lipid-free and lipid-bound human apo A-I. Roberts LM, et al.
Biochemistry 1997 Jun 17;36(24):7615-24

Truncation of the amino terminus of human apolipoprotein A-I substantially alters only the lipid-free conformation. Rogers DP, et al. **Biochemistry** 1997 Jan 14;36(2):288-300

Effect of the apolipoprotein A-I and surface lipid composition of reconstituted discoidal HDL on cholesterol efflux from cultured fibroblasts. Zhao Y, et al.
Biochemistry 1996 Dec 24;35(51):16510-8

Structure of apo A-I high-density lipoproteins: a review. Titov VN. **Biochemistry (Mosc)** 1997 Jan;62(1):1-14 (73 ref.)

Apolipoprotein A-I structural modification and the functionality of reconstituted high density lipoprotein particles in cellular cholesterol efflux. Gillotte KL, et al.
J Biol Chem 1996 Sep 27;271(39):23792-8

Evolution of mammalian apolipoprotein A-I and conservation of antigenicity: correlation with primary and secondary structure. Collet X, et al. **J Lipid Res** 1997 Apr; 38(4):634-44

High yield overexpression and characterization of human recombinant proapolipoprotein A-I. McGuire KA, et al.
J Lipid Res 1996 Jul;37(7):1519-28

Long-chain polyunsaturated fatty acids in the sn-2 position

of phosphatidylcholine decrease the stability of recombinant high density lipoprotein apolipoprotein A-I and the activation energy of the lecithin:cholesterol acyltransferase reaction. Parks JS, et al. **J Lipid Res** 1997 Feb;38(2):266-75

Heterogeneity of high-density lipoproteins and apolipoprotein A-I as related to quantification of apolipoprotein A-I. Kunitake ST, et al. **Methods Enzymol** 1996;263:260-7

Structure of sperm activating protein. Leijonhufvud P, et al. **Mol Hum Reprod** 1997 Mar;3(3):249-53

Improvements to the TMSBr method of peptide resin deprotection and cleavage: application to large peptides. Sparrow JT, et al. **Pept Res** 1996 Sep-Oct;9(5):218-22

The role of apolipoprotein AI domains in lipid binding. Davidson WS, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13605-10

Expression and purification of recombinant human apolipoprotein A-I in Chinese hamster ovary cells. Schmidt HH, et al. **Protein Expr Purif** 1997 Jul;10(2):226-36

[Effect of denaturing agents, ionic strength and 2-chloroethanol on the structure of spin-labelled apolipoprotein A-I in solution] Medvedeva NV, et al. **Bioorg Khim** 1996 Jun;22(6):415-9 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Subclasses of LpA-I in coronary artery disease: distribution and cholesterol efflux ability. Decossin C, et al. **Eur J Clin Invest** 1997 Apr;27(4):299-307

DEFICIENCY

Delayed loss of cholesterol from a localized lipoprotein depot in apolipoprotein A-I-deficient mice. Stein O, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2;94(18):9820-4

GENETICS

Studies on the role of PPAR in the fibrate-modulated gene expression of apolipoprotein A-I, plasminogen activator inhibitor 1, and fibrinogen in primary hepatocyte cultures from cynomolgus monkey. Kockx M, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:711-2

Synergistic activation of the hydratase but not the ApoA1 gene by gemfibrozil and retinoids. Mukherjee R, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:734-5

Transgenic rabbits expressing human apolipoprotein A-I in the liver. Duverger N, et al. **Arterioscler Thromb Vasc Biol** 1996 Dec;16(12):1424-9

Polymorphisms of the genes encoding apoproteins A-I, B, C-III, and E and LDL receptor, and cholesterol and LDL metabolism during increased cholesterol intake. Common alleles of the apoprotein E gene show the greatest regulatory impact. Gylling H, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):38-44

Apolipoprotein A-IFin. Dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene. Miettinen HE, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):83-90

A cysteine-containing truncated apo A-I variant associated with HDL deficiency. Moriyama K, et al. **Arterioscler Thromb Vasc Biol** 1996 Dec;16(12):1416-23

Subjects with ApoA-I(Lys107-->0) exhibit enhanced fractional catabolic rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI with AII). Tilly-Kiesi M, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):873-80

The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-IMilano. Bruckert E, et al. **Atherosclerosis** 1997 Jan 3;128(1):121-8

Delayed postprandial retinyl palmitate and squalene removal in a patient heterozygous for apolipoprotein A-IFIN mutation (Leu 159-->Arg) and low HDL cholesterol level without coronary artery disease. Gylling H, et al. **Atherosclerosis** 1996 Dec 20;127(2):239-43

Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol. Kamboh MI, et al. **Atherosclerosis** 1996 Dec 20; 127(2):255-62

In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107-->0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency. Tilly-Kiesi M, et al. **Atherosclerosis** 1997 Feb 10;128(2):213-22

NFY transcription factor binds to regulatory element AIC and transactivates the human apolipoprotein A-I promoter in HEPG2 cells. Novak EM, et al. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):140-3

Genetic characterization of equine apolipoprotein A-I using isoelectric focusing. Kakoi H, et al. **Biochem Genet** 1996 Oct;34(9-10):343-9

Deletion of central alpha-helices in human apolipoprotein A-I: effect on phospholipid association. Frank PG, et al. **Biochemistry** 1997 Feb 18;36(7):1798-806

Hepatocyte nuclear factor 4 inhibits the activity of site A from the rat apolipoprotein AI gene. Murao K, et al. **Biochemistry** 1997 Jan 14;36(2):301-6

Viscosity regulates apolipoprotein A-1 gene expression in experimental models of secondary hyperlipidemia and in cultured hepatocytes. Nuño P, et al. **Biochim Biophys Acta** 1997 Feb 18;1344(3):262-9

DNA polymorphisms of apolipoprotein B and AI-CII-AIV genes in a Brazilian population: a preliminary report. Bydlowski SP, et al. **Braz J Med Biol Res** 1996 Oct; 29(10):1269-74

Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Miccoli R, et al. **Circulation** 1996 Oct 1;94(7):1622-8

Association between genetic variations of apo AI-CIII-AIV cluster gene and hypertriglyceridemic subjects. Hong SH, et al. **Clin Chem** 1997 Jan;43(1):13-7

A novel polymorphism (1121 C/T) in intron 3 of the human apolipoprotein A-I gene. Motti C, et al. **Clin Genet** 1997 Feb;51(2):127-8

Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: interaction between genotype, gender, and smoking status. Peacock RE, et al. **Genet Epidemiol** 1997;14(3):265-82

Identification of two apolipoprotein variants, A-I Kaho (Asp 51-->Val) and A-I Lys 107 deletion. Moriyama K, et al. **J Atheroscler Thromb** 1996;3(1):12-6

Utilization of recombinant adenovirus and dominant negative mutants to characterize hepatocyte nuclear factor 4-regulated apolipoprotein AI and CIII expression. Fraser JD, et al. **J Biol Chem** 1997 May 23;272(21):13892-8

Differential interaction of the human cholesteryl ester transfer protein with plasma high density lipoproteins (HDLs) from humans, control mice, and transgenic mice to human HDL apolipoproteins. Lack of lipid transfer inhibitory activity in transgenic mice expressing human apoA-I. Masson D, et al. **J Biol Chem** 1997 Sep 26; 272(39):24287-93

Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity. Sorci-Thomas MG, et al. **J Biol Chem** 1997 Mar 14;272(11):7278-84

Efflux of cellular cholesterol and phospholipid to apolipoprotein A-I mutants. Sviridov D, et al. **J Biol Chem** 1996 Dec 27;271(52):33277-83

Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor RORalpha. Vu-Dac N, et al. **J Biol Chem** 1997 Sep 5;272(36):22401-4

Protein-DNA interactions at a drug-responsive element of the human apolipoprotein A-I gene. Zhang X, et al. **J Biol Chem** 1996 Oct 25;271(43):27152-60

Analysis of a new polymorphism in the human apolipoprotein A-I gene: association with serum lipoprotein levels and coronary heart disease. Bai H, et al. **J Cardiol** 1996 Oct; 28(4):207-12

Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene. Naganawa S, et al. **J Clin Invest** 1997 Apr 15;99(8):1958-65

Plasma lipoprotein(a) levels and expression of the apolipoprotein(a) gene are dependent on the nucleotide polymorphisms in its 5'-flanking region. Suzuki K, et al. **J Clin Invest** 1997 Mar 15;99(6):1361-6

Influence of apolipoprotein A-1 promoter polymorphism on lipid levels and responses to dietary change in Finnish adults. Meng QH, et al. **J Intern Med** 1997 May; 241(5):373-8

Cholesterol 7alpha-hydroxylase influences the expression of hepatic apoA-I in two inbred mouse strains displaying different susceptibilities to atherosclerosis and in hepatoma cells. Dueland S, et al. **J Lipid Res** 1997 Jul;38(7):1445-53

Heterozygosity for apolipoprotein A-I(R160L)Oslo is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL-subclass LpA-I. Leren TP, et al. **J Lipid Res** 1997 Jan;38(1):121-31

Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. Marcil M, et al. **J Lipid Res** 1996 Feb;37(2):309-19

Effect of experimental nephrosis on hepatic lipoprotein secretion and urinary lipoprotein excretion in rats expressing the human apolipoprotein A-I gene. Marsh JB, et al. **J Lipid Res** 1996 May;37(5):1113-24

ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes. Plump AS, et al. **J Lipid Res** 1997 May; 38(5):1033-47

Glucocorticoid increases rat apolipoprotein A-I promoter activity. Taylor AH, et al. **J Lipid Res** 1996 Oct; 37(10):2232-43

Ascorbic acid deficiency reduces hepatic apolipoprotein A-I mRNA in scurvy-prone ODS rats. Ikeda S, et al. **J Nutr** 1996 Oct;126(10):2505-11

I/D polymorphism at the locus for ACE and apo A-I gene promoter polymorphism as risk factors for coronary artery disease in patients with familial hypercholesterolemia. Petrovič D, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R197-8

Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development. Babin PJ, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8622-7

[Directed transfer of the human apolipoprotein A-I gene and bacterial genes-markers into rat liver] Perevozchikov AP, et al. **Dokl Akad Nauk** 1997 Feb;352(4):571-4 **(Rus)**

[Expression of the human apolipoprotein A-I gene transferred in vitro into mammalian cells and in vivo into rat liver] Perevozchikov AP, et al. **Mol Biol (Mosk)** 1997 Mar-Apr;31(2):216-23 **(Rus)**

[The effect of the implantation of the human apo A-I gene on the function of the hepatocyte plasma membrane in rats] Frol'kis VV, et al. **Ukr Biokhim Zh** 1996 Mar-Apr; 68(2):73-7 (Eng. Abstr.) **(Rus)**

[Apolipoprotein AI-CIII, B, and CII gene polymorphisms in patients with non-insulin dependent diabetes mellitus. Association with hyperlipemia] Gutiérrez C, et al. **Med Clin (Barc)** 1996 Nov 2;107(15):561-5 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Cloning and characterization of cDNAs coding for heavy and light chains of a monoclonal antibody (MabA34) specific for human plasma apolipoprotein A-I. Kwak JW, et al. **Gene** 1996 Sep 16;173(2):257-9

Monoclonal antibody production and characterization for the measurement of plasma high density lipoprotein. Lee SH, et al. **J Korean Med Sci** 1996 Oct;11(5):390-6

Evolution of mammalian apolipoprotein A-I and conservation of antigenicity: correlation with primary and secondary structure. Collet X, et al. **J Lipid Res** 1997 Apr; 38(4):634-44

Localization of apolipoprotein A-I epitopes involved in the activation of lecithin:cholesterol acyltransferase. Uboldi P, et al. **J Lipid Res** 1996 Dec;37(12):2557-68

ISOLATION & PURIFICATION

Characterization of human apolipoprotein A-I expressed in Escherichia coli. Bergeron J, et al. **Biochim Biophys Acta** 1997 Jan 21;1344(2):139-52

Identification of an endogenous inhibitor of the UDP-N-acetylgalactosamine: GM3, N-acetylgalactosaminyl transferase as apolipoprotein A1. Conde CB, et al. **Neurochem Res** 1997 Apr;22(4):483-90

Expression and purification of recombinant human apolipoprotein A-I in Chinese hamster ovary cells. Schmidt HH, et al. **Protein Expr Purif** 1997 Jul;10(2):226-36

METABOLISM

Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Mackness B, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1233-8

Subjects with ApoA-I(Lys107-->0) exhibit enhanced fractional catabolic rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI with AII). Tilly-Kiesi M, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):873-80

Structural analysis of apolipoprotein A-I: limited proteolysis of methionine-reduced and -oxidized lipid-free and lipid-bound human apo A-I. Roberts LM, et al. **Biochemistry** 1997 Jun 17;36(24):7615-24

Remodeling of HDL containing apoA-I but not apoA-II (LpA-I) by lipoprotein-deficient plasma and hepatic lipase: its effect on the structure and cellular cholesterol-reducing capacity of LpA-I. Ohta T, et al. **Biochim Biophys Acta** 1996 Sep 27;1303(2):137-44

Role of liver extracellular matrix in transcriptional and post-transcriptional regulation of apolipoprotein A-I by hepatocytes. Paradis V, et al. **Cell Mol Biol (Noisy-le-grand)** 1996 Jun;42(4):525-34

Ageing and amyloid fibrillogenesis: lessons from apolipoprotein AI, transthyretin and islet amyloid polypeptide. Westermark P, et al. **Ciba Found Symp** 1996; 199:205-18; discussion 218-22

Role of the carboxy-terminal domain of human apolipoprotein AI in high-density-lipoprotein metabolism--a study based on deletion and substitution variants in transgenic mice. Holvoet P, et al. **Eur J Biochem** 1997 May 1;245(3):642-7

The ratio of non-oxidized/oxidized forms of apolipoprotein A-I can affect cholesterol efflux from human skin fibroblasts mediated by high density lipoprotein [letter] Sigalov AB, et al. **Eur J Clin Chem Clin Biochem** 1997 May;35(5):395-6

Role of the Arg123-Tyr166 paired helix of apolipoprotein A-I in lecithin:cholesterol acyltransferase activation. Dhoest A, et al. **J Biol Chem** 1997 Jun 20;272(25):15967-72

The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein. Laccotripe M, et al. **J Biol Chem** 1997 Jul 11;272(28):17511-22

Kinetic parameters for high density lipoprotein apoprotein AI and cholesteryl ester transport in the hamster. Woollett LA, et al. **J Clin Invest** 1997 Apr 1;99(7):1704-13

Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. Pajkrt D, et al. **J Exp Med** 1996 Nov 1;184(5):1601-8

Formation of new HDL particles from lipid-free apolipoprotein A-I. Clay MA, et al. **J Lipid Res** 1996 Aug; 37(8):1722-32

Remodelling of reconstituted high density lipoproteins by lecithin: cholesterol acyltransferase. Liang HQ, et al. **J Lipid Res** 1996 Sep;37(9):1962-70

Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: role of apolipoprotein A-I. Massamiri T, et al. **J Lipid Res** 1997 Mar;38(3):516-25

A natural apolipoprotein A-I variant, apoA-I (L141R)Pisa, interferes with the formation of alpha-high density

lipoproteins (HDL) but not with the formation of pre beta 1-HDL and influences efflux of cholesterol into plasma. Miccoli R, et al. **J Lipid Res** 1997 Jun;38(6):1242-53

Influence of vesicle surface composition on the interfacial binding of lecithin:cholesterol acyltransferase and apolipoprotein A-I. Miller KR, et al. **J Lipid Res** 1997 Jun;38(6):1094-102

Effect of cholesterol on apolipoprotein A-I binding to lipid bilayers and emulsions. Saito H, et al. **J Lipid Res** 1997 Feb;38(2):287-94

Synthesis and secretion of B-100 and A-I apolipoproteins in response to the changes of intracellular cholesteryl ester content in chick liver. Tarugi P, et al. **J Lipid Res** 1996 Mar;37(3):493-507

Secretion and processing of apolipoprotein A-I in the avian sciatic nerve during development. Lemieux MJ, et al. **J Neurosci Res** 1996 Jun 15;44(6):594-605

Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism. Shah GM, et al. **Kidney Int** 1996 Dec;50(6):2079-87

Effect of acute feeding of diets of varying fatty acid composition on intestinal apolipoprotein expression in the newborn swine. Wang H, et al. **Pediatr Res** 1996 Jun; 39(6):1078-84

On the affinity between the plasminogen activator inhibitor type 2 and apolipoprotein A1. Astedt B, et al. **Scand J Clin Lab Invest** 1996 Oct;56(6):491-6

PHARMACOLOGY

Complexes of apoA-1 with phosphatidylcholine suppress dysregulation of arterial tone by oxidized LDL. Ota Y, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1215-22

Inhibitory effects of HepG2 cell-derived apolipoprotein A-I-containing lipoproteins on cholesteryl ester accumulation in macrophages. Kawano T, et al. **Biochemistry** 1997 Aug 12;36(32):9816-25

Effect of the apolipoprotein A-I and surface lipid composition of reconstituted discoidal HDL on cholesterol efflux from cultured fibroblasts. Zhao Y, et al. **Biochemistry** 1996 Dec 24;35(51):16510-8

Pharmacology of apolipoprotein A-I. Andersson LO. **Curr Opin Lipidol** 1997 Aug;8(4):225-8 (18 ref.)

The uptake of cholesterol at the small-intestinal brush border membrane is inhibited by apolipoproteins. Boffelli D, et al. **FEBS Lett** 1997 Jul 7;411(1):7-11

Specific phospholipid association with apolipoprotein A-I stimulates cholesterol efflux from human fibroblasts. Studies with reconstituted sonicated lipoproteins. Zhao Y, et al. **J Biol Chem** 1996 Oct 11;271(41):25145-51

Haptoglobin-related protein and apolipoprotein AI are components of the two trypanolytic factors in human serum. Tomlinson S, et al. **Mol Biochem Parasitol** 1997 May;86(1):117-20

PHYSIOLOGY

Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Syvänne M, et al. **Atherosclerosis** 1996 Dec 20; 127(2):245-53

Role of high-density lipoproteins and apolipoprotein A-I in steroid hormone synthesis. Vischer U. **Eur J Endocrinol** 1996 Nov;135(5):538-9

Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. Xu S, et al. **J Lipid Res** 1997 Jul; 38(7):1289-98

Structure of sperm activating protein. Leijonhufvud P, et al. **Mol Hum Reprod** 1997 Mar;3(3):249-53

SECRETION

Rapid movement of newly synthesized chicken apolipoprotein AI to trans-Golgi network and its secretion in Madin-Darby canine kidney cells. Banerjee D, et al. **Exp Cell Res** 1997 Sep 15;235(2):334-44

THERAPEUTIC USE

Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. Pajkrt D, et al. **J Exp Med** 1996 Nov 1;184(5):1601-8

APOLIPOPROTEIN A-II

ANALYSIS

Apolipoprotein AIV of human interstitial fluid is associated with apolipoprotein AI-containing but not with AII-containing particles. Ghalim N, et al. **Int J Clin Lab Res** 1996;26(4):224-8

BIOSYNTHESIS

The proximal element of the human apolipoprotein A-II promoter increases the enhancer activity of the distal region. Lacorte JM, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):681-8

BLOOD

Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy. McPherson R, et al. **Arterioscler Thromb Vasc Biol** 1996 Nov;16(11):1340-6

Increased esterification of cholesterol and transfer of cholesteryl ester to apo B-containing lipoproteins in Type 2 diabetes: relationship to serum lipoproteins A-I and A-II. Jones RJ, et al. **Atherosclerosis** 1996 Jan 26;119(2):151-7

In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107-->0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency. Tilly-Kiesi M, et al. **Atherosclerosis** 1997 Feb 10;128(2):213-22

Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Castro G, et al. **Biochemistry** 1997 Feb 25; 36(8):2243-9

Effect of bezafibrate on HDL with APO A-I and APO A-II and on HDL with APO A-I without APO A-II in hyperlipidaemic patients. Branchi A, et al. **Int J Clin Pharmacol Res** 1995;15(4):153-8

ApoA-II/apoA-I molar ratio in the HDL particle influences phospholipid transfer protein-mediated HDL interconversion. Pussinen PJ, et al. **J Lipid Res** 1997 Jan; 38(1):12-21

[Subfractionation of serum high density lipoproteins and its clinical significance] Hua F, et al. **Rinsho Byori** 1996 Aug; 44(8):802-6 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Conformational studies of an amphipathic peptide corresponding to human apolipoprotein A-II residues 18-30 with a C-terminal lipid binding motif EWLNS. Buchko GW, et al. **Int J Pept Protein Res** 1996 Jul; 48(1):21-30

Comparison of the structural and functional effects of monomeric and dimeric human apolipoprotein A-II in high density lipoprotein particles. Lund-Katz S, et al. **Lipids** 1996 Nov;31(11):1107-13

High- and low-temperature unfolding of human high-density apolipoprotein A-2. Gursky O, et al. **Protein Sci** 1996 Sep; 5(9):1874-82

GENETICS

Interstitial deletion of chromosome 1q [del(1)(q24q25.3)] identified by fluorescence in situ hybridization and gene dosage analysis of apolipoprotein A-II, coagulation factor V, and antithrombin III. Takano T, et al. **Am J Med Genet** 1997 Jan 20;68(2):207-10

The MspI polymorphism of the apolipoprotein A-II gene as a modulator of the dyslipidemic state found in visceral obesity. Vohl MC, et al. **Atherosclerosis** 1997 Feb 10; 128(2):183-90

Two regulatory elements of similar structure and placed in tandem account for the repressive activity of the first intron of the human apolipoprotein A-II gene. Bossu JP, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):547-53

The proximal element of the human apolipoprotein A-II promoter increases the enhancer activity of the distal region. Lacorte JM, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):681-8

Modulation of the hepatic expression of the estrogen-regulated mRNA stabilizing factor by estrogenic and antiestrogenic nonsteroidal xenobiotics. Ratnasabapathy R, et al. **Biochem Pharmacol** 1997 May 15; 53(10):1425-34

Regulation of the metabolism of plasma lipoproteins by apolipoprotein A-II. Wang J, et al. **Biochim Biophys Acta** 1997 Apr 21;1345(3):248-58

DNA polymorphisms in linkage disequilibrium at the 3' end of the human APO AII gene: relationships with lipids, apolipoproteins and coronary heart disease. Dupuy-Gorce AM, et al. **Clin Genet** 1996 Oct;50(4):191-8

Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Weng W, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14788-94

Restriction fragment length polymorphism of the human apo B and apo AII gene regions among type II diabetics. Ghusn H, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jul; 93(1):25-32

METABOLISM

Subjects with ApoA-I(Lys107-->0) exhibit enhanced fractional catabolic rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI with AII). Tilly-Kiesi M, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):873-80

Interstitial fluid apolipoprotein A-II: an association with the occurrence of myocardial infarction. Luc G, et al. **Atherosclerosis** 1996 Nov 15;127(1):131-7

Accumulation of pro-apolipoprotein A-II in mouse senile amyloid fibrils. Higuchi K, et al. **Biochem J** 1997 Aug 1; 325 (Pt 3):653-9

Remodeling of HDL containing apoA-I but not apoA-II (LpA-I) by lipoprotein-deficient plasma and hepatic lipase: its effect on the structure and cellular cholesterol-reducing capacity of LpA-I. Ohta T, et al. **Biochim Biophys Acta** 1996 Sep 27;1303(2):137-44

Lipid-binding properties of synthetic peptide fragments of human apolipoprotein A-II. Benetollo C, et al. **Eur J Biochem** 1996 Dec 15;242(3):657-64

Conformational studies of an amphipathic peptide corresponding to human apolipoprotein A-II residues 18-30 with a C-terminal lipid binding motif EWLNS. Buchko GW, et al. **Int J Pept Protein Res** 1996 Jul; 48(1):21-30

Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. Castellani LW, et al. **J Clin Invest** 1997 Jul 15; 100(2):464-74

ApoA-II kinetics in humans using endogenous labeling with stable isotopes: slower turnover of apoA-II compared with the exogenous radiotracer method. Ikewaki K, et al. **J Lipid Res** 1996 Feb;37(2):399-407

PHARMACOLOGY

Human apolipoprotein A-II inhibits the formation of pre-beta high density lipoproteins. Calabresi L, et al. **Biochim Biophys Acta** 1996 Nov 11;1304(1):32-42

PHYSIOLOGY

Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Syvänne M, et al. **Atherosclerosis** 1996 Dec 20; 127(2):245-53

Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. Xu S, et al. **J Lipid Res** 1997 Jul; 38(7):1289-98

APOLIPOPROTEINS

Effects of charged lipids on the interaction of cholesteryl ester transfer protein with lipid microemulsions. Rajaram OV, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):159-65

Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Lendon CL, et al. **Neurosci Lett** 1997 Feb 7;222(3):187-90

ANALYSIS

Analysis of apolipoproteins. Laker MF, et al. **Ann Clin Biochem** 1996 Jan;33 (Pt 1):5-22 (226 ref.)

Measurement of serum amyloid A by commonly used automated analysers [letter] Wada A, et al. **Ann Clin Biochem** 1997 Sep;34 (Pt 5):569-70

Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. Hall RE, et al. **Br J Cancer** 1996 Oct; 74(8):1175-80

Prominence of apolipoproteins B, (a), and E in the intimae of coronary arteries in transplanted human hearts: geographic relationship to vessel wall proteoglycans. Lin H, et al. **J Heart Lung Transplant** 1996 Dec;15(12):1223-32

Quantification of apolipoprotein D by an immunoassay with time-resolved fluorescence spectroscopy. Knipping G, et al. **J Immunol Methods** 1997 Mar 10;202(1):85-95

Electrophoretic methods for quantitation of lipoprotein [a] Gaubatz JW, et al. **Methods Enzymol** 1996;263:218-37

Pancreas-specific protein (PASP), serum amyloid A (SAA), and neopterin (NEOP) in the diagnosis of rejection after simultaneous pancreas and kidney transplantation. Müller TF, et al. **Transpl Int** 1997;10(3):185-91

BIOSYNTHESIS

An in vitro system for identifying agents capable of changing serum lipoprotein(a) concentration by regulating the transcriptional activity of the apolipoprotein(a) gene promoter. Azuma H, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):570-5

Molecular cloning of the mouse apolipoprotein D gene and its upregulated expression in Niemann-Pick disease type C mouse model. Yoshida K, et al. **DNA Cell Biol** 1996 Oct;15(10):873-82

Lipid, apolipoprotein, and lipoprotein synthesis and secretion during cellular differentiation in Caco-2 cells. Mehran M, et al. **In Vitro Cell Dev Biol Anim** 1997 Feb;33(2):118-28

Retinoic acid-induced expression of apolipoprotein D and concomitant growth arrest in human breast cancer cells are mediated through a retinoic acid receptor RARalpha-dependent signaling pathway. López-Boado YS, et al. **J Biol Chem** 1996 Dec 13;271(50):32105-11

Expression of apolipoprotein[a] and plasminogen mRNAs in cynomolgus monkey liver and extrahepatic tissues. Ramharack R, et al. **J Lipid Res** 1996 Sep;37(9):2029-40

Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Liang JS, et al. **Neurosci Lett** 1997 Apr 4;225(2):73-6

Messenger RNA deadenylylation precedes decapping in mammalian cells. Couttet P, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5628-33

Regulation of extrahepatic apolipoprotein serum amyloid A (ApoSAA) gene expression by interleukin-1 alpha alone: synthesis and secretion of ApoSAA by cultured aortic smooth muscle cells. Kumon Y, et al. **Scand J Immunol** 1997 Sep;46(3):284-91

BLOOD

Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin. Kesteloot H, et al. **Acta Cardiol** 1997;52(2):107–16

Case–control study of serum lipoprotein(a) and apolipoproteins A–I and B in stroke in the young. Christopher R, et al. **Acta Neurol Scand** 1996 Aug; 94(2):127–30

Ethnic variation of cord plasma apolipoprotein levels in relation to coronary risk level: a study in three ethnic groups of Singapore. Low PS, et al. **Acta Paediatr** 1996 Dec;85(12):1476–82

Changes in apolipoproteins during the acute phase of Kawasaki disease. Kim H, et al. **Acta Paediatr Jpn** 1995 Dec;37(6):672–6

Serum lipoproteins and apolipoproteins in children during the first five years of diabetes. Kobbah M, et al. **Acta Paediatr Suppl** 1997 Feb;418:11–4

Effect of dietary taurine on lipid metabolism in normcholesterolemic and hypercholesterolemic stroke-prone spontaneously hypertensive rats. Ogawa H. **Adv Exp Med Biol** 1996;403:107–15

Phospholipid binding plasma proteins required for antiphospholipid antibody detection—an overview. McIntyre JA, et al. **Am J Reprod Immunol** 1997 Jan; 37(1):101–10 (86 ref.)

Radioimmunoassay for serum apolipoprotein D, an atypical apolipoprotein: validation and clinical application. Osundeko O, et al. **Ann Clin Biochem** 1997 Sep;34 (Pt 5):537–42

A modified sodium dodecyl sulphate–agarose gel/immunoblotting method for apolipoprotein(a) phenotyping using alkaline phosphatase–linked chemiluminescent detection. Pang RW, et al. **Ann Clin Biochem** 1997 May;34 (Pt 3):314–6

Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly. Räihä I, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul; 17(7):1224–32

Effect of a new HMG–CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Alaupovic P, et al. **Atherosclerosis** 1997 Aug; 133(1):123–33

Plasma lipids and apolipoproteins in a population of Orang Asli ('aborigines') from West Malaysia. Candlish JK, et al. **Atherosclerosis** 1997 Feb 28;129(1):49–51

Increased plasma cholesteryl ester transfer activity in obese children. Hayashibe H, et al. **Atherosclerosis** 1997 Feb 28; 129(1):53–8

Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case–control study. Klausen IC, et al. **Atherosclerosis** 1997 Jul 11;132(1):77–84

Effects of regular and extended–release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels. Schaefer EJ, et al. **Atherosclerosis** 1996 Nov 15;127(1):113–22

Influence of apolipoprotein E polymorphism on the tracking of childhood levels of serum lipids and apolipoproteins over a 6–year period. The Bogalusa Heart Study. Srinivasan SR, et al. **Atherosclerosis** 1996 Nov 15;127(1):73–9

Lipoproteins and apolipoproteins in the young and familial risk of coronary atherosclerosis. Uiterwaal CS, et al. **Atherosclerosis** 1996 May;122(2):235–44

Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial. Schmitz G, et al. **Blood Press** 1996 Nov;5(6):354–9

Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Morales M, et al. **Breast Cancer Res Treat** 1996;40(3):265–70

Screening study of abdominal aortic aneurysm in a general population: lipid parameters. Simoni G, et al. **Cardiovasc Surg** 1996 Aug;4(4):445–8

Serum apolipoprotein A1, B, CII, CIII, E, and lipoprotein (a) levels in children [published erratum appears in Clin Biochem 1997 Jun;30(4):365] Baroni S, et al. **Clin Biochem** 1996 Dec;29(6):603–5

Changes in serum apolipoprotein and lipoprotein profile induced by chronic alcohol consumption and withdrawal: determinant effect on heart disease? Lecomte E, et al. **Clin Chem** 1996 Oct;42(10):1666–75

Effect of storage at –70 degrees C on lipid, lipoprotein and apolipoprotein concentrations. Evans K, et al. **Clin Chim Acta** 1997 Feb 17;258(2):219–29

Effects of apo B and apo E gene polymorphisms on lipid and apolipoprotein concentrations after a test meal. Regis–Bailly A, et al. **Clin Chim Acta** 1996 Sep 30; 253(1–2):127–43

Characterization of serum amyloid A4 as a plasma apolipoprotein. Yamada T, et al. **Clin Chim Acta** 1996 Jul 15;251(1):105–12

The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII and E. O'Brien T, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):17–20

Plasma lipids and lipoproteins in juvenile chronic arthritis. Bakkaloglu A, et al. **Clin Rheumatol** 1996 Jul;15(4):341–5

Changes in plasma lipoproteins and liver lipids in neonatal rats. Garcia–Molina V, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Apr; 113(4):789–93

Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy. Tarnow L, et al. **Diabetes Care** 1996 Dec;19(12):1382–7

Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non–insulin–dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins. Vaverková H, et al. **Exp Clin Endocrinol Diabetes** 1997;105 Suppl 2:74–7

Association between common alleles of the low–density lipoprotein receptor gene region and interindividual variation in plasma lipid and apolipoprotein levels in a population–based sample from Rochester, Minnesota. Haviland MB, et al. **Hum Genet** 1997 Jan;99(1):108–14

Polymorphisms in the apolipoprotein(a) gene and their relationship to allele size and plasma lipoprotein(a) concentration. Puckey LH, et al. **Hum Mol Genet** 1997 Jul;6(7):1099–107

Training intensity, blood lipids, and apolipoproteins in men with high cholesterol. Crouse SF, et al. **J Appl Physiol** 1997 Jan;82(1):270–7

Relationship of lipoproteins, apolipoproteins, triglycerides and lipid ratios to plasma total cholesterol in young adults: the CARDIA Study. Coronary Artery Risk Development in Young Adults. Iribarren C, et al. **J Cardiovasc Risk** 1996 Aug;3(4):391–6

Cyclic changes in lipoprotein and apolipoprotein levels during the menstrual cycle in healthy premenopausal women on a controlled diet. Muesing RA, et al. **J Clin Endocrinol Metab** 1996 Oct;81(10):3599–603

Hepatic origin of cholesteryl oleate in coronary artery atherosclerosis in African green monkeys. Enrichment by dietary monounsaturated fat. Rudel LL, et al. **J Clin Invest** 1997 Jul 1;100(1):74–83

Serum lipid, lipoprotein and apolipoprotein changes in gestational diabetes mellitus: a cross–sectional and prospective study. Koukkou E, et al. **J Clin Pathol** 1996 Aug;49(8):634–7

Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygotes for lipoprotein lipase deficiency. Bijvoet S, et al. **J Lipid Res** 1996 Mar; 37(3):640–50

Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. Chiba H, et al. **J Lipid Res** 1997 Jun;38(6):1204–16

Apolipoprotein A–I/C–III/A–IV gene cluster in familial combined hyperlipidemia: effects on LDL–cholesterol and apolipoproteins B and C–III. Dallinga–Thie GM, et al. **J Lipid Res** 1996 Jan;37(1):136–47

Heterozygosity for apolipoprotein A–I(R160L)Oslo is associated with low levels of high density lipoprotein cholesterol and HDL–subclass LpA–I/A–II but normal levels of HDL–subclass LpA–I. Leren TP, et al. **J Lipid Res** 1997 Jan;38(1):121–31

Dyslipidemia in chronic renal failure patients [editorial] Almeida AF, et al. **J Postgrad Med** 1994 Apr–Jun; 40(2):52–4 (26 ref.)

Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate. Castelo–Branco C, et al. **J Reprod Med** 1996 Nov; 41(11):833–8

The effect of dietary arachidonic acid on plasma lipoprotein distributions, apoproteins, blood lipid levels, and tissue fatty acid composition in humans. Nelson GJ, et al. **Lipids** 1997 Apr;32(4):427–33

Physical activity, lipids, apolipoproteins, and Lp(a) in the Northern Ireland Health and Activity Survey. MacAuley D, et al. **Med Sci Sports Exerc** 1996 Jun;28(6):720–36

Lipoproteins, apolipoproteins, and low–density lipoprotein size among diabetics in the Framingham offspring study. Siegel RD, et al. **Metabolism** 1996 Oct;45(10):1267–72

Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Alaupovic P. **Methods Enzymol** 1996;263:32–60 (219 ref.)

Quantitation of lipoprotein (a) after lysine–sepharose chromatography and density gradient centrifugation. Fless GM, et al. **Methods Enzymol** 1996;263:238–51

Electrophoretic methods for quantitation of lipoprotein [a] Gaubatz JW, et al. **Methods Enzymol** 1996;263:218–37

Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet. Allegra V, et al. **Nephrol Dial Transplant** 1997 May;12(5):924–32

Apolipoprotein (a) levels and phenotypes in NIDDM patients with microalbuminuria and albuminuria. Lam KS, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2229–36

Serum lipoprotein patterns in long–term anabolic steroid users. Sachtleben TR, et al. **Res Q Exerc Sport** 1997 Mar; 68(1):110–5

Interrelationship of triglyceride–rich lipoproteins, serum lipoprotein (a) concentration and apolipoprotein(a) size. Sentí M, et al. **Scand J Clin Lab Invest** 1996 Jul;56(4):311–8

Cyclosporin A trough levels correlate with serum lipoproteins and apolipoproteins: implications for therapeutic drug monitoring of cyclosporin A. von Ahsen N, et al. **Ther Drug Monit** 1997 Apr;19(2):140–5

[Lipid, apoprotein and fibrinogen levels in the blood of male patients following myocardial infarct and the effect of diet on these parameters in ischemic heart disease] Márk L, et al. **Orv Hetil** 1996 Nov 3;137(44):2447–50 (40 ref.) (Eng. Abstr.) **(Hun)**

[Plasma apolipoproteins: their role in cardiovascular diseases and usefulness of their blood concentration determination. Committee of the Study of Apolipoproteins, Italian Heart Foundation] **Cardiologia** 1997 Feb;42 Suppl 1:1–39 (279 ref.) **(Ita)**

[Levels of Lp(a) and apolipoproteins in vegetarians and their informative value in hyperlipidemia] Koprivičová J, et al. **Bratisl Lek Listy** 1997 Jan;98(1):17–21 (Eng. Abstr.) **(Slo)**

[Distribution of lipidic values in teenagers that smoke] Palau Bondía J, et al. **An Esp Pediatr** 1997 Mar;46(3):245–51 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Marked increases in concentrations of apolipoprotein in the cerebrospinal fluid of poliovirus–infected macaques: relations between apolipoprotein concentrations and severity of brain injury. Saito K, et al. **Biochem J** 1997 Jan 1;321 (Pt 1):145–9

A zone immunoelectrophoresis assay method for quantification of apolipoprotein D in human cerebrospinal fluid. Holmquist L, et al. **J Biochem Biophys Methods** 1996 Oct 15;33(1):1–8

CHEMISTRY

Fluorescence studies of lipid association–induced conformational adaptations of an exchangeable amphipathic apolipoprotein. Narayanaswami V, et al. **Arch Biochem Biophys** 1996 Oct 1;334(1):143–50

Merck Frosst award lecture 1995. La conference Merck Frosst 1995. Structural studies of lipoproteins and their apolipoprotein components. Ryan RO. **Biochem Cell Biol** 1996;74(2):155–64 (48 ref.)

Structural organization of lipid phase and protein–lipid interface in apolipoprotein–phospholipid recombinants: influence of cholesterol. Dergunov AD, et al. **Biochim Biophys Acta** 1997 Jun 2;1346(2):131–46

Evaluation of the genotyping and phenotyping approaches in the investigation of apolipoprotein (a) size polymorphism. Valenti K, et al. **Clin Chim Acta** 1997 Jul 25;263(2):249–60

Disulfide bond engineering to monitor conformational opening of apolipophorin III during lipid binding. Narayanaswami V, et al. **J Biol Chem** 1996 Oct 25; 271(43):26855–62

Hydrogen/deuterium exchange kinetics of apolipophorin–III in lipid–free and phospholipid–bound states. An analysis by Fourier transform infrared spectroscopy. Raussens V, et al. **J Biol Chem** 1996 Sep 20;271(38):23089–95

The human factor H–related protein 4 (FHR–4). A novel short consensus repeat–containing protein is associated with human triglyceride–rich lipoproteins. Skerka C, et al. **J Biol Chem** 1997 Feb 28;272(9):5627–34

Insight into lipid surface recognition and reversible conformational adaptations of an exchangeable apolipoprotein by multidimensional heteronuclear NMR techniques. Wang J, et al. **J Biol Chem** 1997 Jul 18; 272(29):17912–20

Characterization of the carbohydrate structures of apolipoprotein H through concanavalin A affinity chromatography. Gambino R, et al. **J Lipid Mediat Cell Signal** 1997 May;16(1):11–21

Probing structure and function of VLDL by synthetic amphipathic helical peptides. Chung BH, et al. **J Lipid Res** 1996 May;37(5):1099–112

Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Alaupovic P. **Methods Enzymol** 1996;263:32–60 (219 ref.)

Probing the structure of the ligand binding cavity of lipocalins by fluorescence spectroscopy. Patel RC, et al. **Protein Eng** 1997 Jun;10(6):621–5

A thyroid hormone binding motif is evolutionarily conserved in apolipoproteins. Benvenga S. **Thyroid** 1997 Aug; 7(4):605–11

DEFICIENCY

[Abnormality of HDL subfractions in cholesteryl ester transfer protein deficiency] Miida T, et al. **Rinsho Byori** 1996 Sep;44(9):865–70 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Body composition, atherogenic risk factors and apolipoproteins following growth hormone treatment. Hassan HM, et al. **Acta Paediatr** 1996 Aug;85(8):899–901

GENETICS

The age dependency of gene expression for plasma lipids, lipoproteins, and apolipoproteins. Snieder H, et al. **Am J Hum Genet** 1997 Mar;60(3):638–50

Apolipoprotein(a) and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease. Amemiya H, et al. **Atherosclerosis** 1996 Jun;123(1–2):181–91

Characterization of the genetic elements controlling lipoprotein(a) concentrations in Mexican Americans. Evidence for at least three controlling elements linked to LPA, the locus encoding apolipoprotein(a). Rainwater DL, et al. **Atherosclerosis** 1997 Feb 10;128(2):223–33

Lipoprotein (a) concentrations and apolipoprotein (a) phenotypes in normoglycaemic relatives of type 2 diabetic

patients. Stewart MW, et al. **Atherosclerosis** 1996 Jul; 124(1):119–24

An in vitro system for identifying agents capable of changing serum lipoprotein(a) concentration by regulating the transcriptional activity of the apolipoprotein(a) gene promoter. Azuma H, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):570–5

Involvement of an SAF-like transcription factor in the activation of serum amyloid A gene in monocyte/macrophage cells by lipopolysaccharide. Ray BK, et al. **Biochemistry** 1997 Apr 15;36(15):4662–8

Growth inhibition of human breast cancer cells by 1,25-dihydroxyvitamin D3 is accompanied by induction of apolipoprotein D expression. López-Boado YS, et al. **Cancer Res** 1997 Sep 15;57(18):4091–7

Evaluation of the genotyping and phenotyping approaches in the investigation of apolipoprotein (a) size polymorphism. Valenti K, et al. **Clin Chim Acta** 1997 Jul 25;263(2):249–60

Serum amyloid A gene expression in rabbit, mink and mouse. Marhaug G, et al. **Clin Exp Immunol** 1997 Feb; 107(2):425–34

Lipoprotein(a), apolipoprotein(a) phenotypes, and nephropathy in NIDDM patients [letter] Akita H, et al. **Diabetes Care** 1996 Sep;19(9):1036–7

Serum amyloid A gene expression level in liver in response to different inflammatory agents is dependent upon the nature of activated transcription factors. Ray A, et al. **DNA Cell Biol** 1997 Jan;16(1):1–7

Molecular cloning of the mouse apolipoprotein D gene and its upregulated expression in Niemann-Pick disease type C mouse model. Yoshida K, et al. **DNA Cell Biol** 1996 Oct;15(10):873–82

Apolipoprotein function in health and disease: insights from natural mutations. Franceschini G. **Eur J Clin Invest** 1996 Sep;26(9):733–46 (109 ref.)

Characterization of the 5'-flanking regions of plasminogen-related genes A and B. Kida M, et al. **FEBS Lett** 1997 Mar 3;404(1):95–9

Molecular basis of the apolipoprotein H (beta 2-glycoprotein I) protein polymorphism. Sanghera DK, et al. **Hum Genet** 1997 Jul;100(1):57–62

Polymorphisms in the apolipoprotein(a) gene and their relationship to allele size and plasma lipoprotein(a) concentration. Puckey LH, et al. **Hum Mol Genet** 1997 Jul;6(7):1099–107

Mapping of the mouse serum amyloid A gene cluster by long-range polymerase chain reaction. Butler A, et al. **Immunogenetics** 1996;44(6):468–74

The precursor protein of the structural apolipoproteins of lipophorin: cDNA and deduced amino acid sequence. Sundermeyer K, et al. **Insect Biochem Mol Biol** 1996 Sep–Oct;26(8–9):735–8

Diet-gene interactions in human lipoprotein metabolism. Dreon DM, et al. **J Am Coll Nutr** 1997 Aug;16(4):313–24 (146 ref.)

Exon/intron organization, chromosome localization, alternative splicing, and transcription units of the human apolipoprotein E receptor 2 gene. Kim DH, et al. **J Biol Chem** 1997 Mar 28;272(13):8498–504

Human cholesteryl ester transfer protein gene proximal promoter contains dietary cholesterol positive responsive elements and mediates expression in small intestine and periphery while predominant liver and spleen expression is controlled by 5'-distal sequences. Cis-acting sequences mapped in transgenic mice. Oliveira HCF, et al. **J Biol Chem** 1996 Dec 13;271(50):31831–8

Lipoprotein(a) plasma concentrations, apolipoprotein (a) polymorphism and family history of coronary heart disease in patients with essential hypertension. Gazzaruso C, et al. **J Cardiovasc Risk** 1996 Apr;3(2):191–7

Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. Dallinga-Thie GM, et al. **J Clin Invest** 1997 Mar 1;99(5):953–61

Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. Dallinga-Thie GM, et al. **J Lipid Res** 1996 Jan;37(1):136–47

Apolipoprotein E genotype and concomitant clinical features in early-onset Alzheimer's disease. Bronzova J, et al. **J Neurol** 1996 Jun;243(6):465–8

Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups. Kurz A, et al. **J Neurol** 1996 Jun;243(6):452–6

Determination of apolipoprotein mRNA levels by ribonuclease protection assay. Mitchell A, et al. **Methods Enzymol** 1996;263:351–63

Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease. Kim SB, et al. **Perit Dial Int** 1997 May-Jun;17(3):236–42

Efficient in vitro cleavage of mouse acute phase serum amyloid A mRNA mediated by a synthetic hammerhead ribozyme. Gaughan DJ, et al. **Scand J Immunol** 1997 Jul; 46(1):51–8

[Analysis of apolipoprotein gene family in codon space--non-random selection of nucleotide changes in evolution] Wang L, et al. **I Chuan Hsueh Pao** 1996; 23(5):329–37 (Eng. Abstr.) **(Chi)**

[Molecular biology of hyperlipidemias. Genetic variation of apolipoproteins] Novok EM, et al. **Arq Bras Cardiol** 1996 Dec;67(6):411–7 (129 ref.) **(Por)**

IMMUNOLOGY

Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI. García CO, et al. **Am J Reprod Immunol** 1997 Jan; 37(1):118–24

Antibodies to beta2-glycoprotein I in patients with systemic lupus erythematosus: comment on the articles by Tsutsumi et al and Roubey et al [letter; comment] Inanç M, et al. **Arthritis Rheum** 1997 Jul;40(7):1366–8. Comment on: Arthritis Rheum 1996 Sep;39(9):1466–74. Comment on: Arthritis Rheum 1996 Sep;39(9):1606–7.

Selection of monoclonal antibodies for linear epitopes of an apolipoprotein yields antibodies with comparable affinity for lipid-free and lipid-associated apolipoprotein. Curtiss LK, et al. **J Lipid Res** 1996 Apr;37(4):884–92

The antiphospholipid/cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to beta 2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. Alarcon-Segovia D, et al. **J Rheumatol** 1997 Aug;24(8):1545–51

Analytical and clinical relationships between human IgG autoantibodies to beta 2 glycoprotein I and anticardiolipin antibodies. El-Kadi HS, et al. **J Rheumatol** 1995 Dec; 22(12):2233–7

[Synthesis and antigenic properties of peptide fragments of beta2-glycoprotein-I] Pal'keeva ME, et al. **Bioorg Khim** 1996 Sep;22(9):678–85 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

A novel method for the rapid separation of plasma lipoproteins using self-generating gradients of iodixanol. Graham JM, et al. **Atherosclerosis** 1996 Jul;124(1):125–35

Apolipoprotein H: a two-step isolation method. Gambino R, et al. **J Lipid Res** 1996 Apr;37(4):902–4

Purification of apolipoprotein H by polyethylene glycol precipitation. Cai G, et al. **Protein Expr Purif** 1996 Nov; 8(3):341–6

METABOLISM

Human plasmatic apolipoprotein H binds human immunodeficiency virus type 1 and type 2 proteins. Stefas E, et al. **AIDS Res Hum Retroviruses** 1997 Jan 1; 13(1):97–104

Extracellular matrix-anchored serum amyloid A preferentially induces mast cell adhesion. Hershkoviz R, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C179–87

Apolipoprotein secretion and lipid synthesis: regulation by fatty acids in newborn swine intestinal epithelial cells. Wang H, et al. **Am J Physiol** 1997 May;272(5 Pt 1):G935–42

Design of a new class of amphipathic helical peptides for the plasma apolipoproteins that promote cellular cholesterol efflux but do not activate LCAT. Labeur C, et al. **Arterioscler Thromb Vasc Biol** 1997 Mar;17(3):580–8

Effects of charged lipids on the interaction of cholesteryl ester transfer protein with lipid microemulsions. Rajaram OV, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):159–65

Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol. Tsujita M, et al. **Biochemistry** 1996 Oct 8;35(40):13011–20

Structural organization of lipid phase and protein-lipid interface in apolipoprotein-phospholipid recombinants: influence of cholesterol. Dergunov AD, et al. **Biochim Biophys Acta** 1997 Jun 2;1346(2):131–46

LPS and cytokines regulate extra hepatic mRNA levels of apolipoproteins during the acute phase response in Syrian hamsters. Hardardóttir I, et al. **Biochim Biophys Acta** 1997 Feb 18;1344(3):210–20

Novel interaction of apolipoprotein(a) with beta-2 glycoprotein I mediated by the kringle IV domain. Köchl S, et al. **Blood** 1997 Aug 15;90(4):1482–9

Non-covalent associations of proteins in plasma: self-, mixed fibrin(ogen), mixed protein-non-protein associations. London M. **Clin Biochem** 1997 Mar;30(2):83–9

Increased plasma concentrations of serum amyloid A: an indicator of the acute-phase response after cardiopulmonary bypass. Berendes E, et al. **Crit Care Med** 1997 Sep;25(9):1527–33

Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Rader DJ, et al. **Curr Opin Lipidol** 1996 Jun;7(3):117–23 (74 ref.)

Effect of serum amyloid A on cellular affinity of low density lipoprotein. Yamada T, et al. **Eur J Clin Chem Clin Biochem** 1997 Jun;35(6):421–6

Mouse microsomal triglyceride transfer protein large subunit: cDNA cloning, tissue-specific expression and chromosomal localization. Nakamuta M, et al. **Genomics** 1996 Apr 15;33(2):313–6

Binding of human serum amyloid A (hSAA) and its high-density lipoprotein3 complex (hSAA-HDL3) to human neutrophils. Possible implication to the function of a protein of an unknown physiological role. Preciado-Patt L, et al. **Int J Pept Protein Res** 1996 Dec;48(6):503–13

Characterization of high affinity binding between laminin and the acute-phase protein, serum amyloid A. Ancsin JB, et al. **J Biol Chem** 1997 Jan 3;272(1):406–13

Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments. Edelstein C, et al. **J Biol Chem** 1997 Apr 25; 272(17):11079–87

Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. White AL, et al. **J Biol Chem** 1997 Feb 21;272(8):5048–55

Selective effects of hydrocortisone on intestinal lipoprotein and apolipoprotein synthesis in the human fetus. Loirdighi N, et al. **J Cell Biochem** 1997 Jul 1;66(1):65–76

Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. Mooser V, et al. **J Clin Invest** 1996 Nov 15;98(10):2414–24

Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin. Yamada T, et al. **J Immunol** 1996 Jul 15;157(2):901–7

Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein[a] Edelstein C, et al. **J Lipid Res** 1996 Aug; 37(8):1786–801

Apolipoprotein-mediated cellular cholesterol and phospholipid efflux depend on a functional Golgi apparatus. Mendez AJ, et al. **J Lipid Res** 1996 Dec;37(12):2510–24

Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. Oram JF, et al. **J Lipid Res** 1996 Dec; 37(12):2473–91 (164 ref.)

Interaction of apolipoprotein[a] with apolipoproteinB-100 Cys3734 region in lipoprotein[a] is confirmed immunochemically. Guevara J Jr, et al. **J Protein Chem** 1996 Jan;15(1):17–25

Determination of the radiation dose from administered apolipoprotein tracers in humans. Venkatakrishnan V, et al. **Metabolism** 1997 Oct;46(10):1231–9

Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Liang JS, et al. **Neurosci Lett** 1997 Apr 4;225(2):73–6

Differential expression of apolipoprotein D and apolipoprotein E in the kainic acid-lesioned rat hippocampus. Ong WY, et al. **Neuroscience** 1997 Jul; 79(2):359–67

The localization of tissue factor and apolipoprotein(a) in atherosclerotic lesions of the human aorta and their relation to fibrinogen-fibrin transition. Ichikawa K, et al. **Pathol Res Pract** 1996 Mar;192(3):224–32

Characterisation of the acute phase response of heifers to a prolonged low dose infusion of lipopolysaccharide. Werling D, et al. **Res Vet Sci** 1996 Nov;61(3):252–7

A thyroid hormone binding motif is evolutionarily conserved in apolipoproteins. Benvenga S. **Thyroid** 1997 Aug; 7(4):605–11

[Characteristics of apolipoprotein polymorphism in a Hungarian population] Császár A. **Orv Hetil** 1997 Sep 7; 138(36 Suppl 2):2296–7 (Eng. Abstr.) **(Hun)**

PHARMACOLOGY

Extracellular matrix-anchored serum amyloid A preferentially induces mast cell adhesion. Hershkoviz R, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):C179–87

Serum amyloid A has little effect on high density lipoprotein (HDL) binding to U937 monocytes but may influence HDL mediated cholesterol transfer. Hayat S, et al. **Biochem Soc Trans** 1997 May;25(2):348S

Inhibition of cholesteryl ester transfer protein by apolipoproteins, lipopolysaccharides, and cholesteryl sulfate. Connolly DT, et al. **Biochim Biophys Acta** 1996 Nov 22;1304(2):145–60

Studies on the interaction of placental anticoagulant protein I, beta 2 glycoprotein 1, and antiphospholipid antibodies in the prothrombinase reaction and in the solid phase anticardiolipin assays. Pierangeli SS, et al. **J Lab Clin Med** 1996 Aug;128(2):194–201

PHYSIOLOGY

Selective down-regulation by protein kinase C inhibitors of apolipoprotein-mediated cellular cholesterol efflux in macrophages. Li Q, et al. **Biochemistry** 1997 Oct 7; 36(40):12045–52

Apolipoproteins: pathophysiology and clinical implications. Patsch W, et al. **Methods Enzymol** 1996;263:3–32 (258 ref.)

[Apolipoproteins: pharmacologic targets in cardio-cerebrovascular diseases--the place of apolipoprotein E] Siest G. **J Pharm Belg** 1997 Mar-Apr; 52(2):99 **(Fre)**

SECRETION

Lipoprotein and apolipoprotein secretion by a newborn piglet intestinal cell line (IPEC-1). Gonzalez-Vallina R, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G249–59

Alzheimer's soluble amyloid beta protein is secreted by HepG2 cells as an apolipoprotein. Koudinov AR, et al. **Cell Biol Int** 1997 May;21(5):265–71

APOLIPOPROTEINS A

ANALYSIS

Apolipoprotein AIV of human interstitial fluid is associated with apolipoprotein AI-containing but not with AII-containing particles. Ghalim N, et al. **Int J Clin Lab Res** 1996;26(4):224–8

Evidence that Lp[a] contains one molecule of apo[a] and one molecule of apoB: evaluation of amino acid analysis data. Albers JJ, et al. **J Lipid Res** 1996 Jan;37(1):192–6

Factors influencing Lp[a]- particle size as determined by gradient gel electrophoresis. O'Neal D, et al.

J Lipid Res 1996 Aug;37(8):1655–63

Immunochemical methods for quantification of apolipoprotein A–IV. Fidge NH. **Methods Enzymol** 1996; 263:297–309

BIOSYNTHESIS

Apolipoprotein A–IV synthesis in proximal jejunum is stimulated by ileal lipid infusion. Kalogeris TJ, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):G277–86

Rapid synthesis and secretion of intestinal apolipoprotein A–IV after gastric fat loading in rats. Rodriguez MD, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1170–7

Control of synthesis and secretion of intestinal apolipoprotein A–IV by lipid. Kalogeris TJ, et al. **J Nutr** 1997 Mar; 127(3):537S–543S (87 ref.)

Intestinal synthesis and lymphatic secretion of apolipoprotein A–IV vary with chain length of intestinally infused fatty acids in rats. Kalogeris TJ, et al. **J Nutr** 1996 Nov; 126(11):2720–9

BLOOD

Elevated levels of serum lipoprotein(a) and apolipoprotein(a) phenotype are not related to pre–eclampsia. Leerink CB, et al. **Acta Obstet Gynecol Scand** 1997 Aug;76(7):625–8 (20 ref.)

Lipoprotein(a) plasma levels and apo(a) isoforms are not associated with longevity or disability in a sample of Italian octo–nonagenarians. Associazione Medica Sabin. Zuliani G, et al. **Aging (Milano)** 1995 Oct;7(5):385–91

Lipid, apolipoprotein AI and B levels in Ivorian patients with sickle cell anaemia. Monnet D, et al. **Ann Biol Clin (Paris)** 1996;54(7):285–8

A quantitative immunoassay for the lysine–binding function of lipoprotein(a). Application to recombinant apo(a) and lipoprotein(a) in plasma. Hoover–Plow JL, et al. **Arterioscler Thromb Vasc Biol** 1996 May;16(5):656–64

A prospective case–control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five–City Project participants [published erratum appears in Arterioscler Throm Vasc Biol 1997 May;17(5):1010] Wild SH, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb; 17(2):239–45

Growth hormone therapy transiently increases apolipoprotein(a) in short beta–thalassaemia major children with normal growth hormone reserve. Tam SC, et al. **Atherosclerosis** 1997 Feb 10;128(2):175–82

Association of Lp(a) rather than integrally–bound apo(a) with triglyceride–rich lipoproteins of human subjects. Marcoux C, et al. **Biochim Biophys Acta** 1997 Jun 23;1346(3):261–74

Response of apolipoprotein AIV and lipoproteins to glycaemic control in young people with insulin–dependent diabetes mellitus. Attia N, et al. **Diabet Med** 1997 Mar; 14(3):242–7

Macrovascular disease is associated with increased plasma apolipoprotein A–IV levels in NIDDM. Vergès BL, et al. **Diabetes** 1997 Jan;46(1):125–32

The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Hervio L, et al. **Eur J Clin Invest** 1996 May; 26(5):411–7

Apolipoprotein E polymorphism in a French Canadian population of northeastern Quebec: allele frequencies and effects on blood lipid and lipoprotein levels. Robitaille N, et al. **Hum Biol** 1996 Jun;68(3):357–70

Changes in the concentration and distribution of lipoprotein (a) in plasma after fat intake. Ishikawa T, et al. **J Atheroscler Thromb** 1995;2 Suppl 1:S17–21

[Estrogen–progestin contraception and biohumoral response of new markers of the atheroma risk. Behavior of lipoprotein(a) and apolipoproteins A and B] Porcelli A, et al. **Minerva Ginecol** 1997 Mar;49(3):63–6 (Eng. Abstr.) **(Ita)**

CHEMISTRY

The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Kraft HG, et al. **Atherosclerosis** 1996 Aug 23;125(1):53–61

Structural and functional properties of full–length and truncated human proapolipoprotein AI expressed in escherichia coli. Pyle LE, et al. **Biochemistry** 1996 Sep 17; 35(37):12046–52

Lipoprotein(a): structural implications for pathophysiology. Koschinsky ML, et al. **Int J Clin Lab Res** 1997;27(1):14–23 (94 ref.)

The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. Brunner C, et al. **J Biol Chem** 1996 Dec 13; 271(50):32403–10

Effects of apoE gene polymorphism on Lp(a) concentrations depend on the size of apo(a): a study of 466 white men. Klausen IC, et al. **J Mol Med** 1996 Nov;74(11):685–90

Purification, isoform characterization, and quantitation of human apolipoprotein A–IV. Weinberg RB, et al. **Methods Enzymol** 1996;263:282–96

The role of apo–(a) kringle–IVs in the assembly of lipoprotein–(a). Frank S, et al. **Protein Eng** 1997 Mar; 10(3):291–8

GENETICS

The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. Mooser V, et al. **Am J Hum Genet** 1997 Aug;61(2):402–17

Urbanization elicits a more atherogenic lipoprotein profile in carriers of the apolipoprotein A–IV–2 allele than in A–IV–1 homozygotes. Campos H, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1074–81

Effect of 347–serine mutation in apoprotein A–IV on plasma LDL cholesterol response to dietary fat. Jansen S, et al. **Arterioscler Thromb Vasc Biol** 1997 Aug;17(8):1532–8

Influence of two apo A4 polymorphisms at codons 347 and 360 on non–fasting plasma lipoprotein–lipids and apolipoproteins in Asian Indians. Saha N, et al. **Atherosclerosis** 1997 Jun;131(2):249–55

Comparative analysis of apo(a) gene alleles: distribution of pentanucleotide repeats in position –1373 and C/T transition in position +93 among patients with myocardial infarction and a control group in St. Petersburg, Russia. Volkova MV, et al. **Biochem Mol Med** 1997 Aug; 61(2):208–13

Identification of the C–>T polymorphism in the +93 position of the apo(a) gene by mismatch PCR–mediated site–directed mutagenesis and restriction enzyme digestion [letter] Volkova MV, et al. **Biochem Mol Med** 1996 Oct; 59(1):91–2

Elevated serum Lp(a) concentration and the rare apo(a) phenotype in a patient with myocardial infarction. Hibino T, et al. **Clin Cardiol** 1996 Sep;19(9):758–9

Association between genetic variations of apo AI–CIII–AIV cluster gene and hypertriglyceridemic subjects. Hong SH, et al. **Clin Chem** 1997 Jan;43(1):13–7

Polymorphism of the apolipoprotein A–IV gene and its significance in lipid metabolism and coronary heart disease in a Japanese population. Bai H, et al. **Eur J Clin Invest** 1996 Dec;26(12):1115–24

Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non–random. Kraft HG, et al. **Eur J Hum Genet** 1996;4(2):74–87

Serum distribution of lipoprotein(a) in African Americans and Nigerians: potential evidence for a genotype–environmental effect. Rotimi CN, et al. **Genet Epidemiol** 1997;14(2):157–68

Two novel apolipoprotein A–IV variants in individuals with familial combined hyperlipidemia and diminished levels of lipoprotein lipase activity. Deeb SS, et al. **Hum Mutat** 1996; 8(4):319–25

Modulation of apolipoprotein gene expression in fatty liver of obese rats: enhanced APOA–IV, but no APOB expression by a high sucrose diet. Inui Y, et al. **Int J Obes Relat Metab Disord** 1997 Mar;21(3):231–8

Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A–IV. Cohen RD, et al. **J Clin Invest** 1997 Apr 15;99(8):1906–16

Sib–pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective ApoB. van der Hoek YY, et al. **J Clin Invest** 1997 May 1;99(9):2269–73

Reduction of intestinal apo A–IV mRNA levels in the cirrhotic rat. Seishima M, et al. **J Gastroenterol Hepatol** 1996 Aug;11(8):746–51

Identification of promoter sequences in the 5' untranslated region of the baboon apolipoprotein[a] gene. Hixson JE, et al. **J Lipid Res** 1996 Nov;37(11):2324–31

Lack of association of the apolipoprotein A–I–C–III–A–IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. Marcil M, et al. **J Lipid Res** 1996 Feb;37(2):309–19

Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. Marcovina SM, et al. **J Lipid Res** 1996 Dec;37(12):2569–85

Apolipoproteins(a): a puzzling evolutionary story [letter] Lawn R, et al. **J Mol Evol** 1997 Feb;44(2):234–6

Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target–organ damage in arterial hypertension. Sechi LA, et al. **JAMA** 1997 Jun 4;277(21):1689–95

Association of the apolipoprotein A–IV codon 360 mutation in patients with Alzheimer's disease. Császár A, et al. **Neurosci Lett** 1997 Jul 25;230(3):151–4

Expression of a recombinant kringle V of human apolipoprotein(a): antibody characterization and species specificity. Chenivesse X, et al. **Protein Expr Purif** 1996 Sep;8(2):145–50

[Plasminogen and apolipoproteins A] Ichinose A. **Nippon Naika Gakkai Zasshi** 1997 Jun 10;86(6):993–8 **(Jpn)**

[Changes in serum Lp(a) and apo(a)phenotype in patients with acute cerebral stroke] Fukushima M, et al. **Nippon Ronen Igakkai Zasshi** 1996 Nov;33(11):852–61 (Eng. Abstr.) **(Jpn)**

[Apo(a) phenotype as a risk factor for the silent brain infarction] Notsu Y, et al. **Rinsho Byori** 1997 Feb; 45(2):122–6 (Eng. Abstr.) **(Jpn)**

[Lipoprotein(a) concentrations and apolipoprotein(a) phenotype frequencies in cord blood of newborn infants and sera of children in Japan] Shimura Y, et al. **Rinsho Byori** 1997 Mar;45(3):255–9 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Purification, isoform characterization, and quantitation of human apolipoprotein A–IV. Weinberg RB, et al. **Methods Enzymol** 1996;263:282–96

METABOLISM

Stimulation of intestinal apolipoprotein A–IV by lipid is independent of capsaicin–sensitive afferent signals. Kalogeris TJ, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R981–90

Effects of lipid administration on lymphatic apolipoprotein A–IV and B output and synthesis. Nishimura M, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G322–9

Postabsorptive factors are important for satiation in rats after a lipid meal. Sakata Y, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):G438–42

Plasma lipoprotein composition, apolipoprotein(a) concentration and isoforms in beta–thalassemia. Maioli M, et al. **Atherosclerosis** 1997 May;131(1):127–33

Structural and functional properties of full–length and truncated human proapolipoprotein AI expressed in escherichia coli. Pyle LE, et al. **Biochemistry** 1996 Sep 17; 35(37):12046–52

The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin–modified fibrinogen surface. Sangrar W, et al. **Biochemistry** 1997 Aug 26;36(34):10353–63

Postprandial lipaemia is associated with increased levels of apolipoprotein A–IV in the triacylglycerol–rich fraction and decreased levels in the denser plasma fractions. Dallongeville J, et al. **Br J Nutr** 1997 Feb;77(2):213–23

Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). Bonen DK, et al. **J Biol Chem** 1997 Feb 28;272(9):5659–67

Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. Lawn RM, et al. **J Biol Chem** 1996 Dec 6;271(49):31367–71

Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A–IV. Cohen RD, et al. **J Clin Invest** 1997 Apr 15;99(8):1906–16

High level secretion of wild–type and mutant forms of human proapoA–I using baculovirus–mediated Sf–9 cell expression. Sorci–Thomas MG, et al. **J Lipid Res** 1996 Mar; 37(3):673–83

Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2. Tam SP, et al. **J Lipid Res** 1996 Mar;37(3):518–33

Immunohistochemical distribution of surfactant apoprotein–A in congenital diaphragmatic hernia. Asabe K, et al. **J Pediatr Surg** 1997 May;32(5):667–72

Oral physiological magnesium supplementation for 6 weeks with 1 g/d magnesium oxide does not affect increased Lp(a) levels in hypercholesterolaemic subjects. Hoogerbrugge N, et al. **Magnes Res** 1996 Jun;9(2):129–32

PHARMACOLOGY

Apolipoprotein A–IV acts in the brain to inhibit gastric emptying in the rat. Okumura T, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):G49–53

Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Biemond BJ, et al. **Circulation** 1997 Sep 2;96(5):1612–5

PHYSIOLOGY

Role of apolipoprotein A–IV in hepatic lipase–catalyzed dolichol acylation and phospholipid hydrolysis. Sindelar PJ, et al. **Biochemistry** 1997 Feb 18;36(7):1807–13

SECRETION

Neomycin inhibits secretion of apolipoprotein[a] by increasing retention on the hepatocyte cell surface. Lanford RE, et al. **J Lipid Res** 1996 Oct;37(10):2055–64

Intestinal synthesis and lymphatic secretion of apolipoprotein A–IV vary with chain length of intestinally infused fatty acids in rats. Kalogeris TJ, et al. **J Nutr** 1996 Nov; 126(11):2720–9

URINE

Urinary apo(a) discriminates coronary artery disease patients from controls. Kostner KM, et al. **Atherosclerosis** 1997 Feb 28;129(1):103–10

LDL–apheresis significantly reduces urinary apo(a) excretion. Kostner KM, et al. **Eur J Clin Invest** 1997 Jan; 27(1):93–5

APOLIPOPROTEINS B

ANALYSIS

Comparison of four methods for isolating large mRNA: apolipoprotein B mRNA in bovine and rat livers. Gruffat D, et al. **Anal Biochem** 1996 Nov 1;242(1):77–83

The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48–containing lipoproteins. Nishimaki–Mogami T, et al. **Biochim Biophys Acta** 1996 Nov 11;1304(1):21–31

Denaturing gradient-gel electrophoresis screening of familial defective apolipoprotein B-100 in a mixed Asian cohort: two cases of arginine3500-->tryptophan mutation associated with a unique haplotype. Choong ML, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):916-23

Peroxidation status of erythrocytes and apolipoprotein B containing lipoproteins in hypercholesterolemic subjects. Ozdemirler G, et al. **Int J Vitam Nutr Res** 1997;67(2):130-3

Apoprotein B in subretinal fluid. Huerva V, et al. **Int Ophthalmol** 1996-97;20(4):181-5

Screening and identification of familial defective apolipoprotein B-100 in clinical samples by capillary gel electrophoresis. Lehmann R, et al. **J Chromatogr A** 1996 Sep 13;744(1-2):187-94

Prominence of apolipoproteins B, (a), and E in the intimae of coronary arteries in transplanted human hearts: geographic relationship to vessel wall proteoglycans. Lin H, et al. **J Heart Lung Transplant** 1996 Dec;15(12):1223-32

Evidence that Lp[a] contains one molecule of apo[a] and one molecule of apoB: evaluation of amino acid analysis data. Albers JJ, et al. **J Lipid Res** 1996 Jan;37(1):192-6

A single copy of apolipoprotein B-48 is present on the human chylomicron remnant. Phillips ML, et al. **J Lipid Res** 1997 Jun;38(6):1170-7

Effect of lipid transfer activity and triglyceride hydrolysis on apolipoprotein B immunoreactivity in modified low density lipoproteins. Viens L, et al. **J Lipid Res** 1997 Jun; 38(6):1129-38

Apolipoprotein B-48: problems related to quantification. Lee DM. **Methods Enzymol** 1996;263:146-65

Quantitation of apolipoprotein B by chemical methods. Vega GL, et al. **Methods Enzymol** 1996;263:63-82

Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Holvoet P, et al. **Thromb Haemost** 1996 Nov;76(5):663-9

BIOSYNTHESIS

Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Watts GF, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E462-70

Interactions between lipid and insulin in the regulation of apolipoprotein B secretion. Brown AM, et al. **Biochem Soc Trans** 1996 May;24(2):183S

Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly. Gordon DA. **Curr Opin Lipidol** 1997 Jun; 8(3):131-7 (41 ref.)

Insulin modulation of newly synthesized apolipoproteins B-100 and B-48 in human fetal intestine: gene expression and mRNA editing are not involved. Levy E, et al. **FEBS Lett** 1996 Sep 16;393(2-3):253-8

Inhibition of the microsomal triglyceride transfer protein blocks the first step of apolipoprotein B lipoprotein assembly but not the addition of bulk core lipids in the second step. Gordon DA, et al. **J Biol Chem** 1996 Dec 20;271(51):33047-53

Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Véniant MM, et al. **J Clin Invest** 1997 Jul 1;100(1):180-8

Hepatic gene expression of apolipoprotein B100 during early lactation in underfed, high producing dairy cows. Gruffat D, et al. **J Dairy Sci** 1997 Apr;80(4):657-66

Effect of ethanol on the synthesis and secretion of apoA-I- and apoB-containing lipoproteins in HepG2 cells. Dashti N, et al. **J Lipid Res** 1996 Apr;37(4):810-24

Estrogen dependence of synthesis and secretion of apolipoprotein B-containing lipoproteins in the chicken hepatoma cell line, LMH-2A. Hermann M, et al. **J Lipid Res** 1997 Jul;38(7):1308-17

Increased hepatic synthesis and accumulation of plasma apolipoprotein B100 in copper-deficient rats does not result from modification in apolipoprotein B mRNA editing. Nassir F, et al. **Lipids** 1996 Apr;31(4):433-6

Normal intestinal dietary fat and cholesterol absorption, intestinal apolipoprotein B (ApoB) mRNA levels, and ApoB-48 synthesis in a hypobetalipoproteinemic kindred without any ApoB truncation. Pulai JI, et al. **Metabolism** 1997 Sep;46(9):1095-100

An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Jamil H, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11991-5

BLOOD

Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Curtin A, et al. **Acta Diabetol** 1996 Sep;33(3):205-10

Serum cholesterol and apolipoprotein B levels may reflect disease activity in ovarian cancer patients. Avall-Lundqvist EH, et al. **Acta Oncol** 1996;35(8):1007-10

Serum apolipoproteins A-I and B in male and female full-term newborns of the Toledo study (Spain). Bastida S, et al. **Acta Paediatr** 1996 Jun;85(6):750-2

Decreased serum apolipoprotein B-100 and A-I concentrations in cows with ketosis and left displacement of the abomasum. Oikawa S, et al. **Am J Vet Res** 1997 Feb;58(2):121-5

Lipid, apolipoprotein AI and B levels in Ivorian patients with sickle cell anaemia. Monnet D, et al. **Ann Biol Clin (Paris)** 1996;54(7):285-8

A highly sensitive assay for quantitation of apolipoprotein B48 using an antibody to human apolipoprotein B and enhanced chemiluminescence. Smith D, et al. **Ann Clin Biochem** 1997 Mar;34 (Pt 2):185-9

Relationship between bilirubin, apolipoprotein B, and coronary artery disease. Levinson SS. **Ann Clin Lab Sci** 1997 May-Jun;27(3):185-92

A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy. Aguilar-Salinas CA, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan; 17(1):72-82

Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia. Bredie SJ, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):834-40

Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Laws A, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan; 17(1):64-71

Associations between diet and the hyperapobetalipoproteinemia phenotype expression in children and young adults: the Cardiovascular Risk in Young Finns Study. Nuotio IO, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):820-5

Decreased production and increased catabolism of apolipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes. Welty FK, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):881-8

Antibodies released from immunoadsorbents: effect of support, activation and elution conditions. Ubrich N, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1996 Jan; 24(1):65-75

Serum HDL cholesterol values are associated with apoB-containing lipoprotein metabolism and triglyceride-body fat interrelation in young Japanese men. Kazumi T, et al. **Atherosclerosis** 1997 Apr;130(1-2):93-100

Plasma cholesteryl ester transfer protein concentration, high-density lipoprotein cholesterol esterification and transfer rates to lighter density lipoproteins in the fasting state and after a test meal are similar in Type II diabetics and normal controls. Lottenberg SA, et al. **Atherosclerosis** 1996 Nov 15;127(1):81-90

Distribution of apolipoprotein E between apo B- and non apo B-containing lipoproteins according to apo E phenotype. Luc G, et al. **Atherosclerosis** 1997 Jun; 131(2):257-62

Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Meyer E, et al. **Atherosclerosis** 1996 Aug 2;124(2):221-35

Binding and transport of benzo[a]pyrene by blood plasma lipoproteins: the possible role of apolipoprotein B in this process. Polyakov LM, et al. **Bioconjug Chem** 1996 Jul-Aug;7(4):396-400

Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians. Weber M, et al. **Can J Cardiol** 1997 Mar; 13(3):253-60

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. Lamarche B, et al. **Circulation** 1996 Aug 1;94(3):273-8

Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population. Welty FK, et al. **Circulation** 1997 Feb 18; 95(4):825-30

Higher level of plasma cholesteryl ester transfer activity from high-density lipoprotein to apo B-containing lipoproteins in subjects with angiographically detectable coronary artery disease. Hibino T, et al. **Clin Cardiol** 1996 Jun; 19(6):483-6

Automated measurement of mouse apolipoprotein B: convenient screening tool for mouse models of atherosclerosis. Levine DM, et al. **Clin Chem** 1997 Apr; 43(4):669-74

Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia. Planella T, et al. **Clin Chem** 1997 May;43(5):808-15

Counterpoint: to (measure apo) B or not to (measure apo) B: a critique of modern medical decision-making. Sniderman AD. **Clin Chem** 1997 Aug;43(8 Pt 1):1310-4

Comparison of methods for measurement of apolipoprotein B and cholesterol in low-density lipoproteins. Vrga L, et al. **Clin Chem** 1997 Feb;43(2):390-3

Hyperglycemia-induced hyperinsulinemia acutely lowers plasma apolipoprotein B but not lipoprotein (a) in man. Riemens SC, et al. **Clin Chim Acta** 1997 May 28; 261(2):149-58

Determinants of the kinetics of very low-density lipoprotein apolipoprotein B-100 in non-obese men. Watts GF, et al. **Clin Exp Pharmacol Physiol** 1997 Aug;24(8):556-62

Isolation of low density lipoprotein subfraction containing apolipoprotein B-like protein from Japanese eel Anguilla japonica plasma using dextran sulfate cellulose. Ando S, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 Feb;116(2):191-6

Assessment of postprandial lipemia: nutritional influences. Bergeron N, et al. **Curr Opin Lipidol** 1997 Feb;8(1):43-52 (59 ref.)

Hyperlipidaemia and cardiovascular disease [editorial] Somers VK, et al. **Curr Opin Lipidol** 1996 Dec; 7(6):U193-201 (13 ref.)

The apoB-100 gene EcoRI polymorphism influences the relationship between features of the insulin resistance syndrome and the hyper-apoB and dense LDL phenotype in men. Vohl MC, et al. **Diabetes** 1996 Oct;45(10):1405-11

Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Malmström R, et al. **Diabetologia** 1997 Apr;40(4):454-62

Effects of simvastatin on the number and composition of apoproteinB-containing lipoproteins in hypercholesterolemia: analysis of apoproteinB in each lipoprotein fraction by highly sensitive latex method. Ikeda Ryomoto K, et al. **Endocr J** 1996 Oct;43(5):469-75

Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia. Rašlová K, et al. **Eur J Clin Pharmacol** 1997;52(2):101-6

The age-related rise of plasma cholesterol in humans is not caused by a cell removal defect of LDL particles: 'in vitro' studies in peripheral mononuclear blood cells. Neves MQ, et al. **Gerontology** 1997;43(4):232-41

Elevated plasma lipoprotein(a) levels and hypoalbuminemia in peritoneal dialysis patients. Ross EA, et al. **Int J Artif Organs** 1995 Dec;18(12):751-6

Abnormal protein tyrosine phosphorylation in fibroblasts from hyperapobetalipoproteinemia subjects. Motevalli M, et al. **J Biol Chem** 1997 Sep 26;272(39):24703-9

A novel abetalipoproteinemia genotype. Identification of a missense mutation in the 97-kDa subunit of the microsomal triglyceride transfer protein that prevents complex formation with protein disulfide isomerase. Rehberg EF, et al. **J Biol Chem** 1996 Nov 22;271(47):29945-52

Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidaemia of adult growth hormone deficiency. Cummings MH, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):2010-3

Rate of low-density lipoprotein cholesterol and apolipoprotein B changes on initiation and discontinuation of atorvastatin treatment. Stern RH, et al. **J Clin Pharmacol** 1997 Apr;37(4):291-6

Alterations of VLDL composition during alimentary lipemia. Björkegren J, et al. **J Lipid Res** 1997 Feb;38(2):301-14

Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in abetalipoproteinemia. Du EZ, et al. **J Lipid Res** 1996 Jun;37(6):1309-15

Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde. Luc G, et al. **J Lipid Res** 1996 Mar;37(3):508-17

Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia. Parhofer KG, et al. **J Lipid Res** 1996 Nov;37(11):2383-93

Monomethylethanolamine reduces plasma triacylglycerols and apolipoprotein B and increases apolipoprotein A-I rats without induction of fatty liver. Rusiñol AE, et al. **J Lipid Res** 1996 Nov;37(11):2296-304

Serum apolipoprotein B-100 concentrations in healthy and diseased cattle. Itoh H, et al. **J Vet Med Sci** 1997 Jul; 59(7):587-91

Increased hepatic synthesis and accumulation of plasma apolipoprotein B100 in copper-deficient rats does not result from modification in apolipoprotein B mRNA editing. Nassir F, et al. **Lipids** 1996 Apr;31(4):433-6

Erdheim-Chester disease: low low-density lipoprotein levels due to rapid catabolism. Schmidt HH, et al. **Metabolism** 1997 Oct;46(10):1215-9

Simultaneous quantification of apolipoproteins B-100, B-48, and E separated by SDS-PAGE. Bergeron N, et al. **Methods Enzymol** 1996;263:82-94

Apolipoprotein B-48. Karpe F, et al. **Methods Enzymol** 1996; 263:95-104

Quantitation of apolipoprotein B by chemical methods. Vega GL, et al. **Methods Enzymol** 1996;263:63-82

Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia. Bredie SJ, et al. **Neth J Med** 1996 Aug; 49(2):59-67

Serum levels of carnitine, apolipoprotein A I, and apolipoprotein B in children with nephrotic proteinuria [letter] Bircan Z, et al. **Pediatr Nephrol** 1996 Oct;10(5):680

Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives. Tonstad S, et al. **Pediatr Res** 1996 Jul;40(1):47-52

Measurement of fractional esterification rate of cholesterol in plasma depleted of apoprotein B containing lipoprotein: methods and normal values. Dobiášová M, et al. **Physiol Res** 1996;45(1):65-73

Apolipoprotein B-48 as a marker for chylomicrons and their remnants: studies in the postprandial state. Isherwood SG, et al. **Proc Nutr Soc** 1997 Mar;56(1B):497-505 (53 ref.)

Lipaemia and lipoproteinaemia in a Spanish male nonsmoker population consuming sunflower oil. Sánchez-Muniz FJ, et al. **Z Ernahrungswiss** 1996 Sep;35(3):259-65

[Evaluation of atherogenic risk in homozygous sickle cell disease: study of lipid and apolipoprotein AI and B plasma levels] Monnet PD, et al. **Bull Soc Pathol Exot** 1996; 89(4):278-81 (Eng. Abstr.) **(Fre)**

[Estrogen-progestin contraception and biohumoral response

of new markers of the atheroma risk. Behavior of lipoprotein(a) and apolipoproteins A and B] Porcelli A, et al. **Minerva Ginecol** 1997 Mar;49(3):63–6 (Eng. Abstr.) **(Ita)**

[A study of serum protein fraction binding to indocyanine green (ICG) by combined method of immunoelectrophoresis and ICG fundus videosystem] Saito T, et al. **Nippon Ganka Gakkai Zasshi** 1996 Aug; 100(8):617–23 (Eng. Abstr.) **(Jpn)**

[Lipid and lipoprotein profile of Japanese centenarians—high prevalence of hypo beta lipoproteinemia] Arai Y, et al. **Nippon Ronen Igakkai Zasshi** 1997 Mar;34(3):202–8 (Eng. Abstr.) **(Jpn)**

[Astaxanthine-induced inhibition of oxidation of apolipoprotein B–containing lipoproteins in human blood] Kukharchuk VV, et al. **Biull Eksp Biol Med** 1997 Mar; 123(3):285–8 **(Rus)**

[Serum apolipoprotein B (apoB) in patients with hypothyroidism] Oravec S, et al. **Bratisl Lek Listy** 1996 Dec;97(12):717–9 (Eng. Abstr.) **(Slo)**

CHEMISTRY

The mechanism of apolipoprotein B–100 thiol depletion during oxidative modification of low–density lipoprotein. Ferguson E, et al. **Arch Biochem Biophys** 1997 May 15; 341(2):287–94

Apolipoprotein B carbonyl formation is enhanced by lipid peroxidation during copper–mediated oxidation of human low–density lipoproteins. Yan LJ, et al. **Arch Biochem Biophys** 1997 Mar 1;339(1):165–71

Immunochemical detection of carboxymethylated Apo B–100 in copper–oxidized LDL. Kato Y, et al. **Biochem Biophys Res Commun** 1996 Sep 24;226(3):923–7

Reduced beta–strand content in apoprotein B–100 in smaller and denser low–density lipoprotein subclasses as probed by Fourier–transform infrared spectroscopy. Tanfani F, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):765–9

Folding of the amino–terminal domain of apolipoprotein B initiates microsomal triglyceride transfer protein–dependent lipid transfer to nascent very low density lipoprotein. Ingram MF, et al. **J Biol Chem** 1997 Apr 11;272(15):10279–86

Systematic expression of the complete coding sequence of apoB–100 does not reveal transmembrane determinants. Leiper JM, et al. **J Lipid Res** 1996 Oct;37(10):2215–31

Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B. McNamara JR, et al. **J Lipid Res** 1996 Sep;37(9):1924–35

Sialic acids and the metabolism of low density lipoprotein. Melajärvi N, et al. **J Lipid Res** 1996 Aug;37(8):1625–31

Comparison between copper–mediated and hypochlorite–mediated modifications of human low density lipoproteins evaluated by protein carbonyl formation. Yan LJ, et al. **J Lipid Res** 1997 May;38(5):992–1001

Identification and characterization of truncated forms of apolipoprotein B in hypobetalipoproteinemia. Young SG, et al. **Methods Enzymol** 1996;263:120–45

DEFICIENCY

Familial defective apolipoprotein B–100: a study of patients from lipid clinics in Scotland and Wales. Wenham PR, et al. **Ann Clin Biochem** 1996 Sep;33 (Pt 5):443–50

Detecting familial defective apolipoprotein B–100: three molecular scanning methods compared. Henderson BG, et al. **Clin Chem** 1997 Sep;43(9):1630–4

GENETICS

Copper deficiency increases hepatic apolipoprotein B secretion and mRNA editing in rats. Reaves SK, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C595–604

Comparison of four methods for isolating large mRNA: apolipoprotein B mRNA in bovine and rat livers. Gruffat D, et al. **Anal Biochem** 1996 Nov 1;242(1):77–83

Polymorphisms of the genes encoding apoproteins A–I, B, C–III, and E and LDL receptor, and cholesterol and LDL metabolism during increased cholesterol intake. Common alleles of the apoprotein E gene show the greatest regulatory impact. Gylling H, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):38–44

Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries. Hansen PS, et al. **Arterioscler Thromb Vasc Biol** 1997 Apr;17(4):741–7

Differences in the phenotype between children with familial defective apolipoprotein B–100 and familial hypercholesterolemia. Pimstone SN, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):826–33

Homozygous familial defective apolipoprotein B–100. Enhanced removal of apolipoprotein E–containing VLDLs and decreased production of LDLs. Schaefer JR, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):348–53

Effective lowering of plasma, LDL, and esterified cholesterol in LDL receptor–knockout mice by adenovirus–mediated gene delivery of ApoB mRNA editing enzyme (Apobec1). Teng B, et al. **Arterioscler Thromb Vasc Biol** 1997 May; 17(5):889–97

Decreased production and increased catabolism of apolipoprotein B–100 in apolipoprotein B–67/B–100 heterozygotes. Welty FK, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):881–8

The association between free fatty acid concentrations and triglyceride–rich lipoproteins in the post–prandial state is altered by a common deletion polymorphism of the apo B signal peptide. Byrne CD, et al. **Atherosclerosis** 1996 Nov 15;127(1):35–42

Screening of the 3' two–thirds of the coding area of the apo B gene in Finnish hypercholesterolemic patients report of six new genetic variants. Ilmonen M, et al. **Atherosclerosis** 1997 Feb 10;128(2):191–9

Polymorphism of the apolipoprotein B gene and blood lipid concentrations in Japanese and Caucasian population samples. Iso H, et al. **Atherosclerosis** 1996 Oct 25; 126(2):233–41

Familial defective apolipoprotein B–100 (FDB): effect of simvastatin therapy on LDL–receptor binding. Mamotte CD, et al. **Atherosclerosis** 1996 Aug 23;125(1):103–10

The effects of the apolipoprotein B signal peptide (ins/del) and XbaI polymorphisms on plasma lipid responses to dietary change. Pajukanta PE, et al. **Atherosclerosis** 1996 Apr 26;122(1):1–10

Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. Raal FJ, et al. **Atherosclerosis** 1997 Feb 28;129(1):97–102

Rapid testing for three mutations causing familial defective apolipoprotein B100 in 562 patients with familial hypercholesterolaemia [letter] Talmud PJ, et al. **Atherosclerosis** 1996 Aug 23;125(1):135–7

Familial ligand–defective apolipoprotein B–100: detection, biochemical features and haplotype analysis of the R3531C mutation in the UK. Wenham PR, et al. **Atherosclerosis** 1997 Mar 21;129(2):185–92

Effects of apo E deficiency on plasma lipid levels in mice lacking APOBEC–1. Osuga J, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):375–8

Apolipoprotein B gene regulatory factor–2 (BRF–2) is structurally and immunologically highly related to hepatitis B virus X associated protein–1 (XAP–1). Krishnamoorthy RR, et al. **Biochemistry** 1997 Jan 28;36(4):960–9

Apobec–1 and apolipoprotein B mRNA editing. Chan L, et al. **Biochim Biophys Acta** 1997 Mar 10;1345(1):11–26 (90 ref.)

Nonradioactive PCR–SSCP assay to detect apoB Arg3500 to Gln mutation using a minigel format. Hennessy LK, et al. **Biotechniques** 1997 Mar;22(3):446–7

DNA polymorphisms of apolipoprotein B and AI–CII–AIV genes in a Brazilian population: a preliminary report. Bydlowski SP, et al. **Braz J Med Biol Res** 1996 Oct; 29(10):1269–74

Denaturing gradient–gel electrophoresis screening of familial defective apolipoprotein B–100 in a mixed Asian cohort: two cases of arginine3500—>tryptophan mutation associated with a unique haplotype. Choong ML, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):916–23

Detecting familial defective apolipoprotein B–100: three molecular scanning methods compared. Henderson BG, et al. **Clin Chem** 1997 Sep;43(9):1630–4

Study of apoB gene signal peptide insertion/deletion polymorphism in a healthy Serbian population: no association with serum lipid levels. Glišić S, et al. **Clin Chim Acta** 1997 Jul 4;263(1):57–65

Analysis of novel apolipoprotein B mutations using a modified U937 cell line LDL binding assay. Meng QH, et al. **Clin Chim Acta** 1996 Dec 9;256(1):27–36

Effects of apo B and apo E gene polymorphisms on lipid and apolipoprotein concentrations after a test meal. Regis–Bailly A, et al. **Clin Chim Acta** 1996 Sep 30; 253(1–2):127–43

Apolipoproteins B and E, and angiotensin I–converting enzyme (ACE) genetic polymorphisms in Italian women with coronary artery disease (CAD) and their relationships with plasma lipid and apolipoprotein levels. Corbo RM, et al. **Clin Genet** 1997 Aug;52(2):77–82

Genetic contributions to LDL–C, Apo–B and LDL–C/Apo–B ratio in a sample of Israeli offspring with a parental history of myocardial infarction. Friedlander Y. **Clin Genet** 1996 Jul;50(1):1–9

Frequencies of five genetic polymorphisms in coronarographed patients and effects on lipid levels in a supposedly healthy population. Régis–Bailly A, et al. **Clin Genet** 1996 Nov;50(5):339–47

Genetics and molecular biology [editorial] Chamberlain JC. **Curr Opin Lipidol** 1996 Dec;7(6):U179–83 (15 ref.)

The apoB–100 gene EcoRI polymorphism influences the relationship between features of the insulin resistance syndrome and the hyper–apoB and dense LDL phenotype in men. Vohl MC, et al. **Diabetes** 1996 Oct;45(10):1405–11

Resolution of apolipoprotein B repeat unit position variants on agarose, denaturing, and native polyacrylamide gels. Prinz M, et al. **Electrophoresis** 1996 Jul;17(7):1190–3

Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. Tarugi P, et al. **Gastroenterology** 1996 Oct;111(4):1125–33

Two distinct apolipoprotein B alleles in mice generated by a single 'in–out' targeting. Toth LR, et al. **Gene** 1996 Oct 31;178(1–2):161–8

Linkage disequilibrium studies in the thyroid peroxidase and apolipoprotein B genes. De Benedictis G, et al. **Hum Biol** 1996 Feb;68(1):147–54

Genotype associations among seven apolipoprotein B polymorphisms in a population of Orang Asli of western Malaysia. Gajra B, et al. **Hum Biol** 1997 Oct;69(5):629–40

Apolipoprotein B and E genetic polymorphisms in the Cayapa Indians of Ecuador. Scacchi R, et al. **Hum Biol** 1997 Jun;69(3):375–82

Gene transfer of cytidine deaminase apoBEC–1 lowers lipoprotein(a) in transgenic mice and induces apolipoprotein B editing in rabbits. Hughes SD, et al. **Hum Gene Ther** 1996 Jan;7(1):39–49

DNA multiallelic systems reveal gene/longevity associations not detected by diallelic systems. The APOB locus. De Benedictis G, et al. **Hum Genet** 1997 Mar;99(3):312–8

The apolipoprotein B Q3405E polymorphism has no effect on its low–density–lipoprotein receptor binding affinity. Pullinger CR, et al. **Hum Genet** 1996 Dec;98(6):678–80

Detection of new variants in the apolipoprotein B (Apo B) gene by PCR–SSCP. Poirier O, et al. **Hum Mutat** 1996; 8(3):282–5

Familial ligand–defective apolipoprotein B–100: simultaneous detection of the ARG3500—>GLN and ARG3531—>CYS mutations in a French population. Rabès JP, et al. **Hum Mutat** 1997;10(2):160–3

Population genetic study of the AmpFLP system APO B in an Austrian population sample. Neuhuber F, et al. **Int J Legal Med** 1996;109(1):45–6

Modulation of apolipoprotein gene expression in fatty liver of obese rats: enhanced APOA–IV, but no APOB expression by a high sucrose diet. Inui Y, et al. **Int J Obes Relat Metab Disord** 1997 Mar;21(3):231–8

Using genetically modified mice to study apolipoprotein B. Young SG. **J Atheroscler Thromb** 1996;3(2):62–74 (45 ref.)

Cloning of an Apobec–1–binding protein that also interacts with apolipoprotein B mRNA and evidence for its involvement in RNA editing. Lau PP, et al. **J Biol Chem** 1997 Jan 17;272(3):1452–5

Reading–frame restoration by transcriptional slippage at long stretches of adenine residues in mammalian cells. Linton MF, et al. **J Biol Chem** 1997 May 30;272(22):14127–32

Transgenic mice expressing human ApoB95 and ApoB97. Evidence that sequences within the carboxyl–terminal portion of human apoB100 are important for the assembly of lipoprotein. McCormick SP, et al. **J Biol Chem** 1997 Sep 19;272(38):23616–22

Apobec–1 interacts with a 65–kDa complementing protein to edit apolipoprotein–B mRNA in vitro. Mehta A, et al. **J Biol Chem** 1996 Nov 8;271(45):28294–9

Complete phenotypic characterization of apobec–1 knockout mice with a wild–type genetic background and a human apolipoprotein B transgenic background, and restoration of apolipoprotein B mRNA editing by somatic gene transfer of Apobec–1. Nakamuta M, et al. **J Biol Chem** 1996 Oct 18;271(42):25981–8

Tissue–specific inhibition of apolipoprotein B mRNA editing in the liver by adenovirus–mediated transfer of a dominant negative mutant APOBEC–1 leads to increased low density lipoprotein in mice. Oka K, et al. **J Biol Chem** 1997 Jan 17;272(3):1456–60

Screening and identification of familial defective apolipoprotein B–100 in clinical samples by capillary gel electrophoresis. Lehmann R, et al. **J Chromatogr A** 1996 Sep 13;744(1–2):187–94

Sib–pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective ApoB. van der Hoek YY, et al. **J Clin Invest** 1997 May 1;99(9):2269–73

Hepatic gene expression of apolipoprotein B100 during early lactation in underfed, high producing dairy cows. Gruffat D, et al. **J Dairy Sci** 1997 Apr;80(4):657–66

Apolipoprotein B gene polymorphisms in Taiwanese ischemic stroke patients. Chen CH, et al. **J Formos Med Assoc** 1997 Jul;96(7):499–502

Molecular genetics of familial hypercholesterolaemia in Norway. Leren TP, et al. **J Intern Med** 1997 Mar; 241(3):185–94

Characterization of the human apobec–1 gene: expression in gastrointestinal tissues determined by alternative splicing with production of a novel truncated peptide. Hirano K, et al. **J Lipid Res** 1997 May;38(5):847–59

Asymmetric distribution of pause transfer sequences in apolipoprotein B–100. Kivlen MH, et al. **J Lipid Res** 1997 Jun;38(6):1149–62

Metabolism of apolipoprotein B–100 in a kindred with familial hypobetalipoproteinemia without a truncated form of apoB. Latour MA, et al. **J Lipid Res** 1997 Mar; 38(3):592–9

Systematic expression of the complete coding sequence of apoB–100 does not reveal transmembrane determinants. Leiper JM, et al. **J Lipid Res** 1996 Oct;37(10):2215–31

Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins. Ludwig EH, et al. **J Lipid Res** 1997 Jul;38(7):1361–73

Microsomal triglyceride transfer protein in CaCo–2 cells: characterization and regulation. Mathur SN, et al. **J Lipid Res** 1997 Jan;38(1):61–7

Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: in vivo studies in human apoB–89, apoB–75, apoB–54.8, and apoB–31 heterozygotes. Parhofer KG, et al. **J Lipid Res** 1996 Apr; 37(4):844–52

Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B–100: a stable isotope approach. Pietzsch J, et al. **J Lipid Res** 1996 Oct;37(10):2074–87

Evaluation of the function of the human apolipoprotein B gene nuclear matrix association regions in transgenic mice.

Wang DM, et al. **J Lipid Res** 1996 Oct;37(10):2117–24

Control of apolipoprotein B mRNA editing: implication of mRNA dynamics at various maturation stages. Chen L, et al. **J Theor Biol** 1996 Dec 21;183(4):391–407

Normal intestinal dietary fat and cholesterol absorption, intestinal apolipoprotein B (ApoB) mRNA levels, and ApoB–48 synthesis in a hypobetalipoproteinemic kindred without any ApoB truncation. Pulai JI, et al. **Metabolism** 1997 Sep;46(9):1095–100

A new apolipoprotein B truncation (apo B–43.7) in familial hypobetalipoproteinemia: genetic and metabolic studies. Srivastava N, et al. **Metabolism** 1996 Oct;45(10):1296–304

Restriction fragment length polymorphism of the human apo B and apo AII gene regions among type II diabetics. Ghusn H, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jul; 93(1):25–32

A simple PCR method for detection of defined point mutations. Glišić S, et al. **Trends Genet** 1996 Oct; 12(10):391–2

[Analysis of polymorphism of the hypervariable locus of the apolipoprotein–B gene in populations of the Volga–Ural region] Khusnutdinova EK, et al. **Genetika** 1996 Dec; 32(12):1678–82 (Eng. Abstr.) **(Rus)**

[Analysis of polymorphism of the 5'-terminal region of apolipoprotein B gene in patients with ischemic heard disease] Shadrina MI, et al. **Genetika** 1996 Aug;32(8):1041–4 (Eng. Abstr.) **(Rus)**

[Highly polymorphic regions of the genes for apolipoprotein B and angiotensin–converting enzyme in the Udmurt population] Spitsyn VA, et al. **Genetika** 1997 Feb; 33(2):269–73 (Eng. Abstr.) **(Rus)**

[A population genetics study of the allelic polymorphism in the hypervariable region of the apolipoprotein B gene in the population of different regions of Ukraine] Kravchenko SA, et al. **Tsitol Genet** 1996 Sep–Oct;30(5):35–41 (Eng. Abstr.) **(Rus)**

[Apolipoprotein AI–CIII, B, and CII gene polymorphisms in patients with non–insulin dependent diabetes mellitus. Association with hyperlipemia] Gutiérrez C, et al. **Med Clin (Barc)** 1996 Nov 2;107(15):561–5 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

A highly sensitive assay for quantitation of apolipoprotein B48 using an antibody to human apolipoprotein B and enhanced chemiluminescence. Smith D, et al. **Ann Clin Biochem** 1997 Mar;34 (Pt 2):185–9

Dissociation of LPL and LDL: effects of lipoproteins and anti–apoB antibodies. Choi SY, et al. **J Lipid Res** 1997 Jan; 38(1):77–85

Characterization of a specific polyclonal antibody against 13–hydroperoxyoctadecadienoic acid–modified protein: formation of lipid hydroperoxide–modified apoB–100 in oxidized LDL. Kato Y, et al. **J Lipid Res** 1997 Jul; 38(7):1334–46

ISOLATION & PURIFICATION

Sequential purification of human apolipoprotein B–100, albumin, and fibrinogen by immunoaffinity chromatography for measurement of protein synthesis. Fu AZ, et al. **Anal Biochem** 1997 May 1;247(2):228–36

Purification and characterization of low density lipoprotein containing apolipoprotein B–48 from the plasma of an apoE–deficient patient. Hashimoto Y, et al. **Clin Chim Acta** 1997 Mar 18;259(1–2):109–16

Analysis of human specificity in AFLP systems APOB, PAH, and D1S80. Latorra D, et al. **Forensic Sci Int** 1996 Nov 11;83(1):15–25 (22 ref.)

Separation and quantification of apolipoprotein B–48 and other apolipoproteins by dynamic sieving capillary electrophoresis. Proctor SD, et al. **J Lipid Res** 1997 Feb; 38(2):410–4

Immunochemical separation of apolipoprotein B–48–and B–100–containing lipoproteins. Milne RW. **Methods Enzymol** 1996;263:166–70

Chromatographic method for isolation and quantification of apolipoproteins B–100 and B–48. Sparks JD, et al. **Methods Enzymol** 1996;263:104–20

[ApoB–lipoprotein hydroperoxides isolated by immunoaffine chromatography] Kuznetsov AS, et al. **Biull Eksp Biol Med** 1996 Aug;122(8):160–3 **(Rus)**

METABOLISM

Lipoproteins accumulate in immune deposits and are modified by lipid peroxidation in passive Heymann nephritis. Exner M, et al. **Am J Pathol** 1996 Oct; 149(4):1313–20

Effects of lipid administration on lymphatic apolipoprotein A–IV and B output and synthesis. Nishimura M, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):G322–9

Copper deficiency increases hepatic apolipoprotein B secretion and mRNA editing in rats. Reaves SK, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):C595–604

Presence of apolipoprotein B–100 in human intestine epithelial cells. Tamura M, et al. **Ann N Y Acad Sci** 1997 Apr 15;811:488–92

Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Hurt–Camejo E, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun;17(6):1011–7 (101 ref.)

Effect of the ACAT inhibitor CL 277,082 on apolipoprotein B48 transport in mesenteric lymph and on plasma clearance of chylomicrons and remnants. Martins IJ, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):211–6

Lipoprotein kinetics in patients with analbuminemia. Evidence for the role of serum albumin in controlling lipoprotein metabolism. Maugeais C, et al. **Arterioscler Thromb Vasc Biol** 1997 Jul;17(7):1369–75

Possible functional interactions of apolipoprotein B–100 segments that associate with cell proteoglycans and the ApoB/E receptor. Olsson U, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):149–55

Organ loci of catabolism of short truncations of apoB. Zhu XF, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun; 17(6):1032–8

Increased esterification of cholesterol and transfer of cholesteryl ester to apo B–containing lipoproteins in Type 2 diabetes: relationship to serum lipoproteins A–I and A–II. Jones RJ, et al. **Atherosclerosis** 1996 Jan 26;119(2):151–7

Activation of a cryptic splice–site in intron 24 leads to the formation of apolipoprotein B–27.6. Nemeth–Slany A, et al. **Atherosclerosis** 1997 Sep;133(2):163–70

Decreased intracellular degradation and increased secretion of apo B–100 in Hep G2 cells after inhibition of cholesteryl ester synthesis. Ooyen C, et al. **Atherosclerosis** 1997 Apr; 130(1–2):143–52

In vitro translation and translocation of apolipoprotein B in a cell–free system from HepG2 cells. Mohammadi A, et al. **Biochem Biophys Res Commun** 1996 Nov 21; 228(3):852–8

Retention of orotic acid effect on very low density lipoproteins secretion in cultured hepatocytes. Hebbachi AM, et al. **Biochem Soc Trans** 1996 May;24(2):177S

Ubiquitin–proteasome pathway mediates intracellular degradation of apolipoprotein B. Yeung SJ, et al. **Biochemistry** 1996 Oct 29;35(43):13843–8

Immunoenzyme assessment of human apoB–lipoprotein binding to immobilized receptor of low density lipoproteins. 1. Preparation of anti–receptor monoclonal antibodies. Tsibulsky VP, et al. **Biochemistry (Mosc)** 1997 Jun;62(6):596–602

Immunoenzyme assessment of human apoB–lipoprotein binding to immobilized receptor of low density lipoproteins. 2. Binding of isolated lipoproteins. Tsibulsky VP, et al. **Biochemistry (Mosc)** 1997 Jun;62(6):603–8

Alterations in the structure of apolipoprotein B–100 determine the behaviour of LDL towards thromboplastin. Ettelaie C, et al. **Biochim Biophys Acta** 1997 Apr 21; 1345(3):237–47

The interaction of lower alcohols with apoB in spin labeled human plasma low density lipoproteins (LDL). Kveder M, et al. **Chem Phys Lipids** 1997 Jul 14;87(2):125–35

Role of lipid synthesis, chaperone proteins and proteasomes in the assembly and secretion of apoprotein B–containing lipoproteins from cultured liver cells. Ginsberg HN. **Clin Exp Pharmacol Physiol** 1997 May;24(5):A29–32 (61 ref.)

Apolipoprotein B metabolism in primary and secondary hyperlipidaemias. Gaw A, et al. **Curr Opin Lipidol** 1996 Jun;7(3):149–54 (39 ref.)

Regulation of hepatic apolipoprotein–B–containing lipoprotein secretion. Pease RJ, et al. **Curr Opin Lipidol** 1996 Jun;7(3):132–8 (51 ref.)

Cholesterol absorption, synthesis, and LDL metabolism in NIDDM. Gylling H, et al. **Diabetes Care** 1997 Jan; 20(1):90–5

Microsomal triacylglycerol transfer protein prevents presecretory degradation of apolipoprotein B–100. A dithiothreitol–sensitive protease is involved. Benoist F, et al. **Eur J Biochem** 1996 Sep 15;240(3):713–20

Prostaglandin E1 decreases human arterial accumulation of radiolabeled apo B–containing lipoproteins in vivo. Kritz H, et al. **Eur J Clin Pharmacol** 1997;52(3):191–7

Studies of apolipoprotein B–100 metabolism using radiotracers and stable isotopes. Demant T, et al. **Eur J Pediatr** 1997 Aug;156 Suppl 1:S75–7 (9 ref.)

Oxidative modifications of apoB–100 by exposure of low density lipoproteins to HOCL in vitro. Yang CY, et al. **Free Radic Biol Med** 1997;23(1):82–9

Induction of hepatic apolipoprotein B mRNA editing for reducing serum cholesterol levels: a breakthrough or a disaster? Greeve J, et al. **Hepatology** 1996 Oct;24(4):964–6

Apolipoprotein B is intracellularly associated with an ER–60 protease homologue in HepG2 cells. Adeli K, et al. **J Biol Chem** 1997 Sep 5;272(36):22489–94

Intracellular assembly and degradation of apolipoprotein B–100–containing lipoproteins in digitonin–permeabilized HEP G2 cells. Adeli K, et al. **J Biol Chem** 1997 Feb 21; 272(8):5031–9

Co–translational degradation of apolipoprotein B100 by the proteasome is prevented by microsomal triglyceride transfer protein. Synchronized translation studies on HepG2 cells treated with an inhibitor of microsomal triglyceride transfer protein. Benoist F, et al. **J Biol Chem** 1997 Aug 15;272(33):20435–42

First direct evidence for lipid/protein conjugation in oxidized human low density lipoprotein. Bolgar MS, et al. **J Biol Chem** 1996 Nov 8;271(45):27999–8001

The degradation of apolipoprotein B100 is mediated by the ubiquitin–proteasome pathway and involves heat shock protein 70. Fisher EA, et al. **J Biol Chem** 1997 Aug 15; 272(33):20427–34

Studies on intracellular translocation of apolipoprotein B in a permeabilized HepG2 system. Macri J, et al. **J Biol Chem** 1997 Mar 14;272(11):7328–37

In vitro reconstitution of assembly of apolipoprotein B48–containing lipoproteins. Rusiñol AE, et al. **J Biol Chem** 1997 Mar 21;272(12):8019–25

Role of the Golgi apparatus in the phosphorylation of apolipoprotein B. Swift LL. **J Biol Chem** 1996 Dec 6; 271(49):31491–5

Normal activity of microsomal triglyceride transfer protein is required for the oleate–induced secretion of very low density lipoproteins containing apolipoprotein B from McA–RH7777 cells. Wang Y, et al. **J Biol Chem** 1997 May 9;272(19):12272–8

A two–site model for ApoB degradation in HepG2 cells. Wu X, et al. **J Biol Chem** 1997 Apr 25;272(17):11575–80

Changes in fatty acid metabolism in rat hepatocytes in response to dietary n–3 fatty acids are associated with changes in the intracellular metabolism and secretion of apolipoprotein B–48. Brown AM, et al. **J Lipid Res** 1997 Mar;38(3):469–81

Apolipoprotein B–100 destined for lipoprotein assembly and intracellular degradation undergoes efficient translocation across the endoplasmic reticulum membrane. Ingram MF, et al. **J Lipid Res** 1996 Oct;37(10):2202–14

Amino terminus of apolipoprotein B suffices to produce recognition of malondialdehyde–modified low density lipoprotein by the scavenger receptor of human monocyte–macrophages. Kreuzer J, et al. **J Lipid Res** 1997 Feb;38(2):324–42

Metabolism of apolipoprotein B–100 in a kindred with familial hypobetalipoproteinemia without a truncated form of apoB. Latour MA, et al. **J Lipid Res** 1997 Mar; 38(3):592–9

Role of intramolecular disulfide bond formation in the assembly and secretion of apolipoprotein B–100–containing lipoproteins. Shelness GS, et al. **J Lipid Res** 1996 Feb; 37(2):408–19

Mode of growth hormone administration influences triacylglycerol synthesis and assembly of apolipoprotein B–containing lipoproteins in cultured rat hepatocytes. Sjöberg A, et al. **J Lipid Res** 1996 Feb;37(2):275–89

Synthesis and secretion of B–100 and A–I apolipoproteins in response to the changes of intracellular cholesteryl ester content in chick liver. Tarugi P, et al. **J Lipid Res** 1996 Mar;37(3):493–507

Binding affinity and particle size of LDL in subjects with moderate hypercholesterolemia: relationship with in vivo LDL metabolism. Yamane K, et al. **J Lipid Res** 1996 Aug; 37(8):1646–54

Interaction of apolipoprotein[a] with apolipoproteinB–100 Cys3734 region in lipoprotein[a] is confirmed immunochemically. Guevara J Jr, et al. **J Protein Chem** 1996 Jan;15(1):17–25

Effect of serum subfractions from peritoneal dialysis patients on Hep–G2 cell apolipoprotein A–I and B metabolism. Shah GM, et al. **Kidney Int** 1996 Dec;50(6):2079–87

Stearic acid modifies very low density lipoprotein lipid composition and particle size differently from shorter–chain saturated fatty acids in cultured rat hepatocytes. Pai T, et al. **Lipids** 1997 Feb;32(2):143–9

Use of cyclodextrin to deliver lipids and to modulate apolipoprotein B–100 production in HepG2 cells. Peluso MR, et al. **Lipids** 1997 Aug;32(8):811–23

Site–specific modification of apolipoprotein B by advanced glycosylation end–products: implications for lipoprotein clearance and atherogenesis. Bucala R. **Nephrol Dial Transplant** 1996;11 Suppl 5:17–9 (20 ref.)

Effect of acute feeding of diets of varying fatty acid composition on intestinal apolipoprotein expression in the newborn swine. Wang H, et al. **Pediatr Res** 1996 Jun; 39(6):1078–84

PHARMACOLOGY

The mechanism of inhibition of factor III (thromboplastin) activity by apolipoprotein B–100. Protein–protein interactions. Ettelaie C, et al. **Arterioscler Thromb Vasc Biol** 1996 May;16(5):639–47

Apolipoprotein B inhibits the hemolytic activity of asp–hemolysin from Aspergillus fumigatus. Fukuchi Y, et al. **Biol Pharm Bull** 1996 Apr;19(4):547–50

Analysis of novel apolipoprotein B mutations using a modified U937 cell line LDL binding assay. Meng QH, et al. **Clin Chim Acta** 1996 Dec 9;256(1):27–36

PHYSIOLOGY

A novel function for apolipoprotein B: lipoprotein synthesis in the yolk sac is critical for maternal–fetal lipid transport in mice. Farese RV Jr, et al. **J Lipid Res** 1996 Feb; 37(2):347–60

A novel functional role for apolipoprotein B in male infertility in heterozygous apolipoprotein B knockout mice. Huang LS, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1; 93(20):10903–7

[Adipsin system––acylation–stimulation protein (ASP) and hyperapo–B] Rato Q, et al. **Rev Port Cardiol** 1996 May; 15(5):433–8, 366 (39 ref.) (Eng. Abstr.) **(Por)**

SECRETION

Regulation of apolipoprotein B–containing lipoproteins by dietary soluble fiber in guinea pigs. Fernandez ML, et al. **Am J Clin Nutr** 1997 Mar;65(3):814–22

Cytokines regulate apolipoprotein B secretion by Caco-2 cells: differential effects of IL-6 and TGF-beta 1. Murthy S, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):G94-102

ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools. Benoist F, et al. **Arterioscler Thromb Vasc Biol** 1996 Oct;16(10):1229-35

Suppression of the protein tyrosine phosphatase LAR reduces apolipoprotein B secretion by McA-RH7777 rat hepatoma cells. Phung TL, et al. **Biochem Biophys Res Commun** 1997 Aug 18;237(2):367-71

Decreased secretion of very-low-density lipoprotein triacylglycerol and apolipoprotein B is associated with decreased intracellular triacylglycerol lipolysis in hepatocytes derived from rats fed orotic acid or n-3 fatty acids. Hebbachi AM, et al. **Biochem J** 1997 Aug 1;325 (Pt 3):711-9

Effects of fatty acids on apolipoprotein B secretion by McArdle RH-7777 rat hepatoma cells. Sparks JD, et al. **Biochim Biophys Acta** 1997 Jul 12;1347(1):51-61

The effect of individual amino acids on ApoB100 and Lp(a) secretion by HepG2 cells. Cianflone K, et al. **J Biol Chem** 1996 Nov 15;271(46):29136-45

Coordinate regulation of lipogenesis, the assembly and secretion of apolipoprotein B-containing lipoproteins by sterol response element binding protein 1. Wang SL, et al. **J Biol Chem** 1997 Aug 1;272(31):19351-8

Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (HepG2). Haghpassand M, et al. **J Lipid Res** 1996 Jul;37(7):1468-80

Estrogen dependence of synthesis and secretion of apolipoprotein B-containing lipoproteins in the chicken hepatoma cell line, LMH-2A. Hermann M, et al. **J Lipid Res** 1997 Jul;38(7):1308-17

Obesity in db and ob animals leads to impaired hepatic very low density lipoprotein secretion and differential secretion of apolipoprotein B-48 and B-100. Li X, et al. **J Lipid Res** 1997 Jul;38(7):1277-88

Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. Li X, et al. **J Lipid Res** 1996 Jan;37(1):210-20

Inhibition of apolipoprotein B secretion by IL-6 is mediated by EGF or an EGF-like molecule in CaCo-2 cells. Murthy S, et al. **J Lipid Res** 1997 Feb;38(2):206-16

Inhibition of acyl-CoA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. Musanti R, et al. **J Lipid Res** 1996 Jan; 37(1):1-14

Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: in vivo studies in human apoB-89, apoB-75, apoB-54.8, and apoB-31 heterozygotes. Parhofer KG, et al. **J Lipid Res** 1996 Apr; 37(4):844-52

Role of cholesterol in regulating apolipoprotein B secretion by the liver. Thompson GR, et al. **J Lipid Res** 1996 Mar; 37(3):439-47 (64 ref.)

Phosphatidylcholine biosynthesis is required for secretion of truncated apolipoprotein Bs from McArdle RH7777 cells only when a neutral lipid core is formed. Vermeulen PS, et al. **J Lipid Res** 1997 Mar;38(3):447-58

Low rates of apoB secretion from HepG2 cells result from reduced delivery of newly synthesized triglyceride to a "secretion-coupled" pool. Wu X, et al. **J Lipid Res** 1996 Jun;37(6):1198-206

APOLIPOPROTEINS C

BLOOD

Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity against apolipoprotein CII-deficient chylomicrons. Olivecrona G, et al. **Arterioscler Thromb Vasc Biol** 1997 Aug;17(8):1545-9

Apolipoprotein CII & CIII in non-insulin dependent diabetic patients. Kodikara M, et al. **Biochem Soc Trans** 1996 May; 24(2):172S

Alterations of VLDL composition during alimentary lipemia. Björkegren J, et al. **J Lipid Res** 1997 Feb;38(2):301-14

Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. Fredenrich A, et al. **J Lipid Res** 1997 Jul;38(7):1421-32

Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur Infarctus du Myocarde. Luc G, et al. **J Lipid Res** 1996 Mar;37(3):508-17

Quantification of apolipoprotein C-II by immunochemical and chromatographic methods. Connelly PW, et al. **Methods Enzymol** 1996;263:188-208

Immunochemical methods for quantification of human apolipoprotein C-III. Kashyap ML. **Methods Enzymol** 1996;263:208-18

Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia. Bredie SJ, et al. **Neth J Med** 1996 Aug; 49(2):59-67

CHEMISTRY

Apolipoprotein CII from chicken (Gallus domesticus). The amino-terminal domain is different from corresponding domains in mammals. Andersson Y, et al. **J Biol Chem** 1996 Dec 20;271(51):33060-6

DEFICIENCY

Reduced very-low-density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice. Jong MC, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):445-50

GENETICS

Influence of the SstI polymorphism at the apolipoprotein C-III gene locus on the plasma low-density-lipoprotein-cholesterol response to dietary monounsaturated fat. López-Miranda J, et al. **Am J Clin Nutr** 1997 Jul;66(1):97-103

Hypolipidemic effect of peroxisome proliferators. Transcriptional suppression of apolipoprotein C-III. Hertz R, et al. **Ann N Y Acad Sci** 1996 Dec 27;804:731-3

Polymorphisms of the genes encoding apoproteins A-I, B, C-III, and E and LDL receptor, and cholesterol and LDL metabolism during increased cholesterol intake. Common alleles of the apoprotein E gene show the greatest regulatory impact. Gylling H, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):38-44

Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. Hegele RA, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun; 17(6):1060-6

Distal apolipoprotein C-III regulatory elements F to J act as a general modular enhancer for proximal promoters that contain hormone response elements. Synergism between hepatic nuclear factor-4 molecules bound to the proximal promoter and distal enhancer sites. Kardassis D, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):222-32

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Auwerx J, et al. **Atherosclerosis** 1996 Jul;124 Suppl:S29-37 (59 ref.)

Analysis of the apo E/apo C-I, angiotensin converting enzyme and methylenetetrahydrofolate reductase genes as candidates affecting human longevity. Galinsky D, et al. **Atherosclerosis** 1997 Mar 21;129(2):177-83

A G+1 to C mutation in a donor splice site of intron 2 in the apolipoprotein (apo) C-II gene in a patient with apo C-II deficiency. A possible interaction between apo C-II deficiency and apo E4 in a severely hypertriglyceridemic patient. Okubo M, et al. **Atherosclerosis** 1997 Apr;130(1-2):153-60

Reduced very-low-density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice. Jong MC, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):445-50

Genetic variations of the apo E-CI-CII cluster gene in Koreans. Hong SH, et al. **Clin Biochem** 1997 Apr; 30(3):215-9

Association between genetic variations of apo AI-CIII-AIV cluster gene and hypertriglyceridemic subjects. Hong SH, et al. **Clin Chem** 1997 Jan;43(1):13-7

An AvaII polymorphism in the human apolipoprotein C-II gene. Geisel J, et al. **Clin Genet** 1996 Mar;49(3):163

Genetics and molecular biology [editorial] Chappell DA. **Curr Opin Lipidol** 1997 Aug;8(4):U49-50

Apolipoprotein C-III gene variation and dyslipidaemia. Talmud PJ, et al. **Curr Opin Lipidol** 1997 Jun;8(3):154-8 (24 ref.)

A population association study of four candidate genes (hexokinase II, glucagon-like peptide-1 receptor, fatty acid binding protein-2, and apolipoprotein C-II) with type 2 diabetes and impaired glucose tolerance in Japanese subjects. Yagi T, et al. **Diabet Med** 1996 Oct;13(10):902-7

Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: interaction between genotype, gender, and smoking status. Peacock RE, et al. **Genet Epidemiol** 1997;14(3):265-82

Genetic association study between senile dementia of Alzheimer's type and APOE/C1/C2 gene cluster. Kamino K, et al. **Gerontology** 1996;42 Suppl 1:12-9

Interaction between obesity and genetic polymorphisms in the apolipoprotein CIII gene and lipoprotein lipase gene on the risk of hypertriglyceridemia in Chinese. Ko YL, et al. **Hum Genet** 1997 Sep;100(3-4):327-33

Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. Shoulders CC, et al. **Hum Genet** 1996 Nov;98(5):557-66

In vivo footprinting analysis of the hepatic control region of the human apolipoprotein E/C-I/C-IV/C-II gene locus. Dang Q, et al. **J Biol Chem** 1996 Nov 8; 271(45):28667-76

Utilization of recombinant adenovirus and dominant negative mutants to characterize hepatocyte nuclear factor 4-regulated apolipoprotein AI and CIII expression. Fraser JD, et al. **J Biol Chem** 1997 May 23;272(21):13892-8

In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. Jong MC, et al. **J Clin Invest** 1996 Nov 15;98(10):2259-67

Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene. Naganawa S, et al. **J Clin Invest** 1997 Apr 15;99(8):1958-65

Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. Aalto-Setälä K, et al. **J Lipid Res** 1996 Aug;37(8):1802-11

Expression of a novel human apolipoprotein (apoC-IV) causes hypertriglyceridemia in transgenic mice. Allan CM, et al. **J Lipid Res** 1996 Jul;37(7):1510-8

Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. Marcil M, et al. **J Lipid Res** 1996 Feb;37(2):309-19

A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia. Ribalta J, et al. **J Lipid Res** 1997 Jun;38(6):1061-9

A single nucleotide substitution in the promoter region of the apolipoprotein C-II gene identified in individuals with chylomicronemia. Streicher R, et al. **J Lipid Res** 1996 Dec; 37(12):2599-607

A mouse model with features of familial combined hyperlipidemia. Masucci-Magoulas L, et al. **Science** 1997 Jan 17;275(5298):391-4

[Apolipoprotein AI-CIII, B, and CII gene polymorphisms in patients with non-insulin dependent diabetes mellitus. Association with hyperlipemia] Gutiérrez C, et al. **Med Clin (Barc)** 1996 Nov 2;107(15):561-5 (Eng. Abstr.) **(Spa)**

METABOLISM

Activation of CAAT enhancer-binding protein delta (C/EBPdelta) by interleukin-1 negatively influences apolipoprotein C-III expression. Lacorte JM, et al. **J Biol Chem** 1997 Sep 19;272(38):23578-84

Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. Ebara T, et al. **J Clin Invest** 1997 Jun 1;99(11):2672-81

PHARMACOLOGY

Effect of the apolipoprotein C-II/C-III1 ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles. Lambert DA, et al. **Atherosclerosis** 1996 Dec 20;127(2):205-12

A new fluorometric method for measuring the action of C apolipoproteins on milk lipoprotein lipase. Lambert DA, et al. **Clin Chim Acta** 1997 Aug 8;264(1):75-90

PHYSIOLOGY

Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. Xu S, et al. **J Lipid Res** 1997 Jul; 38(7):1289-98

APOLIPOPROTEINS E

Population distributions of APOE, APOH, and APOA4 polymorphisms and their relationships with quantitative plasma lipid levels among the Evenki herders of Siberia. Kamboh MI, et al. **Hum Biol** 1996 Apr;68(2):231-43

Apolipoprotein E in Alzheimer's disease risk and case detection: a case-control study. Kukull WA, et al. **J Clin Epidemiol** 1996 Oct;49(10):1143-8

[Apolipoprotein E and its receptors in Alzheimer's disease] Ikeda K. **Tanpakushitsu Kakusan Koso** 1996 Aug; 41(10):1465-9 (29 ref.) **(Jpn)**

ANALYSIS

The neurochemistry of Alzheimer's disease. Blennow K, et al. **Acta Neurol Scand Suppl** 1996;168:77-86 (129 ref.)

Transient expression of apolipoprotein-E in neonates with pontosubicular neuron necrosis. Arai Y, et al. **Acta Neuropathol (Berl)** 1996;91(4):396-9

Distinct distribution of apolipoprotein E and beta-amyloid immunoreactivity in the hippocampus of Parkinson dementia complex of Guam. Schwab C, et al. **Acta Neuropathol (Berl)** 1996 Oct;92(4):378-85

Distribution of apolipoprotein E in senile plaques in brains with Alzheimer's disease: investigation with the confocal laser scan microscope. Nishiyama E, et al. **Brain Res** 1997 Mar 7;750(1-2):20-4

Glial cells in Alzheimer's disease: preferential effect of APOE risk on scattered microglia. Saitoh T, et al. **Gerontology** 1997;43(1-2):109-18

Immunohistochemical localization of apolipoprotein E in renal amyloidosis. Taniguchi Y, et al. **Hiroshima J Med Sci** 1996 Mar;45(1):11-4

Determination of apolipoprotein E in high density lipoprotein fraction by immunofixation method and turbidimetric immunoassay after precipitation. Okamoto Y, et al. **J Atheroscler Thromb** 1994;1(1):23-9

Prominence of apolipoproteins B, (a), and E in the intimae of coronary arteries in transplanted human hearts: geographic relationship to vessel wall proteoglycans. Lin H, et al. **J Heart Lung Transplant** 1996 Dec;15(12):1223-32

Changes in CD44 and ApoE immunoreactivities due to retinal pathology of man and rat. Kuhrt H, et al. **J Hirnforsch** 1997;38(2):223–9

Isolation and characterization of two distinct species of human very low density lipoproteins lacking apolipoprotein E. Campos E, et al. **J Lipid Res** 1996 Sep;37(9):1897–906

Changes in distribution of cystatin C, apolipoprotein E and ferritin in rat hypothalamus after hypophysectomy. Katakai K, et al. **J Neuroendocrinol** 1997 Apr;9(4):247–53

Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease. Chargé SB, et al. **J Pathol** 1996 Aug;179(4):443–7

Arteriosclerosis, apolipoprotein E, and Alzheimer's disease [letter; comment] Kalaria RN. **Lancet** 1997 Apr 19; 349(9059):1174. Comment on: Lancet 1997 Jan 18;349(9046):151–4.

Quantitation of apolipoprotein E. Krul ES, et al. **Methods Enzymol** 1996;263:170–87

Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. Biere AL, et al. **Neurobiol Dis** 1995 Jun; 2(3):177–87

Identification of a unique apolipoprotein E allele in Microcebus murinus; ApoE brain distribution and co-localization with beta-amyloid and tau proteins. Calenda A, et al. **Neurobiol Dis** 1995 Jun;2(3):169–76

ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Blacker D, et al. **Neurology** 1997 Jan; 48(1):139–47

Scrapie in mice deficient in apolipoprotein E or glial fibrillary acidic protein. Tatzelt J, et al. **Neurology** 1996 Aug; 47(2):449–53

Reduced survival of apolipoprotein E4 homozygotes in Down's syndrome? Holder JL, et al. **Neuroreport** 1996 Nov 4;7(15–17):2455–6

In an epidemiological sample the apolipoprotein E4 allele is associated to dementia and loss of memory function only in the very old. Gessner R, et al. **Neurosci Lett** 1997 Jan 24;222(1):29–32

BIOSYNTHESIS

Differential pattern of beta-amyloid, amyloid precursor protein and apolipoprotein E expression in cortical senile plaques. Thal DR, et al. **Acta Neuropathol (Berl)** 1997 Sep; 94(3):255–65

Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Schaefer JR, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):348–53

Synthesis and messenger ribonucleic acid expression of apolipoproteins E and A-I by the bovine corpus luteum during the estrous cycle and pregnancy. Ndikum-Moffor FM, et al. **Biol Reprod** 1997 Mar;56(3):745–56

Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. Sullivan PM, et al. **J Biol Chem** 1997 Jul 18; 272(29):17972–80

Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. Zhang WY, et al. **J Biol Chem** 1996 Nov 8;271(45):28641–6

Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. Tsukamoto K, et al. **J Clin Invest** 1997 Jul 1;100(1):107–14

Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Mann DM, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):81–4

Expression of apolipoprotein E mRNA in rat microglia. Nakai M, et al. **Neurosci Lett** 1996 Jun 14;211(1):41–4

Alterations in apolipoprotein E expression during aging and neurodegeneration. Masliah E, et al. **Prog Neurobiol** 1996 Dec;50(5–6):493–503 (80 ref.)

Single-step purification of two functional human apolipoprotein E variants hyperexpressed in Escherichia coli. Pillot T, et al. **Protein Expr Purif** 1996 Jun;7(4):407–14

BLOOD

The frequency of apolipoprotein E4 allele is not increased in patients with probable vascular dementia. Pirttilä T, et al. **Acta Neurol Scand** 1996 May;93(5):352–4

Chronic ethanol induced impairment of hepatic glycosylation machinery in rat is independent of dietary carbohydrate. Ghosh P, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):76–81

Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. O'Meara ES, et al. **Am J Epidemiol** 1997 Sep 1;146(5):373–84

High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. Hasegawa H, et al. **Arthritis Rheum** 1996 Oct;39(10):1728–32

Distribution of apolipoprotein E between apo B- and non apo B-containing lipoproteins according to apo E phenotype. Luc G, et al. **Atherosclerosis** 1997 Jun; 131(2):257–62

Triglyceride-rich lipoproteins from apolipoprotein E3/2 subjects with hypertriglyceridemia enhance cholesteryl ester synthesis in human macrophages. Saito M, et al. **Atherosclerosis** 1997 Feb 28;129(1):73–7

Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients. Sijbrands EJ, et al. **Atherosclerosis** 1996 Oct 25;126(2):197–205

Increased serum remnant lipoproteins in patients with apolipoprotein E7 (apo E Suita). Yanagi K, et al. **Atherosclerosis** 1997 May;131(1):49–58

Apolipoprotein E-epsilon 4 frequency in geriatric depression [see comments] Krishnan KR, et al. **Biol Psychiatry** 1996 Jul 1;40(1):69–71. Comment in: Biol Psychiatry 1997 Apr 15;41(8):912–3.

A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. Steffens DC, et al. **Biol Psychiatry** 1997 Apr 15;41(8):851–6

Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians. Weber M, et al. **Can J Cardiol** 1997 Mar; 13(3):253–60

Assessment of postprandial lipemia: nutritional influences. Bergeron N, et al. **Curr Opin Lipidol** 1997 Feb;8(1):43–52 (59 ref.)

Effect of estrogen replacement therapy on hepatic triglyceride lipase, lipoprotein lipase and lipids including apolipoprotein E in climacteric and elderly women. Urabe M, et al. **Endocr J** 1996 Dec;43(6):737–42

Population distributions of APOE, APOH, and APOA4 polymorphisms and their relationships with quantitative plasma lipid levels among the Evenki herders of Siberia. Kamboh MI, et al. **Hum Biol** 1996 Apr;68(2):231–43

Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. Fredenrich A, et al. **J Lipid Res** 1997 Jul;38(7):1421–32

Apoprotein E phenotype determines serum cholesterol in infants during both high-cholesterol breast feeding and low-cholesterol formula feeding. Kallio MJ, et al. **J Lipid Res** 1997 Apr;38(4):759–64

Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE. Krimbou L, et al. **J Lipid Res** 1997 Jan; 38(1):35–48

Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur Infarctus du Myocarde. Luc G, et al. **J Lipid Res** 1996 Mar;37(3):508–17

The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. Landén M, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):352–6

Apolipoprotein E polymorphism and late onset Alzheimer's disease in Argentina [letter] Morelli L, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):426–7

Simultaneous quantification of apolipoproteins B-100, B-48, and E separated by SDS-PAGE. Bergeron N, et al. **Methods Enzymol** 1996;263:82–94

Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Taddei K, et al. **Neurosci Lett** 1997 Feb 14;223(1):29–32

Apolipoprotein E polymorphism and serum lipids in a randomized, prospective trial of an infant diet with reduced saturated fat and cholesterol. Lapinleimu H, et al. **Pediatrics** 1996 Oct;98(4 Pt 1):757–62

Characterization and quantification of apolipoprotein E in the genetically hypercholesterolemic rat (RICO). Cardona-Sanclemente LE, et al. **Rev Esp Fisiol** 1996 Mar; 52(1):15–22

[Tokyo Centenarian Study. 4. Apolipoprotein E phenotype in Japanese centenarians living in the Tokyo Metropolitan area] Hirose N, et al. **Nippon Ronen Igakkai Zasshi** 1997 Apr;34(4):267–72 (Eng. Abstr.) **(Jpn)**

[Apo E phenotype. A touch of attention (letter)] Castells Gasulla A, et al. **Med Clin (Barc)** 1996 Nov 30;107(19):758 **(Spa)**

[Apo E: blood lipids, ischemic cardiopathy and Alzheimer's disease] Lahoz C, et al. **Med Clin (Barc)** 1997 May 31; 109(1):31–6 (82 ref.) **(Spa)**

CEREBROSPINAL FLUID

The frequency of apolipoprotein E4 allele is not increased in patients with probable vascular dementia. Pirttilä T, et al. **Acta Neurol Scand** 1996 May;93(5):352–4

Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions. Skoog I, et al. **Arch Neurol** 1997 Mar;54(3):267–72

Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease. Zerr I, et al. **Arch Neurol** 1996 Dec;53(12):1233–8

Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. Landén M, et al. **Dementia** 1996 Sep-Oct;7(5):273–8

Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: impact on non Alzheimer's dementia? Rösler N, et al. **J Neural Transm Suppl** 1996;47:259–66

Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. Merched A, et al. **J Neurol Sci** 1997 Jan;145(1):33–9

Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor. Gutman CR, et al. **J Neurosci** 1997 Aug 15;17(16):6114–21

Effects of triamcinolone on brain and cerebrospinal fluid apolipoprotein E levels in rats. Chiba H, et al. **Life Sci** 1997;60(20):1757–61

Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. Hahne S, et al. **Neurosci Lett** 1997 Mar 14;224(2):99–102

Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Lefranc D, et al. **Neurosci Lett** 1996 Jul 12;212(2):91–4

Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Lindh M, et al. **Neurosci Lett** 1997 Jun 27;229(2):85–8

CHEMICAL SYNTHESIS

Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Rensen PCN, et al. **Mol Pharmacol** 1997 Sep;52(3):445–55

CHEMISTRY

Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg136-->Cys) variant. Feussner G, et al. **Atherosclerosis** 1996 Oct 25; 126(2):177–84

Bacterial overexpression, isotope enrichment, and NMR analysis of the N-terminal domain of human apolipoprotein E. Fisher CA, et al. **Biochem Cell Biol** 1997;75(1):45–53

Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein. Haas C, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):169–75

Conformationally specific enhancement of receptor-mediated LDL binding and internalization by peptide models of a conserved anionic N-terminal domain of human apolipoprotein E. Braddock DT, et al. **Biochemistry** 1996 Nov 5;35(44):13975–84

Composition and structural and functional properties of discoidal and spherical phospholipid-apoE3 complexes. De Pauw M, et al. **Biochemistry (Mosc)** 1997 Mar;62(3):251–63

Characterization of three human apolipoprotein E isoforms (E2, E3 and E4) expressed in Escherichia coli. Barbier A, et al. **Eur J Clin Chem Clin Biochem** 1997 Aug;35(8):581–9

Insight into lipid surface recognition and reversible conformational adaptations of an exchangeable apolipoprotein by multidimensional heteronuclear NMR techniques. Wang J, et al. **J Biol Chem** 1997 Jul 18; 272(29):17912–20

Neurotoxicity of apolipoprotein E thrombin cleavage fragments: implications for Alzheimer's disease [letter] Gurwitz D. **Neuroreport** 1997 Mar 3;8(4):1067–8

Alzheimer's beta-amyloid peptide is conformationally modified by apolipoprotein E in vitro. Soto C, et al. **Neuroreport** 1996 Feb 29;7(3):721–5

[Alzheimer's disease and apolipoprotein E] Yamaguchi H. **No To Shinkei** 1996 Nov;48(11):981–90 (74 ref.) **(Jpn)**

CLASSIFICATION

Clearance of postprandial lipoproteins in normolipemics: role of the apolipoprotein E phenotype. Orth M, et al. **Biochim Biophys Acta** 1996 Sep 6;1303(1):22–30

DEFICIENCY

Beta-amyloid protein-containing inclusions in skeletal muscle of apolipoprotein-E-deficient mice. Robertson TA, et al. **Am J Pathol** 1997 Feb;150(2):417–27

Uptake by J774 macrophages of very-low-density lipoproteins isolated from apoE-deficient mice is mediated by a distinct receptor and stimulated by lipoprotein lipase. Hendriks WL, et al. **Arterioscler Thromb Vasc Biol** 1997 Mar;17(3):498–504

"Tall oil"-derived phytosterols reduce atherosclerosis in ApoE-deficient mice. Moghadasian MH, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):119–26

The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Keidar S, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):622–5

Effects of apo E deficiency on plasma lipid levels in mice lacking APOBEC-1. Osuga J, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):375–8

Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Masliah E, et al. **Brain Res** 1997 Mar 21;751(2):307–14

Increased 3-nitrotyrosine in brains of Apo E-deficient mice. Matthews RT, et al. **Brain Res** 1996 Apr 29;718(1–2):181–4

Purification and characterization of low density lipoprotein containing apolipoprotein B-48 from the plasma of an apoE-deficient patient. Hashimoto Y, et al. **Clin Chim Acta** 1997 Mar 18;259(1–2):109–16

Characterization of low-density-lipoprotein in apolipoprotein E deficiency in a patient without coronary atherosclerosis. Teramoto T, et al. **Clin Chim Acta** 1996 Mar 29;247(1–2):159–66

Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. Ishibashi S, et al. **J Biol Chem** 1996 Sep 13;271(37):22422–7

Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. Mezdour H, et al. **J Biol Chem** 1997 May 23;272(21):13570-5

Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. Laskowitz DT, et al. **J Cereb Blood Flow Metab** 1997 Jul;17(7):753-8

IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. Gupta S, et al. **J Clin Invest** 1997 Jun 1; 99(11):2752-61

Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. Tsukamoto K, et al. **J Clin Invest** 1997 Jul 1;100(1):107-14

Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Véniant MM, et al. **J Clin Invest** 1997 Jul 1;100(1):180-8

Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. Zhang SH, et al. **J Clin Invest** 1997 Jun 15;99(12):2858-66

Severe xanthomatosis associated with familial apolipoprotein E deficiency. Feussner G. **J Clin Pathol** 1996 Dec; 49(12):985-9

The emergence of mouse models of atherosclerosis and their relevance to clinical research. Smith JD, et al. **J Intern Med** 1997 Aug;242(2):99-109 (99 ref.)

Biochemical and cognitive studies of apolipoprotein-E-deficient mice. Gordon I, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):97-103

Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Chen Y, et al. **Neuroscience** 1997 Oct;80(4):1255-62

Reduced levels of antioxidants in brains of apolipoprotein E-deficient mice following closed head injury. Lomnitski L, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):669-73

Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Bourassa PA, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10022-7

T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Dansky HM, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4642-6

Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Fazio S, et al. **Proc Natl Acad Sci U S A** 1997 Apr 29;94(9):4647-52

Absence of central cholinergic deficits in ApoE knockout mice. Anderson R, et al. **Psychopharmacology (Berl)** 1997 Jul;132(2):135-44

Apolipoprotein E-deficient mouse model of human atherosclerosis. O'Neill TP. **Toxicol Pathol** 1997 Jan-Feb; 25(1):20-1 (9 ref.)

DRUG EFFECTS

Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Stone DJ, et al. **Exp Neurol** 1997 Feb;143(2):313-8

Pupil dilatation assay by tropicamide is modulated by apolipoprotein E epsilon 4 allele dosage in Alzheimer's disease. Arai H, et al. **Neuroreport** 1996 Mar 22;7(4):918-20

GENETICS

HIV dementia and apolipoprotein E. Dunlop O, et al. **Acta Neurol Scand** 1997 May;95(5):315-8

Apolipoprotein E allele frequencies in patients with late-onset sporadic Alzheimer's dementia in Hungary. Kálmán J, et al. **Acta Neurol Scand** 1997 Jan;95(1):56-9

Apolipoprotein E in Guamanian amyotrophic lateral sclerosis/parkinsonism-dementia complex: genotype analysis and relationships to neuropathological changes. Buée L, et al. **Acta Neuropathol (Berl)** 1996;91(3):247-53

Differential pattern of beta-amyloid, amyloid precursor protein and apolipoprotein E expression in cortical senile plaques. Thal DR, et al. **Acta Neuropathol (Berl)** 1997 Sep; 94(3):255-65

Inconstant apolipoprotein E (ApoE)-like immunoreactivity in amyloid beta protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease. Uchihara T, et al. **Acta Neuropathol (Berl)** 1996 Aug;92(2):180-5

Effect of apolipoprotein E phenotype on plasma lipids and lipoproteins in alcohol abusers. Liinamaa MJ, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):606-12

Development of a national prospective study of Alzheimer disease. Mayeux R. **Alzheimer Dis Assoc Disord** 1996 Fall; 10 Suppl 1:38-44

Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: in vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Fuhrman B, et al. **Am J Clin Nutr** 1997 Aug;66(2):267-75

The effect of short-term fasting, apolipoprotein E gene polymorphism, and sex on plasma lipids. Lehtimäki T, et al. **Am J Clin Nutr** 1997 Sep;66(3):599-605

Apolipoprotein E phenotype and diet-induced alteration in blood pressure. Rantala M, et al. **Am J Clin Nutr** 1997 Feb;65(2):543-50

Long-term effect of soluble-fiber foods on postprandial fat metabolism in dyslipidemic subjects with apo E3 and apo E4 genotypes. Wolever TM, et al. **Am J Clin Nutr** 1997 Sep;66(3):584-90

Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. O'Meara ES, et al. **Am J Epidemiol** 1997 Sep 1;146(5):373-84

The apolipoprotein E epsilon 4 allele is associated with increased behavioral disturbance in Alzheimer's disease [letter] Murphy GM Jr, et al. **Am J Geriatr Psychiatry** 1997 Winter;5(1):88-9

Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Bickeböller H, et al. **Am J Hum Genet** 1997 Feb;60(2):439-46

Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males: a longitudinal analysis. Jarvik GP, et al. **Am J Hum Genet** 1997 Jul;61(1):171-81

A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype. Payami H, et al. **Am J Hum Genet** 1997 Apr;60(4):948-56

Mild-to-moderate hypertension and apolipoprotein E gene polymorphism [letter] Isbir T, et al. **Am J Hypertens** 1997 Jul;10(7 Pt 1):827-8

APOE genotype influences functional status among elderly without dementia. Albert SM, et al. **Am J Med Genet** 1995 Dec 18;60(6):583-7

No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. Fallin D, et al. **Am J Med Genet** 1997 Apr 18; 74(2):192-4

Allelic association but only weak evidence for linkage to the apolipoprotein E locus in late-onset Swedish Alzheimer families. Liu L, et al. **Am J Med Genet** 1996 May 31; 67(3):306-11

Allele doses of apolipoprotein E type epsilon 4 in sporadic late-onset Alzheimer's disease. Lucotte G, et al. **Am J Med Genet** 1995 Dec 18;60(6):566-9

ApoE genotype does not affect plasma tPA and PAI-1 antigen levels. Mermod JJ, et al. **Am J Med Genet** 1997 Apr 18;74(2):172-5

The use of apolipoprotein E genotype for preclinical detection of risk's group for Alzheimer's disease [letter] Oliveira JR, et al. **Am J Med Genet** 1997 Apr 18;74(2):216-7

Evidence for apolipoprotein E epsilon 4 association in early-onset Alzheimer's patients with late-onset relatives. Pérez-Tur J, et al. **Am J Med Genet** 1995 Dec 18; 60(6):550-3

Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Montine KS, et al. **Am J Pathol** 1997 Feb;150(2):437-43

Apolipoprotein E epsilon 4 allele and pupillary response to tropicamide. Higuchi S, et al. **Am J Psychiatry** 1997 May; 154(5):694-6

No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. Murphy GM Jr, et al. **Am J Psychiatry** 1997 May;154(5):603-8

APO E genotype and familial hypercholesterolaemia. Duly EB, et al. **Ann Clin Biochem** 1997 Sep;34 (Pt 5):534-6

Genetic predictors of common disease: apolipoprotein E genotype as a paradigm. Jarvik GP. **Ann Epidemiol** 1997 Jul;7(5):357-62 (39 ref.)

Apolipoprotein E genotype epsilon 4/epsilon 2 in the STANISLAS Cohort Study--dominance of the epsilon 2 allele? Bohnet K, et al. **Ann Hum Genet** 1996 Nov;60 (Pt 6):509-16

Apolipoprotein E genotyping in Alzheimer's disease. Chicago, Illinois, October 21-22, 1995. Proceedings. **Ann N Y Acad Sci** 1996 Dec 16;802:1-224

Polygenic determinants of Alzheimer's disease: modulation of the risk by alpha-1-antichymotrypsin. DeKosky ST, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:27-34

Apolipoprotein E genotype and gender influence response to tacrine therapy. Farlow MR, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:101-10

Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. Hyman BT, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:1-5

Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. Kaplitt M, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:42-9

Medicolegal, employment, and insurance issues in APOE genotyping and Alzheimer's disease. Kapp MB. **Ann N Y Acad Sci** 1996 Dec 16;802:139-48

A pilot experience in genetic counseling for Alzheimer's disease. Findings relevant to the potential use of APOE genotyping in cognitively impaired individuals. Karlinsky H, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:120-7

NIA/AIzA Conference on apolipoprotein E genotyping in Alzheimer's disease. Bibliography. Kwon YJ, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:177-224

Familial and population-based studies of apolipoprotein E and Alzheimer's disease. Mullan M, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:16-26

Predictive value of APOE genotyping in incipient Alzheimer's disease. Petersen RC, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:58-69

On not jumping the gun: ethical aspects of APOE gene testing for Alzheimer's disease. Post SG. **Ann N Y Acad Sci** 1996 Dec 16;802:111-9

The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease. Relkin NR, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:149-76

Apolipoprotein E and Alzheimer's disease. A rapidly expanding field with medical and epidemiological consequences. Roses AD. **Ann N Y Acad Sci** 1996 Dec 16;802:50-7

The effect of apolipoprotein E genotype on biochemical markers of Alzheimer's disease. Schenk D, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:92-100

Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Small GW, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:70-8

Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer's disease. Tang MX, et al. **Ann N Y Acad Sci** 1996 Dec 16;802:6-15

The use of apolipoprotein E genotyping as a diagnostic test in suspected Alzheimer's disease. van Gool WA. **Ann N Y Acad Sci** 1996 Dec 16;802:79-91

Lack of association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease [letter] Bachus R, et al. **Ann Neurol** 1997 Mar;41(3):417

Dutch hereditary cerebral amyloid angiopathy: structural lesions and apolipoprotein E genotype. Bornebroek M, et al. **Ann Neurol** 1997 May;41(5):695-8

Clinical correlates of apolipoprotein E in Alzheimer's disease [letter] Frisoni GB, et al. **Ann Neurol** 1996 Oct;40(4):688-9

Increased apolipoprotein E epsilon 4 in epilepsy with senile plaques. Gouras GK, et al. **Ann Neurol** 1997 Mar; 41(3):402-4

Cerebral amyloid angiopathy and apolipoprotein E: bad news for the good allele? [editorial; comment] Greenberg SM, et al. **Ann Neurol** 1997 Jun;41(6):701-2. Comment on: Ann Neurol 1997 Jun;41(6):716-21.

A subset of senile dementia with high incidence of the apolipoprotein E epsilon2 allele. Ikeda K, et al. **Ann Neurol** 1997 May;41(5):693-5

Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies. Mirabella M, et al. **Ann Neurol** 1996 Dec;40(6):864-72

Apolipoprotein E and alpha1-antichymotrypsin polymorphism in Alzheimer's disease. Nacmias B, et al. **Ann Neurol** 1996 Oct;40(4):678-80

High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy [see comments] Nicoll JA, et al. **Ann Neurol** 1997 Jun; 41(6):716-21. Comment in: Ann Neurol 1997 Jun;41(6):701-2.

Onset of dementia is associated with apolipoprotein E epsilon4 in Down's syndrome. Schupf N, et al. **Ann Neurol** 1996 Nov;40(5):799-801

Apolipoprotein E epsilon2 does not increase risk of early-onset sporadic Alzheimer's disease. Scott WK, et al. **Ann Neurol** 1997 Sep;42(3):376-8

The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Stern Y, et al. **Ann Neurol** 1997 May;41(5):615-20

Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer's Disease. Welsh-Bohmer KA, et al. **Ann Neurol** 1997 Sep;42(3):319-25

alpha 1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E epsilon 4 allele carriers. Yoshiiwa A, et al. **Ann Neurol** 1997 Jul; 42(1):115-7

Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Tardiff BE, et al. **Ann Thorac Surg** 1997 Sep;64(3):715-20

Apolipoprotein E and Alzheimer's disease. Strittmatter WJ, et al. **Annu Rev Neurosci** 1996;19:53-77 (90 ref.)

Apolipoprotein E genotype and the rate of decline in probable Alzheimer disease [letter; comment] Corder EH, et al. **Arch Neurol** 1996 Nov;53(11):1094-5. Comment on: Arch Neurol 1996 Apr;53(4):345-50.

No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Corder EH, et al. **Arch Neurol** 1997 Mar; 54(3):273-7

Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease [see comments] Dal Forno G, et al. **Arch Neurol** 1996 Apr;53(4):345-50. Comment in: Arch Neurol 1996 Nov;53(11):1094-5.

D2 dopamine receptor A1 allele in Alzheimer disease and aging. Small GW, et al. **Arch Neurol** 1997 Mar;54(3):281-5

Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Yaffe K, et al. **Arch Neurol** 1997 Sep;54(9):1110-4

Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease. Zerr I, et al. **Arch Neurol** 1996 Dec;53(12):1233-8

Polymorphism of the apolipoprotein E gene and early carotid atherosclerosis defined by ultrasonography in asymptomatic adults. Cattin L, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):91-4

The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. de Villiers WJ, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):865-72

Polymorphisms of the genes encoding apoproteins A-I, B, C-III, and E and LDL receptor, and cholesterol and LDL metabolism during increased cholesterol intake. Common alleles of the apoprotein E gene show the greatest regulatory impact. Gylling H, et al. **Arterioscler Thromb Vasc Biol** 1997 Jan;17(1):38-44

Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. Hegele RA, et al. **Arterioscler Thromb Vasc Biol** 1997 Jun;

17(6):1060–6
Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Wilson PW, et al. **Arterioscler Thromb Vasc Biol** 1996 Oct;16(10):1250–5
Remnant-like particles (RLP) from NIDDM patients with apolipoprotein E3/3 phenotype stimulate cholesteryl ester synthesis in human monocyte-derived macrophages. Saito M, et al. **Artery** 1996;22(3):155–63
Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia. Bredie SJ, et al. **Atherosclerosis** 1996 Oct 25;126(2):313–24
Apo E variants in patients with type III hyperlipoproteinemia. Civeira F, et al. **Atherosclerosis** 1996 Dec 20;127(2):273–82
Influence of apo E phenotype on postprandial triglyceride and glucose responses in subjects with and without coronary heart disease. Dart A, et al. **Atherosclerosis** 1997 Apr;130(1–2):161–70
Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg136–>Cys) variant. Feussner G, et al. **Atherosclerosis** 1996 Oct 25; 126(2):177–84
Analysis of the apo E/apo C-I, angiotensin converting enzyme and methylenetetrahydrofolate reductase genes as candidates affecting human longevity. Galinsky D, et al. **Atherosclerosis** 1997 Mar 21;129(2):177–83
Apolipoprotein E1-Hammersmith (Lys146–>Asn;Arg147–>Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia. Hoffer MJ, et al. **Atherosclerosis** 1996 Aug 2;124(2):183–9
Distribution of apolipoprotein E between apo B- and non apo B-containing lipoproteins according to apo E phenotype. Luc G, et al. **Atherosclerosis** 1997 Jun; 131(2):257–62
A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Nestel P, et al. **Atherosclerosis** 1997 Mar 21;129(2):231–9
A G+1 to C mutation in a donor splice site of intron 2 in the apolipoprotein (apo) C-II gene in a patient with apo C-II deficiency. A possible interaction between apo C-II deficiency and apo E4 in a severely hypertriglyceridemic patient. Okubo M, et al. **Atherosclerosis** 1997 Apr;130(1–2):153–60
Importance of apo E2 heterozygosity, insulin, and hypertriglyceridemia for very low density lipoproteins [letter] Özçürümez M, et al. **Atherosclerosis** 1997 Jul 25; 132(2):255–7
A dietary and behavioral intervention designed to lower coronary heart disease. Risk factors are unaffected by variation at the APOE gene locus. Pasagian-Macaulay A, et al. **Atherosclerosis** 1997 Jul 25;132(2):221–7
Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136–>Ser) variant in multigenerational pedigree studies. Pocovi M, et al. **Atherosclerosis** 1996 Apr 26; 122(1):33–46
Increased J774 macrophage cytotoxicity of late postprandial triglyceride-rich lipoproteins from normolipidemic young men expressing an apolipoprotein epsilon 4 allele. Ragogna F, et al. **Atherosclerosis** 1997 Jul 25;132(2):157–63
Apolipoprotein E polymorphism has no independent effect on plasma levels of lipoprotein(a). Ritter MM, et al. **Atherosclerosis** 1997 Jun;131(2):243–8
Apolipoprotein E polymorphism does not predict risk of restenosis after coronary angioplasty. Samani NJ, et al. **Atherosclerosis** 1996 Sep 6;125(2):209–16
Quantitative effects of the apolipoprotein E polymorphism in a biracial sample of 9–10-year-old girls. Sanghera DK, et al. **Atherosclerosis** 1996 Sep 27;126(1):35–42
The relation of apolipoprotein E polymorphism to multiple cardiovascular risk in children: the Bogalusa Heart Study. Srinivasan SR, et al. **Atherosclerosis** 1996 Jun; 123(1–2):33–42
Influence of apolipoprotein E polymorphism on the tracking of childhood levels of serum lipids and apolipoproteins over a 6-year period. The Bogalusa Heart Study. Srinivasan SR, et al. **Atherosclerosis** 1996 Nov 15;127(1):73–9
Apolipoprotein E genotyping in Alzheimer's disease in an Australian sample. Yang JG, et al. **Aust N Z J Med** 1996 Oct;26(5):658–61
Apolipoprotein E gene expression in various tissues of mouse and regulation by estrogen. Srivastava RA, et al. **Biochem Mol Biol Int** 1996 Feb;38(1):91–101
No association between apolipoprotein E genotype and late-onset depression in Alzheimer's disease. Cantillon M, et al. **Biol Psychiatry** 1997 Jan 15;41(2):246–8
Lower frequency of apolipoprotein E4 allele in an "elderly" Down's syndrome population. Cosgrave M, et al. **Biol Psychiatry** 1996 Oct 15;40(8):811–3
Apolipoprotein E-epsilon 4 allele frequency in late-onset depression [letter; comment] Heidrich A, et al. **Biol Psychiatry** 1997 Apr 15;41(8):912–3. Comment on: Biol Psychiatry 1996 Jul 1;40(1):69–71.
Apolipoprotein E genotype and psychosis. Igata-Yi R, et al. **Biol Psychiatry** 1997 Apr 15;41(8):906–8
Apolipoprotein E-epsilon 4 frequency in patients with schizophrenia. Lan TH, et al. **Biol Psychiatry** 1997 Aug 1;42(3):225–7
The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles. Tsuang D, et al. **Biol Psychiatry** 1997 Jan 15;41(2):191–5
Association of the APOE epsilon 4 allele with clinical subtypes of late life depression. Zubenko GS, et al. **Biol Psychiatry** 1996 Nov 15;40(10):1008–16
High-resolution separation of PCR product and gene diagnosis by Capillary gel electrophoresis [letter; comment] Schlenck A, et al. **Biomed Chromatogr** 1996 Jan-Feb; 10(1):48–50. Comment on: Biomed Chromatogr 1994 Nov-Dec;8(6):291–3.
High sensitivity of laser-induced fluorescence detection in capillary gel electrophoresis for accurate apolipoprotein E genotyping. Schlenck A, et al. **Biotechniques** 1997 Apr; 22(4):736–42
Do neuroleptic drugs hasten cognitive decline in dementia? Authors have not proved their argument [letter; comment] Bentham PW, et al. **BMJ** 1997 May 10;314(7091):1412. Comment on: BMJ 1997 Jan 25;314(7076):266–70.
Do neuroleptic drugs hasten cognitive decline in dementia? Carriers of apolipoprotein E epsilon 4 allele seem particularly susceptible to their effects [letter; comment] Holmes C, et al. **BMJ** 1997 May 10;314(7091):1411; discussion 1412. Comment on: BMJ 1997 Jan 25;314(7076):266–70.
Longitudinal study of the effect of apolipoprotein e4 allele on the association between education and cognitive decline in elderly men. Kalmijn S, et al. **BMJ** 1997 Jan 4; 314(7073):34–5
Do neuroleptic drugs hasten cognitive decline in dementia? Trials must determine which neuroleptics are best in dementia [letter; comment] Tobiansky R, et al. **BMJ** 1997 May 10;314(7091):1411; discussion 1412. Comment on: BMJ 1997 Jan 25;314(7076):266–70.
Abeta1–40 but not Abeta1–42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Ishii K, et al. **Brain Res** 1997 Feb 14; 748(1–2):250–2
Distribution of apolipoprotein E in senile plaques in brains with Alzheimer's disease: investigation with the confocal laser scan microscope. Nishiyama E, et al. **Brain Res** 1997 Mar 7;750(1–2):20–4
Severe learning deficits in apolipoprotein E-knockout mice in a water maze task. Oitzl MS, et al. **Brain Res** 1997 Mar 28;752(1–2):189–96
Induction of apolipoprotein E mRNA in the hippocampus of the gerbil after transient global ischemia. Ali SM, et al. **Brain Res Mol Brain Res** 1996 May;38(1):37–44
Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Reckless J, et al. **Circulation** 1997 Mar 18;95(6):1542–8
Apolipoprotein E genotyping in patients with neurodegenerative diseases. Ballering LA, et al. **Clin Biochem** 1997 Jul;30(5):405–11
Genetic variations of the apo E-CI-CII cluster gene in Koreans. Hong SH, et al. **Clin Biochem** 1997 Apr; 30(3):215–9
Apolipoprotein E genotyping and phenotyping in type II diabetes mellitus patients with hypertriglyceridemia. Kim JH, et al. **Clin Biochem** 1997 Feb;30(1):47–52
Apolipoprotein E genotyping by capillary electrophoretic analysis of restriction fragments. de Bellis G, et al. **Clin Chem** 1997 Aug;43(8 Pt 1):1321–4
Frequency of phenotype-genotype discrepancies at the apolipoprotein E locus in a large population study. Lahoz C, et al. **Clin Chem** 1996 Nov;42(11):1817–23
Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Zivelin A, et al. **Clin Chem** 1997 Sep;43(9):1657–9
Effects of apo B and apo E gene polymorphisms on lipid and apolipoprotein concentrations after a test meal. Regis-Bailly A, et al. **Clin Chim Acta** 1996 Sep 30; 253(1–2):127–43
Influence of apolipoprotein E phenotypes on total serum cholesterol in Japanese children. Tozuka M, et al. **Clin Chim Acta** 1996 Mar 29;247(1–2):175–80
Apolipoproteins B and E, and angiotensin I-converting enzyme (ACE) genetic polymorphisms in Italian women with coronary artery disease (CAD) and their relationships with plasma lipid and apolipoprotein levels. Corbo RM, et al. **Clin Genet** 1997 Aug;52(2):77–82
Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Eto M, et al. **Clin Genet** 1995 Dec; 48(6):288–92
Apolipoprotein E allele frequencies in a South African Indian female population. Gounden N, et al. **Clin Genet** 1995 Nov; 48(5):243–5
The apolipoprotein E gene in Binswanger's disease and vascular dementia. Higuchi S, et al. **Clin Genet** 1996 Dec; 50(6):459–61
The role of the apolipoprotein E polymorphism in the prediction of coronary artery disease age of onset. Moore JH, et al. **Clin Genet** 1997 Jan;51(1):22–5
Frequencies of five genetic polymorphisms in coronarographed patients and effects on lipid levels in a supposedly healthy population. Régis-Bailly A, et al. **Clin Genet** 1996 Nov;50(5):339–47
Apolipoprotein E e4 allele in the normal elderly: neuropsychologic and brain MRI correlates. Schmidt H, et al. **Clin Genet** 1996 Nov;50(5):293–9
APO E polymorphism in Spanish and Moroccan populations. Valveny N, et al. **Clin Genet** 1997 May;51(5):354–6
Compound heterozygote for both rare apolipoprotein E1 (Gly127–>Asp, Arg158–>Cys) and E3(Cys112–>Arg, Arg251–>Gly) alleles in a multigeneration pedigree with hyperlipoproteinaemia. Richard P, et al. **Clin Sci (Colch)** 1997 Jul;93(1):89–95
Changes in phenotypes of apolipoprotein E and apolipoprotein(a) in liver transplant recipients. Fernández-Miranda C, et al. **Clin Transplant** 1997 Aug; 11(4):325–7
Apolipoprotein E phenotype and renal disease. Oda H, et al. **Contrib Nephrol** 1997;120:22–9
Lipoprotein glomerulopathy and its pathogenesis. Saito T, et al. **Contrib Nephrol** 1997;120:30–8
Genetics and molecular biology [editorial] Cattin L, et al. **Curr Opin Lipidol** 1997 Feb;8(1):U4–5
Genetics and molecular biology [editorial] Chappell DA. **Curr Opin Lipidol** 1997 Aug;8(4):U49–50
Apolipoprotein E as a risk factor for coronary heart disease: a genetic and molecular biology approach. de Knijff P, et al. **Curr Opin Lipidol** 1996 Apr;7(2):59–63 (41 ref.)
The Alzheimer diseases. Roses AD. **Curr Opin Neurobiol** 1996 Oct;6(5):644–50 (48 ref.)
Apolipoprotein E in neurology. Roses AD. **Curr Opin Neurol** 1996 Aug;9(4):265–70 (63 ref.)
Apolipoprotein-E genotyping in Alzheimer's disease and frontotemporal dementia. Gustafson L, et al. **Dement Geriatr Cogn Disord** 1997 Jul-Aug;8(4):240–3
Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein. Mukaetova-Ladinska EB, et al. **Dement Geriatr Cogn Disord** 1997 Sep-Oct;8(5):288–95
Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. Brayne C, et al. **Dementia** 1996 May-Jun; 7(3):169–74 (37 ref.)
The gain of apolipoprotein E genotyping to separate patients with Alzheimer's disease from normal individuals: relevance to community studies. Frisoni GB, et al. **Dementia** 1996 Nov-Dec;7(6):336–42
Apolipoprotein E and Alzheimer's disease: strength of association is related to age at onset. Murman DL, et al. **Dementia** 1996 Sep-Oct;7(5):251–5
Effect of polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Kogawa K, et al. **Diabetes** 1997 Apr;46(4):682–7
Effects of apolipoprotein E phenotype on serum cholesterol level and cholesterol response to diet therapy in patients with hypercholesterolemia. Honda K, et al. **Endocr J** 1997 Jun;44(3):425–9
Association of the epsilon 4 allele of apolipoprotein E with poor performance on a dementia screen in African Americans. Hui SL, et al. **Ethn Dis** 1996 Autumn; 6(3–4):266–71
Lack of association between schizophrenia and the apolipoprotein E epsilon 4 allele. Jönsson E, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(4):182–4
Characterization of three human apolipoprotein E isoforms (E2, E3 and E4) expressed in Escherichia coli. Barbier A, et al. **Eur J Clin Chem Clin Biochem** 1997 Aug;35(8):581–9
Identification of apolipoprotein E polymorphisms using temperature cycled primer oligo base extension and mass spectrometry. Little DP, et al. **Eur J Clin Chem Clin Biochem** 1997 Jul;35(7):545–8
Transcriptional regulation of apolipoprotein E expression by cyclic AMP. Andreani-Mangeney M, et al. **FEBS Lett** 1996 Nov 18;397(2–3):155–8
Apolipoprotein E polymorphism and gallstones [see comments] Bertomeu A, et al. **Gastroenterology** 1996 Dec; 111(6):1603–10. Comment in: Gastroenterology 1996 Dec;111(6):1764–7.
Apolipoprotein E polymorphism: another player in the genetics of colon cancer susceptibility? [editorial; comment] Davidson NO. **Gastroenterology** 1996 Jun;110(6):2006–9 (21 ref.). Comment on: Gastroenterology 1996 Jun;110(6):1785–90.
Is the development of adenoma and carcinoma in proximal colon related to apolipoprotein E phenotype? [see comments] Kervinen K, et al. **Gastroenterology** 1996 Jun; 110(6):1785–90. Comment in: Gastroenterology 1996 Jun;110(6):2006–9.
Apolipoprotein E4: another risk factor for cholesterol gallstone formation? [editorial; comment] Van Erpecum KJ, et al. **Gastroenterology** 1996 Dec;111(6):1764–7. Comment on: Gastroenterology 1996 Dec;111(6):1603–10.
No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Fallin D, et al. **Genet Epidemiol** 1997;14(3):299–305
Genetics of type III hyperlipoproteinemia. Feussner G, et al. **Genet Epidemiol** 1997;14(3):283–97
Influence of apolipoprotein E genotypes on plasma lipid and lipoprotein concentrations: results from a segregation analysis in pedigrees with molecularly defined familial hypercholesterolemia. Friedlander Y, et al. **Genet Epidemiol** 1996;13(2):159–77
Gender-specific nonrandom association between the alpha 1-antichymotrypsin and apolipoprotein E polymorphisms in the general population and its implication for the risk

of Alzheimer's disease. Kamboh MI, et al. **Genet Epidemiol** 1997;14(2):169–80

Apolipoprotein E–epsilon 4 allele and familial risk in Alzheimer's disease. Li G, et al. **Genet Epidemiol** 1996; 13(3):285–98

Apolipoprotein E phenotype, arterial disease, and mortality among older women: the study of osteoporotic fractures. Vogt MT, et al. **Genet Epidemiol** 1997;14(2):147–56

Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Arai H, et al. **Gerontology** 1997;43 Suppl 1:2–10 (35 ref.)

Genetic association study between senile dementia of Alzheimer's type and APOE/C1/C2 gene cluster. Kamino K, et al. **Gerontology** 1996;42 Suppl 1:12–9

Apolipoprotein E4 genotype and gallbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shock-wave lithotripsy. Portincasa P, et al. **Hepatology** 1996 Sep;24(3):580–7

Helping Alzheimer's research [letter] **Hosp Pract (Off Ed)** 1996 Oct 15;31(10):40, 42

Alzheimer's disease: the genetics of risk. Roses AD. **Hosp Pract (Off Ed)** 1997 Jul 15;32(7):51–5, 58–63, 67–9 (9 ref.)

Pattern of gradient of apolipoprotein E allele *4 frequencies in western Europe. Lucotte G, et al. **Hum Biol** 1997 Apr; 69(2):253–62

Apolipoprotein B and E genetic polymorphisms in the Cayapa Indians of Ecuador. Scacchi R, et al. **Hum Biol** 1997 Jun;69(3):375–82

High frequency of the apolipoprotein E *4 allele in African pygmies and most of the African populations in sub-Saharan Africa. Zekraoui L, et al. **Hum Biol** 1997 Aug; 69(4):575–81

The apolipoprotein E polymorphism in Greenland Inuit in its global perspective. Gerdes LU, et al. **Hum Genet** 1996 Nov;98(5):546–50

Distribution of apolipoprotein E gene polymorphisms in Japanese patients with Alzheimer's disease and in Japanese centenarians. Yamagata Z, et al. **Hum Hered** 1997 Jan–Feb; 47(1):22–6

Apolipoprotein E and the cost of Alzheimer's disease [letter] Frisoni GB, et al. **Int J Geriatr Psychiatry** 1997 May; 12(5):588–9

Apolipoprotein E genotypes and serum lipid levels in Alzheimer's disease and multi-infarct dementia. Wieringa GE, et al. **Int J Geriatr Psychiatry** 1997 Mar;12(3):359–62

Mutational and susceptibility genetics are different clinical paradigms [editorial] Roses AD. **Int Psychogeriatr** 1997 Mar;9(1):7–10 (11 ref.)

Familial type V hyperlipoproteinemia with hyper-remnant-like particle-cholesterol accompanied with apolipoprotein E3/E4 phenotype. Nagai T, et al. **Intern Med** 1996 May;35(5):388–91

Apolipoprotein E genotype: utility in clinical practice in Alzheimer's disease [see comments] Hyman BT. **J Am Geriatr Soc** 1996 Dec;44(12):1469–71. Comment in: J Am Geriatr Soc 1996 Dec;44(12):1479–81.

APOE4 genotyping [letter] Kandel R. **J Am Geriatr Soc** 1997 Sep;45(9):1154–6

APOE4 testing for Alzheimer's disease [letter] Karlawish JH, et al. **J Am Geriatr Soc** 1997 Sep;45(9):1153–4

Apolipoprotein E Sendai (arginine 145–>proline): a new variant associated with lipoprotein glomerulopathy [see comments] Oikawa S, et al. **J Am Soc Nephrol** 1997 May; 8(5):820–3. Comment in: J Am Soc Nephrol 1997 May;8(5):840–2.

Apolipoprotein E genotypes and risk of diabetic nephropathy. Onuma T, et al. **J Am Soc Nephrol** 1996 Jul; 7(7):1075–8

Expression of apolipoprotein E mRNA in the epithelium and interstitium of the testis and the epididymis. Law GL, et al. **J Androl** 1997 Jan–Feb;18(1):32–42

In vivo footprinting analysis of the hepatic control region of the human apolipoprotein E/C-I/C-IV/C-II gene locus. Dang Q, et al. **J Biol Chem** 1996 Nov 8; 271(45):28667–76

Apolipoprotein E2 transgenic rabbits. Modulation of teh type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. Huang Y, et al. **J Biol Chem** 1997 Sep 5;272(36):22685–94

Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2. Huang Y, et al. **J Biol Chem** 1996 Nov 15;271(46):29146–51

Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. Sullivan PM, et al. **J Biol Chem** 1997 Jul 18; 272(29):17972–80

Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease. Small GW. **J Clin Psychiatry** 1996;57 Suppl 14:9–13 (41 ref.)

Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis. Vuoristo M, et al. **J Hepatol** 1997 Jul;27(1):136–42

Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. Bohnet K, et al. **J Lipid Res** 1996 Jun;37(6):1316–24

Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort. Salah D, et al. **J Lipid Res** 1997 May; 38(5):904–12

Apolipoprotein E genotype does not affect age at onset in patients with chromosome 14 encoded Alzheimer's disease [letter] **J Med Genet** 1996 Feb;33(2):174–5

Effects of apoE gene polymorphism on Lp(a) concentrations depend on the size of apo(a): a study of 466 white men. Klausen IC, et al. **J Mol Med** 1996 Nov;74(11):685–90

Alzheimer's disease, blood lipids, and heart disease: what are the interrelationships? [comment] Luft FC. **J Mol Med** 1997 Feb;75(2):73–4. Comment on: J Mol Med 1997 Feb;75(2):130–8.

Alpha 1-antichymotrypsin gene polymorphism and risk for Alzheimer's disease. Muramatsu T, et al. **J Neural Transm** 1996;103(10):1205–10

Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. Blennow K, et al. **J Neural Transm Gen Sect** 1996;103(5):603–18

Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias. Morris CM, et al. **J Neural Transm Suppl** 1996;47:205–18

Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. Gozes I, et al. **J Neurobiol** 1997 Sep;33(3):329–42

Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease [letter] Ballard C, et al. **J Neurol Neurosurg Psychiatry** 1997 Aug; 63(2):273–4

No effect of the alpha1-antichymotrypsin A allele in Alzheimer's disease. Didierjean O, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):103–5

Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. Holmes C, et al. **J Neurol Neurosurg Psychiatry** 1996 Dec;61(6):580–3

Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence. Jelic V, et al. **J Neurol Neurosurg Psychiatry** 1997 Jul;63(1):59–65

Frequency of the apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease. Whitehead AS, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):347–51

Effect of cerebrospinal fluid from normal and Alzheimer's patients with different apolipoprotein E phenotypes on in vitro aggregation of amyloid beta-protein. Chauhan A, et al. **J Neurol Sci** 1996 Sep 15;141(1-2):54–8

The apolipoprotein E epsilon4 allele causes a faster decline of cognitive performances in Down's syndrome subjects. Del Bo R, et al. **J Neurol Sci** 1997 Jan;145(1):87–91

Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. Moulard B, et al. **J Neurol Sci** 1996 Aug;139 Suppl:34–7

Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. Sparks DL, et al. **J Neurol Sci** 1996 Jun;138(1-2):97–104

Depression, delusions, and hallucinations in Alzheimer's disease: no relationship to apolipoprotein E genotype. Lyketsos CG, et al. **J Neuropsychiatry Clin Neurosci** 1997 Winter;9(1):64–7

Transcription factor AP-2 regulates human apolipoprotein E gene expression in astrocytoma cells. García MA, et al. **J Neurosci** 1996 Dec 1;16(23):7550–6

Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons [see comments] Evans DA, et al. **JAMA** 1997 Mar 12; 277(10):822–4. Comment in: ACP J Club 1997 Sep-Oct;127(2):49.

Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. Jordan BD, et al. **JAMA** 1997 Jul 9;278(2):136–40

Exploring the etiology of Alzheimer disease using molecular genetics. Lendon CL, et al. **JAMA** 1997 Mar 12; 277(10):825–31 (130 ref.)

Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation [see comments] Slooter AJ, et al. **JAMA** 1997 Mar 12;277(10):818–21. Comment in: ACP J Club 1997 Sep-Oct;127(1):48–9.

Researchers find evidence of a new gene for late-onset Alzheimer disease [news] Stephenson J. **JAMA** 1997 Mar 12;277(10):775

Apolipoprotein E genotype and cognition in the very old [letter] Altstiel LD, et al. **Lancet** 1997 May 17; 349(9063):1451

Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study [see comments] Hofman A, et al. **Lancet** 1997 Jan 18; 349(9046):151–4. Comment in: Lancet 1997 Apr 19;349(9059):1174.

APOE epsilon 4 allele in Alzheimer's and non-Alzheimer's dementias [letter; comment] Itabashi S, et al. **Lancet** 1996 Oct 5;348(9032):960–1. Comment on: Lancet 1996 Jul 13;348(9020):90–3.

Herpes simplex virus and risk of Alzheimer's disease [letter; comment] Itabashi S, et al. **Lancet** 1997 Apr 12; 349(9058):1102. Comment on: Lancet 1997 Jan 25;349(9047):241–4.

Alzheimer's disease and apolipoprotein E epsilon 4 allele in older drivers who died in automobile accidents [letter] Johansson K, et al. **Lancet** 1997 Apr 19;349(9059):1143–4

Herpes simplex virus and risk of Alzheimer's disease [letter; comment] Latchman DS. **Lancet** 1997 Apr 12; 349(9058):1101; discussion 1101–2. Comment on: Lancet 1997 Jan 25;349(9047):241–4.

Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia [letter] Pickar D, et al. **Lancet** 1997 Sep 27; 350(9082):930–1

APOE genotyping and response to drug treatment in Alzheimer's disease [letter] Richard F, et al. **Lancet** 1997 Feb 22;349(9051):539

Characteristics of Alzheimer's disease patients with and without ApoE4 allele [letter] Ritchie K, et al. **Lancet** 1996 Oct 5;348(9032):960

Presenilin polymorphisms in Alzheimer's disease [letter] Singleton AB, et al. **Lancet** 1997 Sep 27;350(9082):958–9

Antioxidant dietary status and genetic cardiovascular risk, or how an adequate intake of a-tocopherol, selenium, taurine, magnesium and various other natural antioxidants may overcome the deleterious metabolic consequences related to the E4-4 type of apolipoprotein E [editorial] Durlach J, et al. **Magnes Res** 1996 Jun;9(2):139–41 (24 ref.)

APOE-related frequency of cognitive and noncognitive symptoms in dementia. Cacabelos R, et al. **Methods Find Exp Clin Pharmacol** 1996 Dec;18(10):693–706

Neurotropic viruses and Alzheimer disease. Interaction of herpes simplex type 1 virus and apolipoprotein E in the etiology of the disease. Lin WR, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):135–41

Herpes simplex virus and Alzheimer's disease [news] Jack DB. **Mol Med Today** 1996 Jul;2(7):270

Apolipoprotein E in progressive supranuclear palsy in Japan. Sawa A, et al. **Mol Psychiatry** 1997 Jul;2(4):341–2

Apolipoprotein E allele frequencies in sporadic inclusion body myositis. Love S, et al. **Muscle Nerve** 1996 Dec; 19(12):1605–7

Evaluation of suspected dementia [letter; comment] Roses AD, et al. **N Engl J Med** 1996 Dec 26;335(26):1996; discussion 1997–8. Comment on: N Engl J Med 1996 Aug 1;335(5):330–6.

Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. Eggertsen G, et al. **Nephrol Dial Transplant** 1997 Jan;12(1):141–4

Preliminary evidence for a role of apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk. Olmer M, et al. **Nephrol Dial Transplant** 1997 Apr; 12(4):691–3

Spectral analysis of EEG in Alzheimer's disease: relation to apolipoprotein E polymorphism. Lehtovirta M, et al. **Neurobiol Aging** 1996 Jul-Aug;17(4):523–6

Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains. Pirttilä T, et al. **Neurobiol Aging** 1997 Jan-Feb;18(1):121–7

Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Xu PT, et al. **Neurobiol Dis** 1996; 3(3):229–45

Lack of association of apolipoprotein E epsilon 4 allele with progressive supranuclear palsy [letter] Arai H, et al. **Neurodegeneration** 1996 Jun;5(2):194–5

Alzheimer's disease and history of blood transfusion by apolipoprotein-E genotype. O'Meara ES, et al. **Neuroepidemiology** 1997;16(2):86–93

Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. Anouti A, et al. **Neurology** 1996 Apr; 46(4):1156–7

ApoE epsilon 4 allele and cognitive decline in patients with Alzheimer's disease [see comments] Asada T, et al. **Neurology** 1996 Aug;47(2):603. Comment in: Neurology 1996 Aug;47(2):317–20.

ApoE and CYP2D6 polymorphism with and without parkinsonism-dementia complex in the people of Chamorro, guam. Chen X, et al. **Neurology** 1996 Sep; 47(3):779–84

Alzheimer's disease: clinical implications of the apolipoprotein E genotype. Farlow MR. **Neurology** 1997 May;48(5 Suppl 6):S30–4 (46 ref.)

Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease [see comments] Growdon JH, et al. **Neurology** 1996 Aug;47(2):444–8. Comment in: Neurology 1996 Aug;47(2):317–20.

Effects of apolipoprotein E on dementia and aging in the Shanghai Survey of Dementia. Katzman R, et al. **Neurology** 1997 Sep;49(3):779–85

Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease [see comments] Kurz A, et al. **Neurology** 1996 Aug; 47(2):440–3. Comment in: Neurology 1996 Aug;47(2):317–20.

Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Lippa CF, et al. **Neurology** 1997 Feb;48(2):515–9

The apolipoprotein E epsilon 4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Lopez OL, et al. **Neurology** 1997 Sep; 49(3):794–7

Apolipoprotein E genotypes in primary progressive aphasia. Mesulam MM, et al. **Neurology** 1997 Jul;49(1):51–5

Lack of association between alpha 1-antichymotrypsin polymorphism, Alzheimer's disease, and allele epsilon 4 of apolipoprotein E. Müller U, et al. **Neurology** 1996 Dec;

47(6):1575–7
The impact of apolipoprotein E4 on cause of death in Alzheimer's disease. Olichney JM, et al. **Neurology** 1997 Jul;49(1):76–81
Apolipoprotein E epsilon 4 allele and hippocampal volume in twins with normal cognition. Plassman BL, et al. **Neurology** 1997 Apr;48(4):985–9
Apolipoprotein E and cognitive decline in Alzheimer's disease [editorial; comment] Plassman BL, et al. **Neurology** 1996 Aug;47(2):317–20. Comment on: Neurology 1996 Aug;47(2):440–3. Comment on: Neurology 1996 Aug;47(2):444–8. Comment on: Neurology 1996 Aug;47(2):603.
Apolipoprotein E gene and sporadic frontal lobe dementia. Stevens M, et al. **Neurology** 1997 Jun;48(6):1526–9
Apolipoprotein E genotype in schizophrenia: frequency, age of onset, and neuropathologic features. Arnold SE, et al. **Neuroreport** 1997 Apr 14;8(6):1523–6
The apolipoprotein E epsilon 4 allele is not associated with early onset temporal lobe epilepsy. Blümcke I, et al. **Neuroreport** 1997 Mar 24;8(5):1235–7
Allelic variability in D21S11, but not in APP or APOE, is associated with cognitive decline in Down syndrome. Farrer MJ, et al. **Neuroreport** 1997 May 6;8(7):1645–9
Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and alpha1-antichymotrypsin type A allele in Alzheimer's disease. Higuchi M, et al. **Neuroreport** 1997 Aug 18; 8(12):2639–43
The intracellular fate of apolipoprotein E is tau dependent and apoe allele-specific. Lovestone S, et al. **Neuroreport** 1996 Apr 10;7(5):1005–8
Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Blomberg M, et al. **Neurosci Lett** 1996 Aug 23;214(2–3):163–6
Apolipoprotein E e4 allele frequency in patients with multiple system atrophy. Cairns NJ, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):161–4
Significantly increased frequency of the apolipoprotein E epsilon 4 allele in elderly non-demented leprosy patients. Endoh M, et al. **Neurosci Lett** 1996 Apr 5;207(3):206–8
No association between alpha1-antichymotrypsin polymorphism, apolipoprotein E and patients with late-onset Alzheimer's disease. Helisalmi S, et al. **Neurosci Lett** 1997 Aug 1;231(1):56–8
Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study. Helkala EL, et al. **Neurosci Lett** 1996 Feb 9;204(3):177–80
Apolipoprotein E epsilon2 allele and early onset schizophrenia. Kimura T, et al. **Neurosci Lett** 1997 Aug 1;231(1):53–5
Analysis of the APOE alleles impact in Down's syndrome. Lambert JC, et al. **Neurosci Lett** 1996 Dec 6;220(1):57–60
Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Mann DM, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):81–4
Analysis of apolipoprotein E, alpha1-antichymotrypsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man. Nacmias B, et al. **Neurosci Lett** 1997 Jul 4;229(3):177–80
Apolipoprotein-E genotype in normal aging, age-associated memory impairment, Alzheimer's disease and vascular dementia patients. Palumbo B, et al. **Neurosci Lett** 1997 Aug 1;231(1):59–61
No association between apolipoprotein E epsilon4 allele and the age of onset in type I familial amyloid polyneuropathy. Satoh S, et al. **Neurosci Lett** 1996 Feb 9;204(3):209–11
Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Svensson AL, et al. **Neurosci Lett** 1997 Aug 22;232(1):37–40
Lack of association of the apoE4 allele with hippocampal sclerosis dementia. Troncoso JC, et al. **Neurosci Lett** 1996 Feb 2;204(1–2):138–40
Relation of apolipoprotein E polymorphism to lipid metabolism in obese children. Parlier G, et al. **Pediatr Res** 1997 May;41(5):682–5
Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development. Babin PJ, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8622–7
Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Xiao Q, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10335–40
Apolipoprotein E genotype distribution in schizophrenia. Zhu S, et al. **Psychiatr Genet** 1996 Summer;6(2):75–9
Pathogenesis of Alzheimer's disease: current status on apolipoprotein E4 gene research. Das HK, et al. **Rev Neurosci** 1996 Oct–Dec;7(4):277–83 (25 ref.)
Screening for Alzheimer's disease [editorial] Krause A, et al. **S Afr Med J** 1997 Feb;87(2):128–30
Alzheimer's disease: genotypes, phenotypes, and treatments. Selkoe DJ. **Science** 1997 Jan 31;275(5300):630–1 (17 ref.)
Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Kalmijn S, et al. **Stroke** 1996 Dec;27(12):2230–5
Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Schmidt R, et al. **Stroke** 1997 May;28(5):951–6
Apolipoprotein E polymorphism is associated with segment-specific extracranial carotid artery intima-media thickening. Terry JG, et al. **Stroke** 1996 Oct;27(10):1755–9
Lipids, apolipoprotein-E genotypes and other risk factors of patients with coronary artery disease in Curaçao. Brouwer DA, et al. **West Indian Med J** 1997 Jun; 46(2):47–52
Apolipoprotein E polymorphism and plasma cholesterol response to dietary change. Tikkanen MJ. **World Rev Nutr Diet** 1997;80:15–21 (53 ref.)
[Apolipoprotein E genotypes in patients investigated for dementia] Johannsen P, et al. **Ugeskr Laeger** 1997 Sep 15; 159(38):5658–61 (Eng. Abstr.) **(Dan)**
[The role of apolipoproteins E genotyping in the differential diagnosis of dementia] Slooter AJ, et al. **Ned Tijdschr Geneeskd** 1996 Oct 19;140(42):2073–6 **(Dut)**
[Apolipoprotein E epsilon 4 allel frequencies, plasma alpha 2-macroglobulin and plasminogen activator inhibitor 1 levels in residents of a rural area in Gunma prefecture] Muramatsu S, et al. **Nippon Ronen Igakkai Zasshi** 1997 Mar; 34(3):196–201 (Eng. Abstr.) **(Jpn)**
[Alzheimer's disease and apolipoprotein E] Yamaguchi H. **No To Shinkei** 1996 Nov;48(11):981–90 (74 ref.) **(Jpn)**
[Molecular genetics of apolipoprotein E and its receptors, implications for genetic risk factors of Alzheimer's disease] Okuizumi K, et al. **Tanpakushitsu Kakusan Koso** 1996 Aug; 41(10):1460–4 (20 ref.) **(Jpn)**
[Apolipoprotein E and disease (editorial)] Pedro-Botet J, et al. **Med Clin (Barc)** 1997 Jul 5;109(6):216–8 **(Spa)**
[Apolipoprotein E and Alzheimer's disease (editorial)] Lahoz C, et al. **Rev Clin Esp** 1997 Feb;197(2):73–4 **(Spa)**

IMMUNOLOGY

Inconstant apolipoprotein E (ApoE)-like immunoreactivity in amyloid beta protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease. Uchihara T, et al. **Acta Neuropathol (Berl)** 1996 Aug;92(2):180–5
Further characterization of a monoclonal antibody recognizing apolipoprotein E peptides in amyloid deposits. Yamada T, et al. **Ann Clin Lab Sci** 1997 Jul-Aug; 27(4):276–81

ISOLATION & PURIFICATION

Remnant-like very-low-density lipoprotein isolated from hypertriglyceridemic patients by immunoaffinity chromatography suppressed 3-hydroxy-3-methylglutaryl coenzyme A activity of cultured human skin fibroblasts. Shige H, et al. **Clin Chim Acta** 1997 Feb 17;258(2):145–58

METABOLISM

APOE-epsilon 4 in patients with Alzheimer disease and vascular dementia. Treves TA, et al. **Alzheimer Dis Assoc Disord** 1996 Winter;10(4):189–91
Molecular basis of Alzheimer's disease. Gooch MD, et al. **Am J Health Syst Pharm** 1996 Jul 1;53(13):1545–57; quiz 1603–4 (122 ref.)
Lipoproteins accumulate in immune deposits and are modified by lipid peroxidation in passive Heymann nephritis. Exner M, et al. **Am J Pathol** 1996 Oct; 149(4):1313–20
Interaction of apo E-containing lipoproteins with the LDL receptor-related protein LRP. Küchenhoff A, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C369–82
Apolipoprotein E and inclusion body myositis [editorial] Garlepp MJ, et al. **Ann Neurol** 1996 Dec;40(6):826–8
Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies. Mirabella M, et al. **Ann Neurol** 1996 Dec;40(6):864–72
A comparison of the quantitation of macrophage foam cell populations and the extent of apolipoprotein E deposition in developing atherosclerotic lesions in young people: high and low serum thiocyanate groups as an indication of smoking. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Botti TP, et al. **Atherosclerosis** 1996 Aug 2;124(2):191–202
Scavenger receptor activity and expression of apolipoprotein E mRNA in monocyte-derived macrophages of young and old healthy men. Friedman G, et al. **Atherosclerosis** 1997 Jan 3;128(1):67–73
Regulation of serum-induced lipid accumulation in human monocyte-derived macrophages by interferon-gamma. Correlations with apolipoprotein E production, lipoprotein lipase activity and LDL receptor-related protein expression. Garner B, et al. **Atherosclerosis** 1997 Jan 3; 128(1):47–58
Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein. Haas C, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):169–75
Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1–40). Relevance to Alzheimer's disease. Aleshkov S, et al. **Biochemistry** 1997 Aug 26;36(34):10571–80
Conformationally specific enhancement of receptor-mediated LDL binding and internalization by peptide models of a conserved anionic N-terminal domain of human apolipoprotein E. Braddock DT, et al. **Biochemistry** 1996 Nov 5;35(44):13975–84
Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. Naiki H, et al. **Biochemistry** 1997 May 20;36(20):6243–50
Composition and structural and functional properties of discoidal and spherical phospholipid-apoE3 complexes. De Pauw M, et al. **Biochemistry (Mosc)** 1997 Mar;62(3):251–63
Co-localization of beta-amyloid peptides, apolipoprotein E and glial markers in senile plaques in the prefrontal cortex of old rhesus monkeys. Härtig W, et al. **Brain Res** 1997 Mar 21;751(2):315–22
Marked alterations in the cellular localisation and levels of apolipoprotein E following acute subdural haematoma in rat. Horsburgh K, et al. **Brain Res** 1997 Jul 18;763(1):103–10
Cystatin C and apolipoprotein E immunoreactivities in CA1 neurons in ischemic gerbil hippocampus. Ishimaru H, et al. **Brain Res** 1996 Feb 19;709(2):155–62
Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls. Pirttilä T, et al. **Brain Res** 1996 May 25;722(1–2):71–7
Quantification of APP and APLP2 mRNA in APOE genotyped Alzheimer's disease brains. Johnston JA, et al. **Brain Res Mol Brain Res** 1996 Dec 31;43(1–2):85–95
Isoform-specific binding of human apolipoprotein E to the non-amyloid beta component of Alzheimer's disease amyloid. Olesen OF, et al. **Brain Res Mol Brain Res** 1997 Feb;44(1):105–12
An ApoE-Abeta inhibition complex in Abeta fibril extension. Wood SJ, et al. **Chem Biol** 1996 Nov;3(11):949–56
Apolipoprotein E and amyloidogenesis. Frangione B, et al. **Ciba Found Symp** 1996;199:132–41; discussion 141–5
Senile dementia and apolipoprotein E4 [letter] McConathy W, et al. **Dement Geriatr Cogn Disord** 1997 Jul-Aug; 8(4):258
Apolipoprotein E genotype does not promote the clinical progression of manifest Alzheimer's disease [letter] Sarochan M, et al. **Dementia** 1996 Mar-Apr;7(2):120
Low apolipoprotein E4 allelic frequency in Alzheimer's disease and functional psychiatric disorders [letter] Thilmann P, et al. **Dementia** 1996 Mar-Apr;7(2):118–9
Injury-induced synthesis and release of apolipoprotein E and clusterin from rat neural cells. Messmer-Joudrier S, et al. **Eur J Neurosci** 1996 Dec;8(12):2652–61
Role of apolipoprotein E in lipoprotein metabolism and in the process of atherosclerosis. Yamada N, et al. **J Atheroscler Thromb** 1995;2 Suppl 1:S29–33
Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. Fagan AM, et al. **J Biol Chem** 1996 Nov 22;271(47):30121–5
Lipoprotein lipase reduces secretion of apolipoprotein E from macrophages. Lucas M, et al. **J Biol Chem** 1997 May 16; 272(20):13000–5
Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. Smith JD, et al. **J Biol Chem** 1996 Nov 29;271(48):30647–55
Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. Ebara T, et al. **J Clin Invest** 1997 Jun 1;99(11):2672–81
Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. LaFerla FM, et al. **J Clin Invest** 1997 Jul 15;100(2):310–20
Diffuse Lewy body disease without amyloid plaques in a patient homozygous for apolipoprotein E allele epsilon 4: a case report. Seltzer B, et al. **J Geriatr Psychiatry Neurol** 1996 Oct;9(4):181–4
Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. Bohnet K, et al. **J Lipid Res** 1996 Jun;37(6):1316–24
Investigation of plasma membrane-associated apolipoprotein E in primary macrophages. Deng J, et al. **J Lipid Res** 1997 Feb;38(2):217–27
Apolipoprotein E5 (Glu212-->Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts. Feussner G, et al. **J Lipid Res** 1996 Aug;37(8):1632–45
Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. Rensen PC, et al. **J Lipid Res** 1997 Jun;38(6):1070–84
ApoE enhances lipid uptake by macrophages in lipoprotein lipase deficiency during pregnancy. Steinberg FM, et al. **J Lipid Res** 1996 May;37(5):972–84
Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. Yang DS, et al. **J Neurochem** 1997 Feb;68(2):721–5
Astrocyte-apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: a regional immunohistochemical study. Shao Y, et al. **J Neuropathol Exp Neurol** 1997 Apr;56(4):376–81
Apo-E genotype and verbal deficits in Alzheimer's disease. Rasmusson DX, et al. **J Neuropsychiatry Clin Neurosci** 1996 Summer;8(3):335–7
Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. LaDu MJ, et al. **J Neurosci Res** 1997 Jul 1;49(1):9–18
Effects of triamcinolone on brain and cerebrospinal fluid apolipoprotein E levels in rats. Chiba H, et al. **Life Sci** 1997;60(20):1757–61

Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Zlokovic BV. **Life Sci** 1996; 59(18):1483-97 (83 ref.)

Antioxidant dietary status and genetic cardiovascular risk, or how an adequate intake of a-tocopherol, selenium, taurine, magnesium and various other natural antioxidants may overcome the deleterious metabolic consequences related to the E4-4 type of apolipoprotein E [editorial] Durlach J, et al. **Magnes Res** 1996 Jun;9(2):139-41 (24 ref.)

Lipoprotein lipase-enhanced binding of lipoprotein(a) [Lp(a)] to heparan sulfate is improved by apolipoprotein E (apoE) saturation: secretion-capture process of apoE is a possible route for the catabolism of Lp(a). van Barlingen HH, et al. **Metabolism** 1997 Jun;46(6):650-5

Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Zhou Z, et al. **Mol Med** 1996 Mar;2(2):175-80

Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Rensen PCN, et al. **Mol Pharmacol** 1997 Sep;52(3):445-55

Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Barger SW, et al. **Nature** 1997 Aug 28;388(6645):878-81

APOE alleles in Alzheimer's disease and vascular dementia in a population aged 85+. Sulkava R, et al. **Neurobiol Aging** 1996 May-Jun;17(3):373-6

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Lemere CA, et al. **Neurobiol Dis** 1996 Feb;3(1):16-32

Apolipoprotein E uptake and low-density lipoprotein receptor-related protein expression by the NTera2/D1 cell line: a cell culture model of relevance for late-onset Alzheimer's disease. Williams KR, et al. **Neurobiol Dis** 1997;4(1):58-67

Apolipoprotein E [letter; comment] Frisoni GB, et al. **Neurology** 1996 Nov;47(5):1352-3. Comment on: Neurology 1996 Jan;46(1):149-54.

Selective alterations in the cellular distribution of apolipoprotein E immunoreactivity following transient cerebral ischaemia in the rat. Horsburgh K, et al. **Neuropathol Appl Neurobiol** 1996 Aug;22(4):342-9

Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression. Sheng JG, et al. **Neuropathol Appl Neurobiol** 1996 Aug;22(4):334-41

Relation of age and apolipoprotein E to cognitive function in Down syndrome adults. Alexander GE, et al. **Neuroreport** 1997 May 27;8(8):1835-40

Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain. Bao F, et al. **Neuroreport** 1996 Jul 29;7(11):1733-9

Accumulation of apolipoprotein E and beta-amyloid-like protein in a trace of the hippocampal CA1 pyramidal cell layer after ischaemic delayed neuronal death. Ishimaru H, et al. **Neuroreport** 1996 Nov 25;7(18):3063-7

A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. Marques MA, et al. **Neuroreport** 1996 Nov 4;7(15-17):2529-32

Human APOE protein localized in brains of transgenic mice. Bowman BH, et al. **Neurosci Lett** 1996 Nov 15;219(1):57-9

Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Golombowski S, et al. **Neurosci Lett** 1997 Apr 11;225(3):213-5

Apolipoprotein E polymorphism in patients with different neurodegenerative disorders. Helisalmi S, et al. **Neurosci Lett** 1996 Feb 16;205(1):61-4

Apolipoprotein E is highly susceptible to oxidation by myeloperoxidase, an enzyme present in the brain. Jolivalt C, et al. **Neurosci Lett** 1996 May 24;210(1):61-4

Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease. Li YM, et al. **Neurosci Lett** 1997 May 2;226(3):155-8

The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. Minthon L, et al. **Neurosci Lett** 1997 Apr 18; 226(1):65-7

Expression of apolipoprotein E inhibits aggregation of the C-terminal fragments of beta-amyloid precursor protein. Ohman T, et al. **Neurosci Lett** 1996 May 24;210(1):65-8

Differential expression of apolipoprotein D and apolipoprotein E in the kainic acid-lesioned rat hippocampus. Ong WY, et al. **Neuroscience** 1997 Jul; 79(2):359-67

Apolipoprotein E in the subretinal fluid of rhegmatogenous and exudative retinal detachments. Schneeberger SA, et al. **Retina** 1997;17(1):38-43

Apolipoprotein E, memory and Alzheimer's disease. Soininen HS, et al. **Trends Neurosci** 1996 Jun;19(6):224-8

[Physiology and pathology of the lipid transport in the brain] Chiba H. **Rinsho Byori** 1996 Mar;44(3):231-6 (21 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Native immunoaffinity-isolated apolipoprotein E-containing high-density lipoprotein particles inhibit platelet aggregation. Riddell DR, et al. **Biochem Soc Trans** 1996 Aug;24(3):454S

Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Wood SJ, et al. **Biochemistry** 1996 Sep 24;35(38):12623-8

Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates beta-amyloid protein activation of complement in vitro. McGeer PL, et al. **Brain Res** 1997 Feb 21; 749(1):135-8

Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Masliah E, et al. **Brain Res** 1997 Mar 21;751(2):307-14

Specific modulation of the fusogenic properties of the Alzheimer beta-amyloid peptide by apolipoprotein E isoforms. Pillot T, et al. **Eur J Biochem** 1997 Feb 1; 243(3):650-9

Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease. Riddell DR, et al. **J Biol Chem** 1997 Jan 3; 272(1):89-95

Rapid elevation of neuronal cytoplasmic calcium by apolipoprotein E peptide. Wang XS, et al. **J Cell Physiol** 1997 Oct;173(1):73-83

Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo. Rensen PC, et al. **J Clin Invest** 1997 May 15;99(10):2438-45

Isoform-specific modulation by apolipoprotein E of the activities of secreted beta-amyloid precursor protein. Barger SW, et al. **J Neurochem** 1997 Jul;69(1):60-7

Effect of apolipoprotein E on neurite outgrowth and beta-amyloid-induced toxicity in developing rat primary hippocampal cultures. Puttfarcken PS, et al. **J Neurochem** 1997 Feb;68(2):760-9

Apolipoprotein E suppresses glial cell secretion of TNF alpha. Laskowitz DT, et al. **J Neuroimmunol** 1997 Jun; 76(1-2):70-4

Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. Ma J, et al. **Neurobiol Aging** 1996 Sep-Oct; 17(5):773-80

High density lipoprotein decreases beta-amyloid toxicity in cortical cell culture. Farhangrazi ZS, et al. **Neuroreport** 1997 Mar 24;8(5):1127-30

A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. Marques MA, et al. **Neuroreport** 1996 Nov 4;7(15-17):2529-32

Inhibition of ADP-induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion [corrected and republished article originally printed in Thromb Res 1995 Dec 15;80(6):499-508] Riddell DR, et al. **Thromb Res** 1996 Mar 1;81(5):597-606

PHYSIOLOGY

The underlying molecular mechanism of apolipoprotein E polymorphism: relationships to lipid disorders, cardiovascular disease, and Alzheimer's disease. Contois JH, et al. **Clin Lab Med** 1996 Mar;16(1):105-23 (109 ref.)

Human apolipoprotein E: the Alzheimer's disease connection. Weisgraber KH, et al. **FASEB J** 1996 Nov;10(13):1485-94 (58 ref.)

Lipoprotein glomerulopathy: a new role for apolipoprotein E? [editorial; comment] Karet FE, et al. **J Am Soc Nephrol** 1997 May;8(5):840-2 (21 ref.). Comment on: J Am Soc Nephrol 1997 May;8(5):820-3.

In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 --> Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice. van Vlijmen BJ, et al. **J Biol Chem** 1996 Nov 29;271(48):30595-602

Clinical chemistry of common apolipoprotein E isoforms. Brouwer DA, et al. **J Chromatogr B Biomed Appl** 1996 Mar 29;678(1):23-41 (117 ref.)

Apolipoprotein E in the brain and its role in Alzheimer's disease. Poirier J. **J Psychiatry Neurosci** 1996 Mar; 21(2):128-34

Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Urmoneit B, et al. **Lab Invest** 1997 Aug;77(2):157-66

Early effect of ApoE-epsilon 4 allele on cognitive results in a group of highly performing subjects: the EVA study. Etude sur le Vieillissement Artériel. Berr C, et al. **Neurosci Lett** 1996 Oct 25;218(1):9-12

Apolipoprotein E and Alzheimer's disease: a review of recent studies. Higgins GA, et al. **Pharmacol Biochem Behav** 1997 Apr;56(4):675-85 (118 ref.)

Absence of central cholinergic deficits in ApoE knockout mice. Anderson R, et al. **Psychopharmacology (Berl)** 1997 Jul;132(2):135-44

Lipoprotein glomerulopathy: a new apolipoprotein-E-related disease that recurs after renal transplantation. Mourad G, et al. **Transplant Proc** 1997 Aug;29(5):2376

[Apolipoproteins: pharmacologic targets in cardio-cerebrovascular diseases--the place of apolipoprotein E] Siest G. **J Pharm Belg** 1997 Mar-Apr; 52(2):99 **(Fre)**

SECRETION

Apolipoprotein E secretion by macrophages: its potential physiological functions. Mazzone T. **Curr Opin Lipidol** 1996 Oct;7(5):303-7 (46 ref.)

Stimulation of apolipoprotein E secretion in human hepatoma Hep G2 cells by a cyclic acylpeptide, N-4909 [letter] Hiramoto S, et al. **J Antibiot (Tokyo)** 1996 Sep;49(9):949-52

Mechanisms of enhanced macrophage apoE secretion by oxidized LDL. Cader AA, et al. **J Lipid Res** 1997 May; 38(5):981-91

Altered apolipoprotein E secretion in cytokine treated human astrocyte cultures. Baskin F, et al. **J Neurol Sci** 1997 May 1;148(1):15-8

TOXICITY

Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. Tolar M, et al. **J Neurosci** 1997 Aug 1;17(15):5678-86

Neurotoxicity of apolipoprotein E thrombin cleavage fragments: implications for Alzheimer's disease [letter] Gurwitz D. **Neuroreport** 1997 Mar 3;8(4):1067-8

APOMORPHINE

ADMINISTRATION & DOSAGE

Comparison between percutaneous and subcutaneous routes of administration of apomorphine in rabbit. Durif F, et al. **Clin Neuropharmacol** 1994 Oct;17(5):445-53

Continuous infusion of apomorphine improves torsion dystonia in a boy unresponsive to other dopaminergic drugs. Zuddas A, et al. **J Child Neurol** 1996 Jul;11(4):343-5

Effect of route and frequency of administration of apomorphine on growth hormone release in African catfish (Clarias gariepinus). Lescroart O, et al. **Life Sci** 1997; 60(20):1771-9

Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects. Eichhorn TE, et al. **Mov Disord** 1996 May;11(3):289-97

Transient atrial fibrillation after subcutaneous apomorphine bolus. Stocchi F, et al. **Mov Disord** 1996 Sep;11(5):584-5

Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Tison F, et al. **Mov Disord** 1996 Nov;11(6):729-32

A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease. van Laar T, et al. **Mov Disord** 1996 Nov;11(6):633-8

ADVERSE EFFECTS

Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease. Courty E, et al. **Clin Neuropharmacol** 1997 Apr;20(2):140-7

Allergic contact dermatitis from apomorphine. Carboni GP, et al. **Contact Dermatitis** 1997 Mar;36(3):177-8

Transient atrial fibrillation after subcutaneous apomorphine bolus. Stocchi F, et al. **Mov Disord** 1996 Sep;11(5):584-5

Locomotor activity and dopamine synthesis following 1 and 15 days of withdrawal from repeated apomorphine treatments. Rowlett JK, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):13-8

ANALOGS & DERIVATIVES

Ontogeny of dopamine agonist-induced sensitization: role of NMDA receptors. Duke MA, et al. **Psychopharmacology (Berl)** 1997 Jan;129(2):153-60

ANALYSIS

Analysis of aporphine and quinolizidine alkaloids from Caulophyllum thalictroides by densitometry and HPLC. Woldemariam TZ, et al. **J Pharm Biomed Anal** 1997 Mar; 15(6):839-43

ANTAGONISTS & INHIBITORS

Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) after subchronic treatment in rats. Sontag KH, et al. **J Neural Transm Suppl** 1995;46:283-9

Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects. Doyle E, et al. **Neurochem Res** 1996 Jun;21(6):649-52

Adenosine A2a receptors in the nucleus accumbens modulate prepulse inhibition of the startle response. Hauber W, et al. **Neuroreport** 1997 Apr 14;8(6):1515-8

BLOOD

Determination of apomorphine in human plasma by alumina extraction and high-performance liquid chromatography with electrochemical detection. Bolner A, et al. **Forensic Sci Int** 1997 Sep 19;89(1-2):81-91

Stereoselective determination of apomorphine enantiomers in serum with a cellulose-based high-performance liquid chromatographic chiral column using solid-phase extraction and ultraviolet detection. Ameyibor E, et al. **J Chromatogr B Biomed Appl** 1996 Nov 15;686(2):297-300

Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. Priston MJ, et al. **J Chromatogr B Biomed Appl** 1996 May 31;681(1):161-7

APOMORPHINE

CHEMISTRY

Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Gassen M, et al. **Eur J Pharmacol** 1996 Jul 18;308(2):219–25

DIAGNOSTIC USE

Reduced dopaminergic function in alcoholics is related to severe dependence. Schmidt LG, et al. **Biol Psychiatry** 1996 Feb 1;39(3):193–8

Dopamine hypersensitivity in migraine: role of the apomorphine test. Cerbo R, et al. **Clin Neuropharmacol** 1997 Feb;20(1):36–41

The growth hormone response to apomorphine at 4 days postpartum in women with a history of major depression. Mc Ivor RJ, et al. **J Affect Disord** 1996 Oct 14;40(3):131–6

METABOLISM

The effect of Yohimbine, an alpha2 adrenergic receptor antagonist, on the growth hormone response to apomorphine in normal subjects. Lal S, et al. **J Psychiatry Neurosci** 1996 Mar;21(2):96–100

PHARMACOKINETICS

Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid. Sam E, et al. **Eur J Pharmacol** 1997 Jun 18;329(1):9–15

Effect of tolcapone on plasma and striatal apomorphine disposition in rats. Coudoré F, et al. **Neuroreport** 1997 Mar 3;8(4):877–80

PHARMACOLOGY

Apomorphine and 7–OH DPAT reduce ethanol intake of P and HAD rats. Russell RN, et al. **Alcohol** 1996 Sep–Oct; 13(5):515–9

Apomorphine produces an acute dose–dependent therapeutic effect on neglect produced by unilateral destruction of the posterior parietal cortex in rats. Corwin JV, et al. **Behav Brain Res** 1996 Sep;79(1–2):41–9

The effects of cooling the area postrema of male rats on conditioned taste aversions induced by LiCl and apomorphine. Wang Y, et al. **Behav Brain Res** 1997 Jan; 82(2):149–58

A study of tolerance to apomorphine. Montastruc JL, et al. **Br J Pharmacol** 1996 Mar;117(5):781–6

Changes in apomorphine pharmacodynamics following repeated treatment in 6–hydroxydopamine–lesioned rats. Gancher S, et al. **Brain Res** 1996 Aug 12;729(2):190–6

Differential effects of SCH 23390 on the apomorphine subsensitivity in the substantia nigra and ventral tegmental area 1 day following withdrawal from continuous or intermittent cocaine pretreatment. Lee TH, et al. **Brain Res** 1997 Jan 9;744(2):293–301

Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites. Little KY, et al. **Brain Res** 1996 Dec 2;742(1–2):313–6

Enhancement of the locomotor response to apomorphine in pertussis toxin–treated animals depends on the site of pertussis toxin injection into the ventral tegmental area. Narayanan S, et al. **Brain Res** 1997 Feb 14;748(1–2):263–6

Rats bred for enhanced apomorphine susceptibility have elevated tyrosine hydroxylase mRNA and dopamine D2–receptor binding sites in nigrostriatal and tuberoinfundibular dopamine systems. Rots NY, et al. **Brain Res** 1996 Feb 26;710(1–2):189–96

Effect of dopaminergic drugs on processing and degradative neuropeptidase mRNA in rat frontal cortex and caudate–putamen. Waters SM, et al. **Brain Res** 1997 Apr 18;754(1–2):28–34

Differential action of secreto–inhibitors on proopiomelanocortin biosynthesis in the intermediate pituitary of Xenopus laevis. Dotman CH, et al. **Endocrinology** 1996 Nov;137(11):4551–7

Subthalamic ablation reverses changes in basal ganglia oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion in rats. Blandini F, et al. **Eur J Neurosci** 1997 Jul;9(7):1407–13

Dopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus: correlation with penile erection and yawning. Melis MR, et al. **Eur J Neurosci** 1996 Oct;8(10):2056–63

Dopamine D2 receptors play a role in the (–)–apomorphine–like discriminative stimulus effects of (+)–PD 128907. Kleven MS, et al. **Eur J Pharmacol** 1997 Feb 19;321(1):1–4

The behavioral effects of habituation and challenge with apomorphine after 6–OHDA lesioning of the nucleus accumbens in rats. Vos PE, et al. **Eur Neuropsychopharmacol** 1995 Dec;5(4):471–6

Circling behaviour induced by apomorphine after lesions of the habenula. Wickens AP, et al. **Exp Brain Res** 1996 Apr; 109(1):17–21

Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6–hydroxydopamine–lesioned rat is temporally correlated with a rise in striatal preproenkephalin–B, but not preproenkephalin–A, gene expression. Duty S, et al. **Exp Neurol** 1997 Apr;144(2):423–32

Suppressive effects of chronic hyperprolactinemia on penile erection and yawning following administration of apomorphine to pituitary–transplanted rats. Sato F, et al. **J Androl** 1997 Jan–Feb;18(1):21–5

Dopaminergic modulation of visual responses in toads. I. Apomorphine–induced effects on visually directed appetitive and consummatory prey–catching behavior. Glagow M, et al. **J Comp Physiol [A]** 1997 Jan;180(1):1–9

Dopaminergic modulation of visual responses in toads. II. Influences of apomorphine on retinal ganglion cells and tectal cells. Glagow M, et al. **J Comp Physiol [A]** 1997 Jan;180(1):11–8

Time course and regional basis of Pb–induced changes in MK–801 binding: reversal by chronic treatment with the dopamine agonist apomorphine but not the D1 agonist SKF–82958. Cory–Slechta DA, et al. **J Neurochem** 1997 May;68(5):2012–23

Preferential vulnerability of nucleus accumbens dopamine binding sites to low–level lead exposure: time course of effects and interactions with chronic dopamine agonist treatments. Pokora MJ, et al. **J Neurochem** 1996 Oct; 67(4):1540–50

Neonatal maternally deprived rats have as adults elevated basal pituitary–adrenal activity and enhanced susceptibility to apomorphine. Rots NY, et al. **J Neuroendocrinol** 1996 Jul;8(7):501–6

Local and distributed effects of apomorphine on fronto–temporal function in acute unmedicated schizophrenia. Fletcher PC, et al. **J Neurosci** 1996 Nov 1;16(21):7055–62

Growth hormone response to apomorphine in obsessive–compulsive disorder. Pitchot W, et al. **J Psychiatry Neurosci** 1996 Nov;21(5):343–5

Modulation of apomorphine–induced rotations in unilaterally 6–hydroxydopamine lesioned rats by cholinergic agonists and antagonists. Gao ZG, et al. **Life Sci** 1997;60(22):PL 317–23

Prevention by morphine of apomorphine– and oxytocin–induced penile erection and yawning: involvement of nitric oxide. Melis MR, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 May; 355(5):595–600

Dopaminergic reduction of excitability in nucleus accumbens neurons recorded in vitro. O'Donnell P, et al. **Neuropsychopharmacology** 1996 Jul;15(1):87–97

Involvement of the presynaptic dopamine D2 receptor in the depression of spinal reflex by apomorphine. Gajendiran M, et al. **Neuroreport** 1996 Jan 31;7(2):513–6

Apomorphine–induced suppression of prey oriented turning in toads is correlated with activity changes in pretectum and tectum: [14C]2DG studies and single cell recordings. Glagow M, et al. **Neurosci Lett** 1996 Dec 20;220(3):215–8

The novel atypical antipsychotic olanzapine, but not the CCK–B antagonist LY288513, blocks apomorphine–induced disruption of pre–pulse inhibition. Rasmussen K, et al. **Neurosci Lett** 1997 Jan 24;222(1):61–4

The effect of nigral implantation on sensitization to dopamine agonists in 6–hydroxydopamine–lesioned rats. Gancher S, et al. **Neuroscience** 1997 Aug;79(4):963–72

Apomorphine and dopamine D(1) receptor agonists increase the firing rates of subthalamic nucleus neurons. Kreiss DS, et al. **Neuroscience** 1996 Jun;72(3):863–76

Apomorphine priming alters the response of striatal outflow pathways to D2 agonist stimulation in 6–hydroxydopamine–lesioned rats. Pollack AE, et al. **Neuroscience** 1997 Jul;79(1):79–93

Effects of spinal alpha 1–adrenoceptor antagonism on bladder activity induced by apomorphine in conscious rats with and without bladder outlet obstruction. Ishizuka O, et al. **Neurourol Urodyn** 1997;16(3):191–200

Measurement issues in curve–shift analysis of apomorphine effects on rewarding brain stimulation. Hall FS, et al. **Pharmacol Biochem Behav** 1996 Feb;53(2):417–23

Low–dose apomorphine attenuates morphine–induced enhancement of brain stimulation reward. Knapp CM, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):87–91

Low doses of apomorphine suppress operant motor performance in rats. Liu X, et al. **Pharmacol Biochem Behav** 1996 Feb;53(2):335–40

Increased S(–)–apomorphine–induced vacuous chewing and attenuated effect of chronic haloperidol treatment in streptozotocin–induced diabetic rat. Sumiyoshi T, et al. **Pharmacol Biochem Behav** 1997 May–Jun;57(1–2):19–22

Pharmacological characterization of the enhancement of apomorphine–induced gnawing in mice by cocaine. Tirelli E, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):135–40

Effect of apomorphine on the conflict–induced jumping stereotypy in bank voles. Vandebroek I, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):863–8

Modulation of apomorphine–induced stereotyped behavior by cholecystokinin. Tieppo CA, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 May; 21(4):683–95

Comparative behavioral sensitization to stereotypy by direct and indirect dopamine agonists in CF–1 mice. Bedingfield JB, et al. **Psychopharmacology (Berl)** 1996 Apr; 124(3):219–25

Brain dopamine receptor plasticity: testing a diathesis–stress hypothesis in an animal model. Cabib S, et al. **Psychopharmacology (Berl)** 1997 Jul;132(2):153–60

Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7–OH–DPAT: comparison with quinpirole and apomorphine. Depoortere R, et al. **Psychopharmacology (Berl)** 1996 Apr;124(3):231–40

Repeated 7–OH–DPAT treatments: behavioral sensitization, dopamine synthesis and subsequent sensitivity to apomorphine and cocaine. Mattingly BA, et al. **Psychopharmacology (Berl)** 1996 May;125(1):33–42

Stimulus and response factors affecting the development of behavioral sensitization to apomorphine. Mattingly BA, et al. **Psychopharmacology (Berl)** 1997 Mar;130(2):109–16

Discriminative stimulus effects of apomorphine and 7–OH–DPAT: a potential role for dopamine D3 receptors. Sanger DJ, et al. **Psychopharmacology (Berl)** 1997 Apr; 130(4):387–95

Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine–induced behaviors in the rat. Rajakumar N, et al. **Synapse** 1997 Jul;26(3):199–208

Dopamine efflux in the rat nucleus accumbens evoked by dopamine receptor stimulation in the entorhinal cortex is modulated by oestradiol and progesterone. Saigusa T, et al. **Synapse** 1997 Jan;25(1):37–43

Effects of maternal exposure to 3,3',4,4'–tetrachlorobiphenyl or propylthiouracil in rats trained to discriminate apomorphine from saline. Lilienthal H, et al. **Toxicol Appl Pharmacol** 1997 Sep;146(1):162–9

[Prevention of immunosuppression in the stressed mice by changing the activity of the neuromediator systems] Idova GV, et al. **Biull Eksp Biol Med** 1996 Jul;122(7):22–4 **(Rus)**

[A comparison of the effects of dopamine agonists on self–stimulation of the hypothalamus with destruction of the mesolimbic brain structures in rats raised under conditions of social isolation] Panchenko GN, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Sep–Oct; 46(5):937–43 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone. Gálvez–Jiménez N, et al. **Can J Neurol Sci** 1996 Aug; 23(3):198–203

Intranasal apomorphine rescue therapy for parkinsonian "off" periods. Dewey RB Jr, et al. **Clin Neuropharmacol** 1996 Jun;19(3):193–201

Long–term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa–related motor fluctuations. Esteban Muñoz J, et al. **Clin Neuropharmacol** 1997 Jun;20(3):245–52

Apomorphine tolerance in Parkinson's disease: lack of a dose effect. Gancher ST, et al. **Clin Neuropharmacol** 1996 Feb; 19(1):59–64

Drug–induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L–Dopa and apomorphine. Merello M, et al. **Clin Neuropharmacol** 1996 Oct;19(5):439–43

Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double–blind single–dose study. Merello M, et al. **Clin Neuropharmacol** 1997 Apr;20(2):165–7

Different effects of levodopa and apomorphine on blink reflex recovery cycle in essential blepharospasm. Napolitano A, et al. **Eur Neurol** 1997;38(2):119–22

Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Verhagen Metman L, et al. **Neurology** 1997 Feb;48(2):369–72

[Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease] Castillo JL, et al. **Rev Med Chil** 1996 Mar;124(3):301–6 (Eng. Abstr.) **(Spa)**

APOPLEXY see **CEREBROVASCULAR DISORDERS**

APOPLEXY, PITUITARY see **PITUITARY APOPLEXY**

APOPROTEINS

Recombinant apoaequorin acting as a pseudo–luciferase reports micromolar changes in the endoplasmic reticulum free Ca2+ of intact cells. Kendall JM, et al. **Biochem J** 1996 Sep 1;318 (Pt 2):383–7

[Recent advances in molecular biology with respect to pulmonary surfactant apoproteins] Kuroki Y, et al. **Nippon Rinsho** 1996 Feb;54(2):334–40 (30 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

APF/CBP, the small, amphipathic, anionic protein(s) in bile and gallstones, consists of lipid–binding and calcium–binding forms. Lafont H, et al. **Hepatology** 1997 May;25(5):1054–63

Lipoprotein and apoprotein profiles of hyperlipidemic atherosclerosis–prone Japanese quail. Nagata J, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Feb;43(1):47–57

BIOSYNTHESIS

Mitochondrial protein synthesis in rat brain synaptosomes. Loguercio Polosa P, et al. **Methods Enzymol** 1996; 264:211–7

BLOOD

Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin. Sampietro T, et al. **Cardiovasc Drugs Ther** 1995 Dec;9(6):785–9

Effects of chemotherapy–induced castration on serum lipids

and apoproteins in premenopausal women with node-positive breast cancer. Saarto T, et al. **J Clin Endocrinol Metab** 1996 Dec;81(12):4453-7

CHEMISTRY

Characterization and quantitation of the apoproteins of high-density lipoprotein by capillary electrophoresis. Cruzado ID, et al. **Anal Biochem** 1996 Dec 1;243(1):100-9

Role of the heme propionates in the interaction of heme with apomyoglobin and apocytochrome b5. Hunter CL, et al. **Biochemistry** 1997 Feb 4;36(5):1010-7

Evidence for the molten globule state of human apo-ceruloplasmin. De Filippis V, et al. **Biochim Biophys Acta** 1996 Oct 17;1297(2):119-23

Probing pH and pressure effects on the apomyoglobin heme pocket with the 2'-(N,N-dimethylamino)-6-naphthoyl-4-trans-cyclohexanoic acid fluorophore. Sire O, et al. **Biophys J** 1996 Jun;70(6):2903-14

1H-NMR study of inter-segmental hydrogen bonds in sperm whale and horse apomyoglobins. Yamamoto Y. **Eur J Biochem** 1997 Jan 15;243(1-2):292-8

Electrospray ionization mass spectrometry analysis of the apo- and metal-substituted forms of the Fur protein. Michaud-Soret I, et al. **FEBS Lett** 1997 Aug 25; 413(3):473-6

Nereis sarcoplasmic Ca2+-binding protein has a highly unstructured apo state which is switched to the native state upon binding of the first Ca2+ ion. Prêcheur B, et al. **FEBS Lett** 1996 Oct 14;395(1):89-94

Cooperative thermal transitions of bovine and human apo-alpha-lactalbumins: evidence for a new intermediate state. Veprintsev DB, et al. **FEBS Lett** 1997 Aug 4; 412(3):625-8

H NMR probes for inter-segmental hydrogen bonds in myoglobins. Yamamoto Y. **J Biochem (Tokyo)** 1996 Jul; 120(1):126-32

Spectral demonstration of semihemoglobin formation during CN-hemin incorporation into human apohemoglobins. Vasudevan G, et al. **J Biol Chem** 1997 Jan 3;272(1):517-24

Triangular kinetic schemes applied to the stability of a heme-globin complex. Stephanos JJ, et al. **J Inorg Biochem** 1997 May 1;66(2):83-98

Is apomyoglobin a molten globule? Structural characterization by NMR. Eliezer D, et al. **J Mol Biol** 1996 Nov 8;263(4):531-8

Probing the conformational state of apomyoglobin by limited proteolysis. Fontana A, et al. **J Mol Biol** 1997 Feb 21; 266(2):223-30

Conservation of topology, but not conformation, of the proteolipid proteins of the myelin sheath. Gow A, et al. **J Neurosci** 1997 Jan 1;17(1):181-9

Observation of distinct nanosecond and microsecond protein folding events [letter] Ballew RM, et al. **Nat Struct Biol** 1996 Nov;3(11):923-6

Fast events in protein folding: relaxation dynamics of secondary and tertiary structure in native apomyoglobin. Gilmanshin R, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3709-13

Essential dynamics of the cellular retinol-binding protein--evidence for ligand-induced conformational changes. van Aalten DM, et al. **Protein Eng** 1995 Nov; 8(11):1129-35

Oligomerization state of S100B at nanomolar concentration determined by large-zone analytical gel filtration chromatography. Drohat AC, et al. **Protein Sci** 1997 Jul; 6(7):1577-82

Conformational stability of apoflavodoxin. Genzor CG, et al. **Protein Sci** 1996 Jul;5(7):1376-88

The native state of apomyoglobin described by proton NMR spectroscopy: the A-B-G-H interface of wild-type sperm whale apomyoglobin. Lecomte JT, et al. **Proteins** 1996 Jul; 25(3):267-85

DRUG EFFECTS

The effect of simvastatin on HDL cholesterol in hyperlipidemic patients. Evidence of a relationship with the changes in serum triglyceride level. Branchi A, et al. **Int J Clin Pharmacol Ther** 1996 Sep;34(9):384-9

GENETICS

The apocytochrome-b gene in Chlorogonium elongatum (Chlamydomonadaceae): an intronic GIY-YIG ORF in green algal mitochondria. Kroymann J, et al. **Curr Genet** 1997 May;31(5):414-8

GTG as translation initiation codon in the apocytochrome b gene of sunflower mitochondria. Siculella L, et al. **DNA Seq** 1996;6(6):365-9

Regeneration and luminescence of aequorin in Chinese hamster ovary cells transformed with cDNA for apoaequorin. Sanchez-Bueno A, et al. **Int J Biochem Cell Biol** 1996 Sep;28(9):1045-9

Integration host factor is required for 1,2-propanediol-dependent transcription of the cob/pdu regulon in Salmonella typhimurium LT2. Rondon MR, et al. **J Bacteriol** 1997 Jun;179(11):3797-800

Refined genetic mapping and proteolipid protein mutation analysis in X-linked pure hereditary spastic paraplegia. Cambi F, et al. **Neurology** 1996 Apr;46(4):1112-7

Mutations in the proteolipid protein gene in Japanese families with Pelizaeus-Merzbacher disease. Inoue K, et al. **Neurology** 1997 Jan;48(1):283-5

A deletion in the PHYD gene of the Arabidopsis Wassilewskija ecotype defines a role for phytochrome D in red/far-red light sensing. Aukerman MJ, et al. **Plant Cell** 1997 Aug;9(8):1317-26

[Proliferation of alveolar epithelial cells and gene expression of surfactant proteins in adult respiratory distress syndrome (ARDS)] Sugahara K. **Nippon Rinsho** 1996 Feb;54(2):341-5 (12 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Identification of an epitope derived from human proteolipid protein that can induce autoreactive CD8+ cytotoxic T lymphocytes restricted by HLA-A3: evidence for cross-reactivity with an environmental microorganism. Honma K, et al. **J Neuroimmunol** 1997 Mar;73(1-2):7-14

Monoclonal antibody O10 defines a conformationally sensitive cell-surface epitope of proteolipid protein (PLP): evidence that PLP misfolding underlies dysmyelination in mutant mice. Jung M, et al. **J Neurosci** 1996 Dec 15; 16(24):7920-9

METABOLISM

Differential changes in SP-A and disaturated phospholipids in the isolated perfused rat lung and in vivo. Doyle IR, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):L374-82

SP-A-binding protein BP55 is involved in surfactant endocytosis by type II pneumocytes. Wissel H, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):L432-40

The use of Renilla luciferase, Oplophorus luciferase, and apoaequorin as bioluminescent reporter protein in the presence of coelenterazine analogues as substrate. Inouye S, et al. **Biochem Biophys Res Commun** 1997 Apr 17; 233(2):349-53

Lipids may not be involved in the recognition of apocytochrome C during its transportation. Ma QF, et al. **Biochem Mol Biol Int** 1997 Mar;41(3):487-96

Role of the heme propionates in the interaction of heme with apomyoglobin and apocytochrome b5. Hunter CL, et al. **Biochemistry** 1997 Feb 4;36(5):1010-7

The apoprotein of cytochrome P450 3A2 does not selectively direct alkylation to one of four pyrrole rings of N-vinylprotoporphyrin IX. McNamee JP, et al. **Can J Physiol Pharmacol** 1996 Aug;74(8):996-1000

Measurement of changes in sarcoplasmic reticulum [Ca2+] in rat tail artery with targeted apoaequorin delivered by an adenoviral vector. Rembold CM, et al. **Cell Calcium** 1997 Jan;21(1):69-79

Translocation to the periplasm and signal sequence cleavage of preapocytochrome c depend on sec and lep, but not on the ccm gene products. Thöny-Meyer L, et al. **Eur J Biochem** 1997 Jun 15;246(3):794-9

Low affinity of Trypanosoma brucei transferrin receptor to apotransferrin at pH 5 explains the fate of the ligand during endocytosis. Maier A, et al. **FEBS Lett** 1996 Oct 28; 396(1):87-9

Covalent crosslinking of the heme prosthetic group to myoglobin by H2O2: toxicological implications. Osawa Y, et al. **Free Radic Biol Med** 1996;21(1):35-41

Purification and activation properties of UreD-UreF-urease apoprotein complexes. Moncrief MB, et al. **J Bacteriol** 1996 Sep;178(18):5417-21

In vitro synthesis of the iron-molybdenum cofactor and maturation of the nif-encoded apodinitrogenase. Effect of substitution of VNFH for NIFH. Chatterjee R, et al. **J Biol Chem** 1997 Aug 22;272(34):21604-8

Stabilization of chlorophyll a-binding apoproteins P700, CP47, CP43, D2, and D1 by chlorophyll a or Zn-pheophytin a. Eichacker LA, et al. **J Biol Chem** 1996 Dec 13;271(50):32174-9

Apotransferrin and holotransferrin undergo different endocytic cycles in intestinal epithelia (Caco-2) cells. Núñez MT, et al. **J Biol Chem** 1997 Aug 1;272(31):19425-8

Probing the conformational state of apomyoglobin by limited proteolysis. Fontana A, et al. **J Mol Biol** 1997 Feb 21; 266(2):223-30

Monoclonal antibody O10 defines a conformationally sensitive cell-surface epitope of proteolipid protein (PLP): evidence that PLP misfolding underlies dysmyelination in mutant mice. Jung M, et al. **J Neurosci** 1996 Dec 15; 16(24):7920-9

The Paracoccus denitrificans ccmA, B and C genes: cloning and sequencing, and analysis of the potential of their products to form a haem or apo- c-type cytochrome transporter. Page MD, et al. **Microbiology** 1997 Feb;143 (Pt 2):563-76

A monoclonal antibody affects chromophore apoprotein interactions of phytochrome A. Nakazawa M, et al. **Photochem Photobiol** 1997 Apr;65(4):745-9

PHARMACOKINETICS

Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. Laske DW, et al. **J Neurosurg** 1997 Oct;87(4):586-94

PHARMACOLOGY

Single intracranial injection of apotransferrin in young rats increases the expression of specific myelin protein mRNA. Escobar Cabrera OE, et al. **J Neurosci Res** 1997 Mar 15; 47(6):603-8

PHYSIOLOGY

Ceruloplasmin, transferrin and apotransferrin facilitate iron release from human liver cells. Young SP, et al. **FEBS Lett** 1997 Jul 7;411(1):93-6

SECRETION

Biliary secretion of anionic polypeptide fraction is not coupled to that of phospholipids and cholesterol in rats. Verkade HJ, et al. **Hepatology** 1997 Jan;25(1):38-47

APOPTOSIS

see related

GERMINAL CENTER

Apoptosis in adult mouse testis induced by experimental cryptorchidism. Ohta Y, et al. **Acta Anat (Basel)** 1996; 157(3):195-204

Apoptosis and cytologic differentiation in hepatocellular carcinoma on fine needle aspiration samples. Zeppa P, et al. **Acta Cytol** 1996 Sep-Oct;40(5):861-6

Apoptosis (programmed cell death) in idiopathic (primary) osteo-/myelofibrosis: naked nuclei in megakaryopoiesis reveal features of para-apoptosis. Thiele J, et al. **Acta Haematol** 1997;97(3):137-43

Apoptosis and secondary necrosis of lymphocytes in culture. Vermes I, et al. **Acta Haematol** 1997;98(1):8-13

Spatiotemporal relationship of apoptotic cell death to lymphomonocytic infiltration in photochemically induced focal ischemia of the rat cerebral cortex. Braun JS, et al. **Acta Neuropathol (Berl)** 1996 Sep;92(3):255-63

Apoptotic cell death is an important cause of neuronal injury in experimental Venezuelan equine encephalitis virus infection of mice. Jackson AC, et al. **Acta Neuropathol (Berl)** 1997 Apr;93(4):349-53

p53 accumulation and apoptosis in embolized meningiomas. Nakasu S, et al. **Acta Neuropathol (Berl)** 1997 Jun; 93(6):599-605

Apoptosis in epithelial hyperplastic laryngeal lesions. Hellquist HB. **Acta Otolaryngol Suppl (Stockh)** 1997; 527:25-9

Apoptosis of germinal centers in postnatal development of rabbit tonsil. Kawabata I, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:60-3

A study of apoptosis in the human palatine tonsil. Kuki K, et al. **Acta Otolaryngol Suppl (Stockh)** 1996;523:68-70

Functional aspects of apoptosis in hematopoiesis and consequences of failure. McKenna SL, et al. **Adv Cancer Res** 1997;71:121-64 (284 ref.)

Nicotinamide methyltransferase activity and cell-death in the liver of the mouse bearing Ehrlich ascites tumor. Fujimura S, et al. **Adv Exp Med Biol** 1996;398:507-11

Fas splicing variants and their effect on apoptosis. Ruberti G, et al. **Adv Exp Med Biol** 1996;406:125-34 (67 ref.)

The mycotoxin fumonisin induces apoptosis in cultured human cells and in livers and kidneys of rats. Tolleson WH, et al. **Adv Exp Med Biol** 1996;392:237-50

Redox signaling and the control of cell growth and death. Powis G, et al. **Adv Pharmacol** 1997;38:329-59 (204 ref.)

Apoptosis of skeletal and cardiac muscles and physical exercise. Carraro U, et al. **Aging (Milano)** 1997 Feb-Apr; 9(1-2):19-34 (118 ref.)

Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin. Lang ME, et al. **AIDS** 1997 Sep;11(11):1333-40

Detection of apoptotic cells from peripheral blood of HIV-infected individuals using a novel monoclonal antibody [letter] Seth A, et al. **AIDS** 1997 Jul;11(8):1059-61

Induction of apoptosis by primary HIV-1 isolates correlates with productive infection in peripheral blood mononuclear cells. Zhang YJ, et al. **AIDS** 1997 Aug;11(10):1219-25

Apoptosis in HIV-infected individuals is an early marker occurring independently of high viremia. Rothen M, et al. **AIDS Res Hum Retroviruses** 1997 Jun 10;13(9):771-9

Progressive B cell apoptosis and expression of Fas ligand during human immunodeficiency virus type 1 infection. Samuelsson A, et al. **AIDS Res Hum Retroviruses** 1997 Aug 10;13(12):1031-8

Is apoptosis involved in alcoholic hepatitis? Kawahara H, et al. **Alcohol Alcohol** 1994;29 Suppl 1:113-8

Mast cell apoptosis: from the DNA to the bedside. Mekori AY. **Allerg Immunol (Paris)** 1997 Jan;29(1):4-6 (13 ref.)

Detection of apoptosis by in situ labeling in pilomatricoma. Kishimoto S, et al. **Am J Dermatopathol** 1996 Aug; 18(4):339-43

Proliferation and apoptosis within juvenile capillary hemangiomas. Mancini AJ, et al. **Am J Dermatopathol** 1996 Oct;18(5):505-14

Apoptosis in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma. Westermann FN, et al. **Am J Dermatopathol** 1997 Jun;19(3):228-31

Physiologic apoptosis, beta 2-glycoprotein I, and antiphospholipid autoantibodies [letter; comment] Cheng HM. **Am J Obstet Gynecol** 1996 Nov;175(5):1393. Comment on: Am J Obstet Gynecol 1995 Nov;173(5):1410-5.

Enhanced deoxyribonucleic acid damage and repair but unchanged apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone agonist. Huang SC, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):417-24

APOPTOSIS

Bcl-2 and Fas expression in eutopic and ectopic human endometrium during the menstrual cycle in relation to endometrial cell apoptosis. Watanabe H, et al. **Am J Obstet Gynecol** 1997 Feb;176(2):360–8

Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Brambilla E, et al. **Am J Pathol** 1996 Dec;149(6):1941–52

Troponin T cross-linking in human apoptotic cardiomyocytes. Gorza L, et al. **Am J Pathol** 1997 Jun; 150(6):2087–97

Apoptosis induced by tumor necrosis factor-alpha in rat hepatocyte cell lines expressing hepatitis B virus. Guilhot S, et al. **Am J Pathol** 1996 Mar;148(3):801–14

The presence of apoptotic cells in human atherosclerotic lesions [letter; comment] Hegyi L, et al. **Am J Pathol** 1997 Jan;150(1):371–3. Comment on: Am J Pathol 1996 Aug;149(2):367–80.

Aging accelerates but life-long dietary restriction suppresses apoptosis-related Fas expression on hepatocytes. Higami Y, et al. **Am J Pathol** 1997 Sep;151(3):659–63

Neutrophil fate in experimental glomerular capillary injury in the rat. Emigration exceeds in situ clearance by apoptosis. Hughes J, et al. **Am J Pathol** 1997 Jan; 150(1):223–34

Macrophage apoptosis in rat crescentic glomerulonephritis. Lan HY, et al. **Am J Pathol** 1997 Aug;151(2):531–8

Lymphocyte apoptosis during early phase of Listeria infection in mice. Merrick JC, et al. **Am J Pathol** 1997 Sep;151(3):785–92

Pi-class glutathione-S-transferase-positive hepatocytes in aging B6C3F1 mice undergo apoptosis induced by dietary restriction. Muskhelishvili L, et al. **Am J Pathol** 1996 Nov; 149(5):1585–91

Apoptosis and expression of inducible nitric oxide synthase are mutually exclusive in renal mesangial cells. Nitsch DD, et al. **Am J Pathol** 1997 Mar;150(3):889–900

Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Tompkins MM, et al. **Am J Pathol** 1997 Jan;150(1):119–31

Localization of the cell proliferation and apoptosis-associated CAS protein in lymphoid neoplasms. Wellmann A, et al. **Am J Pathol** 1997 Jan;150(1):25–30

Apoptosis: a mechanism contributing to remodeling of skeletal muscle in response to hindlimb unweighting. Allen DL, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):C579–87

Characterization of cell volume loss in CEM-C7A cells during dexamethasone-induced apoptosis. Benson RS, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):C1190–203

Absence of volume regulatory mechanisms contributes to the rapid activation of apoptosis in thymocytes. Bortner CD, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):C950–61

CD40 inhibits B cell apoptosis by upregulating bcl-xL expression and blocking oxidant accumulation. Fang W, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C950–6

Human alveolar macrophages prevent apoptosis in polymorphonuclear leukocytes. Herlihy JP, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):L681–7

Bile salt-induced apoptosis of hepatocytes involves activation of protein kinase C. Jones BA, et al. **Am J Physiol** 1997 May;272(5 Pt 1):G1109–15

Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Kajstura J, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):H1215–28

Role of apoptotic and nonapoptotic cell death in removal of intercalated cells from developing rat kidney. Kim J, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):F575–92

Actin polymerization and depolymerization during apoptosis in HL-60 cells. Levee MG, et al. **Am J Physiol** 1996 Dec; 271(6 Pt 1):C1981–92

Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Li Z, et al. **Am J Physiol** 1997 May;272(5 Pt 2):H2313–9

Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Lieberthal W, et al. **Am J Physiol** 1996 Apr;270(4 Pt 2):F700–8

Apoptosis in circulating PMN: increased susceptibility in L-selectin-deficient PMN. Matsuba KT, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):H2852–8

Uninephrectomy reduces apoptotic cell death and enhances renal tubular cell regeneration in ischemic ARF in rats. Nakajima T, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):F846–53

Tissue remodeling during tumor necrosis factor-induced apoptosis in LLC-PK1 renal epithelial cells. Peralta Soler A, et al. **Am J Physiol** 1996 May;270(5 Pt 2):F869–79

Epithelial cell growth and differentiation. II. Intestinal apoptosis. Potten CS. **Am J Physiol** 1997 Aug;273(2 Pt 1):G253–7 (16 ref.)

Development and initial application of an in vitro model of apoptosis in rodent cholangiocytes. Que FG, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):G106–15

Cell cycle regulation of membrane glucocorticoid receptor in CCRF-CEM human ALL cells: correlation to apoptosis. Sackey FN, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E571–83

Involvement of ICE family proteases in apoptosis induced by reoxygenation of hypoxic hepatocytes. Shimizu S, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):G949–58

Induction of human endothelial cell apoptosis requires both heat shock and oxidative stress responses. Wang JH, et al. **Am J Physiol** 1997 May;272(5 Pt 1):C1543–51

Induction of hepatoma cell apoptosis by c-myc requires zinc and occurs in the absence of DNA fragmentation. Xu J, et al. **Am J Physiol** 1996 Jan;270(1 Pt 1):G60–70

Unexpected protection of glomerular mesangial cells from oxidant-triggered apoptosis by bioflavonoid quercetin. Yokoo T, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):F206–12

Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Hagimoto N, et al. **Am J Respir Cell Mol Biol** 1997 Jan;16(1):91–101

A glass fiber/diethylaminoethyl double filter binding assay that measures apoptotic internucleosomal DNA fragmentation. Erusalimsky JD, et al. **Anal Biochem** 1996 Nov 15;242(2):187–96

An assay for DNA fragmentation in apoptosis without phenol/chloroform extraction and ethanol precipitation. Zhu N, et al. **Anal Biochem** 1997 Mar 1;246(1):155–8

Cell death during tooth eruption in the rat: surrounding tissues of the crown. Kaneko H, et al. **Anat Embryol (Berl)** 1997 May;195(5):427–34

Patterns of cell death during gastrulation in chick and mouse embryos. Sanders EJ, et al. **Anat Embryol (Berl)** 1997 Feb; 195(2):147–54

Expression of p53 and hsp70 in relation to apoptosis during Meckel's cartilage development in the mouse. Trichilis A, et al. **Anat Embryol (Berl)** 1997 Aug;196(2):107–13

Apoptotic condensations in M-phase cells. Sit KH, et al. **Anat Rec** 1997 Jun;248(2):149–58

Programmed cell death and cancer. Hwang PL. **Ann Acad Med Singapore** 1996 Mar;25(2):259–64 (46 ref.)

Apoptosis. Fleisher TA. **Ann Allergy Asthma Immunol** 1997 Mar;78(3):245–9; quiz 249–50 (28 ref.)

Expression of the tyrosine kinase Lyn during B cell receptor engagement and apoptosis. Huck S, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:122–3

Requirements for mIgM-triggered activation versus apoptosis in human B cells. Mongini P, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:469–71

Markedly diminished radiation-induced lymphocyte apoptosis in lpr mice suggests a role for Fas in eliminating damaged cells. Reap EA, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:116–8

Apoptosis induced by interleukin-12 measured by DNA electrophoresis and in situ end labeling in leukemia. Stine KC, et al. **Ann N Y Acad Sci** 1996 Oct 31;795:420–1

Apoptosis induced in human colorectal carcinoma by anti-Fas antibody. Meterissian SH, et al. **Ann Surg Oncol** 1997 Mar;4(2):169–75

Differences in the apoptosis-inducing properties of Viscum album L. extracts. Büssing A, et al. **Anticancer Drugs** 1997 Apr;8 Suppl 1:S9–14 (30 ref.)

Photodynamic anticancer agent merocyanine540 inhibits cell growth by apoptosis. Chen YC, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2781–8

Enhanced expression of cyclin-dependent kinase inhibitor in apoptosis of androgen-independent prostatic cancer cell line induced by calcium ionophore. Furuya Y, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2391–4

Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy. Garzetti GG, et al. **Anticancer Res** 1996 Sep-Oct;16(5B):3229–34

Correlation of apoptosis with the distribution and composition of lymphocytic infiltrate in human breast carcinomas. Grekou AN, et al. **Anticancer Res** 1996 Nov-Dec;16(6C):3991–5

Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients. Kapranos N, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2499–505

5-Fluorouracil induces apoptotic cell death with G2 phase arrest in human breast cancer grafted in nude mice. Okamoto S, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2699–704

Molecular mechanisms in the antiproliferative action of taxol and tiazofurin. Olah E, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2469–77

Paclitaxel and irradiation induce apoptosis in squamous cell carcinoma cell lines in an additive way. Pulkkinen JO, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2923–9

Effect of methionine depletion on growth and apoptosis in various tumor cell lines. Sakagami H, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2407–10

Cytotoxic effect of sodium nitroprusside on cancer cells: involvement of apoptosis and suppression of c-myc and c-myb proto-oncogene expression. Sumitani K, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):865–71

Incidence of apoptosis, cell proliferation and P53 expression in renal cell carcinomas. Tannapfel A, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):1155–62

Study of apoptosis in peripheral blood of patients with acute lymphoblastic leukemia during induction therapy. Tsangaris GT, et al. **Anticancer Res** 1996 Sep-Oct; 16(5B):3133–40

Role of apoptosis, proliferating cell nuclear antigen and p53 protein in chemically induced colon cancer in rats fed corncob fiber treated with the fungus Pleurotus ostreatus. Zusman I, et al. **Anticancer Res** 1997 May-Jun; 17(3C):2105–13

The anti-human immunodeficiency virus agent 3'-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Sundseth R, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):331–5

Detection of apoptotic cells and expression of Ki-67 antigen, Bcl-2, p53 oncoproteins in human parathyroid adenoma. Wang W, et al. **APMIS** 1996 Nov;104(11):789–96

Early redox changes during rat thymocyte apoptosis. Bustamante J, et al. **Arch Biochem Biophys** 1997 Jan 1; 337(1):121–8

Superoxide-mediated cytotoxicity in superoxide dismutase-deficient fetal fibroblasts. Huang TT, et al. **Arch Biochem Biophys** 1997 Aug 15;344(2):424–32

Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration. Inachi S, et al. **Arch Dermatol** 1997 Jul;133(7):845–9

Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases. Kikuchi A, et al. **Arch Dermatol** 1997 Jul;133(7):829–33

Induction of apoptosis in human HaCaT keratinocytes. Henseleit U, et al. **Arch Dermatol Res** 1996 Oct; 288(11):676–83

Apoptosis identified with DNA fragmentation in basal cell carcinomas. Mori O, et al. **Arch Dermatol Res** 1996 May; 288(5–6):258–61

Experimental induction and ultrastructural characterization of apoptosis in murine acute cutaneous graft-versus-host disease. Yoo YH, et al. **Arch Dermatol Res** 1997 Jun; 289(7):389–98

Morphological and flow cytofluorometrical analyses of regenerated rat thymus after irradiation. Fujikura Y, et al. **Arch Histol Cytol** 1997 Mar;60(1):79–87

Analysis of apoptosis morphology in Epstein-Barr virus positive and negative Burkitt's lymphoma cells. Ishii H, et al. **Arch Histol Cytol** 1997 Jun;60(2):143–52

Glucocorticoid-induced thymocyte death in the murine thymus: the effect at later stages. Ishii T, et al. **Arch Histol Cytol** 1997 Mar;60(1):65–78

Elimination of apoptotic granulosa cells by intact granulosa cells and macrophages in atretic mature follicles of the guinea pig ovary. Kasuya K. **Arch Histol Cytol** 1997 Jun; 60(2):175–84

TUNEL-positive ganglion cells in human primary open-angle glaucoma. Kerrigan LA, et al. **Arch Ophthalmol** 1997 Aug;115(8):1031–5

p53 regulates apoptosis in human retinoblastoma. Nork TM, et al. **Arch Ophthalmol** 1997 Feb;115(2):213–9

Progressive increase of apoptosis in prostatic intraepithelial neoplasia and carcinoma: comparison between in situ end-labeling of fragmented DNA and detection by routine hematoxylin-eosin staining. Drachenberg CB, et al. **Arch Pathol Lab Med** 1997 Jan;121(1):54–8

Apoptosis. Ross DW. **Arch Pathol Lab Med** 1997 Jan; 121(1):83

Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Katada N, et al. **Arch Surg** 1997 Jul;132(7):728–33

Interleukin-6 and a delay of neutrophil apoptosis after major surgery. Kobayashi E, et al. **Arch Surg** 1997 Feb; 132(2):209–10

Detection of apoptosis induced in peripheral blood lymphocytes from cats infected with feline immunodeficiency virus. Momoi Y, et al. **Arch Virol** 1996; 141(9):1651–9

Apoptosis and CD8-down-regulation in the thymus of chickens infected with Marek's disease virus. Morimura T, et al. **Arch Virol** 1996;141(11):2243–9

Differentiation, dedifferentiation, and apoptosis of smooth muscle cells during the development of the human ductus arteriosus. Slomp J, et al. **Arterioscler Thromb Vasc Biol** 1997 May;17(5):1003–9

Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Kong L, et al. **Arthritis Rheum** 1997 Jan;40(1):87–97

In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Lorenz HM, et al. **Arthritis Rheum** 1997 Feb;40(2):306–17

Increased rate of apoptosis and decreased expression of bcl-2 protein in peripheral blood lymphocytes from patients with active systemic lupus erythematosus. Chan EY, et al. **Asian Pac J Allergy Immunol** 1997 Mar;15(1):3–7

Relationship between endothelial cell turnover and permeability to horseradish peroxidase. Chen YL, et al. **Atherosclerosis** 1997 Aug;133(1):7–14

Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Crisby M, et al. **Atherosclerosis** 1997 Apr;130(1–2):17–27

Regulation of CD95 ligand expression: a key element in immune regulation? Brunner T, et al. **Behring Inst Mitt** 1996 Oct;(97):161–74 (81 ref.)

Apoptosis and cancer chemotherapy. Chresta CM, et al. **Behring Inst Mitt** 1996 Oct;(97):232–40 (35 ref.)

Apoptosis in HIV-1 Infection. Cotton MF, et al. **Behring Inst Mitt** 1996 Oct;(97):220–31 (48 ref.)

ICE-like proteases and cell death. Dost B, et al. **Behring Inst Mitt** 1996 Oct;(97):127–43 (92 ref.)

Effects of viral inhibitors of apoptosis in models of mammalian cell death. Häcker G, et al. **Behring Inst Mitt** 1996 Oct;(97):118–26

p53-mediated apoptosis: mechanisms and regulation. Haupt Y, et al. **Behring Inst Mitt** 1996 Oct;(97):32–59

The role of Fas/FasL interactions in the regulation of B cell function. Jacobson BA, et al. **Behring Inst Mitt** 1996 Oct; (97):185–99 (44 ref.)

FasL/Fas and TNF/TNFR interactions in the regulation of immune responses and disease. Lynch DH, et al.

Behring Inst Mitt 1996 Oct;(97):175–84 (36 ref.)
Autoimmune disease results from multiple interactive defects in apoptosis induction molecules and signaling pathways. Mountz JD, et al. **Behring Inst Mitt** 1996 Oct;(97):200–19 (116 ref.)
A death factor—the other side of the coin. Nagata S. **Behring Inst Mitt** 1996 Oct;(97):1–11 (48 ref.)
Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Reed JC. **Behring Inst Mitt** 1996 Oct;(97):72–100 (193 ref.)
Lessons from bcl-2 transgenic mice for immunology, cancer biology and cell death research. Strasser A, et al. **Behring Inst Mitt** 1996 Oct;(97):101–17 (120 ref.)
Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family. Wallach D, et al. **Behring Inst Mitt** 1996 Oct;(97):144–55 (69 ref.)
The role of p53 as a transcription factor in the induction of apoptosis. Yonish-Rouach E, et al. **Behring Inst Mitt** 1996 Oct;(97):60–71 (104 ref.)
Possible involvement of Bcl-2 pathway in retinoid X receptor alpha-induced apoptosis of HL-60 cells. Agarwal N, et al. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):251–3
Rat TAFII31 gene is induced upon programmed cell death in differentiated PC12 cells deprived of NGF. Aoki T, et al. **Biochem Biophys Res Commun** 1997 May 8;234(1):230–4
Lack of induction of tissue transglutaminase but activation of the preexisting enzyme in c-Myc-induced apoptosis of CHO cells. Balajthy Z, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):280–4
Deficient apoptotic process in cisplatin-resistant L1210 cells cannot account for the cellular response to various drug treatments. Canitrot Y, et al. **Biochem Biophys Res Commun** 1997 May 29;234(3):573–7
Differential migration of acylphosphatase isoenzymes from cytoplasm to nucleus during apoptotic cell death. Chiarugi P, et al. **Biochem Biophys Res Commun** 1997 Feb 24; 231(3):717–21
Granzyme B/perforin-mediated apoptosis of Jurkat cells results in cleavage of poly(ADP-ribose) polymerase to the 89-kDa apoptotic fragment and less abundant 64-kDa fragment. Froelich CJ, et al. **Biochem Biophys Res Commun** 1996 Oct 23;227(3):658–65
3,3'-Diindolylmethane induces apoptosis in human cancer cells. Ge X, et al. **Biochem Biophys Res Commun** 1996 Nov 1;228(1):153–8
Inhibition of Fas-induced apoptotic cell death by osmotic cell shrinkage. Gulbins E, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):517–21
Cellular changes and induction of apoptosis in human promyelocytic HL-60 cells infected with the agent of human granulocytic ehrlichiosis (HGE). Hsieh TC, et al. **Biochem Biophys Res Commun** 1997 Mar 17;232(2):298–303
Solamargine purified from Solanum incanum Chinese herb triggers gene expression of human TNFR I which may lead to cell apoptosis. Hsu SH, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):1–5
Induction of apoptosis by sphingosine-1-phosphate in human hepatoma cells is associated with enhanced expression of bax gene product. Hung WC, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):11–5
Lack of hemodynamic forces triggers apoptosis in vascular endothelial cells. Kaiser D, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):586–90
Apoptosis in the absence of poly-(ADP-ribose) polymerase. Leist M, et al. **Biochem Biophys Res Commun** 1997 Apr 17;233(2):518–22
Purification of a vascular apoptosis-inducing factor from hemorrhagic snake venom. Masuda S, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):59–63
Geranylgeraniol potently induces caspase-3-like activity during apoptosis in human leukemia U937 cells. Masuda Y, et al. **Biochem Biophys Res Commun** 1997 May 29; 234(3):641–5
Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide. Mohr S, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):387–91
Geranylgeraniol causes a decrease in levels of calreticulin and tyrosine phosphorylation of a 36-kDa protein prior to the appearance of apoptotic features in HL-60 cells. Nakajo S, et al. **Biochem Biophys Res Commun** 1996 Sep 24;226(3):741–5
Occurrence of DNase gamma-like apoptotic endonucleases in hematopoietic cells in Xenopus laevis and their relation to metamorphosis. Nishikawa A, et al. **Biochem Biophys Res Commun** 1997 Feb 13;231(2):305–8
Fragile mitochondrial DNA: the missing link in the apoptotic neuronal cell death in Parkinson's disease. Ozawa T, et al. **Biochem Biophys Res Commun** 1997 Jun 9;235(1):158–61
Direct interaction of the mitochondrial membrane protein carnitine palmitoyltransferase I with Bcl-2. Paumen MB, et al. **Biochem Biophys Res Commun** 1997 Feb 24; 231(3):523–5
Multiple pathways of Fas-induced apoptosis in primary culture of hepatocytes. Rouquet N, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):27–35
Fas-mediated stimulation induces IL-8 secretion by rheumatoid arthritis synoviocytes independently of CPP32-mediated apoptosis. Sekine C, et al. **Biochem Biophys Res Commun** 1996 Nov 1;228(1):14–20
Different cleavage pattern for poly(ADP-ribose) polymerase during necrosis and apoptosis in HL-60 cells. Shah GM, et al. **Biochem Biophys Res Commun** 1996 Dec 24; 229(3):838–44
Fas-signaling and effects on receptor tyrosine kinase signal transduction in human breast epithelial cells. Shen K, et al. **Biochem Biophys Res Commun** 1997 Jan 3;230(1):89–93
Rapid loss in the mitochondrial membrane potential during geranylgeranoic acid-induced apoptosis. Shidoji Y, et al. **Biochem Biophys Res Commun** 1997 Jan 3;230(1):58–63
A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo. Shimizu M, et al. **Biochem Biophys Res Commun** 1996 Nov 12;228(2):375–9
Specific cleavage of the large subunit of replication factor C in apoptosis is mediated by CPP32-like protease. Song Q, et al. **Biochem Biophys Res Commun** 1997 Apr 17; 233(2):343–8
Staurosporine induces telophase arrest and apoptosis blocking mitosis exit in human Chang liver cells. Swe M, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):594–8
Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Tamura T, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):21–6
Involvement of cellular proteolytic machinery in apoptosis. Zhivotovsky B, et al. **Biochem Biophys Res Commun** 1997 Jan 23;230(3):481–8 (74 ref.)
Two different proteases are involved in the proteolysis of lamin during apoptosis. Zhivotovsky B, et al. **Biochem Biophys Res Commun** 1997 Apr 7;233(1):96–101
Effects of ultraviolet light in vascular cells in vitro and in intact atherosclerotic explants: potential role of apoptosis in vascular biology. López-Candales A, et al. **Biochem Cell Biol** 1996;74(3):333–45
Role of p70 S6 kinase in cytokine-regulated hemopoietic cell survival [published erratum appears in Biochem Cell Biol 1997;75(1):93] Scheid MP, et al. **Biochem Cell Biol** 1996; 74(4):595–600
The study of cell-death proteins in the outer mitochondrial membrane by chemical cross-linking. Ali ST, et al. **Biochem J** 1997 Jul 15;325 (Pt 2):321–4
Actin is cleaved during constitutive apoptosis. Brown SB, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):233–7
Activation of CPP32 and Mch3 alpha in wild-type p53-induced apoptosis. Chandler JM, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):19–23
Non-erythroid alpha-spectrin breakdown by calpain and interleukin 1 beta-converting-enzyme-like protease(s) in apoptotic cells: contributory roles of both protease families in neuronal apoptosis. Nath R, et al. **Biochem J** 1996 Nov 1;319 (Pt 3):683–90
Bcl-2 does not require Raf kinase activity for its death-protective function. Olivier R, et al. **Biochem J** 1997 May 15;324 (Pt 1):75–83
Purification and properties of DNase gamma from apoptotic rat thymocytes. Shiokawa D, et al. **Biochem J** 1997 Sep 15;326 (Pt 3):675–81
Evidence against an early signalling role for ceramide in Fas-mediated apoptosis. Sillence DJ, et al. **Biochem J** 1997 May 15;324 (Pt 1):29–32
Thromboxane A2 mediates cisplatin-induced apoptosis of renal tubule cells. Jariyawat S, et al. **Biochem Mol Biol Int** 1997 Jun;42(1):113–21
Apoptosis and free radicals. Stoian I, et al. **Biochem Mol Med** 1996 Dec;59(2):93–7 (43 ref.)
Diabetes-induced apoptosis in rat kidney. Zhang W, et al. **Biochem Mol Med** 1997 Jun;61(1):58–62
Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Baier-Bitterlich G, et al. **Biochem Pharmacol** 1997 Mar 21;53(6):755–63 (123 ref.)
Induction of mitochondrial dysfunction and apoptosis in HeLa cells by bis-pyridinium oximes, a newly synthesized family of lipophilic biscations. Nocentini S, et al. **Biochem Pharmacol** 1997 May 15;53(10):1543–52
Stress-induced apoptosis and the sphingomyelin pathway. Peña LA, et al. **Biochem Pharmacol** 1997 Mar 7; 53(5):615–21 (63 ref.)
Apoptosis in AIDS. Genetic control and relevance for AIDS pathogenesis. Gougeon ML. **Biochem Soc Trans** 1996 Nov; 24(4):1055–8 (34 ref.)
Apoptosis as a trigger of inflammation in Shigella-induced cell death. Guichon A, et al. **Biochem Soc Trans** 1996 Nov; 24(4):1051–4 (26 ref.)
Cell death signal transduction and Bcl-2 function. Herrmann JL, et al. **Biochem Soc Trans** 1996 Nov;24(4):1059–65 (64 ref.)
Polyamine acetylation and apoptosis. Lindsay GS, et al. **Biochem Soc Trans** 1996 May;24(2):229S
Activation of phosphatidylinositol 3-kinase following Fas engagement is not required for Fas-mediated apoptosis in Jurkat T cells. McLeod JD, et al. **Biochem Soc Trans** 1997 May;25(2):241S
Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signalling through CD40 and interleukin-4 receptor: role for inhibition of an early response gene, Berg36. Ning ZQ, et al. **Biochem Soc Trans** 1997 May;25(2):306S
Dithiocarbamates and the redox regulation of cell death. Orrenius S, et al. **Biochem Soc Trans** 1996 Nov;24(4):1032–8 (43 ref.)
The regulation of apoptosis in resting T lymphocytes. Pilling D, et al. **Biochem Soc Trans** 1997 May;25(2):242S
CD40 signalling in B cell apoptosis and rescue. Reid SD, et al. **Biochem Soc Trans** 1997 May;25(2):299S
cAMP and 'death signals' in a myeloid leukaemia cell: from membrane receptors to nuclear responses: a review. Ruchaud S, et al. **Biochem Soc Trans** 1997 May;25(2):410–5 (56 ref.)
Phagocyte recognition of apoptotic cells. Savill J. **Biochem Soc Trans** 1996 Nov;24(4):1065–9 (29 ref.)
Lipid signalling in lymphocyte activation and cell death. Seatter SD, et al. **Biochem Soc Trans** 1997 May;25(2):300S
Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Robinson LJ, et al. **Biochemistry** 1997 Sep 16;36(37):11169–78
Generation of free radicals during lipid hydroperoxide-triggered apoptosis in PC12h cells. Aoshima H, et al. **Biochim Biophys Acta** 1997 Mar 10; 1345(1):35–42
Changes in metabolism of inorganic polyphosphate in rat tissues and human cells during development and apoptosis. Lorenz B, et al. **Biochim Biophys Acta** 1997 Apr 17; 1335(1-2):51–60
NF kappa B/I kappa B proteins. Their role in cell growth, differentiation and development. Madrid, Spain, July 7–10, 1996. Siebenlist U. **Biochim Biophys Acta** 1997 Feb 22; 1332(1):R7–13
Origin of eukaryotic programmed cell death: a consequence of aerobic metabolism? Frade JM, et al. **Bioessays** 1997 Sep;19(9):827–32 (58 ref.)
Epithelial apoptosis. Metcalfe A, et al. **Bioessays** 1997 Aug; 19(8):711–20 (90 ref.)
Death substrates come alive. Porter AG, et al. **Bioessays** 1997 Jun;19(6):501–7 (60 ref.)
Induction of apoptosis in HeLa cells by MSSP, c-myc binding proteins. Iida M, et al. **Biol Pharm Bull** 1997 Jan; 20(1):10–4
Induction of apoptosis in equine chorionic gonadotropin (eCG)-primed rat ovaries by anti-eCG antibody. Boone DL, et al. **Biol Reprod** 1997 Aug;57(2):420–7
Granulosa cell apoptosis, aromatase activity, cyclic adenosine 3',5'-monophosphate response to gonadotropins, and follicular fluid steroid levels during spontaneous and induced follicular atresia in ewes. Jolly PD, et al. **Biol Reprod** 1997 Apr;56(4):830–6
Morphological evidence of apoptosis and the prevalence of apoptotic versus mitotic cells in the membrana granulosa of ovarian follicles during spontaneous and induced atresia in ewes. Jolly PD, et al. **Biol Reprod** 1997 Apr;56(4):837–46
In situ demonstration of germinal cell apoptosis during diethylstilbestrol-induced testis regression in adult male Syrian hamsters. Nonclercq D, et al. **Biol Reprod** 1996 Dec; 55(6):1368–76
Increased bax and interleukin-1beta-converting enzyme messenger ribonucleic acid levels coincide with apoptosis in the bovine corpus luteum during structural regression. Rueda BR, et al. **Biol Reprod** 1997 Jan;56(1):186–93
Macrophages and apoptotic cells in human colorectal tumours. Higgins CA, et al. **Biologicals** 1996 Dec; 24(4):329–32
Apoptosis and the dynamics of infection and disease. Leaver HA, et al. **Biologicals** 1996 Dec;24(4):293–4
The importance of apoptosis: is it real or imaginary? Malcomson RD, et al. **Biologicals** 1996 Dec;24(4):295–9 (25 ref.)
Synthesis of chemoreversible prodrugs of ara-C with variable time-release profiles. Biological evaluation of their apoptotic activity. Wipf P, et al. **Bioorg Med Chem** 1996 Oct;4(10):1585–96
Role of the mitochondrial permeability transition pore in apoptosis. Hirsch T, et al. **Biosci Rep** 1997 Feb;17(1):67–76 (60 ref.)
Non-isotopic technique for the identification of endonucleases involved in apoptosis. Boone DL, et al. **Biotechniques** 1997 Apr;22(4):648–9
Detection of early and late stage apoptosis with field inversion gel electrophoresis. Luo Y, et al. **Biotechniques** 1996 Nov;21(5):812, 814, 816
Application of 5-bromo-2'deoxyuridine as a label for in situ hybridization in chromosome microdissection and painting, and 3' OH DNA end labeling for apoptosis. Mühlmann-Díaz MC, et al. **Biotechniques** 1996 Jul; 21(1):82–6
Simultaneous in situ detection of apoptosis and necrosis in monolayer cultures by TUNEL and trypan blue staining. Perry SW, et al. **Biotechniques** 1997 Jun;22(6):1102–6
Spatial visualization of apoptosis using a whole-mount in situ DNA end-labeling technique. Smith SM, et al. **Biotechniques** 1997 May;22(5):832–4
Direct in situ end-labeling for detection of apoptotic cells in tissue sections. Zhang Z, et al. **Biotechniques** 1997 May; 22(5):834–6
CD2 rescues T cells from T-cell receptor/CD3 apoptosis: a role for the Fas/Fas-L system. Ayroldi E, et al. **Blood** 1997 May 15;89(10):3717–26
Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Bellosillo B, et al. **Blood** 1997 May 1;89(9):3378–84
Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blankenberg FG, et al. **Blood** 1997 May 15;89(10):3778–86
Apoptotic vascular endothelial cells become procoagulant. Bombeli T, et al. **Blood** 1997 Apr 1;89(7):2429–42
Modulation of Bcl-2 protein by CD4 cross-linking: a possible mechanism for lymphocyte apoptosis in human immunodeficiency virus infection and for rescue of apoptosis by interleukin-2. Hashimoto F, et al. **Blood** 1997

Jul 15;90(2):745–53

Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO–1)–mediated apoptosis of neutrophils. Kasahara Y, et al. **Blood** 1997 Mar 1; 89(5):1748–53

Apoptosis of late–stage erythroblasts in megaloblastic anemia: association with DNA damage and macrocyte production. Koury MJ, et al. **Blood** 1997 Jun 15;89(12):4617–23

Fas–mediated apoptosis of the hematopoietic progenitor cells in mice infected with murine cytomegalovirus. Mori T, et al. **Blood** 1997 May 15;89(10):3565–73

Phosphatidylserine externalization is a downstream event of interleukin–1 beta–converting enzyme family protease activation during apoptosis. Naito M, et al. **Blood** 1997 Mar 15;89(6):2060–6

Role of Fas ligand and receptor in the mechanism of T–cell depletion in acquired immunodeficiency syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication. Sloand EM, et al. **Blood** 1997 Feb 15;89(4):1357–63

Clincial, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Sneller MC, et al. **Blood** 1997 Feb 15;89(4):1341–8

Cellular expression of antiapoptotic BCL–2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study. Uckun FM, et al. **Blood** 1997 May 15;89(10):3769–77

Overexpression of PU.1 induces growth and differentiation inhibition and apoptotic cell death in murine erythroleukemia cells. Yamada T, et al. **Blood** 1997 Feb 15;89(4):1383–93

In vitro senescence and apoptotic cell death of human megakaryocytes. Zauli G, et al. **Blood** 1997 Sep 15; 90(6):2234–43

Anti–Fas/Apo–1 monoclonal antibody CH–11 depletes glutathione and kills multidrug–resistant human leukemic cells. Efferth T, et al. **Blood Cells Mol Dis** 1996;22(1):2–9; discussion 10

In vitro exposure of murine macrophages to ultraviolet light induces apoptosis. López–Candales A, et al. **Bol Asoc Med P R** 1996 Jul–Sep;88(7–9):57–62

Effects of triiodothyronine on the morphology of cells and matrix, the localization of alkaline phosphatase, and the frequency of apoptosis in long–term cultures of MC3T3–E1 cells. Fratzl–Zelman N, et al. **Bone** 1997 Mar;20(3):225–36

Apoptosis and proliferation in thyroid carcinoma: correlation with bcl–2 and p53 protein expression. Basolo F, et al. **Br J Cancer** 1997;75(4):537–41

Cell–cell contact and specific cytokines inhibit apoptosis of colonic epithelial cells: growth factors protect against c–myc–independent apoptosis. Hague A, et al. **Br J Cancer** 1997;75(7):960–8

Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl–2 and apoptosis are not pronounced: a preliminary report. Hellquist HB, et al. **Br J Cancer** 1997;76(2):175–9

Cell proliferation, cell loss and expression of bcl–2 and p53 in human pulmonary neoplasms. Kennedy MM, et al. **Br J Cancer** 1997;75(4):545–7

Apoptosis, cell proliferation and expression of Bcl–2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Koshida Y, et al. **Br J Cancer** 1997;75(3):367–73

Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro. Lai PB, et al. **Br J Cancer** 1996 Nov;74(9):1375–83

Bcl–2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Pepper C, et al. **Br J Cancer** 1997;76(7):935–8

Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Albrecht T, et al. **Br J Haematol** 1996 Dec;95(3):501–7

CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Bergamo A, et al. **Br J Haematol** 1997 Jun;97(3):652–5

Expression and function of CD95 (FAS/APO–1) in leukaemia–lymphoma tumour lines. Dirks W, et al. **Br J Haematol** 1997 Mar;96(3):584–93

In leukaemic CD5+ B cells the expression of BCL–2 gene family is shifted toward protection from apoptosis. Gottardi D, et al. **Br J Haematol** 1996 Sep;94(4):612–8

Evaluation of DNA analysis for evidence of apoptosis in megaloblastic anaemia. Ingram CF, et al. **Br J Haematol** 1997 Mar;96(3):576–83

Is apoptosis a massive process in myelodysplastic syndromes? Lepelley P, et al. **Br J Haematol** 1996 Nov;95(2):368–71

Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review. Rose LM, et al. **Br J Rheumatol** 1997 Feb;36(2):158–63 (49 ref.)

Apoptosis, tumour invasion and prostate cancer. Tenniswood M. **Br J Urol** 1997 Apr;79 Suppl 2:27–34 (82 ref.)

Programmed cell death in the developing nervous system. Burek MJ, et al. **Brain Pathol** 1996 Oct;6(4):427–46 (156 ref.)

Mechanisms of neuronal death in Alzheimer's disease. Cotman CW, et al. **Brain Pathol** 1996 Oct;6(4):493–506 (83 ref.)

Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Gratas C, et al. **Brain Pathol** 1997 Jul;7(3):863–9

Neuronal death in developmental models: possible implications in neuropathology. Johnson EM Jr, et al. **Brain Pathol** 1996 Oct;6(4):397–409 (88 ref.)

Pharmacological characterization of apoptotic cell death in a model of photothrombotic brain injury in rats. Kharlamov A, et al. **Brain Res** 1996 Sep 23;734(1–2):1–9

Oxygen–induced apoptosis in PC12 cells with special reference to the role of Bcl–2. Kubo T, et al. **Brain Res** 1996 Sep 16;733(2):175–83

Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus. MacGibbon GA, et al. **Brain Res** 1997 Mar 7;750(1–2):223–34

Staurosporine differentiated human SH–SY5Y neuroblastoma cultures exhibit transient apoptosis and trophic factor independence. Prince JA, et al. **Brain Res Bull** 1997; 43(6):515–23

Loss of Ref–1 protein expression precedes DNA fragmentation in apoptotic neurons. Walton M, et al. **Brain Res Mol Brain Res** 1997 Feb;44(1):167–70

Apoptotic death in cortical neurons of mice subjected to focal ischemia. Guégan C, et al. **C R Acad Sci III** 1996 Oct; 319(10):879–85

Membrane fluidity increases during apoptosis of sheep ileal Peyer's patch B cells. Jourd'heuil D, et al. **Can J Physiol Pharmacol** 1996 Jun;74(6):706–11

Programmed cell death (apoptosis) and the resolution of systemic inflammation. Marshall JC, et al. **Can J Surg** 1997 Jun;40(3):169–74 (25 ref.)

Retinoblastoma protein expression and MIB–1 correlate with survival of patients with malignant astrocytoma. Nakamura M, et al. **Cancer** 1997 Jul 15;80(2):242–9

Spontaneous apoptosis in gallbladder carcinoma. Relationships with clinicopathologic factors, expression of E–cadherin, bcl–2 protooncogene, and p53 oncosuppressor gene. Sasatomi E, et al. **Cancer** 1996 Nov 15;78(10):2101–10

Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5–fluorouracil. Sugamura K, et al. **Cancer** 1997 Jan 1;79(1):12–7

Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Yang G, et al. **Cancer** 1996 Sep 15;78(6):1267–71

Antisense down–regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Abdel–Mageed A, et al. **Cancer Gene Ther** 1997 May–Jun;4(3):199–207

Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific–antibody–activated cytotoxic T cells. Renner C, et al. **Cancer Immunol Immunother** 1997 Apr;44(2):70–6

Alteration of proto–oncogenes during apoptosis in the oral squamous cell carcinoma cell line, SAS, induced by staurosporine. Abiko Y, et al. **Cancer Lett** 1997 Sep 16; 118(1):101–7

Calcium ionophore A 23187 induces apoptotic cell death in rat thymocytes. Azmi S, et al. **Cancer Lett** 1996 Oct 1; 107(1):97–103

Adriamycin induces apoptosis in rat thymocytes. Azmi S, et al. **Cancer Lett** 1997 Jan 1;111(1–2):225–31

Reduced glutathione and S–acetylglutathione as selective apoptosis–inducing agents in cancer therapy [published erratum appears in Cancer Lett 1997 May 19;115(2):265] Donnerstag B, et al. **Cancer Lett** 1996 Dec 20; 110(1–2):63–70

Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Huang TS, et al. **Cancer Lett** 1996 Dec 20;110(1–2):77–85

Apoptosis bcl–2 and p53 expression and their relation to tumour stage in non–small cell lung carcinomas (NSCLC). Kargi HA, et al. **Cancer Lett** 1997 Jun 24;116(2):185–9

Expression of Fas–estrogen receptor fusion protein induces cell death in pancreatic cancer cell lines. Kawaguchi Y, et al. **Cancer Lett** 1997 Jun 3;116(1):53–9

Apoptosis induced by retinoic acid in Hep 3B cells in vitro. Kim DG, et al. **Cancer Lett** 1996 Oct 1;107(1):149–59

DMSO induces apoptosis in SV40–transformed human keratinocytes, but not in normal keratinocytes. Koike M, et al. **Cancer Lett** 1996 Nov 29;108(2):185–93

Apoptosis of pregnancy–dependent mammary tumor and transplantable pregnancy–dependent mammary tumor in mice. Kojima H, et al. **Cancer Lett** 1996 Dec 20; 110(1–2):113–21

Staurosporine inhibits the proliferation, alters the cell cycle distribution and induces apoptosis in HT–29 human colon adenocarcinoma cells. Qiao L, et al. **Cancer Lett** 1996 Oct 1;107(1):83–9

Coordinated expression of matrilysin during TPA–induced apoptosis of LNCaP cells: two parallel processes affected by TPA. Sundareshan P, et al. **Cancer Lett** 1997 Feb 26; 113(1–2):17–24

Adriamycin activates c–jun N–terminal kinase in human leukemia cells: a relevance to apoptosis. Yu R, et al. **Cancer Lett** 1996 Oct 1;107(1):73–81

Cholera toxin triggers apoptosis in human lung cancer cell lines. Allam M, et al. **Cancer Res** 1997 Jul 1;57(13):2615–8

Toxin–induced increase in survival factor receptors: modulation of the threshold for apoptosis. Boyle CC, et al. **Cancer Res** 1997 Jun 15;57(12):2404–9

Activation of actin–cleavable interleukin 1beta–converting enzyme (ICE) family protease CPP–32 during chemotherapeutic agent–induced apoptosis in ovarian carcinoma cells. Chen Z, et al. **Cancer Res** 1996 Nov 15; 56(22):5224–9

Protective effect of the insulin–like growth factor I receptor on apoptosis induced by okadaic acid. D'Ambrosio C, et al. **Cancer Res** 1997 Aug 1;57(15):3264–71

Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide. Eymin B, et al. **Cancer Res** 1997 Feb 15;57(4):686–95

Abrogation of taxol–induced G2–M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Frankel A, et al. **Cancer Res** 1997 Jun 15; 57(12):2388–93

p53–dependent DNA damage–induced apoptosis requires Fas/APO–1–independent activation of CPP32beta. Fuchs EJ, et al. **Cancer Res** 1997 Jul 1;57(13):2550–4

HSP27 as a mediator of confluence–dependent resistance to cell death induced by anticancer drugs. Garrido C, et al. **Cancer Res** 1997 Jul 1;57(13):2661–7

Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Guo N, et al. **Cancer Res** 1997 May 1; 57(9):1735–42

Oxidative DNA damage and apoptosis induced by benzene metabolites. Hiraku Y, et al. **Cancer Res** 1996 Nov 15; 56(22):5172–8

Fas expression and function in normal and malignant breast cell lines. Keane MM, et al. **Cancer Res** 1996 Oct 15; 56(20):4791–8

Overexpression of Bcl–X(L) inhibits Ara–C–induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Kim CN, et al. **Cancer Res** 1997 Aug 1;57(15):3115–20

Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase–3), a cell death protease. Krajewska M, et al. **Cancer Res** 1997 Apr 15;57(8):1605–13

Farnesyl transferase inhibitors induce apoptosis of Ras–transformed cells denied substratum attachment. Lebowitz PF, et al. **Cancer Res** 1997 Feb 15;57(4):708–13

Spontaneous apoptosis is inversely related to intratumoral microvessel density in gastric carcinoma. Lu C, et al. **Cancer Res** 1997 Jan 15;57(2):221–4

Induction of caspase–3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c–dependent pathway. Medina V, et al. **Cancer Res** 1997 Sep 1;57(17):3697–707

Wilms' tumor 1–KTS isoforms induce p53–independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor. Menke AL, et al. **Cancer Res** 1997 Apr 1; 57(7):1353–63

A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Nagane M, et al. **Cancer Res** 1996 Nov 1;56(21):5079–86

The tryphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl–2. Palumbo GA, et al. **Cancer Res** 1997 Jun 15; 57(12):2434–9

Apoptosis primarily accounts for the growth–inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Piazza GA, et al. **Cancer Res** 1997 Jun 15;57(12):2452–9

Quiescence in R3327–G rat prostate tumors after androgen ablation. Pollack A, et al. **Cancer Res** 1997 Jun 15; 57(12):2493–500

Effects of alterations in calcium homeostasis on apoptosis during neoplastic progression. Preston GA, et al. **Cancer Res** 1997 Feb 1;57(3):537–42

Two cytodifferentiation agent–induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells. Richon VM, et al. **Cancer Res** 1997 Jul 1;57(13):2789–98

Deregulated apoptosis is a hallmark of the Fanconi anemia syndrome. Ridet A, et al. **Cancer Res** 1997 May 1; 57(9):1722–30

Apoptosis, cell replication, and Western–style diet–induced tumorigenesis in mouse colon. Risio M, et al. **Cancer Res** 1996 Nov 1;56(21):4910–6

Fas–mediated apoptosis in human prostatic carcinoma cell lines. Rokhlin OW, et al. **Cancer Res** 1997 May 1; 57(9):1758–68

Dominant nature of the resistance to Fas– and tumor necrosis factor–alpha–mediated apoptosis in human prostatic carcinoma cell lines. Rokhlin OW, et al. **Cancer Res** 1997 Sep 15;57(18):3941–3

Apoptosis in the subependyma of young adult rats after single and fractionated doses of X–rays. Shinohara C, et al. **Cancer Res** 1997 Jul 1;57(13):2694–702

Apoptosis of Ewing's sarcoma cells is accompanied by accumulation of ubiquitinated proteins. Soldatenkov VA, et al. **Cancer Res** 1997 Sep 15;57(18):3881–5

AAC–11, a novel cDNA that inhibits apoptosis after growth factor withdrawal. Tewari M, et al. **Cancer Res** 1997 Sep 15;57(18):4063–9

Rb functions to inhibit apoptosis during myocyte differentiation. Wang J, et al. **Cancer Res** 1997 Feb 1; 57(3):351–4

Factors affecting topotecan–induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP–ribose)polymerase. Whitacre CM, et al.

Cancer Res 1997 Jun 1;57(11):2157–63

Vitamin E inhibits apoptosis, DNA modification, and cancer incidence induced by iron–mediated peroxidation in Wistar rat kidney. Zhang D, et al. **Cancer Res** 1997 Jun 15; 57(12):2410–4

Bcl–2 family proteins and the regulation of programmed cell death in leukemia and lymphoma. Reed JC, et al. **Cancer Treat Res** 1996;84:31–72 (231 ref.)

Programmed cell death and mammary neoplasia. Schedin PJ, et al. **Cancer Treat Res** 1996;83:3–22 (73 ref.)

Predictive value of proliferation, differentiation and apoptosis as intermediate markers for colon tumorigenesis. Chang WC, et al. **Carcinogenesis** 1997 Apr;18(4):721–30

p53 induction, cell cycle checkpoints, and apoptosis in DNAPK–deficient scid mice. Gurley KE, et al. **Carcinogenesis** 1996 Dec;17(12):2537–42

Reversibility and apoptosis in rat urinary bladder papillomatosis induced by uracil. Otori K, et al. **Carcinogenesis** 1997 Aug;18(8):1485–9

Selective elimination of human lymphoid cells with unstable chromosome aberrations by p53–dependent apoptosis. Schwartz JL, et al. **Carcinogenesis** 1997 Jan;18(1):201–5

Induction of the apoptosis–promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Stayrook KR, et al. **Carcinogenesis** 1997 Aug;18(8):1655–8

Apoptosis meets signal transduction: elimination of a BAD influence [comment] Gajewski TF, et al. **Cell** 1996 Nov 15;87(4):589–92. Comment on: Cell 1996 Nov 15;87(4):619–28. Comment on: Cell 1996 Nov 15;87(4):629–38.

Programmed cell death in animal development. Jacobson MD, et al. **Cell** 1997 Feb 7;88(3):347–54 (71 ref.)

Involution of mouse mammary glands during whole organ culture occurs via apoptosis of epithelial tissue. Casey TM, et al. **Cell Biol Int** 1996 Nov;20(11):763–7

Programmed cell death in the honey–bee (Apis mellifera L.) larvae midgut. Gregorc A, et al. **Cell Biol Int** 1997 Mar; 21(3):151–8

Protein kinase C–beta 2 inhibits cycling and decreases c–myc–induced apoptosis in small cell lung cancer cells. Barr LF, et al. **Cell Growth Differ** 1997 Apr;8(4):381–92

Overexpression of cyclin A in the mammary glands of transgenic mice results in the induction of nuclear abnormalities and increased apoptosis. Bortner DM, et al. **Cell Growth Differ** 1995 Dec;6(12):1579–89

Transformation by v–Jun prevents cell cycle exit and promotes apoptosis in the absence of serum growth factors. Clark W, et al. **Cell Growth Differ** 1997 Apr;8(4):371–80

Down–regulation of apurinic/apyrimidinic endonuclease expression is associated with the induction of apoptosis in differentiating myeloid leukemia cells. Robertson KA, et al. **Cell Growth Differ** 1997 Apr;8(4):443–9

Induction of apoptosis and inhibition of cell growth are independent responses to interferon–alpha in hematopoietic cell lines. Sangfelt O, et al. **Cell Growth Differ** 1997 Mar; 8(3):343–52

All–trans–retinoic acid mediates G1 arrest but not apoptosis of normal human mammary epithelial cells. Seewaldt VL, et al. **Cell Growth Differ** 1997 Jun;8(6):631–41

Neonatal diethylstilbestrol treatment alters the estrogen–regulated expression of both cell proliferation and apoptosis–related proto–oncogenes (c–jun, c–fos, c–myc, bax, bcl–2, and bcl–x) in the hamster uterus. Zheng X, et al. **Cell Growth Differ** 1997 Apr;8(4):425–34

Natural killer cell as the effector which mediates in vivo apoptosis in AK–5 tumor cells. Khar A, et al. **Cell Immunol** 1997 Apr 10;177(1):86–92

The application of NMR spectroscopy to the study of apoptosis. Bhakoo KK, et al. **Cell Mol Biol (Noisy–le–grand)** 1997 Jul;43(5):621–9 (28 ref.)

Annexin V, the regulator of phosphatidylserine–catalyzed inflammation and coagulation during apoptosis. Reutelingsperger CP, et al. **Cell Mol Life Sci** 1997 Jun; 53(6):527–32 (58 ref.)

Transient expression of neuropeptide Y (NPY) immunoreactivity in the developing hamster paraventricular thalamic area is due to apoptosis. Botchkina GI, et al. **Cell Mol Neurobiol** 1996 Dec;16(6):649–59

Apoptosis and mitosis in oral and oropharyngeal epithelia: evidence for a topographical switch in premalignant lesions. Birchall M, et al. **Cell Prolif** 1996 Aug;29(8):447–56

Morphological patterns and DNA polymerase regulation in apoptotic HL60 cells. Falcieri E, et al. **Cell Struct Funct** 1996 Jun;21(3):213–20

Apoptosis involved in density–dependent regulation of rat fibroblastic 3Y1 cell culture. Yasaka T, et al. **Cell Struct Funct** 1996 Dec;21(6):483–9

GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro. Clarkson ED, et al. **Cell Tissue Res** 1997 Aug;289(2):207–10

Apoptosis in phagocytotic cells of lymphoid tissues in rainbow trout (Oncorhynchus mykiss) following administration of clodronate liposomes. Espenes A, et al. **Cell Tissue Res** 1997 Aug;289(2):323–31

Effect of aging and dietary restriction on hepatocyte proliferation and death in male F344 rats. Higami Y, et al. **Cell Tissue Res** 1997 Apr;288(1):69–77

Apoptosis induced by methylazoxymethanol in developing rat cerebellum: organization of the cell nucleus and its relationship to DNA and rRNA degradation. Lafarga M, et al. **Cell Tissue Res** 1997 Jul;289(1):25–38

The use of isolated lung cells in in vitro pulmonary toxicology: studies of DNA damage, apoptosis and alteration of gene expression. Schwarze PE, et al. **Cent Eur J Public Health** 1996;4 Suppl:6–10

Apoptosis in ischemic and reperfused rat myocardium. Fliss H, et al. **Circ Res** 1996 Nov;79(5):949–56

Colocalization of CPP–32 with apoptotic cells in human atherosclerotic plaques. Mallat Z, et al. **Circulation** 1997 Jul 15;96(2):424–8

Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury [see comments] Periman H, et al. **Circulation** 1997 Feb 18;95(4):981–7. Comment in: Circulation 1997 Feb 18;95(4):782–6.

Ischemic preconditioning decreases apoptosis in rat hearts in vivo. Piot CA, et al. **Circulation** 1997 Sep 2; 96(5):1598–604

Apoptosis in human acute myocardial infarction. Saraste A, et al. **Circulation** 1997 Jan 21;95(2):320–3

Apoptosis of cardiac myocytes during cardiac allograft rejection. Relation to induction of nitric oxide synthase. Szabolcs M, et al. **Circulation** 1996 Oct 1;94(7):1665–73

Ultrastructure of apoptosis of smooth muscle cells [letter; comment] Takemura G, et al. **Circulation** 1996 Oct 1; 94(7):1787–8. Comment on: Circulation 1995 Jun 1;91(11):2703–11.

Life and death in the cardiovascular system [editorial; comment] Yeh ET. **Circulation** 1997 Feb 18;95(4):782–6 (42 ref.). Comment on: Circulation 1997 Feb 18;95(4):981–7.

Mechanisms of human eosinophil survival and apoptosis. Walsh GM. **Clin Exp Allergy** 1997 May;27(5):482–7 (62 ref.)

Heat shock–enhanced T cell apoptosis with heat shock protein 70 on T cell surface in multicentric Castleman's disease. Ishiyama T, et al. **Clin Exp Immunol** 1996 Nov; 106(2):351–6

Combined immunodeficiency phenotype associated with inappropriate spontaneous and activation–induced apoptosis. Pignata C, et al. **Clin Exp Immunol** 1997 Jun; 108(3):484–9

Macrophages, multinucleated giant cells, and apoptosis in HIV+ patients and normal blood donors. Ruibal–Ares B, et al. **Clin Immunol Immunopathol** 1997 Feb;82(2):102–16

Apoptosis in the retina. Rosenbaum PS, et al. **Clin Neurosci** 1997;4(5):224–32 (100 ref.)

The phenotypic switch from chondrocytes to bone–forming cells involves asymmetric cell division and apoptosis. Roach HI, et al. **Connect Tissue Res** 1996;35(1–4):85–91

Activate NF–kappa B or die? Baichwal VR, et al. **Curr Biol** 1997 Feb 1;7(2):R94–6 (15 ref.)

Bcl–2 regulates activation of apoptotic proteases in a cell–free system. Cosulich SC, et al. **Curr Biol** 1996 Aug 1; 6(8):997–1005

Apoptosis: Bcl–2–related proteins get connected. Jacobson MD. **Curr Biol** 1997 May 1;7(5):R277–81 (26 ref.)

CED–4 induces chromatin condensation in Schizosaccharomyces pombe and is inhibited by direct physical association with CED–9. James C, et al. **Curr Biol** 1997 Apr 1;7(4):246–52

Activation of apoptosis by Apo–2 ligand is independent of FADD but blocked by CrmA. Marsters SA, et al. **Curr Biol** 1996 Jun 1;6(6):750–2

Is programmed cell death required for neural tube closure? Weil M, et al. **Curr Biol** 1997 Apr 1;7(4):281–4

The cell shedding rate of the corneal epithelium--a comparison of collection methods. Ren H, et al. **Curr Eye Res** 1996 Oct;15(10):1054–9

Myocyte death in heart failure. Anversa P, et al. **Curr Opin Cardiol** 1996 May;11(3):245–51 (55 ref.)

Myocyte cell death and ventricular remodeling [see comments] Anversa P, et al. **Curr Opin Nephrol Hypertens** 1997 Mar;6(2):169–76 (68 ref.). Comment in: Curr Opin Nephrol Hypertens 1997 Mar;6(2):167–8.

What role does apoptosis play in progression of renal disease? Savill J, et al. **Curr Opin Nephrol Hypertens** 1996 Jul; 5(4):369–74 (62 ref.)

Ischemia–induced neuronal apoptosis. Choi DW. **Curr Opin Neurobiol** 1996 Oct;6(5):667–72 (55 ref.)

ICE–like proteases execute the neuronal death program. Martinou JC, et al. **Curr Opin Neurobiol** 1996 Oct; 6(5):609–14 (46 ref.)

TNF–alpha–induced apoptosis in Daudi cells: multiparametric analysis. Di Pietro R, et al. **Cytokine** 1997 Jul;9(7):463–70

Interleukin 10 protects activated human T lymphocytes against growth factor withdrawal–induced cell death but only anti–fas antibody can prevent activation–induced cell death. Pawelec G, et al. **Cytokine** 1996 Dec;8(12):877–81

Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Darzynkiewicz Z, et al. **Cytometry** 1997 Jan 1;27(1):1–20 (108 ref.)

An unusual artefact in the terminal deoxynucleotidyl transferase assay for apoptotic cells. Detre S, et al. **Cytometry** 1997 Jul 1;28(3):264–7

Correlated flow cytometric analysis of terminal events in apoptosis reveals the absence of some changes in some model systems. Frey T. **Cytometry** 1997 Jul 1;28(3):253–63

Apoptosis in hematopoietic cells is associated with an extensive decrease in cellular phosphotyrosine content that can be inhibited by the tyrosine phosphatase antagonist pervanadate. Lund–Johansen F, et al. **Cytometry** 1996 Oct 1;25(2):182–90

Annexin–V and TUNEL use in monitoring the progression of apoptosis in plants. O'Brien IE, et al. **Cytometry** 1997 Sep 1;29(1):28–33

Discrimination of late apoptotic/necrotic cells (type III) by flow cytometry in solid tumors. O'Brien MC, et al. **Cytometry** 1997 May 1;28(1):81–9

Detection of apoptosis in live cells by MitoTracker red CMXRos and SYTO dye flow cytometry. Poot M, et al. **Cytometry** 1997 Apr 1;27(4):358–64

IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells. Vitale M, et al. **Cytometry** 1997 Feb 15;30(1):61–6

Measurement of apoptosis in heterogenous cell populations. Weber GF, et al. **Cytometry** 1997 Feb 1;27(2):136–44

Activation of the reaper gene during ectopic cell killing in Drosophila. Nordstrom W, et al. **Dev Biol** 1996 Nov 25; 180(1):213–26

Genes induced in programmed cell death of neuronal PC12 cells and developing sympathetic neurons in vivo. Wang S, et al. **Dev Biol** 1997 Aug 15;188(2):322–36

Rescue of the limb deformity in hammertoe mutant mice by retinoic acid–induced cell death. Ahuja HS, et al. **Dev Dyn** 1997 Apr;208(4):466–81

Morphogenetic potential of the chick leg interdigital mesoderm when diverted from the cell death program. Ros MA, et al. **Dev Dyn** 1997 Mar;208(3):406–19

Trypsin–induced follicular papilla apoptosis results in delayed hair growth and pigmentation. Seiberg M, et al. **Dev Dyn** 1997 Apr;208(4):553–64

Inhibition of cell death by lens–specific overexpression of bcl–2 in transgenic mice. Fromm L, et al. **Dev Genet** 1997; 20(3):276–87

The programmed cell death of an immature thymocyte cell line transgenic for an alpha beta TCR and the c–myc proto–oncogene. Murdjeva M, et al. **Dev Immunol** 1996; 4(4):279–88

Cross–linking the TCR complex induces apoptosis in CD4+8+ thymocytes in the presence of cyclosporin A. Poetschke HL, et al. **Dev Immunol** 1996;5(1):1–15

Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis. Humphreys RC, et al. **Development** 1996 Dec;122(12):4013–22

Role of BMP–2 and OP–1 (BMP–7) in programmed cell death and skeletogenesis during chick limb development. Macias D, et al. **Development** 1997 Mar;124(6):1109–17

A relationship between apoptosis and flow during programmed capillary regression is revealed by vital analysis. Meeson A, et al. **Development** 1996 Dec; 122(12):3929–38

Bax promotes neuronal cell death and is downregulated during the development of the nervous system. Vekrellis K, et al. **Development** 1997 Mar;124(6):1239–49

BMP–2/–4 mediate programmed cell death in chicken limb buds. Yokouchi Y, et al. **Development** 1996 Dec; 122(12):3725–34

Apoptosis is the mode of beta–cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse. O'Brien BA, et al. **Diabetes** 1997 May;46(5):750–7

Abnormalities of epithelial apoptosis in multistep colorectal neoplasia demonstrated by terminal deoxyuridine nick end labeling. Moss SF, et al. **Dig Dis Sci** 1996 Nov; 41(11):2238–47

ITA, a vertebrate homologue of IAP that is expressed in T lymphocytes. Digby MR, et al. **DNA Cell Biol** 1996 Nov; 15(11):981–8

Murine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of the brain most susceptible to hypoxic and ischemic injury. Ichimiya S, et al. **DNA Cell Biol** 1997 Mar;16(3):311–21

In situ detection of apoptosis in regressing corpus luteum of pregnant sow: evidence of an early presence of DNA fragmentation. Bacci ML, et al. **Domest Anim Endocrinol** 1996 Jul;13(4):361–72

Use of two–dimensional gel electrophoresis to characterize protein synthesis during neuronal death in cerebellar culture. Charriaut–Marlangue C, et al. **Electrophoresis** 1996 Nov;17(11):1781–6

Analysis of phosphorylated isoforms of the p53 tumor suppressor protein in human lung carcinoma cells undergoing apoptosis. Maxwell SA, et al. **Electrophoresis** 1996 Nov;17(11):1772–5

Induction of apoptosis by the transcription factor c–Jun. Bossy–Wetzel E, et al. **EMBO J** 1997 Apr 1;16(7):1695–709

Identification of a novel regulatory domain in Bcl–X(L) and Bcl–2. Chang BS, et al. **EMBO J** 1997 Mar 3;16(5):968–77

T–cell receptor ligation by peptide/MHC induces activation of a caspase in immature thymocytes: the molecular basis of negative selection. Clayton LK, et al. **EMBO J** 1997 May 1;16(9):2282–93

DAP–kinase is a Ca2+/calmodulin–dependent, cytoskeletal–associated protein kinase, with cell death–inducing functions that depend on its catalytic activity. Cohen O, et al. **EMBO J** 1997 Mar 3; 16(5):998–1008

Crk is required for apoptosis in Xenopus egg extracts. Evans EK, et al. **EMBO J** 1997 Jan 15;16(2):230–41

Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. Faleiro L, et al. **EMBO J** 1997 May 1;16(9):2271–81

Identification of a Drosophila melanogaster

ICE/CED-3-related protease, drICE. Fraser AG, et al. **EMBO J** 1997 May 15;16(10):2805-13

G protein betagamma complex-mediated apoptosis by familial Alzheimer's disease mutant of APP. Giambarella U, et al. **EMBO J** 1997 Aug 15;16(16):4897-907

harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). Inohara N, et al. **EMBO J** 1997 Apr 1;16(7):1686-94

Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. Jänicke RU, et al. **EMBO J** 1996 Dec 16;15(24):6969-78

Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. Khwaja A, et al. **EMBO J** 1997 May 15;16(10):2783-93

Caspase activity is required for commitment to Fas-mediated apoptosis. Longthorne VL, et al. **EMBO J** 1997 Jul 1; 16(13):3805-12

FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). Medema JP, et al. **EMBO J** 1997 May 15;16(10):2794-804

An early and massive wave of germinal cell apoptosis is required for the development of functional spermatogenesis. Rodriguez I, et al. **EMBO J** 1997 May 1;16(9):2262-70

Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. Wu M, et al. **EMBO J** 1996 Sep 2;15(17):4682-90

Evaluation of apoptotic parameters in normal and neoplastic human adrenal. Wolkersdörfer GW, et al. **Endocr Res** 1996 Nov;22(4):411-9

Programmed cell death of chondrocytes and aberrant chondrogenesis in mice homozygous for parathyroid hormone-related peptide gene deletion. Amizuka N, et al. **Endocrinology** 1996 Nov;137(11):5055-67

Regulation of apoptosis in uterine leiomyomata. Burroughs KD, et al. **Endocrinology** 1997 Jul;138(7):3056-64

Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung. Catlin EA, et al. **Endocrinology** 1997 Feb;138(2):790-6

Opposing actions of hepatocyte growth factor and basic fibroblast growth factor on cell contact, intracellular free calcium levels, and rat ovarian surface epithelial cell viability. Gulati R, et al. **Endocrinology** 1997 May; 138(5):1847-56

Multiple extracellular signals promote osteoblast survival and apoptosis. Hill PA, et al. **Endocrinology** 1997 Sep; 138(9):3849-58

Targeted overexpression of Bcl-2 in ovaries of transgenic mice leads to decreased follicle apoptosis, enhanced folliculogenesis, and increased germ cell tumorigenesis. Hsu SY, et al. **Endocrinology** 1996 Nov;137(11):4837-43

Role of prepancreatic (pro)insulin and the insulin receptor in prevention of embryonic apoptosis. Morales AV, et al. **Endocrinology** 1997 Sep;138(9):3967-75

In vivo resistance to glucocorticoid-induced apoptosis in rat thymocytes with normal steroid receptor function in vitro. Oldenburg NB, et al. **Endocrinology** 1997 Feb;138(2):810-8

Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Scaglia L, et al. **Endocrinology** 1997 Apr;138(4):1736-41

Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Wang QF, et al. **Endocrinology** 1996 Dec; 137(12):5476-83

Induction of apoptotic cell death in hen granulosa cells by ceramide. Witty JP, et al. **Endocrinology** 1996 Dec; 137(12):5269-77

Apoptosis in the normal olfactory epithelium of the adult guinea pig. Nakagawa T, et al. **Eur Arch Otorhinolaryngol** 1996;253(6):371-3

Internucleosomal DNA fragmentation in cultured cells under conditions reported to induce apoptosis may be caused by mycoplasma endonucleases. Paddenberg R, et al. **Eur J Cell Biol** 1996 Sep;71(1):105-19

Differential expression of apoptosis, Bcl-x and c-Myc in normal and malignant lymphoid tissues. Hermann M, et al. **Eur J Haematol** 1997 Jul;59(1):20-30

The propensity to apoptosis of centrocytes and centroblasts correlates with elevated levels of intracellular myc protein. Cutrona G, et al. **Eur J Immunol** 1997 Jan;27(1):234-8

Germinal center B cells rescued from apoptosis by CD40 ligation or attachment to follicular dendritic cells, but not by engagement of surface immunoglobulin or adhesion receptors, become resistant to CD95-induced apoptosis. Koopman G, et al. **Eur J Immunol** 1997 Jan;27(1):1-7

Redox regulation of apoptosis: impact of thiol oxidation status on mitochondrial function. Marchetti P, et al. **Eur J Immunol** 1997 Jan;27(1):289-96

Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signaling through CD40 and interleukin-4 receptor: role for inhibition of an early response gene, Berg36. Ning ZQ, et al. **Eur J Immunol** 1996 Oct; 26(10):2356-63

Evidence that spinal interneurons undergo programmed cell death postnatally in the rat. Lawson SJ, et al. **Eur J Neurosci** 1997 Apr;9(4):794-9

Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrine excitotoxicity. Leist M, et al. **Eur J Neurosci** 1997 Jul;9(7):1488-98

Susceptibility of cerebellar granule neurons derived from Bcl-2-deficient and transgenic mice to cell death. Tanabe H, et al. **Eur J Neurosci** 1997 Apr;9(4):848-56

Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma. Higashijima T, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Sep;68(1-2):169-73

Nuclear DNA fragmentation during postnatal tooth development of mouse and hamster and during dentin repair in the rat. Bronckers AL, et al. **Eur J Oral Sci** 1996 Apr;104(2 (Pt 1)):102-11

Apoptosis in human and rat dental pulp. Vermelin L, et al. **Eur J Oral Sci** 1996 Oct-Dec;104(5-6):547-53

The role of apoptosis in the pathogenesis and treatment of diseases. Solary E, et al. **Eur Respir J** 1996 Jun; 9(6):1293-305 (152 ref.)

Altered sensitivity to retinoid-induced apoptosis associated with changes in the subcellular distribution of Bcl-2. Bruel A, et al. **Exp Cell Res** 1997 Jun 15;233(2):281-7

Exposure of phosphatidylethanolamine on the surface of apoptotic cells. Emoto K, et al. **Exp Cell Res** 1997 May 1;232(2):430-4

Apoptosis of terminally differentiated chondrocytes in culture. Gibson G, et al. **Exp Cell Res** 1997 Jun 15; 233(2):372-82

Cleavage of the nuclear matrix protein NuMA during apoptosis. Gueth-Hallonet C, et al. **Exp Cell Res** 1997 May 25;233(1):21-4

Incomplete differentiation of fetal keratinocytes in the skin equivalent leads to the default pathway of apoptosis. Haake AR, et al. **Exp Cell Res** 1997 Feb 25;231(1):83-95

Heterotrimeric G-proteins are implicated in the regulation of apoptosis in pancreatic beta-cells. Loweth AC, et al. **Exp Cell Res** 1996 Nov 25;229(1):69-76

Altered gene expression associated with apoptosis in a pre-B-leukemic cell line following cross-linking of MHC class I. Nilsson N, et al. **Exp Cell Res** 1997 Feb 25; 231(1):190-7

The cleavage of nuclear DNA into high molecular weight DNA fragments occurs not only during apoptosis but also accompanies changes in functional activity of the nonapoptotic cells. Solov'yan VT, et al. **Exp Cell Res** 1997 Aug 25;235(1):130-7

Involvement of cytoplasmic serine proteinase and CPP32 subfamily in the molecular machinery of caspase 3 activation during Fas-mediated apoptosis. Suzuki A, et al. **Exp Cell Res** 1997 May 25;233(1):48-55

Pressure-induced apoptosis in human lymphoblasts. Takano KJ, et al. **Exp Cell Res** 1997 Aug 25;235(1):155-60

Expression of apoptosis-related proteins in thyroid tumors and thyroid carcinoma cell lines. Bröcker M, et al. **Exp Clin Endocrinol Diabetes** 1996;104 Suppl 4:20-3

Herpes simplex virus type-1 infection of corneal epithelial cells induces apoptosis of the underlying keratocytes. Wilson SE, et al. **Exp Eye Res** 1997 May;64(5):775-9

Myotonic dystrophy: decreased levels of myotonin protein kinase (Mt-PK) leads to apoptosis in muscle cells. Bhagwati S, et al. **Exp Neurol** 1997 Jul;146(1):277-81

PrP deposition, microglial activation, and neuronal apoptosis in murine scrapie. Williams A, et al. **Exp Neurol** 1997 Apr; 144(2):433-8

Transglutaminase induction by various cell death and apoptosis pathways. Fesus L, et al. **Experientia** 1996 Oct 31;52(10-11):942-9 (84 ref.)

Recognition of apoptotic cells by phagocytes. Hart SP, et al. **Experientia** 1996 Oct 31;52(10-11):950-6 (35 ref.)

Divergence towards a dead end? Cleavage of the divergent domains of ribosomal RNA in apoptosis. Houge G, et al. **Experientia** 1996 Oct 31;52(10-11):963-7 (29 ref.)

Role of protein kinase activity in apoptosis. Lavin MF, et al. **Experientia** 1996 Oct 31;52(10-11):979-94 (246 ref.)

Importance of the Bcl-2 family in cell death regulation. McDonnell TJ, et al. **Experientia** 1996 Oct 31; 52(10-11):1008-17 (110 ref.)

Cellular catabolism in apoptosis: DNA degradation and endonuclease activation. Montague JW, et al. **Experientia** 1996 Oct 31;52(10-11):957-62 (59 ref.)

dNTP pools imbalance as a signal to initiate apoptosis. Oliver FJ, et al. **Experientia** 1996 Oct 31;52(10-11):995-1000 (40 ref.)

Apoptosis — the story so far.... Samali A, et al. **Experientia** 1996 Oct 31;52(10-11):933-41 (124 ref.)

The p53 tumour suppressor gene: a mediator of a G1 growth arrest and of apoptosis. Yonish-Rouach E. **Experientia** 1996 Oct 31;52(10-11):1001-7 (116 ref.)

Proteases in apoptosis. Zhivotovsky B, et al. **Experientia** 1996 Oct 31;52(10-11):968-78 (96 ref.)

Infiltrating inflammatory cell phenotypes and apoptosis in rejected human corneal allografts. Larkin DF, et al. **Eye** 1997;11 (Pt 1):68-74

Apoptosis in Xenopus tadpole tail muscles involves Bax-dependent pathways. Sachs LM, et al. **FASEB J** 1997 Aug;11(10):801-8

Cyclosporin A but not FK506 inhibits thyroid hormone-induced apoptosis in tadpole intestinal epithelium. Su Y, et al. **FASEB J** 1997 Jun;11(7):559-65

Cyclooxygenase-2: an essential regulator of NO-mediated apoptosis. von Knethen A, et al. **FASEB J** 1997 Sep; 11(11):887-95

Calmodulin-dependent protein kinase II mediates signal transduction in apoptosis. Wright SC, et al. **FASEB J** 1997 Sep;11(11):843-9

Calcineurin and mitochondrial function in glutamate-induced neuronal cell death. Ankarcrona M, et al. **FEBS Lett** 1996 Oct 7;394(3):321-4

Interaction of Fas(Apo-1/CD95) with proteins implicated in the ubiquitination pathway. Becker K, et al. **FEBS Lett** 1997 Jul 21;412(1):102-6

Cell cycle specificity of Fas-mediated apoptosis in WIL-2 cells. Beletskaya IV, et al. **FEBS Lett** 1997 Jul 21; 412(1):91-3

Susceptibility of different subsets of immature thymocytes to apoptosis. Chow SC, et al. **FEBS Lett** 1997 May 19; 408(2):141-6

Alzheimer-associated presenilin-2 confers increased sensitivity to apoptosis in PC12 cells. Deng G, et al. **FEBS Lett** 1996 Nov 11;397(1):50-4

The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells. Geley S, et al. **FEBS Lett** 1997 Jan 27;402(1):36-40

Involvement of extracellular calcium in phosphatidylserine exposure during apoptosis. Hampton MB, et al. **FEBS Lett** 1996 Dec 16;399(3):277-82

Bcl-2 protein inhibits oxysterol-induced apoptosis through suppressing CPP32-mediated pathway. Harada K, et al. **FEBS Lett** 1997 Jul 7;411(1):63-6

Nitric oxide induces apoptosis via triggering mitochondrial permeability transition. Hortelano S, et al. **FEBS Lett** 1997 Jun 30;410(2-3):373-7

Chromatin fragmentation associated with apoptotic changes in tobacco cells exposed to cold stress. Koukalová B, et al. **FEBS Lett** 1997 Sep 8;414(2):289-92

Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid-dependent signaling. Lacal JC. **FEBS Lett** 1997 Jun 23;410(1):73-7 (59 ref.)

Involvement of histone hyperacetylation in triggering DNA fragmentation of rat thymocytes undergoing apoptosis. Lee E, et al. **FEBS Lett** 1996 Oct 21;395(2-3):183-7

Expression of a 26S proteasome ATPase subunit, MS73, in muscles that undergo developmentally programmed cell death, and its control by ecdysteroid hormones in the insect Manduca sexta. Löw P, et al. **FEBS Lett** 1997 Jan 6; 400(3):345-9

Evidence for the involvement of cGMP and protein kinase G in nitric oxide-induced apoptosis in the pancreatic B-cell line, HIT-T15. Loweth AC, et al. **FEBS Lett** 1997 Jan 6;400(3):285-8

DNA fragmentation is a feature of cystic fibrosis epithelial cells: a disease with inappropriate apoptosis? Maiuri L, et al. **FEBS Lett** 1997 May 19;408(2):225-31

Ectopic expression of CHOP (GADD153) induces apoptosis in M1 myeloblastic leukemia cells. Matsumoto M, et al. **FEBS Lett** 1996 Oct 21;395(2-3):143-7

Resistance to apoptosis in Fanconi's anaemia. An ex vivo study in peripheral blood mononuclear cells. Monti D, et al. **FEBS Lett** 1997 Jun 16;409(3):365-9

NF-kappaB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. Ozaki K, et al. **FEBS Lett** 1997 Jun 30;410(2-3):297-300

Effect of anti-apoptotic genes and peptide inhibitors on cytoplasmic acidification during apoptosis. Pardhasaradhi BV, et al. **FEBS Lett** 1997 Jul 7;411(1):67-70

Mitochondria and programmed cell death: back to the future. Petit PX, et al. **FEBS Lett** 1996 Oct 28;396(1):7-13 (85 ref.)

Removal of proteasomes from the nucleus and their accumulation in apoptotic blebs during programmed cell death. Pitzer F, et al. **FEBS Lett** 1996 Sep 23;394(1):47-50

Apoptosis induced by HIV-gp120 in a Th1 clone involves the generation of reactive oxygen intermediates downstream CD95 triggering. Radrizzani M, et al. **FEBS Lett** 1997 Jul 7;411(1):87-92

JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. Salvioli S, et al. **FEBS Lett** 1997 Jul 7; 411(1):77-82

Direct excision of 50 kb pair DNA fragments from megabase-sized fragments produced during apoptotic cleavage of genomic DNA. Sestili P, et al. **FEBS Lett** 1996 Nov 4;396(2-3):337-42

Why are mitochondria involved in apoptosis? Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-producing mitochondria and cell. Skulachev VP. **FEBS Lett** 1996 Nov 11;397(1):7-10

Induction of glutathione synthetase by 1,10-phenanthroline. Sun Y. **FEBS Lett** 1997 May 12;408(1):16-20

Differential expression of tissue transglutaminase during in vivo apoptosis of thymocytes induced via distinct signalling pathways. Szondy Z, et al. **FEBS Lett** 1997 Mar 10; 404(2-3):307-13

Enhancement of macrophage phagocytosis upon iC3b deposition on apoptotic cells. Takizawa F, et al. **FEBS Lett** 1996 Nov 18;397(2-3):269-72

Cell death induction by receptors of the TNF family: towards a molecular understanding. Wallach D, et al. **FEBS Lett** 1997 Jun 23;410(1):96-106 (155 ref.)

Granulocytic differentiation of HL-60 cells results in spontaneous apoptosis mediated by increased caspase expression. William R, et al. **FEBS Lett** 1997 Aug 4; 412(3):603-9

CPP32 activation during dolichyl phosphate-induced apoptosis in U937 leukemia cells. Yokoyama Y, et al. **FEBS Lett** 1997 Jul 21;412(1):153-6

Detection of measles virus-induced apoptosis of human monocytic cell line (THP-1) by DNA fragmentation ELISA. Ito M, et al. **FEMS Immunol Med Microbiol** 1996 Sep;15(2-3):115-22

Apoptotic cell death of vascular endothelial cells and renal tubular cells in the generalized Shwartzman reaction. Koide N, et al. **FEMS Immunol Med Microbiol** 1996 Dec 31; 16(3-4):205-11

The incidence of apoptotic bodies in membrana granulosa can predict prognosis of ova from patients participating in in vitro fertilization programs. Nakahara K, et al. **Fertil Steril** 1997 Aug;68(2):312-7

Incidence of apoptotic bodies in membrana granulosa of the patients participating in an in vitro fertilization program. Nakahara K, et al. **Fertil Steril** 1997 Feb;67(2):302-8

Investigation on apoptosis in Leydig cells cultured in vitro. Jankowska A, et al. **Folia Histochem Cytobiol** 1997; 35(2):97-8

Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts. Brunk UT, et al. **Free Radic Biol Med** 1997;23(4):616-26

16S mitochondrial ribosomal RNA degradation is associated with apoptosis. Crawford DR, et al. **Free Radic Biol Med** 1997;22(7):1295-300

TGF-beta1 triggers oxidative modifications and enhances apoptosis in HIT cells through accumulation of reactive oxygen species by suppression of catalase and glutathione peroxidase. Islam KN, et al. **Free Radic Biol Med** 1997; 22(6):1007-17

Fetal growth retardation in rats may result from apoptosis: role of peroxynitrite. Miller MJ, et al. **Free Radic Biol Med** 1996;21(5):619-29

Role of glutathione metabolism and apoptosis in the regression of liver hemopoiesis. Yamamasu S, et al. **Free Radic Biol Med** 1997;23(1):100-9

Cancer therapy and apoptosis. Inoue S. **Gan To Kagaku Ryoho** 1997 May;24 Suppl 1:102-14 (59 ref.)

Epithelial apoptosis as a very early marker of drug-induced colitis: the example of ranitidine [letter] Beaugerie L, et al. **Gastroenterol Clin Biol** 1996;20(10):918-9

New gene product prevents apoptosis in colon, pancreas cancers [news] **Gastroenterology** 1997 Oct;113(4):1060

Lack of butyrate is associated with induction of Bax and subsequent apoptosis in the proximal colon of guinea pig [comment] Hass R, et al. **Gastroenterology** 1997 Mar; 112(3):875-81. Comment on: Gastroenterology 1997 Mar;112(3):1036-40.

Apoptotic versus necrotic cell death in acute pancreatitis [letter; comment] Kaiser AM. **Gastroenterology** 1996 Dec; 111(6):1781-2. Comment on: Gastroenterology 1996 Mar;110(3):875-84.

Rat Kupffer cell-derived nitric oxide suppresses proliferation and induces apoptosis of syngeneic hepatoma cells. Kurose I, et al. **Gastroenterology** 1996 Oct;111(4):1058-70

Fas and the immunologically underprivileged intestine [editorial; comment] Ma A. **Gastroenterology** 1997 Jul; 113(1):345-8. Comment on: Gastroenterology 1997 Jul;113(1):160-7. Comment on: Gastroenterology 1997 Jul;113(1):168-74.

Inward growth of colonic adenomatous polyps. Moss SF, et al. **Gastroenterology** 1996 Dec;111(6):1425-32

Rapid onset of apoptosis in vitro follows disruption of beta 1-integrin/matrix interactions in human colonic crypt cells. Sträter J, et al. **Gastroenterology** 1996 Jun;110(6):1776-84

The highly conserved DAD1 protein involved in apoptosis is required for N-linked glycosylation. Makishima T, et al. **Genes Cells** 1997 Feb;2(2):129-41

E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Hsieh JK, et al. **Genes Dev** 1997 Jul 15;11(14):1840-52

Chromosomal mapping of cell death proteases CPP32, MCH2, and MCH3. Bullrich F, et al. **Genomics** 1996 Sep 1;36(2):362-5

Mapping of a newly discovered human gene homologous to the apoptosis associated-murine mammary protein, MFG-E8, to chromosome 15q25. Collins C, et al. **Genomics** 1997 Jan 1;39(1):117-8

Genomic organization and primary characterization of miap-3: the murine homologue of human X-linked IAP. Farahani R, et al. **Genomics** 1997 Jun 15;42(3):514-8

Apoptotic cell death in proliferative vitreoretinopathy. Esser P, et al. **Ger J Ophthalmol** 1996 Mar;5(2):73-8

Photoreceptor decay over time and apoptosis in experimental retinal detachment. Berglin L, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 May;235(5):306-12

Reattachment to a substrate prevents apoptosis of human retinal pigment epithelium. Tezel TH, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Jan;235(1):41-7

Association between cervical neoplasia and apoptosis as detected by in situ nuclear labeling. Sheets EE, et al. **Gynecol Oncol** 1996 Oct;63(1):94-100

Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Yamasaki F, et al. **Gynecol Oncol** 1997 Sep;66(3):439-48

Injury models of the vascular endothelium: apoptosis and loss of thromboresistance induced by a viral protein. Eldor A, et al. **Haemostasis** 1996 Oct;26 Suppl 4:37-45 (46 ref.)

Apoptosis in cardiovascular disease. Davies MJ. **Heart** 1997 Jun;77(6):498-501 (32 ref.)

Apoptosis in blood diseases. Review new data. Binet JL, et al. **Hematol Cell Ther** 1996 Jul;38(3):253-64 (123 ref.)

Apoptosis in chronic gastritis: evaluation of the gastric mucosa by DNA flow cytometry and the expression of the high molecular weight cytokeratin. Attallah AM, et al. **Hepatogastroenterology** 1996 Sep-Oct;43(11):1305-12

Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Grasl-Kraupp B, et al. **Hepatology** 1997 Apr;25(4):906-12

Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Harnois DM, et al. **Hepatology** 1997 Oct;26(4):884-90

Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Koga H, et al. **Hepatology** 1997 May;25(5):1077-84

Apoptosis of neutrophils and their elimination by Kupffer cells in rat liver. Shi J, et al. **Hepatology** 1996 Nov; 24(5):1256-63

Nuclear ribonucleoprotein-containing structures undergo severe rearrangement during spontaneous thymocyte apoptosis. A morphological study by electron microscopy. Biggiogera M, et al. **Histochem Cell Biol** 1997 Apr; 107(4):331-6

Distribution of deoxyribonuclease I (DNase I) and p53 in rat testis and their correlation with apoptosis. Stephan H, et al. **Histochem Cell Biol** 1996 Oct;106(4):383-93

Ultrastructural identification of apoptotic nuclei using the TUNEL technique. Sanders EJ, et al. **Histochem J** 1996 Apr;28(4):275-81

Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Anglade P, et al. **Histol Histopathol** 1997 Jan;12(1):25-31

Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Anglade P, et al. **Histol Histopathol** 1997 Jul;12(3):603-10

Melanosis coli is associated with an increase in colonic epithelial apoptosis and not with laxative use. Byers RJ, et al. **Histopathology** 1997 Feb;30(2):160-4

Proliferation and apoptosis in primary gastric B-cell non-Hodgkin's lymphoma. Gisbertz IA, et al. **Histopathology** 1997 Feb;30(2):152-9

Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours. Lipponen PK, et al. **Histopathology** 1996 Feb;28(2):135-40

Apoptosis and proliferation in gastric carcinoma: the association with histological type. Shinohara T, et al. **Histopathology** 1996 Aug;29(2):123-9

Involvement of cell-mediated killing in apoptosis in histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease). Takakuwa T, et al. **Histopathology** 1996 Jan; 28(1):41-8

Incidence of apoptosis in HIV-myelopathy, myelodysplastic syndromes and non-specific inflammatory lesions of the bone marrow. Thiele J, et al. **Histopathology** 1997 Apr; 30(4):307-11

Does apoptosis contribute follicular atresia and luteal regression in human ovary? Fukaya T, et al. **Horm Res** 1997;48 Suppl 3:20-6

Apoptosis in human endometrial and endometriotic tissues. Suganuma N, et al. **Horm Res** 1997;48 Suppl 3:42-7 (43 ref.)

TUNEL--morituri te salutant. Quantitative in situ image analysis of apoptosis in well and poorly differentiated tumors from rat liver. Roberts RA. **Hum Exp Toxicol** 1996 May;15(5):457-8

Expression of the bcl-2 gene from a defective HSV-1 amplicon vector protects pancreatic beta-cells from apoptosis. Liu Y, et al. **Hum Gene Ther** 1996 Sep 10; 7(14):1719-26

Early apoptosis in human myocardial infarcts. Veinot JP, et al. **Hum Pathol** 1997 Apr;28(4):485-92

Immunolocalization of the apoptosis regulating proteins Bcl-2 and Bax in human endometrium and isolated peritoneal fluid macrophages in endometriosis. McLaren J, et al. **Hum Reprod** 1997 Jan;12(1):146-52

Nitric oxide concentrations in the follicular fluid and apoptosis of granulosa cells in human follicles. Sugino N, et al. **Hum Reprod** 1996 Nov;11(11):2484-7

Gonadal cell apoptosis: hormone-regulated cell demise. Billig H, et al. **Hum Reprod Update** 1996 Mar-Apr;2(2):103-17 (167 ref.)

Involvement of programmed cell death in preimplantation embryo demise. Jurisicova A, et al. **Hum Reprod Update** 1995 Nov;1(6):558-66 (65 ref.)

Signals and molecular pathways involved in apoptosis, with special emphasis on human endometrium. Tabibzadeh S. **Hum Reprod Update** 1995 Jul;1(4):303-23 (211 ref.)

Altered balance between cell replication and apoptosis in hearts and kidneys of newborn SHR. Moreau P, et al. **Hypertension** 1997 Sep;30(3 Pt 2):720-4

TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Bodmer JL, et al. **Immunity** 1997 Jan;6(1):79-88

Fas modulation of apoptosis during negative selection of thymocytes. Castro JE, et al. **Immunity** 1996 Dec; 5(6):617-27

A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Coxon A, et al. **Immunity** 1996 Dec; 5(6):653-66

Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Huang S, et al. **Immunity** 1997 Jun;6(6):739-49

Casper is a FADD- and caspase-related inducer of apoptosis. Shu HB, et al. **Immunity** 1997 Jun;6(6):751-63

Antigen-specific apoptosis in immortalized T cells by soluble MHC class II-peptide complexes. Arimilli S, et al. **Immunol Cell Biol** 1996 Feb;74(1):96-104

Uncontrolled triggering of programmed cell death (apoptosis) in haematopoietic stem cells: a new hypothesis for the pathogenesis of aplastic anaemia. Laveder F, et al. **Immunol Cell Biol** 1996 Apr;74(2):159-62

The time course, localization and quantitation of T- and B-cell mitogen-driven apoptosis in vivo. Grant P, et al. **Immunol Lett** 1995 Sep;47(3):227-31

Calorie restriction modulates lymphocyte subset phenotype and increases apoptosis in MRL/lpr mice. Luan X, et al. **Immunol Lett** 1995 Sep;47(3):181-6

Analysis of apoptosis and a Th1/Th2 phenotype in HIV-infected patients. Sarih M, et al. **Immunol Lett** 1996 May;50(3):125-9

Expression of alkaline phosphatase by a B-cell hybridoma and its modulation during cell growth and apoptosis. Souvannavong V, et al. **Immunol Lett** 1995 Sep; 47(3):163-70

TGF beta 1 induces growth arrest and apoptosis but not ciliated cell differentiation in rat tracheal epithelial cell cultures. Antoshina E, et al. **In Vitro Cell Dev Biol Anim** 1997 Mar;33(3):212-7

Mycobacterium tuberculosis heat shock protein 10 increases both proliferation and death in mouse P19 teratocarcinoma cells. Galli G, et al. **In Vitro Cell Dev Biol Anim** 1996 Jul-Aug;32(7):446-50

Enhanced apoptosis in transformed human lung fibroblasts after exposure to sodium butyrate. Thomas GL, et al. **In Vitro Cell Dev Biol Anim** 1996 Sep;32(8):505-13

Apoptosis of monocytes and prolonged survival of granulocytes as a result of phagocytosis of bacteria. Baran J, et al. **Infect Immun** 1996 Oct;64(10):4242-8

Effect of in vitro infection of human monocytes with low numbers of Mycobacterium tuberculosis bacteria on monocyte apoptosis. Dürrbaum-Landmann I, et al. **Infect Immun** 1996 Dec;64(12):5384-9

Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Keane J, et al. **Infect Immun** 1997 Jan;65(1):298-304

Butyric acid-induced apoptosis of murine thymocytes, splenic T cells, and human Jurkat T cells. Kurita-Ochiai T, et al. **Infect Immun** 1997 Jan;65(1):35-41

Invasion of Vero cells and induction of apoptosis in macrophages by pathogenic Leptospira interrogans are correlated with virulence. Merien F, et al. **Infect Immun** 1997 Feb;65(2):729-38

Evidence for apoptosis of human macrophage-like HL-60 cells by Legionella pneumophila infection. Müller A, et al. **Infect Immun** 1996 Dec;64(12):4900-6

In vivo apoptosis in Shigella flexneri infections. Zychlinsky A, et al. **Infect Immun** 1996 Dec;64(12):5357-65

Molecular mechanisms of defective eosinophil apoptosis in diseases associated with eosinophilia. Simon HU. **Int Arch Allergy Immunol** 1997 May-Jul;113(1-3):206-8 (30 ref.)

Wortmannin-mediated inhibition of phosphatidylinositol 3-kinase activity triggers apoptosis in normal and neoplastic B lymphocytes which are in cell cycle. Padmore L, et al. **Int Immunol** 1996 Apr;8(4):585-94

Role of c-myc and CD45 in spontaneous and anti-receptor-induced apoptosis in adult murine B cells. Scott DW, et al. **Int Immunol** 1996 Sep;8(9):1375-85

HIV envelope-directed signaling aberrancies and cell death of CD4+ T cells in the absence of TCR co-stimulation. Tian H, et al. **Int Immunol** 1996 Jan;8(1):65-74

Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Fajac A, et al. **Int J Cancer** 1996 Sep 27;68(1):67-74

Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines. Fellenberg J, et al. **Int J Cancer** 1997 Jul 29;72(3):536-42

Induction of apoptosis in androgen-independent mouse mammary cell line by 1, 25-dihydroxyvitamin D3. Furuya Y, et al. **Int J Cancer** 1996 Sep 27;68(1):143-8

Apoptosis in rat prostatic adenocarcinoma is associated with rapid infiltration of cytotoxic T-cells and activated macrophages. Landström M, et al. **Int J Cancer** 1997 May 2;71(3):451-5

Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)hydroxyphenyl]-2-naphtalene carboxylic acid (CD437). Oridate N, et al. **Int J Cancer** 1997 Feb 7;70(4):484-7

Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. Rozzo C, et al. **Int J Cancer** 1997 Mar 17;70(6):688-98

Stage-related differences of mitotic and apoptotic indices, and bcl-2 protein expression in diffusely growing non-Hodgkin's lymphomas. Spina D, et al. **Int J Cancer** 1996 Nov 15;68(4):436-40

A function in apoptosis other than transactivation inherent in the NH2-terminal domain of p53. Theis S, et al. **Int J Cancer** 1997 May 29;71(5):858-66

Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Toma S, et al. **Int J Cancer** 1997 Mar 4; 70(5):619-27

APOPTOSIS

Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Tu H, et al. **Int J Cancer** 1996 Oct 21;69(5):357-63

rIFN-gamma-activated rat neutrophils induce tumor cell apoptosis by nitric oxide. Uchida T, et al. **Int J Cancer** 1997 Apr 10;71(2):231-6

Chondrocytes of the tibial dyschondroplastic lesion are apoptotic. Praul CA, et al. **Int J Dev Biol** 1997 Aug; 41(4):621-6

Expression of Fas and apoptosis of a Hodgkin's disease cell line (HD-70) [letter] Kubonishi I, et al. **Int J Hematol** 1997 Apr;65(3):305-7

Redifferentiation and apoptosis of pancreatic cells during acute pancreatitis. Iovanna JL. **Int J Pancreatol** 1996 Oct; 20(2):77-84 (88 ref.)

The molecular regulation of apoptosis and implications for radiation oncology. Blank KR, et al. **Int J Radiat Biol** 1997 May;71(5):455-66 (106 ref.)

Persistent increase in the rates of apoptosis and dicentric chromosomes in surviving V79 cells after X-irradiation. Jamali M, et al. **Int J Radiat Biol** 1996 Dec;70(6):705-9

Heat-induced apoptosis and p53 in cultured mammalian cells. Nakano H, et al. **Int J Radiat Biol** 1997 May;71(5):519-29

Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. Komaki R, et al. **Int J Radiat Oncol Biol Phys** 1996 Oct 1;36(3):601-5

Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction. Saito Y, et al. **Int J Radiat Oncol Biol Phys** 1997 Jun 1; 38(3):623-31

Vitamin A and apoptosis in colonic tumor cells. Maziere S, et al. **Int J Vitam Nutr Res** 1997;67(4):237-41

Apoptosis and the B cell response to antigen. Tarlinton DM, et al. **Int Rev Immunol** 1997;15(1-2):53-71 (38 ref.)

Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases. Kamihira S, et al. **Intern Med** 1997 Mar;36(3):166-70

Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Adamus G, et al. **Invest Ophthalmol Vis Sci** 1997 Feb;38(2):283-91

Induction of apoptosis in cultured human retinal pigment epithelial cells is counteracted by flupirtine. Osborne NN, et al. **Invest Ophthalmol Vis Sci** 1997 Jun;38(7):1390-400

Apoptosis and cutaneous biology. Raskin CA. **J Am Acad Dermatol** 1997 Jun;36(6 Pt 1):885-96; quiz 897-8 (93 ref.)

Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. Nishigaki K, et al. **J Am Coll Cardiol** 1997 May;29(6):1214-20

Growth factors and apoptosis in neonatal ureteral obstruction. Chevalier RL. **J Am Soc Nephrol** 1996 Aug; 7(8):1098-105 (54 ref.)

Early effects of vasectomy on testicular structure and on germ cell and macrophage apoptosis in the hamster. Lue Y, et al. **J Androl** 1997 Mar-Apr;18(2):166-73

Heat stress causes testicular germ cell apoptosis in adult mice. Yin Y, et al. **J Androl** 1997 Mar-Apr;18(2):159-65

The penetration of autoantibodies into cells may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimmune disease by dysregulation and/or cell damage. Alarcón-Segovia D, et al. **J Autoimmun** 1996 Apr; 9(2):295-300

Programmed cell death in the pathogenesis of murine IDDM: resistance to apoptosis induced in lymphocytes by cyclophosphamide. Colucci F, et al. **J Autoimmun** 1996 Apr;9(2):271-6

Apoptosis of T cells and macrophages in the central nervous system of intact and adrenalectomized Lewis rats during experimental allergic encephalomyelitis. Smith T, et al. **J Autoimmun** 1996 Apr;9(2):167-74

Expression of the apoptosis-mediator Fas is enhanced by dysfunctional mitochondria. Asoh S, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):600-7

Mitochondrial implication in accidental and programmed cell death: apoptosis and necrosis. Zamzami N, et al. **J Bioenerg Biomembr** 1997 Apr;29(2):185-93 (75 ref.)

Bcl-2 and the outer mitochondrial membrane in the inactivation of cytochrome c during Fas-mediated apoptosis. Adachi S, et al. **J Biol Chem** 1997 Aug 29; 272(35):21878-82

The condensation of chromatin in apoptotic thymocytes shows a specific structural change. Allera C, et al. **J Biol Chem** 1997 Apr 18;272(16):10817-22

Constitutively active Galphaq and Galpha13 trigger apoptosis through different pathways. Althoefer H, et al. **J Biol Chem** 1997 Sep 26;272(39):24380-6

Induction of apoptosis by DPC4, a transcriptional factor regulated by transforming growth factor-beta through stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling pathway. Atfi A, et al. **J Biol Chem** 1997 Oct 3;272(40):24731-4

Glutathione levels and sensitivity to apoptosis are regulated by changes in transaldolase expression. Banki K, et al. **J Biol Chem** 1996 Dec 20;271(51):32994-3001

Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. Brenner B, et al. **J Biol Chem** 1997 Aug 29;272(35):22173-81

Characterization of a CD43/leukosialin-mediated pathway for inducing apoptosis in human T-lymphoblastoid cells. Brown TJ, et al. **J Biol Chem** 1996 Nov 1;271(44):27686-95

c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation. Butterfield L, et al. **J Biol Chem** 1997 Apr 11; 272(15):10110-6

IkappaB alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-kappaB activation but not tumor necrosis factor-alpha-induced apoptosis. Cai Z, et al. **J Biol Chem** 1997 Jan 3;272(1):96-101

Adenovirus E1B 19-kDa death suppressor protein interacts with Bax but not with Bad. Chen G, et al. **J Biol Chem** 1996 Sep 27;271(39):24221-5

Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. Chen L, et al. **J Biol Chem** 1997 Sep 5; 272(36):22966-73

Apoptotic activity of REAPER is distinct from signaling by the tumor necrosis factor receptor 1 death domain. Chen P, et al. **J Biol Chem** 1996 Oct 18;271(42):25735-7

Specific cleavage of alpha-fodrin during Fas- and tumor necrosis factor-induced apoptosis is mediated by an interleukin-1beta-converting enzyme/Ced-3 protease distinct from the poly(ADP-ribose) polymerase protease. Cryns VL, et al. **J Biol Chem** 1996 Dec 6;271(49):31277-82

Caspase-3-mediated cleavage of protein kinase C theta in induction of apoptosis. Datta R, et al. **J Biol Chem** 1997 Aug 15;272(33):20317-20

Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway. Day ML, et al. **J Biol Chem** 1997 Mar 28;272(13):8125-8

Functional dissection of the pro-apoptotic protein Bik. Heterodimerization with anti-apoptosis proteins is insufficient for induction of cell death. Elangovan B, et al. **J Biol Chem** 1997 Sep 26;272(39):24494-8

A novel link between REC2, a DNA recombinase, the retinoblastoma protein, and apoptosis. Fan G, et al. **J Biol Chem** 1997 Aug 1;272(31):19413-7

New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. Froelich CJ, et al. **J Biol Chem** 1996 Nov 15;271(46):29073-9

Selective involvement of ceramide in cytokine-induced apoptosis. Ceramide inhibits phorbol ester activation of nuclear factor kappaB. Gamard CJ, et al. **J Biol Chem** 1997 Jun 27;272(26):16474-81

Energy metabolism during apoptosis. Bcl-2 promotes survival in hematopoietic cells induced to apoptose by growth factor withdrawal by stabilizing a form of metabolic arrest. Garland JM, et al. **J Biol Chem** 1997 Feb 21;272(8):4680-8

CASH, a novel caspase homologue with death effector domains. Goltsev YV, et al. **J Biol Chem** 1997 Aug 8; 272(32):19641-4

Fas-induced apoptosis is mediated by activation of a Ras and Rac protein-regulated signaling pathway. Gulbins E, et al. **J Biol Chem** 1996 Oct 18;271(42):26389-94

DNA-dependent protein kinase is a target for a CPP32-like apoptotic protease. Han Z, et al. **J Biol Chem** 1996 Oct 4;271(40):25035-40

Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. Hollander MC, et al. **J Biol Chem** 1997 May 23;272(21):13731-7

Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. Horiuchi M, et al. **J Biol Chem** 1997 Jul 25;272(30):19022-6

Interferon regulatory factor-1 up-regulates angiotensin II type 2 receptor and induces apoptosis. Horiuchi M, et al. **J Biol Chem** 1997 May 2;272(18):11952-8

I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. Hu S, et al. **J Biol Chem** 1997 Jul 11;272(28):17255-7

Molecular cloning of a novel polypeptide, DP5, induced during programmed neuronal death. Imaizumi K, et al. **J Biol Chem** 1997 Jul 25;272(30):18842-8

Bcl-2 phosphorylation required for anti-apoptosis function. Ito T, et al. **J Biol Chem** 1997 May 2;272(18):11671-3

Transcription factor activation during signal-induced apoptosis of immature CD4(+)CD8(+) thymocytes. A protective role of c-Fos. Ivanov VN, et al. **J Biol Chem** 1997 Mar 28;272(13):8558-66

The apoptosis-inducing granulocyte-macrophage colony-stimulating factor (GM-CSF) analog E21R functions through specific regions of the heterodimeric GM-CSF receptor and requires interleukin-1beta-converting enzyme-like proteases. Iversen PO, et al. **J Biol Chem** 1997 Apr 11;272(15):9877-83

Mitogenic signaling and inhibition of apoptosis via the erythropoietin receptor Box-1 domain. Joneja B, et al. **J Biol Chem** 1997 Apr 25;272(17):11176-84

Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1. Karsan A, et al. **J Biol Chem** 1996 Nov 1;271(44):27201-4

Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. Kawasaki H, et al. **J Biol Chem** 1997 Jul 25;272(30):18518-21

Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. Kummer JL, et al. **J Biol Chem** 1997 Aug 15; 272(33):20490-4

Activation of caspase-2 in apoptosis. Li H, et al. **J Biol Chem** 1997 Aug 22;272(34):21010-7

Nuclear factor-kappaB is activated by hyperoxia but does not protect from cell death. Li Y, et al. **J Biol Chem** 1997 Aug 15;272(33):20646-9

Stress, apoptosis, and mitosis induce phosphorylation of human keratin 8 at Ser-73 in tissues and cultured cells. Liao J, et al. **J Biol Chem** 1997 Jul 11;272(28):17565-73

Endoplasmic reticulum chaperones GRP78 and calreticulin prevent oxidative stress, Ca2+ disturbances, and cell death in renal epithelial cells. Liu H, et al. **J Biol Chem** 1997 Aug 29;272(35):21751-9

The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis. Liu L, et al. **J Biol Chem** 1997 Apr 4;272(14):8983-8

Mouse lymphoma cells destined to undergo apoptosis in response to thapsigargin treatment fail to generate a calcium-mediated grp78/grp94 stress response. McCormick TS, et al. **J Biol Chem** 1997 Feb 28; 272(9):6087-92

Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity. Martin SJ, et al. **J Biol Chem** 1996 Nov 15;271(46):28753-6

Alterations in the catalytic activity of yeast DNA topoisomerase I result in cell cycle arrest and cell death. Megonigal MD, et al. **J Biol Chem** 1997 May 9; 272(19):12801-8

Evidence for CPP32 activation in the absence of apoptosis during T lymphocyte stimulation. Miossec C, et al. **J Biol Chem** 1997 May 23;272(21):13459-62

Native recombinant cyclophilins A, B, and C degrade DNA independently of peptidylprolyl cis-trans-isomerase activity. Potential roles of cyclophilins in apoptosis. Montague JW, et al. **J Biol Chem** 1997 Mar 7; 272(10):6677-84

Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. Murao K, et al. **J Biol Chem** 1997 Jul 11;272(28):17551-7

FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. Muzio M, et al. **J Biol Chem** 1997 Jan 31;272(5):2952-6

Identification of cytoplasmic actin as an abundant glutaminyl substrate for tissue transglutaminase in HL-60 and U937 cells undergoing apoptosis. Nemes Z Jr, et al. **J Biol Chem** 1997 Aug 15;272(33):20577-83

Requirement of the caspase-3/CPP32 protease cascade for apoptotic death following cytokine deprivation in hematopoietic cells. Ohta T, et al. **J Biol Chem** 1997 Sep 12;272(37):23111-6

Overexpression of a heterologous thymidine kinase delays apoptosis induced by factor deprivation and inhibitors of deoxynucleotide metabolism. Oliver FJ, et al. **J Biol Chem** 1997 Apr 18;272(16):10624-30

Bik and Bak induce apoptosis downstream of CrmA but upstream of inhibitor of apoptosis. Orth K, et al. **J Biol Chem** 1997 Apr 4;272(14):8841-4

Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. Párrizas M, et al. **J Biol Chem** 1997 Jan 3;272(1):154-61

Selective activation of caspases during apoptotic induction in HL-60 cells. Effects Of a tetrapeptide inhibitor. Polverino AJ, et al. **J Biol Chem** 1997 Mar 14; 272(11):7013-21

Intracellular calcium stores are not required for Bcl-2-mediated protection from apoptosis. Reynolds JE, et al. **J Biol Chem** 1996 Nov 1;271(44):27739-43

Apoptosis but not other activation events is inhibited by a mutation in the transmembrane domain of T cell receptor beta that impairs CD3zeta association. Rodríguez-Tarduchy G, et al. **J Biol Chem** 1996 Nov 29; 271(48):30417-25

Cell density-dependent apoptosis in HL-60 cells, which is mediated by an unknown soluble factor, is inhibited by transforming growth factor beta1 and overexpression of Bcl-2. Saeki K, et al. **J Biol Chem** 1997 Aug 8; 272(32):20003-10

The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells. Sakai I, et al. **J Biol Chem** 1997 May 9;272(19):12350-8

Ceramide-induced translocation of protein kinase C-delta and -epsilon to the cytosol. Implications in apoptosis. Sawai H, et al. **J Biol Chem** 1997 Jan 24;272(4):2452-8

Autocrine nitric oxide modulates CD95-induced apoptosis in gammadelta T lymphocytes. Sciorati C, et al. **J Biol Chem** 1997 Sep 12;272(37):23211-5

Recognition of phosphatidylserine on the surface of apoptotic spermatogenic cells and subsequent phagocytosis by Sertoli cells of the rat. Shiratsuchi A, et al. **J Biol Chem** 1997 Jan 24;272(4):2354-8

Bax homodimerization is not required for Bax to accelerate chemotherapy-induced cell death. Simonian PL, et al. **J Biol Chem** 1996 Dec 13;271(50):32073-7

Type I insulin-like growth factor receptor activation regulates apoptotic proteins. Singleton JR, et al. **J Biol Chem** 1996 Dec 13;271(50):31791-4

FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. Srinivasula SM, et al. **J Biol Chem** 1997 Jul 25;272(30):18542-5

The Ced-3/interleukin 1beta converting enzyme-like

homolog Mch6 and the lamin-cleaving enzyme Mch2alpha are substrates for the apoptotic mediator CPP32. Srinivasula SM, et al. **J Biol Chem** 1996 Oct 25; 271(43):27099-106

Induction of CPP32-like activity in PC12 cells by withdrawal of trophic support. Dissociation from apoptosis. Stefanis L, et al. **J Biol Chem** 1996 Nov 29;271(48):30663-71

Rapid attenuation of AP-1 transcriptional factors associated with nitric oxide (NO)-mediated neuronal cell death. Tabuchi A, et al. **J Biol Chem** 1996 Dec 6;271(49):31061-7

Apoxin I, a novel apoptosis-inducing factor with L-amino acid oxidase activity purified from Western diamondback rattlesnake venom. Torii S, et al. **J Biol Chem** 1997 Apr 4;272(14):9539-42

The large subunit of the DNA replication complex C (DSEB/RF-C140) cleaved and inactivated by caspase-3 (CPP32/YAMA) during Fas-induced apoptosis. Ubeda M, et al. **J Biol Chem** 1997 Aug 1;272(31):19562-8

Growth and survival signals transmitted via two distinct NPXY motifs within leukocyte tyrosine kinase, an insulin receptor-related tyrosine kinase. Ueno H, et al. **J Biol Chem** 1996 Nov 1;271(44):27707-14

Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. Vanags DM, et al. **J Biol Chem** 1996 Dec 6;271(49):31075-85

Fas-associated death domain protein interleukin-1beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling. Vincenz C, et al. **J Biol Chem** 1997 Mar 7;272(10):6578-83

Requirement of the familial Alzheimer's disease gene PS2 for apoptosis. Opposing effect of ALG-3. Vito P, et al. **J Biol Chem** 1996 Dec 6;271(49):31025-8

Heteronuclear ribonucleoproteins C1 and C2, components of the spliceosome, are specific targets of interleukin 1beta-converting enzyme-like proteases in apoptosis. Waterhouse N, et al. **J Biol Chem** 1996 Nov 15; 271(46):29335-41

Protein kinase CbetaII activation by 1-beta-D-arabinofuranosylcytosine is antagonistic to stimulation of apoptosis and Bcl-2alpha down-regulation. Whitman SP, et al. **J Biol Chem** 1997 Sep 19; 272(38):23481-4

Anti-immunoglobulin-induced apoptosis in WEHI 231 cells involves the slow formation of ceramide from sphingomyelin and is blocked by bcl-XL. Wiesner DA, et al. **J Biol Chem** 1997 Apr 11;272(15):9868-76

Interaction and regulation of the Caenorhabditis elegans death protease CED-3 by CED-4 and CED-9. Wu D, et al. **J Biol Chem** 1997 Aug 22;272(34):21449-54

The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. Yanagisawa J, et al. **J Biol Chem** 1997 Mar 28;272(13):8539-45

BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. Zha J, et al. **J Biol Chem** 1997 Sep 26;272(39):24101-4

Expression of neutral sphingomyelinase identifies a distinct pool of sphingomyelin involved in apoptosis. Zhang P, et al. **J Biol Chem** 1997 Apr 11;272(15):9609-12

Investigation of the potential role of membrane CD38 in protection against cell death induced by HIV-1. Savarino A, et al. **J Biol Regul Homeost Agents** 1996 Jan-Mar; 10(1):13-8

Apoptosis and proliferation of growth plate chondrocytes in rabbits. Aizawa T, et al. **J Bone Joint Surg Br** 1997 May;79(3):483-6

Induction of apoptotic cell death by direct-current treatment in human leukemic cell lines. Kurokawa M, et al. **J Cancer Res Clin Oncol** 1997;123(7):370-6

Apoptosis of human BEL-7402 hepatocellular carcinoma cells released by antisense H-ras DNA--in vitro and in vivo studies. Liao Y, et al. **J Cancer Res Clin Oncol** 1997; 123(1):25-33

Apoptosis, proliferative activity and Bcl-2 expression in Epstein-Barr-virus-positive non-Hodgkin's lymphomas. Takano Y, et al. **J Cancer Res Clin Oncol** 1997; 123(7):395-401

Characterization of senescence- and apoptosis-dependent forms of terminin as derived from a precursor found in replicating and nonreplicating cells. Wang E, et al. **J Cell Biochem** 1996 Jan;60(1):107-20

Strategies for manipulating apoptosis for cancer therapy with tumor necrosis factor and lymphotoxin. Wong GH, et al. **J Cell Biochem** 1996 Jan;60(1):56-60 (29 ref.)

Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. Alexander CM, et al. **J Cell Biol** 1996 Dec;135(6 Pt 1):1669-77

Dissecting processing and apoptotic activity of a cysteine protease by mutant analysis. Allet B, et al. **J Cell Biol** 1996 Oct;135(2):479-86

Bi-transgenic mice reveal that K-rasVal12 augments a p53-independent apoptosis when small intestinal villus enterocytes reenter the cell cycle. Coopersmith CM, et al. **J Cell Biol** 1997 Jul 14;138(1):167-79

Genetic and metabolic status of NGF-deprived sympathetic neurons saved by an inhibitor of ICE family proteases. Deshmukh M, et al. **J Cell Biol** 1996 Dec;135(5):1341-54

Presence of double-strand breaks with single-base 3' overhangs in cells undergoing apoptosis but not necrosis. Didenko VV, et al. **J Cell Biol** 1996 Dec;135(5):1369-76

A role for Jun-N-terminal kinase in anoikis; suppression by bcl-2 and crmA. Frisch SM, et al. **J Cell Biol** 1996 Dec; 135(5):1377-82

Inhibition of pp125FAK in cultured fibroblasts results in apoptosis. Hungerford JE, et al. **J Cell Biol** 1996 Dec; 135(5):1383-90

Androgen ablation leads to an upregulation and intranuclear accumulation of deoxyribonuclease I in rat prostate epithelial cells paralleling their apoptotic elimination. Rauch F, et al. **J Cell Biol** 1997 May 19;137(4):909-23

Influence of Bcl-2 overexpression on Na+/K(+)-ATPase pump activity: correlation with radiation-induced programmed cell death. Gilbert M, et al. **J Cell Physiol** 1997 Jun;171(3):299-304

Collagen phagocytosis and apoptosis are induced by high level alkaline phosphatase expression in rat fibroblasts. Hui MZ, et al. **J Cell Physiol** 1997 Sep;172(3):323-33

Apoptotic cell death in neuronal differentiation of P19 EC cells: cell death follows reentry into S phase. Ninomiya Y, et al. **J Cell Physiol** 1997 Jul;172(1):25-35

Apoptosis of W256 carcinosarcoma cells of the monocytoid origin induced by NDGA involves lipid peroxidation and depletion of GSH: role of 12-lipoxygenase in regulating tumor cell survival. Tang DG, et al. **J Cell Physiol** 1997 Aug;172(2):155-70

c-myc-Dependent hepatoma cell apoptosis results from oxidative stress and not a deficiency of growth factors. Xu Y, et al. **J Cell Physiol** 1997 Feb;170(2):192-9

Role of acid/base homeostasis in the suppression of apoptosis in haemopoietic cells by v-Abl protein tyrosine kinase. Chen Q, et al. **J Cell Sci** 1997 Feb;110 (Pt 3):379-87

Intracellular acidification induces apoptosis by stimulating ICE-like protease activity. Furlong IJ, et al. **J Cell Sci** 1997 Mar;110 (Pt 5):653-61

Down-regulation of actin genes precedes microfilament network disruption and actin cleavage during p53-mediated apoptosis. Guénal I, et al. **J Cell Sci** 1997 Feb;110 (Pt 4):489-95

Pathogen-induced programmed cell death in tobacco. Mittler R, et al. **J Cell Sci** 1997 Jun;110 (Pt 11):1333-44

EGF-R dependent regulation of keratinocyte survival. Rodeck U, et al. **J Cell Sci** 1997 Jan;110 (Pt 2):113-21

Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. Chopp M, et al. **J Cereb Blood Flow Metab** 1996 Jul; 16(4):578-84

Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. Bamberger AM, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3173-5

Testosterone regulates apoptosis in adult human seminiferous tubules in vitro. Erkkilä K, et al. **J Clin Endocrinol Metab** 1997 Jul;82(7):2314-21

Apoptosis in the human uterine endometrium during the menstrual cycle. Kokawa K, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4144-7

Lovastatin-induced apoptosis in prostate stromal cells. Padayatty SJ, et al. **J Clin Endocrinol Metab** 1997 May; 82(5):1434-9

Apoptosis of human corpora lutea during cyclic luteal regression and early pregnancy. Shikone T, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2376-80

The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. Tomkinson A, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3128-35

Programmed cell death in human ovary is a function of follicle and corpus luteum status. Yuan W, et al. **J Clin Endocrinol Metab** 1997 Sep;82(9):3148-55

The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. Aupeix K, et al. **J Clin Invest** 1997 Apr 1; 99(7):1546-54

Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. Boirivant M, et al. **J Clin Invest** 1996 Dec 1;98(11):2616-22

Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. Broaddus VC, et al. **J Clin Invest** 1996 Nov 1;98(9):2050-9

Priming of human CD4+ antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. A two-step mechanism involving the gp120 molecule. Cottrez F, et al. **J Clin Invest** 1997 Jan 15;99(2):257-66

Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. Del Bufalo D, et al. **J Clin Invest** 1996 Sep 1;98(5):1165-73

Extracellular deposition of beta-amyloid upon p53-dependent neuronal cell death in transgenic mice. LaFerla FM, et al. **J Clin Invest** 1996 Oct 1;98(7):1626-32

A program of cell death and extracellular matrix degradation is activated in the amnion before the onset of labor [see comments] Lei H, et al. **J Clin Invest** 1996 Nov 1; 98(9):1971-8. Comment in: J Clin Invest 1996 Nov 1;98(9):1971-8.

p53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes. Long X, et al. **J Clin Invest** 1997 Jun 1;99(11):2635-43

Soluble factor(s) produced by adult bone marrow stroma inhibit in vitro proliferation and differentiation of fetal liver BFU-E by inducing apoptosis. Roy V, et al. **J Clin Invest** 1997 Aug 15;100(4):912-20

Apoptosis induced by HIV-1 infection of the central nervous system. Shi B, et al. **J Clin Invest** 1996 Nov 1;98(9):1979-90

Transient cerebral ischemia. Association of apoptosis induction with hypoperfusion. Vexler ZS, et al. **J Clin Invest** 1997 Mar 15;99(6):1453-9

Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. Wada J, et al. **J Clin Invest** 1997 May 15;99(10):2452-61

Perspectives series: host/pathogen interactions. Apoptosis in bacterial pathogenesis. Zychlinsky A, et al. **J Clin Invest** 1997 Aug 1;100(3):493-5 (44 ref.)

Protease-defective, gp120-containing human immunodeficiency virus type 1 particles induce apoptosis more efficiently than does wild-type virus or recombinant gp120 protein in healthy donor-derived peripheral blood T cells. Kameoka M, et al. **J Clin Microbiol** 1997 Jan; 35(1):41-7

Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. Colecchia M, et al. **J Clin Pathol** 1997 May;50(5):384-8

Apoptosis in haematological malignancies. DiGiuseppe JA, et al. **J Clin Pathol** 1997 May;50(5):361-4

Excitotoxic neuronal death in the immature brain is an apoptosis-necrosis morphological continuum. Portera-Cailliau C, et al. **J Comp Neurol** 1997 Feb 3; 378(1):70-87

Non-NMDA and NMDA receptor-mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: further evidence for an apoptosis-necrosis continuum. Portera-Cailliau C, et al. **J Comp Neurol** 1997 Feb 3; 378(1):88-104

Apoptosis in lymph nodes in acute African swine fever. Carrasco L, et al. **J Comp Pathol** 1996 Nov;115(4):415-28

Growth of Newcastle disease virus in chicken macrophages. Lam KM. **J Comp Pathol** 1996 Oct;115(3):253-63

Newcastle disease virus-induced apoptosis in the peripheral blood mononuclear cells of chickens. Lam KM. **J Comp Pathol** 1996 Jan;114(1):63-71

Morphological evidence of apoptosis in chickens infected with infectious bursal disease virus. Lam KM. **J Comp Pathol** 1997 May;116(4):367-77

Apoptotic cell death of neutrophils in development of skin lesions of patients with anaphylactoid purpura. Banno S, et al. **J Dermatol** 1997 Feb;24(2):94-9

Immunohistochemical studies of basement membrane proteins and proliferation and apoptosis markers in sulfur mustard induced cutaneous lesions in weanling pigs. Smith KJ, et al. **J Dermatol Sci** 1997 Sep;15(3):173-82

Induction of apoptosis in rat thecal/interstitial cells by transforming growth factor alpha plus transforming growth factor beta in vitro. Foghi A, et al. **J Endocrinol** 1997 Apr; 153(1):169-78

Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. Badley AD, et al. **J Exp Med** 1997 Jan 6;185(1):55-64

Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-alpha: CrmA and Bcl-2 target distinct components in the apoptotic pathway. Dbaibo GS, et al. **J Exp Med** 1997 Feb 3;185(3):481-90

Microglia induce CD4 T lymphocyte final effector function and death. Ford AL, et al. **J Exp Med** 1996 Nov 1; 184(5):1737-45

Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis. Ghayur T, et al. **J Exp Med** 1996 Dec 1; 184(6):2399-404

Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. Gilligan HM, et al. **J Exp Med** 1996 Dec 1;184(6):2231-41

An apoptosis-inducing isoform of neu differentiation factor (NDF) identified using a novel screen for dominant, apoptosis-inducing genes. Grimm S, et al. **J Exp Med** 1997 Mar 17;185(6):1137-42

A new mouse gene, SRG3, related to the SWI3 of Saccharomyces cerevisiae, is required for apoptosis induced by glucocorticoids in a thymoma cell line. Jeon SH, et al. **J Exp Med** 1997 May 19;185(10):1827-36

Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. Kiener PA, et al. **J Exp Med** 1997 Apr 21;185(8):1511-6

Germinal center founder cells display propensity for apoptosis before onset of somatic mutation. Lebecque S, et al. **J Exp Med** 1997 Feb 3;185(3):563-71

Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. Leist M, et al. **J Exp Med** 1997 Apr 21;185(8):1481-6

Mitochondrial permeability transition is a central coordinating event of apoptosis. Marchetti P, et al. **J Exp Med** 1996 Sep 1;184(3):1155-60

Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. Perillo NL, et al. **J Exp Med** 1997 May 19;185(10):1851-8

Different interleukin-1 beta converting enzyme (ICE) family protease requirements for the apoptotic death of T lymphocytes triggered by diverse stimuli. Sarin A, et al. **J Exp Med** 1996 Dec 1;184(6):2445-50

Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. Shi L, et al. **J Exp Med** 1997 Mar 3; 185(5):855-66

APOPTOSIS

A regulatory role for TRAF1 in antigen-induced apoptosis of T cells. Speiser DE, et al. **J Exp Med** 1997 May 19; 185(10):1777–83

Apoptosis of Fashigh CD4+ synovial T cells by borrelia-reactive Fas-ligand(high) gamma delta T cells in Lyme arthritis. Vincent MS, et al. **J Exp Med** 1996 Dec 1;184(6):2109–17

Rescue of thymocytes from glucocorticoid-induced cell death mediated by CD28/CTLA-4 costimulatory interactions with B7-1/B7-2. Wagner DH Jr, et al. **J Exp Med** 1996 Nov 1;184(5):1631–8

Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. Wang J, et al. **J Exp Med** 1996 Sep 1;184(3):831–8

Role of tyrosine phosphorylation of HS1 in B cell antigen receptor-mediated apoptosis. Yamanashi Y, et al. **J Exp Med** 1997 Apr 7;185(7):1387–92

Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. Zhang X, et al. **J Exp Med** 1997 May 19; 185(10):1837–49

p53, apoptosis and human cancers. Wang TH, et al. **J Formos Med Assoc** 1996 Jul;95(7):509–22 (151 ref.)

Identification of apoptotic hepatocytes in situ in rat liver after lead nitrate administration. Nakajima T, et al. **J Gastroenterol** 1995 Dec;30(6):725–30

Apoptosis of acinar cells in rat pancreatic duct ligation. Wada M, et al. **J Gastroenterol** 1995 Dec;30(6):813–4

The role of apoptosis in intestinal disease. Watson AJ. **J Gastroenterol** 1997 Jun;32(3):414–23 (100 ref.)

Productive replication of caprine arthritis-encephalitis virus is associated with induction of apoptosis. Gendelman R, et al. **J Gen Virol** 1997 Apr;78 (Pt 4):801–5

A highly cytopathogenic influenza C virus variant induces apoptosis in cell culture. Hechtfischer A, et al. **J Gen Virol** 1997 Jun;78 (Pt 6):1327–30

Apoptosis of cord blood T lymphocytes by herpes simplex virus type 1. Ito M, et al. **J Gen Virol** 1997 Aug;78 (Pt 8):1971–5

Apoptosis: a mechanism of cell killing and lymphoid organ impairment during acute African swine fever virus infection. Ramiro-Ibáñez F, et al. **J Gen Virol** 1996 Sep; 77 (Pt 9):2209–19

Bovine leukaemia virus-induced lymphocytosis in sheep is associated with reduction of spontaneous B cell apoptosis. Schwartz-Cornil I, et al. **J Gen Virol** 1997 Jan;78 (Pt 1):153–62

Identification of programmed cell death (apoptosis) in situ by means of specific labeling of nuclear DNA fragments in heart biopsy samples during acute rejection episodes. Laguens RP, et al. **J Heart Lung Transplant** 1996 Sep; 15(9):911–8

Liver apoptosis. Feldmann G. **J Hepatol** 1997;26 Suppl 2:1–11 (117 ref.)

Apoptosis in liver disease. Galle PR. **J Hepatol** 1997 Aug; 27(2):405–12 (87 ref.)

The apoptosis protector, bcl-2 protein, is downregulated in bile duct epithelial cells of human liver allografts. Gapany C, et al. **J Hepatol** 1997 Mar;26(3):535–42

Major DNA fragmentation is a late event in apoptosis. Collins JA, et al. **J Histochem Cytochem** 1997 Jul;45(7):923–34

Demonstration of apoptotic cells in tissue sections by in situ hybridization using digoxigenin-labeled poly(A) oligonucleotide probes to detect thymidine-rich DNA sequences. Hilton DA, et al. **J Histochem Cytochem** 1997 Jan;45(1):13–20

Differential staining of apoptotic nuclei in living cells: application to macronuclear elimination in Tetrahymena. Mpoke SS, et al. **J Histochem Cytochem** 1997 May; 45(5):675–83

In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. Negoescu A, et al. **J Histochem Cytochem** 1996 Sep; 44(9):959–68

Phagocytotic processing of apoptotic bodies of transitional ameloblasts by MHC Class II-expressing macrophages in rat incisor. Nishikawa S, et al. **J Histochem Cytochem** 1996 Dec;44(12):1459–67

Apoptosis and proliferation of fibroblasts during postnatal skin development and scleroderma in the tight-skin mouse. Pablos JL, et al. **J Histochem Cytochem** 1997 May; 45(5):711–9

Chromatin condensation in erythropoiesis resolved by multipixel spectral imaging: differentiation versus apoptosis. Rothmann C, et al. **J Histochem Cytochem** 1997 Aug;45(8):1097–108

Automated double labeling of proliferation and apoptosis in glutathione S-transferase-positive hepatocytes in rats. Short BG, et al. **J Histochem Cytochem** 1997 Sep; 45(9):1299–305

Simultaneous in situ detection of mRNA and apoptotic cells by combined hybridization and TUNEL. Sträter J, et al. **J Histochem Cytochem** 1996 Dec;44(12):1497–9

The time window of apoptosis: a new component in the therapeutic strategy for cardiovascular remodeling. Hamet P, et al. **J Hypertens Suppl** 1996 Dec;14(5):S65–70 (38 ref.)

T cell antigen receptor-induced IL-2 production and apoptosis have different requirements for Lck activities. Chung CD, et al. **J Immunol** 1997 Aug 15;159(4):1758–66

Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages. Fratazzi C, et al. **J Immunol** 1997 May 1;158(9):4320–7

The avian chB6 (Bu-1) alloantigen can mediate rapid cell death. Funk PE, et al. **J Immunol** 1997 Aug 15; 159(4):1695–702

Lck is necessary and sufficient for Fas-ligand expression and apoptotic cell death in mature cycling T cells. Gonzalez-Garcia A, et al. **J Immunol** 1997 May 1; 158(9):4104–12

Heat shock protein 65 induced by gammadelta T cells prevents apoptosis of macrophages and contributes to host defense in mice infected with Toxoplasma gondii. Hisaeda H, et al. **J Immunol** 1997 Sep 1;159(5):2375–81

C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. Korb LC, et al. **J Immunol** 1997 May 15;158(10):4525–8

Rapid commitment to negative selection of a thymocyte line independent of CD4 co-engagement. Kovalik JP, et al. **J Immunol** 1996 Dec 15;157(12):5290–9

Apoptosis during B lymphopoiesis in mouse bone marrow. Lu L, et al. **J Immunol** 1997 Jun 1;158(11):5136–45

Glutathione depletion is an early and calcium elevation is a late event of thymocyte apoptosis. Macho A, et al. **J Immunol** 1997 May 15;158(10):4612–9

Expression and role in apoptosis of the alpha- and beta-chains of the IFN-gamma receptor on human Th1 and Th2 clones. Novelli F, et al. **J Immunol** 1997 Jul 1; 159(1):206–13

Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. Qian S, et al. **J Immunol** 1997 May 15;158(10):4654–61

The balance between nitric oxide and superoxide determines apoptotic and necrotic death of rat mesangial cells. Sandau K, et al. **J Immunol** 1997 May 15;158(10):4938–46

Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. Simon HU, et al. **J Immunol** 1997 Apr 15;158(8):3902–8

Calpain, an upstream regulator of thymocyte apoptosis. Squier MK, et al. **J Immunol** 1997 Apr 15;158(8):3690–7

Adenosine A2a receptor activation delays apoptosis in human neutrophils. Walker BA, et al. **J Immunol** 1997 Mar 15; 158(6):2926–31

Activation of the aryl hydrocarbon receptor/transcription factor and bone marrow stromal cell-dependent preB cell apoptosis. Yamaguchi K, et al. **J Immunol** 1997 Mar 1; 158(5):2165–73

A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. Zhang C, et al. **J Immunol** 1996 Nov 1;157(9):3980–7

The use of Apostain in identifying early apoptosis. Ferlini C, et al. **J Immunol Methods** 1997 Jun 23;205(1):95–101

Tumor necrosis factor-alpha contributes to apoptosis in hippocampal neurons during experimental group B streptococcal meningitis. Bogdan I, et al. **J Infect Dis** 1997 Sep;176(3):693–7

Clinical isolates of Shigella species induce apoptosis in macrophages. Guichon A, et al. **J Infect Dis** 1997 Feb; 175(2):470–3

A role for apoptosis in the pathogenesis of AIDS-related idiopathic esophageal ulcers. Houghton JM, et al. **J Infect Dis** 1997 May;175(5):1216–9

Herpes simplex virus type 1 induces apoptosis in peripheral blood T lymphocytes. Ito M, et al. **J Infect Dis** 1997 May; 175(5):1220–4

Apoptosis is the predominant form of epithelial target cell injury in acute experimental graft-versus-host disease. Gilliam AC, et al. **J Invest Dermatol** 1996 Sep; 107(3):377–83

Apoptosis and in vivo distribution and clearance of eosinophils in normal and Trichinella spiralis-infected rats. Gon S, et al. **J Leukoc Biol** 1997 Sep;62(3):309–17

Infection by Candida albicans inhibits apoptosis of human monocytes and monocytic U937 cells. Heidenreich S, et al. **J Leukoc Biol** 1996 Dec;60(6):737–43

Monocytic differentiation modulates apoptotic response to cytotoxic anti-Fas antibody and tumor necrosis factor alpha in human monoblast U937 cells. Kikuchi H, et al. **J Leukoc Biol** 1996 Dec;60(6):778–83

Coupling of neutrophil apoptosis to recognition by macrophages: coordinated acceleration by protein synthesis inhibitors. Whyte MK, et al. **J Leukoc Biol** 1997 Aug; 62(2):195–202

Saturated but not mono-unsaturated fatty acids induce apoptotic cell death in neonatal rat ventricular myocytes. de Vries JE, et al. **J Lipid Res** 1997 Jul;38(7):1384–94

Membrane changes associated with the early stages of apoptosis in HEp-2 cells decrease susceptibility to adherence by Candida albicans. Cotter G, et al. **J Med Vet Mycol** 1997 May-Jun;35(3):219–24

Induction of apoptosis in HT-29 cells infected with SA-11 rotavirus. Superti F, et al. **J Med Virol** 1996 Dec; 50(4):325–34

Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. Olivetti G, et al. **J Mol Cell Cardiol** 1996 Sep;28(9):2005–16

Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. Spyridopoulos I, et al. **J Mol Cell Cardiol** 1997 May;29(5):1321–30

You say tomato and I say tomahto: getting a handle on pronouncing apoptosis [letter] [see comments] Longo DL. **J Natl Cancer Inst** 1997 May 7;89(9):657. Comment in: J Natl Cancer Inst 1997 Jul 2;89(13):970.

Re: you say tomato and I say tomahto: getting a handle on pronouncing apoptosis [letter; comment] Sternberg SS. **J Natl Cancer Inst** 1997 Jul 2;89(13):970. Comment on: J Natl Cancer Inst 1997 May 7;89(9):657.

Mechanisms of cell death in Alzheimer's disease. Bancher C, et al. **J Neural Transm Suppl** 1997;50:141–52

Cell death in prion disease. Kretzschmar HA, et al. **J Neural Transm Suppl** 1997;50:191–210 (72 ref.)

Central nervous system cytokines and their relevance for neurotoxicity and apoptosis. Licinio J. **J Neural Transm Suppl** 1997;49:169–75 (28 ref.)

Apoptosis in neurodegenerative disorders. Mochizuki H, et al. **J Neural Transm Suppl** 1997;50:125–40

Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. Tatton WG, et al. **J Neural Transm Suppl** 1997;49:245–68 (156 ref.)

Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease? Ziv I, et al. **J Neural Transm Suppl** 1997;49:195–202 (21 ref.)

Sexually dimorphic neuron addition to an avian song-control region is not accounted for by sex differences in cell death. Burek MJ, et al. **J Neurobiol** 1997 Jul;33(1):61–71

Target muscles and sensory afferents do not influence steroid-regulated, segment-specific death of identified motoneurons in Manduca sexta. Lubischer JL, et al. **J Neurobiol** 1996 Dec;31(4):449–60

Aberrant expression of c-Fos accompanies photoreceptor cell death in the rd mouse. Rich KA, et al. **J Neurobiol** 1997 Jun 5;32(6):593–612

Amyloid beta-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. Blanc EM, et al. **J Neurochem** 1997 May;68(5):1870–81

Apoptosis induced by differentiation or serum deprivation in an immortalized central nervous system neuronal cell line. Eves EM, et al. **J Neurochem** 1996 Nov;67(5):1908–20

Two types of apoptotic cell death of rat central nervous system-derived neuroblastoma B50 and B104 cells: apoptosis induced during proliferation and after differentiation. Honma N, et al. **J Neurochem** 1996 Nov; 67(5):1856–65

Apoptosis induced via AMPA-selective glutamate receptors in cultured murine cortical neurons. Larm JA, et al. **J Neurochem** 1997 Aug;69(2):617–22

Cyclosporin A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor. Mosieniak G, et al. **J Neurochem** 1997 Mar;68(3):1142–9

Apoptosis of retinal photoreceptors during development in vitro: protective effect of docosahexaenoic acid. Rotstein NP, et al. **J Neurochem** 1997 Aug;69(2):504–13

Is differential regulation of mitochondrial transcripts in Parkinson's disease related to apoptosis? Ruberg M, et al. **J Neurochem** 1997 May;68(5):2098–110

Comparison between the timing of JNK activation, c-Jun phosphorylation, and onset of death commitment in sympathetic neurones. Virdee K, et al. **J Neurochem** 1997 Aug;69(2):550–61

Changes in the activity and mRNA levels of phospholipase D during ceramide-induced apoptosis in rat C6 glial cells. Yoshimura S, et al. **J Neurochem** 1997 Aug;69(2):713–20

Apoptotic cell death of photoreceptor cells in mice deficient for the adhesion molecule on glia (AMOG, the beta 2-subunit of the Na, K-ATPase). Molthagen M, et al. **J Neurocytol** 1996 Apr;25(4):243–55

The apoptotic death of neuroblastoma cells caused by serum from patients with insulin-dependent diabetes and neuropathy may be Fas-mediated. Pittenger GL, et al. **J Neuroimmunol** 1997 Jun;76(1-2):153–60

6-Hydroxydopamine induces thymocyte apoptosis in mice. Tsao CW, et al. **J Neuroimmunol** 1996 Apr;65(2):91–5

Cell death and birth in multiple sclerosis brain. Dowling P, et al. **J Neurol Sci** 1997 Jul;149(1):1–11

Granule cell apoptosis and protein expression in hippocampal dentate gyrus after forebrain ischemia in the rat. Li Y, et al. **J Neurol Sci** 1997 Sep 10;150(2):93–102

Apoptosis of V beta 8.2+ T lymphocytes in the spinal cord during recovery from experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. McCombe PA, et al. **J Neurol Sci** 1996 Jul;139(1):1–6

Evidence of apoptosis in neuroblastoma at onset and relapse. An analysis of a large series of tumors. Tonini GP, et al. **J Neurooncol** 1997 Jan;31(1-2):209–15

Adenovirus-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. Li H, et al. **J Neuropathol Exp Neurol** 1997 Aug;56(8):872–8

Quantifying apoptosis in banked human brains using flow cytometry. Olano JP, et al. **J Neuropathol Exp Neurol** 1996 Nov;55(11):1164–72

Exercise induces myonuclear ubiquitination and apoptosis in dystrophin-deficient muscle of mice. Sandri M, et al. **J Neuropathol Exp Neurol** 1997 Jan;56(1):45–57

Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. Su JH, et al.

J Neuropathol Exp Neurol 1997 Jan;56(1):86–93
DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. Anderson AJ, et al. **J Neurosci** 1996 Mar 1;16(5):1710–9
TGF-beta-induced apoptosis of cerebellar granule neurons is prevented by depolarization. de Luca A, et al. **J Neurosci** 1996 Jul 1;16(13):4174–85
Axonal transport blockade in the neonatal rat optic nerve induces limited retinal ganglion cell death. Fagiolini M, et al. **J Neurosci** 1997 Sep 15;17(18):7045–52
Axonal interactions regulate Schwann cell apoptosis in developing peripheral nerve: neuregulin receptors and the role of neuregulins. Grinspan JB, et al. **J Neurosci** 1996 Oct 1;16(19):6107–18
Transgenic mice expressing the intracellular domain of the p75 neurotrophin receptor undergo neuronal apoptosis. Majdan M, et al. **J Neurosci** 1997 Sep 15;17(18):6988–98
Apoptosis of bcl-x-deficient telencephalic cells in vitro. Roth KA, et al. **J Neurosci** 1996 Mar 1;16(5):1753–8
Bcl-2 expression in neural cells blocks activation of ICE/CED-3 family proteases during apoptosis. Srinivasan A, et al. **J Neurosci** 1996 Sep 15;16(18):5654–60
Apoptosis and its relation to the cell cycle in the developing cerebral cortex. Thomaidou D, et al. **J Neurosci** 1997 Feb 1;17(3):1075–85
Target and afferents interact to control developmental cell death in the mesencephalic parabigeminal nucleus of the rat. Piñón LG, et al. **J Neurosci Res** 1996 Jul 15; 45(2):174–82
Increased surface phosphatidylserine is an early marker of neuronal apoptosis. Rimon G, et al. **J Neurosci Res** 1997 Jun 15;48(6):563–70
MPP+ induced apoptotic cell death in SH-SY5Y neuroblastoma cells: an electron microscope study. Sheehan JP, et al. **J Neurosci Res** 1997 May 1;48(3):226–37
Apoptosis of human glioma cells in vitro and in vivo induced by a neutralizing antibody against human basic fibroblast growth factor. Murai N, et al. **J Neurosurg** 1996 Dec; 85(6):1072–7
Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. Schrell UM, et al. **J Neurosurg** 1997 May;86(5):845–52
Relationship of decreased chemotaxis of technetium-99m-HMPAO-labeled lymphocytes to apoptosis. Van de Wiele C, et al. **J Nucl Med** 1997 Sep; 38(9):1417–21
Apoptosis-associated markers in oral lichen planus. Dekker NP, et al. **J Oral Pathol Med** 1997 Apr;26(4):170–5
Apoptosis in operated small cell lung carcinoma is inversely related to tumour necrosis and p53 immunoreactivity. Eerola AK, et al. **J Pathol** 1997 Feb;181(2):172–7
Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. Hammond LJ, et al. **J Pathol** 1997 Jun;182(2):138–44
Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki-67 and bcl-2 expression and of in situ end labelling (TUNEL). Hellquist HB, et al. **J Pathol** 1997 Mar;181(3):323–9
Apoptosis of crypt epithelial cells in ulcerative colitis. Iwamoto M, et al. **J Pathol** 1996 Oct;180(2):152–9
High frequency of apoptosis in infantile capillary haemangioma. Iwata J, et al. **J Pathol** 1996 Aug; 179(4):403–8
Ultrastructural and confocal laser scanning microscopic examination of TUNEL-positive cells. Kimura K, et al. **J Pathol** 1997 Feb;181(2):235–42
Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c-myc and bcl-2 protein products. Langlois NE, et al. **J Pathol** 1997 Aug;182(4):392–7
Apoptosis in autoimmune and non-autoimmune thyroid disease [editorial] Ludgate M, et al. **J Pathol** 1997 Jun; 182(2):123–4
Apoptosis of human monocytes/macrophages in Mycobacterium tuberculosis infection. Placido R, et al. **J Pathol** 1997 Jan;181(1):31–8
Apoptosis and transmethylation metabolites in HL-60 cells. Endresen PC, et al. **J Pharmacol Exp Ther** 1996 Sep; 278(3):1318–24
Morphological and biochemical characterization and analysis of apoptosis. Allen RT, et al. **J Pharmacol Toxicol Methods** 1997 Jun;37(4):215–28 (68 ref.)
Zinc and DNA fragmentation in keratinocyte apoptosis: its inhibitory effect in UVB irradiated cells. Parat MO, et al. **J Photochem Photobiol B** 1997 Jan;37(1–2):101–6
An apoptotic response to photodynamic therapy with endogenous protoporphyrin in vivo. Webber J, et al. **J Photochem Photobiol B** 1996 Sep;35(3):209–11
Quantitative analysis of apoptosis and bcl-2 in Sjögren's syndrome. Manganelli P, et al. **J Rheumatol** 1997 Aug; 24(8):1552–7
Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts. Matsumoto S, et al. **J Rheumatol** 1996 Aug;23(8):1345–52
Apoptosis occurs in endothelial cells during hypertension-induced microvascular rarefaction. Gobé G, et al. **J Struct Biol** 1997 Feb;118(1):63–72
Apoptotic cells in peripheral blood from patients with low serum cobalamin. Bunting RW, et al. **J Submicrosc Cytol Pathol** 1997 Apr;29(2):223–7
Factors responsible for peritoneal granulocyte apoptosis during sepsis. Ayala A, et al. **J Surg Res** 1997 Apr; 69(1):67–75
Ischemia-reperfusion injury on the pancreas in rats: identification of acinar cell apoptosis. Fujimoto K, et al. **J Surg Res** 1997 Aug;71(2):127–36
Adenoviral transfection of isolated pancreatic islets: a study of programmed cell death (apoptosis) and islet function. Weber M, et al. **J Surg Res** 1997 Apr;69(1):23–32
Inducible macrophage apoptosis following sepsis is mediated by cysteine protease activation and nitric oxide release. Williams TE, et al. **J Surg Res** 1997 Jul 1;70(2):113–8
Mechanism of intestinal mucosal immune dysfunction following trauma-hemorrhage: increased apoptosis associated with elevated Fas expression in Peyer's patches. Xu YX, et al. **J Surg Res** 1997 Jun;70(1):55–60
Trauma-hemorrhage induces increased thymic apoptosis while decreasing IL-3 release and increasing GM-CSF. Xu YX, et al. **J Surg Res** 1997 Feb 15;68(1):24–30
Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation [see comments] Cardillo M, et al. **J Urol** 1997 Jul;158(1):212–6 . Comment in: J Urol 1997 Jul;158(1):2–3.
This month in investigative urology. Apoptosis and benign prostatic hypertrophy [comment] Gomella LG, et al. **J Urol** 1997 Jul;158(1):2–3. Comment on: J Urol 1997 Jul;158(1):212–6. Comment on: J Urol 1997 Jul;158(1):217–21.
Apoptosis in the rat penis after penile denervation. Klein LT, et al. **J Urol** 1997 Aug;158(2):626–30
Apoptosis in transitional cell carcinoma of the renal pelvis and ureter: association with proliferative activity, bcl-2 expression and prognosis. Masuda M, et al. **J Urol** 1997 Sep;158(3 Pt 1):750–3
Apoptosis-like cell death in experimentally-induced cryptorchidism in adult mice. Ito K, et al. **J Vet Med Sci** 1997 May;59(5):353–9
Macrophages infected with cytopathic bovine viral diarrhea virus release a factor(s) capable of priming uninfected macrophages for activation-induced apoptosis. Adler B, et al. **J Virol** 1997 Apr;71(4):3255–8
Rhabdovirus-induced apoptosis in a fish cell line is inhibited by a human endogenous acid cysteine proteinase inhibitor. Björklund HV, et al. **J Virol** 1997 Jul;71(7):5658–62
Glycoprotein Erns of pestiviruses induces apoptosis in lymphocytes of several species. Bruschke CJ, et al. **J Virol** 1997 Sep;71(9):6692–6
Identification of a novel antiapoptotic protein, GAM-1, encoded by the CELO adenovirus. Chiocca S, et al. **J Virol** 1997 Apr;71(4):3168–77
p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. Chiou SK, et al. **J Virol** 1997 May;71(5):3515–25
Identification of a novel antiapoptotic functional domain in simian virus 40 large T antigen. Conzen SD, et al. **J Virol** 1997 Jun;71(6):4536–43
Responses of insect cells to baculovirus infection: protein synthesis shutdown and apoptosis. Du X, et al. **J Virol** 1997 Oct;71(10):7866–72
The major antigenic protein of infectious bursal disease virus, VP2, is an apoptotic inducer. Fernández-Arias A, et al. **J Virol** 1997 Oct;71(10):8014–8
Expression of the Autographa californica nuclear polyhedrosis virus apoptotic suppressor gene p35 in nonpermissive Spodoptera littoralis cells. Gershburg E, et al. **J Virol** 1997 Oct;71(10):7593–9
Induction of T-cell apoptosis by human herpesvirus 6. Inoue Y, et al. **J Virol** 1997 May;71(5):3751–9
Apoptosis plays an important role in experimental rabies virus infection. Jackson AC, et al. **J Virol** 1997 Jul;71(7):5603–7
Theiler's murine encephalomyelitis virus kills restrictive but not permissive cells by apoptosis. Jelachich ML, et al. **J Virol** 1996 Oct;70(10):6856–61
Epstein-Barr virus BHRF1 protein protects intestine 407 epithelial cells from apoptosis induced by tumor necrosis factor alpha and anti-Fas antibody. Kawanishi M. **J Virol** 1997 Apr;71(4):3319–22
Role of early and late replication events in induction of apoptosis by baculoviruses. LaCount DJ, et al. **J Virol** 1997 Feb;71(2):1530–7
Effect of enforced expression of human bcl-2 on Japanese encephalitis virus-induced apoptosis in cultured cells. Liao CL, et al. **J Virol** 1997 Aug;71(8):5963–71
Baculovirus inhibitor of apoptosis functions at or upstream of the apoptotic suppressor P35 to prevent programmed cell death. Manji GA, et al. **J Virol** 1997 Jun;71(6):4509–16
Dengue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death. Marianneau P, et al. **J Virol** 1997 Apr;71(4):3244–9
Induction of apoptosis by La Crosse virus infection and role of neuronal differentiation and human bcl-2 expression in its prevention. Pekosz A, et al. **J Virol** 1996 Aug; 70(8):5329–35
bcl-2 acts early to restrict Semliki Forest virus replication and delays virus-induced programmed cell death. Scallan MF, et al. **J Virol** 1997 Feb;71(2):1583–90
Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. Stewart SA, et al. **J Virol** 1997 Jul;71(7):5579–92
Regulation of p53-dependent apoptosis, transcriptional repression, and cell transformation by phosphorylation of the 55-kilodalton E1B protein of human adenovirus type 5. Teodoro JG, et al. **J Virol** 1997 May;71(5):3620–7
Rabies virus infects mouse and human lymphocytes and induces apoptosis. Thoulouze MI, et al. **J Virol** 1997 Oct; 71(10):7372–80
Importance of the Ser-132 phosphorylation site in cell transformation and apoptosis induced by the adenovirus type 5 E1A protein. Whalen SG, et al. **J Virol** 1996 Aug; 70(8):5373–83
Induction of p53-independent apoptosis associated with G2M arrest following DNA damage in human colon cancer cell lines. Arita D, et al. **Jpn J Cancer Res** 1997 Jan;88(1):39–43
Expression of Fas antigen and its mediation of apoptosis in human gastric cancer cell lines. Hayashi H, et al. **Jpn J Cancer Res** 1997 Jan;88(1):49–55
Features of DNA oligonucleosomal fragmentation in human tumor cell lines and its detection by flow cytometry: utility and limitations. Kikuchi H, et al. **Jpn J Cancer Res** 1997 Jan;88(1):56–63
Suppressed apoptotic induction in esophageal squamous cell carcinomas expressing extensive p53 protein. Hamada M, et al. **Jpn J Clin Oncol** 1996 Dec;26(6):398–404
Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes. Okisaka S, et al. **Jpn J Ophthalmol** 1997 Mar-Apr;41(2):84–8
Induction of apoptosis in human leukemic cells by magnetic fields. Hisamitsu T, et al. **Jpn J Physiol** 1997 Jun; 47(3):307–10
Apoptosis (programmed cell death) of transitional ameloblasts and MHC class II expression in rat incisors. Nishikawa S, et al. **Kaibogaku Zasshi** 1996 Dec; 71(6):597–603 (22 ref.)
Pyelonephritis provokes growth retardation and apoptosis in infant rat renal cortex. Serlachius E, et al. **Kidney Int** 1997 Jun;51(6):1855–62
Cell apoptosis and proliferation in experimental chronic obstructive uropathy. Truong LD, et al. **Kidney Int** 1996 Jul;50(1):200–7
Automated monitoring of apoptosis in suspension cell cultures. Kravtsov VD, et al. **Lab Invest** 1996 Feb; 74(2):557–70
Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Magi-Galluzzi C, et al. **Lab Invest** 1997 Jan; 76(1):37–51
Apoptosis in keratinocytes is not dependent on induction of differentiation. Mitra RS, et al. **Lab Invest** 1997 Jan; 76(1):99–107
Increased apoptosis in the contralateral testis in patients with testicular torsion [letter] Hadziselimovic F, et al. **Lancet** 1997 Jul 12;350(9071):118
Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. Gisslinger H, et al. **Leuk Lymphoma** 1997 Mar;25(1–2):121–33
Fas receptor (CD95)-mediated apoptosis in leukemic cells. Komada Y, et al. **Leuk Lymphoma** 1997 Mar;25(1–2):9–21 (65 ref.)
Mitotic activity and nuclear DNA damage of large cells in Hodgkin's disease: comparison with the expression of p53 and bcl-2 proteins and the presence of Epstein-Barr virus. Leoncini L, et al. **Leuk Lymphoma** 1997 Mar; 25(1–2):153–61
Apoptosis in acute myeloblastic leukemia: follow-up study on trephine biopsies of the bone marrow. Thiele J, et al. **Leuk Lymphoma** 1996 Jun;22(1–2):77–82
Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin [see comments] Hellström-Lindberg E, et al. **Leuk Res** 1997 May; 21(5):415–25. Comment in: Leuk Res 1997 May;21(5):427–8.
Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with A t(8;21) chromosome translocation. Miyoshi H, et al. **Leuk Res** 1997 Jan;21(1):45–50
Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes [see comments] Shetty V, et al. **Leuk Res** 1996 Nov-Dec; 20(11–12):891–900. Comment in: Leuk Res 1996 Nov-Dec;20(11–12):881–90.
Ether lipids are effective cytotoxic drugs against multidrug-resistant acute leukemia cells and can act by the induction of apoptosis. Verdonck LF, et al. **Leuk Res** 1997 Jan;21(1):37–43
Apoptosis as a parameter of cytokine treatment in myelodysplasia [comment] Yoshida Y. **Leuk Res** 1997 May; 21(5):427–8 (11 ref.). Comment on: Leuk Res 1997 May;21(5):415–25.
Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis. Bailly JD, et al. **Leukemia** 1997 Sep;11(9):1523–32
Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Bogdanović AD, et al. **Leukemia** 1997 May;11(5):656–9
Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Bouscary D, et al. **Leukemia** 1997 Jun;11(6):839–45
p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. Haupt Y, et al. **Leukemia** 1997 Apr;11 Suppl 3:337–9
The p53-deficient hemopoietic stem cells: their resistance

to radiation-apoptosis, but lasted transiently. Hirabayashi Y, et al. **Leukemia** 1997 Apr;11 Suppl 3:489–92

Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Karawajew L, et al. **Leukemia** 1997 Aug;11(8):1245–52

p53-mediated cell cycle arrest and apoptosis. Lin Y, et al. **Leukemia** 1997 Apr;11 Suppl 3:324–6

In vitro study using leukemia cell line panel to demonstrate rapid thymic T cell death due to contact with HIV-1 carrier cell clones. Minowada J, et al. **Leukemia** 1997 May; 11(5):714–22

Role of p53 tumor suppressor gene and Fas/Apo-1 in induction of apoptosis and differentiation of cancer cells. Takahashi R. **Leukemia** 1997 Apr;11 Suppl 3:331–3

Bcl-2 and Bcl-xL block apoptosis as well as necrosis: possible involvement of common mediators in apoptotic and necrotic signal transduction pathways. Tsujimoto Y, et al. **Leukemia** 1997 Apr;11 Suppl 3:380–2

Induction of apoptosis by overexpression of the PU. 1/Spi-1 gene in murine erythroleukemia cells. Yamada T, et al. **Leukemia** 1997 Apr;11 Suppl 3:480–1

Comparison of susceptibility to apoptosis induced by rhTNF-alpha and cycloheximide between human circulating and exudated neutrophils. Niwa M, et al. **Life Sci** 1997;61(2):205–15

Defective phagocytosis of apoptotic cells: possible explanation for the induction of autoantibodies in SLE. Kalden JR. **Lupus** 1997;6(3):326–7

The effect of time delays on the dynamics of avascular tumor growth. Byrne HM. **Math Biosci** 1997 Sep;144(2):83–117

Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Baumann CA, et al. **Mech Ageing Dev** 1997 Mar;94(1-3):85–101

Increased apoptosis of CD45RO- T cells with aging. Herndon FJ, et al. **Mech Ageing Dev** 1997 Mar; 94(1-3):123–34

Excessive apoptosis of mature T lymphocytes is a characteristic feature of human immune senescence. Phelouzat MA, et al. **Mech Ageing Dev** 1996 Jul 5; 88(1-2):25–38

The accumulation of non-replicative, non-functional, senescent T cells with age is avoided in calorically restricted mice by an enhancement of T cell apoptosis. Spaulding CC, et al. **Mech Ageing Dev** 1997 Feb; 93(1-3):25–33

Motor neurone disease and the life of motor neurones [letter; comment] Vaux DL, et al. **Med J Aust** 1997 Jan 20; 166(2):109, discussion 109–10. Comment on: Med J Aust 1996 Aug 19;165(4):180–1.

HIV-1-infected myelomonocytic cells are resistant to Fas-mediated apoptosis: effect of tumor necrosis factor-alpha on their Fas expression and apoptosis. Okamoto M, et al. **Med Microbiol Immunol (Berl)** 1997 Jun;186(1):11–7

Apoptosis in Xenopus egg extracts. Kornbluth S. **Methods Enzymol** 1997;283:600–14

Small pool expression screening: identification of genes involved in cell cycle control, apoptosis, and early development. Lustig KD, et al. **Methods Enzymol** 1997; 283:83–99

Apoptosis during HIV infection and in neurodegenerative disorders. Lombardi VR, et al. **Methods Find Exp Clin Pharmacol** 1996 Oct;18(8):539–55 (116 ref.)

Replication of feline syncytial virus in feline T-lymphoblastoid cells and induction of apoptosis in the cells. Ikeda Y, et al. **Microbiol Immunol** 1997;41(5):431–5

Kinase cascades regulating entry into apoptosis. Anderson P. **Microbiol Mol Biol Rev** 1997 Mar;61(1):33–46 (189 ref.)

Correlation of DNA fragmentation and chromatin condensation in apoptotic nuclei of the Ser 6 mouse retina. Chang GQ, et al. **Microsc Res Tech** 1997 Jan 15;36(2):123–9

Histiocytic necrotizing lymphadenitis (Kikuchi's disease): in situ end-labeling, immunohistochemical, and serologic evidence supporting cytotoxic lymphocyte-mediated apoptotic cell death. Felgar RE, et al. **Mod Pathol** 1997 Mar;10(3):231–41

p53 overexpression in myeloid leukemic disorders is associated with increased apoptosis of hematopoietic marrow cells and ineffective hematopoiesis. Orazi A, et al. **Mod Pathol** 1996 Jan;9(1):48–52

Bax- and Bak-induced cell death in the fission yeast Schizosaccharomyces pombe. Jürgensmeier JM, et al. **Mol Biol Cell** 1997 Feb;8(2):325–39

Persistent DNA damage inhibits S-phase and G2 progression, and results in apoptosis. Orren DK, et al. **Mol Biol Cell** 1997 Jun;8(6):1129–42

Multiple systems for recognition of apoptotic lymphocytes by macrophages. Pradhan D, et al. **Mol Biol Cell** 1997 May; 8(5):767–78

Suppression of nitric oxide-induced apoptosis by N-acetyl-L-cysteine through modulation of glutathione, bcl-2, and bax protein levels. Ho YS, et al. **Mol Carcinog** 1997 Jun;19(2):101–13

Apoptosis in the heart: when and why? Brömme HJ, et al. **Mol Cell Biochem** 1996 Oct-Nov;163-164:261–75 (150 ref.)

Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Chin YE, et al. **Mol Cell Biol** 1997 Sep;17(9):5328–37

Ectopic TAL-1/SCL expression in phenotypically normal or leukemic myeloid precursors: proliferative and antiapoptotic effects coupled with a differentiation blockade. Condorelli GL, et al. **Mol Cell Biol** 1997 May; 17(5):2954–69

Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. Gorospe M, et al. **Mol Cell Biol** 1996 Dec; 16(12):6654–60

Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K. Han J, et al. **Mol Cell Biol** 1996 Oct;16(10):5857–64

Doom, a product of the Drosophila mod(mdg4) gene, induces apoptosis and binds to baculovirus inhibitor-of-apoptosis proteins. Harvey AJ, et al. **Mol Cell Biol** 1997 May; 17(5):2835–43

Human Bak induces cell death in Schizosaccharomyces pombe with morphological changes similar to those with apoptosis in mammalian cells. Ink B, et al. **Mol Cell Biol** 1997 May;17(5):2468–74

Cyclin D3 sensitizes tumor cells to tumor necrosis factor-induced, c-Myc-dependent apoptosis. Jänicke RU, et al. **Mol Cell Biol** 1996 Oct;16(10):5245–53

T cells deficient in inositol 1,4,5-trisphosphate receptor are resistant to apoptosis. Jayaraman T, et al. **Mol Cell Biol** 1997 Jun;17(6):3005–12

Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mosser DD, et al. **Mol Cell Biol** 1997 Sep;17(9):5317–27

Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Polunovsky VA, et al. **Mol Cell Biol** 1996 Nov;16(11):6573–81

Expression and function of the leucine zipper protein Par-4 in apoptosis. Sells SF, et al. **Mol Cell Biol** 1997 Jul; 17(7):3823–32

DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Stanulla M, et al. **Mol Cell Biol** 1997 Jul; 17(7):4070–9

Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Wilson BE, et al. **Mol Cell Biol** 1996 Oct;16(10):5546–56

Structure-function comparisons of the proapoptotic protein Bax in yeast and mammalian cells. Zha H, et al. **Mol Cell Biol** 1996 Nov;16(11):6494–508

Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Heisler LE, et al. **Mol Cell Endocrinol** 1997 Jan 3;126(1):59–73

Tail regression, apoptosis and thyroid hormone regulation of myosin heavy chain isoforms in Xenopus tadpoles. Sachs LM, et al. **Mol Cell Endocrinol** 1997 Aug 8;131(2):211–9

Neural crest apoptosis and the establishment of craniofacial pattern: an honorable death. Graham A, et al. **Mol Cell Neurosci** 1996;8(2-3):76–83 (26 ref.)

Neurodegeneration in Alzheimer disease. Is apoptosis involved? Kusiak JW, et al. **Mol Chem Neuropathol** 1996 May-Aug;28(1-3):153–62 (41 ref.)

Expression of Ad4-BP/cytochrome P450 side chain cleavage enzyme and induction of cell death in long-term cultures of human granulosa cells. Breckwoldt M, et al. **Mol Hum Reprod** 1996 Jun;2(6):391–400

Detection of apoptosis in human endometriotic tissues. Harada M, et al. **Mol Hum Reprod** 1996 May;2(5):307–15

Programmed cell death and human embryo fragmentation. Jurisicova A, et al. **Mol Hum Reprod** 1996 Feb;2(2):93–8

Neurovirulent simian immunodeficiency virus infection induces neuronal, endothelial, and glial apoptosis. Adamson DC, et al. **Mol Med** 1996 Jul;2(4):417–28

The Fas counterattack: a molecular mechanism of tumor immune privilege. O'Connell J, et al. **Mol Med** 1997 May; 3(5):294–300 (75 ref.)

Proteolytic cleavage during chemotherapy-induced apoptosis. Kaufmann SH. **Mol Med Today** 1996 Jul; 2(7):298–303 (44 ref.)

Salmonella spp. are cytotoxic for cultured macrophages. Chen LM, et al. **Mol Microbiol** 1996 Sep;21(5):1101–15

Apoptosis of mouse dendritic cells is triggered by listeriolysin, the major virulence determinant of Listeria monocytogenes. Guzmán CA, et al. **Mol Microbiol** 1996 Apr;20(1):119–26

In situ end labelling: effect of proteolytic enzyme pretreatment and hydrochloric acid. Carr NJ, et al. **Mol Pathol** 1997 Jun;50(3):160–3

6-Mercaptopurine decreases the Bcl-2/Bax ratio and induces apoptosis in activated splenic B lymphocytes. Hortelano S, et al. **Mol Pharmacol** 1997 Mar;51(3):414–21

Enhanced apoptosis in metallothionein null cells. Kondo Y, et al. **Mol Pharmacol** 1997 Aug;52(2):195–201

Cytotoxic and genotoxic effects of cleistanthin B in normal and tumour cells. Prabhakaran C, et al. **Mutagenesis** 1996 Nov;11(6):553–7

Apoptosis and cancer risk assessment. Goldsworthy TL, et al. **Mutat Res** 1996 Sep;365(1-3):71–90 (95 ref.)

Use of coronary angiography and revascularization after acute myocardial infarction [letter; comment] Abrams J. **N Engl J Med** 1997 Apr 3;336(14):1024–5; discussion 1025 . Comment on: N Engl J Med 1996 Oct 17;335(16):1198–205.

Apoptosis in the heart [editorial; comment] Colucci WS. **N Engl J Med** 1996 Oct 17;335(16):1224–6. Comment on: N Engl J Med 1996 Oct 17;335(16):1182–9. Comment on: N Engl J Med 1996 Oct 17;335(16):1190–6.

Evidence of apoptosis in arrhythmogenic right ventricular dysplasia [see comments] Mallat Z, et al. **N Engl J Med** 1996 Oct 17;335(16):1190–6. Comment in: N Engl J Med 1996 Oct 17;335(16):1224–6.

Apoptosis in myocytes in end-stage heart failure [see comments] Narula J, et al. **N Engl J Med** 1996 Oct 17; 335(16):1182–9. Comment in: N Engl J Med 1996 Oct 17;335(16):1224–6. Comment in: N Engl J Med 1997 Apr 3;336(14):1025–6; discussion 1026.

Apoptosis in the failing human heart. Olivetti G, et al. **N Engl J Med** 1997 Apr 17;336(16):1131–41

Apoptosis in the heart [letter; comment] Saraste A, et al. **N Engl J Med** 1997 Apr 3;336(14):1025–6; discussion 1026 . Comment on: N Engl J Med 1996 Oct 17;335(16):1182–9.

Raf revealed in life-or-death decisions [news; comment] Pritchard C, et al. **Nat Genet** 1997 Jul;16(3):214–5. Comment on: Nat Genet 1997 Jul;16(3):293–7.

Endothelial apoptosis in Braf-deficient mice [see comments] Wojnowski L, et al. **Nat Genet** 1997 Jul;16(3):293–7. Comment in: Nat Genet 1997 Jul;16(3):214–5.

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Selivanova G, et al. **Nat Med** 1997 Jun;3(6):632–8

Picture story. Death grip. Felsenfeld AL. **Nat Struct Biol** 1997 Mar;4(3):184

Acute oral toxicity of microcystin-LR, a cyanobacterial hepatotoxin, in mice. Yoshida T, et al. **Nat Toxins** 1997; 5(3):91–5

Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Casaccia-Bonnefil P, et al. **Nature** 1996 Oct 24; 383(6602):716–9

Role of CED-4 in the activation of CED-3 [letter] [see comments] Chinnaiyan AM, et al. **Nature** 1997 Aug 21; 388(6644):728–9. Comment in: Nature 1997 Aug 21;388(6644):714–5.

RAIDD is a new 'death' adaptor molecule. Duan H, et al. **Nature** 1997 Jan 2;385(6611):86–9

Apoptosis. CED-4 is a stranger no more [news; comment] Hengartner MO. **Nature** 1997 Aug 21;388(6644):714–5. Comment on: Nature 1997 Aug 21;388(6644):728–9.

Inhibition of death receptor signals by cellular FLIP [see comments] Irmler M, et al. **Nature** 1997 Jul 10; 388(6638):190–5. Comment in: Nature 1997 Jul 10;388(6638):123, 125–6.

p73 is a human p53-related protein that can induce apoptosis [see comments] Jost CA, et al. **Nature** 1997 Sep 11; 389(6647):191–4. Comment in: Nature 1997 Sep 11;389(6647):122–3.

Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Kauffmann-Zeh A, et al. **Nature** 1997 Feb 6;385(6616):544–8

A death-domain-containing receptor that mediates apoptosis. Kitson J, et al. **Nature** 1996 Nov 28;384(6607):372–5

Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Kuida K, et al. **Nature** 1996 Nov 28;384(6607):368–72

S-nitrosylation regulates apoptosis [letter] Melino G, et al. **Nature** 1997 Jul 31;388(6641):432–3

Double identity for proteins of the Bcl-2 family. Reed JC. **Nature** 1997 Jun 19;387(6635):773–6 (40 ref.)

Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Thome M, et al. **Nature** 1997 Apr 3;386(6624):517–21

Antiapoptotic effect of ras in the apoptosis induced by serum deprivation and exposure to actinomycin D. Chou CC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Feb; 355(2):177–82

Apoptosis in proliferative glomerulonephritis: decreased apoptosis expression in lupus nephritis. Soto H, et al. **Nephrol Dial Transplant** 1997 Feb;12(2):273–80

NADPH diaphorase-containing striatal or cortical neurons are resistant to apoptosis. Behrens MI, et al. **Neurobiol Dis** 1996 Feb;3(1):72–5

Cyclic AMP and sympathetic neuronal programmed cell death. Chang JY, et al. **Neurochem Int** 1997 Aug; 31(2):161–7

Cytokine-mediated neuronal apoptosis. Hu S, et al. **Neurochem Int** 1997 Apr-May;30(4-5):427–31

Possible involvement of ADP-ribosylation of particular enzymes in cell death induced by nitric oxide-donors in human neuroblastoma cells. Kamoshima W, et al. **Neurochem Int** 1997 Mar;30(3):305–11

Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease. Offen D, et al. **Neurochem Int** 1997 Aug;31(2):207–16

DNA fragmentation characteristic of apoptosis and cell loss induced by kainic acid in rabbit retinas. Perez MT, et al. **Neurochem Int** 1997 Aug;31(2):251–60

Serum deprivation inhibits glutathione depletion-induced death in embryonic cortical neurons: evidence against oxidative stress as a final common mediator of neuronal apoptosis. Ratan RR, et al. **Neurochem Int** 1996 Aug; 29(2):153–7

Role of apoptosis in the prognosis of oligodendrogliomas. Schiffer D, et al. **Neurochem Int** 1997 Aug;31(2):245–50

Induction of apoptosis in cultured human retinal pigmented epithelial cells: the effect of protein kinase C activation and inhibition. Wood JP, et al. **Neurochem Int** 1997 Aug;

31(2):261–73
Induction of oligodendrocyte apoptosis by C2-ceramide. Larocca JN, et al. **Neurochem Res** 1997 Apr;22(4):529–34
Cellular adaptive responses to low oxygen tension: apoptosis and resistance. Yun JK, et al. **Neurochem Res** 1997 Apr; 22(4):517–21 (44 ref.)
Programmed cell death in the developing nervous system. Henderson CE. **Neuron** 1996 Oct;17(4):579–85 (26 ref.)
Evidence for neuronal apoptosis in pontosubicular neuron necrosis. Brück Y, et al. **Neuropathol Appl Neurobiol** 1996 Feb;22(1):23–9
Expression of pro- and anti-apoptosis gene products in brains from paediatric patients with HIV-1 encephalitis. Krajewski S, et al. **Neuropathol Appl Neurobiol** 1997 Jun; 23(3):242–53
Apoptosis in measles virus-infected human central nervous system tissues. McQuaid S, et al.
Neuropathol Appl Neurobiol 1997 Jun;23(3):218–24
c-Jun and cyclin D1 proteins as mediators of neuronal death after a focal ischaemic insult. Guégan C, et al.
Neuroreport 1997 Mar 3;8(4):1003–7
Apoptosis is restricted to the thalamus in thiamine-deficient rats. Matsushima K, et al. **Neuroreport** 1997 Mar 3; 8(4):867–70
Apoptotic, injury-induced cell death in cultured mouse murine motor neurons. Citron BA, et al. **Neurosci Lett** 1997 Jul 11;230(1):25–8
Strong c-Jun immunoreactivity is associated with apoptotic cell death in human tumors of the central nervous system. Ferrer I, et al. **Neurosci Lett** 1996 Aug 16;214(1):49–52
Increased expression of cyclin-dependent kinase 5 in induced apoptotic neuron death in rat substantia nigra. Henchcliffe C, et al. **Neurosci Lett** 1997 Jul 11;230(1):41–4
Apoptotic neuron death in rat substantia nigra induced by striatal excitotoxic injury is developmentally dependent. Kelly WJ, et al. **Neurosci Lett** 1996 Dec 13;220(2):85–8
Induction of apoptosis in a Drosophila neuronal cell line by calcium ionophore. Ui-Tei K, et al. **Neurosci Lett** 1996 Jan 26;203(3):191–4
Naturally occurring neuronal death during the development of the inferior olive in the chick. López-Román A, et al. **Neurosci Res** 1996 Oct;26(2):171–9
Axonal outgrowth and neuronal apoptosis in cultured adult mouse dorsal root ganglion preparations: effects of neurotrophins, of inhibition of neurotrophin actions and of prior axotomy. Edström A, et al. **Neuroscience** 1996 Dec; 75(4):1165–74
Kainate induces apoptosis in neurons. Simonian NA, et al. **Neuroscience** 1996 Oct;74(3):675–83
A new approach for the electrophoretic detection of apoptosis. Eldadah BA, et al. **Nucleic Acids Res** 1996 Oct 15;24(20):4092–3
Detection of DNA breaks in apoptotic cells utilizing the DNA binding domain of poly(ADP-ribose) polymerase with fluorescence microscopy. Rosenthal DS, et al.
Nucleic Acids Res 1997 Apr 1;25(7):1437–41
Relationship among colonocyte proliferation, differentiation, and apoptosis as a function of diet and carcinogen. Hong MY, et al. **Nutr Cancer** 1997;28(1):20–9
Evidence for role of transforming growth factor-beta in RRR-alpha-tocopheryl succinate-induced apoptosis of human MDA-MB-435 breast cancer cells. Yu W, et al. **Nutr Cancer** 1997;27(3):267–78
Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. El-Ashry D, et al. **Oncogene** 1997 Jul 24;15(4):423–35
Induction of apoptosis by p75 neurotrophin receptor in human neuroblastoma cells. Bunone G, et al. **Oncogene** 1997 Mar 27;14(12):1463–70
The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate. Chernov MV, et al. **Oncogene** 1997 May 29;14(21):2503–10
ICE-proteases mediate HTLV-I Tax-induced apoptotic T-cell death. Chlichlia K, et al. **Oncogene** 1997 May 15; 14(19):2265–72
p53, mutation frequency and apoptosis in the murine small intestine. Clarke AR, et al. **Oncogene** 1997 May 1; 14(17):2015–8
Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells. Friedman SL, et al. **Oncogene** 1997 Jul 3;15(1):63–70
p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Gorospe M, et al. **Oncogene** 1997 Feb 27;14(8):929–35
Bcl-2 and Hsp27 act at different levels to suppress programmed cell death. Guénal I, et al. **Oncogene** 1997 Jul 17;15(3):347–60
Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Huang DC, et al. **Oncogene** 1997 Jan 30;14(4):405–14
Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Huang S, et al. **Oncogene** 1996 Dec 5; 13(11):2339–47
Involvement of caspase-4(-like) protease in Fas-mediated apoptotic pathway. Kamada S, et al. **Oncogene** 1997 Jul 17;15(3):285–90
Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis. Kaufmann AM, et al. **Oncogene** 1996 Dec 5;13(11):2349–58
Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells. Kinoshita T, et al. **Oncogene** 1997 Aug 7;15(6):619–27
The proto-oncogene c-fos increases the sensitivity of keratinocytes to apoptosis. Mils V, et al. **Oncogene** 1997 Apr 3;14(13):1555–61
The polyproline region of p53 is required to activate apoptosis but not growth arrest. Sakamuro D, et al.
Oncogene 1997 Aug 18;15(8):887–98
Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CrmA-sensitive caspase-8. Takahashi A, et al.
Oncogene 1997 Jun 12;14(23):2741–52
p53 induced by ionizing radiation mediates DNA end-jointing activity, but not apoptosis of thyroid cells. Yang T, et al. **Oncogene** 1997 Apr 3;14(13):1511–9
Abrogation of p53 function by HPV16 E6 gene delays apoptosis and enhances mutagenesis but does not alter radiosensitivity in TK6 human lymphoblast cells. Yu Y, et al. **Oncogene** 1997 Apr 10;14(14):1661–7
Co-operation of simian virus 40 T antigen and insulin receptor substrate-1 in protection from apoptosis induced by interleukin-3 withdrawal. Zhou-Li F, et al.
Oncogene 1997 Aug 18;15(8):961–70
v-Rel prevents apoptosis in transformed lymphoid cells and blocks TNFalpha-induced cell death. Zong WX, et al.
Oncogene 1997 Aug 18;15(8):971–80
Regulation of cell cycle and apoptosis by protein kinase C in rat myeloid leukemia cell line. Leszczynski D.
Oncol Res 1995;7(9):471–80
Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade. Martin DS, et al. **Oncol Res** 1997;9(1):1–5
Apoptosis in oral erythema multiforme. Chrysomali E, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1997 Feb;83(2):272–80
Role of apoptosis in duct obstruction-induced pancreatic involution in rats. Doi R, et al. **Pancreas** 1997 Jan; 14(1):39–46
Apoptosis in the pancreas of genetically diabetic rats with a disrupted cholecystokinin (CCK-A) receptor gene. Jimi A, et al. **Pancreas** 1997 Mar;14(2):109–12
Is the induction of apoptosis the mechanism of the protective effects of TNF alpha in helminth infection? Garside P, et al. **Parasite Immunol** 1996 Mar;18(3):111–3 (30 ref.)
Expression of the antiapoptotic protein bcl-2 is not dependent on the tumor suppressor p53 protein in Indian breast carcinoma. Kesari AL, et al. **Pathobiology** 1997; 65(2):108–12
Fas antigen expression and its relationship with apoptosis in transplanted kidney. Kato S, et al. **Pathol Int** 1997 Apr; 47(4):230–7
Immunohistochemical study of necrotizing lymphadenitis: a possible mechanism for apoptosis involving perforin and granzyme-producing cytotoxic T cells. Mori N, et al.
Pathol Int 1997 Jan;47(1):31–7
Enhancement of ectopic bone formation in mice with a deficit in Fas-mediated apoptosis. Mori S, et al. **Pathol Int** 1997 Feb-Mar;47(2-3):112–6
Apoptosis and proliferative activity of non-Hodgkin's lymphomas: comparison with expression of bcl-2, p53 and c-myc proteins. Takano Y, et al. **Pathol Int** 1997 Feb-Mar; 47(2-3):90–4
Quantitative evaluation of apoptosis and proliferation in renal cell carcinoma. Correlation to tumor subtype, cytological grade according to thoenes-classification and the occurrence of metastasis. Hindermann W, et al.
Pathol Res Pract 1997;193(1):1–7
Apoptosis: is cell death a crucial step in cardiac development? Abdulla R. **Pediatr Cardiol** 1997 Jul-Aug;18(4):308
CD95-induced apoptosis contributes to loss of primed/memory but not resting/naive T cells in children infected with human immunodeficiency virus type 1. Böhler T, et al. **Pediatr Res** 1997 Jun;41(6):878–85
Death in the balance. Dibenedetto AJ, et al.
Perspect Dev Neurobiol 1996;3(2):111–20 (66 ref.)
Extracorporeal photochemotherapy (photopheresis) induces apoptosis in lymphocytes: a possible mechanism of action of PUVA therapy. Enomoto DN, et al.
Photochem Photobiol 1997 Jan;65(1):177–80
The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Kessel D, et al.
Photochem Photobiol 1997 Mar;65(3):422–6
Apoptotic changes occur in syncytiotrophoblast of human placental villi where fibrin type fibrinoid is deposited at discontinuities in the villous trophoblast. Nelson DM.
Placenta 1996 Sep;17(7):387–91
dad-1, A putative programmed cell death suppressor gene in rice. Tanaka Y, et al. **Plant Cell Physiol** 1997 Mar; 38(3):379–83
Characterization of nuclease activities and DNA fragmentation induced upon hypersensitive response cell death and mechanical stress. Mittler R, et al.
Plant Mol Biol 1997 May;34(2):209–21
Apoptosis in barley aleurone during germination and its inhibition by abscisic acid. Wang M, et al.
Plant Mol Biol 1996 Dec;32(6):1125–34
Apoptosis of T lymphoma cells and its inhibition by monoclonal antibodies against cell surface adhesion molecules. Tsuruo T, et al. **Princess Takamatsu Symp** 1994; 24:91–8 (18 ref.)
Induction of "tissue" transglutaminase in HIV pathogenesis: evidence for high rate of apoptosis of CD4+ T lymphocytes and accessory cells in lymphoid tissues. Amendola A, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):11057–62
Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Bernasconi M, et al.
Proc Natl Acad Sci U S A 1996 Nov 12;93(23):13164–9
Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Boise LH, et al.
Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3759–64
Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Danen-Van Oorschot AA, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5843–7
A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Der SD, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3279–83
Fas (CD95) expression and death-mediating function are induced by CD4 cross-linking on CD4+ T cells. Desbarats J, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):11014–8
Increased sensitivity to apoptotic stimuli in c-abl-deficient progenitor B-cell lines. Dorsch M, et al.
Proc Natl Acad Sci U S A 1996 Nov 12;93(23):13131–6
In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Fernandes-Alnemri T, et al.
Proc Natl Acad Sci U S A 1996 Jul 23;93(15):7464–9
Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Goillot E, et al.
Proc Natl Acad Sci U S A 1997 Apr 1;94(7):3302–7
Involvement of stress-activated protein kinase and p38 mitogen-activated protein kinase in mIgM-induced apoptosis of human B lymphocytes. Graves JD, et al.
Proc Natl Acad Sci U S A 1996 Nov 26;93(24):13814–8
RIP and FADD: two "death domain"-containing proteins can induce apoptosis by convergent, but dissociable, pathways. Grimm S, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10923–7
Inhibition of interleukin 1 beta-converting enzyme-mediated apoptosis of mammalian cells by baculovirus IAP. Hawkins CJ, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26; 93(24):13786–90
Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit protooncogene. He J, et al.
Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3954–9
Thymineless death in colon carcinoma cells is mediated via fas signaling. Houghton JA, et al.
Proc Natl Acad Sci U S A 1997 Jul 22;94(15):8144–9
Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Hsu YT, et al.
Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3668–72
Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Jamora C, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23; 93(15):7690–4
Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Jiang X, et al.
Proc Natl Acad Sci U S A 1996 Oct 1;93(20):11236–41
Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Johnson TM, et al.
Proc Natl Acad Sci U S A 1996 Oct 15;93(21):11848–52
Bruton's tyrosine kinase regulates apoptosis and JNK/SAPK kinase activity. Kawakami Y, et al.
Proc Natl Acad Sci U S A 1997 Apr 15;94(8):3938–42
Beta cell apoptosis in T cell-mediated autoimmune diabetes. Kurrer MO, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):213–8
p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Lanni JS, et al.
Proc Natl Acad Sci U S A 1997 Sep 2;94(18):9679–83
The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus. Leopardi R, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):7891–6
Cytokine suppression of protease activation in wild-type p53-dependent and p53-independent apoptosis. Lotem J, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9349–53
bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. McCurrach ME, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2345–9
Developmental parameters of cell death in the wing disc of Drosophila. Milán M, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5691–6
Apoptosis and APC in colorectal tumorigenesis. Morin PJ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):7950–4
A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Nocentini G, et al.
Proc Natl Acad Sci U S A 1997 Jun 10;94(12):6216–21
Role for the class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes in vitro. Platt N, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29; 93(22):12456–60
CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Prasad KV, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6346–51
LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Screaton GR, et al. **Proc Natl Acad Sci U S A** 1997 Apr

29;94(9):4615–9
Activation of an interleukin 1 converting enzyme–dependent apoptosis pathway by granzyme B. Shi L, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):11002–7
Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Shiraki K, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6420–5
Resistance of actin to cleavage during apoptosis. Song Q, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):157–62
Molecular ordering of the Fas–apoptotic pathway: the Fas/APO–1 protease Mch5 is a CrmA–inhibitable protease that activates multiple Ced–3/ICE–like cysteine proteases. Srinivasula SM, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14486–91
BAX enhances paclitaxel–induced apoptosis through a p53–independent pathway. Strobel T, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):14094–9
Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Su F, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8744–9
Differential ability of T cell subsets to undergo activation–induced cell death. Varadhachary AS, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5778–83
Antigen therapy eliminates T cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2. Weishaupt A, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1338–43
Regulation of DNA damage–induced apoptosis by the c–Abl tyrosine kinase. Yuan ZM, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18;94(4):1437–40
The role of apoptosis in neurodegenerative diseases. Hajimohamadreza I, et al. **Prog Drug Res** 1997;48:55–98 (172 ref.)
Does an IGF–binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis? Tonner E, et al. **Prog Growth Factor Res** 1995;6(2–4):409–14 (21 ref.)
Active cell death (apoptosis) in liver biology and disease. Schulte–Hermann R, et al. **Prog Liver Dis** 1995;13:1–35 (246 ref.)
Apoptosis of mature T lymphocytes: putative role in the regulation of cellular immune responses and in the pathogenesis of HIV infection. Kabelitz D, et al. **Prog Mol Subcell Biol** 1996;16:58–71 (80 ref.)
Myc–mediated apoptosis. Kuchino Y, et al. **Prog Mol Subcell Biol** 1996;16:104–29 (65 ref.)
Apoptosis mediated by the Fas system. Nagata S. **Prog Mol Subcell Biol** 1996;16:87–103 (70 ref.)
Cytopathic feline leukemia viruses cause apoptosis in hemolymphatic cells. Rojko JL, et al. **Prog Mol Subcell Biol** 1996;16:13–43 (150 ref.)
bcl–2: antidote for cell death. Tsujimoto Y. **Prog Mol Subcell Biol** 1996;16:72–86 (80 ref.)
A 5–lipoxygenase inhibitor at micromolar concentration raises intracellular calcium in U937 cells prior to their physiologic cell death. Buyn T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jan; 56(1):69–77
Apoptotic program is initiated but not completed in LNCaP cells in response to growth in charcoal–stripped media. Saeed B, et al. **Prostate** 1997 May 15;31(3):145–52
Target to apoptosis: a hopeful weapon for prostate cancer. Tang DG, et al. **Prostate** 1997 Sep 1;32(4):284–93 (115 ref.)
Cloning, expression, and affinity purification of recombinant Shigella flexneri invasion plasmid antigens IpaB and IpaC. Picking WL, et al. **Protein Expr Purif** 1996 Dec;8(4):401–8
Apoptosis in heat–induced cell killing: the protective role of hsp–70 and the sensitization effect of the c–myc gene. Li WX, et al. **Radiat Res** 1996 Mar;145(3):324–30
Apoptosis regulation by Raf, Bcl–2, and R–Ras. Troppmair J, et al. **Recent Results Cancer Res** 1997;143:245–9 (16 ref.)
Induction of acute gastritis and epithelial apoptosis by Helicobacter pylori lipopolysaccharide. Piotrowski J, et al. **Scand J Gastroenterol** 1997 Mar;32(3):203–11
Key morphologic changes and DNA strand breaks in human lymphoid cells: discriminating apoptosis from necrosis. Fairbairn DW, et al. **Scanning** 1996 Sep;18(6):407–16
Apoptosis and calcification. Kim KM. **Scanning Microsc** 1995;9(4):1137–75; discussion 1175–8 (350 ref.)
Cell suicide in health and disease. Duke RC, et al. **Sci Am** 1996 Dec;275(6):80–7
Life–death balance within the cell [news; comment] Barinaga M. **Science** 1996 Nov 1;274(5288):724. Comment on: Science 1996 Nov 1;274(5288):782–4. Comment on: Science 1996 Nov 1;274(5288):784–7. Comment on: Science 1996 Nov 1;274(5288):787–9.
New view of spinal cord injury [news] Barinaga M. **Science** 1996 Nov 29;274(5292):1466
Signal transduction by DR3, a death domain–containing receptor related to TNFR–1 and CD95. Chinnaiyan AM, et al. **Science** 1996 Nov 8;274(5289):990–2
Interaction of CED–4 with CED–3 and CED–9: a molecular framework for cell death [see comments] Chinnaiyan AM, et al. **Science** 1997 Feb 21;275(5303):1122–6. Comment in: Science 1997 Feb 21;275(5303):1081–2.
Requirement for GD3 ganglioside in CD95– and ceramide–induced apoptosis. De Maria R, et al. **Science** 1997 Sep 12;277(5332):1652–5
Regulation of neuronal survival by the serine–threonine protein kinase Akt [see comments] Dudek H, et al. **Science** 1997 Jan 31;275(5300):661–5. Comment in: Science 1997 Jan 31;275(5300):628–30.
Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis [see comments] Giordano C, et al. **Science** 1997 Feb 14;275(5302):960–3. Comment in: Science 1997 Feb 14;275(5302):926.
Controlling cell death [comment] Golstein P. **Science** 1997 Feb 21;275(5303):1081–2. Comment on: Science 1997 Feb 21;275(5303):1122–6. Comment on: Science 1997 Feb 21;275(5303):1126–9. Comment on: Science 1997 Feb 21;275(5303):1129–32. Comment on: Science 1997 Feb 21;275(5303):1132–6.
How TRAIL kills cancer cells, but not normal cells [news; comment] Gura T. **Science** 1997 Aug 8;277(5327):768. Comment on: Science 1997 Aug 8;277(5327):815–8. Comment on: Science 1997 Aug 8;277(5327):818–21.
Melanoma cell expression of Fas(Apo–1/CD95) ligand: implications for tumor immune escape [see comments] Hahne M, et al. **Science** 1996 Nov 22;274(5291):1363–6. Comment in: Science 1996 Nov 22;274(5291):1302.
Functions of ceramide in coordinating cellular responses to stress. Hannun YA. **Science** 1996 Dec 13;274(5294):1855–9 (55 ref.)
Akt signaling: linking membrane events to life and death decisions [comment] Hemmings BA. **Science** 1997 Jan 31; 275(5300):628–30 (25 ref.). Comment on: Science 1997 Jan 31;275(5300):661–5. Comment on: Science 1997 Jan 31;275(5300):665–8.
Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Ichijo H, et al. **Science** 1997 Jan 3;275(5296):90–4
The release of cytochrome c from mitochondria: a primary site for Bcl–2 regulation of apoptosis [see comments] Kluck RM, et al. **Science** 1997 Feb 21;275(5303):1132–6. Comment in: Science 1997 Feb 21;275(5303):1081–2.
Caspase–3–generated fragment of gelsolin: effector of morphological change in apoptosis. Kothakota S, et al. **Science** 1997 Oct 10;278(5336):294–8
The receptor for the cytotoxic ligand TRAIL. Pan G, et al. **Science** 1997 Apr 4;276(5309):111–3
An antagonist decoy receptor and a death domain–containing receptor for TRAIL [see comments] Pan G, et al. **Science** 1997 Aug 8;277(5327):815–8. Comment in: Science 1997 Aug 8;277(5327):768.
Basal forebrain neuronal loss in mice lacking neurotrophin receptor p75 [letter; comment] Peterson DA, et al. **Science** 1997 Aug 8;277(5327):837–9. Comment on: Science 1996 Dec 6;274(5293):1729–32.
Membrane and morphological changes in apoptotic cells regulated by caspase–mediated activation of PAK2. Rudel T, et al. **Science** 1997 Jun 6;276(5318):1571–4
Control of TRAIL–induced apoptosis by a family of signaling and decoy receptors [see comments] Sheridan JP, et al. **Science** 1997 Aug 8;277(5327):818–21. Comment in: Science 1997 Aug 8;277(5327):768.
DCP–1, a Drosophila cell death protease essential for development [published erratum appears in Science 1997 Jul 11;277(5323):167] Song Z, et al. **Science** 1997 Jan 24; 275(5299):536–40
Suppression of TNF–alpha–induced apoptosis by NF–kappaB [see comments] Van Antwerp DJ, et al. **Science** 1996 Nov 1;274(5288):787–9. Comment in: Science 1996 Nov 1;274(5288):724. Comment in: Science 1997 Apr 11;276(5310):185.
Survival of cholinergic forebrain neurons in developing p75NGFR–deficient mice [see comments] Van der Zee CE, et al. **Science** 1996 Dec 6;274(5293):1729–32. Comment in: Science 1997 Aug 8;277(5327):837–9.
TNF– and cancer therapy–induced apoptosis: potentiation by inhibition of NF–kappaB [see comments] Wang CY, et al. **Science** 1996 Nov 1;274(5288):784–7. Comment in: Science 1996 Nov 1;274(5288):724. Comment in: Science 1997 Apr 11;276(5310):185.
Transcription factors, oncogenes, and apoptosis [letter; comment] White DW, et al. **Science** 1997 Apr 11; 276(5310):185. Comment on: Science 1996 Nov 1;274(5288):782–4. Comment on: Science 1996 Nov 1;274(5288):784–7. Comment on: Science 1996 Nov 1;274(5288):787–9.
Tumor cells fight back to beat immune system [news; comment] Williams N. **Science** 1996 Nov 22;274(5291):1302 . Comment on: Science 1996 Nov 22;274(5291):1363–6.
Thyroid disease: a case of cell suicide? [news; comment] Williams N. **Science** 1997 Feb 14;275(5302):926. Comment on: Science 1997 Feb 14;275(5302):960–3.
Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Wolozin B, et al. **Science** 1996 Dec 6;274(5293):1710–3
Interaction and regulation of subcellular localization of CED–4 by CED–9 [see comments] Wu D, et al. **Science** 1997 Feb 21;275(5303):1126–9. Comment in: Science 1997 Feb 21;275(5303):1081–2.
Prevention of apoptosis by Bcl–2: release of cytochrome c from mitochondria blocked [see comments] Yang J, et al. **Science** 1997 Feb 21;275(5303):1129–32. Comment in: Science 1997 Feb 21;275(5303):1081–2.
Mediation of neuronal apoptosis by enhancement of outward potassium current. Yu SP, et al. **Science** 1997 Oct 3; 278(5335):114–7
Fas and other cell death signaling pathways. Depraetere V, et al. **Semin Immunol** 1997 Apr;9(2):93–107 (186 ref.)
Do CTL kill target cells by inducing apoptosis? Henkart PA, et al. **Semin Immunol** 1997 Apr;9(2):135–44 (57 ref.)
Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Ayala A, et al. **Shock** 1996;6 Suppl 1:S27–38 (134 ref.)
Isolation of DNA markers for the rat Sai 1 gene for suppression of anchorage independence by using representational difference analysis. Lü XC, et al. **Somat Cell Mol Genet** 1997 Jan;23(1):63–74
Regulation of T cell apoptosis via T cell receptors and steroid receptors. Iwata M, et al. **Stem Cells** 1996 Nov;14(6):632–41 (66 ref.)
Signal transduction pathways in apoptosis. McConkey DJ, et al. **Stem Cells** 1996 Nov;14(6):619–31 (175 ref.)
Increased apoptosis rate by hyperthermochemoradiotherapy for advanced rectal cancers. Sakakura C, et al. **Surg Today** 1997;27(8):773–6
Integrin regulation of polymorphonuclear leukocyte apoxis during hypoxia is primarily dependent on very late activation antigens 3 and 5. Leuenroth S, et al. **Surgery** 1997 Aug;122(2):153–62
Impaired apoptotic death signaling in inflammatory lung neutrophils is associated with decreased expression of interleukin–1 beta converting enzyme family proteases (caspases). Watson RW, et al. **Surgery** 1997 Aug; 122(2):163–71; discussion 171–2
Apoptosis induced in cultured rat embryos by intra–amniotically microinjected sodium nitroprusside. Lee QP, et al. **Teratology** 1996 Jan;53(1):21–30
Separation of germ cell apoptosis from toxin–induced cell death by necrosis using in situ end–labeling histochemistry after glutaraldehyde fixation. Hikim AP, et al. **Tissue Cell** 1997 Aug;29(4):487–93
Apoptosis is coordinately regulated with osteoblast formation during bone healing. Landry P, et al. **Tissue Cell** 1997 Aug; 29(4):413–9
Induction of apoptosis in myocardial infarction and its possible relationship to nitric oxide synthase in macrophages. Suzuki H, et al. **Tissue Cell** 1996 Feb; 28(1):89–97
Study of apoptosis in human lymphocytes by toxic substances implicated in toxic oil syndrome. Gallardo S, et al. **Toxicology** 1997 Mar 14;118(1):71–82
Apoptosis in human retinal degenerations. Xu GZ, et al. **Trans Am Ophthalmol Soc** 1996;94:411–30; discussion 430–1
MHC class II tolerant T cells undergo apoptosis upon re–exposure to tolerogen in vivo. Alard P, et al. **Transpl Immunol** 1996 Mar;4(1):76–80
Nitric oxide production by dendritic cells is associated with impairment of T cell responses. Bonham CA, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1116–7
Induction of apoptosis following antigen presentation by T cells: anergy and apoptosis are two separate phenomena. Hargreaves RG, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):1102–4
Blocking of the B7–CD28 pathway increases apoptosis induced in activated T cells by in vitro–generated CD95L (FasL) positive dendritic cells. Lu L, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1094–5
Fas antigen expression and apoptosis in kidney allografts. Matsuno T, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):177–8
Apoptosis occurs in freshly isolated human islets under standard culture conditions. Paraskevas S, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):750–2
Apoptosis of graft–infiltrating cytotoxic T cells: a mechanism underlying "split tolerance" in mouse liver transplantation. Qian S, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1168–9
Activation of apoptosis during early phase of reperfusion after liver transplantation. Sasaki H, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):406–7
Apoptosis is involved in endothelial cell damage during preservation and influenced by organ storage solutions. Trieb K, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):416–8
Class I MHC mediates programmed cell death in a Fas–independent manner. Woodle ES, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1101
Apoptosis in bronchiolitis obliterans, chronic rejection and infection after lung transplantation in rats. Yagyu K, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1532–5
Apoptosis in pig endothelial cells after reperfusion and its prevention by genetic induction of human Cu, Zn–SOD cDNA. Yokoyama I, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):1364
Apoptosis in murine cardiac grafts. Bergese SD, et al. **Transplantation** 1997 Jan 27;63(2):320–5
Apoptosis in the small intestinal allograft of the rat. Fayyazi A, et al. **Transplantation** 1997 Apr 15;63(7):947–51
Apoptosis of mononuclear cell infiltrates in cardiac allograft biopsy specimens questions studies of biopsy–cultured cells. Jollow KC, et al. **Transplantation** 1997 May 27; 63(10):1482–9
Apoptotic cell death in human chronic renal allograft rejection. Laine J, et al. **Transplantation** 1997 Jan 15; 63(1):101–5
The CARD domain: a new apoptotic signalling motif. Hofmann K, et al. **Trends Biochem Sci** 1997 May; 22(5):155–6
Reactive oxygen species and programmed cell death. Jacobson MD. **Trends Biochem Sci** 1996 Mar;21(3):83–6 (47 ref.)
Lymphocyte dynamics, apoptosis and HIV infection. Frost SD, et al. **Trends Microbiol** 1996 Feb;4(2):77–82 (27 ref.)
Viral inhibition of apoptosis. Gillet G, et al. **Trends Microbiol** 1996 Aug;4(8):312–7 (50 ref.)

Pathological and genetic correlates of apoptosis in the progression of colorectal neoplasia. Hawkins N, et al. **Tumour Biol** 1997;18(3):146–56

Detection of apoptosis in peripheral blood cells of 31 subjects affected by Down syndrome before and after zinc therapy. Antonucci A, et al. **Ultrastruct Pathol** 1997 Sep–Oct; 21(5):449–52

Human retinoblastoma: a morphological study of apoptotic, leukocytic, and vascular elements. Madigan MC, et al. **Ultrastruct Pathol** 1997 Mar–Apr;21(2):95–107

Localization of Bax and Bcl-2 proteins, regulators of programmed cell death, in the human central nervous system. Hara A, et al. **Virchows Arch** 1996 Nov; 429(4–5):249–53

Immunohistochemical study on tissue transglutaminase and copper-zinc superoxide dismutase in human myocardium: its relevance to apoptosis detected by the nick end labelling method [published erratum appears in Virchows Arch 1997 Jun;430(6):513] Kashima K, et al. **Virchows Arch** 1997 Apr; 430(4):333–8

Proliferation and apoptosis in proliferative lesions of the colon and rectum. Kikuchi Y, et al. **Virchows Arch** 1997 Aug;431(2):111–7

Repression of bax gene expression by the HTLV-1 Tax protein: implications for suppression of apoptosis in virally infected cells. Brauweiler A, et al. **Virology** 1997 Apr 28; 231(1):135–40

Bovine herpesvirus 1-induced apoptosis occurs at the G0/G1 phase of the cell cycle. Hanon E, et al. **Virology** 1997 Jun 9;232(2):351–8

Expression of Epstein-Barr virus latent membrane protein 1 protects Jurkat T cells from apoptosis induced by serum deprivation. Kawanishi M. **Virology** 1997 Feb 17; 228(2):244–50

The apoptosis pathway triggered by the interferon-induced protein kinase PKR requires the third basic domain, initiates upstream of Bcl-2, and involves ICE-like proteases. Lee SB, et al. **Virology** 1997 Apr 28;231(1):81–8

CfMNPV blocks AcMNPV-induced apoptosis in a continuous midgut cell line. Palli SR, et al. **Virology** 1996 Aug 1;222(1):201–13

Suppression of apoptotic cell death by hepatitis C virus core protein. Ray RB, et al. **Virology** 1996 Dec 15;226(2):176–82

Inhibition of apoptosis by the African swine fever virus Bcl-2 homologue: role of the BH1 domain. Revilla Y, et al. **Virology** 1997 Feb 17;228(2):400–4

Induction of apoptosis by calmodulin-dependent intracellular Ca2+ elevation in CD4+ cells expressing gp 160 of HIV. Sasaki M, et al. **Virology** 1996 Oct 1;224(1):18–24

Programmed endothelial cell death induced by an avian hemangioma retrovirus is density dependent. Sela-Donenfeld D, et al. **Virology** 1996 Sep 1;223(1):233–7

Apoptosis in acute and chronic central nervous system disease induced by Theiler's murine encephalomyelitis virus. Tsunoda I, et al. **Virology** 1997 Feb 17;228(2):388–93

Induction of apoptosis and cleavage of poly(ADP-ribose) polymerase by cytopathic bovine viral diarrhea virus infection. Hoff HS, et al. **Virus Res** 1997 May;49(1):101–13

Simian foamy virus type 1 (SFV-1) induces apoptosis. Mergia A, et al. **Virus Res** 1997 Aug;50(2):129–37

Pathways of p53-dependent apoptosis. Grasso L, et al. **Vitam Horm** 1997;53:139–73 (210 ref.)

Cell cycle checkpoints and apoptosis: potential for improving radiation therapy. Muschel RJ, et al. **Vitam Horm** 1997; 53:1–25 (149 ref.)

Viral inhibitors of apoptosis. Uren AG, et al. **Vitam Horm** 1997;53:175–93 (105 ref.)

Triton X-100 induces apoptosis in human hepatoma cell lines. Ahn JM, et al. **Yonsei Med J** 1997 Feb;38(1):52–9

[In situ observation of the relationship between apoptosis and proliferation in large bowel carcinoma and its precancerous lesion] Sun B, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Nov;76(11):848–51 (Eng. Abstr.) **(Chi)**

[Hormones and apoptosis] Liu J, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):712–5 (18 ref.) **(Chi)**

[Apoptosis and blood disorders (editorial)] Zhang Z. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):651–2 **(Chi)**

[The bcl-2 gene family, an important regulator of apoptosis] Bao FK. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):67–9 (10 ref.) **(Chi)**

[Apoptosis in the morphology of Lyme borreliosis] Barták P, et al. **Cas Lek Cesk** 1997 Mar 12;136(5):146–7 (Eng. Abstr.) **(Cze)**

[Apoptosis and human viral infections] Wattre P, et al. **Ann Biol Clin (Paris)** 1996;54(5):189–97 (51 ref.) (Eng. Abstr.) **(Fre)**

[Neuronal apoptosis in the course of human immunodeficiency virus infection] Gray F, et al. **Bull Acad Natl Med** 1996 Nov;180(8):1855–67; discussion 1867–8 (Eng. Abstr.) **(Fre)**

[Report of the 38th meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, 27–31 October 1996] Coquard R, et al. **Cancer Radiother** 1997;1(1):88–93 **(Fre)**

[Apoptosis: death not always planned (editorial)] Tranchant C, et al. **Rev Neurol (Paris)** 1996 Jun–Jul;152(6–7):418–21 **(Fre)**

[The molecular mechanism of apoptosis. Report of the 4th European Conference on Apoptosis] Dibbert B, et al. **Dtsch Med Wochenschr** 1997 Apr 18;122(16):523–6 **(Ger)**

[Programmed cell death] Simon HU. **Dtsch Med Wochenschr** 1997 Feb 7;122(6):167–8 **(Ger)**

[Prognostic significance of proliferative and apoptotic fractions in low grade follicular non-Hodgkin's lymphoma] Bartkowiak D, et al. **Strahlenther Onkol** 1996 Sep; 172(9):519–21 **(Ger)**

[Hypoxia-mediated selection of p53-mutated cells] Dunst J, et al. **Strahlenther Onkol** 1997 Jul;173(7):389 **(Ger)**

[CD95 (APO-1/Fas) and CD95-ligand (CD95L). Implications of these apoptosis mediating receptor/ligand systems in the pathogenesis of autoimmune diseases] Möller P, et al. **Verh Dtsch Ges Pathol** 1996;80:12–20 (38 ref.) (Eng. Abstr.) **(Ger)**

[Apoptosis in chronic gastritis: correlation of glandular apoptosis with antigastric autoantibodies] Steininger H, et al. **Verh Dtsch Ges Pathol** 1996;80:185–90 (Eng. Abstr.) **(Ger)**

[Normal colon epithelium is highly sensitive to CD95-induced apoptosis.Indication for a role of cell death-induced CD95/CL95L systems under inflammatory inflammatory conditions?] Sträter J, et al. **Verh Dtsch Ges Pathol** 1996;80:217 **(Ger)**

[Apoptosis in the regulation of immune processes and in the pathogenesis of autoimmune diseases (see comments)] Müzes G, et al. **Orv Hetil** 1997 May 25;138(21):1315–20 (45 ref.) (Eng. Abstr.). Comment in: Orv Hetil 1997 Aug 24;138(34):2157. **(Hun)**

[Apoptosis (letter; comment)] Sinkovics J. **Orv Hetil** 1997 Aug 24;138(34):2157. Comment on: Orv Hetil 1997 May 25;138(21):1315–20. **(Hun)**

[Indult and redemption (letter)] Masoni A. **G Ital Cardiol** 1997 Aug;27(8):850–2 **(Ita)**

[Mechanism of regression of metastatic liver tumors in rats treated with angiogenesis inhibitor with special reference to apoptosis] Arai T, et al. **Gan To Kagaku Ryoho** 1997 Jul;24 Suppl 2:296–300 (Eng. Abstr.) **(Jpn)**

[Morphological changes involving apoptosis caused by microwave tissue coagulation in the liver] Otani S, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1861–3 **(Jpn)**

[Correlations between cell proliferating activity and apoptosis in the colorectal cancer and apoptosis in the mucosa adjacent to colorectal cancer] Watanabe I, et al. **Gan To Kagaku Ryoho** 1997 Jul;24 Suppl 2:301–6 (Eng. Abstr.) **(Jpn)**

[Studies on susceptibility of promonocytic cell line U937-derived subclones to HIV-1 infection and apoptosis induction] Kameoka M. **Hokkaido Igaku Zasshi** 1996 Jul; 71(4):489–508 (Eng. Abstr.) **(Jpn)**

[Abnormality in B cell apoptosis in mice with spontaneous systemic autoimmune disease] Tsubata T. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Dec;19(6):603–4 (10 ref.) **(Jpn)**

[Physiological roles of Fas, an apoptosis inductor cell surface receptor molecule] Yonehara N. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Dec;18(6):581–2 (0 ref.) **(Jpn)**

[Glycohistochemical analysis of apoptotic bodies in eyelid tumor] Uehara F, et al. **Nippon Ganka Gakkai Zasshi** 1997 Jul;101(7):611–6 (Eng. Abstr.) **(Jpn)**

[Expression of Fas/Fas ligand and proto-oncogenes in rheumatoid synovial tissues] Asahara H, et al. **Nippon Rinsho** 1996 Jul;54(7):1960–4 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Apoptosis and cell growth fraction in normal, dysplastic and neoplastic squamous epithelium of uterine cervix] Furuya H, et al. **Nippon Rinsho** 1996 Jul;54(7):1916–21 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Cytokines regulate apoptosis of leukemic cells] Handa A. **Nippon Rinsho** 1996 Jul;54(7):1797–802 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Detection of apoptosis and expression of Fas antigen in human colorectal cancer] Hashimoto S, et al. **Nippon Rinsho** 1996 Jul;54(7):1912–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Characteristics of hyperthermia-induced apoptotic cell death] Honma T. **Nippon Rinsho** 1996 Jul;54(7):1949–54 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Overexpression of c-Fos induces apoptosis of CD43+ pro-B cells] Hu L, et al. **Nippon Rinsho** 1996 Jul; 54(7):1876–80 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Fas antigen is expressed in human diseased muscles, but does not link to apoptosis] Inukai A, et al. **Nippon Rinsho** 1996 Jul;54(7):1992–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Overexpression of bcl-2 suppresses apoptotic cell death of the human leukemic cell line TF-1] Ito T, et al. **Nippon Rinsho** 1996 Jul;54(7):1815–21 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of Fas and Fas-ligand in epithelium of ulcerative colitis] Iwamoto M, et al. **Nippon Rinsho** 1996 Jul; 54(7):1970–4 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Regulation of thymocyte apoptosis and positive selection] Iwata M. **Nippon Rinsho** 1996 Jul;54(7):1753–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Apoptosis induced by myc family genes] Kagaya S, et al. **Nippon Rinsho** 1996 Jul;54(7):1869–75 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Anti-apoptotic function of the Epstein-Barr virus LMP1 and BHRF1 proteins] Kawanishi M. **Nippon Rinsho** 1996 Jul;54(7):1848–54 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Programmed thymic T cell death and negative selection via Fas and TCR/CD3 complex] Kishi S. **Nippon Rinsho** 1996 Jul;54(7):1760–7 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Function of HS1 protein in B-cell antigen-receptor signaling and induction of apoptosis] Kitamura D. **Nippon Rinsho** 1996 Jul;54(7):1773–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

[The molecular structure and biological significance of soluble Fas] Kobayashi S, et al. **Nippon Rinsho** 1996 Jul; 54(7):1741–6 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Apoptosis induction and its mechanism in HIV infection] Koga Y. **Nippon Rinsho** 1996 Jul;54(7):1842–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of Bcl-2 and Bax in human gastric cancer tissue] Komatsu K, et al. **Nippon Rinsho** 1996 Jul;54(7):1929–34 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Cancer chemotherapy and apoptosis] Mashima T, et al. **Nippon Rinsho** 1996 Jul;54(7):1935–42 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular biology of Fas antigen-Fas ligand system] Mita E, et al. **Nippon Rinsho** 1996 Jul;54(7):1736–40 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Ice/ced-3 family gene and apoptosis] Miura M. **Nippon Rinsho** 1996 Jul;54(7):1860–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

[RP105 and B cell apoptosis] Miura Y, et al. **Nippon Rinsho** 1996 Jul;54(7):1784–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Fas antigen expression on human hematopoietic progenitor cells] Nagafuji K, et al. **Nippon Rinsho** 1996 Jul; 54(7):1790–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Degradation of topoisomerase II alpha precedes nuclei degeneration during adenovirus E1A-induced apoptosis and is mediated by the activation of the ubiquitin dependent proteolysis system] Nakajima T. **Nippon Rinsho** 1996 Jul; 54(7):1828–35 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Inhibition of apoptosis by a baculovirus p35 gene] Ohtsubo T, et al. **Nippon Rinsho** 1996 Jul;54(7):1907–11 (19 ref.) (Eng. Abstr.) **(Jpn)**

[NGFI-B/nur77 family involved in T-cell apoptosis] Okabe T, et al. **Nippon Rinsho** 1996 Jul;54(7):1768–72 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Involvement of Fas and Fas ligand in case of human fulminant hepatitis] Ryo K, et al. **Nippon Rinsho** 1996 Jul; 54(7):1965–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Fas antigen (CD95) expressions and apoptosis of neoplastic cells from various lymphoid malignancies including adult T-cell leukemia/lymphoma] Sasao T, et al. **Nippon Rinsho** 1996 Jul;54(7):1986–91 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Apoptosis in the process from viral myocarditis to dilated cardiomyopathy] Satoh M, et al. **Nippon Rinsho** 1996 Jul; 54(7):1982–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Ceramide: a lipid mediator of apoptotic signal transduction] Sawai H, et al. **Nippon Rinsho** 1996 Jul;54(7):1803–8 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Induction of apoptosis by fibronectin via its interaction with VLA5] Sugahara H. **Nippon Rinsho** 1996 Jul;54(7):1809–14 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Role of apoptosis in renal injury] Sugiyama H, et al. **Nippon Rinsho** 1996 Jul;54(7):1975–81 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Role of LFA-1/ICAM-1-dependent cell adhesion in CD40-mediated inhibition of anti-IgM antibody-induced B-cell death] Sumimoto S, et al. **Nippon Rinsho** 1996 Jul; 54(7):1779–83 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular mechanism of apoptosis operated in the immune system] Tadakuma T. **Nippon Rinsho** 1997 Jun; 55(6):1337–44 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Role of the p53 gene in apoptosis] Takahashi R, et al. **Nippon Rinsho** 1996 Jul;54(7):1881–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

[TNF/TNFR gene and apoptosis] Takeda Y, et al. **Nippon Rinsho** 1996 Jul;54(7):1888–94 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of the induction of apoptosis by influenza virus infection] Takizawa T. **Nippon Rinsho** 1996 Jul; 54(7):1836–41 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Prevention of cell death by Bcl-2 family genes] Tsujimoto Y. **Nippon Rinsho** 1996 Jul;54(7):1895–902 (19 ref.) (Eng. Abstr.) **(Jpn)**

[The human T-cell leukemia virus type I (HTLV-I) tax protein induces apoptosis] Yamada T. **Nippon Rinsho** 1996 Jul;54(7):1855–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Apoptosis: concept, research history and clinical significance] Yamada T, et al. **Nippon Rinsho** 1996 Jul; 54(7):1731–5 (11 ref.) **(Jpn)**

[Radiation induced apoptosis in cultured human epithelial tumor cells] Yanagihara K. **Nippon Rinsho** 1996 Jul; 54(7):1943–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

[The mechanism of apoptosis induced by anticancer agents in human leukemia cells] Yoshida A, et al. **Nippon Rinsho** 1996 Jul;54(7):1822–7 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Apoptosis in the reproductive system] Nakano R, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Aug; 48(8):721–32 (4 ref.) **(Jpn)**

[Up-regulation of NGF, trkA, Fas, down-regulation of bcl-2, and induction of apoptosis by propentofylline in human glioma cell lines] Kamada H, et al. **No To Shinkei** 1996 Nov;48(11):1022–8 (Eng. Abstr.) **(Jpn)**

[Apoptosis and myopathies] Inukai A, et al. **Rinsho Byori** 1997 Jul;45(7):621–7 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Overexpression of bcl-2 suppresses apoptosis in the human leukemia cell line TF-1] Ito T. **Rinsho Byori** 1997 Jul;

45(7):628–37 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Apoptosis in uremic complication] Matsumoto Y, et al. **Rinsho Byori** 1997 Jul;45(7):638–42 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Apoptosis in human diseases: role of Fas system in liver cell injury by viral hepatitis] Mita E, et al. **Rinsho Byori** 1997 May;45(5):477–82 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Study of apoptosis in Sjögren's syndrome] Ogawa N, et al. **Rinsho Byori** 1997 Jul;45(7):643–8 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Ischemic heart disease and apoptosis] Takemura G, et al. **Rinsho Byori** 1997 Jul;45(7):606–13 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Thrombosis and apoptosis] Takeya H, et al. **Rinsho Byori** 1997 Jul;45(7):614–20 (32 ref.) (Eng. Abstr.) **(Jpn)**
[Apoptosis in MDS] Anzai N, et al. **Rinsho Ketsueki** 1996 Jul;37(7):536–41 (Eng. Abstr.) **(Jpn)**
[Ineffective erythropoiesis and apoptosis] Muta K, et al. **Rinsho Ketsueki** 1996 Jul;37(7):531–5 **(Jpn)**
[Role of c-jun in the inhibition of apoptosis through the erythropoietin receptor] Shimizu R, et al. **Rinsho Ketsueki** 1996 Jul;37(7):526–30 (5 ref.) **(Jpn)**
[Apoptosis in leukemic cell proliferation and differentiation] Terui Y, et al. **Rinsho Ketsueki** 1996 Jul;37(7):547–51 (11 ref.) **(Jpn)**
[Pathophysiology of ATL from the aspect of apoptosis] Tsuda H. **Rinsho Ketsueki** 1996 Jul;37(7):558–63 (16 ref.) **(Jpn)**
[The role of bone marrow stromal cells in apoptosis in myelodysplastic syndrome] Yaguchi M, et al. **Rinsho Ketsueki** 1996 Jul;37(7):542–6 (10 ref.) **(Jpn)**
[Activin A induces apoptotic cell death of myeloma cells] Yamato K, et al. **Rinsho Ketsueki** 1996 Jul;37(7):564–73 (18 ref.) **(Jpn)**
["Sphingosine pathway": a novel apoptosis inducing pathway] Kozutsumi Y, et al. **Seikagaku** 1996 Jun;68(6):444–52 (41 ref.) **(Jpn)**
[Mechanism of the induction of apoptosis in cancer cells] Nakaya K. **Seikagaku** 1996 Dec;68(12):1808–12 (16 ref.) **(Jpn)**
[Sphingomyelin cycle: role in cell functions inducing apoptosis] Okazaki T. **Seikagaku** 1996 Jun;68(6):431–43 (84 ref.) **(Jpn)**
[Regulatory mechanisms for B lymphocyte apoptosis] Tsubata T. **Seikagaku** 1997 May;69(5):299–310 (59 ref.) **(Jpn)**
[Virus-induced apoptosis as a host defence mechanism] Koyama AH. **Tanpakushitsu Kakusan Koso** 1996 Jul; 41(9):1363–71; discussion 1396–7 (36 ref.) **(Jpn)**
[Roles of protein tyrosine kinases in activation, proliferation and apoptosis of immuno-hematopoietic cells] Minami Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Sep;41(12 Suppl):1666–72 (25 ref.) **(Jpn)**
[Regulation of apoptosis through altered expression of Fas-ligand and Fas genes] Nakanishi Y. **Tanpakushitsu Kakusan Koso** 1996 Dec;41(16):2552–8 (26 ref.) **(Jpn)**
[Apoptosis and cancer] Romanenko AM. **Arkh Patol** 1996 May-Jun;58(3):18–23 (85 ref.) (Eng. Abstr.) **(Rus)**
[In its intermembrane space the mitochondrion hides the "suicide protein", which being released into cytosol causes apoptosis] Skulachev VP. **Biokhimiia** 1996 Nov; 61(11):2060–3 **(Rus)**
[Apoptosis: an important stage in the assessment of the immune system according to the pathogenetic principle] Cheredeev AN, et al. **Klin Lab Diagn** 1997 Jul;(7):31–5 **(Rus)**
[Increased apoptosis of immunocompetent cells as a possible mechanism in the development of immunodeficiency in patients with acutely progressive tuberculosis] Khomenko AG, et al. **Probl Tuberk** 1996;(6):6–10 (Eng. Abstr.) **(Rus)**
[Programmed cell death and apoptosis: their significance for the development and functioning of the immune system] Pevnitskiĭ LA. **Vestn Ross Akad Med Nauk** 1996;(6):43–50 (97 ref.) **(Rus)**
[Apoptosis: the beginning of the future] Maianskiĭ AN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1997 Mar-Apr; (2):88–94 (43 ref.) **(Rus)**
[Images of apoptosis] Benítez-Bribiesca L. **Gac Med Mex** 1996 Nov-Dec;132(6):641–2 **(Spa)**
[Dopaminergic system and neuronal death] Luquin MR, et al. **Rev Neurol** 1997 Aug;25 Suppl 2:S129–40 (88 ref.) (Eng. Abstr.) **(Spa)**
[Programmed cell death is a condition for life. When the balance is upset, disease appears] Rasmuson M. **Lakartidningen** 1997 May 28;94(22):2084–5 (Eng. Abstr.) **(Swe)**

DRUG EFFECTS

Interference between DNA binding activities of AP-1 and GR transcription factors in rat thymocytes undergoing dexamethasone-induced apoptosis. Sikora E, et al. **Acta Biochim Pol** 1996;43(4):721–31
Changes in cellular ultrastructure induced by gamma-interferon in K562 cells may be prerequisite for apoptosis. Iwagaki H, et al. **Acta Med Okayama** 1996 Aug; 50(4):223–5
Ubiquitination of apoptotic cells in the developing cerebellum of the rat following ionizing radiation or methylazoxymethanol injection. Ferrer I, et al. **Acta Neuropathol (Berl)** 1997 Apr;93(4):402–7
Apoptosis in hormone-responsive malignancies. Denmeade SR, et al. **Adv Pharmacol** 1997;41:553–83 (126 ref.)
Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Denmeade SR, et al. **Adv Pharmacol** 1996;35:281–306 (78 ref.)
Control of apoptosis by cytokines. May WS Jr. **Adv Pharmacol** 1997;41:219–46 (216 ref.)
Chemotherapy-induced apoptosis. Mesner PW Jr, et al. **Adv Pharmacol** 1997;41:461–99 (268 ref.)
Role of Bcr-Abl kinase in resistance to apoptosis. Samali A, et al. **Adv Pharmacol** 1997;41:533–52 (124 ref.)
Stavudine selectively induces apoptosis in HIV type 1-infected cells. Hashimoto KI, et al. **AIDS Res Hum Retroviruses** 1997 Jan 20;13(2):193–9
Alcohol-induced thymocyte apoptosis is accompanied by impaired mitochondrial function. Wang JF, et al. **Alcohol** 1997 Jan-Feb;14(1):99–105
Ethanol-induced apoptosis and oxidative stress in hepatocytes. Higuchi H, et al. **Alcohol Clin Exp Res** 1996 Dec;20(9 Suppl):340A–346A (65 ref.)
Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase. Yang JJ, et al. **Am J Pathol** 1996 Nov;149(5):1617–26
IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils. Cox G. **Am J Physiol** 1996 Oct;271(4 Pt 1):L566–71
Asbestos induces apoptosis in human alveolar macrophages. Hamilton RF, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):L813–9
Effects of cycloheximide on pancreatic endonuclease activity, apoptosis, and severity of acute pancreatitis. Kaiser AM, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):C982–93
Novel cell imaging techniques show induction of apoptosis and proliferation in mesothelial cells by asbestos. Goldberg JL, et al. **Am J Respir Cell Mol Biol** 1997 Sep;17(3):265–71
Implication of tyrosine kinases and protein kinase C in dimethyl sulfoxide-induced apoptosis. Ginestier-Verne C, et al. **Anal Cell Pathol** 1996 Jul;11(2):115–26
In vivo inhibition of programmed cell death by local administration of FGF-2 and FGF-4 in the interdigital areas of the embryonic chick leg bud. Macias D, et al. **Anat Embryol (Berl)** 1996 Jun;193(6):533–41
Hoechst 33342-induced apoptosis in BC3H-1 myocytes. Zhang X, et al. **Ann Clin Lab Sci** 1997 Jul-Aug; 27(4):260–75
Activation of pituitary adenylate cyclase-activating polypeptide receptors prevents apoptotic cell death in cultured cerebellar granule cells. Canonico PL, et al. **Ann N Y Acad Sci** 1996 Dec 26;805:470–2
Induction of apoptosis in malignant and camptothecin-resistant human cells. Chatterjee D, et al. **Ann N Y Acad Sci** 1996 Dec 13;803:143–56
Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators. Roberts RA. **Ann N Y Acad Sci** 1996 Dec 27;804:588–611 (97 ref.)
Bacterial immunomodulators affect programmed cell death of mouse spleen lymphocytes. Sinkora M, et al. **Ann N Y Acad Sci** 1997 Apr 5;815:492–5
Induction of apoptosis by camptothecin and topotecan. Traganos F, et al. **Ann N Y Acad Sci** 1996 Dec 13; 803:101–10
Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures [see comments] McDonald JW, et al. **Ann Neurol** 1996 Nov;40(5):750–8. Comment in: Ann Neurol 1997 Apr;41(4):563–4.
Liarozole amplifies retinoid-induced apoptosis in human prostate cancer cells. Hall AK. **Anticancer Drugs** 1996 May; 7(3):312–20
An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells. Anderson KM, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2589–99
Apoptosis in androgen-independent mouse mammary tumor cells induced by 5-fluorodeoxyuridine but not by androgen withdrawal. Furuya Y, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):2613–8
Apoptosis of androgen-independent mammary and prostate cell lines induced by topoisomerase inhibitors: common pathway of gene regulation. Furuya Y, et al. **Anticancer Res** 1997 May-Jun;17(3C):2089–93
Cytotoxic properties of a phosphoglycoconjugated derivative of 7 beta-hydroxycholesterol upon normal and tumor cells in culture. Hyun JW, et al. **Anticancer Res** 1997 Jul-Aug; 17(4A):2621–6
5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. Inada T, et al. **Anticancer Res** 1997 May-Jun; 17(3C):1965–71
Modulation of S-nitroso-N-acetyl-D,L-penicillamine (SNAP) induced HL-60 cell death by tetrahydrobiopterin. Kojima S, et al. **Anticancer Res** 1997 Mar-Apr; 17(2A):929–37
Induction of apoptotic cell death in three human osteosarcoma cell lines by a polyamine synthesis inhibitor, methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP). Mori K, et al. **Anticancer Res** 1997 Jul-Aug; 17(4A):2385–9
Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Nakamura S, et al. **Anticancer Res** 1997 Jan-Feb; 17(1A):173–9
Induction of apoptosis in various tumor cell lines by geranylgeraniol. Ohizumi H, et al. **Anticancer Res** 1997 Mar-Apr;17(2A):1051–7
The effect of etoposide (VP-16) on mouse L fibroblasts: modulation of stress response, growth and apoptosis genes. Sacchi CM, et al. **Anticancer Res** 1996 Nov-Dec; 16(6B):3659–64
Possible role of radical intensity and oxidation potential for gallic acid-induced apoptosis. Sakagami H, et al. **Anticancer Res** 1997 Jan-Feb;17(1A):377–80
Methionine oxidation and apoptosis induction by ascorbate, gallate and hydrogen peroxide. Sakagami H, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2565–70
Copper, but not iron, enhances apoptosis-inducing activity of antioxidants. Satoh K, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2487–90
Modulation of apoptosis signaling in etoposide-treated lymphoma cells. Sebestyén A, et al. **Anticancer Res** 1997 Jul-Aug;17(4A):2609–14
4,9-diazapyrenium dications induce apoptosis in human tumor cells. Steiner-Biočić I, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3705–8
Ca2+ mobilization during cell death induction by sodium 5, 6-benzylidene-L-ascorbate. Takahashi H, et al. **Anticancer Res** 1996 Sep-Oct;16(5A):2629–34
Antisense oligonucleotides to p53 tumor suppressor suppress the induction of apoptosis by epidermal growth factor in NCI-H 596 human lung cancer cells. Murayama Y, et al. **Antisense Nucleic Acid Drug Dev** 1997 Apr;7(2):109–14
Calpain inhibitors and serine protease inhibitors can produce apoptosis in HL-60 cells. Lu Q, et al. **Arch Biochem Biophys** 1996 Oct 1;334(1):175–81
Acidic fibroblast growth factor enhances peroxynitrite-induced apoptosis in primary murine fibroblasts. Shin JT, et al. **Arch Biochem Biophys** 1996 Nov 1;335(1):32–41
Differential apoptotic pattern induced by photodynamic therapy and cisplatin in human squamous cell carcinoma cell line. Matsumoto Y, et al. **Arch Dermatol Res** 1996 Dec; 289(1):52–4
Apoptotic cell death following exposure to fluoride in rat alveolar macrophages. Hirano S, et al. **Arch Toxicol** 1996; 70(3–4):249–51
Early effects of CI-924 on hepatic peroxisome proliferation, microsomal enzyme induction, PCNA, and apoptosis in B6C3F1 mice and Wistar rats. Hofstra AH, et al. **Arch Toxicol** 1997;71(4):250–7
Cyclophosphamide-induced apoptosis induces phocomelia in the mouse. Nomura M, et al. **Arch Toxicol** 1996; 70(10):672–7
Dimethylarsinic acid causes apoptosis in HL-60 cells via interaction with glutathione. Ochi T, et al. **Arch Toxicol** 1996;70(12):815–21
Oxidized LDLs induce massive apoptosis of cultured human endothelial cells through a calcium-dependent pathway. Prevention by aurintricarboxylic acid. Escargueil-Blanc I, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):331–9
Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Efferth T, et al. **Arzneimittelforschung** 1996 Feb;46(2):196–200
17beta-estradiol inhibits apoptosis of endothelial cells. Alvarez RJ, et al. **Biochem Biophys Res Commun** 1997 Aug 18;237(2):372–81
Early cytoplasmic acidification in retinamide-mediated apoptosis of human promyelocytic leukemia cells. Angoli D, et al. **Biochem Biophys Res Commun** 1996 Dec 13; 229(2):681–5
Cytokine and low-level nitric oxide prestimulation block p53 accumulation and apoptosis of RAW 264.7 macrophages. Brüne B, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):396–401
RGD-containing peptides trigger apoptosis in glomerular mesangial cells of adult human kidneys. Chen X, et al. **Biochem Biophys Res Commun** 1997 May 29;234(3):594–9
Growth inhibition and induction of apoptosis by HGF in transformed rat liver epithelial cells. Conner EA, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):396–401
Suppression of actinomycin D-induced apoptosis by the NS3 protein of hepatitis C virus. Fujita T, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):825–31
Attenuation of TGF-beta-induced apoptosis in primary cultures of hepatocytes by calpain inhibitors. Gressner AM, et al. **Biochem Biophys Res Commun** 1997 Feb 13; 231(2):457–62
A role of peroxides in Ca2+ ionophore-induced apoptosis in cultured rat cortical neurons. Hatanaka Y, et al. **Biochem Biophys Res Commun** 1996 Oct 14;227(2):513–8
Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1alpha,25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells. Hsieh T, et al. **Biochem Biophys Res Commun** 1997 Jun 27;235(3):539–44
Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. Ishizuka T, et al. **Biochem Biophys Res Commun** 1997 Jan 13; 230(2):386–91
Nerve growth factor rescues PC12 cells from apoptosis by increasing amount of bcl-2. Katoh S, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):653–7
Specific expression of CPP32 in sensory neurons of mouse embryos and activation of CPP32 in the apoptosis induced

by a withdrawal of NGF. Mukasa T, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):770–4

Effect of concentration on the cytotoxic mechanism of doxorubicin--apoptosis and oxidative DNA damage. Müller I, et al. **Biochem Biophys Res Commun** 1997 Jan 13;230(2):254–7

Role for Bcl-xL in the regulation of apoptosis by EGF and TGF beta 1 in c-myc overexpressing mammary epithelial cells. Nass SJ, et al. **Biochem Biophys Res Commun** 1996 Oct 3;227(1):248–56

Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Nickerson T, et al. **Biochem Biophys Res Commun** 1997 Aug 28; 237(3):690–3

Oxysterols induced apoptosis in cultured smooth muscle cells through CPP32 protease activation and bcl-2 protein downregulation. Nishio E, et al. **Biochem Biophys Res Commun** 1996 Sep 24;226(3):928–34

Actin cytoskeleton as a target for 2-chloro adenosine: evidence for induction of apoptosis in C2C12 myoblastic cells. Rufini S, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):361–6

Cytotoxic effect of cytokines on murine colon carcinoma cells involves TNF-mediated apoptosis. Sveinbjørnsson B, et al. **Biochem Biophys Res Commun** 1997 Apr 7; 233(1):270–5

Phosphorothioate-capped antisense oligonucleotides to Ras GAP inhibit cell proliferation and trigger apoptosis but fail to downregulate GAP gene expression. White JR, et al. **Biochem Biophys Res Commun** 1996 Oct 3;227(1):118–24

Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Yao Y, et al. **Biochem Biophys Res Commun** 1997 Mar 17; 232(2):317–22

Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Yoo YC, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):624–8

Responsiveness of human neutrophils to interleukin-4: induction of cytoskeletal rearrangements, de novo protein synthesis and delay of apoptosis. Girard D, et al. **Biochem J** 1997 Jul 1;325 (Pt 1):147–53

Activation of mitogen-activated protein kinase and p70S6 kinase is not correlated with cerebellar granule cell survival. Gunn-Moore FJ, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):365–9

Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta-cells by provoking oxidative stress through the glycation reaction. Kaneto H, et al. **Biochem J** 1996 Dec 15;320 (Pt 3):855–63

Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. Messmer UK, et al. **Biochem J** 1996 Oct 1;319 (Pt 1):299–305

Mechanism of apoptotic cell death of human gastric carcinoma cells mediated by transforming growth factor beta. Ohta S, et al. **Biochem J** 1997 Jun 15;324 (Pt 3):777–82

ATP depletion inhibits glucocorticoid-induced thymocyte apoptosis. Stefanelli C, et al. **Biochem J** 1997 Mar 15;322 (Pt 3):909–17

A novel DNA cleaving agent, 2,2'-bis(2-aminoethyl)-4,4'-bithiazole, induces thymocyte apoptosis. Lee E, et al. **Biochem Mol Biol Int** 1996 Sep; 40(1):151–7

Induction of apoptosis in primary culture of rat hepatocytes by protease inhibitors. Maeda S, et al. **Biochem Mol Biol Int** 1996 Jun;39(3):447–53

Helicobacter pylori lipopolysaccharide induces gastric epithelial cells apoptosis. Piotrowski J, et al. **Biochem Mol Biol Int** 1996 Oct;40(3):597–602

Gastric mucosal apoptosis induced by ethanol: effect of antiulcer agents. Piotrowski J, et al. **Biochem Mol Biol Int** 1997 Jun;42(2):247–54

Streptozotocin at low doses induces apoptosis and at high doses causes necrosis in a murine pancreatic beta cell line, INS-1. Saini KS, et al. **Biochem Mol Biol Int** 1996 Aug; 39(6):1229–36

Preincubation of thymocytes with 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) induces apoptosis in non-stimulated thymocytes. Sakurai Y, et al. **Biochem Mol Biol Int** 1997 Jul;42(3):433–41

Effects of transcription and translation inhibitors on a human gastric carcinoma cell line. Potential role of Bcl-X(S) in apoptosis triggered by these inhibitors. Chang TC, et al. **Biochem Pharmacol** 1997 Apr 4;53(7):969–77

Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. McBain JA, et al. **Biochem Pharmacol** 1997 May 9;53(9):1357–68

Inhibition of thymocyte apoptosis by berberine. Miura N, et al. **Biochem Pharmacol** 1997 May 9;53(9):1315–22

Involvement of gene-specific DNA damage and apoptosis in the differential toxicity of mitomycin C analogs towards B-lineage versus T-lineage lymphoma cells. Muscarella DE, et al. **Biochem Pharmacol** 1997 Mar 21;53(6):811–22

Position 16 of the steroid nucleus modulates glucocorticoid-induced apoptosis at the transcriptional level in murine T-lymphocytes. Perrin-Wolff M, et al. **Biochem Pharmacol** 1996 Nov 8;52(9):1469–76

Regulation of neutrophil apoptosis by diadenosine pentaphosphate and GM-CSF. Gasmi L, et al. **Biochem Soc Trans** 1996 Aug;24(3):491S

Induction of apoptosis within T lymphoblastoid cells by a topoisomerase I inhibitor. Johnson N, et al. **Biochem Soc Trans** 1997 May;25(2):240S

Modulation of neutrophil apoptosis by pharmacological agents. Moulding DA, et al. **Biochem Soc Trans** 1996 Aug; 24(3):492S

S100 beta induces apoptotic cell death in cultured astrocytes via a nitric oxide-dependent pathway. Hu J, et al. **Biochim Biophys Acta** 1996 Oct 11;1313(3):239–45

Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Kuo ML, et al. **Biochim Biophys Acta** 1996 Nov 15;1317(2):95–100

Induction of embryonal carcinoma cell differentiation by deferoxamine, a potent therapeutic iron chelator. Tanaka T, et al. **Biochim Biophys Acta** 1997 Jun 5;1357(1):91–7

Transient induction of apoptosis in serum-starved glioma cells by insulin and IGF-1. Yang BC, et al. **Biochim Biophys Acta** 1996 Nov 8;1314(1-2):83–92

Induction of apoptosis in the germ cells of adult male rats after exposure to cyclophosphamide. Cai L, et al. **Biol Reprod** 1997 Jun;56(6):1490–7

Apoptosis induced by selenium in human glioma cell lines. Zhu Z, et al. **Biol Trace Elem Res** 1996 Aug;54(2):123–34

Regulation of neutrophil apoptosis by sodium butyrate. Moulding D, et al. **Biologicals** 1996 Dec;24(4):301–6

Induction of apoptosis by ubenimex (Bestatin) in human non-small-cell lung cancer cell lines. Ezawa K, et al. **Biomed Pharmacother** 1996;50(6-7):283–9

Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Banker DE, et al. **Blood** 1997 Jan 1;89(1):243–55

Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro. Borge OJ, et al. **Blood** 1996 Oct 15;88(8):2859–70

Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Carlo-Stella C, et al. **Blood** 1996 Oct 15;88(8):3091–100

Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Chauhan D, et al. **Blood** 1997 Jan 1; 89(1):227–34

Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Douglas RS, et al. **Blood** 1997 Feb 1;89(3):941–7

Apoptosis and the dilemma of cancer chemotherapy. Hannun YA. **Blood** 1997 Mar 15;89(6):1845–53 (95 ref.)

Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Hsu CA, et al. **Blood** 1997 Jun 15;89(12):4470–9

Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21R. Iversen PO, et al. **Blood** 1996 Oct 1; 88(7):2634–9

Selection for drug resistance results in resistance to Fas-mediated apoptosis. Landowski TH, et al. **Blood** 1997 Mar 15;89(6):1854–61

Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Lisovsky M, et al. **Blood** 1996 Nov 15;88(10):3987–97

Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1. Lømo J, et al. **Blood** 1997 Jun 15; 89(12):4415–24

Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Mitra D, et al. **Blood** 1997 Feb 15;89(4):1224–34

CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Osorio LM, et al. **Blood** 1997 Apr 15;89(8):2833–41

Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Weber-Nordt RM, et al. **Blood** 1996 Oct 1;88(7):2549–58

Inhibition of apoptosis in a human pre-B-cell line by CD23 is mediated via a novel receptor. White LJ, et al. **Blood** 1997 Jul 1;90(1):234–43

A cysteine protease inhibitor prevents activation-induced T-cell apoptosis and death of peripheral blood cells from human immunodeficiency virus-infected individuals by inhibiting upregulation of Fas ligand [see comments] Yang Y, et al. **Blood** 1997 Jan 15;89(2):550–7. Comment in: Blood 1997 Jul 15;90(2):886–8.

Ceramide-induced nuclear translocation of NF-kappa B is a potential mediator of the apoptotic response to TNF-alpha in murine clonal osteoblasts. Kitajima I, et al. **Bone** 1996 Sep;19(3):263–70

Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells [letter; comment] Benson JR, et al. **Br J Cancer** 1996 Sep;74(6):993–4. Comment on: Br J Cancer 1995 Dec;72(6):1441–6.

Apoptosis and 1-methyl-2-nitroimidazole toxicity in CHO cells. Brezden CB, et al. **Br J Cancer** 1997;76(2):180–8

Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Ferlini C, et al. **Br J Cancer** 1997;75(6):884–91

The sensitivity of Fanconi anaemia group C cells to apoptosis induced by mitomycin C is due to oxygen radical generation, not DNA crosslinking. Clarke AA, et al. **Br J Haematol** 1997 Feb;96(2):240–7

Dissociation of the effects of the antitumour ether lipid ET-18-OCH3 on cytosolic calcium and on apoptosis. Alonso MT, et al. **Br J Pharmacol** 1997 Aug;121(7):1364–8

Attenuation of p53 expression and Bax down-regulation during phorbol ester mediated inhibition of apoptosis. Messmer UK, et al. **Br J Pharmacol** 1997 Jun;121(4):625–34

In vitro studies of spontaneous and corticosteroid-induced apoptosis of lymphocyte populations from metamorphosing frogs/RU486 inhibition. Barker KS, et al. **Brain Behav Immun** 1997 Jun;11(2):119–31

Dexamethasone prevents apoptosis in a neonatal rat model of hypoxic-ischemic encephalopathy (HIE) by a reactive oxygen species-independent mechanism. Ekert P, et al. **Brain Res** 1997 Jan 30;747(1):9–17

Carbamazepine induction of apoptosis in cultured cerebellar neurons: effects of N-methyl-D-aspartate, aurintricarboxylic acid and cycloheximide. Gao XM, et al. **Brain Res** 1995 Dec 12;703(1-2):63–71

Polyamines prevent apoptotic cell death in cultured cerebellar granule neurons. Harada J, et al. **Brain Res** 1997 Apr 11;753(2):251–9

Beta-amyloid induces apoptosis in human-derived neurotypic SH-SY5Y cells. Li YP, et al. **Brain Res** 1996 Nov 4;738(2):196–204

Effect of systemic zinc administration on delayed neuronal death in the gerbil hippocampus. Matsushita K, et al. **Brain Res** 1996 Dec 16;743(1-2):362–5

Stimulation of N-methyl-D-aspartate receptors induces apoptosis in rat brain. Qin ZH, et al. **Brain Res** 1996 Jul 1;725(2):166–76

Apoptosis in the striatum of rats following intraperitoneal injection of 3-nitropropionic acid. Sato S, et al. **Brain Res** 1997 Jan 16;745(1-2):343–7

Apoptosis is induced by choline deficiency in fetal brain and in PC12 cells. Holmes-McNary MQ, et al. **Brain Res Dev Brain Res** 1997 Jul 18;101(1-2):9–16

CeReS-18, a novel cell surface sialoglycopeptide, induces cell cycle arrest and apoptosis in a calcium-sensitive manner. Betz NA, et al. **Breast Cancer Res Treat** 1997 Jan; 42(2):137–48

Changes of biological features in breast cancer cells determined by primary chemotherapy. Frassoldati A, et al. **Breast Cancer Res Treat** 1997 Jul;44(3):185–92

Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Huang Y, et al. **Breast Cancer Res Treat** 1997 Jan;42(1):73–81

Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Simboli-Campbell M, et al. **Breast Cancer Res Treat** 1997 Jan;42(1):31–41

Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Bu SZ, et al. **Cancer** 1997 May 15;79(10):1944–50

Potentiation of etoposide-induced apoptosis by staurosporine in human tumor cells is associated with events downstream of DNA-protein complex formation. Lock RB, et al. **Cancer Chemother Pharmacol** 1997;39(5):399–409

Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Nakatsu S, et al. **Cancer Chemother Pharmacol** 1997;39(5):417–23

Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion. Nord LD, et al. **Cancer Chemother Pharmacol** 1997;40(5):376–84

The role of apoptosis in the modulation of colon carcinogenesis by dietary fat and by the organoselenium compound 1,4-phenylenebis(methylene)selenocyanate. Samaha HS, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Sep;6(9):699–704

Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: enhancement with interferon gamma. Takamuku K, et al. **Cancer Immunol Immunother** 1996 Dec;43(4):220–5

Perspective: the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Martin DS, et al. **Cancer Invest** 1997; 15(4):372–81 (97 ref.)

The role of cell death and cell proliferation in the promotion of rat liver tumours by tamoxifen. Carthew P, et al. **Cancer Lett** 1996 Sep 10;106(2):163–9

Colon tumor promotion: is it a selective process? Effects of cholate, phytate, and food restriction in rats on proliferation and apoptosis in normal and aberrant crypts. Corpet DE, et al. **Cancer Lett** 1997 Mar 19;114(1-2):135–8

High-risk HPV-positive human cancer cell lines show different sensitivity to cisplatin-induced apoptosis correlated with the p21Waf1/Cip1 level. Funaoka K, et al. **Cancer Lett** 1996 Nov 12;108(1):15–23

Deoxycholic acid and SCFA-induced apoptosis in the human tumor cell-line HT-29 and possible mechanisms. Marchetti C, et al. **Cancer Lett** 1997 Mar 19;114(1-2):97–9

Vitamin D3 reduces the apoptotic effect of IFN-gamma but does not facilitate HLA class II inducibility in RB-defective cells. Schmidt B, et al. **Cancer Lett** 1996 Dec 20;110(1-2):169–76

Induction of differentiation and apoptosis by sodium selenite

in human colonic carcinoma cells (HT29). Stewart MS, et al. **Cancer Lett** 1997 Jul 15;117(1):35–40

Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Wang TT, et al. **Cancer Lett** 1996 Oct 1;107(1):65–71

Effects of dehydroepiandrosterone and calorie restriction on the Bcl-2/Bax-mediated apoptotic pathway in p53-deficient mice. Wang TT, et al. **Cancer Lett** 1997 Jun 3;116(1):61–9

Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination. Adam L, et al. **Cancer Res** 1997 Mar 15;57(6):1023–9

Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Daly JM, et al. **Cancer Res** 1997 Sep 1;57(17):3804–11

Two- and three-dimensional cell structures govern epidermal growth factor survival function in human bladder carcinoma cell lines. Dangles V, et al. **Cancer Res** 1997 Aug 15;57(16):3360–4

p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Debernardis D, et al. **Cancer Res** 1997 Mar 1;57(5):870–4

Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Decaudin D, et al. **Cancer Res** 1997 Jan 1;57(1):62–7

Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis. Dricu A, et al. **Cancer Res** 1997 Feb 1;57(3):543–8

Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Dunn SE, et al. **Cancer Res** 1997 Jul 1;57(13):2687–93

The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Fulda S, et al. **Cancer Res** 1997 Sep 1;57(17):3823–9

Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression. Geley S, et al. **Cancer Res** 1996 Nov 1;56(21):5033–8

Bcl2 is the guardian of microtubule integrity. Haldar S, et al. **Cancer Res** 1997 Jan 15;57(2):229–33

Inhibition of apoptosis in colon tumors induced in the rat by 2-amino-3-methylimidazo[4,5-f]quinoline. Hayashi R, et al. **Cancer Res** 1996 Oct 1;56(19):4307–10

Endometrial hyperplasia and apoptosis following neonatal diethylstilbestrol exposure and subsequent estrogen stimulation in both host and transplanted hamster uteri. Hendry WJ 3rd, et al. **Cancer Res** 1997 May 15; 57(10):1903–8

Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. Huang TS, et al. **Cancer Res** 1997 Jul 15;57(14):2974–8

Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Ibrado AM, et al. **Cancer Res** 1996 Oct 15;56(20):4743–8

Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Ibrado AM, et al. **Cancer Res** 1997 Mar 15;57(6):1109–15

Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Jansen B, et al. **Cancer Res** 1997 Feb 1;57(3):362–5

Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins. Krystal GW, et al. **Cancer Res** 1997 Jun 1;57(11):2203–8

Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. McConkey DJ, et al. **Cancer Res** 1996 Dec 15;56(24):5594–9

GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Miquel K, et al. **Cancer Res** 1997 May 15;57(10):1846–50

Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Mollinedo F, et al. **Cancer Res** 1997 Apr 1; 57(7):1320–8

Phenobarbital causes apoptosis in conditionally immortalized mouse hepatocytes depending on deregulated c-myc expression: characterization of an unexpected effect. Osanai M, et al. **Cancer Res** 1997 Jul 15;57(14):2896–903

Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Samaha HS, et al. **Cancer Res** 1997 Apr 1;57(7):1301–5

Involvement of hydrogen peroxide production in erbstatin-induced apoptosis in human small cell lung carcinoma cells. Simizu S, et al. **Cancer Res** 1996 Nov 1; 56(21):4978–82

Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Turley JM, et al. **Cancer Res** 1997 Mar 1;57(5):881–90

Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Watabe M, et al. **Cancer Res** 1997 Aug 1;57(15):3097–100

Apoptosis and cancer chemotherapy. Lutzker SG, et al. **Cancer Treat Res** 1996;87:345–56 (75 ref.)

Short exposures to tunicamycin induce apoptosis in SV40-transformed but not in normal human fibroblasts. Carlberg M, et al. **Carcinogenesis** 1996 Dec;17(12):2589–96

Effects of the carcinogen, acrylonitrile, on forestomach cell proliferation and apoptosis in the rat: comparison with methacrylonitrile. Ghanayem BI, et al. **Carcinogenesis** 1997 Apr;18(4):675–80

Iron-induced apoptosis in mouse renal proximal tubules after an injection of a renal carcinogen, iron-nitrilotriacetate. Kawabata T, et al. **Carcinogenesis** 1997 Jul;18(7):1389–94

Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Redman C, et al. **Carcinogenesis** 1997 Jun;18(6):1195–202

Butyrate can act as a stimulator of growth or inducer of apoptosis in human colonic epithelial cell lines depending on the presence of alternative energy sources. Singh B, et al. **Carcinogenesis** 1997 Jun;18(6):1265–70

Alterations in immunoglobulin synthesis during adriamycin-induced apoptosis in mouse hybridoma cells. Meliksetian MB, et al. **Cell Biol Int** 1997 Feb;21(2):69–74

Nuclear factor of activated T cells (NFAT) is a possible target for dexamethasone in thymocyte apoptosis. Wisniewska M, et al. **Cell Biol Int** 1997 Mar;21(3):127–32

Distinct Ca2+ response patterns in human natural killer cells during induction of necrosis or apoptosis of target cells. Honda Y, et al. **Cell Calcium** 1996 Apr;19(4):297–306

Response of a primary human fibroblast cell line to H2O2: senescence-like growth arrest or apoptosis? Bladier C, et al. **Cell Growth Differ** 1997 May;8(5):589–98

Retinoic acid and IFN inhibition of cell proliferation is associated with apoptosis in squamous carcinoma cell lines: role of IRF-1 and TGase II-dependent pathways. Giandomenico V, et al. **Cell Growth Differ** 1997 Jan; 8(1):91–100

Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67). Grant S, et al. **Cell Growth Differ** 1996 May;7(5):603–13

Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Gulli LF, et al. **Cell Growth Differ** 1996 Feb;7(2):173–8

Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Heerdt BG, et al. **Cell Growth Differ** 1997 May;8(5):523–32

Time correlation of commitment to calcium-induced apoptosis and terminal differentiation in human ectocervical keratinocytes in suspension cultures. Kikuchi K, et al. **Cell Growth Differ** 1997 May;8(5):571–9

Persistent membrane translocation of protein kinase C alpha during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Powell CT, et al. **Cell Growth Differ** 1996 Apr;7(4):419–28

Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Ray S, et al. **Cell Growth Differ** 1996 Dec;7(12):1617–23

Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Roberson KM, et al. **Cell Growth Differ** 1997 Jan; 8(1):101–11

p53-independent induction of apoptosis by cyclin-dependent kinase inhibition. Shibata Y, et al. **Cell Growth Differ** 1996 Jul;7(7):887–91

Treatment of U937 cells with bufalin induces the translocation of casein kinase 2 and modulates the activity of topoisomerase II prior to the induction of apoptosis. Watabe M, et al. **Cell Growth Differ** 1997 Aug;8(8):871–9

Apoptosis induced by inhibitors of the plasma membrane NADH-oxidase involves Bcl-2 and calcineurin. Wolvetang EJ, et al. **Cell Growth Differ** 1996 Oct;7(10):1315–25

Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Xu LH, et al. **Cell Growth Differ** 1996 Apr;7(4):413–8

Potentiation of the activity of nitric oxide by the protein kinase C activator phorbol ester in human myeloid leukemic HL-60 cells: association with enhanced fragmentation of mature genomic DNA. Jun CD, et al. **Cell Immunol** 1997 Feb 25;176(1):41–9

Augmentation of lipopolysaccharide-induced thymocyte apoptosis by interferon-gamma. Kato Y, et al. **Cell Immunol** 1997 May 1;177(2):103–8

The apoptosis and proliferation of SAC-activated B cells by IL-10 are associated with changes in Bcl-2, Bcl-xL, and Mcl-1 expression. Li L, et al. **Cell Immunol** 1997 May 25;178(1):33–41

Membrane form of TNF alpha induces both cell lysis and apoptosis in susceptible target cells. Monastra G, et al. **Cell Immunol** 1996 Jul 10;171(1):102–10

Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Zettl UK, et al. **Cell Immunol** 1997 May 25;178(1):1–8

Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2. Offen D, et al. **Cell Mol Neurobiol** 1997 Jun;17(3):289–304

Growth factors and apoptosis. Granérus M, et al. **Cell Prolif** 1996 Jun;29(6):309–14

Cell proliferation and nuclear abnormalities are increased and apoptosis is decreased in the epidermis of the p53 null mouse after topical application of benzo[a]pyrene. Miller ML, et al. **Cell Prolif** 1996 Oct;29(10):561–76

The apoptosis of HEL cells induced by hydroxyurea. Gui CY, et al. **Cell Res** 1997 Jun;7(1):91–7

Terminal transferase positive rat thymocytes are resistant to steroid-induced apoptosis. Trubiani O, et al. **Cell Struct Funct** 1995 Dec;20(6):455–63

Withdrawal of butyrate from the colonic mucosa triggers "mass apoptosis" primarily in the G0/G1 phase of the cell cycle. Luciano L, et al. **Cell Tissue Res** 1996 Oct; 286(1):81–92

Mechanism of dithiocarbamate inhibition of apoptosis: thiol oxidation by dithiocarbamate disulfides directly inhibits processing of the caspase-3 proenzyme. Nobel CS, et al. **Chem Res Toxicol** 1997 Jun;10(6):636–43

Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Pollman MJ, et al. **Circ Res** 1996 Oct; 79(4):748–56

Ceramide is not a signal for tumor necrosis factor-induced gene expression but does cause programmed cell death in human vascular endothelial cells. Slowik MR, et al. **Circ Res** 1996 Oct;79(4):736–47

Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the 'response to injury' hypothesis. Dimmeler S, et al. **Circulation** 1997 Apr 1;95(7):1760–3

The bcl-2 gene product prevents programmed cell death of ventricular myocytes. Kirshenbaum LA, et al. **Circulation** 1997 Sep 2;96(5):1580–5

The prolonged survival of human eosinophils with interleukin-5 and its inhibition by theophylline via apoptosis. Ohta K, et al. **Clin Exp Allergy** 1996 Mar;26 Suppl 2:10–5

Effects of rapamycin on apoptosis of rheumatoid synovial cells. Migita K, et al. **Clin Exp Immunol** 1997 May; 108(2):199–203

IL-5 but not interferon-gamma (IFN-gamma) inhibits eosinophil apoptosis by up-regulation of bcl-2 expression. Ochiai K, et al. **Clin Exp Immunol** 1997 Jan;107(1):198–204

The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720. Suzuki S, et al. **Clin Exp Immunol** 1997 Jan;107(1):103–11

Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF-alpha production in SLE but not in normal cultures. Evans MJ, et al. **Clin Immunol Immunopathol** 1997 Mar;82(3):258–62

Can zinc prevent apoptosis of anterior keratocytes after superficial keratectomy? Kuo IC, et al. **Cornea** 1997 Sep; 16(5):550–5

ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis. Rouquet N, et al. **Curr Biol** 1996 Sep 1;6(9):1192–5

1 alpha, 25-dihydroxyvitamin D3 (calcitriol) induces apoptosis in stimulated T cells through an IL-2 dependent mechanism. Pintado CO, et al. **Cytokine** 1996 May; 8(5):342–5

Bax upregulation is an early event in cisplatin-induced apoptosis in human testicular germ-cell tumor cell line NT2, as quantitated by flow cytometry. Boersma AW, et al. **Cytometry** 1997 Mar 1;27(3):275–82

Caffeine induces S-phase apoptosis in cis-diamminedichloroplatinum-treated cells, whereas cis-diamminedichloroplatinum induces a block in G2/M. Shinomiya N, et al. **Cytometry** 1997 Apr 1;27(4):365–73

Specific induction of apoptosis in P19 embryonal carcinoma cells by retinoic acid and BMP2 or BMP4. Glozak MA, et al. **Dev Biol** 1996 Nov 1;179(2):458–70

Steroid hormones act directly to trigger segment-specific programmed cell death of identified motoneurons in vitro. Streichert LC, et al. **Dev Biol** 1997 Mar 1;183(1):95–107

Induction of bimodal programmed cell death in malignant cells by the derivative Ukrain (NSC-631570). Liepins A, et al. **Drugs Exp Clin Res** 1996;22(3-5):73–9

HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. Bardelli A, et al. **EMBO J** 1996 Nov 15;15(22):6205–12

Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. Dubrez L, et al. **EMBO J** 1996 Oct 15;15(20):5504–12

A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL-3. Gotoh N, et al. **EMBO J** 1996 Nov 15;15(22):6197–204

Ras signaling in tumor necrosis factor-induced apoptosis. Trent JC 2nd, et al. **EMBO J** 1996 Sep 2;15(17):4497–505

Cytokines induce deoxyribonuclei acid strand breaks and apoptosis in human pancreatic islet cells. Delaney CA, et al. **Endocrinology** 1997 Jun;138(6):2610–4

Tumor necrosis factor-alpha and its second messenger, ceramide, stimulate apoptosis in cultured ovarian follicles. Kaipia A, et al. **Endocrinology** 1996 Nov;137(11):4864–70

Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial cells. Kato H, et al. **Endocrinology** 1997 Jun;138(6):2615–20

Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Kawakami A, et al. **Endocrinology** 1996 Aug;137(8):3163–9

Preantral ovarian follicles in serum-free culture: suppression of apoptosis after activation of the cyclic guanosine 3',5'-monophosphate pathway and stimulation of growth and differentiation by follicle-stimulating hormone. McGee

E, et al. **Endocrinology** 1997 Jun;138(6):2417–24
Insulin–like growth factor–1 inhibition of apoptosis is associated with increased expression of the bcl–xL gene product. Párrizas M, et al. **Endocrinology** 1997 Mar; 138(3):1355–8
3,5,3'–Triiodo–L–thyronine potentiates all–trans–retinoic acid–induced apoptosis during differentiation of the promyeloleukemic cell HL–60. Suzuki S, et al. **Endocrinology** 1997 Feb;138(2):805–9
Basic fibroblast growth factor and N–cadherin maintain rat granulosa cell and ovarian surface epithelial cell viability by stimulating the tyrosine phosphorylation of the fibroblast growth factor receptors. Trolice MP, et al. **Endocrinology** 1997 Jan;138(1):107–13
Gentamicin ototoxicity induced apoptosis of the vestibular hair cells of guinea pigs. Nakagawa T, et al. **Eur Arch Otorhinolaryngol** 1997;254(1):9–14
Cell death caused by the acute effects of aminoglycoside and zinc in the ampullary cristae of guinea pigs. Nakagawa T, et al. **Eur Arch Otorhinolaryngol** 1997;254(3):153–7
Induction by interferons of human eosinophil apoptosis and regulation by interleukin–3, granulocyte/macrophage–colony stimulating factor and interleukin–5. Morita M, et al. **Eur Cytokine Netw** 1996 Dec;7(4):725–32
Membrane modifications in human erythroleukemia K562 cells during induction of programmed cell death by transforming growth factor beta 1 or cisplatin. Maccarrone M, et al. **Eur J Biochem** 1996 Oct 1;241(1):297–302
Induction of programmed cell death and immunosuppression by exogenous sphingolipids are separate processes. Olshefski R, et al. **Eur J Biochem** 1996 Oct 1;241(1):47–55
7alpha–Hydroxylation and 3–dehydrogenation abolish the ability of 25–hydroxycholesterol and 27–hydroxycholesterol to induce apoptosis in thymocytes. Zhang J, et al. **Eur J Biochem** 1997 Jul 1;247(1):129–35
Etoposide at different concentrations may open different apoptotic pathways in thymocytes. Pellicciari C, et al. **Eur J Histochem** 1996;40(4):289–98
Thiols prevent Fas (CD95)–mediated T cell apoptosis by down–regulating membrane Fas expression. Delneste Y, et al. **Eur J Immunol** 1996 Dec;26(12):2981–8
Sensitivity of Epstein–Barr virus–induced B cell tumor to apoptosis mediated by anti–CD95/Apo–1/fas antibody. Durandy A, et al. **Eur J Immunol** 1997 Feb;27(2):538–43
Modulation of Apo–1/Fas (CD95)–induced programmed cell death in myeloma cells by interferon–alpha 2. Egle A, et al. **Eur J Immunol** 1996 Dec;26(12):3119–26
T cell sensitivity to HLA class I–mediated apoptosis is dependent on interleukin–2 and interleukin–4. Genestier L, et al. **Eur J Immunol** 1997 Feb;27(2):495–9
Spontaneously produced anti–DNA/DNase I autoantibodies modulate nuclear apoptosis in living cells. Madaio MP, et al. **Eur J Immunol** 1996 Dec;26(12):3035–41
CD43 expression in a B cell lymphoma, WEHI 231, reduces susceptibility to G1 arrest and extends survival in culture upon serum depletion. Misawa Y, et al. **Eur J Immunol** 1996 Nov;26(11):2573–81
Substitution of testosterone in a HIV–1 positive patient with hypogonadism and Wasting–syndrome led to a reduced rate of apoptosis. Klein SA, et al. **Eur J Med Res** 1997 Jan; 2(1):30–2
Maturation–dependent modulation of apoptosis in cultured cerebellar granule neurons by cytokines and neurotrophins. de Luca A, et al. **Eur J Neurosci** 1996 Sep;8(9):1994–2005
Noradrenaline inhibits the programmed cell death induced by 1,25–dihydroxyvitamin D3 in glioma. Canova C, et al. **Eur J Pharmacol** 1997 Jan 29;319(2–3):365–8
Role of glutathione metabolism in the glutamate–induced programmed cell death of neuronal–like PC12 cells. Froissard P, et al. **Eur J Pharmacol** 1997 May 12; 326(1):93–9
Quinine inhibits release of tumor necrosis factor, apoptosis, necrosis and mortality in a murine model of septic liver failure. Gantner F, et al. **Eur J Pharmacol** 1995 Dec 27; 294(1):353–5
Tyrosine kinase inhibitors and cycloheximide inhibit Li+ protection of cerebellar granule neurons switched to non–depolarizing medium. Grignon S, et al. **Eur J Pharmacol** 1996 Nov 7;315(1):111–4
Vitamin C and E prevent lipopolysaccharide–induced apoptosis in human endothelial cells by modulation of Bcl–2 and Bax. Haendeler J, et al. **Eur J Pharmacol** 1996 Dec 19;317(2–3):407–11
Nitric oxide donors induce apoptosis in glomerular mesangial cells, epithelial cells and endothelial cells. Mühl H, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):137–49
Increased brain NAD prevents neuronal apoptosis in vivo. Mukherjee SK, et al. **Eur J Pharmacol** 1997 Jul 2; 330(1):27–34
Low levels of hydrogen peroxide and L–histidine induce DNA double–strand breakage and apoptosis. Palomba L, et al. **Eur J Pharmacol** 1996 Dec 27;318(1):167–73
Flupirtine increases the levels of glutathione and Bcl–2 in hNT (human Ntera/D1) neurons: mode of action of the drug–mediated anti–apoptotic effect. Perovic S, et al. **Eur J Pharmacol** 1996 Dec 12;317(1):157–64
Apoptotic effects of imidazo[1,2–a]pyrazine derivatives in the human Dami cell line. Zurbonsen K, et al. **Eur J Pharmacol** 1997 Feb 12;320(2–3):215–21
Process of the development of T–2 toxin–induced apoptosis in the lymphoid organs of mice. Shinozuka J, et al. **Exp Anim** 1997 Apr;46(2):117–26
FGF–2 inhibits apoptosis in human teratocarcinoma cells during differentiation on collagen substratum. Alanko T, et al. **Exp Cell Res** 1996 Nov 1;228(2):306–12
Apoptosis of L929 cells by etoposide: a quantitative and kinetic approach. Bonelli G, et al. **Exp Cell Res** 1996 Nov 1;228(2):292–305
Angiotensin II activates programmed myocyte cell death in vitro. Cigola E, et al. **Exp Cell Res** 1997 Mar 15; 231(2):363–71
FGF2–stimulated release of endogenous FGF1 is associated with reduced apoptosis in retinal pigmented epithelial cells. Guillonneau X, et al. **Exp Cell Res** 1997 May 25; 233(1):198–206
Induction of apoptotic cell death in a neuroblastoma cell line by dibucaine. Kim M, et al. **Exp Cell Res** 1997 Mar 15; 231(2):235–41
Glutamate–treated rat cortical neuronal cultures die in a way different from the classical apoptosis induced by staurosporine. MacManus JP, et al. **Exp Cell Res** 1997 Jun 15;233(2):310–20
Differentiation to an NGF–dependent state and apoptosis following NGF removal both occur asynchronously in cultures of PC12 cells. Mills JC, et al. **Exp Cell Res** 1997 Mar 15;231(2):337–45
Suppression of apoptotic cell death of IL–3–dependent cell lines by ER/SR Ca2+–ATPase inhibitors upon IL–3 deprivation. Palaga T, et al. **Exp Cell Res** 1996 Oct 10; 228(1):92–7
Tumor necrosis factor–alpha–induced apoptosis in a human keratinocyte cell line (HaCaT) is counteracted by transforming growth factor–alpha. Reinartz J, et al. **Exp Cell Res** 1996 Nov 1;228(2):334–40
7–Hydroxystaurosporine (UCN–01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53. Shao RG, et al. **Exp Cell Res** 1997 Aug 1; 234(2):388–97
Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53. Shao RG, et al. **Exp Cell Res** 1996 Sep 15;227(2):190–6
Inhibition of ICE–related proteases (caspases) and nuclear apoptosis by phenylarsine oxide. Takahashi A, et al. **Exp Cell Res** 1997 Feb 25;231(1):123–31
Antiapoptotic action of 1,25–dihydroxyvitamin D3 is associated with increased mitochondrial MCL–1 and RAF–1 proteins and reduced release of cytochrome c. Wang X, et al. **Exp Cell Res** 1997 Aug 25;235(1):210–7
Cyclosporin A rescues thymocytes from apoptosis induced by very low concentrations of thapsigargin: effects on mitochondrial function. Waring P, et al. **Exp Cell Res** 1996 Sep 15;227(2):264–76
Vascular permeability factor/vascular endothelial growth factor inhibits anchorage–disruption–induced apoptosis in microvessel endothelial cells by inducing scaffold formation. Watanabe Y, et al. **Exp Cell Res** 1997 Jun 15; 233(2):340–9
Biochemical differences between staurosporine–induced apoptosis and premature mitosis. Yoshida M, et al. **Exp Cell Res** 1997 May 1;232(2):225–39
Stimulation of B–chronic lymphocytic leukemia cells by murine fibroblasts, IL–4, anti–CD40 antibodies, and the soluble CD40 ligand. Buske C, et al. **Exp Hematol** 1997 Apr;25(4):329–37
Induction of apoptosis in megakaryocytic leukemia cell lines by MX2, a morpholino anthracycline. Katsurada T, et al. **Exp Hematol** 1997 Sep;25(10):1077–83
Differential regulation by hematopoietic growth factors of apoptosis and mitosis in acute myeloblastic leukemia cells. Murohashi I, et al. **Exp Hematol** 1997 Sep;25(10):1042–50
Characterization of zinc–induced neuronal death in primary cultures of rat cerebellar granule cells. Manev H, et al. **Exp Neurol** 1997 Jul;146(1):171–8
Prevention of dopamine–induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Offen D, et al. **Exp Neurol** 1996 Sep; 141(1):32–9
Apoptosis and delayed neuronal damage after carbon monoxide poisoning in the rat. Piantadosi CA, et al. **Exp Neurol** 1997 Sep;147(1):103–14
Liver apoptosis after dimethylnitrosamine administration in shrews. Shikata N, et al. **Exp Toxicol Pathol** 1996 Jun; 48(4):307–11
Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. Mansat V, et al. **FASEB J** 1997 Jul; 11(8):695–702
The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells. Simantov R, et al. **FASEB J** 1997 Feb;11(2):141–6
Differential involvement of caspases in apoptosis of myeloid leukemic cells induced by chemotherapy versus growth factor withdrawal. Barge RM, et al. **FEBS Lett** 1997 Jun 9;409(2):207–10
The induction of apoptosis in proliferating human fibroblasts by oxygen radicals is associated with a p53– and p21WAF1CIP1 induction. Gansauge S, et al. **FEBS Lett** 1997 Mar 3;404(1):6–10
Ceramides induce a form of apoptosis in human acute lymphoblastic leukemia cells that is inhibited by Bcl–2, but not by CrmA. Geley S, et al. **FEBS Lett** 1997 Jan 2; 400(1):15–8
Role of peroxide and superoxide anion during tumour cell apoptosis. Gorman A, et al. **FEBS Lett** 1997 Mar 3; 404(1):27–33
Ceramide induces apoptosis in PC12 cells. Hartfield PJ, et al. **FEBS Lett** 1997 Jan 20;401(2–3):148–52
Involvement of u–PA in the anti–apoptotic activity of TGFbeta for vascular smooth muscle cells. Herbert JM, et al. **FEBS Lett** 1997 Aug 25;413(3):401–4
Bafilomycin A1 induces apoptosis in PC12 cells independently of intracellular pH [published erratum appears in FEBS Lett 1997 Feb 10;403(1):112] Kinoshita K, et al. **FEBS Lett** 1996 Nov 25;398(1):61–6
G2 cell cycle arrest and apoptosis are induced in Burkitt's lymphoma cells by the anticancer agent oracin. Klucar J, et al. **FEBS Lett** 1997 Jan 2;400(1):127–30
Regulatory effects of aggregated LDL on apoptosis during foam cell formation of human peripheral blood monocytes. Kubo N, et al. **FEBS Lett** 1997 Jun 9;409(2):177–82
Reactive oxygen species induce apoptosis of vascular smooth muscle cell. Li PF, et al. **FEBS Lett** 1997 Mar 10; 404(2–3):249–52
Met–enkephalin induces cytolytic processes of apoptotic type in K562 human erythroid leukemia cells. Mernenko OA, et al. **FEBS Lett** 1996 Apr 1;383(3):230–2
Inhibition of ICE–family cysteine proteases rescues murine lymphocytes from lipoxygenase inhibitor–induced apoptosis. Mirzoeva OK, et al. **FEBS Lett** 1996 Nov 4; 396(2–3):266–70
Ceramide induces apoptosis via CPP32 activation. Mizushima N, et al. **FEBS Lett** 1996 Oct 21;395(2–3):267–71
Neopterin and 7,8–dihydroneopterin induce apoptosis in the rat alveolar epithelial cell line L2. Schobersberger W, et al. **FEBS Lett** 1996 Nov 18;397(2–3):263–8
Lipoxygenase inhibitors block CD95 ligand–mediated apoptosis of human malignant glioma cells. Wagenknecht B, et al. **FEBS Lett** 1997 Jun 2;409(1):17–23
Bcl–2 antagonizes apoptotic cell death induced by two new ceramide analogues. Wieder T, et al. **FEBS Lett** 1997 Jul 14;411(2–3):260–4
Role of tumor necrosis factor–alpha and glucocorticoid on lipopolysaccharide (LPS)–induced apoptosis of thymocytes. Kato Y, et al. **FEMS Immunol Med Microbiol** 1995 Dec;12(3–4):195–204
Mycoplasma fermentans enhances concanavalin A–induced apoptosis of mouse splenic T cells. Shibata K, et al. **FEMS Immunol Med Microbiol** 1997 Feb;17(2):103–9
Lipopolysaccharide induces apoptotic cell death of B memory cells and regulates B cell memory in antigen–nonspecific manner. Yokochi T, et al. **FEMS Immunol Med Microbiol** 1996 Aug;15(1):1–8
Apoptosis of WEHI–3B cells after Maphosphamide treatment. Kawiak J, et al. **Folia Histochem Cytobiol** 1996; 34 Suppl 1:39–40
Apoptotic vs. nonapoptotic cytotoxicity induced by hydrogen peroxide. Gardner AM, et al. **Free Radic Biol Med** 1997;22(1–2):73–83
Effect on an iron–chelator on ascorbate–induced cytotoxicity. Sakagami H, et al. **Free Radic Biol Med** 1997; 23(2):260–70
Peroxynitrite–induced apoptosis in T84 and RAW 264.7 cells: attenuation by L–ascorbic acid. Sandoval M, et al. **Free Radic Biol Med** 1997;22(3):489–95
The in vivo effect of the tumor promoter 12–O–tetradecanoylphorbol–13–acetate on N–methyl–N–nitrosourea–induced apoptosis in mouse hair follicles. Hai H, et al. **Fundam Appl Toxicol** 1997 Feb; 35(2):177–81
Perturbation of the mitosis/apoptosis balance: a fundamental mechanism in toxicology. Roberts RA, et al. **Fundam Appl Toxicol** 1997 Aug;38(2):107–15 (44 ref.)
Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes [see comments] Fau D, et al. **Gastroenterology** 1997 Oct;113(4):1334–46. Comment in: Gastroenterology 1997 Oct;113(4):1408–12.
Tumor necrosis factor–induced apoptosis during the poisoning of mice with hepatotoxins. Leist M, et al. **Gastroenterology** 1997 Mar;112(3):923–34
Apoptosis–like (possible quantum thermodynamic) cell death induced by Yoshixol and wood oil of Chamaecyparis obtusa (Kiso–Hinoki) on HeLa cell. Koyama S, et al. **Gen Pharmacol** 1997 May;28(5):805–11
Elevation of an alpha(1,3)fucosyltransferase activity correlated with apoptosis in the human colon adenocarcinoma cell line, HT–29. Akamatsu S, et al. **Glycoconj J** 1996 Dec;13(6):1021–9
Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gibb RK, et al. **Gynecol Oncol** 1997 Apr;65(1):13–22
Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara–C on blast cells from patients with blast crisis chronic myeloproliferative disorders. Santini V, et al. **Haematologica** 1997 Jan–Feb;82(1):11–5
All–trans retinoic acid might also induce apoptosis in freshly isolated chronic myeloid leukemia cells [letter; comment] Stagno F, et al. **Haematologica** 1997 Jan–Feb;82(1):125. Comment on: Haematologica 1995 Jul–Aug;80(4):390–1. Comment on: Haematologica 1996 May–Jun;81(3):286–7.
Different effects of cyclic AMP and butyrate on eosinophilic differentiation, apoptosis and bcl–2 expression of a human eosinophilic leukemia cell line, EoL–1. Tai G, et al. **Hematol Oncol** 1996 Dec;14(4):181–92
Cycloheximide prevents apoptosis, reactive oxygen species production, and glutathione depletion induced by

transforming growth factor beta in fetal rat hepatocytes in primary culture. Sánchez A, et al. **Hepatology** 1997 Oct; 26(4):935–43

Cytoprotection by fructose and other ketohexoses during bile salt–induced apoptosis of hepatocytes. Zeid IM, et al. **Hepatology** 1997 Jan;25(1):81–6

5-Azacytidine (5Az) induces apoptosis in PC12 cells: a model for 5Az-induced apoptosis in developing neuronal cells. Hossain MM, et al. **Histol Histopathol** 1997 Apr; 12(2):439–45

Morphology of ricin and abrin exposed endothelial cells is consistent with apoptotic cell death. Hughes JN, et al. **Hum Exp Toxicol** 1996 May;15(5):443–51

Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. deBlois D, et al. **Hypertension** 1997 Jan;29(1 Pt 2):340–9

Oxysterol–induced apoptosis in human monocytic cell lines. Aupeix K, et al. **Immunobiology** 1995 Nov;194(4–5):415–28

Homologous complement activation on drug–induced apoptotic cells from a human lung adenocarcinoma cell line. Hara T, et al. **Immunobiology** 1996–97;196(5):491–503

Monocyte–derived macrophages prime peripheral T cells to undergo apoptosis by cell–cell contact via ICAM–1/LFA–1–dependent mechanism. Zen K, et al. **Immunobiology** 1996 Aug;195(3):323–33

Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl–2. Tangye SG, et al. **Immunol Cell Biol** 1997 Apr;75(2):127–35

ICE–protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF–alpha. Künstle G, et al. **Immunol Lett** 1997 Jan;55(1):5–10

Nitric oxide induces apoptosis in mouse splenic T lymphocytes. Okuda Y, et al. **Immunol Lett** 1996 Sep; 52(2–3):135–8

Dimethyl sulfoxide induces programmed cell death and reversible G1 arrest in the cell cycle of human lymphoid pre–T cell line. Trubiani O, et al. **Immunol Lett** 1996 Apr; 50(1–2):51–7

Fas, apoptosis and the cell cycle [letter; comment] Manfredi AA, et al. **Immunol Today** 1996 Jul;17(7):345–6. Comment on: Immunol Today 1995 Dec;16(12):569–74.

A new immunosuppressant, FTY720, induces bcl–2–associated apoptotic cell death in human lymphocytes. Suzuki S, et al. **Immunology** 1996 Dec; 89(4):518–23

Interferon–gamma promotes the survival and Fc epsilon RI–mediated histamine release in cultured human mast cells. Yanagida M, et al. **Immunology** 1996 Dec; 89(4):547–52

Effect of thalidomide on apoptosis of lymphocytes and neutrophils. Aseffa A, et al. **Immunopharmacol Immunotoxicol** 1997 Aug;19(3):313–26

Induction of selective cell death targeting on mature T–lymphocytes in rats by a novel immunosuppressant, FTY720. Enosawa S, et al. **Immunopharmacology** 1996 Sep; 34(2–3):171–9

Selective mitomycin C and cyclophosphamide induction of apoptosis in differentiating B lymphocytes compared to T lymphocytes in vivo. Hemendinger RA, et al. **Immunopharmacology** 1996 Oct;35(1):71–82

Generation of reactive oxygen species is required for bucillamine, a novel anti–rheumatic drug, to induce apoptosis in concert with copper. Sawada T, et al. **Immunopharmacology** 1997 Jan;35(3):195–202

N–methyl–N–nitrosourea–induced photoreceptor apoptosis in the mouse retina. Yuge K, et al. **In Vivo** 1996 Sep–Oct; 10(5):483–8

In vivo induction of apoptosis in the thymus by administration of mycobacterial cord factor (trehalose 6,6'–dimycolate). Ozeki Y, et al. **Infect Immun** 1997 May; 65(5):1793–9

2,5–Hexanedione induced apoptosis in cultured mouse DRG neurons. Ogawa Y, et al. **Int Arch Occup Environ Health** 1996;68(6):495–7

CD40 ligation counteracts Fas–induced apoptosis of human dendritic cells. Björck P, et al. **Int Immunol** 1997 Mar; 9(3):365–72

Activation–induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Brunner T, et al. **Int Immunol** 1996 Jul;8(7):1017–26

Induction of Fas–dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis. Hasunuma T, et al. **Int Immunol** 1996 Oct;8(10):1595–602

IL–4 and anti–CD40 protect against Fas–mediated B cell apoptosis and induce B cell growth and differentiation. Nakanishi K, et al. **Int Immunol** 1996 May;8(5):791–8

Physical and functional association of CD45 and CD3–TCR complex on CD1+ human thymocytes. Evidence that the engagement of CD45 molecules can prevent CD1+ thymocytes from apoptosis. Poggi A, et al. **Int Immunol** 1996 Dec;8(12):1947–53

S–adenosylhomocysteine as a physiological modulator of Apo–1–mediated apoptosis. Ratter F, et al. **Int Immunol** 1996 Jul;8(7):1139–47

Elevated expression of Bcl–2 and Bcl–x by intestinal intraepithelial lymphocytes: resistance to apoptosis by glucocorticoids and irradiation. Van Houten N, et al. **Int Immunol** 1997 Jul;9(7):945–53

Possible involvement of protein kinase C–epsilon in phorbol ester–induced growth inhibition of human lymphoblastic cells. Mihalik R, et al. **Int J Biochem Cell Biol** 1996 Aug; 28(8):925–33

Phorbol ester (12–O–tetradecanoylphorbol 13–acetate) prevents ornithine decarboxylase inhibition and apoptosis and L1210 leukemic cells exposed to TGF–beta 1. Motyl T, et al. **Int J Biochem Cell Biol** 1996 Dec;28(12):1327–35

Links between pharmacological properties of retinoids and nuclear retinoid receptors. Bollag W, et al. **Int J Cancer** 1997 Feb 7;70(4):470–2

Induction of apoptosis by ribosome–inactivating proteins and related immunotoxins. Bolognesi A, et al. **Int J Cancer** 1996 Nov 4;68(3):349–55

Cellular responses of HPV–positive cancer cells to genotoxic anti–cancer agents: repression of E6/E7–oncogene expression and induction of apoptosis. Butz K, et al. **Int J Cancer** 1996 Nov 15;68(4):506–13

Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Ellis PA, et al. **Int J Cancer** 1997 Aug 7;72(4):608–13

Glucocorticoid–receptor–gene defects and resistance to glucocorticoid–induced apoptosis in human leukemic cell lines. Hala M, et al. **Int J Cancer** 1996 Nov 27;68(5):663–8

Interference of bcl–2 with intercellular control of carcinogenesis. Jürgensmeier JM, et al. **Int J Cancer** 1997 May 16;71(4):698–704

Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways. Kamohara H, et al. **Int J Cancer** 1997 Aug 7;72(4):687–95

Abrogation of apoptosis induced by DNA–damaging agents in human bladder–cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Kawasaki T, et al. **Int J Cancer** 1996 Nov 15;68(4):501–5

Protection of 5alpha–dihydrotestosterone against TGF–beta–induced apoptosis in FaO cells and induction of mitosis in HepG2 cells. Lim IK, et al. **Int J Cancer** 1997 Jul 17;72(2):351–5

Activation of protein kinase C prevents induction of apoptosis by geranylgeraniol in human leukemia HL60 cells. Masuda Y, et al. **Int J Cancer** 1997 May 16; 71(4):691–7

Paclitaxel–induced apoptosis in MCF–7 breast–cancer cells. Saunders DE, et al. **Int J Cancer** 1997 Jan 17;70(2):214–20

Tetrapeptide DEVD–aldehyde or YVAD–chloromethylketone inhibits Fas/Apo–1(CD95)–mediated apoptosis in renal–cell–cancer cells. Tomita Y, et al. **Int J Cancer** 1996 Sep 27;68(1):132–5

Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5–fluorouracil. Ueda M, et al. **Int J Cancer** 1997 May 16;71(4):668–74

The anti–tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Wang SY, et al. **Int J Cancer** 1997 Mar 17; 70(6):699–705

Control of skeletogenesis and programmed cell death in the developing avian limb bud by growth factors. Gañan Y, et al. **Int J Dev Biol** 1996;Suppl 1:189S

Cytoarchitectural changes during retinoic acid–induced apoptosis in F9 embryonal carcinoma cells. García–Sanz M, et al. **Int J Dev Biol** 1996;Suppl 1:195S–196S

Correlation between RA–induced apoptosis and patterning defects in regenerating fins and limbs. Géraudie J, et al. **Int J Dev Biol** 1997 Jun;41(3):529–32

Veratridine delays apoptotic neuronal death induced by NGF deprivation through a Na(+)–dependent mechanism in cultured rat sympathetic neurons. Tanaka S, et al. **Int J Dev Neurosci** 1997 Feb;15(1):15–27

In the absence of Epstein–Barr virus infection, phorbol ester modulates apoptosis in cycloheximide–treated Burkitt's lymphoma (BJA–B) cells. Ishii H, et al. **Int J Exp Pathol** 1997 Jun;78(3):123–31

Effects of colony–stimulating factors (CSFs) on neutrophil apoptosis: possible roles at inflammation site. Hu B, et al. **Int J Hematol** 1997 Aug;66(2):179–88

Apoptotic cell death of human T lymphoblastoid cells induced by arginine deiminase. Komada Y, et al. **Int J Hematol** 1997 Feb;65(2):129–41

Differential induction of apoptosis on human lymphoblastic leukemia Nalm–6 and Molt–4 cells by various antitumor drugs. Tsurusawa M, et al. **Int J Hematol** 1997 Jul; 66(1):79–88

Induction of apoptotic cell death in rat thymus and spleen after a bolus injection of methamphetamine. Iwasa M, et al. **Int J Legal Med** 1996;109(1):23–8

Cell proliferation and death in the irradiated pituitary gland and its modification by growth stimulants. Guo YP, et al. **Int J Radiat Oncol Biol Phys** 1997 Apr 1;38(1):175–81

Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL–5. Adachi T, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S207–15

Negative signaling in B cells by surface immunoglobulins. Mayumi M, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S238–47 (102 ref.)

Cell aggregation and apoptosis induced by hemodialysis membranes. Carracedo J, et al. **J Am Soc Nephrol** 1995 Dec;6(6):1586–91

Neutrophil superoxide release is required for spontaneous and FMLP–mediated but not for TNF alpha–mediated apoptosis. Kettritz R, et al. **J Am Soc Nephrol** 1997 Jul; 8(7):1091–100

Reactive oxygen species induce apoptosis in cultured human mesangial cells. Sugiyama H, et al. **J Am Soc Nephrol** 1996 Nov;7(11):2357–63

2–Methoxyacetic acid (MAA)–induced spermatocyte apoptosis in human and rat testes: an in vitro comparison. Li LH, et al. **J Androl** 1996 Sep–Oct;17(5):538–49

Leydig cell apoptosis in response to ethane dimethanesulphonate after both in vivo and in vitro treatment. Morris AJ, et al. **J Androl** 1997 May–Jun; 18(3):274–80

Cytotrienin A, a novel apoptosis inducer in human leukemia HL–60 cells [letter] Kakeya H, et al. **J Antibiot (Tokyo)** 1997 Apr;50(4):370–2

Inhibitors of phospholipase promote apoptosis of human endothelial cells. Miao JY, et al. **J Biochem (Tokyo)** 1997 Mar;121(3):612–8

Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells. Tanimoto Y, et al. **J Biochem (Tokyo)** 1997 Mar;121(3):542–9

Paclitaxel–induced apoptosis in HeLa cells is serum dependent. Maldonado V, et al. **J Biochem Toxicol** 1996; 11(4):183–8

Dysregulation of bcl–2, c–myc, and Fas expression during tricyclic antidepressant–induced apoptosis in human peripheral lymphocytes. Xia Z, et al. **J Biochem Toxicol** 1996;11(4):203–4

Cleavage of PITSLRE kinases by ICE/CASP–1 and CPP32/CASP–3 during apoptosis induced by tumor necrosis factor. Beyaert R, et al. **J Biol Chem** 1997 May 2;272(18):11694–7

Superoxide formation and macrophage resistance to nitric oxide–mediated apoptosis. Brüne B, et al. **J Biol Chem** 1997 Mar 14;272(11):7253–8

Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1. Chen Q, et al. **J Biol Chem** 1997 Jun 6;272(23):14532–41

Transcriptional activation of the cdc2 gene is associated with Fas–induced apoptosis of human hematopoietic cells. Furukawa Y, et al. **J Biol Chem** 1996 Nov 8; 271(45):28469–77

A novel family of viral death effector domain–containing molecules that inhibit both CD–95– and tumor necrosis factor receptor–1–induced apoptosis. Hu S, et al. **J Biol Chem** 1997 Apr 11;272(15):9621–4

Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor–alpha–induced apoptosis by inducing heat shock protein 70 expression. Kim YM, et al. **J Biol Chem** 1997 Jan 10;272(2):1402–11

p53–dependent induction of apoptosis by proteasome inhibitors. Lopes UG, et al. **J Biol Chem** 1997 May 16; 272(20):12893–6

Activation of multiple interleukin–1beta converting enzyme homologues in cytosol and nuclei of HL–60 cells during etoposide–induced apoptosis. Martins LM, et al. **J Biol Chem** 1997 Mar 14;272(11):7421–30

Interferon–gamma modulates a p53–independent apoptotic pathway and apoptosis–related gene expression. Ossina NK, et al. **J Biol Chem** 1997 Jun 27;272(26):16351–7

Activation of c–Jun N–terminal kinase antagonizes an anti–apoptotic action of Bcl–2. Park J, et al. **J Biol Chem** 1997 Jul 4;272(27):16725–8

Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate–induced apoptosis. Paumen MB, et al. **J Biol Chem** 1997 Feb 7;272(6):3324–9

Progestins prevent apoptosis in a rat endometrial cell line and increase the ratio of bcl–XL to bcl–XS. Pecci A, et al. **J Biol Chem** 1997 May 2;272(18):11791–8

Zinc is a potent inhibitor of the apoptotic protease, caspase–3. A novel target for zinc in the inhibition of apoptosis. Perry DK, et al. **J Biol Chem** 1997 Jul 25;272(30):18530–3

Implication of mitochondrial hydrogen peroxide generation in ceramide–induced apoptosis. Quillet–Mary A, et al. **J Biol Chem** 1997 Aug 22;272(34):21388–95

1–(5–Isoquinolinesulfonyl)–2–methylpiperazine induces apoptosis in human neuroblastoma cells, SH–SY5Y, through a p53–dependent pathway. Ronca F, et al. **J Biol Chem** 1997 Feb 14;272(7):4252–60

c–Jun NH2–terminal kinase–mediated activation of interleukin–1beta converting enzyme/CED–3–like protease during anticancer drug–induced apoptosis. Seimiya H, et al. **J Biol Chem** 1997 Feb 14;272(7):4631–6

Cardiotrophin 1 (CT–1) inhibition of cardiac myocyte apoptosis via a mitogen–activated protein kinase–dependent pathway. Divergence from downstream CT–1 signals for myocardial cell hypertrophy. Sheng Z, et al. **J Biol Chem** 1997 Feb 28;272(9):5783–91

Bax can antagonize Bcl–XL during etoposide and cisplatin–induced cell death independently of its heterodimerization with Bcl–XL. Simonian PL, et al. **J Biol Chem** 1996 Sep 13;271(37):22764–72

Degradation of retinoblastoma protein in tumor necrosis factor– and CD95–induced cell death. Tan X, et al. **J Biol Chem** 1997 Apr 11;272(15):9613–6

Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. Wu CF, et al. **J Biol Chem** 1997 Jun 6;272(23):14860–6

Induction of apoptosis and CPP32 expression by thyroid hormone in a myoblastic cell line derived from tadpole tail. Yaoita Y, et al. **J Biol Chem** 1997 Feb 21;272(8):5122–7

Specific inhibitors of vacuolar H(+)–ATPase trigger apoptotic cell death of osteoclasts. Okahashi N, et al. **J Bone Miner Res** 1997 Jul;12(7):1116–23

Bisphosphonates induce apoptosis in mouse macrophage–like cells in vitro by a nitric oxide–independent mechanism.

Rogers MJ, et al. **J Bone Miner Res** 1996 Oct; 11(10):1482–91

Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. Zimra Y, et al. **J Cancer Res Clin Oncol** 1997;123(3):152–60

Human papillomavirus (HPV) 16 E6 sensitizes cells to atractyloside-induced apoptosis: role of p53, ICE-like proteases and the mitochondrial permeability transition. Brown J, et al. **J Cell Biochem** 1997 Aug 1;66(2):245–55

Methyl-group donors cannot prevent apoptotic death of rat hepatocytes induced by choline-deficiency. Shin OH, et al. **J Cell Biochem** 1997 Feb;64(2):196–208

Final checkpoint in the drug-promoted and poliovirus-promoted apoptosis is under post-translational control by growth factors. Tolskaya EA, et al. **J Cell Biochem** 1996 Dec 15;63(4):422–31

Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. Schadendorf D, et al. **J Cell Biol** 1996 Dec;135(6 Pt 2):1889–98

Cell susceptibility to apoptosis by glutamine deprivation and rescue: survival and apoptotic death in cultured lymphoma-leukemia cell lines. Petronini PG, et al. **J Cell Physiol** 1996 Oct;169(1):175–85

Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. Wang TS, et al. **J Cell Physiol** 1996 Nov;169(2):256–68

DNA fragmentation and Prolonged expression of c-fos, c-jun, and hsp70 in kainic acid-induced neuronal cell death in transgenic mice overexpressing human CuZn-superoxide dismutase. Kondo T, et al. **J Cereb Blood Flow Metab** 1997 Mar;17(3):241–56

Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32. Adjei PN, et al. **J Clin Invest** 1996 Dec 1; 98(11):2588–96

Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function. Higuchi M, et al. **J Clin Invest** 1997 Apr 1; 99(7):1751–8

Glucose promotes survival of rat pancreatic beta cells by activating synthesis of proteins which suppress a constitutive apoptotic program. Hoorens A, et al. **J Clin Invest** 1996 Oct 1;98(7):1568–74

Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. Krown KA, et al. **J Clin Invest** 1996 Dec 15;98(12):2854–65

Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. Müller M, et al. **J Clin Invest** 1997 Feb 1;99(3):403–13

Antisense oligonucleotides to Cux-1, a Cut-related homeobox gene, cause increased apoptosis in mouse embryonic kidney cultures. Quaggin SE, et al. **J Clin Invest** 1997 Feb 15;99(4):718–24

Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. Redondo C, et al. **J Clin Invest** 1996 Sep 1; 98(5):1245–52

Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. Wright AS, et al. **J Clin Invest** 1996 Dec 1;98(11):2558–63

Cycloheximide-induced apoptosis in melanoma cells derived from regressing cutaneous tumours of Sinclair swine. Gossett R, et al. **J Comp Pathol** 1996 Nov;115(4):353–72

Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. Kameda T, et al. **J Exp Med** 1997 Aug 18;186(4):489–95

Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. Susin SA, et al. **J Exp Med** 1996 Oct 1; 184(4):1331–41

Expression of Fas and anti-Fas-mediated apoptosis in human hepatocellular carcinoma cell lines. Yano H, et al. **J Hepatol** 1996 Oct;25(4):454–64

IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection: correlation with its ability to block culture-induced down-modulation of Bcl-2. Adachi Y, et al. **J Immunol** 1996 Nov 1;157(9):4184–93

Intracellular Ca2+ elevation and cyclosporin A synergistically induce TGF-beta 1-mediated apoptosis in lymphocytes. Andjelic S, et al. **J Immunol** 1997 Mar 15; 158(6):2527–34

Increased heat shock protein 90 (hsp90) expression leads to increased apoptosis in the monoblastoid cell line U937 following induction with TNF-alpha and cycloheximide: a possible role in immunopathology. Galea-Lauri J, et al. **J Immunol** 1996 Nov 1;157(9):4109–18

Apoptosis induced by HIV infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas(CD95) antagonist. Glynn JM, et al. **J Immunol** 1996 Oct 1; 157(7):2754–8

Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids. Hébert MJ, et al. **J Immunol** 1996 Oct 1; 157(7):3105–15

Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion: possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state. Iwata S, et al. **J Immunol** 1997 Apr 1;158(7):3108–17

TNF receptor-2-triggered apoptosis is associated with the down-regulation of Bcl-xL on activated T cells and can be prevented by CD28 costimulation. Lin RH, et al. **J Immunol** 1997 Jan 15;158(2):598–603

Activation of phosphatidylinositol 3'-kinase by insulin-like growth factor-I rescues promyeloid cells from apoptosis and permits their differentiation into granulocytes. Liu Q, et al. **J Immunol** 1997 Jul 15;159(2):829–37

Dual role of HIV Tat in regulation of apoptosis in T cells. McCloskey TW, et al. **J Immunol** 1997 Jan 15;158(2):1014–9

Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor. Novelli F, et al. **J Immunol** 1996 Sep 1; 157(5):1935–43

Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. Okura T, et al. **J Immunol** 1996 Nov 15;157(10):4277–81

IL-4 and IL-10 modulation of CD40-mediated signaling of monocyte IL-1beta synthesis and rescue from apoptosis. Poe JC, et al. **J Immunol** 1997 Jul 15;159(2):846–52

Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. Potvin F, et al. **J Immunol** 1997 Feb 15;158(4):1872–9

TGF-beta 1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. Riedl E, et al. **J Immunol** 1997 Feb 15;158(4):1591–7

Granzyme B induces apoptosis and cyclin A-associated cyclin-dependent kinase activity in all stages of the cell cycle. Shi L, et al. **J Immunol** 1996 Sep 15;157(6):2381–5

Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. Suda T, et al. **J Immunol** 1996 Nov 1;157(9):3918–24

Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice. Van Molle W, et al. **J Immunol** 1997 Oct 1;159(7):3555–64

I-309/T cell activation gene-3 chemokine protects murine T cell lymphomas against dexamethasone-induced apoptosis. Van Snick J, et al. **J Immunol** 1996 Sep 15; 157(6):2570–6

The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. Veiby OP, et al. **J Immunol** 1996 Oct 1;157(7):2953–60

Neutrophil apoptosis is modulated by endothelial transmigration and adhesion molecule engagement. Watson RW, et al. **J Immunol** 1997 Jan 15;158(2):945–53

Critical role of Lyn kinase in inhibition of neutrophil apoptosis by granulocyte-macrophage colony-stimulating factor. Wei S, et al. **J Immunol** 1996 Dec 1;157(11):5155–62

IL-1beta depresses expression of the 70-kilodalton heat shock protein and sensitizes glomerular cells to oxidant-initiated apoptosis. Yokoo T, et al. **J Immunol** 1997 Sep 15; 159(6):2886–92

IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway. Zamorano J, et al. **J Immunol** 1996 Dec 1; 157(11):4926–34

Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes. Zauli G, et al. **J Immunol** 1996 Sep 1;157(5):2216–24

Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. Zipp F, et al. **J Immunol** 1997 Sep 1;159(5):2108–15

TNF-induced intracellular signaling leading to gene induction or to cytotoxicity by necrosis or by apoptosis. Fiers W, et al. **J Inflamm** 1995-96;47(1-2):67–75 (27 ref.)

Mechanisms in interleukin-2 protection against glucocorticoid-induced apoptosis: regulation of AP-1 and glucocorticoid receptor transcriptional activities. Guizani L, et al. **J Interferon Cytokine Res** 1996 Aug;16(8):601–9

Treatment of ME180 cells with interferon-gamma causes apoptosis as a result of tryptophan starvation. Konan KV, et al. **J Interferon Cytokine Res** 1996 Sep;16(9):751–6

Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. Freiberg RA, et al. **J Invest Dermatol** 1997 Feb;108(2):215–9

Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism. Scott G, et al. **J Invest Dermatol** 1997 Feb;108(2):147–53

The effect of cyclophosphamide on Fas-mediated apoptosis. Lee JH, et al. **J Korean Med Sci** 1997 Jun;12(3):185–9

Dexamethasone-induced suppression of apoptosis in human neutrophils requires continuous stimulation of new protein synthesis. Cox G, et al. **J Leukoc Biol** 1997 Feb; 61(2):224–30

Apoptotic cell death in activated monocytes following incorporation of clodronate-liposomes [letter; comment] Moghimi SM. **J Leukoc Biol** 1997 May;61(5):643–5. Comment on: J Leukoc Biol 1996 Aug;60(2):230–44.

Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro. Naito M, et al. **J Leukoc Biol** 1996 Sep;60(3):337–44

Mechanisms involved in sodium arsenite-induced apoptosis of human neutrophils. Watson RW, et al. **J Leukoc Biol** 1996 Nov;60(5):625–32

Growth-inhibitory and apoptosis-inducing activities of calprotectin derived from inflammatory exudate cells on normal fibroblasts: regulation by metal ions. Yui S, et al. **J Leukoc Biol** 1997 Jan;61(1):50–7

Evaluation of a trans configuration for the apoptosis-inducing activity of ceramide. Kishida E, et al. **J Lipid Mediat Cell Signal** 1997 Jul;16(3):127–37

Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-alpha-induced apoptosis and toxicity in the liver. Saavedra JE, et al. **J Med Chem** 1997 Jun 20; 40(13):1947–54

Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. Kajstura J, et al. **J Mol Cell Cardiol** 1997 Mar;29(3):859–70

Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. Zhang J, et al. **J Mol Cell Cardiol** 1996 Sep;28(9):1931–43

Acetaminophen, N-acetyl-benzo-quinoneimine, and apoptosis [comment] Luft FC. **J Mol Med** 1997 Jul; 75(7):465–6 (8 ref.). Comment on: J Mol Med 1997 Jul;75(7):522–7.

Apoptosis induced in neuronal cultures by either the phosphatase inhibitor okadaic acid or the kinase inhibitor staurosporine is attenuated by isoquinolinesulfonamides H-7, H-8, and H-9. Cagnoli CM, et al. **J Mol Neurosci** 1996 Spring;7(1):65–76

Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. Arcamone F, et al. **J Natl Cancer Inst** 1997 Aug 20;89(16):1217–23

Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play [editorial] Debatin KM. **J Natl Cancer Inst** 1997 Jun 4;89(11):750–1 (17 ref.)

Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA [see comments] Dixit M, et al. **J Natl Cancer Inst** 1997 Mar 5;89(5):365–73. Comment in: J Natl Cancer Inst 1997 Mar 5;89(5):341–3.

N-(4-hydroxyphenyl)retinamide activation of a distinct pathway signaling apoptosis [editorial; comment] Dmitrovsky E. **J Natl Cancer Inst** 1997 Aug 20; 89(16):1179–81. Comment on: J Natl Cancer Inst 1997 Aug 20;89(16):1191–8.

Researchers seek the role of antioxidants in apoptosis [news] Holzman D. **J Natl Cancer Inst** 1997 Mar 19;89(6):413–4

Apoptosis of N-type neuroblastoma cells after differentiation with 9-cis-retinoic acid and subsequent washout. Lovat PE, et al. **J Natl Cancer Inst** 1997 Mar 19;89(6):446–52

Baseline apoptosis of tumor cells as a response predictor to chemotherapy [letter; comment] Provinciali M, et al. **J Natl Cancer Inst** 1997 Jun 18;89(12):889–90. Comment on: J Natl Cancer Inst 1996 Sep 18;88(18):1308–14.

Induction of mitosis-related genes during dopamine-triggered apoptosis in sympathetic neurons. Shirvan A, et al. **J Neural Transm Suppl** 1997;50:67–78

(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. Tatton WG, et al. **J Neural Transm Suppl** 1996;48:45–59 (98 ref.)

Ethanol promotes apoptosis in cerebellar granule cells by inhibiting the trophic effect of NMDA. Bhave SV, et al. **J Neurochem** 1997 Feb;68(2):578–86

Chronic exposure to kappa-opioids enhances the susceptibility of immortalized neurons (F-11kappa 7) to apoptosis-inducing drugs by a mechanism that may involve ceramide. Dawson G, et al. **J Neurochem** 1997 Jun; 68(6):2363–70

Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion. Müller WE, et al. **J Neurochem** 1997 Jun;68(6):2371–7

Biochemical and temporal analysis of events associated with apoptosis induced by lowering the extracellular potassium concentration in mouse cerebellar granule neurons. Nardi N, et al. **J Neurochem** 1997 Feb;68(2):750–9

Cocaine induces apoptosis in cortical neurons of fetal mice. Nassogne MC, et al. **J Neurochem** 1997 Jun;68(6):2442–50

Ca2+ and reactive oxygen species in staurosporine-induced neuronal apoptosis. Prehn JH, et al. **J Neurochem** 1997 Apr; 68(4):1679–85

Two waves of cyclin B and proliferating cell nuclear antigen expression during dopamine-triggered neuronal apoptosis. Shirvan A, et al. **J Neurochem** 1997 Aug;69(2):539–49

Nerve growth factor protects PC12 cells against peroxynitrite-induced apoptosis via a mechanism dependent on phosphatidylinositol 3-kinase. Spear N, et al. **J Neurochem** 1997 Jul;69(1):53–9

Retinoic acid induces apoptosis in PC12 cells independent of neurotrophic factors. Tong L, et al. **J Neurochem** 1997 Apr;68(4):1424–35

2'-deoxyadenosine induces apoptosis in rat chromaffin cells. Wakade AR, et al. **J Neurochem** 1996 Dec;67(6):2273–81

Enhancement of apoptosis in developing chick neural retina cells by basic fibroblast growth factor. Yokoyama Y, et al. **J Neurochem** 1997 May;68(5):2212–5

Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of V beta 8.2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of V beta 8.2+ cells. McCombe PA,

et al. **J Neuroimmunol** 1996 Nov;70(2):93–101

The cell cycle and induction of apoptosis in a hamster fibrosarcoma cell line treated with anti-cancer drugs: its importance to solid tumour chemotherapy. el Alaoui S, et al. **J Neurooncol** 1997 Jan;31(1–2):195–207

Methylazoxymethanol acetate–induced apoptosis in the external granule cell layer of the developing cerebellum of the rat is associated with strong c-Jun expression and formation of high molecular weight c-Jun complexes. Ferrer I, et al. **J Neuropathol Exp Neurol** 1997 Jan;56(1):1–9

Increased apoptosis of T lymphocytes and macrophages in the central and peripheral nervous systems of Lewis rats with experimental autoimmune encephalomyelitis treated with dexamethasone. Nguyen KB, et al. **J Neuropathol Exp Neurol** 1997 Jan;56(1):58–69

Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. Donovan FM, et al. **J Neurosci** 1997 Jul 15;17(14):5316–26

Neurotrophins suppress apoptosis induced by deafferentation of an avian motor-cortical region. Johnson F, et al. **J Neurosci** 1997 Mar 15;17(6):2101–11

Glial growth factor rescues Schwann cells of mechanoreceptors from denervation–induced apoptosis. Kopp DM, et al. **J Neurosci** 1997 Sep 1;17(17):6697–706

Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. Pappolla MA, et al. **J Neurosci** 1997 Mar 1;17(5):1683–90

G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin–induced neuronal apoptosis. Park DS, et al. **J Neurosci** 1997 Feb 15;17(4):1256–70

Pituitary adenylate cyclase–activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. Villalba M, et al. **J Neurosci** 1997 Jan 1;17(1):83–90

Anabolic steroids induce injury and apoptosis of differentiated skeletal muscle. Abu-Shakra S, et al. **J Neurosci Res** 1997 Jan 15;47(2):186–97

1,25-Dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line. Baudet C, et al. **J Neurosci Res** 1996 Dec 1;46(5):540–50

4-Aminopyridine causes apoptosis and blocks an outward rectifier K+ channel in malignant astrocytoma cell lines. Chin LS, et al. **J Neurosci Res** 1997 Apr 15;48(2):122–7

Ethanol–exposed central neurons fail to migrate and undergo apoptosis. Liesi P. **J Neurosci Res** 1997 Jun 1;48(5):439–48

TGF-beta1 prevents gp120–induced impairment of Ca2+ homeostasis and rescues cortical neurons from apoptotic death. Scorziello A, et al. **J Neurosci Res** 1997 Sep 1; 49(5):600–7

Basic fibroblast growth factor prevents cAMP–induced apoptosis in cultured Schwann cells. Shaw R, et al. **J Neurosci Res** 1997 Feb 15;47(4):400–4

Dopamine induces apoptosis in cultured rat striatal neurons; possible mechanism of D2-dopamine receptor neuron loss during aging. Shinkai T, et al. **J Neurosci Res** 1997 Feb 15;47(4):393–9

Inhibition of nuclear factor kappa B (NFkappaB) activity induces nerve growth factor–resistant apoptosis in PC12 cells. Taglialatela G, et al. **J Neurosci Res** 1997 Jan 15; 47(2):155–62

MK-801 induces apoptotic neuronal death in the rat retrosplenial cortex: prevention by cycloheximide and R(-)-2-hexyl-N-methylpropargylamine. Zhang X, et al. **J Neurosci Res** 1996 Oct 1;46(1):82–9

Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application. Hamilton HB, et al. **J Neurosurg** 1996 Aug;85(2):329–34

Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. New DR, et al. **J Neurovirol** 1997 Apr;3(2):168–73

Antioxidative mechanism and apoptosis induction by 3-hydroxyanthranilic acid, an antioxidant in Indonesian food Tempeh, in the human hepatoma-derived cell line, HuH-7. Matsuo M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Apr;43(2):249–59

Apoptosis and proliferation (PCNA labelling) in CML--a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy. Thiele J, et al. **J Pathol** 1997 Mar;181(3):316–22

The tricyclic antidepressants clomipramine and citalopram induce apoptosis in cultured human lymphocytes [letter] Xia Z, et al. **J Pharm Pharmacol** 1996 Jan;48(1):115–6

Lead (Pb+2) promotes apoptosis in newborn rat cerebellar neurons: pathological implications. Oberto A, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):435–42

Protection of acetaminophen–induced hepatocellular apoptosis and necrosis by cholesteryl hemisuccinate pretreatment. Ray SD, et al. **J Pharmacol Exp Ther** 1996 Dec;279(3):1470–83

Inhibitors of coenzyme A–independent transacylase induce apoptosis in human HL-60 cells. Winkler JD, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):956–66

Concentration-dependent modes of cell death in Chinese hamster V79 cells after treatments with H2O2. Hiraoka W, et al. **J Radiat Res (Tokyo)** 1997 Jun;38(2):95–102

Apoptosis pattern elicited by oestradiol treatment of the seminiferous epithelium of the adult rat. Blanco-Rodríguez J, et al. **J Reprod Fertil** 1997 May;110(1):61–70

Teratogen–induced apoptosis may be affected by immunopotentiation. Toder V, et al. **J Reprod Immunol** 1996 May;30(2-3):173–85

Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. James SY, et al. **J Steroid Biochem Mol Biol** 1996 Jul;58(4):395–401

1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. Simboli-Campbell M, et al. **J Steroid Biochem Mol Biol** 1996 Jul;58(4):367–76

Changes in levels of mRNAs of transforming growth factor (TGF)-beta1, -beta2, -beta3, TGF-beta type II receptor and sulfated glycoprotein-2 during apoptosis of mouse uterine epithelium. Wada K, et al. **J Steroid Biochem Mol Biol** 1996 Dec;59(5–6):367–75

Effect of preoperative 5-fluorouracil on apoptosis of advanced gastric cancer. Inada T, et al. **J Surg Oncol** 1997 Jun;65(2):106–10

Cadmium–induced apoptosis in the urogenital organs of the male rat and its suppression by chelation. Yan H, et al. **J Toxicol Environ Health** 1997 Oct 10;52(2):149–68

Rapid apoptotic changes in the gastric glandular epithelium of rats administered intraperitoneally with fusarenon-X. Li J, et al. **J Vet Med Sci** 1997 Jan;59(1):17–22

Course of apoptotic changes in the rat gastric mucosa caused by oral administration of fusarenon-X. Li J, et al. **J Vet Med Sci** 1997 Mar;59(3):191–9

Effect of brefeldin A on influenza A virus–induced apoptosis in vitro. Saito T, et al. **J Vet Med Sci** 1996 Nov; 58(11):1137–9

The adenovirus E3–14.7K protein and the E3–10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)–induced apoptosis, also independently inhibit TNF–induced release of arachidonic acid. Krajcsi P, et al. **J Virol** 1996 Aug;70(8):4904–13

Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Hara A, et al. **Jpn J Cancer Res** 1997 Jun;88(6):600–4

Immunocytochemistry of apoptosis induced by bromodeoxyuridine in human leukemic HL-60 cells. Kondo K, et al. **Jpn J Cancer Res** 1997 Jan;88(1):44–8

Apoptosis in mesangial cells induced by ionizing radiation and cytotoxic drugs. Cha DR, et al. **Kidney Int** 1996 Nov; 50(5):1565–71

Native and oxidized low density lipoproteins modulate mesangial cell apoptosis. Sharma P, et al. **Kidney Int** 1996 Nov;50(5):1604–11

Peritoneal dialysis solution induces apoptosis of mesothelial cells. Yang AH, et al. **Kidney Int** 1997 Apr;51(4):1280–8

Apoptosis of hair follicle cells during doxorubicin–induced alopecia in rats. Cece R, et al. **Lab Invest** 1996 Oct; 75(4):601–9

Insulin-like growth factors prevent apoptosis in cortical neurons isolated from stroke-prone spontaneously hypertensive rats. Tagami M, et al. **Lab Invest** 1997 May; 76(5):603–12

Insulin-like growth factor-1 attenuates apoptosis in hippocampal neurons caused by cerebral ischemia and reperfusion in stroke-prone spontaneously hypertensive rats. Tagami M, et al. **Lab Invest** 1997 May;76(5):613–7

Preoperative chemotherapy induces apoptosis in early breast cancer [letter] Ellis PA, et al. **Lancet** 1997 Mar 22; 349(9055):849

Differential effects of retinoic acid and N-(4-hydroxyphenyl)retinamide on head and neck squamous cell carcinoma cells. Eicher SA, et al. **Laryngoscope** 1996 Dec;106(12 Pt 1):1471–5

N-(4-hydroxyphenyl)retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells. Chan LN, et al. **Leuk Lymphoma** 1997 Apr;25(3-4):271–80

Morphologic evidence of apoptosis in childhood acute myeloblastic leukemia treated with high-dose methylprednisolone. Hiçsönmez G, et al. **Leuk Lymphoma** 1996 Jun;22(1-2):91–6,follow.186,color plate VII–III

Interferon-alpha, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia. Jewell AP. **Leuk Lymphoma** 1996 Mar;21(1-2):43–7 (48 ref.)

C-Myc and Bcl-2 protein expression during the induction of apoptosis and differentiation in TNF alpha-treated HL-60 cells. Kumakura S, et al. **Leuk Lymphoma** 1996 Oct; 23(3-4):383–94

Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia. Mainou-Fowler T, et al. **Leuk Lymphoma** 1996 May;21(5-6):369–77 (126 ref.)

Rotenone, a mitochondrial NADH dehydrogenase inhibitor, induces cell surface expression of CD13 and CD38 and apoptosis in HL-60 cells. Matsunaga T, et al. **Leuk Lymphoma** 1996 Feb;20(5-6):487–94

Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Reittie JE, et al. **Leuk Lymphoma** 1996 Jun;22(1-2):83–90, follow. 186, color plate VI

Interleukin-4 is a pleotropic cytokine with effects on B-cell malignancies [comment] Dutcher JP, et al. **Leuk Res** 1997 Jan;21(1):17–9. Comment on: Leuk Res 1997 Jan;21(1):9–16.

Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients [see comments] Frankfurt OS, et al. **Leuk Res** 1997 Jan;21(1):9–16. Comment in: Leuk Res 1997 Jan;21(1):17–9.

Purging effect of dibutyl phthalate on leukemic cells associated with apoptosis. Lisheng W, et al. **Leuk Res** 1996 Nov-Dec;20(11-12):989–92

Multiple centrosomal microtubule organising centres and increased microtubule stability are early features of VP-16–induced apoptosis in CCRF-CEM cells. Pittman S, et al. **Leuk Res** 1997 Jun;21(6):491–9

Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells. Vial JP, et al. **Leuk Res** 1997 Feb; 21(2):163–72

Triiodothyronine blocks potentiation of HL60 monocyte differentiation by anti-inflammatory agents and by steroids and induces apoptosis of all-trans retinoic acid "primed" cells. Wallington LA, et al. **Leuk Res** 1997 Jul;21(7):623–34

Apoptosis of human myeloid leukemia cells induced by an inhibitor of protein phosphatases (okadaic acid) is prevented by Bcl-2 and Bcl-X(L). Benito A, et al. **Leukemia** 1997 Jul;11(7):940–4

Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein. Bullock G, et al. **Leukemia** 1996 Nov;10(11):1731–40

TGF-beta inhibits growth and induces apoptosis in leukemic B cell precursors. Buske C, et al. **Leukemia** 1997 Mar; 11(3):386–92

Induction of apoptosis by 2-chlorodeoxyadenosine in B cell chronic lymphocytic leukemia. Castejón R, et al. **Leukemia** 1997 Aug;11(8):1253–7

Apoptosis and resistance to daunorubicin in human leukemic cells. Efferth T, et al. **Leukemia** 1997 Jul;11(7):1180–6

Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug–mediated apoptosis in human myeloid leukemia cells (HL-60). Freemerman AJ, et al. **Leukemia** 1997 Apr;11(4):504–13

Granulocyte-colony stimulating factor induced apoptosis in radiation–induced murine leukemia cell line. Handa A, et al. **Leukemia** 1997 Apr;11 Suppl 3:387–8

Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. König A, et al. **Leukemia** 1997 Feb;11(2):258–65

Cell-permeable ceramide inhibits the growth of B lymphoma Raji cells lacking TNF-alpha-receptors by inducing G0/G1 arrest but not apoptosis: a new model for dissecting cell-cycle arrest and apoptosis. Kuroki J, et al. **Leukemia** 1996 Dec;10(12):1950–8

Inhibition of apoptotic cell death in B-CLL by interferon gamma correlates with clinical stage. Rojas R, et al. **Leukemia** 1996 Nov;10(11):1782–8

Camptothecin–induced apoptosis in p53–null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Shimizu T, et al. **Leukemia** 1997 Aug;11(8):1238–44

Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Visani G, et al. **Leukemia** 1997 May;11(5):624–8

Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid. Yaguchi M, et al. **Leukemia** 1997 Jun;11(6):779–87

Changes in apoptosis of human polymorphonuclear granulocytes with aging. Fülöp T Jr, et al. **Mech Ageing Dev** 1997 Jun;96(1-3):15–34

Effect of melatonin and pineal grafting on thymocyte apoptosis in aging mice. Provinciali M, et al. **Mech Ageing Dev** 1996 Sep 9;90(1):1–19

Assay for detection of nitric oxide–induced apoptosis. Fehsel K, et al. **Methods Enzymol** 1996;269:426–34

Apoptosis of intestinal intraepithelial lymphocytes induced by exogenous and endogenous glucocorticoids. Murosaki S, et al. **Microbiol Immunol** 1997;41(2):139–48

Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function. Kuo ML, et al. **Mol Carcinog** 1997 Apr;18(4):221–31

Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. Zhao B, et al. **Mol Carcinog** 1997 Jul;19(3):180–90

Effect of apoptosis-related compounds on Ca2+ transport system in isolated rat liver nuclei. Ueoka S, et al. **Mol Cell Biochem** 1997 Jan;166(1-2):183–9

Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl–transformed cells. Weissinger EM, et al. **Mol Cell Biol** 1997 Jun;17(6):3229–41

Crosstalk during Ca2+-, cAMP-, and glucocorticoid–induced gene expression in lymphocytes. Dowd DR, et al. **Mol Cell Endocrinol** 1997 Apr 4; 128(1-2):29–37

Brain-derived neurotrophic factor suppresses programmed death of cerebellar granule cells through a posttranslational mechanism. Suzuki K, et al. **Mol Chem Neuropathol** 1997 Jan-Feb;30(1-2):101–24

Transcriptional control of steroid-regulated apoptosis in murine thymoma cells. Chapman MS, et al. **Mol Endocrinol** 1996 Aug;10(8):967–78

Role of c-jun induction in the glucocorticoid-evoked apoptotic pathway in human leukemic lymphoblasts. Zhou F, et al. **Mol Endocrinol** 1996 Mar;10(3):306–16

Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Kyle E, et al. **Mol Pharmacol** 1997 Feb; 51(2):193–200

Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Masserano JM, et al. **Mol Pharmacol** 1996 Nov;50(5):1309–15

Induction of apoptosis by benzene metabolites in HL60 and CD34+ human bone marrow progenitor cells. Moran JL, et al. **Mol Pharmacol** 1996 Sep;50(3):610–5

Characteristics of clodronate–induced apoptosis in osteoclasts and macrophages. Selander KS, et al. **Mol Pharmacol** 1996 Nov;50(5):1127–38

Induction of apoptosis by retinoids and retinoic acid receptor gamma–selective compounds in mouse thymocytes through a novel apoptosis pathway. Szondy Z, et al. **Mol Pharmacol** 1997 Jun;51(6):972–82

Inhibition of O6–alkylguanine DNA–alkyltransferase or poly(ADP–ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Tentori L, et al. **Mol Pharmacol** 1997 Aug;52(2):249–58

2–Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress–activated protein kinase signaling pathway and Fas expression. Yue TL, et al. **Mol Pharmacol** 1997 Jun;51(6):951–62

Changes in gene transcription during a beta–mediated cell death. Iwasaki K, et al. **Mol Psychiatry** 1996 Mar;1(1):65–71

Inhibition of the interleukin–1 beta converting enzyme family rescues neurons from apoptotic death. Lynch T, et al. **Mol Psychiatry** 1997 May;2(3):227–38

Endotoxin–induced apoptosis in ovarian follicles is partially blocked by 2–methylthioATP or 2–chloroATP. Perez GI, et al. **Mol Reprod Dev** 1996 Jul;44(3):360–9

Levodopa induces apoptosis in cultured neuronal cells––a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Ziv I, et al. **Mov Disord** 1997 Jan; 12(1):17–23

A role for apoptosis in the toxicity and mutagenicity of bleomycin in AHH–1 tk+/– human lymphoblastoid cells. Morris SM, et al. **Mutat Res** 1996 Oct 25;357(1–2):143–65

Reduced expression of mature TGF beta 1 correlates with the suppression of rat hepatocyte apoptosis by the peroxisome proliferator, nafenopin. Strange J, et al. **Mutat Res** 1996 Nov 11;372(1):107–13

The inhibition of pro–apoptotic ICE–like proteases enhances HIV replication. Chinnaiyan AM, et al. **Nat Med** 1997 Mar; 3(3):333–7

Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–beta. Hughes DE, et al. **Nat Med** 1996 Oct; 2(10):1132–6

Novel retinoid–related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Lu XP, et al. **Nat Med** 1997 Jun;3(6):686–90

Selective radiosensitization of p53–deficient cells by caffeine–mediated activation of p34cdc2 kinase. Yao SL, et al. **Nat Med** 1996 Oct;2(10):1140–3

Transient elevation of intracellular calcium ion levels as an early event in T–2 toxin–induced apoptosis in human promyelotic cell line HL–60. Yoshino N, et al. **Nat Toxins** 1996;4(5):234–41

Inhibitors of ser/thr phosphatases 1 and 2A induce apoptosis in pituitary GH3 cells. Tergau F, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jul; 356(1):8–16

Dose–dependent effects of berberine on cell cycle pause and apoptosis in Balb/c 3T3 cells. Yang IW, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Jul; 354(2):102–8

Protein kinase inhibitors: induction of apoptosis and drug–resistance modulation in neoplastic cell lines. Chorváth B, et al. **Neoplasma** 1996;43(1):3–9 (71 ref.)

Stimulation of 1–(beta–D–arabinofuranosyl)cytosine (AraC)–induced apoptosis in the multidrug resistant human promyelocytic leukemia cell lines with protein kinase inhibitors. Hunáková L, et al. **Neoplasma** 1996;43(5):291–5

Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Dugan LL, et al. **Neurobiol Dis** 1996 Apr; 3(2):129–35

Prevention of apoptotic motoneuron death in vitro by neurotrophins and muscle extract. Kaal EC, et al. **Neurochem Int** 1997 Aug;31(2):193–201

Characterization of hydrogen peroxide toxicity in cultured rat forebrain neurons. Hoyt KR, et al. **Neurochem Res** 1997 Mar;22(3):333–40

Selective role of glutathione in protecting human neuronal cells from dopamine–induced apoptosis. Gabby M, et al. **Neuropharmacology** 1996 May;35(5):571–8

The HIV–1 envelope protein gp120 induces neuronal apoptosis in hippocampal slices. Aggoun–Zouaoui D, et al. **Neuroreport** 1996 Jan 31;7(2):433–6

The HIV–1 gp120 causes ultrastructural changes typical of apoptosis in the rat cerebral cortex. Bagetta G, et al. **Neuroreport** 1996 Jul 29;7(11):1722–4

Beta–carbolines induce apoptotic death of cerebellar granule neurones in culture. Malgrange B, et al. **Neuroreport** 1996 Nov 25;7(18):3041–5

Effects of ICE–like protease and calpain inhibitors on neuronal apoptosis. Nath R, et al. **Neuroreport** 1996 Dec 20;8(1):249–55

N omega–nitro–L–arginine methyl ester prevents apoptosis induced in the lateral geniculate nucleus by light deprivation in adult rabbit. Nucci C, et al. **Neuroreport** 1996 Nov 25;7(18):2863–6

Immunostimulation protects microglial cells from nitric oxide–mediated apoptosis. Sugaya K, et al. **Neuroreport** 1997 Jul 7;8(9–10):2241–5

Manganese and 1–methyl–4–(2'–ethylpheny1)–1,2,3,6–tetrahydropyridine induce apoptosis in PC12 cells. Desole MS, et al. **Neurosci Lett** 1996 May 17;209(3):193–6

Anti–apoptotic action of angiotensin fragments to neuronal cells from angiotensinogen knock–out mice. Kakinuma Y, et al. **Neurosci Lett** 1997 Sep 5;232(3):167–70

Nerve growth factor and forskolin prevent H2O2–induced apoptosis in PC12 cells by glutathione independent mechanism. Kamata H, et al. **Neurosci Lett** 1996 Jul 19; 212(3):179–82

(–)–Deprenyl protection of 1–methyl–4 phenylpyridium ion (MPP+)–induced apoptosis independent of MAO–B inhibition [published erratum appears in Neurosci Lett 1997 May 30;228(1):67] Le W, et al. **Neurosci Lett** 1997 Mar 21;224(3):197–200

A neurotoxin N–methyl(R)salsolinol induces apoptotic cell death in differentiated human dopaminergic neuroblastoma SH–SY5Y cells. Maruyama W, et al. **Neurosci Lett** 1997 Sep 5;232(3):147–50

Preventive effect of Ginkgo biloba extract on apoptosis in rat cerebellar neuronal cells induced by hydroxyl radicals. Ni Y, et al. **Neurosci Lett** 1996 Aug 23;214(2–3):115–8

In situ nick end–labeling detects necrosis of hippocampal pyramidal cells induced by kainic acid. Nishiyama K, et al. **Neurosci Lett** 1996 Jul 12;212(2):139–42

N–methyl–D–aspartate (NMDA) and non–NMDA glutamate receptor antagonists protect from apoptosis induced in the lateral geniculate nucleus of rabbits exposed to the dark. Nucci C, et al. **Neurosci Lett** 1997 Jul 4;229(3):185–8

Apoptosis induced by glufosinate ammonium in the neuroepithelium of developing mouse embryos in culture. Watanabe T. **Neurosci Lett** 1997 Jan 24;222(1):17–20

Unlike MPP+, apoptosis induced by 6–OHDA in PC12 cells is independent of mitochondrial inhibition. Wu Y, et al. **Neurosci Lett** 1996 Dec 27;221(1):69–71

Transforming growth factor–beta1 induces apoptosis of rat microglia without relation to bcl–2 oncoprotein expression. Xiao BG, et al. **Neurosci Lett** 1997 Apr 25;226(2):71–4

Estrogen and apoptosis in the developing sexually dimorphic preoptic area in female rats. Arai Y, et al. **Neurosci Res** 1996 Aug;25(4):403–7

Apoptosis of cultured microglia by the deprivation of macrophage colony–stimulating factor. Tomozawa Y, et al. **Neurosci Res** 1996 May;25(1):7–15

Cross–linking of concanavalin A receptors on cortical neurons induces programmed cell death. Cribbs DH, et al. **Neuroscience** 1996 Nov;75(1):173–85

Radiation–induced apoptosis in developing rats and kainic acid–induced excitotoxicity in adult rats are associated with distinctive morphological and biochemical c–Jun/AP–1 (N) expression. Ferrer I, et al. **Neuroscience** 1997 Sep; 80(2):449–58

Nerve growth factor inhibits apoptosis induced by S–100 binding in neuronal PC12 cells. Fulle S, et al. **Neuroscience** 1997 Jan;76(1):159–66

Brain–derived neurotrophic factor, acidic and basic fibroblast growth factors, insulin–like growth factor–I, and various antioxidants do not prevent the apoptotic death of developing septal cholinergic neurons following nerve growth factor withdrawal in vitro. Kew JN, et al. **Neuroscience** 1997 Feb;76(3):809–20

Insulin–like growth factor–I is an osmoprotectant in human neuroblastoma cells. Matthews CC, et al. **Neuroscience** 1997 Jul;79(2):525–34

Induction of apoptosis in vitro and in vivo by the cholinergic neurotoxin ethylcholine aziridinium. Rinner WA, et al. **Neuroscience** 1997 Jul;79(2):535–42

Dopamine–induced apoptosis in human neuronal cells: inhibition by nucleic acids antisense to the dopamine transporter. Simantov R, et al. **Neuroscience** 1996 Sep; 74(1):39–50

Kainic acid induces apoptosis in neurons. Simonian NA, et al. **Neuroscience** 1996 Dec;75(4):1047–55

Prediction of drug cytotoxicity in 9L rat brain tumor by using flow cytometry with a deoxyribonucleic acid–binding dye. Iwadate Y, et al. **Neurosurgery** 1997 Apr;40(4):782–7; discussion 787–8

Tumor blood flow and the cytotoxic effects of estramustine and its constituents in a rat glioma model. Johansson M, et al. **Neurosurgery** 1997 Jul;41(1):237–43; discussion 243–4

Ethanol–induced cell death in cultured rat astroglia. Holownia A, et al. **Neurotoxicol Teratol** 1997 Mar–Apr; 19(2):141–6

Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Jiang MC, et al. **Nutr Cancer** 1996;26(1):111–20

Possible mechanisms involved in apoptosis of colon tumor cell lines induced by deoxycholic acid, short–chain fatty acids, and their mixtures. Marchetti MC, et al. **Nutr Cancer** 1997;28(1):74–80

RRR–alpha–tocopheryl succinate induces apoptosis in avian retrovirus–transformed lymphoid cells. Qian M, et al. **Nutr Cancer** 1996;25(1):9–26

dl–alpha–tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Sigounas G, et al. **Nutr Cancer** 1997;28(1):30–5

RRR–alpha–tocopheryl succinate inhibits EL4 thymic lymphoma cell growth by inducing apoptosis and DNA synthesis arrest. Yu W, et al. **Nutr Cancer** 1997;27(1):92–101

Trophoblastic apoptosis in mice with preterm delivery and its suppression by urinary trypsin inhibitor. Kakinuma C, et al. **Obstet Gynecol** 1997 Jul;90(1):117–24

Influence of Bcl–2 overexpression on the ceramide pathway in daunorubicin–induced apoptosis of leukemic cells. Allouche M, et al. **Oncogene** 1997 Apr 17;14(15):1837–45

Role of 7,8–dihydroneopterin in T–cell apoptosis and HTLV–1 transcription in vitro. Baier–Bitterlich G, et al. **Oncogene** 1996 Nov 21;13(10):2281–5

Characterization of factor–independent variants derived from TF–1 hematopoietic progenitor cells: the role of the Raf/MAP kinase pathway in the anti–apoptotic effect of GM–CSF. Chao JR, et al. **Oncogene** 1997 Feb 13; 14(6):721–8

Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Chauhan D, et al. **Oncogene** 1997 Aug 14;15(7):837–43

CD40–induced growth inhibition in epithelial cells is mimicked by Epstein–Barr Virus–encoded LMP1: involvement of TRAF3 as a common mediator. Eliopoulos AG, et al. **Oncogene** 1996 Nov 21;13(10):2243–54

WAF1/CIP1 increases the susceptibility of p53 non–functional malignant glioma cells to cisplatin–induced apoptosis. Kondo S, et al. **Oncogene** 1996 Sep 19; 13(6):1279–85

Interleukin–7 inhibits apoptosis of mouse malignant T–lymphoma cells by both suppressing the CPP32–like protease activation and inducing the Bcl–2 expression. Lee SH, et al. **Oncogene** 1996 Nov 21;13(10):2131–9

In bone marrow derived Baf–3 cells, inhibition of apoptosis by IL–3 is mediated by two independent pathways. Leverrier Y, et al. **Oncogene** 1997 Jan 30;14(4):425–30

ts BCR–ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Nishii K, et al. **Oncogene** 1996 Nov 21;13(10):2225–34

Baculovirus p35 and Z–VAD–fmk inhibit thapsigargin–induced apoptosis of breast cancer cells. Qi XM, et al. **Oncogene** 1997 Sep 4;15(10):1207–12

c–Jun involvement in vitamin E succinate induced apoptosis of reticuloendotheliosis virus transformed avian lymphoid cells. Qian M, et al. **Oncogene** 1997 Jul 10;15(2):223–30

The transcriptional repressor ICER and cAMP–induced programmed cell death. Ruchaud S, et al. **Oncogene** 1997 Aug 14;15(7):827–36

TNF–induced apoptosis in multidrug resistant friend erythroleukemia is not influenced by the P–glycoprotein and glutathione status of the cell line [published erratum appears in Oncol Res 1996;8(3):145] Flugy A, et al. **Oncol Res** 1995;7(10–11):559–64

Involvement of a CrmA–insensitive ICE/Ced–3–like protease in ceramide–induced apoptosis. Kojima H, et al. **Oncol Res** 1996;8(12):497–501

C–JUN/AP–1 as possible mediators of tumor necrosis factor–alpha–induced apoptotic response in mouse JB6 tumor cells. Singh N, et al. **Oncol Res** 1995;7(7–8):353–62

Suppressive factor or factors derived from head and neck squamous cell carcinoma induce apoptosis in activated lymphocytes. Billings KR, et al. **Otolaryngol Head Neck Surg** 1997 Apr;116(4):458–65

Effects of all–trans–retinoic acid (ATRA) and retinoic acid receptor (RAR) expression on secretion, growth, and apoptosis of insulin–secreting RINm5F cells. Chertow BS, et al. **Pancreas** 1997 Aug;15(2):122–31

Subcutaneous arginine administration causes apoptosis of rat pancreas [letter] Otani T, et al. **Pancreas** 1997 Apr; 14(3):316–8

Mineral fibers induce apoptosis in Syrian hamster embryo fibroblasts. Dopp E, et al. **Pathobiology** 1995;63(4):213–21

Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13. Kovar J, et al. **Pathobiology** 1997;65(2):61–8

Enzymatic programming of apoptotic cell death. Mundle SD, et al. **Pathobiology** 1996;64(3):161–70 (65 ref.)

Glucocorticoid–induced apoptosis and treatment sensitivity in acute lymphoblastic leukemia of children. Csóka M, et al. **Pediatr Hematol Oncol** 1997 Sep–Oct;14(5):433–42

Apoptotic cell death in the normal and cryptorchid human testis: the effect of human chorionic gonadotropin on testicular cell survival. Heiskanen P, et al. **Pediatr Res** 1996 Aug;40(2):351–6

Prevention of neuronal apoptotic death by neurotrophic agents and ganglioside GM1: insights and speculations regarding a common mechanism. Ferrari G, et al. **Perspect Dev Neurobiol** 1996;3(2):93–100 (67 ref.)

Dopamine and iron induce apoptosis in PC12 cells. Velez–Pardo C, et al. **Pharmacol Toxicol** 1997 Feb; 80(2):76–84

Apoptosis is an early event during phthalocyanine photodynamic therapy–induced ablation of chemically induced squamous papillomas in mouse skin. Agarwal R, et al. **Photochem Photobiol** 1996 Apr;63(4):547–52

Silicon phthalocyanine Pc 4 and red light causes apoptosis in HIV–infected cells. Ben–Hur E, et al. **Photochem Photobiol** 1997 Mar;65(3):456–60

Rapid initiation of apoptosis by photodynamic therapy. Luo Y, et al. **Photochem Photobiol** 1996 Apr;63(4):528–34

Synthesis, photoreactivity and cytotoxic activity of caged compounds of L–leucyl–L–leucine methyl ester, an apoptosis inducer. Odaka M, et al. **Photochem Photobiol** 1996 Jun;63(6):800–6

Effect of L–carnitine treatment in vivo on apoptosis and

ceramide generation in peripheral blood lymphocytes from AIDS patients. Cifone MG, et al. **Proc Assoc Am Physicians** 1997 Mar;109(2):146–53

Influence of L-carnitine on CD95 cross-lining-induced apoptosis and ceramide generation in human cell lines: correlation with its effects on purified acidic and neutral sphingomyelinases in vitro. Di Marzio L, et al. **Proc Assoc Am Physicians** 1997 Mar;109(2):154–63

Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Ahmed NN, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3627–32

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Ghetie MA, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7509–14

A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Kéri G, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12513–8

Differential suppression by protease inhibitors and cytokines of apoptosis induced by wild-type p53 and cytotoxic agents [published erratum appears in Proc Natl Acad Sci U S A 1997 Feb 18;94(4):1603] Lotem J, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12507–12

Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Pritchard DM, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4;94(5):1795–9

Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Schwenger P, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):2869–73

Cell death in the Schwann cell lineage and its regulation by neuregulin. Syroid DE, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9229–34

An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells. Yeung MC, et al. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12451–5

The role of butyrate in human colonic epithelial cells: an energy source or inducer of differentiation and apoptosis? Hague A, et al. **Proc Nutr Soc** 1996 Nov;55(3):937–43 (42 ref.)

Neurotoxicity in rat cortical cells caused by N-methyl-D-aspartate (NMDA) and gp120 of HIV-1: induction and pharmacological intervention. Müller WE, et al. **Prog Mol Subcell Biol** 1996;16:44–57

Induction of c-fos protooncogene transcription and apoptosis by delta 12-prostaglandin J2 in human Pl-21 myeloid leukemia and RC-K8 pre-B lymphoma cells. Higashiyama K, et al. **Prostaglandins** 1996 Sep;52(3):143–56

Intracellular glutathione level modulates the induction of apoptosis by delta 12-prostaglandin J2. Kim HS, et al. **Prostaglandins** 1996 Jun;51(6):413–25

Differential effects of indomethacin on the sheep ovary: prostaglandin biosynthesis, intracellular calcium, apoptosis, and ovulation. Murdoch WJ. **Prostaglandins** 1996 Dec; 52(6):497–506

The induction of apoptosis in human cervical carcinoma (HeLa) cells by gamma-linolenic acid. de Kock M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Dec; 55(6):403–11

Effects of gamma-linolenic acid and arachidonic acid on cell cycle progression and apoptosis induction in normal and transformed cells. Seegers JC, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Apr; 56(4):271–80

Caffeine-induced apoptosis reveals a persistent lesion after treatment with bromodeoxyuridine and ultraviolet-B light. Hagan MP, et al. **Radiat Res** 1997 Jun;147(6):674–9

Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin. Palayoor ST, et al. **Radiat Res** 1997 Aug; 148(2):105–14

Prevention of neutrophil apoptosis by monosodium urate crystals. Akahoshi T, et al. **Rheumatol Int** 1997;16(6):231–5

Induction of tumor necrosis factor-alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine. Slomiany BL, et al. **Scand J Gastroenterol** 1997 Jul;32(7):638–42

Inhibition of neutrophil apoptosis by antioxidants in culture medium. Oishi K, et al. **Scand J Immunol** 1997 Jan; 45(1):21–7

Induction of apoptosis and cytokine gene expression in T-cell lines by sera of patients with systemic lupus erythematosus. Yang BC, et al. **Scand J Immunol** 1997 Jan;45(1):96–102

Induction of heat shock protein 70 by zinc-bis-(DL-hydrogenaspartate) reduces cytokine liberation, apoptosis, and mortality rate in a rat model of LD100 endotoxemia. Klosterhalfen B, et al. **Shock** 1997 Apr;7(4):254–62

2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA). Gruber J, et al. **Stem Cells** 1996 May;14(3):351–62

Hydroquinone, a bioreactive metabolite of benzene, inhibits apoptosis in myeloblasts. Hazel BA, et al. **Stem Cells** 1996 Nov;14(6):730–42

Thrombopoietin suppresses apoptosis and behaves as a survival factor for the human growth factor-dependent cell line, M07e. Ritchie A, et al. **Stem Cells** 1996 May; 14(3):330–6

Apoptosis down-regulates inflammation under the advancing epithelial wound edge: delayed patterns in diabetes and improvement with topical growth factors. Brown DL, et al. **Surgery** 1997 Apr;121(4):372–80

Methamphetamine induces apoptosis in immortalized neural cells: protection by the proto-oncogene, bcl-2. Cadet JL, et al. **Synapse** 1997 Feb;25(2):176–84

Cyclophosphamide-induced teratogenesis in ICR mice: the role of apoptosis. Torchinsky A, et al. **Teratog Carcinog Mutagen** 1995;15(4):179–90

Tumour dormancy and cell signalling—III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Marches R, et al. **Ther Immunol** 1995 Jun;2(3):125–36

Apoptosis following interleukin-2 withdrawal from T cells: evidence for a regulatory role of CD18 (beta 2-integrin) molecules. Röpke C, et al. **Tissue Antigens** 1996 Aug; 48(2):127–35

Affinity of methylmercury to the site of induction of apoptosis [letter] Berg GG. **Toxicol Appl Pharmacol** 1997 Sep;146(1):171

Sulfur mustard induces apoptosis and necrosis in endothelial cells. Dabrowska MI, et al. **Toxicol Appl Pharmacol** 1996 Dec;141(2):568–83

Differential sensitivity of normal and H-ras oncogene-transformed rat kidney epithelial cells to okadaic acid-induced apoptosis. Davis MA, et al. **Toxicol Appl Pharmacol** 1996 Nov;141(1):93–101

Silica-induced apoptosis mediated via scavenger receptor in human alveolar macrophages. Iyer R, et al. **Toxicol Appl Pharmacol** 1996 Nov;141(1):84–92

Evidence for the induction of apoptosis in thymocytes by 2,3,7,8-tetrachlorodibenzo-p-dioxin in vivo. Kamath AB, et al. **Toxicol Appl Pharmacol** 1997 Feb;142(2):367–77

4-hydroxy-2-nonenal-protein adducts and apoptosis in murine lung cells after acute ozone exposure. Kirichenko A, et al. **Toxicol Appl Pharmacol** 1996 Dec;141(2):416–24

Protection against methoxyacetic-acid-induced spermatocyte apoptosis with calcium channel blockers in cultured rat seminiferous tubules: possible mechanisms. Li LH, et al. **Toxicol Appl Pharmacol** 1997 May;144(1):105–19

Furan-mediated uncoupling of hepatic oxidative phosphorylation in Fischer-344 rats: an early event in cell death. Mugford CA, et al. **Toxicol Appl Pharmacol** 1997 May;144(1):1–11

Inhibition of bile-salt-induced hepatocyte apoptosis by the antioxidant lazaroid U83836E. Patel T, et al. **Toxicol Appl Pharmacol** 1997 Jan;142(1):116–22

Induction of apoptosis in human T-cells by organomercuric compounds: a flow cytometric analysis. Shenker BJ, et al. **Toxicol Appl Pharmacol** 1997 Apr;143(2):397–406

Involvement of apoptosis in 4-vinylcyclohexene diepoxide-induced ovotoxicity in rats. Springer LN, et al. **Toxicol Appl Pharmacol** 1996 Aug;139(2):394–401

Comparison of ribosome-inactivating proteins in the induction of apoptosis. Williams JM, et al. **Toxicol Lett** 1997 Apr 28;91(2):121–7

Apoptosis-mediated immunotoxicity of polychlorinated biphenyls (PCBs) in murine splenocytes. Yoo BS, et al. **Toxicol Lett** 1997 Apr 28;91(2):83–9

Importance of and approaches to quantification of hepatocyte apoptosis. Goldsworthy TL, et al. **Toxicol Pathol** 1996 Jan-Feb;24(1):24–35 (47 ref.)

Apoptotic cell death of erythrocytes in Xenopus larvae exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Sakamoto MK, et al. **Toxicol Pathol** 1997 Jul-Aug;25(4):398–402

The pathways of cell death: oncosis, apoptosis, and necrosis. Trump BF, et al. **Toxicol Pathol** 1997 Jan-Feb;25(1):82–8 (35 ref.)

The semiconductor elements arsenic and indium induce apoptosis in rat thymocytes. Bustamante J, et al. **Toxicology** 1997 Mar 28;118(2-3):129–36

Furan-induced liver cell proliferation and apoptosis in female B6C3F1 mice. Fransson-Steen R, et al. **Toxicology** 1997 Mar 28;118(2-3):195–204

Selenite suppression of cadmium-induced testicular apoptosis. Jones MM, et al. **Toxicology** 1997 Jan 15; 116(1-3):169–75

Thymic regression and apoptosis in the rat after treatment with the Leydig cell cytotoxin ethylene dimethanesulphonate (EDS). Morris ID, et al. **Toxicology** 1997 Jun 6;120(1):19–27

Induction of lymphocyte apoptosis by a novel immunosuppressant FTY720: relation with Fas, Bcl-2 and Bax expression. Li XK, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1267–8

Apoptosis induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Migita K, et al. **Transplantation** 1997 Feb 27;63(4):583–7

Antiapoptotic compound to enhance hypothermic liver preservation. Wu G, et al. **Transplantation** 1997 Mar 27; 63(6):803–9

Apoptotic features of selective neuronal death in ischemia, epilepsy and gp 120 toxicity. Charriaut-Marlangue C, et al. **Trends Neurosci** 1996 Mar;19(3):109–14 (87 ref.)

Induction of apoptosis in human hepatoma cells by alpha-fetoprotein. Semenkova LN, et al. **Tumour Biol** 1997; 18(5):261–73

Programmed cell death of peripheral myeloid precursor cells in Down patients: effect of zinc therapy. Trubiani O, et al. **Ultrastruct Pathol** 1996 Sep-Oct;20(5):457–62

Radioresistance, chemoresistance, and apoptosis resistance. The past, present, and future. Bergman PJ, et al. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):47–57 (42 ref.)

Apoptosis induction by human immunodeficiency virus type 1 (HIV-1) gp120 peptides. Pugliese O, et al. **Viral Immunol** 1997;10(2):95–102

Induction of apoptosis in a human hepatocellular carcinoma cell line by a neutralizing antibody to transforming growth factor-alpha. Seki S, et al. **Virchows Arch** 1997 Jan; 430(1):29–35

Gonadotropin suppression of apoptosis in follicle somatic cells. Galeati G, et al. **Zygote** 1996 Nov;4(4):299–303

[Implication of type II glucocorticoid receptors in aldosterone induced apoptosis of rat thymocytes] Ben Rhouma K, et al. **Arch Physiol Biochem** 1997 Apr; 105(2):216–24 (Eng. Abstr.) **(Fre)**

[Cell cycle and apoptosis in cancer induced by the artepillin C extracted from Brazilian propolis] Kimoto T, et al. **Gan To Kagaku Ryoho** 1996 Nov;23(13):1855–9 **(Jpn)**

[Involvement of ICE/CED 3 family proteases in antitumor agent-induced apoptosis] Mashima T, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):211–5 (Eng. Abstr.) **(Jpn)**

[Apoptosis and chemosensitivity] Nishio K, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):216–21 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Development of anti cancer drugs targeted on Fas-mediated apoptosis signal] Takahashi M, et al. **Gan To Kagaku Ryoho** 1997 Jan;24(2):222–8 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular design of apoptosis inducing agents derived from bleomycin] Umezawa K, et al. **Gan To Kagaku Ryoho** 1997 Feb;24(4):412–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Protective effect of onpi-to (TJ-8117) on the expression of apoptosis in 5/6 nephrectomized rats] Hattori T, et al. **Nippon Jinzo Gakkai Shi** 1997 May;39(4):377–86 (Eng. Abstr.) **(Jpn)**

[The mechanism of apoptosis induced by anticancer agents in human leukemia HL-60 cells] Yoshida A, et al. **Rinsho Ketsueki** 1996 Jul;37(7):552–7 (Eng. Abstr.) **(Jpn)**

[The nuclease activity of the cell nuclei in 2 lines of murine myeloma sp2/0 differing in their resistance to cytostatics in adriamycin-induced apoptosis] Meliksetian MB, et al. **Tsitologiia** 1996;38(6):611–5 (Eng. Abstr.) **(Rus)**

GENETICS

Apoptosis in focal cerebral ischemia. Chopp M, et al. **Acta Neurochir Suppl (Wien)** 1996;66:21–6 (43 ref.)

Molecular correlates of delayed neuronal death following transient forebrain ischemia in the rat. Wiessner C, et al. **Acta Neurochir Suppl (Wien)** 1996;66:1–7

Apoptosis and its regulation. Cohen JJ. **Adv Exp Med Biol** 1996;406:11–20 (88 ref.)

Apoptosis/programmed cell death. A historical perspective. Gupta S. **Adv Exp Med Biol** 1996;406:1–9 (88 ref.)

Genetic regulation of apoptosis in the mouse thymus. Osborne BA, et al. **Adv Exp Med Biol** 1996;406:199–207 (41 ref.)

Genetics of apoptosis. Desnoyers S, et al. **Adv Pharmacol** 1997;41:35–56 (150 ref.)

Apoptosis: an overview of the process and its relevance in disease. Webb SJ, et al. **Adv Pharmacol** 1997;41:1–34 (174 ref.)

In situ DNA fragmentation assay for detection of apoptosis in paraffin-embedded tissue sections. Technical considerations. Bardales RH, et al. **Am J Clin Pathol** 1997 Mar;107(3):332–6

The role of p53 tumor suppressor gene and bcl-2 protooncogene in rat corpus luteum death. Trott EA, et al. **Am J Obstet Gynecol** 1997 Aug;177(2):327–31; discussion 331–2

Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Firestein GS, et al. **Am J Pathol** 1996 Dec;149(6):2143–51

Detection of apoptosis in colorectal carcinoma by light microscopy and in situ end labelling. Hawkins NJ, et al. **Anal Quant Cytol Histol** 1997 Jun;19(3):227–32

Smooth muscle cell apoptosis and p53 expression in human abdominal aortic aneurysms. Holmes DR, et al. **Ann N Y Acad Sci** 1996 Nov 18;800:286–7

Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. Dixon SC, et al. **Ann Pharmacother** 1997 Jan;31(1):76–82 (80 ref.)

Genomic effects of tamoxifen. Kellen JA. **Anticancer Res** 1996 Nov-Dec;16(6B):3537–41 (52 ref.)

Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma. Lee WY, et al. **Anticancer Res** 1996 Sep-Oct; 16(5A):3007–12

The dual role of mutant p53 protein in chemosensitivity of human cancers. Mueller H, et al. **Anticancer Res** 1996 Nov-Dec;16(6B):3845–8 (25 ref.)

bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers. Wikonkal NM, et al. **Arch Dermatol** 1997 May;133(5):599–602

Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy. Chang EH, et al. **Arch Otolaryngol Head Neck Surg** 1997 May; 123(5):507–12

Lymphocyte apoptosis and apoptosis-associated gene

expression in Sjögren's syndrome. Ogawa N, et al. **Arthritis Rheum** 1996 Nov;39(11):1875–85

Regulation of tumor necrosis factor-and Fas-mediated apoptotic cell death by a novel cDNA TR2L. Cao H, et al. **Biochem Biophys Res Commun** 1996 Oct 3;227(1):266–72

The expression of genes modulating programmed cell death in normal human polymorphonuclear neutrophils. Hsieh SC, et al. **Biochem Biophys Res Commun** 1997 Apr 28; 233(3):700–6

Apoptosis of human lymphocytes in the absence or presence of internucleosomal DNA cleavage. Marini M, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):910–5

The proto-oncogene Crk-II enhances apoptosis by a Ras-dependent, Raf-1/MAP kinase-independent pathway. Parrizas M, et al. **Biochem Biophys Res Commun** 1997 May 29;234(3):616–20

Programmed cell death and the mammary gland--the involvement of the Bcl-2 family members in the control of epithelial apoptosis. Metcalfe AD, et al. **Biochem Soc Trans** 1996 Aug;24(3):347S

Expression of programmed cell death-related genes in dystrophic mdx and control mouse muscle. Veal EA, et al. **Biochem Soc Trans** 1996 Aug;24(3):486S

The IGF-I receptor in cell growth, transformation and apoptosis. Baserga R, et al. **Biochim Biophys Acta** 1997 Jun 7;1332(3):F105–26

The control and execution of programmed cell death: an update. Duckett CS, et al. **Biochim Biophys Acta** 1997 Jun 7;1332(3):R45–7

Chemiluminescent detection of apoptotic DNA: a qualitative and quantitative method. Phelouzat MA, et al. **Biotechniques** 1996 Aug;21(2):214–6

Suppression of apoptosis in hematopoietic factor-dependent progenitor cell lines by expression of the FAC gene. Cumming RC, et al. **Blood** 1996 Dec 15;88(12):4558–67

Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Dianzani U, et al. **Blood** 1997 Apr 15;89(8):2871–9

Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Findley HW, et al. **Blood** 1997 Apr 15;89(8):2986–93

Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Rajapaksa R, et al. **Blood** 1996 Dec 1;88(11):4275–87

Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Rathbun RK, et al. **Blood** 1997 Aug 1;90(3):974–85

Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Simonian PL, et al. **Blood** 1997 Aug 1;90(3):1208–16

Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Zhou P, et al. **Blood** 1997 Jan 15;89(2):630–43

Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma. Hoehner JC, et al. **Br J Cancer** 1997;75(8):1185–94

Down-regulation of striatal enkephalinergic (PPA) messenger RNA without prior apoptotic features following reversible focal ischemia in rat. Popovici T, et al. **Brain Res** 1997 Jan 2;744(1):185–7

Apoptosis in the cerebellum of adult teleost fish, Apteronotus leptorhynchus. Soutschek J, et al. **Brain Res Dev Brain Res** 1996 Dec 23;97(2):279–86

Decreased IGF-I gene expression during the apoptosis of Purkinje cells in pcd mice. Zhang W, et al. **Brain Res Dev Brain Res** 1997 Feb 20;98(2):164–76

Global ischemia induces apoptosis-associated genes in hippocampus. Honkaniemi J, et al. **Brain Res Mol Brain Res** 1996 Nov;42(1):79–88

Multigene effects influencing each other. International Union Against Cancer Study Group on Basic and Clinical Cancer Research. Burger MM, et al. **Cancer** 1997 Jan 15; 79(2):416–9

Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Ward RL, et al. **Cancer** 1997 Mar 15;79(6):1106–13

p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis. Stuppia L, et al. **Cancer Genet Cytogenet** 1997 Oct 1;98(1):28–35

Modulation of c-Myc activity and apoptosis in vivo. Alarcon RM, et al. **Cancer Res** 1996 Oct 1;56(19):4315–9

Bcl-xS enhances adenoviral vector-induced apoptosis in neuroblastoma cells. Dole MG, et al. **Cancer Res** 1996 Dec 15;56(24):5734–40

A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Helbing CC, et al. **Cancer Res** 1997 Apr 1;57(7):1255–8

Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. Hundley JE, et al. **Cancer Res** 1997 Feb 15;57(4):600–3

Choline deficiency selects for resistance to p53-independent apoptosis and causes tumorigenic transformation of rat hepatocytes. Zeisel SH, et al. **Carcinogenesis** 1997 Apr; 18(4):731–8

Oncoprotein networks. Hunter T. **Cell** 1997 Feb 7; 88(3):333–46 (126 ref.)

Induction of apoptosis but not G1 arrest by expression of the wild-type p53 gene in small cell lung carcinoma. Adachi J, et al. **Cell Growth Differ** 1996 Jul;7(7):879–86

Modulation of apoptosis-associated genes bcl-2, bcl-x, and bax during rat liver regeneration. Kren BT, et al. **Cell Growth Differ** 1996 Dec;7(12):1633–42

Expression of a viral oncoprotein during mammary gland development alters cell fate and function: induction of p53-independent apoptosis is followed by impaired milk protein production in surviving cells. Li M, et al. **Cell Growth Differ** 1996 Jan;7(1):3–11

Bcl-x expression influences keratinocyte cell survival but not terminal differentiation. Pena JC, et al. **Cell Growth Differ** 1997 Jun;8(6):619–29

Established cell lines transformed by E2F-1 overexpression contain wild-type p53. Sladek TL. **Cell Prolif** 1996 Nov; 29(11):579–88

Spontaneous apoptosis in human colon tumor cell lines and the relation of wt p53 to apoptosis. Wang C, et al. **Chin Med J (Engl)** 1996 Jul;109(7):537–41

A study of apoptosis in brain tumors by in situ end-labeling method. Patsouris E, et al. **Clin Neuropathol** 1996 Nov-Dec;15(6):337–41

Gossypol-induced apoptotic DNA fragmentation correlates with inhibited protein kinase C activity in spermatocytes. Teng CS. **Contraception** 1995 Dec;52(6):389–95

Gene regulation associated with apoptosis. Jehn BM, et al. **Crit Rev Eukaryot Gene Expr** 1997;7(1-2):179–93 (98 ref.)

The ABL genes in normal and abnormal cell development. Chung SW, et al. **Crit Rev Oncog** 1996;7(1-2):33–48 (184 ref.)

The cell-death machine. Chinnaiyan AM, et al. **Curr Biol** 1996 May 1;6(5):555–62 (113 ref.)

Caenorhabditis elegans CED-4 stimulates CED-3 processing and CED-3-induced apoptosis. Seshagiri S, et al. **Curr Biol** 1997 Jul 1;7(7):455–60

Programmed cell death in invertebrates. Hengartner MO. **Curr Opin Genet Dev** 1996 Feb;6(1):34–8 (37 ref.)

Zygotic transcription is required to block a maternal program of apoptosis in Xenopus embryos. Sible JC, et al. **Dev Biol** 1997 Sep 15;189(2):335–46

Dying by default, the biology of apoptosis: a review [see comments] Olasode BJ. **East Afr Med J** 1997 Feb; 74(2):108–11 (21 ref.). Comment in: East Afr Med J 1997 Feb;74(2):61.

Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. Amicone L, et al. **EMBO J** 1997 Feb 3;16(3):495–503

The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. Huang DC, et al. **EMBO J** 1997 Aug 1;16(15):4628–38

Anti-apoptotic activity of low levels of wild-type p53. Lassus P, et al. **EMBO J** 1996 Sep 2;15(17):4566–73

Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. Macleod KF, et al. **EMBO J** 1996 Nov 15; 15(22):6178–88

Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. Spengler D, et al. **EMBO J** 1997 May 15; 16(10):2814–25

Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. Amsterdam A, et al. **Endocr Rev** 1997 Aug;18(4):435–61 (367 ref.)

Apoptosis and carcinogenesis. Wyllie AH. **Eur J Cell Biol** 1997 Jul;73(3):189–97 (107 ref.)

Involvement of p53 in DNA strand break-induced apoptosis in postmitotic CNS neurons. Enokido Y, et al. **Eur J Neurosci** 1996 Sep;8(9):1812–21

Fas-independent apoptosis of photoreceptor cells in C3H mice. Nambu H, et al. **Exp Anim** 1996 Oct;45(4):309–15

Sensitivity of transformed fibroblasts for intercellular induction of apoptosis is determined by their transformed phenotype. Beck E, et al. **Exp Cell Res** 1997 Jul 10; 234(1):47–56

Expression and localization of the retinoblastoma gene during radiation-induced apoptosis in neonatal rat kidney. Gobé GC, et al. **Exp Cell Res** 1997 Sep 15;235(2):354–61

The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells. Murata Y, et al. **FEBS Lett** 1997 Jun 2;409(1):41–5

Sphingosine induces apoptosis in androgen-independent human prostatic carcinoma DU-145 cells by suppression of bcl-X(L) gene expression. Shirahama T, et al. **FEBS Lett** 1997 Apr 21;407(1):97–100

Trypanosoma cruzi elongation factor 1-alpha: nuclear localization in parasites undergoing apoptosis. Billaut-Mulot O, et al. **Gene** 1996 Sep 26;174(1):19–26

Lymphocyte apoptosis: induction by gene transfer techniques. Ebert O, et al. **Gene Ther** 1997 Apr; 4(4):296–302

Fas-induced apoptosis, and diseases caused by its abnormality. Nagata S. **Genes Cells** 1996 Oct;1(10):873–9 (51 ref.)

Specific arrest of spermatogenesis caused by apoptotic cell death in transgenic mice. Suzuki M, et al. **Genes Cells** 1996 Dec;1(12):1077–86

Oncogene-dependent apoptosis in extracts from drug-resistant cells. Fearnhead HO, et al. **Genes Dev** 1997 May 15;11(10):1266–76

The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Naik P, et al. **Genes Dev** 1996 Sep 1;10(17):2105–16

A dominant interfering Myb mutant causes apoptosis in T cells. Taylor D, et al. **Genes Dev** 1996 Nov 1;10(21):2732–44

PARP is important for genomic stability but dispensable in apoptosis. Wang ZQ, et al. **Genes Dev** 1997 Sep 15; 11(18):2347–58

Apoptosis susceptibility genes on mouse chromosome 9 (Rapop2) and chromosome 3 (Rapop3). Mori N, et al. **Genomics** 1995 Dec 10;30(3):553–7

Assignment of human inhibitor of apoptosis protein (IAP) genes xiap, hiap-1, and hiap-2 to chromosomes Xq25 and 11q22-q23 by fluorescence in situ hybridization. Rajcan-Separovic E, et al. **Genomics** 1996 Nov 1; 37(3):404–6

Restrictin-P/stromal activin A, kills its target cells via an apoptotic mechanism. Sternberg D, et al. **Growth Factors** 1995;12(4):277–87

The molecular basis of myelodysplastic syndromes. Gallagher A, et al. **Haematologica** 1997 Mar-Apr;82(2):191–204 (202 ref.)

Simultaneous in situ hybridization and TUNEL to identify cells undergoing apoptosis. Gochuico BR, et al. **Histochem J** 1997 May;29(5):413–8

Apoptosis: gene-directed cell death. An overview. Nakano R. **Horm Res** 1997;48 Suppl 3:2–4 (28 ref.)

Exits from the maze of apoptosis? Kass GE. **Hum Exp Toxicol** 1996 Aug;15(8):694–5

Apoptosis in renal cell carcinoma: detection by in situ end-labeling of fragmented DNA and correlation with other prognostic factors. Todd D, et al. **Hum Pathol** 1996 Oct;27(10):1012–7

Is the regulation of apoptosis altered in smooth muscle cells of adult spontaneously hypertensive rats? Díez J, et al. **Hypertension** 1997 Mar;29(3):776–80

A highly conserved apoptotic suppressor gene is located near the chicken T-cell receptor alpha chain constant region. Wang K, et al. **Immunogenetics** 1997;46(5):376–82

Mitochondrial control of apoptosis. Kroemer G, et al. **Immunol Today** 1997 Jan;18(1):44–51 (71 ref.)

Increased apoptosis in AK-5 tumor cells after transfection with wild type p53 gene. Pardhasaradhi BV, et al. **Indian J Exp Biol** 1996 Oct;34(10):945–8

Allelic variation of the polyubiquitin gene in the tobacco hawkmoth, Manduca sexta, and its regulation by heat shock and programmed cell death. Myer A, et al. **Insect Biochem Mol Biol** 1996 Dec;26(10):1037–46

Vascular lesions in mice with a deficit in Fas-mediated apoptosis and their transfer. Nose M, et al. **Int J Cardiol** 1997 Aug;54 Suppl:S11–20

Lack of correlation between c-myc expression and programmed or experimentally-induced cell death during chick limb development. Ros MA, et al. **Int J Dev Biol** 1995 Dec;39(6):1021–6

Radiation-induced apoptosis in different pH environments in vitro. Lee HS, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15;38(5):1079–87

Transfection of p53-knockout mouse fibroblasts with wild-type p53 increases the thermosensitivity and stimulates apoptosis induced by heat stress. Matsumoto H, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15; 38(5):1089–95

Transfection of p53-knockout mouse fibroblasts with wild-type p53 increases the thermosensitivity and stimulates apoptosis induced by heat stress. Matsumoto H, et al. **Int J Radiat Oncol Biol Phys** 1997 Aug 1; 39(1):197–203

Retarding photoreceptor degeneration in Pdegtm1/Pdegtml mice by an apoptosis suppressor gene. Tsang SH, et al. **Invest Ophthalmol Vis Sci** 1997 Apr;38(5):943–50

Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway. Endo F, et al. **J Biol Chem** 1997 Sep 26;272(39):24426–32

Bcl-2 modulates telomerase activity. Mandal M, et al. **J Biol Chem** 1997 May 30;272(22):14183–7

Degradation of topoisomerase IIalpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. Nakajima T, et al. **J Biol Chem** 1996 Oct 4;271(40):24842–9

Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation. Yan Y, et al. **J Biol Chem** 1997 Jun 13; 272(24):15220–6

Fas-induced changes in cdc2 and cdk2 kinase activity are not sufficient for triggering apoptosis in HUT-78 cells. De Luca A, et al. **J Cell Biochem** 1997 Mar 15;64(4):579–85

Up-regulated P21CIP1 expression is part of the regulation quantitatively controlling serum deprivation-induced apoptosis. Duttaroy A, et al. **J Cell Biochem** 1997 Mar 1;64(3):434–46

Regulation of apoptosis by oncogenes. Green DR, et al. **J Cell Biochem** 1996 Jan;60(1):33–8 (25 ref.)

Genes that regulate apoptosis in the mouse thymus. Osborne BA, et al. **J Cell Biochem** 1996 Jan;60(1):18–22 (18 ref.)

BCL-2, a novel regulator of apoptosis. Park JR, et al. **J Cell Biochem** 1996 Jan;60(1):12–7 (35 ref.)

BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. Reed JC, et al. **J Cell Biochem** 1996 Jan;60(1):23–32 (55 ref.)

Final checkpoint in the drug-promoted and

poliovirus-promoted apoptosis is under post-translational control by growth factors. Tolskaya EA, et al. **J Cell Biochem** 1996 Dec 15;63(4):422-31

Apoptosis mediated by the TNF-related cytokine and receptor families. Ware CF, et al. **J Cell Biochem** 1996 Jan;60(1):47-55 (48 ref.)

Evolutionary conservation of a genetic pathway of programmed cell death. Yuan J. **J Cell Biochem** 1996 Jan; 60(1):4-11 (53 ref.)

Glucose deprivation-induced cytotoxicity in drug resistant human breast carcinoma MCF-7/ADR cells: role of c-myc and bcl-2 in apoptotic cell death. Lee YJ, et al. **J Cell Sci** 1997 Mar;110 (Pt 5):681-6

Apoptosis repressor genes Bcl-2 and Bcl-x-long are expressed in the rat brain following global ischemia. Chen J, et al. **J Cereb Blood Flow Metab** 1997 Jan;17(1):2-10

Up-regulation of the Nedd2 gene encoding an ICE/Ced-3-like cysteine protease in the gerbil brain after transient global ischemia. Kinoshita M, et al. **J Cereb Blood Flow Metab** 1997 May;17(5):507-14

Gene expression induced by cerebral ischemia: an apoptotic perspective. MacManus JP, et al. **J Cereb Blood Flow Metab** 1997 Aug;17(8):815-32 (191 ref.)

Differential expression of members of the bcl-2 gene family in proliferative and secretory human endometrium: glandular epithelial cell apoptosis is associated with increased expression of bax. Tao XJ, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2738-46

BCL-2: the pendulum of the cell fate. Blandino G, et al. **J Exp Clin Cancer Res** 1997 Mar;16(1):3-10

Overexpression of c-Fos induces apoptosis of CD43+ pro-B cells. Hu L, et al. **J Immunol** 1996 Nov 1;157(9):3804-11

Dissociation of apoptosis and activation of IL-1beta-converting enzyme/Ced-3 proteases by ALG-2 and the truncated Alzheimer's gene ALG-3. Lacanà E, et al. **J Immunol** 1997 Jun 1;158(11):5129-35

High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis. Marth T, et al. **J Immunol** 1996 Sep 15;157(6):2348-57

Down-modulation of c-myc expression induces apoptosis of B lymphocyte models of tolerance via clonal deletion. Sonenshein GE. **J Immunol** 1997 Mar 1;158(5):1994-7

Rapid identification of differentially expressed RNA transcripts in apoptotic T lymphocytes. Zhang J, et al. **J Immunol Methods** 1996 Sep 9;195(1-2):113-23

Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. Ortiz A, et al. **J Investig Med** 1997 Feb;45(2):50-6

Loss of the xeroderma pigmentosum group A gene (XPA) enhances apoptosis of cultured cerebellar neurons induced by UV but not by low-K+ medium. Enokido Y, et al. **J Neurochem** 1997 Jul;69(1):246-51

Induction of apoptosis by baculovirus transactivator IE1. Prikhod'ko EA, et al. **J Virol** 1996 Oct;70(10):7116-24

Evidence that expression of a mutated p53 gene attenuates apoptotic cell death in human gastric intestinal-type carcinomas in vivo. Ishida M, et al. **Jpn J Cancer Res** 1997 May;88(5):468-75

Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase. Handa H, et al. **Leuk Res** 1997 Jun;21(6):479-89

Characterization of a mammalian cell death gene Nedd2. Kumar S, et al. **Leukemia** 1997 Apr;11 Suppl 3:385-6

Transfected glucocorticoid receptor and certain GR fragments evoke cell death in malignant lymphoid, not myeloid cell lines. Nazareth LV, et al. **Leukemia** 1996 Nov; 10(11):1789-95

Localization of the cell death genes CPP32 and Mch-2 to human chromosome 4q. Nasir J, et al. **Mamm Genome** 1997 Jan;8(1):56-9

Interleukin-1beta-converting enzyme (ICE) and related cell death genes ICErel-II and ICErel-III map to the same PAC clone at band 11q22.2-22.3. Nasir J, et al. **Mamm Genome** 1997 Aug;8(8):611-3

Bax and Bcl-xs are induced at the onset of apoptosis in involuting mammary epithelial cells. Heermeier K, et al. **Mech Dev** 1996 May;56(1-2):197-207

The application of differential display to the brain. Adaptations for the study of heterogeneous tissue. Babity JM, et al. **Methods Mol Biol** 1997;85:285-95

Upregulation of endogenous p53 and induction of in vivo apoptosis in B-lineage lymphomas of E(mu)-myc transgenic mice by deregulated c-myc transgene. Prasad VS, et al. **Mol Carcinog** 1997 Feb;18(2):66-77

The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Almog N, et al. **Mol Cell Biol** 1997 Feb;17(2):713-22

A targeted mutation at the T-cell receptor alpha/delta locus impairs T-cell development and reveals the presence of the nearby antiapoptosis gene Dad1. Hong NA, et al. **Mol Cell Biol** 1997 Apr;17(4):2151-7

Interference with the expression of a novel human polycomb protein, hPc2, results in cellular transformation and apoptosis. Satijn DP, et al. **Mol Cell Biol** 1997 Oct; 17(10):6076-86

The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure. Leist M, et al. **Mol Med** 1996 Jan; 2(1):109-24

Looking beneath the surface: the cell death pathway of Fas/APO-1 (CD95). Stanger BZ. **Mol Med** 1996 Jan; 2(1):7-20 (112 ref.)

Programmed cell death in bacteria: translational repression by mRNA end-pairing. Franch T, et al. **Mol Microbiol** 1996 Sep;21(5):1049-60

atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Westphal CH, et al. **Nat Genet** 1997 Aug; 16(4):397-401

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Ambrosini G, et al. **Nat Med** 1997 Aug; 3(8):917-21

The absence of c-fos prevents light-induced apoptotic cell death of photoreceptors in retinal degeneration in vivo [see comments] Hafezi F, et al. **Nat Med** 1997 Mar;3(3):346-9 . Comment in: Nat Med 1997 Mar;3(3):280.

The proto-oncogene Bcl-2 and its role in regulating apoptosis [published erratum appears in Nat Med 1997 Aug;3(8):934] Kroemer G. **Nat Med** 1997 Jun;3(6):614-20 (64 ref.)

Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Sandig V, et al. **Nat Med** 1997 Mar;3(3):313-9

Narrowing the focus on retinal degeneration [news; comment] Steele FR. **Nat Med** 1997 Mar;3(3):280. Comment on: Nat Med 1997 Mar;3(3):346-9.

Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Yin C, et al. **Nature** 1997 Feb 13;385(6617):637-40

Gene expression and apoptosis in the spinal cord neurons after sciatic nerve injury. Gu ZZ, et al. **Neurochem Int** 1997 Apr-May;30(4-5):417-26

Evidence for DNA fragmentation in the CNS of aged Fischer-344 rats. Taglialatela G, et al. **Neuroreport** 1996 Apr 10;7(5):977-80

Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells. Cañelles M, et al. **Oncogene** 1997 Mar 20; 14(11):1315-27

Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Delia D, et al. **Oncogene** 1997 May 8; 14(18):2137-47

c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis in human monocytic leukemia U937 cells. Dong J, et al. **Oncogene** 1997 Aug 7;15(6):639-47

The growth-inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by E1a and Ras. Hansen RS, et al. **Oncogene** 1996 Sep 5;13(5):995-1007

Molecular characterization and modular analysis of human MyD88. Hardiman G, et al. **Oncogene** 1996 Dec 5; 13(11):2467-75

Apoptosis of NIH3T3 cells overexpressing the Src homology 2 domain protein Shb. Karlsson T, et al. **Oncogene** 1996 Sep 5;13(5):955-61

Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apoptotic cell death in response to retinoic acid. Kudoh T, et al. **Oncogene** 1996 Oct 3;13(7):1431-9

Enhanced apoptosis in the thymus of transgenic mice expressing constitutively activated forms of human Rac2GTPase. Lorès P, et al. **Oncogene** 1997 Jul 31; 15(5):601-5

The product of the v-src-inducible gene nr-13 is a potent anti-apoptotic factor. Mangeney M, et al. **Oncogene** 1996 Oct 3;13(7):1441-6

A human papillomavirus type 18 E6/E7 transgene sensitizes mouse lens cells to human wild-type p53-mediated apoptosis. Nakamura T, et al. **Oncogene** 1997 Jun 26; 14(25):2991-8

Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Parker GA, et al. **Oncogene** 1996 Dec 19;13(12):2541-9

A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Shtivelman E. **Oncogene** 1997 May 8;14(18):2167-73

Induction of apoptosis in Mv1Lu cells by expression of competitive RB1 mutants. Whitaker LL, et al. **Oncogene** 1997 Aug 28;15(9):1069-77

Bcl-2 and CrmA have different effects on transformation, apoptosis and the stability of I kappa B-alpha in chicken spleen cells transformed by temperature-sensitive v-Rel oncoproteins. White DW, et al. **Oncogene** 1996 Sep 5; 13(5):891-9

Research helps shed light on role of apoptosis in tumor development and growth [news] **Oncology (Huntingt)** 1997 Aug;11(8):1240

Apoptosis in ocular disease: a molecular overview. Nickells RW, et al. **Ophthalmic Genet** 1996 Dec;17(4):145-65 (121 ref.)

Gene alterations and apoptosis in rhabdomyosarcoma. Boman F, et al. **Pediatr Pathol Lab Med** 1997 Mar-Apr; 17(2):233-47

An Arabidopsis thaliana cDNA complementing a hamster apoptosis suppressor mutant. Gallois P, et al. **Plant J** 1997 Jun;11(6):1325-31

Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria. Brodsky RA, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8756-60

The hepatitis B virus X gene induces p53-mediated programmed cell death. Chirillo P, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8162-7

Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Colucci F, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8670-4

Distinct roles for E2F proteins in cell growth control and apoptosis. DeGregori J, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7245-50

The Gfi-1 protooncoprotein represses Bax expression and inhibits T-cell death. Grimes HL, et al. **Proc Natl Acad Sci U S A** 1996 Dec 10;93(25):14569-73 (Eng. Abstr.)

Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Kharbanda S, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):6939-42

Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression. Nemani M, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9039-42

Identification of genes induced by factor deprivation in hematopoietic cells undergoing apoptosis using gene-trap mutagenesis and site-specific recombination. Russ AP, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15279-84

Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of BCL-2 expression and Myb-dependent regulation of bcl-2 promoter activity. Salomoni P, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3296-301

Inhibition of DLX-7 homeobox gene causes decreased expression of GATA-1 and c-myc genes and apoptosis. Shimamoto T, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):3245-9

Genetic control of cellular suicide. Yuan J. **Reprod Toxicol** 1997 Mar-Jun;11(2-3):377-84 (73 ref.)

Functional cloning of genes involved in T-cell receptor-induced programmed cell death. D'Adamio L, et al. **Semin Immunol** 1997 Feb;9(1):17-23 (61 ref.)

The role of the Bcl-2 family of apoptosis regulatory proteins in the immune system. Hawkins CJ, et al. **Semin Immunol** 1997 Feb;9(1):25-33 (93 ref.)

Genes involved in T-cell receptor-mediated apoptosis of thymocytes and T-cell hybridomas. Winoto A. **Semin Immunol** 1997 Feb;9(1):51-8 (79 ref.)

Identifying the molecular control of T-cell death; on the hunt for killer genes. Wong B, et al. **Semin Immunol** 1997 Feb;9(1):7-16 (53 ref.)

Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Potten CS, et al. **Stem Cells** 1997;15(2):82-93 (96 ref.)

Expression of wild-type p53 tumor suppressor gene and its possible involvement in the apoptosis of thyroid tumors. Kikuchi S, et al. **Surg Today** 1997;27(3):226-33

Overexpression of bax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide. Sakakura C, et al. **Surg Today** 1997;27(7):676-9

Facing death in the fly: genetic analysis of apoptosis in Drosophila. McCall K, et al. **Trends Genet** 1997 Jun; 13(6):222-6 (54 ref.)

Cell death in vertebrates: lessons from the worm. Osborne BA. **Trends Genet** 1996 Dec;12(12):489-91

Growth controllers knocked out. Superti-Furga G. **Trends Genet** 1996 Aug;12(8):324-5

[Apoptosis and leukemia] Ma D, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Oct;34(10):709-11 (22 ref.) **(Chi)**

[Flow cytometry measurement of DNA fragmentation in the course of cell death via apoptosis. New techniques for evaluation of DNA status for the pathologist] Lizard G, et al. **Ann Pathol** 1997 Mar;17(1):61-6 (45 ref.) (Eng. Abstr.) **(Fre)**

[Apoptosis and anti-apoptosis genes in the Bcl-2 family] Dietrich JB. **Arch Physiol Biochem** 1997 Apr;105(2):125-35 (73 ref.) (Eng. Abstr.) **(Fre)**

[Incidence and localization of apoptosis bodies in human arteriosclerosis lesions] Bauriedel G, et al. **Z Kardiol** 1996 Jul;85(7):509-18 (Eng. Abstr.) **(Ger)**

[Antioncogene p53 and apoptosis response: new hypotheses on the molecular bases of tumor resistance to radiotherapy] Corvò R. **Radiol Med (Torino)** 1996 Sep;92(3):298-302 (21 ref.) (Eng. Abstr.) **(Ita)**

[Expression of bc1-2 protein in collagen vascular diseases with pulmonary interstitial involvement] Nambu Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Dec;33 Suppl:284-90 (Eng. Abstr.) **(Jpn)**

[Apoptosis related gene, Pim-1] Ariga H, et al. **Nippon Rinsho** 1996 Jul;54(7):1903-6 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of apoptosis-related gene products in human brain tumors and apoptosis-inducing therapy] Tabuchi K, et al. **Nippon Rinsho** 1996 Jul;54(7):1922-8 (18 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Apoptosis in the aged dog brain. Kiatipattanasakul W, et al. **Acta Neuropathol (Berl)** 1996 Sep;92(3):242-8

Regulation of B cell apoptosis. Ashman RF, et al. **Adv Exp Med Biol** 1996;406:145-54 (21 ref.)

Cell cycle control of T cell apoptosis induced by activation through the T cell antigen receptor. Chalupny NJ, et al. **Adv Exp Med Biol** 1996;406:57-67 (31 ref.)

Signals for survival and apoptosis in normal and neoplastic B lymphocytes. Gordon J, et al. **Adv Exp Med Biol** 1996; 406:139–44 (10 ref.)
Apoptotic cell death in the chicken bursa of Fabricius. Jacobsen KA, et al. **Adv Exp Med Biol** 1996;406:155–65 (22 ref.)
The role of FasL and TNF in the homeostatic regulation of immune responses. Lynch DH. **Adv Exp Med Biol** 1996; 406:135–8 (23 ref.)
Cytotoxic lymphocyte killing enters the ice age. Martin SJ, et al. **Adv Exp Med Biol** 1996;406:29–37 (67 ref.)
Fas-mediated apoptosis. Nagata S. **Adv Exp Med Biol** 1996; 406:119–24 (36 ref.)
Regulation of lymphoid apoptosis by Bcl-2 and Bcl-XL. Nuñez G, et al. **Adv Exp Med Biol** 1996;406:75–82 (36 ref.)
Inducible resistance to Fas-mediated apoptosis in primary B lymphocytes. Rothstein TL, et al. **Adv Exp Med Biol** 1996;406:177–89
Mechanisms for recognition and phagocytosis of apoptotic lymphocytes by macrophages. Schlegel RA, et al. **Adv Exp Med Biol** 1996;406:21–8 (26 ref.)
Role of antibody signaling in inducing tumor dormancy. Uhr JW, et al. **Adv Exp Med Biol** 1996;406:69–74 (32 ref.)
Mature T lymphocyte apoptosis in the healthy and diseased immune system. Zheng L, et al. **Adv Exp Med Biol** 1996; 406:229–39
Role of p53 in apoptosis. Canman CE, et al. **Adv Pharmacol** 1997;41:429–60 (241 ref.)
Virus-induced apoptosis. Hardwick JM. **Adv Pharmacol** 1997;41:295–336 (337 ref.)
Antigen-stimulated apoptotic T-cell death in HIV infection is selective for CD4+ T cells, modulated by cytokines and effected by lymphotoxin. Clerici M, et al. **AIDS** 1996 Jun; 10(6):603–11
Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. Silvestris F, et al. **AIDS** 1996 Feb;10(2):131–41
Enhanced lymphocyte longevity and absence of proliferation and lymphocyte apoptosis in Quilty effects of human heart allografts. Dong C, et al. **Am J Pathol** 1997 Jul; 151(1):121–30
Lymphocytes from orally tolerized mice display enhanced susceptibility to death by apoptosis when cultured in the absence of antigen in vitro. Garside P, et al. **Am J Pathol** 1996 Dec;149(6):1971–9
Induction of fibroblast apoptosis by anti-CD44 antibody: implications for the treatment of fibroproliferative lung disease. Henke C, et al. **Am J Pathol** 1996 Nov; 149(5):1639–50
Extensive apoptosis of lung T-lymphocytes maintained in vitro. Herry I, et al. **Am J Respir Cell Mol Biol** 1996 Sep; 15(3):339–47
Implication of tyrosine kinases and protein kinase C in dimethyl sulfoxide-induced apoptosis. Ginestier-Verne C, et al. **Anal Cell Pathol** 1996 Jul;11(2):115–26
The possible contribution of cell apoptosis and necrosis to the generation of phospholipid-binding antibodies. Eschwège V, et al. **Ann Med Interne (Paris)** 1996 Sep;147 Suppl 1:33–5 (27 ref.)
Fas/APO-1(CD95)-induced apoptosis of primary hepatocytes is inhibited by cAMP. Fladmark KE, et al. **Biochem Biophys Res Commun** 1997 Mar 6;232(1):20–5
Fas/APO-1-mediated apoptosis of human renal cell carcinoma. Nonomura N, et al. **Biochem Biophys Res Commun** 1996 Dec 24;229(3):945–51
Requirement of cell–cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells. Oyaizu N, et al. **Biochem Biophys Res Commun** 1997 Sep 18;238(2):670–5
Regulation of apoptosis through CD95 (APO-1/Fas) receptor–ligand interaction. Debatin KM, et al. **Biochem Soc Trans** 1997 May;25(2):405–10 (48 ref.)
Differential susceptibility to HIV-GP120–sensitized apoptosis in CD4+ T-cell clones with different T-helper phenotypes: role of CD95/CD95L interactions. Accornero P, et al. **Blood** 1997 Jan 15;89(2):558–69
Apoptotic antigens, B2-glycoprotein I, and antiphospholipid autoantibodies [letter; comment] Cheng HM. **Blood** 1996 Dec 1;88(11):4396. Comment on: Blood 1996 Jun 15;87(12):5185–95.
Antibodies to HLA class I alpha1 domain trigger apoptosis of CD40-activated human B lymphocytes. Genestier L, et al. **Blood** 1997 Jul 15;90(2):726–35
HLA-DR-mediated signals for hematopoiesis and induction of apoptosis involve but are not limited to a nitric oxide pathway. Lee JW, et al. **Blood** 1997 Jul 1;90(1):217–25
Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Ross ME, et al. **Blood** 1997 Feb 1;89(3):910–8
Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Selleri C, et al. **Blood** 1997 Feb 1;89(3):957–64
HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. Truman JP, et al. **Blood** 1997 Mar 15;89(6):1996–2007
B-cell antigen receptor-induced apoptosis requires both Ig alpha and Ig beta. Tseng J, et al. **Blood** 1997 Mar 1; 89(5):1513–20
Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells. Komada Y, et al. **Br J Haematol** 1997 Jan;96(1):147–57
CD2 ligation abrogates antigen-independent apoptosis in B cells. Baixeras E, et al. **Cell Immunol** 1996 Jul 10; 171(1):55–61
CD69-induced monocyte apoptosis involves multiple nonredundant signaling pathways. Ramírez R, et al. **Cell Immunol** 1996 Sep 15;172(2):192–9
The role of apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayers of human squamous cell carcinoma of the head and neck targets. Sung MW, et al. **Cell Immunol** 1996 Jul 10;171(1):20–9
HLA class II molecule signal transduction leads to either apoptosis or activation via two different pathways. Truman JP, et al. **Cell Immunol** 1996 Sep 15;172(2):149–57
Up-regulation of Bcl-xL expression protects CD40-activated human B cells from Fas-mediated apoptosis. Zhang X, et al. **Cell Immunol** 1996 Oct 10;173(1):149–54
Thymic nurse cell rescue of early CD4+CD8+ thymocytes from apoptosis. Pezzano M, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Dec;41(8):1099–111
Mycobacterium tuberculosis induces apoptosis in gamma/delta T lymphocytes from patients with advanced clinical forms of active tuberculosis. Duarte R, et al. **Clin Diagn Lab Immunol** 1997 Jan;4(1):14–8
Measles virus induces apoptotic cell death in lymphocytes activated with phorbol 12-myristate 13-acetate (PMA) plus calcium ionophore. Ito M, et al. **Clin Exp Immunol** 1997 May;108(2):266–71
Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. Kaneko S, et al. **Clin Exp Immunol** 1997 Jul;109(1):185–93
C1q, a subunit of the first component of complement, enhances antibody-mediated apoptosis of cultured rat glomerular mesangial cells. Sato T, et al. **Clin Exp Immunol** 1997 Sep;109(3):510–7
Role of macrophages in the development of arteritis in MRL strains of mice with a deficit in Fas-mediated apoptosis. Taniguchi Y, et al. **Clin Exp Immunol** 1996 Oct; 106(1):26–34
Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-alpha. Kovacs B, et al. **Clin Immunol Immunopathol** 1996 Dec;81(3):293–302
Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice [see comments] Hotchkiss RS, et al. **Crit Care Med** 1997 Aug; 25(8):1298–307. Comment in: Crit Care Med 1997 Aug;25(8):1261–2.
IgM-mediated B cell apoptosis. Mayumi M, et al. **Crit Rev Immunol** 1995;15(3–4):255–69 (148 ref.)
Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Spencer DM, et al. **Curr Biol** 1996 Jul 1;6(7):839–47
Killing mechanisms of cytotoxic lymphocytes. Berke G. **Curr Opin Hematol** 1997 Jan;4(1):32–40 (83 ref.)
Apoptosis and the maintenance of homoeostasis in the immune system. Osborne BA. **Curr Opin Immunol** 1996 Apr;8(2):245–54 (89 ref.)
Signals and susceptibility to programmed death in b cells. Rothstein TL. **Curr Opin Immunol** 1996 Jun;8(3):362–71 (133 ref.)
Cell death in the regulation of immune responses. Winoto A. **Curr Opin Immunol** 1997 Jun;9(3):365–70 (79 ref.)
Pathways leading to cell death in T cells. Wong B, et al. **Curr Opin Immunol** 1997 Jun;9(3):358–64 (69 ref.)
Apoptosis and autoimmunity. Koh JS, et al. **Curr Opin Nephrol Hypertens** 1997 May;6(3):259–66 (68 ref.)
Regulation of Fas-mediated apoptosis. Gottlieb RA, et al. **Curr Top Cell Regul** 1997;35:69–105 (213 ref.)
Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis. Cheng LE, et al. **EMBO J** 1997 Apr 15;16(8):1865–75
Antigen receptor-induced apoptosis of human germinal center B cells is targeted to a centrocytic subset. Billian G, et al. **Eur J Immunol** 1997 Feb;27(2):405–14
Activation and activation-induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO-1) ligand expression and function. Daniel PT, et al. **Eur J Immunol** 1997 Apr;27(4):1029–34
Sensitivity of Epstein-Barr virus-induced B cell tumor to apoptosis mediated by anti-CD95/Apo-1/fas antibody. Durandy A, et al. **Eur J Immunol** 1997 Feb;27(2):538–43
Ras activation leads to cell proliferation or apoptotic cell death upon interleukin-2 stimulation or lymphokine deprivation, respectively. Gómez J, et al. **Eur J Immunol** 1997 Jul;27(7):1610–8
Reduced susceptibility to Fas-mediated apoptosis in B-1 cells. Masuda K, et al. **Eur J Immunol** 1997 Feb; 27(2):449–55
Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Peter ME, et al. **Eur J Immunol** 1997 May;27(5):1207–12
The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium. Rubartelli A, et al. **Eur J Immunol** 1997 Aug;27(8):1893–900
Activation of protein kinase C attenuates early signals in Fas-mediated apoptosis. Ruiz-Ruiz MC, et al. **Eur J Immunol** 1997 Jun;27(6):1442–50
Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants. Thilenius AR, et al. **Eur J Immunol** 1997 May; 27(5):1108–14
Th1 and Th2 subsets equally undergo Fas-dependent and -independent activation-induced cell death. Watanabe N, et al. **Eur J Immunol** 1997 Aug;27(8):1858–64
Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. Wagenknecht B, et al. **FEBS Lett** 1997 Jun 2;409(1):17–23
Expression of Fas-Fas ligand system associated with atresia through apoptosis in murine ovary. Mori T, et al. **Horm Res** 1997;48 Suppl 3:11–9
Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Fukada T, et al. **Immunity** 1996 Nov; 5(5):449–60
Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Liu F, et al. **Immunity** 1996 Nov;5(5):491–501
Homologous complement activation on drug-induced apoptotic cells from a human lung adenocarcinoma cell line. Hara T, et al. **Immunobiology** 1996–97;196(5):491–503
Monocyte-derived macrophages prime peripheral T cells to undergo apoptosis by cell–cell contact via ICAM-1/LFA-1-dependent mechanism. Zen K, et al. **Immunobiology** 1996 Aug;195(3):323–33
Evasion of apoptosis by DNA viruses. Cuff S, et al. **Immunol Cell Biol** 1996 Dec;74(6):527–37 (137 ref.)
Decreased levels of TNF-beta in cultured PBLs from HIV+ patients occur concomitantly to increased apoptosis and impaired PWM-induced proliferation and dehydrogenase activity. Lavergne JA, et al. **Immunol Invest** 1996 Jul; 25(4):279–89
Membrane unpacking and the rapid disposal of apoptotic cells. Ashman RF, et al. **Immunol Lett** 1995 Dec; 48(3):159–66
Comparative analysis of apoptosis in HIV-infected humans and chimpanzees: relation with lymphocyte activation. Gougeon ML, et al. **Immunol Lett** 1996 Jun;51(1–2):75–81
Induction of cell death via Fas (CD95, Apo-1) may be associated with but is not dependent on Fas-induced tyrosine phosphorylation. Janssen O, et al. **Immunol Lett** 1996 Jan;49(1–2):63–9
Differentiation and apoptosis of human germinal center B-lymphocytes. Choi YS. **Immunol Res** 1997;16(2):161–74 (105 ref.)
Fas expression and apoptosis in human B cells. Schattner E, et al. **Immunol Res** 1996;15(3):246–57 (82 ref.)
Cellular environments and apoptosis: tissue microenvironments control activated T-cell death. Akbar AN, et al. **Immunol Today** 1997 Feb;18(2):72–6 (43 ref.)
Do macrophages kill through apoptosis? Aliprantis AO, et al. **Immunol Today** 1996 Dec;17(12):573–6 (45 ref.)
Protein tyrosine phosphatases in T-cell development, apoptosis and signalling. Frearson JA, et al. **Immunol Today** 1996 Aug;17(8):385–91 (57 ref.)
The role of FasL-induced apoptosis in immune privilege [published erratum appears in Imunol Today 1997 Jul;18(7):361] Griffith TS, et al. **Immunol Today** 1997 May; 18(5):240–4 (46 ref.)
Factors that influence activated CD8+ T-cell apoptosis in patients with acute herpesvirus infections: loss of costimulatory molecules CD28, CD5 and CD6 but relative maintenance of Bax and Bcl-X expression. Borthwick NJ, et al. **Immunology** 1996 Aug;88(4):508–15
Apoptosis in a Fas-resistant, T-cell receptor-sensitive human leukaemic T-cell clone. Delehanty LL, et al. **Immunology** 1997 Mar;90(3):383–7
Fibroblasts prevent apoptosis of IL-2-deprived T cells without inducing proliferation: a selective effect on Bcl-XL expression. Gombert W, et al. **Immunology** 1996 Nov; 89(3):397–404
Enhancement of CD3-mediated thymocyte apoptosis by the cross-linkage of heat-stable antigen. Hitsumoto Y, et al. **Immunology** 1996 Oct;89(2):200–4
Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Martínez-Lorenzo MJ, et al. **Immunology** 1996 Dec; 89(4):511–7
Proliferation and apoptosis of follicular lymphocytes: relationship to follicular dendritic cell-associated clusters. Orui H, et al. **Immunology** 1997 Apr;90(4):489–95
Lipopolysaccharide prevents apoptosis and induces responsiveness to antigen receptor cross-linking in immature B cells. Wechsler-Reya RJ, et al. **Immunology** 1996 Nov;89(3):356–62
Role of CD14 molecules in internalization of Actinobacillus actinomycetemcomitans by macrophages and subsequent induction of apoptosis. Muro M, et al. **Infect Immun** 1997 Apr;65(4):1147–51
Tumor necrosis factor receptor p55 is essential for intrahepatic granuloma formation and hepatocellular apoptosis in a murine model of bacterium-induced fulminant hepatitis. Tsuji H, et al. **Infect Immun** 1997 May; 65(5):1892–8
Virus-induced polyclonal T cell activation is followed by apoptosis: partitioning of CD8+ T cells based on alpha 4 integrin expression. Christensen JP, et al. **Int Immunol** 1996 May;8(5):707–15
Thiol-mediated inhibition of FAS and CD2 apoptotic signaling in activated human peripheral T cells. Deas O,

et al. **Int Immunol** 1997 Jan;9(1):117–25

Induction of cell death by chimeric L–selectin–Fas receptors. Ishiwatari–Hayasaka H, et al. **Int Immunol** 1997 Apr; 9(4):627–35

Induction of apoptosis by protease–defective particle preparations of human immunodeficiency virus type 1 is specific to a subset of U937–derived subclones. Kameoka M, et al. **Int Immunol** 1996 Nov;8(11):1687–97

Activation–induced peripheral blood T cell apoptosis is Fas independent in HIV–infected individuals. Katsikis PD, et al. **Int Immunol** 1996 Aug;8(8):1311–7

HIV type 1 Tat protein enhances activation–but not Fas (CD95)–induced peripheral blood T cell apoptosis in healthy individuals. Katsikis PD, et al. **Int Immunol** 1997 Jun;9(6):835–41

Activation–mediated CD4+ T cell unresponsiveness during acute Toxoplasma gondii infection in mice. Khan IA, et al. **Int Immunol** 1996 Jun;8(6):887–96

Cross–linking of cell surface ganglioside GM1 induces the selective apoptosis of mature CD8+ T lymphocytes. Nahar TO, et al. **Int Immunol** 1996 May;8(5):731–6 (24 ref.)

In vivo analysis of Fas antigen–mediated apoptosis: effects of agonistic anti–mouse Fas mAb on thymus, spleen and liver. Nishimura Y, et al. **Int Immunol** 1997 Feb;9(2):307–16

Antigen receptor–mediated B cell death is blocked by signaling via CD72 or treatment with dextran sulfate and is defective in autoimmunity–prone mice. Nomura T, et al. **Int Immunol** 1996 Jun;8(6):867–75

S–adenosylhomocysteine as a physiological modulator of Apo–1–mediated apoptosis. Ratter F, et al. **Int Immunol** 1996 Jul;8(7):1139–47

Fas (CD95)–independent regulation of immune responses by antigen–specific CD4–CD8+ T cells. Teh SJ, et al. **Int Immunol** 1996 May;8(5):675–81

Direct visualization of thymocyte apoptosis in neglect, acute and steady–state negative selection. Wack A, et al. **Int Immunol** 1996 Oct;8(10):1537–48

Ligation of MHC class I induces apoptosis in human pre–B cell lines, in promyelocytic cell lines and in CD40–stimulated mature B cells. Wallén–Ohman M, et al. **Int Immunol** 1997 Apr;9(4):599–606

Negative signaling in B cells by surface immunoglobulins. Mayumi M, et al. **J Allergy Clin Immunol** 1996 Dec;98(6 Pt 2):S238–47 (102 ref.)

Immunoregulatory effects of Fas–mediated signalling. Lynch DH, et al. **J Cell Biochem** 1996 Jan;60(1):39–46 (34 ref.)

Programmed cell death (apoptosis) in cord blood lymphocytes. Aggarwal S, et al. **J Clin Immunol** 1997 Jan; 17(1):63–73

Impaired induction of the apoptosis–protective protein Bcl–xL in activated PBMC from asymptomatic HIV–infected individuals. Blair PJ, et al. **J Clin Immunol** 1997 May;17(3):234–46

Kinetics of Fas–induced apoptosis in thymic organ culture. Zhou T, et al. **J Clin Immunol** 1997 Jan;17(1):74–84

Lung lymphocyte elimination by apoptosis in the murine response to intratracheal particulate antigen. Milik AM, et al. **J Clin Invest** 1997 Mar 1;99(5):1082–91

Inhibition of T cell apoptosis in the rheumatoid synovium. Salmon M, et al. **J Clin Invest** 1997 Feb 1;99(3):439–46

Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin–mediated cytotoxicity. Spencer MJ, et al. **J Clin Invest** 1997 Jun 1;99(11):2745–51

Apoptosis is induced by anti–Fas antibody alone in cultured human keratinocytes. Sung KJ, et al. **J Dermatol** 1997 Jul; 24(7):427–34

Resistance to fas–mediated apoptosis of peripheral T cells in human T lymphocyte virus type I (HTLV–I) transgenic mice with autoimmune arthropathy. Kishi S, et al. **J Exp Med** 1997 Jul 7;186(1):57–64

Induction of apoptosis and T helper 2 (Th2) responses correlates with peptide affinity for the major histocompatibility complex in self–reactive T cell receptor transgenic mice. Pearson CI, et al. **J Exp Med** 1997 Feb 17;185(4):583–99

The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO–1/CD95– and ceramide–induced apoptosis. Susin SA, et al. **J Exp Med** 1997 Jul 7;186(1):25–37

Proteins phosphorylated during stress–induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. Utz PJ, et al. **J Exp Med** 1997 Mar 3;185(5):843–54

Vaccinia virus serpin B13R (SPI–2) inhibits interleukin–1beta–converting enzyme and protects virus–infected cells from TNF– and Fas–mediated apoptosis, but does not prevent IL–1beta–induced fever. Kettle S, et al. **J Gen Virol** 1997 Mar;78 (Pt 3):677–85

Intracellular Ca2+ elevation and cyclosporin A synergistically induce TGF–beta 1–mediated apoptosis in lymphocytes. Andjelić S, et al. **J Immunol** 1997 Mar 15; 158(6):2527–34

Inhibition of human neutrophil apoptosis by platelets. Andonegui G, et al. **J Immunol** 1997 Apr 1;158(7):3372–7

Apoptosis of immature thymocytes mediated by E2/CD99. Bernard G, et al. **J Immunol** 1997 Mar 15;158(6):2543–50

Induction of T cell clonal anergy results in resistance, whereas CD28–mediated costimulation primes for susceptibility to Fas– and Bax–mediated programmed cell death. Boussiotis VA, et al. **J Immunol** 1997 Oct 1; 159(7):3156–67

B cell receptor cross–linking prevents Fas–induced ceil death by inactivating the IL–1 beta–converting enzyme protease and regulating Bcl–2/Bcl–x expression. Brás A, et al. **J Immunol** 1997 Oct 1;159(7):3168–77

Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. Castedo M, et al. **J Immunol** 1996 Jul 15;157(2):512–21

Increased lymphocyte apoptosis in Fas ligand transgenic mice. Cheng J, et al. **J Immunol** 1997 Jul 15;159(2):674–84

ZAP–70 tyrosine kinase is required for the up–regulation of Fas ligand in activation–induced T cell apoptosis. Eischen CM, et al. **J Immunol** 1997 Aug 1;159(3):1135–9

Intracellular signaling for inducible antigen receptor–mediated Fas resistance in B cells. Foote LC, et al. **J Immunol** 1996 Sep 1;157(5):1878–85

Human T cells require IL–2 but not G1/S transition to acquire susceptibility to Fas–mediated apoptosis. Fournel S, et al. **J Immunol** 1996 Nov 15;157(10):4309–15

Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity. Fuss IJ, et al. **J Immunol** 1997 Feb 15;158(4):1912–8

Critical role of Ras in the proliferation and prevention of apoptosis mediated by IL–2. Gómez J, et al. **J Immunol** 1996 Sep 15;157(6):2272–81

Lack of chronic immune activation in HIV–infected chimpanzees correlates with the resistance of T cells to Fas/Apo–1 (CD95)–induced apoptosis and preservation of a T helper 1 phenotype. Gougeon ML, et al. **J Immunol** 1997 Mar 15;158(6):2964–76

TCR engagement of CD4+CD8+ thymocytes in vitro induces early aspects of positive selection, but not apoptosis. Groves T, et al. **J Immunol** 1997 Jan 1; 158(1):65–75

Dissociation of T cell anergy from apoptosis by blockade of Fas/Apo–1 (CD95) signaling. Hargreaves RG, et al. **J Immunol** 1997 Apr 1;158(7):3099–107

CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages. Hart SP, et al. **J Immunol** 1997 Jul 15; 159(2):919–25

Regulation of human monocyte apoptosis by the CD14 molecule. Heidenreich S, et al. **J Immunol** 1997 Oct 1; 159(7):3178–88

CD94 ligation induces apoptosis in a subset of IL–2–stimulated NK cells. Ida H, et al. **J Immunol** 1997 Sep 1;159(5):2154–60

HLA–DR–triggered inhibition of hemopoiesis involves Fas/Fas ligand interactions and is prevented by c–kit ligand. Lee JW, et al. **J Immunol** 1997 Oct 1;159(7):3211–9

The DNA–dependent protein kinase catalytic subunit (p460) is cleaved during Fas–mediated apoptosis in Jurkat cells. McConnell KR, et al. **J Immunol** 1997 Mar 1;158(5):2083–9

Relationship between proliferation and susceptibility to CD95– and CD2–mediated apoptosis in stimulated primary T lymphocytes: T cells manifesting proliferative unresponsiveness are preferentially susceptible to CD95–mediated apoptosis. Mollereau B, et al. **J Immunol** 1997 Sep 15;159(6):2668–77

TCR triggering of anergic CD4 T cells in murine AIDS induces apoptosis rather than cytokine synthesis and proliferation. Muralidhar G, et al. **J Immunol** 1996 Jul 15; 157(2):625–35

The integrin–triggered rescue of T lymphocyte apoptosis is blocked in HIV–1–infected individuals. Ng TT, et al. **J Immunol** 1997 Mar 15;158(6):2984–99

Protection against Fas/APO–1– and tumor necrosis factor–mediated cell death by a novel protein, sentrin. Okura T, et al. **J Immunol** 1996 Nov 15;157(10):4277–81

Monocytes express Fas ligand upon CD4 cross–linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. Oyaizu N, et al. **J Immunol** 1997 Mar 1;158(5):2456–63

CD4+ T cells kill CD8+ T cells via Fas/Fas ligand–mediated apoptosis. Piazza C, et al. **J Immunol** 1997 Feb 15;158(4):1503–6

Anti–phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2–glycoprotein I–dependent manner. Price BE, et al. **J Immunol** 1996 Sep 1; 157(5):2201–8

Bcl–2 expression in target cells leads to functional inhibition of caspase–3 protease family in human NK and lymphokine–activated killer cell granule–mediated apoptosis. Renvoizé C, et al. **J Immunol** 1997 Jul 1; 159(1):126–34

Differential induction of apoptosis by virulent Mycobacterium tuberculosis in resistant and susceptible murine macrophages: role of nitric oxide and mycobacterial products. Rojas M, et al. **J Immunol** 1997 Aug 1; 159(3):1352–61

Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. Sabelko KA, et al. **J Immunol** 1997 Oct 1;159(7):3096–9

Viral regulation of CD95 expression and apoptosis in T lymphocytes. Sieg S, et al. **J Immunol** 1997 Aug 1; 159(3):1192–9

MHC class I ligation of human T cells activates the ZAP70 and p56lck tyrosine kinases, leads to an alternative phenotype of the TCR/CD3 zeta–chain, and induces apoptosis. Skov S, et al. **J Immunol** 1997 Apr 1; 158(7):3189–96

IL–1 beta convertase (ICE) does not play a requisite role in apoptosis induced in T lymphoblasts by Fas–dependent or Fas–independent CTL effector mechanisms. Smith DJ, et al. **J Immunol** 1997 Jan 1;158(1):163–70

Suppression of concanavalin A–induced hepatitis in IFN–gamma(–/–) mice, but not in TNF–alpha(–/–) mice: role for IFN–gamma in activating apoptosis of hepatocytes. Tagawa Y, et al. **J Immunol** 1997 Aug 1;159(3):1418–28

Platelet–activating factor abrogates apoptosis induced by cross–linking of the surface IgM receptor in a human B lymphoblastoid cell line. Toledano BJ, et al. **J Immunol** 1997 Apr 15;158(8):3705–15

Functional responses and apoptosis of CD25 (IL–2R alpha)–deficient T cells expressing a transgenic antigen receptor. Van Parijs L, et al. **J Immunol** 1997 Apr 15; 158(8):3738–45

Anti–human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen–mediated pathway. Woodle ES, et al. **J Immunol** 1997 Mar 1; 158(5):2156–64

Requirement of Fas(CD95), CD45, and CD11a/CD18 in monocyte–dependent apoptosis of human T cells. Wu MX, et al. **J Immunol** 1996 Jul 15;157(2):707–13

Fas system–mediated apoptosis suppresses lymphopoiesis. Yasutomo K, et al. **J Immunol** 1996 Sep 1;157(5):1981–6

Ca2+–dependent, Fas– and perforin–independent apoptotic death of allografted tumor cells by a type of activated macrophage. Yoshida R, et al. **J Immunol** 1997 Jul 1; 159(1):15–21

Induction of apoptosis by anti–CD3 epsilon F(ab')2 in antigen receptor transgenic murine T cells activated by specific peptide. Yu XZ, et al. **J Immunol** 1996 Oct 15;157(8):3420–9

Comparative analysis of flow cytometric methods for apoptosis quantitation in murine thymocytes and human peripheral lymphocytes from controls and HIV–infected persons. Evidence for interference by granulocytes and erythrocytes. Lecoeur H, et al. **J Immunol Methods** 1996 Oct 30;198(1):87–99

Induction and detection of apoptosis in human periphery blood T–cells. Wu MX, et al. **J Immunol Methods** 1997 Aug 7;206(1–2):153–62

Fas involvement in human NK cell apoptosis: lack of a requirement for CD16–mediated events. Ortaldo JR, et al. **J Leukoc Biol** 1997 Feb;61(2):209–15

Evolution of neuroendocrine thymus: studies on POMC–derived peptides, cytokines and apoptosis in lower and higher vertebrates. Ottaviani E, et al. **J Neuroimmunol** 1997 Jan;72(1):67–74

Augmentation of anti–Fas antibody–mediated apoptosis on human glioma cells by liposomes associated with the antibody. Ohta S, et al. **J Neurooncol** 1997 Oct;35(1):7–11

MHC class I–mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. Schneider C, et al. **J Neuropathol Exp Neurol** 1996 Dec;55(12):1205–9

Apoptosis and autoimmunity. Elkon KB. **J Rheumatol** 1997 Sep;24 Suppl 50:6–7 (2 ref.)

Novel mechanisms of selective apoptosis in synovial T cells of patients with rheumatoid arthritis. Hoa TT, et al. **J Rheumatol** 1996 Aug;23(8):1332–7

Altered susceptibility to tumor necrosis factor alpha–induced apoptosis of mouse cells expressing polyomavirus middle and small T antigens. Bergqvist A, et al. **J Virol** 1997 Jan; 71(1):276–83

Both wild–type and strongly attenuated bovine leukemia viruses protect peripheral blood mononuclear cells from apoptosis. Dequiedt F, et al. **J Virol** 1997 Jan;71(1):630–9

T–lymphocyte downregulation after acute viral infection is not dependent on CD95 (Fas) receptor–ligand interactions. Lohman BL, et al. **J Virol** 1996 Nov;70(11):8199–203

Efficient induction of apoptosis in cultured rat glomerular mesangial cells by dimeric monoclonal IgA anti–Thy–1 antibodies. Sato T, et al. **Kidney Int** 1997 Jan;51(1):173–81

Cytotoxicity and apoptosis in human renal allografts: identification, distribution, and quantitation of cells with a cytotoxic granule protein GMP–17 (TIA–1) and cells with fragmented nuclear DNA. Meehan SM, et al. **Lab Invest** 1997 May;76(5):639–49

Fas/Apo–1 (CD95)–mediated and CD95–independent apoptosis of malignant plasma cells. Hata H, et al. **Leuk Lymphoma** 1996 Dec;24(1–2):35–42 (21 ref.)

Susceptibility to apoptosis of T lymphocytes from elderly humans is associated with increased in vivo expression of functional Fas receptors. Phelouzat MA, et al. **Mech Ageing Dev** 1997 Jun;96(1–3):35–46

Involvement of two types of TNF receptor in TNF–alpha induced neutrophil apoptosis. Gon S, et al. **Microbiol Immunol** 1996;40(6):463–5

Apoptosis of intestinal intraepithelial lymphocytes induced by exogenous and endogenous glucocorticoids. Murosaki S, et al. **Microbiol Immunol** 1997;41(2):139–48

Antinuclear autoantibodies: probes for defining proteolytic events associated with apoptosis. Casiano CA, et al. **Mol Biol Rep** 1996;23(3–4):211–6 (44 ref.)

What triggers anti–dsDNA antibodies? Herrmann M, et al. **Mol Biol Rep** 1996;23(3–4):265–7 (12 ref.)

Regulation of bcl–xL expression and Fas susceptibility in mouse B cells by CD40 ligation, surface IgM crosslinking and IL–4. Koizumi T, et al. **Mol Immunol** 1996 Nov; 33(16):1247–53

Gene activating and proapoptotic potential are independent properties of different CD4 epitopes. Milia E, et al.

Mol Immunol 1997 Mar;34(4):287–96

Breast cancer–associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Gimmi CD, et al. **Nat Med** 1996 Dec;2(12):1367–70

Tumor cells induce apoptosis in lymphocytes [letter; comment] Rubio CA. **Nat Med** 1997 Mar;3(3):253–4. Comment on: Nat Med 1996 Dec;2(12):1361–6.

Antitumor effect of locally produced CD95 ligand. Seino K, et al. **Nat Med** 1997 Feb;3(2):165–70

Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells—a mechanism of immune evasion? [see comments] Strand S, et al. **Nat Med** 1996 Dec;2(12):1361–6. Comment in: Nat Med 1996 Dec;2(12):1306–7. Comment in: Nat Med 1997 Mar;3(3):253–4.

Setback to immunotherapy strategies of breast cancer. Naresh KN. **Natl Med J India** 1997 May–Jun;10(3):128–9

Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis–related antigens (bcl–2, c–myc, Fas, Lewis(y) and p53) in human cholangiocarcinomas and hepatocellular carcinomas. Terada T, et al. **Pathol Int** 1996 Oct;46(10):764–70

Association of apoptosis of neutrophils and eosinophils and their ingestion by macrophages with resolution of the allergen–induced cutaneous late–phase response in atopic human subjects. Ying S, et al.
Proc Assoc Am Physicians 1997 Jan;109(1):42–50

Proteasome regulation of activation–induced T cell death. Cui H, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8; 94(14):7515–20

Precursor B cells for autoantibody production in genomically Fas–intact autoimmune disease are not subject to Fas–mediated immune elimination. Hirose S, et al.
Proc Natl Acad Sci U S A 1997 Aug 19;94(17):9291–5

Self–antigen does not accelerate immature B cell apoptosis, but stimulates receptor editing as a consequence of developmental arrest. Melamed D, et al.
Proc Natl Acad Sci U S A 1997 Aug 19;94(17):9267–72

Fas–induced apoptosis of T cells occurs independently of ceramide generation. Watts JD, et al.
Proc Natl Acad Sci U S A 1997 Jul 8;94(14):7292–6

Apoptosis: function and regulation of cell death. Abastado JP. **Res Immunol** 1996 Sep;147(7):443–56 (72 ref.)

Role for NK–cell–associated Fas ligand in cell–mediated cytotoxicity and apoptosis. Eischen CM, et al.
Res Immunol 1997 Mar–Apr;148(3):164–9 (43 ref.)

Differential role for IL–2 and IL–15 in the inhibition of apoptosis in short–term activated human lymphocytes. Lorenz HM, et al. **Scand J Immunol** 1997 Jun;45(6):660–9

Granulocyte clearance by apoptosis in the resolution of inflammation. Savill J, et al. **Semin Cell Biol** 1995 Dec; 6(6):385–93 (72 ref.)

Portrait of an executioner: the molecular mechanism of FAS/APO–1–induced apoptosis. Chinnaiyan AM, et al.
Semin Immunol 1997 Feb;9(1):69–76 (84 ref.)

The molecular regulation of lymphocyte apoptosis. Lenardo MJ. **Semin Immunol** 1997 Feb;9(1):1–5 (33 ref.)

The CD95 system and the death of a lymphocyte. Matiba B, et al. **Semin Immunol** 1997 Feb;9(1):59–68 (108 ref.)

ALPS: an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Puck JM, et al. **Semin Immunol** 1997 Feb;9(1):77–84

Stimulation through CD50 (ICAM–3) induces both activation and programmed cell death of human thymocytes. Martinez–Cáceres E, et al. **Tissue Antigens** 1996 Dec;48(6):626–35

Apoptosis–mediated immunotoxicity of polychlorinated biphenyls (PCBs) in murine splenocytes. Yoo BS, et al. **Toxicol Lett** 1997 Apr 28;91(2):83–9

CD2 induced apoptosis of peripheral T cells. Rouleau M, et al. **Transplant Proc** 1997 Aug;29(5):2377–8 (3 ref.)

Apoptosis as a proinflammatory event: what can we learn from bacteria–induced cell death? Zychlinsky A, et al.
Trends Microbiol 1997 May;5(5):201–4 (42 ref.)

Flow cytometric detection of activation–induced cell death (apoptosis) in peripheral blood lymphocyte subpopulations from healthy cats. Holznagel E, et al.
Vet Immunol Immunopathol 1996 Jun 15;52(1–2):1–14

Apoptosis induction by human immunodeficiency virus type 1 (HIV–1) gp120 peptides. Pugliese O, et al.
Viral Immunol 1997;10(2):95–102

Apoptosis correlates with immune activation in intestinal lymphoid tissue from macaques acutely infected by a highly enteropathic simian immunodeficiency virus, SIVsmmPBj14. Gummuluru S, et al. **Virology** 1996 Nov 1;225(1):21–32

HIV envelope glycoprotein–induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells. Jacotot E, et al. **Virology** 1996 Sep 15;223(2):318–30

[Pro–inflammatory cytokines regulate apoptosis of granulocytes during systemic inflammation] Ertel W, et al.
Langenbecks Arch Chir Suppl Kongressbd 1997;114:627–9 (Eng. Abstr.) **(Ger)**

[Tissue–specific tolerance induction by CD95 ligand expression] Hoffmann MW, et al.
Langenbecks Arch Chir Suppl Kongressbd 1997;114:285–8 (Eng. Abstr.) **(Ger)**

[Increased expression of apoptosis–inducing proteins Fas antigen and Fas ligand on mononuclear cells of septic patients] Ungethüm U, et al.
Langenbecks Arch Chir Suppl Kongressbd 1997;114:623–5 (Eng. Abstr.) **(Ger)**

[Expression of Fas/APO–1/CD95 antigen mediating the apoptosis in human leukemic cells] Shishkin IuV, et al.
Biull Eksp Biol Med 1996 Nov;122(11):544–6 **(Rus)**

PHYSIOLOGY

Apoptotic and necrotic cell death following kindling induced seizures. Pretel S, et al. **Acta Histochem** 1997 Mar; 99(1):71–9

Loss and apoptosis of smooth muscle cells in intracranial aneurysms. Studies with in situ DNA end labeling and antibody against single–stranded DNA. Sakaki T, et al.
Acta Neurochir (Wien) 1997;139(5):469–74; discussion 474–5

The retinoblastoma gene product is a negative modulator of the apoptotic pathway. Fan G, et al.
Adv Enzyme Regul 1996;36:283–303

Cross–talk between ceramide and PKC activity in the control of apoptosis in WEHI–231. Chmura SJ, et al.
Adv Exp Med Biol 1996;406:39–55

Apoptosis and its regulation. Cohen JJ.
Adv Exp Med Biol 1996;406:11–20 (88 ref.)

Role of ICE–proteases in apoptosis. Dixit VM.
Adv Exp Med Biol 1996;406:113–7 (44 ref.)

NO as a physiological signal molecule that triggers thymocyte apoptosis. Fehsel K, et al.
Adv Exp Med Biol 1996;387:195–8

Granzyme B–induced apoptosis. Greenberg AH.
Adv Exp Med Biol 1996;406:219–28 (69 ref.)

The Epstein–Barr virus gene BHRF1, a homologue of the cellular oncogene Bcl–2, inhibits apoptosis induced by gamma radiation and chemotherapeutic drugs. McCarthy NJ, et al. **Adv Exp Med Biol** 1996;406:83–97

Regulation of programmed cell death by interleukin–1 beta–converting enzyme family of proteases. Miura M, et al. **Adv Exp Med Biol** 1996;389:165–72 (57 ref.)

Participation of cathepsins B, H, and L in perikaryal condensation of CA1 pyramidal neurons undergoing apoptosis after brief ischemia. Nitatori T, et al.
Adv Exp Med Biol 1996;389:177–85

Fas splicing variants and their effect on apoptosis. Ruberti G, et al. **Adv Exp Med Biol** 1996;406:125–34 (67 ref.)

Tryptophan starvation is involved in human interferon–gamma mediated apoptosis. Taylor MW, et al.
Adv Exp Med Biol 1996;398:155–9

Nitric oxide in the liver: physiopathological roles. Suzuki H, et al. **Adv Neuroimmunol** 1995;5(4):379–410 (145 ref.)

Is ischemic cell death of the apoptotic type? Charriaut–Marlangue C, et al. **Adv Neurol** 1996;71:425–30; discussion 430–1

Neuronal necrosis and apoptosis: two distinct events induced by exposure to glutamate or oxidative stress. Nicotera P, et al. **Adv Neurol** 1997;72:95–101 (53 ref.)

Related mechanisms of action of growth factors and antioxidants in apoptosis: an overview. Oppenheim RW.
Adv Neurol 1997;72:69–78 (40 ref.)

Neurotrophins and programmed cell death during cerebellar development. Segal RA, et al. **Adv Neurol** 1997;72:79–86 (53 ref.)

Apoptosis in AIDS. Badley AD, et al. **Adv Pharmacol** 1997; 41:271–94 (154 ref.)

Apoptosis in the mammalian kidney: incidence, effectors, and molecular control in normal development and disease states. Buttyan R, et al. **Adv Pharmacol** 1997;41:369–81 (58 ref.)

Glucocorticoid–induced apoptosis. Distelhorst CW.
Adv Pharmacol 1997;41:247–70 (175 ref.)

The Fas pathway in apoptosis. Eischen CM, et al.
Adv Pharmacol 1997;41:107–32 (163 ref.)

Methods utilized in the study of apoptosis. Mesner PW Jr, et al. **Adv Pharmacol** 1997;41:57–87 (113 ref.)

Apoptosis in neurodegenerative diseases. Nishimoto I, et al.
Adv Pharmacol 1997;41:337–68 (267 ref.)

Apoptosis and the gastrointestinal system. Que F, et al.
Adv Pharmacol 1997;41:409–28 (81 ref.)

Ceramide: a novel lipid mediator of apoptosis. Smyth MJ, et al. **Adv Pharmacol** 1997;41:133–54 (104 ref.)

In vitro systems for the study of apoptosis. Takahashi A, et al. **Adv Pharmacol** 1997;41:89–106 (77 ref.)

Control of apoptosis by proteases. Thornberry NA, et al.
Adv Pharmacol 1997;41:155–77 (152 ref.)

Apoptosis in the heart. Umansky SR, et al.
Adv Pharmacol 1997;41:383–407 (85 ref.)

Apoptosis: an overview of the process and its relevance in disease. Webb SJ, et al. **Adv Pharmacol** 1997;41:1–34 (174 ref.)

Recent advances in understanding mechanisms of renal tubular injury. Ueda N, et al. **Adv Ren Replace Ther** 1997 Apr;4(2 Suppl 1):17–24 (13 ref.)

Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome. Cossarizza A, et al. **AIDS** 1997 Jan; 11(1):19–26

A comparative study of apoptosis and cell proliferation in infantile and adult fibrosarcomas. Kihara S, et al.
Am J Clin Pathol 1996 Oct;106(4):493–7

Placental apoptosis in normal human pregnancy. Smith SC, et al. **Am J Obstet Gynecol** 1997 Jul;177(1):57–65

Apoptosis, necrosis, and proliferation: possible implications in the etiology of keloids. Appleton I, et al.
Am J Pathol 1996 Nov;149(5):1441–7

Cell–matrix and cell–cell interactions modulate apoptosis of bronchial epithelial cells. Aoshiba K, et al.
Am J Physiol 1997 Jan;272(1 Pt 1):L28–37

Roles of cytoplasmic Ca2+ and intracellular Ca2+ stores in induction and suppression of apoptosis in S49 cells. Bian X, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1241–9

Extracellular ATP and adenosine cause apoptosis of pulmonary artery endothelial cells. Dawicki DD, et al.
Am J Physiol 1997 Aug;273(2 Pt 1):L485–94

Bcl–2 inhibits selective oxidation and externalization of phosphatidylserine during paraquat–induced apoptosis. Fabisiak JP, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):C675–84

Protection from apoptosis in human neutrophils is determined by the surface of adhesion. Ginis I, et al.
Am J Physiol 1997 Jan;272(1 Pt 1):C295–309

Role of vacuolation in the death of gastric epithelial cells. Hagen SJ, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):C48–58

Role of apoptosis in development of the ascending thin limb of the loop of Henle in rat kidney. Kim J, et al.
Am J Physiol 1996 Oct;271(4 Pt 2):F831–45

Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury. Lieberthal W, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F477–88 (126 ref.)

Role of nitric oxide in autocrine control of growth and apoptosis of endothelial cells. López–Farré A, et al.
Am J Physiol 1997 Feb;272(2 Pt 2):H760–8

F–actin disorganization in apoptotic cell death of cultured rat renal proximal tubular cells. Van de Water B, et al.
Am J Physiol 1996 Apr;270(4 Pt 2):F593–603

Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Hagimoto N, et al.
Am J Respir Cell Mol Biol 1997 Sep;17(3):272–8

The heat–shock response attenuates lipopolysaccharide–mediated apoptosis in cultured sheep pulmonary artery endothelial cells. Wong HR, et al.
Am J Respir Cell Mol Biol 1996 Dec;15(6):745–51

Apoptosis. Cummings MC, et al. **Am J Surg Pathol** 1997 Jan;21(1):88–101 (130 ref.)

Purification of the death substrate poly(ADP–ribose) polymerase. D'Amours D, et al. **Anal Biochem** 1997 Jun 15;249(1):106–8

The role of macrophages in clearing programmed cell death in the developing kidney. Camp V, et al.
Anat Embryol (Berl) 1996 Oct;194(4):341–8

Ultrastructural and cytochemical identification of apoptotic cell death accompanying development of the fetal rat olfactory nerve layer. Pellier V, et al.
Anat Embryol (Berl) 1996 Jul;194(1):99–109

Apoptotic cell death during the estrous cycle in the rat uterus and vagina. Sato T, et al. **Anat Rec** 1997 May;248(1):76–83

Type 1 and type 2 cytokines in HIV infection — a possible role in apoptosis and disease progression [editorial] Clerici M, et al. **Ann Med** 1997 Jun;29(3):185–8

The role of apoptosis in gynaecological malignancies. Sheets EE, et al. **Ann Med** 1997 Apr;29(2):121–6 (53 ref.)

Enhancement of apoptosis in cerebral endothelial cells by selected inflammatory signals. Hsu CY, et al.
Ann N Y Acad Sci 1997 Aug 14;823:148–53

Multiple sclerosis: oligodendrocytes display cell death–related molecules in situ but do not undergo apoptosis. Bonetti B, et al. **Ann Neurol** 1997 Jul;42(1):74–84

Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target. Dixon SC, et al. **Ann Pharmacother** 1997 Jan;31(1):76–82 (80 ref.)

Apoptosis and disease: regulation and clinical relevance of programmed cell death. Rudin CM, et al.
Annu Rev Med 1997;48:267–81 (94 ref.)

Ascorbate and alpha–tocopherol prevent apoptosis induced by serum removal independent of Bcl–2. Barroso MP, et al. **Arch Biochem Biophys** 1997 Jul 15;343(2):243–8

Trolox inhibits peroxynitrite–mediated oxidative stress and apoptosis in rat thymocytes. Salgo MG, et al.
Arch Biochem Biophys 1996 Sep 15;333(2):482–8

Upregulated expression of Fas antigen on cultured human keratinocytes with induction of apoptosis by cisplatin. Matsumoto Y, et al. **Arch Dermatol Res** 1996 May; 288(5–6):267–9

Hypoxia, ischaemia, and apoptosis. Mehmet H, et al.
Arch Dis Child Fetal Neonatal Ed 1996 Sep;75(2):F73–5 (34 ref.)

Regulation and mechanisms of apoptosis in T lymphocytes. van den Dobbelsteen DJ, et al. **Arch Toxicol Suppl** 1997; 19:77–85 (30 ref.)

Lymphocyte apoptosis and apoptosis–associated gene expression in Sjögren's syndrome. Ogawa N, et al.
Arthritis Rheum 1996 Nov;39(11):1875–85

The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions. Cai W, et al.
Atherosclerosis 1997 Jun;131(2):177–86

Bcl–2 completely blocks Fas–mediated apoptosis in mtDNA–depleted HeLa cells. Asoh S, et al.
Biochem Biophys Res Commun 1997 Aug 28;237(3):659–62

The shape of cell death. Leist M, et al.
Biochem Biophys Res Commun 1997 Jul 9;236(1):1–9 (164 ref.)

Reactive oxygen species participate in peroxynitrite–induced apoptosis in HL–60 cells. Lin KT, et al.
Biochem Biophys Res Commun 1997 Jan 3;230(1):115–9

CD45 regulates apoptosis induced by extracellular adenosine triphosphate and cytotoxic T lymphocytes. Macino B, et al. **Biochem Biophys Res Commun** 1996 Sep 24; 226(3):769–76

Integrin beta4 is involved in apoptotic signal transduction in endothelial cells. Miao JY, et al.

Biochem Biophys Res Commun 1997 Apr 7;233(1):182–6
Shift of DNA polymerase alpha nuclear distribution and activity in apoptotic human leukaemia cells. Miscia S, et al. **Biochem Biophys Res Commun** 1997 May 19; 234(2):303–8
Processing of Alzheimer's amyloid precursor protein during H2O2–induced apoptosis in human neuronal cells. Zhang L, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):845–8
Chromatin condensation during apoptosis requires ATP. Kass GE, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):749–52
Subcellular redistribution of HSP72 protein during cisplatin–induced apoptosis in HeLa cells.
Meléndez–Zajgla J, et al. **Biochem Mol Biol Int** 1996 Oct; 40(2):253–61
Detection of apoptosis in the brain of the zitter rat with genetic spongiform encephalopathy. Ookohchi T, et al. **Biochem Mol Biol Int** 1997 Feb;41(2):279–84
Regulation of granulocyte apoptosis by PKC inhibition and elevation of [Ca2+]i. Cousin JM, et al.
Biochem Soc Trans 1997 May;25(2):243S
Effect of the protein phosphatase inhibitors, okadaic acid and calyculin A, on dexamethasone–mediated inhibition of neutrophil apoptosis. Cousin JM, et al.
Biochem Soc Trans 1997 May;25(2):246S
The role of the extracellular matrix and lactogenic hormones in mammary gland apoptosis. Goberdhan N, et al.
Biochem Soc Trans 1996 Aug;24(3):348S
Transforming growth factor–beta increases the inhibitory effects of GM–CSF and dexamethasone on neutrophil apoptosis. Ward C, et al. **Biochem Soc Trans** 1997 May; 25(2):244S
Interleukin–10 does not directly affect the constitutive rate of human neutrophil or eosinophil apoptosis. Ward C, et al. **Biochem Soc Trans** 1997 May;25(2):245S
Apoptosis is associated with an increase in saturated fatty acid containing phospholipids in the neuronal cell line, HN2–5 [published erratum appears in Biochim Biophys Acta 1997 Jun 2;1346(2):205–6] Singh JK, et al.
Biochim Biophys Acta 1996 Dec 13;1304(3):171–8
Induction of apoptotic cell death by DNA topoisomerase II inhibitors. Negri C, et al. **Biochimie** 1995;77(11):893–9
Apoptosis–induced concomitant release of cytosolic proteins and factors which prevent cell death. Endrich MM, et al. **Biol Cell** 1996;88(1–2):15–22
Transglutaminase and clusterin induction during normal and abnormal limb development in the mouse. Adel Moallem S, et al. **Biol Reprod** 1996 Aug;55(2):281–90
Apoptosis during mouse blastocyst formation: evidence for a role for survival factors including transforming growth factor alpha. Brison DR, et al. **Biol Reprod** 1997 May; 56(5):1088–96
Cyclophilin A is present in rat germ cells and is associated with spermatocyte apoptosis. Reproductive Toxicology Group. Wine RN, et al. **Biol Reprod** 1997 Feb;56(2):439–46
Apoptosis: an identical central or collateral mechanism in the development, function and death of neurons [editorial] Mathé G. **Biomed Pharmacother** 1997;51(3):97–100 (43 ref.)
Fc gammaRII (CD32) is linked to apoptotic pathways in murine granulocyte precursors and mature eosinophils. de Andrés B, et al. **Blood** 1997 Aug 1;90(3):1267–74
Comparison of apoptosis in wild–type and Fas–resistant cells: chemotherapy–induced apoptosis is not dependent on Fas/Fas ligand interactions. Eischen CM, et al. **Blood** 1997 Aug 1;90(3):935–43
A role for T–helper type–1 and type–2 cytokines in the regulation of human monocyte apoptosis. Estaquier J, et al. **Blood** 1997 Aug 15;90(4):1618–25
Thrombin generation by apoptotic vascular smooth muscle cells. Flynn PD, et al. **Blood** 1997 Jun 15;89(12):4378–84
Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines. Lindner H, et al. **Blood** 1997 Mar 15; 89(6):1931–8
Indication of an involvement of interleukin–1 beta converting enzyme–like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Mundle SD, et al. **Blood** 1996 Oct 1; 88(7):2640–7
p53 is not required for regulation of apoptosis or radioprotection by interleukin–3. Silva A, et al. **Blood** 1997 Apr 15;89(8):2717–22
Augmented intracellular glutathione inhibits Fas–triggered apoptosis of activated human neutrophils. Watson RW, et al. **Blood** 1997 Jun 1;89(11):4175–81
Identification of apoptotic changes in osteocytes in normal and pathological human bone. Noble BS, et al. **Bone** 1997 Mar;20(3):273–82
What is an apoptotic index measuring? A commentary. Potten CS. **Br J Cancer** 1996 Dec;74(11):1743–8
Increased apoptotic cells in bone marrow biopsies from patients with aplastic anaemia. Callera F, et al.
Br J Haematol 1997 Jul;98(1):18–20
Neutrophil apoptosis is delayed by the diadenosine polyphosphates, Ap5A and Ap6A: synergism with granulocyte–macrophage colony–stimulating factor. Gasmi L, et al. **Br J Haematol** 1996 Dec;95(4):637–9
G–CSF–mobilized CD34 peripheral blood stem cells are significantly less apoptotic than unstimulated peripheral blood CD34 cells: role of G–CSF as survival factor. Philpott NJ, et al. **Br J Haematol** 1997 Apr;97(1):146–52
Interleukin–4 prevents spontaneous in–vitro apoptosis in chronic lymphatic leukaemia but sensitizes B–CLL cells to melphalan cytotoxicity. Pu QQ, et al. **Br J Haematol** 1997 Aug;98(2):413–7
Recombinant human thrombopoietin (TPO) stimulates erythropoiesis by inhibiting erythroid progenitor cell apoptosis. Ratajczak MZ, et al. **Br J Haematol** 1997 Jul; 98(1):8–17
Conservation of apoptosis as an immune regulatory mechanism: effects of cortisol and cortisone on carp lymphocytes. Weyts FAA, et al. **Brain Behav Immun** 1997 Jun;11(2):95–105
Pitfalls in the evaluation of apoptosis using TUNEL [letter; comment] Cervos–Navarro J, et al. **Brain Pathol** 1996 Jul; 6(3):347–8. Comment on: Brain Pathol 1995 Jul;5(3):283–8.
Cell death in C. elegans: molecular insights into mechanisms conserved between nematodes and mammals. Driscoll M. **Brain Pathol** 1996 Oct;6(4):411–25 (107 ref.)
p53 and Bax activation in 6–hydroxydopamine–induced apoptosis in PC12 cells. Blum D, et al. **Brain Res** 1997 Mar 14;751(1):139–42
Apoptotic morphology of dentate gyrus granule cells following experimental cortical impact injury in rats: possible role in spatial memory deficits. Colicos MA, et al. **Brain Res** 1996 Nov 11;739(1–2):120–31
The role of apoptosis in sexual differentiation of the rat sexually dimorphic nucleus of the preoptic area. Davis EC, et al. **Brain Res** 1996 Sep 23;734(1–2):10–8
Cell death in the inner ear associated with aging is apoptosis? Usami S, et al. **Brain Res** 1997 Jan 30;747(1):147–50
Evidence of apoptosis in primary neuronal cultures after heat shock. Vogel P, et al. **Brain Res** 1997 Aug 1; 764(1–2):205–13
Nerve growth factor, central nervous system apoptosis, and adrenocortical activity in aged Fischer–344/brown Norway F1 hybrid rats. Taglialatela G, et al.
Brain Res Bull 1997;43(2):229–33
Growth conditions influence DNA methylation in cultured cerebellar granule cells. Bertino L, et al.
Brain Res Dev Brain Res 1996 Aug 20;95(1):38–43
Apoptosis in the rostral migratory stream of the developing rat. Brunjes PC, et al. **Brain Res Dev Brain Res** 1996 Apr 30;92(2):219–22
Expression of cyclin A decreases during neuronal apoptosis in cultured rat cerebellar granule neurons. Oka T, et al. **Brain Res Dev Brain Res** 1996 Nov 22;97(1):96–106
Involvement of phosphatidylinositol–3 kinase in prevention of low K(+)–induced apoptosis of cerebellar granule neurons. Shimoke K, et al. **Brain Res Dev Brain Res** 1997 Jul 18;101(1–2):197–206
Cultured neurons expressing phosphorylated tau are more resistant to apoptosis induced by NMDA or serum deprivation. Lesort M, et al. **Brain Res Mol Brain Res** 1997 Apr;45(1):127–32
Apoptosis and vascular wall remodeling in hypertension. Hamet P, et al. **Can J Physiol Pharmacol** 1996 Jul; 74(7):850–61 (90 ref.)
Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Vollmers HP, et al. **Cancer** 1997 Feb 1;79(3):433–40
Ribozyme–mediated suppression of v–myc expression abrogates apoptosis in transformed monocytes. Dolnikov A, et al. **Cancer Gene Ther** 1996 Sep–Oct;3(5):289–95
Bcl–2 protects cells from cytokine–induced nitric–oxide–dependent apoptosis. Xie K, et al.
Cancer Immunol Immunother 1996 Oct;43(2):109–15
Perspective: the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Martin DS, et al. **Cancer Invest** 1997; 15(4):372–81 (97 ref.)
Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Glinsky GV, et al. **Cancer Lett** 1997 May 19;115(2):185–93
Isolation of chromatin fragments released by apoptotic cells. Vodenicharov MD, et al. **Cancer Lett** 1996 Aug 23; 106(1):51–8
CRADD, a novel human apoptotic adaptor molecule for caspase–2, and FasL/tumor necrosis factor receptor–interacting protein RIP. Ahmad M, et al.
Cancer Res 1997 Feb 15;57(4):615–9
Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Eguchi Y, et al. **Cancer Res** 1997 May 15;57(10):1835–40
Nitrotyrosine formation, apoptosis, and oxidative damage: relationships to nitric oxide production in SJL mice bearing the RcsX tumor. Gal A, et al. **Cancer Res** 1997 May 15; 57(10):1823–8
DNA damage–associated dysregulation of the cell cycle and apoptosis control in cells with germ–line p53 mutation. Goi K, et al. **Cancer Res** 1997 May 15;57(10):1895–902
p53 status affects the rate of the onset but not the overall extent of doxorubicin–induced cell death in rat–1 fibroblasts constitutively expressing c–Myc. Han JW, et al.
Cancer Res 1997 Jan 1;57(1):176–82
Regulation of apoptosis induced by transforming growth factor–beta1 in nontumorigenic rat prostatic epithelial cell lines. Hsing AY, et al. **Cancer Res** 1996 Nov 15; 56(22):5146–9
Baculovirus P35 inhibits the glucocorticoid–mediated pathway of cell death. Robertson NM, et al.
Cancer Res 1997 Jan 1;57(1):43–7
Insulin–like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Singleton JR, et al. **Cancer Res** 1996 Oct 1;56(19):4522–9
Drug–induced apoptosis is associated with enhanced Fas (Apo–1/CD95) ligand expression but occurs independently of Fas (Apo–1/CD95) signaling in human T–acute lymphatic leukemia cells. Villunger A, et al.
Cancer Res 1997 Aug 15;57(16):3331–4
Germinal center–derived signals act with Bcl–2 to decrease apoptosis and increase clonogenicity of drug–treated human B lymphoma cells. Walker A, et al. **Cancer Res** 1997 May 15;57(10):1939–45
Expression of the Epstein Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl–2 homologue Mcl–1 levels in B–cell lines. Wang S, et al. **Cancer Res** 1996 Oct 15;56(20):4610–3
Requirement of p34cdc2 kinase for apoptosis mediated by the Fas/APO–1 receptor and interleukin 1beta–converting enzyme–related proteases. Yao SL, et al. **Cancer Res** 1996 Oct 15;56(20):4551–5
Retroviral delivery and tetracycline–dependent expression of IL–1beta–converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. Yu JS, et al. **Cancer Res** 1996 Dec 1; 56(23):5423–7
Apoptosis and proliferation under conditions of deoxynucleotide pool imbalance in liver of folate/methyl deficient rats. James SJ, et al. **Carcinogenesis** 1997 Feb; 18(2):287–93
Bcl–2 deregulation leads to inhibition of sodium butyrate–induced apoptosis in human colorectal carcinoma cells. Mandal M, et al. **Carcinogenesis** 1997 Jan;18(1):229–32
Fibroblasts transformed by chemical carcinogens are sensitive to intercellular induction of apoptosis: implications for the control of oncogenesis. Panse J, et al. **Carcinogenesis** 1997 Feb;18(2):259–64
CAR1, a TNFR–related protein, is a cellular receptor for cytopathic avian leukosis–sarcoma viruses and mediates apoptosis. Brojatsch J, et al. **Cell** 1996 Nov 29;87(5):845–55
The regulation of anoikis: MEKK–1 activation requires cleavage by caspases. Cardone MH, et al. **Cell** 1997 Jul 25;90(2):315–23
PI3K: downstream AKTion blocks apoptosis. Franke TF, et al. **Cell** 1997 Feb 21;88(4):435–7 (20 ref.)
Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF–kappaB activation prevents cell death. Liu ZG, et al. **Cell** 1996 Nov 1;87(3):565–76
Apoptosis by death factor. Nagata S. **Cell** 1997 Feb 7; 88(3):355–65 (85 ref.)
CED–4—the third horseman of apoptosis [comment] Vaux DL. **Cell** 1997 Aug 8;90(3):389–90 (17 ref.). Comment on: Cell 1997 Aug 8;90(3):405–13.
Bcl–2 targets the protein kinase Raf–1 to mitochondria [see comments] Wang HG, et al. **Cell** 1996 Nov 15;87(4):629–38 . Comment in: Cell 1996 Nov 15;87(4):589–92.
Daxx, a novel Fas–binding protein that activates JNK and apoptosis. Yang X, et al. **Cell** 1997 Jun 27;89(7):1067–76
Cell–adhesion to crystal surfaces. Adhesion–induced physiological cell death. Hanein D, et al.
Cell Adhes Commun 1996 Nov;4(4–5):341–54
REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis. Varner JA, et al. **Cell Adhes Commun** 1995 Nov; 3(4):367–74 (60 ref.)
Cell–cell and cell–ECM interactions in epithelial apoptosis and cell renewal during frog intestinal development. Shi YB. **Cell Biochem Biophys** 1995;27(3):179–202 (85 ref.)
Bcl–2 acts subsequent to and independent of Ca2+ fluxes to inhibit apoptosis in thapsigargin– and glucocorticoid–treated mouse lymphoma cells. Distelhorst CW, et al. **Cell Calcium** 1996 Jun;19(6):473–83
Immunohistochemical analysis of the proapoptotic protein Par–4 in normal rat tissues. Boghaert ER, et al.
Cell Growth Differ 1997 Aug;8(8):881–90
Involvement of caspase family proteases in transforming growth factor–beta–induced apoptosis. Chen RH, et al.
Cell Growth Differ 1997 Jul;8(7):821–7
Relationship of sequence–specific transactivation and p53–regulated apoptosis in interleukin 3–dependent hematopoietic cells. Gottlieb E, et al.
Cell Growth Differ 1996 Mar;7(3):301–10
Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Han EK, et al. **Cell Growth Differ** 1996 Jun;7(6):699–710
Bcl–xL overexpression inhibits taxol–induced Yama protease activity and apoptosis. Ibrado AM, et al.
Cell Growth Differ 1996 Aug;7(8):1087–94
Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Jones JM, et al. **Cell Growth Differ** 1997 Aug;8(8):829–38
Transforming growth factor beta 1–induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N–acetylcysteine and bcl–2. Lafon C, et al.
Cell Growth Differ 1996 Aug;7(8):1095–104
Apoptosis and remodeling of mammary gland tissue during involution proceeds through p53–independent pathways. Li M, et al. **Cell Growth Differ** 1996 Jan;7(1):13–20
Bcl–2 expression regulates sodium butyrate–induced apoptosis in human MCF–7 breast cancer cells. Mandal M, et al. **Cell Growth Differ** 1996 Mar;7(3):311–8
Expression of p53 in Saos–2 osteosarcoma cells induces apoptosis which can be inhibited by Bcl–2 or the

adenovirus E1B-55 kDa protein. Marcellus RC, et al. **Cell Growth Differ** 1996 Dec;7(12):1643-50

Apoptosis is accompanied by changes in Bcl-2 and Bax expression, induced by loss of attachment, and inhibited by specific extracellular matrix proteins in mammary epithelial cells. Merio GR, et al. **Cell Growth Differ** 1997 Feb;8(2):251-60

Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Ronen D, et al. **Cell Growth Differ** 1996 Jan;7(1):21-30

Interleukin 1 beta converting enzyme-like proteases are essential for p53-mediated transcriptionally dependent apoptosis. Sabbatini P, et al. **Cell Growth Differ** 1997 Jun; 8(6):643-53

The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. Shan B, et al. **Cell Growth Differ** 1996 Jun; 7(6):689-97

Cell cycle-independent regulation of p21Waf1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of Bax protein in human breast carcinoma cells. Sheikh MS, et al. **Cell Growth Differ** 1996 Dec;7(12):1599-607

Regulation of Myc-dependent apoptosis by p53, c-Jun N-terminal kinases/stress-activated protein kinases, and Mdm-2. Yu K, et al. **Cell Growth Differ** 1997 Jul; 8(7):731-42

Monoamine-induced apoptotic neuronal cell death. Zilkha-Falb R, et al. **Cell Mol Neurobiol** 1997 Feb; 17(1):101-18

Probing chromatin structure in the early phases of apoptosis. Ferlini C, et al. **Cell Prolif** 1996 Jul;29(7):427-36

Activation of Ras and protection from apoptotic cell death by BDNF in PC12 cells expressing TrkB. Jian Z, et al. **Cell Signal** 1996 Aug;8(5):365-70

The dual role of S-nitrosoglutathione (GSNO) during thymocyte apoptosis. Sandau K, et al. **Cell Signal** 1996 Mar; 8(3):173-7

Apoptosis and cell proliferation in the Xenopus small intestine during metamorphosis. Ishizuya-Oka A, et al. **Cell Tissue Res** 1996 Dec;286(3):467-76

Apoptosis in mouse taste buds after denervation. Takeda M, et al. **Cell Tissue Res** 1996 Oct;286(1):55-62

Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. Belshaw PJ, et al. **Chem Biol** 1996 Sep; 3(9):731-8

ATP receptors in sickness, pain and death. Brake A, et al. **Chem Biol** 1996 Apr;3(4):229-32 (23 ref.)

Chiasmal gliomas with spontaneous regression: proliferation and apoptosis. Takenchi H, et al. **Childs Nerv Syst** 1997 Apr;13(4):229-33

Death by design. Programmed cell death in cardiovascular biology and disease. MacLellan WR, et al. **Circ Res** 1997 Aug;81(2):137-44 (102 ref.)

In vivo gene transfection of human endothelial cell nitric oxide synthase in cardiomyocytes causes apoptosis-like cell death. Identification using Sendai virus-coated liposomes. Kawaguchi H, et al. **Circulation** 1997 May 20;95(10):2441-7

Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Misao J, et al. **Circulation** 1996 Oct 1;94(7):1506-12

Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. Spyridopoulos I, et al. **Circulation** 1997 Mar 18;95(6):1505-14

Cell death in the developing chick knee joint: I. Spatial and temporal patterns. Abu-Hijleh G, et al. **Clin Anat** 1997; 10(3):183-200

Physiological cell death in endocrine-dependent tissues: an ovarian perspective. Martimbeau S, et al. **Clin Endocrinol (Oxf)** 1997 Mar;46(3):241-54 (169 ref.)

Preferential elimination of CD28+ T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis. Kaneko H, et al. **Clin Exp Immunol** 1996 Nov;106(2):218-29

Signaling events in T lymphocytes leading to cellular activation or programmed cell death. Musci MA, et al. **Clin Immunol Immunopathol** 1997 Jun;83(3):205-22 (197 ref.)

Role of nitric oxide in retinal cell death. Roth S. **Clin Neurosci** 1997;4(5):216-23 (98 ref.)

Apoptosis in the rabbit cornea after photorefractive keratectomy. Gao J, et al. **Cornea** 1997 Mar;16(2):200-8

Lymphoid apoptosis during sepsis: now that we've found it, what do we do with it? [editorial; comment] Ayala A. **Crit Care Med** 1997 Aug;25(8):1261-2. Comment on: Crit Care Med 1997 Aug;25(8):1298-1307.

Apoptosis in normal and neoplastic hematopoiesis. Yoshida Y, et al. **Crit Rev Oncol Hematol** 1996 Nov;24(3):185-211 (273 ref.)

Differential effect of components of the extracellular matrix on differentiation and apoptosis. Aharoni D, et al. **Curr Biol** 1997 Jan 1;7(1):43-51

Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3. Chinnaiyan AM, et al. **Curr Biol** 1996 Jul 1;6(7):897-9

Apoptosis: does stress kill? Cosulich S, et al. **Curr Biol** 1996 Dec 1;6(12):1586-8 (18 ref.)

Calcium-mediated apoptosis in a plant hypersensitive disease resistance response. Levine A, et al. **Curr Biol** 1996 Apr 1;6(4):427-37

Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Marsters SA, et al. **Curr Biol** 1996 Dec 1;6(12):1669-76

Apoptosis: telling cells their time is up. Nagata S. **Curr Biol** 1996 Oct 1;6(10):1241-3 (23 ref.)

Apoptosis and change of competence limit the size of the vulva equivalence group in Pristionchus pacificus: a genetic analysis. Sommer RJ, et al. **Curr Biol** 1996 Jan 1;6(1):52-9

A new twist to the tale? Apoptosis. Warbrick E. **Curr Biol** 1996 Sep 1;6(9):1057-9 (10 ref.)

Teratogen-induced eye defects mediated by p53-dependent apoptosis [published erratum appears in Curr Biol 1996 Jun 1;6(6):753] Wubah JA, et al. **Curr Biol** 1996 Jan 1;6(1):60-9

Comparison between serum-free and fibroblast-cocultured single-cell clonal culture systems: evidence showing that epithelial anti-apoptotic activity is present in 3T3 fibroblast-conditioned media. Tseng SC, et al. **Curr Eye Res** 1996 Sep;15(9):973-84

Transducing signals of life and death. Yuan J. **Curr Opin Cell Biol** 1997 Apr;9(2):247-51 (31 ref.)

p53 in signaling checkpoint arrest or apoptosis. Bates S, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):12-8 (68 ref.)

New members of the Bcl-2 family and their protein partners. Farrow SN, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):45-9 (34 ref.)

p53; from inductive signal to cellular effect. Hansen R, et al. **Curr Opin Genet Dev** 1997 Feb;7(1):46-51 (72 ref.)

Bcl-2 and the ICE family of apoptotic regulators: making a connection. Rao L, et al. **Curr Opin Genet Dev** 1997 Feb; 7(1):52-8 (60 ref.)

ICE-related proteases in apoptosis. Takahashi A, et al. **Curr Opin Genet Dev** 1996 Feb;6(1):50-5 (53 ref.)

Apoptosis in neurodegenerative disorders. Stefanis L, et al. **Curr Opin Neurol** 1997 Aug;10(4):299-305 (78 ref.)

Regulation of Fas-mediated apoptosis. Gottlieb RA, et al. **Curr Top Cell Regul** 1997;35:69-105 (213 ref.)

Aging and regulation of apoptosis. Warner HR. **Curr Top Cell Regul** 1997;35:107-21 (88 ref.)

Mechanisms of programmed cell death in Caenorhabditis elegans and vertebrates. Miura M, et al. **Curr Top Dev Biol** 1996;32:139-74 (192 ref.)

Life-and-death decisions influenced by retinoids. Rogers MB. **Curr Top Dev Biol** 1997;35:1-46 (274 ref.)

Alterations in cell cycle control during tumor progression: effects on apoptosis and the response to therapeutic agents. Muschel RJ, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 2):197-213 (110 ref.)

Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in chinese hamster ovary cell cultures treated with cisplatin. Boersma AW, et al. **Cytometry** 1996 Jun 1;24(2):123-30

A novel method for detecting apoptosis shows that hepatocytes undergo a time dependent increase in DNA cleavage and chromatin condensation which is augmented after TGF-beta 1 treatment. Cain K, et al. **Cytometry** 1996 Apr 1;23(4):312-21

Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Ferlini C, et al. **Cytometry** 1996 Jun 1;24(2):106-15

Adaptation of a simple flow cytometric assay to identify different stages during apoptosis. Hamel W, et al. **Cytometry** 1996 Oct 1;25(2):173-81

A novel flow cytometric method for quantifying phagocytosis of apoptotic cells. Hess KL, et al. **Cytometry** 1997 Feb 1;27(2):145-52

Chloromethyl-X-Rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis. Macho A, et al. **Cytometry** 1996 Dec 1; 25(4):333-40

Apoptosis of cells in aged samples as detected by the ProCOUNT reagent. Manion K, et al. **Cytometry** 1996 Dec 15;26(4):317-22

Image cytometry of early nuclear events during apoptosis induced by camptothecin in HL-60 leukemic cells. Palissot V, et al. **Cytometry** 1996 Dec 1;25(4):341-8

Detection of apoptosis by flow cytometry of cells simultaneously stained for intracellular pH (carboxy SNARF-1) and membrane permeability (Hoechst 33342). Reynolds JE, et al. **Cytometry** 1996 Dec 1;25(4):349-57

Cytofluorographic evidence that thymocyte dipeptidyl peptidase IV (CD26) activity is altered with stage of ontogeny and apoptotic status. Ruiz P, et al. **Cytometry** 1996 Apr 1;23(4):322-9

Association between flow cytometric S-phase fraction and apoptotic rate in breast cancer. Samoszuk MK, et al. **Cytometry** 1996 Dec 15;26(4):281-5

Flow cytometric analysis of apoptosis and bcl-2 in primary breast carcinomas: clinical and biological implications. Steck K, et al. **Cytometry** 1996 Jun 1;24(2):116-22

A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. van Engeland M, et al. **Cytometry** 1996 Jun 1;24(2):131-9

Toward a new method to in situ study of apoptosis and its relations with cell cycle. Wallet F, et al. **Cytometry** 1996 Nov 1;25(3):263-70

Supravital exposure to propidium iodide identifies apoptotic cells in the absence of nucleosomal DNA fragmentation. Zamai L, et al. **Cytometry** 1996 Apr 1;23(4):303-11

Anti-BrdUrd labeling of newly synthesized DNA in HL-60 cells triggered to apoptosis. Zamai L, et al. **Cytometry** 1996 Dec 1;25(4):324-32

Apoptosis--its role in tumour growth and therapy. Ellis PA, et al. **Cytopathology** 1996 Jun;7(3):201-3 (18 ref.)

Rescue of sensory ganglia that are programmed to degenerate in normal development: evidence that NGF modulates proliferation of DRG cells in vivo. Geffen R, et al. **Dev Biol** 1996 Aug 25;178(1):51-62

Msx2 is a transcriptional regulator in the BMP4-mediated programmed cell death pathway. Marazzi G, et al. **Dev Biol** 1997 Jun 15;186(2):127-38

Mouse vaginal opening is an apoptosis-dependent process which can be prevented by the overexpression of Bcl2. Rodriguez I, et al. **Dev Biol** 1997 Apr 1;184(1):115-21

Cyclin-dependent kinase 5 is associated with apoptotic cell death during development and tissue remodeling. Zhang Q, et al. **Dev Biol** 1997 Mar 15;183(2):222-33

Apoptosis removes chick embryo tail gut and remnant of the primitive streak. Miller SA, et al. **Dev Dyn** 1996 Jun; 206(2):212-8

Morphological analysis of germ cell apoptosis during postnatal testis development in normal and Hsp 70-2 knockout mice. Mori C, et al. **Dev Dyn** 1997 Jan; 208(1):125-36

Involvement of programmed cell death in morphogenesis of the vertebrate inner ear. Fekete DM, et al. **Development** 1997 Jun;124(12):2451-61

Developmentally regulated activation of apoptosis early in Xenopus gastrulation results in cyclin A degradation during interphase of the cell cycle. Stack JH, et al. **Development** 1997 Aug;124(16):3185-95

Neural tube defects in embryos of diabetic mice: role of the Pax-3 gene and apoptosis. Phelan SA, et al. **Diabetes** 1997 Jul;46(7):1189-97

Cellular and molecular features of lens differentiation: a review of recent advances. Wride MA. **Differentiation** 1996 Dec;61(2):77-93 (226 ref.)

DNase I primary transcript is alternatively spliced in both normal and apoptotic cells: no evidence of up-regulation in apoptosis. Liu QY, et al. **DNA Cell Biol** 1997 Aug; 16(8):911-8

Apoptosis through CD95 (Fas/APO-1), but not a CD40/CD95 chimeric receptor, is inhibited by phorbol-12-myristate-13-acetate. Rudert F, et al. **DNA Cell Biol** 1997 Feb;16(2):197-205

Expression of exogenous NF-IL6 induces apoptosis in Sp2/0-Ag14 myeloma cells. Zhu MS, et al. **DNA Cell Biol** 1997 Feb;16(2):127-35

Apoptosis or programmed cell death [editorial; comment] Nyong'o A. **East Afr Med J** 1997 Feb;74(2):61. Comment on: East Afr Med J 1997 Feb;74(2):108-11.

Dying by default, the biology of apoptosis: a review [see comments] Olasode BJ. **East Afr Med J** 1997 Feb; 74(2):108-11 (21 ref.). Comment in: East Afr Med J 1997 Feb;74(2):61.

Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. Desaintes C, et al. **EMBO J** 1997 Feb 3;16(3):504-14

The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. Huang DC, et al. **EMBO J** 1997 Aug 1;16(15):4628-38

A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. Israeli D, et al. **EMBO J** 1997 Jul 16;16(14):4384-92

STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. Iwama A, et al. **EMBO J** 1996 Nov 1;15(21):5866-75

Cytochrome c activation of CPP32-like proteolysis plays a critical role in a Xenopus cell-free apoptosis system. Kluck RM, et al. **EMBO J** 1997 Aug 1;16(15):4639-49

Inhibition of apoptosis by the actin-regulatory protein gelsolin. Ohtsu M, et al. **EMBO J** 1997 Aug 1;16(15):4650-6

CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease. Smith KG, et al. **EMBO J** 1996 Oct 1;15(19):5167-76

RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. Ting AT, et al. **EMBO J** 1996 Nov 15;15(22):6189-96

Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. Wang LC, et al. **EMBO J** 1997 Jul 16;16(14):4374-83

Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. Zhu W, et al. **EMBO J** 1996 Aug 15;15(16):4130-41

Prolactin expresses differential effects on apoptotic cell death of luteal cells in vivo and in vitro. Kanuka H, et al. **Endocr J** 1997 Feb;44(1):11-22

The Fas system is a key regulator of germ cell apoptosis in the testis. Lee J, et al. **Endocrinology** 1997 May; 138(5):2081-8

Rapid modulation of the apoptosis regulatory genes, bcl-2 and bax by prolactin in rat Nb2 lymphoma cells. Leff MA, et al. **Endocrinology** 1996 Dec;137(12):5456-62

Cellular evidence for arrhythmogenic right ventricular dysplasia being an evolving disease [letter; comment] Cheng TO. **Eur Heart J** 1997 Apr;18(4):703-4. Comment on: Eur Heart J 1996 Nov;17(11):1717-22.

The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Herwig S, et al. **Eur J Biochem** 1997 Jun 15;246(3):581-601 (396 ref.)

Subcellular localization of proteasomes in apoptotic lung tumor cells and persistence as compared to intermediate

filaments. Machiels BM, et al. **Eur J Cell Biol** 1996 Jul; 70(3):250–9

Milk accumulation triggers apoptosis of mammary epithelial cells. Marti A, et al. **Eur J Cell Biol** 1997 Jun;73(2):158–65

Expression and activation of tissue transglutaminase in apoptotic cells of involuting rodent mammary tissue. Nemes Z Jr, et al. **Eur J Cell Biol** 1996 Jun;70(2):125–33

Increased p34cdc2–dependent kinase activity during apoptosis: a possible activation mechanism of DNase I leading to DNA breakdown. Schroter M, et al. **Eur J Cell Biol** 1996 Feb;69(2):143–50

Apoptosis and p53 suppressor gene protein expression in human anterior pituitary adenomas. Green VL, et al. **Eur J Endocrinol** 1997 Apr;136(4):382–7

Hypothesis: patient with possible disturbance in programmed cell death [letter] Hennekam RC, et al. **Eur J Hum Genet** 1995;3(6):374–7

Naturally occurring (programmed) and radiation–induced apoptosis are associated with selective c–Jun expression in the developing rat brain. Ferrer I, et al. **Eur J Neurosci** 1996 Jun;8(6):1286–98

Up–regulation of Bax protein in degenerating retinal ganglion cells precedes apoptotic cell death after optic nerve lesion in the rat. Isenmann S, et al. **Eur J Neurosci** 1997 Aug; 9(8):1763–72

Morphological and biochemical changes in neurons: apoptosis versus mitosis. Philpott KL, et al. **Eur J Neurosci** 1996 Sep;8(9):1906–15

Apoptosis: a programmed cell death involved in ovarian and uterine physiology. Vinatier D, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Aug;67(2):85–102 (282 ref.)

Hypoxia–induced apoptosis in human cells with normal p53 status and function, without any alteration in the nuclear protein level. Amellem O, et al. **Exp Cell Res** 1997 May 1;232(2):361–70

Characteristics of 25–hydroxycholesterol–induced apoptosis in the human leukemic cell line CEM. Ayala–Torres S, et al. **Exp Cell Res** 1997 Aug 25;235(1):35–47

Role of proliferation for intercellular induction of apoptosis. Bassler D, et al. **Exp Cell Res** 1997 May 1;232(2):349–52

Still immunodetectable nuclear RNPs are extruded from the cytoplasm of spontaneously apoptotic thymocytes. Biggiogera M, et al. **Exp Cell Res** 1997 Aug 1;234(2):512–20

Dominant suppression of lymphocyte apoptosis by hepatoma cells. Evans–Storms RB, et al. **Exp Cell Res** 1997 Jan 10; 230(1):121–32

Induction of apoptosis through the PKC pathway in cultured dermal papilla fibroblasts. Ferraris C, et al. **Exp Cell Res** 1997 Jul 10;234(1):37–46

Aggregation of Thy–1 glycoprotein induces thymocyte apoptosis through activation of CPP32–like proteases. Fujita N, et al. **Exp Cell Res** 1997 May 1;232(2):400–6

Variation of heat shock protein 70 through the cell cycle in HL–60 cells and its relationship to apoptosis. He L, et al. **Exp Cell Res** 1997 Apr 10;232(1):64–71

Regulation of lipid signaling pathways for cell survival and apoptosis by bcl–2 in prostate carcinoma cells. Herrmann JL, et al. **Exp Cell Res** 1997 Aug 1;234(2):442–51

Apoptosis–resistant phenotype selected by alternating exposure to camptothecin and etoposide. Kubota M, et al. **Exp Cell Res** 1997 Aug 25;235(1):138–44

Retinoic acid receptors alpha and gamma mediate the induction of "tissue" transglutaminase activity and apoptosis in human neuroblastoma cells. Melino G, et al. **Exp Cell Res** 1997 Aug 25;235(1):55–61

The protein phosphatase inhibitors okadaic acid and calyculin A induce apoptosis in human osteoblastic cells. Morimoto Y, et al. **Exp Cell Res** 1997 Feb 1;230(2):181–6

Multiparametric staining to identify apoptotic human cells. Negri C, et al. **Exp Cell Res** 1997 Jul 10;234(1):174–7

Constitutive expression of human ribosomal protein L7 arrests the cell cycle in G1 and induces apoptosis in Jurkat T–lymphoma cells. Neumann F, et al. **Exp Cell Res** 1997 Feb 1;230(2):252–61

Spontaneous apoptosis of thymocytes is uncoupled with progression through the cell cycle. Pellicciari C, et al. **Exp Cell Res** 1996 Dec 15;229(2):370–7

p53 Induces myocyte apoptosis via the activation of the renin–angiotensin system. Pierzchalski P, et al. **Exp Cell Res** 1997 Jul 10;234(1):57–65

Induction of apoptosis and potentiation of TNF– and Fas–mediated apoptosis in U937 cells by the xanthogenate compound D609. Pörn–Ares MI, et al. **Exp Cell Res** 1997 Aug 25;235(1):48–54

Intact cell evidence for the early synthesis, and subsequent late apopain–mediated suppression, of poly(ADP–ribose) during apoptosis. Rosenthal DS, et al. **Exp Cell Res** 1997 May 1;232(2):313–21

Sequential operation of ceramide synthesis and ICE cascade in CPT–11–initiated apoptotic death signaling. Suzuki A, et al. **Exp Cell Res** 1997 May 25;233(1):41–7

Plasma membrane alterations and cytoskeletal changes in apoptosis. van Engeland M, et al. **Exp Cell Res** 1997 Sep 15;235(2):421–30

The temporal relationship between protein phosphatase, ICE/CED–3 proteases, intracellular acidification, and DNA fragmentation in apoptosis. Wolf CM, et al. **Exp Cell Res** 1997 Jan 10;230(1):22–7

Loss of intracellular putrescine pool–size regulation induces apoptosis. Xie X, et al. **Exp Cell Res** 1997 Feb 1; 230(2):386–92

Apoptosis of chondrocytes in transgenic mice lacking collagen II. Yang C, et al. **Exp Cell Res** 1997 Sep 15; 235(2):370–3

Association of nuclear matrix proteins with granular and threaded nuclear bodies in cell lines undergoing apoptosis. Zweyer M, et al. **Exp Cell Res** 1997 Feb 1;230(2):325–36

Unscheduled DNA replication precedes apoptosis of photoreceptors expressing SV40 T antigen. Al–Ubaidi MR, et al. **Exp Eye Res** 1997 Apr;64(4):573–85

The role of BCL–2 and bax protein in monocyte–mediated apoptosis in human leukemic cell lines. Legdeur MC, et al. **Exp Hematol** 1996 Nov;24(13):1530–9

HLA class II signaling mediates cellular activation and programmed cell death. Truman JP, et al. **Exp Hematol** 1996 Oct;24(12):1409–15

Apoptotic death of olfactory sensory neurons in the adult rat. Deckner ML, et al. **Exp Neurol** 1997 Jan;143(1):132–40

Myc: a single gene controls both proliferation and apoptosis in mammalian cells. Desbarats L, et al. **Experientia** 1996 Dec 15;52(12):1123–9 (51 ref.)

p53 Deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage. Bellamy CO, et al. **FASEB J** 1997 Jun;11(7):591–9

Shear stress inhibits apoptosis of human endothelial cells. Dimmeler S, et al. **FEBS Lett** 1996 Dec 9;399(1–2):71–4

Bcl–2 prevents nitric oxide–mediated apoptosis and poly(ADP–ribose) polymerase cleavage. Mělková Z, et al. **FEBS Lett** 1997 Feb 24;403(3):273–8

Apoptosis and the ovary: a fashionable trend or food for thought? [editorial] Tilly JL. **Fertil Steril** 1997 Feb; 67(2):226–8

Ex vivo induction of apoptosis in lymphocytes is mediated by oxidative stress: role for lymphocyte loss in HIV infection. Dobmeyer TS, et al. **Free Radic Biol Med** 1997; 22(5):775–85

Do reactive oxygen species underlie the mechanism of apoptosis in the tadpole tail? Hanada H, et al. **Free Radic Biol Med** 1997;23(2):294–301

Decreased production of reactive oxygen intermediates is an early event during in vitro apoptosis of rat thymocytes. Wang JF, et al. **Free Radic Biol Med** 1996;20(4):533–42

CD95 (APO–1/Fas)–mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis [see comments] Sträter J, et al. **Gastroenterology** 1997 Jul;113(1):160–7. Comment in: Gastroenterology 1997 Jul;113(1):345–8.

A single point mutation of hamster aminoacyl–tRNA synthetase causes apoptosis by deprivation of cognate amino acid residue. Fukushima K, et al. **Genes Cells** 1996 Dec;1(12):1087–99

Essential role of active nuclear transport in apoptosis. Yasuhara N, et al. **Genes Cells** 1997 Jan;2(1):55–64

p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Chen X, et al. **Genes Dev** 1996 Oct 1;10(19):2438–51

v–Myb of E26 leukemia virus up–regulates bcl–2 and suppresses apoptosis in myeloid cells. Frampton J, et al. **Genes Dev** 1996 Nov 1;10(21):2720–31

The PI 3–kinase/Akt signaling pathway delivers an anti–apoptotic signal. Kennedy SG, et al. **Genes Dev** 1997 Mar 15;11(6):701–13

Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP–2beta. Moser M, et al. **Genes Dev** 1997 Aug 1;11(15):1938–48

Wild–type p53 negatively regulates the expression of a microtubule–associated protein. Murphy M, et al. **Genes Dev** 1996 Dec 1;10(23):2971–80

Induction of DNA synthesis and apoptosis are separable functions of E2F–1. Phillips AC, et al. **Genes Dev** 1997 Jul 15;11(14):1853–63

BID: a novel BH3 domain–only death agonist. Wang K, et al. **Genes Dev** 1996 Nov 15;10(22):2859–69

Possible participation of Fas–mediated apoptosis in the mechanism of atherosclerosis. Fukuo K, et al. **Gerontology** 1997;43 Suppl 1:35–42

Cell death—where is thy sting? [comment] Lewin D, et al. **Gut** 1996 Dec;39(96):883–4. Comment on: Gut 1996 Dec;39(96):811–7.

Increased small intestinal apoptosis in coeliac disease [see comments] Moss SF, et al. **Gut** 1996 Dec;39(96):811–7. Comment in: Gut 1996 Dec;39(96):883–4.

Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia. Lacombe F, et al. **Hematol Cell Ther** 1996 Dec;38(6):495–504 (52 ref.)

Processing/activation of CPP32–like proteases is involved in transforming growth factor beta1–induced apoptosis in rat hepatocytes. Inayat–Hussain SH, et al. **Hepatology** 1997 Jun;25(6):1516–26

Oxidative stress–mediated apoptosis of hepatocytes exposed to acute ethanol intoxication. Kurose I, et al. **Hepatology** 1997 Feb;25(2):368–78

Hepatocyte apoptosis in hepatic iron overload diseases. Zhao M, et al. **Histol Histopathol** 1997 Apr;12(2):367–74

Apoptosis occurs independently of bcl–2 and p53 over–expression in non–small cell lung carcinoma. O'Neill AJ, et al. **Histopathology** 1996 Jul;29(1):45–50

Androgen spares androgen–insensitive motoneurons from apoptosis in the spinal nucleus of the bulbocavernosus in rats. Freeman LM, et al. **Horm Behav** 1996 Dec; 30(4):424–33

In–situ end labelling with bromodeoxyuridine—an advanced technique for the visualization of apoptotic cells in histological specimens. Aschoff A, et al. **Horm Metab Res** 1996 Jul;28(7):311–4

Apoptosis of human ovary and uterine endometrium during the menstrual cycle. Shikone T, et al. **Horm Res** 1997;48 Suppl 3:27–34

Analysis of relationship between programmed cell death and cell cycle in limb–bud. Toné S, et al. **Horm Res** 1997;48 Suppl 3:5–10

A brief overview of apoptosis. Hashimoto Y. **Hum Cell** 1996 Sep;9(3):194–6 (0 ref.)

Apoptosis in cancer. Kuchino Y, et al. **Hum Cell** 1996 Sep; 9(3):223–8 (25 ref.)

Apoptotic human SH–SY5Y neuroblastoma cells have regularly spaced single strand DNA breaks and increased DNA–dependent protein kinase activity. MacManus JP, et al. **Hum Cell** 1996 Sep;9(3):197–204

Neuronal apoptosis by glial NO: involvement of inhibition of glyceraldehyde–3–phosphate dehydrogenase. Nomura Y, et al. **Hum Cell** 1996 Sep;9(3):205–14

Regulation of neutrophil apoptosis—its biological significance in inflammation and the immune response. Sendo F, et al. **Hum Cell** 1996 Sep;9(3):215–22 (32 ref.)

Adenovirus–mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo–infected pancreatic islet allografts and isografts. Muruve DA, et al. **Hum Gene Ther** 1997 May 20;8(8):955–63

Extent of apoptosis in relation to p53 and bcl–2 expression in germ cell tumors. Soini Y, et al. **Hum Pathol** 1996 Nov; 27(11):1221–6

The immunolocalization of bcl–2 at the maternal–fetal interface in healthy and failing pregnancies. Lea RG, et al. **Hum Reprod** 1997 Jan;12(1):153–8

Protection of B lymphocyte hybridoma against starvation–induced apoptosis: survival–signal role of some amino acids. Franěk F, et al. **Immunol Lett** 1996 Sep; 52(2–3):139–44

Mitochondrial control of apoptosis. Kroemer G, et al. **Immunol Today** 1997 Jan;18(1):44–51 (71 ref.)

Eosinophilia: inhibition of apoptosis or differentiation? [letter; comment] Riehemann K, et al. **Immunol Today** 1996 Feb; 17(2):98–9. Comment on: Immunol Today 1995 Feb;16(2):53–5.

Fas–induced programmed cell death is mediated by a Ras–regulated O2– synthesis. Gulbins E, et al. **Immunology** 1996 Oct;89(2):205–12

Facilitation of apoptosis by autologous serum and related immunosuppression in the splenocyte culture. Kim HM, et al. **Immunopharmacology** 1996 Aug;34(1):39–50

Selective lysis of early embryonic cells by the alternative pathway of complement—a possible mechanism for programmed cell death in embryogenesis. Kircheis R, et al. **In Vivo** 1996 Jul–Aug;10(4):389–403

Development of a quantitative method for the study of apoptosis in peripheral blood. Tsangaris GT, et al. **In Vivo** 1996 Jul–Aug;10(4):435–43

Apoptosis. Ghosh K. **Indian J Med Sci** 1995 Jul;49(7):164–70 (8 ref.)

Apoptosis: insight into its role in inflammation. Winkler J, et al. **Inflamm Res** 1997 Jan;46(1):3

Programmed cell death of the prothoracic glands of Manduca sexta during pupal–adult metamorphosis. Dai JD, et al. **Insect Biochem Mol Biol** 1997 Jan;27(1):69–78

Characterization of the spontaneous apoptosis of rat thymocytes in vitro. Rinner I, et al. **Int Arch Allergy Immunol** 1996 Nov;111(3):230–7

Activation of signaling pathways and prevention of apoptosis by cytokines in eosinophils. Yousefi S, et al. **Int Arch Allergy Immunol** 1997 Jan;112(1):9–12 (29 ref.)

Induction of B cell apoptosis by co–cross–linking CD23 and sIg involves aberrant regulation of c–myc and is inhibited by bcl–2. Campbell KA, et al. **Int Immunol** 1997 Aug; 9(8):1131–40

Induction of apoptotic cell death in the seminiferous tubule of the adult rat testis: assessment of the germ cell types that exhibit the ability to enter apoptosis after hormone suppression by oestradiol treatment. Blanco–Rodríguez J, et al. **Int J Androl** 1996 Aug;19(4):237–47

Apoptosis is increased in a model of diabetes–impaired wound healing in genetically diabetic mice. Darby IA, et al. **Int J Biochem Cell Biol** 1997 Jan;29(1):191–200

Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. Desmoulière A, et al. **Int J Biochem Cell Biol** 1997 Jan;29(1):19–30 (78 ref.)

The apoptotic cysteine protease CPP32. Kumar S. **Int J Biochem Cell Biol** 1997 Mar;29(3):393–6 (18 ref.)

Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Bladou F, et al. **Int J Cancer** 1996 Sep 17;67(6):785–90

Low frequency of apoptosis in Epstein–Barr virus–associated gastric carcinoma with lymphoid stroma. Ohfuji S, et al. **Int J Cancer** 1996 Dec 11;68(6):710–5

Mouse molar morphogenesis revisited by three–dimensional reconstruction. II. Spatial distribution of mitoses and apoptosis in cap to bell staged first and second upper molar teeth. Lesot H, et al. **Int J Dev Biol** 1996 Oct;40(5):1017–31

Involvement of free radicals in signalling of low–potassium induced apoptosis in cultured cerebellar granule cells. Martin–Romero FJ, et al. **Int J Dev Biol** 1996;Suppl 1:197S–198S

Characterization of apoptosis in prostatic androgen–independent cell lines. Salido M, et al. **Int J Dev Biol** 1996;Suppl 1:191S–192S

Apoptosis is involved in the disappearance of the diastemal dental primordia in mouse embryo. Turečková J, et al. **Int J Dev Biol** 1996 Apr;40(2):483–9

Reversal of phenobarbital-induced hyperplasia and hypertrophy in the livers of lpr mice. Sarraf CE, et al. **Int J Exp Pathol** 1997 Feb;78(1):49–56

Regional differences in apoptosis in murine gliosarcoma (T9) induced by mild hyperthermia. Moroi J, et al. **Int J Hyperthermia** 1996 May–Jun;12(3):345–54

Selective depletion of cyclin-dependent kinases is associated with Fas-mediated apoptosis in human leukemia T-cell lines. Oguri-Hyakumachi N, et al. **Int J Immunopharmacol** 1995 Nov;17(11):913–21

Chemical-induced changes in intracellular redox state and in apoptosis. Jajte JM. **Int J Occup Med Environ Health** 1997;10(2):203–12 (44 ref.)

Elevated frequency of p53-independent apoptosis after irradiation increases levels of DNA breaks in ataxia telangiectasia lymphoblasts. Humar B, et al. **Int J Radiat Biol** 1997 Sep;72(3):257–69

Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Joon DL, et al. **Int J Radiat Oncol Biol Phys** 1997 Jul 15;38(5):1071–7

Apoptosis: its role in the progression of and chemotherapy for carcinoma. Meterissian SH. **J Am Coll Surg** 1997 Jun; 184(6):658–66 (87 ref.)

What does cell death have to do with aging? Warner HR, et al. **J Am Geriatr Soc** 1997 Sep;45(9):1140–6 (104 ref.)

Neutrophil superoxide release is required for spontaneous and FMLP-mediated but not for TNF alpha-mediated apoptosis. Kettritz R, et al. **J Am Soc Nephrol** 1997 Jul; 8(7):1091–100

Skeleton pattern and joint formation in chorioallantoic grafts lacking the anterior or posterior necrotic zones. Rizgeliene R. **J Anat** 1996 Dec;189 (Pt 3):601–8

Involution of the sheep mammary gland. Tatarczuch L, et al. **J Anat** 1997 Apr;190 (Pt 3):405–16

Modulation of endothelial cell apoptosis: mechanisms and pathophysiological roles. Karsan A, et al. **J Atheroscler Thromb** 1996;3(2):75–80 (54 ref.)

Induction of Bip mRNA upon programmed cell death of differentiated PC12 cells as well as rat sympathetic neurons. Aoki T, et al. **J Biochem (Tokyo)** 1997 Jan;121(1):122–7

Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. Matsuda R, et al. **J Biochem (Tokyo)** 1995 Nov;118(5):959–64

Free radical-independent protection by nerve growth factor and Bcl-2 of PC12 cells from hydrogen peroxide-triggered apoptosis. Satoh T, et al. **J Biochem (Tokyo)** 1996 Sep; 120(3):540–6

Functional activation of Nedd2/ICH-1 (caspase-2) is an early process in apoptosis. Harvey NL, et al. **J Biol Chem** 1997 May 16;272(20):13134–9

Nitric oxide inhibits Fas-induced apoptosis. Mannick JB, et al. **J Biol Chem** 1997 Sep 26;272(39):24125–8

Early growth response-1-dependent apoptosis is mediated by p53. Nair P, et al. **J Biol Chem** 1997 Aug 8; 272(32):20131–8

Distinctive functions of Syk and Lyn in mediating osmotic stress- and ultraviolet C irradiation-induced apoptosis in chicken B cells. Qin S, et al. **J Biol Chem** 1997 Jul 18; 272(29):17994–9

Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. Rajah R, et al. **J Biol Chem** 1997 May 2;272(18):12181–8

Specific activation of retinoic acid receptors (RARs) and retinoid X receptors reveals a unique role for RARgamma in induction of differentiation and apoptosis of S91 melanoma cells. Spanjaard RA, et al. **J Biol Chem** 1997 Jul 25;272(30):18990–9

Modulation of cell death in yeast by the Bcl-2 family of proteins. Tao W, et al. **J Biol Chem** 1997 Jun 13; 272(24):15547–52

A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. Thornberry NA, et al. **J Biol Chem** 1997 Jul 18; 272(29):17907–11

Apoptosis induced by gliotoxin is preceded by phosphorylation of histone H3 and enhanced sensitivity of chromatin to nuclease digestion. Waring P, et al. **J Biol Chem** 1997 Jul 18;272(29):17929–36

Distinct roles for MAX protein isoforms in proliferation and apoptosis. Zhang H, et al. **J Biol Chem** 1997 Jul 11; 272(28):17416–24

Retinoblastoma protein-dependent growth signal conflict and caspase activity are required for protein kinase C-signaled apoptosis of prostate epithelial cells. Zhao X, et al. **J Biol Chem** 1997 Sep 5;272(36):22751–7

New aspects of endochondral ossification in the chick: chondrocyte apoptosis, bone formation by former chondrocytes, and acid phosphatase activity in the endochondral bone matrix. Roach HI. **J Bone Miner Res** 1997 May;12(5):795–805

Mammalian cell death proteases: a family of highly conserved aspartate specific cysteine proteases. Alnemri ES. **J Cell Biochem** 1997 Jan;64(1):33–42 (45 ref.)

Characterization of mice deficient in interleukin-1 beta converting enzyme. Li P, et al. **J Cell Biochem** 1997 Jan; 64(1):27–32

The interleukin-1 beta converting enzyme family of cysteine proteases. Miller DK, et al. **J Cell Biochem** 1997 Jan; 64(1):2–10 (2 ref.)

Macromolecular substrates for the ICE-like proteases during apoptosis. Rosen A, et al. **J Cell Biochem** 1997 Jan; 64(1):50–4 (24 ref.)

Role of apoptosis in the regulation of virus-induced T cell responses, immune suppression, and memory. Welsh RM, et al. **J Cell Biochem** 1995 Oct;59(2):135–42

Proteases in Fas-mediated apoptosis. Zhivotovsky B, et al. **J Cell Biochem** 1997 Jan;64(1):43–9 (54 ref.)

Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. Caulín C, et al. **J Cell Biol** 1997 Sep 22;138(6):1379–94

Temporal phases in apoptosis defined by the actions of Src homology 2 domains, ceramide, Bcl-2, interleukin-1beta converting enzyme family proteases, and a dense membrane fraction. Farschon DM, et al. **J Cell Biol** 1997 Jun 2; 137(5):1117–25

Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak. McCarthy NJ, et al. **J Cell Biol** 1997 Jan 13;136(1):215–27

Processing/activation of at least four interleukin-1beta converting enzyme-like proteases occurs during the execution phase of apoptosis in human monocytic tumor cells. MacFarlane M, et al. **J Cell Biol** 1997 Apr 21; 137(2):469–79

Loss of matrix adhesion triggers rapid transformation-selective apoptosis in fibroblasts. McGill G, et al. **J Cell Biol** 1997 Aug 25;138(4):901–11

Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. Mancini M, et al. **J Cell Biol** 1997 Jul 28;138(2):449–69

Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. Mariani SM, et al. **J Cell Biol** 1997 Apr 7;137(1):221–9

Lamin proteolysis facilitates nuclear events during apoptosis. Rao L, et al. **J Cell Biol** 1996 Dec;135(6 Pt 1):1441–55

Adenovirus-mediated gene transfer of the tumor suppressor, p53, induces apoptosis in postmitotic neurons. Slack RS, et al. **J Cell Biol** 1996 Nov;135(4):1085–96

Cell susceptibility to apoptosis by glutamine deprivation and rescue: survival and apoptotic death in cultured lymphoma-leukemia cell lines. Petronini PG, et al. **J Cell Physiol** 1996 Oct;169(1):175–85

An apoptotic endonuclease activated either by decreasing pH or by increasing calcium. Collins MK, et al. **J Cell Sci** 1996 Sep;109 (Pt 9):2393–9

Endo-exonuclease of human leukaemic cells: evidence for a role in apoptosis. Fraser MJ, et al. **J Cell Sci** 1996 Sep; 109 (Pt 9):2343–60

Dynamic changes of NuMA during the cell cycle and possible appearance of a truncated form of NuMA during apoptosis. Hsu HL, et al. **J Cell Sci** 1996 Feb;109 (Pt 2):277–88

Cleavage and inactivation of DNA-dependent protein kinase catalytic subunit during apoptosis in Xenopus egg extracts. Le Romancer M, et al. **J Cell Sci** 1996 Dec;109 (Pt 13):3121–7

Clusterin/ApoJ expression is associated with neuronal apoptosis in the olfactory mucosa of the adult mouse. Michel D, et al. **J Cell Sci** 1997 Jul;110 (Pt 14):1635–45

Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. Pullan S, et al. **J Cell Sci** 1996 Mar;109 (Pt 3):631–42

Cell death of AKR-2B fibroblasts after serum removal: a process between apoptosis and necrosis. Simm A, et al. **J Cell Sci** 1997 Apr;110 (Pt 7):819–28

Degradation of nuclear matrix and DNA cleavage in apoptotic thymocytes. Weaver VM, et al. **J Cell Sci** 1996 Jan;109 (Pt 1):45–56

Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. Zoellner H, et al. **J Cell Sci** 1996 Oct; 109 (Pt 10):2571–80

Detection of higher-order 50- and 10-kbp DNA fragments before apoptotic internucleosomal cleavage after transient cerebral ischemia. MacManus JP, et al. **J Cereb Blood Flow Metab** 1997 Apr;17(4):376–87

Expression of the apoptosis-suppressing gene BCL-2 in pheochromocytoma is associated with the expression of C-MYC. Wang DG, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1949–52

Differential regulation of apoptosis in the normal human adrenal gland. Wolkersdörfer GW, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4129–36

Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome. Pitrak DL, et al. **J Clin Invest** 1996 Dec 15;98(12):2714–9

Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. Tachibana I, et al. **J Clin Invest** 1997 May 15;99(10):2365–74

Apoptosis in human hepatocellular carcinoma and in liver cell dysplasia is correlated with p53 protein immunoreactivity. Zhao M, et al. **J Clin Pathol** 1997 May; 50(5):394–400

Apoptosis: neuronal death by design. Stahl SM. **J Clin Psychiatry** 1997 May;58(5):183–4

Distinct populations of cells in the adult dentate gyrus undergo mitosis or apoptosis in response to adrenalectomy. Cameron HA, et al. **J Comp Neurol** 1996 May 20; 369(1):56–63

Detection of jun but not fos protein during developmental cell death in sympathetic neurons. Messina A, et al. **J Comp Neurol** 1996 Sep 2;372(4):544–50

Apoptotic cell death in formation of vesicular skin lesions in patients with acquired zinc deficiency. Mori H, et al. **J Cutan Pathol** 1996 Aug;23(4):359–63

Regulation of a physiological apoptosis: mouse mammary involution. Jaggi R, et al. **J Dairy Sci** 1996 Jun; 79(6):1074–84

A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. Castelli JC, et al. **J Exp Med** 1997 Sep 15;186(6):967–72

Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. Dimmeler S, et al. **J Exp Med** 1997 Feb 17;185(4):601–7

Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. Friedlander RM, et al. **J Exp Med** 1997 Mar 3;185(5):933–40

T cell apoptosis in human immunodeficiency virus type 2- and simian immunodeficiency virus-infected macaques. Dittmer U, et al. **J Gen Virol** 1996 Oct;77 (Pt 10):2433–6

Myocardial apoptosis in a heterotopic murine heart transplantation model of chronic rejection and graft vasculopathy. White WL, et al. **J Heart Lung Transplant** 1997 Feb;16(2):250–5

TGF-beta-mediated hepatocellular apoptosis by rat and human hepatoma cells and primary rat hepatocytes. Gressner AM, et al. **J Hepatol** 1997 May;26(5):1079–92

Reducing environment protects sinusoidal lymphocytes isolated from normal human liver from apoptosis. Kinoshita K, et al. **J Hepatol** 1997 Jan;26(1):103–10

Fas ligand expression is restricted to nonlymphoid thymic components in situ. French LE, et al. **J Immunol** 1997 Sep 1;159(5):2196–202

Overexpression of the heat shock protein 70 enhances the TCR/CD3- and Fas/Apo-1/CD95-mediated apoptotic cell death in Jurkat T cells. Liossis SN, et al. **J Immunol** 1997 Jun 15;158(12):5668–75

Mitochondrial permeability transition triggers lymphocyte apoptosis. Marchetti P, et al. **J Immunol** 1996 Dec 1; 157(11):4830–6

Apoptosis signaling pathways in normal T cells: differential activity of Bcl-2 and IL-1beta-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity. Moreno MB, et al. **J Immunol** 1996 Nov 1; 157(9):3845–9

Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. Oshimi Y, et al. **J Immunol** 1996 Oct 1;157(7):2909–15

Role of alpha 5 beta 1 integrin in TGF-beta 1-costimulated CD8+ T cell growth and apoptosis. Rich S, et al. **J Immunol** 1996 Oct 1;157(7):2916–23

Bcl-2 prevents apoptosis induced by perforin and granzyme B, but not that mediated by whole cytotoxic lymphocytes. Sutton VR, et al. **J Immunol** 1997 Jun 15;158(12):5783–90

Intracellular IL-1beta is an inhibitor of Fas-mediated apoptosis. Tatsuta T, et al. **J Immunol** 1996 Nov 1; 157(9):3949–57

IL-6 rescues resting mouse T cells from apoptosis. Teague TK, et al. **J Immunol** 1997 Jun 15;158(12):5791–6

Critical role of Lyn kinase in inhibition of neutrophil apoptosis by granulocyte-macrophage colony-stimulating factor. Wei S, et al. **J Immunol** 1996 Dec 1;157(11):5155–62

Induction of cell death by myristylated death domain of p55 TNF receptor is not abolished by Iprcg-like point mutation in death domain. Kim CH, et al. **J Inflamm** 1995; 45(4):312–22

Induction of apoptotic nuclei by interferon-gamma and by predesquamin in cultured keratinocytes. Brysk MM, et al. **J Interferon Cytokine Res** 1995 Dec;15(12):1029–35

Defects in intracellular oxidative metabolism of neutrophils undergoing apoptosis. Narayanan PK, et al. **J Leukoc Biol** 1997 Apr;61(4):481–8

Apoptosis in resolution of inflammation. Savill J. **J Leukoc Biol** 1997 Apr;61(4):375–80 (58 ref.)

T cell rescue of monocytes from apoptosis: role of the CD40–CD40L interaction and requirement for CD40-mediated induction of protein tyrosine kinase activity. Suttles J, et al. **J Leukoc Biol** 1996 Nov; 60(5):651–7

Developmental and genetic regulation of programmed neuronal death. Weller M, et al. **J Neural Transm Suppl** 1997;50:115–23 (29 ref.)

Growth, proliferation, and cell death in the ontogeny of transient DRG (Froriep's ganglia) of chick embryos. Rosen O, et al. **J Neurobiol** 1996 Jun;30(2):219–30

Cytoskeletal breakdown and apoptosis elicited by NO donors in cerebellar granule cells require NMDA receptor activation. Bonfoco E, et al. **J Neurochem** 1996 Dec; 67(6):2484–93

Early detection of DNA strand breaks in the brain after transient focal ischemia: implications for the role of DNA damage in apoptosis and neuronal cell death. Chen J, et al. **J Neurochem** 1997 Jul;69(1):232–45

Select alterations in protein kinases and phosphatases during

apoptosis of differentiated PC12 cells. Davis PK, et al. **J Neurochem** 1997 Jun;68(6):2338–47

ICE/CED–3 family executes oligodendrocyte apoptosis by tumor necrosis factor. Hisahara S, et al. **J Neurochem** 1997 Jul;69(1):10–20

Apoptosis regulates the number of Schwann cells at the premyelinating stage. Nakao J, et al. **J Neurochem** 1997 May;68(5):1853–62

Characterization of CPP32–like protease activity following apoptotic challenge in SH–SY5Y neuroblastoma cells. Posmantur R, et al. **J Neurochem** 1997 Jun;68(6):2328–37

Apoptosis in cerebellar granule neurones: involvement of interleukin–1 beta converting enzyme–like proteases. Taylor J, et al. **J Neurochem** 1997 Apr;68(4):1598–605

Increased apoptotic response to 2–deoxy–D–ribose in ataxia–telangiectasia. Battisti C, et al. **J Neurol Sci** 1996 Dec;144(1–2):128–34

Oxidative stress and apoptosis in neurodegeneration. Gorman AM, et al. **J Neurol Sci** 1996 Aug;139 Suppl:45–52 (75 ref.)

Histochemical detection of apoptosis in Parkinson's disease. Mochizuki H, et al. **J Neurol Sci** 1996 May;137(2):120–3

Apoptosis–related proteins in skeletal muscle fibers of spinal muscular atrophy. Tews DS, et al. **J Neuropathol Exp Neurol** 1997 Feb;56(2):150–6

Deafferentation causes apoptosis in cortical sensory neurons in the adult rat. Capurso SA, et al. **J Neurosci** 1997 Oct 1;17(19):7372–84

The role of CED–3–related cysteine proteases in apoptosis of cerebellar granule cells. Eldadah BA, et al. **J Neurosci** 1997 Aug 15;17(16):6105–13

Establishment of a cell–free system of neuronal apoptosis: comparison of premitochondrial, mitochondrial, and postmitochondrial phases. Ellerby HM, et al. **J Neurosci** 1997 Aug 15;17(16):6165–78

Aggregated amyloid–beta protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction. Estus S, et al. **J Neurosci** 1997 Oct 15; 17(20):7736–45

The in vivo time course for elimination of adrenalectomy–induced apoptotic profiles from the granule cell layer of the rat hippocampus. Hu Z, et al. **J Neurosci** 1997 Jun 1;17(11):3981–9

p53 expression induces apoptosis in hippocampal pyramidal neuron cultures. Jordán J, et al. **J Neurosci** 1997 Feb 15; 17(4):1397–405

Evidence that 4–hydroxynonenal mediates oxidative stress–induced neuronal apoptosis. Kruman I, et al. **J Neurosci** 1997 Jul 1;17(13):5089–100

Neuronal and glial apoptosis after traumatic spinal cord injury. Liu XZ, et al. **J Neurosci** 1997 Jul 15; 17(14):5395–406

Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra. Marti MJ, et al. **J Neurosci** 1997 Mar 15; 17(6):2030–9

Metabolic and genetic analyses of apoptosis in potassium/serum–deprived rat cerebellar granule cells. Miller TM, et al. **J Neurosci** 1996 Dec 1;16(23):7487–95

Cloning and expression of a rat brain interleukin–1beta–converting enzyme (ICE)–related protease (IRP) and its possible role in apoptosis of cultured cerebellar granule neurons. Ni B, et al. **J Neurosci** 1997 Mar 1;17(5):1561–9

Nedd2 is required for apoptosis after trophic factor withdrawal, but not superoxide dismutase (SOD1) downregulation, in sympathetic neurons and PC12 cells. Troy CM, et al. **J Neurosci** 1997 Mar 15;17(6):1911–8

Activation of CPP32–like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. Yakovlev AG, et al. **J Neurosci** 1997 Oct 1;17(19):7415–24

Different pathways of apoptosis revealed by 2–chloro–adenosine and deoxy–D–ribose in mammalian astroglial cells. Ceruti S, et al. **J Neurosci Res** 1997 Feb 15;47(4):372–83

Activation of CPP32 during apoptosis of neurons and astrocytes. Keane RW, et al. **J Neurosci Res** 1997 Apr 15; 48(2):168–80

p53 protein in sympathetic neurons: cytoplasmic localization and no apparent function in apoptosis. Sadoul R, et al. **J Neurosci Res** 1996 Mar 1;43(5):594–601

Effect of nerve growth factor on AP–1, NF–kappa B, and Oct DNA binding activity in apoptotic PC12 cells: extrinsic and intrinsic elements. Tong L, et al. **J Neurosci Res** 1996 Jul 1;45(1):1–12

Expression of mutant amyloid precursor proteins induces apoptosis in PC12 cells. Zhao B, et al. **J Neurosci Res** 1997 Feb 1;47(3):253–63

Foam cell apoptosis and the development of the lipid core of human atherosclerosis. Hegyi L, et al. **J Pathol** 1996 Dec;180(4):423–9

Apoptosis induced by gamma–irradiation, but not CD4 ligation, of peripheral T lymphocytes in vivo is p53–dependent. Malcomson RD, et al. **J Pathol** 1997 Feb; 181(2):166–71

Differential growth of N– and S–type human neuroblastoma cells xenografted into scid mice. correlation with apoptosis. Piacentini M, et al. **J Pathol** 1996 Dec;180(4):415–22

Bcl–2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. Saegusa M, et al. **J Pathol** 1996 Nov;180(3):275–82

Morphological and biochemical evidence for apoptosis in the terminal hypertrophic chondrocytes of the growth plate. Zenmyo M, et al. **J Pathol** 1996 Dec;180(4):430–3

In situ detection of DNA fragmentation and expression of bcl–2 in human neuroblastoma: relation to apoptosis and spontaneous regression. Oue T, et al. **J Pediatr Surg** 1996 Feb;31(2):251–7

Necrosis and apoptosis associated with distinct Ca2+ response patterns in target cells attacked by human natural killer cells. Oshimi Y, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):319–29

Molecular cell biology for the refractive corneal surgeon: programmed cell death and wound healing. Wilson SE. **J Refract Surg** 1997 Mar–Apr;13(2):171–5

Association of expression of mRNA encoding the PGF2 alpha receptor with luteal cell apoptosis in ovaries of pseudopregnant mice. Hasumoto K, et al. **J Reprod Fertil** 1997 Jan;109(1):45–51

Apoptosis in human ejaculated sperm cells (notulae seminologicae 9). Baccetti B, et al. **J Submicrosc Cytol Pathol** 1996 Oct;28(4):587–96

Renal apoptosis and clusterin following ureteral obstruction: the role of maturation [see comments] Chevalier RL, et al. **J Urol** 1996 Oct;156(4):1474–9. Comment in: J Urol 1996 Oct;156(4):1244.

The ability of BHRF1 to inhibit apoptosis is dependent on stimulus and cell type. Foghsgaard L, et al. **J Virol** 1997 Oct;71(10):7509–17

Epstein–Barr virus latent membrane protein 1 blocks p53–mediated apoptosis through the induction of the A20 gene. Fries KL, et al. **J Virol** 1996 Dec;70(12):8653–9

Apoptosis and T–cell depletion during feline infectious peritonitis. Haagmans BL, et al. **J Virol** 1996 Dec; 70(12):8977–83

Dominant inhibitory Ras delays Sindbis virus–induced apoptosis in neuronal cells. Joe AK, et al. **J Virol** 1996 Nov;70(11):7744–51

Double–stranded RNA is a trigger for apoptosis in vaccinia virus–infected cells. Kibler KV, et al. **J Virol** 1997 Mar; 71(3):1992–2003

Suppression of apoptotic DNA fragmentation in herpes simplex virus type 1–infected cells. Koyama AH, et al. **J Virol** 1997 Mar;71(3):2567–71

Reovirus infection and tissue injury in the mouse central nervous system are associated with apoptosis. Oberhaus SM, et al. **J Virol** 1997 Mar;71(3):2100–6

Reovirus–induced apoptosis of MDCK cells is not linked to viral yield and is blocked by Bcl–2. Rodgers SE, et al. **J Virol** 1997 Mar;71(3):2540–6

Distinct domains of M–T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. Schreiber M, et al. **J Virol** 1997 Mar;71(3):2171–81

Possible involvement of double–stranded RNA–activated protein kinase in cell death by influenza virus infection. Takizawa T, et al. **J Virol** 1996 Nov;70(11):8128–32

Regulation of apoptosis by viral gene products. Teodoro JG, et al. **J Virol** 1997 Mar;71(3):1739–46 (103 ref.)

The activity of cytosolic phospholipase A2 is required for the lysis of adenovirus–infected cells by tumor necrosis factor. Thorne TE, et al. **J Virol** 1996 Dec;70(12):8502–7

Linkage between reovirus–induced apoptosis and inhibition of cellular DNA synthesis: role of the S1 and M2 genes. Tyler KL, et al. **J Virol** 1996 Nov;70(11):7984–91

Apoptosis by CD95 (Fas)–dependent and –independent mechanisms in Peyer's patch lymphocytes in murine retrovirus–induced immunodeficiency syndrome. Usami J, et al. **J Virol** 1996 Dec;70(12):8917–25

Apoptosis regulated by growth factors in multicellular spheroids of trabecular cells. Matsuo T, et al. **Jpn J Ophthalmol** 1996;40(3):356–66

Agonistic anti–Fas antibodies induce glomerular cell apoptosis in mice in vivo. González–Cuadrado S, et al. **Kidney Int** 1997 Jun;51(6):1739–46

Thiazide treatment of rats provokes apoptosis in distal tubule cells. Loffing J, et al. **Kidney Int** 1996 Oct;50(4):1180–90

Apoptosis of cultured rat glomerular mesangial cells induced by IgG2a monoclonal anti–Thy–1 antibodies. Sato T, et al. **Kidney Int** 1996 Feb;49(2):403–12

Apoptosis in glomerular sclerosis. Sugiyama H, et al. **Kidney Int** 1996 Jan;49(1):103–11

Deregulation of cell survival in cystic and dysplastic renal development. Winyard PJ, et al. **Kidney Int** 1996 Jan; 49(1):135–46

Apoptosis and renal scarring. Savill J, et al. **Kidney Int Suppl** 1996 May;54:S14–7 (57 ref.)

Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin–1–converting enzyme–like protease–dependent and –independent pathways. Slowik MR, et al. **Lab Invest** 1997 Sep; 77(3):257–67

Neocytolysis: physiological down–regulator of red–cell mass. Alfrey CP, et al. **Lancet** 1997 May 10;349(9062):1389–90 (18 ref.)

What does apoptosis mean in CLL? Binet JL, et al. **Leuk Lymphoma** 1996 Oct;22 Suppl 2:47–52 (20 ref.)

Role of interleukin–1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death. Estrov Z, et al. **Leuk Lymphoma** 1997 Feb; 24(5–6):379–91 (113 ref.)

Nasal T/NK cell lymphoma: a clinico pathologic study of 30 west Chinese patients with special reference to proliferation and apoptosis. Lorenzen J, et al. **Leuk Lymphoma** 1996 Nov;23(5–6):593–602

Mechanisms of apoptotic cell death. Rowan S, et al. **Leukemia** 1997 Apr;11(4):457–65 (151 ref.)

DNA damage–induced apoptosis and Ice gene induction in mitogenically activated T lymphocytes require IRF–1. Tamura T, et al. **Leukemia** 1997 Apr;11 Suppl 3:439–40

Apoptosis: mechanisms and relation to AIDS. Famularo G, et al. **Med Hypotheses** 1997 May;48(5):423–9 (73 ref.)

The role of apoptosis in the inhibition of a secondary tumor by concomitant resistance in a mouse model of metastases. Franco M, et al. **Medicina (B Aires)** 1996;56(4):393–6

Apoptosis—molecular mechanisms and biomedical implications. McConkey DJ, et al. **Mol Aspects Med** 1996 Feb;17(1):1–110 (450 ref.)

Increased apoptosis during papilloma development in mice susceptible to tumor progression. Stern MC, et al. **Mol Carcinog** 1997 Sep;20(1):137–42

Involvement of activator protein–1 (AP–1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. Zhao B, et al. **Mol Carcinog** 1997 Jul;19(3):180–90

Positioning atypical protein kinase C isoforms in the UV–induced apoptotic signaling cascade. Berra E, et al. **Mol Cell Biol** 1997 Aug;17(8):4346–54

Antiapoptotic signalling by the insulin–like growth factor I receptor, phosphatidylinositol 3–kinase, and Akt. Kulik G, et al. **Mol Cell Biol** 1997 Mar;17(3):1595–606

Lack of a role for Jun kinase and AP–1 in Fas–induced apoptosis. Lenczowski JM, et al. **Mol Cell Biol** 1997 Jan; 17(1):170–81

DAP–5, a novel homolog of eukaryotic translation initiation factor 4G isolated as a putative modulator of gamma interferon–induced programmed cell death. Levy–Strumpf N, et al. **Mol Cell Biol** 1997 Mar;17(3):1615–25

E2F–1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53–independent apoptosis. Nip J, et al. **Mol Cell Biol** 1997 Mar;17(3):1049–56

Identification of domains of the insulin–like growth factor I receptor that are required for protection from apoptosis. O'Connor R, et al. **Mol Cell Biol** 1997 Jan;17(1):427–35

Tissue transglutaminase–dependent posttranslational modification of the retinoblastoma gene product in promonocytic cells undergoing apoptosis. Oliverio S, et al. **Mol Cell Biol** 1997 Oct;17(10):6040–8

The insulin–like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin–3 withdrawal. Prisco M, et al. **Mol Cell Biol** 1997 Mar; 17(3):1084–92

Characterization of reaper– and FADD–induced apoptosis in a lepidopteran cell line. Vucic D, et al. **Mol Cell Biol** 1997 Feb;17(2):667–76

Subtype–selective induction of wild–type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Sharma K, et al. **Mol Endocrinol** 1996 Dec; 10(12):1688–96

Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Deacon EM, et al. **Mol Pathol** 1997 Jun;50(3):124–31 (140 ref.)

Apoptosis in bone physiology and disease. Hughes DE, et al. **Mol Pathol** 1997 Jun;50(3):132–7 (53 ref.)

Programmed cell death in neurons: focus on the pathway of nerve growth factor deprivation–induced death of sympathetic neurons. Deshmukh M, et al. **Mol Pharmacol** 1997 Jun;51(6):897–906 (126 ref.)

Overexpression of glyceraldehyde–3–phosphate dehydrogenase is involved in low K+–induced apoptosis but not necrosis of cultured cerebellar granule cells. Ishitani R, et al. **Mol Pharmacol** 1997 Apr;51(4):542–50

DNA–damaging agents induce both p53–dependent and p53–independent apoptosis in immature thymocytes. MacFarlane M, et al. **Mol Pharmacol** 1996 Oct;50(4):900–11

Induction of apoptosis by retinoids and retinoic acid receptor gamma–selective compounds in mouse thymocytes through a novel apoptosis pathway. Szondy Z, et al. **Mol Pharmacol** 1997 Jun;51(6):972–82

ICE and apoptosis [news] Wolozin B. **Mol Psychiatry** 1997 May;2(3):184–7

Overexpression of c–myc induces apoptosis at the prophase of meiosis of rat primary spermatocytes. Kodaira K, et al. **Mol Reprod Dev** 1996 Dec;45(4):403–10

Involvement of Fas antigen in ovarian follicular atresia and luteolysis. Sakamaki K, et al. **Mol Reprod Dev** 1997 May; 47(1):11–8

Expression of Fas antigen is not associated with apoptosis in human myopathies. Inukai A, et al. **Muscle Nerve** 1997 Jun;20(6):702–9

Apoptosis is not the mechanism of cell death of muscle fibers in human muscular dystrophies and inflammatory myopathies. Olivé M, et al. **Muscle Nerve** 1997 Oct; 20(10):1328–30

Analysis of apoptosis in culture models and intact tissues. Horton WE Jr, et al. **Muscle Nerve Suppl** 1997;5:S79–82

Bcl–2 and Bax function independently to regulate cell death. Knudson CM, et al. **Nat Genet** 1997 Aug;16(4):358–63

Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys [published erratum appears in Nat Med 1997 Feb;3(2):240] Crowe MJ, et al. **Nat Med** 1997 Jan; 3(1):73–6

X–linked IAP is a direct inhibitor of cell–death proteases. Devereaux QL, et al. **Nature** 1997 Jul 17;388(6639):300–4

Stress–signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3. Nishina H, et al.

Nature 1997 Jan 23;385(6614):350–3
A model for p53–induced apoptosis [see comments] Polyak K, et al. **Nature** 1997 Sep 18;389(6648):300–5. Comment in: Nature 1997 Sep 18;389(6648):237–8.
Interaction between the C. elegans cell–death regulators CED–9 and CED–4. Spector MS, et al. **Nature** 1997 Feb 13;385(6617):653–6
Apoptosis. Placing death under control [news; comment] Wallach D. **Nature** 1997 Jul 10;388(6638):123, 125–6. Comment on: Nature 1997 Jul 10;388(6638):190–5.
Apoptosis. Clues in the p53 murder mystery [news; comment] Wyllie A. **Nature** 1997 Sep 18;389(6648):237–8. Comment on: Nature 1997 Sep 18;389(6648):300–5.
In U–937 promonocytes, misteltoe lectin I increases basal [Ca2+]i, enhances histamine H1– and complement C5a–receptor–mediated rises in [Ca2+]i, and induces cell death. Wenzel–Seifert K, et al.
Naunyn Schmiedebergs Arch Pharmacol 1997 Feb; 355(2):190–7
Thy–1 antigen mediates apoptosis of rat glomerular cells in vitro and in vivo. Morita H, et al. **Nephron** 1996;73(2):293–8
Role of oxidative stress in the manganese and 1–methyl–4–(2'–ethylphenyl)–1,2,3,6–tetrahydropyridine–induced apoptosis in PC12 cells. Desole MS, et al.
Neurochem Int 1997 Aug;31(2):169–76
Cellular and molecular correlates of glutamate–evoked neuronal programmed cell death in the in vitro cultures of rat hippocampal dentate gyrus. Figiel I, et al.
Neurochem Int 1997 Aug;31(2):229–40
GABA and NMDA in the prevention of apoptotic–like cell death in vitro. Ikonomovic S, et al. **Neurochem Int** 1997 Aug;31(2):283–90
Autocrine regulation of apoptosis and bcl–2 expression by nerve growth factor in early differentiating cerebellar granule neurons involves low affinity neurotrophin receptor. Muller Y, et al. **Neurochem Int** 1997 Aug; 31(2):177–91
Protein kinases selectively modulate apoptosis in the developing retina in vitro. Varella MH, et al.
Neurochem Int 1997 Aug;31(2):217–27
Morphological and biochemical changes during programmed cell death of rat cerebellar granule cells. Chang JY, et al. **Neurochem Res** 1997 Jan;22(1):43–8
Apoptosis in perinatal hypoxic–ischaemic cerebral damage. Edwards AD, et al. **Neuropathol Appl Neurobiol** 1996 Dec; 22(6):494–8 (33 ref.)
DNA–fragmentation and expression of apoptosis–related proteins in experimentally denervated and reinnervated rat facial muscle. Tews DS, et al.
Neuropathol Appl Neurobiol 1997 Apr;23(2):141–9
Apoptosis and necrosis in the newborn piglet brain following transient cerebral hypoxia–ischaemia. Yue X, et al.
Neuropathol Appl Neurobiol 1997 Feb;23(1):16–25
Lamin and beta–tubulin fragmentation precede chromatin degradation in glutamate–induced neuronal apoptosis. Ankarcrona M, et al. **Neuroreport** 1996 Nov 4; 7(15–17):2659–64
BCL–2 delay apoptosis and PARP cleavage induced by NO donors in GT1–7 cells. Bonfoco E, et al. **Neuroreport** 1996 Dec 20;8(1):273–6
Apoptosis occurs independently of the release of interleukin–1 beta in the anterior pituitary of end–lactating rats. Chauvet N, et al. **Neuroreport** 1996 Nov 4; 7(15–17):2593–6
NT–4/5 protects against adrenalectomy–induced apoptosis of rat hippocampal granule cells. Qiao X, et al.
Neuroreport 1996 Jan 31;7(2):682–6
p53–deficient mice are protected against adrenalectomy–induced apoptosis. Sakhi S, et al.
Neuroreport 1996 Dec 20;8(1):233–5
Apoptosis and c–Jun in the thalamus of the rat following cortical infarction. Soriano MA, et al. **Neuroreport** 1996 Jan 31;7(2):425–8
Concomitant induction of apoptosis and necrosis in cerebellar granule cells following serum and potassium withdrawal. Villalba M, et al. **Neuroreport** 1997 Mar 3;8(4):981–5
Induction and its spread of apoptosis in rat spinal cord after mechanical trauma. Katoh K, et al. **Neurosci Lett** 1996 Sep 20;216(1):9–12
NMDA induces apoptosis and necrosis in neuronal cultures. Increased APP immunoreactivity is linked to apoptotic cells. Lesort M, et al. **Neurosci Lett** 1997 Jan 17; 221(2–3):213–6
Apoptosis induced in the spinal cord and dorsal root ganglion by infection of herpes simplex virus type 2 in the mouse. Ozaki N, et al. **Neurosci Lett** 1997 Jun 6;228(2):99–102
Ultrastructural morphological changes are not characteristic of apoptotic cell death following focal cerebral ischaemia in the rat. van Lookeren Campagne M, et al.
Neurosci Lett 1996 Aug 2;213(2):111–4
Strong c–Jun/AP–1 immunoreactivity is restricted to apoptotic cells following intracerebral ibotenic acid injection in developing rats. Ferrer I, et al.
Neurosci Res 1997 May;28(1):21–31
Soluble macrophage factors trigger apoptosis in cultured hippocampal neurons. Flavin MP, et al. **Neuroscience** 1997 Sep;80(2):437–48
Apoptosis mediates cell death following traumatic injury in rat hippocampal neurons. Shah PT, et al. **Neuroscience** 1997 Aug;79(4):999–1004
In situ detection of apoptotic nuclei in the substantia nigra compacta of 1–methyl–4–phenyl–1,2,3,6–tetrahydropyridine–treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Tatton NA, et al.
Neuroscience 1997 Apr;77(4):1037–48
Hypoxia–mediated selection of cells with diminished apoptotic potential to solid tumours [letter] Van Meir E. **Neurosurgery** 1996 Oct;39(4):878–9
An ELISA for detection of apoptosis. Salgame P, et al.
Nucleic Acids Res 1997 Feb 1;25(3):680–1
Influence of Bcl–2 overexpression on the ceramide pathway in daunorubicin–induced apoptosis of leukemic cells. Allouche M, et al. **Oncogene** 1997 Apr 17;14(15):1837–45
CD95 (APO–1/Fas) induces activation of SAP kinases downstream of ICE–like proteases. Cahill MA, et al.
Oncogene 1996 Nov 21;13(10):2087–96
Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding. Chen WD, et al. **Oncogene** 1997 Mar 13; 14(10):1243–8
Suppression of apoptosis by Bcl–2 or Bcl–xL promotes susceptibility to mutagenesis. Cherbonnel–Lasserre C, et al. **Oncogene** 1996 Oct 3;13(7):1489–97
The BCR–ABL tyrosine kinase inhibits apoptosis by activating a Ras–dependent signaling pathway. Cortez D, et al. **Oncogene** 1996 Dec 19;13(12):2589–94
Intercellular induction of apoptosis in transformed cells does not depend on p53. Hipp ML, et al. **Oncogene** 1997 Aug 14;15(7):791–7
A variant form of ETS1 induces apoptosis in human colon cancer cells. Huang CC, et al. **Oncogene** 1997 Aug 14; 15(7):851–6
Regulation of Fas–dependent activation–induced T cell apoptosis by cAMP signaling: a potential role for transcription factor NF–kappa B. Ivanov VN, et al.
Oncogene 1997 May 22;14(20):2455–64
Suppression of interleukin–1beta converting enzyme (ICE)–induced apoptosis by SV40 large T antigen. Jung YK, et al. **Oncogene** 1997 Mar 13;14(10):1207–14
Over–expression of p55Cdc inhibits granulocyte differentiation and accelerates apoptosis in myeloid cells. Kao CT, et al. **Oncogene** 1996 Sep 19;13(6):1221–9
Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Lanoix J, et al. **Oncogene** 1996 Sep 19; 13(6):1153–60
The human retinoblastoma gene product suppresses ceramide–induced apoptosis in human bladder tumor cells. McConkey DJ, et al. **Oncogene** 1996 Oct 17;13(8):1693–700
Actin cleavage by CPP–32/apopain during the development of apoptosis. Mashima T, et al. **Oncogene** 1997 Mar 6; 14(9):1007–12
Apoptosis in small intestinal epithelial from p53–null mice: evidence for a delayed, p53–independent G2/M–associated cell death after gamma–irradiation. Merritt AJ, et al.
Oncogene 1997 Jun 12;14(23):2759–66
Induction of apoptosis in human lung cancer cells after wild–type p53 activation by methoxyestradiol.
Mukhopadhyay T, et al. **Oncogene** 1997 Jan 23;14(3):379–84
Apoptosis in human papillomavirus16 E7–, but not E6–immortalized human uroepithelial cells. Puthenveettil JA, et al. **Oncogene** 1996 Sep 19;13(6):1123–31
Chimeric oncoprotein E2a–Pbx1 induces apoptosis of hematopoietic cells by a p53–independent mechanism that is suppressed by Bcl–2. Smith KS, et al. **Oncogene** 1997 Jun 19;14(24):2917–26
Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E. Sofer–Levi Y, et al. **Oncogene** 1996 Dec 5; 13(11):2431–7
Radiation–induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells. Strobel T, et al. **Oncogene** 1997 Jun 12;14(23):2753–8
Anti–cell death activity promotes pulmonary metastasis of melanoma cells. Takaoka A, et al. **Oncogene** 1997 Jun 19; 14(24):2971–7
Nitric oxide–mediated apoptosis of K–1735 melanoma cells is associated with downregulation of Bcl–2. Xie K, et al.
Oncogene 1997 Aug 14;15(7):771–9
Inhibition of apoptosis by normal and aberrant Fli–1 and erg proteins involved in human solid tumors and leukemias. Yi H, et al. **Oncogene** 1997 Mar 20;14(11):1259–68
Origin of intraepithelial apoptotic cells in human colorectal adenomas [letter] Arai T, et al. **Pathol Int** 1997 May; 47(5):333–5
Apoptosis: pathophysiology of programmed cell death. Bosman FT, et al. **Pathol Res Pract** 1996 Jul;192(7):676–83 (71 ref.)
Depth of infiltration of primary gastric B–cell lymphomas—correlations with proliferation, apoptosis and expression of p53 and bcl–2. Eidt S, et al.
Pathol Res Pract 1996 Sep;192(9):925–30
A high apoptotic index occurs in subtypes of endometrial adenocarcinoma associated with a poor prognosis. Heatley MK. **Pathology** 1997 Aug;29(3):272–5
Apoptosis in development and disease of the nervous system: II. Apoptosis in childhood neurologic disease. Gelbard HA, et al. **Pediatr Neurol** 1997 Feb;16(2):93–7 (57 ref.)
Apoptosis in development and disease of the nervous system: I. Naturally occurring cell death in the developing nervous system. Narayanan V. **Pediatr Neurol** 1997 Jan;16(1):9–13 (48 ref.)
Genetic control of neural cell apoptosis. Bredesen DE.
Perspect Dev Neurobiol 1996;3(2):101–9 (90 ref.)
Treatment of solid tumors should obligatorily be combined with the in vivo codepletion of tumor–protecting, CD8+/HLA–DR(+)–suppressor T cells by alloreactive donor T cells whose preprogrammed cell death allows a high GvL–effect before GvHD can be established. Results of animal experiments, including more than 6000 mice. Leskovar P, et al. **Pflugers Arch** 1996;431(6 Suppl 2):R229–30
Apoptosis: molecular mechanisms and implications for cancer chemotherapy. Guchelaar HJ, et al. **Pharm World Sci** 1997 Jun;19(3):119–25 (93 ref.)
Complex interplay among apoptosis factors: RB, p53, E2F, TGF–beta, cell cycle inhibitors and the bcl2 gene family. Chiarugi V, et al. **Pharmacol Res** 1997 Apr;35(4):257–61 (46 ref.)
Apoptosis and gastrointestinal pharmacology. Pritchard DM, et al. **Pharmacol Ther** 1996;72(2):149–69 (230 ref.)
Molecular and clinical aspects of apoptosis. Uren AG, et al.
Pharmacol Ther 1996;72(1):37–50 (165 ref.)
Involvement of apoptosis and lysosomal hydrolase activity in the oviducal regression during induced molting in chickens: a cytochemical study for end labeling of fragmented DNA and acid phosphatase. Heryanto B, et al. **Poult Sci** 1997 Jan;76(1):67–72
The control of cell death in the early chick embryo wing bud. MacCabe JA, et al. **Poult Sci** 1997 Jan;76(1):105–10
Interaction of tumor necrosis factor–alpha and granulocyte colony–stimulating factor on neutrophil apoptosis, receptor expression, and bactericidal function. Sullivan GW, et al.
Proc Assoc Am Physicians 1996 Nov;108(6):455–66
Death effector domain–containing herpesvirus and poxvirus proteins inhibit both Fas– and TNFR1–induced apoptosis. Bertin J, et al. **Proc Natl Acad Sci U S A** 1997 Feb 18; 94(4):1172–6
Suppression of tumor necrosis factor–induced cell death by inhibitor of apoptosis c–IAP2 is under NF–kappaB control. Chu ZL, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16; 94(19):10057–62
Activation of the cell death program by inhibition of proteasome function. Drexler HC.
Proc Natl Acad Sci U S A 1997 Feb 4;94(3):855–60
Programmed cell death: a way of life for plants. Greenberg JT. **Proc Natl Acad Sci U S A** 1996 Oct 29;93(22):12094–7 (59 ref.)
Cellular oxidative stress and the control of apoptosis by wild–type p53, cytotoxic compounds, and cytokines. Lotem J, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20; 93(17):9166–71
Yersinia signals macrophages to undergo apoptosis and YopJ is necessary for this cell death. Monack DM, et al.
Proc Natl Acad Sci U S A 1997 Sep 16;94(19):10385–90
Radiation and stress–induced apoptosis: a role for Fas/Fas ligand interactions. Reap EA, et al.
Proc Natl Acad Sci U S A 1997 May 27;94(11):5750–5
Inhibition of reaper–induced apoptosis by interaction with inhibitor of apoptosis proteins (IAPs). Vucic D, et al.
Proc Natl Acad Sci U S A 1997 Sep 16;94(19):10183–8
BAX–induced cell death may not require interleukin 1 beta–converting enzyme–like proteases. Xiang J, et al.
Proc Natl Acad Sci U S A 1996 Dec 10;93(25):14559–63
Axotomy–induced retinal ganglion cell death in development: its time–course and its diminution by antioxidants. Castagné V, et al.
Proc R Soc Lond B Biol Sci 1996 Sep 22;263(1374):1193–7
A reappraisal of the role of zinc in life and death decisions of cells. Fraker PJ, et al. **Proc Soc Exp Biol Med** 1997 Jul;215(3):229–36 (34 ref.)
Clusterin: a role in cell survival in the face of apoptosis? Koch–Brandt C, et al. **Prog Mol Subcell Biol** 1996; 16:130–49 (95 ref.)
An endonuclease responsible for apoptosis. Tanuma S, et al.
Prog Mol Subcell Biol 1996;16:1–12
An adaptationist view of apoptosis. LeGrand EK.
Q Rev Biol 1997 Jun;72(2):135–47 (73 ref.)
Apoptosis: function and regulation of cell death. Abastado JP. **Res Immunol** 1996 Sep;147(7):443–56 (72 ref.)
Apoptosis in autoimmune diseases. Klimiuk PA, et al.
Rocz Akad Med Bialymst 1995;40(2):227–32 (36 ref.)
Apoptosis II: Apoptosis in the pathogenesis and treatment of diseases. Moldoveanu E, et al.
Rom J Morphol Embryol 1996 Jan–Jun;42(1–2):41–51 (37 ref.)
Induction of apoptosis and p53 expression in immature thymocytes by direct interaction with thymic epithelial cells. Schreiber L, et al. **Scand J Immunol** 1996 Oct; 44(4):314–22
Geometric control of cell life and death. Chen CS, et al.
Science 1997 May 30;276(5317):1425–8
Apoptosis of microvascular endothelial cells in the pathophysiology of thrombotic thrombocytopenic purpura/sporadic hemolytic uremic syndrome. Laurence J, et al. **Semin Hematol** 1997 Apr;34(2):98–105 (34 ref.)
The role of the Caspase family of cysteine proteases in apoptosis. Miller DK. **Semin Immunol** 1997 Feb;9(1):35–49 (161 ref.)
Growth factors in ovarian follicle atresia. Chun SY, et al.
Semin Reprod Endocrinol 1996 Aug;14(3):197–202 (39 ref.)
Endotoxic shock leads to apoptosis in vivo and reduces Bcl–2. Haendeler J, et al. **Shock** 1996 Dec;6(6):405–9
Cecal ligation and puncture (CLP) induces apoptosis in thymus, spleen, lung, and gut by an endotoxin and TNF–independent pathway. Hiramatsu M, et al. **Shock**

1997 Apr;7(4):247–53
Bacterial ingestion, tumor necrosis factor–alpha, and heat induce programmed cell death in activated neutrophils. William R, et al. **Shock** 1996 Jan;5(1):47–51
Apoptosis in steroidogenic cells: structure–function analysis. Amsterdam A, et al. **Steroids** 1997 Jan;62(1):207–11 (33 ref.)
Stopping death cold. Werner MH. **Structure** 1996 Aug 15; 4(8):879–83 (23 ref.)
Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis. Tzeng E, et al. **Surgery** 1997 Aug;122(2):255–63
The polycystic ovarian (PCO) condition: apoptosis and epithelialization of the ovarian antral follicles are aspects of cystogenesis in the dehydroepiandrosterone (DHEA)–treated rat model. Anderson E, et al. **Tissue Cell** 1997 Apr;29(2):171–89
Effects of 4–hydroxynonenal and N–acetyl–L–cysteine on Myc–induced apoptosis. Yildiz D, et al. **Toxicol Lett** 1996 Dec 31;89(3):215–21
Class I MHC mediates programmed cell death in human lymphoid cells. Woodle ES, et al. **Transplantation** 1997 Jul 15;64(1):140–6
Caspases: killer proteases. Nicholson DW, et al. **Trends Biochem Sci** 1997 Aug;22(8):299–306 (57 ref.)
Diverse molecular provocation of programmed cell death. Wertz IE, et al. **Trends Biochem Sci** 1996 Oct;21(10):359–64
To sting or be stung: bacteria–induced apoptosis [letter] Lindgren SW, et al. **Trends Microbiol** 1997 Jul;5(7):263–4
Sacrifice in the face of foes: pathogen–induced programmed cell death in plants. Mittler R, et al. **Trends Microbiol** 1996 Jan;4(1):10–15 (37 ref.)
p75NTR and apoptosis: Trk–dependent and Trk–independent effects. Bredesen DE, et al. **Trends Neurosci** 1997 Jul; 20(7):287–90 (36 ref.)
T–cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune–defense mechanisms. Gold R, et al. **Trends Neurosci** 1997 Sep;20(9):399–404 (64 ref.)
Cold thoughts of death: the role of ICE proteases in neuronal cell death. Schwartz LM, et al. **Trends Neurosci** 1996 Dec; 19(12):555–62 (84 ref.)
Resolution of chronic inflammation by therapeutic induction of apoptosis. Anderson GP. **Trends Pharmacol Sci** 1996 Dec;17(12):438–42 (27 ref.)
Bcl–2 related proteins, apoptosis and disease. Anderson GP. **Trends Pharmacol Sci** 1997 Feb;18(2):51 (2 ref.)
Nitric oxide: inducer or suppressor of apoptosis? Nicotera P, et al. **Trends Pharmacol Sci** 1997 Jun;18(6):189–90 (8 ref.)
Epidermal growth factor suppresses renal tubular apoptosis following ureteral obstruction. Kennedy WA 2nd, et al. **Urology** 1997 Jun;49(6):973–80
Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis. Kuroki T, et al. **Virchows Arch** 1996 Oct;429(2–3):119–29
Proliferative activity and p53 protein accumulation correlate with early invasive trend, and apoptosis correlates with differentiation grade in oesophageal squamous cell carcinomas. Ohashi K, et al. **Virchows Arch** 1997 Feb; 430(2):107–15
African swine fever virus gene A179L, a viral homologue of bcl–2, protects cells from programmed cell death. Brun A, et al. **Virology** 1996 Nov 1;225(1):227–30
Sensitization to Fas–mediated apoptosis by hepatitis C virus core protein. Ruggieri A, et al. **Virology** 1997 Mar 3; 229(1):68–76
The role of the IGF–I receptor in apoptosis. Baserga R, et al. **Vitam Horm** 1997;53:65–98 (124 ref.)
Mitotic phase distribution, mitotic activity and apoptosis in basal cell tumours of canine skin. Maiolino P, et al. **Zentralbl Veterinarmed A** 1996 Dec;43(10):619–24
[Apoptosis and aging] Yang DL, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jan;27(1):64–6 (10 ref.) **(Chi)**
[Apoptosis: cellular and clinical aspects] Løvschall H, et al. **Nord Med** 1997 Apr;112(4):133–7 (15 ref.) (Eng. Abstr.) **(Dan)**
[Cell death and lupus] Fournié G. **Ann Med Interne (Paris)** 1996;147(7):472–9 (63 ref.) (Eng. Abstr.) **(Fre)**
[Growth potential of malignant tumors: balance between proliferation and apoptosis (editorial)] Sastre X. **Ann Pathol** 1997 Jul;17(3):169–70 **(Fre)**
[Oxidative stress and apoptosis] Mathieu J, et al. **Ann Pharm Fr** 1996;54(5):193–201 (88 ref.) (Eng. Abstr.) **(Fre)**
[Oxygen radical—induced apoptosis of proliferating human fibroblasts] Gansauge F, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:359–62 (Eng. Abstr.) **(Ger)**
[Significance of apoptosis–induced fas antigen–fas ligand system for post–traumatic brain edema] Keel M, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:481–3 (Eng. Abstr.) **(Ger)**
[Heart failure: oxidative stress and apoptosis (editorial)] Heinzl S. **Med Monatsschr Pharm** 1996 Nov;19(11):319 **(Ger)**
[Apoptosis in the immune system: murder or suicide] Krammer PH. **Pharm Unserer Zeit** 1996 Nov;25(6):306–10 (29 ref.) **(Ger)**
[Dysregulated apoptosis in chronic eosinophilic diseases—new therapeutic strategies for allergies and bronchial asthma] Simon HU. **Pneumologie** 1996 Nov; 50(11):790–6 (56 ref.) **(Ger)**
[Apoptosis—principles and importance of programmed cell death for prostatic carcinoma] Gschwend JE. **Urologe A** 1996 Sep;35(5):390–9 (71 ref.) (Eng. Abstr.) **(Ger)**
[Do we die from myocardial apoptosis? Fashion and reality of different types of cell death in cardiovascular diseases (editorial)] Baroldi G. **G Ital Cardiol** 1997 Apr; 27(4):399–402 **(Ita)**
[Methods for assessing programmed cell death] Cafforio P, et al. **Recenti Prog Med** 1996 Jul–Aug;87(7–8):366–73 (31 ref.) (Eng. Abstr.) **(Ita)**
[A brief overview of apoptosis] Hashimoto Y. **Gan To Kagaku Ryoho** 1997 Jan;24(2):205–10 (21 ref.) (Eng. Abstr.) **(Jpn)**
[The essential region of CD40 cytoplasmic domain for signal transduction in WEHI231 cells] Hara T. **Hokkaido Igaku Zasshi** 1997 May;72(3):309–17 (Eng. Abstr.) **(Jpn)**
[Molecular mechanism of regulation of apoptosis and related diseases] Ohta S, et al. **Nippon Ika Daigaku Zasshi** 1996 Apr;63(2):95–105 (128 ref.) **(Jpn)**
[Role of apoptosis in the progression of secondary hyperparathyroidism] Uda S, et al. **Nippon Jinzo Gakkai Shi** 1996 Aug;38(8):323–8 (Eng. Abstr.) **(Jpn)**
[Apoptosis and immunologic anomalies] Miyasaka N. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1775–80 (5 ref.) **(Jpn)**
[Regulation of apoptosis by the latent infection membrane protein 1 of Epstein–Barr virus] Kawanishi M. **Nippon Rinsho** 1997 Feb;55(2):305–10 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Apoptosis of prolactin induced structural luteolysis in rat] Kiya T, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Feb;48(2):147–8 **(Jpn)**
[Molecular biology of apoptosis] Eguchi Y, et al. **Rinsho Byori** 1997 May;45(5):470–6 (Eng. Abstr.) **(Jpn)**
[Definition and morphological features of apoptosis] Hiramine C. **Rinsho Byori** 1997 May;45(5):459–69 (31 ref.) (Eng. Abstr.) **(Jpn)**
[Adhesion molecules and apoptosis] Ishikawa J, et al. **Rinsho Byori** 1996 Sep;Suppl 102:78–83 (16 ref.) **(Jpn)**
[Mechanisms of growth and apoptosis in myeloma cells] Hata H, et al. **Rinsho Ketsueki** 1997 Apr;38(4):266–70 (6 ref.) **(Jpn)**
[The biology of apoptosis] Ohyama H, et al. **Rinsho Ketsueki** 1997 May;38(5):355–9 (12 ref.) **(Jpn)**
[Stimuli sensitive changes in electrical surface properties of soft membranes: from a synthesized polymer to a biological system] Makino K. **Yakugaku Zasshi** 1997 Jan;117(1):18–31 (40 ref.) (Eng. Abstr.) **(Jpn)**
[Cell cycle and apoptosis: death of a senescent cell] Sikora E. **Postepy Biochem** 1996;42(2):108–13 (69 ref.) **(Pol)**
[Apoptosis] Tsyplenkova VG, et al. **Arkh Patol** 1996 Sep–Oct;58(5):71–4 (50 ref.) (Eng. Abstr.) **(Rus)**
[Apoptosis. Its role in the immune system ontogeny and in HIV infection (letter; comment)] Perandones CE. **Medicina (B Aires)** 1996;56(1):110–1. Comment on: Medicina (B Aires) 1994;54(6):661–70. **(Spa)**
[Particpation of apoptosis in immunologic processes] Dabancens A. **Rev Med Chil** 1995 Oct;123(10):1285–8 (27 ref.) (Eng. Abstr.) **(Spa)**
[Apoptosis in the nervous system] Macaya A. **Rev Neurol** 1996 Nov;24(135):1356–60 (41 ref.) (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Ubiquitination of apoptotic cells in the developing cerebellum of the rat following ionizing radiation or methylazoxymethanol injection. Ferrer I, et al. **Acta Neuropathol (Berl)** 1997 Apr;93(4):402–7
Implications of radiation induced apoptosis on calculated radial cell inactivation for a linear 192Ir source. Olsen DR. **Acta Oncol** 1997;36(3):261–6
Interleukin–1beta–converting enzyme and CPP32 are involved in ultraviolet B–induced apoptosis of SV40–transformed human keratinocytes. Takahashi H, et al. **Biochem Biophys Res Commun** 1997 Jul 9;236(1):194–8
Effects of low–intensity AC and/or DC electromagnetic fields on cell attachment and induction of apoptosis. Blumenthal NC, et al. **Bioelectromagnetics** 1997; 18(3):264–72
Radiation–induced apoptosis in microvascular endothelial cells. Langley RE, et al. **Br J Cancer** 1997;75(5):666–72
Selective c–Jun overexpression is associated with ionizing radiation–induced apoptosis in the developing cerebellum of the rat. Ferrer I, et al. **Brain Res Mol Brain Res** 1996 May;38(1):91–100
Programmed cell death and radioresistance. Meyn RE, et al. **Cancer Metastasis Rev** 1996 Mar;15(1):119–31 (78 ref.)
Loss of ceramide production confers resistance to radiation–induced apoptosis. Chmura SJ, et al. **Cancer Res** 1997 Apr 1;57(7):1270–5
Oligodendrocytes in the adult rat spinal cord undergo radiation–induced apoptosis. Li YQ, et al. **Cancer Res** 1996 Dec 1;56(23):5417–22
Resistance to radiation–induced apoptosis in Burkitt's lymphoma cells is associated with defective ceramide signaling. Michael JM, et al. **Cancer Res** 1997 Aug 15; 57(16):3600–5
Overxpression of Bcl–2 inhibits UVA–mediated immediate apoptosiinrat 6 fibroblasts: evidence for the involvement of Bcl–2 as an antioxidant. Pourzand C, et al. **Cancer Res** 1997 Apr 15;57(8):1405–11
Effect of intravascular irradiation on cell proliferation, apoptosis, and vascular remodeling after balloon overstretch injury of porcine coronary arteries. Waksman R, et al. **Circulation** 1997 Sep 16;96(6):1944–52
A comparison of continuous versus intermittent light exposure on apoptosis. Li S, et al. **Curr Eye Res** 1996 Sep; 15(9):914–22
Fas/Fas ligand interaction contributes to UV–induced apoptosis in human keratinocytes. Leverkus M, et al. **Exp Cell Res** 1997 May 1;232(2):255–62
Light–induced apoptosis: differential timing in the retina and pigment epithelium. Hafezi F, et al. **Exp Eye Res** 1997 Jun; 64(6):963–70
Radiation–induced apoptosis in human lymphocytes: potential as a biological dosimeter. Boreham DR, et al. **Health Phys** 1996 Nov;71(5):685–91
Induction of apoptotic cell death in human leukemic cell line, HL–60, by extremely low frequency electric magnetic fields: analysis of the possible mechanisms in vitro. Narita K, et al. **In Vivo** 1997 Jul–Aug;11(4):329–35
Induction of apoptosis by ionizing radiation in Chinese hamster V79 cells and a radioresistant cell strain derived from V79. Ghosh R, et al. **Indian J Exp Biol** 1996 Sep; 34(9):863–7
Elevated expression of Bcl–2 and Bcl–x by intestinal intraepithelial lymphocytes: resistance to apoptosis by glucocorticoids and irradiation. Van Houten N, et al. **Int Immunol** 1997 Jul;9(7):945–53
bcl–2 over–expression delays radiation–induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Kyprianou N, et al. **Int J Cancer** 1997 Jan 27;70(3):341–8
Induction of apoptotic DNA fragmentation and cell death in U937 human cells by ultraviolet B irradiation. Fernández–Segura E, et al. **Int J Dev Biol** 1996;Suppl 1:199S–200S
Apoptosis and mitotic cell death: their relative contributions to normal–tissue and tumour radiation response. Hendry JH, et al. **Int J Radiat Biol** 1997 Jun;71(6):709–19
Flow cytometry as a quantitative and sensitive method to evaluate low dose radiation induced apoptosis in vitro in human peripheral blood lymphocytes. Hertveldt K, et al. **Int J Radiat Biol** 1997 Apr;71(4):429–33
Elevated frequency of p53–independent apoptosis after irradiation increases levels of DNA breaks in ataxia telangiectasia lymphoblasts. Humar B, et al. **Int J Radiat Biol** 1997 Sep;72(3):257–69
Radiation–induced apoptosis in the rat spinal cord: lack of equal effect per fraction. Li YQ, et al. **Int J Radiat Biol** 1997 Apr;71(4):413–20
Apoptosis: an indicator of radiosensitivity in vitro? Olive PL, et al. **Int J Radiat Biol** 1997 Jun;71(6):695–707 (89 ref.)
Modulating Ca2+ in radiation–induced apoptosis suppresses DNA fragmentation but does not enhance clonogenic survival. Voehringer DW, et al. **Int J Radiat Biol** 1997 Mar;71(3):237–43
Strain difference in jejunal crypt cell susceptibility to radiation–induced apoptosis. Weil MM, et al. **Int J Radiat Biol** 1996 Nov;70(5):579–85
Cell proliferation and death in the irradiated pituitary gland and its modification by growth stimulants. Guo YP, et al. **Int J Radiat Oncol Biol Phys** 1997 Apr 1;38(1):175–81
p53–dependent G1 arrest and p53–independent apoptosis influence the radiobiologic response of glioblastoma. Haas–Kogan DA, et al. **Int J Radiat Oncol Biol Phys** 1996 Aug 1;36(1):95–103
Potential molecular targets for manipulating the radiation response. Maity A, et al. **Int J Radiat Oncol Biol Phys** 1997 Feb 1;37(3):639–53 (180 ref.)
Rapid assay of intrinsic radiosensitivity based on apoptosis in human CD4 and CD8 T–lymphocytes. Ozsahin M, et al. **Int J Radiat Oncol Biol Phys** 1997 May 1;38(2):429–40
Stage–specific apoptosis in the rat seminiferous epithelium: quantification of irradiation effects. Henriksén K, et al. **J Androl** 1996 Jul–Aug;17(4):394–402
The role of c–Jun N–terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. Chen YR, et al. **J Biol Chem** 1996 Dec 13; 271(50):31929–36
Activation of a CrmA–insensitive, p35–sensitive pathway in ionizing radiation–induced apoptosis. Datta R, et al. **J Biol Chem** 1997 Jan 17;272(3):1965–9
The study of ultraviolet B–induced apoptosis in cultured mouse keratinocytes and in mouse skin. Baba T, et al. **J Dermatol Sci** 1996 Apr;12(1):18–23
UV–induced apoptosis in rat skin. Iwasaki K, et al. **J Dermatol Sci** 1996 Apr;12(1):31–5
Apoptosis in bone marrow cells of mice with different p53 genotypes after gamma–rays irradiation in vitro. Cui YF, et al. **J Environ Pathol Toxicol Oncol** 1995;14(3–4):159–63
Ultraviolet B radiation sensitizes a murine epidermal dendritic cell line (XS52) to undergo apoptosis upon antigen presentation to T cells. Kitajima T, et al. **J Immunol** 1996 Oct 15;157(8):3312–6
Two pathways for induction of apoptosis by ultraviolet radiation in cultured human keratinocytes. Gniadecki R, et al. **J Invest Dermatol** 1997 Aug;109(2):163–9

Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action. Yoo EK, et al. **J Invest Dermatol** 1996 Aug;107(2):235–42

Apoptosis in the chicken bursa of fabricius induced by X-irradiation. Arai S, et al. **J Vet Med Sci** 1996 Oct; 58(10):1001–6

Apoptosis in mesangial cells induced by ionizing radiation and cytotoxic drugs. Cha DR, et al. **Kidney Int** 1996 Nov; 50(5):1565–71

Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Casciola-Rosen L, et al. **Lupus** 1997;6(2):175–80 (52 ref.)

Ionizing radiation induces apoptosis and elevates cyclin A1-Cdk2 activity before but not after the midblastula transition in Xenopus. Anderson JA, et al. **Mol Biol Cell** 1997 Jul;8(7):1195–206

Radiation induced apoptosis. Harms-Ringdahl M, et al. **Mutat Res** 1996 Nov;366(2):171–9 (63 ref.)

Thymocyte apoptosis in response to low-dose radiation. Liu SZ, et al. **Mutat Res** 1996 Nov 4;358(2):185–91

Apoptosis is induced in the subependyma of young adult rats by ionizing irradiation. Bellinzona M, et al. **Neurosci Lett** 1996 Apr 26;208(3):163–6

Radiation-induced apoptosis in developing rats and kainic acid-induced excitotoxicity in adult rats are associated with distinctive morphological and biochemical c-Jun/AP-1 (N) expression. Ferrer I, et al. **Neuroscience** 1997 Sep; 80(2):449–58

Down-regulation of gadd153 by c-myc in rat fibroblasts and its effect on cell growth and radiation-induced apoptosis. Chen C, et al. **Oncogene** 1996 Oct 17;13(8):1659–65

gamma-Ray-induced apoptosis in transgenic mice with proliferative abnormalities in their intestinal epithelium: re-entry of villus enterocytes into the cell cycle does not affect their radioresistance but enhances the radiosensitivity of the crypt by inducing p53. Coopersmith CM, et al. **Oncogene** 1997 Jul 10;15(2):131–41

The apoptosis-associated gamma-ray response of BCL-X(L) depends on normal p53 function. Zhan Q, et al. **Oncogene** 1996 Nov 21;13(10):2287–93

Apoptosis and response to radiation: implications for radiation therapy. Meyn RE. **Oncology (Huntingt)** 1997 Mar;11(3):349–56; discussion 356, 361, 365 (45 ref.)

Silicon phthalocyanine Pc 4 and red light causes apoptosis in HIV-infected cells. Ben-Hur E, et al. **Photochem Photobiol** 1997 Mar;65(3):456–60

Preprogrammed and programmed cell death mechanisms of apoptosis: UV-induced immediate and delayed apoptosis. Godar DE. **Photochem Photobiol** 1996 Jun;63(6):825–30

Rapid initiation of apoptosis by photodynamic therapy. Luo Y, et al. **Photochem Photobiol** 1996 Apr;63(4):528–34

UV irradiation-induced apoptosis leads to activation of a 36-kDa myelin basic protein kinase in HL-60 cells. Lu ML, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20; 93(17):8977–82

Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of prostate cancer cells. Kyprianou N, et al. **Prostate** 1997 Sep 1;32(4):266–71

p53 protein expression and radiation-induced apoptosis in human tumors transplanted to nude mice. Hasegawa M, et al. **Radiat Med** 1997 May-Jun;15(3):171–6

Apoptosis and other effects of radiation in normal human urothelial cells. Mothersill C, et al. **Radiat Oncol Investig** 1997;5(3):150–3

Enhanced expression of the Kin17 protein immediately after low doses of ionizing radiation. Biard DS, et al. **Radiat Res** 1997 Apr;147(4):442–50

Ultraviolet B-radiation dose influences the induction of apoptosis and p53 in human keratinocytes. Cotton J, et al. **Radiat Res** 1997 Feb;147(2):148–55

Characterization of radiation-induced apoptosis in rodent cell lines. Guo M, et al. **Radiat Res** 1997 Mar;147(3):295–303

Radiation-induced cell death in the mouse testis: relationship to apoptosis. Hasegawa M, et al. **Radiat Res** 1997 Apr; 147(4):457–67

Radiation-induced apoptosis in HL60 cells: oxygen effect, relationship between apoptosis and loss of clonogenicity, and dependence of time to apoptosis on radiation dose [see comments] Hopcia KL, et al. **Radiat Res** 1996 Mar; 145(3):315–23. Comment in: Radiat Res 1996 Jul;146(1):116–9.

Radiosensitivity, apoptosis and repair of DNA double-strand breaks in radiation-sensitive Chinese hamster ovary cell mutants treated at different dose rates. Hu Q, et al. **Radiat Res** 1996 Dec;146(6):636–45

Radiation-induced apoptosis in thymocytes: inhibition by diethyldithiocarbamate and zinc. Mathieu J, et al. **Radiat Res** 1996 Dec;146(6):652–9

Further investigation of the response of human uroepithelium to low doses of cobalt-60 gamma radiation. Mothersill C, et al. **Radiat Res** 1997 Feb;147(2):156–65

Development of apoptosis and polyploidy in human lymphoblast cells as a function of position in the cell cycle at the time of irradiation. Olive PL, et al. **Radiat Res** 1996 Dec;146(6):595–602

Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Reinke V, et al. **Radiat Res** 1997 Aug; 148(2):115–22

Induction of apoptosis in cultured midbrain cells from embryonic mice. Wang B, et al. **Radiat Res** 1997 Mar; 147(3):304–8

Genetic basis of strain variation in levels of radiation-induced apoptosis of thymocytes. Weil MM, et al. **Radiat Res** 1996 Dec;146(6):646–51

Thymocyte proliferation and apoptosis induced by ionizing radiation. Shaposhnikova VV, et al. **Scanning Microsc** 1995; 9(4):1203–6

Tumor cell proliferation and apoptosis associated with the Gamma Knife effect. Tsuzuki T, et al. **Stereotact Funct Neurosurg** 1996;66 Suppl 1:39–48

Radioresistance, chemoresistance, and apoptosis resistance. The past, present, and future. Bergman PJ, et al. **Vet Clin North Am Small Anim Pract** 1997 Jan;27(1):47–57 (42 ref.)

[Apoptosis and radiotherapy] Cosset JM. **Bull Cancer Radiother** 1996;83(4):222–9 (53 ref.) **(Fre)**

[Induction and inhibition of rat thymocyte apoptosis by ultraviolet irradiation] Lonskaia IA, et al. **Biofizika** 1997 May-Jun;42(3):680–6 (Eng. Abstr.) **(Rus)**

[Disruption of plasma cell membrane permeability for Ca2+ ions in radiation-induced apoptosis of thymocytes] Shevchenko AS, et al. **Dokl Akad Nauk** 1997 Mar; 353(2):284–6 **(Rus)**

[Increased plasma membrane permeability for Ca2+ in radiation-induced thymocyte apoptosis] Shevchenko AS, et al. **Radiats Biol Radioecol** 1997 Mar-Apr;37(2):220–7 (Eng. Abstr.) **(Rus)**

APORPHINES

BLOOD

Determination of dicentrine in rat plasma by high-performance liquid chromatography and its application to pharmacokinetics. Tsai TH, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):277–81

CHEMISTRY

N-allylsecoboldine as a novel antioxidant against peroxidative damage. Teng CM, et al. **Eur J Pharmacol** 1996 May 6;303(1-2):129–39

ISOLATION & PURIFICATION

Faurine and O-methylfaurine, two novel benzyl-aporphine dimers from Thalictrum fauriei. Lee SS, et al. **J Nat Prod** 1996 Aug;59(8):738–43

Determination of lauraceous aporphine alkaloids by high-performance liquid chromatography. Sun SW, et al. **J Pharm Biomed Anal** 1996 Jun;14(8-10):1383–7

METABOLISM

Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells. Chen G, et al. **Anticancer Res** 1996 Nov-Dec; 16(6B):3499–505

PHARMACOKINETICS

Determination of dicentrine in rat plasma by high-performance liquid chromatography and its application to pharmacokinetics. Tsai TH, et al. **J Chromatogr B Biomed Appl** 1996 Jun 7;681(2):277–81

PHARMACOLOGY

Electrophysiological mechanisms for antiarrhythmic efficacy and positive inotropy of liriodenine, a natural aporphine alkaloid from Fissistigma glaucescens. Chang GJ, et al. **Br J Pharmacol** 1996 Aug;118(7):1571–83

The effect of S-(+)-boldine on the alpha 1-adrenoceptor of the guinea-pig aorta. Chuliá S, et al. **Br J Pharmacol** 1996 Dec;119(7):1305–12

A possible structural determinant of selectivity of boldine and derivatives for the alpha 1A-adrenoceptor subtype. Madrero Y, et al. **Br J Pharmacol** 1996 Dec;119(8):1563–8

N-allylsecoboldine as a novel antioxidant against peroxidative damage. Teng CM, et al. **Eur J Pharmacol** 1996 May 6;303(1-2):129–39

Boldine prevents human liver microsomal lipid peroxidation and inactivation of cytochrome P4502E1. Kringstein P, et al. **Free Radic Biol Med** 1995 Mar;18(3):559–63

Cell cycle effects of thaliblastine. Seifert F, et al. **J Cancer Res Clin Oncol** 1996;122(11):707–10

Pharmacological evaluation of ocoteine, isolated from Cassytha filiformis, as an alpha 1-adrenoceptor antagonist in rat thoracic aorta. Chang CW, et al. **Jpn J Pharmacol** 1997 Mar;73(3):207–14

Immunopharmacological activity of aporphinoid alkaloid oxoglaucine. Ivanovska N, et al. **Pharmacol Res** 1997 Apr; 35(4):267–72

New p-quinonoid aporphine alkaloids and antiplatelet aggregation constituents of Hernandia sonora. Chen IS, et al. **Planta Med** 1995 Dec;61(6):537–9

Inhibition of tyrosine hydroxylase by bulbocapnine [letter] Zhang YH, et al. **Planta Med** 1997 Aug;63(4):362–3

THERAPEUTIC USE

Renin-angiotensin system in the antihypertensive effect of isoteoline in spontaneously hypertensive rats. Markov M, et al. **Clin Exp Pharmacol Physiol Suppl** 1995;1:S368–70

Protective effect of boldine in experimental colitis. Gotteland M, et al. **Planta Med** 1997 Aug;63(4):311–5

APPARATUS AND INSTRUMENTS see **EQUIPMENT AND SUPPLIES**

APPENDECTOMY

Delayed appendectomy for appendicitis: causes and consequences. Von Titte SN, et al. **Am J Emerg Med** 1996 Nov;14(7):620–2

Contribution of ANP to plasma protein escape during VE: effects of thiorphan and atrial appendectomy. Tucker VL. **Am J Physiol** 1996 Sep;271(3 Pt 2):R610–8

Is wound infiltration with anesthetic effective as pre-emptive analgesia? A clinical trial in appendectomy patients [see comments] Willard PT, et al. **Can J Surg** 1997 Jun; 40(3):213–7. Comment in: Can J Surg 1997 Jun;40(3):166.

Role of appendectomy and tonsillectomy in pathogenesis of ulcerative colitis. Minocha A, et al. **Dig Dis Sci** 1997 Jul; 42(7):1567–9

Role of appendicectomy in the surgical management of ovarian cancer. Fawzi HW, et al. **Eur J Gynaecol Oncol** 1997;18(1):34–5

Mechanical small-bowel obstruction after conventional appendectomy in children. Ahlberg G, et al. **Eur J Pediatr Surg** 1997 Feb;7(1):13–5

Postrenal anuria after appendectomy in childhood. Timm K, et al. **Eur J Pediatr Surg** 1997 Aug;7(4):237–8

Laparoscopic compared with open appendicectomy for acute appendicitis: a prospective study. Chiarugi M, et al. **Eur J Surg** 1996 May;162(5):385–90

White blood cell count, leucocyte elastase activity, and serum concentrations of interleukin-6 and C-reactive protein after open appendicectomy. Eriksson S, et al. **Eur J Surg** 1997 Feb;163(2):123–7

Appendectomy, mucosal immunity, and colitis. Shanahan F, et al. **Gastroenterology** 1997 May;112(5):1766–7

Incidental appendectomy. **Int J Gynaecol Obstet** 1996 Mar; 52(3):317–8

Appendectomy in the surgical staging of ovarian carcinoma. Beşe T, et al. **Int J Gynaecol Obstet** 1996 Jun;53(3):249–52

Acute appendicitis in pregnancy. A review of 52 cases. Al-Mulhim AA. **Int Surg** 1996 Jul-Sep;81(3):295–7

Prospective evaluation of laparoscopic appendectomy in women with chronic right lower quadrant pain. AlSalilli M, et al. **J Am Assoc Gynecol Laparosc** 1995 Feb; 2(2):139–42

Review of 47 laparoscopic appendectomies. Lueken RP, et al. **J Am Assoc Gynecol Laparosc** 1995 May;2(3):269–72

Is interval appendectomy necessary after rupture of an appendiceal mass? Ein SH, et al. **J Pediatr Surg** 1996 Jun; 31(6):849–50

Recurrent appendicitis after initial conservative management of appendiceal abscess. Price MR, et al. **J Pediatr Surg** 1996 Feb;31(2):291–4

Management of patients with equivocal signs of appendicitis. Senbanjo RO. **J R Coll Surg Edinb** 1997 Apr;42(2):85–8

Patient controlled analgesia (PCA) in paediatric surgery: a prospective study following laparoscopic and open appendicectomy. Till H, et al. **Paediatr Anaesth** 1996; 6(1):29–32

Anaesthesia for appendicectomy in childhood: a survey of practice in Northern Ireland. Weir PS. **Ulster Med J** 1997 May;66(1):34–7

Prospective randomized comparison of open versus laparoscopic appendectomy in men. Cox MR, et al. **World J Surg** 1996 Mar-Apr;20(3):263–6

[Value of ilio-hypogastric block in appendectomy in children] Courrèges P, et al. **Cah Anesthesiol** 1996; 44(4):293–6 (Eng. Abstr.) **(Fre)**

[Effect of endoscopic surgery techniques in children on ventilation] Schäfer R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1997 Jun; 32(6):343–7 (Eng. Abstr.) **(Ger)**

[Topic for discussion. Ambulatory appendectomy by the established surgeon] Hierholzer E. **Chirurg** 1997 Mar; 68(3):suppl 76–9 **(Ger)**

[Problems with studies of open versus laparoscopic appendectomy (comment)] Krähenbühl L, et al. **Chirurg** 1997 Jan;68(1):30–2. Comment on: Chirurg 1996 May;67(5):522–5; discussion 522. Comment on: Chirurg 1996 May;67(5):526–30; discussion 522. **(Ger)**

[Value of laparoscopy in suspected appendicitis] Coburg AJ, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:550–2 (Eng. Abstr.) **(Ger)**

[Diagnostic problems in acute appendicitis and indications for laparoscopic appendectomy] Hallfeldt K, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:553–5 (Eng. Abstr.) **(Ger)**

[Mycotic aortic aneurysm after appendectomy] Rhomberg M, et al. **Vasa** 1996;25(1):90–3 (Eng. Abstr.) **(Ger)**

[Anomalous implantation of the appendiceal base. A case report] Lentini G, et al. **Minerva Chir** 1997 Mar;52(3):281–2 (Eng. Abstr.) **(Ita)**

[The role of surgery in the treatment of appendicular abscesses] Zarba Meli E, et al. **Minerva Chir** 1997 May; 52(5):577–81 (Eng. Abstr.) **(Ita)**

[Evaluation of the basis for elective appendectomy in gynecologic laparotomy] Grys E, et al. **Ginekol Pol** 1996 Jul;67(7):357–60 (Eng. Abstr.) **(Pol)**

[Pros and cons of elective appendectomy in gynecologic

laparotomy] Grys E, et al. **Ginekol Pol** 1996 Jul;67(7):361–5 (30 ref.) (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Case of the month. Hanzlick R. **Arch Intern Med** 1997 Aug 11–25;157(15):1645

'Residual' appendicitis following incomplete laparoscopic appendectomy [letter; comment] Demartines N, et al. **Br J Surg** 1996 Oct;83(10):1481. Comment on: Br J Surg 1996 Feb;83(2):217. Comment on: Br J Surg 1996 Jun;83(6):869.

Caecocolic intussusception in a child: a postoperative complication of appendicectomy. Liu KK, et al. **Eur J Surg** 1996 Aug;162(8):665–6

Cecocutaneous fistula forty years after appendicectomy. Shanmugam RP. **Indian J Gastroenterol** 1995 Oct; 14(4):154–5

Ureteral injury during appendectomy. Baykal K, et al. **Int Urol Nephrol** 1996;28(5):709–11

Comment on the article by Leuken et al (2(3)269–272, 1995) [letter] Wright BD. **J Am Assoc Gynecol Laparosc** 1995 Nov;3(1):121–2

Do appendectomy and tonsillectomy reduce the risk of rheumatoid arthritis? [letter] Koumantaki Y, et al. **J Rheumatol** 1997 Jun;24(6):1241–2

Infected hydrocele following laparoscopic appendectomy: case report. Lantsberg L, et al. **Surg Laparosc Endosc** 1997 Jun;7(3):262

[Does laparoscopy increase the bacteriological risk of appendectomy? Results of a randomized prospective study] Sezeur A, et al. **Ann Chir** 1997;51(3):243–7 (Eng. Abstr.) **(Fre)**

[Multiple brain abscesses following appendicectomy: case report] Schops M, et al. **Arq Neuropsiquiatr** 1996 Jun; 54(2):328–30 (Eng. Abstr.) **(Por)**

[A retroperitoneal hematoma after appendectomy] Astakhov GI, et al. **Vestn Khir Im I I Grek** 1997;156(1):110 **(Rus)**

[Streptococcal septic shock secondary to peritonitis (letter)] Merlo VE, et al. **Enferm Infecc Microbiol Clin** 1996 Nov; 14(9):574–5 **(Spa)**

ECONOMICS

Cost–utility analysis of contaminated appendectomy wounds. Brasel KJ, et al. **J Am Coll Surg** 1997 Jan;184(1):23–30

Appendectomy [letter] Perone N. **South Med J** 1997 Feb; 90(2):263

HISTORY

Appendicitis, appendectomy, and the surgeon. Smith DC. **Bull Hist Med** 1996 Fall;70(3):414–41

INSTRUMENTATION

[Appendectomy 1997—open or closed?] Becker H, et al. **Chirurg** 1997 Jan;68(1):17–29 (65 ref.) (Eng. Abstr.) **(Ger)**

[Clamping the tip of the appendix in appendectomy (letter)] Eigler FW. **Chirurg** 1997 Jul;68(7):750 **(Ger)**

[Technique and significance of stump management for outcome of laparoscopic appendectomy] Klima S, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:556–8 (Eng. Abstr.) **(Ger)**

METHODS

Laparoscopic appendicectomy: pros & cons—literature review of 4190 cases. Hermans BP, et al. **Acta Chir Belg** 1997 Jun;97(3):110–7 (29 ref.)

Laparoscopic appendectomy (LA) with a new technique. Antal A, et al. **Acta Chir Hung** 1995–96;35(3–4):225–8

Laparoscopic versus open appendectomy [letter; comment] Hotz TK. **Am J Surg** 1997 Feb;173(2):150. Comment on: Am J Surg 1996 May;171(5):533–7.

Simple ligation vs stump inversion in appendicectomy. Lavonius MI, et al. **Ann Chir Gynaecol** 1996;85(3):222–4

Laparoscopic vs open appendectomy. Prospective randomized study of outcomes. Minné L, et al. **Arch Surg** 1997 Jul;132(7):708–11; discussion 712

Laparoscopic versus open appendicectomy [letter; comment] Abu–Zidan FM, et al. **Aust N Z J Surg** 1996 Dec; 66(12):838–40. Comment on: Aust N Z J Surg 1996 Mar;66(3):178–80.

Laparoscopic appendectomy in paediatric patients: optimization with a new method of port insertion. Yip KF, et al. **Aust N Z J Surg** 1997 Apr;67(4):204–5

Safe laparoscopic appendicectomy in suppurative appendicitis. Goudet P, et al. **Br J Surg** 1997 May;84(5):651

Systematic review of randomized controlled trials comparing laparoscopic with open appendicectomy. McCall JL, et al. **Br J Surg** 1997 Aug;84(8):1045–50 (39 ref.)

Timing of operation for appendicitis. Murphy E, et al. **Br J Surg** 1997 Jul;84(7):1004–5

Randomized controlled trial with sequential design of laparoscopic versus conventional appendicectomy. Reiertsen O, et al. **Br J Surg** 1997 Jun;84(6):842–7

Laparoscopic appendicectomy [see comments] Tate JJ. **Br J Surg** 1996 Sep;83(9):1169–70 (9 ref.). Comment in: Br J Surg 1997 May;84(5):726–7.

Laparoscopic appendicectomy [letter; comment] Windsor J. **Br J Surg** 1997 May;84(5):726–7. Comment on: Br J Surg 1996 Sep;83(9):1169–70.

Laparoscopic versus open appendectomy: a prospective randomized trial of 81 patients. Hart R, et al. **Can J Surg** 1996 Dec;39(6):457–62

Laparoscopic appendectomy [letter; comment] Thomas EJ. **Can J Surg** 1996 Apr;39(2):168. Comment on: Can J Surg 1995 Oct;38(5):449–53.

Laparoscopy as an adjuvant in appendectomy. Verborg SA, et al. **Endoscopy** 1996 Jun;28(5):463

Laparoscopic appendicectomy—a successful operation in adults and children. Fleming PP, et al. **Ir J Med Sci** 1997 Jan–Mar;166(1):13–5

Appendicitis after laparoscopic appendectomy: a warning. Greenberg JJ, et al. **J Laparoendosc Surg** 1996 Jun; 6(3):185–7

Vaginal appendectomy at laparoscopic–assisted vaginal hysterectomy: a surgical option. Pelosi MA 3rd, et al. **J Laparoendosc Surg** 1996 Dec;6(6):399–403

Histopathologic analysis of interval appendectomy specimens: support for the role of interval appendectomy. Mazziotti MV, et al. **J Pediatr Surg** 1997 Jun;32(6):806–9

Appendectomy [letter] Perone N. **South Med J** 1997 Feb; 90(2):263

Appendectomy–laparoscopic or open? [editorial; comment] Cuschieri A. **Surg Endosc** 1997 Apr;11(4):319–20. Comment on: Surg Endosc 1997 Apr;11(4):336–40.

Pelvic abscess following laparoscopic appendectomy [letter] Frizelle FA, et al. **Surg Endosc** 1996 Sep;10(9):947–8 (30 ref.)

Laparoscopic vs open appendectomy. A randomized clinical trial [see comments] Kazemier G, et al. **Surg Endosc** 1997 Apr;11(4):336–40. Comment in: Surg Endosc 1997 Apr;11(4):319–20.

Laparoscopic appendectomy–is it worthwhile? A prospective, randomized study in young women. Laine S, et al. **Surg Endosc** 1997 Feb;11(2):95–7

Laparoscopic surgery during pregnancy. Lemaire BM, et al. **Surg Endosc** 1997 Jan;11(1):15–8 (20 ref.)

Laparoscopic stapler appendectomy. A prospective study of 267 consecutive cases. Wagner M, et al. **Surg Endosc** 1996 Sep;10(9):895–9

Laparoscopic versus open appendectomy: a prospective randomized trial. Macarulla E, et al. **Surg Laparosc Endosc** 1997 Aug;7(4):335–9

One–puncture laparoscopic appendectomy. Ng PC. **Surg Laparosc Endosc** 1997 Feb;7(1):22–4

Laparoscopic appendectomy: comparison with open appendectomy in 720 patients. Richards KF, et al. **Surg Laparosc Endosc** 1996 Jun;6(3):205–9

Stump appendicitis—a potential problem after laparoscopic appendicectomy. Walsh DC, et al. **Surg Laparosc Endosc** 1997 Aug;7(4):357–8

[Laparoscopy–assisted appendectomy in children] Koudelka J, et al. **Rozhl Chir** 1996 Oct;75(10):482–5 (Eng. Abstr.) **(Cze)**

[Laparoscopic appendectomy using the out–transumbilical method— personal experience] Straślipka J. **Rozhl Chir** 1997 Feb;76(2):85–6 (Eng. Abstr.) **(Cze)**

[Indications for appendectomy using the so–called "3–day rule". 10 years' experiences] Willmen HR, et al. **Chirurg** 1996 Aug;67(8):826–31; discussion 831–2 (Eng. Abstr.) **(Ger)**

[Laparoscopic appendicectomy. Personal experience and results] De Cesare A, et al. **Minerva Chir** 1997 Jan–Feb; 52(1–2):1–5 (Eng. Abstr.) **(Ita)**

[Laparoscopic appendectomy in obese patients. A comparative study with open appendectomy] Jitea N, et al. **Chirurgia (Bucur)** 1996 Jul–Aug;45(4):203–5 (Eng. Abstr.) **(Rum)**

[Comparison of open and laparoscopic appendectomy] Perko Z, et al. **Lijec Vjesn** 1996 Nov–Dec;118(11–12):291–5 (Eng. Abstr.) **(Scr)**

STANDARDS

Appendectomy. Improving care through quality improvement. Hale DA, et al. **Arch Surg** 1997 Feb; 132(2):153–7

Appendectomy and the risk of developing ulcerative colitis or Crohn's disease: results of a large case–control study. South Limburg Inflammatory Bowel Disease Study Group. Russel MG, et al. **Gastroenterology** 1997 Aug;113(2):377–82

[Quality control—results of the first survey of pediatric surgery in Hungary] Dávidovics S. **Orv Hetil** 1997 Aug 31;138(35):2181–3 (Eng. Abstr.) **(Hun)**

[Laparoscopic appendicectomy. Personal experience and results] De Cesare A, et al. **Minerva Chir** 1997 Jan–Feb; 52(1–2):1–5 (Eng. Abstr.) **(Ita)**

STATISTICS & NUMERICAL DATA

Appendectomy: a cor.temporary appraisal. Hale DA, et al. **Ann Surg** 1997 Mar;225(3):252–61 (23 ref.)

Appendectomy for appendicitis: are things the same? Soybel DI. **Gastroenterology** 1997 Oct;113(4):1415–7

UTILIZATION

Appendicectomy in Scotland: a 20–year epidemiological comparison. Bisset AF. **J Public Health Med** 1997 Jun; 19(2):213–8

Acute abdominal pain in children: an analysis of admissions over a three year period. Holland A, et al. **J Qual Clin Pract** 1996 Sep;16(3):151–5

APPENDICEAL NEOPLASMS

see related
PSEUDOMYXOMA PERITONEI

Lymphoma of the appendix. A case report. Hanna GB, et al. **G Chir** 1997 Apr;18(4):219–21

[Mucinous cystadenocarcinoma of the appendix. A rare case] Caponnetto A, et al. **Minerva Chir** 1997 Jan–Feb; 52(1–2):103–5 (Eng. Abstr.) **(Ita)**

CHEMISTRY

Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression. Guerrieri C, et al. **Hum Pathol** 1997 Sep;28(9):1039–45

COMPLICATIONS

Mucinous cystadenoma of the appendix causing intussusception in an adult. Jones CD, et al. **Am J Gastroenterol** 1997 May;92(5):898–9

Appendiceal intussusception as a manifestation of mucinous cystadenoma of the appendix: an interesting clinical entity. Heithold DL, et al. **Am Surg** 1997 May;63(5):390–1

Spontaneous appendicocutaneous fistula. Jagdish S, et al. **Indian J Gastroenterol** 1996 Jan;15(1):31

Mucinous cystadenoma of appendix concomitant with perityphlic granuloma. Sato T, et al. **J Gastroenterol** 1995 Dec;30(6):779–82

DIAGNOSIS

Carcinoid tumor in the appendix in a patient with acquired immunodeficiency syndrome [letter] Warner D, et al. **Arch Intern Med** 1997 Sep 22;157(17):2016

Mucinous cystadenoma of the appendix with raised serum carcinoembryonic antigen concentration: clinical and pathological features. Shimizu T, et al. **J Clin Pathol** 1997 Jul;50(7):613–4

Abdominal mass in a 19–year–old with neurofibromatosis. Samuel I, et al. **Postgrad Med J** 1997 Jun;73(860):325–6

Unusual tumors of the appendix and pseudomyxoma peritonei. Carr NJ, et al. **Semin Diagn Pathol** 1996 Nov; 13(4):314–25 (83 ref.)

Pseudomyxoma peritonei concomitant with early gastric cancer: report of a case. Ikejiri K, et al. **Surg Today** 1996; 26(11):923–5

[Appendiceal mucocele. Apropos of 6 cases] Abdelouafi A, et al. **Ann Radiol (Paris)** 1996;39(3):119–25 (Eng. Abstr.) **(Fre)**

[Appendicular carcinoid. The diagnostic and treatment problems] Ticmeanu F, et al. **Chirurgia (Bucur)** 1996 Mar–Apr;45(2):91–2 (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. Sugarbaker PH. **Cancer Treat Res** 1996; 82:317–25

GENETICS

Cytogenetic analysis of several pseudomyxoma peritonei lesions originating from a mucinous cystadenoma of the appendix. Teixeira MR, et al. **Cancer Genet Cytogenet** 1997 Feb;93(2):157–9

IMMUNOLOGY

Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Ronnett BM, et al. **Int J Gynecol Pathol** 1997 Jan;16(1):1–9

MORTALITY

Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. Sugarbaker PH, et al. **Cancer Treat Res** 1996;81:89–104

PATHOLOGY

Malignant pleural effusions due to adeno–endocrine–cell carcinoma of the appendix: a case report. Kobayashi TK, et al. **Diagn Cytopathol** 1997 Jun;16(6):522–5

Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. Zoetmulder FA, et al. **Eur J Cancer** 1996 Sep;32A(10):1727–33

Villous adenoma of the distal appendix. Taylor JV, et al. **Eur J Surg Oncol** 1997 Apr;23(2):185–6

Bilateral Krukenberg tumors due to appendiceal mucinous carcinoid. Klein EA, et al. **Int J Gynecol Pathol** 1996 Jan; 15(1):85–8

Unusual tumors of the appendix and pseudomyxoma peritonei. Carr NJ, et al. **Semin Diagn Pathol** 1996 Nov; 13(4):314–25 (83 ref.)

Appendix carcinoma invading the urinary bladder. Dahms SE, et al. **Urol Int** 1997;58(2):124–7 (24 ref.)

[Primary colonic type appendicular adenocarcinoma in a 17 years old patient. Plea for routine pathologic examination in the young (letter)] Finkeltin F, et al. **Ann Chir** 1996; 50(6):474 **(Fre)**

[Krukenberg tumors. Analysis of a series of 28 cases] Savey L, et al. **J Chir (Paris)** 1996;133(9–10):427–31 (Eng. Abstr.)

(Fre)

[Hyperplasic polyp of the appendix] Urso C, et al. **Pathologica** 1996 Jun;88(3):200–1 (Eng. Abstr.) (Ita)

RADIOGRAPHY

[Carcinoma of the appendix—rare but important] Ben-Nun A, et al. **Harefuah** 1996 Jul;131(1-2):22–3, 70 (Eng. Abstr.) (Heb)

RADIONUCLIDE IMAGING

Incidental appendix carcinoid. Value of somatostatin receptor imaging. Hoegerle S, et al. **Clin Nucl Med** 1997 Jul; 22(7):467–9

SECONDARY

Acute appendicitis secondary to metastatic bronchogenic adenocarcinoma. Gopez EV, et al. **Am Surg** 1997 Sep; 63(9):778–80

The appendix as a metastatic target for male urogenital tumours. Stein A, et al. **Br J Urol** 1996 Oct;78(4):647–8

Appendectomy in the surgical staging of ovarian carcinoma. Beşe T, et al. **Int J Gynaecol Obstet** 1996 Jun;53(3):249–52

Isolated appendiceal metastasis in early ovarian carcinoma. Rose PG, et al. **J Surg Oncol** 1997 Mar;64(3):246–7

SURGERY

Appendectomy in the surgical staging of ovarian carcinoma. Beşe T, et al. **Int J Gynaecol Obstet** 1996 Jun;53(3):249–52

[Mycotic aortic aneurysm after appendectomy] Rhomberg M, et al. **Vasa** 1996;25(1):90–3 (Eng. Abstr.) (Ger)

[Carcinoids in emergency surgery] Scarabelli R, et al. **Minerva Chir** 1996 Dec;51(12):1039–42 (Eng. Abstr.) (Ita)

THERAPY

Appendiceal carcinoma: patterns of failure following surgery and implications for adjuvant therapy. Proulx GM, et al. **J Surg Oncol** 1997 Sep;66(1):51–3

APPENDICITIS

Acute appendicitis in children in a community hospital: a five year review. Young I, et al. **Alaska Med** 1997 Apr–Jun; 39(2):34–42

Acute abdominal pain in children: an analysis of admissions over a three year period. Holland A, et al. **J Qual Clin Pract** 1996 Sep;16(3):151–5

[Appendicitis. Recommendations and medical references. Agence Nationale pour le Développement de l'Evaluation Médicale] **Gastroenterol Clin Biol** 1997;21(1):50–70 (247 ref.) (Fre)

BLOOD

White blood cell count, leucocyte elastase activity, and serum concentrations of interleukin-6 and C-reactive protein after open appendicectomy. Eriksson S, et al. **Eur J Surg** 1997 Feb;163(2):123–7

Are serum inflammatory markers age dependent in acute appendicitis? Paajanen H, et al. **J Am Coll Surg** 1997 Mar; 184(3):303–8

CHEMICALLY INDUCED

No association between non-steroidal anti-inflammatory drugs and acute appendicitis in a case-control study. Evans JM, et al. **Br J Surg** 1997 Mar;84(3):372–4

[Late pseudo-appendicular syndrome after Roundup poisoning (letter)] Delcenserie R, et al. **Gastroenterol Clin Biol** 1997;21(5):435–7 (Fre)

CLASSIFICATION

Appendectomy for appendicitis: are things the same? Soybel DI. **Gastroenterology** 1997 Oct;113(4):1415–7

COMPLICATIONS

Intraoperative US diagnosis of pylephlebitis (portal vein thrombosis) as a complication of appendicitis: a case report. Farin P, et al. **Abdom Imaging** 1997 Jul–Aug;22(4):401–3

Ruptured ectopic pregnancy with undetectable beta-hCG levels coexisting with acute appendicitis. Bozoklu S, et al. **Acta Obstet Gynecol Scand** 1997 Feb;76(2):181–2

Perforated appendicitis in a 4-month-old infant. Ko YS, et al. **Acta Paediatr Sin** 1996 Jul–Aug;37(4):283–5

Perforated appendicitis within an inguinal hernia: case report and review of the literature. Lyass S, et al. **Am J Gastroenterol** 1997 Apr;92(4):700–2 (10 ref.)

Effect of transfer on outcome in patients with appendicitis. Norton VC, et al. **Ann Emerg Med** 1997 Apr;29(4):467–73

Case of the month. Hanzlick R. **Arch Intern Med** 1997 Aug 11–25;157(15):1645

Acute appendicitis and colonic carcinoma in the young: report of two cases. Adebamowo AC, et al. **East Afr Med J** 1996 Aug;73(8):563–4

Appendicitis in patients with acquired immunodeficiency syndrome. Flum DR, et al. **J Am Coll Surg** 1997 May; 184(5):481–6

An unusual complication of missed appendicitis. Bobrow BJ, et al. **J Emerg Med** 1996 Nov–Dec;14(6):719–22

The management of acute abdominal pain in children [see comments] Simpson ET, et al. **J Paediatr Child Health** 1996 Apr;32(2):110–2. Comment in: J Paediatr Child Health 1996 Oct;32(5):469. Comment in: J Paediatr Child Health 1996 Dec;32(6):546.

Spontaneous perforation of the gallbladder from cholecystitis with acute appendicitis in pregnancy. A case report. Grimes DA. **J Reprod Med** 1996 Jun;41(6):450–2

Acute appendicitis presenting as a perinephric abscess. Bologna RA, et al. **J Urol** 1996 Nov;156(5):1758

Appendicitis in an eleven-year-old boy complicated by thrombosis of the portal and superior mesenteric veins. van Spronsen FJ, et al. **Pediatr Infect Dis J** 1996 Oct; 15(10):910–2 (10 ref.)

An endoscopic diagnosis of appendicular intussusception in chronic appendicitis. Nyam DC, et al. **Singapore Med J** 1997 Mar;38(3):131 (10 ref.)

[Acute gangrenous appendicitis in incarcerated inguinal hernia. A case report] Ottaviani M, et al. **Minerva Chir** 1997 Jun;52(6):831–3 (Eng. Abstr.) (Ita)

[Acute complicated appendicitis: report of a case diagnosed with computerized tomography] Scaglione M, et al. **Radiol Med (Torino)** 1996 Nov;92(5):655–7 (Ita)

[Hydronephrosis as a complication of appendicitis: a case report] Kubo M, et al. **Hinyokika Kiyo** 1996 Sep; 42(9):679–81 (11 ref.) (Eng. Abstr.) (Jpn)

[Combination of appendicitis with gynecologic diseases] Makhovskii VZ, et al. **Khirurgiia (Mosk)** 1997;(6):29–32 (Eng. Abstr.) (Rus)

[Laparoscopic cleansing of the abdominal cavity in appendicular peritonitis in children] Roshal' LM, et al. **Khirurgiia (Mosk)** 1996;(4):35–7 (Rus)

[Treatment of appendiceal peritonitis] Tarshis VE, et al. **Khirurgiia (Mosk)** 1996;(2):64–6 (Eng. Abstr.) (Rus)

[A rare association of acute appendicitis and right-sided lower lobe pleuropneumonia] Alekseev AV, et al. **Klin Khir** 1996;(8):50–1 (Rus)

[Pylephlebitis as a preoperative complication of acute appendicitis] Shuliarenko VA, et al. **Lik Sprava** 1995 Sep–Dec;(9–12):173–4 (Rus)

[Internal appendicular-organic fistulae—a complication of acute appendicitis] Bokhan KL. **Vestn Khir Im I I Grek** 1997;156(2):137–9 (28 ref.) (Rus)

[A combination of perforated stomach ulcer and gangrenous appendicitis] Borodinov VP. **Vestn Khir Im I I Grek** 1996; 155(5):91 (Rus)

[Hazards and complications in the diagnosis and treatment of acute appendicitis] Korepanova MV. **Vestn Khir Im I I Grek** 1997;156(1):111–5 (48 ref.) (Rus)

[Acute appendicitis complicated by destruction of the large intestine and septic shock] Kulibaba DM, et al. **Vestn Khir Im I I Grek** 1997;156(2):117–8 (Rus)

CONGENITAL

Prenatal perforated appendicitis. Govani RV. **J Indian Med Assoc** 1996 Feb;94(2):83

DIAGNOSIS

Recurrent abdominal pain. Dire DJ. **Acad Emerg Med** 1996 Oct;3(10):952, 957–9

Acute appendicitis in females—a clinical study of 366 cases. Abu-Eshy SA, et al. **Afr J Med Med Sci** 1995 Sep; 24(3):227–30

Acute appendicitis: MR imaging and sonographic correlation. Incesu L, et al. **AJR Am J Roentgenol** 1997 Mar; 168(3):669–74

Acute appendicitis: the myths of migratory pain and gradual onset of symptoms [letter] Wigder HN, et al. **Am J Emerg Med** 1997 Jan;15(1):111–2

Importance of diarrhea as a presenting symptom of appendicitis in very young children. Horwitz JR, et al. **Am J Surg** 1997 Feb;173(2):80–2

A useful sign for the diagnosis of peritoneal irritation in the right iliac fossa and Can serum interleukin-6 levels predict the outcome of patients with right iliac fossa pain? [letter; comment] Davenport M. **Ann R Coll Surg Engl** 1997 Jul; 79(4):310–1. Comment on: Ann R Coll Surg Engl 1997 Mar;79(2):128–9. Comment on: Ann R Coll Surg Engl 1997 Mar;79(2):130–3.

Can serum interleukin-6 levels predict the outcome of patients with right iliac fossa pain? [see comments] Goodwin AT, et al. **Ann R Coll Surg Engl** 1997 Mar; 79(2):130–3. Comment in: Ann R Coll Surg Engl 1997 Jul;79(4):310–1.

A useful sign for the diagnosis of peritoneal irritation in the right iliac fossa [see comments] Lane R, et al. **Ann R Coll Surg Engl** 1997 Mar;79(2):128–9. Comment in: Ann R Coll Surg Engl 1997 Jul;79(4):310–1.

A prospective evaluation of the modified Alvarado score for acute appendicitis in children. Macklin CP, et al. **Ann R Coll Surg Engl** 1997 May;79(3):203–5

The recurrent appendix. Harris RA, et al. **Aust N Z J Surg** 1997 Sep;67(9):666–7

Appendicitis. Graffeo CS, et al. **Emerg Med Clin North Am** 1996 Nov;14(4):653–71 (127 ref.)

Diagnostic value of C-reactive protein in children with perforated appendicitis. Chung JL, et al. **Eur J Pediatr** 1996 Jul;155(7):529–31

Leucocyte elastase as a marker in the diagnosis of acute appendicitis. Eriksson S, et al. **Eur J Surg** 1995 Dec; 161(12):901–5

Acute appendicitis—ways to improve diagnostic accuracy. Eriksson S. **Eur J Surg** 1996 Jun;162(6):435–42 (93 ref.)

Estimating the probability of acute appendicitis using clinical criteria of a structured record sheet: the physician against the computer. Hallan S, et al. **Eur J Surg** 1997 Jun; 163(6):427–32

Additional value of biochemical tests in suspected acute appendicitis. Hallan S, et al. **Eur J Surg** 1997 Jul; 163(7):533–8

Comparison of clinical judgment and diagnostic ultrasonography in the diagnosis of acute appendicitis: experience with a score-aided diagnosis. Jahn H, et al. **Eur J Surg** 1997 Jun;163(6):433–43

Evaluation of plasma serotonin concentration in acute appendicitis. Kalra U, et al. **Indian J Gastroenterol** 1997 Jan;16(1):18–9

Laparoscopic diagnosis of acute appendicitis in women. Tronin RJ, et al. **J Am Assoc Gynecol Laparosc** 1996 Feb; 3(2):257–61

Diagnosis of appendicitis [letter; comment] Olive ST, et al. **J Am Board Fam Pract** 1996 Jul–Aug;9(4):306–7. Comment on: J Am Board Fam Pract 1996 Mar–Apr;9(2):75–8.

Eustrongylidiasis—a parasitic infection acquired by eating live minnows. Narr LL, et al. **J Am Osteopath Assoc** 1996 Jul;96(7):400–2

Appendicitis: trends and risks, 1996. Delany HM. **J Assoc Acad Minor Phys** 1996;7(3):70–7 (37 ref.)

Imaging findings in patients with-right lower quadrant pain: alternative diagnoses to appendicitis. Jain KA, et al. **J Comput Assist Tomogr** 1997 Sep–Oct;21(5):693–8 (8 ref.)

An unusual complication of missed appendicitis. Bobrow BJ, et al. **J Emerg Med** 1996 Nov–Dec;14(6):719–22

Schistosomiasis: an unusual cause of right lower quadrant abdominal pain. Donaldson BA, et al. **J Natl Med Assoc** 1997 Jul;89(7):461–3

The management of acute abdominal pain in children [letter; comment] Mawdsley JA, et al. **J Paediatr Child Health** 1996 Oct;32(5):469. Comment on: J Paediatr Child Health 1996 Apr;32(2):110–2.

The management of acute abdominal pain in children [see comments] Simpson ET, et al. **J Paediatr Child Health** 1996 Apr;32(2):110–2. Comment in: J Paediatr Child Health 1996 Oct;32(5):469. Comment in: J Paediatr Child Health 1996 Dec;32(6):546.

Management of patients with equivocal signs of appendicitis. Senbanjo RO. **J R Coll Surg Edinb** 1997 Apr;42(2):85–8

Does this patient have appendicitis? [letter; comment] Alvarado A. **JAMA** 1997 Feb 26;277(8):626; discussion 626–7. Comment on: JAMA 1996 Nov 20;276(19):1589–94.

Does this patient have appendicitis? [letter; comment] Babb RR. **JAMA** 1997 Feb 26;277(8):625–6; discussion 626–7. Comment on: JAMA 1996 Nov 20;276(19):1589–94.

Does this patient have appendicitis? [letter; comment] Hall FM. **JAMA** 1997 Feb 26;277(8):626; discussion 626–7. Comment on: JAMA 1996 Nov 20;276(19):1589–94.

Likelihood ratios to determine 'does this patient have appendicitis?': comment and clarification [letter] Klovning A. **JAMA** 1997 Sep 10;278(10):819; discussion 819–20

Does this patient have appendicitis? [letter; comment] Moustafa MH, et al. **JAMA** 1997 Feb 26;277(8):625; discussion 626–7. Comment on: JAMA 1996 Nov 20;276(19):1589–94.

Does this patient have appendicitis? [letter; comment] Schneider TM. **JAMA** 1997 Feb 26;277(8):625; discussion 626–7. Comment on: JAMA 1996 Nov 20;276(19):1589–94.

Does this patient have appendicitis? [see comments] Wagner JM, et al. **JAMA** 1996 Nov 20;276(19):1589–94. Comment in: JAMA 1997 Feb 26;277(8):625; discussion 626–7. Comment in: JAMA 1997 Feb 26;277(8):625–6; discussion 626–7. Comment in: JAMA 1997 Feb 26;277(8):626; discussion 626–7.

Likelihood ratios to determine 'does this patient have appendicitis?': comment and clarification [letter] Witt K, et al. **JAMA** 1997 Sep 10;278(10):819; discussion 819–20

Are we overinvestigating appendicitis [letter] Gnanalingham KK, et al. **Lancet** 1997 Jun 28;349(9069):1918

Diagnosis of appendicitis [letter] Malone AJ, et al. **Lancet** 1997 Jun 14;349(9067):1774

The accuracy of C-reactive protein in diagnosing acute appendicitis—a meta-analysis. Hallan S, et al. **Scand J Clin Lab Invest** 1997 Aug;57(5):373–80

A chance of misdiagnosis between acute appendicitis and renal colic. Paajanen H, et al. **Scand J Urol Nephrol** 1996 Oct;30(5):363–6

Iliopsoas myositis mimicking appendicitis: MRI diagnosis. Wysoki MG, et al. **Skeletal Radiol** 1997 May;26(5):316–8

Acute appendicitis—a clear-cut case in men, a guessing game in young women. A prospective study on the role of laparoscopy. Borgstein PJ, et al. **Surg Endosc** 1997 Sep; 11(9):923–7

The appearance of a normal appendix on barium enema examination does not rule out a diagnosis of chronic appendicitis: report of a case and review of the literature. Okamoto T, et al. **Surg Today** 1997;27(6):550–3 (16 ref.)

Primary torsion of the omentum mimicking acute appendicitis: report of a case. Saraç AM, et al. **Surg Today** 1997;27(3):251–3

[Causes of late diagnosis of appendicitis in children] Zlámal Z. **Rozhl Chir** 1996 Jul;75(7):351–4 (Eng. Abstr.) (Cze)

[Primary pneumococcal peritonitis in children] Barguellil F,

et al. **Med Trop (Mars)** 1996;56(3):279–81 (Eng. Abstr.) **(Fre)**

[Abdominal pain of uncertain origin––value of laparoscopy. "If in doubt, carry it out"] Bruch HP, et al. **Chirurg** 1997 Jan;68(1):12–6 (Eng. Abstr.) **(Ger)**

[Necrotizing vasculitis of the appendix and cecum in systemic lupus erythematosus] Schmidt WA, et al. **Z Rheumatol** 1996 Jul–Aug;55(4):267–71 (Eng. Abstr.) **(Ger)**

[Acute appendicitis in pregnancy. Our experience] De Rosa G, et al. **Minerva Chir** 1996 Nov;51(11):939–44 (Eng. Abstr.) **(Ita)**

[Acute diverticulitis of the appendix. A clinical case] Palestini N, et al. **Minerva Gastroenterol Dietol** 1996 Jun; 42(2):99–102 (9 ref.) (Eng. Abstr.) **(Ita)**

[Acute-phase proteins in appendicitis in childhood: new findings] Meucci D, et al. **Pediatr Med Chir** 1996 Nov–Dec; 18(6):601–6 (Eng. Abstr.) **(Ita)**

[Wrong diagnoses of acute appendicitis in women] Barczyński M, et al. **Przegl Lek** 1995;52(12):575–7 (Eng. Abstr.) **(Pol)**

[Acute nondestructive appendicitis: arguable questions in its diagnosis and treatment] Baraev TM. **Klin Khir** 1995; (2):34–6 (38 ref.) **(Rus)**

[Retrospective analysis of errors in the diagnosis of acute appendicitis] Beliavskaia BM. **Klin Khir** 1996;(4):12–4 **(Rus)**

[The use of laparoscopy in patients with a presumed diagnosis of acute appendicitis] Kapshitar' AV. **Klin Khir** 1995; (2):19–20 **(Rus)**

[The use of lumbar sound blockade in the differential diagnosis of acute appendicitis and right-sided renal colic] Polous IuM, et al. **Klin Khir** 1995;(2):22–3 **(Rus)**

[The activity of trypsin and proteolytic inhibitors in complicated forms of appendicitis in children] Sukhanova GA, et al. **Klin Lab Diagn** 1996 Nov–Dec;(6):31–3 (Eng. Abstr.) **(Rus)**

[Laparoscopy in the differential diagnosis and treatment of acute appendicitis and acute gynecological diseases] Kulik IaP, et al. **Vestn Khir Im I I Grek** 1996;155(3):31–3 (Eng. Abstr.) **(Rus)**

[Prospective study of 288 cases of acute appendicitis during childhood: characteristics in preschool children] Alvarez Bernaldo de Quirós M, et al. **An Esp Pediatr** 1997 Apr; 46(4):351–6 (Eng. Abstr.) **(Spa)**

[Appendicitis in the elderly: delay between the first symptoms and surgical procedure] Moro MJ, et al.
An Med Interna 1996 Dec;13(12):580–3 (Eng. Abstr.) **(Spa)**

[Diagnostic validity of signs and symptoms defining the diagnosis of acute appendicitis] Alvarez Sánchez JA, et al. **Gastroenterol Hepatol** 1997 Jan;20(1):11–6 (Eng. Abstr.) **(Spa)**

[Perforated appendicitis in children: the evaluation of a delayed diagnosis (letter)] González Keelan C.
P R Health Sci J 1996 Jun;15(2):127 **(Spa)**

[The respiratory symptoms of acute appendicitis] Ostrovs'kyi VP, et al. **Klin Khir** 1995;(2):48 **(Ukr)**

DRUG THERAPY

An alternative approach to common bile duct stones [letter] Grabham J, et al. **Br J Surg** 1997 Apr;84(4):581

Comparative trial of four antibiotic combinations for perforated appendicitis in children. Ciftci AO, et al.
Eur J Surg 1997 Aug;163(8):591–6

Is interval appendectomy necessary after rupture of an appendiceal mass? Ein SH, et al. **J Pediatr Surg** 1996 Jun; 31(6):849–50

[Lymph dilution as a method of treatment in endotoxicosis] Iarema IV, et al. **Anesteziol Reanimatol** 1997 May–Jun; (3):57–9 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

The effect of acute ligation of the rabbit appendix on antioxidant enzymes. Turan C, et al.
Res Exp Med (Berl) 1996;196(1):45–51

EPIDEMIOLOGY

Prevalence of appendectomy in Japanese families. Hiraiwa H, et al. **Acta Paediatr Jpn** 1995 Dec;37(6):691–3

The influence of age on the severity of peritonitis. Watters JM, et al. **Can J Surg** 1996 Apr;39(2):142–6

Acute appendicitis––a clear-cut case in men, a guessing game in young women. A prospective study on the role of laparoscopy. Borgstein PJ, et al. **Surg Endosc** 1997 Sep; 11(9):923–7

Incidence of acute nonperforated and perforated appendicitis: age-specific and sex-specific analysis. Körner H, et al.
World J Surg 1997 Mar–Apr;21(3):313–7

[Epidemiology of appendicitis] Treutner KH, et al.
Chirurg 1997 Jan;68(1):1–5 (Eng. Abstr.) **(Ger)**

ETHNOLOGY

Acute appendicitis in minority communities: an epidemiologic study. Gerst PH, et al.
J Natl Med Assoc 1997 Mar;89(3):168–72

ETIOLOGY

Acute appendicitis immediately after colonoscopy. Hirata K, et al. **Am J Gastroenterol** 1996 Oct;91(10):2239–40

Acute appendicitis secondary to metastatic bronchogenic adenocarcinoma. Gopez EV, et al. **Am Surg** 1997 Sep; 63(9):778–80

'Residual' appendicitis following incomplete laparoscopic appendectomy [letter; comment] Demartines N, et al.
Br J Surg 1996 Oct;83(10):1481. Comment on: Br J Surg 1996 Feb;83(2):217. Comment on: Br J Surg 1996 Jun;83(6):869.

Sarcoidosis manifesting as acute appendicitis: report of a case. Cullinane DC, et al. **Dis Colon Rectum** 1997 Jan; 40(1):109–11 (11 ref.)

Appendicitis after blunt abdominal trauma: cause or coincidence? Ciftci AO, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):350–3 (26 ref.)

Perforated appendicitis and ectopic pregnancy following in-vitro fertilization. Akman MA, et al. **Hum Reprod** 1995 Dec;10(12):3325–6

Granulomatous appendicitis: Crohn's disease, atypical Crohn's or not Crohn's at all? Richards ML, et al.
J Am Coll Surg 1997 Jul;185(1):13–7

Involvement of the appendix in pseudomembranous colitis. Coyne JD, et al. **J Clin Pathol** 1997 Jan;50(1):70–1

Recurrent appendicitis after initial conservative management of appendiceal abscess. Price MR, et al. **J Pediatr Surg** 1996 Feb;31(2):291–4

Appendiceal perforation: a potentially lethal initial mode of presentation of Hirschsprung's disease. Sarioğlu A, et al. **J Pediatr Surg** 1997 Jan;32(1):123–4 (11 ref.)

Bilateral ureteral obstruction after asymptomatic appendicitis. Green JT, et al. **J Urol** 1997 Jun;157(6):2251

The effect of acute ligation of the rabbit appendix on antioxidant enzymes. Turan C, et al.
Res Exp Med (Berl) 1996;196(1):45–51

Ascaris lumbricoides appendicitis in the tropics. Singh PA, et al. **Trop Doct** 1997 Oct;27(4):241

[The role of Enterobius vermicularis in etiopathogenesis of appendicitis] Listorto G, et al. **Minerva Chir** 1996 May; 51(5):293–6 (Eng. Abstr.) **(Ita)**

[A case of appendiceal lesion prior to the manifestation of ulcerative colitis: so-called "ulcerative appendicitis" as an antecedent lesion] Takizawa H, et al.
Nippon Shokakibyo Gakkai Zasshi 1996 Feb;93(2):109–13 **(Jpn)**

[Appendiceal abscess in the third gestational trimester of pregnancy, complications pre and postoperatively] Cyrkowicz A, et al. **Przegl Lek** 1996;53(12):877–8 (Eng. Abstr.) **(Pol)**

HISTORY

Appendicitis, appendectomy, and the surgeon. Smith DC.
Bull Hist Med 1996 Fall;70(3):414–41

METABOLISM

Penetration of clindamycin and metronidazole into inflamed appendiceal tissue. Levy Y, et al. **Eur J Surg** 1996 Aug; 162(8):633–5

MICROBIOLOGY

Escherichia coli and appendicitis: phenotypic characteristics of E. coli isolates from inflamed and noninflamed appendices. Saxén H, et al. **Clin Infect Dis** 1996 Nov; 23(5):1038–42

Acute appendicitis secondary to non-0 group I Vibrio cholerae. Cook MA, et al. **J Am Osteopath Assoc** 1996 Jul;96(7):432–3

Haemophilus influenzae and appendix mass [letter] Cousin GC, et al. **J Infect** 1997 Mar;34(2):157

An uncommon presentation of Salmonella. Deutsch A, et al. **Pediatr Emerg Care** 1996 Aug;12(4):285–7 (16 ref.)

[Acute appendicitis caused by mucorales in a patient with severe aplastic anemia: report of an autopsy case] Sasaki S, et al. **Rinsho Ketsueki** 1996 Feb;37(2):152–7 (Eng. Abstr.) **(Jpn)**

MORTALITY

[Mortality in acute appendicitis––an analysis of a ten-year period] Lulchev D. **Khirurgiia (Sofiia)** 1996;49(6):11–6 (Eng. Abstr.) **(Bul)**

PARASITOLOGY

Schistosomiasis of the appendix in the UK. Jones HJ, et al.
Br J Clin Pract 1997 Apr–May;51(3):183

Appendiceal spirochetosis. Yang M, et al. **South Med J** 1997 Jan;90(1):30–2

Enterobius vermicularis (pin worm) causing symptoms of appendicitis. Ajao OG, et al. **Trop Doct** 1997 Jul; 27(3):182–3

PATHOLOGY

Recognition of a pathological appendix during laparoscopy: a prospective study of 81 cases. Champault G, et al.
Br J Surg 1997 May;84(5):671

Duplication of the vermiform appendix. Lin BC, et al.
Eur J Surg 1996 Jul;162(7):589–91

Villous adenoma of the distal appendix. Taylor JV, et al.
Eur J Surg Oncol 1997 Apr;23(2):185–6

Histochemical study of expression of lectin-reactive carbohydrate epitopes and glycoligand-binding sites in normal human appendix vermiformis, colonic mucosa, acute appendicitis and colonic adenoma. Brinck U, et al.
Histol Histopathol 1996 Oct;11(4):919–30

The accessory cell populations in ulcerative colitis: a comparison between the colon and appendix in colitis and acute appendicitis. Waraich T, et al. **Hum Pathol** 1997 Mar; 28(3):297–303

Granulomatous appendicitis: Crohn's disease, atypical Crohn's or not Crohn's at all? Richards ML, et al.
J Am Coll Surg 1997 Jul;185(1):13–7

Tissue superoxide dismutase (SOD) activity and immunohistochemical staining in acute appendicitis: correlation with degree of inflammation. Satomi A, et al.
J Gastroenterol 1996 Oct;31(5):639–45

'Pilonidal appendicitis' or 'the hair of the dog': an unusual case of foreign body perforation of the appendix. Miller GG, et al. **J Pediatr Surg** 1996 May;31(5):703

Another look at chronic appendicitis resembling Crohn's disease. Huang JC, et al. **Mod Pathol** 1996 Oct;9(10):975–81

[Primary colonic type appendicular adenocarcinoma in a 17 years old patient. Plea for routine pathologic examination in the young (letter)] Finkeltin F, et al. **Ann Chir** 1996; 50(6):474 **(Fre)**

[Pathomorphological aspects of acute appendicitis] Gerharz CD, et al. **Chirurg** 1997 Jan;68(1):6–11 (29 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Appendicitis. Graffeo CS, et al.
Emerg Med Clin North Am 1996 Nov;14(4):653–71 (127 ref.)

The menstrual cycle and acute appendicitis. Eldar S, et al.
Eur J Surg 1995 Dec;161(12):897–900

RADIOGRAPHY

CT appearance of acute appendicitis in childhood. Friedland JA, et al. **AJR Am J Roentgenol** 1997 Feb;168(2):439–42

Unenhanced helical CT for suspected acute appendicitis. Lane MJ, et al. **AJR Am J Roentgenol** 1997 Feb; 168(2):405–9

A focused appendiceal CT technique to reduce the cost of caring for patients with clinically suspected appendicitis. Rhea JT, et al. **AJR Am J Roentgenol** 1997 Jul;169(1):113–8

Computed tomography of the normal appendix and acute appendicitis. Ghiatas AA, et al. **Eur Radiol** 1997;7(7):1043–7

CT of appendicitis in children. Jabra AA, et al.
J Comput Assist Tomogr 1997 Jul–Aug;21(4):661–6

Sensitivity and specificity of the individual CT signs of appendicitis: experience with 200 helical appendiceal CT examinations. Rao PM, et al. **J Comput Assist Tomogr** 1997 Sep–Oct;21(5):686–92

Radiologists learn results of new therapy trials, hear latest speculations on cause of old disorder [news] Skolnick AA.
JAMA 1997 Feb 5;277(5):367–9

Focused appendix CT technique: a commentary [editorial; comment] Federle MP. **Radiology** 1997 Jan;202(1):20–1. Comment on: Radiology 1997 Jan;202(1):139–44. Comment on: Radiology 1997 Jan;202(1):145–9.

Helical CT technique for the diagnosis of appendicitis: prospective evaluation of a focused appendix CT examination [see comments] Rao PM, et al. **Radiology** 1997 Jan;202(1):139–44. Comment in: Radiology 1997 Jan;202(1):20–1.

Distal appendicitis: CT appearance and diagnosis. Rao PM, et al. **Radiology** 1997 Sep;204(3):709–12

Appendicitis: use of arrowhead sign for diagnosis at CT. Rao PM, et al. **Radiology** 1997 Feb;202(2):363–6

[Can we recognize the pathological character of the appendix during laparoscopy? Prospective study: 81 cases] Champault G, et al. **J Chir (Paris)** 1996 Nov;133(7):320–3 (Eng. Abstr.) **(Fre)**

[Appendicitis in the sub-hepatic site] Hornoy B, et al.
J Radiol 1997 May;78(5):388–92 **(Fre)**

[Acute complicated appendicitis: report of a case diagnosed with computerized tomography] Scaglione M, et al.
Radiol Med (Torino) 1996 Nov;92(5):655–7 **(Ita)**

RADIONUCLIDE IMAGING

Tc-99m-HMPAO white blood cell scan for diagnosis of acute appendicitis in patients with equivocal clinical presentation. Rypins EB, et al. **Ann Surg** 1997 Jul; 226(1):58–65

Tc-99m HMPAO-labeled WBC scans to detect appendicitis in women. Kao CH, et al. **Clin Nucl Med** 1996 Oct; 21(10):768–71

Diagnostic value of Tc-99m HIG scintigraphy in the detection of acute appendicitis. Varoğlu E, et al.
Clin Nucl Med 1996 Aug;21(8):645–7

Technetium-99m IgG immunodetection of acute appendicitis in rats. Wong DW, et al. **Nucl Med Biol** 1996 May; 23(4):473–8

99Tcm-HMPAO-labelled white blood cell scans to detect acute appendicitis in older patients with an atypical clinical presentation. Lin WY, et al. **Nucl Med Commun** 1997 Jan; 18(1):75–8

SURGERY

Diagnostic accuracy of ultrasonography and surgical decision-making in patients referred for suspicion of appendicitis. Verroken R, et al. **Acta Chir Belg** 1996 Jul–Aug;96(4):158–60

Delayed appendectomy for appendicitis: causes and

consequences. Von Titte SN, et al. **Am J Emerg Med** 1996 Nov;14(7):620–2
Delay of surgery in acute appendicitis. Eldar S, et al. **Am J Surg** 1997 Mar;173(3):194–8
Simple ligation vs stump inversion in appendicectomy. Lavonius MI, et al. **Ann Chir Gynaecol** 1996;85(3):222–4
Appendectomy: a contemporary appraisal. Hale DA, et al. **Ann Surg** 1997 Mar;225(3):252–61 (23 ref.)
Appendectomy. Improving care through quality improvement. Hale DA, et al. **Arch Surg** 1997 Feb; 132(2):153–7
Preemptive analgesia in patients undergoing appendectomy. Ko CY, et al. **Arch Surg** 1997 Aug;132(8):874–7; discussion 877–8
Laparoscopic vs open appendectomy. Prospective randomized study of outcomes. Minné L, et al. **Arch Surg** 1997 Jul;132(7):708–11; discussion 712
Safe laparoscopic appendicectomy in suppurative appendicitis. Goudet P, et al. **Br J Surg** 1997 May;84(5):651
Systematic review of randomized controlled trials comparing laparoscopic with open appendicectomy. McCall JL, et al. **Br J Surg** 1997 Aug;84(8):1045–50 (39 ref.)
Timing of operation for appendicitis. Murphy E, et al. **Br J Surg** 1997 Jul;84(7):1004–5
Randomized controlled trial with sequential design of laparoscopic versus conventional appendicectomy. Reiertsen O, et al. **Br J Surg** 1997 Jun;84(6):842–7
Laparoscopic appendicectomy [see comments] Tate JJ. **Br J Surg** 1996 Sep;83(9):1169–70 (9 ref.). Comment in: Br J Surg 1997 May;84(5):726–7.
Laparoscopic appendectomy [letter; comment] Thomas EJ. **Can J Surg** 1996 Apr;39(2):168. Comment on: Can J Surg 1995 Oct;38(5):449–53.
Appendicitis complicating pregnancy. Attapattu AA, et al. **Ceylon Med J** 1996 Sep;41(3):104–6
Appendicitis and the surgeon's bread and butter. Schnee C. **Del Med J** 1996 Oct;68(10):504–5
Laparoscopy as an adjuvant in appendectomy. Verborg SA, et al. **Endoscopy** 1996 Jun;28(5):463
Mechanical small-bowel obstruction after conventional appendectomy in children. Ahlberg G, et al. **Eur J Pediatr Surg** 1997 Feb;7(1):13–5
Postrenal anuria after appendectomy in childhood. Timm K, et al. **Eur J Pediatr Surg** 1997 Aug;7(4):237–8
Laparoscopic compared with open appendicectomy for acute appendicitis: a prospective study. Chiarugi M, et al. **Eur J Surg** 1996 May;162(5):385–90
Penetration of clindamycin and metronidazole into inflamed appendiceal tissue. Levy Y, et al. **Eur J Surg** 1996 Aug; 162(8):633–5
Acute appendicitis in pregnancy. A review of 52 cases. Al-Mulhim AA. **Int Surg** 1996 Jul-Sep;81(3):295–7
Appendicitis after laparoscopic appendectomy: a warning. Greenberg JJ, et al. **J Laparoendosc Surg** 1996 Jun; 6(3):185–7
Appendicitis in children in the managed care era. Adolph VR, et al. **J Pediatr Surg** 1996 Aug;31(8):1035–6; discussion 1036–7
Is interval appendectomy necessary after rupture of an appendiceal mass? Ein SH, et al. **J Pediatr Surg** 1996 Jun; 31(6):849–50
Histopathologic analysis of interval appendectomy specimens: support for the role of interval appendectomy. Mazziotti MV, et al. **J Pediatr Surg** 1997 Jun;32(6):806–9
Insurance-related differences in the presentation of pediatric appendicitis. O'Toole SJ, et al. **J Pediatr Surg** 1996 Aug; 31(8):1032–4
Fortuitous diagnosis of cystic fibrosis at laparotomy for acute appendicitis. Avolio L, et al. **Pediatr Surg Int** 1997 Jul; 12(5–6):441–2
Laparoscopic vs open appendectomy. A randomized clinical trial [see comments] Kazemier G, et al. **Surg Endosc** 1997 Apr;11(4):336–40. Comment in: Surg Endosc 1997 Apr;11(4):319–20.
Laparoscopic appendectomy–is it worthwhile? A prospective, randomized study in young women. Laine S, et al. **Surg Endosc** 1997 Feb;11(2):95–7
Laparoscopic stapler appendectomy. A prospective study of 267 consecutive cases. Wagner M, et al. **Surg Endosc** 1996 Sep;10(9):895–9
"Surgical" ultrasound in suspected acute appendicitis. Zielke A, et al. **Surg Endosc** 1997 Apr;11(4):362–5
Laparoscopic versus open appendectomy: a prospective randomized trial. Macarulla E, et al. **Surg Laparosc Endosc** 1997 Aug;7(4):335–9
One-puncture laparoscopic appendectomy. Ng PC. **Surg Laparosc Endosc** 1997 Feb;7(1):22–4
Stump appendicitis--a potential problem after laparoscopic appendicectomy. Walsh DC, et al. **Surg Laparosc Endosc** 1997 Aug;7(4):357–8
Prospective randomized comparison of open versus laparoscopic appendectomy in men. Cox MR, et al. **World J Surg** 1996 Mar-Apr;20(3):263–6
[Laparoscopic treatment of appendiceal peritonitis in adults] Fabiani P, et al. **Ann Chir** 1996;50(10):892–5 (Eng. Abstr.) **(Fre)**
[Appendectomy 1997--open or closed?] Becker H, et al. **Chirurg** 1997 Jan;68(1):17–29 (65 ref.) (Eng. Abstr.) **(Ger)**
[Clamping the tip of the appendix in appendectomy (letter)] Eigler FW. **Chirurg** 1997 Jul;68(7):750 **(Ger)**
[Problems with studies of open versus laparoscopic appendectomy (comment)] Krähenbühl L, et al. **Chirurg** 1997 Jan;68(1):30–2. Comment on: Chirurg 1996 May;67(5):522–5; discussion 522. Comment on: Chirurg 1996 May;67(5):526–30; discussion 522. **(Ger)**
[Indications for appendectomy using the so-called "3-day rule". 10 years' experiences] Willmen HR, et al. **Chirurg** 1996 Aug;67(8):826–31; discussion 831–2 (Eng. Abstr.) **(Ger)**
[Value of laparoscopy in suspected appendicitis] Coburg AJ, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:550–2 (Eng. Abstr.) **(Ger)**
[Diagnostic problems in acute appendicitis and indications for laparoscopic appendectomy] Hallfeldt K, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:553–5 (Eng. Abstr.) **(Ger)**
[Technique and significance of stump management for outcome of laparoscopic appendectomy] Klima S, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996;113:556–8 (Eng. Abstr.) **(Ger)**
[Anomalous implantation of the appendiceal base. A case report] Lentini G, et al. **Minerva Chir** 1997 Mar;52(3):281–2 (Eng. Abstr.) **(Ita)**
[Multiple brain abscesses following appendicectomy: case report] Schops M, et al. **Arq Neuropsiquiatr** 1996 Jun; 54(2):328–30 (Eng. Abstr.) **(Por)**
[A combination of a liver tumor and destructive appendicitis in a child] Litovka VK, et al. **Klin Khir** 1996;(7):53 **(Rus)**
[Cases of acute appendicitis in incomplete intestinal rotation] Rukhalo VG, et al. **Klin Khir** 1995;(2):45 **(Rus)**
[Laparoscopy in the differential diagnosis and treatment of acute appendicitis and acute gynecological diseases] Kulik IaP, et al. **Vestn Khir Im I I Grek** 1996;155(3):31–3 (Eng. Abstr.) **(Rus)**
[Gangrenous appendicitis in a patient with internal strangulated hernia] Grishchuk IaI, et al. **Klin Khir** 1996; (6):52 **(Ukr)**
[Once again about tactics of the treatment in acute appendicitis] Mil'kov BO. **Klin Khir** 1996;(5):43–5 **(Ukr)**
[Prognostication of the development of early intestinal obstruction in children with abdominal pathology] Nikolaeva NG, et al. **Klin Khir** 1996;(10):36–8 **(Ukr)**
[The prevention of postoperative suppurative-septic complications in patients with acute appendicitis] Ohonovs'kyĭ VK. **Klin Khir** 1995;(2):5–6 **(Ukr)**

THERAPY

Role of the primary care provider in the care of children with acute appendicitis: experiences from a public hospital [letter; comment] Park JW. **Arch Pediatr Adolesc Med** 1997 Feb;151(2):210. Comment on: Arch Pediatr Adolesc Med 1996 Jul;150(7):703–6.
Recurrent appendicitis. Barber MD, et al. **Br J Surg** 1997 Jan;84(1):110–2
Cytomegalovirus appendicitis in a patient with acquired immunodeficiency syndrome: a case report. Tarng YW, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1997 Jul; 60(1):48–51
[The treatment of appendicular peritonitis complicated by septic shock in childhood] Gumerov AA, et al. **Vestn Khir Im I I Grek** 1997;156(1):91–3 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Saline-filled appendiceal ultrasonography in clinically equivocal acute appendicitis. Cha SH, et al. **Abdom Imaging** 1996 Nov-Dec;21(6):525–9
Cost-effectiveness of sonographic diagnosis of appendicitis in children. Jorulf H, et al. **Acad Radiol** 1996 Apr;3 Suppl 1:S54–6
Use of sonography in diagnosing acute appendicitis: comparison of a teaching hospital and a community hospital. Sabra J, et al. **Acad Radiol** 1996 May;3(5):438–41
Diagnostic accuracy of ultrasonography and surgical decision-making in patients referred for suspicion of appendicitis. Verroken R, et al. **Acta Chir Belg** 1996 Jul-Aug;96(4):158–60
Sonography of appendicitis and acute diseases of the lower abdomen. Van Ruyssevelt C, et al. **Acta Gastroenterol Belg** 1996 Apr-Jun;59(2):152–3
Acute appendicitis: MR imaging and sonographic correlation. Incesu L, et al. **AJR Am J Roentgenol** 1997 Mar; 168(3):669–74
Ultrasound diagnosis of acute appendicitis. Patterson EJ, et al. **Can J Surg** 1997 Aug;40(4):251–2
Radiology case of the month. Evaluation of right lower quadrant pain. Acute appendicitis. Lobrano ME, et al. **J La State Med Soc** 1996 Aug;148(8):335–6
Ultrasonography in the diagnosis of acute appendicitis. Zeidan BS, et al. **J R Coll Surg Edinb** 1997 Feb;42(1):24–6
Ruptured pelvic appendix diagnosed by transvaginal sonography. Wojak JC, et al. **Obstet Gynecol** 1994 Oct;84(4 Pt 2):706–8
Appendicitis: usefulness of color Doppler US. Lim HK, et al. **Radiology** 1996 Oct;201(1):221–5
Spontaneously resolving acute appendicitis: clinical and sonographic documentation [see comments] Migraine S, et al. **Radiology** 1997 Oct;205(1):55–8. Comment in: Radiology 1997 Oct;205(1):41–2.
An inflamed appendix at sonography when symptoms are improving: to operate or not to operate? [editorial; comment] Puylaert JB, et al. **Radiology** 1997 Oct; 205(1):41–2. Comment on: Radiology 1997 Oct;205(1):55–8.
"Surgical" ultrasound in suspected acute appendicitis. Zielke A, et al. **Surg Endosc** 1997 Apr;11(4):362–5
Acute appendicitis: diagnosis by transvaginal sonography. Caspi B, et al. **Ultrasound Obstet Gynecol** 1996 May; 7(5):359–60
Detection of appendicitis by transvaginal ultrasound: a case report. Larcos G. **Ultrasound Obstet Gynecol** 1996 May; 7(5):361–2
Imaging of appendicitis. Hulett R. **West J Med** 1996 Jul-Aug; 165(1–2):54–5
[Appendicitis in childhood] Hahn H, et al. **Radiologe** 1997 Jun;37(6):454–8 (Eng. Abstr.) **(Ger)**
[Vaginal ultrasound in perityphlitic abscess] Hönigl W, et al. **Ultraschall Med** 1997 Feb;18(1):39–41 (Eng. Abstr.) **(Ger)**
[Ultrasonographic diagnosis of acute appendicitis] Grebeldinger S. **Med Pregl** 1996;49(11–12):487–91 (Eng. Abstr.) **(Scr)**

VIROLOGY

[Perforation of cytomegalovirus appendicitis in a patient with human immunodeficiency virus infection (letter)] Mazza D, et al. **Gastroenterol Clin Biol** 1997;21(4):346–7 **(Fre)**
[Measles-related appendicitis (letter)] Torres-Melero J, et al. **Rev Clin Esp** 1996 Jan;196(1):58–9 **(Spa)**

APPENDIX

see related

APPENDECTOMY

Intussusception of vermiform appendix. A case report and review of the literature. Kegelaers B, et al. **Acta Chir Belg** 1996 Nov-Dec;96(6):287–90 (22 ref.)
Appendiceal intussusception as a manifestation of mucinous cystadenoma of the appendix: an interesting clinical entity. Heithold DL, et al. **Am Surg** 1997 May;63(5):390–1
Incidental 67Ga uptake into an appendiceal mucocele in a patient with sigmoid colon cancer. Ohta H, et al. **Ann Nucl Med** 1996 May;10(2):257–9
Image of the month. Appendiceal and sigmoid diverticulosis. Triadacilopoulos G. **Gastroenterology** 1997 Oct; 113(4):1062, 1424
Melanosis of the appendix: prevalence, distribution and review of the pathogenesis of 47 cases. Rutty GN, et al. **Histopathology** 1997 Apr;30(4):319–23
Spontaneous appendicocutaneous fistula. Jagdish S, et al. **Indian J Gastroenterol** 1996 Jan;15(1):31
Incidental appendectomy. **Int J Gynaecol Obstet** 1996 Mar; 52(3):317–8
Pelviscopic removal of an appendiceal mucocele. Huang CC, et al. **J Am Assoc Gynecol Laparosc** 1994 Feb;1(2):174–6
Abdominal inflammatory myofibroblastic tumors in children: report of an appendiceal case and review of the literature. Bonnet JP, et al. **J Pediatr Surg** 1996 Sep;31(9):1311–4 (28 ref.)
'Pilonidal appendicitis' or 'the hair of the dog': an unusual case of foreign body perforation of the appendix. Miller GG, et al. **J Pediatr Surg** 1996 May;31(5):703
Recurrent appendicitis after initial conservative management of appendiceal abscess. Price MR, et al. **J Pediatr Surg** 1996 Feb;31(2):291–4
Malakoplakia of the appendix. Borghesi MR, et al. **Minerva Chir** 1997 Apr;52(4):465–7 (9 ref.)
Drain site evisceration of the appendix: report of a case. Duraker N, et al. **Surg Today** 1997;27(7):651–2
A case of appendicular diverticulitis leading to mucocele of the appendix. Sivam NS, et al. **Trop Gastroenterol** 1997 Jan-Mar;18(1):36–7
[A case of strangulated intestinal obstruction by the vermiform appendix (letter)] Ivoulsou DP, et al. **Med Trop (Mars)** 1996;56(4):413–4 **(Fre)**
[Mucocele of the appendix with pseudomyxoma peritonei--a rare cause of a paraneoplastic syndrome] Pollack T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1997 Mar;166(3):266–8 (13 ref.) **(Ger)**
[Delayed appendico-cutaneous fistula--a rare complication of simple abdominal drainage] Brünagel G, et al. **Zentralbl Chir** 1996;121(1):67–9 (Eng. Abstr.) **(Ger)**
[Diverticular disease of the appendix] Greenberg R, et al. **Harefuah** 1997 Feb 2;132(3):180–2, 239 (Eng. Abstr.) **(Heb)**
[The role of surgery in the treatment of appendicular abscesses] Zarba Meli E, et al. **Minerva Chir** 1997 May; 52(5):577–81 (Eng. Abstr.) **(Ita)**
[A case of perforated appendix caused by secondary amyloidosis associated with rheumatoid arthritis] Kawashima I, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Aug;93(8):569–72 **(Jpn)**
[Debatable questions of surgical tactics in appendiceal infiltrates and periappendiceal abscess] Aliev SA. **Khirurgiia (Mosk)** 1997;(4):48–54 (Eng. Abstr.) **(Rus)**
[Simultaneous strangulation of a fallopian tube and the appendix in an inguinal hernia] Kolesnik AV, et al. **Klin Khir** 1995;(2):52 **(Rus)**
[Internal appendicular-organic fistulae--a complication of acute appendicitis] Bokhan KL. **Vestn Khir Im I I Grek** 1997;156(2):137–9 (28 ref.) **(Rus)**
[Mucocele of the vermiform appendix] Martínez-González MD, et al. **Rev Gastroenterol Mex** 1996 Oct-Dec;

APPENDIX

61(4):366–70 (Eng. Abstr.) **(Spa)**
[A case report. A pin in the appendix caused hepatic abscess] Acosta S, et al. **Lakartidningen** 1996 Nov 20;93(47):4278 **(Swe)**
[Strangulation of the appendix in a femoral hernia] Pidopryhora AP, et al. **Klin Khir** 1995;(2):51–2 **(Ukr)**

ABNORMALITIES

Duplicated vermiform appendix. Kjossev KT, et al. **Br J Surg** 1996 Sep;83(9):1259
A caecal diaphragm in cystic fibrosis. Lucas JS, et al. **Eur J Gastroenterol Hepatol** 1997 Jun;9(6):629–31
Segmental cecal dilatation with absent appendix: a case of failure of appendiceal regression? Uroz–Tristan J, et al. **Eur J Pediatr Surg** 1996 Dec;6(6):373–4
Duplication of the vermiform appendix. Lin BC, et al. **Eur J Surg** 1996 Jul;162(7):589–91
Fecolith impaction in a duplex vermiform appendix: an unusual presentation of colonic duplication. McNeill SA, et al. **J Pediatr Surg** 1996 Oct;31(10):1435–7
[Anomalous implantation of the appendiceal base. A case report] Lentini G, et al. **Minerva Chir** 1997 Mar;52(3):281–2 (Eng. Abstr.) **(Ita)**
[Duplication of the appendix in a child] Konstantinov PI, et al. **Vestn Khir Im I I Grek** 1997;156(1):109 **(Rus)**

CHEMISTRY

The accessory cell populations in ulcerative colitis: a comparison between the colon and appendix in colitis and acute appendicitis. Waraich T, et al. **Hum Pathol** 1997 Mar; 28(3):297–303

CYTOLOGY

Histochemical study of expression of lectin–reactive carbohydrate epitopes and glycoligand–binding sites in normal human appendix vermiformis, colonic mucosa, acute appendicitis and colonic adenoma. Brinck U, et al. **Histol Histopathol** 1996 Oct;11(4):919–30
RAG1 and RAG2 in developing rabbit appendix subpopulations. Fuschiotti P, et al. **J Immunol** 1997 Jan 1;158(1):55–64

IMMUNOLOGY

Postrearrangement diversification processes in gut–associated lymphoid tissues. Reynaud CA, et al. **Curr Top Microbiol Immunol** 1996;212:7–15 (28 ref.)
CD5 is a potential selecting ligand for B cell surface immunoglobulin framework region sequences. Pospisil R, et al. **J Exp Med** 1996 Oct 1;184(4):1279–84

METABOLISM

Penetration of clindamycin and metronidazole into inflamed appendiceal tissue. Levy Y, et al. **Eur J Surg** 1996 Aug; 162(8):633–5
RAG1 and RAG2 in developing rabbit appendix subpopulations. Fuschiotti P, et al. **J Immunol** 1997 Jan 1;158(1):55–64

PARASITOLOGY

Schistosomiasis: an unusual cause of right lower quadrant abdominal pain. Donaldson BA, et al. **J Natl Med Assoc** 1997 Jul;89(7):461–3

PATHOLOGY

Symptomatic appendiceal wall thickening in an HIV–infected patient caused by interleukin–2 therapy. Avila NA, et al. **AJR Am J Roentgenol** 1997 Aug;169(2):499–500
Histochemical study of expression of lectin–reactive carbohydrate epitopes and glycoligand–binding sites in normal human appendix vermiformis, colonic mucosa, acute appendicitis and colonic adenoma. Brinck U, et al. **Histol Histopathol** 1996 Oct;11(4):919–30
Dual carcinoid/epithelial neoplasia of the appendix. Carr NJ, et al. **Histopathology** 1995 Dec;27(6):557–62
Neural hyperplasia in appendix. Naik R. **Indian J Med Sci** 1996 Dec;50(12):339–41
Mucinous cystadenoma of appendix concomitant with perityphlic granuloma. Sato T, et al. **J Gastroenterol** 1995 Dec;30(6):779–82
Histopathologic analysis of interval appendectomy specimens: support for the role of interval appendectomy. Mazziotti MV, et al. **J Pediatr Surg** 1997 Jun;32(6):806–9
Benign epithelial structures on the surface of appendices. Michal M. **Pathology** 1997 Aug;29(3):267–9
Primary acute torsion of the vermiform appendix. Val–Bernal JF, et al. **Pediatr Pathol Lab Med** 1996 Jul–Aug; 16(4):655–61 (25 ref.)
Laparoscopic diagnosis of appendicovesical fistula in a pediatric patient. Yamamoto H, et al. **Surg Laparosc Endosc** 1997 Jun;7(3):266–7
[Mucosal hyperplasia of the appendix (letter)] Paraf F, et al. **Ann Pathol** 1996;16(3):225–6 **(Fre)**
[Hyperplasic polyp of the appendix] Urso C, et al. **Pathologica** 1996 Jun;88(3):200–1 (Eng. Abstr.) **(Ita)**
[Ileocecal and appendiceal lymphoid nodular hyperplasia in a non–immunocompromised patient (letter)] Martínez Albaladejo M, et al. **Rev Esp Enferm Dig** 1996 Dec; 88(12):882–3 **(Spa)**
[Appendiceal mucocele] Flores Rivera AR, et al. **Rev Gastroenterol Mex** 1996 Oct–Dec;61(4):376 **(Spa)**

PHYSIOLOGY

The effect of acute ligation of the rabbit appendix on antioxidant enzymes. Turan C, et al. **Res Exp Med (Berl)** 1996;196(1):45–51

RADIOGRAPHY

Computed tomography of the normal appendix and acute appendicitis. Ghiatas AA, et al. **Eur Radiol** 1997;7(7):1043–7
Helical CT technique for the diagnosis of appendicitis: prospective evaluation of a focused appendix CT examination [see comments] Rao PM, et al. **Radiology** 1997 Jan;202(1):139–44. Comment in: Radiology 1997 Jan;202(1):20–1.
[Can we recognize the pathological character of the appendix during laparoscopy? Prospective study: 81 cases] Champault G, et al. **J Chir (Paris)** 1996 Nov;133(7):320–3 (Eng. Abstr.) **(Fre)**

SURGERY

The in situ appendix in the Malone antegrade continence enema procedure for faecal incontinence. Gerharz EW, et al. **Br J Urol** 1997 Jun;79(6):985–6
Upper gastrointestinal surgery and the appendix. Heemken R, et al. **Eur J Surg Suppl** 1996;(576):61–2
Clinical experience with the detubularized ileocecal reservoir and continent appendicoumbilical stoma in urinary diversion. Nurmi M, et al. **Eur Urol** 1997;31(2):169–72
Mainz pouch with appendix–umbilical stoma using catheterizable conduit elongated with continuous cecal segment: a case report. Okada Y, et al. **Hinyokika Kiyo** 1996 Dec;42(12):973–5
Vermiform appendix sealing sigmoid colon perforation [letter] Adachi Y, et al. **J Clin Gastroenterol** 1996 Sep; 23(2):164
Cholecystoappendicostomy in a child with Alagille syndrome. Gauderer MW, et al. **J Pediatr Surg** 1997 Feb; 32(2):166–7
Laparoscopic appendicostomy for management of fecal incontinence. Webb HW, et al. **J Pediatr Surg** 1997 Mar; 32(3):457–8
Appendiceal cecoplication: a modification of the Malone antegrade colonic enema procedure. Stock JA, et al. **Tech Urol** 1996 Spring;2(1):40–2
[Hepatoporto–appendicostomy. Our experience in 3 cases of biliary cystic disease] Vila JJ, et al. **Cir Pediatr** 1997 Apr; 10(2):82–5 (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

Mucocele formation 20 years after an appendiceal uterine transplantation for infertility mistaken for hydrops tubae profluens. Grisaru D, et al. **Hum Reprod** 1996 Jul; 11(7):1433–4
Urinary reconstruction using appendix as a urinary and catheterizable conduit in 12 patients. Okada Y, et al. **Int J Urol** 1997 Jan;4(1):17–20
Ureteral reconstruction using the vermiform appendix flap in a patient with a post traumatic uretero cutaneous fistula. Astini C, et al. **Trop Doct** 1997 Jan;27(1):47–8
[Ureteral replacement with appendix] Valero Puerta JA, et al. **Arch Esp Urol** 1997 Apr;50(3):297–9 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Acute appendicitis: diagnosis by transvaginal sonography. Caspi B, et al. **Ultrasound Obstet Gynecol** 1996 May; 7(5):359–60
Detection of appendicitis by transvaginal ultrasound: a case report. Larcos G. **Ultrasound Obstet Gynecol** 1996 May; 7(5):361–2
[Mucus secreting tumor of the appendix (appendiceal mucocele)] Merran S. **Presse Med** 1997 Jun 7;26(19):933 **(Fre)**
[Ultrasonography of the normal vermiform appendix] Rettenbacher T, et al. **Ultraschall Med** 1997 Jun; 18(3):139–42 (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

[The endocrinocyte differentiation of the mucosal epithelium of the human appendix] Kostiukevich SV. **Tsitologiia** 1996; 38(10):1069–74 (Eng. Abstr.) **(Rus)**

VIROLOGY

[Adenovirus and intranuclear inclusions in the appendix in children with acute intussusception] Berrebi D, et al. **Ann Pathol** 1997 Apr;17(2):89–93 (Eng. Abstr.) **(Fre)**

APPETITE

see related

APPETITE DEPRESSANTS

Brain Serotonin, Carbohydrate–craving, obesity and depression. Wurtman RJ, et al. **Adv Exp Med Biol** 1996; 398:35–41 (33 ref.)
Hyperpolarization of hepatocytes by 2,5–AM: implications for hepatic control of food intake. Scharrer E, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R874–8
Effect of amount and type of dietary fiber on food intake in energy–restricted dogs. Butterwick RF, et al. **Am J Vet Res** 1997 Mar;58(3):272–6
Impact of definition on prevalence of food cravings in a random sample of young women. Gendall KA, et al. **Appetite** 1997 Feb;28(1):63–72
Independent effects of palatability and within–meal pauses on intake and appetite ratings in human volunteers. Yeomans MR, et al. **Appetite** 1997 Aug;29(1):61–76
Acute effects of exercise on energy intake and feeding behaviour. Imbeault P, et al. **Br J Nutr** 1997 Apr; 77(4):511–21
Effects of short–term exercise on appetite responses in unrestrained females. King NA, et al. **Eur J Clin Nutr** 1996 Oct;50(10):663–7
Gastrointestinal nematodes depress food intake in naturally infected reindeer. Arneberg P, et al. **Parasitology** 1996 Feb; 112 (Pt 2):213–9

DRUG EFFECTS

Leptin–induced decrease in food intake is not associated with changes in gastric emptying in lean mice. Barrachina MD, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R1007–11
Central infusion of the AT1 receptor antagonist losartan inhibits thirst but not sodium appetite in cattle. Blair–West JR, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1940–5
Rapid elicitation of salt appetite by an intravenous infusion of angiotensin II in rats. Fitts DA, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R1092–8
Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Moran TH, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1245–51
Polyethylene glycol–induced calcium appetite. Tordoff MG. **Am J Physiol** 1997 Aug;273(2 Pt 2):R587–96
Effect of alpha–helical–CRF[9–41] on feeding in goldfish: involvement of cortisol and catecholamines. de Pedro N, et al. **Behav Neurosci** 1997 Apr;111(2):398–403
Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? Nierenberg AA, et al. **Biol Psychiatry** 1996 Oct 15;40(8):691–6
Effect of naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study. Zimmermann U, et al. **Biol Psychiatry** 1997 Mar 15; 41(6):747–9
The weight–reducing effect of an intracerebroventricular bolus injection of leptin in genetically obese fa/fa rats. Reduced sensitivity compared with lean animals. Cusin I, et al. **Diabetes** 1996 Oct;45(10):1446–50
Adrenomedullin inhibits salt appetite. Samson WK, et al. **Endocrinology** 1997 Feb;138(2):613–6
Effect of fat– and sucrose–containing foods on the size of eating episodes and energy intake in lean dietary restrained and unrestrained females: potential for causing overconsumption. Green SM, et al. **Eur J Clin Nutr** 1996 Sep;50(9):625–35
Intracerebral administration of mineralocorticoid receptor antisense oligonucleotides attenuate adrenal steroid–induced salt appetite in rats. Sakai RR, et al. **Neuroendocrinology** 1996 Dec;64(6):425–9
Improvements in appetite and growth in helminth–infected schoolboys three and seven weeks after a single dose of pyrantel pamoate. Hadju V, et al. **Parasitology** 1996 Nov; 113 (Pt 5):497–504
Carnitine supplementation accelerates normalization of food intake depressed during TPN. Laviano A, et al. **Physiol Behav** 1996 Jul;60(1):317–20
Short–term effects of alcohol consumption on appetite and energy intake. Poppitt SD, et al. **Physiol Behav** 1996 Oct; 60(4):1063–70
Agmatine enhances caloric intake and dietary carbohydrate preference in satiated rats. Prasad A, et al. **Physiol Behav** 1996 Oct;60(4):1187–9
Deoxycorticosterone acetate (DOCA)–induced sodium appetite in group–housed mice. Rodd ZA, et al. **Physiol Behav** 1996 Nov;60(5):1387–9
The effects of low–, medium–, and high–fat diets on 2–deoxy–D–glucose– and mercaptoacetate–induced feeding. Singer–Koegler LK, et al. **Physiol Behav** 1996 Jul; 60(1):321–3
Effects of beta–CCE on retention of aversively– and appetitively–motivated tasks in rats. Wichlinski LJ, et al. **Physiol Behav** 1996 Oct;60(4):1121–4
Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetizer effect. Yeomans MR, et al. **Physiol Behav** 1997 Jul;62(1):15–21
Brain oxytocin receptor antagonism disinhibits sodium appetite in preweanling rats. Chow SY, et al. **Regul Pept** 1997 Jan 29;68(2):119–24
[Supportive treatment with megestrol acetate during radio(chemo)therapy in patients with tumors in the head–neck area. A randomized study] Fietkau R, et al. **Strahlenther Onkol** 1996 Mar;172(3):162–8 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Altered concentrations of appetite regulators may contribute to the development and maintenance of HIV–associated wasting. Arnalich F, et al. **AIDS** 1997 Jul 15;11(9):1129–34
Effects of small intestinal nutrient infusion on appetite and pyloric motility are modified by age. Cook CG, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):R755–61

Sodium appetite in the sham-drinking rat after chorda tympani nerve transection. Frankmann SP, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):R339-45

Appetite regulation by carbohydrate: role of blood glucose and gastrointestinal hormones. Lavin JH, et al. **Am J Physiol** 1996 Aug;271(2 Pt 1):E209-14

Lateral parabrachial nucleus and serotonergic mechanisms in the control of salt appetite in rats. Menani JV, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):R162-8

Role of renal nerves in sodium depletion-induced salt appetite. Thunhorst RL, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):R806-12

Role of brain angiotensin II in thirst and sodium appetite of sheep. Weisinger RS, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R187-96

Control of human appetite: implications for the intake of dietary fat. Blundell JE, et al. **Annu Rev Nutr** 1996; 16:285-319 (117 ref.)

Palatability and the micro-structure of feeding in humans: the appetizer effect. Yeomans MR. **Appetite** 1996 Oct; 27(2):119-33

Absence of a salt (NaCl) preference or appetite in sodium-replete or depleted kittens. Yu S, et al. **Appetite** 1997 Aug;29(1):1-10

Brainstem lesions and gustatory function: II. The role of the nucleus of the solitary tract in Na+ appetite, conditioned taste aversion, and conditioned odor aversion in rats. Grigson PS, et al. **Behav Neurosci** 1997 Feb;111(1):169-79

Intragastric carbohydrate exerts both intake-stimulating and intake-suppressing effects. Ramirez I. **Behav Neurosci** 1997 Jun;111(3):612-22

Dopamine and sodium appetite: antagonists suppress sham drinking of NaCl solutions in the rat. Roitman MF, et al. **Behav Neurosci** 1997 Jun;111(3):606-11

Gustatory functions, sodium appetite, and conditioned taste aversion survive excitotoxic lesions of the thalamic taste area. Scalera G, et al. **Behav Neurosci** 1997 Jun; 111(3):633-45

Interaction of hydration and subfornical organ lesions in sodium-depletion induced salt appetite. Starbuck EM, et al. **Behav Neurosci** 1997 Feb;111(1):206-13

Overconsumption as a cause of weight gain: behavioural-physiological interactions in the control of food intake (appetite). Blundell JE, et al. **Ciba Found Symp** 1996;201:138-54; discussion 154-8, 188-93 (69 ref.)

Sodium status, corticosteroid metabolism and blood pressure in normal human subjects and in a patient with abnormal salt appetite. Ingram MC, et al. **Clin Exp Pharmacol Physiol** 1996 May;23(5):375-8

Shedding new light on obesity. Appetite regulation. Billington CJ, et al. **Curr Biol** 1996 Aug 1;6(8):920-3 (29 ref.)

Effect of overfeeding macronutrients on day-to-day food intake in man. Johnstone AM, et al. **Eur J Clin Nutr** 1996 Jul;50(7):418-30

High dose exercise does not increase hunger or energy intake in free living males. King NA, et al. **Eur J Clin Nutr** 1997 Jul;51(7):478-83

Breakfasts high in protein, fat or carbohydrate: effect on within-day appetite and energy balance. Stubbs RJ, et al. **Eur J Clin Nutr** 1996 Jul;50(7):409-17

The neuroendocrinology of thirst and salt appetite: visceral sensory signals and mechanisms of central integration. Johnson AK, et al. **Front Neuroendocrinol** 1997 Jul; 18(3):292-353 (369 ref.)

Reduced meal-related gastrointestinal hormone response to adrenocorticotropic hormone stimulation test in female athletes. Lindén Hirschberg A, et al. **Gynecol Endocrinol** 1997 Apr;11(2):83-9

Menstrual cycle and appetite control: implications for weight regulation. Dye L, et al. **Hum Reprod** 1997 Jun; 12(6):1142-51 (104 ref.)

Gender-specific aspects of obesity. Legato MJ. **Int J Fertil Womens Med** 1997 May-Jun;42(3):184-97 (162 ref.)

Effects of amount and type of dietary fibre (soluble and insoluble) on short-term control of appetite. Delargy HJ, et al. **Int J Food Sci Nutr** 1997 Jan;48(1):67-77

Treatment with weak electromagnetic fields attenuates carbohydrate craving in a patients with multiple sclerosis. Sandyk R. **Int J Neurosci** 1996 Jul;86(1-2):67-77

Inhibitory avoidance and appetitive learning in aged normal mice: comparison with transgenic mice having elevated plasma growth hormone levels. Meliska CJ, et al. **Neurobiol Learn Mem** 1997 Jul;68(1):1-12

Appetite and body weight regulation: is it all in the brain? Kalra SP. **Neuron** 1997 Aug;19(2):227-30 (22 ref.)

Neural cell adhesion molecules play a role in rat memory formation in appetitive as well as aversive tasks. Roullet P, et al. **Neuroreport** 1997 May 27;8(8):1907-11

Increased sodium appetite stimulates c-fos expression in the organum vasculosum of the lamina terminalis. Lane JM, et al. **Neuroscience** 1997 Jun;78(4):1167-76

Relationship between serum amino acid concentration and fluctuations in appetite. 1956 [classical article] [see comments] Mellinkoff SM, et al. **Obes Res** 1997 Jul; 5(4):381-4. Comment in: Obes Res 1997 Jul;5(4):373-6.

Na depletion-induced Na appetite of sheep is independent of brain angiotensin II. Weisinger RS, et al. **Physiol Behav** 1997 Jul;62(1):43-51

The role of angiotensin II in ingestive behaviour: a brief review of angiotensin II, thirst and Na appetite. Weisinger RS, et al. **Regul Pept** 1996 Oct 8;66(1-2):73-81 (100 ref.)

APPETITE DEPRESSANTS

Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Moran TH, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1245-51

An examination of subtype criteria for bulimia nervosa. Tobin DL, et al. **Int J Eat Disord** 1997 Sep;22(2):179-86

Dexfenfluramine [editorial] Goldstein DJ. **Nutrition** 1997 Jan; 13(1):51-2

ADMINISTRATION & DOSAGE

A dangerous duo? A combination of common diet drugs (fen-phen) may lead to heart valve disease [editorial] Boughner DR. **CMAJ** 1997 Sep 15;157(6):705-6

ADVERSE EFFECTS

Pharmacovigilance--should the experts agree to differ? Dower M. **Adverse Drug React Toxicol Rev** 1996 Aug; 15(3):167-71

Report links appetite suppressants with heart disease. FDA encourages reporting of like events [news] **Am J Health Syst Pharm** 1997 Aug 15;54(16):1785, 1788

FDA proposes constraints on ephedrine dietary supplements [news] **Am J Health Syst Pharm** 1997 Jul 15;54(14):1578

Effects of chronic dexfenfluramine treatment on pulmonary hemodynamics in dogs. Naeije R, et al. **Am J Respir Crit Care Med** 1996 Nov;154(5):1347-50

Obesity, dexfenfluramine, and pulmonary hypertension. A lesson not learned? Voelkel NF, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):786-8

Mitral valve disease associated with use of anorexigenic medications [letter] Newman R. **Ann Thorac Surg** 1997 Jul; 64(1):294

Weighing benefits and risks of drug to treat obesity [letter] [see comments] Sukkari SR. **Can Med Assoc J** 1997 Mar 15;156(6):768-9. Comment in: Can Med Assoc J 1997 Apr 1;156(7):978. Comment in: CMAJ 1997 Jul 1;157(1):14, 16.

Primary pulmonary hypertension and long-term use of appetite suppressants [news] Sztuke-Fournier A. **Can Med Assoc J** 1997 Jan 1;156(1):89-90, 93-4 **(Eng, Fre)**

The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Frank H, et al. **Chest** 1997 Sep;112(3):714-21

Fen-phen and risk of valvular disease [news] SoRelle R. **Circulation** 1997 Sep 16;96(6):1705-6

Pupillary changes associated with the development of stimulant-induced mania: a case report. Rosse RB, et al. **Clin Neuropharmacol** 1997 Jun;20(3):270-5

A dangerous duo? A combination of common diet drugs (fen-phen) may lead to heart valve disease [editorial] Boughner DR. **CMAJ** 1997 Sep 15;157(6):705-6

Debate over dexfenfluramine [letter; comment] Deitel M. **CMAJ** 1997 Jul 1;157(1):14, 16. Comment on: Can Med Assoc J 1997 Mar 15;156(6):768-9.

Obesity and an abnormal ECG. Hancock EW. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):19-20

Phentermine, psychosis, and family history [letter] Cleare AJ. **J Clin Psychopharmacol** 1996 Dec;16(6):470-1

Diet drugs and pulmonary hypertension. Havron MD Jr. **J Fam Pract** 1996 Nov;43(5):434-5

Obesity and the diet pill dilemma [editorial] Healy BP. **J Womens Health** 1997 Aug;6(4):391-2

Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. McCann UD, et al. **JAMA** 1997 Aug 27;278(8):666-72 (107 ref.)

From the Food and Drug Administration. Nightingale SL. **JAMA** 1997 Aug 6;278(5):379

Valvular heart disease associated with dexfenfluramine [letter] Cannistra LB, et al. **N Engl J Med** 1997 Aug 28; 337(9):636

Valvular heart disease associated with fenfluramine-phentermine [see comments] Connolly HM, et al. **N Engl J Med** 1997 Aug 28;337(9):581-8. Comment in: N Engl J Med 1997 Aug 28;337(9):629-30.

Diet pills redux [editorial; comment] Curfman GD. **N Engl J Med** 1997 Aug 28;337(9):629-30. Comment on: N Engl J Med 1997 Aug 28;337(9):581-8. Comment on: N Engl J Med 1997 Aug 28;337(9):602-6.

Appetite-suppressant drugs and primary pulmonary hypertension [letter; comment] Dhurandhar NV, et al. **N Engl J Med** 1997 Feb 13;336(7):511-2; discussion 512-3 . Comment on: N Engl J Med 1996 Aug 29;335(9):609-16.

Appetite-suppressant drugs and primary pulmonary hypertension [letter; comment] Fishman AP. **N Engl J Med** 1997 Feb 13;336(7):511; discussion 512-3. Comment on: N Engl J Med 1996 Aug 29;335(9):609-16.

Further cases of valvular heart disease associated with fenfluramine-phentermine [letter] Graham DJ, et al. **N Engl J Med** 1997 Aug 28;337(9):635

Appetite-suppressant drugs and primary pulmonary hypertension [letter; comment] Hoffman RM, et al. **N Engl J Med** 1997 Feb 13;336(7):511; discussion 512-3. Comment on: N Engl J Med 1996 Aug 29;335(9):609-16.

Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine [see comments] Mark EJ, et al. **N Engl J Med** 1997 Aug 28;337(9):602-6. Comment in: N Engl J Med 1997 Aug 28;337(9):629-30.

Appetite-suppressant drugs and primary pulmonary hypertension [letter; comment] Schembre DB, et al. **N Engl J Med** 1997 Feb 13;336(7):510-1; discussion 512-3 . Comment on: N Engl J Med 1996 Aug 29;335(9):609-16.

Appetite-suppressant drugs and primary pulmonary hypertension [letter; comment] Williamson DF. **N Engl J Med** 1997 Feb 13;336(7):512; discussion 512-3. Comment on: N Engl J Med 1996 Aug 29;335(9):609-16.

Cerebral hemorrhage in a patient taking fenfluramine and phentermine for obesity. Wen PY, et al. **Neurology** 1997 Aug;49(2):632-3

d-fenfluramine anorexia: dissociation of ingestion rate, meal duration, and meal size effects. Kaplan JM, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):223-9

Drug-induced pulmonary hypertension: must history repeat itself? [editorial] Voelkel NF. **Pulm Pharmacol** 1996 Apr; 9(2):67-8

Dangerously revved. Ephedrine misuse poses health hazards. Jones TL. **Tex Med** 1996 May;92(5):52-3

[Treatment of obesity: are anorectics safe?] Kutnowski M. **J Pharm Belg** 1996 Jul-Aug;51(4):227 **(Fre)**

[Appetite depressant drugs and the risk of primary pulmonary hypertension] Olschewski H. **Pneumologie** 1997 Jun; 51(6):575-6 **(Ger)**

[Pharmacological, toxicological, deontologic, and medico-legal aspects of the use of appetite suppressant agents in "weight-loss cures"] Carolei L, et al. **Minerva Med** 1997 Jul-Aug;88(7-8):317-26 (Eng. Abstr.) **(Ita)**

[Behavioral changes induced by repeated administration of mazindol, an anorexiant, in rats] Kawakami Y, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Aug; 16(4):139-43 (Eng. Abstr.) **(Jpn)**

[Interactions with cold remedies and weight reducing drugs (letter)] Iwata J, et al. **Nippon Naika Gakkai Zasshi** 1996 Oct 10;85(10):1786 **(Jpn)**

ANALYSIS

Chiral gas chromatographic determination of ephedrine-type alkaloids in dietary supplements containing Má Huáng. Betz JM, et al. **J AOAC Int** 1997 Mar-Apr;80(2):303-15

Fluorimetric method of analysis for D-norpseudoephedrine hydrochloride, glycine and L-glutamic acid by reversed-phase high-performance liquid chromatography. Swanepoel E, et al. **J Chromatogr A** 1996 Apr 5; 729(1-2):287-91

METABOLISM

Acetylation of or beta-cyclodextrin addition to potato beneficial effect on glucose metabolism and appetite sensations. Raben A, et al. **Am J Clin Nutr** 1997 Aug; 66(2):304-14

Detection of amphetamine following administration of fenproporex. Cody JT, et al. **J Anal Toxicol** 1996 Oct; 20(6):425-31

Measurement of dexfenfluramine metabolism in rat liver microsomes by gas chromatography-mass spectrometry. Haritos VS, et al. **J Chromatogr B Biomed Appl** 1997 Jun 6;693(2):327-36

Location and effect of obesity on putative anorectic binding sites in the rat brain. Dunn-Meynell AA, et al. **Obes Res** 1997 May;5(3):201-7

PHARMACOLOGY

A central cholinergic link in the cardiovascular effects of the benzodiazepine receptor partial inverse agonist FG 7142. Berntson GG, et al. **Behav Brain Res** 1996 Jan; 74(1-2):91-103

Satietin: Fos mapping of putative brain sites of action. Rowland NE, et al. **Brain Res** 1996 Apr 22;717(1-2):189-92

A comparative study of the anorectic and behavioral effects of fenproporex on male and female rats. Mattei R, et al. **Braz J Med Biol Res** 1996 Aug;29(8):1025-30

Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Weir EK, et al. **Circulation** 1996 Nov 1;94(9):2216-20

Anti-obesity and anti-diabetic effects of mazindol in yellow KK mice: its activating effect on brown adipose tissue thermogenesis. Yoshida T, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul;23(6-7):476-82

The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain. Nørregaard J, et al. **Clin Pharmacol Ther** 1996 Dec;60(6):679-86

An investigation of the mechanism responsible for fluoxetine-induced hypophagia in rats. Lightowler S, et al. **Eur J Pharmacol** 1996 Jan 25;296(2):137-43

Metabolic indices in relation to body composition changes during weight loss on Dexfenfluramine in obese women from two South African ethnic groups. van der Merwe MT, et al. **Int J Obes Relat Metab Disord** 1996 Aug; 20(8):768-76

Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent. Hirst GC, et al. **J Med Chem** 1996 Dec 20;39(26):5236-45

Effects of dietary Spirulina maxima on endothelium dependent vasomotor responses of rat aortic rings. Paredes-Carbajal MC, et al. **Life Sci** 1997;61(15):PL 211-9

In vitro and in vivo effects of the anorectic agent

dexfenfluramine on the central serotoninergic neuronal systems of non-human primates. A comparison with the rat. Mennini T, et al.
Naunyn Schmiedebergs Arch Pharmacol 1996 May; 353(6):641-7

Clozapine reverses the spatial working memory deficits induced by FG7142 in monkeys. Murphy BL, et al.
Neuropsychopharmacology 1997 Jun;16(6):433-7

Anorexia induced by activators of the signal transducer gp 130. Plata-Salamán CR. **Neuroreport** 1996 Feb 29; 7(3):841-4

The fenfluramine/phentermine combination for weight loss [letter] Garrett SD, et al. **Nurse Pract** 1997 Aug;22(8):166, 168, 170 (13 ref.)

The histaminergic, but not the serotoninergic, system mediates amylin's anorectic effect. Lutz TA, et al.
Peptides 1996;17(8):1317-22

Neuropharmacological effects of low and high doses of repeated oral dexfenfluramine in rats: a comparison with fluoxetine. Caccia S, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):851-6

Amylin and food intake in mice: effects on motivation to eat and mechanism of action. Morley JE, et al.
Pharmacol Biochem Behav 1997 Jan;56(1):123-9

Tolerance does not develop to the suppressant effects of (-)-norpseudoephedrine on ingestive behavior in the rat. Nencini P, et al. **Pharmacol Biochem Behav** 1996 Feb; 53(2):297-301

Effects of the alpha 1a-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats. Wellman PJ, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):281-4

Clobenzorex: evidence for amphetamine-like behavioral actions. Young R, et al. **Pharmacol Biochem Behav** 1997 Feb;56(2):311-6

Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory. Foltin RW, et al. **Physiol Behav** 1996 Feb;59(2):295-305

Devazepide attenuates dl-fenfluramine-induced suppression of gastric emptying but not food intake in the 17 h food-deprived rat. Francis J, et al. **Physiol Behav** 1997 Sep; 62(3):545-50

d-fenfluramine's effects on normal ingestion assessed with taste reactivity measures. Gray RW, et al.
Physiol Behav 1996 Jun;59(6):1129-35

Glucoprivation attenuates the hypophagia induced by epinephrine in mice. Villanueva I, et al. **Physiol Behav** 1996 Nov;60(5):1383-6

Exposure to sweetened solutions enhances the anorectic effect of naloxone but not d-fenfluramine. Yeomans MR, et al. **Physiol Behav** 1997 Aug;62(2):255-62

Contribution of caudal brainstem to d-fenfluramine anorexia. Grill HJ, et al. **Psychopharmacology (Berl)** 1997 Apr; 130(4):375-81

Behavioral reactivity to aversive stimuli in a transgenic mouse model of impaired glucocorticoid (type II) receptor function: effects of diazepam and FG-7142. Rochford J, et al. **Psychopharmacology (Berl)** 1997 Jul;132(2):145-52

Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype. Vickers SP, et al. **Psychopharmacology (Berl)** 1996 May; 125(2):168-75

Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability [see comments] Curzon G, et al. **Trends Pharmacol Sci** 1997 Jan;18(1):21-5 (51 ref.). Comment in: Trends Pharmacol Sci 1997 Jun;18(6):191-2.

POISONING

Poisoning with fenfluramine. Gupta D, et al.
J Assoc Physicians India 1996 Oct;44(10):739

From the Centers for Disease Control and Prevention. Adverse events associated with ephedrine-containing products--Texas, December 1993-September 1995.
JAMA 1996 Dec 4;276(21):1711-2

THERAPEUTIC USE

d-fenfluramine treatment of binge eating disorder. Stunkard A, et al. **Am J Psychiatry** 1996 Nov;153(11):1455-9

Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity [letter] Anchors M.
Arch Intern Med 1997 Jun 9;157(11):1270

A case of Prader-Willi syndrome with long-term mazindol treatment [letter] Inui A, et al. **Arch Intern Med** 1997 Feb 24;157(4):464

The treatment of obesity. A call for prudence and professionalism. Kushner R. **Arch Intern Med** 1997 Mar 24;157(6):602-4 (19 ref.)

Drugs for obesity are last resort treatment [news] Bower H. **BMJ** 1997 Jun 7;314(7095):1643

Drug to treat obesity: editorial writer responds [letter; comment] Faich GA. **Can Med Assoc J** 1997 Apr 1; 156(7):978. Comment on: Can Med Assoc J 1997 Mar 15;156(6):768-9.

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Davis R, et al. **Drugs** 1996 Nov;52(5):696-724 (167 ref.)

Effect of mazindol on body weight and insulin sensitivity in severely obese patients after a very-low-calorie diet therapy. Nishikawa T, et al. **Endocr J** 1996 Dec;43(6):671-7

Medicating the obese patient. Ryan DH.
Endocrinol Metab Clin North Am 1996 Dec;25(4):989-1004 (32 ref.)

Evaluation of dexfenfluramine in a weight loss program for obese infertile women. Galletly C, et al.
Int J Eat Disord 1996 Mar;19(2):209-12

Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. Swinburn BA, et al.
Int J Obes Relat Metab Disord 1996 Nov;20(11):1033-40

Serotoninergic drug-induced weight loss in carbohydrate craving obese patients. Toornvliet AC, et al.
Int J Obes Relat Metab Disord 1996 Oct;20(10):917-20

Iowa patients want new anti-obesity drug. Belling W.
Iowa Med 1996 Sep;86(7):278-9

The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity. Ditschuneit HH, et al.
J Cardiovasc Risk 1996 Aug;3(4):397-403

Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. Pontiroli AE, et al.
J Clin Endocrinol Metab 1996 Oct;81(10):3727-32

New agent for obesity management [letter; comment] Barkin RL. **J Fam Pract** 1996 Sep;43(3):224. Comment on: J Fam Pract 1996 Mar;42(3):287-92.

Appetite suppressants for obesity [letter; comment] Budenholzer B. **J Fam Pract** 1997 Jan;44(1):19-20. Comment on: J Fam Pract 1996 Mar;42(3):287-92. Comment on: J Fam Pract 1996 Sep;43(3):224; discussion 225. Comment on: J Fam Pract 1996 Sep;43(3):225.

New agent for obesity management [letter; comment] [see comments] Clemenson ND. **J Fam Pract** 1996 Sep; 43(3):224; discussion 225. Comment on: J Fam Pract 1996 Mar;42(3):287-92. Comment in: J Fam Pract 1997 Jan;44(1):19-20.

New agent for obesity management [letter; comment] [see comments] Schmitt SA. **J Fam Pract** 1996 Sep;43(3):225. Comment on: J Fam Pract 1996 Mar;42(3):287-92. Comment in: J Fam Pract 1997 Jan;44(1):19-20.

The pharmacologic management of obesity. Cerda JJ.
J Fla Med Assoc 1997 Feb;84(2):89-92

Predictors of weight loss during treatment with d-fenfluramine. Toornvliet AC, et al. **J Intern Med** 1997 May;241(5):401-6

Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity [see comments] **JAMA** 1996 Dec 18; 276(23):1907-15 (117 ref.). Comment in: JAMA 1997 Apr 16;277(15):1201; discussion 1202. Comment in: JAMA 1997 Apr 16;277(15):1201-2; discussion 1202.

Pharmacotherapy in the management of obesity [letter; comment] Steelman M. **JAMA** 1997 Apr 16;277(15):1201-2; discussion 1202. Comment on: JAMA 1996 Dec 18;276(23):1907-15.

Pharmacotherapy in the management of obesity [letter; comment] Tiedt TN. **JAMA** 1997 Apr 16;277(15):1201; discussion 1202. Comment on: JAMA 1996 Dec 18;276(23):1907-15.

Three cases of comprehensive dietary therapy and pharmacotherapy of patients with complex obesity-related diseases. DeMeo MT, et al. **Nutr Rev** 1997 Aug; 55(8):297-302

Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. Wadden TA, et al. **Obes Res** 1997 May; 5(3):218-26

[Treatment of obesity: are drug combinations effective?] Jandrain B. **J Pharm Belg** 1996 Jul-Aug;51(4):228-30 **(Fre)**

[Treatment of obesity: are anorectics effective?] Thissen JP. **J Pharm Belg** 1996 Jul-Aug;51(4):226 **(Fre)**

[Tolerance and acceptability of dexfenfluramine in the long-term treatment of obesity in private practice. ESIM Group] Héraïef E. **Rev Med Suisse Romande** 1997 Jan; 117(1):19-24 (Eng. Abstr.) **(Fre)**

[A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group] Enzi G. **Ter Arkh** 1997;69(5):71-5 (Eng. Abstr.) **(Rus)**

[The psychophysiological aspects of treating obesity with Izolipan] Voznesenskaia TG, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1996;96(4):59-62 (Eng. Abstr.) **(Rus)**

TOXICITY

Effects of phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse brain. Baumann MH, et al. **Drug Alcohol Depend** 1996 May;41(1):71-4

Chronic fenfluramine treatment of rats with different ages: effects on brain oxidative stress-related parameters. D'Almeida V, et al. **J Biochem Toxicol** 1996;11(4):197-201

The effects of aminorex and related compounds on brain monoamines and metabolites in CBA mice. Zheng Y, et al. **J Pharm Pharmacol** 1997 Jan;49(1):89-96

Repeated administration of escalating high doses of dexfenfluramine does not produce morphological evidence for neurotoxicity in the cortex of rats. Rose S, et al.
Neurodegeneration 1996 Jun;5(2):145-52

Assessment of the role of oxytocin receptors in phenylpropanolamine-induced anorexia in rats. McMahon LR, et al. **Pharmacol Biochem Behav** 1997 Aug;57(4):767-70

Experimental toxicity of verbesina encelioides in sheep and isolation of galegine. Lopez TA, et al.
Vet Hum Toxicol 1996 Dec;38(6):417-9

APPETITE DISORDERS see EATING DISORDERS

APPETITE REGULATION

Substitution and caloric regulation in a closed economy. Bauman RA, et al. **J Exp Anal Behav** 1996 Mar; 65(2):401-22

DRUG EFFECTS

Present and future pharmacological approaches. Finer N.
Br Med Bull 1997;53(2):409-32 (109 ref.)

Full expression of the exaggerated salt appetite of the spontaneously hypertensive rat requires a prenatal factor. Erkadius E, et al. **Clin Exp Pharmacol Physiol** 1996 Jun-Jul; 23(6-7):619-20

Sodium mercaptoacetate is not a useful probe to study the role of fat in regulation of feed intake in dairy cattle. Choi BR, et al. **J Nutr** 1997 Jan;127(1):171-6

GENETICS

Sucrose consumption in mice: major influence of two genetic loci affecting peripheral sensory responses. Bachmanov AA, et al. **Mamm Genome** 1997 Aug;8(8):545-8

PHYSIOLOGY

Serum leptin and short-term regulation of eating in obese women. Karhunen L, et al. **Clin Sci (Colch)** 1997 Jun; 92(6):573-8

Regulation of appetite and body weight. Schwartz MW.
Hosp Pract (Off Ed) 1997 Jul 15;32(7):109-12, 117-9 (6 ref.)

Effects of exercise on appetite control: implications for energy balance. King NA, et al. **Med Sci Sports Exerc** 1997 Aug;29(8):1076-89 (110 ref.)

Ill fitting genes: the biology of weight and shape control in relation to body composition and eating disorders [editorial] Treasure J, et al. **Psychol Med** 1997 May; 27(3):505-8

Increased sodium appetite and thirst in rat induced by the ingredients of liquorice, glycyrrhizic acid and glycyrrhetinic acid. Cooney AS, et al. **Regul Pept** 1996 Oct 8;66(1-2):127-33

Angiotensin II receptor subtype antagonists can both stimulate and inhibit salt appetite in rats. Liénard F, et al. **Regul Pept** 1996 Oct 8;66(1-2):87-94

Effects of the selective tachykinin NK3 receptor agonist NH2-senktide on intraoral intake and taste reactivity responses elicited by NaCl in sodium-replete rats. Polidori C, et al. **Regul Pept** 1996 Oct 8;66(1-2):101-4

Central inhibition of salt appetite by oxytocin in rats. Stricker EM, et al. **Regul Pept** 1996 Oct 8;66(1-2):83-5 (25 ref.)

Increased salt preference in adult offspring raised by mother rats consuming excessive amounts of salt and water. Vijande M, et al. **Regul Pept** 1996 Oct 8;66(1-2):105-8

APPETITE STIMULANTS

ADMINISTRATION & DOSAGE

Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Chance WT, et al. **Peptides** 1996;17(5):797-801

ADVERSE EFFECTS

The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Whitfield RM, et al. **Alcohol Clin Exp Res** 1997 Feb;21(1):122-7

Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Mann M, et al. **Arch Intern Med** 1997 Aug 11-25; 157(15):1651-6 (23 ref.)

Hypospadias associated with the use of high dose megestrol acetate in an HIV infected woman [letter] Farrar DJ, et al. **Genitourin Med** 1997 Jun;73(3):226

PHARMACOLOGY

Effect of the appetite stimulant cyproheptadine on deoxynivalenol-induced reductions in feed consumption and weight gain in the mouse. Prelusky DB, et al.
J Environ Sci Health B 1997 May;32(3):429-48

Interaction of the hypothalamic paraventricular nucleus and central nucleus of the amygdala in naloxone blockade of neuropeptide Y-induced feeding revealed by c-fos expression. Pomonis JD, et al. **J Neurosci** 1997 Jul 1; 17(13):5175-82

Neuropeptide Y-enhanced diuresis and natriuresis in anaesthetized rats is independent of renal blood flow reduction. Bischoff A, et al. **J Physiol (Lond)** 1996 Sep 1;495 (Pt 2):525-34

Neuropeptide Y treatment and food deprivation increase cyclic AMP response element-binding in rat hypothalamus. Sheriff S, et al. **Mol Pharmacol** 1997 Apr;51(4):597-604

Effect of cyproheptadine hydrochloride on ingestive behaviors. Konstandi M, et al. **Pharmacol Res** 1996 Jan;

33(1):35–40
Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis. Playford RJ, et al. **Trends Pharmacol Sci** 1996 Dec;17(12):436–8 (41 ref.)

THERAPEUTIC USE

Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumours. Azcona C, et al. **Aliment Pharmacol Ther** 1996 Aug;10(4):577–86
Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. Beller E, et al. **Ann Oncol** 1997 Mar;8(3):277–83
The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Strang P. **Anticancer Res** 1997 Jan–Feb;17(1B):657–62 (36 ref.)
Megestrol for appetite stimulation and as a progestin in hormone replacement therapy [letter] Rance LB, et al. **Arch Intern Med** 1996 Nov 25;156(21):2498
A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. McMillan DC, et al. **Br J Cancer** 1997;76(6):788–90
Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. Fietkau R, et al. **Eur J Cancer** 1997 Jan;33(1):75–9
Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Beal JE, et al. **J Pain Symptom Manage** 1997 Jul;14(1):7–14
Re: Donnelley and Walsh letter to the editor [letter; comment] Daniels M. **J Pain Symptom Manage** 1996 Oct; 12(4):208. Comment on: J Pain Symptom Manage 1995 Apr;10(3):182–3.
Effect of megestrol acetate and prepulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy. Chen HC, et al. **Radiother Oncol** 1997 Apr;43(1):75–9

APPETITE SUPPRESSANTS see **APPETITE DEPRESSANTS**

APPETITIVE BEHAVIOR

see related
CEREMONIAL

Behavioural feedback to risk variation ensues from unsatisfied appetency. Dussault C. **Accid Anal Prev** 1996 Jul; 28(4):477–86 (20 ref.)
Sensitization of ingestive responding in preweanling rats: time course and specificity. Myers KP, et al. **Behav Neurosci** 1997 Apr;111(2):413–23
Ontogeny of copepod predation in juvenile squid (Loligo opalescens). Chen DS, et al. **Biol Bull** 1996 Feb; 190(1):69–81
Olfactory basis of host location by mosquitoes and other haematophagous Diptera. Cork A. **Ciba Found Symp** 1996; 200:71–84; discussion 84–8 (78 ref.)
Odours for host-finding mosquitoes. Costantini C. **Ciba Found Symp** 1996;200:124–31 (48 ref.)
An overview of mosquito biology, behaviour and importance. Curtis CF. **Ciba Found Symp** 1996;200:3–7 (15 ref.)
Olfactory control of mosquito behaviour. Davis EE. **Ciba Found Symp** 1996;200:48–53 (12 ref.)
Genetics, ecology and behaviour of anophelines. Gibson G. **Ciba Found Symp** 1996;200:22–37; discussion 37–47 (43 ref.)
Endogenous factors regulating mosquito host-seeking behaviour. Klowden MJ. **Ciba Found Symp** 1996; 200:212–23; discussion 223–32 (51 ref.)
Ecology: engineered food webs. Manne L, et al. **Curr Biol** 1996 Jan 1;6(1):29–31 (5 ref.)
The influence of natural preference for tactile stimuli on appetitive learning in rat pups. Rakover-Atar S, et al. **Dev Psychobiol** 1997 Jan;30(1):29–39
Effects of short-term food deprivation and chronic dietary restraint on the selective processing of appetitive-related cues. Stewart SH, et al. **Int J Eat Disord** 1997 Mar; 21(2):129–35
Response of wild Anopheles funestus to repellent-protected volunteers is unaffected by malaria infection of the vector. Copeland RS, et al. **J Am Mosq Control Assoc** 1995 Dec; 11(4):438–40
Nectar-related olfactory and visual attractants for mosquitoes. Foster WA, et al. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 2):288–96 (83 ref.)
Endogenous regulation of the attraction of Aedes aegypti mosquitoes. Klowden MJ. **J Am Mosq Control Assoc** 1994 Jun;10(2 Pt 2):326–32 (55 ref.)
Differential attraction of Venezuelan Anophelines to human collectors. Rubio-Palis Y. **J Am Mosq Control Assoc** 1995 Dec;11(4):482–4
Factors affecting membrane feeding of Anopheles stephensi. Samish M, et al. **J Am Mosq Control Assoc** 1995 Dec; 11(4):408–15
Use of olfactory cues in foraging by owl monkeys (Aotus nancymai) and capuchin monkeys (Cebus apella). Bolen RH, et al. **J Comp Psychol** 1997 Jun;111(2):152–8
Mode of foraging competition is related to tutor preference in Zenaida aurita. Dolman CS, et al. **J Comp Psychol** 1996 Mar;110(1):45–54
Developmental changes in manipulation in tufted capuchins (Cebus apella) from birth through 2 years and their relation to foraging and weaning. Fragaszy DM, et al. **J Comp Psychol** 1997 Jun;111(2):201–11
Development of stone tool use by wild chimpanzees (Pan troglodytes). Inoue-Nakamura N, et al. **J Comp Psychol** 1997 Jun;111(2):159–73
Spontaneous use of matching visual cues during foraging by long-tailed macaques (Macaca fascicularis). Menzel CR. **J Comp Psychol** 1996 Dec;110(4):370–6
Substitution and caloric regulation in a closed economy. Bauman RA, et al. **J Exp Anal Behav** 1996 Mar; 65(2):401–22
Running and responding reinforced by the opportunity to run: effect of reinforcer duration. Belke TW. **J Exp Anal Behav** 1997 May;67(3):337–51
Meal patterns of cats encountering variable food procurement cost. Collier G, et al. **J Exp Anal Behav** 1997 May; 67(3):303–10
Body weight and response acquisition with delayed reinforcement. Lattal KA, et al. **J Exp Anal Behav** 1997 Jan;67(1):131–43
Key-peck probability and topography in a concurrent variable-interval variable-interval schedule with food and water reinforcers. Ploog BO, et al. **J Exp Anal Behav** 1997 Jan;67(1):109–29
Determination of discount functions in rats with an adjusting-amount procedure. Richards JB, et al. **J Exp Anal Behav** 1997 May;67(3):353–66
Key pecking during extinction after intermittent or continuous reinforcement as a function of the number of reinforcers delivered during training. Zarcone TJ, et al. **J Exp Anal Behav** 1997 Jan;67(1):91–108
Effects of repeated disorientation on the acquisition of spatial tasks in rats: dissociation between the appetitive radial arm maze and aversive water maze. Dudchenko PA, et al. **J Exp Psychol Anim Behav Process** 1997 Apr;23(2):194–210
Bayesian analysis of foraging by pigeons (Columba livia). Killeen PR, et al. **J Exp Psychol Anim Behav Process** 1996 Oct;22(4):480–96
Cyclic responding by pigeons on the peak timing procedure. Kirkpatrick-Steger K, et al. **J Exp Psychol Anim Behav Process** 1996 Oct;22(4):447–60
Adjusting to changes in the time of reinforcement: peak-interval transitions in rats. Lejeune H, et al. **J Exp Psychol Anim Behav Process** 1997 Apr;23(2):211–31
The work costs of earning food as a determinant of patch leaving. Mitchell SH, et al. **J Exp Psychol Anim Behav Process** 1997 Apr;23(2):136–44
Host-feeding patterns of domiciliary Triatoma infestans (Hemiptera: Reduviidae) in Northwest Argentina: seasonal and instar variation. Gurtler RE, et al. **J Med Entomol** 1996 Jan;33(1):15–26
Attraction and trapping of Aedes aegypti (Diptera: Culicidae) with host odors in the laboratory. McCall PJ, et al. **J Med Entomol** 1996 Jan;33(1):177–9
Human individuals vary in attractiveness for host-seeking black flies (Diptera: Simuliidae) based on exhaled carbon dioxide. Schofield SW, et al. **J Med Entomol** 1996 Jan; 33(1):102–8
The responses of Lucilia cuprina to odours from sheep, offal and bacterial cultures. Morris MC, et al. **Med Vet Entomol** 1997 Jan;11(1):58–64
Schistosoma mansoni miracidial host-finding: species specificity of an Egyptian strain. Kalbe M, et al. **Parasitol Res** 1996;82(1):8–13
Why do pouched mice (Saccostomus campestris) hoard food? Ellison GT. **Physiol Behav** 1996 Feb;59(2):375–81
Landmark stability: further studies pointing to a role in spatial learning. Biegler R, et al. **Q J Exp Psychol B** 1996 Nov; 49(4):307–45
Bidirectional instrumental conditioning. Dickinson A, et al. **Q J Exp Psychol B** 1996 Nov;49(4):289–306
Combining operant-baseline-derived conditioned excitors and inhibitors from the same and different incentive classes: an investigation of appetitive-aversive interactions. Weiss SJ, et al. **Q J Exp Psychol B** 1996 Nov;49(4):357–81
Malaria in Côte d'Ivoire wet savannah region: the entomological input. Dossou-yovo J, et al. **Trop Med Parasitol** 1995 Dec;46(4):263–9

DRUG EFFECTS

Lead-induced changes in NMDA receptor complex binding: correlations with learning accuracy and with sensitivity to learning impairments caused by MK-801 and NMDA administration. Cory-Slechta DA, et al. **Behav Brain Res** 1997 May;85(2):161–74
Aromatase inhibition blocks the activation and sexual differentiation of appetitive male sexual behavior in Japanese quail. Balthazart J, et al. **Behav Neurosci** 1997 Apr;111(2):381–97
Tolerance and cross tolerance to the accuracy- and rate-decreasing effects of mu opioids in rats responding under a fixed-consecutive-number schedule. Smith MA, et al. **Drug Alcohol Depend** 1997 Jun 6;46(1–2):19–30
Dopaminergic modulation of visual responses in toads. I. Apomorphine-induced effects on visually directed appetitive and consummatory prey-catching behavior. Glagow M, et al. **J Comp Physiol [A]** 1997 Jan;180(1):1–9
Aspartame's effects on behavioral thermoregulation in albino rats. Vituli WF, et al. **Percept Mot Skills** 1996 Aug; 83(1):15–20
Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype. Vickers SP, et al. **Psychopharmacology (Berl)** 1996 May; 125(2):168–75

PHYSIOLOGY

Neurobiological constraints on behavioral models of motivation. Nader K, et al. **Annu Rev Psychol** 1997; 48:85–114 (165 ref.)
Unilateral amygdala inactivation after training attenuates memory for reduced reward. Coleman-Mesches K, et al. **Behav Brain Res** 1996 May;77(1–2):175–80
Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task. Lindner MD, et al. **Behav Brain Res** 1997 Jun;86(1):25–40
Fluid intake and behavioral changes in rats associated with the distension of the small and large intestine. Bárdos G. **Behav Neurosci** 1997 Aug;111(4):834–44
A kinematic analysis of sex-typical movement patterns used during evasive dodging to protect a food item: the role of testicular hormones. Field EF, et al. **Behav Neurosci** 1997 Aug;111(4):808–15
Contextual control of conditioned responding in rats with dorsal hippocampal lesions. Hall G, et al. **Behav Neurosci** 1996 Oct;110(5):933–45
Hippocampus and memory in a food-storing and in a nonstoring bird species. Hampton RR, et al. **Behav Neurosci** 1996 Oct;110(5):946–64
Autonomic and behavioral correlates of appetitive conditioning in rats. Hunt PS, et al. **Behav Neurosci** 1997 Jun;111(3):494–502
Gustatory thalamus lesions in the rat: II. Aversive and appetitive taste conditioning. Reilly S, et al. **Behav Neurosci** 1996 Aug;110(4):746–59
The hippocampus and reward: effects of hippocampal lesions on progressive-ratio responding. Schmelzeis MC, et al. **Behav Neurosci** 1996 Oct;110(5):1049–66
Brainstem lesions and gustatory function: I. The role of the nucleus of the solitary tract during a brief intake test in rats. Shimura T, et al. **Behav Neurosci** 1997 Feb; 111(1):155–68
Food storing and the hippocampus in Paridae. Healy SD, et al. **Brain Behav Evol** 1996;47(4):195–9
Relative hippocampal volume in relation to food-storing behavior in four species of woodpeckers. Volman SF, et al. **Brain Behav Evol** 1997;49(2):110–20
Vision: simple stereopsis. Collett TS. **Curr Biol** 1996 Nov 1;6(11):1392–5 (14 ref.)
Oral grasping of a surrogate nipple by the newborn rat. Smotherman WP, et al. **Dev Psychobiol** 1997 Jul;31(1):3–17
Alpha-helical CRF blocks differential influence of corticotropin releasing factor (CRF) on appetitive and aversive memory retrieval in rats. Kumar KB, et al. **J Neural Transm** 1996;103(8–9):1117–26
Frontal-subcortical circuits: the anatomic basis of executive, social and motivated behaviors. Masterman DL, et al. **J Psychopharmacol (Oxf)** 1997;11(2):107–14 (60 ref.)
The role of cattle as hosts of Glossina longipennis at Galana Ranch, south-eastern Kenya. Makumi JN, et al. **Med Vet Entomol** 1996 Oct;10(4):331–6
Effects of chronic stress on food acquisition, plasma hormones, and the estrous cycle of female rats. Anderson SM, et al. **Physiol Behav** 1996 Jul;60(1):325–9
The food-hoarding threshold is not raised by acute intraventricular NPY in male rats. Cabanac M, et al. **Physiol Behav** 1997 Jan;61(1):131–5
Endogenous mu opioid systems and perioral responsiveness in the rat fetus. Petrov ES, et al. **Physiol Behav** 1997 Jul; 62(1):31–7

APPLE see **FRUIT**

APPOINTMENTS AND SCHEDULES

Applications of information systems to operating room scheduling [editorial; comment] Dexter F, et al. **Anesthesiology** 1996 Dec;85(6):1232–4. Comment on: Anesthesiology 1996 Dec;85(6):1235–45.
Statistical modeling to predict elective surgery time. Comparison with a computer scheduling system and surgeon-provided estimates [see comments] Wright IH, et al. **Anesthesiology** 1996 Dec;85(6):1235–45. Comment in: Anesthesiology 1996 Dec;85(6):1232–4.
Administrative aspects of a general surgical firm: an audit of accuracy of operation lists and timeliness of discharge summaries. Aziz MM, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4 Suppl):183–5
Is an outpatient appointment required for patients referred for a minor operation under local anaesthetic? Johnson RC, et al. **Ann R Coll Surg Engl** 1996 Sep;78(5 Suppl):223–5
Patient focus [editorial] Grace M. **Br Dent J** 1997 Apr 26; 182(8):283
The prevention of failed appointments in general dental practice. Reekie D, et al. **Br Dent J** 1997 Feb 22; 182(4):139–43
Evaluation of a computerized appointment system in general practice. Campbell SM, et al. **Br J Gen Pract** 1996 Aug; 46(409):477–8
Are postoperative review appointments necessary following uncomplicated minor oral surgery? Worrall SF. **Br J Oral Maxillofac Surg** 1996 Dec;34(6):495–9
A study of waiting times and waiting lists for radiation therapy patients. Cormack DV, et al. **Can J Oncol** 1996

Jun;6(1):427–34
Revisiting Rick: more bad news on the HMO front [letter; comment] Gordon M. **Can Med Assoc J** 1997 Mar 1; 156(5):632–3. Comment on: Can Med Assoc J 1996 Jan 15;154(2):142–3.
Continuity of care between obstetrical and pediatric preventive care: indicators of nonattendance at the first well–child appointment. Grossman LK, et al. **Clin Pediatr (Phila)** 1996 Nov;35(11):563–9
An audit of waiting times in the diabetic outpatient clinic: role of patients' punctuality and level of medical staffing. Perros P, et al. **Diabet Med** 1996 Jul;13(7):669–73
Scheduling. Winding down the wait. Greene J. **Hosp Health Netw** 1997 Feb 5;71(3):74
Setting up waiting–time targets to satisfy patients: an application of mathematical programming. Huang XM, et al. **IMA J Math Appl Med Biol** 1995 Sep–Dec; 12(3–4):235–47
Patient flow analysis in a children's clinic. Asefzadeh S. **Int J Qual Health Care** 1997 Apr;9(2):143–7
Compliance with mammography screening in Israeli women: the impact of a pre–scheduled appointment and of the letter–style. Ore L, et al. **Isr J Med Sci** 1997 Feb; 33(2):103–11
Scheduling for productivity, profitability and stress control. Jameson C. **J Am Dent Assoc** 1996 Dec;127(12):1777–82
Patient cancellations [letter] Schwartz S. **J Am Dent Assoc** 1996 Oct;127(10):1462
The accelerated intake: a method for increasing initial attendance to outpatient cocaine treatment. Festinger DS, et al. **J Appl Behav Anal** 1996 Fall;29(3):387–9
In vitro fertilization programmed for weekday–only oocyte harvest: analysis of outcome based on actual retrieval day. Ben–Chetrit A, et al. **J Assist Reprod Genet** 1997 Jan; 14(1):26–31
Influence of case scheduling on outcome in cardiac surgery. Klima U, et al. **J Cardiovasc Surg (Torino)** 1997 Feb; 38(1):63–8
Benchmarking the perioperative process. I. Patient routing systems: a method for continual improvement of patient flow and resource utilization. Rotondi AJ, et al. **J Clin Anesth** 1997 Mar;9(2):159–69
Cancellation of pediatric outpatient surgery: economic and emotional implications for patients and their families. Tait AR, et al. **J Clin Anesth** 1997 May;9(3):213–9
So much to do, so little time [editorial; comment] Liss D. **J Gen Intern Med** 1997 Feb;12(2):135–6. Comment on: J Gen Intern Med 1997 Feb;12(2):107–13.
Evaluation of a reduced–frequency prenatal visit schedule for low–risk women at a free–standing birthing center. Walker DS, et al. **J Nurse Midwifery** 1997 Jul–Aug; 42(4):295–303
Failure of patients to attend a medical outpatient clinic [letter; comment] Bateson MC. **J R Coll Physicians Lond** 1997 May–Jun;31(3):340. Comment on: J R Coll Physicians Lond 1997 Jan–Feb;31(1):70–3.
Failure of patients to attend a medical outpatient clinic [letter; comment] Burns–Cox CJ. **J R Coll Physicians Lond** 1997 May–Jun;31(3):340. Comment on: J R Coll Physicians Lond 1997 Jan–Feb;31(1):70–3.
Failure of patients to attend a medical outpatient clinic [see comments] Simmons AV, et al. **J R Coll Physicians Lond** 1997 Jan–Feb;31(1):70–3. Comment in: J R Coll Physicians Lond 1997 May–Jun;31(3):340.
An introduction to using computer simulation in healthcare: patient wait case study. Benneyan JC. **J Soc Health Syst** 1997;5(3):1–15
Surgical process scheduling: a structured review. Blake JT, et al. **J Soc Health Syst** 1997;5(3):17–30 (39 ref.)
Using simulation to improve the operational efficiency of a multi–disciplinary clinic. Kalton AG, et al. **J Soc Health Syst** 1997;5(3):43–62
An emergency department simulation and a neural network metamodel. Kilmer RA, et al. **J Soc Health Syst** 1997; 5(3):63–79
Using simulation to reduce length of stay in emergency departments. McGuire F. **J Soc Health Syst** 1997;5(3):81–90
Effect of a transportation incentive on compliance with the first prenatal appointment: a randomized trial. Melnikow J, et al. **Obstet Gynecol** 1997 Jun;89(6):1023–7
Appointment scheduling on computer. Mercando AD. **Pacing Clin Electrophysiol** 1997 Jul;20(7):1860–2
A comparison of interventions to improve clinic follow–up compliance after a pediatric emergency department visit. Komoroski EM, et al. **Pediatr Emerg Care** 1996 Apr; 12(2):87–90
Early discharge from the newborn nursery–effect on scheduling of follow–up visits by pediatricians. Maisels MJ, et al. **Pediatrics** 1997 Jul;100(1):72–4
Factors affecting peritoneal efficiency in different treatment schedules. Nolph KD. **Perit Dial Int** 1997;17 Suppl 2:S98–101 (19 ref.)
Psychiatrists' hours by work setting. Chartock LR, et al. **Psychiatr Serv** 1996 Feb;47(2):133
Predictors of missed appointments for psychiatric consultations in a primary care clinic. Grunebaum M, et al. **Psychiatr Serv** 1996 Aug;47(8):848–52
Picture activity schedules and engagement of adults with mental retardation in a group home. Anderson MD, et al. **Res Dev Disabil** 1997 Jul–Aug;18(4):231–50
Why patients fail to attend psychiatric outpatient follow–up: a pilot study. Lim LE, et al. **Singapore Med J** 1995 Aug; 36(4):403–5
Using self–reported questionnaire data to prioritize OSA patients for polysomnography. Pouliot Z, et al. **Sleep** 1997 Mar;20(3):232–6
A prospective outcome study of patients missing regular psychiatric outpatient appointments. Pang AH, et al. **Soc Psychiatry Psychiatr Epidemiol** 1996 Sep;31(5):299–302
[Reimbursement budgets and treatment demands require cost saving—a short operations day as a possible solution in the hospital] Bergler W, et al. **Laryngorhinootologie** 1997 Apr;76(4):258–62 (Eng. Abstr.) **(Ger)**

APPROPRIATENESS REVIEW see **REGIONAL HEALTH PLANNING**

APRAXIA

The specific relation between perception and production errors for place of articulation in developmental apraxia of speech. Groenen P, et al. **J Speech Hear Res** 1996 Jun; 39(3):468–82
Speech timing in apraxia of speech versus conduction aphasia. Seddoh SA, et al. **J Speech Hear Res** 1996 Jun; 39(3):590–603
Chromosomal translocation in a child with SLI and apraxia. Weistuch L, et al. **J Speech Hear Res** 1996 Jun;39(3):668–71

CHEMICALLY INDUCED

Dysarthria and apraxia of speech associated with FK–506 (tacrolimus). Boeve BF, et al. **Mayo Clin Proc** 1996 Oct; 71(10):969–72
Withdrawal syndrome is not precipitated when butorphanol is added to opiate or opioid therapy. A comment on intranasal butorphanol–induced apraxia reversed by naloxone [comment] Barkin RL. **Pharmacotherapy** 1996 Sep–Oct;16(5):969. Comment on: Pharmacotherapy 1995 Nov–Dec;15(6):798–800.

COMPLICATIONS

Use of the distraction hearing test in children with congenital ocular motor apraxia. Rowe FJ, et al. **Br J Audiol** 1996 Oct;30(5):346–8
Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic–induced parkinsonism. Leiguarda RC, et al. **Brain** 1997 Jan;120 (Pt 1):75–90
Alien hand syndrome of the dominant hand and ideomotor apraxia of the nondominant hand. Kischka U, et al. **Eur Neurol** 1996;36(1):39–42
Floating–Harbor syndrome. A neuropsychological approach. Davalos IP, et al. **Genet Couns** 1996;7(4):283–8

DIAGNOSIS

The assessment of limb apraxia: an investigation of task effects and their cause. Belanger SA, et al. **Brain Cogn** 1996 Dec; 32(3):384–404
The significance of body part as tool errors in limb apraxia. Raymer AM, et al. **Brain Cogn** 1997 Jul;34(2):287–92
Slowly progressive limb–kinetic apraxia. Otsuki M, et al. **Eur Neurol** 1997;37(2):100–3 (17 ref.)
Use of the clock drawing task in the diagnosis of mild and very mild Alzheimer's disease. Lee H, et al. **Int Psychogeriatr** 1996 Fall;8(3):469–76
Sign language and motor functioning in students with autistic disorder. Seal BC, et al. **J Autism Dev Disord** 1997 Aug; 27(4):437–66
Pure progressive clumsiness due to parietal atrophy in a young adult. Uchihara T, et al. **J Neurol Sci** 1996 Nov; 143(1–2):173–5
Effects of length and linguistic complexity on temporal acoustic measures in apraxia of speech. Strand EA, et al. **J Speech Hear Res** 1996 Oct;39(5):1018–33
Developmental apraxia of speech: III. A subtype marked by inappropriate stress. Shriberg LD, et al. **J Speech Lang Hear Res** 1997 Apr;40(2):313–37
Developmental apraxia of speech: I. Descriptive and theoretical perspectives. Shriberg LD, et al. **J Speech Lang Hear Res** 1997 Apr;40(2):273–85
Developmental apraxia of speech: II. Toward a diagnostic marker. Shriberg LD, et al. **J Speech Lang Hear Res** 1997 Apr;40(2):286–312
Apraxia of lid opening: a review. Boghen D. **Neurology** 1997 Jun;48(6):1491–4 (43 ref.)
Developmental dyspraxia and developmental coordination disorder. Miyahara M, et al. **Neuropsychol Rev** 1995 Dec; 5(4):245–68 (112 ref.)
An "ecological" constructional test. Trojano L, et al. **Percept Mot Skills** 1997 Aug;85(1):51–7
[Tests for aphasia, apraxia and agnosia] Hasegawa T, et al. **Nippon Rinsho** 1997 Mar;55 Suppl 1:318–21 (11 ref.) **(Jpn)**

DRUG THERAPY

Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Piccione F, et al. **Arch Phys Med Rehabil** 1997 May; 78(5):525–9
[Keratitis and corneal edema associated with levodopa use—a case report] Nakamagoe K, et al. **Rinsho Shinkeigaku** 1996 Jul;36(7):886–8 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Aphasia, apraxia, and agnosia in the diagnosis of dementia. Kramer JH, et al. **Dementia** 1996 Jan–Feb;7(1):23–6
Selective drawing disorders after right subcortical stroke: a neuropsychological premorbid and follow–up case study. Grossi D, et al. **Ital J Neurol Sci** 1996 Jun;17(3):241–8
Apraxia of eyelid opening after bilateral stereotaxic subthalamotomy. Klostermann W, et al. **J Neuroophthalmol** 1997 Jun;17(2):122–3
Medial frontal cortex lesions selectively attenuate the hot plate response: possible nocifensive apraxia in the rat. Pastoriza LN, et al. **Pain** 1996 Jan;64(1):11–7
[A case of amyotrophic lateral sclerosis with apraxia of eyelid opening] Terakawa H, et al. **Nippon Naika Gakkai Zasshi** 1996 May 10;85(5):757–8 **(Jpn)**
[A case with dressing apraxia] Hayakawa Y, et al. **No To Shinkei** 1996 Feb;49(2):171–5 (Eng. Abstr.) **(Jpn)**
[A case of frontal gait apraxia caused by hypoxic encephalopathy] Nakamagoe K, et al. **No To Shinkei** 1997 May;49(5):455–9 (Eng. Abstr.) **(Jpn)**

GENETICS

Oculomotor apraxia in a case of Gaucher's disease with homozygous T1448C mutation. Tsai LP, et al. **Acta Paediatr Sin** 1996 Jan–Feb;37(1):52–5

PATHOLOGY

Primary progressive apraxia in Pick's disease: a clinicopathologic study. Fukui T, et al. **Neurology** 1996 Aug;47(2):467–73
Conceptual apraxia from lateralized lesions. Heilman KM, et al. **Neurology** 1997 Aug;49(2):457–64

PHYSIOPATHOLOGY

The mechanisms for adult–onset apraxia and developmental dyspraxia: an examination and comparison of error patterns. Poole JL, et al. **Am J Occup Ther** 1997 May;51(5):339–46
Kinematic analysis of movement imitation in apraxia. Hermsdörfer J, et al. **Brain** 1996 Oct;119 (Pt 5):1575–86
The assessment of limb apraxia: an investigation of task effects and their cause. Belanger SA, et al. **Brain Cogn** 1996 Dec; 32(3):384–404
Ideomotor apraxia: behavioral dimensions and neuroanatomical basis. Schnider A, et al. **Brain Lang** 1997 Jun 1;58(1):125–36
Spatio–temporal impairments in limb and body movements during righting in an hemiparkinsonian rat analogue: relevance to axial apraxia in humans. Martens DJ, et al. **Brain Res** 1996 Sep 16;733(2):253–62
Ideomotor apraxia and cerebral dominance for motor control. Goldenberg G, et al. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):95–100 (24 ref.)
On crossed apraxia. Description of a right–handed apraxic patient with right supplementary motor area damage. Marchetti C, et al. **Cortex** 1997 Jun;33(2):341–54
Neuroradiological and eye movement correlates in children with intermittent saccade failure: "ocular motor apraxia". Shawkat FS, et al. **Neuropediatrics** 1995 Dec;26(6):298–305
The meaning of meaningless gestures: a study of visuo–imitative apraxia. Goldenberg G, et al. **Neuropsychologia** 1997 Mar;35(3):333–41
[Neural mechanisms of apraxia] Yamadori A. **No To Shinkei** 1996 Nov;48(11):991–8 (73 ref.) **(Jpn)**

PSYCHOLOGY

Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex. Nielson KA, et al. **Brain Res** 1996 Nov 25;741(1–2):284–93
Ideomotor apraxia and cerebral dominance for motor control. Goldenberg G, et al. **Brain Res Cogn Brain Res** 1996 Mar; 3(2):95–100 (24 ref.)
Conceptual apraxia from lateralized lesions. Heilman KM, et al. **Neurology** 1997 Aug;49(2):457–64
Selective deficit of praxis imagery in ideomotor apraxia. Ochipa C, et al. **Neurology** 1997 Aug;49(2):474–80

RADIONUCLIDE IMAGING

Anterior operculum syndrome localized by SPECT. Lampl Y, et al. **J Nucl Med** 1997 Jul;38(7):1122–4

APRICOT see **FRUIT**

APRINDINE

PHARMACOLOGY

Effects of aprindine on ischemia/reperfusion–induced cardiac contractile dysfunction of perfused rat heart. Kamiyama T, et al. **Jpn J Pharmacol** 1996 Mar;70(3):227–34

APROCARB

An insensitive acetylcholinesterase in Culex pipiens (Diptera:Culicidae) from Portugal. Bourguet D, et al. **J Econ Entomol** 1996 Oct;89(5):1060–6
Adaptive larval thermotolerance and induced cross–tolerance to propoxur insecticide in mosquitoes Anopheles stephensi

and Aedes aegypti. Patil NS, et al. **Med Vet Entomol** 1996 Jul;10(3):277–82

PHARMACOKINETICS

The influence of skin moisture on the dermal absorption of propoxur in human volunteers: a consideration for biological monitoring practices. Meuling WJ, et al. **Sci Total Environ** 1997 Jun 20;199(1–2):165–72

TOXICITY

Assessment of the ability of propoxur, methomyl, and aldicarb, three carbamate insecticides, to induce micronuclei in vitro in cultured Chinese hamster ovary cells and in vivo in BALB/c mice. Wei LY, et al. **Environ Mol Mutagen** 1997;29(4):386–93

APROTININ

Hemostatic efficacy and safety of TachoComb in surgery. Ready to use and rapid hemostatic agent. Agus GB, et al. **Int Surg** 1996 Jul–Sep;81(3):316–9

[Conclusions from the clinical trials of TachoComb, a hemostatic] Vykouřil L, et al. **Rozhl Chir** 1996 Apr; 75(4):216–8 (Eng. Abstr.) **(Cze)**

ADMINISTRATION & DOSAGE

"Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release. Ashraf S, et al. **Ann Thorac Surg** 1997 Jan;63(1):68–73

Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. Davies MJ, et al. **Ann Thorac Surg** 1997 Feb;63(2):497–503

Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens [see comments] Lemmer JH Jr, et al. **Ann Thorac Surg** 1996 Dec; 62(6):1659–67; discussion 1667–8. Comment in: Ann Thorac Surg 1996 Dec;62(6):1575–7.

Aprotinin: safe and effective only with the full-dose regimen [editorial; comment] Smith PK, et al. **Ann Thorac Surg** 1996 Dec;62(6):1575–7. Comment on: Ann Thorac Surg 1996 Dec;62(6):1659–7; discussion 1667–8.

Reduction in costs, blood products, and operating time in patients undergoing open heart surgery. Lazzara RR, et al. **Arch Surg** 1997 Aug;132(8):858–60; discussion 861

Effects of aprotinin on plasma levels of neutrophil elastase and postoperative blood loss in cardiac surgery. Dernek S, et al. **Cardiovasc Surg** 1996 Aug;4(4):515–9

Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Shigeta O, et al. **Circulation** 1997 Jul 15;96(2):569–74

The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations [letter] Landymore RW, et al. **Eur J Cardiothorac Surg** 1997 Apr;11(4):798–800

Aprotinin and deep hypothermic circulatory arrest: there are no benefits even when appropriate amounts of heparin are given. Parolari A, et al. **Eur J Cardiothorac Surg** 1997 Jan; 11(1):149–56

Aprotinin in aortic surgery requiring profound hypothermia and circulatory arrest. Rooney SJ, et al. **Eur J Cardiothorac Surg** 1997 Feb;11(2):373–8

Randomized, placebo-controlled, double-blind study of an ultra-low-dose aprotinin regimen in reoperative and/or complex cardiac operations. Hardy JF, et al. **J Card Surg** 1997 Jan–Feb;12(1):15–22

Methylprednisolone and full-dose aprotinin reduce reperfusion injury after cardiopulmonary bypass. Diego RP, et al. **J Cardiothorac Vasc Anesth** 1997 Feb;11(1):29–31

Lack of pharmacological effect of subcutaneous octreotide in an insulin-dependent diabetic patient: reversal after mixing with aprotinin. Lunetta M, et al. **J Endocrinol Invest** 1997 Jun;20(6):331–4

Use of aprotinin after cardiac operations [letter] Alvarez JM. **J Thorac Cardiovasc Surg** 1997 Sep;114(3):513–4

Postoperative use of aprotinin in cardiac operations: an alternative to its prophylactic use. Çiçek S, et al. **J Thorac Cardiovasc Surg** 1996 Dec;112(6):1462–7

Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. D'Ambra MN, et al. **J Thorac Cardiovasc Surg** 1996 Oct; 112(4):1081–9

Effects of minimal-dose aprotinin on coronary artery bypass grafting. Hayashida N, et al. **J Thorac Cardiovasc Surg** 1997 Aug;114(2):261–9

[Effect of local administration of aprotinin on surgical blood loss after myocardial revascularization] Mandák J, et al. **Rozhl Chir** 1996 May;75(5):272–5 (Eng. Abstr.) **(Cze)**

[Reduction of blood loss in orthotopic liver transplantation with the use of aprotinin] Légaré G, et al. **Ann Chir** 1996; 50(8):601–5 (Eng. Abstr.) **(Fre)**

[Combined erythropoietin and aprotinin use for blood conservation in elderly coronary bypass patients] Oshima N, et al. **Kyobu Geka** 1997 Jul;50(8 Suppl):707–10 (Eng. Abstr.) **(Jpn)**

[Effect of aprotinin on endothelial cell functions during cardiopulmonary bypass] Takaori M, et al. **Masui** 1996 Aug;45(8):928–32 (Eng. Abstr.) **(Jpn)**

[Aprotinin 2 million KIU reduces perioperative blood loss in patients undergoing primary total hip replacement] Utada K, et al. **Masui** 1997 Jan;46(1):77–82 (Eng. Abstr.) **(Jpn)**

[Clinical effectiveness of aprotinin aerosol in influenza and parainfluenza] Zhirnov OP, et al. **Vestn Ross Akad Med Nauk** 1996;(5):26–31 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Acute respiratory distress syndrome after aprotinin infusion. Vucicevic Z, et al. **Ann Pharmacother** 1997 Apr; 31(4):429–32

Anaphylactic shock after aprotinin reexposure: time course of aprotinin-specific antibodies. Scheule AM, et al. **Ann Thorac Surg** 1997 Jan;63(1):242–4

Is use of aprotinin safe with deep hypothermic circulatory arrest in aortic surgery? Investigations on blood coagulation. Okita Y, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II177–81

Fatal thromboembolism in acute promyelocytic leukaemia treated with a combination of all-trans retinoic acid and aprotonin. Mahendra P, et al. **Clin Lab Haematol** 1996 Mar; 18(1):51–2

Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. Dietrich W, et al. **J Thorac Cardiovasc Surg** 1997 Jan;113(1):194–201

A brief review of studies evaluating the adverse effects of aprotinin therapy in aortocoronary bypass surgery [letter] Ray MJ, et al. **Thromb Haemost** 1997 May;77(5):1038–40 (17 ref.)

Aprotinin in aortocoronary bypass surgery: increased risk of vein-graft occlusion and myocardial infarction? Supportive evidence from a retrospective study. van der Meer J, et al. **Thromb Haemost** 1996 Jan;75(1):1–3

Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass. Wahba A, et al. **Thromb Haemost** 1996 May;75(5):844–8

[Pit fall of aprotinin administration during open heart surgery] Irie H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Aug;44(8):1119–23 (Eng. Abstr.) **(Jpn)**

[Effect of aprotinin on bleeding during and graft patency after coronary artery bypass grafting] Minohara S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):821–4 (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

Internal packing conditions and fluctuations of amino acid residues in globular proteins. Bhaskaran R, et al. **J Biomol Struct Dyn** 1996 Feb;13(4):627–39

A folded protein can be transported across the chloroplast envelope and thylakoid membranes. Clark SA, et al. **Mol Biol Cell** 1997 May;8(5):923–34

BLOOD

Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen. Bennett-Guerrero E, et al. **Anesth Analg** 1996 Dec;83(6):1189–92

The effect of chronic renal failure on plasma aprotinin levels during cardiac surgery. O'Connor CJ, et al. **Anesth Analg** 1997 Oct;85(4):763–5

CHEMICAL SYNTHESIS

Reduction of the infectivity of scrapie agent as a model for BSE in the manufacturing process of Trasylol. Gölker CF, et al. **Biologicals** 1996 Jun;24(2):103–11

CHEMISTRY

Rapid formation of the native 14–38 disulfide bond in the early stages of BPTI folding. Dadlez M, et al. **Biochemistry** 1996 Dec 17;35(50):16153–64

Hydrophobic interactions accelerate early stages of the folding of BPTI. Dadlez M. **Biochemistry** 1997 Mar 11; 36(10):2788–97

A pulsed-field gradient NMR study of bovine pancreatic trypsin inhibitor self-association. Ilyina E, et al. **Biochemistry** 1997 Mar 18;36(11):3383–8

Local fluctuations and global unfolding of partially folded BPTI detected by NMR. Barbar E, et al. **Biophys Chem** 1997 Feb 28;64(1–3):45–57

Probing protein structure by solvent perturbation of NMR spectra: the surface accessibility of bovine pancreatic trypsin inhibitor. Molinari H, et al. **Biophys J** 1997 Jul; 73(1):382–96

The thrombin E192Q-BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulin. van de Locht A, et al. **EMBO J** 1997 Jun 2;16(11):2977–84

Unfolded BPTI variants with a single disulfide bond have diminished non-native structure distant from the crosslink. Barbar E, et al. **Fold Des** 1996;1(1):65–76

Local interactions of aromatic residues in short peptides in aqueous solution: a combined database and energetic analysis. Nardi F, et al. **Fold Des** 1997;2(4):S62–8

Temperature dependence of 1H chemical shifts in proteins. Baxter NJ, et al. **J Biomol NMR** 1997 Jun;9(4):359–69

Molecular dynamics simulations of peptides from BPTI: a closer look at amide-aromatic interactions. van der Spoel D, et al. **J Biomol NMR** 1996 Oct;8(3):229–38

Enhanced protein flexibility caused by a destabilizing amino acid replacement in BPTI. Beeser SA, et al. **J Mol Biol** 1997 May 30;269(1):154–64

Comment on a "fluctuation and cross correlation analysis of protein motions observed in nanosecond molecular dynamics simulations". Karplus M, et al. **J Mol Biol** 1996 Oct 25;263(2):120–2

Crystal structure of the bovine alpha-chymotrypsin:Kunitz inhibitor complex. An example of multiple protein:protein recognition sites. Capasso C, et al. **J Mol Recognit** 1997 Jan–Feb;10(1):26–35

Reactivity of singlet oxygen toward proteins: the effect of structure in basic pancreatic trypsin inhibitor and in ribonuclease A. Michaeli A, et al. **Photochem Photobiol** 1997 Feb;65(2):309–15

Foci of amino acid residue conservation in the 3D structures of the Kunitz BPTI proteinase inhibitors: how do variants from snake venom differ? Cardle L, et al. **Protein Eng** 1997 Feb;10(2):131–6

Denaturants can accelerate folding rates in a class of globular proteins. Camacho CJ, et al. **Protein Sci** 1996 Sep; 5(9):1826–32

Identification of cooperative folding units in a set of native proteins. Wallqvist A, et al. **Protein Sci** 1997 Aug; 6(8):1627–42

Prediction of titration properties of structures of a protein derived from molecular dynamics trajectories. Wlodek ST, et al. **Protein Sci** 1997 Feb;6(2):373–82

Mutational analysis of the BPTI folding pathway: I. Effects of aromatic-->leucine substitutions on the distribution of folding intermediates. Zhang JX, et al. **Protein Sci** 1997 Jul;6(7):1549–62

Mutational analysis of the BPTI folding pathway: II. Effects of aromatic-->leucine substitutions on folding kinetics and thermodynamics. Zhang JX, et al. **Protein Sci** 1997 Jul; 6(7):1563–76

A multicopy modeling of the water distribution in macromolecular crystals. Podjarny AD, et al. **Proteins** 1997 Jul;28(3):303–12

Structural stability of disulfide mutants of basic pancreatic trypsin inhibitor: a molecular dynamics study. Schiffer CA, et al. **Proteins** 1996 Sep;26(1):66–71

A simple two-dimensional representation for the common secondary structural elements of polypeptides and proteins. Smith PE, et al. **Proteins** 1997 Feb;27(2):227–34

Molecular mechanisms of pressure induced conformational changes in BPTI. Wroblowski B, et al. **Proteins** 1996 Aug; 25(4):446–55

GENETICS

The rkpGHI and -J genes are involved in capsular polysaccharide production by Rhizobium meliloti. Kiss E, et al. **J Bacteriol** 1997 Apr;179(7):2132–40

The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells. Ho L, et al. **J Biol Chem** 1996 Nov 29;271(48):30929–34

IMMUNOLOGY

Strong crossreaction of human anti-aprotinin antibodies from heart transplant patient with [Arg15]aprotinin. Brinkmann T, et al. **Immunopharmacology** 1997 Jan;35(3):221–8

METABOLISM

An investigation of the binding of protein proteinase inhibitors to trypsin by electrospray ionization mass spectrometry. Kraunsoe JA, et al. **FEBS Lett** 1996 Oct 28;396(1):108–12

Enhanced protein flexibility caused by a destabilizing amino acid replacement in BPTI. Beeser SA, et al. **J Mol Biol** 1997 May 30;269(1):154–64

Crystal structure of the bovine alpha-chymotrypsin:Kunitz inhibitor complex. An example of multiple protein:protein recognition sites. Capasso C, et al. **J Mol Recognit** 1997 Jan–Feb;10(1):26–35

Dimethyl sulfoxide binding to globular proteins: a nuclear magnetic relaxation dispersion study. Jóhannesson H, et al. **Protein Sci** 1997 Aug;6(8):1756–63

PHARMACOKINETICS

Pharmacokinetics of aprotinin in two patients with chronic renal impairment [letter] Müller FO, et al. **Br J Clin Pharmacol** 1996 Jun;41(6):619–20

PHARMACOLOGY

The effect of aprotinin on thrombelastography in vitro [see comments] Chalkiadis GA, et al. **Anaesth Intensive Care** 1996 Oct;24(5):552–4. Comment in: Anaesth Intensive Care 1997 Apr;25(2):195–6.

Aprotinin and the TEG [letter; comment] Jenkins IR. **Anaesth Intensive Care** 1997 Apr;25(2):195–6. Comment on: Anaesth Intensive Care 1996 Oct;24(5):552–4.

Aprotinin but not tranexamic acid inhibits cytokine-induced inducible nitric oxide synthase expression. Hill GE, et al. **Anesth Analg** 1997 Jun;84(6):1198–202

Differing effects of aprotinin and epsilon-aminocaproic acid on cytokine-induced inducible nitric oxide synthase expression. Hill GE, et al. **Ann Thorac Surg** 1997 Jan; 63(1):74–7

Reduction of blood activation in patients receiving aprotinin during cardiopulmonary bypass for coronary artery

surgery. Baufreton C, et al. **ASAIO J** 1996 Sep–Oct; 42(5):M417–23

Effect of aprotinin on insulin sensitivity in non–insulin–dependent diabetes mellitus. Laurenti O, et al. **Diabet Med** 1996 Jul;13(7):642–5

Dose dependent effect of aprotinin on rate of clot formation. De Hert SG, et al. **Eur J Anaesthesiol** 1996 Sep;13(5):463–7

Evaluation of the anticoagulant properties of aprotinin in vitro. Mortier E, et al. **Eur J Anaesthesiol** 1996 Sep; 13(5):468–70

Bioavailability of 1–deamino–8–D–arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. Fjellestad–Paulsen A, et al. **Eur J Clin Pharmacol** 1996;50(6):491–5

Heparin–coated devices and high–dose aprotinin optimally inhibit contact system activation in an in vitro cardiopulmonary bypass model. Wendel HP, et al. **Immunopharmacology** 1996 May;32(1–3):128–30

Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model. Wendel HP, et al. **Immunopharmacology** 1996 May; 32(1–3):57–61

Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV–1 replication in H9 cells by recombinant aprotinin and bikunin homologues. Brinkmann T, et al. **J Protein Chem** 1997 Aug;16(6):651–60

Effect of aprotinin on smooth muscle cell proliferation, migration, and extracellular matrix synthesis. Horodyski J, et al. **J Surg Res** 1996 Dec;66(2):115–8

Effect of aprotinin on vascular reactivity of coronary bypass grafts. Allen S, et al. **J Thorac Cardiovasc Surg** 1997 Feb; 113(2):319–26

Thromboelastographic analysis of patients receiving aprotinin with comparisons to platelet aggregation and other assays. Koza MJ, et al. **Semin Thromb Hemost** 1995;21 Suppl 4:80–5

Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass. Hill GE, et al. **Surgery** 1997 Apr;121(4):449–55

PHYSIOLOGY

Preventing the inflammatory response to open–heart surgery: the role of aprotinin and other protease inhibitors. Royston D. **Int J Cardiol** 1996 Apr 26;53 Suppl:S11–37 (137 ref.)

THERAPEUTIC USE

Coagulation in cardiac surgery. Royston D. **Adv Card Surg** 1996;8:19–45 (125 ref.)

Randomized blinded study of aprotinin infusion for liver crush injuries in the pig model. Thomae KR, et al. **Am Surg** 1997 Feb;63(2):113–20

The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. D'Errico CC, et al. **Anesth Analg** 1996 Dec;83(6):1193–9

Aprotinin reduces interleukin–8 production and lung neutrophil accumulation after cardiopulmonary bypass. Hill GE, et al. **Anesth Analg** 1996 Oct;83(4):696–700

Aprotinin reduces blood loss in patients undergoing elective liver resection. Lentschener C, et al. **Anesth Analg** 1997 Apr;84(4):875–81

Use of aprotinin therapy in a patient with factor V Leiden. Robbins P, et al. **Anesth Analg** 1997 Mar;84(3):694–8

Aprotinin effects related to oxidative stress in cardiosurgery with mechanical cardiorespiratory support (CMCS). Broche VF, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:521–4

Aprotinin protects against myocardial and oxidant formation and endothelial cell damage during open heart surgery. Rao PS, et al. **Ann N Y Acad Sci** 1996 Sep 30;793:514–6

Heparin coating with aprotinin reduces blood activation during coronary artery operations. Baufreton C, et al. **Ann Thorac Surg** 1997 Jan;63(1):50–6

Effect of aprotinin on plasma fibronectin levels during cardiopulmonary bypass. al Khudhairi DM, et al. **Ann Thorac Surg** 1997 Jan;63(1):64–7

Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass. Ray MJ, et al. **Ann Thorac Surg** 1997 Jan;63(1):57–63

Aprotinin improves outcome of single–ventricle palliation. Tweddell JS, et al. **Ann Thorac Surg** 1996 Nov; 62(5):1329–35; discussion 1335–6

The use of aprotinin for patients undergoing coronary artery bypass graft procedures. Whitener RT, et al. **AORN J** 1996 Jan;63(1):229–34

Proteinase inhibitors and pemphigus vulgaris. An in vitro and in vivo study. Dobrev H, et al. **Arch Dermatol Res** 1996 Oct;288(11):648–55

Elective surgery in an anaemic Jehovah's Witness. Cooper R, et al. **Br J Hosp Med** 1996 Jul 10–Aug 20;56(2–3):107–8

Prospective randomized placebo–controlled trial of aprotinin for elective aortic reconstruction. Ranaboldo CJ, et al. **Br J Surg** 1997 Aug;84(8):1110–3

Activated clotting time measurements and aprotinin studies [letter; comment] Abramson DC, et al. **Circulation** 1996 Oct 1;94(7):1791–2. Comment on: Circulation 1995 Oct 15;92(8):2236–44.

Half–dose aprotinin does not affect haemorheological properties in patients undergoing bypass surgery. Liu B, et al. **Coron Artery Dis** 1996 Aug;7(8):609–13

Pharmacological prophylaxis of bleeding in surgical patients treated with aspirin. Flordal PA. **Eur J Anaesthesiol Suppl** 1997 Mar;14:38–41 (29 ref.)

Aprotinin diminishes inflammatory processes. Soeparwata R, et al. **Int J Cardiol** 1996 Apr 26;53 Suppl:S55–63

The management of bleeding following surgery requiring hypothermic circulatory arrest. Rooney SJ, et al. **J Card Surg** 1997 Mar–Apr;12(2 Suppl):238–42

A case for aprotinin in patients having deep hypothermic circulatory arrest. Royston D. **J Card Surg** 1997 Mar–Apr; 12(2 Suppl):214–20; discussion 220–1 (54 ref.)

Safety and efficacy of aprotinin in profoundly hypothermic circulatory arrest. Westaby S. **J Card Surg** 1997 Mar–Apr; 12(2 Suppl):207–13 (32 ref.)

Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? Dietrich W. **J Cardiovasc Pharmacol** 1996;27 Suppl 1:S50–7 (53 ref.)

The efficacy of single–dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. Hayes A, et al. **J Clin Anesth** 1996 Aug;8(5):357–60

Effects of high–dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis. Berling R, et al. **J Gastroenterol** 1996 Oct;31(5):702–9

Is aprotinin indicated for reoperative valvular surgery? Goldstein DJ, et al. **J Heart Valve Dis** 1997 Jan;6(1):88–92

Failure of aprotinin to prevent graft pancreatitis in porcine pancreas transplantation [letter] Källén R, et al. **Pancreas** 1996 Jan;12(1):103–5

The effect of high dose aprotinin therapy on the systemic inflammatory response in a porcine model of cardiopulmonary bypass. Ali M, et al. **Perfusion** 1996 May; 11(3):278–80

Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: a placebo–controlled randomized double–blind study. Rodrigus IE, et al. **Perfusion** 1996 Jul;11(4):313–8

[The effects of aprotinin. Blood loss and coagulation parameters in orthotopic liver transplantation: A clinical–experimental, prospective and randomized double–blind study] Kratzer MA, et al. **Anaesthesist** 1997 Apr;46(4):294–302 (Eng. Abstr.) **(Ger)**

[Effect of aprotinin on bleeding during and graft patency after coronary artery bypass grafting] Minohara S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1997 Jun;45(6):821–4 (Eng. Abstr.) **(Jpn)**

[Aprotinin reduces homologous blood transfusions when pediatric cardiac surgery must be redone] Ohuchi H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Nov; 44(11):1980–5 (Eng. Abstr.) **(Jpn)**

[Aprotinin in orthotopic liver transplantation (letter; comment)] García Huete L, et al. **Med Clin (Barc)** 1997 Mar 22;108(11):439. Comment on: Med Clin (Barc) 1996 Mar 2;106(8):307–16. **(Spa)**

APSAC see **ANISTREPLASE**

APTITUDE

The interaction of knowledge, aptitude, and strategies in children's memory performance. Bjorklund DF, et al. **Adv Child Dev Behav** 1996;26:59–89 (98 ref.)

Reported communication abilities of individuals with severe mental retardation. McLean LK, et al. **Am J Ment Retard** 1996 May;100(6):580–9

Significant others' contribution to early adolescents' perceptions of their competence. Trent LM, et al. **Br J Educ Psychol** 1996 Mar;66 (Pt 1):95–107

Development of arithmetical competencies in Chinese and American children: influence of age, language, and schooling. Geary DC, et al. **Child Dev** 1996 Oct; 67(5):2022–44

Seriation, conservation, and theory of mind abilities in individuals with autism, individuals with mental retardation, and normally developing children. Yirmiya N, et al. **Child Dev** 1996 Oct;67(5):2045–59

Effects of day care on the development of cognitive abilities in 8–year–olds: a longitudinal study. Broberg AG, et al. **Dev Psychol** 1997 Jan;33(1):62–9

Exploring the genetic etiology of low general cognitive ability from 14 to 36 months. Petrill SA, et al. **Dev Psychol** 1997 May;33(3):544–8

Changing relations between phonological processing abilities and word–level reading as children develop from beginning to skilled readers: a 5–year longitudinal study. Wagner RK, et al. **Dev Psychol** 1997 May;33(3):468–79

Judgements of ordinality and summation of number symbols by squirrel monkeys (Saimiri sciureus). Olthof A, et al. **J Exp Psychol Anim Behav Process** 1997 Jul;23(3):325–39

Oral conditions and aptitude to receive implants in patients with removable partial dentures: a cross–sectional study. part I. oral conditions. Bassi F, et al. **J Oral Rehabil** 1996 Jan;23(1):50–4

Ability analysis of gender relevance and sex differences in cardiovascular response to behavioral challenge. Wright RA, et al. **J Pers Soc Psychol** 1997 Aug;73(2):405–17

The internal/external dimension in psychoepistemic orientation and measures of ability. Hill OW. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):872–4

Issues in development of a protocol to evaluate children's reasoning about ability and effort in sport. Whitehead J, et al. **Percept Mot Skills** 1996 Oct;83(2):355–64

A savant poet. Dowker A, et al. **Psychol Med** 1996 Sep; 26(5):913–24

Short–term memory impairment and arithmetical ability. Butterworth B, et al. **Q J Exp Psychol A** 1996 Feb; 49(1):251–62

Gender and grade differences in latent ability variables. Härnqvist K. **Scand J Psychol** 1997 Mar;38(1):55–62

[100 years after Billroth: "Who has surgical abilities"?] Horn J. **Chirurg** 1996 Sep;67(9):suppl 211–4 **(Ger)**

[The cytoarchitectonic characteristics of the frontal fields of the brain in gifted people] Orzhekhovskaia NS. **Morfologiia** 1996;109(3):7–9 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Assessment of functional ability with the bed rise difficulty scale in a group of elderly patients. Boffelli S, et al. **Gerontology** 1996;42(5):294–300

APTITUDE TESTS

Trace element and hormonal responses during flight aptitude test. Kobayashi A. **Aviat Space Environ Med** 1996 Apr; 67(4):333–7

Reactions to cognitive ability tests: the relationships between race, test performance, face validity perceptions, and test–taking motivation. Chan D, et al. **J Appl Psychol** 1997 Apr;82(2):300–10

Racial subgroup differences in predictive validity perceptions on personality and cognitive ability tests. Chan D. **J Appl Psychol** 1997 Apr;82(2):311–20

Developing a medical achievement reading test to evaluate patient literacy skills: a preliminary study. Hanson–Divers EC. **J Health Care Poor Underserved** 1997 Feb;8(1):56–69

[Specific features of conducting medical and psychophysiological selection of occupation] Novichkova NI, et al. **Gig Sanit** 1996 Sep–Oct;(5):15–7 **(Rus)**

[Top marks are not necessary. Motivation and suitability are selection criteria for medical education at KI (Karolinska Institute)] Aberg H, et al. **Lakartidningen** 1997 Mar 19; 94(12):1075–8 **(Swe)**

[Admission after interview. New principles of selection for medical education] Westerling R. **Lakartidningen** 1997 Mar 19;94(12):1053–4 **(Swe)**

STANDARDS

Medicolegal death investigator preemployment test development. Jentzen JM, et al. **Am J Forensic Med Pathol** 1996 Jun;17(2):112–6

Male–female performance on U.S. Air Force pilot selection tests. Carretta TR. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):818–23

STATISTICS & NUMERICAL DATA

Gender and grade differences in latent ability variables. Härnqvist K. **Scand J Psychol** 1997 Mar;38(1):55–62

APUD CELLS

CHEMISTRY

An immunohistochemical study of the endocrine cells within the pancreas, intestine, and stomach of the gar (Lepisosteus osseus L.) Groff KE, et al. **Gen Comp Endocrinol** 1997 Apr; 106(1):1–16

CYTOLOGY

Ontogeny, distribution and amine/peptide content of chromogranin A– and B–immunoreactive endocrine cells in the small and large intestine of the chicken. Salvi E, et al. **Anat Embryol (Berl)** 1996 Jul;194(1):89–98

Neuroendocrine differentiation in the precursors of prostate cancer. di Sant'Agnese PA. **Eur Urol** 1996;30(2):185–90 (42 ref.)

[Gastrointestinal endocrine cells: brief history and main identification methods under light microscopy] Santos GC, et al. **Arq Gastroenterol** 1996 Jan–Mar;33(1):36–49 (93 ref.) (Eng. Abstr.) **(Por)**

[The cytogenesis and differentiation of the epithelial endocrinocytes of the large intestine in hens and rats in ontogeny] Ivanova OV, et al. **Morfologiia** 1996; 110(6):106–11 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

[The effect of choleragen poisoning on the intestinal apudocytes of gnotobiotic minipigs] Isupov IV, et al. **Arkh Patol** 1996 Nov–Dec;58(6):59–62 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Pulmonary endocrine cell hyperplasia and papilloma in rats induced by intratracheal injections of extract from particulate air pollutants. Ito T, et al. **Exp Toxicol Pathol** 1997 Feb;49(1–2):65–70

Carcinoid tumor with uterine location. Case report. Lazăr E, et al. **Rom J Morphol Embryol** 1996 Jan–Jun; 42(1–2):89–94

[Changes in the gastric mucosa in endocrine–cell cancer] Derizhanova IS, et al. **Arkh Patol** 1996 Jul–Aug;58(4):32–5 (Eng. Abstr.) **(Rus)**

[Metachronous cancer of the gastro–intestinal tract with signs

of endocrine-cell differentiation] Turbin DA, et al. **Arkh Patol** 1996 Jul-Aug;58(4):28-32 (Eng. Abstr.) **(Rus)**

[Helicobacter pylori, endocrine cells of the gastric mucosa, and their function in duodenal ulcer] Zverkov IV, et al. **Arkh Patol** 1996 Jan-Feb;58(1):33-7 (Eng. Abstr.) **(Rus)**

APUDOMA

see related

MULTIPLE ENDOCRINE NEOPLASIA

[Apudomas: nosographic and physiopathological aspects] Bruzzese A, et al. **Minerva Chir** 1996 May;51(5):313-20 (19 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid. Hanna FW, et al. **J Endocrinol** 1997 Feb;152(2):275-81

RADIONUCLIDE IMAGING

The role of 111In-octreotide scintigraphy in the detection of APUD tumours: our experience in eighteen patients. Borsato N, et al. **Q J Nucl Med** 1995 Dec;39(4 Suppl 1):113-5

APURINIC ACID

CHEMISTRY

Apurinic sites are position-specific topoisomerase II poisons. Kingma PS, et al. **J Biol Chem** 1997 Jan 10;272(2):1148-55

GENETICS

Normal processing of AP sites in Apn1-deficient Saccharomyces cerevisiae is restored by Escherichia coli genes expressing either exonuclease III or endonuclease III. Masson JY, et al. **Mol Microbiol** 1997 May;24(4):711-21

APYRASE

ANALYSIS

Apyrase and alpha-glucosidase in the salivary glands of Aedes albopictus. Marinotti O, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Apr; 113(4):675-9

Human placental ecto-enzymes: studies on the plasma membrane anchorage and effect of inhibitors of ATP-metabolizing enzymes. Chayet L, et al. **Res Commun Mol Pathol Pharmacol** 1997 Apr;96(1):14-24

ANTAGONISTS & INHIBITORS

Inhibition of mosquito salivary gland apyrase activity by antibodies produced in mice immunized by bites of Anopheles stephensi mosquitoes. Mathews GV, et al. **Am J Trop Med Hyg** 1996 Oct;55(4):417-23

Free radical-induced inhibition of ATP diphosphohydrolase activity (EC 3.6.1.5) from rat blood platelets. Frassetto SS, et al. **Biochem Mol Biol Int** 1997 Jan;41(1):161-8

Action of suramin upon ecto-apyrase activity and synaptic depression of Torpedo electric organ. Martí E, et al. **Br J Pharmacol** 1996 Jul;118(5):1232-6

Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA) on ATP diphosphohydrolase (EC 3.6.1.5) and 5'-nucleotidase (EC 3.1.3.5) from rat brain synaptosomes. Bonan CD, et al. **Gen Pharmacol** 1997 May;28(5):761-6

BIOSYNTHESIS

Stage-specific expression of P2Y receptors, ecto-apyrase, and ecto-5'-nucleotidase in myeloid leukocytes. Clifford EE, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):C973-87

Modulation of glomerular ECTO-ADPase expression by oestradiol. A histochemical study. Faas MM, et al. **Thromb Haemost** 1997 Apr;77(4):767-71

BLOOD

Free radical-induced inhibition of ATP diphosphohydrolase activity (EC 3.6.1.5) from rat blood platelets. Frassetto SS, et al. **Biochem Mol Biol Int** 1997 Jan;41(1):161-8

CHEMISTRY

ATP-diphosphophydrolase activity in rat heart tissue. Espinosa V, et al. **Biochem Mol Biol Int** 1996 Aug; 39(5):905-15

DEFICIENCY

Loss of rat glomerular ATP diphosphohydrolase activity during reperfusion injury is associated with oxidative stress reactions. Candinas D, et al. **Thromb Haemost** 1996 Nov; 76(5):807-12

GENETICS

Characterization of brain ecto-apyrase: evidence for only one ecto-apyrase (CD39) gene. Wang TF, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1-2):295-302

ISOLATION & PURIFICATION

Purification, characterization, and localization of two ATP diphosphohydrolase isoforms in bovine heart. Beaudoin AR, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H673-81

Purification and immunohistochemical localization of the ATP diphosphohydrolase in bovine lungs. Sévigny J, et al. **Am J Physiol** 1997 May;272(5 Pt 1):L939-50

Purification of the blood vessel ATP diphosphohydrolase, identification and localisation by immunological techniques. Sévigny J, et al. **Biochim Biophys Acta** 1997 Feb 11;1334(1):73-88

METABOLISM

Purification, characterization, and localization of two ATP diphosphohydrolase isoforms in bovine heart. Beaudoin AR, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H673-81

Purification and immunohistochemical localization of the ATP diphosphohydrolase in bovine lungs. Sévigny J, et al. **Am J Physiol** 1997 May;272(5 Pt 1):L939-50

Enzymatic treatment to eliminate the extracellular ATP for improving the detectability of bacterial intracellular ATP. Sakakibara T, et al. **Anal Biochem** 1997 Aug 1;250(2):157-61

ATP-diphosphophydrolase activity in rat heart tissue. Espinosa V, et al. **Biochem Mol Biol Int** 1996 Aug; 39(5):905-15

Effects of aluminum chloride on the kinetics of rat cortex synaptosomal ATP diphosphohydrolase (EC 3.6.1.5). Schetinger MR, et al. **Biol Trace Elem Res** 1995 Dec; 50(3):209-19

Modulation of vascular ATP diphosphohydrolase by fatty acids. Robson SC, et al. **Blood Coagul Fibrinolysis** 1997 Jan;8(1):21-7

Comparison of the biochemical properties, regulation and function of ATP-diphosphohydrolase from human placenta and rat kidney. Valenzuela MA, et al. **Braz J Med Biol Res** 1996 May;29(5):589-97

Kinetic characteristics of nucleoside mono-, di- and triphosphatase activities of the periplasmic 5'-nucleotidase of Escherichia coli. García L, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):135-42

Enzyme kinetics and the activation energy of Mg-ATPase in cardiac sarcolemma: ADP as an alternative substrate. Vrbjar N, et al. **Gen Physiol Biophys** 1995 Aug;14(4):313-21

Immunolocalization of the ecto-ATPase and ecto-apyrase in chicken gizzard and stomach. Purification and N-terminal sequence of the stomach ecto-apyrase. Lewis-Carl S, et al. **J Biol Chem** 1997 Sep 19; 272(38):23645-52

Loss of ATP diphosphohydrolase activity with endothelial cell activation. Robson SC, et al. **J Exp Med** 1997 Jan 6;185(1):153-63

Characterization and localization of an ATP diphosphohydrolase activity (EC 3.6.1.5) in sarcolemmal membrane from rat heart. Menezes de Oliveira E, et al. **Mol Cell Biochem** 1997 May;170(1-2):115-23

Sensitivity of ATPase-ADPase activities from synaptic plasma membranes of rat forebrain to lipid peroxidation in vitro and the protective effect of vitamin E. Vietta M, et al. **Neurochem Res** 1996 Mar;21(3):299-304

PHARMACOLOGY

The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. Marcus AJ, et al. **J Clin Invest** 1997 Mar 15;99(6):1351-60

Apyrase administration prolongs discordant xenograft survival. Koyamada N, et al. **Transplantation** 1996 Dec 27; 62(12):1739-43

PHYSIOLOGY

Ectonucleotidases, purine nucleoside transporter, and function of the bile canalicular plasma membrane of the hepatocyte. Che M, et al. **FASEB J** 1997 Feb;11(2):101-8 (86 ref.)

AQUACULTURE

Salt dermatitis in the aquarium industry. Tong D. **Contact Dermatitis** 1996 Jan;34(1):59-60

Fish Vaccinology. Oslo, Norway, June 5-7, 1996. Symposium proceedings and abstracts. **Dev Biol Stand** 1997; 90:1-484

Chlorinated pesticides and PCB content in thermal aquaculture of sturgeon (Acipenser naccarii). Bressa G, et al. **Food Addit Contam** 1996 Oct;13(7):843-50

Overview of "bumper car" disease--impact on the North American lobster fishery. Cawthorn RJ. **Int J Parasitol** 1997 Feb;27(2):167-72 (27 ref.)

Rapid liquid chromatographic method to distinguish wild salmon from aquacultured salmon fed synthetic astaxanthin. Turujman SA, et al. **J AOAC Int** 1997 May-Jun; 80(3):622-32

Major viral diseases affecting fish aquaculture in Spain. Pérez SI, et al. **Microbiologia** 1997 Jun;13(2):149-60 (43 ref.)

Historical aspects of international movement of living aquatic species. Bartley DM, et al. **Rev Sci Tech** 1996 Jun; 15(2):387-400 (25 ref.)

Review of disease control in aquaculture in the Republic of South Africa. Brückner GK. **Rev Sci Tech** 1996 Jun; 15(2):703-10 (9 ref.)

Current status of trade in cultured shrimps. Chen SN. **Rev Sci Tech** 1996 Jun;15(2):517-21 (8 ref.)

Importation of aquaculture seedlings to Japan. Wakabayashi H. **Rev Sci Tech** 1996 Jun;15(2):409-22 (17 ref.)

[International trade in bivalve mollusks and the current situation in France and in Europe] Le Borgne Y. **Rev Sci Tech** 1996 Jun;15(2):491-8 (6 ref.) (Eng. Abstr.) **(Fre)**

[International trade in living penaeid shrimp between countries in the Pacific and the Atlantic areas and in Europe] Michel A. **Rev Sci Tech** 1996 Jun;15(2):499-515 (35 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Overview of the current international trade in ornamental fish, with special reference to Singapore. Cheong L. **Rev Sci Tech** 1996 Jun;15(2):445-81 (4 ref.)

EDUCATION

Survey of veterinary college curriculum requirements relevant to aquatic medicine. The AVMA Aquaculture and Seafood Advisory Committee. **J Am Vet Med Assoc** 1997 Mar 15;210(6):764-5

LEGISLATION & JURISPRUDENCE

Chilean legislation for the control of diseases of aquatic species. Campos Larraín MC, et al. **Rev Sci Tech** 1996 Jun; 15(2):675-86 (16 ref.)

Animal health and the trade in aquatic animals within and to the European Union. Daelman W. **Rev Sci Tech** 1996 Jun;15(2):711-22 (6 ref.)

Synopsis of freshwater aquaculture legislation in Germany since national reunification. Schlotfeldt HJ. **Rev Sci Tech** 1996 Jun;15(2):687-701 (8 ref.)

METHODS

Offshore suspension relaying to reduce levels of Vibrio vulnificus in oysters (Crassostrea virginica). Motes ML, et al. **Appl Environ Microbiol** 1996 Oct;62(10):3875-7

[Bioassay of rainbow trout (Oncorhynchus mykiss) pigmentation using ancho chili (Capsicum annuum) extracts] Carter JV, et al. **Arch Latinoam Nutr** 1994 Dec; 44(4):252-5 (Eng. Abstr.) **(Spa)**

STANDARDS

Gas bubble disease in farmed fish in Saudi Arabia. Saeed MO, et al. **Vet Rec** 1997 Jun 28;140(26):682-4

Water quality parameters associated with Aeromonas spp-affected hatcheries. Ortega C, et al. **Vet Res** 1996; 27(6):553-60

TRENDS

[Problems and outlook for animal production in the aquatic environment] Kaushik S. **Bull Acad Natl Med** 1996 Nov; 180(8):1933-41; discussion 1941-2 (26 ref.) (Eng. Abstr.) **(Fre)**

AQUAREOVIRUS see **REOVIRIDAE**

AQUEDUCT OF SYLVIUS see **CEREBRAL AQUEDUCT**

AQUEOUS HUMOR

Measurement of protein concentration of aqueous humour in vivo: correlation between laser flare measurements and chemical protein determination. Saari KM, et al. **Acta Ophthalmol Scand** 1997 Feb;75(1):63-6

Cyanoacrylate glue treatment for persistent aqueous leak following postkeratoplasty relaxing incisions with compression sutures. Karabatsas CH, et al. **Doc Ophthalmol** 1996-97;92(2):93-6

Amsler's sign associated significantly with Fuch's heterochromic cyclitis (FHC). Bloch-Michel E, et al. **Int Ophthalmol** 1995-96;19(3):169-71

Effects of age and long-term caloric restriction on the aqueous collecting channel in the mouse eye. Li Y, et al. **J Glaucoma** 1997 Feb;6(1):18-22

Annular peripheral choroidal detachment simulating aqueous misdirection after glaucoma surgery. Dugel PU, et al. **Ophthalmology** 1997 Mar;104(3):439-44

CHEMISTRY

Comparative intraocular penetration of topical and injected cefuroxime [see comments] Jenkins CD, et al. **Br J Ophthalmol** 1996 Aug;80(8):685-8. Comment in: Br J Ophthalmol 1996 Aug;80(8):681-2.

Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated [letter] Sone H, et al. **Diabetes Care** 1996 Nov; 19(11):1306-7

High-performance liquid chromatographic assay of bromocriptine in plasma and eye tissue of the rabbit. Choi YJ, et al. **J Chromatogr B Biomed Appl** 1997 Jul 4; 694(2):415-20

Quantitative colorimetric and gas chromatographic determination of arecaidine propargyl ester. Langer K, et al. **J Chromatogr B Biomed Appl** 1997 May 9;692(2):345-50

Determination of ofloxacin in human aqueous humour by high-performance liquid chromatography with

fluorescence detection. Basci NE, et al.
J Pharm Biomed Anal 1997 Feb;15(5):663–6
Rapid liquid chromatographic assay of ciprofloxacin in human aqueous humor. Basci NE, et al.
J Pharm Biomed Anal 1996 Jan;14(3):353–6
[Quantitative evaluation of aqueous flare in psoriasis using a laser flare-cell meter] Okamoto F, et al.
Nippon Ganka Gakkai Zasshi 1997 Jun;101(6):487–91 (Eng. Abstr.) **(Jpn)**
[Level of uric acid in aqueous humor of patients with cataract] Kałużny J, et al. **Klin Oczna** 1996 Feb;98(2):97–9 (Eng. Abstr.) **(Pol)**
[Level of uric acid in aqueous and vitreous humor of man] Kałużny JJ, et al. **Klin Oczna** 1996 Feb;98(2):93–6 (Eng. Abstr.) **(Pol)**
[Tissue plasminogen activator (t-PA) in aqueous humor of patients with cataract] Kotschy M, et al. **Klin Oczna** 1996 Mar;98(3):201–3 (Eng. Abstr.) **(Pol)**

CYTOLOGY

Quantitative determination of aqueous flare and cells in healthy eyes. Guillén-Monterrubio OM, et al.
Acta Ophthalmol Scand 1997 Feb;75(1):58–62
Identification and characterization of cells infiltrating the graft and aqueous humour in rat corneal allograft rejection. Larkin DF, et al. **Clin Exp Immunol** 1997 Feb;107(2):381–91
Immunologic and virologic characterization of the primary infiltrating cells in the aqueous humor of human T-cell leukemia virus type-1 uveitis. Accumulation of the human T-cell leukemia virus type-1-infected cells and constitutive expression of viral and interleukin-6 messenger ribonucleic acids. Ono A, et al. **Invest Ophthalmol Vis Sci** 1997 Mar; 38(3):676–89
Lens epithelial cells in postoperative aqueous humor. Majima K. **Jpn J Ophthalmol** 1997 Jan–Feb;41(1):55–8
Comparison of T helper/T suppressor ratios in aqueous humor and blood samples by flow cytometric analysis. Avunduk AM, et al. **Ophthalmologica** 1997;211(2):84–6
[Tyndallometry and cell count in the anterior chamber in retinal detachment] Amann T, et al.
Klin Monatsbl Augenheilkd 1997 Jan;210(1):43–7 (Eng. Abstr.) **(Ger)**
[A clinical comparative study of tyndallometry using 2 laser flare meters] Nguyen NX, et al.
Klin Monatsbl Augenheilkd 1996 Aug–Sep;209(2–3):89–93 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis [see comments] Banker AS, et al. **Am J Ophthalmol** 1997 Aug;124(2):168–80. Comment in: Am J Ophthalmol 1997 Aug;124(2):227–33.
Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Maus TL, et al.
Arch Ophthalmol 1997 Jan;115(1):45–9
Inhibition of glutamate uptake causes an acute increase in aqueous humor protein. Langford MP, et al.
Exp Eye Res 1997 Feb;64(2):157–65
Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Tian B, et al. **Exp Eye Res** 1997 Jun;64(6):979–89
Effect of haloperidol, a dopamine antagonist on aqueous humour dynamics in experimental glaucoma. Khosla P, et al. **Indian J Exp Biol** 1996 Nov;34(11):1152–4
Timolol decreases aqueous humor flow but not Na+ movement from plasma to aqueous. Maren TH, et al.
Invest Ophthalmol Vis Sci 1997 May;38(6):1274–7
Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor of the uninflamed human eye. Akkan AG, et al. **J Chemother** 1997 Aug; 9(4):257–62
Atriopeptin lowers aqueous humor formation and intraocular pressure and elevates ciliary cyclic GMP but lacks uveal vascular effects in the bovine perfused eye. Millar JC, et al. **J Ocul Pharmacol Ther** 1997 Feb;13(1):1–11
Effects of endothelin A and B receptors on aqueous humor dynamics in the rabbit eye. Taniguchi T, et al.
J Ocul Pharmacol Ther 1996 Summer;12(2):123–30
The inflammatory potential of surgical glove lubricants: Biosorb, Keoflo, calcium carbonate and Hydrocote after intravitreal injection. Park HS, et al.
Korean J Ophthalmol 1997 Jun;11(1):51–9
Oxymetazoline: potential mechanisms of inhibitory effects on aqueous humor dynamics. Chu TC, et al. **Pharmacology** 1996 Oct;53(4):259–70
Experimental vitreous and aqueous replacement with perfluorophenanthrene. Clinical, histologic, and electrophysiologic results. Stolba U, et al. **Retina** 1997; 17(2):146–53
[Effect of nipradilol on aqueous flow in glaucoma patients treated with timolol] Nagataki S, et al.
Nippon Ganka Gakkai Zasshi 1997 Mar;101(3):252–6 (Eng. Abstr.) **(Jpn)**
[Effects of beta-adrenergic agonists and phosphodiesterase inhibitors on the outflow facility of the eye] Suzuki R, et al. **Nippon Ganka Gakkai Zasshi** 1997 Jul;101(7):551–7 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Cathepsin A activity of normal bovine ocular tissues and pathological human intraocular fluids. Obuchowska I, et al. **Acta Biochim Pol** 1996;43(4):687–92
Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Di Girolamo N, et al. **Curr Eye Res** 1996 Oct;15(10):1060–8

IMMUNOLOGY

Correlation between intraocular lens hydrophilicity and anterior capsule opacification and aqueous flare. Miyake K, et al. **J Cataract Refract Surg** 1996;22 Suppl 1:764–9
Postoperative inflammatory response to phacoemulsification and extracapsular cataract surgery: aqueous flare and cells. Pande MV, et al. **J Cataract Refract Surg** 1996;22 Suppl 1:770–4
Presence of antibodies in the aqueous humour and cerebrospinal fluid during Leishmania infections in dogs. Pathological features at the central nervous system. Garcia-Alonso M, et al. **Parasite Immunol** 1996 Nov; 18(11):539–46
Feline ocular and cerebrospinal fluid Toxoplasma gondii-specific humoral immune responses following specific and nonspecific immune stimulation. Lappin MR, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1–3):23–31
[Ocular toxoplasmosis: value of immunoblotting for the determination of an intra-ocular synthesis of antibodies] Riss JM, et al. **Pathol Biol (Paris)** 1995 Nov;43(9):772–8 (Eng. Abstr.) **(Fre)**
[T lymphocyte subsets in aqueous humor from patients with uveitis] Ohta K. **Nippon Ganka Gakkai Zasshi** 1996 Nov; 100(11):899–904 (Eng. Abstr.) **(Jpn)**

METABOLISM

Quenching of UV-induced fluorescence by ascorbic acid in the aqueous humour. Ringvold A.
Acta Ophthalmol Scand 1995 Dec;73(6):529–33
Cataract and aqueous flare levels in patients with atopic dermatitis. Matsuo T, et al. **Am J Ophthalmol** 1997 Jul; 124(1):36–9
Role of ion channels in aqueous humor formation. Jacob TJ, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):C703–20 (166 ref.)
Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Jaruratanasirikul S, et al. **Antimicrob Agents Chemother** 1996 Mar;40(3):825–6
Intracorneal, aqueous humor, and vitreous humor penetration of topical and oral ofloxacin. Donnenfeld ED, et al.
Arch Ophthalmol 1997 Feb;115(2):173–6
Aqueous humor penetration of topically applied ciprofloxacin, ofloxacin and tobramycin. Durmaz B, et al. **Arzneimittelforschung** 1997 Apr;47(4):413–5
Nitric oxide and transforming growth factor-beta levels during experimental uveitis in the rabbit [see comments] Rocha G, et al. **Can J Ophthalmol** 1997 Feb;32(1):17–24. Comment in: Can J Ophthalmol 1997 Feb;32(1):1–3.
Horseradish peroxidase: a reliable or a misleading tool for the investigations on the origin of the proteins of the aqueous humor? Mestriner AC, et al. **Cell Tissue Res** 1997 Jul;289(1):85–96
Extracellular glutathione peroxidase and ascorbic acid in aqueous humor and serum of patients operated on for cataract. Haung W, et al. **Clin Chim Acta** 1997 May 28; 261(2):117–30
Ocular penetration and pharmacokinetics of topical fluconazole. Yee RW, et al. **Cornea** 1997 Jan;16(1):64–71
Effect of 5-methylurapidil, an alpha 1a-adrenergic antagonist and 5-hydroxytryptamine1a agonist, on aqueous humor dynamics in monkeys and rabbits. Wang RF, et al.
Curr Eye Res 1997 Aug;16(8):769–75
Ocular penetration kinetics of fosfomycin administered as a one-hour infusion. Forestier F, et al. **Eur J Ophthalmol** 1996 Apr-Jun;6(2):137–42
Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. Madu AA, et al. **Exp Eye Res** 1996 Aug;63(2):129–36
The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%. Diestelhorst M, et al. **Graefes Arch Clin Exp Ophthalmol** 1997 Jan; 235(1):20–6
Ascorbic acid and amino acid values in the aqueous humor of a patient with Lowe's syndrome. Hayasaka S, et al.
Graefes Arch Clin Exp Ophthalmol 1997 Apr;235(4):217–21
How can the bioavailability of timolol be enhanced? A pharmacokinetic pilot study of novel hydrogels. von der Ohe N, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jul; 234(7):452–6
Timolol decreases aqueous humor flow but not Na+ movement from plasma to aqueous. Maren TH, et al.
Invest Ophthalmol Vis Sci 1997 May;38(6):1274–7
High-performance liquid chromatographic determination of vancomycin in rabbit serum, vitreous and aqueous humour after intravitreal injection of the drug. Del Nozal MJ, et al. **J Chromatogr A** 1996 Mar 15;727(2):231–8
Plasma and aqueous humor endothelin levels in primary open-angle glaucoma. Tezel G, et al. **J Glaucoma** 1997 Apr;6(2):83–9
Neuropeptide Y levels in the aqueous humor of rabbits. Hirota A, et al. **J Ocul Pharmacol Ther** 1996 Spring; 12(1):51–6
The penetration of topical cysteamine into the human eye. Hsuan JD, et al. **J Ocul Pharmacol Ther** 1996 Winter; 12(4):499–502
Effect of collagen cross-linking in collagen corneal shields on ocular drug delivery. Kuwano M, et al.
J Ocul Pharmacol Ther 1997 Feb;13(1):31–40
Microplate assay of ascorbic acid in aqueous humor with bicinchoninic acid. Shichi H, et al.
J Ocul Pharmacol Ther 1997 Jun;13(3):201–6
Effect of diclofenac on prostaglandin liberation in the rabbit after photorefractive keratectomy. Tomas-Barberan S, et al. **J Refract Surg** 1997 Mar-Apr;13(2):154–7
Excimer laser corneal surgery and free oxygen radicals. Bilgihan K, et al. **Jpn J Ophthalmol** 1996;40(2):154–7
Endothelin-1 and intraocular inflammation in pigmented rabbit eyes. Shoji N, et al. **Jpn J Ophthalmol** 1997 May–Jun; 41(3):150–3
Hypoxanthine and xanthine levels in human aqueous humor from cataractous eyes. Spoto G, et al. **Life Sci** 1996; 59(25–26):PL387–90
Electroconvulsive treatment evokes release of preprotachykinin-A mRNA into the cerebrospinal fluid and ocular aqueous humor of rabbits. Wang ZY, et al.
Neurosci Lett 1997 May 2;226(3):151–4
Effects of a nitric oxide synthase inhibitor on prostaglandin-induced aqueous flare elevation in pigmented rabbits. Hiraki S, et al. **Ophthalmic Res** 1996; 28(4):260–4
Effect of consecutively applied fluorescein eye drops on corneal and aqueous concentrations of fluorescein. Lindén C, et al. **Ophthalmic Res** 1997;29(2):57–60
Intracameral ascorbic acid, glutathione and protein levels in albino and pigmented rabbits. Numata K, et al.
Ophthalmic Res 1995;27(6):347–9
Decreased aqueous-flare reaction to repeated applications of prostaglandin E2 to the cornea in pigmented rabbits. Numata-Watanabe K, et al. **Ophthalmic Res** 1996; 28(3):147–52
Growth factors and their receptors in the anterior chamber. Absence of epidermal growth factor and transforming growth factor alpha in human aqueous humor. van Setten GB, et al. **Ophthalmic Res** 1996;28(6):361–4
Free radical production by Nd:YAG laser photodisruption. Timberlake GT, et al. **Ophthalmic Surg Lasers** 1997 Jul; 28(7):582–9
Penetration of oral cefuroxime axetil into the human aqueous humor. Ghia M, et al. **Ophthalmologica** 1997;211(4):229–31
Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Toris CB, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S69–75 (49 ref.)
[An experimental study on corneal collagen shield vehicle for delivery of pilocarpine] Sun X, et al.
Chung Hua Yen Ko Tsa Chih 1996 Mar;32(2):143–6 (Eng. Abstr.) **(Chi)**
[Contribution of free-radical reactions of chamber humor to the development of primary open-angle glaucoma] Kurysheva NI, et al. **Vestn Oftalmol** 1996 Sep–Oct; 112(4):3–5 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Uveitis: is ocular toxoplasmosis only a clinical diagnosis? Bornand JE, et al. **Ophthalmologica** 1997;211(2):87–9

PARASITOLOGY

Serological and polymerase chain reaction-based analysis of aqueous humour samples in patients with AIDS and necrotizing retinitis. Verbraak FD, et al. **AIDS** 1996 Sep; 10(10):1091–9
Polymerase chain reaction for the detection of Toxoplasma gondii in aqueous humor of cats. Lappin MR, et al.
Am J Vet Res 1996 Nov;57(11):1589–93
Chorioretinitis following liver transplantation: detection of Toxoplasma gondii in aqueous humor. Blanc-Jouvan M, et al. **Clin Infect Dis** 1996 Jan;22(1):184–5
Use of polymerase chain reaction assays of aqueous humor in the differential diagnosis of retinitis in patients infected with human immunodeficiency virus. Danise A, et al.
Clin Infect Dis 1997 Jun;24(6):1100–6

PHYSIOLOGY

Corrosion casts of the suprachoroidal space and uveoscleral drainage routes in the human eye. Krohn J, et al.
Acta Ophthalmol Scand 1997 Feb;75(1):32–5
Pathological dilemmas in the outflow system in primary open-angle glaucoma. Grierson I, et al.
Acta Ophthalmol Scand Suppl 1997;(220):7–12; discussion 13–4 (39 ref.)
Expanding forces in aqueous outflow pathways of a nonaccommodating mammal: an approach via comparative dynamic morphology. Carreras FJ, et al.
Comp Biochem Physiol A Physiol 1997 Jun;117(2):197–209
Atropine reduces but does not eliminate the age-related decline in perfusion outflow facility in monkeys. Kiland JA, et al. **Exp Eye Res** 1997 May;64(5):831–5
The role of soluble proteins in generating aqueous outflow resistance in the bovine and human eye. Sit AJ, et al.
Exp Eye Res 1997 May;64(5):813–21
Circadian aqueous flow mediated by beta-arrestin induced homologous desensitization. Wan XL, et al.
Exp Eye Res 1997 Jun;64(6):1005–11
Effects of Er:YAG laser trabecular ablation on outflow facility in cadaver porcine eyes. Jacobi PC, et al.

Graefes Arch Clin Exp Ophthalmol 1996 Aug;234 Suppl 1:S204–8

Determination of the pseudofacility by fluorophotometry in the human eye. Beneyto Martin P, et al. **Int Ophthalmol** 1995–96;19(4):219–23

Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Apte RS, et al. **Invest Ophthalmol Vis Sci** 1997 May;38(6):1277–82

Nonsulfhydryl-reactive phenoxyacetic acids increase aqueous humor outflow facility. Epstein DL, et al. **Invest Ophthalmol Vis Sci** 1997 Jul;38(8):1526–34

Comparative analysis of the fluidics of the AMO Prestige, Alcon Legacy, and Storz Premiere phacoemulsification systems. Wilbrandt HR. **J Cataract Refract Surg** 1997 Jun; 23(5):766–80

Aqueous humor flow in unilateral carotid stenosis. Kaplan BH, et al. **J Glaucoma** 1996 Aug;5(4):237–40

Effects of adrenergic agents and phosphodiesterase inhibitors on outflow facility and cell shape of bovine trabecular meshwork. Suzuki R, et al. **Jpn J Ophthalmol** 1997 Jan–Feb;41(1):31–7

Effect of dapiprazole, an alpha-adrenergic blocking agent, on aqueous humor dynamics in pigmentary glaucoma. Mastropasqua L, et al. **Ophthalmic Res** 1996;28(5):312–8

Aceclidine effects on outflow facility after ciliary muscle disinsertion. Hubbard WC, et al. **Ophthalmologica** 1996; 210(5):303–7

The effect of phacoemulsification on aqueous outflow facility. Meyer MA, et al. **Ophthalmology** 1997 Aug; 104(8):1221–7

Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Mishima HK, et al. **Surv Ophthalmol** 1997 Feb;41 Suppl 2:S139–44 (26 ref.)

Facility changes mediated by cAMP in the bovine anterior segment in vitro. Gilabert R, et al. **Vision Res** 1997 Jan; 37(1):9–15

[Regulation of glutathione level in venous plasma and aqueous humor in cataracta senilis provecta] Stahl E, et al. **Ophthalmologe** 1996 Feb;93(1):54–8 (Eng. Abstr.) **(Ger)**

[Prostaglandins increase the response of intraocular muscle and outflow facility of the eye] Suzuki R. **J Smooth Muscle Res** 1996 Oct;32(5):213–8 (Eng. Abstr.) **(Jpn)**

[Biomechanical characteristics of interactions between the drainage and accommodation regulatory systems of the eye in health and in contusion sens subluxation] Volkov VV, et al. **Vestn Oftalmol** 1997 May–Jun;113(3):5–7 (21 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Quenching of UV-induced fluorescence by ascorbic acid in the aqueous humour. Ringvold A. **Acta Ophthalmol Scand** 1995 Dec;73(6):529–33

Modulation of the blood–aqueous barrier by light exposure in patients with uveitis. Cuzzani O, et al. **Can J Ophthalmol** 1997 Jun;32(4):244–9

Free radical production by Nd:YAG laser photodisruption. Timberlake GT, et al. **Ophthalmic Surg Lasers** 1997 Jul; 28(7):582–9

An apparatus for ultraviolet B irradiation of small volumes of biological fluid under controlled oxygen tension. Richer SP, et al. **Optom Vis Sci** 1996 Nov;73(11):683–8

SECRETION

Retinal complications after aqueous shunt surgical procedures for glaucoma. Law SK, et al. **Arch Ophthalmol** 1996 Dec; 114(12):1473–80

Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Maus TL, et al. **Arch Ophthalmol** 1997 Jan;115(1):45–9

Aqueous humor dynamics in rats. Mermoud A, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Aug;234 Suppl 1:S198–203

Increase in aqueous humor production following D1 receptors activation by means of ibopamine. Virno M, et al. **Int Ophthalmol** 1996–97;20(1–3):141–6

Anterior segment physiology after bumetanide inhibition of Na–K–Cl cotransport. Gabelt BT, et al. **Invest Ophthalmol Vis Sci** 1997 Aug;38(9):1700–7

Effects of time of storage, albumin, and osmolality changes on outflow facility (C) of bovine anterior segment in vitro. Gual A, et al. **Invest Ophthalmol Vis Sci** 1997 Sep; 38(10):2165–71

Gene expression of the neurotrophic pigment epithelium-derived factor in the human ciliary epithelium. Synthesis and secretion into the aqueous humor. Ortego J, et al. **Invest Ophthalmol Vis Sci** 1996 Dec;37(13):2759–67

Ocular outflow facility with emphasis on neuronal regulation of intraocular smooth muscles. Suzuki R. **J Smooth Muscle Res** 1996 Dec;32(6):229–47 (82 ref.)

VIROLOGY

Serological and polymerase chain reaction-based analysis of aqueous humour samples in patients with AIDS and necrotizing retinitis. Verbraak FD, et al. **AIDS** 1996 Sep; 10(10):1091–9

Use of polymerase chain reaction assays of aqueous humor in the differential diagnosis of retinitis in patients infected with human immunodeficiency virus. Danise A, et al. **Clin Infect Dis** 1997 Jun;24(6):1100–6

AQUEOUS SHUNTS see **MOLTENO IMPLANTS**

ARA-A see **VIDARABINE**

ARA-AMP see **VIDARABINE PHOSPHATE**

ARA-C see **CYTARABINE**

ARA-CTP see **ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE**

ARA-U see **ARABINOFURANOSYLURACIL**

ARAB WORLD

Women's health problems in the Arab World: a holistic policy perspective. Zurayk H, et al. **Int J Gynaecol Obstet** 1997 Jul;58(1):13–21

HISTORY

Destruction of a hospital. Galton DJ. **J R Soc Med** 1997 Jul;90(7):406–8

ARABIDOPSIS

In vitro motility of AtKCBP, a calmodulin-binding kinesin protein of Arabidopsis. Song H, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):322–7

ANATOMY & HISTOLOGY

Determination of floral organ identity by Arabidopsis MADS domain homeotic proteins AP1, AP3, PI, and AG is independent of their DNA-binding specificity. Riechmann JL, et al. **Mol Biol Cell** 1997 Jul;8(7):1243–59

CHEMISTRY

The heterologous interactions among plant 14–3–3 proteins and identification of regions that are important for dimerization. Wu K, et al. **Arch Biochem Biophys** 1997 Mar 1;339(1):2–8

Proton pump and auxin effect in Arabidopsis thaliana leaves during the development. Bellamine J, et al. **Biochem Mol Biol Int** 1996 Sep;40(1):127–33

Osmotic stress activated expression of an Arabidopsis plasma membrane-associated protein: sequence and predicted secondary structure. Galaud JP, et al. **Biochim Biophys Acta** 1997 Aug 15;1341(1):79–86

Arabidopsis thaliana ECP63 encoding a LEA protein is located in chromosome 4. Yang H, et al. **Gene** 1997 Jan 3;184(1):83–8

Characterization of a zinc-dependent transcriptional activator from Arabidopsis. de Pater S, et al. **Nucleic Acids Res** 1996 Dec 1;24(23):4624–31

Evidence for FUS6 as a component of the nuclear-localized COP9 complex in Arabidopsis. Staub JM, et al. **Plant Cell** 1996 Nov;8(11):2047–56

Arabidopsis cryptochrome 1 is a soluble protein mediating blue light-dependent regulation of plant growth and development. Lin C, et al. **Plant J** 1996 Nov;10(5):893–902

Mutants of Arabidopsis thaliana with altered cell wall polysaccharide composition. Reiter WD, et al. **Plant J** 1997 Aug;12(2):335–45

Comparative modeling of the three-dimensional structure of the calmodulin-related TCH2 protein from Arabidopsis. Khan AR, et al. **Proteins** 1997 Jan;27(1):144–53

The crystal structure of a major allergen from plants. Thorn KS, et al. **Structure** 1997 Jan 15;5(1):19–32

CYTOLOGY

Developmental regulation of cell interactions in the Arabidopsis fiddlehead-1 mutant: a role for the epidermal cell wall and cuticle. Lolle SJ, et al. **Dev Biol** 1997 Sep 15;189(2):311–21

Plastid distribution in columella cells of a starchless Arabidopsis mutant grown in microgravity. Hilaire E, et al. **Plant Cell Physiol** 1997 Apr;38(4):490–4

Modulation of cyclin transcript levels in cultured cells of Arabidopsis thaliana. Fuerst RA, et al. **Plant Physiol** 1996 Nov;112(3):1023–33

Cellular differentiation regulated by gibberellin in the Arabidopsis thaliana pickle mutant. Ogas J, et al. **Science** 1997 Jul 4;277(5322):91–4

Epidermal cell differentiation in Arabidopsis determined by a Myb homolog, CPC. Wada T, et al. **Science** 1997 Aug 22;277(5329):1113–6

DRUG EFFECTS

Ethylene induces stomata differentiation in Arabidopsis. Serna L, et al. **Int J Dev Biol** 1996;Suppl 1:123S–124S

Herbicide safener-inducible gene expression in Arabidopsis thaliana. De Veylder L, et al. **Plant Cell Physiol** 1997 May; 38(5):568–77

Interactions between the ABI1 and the ectopically expressed ABI3 genes in controlling abscisic acid responses in Arabidopsis vegetative tissues. Parcy F, et al. **Plant J** 1997 Apr;11(4):693–702

The Arabidopsis homeobox gene ATHB-7 is induced by water deficit and by abscisic acid. Söderman E, et al. **Plant J** 1996 Aug;10(2):375–81

Adenylosuccinate synthetase: site of action of hydantocidin, a microbial phytotoxin. Siehl DL, et al. **Plant Physiol** 1996 Mar;110(3):753–8

Gibberellins and stem growth in Arabidopsis thaliana. Effects of photoperiod on expression of the GA4 and GA5 loci. Xu YL, et al. **Plant Physiol** 1997 Aug;114(4):1471–6

EMBRYOLOGY

Induction and expression of seed-specific promoters in Arabidopsis embryo-defective mutants. Devic M, et al. **Plant J** 1996 Feb;9(2):205–15

ENZYMOLOGY

Formaldehyde dehydrogenase from yeast and plant. Implications for the general functional and structural significance of class III alcohol dehydrogenase. Fernández MR, et al. **Adv Exp Med Biol** 1997;414:373–81

Expression of CYP71B7, a cytochrome P450 expressed sequence Tag from Arabidopsis thaliana. Maughan JA, et al. **Arch Biochem Biophys** 1997 May 1;341(1):104–11

A mutant of Arabidopsis thaliana (L.) Heynh. with modified control of aspartate kinase by threonine. Heremans B, et al. **Biochem Genet** 1997 Apr;35(3–4):139–53

From sequence analysis of three novel ascorbate peroxidases from Arabidopsis thaliana to structure, function and evolution of seven types of ascorbate peroxidase. Jespersen HM, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):305–10

Purification and properties of cystathionine beta-lyase from Arabidopsis thaliana overexpressed in Escherichia coli. Ravanel S, et al. **Biochem J** 1996 Dec 1;320 (Pt 2):383–92

Evidence for multiple forms of biotin holocarboxylase synthetase in pea (Pisum sativum) and in Arabidopsis thaliana: subcellular fractionation studies and isolation of a cDNA clone. Tissot G, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):179–88

Identification of a putative flexible loop in Arabidopsis glutathione synthetase. Wang CL, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):241–4

Glutathione synthetase: similarities of the proteins from Schizosaccharomyces pombe and Arabidopsis thaliana. Wang CL, et al. **Biochem J** 1997 Sep 1;326 (Pt 2):563–6

Cloning of a cDNA encoding a putative metal-transporting P-type ATPase from Arabidopsis thaliana. Tabata K, et al. **Biochim Biophys Acta** 1997 May 22;1326(1):1–6

The CLAVATA1 gene encodes a putative receptor kinase that controls shoot and floral meristem size in Arabidopsis. Clark SE, et al. **Cell** 1997 May 16;89(4):575–85

Protein phosphatase activity of abscisic acid insensitive 1 (ABI1) protein from Arabidopsis thaliana. Bertauche N, et al. **Eur J Biochem** 1996 Oct 1;241(1):193–200

Differential expression of three Arabidopsis genes encoding the B' regulatory subunit of protein phosphatase 2A. Latorre KA, et al. **Eur J Biochem** 1997 Apr 1;245(1):156–63

Arabidopsis formaldehyde dehydrogenase. Molecular properties of plant class III alcohol dehydrogenase provide further insights into the origins, structure and function of plant class p and liver class I alcohol dehydrogenases. Martínez MC, et al. **Eur J Biochem** 1996 Nov 1; 241(3):849–57

Complex ATP-activation kinetics of plant H+-transporting ATPase may or may not require two substrate sites. Roberts G, et al. **Eur J Biochem** 1997 May 15;246(1):228–32

Structure and regulation of ferredoxin-dependent glutamase synthase from Arabidopsis thaliana. Cloning of cDNA expression in different tissues of wild-type and gltS mutant strains, and light induction. Suzuki A, et al. **Eur J Biochem** 1997 Feb 1;243(3):708–18

The Arabidopsis Cks1At protein binds the cyclin-dependent kinases Cdc2aAt and Cdc2bAt. De Veylder L, et al. **FEBS Lett** 1997 Aug 4;412(3):446–52

Purification and characterization of a fusion protein of plant acetohydroxy acid synthase and acetohydroxy acid isomeroreductase. Dumas R, et al. **FEBS Lett** 1997 May 19;408(2):156–60

Structure and organ specificity of an anionic peroxidase from Arabidopsis thaliana cell suspension culture. Ostergaard L, et al. **FEBS Lett** 1996 Dec 2;398(2–3):243–7

Regulation of catalases in Arabidopsis. McClung CR. **Free Radic Biol Med** 1997;23(3):489–96 (66 ref.)

Cloning and characterization of the gene encoding IMP dehydrogenase from Arabidopsis thaliana. Collart FR, et al. **Gene** 1996 Oct 3;174(2):217–20

Molecular cloning and characterization of a cDNA that encodes protoporphyrinogen oxidase of Arabidopsis thaliana. Narita S, et al. **Gene** 1996 Dec 5;182(1–2):169–75

Cloning of the Arabidopsis and rice formaldehyde dehydrogenase genes: implications for the origin of plant ADH enzymes. Dolferus R, et al. **Genetics** 1997 Jul; 146(3):1131–41

Intragenic recombination in the Adh locus of the wild plant Arabidopsis thaliana. Innan H, et al. **Genetics** 1996 Aug; 143(4):1761–70

An allelic series of blue fluorescent trp1 mutants of Arabidopsis thaliana. Rose AB, et al. **Genetics** 1997 Jan; 145(1):197–205

Specificity and stoichiometry of the Arabidopsis H+/amino acid transporter AAP5. Boorer KJ, et al. **J Biol Chem** 1997 May 16;272(20):13040–6

The Arabidopsis thaliana FPS1 gene generates a novel mRNA that encodes a mitochondrial farnesyl-diphosphate

synthase isoform. Cunillera N, et al. **J Biol Chem** 1997 Jun 13;272(24):15381–8

Reconstitution of yeast and Arabidopsis RNA polymerase alpha–like subunit heterodimers. Larkin RM, et al. **J Biol Chem** 1997 May 9;272(19):12824–30

Siroheme biosynthesis in higher plants. Analysis of an S–adenosyl–L–methionine–dependent uroporphyrinogen III methyltransferase from Arabidopsis thaliana. Leustek T, et al. **J Biol Chem** 1997 Jan 31;272(5):2744–52

Identification, characterization, and molecular cloning of a homologue of the bacterial FtsH protease in chloroplasts of higher plants. Lindahl M, et al. **J Biol Chem** 1996 Nov 15;271(46):29329–34

Identification and characterization of a novel plant phospholipase D that requires polyphosphoinositides and submicromolar calcium for activity in Arabidopsis. Pappan K, et al. **J Biol Chem** 1997 Mar 14;272(11):7048–54

TOUSLED is a nuclear serine/threonine protein kinase that requires a coiled–coil region for oligomerization and catalytic activity. Roe JL, et al. **J Biol Chem** 1997 Feb 28;272(9):5838–45

Cloning and functional analysis of the beta–carotene hydroxylase of Arabidopsis thaliana. Sun Z, et al. **J Biol Chem** 1996 Oct 4;271(40):24349–52

Cloning, yeast expression, and characterization of the coupling of two distantly related Arabidopsis thaliana NADPH–cytochrome P450 reductases with P450 CYP73A5. Urban P, et al. **J Biol Chem** 1997 Aug 1; 272(31):19176–86

Genetic and biochemical analysis of the transmembrane domain of Arabidopsis 3–hydroxy–3–methylglutaryl coenzyme A reductase. Re EB, et al. **J Cell Biochem** 1997 Jun 15;65(4):443–59

Crystal structure of Arabidopsis thaliana NADPH dependent thioredoxin reductase at 2.5 A resolution. Dai S, et al. **J Mol Biol** 1996 Dec 20;264(5):1044–57

Cloning of CTP:phosphocholine cytidylyltransferase cDNA from Arabidopsis thaliana. Choi SB, et al. **Mol Cells** 1997 Feb 28;7(1):58–63

AtUBP3 and AtUBP4 are two closely related Arabidopsis thaliana ubiquitin–specific proteases present in the nucleus. Chandler JS, et al. **Mol Gen Genet** 1997 Jul;255(3):302–10

Telomerase activity in plant extracts. Heller K, et al. **Mol Gen Genet** 1996 Sep 13;252(3):342–5

Characterization of tryptophan synthase alpha subunit mutants of Arabidopsis thaliana. Radwanski ER, et al. **Mol Gen Genet** 1996 Dec 13;253(3):353–61

An enzyme similar to animal type II photolyases mediates photoreactivation in Arabidopsis. Ahmad M, et al. **Plant Cell** 1997 Feb;9(2):199–207

Distinct UV–B and UV–A/blue light signal transduction pathways induce chalcone synthase gene expression in Arabidopsis cells. Christie JM, et al. **Plant Cell** 1996 Sep; 8(9):1555–67

Functional analysis of the beta and epsilon lycopene cyclase enzymes of Arabidopsis reveals a mechanism for control of cyclic carotenoid formation. Cunningham FX Jr, et al. **Plant Cell** 1996 Sep;8(9):1613–26

Hexokinase as a sugar sensor in higher plants. Jang JC, et al. **Plant Cell** 1997 Jan;9(1):5–19

A nuclear gene encoding mitochondrial proline dehydrogenase, an enzyme involved in proline metabolism, is upregulated by proline but downregulated by dehydration in Arabidopsis. Kiyosue T, et al. **Plant Cell** 1996 Aug;8(8):1323–35

A chlorate–resistant mutant defective in the regulation of nitrate reductase gene expression in Arabidopsis defines a new HY locus. Lin Y, et al. **Plant Cell** 1997 Jan;9(1):21–35

Effects of synergistic signaling by phytochrome A and cryptochrome1 on circadian clock–regulated catalase expression. Zhong HH, et al. **Plant Cell** 1997 Jun; 9(6):947–55

Hydroxypyruvate reductase with a carboxy–terminal targeting signal to microbodies is expressed in Arabidopsis. Mano S, et al. **Plant Cell Physiol** 1997 Apr;38(4):449–55

Cloning and functional expression of a novel geranylgeranyl pyrophosphate synthase gene from Arabidopsis thaliana in Escherichia coli. Zhu XF, et al. **Plant Cell Physiol** 1997 Mar;38(3):357–61

Modified plant plasma membrane H(+)–ATPase with improved transport coupling efficiency identified by mutant selection in yeast. Baunsgaard L, et al. **Plant J** 1996 Sep; 10(3):451–8

Interaction of the maize and Arabidopsis kinase interaction domains with a subset of receptor–like protein kinases: implications for transmembrane signaling in plants. Braun DM, et al. **Plant J** 1997 Jul;12(1):83–95

Nitrite reductase expression is regulated at the post–transcriptional level by the nitrogen source in Nicotiana plumbaginifolia and Arabidopsis thaliana. Crété P, et al. **Plant J** 1997 Apr;11(4):625–34

Isolation and characterization of an Arabidopsis thaliana cDNA encoding a delta 7–sterol–C–5–desaturase by functional complementation of a defective yeast mutant. Gachotte D, et al. **Plant J** 1996 Mar;9(3):391–8

Light modulates the spatial patterns of 3–hydroxy–3–methylglutaryl coenzyme A reductase gene expression in Arabidopsis thaliana. Learned RM, et al. **Plant J** 1997 Mar;11(3):499–511

Very–long–chain fatty acid biosynthesis is controlled through the expression and specificity of the condensing enzyme. Millar AA, et al. **Plant J** 1997 Jul;12(1):121–31

Possible involvement of differential splicing in regulation of the activity of Arabidopsis ANP1 that is related to mitogen–activated protein kinase kinase kinases (MAPKKKs). Nishihama R, et al. **Plant J** 1997 Jul; 12(1):39–48

Developmental regulation of the gibberellin biosynthetic gene GA1 in Arabidopsis thaliana. Silverstone AL, et al. **Plant J** 1997 Jul;12(1):9–19

A novel nucleic acid helicase gene identified by promoter trapping in Arabidopsis. Wei W, et al. **Plant J** 1997 Jun; 11(6):1307–14

Aspartic proteinase genes in the Brassicaceae Arabidopsis thaliana and Brassica napus. D'Hondt K, et al. **Plant Mol Biol** 1997 Jan;33(1):187–92

Molecular characterization of an Arabidopsis thaliana cDNA coding for a monofunctional aspartate kinase. Frankard V, et al. **Plant Mol Biol** 1997 May;34(2):233–42

AtPLC2, a gene encoding phosphoinositide–specific phospholipase C, is constitutively expressed in vegetative and floral tissues in Arabidopsis thaliana. Hirayama T, et al. **Plant Mol Biol** 1997 May;34(1):175–80

Isolation of a cDNA encoding an Arabidopsis galactokinase by functional expression in yeast. Kaplan CP, et al. **Plant Mol Biol** 1997 Jun;34(3):497–506

Cloning and expression of an Arabidopsis thaliana cDNA encoding a monofunctional aspartate kinase homologous to the lysine–sensitive enzyme of Escherichia coli. Tang G, et al. **Plant Mol Biol** 1997 May;34(2):287–93

Cinnamate–4–hydroxylase expression in Arabidopsis. Regulation in response to development and the environment. Bell–Lelong DA, et al. **Plant Physiol** 1997 Mar;113(3):729–38

Targeting of two Arabidopsis H(+)–ATPase isoforms to the plasma membrane. DeWitt ND, et al. **Plant Physiol** 1996 Oct;112(2):833–44

Catalase is encoded by a multigene family in Arabidopsis thaliana (L.) Heynh. Frugoli JA, et al. **Plant Physiol** 1996 Sep;112(1):327–36

Developmental regulation of pyrroline–5–carboxylate reductase gene expression in Arabidopsis. Hua XJ, et al. **Plant Physiol** 1997 Aug;114(4):1215–24

Sequences necessary for nitrate–dependent transcription of Arabidopsis nitrate reductase genes. Hwang CF, et al. **Plant Physiol** 1997 Mar;113(3):853–62

Isolation of a cDNA and a genomic clone encoding cinnamate 4–hydroxylase from Arabidopsis and its expression manner in planta. Mizutani M, et al. **Plant Physiol** 1997 Mar;113(3):755–63

Biotin synthase from Arabidopsis thaliana. cDNA isolation and characterization of gene expression. Patton DA, et al. **Plant Physiol** 1996 Sep;112(1):371–8

Characterization of flavonol synthase and leucoanthocyanidin dioxygenase genes in Arabidopsis. Further evidence for differential regulation of "early" and "late" genes. Pelletier MK, et al. **Plant Physiol** 1997 Apr; 113(4):1437–45

Spaceflight exposure effects on transcription, activity, and localization of alcohol dehydrogenase in the roots of Arabidopsis thaliana. Porterfield DM, et al. **Plant Physiol** 1997 Mar;113(3):685–93

13C nuclear magnetic resonance detection of interactions of serine hydroxymethyltransferase with C1–tetrahydrofolate synthase and glycine decarboxylase complex activities in Arabidopsis. Prabhu V, et al. **Plant Physiol** 1996 Sep; 112(1):207–16

Characterization and expression of NAD(H)–dependent glutamate dehydrogenase genes in Arabidopsis. Turano FJ, et al. **Plant Physiol** 1997 Apr;113(4):1329–41

Three members of a novel small gene–family from Arabidopsis thaliana able to complement functionally an Escherichia coli mutant defective in PAPS reductase activity encode proteins with a thioredoxin–like domain and "APS reductase" activity. Gutierrez–Marcos JF, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13377–82

Sulfate reduction in higher plants: molecular evidence for a novel 5'–adenylylsulfate reductase. Setya A, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13383–8

A possible role for kinase–associated protein phosphatase in the Arabidopsis CLAVATA1 signaling pathway. Williams RW, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16; 94(19):10467–72

Mitochondrial and chloroplast phage–type RNA polymerases in Arabidopsis. Hedtke B, et al. **Science** 1997 Aug 8; 277(5327):809–11

GENETICS

The genetics of flower development: from floral induction to ovule morphogenesis. Weigel D. **Annu Rev Genet** 1995; 29:19–39 (93 ref.)

Evolution of a mitochondrial tRNA PHE gene in A. thaliana: import of cytosolic tRNA PHE into mitochondria. Chen HC, et al. **Biochem Biophys Res Commun** 1997 Aug 18; 237(2):432–7

Characterization of a cDNA encoding Arabidopsis thaliana inositol 1,3,4–trisphosphate 5/6–kinase. Wilson MP, et al. **Biochem Biophys Res Commun** 1997 Mar 27;232(3):678–81

Molecular cloning and characterization of the thiolesterase glyoxalase II from Arabidopsis thaliana. Ridderström M, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):449–54

The methylation pattern of a cytosine DNA–methyltransferase gene in Arabidopsis thaliana plants. Kutueva LI, et al. **Biochem Mol Biol Int** 1996 Oct; 40(2):347–53

Cysteine biosynthesis in higher plants: a new member of the Arabidopsis thaliana serine acetyltransferase small gene–family obtained by functional complementation of an Escherichia coli cysteine auxotroph. Howarth JR, et al. **Biochim Biophys Acta** 1997 Feb 7;1350(2):123–7

Exon prediction in eucaryotic genomes. Vignal L, et al. **Biochimie** 1996;78(5):327–34

Developmental phenotypic plasticity: where ecology and evolution meet molecular biology. Callahan HS, et al. **Bioessays** 1997 Jun;19(6):519–25 (58 ref.)

Genetic analysis of genomic methylation patterns in plants and mammals. Yoder JA, et al. **Biol Chem** 1996 Oct; 377(10):605–10 (32 ref.)

The rps4–gene is encoded upstream of the nad2–gene in Arabidopsis mitochondria. Lippok B, et al. **Biol Chem Hoppe Seyler** 1996 Apr;377(4):251–7

Simplified selection of transgenic Arabidopsis thaliana seed in liquid culture. Nichols KW, et al. **Biotechniques** 1997 Jan;22(1):62–3

The Arabidopsis NPR1 gene that controls systemic acquired resistance encodes a novel protein containing ankyrin repeats. Cao H, et al. **Cell** 1997 Jan 10;88(1):57–63

The CLAVATA1 gene encodes a putative receptor kinase that controls shoot and floral meristem size in Arabidopsis. Clark SE, et al. **Cell** 1997 May 16;89(4):575–85

A novel zinc finger protein is encoded by the Arabidopsis LSD1 gene and functions as a negative regulator of plant cell death. Dietrich RA, et al. **Cell** 1997 Mar 7;88(5):685–94

FCA, a gene controlling flowering time in Arabidopsis, encodes a protein containing RNA–binding domains. Macknight R, et al. **Cell** 1997 May 30;89(5):737–45

Serine acetyltransferase from Arabidopsis thaliana can functionally complement the cysteine requirement of a cysE mutant strain of Escherichia coli. Murillo M, et al. **Cell Mol Biol Res** 1995;41(5):425–33

Multiple repetitive DNA sequences in the paracentromeric regions of Arabidopsis thaliana L. Brandes A, et al. **Chromosome Res** 1997 Jun;5(4):238–46

Flower development: repressing reproduction. Weigel D. **Curr Biol** 1997 Jun 1;7(6):R373–5 (14 ref.)

lem7, a novel temperature–sensitive Arabidopsis mutation that reversibly inhibits vegetative development. Meisel L, et al. **Dev Biol** 1996 Oct 10;179(1):116–34

sidecar pollen, an Arabidopsis thaliana male gametophytic mutant with aberrant cell divisions during pollen development. Chen YC, et al. **Development** 1996 Oct; 122(10):3243–53

SHORT INTEGUMENT (SIN1), a gene required for ovule development in Arabidopsis, also controls flowering time. Ray A, et al. **Development** 1996 Sep;122(9):2631–8

Pollen tube guidance by the female gametophyte. Ray SM, et al. **Development** 1997 Jun;124(12):2489–98

Structural and genetic analysis of epidermal cell differentiation in Arabidopsis primary roots. Schneider K, et al. **Development** 1997 May;124(9):1789–98

Dissection of sexual organ ontogenesis: a genetic analysis of ovule development in Arabidopsis thaliana. Schneitz K, et al. **Development** 1997 Apr;124(7):1367–76

TETRASPORE is required for male meiotic cytokinesis in Arabidopsis thaliana. Spielman M, et al. **Development** 1997 Jul;124(13):2645–57

Nucleotide sequence of the psbP gene encoding precursor of 23–kDa polypeptide of oxygen–evolving complex in Arabidopsis thaliana and its expression in the wild–type and a constitutively photomorphogenic mutant. Kochhar A, et al. **DNA Res** 1996 Oct 31;3(5):277–85

Genomic recombination of the mitochondrial atp6 gene in Arabidopsis thaliana at the protein processing site creates two different presequences. Marienfeld J, et al. **DNA Res** 1996 Oct 31;3(5):287–90

Amplification of long targets of approximately 50 kb from cloned cosmid inserts of Arabidopsis thaliana. Seki M, et al. **DNA Res** 1996 Apr 30;3(2):107–8

New structure and function in plant K+ channels: KCO1, an outward rectifier with a steep Ca2+ dependency. Czempinski K, et al. **EMBO J** 1997 May 15;16(10):2565–75

Structure and regulation of ferredoxin–dependent glutamase synthase from Arabidopsis thaliana. Cloning of cDNA expression in different tissues of wild–type and gltS mutant strains, and light induction. Suzuki A, et al. **Eur J Biochem** 1997 Feb 1;243(3):708–18

The Arabidopsis thaliana cDNA sequencing projects. Delseny M, et al. **FEBS Lett** 1997 Mar 24;405(2):129–32 (30 ref.)

The Arabidopsis thaliana cDNA sequencing projects. Delseny M, et al. **FEBS Lett** 1997 Feb 24;403(3):221–4 (30 ref.)

Characterization of three cDNA species encoding plastid RNA polymerase sigma factors in Arabidopsis thaliana: evidence for the sigma factor heterogeneity in higher plant plastids. Tanaka K, et al. **FEBS Lett** 1997 Aug 18; 413(2):309–13

Differential expression of genes coding for ABC transporters after treatment of Arabidopsis thaliana with xenobiotics. Tommasini R, et al. **FEBS Lett** 1997 Jul 14;411(2–3):206–10

Sequence and characterization of two Arabidopsis thaliana cDNAs isolated by functional complementation of a yeast gln3 gdh1 mutant. Truong HN, et al. **FEBS Lett** 1997 Jun 30;410(2–3):213–8

Isolation and characterization of a cDNA clone encoding an osmotin–like protein from Arabidopsis thaliana. Capelli

N, et al. **Gene** 1997 May 20;191(1):51–6
Cloning and characterization of the gene encoding IMP dehydrogenase from Arabidopsis thaliana. Collart FR, et al. **Gene** 1996 Oct 3;174(2):217–20
The ROOT HAIR DEFECTIVE3 gene encodes an evolutionarily conserved protein with GTP–binding motifs and is required for regulated cell enlargement in Arabidopsis. Wang H, et al. **Genes Dev** 1997 Mar 15; 11(6):799–811
DNA regions flanking the major Arabidopsis thaliana satellite are principally enriched in Athila retroelement sequences. Pélissier T, et al. **Genetica** 1996 Mar;97(2):141–51
Interactions among genes regulating ovule development in Arabidopsis thaliana. Baker SC, et al. **Genetics** 1997 Apr; 145(4):1109–24
Isolation of Arabidopsis mutants with enhanced disease susceptibility by direct screening. Glazebrook J, et al. **Genetics** 1996 Jun;143(2):973–82
Phytoalexin–deficient mutants of Arabidopsis reveal that PAD4 encodes a regulatory factor and that four PAD genes contribute to downy mildew resistance. Glazebrook J, et al. **Genetics** 1997 May;146(1):381–92
Intragenic recombination in the Adh locus of the wild plant Arabidopsis thaliana. Innan H, et al. **Genetics** 1996 Aug; 143(4):1761–70
Structure and evolution of the actin gene family in Arabidopsis thaliana. McDowell JM, et al. **Genetics** 1996 Feb;142(2):587–602
Mutants of Arabidopsis thaliana hypersensitive to DNA–damaging treatments. Masson JE, et al. **Genetics** 1997 May;146(1):401–7
Comparison of flowering time genes in Brassica rapa, B. napus and Arabidopsis thaliana. Osborn TC, et al. **Genetics** 1997 Jul;146(3):1123–9
Extragenic suppressors of the Arabidopsis det1 mutant identify elements of flowering–time and light–response regulatory pathways. Pepper AE, et al. **Genetics** 1997 Apr; 145(4):1125–37
Fitness consequences of genetically engineered herbicide and antibiotic resistance in Arabidopsis thaliana. Purrington CB, et al. **Genetics** 1997 Mar;145(3):807–14
The new RGA locus encodes a negative regulator of gibberellin response in Arabidopsis thaliana. Silverstone AL, et al. **Genetics** 1997 Jul;146(3):1087–99
Multiple non–LTR retrotransposons in the genome of Arabidopsis thaliana. Wright DA, et al. **Genetics** 1996 Feb; 142(2):569–78
Genetic and contig map of a 2200–kb region encompassing 5.5 cM on chromosome 1 of Arabidopsis thaliana. Hardtke CS, et al. **Genome** 1996 Dec;39(6):1086–92
Addition–deletion mutations in transgenic Arabidopsis thaliana generated by the seed co–cultivation method. Negruk V, et al. **Genome** 1996 Dec;39(6):1117–22
Mapping expressed sequence tag sites on yeast artificial chromosome clones of Arabidopsis thaliana DNA. Agyare FD, et al. **Genome Res** 1997 Jan;7(1):1–9
Genome DNA sequencing around the EF–1 alpha multigene locus of Arabidopsis thaliana indicates a high gene density and a shuffling of noncoding regions. Tremousaygue D, et al. **Genome Res** 1997 Mar;7(3):198–209
Genetic variation at marker loci and in quantitative traits in natural populations of Arabidopsis thaliana. Kuittinen H, et al. **Heredity** 1997 Aug;79 (Pt 2):144–52
QTL analysis of seed dormancy in Arabidopsis using recombinant inbred lines and MQM mapping. van Der Schaar W, et al. **Heredity** 1997 Aug;79 (Pt 2):190–200
Different roles of flowering time genes in the activation of floral initiation genes in Arabidopsis. Madueño F, et al. **Int J Dev Biol** 1996;Suppl 1:125S–126S
Clonal analysis by transposon excision of stomatal clusters in Arabidopsis. Serna L, et al. **Int J Dev Biol** 1996;Suppl 1:131S–132S
Cytokinin induction of RNA polymerase I transcription in Arabidopsis thaliana. Gaudino RJ, et al. **J Biol Chem** 1997 Mar 7;272(10):6799–804
A family of putative chloride channels from Arabidopsis and functional complementation of a yeast strain with a CLC gene disruption. Hechenberger M, et al. **J Biol Chem** 1996 Dec 27;271(52):33632–8
Molecular cloning and functional analysis of polyphosphoinositide–dependent phospholipase D, PLDbeta, from Arabidopsis. Pappan K, et al. **J Biol Chem** 1997 Mar 14;272(11):7055–61
Analysis of flowering time in ecotypes of Arabidopsis thaliana. Sanda S, et al. **J Hered** 1997 Jan–Feb;88(1):69–72
Manipulation of host gene expression by root–knot nematodes. Bird DM. **J Parasitol** 1996 Dec;82(6):881–8 (56 ref.)
Regulation of the Arabidopsis thaliana aquaporin gene AthH2 (PIP1b). Kaldenhoff R, et al. **J Photochem Photobiol B** 1996 Dec;36(3):351–4
Evolution of microsatellites in Arabis petraea and Arabis lyrata, outcrossing relatives of Arabidopsis thaliana. van Treuren R, et al. **Mol Biol Evol** 1997 Mar;14(3):220–9
Cloning of CTP:phosphocholine cytidylyltransferase cDNA from Arabidopsis thaliana. Choi SB, et al. **Mol Cells** 1997 Feb 28;7(1):58–63
Structure and expression of the AWI 31 gene specifically induced by wounding in Arabidopsis thaliana. Yang KY, et al. **Mol Cells** 1997 Feb 28;7(1):131–5
The KEULE gene is involved in cytokinesis in Arabidopsis. Assaad FF, et al. **Mol Gen Genet** 1996 Dec 13;253(3):267–77
Chromosome landing at the Arabidopsis TORNADO1 locus using an AFLP–based strategy. Cnops G, et al. **Mol Gen Genet** 1996 Nov 27;253(1–2):32–41
A new method for the identification and isolation of genes essential for Arabidopsis thaliana seed germination. Dubreucq B, et al. **Mol Gen Genet** 1996 Aug 27; 252(1–2):42–50
Correlation of nonanucleotide motifs with transcript initiation of 18S rRNA genes in mitochondria of pea, potato and Arabidopsis. Giese A, et al. **Mol Gen Genet** 1996 Sep 25; 252(4):429–36
PHH1, a novel gene from Arabidopsis thaliana that encodes a protein similar to plant blue–light photoreceptors and microbial photolyases. Hoffman PD, et al. **Mol Gen Genet** 1996 Nov 27;253(1–2):259–65
An Hsp70 antisense gene affects the expression of HSP70/HSC70, the regulation of HSF, and the acquisition of thermotolerance in transgenic Arabidopsis thaliana. Lee JH, et al. **Mol Gen Genet** 1996 Aug 27;252(1–2):11–9
Gene isolation in Arabidopsis thaliana by conditional overexpression of cDNAs toxic to Saccharomyces cerevisiae: identification of a novel early response zinc–finger gene. Martínez–García M, et al. **Mol Gen Genet** 1996 Oct 16;252(5):587–96
Cloning and molecular analysis of the Arabidopsis gene Terminal Flower 1. Ohshima S, et al. **Mol Gen Genet** 1997 Mar 26;254(2):186–94
Repeated sequences from the Arabidopsis thaliana genome function as enhancers in transgenic tobacco. Ott RW, et al. **Mol Gen Genet** 1996 Oct 16;252(5):563–71
Reciprocal regulation of delta 1–pyrroline–5–carboxylate synthetase and proline dehydrogenase genes controls proline levels during and after osmotic stress in plants. Peng Z, et al. **Mol Gen Genet** 1996 Dec 13;253(3):334–41
The 28.5–kDa iron–sulfur protein of mitochondrial complex I is encoded in the nucleus in plants. Schmidt–Bleek K, et al. **Mol Gen Genet** 1997 Jan 27;253(4):448–54
A novel repetitive sequence associated with the centromeric regions of Arabidopsis thaliana chromosomes. Thompson H, et al. **Mol Gen Genet** 1996 Nov 27;253(1–2):247–52
Novel structure of a high molecular weight FK506 binding protein from Arabidopsis thaliana. Vucich VA, et al. **Mol Gen Genet** 1996 Oct 16;252(5):510–7
Characterization of cauliflower mosaic virus (CaMV) resistance in virus–resistant ecotypes of Arabidopsis. Callaway A, et al. **Mol Plant Microbe Interact** 1996 Dec; 9(9):810–8
Salicylate–independent lesion formation in Arabidopsis lsd mutants. Hunt MD, et al. **Mol Plant Microbe Interact** 1997 Jul;10(5):531–6
Identification and map location of TTR1, a single locus in Arabidopsis thaliana that confers tolerance to tobacco ringspot nepovirus. Lee JM, et al. **Mol Plant Microbe Interact** 1996 Nov;9(8):729–35
Characterization of a salicylic acid–insensitive mutant (sai1) of Arabidopsis thaliana, identified in a selective screen utilizing the SA–inducible expression of the tms2 gene. Shah J, et al. **Mol Plant Microbe Interact** 1997 Jan; 10(1):69–78
A dominant mutant receptor from Arabidopsis confers ethylene insensitivity in heterologous plants. Wilkinson JQ, et al. **Nat Biotechnol** 1997 May;15(5):444–7
The mitochondrial genome of Arabidopsis thaliana contains 57 genes in 366,924 nucleotides. Unseld M, et al. **Nat Genet** 1997 Jan;15(1):57–61
Non–canonical introns are at least 10(9) years old [letter] Wu HJ, et al. **Nat Genet** 1996 Dec;14(4):383–4
A Polycomb–group gene regulates homeotic gene expression in Arabidopsis [see comments] Goodrich J, et al. **Nature** 1997 Mar 6;386(6620):44–51. Comment in: Nature 1997 Mar 6;385(6620):17.
Memorizing the floral ABC [news; comment] Jürgens G. **Nature** 1997 Mar 6;386(6620):17. Comment on: Nature 1997 Mar 6;385(6620):44–51.
Activation of floral meristem identity genes in Arabidopsis. Simon R, et al. **Nature** 1996 Nov 7;384(6604):59–62
A plant cyclin–dependent kinase inhibitor gene [letter] Wang H, et al. **Nature** 1997 Apr 3;386(6624):451–2
19 ORFs and putative genes on the 81 kb contig of Arabidopsis thaliana chromosome III [letter] Fujiyama K, et al. **Nucleic Acids Res** 1997 May 1;25(9):1875
Splice site prediction in Arabidopsis thaliana pre–mRNA by combining local and global sequence information. Hebsgaard SM, et al. **Nucleic Acids Res** 1996 Sep 1; 24(17):3439–52
Sequence analysis of an 81 kb contig from Arabidopsis thaliana chromosome III. Quigley F, et al. **Nucleic Acids Res** 1996 Nov 1;24(21):4313–8
A branch point consensus from Arabidopsis found by non–circular analysis allows for better prediction of acceptor sites. Tolstrup N, et al. **Nucleic Acids Res** 1997 Aug 1;25(15):3159–63
Mutants of Arabidopsis as tools to understand the regulation of phenylpropanoid pathway and UVB protection mechanisms. Bharti AK, et al. **Photochem Photobiol** 1997 May;65(5):765–76 (104 ref.)
A negative regulatory factor for the dark repression of Arabidopsis thaliana cab1 gene. Choi DK, et al. **Photochem Photobiol** 1996 Nov;64(5):870–5
Genes involved in organ separation in Arabidopsis: an analysis of the cup–shaped cotyledon mutant. Aida M, et al. **Plant Cell** 1997 Jun;9(6):841–57
A deletion in the PHYD gene of the Arabidopsis Wassilewskija ecotype defines a role for phytochrome D in red/far–red light sensing. Aukerman MJ, et al. **Plant Cell** 1997 Aug;9(8):1317–26
A pollen–, ovule–, and early embryo–specific poly(A) binding protein from Arabidopsis complements essential functions in yeast. Belostotsky DA, et al. **Plant Cell** 1996 Aug;8(8):1261–75
Enhancement of somatic intrachromosomal homologous recombination in Arabidopsis by the HO endonuclease. Chiurazzi M, et al. **Plant Cell** 1996 Nov;8(11):2057–66
Distinct UV–B and UV–A/blue light signal transduction pathways induce chalcone synthase gene expression in Arabidopsis cells. Christie JM, et al. **Plant Cell** 1996 Sep; 8(9):1555–67
KNAT1 induces lobed leaves with ectopic meristems when overexpressed in Arabidopsis. Chuck G, et al. **Plant Cell** 1996 Aug;8(8):1277–89
Molecular organization and tissue–specific expression of an Arabidopsis 14–3–3 gene. Daugherty CJ, et al. **Plant Cell** 1996 Aug;8(8):1239–48
Overexpression of an endogenous thionin enhances resistance of Arabidopsis against Fusarium oxysporum. Epple P, et al. **Plant Cell** 1997 Apr;9(4):509–20
FON1, an Arabidopsis gene that terminates floral meristem activity and controls flower organ number. Huang H, et al. **Plant Cell** 1997 Feb;9(2):115–34
FPF1 promotes flowering in Arabidopsis. Kania T, et al. **Plant Cell** 1997 Aug;9(8):1327–38
Photosynthetic electron transport regulates the expression of cytosolic ascorbate peroxidase genes in Arabidopsis during excess light stress. Karpinski S, et al. **Plant Cell** 1997 Apr;9(4):627–40
A nuclear gene encoding mitochondrial proline dehydrogenase, an enzyme involved in proline metabolism, is upregulated by proline but downregulated by dehydration in Arabidopsis. Kiyosue T, et al. **Plant Cell** 1996 Aug;8(8):1323–35
A chlorate–resistant mutant defective in the regulation of nitrate reductase gene expression in Arabidopsis defines a new HY locus. Lin Y, et al. **Plant Cell** 1997 Jan;9(1):21–35
Identification of a meristem L1 layer–specific gene in Arabidopsis that is expressed during embryonic pattern formation and defines a new class of homeobox genes. Lu P, et al. **Plant Cell** 1996 Dec;8(12):2155–68
Expression of an N–terminal fragment of COP1 confers a dominant–negative effect on light–regulated seedling development in Arabidopsis. McNellis TW, et al. **Plant Cell** 1996 Sep;8(9):1491–503
Hormones act downstream of TTG and GL2 to promote root hair outgrowth during epidermis development in the Arabidopsis root. Masucci JD, et al. **Plant Cell** 1996 Sep; 8(9):1505–17
Genetic dissection of carotenoid synthesis in arabidopsis defines plastoquinone as an essential component of phytoene desaturation. Norris SR, et al. **Plant Cell** 1995 Dec;7(12):2139–49
Photo and hormonal control of meristem identity in the Arabidopsis flower mutants apetala2 and apetala1. Okamuro JK, et al. **Plant Cell** 1997 Jan;9(1):37–47
The ABSCISIC ACID–INSENSITIVE3, FUSCA3, and LEAFY COTYLEDON1 loci act in concert to control multiple aspects of Arabidopsis seed development. Parcy F, et al. **Plant Cell** 1997 Aug;9(8):1265–77
Characterization of eds1, a mutation in Arabidopsis suppressing resistance to Peronospora parasitica specified by several different RPP genes. Parker JE, et al. **Plant Cell** 1996 Nov;8(11):2033–46
Systemic resistance in Arabidopsis induced by biocontrol bacteria is independent of salicylic acid accumulation and pathogenesis–related gene expression. Pieterse CM, et al. **Plant Cell** 1996 Aug;8(8):1225–37
Arabidopsis carotenoid mutants demonstrate that lutein is not essential for photosynthesis in higher plants. Pogson B, et al. **Plant Cell** 1996 Sep;8(9):1627–39
Salt stress–induced proline transporters and salt stress–repressed broad specificity amino acid permeases identified by suppression of a yeast amino acid permease–targeting mutant. Rentsch D, et al. **Plant Cell** 1996 Aug;8(8):1437–46
Altered mitochondrial gene expression in a maternal distorted leaf mutant of Arabidopsis induced by chloroplast mutator. Sakamoto W, et al. **Plant Cell** 1996 Aug;8(8):1377–90
Divergence of function and regulation of class B floral organ identity genes. Samach A, et al. **Plant Cell** 1997 Apr; 9(4):559–70
Arabidopsis at 7: still growing like a weed. Somerville S, et al. **Plant Cell** 1996 Nov;8(11):1917–33 (26 ref.)
Regulation of lysine catabolism through lysine–ketoglutarate reductase and saccharopine dehydrogenase in Arabidopsis. Tang G, et al. **Plant Cell** 1997 Aug;9(8):1305–16
Collapsed xylem phenotype of Arabidopsis identifies mutants deficient in cellulose deposition in the secondary cell wall. Turner SR, et al. **Plant Cell** 1997 May;9(5):689–701
An Arabidopsis gene isolated by a novel method for detecting genetic interaction in yeast encodes the GDP dissociation inhibitor of Ara4 GTPase. Ueda T, et al. **Plant Cell** 1996 Nov;8(11):2079–91
A Myb–related transcription factor is involved in the phytochrome regulation of an Arabidopsis Lhcb gene. Wang ZY, et al. **Plant Cell** 1997 Apr;9(4):491–507
Cloning and characterization of CER2, an Arabidopsis gene

that affects cuticular wax accumulation. Xia Y, et al. **Plant Cell** 1996 Aug;8(8):1291–304
Interactions between distinct types of DNA binding proteins enhance binding to ocs element promoter sequences. Zhang B, et al. **Plant Cell** 1995 Dec;7(12):2241–52
Herbicide safener–inducible gene expression in Arabidopsis thaliana. De Veylder L, et al. **Plant Cell Physiol** 1997 May; 38(5):568–77
Isolation and responses to stress of a gene that encodes a luminal binding protein in Arabidopsis thaliana. Koizumi N. **Plant Cell Physiol** 1996 Sep;37(6):862–5
Two–dimensional protein patterns of Arabidopsis wild–type and auxin insensitive mutants, axr1, axr2, reveal interactions between drought and hormonal responses. Leymarie J, et al. **Plant Cell Physiol** 1996 Oct;37(7):966–75
Pollen of a male–sterile mutant of Arabidopsis thaliana isolated from a T–DNA insertion pool is not effectively released from the anther locule. Park SK, et al. **Plant Cell Physiol** 1996 Jul;37(5):580–5
Somatic excision of the Ac transposable element in transgenic Arabidopsis thaliana after 5–azacytidine treatment. Scortecci KC, et al. **Plant Cell Physiol** 1997 Mar; 38(3):336–43
Mutations in the SGR4, SGR5 and SGR6 loci of Arabidopsis thaliana alter the shoot gravitropism. Yamauchi Y, et al. **Plant Cell Physiol** 1997 May;38(5):530–5
Genetic characterization of five powdery mildew disease resistance loci in Arabidopsis thaliana. Adam L, et al. **Plant J** 1996 Mar;9(3):341–56
The pef mutants of Arabidopsis thaliana define lesions early in the phytochrome signaling pathway. Ahmad M, et al. **Plant J** 1996 Dec;10(6):1103–10
Isolation and characterization of cDNAs encoding transcription factor IIB from Arabidopsis and soybean. Baldwin DA, et al. **Plant J** 1996 Sep;10(3):561–8
fhy1 defines a branch point in phytochrome A signal transduction pathways for gene expression. Barnes SA, et al. **Plant J** 1996 Dec;10(6):1155–61
Arabidopsis intron mutations and pre–mRNA splicing. Brown JW. **Plant J** 1996 Nov;10(5):771–80 (73 ref.)
Analysis of fast neutron–generated mutants at the Arabidopsis thaliana HY4 locus. Bruggemann E, et al. **Plant J** 1996 Oct;10(4):755–60
Use of Arabidopsis recombinant inbred lines reveals a monogenic and a novel digenic resistance mechanism to Xanthomonas campestris pv campestris. Buell CR, et al. **Plant J** 1997 Jul;12(1):21–9
Arabidopsis mutants showing an altered response to vernalization. Chandler J, et al. **Plant J** 1996 Oct; 10(4):637–44
Identification of cis–elements regulating the expression of an Arabidopsis histone H4 gene. Chaubet N, et al. **Plant J** 1996 Sep;10(3):425–35
The promoter of a H2O2–inducible, Arabidopsis glutathione S–transferase gene contains closely linked OBF– and OBP1–binding sites. Chen W, et al. **Plant J** 1996 Dec; 10(6):955–66
Arabidopsis profilins are functionally similar to yeast profilins: identification of a vascular bundle–specific profilin and a pollen–specific profilin. Christensen HE, et al. **Plant J** 1996 Aug;10(2):269–79
Identification of members of gene families in Arabidopsis thaliana by contig construction from partial cDNA sequences: 106 genes encoding 50 cytoplasmic ribosomal proteins. Cooke R, et al. **Plant J** 1997 May;11(5):1127–40
RFLP and physical mapping with an rDNA–specific endonuclease reveals that nucleolus organizer regions of Arabidopsis thaliana adjoin the telomeres on chromosomes 2 and 4. Copenhaver GP, et al. **Plant J** 1996 Feb; 9(2):259–72
Two–dimensional RFLP analyses reveal megabase–sized clusters of rRNA gene variants in Arabidopsis thaliana, suggesting local spreading of variants as the mode for gene homogenization during concerted evolution. Copenhaver GP, et al. **Plant J** 1996 Feb;9(2):273–82
Nitrite reductase expression is regulated at the post–transcriptional level by the nitrogen source in Nicotiana plumbaginifolia and Arabidopsis thaliana. Crété P, et al. **Plant J** 1997 Apr;11(4):625–34
Identification of an Arabidopsis locus required for resistance to turnip crinkle virus. Dempsey DA, et al. **Plant J** 1997 Feb;11(2):301–11
The rosette habit of Arabidopsis thaliana is dependent upon phytochrome action: novel phytochromes control internode elongation and flowering time. Devlin PF, et al. **Plant J** 1996 Dec;10(6):1127–34
The Arabidopsis Athb–10 (GLABRA2) is an HD–Zip protein required for regulation of root hair development. Di Cristina M, et al. **Plant J** 1996 Sep;10(3):393–402
Cytosolic and plastidic chorismate mutase isozymes from Arabidopsis thaliana: molecular characterization and enzymatic properties. Eberhard J, et al. **Plant J** 1996 Nov; 10(5):815–21
The SHOOT MERISTEMLESS gene is required for maintenance of undifferentiated cells in Arabidopsis shoot and floral meristems and acts at a different regulatory level than the meristem genes WUSCHEL and ZWILLE. Endrizzi K, et al. **Plant J** 1996 Dec;10(6):967–79
Specific expression of the AGL1 MADS–box gene suggests regulatory functions in Arabidopsis gynoecium and ovule development. Flanagan CA, et al. **Plant J** 1996 Aug; 10(2):343–53
High–resolution physical mapping in Arabidopsis thaliana and tomato by fluorescence in situ hybridization to extended DNA fibres. Fransz PF, et al. **Plant J** 1996 Mar; 9(3):421–30
Isolation and characterization of an Arabidopsis thaliana cDNA encoding a delta 7–sterol–C–5–desaturase by functional complementation of a defective yeast mutant. Gachotte D, et al. **Plant J** 1996 Mar;9(3):391–8
An Arabidopsis thaliana cDNA complementing a hamster apoptosis suppressor mutant. Gallois P, et al. **Plant J** 1997 Jun;11(6):1325–31
Tissue–specific expression of ATCYS–3A, a gene encoding the cytosolic isoform of O–acetylserine(thiol)lyase in Arabidopsis. Gotor C, et al. **Plant J** 1997 Feb;11(2):347–52
Characterization of proteins that interact with the GTP–bound form of the regulatory GTPase Ran in Arabidopsis. Haizel T, et al. **Plant J** 1997 Jan;11(1):93–103
The ELONGATED gene of Arabidopsis acts independently of light and gibberellins in the control of elongation growth. Halliday K, et al. **Plant J** 1996 Mar;9(3):305–12
The CER3 gene of Arabidopsis thaliana is expressed in leaves, stems, roots, flowers and apical meristems. Hannoufa A, et al. **Plant J** 1996 Sep;10(3):459–67
The ubiquitin–activating enzyme (E1) gene family in Arabidopsis thaliana. Hatfield PM, et al. **Plant J** 1997 Feb; 11(2):213–26
The Arabidopsis thaliana ACT4/ACT12 actin gene subclass is strongly expressed throughout pollen development. Huang S, et al. **Plant J** 1996 Aug;10(2):189–202
Targeted misexpression of AGAMOUS in whorl 2 of Arabidopsis flowers. Jack T, et al. **Plant J** 1997 Apr; 11(4):825–39
Increased Ac excision (iae): Arabidopsis thaliana mutations affecting Ac transposition. Jarvis P, et al. **Plant J** 1997 May;11(5):907–19
Inefficient and incorrect processing of the Ac transposase transcript in iae1 and wild–type Arabidopsis thaliana. Jarvis P, et al. **Plant J** 1997 May;11(5):921–31
AtDMC1, the Arabidopsis homologue of the yeast DMC1 gene: characterization, transposon–induced allelic variation and meiosis–associated expression. Klimyuk VI, et al. **Plant J** 1997 Jan;11(1):1–14
Isolation and characterization of a cDNA encoding mitochondrial chaperonin 10 from Arabidopsis thaliana by functional complementation of an Escherichia coli groES mutant. Koumoto Y, et al. **Plant J** 1996 Dec;10(6):1119–25
Isolation and characterization of abscisic acid–deficient Arabidopsis mutants at two new loci. Léon–Kloosterziel KM, et al. **Plant J** 1996 Oct;10(4):655–61
Mutations in the AXR3 gene of Arabidopsis result in altered auxin response including ectopic expression from the SAUR–AC1 promoter. Leyser HM, et al. **Plant J** 1996 Sep;10(3):403–13
Li(+)–regulated 1–aminocyclopropane–1–carboxylate synthase gene expression in Arabidopsis thaliana. Liang X, et al. **Plant J** 1996 Dec;10(6):1027–36
Isolation and mapping of a new set of 129 RFLP markers in Arabidopsis thaliana using recombinant inbred lines. Liu YG, et al. **Plant J** 1996 Oct;10(4):733–6
Ds elements on all five Arabidopsis chromosomes and assessment of their utility for transposon tagging. Long D, et al. **Plant J** 1997 Jan;11(1):145–8
Alternative processing of the maize Ac transcript in Arabidopsis. Martin DJ, et al. **Plant J** 1997 May; 11(5):933–43
Mutants of Arabidopsis thaliana with pleiotropic effects on the expression of the gene for beta–amylase and on the accumulation of anthocyanin that are inducible by sugars. Mita S, et al. **Plant J** 1997 Apr;11(4):841–51
Physical mapping of the 5S ribosomal RNA genes in Arabidopsis thaliana by multi–color fluorescence in situ hybridization with cosmid clones. Murata M, et al. **Plant J** 1997 Jul;12(1):31–7
Molecular cloning and characterization of the CER2 gene of Arabidopsis thaliana. Negruk V, et al. **Plant J** 1996 Feb; 9(2):137–45
Induction of cdc2a and cyc1At expression in Arabidopsis thaliana during early phases of nematode–induced feeding cell formation. Niebel A, et al. **Plant J** 1996 Dec; 10(6):1037–43
Interactions between the ABI1 and the ectopically expressed ABI3 genes in controlling abscisic acid responses in Arabidopsis vegetative tissues. Parcy F, et al. **Plant J** 1997 Apr;11(4):693–702
A defect in synapsis causes male sterility in a T–DNA–tagged Arabidopsis thaliana mutant. Peirson BN, et al. **Plant J** 1997 Apr;11(4):659–69
Mutants of Arabidopsis thaliana with altered cell wall polysaccharide composition. Reiter WD, et al. **Plant J** 1997 Aug;12(2):335–45
Introns act post–transcriptionally to increase expression of the Arabidopsis thaliana tryptophan pathway gene PAT1. Rose AB, et al. **Plant J** 1997 Mar;11(3):455–64
The flow karyotype of Arabidopsis thaliana interphase chromosomes. Samoylova TI, et al. **Plant J** 1996 Nov; 10(5):949–54
Description of 31 YAC contigs spanning the majority of Arabidopsis thaliana chromosome 5. Schmidt R, et al. **Plant J** 1997 Mar;11(3):563–72
The Arabidopsis cyclin–dependent kinase gene cdc2bAt is preferentially expressed during S and G2 phases of the cell cycle. Segers G, et al. **Plant J** 1996 Oct;10(4):601–12
Rapid construction of a transcription map for a cosmid contig of Arabidopsis thaliana genome using a novel cDNA selection method. Seki M, et al. **Plant J** 1997 Aug; 12(2):481–7
Localization of expression of KNAT3, a class 2 knotted1–like gene. Serikawa KA, et al. **Plant J** 1997 Apr;11(4):853–61
Domain exchanges between KNAT3 and KNAT1 suggest specificity of the kn1–like homeodomains requires sequences outside of the third helix and N–terminal arm of the homeodomain. Serikawa KA, et al. **Plant J** 1997 Apr;11(4):863–9
Characterization and mapping of Ds–GUS–T–DNA lines for targeted insertional mutagenesis. Smith D, et al. **Plant J** 1996 Oct;10(4):721–32
The cloning of two Arabidopsis genes belonging to a phosphate transporter family. Smith FW, et al. **Plant J** 1997 Jan;11(1):83–92
The Arabidopsis homeobox gene ATHB–7 is induced by water deficit and by abscisic acid. Söderman E, et al. **Plant J** 1996 Aug;10(2):375–81
Independent modulation of Arabidopsis thaliana polyubiquitin mRNAs in different organs and in response to environmental changes. Sun CW, et al. **Plant J** 1997 May;11(5):1017–27
Fine–scale molecular genetic (RFLP) and physical mapping of a 8.9 cM region on the top arm of Arabidopsis chromosome 5 encompassing the male sterility gene, ms1. Thorlby GJ, et al. **Plant J** 1997 Aug;12(2):471–9
An S–locus–related gene in Arabidopsis encodes a functional kinase and produces two classes of transcripts. Tobias CM, et al. **Plant J** 1996 Sep;10(3):523–31
The GURKE gene is required for normal organization of the apical region in the Arabidopsis embryo. Torres–Ruiz RA, et al. **Plant J** 1996 Dec;10(6):1005–16
A transposon insertion in the Arabidopsis SSR16 gene causes an embryo–defective lethal mutation. Tsugeki R, et al. **Plant J** 1996 Sep;10(3):479–89
A transcriptional activation domain of ATMYB2, a drought–inducible Arabidopsis Myb–related protein. Urao T, et al. **Plant J** 1996 Dec;10(6):1145–8
adg2–1 represents a missense mutation in the ADPG pyrophosphorylase large subunit gene of Arabidopsis thaliana. Wang SM, et al. **Plant J** 1997 May;11(5):1121–6
Ribosomal transcription units integrated via T–DNA transformation associate with the nucleolus and do not require upstream repeat sequences for activity in Arabidopsis thaliana. Wanzenböck EM, et al. **Plant J** 1997 May;11(5):1007–16
Identification of plant cytoskeletal, cell cycle–related and polarity–related proteins using Schizosaccharomyces pombe. Xia G, et al. **Plant J** 1996 Oct;10(4):761–9
The Arabidopsis ELF3 gene regulates vegetative photomorphogenesis and the photoperiodic induction of flowering. Zagotta MT, et al. **Plant J** 1996 Oct; 10(4):691–702
A drought–stress–inducible histone gene in Arabidopsis thaliana is a member of a distinct class of plant linker histone variants. Ascenzi R, et al. **Plant Mol Biol** 1997 Jul; 34(4):629–41
Arabidopsis consensus intron sequences. Brown JW, et al. **Plant Mol Biol** 1996 Nov;32(3):531–5
RAP–1 is an Arabidopsis MYC–like R protein homologue, that binds to G–box sequence motifs. de Pater S, et al. **Plant Mol Biol** 1997 May;34(1):169–74
Aspartic proteinase genes in the Brassicaceae Arabidopsis thaliana and Brassica napus. D'Hondt K, et al. **Plant Mol Biol** 1997 Jan;33(1):187–92
Molecular characterization of an Arabidopsis thaliana cDNA coding for a monofunctional aspartate kinase. Frankard V, et al. **Plant Mol Biol** 1997 May;34(2):233–42
Regulatory activity exerted by the SAUR–AC1 promoter region in transgenic plants. Gil P, et al. **Plant Mol Biol** 1997 Jul;34(5):803–8
Chromosomal location and expression of the single–copy gene encoding high–mobility–group protein HMG–I/Y in Arabidopsis thaliana. Gupta R, et al. **Plant Mol Biol** 1997 Jun;34(3):529–36
Genetic similarity among Arabidopsis thaliana ecotypes estimated by DNA sequence comparison. Hardtke CS, et al. **Plant Mol Biol** 1996 Dec;32(5):915–22
A new Arabidopsis nucleic–acid–binding protein gene is highly expressed in dividing cells during development. Hecht V, et al. **Plant Mol Biol** 1997 May;34(1):119–24
AtPLC2, a gene encoding phosphoinositide–specific phospholipase C, is constitutively expressed in vegetative and floral tissues in Arabidopsis thaliana. Hirayama T, et al. **Plant Mol Biol** 1997 May;34(1):175–80
Cloning and expression of a PR5–like protein from Arabidopsis: inhibition of fungal growth by bacterially expressed protein. Hu X, et al. **Plant Mol Biol** 1997 Aug; 34(6):949–59
Constitutive non–inducible expression of the Arabidopsis thaliana Nia 2 gene in two nitrate reductase mutants of Nicotiana plumbaginifolia. Kaye C, et al. **Plant Mol Biol** 1997 Apr;33(6):953–64
Cloning and analysis of the gene for cystathionine gamma–synthase from Arabidopsis thaliana. Kim J, et al. **Plant Mol Biol** 1996 Dec;32(6):1117–24
Sequence and RT–PCR expression analysis of two peroxidases from Arabidopsis thaliana belonging to a novel evolutionary branch of plant peroxidases. Kjaersgård IV, et al. **Plant Mol Biol** 1997 Mar;33(4):699–708

A phosphate-starvation inducible beta-glucosidase gene (psr3.2) isolated from Arabidopsis thaliana is a member of a distinct subfamily of the BGA family. Malboobi MA, et al. **Plant Mol Biol** 1997 May;34(1):57–68

Isolation and characterisation of a diverse family of Arabidopsis two and three-fingered C2H2 zinc finger protein genes and cDNAs. Meissner R, et al. **Plant Mol Biol** 1997 Mar;33(4):615–24

Identification of a light-regulated MYB gene from an Arabidopsis transcription factor gene collection. Quaedvlieg N, et al. **Plant Mol Biol** 1996 Dec;32(5):987–93

Three knotted1-like homeobox genes in Arabidopsis. Serikawa KA, et al. **Plant Mol Biol** 1996 Nov;32(4):673–83

Cloning and characterization of elongation specific endo-1,4-beta-glucanase (cel1) from Arabidopsis thaliana. Shani Z, et al. **Plant Mol Biol** 1997 Aug;34(6):837–42

A model for the evolution of polyubiquitin genes from the study of Arabidopsis thaliana ecotypes. Sun CW, et al. **Plant Mol Biol** 1997 Jul;34(5):745–58

Expression analysis of an Arabidopsis C2H2 zinc finger protein gene. Tague BW, et al. **Plant Mol Biol** 1996 Dec; 32(5):785–96

Cloning and expression of an Arabidopsis thaliana cDNA encoding a monofunctional aspartate kinase homologous to the lysine-sensitive enzyme of Escherichia coli. Tang G, et al. **Plant Mol Biol** 1997 May;34(2):287–93

Analysis of the occurrence and nature of repeated DNA in an 850 kb region of Arabidopsis thaliana chromosome 4. Thompson HL, et al. **Plant Mol Biol** 1996 Nov;32(3):553–7

Mitochondrial DNA variations and nuclear RFLPs reflect different genetic similarities among 23 Arabidopsis thaliana ecotypes. Ullrich H, et al. **Plant Mol Biol** 1997 Jan; 33(1):37–45

Molecular cloning and characterization of a gene that encodes a MYC-related protein in Arabidopsis. Urao T, et al. **Plant Mol Biol** 1996 Nov;32(3):571–6

Nucleotide sequences of nuclear tRNA(Cys) genes from Nicotiana and Arabidopsis and expression in HeLa cell extract. Urban C, et al. **Plant Mol Biol** 1996 Nov; 32(3):549–52

Isolation and characterization of cDNA clones corresponding to the genes expressed preferentially in floral organs of Arabidopsis thaliana. Utsugi S, et al. **Plant Mol Biol** 1996 Nov;32(4):759–65

Cloning of the cDNA and genomic clones for glutathione synthetase from Arabidopsis thaliana and complementation of a gsh2 mutant in fission yeast. Wang CL, et al. **Plant Mol Biol** 1996 Sep;31(6):1093–104

Frequent collinear long transfer of DNA inclusive of the whole binary vector during Agrobacterium-mediated transformation. Wenck A, et al. **Plant Mol Biol** 1997 Aug; 34(6):913–22

Cloning and expression of an Arabidopsis gene encoding a putative peroxisomal ascorbate peroxidase. Zhang H, et al. **Plant Mol Biol** 1997 Aug;34(6):967–71

Cloning and subcellular location of an Arabidopsis receptor-like protein that shares common features with protein-sorting receptors of eukaryotic cells. Ahmed SU, et al. **Plant Physiol** 1997 May;114(1):325–36

Novel molecular markers for late phases of the growth cycle of Arabidopsis thaliana cell-suspension cultures are expressed during organ senescence. Callard D, et al. **Plant Physiol** 1996 Oct;112(2):705–15

Isolation and characterization of mutants of Arabidopsis thaliana with increased resistance to growth inhibition by indoleacetic acid-amino acid conjugates. Campanella JJ, et al. **Plant Physiol** 1996 Oct;112(2):735–45

Catalase is encoded by a multigene family in Arabidopsis thaliana (L.) Heynh. Frugoli JA, et al. **Plant Physiol** 1996 Sep;112(1):327–36

SGR1, SGR2, SGR3: novel genetic loci involved in shoot gravitropism in Arabidopsis thaliana. Fukaki H, et al. **Plant Physiol** 1996 Mar;110(3):945–55

Evidence for transcriptional regulation of plastid photosynthesis genes in Arabidopsis thaliana roots. Isono K, et al. **Plant Physiol** 1997 Jun;114(2):623–30

Structure of the CAC1 gene and in situ characterization of its expression. The Arabidopsis thaliana gene coding for the biotin-containing subunit of the plastidic acetyl-coenzyme A carboxylase. Ke J, et al. **Plant Physiol** 1997 Feb;113(2):357–65

Complementary DNAs encoding eukaryotic-type cytidine-5'-diphosphate-diacylglycerol synthases of two plant species. Kopka J, et al. **Plant Physiol** 1997 Mar; 113(3):997–1002

Molecular basis of alpha-methyltryptophan resistance in amt-1, a mutant of Arabidopsis thaliana with altered tryptophan metabolism. Kreps JA, et al. **Plant Physiol** 1996 Apr;110(4):1159–65

Arabidopsis mutants with increased sensitivity to aluminum. Larsen PB, et al. **Plant Physiol** 1996 Mar;110(3):743–51

Proline accumulation and salt-stress-induced gene expression in a salt-hypersensitive mutant of Arabidopsis. Liu J, et al. **Plant Physiol** 1997 Jun;114(2):591–6

Negative regulation in the expression of a sugar-inducible gene in Arabidopsis thaliana. A recessive mutation causing enhanced expression of a gene for beta-amylase. Mita S, et al. **Plant Physiol** 1997 Jun;114(2):575–82

Cis-acting elements essential for light regulation of the nuclear gene encoding the A subunit of chloroplast glyceraldehyde 3-phosphate dehydrogenase in Arabidopsis thaliana. Park SC, et al. **Plant Physiol** 1996 Dec; 112(4):1563–71

Characterization of flavonol synthase and leucoanthocyanidin dioxygenase genes in Arabidopsis. Further evidence for differential regulation of "early" and "late" genes. Pelletier MK, et al. **Plant Physiol** 1997 Apr; 113(4):1437–45

Gibberellin deficiency and response mutations suppress the stem elongation phenotype of phytochrome-deficient mutants of Arabidopsis. Peng J, et al. **Plant Physiol** 1997 Apr;113(4):1051–8

Targeting of the Arabidopsis homomeric acetyl-coenzyme A carboxylase to plastids of rapeseeds. Roesler K, et al. **Plant Physiol** 1997 Jan;113(1):75–81

The construction of Arabidopsis expressed sequence tag assemblies. A new resource to facilitate gene identification. Rounsley SD, et al. **Plant Physiol** 1996 Nov;112(3):1177–83

Biochemical characterization of the aba2 and aba3 mutants in Arabidopsis thaliana. Schwartz SH, et al. **Plant Physiol** 1997 May;114(1):161–6

Overexpression of the FAD3 desaturase gene in a mutant of Arabidopsis. Shah S, et al. **Plant Physiol** 1997 Aug; 114(4):1533–9

NO3- and ClO3- fluxes in the chl1-5 mutant of Arabidopsis thaliana. Does the CHL1-5 gene encode a low-affinity NO3- transporter? Touraine B, et al. **Plant Physiol** 1997 May;114(1):137–44

Characterization and expression of NAD(H)-dependent glutamate dehydrogenase genes in Arabidopsis. Turano FJ, et al. **Plant Physiol** 1997 Apr;113(4):1329–41

Characterization of the cDNA and gene coding for the biotin synthase of Arabidopsis thaliana. Weaver LM, et al. **Plant Physiol** 1996 Mar;110(3):1021–8

The major intrinsic protein family of Arabidopsis has 23 members that form three distinct groups with functional aquaporins in each group. Weig A, et al. **Plant Physiol** 1997 Aug;114(4):1347–57

Low-temperature damage and subsequent recovery of fab1 mutant Arabidopsis exposed to 2 degrees C. Wu J, et al. **Plant Physiol** 1997 Feb;113(2):347–56

The Arabidopsis 14-3-3 multigene family. Wu K, et al. **Plant Physiol** 1997 Aug;114(4):1421–31

The MUR1 gene of Arabidopsis thaliana encodes an isoform of GDP-D-mannose-4,6-dehydratase, catalyzing the first step in the de novo synthesis of GDP-L-fucose. Bonin CP, et al. **Proc Natl Acad Sci U S A** 1997 Mar 4; 94(5):2085–90

Fertilization-independent seed development in Arabidopsis thaliana. Chaudhury AM, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):4223–8

Mutations of Arabidopsis thaliana that transform leaves into cotyledons. Conway LJ, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10209–14

Annexin-like protein from Arabidopsis thaliana rescues delta oxyR mutant of Escherichia coli from H2O2 stress. Gidrol X, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1; 93(20):11268–73

Three members of a novel small gene-family from Arabidopsis thaliana able to complement functionally an Escherichia coli mutant defective in PAPS reductase activity encode proteins with a thioredoxin-like domain and "APS reductase" activity. Gutierrez-Marcos JF, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13377–82

SPINDLY, a tetratricopeptide repeat protein involved in gibberellin signal transduction in Arabidopsis. Jacobsen SE, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9292–6

Identification of transferred DNA insertions within Arabidopsis genes involved in signal transduction and ion transport. Krysan PJ, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8145–50

ECA1 complements yeast mutants defective in Ca2+ pumps and encodes an endoplasmic reticulum-type Ca2+-ATPase in Arabidopsis thaliana. Liang F, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8579–84

AtMRP1 gene of Arabidopsis encodes a glutathione S-conjugate pump: isolation and functional definition of a plant ATP-binding cassette transporter gene. Lu YP, et al. **Proc Natl Acad Sci U S A** 1997 Jul 22;94(15):8243–8

Overexpression of an Arabidopsis thaliana high-affinity phosphate transporter gene in tobacco cultured cells enhances cell growth under phosphate-limited conditions. Mitsukawa N, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):7098–102

The AP2 domain of APETALA2 defines a large new family of DNA binding proteins in Arabidopsis. Okamuro JK, et al. **Proc Natl Acad Sci U S A** 1997 Jun 24;94(13):7076–81

Flowers into shoots: photo and hormonal control of a meristem identity switch in Arabidopsis. Okamuro JK, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13831–6

Arabidopsis thaliana CBF1 encodes an AP2 domain-containing transcriptional activator that binds to the C-repeat/DRE, a cis-acting DNA regulatory element that stimulates transcription in response to low temperature and water deficit. Stockinger EJ, et al. **Proc Natl Acad Sci U S A** 1997 Feb 4;94(3):1035–40

Genetic identification of a gene involved in constitutive, high-affinity nitrate transport in higher plants. Wang R, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20; 93(17):9297–301

RIGS (repeat-induced gene silencing) in Arabidopsis is transcriptional and alters chromatin configuration. Ye F, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10881–6

Suspensor-derived polyembryony caused by altered expression of valyl-tRNA synthetase in the twn2 mutant of Arabidopsis. Zhang JZ, et al. **Proc Natl Acad Sci U S A** 1997 Jul 8;94(14):7349–55

Costs of resistance: a test using transgenic Arabidopsis thaliana. Bergelson J, et al. **Proc R Soc Lond B Biol Sci** 1996 Dec 22;263(1377):1659–63

Corn genome initiative [letter; comment] Bevan MW. **Science** 1997 Aug 15;277(5328):885–6. Comment on: Science 1997 Jun 27;276(5321):1960–2.

Inflorescence commitment and architecture in Arabidopsis. Bradley D, et al. **Science** 1997 Jan 3;275(5296):80–3

Hypermethylated SUPERMAN epigenetic alleles in arabidopsis. Jacobsen SE, et al. **Science** 1997 Aug 22; 277(5329):1100–3

Epidermal cell differentiation in Arabidopsis determined by a Myb homolog, CPC. Wada T, et al. **Science** 1997 Aug 22;277(5329):1113–6

Sequencing and mapping the Arabidopsis genome: a weed model for real crops. Delseny M, et al. **Symp Soc Exp Biol** 1996;50:5–9

T-DNA insertion mutagenesis in Arabidopsis: going back and forth. Azpiroz-Leehan R, et al. **Trends Genet** 1997 Apr;13(4):152–6 (44 ref.)

A useful weed put to work: genetic analysis of disease resistance in Arabidopsis thaliana. Kunkel BN. **Trends Genet** 1996 Feb;12(2):63–9

Polycomb in plants. Ma H. **Trends Genet** 1997 May;13(5):167

GROWTH & DEVELOPMENT

The genetics of flower development: from floral induction to ovule morphogenesis. Weigel D. **Annu Rev Genet** 1995; 29:19–39 (93 ref.)

The STUD gene is required for male-specific cytokinesis after telophase II of meiosis in Arabidopsis thaliana. Hulskamp M, et al. **Dev Biol** 1997 Jul 1;187(1):114–24

lem7, a novel temperature-sensitive Arabidopsis mutation that reversibly inhibits vegetative development. Meisel L, et al. **Dev Biol** 1996 Oct 10;179(1):116–34

The SAR1 gene of Arabidopsis acts downstream of the AXR1 gene in auxin response. Cernac A, et al. **Development** 1997 Apr;124(8):1583–91

TSO1 functions in cell division during Arabidopsis flower development. Liu Z, et al. **Development** 1997 Feb; 124(3):665–72

Organization and cell differentiation in lateral roots of Arabidopsis thaliana. Malamy JE, et al. **Development** 1997 Jan;124(1):33–44

Structural and genetic analysis of epidermal cell differentiation in Arabidopsis primary roots. Schneider K, et al. **Development** 1997 May;124(9):1789–98

Phase change and the regulation of trichome distribution in Arabidopsis thaliana. Telfer A, et al. **Development** 1997 Feb;124(3):645–54

Different roles of flowering time genes in the activation of floral initiation genes in Arabidopsis. Madueño F, et al. **Int J Dev Biol** 1996;Suppl 1:125S–126S

Ethylene induces stomata differentiation in Arabidopsis. Serna L, et al. **Int J Dev Biol** 1996;Suppl 1:123S–124S

Clonal analysis by transposon excision of stomatal clusters in Arabidopsis. Serna L, et al. **Int J Dev Biol** 1996;Suppl 1:131S–132S

KNAT1 induces lobed leaves with ectopic meristems when overexpressed in Arabidopsis. Chuck G, et al. **Plant Cell** 1996 Aug;8(8):1277–89

FPF1 promotes flowering in Arabidopsis. Kania T, et al. **Plant Cell** 1997 Aug;9(8):1327–38

Epidermal cell fate and patterning in leaves. Larkin JC, et al. **Plant Cell** 1997 Jul;9(7):1109–20 (65 ref.)

Expression of an N-terminal fragment of COP1 confers a dominant-negative effect on light-regulated seedling development in Arabidopsis. McNellis TW, et al. **Plant Cell** 1996 Sep;8(9):1491–503

Hormones act downstream of TTG and GL2 to promote root hair outgrowth during epidermis development in the Arabidopsis root. Masucci JD, et al. **Plant Cell** 1996 Sep; 8(9):1505–17

Determination of Arabidopsis floral meristem identity by AGAMOUS. Mizukami Y, et al. **Plant Cell** 1997 Mar; 9(3):393–408

Photo and hormonal control of meristem identity in the Arabidopsis flower mutants apetala2 and apetala1. Okamuro JK, et al. **Plant Cell** 1997 Jan;9(1):37–47

TOUSLED participates in apical tissue formation during gynoecium development in Arabidopsis. Roe JL, et al. **Plant Cell** 1997 Mar;9(3):335–53

Building a root: the control of patterning and morphogenesis during root development. Schiefelbein JW, et al. **Plant Cell** 1997 Jul;9(7):1089–98 (60 ref.)

Specific expression of the AGL1 MADS-box gene suggests regulatory functions in Arabidopsis gynoecium and ovule development. Flanagan CA, et al. **Plant J** 1996 Aug; 10(2):343–53

Cell fate in the development of the Arabidopsis flower. Furner IJ. **Plant J** 1996 Oct;10(4):645–54

A new Arabidopsis nucleic-acid-binding protein gene is highly expressed in dividing cells during development. Hecht V, et al. **Plant Mol Biol** 1997 May;34(1):119–24

Growth and photosynthesis under high and low irradiance of Arabidopsis thaliana antisense mutants with reduced ribulose-1,5-bisphosphate carboxylase/oxygenase activase content. Eckardt NA, et al. **Plant Physiol** 1997 Feb; 113(2):575–86

Cellular basis of hypocotyl growth in Arabidopsis thaliana. Gendreau E, et al. **Plant Physiol** 1997 May;114(1):295–305
A complement of ten essential and pleiotropic arabidopsis COP/DET/FUS genes is necessary for repression of photomorphogenesis in darkness. Kwok SF, et al. **Plant Physiol** 1996 Mar;110(3):731–42
Synthesis of small heat-shock proteins is part of the developmental program of late seed maturation. Wehmeyer N, et al. **Plant Physiol** 1996 Oct;112(2):747–57
Flowers into shoots: photo and hormonal control of a meristem identity switch in Arabidopsis. Okamuro JK, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13831–6
Inflorescence commitment and architecture in Arabidopsis. Bradley D, et al. **Science** 1997 Jan 3;275(5296):80–3

IMMUNOLOGY

ESTs reveal a multigene family for plant defensins in Arabidopsis thaliana. Epple P, et al. **FEBS Lett** 1997 Jan 3;400(2):168–72
The Arabidopsis downy mildew resistance gene RPP5 shares similarity to the toll and interleukin-1 receptors with N and L6. Parker JE, et al. **Plant Cell** 1997 Jun;9(6):879–94

METABOLISM

Elicitor-induced generation of active oxygen in suspension cultures of Arabidopsis thaliana. Desikan R, et al. **Biochem Soc Trans** 1996 May;24(2):199S
Femtosecond transient absorption study of carotenoid to chlorophyll energy transfer in the light-harvesting complex II of photosystem II. Connelly JP, et al. **Biochemistry** 1997 Jan 14;36(2):281–7
Modification of the water oxidizing complex in leaves of the dgd1 mutant of Arabidopsis thaliana deficient in the galactolipid digalactosyldiacylglycerol. Reifarth F, et al. **Biochemistry** 1997 Sep 30;36(39):11769–76
Cysteine biosynthesis in higher plants: a new member of the Arabidopsis thaliana serine acetyltransferase small gene-family obtained by functional complementation of an Escherichia coli cysteine auxotroph. Howarth JR, et al. **Biochim Biophys Acta** 1997 Feb 7;1350(2):123–7
Activation of the ethylene gas response pathway in Arabidopsis by the nuclear protein ETHYLENE-INSENSITIVE3 and related proteins. Chao Q, et al. **Cell** 1997 Jun 27;89(7):1133–44
Fibrillar arrays of a 110-kDa myosin-like protein in Arabidopsis pistils. La Claire JW 2nd, et al. **Cell Biol Int** 1996 Jun;20(6):451–3
A light microscopic atlas of meiosis in Arabidopsis thaliana. Ross KJ, et al. **Chromosome Res** 1996 Nov;4(7):507–16
Cell signaling in root development. Scheres B. **Curr Opin Genet Dev** 1997 Aug;7(4):501–6 (27 ref.)
Two-dimensional electrophoresis of plant proteins and standardization of gel patterns. Tsugita A, et al. **Electrophoresis** 1996 May;17(5):855–65
The Arabidopsis Cks1At protein binds the cyclin-dependent kinases Cdc2aAt and Cdc2bAt. De Veylder L, et al. **FEBS Lett** 1997 Aug 4;412(3):446–52
The G protein alpha subunit (GP alpha1) is associated with the ER and the plasma membrane in meristematic cells of Arabidopsis and cauliflower. Weiss CA, et al. **FEBS Lett** 1997 May 5;407(3):361–7
The AtVAM3 encodes a syntaxin-related molecule implicated in the vacuolar assembly in Arabidopsis thaliana. Sato MH, et al. **J Biol Chem** 1997 Sep 26;272(39):24530–5
A kinetic model with ordered cytoplasmic dissociation for SUC1, an Arabidopsis H+/sucrose cotransporter expressed in Xenopus oocytes. Zhou J, et al. **J Membr Biol** 1997 Sep 15;159(2):113–25
Photosynthesis, chlorophyll fluorescence, light-harvesting system and photoinhibition resistance of a zeaxanthin-accumulating mutant of Arabidopsis thaliana. Tardy F, et al. **J Photochem Photobiol B** 1996 Jun; 34(1):87–94
Abscisic acid-independent and abscisic acid-dependent regulation of proline biosynthesis following cold and osmotic stresses in Arabidopsis thaliana. Savouré A, et al. **Mol Gen Genet** 1997 Mar 18;254(1):104–9
Role of the proline knot motif in oleosin endoplasmic reticulum topology and oil body targeting. Abell BM, et al. **Plant Cell** 1997 Aug;9(8):1481–93
A pollen-, ovule-, and early embryo-specific poly(A) binding protein from Arabidopsis complements essential functions in yeast. Belostotsky DA, et al. **Plant Cell** 1996 Aug;8(8):1261–75
The syntaxin homolog AtPEP12p resides on a late post-Golgi compartment in plants. da Silva Conceição A, et al. **Plant Cell** 1997 Apr;9(4):571–82
Sucrose control of phytochrome A signaling in Arabidopsis. Dijkwel PP, et al. **Plant Cell** 1997 Apr;9(4):583–95
CHL1 encodes a component of the low-affinity nitrate uptake system in Arabidopsis and shows cell type-specific expression in roots. Huang NC, et al. **Plant Cell** 1996 Dec; 8(12):2183–91
Phytochrome A and phytochrome B mediate the hypocotyl-specific downregulation of TUB1 by light in arabidopsis. Leu WM, et al. **Plant Cell** 1995 Dec; 7(12):2187–96
Characterization of a novel arginine/serine-rich splicing factor in Arabidopsis. Lopato S, et al. **Plant Cell** 1996 Dec; 8(12):2255–64
Genetic dissection of carotenoid synthesis in arabidopsis defines plastoquinone as an essential component of phytoene desaturation. Norris SR, et al. **Plant Cell** 1995 Dec;7(12):2139–49
Systemic resistance in Arabidopsis induced by biocontrol bacteria is independent of salicylic acid accumulation and pathogenesis-related gene expression. Pieterse CM, et al. **Plant Cell** 1996 Aug;8(8):1225–37
Arabidopsis carotenoid mutants demonstrate that lutein is not essential for photosynthesis in higher plants. Pogson B, et al. **Plant Cell** 1996 Sep;8(9):1627–39
Salt stress-induced proline transporters and salt stress-repressed broad specificity amino acid permeases identified by suppression of a yeast amino acid permease-targeting mutant. Rentsch D, et al. **Plant Cell** 1996 Aug;8(8):1437–46
Regulation of lysine catabolism through lysine-ketoglutarate reductase and saccharopine dehydrogenase in Arabidopsis. Tang G, et al. **Plant Cell** 1997 Aug;9(8):1305–16
Cloning and characterization of CER2, an Arabidopsis gene that affects cuticular wax accumulation. Xia Y, et al. **Plant Cell** 1996 Aug;8(8):1291–304
Interactions between distinct types of DNA binding proteins enhance binding to ocs element promoter sequences. Zhang B, et al. **Plant Cell** 1995 Dec;7(12):2241–52
Coordinate regulation of the tryptophan biosynthetic pathway and indolic phytoalexin accumulation in Arabidopsis. Zhao J, et al. **Plant Cell** 1996 Dec; 8(12):2235–44
Effects of abscisic acid and cytoplasmic pH on potassium and chloride efflux in Arabidopsis thaliana seedlings. Beffagna N, et al. **Plant Cell Physiol** 1997 May;38(5):503–10
A serine/threonine protein kinase gene isolated by an in vivo binding procedure using the Arabidopsis floral homeotic gene product, AGAMOUS. Ito T, et al. **Plant Cell Physiol** 1997 Mar;38(3):248–58
BANYULS, a novel negative regulator of flavonoid biosynthesis in the Arabidopsis seed coat. Albert S, et al. **Plant J** 1997 Feb;11(2):289–99
Arabidopsis profilins are functionally similar to yeast profilins: identification of a vascular bundle-specific profilin and a pollen-specific profilin. Christensen HE, et al. **Plant J** 1996 Aug;10(2):269–79
Characterization of csi52, a Cs+ resistant mutant of Arabidopsis thaliana altered in K+ transport. Maathuis FJ, et al. **Plant J** 1996 Oct;10(4):579–89
Mutants of Arabidopsis thaliana with pleiotropic effects on the expression of the gene for beta-amylase and on the accumulation of anthocyanin that are inducible by sugars. Mita S, et al. **Plant J** 1997 Apr;11(4):841–51
Introns act post-transcriptionally to increase expression of the Arabidopsis thaliana tryptophan pathway gene PAT1. Rose AB, et al. **Plant J** 1997 Mar;11(3):455–64
Lysine and threonine metabolism are subject to complex patterns of regulation in Arabidopsis. Ben-Tzvi Tzchori I, et al. **Plant Mol Biol** 1996 Nov;32(4):727–34
Overexpression of D-myo-inositol-3-phosphate synthase leads to elevated levels of inositol in Arabidopsis. Smart CC, et al. **Plant Mol Biol** 1997 Mar;33(5):811–20
DNA-binding properties, genomic organization and expression pattern of TGA6, a new member of the TGA family of bZIP transcription factors in Arabidopsis thaliana. Xiang C, et al. **Plant Mol Biol** 1997 Jun;34(3):403–15
Cloning and subcellular location of an Arabidopsis receptor-like protein that shares common features with protein-sorting receptors of eukaryotic cells. Ahmed SU, et al. **Plant Physiol** 1997 May;114(1):325–36
Accumulation of ricinoleic, lesquerolic, and densipolic acids in seeds of transgenic Arabidopsis plants that express a fatty acyl hydroxylase cDNA from castor bean. Broun P, et al. **Plant Physiol** 1997 Mar;113(3):933–42
Reduced Na+ uptake in the NaCl-hypersensitive sos1 mutant of Arabidopsis thaliana. Ding L, et al. **Plant Physiol** 1997 Mar;113(3):795–9
hcf5, a nuclear photosynthetic electron transport mutant of Arabidopsis thaliana with a pleiotropic effect on chloroplast gene expression. Dinkins RD, et al. **Plant Physiol** 1997 Apr;113(4):1023–31
Sinapic acid ester metabolism in wild type and a sinapoylglucose-accumulating mutant of arabidopsis. Lorenzen M, et al. **Plant Physiol** 1996 Dec;112(4):1625–30
Purification and immunological identification of metallothioneins 1 and 2 from Arabidopsis thaliana. Murphy A, et al. **Plant Physiol** 1997 Apr;113(4):1293–301
Abundant accumulation of the calcium-binding molecular chaperone calreticulin in specific floral tissues of Arabidopsis thaliana. Nelson DE, et al. **Plant Physiol** 1997 May;114(1):29–37
Importin alpha from Arabidopsis thaliana is a nuclear import receptor that recognizes three classes of import signals. Smith HM, et al. **Plant Physiol** 1997 Jun;114(2):411–7
Antisense expression of the peptide transport gene AtPTR2-B delays flowering and arrests seed development in transgenic Arabidopsis plants. Song W, et al. **Plant Physiol** 1997 Jul;114(3):927–35
NO3- and ClO3- fluxes in the chl1-5 mutant of Arabidopsis thaliana. Does the CHL1-5 gene encode a low-affinity NO3- transporter? Touraine B, et al. **Plant Physiol** 1997 May;114(1):137–44
Convergence of the abscisic acid, CO2, and extracellular calcium signal transduction pathways in stomatal guard cells. Webb AA, et al. **Plant Physiol** 1997 Aug; 114(4):1557–60
Origin of the thiazole ring of camalexin, a phytoalexin from Arabidopsis thaliana. Zook M, et al. **Plant Physiol** 1997 Feb;113(2):463–8
Arabidopsis thaliana ethylene-responsive element binding protein (AtEBP), an ethylene-inducible, GCC box DNA-binding protein interacts with an ocs element binding protein. Büttner M, et al. **Proc Natl Acad Sci U S A** 1997 May 27;94(11):5961–6
A cdc5+ homolog of a higher plant, Arabidopsis thaliana. Hirayama T, et al. **Proc Natl Acad Sci U S A** 1996 Nov 12;93(23):13371–6
Phosphate transporters from the higher plant Arabidopsis thaliana. Muchhal US, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10519–23
Signaling in plants. Mulligan RM, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):2793–5
Histone H1 overexpressed to high level in tobacco affects certain developmental programs but has limited effect on basal cellular functions. Prymakowska-Bosak M, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10250–5
Dinor-oxo-phytodienoic acid: a new hexadecanoid signal in the jasmonate family. Weber H, et al. **Proc Natl Acad Sci U S A** 1997 Sep 16;94(19):10473–8
Expression of an inward-rectifying potassium channel by the Arabidopsis KAT1 cDNA. Schachtman DP, et al. **Science** 1994 Dec 2;258(5088):1654–8
Interaction of the viral protein genome linked of turnip mosaic potyvirus with the translational eukaryotic initiation factor (iso) 4E of Arabidopsis thaliana using the yeast two-hybrid system. Wittmann S, et al. **Virology** 1997 Jul 21;234(1):84–92

MICROBIOLOGY

Attachment of Agrobacterium tumefaciens to carrot cells and Arabidopsis wound sites is correlated with the presence of a cell-associated, acidic polysaccharide. Reuhs BL, et al. **J Bacteriol** 1997 Sep;179(17):5372–9
Specific flavonoids promote intercellular root colonization of Arabidopsis thaliana by Azorhizobium caulinodans ORS571. Gough C, et al. **Mol Plant Microbe Interact** 1997 Jul;10(5):560–70
Mode of action of the Arabidopsis thaliana phytoalexin camalexin and its role in Arabidopsis-pathogen interactions. Rogers EE, et al. **Mol Plant Microbe Interact** 1996 Nov;9(8):748–57
Differential induction of systemic resistance in Arabidopsis by biocontrol bacteria. Van Wees SC, et al. **Mol Plant Microbe Interact** 1997 Aug;10(6):716–24
Genetic characterization of five powdery mildew disease resistance loci in Arabidopsis thaliana. Adam L, et al. **Plant J** 1996 Mar;9(3):341–56
Use of Arabidopsis recombinant inbred lines reveals a monogenic and a novel digenic resistance mechanism to Xanthomonas campestris pv campestris. Buell CR, et al. **Plant J** 1997 Jul;12(1):21–9

PARASITOLOGY

Continual green-fluorescent protein monitoring of cauliflower mosaic virus 35S promoter activity in nematode-induced feeding cells in Arabidopsis thaliana. Urwin PE, et al. **Mol Plant Microbe Interact** 1997 Apr; 10(3):394–400
Induction of cdc2a and cyc1At expression in Arabidopsis thaliana during early phases of nematode-induced feeding cell formation. Niebel A, et al. **Plant J** 1996 Dec; 10(6):1037–43
Resistance to both cyst and root-knot nematodes conferred by transgenic Arabidopsis expressing a modified plant cystatin. Urwin PE, et al. **Plant J** 1997 Aug;12(2):455–61
Induction of phloem unloading in Arabidopsis thaliana roots by the parasitic nematode Heterodera schachtii. Böckenhoff A, et al. **Plant Physiol** 1996 Dec;112(4):1421–7

PHYSIOLOGY

Oxidative stress and responses in Arabidopsis thaliana and Oryza sativa subjected to chilling and salinity stress. Burdon RH, et al. **Biochem Soc Trans** 1996 May; 24(2):469–72 (17 ref.)
The genetics of phototransduction and circadian rhythms in Arabidopsis. Millar AJ, et al. **Bioessays** 1997 Mar; 19(3):209–14 (41 ref.)
A LEAFY co-regulator encoded by UNUSUAL FLORAL ORGANS. Lee I, et al. **Curr Biol** 1997 Feb 1;7(2):95–104
Maternal effects of the short integument mutation on embryo development in Arabidopsis. Ray S, et al. **Dev Biol** 1996 Nov 25;180(1):365–9
Voltage-dependent anion channel of Arabidopsis hypocotyls: nucleotide regulation and pharmacological properties. Thomine S, et al. **J Membr Biol** 1997 Sep 1;159(1):71–82
Mode of action of the Arabidopsis thaliana phytoalexin camalexin and its role in Arabidopsis-pathogen interactions. Rogers EE, et al. **Mol Plant Microbe Interact** 1996 Nov;9(8):748–57
Characterization of a salicylic acid-insensitive mutant (sai1) of Arabidopsis thaliana, identified in a selective screen utilizing the SA-inducible expression of the tms2 gene. Shah J, et al. **Mol Plant Microbe Interact** 1997 Jan; 10(1):69–78
Molecular characterization of the CER1 gene of arabidopsis involved in epicuticular wax biosynthesis and pollen fertility. Aarts MG, et al. **Plant Cell** 1995 Dec;7(12):2115–27

Last exit: senescence, abscission, and meristem arrest in Arabidopsis. Bleecker AB, et al. **Plant Cell** 1997 Jul; 9(7):1169–79 (50 ref.)

UV-B, UV-A, and blue light signal transduction pathways interact synergistically to regulate chalcone synthase gene expression in Arabidopsis. Fuglevand G, et al. **Plant Cell** 1996 Dec;8(12):2347–57

Environmental and genetic effects on circadian clock-regulated gene expression in Arabidopsis. Kreps JA, et al. **Plant Cell** 1997 Mar;9(3):297–304

Regulation of photomorphogenesis by expression of mammalian biliverdin reductase in transgenic Arabidopsis plants. Lagarias DM, et al. **Plant Cell** 1997 May;9(5):675–88

The Arabidopsis ABSCISIC ACID-INSENSITIVE2 (ABI2) and ABI1 genes encode homologous protein phosphatases 2C involved in abscisic acid signal transduction. Leung J, et al. **Plant Cell** 1997 May; 9(5):759–71

Identification of a meristem L1 layer-specific gene in Arabidopsis that is expressed during embryonic pattern formation and defines a new class of homeobox genes. Lu P, et al. **Plant Cell** 1996 Dec;8(12):2155–68

Differences in susceptibility of Arabidopsis ecotypes to crown gall disease may result from a deficiency in T-DNA integration. Nam J, et al. **Plant Cell** 1997 Mar;9(3):317–33

Differential abscisic acid regulation of guard cell slow anion channels in Arabidopsis wild-type and abi1 and abi2 mutants. Pei ZM, et al. **Plant Cell** 1997 Mar;9(3):409–23

Pathogen-induced systemic activation of a plant defensin gene in Arabidopsis follows a salicylic acid-independent pathway. Penninckx IA, et al. **Plant Cell** 1996 Dec; 8(12):2309–23

Arabidopsis enhanced disease susceptibility mutants exhibit enhanced susceptibility to several bacterial pathogens and alterations in PR-1 gene expression. Rogers EE, et al. **Plant Cell** 1997 Mar;9(3):305–16

Reduced naphthylphthalamic acid binding in the tir3 mutant of Arabidopsis is associated with a reduction in polar auxin transport and diverse morphological defects. Ruegger M, et al. **Plant Cell** 1997 May;9(5):745–57

The Arabidopsis NIM1 protein shows homology to the mammalian transcription factor inhibitor I kappa B. Ryals J, et al. **Plant Cell** 1997 Mar;9(3):425–39

Molecular dissection of the AGAMOUS control region shows that cis elements for spatial regulation are located intragenically. Sieburth LE, et al. **Plant Cell** 1997 Mar; 9(3):355–65

ALBINO3, an Arabidopsis nuclear gene essential for chloroplast differentiation, encodes a chloroplast protein that shows homology to proteins present in bacterial membranes and yeast mitochondria. Sundberg E, et al. **Plant Cell** 1997 May;9(5):717–30

The sink-specific and stress-regulated Arabidopsis STP4 gene: enhanced expression of a gene encoding a monosaccharide transporter by wounding, elicitors, and pathogen challenge. Truernit E, et al. **Plant Cell** 1996 Dec; 8(12):2169–82

RED1 is necessary for phytochrome B-mediated red light-specific signal transduction in Arabidopsis. Wagner D, et al. **Plant Cell** 1997 May;9(5):731–43

The RHG gene is involved in root and hypocotyl gravitropism in Arabidopsis thaliana. Fukaki H, et al. **Plant Cell Physiol** 1997 Jul;38(7):804–10

Reduced gravitropism in hypocotyls of starch-deficient mutants of Arabidopsis. Kiss JZ, et al. **Plant Cell Physiol** 1997 May;38(5):518–25

The blue-light receptor cryptochrome 1 shows functional dependence on phytochrome A or phytochrome B in Arabidopsis thaliana. Ahmad M, et al. **Plant J** 1997 Mar; 11(3):421–7

Functional analysis of the Arabidopsis thaliana SBP-box gene SPL3: a novel gene involved in the floral transition. Cardon GH, et al. **Plant J** 1997 Aug;12(2):367–77

Transformation of Arabidopsis thaliana with the codA gene for choline oxidase; accumulation of glycinebetaine and enhanced tolerance to salt and cold stress. Hayashi H, et al. **Plant J** 1997 Jul;12(1):133–42

Characterization of a novel eukaryotic ATP/ADP translocator located in the plastid envelope of Arabidopsis thaliana L. Neuhaus HE, et al. **Plant J** 1997 Jan;11(1):73–82

Cytoplasmic free calcium distributions during the development of root hairs of Arabidopsis thaliana. Wymer CL, et al. **Plant J** 1997 Aug;12(2):427–39

The Arabidopsis ACT11 actin gene is strongly expressed in tissues of the emerging inflorescence, pollen, and developing ovules. Huang S, et al. **Plant Mol Biol** 1997 Jan;33(1):125–39

A phosphate-starvation inducible beta-glucosidase gene (psr3.2) isolated from Arabidopsis thaliana is a member of a distinct subfamily of the BGA family. Malboobi MA, et al. **Plant Mol Biol** 1997 May;34(1):57–68

Differential display-mediated isolation of a genomic sequence for a putative mitochondrial LMW HSP specifically expressed in condition of induced thermotolerance in Arabidopsis thaliana (L.) heynh. Visioli G, et al. **Plant Mol Biol** 1997 Jun;34(3):517–27

Flavonols are not essential for fertilization in Arabidopsis thaliana. Ylstra B, et al. **Plant Mol Biol** 1996 Dec; 32(6):1155–8

Phytochrome A enhances the promotion of hypocotyl growth caused by reductions in levels of phytochrome B in its far-red-light-absorbing form in light-grown Arabidopsis thaliana. Casal JJ. **Plant Physiol** 1996 Nov; 112(3):965–73

Modulation of cyclin transcript levels in cultured cells of Arabidopsis thaliana. Fuerst RA, et al. **Plant Physiol** 1996 Nov;112(3):1023–33

Gravitropic response of inflorescence stems in Arabidopsis thaliana. Fukaki H, et al. **Plant Physiol** 1996 Mar; 110(3):933–43

Cytokinin, acting through ethylene, restores gravitropism to Arabidopsis seedlings grown under red light. Golan A, et al. **Plant Physiol** 1996 Nov;112(3):901–4

Identification of a receptor-like protein kinase gene rapidly induced by abscisic acid, dehydration, high salt, and cold treatments in Arabidopsis thaliana. Hong SW, et al. **Plant Physiol** 1997 Apr;113(4):1203–12

Multiple phytochromes are involved in red-light-induced enhancement of first-positive phototropism in Arabidopsis thaliana. Janoudi AK, et al. **Plant Physiol** 1997 Mar; 113(3):975–9

Cytoplasmic free Ca2+ in Arabidopsis roots changes in response to touch but not gravity. Legué V, et al. **Plant Physiol** 1997 Jul;114(3):789–800

Pressure regulation of the electrical properties of growing Arabidopsis thaliana L. root hairs. Lew RR. **Plant Physiol** 1996 Nov;112(3):1089–100

Mutations of Arabidopsis in potential transduction and response components of the phototropic signaling pathway. Liscum E, et al. **Plant Physiol** 1996 Sep;112(1):291–6

Identification of an Arabidopsis thaliana ribulose-1,5-bisphosphate carboxylase/oxygenase activase (RCA) minimal promoter regulated by light and the circadian clock. Liu Z, et al. **Plant Physiol** 1996 Sep; 112(1):43–51

Seed germination of Arabidopsis thaliana phyA/phyB double mutants is under phytochrome control. Poppe C, et al. **Plant Physiol** 1997 Aug;114(4):1487–92

Phytochrome B affects responsiveness to gibberellins in Arabidopsis. Reed JW, et al. **Plant Physiol** 1996 Sep; 112(1):337–42

Characterization of chloroplast division using the Arabidopsis mutant arc5. Robertson EJ, et al. **Plant Physiol** 1996 Sep; 112(1):149–59

De novo purine synthesis in Arabidopsis thaliana. II. The PUR7 gene encoding 5'-phosphoribosyl-4-(N-succinocarboxamide)-5-aminoimidazole synthetase is expressed in rapidly dividing tissues. Senecoff JF, et al. **Plant Physiol** 1996 Nov; 112(3):905–17

Genetic and developmental control of nuclear accumulation of COP1, a repressor of photomorphogenesis in Arabidopsis. von Arnim AG, et al. **Plant Physiol** 1997 Jul; 114(3):779–88

The role of the COP/DET/FUS genes in light control of arabidopsis seedling development. Wei N, et al. **Plant Physiol** 1996 Nov;112(3):871–8 (46 ref.)

Changes in voltage activation, Cs+ sensitivity, and ion permeability in H5 mutants of the plant K+ channel KAT1. Becker D, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8123–8

Expression of an Arabidopsis plasma membrane aquaporin in Dictyostelium results in hypoosmotic sensitivity and developmental abnormalities. Chaumont F, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6202–9

An anion channel in Arabidopsis hypocotyls activated by blue light. Cho MH, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8134–8

Removal of a cryptic intron and subcellular localization of green fluorescent protein are required to mark transgenic Arabidopsis plants brightly. Haseloff J, et al. **Proc Natl Acad Sci U S A** 1997 Mar 18;94(6):2122–7

AtGRP7, a nuclear RNA-binding protein as a component of a circadian-regulated negative feedback loop in Arabidopsis thaliana. Heintzen C, et al. **Proc Natl Acad Sci U S A** 1997 Aug 5;94(16):8515–20

Molecular recognition of pathogen attack occurs inside of plant cells in plant disease resistance specified by the Arabidopsis genes RPS2 and RPM1. Leister RT, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15497–502

Integration of circadian and phototransduction pathways in the network controlling CAB gene transcription in Arabidopsis. Millar AJ, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15491–6

A homolog of the mammalian GTPase Rab2 is present in Arabidopsis and is expressed predominantly in pollen grains and seedlings. Moore I, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21;94(2):762–7

Essential role of a kinesin-like protein in Arabidopsis trichome morphogenesis. Oppenheimer DG, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10;94(12):6261–6

Action spectra for phytochrome A- and B-specific photoinduction of seed germination in Arabidopsis thaliana. Shinomura T, et al. **Proc Natl Acad Sci U S A** 1996 Jul 23;93(15):8129–33

Conditional circadian dysfunction of the Arabidopsis early-flowering 3 mutant. Hicks KA, et al. **Science** 1996 Nov 1;274(5288):790–2

CKI1, a histidine kinase homolog implicated in cytokinin signal transduction. Kakimoto T. **Science** 1996 Nov 8; 274(5289):982–5

Self-sterility in Arabidopsis due to defective pollen tube guidance. Wilhelmi LK, et al. **Science** 1996 Nov 29; 274(5292):1535–7

RADIATION EFFECTS

Effects of heavy ions on the germination and survival of Arabidopsis thaliana. Tanaka A, et al. **Int J Radiat Biol** 1997 Jul;72(1):121–7

A negative regulatory factor for the dark repression of Arabidopsis thaliana cab1 gene. Choi DK, et al. **Photochem Photobiol** 1996 Nov;64(5):870–5

The pef mutants of Arabidopsis thaliana define lesions early in the phytochrome signaling pathway. Ahmad M, et al. **Plant J** 1996 Dec;10(6):1103–10

fhy1 defines a branch point in phytochrome A signal transduction pathways for gene expression. Barnes SA, et al. **Plant J** 1996 Dec;10(6):1155–61

Analysis of fast neutron-generated mutants at the Arabidopsis thaliana HY4 locus. Bruggemann E, et al. **Plant J** 1996 Oct;10(4):755–60

The Arabidopsis ELF3 gene regulates vegetative photomorphogenesis and the photoperiodic induction of flowering. Zagotta MT, et al. **Plant J** 1996 Oct; 10(4):691–702

Antagonistic but complementary actions of phytochromes A and B allow seedling de-etiolation. Smith H, et al. **Plant Physiol** 1997 Jun;114(2):637–41

An Arabidopsis photolyase mutant is hypersensitive to ultraviolet-B radiation. Landry LG, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):328–32

ULTRASTRUCTURE

A simple and rapid technique for the immunofluorescence confocal microscopy of intact Arabidopsis root tips. Harper JD, et al. **Cytobios** 1996;87(349):71–8

VIROLOGY

Characterization of cauliflower mosaic virus (CaMV) resistance in virus-resistant ecotypes of Arabidopsis. Callaway A, et al. **Mol Plant Microbe Interact** 1996 Dec; 9(9):810–8

Identification and map location of TTR1, a single locus in Arabidopsis thaliana that confers tolerance to tobacco ringspot nepovirus. Lee JM, et al. **Mol Plant Microbe Interact** 1996 Nov;9(8):729–35

ARABIDOPSIS THALIANA see **ARABIDOPSIS**

ARABINOFURANOSYLADENINE see **VIDARABINE**

ARABINOFURANOSYLADENINE MONOPHOSPHATE see **VIDARABINE PHOSPHATE**

ARABINOFURANOSYLCYTOSINE see **CYTARABINE**

ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE

BLOOD

Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. Hiddemann W, et al. **Ther Drug Monit** 1996 Aug;18(4):341–9

METABOLISM

Intracellular pharmacodynamics of ara-C and flowcytometric analysis of cell cycle progression in leukemia chemotherapy. Nakamura T, et al. **Leukemia** 1997 Apr;11 Suppl 3:548–51

PHARMACOKINETICS

[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters] Schiller M, et al. **Klin Padiatr** 1996 Jul-Aug;208(4):151–9 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Application of an in vitro system in the study of chemotherapeutic drug effects on DNA replication. Diaz-Perez MJ, et al. **J Cell Biochem** 1996 Jun 1; 61(3):444–51

ARABINOFURANOSYLNUCLEOSIDES see **ARABINONUCLEOSIDES**

ARABINOFURANOSYLNUCLEOTIDES see **ARABINONUCLEOTIDES**

ARABINOFURANOSYLURACIL

ANALOGS & DERIVATIVES

Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Balakrishna Pai S, et al. **Antimicrob Agents Chemother** 1996 Feb;40(2):380–6

Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Wang

ARABINOFURANOSYLURACIL

J, et al. **Antimicrob Agents Chemother** 1996 Jun; 40(6):1555–7

Mechanisms for the anti–hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU). Colacino JM. **Antiviral Res** 1996 Mar;29(2–3):125–39 (66 ref.)

Fialuridine is phosphorylated and inhibits DNA synthesis in isolated rat hepatic mitochondria. Horn DM, et al. **Antiviral Res** 1997 Mar;34(1):71–4

Discontinuous oral absorption pharmacokinetic model and bioavailability of 1–(2–fluoro–5–methyl–beta–L–arabinofuranosyl)uracil (L–FMAU) in rats. Wright JD, et al. **Biopharm Drug Dispos** 1996 Apr;17(3):197–207

The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Yan J, et al. **Clin Pharmacol Ther** 1997 May;61(5):563–73

Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5–fluorouracil prodrugs [corrected and republished with original paging, article originally printed in Drug Metab Dispos 1997 Feb;25(2):270–3] Okuda H, et al. **Drug Metab Dispos** 1997 May;25(5):270–3

Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5–fluorouracil prodrugs [corrected and republished in Drug Metab Dispos 1997 May;25(5):270–3] Okuda H, et al. **Drug Metab Dispos** 1997 Feb;25(2):270–3

Mitochondrial injury. Lessons from the fialuridine trial. Honkoop P, et al. **Drug Saf** 1997 Jul;17(1):1–7 (37 ref.)

Fialuridine toxicity [letter] Schmid R. **Hepatology** 1997 Jun; 25(6):1548

Pharmacokinetics of netivudine, a potent anti–varicella zoster virus drug, in patients with renal impairment. Fillastre JP, et al. **J Antimicrob Chemother** 1996 May;37(5):965–74

Pharmacokinetics of netivudine in haemodialysis patients [letter] Le Roy F, et al. **J Antimicrob Chemother** 1996 Nov; 38(5):913–5

Multiple dose netivudine, a potent anti–varicella zoster virus agent, in healthy elderly volunteers and patients with shingles. Peck RW, et al. **J Antimicrob Chemother** 1996 Mar;37(3):583–97

Evaluation of sorivudine (BV–araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus–infected adults. The Multinational Sorivudine Study Group. Bodsworth NJ, et al. **J Infect Dis** 1997 Jul;176(1):103–11

Synthesis and anti–hepatitis B virus activity of 9–(2–deoxy–2–fluoro–beta–L–arabinofuranosyl) purine nucleosides. Ma T, et al. **J Med Chem** 1997 Aug 15; 40(17):2750–4

Comparison of the DNA incorporation in human MOLT–4 cells of two 2'–beta–fluoronucleosides, 2'–beta–fluoro–2',3'–dideoxyadenosine and fialuridine. Ahluwalia GS, et al. **J Pharm Sci** 1996 Apr;85(4):454–5

Strategic proposals for predicting drug–drug interactions during new drug development: based on sixteen deaths caused by interactions of the new antiviral sorivudine with 5–fluorouracil prodrugs. Watabe T. **J Toxicol Sci** 1996 Dec; 21(5):299–300

Leukopenia–inducing effect of a combination of a new 5–fluorouracil (5–FU)–derived drug, BOF–A2 (emitefur), with other 5–FU–derived drugs or BV–araU (sorivudine) in rats. Miyauchi S, et al. **Jpn J Pharmacol** 1996 Feb; 70(2):139–48

Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lewis W, et al. **Lab Invest** 1997 Jan;76(1):77–87

Mitochondrial and cellular toxicity induced by fialuridine in human muscle in vitro. Semino–Mora C, et al. **Lab Invest** 1997 Apr;76(4):487–95

Histopathologic changes associated with fialuridine hepatotoxicity. Kleiner DE, et al. **Mod Pathol** 1997 Mar; 10(3):192–9

Differential effects of the incorporation of 1–(2–deoxy–2–fluoro–beta–D–arabinofuranosyl)–5–iodouracil (FIAU) on the binding of the transcription factors, AP–1 and TFIID, to their cognate target DNA sequences. Staschke KA, et al. **Nucleic Acids Res** 1996 Nov 1;24(21):4111–6

Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5–(E)–(2–bromovinyl)uracil that increases the level and toxicity of 5–fluorouracil. Nakayama H, et al. **Pharmacogenetics** 1997 Feb;7(1):35–43

BLOOD

Chromatographic analysis (TLC) of uracil arabinoside, cytosine arabinoside, uracil and cytosine in human plasma. Paw B, et al. **Acta Pol Pharm** 1995 Nov–Dec;52(6):455–7

Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. Hiddemann W, et al. **Ther Drug Monit** 1996 Aug;18(4):341–9

ARABINONUCLEOSIDES

BLOOD

Stability and analysis of 2–chloro–2'–deoxyadenosine, 2–chloro–2'–arabino–fluoro–2'–deoxyadenosine and 2–chloroadenine in human blood plasma. Lindemalm S, et al. **Anticancer Drugs** 1997 Jun;8(5):445–53

CHEMICAL SYNTHESIS

Synthesis and antiviral activity of 6–chloropurine arabinoside and its 2'–deoxy–2'–fluoro derivative. Maruyama T, et al. **Chem Pharm Bull (Tokyo)** 1996 Dec;44(12):2331–4

A facile, alternative synthesis of 4'–thioarabinonucleosides and their biological activities. Yoshimura Y, et al. **J Med Chem** 1997 Jul 4;40(14):2177–83

A facile synthesis of 4'–thio–arabinonucleosides as potential antiviral agents from D–glucose. Yoshimura Y, et al. **Nucleic Acids Symp Ser** 1995;(34):21–2

CHEMISTRY

Structure of a DNA duplex containing a single 2'–O–methyl–beta–D–araT: combined use of NMR, restrained molecular dynamics, and full relaxation matrix refinement. Gotfredsen CH, et al. **Bioconjug Chem** 1996 Nov–Dec;7(6):680–8

Synthesis and properties of alpha– and beta–oligodeoxynucleotides containing alpha– and beta–1–(2–O–methyl–D–arabino–furanosyl)thymine. Gotfredsen CH, et al. **Bioorg Med Chem** 1996 Aug; 4(8):1217–25

METABOLISM

In situ color detection of alpha–L–arabinofuranosidase, a "no–background" reporter gene, with 5–bromo–3–indolyl–alpha–L–arabinofuranoside. Berlin W, et al. **Anal Biochem** 1996 Dec 1;243(1):171–5

THERAPEUTIC USE

Clinical trials referral resource. Clinical trials using compound 506U78. Ho PT, et al. **Oncology (Huntingt)** 1996 Dec;10(12):1831–2

ARABINONUCLEOTIDES

ADMINISTRATION & DOSAGE

Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony–stimulating factor. Okumura H, et al. **Int J Hematol** 1997 Apr;65(3):263–8

The effect of YNK–01 (an oral prodrug of cytarabine) on hepatocellular carcinoma. Suto T, et al. **Semin Oncol** 1997 Apr;24(2 Suppl 6):S6–122–S6–129

[Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate] Nishi T, et al. **Gan To Kagaku Ryoho** 1996 Sep;23(10):1331–4 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone. Braess J, et al. **Ann Hematol** 1996 Oct;73(4):201–4

Combination therapy with granulocyte colony–stimulating factor, all–trans retinoic acid, and low–dose cytotoxic drugs for acute myelogenous leukemia. Usuki K, et al. **Intern Med** 1995 Dec;34(12):1186–9

ARABINOSE

ANALOGS & DERIVATIVES

Synthesis and utilization of GDP–D–arabinopyranoside. Park S, et al. **Anal Biochem** 1997 Jan 15;244(2):321–7

GENETICS

The Bacillus subtilis L–arabinose (ara) operon: nucleotide sequence, genetic organization and expression. Sá–Nogueira I, et al. **Microbiology** 1997 Mar;143 (Pt 3):957–69

METABOLISM

Development of an arabinose–fermenting Zymomonas mobilis strain by metabolic pathway engineering. Deanda K, et al. **Appl Environ Microbiol** 1996 Dec;62(12):4465–70

Negative regulation of L–arabinose metabolism in Bacillus subtilis: characterization of the araR (araC) gene. Sá–Nogueira I, et al. **J Bacteriol** 1997 Mar;179(5):1598–608

PHARMACOLOGY

L–arabinose selectively inhibits intestinal sucrase in an uncompetitive manner and suppresses glycemic response after sucrose ingestion in animals. Seri K, et al. **Metabolism** 1996 Nov;45(11):1368–74

PHYSIOLOGY

Identification of the sugars involved in mycobacterial cell aggregation. Anton V, et al. **FEMS Microbiol Lett** 1996 Nov 1;144(2–3):167–70

ARABINOSYLADENINE see **VIDARABINE**

ARABINOSYLCYTOSINE see **CYTARABINE**

ARABINOSYLCYTOSINE TRIPHOSPHATE see **ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE**

ARABINOSYLURACIL see **ARABINOFURANOSYLURACIL**

ARABS

see related
ISLAM

Genotypic/phenotypic heterogeneity of selective vitamin B12 malabsorption (Grasbeck–Imerslund syndrome) in two Bedouin families. Ismail EA, et al. **Acta Paediatr** 1997 Apr; 86(4):424–5

Greig cephalopolysyndactyly syndrome with dysgenesis of the corpus callosum in a Bedouin family. Marafie MJ, et al. **Am J Med Genet** 1996 Dec 18;66(3):261–4

Kenny–Caffey syndrome in six Bedouin sibships: autosomal recessive inheritance is confirmed. Tahseen K, et al. **Am J Med Genet** 1997 Mar 17;69(2):126–32

De novo direct duplication 7p (p11.2–>pter) in an Arab child with MCA/MR syndrome: trisomy 7p a delineated syndrome? Redha MA, et al. **Ann Genet** 1996;39(1):5–9 (18 ref.)

Thrombophilia in ethnic Arabs in Kuwait. Mohanty D, et al. **Ann Hematol** 1996 Dec;73(6):283–90

Familial Mediterranean fever in Arab children: the high prevalence and gene frequency. Rawashdeh MO, et al. **Eur J Pediatr** 1996 Jul;155(7):540–4

Prenatal diagnosis of diffuse mesangial glomerulosclerosis by ultrasonography: a longitudinal study of a case in an affected family. Hofstaetter C, et al. **Fetal Diagn Ther** 1996 Mar–Apr;11(2):126–31

Lymphoepithelial carcinoma of salivary glands. Abdulla AK, et al. **Head Neck** 1996 Nov–Dec;18(6):577–81 (23 ref.)

Novel HEXA mutation in a Bedouin Tay–Sachs patient associated with exon skipping and reduced transcript level. Drucker L, et al. **Hum Mutat** 1997;9(3):260–4

Juvenile ECG pattern in adult black Arabs. Assali AR, et al. **J Electrocardiol** 1997 Apr;30(2):87–90

The prevalence and awareness of hypertension among Israeli Arabs. Amad S, et al. **J Hum Hypertens** 1996 Sep;10 Suppl 3:S31–3

Kimura's disease. Pamaraju N, et al. **J Laryngol Otol** 1996 Nov;110(11):1084–7

Femoral hypoplasia–unusual facies syndrome with bifid hallux, absent tibia, and macrophallus: a report of a Bedouin baby. Sabry MA, et al. **J Med Genet** 1996 Feb;33(2):165–7 (9 ref.)

Clitoral and penile sizes of full term newborns in two different ethnic groups. Phillip M, et al. **J Pediatr Endocrinol Metab** 1996 Mar–Apr;9(2):175–9

A new Arabic distance visual acuity chart. Al–Mufarrej MM, et al. **Optom Vis Sci** 1996 Jan;73(1):59–61

Changing epidemiology of invasive Streptococcus pyogenes infections in southern Israel: differences between two ethnic population groups. Chiobotaru P, et al. **Pediatr Infect Dis J** 1997 Feb;16(2):195–9

Clinicolaboratory profile of 33 Arabs with systemic lupus erythematosus. al–Attia HM. **Postgrad Med J** 1996 Nov; 72(853):677–9

Factor XIII deficiency due to a Leu660Pro mutation in the factor XIII subunit–a gene in three unrelated Palestinian Arab families. Inbal A, et al. **Thromb Haemost** 1997 Jun; 77(6):1062–7

[Reporting maternal behavior during diarrhea in Bedouin children] Bilenko N, et al. **Harefuah** 1997 May 15; 132(10):699–702, 743 (Eng. Abstr.) **(Heb)**

EDUCATION

Attitudes and reactions of Arab medical students to the dissecting room. Abu–Hijleh MF, et al. **Clin Anat** 1997; 10(4):272–8

GENETICS

Correlation between the incidence of myotonic dystrophy in different groups in Israel and the number of CTG trinucleotide repeats in the myotonin gene. Mor–Cohen R, et al. **Am J Med Genet** 1997 Aug 8;71(2):156–9

Genetic disorders among Palestinian Arabs. 2. Hydrocephalus and neural tube defects. Zlotogora J. **Am J Med Genet** 1997 Jul 11;71(1):33–5

Lissencephaly associated with cerebellar hypoplasia and myoclonic epilepsy in a Bedouin kindred: a new syndrome? Farah S, et al. **Clin Genet** 1997 May;51(5):326–30

The first HLA anthropological study in the Kuwaiti population. al–Harbi S, et al. **Eur J Immunogenet** 1994 Oct; 21(5):295–300

Distribution of HLA–DQA1 alleles in Arab and Pakistani individuals from Dubai, United Arab Emirates. Tahir MA, et al. **Forensic Sci Int** 1997 Mar 14;85(3):219–23

Orosomucoid (ORM1) polymorphism in Arabs and Jews of Israel: more evidence for a middle eastern origin of the Jews. Nevo S, et al. **Hum Biol** 1996 Apr;68(2):217–29

Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. Desgeorges M, et al. **Hum Genet** 1997 Aug;100(2):279–83

Deletion analysis of the SMN and NAIP genes in Kuwaiti patients with spinal muscular atrophy. Samilchuk E, et al. **Hum Genet** 1996 Nov;98(5):524–7

The distribution of the vWF alleles and genotypes in the Palestinian population. Khatib H, et al. **J Forensic Sci** 1997

May;42(3):504–5
HLA and graft–versus–host disease: a population–based study of HLA phenotypes of Jewish and Arabic bone marrow transplanted patients in Israel. Bishara A, et al. **Leuk Res** 1997 Feb;21(2):111–8
Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Goldstein JA, et al. **Pharmacogenetics** 1997 Feb;7(1):59–64
Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. Woolhouse NM, et al. **Pharmacogenetics** 1997 Feb;7(1):73–82
Gender identity and role in a pedigree of Arabs with intersex due to 5 alpha reductase–2 deficiency. al–Attia HM. **Psychoneuroendocrinology** 1996 Nov;21(8):651–7

PSYCHOLOGY

What do Israeli Jewish and Arab adolescents know about drinking and driving? Weiss S. **Accid Anal Prev** 1996 Nov; 28(6):765–9
Reliability and validity of Palestinian Student Alienation Scale. Abdallah T. **Adolescence** 1997 Summer; 32(126):367–71
Israeli Arab and Jewish youth knowledge and opinion about alcohol warning labels: pre–intervention data. Weiss S. **Alcohol Alcohol** 1997 May–Jun;32(3):251–7
Children's fears: cultural and developmental perspectives. Elbedour S, et al. **Behav Res Ther** 1997 Jun;35(6):491–6
Addressing the repressed needs of the Arabic client. Dwairy M. **Cult Divers Ment Health** 1997;3(1):1–12
Menstrual synchrony under optimal conditions: Bedouin families. Weller A, et al. **J Comp Psychol** 1997 Jun; 111(2):143–51
Reading in Arabic orthography: the effect of vowels and context on reading accuracy of poor and skilled native Arabic readers in reading paragraphs, sentences, and isolated words. Abu–Rabia S. **J Psycholinguist Res** 1997 Jul;26(4):465–82
The healing significance of the Negev's Bedouin Dervish. al–Krenawi A, et al. **Soc Sci Med** 1996 Jul;43(1):13–21

STATISTICS & NUMERICAL DATA

Demographic characteristics of the Israeli Arab community in connection with consanguinity. Jaber L, et al. **Isr J Med Sci** 1996 Dec;32(12):1286–9
Progressive familial intrahepatic cholestasis among the Arab population in Israel. Naveh Y, et al. **J Pediatr Gastroenterol Nutr** 1997 May;24(5):548–54

ARAC GENES see **GENES, ARAC**

ARACHIDIC ACIDS see **EICOSANOIC ACIDS**

ARACHIDONATE 5-LIPOXYGENASE

ANTAGONISTS & INHIBITORS

Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinflammatory drugs. Scioscia KA, et al. **Am J Otolaryngol** 1997 Jan–Feb;18(1):1–8
Lipid mediators in oxygen–induced airway remodeling and hyperresponsiveness in newborn rats. Burghardt JS, et al. **Am J Respir Crit Care Med** 1996 Oct;154(4 Pt 1):837–42
Eosinophil chemotaxis inhibited by 5–lipoxygenase blockade and leukotriene receptor antagonism. Muñoz NM, et al. **Am J Respir Crit Care Med** 1997 Apr;155(4):1398–403
The effect of ABT–761, a novel 5–lipoxygenase inhibitor, on exercise– and adenosine–induced bronchoconstriction in asthmatic subjects. Van Schoor J, et al. **Am J Respir Crit Care Med** 1997 Mar;155(3):875–80
An in vivo inhibitor of 5–lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells. Anderson KM, et al. **Anticancer Res** 1996 Sep–Oct;16(5A):2589–99
N–omega–carbethoxypentyl–4–quinolones: a new class of leukotriene biosynthesis inhibitors. Desideri N, et al. **Arch Pharm (Weinheim)** 1997 Apr;330(4):100–6
Beditine, a new benzodioxane derivative, as a suppressor of human polymorphonuclear leukocyte and platelet activation. Panossian A, et al. **Biochem Pharmacol** 1997 Jun 1;53(11):1753–5
Conversion of cyclooxygenase inhibitors into hydroxythiazole 5–lipoxygenase inhibitors. Kerdesky FA, et al. **Bioorg Med Chem** 1997 Feb;5(2):393–6
Mechanism of the anti–tumour effect of 2,3,5–trimethyl–6–(3–pyridylmethyl) 1,4–benzoquinone (CV–6504). Hussey HJ, et al. **Br J Cancer** 1997;75(6):845–9
Effect of manoalide on human 5–lipoxygenase activity. Cabré F, et al. **Inflamm Res** 1996 May;45(5):218–23
Tenidap inhibits 5–lipoxygenase product formation in vitro, but this activity is not observed in three animal models. Carty TJ, et al. **Inflamm Res** 1997 May;46(5):168–79
The effect of 5–lipoxygenase inhibition on Ascaris antigen (Ag)–induced responses in atopic monkeys. Turner CR, et al. **Inflamm Res** 1996 Jan;45(1):42–9
The effect of a selective 5–lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats. Zarif A, et al. **Inflammation** 1996 Jun;20(3):217–27
Acute and chronic effects of a 5–lipoxygenase inhibitor in asthma: a 6–month randomized multicenter trial. Zileuton Study Group. Liu MC, et al. **J Allergy Clin Immunol** 1996 Nov;98(5 Pt 1):859–71
Inhibition of 5–lipoxygenase blocks IL–1 beta–induced vascular adhesion molecule–1 gene expression in human endothelial cells. Lee S, et al. **J Immunol** 1997 Apr 1; 158(7):3401–7
5–Lipoxygenase inhibitors potentiate effects of TGF–beta 1 on the differentiation of human leukemia HL–60 cells. Kozubík A, et al. **J Leukoc Biol** 1997 Aug;62(2):240–8
Bicyclic N–hydroxyurea inhibitors of 5–lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N–hydroxy–N–(2,3–dihydro–6–(phenylmethoxy)–3–benzofuranyl)urea. Adams JL, et al. **J Med Chem** 1996 Dec 20;39(26):5035–46
5–Lipoxygenase inhibitors: synthesis and structure–activity relationships of a series of 1–aryl–2H,4H–tetrahydro–1,2,4–triazin–3–ones. Bhatia PA, et al. **J Med Chem** 1996 Sep 27;39(20):3938–50
1–substituted 4–aryl–5–pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5–lipoxygenase and cyclooxygenase inhibitory potency. Boehm JC, et al. **J Med Chem** 1996 Sep 27;39(20):3929–37
Dioxabicyclooctanyl naphthalenenitriles as nonredox 5–lipoxygenase inhibitors: structure–activity relationship study directed toward the improvement of metabolic stability. Delorme D, et al. **J Med Chem** 1996 Sep 27; 39(20):3951–70
Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5–lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L–739,010. Hamel P, et al. **J Med Chem** 1997 Aug 29;40(18):2866–75
Nonsteroidal anti–inflammatory drugs as scaffolds for the design of 5–lipoxygenase inhibitors. Kolasa T, et al. **J Med Chem** 1997 Feb 28;40(5):819–24
Structure–activity relationships of N–hydroxyurea 5–lipoxygenase inhibitors. Stewart AO, et al. **J Med Chem** 1997 Jun 20;40(13):1955–68
Polymorphism and crystallization behavior of Abbott–79175, a second–generation 5–lipoxygenase inhibitor. Li R, et al. **J Pharm Sci** 1996 Jul;85(7):773–80
ABT–761 attenuates bronchoconstriction and pulmonary inflammation in rodents. Bell RL, et al. **J Pharmacol Exp Ther** 1997 Mar;280(3):1366–73
Evaluation of the antiinflammatory activity of a dual cyclooxygenase–2 selective/5–lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. Kirchner T, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):1094–101
Effects of the 5–lipoxygenase inhibitor A–64077 on intestinal hypothermic organ preservation injury. Mangino MJ, et al. **J Pharmacol Exp Ther** 1997 May;281(2):950–6
Concomitant treatment with a 5–lipoxygenase inhibitor improves the anti–inflammatory effect of the inhibition of nitric oxide synthase during the early phase of endotoxin–induced uveitis in the rabbit. Bellot JL, et al. **Ophthalmic Res** 1997;29(4):227–36
Pharmacology of leukotriene receptor antagonists and 5–lipoxygenase inhibitors in the management of asthma. Drazen JM. **Pharmacotherapy** 1997 Jan–Feb;17(1 Pt 2):22S–30S (58 ref.)
New frontiers in asthma therapy: leukotriene receptor antagonists and 5–lipoxygenase inhibitors. Introduction. Hendeles L. **Pharmacotherapy** 1997 Jan–Feb;17(1 Pt 2):1S–2S
The use of 5–lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma. Sorkness CA. **Pharmacotherapy** 1997 Jan–Feb;17(1 Pt 2):50S–54S (14 ref.)
Dual inhibitory activities of tannins from Hamamelis virginiana and related polyphenols on 5–lipoxygenase and lyso–PAF: acetyl–CoA acetyltransferase. Hartisch C, et al. **Planta Med** 1997 Apr;63(2):106–10
5–Lipoxygenase and cyclooxygenase inhibitory active constituents from Qianghuo (Notopterygium incisum). Zschocke S, et al. **Planta Med** 1997 Jun;63(3):203–6
A 5–lipoxygenase inhibitor at micromolar concentration raises intracellular calcium in U937 cells prior to their physiologic cell death. Buyn T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jan; 56(1):69–77
Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5–lipoxygenase, on events associated with NSAID–induced gastrointestinal inflammation. Kirchner T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jun;56(6):417–23
[Lipoamino acids and lipopeptides as potential 5– and 12–lipoxygenase inhibitors] Presenz P. **Pharmazie** 1997 Feb; 52(2):164–5 **(Ger)**
[5–lipoxygenase inhibitors in asthma therapy] Tanaka R. **Nippon Rinsho** 1996 Nov;54(11):3040–4 (5 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Epstein–Barr virus modulates 5–lipoxygenase product synthesis in human peripheral blood mononuclear cells. Gosselin J, et al. **Blood** 1997 Mar 15;89(6):2122–30

BLOOD

Epstein–Barr virus modulates 5–lipoxygenase product synthesis in human peripheral blood mononuclear cells. Gosselin J, et al. **Blood** 1997 Mar 15;89(6):2122–30
5–Lipoxygenase metabolites of arachidonic acid regulate volume decrease by mudpuppy red blood cells. Light DB, et al. **J Membr Biol** 1997 Aug 1;158(3):229–39
Plasmin is a specific stimulus of the 5–lipoxygenase pathway of human peripheral monocytes. Weide I, et al. **Thromb Haemost** 1996 Oct;76(4):561–8

CHEMISTRY

Physiochemical characterization of ATP binding to human 5–lipoxygenase. Noguchi M, et al. **Lipids** 1996 Apr; 31(4):367–71

DEFICIENCY

5–Lipoxygenase products are necessary for ovalbumin–induced airway responsiveness in mice. Irvin CG, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):L1053–8
Leukotriene–deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. Bailie MB, et al. **J Immunol** 1996 Dec 15;157(12):5221–4

GENETICS

Repression of the 5–lipoxygenase gene by c–myb overexpression in differentiated HL–60 cells. Ponton A, et al. **Prostaglandins** 1997 Jan;53(1):49–58
Cloning, sequencing and expression of a 5–lipoxygenase from Syrian hamster embryo fibroblasts. Kitzler JW, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Oct; 55(4):269–77
Changes in chromatin conformation regulate the 5–lipoxygenase gene expression during differentiation of HL60 cells. Ponton A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Sep; 55(3):139–43
Genetically determined leukotriene B4 production is not required for cytotoxic effector cell development during allograft rejection. Gignac MR, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1052

METABOLISM

5–Lipoxygenase products are necessary for ovalbumin–induced airway responsiveness in mice. Irvin CG, et al. **Am J Physiol** 1997 Jun;272(6 Pt 1):L1053–8
Age–related enhancement of 5–lipoxygenase metabolic capacity in cattle alveolar macrophages. Lu MC, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):L547–54
Eosinophil VLA–4 binding to fibronectin augments bronchial narrowing through 5–lipoxygenase activation. Muñoz NM, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L587–94
Colchicine inhibits arachidonate release and 5–lipoxygenase action in alveolar macrophages. Peters–Golden M, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):L1004–13
Human monocytes lose 5–lipoxygenase and FLAP as they mature into monocyte–derived macrophages in vitro. Ring WL, et al. **Am J Physiol** 1996 Jul;271(1 Pt 1):C372–7
Leukotriene B4 costimulates 5–lipoxygenase activity in neutrophils via increased 5–lipoxygenase translocation. Serio KJ, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):C1329–34
Quantitation of 5–lipoxygenase products by electrospray mass spectrometry: effect of ethanol on zymosan–stimulated production of 5–lipoxygenase products by human neutrophils. Wheelan P, et al. **Anal Biochem** 1997 Jan 1; 244(1):110–5
Modulation of glioma cell growth and 5–lipoxygenase expression by interferon. Naidu KA, et al. **Anticancer Res** 1996 Nov–Dec;16(6B):3475–82
Arachidonic acid stimulates prostate cancer cell growth: critical role of 5–lipoxygenase. Ghosh J, et al. **Biochem Biophys Res Commun** 1997 Jun 18;235(2):418–23
Leukotriene synthesis by isolated perinatal ovine intrapulmonary vessels correlates with age–related changes in 5–lipoxygenase protein. Ibe BO, et al. **Biochem Mol Med** 1997 Jun;61(1):63–71
Discovery of 5R–lipoxygenase activity in oocytes of the surf clam, Spisula solidissima. Hada T, et al. **Biochim Biophys Acta** 1997 Jun 2;1346(2):109–19
Arachidonate–induced eicosanoid synthesis in RBL–2H3 cells: stimulation with antigen or A23187 induces prolonged activation of 5–lipoxygenase. Westcott JY, et al. **Biochim Biophys Acta** 1996 Sep 6;1303(1):74–81
Dexamethasone increases expression of 5–lipoxygenase and its activating protein in human monocytes and THP–1 cells. Riddick CA, et al. **Eur J Biochem** 1997 May 15; 246(1):112–8
Selenium–dependent peroxidases suppress 5–lipoxygenase activity in B–lymphocytes and immature myeloid cells. The presence of peroxidase–insensitive 5–lipoxygenase activity in differentiated myeloid cells. Werz O, et al. **Eur J Biochem** 1996 Nov 15;242(1):90–7
Effect of manoalide on human 5–lipoxygenase activity. Cabré F, et al. **Inflamm Res** 1996 May;45(5):218–23
Differential effects of cell density on 5–lipoxygenase (5–LO), five–lipoxygenase–activating protein (FLAP) and interleukin–1 beta (IL–1 beta) expression in human neutrophils. Jobin C, et al. **Inflammation** 1997 Apr; 21(2):235–50
Rapid import of cytosolic 5–lipoxygenase into the nucleus of neutrophils after in vivo recruitment and in vitro adherence. Brock TG, et al. **J Biol Chem** 1997 Mar 28;

ARACHIDONATE 5-LIPOXYGENASE

272(13):8276–80

Lipoxygenase metabolism is required for interleukin-3 dependent proliferation and cell cycle progression of the human M-07e cell line. Miller AM, et al. **J Cell Physiol** 1997 Mar;170(3):309–15

Thrombin stimulates activation of the cerebral 5-lipoxygenase pathway during blood–brain cell contact. Winking M, et al. **J Cereb Blood Flow Metab** 1996 Jul; 16(4):737–45

Transcellular metabolism of leukotriene A4 by rabbit blood cells: lack of relevant LTC4-synthase activity in rabbit platelets. Sala A, et al. **J Lipid Res** 1997 Apr;38(4):627–33

Contrasting effects of proinflammatory and T-helper lymphocyte subset-2 cytokines on the 5-lipoxygenase pathway in monocytes. Nassar GM, et al. **Kidney Int** 1997 May;51(5):1520–8

Physiochemical characterization of ATP binding to human 5-lipoxygenase. Noguchi M, et al. **Lipids** 1996 Apr; 31(4):367–71

Hemodialysis-induced upregulation of granulocyte adhesion molecules CD11b/CD18 is independent from 5-lipoxygenase activity. Sellmayer A, et al. **Nephron** 1997; 76(4):418–24

Benzophenanthridine alkaloids of Chelidonium majus; I. Inhibition of 5- and 12-lipoxygenase by a non-redox mechanism. Vavrečková C, et al. **Planta Med** 1996 Oct; 62(5):397–401

The role of cyclooxygenase and 5-lipoxygenase metabolites in potentiated endothelin-1-evoked contractions in bovine bronchi. Nally JE, et al. **Pulm Pharmacol** 1996 Aug; 9(4):211–7

Increased 5-lipoxygenase metabolism in the lungs of human subjects exposed to ozone. Coffey MJ, et al. **Toxicology** 1996 Dec 18;114(3):187–97

Genetically determined leukotriene B4 production is not required for cytotoxic effector cell development during allograft rejection. Gignac MR, et al. **Transplant Proc** 1997 Feb-Mar;29(1-2):1052

ARACHIDONATE 12-LIPOXYGENASE

ANALYSIS

Elevated 12-lipoxygenase activity in the spontaneously hypertensive rat. Sasaki M, et al. **Am J Hypertens** 1997 Apr;10(4 Pt 1):371–8

Subcellular localization of arachidonate 12-lipoxygenase and morphological effect of its overexpression on murine keratinocytes. Nakamura M, et al. **Cell Tissue Res** 1997 May;288(2):327–34

ANTAGONISTS & INHIBITORS

(Carboxyalkyl)benzyl propargyl ethers as selective inhibitors of leukocyte-type 12-lipoxygenases. Gorins G, et al. **J Med Chem** 1996 Dec 6;39(25):4871–8

Effects of nonanal, trans-2-nonenal and 4-hydroxy-2,3-trans-nonenal on cyclooxygenase and 12-lipoxygenase metabolism of arachidonic acid in rabbit platelets. Sakuma S, et al. **J Pharm Pharmacol** 1997 Feb; 49(2):150–3

Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle. Gu JL, et al. **Mol Cell Biochem** 1997 Jul;172(1-2):47–57

[Lipoamino acids and lipopeptides as potential 5- and 12-lipoxygenase inhibitors] Presenz P. **Pharmazie** 1997 Feb; 52(2):164–5 **(Ger)**

BIOSYNTHESIS

Transcriptional activation of human 12-lipoxygenase gene promoter is mediated through Sp1 consensus sites in A431 cells. Liu YW, et al. **Biochem J** 1997 May 15;324 (Pt 1):133–40

Requirement for epidermal growth factor receptor tyrosine kinase and for 12-lipoxygenase activity in the expression of 12-lipoxygenase in human epidermoid carcinoma cells. Hagmann W, et al. **Biochem Pharmacol** 1997 Apr 4; 53(7):937–42

12-Lipoxygenase in A431 cells: genetic identity, modulation of expression, and intracellular localization. Hagmann W, et al. **Exp Cell Res** 1996 Nov 1;228(2):197–205

Murine epidermal lipoxygenase (Aloxe) encodes a 12-lipoxygenase isoform. Kinzig A, et al. **FEBS Lett** 1997 Feb 3;402(2-3):162–6

BLOOD

Qualitative platelet 12-lipoxygenase abnormality in a patient with essential thrombocythemia. Tomo K, et al. **Thromb Haemost** 1997 Feb;77(2):294–7

CHEMISTRY

Leukocyte 12-lipoxygenase: expression, purification, and investigation of the role of methionine residues in turnover-dependent inactivation and 5,8,11,14-eicosatetraynoic acid inhibition. Richards KM, et al. **Biochemistry** 1997 Jun 3;36(22):6692–9

DRUG EFFECTS

Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle. Gu JL, et al. **Mol Cell Biochem** 1997 Jul;172(1-2):47–57

GENETICS

Transcriptional activation of human 12-lipoxygenase gene promoter is mediated through Sp1 consensus sites in A431 cells. Liu YW, et al. **Biochem J** 1997 May 15;324 (Pt 1):133–40

Leukocyte 12-lipoxygenase: expression, purification, and investigation of the role of methionine residues in turnover-dependent inactivation and 5,8,11,14-eicosatetraynoic acid inhibition. Richards KM, et al. **Biochemistry** 1997 Jun 3;36(22):6692–9

Overexpression of Ha-ras enhances the transcription of human arachidonate 12-lipoxygenase promoter in A431 cells. Chen BK, et al. **Biochim Biophys Acta** 1997 Feb 18; 1344(3):270–7

The 12-lipoxygenase gene-transfected MCF-7 human breast cancer cell line exhibits estrogen-independent, but estrogen and omega-6 fatty acid-stimulated proliferation in vitro, and enhanced growth in athymic nude mice. Liu XH, et al. **Cancer Lett** 1996 Dec 3;109(1-2):223–30

12-Lipoxygenase in A431 cells: genetic identity, modulation of expression, and intracellular localization. Hagmann W, et al. **Exp Cell Res** 1996 Nov 1;228(2):197–205

Murine epidermal lipoxygenase (Aloxe) encodes a 12-lipoxygenase isoform. Kinzig A, et al. **FEBS Lett** 1997 Feb 3;402(2-3):162–6

Expression of arachidonate platelet-type 12-lipoxygenase in human rheumatoid arthritis type B synoviocytes. Liagre B, et al. **FEBS Lett** 1997 Sep 1;414(1):159–64

METABOLISM

Platelet-type arachidonate 12-lipoxygenase. Nakamura M, et al. **Adv Exp Med Biol** 1996;416:355–9 (14 ref.)

Multiple use of a signal transduction pathway in tumor cell invasion. Timár J, et al. **Anticancer Res** 1996 Nov-Dec; 16(6A):3299–306

Diurnal change of arachidonate 12-lipoxygenase in rat pineal gland. Kawajiri H, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):229–33

Activation of 12- and 15-lipoxygenase in the cardiopulmonary system by hemorrhagic events. Bailey JM, et al. **Biochem Soc Trans** 1996 Aug;24(3):435S

Epidermal growth factor enhances transcription of human arachidonate 12-lipoxygenase in A431 cells. Liu YW, et al. **Biochim Biophys Acta** 1997 Jan 7;1344(1):38–46

Involvement of the 12-lipoxygenase pathway of arachidonic acid metabolism in homosynaptic long-term depression of the rat hippocampus. Normandin M, et al. **Brain Res** 1996 Aug 19;730(1-2):40–6

Nitric oxide enhances 12-HETE versus LTB4 generation in pancreatic transplantation. Hotter G, et al. **Inflammation** 1996 Feb;20(1):23–31

Effect of the PAF-receptor antagonist SM-12502 on human platelets. Köller M, et al. **Inflammation** 1996 Feb; 20(1):71–85

Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. Scheidegger KJ, et al. **J Biol Chem** 1997 Aug 22;272(34):21609–15

Platelet-derived growth factor BB mediated regulation of 12-lipoxygenase in porcine aortic smooth muscle cells. Natarajan R, et al. **J Cell Physiol** 1996 Nov;169(2):391–400

Increased 12-lipoxygenase expression in breast cancer tissues and cells. Regulation by epidermal growth factor. Natarajan R, et al. **J Clin Endocrinol Metab** 1997 Jun; 82(6):1790–8

Benzophenanthridine alkaloids of Chelidonium majus; I. Inhibition of 5- and 12-lipoxygenase by a non-redox mechanism. Vavrečková C, et al. **Planta Med** 1996 Oct; 62(5):397–401

PHARMACOLOGY

Effects of phospholipase A2, 12-lipoxygenase, and cyclooxygenase inhibitors in the feline pulmonary bed. Kaye AD, et al. **Am J Physiol** 1997 Apr;272(4 Pt 1):L573–9

A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Li Y, et al. **Neuron** 1997 Aug; 19(2):453–63

PHYSIOLOGY

Mechanisms of ANG II-induced mitogenic responses: role of 12-lipoxygenase and biphasic MAP kinase. Wen Y, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1212–20

Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein. Sun D, et al. **J Biol Chem** 1996 Sep 27; 271(39):24055–62

Apoptosis of W256 carcinosarcoma cells of the monocytoid origin induced by NDGA involves lipid peroxidation and depletion of GSH: role of 12-lipoxygenase in regulating tumor cell survival. Tang DG, et al. **J Cell Physiol** 1997 Aug;172(2):155–70

ARACHIDONATE 15-LIPOXYGENASE

ANTAGONISTS & INHIBITORS

Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Sendobry SM, et al. **Br J Pharmacol** 1997 Apr;120(7):1199–206

BIOSYNTHESIS

Discovery of a second 15S-lipoxygenase in humans. Brash AR, et al. **Proc Natl Acad Sci U S A** 1997 Jun 10; 94(12):6148–52

CHEMISTRY

Defining the arachidonic acid binding site of human 15-lipoxygenase. Molecular modeling and mutagenesis. Gan QF, et al. **J Biol Chem** 1996 Oct 11;271(41):25412–8

Phenylalanine 353 is a primary determinant for the positional specificity of mammalian 15-lipoxygenases. Borngräber S, et al. **J Mol Biol** 1996 Dec 20;264(5):1145–53

GENETICS

Characterization and sequence of an additional 15-lipoxygenase transcript and of the human gene. Kritzik MR, et al. **Biochim Biophys Acta** 1997 Jun 26; 1352(3):267–81

mRNA silencing in erythroid differentiation: hnRNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3' end. Ostareck DH, et al. **Cell** 1997 May 16;89(4):597–606

Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. Shen J, et al. **J Clin Invest** 1996 Nov 15;98(10):2201–8

METABOLISM

Reactivity of mammalian 15-lipoxygenase with phospholipids in large unilamellar liposomes. Arai H, et al. **Biochem Biophys Res Commun** 1996 Nov 21; 228(3):675–82

Characterization of a 15-lipoxygenase in human breast carcinoma BT-20 cells: stimulation of 13-HODE formation by TGF alpha/EGF. Reddy N, et al. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):111–6

Activation of 12- and 15-lipoxygenase in the cardiopulmonary system by hemorrhagic events. Bailey JM, et al. **Biochem Soc Trans** 1996 Aug;24(3):435S

Fatty acid binding proteins reduce 15-lipoxygenase-induced oxygenation of linoleic acid and arachidonic acid. Ek BA, et al. **Biochim Biophys Acta** 1997 May 17;1346(1):75–85

The role of 15-lipoxygenase in atherogenesis: pro- and antiatherogenic actions. Kühn H, et al. **Curr Opin Lipidol** 1997 Apr;8(2):111–7 (68 ref.)

Oxidation of human low-density lipoprotein by soybean 15-lipoxygenase in combination with copper (II) or met-myoglobin. O'Leary VJ, et al. **Free Radic Biol Med** 1996;20(4):525–32

Oxygenation of biomembranes by mammalian lipoxygenases: the role of ubiquinone. Schnurr K, et al. **Free Radic Biol Med** 1996;20(1):11–21

Defining the arachidonic acid binding site of human 15-lipoxygenase. Molecular modeling and mutagenesis. Gan QF, et al. **J Biol Chem** 1996 Oct 11;271(41):25412–8

Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. Scheidegger KJ, et al. **J Biol Chem** 1997 Aug 22;272(34):21609–15

In vivo action of 15-lipoxygenase in early stages of human atherogenesis. Kühn H, et al. **J Clin Invest** 1997 Mar 1; 99(5):888–93

Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. Shen J, et al. **J Clin Invest** 1996 Nov 15;98(10):2201–8

Oxidation of LDL by recombinant human 15-lipoxygenase: evidence for alpha-tocopherol-dependent oxidation of esterified core and surface lipids. Upston JM, et al. **J Lipid Res** 1996 Dec;37(12):2650–61

Lipophilic flavonoids from Orthosiphon spicatus prevent oxidative inactivation of 15-lipoxygenase. Lyckander IM, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Apr; 54(4):239–46

PHARMACOLOGY

Oxygenation of biomembranes by mammalian lipoxygenases: the role of ubiquinone. Schnurr K, et al. **Free Radic Biol Med** 1996;20(1):11–21

PHYSIOLOGY

Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein. Sun D, et al. **J Biol Chem** 1996 Sep 27; 271(39):24055–62

ARACHIDONATE LIPOXYGENASES

GENETICS

Molecular cloning and functional expression of a phorbol ester-inducible 8S-lipoxygenase from mouse skin. Jisaka M, et al. **J Biol Chem** 1997 Sep 26;272(39):24410–6

METABOLISM

Identification of an 8-lipoxygenase pathway in nervous tissue of Aplysia californica. Steel DJ, et al. **J Biol Chem** 1997 Jul 25;272(30):18673-81

Novel oxylipins from the temperate red alga Polyneura latissima: evidence for an arachidonate 9(S)-lipoxygenase. Jiang ZD, et al. **Lipids** 1997 Mar;32(3):231-5

ARACHIDONIC ACID

Vascular smooth muscle thromboxane A2 receptors mediate arachidonic acid-induced sudden death in rabbits. Pfister SL, et al. **Hypertension** 1997 Jan;29(1 Pt 2):303-9

Effect of topically applied cyclooxygenase-2-selective inhibitors on arachidonic acid- and tetradecanoylphorbol acetate-induced dermal inflammation in the mouse. Puigneró V, et al. **Inflammation** 1997 Aug;21(4):431-42

Involvement of phospholipase D activation in endothelin-1-induced release of arachidonic acid in osteoblast-like cells. Kozawa O, et al. **J Cell Biochem** 1997 Mar 1;64(3):376-81

ADMINISTRATION & DOSAGE

A human dietary arachidonic acid supplementation study conducted in a metabolic research unit: rationale and design. Nelson GJ, et al. **Lipids** 1997 Apr;32(4):415-20

ANALOGS & DERIVATIVES see ARACHIDONIC ACIDS

ANTAGONISTS & INHIBITORS

Inhibitors of arachidonate metabolism and effects on PAF production. Winkler JD, et al. **Adv Exp Med Biol** 1996; 416:11-5

Inhibition of brain P-450 arachidonic acid epoxygenase decreases baseline cerebral blood flow. Alkayed NJ, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1541-6

Long-term renal preservation and prevention of acute tubular necrosis by inhibition of arachidonate metabolism. Schilling M, et al. **Swiss Surg** 1995;(4):205-9

BIOSYNTHESIS

Spontaneously hypertensive rats: eicosa-8,11,14-trienoic acid metabolism and arachidonic acid biosynthesis. Hurtado de Catalfo GE, et al. **Biochem Mol Biol Int** 1996 Nov; 40(4):759-68

Different routes of Ca2+ influx in NMDA-mediated generation of nitric oxide and arachidonic acid. Rodriguez-Alvarez J, et al. **Eur J Neurosci** 1997 Apr; 9(4):867-70

[3-13C] gamma-linolenic acid: a new probe for 13C nuclear magnetic resonance studies of arachidonic acid synthesis in the suckling rat. Cunnane SC, et al. **Lipids** 1997 Feb; 32(2):211-7

Heneicosapentaenoate (21:5n-3): its incorporation into lipids and its effects on arachidonic acid and eicosanoid synthesis. Larsen LN, et al. **Lipids** 1997 Jul;32(7):707-14

The very low birth weight premature infant is capable of synthesizing arachidonic and docosahexaenoic acids from linoleic and linolenic acids. Carnielli VP, et al. **Pediatr Res** 1996 Jul;40(1):169-74

Intermediates in endogenous synthesis of C22:6 omega 3 and C20:4 omega 6 by term and preterm infants. Sauerwald TU, et al. **Pediatr Res** 1997 Feb;41(2):183-7

BLOOD

Arachidonic acid of platelet phospholipids is decreased after extracorporeal removal of plasma low density lipoproteins in patients with familial hypercholesterolemia. Bräutigam R, et al. **Atherosclerosis** 1997 May;131(1):97-106

Plasma arachidonic acid-rich phospholipids in Crohn's disease: response to treatment. Pereira SP, et al. **Clin Sci (Colch)** 1996 Oct;91(4):509-12

Human polymorphonuclear leukocytes: effect of chloroquine on aggregation, arachidonic acid liberation and thromboxane B2 generation. Kotuliaková K, et al. **Gen Physiol Biophys** 1996 Dec;15(6):489-94

The effect of bradykinin and substance P on the arachidonate cascade of platelets. Gecse A, et al. **Immunopharmacology** 1996 Jun;33(1-3):167-70

Age-related changes of platelet arachidonic acid metabolism in normal subjects [letter] Tomo K, et al. **Int J Hematol** 1997 Aug;66(2):249-51

Protein-facilitated export of arachidonic acid from pig neutrophils. Krischer SM, et al. **J Biol Chem** 1997 Apr 18;272(16):10601-7

Enhanced arachidonic acid and calcium metabolism in cholesteryl sulfate-enriched rat platelets. Blache D. **J Lipid Mediat Cell Signal** 1996 Mar;13(2):127-38

Effect of tumor necrosis factor-alpha on the metabolism of arachidonic acid in human neutrophils. Robinson BS, et al. **J Lipid Res** 1996 Jun;37(6):1234-45

5-Lipoxygenase metabolites of arachidonic acid regulate volume decrease by mudpuppy red blood cells. Light DB, et al. **J Membr Biol** 1997 Aug 1;158(3):229-39

Impact of solid food on plasma arachidonic and docosahexaenoic acid status of term infants at 8 months of age. Luukkainen P, et al. **J Pediatr Gastroenterol Nutr** 1996 Oct;23(3):229-34

Blood lipid docosahexaenoic and arachidonic acid in term gestation infants fed formulas with high docosahexaenoic acid, low eicosapentaenoic acid fish oil. Innis SM, et al. **Lipids** 1996 Jun;31(6):617-25

In vivo incorporation from plasma of radiolabeled palmitate and arachidonate into rat brain microvessels. Williams WM, et al. **Microvasc Res** 1997 Mar;53(2):163-6

Plasma arachidonic acid and serum thromboxane B2 concentrations in phenylketonuric children negatively correlate with dietary compliance. Agostoni C, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Mar; 56(3):219-22

Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Mahadik SP, et al. **Psychiatry Res** 1996 Jul 31; 63(2-3):133-42

Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. Yao JK, et al. **Psychiatry Res** 1996 Feb 28;60(1):11-21

Ionomycin-stimulated arachidonic acid release in human platelets: a role for protein kinase C and tyrosine phosphorylation. Hargreaves PG, et al. **Thromb Haemost** 1996 Aug;76(2):248-52

CHEMISTRY

Non-steroidal anti-inflammatory agents, Part 24. Pyrrolidino enaminones as models to mimic arachidonic acid. Dannhardt G, et al. **Arch Pharm (Weinheim)** 1997 Mar; 330(3):74-82

2-Hydroxy-succinaldehyde, a lipid peroxidation product proving that polyunsaturated fatty acids are able to react with three molecules of oxygen. Mlakar A, et al. **Free Radic Res** 1997 Jan;26(1):57-62

Effect of degree of unsaturation in dietary fatty acids on arachidonic acid mobilization by peritoneal macrophages. Mitjavila MT, et al. **Lipids** 1996 Jun;31(6):661-6

Formation of hydroxyeicosatetraenoic acids from hemozoin-catalyzed oxidation of arachidonic acid. Green MD, et al. **Mol Biochem Parasitol** 1996 Dec 20;83(2):183-8

IMMUNOLOGY

Airway hyperresponsiveness to acetylcholine induced by aerosolized arachidonic acid metabolites in guinea-pigs. Sato T, et al. **Clin Exp Allergy** 1996 Aug;26(8):957-63

METABOLISM

Arachidonate-phospholipid remodeling and cell proliferation. Chilton FH, et al. **Adv Exp Med Biol** 1996; 416:169-72

Metabolism of exogenous and endogenous arachidonic acid in cancer. Phinney SD. **Adv Exp Med Biol** 1996;399:87-94 (30 ref.)

Inhibitors of arachidonate metabolism and effects on PAF production. Winkler JD, et al. **Adv Exp Med Biol** 1996; 416:11-5

Endothelium-derived hyperpolarizing factor: characterization as a cytochrome P450 1A-linked metabolite of arachidonic acid in perfused rat mesenteric prearteriolar bed. Adeagbo AS. **Am J Hypertens** 1997 Jul; 10(7 Pt 1):763-71

The role of the cytochrome P450-dependent metabolites of arachidonic acid in blood pressure regulation and renal function: a review. Rahman M, et al. **Am J Hypertens** 1997 Mar;10(3):356-65 (104 ref.)

Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinflammatory drugs. Scioscia KA, et al. **Am J Otolaryngol** 1997 Jan-Feb;18(1):1-8

Tannin stimulates arachidonic acid release from bovine tracheal epithelial cells. Cloutier MM, et al. **Am J Physiol** 1996 Apr;270(4 Pt 1):L613-8

Caerulein-stimulated arachidonic acid release in rat pancreatic acini: a diacylglycerol lipase affair. Hou W, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):C1735-42

Role of PLA2, PLC, and PLD in bradykinin-induced release of arachidonic acid in MDCK cells. Kennedy CR, et al. **Am J Physiol** 1996 Oct;271(4 Pt 1):C1064-72

Effect of hypoxia on steady-state arachidonic acid metabolism in bovine aortic endothelial cells. Patton GM, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):H1426-36

Colchicine inhibits arachidonate release and 5-lipoxygenase action in alveolar macrophages. Peters-Golden M, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):L1004-13

Vasorelaxation by an endothelium-derived metabolite of arachidonic acid. Pfister SL, et al. **Am J Physiol** 1996 Mar; 270(3 Pt 2):H1021-30

Antisense inhibition of 85-kDa cPLA2 blocks arachidonic acid release from airway epithelial cells. Wu T, et al. **Am J Physiol** 1997 Aug;273(2 Pt 1):L331-8

Endothelin-1-evoked arachidonic acid release: a Ca(2+)-dependent pathway. Wu-Wong JR, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):C869-77

Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics. Bowton DL, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):421-5

Influence of superoxide radical and hydrogen peroxide on arachidonic acid mobilization. Martínez J, et al. **Arch Biochem Biophys** 1996 Dec 15;336(2):191-8

Cloning, sequencing, and cDNA-directed expression of the rat renal CYP4A2: arachidonic acid omega-hydroxylation and 11,12-epoxidation by CYP4A2 protein. Wang MH, et al. **Arch Biochem Biophys** 1996 Dec 15;336(2):240-50

Metabolism of arachidonic acid during amebic abscess formation in hamster. Sánchez-Ramírez BE, et al. **Arch Med Res** 1997;28 Spec No:217-9

Effect of diclofenac, ketorolac, and fluorometholone on arachidonic acid metabolites following excimer laser corneal surgery. Phillips AF, et al. **Arch Ophthalmol** 1996 Dec;114(12):1495-8

Involvement of phosphatidylcholine hydrolysis by phospholipase D in extracellular ATP-induced arachidonic acid release in aortic smooth muscle cells. Shinoda J, et al. **Arterioscler Thromb Vasc Biol** 1997 Feb;17(2):295-9

Synthesis and inhibitory effects of 2-pyridyl-2-thiobenzoxazole and 2-pyridyl-2-thiobenzimidazole derivatives on arachidonic acid metabolism. Lagorce JF, et al. **Arzneimittelforschung** 1995 Nov;45(11):1207-10

Metabolites produced during the peroxisomal beta-oxidation of linoleate and arachidonate move to microsomes for conversion back to linoleate. Luthria DL, et al. **Biochem Biophys Res Commun** 1997 Apr 17;233(2):438-41

Correlation between arachidonic acid oxygenation and luminol-induced chemiluminescence in neutrophils: inhibition by diethyldithiocarbamate. Chabannes B, et al. **Biochem Pharmacol** 1997 Apr 4;53(7):927-35

Effect of flavonoids on arachidonic acid metabolism and prostacyclin (PGI2) formation in human vascular endothelial cells. Khaza'ai H, et al. **Biochem Soc Trans** 1996 May;24(2):173S

Detection of an Fe2+-protoporphyrin-IX intermediate during aspirin-treated prostaglandin H2 synthase II catalysis of arachidonic acid to 15-HETE. Tang MS, et al. **Biochemistry** 1997 Jun 17;36(24):7527-34

Fatty acid binding proteins reduce 15-lipoxygenase-induced oxygenation of linoleic acid and arachidonic acid. Ek BA, et al. **Biochim Biophys Acta** 1997 May 17;1346(1):75-85

Macrophage recognition of LDL modified by levuglandin E2, an oxidation product of arachidonic acid. Hoppe G, et al. **Biochim Biophys Acta** 1997 Jan 7;1344(1):1-5

Phospholipase A2 has a role in proliferation but not in differentiation of HL-60 cells. Liu Y, et al. **Biochim Biophys Acta** 1997 Mar 1;1355(3):270-80

Effect of interleukin-4 on allergen-induced arachidonic acid metabolism of rat peritoneal macrophages during immediate hypersensitivity reactions. M'Rini C, et al. **Biochim Biophys Acta** 1997 Jul 24;1357(3):319-28

The metabolism of 22:5(-6) and of docosahexaenoic acid [22:6(-3)] compared in rat hepatocytes. Retterstøl K, et al. **Biochim Biophys Acta** 1996 Oct 18;1303(3):180-6

Docosahexaenoic acid causes accumulation of free arachidonic acid in rat pineal gland and hippocampus to form hepoxilins from both substrates. Reynaud D, et al. **Biochim Biophys Acta** 1997 Jun 23;1346(3):305-16

Delayed release of prostaglandins from arachidonic acid and kinetic changes in prostaglandin H synthase activity on the induction of prostaglandin H synthase-2 after lipopolysaccharide-treatment of RAW264.7 macrophage-like cells. Tanaka Y, et al. **Biol Pharm Bull** 1997 Apr;20(4):322-6

Arachidonate metabolites and serotonin contraction of femoral arteries from DOCA-salt hypertensive rats. Kanagy NL, et al. **Blood Press** 1996 Mar;5(2):113-20

The relationships between dietary alpha-linolenic:linoleic acid and rat platelet eicosapentaenoic and arachidonic acids. Leece EA, et al. **Br J Nutr** 1996 Sep;76(3):447-52

Evidence against a role of cytochrome P450-derived arachidonic acid metabolites in endothelium-dependent hyperpolarization by acetylcholine in rat isolated mesenteric artery. Fukao M, et al. **Br J Pharmacol** 1997 Feb;120(3):439-46

Brain incorporation of [1-11C]arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography. Chang MC, et al. **Brain Res** 1997 Apr 25;755(1):74-83

The effect of basic fibroblast growth factor on glutamate-injured neuroarchitecture and arachidonic acid release in adult hippocampal neurons. Himmelseher S, et al. **Brain Res** 1996 Jan 22;707(1):54-63

Involvement of the 12-lipoxygenase pathway of arachidonic acid metabolism in homosynaptic long-term depression of the rat hippocampus. Normandin M, et al. **Brain Res** 1996 Aug 19;730(1-2):40-6

Production of arachidonic acid metabolites by the colon adenocarcinoma cell line HT29 cl.19A and their effect on chloride secretion. Battu S, et al. **Cancer Lett** 1997 Jun 24;116(2):213-23

Modulation of presynaptic calcium homeostasis by nitric oxide. Martínez-Serrano A, et al. **Cell Calcium** 1996 Sep; 20(3):293-302

Basic fibroblast growth factor-stimulated arachidonic acid release in rat pancreatic acini: sequential action of tyrosine kinase, phospholipase C, protein kinase C and diacylglycerol lipase. Hou W, et al. **Cell Signal** 1996 Nov; 8(7):487-96

Previously unknown aldehydic lipid peroxidation compounds of arachidonic acid. Mlakar A, et al. **Chem Phys Lipids** 1996 Jan 25;79(1):47-53

Airway hyperresponsiveness to acetylcholine induced by aerosolized arachidonic acid metabolites in guinea-pigs. Sato T, et al. **Clin Exp Allergy** 1996 Aug;26(8):957-63

Altered arachidonic acid metabolism contributes to the failure of dopamine to inhibit Na+,K(+)-ATPase in

kidney of spontaneously hypertensive rats. Hussain T, et al. **Clin Exp Hypertens** 1996 Oct;18(7):963–74

Genetic basis of disease: studies of eicosanoids, and some complex disease traits. Tay A. **Clin Sci (Colch)** 1996 Sep; 91(3):264–6 (22 ref.)

Indomethacin alters phospholipid and arachidonate metabolism in Tetrahymena pyriformis. Kovács P, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1997 Jul;117(3):311–5

Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+–induced arachidonic acid release by epithelial cells. Miele L, et al. **DNA Cell Biol** 1997 Jun;16(6):749–59

Assessing free radical damage [news] **Environ Health Perspect** 1996 Nov;104(11):1148–9

Phospholipase A2 is involved in the mechanism of activation of neutrophils by polychlorinated biphenyls. Tithof PK, et al. **Environ Health Perspect** 1996 Jan;104(1):52–8

Involvement of phosphatidylinositol 3'-kinase in stem-cell-factor-induced phospholipase D activation and arachidonic acid release. Kozawa O, et al. **Eur J Biochem** 1997 Aug 15;248(1):149–55

Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Sugiura T, et al. **Eur J Biochem** 1996 Aug 15;240(1):53–62

Mediation by arachidonic acid metabolites of the H2O2-induced stimulation of mitogen-activated protein kinases (extracellular-signal-regulated kinase and c-Jun NH2-terminal kinase). Tournier C, et al. **Eur J Biochem** 1997 Mar 1;244(2):587–95

Modulatory actions of progesterone on gonadotropin-releasing hormone-induced arachidonic acid liberation from perifused rat pituitary cells. Ortmann O, et al. **Eur J Endocrinol** 1996 Nov;135(5):626–30

Mechanism of angiotensin II-induced arachidonic acid metabolite release in aortic smooth muscle cells: involvement of phospholipase D. Shinoda J, et al. **Eur J Endocrinol** 1997 Feb;136(2):207–12

Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Capasso A, et al. **Eur J Pharmacol** 1997 Jul 9; 330(2–3):199–204

Eicosanoid inhibitors enhance synergistically the effect of transforming growth factor beta 1 on CCL 64 cell proliferation. Kozubík A, et al. **Eur J Pharmacol** 1996 Dec 5;316(2–3):349–57

Priming effects of lipopolysaccharide on UTP-induced arachidonic acid release in RAW 264.7 macrophages. Lin WW. **Eur J Pharmacol** 1997 Feb 19;321(1):121–7

Antiflammin-2, a nonapeptide of lipocortin-1, inhibits leukocyte chemotaxis but not arachidonic acid mobilization. Moreno JJ. **Eur J Pharmacol** 1996 Oct 24; 314(1–2):129–35

Pharmacological profiles of two bombesin analogues in cells transfected with human neuromedin B receptors. Ryan RR, et al. **Eur J Pharmacol** 1996 Jun 13;306(1–3):307–14

Arachidonic acid products-mediated contraction induced by bradykinin in relaxed mesenteric arterial rings from Holtzman rats. Weinberg ML, et al. **Eur J Pharmacol** 1997 Feb 12;320(2–3):145–50

Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system. Makita K, et al. **FASEB J** 1996 Nov;10(13):1456–63 (42 ref.)

Phospholipase D is involved in cytosolic phospholipase A2-dependent selective release of arachidonic acid by fMLP-stimulated rat neutrophils. Fujita K, et al. **FEBS Lett** 1996 Oct 21;395(2–3):293–8

The heterodimer of the Ca2+–binding proteins MRP8 and MRP14 binds to arachidonic acid. Klempt M, et al. **FEBS Lett** 1997 May 12;408(1):81–4

Expression of arachidonate platelet-type 12-lipoxygenase in human rheumatoid arthritis type B synoviocytes. Liagre B, et al. **FEBS Lett** 1997 Sep 1;414(1):159–64

Identification of radical adducts formed in the reactions of unsaturated fatty acids with soybean lipoxygenase using continuous flow fast atom bombardment with tandem mass spectrometry. Iwahashi H, et al. **Free Radic Res** 1996 Sep; 25(3):255–74

Nucleation of biliary cholesterol, arachidonate, prostaglandin E2, and glycoproteins in postmenopausal women. Marks JW, et al. **Gastroenterology** 1997 Apr;112(4):1271–6

A comparative study of arachidonic acid metabolism in rabbit cultured astrocytes and human astrocytoma cells (1321N1). Ishimoto H, et al. **Gen Pharmacol** 1996 Mar;27(2):313–17

Prostaglandin E2 is the major arachidonic acid metabolite secreted by esophageal mucosal cells in rabbits. Jiménez P, et al. **Inflammation** 1997 Aug;21(4):419–29

Altered arachidonic acid metabolism in urate crystal induced inflammation. Margalit A, et al. **Inflammation** 1997 Apr; 21(2):205–22

Arachidonic acid remodeling in human inflammatory cells migrating to the lung in vivo. Triggiani M, et al. **Int Arch Allergy Immunol** 1997 May-Jul;113(1–3):190–2

Role of kinases and G-proteins on arachidonate release induced by zymosan in mouse peritoneal macrophages. Lloret S, et al. **Int J Biochem Cell Biol** 1996 Apr; 28(4):465–72

Effect of retinoids on dermal inflammation and on arachidonic acid mobilization and metabolism in murine 3T6 fibroblasts retinoids, arachidonate release and metabolism. Moreno JJ. **Int J Immunopharmacol** 1996 Aug–Sep;18(8–9):459–65

Dietary alteration of dihomogamma-linolenic acid/arachidonic acid ratio in a rat 5/6-renal-ablation model. The Nutrition & Kidney Disease Research Group. Ingram AJ, et al. **J Am Soc Nephrol** 1996 Jul;7(7):1024–31

Importance of the phospholipase D-initiated sequential pathway for arachidonic acid release and prostaglandin D2 generation by rat peritoneal mast cells. Ishimoto T, et al. **J Biochem (Tokyo)** 1996 Sep;120(3):616–23

Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages. Balboa MA, et al. **J Biol Chem** 1996 Dec 13;271(50):32381–4

Inflammatory activation of arachidonic acid signaling in murine P388D1 macrophages via sphingomyelin synthesis. Balsinde J, et al. **J Biol Chem** 1997 Aug 15;272(33):20373–7

Defining the arachidonic acid binding site of human 15-lipoxygenase. Molecular modeling and mutagenesis. Gan QF, et al. **J Biol Chem** 1996 Oct 11;271(41):25412–8

Synergy by secretory phospholipase A2 and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. Kolko M, et al. **J Biol Chem** 1996 Dec 20;271(51):32722–8

Calcium/calmodulin-dependent protein kinase IIalpha mediates activation of mitogen-activated protein kinase and cytosolic phospholipase A2 in norepinephrine-induced arachidonic acid release in rabbit aortic smooth muscle cells. Muthalif MM, et al. **J Biol Chem** 1996 Nov 22; 271(47):30149–57

Arachidonic acid drives mini-glucagon action in cardiac cells. Sauvadet A, et al. **J Biol Chem** 1997 May 9; 272(19):12437–45

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) potentiate the glutamate-evoked release of arachidonic acid from mouse cortical neurons. Evidence for a cAMP-independent mechanism. Stella N, et al. **J Biol Chem** 1996 Sep 27; 271(39):23705–10

Depletion of intracellular calcium stores activates smooth muscle cell calcium-independent phospholipase A2. A novel mechanism underlying arachidonic acid mobilization. Wolf MJ, et al. **J Biol Chem** 1997 Jan 17;272(3):1522–6

Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-alpha and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases. Zhang C, et al. **J Biol Chem** 1997 May 16;272(20):13397–402

Effects of hypercholesterolemia on the contractions to angiotensin II in the isolated aorta and iliac artery of the rabbit: role of arachidonic acid metabolites. Dam JP, et al. **J Cardiovasc Pharmacol** 1997 Jul;30(1):118–23

Contribution of arachidonic acid metabolites to reduced norepinephrine-induced contractions in hypercholesterolemic rabbit aortas. Pfister SL, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):784–91

Calcium-calmodulin plays a major role in bradykinin-induced arachidonic acid release by bovine aortic endothelial cells. Briand SI, et al. **J Cell Biochem** 1996 Dec 1;63(3):292–301

Protein kinase C activation inhibits stress-induced synthesis of heat shock protein 27 in osteoblast-like cells: function of arachidonic acid. Suzuki A, et al. **J Cell Biochem** 1996 Jul;62(1):69–75

Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. Barry OP, et al. **J Clin Invest** 1997 May 1;99(9):2118–27

Dual role of protein kinase C in the regulation of cPLA2-mediated arachidonic acid release by P2U receptors in MDCK-D1 cells: involvement of MAP kinase-dependent and -independent pathways. Xing M, et al. **J Clin Invest** 1997 Feb 15;99(4):805–14

Evaluation of anti-inflammatory potential of fixed oil of Ocimum sanctum (Holybasil) and its possible mechanism of action. Singh S, et al. **J Ethnopharmacol** 1996 Oct; 54(1):19–26

Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation. Grimminger F, et al. **J Exp Med** 1996 Oct 1;184(4):1567–72

NKR-P1A stimulation of arachidonate-generating enzymes in rat NK cells is associated with granule release and cytotoxic activity. Grazia Cifone M, et al. **J Immunol** 1997 Jul 1;159(1):309–17

Effects of hydroxyethyl starch-deferoxamine on arachidonic acid metabolism and small bowel wall perfusion in early sepsis. Schröppel B, et al. **J Invest Surg** 1997 Jul–Aug; 10(4):173–82

Arachidonic acid synthesis and lipid metabolism in retinoic acid-differentiated neuroblastoma cells. Petroni A, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):39–44

Platelet-activating factor and somatostatin activate mitogen-activated protein kinase (MAP kinase) and arachidonate release. Shimizu T, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):103–8 (22 ref.)

Modulation of cardiac gap junctions: the mode of action of arachidonic acid. Schmilinsky-Fluri G, et al. **J Mol Cell Cardiol** 1997 Jun;29(6):1703–13

Identification of two molecular species of rat brain phosphatidylcholine that rapidly incorporate and turn over arachidonic acid in vivo. Shetty HU, et al. **J Neurochem** 1996 Oct;67(4):1702–10

Cyclothiazide unmasks an AMPA-evoked release of arachidonic acid from cultured striatal neurones. Williams RJ, et al. **J Neurochem** 1996 Oct;67(4):1551–8

Role of protein kinase C alpha in nerve growth factor-induced arachidonic acid release from PC12 cells. Zheng WH, et al. **J Neurochem** 1996 May;66(5):1868–75

Different contribution of phospholipid and triacylglycerol metabolism to esterification of free intracellular arachidonate: a study on SK-N-BE(2) human neuroblastoma cells. Spinedi A. **J Neurooncol** 1997 Jan; 31(1–2):133–9

Lipid peroxidation, CYP2E1 and arachidonic acid metabolism in alcoholic liver disease in rats. French SW, et al. **J Nutr** 1997 May;127(5 Suppl):907S–911S

Effect of nicotine on arachidonic acid metabolites and epithelial parameters in rat oral mucosa. Ringdahl BE, et al. **J Oral Pathol Med** 1997 Jan;26(1):40–5

Effects of nonanal, trans-2-nonenal and 4-hydroxy-2,3-trans-nonenal on cyclooxygenase and 12-lipoxygenase metabolism of arachidonic acid in rabbit platelets. Sakuma S, et al. **J Pharm Pharmacol** 1997 Feb; 49(2):150–3

Differential inhibition of murine prostaglandin synthase-1 and -2 by nonsteroidal anti-inflammatory drugs using exogenous and endogenous sources of arachidonic acid. Chulada PC, et al. **J Pharmacol Exp Ther** 1997 Feb; 280(2):606–13

Microsomal cytochrome P450 peroxygenase metabolism of arachidonic acid in guinea pig liver. McCallum GP, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1188–94

Thrombin receptor-activating peptide releases arachidonic acid from human platelets: a comparison with thrombin and trypsin. McNicol A, et al. **J Pharmacol Exp Ther** 1997 May;281(2):861–7

Functional dissociation between glucocorticoid-induced decrease in arachidonic acid release and inhibition of adrenocorticotropic hormone secretion in AtT-20 corticotrophs. Pompeo A, et al. **J Steroid Biochem Mol Biol** 1997 Jan;60(1–2):51–7

Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue. Harder DR, et al. **J Vasc Res** 1997 May-Jun;34(3):237–43 (35 ref.)

The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. Krajcsi P, et al. **J Virol** 1996 Aug;70(8):4904–13

Effects of lipoproteins on cyclo-oxygenase and lipoxygenase pathways in human platelets. Saeed SA, et al. **JPMA J Pak Med Assoc** 1997 Mar;47(3):84–8

Longitudinal evaluation of peritoneal macrophage function and activation during CAPD: maturity, cytokine synthesis and arachidonic acid metabolism. McGregor SJ, et al. **Kidney Int** 1996 Feb;49(2):525–33

Interactions between cAMP- and cGMP-dependent protein kinase inhibitors and phosphodiesterase IV inhibitors on arachidonate release from human monocytes. Hichami A, et al. **Life Sci** 1996;59(16):PL255–61

Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Hunter SA, et al. **Life Sci** 1997;60(18):1563–73

Stimulatory action of endothelin-1 on rat Leydig cells: involvement of endothelin-A subtype receptor and phospholipase A2-arachidonate metabolism system. Romanelli F, et al. **Life Sci** 1997;61(5):557–66

Effect of degree of unsaturation in dietary fatty acids on arachidonic acid mobilization by peritoneal macrophages. Mitjavila MT, et al. **Lipids** 1996 Jun;31(6):661–6

Availability of arachidonic acid in major phospholipids of mucosa and the stomach wall of rats. Olafsson SO, et al. **Lipids** 1996 Dec;31(12):1323–5

On the molecular etiology of decreased arachidonic (20:4n-6), docosapentaenoic (22:5n-6) and docosahexaenoic (22:6n-3) acids in Zellweger syndrome and other peroxisomal disorders. Infante JP, et al. **Mol Cell Biochem** 1997 Mar;168(1–2):101–15 (167 ref.)

Infra-red laser irradiation enhances interleukin-1 receptor antagonist, increases 3H-thymidine incorporation and the release of [3H]arachidonic acid in human monocytes. Reale M, et al. **Mol Cell Biochem** 1997 Apr;169(1–2):51–9

Nitric oxide responsible for NMDA receptor-evoked inhibition of arachidonic acid incorporation into lipids of brain membrane. Samochocki M, et al. **Mol Chem Neuropathol** 1996 Sep;29(1):79–92

5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism. Berg KA, et al. **Mol Pharmacol** 1996 Oct;50(4):1017–23

Cytochrome P450 4A expression and arachidonic acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat. Schwartzman ML, et al. **Nephron** 1996; 73(4):652–63

Activation of serotonergic 5-HT1A receptor reduces Ca(2+)- and glutamatergic receptor-evoked arachidonic acid and No/cGMP release in adult hippocampus. Strosznajder J, et al. **Neurochem Int** 1996 Apr;28(4):439–44

Somatostatin stimulates BKCa channels in rat pituitary tumor cells through lipoxygenase metabolites of arachidonic acid. Duerson K, et al. **Neuropharmacology** 1996;35(7):949–61

Lithium decreases turnover of arachidonate in several brain phospholipids [published erratum appears in Neurosci Lett 1997 Jan 31;222(2):141] Chang MC, et al. **Neurosci Lett**

1996 Dec 20;220(3):171–4

Arachidonate transport through the blood–retina and blood–brain barrier of the rat during aging. Strosznajder J, et al. **Neurosci Lett** 1996 May 17;209(3):145–8

Properties of the omega-hydroxylation system of docosahexaenoic or arachidonic acid in brain or liver homogenate of rat. Yamane M, et al. **Neurosci Lett** 1995 Nov 24;200(3):203–6

Reduced glucose metabolism enhances the glutamate–evoked release of arachidonic acid from striatal neurons. Williams RJ, et al. **Neuroscience** 1996 Sep;74(2):461–8

Ischemia–reperfusion injury in the intestines of newborn pigs. Papparella A, et al. **Pediatr Res** 1997 Aug;42(2):180–8

Modified natural porcine surfactant inhibits superoxide anions and proinflammatory mediators released by resting and stimulated human monocytes. Walti H, et al. **Pediatr Res** 1997 Jan;41(1):114–9

Muscarinic regulation of phospholipase D and its role in arachidonic acid release in rat submandibular acinar cells. Chung HC, et al. **Pflugers Arch** 1995 Dec;431(2):161–8

Proliferation–dependent changes in arachidonic acid mobilization from phospholipids of 3T6 fibroblasts. Lloret S, et al. **Pflugers Arch** 1996 Aug;432(4):655–62

Dissociate arachidonic acid release from eicosanoid synthesis in rat peritoneal macrophages is possible using concomitantly eicosapentanoic acid as a phospholipid analogue. Bourass J, et al. **Pharmacol Res** 1996 Jun; 33(6):343–7

Arachidonic acid metabolites: mediators of inflammation in asthma. Wenzel SE. **Pharmacotherapy** 1997 Jan–Feb;17(1 Pt 2):3S–12S (42 ref.)

Arachidonate metabolism in human placenta, fetal membranes, decidua and myometrium: lipoxygenase and cytochrome P450 metabolites as main products in HPLC profiles. Schäfer WR, et al. **Placenta** 1996 May;17(4):231–8

A novel arachidonate–preferring acyl–CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. Kang MJ, et al. **Proc Natl Acad Sci U S A** 1997 Apr 1;94(7):2880–4

The influence of nicardipine and ifenprodil on the brain free arachidonic acid level and behavior in hypoxia–exposed rats. Eraković V, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 May; 21(4):633–47

The influence of nimodipine and MK–801 on the brain free arachidonic acid level and the learning ability in hypoxia–exposed rats. Mršić J, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 Feb; 21(2):345–58

Thromboxane A2 stimulates mitogen–activated protein kinase and arachidonic acid liberation in rabbit platelets. Ohkubo S, et al. **Prostaglandins** 1996 Nov;52(5):403–13

Protein kinase C–independent activation of a novel nonspecific phospholipase C pathway by phorbol myristate acetate releases arachidonic acid for prostaglandin synthesis in MC3T3–E1 osteoblasts. Rapuano BE, et al. **Prostaglandins** 1997 Mar;53(3):163–86

Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Reich R, et al. **Prostaglandins** 1996 Jan;51(1):1–17

Influence of underfeeding on the spontaneous contraction and on metabolism of labelled arachidonic acid in uteri isolated from intact and ovariectomized rats. Casalino SM, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Sep; 55(3):155–8

Effects of 17 beta estradiol on the metabolism of labelled arachidonic acid in uteri isolated from intact and ovariectomized rats. Influence of a restricted diet. Casalino–Matsuda SM, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jun; 56(6):457–60

Effect of fasting on the contractile activity and metabolism of labelled glucose and arachidonic acid in uteri isolated from intact and ovariectomized rat. Casalino–Matsuda SM, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jan; 56(1):79–83

Tumor cell–endothelial cell interactions: evidence for roles for lipoxygenase products of arachidonic acid in metastasis. Damtew B, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Apr; 56(4):295–300

Metabolism of [3H]arachidonic acid by n–3 polyunsaturated fatty acid–enriched piglet alveolar macrophages. Fritsche KL, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Nov;55(5):315–23

Bile but not chyle lipoprotein is an important source of arachidonic acid for the rat small intestine. Melin T, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Nov; 55(5):337–43

Differential effects of 1,25–(OH)2D3 on acyl hydrolase and cyclooxygenase activities in interleukin 1 beta–stimulated human synovial fibroblast cultures. Meyer FA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Sep; 55(3):191–4

Effects of non–steroidal anti–inflammatory drugs on prostaglandin E2 production by cyclooxygenase–2 from endogenous and exogenous arachidonic acid in rat peritoneal macrophages stimulated with lipopolysaccharide. Nakatsugi S, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Dec; 55(6):451–7

Actions of cytokines in relation to arachidonic acid metabolism and eicosanoid production. Peplow PV. **Prostaglandins Leukot Essent Fatty Acids** 1996 May; 54(5):303–17 (147 ref.)

Arachidonic acid metabolism in murine lymphoma cell sublines differing in radiation sensitivity. Sochanowicz B, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Oct; 55(4):241–7

Conversion of arachidonic acid to tetradecadienoic acid by peroxisomal oxidation. Spector AA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):101–5

Accumulation of arachidonic acid in ischemic/reperfused cardiac tissue: possible causes and consequences. Van der Vusse GJ, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jul; 57(1):85–93 (50 ref.)

Azelastine suppresses the release of arachidonic acid metabolites from cultured human umbilical vein endothelial cells. Watanabe K, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Mar; 56(3):209–11

Tumor necrosis factor alpha stimulates arachidonic acid metabolism in human osteoblastic osteosarcomal cells. Zhang W, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Jun; 54(6):427–31

The role of cyclooxygenase and 5–lipoxygenase metabolites in potentiated endothelin–1–evoked contractions in bovine bronchi. Nally JE, et al. **Pulm Pharmacol** 1996 Aug; 9(4):211–7

Involvement of phospholipase A2 and arachidonic acid in cholecystokinin–8–induced insulin secretion in rat islets. Simonsson E, et al. **Regul Pept** 1996 Sep 9;65(2):101–7

Inositol phosphate turnover in human airways: effect of arachidonic acid metabolism. Marmy N, et al. **Respir Physiol** 1996 Apr–May;104(1):77–84

Crossroads of L–arginine/arachidonate metabolism. Gryglewski RJ, et al. **Thromb Haemost** 1997 Jul;78(1):191–4

Tumor necrosis factor alpha stimulates arachidonic acid metabolisms and mucus production in rat tracheal epithelial cell cultures. Nettesheim P, et al. **Toxicol Lett** 1996 Nov; 88(1–3):35–7

[Neoadjuvant chemotherapy and cyclo–oxygenase pathway of arachidonic acid metabolism in osteogenic sarcoma] Kushlinskii, et al. **Biull Eksp Biol Med** 1996 Nov; 122(11):551–6 **(Rus)**

[Effect of lipoxygenase inhibitors on oxidation of arachidonic acid and phenophtorasole on rat thymocyte cytoplasmal pH, induced by concanavalin A] Astashkin EI, et al. **Dokl Akad Nauk** 1992;325(4):869–73 **(Rus)**

[Metabolic changes in arachidonic acid during aspirin desensitization] Salazar Villa RM, et al. **Rev Alerg Mex** 1996 May–Jun;43(3):56–61 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Glutamate, arachidonic acid, and calcium regulation in cultured hippocampal astrocytes: involvement in ischemia? Madden KS, et al. **Adv Neurol** 1996;71:53–9

Dietary polyunsaturated fatty acid prevents malformations in offspring of diabetic rats. Reece EA, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):818–23

Arachidonic acid enhances contraction and intracellular Ca2+ transients in individual rat ventricular myocytes. Damron DS, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):H350–9

Arachidonic acid inhibits activity of cloned renal K+ channel, ROMK1. Macica CM, et al. **Am J Physiol** 1996 Sep;271(3 Pt 2):F588–94

Modulation of beta–adrenergic receptor–stimulated lipolysis in the heart by prostaglandins. Ruan Y, et al. **Am J Physiol** 1996 Sep;271(3 Pt 1):E556–62

Impact of arachidonic versus eicosapentaenoic acid on exotonin–induced lung vascular leakage: relation to 4–series versus 5–series leukotriene generation. Grimminger F, et al. **Am J Respir Crit Care Med** 1997 Feb;155(2):513–9

Nuclear factor kB is activated by arachidonic acid but not by eicosapentaenoic acid. Camandola S, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):643–7

Arachidonic acid stimulates prostate cancer cell growth: critical role of 5–lipoxygenase. Ghosh J, et al. **Biochem Biophys Res Commun** 1997 Jun 18;235(2):418–23

Regulation of intracellular calcium release channel function by arachidonic acid and leukotriene B4. Striggow F, et al. **Biochem Biophys Res Commun** 1997 Aug 18; 237(2):413–8

Arachidonic acid activates a proton conductance pathway and the Na+/H+ exchanger in platelets. Cavallini L, et al. **Biochem J** 1996 Oct 15;319 (Pt 2):567–74

The arachidonate–activatable, NADPH oxidase–associated H+ channel is contained within the multi–membrane–spanning N–terminal region of gp91–phox. Henderson LM, et al. **Biochem J** 1997 Aug 1;325 (Pt 3):701–5

Inhibition of glucose–induced insulin secretion by the diacylglycerol lipase inhibitor RHC 80267 and the phospholipase A2 inhibitor ACA through stimulation of K+ permeability without diminution by exogenous arachidonic acid. Thams P, et al. **Biochem Pharmacol** 1997 Apr 25;53(8):1077–86

Platelet membrane glycoprotein IV (CD36) is involved in arachidonic acid induced–platelet aggregation. Dutta–Roy AK, et al. **Biochem Soc Trans** 1996 May;24(2):167S

Arachidonic acid inhibits capacitative calcium entry in rat thymocytes and human neutrophils. Alonso–Torre SR, et al. **Biochim Biophys Acta** 1997 Sep 4;1328(2):207–13

Synergistic activation of protein kinase C by arachidonic acid and diacylglycerols in vitro: generation of a stable membrane–bound, cofactor–independent state of protein kinase C activity. Schachter JB, et al. **Biochim Biophys Acta** 1996 Oct 24;1291(2):167–76

Arachidonate–induced eicosanoid synthesis in RBL–2H3 cells: stimulation with antigen or A23187 induces prolonged activation of 5–lipoxygenase. Westcott JY, et al. **Biochim Biophys Acta** 1996 Sep 6;1303(1):74–81

Effects of gangliosides, ouabain and arachidonic acid on glutamate cytotoxicity in PC12 cells. Cunha GM, et al. **Biol Pharm Bull** 1997 Feb;20(2):149–52

Differences in mechanisms for cell–free NADPH oxidase activation between arachidonate and sodium dodecyl sulfate. Okamura N, et al. **Biol Pharm Bull** 1996 Sep; 19(9):1130–5

Arachidonic acid activation of monocyte and neutrophil reactive oxygen in lung cancer patients undergoing pulmonary resection. Leaver HA, et al. **Biologicals** 1996 Dec;24(4):319–24

Arachidonic acid mediates interleukin–1 and tumor necrosis factor–alpha–induced activation of the c–jun amino–terminal kinases in stromal cells. Rizzo MT, et al. **Blood** 1996 Nov 15;88(10):3792–800

The involvement of reactive oxygen species and arachidonic acid in alpha 1–adrenoceptor–induced smooth muscle cell proliferation and migration. Nishio E, et al. **Br J Pharmacol** 1997 Jun;121(4):665–70

Some evidence against the involvement of arachidonic acid in muscarinic suppression of voltage–gated calcium channel current in guinea–pig ileal smooth muscle cells. Unno T, et al. **Br J Pharmacol** 1996 Sep;119(2):213–22

Stimulatory effect of arachidonic acid on the release of GABA in matrix–enriched areas from the rat striatum. Chéramy A, et al. **Brain Res** 1996 Dec 2;742(1–2):185–94

P450 arachidonate metabolites mediate bradykinin–dependent inhibition of NaCl transport in the rat thick ascending limb. Grider JS, et al. **Can J Physiol Pharmacol** 1997 Feb;75(2):91–6

Arachidonic acid stimulates the intrinsic activity of ubiquitous glucose transporter (GLUT1) in 3T3–L1 adipocytes by a protein kinase C–independent mechanism. Fong JC, et al. **Cell Signal** 1996 Mar;8(3):179–83

Arachidonic acid increases activation of NADPH oxidase in monocytic U937 cells by accelerated translocation of p47–phox and co–stimulation of protein kinase C. Sellmayer A, et al. **Cell Signal** 1996 Aug;8(5):397–402

Inhibition of stimulus–induced endothelial cell intercellular adhesion molecule–1, E–selectin, and vascular cellular adhesion molecule–1 expression by arachidonic acid and its hydroxy and hydroperoxy derivatives. Huang ZH, et al. **Circ Res** 1997 Feb;80(2):149–58

Modulatory effects of arachidonic acid on the delayed rectifier K+ current in rat pulmonary arterial myocytes. Structural aspects and involvement of protein kinase C. Smirnov SV, et al. **Circ Res** 1996 Jul;79(1):20–31

Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3–L1 cells. Casimir DA, et al. **Differentiation** 1996 Jul; 60(4):203–10

Arachidonic acid up–regulates and prostaglandin E2 down–regulates the expression of pancreatic–type phospholipase A2 and prostaglandin–endoperoxide synthase 2 in uterine stromal cells. Prigent–Tessier A, et al. **Eur J Biochem** 1996 Nov 1;241(3):872–8

The synergism between ACPD and arachidonic acid on glutamate release in hippocampus is age–dependent. McGahon B, et al. **Eur J Pharmacol** 1996 Aug 15; 309(3):323–6

Inhibitory effect of arachidonic acid on platelet–activating factor production in rat neutrophils. Naraba H, et al. **Eur J Pharmacol** 1996 Apr 29;302(1–3):117–21

Eosinophils and neutrophils modify arachidonic acid–induced relaxation of guinea–pig trachea. Prié S, et al. **Eur J Pharmacol** 1996 Dec 19;317(2–3):343–51

Effects of anandamide and arachidonic acid on specific binding of (+) –PN200–110, diltiazem and (–) –desmethoxyverapamil to L–type Ca2+ channel. Shimasue K, et al. **Eur J Pharmacol** 1996 Feb 5;296(3):347–50

Regulation of the functional activity of the human dopamine transporter by the arachidonic acid pathway. Zhang L, et al. **Eur J Pharmacol** 1996 Nov 21;315(3):345–54

Activation of human immunodeficiency virus long terminal repeat by arachidonic acid. Carini R, et al. **Free Radic Biol Med** 1997;22(1–2):195–9

Mechanisms of action of free arachidonic acid on ovarian steroid production in the goldfish. Mercure F, et al. **Gen Comp Endocrinol** 1996 Apr;102(1):130–40

Arachidonic acid influences proinflammatory gene induction by stabilizing the inhibitor–kappaBalpha/nuclear factor–kappaB (NF–kappaB) complex, thus suppressing the nuclear translocation of NF–kappaB. Stuhlmeier KM, et al. **J Biol Chem** 1997 Sep 26;272(39):24679–83

Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. Swinney DC, et al. **J Biol Chem** 1997 May 9;272(19):12393–8

Arachidonic acid–induced down–regulation of protein kinase C delta in beta–cells. Knutson KL, et al. **J Cell Biochem** 1996 Sep 15;62(4):543–52

ARACHIDONIC ACID

Arachidonic acid stimulates protein kinase C-epsilon redistribution in heart cells. Huang XP, et al. **J Cell Sci** 1997 Jul;110 (Pt 14):1625-34

Arachidonic acid cascade and gastric mucosal injury, protection, and healing: topics of this decade. Kobayashi K, et al. **J Clin Gastroenterol** 1995;21 Suppl 1:S12-7 (35 ref.)

Altered responses of human macrophages to lipopolysaccharide by hydroperoxy eicosatetraenoic acid, hydroxy eicosatetraenoic acid, and arachidonic acid. Inhibition of tumor necrosis factor production. Ferrante JV, et al. **J Clin Invest** 1997 Mar 15;99(6):1445-52

Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings. Terashita Z, et al. **J Lipid Mediat Cell Signal** 1996 Jan;13(1):1-8

Effects of a trans isomer of arachidonic acid on rat platelet aggregation and eicosanoid production. Berdeaux O, et al. **J Lipid Res** 1996 Oct;37(10):2244-50

Inhibition of the high-affinity uptake of D-[3H]aspartate in rate by L-alpha-aminoadipate and arachidonic acid. Lundy DF, et al. **J Neurol Sci** 1996 Aug;139 Suppl:1-9

Arachidonic acid modulates [14C]stearic acid incorporation into phosphatidylinositol, in human neuroblastoma cells. Pacini L, et al. **J Neurooncol** 1997 Jan;31(1-2):141-6

Arachidonic-acid-activated membrane conductances in dissociated cardiac parasympathetic neurons from Necturus. Mulvaney JM, et al. **J Neurophysiol** 1995 Oct; 74(4):1621-7

Arachidonic acid inhibits transient potassium currents and broadens action potentials during electrographic seizures in hippocampal pyramidal and inhibitory interneurons. Keros S, et al. **J Neurosci** 1997 May 15;17(10):3476-87

Oleic acid incorporation protects cultured hamster fibroblasts from oxygen-induced cytotoxicity. Kinter M, et al. **J Nutr** 1996 Dec;126(12):2952-9

Arachidonic acid offsets the effects on mouse brain and behavior of a diet with a low (n-6):(n-3) ratio and very high levels of docosahexaenoic acid. Wainwright PE, et al. **J Nutr** 1997 Jan;127(1):184-93

Effect of arachidonate on lipid metabolism in ethanol-treated rats fed with lard. Okita M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1997 Jun;43(3):311-26

In-vitro platelet responses to arachidonic acid in the rat. Rodriguez-Linares B, et al. **J Pharm Pharmacol** 1995 Dec; 47(12A):1015-20

Possible role of atypical protein kinase C activated by arachidonic acid in Ca2+ sensitization of rabbit smooth muscle. Gailly P, et al. **J Physiol (Lond)** 1997 Apr 1;500 (Pt 1):95-109

Effects of arachidonic acid upon the volume-sensitive chloride current in rat osteoblast-like (ROS 17/2.8) cells. Gosling M, et al. **J Physiol (Lond)** 1996 Jun 15;493 (Pt 3):613-23

Effect of arachidonic acid on the L-type calcium current in frog cardiac myocytes. Petit-Jacques J, et al. **J Physiol (Lond)** 1996 May 15;493 (Pt 1):67-81

Influence of dietary arachidonic acid on metabolism in vivo of 8cis,11cis,14-eicosatrienoic acid in humans. Emken EA, et al. **Lipids** 1997 Apr;32(4):441-8

Increased dietary arachidonic acid enhances the synthesis of vasoactive eicosanoids in humans. Ferretti A, et al. **Lipids** 1997 Apr;32(4):435-9

Effects of dietary arachidonic acid on human immune response. Kelley DS, et al. **Lipids** 1997 Apr;32(4):449-56

The effect of dietary arachidonic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Nelson GJ, et al. **Lipids** 1997 Apr;32(4):421-5

The effect of dietary arachidonic acid on plasma lipoprotein distributions, apoproteins, blood lipid levels, and tissue fatty acid composition in humans. Nelson GJ, et al. **Lipids** 1997 Apr;32(4):427-33

Membrane fatty acid modifications of PC12 cells by arachidonate or docosahexaenoate affect neurite outgrowth but not norepinephrine release. Ikemoto A, et al. **Neurochem Res** 1997 Jun;22(6):671-8

In vitro effects of arachidonic and L-glutamic acids on the high-affinity choline transport in rat hippocampus. Krištofiková Z, et al. **Neurochem Res** 1997 Jan;22(1):67-73

Developmental changes in arachidonic acid potentiation of NMDA currents in cortical neurones. Horimoto N, et al. **Neuroreport** 1996 Nov 4;7(15-17):2463-7

Arachidonic acid activation of potassium channels in rat visual cortex neurons. Horimoto N, et al. **Neuroscience** 1997 Apr;77(3):661-71

The synergism between metabotropic glutamate receptor activation and arachidonic acid on glutamate release is occluded by induction of long-term potentiation in the dentate gyrus. McGahon B, et al. **Neuroscience** 1996 Jun; 72(3):847-55

Arachidonic acid as a second messenger for hypotonicity-induced calcium transients in rat IMCD cells. Tinel H, et al. **Pflugers Arch** 1997 Jan;433(3):245-53

Arachidonic acid inhibits 3H-glutamate uptake with different potencies in rodent central nervous system regions expressing different transporter subtypes. Manzoni C, et al. **Pharmacol Res** 1997 Feb;35(2):149-51

Arachidonic acid activates c-jun N-terminal kinase through NADPH oxidase in rabbit proximal tubular epithelial cells. Cui XL, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15; 94(8):3771-6

Antiedematous effects of combination therapies with the leukotriene synthesis inhibitor BAY X 1005 in the archidonic acid-induced mouse ear inflammation test. Burchardt ER, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Apr; 56(4):301-6

Effects of dietary supplementation with arachidonic acid rich oils on nerve conduction and blood flow in streptozotocin-diabetic rats. Cotter MA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 May; 56(5):337-43

Effects of gamma-linolenic acid and arachidonic acid on cell cycle progression and apoptosis induction in normal and transformed cells. Seegers JC, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Apr; 56(4):271-80

Effect of n-6 polyunsaturated fatty acids on growth and lipid composition of neoplastic and non-neoplastic canine prostate epithelial cell cultures. Griffiths G, et al. **Prostate** 1997 Apr 1;31(1):29-36

Arachidonic acid-induced calcium signalling in human airway smooth muscle cells. Colliard-Rouiller C, et al. **Respir Physiol** 1997 Mar;107(3):263-73

Accumulation of unphosphorylated calponin in the submembranous cytoskeletons of arachidonic acid-stimulated human platelets. Meyer T, et al. **Thromb Haemost** 1996 Apr;75(4):617-22

PHYSIOLOGY

The role of the cytochrome P450-dependent metabolites of arachidonic acid in blood pressure regulation and renal function: a review. Rahman M, et al. **Am J Hypertens** 1997 Mar;10(3):356-65 (104 ref.)

Effects of arachidonic acid on A-type potassium currents in smooth muscle cells of the guinea pig. Nagano N, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):C860-9

Arachidonic acid mediates interferon-gamma-induced sphingomyelin hydrolysis and monocytic marker expression in HL-60 cell line. Višnjić D, et al. **Blood** 1997 Jan 1;89(1):81-91

Rapid regulation of neurite outgrowth and retraction by phospholipase A2-derived arachidonic acid and its metabolites. Smalheiser NR, et al. **Brain Res** 1996 May 20;721(1-2):39-48

Phospholipases and arachidonic acid contribute independently to sensory transduction and associative neuronal facilitation in Hermissenda type B photoreceptors. Talk AC, et al. **Brain Res** 1997 Mar 21;751(2):196-205

Involvement of arachidonic acid and the lipoxygenase pathway in mediating luteinizing hormone-induced testosterone synthesis in rat Leydig cells. Mele PG, et al. **Endocr Res** 1997 Feb-May;23(1-2):15-26

Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Capasso A, et al. **Eur J Pharmacol** 1997 Jul 9; 330(2-3):199-204

Interactions between arachidonic acid and metabotropic glutamate receptors in the induction of synaptic potentiation in the rat hippocampal slice. Collins DR, et al. **Eur J Pharmacol** 1995 Dec 27;294(1):147-54

Role of arachidonic acid and calmodulin in mediating dopamine D1- and GnRH-stimulated growth hormone release in goldfish pituitary cells. Chang JP, et al. **Gen Comp Endocrinol** 1996 Apr;102(1):88-101

Endogenous arachidonic acid inhibits hypotonically-activated Cl- channels in isolated rat hepatocytes. Sakai H, et al. **Jpn J Physiol** 1996 Aug; 46(4):311-8

Different sites of action of arachidonic acid on steroidogenesis in rat Leydig cells. Marinero MJ, et al. **Mol Cell Endocrinol** 1996 Apr 19;118(1-2):193-200

Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mitchell JA, et al. **Mol Pharmacol** 1997 Jun;51(6):907-12

[Arachidonic acid in physiology and pathology of nervous tissue] Zylińska L, et al. **Postepy Biochem** 1996;42(4):357-63 (49 ref.) **(Pol)**

SECRETION

Phospholipase A2-dependent and -independent pathways of arachidonate release from vascular smooth muscle cells. Cane A, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):327-37

Macrophage arachidonate release via both the cytosolic Ca(2+)-dependent and -independent phospholipases is necessary for cell spreading. Teslenko V, et al. **Biochim Biophys Acta** 1997 Jan 21;1344(2):189-99

Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Berdyshev EV, et al. **Eur J Pharmacol** 1997 Jul 9;330(2-3):231-40

The B2 receptor on cultured human decidua cells: release of arachidonic acid by bradykinin. Rehbock J, et al. **Immunopharmacology** 1996 Jun;33(1-3):164-6

Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytes. Castro M, et al. **Inflammation** 1996 Feb;20(1):107-22

Arachidonic acid release from rat Leydig cells depends on the presence of luteinizing hormone/human chorionic gonadotrophin receptors. Moraga PF, et al. **J Endocrinol** 1997 Aug;154(2):201-9

Endogenous arachidonic acid release and pancreatic amylase secretion. Hou W, et al. **Pancreas** 1997 Apr;14(3):301-8

Mechanism of thrombin-induced arachidonic acid release in osteoblast-like cells. Suzuki A, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Jun; 56(6):467-72

Different requirement of intracellular calcium and protein kinase C for arachidonic acid release and serotonin secretion in cathepsin G-activated platelets. Rotondo S, et al. **Thromb Haemost** 1997 Aug;78(2):919-25

TOXICITY

Preliminary safety assessment of an arachidonic acid-enriched oil derived from Mortierella alpina: summary of toxicological data. Hempenius RA, et al. **Food Chem Toxicol** 1997 Jun;35(6):573-81

High levels of dietary arachidonic acid triglyceride exhibit no subchronic toxicity in rats. Koskelo EK, et al. **Lipids** 1997 Apr;32(4):397-405

ARACHIDONIC ACIDS

The generation and actions of isoprostanes. Roberts LJ 2nd, et al. **Biochim Biophys Acta** 1997 Apr 1;1345(2):121-35 (71 ref.)

ADMINISTRATION & DOSAGE

Influence of feeding artificial-formula milks containing docosahexaenoic and arachidonic acids on the postnatal long-chain polyunsaturated fatty acid status of healthy preterm infants. Foreman-van Drongelen MM, et al. **Br J Nutr** 1996 Nov;76(5):649-67

Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Lake KD, et al. **Hypertension** 1997 May;29(5):1204-10

ANALYSIS

Anandamide and other N-acylethanolamines in mouse peritoneal macrophages. Schmid PC, et al. **Chem Phys Lipids** 1997 Jul 14;87(2):103-10

Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. Felder CC, et al. **FEBS Lett** 1996 Sep 16;393(2-3):231-5

Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. Koga D, et al. **J Chromatogr B Biomed Appl** 1997 Mar 7; 690(1-2):7-13

BIOSYNTHESIS

Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Di Marzo V, et al. **Biochem Biophys Res Commun** 1996 Oct 3;227(1):281-8

Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Bisogno T, et al. **Biochim Biophys Acta** 1997 Apr 21;1345(3):338-48

Biosynthesis of arachiodonic acid metabolites in Limulus polyphemus amebocytes: analysis by liquid chromatography-electrospray ionization mass spectrometry. MacPherson JC, et al. **Biochim Biophys Acta** 1996 Sep 27;1303(2):127-36

Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Sugiura T, et al. **Eur J Biochem** 1996 Aug 15;240(1):53-62

Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Hunter SA, et al. **Life Sci** 1997;60(18):1563-73

Role of cytosolic phospholipase A2 in eicosanoid generation by corpora lutea of pseudopregnant rats: effects of its specific inhibitor. Kurusu S, et al. **Prostaglandins Leukot Essent Fatty Acids** 1997 Aug; 57(2):119-24

Incorporation of 3H-arachidonic acid into platelet phospholipids of patients with schizophrenia. Yao JK, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Aug; 55(1-2):21-6

BLOOD

Cardiovascular effects of homologous bradykinin in rainbow trout. Olson KR, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1112-20

Platelet and aorta arachidonic and eicosapentaenoic acid levels and in vitro eicosanoid production in rats fed high-fat diets. Sanigorski AJ, et al. **Lipids** 1996 Jul; 31(7):729-35

CHEMISTRY

Lipid mimetics: the design and properties of conformationally-restricted arachidonic acid lipidic and peptidic analogues. Bonzom PM, et al. **Biochem Soc Trans** 1997 Feb;25(1):26S

Head group analogs of arachidonylethanolamide, the

endogenous cannabinoid ligand. Khanolkar AD, et al. **J Med Chem** 1996 Oct 25;39(22):4515–9

Novel oxylipins from the temperate red alga Polyneura latissima: evidence for an arachidonate 9(S)–lipoxygenase. Jiang ZD, et al. **Lipids** 1997 Mar;32(3):231–5

METABOLISM

Pilot study of cytokines in emergency department patients with systemic inflammatory response syndrome. Terregino CA, et al. **Acad Emerg Med** 1997 Jul;4(7):684–8

Induction of cyclo–oxygenase and nitric oxide synthase in inflammation. Appleton I, et al. **Adv Pharmacol** 1996; 35:27–78 (329 ref.)

Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Deutsch DG, et al. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):217–21

Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty–acid amide hydrolase. Kurahashi Y, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):512–5

An endogenous cannabinoid as an endothelium–derived vasorelaxant. Randall MD, et al. **Biochem Biophys Res Commun** 1996 Dec 4;229(1):114–20

A fluorescence displacement assay for the measurement of arachidonoyl ethanolamide (anandamide) and oleoyl amide (octadecenoamide) hydrolysis. Thumser AE, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):433–5

Activation of brain–type cannabinoid receptors interferes with preimplantation mouse embryo development. Yang ZM, et al. **Biol Reprod** 1996 Oct;55(4):756–61

Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. Matsuda S, et al. **Exp Eye Res** 1997 May;64(5):707–11

Inhibition of anandamide hydrolysis in rat brain tissue by (E)–6–(bromomethylene) tetrahydro–3–(1–naphthalenyl)–2H–pyran–2–one. Beltramo M, et al. **FEBS Lett** 1997 Feb 24;403(3):263–7

Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase–2. Yu M, et al. **J Biol Chem** 1997 Aug 22;272(34):21181–6

Anandamide—a new look on fatty acid ethanolamides. Berdyshev EV, et al. **J Lipid Mediat Cell Signal** 1996 Dec; 15(1):49–67 (105 ref.)

N–arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues. Sugiura T, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):51–6 (20 ref.)

Enzymes for anandamide biosynthesis and metabolism. Ueda N, et al. **J Lipid Mediat Cell Signal** 1996 Sep;14(1–3):57–61

Structural requirements for binding of anandamide–type compounds to the brain cannabinoid receptor. Sheskin T, et al. **J Med Chem** 1997 Feb 28;40(5):659–67

Ca2+–dependent K+ channels in bovine adrenal chromaffin cells are modulated by lipoxygenase metabolites of arachidonic acid. Twitchell WA, et al. **J Membr Biol** 1997 Jul 1;158(1):69–75

Accumulation of N–arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. Hillard CJ, et al. **J Neurochem** 1997 Aug;69(2):631–8

Interleukin–1 enhances the ATP–evoked release of arachidonic acid from mouse astrocytes. Stella N, et al. **J Neurosci** 1997 May 1;17(9):2939–46

A potential mechanism for proximal tubule angiotensin II–mediated sodium flux associated with receptor–mediated endocytosis and arachidonic acid release. Becker BN, et al. **Kidney Int Suppl** 1996 Dec;57:S66–72

The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. Paria BC, et al. **Mol Reprod Dev** 1996 Oct;45(2):183–92

Modulation of N–methyl–D–aspartate receptor mediated arachidonic acid release by endogenous nitric oxide in cultured neurons. Rodriguez–Alvarez J, et al. **Neurosci Lett** 1996 Nov 1;218(2):95–8

Inhibitors of anandamide breakdown. Deutsch DG, et al. **NIDA Res Monogr** 1997;173:65–84 (39 ref.)

Regulation of arachidonic acid release and prostaglandin formation by cell–cell adhesive interactions in wound repair. Moreno JJ. **Pflugers Arch** 1997 Jan;433(3):351–6

Ibuprofen inhibits the metabolism of the endogenous cannabimimetic agent anandamide. Fowler CJ, et al. **Pharmacol Toxicol** 1997 Feb;80(2):103–7

Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Schmid PC, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15; 94(8):4188–92

Cerebrodiene, arachidonyl–ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors. Boring DL, et al. **Prostaglandins Leukot Essent Fatty Acids** 1996 Sep; 55(3):207–10

Functional role of high–affinity anandamide transport, as revealed by selective inhibition. Beltramo M, et al. **Science** 1997 Aug 22;277(5329):1094–7

[Arachidonate metabolism in mast cells] Murakami M. **Seikagaku** 1997 Feb;69(2):108–13 (23 ref.) **(Jpn)**

PHARMACOKINETICS

20–[18F]fluoroarachidonic acid: tissue biodistribution and incorporation into phospholipids. Nagatsugi F, et al. **Biol Pharm Bull** 1996 Oct;19(10):1316–21

Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. Bisogno T, et al. **J Biol Chem** 1997 Feb 7;272(6):3315–23

The biodisposition and metabolism of anandamide in mice. Willoughby KA, et al. **J Pharmacol Exp Ther** 1997 Jul; 282(1):243–7

PHARMACOLOGY

Renal oxygenases: differential contribution to vasoconstriction induced by ET–1 and ANG II. Oyekan A, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R293–300

Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. De Petrocellis L, et al. **Biochem Biophys Res Commun** 1997 Feb 3;231(1):82–8

Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Wenger T, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):724–8

Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Deutsch DG, et al. **Biochem Pharmacol** 1997 Feb 7;53(3):255–60

Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Fernández–Ruiz JJ, et al. **Biochem Pharmacol** 1997 Jun 15; 53(12):1919–27

Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Stein EA, et al. **Br J Pharmacol** 1996 Sep;119(1):107–14

Time–course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Romero J, et al. **Brain Res** 1995 Oct 2;694(1–2):223–32

Morphine– and anandamide–stimulated nitric oxide production inhibits presynaptic dopamine release. Stefano GB, et al. **Brain Res** 1997 Jul 18;763(1):63–8

Arachidonic acid regulation of vasopressin release and intracellular Ca2+ in neurohypophysial nerve endings. Stuenkel EL, et al. **Brain Res** 1996 Dec 2;742(1–2):129–40

Ontogenetic development of the response to anandamide and delta 9–tetrahydrocannabinol in mice. Fride E, et al. **Brain Res Dev Brain Res** 1996 Aug 20;95(1):131–4

Characterization of anandamide–induced tolerance: comparison to delta 9–THC–induced interactions with dynorphinergic systems. Welch SP. **Drug Alcohol Depend** 1997 Apr 14;45(1–2):39–45

Influence of fatty acid ethanolamides and delta9–tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Berdyshev EV, et al. **Eur J Pharmacol** 1997 Jul 9;330(2–3):231–40

Effects of anandamide and arachidonic acid on specific binding of (+) –PN200–110, diltiazem and (–) –desmethoxyverapamil to L–type Ca2+ channel. Shimasue K, et al. **Eur J Pharmacol** 1996 Feb 5;296(3):347–50

(R)–methanandamide, but not anandamide, substitutes for delta 9–THC in a drug–discrimination procedure. Burkey RT, et al. **Exp Clin Psychopharmacol** 1997 Aug; 5(3):195–202

Mechanism of the hypotensive action of anandamide in anesthetized rats. Varga K, et al. **Hypertension** 1996 Oct; 28(4):682–6

Effects of 5–oxo–6,8,11,14–eicosatetraenoic acid on expression of CD11b, actin polymerization, and adherence in human neutrophils. Powell WS, et al. **J Immunol** 1997 Sep 15;159(6):2952–9

Stimulating properties of 5–oxo–eicosanoids for human monocytes: synergism with monocyte chemotactic protein–1 and –3. Sozzani S, et al. **J Immunol** 1996 Nov 15;157(10):4664–71

Chemotactic 5–oxo–eicosatetraenoic acids induce oxygen radical production, Ca2+–mobilization, and actin reorganization in human eosinophils via a pertussis toxin–sensitive G–protein. Czech W, et al. **J Invest Dermatol** 1997 Jan;108(1):108–12

Anandamide—a new look on fatty acid ethanolamides. Berdyshev EV, et al. **J Lipid Mediat Cell Signal** 1996 Dec; 15(1):49–67 (105 ref.)

Arachidonate and docosahexaenoate added to infant formula influence fatty acid composition and subsequent eicosanoid production in neonatal pigs. Huang MC, et al. **J Nutr** 1996 Sep;126(9):2199–208

Effects of anandamide on gestation in pregnant rats. Wenger T, et al. **Life Sci** 1997;60(26):2361–71

Anandamide may mediate sleep induction [letter] Mechoulam R, et al. **Nature** 1997 Sep 4;389(6646):25–6

Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes. Bloom AS, et al. **Neurochem Res** 1997 May;22(5):563–8

Anandamide, an endogenous cannabinoid, inhibits Shaker–related voltage–gated K+ channels. Poling JS, et al. **Neuropharmacology** 1996;35(7):983–91

Anandamide suppresses nitric oxide and TNF–alpha responses to Theiler's virus or endotoxin in astrocytes. Molina–Holgado F, et al. **Neuroreport** 1997 May 27; 8(8):1929–33

Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits. Hodges LC, et al. **Ophthalmic Res** 1997;29(1):1–5

(R)–methanandamide inhibits receptor–induced calcium responses by depleting internal calcium stores in cultured astrocytes. Venance L, et al. **Pflugers Arch** 1997 May; 434(1):147–9

Lipoxins and novel aspirin–triggered 15–epi–lipoxins (ATL): a jungle of cell–cell interactions or a therapeutic opportunity? Serhan CN. **Prostaglandins** 1997 Feb; 53(2):107–37 (119 ref.)

Regulation of transforming growth factor beta 1 messenger ribonucleic acid expression in porcine thyroid follicles in vitro by growth factors, iodine, or delta–iodolactone. Gärtner R, et al. **Thyroid** 1997 Aug;7(4):633–40

PHYSIOLOGY

Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Valk P, et al. **Blood** 1997 Aug 15; 90(4):1448–57

Making the public and pediatric community aware of the importance of fatty acids in infant nutrition [letter] Oski FA. **Nutrition** 1996 May;12(5):380–1

SECRETION

Vitamin E potentiates arachidonate release and phospholipase A2 activity in rat heart myoblastic cells. Tran K, et al. **Biochem J** 1996 Oct 15;319 (Pt 2):385–91

TOXICITY

Developmental aspects of anandamide: ontogeny of response and prenatal exposure. Fride E, et al. **Psychoneuroendocrinology** 1996 Feb;21(2):157–72

ARACHIS see **PEANUTS**

ARACHNID VECTORS

Risk for acquiring human granulocytic ehrlichiosis: exposure to deer blood or deer ticks? [letter; comment] Telford SR 3rd. **Clin Infect Dis** 1997 Mar;24(3):531–3. Comment on: Clin Infect Dis 1996 Jul;23(1):198.

First isolation and characterisation of Borrelia garinii, agent of Lyme borreliosis, from Irish ticks. Gray JS, et al. **Ir J Med Sci** 1996 Jan–Mar;165(1):24–6

Accelerated infectivity of tick–transmitted Lyme disease spirochetes to vector ticks. Shih CM, et al. **J Clin Microbiol** 1996 Sep;34(9):2297–9

Site–specific geographic association between Amblyomma americanum (Acari: Ixodidae) infestations and Ehrlichia chaffeensis–reactive (Rickettsiales: Ehrlichieae) antibodies in white–tailed deer. Lockhart JM, et al. **J Med Entomol** 1996 Jan;33(1):153–8

The distribution of Dermacentor hunteri and Anaplasma sp. in desert bighorn sheep (Ovis canadensis). Crosbie PR, et al. **J Parasitol** 1997 Feb;83(1):31–7

Interspecific differences between small mammals as hosts of immature Dermacentor variabilis (Acari: Ixodidae) and a model for detection of high risk areas of Rocky Mountain spotted fever. Kollars TM Jr. **J Parasitol** 1996 Oct; 82(5):707–10

A sero–epidemiological survey of equine piroplasmosis in the northern and eastern Cape Provinces of South Africa. Gummow B, et al. **J S Afr Vet Assoc** 1996 Dec;67(4):204–8

The possible role of two common three–host ticks, Rhipicephalus appendiculatus and Amblyomma hebraeum, in the transmission of bovine leukosis virus. Morris SD, et al. **J S Afr Vet Assoc** 1996 Sep;67(3):148–50

A lump on the head from Mongolia [letter] Lankester T, et al. **Lancet** 1997 Mar 1;349(9052):656

Epidemiological aspects of the Brazilian spotted fever: seasonal activity of ticks collected in an endemic area in São Paulo, Brazil. de Lemos ER, et al. **Rev Soc Bras Med Trop** 1997 May–Jun;30(3):181–5

Isolation of a South African vector–specific strain of Babesia canis. Lewis BD, et al. **Vet Parasitol** 1996 May;63(1–2):9–16

[Contacts of the population of the Republic of Sakha (Yakutia) with the tick Ixodes persulcatus Sch., 1930] Egorov IIa, et al. **Med Parazitol (Mosk)** 1996 Apr–Jun; (2):37–40 **(Rus)**

[Antibacterial therapy as a means of preventing ixodid tick–borne borreliosis] Korenberg EI, et al. **Med Parazitol (Mosk)** 1996 Apr–Jun;(2):3–8 (Eng. Abstr.) **(Rus)**

[Infections of the Lyme borreliosis group—ixodid tick–borne borrelioses in Russia] Korenberg EI. **Med Parazitol (Mosk)** 1996 Jul–Sep;(3):14–8 (Eng. Abstr.) **(Rus)**

[Nervous system lesions in patients with ixodid tick–borne borreliosis] Vorob'eva NN, et al. **Med Parazitol (Mosk)** 1996 Jul–Sep;(3):19–22 (Eng. Abstr.) **(Rus)**

[The clinical aspects of the results of antibiotic prophylaxis in ixodid tick–borne borreliosis] Vorob'eva NN, et al. **Med Parazitol (Mosk)** 1996 Apr–Jun;(2):8–10 **(Rus)**

[Ixodid tick–borne borrelioses—a new group of human diseases] Korenberg EI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Jul–Aug; (4):104–8 (59 ref.) **(Rus)**

[Astrakhan fever—a rickettsiosis of the tick–borne spotted fevers caused by a new pathovar of rickettsiae, Rickettsia conorii] Lukin EP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Sep–Oct;(5):96–9 (37 ref.) **(Rus)**

ARACHNID VECTORS

CHEMISTRY

Isolation and characterization of americanin, a specific inhibitor of thrombin, from the salivary glands of the lone star tick Amblyomma americanum (L.). Zhu K, et al. **Exp Parasitol** 1997 Sep;87(1):30–8

ENZYMOLOGY

Assay for phenoloxidase activity in Amblyomma americanum, Dermacentor variabilis, and Ixodes scapularis. Zhioua E, et al. **J Parasitol** 1997 Jun;83(3):553–4

GENETICS

Genetic markers for the identification of two tick species, Amblyomma dissimile and Amblyomma rotundatum. Lampo M, et al. **J Parasitol** 1997 Jun;83(3):382–6

GROWTH & DEVELOPMENT

Ixodid ticks infesting rodents and sheep in diverse biotopes of southern India. Saxena VK. **J Parasitol** 1997 Aug; 83(4):766–7

MICROBIOLOGY

Biological and genetic characterization of Rickettsia sibirica strains isolated in the endemic area of the north Asian tick typhus. Balayeva NM, et al. **Am J Trop Med Hyg** 1996 Dec;55(6):685–92

Inhibition of efficient polymerase chain reaction amplification of Borrelia burgdorferi DNA in blood–fed ticks. Schwartz I, et al. **Am J Trop Med Hyg** 1997 Mar;56(3):339–42

Prevalence of Lyme disease spirochetes in Ixodes persulcatus and wild rodents in far eastern Russia. Sato Y, et al. **Appl Environ Microbiol** 1996 Oct;62(10):3887–9

The role of Leptotrombidium scutellare in the transmission of human diseases. Wu G, et al. **Chin Med J (Engl)** 1996 Sep;109(9):670–3

Clinical and laboratory evidence of the importance of the tick D. marginatus as a vector of B. burgdorferi in some areas of sporadic Lyme disease in Bulgaria. Angelov L, et al. **Eur J Epidemiol** 1996 Oct;12(5):499–502

Prevalence of Borrelia burgdorferi (sensu lato) in Ixodes ricinus (L.) populations in France, according to a phytoecological zoning of the territory. Gilot B, et al. **Eur J Epidemiol** 1996 Aug;12(4):395–401

A simple method of transmission risk assessment in enzootic foci of Lyme borreliosis. Hubálek Z, et al. **Eur J Epidemiol** 1996 Aug;12(4):331–3

Genetic heterogeneity of Borrelia burgdorferi in the United States. Mathiesen DA, et al. **J Infect Dis** 1997 Jan; 175(1):98–107

Transmission of the agent of human granulocytic ehrlichiosis by host–seeking Ixodus scapularis (Acari:Ixodidae) in southern New York state. Des Vignes F, et al. **J Med Entomol** 1997 Jul;34(4):379–82

Vector competence of Ixodes scapularis, I. spinipalpis, and Dermacentor andersoni (Acari:Ixodidae) in transmitting Borrelia burgdorferi, the etiologic agent of Lyme disease. Dolan MC, et al. **J Med Entomol** 1997 Mar;34(2):128–35

Simulation of blacklegged tick (Acari:Ixodidae) population dynamics and transmission of Borrelia burgdorferi. Mount GA, et al. **J Med Entomol** 1997 Jul;34(4):461–84

Ability of the Lyme disease spirochete Borrelia burgdorferi to infect rodents and three species of human–biting ticks (blacklegged tick, American dog tick, lone star tick) (Acari:Ixodidae). Piesman J, et al. **J Med Entomol** 1997 Jul;34(4):451–6

Lyme borreliosis in the southern United States: a review. Oliver JH Jr. **J Parasitol** 1996 Dec;82(6):926–35 (134 ref.)

Unusual strain of Borrelia burgdorferi isolated from Ixodes dentatus in central Georgia. Oliver JH Jr, et al. **J Parasitol** 1996 Dec;82(6):936–40

Transmission of the Lyme disease spirochete, Borrelia garinii, between infected and uninfected immature Ixodes persulcatus during cofeeding on mice. Sato Y, et al. **J Parasitol** 1997 Jun;83(3):547–50

Transmission of Anaplasma marginale with adult Boophilus microplus ticks fed as nymphs on calves with different levels of rickettsaemia. Aguirre DH, et al. **Parasite** 1994 Dec;1(4):405–7

Attempted transmission of human granulocytotropic Ehrlichia (HGE) by Amblyomma americanum and Amblyomma maculatum. Ewing SA, et al. **Vet Parasitol** 1997 Jun;70(1–3):183–90

[The functioning of foci of mixed tick–borne infections on Russian territory] Alekseev AN, et al. **Med Parazitol (Mosk)** 1996 Oct–Dec;(4):9–16 (Eng. Abstr.) **(Rus)**

[Spontaneous tick infection with Borrelia and the degree of their individual infectiousness in different landscape subzones of Tyumen Province] Kolchanova LP. **Med Parazitol (Mosk)** 1997 Jan–Mar;(1):49–50 **(Rus)**

[Standards for reviewing preparations in the study of ixodid tick nymphs by dark–field microscopy in borreliosis foci] Kovalevskiĭ IuV, et al. **Med Parazitol (Mosk)** 1996 Oct–Dec;(4):18–21 (Eng. Abstr.) **(Rus)**

[The localization of Borrelia in the body of the Ixodes persulcatus tick at different developmental stages] Balashov IuS, et al. **Parazitologiia** 1997 Mar–Apr;31(2):97–103 (Eng. Abstr.) **(Rus)**

[The isolation of Borrelia from the tick Ixodes trianguliceps (Ixodidae) and the possible significance of this species in the epizootiology of ixodid tick–borne borrelioses] Gorelova NB, et al. **Parazitologiia** 1996 Jan–Feb;30(1):13–8 (Eng. Abstr.) **(Rus)**

[Neuroborreliosis in Chile. Report of a child probably infected by imported pets] Abarca K, et al. **Rev Med Chil** 1996 Aug;124(8):975–9 (Eng. Abstr.) **(Spa)**

PARASITOLOGY

Cattle infestation by Hyalomma ticks and prevalence of Theileria in H. detritum species in Tunisia. Bouattour A, et al. **Vet Parasitol** 1996 Oct 25;65(3–4):233–45

[The subspecies specificity of Babesia canis] Hauschild S, et al. **Berl Munch Tierarztl Wochenschr** 1996 Jun–Jul; 109(6–7):216–9 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Evaluation of an in vitro method to measure behavioural diapause in the tick Rhipicephalus appendiculatus (Acarina: Ixodidae) in the laboratory. Madder M, et al. **Parasitology** 1997 Jul;115 (Pt 1):97–100

[Ecoepidemiology of Lyme borreliosis in the Rhône–Alps region. Distribution, ecological context, relationship to the distribution of Ixodes ricinus (Linnaeus, 1758)] Pichot J, et al. **Parasite** 1994 Dec;1(4):335–42 (Eng. Abstr.) **(Fre)**

[The place of ixodid ticks (Ixodidae) in forest ecosystems] Balashov IuS. **Parazitologiia** 1996 May–Jun;30(3):193–204 (50 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

[Argas and arbovirus update] Vermeil C, et al. **Bull Soc Pathol Exot** 1996;89(5):363–5 (16 ref.) (Eng. Abstr.) **(Fre)**

[The functioning of foci of mixed tick–borne infections on Russian territory] Alekseev AN, et al. **Med Parazitol (Mosk)** 1996 Oct–Dec;(4):9–16 (Eng. Abstr.) **(Rus)**

[The distribution of tick–borne encephalitis virus–infected ticks along a linear census route] Botvinkin AL, et al. **Med Parazitol (Mosk)** 1996 Jul–Sep;(3):24–8 (Eng. Abstr.) **(Rus)**

ARACHNID VENOMS see **SPIDER VENOMS**

ARACHNIDA

Intradermal reactivity to various insect and arachnid allergens among dogs from the southeastern United States. Willis EL, et al. **J Am Vet Med Assoc** 1996 Oct 15; 209(8):1431–4

GENETICS

Mitochondrial DNA sequencing reveals extreme genetic differentiation in a cryptic species complex of neotropical pseudoscorpions. Wilcox TP, et al. **Mol Phylogenet Evol** 1997 Apr;7(2):208–16

ARACHNIDISM

Scorpion sting reactions. Carbonaro PA, et al. **Cutis** 1996 Mar;57(3):139–41 (28 ref.)

Scorpion sting in Zimbabwe. Bergman NJ. **S Afr Med J** 1997 Feb;87(2):163–7

Opistophthalmus glabrifrons scorpion envenomation [letter] Bergman NJ. **S Afr Med J** 1996 Aug;86(8):981–2

[Snake and scorpion envenomation in Tunisia. Tunis, 26–30 January 1995. Abstracts] **Arch Inst Pasteur Tunis** 1995 Jul–Oct;72(3–4):185–245 **(Fre)**

[Scorpion envenomation] Montoya–Cabrera MA. **Gac Med Mex** 1996 Nov–Dec;132(6):645–8 **(Spa)**

[Scorpion stings in Spain. Popular therapies, proverbs and pharmacopoeias] Monzón–Muñoz FJ. **Gac Med Mex** 1996 Mar–Apr;132(2):211–6 **(Spa)**

COMPLICATIONS

Upper airway obstruction caused by brown recluse spider envenomization of the neck. Goto CS, et al. **Am J Emerg Med** 1996 Nov;14(7):660–2

A red–back spider bite in a lymphoedematous arm. Couser GA, et al. **Med J Aust** 1997 Jun 2;166(11):587–8

Non–cardiogenic pulmonary oedema after scorpion envenomation: a true entity? [letter] Gueron M, et al. **Toxicon** 1996 Apr;34(4):393–5

[Latrodectism: a rare cause of rhabdomyolysis (letter)] Fouché R, et al. **Presse Med** 1997 Jun 14;26(20):954 **(Fre)**

[Brown spider bites (letter)] Gutiérrez Marcos F. **Med Clin (Barc)** 1996 Dec 7;107(20):798 **(Spa)**

DIAGNOSIS

Redback spider is now established in Japan: bites can be recognised by a unique sign [letter] Horton P. **BMJ** 1997 May 17;314(7092):1484

Spider bites in the United States. Anderson PC. **Dermatol Clin** 1997 Apr;15(2):307–11 (14 ref.)

Simulators of hand infections. Kann SE, et al. **Instr Course Lect** 1997;46:69–82 (169 ref.)

Multiple brown recluse spider envenomation. Ruelle AL, et al. **J Am Podiatr Med Assoc** 1996 Apr;86(4):174–6

Spider bites: a web of deception. Gold BS. **Md Med J** 1996 May;45(5):403–6

[Diagnosis in 1348 patients which consulted for a probable spider bite or insect sting] Schenone H. **Bol Chil Parasitol** 1996 Jan–Jun;51(1–2):20–7 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

High–dose hydrocortisone hemisuccinate in scorpion envenomation. Abroug F, et al. **Ann Emerg Med** 1997 Jul; 30(1):23–7

Multiple brown recluse spider envenomation. Ruelle AL, et al. **J Am Podiatr Med Assoc** 1996 Apr;86(4):174–6

Snake and spider antivenin: risks and benefits of therapy. Weisman RS, et al. **J Fla Med Assoc** 1996 Mar;83(3):192–5

Management of the brown recluse spider bite to the glans penis. Broughton G 2nd. **Mil Med** 1996 Oct;161(10):627–9

Severe envenoming by the Indian red scorpion Mesobuthus tamulus: the use of prazosin therapy. Bawaskar HS, et al. **QJM** 1996 Sep;89(9):701–4

Scorpion envenoming and the cardiovascular system. Bawaskar HS, et al. **Trop Doct** 1997 Jan;27(1):6–9

Prazosin: scorpion envenoming and the cardiovascular system [editorial] Warrell DA. **Trop Doct** 1997 Jan;27(1):1

EPIDEMIOLOGY

Scorpion sting epidemiology in Montes Municipality of the State of Sucre, Venezuela: geographic distribution. De Sousa L, et al. **Rev Inst Med Trop Sao Paulo** 1996 Mar–Apr; 38(2):147–52

Clinical description of Parabuthus transvaalicus scorpionism in Zimbabwe. Bergman NJ. **Toxicon** 1997 May;35(5):759–71

HISTORY

The tarantula—poison spider or a case of mistaken identity? **Adverse Drug React Toxicol Rev** 1996 Nov;15(4):199–202

IMMUNOLOGY

Allergic reactions to North African scorpion venom evaluated by skin test and specific IgE. Leynadier F, et al. **J Allergy Clin Immunol** 1997 Jun;99(6 Pt 1):851–3

Systemic inflammatory response syndrome in envenoming [letter; comment] Barraviera B. **Toxicon** 1997 Jan; 35(1):13–4. Comment on: Toxicon 1996 Mar;34(3):389–92.

MORTALITY

Black widow spider case [letter; comment] Robertson WO. **Am J Emerg Med** 1997 Mar;15(2):211. Comment on: Am J Emerg Med 1996 Sep;14(5):469–71.

The black widow: is she deadly to children? Woestman R, et al. **Pediatr Emerg Care** 1996 Oct;12(5):360–4 (19 ref.)

PREVENTION & CONTROL

Malaria vaccine [letter; comment] Bawaskar HS, et al. **Lancet** 1996 Nov 16;348(9038):1379. Comment on: Lancet 1996 Sep 14;348(9029):701–7.

THERAPY

Brown recluse spider envenomation: is hyperbaric oxygen the answer? [editorial; comment] Hobbs GD. **Acad Emerg Med** 1997 Mar;4(3):165–6. Comment on: Acad Emerg Med 1997 Mar;4(3):184–92.

Comparison of hyperbaric oxygen and dapsone therapy for loxosceles envenomation. Hobbs GD, et al. **Acad Emerg Med** 1996 Aug;3(8):758–61

Brown recluse spider envenomation: a prospective trial of hyperbaric oxygen therapy [see comments] Maynor ML, et al. **Acad Emerg Med** 1997 Mar;4(3):184–92. Comment in: Acad Emerg Med 1997 Mar;4(3):165–6.

Black widow spider case [letter; comment] Robertson WO. **Am J Emerg Med** 1997 Mar;15(2):211. Comment on: Am J Emerg Med 1996 Sep;14(5):469–71.

Clinical presentation and outcome of brown recluse spider bite. Wright SW, et al. **Ann Emerg Med** 1997 Jul; 30(1):28–32

Management of the brown recluse spider bite to the glans penis. Broughton G 2nd. **Mil Med** 1996 Oct;161(10):627–9

Management of snake and spider bite in pregnancy. Pantanowitz L, et al. **Obstet Gynecol Surv** 1996 Oct; 51(10):615–20 (48 ref.)

Near fatal envenomation from the funnel–web spider in an infant. Browne GJ. **Pediatr Emerg Care** 1997 Aug; 13(4):271–3

ARACHNODACTYLY see **MARFAN SYNDROME**

ARACHNOID

Detection of malignant cells in cerebrospinal fluid using fluorescence in situ hybridization. van Oostenbrugge RJ, et al. **J Neuropathol Exp Neurol** 1997 Jun;56(6):743–8

Leptomeningeal metastasis with urological presentation. Chua JJ, et al. **Singapore Med J** 1997 Jun;38(6):266–7

ANATOMY & HISTOLOGY

Normal appearance of arachnoid granulations on contrast–enhanced CT and MR of the brain: differentiation from dural sinus disease. Leach JL, et al. **AJNR Am J Neuroradiol** 1996 Sep;17(8):1523–32

Microsurgical anatomy of the arachnoidal trabecular

membranes and cisterns at the level of the tentorium. Vinas FC, et al. **Neurol Res** 1996 Aug;18(4):305–12

BLOOD SUPPLY

The origin of amyloid in cerebral vessels of aged dogs. Wegiel J, et al. **Brain Res** 1995 Dec 24;705(1–2):225–34

Pneumothorax and neonatal stroke [letter; comment] Temesvári P, et al. **Neuropediatrics** 1996 Jun;27(3):167–8. Comment on: Neuropediatrics 1995 Oct;26(5):243–8.

[A case of cerebral aneurysm located at the leptomeningeal artery associated with occlusion of the middle cerebral artery] Kawasaki T, et al. **No Shinkei Geka** 1995 Dec; 23(12):1141–4 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Embryonic and postnatal expression of four gamma-aminobutyric acid transporter mRNAs in the mouse brain and leptomeninges. Evans JE, et al. **J Comp Neurol** 1996 Dec 16;376(3):431–46

Absence of neuronal and glial proteins in human and rat leptomeninges in situ. Calingasan NY, et al. **J Neurol Sci** 1996 Dec;144(1–2):21–3

Expression of NF2 gene product merlin in arachnoid villi and meningiomas. Sakuda K, et al. **Noshuyo Byori** 1996 Nov;13(2):145–8

CYTOLOGY

Human A beta-amyloid and amyloid precursor protein accumulates in rat brain cells after cultured human leptomeningeal fibroblast implants. DeGiorgio LA, et al. **Brain Res** 1997 Mar 28;752(1–2):35–44

Implantation of cultured human leptomeningeal cells into rat brain. DeGiorgio LA, et al. **Int J Dev Neurosci** 1997 Apr; 15(2):231–8

METABOLISM

Amyloid beta-protein (A beta) accumulation in the leptomeninges during aging and in Alzheimer disease. Hamano T, et al. **J Neuropathol Exp Neurol** 1997 Aug; 56(8):922–32

Drainage of CSF through lymphatic pathways and arachnoid villi in sheep: measurement of 125I-albumin clearance. Boulton M, et al. **Neuropathol Appl Neurobiol** 1996 Aug; 22(4):325–33

PATHOLOGY

Arachnoid granulations of the posterior fossa: CT and MR findings. Okamoto K, et al. **Clin Imaging** 1997 Jan–Feb; 21(1):1–5

Primary diffuse leptomeningeal gliomatosis with signs of increased intracranial pressure and progressive meningeal enhancement on MRI. Park JS, et al. **J Neuroimaging** 1996 Oct;6(4):250–4 (16 ref.)

Leptomeningeal metastasis [letter; comment] Chamberlain MC, et al. **J Neurosurg** 1997 Mar;86(3):576–7. Comment on: J Neurosurg 1996 Aug;85(2):225–30.

Treatment of syringomyelia associated with arachnoid scarring caused by arachnoiditis or trauma. Klekamp J, et al. **J Neurosurg** 1997 Feb;86(2):233–40

Posterior vertebral body erosion by arachnoid diverticula in cauda equina syndrome: an unusual manifestation of ankylosing spondylitis. Ginsburg WW, et al. **J Rheumatol** 1997 Jul;24(7):1417–20

Leptomeningeal involvement in chronic lymphocytic leukemia identified by polymerase chain reaction in stored slides: a case report. Garicochea B, et al. **Mod Pathol** 1997 May;10(5):500–3

The MRI signs of spinal arachnoid diverticula. Chen CJ, et al. **Neuroradiology** 1997 Jun;39(6):446–9

[Primary leptomeningeal melanomatosis in a 6-year-old child] Monsó G, et al. **Rev Neurol** 1996 Jan;24(125):87–90 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

The function of arachnoid villi/granulations revisited. Mawera G, et al. **Cent Afr J Med** 1996 Sep;42(9):281–4 (34 ref.)

RADIOGRAPHY

Prevalence of arachnoid granulations as detected with CT venography of the dural sinuses [letter; comment] Casey SO, et al. **AJNR Am J Neuroradiol** 1997 May;18(5):993–4 . Comment on: AJNR Am J Neuroradiol 1996 Apr;17(4):677–83.

ARACHNOID CYSTS

CEREBROSPINAL FLUID

[Intradiploic cysts filled with cerebrospinal fluid. Report of a case] Noviello D, et al. **Radiol Med (Torino)** 1996 Sep; 92(3):308–10 **(Ita)**

COMPLICATIONS

Unusual complication of arachnoid cyst: spontaneous rupture into the subdural space. Ergün R, et al. **Acta Neurochir (Wien)** 1997;139(7):692–4

Optic nerve hypoplasia with hypopituitarism and an arachnoid cyst. Ichiyama T, et al. **Brain Dev** 1996 May–Jun; 18(3):234–5

Coexistence of schizencephaly and middle cranial fossa arachnoid cyst: a report of two patients. Sener RN. **Eur Radiol** 1997;7(3):409–11

Asymptomatic hypothalamic hamartoma associated with an arachnoid cyst--case report. Isaka T, et al. **Neurol Med Chir (Tokyo)** 1996 Oct;36(10):725–8

Temporal lobe arachnoid cyst-attention deficit disorder syndrome: role of the electroencephalogram in diagnosis. Millichap JG. **Neurology** 1997 May;48(5):1435–9

Hirsutism as a first manifestation of a giant arachnoid cyst of the sylvian fissure. Baykal S, et al. **Neurosurg Rev** 1996; 19(4):279–80

Nontraumatic orbital leptomeningeal cyst in an adult: case report. Landa MS, et al. **Ophthal Plast Reconstr Surg** 1997 Mar;13(1):62–7

Acute rupture of an arachnoid cyst after a minor head injury. Lipinski CA, et al. **Pediatr Emerg Care** 1997 Feb;13(1):27–8

Successful epidural anesthesia in a patient with an arachnoid cyst, preeclampsia, and triplets. Gaiser RR, et al. **Reg Anesth** 1996 Nov–Dec;21(6):592–4

[Arachnoid cysts and subdural hematomas] Attané F, et al. **Rev Neurol (Paris)** 1996 Nov;152(11):695–9 (22 ref.) (Eng. Abstr.) **(Fre)**

[Sacral intradural arachnoid cysts as the cause of lumbar syndrome] Russegger L, et al. **Nervenarzt** 1996 Dec; 67(12):1030–3 (Eng. Abstr.) **(Ger)**

[Subdural hematoma associated with arachnoid cyst] Muñoz A, et al. **Neurologia** 1996 Aug–Sep;11(7):263–7 (Eng. Abstr.) **(Spa)**

CONGENITAL

Congenital supratentorial arachnoidal and giant cysts in children: a clinical study with arguments for a conservative approach. Sommer IE, et al. **Childs Nerv Syst** 1997 Jan; 13(1):8–12

Massive intracranial arachnoid cyst in a developmentally normal infant: case report and literature review. Mason TB 2nd, et al. **Pediatr Neurol** 1997 Jan;16(1):59–62 (13 ref.)

DIAGNOSIS

Imaging quiz case 1. Posterior fossa arachnoid cyst. Pollice PA, et al. **Arch Otolaryngol Head Neck Surg** 1997 Jul; 123(7):762, 764–5 (7 ref.)

Arachnoid cysts and pneumosinus dilatans. Sener RN. **Comput Med Imaging Graph** 1997 Mar–Apr;21(2):125–9

Cystic meningiomas, a diagnostic and pathogenic challenge. Awada A, et al. **Eur J Radiol** 1997 Jul;25(1):26–9

Arachnoid cyst with type I Arnold Chiari malformation presenting as syringomyelic syndrome. Shukla R, et al. **J Assoc Physicians India** 1996 Sep;44(9):658–9

Intraspinal extradural arachnoid cyst with spinal cord herniation. Cheng MH. **J Formos Med Assoc** 1996 Sep; 95(9):712–4

Arachnoid cyst of the middle crania fossa, disclosed by bleeding. De Recondo A, et al. **J Neurol Neurosurg Psychiatry** 1996 Nov;61(5):444

Temporal lobe arachnoid cyst-attention deficit disorder syndrome: role of the electroencephalogram in diagnosis. Millichap JG. **Neurology** 1997 May;48(5):1435–9

A meningeal cyst of the thoracic spine presenting as prolonged paresis after ankle injury: case report. Adelson PD, et al. **Neuropediatrics** 1996 Aug;27(4):207–10

Intradiploic arachnoid cyst: case report. Alfieri A, et al. **Neuroradiology** 1996 Aug;38(6):569–71

Contrast-enhanced MRI of intrasellar arachnoid cysts: relationship between the pituitary gland and cyst. Nomura M, et al. **Neuroradiology** 1996 Aug;38(6):566–8

Imaging of thoracic and lumbar spinal extradural arachnoid cysts: report of two cases. Rimmelin A, et al. **Neuroradiology** 1997 Mar;39(3):203–6

Cine magnetic resonance imaging of spinal intradural arachnoid cysts. Shimizu H, et al. **Neurosurgery** 1997 Jul; 41(1):95–100

An intrasellar cystic mass and hypopituitarism. Iida S, et al. **Postgrad Med J** 1996 Jul;72(849):441–2

Epidermoid or arachnoid cyst? Kuzma BB, et al. **Surg Neurol** 1997 Apr;47(4):395–6

[Intrasellar arachnoid cysts: computed tomography and MRI. Apropos of 2 cases] Dietemann JL, et al. **J Neuroradiol** 1997 Aug;24(2):168–73 (Eng. Abstr.) **(Fre)**

[A case of large arachnoid cyst of the vertebral canal] Stępniak U, et al. **Wiad Lek** 1996;49(7–12):132–5 (Eng. Abstr.) **(Pol)**

[Arachnoid cyst and pseudotumor cerebri: case report] Cabral ND, et al. **Arq Neuropsiquiatr** 1996 Jun;54(2):304–8 (Eng. Abstr.) **(Por)**

[Intraventricular arachnoid cyst in the adult] Gelabert-González M, et al. **Rev Neurol** 1997 Jul; 25(143):1095–8 (16 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Listeria monocytogenes meningitis complicated by symptomatic spinal subarachnoid cysts. Abduljabbar T, et al. **Br J Neurosurg** 1996 Jun;10(3):317–9

Leptomeningeal cyst in newborns due to vacuum extraction: report of two cases. Djientcheu VD, et al. **Childs Nerv Syst** 1996 Jul;12(7):399–403

Traumatic interdural arachnoid cyst in the upper cervical spine. Case report. Chen HJ, et al. **J Neurosurg** 1996 Aug; 85(2):351–3

Early onset of leptomeningeal cyst with severe brain herniation: report of two cases. Wang J, et al. **Neuropediatrics** 1997 Jun;28(3):184–8

Middle fossa cyst presenting as a delayed complication of temporal lobectomy: case report. Weaver JP, et al. **Neurosurgery** 1996 May;38(5):1047–50; disussion 1050–1

Symptomatic spinal intradural arachnoid cyst development after lumbar myelography. Case report and review of the literature. Kriss TC, et al. **Spine** 1997 Mar 1;22(5):568–72 (50 ref.)

[Intraventricular arachnoid cyst--on the origin of intraventricular arachnoid cysts] Okamura K, et al. **No To Shinkei** 1996 Nov;48(11):1015–21 (Eng. Abstr.) **(Jpn)**

METABOLISM

Progesterone receptors in arachnoid cysts. An immunocytochemical study in 2 cases. Go KG, et al. **Acta Neurochir (Wien)** 1997;139(4):349–54

PATHOLOGY

Unusual complication of arachnoid cyst: spontaneous rupture into the subdural space. Ergün R, et al. **Acta Neurochir (Wien)** 1997;139(7):692–4

Supratentorial arachnoid cyst and associated subdural hematoma: neuroradiologic studies. Ochi M, et al. **Eur Radiol** 1996;6(5):640–4

Arachnoid cyst [letter; comment] Lorenzana-Honrado L, et al. **J Neurosurg** 1996 Oct;85(4):734–5. Comment on: J Neurosurg 1996 Mar;84(3):526–9.

Arachnoid cyst in the region of the fourth ventricle mimicking clinical picture of normal pressure hydrocephalus. Azzimondi G, et al. **Neurosurg Rev** 1995; 18(4):269–71

PHYSIOPATHOLOGY

Endoscopic observation of a slit-valve mechanism in a suprasellar prepontine arachnoid cyst: case report. Schroeder HW, et al. **Neurosurgery** 1997 Jan;40(1):198–200

PSYCHOLOGY

Cerebellar arachnoid cyst in a firesetter: the weight of organic lesions in arson. Heidrich A, et al. **J Psychiatry Neurosci** 1996 May;21(3):202–6 (35 ref.)

RADIOGRAPHY

Multiple communicating intradural arachnoid cysts: usefulness of myelography and myelo-computed tomography using both lumbar and cervical punctures. Case report. Osuka K, et al. **Neurosurg Rev** 1997;20(2):94–8

[Arachnoid cyst] Merran S. **Presse Med** 1997 Feb 1;26(2):101 **(Fre)**

RADIOTHERAPY

Intracavitary irradiation with colloidal phosphorus-32 for treatment of an arachnoid cyst: a new approach. Kondziolka D. **Minim Invasive Neurosurg** 1997 Jun; 40(2):55–8

SURGERY

Posttraumatic intradiploic arachnoid cyst of the posterior fossa. Martínez-Lage JF, et al. **Childs Nerv Syst** 1997 May; 13(5):293–6 (15 ref.)

Arachnoid cyst resolution [letter; comment] Muthukumar M. **J Neurosurg** 1996 Nov;85(5):983–4. Comment on: J Neurosurg 1995 Dec;83(6):1085–6.

Neuroendoscopic approach to arachnoid cysts. Schroeder HW, et al. **J Neurosurg** 1996 Aug;85(2):293–8

Enhancing neurosurgical endoscopy with the use of virtual reality headgear. McGregor JM. **Minim Invasive Neurosurg** 1997 Jun;40(2):47–9

Treatment of suprasellar arachnoid cyst--two case reports. Oka Y, et al. **Neurol Med Chir (Tokyo)** 1996 Oct; 36(10):721–4

Neurosurgical treatment for hydrocephalus, subdural hematomas, and arachnoid cysts in glutaric aciduria type 1 [letter; comment] Martínez-Lage JF. **Neuropediatrics** 1996 Dec;27(6):335–6. Comment on: Neuropediatrics 1996 Jun;27(3):115–23.

Arachnoid cysts of the middle cranial fossa: experience with 77 patients who were treated with cystoperitoneal shunting. Arai H, et al. **Neurosurgery** 1996 Dec;39(6):1108–12; discussion 1112–3

Arachnoid cysts of the cerebellopontine angle: diagnosis and surgery. Jallo GI, et al. **Neurosurgery** 1997 Jan;40(1):31–7; discussion 37–8 (48 ref.)

Arachnoid cysts associated with subdural hematomas and hygromas: analysis of 16 cases, long-term follow-up, and review of the literature. Parsch CS, et al. **Neurosurgery** 1997 Mar;40(3):483–90 (66 ref.)

Arachnoid cysts in adults: experience with internal shunts to the subdural compartment. Wester K. **Surg Neurol** 1996 Jan;45(1):15–24

[Brainstem hemorrhage after surgical removal of arachnoid cyst of the Sylvian fissure: a case report] Borges G, et al. **Arq Neuropsiquiatr** 1995 Dec;53(4):825–30 (Eng. Abstr.) **(Por)**

ARACHNOID CYSTS

ULTRASONOGRAPHY

Glioependymal and arachnoid cysts: unusual causes of early ventriculomegaly in utero. Hassan J, et al. **Prenat Diagn** 1996 Aug;16(8):729–33

VETERINARY

Subarachnoid cyst in a cat. Shamir MH, et al. **J Am Anim Hosp Assoc** 1997 Mar–Apr;33(2):123–5

Magnetic resonance imaging and computed tomography characteristics of intracranial intra–arachnoid cysts in 6 dogs. Vernau KM, et al. **Vet Radiol Ultrasound** 1997 May–Jun;38(3):171–6 (37 ref.)

ARACHNOIDITIS

CHEMICALLY INDUCED

[High–dose methotrexate and cerebral neurotoxicity. Apropos of a case of arachnoiditis] Brain E, et al. **Presse Med** 1997 Mar 1;26(6):265–8 (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Evaluation of continuous intraspinal narcotic analgesia for chronic pain from benign causes. Yoshida GM, et al. **Am J Orthop** 1996 Oct;25(10):693–4

Treatment of syringomyelia associated with arachnoid scarring caused by arachnoiditis or trauma. Klekamp J, et al. **J Neurosurg** 1997 Feb;86(2):233–40

DIAGNOSIS

MRI demonstration of arachnoiditis in cauda equina syndrome of ankylosing spondylitis. Charlesworth CH, et al. **Neuroradiology** 1996 Jul;38(5):462–5

ETIOLOGY

Intrathecal hematoma and arachnoiditis after prophylactic blood patch through a catheter [letter] Aldrete JA, et al. **Anesth Analg** 1997 Jan;84(1):233–4

Patterns of chronic adhesive arachnoiditis following Myodil myelography: the significance of spinal canal stenosis and previous surgery. Laitt R, et al. **Br J Radiol** 1996 Aug; 69(824):693–8

Postoperative Guillain–Barré syndrome, arachnoiditis, and epidural analgesia. Rosenberg SK, et al. **Reg Anesth** 1996 Sep–Oct;21(5):486–9

Postlaminectomy adhesion of the cauda equina. Changes of postoperative vascular permeability of the equina in rats. Nakano M, et al. **Spine** 1997 May 15;22(10):1105–14

[Spinal tuberculous arachnoiditis] de La Blanchardière A, et al. **Presse Med** 1996 Oct 5;25(29):1333–5 (Eng. Abstr.) **(Fre)**

PATHOLOGY

MR imaging of tubercular spinal arachnoiditis. Sharma A, et al. **AJR Am J Roentgenol** 1997 Mar;168(3):807–12

Myeloscopic observation of adhesive arachnoiditis in patients with lumbar spinal canal stenosis. Kawauchi Y, et al. **Spinal Cord** 1996 Jul;34(7):403–10

PHYSIOPATHOLOGY

Epidural space as a Starling resistor and elevation of inflow resistance in a diseased epidural space. Rocco AG, et al. **Reg Anesth** 1997 Mar–Apr;22(2):167–77

Postlaminectomy adhesion of the cauda equina. Changes of postoperative vascular permeability of the equina in rats. Nakano M, et al. **Spine** 1997 May 15;22(10):1105–14

PREVENTION & CONTROL

The effect of urokinase in preventing the formation of epidural fibrosis and/or leptomeningeal arachnoiditis. Ceviz A, et al. **Surg Neurol** 1997 Feb;47(2):124–7

RADIOGRAPHY

Arachnoiditis ossificans of the cauda equina demonstrated on computed tomography scanogram. A case report. Ng P, et al. **Spine** 1996 Nov 1;21(21):2504–7

ARANEID VENOMS see **SPIDER VENOMS**

ARAURIDINE see **ARABINOFURANOSYLURACIL**

ARBITRATING see **NEGOTIATING**

ARBOVIRUS, GROUP B see **FLAVIVIRUS**

ARBOVIRUS INFECTIONS

COMPLICATIONS

Rheumatic manifestations of tropical diseases. Adebajo AO. **Curr Opin Rheumatol** 1996 Jan;8(1):85–9 (30 ref.)

EPIDEMIOLOGY

Arbovirus encephalitis in the United States and Asia. Lowry PW. **J Lab Clin Med** 1997 Apr;129(4):405–11 (19 ref.)

Mosquito seasonality and arboviral disease incidence in Murray Valley, southeast Australia. Dhileepan K. **Med Vet Entomol** 1996 Oct;10(4):375–84

The global resurgence of arboviral diseases. Gubler DJ. **Trans R Soc Trop Med Hyg** 1996 Sep–Oct;90(5):449–51 (17 ref.)

[Epidemiology of arbovirus diseases: use and value of physiologic age determination of female mosquito vectors] Mondet B. **Bull Soc Pathol Exot** 1996;89(2):155–60 (Eng. Abstr.) **(Fre)**

TRANSMISSION

The review of studies in vector ecology in Russia. Nikolaeva N. **Bull Inst Marit Trop Med Gdynia** 1996;47(1–4):73–83

[Epidemiology of arbovirus diseases: use and value of physiologic age determination of female mosquito vectors] Mondet B. **Bull Soc Pathol Exot** 1996;89(2):155–60 (Eng. Abstr.) **(Fre)**

[Argas and arbovirus update] Vermeil C, et al. **Bull Soc Pathol Exot** 1996;89(5):363–5 (16 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

The role of deer as a possible reservoir host of potosi virus, a newly recognized arbovirus in the United States. McLean RG, et al. **J Wildl Dis** 1996 Jul;32(3):444–52

VIROLOGY

Arbovirus survey in China in recent ten years. Chen B, et al. **Chin Med J (Engl)** 1996 Jan;109(1):13–5 (0 ref.)

Evaluation of arthropod–borne viruses and other infectious disease pathogens as the causes of febrile illnesses in the Khartoum Province of Sudan. McCarthy MC, et al. **J Med Virol** 1996 Feb;48(2):141–6

ARBOVIRUSES

see related
ARENAVIRIDAE
BUNYAVIRIDAE
FLAVIVIRIDAE
REOVIRIDAE

CLASSIFICATION

[Arboviruses of the region (editorial)] Valero–Fuenmayor N. **Invest Clin** 1996 Mar;37(1):1–3 **(Spa)**

DRUG EFFECTS

Ammonium salt of glycyrrhizic acid as an antiviral [letter] Badam L. **Natl Med J India** 1997 Mar–Apr;10(2):98

IMMUNOLOGY

Application of an immunoperoxidase monolayer assay for the detection of arboviral antibodies. Soliman AK, et al. **J Virol Methods** 1997 May;65(2):147–51

ISOLATION & PURIFICATION

Arbovirus survey in China in recent ten years. Chen B, et al. **Chin Med J (Engl)** 1996 Jan;109(1):13–5 (0 ref.)

Arboviruses associated with mosquitoes from nine Florida counties during 1993. Mitchell CJ, et al. **J Am Mosq Control Assoc** 1996 Jun;12(2 Pt 1):255–62

Ecology of mosquitoes and lack of arbovirus activity at Morro Bay, San Luis Obispo County, California. Reisen WK, et al. **J Am Mosq Control Assoc** 1996 Dec; 12(4):679–87

The isolation of Akabane virus (Iriki strain) from calves in Taiwan. Liao YK, et al. **J Basic Microbiol** 1996;36(1):33–9

Arbovirus encephalitis in the United States and Asia. Lowry PW. **J Lab Clin Med** 1997 Apr;129(4):405–11 (19 ref.)

Evaluation of arthropod–borne viruses and other infectious disease pathogens as the causes of febrile illnesses in the Khartoum Province of Sudan. McCarthy MC, et al. **J Med Virol** 1996 Feb;48(2):141–6

The role of deer as a possible reservoir host of potosi virus, a newly recognized arbovirus in the United States. McLean RG, et al. **J Wildl Dis** 1996 Jul;32(3):444–52

Seroprevalence of five arboviruses in Zebu cattle in the Central African Republic. Guilherme JM, et al. **Trans R Soc Trop Med Hyg** 1996 Jan–Feb;90(1):31–3

[Arbovirus circulation in the Republic of Guinea] Butenko AM. **Med Parazitol (Mosk)** 1996 Apr–Jun;(2):40–5 (Eng. Abstr.) **(Rus)**

ARBOVIRUSES, GROUP A see **ALPHAVIRUS**

ARC see **AIDS–RELATED COMPLEX**

ARCHAEA see **ARCHAEOBACTERIA**

ARCHAEBACTERIA see **ARCHAEOBACTERIA**

ARCHAEOBACTERIA

The archaeal flagellum: a unique motility structure. Jarrell KF, et al. **J Bacteriol** 1996 Sep;178(17):5057–64 (62 ref.)

Dating the cenancester of organisms [letter; comment] Gogarten JP, et al. **Science** 1996 Dec 6;274(5293):1750–1; discussion 1751–3. Comment on: Science 1996 Jan 26;271(5248):470–7.

CHEMISTRY

Dissecting contributions to the thermostability of Pyrococcus furiosus rubredoxin: beta–sheet chimeras. Eidsness MK, et al. **Biochemistry** 1997 Aug 26;36(34):10406–13

The signal recognition particle receptor alpha subunit of the hyperthermophilic archaeon Acidianus ambivalens exhibits an intrinsic GTP–hydrolyzing activity. Moll R, et al. **Biochim Biophys Acta** 1997 Apr 17;1335(1–2):218–30

Structure determination of a novel uronic acid residue isolated from the exopolysaccharide produced by a bacterium originating from deep sea hydrothermal vents. Dubreucq G, et al. **Carbohydr Res** 1996 Sep 2;290(2):175–81

The structure of the exopolysaccharide produced by the halophilic Archaeon Haloferax mediterranei strain R4 (ATCC 33500). Parolis H, et al. **Carbohydr Res** 1996 Dec 13;295:147–56

Archaea and the origin(s) of DNA replication proteins. Edgell DR, et al. **Cell** 1997 Jun 27;89(7):995–8 (27 ref.)

Archaeal histones, nucleosomes, and transcription initiation. Reeve JN, et al. **Cell** 1997 Jun 27;89(7):999–1002 (18 ref.)

Unusual fatty acid compositions of the hyperthermophilic archaeon Pyrococcus furiosus and the bacterium Thermotoga maritima. Carballeira NM, et al. **J Bacteriol** 1997 Apr;179(8):2766–8

Characterization of UDP amino sugars as major phosphocompounds in the hyperthermophilic archaeon Pyrococcus furiosus. Ramakrishnan V, et al. **J Bacteriol** 1997 Mar;179(5):1505–12

Voltage–dependent porin–like ion channels in the archaeon Haloferax volcanii. Besnard M, et al. **J Biol Chem** 1997 Jan 10;272(2):992–5

Physical characterization of a totally synthetic rubredoxin. Christen R, et al. **J Inorg Biochem** 1997 Jan;65(1):53–6

Structural characterization of modified folates in Archaea. White RH. **Methods Enzymol** 1997;281:391–401

Purification and characterization of a histone–like protein from the Archaeal isolate AN1, a member of the Thermococcales. Ronimus RS, et al. **Mol Microbiol** 1996 Apr;20(1):77–86

Characterization of a RecA/RAD51 homologue from the hyperthermophilic archaeon Pyrococcus sp. KOD1. Rashid N, et al. **Nucleic Acids Res** 1997 Feb 15;25(4):719–26

Structural basis for thermostability and identification of potential active site residues for adenylate kinases from the archaeal genus Methanococcus. Haney P, et al. **Proteins** 1997 May;28(1):117–30

CLASSIFICATION

Novel group within the kingdom Crenarchaeota from boreal forest soil. Jurgens G, et al. **Appl Environ Microbiol** 1997 Feb;63(2):803–5

Biochemical and phylogenetic characterization of two novel deep–sea Thermococcus isolates with potentially biotechnological applications. Canganella F, et al. **Arch Microbiol** 1997 Apr;167(4):233–8

Ferroglobus placidus gen. nov., sp. nov., A novel hyperthermophilic archaeum that oxidizes Fe2+ at neutral pH under anoxic conditions. Hafenbradl D, et al. **Arch Microbiol** 1996 Nov;166(5):308–14

Rhodospira trueperi gen. nov., spec. nov., a new phototrophic Proteobacterium of the alpha group. Pfennig N, et al. **Arch Microbiol** 1997 Jul;168(1):39–45

Reclassification of the crenarchael orders and families in accordance with 16S rRNA sequence data. Burggraf S, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):657–60

Thermococcus hydrothermalis sp. nov., a new hyperthermophilic archaeon isolated from a deep–sea hydrothermal vent. Godfroy A, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):622–6

Aeropyrum pernix gen. nov., sp. nov., a novel aerobic hyperthermophilic archaeon growing at temperatures up to 100 degrees C. Sako Y, et al. **Int J Syst Bacteriol** 1996 Oct;46(4):1070–7

Wide diversity of Crenarchaeota [letter] Hershberger KL, et al. **Nature** 1996 Dec 5;384(6608):420

Perspectives on archaeal diversity, thermophily and monophyly from environmental rRNA sequences [see comments] Barns SM, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9188–93. Comment in: Proc Natl Acad Sci U S A 1996 Aug 20;93(17):8797–9.

Molecular phylogeny of Archaea from soil. Bintrim SB, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):277–82

At the core of the Archaea [comment] Doolittle WF. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):8797–9. Comment on: Proc Natl Acad Sci U S A 1996 Aug 20;93(17):9188–93.

Methanococcus genome [letter] Golomb SW. **Science** 1996 Nov 8;274(5289):902; discussion 902–3

Microbiology's scarred revolutionary [news] [published erratum appears in Science 1997 Jul 25;277(5325):463] Morell V. **Science** 1997 May 2;276(5313):699–702

CYTOLOGY

The response of selected members of the archaea to the gram stain. Beveridge TJ, et al. **Microbiology** 1996 Oct;142 (Pt 10):2887–95

ENZYMOLOGY

Oxidoreductase–type enzymes and redox proteins involved in fermentative metabolisms of hyperthermophilic Archaea.

Adams MW, et al. **Adv Protein Chem** 1996;48:101–80 (210 ref.)

Proteases and glycosyl hydrolases from hyperthermophilic microorganisms. Bauer MW, et al. **Adv Protein Chem** 1996; 48:271–310 (150 ref.)

Enzymes of central nitrogen metabolism from hyperthermophiles: characterization, thermostability, and genetics. Diruggiero J, et al. **Adv Protein Chem** 1996; 48:311–39 (100 ref.)

Structure and stability of hyperstable proteins: glycolytic enzymes from hyperthermophilic bacterium Thermotoga maritima. Jaenicke R, et al. **Adv Protein Chem** 1996; 48:181–269 (250 ref.)

Respiratory metabolism in hyperthermophilic organisms: hydrogenases, sulfur reductases, and electron transport factors that function at temperatures exceeding 100 degrees C. Maier RJ. **Adv Protein Chem** 1996;48:35–99 (180 ref.)

Thermostable DNA polymerases. Perler FB, et al. **Adv Protein Chem** 1996;48:377–435 (160 ref.)

Characterization of recombinant glutamine synthetase from the hyperthermophilic archaeon Pyrococcus sp. strain KOD1. Adul Rahman RN, et al. **Appl Environ Microbiol** 1997 Jun;63(6):2472–6

Cloning, sequencing, and expression of the gene encoding extracellular alpha-amylase from Pyrococcus furiosus and biochemical characterization of the recombinant enzyme. Dong G, et al. **Appl Environ Microbiol** 1997 Sep; 63(9):3569–76

Cloning, sequencing, and expression of the gene encoding amylopullulanase from Pyrococcus furiosus and biochemical characterization of the recombinant enzyme. Dong G, et al. **Appl Environ Microbiol** 1997 Sep; 63(9):3577–84

Autotrophic carbon dioxide fixation in Acidianus brierleyi. Ishii M, et al. **Arch Microbiol** 1996 Dec;166(6):368–71

Properties and primary structure of a thermostable L-malate dehydrogenase from Archaeoglobus fulgidus. Langelandsvik AS, et al. **Arch Microbiol** 1997 Jul; 168(1):59–67

Carbohydrate metabolism in Thermoproteus tenax: in vivo utilization of the non-phosphorylative Entner-Doudoroff pathway and characterization of its first enzyme, glucose dehydrogenase. Siebers B, et al. **Arch Microbiol** 1997 Aug; 168(2):120–7

RNA splicing ligase activity in the archaeon Haloferax volcanii. Gomes I, et al. **Biochem Biophys Res Commun** 1997 Aug 28;237(3):588–94

Vacuolar-type ATPase in a hyperthermophilic archaeum, Thermococcus sp. KI. Iida T, et al. **Biochem Biophys Res Commun** 1996 Dec 13;229(2):559–64

The stabilizing residues and the functional domains in the hyperthermophilic V-ATPase of Desulfurococcus. Shibui H, et al. **Biochem Biophys Res Commun** 1997 May 19; 234(2):341–5

Genetic information 'created' by archaebacterial DNA polymerase. Ogata N, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):667–71

The crystal structure of citrate synthase from the hyperthermophilic archaeon pyrococcus furiosus at 1.9 A resolution,. Russell RJ, et al. **Biochemistry** 1997 Aug 19; 36(33):9983–94

Purification and characterization of isocitrate dehydrogenase from a hyperthermophilic archaebacterium, Caldococcus noboribetus. Aoshima M, et al. **Biochim Biophys Acta** 1997 Jul 18;1340(2):227–34

A hyperthermostable protease of the subtilisin family bound to the surface layer of the archaeon Staphylothermus marinus. Mayr J, et al. **Curr Biol** 1996 Jun 1;6(6):739–49

Mapping metal ions at the catalytic centres of two intron-encoded endonucleases. Lykke-Andersen J, et al. **EMBO J** 1997 Jun 2;16(11):3272–81

Deep sea microbes and DNA cloning [news] **Environ Health Perspect** 1996 Aug;104(8):820–1

Acid-induced disassembly of glutamate dehydrogenase from the hyperthermophilic archaeon Pyrococcus furiosus occurs below pH 2.0. Chiaraluce R, et al. **Eur J Biochem** 1997 Jul 1;247(1):224–30

Purification and properties of acetyl-CoA synthetase (ADP-forming), an archaeal enzyme of acetate formation and ATP synthesis, from the hyperthermophile Pyrococcus furiosus. Glasemacher J, et al. **Eur J Biochem** 1997 Mar 1;244(2):561–7

4-alpha-glucanotransferase from the hyperthermophilic archaeon Thermococcus litoralis--enzyme purification and characterization, and gene cloning, sequencing and expression in Escherichia coli. Jeon BS, et al. **Eur J Biochem** 1997 Aug 15;248(1):171–8

Biochemical characterisation of ornithine carbamoyltransferase from Pyrococcus furiosus. Legrain C, et al. **Eur J Biochem** 1997 Aug 1;247(3):1046–55

Glucose dehydrogenase from the halophilic Archaeon Haloferax mediterranei: enzyme purification, characterisation and N-terminal sequence. Bonete MJ, et al. **FEBS Lett** 1996 Apr 1;383(3):227–9

Unusual enzyme characteristics of aspartyl-tRNA synthetase from hyperthermophilic archaeon Pyrococcus sp. KOD1. Fujiwara S, et al. **FEBS Lett** 1996 Sep 23;394(1):66–70

Tetrameric triosephosphate isomerase from hyperthermophilic Archaea. Kohlhoff M, et al. **FEBS Lett** 1996 Apr 1;383(3):245–50

Uracil-DNA glycosylase activities in hyperthermophilic micro-organisms. Koulis A, et al. **FEMS Microbiol Lett** 1996 Oct 1;143(2-3):267–71

Cloning, characterization and sequence comparison of the gene coding for IMP dehydrogenase from Pyrococcus furiosus. Collart FR, et al. **Gene** 1996 Oct 3;174(2):209–16

The world of archaea: genome analysis, evolution and thermostable enzymes. Fujiwara S, et al. **Gene** 1996 Nov 7;179(1):165–70

Characterization of the reverse gyrase from the hyperthermophilic archaeon Pyrococcus furiosus. Borges KM, et al. **J Bacteriol** 1997 Mar;179(5):1721–6

Purification and sequence analysis of a novel NADP(H)-dependent type III alcohol dehydrogenase from Thermococcus strain AN1. Li D, et al. **J Bacteriol** 1997 Jul;179(13):4433–7

Characterization of a fourth type of 2-keto acid-oxidizing enzyme from a hyperthermophilic archaeon: 2-ketoglutarate ferredoxin oxidoreductase from Thermococcus litoralis. Mai X, et al. **J Bacteriol** 1996 Oct; 178(20):5890–6

Purification and characterization of two reversible and ADP-dependent acetyl coenzyme A synthetases from the hyperthermophilic archaeon Pyrococcus furiosus. Mai X, et al. **J Bacteriol** 1996 Oct;178(20):5897–903

Aspartate transcarbamylase from the deep-sea hyperthermophilic archaeon Pyrococcus abyssi: genetic organization, structure, and expression in Escherichia coli. Purcarea C, et al. **J Bacteriol** 1997 Jul;179(13):4143–57

Comparison of a beta-glucosidase and a beta-mannosidase from the hyperthermophilic archaeon Pyrococcus furiosus. Purification, characterization, gene cloning, and sequence analysis. Bauer MW, et al. **J Biol Chem** 1996 Sep 27; 271(39):23749–55

Two transcription factors related with the eucaryal transcription factors TATA-binding protein and transcription factor IIB direct promoter recognition by an archaeal RNA polymerase. Hausner W, et al. **J Biol Chem** 1996 Nov 22;271(47):30144–8

Cloning, sequencing, characterization, and expression of an extracellular alpha-amylase from the hyperthermophilic archaeon Pyrococcus furiosus in Escherichia coli and Bacillus subtilis. Jorgensen S, et al. **J Biol Chem** 1997 Jun 27;272(26):16335–42

Structural modules of the large subunits of RNA polymerase. Introducing archaebacterial and chloroplast split sites in the beta and beta' subunits of Escherichia coli RNA polymerase. Severinov K, et al. **J Biol Chem** 1996 Nov 1;271(44):27969–74

Structural studies on the 2.25-MDa homomultimeric phosphoenolpyruvate synthase from Staphylothermus marinus. Harauz G, et al. **J Struct Biol** 1996 Mar-Apr; 116(2):290–301

beta-Lactamases are absent from Archaea (archaebacteria). Martin HH, et al. **Microb Drug Resist** 1996 Summer; 2(2):269–72

Ribonuclease P structure and function in Archaea. Brown JW, et al. **Mol Biol Rep** 1995-96;22(2-3):131–4 (16 ref.)

Gene cloning, sequencing and enzymatic properties of glutamate synthase from the hyperthermophilic archaeon Pyrococcus sp. KOD1. Jongsareejit B, et al. **Mol Gen Genet** 1997 May;254(6):635–42

Indolepyruvate ferredoxin oxidoreductase from Pyrococcus sp. KOD1 possesses a mosaic structure showing features of various oxidoreductases. Siddiqui MA, et al. **Mol Gen Genet** 1997 Apr 28;254(4):433–9

Profile of the DNA recognition site of the archaeal homing endonuclease I-DmoI. Aagaard C, et al. **Nucleic Acids Res** 1997 Apr 15;25(8):1523–30

Pyruvate ferredoxin oxidoreductase from the hyperthermophilic archaeon, Pyrococcus furiosus, functions as a CoA-dependent pyruvate decarboxylase. Ma K, et al. **Proc Natl Acad Sci U S A** 1997 Sep 2; 94(18):9608–13

Ribonucleotide reductase in the archaeon Pyrococcus furiosus: a critical enzyme in the evolution of DNA genomes? Riera J, et al. **Proc Natl Acad Sci U S A** 1997 Jan 21;94(2):475–8

Exchange of domains of glutamate dehydrogenase from the hyperthermophilic archaeon Pyrococcus furiosus and the mesophilic bacterium Clostridium difficile: effects on catalysis, thermoactivity and stability. Lebbink JH, et al. **Protein Eng** 1995 Dec;8(12):1287–94

3-Hydroxy-3-methylglutaryl-coenzyme A reductase of Haloferax volcanii: role of histidine 398 and attenuation of activity by introduction of negative charge at position 404. Bischoff KM, et al. **Protein Sci** 1997 Jan;6(1):156–61

Crystallization and preliminary X-ray diffraction studies of formylmethanofuran: tetrahydromethanopterin formyltransferase from Methanopyrus kandleri. Shima S, et al. **Proteins** 1996 Sep;26(1):118–20

Evidence for a family of archaeal ATPases [letter; comment] Koonin EV. **Science** 1997 Mar 7;275(5305):1489–90. Comment on: Science 1996 Aug 23;273(5278):1058–73.

Isolation, characterization, and substrate specificity of the plasma membrane ATPase of the hlophilic achaeon Haloferax volcanii. Steinert K, et al. **Z Naturforsch [C]** 1996 Jan-Feb;51(1-2):29–39

GENETICS

DNA stability and DNA binding proteins. Grayling RA, et al. **Adv Protein Chem** 1996;48:437–67 (110 ref.)

Characterization of recombinant glutamine synthetase from the hyperthermophilic archaeon Pyrococcus sp. strain KOD1. Adul Rahman RN, et al. **Appl Environ Microbiol** 1997 Jun;63(6):2472–6

Phylogenetic analyses of some extremely halophilic archaea isolated from Dead Sea water, determined on the basis of their 16S rRNA sequences. Arahal DR, et al. **Appl Environ Microbiol** 1996 Oct;62(10):3779–86

Cloning, sequencing, and expression of the gene encoding extracellular alpha-amylase from Pyrococcus furiosus and biochemical characterization of the recombinant enzyme. Dong G, et al. **Appl Environ Microbiol** 1997 Sep; 63(9):3569–76

Cloning, sequencing, and expression of the gene encoding amylopullulanase from Pyrococcus furiosus and biochemical characterization of the recombinant enzyme. Dong G, et al. **Appl Environ Microbiol** 1997 Sep; 63(9):3577–84

Vertical distribution and phylogenetic characterization of marine planktonic Archaea in the Santa Barbara Channel. Massana R, et al. **Appl Environ Microbiol** 1997 Jan; 63(1):50–6

Recovery of crenarchaeotal ribosomal DNA sequences from freshwater-lake sediments. Schleper C, et al. **Appl Environ Microbiol** 1997 Jan;63(1):321–3

Simultaneous detection of different Rhizobium strains marked with either the Escherichia coli gusA gene or the Pyrococcus furiosus celB gene. Sessitsch A, et al. **Appl Environ Microbiol** 1996 Nov;62(11):4191–4

In vitro stabilization and in vivo solubilization of foreign proteins by the beta subunit of a chaperonin from the hyperthermophilic archaeon Pyrococcus sp. strain KOD1. Yan Z, et al. **Appl Environ Microbiol** 1997 Feb;63(2):785–9

Eubacteria-type isocitrate dehydrogenase from an archaeon: cloning, sequencing, and expression of a gene encoding isocitrate dehydrogenase from a hyperthermophilic archaebacterium, Caldococcus noboribetus. Aoshima M, et al. **Arch Biochem Biophys** 1996 Dec 1;336(1):77–85

Recent advances in genetic analyses of hyperthermophilic archaea and bacteria. Noll KM, et al. **Arch Microbiol** 1997 Aug;168(2):73–80 (50 ref.)

Identification of a gene in the euryarchaeal Thermococcus species AN1 encoding a protein homologous to the alpha subunit of the eukaryal signal recognition particle (SRP) receptor. Ronimus RS, et al. **Biochim Biophys Acta** 1997 Mar 20;1351(1-2):1–8

Structural feature of the initiator tRNA gene from Pyrodictium occultum and the thermal stability of its gene product, tRNA(imet). Ushida C, et al. **Biochimie** 1996; 78(10):847–55

Another bridge between kingdoms: tRNA splicing in archaea and eukaryotes. Belfort M, et al. **Cell** 1997 Jun 27; 89(7):1003–6 (17 ref.)

Ancient ciphers: translation in Archaea. Dennis PP. **Cell** 1997 Jun 27;89(7):1007–10 (8 ref.)

Archaea and the origin(s) of DNA replication proteins. Edgell DR, et al. **Cell** 1997 Jun 27;89(7):995–8 (27 ref.)

Properties of H. volcanii tRNA intron endonuclease reveal a relationship between the archaeal and eucaryal tRNA intron processing systems. Kleman-Leyer K, et al. **Cell** 1997 Jun 13;89(6):839–47

Archaeal genomics: an overview. Olsen GJ, et al. **Cell** 1997 Jun 27;89(7):991–4 (12 ref.)

Archaeal histones, nucleosomes, and transcription initiation. Reeve JN, et al. **Cell** 1997 Jun 27;89(7):999–1002 (18 ref.)

The yeast tRNA splicing endonuclease: a tetrameric enzyme with two active site subunits homologous to the archaeal tRNA endonucleases. Trotta CR, et al. **Cell** 1997 Jun 13; 89(6):849–58

Phylogenetic perspective on microbial life in hydrothermal ecosystems, past and present. Barns SM, et al. **Ciba Found Symp** 1996;202:24–32; discussion 32–9

An ABC-transporter system homolog in an organism of the phylogenetic domain Archaea. Jovell RJ, et al. **DNA Seq** 1997;7(3-4):193–7

4-alpha-glucanotransferase from the hyperthermophilic archaeon Thermococcus litoralis--enzyme purification and characterization, and gene cloning, sequencing and expression in Escherichia coli. Jeon BS, et al. **Eur J Biochem** 1997 Aug 15;248(1):171–8

Isolation of the gene encoding Pyrococcus furiosus ornithine carbamoyltransferase and study of its expression profile in vivo and in vitro. Roovers M, et al. **Eur J Biochem** 1997 Aug 1;247(3):1038–45

Cloning and sequencing of a gene encoding 16S ribosomal RNA from a novel hyperthermophilic archaebacterium NC12. Aoshima M, et al. **Gene** 1996 Nov 21;180(1-2):183–7

Cloning, characterization and sequence comparison of the gene coding for IMP dehydrogenase from Pyrococcus furiosus. Collart FR, et al. **Gene** 1996 Oct 3;174(2):209–16

Protein-encoding genes in the sulfothermophilic archaea Sulfolobus and Pyrococcus. De Vendittis E, et al. **Gene** 1996 Oct 17;176(1-2):27–33

The world of archaea: genome analysis, evolution and thermostable enzymes. Fujiwara S, et al. **Gene** 1996 Nov 7;179(1):165–70

Reclassification of the crenarchael orders and families in accordance with 16S rRNA sequence data. Burggraf S, et al. **Int J Syst Bacteriol** 1997 Jul;47(3):657–60

Isolation, sequence, and expression of the gene encoding halocin H4, a bacteriocin from the halophilic archaeon Haloferax mediterranei R4. Cheung J, et al. **J Bacteriol** 1997 Jan;179(2):548–51

Overexpression and characterization of a prolyl

endopeptidase from the hyperthermophilic archaeon Pyrococcus furiosus. Harwood VJ, et al. **J Bacteriol** 1997 Jun;179(11):3613–8

Splicing of intron-containing tRNATrp by the archaeon Haloferax volcanii occurs independent of mature tRNA structure. Armbruster DW, et al. **J Biol Chem** 1997 Aug 8;272(32):19758–62

Parallel origins of the nucleosome core and eukaryotic transcription from Archaea. Ouzounis CA, et al. **J Mol Evol** 1996 Feb;42(2):234–9

Unidentified open reading frames in the genome of Methanococcus jannaschii are similar in sequence to an archaebacterial gene for tRNA nucleotidyltransferase. Thurlow DL, et al. **J Mol Evol** 1997 Jun;44(6):686–9

The detection of nucleotide sequences with strong similarity to hormone responsive elements in the genome of eubacteria and archaebacteria and their possible relation to similar sequences present in the mitochondrial genome. Hatzoglou E, et al. **J Theor Biol** 1997 Feb 7;184(3):339–44

Evolutionary divergence and salinity-mediated selection in halophilic archaea. Dennis PP, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):90–104 (33 ref.)

A RecA/RAD51 homologue from a hyperthermophilic archaeon retains the major RecA domain only. Rashid N, et al. **Mol Gen Genet** 1996 Dec 13;253(3):397–400

FtsZ ring: the eubacterial division apparatus conserved in archaebacteria. Wang X, et al. **Mol Microbiol** 1996 Jul; 21(2):313–9

Avoidance of palindromic words in bacterial and archaeal genomes: a close connection with restriction enzymes. Gelfand MS, et al. **Nucleic Acids Res** 1997 Jun 15; 25(12):2430–9

Genomic and cDNA sequence tags of the hyperthermophilic archaeon Pyrobaculum aerophilum. Völkl P, et al. **Nucleic Acids Res** 1996 Nov 15;24(22):4373–8

Perspectives on archaeal diversity, thermophily and monophyly from environmental rRNA sequences [see comments] Barns SM, et al. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):9188–93. Comment in: Proc Natl Acad Sci U S A 1996 Aug 20;93(17):8797–9.

Molecular phylogeny of Archaea from soil. Bintrim SB, et al. **Proc Natl Acad Sci U S A** 1997 Jan 7;94(1):277–82

At the core of the Archaea [comment] Doolittle WF. **Proc Natl Acad Sci U S A** 1996 Aug 20;93(17):8797–9. Comment on: Proc Natl Acad Sci U S A 1996 Aug 20;93(17):9188–93.

Formation of the 5' end pseudoknot in small subunit ribosomal RNA: involvement of U3-like sequences [letter] Dennis PP, et al. **RNA** 1997 Apr;3(4):337–43

Archaeal introns: splicing, intercellular mobility and evolution. Lykke-Andersen J, et al. **Trends Biochem Sci** 1997 Sep;22(9):326–31 (36 ref.)

PAS domain S-boxes in Archaea, Bacteria and sensors for oxygen and redox. Zhulin IB, et al. **Trends Biochem Sci** 1997 Sep;22(9):331–3

Lessons from an Archaeal genome: what are we learning from Methanococcus jannaschii? Olsen GJ, et al. **Trends Genet** 1996 Oct;12(10):377–9 (14 ref.)

GROWTH & DEVELOPMENT

Plating hyperthermophilic archea on solid surface. Rakhely G, et al. **Anal Biochem** 1996 Dec 1;243(1):181–3

Pressure and temperature effects on growth and viability of the hyperthermophilic archaeon Thermococcus peptonophilus. Canganella F, et al. **Arch Microbiol** 1997 Jul;168(1):1–7

Ion permeability of the cytoplasmic membrane limits the maximum growth temperature of bacteria and archaea. van de Vossenberg JL, et al. **Mol Microbiol** 1995 Dec; 18(5):925–32

ISOLATION & PURIFICATION

Crenarchaeota in Lake Michigan sediment. MacGregor BJ, et al. **Appl Environ Microbiol** 1997 Mar;63(3):1178–81

Vertical distribution and phylogenetic characterization of marine planktonic Archaea in the Santa Barbara Channel. Massana R, et al. **Appl Environ Microbiol** 1997 Jan; 63(1):50–6

Recovery of crenarchaeotal ribosomal DNA sequences from freshwater-lake sediments. Schleper C, et al. **Appl Environ Microbiol** 1997 Jan;63(1):321–3

Characterization of universal small-subunit rRNA hybridization probes for quantitative molecular microbial ecology studies. Zheng D, et al. **Appl Environ Microbiol** 1996 Dec;62(12):4504–13

Ferroglobus placidus gen. nov., sp. nov., A novel hyperthermophilic archaeum that oxidizes Fe2+ at neutral pH under anoxic conditions. Hafenbradl D, et al. **Arch Microbiol** 1996 Nov;166(5):308–14

Rhodospira trueperi gen. nov., spec. nov., a new phototrophic Proteobacterium of the alpha group. Pfennig N, et al. **Arch Microbiol** 1997 Jul;168(1):39–45

Isolation of thermophilic bacteria using bacteriological grade agar at temperatures above 80 degrees C. D'Souza DR, et al. **Biotechniques** 1997 Jun;22(6):1078

Thermococcus fumicolans sp. nov., a new hyperthermophilic archaeon isolated from a deep-sea hydrothermal vent in the north Fiji Basin. Godfroy A, et al. **Int J Syst Bacteriol** 1996 Oct;46(4):1113–9

A pivotal Archaea group [letter] Burggraf S, et al. **Nature** 1997 Feb 27;385(6619):780

METABOLISM

Overview of hyperthermophiles and their heat-shock proteins. Baross JA, et al. **Adv Protein Chem** 1996;48:1–34 (210 ref.)

Autotrophic carbon dioxide fixation in Acidianus brierleyi. Ishii M, et al. **Arch Microbiol** 1996 Dec;166(6):368–71

Comparative analysis of Embden-Meyerhof and Entner-Doudoroff glycolytic pathways in hyperthermophilic archaea and the bacterium Thermotoga. Selig M, et al. **Arch Microbiol** 1997 Apr;167(4):217–32

Protonation changes during the photocycle of sensory rhodopsin II from Natronobacterium pharaonis. Engelhard M, et al. **FEBS Lett** 1996 Oct 21;395(2–3):195–8

Repair of extensive ionizing-radiation DNA damage at 95 degrees C in the hyperthermophilic archaeon Pyrococcus furiosus. DiRuggiero J, et al. **J Bacteriol** 1997 Jul; 179(14):4643–5

Protein-tyrosine phosphorylation in the Archaea. Smith SC, et al. **J Bacteriol** 1997 Apr;179(7):2418–20

Purine biosynthesis in the domain Archaea without folates or modified folates. White RH. **J Bacteriol** 1997 May; 179(10):3374–7

DNA topology in hyperthermophilic archaea: reference states and their variation with growth phase, growth temperature, and temperature stresses. López-García P, et al. **Mol Microbiol** 1997 Mar;23(6):1267–79

Identification of a novel selD homolog from eukaryotes, bacteria, and archaea: is there an autoregulatory mechanism in selenocysteine metabolism? Guimarães MJ, et al. **Proc Natl Acad Sci U S A** 1996 Dec 24;93(26):15086–91

PHYSIOLOGY

Pressure and temperature effects on growth and viability of the hyperthermophilic archaeon Thermococcus peptonophilus. Canganella F, et al. **Arch Microbiol** 1997 Jul;168(1):1–7

Site-directed mutations of the 4Fe-ferredoxin from the hyperthermophilic archaeon Pyrococcus furiosus: role of the cluster-coordinating aspartate in physiological electron transfer reactions. Zhou ZH, et al. **Biochemistry** 1997 Sep 9;36(36):10892–900

Hyperthermophiles in the history of life. Stetter KO. **Ciba Found Symp** 1996;202:1–10; discussion 11–8 (19 ref.)

Evolutionary divergence and salinity-mediated selection in halophilic archaea. Dennis PP, et al. **Microbiol Mol Biol Rev** 1997 Mar;61(1):90–104 (33 ref.)

FtsZ ring: the eubacterial division apparatus conserved in archaebacteria. Wang X, et al. **Mol Microbiol** 1996 Jul; 21(2):313–9

A molecular view of microbial diversity and the biosphere. Pace NR. **Science** 1997 May 2;276(5313):734–40 (52 ref.)

Microbiologists explore life's rich, hidden kingdoms [news] Service RF. **Science** 1997 Mar 21;275(5307):1740–2

RADIATION EFFECTS

Repair of extensive ionizing-radiation DNA damage at 95 degrees C in the hyperthermophilic archaeon Pyrococcus furiosus. DiRuggiero J, et al. **J Bacteriol** 1997 Jul; 179(14):4643–5

VIROLOGY

Characterization of Natronobacterium magadii phage phi Ch1, a unique archaeal phage containing DNA and RNA. Witte A, et al. **Mol Microbiol** 1997 Feb;23(3):603–16

ARCHAEOLOGY

delta 13C analysis of cholesterol preserved in archaeological bones and teeth. Stott AW, et al. **Anal Chem** 1996 Dec 15;68(24):4402–8

Chronic problems in understanding tribal violence and warfare. Chagnon NA. **Ciba Found Symp** 1996;194:202–32; discussion 232–6 (68 ref.)

The world's oldest spears [news; comment] Dennell R. **Nature** 1997 Feb 27;385(6619):767–8. Comment on: Nature 1997 Feb 27;385(6619):807–10.

Contending for the dead. Jones DG, et al. **Nature** 1997 Mar 6;386(6620):15–6

Lower Palaeolithic hunting spears from Germany [see comments] Thieme H. **Nature** 1997 Feb 27; 385(6619):807–10. Comment in: Nature 1997 Feb 27;385(6619):767–8.

Tooling around: dates show early Siberian settlement [news; comment] Holden C. **Science** 1997 Feb 28;275(5304):1268 . Comment on: Science 1997 Feb 28;275(5304):1281–4.

Diring Yuriakh: A lower paleolithic site in central Siberia [see comments] Waters MR, et al. **Science** 1997 Feb 28; 275(5304):1281–4. Comment in: Science 1997 Feb 28;275(5304):1268.

HISTORY

Mary Leakey 1913–96 [news] Wood B. **Nature** 1997 Jan 2; 385(6611):28

ARCHENTERON see **GASTRULA**

ARCHITECTURAL ACCESSIBILITY

Is the typical modern house designed for future adaptation for disabled older people? Frain JP, et al. **Age Ageing** 1996 Sep;25(5):398–401

Library services for people with disabilities: results of a survey. Nelson PP. **Bull Med Libr Assoc** 1996 Jul; 84(3):397–401

An ergonomic perspective on accommodation in accessibility for people with disability. Owens TR, et al. **Disabil Rehabil** 1996 Aug;18(8):402–7

[Aids in general daily activities can hardly replace professional home care. Results of a study among single 75-year-olds or older] de Klerk MM, et al. **Tijdschr Gerontol Geriatr** 1997 Feb;28(1):27–33 (Eng. Abstr.) **(Dut)**

[Age-adaptable to any age] Philippen DP. **Z Gerontol Geriatr** 1996 Jul-Aug;29(4):238–45 (Eng. Abstr.) **(Ger)**

STANDARDS

Making our offices universally accessible: guidelines for physicians [see comments] Jones KE, et al. **Can Med Assoc J** 1997 Mar 1;156(5):647–56 (64 ref.). Comment in: Can Med Assoc J 1997 Mar 1;156(5):657–9.

Attitudes and access: advancing the rights of people with disabilities [editorial; comment] Peat M. **Can Med Assoc J** 1997 Mar 1;156(5):657–9 (8 ref.). Comment on: Can Med Assoc J 1997 Mar 1;156(5):647–56.

STATISTICS & NUMERICAL DATA

Environmental hazards and hip fractures. Parker MJ, et al. **Age Ageing** 1996 Jul;25(4):322–5

ARCHITECTURE

see related

HEALTH FACILITY PLANNING

Fatal occupational falls in the U.S. construction industry, 1980–1989. Cattledge GH, et al. **Accid Anal Prev** 1996 Sep; 28(5):647–54

Nonfatal occupational fall injuries in the West Virginia construction industry. Cattledge GH, et al. **Accid Anal Prev** 1996 Sep;28(5):655–63

Air pollution and the deterioration of historic monuments. Lorusso S, et al. **J Environ Pathol Toxicol Oncol** 1997; 16(2–3):171–3

[Human habitats and the protection of health in Islam] Hadrović A. **Med Arh** 1997;51(1–2):63–5 (Eng. Abstr.) **(Scr)**

[Political urban and architectonic reflections suitable to new population setting] Apestegui B. **Rev Neurol** 1997 Jul;25 Suppl 1:S97–103 **(Spa)**

HISTORY

[A monument to doctors on the Karse] Selivanov VI, et al. **Probl Sotsialnoi Gig Istor Med** 1996 May-Jun;(3):63–4 **(Rus)**

ARCHIVES

A cryptologic based trust center for medical images. Wong ST. **J Am Med Inform Assoc** 1996 Nov-Dec;3(6):410–21

Nursing files--trash or treasure? Fickeissen JL. **J Prof Nurs** 1997 Sep-Oct;13(5):279

Origins of a local hospital: the real story. Lehr TK. **J Public Health Policy** 1996;17(1):71–9

Cyberconference helps archivists manage trove of scientific papers [news] Lamberg L. **JAMA** 1996 Dec 25; 276(24):1935–7

The Strangeways Research Laboratory: archives in the contemporary medical archives centre. Hall LA. **Med Hist** 1996 Apr;40(2):231–8

Digital optical archiving of medical records in hospital information systems--a practical approach towards the computer-based patient record? Dujat C, et al. **Methods Inf Med** 1995 Dec;34(5):489–97

DNA sequencing of formalin-fixed crustaceans from archival research collections. France SC, et al. **Mol Mar Biol Biotechnol** 1996 Dec;5(4):304–13

[Registration and archiving of health services data. A new initiative from the Danish Research Fund] Jørgensen PH, et al. **Ugeskr Laeger** 1997 Feb 10;159(7):963–4 **(Dan)**

[Computerized archives in surgery. Our experience] Verna C, et al. **Minerva Chir** 1997 Jan-Feb;52(1–2):161–6 (Eng. Abstr.) **(Ita)**

[Pediatric autopsies in the historical archives in Bologna (1838–1966)] Scarani P, et al. **Minerva Pediatr** 1995 Dec; 47(12):549–53 **(Ita)**

HISTORY

Illustrations from the Wellcome Institute Library. Wellcome and Osler. Symons J. **Med Hist** 1997 Apr;41(2):213–25

[The first archiatrist of Russia Doctor Erskin: from the history of Russian medicine of the 18th cent.] Mirski MB. **Probl Sotsialnoi Gig Istor Med** 1994 Jul-Aug;(4):53–7 **(Rus)**

ARCUATE NUCLEUS

CHEMISTRY

Neurotensin projections to subfornical organ from arcuate nucleus. Rosas-Arellano MP, et al. **Brain Res** 1996 Jan

15;706(2):323–7
NPY Y1 receptor like immunoreactivity exists in a subpopulation of beta-endorphin immunoreactive nerve cells in the arcuate nucleus: a double immunolabelling analysis in the rat. Fuxe K, et al. **Neurosci Lett** 1997 Mar 28;225(1):49–52

CYTOLOGY

Effects of natriuretic peptides and dopamine on single-unit activity of dorsomedial arcuate neurons in rat brain slices. Pan JT, et al. **Brain Res** 1996 Oct 21;737(1–2):78–82
A subset of estrogen receptor-containing neurons project to the median eminence in the ewe. Jansen HT, et al. **J Neuroendocrinol** 1996 Dec;8(12):921–7
Suckling-induced Fos-immunoreactivity in subgroups of hypothalamic POMC neurons of the lactating rat: investigation of a role for prolactin. Pape JR, et al. **J Neuroendocrinol** 1996 May;8(5):375–86
Local synaptic release of glutamate from neurons in the rat hypothalamic arcuate nucleus. Belousov AB, et al. **J Physiol (Lond)** 1997 Mar 15;499 (Pt 3):747–61

DRUG EFFECTS

The growth hormone-releasing peptide KP-102 induces c-fos expression in the arcuate nucleus. Kamegai J, et al. **Brain Res Mol Brain Res** 1996 Jul;39(1–2):153–9
Action of steroid hormones on growth and differentiation of CNS and spinal cord organotypic cultures. Levy A, et al. **Cell Mol Neurobiol** 1996 Jun;16(3):445–50
delta 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Corchero J, et al. **Eur J Pharmacol** 1997 Apr 4;323(2–3):193–5
Effects of long-term treatment with antidepressant drugs on proopiomelanocortin and neuropeptide Y mRNA expression in the hypothalamic arcuate nucleus of rats. Baker RA, et al. **J Neuroendocrinol** 1996 May;8(5):337–43
Regulation of neurotransmission in the arcuate nucleus of the rat by different neuropeptide Y receptors. Rhim H, et al. **J Neurosci** 1997 May 1;17(9):2980–9
Reserpine-induced immunocytochemical change of neuropeptide Y in the hypothalamic arcuate nucleus. Okamura H, et al. **Neurochem Res** 1996 Feb;21(2):239–43
The arcuate nucleus as a primary site of satiety effect of leptin in rats. Satoh N, et al. **Neurosci Lett** 1997 Mar 21; 224(3):149–52
Naloxone microinjected into the arcuate nucleus has differential effects on ventilation in male and female rats. Schlenker EH, et al. **Physiol Behav** 1997 Sep;62(3):531–6

EMBRYOLOGY

Anatomic relationships of the human arcuate nucleus of the medulla: a DiI-labeling study. Zec N, et al. **J Neuropathol Exp Neurol** 1997 May;56(5):509–22

ENZYMOLOGY

Distribution of catecholamine-synthesizing enzymes and some neuropeptides in the median eminence-arcuate nucleus complex (MEARC) of the immature female pig. Sienkiewicz W, et al. **Acta Histochem** 1996 Nov; 98(4):419–34
Tyrosine hydroxylase and DOPA decarboxylase activities in the medical preoptic area and arcuate nucleus during the estrous cycle: effects of aging. Mohankumar PS, et al. **Brain Res Bull** 1997;42(4):265–71
Role of gonadal steroids in determining sexual differences in expression of Fos-related antigens in tyrosine hydroxylase-immunoreactive neurons in subdivisions of the hypothalamic arcuate nucleus. Cheung S, et al. **Endocrinology** 1997 Sep;138(9):3804–10

METABOLISM

Coexistence of Fos protein and proopiomelanocortin mRNA in hypothalamic arcuate nucleus following electroacupuncture. Zhang J, et al. **Acupunct Electrother Res** 1996 Jan-Mar;21(1):1–5
Chronic food restriction and acute food deprivation decrease mRNA levels of opioid peptides in arcuate nucleus. Kim EM, et al. **Am J Physiol** 1996 May;270(5 Pt 2):R1019–24
Changes in neuropeptide Y immunoreactivity in the arcuate nucleus during and after food restriction in lactating rats. Abizaid A, et al. **Brain Res** 1997 Jul 4;761(2):306–12
Ventromedial hypothalamic lesions produced by gold thioglucose do not impair induction of NPY mRNA in the arcuate nucleus by fasting. Bergen HT, et al. **Brain Res** 1996 Jan 29;707(2):266–71
Consumption of a high dietary dose of monosodium glutamate fails to affect extracellular glutamate levels in the hypothalamic arcuate nucleus of adult rats. Bogdanov MB, et al. **Brain Res** 1996 Oct 14;736(1–2):76–81
Heterogeneity in the neuropeptide Y-containing neurons of the rat arcuate nucleus: GABAergic and non-GABAergic subpopulations. Horvath TL, et al. **Brain Res** 1997 May 9;756(1–2):283–6
Rats bred for enhanced apomorphine susceptibility have elevated tyrosine hydroxylase mRNA and dopamine D2-receptor binding sites in nigrostriatal and tuberoinfundibular dopamine systems. Rots NY, et al. **Brain Res** 1996 Feb 26;710(1–2):189–96
Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Dickson SL, et al. **Endocrinology** 1997 Feb;138(2):771–7
The effect of hypophysectomy and growth hormone replacement on sst1 and sst2 somatostatin receptor subtype messenger ribonucleic acids in the arcuate nucleus. Guo F, et al. **Endocrinology** 1996 Sep;137(9):3928–35
Regulation of hypothalamic somatostatin, growth hormone-releasing hormone, and growth hormone receptor messenger ribonucleic acid by glucocorticoids. Señaris RM, et al. **Endocrinology** 1996 Dec;137(12):5236–41
Retrogradely labelled neurosecretory neurones of the rat hypothalamic arcuate nucleus express Fos protein following systemic injection of GH-releasing peptide-6. Dickson SL, et al. **J Endocrinol** 1996 Nov;151(2):323–31
Continuous intracerebroventricular administration of a corticotropin releasing hormone antagonist amplifies spontaneous growth hormone pulses in the rat. Mounier F, et al. **J Endocrinol** 1997 Mar;152(3):431–6
Coexpression of leptin receptor and preproneuropeptide Y mRNA in arcuate nucleus of mouse hypothalamus. Mercer JG, et al. **J Neuroendocrinol** 1996 Oct;8(10):733–5
Dopaminergic neurons in periventricular and arcuate nuclei of proestrous and ovariectomized rats: endogenous diurnal rhythm of Fos-related antigens expression. Lerant A, et al. **Neuroendocrinology** 1997 Jun;65(6):436–45
Suckling-induced changes in neuropeptide Y and proopiomelanocortin gene expression in the arcuate nucleus of the rat: evaluation of a putative intervention of prolactin. Pape JR, et al. **Neuroendocrinology** 1996 Jun;63(6):540–9
Expression of leptin receptor mRNA in the hypothalamic arcuate nucleus—relationship with NPY neurones. Håkansson ML, et al. **Neuroreport** 1996 Nov 25; 7(18):3087–92

PHYSIOLOGY

Attenuation of leptin-mediated effects by monosodium glutamate-induced arcuate nucleus damage. Dawson R, et al. **Am J Physiol** 1997 Jul;273(1 Pt 1):E202–6
Arcuate nucleus inputs onto subfornical organ neurons that respond to plasma hypernatremia and angiotensin II. Rosas-Arellano MP, et al. **Brain Res** 1996 Jan 29; 707(2):308–13
Inhibitory effect of dopamine on dorsomedial arcuate neurons in rat brain slices: potentiation by coadministration of cocaine. Yen SH, et al. **Brain Res Bull** 1997;42(5):347–51
Neuroplastic changes in the hypothalamic arcuate nucleus: the estradiol effect is accompanied by increased exoendocytotic activity of neuronal membranes. Párducz A, et al. **Cell Mol Neurobiol** 1996 Apr;16(2):259–69
Differential regulation of luteinizing hormone release by gamma-aminobutyric acid receptor subtypes in the arcuate-ventromedial region of the castrated ram. Ferreira SA, et al. **Endocrinology** 1996 Aug;137(8):3453–60
Synaptic remodeling in the arcuate nucleus during the estrous cycle is induced by estrogen and precedes the preovulatory gonadotropin surge. Naftolin F, et al. **Endocrinology** 1996 Dec;137(12):5576–80
Control of gonadotropin feedback: the possible role of estrogen-induced hypothalamic synaptic plasticity. Horvath TL, et al. **Gynecol Endocrinol** 1997 Apr; 11(2):139–43 (12 ref.)
The effect of pentobarbital on the electrical activity of LHRH pulse generator in the ovariectomized rat with or without estrogen priming. Kimura F, et al. **J Neuroendocrinol** 1995 Dec;7(12):911–5
LHRH pulse generator is stimulated by naloxone in the pentobarbital-blocked proestrous rat. Kimura F, et al. **J Neuroendocrinol** 1995 Dec;7(12):917–22
Dopamine inhibition: enhancement of GABA activity and potassium channel activation in hypothalamic and arcuate nucleus neurons. Belousov AB, et al. **J Neurophysiol** 1997 Aug;78(2):674–88
Adenosine modulation of calcium currents and presynaptic inhibition of GABA release in suprachiasmatic and arcuate nucleus neurons. Chen G, et al. **J Neurophysiol** 1997 Jun; 77(6):3035–47
A method for drug infusion into the lateral median eminence and arcuate nucleus of sheep. Anderson ST, et al. **J Neurosci Methods** 1997 Feb;71(2):169–76
Tolerance to mu-opioid receptor agonists but not cross-tolerance to gamma-aminobutyric acid(B) receptor agonists in arcuate A12 dopamine neurons with chronic morphine treatment. Wagner EJ, et al. **J Pharmacol Exp Ther** 1997 Feb;280(2):1057–64
Lack of gonadotropin-positive feedback in the male rat is associated with lack of estrogen-induced synaptic plasticity in the arcuate nucleus. Horvath TL, et al. **Neuroendocrinology** 1997 Feb;65(2):136–40
Tachykinin-induced changes in beta-endorphin gene expression in the rat arcuate nucleus. Magoul R, et al. **Neurosci Lett** 1997 Feb 21;223(2):93–6
Intra-arcuate opiate actions stimulate GRF-dependent and protein-selective feeding. Vaccarino FJ, et al. **Peptides** 1997;18(2):197–205
Hypothalamic NPY and CRF gene expression in the food-deprived Syrian hamster. Mercer JG, et al. **Physiol Behav** 1996 Jul;60(1):121–7
[Excitation of hypothalamic nucleus arcuatus neuron induced decrease of plasma sialic acid level in rats] Chen WF, et al. **Sheng Li Hsueh Pao** 1995 Dec;47(6):597–600 (Eng. Abstr.) (Chi)

PHYSIOPATHOLOGY

Dysregulation of arcuate nucleus preproneuropeptide Y mRNA in diet-induced obese rats. Levin BE, et al. **Am J Physiol** 1997 May;272(5 Pt 2):R1365–70
Dopaminergic neurons of periventricular and arcuate nuclei of pseudopregnant rats: semicircadian rhythm in Fos-related antigens immunoreactivities and in dopamine concentration [see comments] Lerant A, et al. **Endocrinology** 1996 Sep;137(9):3621–8. Comment in: Endocrinology 1996 Sep;137(9):3619–20.

ARCUS SENILIS

ETIOLOGY

Cholesterol accumulation in human cornea: evidence that extracellular cholesteryl ester-rich lipid particles deposit independently of foam cells. Gaynor PM, et al. **J Lipid Res** 1996 Sep;37(9):1849–61

ARDS, HUMAN see **RESPIRATORY DISTRESS SYNDROME, ADULT**

AREA UNDER CURVE

Sampling variability of nonparametric estimates of the areas under receiver operating characteristic curves: an update. Hanley JA, et al. **Acad Radiol** 1997 Jan;4(1):49–58
A limited sampling method for the estimation of flunarizine area under the curve (AUC) and maximum plasma concentration (Cmax). Mahmood I, et al. **Biopharm Drug Dispos** 1997 Mar;18(2):117–26
Partial-area method in bioequivalence assessment: naproxen. Niazi SK, et al. **Biopharm Drug Dispos** 1997 Mar; 18(2):103–16
A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration. Liliemark J, et al. **Cancer Chemother Pharmacol** 1996;38(6):536–40
A limited sampling strategy for estimating sirolimus area-under-the-concentration curve. Kaplan B, et al. **Clin Chem** 1997 Mar;43(3):539–40
Alternative summary indices for the receiver operating characteristic curve. Lee WC, et al. **Epidemiology** 1996 Nov;7(6):605–11
Cmax/AUC, a commentary. Tozer TN, et al. **Pharm Res** 1997 Aug;14(8):967–8
A limited sampling approach in bioequivalence studies. Mahmood I, et al. **Ther Drug Monit** 1997 Aug;19(4):413–9

AREAWIDE PLANNING see **REGIONAL HEALTH PLANNING**

ARECA

Betel nut and smoking. Are they both protective in ulcerative colitis? A pilot study. Lee CN, et al. **Arq Gastroenterol** 1996 Jan-Mar;33(1):3–5
Oral cancer in South Asia [letter] Trivedy C, et al. **Br Dent J** 1997 Mar 22;182(6):206
Use of betel quid and cigarettes among Bangladeshi patients in an inner-city practice: prevalence and knowledge of health effects. Ahmed S, et al. **Br J Gen Pract** 1997 Jul; 47(420):431–4
Correlation between computed tomographic density of lymph node metastases and response to cisplatin-based chemotherapy in patients with head and neck squamous cell carcinoma in an area in which betel quid chewing is prevalent. Wang HM, et al. **Cancer** 1996 Nov 1; 78(9):1972–9
Epidemiological survey of oral submucous fibrosis in Xiangtan City, Hunan Province, China. Tang JG, et al. **Community Dent Oral Epidemiol** 1997 Apr;25(2):177–80
Diabetes in British South Asians: nature, nurture, and culture [letter] Boucher B. **Diabet Med** 1997 Aug;14(8):707–8
Studies on promoting activity of Taiwan betel quid ingredients in hamster buccal pouch carcinogenesis. Jin YT, et al. **Eur J Cancer B Oral Oncol** 1996 Sep;32B(5):343–6
The effect of areca nut on salivary and selected oral microorganisms. de Miranda CM, et al. **Int Dent J** 1996 Aug;46(4):350–6
Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Heinzel PA, et al. **Int J Cancer** 1996 Nov 15;68(4):420–3
A study on betel quid chewing behavior among Kaohsiung residents aged 15 years and above. Chen JW, et al. **J Oral Pathol Med** 1996 Mar;25(3):140–3
Betel chewer's mucosa in elderly Cambodian women. Reichart PA, et al. **J Oral Pathol Med** 1996 Aug; 25(7):367–70
Betel nut chewing and selected psychophysiological variables. Wyatt TA. **Psychol Rep** 1996 Oct;79(2):451–63

CHEMISTRY

The milk-alkali syndrome caused by betelnuts in oyster shell paste. Wu KD, et al. **J Toxicol Clin Toxicol** 1996; 34(6):741–5
Copper content in Areca catechu (betel nut) products and oral submucous fibrosis [letter] [see comments] Trivedy C,

ARECA

et al. **Lancet** 1997 May 17;349(9063):1447. Comment in: Lancet 1997 Jul 19;350(9072):220.

ARECOLINE

ADVERSE EFFECTS

Inhibition of the migration, attachment, spreading, growth and collagen synthesis of human gingival fibroblasts by arecoline, a major areca alkaloid, in vitro. Jeng JH, et al. **J Oral Pathol Med** 1996 Aug;25(7):371–5

ANALOGS & DERIVATIVES

Quantitative colorimetric and gas chromatographic determination of arecaidine propargyl ester. Langer K, et al. **J Chromatogr B Biomed Appl** 1997 May 9;692(2):345–50

PHARMACOKINETICS

Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. Asthana S, et al.
Clin Pharmacol Ther 1996 Sep;60(3):276–82

PHARMACOLOGY

Modulatory influence of arecoline on the phytic acid–altered hepatic biotransformation system enzymes, sulfhydryl content and lipid peroxidation in a murine system. Singh A, et al. **Cancer Lett** 1997 Jul 15;117(1):1–6

Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. Jones CR, et al. **Neurochem Res** 1997 Jun;22(6):663–70

Conditioning of body temperature and natural killer cell activity with arecoline, a muscarinic cholinergic agonist. Ghanta VK, et al. **Neuroimmunomodulation** 1996 Jul–Aug; 3(4):233–8

Effects of cholinergic drugs on scopolamine–induced memory impairment in rhesus monkeys. Hironaka N, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Jun; 16(3):103–8

Effect of arecoline on the curcumin–modulated hepatic biotransformation system enzymes in lactating mice and translactationally exposed F1 pups. Singh A, et al.
Nutr Cancer 1996;25(1):101–10

Acute and chronic arecoline: effects on a scopolamine–induced deficit in complex maze learning. Bratt AM, et al. **Pharmacol Biochem Behav** 1996 Mar; 53(3):713–21

THERAPEUTIC USE

Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease. Raffaele KC, et al. **Neuropsychopharmacology** 1996 Aug;15(2):163–70

TOXICITY

Postnatal effect of arecoline on chlorophyllin–modulated hepatic biotransformation system enzymes in suckling neonate and lactating mice. Singh A, et al.
Teratog Carcinog Mutagen 1996;16(2):89–96

ARENAVIRIDAE

IMMUNOLOGY

[The dynamics of the formation of IgG subclasses in Balb/c and CBA mice infected with the LCM, Lassa and Mopeia viruses and their role in diagnosis] Zaĭtseva VN, et al.
Zh Mikrobiol Epidemiol Immunobiol 1997 Jan–Feb; (1):47–51 (Eng. Abstr.) **(Rus)**

ARENAVIRIDAE INFECTIONS

DIAGNOSIS

[The dynamics of the formation of IgG subclasses in Balb/c and CBA mice infected with the LCM, Lassa and Mopeia viruses and their role in diagnosis] Zaĭtseva VN, et al.
Zh Mikrobiol Epidemiol Immunobiol 1997 Jan–Feb; (1):47–51 (Eng. Abstr.) **(Rus)**

THERAPY

[Experimental study of the effect of the drug desferal and serum against tumor necrosis factor on the course of the infectious process in arenaviral hemorrhagic fever] Ignat'ev GM, et al. **Antibiot Khimioter** 1996 Feb;41(2):30–4 **(Rus)**

VETERINARY

Experimental reproduction of hypoglycemia–spiking mortality syndrome in broiler chickens with the use of homogenized brains containing arenaviruslike particles. Davis JF, et al. **Avian Dis** 1997 Apr–Jun;41(2):442–6

ARENAVIRUS

DRUG EFFECTS

Inhibition of arenavirus multiplication in vitro by phenotiazines. Candurra NA, et al. **Antiviral Res** 1996 Jul; 31(3):149–58

GENETICS

Characterization of arenaviruses using a family–specific primer set for RT–PCR amplification and RFLP analysis. Its potential use for detection of uncharacterized arenaviruses. Lozano ME, et al. **Virus Res** 1997 May; 49(1):79–89

IMMUNOLOGY

[Development and study of immunoglobulins against Lassa fever] Krasniaskiĭ VP, et al. **Vopr Virusol** 1997 Mar–Apr; 42(2):71–4 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Isolation and characterization of pirital virus, a newly discovered South American arenavirus. Fulhorst CE, et al. **Am J Trop Med Hyg** 1997 May;56(5):548–53

Experimental reproduction of hypoglycemia–spiking mortality syndrome in broiler chickens with the use of homogenized brains containing arenaviruslike particles. Davis JF, et al. **Avian Dis** 1997 Apr–Jun;41(2):442–6

Isolation and characterization of Whitewater Arroyo virus, a novel North American arenavirus. Fulhorst CF, et al. **Virology** 1996 Oct 1;224(1):114–20

Characterization of arenaviruses using a family–specific primer set for RT–PCR amplification and RFLP analysis. Its potential use for detection of uncharacterized arenaviruses. Lozano ME, et al. **Virus Res** 1997 May; 49(1):79–89

METABOLISM

Computational characterisation of potential RNA–binding sites in arenavirus nucleocapsid proteins. Parisi G, et al. **Virus Genes** 1996;13(3):247–54

ARENAVIRUS INFECTIONS see **ARENAVIRIDAE INFECTIONS**

ARGENTAFFIN CELLS see **ENTEROCHROMAFFIN CELLS**

ARGENTAFFIN SYSTEM see **CHROMAFFIN SYSTEM**

ARGENTAFFINOMA see **CARCINOID TUMOR**

ARGINASE

ANALYSIS

Nitric oxide synthase and arginase in cells isolated from the rat gastric mucosa. Byrne CR, et al.
Biochim Biophys Acta 1997 Apr 24;1356(2):131–9

ANTAGONISTS & INHIBITORS

Arginase activity in endothelial cells: inhibition by NG–hydroxy–L–arginine during high–output NO production. Buga GM, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1988–98

Inhibition of arginase in rat and rabbit alveolar macrophages by N omega–hydroxy–D,L–indospicine, effects on L–arginine utilization by nitric oxide synthase. Hey C, et al. **Br J Pharmacol** 1997 Jun;121(3):395–400

Interleukin 1beta–mediated inhibition of arginase in RINm5F cells. Cunningham JM, et al. **Cytokine** 1997 Aug;9(8):570–6

BIOSYNTHESIS

Involvement of protein kinase A in the induction of arginase in murine bone marrow–derived macrophages. Corraliza IM, et al. **Biochim Biophys Acta** 1997 Mar 15; 1334(2–3):123–8

Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage–like cell line. Gotoh T, et al. **FEBS Lett** 1996 Oct 21;395(2–3):119–22

Combinatorial regulation of the Saccharomyces cerevisiae CAR1 (arginase) promoter in response to multiple environmental signals. Smart WC, et al. **Mol Cell Biol** 1996 Oct;16(10):5876–87

BLOOD

Arginine deficiency in bile duct–ligated rats after surgery: the role of plasma arginase and gut endotoxin restriction. Houdijk AP, et al. **Gastroenterology** 1997 Oct; 113(4):1375–83

CHEMISTRY

Altering the binuclear manganese cluster of arginase diminishes thermostability and catalytic function. Scolnick LR, et al. **Biochemistry** 1997 Aug 26;36(34):10558–65

EXAFS comparison of the dimanganese core structures of manganese catalase, arginase, and manganese–substituted ribonucleotide reductase and hemerythrin. Stemmler TL, et al. **Biochemistry** 1997 Aug 12;36(32):9847–58

Molecular cloning and sequence analysis of the cDNA for the mouse counterpart to adult hamster liver purified growth inhibitory factor. Hashimoto C, et al.
Biochim Biophys Acta 1997 Mar 1;1355(3):205–8

Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage–like cell line. Gotoh T, et al. **FEBS Lett** 1996 Oct 21;395(2–3):119–22

Structure of a unique binuclear manganese cluster in arginase. Kanyo ZF, et al. **Nature** 1996 Oct 10;383(6600):554–7

DEFICIENCY

Congenital glaucoma associated with an arginase deficit: a case report. Saccà SC, et al. **Eur J Ophthalmol** 1996 Oct–Dec;6(4):421–6

Hyperargininemia presenting as persistent neonatal jaundice and hepatic cirrhosis. Braga AC, et al.
J Pediatr Gastroenterol Nutr 1997 Feb;24(2):218–21

[Proposal for a diet treatment in arginase deficiency (letter)] Sebag O, et al. **Arch Pediatr** 1997 Jul;4(7):687 **(Fre)**

GENETICS

Chromosomal localization of the human arginase II gene and tissue distribution of its mRNA. Gotoh T, et al.
Biochem Biophys Res Commun 1997 Apr 17;233(2):487–91

Loss of function mutations in conserved regions of the human arginase I gene. Vockley JG, et al. **Biochem Mol Med** 1996 Oct;59(1):44–51

Human type II arginase: sequence analysis and tissue–specific expression. Morris SM Jr, et al. **Gene** 1997 Jul 9; 193(2):157–61

Cloning and characterization of the human type II arginase gene. Vockley JG, et al. **Genomics** 1996 Dec 1;38(2):118–23

The glucocorticoid–responsive gene cascade. Activation of the rat arginase gene through induction of C/EBPbeta. Gotoh T, et al. **J Biol Chem** 1997 Feb 7;272(6):3694–8

The cell density factor CMF regulates the chemoattractant receptor cAR1 in Dictyostelium. Van Haastert PJ, et al. **J Cell Biol** 1996 Sep;134(6):1543–9

Combinatorial regulation of the Saccharomyces cerevisiae CAR1 (arginase) promoter in response to multiple environmental signals. Smart WC, et al. **Mol Cell Biol** 1996 Oct;16(10):5876–87

Integration of the multiple controls regulating the expression of the arginase gene CAR1 of Saccharomyces cerevisiae in response to differentnitrogen signals: role of Gln3p, ArgRp–Mcm1p, and Ume6p. Dubois E, et al.
Mol Gen Genet 1997 Feb 20;253(5):568–80

Delivery of cytosolic liver arginase into the mitochondrial matrix space: a possible novel site for gene replacement therapy. Wissmann PB, et al. **Somat Cell Mol Genet** 1996 Nov;22(6):489–98

ISOLATION & PURIFICATION

Arginase of Bacillus brevis Nagano: purification, properties, and implication in gramicidin S biosynthesis. Kanda M, et al. **Arch Biochem Biophys** 1997 Aug 1;344(1):37–42

METABOLISM

Arginase activity in endothelial cells: inhibition by NG–hydroxy–L–arginine during high–output NO production. Buga GM, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1988–98

Arginase of Bacillus brevis Nagano: purification, properties, and implication in gramicidin S biosynthesis. Kanda M, et al. **Arch Biochem Biophys** 1997 Aug 1;344(1):37–42

New type of hexameric ornithine carbamoyltransferase with arginase activity in the cephamycin producers Streptomyces clavuligerus and Nocardia lactamdurans. De la Fuente JL, et al. **Biochem J** 1996 Nov 15;320 (Pt 1):173–9

Evidence for increased anionic arginase activity in pig enterocytes during development. M'Rabet–Touil H, et al.
Biochem Mol Biol Int 1996 Feb;38(1):197–204

Salt sensitivity and arginase activity in Aspergillus nidulans. Attwell NA, et al. **Biochem Soc Trans** 1997 Feb;25(1):98S

Altering the binuclear manganese cluster of arginase diminishes thermostability and catalytic function. Scolnick LR, et al. **Biochemistry** 1997 Aug 26;36(34):10558–65

Alteration in IL–1 and arginase activity of tumor–associated macrophages: a role in the promotion of tumor growth. Parajuli P, et al. **Cancer Lett** 1996 Oct 22;107(2):249–56

Arginase activity determination. A marker of large bowel mucosa proliferation. Kocna P, et al.
Eur J Clin Chem Clin Biochem 1996 Aug;34(8):619–23

Effect of arsenite on urea production by long–term cultures of adult rat hepatocytes. Sierra–Santoyo A, et al.
J Appl Toxicol 1996 Jul–Aug;16(4):281–7

Coinduction of nitric–oxide synthase and arginase I in cultured rat peritoneal macrophages and rat tissues in vivo by lipopolysaccharide. Sonoki T, et al. **J Biol Chem** 1997 Feb 7;272(6):3689–93

PHYSIOLOGY

CAR1, a TNFR–related protein, is a cellular receptor for cytopathic avian leukosis–sarcoma viruses and mediates apoptosis. Brojatsch J, et al. **Cell** 1996 Nov 29;87(5):845–55

ARGININE

Resistance to activated protein C and Arg 506 Gln factor V mutation are uncommon in eastern Asian populations. Kodaira H, et al. **Acta Haematol** 1997;98(1):22–5

D–glyceraldehyde–3–phosphate dehydrogenase. Properties of the enzyme modified at arginine residues. Nagradova NK, et al. **Appl Biochem Biotechnol** 1996 Oct–Nov; 61(1–2):47–56

Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation. Yamada Y, et al. **Biochem Biophys Res Commun** 1997 Jul 30;236(3):772-5

Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. Deloménie C, et al. **Biochem J** 1997 Apr 1; 323 (Pt 1):207-15

Mutation of arginine 121 in lactoferrin destabilizes iron binding by disruption of anion binding: crystal structures of R121S and R121E mutants. Faber HR, et al. **Biochemistry** 1996 Nov 19;35(46):14473-9

Probing the role of positive residues in the ADP/ATP carrier from yeast. The effect of six arginine mutations on transport and the four ATP versus ADP exchange modes. Heidkämper D, et al. **Biochemistry** 1996 Dec 17; 35(50):16144-52

Probing the role of positive residues in the ADP/ATP carrier from yeast. The effect of six arginine mutations of oxidative phosphorylation and AAC expression. Müller V, et al. **Biochemistry** 1996 Dec 17;35(50):16132-43

Chemical rescue by guanidine derivatives of an arginine-substituted site-directed mutant of Escherichia coli ornithine transcarbamylase. Rynkiewicz MJ, et al. **Biochemistry** 1996 Dec 17;35(50):16174-9

Lack of copper insertion into unprocessed cytoplasmic nitrous oxide reductase generated by an R20D substitution in the arginine consensus motif of the signal peptide. Dreusch A, et al. **Biochim Biophys Acta** 1997 Apr 11; 1319(2-3):311-8

Arginine-82 regulates the pKa of the group responsible for the light-driven proton release in bacteriorhodopsin [see comments] Govindjee R, et al. **Biophys J** 1996 Aug; 71(2):1011-23. Comment in: Biophys J 1996 Aug;71(2):541-3.

Corticosteroid usage and binding to arginine: determinants of corticosteroid hypersensitivity. Wilkinson SM, et al. **Br J Dermatol** 1996 Aug;135(2):225-30

X-linked exudative vitreoretinopathy caused by an arginine to leucine substitution (R121L) in the Norrie disease protein. Johnson K, et al. **Clin Genet** 1996 Sep;50(3):113-5

The beta 3-adrenergic receptor gene Trp64Arg mutation is overrepresented in obese women. Effects on weight, BMI, abdominal fat, blood pressure, and reproductive history in an elderly Australian population. Kurabayashi T, et al. **Diabetes** 1996 Oct;45(10):1358-63

No effect of the Trp64Arg beta 3-adrenoceptor variant on in vivo lipolysis in subcutaneous adipose tissue. Snitker S, et al. **Diabetologia** 1997 Jul;40(7):838-42

A plant viral coat protein RNA binding consensus sequence contains a crucial arginine [published erratum appears in EMBO J 1996 Dec 16;15(24):7188-9] Ansel-McKinney P, et al. **EMBO J** 1996 Sep 16;15(18):5077-84

Evidence that Arg-295, Glu-378, and Glu-380 are active-site residues of the ADP-ribosyltransferase activity of iota toxin. Perelle S, et al. **FEBS Lett** 1996 Oct 21; 395(2-3):191-4

Identification by site-directed mutagenesis of three arginines in uncoupling protein that are essential for nucleotide binding and inhibition. Modrianský M, et al. **J Biol Chem** 1997 Oct 3;272(40):24759-62

Alteration of the substrate specificity of the malonyl-CoA/acetyl-CoA:acyl carrier protein S-acyltransferase domain of the multifunctional fatty acid synthase by mutation of a single arginine residue. Rangan VS, et al. **J Biol Chem** 1997 May 2;272(18):11975-8

Arginine 210 is not a critical residue for the allosteric interactions mediated by binding of cyclic AMP to site A of regulatory (RIalpha) subunit of cyclic AMP-dependent protein kinase. Steinberg RA, et al. **J Biol Chem** 1996 Nov 1;271(44):27630-6

Two basic amino acids in the second inner loop of the interleukin-8 receptor are essential for Galpha16 coupling. Xie W, et al. **J Biol Chem** 1997 Oct 3;272(40):24948-51

The conserved asparagine and arginine are essential for catalysis of mammalian adenylyl cyclase. Yan SZ, et al. **J Biol Chem** 1997 May 9;272(19):12342-9

Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists. Sall DJ, et al. **J Med Chem** 1997 Aug 29; 40(18):2843-57

Crystal structures and solution conformations of a dominant-negative mutant of Escherichia coli maltose-binding protein. Shilton BH, et al. **J Mol Biol** 1996 Nov 29;264(2):364-76

Investigation of the Met-267 Arg exchange in isoform 1 of the human plasma membrane calcium pump in patients with essential hypertension by the amplification-created restriction site technique. Benkwitz C, et al. **J Mol Med** 1997 Jan;75(1):62-6

Site-directed mutagenesis in basic amino acid residues of Saccharomyces cerevisiae phosphoenolpyruvate carboxykinase. Chávez R, et al. **J Protein Chem** 1997 Apr; 16(3):233-6

Possible involvement of double-stranded RNA-activated protein kinase in cell death by influenza virus infection. Takizawa T, et al. **J Virol** 1996 Nov;70(11):8128-32

Use of L-arginine and its analogs to study nitric oxide pathway in humans. Vallance P. **Methods Enzymol** 1996; 269:453-9 (25 ref.)

A cell-associated protein complex of Porphyromonas gingivalis W50 composed of Arg- and Lys-specific cysteine proteinases and adhesins. Bhogal PS, et al. **Microbiology** 1997 Jul;143 (Pt 7):2485-95

Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin. Chiron MF, et al. **Mol Microbiol** 1996 Nov;22(4):769-78

A single-base mutation in exon 31 converting glycine 852 to arginine in the collagenous domain in an Alport syndrome patient. Kawai S, et al. **Nephron** 1996;74(2):333-6

A serine/arginine-rich nuclear matrix cyclophilin interacts with the C-terminal domain of RNA polymerase II. Bourquin JP, et al. **Nucleic Acids Res** 1997 Jun 1; 25(11):2055-61

Oxidative stress changes in L-arginine-induced pancreatitis in rats. Varga IS, et al. **Pancreas** 1997 May;14(4):355-9

A critical arginine residue mediates cooperativity in the contact interface between transcription factors NFAT and AP-1. Peterson BR, et al. **Proc Natl Acad Sci U S A** 1996 Nov 26;93(24):13671-6

Effects of supplemental dietary arginine, canola oil, and trace elements on cellular immune function in critically injured patients. Mendez C, et al. **Shock** 1996 Jul;6(1):7-12

ADMINISTRATION & DOSAGE

Dietary L-arginine supplementation normalizes regional blood flow in Dahl-Iwai salt-sensitive rats. He H, et al. **Am J Hypertens** 1997 May;10(5 Pt 2):89S-93S

Long-term dietary supplementation with L-arginine prevents age-related reduction in renal function. Reckelhoff JF, et al. **Am J Physiol** 1997 Jun;272(6 Pt 2):R1768-74

Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. Khan F, et al. **Arthritis Rheum** 1997 Feb;40(2):352-7

Dietary supplementation with L-arginine: modulation of tumour-infiltrating lymphocytes in patients with colorectal cancer. Heys SD, et al. **Br J Surg** 1997 Feb;84(2):238-41

L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle [see comments] Huk I, et al. **Circulation** 1997 Jul 15;96(2):667-75. Comment in: Circulation 1997 Jul 15;96(2):379-82.

Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilatation in the hypercholesterolemic rabbit. Response according to treatment duration, anatomic site, and sex. Jeremy RW, et al. **Circulation** 1996 Aug 1;94(3):498-506

Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats [see comments] Mitani Y, et al. **Circulation** 1997 Jul 15;96(2):689-97. Comment in: Circulation 1997 Jul 15;96(2):379-82.

Dietary supplementation of nucleotides and arginine promotes healing of small bowel ulcers in experimental ulcerative ileitis. Sukumar P, et al. **Dig Dis Sci** 1997 Jul; 42(7):1530-6

Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat. Adawi D, et al. **Hepatology** 1997 Mar;25(3):642-7

Chronic dietary L-arginine prevents endothelial dysfunction secondary to environmental tobacco smoke in normocholesterolemic rabbits. Hutchison SJ, et al. **Hypertension** 1997 May;29(5):1186-91

Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. Wang BY, et al. **J Am Coll Cardiol** 1996 Nov 15; 28(6):1573-9

Dietary arginine requirement of juvenile yellow perch. Twibell RG, et al. **J Nutr** 1997 Sep;127(9):1838-41

Effects of long-term oral administration of L-arginine on the rat erectile response [see comments] Moody JA, et al. **J Urol** 1997 Sep;158(3 Pt 1):942-7. Comment in: J Urol 1997 Sep;158(3 Pt 1):686.

Arginine-enhanced enteral nutrition augments the growth of a nitric oxide-producing tumor. Edwards PD, et al. **JPEN J Parenter Enteral Nutr** 1997 Jul-Aug;21(4):215-9

Nutritional and metabolic effects and significance of mild orotic aciduria during dietary supplementation with arginine or its organic salts after trauma injury in rats. Jeevanandam M, et al. **Metabolism** 1997 Jul;46(7):785-92

Growth inhibition of subcutaneously transplanted hepatomas by alterations of the dietary arginine-methionine balance. Millis RM, et al. **Nutr Cancer** 1996;25(3):317-27

Clinical outcome and immunology of postoperative arginine, omega-3 fatty acids, and nucleotide-enriched enteral feeding: a randomized prospective comparison with standard enteral and low calorie/low fat i.v. solutions. Schilling J, et al. **Nutrition** 1996 Jun;12(6):423-9

Subcutaneous arginine administration causes apoptosis of rat pancreas [letter] Otani T, et al. **Pancreas** 1997 Apr; 14(3):316-8

Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. Gryglewski RJ, et al. **Wien Klin Wochenschr** 1996;108(4):111-6

[Excess dietary arginine inhibits the development of the food-acquisition habit in white rats] Savel'eva KV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Mar-Apr; 46(2):301-8 (Eng. Abstr.) **(Rus)**

ANALOGS & DERIVATIVES

Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Buga GM, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1988-98

Arginine analogues inhibit responses mediated by ATP-sensitive K+ channels. Kontos HA, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1498-506

Low-molecular-weight displacers for high-resolution protein separations. Kundu A, et al. **Anal Biochem** 1997 May 15;248(1):111-6

High-performance liquid chromatographic determination of nitric oxide synthase-related arginine derivatives in vitro and in vivo. Meyer J, et al. **Anal Biochem** 1997 Apr 5; 247(1):11-6

Increased serum NG-hydroxy-L-arginine in patients with rheumatoid arthritis and systemic lupus erythematosus as an index of an increased nitric oxide synthase activity. Wigand R, et al. **Ann Rheum Dis** 1997 May;56(5):330-2

Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. Shipanova IN, et al. **Arch Biochem Biophys** 1997 Aug 1; 344(1):29-36

Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Horie K, et al. **Biochem Biophys Res Commun** 1997 Jul 18;236(2):327-32

Analysis of neuronal NO synthase under single-turnover conditions: conversion of Nomega-hydroxyarginine to nitric oxide and citrulline. Abu-Soud HM, et al. **Biochemistry** 1997 Sep 9;36(36):10811-6

Identification of N(G)-methylarginine residues in human heterogeneous RNP protein A1: Phe/Gly-Gly-Gly-Arg-Gly-Gly-Gly/Phe is a preferred recognition motif. Kim S, et al. **Biochemistry** 1997 Apr 29;36(17):5185-92

Inhibition of endothelial cell amino acid transport System y+ by arginine analogs that inhibit nitric oxide synthase. McDonald KK, et al. **Biochim Biophys Acta** 1997 Feb 21; 1324(1):133-41

Nitric oxide generation from extracellularly applied NG-hydroxy-L-arginine in LPS-activated RAW 264 macrophages. Vetrovsky P, et al. **Biochim Biophys Acta** 1997 Feb 11;1334(1):51-6

Discrimination between neuropeptide Y and peptide YY in the rat tail artery by the neuropeptide Y1-selective antagonist, BIBP 3226. Gicquiaux H, et al. **Br J Pharmacol** 1996 Dec;119(7):1313-8

The neuropeptide Y (NPY) Y1 receptor antagonist BIBP 3226: equal effects on vascular responses to exogenous and endogenous NPY in the pig in vivo. Malmström RE, et al. **Br J Pharmacol** 1997 Jun;121(3):595-603

Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Takahashi M, et al. **Br J Rheumatol** 1997 Jun;36(6):637-42

Kinetic characterization of rat tissue kallikrein using N alpha-substituted arginine 4-nitroanilides and N alpha-benzoyl-L-arginine ethyl ester as substrates. Sousa MO, et al. **Braz J Med Biol Res** 1996 Mar;29(3):327-34

An arginine analog inhibits responses of both the endothelium and smooth muscle of canine in situ vein grafts. Rhee RY, et al. **Cardiovasc Surg** 1997 Apr;5(2):169-75

Subcellular distribution of soluble and membrane-bound Arg-beta-naphthylamide hydrolyzing activities in the developing and aged rat brain. Arechaga G, et al. **Cell Mol Biol Res** 1995;41(5):369-75

The advanced glycation endproduct pentosidine and monocyte activation in uremia. Friedlander MA, et al. **Clin Nephrol** 1996 Jun;45(6):379-82

Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Hricik DE, et al. **Clin Transplant** 1996 Dec;10(6 Pt 1):568-73

Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats. Odetti P, et al. **Diabetologia** 1996 Dec;39(12):1440-7

Mechanisms mediating the vasodilatory effects of N-hydroxy-L-arginine in coronary arteries. Abdul-Hussain MN, et al. **Eur J Pharmacol** 1996 Jun 3; 305(1-3):155-61

Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam. Kask A, et al. **Eur J Pharmacol** 1996 Dec 19;317(2-3):R3-4

Selective inhibition of neuropeptide Y Y1 receptors by BIBP3226 in rat and human epithelial preparations. Tough IR, et al. **Eur J Pharmacol** 1996 Aug 22;310(1):55-60

A possible role of endogenous inhibitor for nitric oxide synthesis in the bovine ciliary muscle. Azuma H, et al. **Exp Eye Res** 1997 May;64(5):823-30

Accumulation of the endogenous L-arginine analogue NG-monomethyl-L-arginine in human end-stage renal failure patients on regular haemodialysis. Mendes Ribeiro AC, et al. **Exp Physiol** 1996 May;81(3):475-81

Oxidation of N(G)-hydroxyl-L-arginine to nitric oxide mediated by respiratory burst: an alternative pathway to NO synthesis. Modolell M, et al. **FEBS Lett** 1997 Jan 20; 401(2-3):123-6

Imidazolone, a novel advanced glycation end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes. Niwa T, et al. **FEBS Lett** 1997 May 5;407(3):297-302

Asymmetrical dimethylarginine, an endogenous nitric oxide

synthase inhibitor, in experimental hypertension. Matsuoka H, et al. **Hypertension** 1997 Jan;29(1 Pt 2):242–7

Possible mechanism of nitric oxide production from N(G)-hydroxy-L-arginine or hydroxylamine by superoxide ion. Vetrovsky P, et al. **Int J Biochem Cell Biol** 1996 Dec;28(12):1311–8

Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. Miyata T, et al. **J Am Soc Nephrol** 1996 Aug; 7(8):1198–206

Transcriptional regulation and locations of Agrobacterium tumefaciens genes required for complete catabolism of octopine. Cho K, et al. **J Bacteriol** 1997 Jan;179(1):1–8

Influence of nitric oxide on luminol-enhanced chemiluminescence measured from porcine-stimulated leukocytes. Demiryürek AT, et al. **J Cardiovasc Pharmacol** 1997 Sep;30(3):332–7

Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. Jin JS, et al. **J Cardiovasc Pharmacol** 1996 Sep; 28(3):439–46

Contractile effects of neuropeptide Y in human subcutaneous resistance arteries are mediated by Y1 receptors. Nilsson T, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):764–8

Determination of N(G),N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. Chen BM, et al. **J Chromatogr B Biomed Appl** 1997 May 9; 692(2):467–71

Determination of N-nitroso-L-arginine in rat brain extracts by capillary electrophoresis using photodiode-array detection. Meulemans A. **J Chromatogr B Biomed Appl** 1996 Aug 30;683(2):273–5

Determination of dimethylated arginines in human plasma by high-performance liquid chromatography. Pettersson A, et al. **J Chromatogr B Biomed Appl** 1997 May 9; 692(2):257–62

Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. Niwa T, et al. **J Clin Invest** 1997 Mar 15;99(6):1272–80

Age-related association of tail tendon break time with tissue pentosidine in DBA/2 vs C57BL/6 mice: the effect of dietary restriction. Sell DR, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):B277–84

Nitric oxide synthase inhibitors and hypertension in children and adolescents. Goonasekera CD, et al. **J Hypertens** 1997 Aug;15(8):901–9

Synthesis and activity of 6-substituted purine linker amino acid immunostimulants. Zacharie B, et al. **J Med Chem** 1997 Aug 29;40(18):2883–94

Solution structure of the HIV-2 TAR-argininamide complex. Brodsky AS, et al. **J Mol Biol** 1997 Apr 4;267(3):624–39

BIBP 3226, suramin and prazosin identify neuropeptide Y, adenosine 5'-triphosphate and noradrenaline as sympathetic cotransmitters in the rat arterial mesenteric bed. Donoso MV, et al. **J Pharmacol Exp Ther** 1997 Aug;282(2):691–8

Synthetic N omega-hydroxy-L-arginine causes endothelium-dependent vascular relaxation both in vitro and in vivo. Sakamaki T, et al. **J Smooth Muscle Res** 1995 Dec;31(6):439–43

Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Miyata T, et al. **Kidney Int** 1997 Mar;51(3):880–7

Chemistry of N-hydroxy-L-arginine. Fukuto JM. **Methods Enzymol** 1996;268:365–75

Nitric oxide synthase inhibitors: amino acids. Griffith OW, et al. **Methods Enzymol** 1996;268:375–92

The effect of the stringent response on mutation rates in Escherichia coli K-12. Wright BE. **Mol Microbiol** 1996 Jan;19(2):213–9

Encapsulating an amino acid in a DNA fold. Lin CH, et al. **Nat Struct Biol** 1996 Dec;3(12):1046–50

Elevated pentosidine content in amyloid deposits and in insoluble amyloid fibrils from patients with beta 2-microglobulin amyloidosis [letter] Argilés A, et al. **Nephrol Dial Transplant** 1996 Nov;11(11):2371–2

Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. MacAllister RJ, et al. **Nephrol Dial Transplant** 1996 Dec;11(12):2449–52

Acetyl-L-carnitine arginine amide prevents beta 25-35-induced neurotoxicity in cerebellar granule cells. Scorziello A, et al. **Neurochem Res** 1997 Mar;22(3):257–65

Relationship between structure and inhibitory effect of arginine analogues on neuronal nitric oxide synthase activity. Yokoi I, et al. **Neurochem Res** 1996 Oct; 21(10):1187–92

Comparative autoradiographic distribution of neuropeptide Y Y1 receptors visualized with the Y1 receptor agonist [125I][Leu31,Pro34]PYY and the non-peptide antagonist [3H]BIBP3226. Dumont Y, et al. **Neuroreport** 1996 Mar 22;7(4):901–4

The non-peptide neuropeptide Y Y1 receptor antagonist BIBP3226 blocks the [Leu31,Pro34]neuropeptide Y-induced modulation of alpha 2-adrenoceptors in the nucleus tractus solitarii of the rat. Yang SN, et al. **Neuroreport** 1996 Nov 4;7(15-17):2701–5

Inhibition of glutamate reuptake potentiates endogenous nitric oxide-facilitated dopamine efflux in the rat striatum: an in vivo microdialysis study. West AR, et al. **Neurosci Lett** 1997 Jul 11;230(1):21–4

Studies on lactam formation during coupling procedures of N alpha-N omega-protected arginine derivatives. Cezari MH, et al. **Pept Res** 1996 Mar-Apr;9(2):88–91

Effects of the neuropeptide Y (NPY)-receptor antagonist BIBP3226 on vascular NPY-receptors with different ligand requirements. Grundemar L, et al. **Pharmacol Toxicol** 1996 Nov;79(5):266–9

Covalent HLA-B27/peptide complex induced by specific recognition of an aziridine mimic of arginine. Weiss GA, et al. **Proc Natl Acad Sci U S A** 1996 Oct 1;93(20):10945–8

BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: a review of its pharmacological properties. Doods HN, et al. **Regul Pept** 1996 Aug 27;65(1):71–7 (48 ref.)

Suppression of intestinal and hepatic cytochrome P4503A in murine Toxoplasma infection. Effects of N-acetylcysteine and N(G)-monomethyl-L-arginine on the hepatic suppression. Berg-Candolfi M, et al. **Xenobiotica** 1996 Apr;26(4):381–94

[Levels of dimethyl-L-arginine in ultrafiltrate and blood pressure in patients during hemodialysis] Popławski A, et al. **Przegl Lek** 1995;52(9):431–5 (Eng. Abstr.) **(Pol)**

ANALYSIS

Unusual abundance of arginine and ornithine in porcine allantoic fluid. Wu G, et al. **Biol Reprod** 1996 Jun; 54(6):1261–5

High-performance liquid chromatography of alpha-amino acids and aztreonam on reversed phase columns with aqueous Cu2+ as eluent. Khedr A. **Biomed Chromatogr** 1996 Jul-Aug;10(4):167–71

Bismuth hematoxylin stain for arginine residues. Roach JB Jr, et al. **Biotech Histochem** 1997 Jan;72(1):49–54

Arginine and NADPH diaphorase in the rat ventroposterior thalamic nucleus. Kharazia VN, et al. **Brain Res** 1997 Jan 2;744(1):151–5

The utilization of 5-hydroxyl-2-amino valeric acid as a specific marker of oxidized arginine and proline residues in proteins. Ayala A, et al. **Free Radic Biol Med** 1996; 21(1):65–80

Bactericidal activity of a synthetic peptide (CG 117-136) of human lysosomal cathepsin G is dependent on arginine content. Shafer WM, et al. **Infect Immun** 1996 Nov; 64(11):4842–5

Trypanosoma brucei gBP21. An arginine-rich mitochondrial protein that binds to guide RNA with high affinity. Köller J, et al. **J Biol Chem** 1997 Feb 7;272(6):3749–57

Immunohistochemical localization of arginine and citrulline in rat renal tissue. Aoki E, et al. **J Histochem Cytochem** 1997 Jun;45(6):875–81

A glycine-to-arginine substitution in the triple-helical domain of type VII collagen in a family with dominant dystrophic epidermolysis bullosa pruriginosa. Lee JY, et al. **J Invest Dermatol** 1997 Jun;108(6):947–9

[Levels of dimethyl-L-arginine in ultrafiltrate and blood pressure in patients during hemodialysis] Popławski A, et al. **Przegl Lek** 1995;52(9):431–5 (Eng. Abstr.) **(Pol)**

ANTAGONISTS & INHIBITORS

Role of membrane potential in hypoxic inhibition of L-arginine uptake by lung endothelial cells. Zharikov SI, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):L78–84

Mechanisms involved in the effect of nitric oxide synthase inhibition on L-arginine-induced insulin secretion. Gross R, et al. **Br J Pharmacol** 1997 Feb;120(3):495–501

Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm. Dawes M, et al. **Circulation** 1997 May 6; 95(9):2293–7

BIOSYNTHESIS

Enhanced production of arginine and urea by genetically engineered Escherichia coli K-12 strains. Tuchman M, et al. **Appl Environ Microbiol** 1997 Jan;63(1):33–8

Identification of the yeast ARG-11 gene as a mitochondrial ornithine carrier involved in arginine biosynthesis. Palmieri L, et al. **FEBS Lett** 1997 Jun 30;410(2-3):447–51

Isolation and analysis of the arg-13 gene of Neurospora crassa. Liu Q, et al. **Genetics** 1996 Jul;143(3):1163–74

Arginine biosynthesis and regulation in Lactobacillus plantarum: the carA gene and the argCJBDF cluster are divergently transcribed. Bringel F, et al. **J Bacteriol** 1997 Apr;179(8):2697–706

Cloning and characterization of argR, a gene that participates in regulation of arginine biosynthesis and catabolism in Pseudomonas aeruginosa PAO1. Park SM, et al. **J Bacteriol** 1997 Sep;179(17):5300–8

The ARG11 gene of Saccharomyces cerevisiae encodes a mitochondrial integral membrane protein required for arginine biosynthesis. Crabeel M, et al. **J Biol Chem** 1996 Oct 4;271(40):25011–8

Cloning, analysis and one-step disruption of the ARG5,6 gene of Candida albicans. Negredo A, et al. **Microbiology** 1997 Feb;143 (Pt 2):297–302

The arginine operon of Bacillus stearothermophilus: characterization of the control region and its interaction with the heterologous B. subtilis arginine repressor. Savchenko A, et al. **Mol Gen Genet** 1996 Aug 27; 252(1-2):69–78

BLOOD

L-arginine/nitric oxide pathway activation in platelets of migraine patients with and without aura. Gallai V, et al. **Acta Neurol Scand** 1996 Aug;94(2):151–60

Separate and joint effects of arginine and glucose on ovine fetal insulin secretion. Gresores A, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E68–73

High-performance liquid chromatographic assay for the quantitation of L-arginine in human plasma. Gopalakrishnan V, et al. **Anal Chem** 1996 Oct 1; 68(19):3520–3

Variations in the platelet arginine/nitric oxide pathway during the ovarian cycle in females affected by menstrual migraine. Sarchielli P, et al. **Cephalalgia** 1996 Nov; 16(7):468–75

A simple micro-method for determining urea cycle intermediates in blood: ornithine, arginine and argininosuccinic acid. Fujimura Y, et al. **Clin Chim Acta** 1996 Sep 30;253(1-2):1–8

Congenital glaucoma associated with an arginase deficit: a case report. Saccà SC, et al. **Eur J Ophthalmol** 1996 Oct-Dec;6(4):421–6

Accumulation of the endogenous L-arginine analogue NG-monomethyl-L-arginine in human end-stage renal failure patients on regular haemodialysis. Mendes Ribeiro AC, et al. **Exp Physiol** 1996 May;81(3):475–81

Plasma L-arginine concentrations in premature infants with necrotizing enterocolitis. Zamora SA, et al. **J Pediatr** 1997 Aug;131(2):226–32

Hyperargininemia presenting as persistent neonatal jaundice and hepatic cirrhosis. Braga AC, et al. **J Pediatr Gastroenterol Nutr** 1997 Feb;24(2):218–21

Glutamine and arginine metabolism in tumor-bearing rats receiving total parenteral nutrition. Yoshida S, et al. **Metabolism** 1997 Apr;46(4):370–3

CHEMISTRY

Functional and structural role of arginine 103 in human erythropoietin. Grodberg J, et al. **Arch Biochem Biophys** 1996 Sep 15;333(2):427–31

A novel nonenzymatic pathway for the generation of nitric oxide by the reaction of hydrogen peroxide and D- or L-arginine. Nagase S, et al. **Biochem Biophys Res Commun** 1997 Apr 7;233(1):150–3

Interaction of truncated human interferon gamma variants with the interferon gamma receptor: crucial importance of Arg-129. Haelewyn J, et al. **Biochem J** 1997 Jun 1;324 (Pt 2):591–5

The role of betaArg-10 in the B800 bacteriochlorophyll and carotenoid pigment environment within the light-harvesting LH2 complex of Rhodobacter sphaeroides. Fowler GJS, et al. **Biochemistry** 1997 Sep 16; 36(37):11282–91

Substitution of lysine for arginine at position 199 of a hypoxanthine phosphoribosyltransferase interferes with binding of the primary substrate to the active site. Craig SP 3rd, et al. **Biochim Biophys Acta** 1997 Apr 25; 1339(1):1–3

A single amino acid can switch the oligomerization state of the alpha-helical coiled-coil domain of cartilage matrix protein. Beck K, et al. **EMBO J** 1997 Jul 1;16(13):3767–77

Correlated bond rotations in interactions of arginine residues with ligand carboxylate groups in protein ligand complexes. Nieto PM, et al. **FEBS Lett** 1997 Mar 17;405(1):16–20

The role of proline beta 5(A2) in the functional properties of human adult hemoglobin. Baudin V, et al. **Hemoglobin** 1996 Feb;20(1):55–62

Probing structure-activity relationship in diamine oxidase--reactivities of lysine and arginine residues. Shah MA, et al. **Int J Biol Macromol** 1996 Feb;18(1-2):77–81

Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals. Zama T, et al. **Int J Hematol** 1996 Dec; 65(1):71–8

Arginine 200 of heparin cofactor II promotes intramolecular interactions of the acidic domain. Implication for thrombin inhibition. Ciaccia AV, et al. **J Biol Chem** 1997 May 30; 272(22):14074–9

Quantitation of an orally available thrombin inhibitor in rat, monkey and human plasma and in human urine by high-performance liquid chromatography and fluorescent post-column derivatization of arginine. Mendoza CB, et al. **J Chromatogr A** 1997 Feb 21;762(1-2):299–310

How amino acids control the binding of Cu(II) ions to DNA (II): effect of basic amino acid residues and the chirality on the orientation of the complexes. Chikira M, et al. **J Inorg Biochem** 1997 May 1;66(2):131–9

NMR pulse schemes for the sequential assignment of arginine side-chain H epsilon protons. Rao NS, et al. **J Magn Reson B** 1996 Dec;113(3):272–6

Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties. Semple JE, et al. **J Med Chem** 1996 Nov 8;39(23):4531–6

High-level misincorporation of lysine for arginine at AGA codons in a fusion protein expressed in Escherichia coli. Calderone TL, et al. **J Mol Biol** 1996 Oct 4;262(4):407–12

Synthesis and antibacterial action of cecropin and proline-arginine-rich peptides from pig intestine. Vunnam

S, et al. **J Pept Res** 1997 Jan;49(1):59–66
Confirmation of the arginine–finger hypothesis for the GAP–stimulated GTP–hydrolysis reaction of Ras [letter] Ahmadian MR, et al. **Nat Struct Biol** 1997 Sep;4(9):686–9
Mass spectrometric structure determination of spider toxins: arginine–containing acylpolyamines from venoms of Brazilian garden spider Nephilengys cruentata. Palma MS, et al. **Nat Toxins** 1997;5(2):47–57
2,3–Butanedione inactivates the [3H]nitrendipine binding sites, whereas diethylpyrocarbonate does not. Costa B, et al. **Neurochem Int** 1996 Dec;29(6):623–7
Specific replacement of consecutive AGG codons results in high–level expression of human cardiac troponin T in Escherichia coli. Hu X, et al. **Protein Expr Purif** 1996 May; 7(3):289–93
Ion pair formation of phosphorylated amino acids and lysine and arginine side chains: a theoretical study. Mavri J, et al. **Proteins** 1996 Apr;24(4):495–501
Polarization–enhanced NMR spectroscopy of biomolecules in frozen solution. Hall DA, et al. **Science** 1997 May 9; 276(5314):930–2
Clinical features in 36 patients homozygous for the ARG 506–>GLN factor V mutation. Emmerich J, et al. **Thromb Haemost** 1997 Apr;77(4):620–3
A novel mutation Gly 1672–>Arg in type 2A and a homozygous mutation in type 2B von Willebrand disease. Hagiwara T, et al. **Thromb Haemost** 1996 Aug;76(2):253–7
Frequency of factor V Arg506 Gln in Italians [letter] [see comments] Mannucci PM, et al. **Thromb Haemost** 1996 Apr;75(4):694. Comment in: Thromb Haemost 1997 Jan;77(1):216–7.
Factor V enhances the cofactor function of protein S in the APC–mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Váradi K, et al. **Thromb Haemost** 1996 Aug;76(2):208–14
[Sequential attachment of arginine residues to peptides catalyzed by subtilisin. II. Effect of the nature of acylating and nucleophilic components and small amounts of water in organic solvents] Iusupova MP, et al. **Bioorg Khim** 1996 Aug;22(8):589–95 (Eng. Abstr.) **(Rus)**

DEFICIENCY

Amino acid profile and nitric oxide pathway in patients on continuous ambulatory peritoneal dialysis: L–arginine depletion in acute peritonitis. Suh H, et al. **Am J Kidney Dis** 1997 May;29(5):712–9
Effects of NO synthase inhibitors, arginine–deficient diet, and amiloride in pregnant rats. Greenberg SS, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1031–45
Arginine deficiency in bile duct–ligated rats after surgery: the role of plasma arginase and gut endotoxin restriction. Houdijk AP, et al. **Gastroenterology** 1997 Oct; 113(4):1375–83
L–arginine deficiency causes suppression of nonadrenergic noncholinergic nerve–mediated smooth muscle relaxation: role of L–citrulline recycling. Chakder S, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):378–84

DIAGNOSTIC USE

L–arginine for testing endothelium–dependent vascular functions in health and disease. Giugliano D, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E606–12
Measurement of NO synthesis in humans by L–[15N2]arginine: application to the response to vaccination. Macallan DC, et al. **Am J Physiol** 1997 Jun; 272(6 Pt 2):R1888–96
Metformin improves hemodynamic and rheological responses to L–arginine in NIDDM patients. Marfella R, et al. **Diabetes Care** 1996 Sep;19(9):934–9
Insulin responses to intravenous glucose, intravenous arginine and a hyperglycaemic clamp in ICA–positive subjects with different degrees of glucose tolerance. Rakotoambinina B, et al. **Diabetes Metab** 1997 Feb;23(1):43–50
Effects of cholinergic blockade by pirenzepine on insulin and glucose response to oral and intravenous glucose and to arginine load in obesity. Maccario M, et al. **J Endocrinol Invest** 1997 Jan;20(1):8–12
[Tolbutamide, glucagon, leucine and arginine tolerance test] Hosaka T, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:423–7 (10 ref.) **(Jpn)**
[Arginine test] Inoue K, et al. **Nippon Rinsho** 1997 Apr;55 Suppl 2:223–4 (5 ref.) **(Jpn)**

GENETICS

Autosomal dominant retinitis pigmentosa with a rhodopsin mutation (Arg–135–Trp). Disease phenotype in a Swedish family. Ponjavic V, et al. **Acta Ophthalmol Scand** 1997 Apr; 75(2):218–23
The invariant ARG91 is required for the rupture of liposomes by cytochrome C. Tuominen EK, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):140–2
Functional interaction of the carboxylic acid group of agonists and the arginine residue of the seventh transmembrane domain of prostaglandin E receptor EP3 subtype. Chang C, et al. **Biochem J** 1997 Mar 1;322 (Pt 2):597–601
Involvement of two basic residues (Lys–270 and Arg–276) of human liver 3 alpha–hydroxysteroid dehydrogenase in NADP(H) binding and activation by sulphobromophthalein: site–directed mutagenesis and kinetic analysis. Matsuura K, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):89–93
Structural analysis of a bovine arginine tRNA(CCG) gene. Eubanks AC, et al. **Biochim Biophys Acta** 1997 May 30; 1352(2):138–44
Construction and characterization of a photosystem II D1 mutant (arginine–269–glycine) of Chlamydomonas reinhardtii. Hutchison RS, et al. **Biochim Biophys Acta** 1996 Nov 12;1277(1–2):83–92
Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene. Nowak–Göttl U, et al. **Blood Coagul Fibrinolysis** 1996 Oct;7(7):684–8
Polymerase chain reaction–based technique for the selective enrichment and analysis of mosaic arg201 mutations in G alpha s from patients with fibrous dysplasia of bone. Candeliere GA, et al. **Bone** 1997 Aug;21(2):201–6
Denaturing gradient–gel electrophoresis screening of familial defective apolipoprotein B–100 in a mixed Asian cohort: two cases of arginine3500–>tryptophan mutation associated with a unique haplotype. Choong ML, et al. **Clin Chem** 1997 Jun;43(6 Pt 1):916–23
Arginine506 to glutamin mutation in the factor V gene in infancy and childhood: evidence of fibrinolytic impairment. Nowak–Göttl U, et al. **Eur J Pediatr** 1997 Mar;156(3):195–8
Genome analysis in Neurospora crassa; cloning of four loci arginine–1 (arg–1), methionine–6 (met–6), unknown–7 (un–7), and ribosome production–1 (rip–1) and associated chromosome walking. Schmidhauser TJ, et al. **Fungal Genet Biol** 1997 Jun;21(3):323–8
The beta3–adrenergic receptor in the obesity and diabetes prone rhesus monkey is very similar to human and contains arginine at codon 64. Walston J, et al. **Gene** 1997 Apr 1; 188(2):207–13
A cluster of missense mutations at Arg356 of human steroid 21–hydroxylase may impair redox partner interaction. Lajic S, et al. **Hum Genet** 1997 Jun;99(6):704–9
Localization of the active site of type II dehydroquinases. Identification of a common arginine–containing motif in the two classes of dehydroquinases. Krell T, et al. **J Biol Chem** 1996 Oct 4;271(40):24492–7
Effects of site–directed mutagenesis of basic residues (Arg 94, Lys 95, Lys 99) of lipopolysaccharide (LPS)–binding protein on binding and transfer of LPS and subsequent immune cell activation. Lamping N, et al. **J Immunol** 1996 Nov 15;157(10):4648–56
Comparative study on the effect of signal peptide codons and arginine codons on the expression of human interferon–alpha 1 gene in Escherichia coli. Saraffova A, et al. **J Interferon Cytokine Res** 1996 Sep;16(9):745–9
Craniosynostosis associated with FGFR3 pro250arg mutation results in a range of clinical presentations including unisutural sporadic craniosynostosis. Reardon W, et al. **J Med Genet** 1997 Aug;34(8):632–6
Mutations of Arg68 of the human chorionic gonadotrophin beta subunit lead to reduced secretion. Shen L, et al. **J Mol Endocrinol** 1996 Dec;17(3):257–62
A racial difference in the prevalence of the Arg506–>Gln mutation. Hooper WC, et al. **Thromb Res** 1996 Mar 1; 81(5):577–81
Identification of a new thyroglobulin variant: a guanine–to–adenine transition resulting in the substitution of arginine 2510 by glutamine. Mendive FM, et al. **Thyroid** 1997 Aug;7(4):587–91

IMMUNOLOGY

Correlation between the amino acid position of arginine in VH–CDR3 and specificity for native DNA among autoimmune antibodies. Krishnan MR, et al. **J Immunol** 1996 Sep 15;157(6):2430–9
HLA–B27 (B*2701) specificity for peptides lacking Arg2 is determined by polymorphism outside the B pocket. García F, et al. **Tissue Antigens** 1997 Jun;49(6):580–7

METABOLISM

Immunobiology of picolinic acid. Melillo G, et al. **Adv Exp Med Biol** 1996;398:135–41 (43 ref.)
L–arginine metabolism in immune–mediated glomerulonephritis in the rat. Ketteler M, et al. **Am J Kidney Dis** 1996 Dec;28(6):878–87
Enhanced metabolism of arginine and glutamine in enterocytes of cortisol–treated pigs. Flynn NE, et al. **Am J Physiol** 1997 Mar;272(3 Pt 1):G474–80
An important role for endogenous synthesis of arginine in maintaining arginine homeostasis in neonatal pigs. Flynn NE, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1149–55
Differential regulation of macrophage arginine metabolism: a proposed role in wound healing. Shearer JD, et al. **Am J Physiol** 1997 Feb;272(2 Pt 1):E181–90
Synthesis of citrulline and arginine from proline in enterocytes of postnatal pigs. Wu G. **Am J Physiol** 1997 Jun;272(6 Pt 1):G1382–90
Arginine degradation in developing porcine enterocytes. Wu G, et al. **Am J Physiol** 1996 Nov;271(5 Pt 1):G913–9
Quantitative aspects of interorgan relationships among arginine and citrulline metabolism. Yu YM, et al. **Am J Physiol** 1996 Dec;271(6 Pt 1):E1098–109
Increased L–arginine transport in a nitric oxide–producing metastatic colon cancer cell line. Cendan JC, et al. **Ann Surg Oncol** 1996 Sep;3(5):501–8
Activation of the L–arginine nitric oxide pathway in severe sepsis. Duke T, et al. **Arch Dis Child** 1997 Mar;76(3):203–9
Citrulline–argininosuccinate–arginine cycle coupled to Ca2+–signaling in rat pancreatic beta–cells. Nakata M, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):619–24
Essential arginine residues in isoprenylcysteine protein carboxyl methyltransferase. Boivin D, et al. **Biochem Cell Biol** 1997;75(1):63–9
Delineation of the arginine– and tetrahydrobiopterin–binding sites of neuronal nitric oxide synthase. Boyhan A, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):131–9
Cell–surface ADP–ribosylation of fibroblast growth factor–2 by an arginine–specific ADP–ribosyltransferase. Jones EM, et al. **Biochem J** 1997 Apr 1;323 (Pt 1):173–7
Multiple components of arginine and phenylalanine transport induced in neutral and basic amino acid transporter–cRNA–injected Xenopus oocytes. Peter GJ, et al. **Biochem J** 1996 Sep 15;318 (Pt 3):915–22
Mutation of Arg154 to Gly154 in urokinase augments its fibrin–specificity. Peng G, et al. **Biochem Mol Biol Int** 1997 Apr;41(5):887–94
Agonist–regulated L–arginine uptake in human platelets. Evidence against intracellular utilization of the amino acid. Vasta V, et al. **Biochem Mol Biol Int** 1996 Apr;38(5):911–9
P2 purinoceptor–stimulated conversion of arginine to citrulline in bovine endothelial cells is reduced by inhibition of protein kinase C. Brown CA, et al. **Biochem Pharmacol** 1996 Dec 24;52(12):1849–54
Arginine metabolism in keratinocytes and macrophages during nitric oxide biosynthesis: multiple modes of action of nitric oxide synthase inhibitors. DeGeorge GL, et al. **Biochem Pharmacol** 1997 Jul 1;54(1):103–12
Metabolism of arginine to citrulline by rat gastric mucosal cells. Byrne CR, et al. **Biochem Soc Trans** 1996 Aug; 24(3):480S
Evidence for murine macrophage nitric oxide synthesis in the absence of exogenous L–arginine. Murphy C, et al. **Biochem Soc Trans** 1996 Aug;24(3):463S
Catabolism of arginine and ornithine in perfused rat liver; localisation and regulation. O'Sullivan D, et al. **Biochem Soc Trans** 1996 Aug;24(3):488S
Mutagenesis of acidic residues in the oxygenase domain of inducible nitric–oxide synthase identifies a glutamate involved in arginine binding. Gachhui R, et al. **Biochemistry** 1997 Apr 29;36(17):5097–103
The 9–arginine residue of alpha–conotoxin GI is responsible for its selective high affinity for the alphagamma agonist site on the electric organ acetylcholine receptor. Hann RM, et al. **Biochemistry** 1997 Jul 22;36(29):9051–6
Peptide, disulfide, and glycosylation mapping of recombinant human thrombopoietin from ser1 to Arg246. Hoffman RC, et al. **Biochemistry** 1996 Nov 26;35(47):14849–61
Phosphatidylinositol–specific phospholipase C: kinetic and stereochemical evidence for an interaction between arginine–69 and the phosphate group of phosphatidylinositol. Hondal RJ, et al. **Biochemistry** 1997 Jun 3;36(22):6633–42
Thermodynamics of oligoarginines binding to RNA and DNA. Mascotti DP, et al. **Biochemistry** 1997 Jun 10; 36(23):7272–9
Evidence for a specific interaction of vitronectin with arginine: effects of reducing agents on the expression of functional domains and immunoepitopes. Seiffert D, et al. **Biochimie** 1997 Apr;79(4):205–10
Catalytic cleavage of vasopressin by human Bence Jones proteins at the arginylglycinamide bond. Matsuura K, et al. **Biol Chem** 1996 Sep;377(9):587–9
Inhibition of arginase in rat and rabbit alveolar macrophages by N omega–hydroxy–D,L–indospicine, effects on L–arginine utilization by nitric oxide synthase. Hey C, et al. **Br J Pharmacol** 1997 Jun;121(3):395–400
Arginine–481 mutation abolishes ligand–binding of the AMPA–selective glutamate receptor channel alpha1–subunit. Kawamoto S, et al. **Brain Res Mol Brain Res** 1997 Jul;47(1–2):339–44
Derangements of the nitric oxide synthase pathway, L–arginine, and cardiovascular diseases [editorial; comment] Cooke JP, et al. **Circulation** 1997 Jul 15; 96(2):379–82 (37 ref.). Comment on: Circulation 1997 Jul 15;96(2):667–75. Comment on: Circulation 1997 Jul 15;96(2):689–97.
Defective L–arginine–nitric oxide pathway in offspring of essential hypertensive patients. Taddei S, et al. **Circulation** 1996 Sep 15;94(6):1298–303
Transport of L–arginine and the nitric oxide inhibitor NG–monomethyl–L–arginine in human erythrocytes in chronic renal failure. Mendes Ribeiro AC, et al. **Clin Sci (Colch)** 1997 Jul;93(1):57–64
Restoration of vascular endothelial function in diabetes. Pieper GM, et al. **Diabetes Res Clin Pract** 1996 Jul;31 Suppl:S157–62
Crystal structure and mechanism of human L–arginine:glycine amidinotransferase: a mitochondrial enzyme involved in creatine biosynthesis. Humm A, et al. **EMBO J** 1997 Jun;16(12):3373–85
Specific arginine and threonine residues control anion binding and transport in the light–driven chloride pump halorhodopsin. Rüdiger M, et al. **EMBO J** 1997 Jul 1; 16(13):3813–21
Arginine aminoacylation identity is context–dependent and ensured by alternate recognition sets in the anticodon loop of accepting tRNA transcripts. Sissler M, et al. **EMBO J** 1996 Sep 16;15(18):5069–76
cDNA cloning, recombinant expression, and site–directed

mutagenesis of bovine liver carnitine octanoyltransferase--Arg505 binds the carboxylate group of carnitine. Cronin CN. **Eur J Biochem** 1997 Aug 1; 247(3):1029–37

The biochemical effect of the naturally occurring Trp64-->Arg mutation on human beta3-adrenoceptor activity. Piétri-Rouxel F, et al. **Eur J Biochem** 1997 Aug 1;247(3):1174–9

Structure/function relationship study of Tyr14 and Arg22 in trichosanthin, a ribosome-inactivating protein. Shaw PC, et al. **Eur J Biochem** 1997 Apr 15;245(2):423–7

Involvement of the L-arginine-nitric oxide pathway in hyperglycaemia-induced coronary artery dysfunction of isolated guinea pig hearts. Wascher TC, et al. **Eur J Clin Invest** 1996 Aug;26(8):707–12

Modulation of vascular tone by low density lipoproteins: effects on L-arginine transport and nitric oxide synthesis. Jay MT, et al. **Exp Physiol** 1997 Mar;82(2):349–60 (60 ref.)

On the unidirectionality of arginine uptake in the yeast Saccharomyces cerevisiae. Opekarová M, et al. **FEMS Microbiol Lett** 1997 Jul 15;152(2):261–7

The importance of L-arginine metabolism in melanoma: an hypothesis for the role of nitric oxide and polyamines in tumor angiogenesis. Joshi M. **Free Radic Biol Med** 1997; 22(3):573–8 (63 ref.)

Identification of four amino acids in the gastrin-releasing peptide receptor that are required for high affinity agonist binding. Akeson M, et al. **J Biol Chem** 1997 Jul 11; 272(28):17405–9

SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors. Colwill K, et al. **J Biol Chem** 1996 Oct 4;271(40):24569–75

Role of the Arg123-Tyr166 paired helix of apolipoprotein A-I in lecithin:cholesterol acyltransferase activation. Dhoest A, et al. **J Biol Chem** 1997 Jun 20;272(25):15967–72

Mutation of a highly conserved arginine in motif IV of Escherichia coli DNA helicase II results in an ATP-binding defect. Hall MC, et al. **J Biol Chem** 1997 Jul 25;272(30):18614–20

Glutamic acid 207 in rodent T-cell RT6 antigens is essential for arginine-specific ADP-ribosylation. Hara N, et al. **J Biol Chem** 1996 Nov 22;271(47):29552–5

Identification of arginyl residues located at the ATP binding site of sarcoplasmic reticulum Ca2+-ATPase. Modification with 1,2-cyclohexanedione. Kimura K, et al. **J Biol Chem** 1996 Nov 15;271(46):28933–41

Specificity for activase is changed by a Pro-89 to Arg substitution in the large subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase. Larson EM, et al. **J Biol Chem** 1997 Jul 4;272(27):17033–7

Role of arginine 132 and lysine 133 in heparin binding to and activation of antithrombin. Meagher JL, et al. **J Biol Chem** 1996 Nov 15;271(46):29353–8

Heparin-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity. Pike RN, et al. **J Biol Chem** 1997 Aug 8;272(32):19652–5

Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-arginine transport. Simmons WW, et al. **J Biol Chem** 1996 Sep 27; 271(39):23928–37

Induced nitric oxide synthesis is dependent on induced alternatively spliced CAT-2 encoding L-arginine transport in brain astrocytes. Stevens BR, et al. **J Biol Chem** 1996 Sep 27;271(39):24017–22

Active-site Arg --> Lys substitutions alter reaction and substrate specificity of aspartate aminotransferase. Vacca RA, et al. **J Biol Chem** 1997 Aug 29;272(35):21932–7

Arginine-specific regulation mediated by the Neurospora crassa arg-2 upstream open reading frame in a homologous, cell-free in vitro translation system. Wang Z, et al. **J Biol Chem** 1997 Jan 3;272(1):255–61

Morphologic evidence for L-citrulline conversion to L-arginine via the argininosuccinate pathway in porcine cerebral perivascular nerves. Yu JG, et al. **J Cereb Blood Flow Metab** 1997 Aug;17(8):884–93

Differential localization of putative amino acid receptors in taste buds of the channel catfish, Ictalurus punctatus. Finger TE, et al. **J Comp Neurol** 1996 Sep 9;373(1):129–38

Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). Jiang XM, et al. **J Immunol Methods** 1996 Nov 29;199(1):55–9

Comparison of five methods for the determination of arginine hydrolysis by viridans streptococci. West PW, et al. **J Med Microbiol** 1996 Dec;45(6):501–4

Glucocorticoids play an important role in mediating the enhanced metabolism of arginine and glutamine in enterocytes of postweaning pigs. Flynn NE, et al. **J Nutr** 1997 May;127(5):732–7

Diabetes and insulin-induced stimulation of L-arginine transport and nitric oxide synthesis in rabbit isolated gastric glands. Contreras R, et al. **J Physiol (Lond)** 1997 Feb 1; 498 (Pt 3):787–96

Arginine metabolism in cat kidney. Levillain O, et al. **J Physiol (Lond)** 1996 Mar 1;491 (Pt 2):471–7

Electrogenic arginine transport mediates stimulus-secretion coupling in mouse pancreatic beta-cells. Smith PA, et al. **J Physiol (Lond)** 1997 Mar 15;499 (Pt 3):625–35

Activation of A2-purinoceptors by adenosine stimulates L-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells. Sobrevia L, et al. **J Physiol (Lond)** 1997 Feb 15;499 (Pt 1):135–40

Altered wound arginine metabolism by corticosterone and retinoic acid. Ulland AE, et al. **J Surg Res** 1997 Jun; 70(1):84–8

Elution and reconcentration of coliphages in water from positively charged membrane filters with urea-arginine phosphate buffer. Jothikumar N, et al. **J Virol Methods** 1997 May;65(2):281–6

Biochemical heterogeneity of arginine metabolism along kidney proximal tubules. Morel F, et al. **Kidney Int** 1996 Jun;49(6):1608–10 (14 ref.)

Comparison of the inhibitory effect of isothiourea and mercapto-alkylguanidine derivatives on the alternative pathways of arginine metabolism in macrophages. Hrabák A, et al. **Life Sci** 1997;60(26):PL395–401

Distribution and disappearance of the radiolabeled carbon derived from L-arginine and taurine in the mouse. Lubec B, et al. **Life Sci** 1997;60(26):2373–81

Contrasting effects of thioacetamide-induced liver damage on the brain uptake indices of ornithine, arginine and lysine: modulation by treatment with ornithine aspartate. Albrecht J, et al. **Metab Brain Dis** 1996 Sep;11(3):229–37

Impairment of osteoblast growth by nitric oxide synthase inhibitors: an effect independent of nitric oxide and arginine transport inhibition. Riancho JA, et al. **Methods Find Exp Clin Pharmacol** 1996 Dec;18(10):663–7

Arginine-, hypoxanthine-, uracil-requiring isolates of Neisseria gonorrhoeae are a clonal lineage with a non-clonal population. Gutjahr TS, et al. **Microbiology** 1997 Feb;143 (Pt 2):633–40

Escherichia coli LT enterotoxin subunit A demonstrates partial toxicity independent of the nicking around Arg192. Tsuji T, et al. **Microbiology** 1997 Jun;143 (Pt 6):1797–804

The contribution of the arginine dihydrolase pathway to energy metabolism by Trichomonas vaginalis. Yarlett N, et al. **Mol Biochem Parasitol** 1996 Jun;78(1–2):117–25

Tumour effect on arginine/ornithine metabolic relationship in hypertrophic mouse kidney. Manteuffel-Cymborowska M, et al. **Mol Cell Biochem** 1997 Mar;168(1–2):51–7

Role of arginine-43 and arginine-69 of the Hin recombinase catalytic domain in the binding of Hin to the hix DNA recombination sites. Adams CW, et al. **Mol Microbiol** 1997 Jun;24(6):1235–47

Role of the transcriptional activator RocR in the arginine-degradation pathway of Bacillus subtilis. Gardan R, et al. **Mol Microbiol** 1997 May;24(4):825–37

Adherence of Porphyromonas gingivalis to matrix proteins via a fimbrial cryptic receptor exposed by its own arginine-specific protease. Kontani M, et al. **Mol Microbiol** 1997 Jun;24(6):1179–87

Nitric oxide precursor arginine and S-nitrosoglutathione in synaptic and glial function. Do KQ, et al. **Neurochem Int** 1996 Sep;29(3):213–24 (94 ref.)

Oxidative stress alters arginine metabolism in rat brain: effect of sub-convulsive hyperbaric oxygen exposure. Ito T, et al. **Neurochem Int** 1996 Aug;29(2):187–95

The characteristics of arginine transport by rat cerebellar and cortical synaptosomes. Aldridge CR, et al. **Neurochem Res** 1996 Dec;21(12):1539–46

Posttranslational arginylation of brain proteins. Hallak ME, et al. **Neurochem Res** 1997 Apr;22(4):467–73 (32 ref.)

[3H]L-arginine transport and nitric oxide synthase activity in foetal hypothalamic cultures. Wayte J, et al. **Neuroreport** 1996 Dec 20;8(1):267–71

Arginine and ornithine decarboxylation in rodent brain: coincidental changes during development and after ischemia. Gilad GM, et al. **Neurosci Lett** 1996 Sep 20; 216(1):33–6

Arginine-related guanidino compounds and nitric oxide synthase in the brain of ornithine transcarbamylase deficient spf mutant mouse: effect of metabolic arginine deficiency. Ratnakumari L, et al. **Neurosci Lett** 1996 Sep 13; 215(3):153–6

Zinc protoporphyrin IX suppresses nitric oxide production through a loss of L-arginine in rat cerebellar slices. Okada D. **Neurosci Res** 1996 Aug;25(4):353–8

Mechanism of DNA transesterification by vaccinia topoisomerase: catalytic contributions of essential residues Arg-130, Gly-132, Tyr-136 and Lys-167. Wittschieben J, et al. **Nucleic Acids Res** 1997 Aug 1;25(15):3001–8

Selective induction of a cationic amino acid transporter by tumor necrosis factor-alpha in vascular endothelium. Durante W, et al. **Proc Assoc Am Physicians** 1996 Sep; 108(5):356–61

Whole body nitric oxide synthesis in healthy men determined from [15N] arginine-to-[15N]citrulline labeling. Castillo L, et al. **Proc Natl Acad Sci U S A** 1996 Oct 15;93(21):11460–5

Effects of cell cycle specific exposure to 3H-thymidine or 3H-arginine on development and cell proliferation of mouse embryos. Müller WU, et al. **Radiat Environ Biophys** 1996 Nov;35(4):267–71

Crossroads of L-arginine/arachidonate metabolism. Gryglewski RJ, et al. **Thromb Haemost** 1997 Jul;78(1):191–4

Effect of L-arginine on in vitro plasmin-generation and fibrinogenolysis. Udvardy M, et al. **Thromb Res** 1997 Jul 1;87(1):75–82

[The L-arginine-nitric oxide system: physiology, physiopathology and clinical relevance] Garini G, et al. **Recenti Prog Med** 1997 Feb;88(2):90–9 (74 ref.) (Eng. Abstr.) **(Ita)**

[Arginine-specific ADP-ribosylation reaction in eukaryotic cells] Tsuchiya M. **Seikagaku** 1996 Sep;68(9):1538–42 (15 ref.) **(Jpn)**

[Activity of basic arginine- and lysine-residue cleaving carboxypeptidase in rats of various ages] Vernigora AN, et al. **Biokhimiia** 1996 Oct;61(10):1848–56 (Eng. Abstr.) **(Rus)**

[Sequential attachment of arginine residues to peptides, catalyzed by subtilisin. 1. Effect of organic solvent composition] Iusupova MP, et al. **Bioorg Khim** 1996 Jul; 22(7):523–7 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Role of membrane potential in hypoxic inhibition of L-arginine uptake by lung endothelial cells. Zharikov SI, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):L78–84

Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. Fornasini G, et al. **Chirality** 1997;9(3):297–302

Biphasic L-arginine uptake by the isolated guinea-pig heart. Kostić MM, et al. **Exp Physiol** 1995 Nov;80(6):969–79

Portacaval shunting and hyperammonemia stimulate the uptake of L-[3H] arginine but not of L-[3H]nitroarginine into rat brain synaptosomes. Rao VL, et al. **J Neurochem** 1997 Jan;68(1):337–43

Norepinephrine suppresses L-arginine uptake in rat glial cells. Feinstein DL, et al. **Neurosci Lett** 1997 Feb 14; 223(1):37–40

PHARMACOLOGY

Role of L-arginine in preventing myocardial and endothelial injury following ischaemia/reperfusion in the rat isolated heart. Li XS, et al. **Acta Physiol Scand** 1996 Jan; 156(1):37–44

L-arginine reverses indomethacin-induced inhibition of inflammatory fluid secretion of the feline gall bladder. Nilsson B, et al. **Acta Physiol Scand** 1997 Jun;160(2):195–6

Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Ceremuzyński L, et al. **Am J Cardiol** 1997 Aug 1;80(3):331–3

Effects of L-arginine infusion on renal hemodynamics and sodium excretion during hypo-, normo-, and hyperinsulinemia, as studied in dogs. García-Robles R, et al. **Am J Hypertens** 1996 Jul;9(7):681–6

L-arginine reverses the adverse pregnancy changes induced by nitric oxide synthase inhibition in the rat. Helmbrecht GD, et al. **Am J Obstet Gynecol** 1996 Oct;175(4 Pt 1):800–5

L-arginine augments nitric oxide production and mesenteric blood flow in ovine endotoxemia. Allman KG, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1296–301

Role of nitric oxide in vasodilator response induced by salbutamol in rat diaphragmatic microcirculation. Chang HY. **Am J Physiol** 1997 May;272(5 Pt 2):H2173–9

L-arginine for testing endothelium-dependent vascular functions in health and disease. Giugliano D, et al. **Am J Physiol** 1997 Sep;273(3 Pt 1):E606–12

Regional blood flow in Dahl-Iwai salt-sensitive rats and the effects of dietary L-arginine supplementation. Tomohiro A, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1013–9

Effect of L-arginine on myoglobin-induced acute renal failure in the rabbit. Wakabayashi Y, et al. **Am J Physiol** 1996 May;270(5 Pt 2):F784–9

Comparison of the effect of different inhibitors of the non-enzymatic glycation of rat tail tendons and bovine serum albumin. Menzel EJ, et al. **Ann Clin Biochem** 1996 May;33 (Pt 3):241–8

L-arginine prevents cyclosporin A-induced pulmonary vascular dysfunction. Mathieu P, et al. **Ann Thorac Surg** 1997 Aug;64(2):414–20

L-arginine administration during reperfusion improves pulmonary function. Shiraishi Y, et al. **Ann Thorac Surg** 1996 Dec;62(6):1580–6; discussion 1586–7

Reduction of neutrophil margination by L-arginine during hypothermic cardiopulmonary bypass in a pig model. Dewanjee MK, et al. **ASAIO J** 1996 Sep-Oct;42(5):M661–6

Insulin secretagogues with an imidazoline structure inhibit arginine-induced secretion from isolated glucagon secretion from isolated rat islets of Langerhans. Mourtada M, et al. **Biochem Biophys Res Commun** 1997 Jul 9; 236(1):162–6

Vascular effects of L-arginine: anything beyond a substrate for the NO-synthase? Wascher TC, et al. **Biochem Biophys Res Commun** 1997 May 8;234(1):35–8

Mechanisms of action of cationic amino acids on insulin-secreting BRIN-BD11 cells. McClenaghan NH, et al. **Biochem Soc Trans** 1997 Feb;25(1):144S

Inhibition of endothelial cell amino acid transport System y+ by arginine analogs that inhibit nitric oxide synthase. McDonald KK, et al. **Biochim Biophys Acta** 1997 Feb 21; 1324(1):133–41

Stimulation of nitric oxide-cyclic GMP pathway by L-arginine increases the release of hepatic lipase from cultured rat hepatocytes. Morita T, et al. **Biol Pharm Bull** 1996 Oct;19(10):1371–3

Role of endogenous angiotensin II in renal hemodynamic and excretory responses to L-arginine infusion. Urabe K, et al. **Biol Pharm Bull** 1996 Sep;19(9):1149–53

A thromboelastography study on the in vitro effects of L-arginine and L-NG-nitro arginine methyl ester on human whole blood coagulation and fibrinolysis. Dambisya YM, et al. **Blood Coagul Fibrinolysis** 1996 Oct;7(7):678–83

Interaction of the islet nitric oxide system with

L-arginine-induced secretion of insulin and glucagon in mice. Akesson B, et al. **Br J Pharmacol** 1996 Oct; 119(4):758–64

N(G)-nitro-L-arginine reverses L-arginine induced changes in morphine antinociception and distribution of morphine in brain regions and spinal cord of the mouse. Bhargava HN, et al. **Brain Res** 1997 Feb 28;749(2):351–3

L-arginine ameliorates recirculation and metabolic derangement in brain ischemia in hypertensive rats. Sadoshima S, et al. **Brain Res** 1997 Jan 9;744(2):246–52

Characteristics of coronary endothelial dysfunction in experimental diabetes. Koltai MZ, et al. **Cardiovasc Res** 1997 Apr;34(1):157–63

L-arginine does not reverse impaired agonist-induced increases in macromolecular efflux during diabetes mellitus. Mayhan WG. **Cardiovasc Res** 1997 Apr;34(1):215–22

L-Arginine inhibits neutrophil adherence and coronary artery dysfunction. Sato H, et al. **Cardiovasc Res** 1996 Jan; 31(1):63–72

Long-term oral administration of L-arginine enhances endothelium-dependent vasorelaxation and inhibits neointimal thickening after endothelial denudation in rats. Wu Z, et al. **Chin Med J (Engl)** 1996 Aug;109(8):592–8

L-arginine reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules [see comments] Adams MR, et al. **Circulation** 1997 Feb 4;95(3):662–8. Comment in: Circulation 1997 Feb 4;95(3):553–4.

L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice [see comments] Aji W, et al. **Circulation** 1997 Jan 21;95(2):430–7 . Comment in: Circulation 1997 Jan 21;95(2):311–2.

Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Giugliano D, et al. **Circulation** 1997 Apr 1;95(7):1783–90

Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Schwarzacher SP, et al. **Circulation** 1997 Apr 1;95(7):1863–9

Effects of L-arginine and N omega-nitro-L-arginine methyl ester on cardiac perfusion and function after 1-day cold preservation of isolated hearts. Stowe DF, et al. **Circulation** 1997 Mar 18;95(6):1623–34

Involvement of nitric oxide in arginine, but not glucose, induced insulin secretion in normal men. Coiro V, et al. **Clin Endocrinol (Oxf)** 1997 Jan;46(1):115–9

Urinary NO3- excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-name in rats. Boger RH, et al. **Clin Exp Pharmacol Physiol** 1996 Jan;23(1):11–5

N-nitro-L-arginine and indomethacin do not affect endothelin-induced constriction of large and small coronary arteries in the anaesthetized greyhound. Woodman OL, et al. **Clin Exp Pharmacol Physiol** 1996 Jan; 23(1):50–6

Depressor effect of L-arginine in normotensive patients on regular dialysis treatment [letter] Nakayama M, et al. **Clin Nephrol** 1996 Oct;46(4):286

Dose-related effect of intravenous L-arginine on muscular blood flow of the calf in patients with peripheral vascular disease: a H215O positron emission tomography study. Schellong SM, et al. **Clin Sci (Colch)** 1997 Aug;93(2):159–65

Haemodynamic and biochemical responses to L-arginine and L-lysine infusions in normal subjects: L-arginine-induced vasodilatation cannot be explained by non-specific effects of cationic amino acids. Smulders RA, et al. **Clin Sci (Colch)** 1997 Apr;92(4):367–74

Arginine, glutamine, and dehydroepiandrosterone reverse the immunosuppressive effect of prednisone during gut-derived sepsis [see comments] Gennari R, et al. **Crit Care Med** 1997 Jul;25(7):1207–14. Comment in: Crit Care Med 1997 Jul;25(7):1110–1.

Nitric oxide and ocular blood flow in patients with IDDM. Schmetterer L, et al. **Diabetes** 1997 Apr;46(4):653–8

Mechanisms of arginine-induced increase in cytosolic calcium concentration in the beta-cell line NIT-1. Weinhaus AJ, et al. **Diabetologia** 1997 Apr;40(4):374–82

In vivo, ex vivo, and in vitro effects of L-NAME and L-arginine on the metabolism of theophylline in the rabbit. Barakat M, et al. **Drug Metab Dispos** 1997 Feb;25(2):191–5

L-arginine is unlikely to exert neuroendocrine effects in humans via the generation of nitric oxide [see comments] Korbonits M, et al. **Eur J Endocrinol** 1996 Nov; 135(5):543–7. Comment in: Eur J Endocrinol 1996 Nov;135(5):533–4.

Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity. Maccario M, et al. **Eur J Endocrinol** 1996 Aug; 135(2):205–10

Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. Valetto MR, et al. **Eur J Endocrinol** 1996 Nov;135(5):568–72

Reactive oxygen species-induced impairment of endothelium-dependent relaxation in rat aortic rings: protection by L-arginine. Gumusel B, et al. **Eur J Pharmacol** 1996 Jun 13;306(1-3):107–12

Arginine-aspartate and haloperidol-induced neurobehavioral effects in the rat. Patacchioli FR, et al. **Eur J Pharmacol** 1996 Mar 28;299(1-3):29–32

Short-term oral administration of L-arginine reverses defective endothelium-dependent relaxation and cGMP generation in diabetes. Pieper GM, et al. **Eur J Pharmacol** 1996 Dec 19;317(2-3):317–20

An unexpected interaction between NG-nitro-L-arginine methyl ester and L-arginine in alpha-naphthylthiourea-induced pulmonary oedema in rats. Sipahi E, et al. **Eur J Pharmacol** 1997 Feb 19; 321(1):45–51

Neuromuscular facilitation and blockade induced by L-arginine and nitric oxide in the rat isolated diaphragm. Ambiel CR, et al. **Gen Pharmacol** 1997 May;28(5):789–94

Influence of opiate tolerance and calcium channel antagonists on the antinociceptive effects of L-arginine and NG-nitro L-arginine. Contreras E, et al. **Gen Pharmacol** 1997 Mar; 28(3):443–8

Role of endogenous nitric oxide in the control of exocrine and endocrine pancreatic secretion in humans. Konturek JW, et al. **Gut** 1997 Jan;40(1):86–91

L-Arginine, nitric oxide, and intestinal secretion: studies in rat jejunum in vivo. Mourad FH, et al. **Gut** 1996 Oct; 39(4):539–44

L-arginine in low concentration improves rat intestinal water and sodium absorption from oral rehydration solutions. Wapnir RA, et al. **Gut** 1997 May;40(5):602–7

The effects of modulation of the L-arginine-nitric oxide pathway on myocardial stunning following repetitive coronary occlusion in dogs. Morishima N. **Hiroshima J Med Sci** 1995 Dec;44(4):119–27

Immunoreactive growth hormone-releasing hormone (IR-GHRH) in the feto-placental circulation and differential effects of L-dopa, L-arginine and somatostatin-14 on the plasma levels of IR-GHRH in normal adults. Saito H, et al. **Horm Metab Res** 1997 Apr; 29(4):184–9

Relationship between insulin resistance and endothelium-dependent vascular relaxation in patients with essential hypertension. Higashi Y, et al. **Hypertension** 1997 Jan;29(1 Pt 2):280–5

Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension. Böger RH, et al. **Int J Clin Pharmacol Ther** 1996 Aug;34(8):323–8

Effect of L-arginine on reactivity of hamster cheek pouch arterioles during diabetes mellitus. Mayhan WG, et al. **Int J Microcirc Clin Exp** 1997 May-Jun;17(3):107–12

Acute effect of amino acid ingestion and resistance exercise on plasma growth hormone concentration in young men. Suminski RR, et al. **Int J Sport Nutr** 1997 Mar;7(1):48–60

Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. Adams MR, et al. **J Am Coll Cardiol** 1997 Mar 1;29(3):491–7

Aging-associated endothelial dysfunction in humans is reversed by L-arginine. Chauhan A, et al. **J Am Coll Cardiol** 1996 Dec;28(7):1796–804

Myocardial contractile effects of L-arginine in the human allograft. Paulus WJ, et al. **J Am Coll Cardiol** 1997 May; 29(6):1332–8

Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. Wolf A, et al. **J Am Coll Cardiol** 1997 Mar 1;29(3):479–85

Arginine-induced pancreatic hormone secretion during exercise in rats. Trabelsi F, et al. **J Appl Physiol** 1996 Dec; 81(6):2528–33

Characterization of the membrane conductance changes underlying the apamin-resistant NANC inhibitory junction potential in the guinea-pig proximal and distal colon. Watson MJ, et al. **J Auton Nerv Syst** 1996 Aug 27; 60(1-2):31–42

The ferrous-dioxy complex of neuronal nitric oxide synthase. Divergent effects of L-arginine and tetrahydrobiopterin on its stability. Abu-Soud HM, et al. **J Biol Chem** 1997 Jul 11;272(28):17349–53

Effects of in vivo and in vitro L-arginine supplementation on healthy human vessels. Chin-Dusting JP, et al. **J Cardiovasc Pharmacol** 1996 Jul;28(1):158–66

L-arginine enhances functional recovery and Ca(2+)-dependent nitric oxide synthase activity after ischemia and reperfusion in the rat heart. Wang QD, et al. **J Cardiovasc Pharmacol** 1997 Feb;29(2):291–6

L-arginine does not improve cortical perfusion or histopathological outcome in spontaneously hypertensive rats subjected to distal middle cerebral artery photothrombotic occlusion. Prado R, et al. **J Cereb Blood Flow Metab** 1996 Jul;16(4):612–22

L-arginine infusion increases basal but not activated cerebral blood flow in humans. Reutens DC, et al. **J Cereb Blood Flow Metab** 1997 Mar;17(3):309–15

The vascular effects of L-Arginine in humans. The role of endogenous insulin. Giugliano D, et al. **J Clin Invest** 1997 Feb 1;99(3):433–8

Insulin and the arginine paradox [editorial] Kurz S, et al. **J Clin Invest** 1997 Feb 1;99(3):369–70

Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). Ye S, et al. **J Clin Invest** 1997 Feb 1;99(3):540–8

Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity. Maccario M, et al. **J Endocrinol Invest** 1996 Apr;19(4):219–23

Arginine is not responsible for the activation of nitric oxide synthase by garlic. Das I, et al. **J Ethnopharmacol** 1996 Jul 26;53(1):5–9

Control of Trypanosoma cruzi epimastigote motility through the nitric oxide pathway. Pereira C, et al. **J Eukaryot Microbiol** 1997 Mar-Apr;44(2):155–6

Role of L-arginine, a substrate for nitric oxide-synthase, in gastroprotection and ulcer healing. Brzozowski T, et al. **J Gastroenterol** 1997 Aug;32(4):442–52

Enhanced nitric oxide production induced by the administration of L-arginine does not inhibit arterial neointimal formation after overwhelming alloimmune injury. Gregory CR, et al. **J Heart Lung Transplant** 1996 Jan;15(1 Pt 1):58–66

NO-mediated vasodilation in the rat liver. Role of hepatocytes and liver endothelial cells. Zhang B, et al. **J Hepatol** 1997 Jun;26(6):1348–55

L-arginine supplementation improves venous endothelial cell but not smooth muscle cell dysfunction induced by prolonged diet-induced hypercholesterolemia. Davies MG, et al. **J Invest Surg** 1996 Nov-Dec;9(6):415–22

L-Arginine infusion after ischaemia-reperfusion of rat kidney enhances lipid peroxidation. Cristol JP, et al. **J Lipid Mediat Cell Signal** 1996 Jan;13(1):9–17

Arginine-modulated receptor-activated calcium influx via a NO/cyclic GMP pathway in human SK-N-SH neuroblastoma cells. Liu PS, et al. **J Neurochem** 1997 Jan; 68(1):376–82

Opposite effects of L-arginine and nitroglycerin on cerebral blood velocity: nitric oxide precursors and cerebral blood velocity. Micieli G, et al. **J Neurol Sci** 1997 Sep 1; 150(1):71–5

Intrathecal infusion of the nitric oxide synthase inhibitor N-methyl L-arginine after experimental spinal cord injury in guinea pigs. Cohen TI, et al. **J Neurotrauma** 1996 Jul; 13(7):361–9

Effects of phenylalanine, histidine, and leucine on basal and GHRH-stimulated GH secretion and on PRL, insulin, and glucose levels in short children. Comparison with the effects of arginine. Bellone J, et al. **J Pediatr Endocrinol Metab** 1996 Sep-Oct;9(5):523–31

The effect of arginine supplementation on growth hormone release and intestinal mucosal growth after massive small bowel resection in growing rats. Hebiguchi T, et al. **J Pediatr Surg** 1997 Aug;32(8):1149–53

L-arginine infusion reduces preterm uterine contractions. Facchinetti F, et al. **J Perinat Med** 1996;24(3):283–5

Mechanism of attenuation of morphine antinociception by chronic treatment with L-arginine. Bhargava HN, et al. **J Pharmacol Exp Ther** 1997 May;281(2):707–12

Mechanisms for stimulation of rat anterior pituitary cells by arginine and other amino acids. Villalobos C, et al. **J Physiol (Lond)** 1997 Jul 15;502 (Pt 2):421–31

Role of exogenous L-arginine in hepatic ischemia-reperfusion injury. Shiraishi M, et al. **J Surg Res** 1997 May;69(2):429–34

Effects of L-arginine supplementation on human lymphocyte proliferation in response to nonspecific and alloantigenic stimulation. Wiebke EA, et al. **J Surg Res** 1997 Jun; 70(1):89–94

This month in investigative urology. L-arginine and penile erection [comment] Melman A. **J Urol** 1997 Sep;158(3 Pt 1):686. Comment on: J Urol 1997 Sep;158(3 Pt 1):942–7.

L-arginine increases exercise-induced vasodilation of the forearm in patients with heart failure. Kubota T, et al. **Jpn Circ J** 1997 Jun;61(6):471–80

Aging abolishes the renal response to L-arginine infusion in essential hypertension. Campo C, et al. **Kidney Int Suppl** 1996 Jun;55:S126–8

Coronary stenosis dilatation induced by L-arginine [letter] Tousoulis D, et al. **Lancet** 1997 Jun 21;349(9068):1812–3

L-arginine but not D-arginine stimulates insulin-mediated glucose uptake. Paolisso G, et al. **Metabolism** 1997 Sep; 46(9):1068–73

Nitric oxide synthase inhibitors: amino acids. Griffith OW, et al. **Methods Enzymol** 1996;268:375–92

The role of the aspartate-arginine-tyrosine triad in the m1 muscarinic receptor: mutations of aspartate 122 and tyrosine 124 decrease receptor expression but do not abolish signaling. Lu ZL, et al. **Mol Pharmacol** 1997 Feb; 51(2):234–41

L-arginine reverses the antinatriuretic effect of cyclosporin in renal transplant patients. Andrés A, et al. **Nephrol Dial Transplant** 1997 Jul;12(7):1437–40

Arginine reduces kidney collagen accumulation, cross-linking, lipid peroxidation, glycoxidation, kidney weight and albuminuria in the diabetic kk mouse. Lubec B, et al. **Nephron** 1997;75(2):213–8

Effect of L-arginine and NG-nitro-L-arginine on delayed neuronal death in the gerbil hippocampus. Nakagomi T, et al. **Neurol Res** 1997 Aug;19(4):426–30

Haloperidol inhibits neuronal nitric oxide synthase activity by preventing electron transfer. Iwahashi K, et al. **Neuropsychobiology** 1996;33(2):76–9

Glutamate uptake is inhibited by L-arginine in mitochondria isolated from rat cerebrum. Dolińska M, et al. **Neuroreport** 1997 Jul 7;8(9-10):2365–8

An unusual effect of application of the amino acid L-arginine on cat visual cortical cells. Rivadulla C, et al. **Neuroreport** 1997 Mar 3;8(4):863–6

Intrabulbar infusions of (+/-)S-nitroso-N-acetylpenicillamine and L-arginine induce functional plasticity in the accessory olfactory bulb of female mice. Okere CO, et al. **Neurosci Lett** 1996 Oct 18;217(2-3):197–9

ARGININE

L-arginine potentiates GABA-mediated synaptic transmission by a nitric oxide-independent mechanism in rat dopamine neurons. Shen KZ, et al. **Neuroscience** 1997 Aug;79(3):649–58

Citrulline and arginine increase the growth of the Ward colon tumor in parenterally fed rats. Grossie VB Jr. **Nutr Cancer** 1996;26(1):91–7

A parenteral nutrition regimen with ornithine substituted for arginine alters the amino acid, but not polyamine, content of the ward colon tumor. Grossie VB Jr, et al. **Nutr Cancer** 1997;27(1):102–6

Distinct effects of N omega-nitro-L-arginine on seizures induced by several drugs in mice. Hara S, et al. **Pharmacol Biochem Behav** 1996 Mar;53(3):673–7

Effect of arginine administration on plasma and brain levels of arginine and various related amino compounds in the rat. Buchmann I, et al. **Pharmacology** 1996 Sep;53(3):133–42

Influence of dietary lysine levels and arginine:lysine ratios on performance of broilers exposed to heat or cold stress during the period of three to six weeks of age. Mendes AA, et al. **Poult Sci** 1997 Mar;76(3):472–81

Cardio-pulmonary function during acute unilateral occlusion of the pulmonary artery in broilers fed diets containing normal or high levels of arginine-HCl. Wideman RF Jr, et al. **Poult Sci** 1996 Dec;75(12):1587–602

Protective effect of L-arginine on liver ischemia-reperfusion injury. Ferraresso M, et al. **Transplant Proc** 1997 Feb–Mar; 29(1–2):393–4

Oral arginine restores endothelium-dependent vasodilation in cyclosporine treated rats. Prieto M, et al. **Transplant Proc** 1997 Feb–Mar;29(1–2):1244–5

L-Arginine and allopurinol protect against cyclosporine nephrotoxicity. Assis SM, et al. **Transplantation** 1997 Apr 27;63(8):1070–3

Improvement of cardiac output and liver blood flow and reduction of pulmonary vascular resistance by intravenous infusion of L-arginine during the early reperfusion period in pig liver transplantation. Längle F, et al. **Transplantation** 1997 May 15;63(9):1225–33

Effect of supplemental L-arginine in a chemical-induced model of colorectal cancer. Ma Q, et al. **World J Surg** 1996 Oct;20(8):1087–91

[Reducing perfusion damage after heart transplantation with the nitric oxide donor L-arginine] Szabó G, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1997;114:7–10 (Eng. Abstr.) **(Ger)**

[Cardiovascular effects of arginine and nitric oxide] Faintuch J, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Nov–Dec; 50(6):334–8 (28 ref.) (Eng. Abstr.) **(Por)**

[The effect of L-arginine on the NADPH-diaphorase activity in Drosophila melanogaster homogenates] Oparina TI, et al. **Zh Evol Biokhim Fiziol** 1996 Mar–Apr;32(2):217–9 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Cardiovascular regulation by L-arginine in the brain of rats: role of the brain renin-angiotensin system and nitric oxide. Nishimura M, et al. **Am J Hypertens** 1997 Apr;10(4 Pt 1):389–96

The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Böger RH, et al. **Atherosclerosis** 1996 Nov 15;127(1):1–11 (120 ref.)

The invariant ARG91 is required for the rupture of liposomes by cytochrome C. Tuominen EK, et al. **Biochem Biophys Res Commun** 1997 Sep 8;238(1):140–2

Highly conserved residue arginine-15 is required for the Ca2+-dependent properties of the gamma-carboxyglutamic acid domain of human anticoagulation protein C and activated protein C. Thariath A, et al. **Biochem J** 1997 Feb 15;322 (Pt 1):309–15

Influence of Arginines 93, 97, and 101 of thrombin to its functional specificity. He X, et al. **Biochemistry** 1997 Jul 22;36(29):8969–76

Role of Arg-277 in the binding of pyridoxal 5'-phosphate to Trypanosoma brucei ornithine decarboxylase. Osterman AL, et al. **Biochemistry** 1997 Apr 15;36(15):4558–67

The crystal structure of Citrobacter freundii tyrosine phenol-lyase complexed with 3-(4'-hydroxyphenyl)propionic acid, together with site-directed mutagenesis and kinetic analysis, demonstrates that arginine 381 is required for substrate specificity. Sundararaju B, et al. **Biochemistry** 1997 May 27; 36(21):6502–10

Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors. Gourlet P, et al. **Biochim Biophys Acta** 1996 Dec 12;1314(3):267–73

Arginine: new and exciting developments for an "old" amino acid. Beaumier L, et al. **Biomed Environ Sci** 1996 Sep; 9(2–3):296–315 (73 ref.)

Ligustrazine-induced endothelium-dependent relaxation in pulmonary arteries via an NO-mediated and exogenous L-arginine-dependent mechanism. Peng W, et al. **Br J Pharmacol** 1996 Nov;119(5):1063–71

Anticonvulsant effects of 7-nitroindazole in rodents with reflex epilepsy may result from L-arginine accumulation or a reduction in nitric oxide or L-citrulline formation. Smith SE, et al. **Br J Pharmacol** 1996 Sep;119(1):165–73

Effect of endogenous L-arginine on the measurement of nitric oxide synthase activity in the rat kidney. Moridani BA, et al. **Can J Physiol Pharmacol** 1996 Nov;74(11):1210–4

Clinical significance of L-arginine--nitric oxide system. Das UN. **J Assoc Physicians India** 1995 Feb;43(2):122–6 (65 ref.)

Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease. Riddell DR, et al. **J Biol Chem** 1997 Jan 3; 272(1):89–95

Angiotensin II and L-arginine in tissue fibrosis: more than blood pressure. Peters H, et al. **Kidney Int** 1997 May; 51(5):1481–6 (63 ref.)

Arginine: NO more than a simple aminoacid? Chowienczyk P, et al. **Lancet** 1997 Sep 27;350(9082):901–2

Ribosome stalling is responsible for arginine-specific translational attenuation in Neurospora crassa. Wang Z, et al. **Mol Cell Biol** 1997 Sep;17(9):4904–13

A common export pathway for proteins binding complex redox cofactors? Berks BC. **Mol Microbiol** 1996 Nov; 22(3):393–404 (90 ref.)

Arginine 52 and histidine 54 located in a conserved amino-terminal hydrophobic region (LX2-R52-G-H54-X3-V-L) are important amino acids for the functional and structural integrity of the human liver UDP-glucuronosyltransferase UGT1*6. Senay C, et al. **Mol Pharmacol** 1997 Mar;51(3):406–13

Assessment of bovine mononuclear phagocytes and neutrophils for induced L-arginine-dependent nitric oxide production. Goff WL, et al. **Vet Immunol Immunopathol** 1996 Dec;55(1–3):45–62

[Pathogenetic aspects of the L-arginine-NO metabolic pathway in arteriosclerosis and possible therapeutic aspects] Böger RH, et al. **Vasa** 1996;25(4):305–16 (107 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Adams MR, et al. **Atherosclerosis** 1997 Mar 21;129(2):261–9

Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Böger RH, et al. **Circulation** 1997 Aug 19;96(4):1282–90

Arginine: a new therapy for atherosclerosis? [editorial; comment] Cooke JP, et al. **Circulation** 1997 Jan 21; 95(2):311–2 (23 ref.). Comment on: Circulation 1997 Jan 21;95(2):430–7.

Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure [see comments] Rector TS, et al. **Circulation** 1996 Jun 15; 93(12):2135–41. Comment in: Circulation 1997 Mar 18;95(6):1674–5.

Early postoperative enteral immunonutrition: clinical outcome and cost-comparison analysis in surgical patients. Senkal M, et al. **Crit Care Med** 1997 Sep;25(9):1489–96

Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM. Contreras I, et al. **Diabetes Care** 1997 May;20(5):832–5

L-Arginine reduces lipid peroxidation in patients with diabetes mellitus. Lubec B, et al. **Free Radic Biol Med** 1997; 22(1–2):355–7

Prophylactic administration of L-arginine improves the intestinal barrier function after mesenteric ischaemia. Schleiffer R, et al. **Gut** 1996 Aug;39(2):194–8

Maturation of the regulation of growth hormone secretion in young males with hypogonadotropic hypogonadism pharmacologically exposed to progressive increments in serum testosterone. Giustina A, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1210–9

L-arginine prevents heart transplant arteriosclerosis by modulating the vascular cell proliferative response to insulin-like growth factor-I and interleukin-6. Lou H, et al. **J Heart Lung Transplant** 1996 Dec;15(12):1248–57

Killing of Leishmania donovani amastigotes by poly ICLC in hamsters. Bhakuni V, et al. **J Interferon Cytokine Res** 1996 Apr;16(4):321–5

L-arginine and superoxide dismutase prevent or reverse cerebral hypoperfusion after fluid-percussion traumatic brain injury. DeWitt DS, et al. **J Neurotrauma** 1997 Apr; 14(4):223–33

Improvement in interstitial cystitis symptom scores during treatment with oral L-arginine [see comments] Smith SD, et al. **J Urol** 1997 Sep;158(3 Pt 1):703–8. Comment in: J Urol 1997 Sep;158(3 Pt 1):794.

Oral arginine supplementation in acute liver injury. Adawi D, et al. **Nutrition** 1996 Jul–Aug;12(7–8):529–33

Dietary L-arginine in renal disease. Peters H, et al. **Semin Nephrol** 1996 Nov;16(6):567–75 (64 ref.)

Intravenous arginine dramatically improved hyperammonemia in a patient with late-onset ornithine transcarbamylase deficiency. Kodama H, et al. **Tohoku J Exp Med** 1996 Sep;180(1):83–6

[Protective and treated effects of L-arginine on hypoxia-induced pulmonary hypertension in rats] Cheng D, et al. **Hua Hsi I Ko Ta Hsueh Hsueh Pao** 1996 Mar; 27(1):68–70 (Eng. Abstr.) **(Chi)**

URINE

Lysinuric protein intolerance with thymic hypoplasia. Hasanoğlu A, et al. **J Inherit Metab Dis** 1996;19(3):372–3

ARGININE CARBOXYPEPTIDASE see **LYSINE CARBOXYPEPTIDASE**

ARGININE KINASE

CHEMISTRY

Purification, characterization, and hydrodynamic properties of arginine kinase from gulf shrimp (Penaeus aztecus). France RM, et al. **Arch Biochem Biophys** 1997 Sep 1; 345(1):73–8

Evolution of phosphagen kinase V. cDNA-derived amino acid sequences of two molluscan arginine kinases from the chiton Liolophura japonica and the turbanshell Battilus cornutus. Suzuki T, et al. **Biochim Biophys Acta** 1997 Jun 20;1340(1):1–6

Conformational changes of arginine kinase induced by photochemical release of nucleotides from caged nucleotides--an infrared difference-spectroscopy investigation. Raimbault C, et al. **Eur J Biochem** 1997 Mar 1;244(2):343–51

Expression, purification from inclusion bodies, and crystal characterization of a transition state analog complex of arginine kinase: a model for studying phosphagen kinases. Zhou G, et al. **Protein Sci** 1997 Feb;6(2):444–9

GENETICS

Evolution of phosphagen kinase V. cDNA-derived amino acid sequences of two molluscan arginine kinases from the chiton Liolophura japonica and the turbanshell Battilus cornutus. Suzuki T, et al. **Biochim Biophys Acta** 1997 Jun 20;1340(1):1–6

Expression of horseshoe crab arginine kinase in Escherichia coli and site-directed mutations of the reactive cysteine peptide. Strong SJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Apr; 113(4):809–16

ISOLATION & PURIFICATION

Purification, characterization, and hydrodynamic properties of arginine kinase from gulf shrimp (Penaeus aztecus). France RM, et al. **Arch Biochem Biophys** 1997 Sep 1; 345(1):73–8

METABOLISM

Mitotic phosphorylation of the lamin B receptor by a serine/arginine kinase and p34(cdc2). Nikolakaki E, et al. **J Biol Chem** 1997 Mar 7;272(10):6208–13

ARGININE OXYTOCIN see **VASOTOCIN**

ARGININE-SPECIFIC TRNA see **RNA, TRANSFER, ARG**

ARGININE VASOPRESSIN see **ARGIPRESSIN**

ARGININE VASOTOCIN see **VASOTOCIN**

ARGININOSUCCINASE see **ARGININOSUCCINATE LYASE**

ARGININOSUCCINATE LYASE

ANALYSIS

Argininosuccinate synthetase and argininosuccinate lyase are localized around mitochondria: an immunocytochemical study. Cohen NS, et al. **J Cell Biochem** 1996 Mar 1; 60(3):334–40

BIOSYNTHESIS

Citrulline-argininosuccinate-arginine cycle coupled to Ca2+-signaling in rat pancreatic beta-cells. Nakata M, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):619–24

Induction of astrocyte argininosuccinate synthetase and argininosuccinate lyase by dibutyryl cyclic AMP and dexamethasone. Jackson MJ, et al. **Neurochem Res** 1996 Oct;21(10):1161–5

BLOOD

Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Sarich TC, et al. **Arch Toxicol** 1996;70(12):835–40

CHEMISTRY

Human argininosuccinate lyase: a structural basis for intragenic complementation. Turner MA, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9063–8

DEFICIENCY

Pregnancy and argininosuccinic aciduria. Worthington S, et al. **J Inherit Metab Dis** 1996;19(5):621–3

Use of amniotic fluid amino acids in prenatal testing for argininosuccinic aciduria and citrullinaemia. Mandell R, et al. **Prenat Diagn** 1996 May;16(5):419–24

GENETICS

Intragenic complementation at the human argininosuccinate lyase locus. Identification of the major complementing alleles. Walker DC, et al. **J Biol Chem** 1997 Mar 7; 272(10):6777–83

Human argininosuccinate lyase: a structural basis for

intragenic complementation. Turner MA, et al. **Proc Natl Acad Sci U S A** 1997 Aug 19;94(17):9063–8

METABOLISM

Morphologic evidence for L-citrulline conversion to L-arginine via the argininosuccinate pathway in porcine cerebral perivascular nerves. Yu JG, et al. **J Cereb Blood Flow Metab** 1997 Aug;17(8):884–93

PHYSIOLOGY

Ornithine cycle in Nostoc PCC 73102: presence of an in vitro functional argininosuccinate lyase. Troshina O, et al. **FEMS Microbiol Lett** 1997 Jul 1;152(1):75–81

ARGININOSUCCINATE SYNTHETASE

ANALYSIS

Presence of argininosuccinate synthetase in glial cells as revealed by peptide-specific antisera. Schmidlin A, et al. **Biol Chem** 1997 Jan;378(1):47–50

Argininosuccinate synthetase and argininosuccinate lyase are localized around mitochondria: an immunocytochemical study. Cohen NS, et al. **J Cell Biochem** 1996 Mar 1; 60(3):334–40

BIOSYNTHESIS

Citrulline–argininosuccinate–arginine cycle coupled to Ca2+–signaling in rat pancreatic beta-cells. Nakata M, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):619–24

Argininosuccinate synthetase overexpression in vascular smooth muscle cells potentiates immunostimulant-induced NO production. Xie L, et al. **J Biol Chem** 1997 Jun 27; 272(26):16624–30

Induction of astrocyte argininosuccinate synthetase and argininosuccinate lyase by dibutyryl cyclic AMP and dexamethasone. Jackson MJ, et al. **Neurochem Res** 1996 Oct;21(10):1161–5

DEFICIENCY

Mutations and DNA diagnoses of classical citrullinemia. Kakinoki H, et al. **Hum Mutat** 1997;9(3):250–9

Case report: recurrent hyperammonaemic encephalopathy due to citrullinaemia in a 52 year old man. Chow WC, et al. **J Gastroenterol Hepatol** 1996 Jul;11(7):621–5

Use of amniotic fluid amino acids in prenatal testing for argininosuccinic aciduria and citrullinaemia. Mandell R, et al. **Prenat Diagn** 1996 May;16(5):419–24

Complete neurological recovery of an adult patient with type II citrullinemia after living related partial liver transplantation. Yazaki M, et al. **Transplantation** 1996 Dec 15;62(11):1679–84

GENETICS

Long-chain fatty acids suppress the induction of urea cycle enzyme genes by glucocorticoid action. Tomomura M, et al. **FEBS Lett** 1996 Dec 16;399(3):310–2

Mutations and DNA diagnoses of classical citrullinemia. Kakinoki H, et al. **Hum Mutat** 1997;9(3):250–9

METABOLISM

Hypoxia inhibits the induction of argininosuccinate synthetase by endotoxin in lung endothelial cells. Su Y, et al. **Am J Physiol** 1997 May;272(5 Pt 1):L934–8

Morphologic evidence for L-citrulline conversion to L-arginine via the argininosuccinate pathway in porcine cerebral perivascular nerves. Yu JG, et al. **J Cereb Blood Flow Metab** 1997 Aug;17(8):884–93

ARGININOSUCCINIC ACID

ANALYSIS

Use of amniotic fluid amino acids in prenatal testing for argininosuccinic aciduria and citrullinaemia. Mandell R, et al. **Prenat Diagn** 1996 May;16(5):419–24

Gestational age-related reference values for amniotic fluid amino acids: a useful tool for prenatal diagnosis of aminoacidopathies. Rabier D, et al. **Prenat Diagn** 1996 Jul; 16(7):623–8

BLOOD

A simple micro-method for determining urea cycle intermediates in blood: ornithine, arginine and argininosuccinic acid. Fujimura Y, et al. **Clin Chim Acta** 1996 Sep 30;253(1–2):1–8

METABOLISM

Citrulline–argininosuccinate–arginine cycle coupled to Ca2+–signaling in rat pancreatic beta-cells. Nakata M, et al. **Biochem Biophys Res Commun** 1997 Jun 27; 235(3):619–24

Synthesis of guanidinosuccinate from argininosuccinate and reactive oxygen in vitro. Aoyagi K, et al. **Enzyme Protein** 1996;49(4):199–204

Role of reactive oxygen and argininosuccinate in guanidinosuccinate synthesis in isolated rat hepatocytes. Aoyagi K, et al. **Enzyme Protein** 1996;49(4):205–11

URINE

Pregnancy and argininosuccinic aciduria. Worthington S, et al. **J Inherit Metab Dis** 1996;19(5):621–3

ARGIPRESSIN

Proconvulsive effect of vasopressin; mediation by a putative V2 receptor subtype in the central nervous system. Croiset G, et al. **Brain Res** 1997 Jun 6;759(1):18–23

ADMINISTRATION & DOSAGE

Heterogeneous vascular response to vasopressin: radial artery versus forearm blood flow. Hayoz D, et al. **J Hypertens** 1997 Jan;15(1):35–41

Effects of arginine vasopressin and 1-desamino-8-D arginine vasopressin on forearm vasculature of healthy subjects and patients with a V2 receptor defect. van Lieburg AF, et al. **J Hypertens** 1995 Dec;13(12 Pt 2):1695–700

Idazoxan and the effect of intracerebroventricular oxytocin or vasopressin on sodium intake of sodium-depleted rats. Sato MA, et al. **Regul Pept** 1997 Apr 30;69(3):137–42

AGONISTS

Noradrenaline activates vasopressin neurons via alpha1-receptor-mediated Ca2+ signaling pathway. Shioda S, et al. **Neurosci Lett** 1997 May 2;226(3):210–2

ANALOGS & DERIVATIVES

Vasopressin and V1-receptor antagonists modulate the activity of NTS neurons receiving baroreceptor input. Hegarty AA, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R143–52

No. 302, a newly synthesized [pGlu4,Cyt6]AVP(4–9) analogue, prevents the disruption of avoidance behavior. Hirate K, et al. **Behav Brain Res** 1997 Feb;83(1–2):205–8

Fluorescence study of neurohypophyseal hormones and their analogues. Distance distributions in a series of arginine-vasopressin analogues. Wiczk W, et al. **Eur Biophys J** 1997;26(2):183–93

Effect of luminal vasopressin on NaCl transport in the medullary thick ascending limb of the rat. Grider J, et al. **Eur J Pharmacol** 1996 Oct 10;313(1–2):115–8

Arginine vasopressin receptor antagonists for treatment of vasogenic brain edema: an experimental study. Kagawa M, et al. **J Neurotrauma** 1996 May;13(5):273–9

Influence of L-naphthylalanine in position 3 of AVP and its analogues on their pharmacological properties. Lammek B, et al. **J Pept Res** 1997 Mar;49(3):261–8

An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin. Manning M, et al. **J Pept Sci** 1995 Jan–Feb; 1(1):66–79

Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists. Manning M, et al. **J Pept Sci** 1997 Jan–Feb;3(1):31–46

Surprising pharmacological activity of analogues designed by substitution of position 3 in arginine vasopressin (AVP) and 8-D-arginine vasopressin with L-2-napthylalanine. Lammek B, et al. **J Pharm Pharmacol** 1996 Mar;48(3):316–9

Effects of [arginine8, glycine-OH9]-vasopressin on pentylenetetrazol seizures in mice. Interaction with adrenaline. Lambadjieva ND, et al. **Methods Find Exp Clin Pharmacol** 1997 Apr;19(3):161–6

Metabolism of vasopressin, oxytocin and their analogues [Mpa1, D-Arg8]-vasopressin (dDAVP) and [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in human kidney and liver homogenates. Fjellestad-Paulsen A, et al. **Regul Pept** 1996 Nov 14;67(1):27–32

Hemodynamic and metabolic effects of vasopressin blockade in endotoxin shock. Matsuoka T, et al. **Surgery** 1997 Feb; 121(2):162–73

[Modeling disorders of platelet hemostasis and correction of them with an analog of vasopressin DGAVP] Golubeva MG, et al. **Dokl Akad Nauk** 1996 May;348(2):270–1 **(Rus)**

ANALYSIS

Characterization of monoclonal antibodies against arginine vasopressin. Smith SC, et al. **Biochem Soc Trans** 1996 May; 24(2):270S

Testicular arginine vasopressin in the developing rat: a possible physiological role. Tyson DL, et al. **Biol Neonate** 1997;71(6):379–84

Chronic intermittent salt loading enhances functional recovery from polydipsia and survival of vasopressinergic cells in the hypothalamic supraoptic nucleus following transection of the hypophysial stalk. Huang YS, et al. **Brain Res** 1996 Sep 2;732(1–2):95–105

ANTAGONISTS & INHIBITORS

Corticosterone inhibition of osmotically stimulated vasopressin from hypothalamic-neurohypophysial explants. Papanek PE, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R158–62

kappa-Opioid agonist inhibition of osmotically induced AVP release: preferential action at hypothalamic sites. Rossi NF, et al. **Am J Physiol** 1996 Feb;270(2 Pt 1):E367–72

Chronic vasopressin antagonism in two-kidney, one-clip renovascular hypertension. Burrell LM, et al. **Clin Exp Hypertens** 1997 Jul–Aug;19(5–6):981–91

Antisense oligonucleotide to c-fos blocks the ability of arginine vasopressin to maintain ethanol tolerance. Szabó G, et al. **Eur J Pharmacol** 1996 Jun 13;306(1–3):67–72

Aspirin inhibits vasopressin-induced hypothalamic-pituitary-adrenal activity in normal humans. Nye EJ, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):812–7

Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Saito T, et al. **J Clin Endocrinol Metab** 1997 Apr;82(4):1054–7

An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin. Manning M, et al. **J Pept Sci** 1995 Jan–Feb; 1(1):66–79

BIOSYNTHESIS

Identification of arginine vasopressin mRNA in rat aortic smooth muscle cells. Nagano K, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):831–4

Heterologous expression of human vasopressin-neurophysin precursors in a pituitary cell line: defective transport of a mutant protein from patients with familial diabetes insipidus. Olias G, et al. **DNA Cell Biol** 1996 Nov; 15(11):929–35

In situ hybridization analysis of vasopressin mRNA expression in the mouse hypothalamus: diurnal variation in the suprachiasmatic nucleus. Smith M, et al. **J Chem Neuroanat** 1996 Dec;12(2):105–12

Sequential exposure to estrogen and testosterone (T) and subsequent withdrawal of T increases the level of arginine vasopressin messenger ribonucleic acid in the hypothalamic paraventricular nucleus of the female rat. Thomas A, et al. **J Neuroendocrinol** 1996 Oct;8(10):793–800

Chronic social stress alters levels of corticotropin-releasing factor and arginine vasopressin mRNA in rat brain. Albeck DS, et al. **J Neurosci** 1997 Jun 15;17(12):4895–903

A sensitive reverse transcriptase polymerase chain reaction assay for measuring the effects of dehydration and gestation on rat amounts of vasopressin and ocytocin mRNAs. LeMoullec JM, et al. **Mol Cell Endocrinol** 1997 Apr 4; 128(1–2):151–9

BLOOD

Arginine vasopressin and renin in acutely ill children: implication for fluid therapy. Gerigk M, et al. **Acta Paediatr** 1996 May;85(5):550–3

Intragastric hypertonic saline increases vasopressin and central Fos immunoreactivity in conscious rats. Carlson SH, et al. **Am J Physiol** 1997 Mar;272(3 Pt 2):R750–8

Sensitivity of the renal medullary circulation to plasma vasopressin. Franchini KG, et al. **Am J Physiol** 1996 Sep; 271(3 Pt 2):R647–53

Vasopressin and renin-angiotensin maintain arterial pressure during PEEP in nonexpanded, conscious dogs. Kaczmarczyk G, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):R1396–402

Endocrine effects of pregnancy and exposure to a simulated open field in rats. Smith FG, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1053–7

Elevated plasma vasopressin and normal cerebrospinal fluid angiotensin-converting enzyme in chronic pain disorder. Wahlbeck K, et al. **Biol Psychiatry** 1996 Nov 15; 40(10):994–9

Role of vasopressin in the haemodynamic response to laparoscopic cholecystectomy. Walder AD, et al. **Br J Anaesth** 1997 Mar;78(3):264–6

Effect of aortic baroreceptor deafferentation on plasma vasopressin and oxytocin in the conscious rat. Ciriello J. **Brain Res** 1996 Nov 11;739(1–2):52–6

Vasopressin levels in Cushing's disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing's disease. Colao A, et al. **Clin Endocrinol (Oxf)** 1996 Aug;45(2):157–66

Inferior petrosal sinus AVP in patients with Cushing's syndrome. Yanovski JA, et al. **Clin Endocrinol (Oxf)** 1997 Aug;47(2):199–206

Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY). Zhang L, et al. **Clin Exp Hypertens** 1996 Feb; 18(2):201–26 (51 ref.)

Effect of progesterone therapy on arginine vasopressin and atrial natriuretic factor in premenstrual syndrome. Watanabe H, et al. **Clin Invest Med** 1997 Aug;20(4):211–23

Plasma arginine vasopressin, atrial natriuretic peptide and brain natriuretic peptide responses to long-term field training in the heat: effects of fluid ingestion and acclimatization. Mudambo KS, et al. **Eur J Appl Physiol** 1997;75(3):219–25

Inferior petrosal sinus arginine vasopressin concentrations in normal volunteers and patients with Cushing's disease. Friedman TC, et al. **J Clin Endocrinol Metab** 1996 Aug; 81(8):3068–72

Drinking-induced plasma vasopressin and norepinephrine

changes in dehydrated humans. Geelen G, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2131-5

Vasopressin and catecholamine responses to 24-hour, steady-state hypoxemia in fetal goats. Sameshima H, et al. **J Matern Fetal Med** 1996 Sep-Oct;5(5):262-7

Comparison of plasma concentrations of arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) in normal and preeclamptic pregnancies. Eguchi K, et al. **J Perinat Med** 1996;24(5):437-43

Blood sampling technique for measurement of plasma arginine vasopressin concentration in conscious and unrestrained rats. Suzuki K, et al. **Lab Anim Sci** 1997 Apr; 47(2):190-3

Interleukin-1 beta-induced effects on plasma oxytocin and arginine vasopressin: role of adrenal steroids and route of administration. Harbuz MS, et al. **Neuroimmunomodulation** 1996 Nov-Dec;3(6):358-63

Arginine vasopressin disposition in the conscious rabbit. Lécrivain A, et al. **Peptides** 1996;17(1):93-9

Sustained elevation of vasopressin plasma levels in healthy young men, but not in abstinent alcoholics, upon expectation of novelty. Ehrenreich H, et al. **Psychoneuroendocrinology** 1997 Jan;22(1):13-24

Influence of the hippocampus/subiculum on antidiuretic hormone levels during stress. Goldman MB, et al. **Psychoneuroendocrinology** 1996 Oct;21(7):593-7

Peripheral measures of arginine vasopressin, atrial natriuretic peptide and adrenocorticotropic hormone in premenstrual syndrome. Rosenstein DL, et al. **Psychoneuroendocrinology** 1996 Apr;21(3):347-59

CHEMICAL SYNTHESIS

Chimeric strategies for the rational design of bioactive analogs of small peptide hormones. Howl J, et al. **FASEB J** 1997 Jun;11(7):582-90

CHEMISTRY

CD conformational studies on synthetic peptides encompassing the processing domain of the ocytocin/neurophysin precursor. Simonetti M, et al. **Biopolymers** 1997 Apr 5;41(4):461-79

Distance distributions from the tyrosyl to disulfide residues in the oxytocin and [Arg8]-vasopressin measured using frequency-domain fluorescence resonance energy transfer. Szmacinski H, et al. **Eur Biophys J** 1996;24(3):185-93

Fluorescence study of neurohypophyseal hormones and their analogues. Distance distributions in a series of arginine-vasopressin analogues. Wiczk W, et al. **Eur Biophys J** 1997;26(2):183-93

The use of proton chemical shifts to define the solution structure of a dimeric peptide. Busetta B, et al. **J Pept Sci** 1996 Jul-Aug;2(4):233-9

Constrained refinement based on NOE and chemical shift information: the monomer form of arginine-vasopressin-like insect factor. Busetta B, et al. **J Pept Sci** 1997 Mar-Apr;3(2):133-40

Conformational studies on synthetic peptides reproducing the dibasic processing site of pro-ocytocin-neurophysin. Di Bello C, et al. **J Pept Sci** 1995 Jul-Aug;1(4):251-65

DIAGNOSTIC USE

Plasma corticotropin and cortisol responses to ovine corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease. Dickstein G, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):2934-41

Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. Lacroix A, et al. **J Clin Endocrinol Metab** 1997 Aug;82(8):2414-22

DRUG EFFECTS

Stimulation of arginine vasopressin secretion by a small increase in blood ionized calcium in normal men. Chiodera P, et al. **Eur J Clin Invest** 1997 Jul;27(7):575-8

Interleukin-1 beta-induced effects on plasma oxytocin and arginine vasopressin: role of adrenal steroids and route of administration. Harbuz MS, et al. **Neuroimmunomodulation** 1996 Nov-Dec;3(6):358-63

The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Patchev VK, et al. **Neuropsychopharmacology** 1996 Dec;15(6):533-40

GENETICS

Disparate expression of the AVP gene in Sabra hypertension-prone and hypertension-resistant rats. Yagil C, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):F806-13

Role of arginine vasopressin and corticotropin-releasing factor in mediating alcohol-induced adrenocorticotropin and vasopressin secretion in male rats bearing lesions of the paraventricular nuclei. Ogilvie KM, et al. **Brain Res** 1997 Jan 2;744(1):83-95

Differential regulation of oxytocin and vasopressin messenger ribonucleic acid levels by gonadal steroids in postpartum rats. Thomas A, et al. **Brain Res** 1996 Oct 28;738(1):48-52

Emergence of an isolated arginine vasopressin (AVP) response to stress after repeated restraint: a study of both AVP and corticotropin-releasing hormone messenger ribonucleic acid (RNA) and heteronuclear RNA. Ma XM, et al. **Endocrinology** 1997 Oct;138(10):4351-7

Heterogeneity in clinical manifestation of autosomal dominant neurohypophyseal diabetes insipidus caused by a mutation encoding Ala-1-->Val in the signal peptide of the arginine vasopressin/neurophysin II/copeptin precursor. Repaske DR, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):51-6

Molecular basis of autosomal dominant neurohypophyseal diabetes insipidus. Cellular toxicity caused by the accumulation of mutant vasopressin precursors within the endoplasmic reticulum. Ito M, et al. **J Clin Invest** 1997 Apr 15;99(8):1897-905

Rapid changes in heteronuclear RNA for corticotrophin-releasing hormone and arginine vasopressin in response to acute stress. Ma XM, et al. **J Endocrinol** 1997 Jan;152(1):81-9

Regulation of stress-induced transcriptional changes in the hypothalamic neurosecretory neurons. Kovács KJ, et al. **J Mol Neurosci** 1996 Summer;7(2):125-33

Repression of vasopressin gene expression by glucocorticoids in transgenic mice: evidence of a direct mechanism mediated by proximal 5' flanking sequence. Burke ZD, et al. **Neuroscience** 1997 Jun;78(4):1177-85

Three novel AVPR2 mutations in three Japanese families with X-linked nephrogenic diabetes insipidus. Tajima T, et al. **Pediatr Res** 1996 Mar;39(3):522-6

IMMUNOLOGY

Characterization of monoclonal antibodies against arginine vasopressin. Smith SC, et al. **Biochem Soc Trans** 1996 May; 24(2):270S

METABOLISM

Oxytocin receptors expressed and coupled to Ca2+ signalling in a human vascular smooth muscle cell line. Yazawa H, et al. **Br J Pharmacol** 1996 Mar;117(5):799-804

GABAergic control of Arg-vasopressin release from suprachiasmatic nucleus slice culture. Isobe Y, et al. **Brain Res** 1997 May 2;755(2):213-20

Identification of hypothalamic vasopressin and oxytocin neurons activated during the exercise pressor reflex in cats. Li J, et al. **Brain Res** 1997 Mar 28;752(1-2):45-51

Distribution of AVP and Ca(2+)-dependent PKC-isozymes in the suprachiasmatic nucleus of the mouse and rabbit. Van der Zee EA, et al. **Brain Res** 1995 Dec 1; 701(1-2):99-107

Release of vasopressin from supraoptic neurons within the median eminence in vivo. A combined microdialysis and push-pull perfusion study in the rat. Wotjak CT, et al. **Brain Res** 1996 Jul 8;726(1-2):237-41

Chronic ACE inhibition by quinapril modulates central vasopressinergic system. Muders F, et al. **Cardiovasc Res** 1997 Jun;34(3):575-81

Little or no response to 24-hr water-deprivation of Fos-like immunoreactivity in vasopressinergic magnocellular neurons in the hypothalamus of hereditary microphthalmic rats. Sugahara K, et al. **Exp Anim** 1997 Apr;46(2):141-5

Transient diabetes insipidus in pregnancy--a consequence of enhanced placental clearance of arginine vasopressin. Soule SG, et al. **Hum Reprod** 1995 Dec;10(12):3322-4

Renal immunocytochemical distribution and pharmacological properties of the dual angiotensin II/AVP receptor. Gonzalez CB, et al. **Hypertension** 1997 Apr;29(4):957-61

Fluid and electrolyte hormonal responses to exercise and acute plasma volume expansion. Grant SM, et al. **J Appl Physiol** 1996 Dec;81(6):2386-92

Synthetic rat V1a vasopressin receptor fragments interfere with vasopressin binding via specific interaction with the receptor. Mendre C, et al. **J Biol Chem** 1997 Aug 22; 272(34):21027-36

Molecular basis of autosomal dominant neurohypophyseal diabetes insipidus. Cellular toxicity caused by the accumulation of mutant vasopressin precursors within the endoplasmic reticulum. Ito M, et al. **J Clin Invest** 1997 Apr 15;99(8):1897-905

Vasopressin and oxytocin levels during normal pregnancy: effects of chronic dietary sodium restriction. van der Post JA, et al. **J Endocrinol** 1997 Mar;152(3):345-54

Short stressor induced long-lasting increases of vasopressin stores in hypothalamic corticotropin-releasing hormone (CRH) neurons in adult rats. Schmidt ED, et al. **J Neuroendocrinol** 1996 Sep;8(9):703-12

Transient suppression of resting corticosterone levels induces sustained increase of AVP stores in hypothalamic CRH-neurons of rats. Schmidt ED, et al. **J Neuroendocrinol** 1997 Jan;9(1):69-77

Release of vasopressin within the rat paraventricular nucleus in response to emotional stress: a novel mechanism of regulating adrenocorticotropic hormone secretion? Wotjak CT, et al. **J Neurosci** 1996 Dec 1;16(23):7725-32

Osmotic and non-osmotic regulation of arginine vasopressin (AVP) release, mRNA, and promoter activity in small cell lung carcinoma (SCLC) cells. Kim JK, et al. **Mol Cell Endocrinol** 1996 Oct 30;123(2):179-86

Intracerebroventricular injection of adrenomedullin inhibits vasopressin release in conscious rats. Yokoi H, et al. **Neurosci Lett** 1996 Sep 20;216(1):65-7

Arginine vasopressin release by acetylcholine or norepinephrine: region-specific and cytokine-specific regulation [published erratum appears in Neuroscience 1996 Jul;73(2):623] Raber J, et al. **Neuroscience** 1996 Apr; 71(3):747-59

Ontogeny and molecular weight of immunoreactive arginine vasopressin and corticotropin-releasing factor in the ovine fetal hypothalamus. Saoud CJ, et al. **Peptides** 1996; 17(1):55-61

Difference in testosterone sensitivity in male spontaneously hypertensive (SHR) and Wistar-Kyoto rats (WKY). Magnusson K, et al. **Physiol Behav** 1996 Sep;60(3):907-12

Gamma-aminobutyric acid mediation of the inhibitory effect of nitric oxide on the arginine vasopressin and oxytocin responses to insulin-induced hypoglycemia. Chiodera P, et al. **Regul Pept** 1996 Nov 14;67(1):21-5

Metabolism of vasopressin, oxytocin and their analogues [Mpa1, D-Arg8]-vasopressin (dDAVP) and [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in human kidney and liver homogenates. Fjellestad-Paulsen A, et al. **Regul Pept** 1996 Nov 14;67(1):27-32

PHARMACOLOGY

Cardiac output mediates the antihypertensive effect of vasopressin in spontaneous hypertension. Balakrishnan S, et al. **Am J Physiol** 1996 Nov;271(5 Pt 2):H1728-33

Myogenic contribution to agonist-induced renal vasoconstriction during normoxia and hypoxia. Eichinger MR, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):H1945-51

Enhanced renal vasoconstriction induced by vasopressin in SHR is mediated by V1 receptors. Feng JJ, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F304-13

Ovine fetal cardiovascular, renal, and fluid balance responses to 3 days of high arginine vasopressin levels. Gibson KJ, et al. **Am J Physiol** 1997 Apr;272(4 Pt 2):R1069-76

Vasopressin and V1-receptor antagonists modulate the activity of NTS neurons receiving baroreceptor input. Hegarty AA, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R143-52

Arginine vasopressin modulation of arterial baroreflex responses in fetal and newborn sheep. Nuyt AM, et al. **Am J Physiol** 1996 Dec;271(6 Pt 2):R1643-53

Administration of AVP to the area postrema alters response of NTS neurons to afferent inputs. Qu L, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R519-25

Alteration in water channel AQP-2 by removal of AVP stimulation in collecting duct cells of dehydrated rats. Saito T, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):F183-91

Extreme vasoreactivity of rat epineurial arterioles to vasopressin. Sasaki H, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1307-13

Arginine vasopressin interacts with thromboxane in hydronephrosis. Takenaka T, et al. **Am J Physiol** 1997 Jan; 272(1 Pt 2):F40-7

Vasopressin constricts outer medullary descending vasa recta isolated from rat kidneys. Turner MR, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):F147-51

Sexual dimorphism in regional blood flow responses to vasopressin in conscious rats. Wang YX, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):R1126-31

Adenylyl cyclase isoforms and vasopressin enhancement of agonist-stimulated cAMP in vascular smooth muscle cells. Zhang J, et al. **Am J Physiol** 1997 Aug;273(2 Pt 2):H971-80

In vitro effects of substance P and arginine-vasopressin on testosterone production in Leydig cells of short and long photoperiodic hamsters. Angelova P, et al. **Andrologia** 1996 Nov-Dec;28(6):321-6

Exploratory behavior correlates with social organization and is responsive to peptide injections in prairie voles. Dharmadhikari A, et al. **Ann N Y Acad Sci** 1997 Jan 15; 807:610-2

Differential Fos expression following microinjection of oxytocin or vasopressin in the prairie vole brain. Gingrich BS, et al. **Ann N Y Acad Sci** 1997 Jan 15;807:504-5

Responsiveness of the glucocorticoid-suppressed pituitary-adrenocortical system of pigeons (Columba livia domestica) to stimulation with arginine vasopressin. Westerhof I, et al. **Avian Dis** 1996 Apr-Jun;40(2):312-20

No evidence for diurnal variation in the responsiveness of the pituitary-adrenocortical axis of the pigeon (Columba livia domestica) to stimulation with adrenocorticotrophin and vasopressin. Westerhof I, et al. **Avian Dis** 1996 Apr-Jun;40(2):453-6

Effect of active fragments of arginine-vasopressin on the disturbance of spatial cognition in rats. Fujiwara M, et al. **Behav Brain Res** 1997 Feb;83(1-2):91-6

Regulation of water channel activity of aquaporin 1 by arginine vasopressin and atrial natriuretic peptide. Patil RV, et al. **Biochem Biophys Res Commun** 1997 Sep 18; 238(2):392-6

1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Saito M, et al. **Biochem Pharmacol** 1997 Jun 1;53(11):1711-7

Autoradiographic localization of arginine vasopressin binding sites in the brain of adult and developing Brazilian opossums. Kuehl-Kovarik MC, et al. **Brain Behav Evol** 1997;49(5):261-75

Glutamate and vasopressin interact to control scent marking in Syrian hamsters (Mesocricetus auratus). Bamshad M, et al. **Brain Res** 1996 Aug 26;731(1-2):213-6

Long-lasting enhancement of synaptic excitability of CA1/subiculum neurons of the rat ventral hippocampus by vasopressin and vasopressin(4-8). Chepkova AN, et al.

Brain Res 1995 Dec 1;701(1-2):255-66
Enhancement of central pressor effect of AVP in SHR and WKY rats by intracranial N(G)-nitro-L-arginine. Paczwa P, et al. **Brain Res** 1997 Feb 14;748(1-2):51-61
Arginine vasopressin reduces the blood-brain transfer of L-tyrosine and L-valine: further evidence of the effect of the peptide on the L-system transporter at the blood-brain barrier. Reichel A, et al. **Brain Res** 1996 Mar 25; 713(1-2):232-9
Ventilatory effects of angiotensin and vasopressin in conscious rats. Walker JK, et al.
Can J Physiol Pharmacol 1996 Nov;74(11):1258-64
Fluorescent analysis in polarized MDCK cell monolayers: intracellular pH and calcium interactions after apical and basolateral stimulation with arginine vasopressin. Vamos S, et al. **Cell Calcium** 1996 Apr;19(4):307-14
Vasopressin modulates membrane properties of taste cells isolated from bullfrogs. Okada Y, et al. **Chem Senses** 1996 Dec;21(6):739-45
Cardiovascular effects of injection of argipressin into lateral septal nuclei in rats. Gao L, et al.
Chung Kuo Yao Li Hsueh Pao 1996 Jan;17(1):49-52
The activation of phospholipase D participates in the mitogenic action of arginine vasopressin in cultured rat glomerular mesangial cells. Kusaka I, et al.
Endocrinology 1996 Dec;137(12):5421-8
Adrenomedullin gene expression in the rat heart is stimulated by acute pressure overload: blunted effect in experimental hypertension. Romppanen H, et al. **Endocrinology** 1997 Jun; 138(6):2636-9
Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Barthelmebs M, et al. **Eur J Pharmacol** 1996 Oct 31;314(3):325-32
Effect of luminal vasopressin on NaCl transport in the medullary thick ascending limb of the rat. Grider J, et al. **Eur J Pharmacol** 1996 Oct 10;313(1-2):115-8
Interaction between head-down tilt and anterior chamber infusions on intraocular pressure of anesthetized rats. Searles RV, et al. **Exp Eye Res** 1996 Jun;62(6):621-6
Vasopressin stimulates translocation of protein kinase C in the toad urinary bladder. Sulimovici S, et al.
Exp Nephrol 1996 May-Jun;4(3):159-65
Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. Chini B, et al. **FEBS Lett** 1996 Nov 18; 397(2-3):201-6
Arginine vasopressin induces contraction and stimulates growth of cultured human hepatic stellate cells. Bataller R, et al. **Gastroenterology** 1997 Aug;113(2):615-24
Excitatory and inhibitory actions of vasopressin on colonic excitation-contraction coupling in dogs. Ward SM, et al. **Gastroenterology** 1997 Oct;113(4):1233-45
The effects of lithium, indomethacin, and neomycin on vasopressin-induced contractions in rat urinary bladder. Dehpour AR, et al. **Gen Pharmacol** 1997 May;28(5):777-80
Action of vasopressin in superfused human granulosa cells in vitro. Rabe T, et al. **Gynecol Endocrinol** 1996 Dec; 10(6):371-4
Release of prolactin as well as adrenocorticotropin after administration of arginine-vasopressin to healthy men. Erfurth EM, et al. **Horm Metab Res** 1996 Nov; 28(11):599-602
Receptor subtype for vasopressin-induced release of nitric oxide from rat kidney. Hirata Y, et al. **Hypertension** 1997 Jan;29(1 Pt 1):58-64
Synthesis and secretion of natriuretic peptides in the hypertensive TGR(mREN-2)27 transgenic rat. Marttila M, et al. **Hypertension** 1996 Dec;28(6):995-1004
Differential effects of arginine vasopressin on isolated guinea pig heart function during perfusion at constant flow and constant pressure. Graf BM, et al.
J Cardiovasc Pharmacol 1997 Jan;29(1):1-7
Aspirin inhibits vasopressin-induced hypothalamic-pituitary-adrenal activity in normal humans. Nye EJ, et al. **J Clin Endocrinol Metab** 1997 Mar; 82(3):812-7
Neural circuitry controlling vasopressin-stimulated scent marking in Syrian hamsters (Mesocricetus auratus). Bamshad M, et al. **J Comp Neurol** 1996 May 27; 369(2):252-63
Effects of vasopressin and elimination of corticotropin-releasing hormone-target cells on pro-opiomelanocortin mRNA levels and adrenocorticotropin secretion in ovine anterior pituitary cells. van de Pavert SA, et al. **J Endocrinol** 1997 Jul; 154(1):139-47
Role of volume status in vasopressin-induced natriuresis: studies in Brattleboro rats. Walter SJ, et al.
J Endocrinol 1996 Oct;151(1):49-54
Arginine vasopressin inhibits interleukin-1 beta-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. Kusano E, et al. **J Hypertens** 1997 Jun;15(6):627-32
Vasopressin/serotonin interactions in the anterior hypothalamus control aggressive behavior in golden hamsters. Ferris CF, et al. **J Neurosci** 1997 Jun 1; 17(11):4331-40
Central histaminergic mechanisms mediate the vasopressin-induced pituitary adrenocortical stimulation. Bugajski J, et al. **J Physiol Pharmacol** 1996 Dec; 47(4):649-59
Cyclosporin A potentiates receptor-activated [Ca2+]c increase. Lo Russo A, et al.
J Recept Signal Transduct Res 1997 Jan-May; 17(1-3):149-61
Comparison of circulatory effects between arginine vasopressin (AVP) and dopamine in conscious newborn goats. Sakamoto H, et al. **J Vet Med Sci** 1996 Jun; 58(6):511-4
Arginine vasopressin and oxytocin increase intracellular calcium and cAMP in human glomerular epithelial cells in culture. Späth M, et al. **Kidney Blood Press Res** 1996; 19(2):81-6
Cellular signaling and proliferative action of AVP in mesangium of SHR: effect of low density lipoprotein. Ishikawa S, et al. **Kidney Int** 1996 Nov;50(5):1506-14
Effect of vasopressin on intracellular Na+ concentration in cortical collecting duct. Breyer MD, et al.
Kidney Int Suppl 1996 Dec;57:S57-61
AVP and aldosterone at physiological concentrations have synergistic effects on Na+ transport in rat CCD. Hawk CT, et al. **Kidney Int Suppl** 1996 Dec;57:S35-41
Pharmacological characterization of a vasopressin V1 receptor in the isolated human gastric artery. Calò G, et al. **Life Sci** 1997;60(4-5):PL63-8
Functional characterization of five V2 vasopressin receptor gene mutations. Wenkert D, et al. **Mol Cell Endocrinol** 1996 Nov 29;124(1-2):43-50
A fully active nonglycosylated V2 vasopressin receptor. Innamorati G, et al. **Mol Pharmacol** 1996 Sep;50(3):467-73
The role of vasopressin on the effect of U-50,488 to block the development of morphine tolerance and physical dependence. Tao PL, et al.
Naunyn Schmiedebergs Arch Pharmacol 1997 Feb; 355(2):281-7
Ovarian hormones alter the behavioral response of the medial preoptic anterior hypothalamus to arginine-vasopressin. Albers HE, et al. **Peptides** 1996;17(8):1359-63
Arginine-vasopressin stimulates CRH and ACTH release by rat adrenal medulla, acting via the V1 receptor subtype and a protein kinase C-dependent pathway. Mazzocchi G, et al. **Peptides** 1997;18(2):191-5
AVP-independent high osmotic water permeability of frog urinary bladder and autacoids. Natochin YV, et al.
Pflugers Arch 1996 Nov-Dec;433(1-2):136-45
Vasopressin-stimulated Ca2+ reabsorption in rabbit cortical collecting system: effects on cAMP and cytosolic Ca2+ van Baal J, et al. **Pflugers Arch** 1996 Nov-Dec; 433(1-2):109-15
Facilitation of passive avoidance response by newly synthesized cationized arginine vasopressin fragment 4-9 in rats. Tanabe S, et al. **Pharmacol Biochem Behav** 1997 May-Jun;57(1-2):251-6
Arginine vasopressin increases renal sodium excretion in the anesthetized rat through V1 receptors. Musabayane CT, et al. **Ren Fail** 1997 Jan;19(1):23-32
Effects of corticotrophin-releasing factor and vasopressin on plasma adrenocorticotrophin molecular forms, aldosterone and corticosterone in young and adult rats and rabbits. Pradier P, et al. **Reprod Fertil Dev** 1996;8(1):111-6

PHYSIOLOGY

Effect of arginine vasopressin on breathing movements of chronically instrumented fetal lambs. Bessho T, et al.
Acta Obstet Gynecol Scand 1997 Feb;76(2):107-11
Differential ventral septal vasopressin release is associated with sexual dimorphism in PGE2 fever. Chen X, et al. **Am J Physiol** 1997 May;272(5 Pt 2):R1664-9
Vasopressin modulation of medullary blood flow and pressure-natriuresis-diuresis in the decerebrated rat. Franchini KG, et al. **Am J Physiol** 1997 May;272(5 Pt 2):R1472-9
Arginine vasopressin and baroreflex function after converting enzyme inhibition in normal humans. Goldsmith SR.
Am J Physiol 1997 Mar;272(3 Pt 1):E429-36
Stress-induced enhancement of colitis in rats: CRF and arginine vasopressin are not involved. Gué M, et al.
Am J Physiol 1997 Jan;272(1 Pt 1):G84-91
Evidence that centrally released arginine vasopressin is involved in central pressor action of angiotensin II. Loń S, et al. **Am J Physiol** 1996 Jan;270(1 Pt 2):H167-73
Dopamine inhibits AVP-dependent Na+ transport and water permeability in rat CCD via a D4-like receptor. Sun D, et al. **Am J Physiol** 1996 Aug;271(2 Pt 2):F391-400
Endogenous AVP systems regulate oral behavior in the rat fetus: neuropeptide systems as ontogenetic adaptations. Varlinskaya EI, et al. **Behav Neurosci** 1996 Oct; 110(5):1148-57
Strain differences in the distribution of arginine-vasopressin- and neuropeptide Y-immunoreactive neurons in the suprachiasmatic nucleus of laboratory rats. Wollnik F, et al. **Brain Res** 1996 Jun 17;724(2):191-9
Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Fink G, et al.
Cell Mol Neurobiol 1996 Jun;16(3):325-44 (87 ref.)
Chronic vasopressin antagonism in two-kidney, one-clip renovascular hypertension. Burrell LM, et al.
Clin Exp Hypertens 1997 Jul-Aug;19(5-6):981-91
Resistance to vasopressin action on the kidney in patients with Cushing's disease. Knoepfelmacher M, et al.
Eur J Endocrinol 1997 Aug;137(2):162-6
Role of vasopressin in essential hypertension: racial differences. Bakris G, et al. **J Hypertens** 1997 May; 15(5):545-50
Vasopressin and developmental onset of flank marking behavior in golden hamsters. Ferris CF, et al.
J Neurobiol 1996 Jun;30(2):192-204
Effect of CRH on the preovulatory LH and FSH surge in the cyclic rat: a role for arginine vasopressin? Roozendaal MM, et al. **J Neuroendocrinol** 1996 Oct;8(10):765-70
Immunotargeted lesions of paraventricular CRF and AVP neurons in developing rats reveal the pattern of maturation of these systems and their functional importance. Walker CD, et al. **J Neuroendocrinol** 1997 Jan;9(1):25-41
Hyponatraemia, hypothyroidism, and role of arginine-vasopressin. Hanna FW, et al. **Lancet** 1997 Sep 13;350(9080):755-6
Aldosterone and vasopressin responses in the heat: hydration level and exercise intensity effects. Montain SJ, et al.
Med Sci Sports Exerc 1997 May;29(5):661-8
Role of arginine vasopressin in the regulation of extracellular fluid volume. Norsk P. **Med Sci Sports Exerc** 1996 Oct; 28(10 Suppl):S36-41 (25 ref.)
Septal vasopressin modulates anxiety-related behaviour in rats. Liebsch G, et al. **Neurosci Lett** 1996 Oct 18; 217(2-3):101-4
Interactions between vasopressin and mu-opioid systems in the rat fetus. Petrov ES, et al. **Physiol Behav** 1996 Jul; 60(1):217-30
Interaction of vasopressin and angiotensin II in central control of blood pressure and thirst.
Szczepańska-Sadowska E. **Regul Pept** 1996 Oct 8; 66(1-2):65-71 (60 ref.)

SECRETION

Mechanisms of centrally administered ET-1-induced increases in systemic arterial pressure and AVP secretion. Rossi NF, et al. **Am J Physiol** 1997 Jan;272(1 Pt 1):E126-32
Mechanism for changes in vasopressin during acute exposure at 3 atm abs air. Torii R, et al. **Am J Physiol** 1997 Jul;273(1 Pt 2):R259-64
Effect of the 5-HT3 receptor antagonist ondansetron on plasma AVP secretion: a study in cancer patients. Barreca T, et al. **Biomed Pharmacother** 1996;50(10):512-4
Activation of anterior lobe corticotrophs by electroacupuncture or noxious stimulation in the anaesthetized rat, as shown by colocalization of Fos protein with ACTH and beta-endorphin and increased hormone release. Pan B, et al. **Brain Res Bull** 1996;40(3):175-82
Vasopressin release during orthostatic hypotension after cardiac transplantation. Lord SW, et al. **Clin Auton Res** 1996 Dec;6(6):351-7
Corticotrophin and vasopressin responses to metoclopramide in patients with hypothalamic amenorrhoea. Seki K, et al. **Clin Endocrinol (Oxf)** 1997 Feb;46(2):203-7
Neurohypophysial peptides. Histaminergic regulation and function in adenohypophysial secretion. Kjaer A.
Dan Med Bull 1996 Dec;43(5):391-406 (188 ref.)
Involvement of arginine vasopressin and renal sodium handling in pathogenesis of hyponatremia in elderly patients. Ishikawa S, et al. **Endocr J** 1996 Feb;43(1):101-8
Parathyroid hormone-related peptide-(1-34) [PTHrP-(1-34)] induces vasopressin release from the rat supraoptic nucleus in vitro through a novel receptor distinct from a type I or type II PTH/PTHrP receptor. Yamamoto S, et al. **Endocrinology** 1997 May;138(5):2066-72
Stimulation of arginine vasopressin secretion by a small increase in blood ionized calcium in normal men. Chiodera P, et al. **Eur J Clin Invest** 1997 Jul;27(7):575-8
Role of Q-type Ca2+ channels in vasopressin secretion from neurohypophysial terminals of the rat. Wang G, et al.
J Physiol (Lond) 1997 Jul 15;502 (Pt 2):351-63
The luteinizing hormone but not the cortisol response to arginine vasopressin is prevented by naloxone and a corticotropin-releasing hormone antagonist in the ovariectomized rhesus monkey. Xiao E, et al.
Neuroendocrinology 1996 Sep;64(3):225-32
Strain, age and sex differences in the release of vasopressin from the pituitary: a study in the spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rat. Magnusson K, et al. **Neuropeptides** 1996 Oct;30(5):465-70
Effect of central administration of the kappa-opiate receptor agonist U 69.593 on neurohypophyseal hormone levels in blood and cerebrospinal fluid. van Wimersma Greidanus TB, et al. **Neuropeptides** 1996 Oct;30(5):452-5
The role of phospholipase C in arginine vasopressin secretion by rat hypothalami in vitro. Wayte J, et al.
Neuroreport 1997 Mar 24;8(5):1277-82
C-type natriuretic peptide suppresses arginine-vasopressin secretion from dissociated magnocellular neurons in newborn rat supraoptic nucleus. Yamamoto S, et al.
Neurosci Lett 1997 Jun 27;229(2):97-100

THERAPEUTIC USE

Arginine vasopressin receptor antagonists for treatment of vasogenic brain edema: an experimental study. Kagawa M, et al. **J Neurotrauma** 1996 May;13(5):273-9

URINE

Role of urinary arginine vasopressin in the sodium excretion in patients with chronic renal failure. Nonoguchi H, et al.
Am J Med Sci 1996 Nov;312(5):195-201
Arginine vasopressin disposition in the conscious rabbit. Lécrivain A, et al. **Peptides** 1996;17(1):93-9

ARGIPRESTOCIN

ARGIPRESTOCIN see **VASOTOCIN**

ARGON

Argon laser and Gherini–Causse Endo–Otoprobe in otologic surgery. Vincent R, et al. **Ear Nose Throat J** 1996 Dec; 75(12):770, 773–8, 780 (22 ref.)

Argon–enhanced cutting and coagulation confers advantages over conventional electrocautery for mastectomy. Kerin MJ, et al. **Eur J Surg Oncol** 1996 Dec;22(6):571–3

Specific ventilation distribution in microgravity. Verbanck S, et al. **J Appl Physiol** 1996 May;80(5):1458–65

Targeted gene transfer in eucaryotic cells by dye–assisted laser optoporation. Palumbo G, et al. **J Photochem Photobiol B** 1996 Oct;36(1):41–6

[Argon plasma coagulation through a flexible endoscope. Evaluation of a new therapeutic method after 1606 uses] Grund KE, et al. **Dtsch Med Wochenschr** 1997 Apr 4; 122(14):432–8 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Welfare implications of gas stunning pigs: 3. The time to loss of somatosensory evoked potentials and spontaneous electrocorticogram of pigs during exposure to gases. Raj AB, et al. **Vet J** 1997 May;153(3):329–39

ADVERSE EFFECTS

Aversive reactions of turkeys to argon, carbon dioxide and a mixture of carbon dioxide and argon. Raj AB. **Vet Rec** 1996 Jun 15;138(24):592–3

PHARMACOLOGY

Effects of pneumoperitoneum with carbon dioxide, argon, or helium on hemodynamic and respiratory function. Junghans T, et al. **Arch Surg** 1997 Mar;132(3):272–8

THERAPEUTIC USE

[Use of argon laser in dermatology] Telegdy E, et al. **Orv Hetil** 1996 Sep 22;137(38):2083–8 (Eng. Abstr.) **(Hun)**

TOXICITY

Carcase and meat quality in broilers either killed with a gas mixture or stunned with an electric current under commercial processing conditions. Raj AB, et al. **Br Poult Sci** 1997 May;38(2):169–74

Effect of the method of killing, interval between killing and neck cutting and blood vessels cut on blood loss in broilers. Raj AB, et al. **Br Poult Sci** 1997 May;38(2):190–4

Susceptibility of hippocampal and cortical neurons to argon–mediated in vitro ischemia. Kusumoto M, et al. **J Neurochem** 1996 Oct;67(4):1613–21

ARGYRIA

COMPLICATIONS

[Argyria and anesthesia (letter)] Donnard G, et al. **Ann Fr Anesth Reanim** 1996;15(2):226 **(Fre)**

ETIOLOGY

Localized argyria caused by silver earrings [see comments] Morton CA, et al. **Br J Dermatol** 1996 Sep;135(3):484–5 . Comment in: Br J Dermatol 1997 Jun;136(6):980.

Argyria and convulsive seizures caused by ingestion of silver in a patient with schizophrenia. Ohbo Y, et al. **Psychiatry Clin Neurosci** 1996 Apr;50(2):89–90

ARHINENCEPHALY see **HOLOPROSENCEPHALY**

ARIZONA BACTERIA see **SALMONELLA ARIZONAE**

ARM

see related
FORELIMB

One case of Stewart–Treves syndrome successfully treated at two years by chemotherapy and radiation therapy in a 73–year–old woman. Malhaire JP, et al. **Acta Oncol** 1997; 36(4):442–3

Deep venous thrombosis of the upper extremity [published erratum appears in Am Fam Physician 1997 Apr;55(5):1586] Stephens MB. **Am Fam Physician** 1997 Feb 1;55(2):533–9 (23 ref.)

Lack of concordance between the ICD–9 classification of soft tissue disorders of the neck and upper limb and chart review diagnosis: one steel mill's experience. Buchbinder R, et al. **Am J Ind Med** 1996 Feb;29(2):171–82

Work organization is significantly associated with upper extremities musculoskeletal disorders among employees engaged in interactive computer–telephone tasks of an international bank subsidiary in São Paulo, Brazil. Ferreira Júnior M, et al. **Am J Ind Med** 1997 Apr;31(4):468–73

Diagnosis of biceps tendon dislocation by kinematic magnetic resonance imaging. Boden BP, et al. **Am J Orthop** 1996 Oct;25(10):709–11

Late presentation of triceps rupture. A case report and review of the literature. Inhofe PD, et al. **Am J Orthop** 1996 Nov; 25(11):790–2 (10 ref.)

Hands–up positioning during asymmetric sternal retraction for internal mammary artery harvest: a possible method to reduce brachial plexus injury. Jellish WS, et al. **Anesth Analg** 1997 Feb;84(2):260–5

Subclavian vein compression and thrombosis presenting as upper extremity pain. Jiha JG, et al. **Anesth Analg** 1997 Jul;85(1):225–6

Upper extremity discoloration caused by subcutaneous indigo carmine injection. O'Hara JF Jr, et al. **Anesth Analg** 1996 Nov;83(5):1126–8

Microwave heating in the management of postmastectomy upper limb lymphedema. Gan JL, et al. **Ann Plast Surg** 1996 Jun;36(6):576–80; discussion 580–1

Blood pressure difference between arms [letter; comment] Bursztyn M. **Arch Intern Med** 1997 Apr 14;157(7):818. Comment on: Arch Intern Med 1996 Sep 23;156(17):2005–8.

Upper–extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Prandoni P, et al. **Arch Intern Med** 1997 Jan 13;157(1):57–62

The Arm Motor Ability Test: reliability, validity, and sensitivity to change of an instrument for assessing disabilities in activities of daily living. Kopp B, et al. **Arch Phys Med Rehabil** 1997 Jun;78(6):615–20

The role of upper limb segment rotations in the development of spin in the tennis forehand. Takahashi K, et al. **Aust J Sci Med Sport** 1996 Dec;28(4):106–13

Melasma of the forearms. O'Brien TJ, et al. **Australas J Dermatol** 1997 Feb;38(1):35–7 (6 ref.)

The distribution of limb pain in decompression sickness. Sowden LM, et al. **Aviat Space Environ Med** 1996 Jan; 67(1):74–80

Proceedings of the 7th International Conference on Hand–Arm Vibration. Prague, May 9–12, 1995. **Cent Eur J Public Health** 1995;3 Suppl:1–141

Results of independent medical interview and examination in the diagnosis and assessment of hand–arm vibration syndrome. McGeoch KL, et al. **Cent Eur J Public Health** 1995;3 Suppl:107–8

Granuloma annulare–like lesions and secondary hyperparathyroidism. Mautner GH, et al. **Cutis** 1996 Mar; 57(3):172–4

An unusual presentation of multiple congenital melanocytic nevi with a limb distribution. Lin YT, et al. **Dermatology** 1997;194(4):362–3

Assessment of upper–extremity function in children with spastic diplegia before and after selective dorsal rhizotomy. Buckon CE, et al. **Dev Med Child Neurol** 1996 Nov; 38(11):967–75

Assessment of the functional abilities of the upper limbs in patients with neuromuscular diseases. Zupan A. **Disabil Rehabil** 1996 Feb;18(2):69–75

Silent period in upper limb muscles after noxious cutaneous stimulation in man. Inghilleri M, et al. **Electroencephalogr Clin Neurophysiol** 1997 Apr; 105(2):109–15

A new method of fitting and analysis of simple uni–joint arm movements. Mescheriakov S, et al. **Eur J Appl Physiol** 1996;74(5):484–6

Effect of maximal arm exercise on skin blood flux in the paralyzed lower limbs in persons with spinal cord injury. Muraki S, et al. **Eur J Appl Physiol** 1996;74(5):481–3

Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial. Uppsala–Orebro Breast Cancer Study Group. Liljegren G, et al. **Eur J Cancer** 1997 Feb;33(2):193–9

'Man–in–the–barrel' syndrome: MRI and SPECT imaging. Benito–León J, et al. **Eur J Radiol** 1997 May;24(3):260–2

Arm and mouth coordination during the eating action in humans: a kinematic analysis. Castiello U. **Exp Brain Res** 1997 Jul;115(3):552–6

Task–dependent effect of limb immobilization on the fatigability of the elbow flexor muscles in humans. Yue GH, et al. **Exp Physiol** 1997 May;82(3):567–92

Anatomy of upper extremity skin flaps. Birkbeck DP, et al. **Hand Clin** 1997 May;13(2):175–87 (71 ref.)

Neural blockade for upper–extremity pain. Fouch RA, et al. **Hand Clin** 1996 Nov;12(4):791–800 (33 ref.)

Rehabilitation of the painful upper extremity. Haines BL. **Hand Clin** 1996 Nov;12(4):801–16 (68 ref.)

Home–based, upper–arm exercise training for patients with chronic obstructive pulmonary disease. Bauldoff GS, et al. **Heart Lung** 1996 Jul–Aug;25(4):288–94

Different acute effects of single–axis and multi–axis hand–arm vibration. Stelling J, et al. **Int Arch Occup Environ Health** 1996;68(4):236–42

Combined effects of hand–arm vibration and noise on temporary threshold shifts of hearing in healthy subjects. Zhu S, et al. **Int Arch Occup Environ Health** 1997; 69(6):433–6

Ankle blood pressure measurement, an acceptable alternative to arm measurements. Block FE, et al. **Int J Clin Monit Comput** 1996 Aug;13(3):167–71

Moment arms and lengths of human upper limb muscles as functions of joint angles. Pigeon P, et al. **J Biomech** 1996 Oct;29(10):1365–70

The relative activation of elbow–flexor muscles in isometric flexion and in flexion/extension movements. van Bolhuis BM, et al. **J Biomech** 1997 Aug;30(8):803–11

Arm training reduces the VO2 and VE cost of unsupported arm exercise and elevation in chronic obstructive pulmonary disease. Epstein SK, et al. **J Cardiopulm Rehabil** 1997 May–Jun;17(3):171–7

Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. Lewis JJ, et al. **J Clin Oncol** 1997 Feb;15(2):646–52

Chemotherapy–induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. Picci P, et al. **J Clin Oncol** 1997 Apr;15(4):1553–9

Possible explanations for trajectory curvature in multijoint arm movements. Osu R, et al. **J Exp Psychol Hum Percept Perform** 1997 Jun; 23(3):890–913

4th Congress of the Federation of the European Societies for Surgery of the Hand (FESSH). Bologna, Italy, 15–18 June 1997. Abstracts. **J Hand Surg [Br]** 1997 Jun;22 Suppl:1–72

Extremity gangrene in utero. Carr MM, et al. **J Hand Surg [Br]** 1996 Oct;21(5):652–5

The role of physical agents in modulating pain. Fedorczyk J. **J Hand Ther** 1997 Apr–Jun;10(2):110–21 (90 ref.)

Myofascial pain syndromes in the upper extremity. Gerwin RD. **J Hand Ther** 1997 Apr–Jun;10(2):130–6 (36 ref.)

Effects of hyperthermic isolated limb perfusion with tumor necrosis factor–alpha and melphalan on pulmonary function assessments. Sleijfer S, et al. **J Immunother** 1997 May; 20(3):202–7

An arm phantom: a digital simulation system for testing sphygmomanometers. Gross H, et al. **J Med Eng Technol** 1996 Mar–Apr;20(2):75–83

Symmetrical cerebral metastasis presenting with bilateral upper extremity weakness. Wilck EJ, et al. **J Neuroimaging** 1996 Oct;6(4):254–6

Tumor quantitation and monitoring in whole–body planar technetium–99m–sestamibi imaging. Van Kriekinge SD, et al. **J Nucl Med** 1997 Mar;38(3):356–61

A prospective study for upper–extremity cumulative trauma disorders of workers in aircraft manufacturing. Melhorn JM. **J Occup Environ Med** 1996 Dec;38(12):1264–71

Lymphedema praecox seen as isolated unilateral arm involvement: case report and review of the literature. Harel L, et al. **J Pediatr** 1997 Mar;130(3):492–4 (14 ref.)

Prevention of heat strain by immersing the hands and forearms in water. House JR, et al. **J R Nav Med Serv** 1997;83(1):26–30

Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma. Didolkar MS, et al. **J Surg Oncol** 1996 Nov;63(3):148–58

Stewart–Treves angiosarcoma of arm and ipsilateral breast in post–traumatic lymphedema. Trattner A, et al. **Lymphology** 1996 Jun;29(2):57–9

Angiomatoid fibrous histiocytoma of the arm treated by radiotherapy for local recurrence—case report. Costa MA, et al. **Med Pediatr Oncol** 1997 May;28(5):373–6

Occurrence of melanomas on the upper and lower limbs in eastern Australia. Green A, et al. **Melanoma Res** 1996 Oct; 6(5):387–94

Imipenem–induced myoclonus. Frucht S, et al. **Mov Disord** 1997 Jul;12(4):621–2

Acoustic and electrical activities during voluntary isometric contraction of biceps brachii muscles in patients with spastic cerebral palsy [see comments] Akataki K, et al. **Muscle Nerve** 1996 Oct;19(10):1252–7. Comment in: Muscle Nerve 1997 Jun;20(6):764–5.

A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH–DY Group. Tawil R, et al. **Neurology** 1997 Jan;48(1):46–9

Molecular genetics of facioscapulohumeral muscular dystrophy (FSHD). Fisher J, et al. **Neuromuscul Disord** 1997 Jan;7(1):55–62 (69 ref.)

Epidemiology of occupational disorders of the upper extremity. Cherniack MG. **Occup Med** 1996 Jul–Sep; 11(3):513–30 (90 ref.)

Upper limb disorders. Cooper C, et al. **Occup Med (Oxf)** 1996 Dec;46(6):435–7

Gas gangrene of the arm due to Enterobacter cloacae in a neutropenic patient. Fata F, et al. **South Med J** 1996 Nov; 89(11):1095–6

Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma. Würl P, et al. **Surg Today** 1997;27(8):719–25

Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan. Santinami M, et al. **Tumori** 1996 Nov–Dec; 82(6):579–84

[Enzyme therapy in the treatment of lymphedema in the arm after breast carcinoma surgery] Adámek J, et al. **Rozhl Chir** 1997 Apr;76(4):203–4 (Eng. Abstr.) **(Cze)**

[Surgical rehabilitation of the upper limbs in tetraplegic patients] Leclercq C. **Chirurgie** 1996;121(6):492–5 (Eng. Abstr.) **(Fre)**

[Asymmetry of posture and truncal musculature following unilateral arm amputation—a clinical, electromyographic, posture analytical and photogrammetric study] Greitemann B, et al. **Z Orthop Ihre Grenzgeb** 1996 Nov–Dec; 134(6):498–510 (39 ref.) (Eng. Abstr.) **(Ger)**

[Repetitive movements of the upper limbs: results of exposure evaluation and clinical investigation in refinishing ceramic ornaments] Arfaioli C, et al. **Med Lav** 1996 Nov–Dec; 87(6):593–7 (Eng. Abstr.) **(Ita)**

[Repetitive movement of the upper limbs: results of exposure evaluation and clinical investigation in wood sanding in Bergamo] Bacis M, et al. **Med Lav** 1996 Nov–Dec; 87(6):613–24 (Eng. Abstr.) **(Ita)**

[Outbreak of carpal tunnel syndrome of the upper limbs in automobile seat assemblers: results of exposure evaluation and clinical investigation] Barbieri PG, et al. **Med Lav** 1996 Nov-Dec;87(6):646-55 (Eng. Abstr.) **(Ita)**

[Repetitive movements of the upper limbs: results of exposure evaluation and clinical investigation in the manual sanding of wood in the Valdichiana region] Biondi MC, et al. **Med Lav** 1996 Nov-Dec;87(6):625-33 (Eng. Abstr.) **(Ita)**

[The application of the concise exposure index to repetitive movement tasks of the upper limbs in various production settings: preliminary experience and validation] Colombini D, et al. **Med Lav** 1996 Nov-Dec;87(6):704-15 (Eng. Abstr.) **(Ita)**

[Guidelines for redesigning jobs with repetitive tasks] Colombini D, et al. **Med Lav** 1996 Nov-Dec;87(6):728-49 (Eng. Abstr.) **(Ita)**

[Criteria for the reintegration to their jobs of workers with musculoskeletal pathologies of the upper limbs based on preliminary practical experiences] Colombini D, et al. **Med Lav** 1996 Nov-Dec;87(6):750-63 (Eng. Abstr.) **(Ita)**

[Occurrence of musculoskeletal disorders in working populations not exposed to repetitive tasks of the upper arms] De Marco F, et al. **Med Lav** 1996 Nov-Dec; 87(6):581-9 (Eng. Abstr.) **(Ita)**

[Clinical studies in working populations: value and significance of anamnestic findings, clinical tests and instrumental tests for the diagnosis of musculoskeletal disorders of the upper extremities] De Marco F, et al. **Med Lav** 1996 Nov-Dec;87(6):561-80 (Eng. Abstr.) **(Ita)**

[Repetitive movement of the upper limbs: results of a current exposure evaluation and a clinical investigation in workers employed in the preparation of pork meat in the province of Modena] Ghersi R, et al. **Med Lav** 1996 Nov-Dec; 87(6):656-74 (Eng. Abstr.) **(Ita)**

[Evaluation of the exposure to biomechanical overload of the upper limbs and clinical investigation in a female population employed in the manual loading of production lines in 2 ceramics factories] Martinelli M, et al. **Med Lav** 1996 Nov-Dec;87(6):675-85 (Eng. Abstr.) **(Ita)**

[Clinical studies in working populations: a model for the anamnestic investigation of the pathology of the upper limbs and its practical application] Menoni O, et al. **Med Lav** 1996 Nov-Dec;87(6):549-60 (Eng. Abstr.) **(Ita)**

[Repetitive movements of the upper limbs: results of exposure evaluation and clinical investigation during the sorting and packaging of apples] Merseburger A. **Med Lav** 1996 Nov-Dec;87(6):603-12 (Eng. Abstr.) **(Ita)**

[Musculoskeletal disorders of upper extremities caused by biomechanical overload: methods and criteria for the description of occupational exposure] Occhipinti E, et al. **Med Lav** 1996 Nov-Dec;87(6):491-525 (Eng. Abstr.) **(Ita)**

[Proposal of a concise index for the evaluation of the exposure to repetitive movements of the upper extremity (OCRA index)] Occhipinti E, et al. **Med Lav** 1996 Nov-Dec;87(6):526-48 (Eng. Abstr.) **(Ita)**

[Criteria for the health surveillance of WMSDs in exposed working populations] Occhipinti E, et al. **Med Lav** 1996 Nov-Dec;87(6):719-27 (Eng. Abstr.) **(Ita)**

[Repetitive movement of the upper limbs: results of exposure evaluation and clinical investigation in cash register operators in supermarkets] Panzone I, et al. **Med Lav** 1996 Nov-Dec;87(6):634-9 (Eng. Abstr.) **(Ita)**

[Repetitive movement of the upper limbs: results of exposure evaluation and clinical investigation during jar packaging of preserved vegetables] Panzone I, et al. **Med Lav** 1996 Nov-Dec;87(6):640-5 (Eng. Abstr.) **(Ita)**

[Repetitive movements of the upper limbs: results of exposure evaluation and clinical investigation in the production and packaging of ice cream] Sannino G, et al. **Med Lav** 1996 Nov-Dec;87(6):598-602 (Eng. Abstr.) **(Ita)**

[Venous hypertension of the arm. A complication of vascular access in hemodialysis] Caruso U, et al. **Minerva Chir** 1996 Oct;51(10):877-9 (Eng. Abstr.) **(Ita)**

[Surgical treatment of post-mastectomy lymphedema of the upper limb] Paroni G, et al. **Minerva Chir** 1996 May; 51(5):297-9 (Eng. Abstr.) **(Ita)**

[Myelopathy due to vitamin B12 deficiency presenting only sensory disturbances in upper extremities: a case report] Imaiso Y, et al. **Rinsho Shinkeigaku** 1997 Feb;37(2):135-8 (Eng. Abstr.) **(Jpn)**

[Dystonic movement of the left upper limb in a case of the right pontine hemorrhage] Sakajiri K, et al. **Rinsho Shinkeigaku** 1997 Jan;37(1):37-40 (Eng. Abstr.) **(Jpn)**

[Lymphangiosarcoma in the framework of marked arm lymphostasis after mastectomy (Stewart-Treves syndrome)] Denisov LE, et al. **Khirurgiia (Mosk)** 1996; (2):117-8 **(Rus)**

[The evaluation of fat and muscles of the arm in the nutritional study in pre-school children in Madrid] Tejedor García V, et al. **An Esp Pediatr** 1997 Apr;46(4):335-43 (Eng. Abstr.) **(Spa)**

[Epithelioid sarcoma of the right arm with brain metastases (letter)] Ulla Anes M, et al. **An Med Interna** 1997 Feb; 14(2):105 **(Spa)**

ABNORMALITIES

A translocation at 12q2 refines the interval containing the Holt-Oram syndrome 1 gene [published erratum appears in Am J Hum Genet 1997 Mar;60(3):750] Terrett JA, et al. **Am J Hum Genet** 1996 Dec;59(6):1337-41

Brachmann-de Lange syndrome: pre- and postnatal findings [see comments] Manouvrier S, et al. **Am J Med Genet** 1996 Mar 29;62(3):268-73. Comment in: Am J Med Genet 1997 Jan 31;68(3):367-8.

Upper limb malformations in chromosome 22q11 deletions [letter] Shalev SA, et al. **Am J Med Genet** 1996 Mar 29; 62(3):302

Kenny-Caffey syndrome in six Bedouin sibships: autosomal recessive inheritance is confirmed. Tahseen K, et al. **Am J Med Genet** 1997 Mar 17;69(2):126-32

Severe limb abnormalities: Nievergelt or new syndrome? Vasil M, et al. **Am J Med Genet** 1997 May 2;70(1):48-51

Perinatal features of omphalocele-exstrophy-imperforate anus-spinal defects (OEIS complex) associated with large meningomyeloceles and severe limb defects. Chen CP, et al. **Am J Perinatol** 1997 May;14(5):275-9

Supernumerary limbs: a case report of a rare congenital anomaly. Kher AS, et al. **Ann Plast Surg** 1996 Nov; 37(5):549-52

Variation in the triceps brachii muscle: a fourth muscular head. Fabrizio PA, et al. **Clin Anat** 1997;10(4):259-63

Spondylo-meta-epiphyseal dysplasia, short limb, abnormal calcification type. al-Gazali LI, et al. **Clin Dysmorphol** 1996 Jul;5(3):197-206

Poland sequence in two siblings suggesting an autosomal inheritance transmission. Cohen A, et al. **Clin Genet** 1996 Aug;50(2):93-5

A mild form of Roberts/SC phocomelia syndrome with asymmetrical reduction of the upper limbs. Concolino D, et al. **Clin Genet** 1996 May;49(5):274-6

Does periconceptional multivitamin use reduce the risk for limb deficiency in offspring? Yang Q, et al. **Epidemiology** 1997 Mar;8(2):157-61

Longitudinal failure of upper-limb formation. Manske PR. **Instr Course Lect** 1997;46:83-110 (95 ref.)

Upper limb triplication with radial dimelia. Mennen U, et al. **J Hand Surg [Br]** 1997 Feb;22(1):80-3

Unilateral hypertrophy of the upper extremity due to aberrant muscles. Tanabe K, et al. **J Hand Surg [Br]** 1997 Apr;22(2):253-7

Cutis marmorata telangiectatica congenita: an unusual presentation with monoatrophy in two Chinese children. Wong V. **J Paediatr Child Health** 1997 Feb;33(1):71-3

Pulmonary agenesis with intrathoracic upper limb. Banerjee S, et al. **J Pediatr Surg** 1997 May;32(5):779-81

Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Bamshad M, et al. **Nat Genet** 1997 Jul;16(3):311-5

Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome [published erratum appears in Nat Genet 1997 Apr;15(4):411] Basson CT, et al. **Nat Genet** 1997 Jan;15(1):30-5

Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family. Li QY, et al. **Nat Genet** 1997 Jan;15(1):21-9

Congenital disorders of the hand and upper extremity. Van Heest AE. **Pediatr Clin North Am** 1996 Oct;43(5):1113-33 (23 ref.)

[Holt-Oram syndrome] Matsuoka R. **Ryoikibetsu Shokogun Shirizu** 1996;(15):267-70 (13 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Body composition assessed on the basis of arm circumference and triceps skinfold thickness: a new index validated in children by magnetic resonance imaging. Rolland-Cachera MF, et al. **Am J Clin Nutr** 1997 Jun;65(6):1709-13

Effect of muscle length on distribution of muscle fiber conduction velocity for M. biceps brachii. Sakamoto K, et al. **Appl Human Sci** 1997 Jan;16(1):1-7

The relationship between arm-span measurement and height with special reference to gender and ethnicity. Reeves SL, et al. **Eur J Clin Nutr** 1996 Jun;50(6):398-400

Auxological and endocrinological evaluation of children with hydrocephalus and/or meningomyelocele. Hochhaus F, et al. **Eur J Pediatr** 1997 Aug;156(8):597-601

Morphological asymmetries of motoneurons innervating upper extremities: clues to the anatomical foundations of handedness? Melsbach G, et al. **Int J Neurosci** 1996 Sep; 86(3-4):217-24

Parameters for modeling the upper extremity. Veeger HE, et al. **J Biomech** 1997 Jun;30(6):647-52

The use of mid-upper-arm circumference to monitor nutritional rehabilitation programmes in rural Bangladesh [letter] de Francisco A, et al. **J Trop Pediatr** 1997 Apr; 43(2):118-9

More growth-chart confusion [letter] Macfarlane SB. **Lancet** 1997 Jul 12;350(9071):150

Validation of an optoelectronic limb volumeter (Perometer). Stanton AW, et al. **Lymphology** 1997 Jun;30(2):77-97

BLOOD SUPPLY

Pulse oxymetry evaluation of oxygen saturation in the upper extremity with an arteriovenous fistula before and during hemodialysis. Lin G, et al. **Am J Kidney Dis** 1997 Feb; 29(2):230-2

Upper extremity blood flow in collegiate and high school baseball pitchers A preliminary report. Bast SC, et al. **Am J Sports Med** 1996 Nov-Dec;24(6):847-51

Upper extremity versus lower extremity deep venous thrombosis. Hingorani A, et al. **Am J Surg** 1997 Aug; 174(2):214-7

Limb ischemia: surgical therapy in acute arterial occlusion. Neuzil DF, et al. **Am Surg** 1997 Mar;63(3):270-4

Upper-extremity arterial injury. Pillai L, et al. **Am Surg** 1997 Mar;63(3):224-7

2-D time-of-flight (TOF) MRA of thrombophlebitis of upper extremity and subclavian veins. A case report. Chang YC, et al. **Angiology** 1996 Oct;47(10):1019-22

Arm vein reconstruction for limb salvage: long-term outcome. Tisi PV, et al. **Ann R Coll Surg Engl** 1996 Nov; 78(6):497-500

Superior patency of perforating antecubital vein arteriovenous fistulae for hemodialysis. Sparks SR, et al. **Ann Vasc Surg** 1997 Mar;11(2):165-7

Upper extremity ischemia from subclavian artery aneurysm caused by bony abnormalities of the thoracic outlet. Nehler MR, et al. **Arch Surg** 1997 May;132(5):527-32

Occlusive arterial disease of the upper extremity: colour Doppler as a screening technique and for assessment of distal circulation. Taneja K, et al. **Australas Radiol** 1996 Aug;40(3):226-9

Arm arterial occlusion cuffs as a means of alleviating high +Gz-associated arm pain. Green ND. **Aviat Space Environ Med** 1997 Aug;68(8):715-21

Low prevalence of thrombophilic coagulation defects in patients with deep vein thrombosis of the upper limbs. Ruggeri M, et al. **Blood Coagul Fibrinolysis** 1997 Apr; 8(3):191-4

Pathogenesis and management of upper-extremity ischemia following angioaccess surgery. Haimov M, et al. **Blood Purif** 1996;14(5):350-4

Local fibrinolysis in native arteriovenous fistulas of haemodialysis patients. Haznedaroğlu IC, et al. **Blood Purif** 1996;14(3):227-33

Forearm vascular responses to serotonin are not mediated by products of cyclooxygenase. Nugent AG, et al. **Br J Clin Pharmacol** 1996 Mar;41(3):241-3

Three year follow-up of a case of giant cell arteritis presenting with a chronic cough and upper limb ischaemic symptoms [letter] Jolobe OM. **Br J Rheumatol** 1997 Apr; 36(4):503

Postoperative regional analgesia following basilic vein transposition for vascular access. Butterworth PC, et al. **Br J Surg** 1997 Apr;84(4):561

High brachial artery bifurcation: a report of 2 cases. Celik HH, et al. **Bull Assoc Anat (Nancy)** 1996 Sep;80(250):13-4

Long-term outcomes after upper limb arterial injuries. van der Sluis CK, et al. **Can J Surg** 1997 Aug;40(4):265-70

MRI of pseudoaneurysm of a brachial venous coronary bypass graft. Duerinckx AJ, et al. **Cathet Cardiovasc Diagn** 1996 Mar;37(3):281-6

The dynamics of changes of upper extremities caused by vibrations and unilateral excessive load after discontinued risk exposure. Havlásková J. **Cent Eur J Public Health** 1996 Feb;4(1):33-5

Reduction of the vibration of the hand-arm system by optimization of rotary hammer drills. Weinert K, et al. **Cent Eur J Public Health** 1996 Feb;4(1):36-9

Hand-arm vibration hazard and prevention in China. Xiao JM, et al. **Cent Eur J Public Health** 1996 Feb;4(1):40-2

Painful vein overdistension in migraine patients: no relationship with serotoninergic parameters. Panconesi A, et al. **Cephalalgia** 1996 Feb;16(1):37-40

Ankle to arm index response to exercise and heat stress in healthy subjects. Desvaux B, et al. **Clin Physiol** 1996 Jan; 16(1):1-7

Management of severe ischemia of the upper extremity. Pederson WC. **Clin Plast Surg** 1997 Jan;24(1):107-20 (56 ref.)

Arm-leg pressure gradients on late follow-up after coarctation repair. Possible causes and implications. Guenthard J, et al. **Eur Heart J** 1996 Oct;17(10):1572-5

Fore quarter gangrene: complication of Blalock-Taussig shunt. Hussain R, et al. **Eur J Cardiothorac Surg** 1997 Mar; 11(3):582-4

Upper and lower extremity somatosensory evoked potential recording during surgery for aneurysms of the descending thoracic aorta. Shahin GM, et al. **Eur J Cardiothorac Surg** 1996;10(5):299-304

Cutaneous vascular control in the arms of women with postmastectomy oedema. Stanton AW, et al. **Exp Physiol** 1996 May;81(3):447-64

Extensive pure venous malformations in the upper or lower limb: a review of 27 cases. Enjolras O, et al. **J Am Acad Dermatol** 1997 Feb;36(2 Pt 1):219-25

Acute ischemia of the upper limb fifteen years after anterior dislocation of the glenohumeral joint and a modified Bristow procedure. A case report. Cappello T, et al. **J Bone Joint Surg Am** 1996 Oct;78(10):1578-82

Digital ischemia associated with a thrombosed aneurysm of the dorsal interosseous artery. A case report. O'Farrell DA, et al. **J Bone Joint Surg Am** 1997 Mar;79(3):441-3

The orthopaedic implications of peripheral limb ischaemia in infants and children. Farrar MJ, et al. **J Bone Joint Surg Br** 1996 Nov;78(6):930-3

Arteriovenous obstruction of arm due to venovenous bypass during liver transplantation. Neelakanta G, et al. **J Clin Anesth** 1997 Sep;9(6):507-9

The diagnostic value of the measurement of the ankle-brachial systolic pressure index in primary health care. Stoffers HE, et al. **J Clin Epidemiol** 1996 Dec; 49(12):1401-5

Major vascular malformations of the upper extremity: long-term observation. Mendel T, et al. **J Hand Surg [Am]** 1997 Mar;22(2):302–6

Vascular injuries of the upper arm. Sriussadaporn S. **J Med Assoc Thai** 1997 Mar;80(3):160–8

Venous varix causing median neuropathy. Case illustration. Zikel OM, et al. **J Neurosurg** 1997 Jul;87(1):130

Microvascular and thrombolytic revascularization of an arm in a 32-week-gestation neonate: case report and review of the literature. Theile RJ, et al. **J Reconstr Microsurg** 1996 Nov;12(8):539–42

Upper extremity deep venous thrombosis. Nemcek A Jr. **J Vasc Interv Radiol** 1996 May–Jun;7(3):378–9

Age-related differences in elastic properties of the upper arm vascular bed in healthy adults. Muntinga JH, et al. **J Vasc Res** 1997 Mar–Apr;34(2):137–47

Distal revascularization-interval ligation for limb salvage and maintenance of dialysis access in ischemic steal syndrome. Berman SS, et al. **J Vasc Surg** 1997 Sep;26(3):393–402; discussion 402–4

Superficial femoral artery eversion endarterectomy: a useful adjunct for infrainguinal bypass in the presence of limited autogenous vein. Taylor SM, et al. **J Vasc Surg** 1997 Sep; 26(3):439–45; discussion 445–6

Superficial brachial arteries observed in bilateral arms. Nakatani T, et al. **Kaibogaku Zasshi** 1996 Aug;71(4):308–12

A complicated variation of the upper extremity vascularisation. Sargon MF, et al. **Kaibogaku Zasshi** 1996 Jun;71(3):211–4

Upper-extremity deep vein thrombosis. Elliott G. **Lancet** 1997 Apr 26;349(9060):1188–9

Are hemodynamic factors important in arm lymphedema after treatment of breast cancer? Martin KP, et al. **Lymphology** 1996 Dec;29(4):155–7

A preliminary study on the effect of hormone replacement therapy on peripheral flow velocity in postmenopausal women. Lau TK, et al. **Maturitas** 1997 Jan;26(1):53–6

Delay in improvement of ankle-arm index and ankle waveforms after lower-extremity revascularization. Tripathi S, et al. **Mil Med** 1997 Apr;162(4):301–3

Pulmonary embolism in deep venous thrombosis of the upper extremity: more often in catheter-related thrombosis. Kooij JD, et al. **Neth J Med** 1997 Jun;50(6):238–42

Transient axillary-upper inner arm subcutaneous fibrous banding [letter; comment] Shiffman MA. **Plast Reconstr Surg** 1997 Feb;99(2):596. Comment on: Plast Reconstr Surg 1996 May;97(6):1304–5.

Cephalic vein cutdown: a new approach [letter] Chitkara N, et al. **Trop Doct** 1997 Jul;27(3):192

Major vessel resection during limb-preserving surgery for soft tissue sarcomas. Karakousis CP, et al. **World J Surg** 1996 Mar–Apr;20(3):345–9; discussion 350

[Transposition of the basilic vein in the arm for vascular access in hemodialysis] Lindner J. **Rozhl Chir** 1997 Mar; 76(3):126–8 (Eng. Abstr.) **(Cze)**

[Thromboembolic complications of central venous catheters (see comments)] Manten A, et al. **Ned Tijdschr Geneeskd** 1996 Sep 7;140(36):1797–800 (32 ref.). Comment in: Ned Tijdschr Geneeskd 1996 Nov 16;140(46):2302. **(Dut)**

[Paresthesia, pain, coldness of the arm and possible responsibility of the thoraco-brachial outlet syndrome] Baste JC, et al. **J Mal Vasc** 1996;21(5):329–32; discussion 333 (Eng. Abstr.) **(Fre)**

[Non-cardiac causes of acute ischemia in the arms] d'Addato M, et al. **J Mal Vasc** 1996;21(5):303–7 (Eng. Abstr.) **(Fre)**

[Severe limb ischemia due to iatrogenic trauma] Melliere D, et al. **J Mal Vasc** 1996;21(3):141–7 (Eng. Abstr.) **(Fre)**

[In situ thrombolysis in the treatment of venous thrombosis of effort in the arm] Pegis JD, et al. **J Mal Vasc** 1997 Jul; 22(3):187–92 (Eng. Abstr.) **(Fre)**

[Aneurysms of the peripheral arteries. II. Aneurysms of the upper limbs] Defraigne JO, et al. **Rev Med Liege** 1997; 52(1):27–30 (23 ref.) **(Fre)**

[Thromboembolectomy with the Fogarty catheter in acute ischemia of the upper extremities] Hernandez-Richter T, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1996; 113:897–8 (Eng. Abstr.) **(Ger)**

[Loss of extremities caused by heparin-induced thrombocytopenia] Wenzl ME, et al. **Unfallchirurg** 1996 Aug;99(8):607–11 (Eng. Abstr.) **(Ger)**

[Treatment concept and results of grade 3 open fractures with arterial injuries requiring reconstruction] Ostermann PA, et al. **Zentralbl Chir** 1996;121(11):990–3 (Eng. Abstr.) **(Ger)**

[The use of isolated and combined thoracic sympathectomy in treating vascular diseases of the upper extremities] Nikonenko AS, et al. **Klin Khir** 1995;(3):24–6 **(Rus)**

[Intra-arterial infusion into the upper radial collateral artery in treating a circulatory disorder in the upper extremity] Pertsov VI. **Klin Khir** 1996;(7):50 **(Rus)**

[The late performance of embolectomy from the major arteries of the extremities] Shor NA, et al. **Klin Khir** 1996; (7):24–6 **(Rus)**

[Our experience in treating patients with embolisms of the aorta and major arteries of the extremities (on the centenary of the first embolectomy)] Barsukov AE, et al. **Vestn Khir Im I I Grek** 1996;(1):10–3 (Eng. Abstr.) **(Rus)**

[The dynamics of the enzyme system indices in the blood serum of patients with acute ischemia of the extremities] Kariakin AM, et al. **Vestn Khir Im I I Grek** 1997; 156(1):76–9 (Eng. Abstr.) **(Rus)**

[Arterial thrombosis associated with anticardiolipin antibodies in a patient with ulcerative colitis (letter)] Zambrana García JL, et al. **Gastroenterol Hepatol** 1997 Jun–Jul;20(6):337 **(Spa)**

[Fever of unknown origin and subacute occurrence of ischemic events in upper limbs] Moro MJ, et al. **Rev Clin Esp** 1996 Jan;196(1):51–2 **(Spa)**

GROWTH & DEVELOPMENT

Appearance of ossification centers of the lower arm, wrist, lower leg, and ankle in immature orangutans and chimpanzees with an assessment of the relationship of ossification to dental development. Winkler LA. **Am J Phys Anthropol** 1996 Jan;99(1):191–203

INJURIES see ARM INJURIES

INNERVATION

Recovery of upper limb motor function in tetraplegia with stellate ganglion block treatment of reflex sympathetic dystrophy: a case report. Levy CE, et al. **Am J Phys Med Rehabil** 1996 Nov–Dec;75(6):479–82

Upper limb functional electrical stimulation for walker ambulation in hemiplegia: a case report. Weingarden HP, et al. **Am J Phys Med Rehabil** 1997 Jan–Feb;76(1):63–7

Prevention of painful neuromas by epineural ligatures, flaps and grafts. Yüksel F, et al. **Br J Plast Surg** 1997 Apr; 50(3):182–5

The dynamics of changes of upper extremities caused by vibrations and unilateral excessive load after discontinued risk exposure. Havlásková J. **Cent Eur J Public Health** 1996 Feb;4(1):33–5

Effect of impulse vibration and noise on vasomotor function of peripheral blood vessels among pneumatic forge hammer operators. Solecki L. **Cent Eur J Public Health** 1995;3 Suppl:88–9

Hand-arm vibration hazard and prevention in China. Xiao JM, et al. **Cent Eur J Public Health** 1996 Feb;4(1):40–2

Effects of transcranial electrical and magnetic stimulation on reciprocal inhibition in the human arm. Mercuri B, et al. **Electroencephalogr Clin Neurophysiol** 1997 Apr; 105(2):87–93

Parkinsonism reduces coordination of fingers, wrist, and arm in fine motor control. Teulings HL, et al. **Exp Neurol** 1997 Jul;146(1):159–70

Morphological asymmetries of motoneurons innervating upper extremities: clues to the anatomical foundations of handedness? Melsbach G, et al. **Int J Neurosci** 1996 Sep; 86(3–4):217–24

Cold intolerance following peripheral nerve injury. Natural history and factors predicting severity of symptoms. Irwin MS, et al. **J Hand Surg [Br]** 1997 Jun;22(3):308–16

Biceps rupture in a patient on long-term anticoagulation leading to compartment syndrome and nerve palsies. Richards AM, et al. **J Hand Surg [Br]** 1997 Jun;22(3):411–2

Physical evaluation of the peripheral nervous system in disorders of pain and dysfunction. Elvey RL. **J Hand Ther** 1997 Apr–Jun;10(2):122–9 (29 ref.)

Medical and pharmacologic management of upper extremity neuropathic pain syndromes. Mackin GA. **J Hand Ther** 1997 Apr–Jun;10(2):96–109 (88 ref.)

Repetitive use and static postures: a source of nerve compression and pain. Novak CB, et al. **J Hand Ther** 1997 Apr–Jun;10(2):151–9 (73 ref.)

Abnormal access of axial vibrotactile input to deafferented somatosensory cortex in human upper limb amputees. Kew JJ, et al. **J Neurophysiol** 1997 May;77(5):2753–64

Direct and indirect corticospinal control of arm and hand motoneurons in the squirrel monkey (Saimiri sciureus). Maier MA, et al. **J Neurophysiol** 1997 Aug;78(2):721–33

Neurologic deficit and recovery in the donor limb following cross-C7 transfer in brachial-plexus injury. Liu J, et al. **J Reconstr Microsurg** 1997 May;13(4):237–42; discussion 242–3

Improved motor function in tetraplegics following neuromuscular stimulation-assisted arm ergometry. Needham-Shropshire BM, et al. **J Spinal Cord Med** 1997 Jan;20(1):49–55

Medial antebrachial cutaneous nerve: a new donor graft for repair of facial nerve defects at the skull base. Haller JR, et al. **Laryngoscope** 1997 Aug;107(8):1048–52

Double-crush syndrome: a critical analysis. Wilbourn AJ, et al. **Neurology** 1997 Jul;49(1):21–9 (84 ref.)

Physiological diagnosis and surgical treatment of recurrent limb shaking: case report. Firlik AD, et al. **Neurosurgery** 1996 Sep;39(3):607–11

Pediatric axillary block with conscious sedation [letter] Margolis JO, et al. **Reg Anesth** 1996 Nov–Dec;21(6):603–5

Nerve conduction abnormalities in the arms of patients with arteriovenous fistula. Klein C, et al. **Ren Fail** 1996 Jan; 18(1):85–9

Giant cell arteritis revealed by bilateral lesions of brachial plexus [letter] Gatfosse M, et al. **Rev Rhum Engl Ed** 1996 Apr;63(4):301–2

Motor cortical mapping of proximal upper extremity muscles following spinal cord injury. Brouwer B, et al. **Spinal Cord** 1997 Apr;35(4):205–12

[A case of Creutzfeldt-Jakob disease (CJD) started with monoparesis of the left arm] Obi T, et al. **Rinsho Shinkeigaku** 1996 Nov;36(11):1245–8 (Eng. Abstr.) **(Jpn)**

[The restoration of the sensitive function of the nerves in replanted upper extremities] Rezkov GI. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(4):29–32 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Infection of the upper extremity by Mycobacterium marinum in a 3-year-old boy—diagnosis by 16S-rDNA analysis. Feddersen A, et al. **Infection** 1996 Jan–Feb;24(1):47–8

PARASITOLOGY

Tropical myiasis: an unwanted holiday souvenir. Kitching J. **J Accid Emerg Med** 1997 May;14(3):178–9

Dermatobia hominis in the accident and emergency department: "I've got you under my skin". MacNamara A, et al. **J Accid Emerg Med** 1997 May;14(3):179–80

PATHOLOGY

Acute biceps compartment syndrome associated with the use of a noninvasive blood pressure monitor. Sutin KM, et al. **Anesth Analg** 1996 Dec;83(6):1345–6

Self-involuting atrophoderma of the lateral-upper arm. A new benign variant of morphea? Inazumi T, et al. **Dermatology** 1997;194(2):147–50

Absolute values or Z scores of mid-upper arm circumference to identify wasting? Evaluation in a community as well as a clinical sample of under fives from Nchelenge, Zambia. Gernaat HB, et al. **J Trop Pediatr** 1996 Feb;42(1):27–33

The use of upper extremity anthropometrics in the clinical assessment of patients with amyotrophic lateral sclerosis. Kasarskis EJ, et al. **Muscle Nerve** 1997 Mar;20(3):330–5

Dedicated extremity MR imaging. An emerging technology. Peterfy CG, et al. **Radiol Clin North Am** 1997 Jan; 35(1):1–20 (32 ref.)

Acquired immobility of the right arm. Bell WE. **Semin Pediatr Neurol** 1996 Sep;3(3):173–6

[Normal anatomy and pathologic features of the supraspinatus muscle: comparison between ultrasonography and surgery. Analysis of the potential sources of diagnostic errors] Montrucchio E, et al. **Radiol Med (Torino)** 1997 Apr;93(4):342–7 (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Differences in mouth occlusion pressure and breathing pattern between arm and leg incremental exercise. Ramonatxo M, et al. **Acta Physiol Scand** 1996 Dec; 158(4):333–41

Pronator teres reflex: reliability and normal value. Shehab D, et al. **Am J Phys Med Rehabil** 1996 Sep–Oct; 75(5):328–31

Effect of muscle length on distribution of muscle fiber conduction velocity for M. biceps brachii. Sakamoto K, et al. **Appl Human Sci** 1997 Jan;16(1):1–7

Blood pressure. Assessment of interarm differences [see comments] Singer AJ, et al. **Arch Intern Med** 1996 Sep 23;156(17):2005–8. Comment in: Arch Intern Med 1997 Apr 14;157(7):818.

The distance shortening phenomenon or the lazy arm sign as a subtle pyramidal sign [letter] Pollak L, et al. **Arch Neurol** 1997 Aug;54(8):935

Three-dimensional joint moments analysis in a vertical quadrupedal posture associated with a leg release. Quaine F, et al. **Arch Physiol Biochem** 1997 Apr;105(2):136–43

Pointing arm movements in short- and long-term spaceflights. Berger M, et al. **Aviat Space Environ Med** 1997 Sep;68(9 Pt 1):781–7

Prehension with trunk assisted reaching. Saling M, et al. **Behav Brain Res** 1996 Oct;80(1–2):153–60

A minimum energy cost hypothesis for human arm trajectories. Alexander RM. **Biol Cybern** 1997 Feb; 76(2):97–105

Self-organization of trajectory formation. I. Experimental evidence. Buchanan JJ, et al. **Biol Cybern** 1997 Apr; 76(4):257–73

Self-organization of trajectory formation. II. Theoretical model. de Guzman GC, et al. **Biol Cybern** 1997 Apr; 76(4):275–84

Two-arm trajectory planning in a manipulation task. Garvin GJ, et al. **Biol Cybern** 1997 Jan;76(1):53–62

Analysis of an optimal control model of multi-joint arm movements. Lan N. **Biol Cybern** 1997 Feb;76(2):107–17

The role of the plant properties in point-to-point arm movements: a robustness study. Myers JD, et al. **Biol Cybern** 1997 Mar;76(3):173–80

A numerical simulation of muscle spindle ensemble encoding during planar movement of the human arm. Wallace KR, et al. **Biol Cybern** 1996 Oct;75(4):339–50

A numerical simulation of muscle spindle ensemble encoding during planar movement of the human arm: correlation sensitivity and parameter dependence. Wallace KR, et al. **Biol Cybern** 1996 Oct;75(4):351–9

Time course of changes in bilateral arm power of swimmers during recovery from injury using a swim bench. Swaine IL. **Br J Sports Med** 1997 Sep;31(3):213–6

Hemispace asymmetries and laterality effects in arm positioning. Imanaka K, et al. **Brain Cogn** 1995 Dec; 29(3):232–53

Neuronal activity in the striatum and pallidum of primates related to the execution of externally cued reaching movements. Jaeger D, et al. **Brain Res** 1995 Oct 2; 694(1–2):111–27

Soleus H-reflex depression induced by ballistic voluntary arm movement in human. Kasai T, et al. **Brain Res** 1996 Apr 1;714(1–2):125–34

Changes in regional cerebral blood flow during self-paced arm and finger movements. A PET study. Kawashima R, et al. **Brain Res** 1996 Apr 15;716(1–2):141–8

Activity of interpositus neurons during a visually guided reach. Gibson AR, et al. **Can J Physiol Pharmacol** 1996 Apr;74(4):499–512

Motor control, excitement, and overarm throwing. Hore J. **Can J Physiol Pharmacol** 1996 Apr;74(4):385–9 (25 ref.)

Cooperative structures for visually guided reach. MacKay WA. **Can J Physiol Pharmacol** 1996 Apr;74(4):463–8 (46 ref.)

The influence of individual factors on the absorption of vibration energy in the hand and arm. Burström L. **Cent Eur J Public Health** 1996 Feb;4(1):50–2

Development of a grip force dependent hand-arm vibration model. Gurram R, et al. **Cent Eur J Public Health** 1996 Feb;4(1):65–8

Measurement and evaluation of coupling forces when using hand-held power tools. Kaulbars U. **Cent Eur J Public Health** 1996 Feb;4(1):57–8

Derivation of mean impedance curves as a basis for mechanical models of the human hand-arm system. Kinne J, et al. **Cent Eur J Public Health** 1996 Feb;4(1):53–6

Consideration of grip and push forces for the assessment of vibration exposure. Riedel S. **Cent Eur J Public Health** 1995;3 Suppl:139–41

Functional anatomy of pointing and grasping in humans. Grafton ST, et al. **Cereb Cortex** 1996 Mar-Apr;6(2):226–37

Post-exercise cutaneous hyperaemia resulting from local exercise of an extremity. Rendell MS, et al. **Clin Physiol** 1997 May;17(3):213–24

Turn/amplitude parameter changes during sustained effort. Finsterer J, et al. **Electroencephalogr Clin Neurophysiol** 1996 Oct;101(5):438–45

Motor control and kinetics during low level concentric and eccentric contractions in man. Søgaard K, et al. **Electroencephalogr Clin Neurophysiol** 1996 Oct; 101(5):453–60

Cardiorespiratory and subjective responses to prolonged arm and leg exercise in healthy young and older men. Aminoff T, et al. **Eur J Appl Physiol** 1997;75(4):363–8

Relationship between maximal oxygen uptake on different ergometers, lean arm volume and strength in paraplegic subjects. Arabi H, et al. **Eur J Appl Physiol** 1997; 76(2):122–7

Effect of electrical stimulation of leg muscles on physiological responses during arm–cranking exercise in healthy men. Eijsbouts XH, et al. **Eur J Appl Physiol** 1997; 75(2):177–81

Influence of electrode position on changes in electromyograph parameters of the upper trapezius muscle during submaximal sustained contractions. Hermans V, et al. **Eur J Appl Physiol** 1997;75(4):319–25

Differences in muscle contractile characteristics among bodybuilders, endurance trainers and control subjects. Jürimäe J, et al. **Eur J Appl Physiol** 1997;75(4):357–62

Volume changes in the forearm and lower limbs during 2 h of acute hypobaric hypoxia in nonacclimatized subjects. Schirlo C, et al. **Eur J Appl Physiol** 1997;75(2):124–31

Visual control of hand-reaching movement: activity in parietal area 7m. Ferraina S, et al. **Eur J Neurosci** 1997 May;9(5):1090–5

The relative contribution of retinal and extraretinal signals in determining the accuracy of reaching movements in normal subjects and a deafferented patient. Blouin J, et al. **Exp Brain Res** 1996 Apr;109(1):148–53

Differential relation of discharge in primary motor cortex and premotor cortex to movements versus actively maintained postures during a reaching task. Crammond DJ, et al. **Exp Brain Res** 1996 Feb;108(1):45–61

The coordination between trunk and arm motion during pointing movements. Kaminski TR, et al. **Exp Brain Res** 1995;106(3):457–66

The role of posterior parietal cortex in visually guided reaching movements in humans. Kertzman C, et al. **Exp Brain Res** 1997 Mar;114(1):170–83

Anatomical distribution of arm-movement-related neurons in the primate superior colliculus and underlying reticular formation in comparison with visual and saccadic cells. Werner W, et al. **Exp Brain Res** 1997 Jun;115(2):206–16

Arm-movement-related neurons in the primate superior colliculus and underlying reticular formation: comparison of neuronal activity with EMGs of muscles of the shoulder, arm and trunk during reaching. Werner W, et al. **Exp Brain Res** 1997 Jun;115(2):191–205

A dynamic neural network identification of electromyography and arm trajectory relationship during complex movements. Cheron G, et al. **IEEE Trans Biomed Eng** 1996 May;43(5):552–8

FES standing: control by handle reactions of leg muscle stimulation (CHRELMS). Donaldson N de N, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):280–4 (12 ref.)

The influence of biodynamic factors on the mechanical impedance of the hand and arm. Burström L. **Int Arch Occup Environ Health** 1997;69(6):437–46

Anticipatory postural adjustments associated with arm movements during balancing on unstable support surface. Gantchev GN, et al. **Int J Psychophysiol** 1996 Apr–May; 22(1–2):117–22

The upper extremity attenuates intermediate frequency vibrations. Pope MH, et al. **J Biomech** 1997 Feb;30(2):103–8

Estimating the contribution of muscles to joint torque based on motor-unit activity. Theeuwen M, et al. **J Biomech** 1996 Jul;29(7):881–9

Evaluating an integrated musculoskeletal model of the human arm. Soechting JF, et al. **J Biomech Eng** 1997 Feb; 119(1):93–102

Arm movements in monkeys: behavior and neurophysiology. Georgopoulos AP. **J Comp Physiol [A]** 1996 Nov; 179(5):603–12 (46 ref.)

Spatial patterns in the control of human arm movement. Haggard P, et al. **J Exp Psychol Hum Percept Perform** 1996 Feb;22(1):42–62

Age-associated loss of power and strength in the upper extremities in women and men. Metter EJ, et al. **J Gerontol A Biol Sci Med Sci** 1997 Sep;52(5):B267–76

Central modifications of reflex parameters may underlie the fastest arm movements. Adamovich SV, et al. **J Neurophysiol** 1997 Mar;77(3):1460–9

Motor adaptation to Coriolis force perturbations of reaching movements: endpoint but not trajectory adaptation transfers to the nonexposed arm. Dizio P, et al. **J Neurophysiol** 1995 Oct;74(4):1787–92

Coordinating two degrees of freedom during human arm movement: load and speed invariance of relative joint torques. Gottlieb GL, et al. **J Neurophysiol** 1996 Nov; 76(5):3196–206

Origins of the power law relation between movement velocity and curvature: modeling the effects of muscle mechanics and limb dynamics. Gribble PL, et al. **J Neurophysiol** 1996 Nov;76(5):2853–60

Errors in the control of joint rotations associated with inaccuracies in overarm throws. Hore I, et al. **J Neurophysiol** 1996 Mar;75(3):1013–25

Changes in the control of arm position, movement, and thalamic discharge during local inactivation in the globus pallidus of the monkey. Inase M, et al. **J Neurophysiol** 1996 Mar;75(3):1087–1104

Comparison of onset time and magnitude of activity for proximal arm muscles and motor cortical cells before reaching movements. Scott SH. **J Neurophysiol** 1997 Feb; 77(2):1016–22

Reaching movements with similar hand paths but different arm orientations. I. Activity of individual cells in motor cortex. Scott SH, et al. **J Neurophysiol** 1997 Feb; 77(2):826–52

Postural dependence of muscle actions: implications for neural control. Buneo CA, et al. **J Neurosci** 1997 Mar 15; 17(6):2128–42

The role of internal models in motion planning and control: evidence from grip force adjustments during movements of hand-held loads. Flanagan JR, et al. **J Neurosci** 1997 Feb 15;17(4):1519–28

Prism adaptation of reaching movements: specificity for the velocity of reaching. Kitazawa S, et al. **J Neurosci** 1997 Feb 15;17(4):1481–92

Inverse dynamics as a tool for motion analysis: arm tracking movements in cerebellar patients. Riener R, et al. **J Neurosci Methods** 1997 Mar;72(1):87–96

Potentiation and depression of the M wave in human biceps brachii. Cupido CM, et al. **J Physiol (Lond)** 1996 Mar 1; 491 (Pt 2):541–50

Selective facilitation of responses to cortical stimulation of proximal and distal arm muscles by precision tasks in man. Schieppati M, et al. **J Physiol (Lond)** 1996 Mar 1;491 (Pt 2):551–62

Methods for determining three-dimensional wheelchair pushrim forces and moments: a technical note. Cooper RA, et al. **J Rehabil Res Dev** 1997 Apr;34(2):162–70

Challenges to clinical deployment of upper limb neuroprostheses. Triolo R, et al. **J Rehabil Res Dev** 1996 Apr;33(2):111–22 (19 ref.)

The effect of age, speed, and arm dominance on shoulder function in untrained men. Gallagher MA, et al. **J Shoulder Elbow Surg** 1996 Jan–Feb;5(1):25–31

Finger flexion does not contribute to ball speed in overarm throws. Hore J, et al. **J Sports Sci** 1996 Aug;14(4):335–42

The interpretation of relative momentum data to assess the contribution of the free limbs to the generation of vertical velocity in sports activities. Lees A, et al. **J Sports Sci** 1996 Dec;14(6):503–11

Estimating propulsive forces in swimming from three-dimensional kinematic data. Payton CJ, et al. **J Sports Sci** 1995 Dec;13(6):447–54

The role of reafference in recalibration of limb movement control and locomotion. Lackner JR, et al. **J Vestib Res** 1997 Jul–Aug;7(4):303–10

Study of isometric lifting strength in normal Chinese adults. Lin JH, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Jul;12(7):400–8

Clinical applications of characteristic frequency measurements: preliminary in vivo study. Blad B. **Med Biol Eng Comput** 1996 Sep;34(5):362–5

Metabolic efficiency during arm and leg exercise at the same relative intensities. Kang J, et al. **Med Sci Sports Exerc** 1997 Mar;29(3):377–82

Parallel direction and extent specification of planar reaching arm movements in humans. Favilla M, et al. **Neuropsychologia** 1996 Jun;34(6):609–13

Kinematics of goal-directed arm movements in neglect: control of hand in space. Karnath HO, et al. **Neuropsychologia** 1997 Apr;35(4):435–44

Reaching movements: programming time course is independent of choice number. Favilla M. **Neuroreport** 1996 Nov 4;7(15–17):2629–34

Quadrupedal locomotor movements in monkeys (M. Fuscata) on a treadmill: kinematic analyses. Mori S, et al. **Neuroreport** 1996 Oct 2;7(14):2277–85

Balance control during lateral arm raising in humans. Vernazza S, et al. **Neuroreport** 1996 Jul 8;7(10):1543–8

Single-unit activity in the primate nucleus tegmenti pedunculopontinus related to voluntary arm movement. Matsumura M, et al. **Neurosci Res** 1997 Jun;28(2):155–65

Trajectory formation of the center-of-mass of the arm during reaching movements. Suzuki M, et al. **Neuroscience** 1997 Jan;76(2):597–610

Spatial coordination in a bimanual task related to regular switching of movement vectors. Gutnik B, et al. **Percept Mot Skills** 1997 Apr;84(2):371–84

3-dimensional kinematics of overarm throwing action of children age 15 to 30 months. Marques-Bruna P, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 2):1267–83

Dynamics of the upper limb during performance of the tasks of everyday living--a review of the current knowledge base. Buckley MA, et al. **Proc Inst Mech Eng [H]** 1996; 210(4):241–7 (44 ref.)

The physiological responses to walking with and without Power Poles on treadmill exercise. Porcari JP, et al. **Res Q Exerc Sport** 1997 Jun;68(2):161–6

Kinetics of oxygen uptake and cardiac output at onset of arm exercise. Koga S, et al. **Respir Physiol** 1996 Feb; 103(2):195–202

Heavy-resistance training in older Scandinavian men and women: short- and long-term effects on arm and leg muscles. Lexell J, et al. **Scand J Med Sci Sports** 1995 Dec; 5(6):329–41

[Search of gravity force in the planning of arm pointing movements] Papaxanthis C, et al. **C R Seances Soc Biol Fil** 1996;190(5–6):613–9 (Eng. Abstr.) **(Fre)**

[About the article "Magnetic field induced by electric current across a man's arm" by Pel'ts CD, Chingin IuA, Sinel'nikova SE] Tukshaitov RKh. **Biofizika** 1996 Sep–Oct; 41(5):1118–20 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

The effect of an inhibitive weight-bearing splint on tone and function: a single-case study. Kinghorn J, et al. **Am J Occup Ther** 1996 Nov–Dec;50(10):807–15

Quantification of upper extremity function using kinematic analysis. Ramos E, et al. **Arch Phys Med Rehabil** 1997 May; 78(5):491–6

Human arm stiffness and equilibrium-point trajectory during multi-joint movement. Gomi H, et al. **Biol Cybern** 1997 Mar;76(3):163–71

The bilateral reach-to-grasp movement of Parkinson's disease subjects. Castiello U, et al. **Brain** 1997 Apr;120 (Pt 4):593–604

Triphasic waves during post-ictal stupor. Ogunyemi A. **Can J Neurol Sci** 1996 Aug;23(3):208–12

Reversible changes of motor cortical outputs following immobilization of the upper limb. Zanette G, et al. **Electroencephalogr Clin Neurophysiol** 1997 Aug; 105(4):269–79

Lateralizing value and semiology of ictal limb posturing and version in temporal lobe and extratemporal epilepsy. Bleasel A, et al. **Epilepsia** 1997 Feb;38(2):168–74

Upper-arm elevation during office work. Fernström EA, et al. **Ergonomics** 1996 Oct;39(10):1221–30

Tri-state myoelectric control of bilateral upper extremity neuroprostheses for tetraplegic individuals. Scott TR, et al. **IEEE Trans Rehabil Eng** 1996 Dec;4(4):251–63 (25 ref.)

Responses to arm exercise in patients with compensated heart failure. Keteyian SJ, et al. **J Cardiopulm Rehabil** 1996 Nov–Dec;16(6):366–71

Respiratory distress and selective muscle involvement in central core disease: report of a case. Chen SL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Nov; 12(11):650–6

Visually guided reaching with the forelimb contralateral to a "blind" hemisphere in the monkey: contribution of the cerebellum. Savaki HE, et al. **Neuroscience** 1996 Nov; 75(1):143–59

Performance of the 'unaffected' upper extremity of elderly stroke patients [see comments] Desrosiers J, et al. **Stroke** 1996 Sep;27(9):1564–70. Comment in: Stroke 1997 Feb;28(2):464.

Neuropathic symptoms and musculoskeletal pain in carpal tunnel syndrome: prognostic and therapeutic implications. Lazaro RP. **Surg Neurol** 1997 Feb;47(2):115–7; discussion 117–9

A model of human aiming movements applied to Parkinson's disease. Suri RE, et al. **Technol Health Care** 1997 Jul; 5(3):177–90

[Motor function outcome and changes in motor impairment level of the upper limbs and fingers in patients with acute carotid-system cerebral infarction] Itoh H, et al. **No To Shinkei** 1997 Jun;49(6):529–36 (Eng. Abstr.) **(Jpn)**

ARM

SURGERY

CAST liposuction of the arm improves aesthetic results. Gilliland MD, et al. **Aesthetic Plast Surg** 1997 Jul–Aug; 21(4):225–9

Outcomes of upper–extremity tendon transfers and functional electrical stimulation in an adolescent with C–5 tetraplegia. Davis SE, et al. **Am J Occup Ther** 1997 Apr;51(4):307–12

Benign giant schwannoma located in the upper arm. Kececi Y, et al. **Ann Plast Surg** 1997 Jul;39(1):100–2

Bilobed fasciocutaneous flap for primary repair of a large upper arm defect with secondary closure of the donor site without a skin graft. Onishi K, et al. **Ann Plast Surg** 1997 Aug;39(2):205–9

Forequarter amputation with fasciocutaneous deltoid flap reconstruction for malignant tumors of the upper extremity. Volpe CM, et al. **Ann Surg Oncol** 1997 Jun;4(4):298–302

Transthoracic forequarter amputation and left pneumonectomy. Fianchini A, et al. **Ann Thorac Surg** 1996 Dec;62(6):1841–3

A new technique for hemodialysis access surgery: use of the pneumatic tourniquet. Dickson CS, et al. **Ann Vasc Surg** 1996 Jul;10(4):373–7

Continuous brachial plexus infusion of butorphanol–mepivacaine mixtures for analgesia after upper extremity surgery. Wajima Z, et al. **Br J Anaesth** 1997 Jan;78(1):83–5

The quadrifoliate flap: a combination of scapular, parascapular, latissimus dorsi and scapula bone flaps. Bakhach J, et al. **Br J Plast Surg** 1996 Oct;49(7):477–81

Free arterialised venous forearm flaps for limb reconstruction. Yilmaz M, et al. **Br J Plast Surg** 1996 Sep; 49(6):396–400

Major ablative procedures in orthopaedic surgery. Soucacos PN, et al. **Bull Hosp Jt Dis** 1996;55(1):46–52

Survival after necrotising streptococcal myositis: a matter of hours. Marck KW, et al. **Eur J Surg** 1996 Dec; 162(12):981–3

Replantation of four severed limbs in one patient. Pei GX, et al. **Injury** 1997 Jan;28(1):73–6

Postoperative infection in a double–occupancy operating room. A prospective study of two thousand four hundred and fifty–eight procedures on the extremities. Kleinert JM, et al. **J Bone Joint Surg Am** 1997 Apr;79(4):503–13

Massive prostheses for malignant bone tumours of the limbs. Cannon SR. **J Bone Joint Surg Br** 1997 May;79(3):497–506 (20 ref.)

Neurocutaneous island flaps in upper limb coverage: experience with 44 clinical cases. Bertelli JA, et al. **J Hand Surg [Am]** 1997 May;22(3):515–26

Sarcomere length changes after flexor carpi ulnaris to extensor digitorum communis tendon transfer. Lieber RL, et al. **J Hand Surg [Am]** 1996 Jul;21(4):612–8

Results of functioning free muscle transplantation for elbow flexion. Chung DC, et al. **J Hand Surg [Br]** 1996 Nov; 21(6):1071–7

Closure of wounds in the upper extremity using a skin stretching device. Stahl S, et al. **J Hand Surg [Br]** 1996 Aug;21(4):534–7

Lateral–arm free flap for reconstruction in the head and neck. Wax MK, et al. **J Otolaryngol** 1996 Jun;25(3):140–4

Principles of treatment of the upper extremity in arthrogryposis multiplex congenita type I. Axt MW, et al. **J Pediatr Orthop B** 1997 Jul;6(3):179–85

A new strategy to prevent the sequelae of severe Volkmann's ischemia. Chuang DC, et al. **Plast Reconstr Surg** 1996 Nov; 98(6):1023–31; discussion 1032–3

Reconstruction following resection of malignancies of the upper extremity. Upton J, et al. **Surg Oncol Clin N Am** 1996 Oct;5(4):847–92 (99 ref.)

[Tissue expansion of the superior limb] Ramos RR, et al. **Rev Assoc Med Bras** 1995 Sep–Oct;41(5):348–52 (Eng. Abstr.) **(Por)**

[Control of the blood supply to the omental flap during its transplantation to the upper extremity] Pertsov VI. **Klin Khir** 1996;(7):47–8 **(Rus)**

[The surgical treatment of amniotic strangulation of the extremities] Mikusev IE. **Vestn Khir Im I I Grek** 1996; 155(2):94–5 **(Rus)**

ULTRASONOGRAPHY

[Normal anatomy and pathologic features of the supraspinatus muscle: comparison between ultrasonography and surgery. Analysis of the potential sources of diagnostic errors] Montrucchio E, et al. **Radiol Med (Torino)** 1997 Apr;93(4):342–7 (Eng. Abstr.) **(Ita)**

ARM ERGOMETRY TEST see **EXERCISE TEST**

ARM INJURIES

Nonspecific work–related upper extremity disorders [see comments] Downs DG. **Am Fam Physician** 1997 Mar; 55(4):1296–302 (22 ref.). Comment in: Am Fam Physician 1997 Mar;55(4):1029–30.

Challenges of work–related upper extremity disorders [editorial; comment] McCahill ME. **Am Fam Physician** 1997 Mar;55(4):1029–30, 1039. Comment on: Am Fam Physician 1997 Mar;55(4):1296–1302.

Direct injury to the axillary nerve in athletes playing contact sports. Perlmutter GS, et al. **Am J Sports Med** 1997 Jan–Feb;25(1):65–8

Elbow, forearm, wrist, and hand injuries among sport rock climbers. Holtzhausen LM, et al. **Clin J Sport Med** 1996 Jul;6(3):196–203 (25 ref.)

Rupture of the long head of the triceps muscle in a child: case report and review of the literature. Sheps D, et al. **J Trauma** 1997 Feb;42(2):318–20

CLASSIFICATION

[Periarticular fractures of the upper and lower extremity. I: ABC classification using the AO principle] Arand M, et al. **Rontgenpraxis** 1997 Jun;50(6):168–74 (16 ref.) **(Ger)**

COMPLICATIONS

Distant entry pneumothorax in a competitive fencer. Harmer PA, et al. **Br J Sports Med** 1996 Sep;30(3):265–6

Dupuytren's contracture after burns of the upper extremity. Balakrishnan C, et al. **J Burn Care Rehabil** 1997 May–Jun; 18(3):245–6

Long–term follow–up evaluation of cold sensitivity following nerve injury. Collins ED, et al. **J Hand Surg [Br]** 1996 Nov;21(6):1078–85

Biceps rupture in a patient on long–term anticoagulation leading to compartment syndrome and nerve palsies. Richards AM, et al. **J Hand Surg [Br]** 1997 Jun;22(3):411–2

False aneurysm presenting as delayed posterior interosseus nerve palsy. Weinstein RN. **J Orthop Trauma** 1996; 10(8):583–5

DIAGNOSIS

Diagnostic criteria for work–related upper limb disorders [editorial] Helliwell PS. **Br J Rheumatol** 1996 Dec; 35(12):1195–6

Pictorial review: magnetic resonance imaging of acute orthopaedic trauma to the upper extremity. Eustace S, et al. **Clin Radiol** 1997 May;52(5):338–44 (15 ref.)

Advanced imaging in orthopaedics: current pitfalls and new applications. Potter HG, et al. **Instr Course Lect** 1997; 46:521–9 (38 ref.)

Predictors of work disability in work–related upper–extremity disorders. Friedman PJ. **J Occup Environ Med** 1997 Apr;39(4):339–43

Pitcher's arm: an electrodiagnostic enigma. Long RR, et al. **Muscle Nerve** 1996 Oct;19(10):1276–81

Management of common pediatric fractures. England SP, et al. **Pediatr Clin North Am** 1996 Oct;43(5):991–1012 (12 ref.)

MR imaging of acute orthopedic trauma to the extremities. Eustace S. **Radiol Clin North Am** 1997 May;35(3):615–29 (68 ref.)

Role of MR imaging in acute injuries to the appendicular skeleton. Ohashi K, et al. **Radiol Clin North Am** 1997 May; 35(3):591–613 (166 ref.)

[Standardized examination of the elbow] Simmelbauer B, et al. **Unfallchirurg** 1996 Aug;99(8):548–54 (Eng. Abstr.) **(Ger)**

[The diagnosis and treatment of injuries to the major vessels of the extremities and neck in wartime] Razmadze AV, et al. **Vestn Khir Im I I Grek** 1996;155(6):61–3 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Methodological limitations in the study of video display terminal use and upper extremity musculoskeletal disorders. Gerr F, et al. **Am J Ind Med** 1996 Jun;29(6):649–56 (38 ref.)

Upper limb repetitive strain injuries in Manitoba. Yassi A, et al. **Am J Ind Med** 1996 Oct;30(4):461–72

Recent trends in work–related cumulative trauma disorders of the upper extremities in the United States: an evaluation of possible reasons. Brogmus GE, et al. **J Occup Environ Med** 1996 Apr;38(4):401–11

Ergonomic risk exposure and upper–extremity cumulative trauma disorders in a maquiladora medical devices manufacturing plant. Meservy D, et al. **J Occup Environ Med** 1997 Aug;39(8):767–73

Recognizing musculoskeletal injury hazards in the upper extremities and lower back. Mital A. **Occup Health Saf** 1997 Aug;66(8):91–9

In–line skate and rollerskate injuries in childhood. Powell EC, et al. **Pediatr Emerg Care** 1996 Aug;12(4):259–62

ETIOLOGY

Mechanisms of burn injury secondary to airbag deployment. Hallock GG. **Ann Plast Surg** 1997 Aug;39(2):111–3

Occupational arm, shoulder, and neck syndrome affecting large animal practitioners. Ailsby RL. **Can Vet J** 1996 Jul; 37(7):411

Dog bites causing upper–limb fractures in children. Wass AR, et al. **Injury** 1996 Jul;27(6):433–5

Hand–arm symptoms related to impact and nonimpact hand–held power tools. Kihlberg S, et al. **Int Arch Occup Environ Health** 1997;69(4):282–8

Assessment of hand–arm vibration exposure among traffic police motorcyclists. Mirbod SM, et al. **Int Arch Occup Environ Health** 1997;70(1):22–8

Repetitive upper–extremity motions in the workplace are not hazardous [see comments] Hadler NM. **J Hand Surg [Am]** 1997 Jan;22(1):19–29 (47 ref.). Comment in: J Hand Surg [Am] 1997 Jan;22(1):1.

Repetitive strain in the workplace [see comments] Mackinnon SE, et al. **J Hand Surg [Am]** 1997 Jan;22(1):2–18 (118 ref.) . Comment in: J Hand Surg [Am] 1997 Jan;22(1):1.

Repetitive strain: putting it in perspective [editorial; comment] Manske PR. **J Hand Surg [Am]** 1997 Jan;22(1):1 . Comment on: J Hand Surg [Am] 1997 Jan;22(1):2–18. Comment on: J Hand Surg [Am] 1997 Jan;22(1):19–29.

Upper limb disorders and work: the importance of physical and psychosocial factors. Buckle P. **J Psychosom Res** 1997 Jul;43(1):17–25

Degloving injury from a helicopter rotor strike. Nelson JM, et al. **Mil Med** 1995 Dec;160(12):644–5

[Injuries during handball. A comparative, retrospective study between regional and upper league teams] Seil R, et al. **Sportverletz Sportschaden** 1997 Jun;11(2):58–62 (Eng. Abstr.) **(Ger)**

METABOLISM

Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. Hopf HW, et al. **Arch Surg** 1997 Sep;132(9):997–1004; discussion 1005

PHYSIOPATHOLOGY

A reassessment of Doppler pressure indices in the detection of arterial lesions in proximity penetrating injuries of extremities: a prospective study. Nassoura ZE, et al. **Am J Emerg Med** 1996 Mar;14(2):151–6

Time course of changes in bilateral arm power of swimmers during recovery from injury using a swim bench. Swaine IL. **Br J Sports Med** 1997 Sep;31(3):213–6

PREVENTION & CONTROL

Review of applicability of existing functional status measures to the study of workers with musculoskeletal disorders of the neck and upper limb. Stock SR, et al. **Am J Ind Med** 1996 Jun;29(6):679–88 (102 ref.)

REHABILITATION

Prognosis of nonspecific work–related musculoskeletal disorders of the neck and upper extremity. Cole DC, et al. **Am J Ind Med** 1996 Jun;29(6):657–68 (46 ref.)

Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG) [published erratum appears in Am J Ind Med 1996 Sep;30(3):372] Hudak PL, et al. **Am J Ind Med** 1996 Jun; 29(6):602–8

Rehabilitation intervention for patients with upper extremity dysfunction: challenges of outcome evaluation. Stiens SA, et al. **Am J Ind Med** 1996 Jun;29(6):590–601 (72 ref.)

Rehabilitation of patient with brachial plexus lesion and break in axillary artery. Case study. Bajuk S, et al. **J Hand Ther** 1996 Oct–Dec;9(4):399–403

[Modified Gilchrist bandage] Giebel G. **Zentralbl Chir** 1997; 122(2):126–7 **(Ger)**

[The rehabilitation of the wounded with combat injuries to the extremities] Briusov PG, et al. **Voen Med Zh** 1997 May; 318(5):17–22 (Eng. Abstr.) **(Rus)**

[Physiotherapy in injuries to the peripheral nerves of the extremities] Strelkova NI. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 May–Jun; (3):48–50 **(Rus)**

[Rehabilitation of war injuries associated with peripheral nerve lesions] Cujić M. **Med Pregl** 1996;49(11–12):469–72 (Eng. Abstr.) **(Scr)**

SURGERY

Outcome and utility of scoring systems in the management of the mangled extremity. Durham RM, et al. **Am J Surg** 1996 Nov;172(5):569–73; discussion 573–4

Upper–extremity arterial injury. Pillai L, et al. **Am Surg** 1997 Mar;63(3):224–7

The role of local fascial flaps as an adjunct to free flaps. Hallock GG. **Ann Plast Surg** 1997 Apr;38(4):388–95

Above–elbow arm replantation during pregnancy. Haws MJ, et al. **Ann Plast Surg** 1996 Jan;36(1):93–6

One–stage reconstruction of war wounds with free osteocutaneous flaps. Džepina I, et al. **Br J Plast Surg** 1997 Feb;50(2):81–7

Elevated compartmental pressures after closure of a forearm burn wound with a skin–stretching device. Hussmann J, et al. **Burns** 1997 Mar;23(2):154–6

Long–term outcomes after upper limb arterial injuries. van der Sluis CK, et al. **Can J Surg** 1997 Aug;40(4):265–70

Functioning free–muscle transplantation for the upper extremity. Chuang DC. **Hand Clin** 1997 May;13(2):279–89 (22 ref.)

Primary closure of fasciotomy incisions with a skin–stretching device in patients with burn and trauma. Caruso DM, et al. **J Burn Care Rehabil** 1997 Mar–Apr; 18(2):125–32

Rupture of the triceps muscle at the musculotendinous junction: a case report. Wagner JR, et al. **J Hand Surg [Am]** 1997 Mar;22(2):341–3

Upper limb traumatic amputees. Review of prosthetic use. Gaine WJ, et al. **J Hand Surg [Br]** 1997 Feb;22(1):73–6

Closure of wounds in the upper extremity using a skin stretching device. Stahl S, et al. **J Hand Surg [Br]** 1996 Aug;21(4):534–7

Vascular injuries of the upper arm. Sriussadaporn S. **J Med Assoc Thai** 1997 Mar;80(3):160–8

Simplified external fixation for primary management of severe musculoskeletal injuries under war and peace time conditions. Hammer RR, et al. **J Orthop Trauma** 1996; 10(8):545–54

Delayed onset of posterior interosseous nerve palsy after distal biceps tendon repair. Katzman BM, et al. **J Shoulder Elbow Surg** 1997 Jul–Aug;6(4):393–5

The fatal fight for upper limb preservation in severe electrical burns. Bahm J. **Microsurgery** 1996;17(5):286–9

Restoring elbow flexion by pectoralis major transplantation in war–injured patients. Ghahremani S, et al. **Microsurgery** 1996;17(2):97–101

The free forearm fillet flap in traumatic arm amputation [letter; comment] Cavadas PC. **Plast Reconstr Surg** 1996 Nov;98(6):1119–20. Comment on: Plast Reconstr Surg 1994 Sep;94(3):507–12. Comment on: Plast Reconstr Surg 1995 Aug;96(2):488–91.

Pedicled latissimus dorsi transfer for immediate soft–tissue coverage and elbow flexion. Mordick TG 2nd, et al. **Plast Reconstr Surg** 1997 May;99(6):1742–4

Complications and nonclosure rates of fasciotomy for trauma and related risk factors. Velmahos GC, et al. **World J Surg** 1997 Mar–Apr;21(3):247–52; discussion 253

[Paralysis of the brachial plexus caused by supraclavicular injuries in the adult. Long–term comparative results of nerve grafts and transfers] Allieu Y, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1997;83(1):51–9 (Eng. Abstr.) **(Fre)**

[Periarticular fractures of the upper and lower extremity. II: Therapeutic principle] Arand M, et al. **Rontgenpraxis** 1997 Jun;50(6):175–81 (19 ref.) **(Ger)**

[Covering soft tissue defects] Kinzl L, et al. **Unfallchirurg** 1996 Oct;99(10):714–26 (29 ref.) (Eng. Abstr.) **(Ger)**

[Late outcome after intermuscular ulnar nerve transposition in trauma surgery indications] Siakos G, et al. **Unfallchirurg** 1996 Oct;99(10):784–7 (Eng. Abstr.) **(Ger)**

[Treatment concept and results of grade 3 open fractures with arterial injuries requiring reconstruction] Ostermann PA, et al. **Zentralbl Chir** 1996;121(11):990–3 (Eng. Abstr.) **(Ger)**

[Restoration of replanted extremity function with use of microsurgical tissue autotransplantation] Shibaev EI, et al. **Khirurgiia (Mosk)** 1997;(2):56–61 (Eng. Abstr.) **(Rus)**

[Restorative operations on the radial nerve in a wound to the upper extremity] Iunusov MIu, et al. **Klin Khir** 1996; (7):22–4 **(Rus)**

THERAPY

Hypnotically–induced vasodilation in the treatment of repetitive strain injuries. Moore LE, et al. **Am J Clin Hypn** 1996 Oct;39(2):97–104

EMLA versus TAC for topical anesthesia of extremity wounds in children. Zempsky WT, et al. **Ann Emerg Med** 1997 Aug;30(2):163–6

[A trial of using a weak geomagnetic field in treating acute and chronic surgical infection] Litvinov GA, et al. **Vestn Khir Im I I Grek** 1996;(1):77–8 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Ultrasound diagnosis of triceps tendon rupture. A report of 2 cases. Kaempffe FA, et al. **Clin Orthop** 1996 Nov; (332):138–42

ARMADILLOS

An axis to grind [news] Mirsky S. **Sci Am** 1997 Sep;277(3):26

BLOOD

Reactivity of a population of armadillo lymphocytes with an antibody to human gamma,delta T–cells. Lathrop G, et al. **Clin Immunol Immunopathol** 1997 Jan;82(1):68–72

EMBRYOLOGY

Molecular documentation of polyembryony and the micro–spatial dispersion of clonal sibships in the nine–banded armadillo, Dasypus novemcinctus. Prodöhl PA, et al. **Proc R Soc Lond B Biol Sci** 1996 Dec 22; 263(1377):1643–9

GENETICS

Phylogenetic analyses of mitochondrial DNA suggest a sister group relationship between Xenarthra (Edentata) and Ferungulates. Arnason U, et al. **Mol Biol Evol** 1997 Jul; 14(7):762–8

Development and application of long–PCR for the assay of full–length animal mitochondrial DNA. Nelson WS, et al. **Mol Ecol** 1996 Dec;5(6):807–10

Molecular documentation of polyembryony and the micro–spatial dispersion of clonal sibships in the nine–banded armadillo, Dasypus novemcinctus. Prodöhl PA, et al. **Proc R Soc Lond B Biol Sci** 1996 Dec 22; 263(1377):1643–9

METABOLISM

Cloning and characterization of a new armadillo family member, p0071, associated with the junctional plaque: evidence for a subfamily of closely related proteins. Hatzfeld M, et al. **J Cell Sci** 1996 Nov;109 (Pt 11):2767–78

PHYSIOLOGY

Axial orthogonal fiber reinforcement in the penis of the nine–banded armadillo (Dasypus novemcinctus). Kelly DA. **J Morphol** 1997 Sep;233(3):249–55

Biological hydrostats. Wrapping the armadillo's penis [news] Wassersug R. **Nature** 1997 Aug 28;388(6645):826–7

ARMED FORCES PERSONNEL see **MILITARY PERSONNEL**

ARNICA

Double–blind, placebo–controlled, randomized clinical trial of homoeopathic arnica C30 for pain and infection after total abdominal hysterectomy [see comments] Hart O, et al. **J R Soc Med** 1997 Feb;90(2):73–8. Comment in: J R Soc Med 1997 Apr;90(4):239–40.

Randomized trial of homeopathic arnica [letter; comment] Youngson RM. **J R Soc Med** 1997 Apr;90(4):239–40. Comment on: J R Soc Med 1997 Feb;90(2):73–8.

CHEMISTRY

Antioxidative constituents in Heterotheca inuloides. Haraguchi H, et al. **Bioorg Med Chem** 1997 May; 5(5):865–71

ARNOLD–CHIARI DEFORMITY

Please don't call me 'Arnold–Chiari' unless you mean it [letter; comment] Blumenthal DT, et al. **Arch Neurol** 1997 Jan;54(1):16. Comment on: Arch Neurol 1996 Jun;53(6):526–31.

CHEMICALLY INDUCED

Arnold–Chiari–like malformation associated with a valproate model of spina bifida in the rat. Briner W, et al. **Teratology** 1995 Nov;52(5):306–11

CLASSIFICATION

Chiari malformation type I: a new MRI classification. Amer TA, et al. **Magn Reson Imaging** 1997;15(4):397–403

COMPLICATIONS

A cloverleaf skull syndrome probably of Beare–Stevenson type associated with Chiari malformation. Ito S, et al. **Brain Dev** 1996 Jul–Aug;18(4):307–11

Neurofibromatosis type 1 and type I Chiari malformation: an unusual association. Battistella PA, et al. **Childs Nerv Syst** 1996 Jun;12(6):336–8

Chiari I malformation associated with callosal dysgenesis and ectopic neurohypophysis. Sener RN. **Comput Med Imaging Graph** 1995 Nov–Dec;19(6):487–9

A case of syringomyelia with type I Arnold–Chiari malformation (ACM): growth hormone (GH) therapy and the size of syrinx on serial MR images. Takakuwa S, et al. **Endocr J** 1996 Oct;43 Suppl:S129–30

Respiratory arrest: a complication of Arnold–Chiari malformation in adults. Omer S, et al. **Eur Neurol** 1996; 36(1):36–8

Syringomyelia and Arnold Chiari in scoliosis initially classified as idiopathic: experience with 25 patients. Emery E, et al. **Eur Spine J** 1997;6(3):158–62

Laryngologic management of infants with the Chiari II syndrome. Linder A, et al. **Int J Pediatr Otorhinolaryngol** 1997 Apr 11;39(3):187–97

Audio–vestibular manifestations of Chiari malformation and outcome of surgical decompression: a case report. Ahmmed AU, et al. **J Laryngol Otol** 1996 Nov;110(11):1060–4

Acquired esotropia due to Arnold–Chiari I malformation. Lewis AR, et al. **J Neuroophthalmol** 1996 Mar;16(1):49–54

Intraorbital cerebellar heterotopia associated with Chiari I malformation. Kagotani Y, et al. **J Pediatr Ophthalmol Strabismus** 1996 Sep–Oct;33(5):262–5

Chiari I malformation and spinal cord injury: cause for concern in contact athletes? Callaway GH, et al. **Med Sci Sports Exerc** 1996 Oct;28(10):1218–20 (17 ref.)

Chiari I malformation associated with syringomyelia and scoliosis. Ghanem IB, et al. **Spine** 1997 Jun 15; 22(12):1313–7; discussion 1318

Pearl jam [letter] Cohen AR. **Surg Neurol** 1997 Sep; 48(3):313–4

[Association of Crouzon syndrome and Arnold–Chiari deformity (letter; comment)] Martinot A, et al. **Arch Pediatr** 1996 Dec;3(12):1278–9. Comment on: Arch Pediatr 1996 May;3(5):433–9. **(Fre)**

[Isolated respiratory insufficiency in Arnold–Chiari malformation] Noseda A, et al. **Rev Mal Respir** 1996; 13(4):440–2 (Eng. Abstr.) **(Fre)**

[Syringomyelia and pregnancy. Report of a clinical case and review of the literature] Castello C, et al. **Minerva Ginecol** 1996 Jun;48(6):253–7 (7 ref.) (Eng. Abstr.) **(Ita)**

[Surgical treatment for syringomyelia associated with Chiari malformation] Iwasaki Y, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1409–11 (Eng. Abstr.) **(Jpn)**

[Pharyngoesophageal dysfunction: report of case and review of literature] Félix VN, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1996 May–Jun; 51(3):103–5 (17 ref.) (Eng. Abstr.) **(Por)**

[The association of hypopituitarism with Arnold–Chiari malformation and optic nerve meningocele (letter)] Díaz Pérez JA, et al. **An Med Interna** 1996 Aug;13(8):410–1 **(Spa)**

DIAGNOSIS

Magnetic resonance (MR) evaluation of a modified surgical technique in hydrosyringomyelia–Chiari complex. A case report. Duprez T, et al. **Acta Neurol Belg** 1997 Mar; 97(1):50–1

Three cases of hindbrain herniation in adults with comments on some diagnostic difficulties. Wurm G, et al. **Br J Neurosurg** 1996 Apr;10(2):137–42

Acute and atypical presentations of syringomyelia. Anwer UE, et al. **Eur Neurol** 1996;36(4):215–8

Arachnoid cyst with type I Arnold Chiari malformation presenting as syringomyelic syndrome. Shukla R, et al. **J Assoc Physicians India** 1996 Sep;44(9):658–9

Chiari I malformation: association with seizures and developmental disabilities. Brill CB, et al. **J Child Neurol** 1997 Feb;12(2):101–6

Aunt Minnie's corner. Chiari I malformation with associated hydrosyringomyelia. Ford KL 3d. **J Comput Assist Tomogr** 1997 May–Jun;21(3):509

Chiari III malformation: MRI. Aribal ME, et al. **Neuroradiology** 1996 May;38 Suppl 1:S184–6

Adult Chiari malformation with headache and trigeminal dysesthesia. Storrs TJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Sep;82(3):284–7

GENETICS

Chiari malformation and tonsillar ectopia in twin brothers and father with autosomal dominant spondylo–epiphyseal dysplasia tarda. Gripp KW, et al. **Skeletal Radiol** 1997 Feb; 26(2):131–3

PATHOLOGY

Mechanisms of sudden death and autopsy findings in patients with Arnold–Chiari malformation and ventriculoatrial catheters. Byard RW. **Am J Forensic Med Pathol** 1996 Sep; 17(3):260–3

Cerebellar agenesis versus vanishing cerebellum in Chiari II malformation. Sener RN. **Comput Med Imaging Graph** 1995 Nov–Dec;19(6):491–4

Deformation of the cervicomedullary junction and spinal cord in a surgically treated adult Chiari I hindbrain hernia associated with syringomyelia: a magnetic resonance microscopic and neuropathological study. Case report. Beuls EA, et al. **J Neurosurg** 1996 Oct;85(4):701–8

Pathogenesis of Chiari malformation: a morphometric study of the posterior cranial fossa. Nishikawa M, et al. **J Neurosurg** 1997 Jan;86(1):40–7

[Magnetic resonance imaging of a case of spontaneous resolution of syringomyelia associated with type I Chiari malformation] Pierallini A, et al. **Radiol Med (Torino)** 1997 May;93(5):621–2 **(Ita)**

PHYSIOPATHOLOGY

[Platybasia, basilar groove, odontoid process and kinking of the brainstem: a common etiology with idiopathic syringomyelia, scoliosis and Chiari malformations] Royo–Salvador MB. **Rev Neurol** 1996 Oct;24(134):1241–50 (Eng. Abstr.) **(Spa)**

SURGERY

The surgical treatment of Chiari I malformation. Klekamp J, et al. **Acta Neurochir (Wien)** 1996;138(7):788–801

Duraplasty with freeze–dried cadaveric dura versus occipital pericranium for Chiari type I malformation: comparative study. Vanaclocha V, et al. **Acta Neurochir (Wien)** 1997; 139(2):112–9

Magnetic resonance (MR) evaluation of a modified surgical technique in hydrosyringomyelia–Chiari complex. A case report. Duprez T, et al. **Acta Neurol Belg** 1997 Mar; 97(1):50–1

Symptomatic subdural hygroma as a complication of foramen magnum decompression for hindbrain herniation (Arnold–Chiari deformity). Ranjan A, et al. **Br J Neurosurg** 1996 Jun;10(3):301–3

Laryngologic management of infants with the Chiari II syndrome. Linder A, et al. **Int J Pediatr Otorhinolaryngol** 1997 Apr 11;39(3):187–97

Intraoperative cardiovascular collapse in an infant with Arnold–Chiari malformation. Tanaka M, et al. **Paediatr Anaesth** 1997;7(2):163–6

Recurrent compression of Chiari malformation [letter; comment] Cochrane DD. **Pediatr Neurosurg** 1996;24(5):277 . Comment on: Pediatr Neurosurg 1995;23(6):323–7.

Bone regrowth and recurrence of symptoms following decompression in the infant with Chiari II malformation [see comments] Hudgins RJ, et al. **Pediatr Neurosurg** 1995; 23(6):323–7. Comment in: Pediatr Neurosurg 1996;24(5):277.

Incidence of postlaminectomy kyphosis after Chiari decompression [published erratum appears in Spine 1997 Jun 1;22(11):1276] McLaughlin MR, et al. **Spine** 1997 Mar 15;22(6):613–7

[Surgical treatment for syringomyelia associated with Chiari

ARNOLD-CHIARI DEFORMITY

malformation] Iwasaki Y, et al. **Rinsho Shinkeigaku** 1995 Dec;35(12):1409–11 (Eng. Abstr.) **(Jpn)**

[A new surgical treatment for syringomyelia, scoliosis, Arnold–Chiari malformation, kinking of the brainstem, odontoid recess, idiopathic basilar impression and platybasia] Royo-Salvador MB. **Rev Neurol** 1997 Apr; 25(140):523–30 (Eng. Abstr.) **(Spa)**

VETERINARY

Central nervous system and vertebral malformation resembling the Arnold–Chiari syndrome in a Simmental calf. LeClerc S, et al. **Can Vet J** 1997 May;38(5):300–1

AROCLORS

ANALYSIS

Modular methodology for determination of polychlorinated biphenyls in soil as Aroclors and individual congeners. Donnelly JR, et al. **J AOAC Int** 1996 Jul–Aug;79(4):953–61

Preliminary assessment of PCB risks to human and ecological health in the lower Passaic River. Finley BL, et al. **J Toxicol Environ Health** 1997 Oct 10;52(2):95–118

Composition-selective detection of polychlorinated biphenyls (PCBs) by oxygen–chlorine exchange reaction in a tandem mass spectrometer (MS/MS). Lopshire RF, et al. **Toxicol Ind Health** 1996 May–Aug;12(3–4):375–91

METABOLISM

Plant compounds that induce polychlorinated biphenyl biodegradation by Arthrobacter sp. strain B1B. Gilbert ES, et al. **Appl Environ Microbiol** 1997 May;63(5):1933–8

Non–, mono–, and di–o–chlorobiphenyl concentrations and their toxic equivalents to 2,3,7,8–tetrachlorodibenzo[p]dioxin in Aroclors(R) and digestive glands from American lobster (Homarus americanus) captured in Atlantic Canada. King TL, et al. **Bull Environ Contam Toxicol** 1996 Sep;57(3):465–72

PHARMACOLOGY

Strain-specific enhancement or inhibition of coumarin hepatotoxicity in mice following pretreatment with two different liver enzyme–inducing agents. Cottrell S, et al. **Fundam Appl Toxicol** 1996 Nov;34(1):47–55

Polychlorinated biphenyls release insulin from RINm5F cells. Fischer LJ, et al. **Life Sci** 1996;59(24):2041–9

Aroclors 1254 and 1260 reduce dopamine concentrations in rat striatal slices. Chishti MA, et al. **Neurotoxicology** 1996 Fall–Winter;17(3–4):653–60

CYP1A induction by beta–naphthoflavone, Aroclor 1254, and 2,3,7,8–tetrachlorodibenzo–p–dioxin and its influence on aflatoxin B1 metabolism and DNA adduction in zebrafish. Troxel CM, et al. **Toxicol Appl Pharmacol** 1997 Sep;146(1):69–78

TOXICITY

Protein tyrosine kinase involvement in the production of superoxide anion by neutrophils exposed to Aroclor 1242, a mixture of polychlorinated biphenyls. Tithof PK, et al. **Biochem Pharmacol** 1997 Jun 15;53(12):1833–42

Lipopolysaccharide–induced hepatic injury is enhanced by polychlorinated biphenyls. Brown AP, et al. **Environ Health Perspect** 1996 Jun;104(6):634–40

Prevalence of endometriosis in rhesus (Macaca mulatta) monkeys ingesting PCB (Aroclor 1254): review and evaluation. Arnold DL, et al. **Fundam Appl Toxicol** 1996 May;31(1):42–55 (108 ref.)

Developmental exposure to Aroclor 1254 produces low–frequency alterations in adult rat brainstem auditory evoked responses. Herr DW, et al. **Fundam Appl Toxicol** 1996 Sep;33(1):120–8

Morphometric changes in the prepubertal female rat thyroid gland following acute exposure to 2,2',4,4'–tetrachlorobiphenyl and Aroclor 1242. Saeed A, et al. **J Toxicol Environ Health** 1997 Aug 8;51(5):503–13

Aroclor 1254–induced alterations in hypothalamic monoamine metabolism in the Atlantic croaker (Micropogonias undulatas): correlation with pituitary gonadotropin release. Khan IA, et al. **Neurotoxicology** 1997; 18(2):553–60

Persistent alterations in regional brain glial fibrillary acidic protein and synaptophysin levels following pre– and postnatal polychlorinated biphenyl exposure. Morse DC, et al. **Toxicol Appl Pharmacol** 1996 Aug;139(2):252–61

Effects of polychlorinated biphenyls on dopamine release from PC12 cells. Angus WG, et al. **Toxicol Lett** 1996 Dec 31;89(3):191–9

Induction of the rat hepatic cytosolic arylamine oxidase by a series of polychlorinated biphenyls: association with the Ah locus. Marczylo T, et al. **Toxicol Lett** 1997 Jul 21; 92(2):81–91

AROMATASE

ANALYSIS

Effects of aromatase inhibitor on sex differentiation and levels of P450 (17 alpha) and P450 arom messenger ribonucleic acid of gonads in chicken embryos. Abinawanto, et al. **Gen Comp Endocrinol** 1996 May;102(2):241–6

Identification of catecholaminergic inputs to and outputs from aromatase–containing brain areas of the Japanese quail by tract tracing combined with tyrosine hydroxylase immunocytochemistry. Balthazart J, et al. **J Comp Neurol** 1997 Jun 9;382(3):401–28

Different levels of 5alpha–reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. Sawaya ME, et al. **J Invest Dermatol** 1997 Sep;109(3):296–300

Vasotocinergic innervation of areas containing aromatase–immunoreactive cells in the quail forebrain. Balthazart J, et al. **J Neurobiol** 1997 Jul;33(1):45–60

Immunolocalization of aromatase P–450 in ovarian tissue from pregnant and nonpregnant mares and in ovarian tumours. Watson ED, et al. **J Reprod Fertil** 1996 Nov; 108(2):239–44

Intraovarian immunolocalization of steroidogenic enzymes in a Hokkaido brown bear, Ursus arctos yesoensis during the mating season. Araki H, et al. **J Vet Med Sci** 1996 Aug;58(8):787–90

ANTAGONISTS & INHIBITORS

Endocrine treatment of advanced breast cancer. Dowsett M. **Acta Oncol** 1996;35 Suppl 5:68–72 (32 ref.)

Aromatase inhibition for breast cancer treatment. Lønning PE. **Acta Oncol** 1996;35 Suppl 5:38–43 (31 ref.)

Proper sequence of endocrine therapies in advanced breast cancer. Rose C. **Acta Oncol** 1996;35 Suppl 5:44–9 (14 ref.)

Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. Trunet PF, et al. **Acta Oncol** 1996;35 Suppl 5:15–8 (27 ref.)

A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. Bajetta E, et al. **Ann Oncol** 1997 Jul;8(7):649–54

Synthesis and in vitro evaluation of 3–(1–azolylmethyl)–1H–indoles and 3–(1–azolyl–1–phenylmethyl)–1H–indoles as inhibitors of P450 arom. Le Borgne M, et al. **Arch Pharm (Weinheim)** 1997 May;330(5):141–5

Studies on the effect of the new non–steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Yano S, et al. **Arzneimittelforschung** 1996 Feb;46(2):192–5

Aromatase inhibition blocks the activation and sexual differentiation of appetitive male sexual behavior in Japanese quail. Balthazart J, et al. **Behav Neurosci** 1997 Apr;111(2):381–97

Mechanism for aromatase inactivation by a suicide substrate, androst–4–ene–3,6,17–trione. The 4 beta, 5 beta–epoxy–19–oxo derivative as a reactive electrophile irreversibly binding to the active site. Numazawa M, et al. **Biochem Pharmacol** 1996 Oct 25;52(8):1253–9

Aromatase inactivation by a suicide substrate, androst–5–ene–4,7,17–trione: the 5beta,6beta–epoxy–19–oxo derivative, as a possible reactive electrophile irreversibly binding to the active site. Numazawa M, et al. **Biol Pharm Bull** 1997 May;20(5):490–5

Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration. Sioufi A, et al. **Biopharm Drug Dispos** 1997 Aug;18(6):489–97

Influence of anastrozole (Arimidex), a selective, non–steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Geisler J, et al. **Br J Cancer** 1996 Oct; 74(8):1286–91

Pre– and post–translational regulation of aromatase by steroidal and non–steroidal aromatase inhibitors. Foidart A, et al. **Brain Res** 1995 Dec 1;701(1–2):267–78

A randomized phase II trial of two dosage levels of letrozole as third–line hormonal therapy for women with metastatic breast carcinoma. Ingle JN, et al. **Cancer** 1997 Jul 15; 80(2):218–24

A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int–5/aromatase gene. Tekmal RR, et al. **Cancer Lett** 1997 Sep 16; 118(1):21–8

Aromatase inhibitors and breast cancer. Miller WR. **Cancer Treat Rev** 1997 May;23(3):171–87 (112 ref.)

Synthesis and aromatase–inhibitory activity of imidazolyl–1,3,5–triazine derivatives. Matsuno T, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb;45(2):291–6

Studies on aromatase inhibitors. II. Synthesis and biological evaluation of 1–amino–1H–1,2,4–triazole derivatives. Okada M, et al. **Chem Pharm Bull (Tokyo)** 1997 Feb; 45(2):333–7

Studies on aromatase inhibitors. I. Synthesis and biological evaluation of 4–amino–4H–1,2,4–triazole derivatives. Okada M, et al. **Chem Pharm Bull (Tokyo)** 1996 Oct; 44(10):1871–9

Studies on aromatase inhibitors. III. Synthesis and biological evaluation of [(4–bromobenzyl)(4–cyanophenyl)amino]azoles and their azine analogs. Okada M, et al. **Chem Pharm Bull (Tokyo)** 1997 Mar;45(3):482–6

Synthesis and biological evaluation of novel pyrrolidine–2,5–dione inhibitors as potential anti–tumour agents. Ahmed S, et al. **Drug Des Discov** 1995 Apr; 12(4):275–87

Molecular modelling study of pyrrolidine–2,5–dione based aromatase inhibitors and other known inhibitors. Ahmed S. **Drug Des Discov** 1996 Mar;14(1):77–89

Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Grimm SW, et al. **Drug Metab Dispos** 1997 May; 25(5):598–602

New aromatase inhibitors for breast cancer. **Drug Ther Bull** 1997 Jul;35(7):55–6 (11 ref.)

Potent and selective aromatase inhibitor: in vitro and in vivo studies with s–triazine derivative SEF19. Takahashi M, et al. **Endocr Res** 1997 Feb–May;23(1–2):1–13

Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Vanderschueren D, et al. **Endocrinology** 1997 Jun;138(6):2301–7

The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Bajetta E, et al. **Eur J Cancer** 1997 Apr;33(4):587–91

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects. Geisler J, et al. **Eur J Cancer** 1996 May;32A(5):789–92

The effect of aromatase inhibitor on basal and testosterone–supplemented estradiol secretion by Leydig cells in vitro. Kmicikiewicz I, et al. **Exp Clin Endocrinol Diabetes** 1997;105(2):113–8

A novel activity for a group of sesquiterpene lactones: inhibition of aromatase. Blanco JG, et al. **FEBS Lett** 1997 Jun 16;409(3):396–400

The effect of the aromatase inhibitor fadrozole and two polynuclear aromatic hydrocarbons on sex steroid secretion by ovarian follicles of coho salmon. Afonso LO, et al. **Gen Comp Endocrinol** 1997 May;106(2):169–74

SNA–60–367, new peptide enzyme inhibitors against aromatase [letter] Kimura K, et al. **J Antibiot (Tokyo)** 1997 Jun;50(6):529–31

High–performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid–solid extraction and fluorescence detection. Marfil F, et al. **J Chromatogr B Biomed Appl** 1996 Aug 30;683(2):251–8

Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin–like growth factor (IGF) I and II, IGF–binding proteins (IGFBPs), and IGFBP–3 protease status in patients with advanced breast cancer. Frost VJ, et al. **J Clin Endocrinol Metab** 1996 Jun; 81(6):2216–21

Three–dimensional quantitative structure–activity relationships of steroid aromatase inhibitors. Oprea TI, et al. **J Comput Aided Mol Des** 1996 Jun;10(3):186–200

Novel 19–(cyclopropylamino)–androst–4–en–3,17–dione: a mechanism–based inhibitor of aromatase. Njar VC, et al. **J Enzyme Inhib** 1996;10(1):47–56

Effect of vorozole, an aromatase enzyme inhibitor, on sexual behavior, aromatase activity and neural immunoreactivity. Rissman EF, et al. **J Neuroendocrinol** 1996 Mar; 8(3):199–210

The role of aromatization in the restoration of male rat reproductive behavior. Vagell ME, et al. **J Neuroendocrinol** 1997 Jun;9(6):415–21

Synthesis and biological evaluation of 3–(prop–2–enyl)– and 3–(prop–2–ynyl)pyrrolidine–2,5–dione derivatives as potential aromatase inhibitors. Barrell KJ, et al. **J Pharm Pharmacol** 1996 Feb;48(2):154–9

Regulation of follicular maturation by human ovarian follicular fluid peptide. Nandedkar TD, et al. **J Reprod Fertil Suppl** 1996;50:95–104

Aromatase inhibition in JAr choriocarcinoma cells by 7alpha–arylaliphatic androgens. Brueggemeier RW, et al. **J Steroid Biochem Mol Biol** 1997 Apr;61(1–2):73–7

Paradoxical effect of an aromatase inhibitor, CGS 20267, on aromatase activity in guinea pig brain. Choate JV, et al. **J Steroid Biochem Mol Biol** 1996 Jul;58(4):411–5

The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)—a potent, selective aromatase inhibitor. Dukes M, et al. **J Steroid Biochem Mol Biol** 1996 Jul;58(4):439–45

Inhibitory effect of a novel non–steroidal aromatase inhibitor, YM511 on the proliferation of MCF–7 human breast cancer cell. Kudoh M, et al. **J Steroid Biochem Mol Biol** 1996 May;58(2):189–94

4–Oxygenated androst–5–en–17–ones and their 7–oxo derivatives as aromatase inhibitors. Numazawa M, et al. **J Steroid Biochem Mol Biol** 1996 Jul;58(4):431–8

7alpha–Arylaliphatic androsta–1,4–diene–3,17–diones as enzyme–activated irreversible inhibitors of aromatase. O'Reilly JM, et al. **J Steroid Biochem Mol Biol** 1996 Sep; 59(1):93–102

Fourteen–day oral combination dose toxicity study of CGS 16949 A (aromatase inhibitor) with 5–fluorouracil or tamoxifen in rats. Matsuda A, et al. **J Toxicol Sci** 1997 Feb;22(1):1–24

Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women [news] Hannaford M. **Nurse Pract** 1997 Mar;22(3):195–6, 201–2 (21 ref.)

Behavioral responses to Depo–Provera, Fadrozole, and estradiol in castrated, testosterone–treated cynomolgus monkeys (Macaca fascicularis): the involvement of progestin receptors. Zumpe D, et al. **Physiol Behav** 1996 Aug;60(2):531–40

Inhibition of 5 alpha–reductase and aromatase by the ellagitannins oenothein A and oenothein B from Epilobium

species. Ducrey B, et al. **Planta Med** 1997 Apr;63(2):111–4

Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Radlmaier A, et al. **Prostate** 1996 Oct; 29(4):199–208

Effect of a specific aromatase inhibitor on oestradiol secretion by porcine corpora lutea at various stages of the luteal phase. Gregoraszczuk EL, et al. **Reprod Nutr Dev** 1996; 36(1):65–72

Recovery of reproductive function in rats treated with the aromatase inhibitor fadrozole. Nunez SB, et al. **Reprod Toxicol** 1996 Sep–Oct;10(5):373–7

Experimentally-induced prostatic hyperplasia in young beagles: a model to evaluate the chemotherapeutic effects of gossypol. Chang WY, et al. **Res Commun Mol Pathol Pharmacol** 1996 Jun;92(3):341–60

Aromatase inhibitors and breast cancer. Brodie AM, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 9):10–20 (118 ref.)

Aromatase inhibitors in metastatic breast cancer. Buzdar AU, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 9):28–32

Aromatase inhibitors in clinical practice: current status and a look to the future. Harvey HA. **Semin Oncol** 1996 Aug; 23(4 Suppl 9):33–8 (13 ref.)

Aromatase inhibitors in the treatment of advanced breast cancer. Introduction. Osborne CK. **Semin Oncol** 1996 Aug; 23(4 Suppl 9):1

Aromatase inhibitors: rationale for use following antiestrogen therapy. Yue W, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 9):21–7

Synthesis of 10 beta-(1'-azirinyl)estr-4-en-3,17-dione as an aromatase inhibitor. Njar VC, et al. **Steroids** 1996 Mar; 61(3):138–43

Studies directed toward a mechanistic evaluation of aromatase inhibition by androst-5-ene-7,17-dione. Time-dependent inactivation by the 19-nor and 5 beta, 6 beta-epoxy derivatives. Numazawa M, et al. **Steroids** 1997 Jul;62(7):516–22

Preparation of an activity-inhibiting monoclonal antibody against human placental aromatase cytochrome P450. Washida N, et al. **Steroids** 1996 Mar;61(3):126–32

Novel non-steroidal aromatase inhibitors: are there new perspectives in the treatment of breast cancer? Bajetta E, et al. **Tumori** 1996 Sep–Oct;82(5):417–22 (44 ref.)

[Selective oral aromatase suppression and thymidilate synthase inhibition] **Chirurg** 1997 Feb;68(2 Suppl):1–16 **(Ger)**

[A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist] Hisamatsu K, et al. **Gan To Kagaku Ryoho** 1997 Aug; 24(10):1327–30 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Astrocytes cultured in vitro produce estradiol-17beta and express aromatase cytochrome P-450 (P-450 AROM) mRNA. Zwain IH, et al. **Biochim Biophys Acta** 1997 Mar 15;1334(2–3):338–48

Differential transcription of steroidogenic enzymes in the equine primary corpus luteum during diestrus and early pregnancy. Albrecht BA, et al. **Biol Reprod** 1997 Apr; 56(4):821–9

A developmental switch in expression from blastocyst to endometrial/placental-type cytochrome P450 aromatase genes in the pig and horse. Choi I, et al. **Biol Reprod** 1997 Mar;56(3):688–96

Aromatase cytochrome P450 gene expression in endometrial carcinoma. Sasano H, et al. **Br J Cancer** 1996 Nov; 74(10):1541–4

Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. Simpson ER, et al. **FASEB J** 1997 Jan;11(1):29–36 (67 ref.)

Effects of aromatase inhibitor on sex differentiation and levels of P450 (17 alpha) and P450 arom messenger ribonucleic acid of gonads in chicken embryos. Abinawanto, et al. **Gen Comp Endocrinol** 1996 May;102(2):241–6

Expression of P450(17 alpha) hydroxylase and P450 aromatase genes in the chicken gonad before and after sexual differentiation. Yoshida K, et al. **Gen Comp Endocrinol** 1996 May;102(2):233–40

Expression of 17 alpha-hydroxylase and aromatase in the syndrome of androgen resistance: a case report. Doldi N, et al. **Gynecol Endocrinol** 1996 Aug;10(4):281–4

Neurotransmitter-mediated regulation of brain aromatase: protein kinase C- and G-dependent induction. Abe-Dohmae S, et al. **J Neurochem** 1996 Nov; 67(5):2087–95

RU486 is a potent inhibitor of aromatase induction in human breast adipose tissue stromal cells. Schmidt M, et al. **J Steroid Biochem Mol Biol** 1997 Feb;60(3–4):197–204

Gonadal sex differentiation in chicken embryos: expression of estrogen receptor and aromatase genes. Smith CA, et al. **J Steroid Biochem Mol Biol** 1997 Mar;60(5–6):295–302

Existence and expression of the untranslated first exon of aromatase mRNA in the rat brain. Yamada-Mouri N, et al. **J Steroid Biochem Mol Biol** 1996 May;58(2):163–6

Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. Zhou C, et al. **J Steroid Biochem Mol Biol** 1996 Oct;59(2):163–71

The prolactin inhibition of follicle-stimulating hormone-induced aromatase activity in cultured rat granulosa cells is in part tyrosine kinase and protein kinase-C dependent. Villanueva LA, et al. **Mol Hum Reprod** 1996 Oct;2(10):725–31

BLOOD

Alterations in steroidogenesis in alligators (Alligator mississippiensis) exposed naturally and experimentally to environmental contaminants. Crain DA, et al. **Environ Health Perspect** 1997 May;105(5):528–33

CHEMISTRY

Molecular modelling study of the binding of inhibitors of aromatase to the cytochrome P-450 heme. Ahmed S, et al. **Drug Des Discov** 1996 Oct;14(2):91–102

Aromatase expression in health and disease. Simpson ER, et al. **Recent Prog Horm Res** 1997;52:185–213; discussion 213–4 (123 ref.)

DEFICIENCY

Clinical review 78: Aromatase deficiency in women and men: would you have predicted the phenotypes? Bulun SE. **J Clin Endocrinol Metab** 1996 Mar;81(3):867–71 (27 ref.)

Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. Mullis PE, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1739–45

Effect of testosterone and estradiol in a man with aromatase deficiency. Carani C, et al. **N Engl J Med** 1997 Jul 10; 337(2):91–5

GENETICS

An optimized protocol for mRNA quantification using nested competitive RT-PCR. Watzka M, et al. **Biochem Biophys Res Commun** 1997 Feb 24;231(3):813–7

Changes in messenger ribonucleic acid encoding luteinizing hormone receptor, cytochrome P450-side chain cleavage, and aromatase are associated with recruitment and selection of bovine ovarian follicles. Bao B, et al. **Biol Reprod** 1997 May;56(5):1158–68

A developmental switch in expression from blastocyst to endometrial/placental-type cytochrome P450 aromatase genes in the pig and horse. Choi I, et al. **Biol Reprod** 1997 Mar;56(3):688–96

Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Kitawaki J, et al. **Biol Reprod** 1997 Sep;57(3):514–9

Effects of hormones and protein kinase inhibitors on expression of steroidogenic enzyme promoters in electroporated primary rat granulosa cells. Orly J, et al. **Biol Reprod** 1996 Jan;54(1):208–18

Rapid sequencing of rabbit aromatase cDNA using RACE PCR. Delarue B, et al. **C R Acad Sci III** 1996 Aug; 319(8):663–70

Closely related genes encode developmental and tissue isoforms of porcine cytochrome P450 aromatase. Choi I, et al. **DNA Cell Biol** 1997 Jun;16(6):769–77

Tissue-specific expression of the bovine aromatase-encoding gene uses multiple transcriptional start sites and alternative first exons. Fürbass R, et al. **Endocrinology** 1997 Jul; 138(7):2813–9

The 5'-flanking region of the ovarian promoter of the bovine CYP19 gene contains a deletion in a cyclic adenosine 3',5'-monophosphate-like responsive sequence. Hinshelwood MM, et al. **Endocrinology** 1997 Sep; 138(9):3704–10

Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Zhao Y, et al. **Endocrinology** 1996 Dec;137(12):5739–42

Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. Simpson ER, et al. **FASEB J** 1997 Jan;11(1):29–36 (67 ref.)

Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Gharani N, et al. **Hum Mol Genet** 1997 Mar;6(3):397–402

Allele detection and population study in Japanese using two STR loci (CYP19 and HUMTH01). Takahashi M, et al. **Int J Legal Med** 1996;108(6):321–2

Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer. Tsugaya M, et al. **Int J Urol** 1996 Jul; 3(4):292–6

P450 aromatase messenger ribonucleic acid expression in male rat germ cells: detection by reverse transcription-polymerase chain reaction amplification. Janulis L, et al. **J Androl** 1996 Nov–Dec;17(6):651–8

Alternatively spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of women. Agarwal VR, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):70–4

Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. Agarwal VR, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):3843–9

Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. Bulun SE, et al. **J Clin Endocrinol Metab** 1996 Mar;81(3):1273–7

Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. Mullis PE, et al. **J Clin Endocrinol Metab** 1997 Jun;82(6):1739–45

Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. Santner SJ, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):200–8

Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. Utsumi T, et al. **J Clin Endocrinol Metab** 1996 Jun;81(6):2344–9

Distribution and steroid hormone regulation of aromatase mRNA expression in the forebrain of adult male and female rats: a cellular-level analysis using in situ hybridization. Wagner CK, et al. **J Comp Neurol** 1996 Jun 17;370(1):71–84

Isolation and characterization of the cDNA encoding the tilapia (Oreochromis niloticus) cytochrome P450 aromatase (P450arom): changes in P450arom mRNA, protein and enzyme activity in ovarian follicles during oogenesis. Chang XT, et al. **J Mol Endocrinol** 1997 Feb;18(1):57–66

Occurrence of steroidogenic enzymes in the bovine mammary gland at different functional stages. Belvedere P, et al. **J Steroid Biochem Mol Biol** 1996 Nov; 59(3–4):339–47

Existence and expression of the untranslated first exon of aromatase mRNA in the rat brain. Yamada-Mouri N, et al. **J Steroid Biochem Mol Biol** 1996 May;58(2):163–6

Expression and distribution of cortical type aromatase mRNA variant in the adult rat brain. Yamada-Mouri N, et al. **J Steroid Biochem Mol Biol** 1997 Mar;60(5–6):325–9

Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Zhao Y, et al. **Mol Endocrinol** 1996 Nov;10(11):1350–7

Isolation, characterization, and expression of cDNAs encoding the medaka (Oryzias latipes) ovarian follicle cytochrome P-450 aromatase. Fukada S, et al. **Mol Reprod Dev** 1996 Nov;45(3):285–90

In vitro increase of aromatase mRNA in diencephalic neurons. Abe-Dohmae S, et al. **Neuroendocrinology** 1996 Jan;63(1):46–52

[In vitro gene expression of aromatase in rat testicular cells] Levallet J, et al. **C R Acad Sci III** 1997 Feb;320(2):123–9 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Androgens stimulate the morphological maturation of embryonic hypothalamic aromatase-immunoreactive neurons in the mouse. Beyer C, et al. **Brain Res Dev Brain Res** 1997 Jan 2;98(1):74–81

Distribution of aromatase-immunoreactive cells in the forebrain of zebra finches (Taeniopygia guttata): implications for the neural action of steroids and nuclear definition in the avian hypothalamus. Balthazart J, et al. **J Neurobiol** 1996 Oct;31(2):129–48

METABOLISM

Levels of serum steroids, aromatase activity, and estrogen receptors in preoptic area, hypothalamus, and amygdala of B6D2F1 male house mice that differ in the display of copulatory behavior after castration. Sinchak K, et al. **Behav Neurosci** 1996 Jun;110(3):593–602

Osteoblast cells (MG-63 and HOS) have aromatase and 5 alpha-reductase activities. Shimodaira K, et al. **Biochem Mol Biol Int** 1996 May;39(1):109–16

Mechanism for aromatase inactivation by a suicide substrate, androst-4-ene-3,6,17-trione. The 4 beta, 5 beta-epoxy-19-oxo derivative as a reactive electrophile irreversibly binding to the active site. Numazawa M, et al. **Biochem Pharmacol** 1996 Oct 25;52(8):1253–9

Granulosa cell apoptosis, aromatase activity, cyclic adenosine 3',5'-monophosphate response to gonadotropins, and follicular fluid steroid levels during spontaneous and induced follicular atresia in ewes. Jolly PD, et al. **Biol Reprod** 1997 Apr;56(4):830–6

Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Kitawaki J, et al. **Biol Reprod** 1997 Sep;57(3):514–9

Temporal changes in inhibin, steroid hormones, and steroidogenic enzymes during induced follicular atresia in the hypophysectomized cyclic hamster. Otsuka M, et al. **Biol Reprod** 1997 Feb;56(2):423–9

Pre- and post-translational regulation of aromatase by steroidal and non-steroidal aromatase inhibitors. Foidart A, et al. **Brain Res** 1995 Dec 1;701(1–2):267–78

The ovary retains male potential after the thermosensitive period for sex determination in the turtle Emys orbicularis. Dorizzi M, et al. **Differentiation** 1996 Jul;60(4):193–201

Incomplete testicular feminization syndrome: studies on androgen receptor(AR) function, AR gene analysis, and aromatase activities at puberty and long-term observations of clinical and hormonal features from infancy to puberty. Isurugi K, et al. **Endocr J** 1996 Oct;43(5):557–64

Aromatase and estrogen 2-hydroxylase activities of human placental microsomes in pregnancy-induced hypertension. Okubo K, et al. **Endocr J** 1996 Aug;43(4):363–8

Expression of 17beta-hydroxysteroid dehydrogenase type 1 and type 2, P450 aromatase, and 20alpha-hydroxysteroid dehydrogenase enzymes in immature, mature, and pregnant rats. Akinola LA, et al. **Endocrinology** 1997 Jul;

138(7):2886-92

Di erse functions of aromatase: O-deethylation of 7-ethoxycoumarin. Toma Y, et al. **Endocrinology** 1996 Sep; 137(9):3791-6

Immunolocalization of aromatase- and androgen receptor-positive neurons in the goldfish brain. Gelinas D, et al. **Gen Comp Endocrinol** 1997 May;106(2):155-68

Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Pasqualini JR, et al. **Int J Cancer** 1997 Mar 17;70(6):639-43

Mouse epididymal sperm contain active P450 aromatase which decreases as sperm traverse the epididymis. Janulis L, et al. **J Androl** 1996 Mar-Apr;17(2):111-6

Localization of testosterone-sensitive and sexually dimorphic aromatase-immunoreactive cells in the quail preoptic area. Balthazart J, et al. **J Chem Neuroanat** 1996 Sep;11(3):147-71

Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. Noble LS, et al. **J Clin Endocrinol Metab** 1997 Feb;82(2):600-6

Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. Santner SJ, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):200-8

Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. Sasano H, et al. **J Clin Endocrinol Metab** 1996 Nov;81(11):4042-6

Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. Sasano H, et al. **J Clin Endocrinol Metab** 1996 Aug;81(8):3063-7

Luteotrophic factors in hyperstimulated pseudopregnant rabbit: I--Evidence for aromatase activity in luteal tissue and luteal cells. Arioua RK, et al. **J Endocrinol** 1997 Aug; 154(2):249-57

Oestrogen formation in breast: clinical and biological importance. Dowsett M, et al. **J Endocrinol** 1996 Sep;150 Suppl:S59-63

Regulation of aromatase and sulphatase in breast tumour cells. Purohit A, et al. **J Endocrinol** 1996 Sep;150 Suppl:S65-71

Estrogen biosynthesis in adipose tissue: regulation by paracrine and autocrine mechanisms. Simpson ER, et al. **J Endocrinol** 1996 Sep;150 Suppl:S51-7

The mechanism of a P-450 enzyme-aromatase; a molecular modelling perspective for the removal of the C(19) methyl and aromatisation of the steroid A ring. Ahmed S. **J Enzyme Inhib** 1997 Apr;12(1):59-70

Expression of androgen-activating enzymes in cultured cells of developing rat brain. Poletti A, et al. **J Neurochem** 1997 Mar;68(3):1298-303

Equine cytochrome P450 aromatase exhibits an estrogen 2-hydroxylase activity in vitro. Almadhidi J, et al. **J Steroid Biochem Mol Biol** 1996 Sep;59(1):55-61

Optimization of a classical aromatase activity assay and application in normal, adenomatous and malignant breast parenchyma. Dikkeschei LD, et al. **J Steroid Biochem Mol Biol** 1996 Nov;59(3-4):305-13

Studies into aromatase activity associated with fetal allantochorionic and maternal endometrial tissues of equine placenta. Identification of metabolites by gas chromatography mass spectrometry. Marshall DE, et al. **J Steroid Biochem Mol Biol** 1996 Nov;59(3-4):281-96

Aromatase activity and CYP19 gene expression in breast cancers. Sourdaine P, et al. **J Steroid Biochem Mol Biol** 1996 Oct;59(2):191-8

11 beta-Hydroxysteroid dehydrogenase 1 activity and gene expression in human adipose stromal cells: effect on aromatase activity. Yang K, et al. **J Steroid Biochem Mol Biol** 1997 Feb;60(3-4):247-53

A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype. Hany MA, et al. **Med Pediatr Oncol** 1997 Feb;28(2):136-8

Detection of aromatase cytochrome P450, 17 alpha-hydroxylase cytochrome P450 and NADPH:P450 reductase on the surface of cells in which they are expressed. Amarneh BA, et al. **Mol Cell Endocrinol** 1996 May 17;119(1):69-74

Functional interactions, phosphorylation, and levels of 3',5'-cyclic adenosine monophosphate-regulatory element binding protein and steroidogenic factor-1 mediate hormone-regulated and constitutive expression of aromatase in gonadal cells. Carlone DL, et al. **Mol Endocrinol** 1997 Mar;11(3):292-304

Aromatase immunoreactivity in axon terminals of the vertebrate brain. An immunocytochemical study on quail, rat, monkey and human tissues. Naftolin F, et al. **Neuroendocrinology** 1996 Feb;63(2):149-55

Sex differences in androgen responsiveness in the rat brain: regional differences in the induction of aromatase activity. Roselli CE, et al. **Neuroendocrinology** 1996 Aug; 64(2):139-45

Activin-A stimulates, while transforming growth factor beta 1 inhibits, chorionic gonadotrophin production and aromatase activity in cultured human placental trophoblasts. Song Y, et al. **Placenta** 1996 Nov;17(8):603-10

Aromatase in hyperplasia and carcinoma of the human prostate. Hiramatsu M, et al. **Prostate** 1997 May 1; 31(2):118-24

Aromatase expression in health and disease. Simpson ER, et al. **Recent Prog Horm Res** 1997;52:185-213; discussion 213-4 (123 ref.)

Are ovine Leydig cells able to aromatize androgens? Bilińska B, et al. **Reprod Fertil Dev** 1997;9(2):193-9

Aromatase activity of ovine follicular walls: technical validation and physiological control. Driancourt MA, et al. **Reprod Fertil Dev** 1996;8(5):875-84

Expression of aromatase in the ovary: down-regulation of mRNA by the ovulatory luteinizing hormone surge. Fitzpatrick SL, et al. **Steroids** 1997 Jan;62(1):197-206

[A study on testicular aromatase activity--spermatogenic damage in high testicular E2 models of rat] Akiyama H. **Nippon Hinyokika Gakkai Zasshi** 1997 Jul;88(7):649-57 (Eng. Abstr.) **(Jpn)**

[Effects of gonadotropin-releasing hormone and its analogue (buserelin) on aromatase in cultured human granulosa cells] Maeda K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Feb;48(2):89-95 (Eng. Abstr.) **(Jpn)**

[Aromatase activity in human muscle tissue] Bershtein LM, et al. **Vopr Med Khim** 1996 Jan-Mar;42(1):76-82 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

New generation of aromatase inhibitors: prospects of a major advantage for the patients [editorial; comment] Cocconi G. **Ann Oncol** 1996 Jul;7(5):433-7. Comment on: Ann Oncol 1996 Jul;7(5):465-9. Comment on: Ann Oncol 1996 Jul;7(5):465-9. Comment on: Ann Oncol 1996 Jul;7(5):471-9.

Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase. Burak WE Jr, et al. **Breast Cancer Res Treat** 1997 May;44(1):57-64

Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Wiseman LR, et al. **Drugs Aging** 1996 Oct; 9(4):292-306 (71 ref.)

PHYSIOLOGY

Neither testicular androgens nor embryonic aromatase activity alters morphology of the neural song system in zebra finches. Wade J, et al. **Biol Reprod** 1996 Nov; 55(5):1126-32

A review of brain aromatase cytochrome P450. Lephart ED. **Brain Res Brain Res Rev** 1996 Jun;22(1):1-26 (335 ref.)

Androgen metabolism in the brain of the green anole lizard (Anolis carolinensis). Wade J. **Gen Comp Endocrinol** 1997 Apr;106(1):127-37

Metabolism of steroids in the brain: a new insight into the role of 5alpha-reductase and aromatase in brain differentiation and functions. Negri-Cesi P, et al. **J Steroid Biochem Mol Biol** 1996 Aug;58(5-6):455-66 (116 ref.)

AROMATHERAPY

Should there be aromatherapy for addiction? [letter] Miller WR, et al. **Addiction** 1997 Apr;92(4):486-7

Single case evaluation of the effects of aromatherapy and massage on disturbed behaviour in severe dementia. Brooker DJ, et al. **Br J Clin Psychol** 1997 May;36 (Pt 2):287-96

Dental anxiety [letter] Smith N. **J Am Dent Assoc** 1997 Aug; 128(8):1066

A comparison of the effects of four therapy procedures on concentration and responsiveness in people with profound learning disabilities. Lindsay WR, et al. **J Intellect Disabil Res** 1997 Jun;41 (Pt 3):201-7

Scents or nonsense: aromatherapy's benefits still subject to debate [news] Nelson NJ. **J Natl Cancer Inst** 1997 Sep 17;89(18):1334-6

Olfactory remediation: current evidence and possible applications. Martin GN. **Soc Sci Med** 1996 Jul;43(1):63-70 (75 ref.)

AROMATIC AMINO ACID DECARBOXYLASES

ANALYSIS

Immunocytochemical colocalizations of insulin, aromatic L-amino acid decarboxylase, dopamine beta-hydroxylase, S-100 protein and chromogranin A in B-cells of the chicken endocrine pancreas. Takayanagi M, et al. **Tissue Cell** 1996 Feb;28(1):17-24

ANTAGONISTS & INHIBITORS

An aromatic L-amino acid decarboxylase inhibitor blocks L-dopa-induced air-stepping in neonatal rats. Arnaiz CO, et al. **Brain Res Dev Brain Res** 1996 Jul 20;94(2):234-7

Sanguinarine and chelerythrine as inhibitors of aromatic amino acid decarboxylase. Držata J, et al. **J Enzyme Inhib** 1996;10(4):231-237

BIOSYNTHESIS

Analysis of an alternative promoter that regulates tissue-specific expression of the human aromatic L-amino acid decarboxylase gene in cultured cell lines. Sumi-Ichinose C, et al. **J Neural Transm** 1996; 103(1-2):1-15

Reciprocal regulation of the content of aromatic L-amino acid decarboxylase and tyrosine hydroxylase mRNA by NGF in PC12 cells. Li XM, et al. **J Neurosci Res** 1997 Feb 15;47(4):449-54

CHEMISTRY

Functionally important residues of aromatic L-amino acid decarboxylase probed by sequence alignment and site-directed mutagenesis. Ishii S, et al. **J Biochem (Tokyo)** 1996 Aug;120(2):369-76

An anomalous side reaction of the Lys303 mutant aromatic L-amino acid decarboxylase unravels the role of the residue in catalysis. Nishino J, et al. **J Biochem (Tokyo)** 1997 Mar; 121(3):604-11

DRUG EFFECTS

Tyrosine hydroxylase and aromatic L-amino acid decarboxylase in mesencephalic cultures after MPP+: the consequences of treatment with GM1 ganglioside. Dalia A, et al. **Brain Res** 1996 Dec 2;742(1-2):260-4

GENETICS

Active rat aromatic-L-amino acid decarboxylase as a fusion protein in Escherichia coli. Jebai F, et al. **C R Acad Sci III** 1997 May;320(5):349-58

Functionally important residues of aromatic L-amino acid decarboxylase probed by sequence alignment and site-directed mutagenesis. Ishii S, et al. **J Biochem (Tokyo)** 1996 Aug;120(2):369-76

Analysis of an alternative promoter that regulates tissue-specific expression of the human aromatic L-amino acid decarboxylase gene in cultured cell lines. Sumi-Ichinose C, et al. **J Neural Transm** 1996; 103(1-2):1-15

Human hair follicles as a peripheral source of tyrosine hydroxylase and aromatic L-amino acid decarboxylase mRNA. Chang YT, et al. **Neurosci Lett** 1997 Feb 7; 222(3):210-2

Tryptophan decarboxylase is encoded by two autonomously regulated genes in Camptotheca acuminata which are differentially expressed during development and stress. López-Meyer M, et al. **Plant J** 1997 Jun;11(6):1167-75

IMMUNOLOGY

Cytochrome P450IA2 and aromatic L-amino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I. Gebre-Medhin G, et al. **FEBS Lett** 1997 Aug 4;412(3):439-45

Autoantibodies against aromatic L-amino acid decarboxylase in autoimmune polyendocrine syndrome type I. Husebye ES, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):147-50

METABOLISM

Antagonistic actions of renal dopamine and 5-hydroxytryptamine: effects of amine precursors on the cell inward transfer and decarboxylation. Soares-da-Silva P, et al. **Br J Pharmacol** 1996 Mar;117(6):1187-92

Immunocytochemical localization of aromatic L-amino acid decarboxylase and catechol-O-methyltransferase in blood vessel wall of the human dental pulp. Nomura T, et al. **Brain Res** 1996 Oct 7;735(2):314-6

The role of L-aromatic amino acid decarboxylase in serotonin-stimulated aldosterone secretion in response to salt intake. Burns N, et al. **Endocr Res** 1996 Nov;22(4):577-8

Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A. Cho S, et al. **Eur J Pharmacol** 1996 Oct 24;314(1-2):51-9

Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Cho S, et al. **Eur J Pharmacol** 1997 Apr 4;323(2-3):149-57

Intrastriatal grafting of Cos cells stably expressing human aromatic L-amino acid decarboxylase: neurochemical effects. Kaddis FG, et al. **J Neurochem** 1997 Apr; 68(4):1520-6

Aromatic L-amino acid decarboxylase: a neglected and misunderstood enzyme. Berry MD, et al. **Neurochem Res** 1996 Sep;21(9):1075-87 (137 ref.)

D2 dopamine receptor antisense increases the activity and mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in mouse brain. Hadjiconstantinou M, et al. **Neurosci Lett** 1996 Oct 18;217(2-3):105-8

AROUSAL

Fatigue, mindset and ecology in the hazard dominant environment. Nelson TM. **Accid Anal Prev** 1997 Jul; 29(4):409-15

Adaptation to the driver as part of a driver monitoring and warning system. Onken R, et al. **Accid Anal Prev** 1997 Jul; 29(4):507-13

Aircrew fatigue in long-haul operations. Samel A, et al. **Accid Anal Prev** 1997 Jul;29(4):439-52

Threefold effect of peripheral precues: alertness, orienting, and response tendencies. van der Lubbe RH, et al. **Acta Psychol (Amst)** 1996 Dec;94(3):319-37

Cue reactivity to food- and body-related stimuli in restrained and unrestrained eaters. Overduin J, et al. **Addict Behav** 1997 May-Jun;22(3):395-404

Morbid obesity, absorption, neuroticism, and the high risk model of threat perception. Wickramasekera I, et al. **Am J Clin Hypn** 1997 Apr;39(4):291-301

Resting cardiovascular measures in patients with panic disorder and social phobia and health control subjects: relationship to habitual exercise frequency. Asmundson GJ, et al. **Anxiety** 1994;1(1):26-30

Dot-probe evaluation of cognitive processing biases in patients with panic disorder: a failure to replicate and extend. Asmundson GJ, et al. **Anxiety** 1994-95;1(3):123-8

Safety signals and human anxiety: a fear-potentiated startle study. Grillon C, et al. **Anxiety** 1994;1(1):13-21

Comparison of anxiety sensitivity in panic disorder and social phobia. Hazen AL, et al. **Anxiety** 1994-95;1(6):298-301

Anxiety sensitivity and treatment outcome in panic disorder. Hazen AL, et al. **Anxiety** 1996;2(1):34-9

Assessment instrument for panic disorder that includes fear of sensation-producing activities: the Albany Panic and Phobia Questionnaire. Rapee RM, et al. **Anxiety** 1994-95; 1(3):114-22

Hypervigilance in patients with obsessive-compulsive disorder. Wiggs CL, et al. **Anxiety** 1996;2(3):123-9

One or many arousal systems? Reflections on some of Giuseppe Moruzzi's foresights and insights about the intrinsic regulation of brain activity. Berlucchi G. **Arch Ital Biol** 1997 Jan;135(1):5-14 (38 ref.)

Sense of relatedness and interpersonal network of adult offspring caregivers: linkages with crisis, emotional arousal, and perceived health. England M. **Arch Psychiatr Nurs** 1996 Apr;10(2):85-95

Classical conditioning of female sexual arousal. Letourneau EJ, et al. **Arch Sex Behav** 1997 Feb;26(1):63-78

Selective encoding of threat in panic disorder: application of a dual priming paradigm. McNally RJ, et al. **Behav Res Ther** 1997 Jun;35(6):543-9

Evidence for attention to threatening stimuli in depression. Mathews A, et al. **Behav Res Ther** 1996 Sep;34(9):695-705

Validation of the spanish version of the Anxiety Sensitivity Index in a clinical sample. Sandin B, et al. **Behav Res Ther** 1996 Mar;34(3):283-90

Cognitive and performance-based treatments for panic attacks in people with varying degrees of agoraphobic disability. Williams SL, et al. **Behav Res Ther** 1996 Mar; 34(3):253-64

Creativity [letter; comment] McClure I. **Br J Psychiatry** 1996 Sep;169(3):379. Comment on: Br J Psychiatry 1996 May;168(5):545-55.

Behavioural vigilance in schizophrenia. Evidence for hyperattentional processing. Mar CM, et al. **Br J Psychiatry** 1996 Dec;169(6):781-9

Auditory vigilance in aphasic individuals: detecting nonlinguistic stimuli with full or divided attention. Erickson RJ, et al. **Brain Cogn** 1996 Mar;30(2):244-53

Behavioural differences between patients who emerged from vegetative state and those who did not. Wilson SL, et al. **Brain Inj** 1996 Jul;10(7):509-16

Is Mr Pac Man eating our children? A review of the effect of video games on children. Emes CE. **Can J Psychiatry** 1997 May;42(4):409-14 (38 ref.)

Fetal neurobehavioral development. DiPietro JA, et al. **Child Dev** 1996 Oct;67(5):2553-67

Temperament and the reactions to unfamiliarity. Kagan J. **Child Dev** 1997 Feb;68(1):139-43

Prenatal maternal reactivity to infant cries predicts postnatal perceptions of infant temperament and marriage appraisal. Pedersen FA, et al. **Child Dev** 1996 Oct;67(5):2541-52

Autonomic and recognition indices of memory in amnesic and healthy control subjects. Diamond BJ, et al. **Cortex** 1996 Sep;32(3):439-59

Sensitizing properties of spectral lights in 4-month-old human infants. Bieber ML, et al. **Dev Psychobiol** 1997 May; 30(4):275-81

Role of experimental conditions in determining differences in exploratory behavior of prenatally stressed rats. Poltyrev T, et al. **Dev Psychobiol** 1996 Jul;29(5):453-62

Augmented prenatal auditory stimulation alters postnatal perception, arousal, and survival in bobwhite quail chicks. Sleigh MJ, et al. **Dev Psychobiol** 1997 Apr;30(3):201-12

Roles of temperamental arousal and gender-segregated play in young children's social adjustment. Fabes RA, et al. **Dev Psychol** 1997 Jul;33(4):693-702

Smoking produces a smaller increase in heart rate in the natural smoking environment than in the laboratory. Mucha RF, et al. **Drug Alcohol Depend** 1996 Nov;42(3):209-15

Physiological changes during computer tasks: responses to mental load or to motor demands? Kohlisch O, et al. **Ergonomics** 1996 Feb;39(2):213-24

Level of operator control and changes in heart rate variability during simulated flight maintenance. Tattersall AJ, et al. **Hum Factors** 1995 Dec;37(4):682-98

Use of computerized visual performance test in assessing day-time vigilance in patients with sleep apneas and restless sleep. Jokinen T, et al. **Int J Clin Monit Comput** 1995; 12(4):225-30

Massage therapy reduces anxiety and enhances EEG pattern of alertness and math computations. Field T, et al. **Int J Neurosci** 1996 Sep;86(3-4):197-205

Daytime sleepiness and REM abnormalities in Prader-Willi syndrome: evidence of generalized hypoarousal. Vgontzas AN, et al. **Int J Neurosci** 1996 Nov;87(3-4):127-39

Expectancy bias in trait anxiety. Chan CK, et al. **J Abnorm Psychol** 1996 Nov;105(4):637-47

Alcohol cue reactivity, negative-mood reactivity, and relapse in treated alcoholic men. Cooney NL, et al. **J Abnorm Psychol** 1997 May;106(2):243-50

Predictors of the generation of episodic stress: a longitudinal study of late adolescent women. Daley SE, et al. **J Abnorm Psychol** 1997 May;106(2):251-9

Electrodermal activity and social network as predictors of outcome of episodes in schizophrenia. Hultman CM, et al. **J Abnorm Psychol** 1996 Nov;105(4):626-36

Heart rate and skin conductance in behaviorally inhibited Mauritian children. Scarpa A, et al. **J Abnorm Psychol** 1997 May;106(2):182-90

The role of anxiety sensitivity in the pathogenesis of panic: prospective evaluation of spontaneous panic attacks during acute stress. Schmidt NB, et al. **J Abnorm Psychol** 1997 Aug;106(3):355-64

A computer-aided comparative study of progressive alertness changes in nurses working two different night-shift rotas. Dingley J. **J Adv Nurs** 1996 Jun;23(6):1247-53

Brief report: autistic children's attentiveness and responsivity improve after touch therapy. Field T, et al. **J Autism Dev Disord** 1997 Jun;27(3):333-8

The effects of anxiety on response times to disease detection and health promotion behaviors. Millar MG, et al. **J Behav Med** 1996 Aug;19(4):401-13

An orienting response model of eye movement desensitization [comment] Armstrong MS, et al. **J Behav Ther Exp Psychiatry** 1996 Mar;27(1):21-32. Comment on: J Behav Ther Exp Psychiatry 1993 Sep;24(3):201-10.

Measuring effectiveness of eye movement desensitization and reprocessing (EMDR) in non-clinical anxiety: a multi-subject, yoked-control design. Dunn TM, et al. **J Behav Ther Exp Psychiatry** 1996 Sep;27(3):231-9

Evaluating the response of mild hypertensives to biofeedback-assisted relaxation using a mental stress test. Paran E, et al. **J Behav Ther Exp Psychiatry** 1996 Jun; 27(2):157-67

Eye movement desensitization and reprocessing: effectiveness and autonomic correlates. Wilson DL, et al. **J Behav Ther Exp Psychiatry** 1996 Sep;27(3):219-29

Polysomnographic analysis of arousal responses in obstructive sleep apnea syndrome by means of the cyclic alternating pattern. Terzano MG, et al. **J Clin Neurophysiol** 1996 Mar;13(2):145-55

Effects of stressful stimuli: a comparison between two time periods. Koslowsky M, et al. **J Clin Psychol** 1996 May; 52(3):279-83

A kinematic analysis of evasive dodging movements used during food protection in the rat (Rattus norvegicus): evidence for sex differences in movement. Field EF, et al. **J Comp Psychol** 1996 Sep;110(3):298-306

Self-talk in youth with anxiety disorders: states of mind, content specificity, and treatment outcome. Treadwell KR, et al. **J Consult Clin Psychol** 1996 Oct;64(5):941-50

A transformation of respondently conditioned stimulus function in accordance with arbitrarily applicable relations. Roche B, et al. **J Exp Anal Behav** 1997 May;67(3):275-301

Converging evidence for one-trial context fear conditioning with an immediate shock: importance of shock potency. Bevins RA, et al. **J Exp Psychol Anim Behav Process** 1997 Jul;23(3):312-24

Psychological stress in people with profound mental retardation. Chaney RH. **J Intellect Disabil Res** 1996 Aug; 40 (Pt 4):305-10

Arousal-modulated attention at four months as a function of intrauterine cocaine exposure and central nervous system injury. Karmel BZ, et al. **J Pediatr Psychol** 1996 Dec; 21(6):821-32

Do gender-relevant characteristics determine cardiovascular reactivity? Match versus mismatch of traits and situation. Davis MC, et al. **J Pers Soc Psychol** 1996 Sep;71(3):527-35

Social comparison and affiliation under threat: effects on recovery from major surgery. Kulik JA, et al. **J Pers Soc Psychol** 1996 Nov;71(5):967-79

Facial asymmetry as an indicator of psychological, emotional, and physiological distress. Shackelford TK, et al. **J Pers Soc Psychol** 1997 Feb;72(2):456-66

Ability analysis of gender relevance and sex differences in cardiovascular response to behavioral challenge. Wright RA, et al. **J Pers Soc Psychol** 1997 Aug;73(2):405-17

Covert visual attention in schizophrenia spectrum personality disordered subjects: visuospatial cuing and alerting effects. Moran MJ, et al. **J Psychiatr Res** 1996 Jul-Aug; 30(4):261-75

Self-efficacy as a component of active coping: effects on cardiovascular reactivity. Gerin W, et al. **J Psychosom Res** 1996 May;40(5):485-93

Predicting vasovagal reactions in volunteer blood donors. Meade MA, et al. **J Psychosom Res** 1996 May; 40(5):495-501

Dimensions of hostility and cardiovascular response to interpersonal stress. Miller SB, et al. **J Psychosom Res** 1996 Jul;41(1):81-95

The effect of condoms in sexually explicit narratives on male sexual arousal. Gaither GA, et al. **J Sex Marital Ther** 1996 Summer;22(2):103-9

Evaluation of activity-based techniques to identify transient arousal in respiratory sleep disorders. Drinnan MJ, et al. **J Sleep Res** 1996 Sep;5(3):173-80

Sleep during arousal episodes as a function of prior torpor duration in hibernating European ground squirrels. Strijkstra AM, et al. **J Sleep Res** 1997 Mar;6(1):36-43

The effects of cognitive and affective perspective taking on empathic concern and altruistic helping. Oswald PA. **J Soc Psychol** 1996 Oct;136(5):613-23

Suspiciousness, mental simulation, and norm theory. Pipes RB, et al. **J Soc Psychol** 1997 Aug;137(4):421-7

Attention, arousal, and memory in posttraumatic stress disorder. Litz BT, et al. **J Trauma Stress** 1996 Jul; 9(3):497-519

Umbilical arterial blood flow and plasma prostaglandin E2 concentrations during arousal and breathing movements in fetal sheep. Hasan SU, et al. **Pediatr Res** 1996 Nov; 40(5):723-31

Influence of sedation on arousal and cardiorespiratory responses to airflow obstruction in sleeping lambs. Jakubowska AE, et al. **Pediatr Res** 1996 Oct;40(4):564-70

The Control Question Test in polygraphic examinations with actual controls for truth. Bradley MT, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 1):755-62

Increasing social smiles of young children with disabilities. Calhoun ML, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 2):1265-6

Performance on the Purdue pegboard and finger tapping by schizophrenics after mellow and frenetic antecedent music. Chambliss C, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1161-2

Corroborative evidence for difference in arousability between internal and external scorers on Rotter's I-E Locus of Control Scale. De Brabander B, et al. **Percept Mot Skills** 1997 Feb;84(1):336-8

Effects of competitive activation on precision movement control. de Melo F, et al. **Percept Mot Skills** 1996 Dec; 83(3 Pt 2):1203-8

Human ethology: eating, security, and curiosity. Freidenberg BM, et al. **Percept Mot Skills** 1996 Oct;83(2):489-90

Number bias, estimation, and sensation seeking. Ginsburg N. **Percept Mot Skills** 1996 Dec;83(3 Pt 1):856-8

Comment regarding Malik, et al.'s (1996) "The method of subliminal psychodynamic activation: do individual thresholds make a difference?" [comment] Greenberg AC. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):1024-6. Comment on: Percept Mot Skills 1996 Dec;83(3 Pt 2):1235-42.

The psychological factors of a premature response based on contingent negative variation. Hiraku S, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 1):1083-90

Cognitive performance after strenuous physical exercise. Hogervorst E, et al. **Percept Mot Skills** 1996 Oct; 83(2):479-88

Effects of smoking on EEG alpha asymmetry during production of random sequences of numbers. Hori T, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):827-34

Effect of sleep deficit, knowledge of results, and stimulus quality on reaction time and response force. Jaśkowski P, et al. **Percept Mot Skills** 1997 Apr;84(2):563-72

Effects of pretest stimulative and sedative music on grip strength. Karageorghis CI, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1347-52

Effects on archery performance of manipulating metamotivational state and felt arousal. Kerr JH, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):819-28

Covert speech behavior during a silent language recitation task. Livesay J, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1355-62

The method of subliminal psychodynamic activation: do individual thresholds make a difference? [see comments] Malik R, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1235-42. Comment in: Percept Mot Skills 1997 Jun;84(3 Pt 1):1024-6.

Effects of pain-incompatible imagery on tolerance of pain, heart rate, and skin resistance. Neumann W, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):939-43

Behavioral components of milk-induced activation in neonatal rat pups. Specht SM, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):903-11

Comparison of passive sensory stimulations on RPE during moderate intensity exercise. White VB, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):819-25

Comparative analysis of anxiety-like behavior in partition and plus-maze tests after agonistic interactions in mice. Avgustinovich DF, et al. **Physiol Behav** 1997 Jan; 61(1):37-43

Sustained stress and fixed interval performance. Kant GJ, et al. **Physiol Behav** 1997 Feb;61(2):279-84

Scanning behavior of rats during eating under stressful noise. Krebs H, et al. **Physiol Behav** 1997 Jul;62(1):151-4

Food neophobia in humans: effects of manipulated arousal and individual differences in sensation seeking. Pliner P, et al. **Physiol Behav** 1997 Feb;61(2):331-5

Behaviour laterality in male rats: influence of practice and stress. Santin LJ, et al. **Physiol Behav** 1996 Jul;60(1):161-4

Sleep deprivation by the "flower pot" technique and spatial reference memory. Youngblood BD, et al **Physiol Behav** 1997 Feb;61(2):249-56

Modulation of memory storage processes by peripherally acting pharmacological agents. Jensen RA. **Proc West Pharmacol Soc** 1996;39:85-9 (19 ref.)

Discrimination and response bias in memory: effects of depression severity and psychomotor retardation. Brébion G, et al. **Psychiatry Res** 1997 May 5;70(2):95-103

Pain and self-injury in borderline patients: sensory decision theory, coping strategies, and locus of control. Russ MJ, et al. **Psychiatry Res** 1996 Jun 26;63(1):57-65

States of overstimulation in early childhood. Rosenblitt DL. **Psychoanal Study Child** 1996;51:542-61

Beyond stress and arousal: a reconceptualization of alcohol-emotion relations with reference to psychophysiological methods. Stritzke WG, et al. **Psychol Bull** 1996 Nov;120(3):376-95 (183 ref.)

Heart rate and heart-rate variability in patients with acute

coronary heart disease classified on Bortner's scale as type A and type B. Catipović-Veselica K, et al. **Psychol Rep** 1997 Jun;80(3 Pt 1):775–84

Locus of control, sensation seeking, and stress. De Brabander B, et al. **Psychol Rep** 1996 Dec;79(3 Pt 2):1307–12

Self-reported locus of control is based on feelings of depression as well as on asymmetry in activation of cerebral hemispheres. De Brabander B, et al. **Psychol Rep** 1997 Jun; 80(3 Pt 2):1227–32

Women with high risk for breast cancer: psychological symptoms. Gilbar O. **Psychol Rep** 1997 Jun;80(3 Pt 1):800–2

Friendships, femininity, and reaction to affective arousal. Jacobs MG, et al. **Psychol Rep** 1996 Aug;79(1):183–90

Menstrual cycle, arousal-induction, and intelligence test performance. Kumari V, et al. **Psychol Rep** 1996 Feb; 78(1):51–8

Chronometrics of attentional processes in anxiety disorders. Horenstein M, et al. **Psychopathology** 1997;30(1):25–35

The influence of resting blood pressure and gender on pain responses. Fillingim RB, et al. **Psychosom Med** 1996 Jul–Aug;58(4):326–32

Treating myopia with acoustic biofeedback: a prospective study on the evolution of visual acuity and psychological distress. Rupolo G, et al. **Psychosom Med** 1997 May–Jun; 59(3):313–7

Influence of ethnicity and gender on cardiovascular responses to active coping and inhibitory–passive coping challenges. Saab PG, et al. **Psychosom Med** 1997 Jul–Aug;59(4):434–46

Somatization, dissociation, and tension-reducing behaviors in psychiatric outpatients. Farley M, et al. **Psychother Psychosom** 1997;66(3):133–40

Tactual sensitivity in hypochondriasis. Haenen MA, et al. **Psychother Psychosom** 1997;66(3):128–32

Does immediate arousal enhance response force in simple reaction time? Ulrich R, et al. **Q J Exp Psychol A** 1996 Nov;49(4):972–90

Sleep, psychological distress, and stress arousal in women with fibromyalgia. Shaver JL, et al. **Res Nurs Health** 1997 Jun;20(3):247–57

Psychological defense mechanisms and electroencephalographic arousal. Eriksen HR, et al. **Scand J Psychol** 1996 Dec;37(4):351–61

Environmental influences on psychological restoration. Hartig T, et al. **Scand J Psychol** 1996 Dec;37(4):378–93

Electrodermal lability in anxiety disorders. Jensen HH, et al. **Scand J Psychol** 1996 Mar;37(1):103–8

Liking, arousal potential, and the emotions expressed by music. North AC, et al. **Scand J Psychol** 1997 Mar; 38(1):45–53

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia. Brekke JS, et al. **Schizophr Bull** 1997;23(1):19–28

The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex. Gruzelier JH, et al. **Schizophr Bull** 1996;22(4):621–34

Abnormal orienting in schizotypal personality disorder. Raine A, et al. **Schizophr Bull** 1997;23(1):75–82

Wakefulness and arousal in neonates born to women with schizophrenia: diminished arousal and its association with neurological deviations. Schubert EW, et al. **Schizophr Res** 1996 Oct 18;22(1):49–59

D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. Siegel BV Jr, et al. **Schizophr Res** 1996 May;20(1–2):29–32

Respiratory and electrocortical responses to acoustic stimulation. Carley DW, et al. **Sleep** 1996 Dec;19(10 Suppl):S189–92

Neurobehavioral consequences of arousals. Chugh DK, et al. **Sleep** 1996 Dec;19(10 Suppl):S198–201 (16 ref.)

Time course of reaction time and EEG while performing a vigilance task during total sleep deprivation. Corsi-Cabrera M, et al. **Sleep** 1996 Sep;19(7):563–9

Arousals and the sleep apnea/hypopnea syndrome. Douglas NJ, et al. **Sleep** 1996 Dec;19(10 Suppl):S196–7 (7 ref.)

Automated recognition of EEG changes accompanying arousal in respiratory sleep disorders. Drinnan MJ, et al. **Sleep** 1996 May;19(4):296–303

Snoring and arousals: a retrospective analysis. Hoffstein V, et al. **Sleep** 1995 Dec;18(10):866–72

Autonomic consequences of arousal from sleep: mechanisms and implications. Horner RL. **Sleep** 1996 Dec;19(10 Suppl):S193–5 (10 ref.)

Morning work: effects of early rising on sleep and alertness. Kecklund G, et al. **Sleep** 1997 Mar;20(3):215–23

Modeling the interaction between arousal and chemical drive in sleep–disordered breathing. Khoo MC, et al. **Sleep** 1996 Dec;19(10 Suppl):S167–9

Maternal sleep and arousals during bedsharing with infants. Mosko S, et al. **Sleep** 1997 Feb;20(2):142–50

Arousals in infants. Thach BT, et al. **Sleep** 1996 Dec;19(10 Suppl):S271–3 (11 ref.)

Comparison of home and clinical blood pressure measurements: clinical applications. de Gaudemaris R, et al. **Z Kardiol** 1996;85 Suppl 3:60–5 (37 ref.)

[Anxiety, aggression, agitation and depression: psychopathologic aspects] Braconnier A, et al. **Encephale** 1997 Jun;23 Spec No 3:43–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[Ethology of panic disorders] Cyrulnik B. **Encephale** 1996 Dec;22 Spec No 5:42–5 (10 ref.) (Eng. Abstr.) **(Fre)**

[Psychophysiologic and psychologic correlates of the emotional family climate in schizophrenic patients and their family] Kraemer S, et al. **Nervenarzt** 1996 Mar;67(3):219–28 (Eng. Abstr.) **(Ger)**

[Damaging health effects on children caused by low flying aircraft and other environmental stresses. Autonomic reactions and psychological symptoms in the developmental stage] Poustka F, et al. **Schriftenr Ver Wasser Boden Lufthyg** 1996;97:1–171 **(Ger)**

[Performance and personality of patients with hypersomnia] Mayer G, et al. **Wien Med Wochenschr** 1996; 146(13–14):298–303 (Eng. Abstr.) **(Ger)**

[Cardiovascular effects of active coping behavior in mental and social stress situations during various incentive conditions] Gramer M, et al. **Z Exp Psychol** 1996; 43(2):256–78 (Eng. Abstr.) **(Ger)**

[The interactive effect of initial position and threat to freedom on psychological reactance] Imajo S. **Shinrigaku Kenkyu** 1996 Feb;66(6):431–6 (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Relationships among physiological and self-report responses produced by cocaine-related cues. Robbins SJ, et al. **Addict Behav** 1997 Mar–Apr;22(2):157–67

The effect of caffeine on cue exposure responses in ex-smokers. Hepple J, et al. **Addiction** 1996 Feb; 91(2):269–73

Prenatal alcohol exposure results in hyperactivity of the hypothalamic–pituitary–adrenal axis of the offspring: modulation by fostering at birth and postnatal handling. Ogilvie KM, et al. **Alcohol Clin Exp Res** 1997 May; 21(3):424–9

Correlated responses to selection in FAST and SLOW mice: effects of ethanol on ataxia, temperature, sedation, and withdrawal. Shen EH, et al. **Alcohol Clin Exp Res** 1996 Jun;20(4):688–96

High-dose subchronic imipramine treatment: effects on anxiety-like (conflict) behavior in rats. Commissaris RL, et al. **Anxiety** 1994–95;1(3):109–13

Noise stress and the development of benzodiazepine dependence in the rat. File SE, et al. **Anxiety** 1994;1(1):8–12

Response to alcohol in social phobia. Naftolowitz DF, et al. **Anxiety** 1994;1(2):96–9

Dose-response effects of intravenous caffeine in normal volunteers. Nickell PV, et al. **Anxiety** 1994–95;1(4):161–8

Primate displacement activities as an ethopharmacological model of anxiety. Schino G, et al. **Anxiety** 1996;2(4):186–91

Orienting-like reaction after ibotenic acid injections into the thalamic centre median nucleus in the cat. Mancia M, et al. **Arch Ital Biol** 1995 Dec;134(1):65–80

Kainic acid versus carbachol induced emotional-defensive response in the cat. Eckersdorf B, et al. **Behav Brain Res** 1996 May;77(1–2):201–10

Behavioral stereotypies induced by "binge' cocaine administration are independent of drug-induced increases in corticosterone levels. Spangler R, et al. **Behav Brain Res** 1997 Jul;86(2):201–4

The effects of extended training and acute administration of an anxiolytic on avoidance learning and intertrial responding in the Syracuse strains of rats. Gendron CM, et al. **Behav Genet** 1996 Nov;26(6):575–80

Effects of the PCP analog dizocilpine on sensory gating: potential relevance to clinical subtypes of schizophrenia. al-Amin HA, et al. **Biol Psychiatry** 1996 Oct 15; 40(8):744–54

Stimulant sensitization in humans [letter; comment] Gorelick DA, et al. **Biol Psychiatry** 1997 Aug 1;42(3):230–1. Comment on: Biol Psychiatry 1996 Nov 1;40(9):872–80.

Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Koszycki D, et al. **Biol Psychiatry** 1996 Oct 1;40(7):648–55

Effect of nitrous oxide on cerebral blood velocity while reclining and standing. Mathew RJ, et al. **Biol Psychiatry** 1997 May 1;41(9):979–84

Increased activation of indirect semantic associations under psilocybin. Spitzer M, et al. **Biol Psychiatry** 1996 Jun 15; 39(12):1055–7

Auditory event-related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication. Stefánsson SB, et al. **Biol Psychiatry** 1996 Jul 1;40(1):19–27

Enhanced response to repeated d-amphetamine challenge: evidence for behavioral sensitization in humans [see comments] Strakowski SM, et al. **Biol Psychiatry** 1996 Nov 1;40(9):872–80. Comment in: Biol Psychiatry 1997 Aug 1;42(3):230–1.

Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls. van Vliet IM, et al. **Biol Psychiatry** 1997 Jul 1;42(1):76–8

Maternal handling during pregnancy reduces DMBA-induced mammary tumorigenesis among female offspring. Hilakivi-Clarke L. **Br J Cancer** 1997;76(2):150–5

Hypercapnia-induced increases in cerebral blood flow: roles of adenosine, nitric oxide and cortical arousal. Estevez AY, et al. **Brain Res** 1997 May 30;758(1–2):1–8

Pupillometric assessment of compensatory effort in a memory search task under physical and pharmacologically-induced suboptimal states. Deijen JB, et al. **Can J Exp Psychol** 1995 Sep;49(3):387–96

Effects of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical performance in patients with COPD. Girault C, et al. **Chest** 1996 Nov;110(5):1203–11

Interaction of CCK-4 induced anxiety and post-cat exposure anxiety in rats. Cohen H, et al. **Depress Anxiety** 1996–97; 4(3):144–5

Prenatal cocaine exposure effects on arousal-modulated attention during the neonatal period. Karmel BZ, et al. **Dev Psychobiol** 1996 Jul;29(5):463–80

Failure of ritanserin to block cocaine cue reactivity in humans. Ehrman RN, et al. **Drug Alcohol Depend** 1996 Nov;42(3):167–74

Mood and physiological effects of subcutaneous nicotine in smokers and never-smokers. Foulds J, et al. **Drug Alcohol Depend** 1997 Mar 14;44(2–3):105–15

Pharmacological potency and biodisposition of phencyclidine via inhalation exposure in mice. Meng Y, et al. **Drug Alcohol Depend** 1996 Dec 2;43(1–2):13–22

Effects of some phenylethylamines in rhesus monkeys trained to discriminate (+)-amphetamine from saline. Woolverton WL, et al. **Drug Alcohol Depend** 1997 Mar 14;44(2–3):79–85

The effects of a cold-water immersion stressor on the reinforcing and subjective effects of fentanyl in healthy volunteers. Zacny JP, et al. **Drug Alcohol Depend** 1996 Oct; 42(2):133–42

Stimulation of adenosine A1 receptors prevents the EEG arousal due to dopamine D1 receptor activation in rabbits. Popoli P, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):123–6

Dextrorphan effects on cocaine and brainstem perturbation. Lundien M, et al. **Integr Physiol Behav Sci** 1996 Jul–Sep; 31(3):224–30

Use of 2% propofol to produce diurnal sedation in critically ill patients. McLeod G, et al. **Intensive Care Med** 1997 Apr; 23(4):428–34

Alcohol outcome expectancies and alcohol use: a latent variable cross-lagged panel study. Sher KJ, et al. **J Abnorm Psychol** 1996 Nov;105(4):561–74

Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response. Slaap BR, et al. **J Affect Disord** 1996 Jun 20;39(1):13–9

Application of the Stages of Change Scale in a clinical drug trial. Wilson M, et al. **J Anxiety Disord** 1997 Jul–Aug; 11(4):395–408

Illustrating caffeine's pharmacological and expectancy effects utilizing a balanced placebo design. Lotshaw SC, et al. **J Drug Educ** 1996;26(1):13–24

Effects of cocaine on briefly signaled versus completely signaled delays to reinforcement. Walker DJ, et al. **J Exp Anal Behav** 1996 Mar;65(2):375–88

Combination of bright light and caffeine as a countermeasure for impaired alertness and performance during extended sleep deprivation. Wright KP Jr, et al. **J Sleep Res** 1997 Mar;6(1):26–35

Individual differences in alcohol responsivity: physiological, psychomotor and subjective response domains. Mundt JC, et al. **J Stud Alcohol** 1997 Mar;58(2):130–40

Vigilance and EEG power in rats: effects of potent inhibitors of the neuronal nitric oxide synthase. Dzoljic E, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1997 Jul; 356(1):56–61

Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal. Aloe L, et al. **Neuropsychobiology** 1997;36(2):65–8

Influence of moclobemide on cognitive functions of nine depressed patients: pilot trial with neurophysiological and neuropsychological indices. Galderisi S, et al. **Neuropsychobiology** 1996;33(1):48–54

Psychophysiological and subjective effects of cigarettes having varying nicotine yields but relatively constant "tar' yields. Pritchard WS, et al. **Neuropsychobiology** 1996; 34(4):208–21

The use of diurnal vigilance changes in the EEG to verify vigilance-enhancing effects of memantine in a clinical pharmacological study. Schulz H, et al. **Neuropsychobiology** 1996;33(1):32–40

Effects of the tranquillizer diazepam and the stimulant methylphenidate on alertness and memory. Unrug A, et al. **Neuropsychobiology** 1997;36(1):42–8

An indirect cholinesterase inhibitor, metrifonate, increases neocortical EEG arousal in rats. Björklund M, et al. **Neuroreport** 1996 Apr 10;7(5):1097–101

The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Ferraro L, et al. **Neurosci Lett** 1996 Dec 6;220(1):5–8

Effects of caffeine- and sugar-free beverages on psychomotor performance. Meliska CJ, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 1):912–4

Fluoxetine alters the effects of cocaine on vigilance task performance of rats. Grilly DM, et al. **Pharmacol Biochem Behav** 1997 Mar;56(3):515–22

Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions. Shekhar A, et al. **Pharmacol Biochem Behav** 1996 Oct; 55(2):249–56

Delayed arousal from anesthesia: a further similarity between stress and beta-1 adrenoceptor blockade. Stone EA, et al. **Pharmacol Biochem Behav** 1996 Sep;55(1):131–3

Neurochemical mediators of anxiety have inconsistent effects on hypothalamic self-stimulation in rats. Borisenko SA, et al. **Pharmacol Toxicol** 1996 May;78(5):354–60

Cocaine self-administration in ovariectomized rats is predicted by response to novelty, attenuated by 17-beta estradiol, and associated with abnormal vaginal cytology. Grimm JW, et al. **Physiol Behav** 1997 May;61(5):755-61

Effects of myocardial infarction and captopril therapy on anxiety-related behaviors in the rat. Prickaerts J, et al. **Physiol Behav** 1996 Jul;60(1):43-50

Differential effects of noradrenergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Mizuki Y, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1996 Nov; 20(8):1353-67

Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Mizuki Y, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1997 May; 21(4):573-90

Hormonal responses to meta-chlorophenylpiperazine (m-CPP) are undiminished by acute m-CPP pretreatment. Coccaro EF, et al. **Psychiatry Res** 1996 May 17; 62(2):139-45

Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers. Grady TA, et al. **Psychiatry Res** 1996 Aug 30;64(1):1-10

Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder. Koszycki D, et al. **Psychiatry Res** 1996 May 17; 62(2):131-8

Effects of ORG-2766 on brain event-related potentials of autistic children. Verbaten MN, et al. **Psychiatry Res** 1996 Jun 26;63(1):33-45

Betel nut chewing and selected psychophysiological variables. Wyatt TA. **Psychol Rep** 1996 Oct;79(2):451-63

Neuroendocrine responses to fenfluramine challenge are influenced by exposure to chronic social stress in adult male cynomolgus macaques. Botchin MB, et al. **Psychoneuroendocrinology** 1994;19(1):1-11

Physiological and behavioral effects of chronic intracerebroventricular infusion of corticotropin-releasing factor in the rat. Buwalda B, et al. **Psychoneuroendocrinology** 1997 Jul;22(5):297-309

Diazepam attenuation of restraint stress-induced corticosterone levels is enhanced by prior exposure to repeated restraint. Kalman BA, et al. **Psychoneuroendocrinology** 1997 Jul;22(5):349-60

A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin. Pietrowsky R, et al. **Psychoneuroendocrinology** 1996 Aug; 21(6):559-72

Responses to alpha 2-adrenoceptor blockade by idazoxan in healthy male and female volunteers. Schmidt ME, et al. **Psychoneuroendocrinology** 1997 Apr;22(3):177-88

Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Sundström I, et al. **Psychoneuroendocrinology** 1997 Jan;22(1):25-38

Does noise stress modulate effects of smoking/nicotine? Mood, vigilance, and EEG responses. Gilbert DG, et al. **Psychopharmacology (Berl)** 1997 Feb;129(4):382-9

Smoking status and nicotine administration differentially modify hemodynamic stress reactivity in men and women. Girdler SS, et al. **Psychosom Med** 1997 May-Jun; 59(3):294-306

Inhibition of subjective and physiological sexual arousal in women by clonidine. Meston CM, et al. **Psychosom Med** 1997 Jul-Aug;59(4):399-407

Persistence of repetitive EEG arousals (K-alpha complexes) in RLS patients treated with L-DOPA. Montplaisir J, et al. **Sleep** 1996 Apr;19(3):196-9

[Chronic prenatal exposure to diazepam, brain metabolism and behavior: long-term consequences in the adult rat] Schroeder H, et al. **Encephale** 1997 Mar-Apr;23(2):131-41 (Eng. Abstr.) **(Fre)**

[Drug onset time of atracurium after pancuronium priming in elderly patients] Geldner G, et al. **Anaesthesiol Reanim** 1997;22(2):46-9 (Eng. Abstr.) **(Ger)**

[Premedication with midazolam in adults with special reference to anxiety treatment] Röse VW. **Anaesthesiol Reanim** 1996;21(1):14-23 (Eng. Abstr.) **(Ger)**

[Prolongation of fentanyl-induced decreased arousal by clonidine] Walz R, et al. **Anaesthesiol Reanim** 1997; 22(2):42-5 (Eng. Abstr.) **(Ger)**

[Perioperative follow-up of physiologic and cognitive functions after oral premedication with midazolam 3.75 mg in women for retrobulbar anesthesia] Weindler J, et al. **Ophthalmologe** 1996 Feb;93(1):59-67 (Eng. Abstr.) **(Ger)**

[Effect of vitamin B12 on sleep quality and performance of shift workers] Bohr KC. **Wien Med Wochenschr** 1996; 146(13-14):289-91 (Eng. Abstr.) **(Ger)**

GENETICS

Decreased measures of experimental anxiety in rats bred for high alcohol preference. Möller C, et al. **Alcohol Clin Exp Res** 1997 Jun;21(4):656-60

Increased mRNA for corticotrophin releasing hormone in the amygdala of fawn-hooded rats: a potential animal model of anxiety. Altemus M, et al. **Anxiety** 1994-95; 1(6):251-7

Changes in gene expression during the sleep-waking cycle: a new view of activating systems. Tononi G, et al. **Arch Ital Biol** 1995 Dec;134(1):21-37 (121 ref.)

Psychobiology of novelty seeking and drug seeking behavior. Bardo MT, et al. **Behav Brain Res** 1996 May;77(1-2):23-43 (205 ref.)

Behavioral reactivity to social and nonsocial stimulations: a multivariate analysis of six inbred rat strains. Berton O, et al. **Behav Genet** 1997 Mar;27(2):155-66

Mapping quantitative trait loci for open-field behavior in mice. Gershenfeld HK, et al. **Behav Genet** 1997 May; 27(3):201-10

Genetic and developmental influences on infant mouse ultrasonic calling. I. A diallel analysis of the calls of 3-day olds. Hahn ME, et al. **Behav Genet** 1997 Mar;27(2):133-43

Hippocampal morphology and open-field behavior in Mus musculus domesticus and Mus spretus inbred mice. Laghmouch A, et al. **Behav Genet** 1997 Jan;27(1):67-73

Identification of quantitative trait loci involved in contextual and auditory-cued fear conditioning in BXD recombinant inbred strains. Owen EH, et al. **Behav Neurosci** 1997 Apr; 111(2):292-300

Neuroelectric correlates of response production and inhibition in individuals at risk to develop alcoholism. Cohen HL, et al. **Biol Psychiatry** 1997 Jul 1;42(1):57-67

Frontal P300 decrements, childhood conduct disorder, family history, and the prediction of relapse among abstinent cocaine abusers. Bauer LO. **Drug Alcohol Depend** 1997 Jan 10;44(1):1-10

Startle modulation in children at risk for anxiety disorders and/or alcoholism. Grillon C, et al. **J Am Acad Child Adolesc Psychiatry** 1997 Jul;36(7):925-32

Elevated plus-maze behavior in adult offspring of selectively bred rats. Dichter GS, et al. **Physiol Behav** 1996 Jul; 60(1):299-304

Mice selected for low and high blood magnesium levels: a new model for stress studies. Henrotte JG, et al. **Physiol Behav** 1997 May;61(5):653-8

Effect of exposure to novelty on brain monoamines in C57BL/6 and DBA/2 mice. Jones BC, et al. **Physiol Behav** 1996 Feb;59(2):361-7

Early environmental influences can attenuate the blood pressure response to acute stress in borderline hypertensive rats. Sanders BJ, et al. **Physiol Behav** 1997 May; 61(5):749-54

Genetic and developmental factors in spontaneous selective attention: a study of normal twins. Myles-Worsley M, et al. **Psychiatry Res** 1997 Aug 8;71(3):163-74

Comparison of the behavioural and endocrine response to forced swimming stress in five inbred strains of rats. Armario A, et al. **Psychoneuroendocrinology** 1995; 20(8):879-90

Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Heinrichs SC, et al. **Psychoneuroendocrinology** 1997 May;22(4):215-24

Suppression of lymphocyte mitogenesis in different rat strains exposed to footshock during early diurnal and nocturnal time periods. Kusnecov AW, et al. **Psychoneuroendocrinology** 1995;20(8):821-35

Behavioural and physiological consequences of a single social defeat in Roman high- and low-avoidance rats. Meerlo P, et al. **Psychoneuroendocrinology** 1997 Apr;22(3):155-68

Effect of a conditioned aversive stimulus on the immune response in three strains of rats. Shurin MR, et al. **Psychoneuroendocrinology** 1995;20(8):837-49

Platelet alpha 2-adrenoreceptors, catecholamines, hemodynamic variables, and anxiety in panic patients and their asymptomatic relatives. Cameron OG, et al. **Psychosom Med** 1996 Jul-Aug;58(4):289-301

Cardiac profile and disruptive behavior in boys at risk for delinquency. Pine DS, et al. **Psychosom Med** 1996 Jul-Aug; 58(4):342-53

The Maudsley Family Study, II: Endogenous event-related potentials in familial schizophrenia. Frangou S, et al. **Schizophr Res** 1997 Jan 17;23(1):45-53

PHYSIOLOGY

Activation PET scanning in pretreatment evaluation of patients with cerebral tumours or vascular lesions in or close to the sensorimotor cortex. Nyberg G, et al. **Acta Neurochir (Wien)** 1996;138(6):684-94

Effects of anxiety arousal and mental stress on the vestibulo-ocular reflex. Yardley L, et al. **Acta Otolaryngol (Stockh)** 1995 Sep;115(5):597-602

Respiratory syncytial virus infection enhances the response to laryngeal chemostimulation and inhibits arousal from sleep in young lambs. Lindgren C, et al. **Acta Paediatr** 1996 Jul;85(7):789-97

Elevated sleep arousal thresholds in enuretic boys: clinical implications. Wolfish NM, et al. **Acta Paediatr** 1997 Apr; 86(4):381-4

EEG delta power and auditory arousal in rested and sleep-deprived rabbits. Opp MR, et al. **Am J Physiol** 1997 Feb;272(2 Pt 2):R648-55

Cutaneous vasoconstriction in conscious rabbits during alerting responses detected by hippocampal theta-rhythm. Yu YH, et al. **Am J Physiol** 1997 Jan;272(1 Pt 2):R208-16

Sleep and arousal: thalamocortical mechanisms. McCormick DA, et al. **Annu Rev Neurosci** 1997;20:185-215 (122 ref.)

Short-term rebound anxiolytic effects and long-term changes in platelet benzodiazepine binding after pentylenetetrazole-kindling in two strains of rat. File SE, et al. **Anxiety** 1996;2(3):109-16

Testing the suffocation false alarm theory of panic disorder [see comments] Klein DF. **Anxiety** 1994;1(1):1-7 (38 ref.) . Comment in: Anxiety 1994-95;1(3):144-8.

Klein's suffocation false alarm theory: another perspective [letter; comment] Panzarella C. **Anxiety** 1994-95;1(3):144-8 . Comment on: Anxiety 1994;1(1):1-7.

Effects of reduction in arousal level caused by long-lasting task on CNV. Higuchi S, et al. **Appl Human Sci** 1997 Jan; 16(1):29-34

Time course of sleep inertia after nighttime and daytime sleep episodes. Achermann P, et al. **Arch Ital Biol** 1995 Dec; 134(1):109-19

The effect of optokinetic stimulation on daytime sleepiness. Leslie KR, et al. **Arch Ital Biol** 1997 Jun;135(3):219-28

Amygdaloid control of alerting and behavioral arousal in rats: involvement of serotonergic mechanisms. Sanford LD, et al. **Arch Ital Biol** 1995 Dec;134(1):81-99

Brain activation, then (1949) and now: coherent fast rhythms in corticothalamic networks. Steriade M. **Arch Ital Biol** 1995 Dec;134(1):5-20 (69 ref.)

Emotional arousal and phobia in transient global amnesia. Inzitari D, et al. **Arch Neurol** 1997 Jul;54(7):866-73

Physiologic parameters associated with sexual arousal in women with incomplete spinal cord injuries. Sipski ML, et al. **Arch Phys Med Rehabil** 1997 Mar;78(3):305-13

Assessing aspects of auditory handicap by means of pupil dilatation. Kramer SE, et al. **Audiology** 1997 May-Jun; 36(3):155-64

Psychophysiological stress in elite golfers during practice and competition. McKay JM, et al. **Aust J Sci Med Sport** 1997 Jun;29(2):55-61

The neurophysiological basis of motor imagery. Decety J. **Behav Brain Res** 1996 May;77(1-2):45-52 (60 ref.)

Behavioral characteristics of defense and vigilance reactions elicited by electrical stimulation of the hypothalamus in rabbits. Duan YF, et al. **Behav Brain Res** 1996 Nov; 81(1-2):33-41

Structure of the mouse behaviour on the elevated plus-maze test of anxiety. Fernández Espejo E. **Behav Brain Res** 1997 Jun;86(1):105-12

Serotonergic functions in arousal and motor activity. Geyer MA. **Behav Brain Res** 1996;73(1-2):31-5 (45 ref.)

Role of hippocampal 5-HT1A receptors on elevated plus maze exploration after a single restraint experience. Netto SM, et al. **Behav Brain Res** 1996 May;77(1-2):215-8

Effects of telencephalic ablation on short-term memory and attention in goldfish. Ohnishi K. **Behav Brain Res** 1997 Jul; 86(2):191-9

Effects of neonatal stimulation on later cognitive function and hippocampal nerve growth factor. Pham TM, et al. **Behav Brain Res** 1997 Jun;86(1):113-20

The effects of the medial and cortical amygdala lesions on post-stress analgesia in rats. Werka T. **Behav Brain Res** 1997 Jun;86(1):59-65

Elevation of plasma beta-endorphin levels of shy elderly in response to novel laboratory experiences. Bell IR, et al. **Behav Med** 1997 Winter;22(4):168-73

Studies in psychoneuroimmunology: psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks. Weiss DW, et al. **Behav Med** 1996 Spring; 22(1):5-14

Blockade of CCK(B) but not CCK(A) receptors before and after the stress of predator exposure prevents lasting increases in anxiety-like behavior: implications for anxiety associated with posttraumatic stress disorder. Adamec RE, et al. **Behav Neurosci** 1997 Apr;111(2):435-49

Subicular lesions disrupt but do not abolish classically conditioned bradycardia in rabbits. Chachich M, et al. **Behav Neurosci** 1996 Aug;110(4):707-17

Psychological stress impairs spatial working memory: relevance to electrophysiological studies of hippocampal function. Diamond DM, et al. **Behav Neurosci** 1996 Aug; 110(4):661-72

Lesions of the perirhinal cortex interfere with conditioned excitation but not with conditioned inhibition of fear. Falls WA, et al. **Behav Neurosci** 1997 Jun;111(3):476-86

D1 dopamine receptor mediation of social and nonsocial emotional reactivity in mice: effects of housing and strain difference in motor activity. Gendreau PL, et al. **Behav Neurosci** 1997 Apr;111(2):424-34

Autonomic and behavioral correlates of appetitive conditioning in rats. Hunt PS, et al. **Behav Neurosci** 1997 Jun;111(3):494-502

Lack of effects of lesions of the dorsal noradrenergic bundle on behavioral vigilance. McGaughy J, et al. **Behav Neurosci** 1997 Jun;111(3):646-52

Olfactory bulbectomy enhances sensitization of the acoustic startle reflex produced by acute or repeated stress. McNish KA, et al. **Behav Neurosci** 1997 Feb;111(1):80-91

Effect of tone-dependent fear conditioning on heart rate and behavior of C57BL/6N mice. Stiedl O, et al. **Behav Neurosci** 1997 Aug;111(4):703-11

Dissociations among the anxiolytic effects of septal, hippocampal, and amygdaloid lesions. Treit D, et al. **Behav Neurosci** 1997 Jun;111(3):653-8

Hippocampal glycogen metabolism, EEG, and behavior. Uecker A, et al. **Behav Neurosci** 1997 Apr;111(2):283-91

Effects of tap withdrawal response habituation on other withdrawal behaviors: the localization of habituation in the nematode Caenorhabditis elegans. Wicks SR, et al. **Behav Neurosci** 1997 Apr;111(2):342-53

Recovery from habituation in Caenorhabditis elegans is

dependent on interstimulus interval and not habituation kinetics. Wicks SR, et al. **Behav Neurosci** 1996 Aug; 110(4):840–4

Carboxyatractylate- and cyclosporin A- sensitive uncoupling in liver mitochondria of ground squirrels during hibernation and arousal. Amerkhanov ZG, et al. **Biochem Mol Biol Int** 1996 Apr;38(5):863–70

Salivary reactivity in women with bulimia nervosa across treatment. Bulik CM, et al. **Biol Psychiatry** 1996 Jun 15; 39(12):1009–12

Blink rate in children with attention-deficit-hyperactivity disorder. Caplan R, et al. **Biol Psychiatry** 1996 Jun 15; 39(12):1032–8

Blink rate, neurocognitive impairments, and symptoms in schizophrenia. Chen EY, et al. **Biol Psychiatry** 1996 Oct 1;40(7):597–603

P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Clementz BA, et al. **Biol Psychiatry** 1997 May 15;41(10):1035–44

Power spectral analysis of heart rate variability in posttraumatic stress disorder patients. Cohen H, et al. **Biol Psychiatry** 1997 Mar 1;41(5):627–9

PET brain mapping study of auditory verbal supraspan memory versus visual fixation in schizophrenia. Ganguli R, et al. **Biol Psychiatry** 1997 Jan 1;41(1):33–42

Abnormality of EEG alpha asymmetry in female adolescent suicide attempters. Graae F, et al. **Biol Psychiatry** 1996 Oct 15;40(8):706–13

Electrodermal activity as a prodromal sign in schizophrenia. Hazlett H, et al. **Biol Psychiatry** 1997 Jan 1;41(1):111–3

Brain metabolism patterns are sensitive to attentional effort associated with a tone recognition task. Holcomb HH, et al. **Biol Psychiatry** 1996 Jun 15;39(12):1013–22

Event-related potentials and performance of attention-deficit hyperactivity disorder: children and normal controls in auditory and visual selective attention tasks. Jonkman LM, et al. **Biol Psychiatry** 1997 Mar 1;41(5):595–611

Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Keuler DJ, et al. **Biol Psychiatry** 1996 Jul 15;40(2):154–6

Diminished cardiac vagal tone in schizophrenia: associations to brain laterality and age of onset. Malaspina D, et al. **Biol Psychiatry** 1997 Mar 1;41(5):612–7

Psychophysiological and clinical value of event-related potentials in obsessive-compulsive disorder. Morault PM, et al. **Biol Psychiatry** 1997 Jul 1;42(1):46–56

N400 abnormalities in late life schizophrenia and related psychoses. Olichney JM, et al. **Biol Psychiatry** 1997 Jul 1;42(1):13–23

Heterogeneity of information-processing alterations according to dimensions of depression: an event-related potentials study. Pierson A, et al. **Biol Psychiatry** 1996 Jul 15;40(2):98–115

Single trial analysis of event related potentials: a comparison between schizophrenics and depressives. Röschke J, et al. **Biol Psychiatry** 1996 Nov 1;40(9):844–52

No dynamic lung function abnormalities in panic disorder patients. Verburg K, et al. **Biol Psychiatry** 1997 Apr 1; 41(7):834–6

Electroencephalographic abnormalities in patients with presenile dementia of the Alzheimer type: quantitative analysis at rest and during photic stimulation. Wada Y, et al. **Biol Psychiatry** 1997 Jan 15;41(2):217–25

Relationships between hormonal profile and novelty seeking in combat-related posttraumatic stress disorder. Wang S, et al. **Biol Psychiatry** 1997 Jan 15;41(2):145–51

Left lateralized P300 amplitude deficit in schizophrenic patients depends on pitch disparity. Weisbrod M, et al. **Biol Psychiatry** 1997 Mar 1;41(5):541–9

Auditory event-related potentials in mentally retarded subjects during active and passive oddball experiments. Zurrón M, et al. **Biol Psychiatry** 1997 Jan 15;41(2):201–8

Aging, stimulus identification and the effect of probability: an event-related potential study. Czigler I, et al. **Biol Psychol** 1996 Mar 8;43(1):27–40

UCS inflation and human aversive autonomic conditioning. de Jong PJ, et al. **Biol Psychol** 1996 Jun 28;43(3):227–39

Waveform reliability of the phase related external suction baroreceptor manipulation method. Rau H, et al. **Biol Psychol** 1996 Apr 12;43(2):187–94

Arousal systems and attentional processes. Robbins TW. **Biol Psychol** 1997 Mar 21;45(1–3):57–71 (67 ref.)

Effects of intermodality change and number of training trials on electrodermal orienting and on the allocation of processing resources. Siddle DA, et al. **Biol Psychol** 1996 Mar 8;43(1):57–67

Individual differences in cortisol responses to a laboratory speech task and their relationship to responses to stressful daily events. van Eck MM, et al. **Biol Psychol** 1996 Mar 8;43(1):69–84

The generation and subtraction of sensory expectations within cerebellum-like structures. Bell C, et al. **Brain Behav Evol** 1997;50 Suppl 1:17–31 (60 ref.)

A study on the emotional-processing of visual stimuli through event-related potentials. Carretié L, et al. **Brain Cogn** 1997 Jul;34(2):207–17

Rapid sampling of extracellular dopamine in the rat prefrontal cortex during food consumption, handling and exposure to novelty. Feenstra MG, et al. **Brain Res** 1996 Dec 2; 742(1–2):17–24

Serotonergic antagonists impair arousal-induced phase shifts of the circadian system of the syrian hamster. Sumova A, et al. **Brain Res** 1996 Feb 12;709(1):88–96

Heart rate, breathing, and subjective responses of a limited-symptom panic patient to 35% carbon dioxide challenge [letter] Bakal D, et al. **Can J Psychiatry** 1996 Dec;41(10):669–70

Synchronized activities of coupled oscillators in the cerebral cortex and thalamus at different levels of vigilance. Steriade M. **Cereb Cortex** 1997 Sep;7(6):583–604 (139 ref.)

Recognition of the mother's face by six-month-old infants: a neurobehavioral study. de Haan M, et al. **Child Dev** 1997 Apr;68(2):187–210

Vagal regulation of heart rate in the prediction of developmental outcome for very low birth weight preterm infants. Doussard-Roosevelt JA, et al. **Child Dev** 1997 Apr; 68(2):173–86

Reactivity of rolandic spikes. Fonseca LC, et al. **Clin Electroencephalogr** 1996 Jul;27(3):116–20

P50 changes with visual interference in normal subjects: a sensory distraction model for schizophrenia. Jin Y, et al. **Clin Electroencephalogr** 1996 Jul;27(3):151–4

Sexuality and the art of arousal in the geriatric woman. Barber HR. **Clin Obstet Gynecol** 1996 Dec;39(4):970–3 (9 ref.)

Functional anatomy of object recognition in humans: evidence from positron emission tomography and functional magnetic resonance imaging. Bly BM, et al. **Curr Opin Neurol** 1997 Feb;10(1):5–9 (27 ref.)

Effects of artificial rearing on electrophysiology and behavior in adult rats. Kaneko WM, et al. **Depress Anxiety** 1996–97; 4(6):279–88

Alteration of corticothalamic perfusion ratios during a PTSD flashback. Liberzon I, et al. **Depress Anxiety** 1996–97; 4(3):146–50

Effects of self-generated sad mood on regional cerebral activity: a PET study in normal subjects. Gemar MC, et al. **Depression** 1996;4(2):81–8

Plaque-forming cell responses and antibody titers following injection of sheep red blood cells in nonstressed, acute, and/or chronically stressed handled and nonhandled animals. Bhatnagar S, et al. **Dev Psychobiol** 1996 Mar; 29(2):171–81

Infants of depressed and nondepressed mothers exhibit differences in frontal brain electrical activity during the expression of negative emotions. Dawson G, et al. **Dev Psychol** 1997 Jul;33(4):650–6

Heart rate variability: sleep stage, time of night, and arousal influences. Bonnet MH, et al. **Electroencephalogr Clin Neurophysiol** 1997 May; 102(5):390–6

The detection of drowsiness and sleep onset periods from ambulatory recorded polygraphic data. Hirvonen K, et al. **Electroencephalogr Clin Neurophysiol** 1997 Feb; 102(2):132–7

The neural correlates of the noradrenergic modulation of human attention, arousal and learning. Coull JT, et al. **Eur J Neurosci** 1997 Mar;9(3):589–98

A thalamic contribution to arousal-induced, non-photic entrainment of the circadian clock of the Syrian hamster. Maywood ES, et al. **Eur J Neurosci** 1997 Aug;9(8):1739–47

Influence of uvulopalatopharyngoplasty on alpha-EEG arousals in nonapnoeic snorers. Boudewyns A, et al. **Eur Respir J** 1997 Jan;10(1):129–32

The effect of sleep deprivation on sleep states, breathing events, peripheral chemoresponsiveness and arousal propensity in healthy 3 month old infants. Thomas DA, et al. **Eur Respir J** 1996 May;9(5):932–8

Behavioural and arousal-related influences on breathing in humans. Shea SA. **Exp Physiol** 1996 Jan;81(1):1–26 (162 ref.)

Linking symptom-specific physiological reactivity to pain severity in chronic low back pain patients: a test of mediation and moderation models. Burns JW, et al. **Health Psychol** 1997 Jul;16(4):319–26

Effects of gonadal sex steroids on sexual behavior in the big brown bat, Eptesicus fuscus, upon arousal from hibernation. Mendonça MT, et al. **Horm Behav** 1996 Jun;30(2):153–61

Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. Dodt C, et al. **Hypertension** 1997 Jul;30(1 Pt 1):71–6

Estimating alertness from the EEG power spectrum. Jung TP, et al. **IEEE Trans Biomed Eng** 1997 Jan;44(1):60–9

EEG concomitants of hypnotic susceptibility. Ray WJ. **Int J Clin Exp Hypn** 1997 Jul;45(3):301–13 (53 ref.)

Psychophysiological responses to food exposure: an experimental study in binge eaters. Vögele C, et al. **Int J Eat Disord** 1997 Mar;21(2):147–57

Alpha sleep and information processing, perception of sleep, pain, and arousability in fibromyalgia. Perlis ML, et al. **Int J Neurosci** 1997 Feb;89(3–4):265–80

Age differences in hemispheric activation to sensory condition. Shapiro DM, et al. **Int J Neurosci** 1996 Nov; 87(3–4):249–56

Measurements by biphasic changes of the alpha band amplitude as indicators of arousal level. Ota T, et al. **Int J Psychophysiol** 1996 Nov;24(1–2):25–37

Adjunctive brainstem behaviors in the rat. Andy OJ, et al. **Integr Physiol Behav Sci** 1996 Oct-Dec;31(4):315–30

Autonomic nervous control of heart rate orienting and alpha responses in dog. Li S, et al. **Integr Physiol Behav Sci** 1997 Apr-Jun;32(2):113–22

Neural regulation of viscera elicited by individual interpretations of life experiences. Wolf S. **Integr Physiol Behav Sci** 1997 Apr-Jun;32(2):109–12 (14 ref.)

Differential effects of sympathetic activation on sexual arousal in sexually dysfunctional and functional women. Meston CM, et al. **J Abnorm Psychol** 1996 Nov; 105(4):582–91

Behavioral and neurophysiological evidence for altered processing of anxiety-related words in panic disorder. Pauli P, et al. **J Abnorm Psychol** 1997 May;106(2):213–20

Primary dysthymia: a study of several psychosocial, endocrine and immune correlates. Ravindran AV, et al. **J Affect Disord** 1996 Sep 9;40(1–2):73–84

Anxiety and autonomic regulation in major depressive disorder: an exploratory study. Tulen JH, et al. **J Affect Disord** 1996 Sep 9;40(1–2):61–71

ADHD and EEG [letter; comment] Diamond JM. **J Am Acad Child Adolesc Psychiatry** 1997 May;36(5):575–7 . Comment on: J Am Acad Child Adolesc Psychiatry 1996 Aug;35(8):1009–17.

Electrocardiographic repolarization during stress from awakening on alarm call. Toivonen L, et al. **J Am Coll Cardiol** 1997 Sep;30(3):774–9

Relaxation-induced EEG alterations in panic disorder patients. Knott V, et al. **J Anxiety Disord** 1997 Jul-Aug; 11(4):365–76

A neuro-evolutionary approach to the anxiety disorders. Stein DJ, et al. **J Anxiety Disord** 1997 Jul-Aug;11(4):409–29 (110 ref.)

Ventilatory dynamics during transient arousal from NREM sleep: implications for respiratory control stability. Khoo MC, et al. **J Appl Physiol** 1996 May;80(5):1475–84

Sequential arousal and airway-defensive behavior of infants in asphyxial sleep environments. Lijowska AS, et al. **J Appl Physiol** 1997 Jul;83(1):219–28

Arousal pattern following central and obstructive breathing abnormalities in infants and children. McNamara F, et al. **J Appl Physiol** 1996 Dec;81(6):2651–7

Neurocirculatory consequences of abrupt change in sleep state in humans. Morgan BJ, et al. **J Appl Physiol** 1996 May;80(5):1627–36

Airway obstruction during sleep increases blood pressure without arousal. O'Donnell CP, et al. **J Appl Physiol** 1996 Mar;80(3):773–81

Intracerebroventricular propranolol prevented vascular resistance increases on arousal from sleep apnea. Zinkovska S, et al. **J Appl Physiol** 1997 May;82(5):1637–43

Subjective alertness rhythms in elderly people. Monk TH, et al. **J Biol Rhythms** 1996 Sep;11(3):268–76

Anxiety, antisocial behavior, and heart rate regulation in adolescent males. Mezzacappa E, et al. **J Child Psychol Psychiatry** 1997 May;38(4):457–69

The effects of neonatal jaundice and respiratory complications on learning and habituation in 5- to 11-month-old infants. Weir C, et al. **J Child Psychol Psychiatry** 1997 Feb;38(2):199–206

Computerized assessment of sustained attention: a review of factors affecting vigilance performance. Ballard JC. **J Clin Exp Neuropsychol** 1996 Dec;18(6):843–63 (231 ref.)

Emotional arousal in temporal lobectomy: autonomic and performance effects of success and failure feedback. Davidson RA, et al. **J Clin Exp Neuropsychol** 1996 Apr; 18(2):249–58

Past and future of computer-assisted sleep analysis and drowsiness assessment. Hasan J. **J Clin Neurophysiol** 1996 Jul;13(4):295–313 (190 ref.)

Suppressed cardiac and electroencephalographic arousal on apnea/hypopnea termination in elderly patients with cerebral infarction. Noda A, et al. **J Clin Neurophysiol** 1997 Jan;14(1):68–72

The cyclic alternating pattern plays a gate-control on periodic limb movements during non-rapid eye movement sleep. Parrino L, et al. **J Clin Neurophysiol** 1996 Jul; 13(4):314–23

Postsuckling behavioral arousal in weanling rats (Rattus norvegicus). Gerrish CJ, et al. **J Comp Psychol** 1997 Mar; 111(1):37–49

Behavioral and glucocorticoid responses of adult domestic dogs (Canis familiaris) to companionship and social separation. Tuber DS, et al. **J Comp Psychol** 1996 Mar; 110(1):103–8

Posttraumatic stress disorder, exposure to combat, and lower plasma cortisol among Vietnam veterans: findings and clinical implications. Boscarino JA. **J Consult Clin Psychol** 1996 Feb;64(1):191–201

Body vigilance in panic disorder: evaluating attention to bodily perturbations. Schmidt NB, et al. **J Consult Clin Psychol** 1997 Apr;65(2):214–20

Rates of rewarming, heart and respiratory rates and their significance for oxygen transport during arousal from torpor in the smallest mammal, the Etruscan shrew Suncus etruscus. Fons R, et al. **J Exp Biol** 1997 May;200 (Pt 10):1451–8

Temporal structure of syntactic parsing: early and late event-related brain potential effects. Friederici AD, et al. **J Exp Psychol Learn Mem Cogn** 1996 Sep;22(5):1219–48

Improvement of hemispatial neglect with cold-water calorics: an electrophysiological test of the arousal hypothesis of neglect. Storrie-Baker HJ, et al. **J Int Neuropsychol Soc** 1997 Jul;3(4):394–402

The effect of the presentation of visual and auditory stimuli on the breathing patterns of two girls with Rett syndrome.

Woodyatt GC, et al. **J Intellect Disabil Res** 1996 Jun;40 (Pt 3):252–9

Testing the alexithymia hypothesis: physiological and subjective responses during relaxation and stress. Friedlander L, et al. **J Nerv Ment Dis** 1997 Apr; 185(4):233–9

Functional MRI of pain– and attention–related activations in the human cingulate cortex. Davis KD, et al. **J Neurophysiol** 1997 Jun;77(6):3370–80

Enhancement of behavioral and electroencephalographic indices of waking following stimulation of noradrenergic beta–receptors within the medial septal region of the basal forebrain. Berridge CW, et al. **J Neurosci** 1996 Nov 1; 16(21):6999–7009

An on–line automated sleep–wake classification system for laboratory animals. Witting W, et al. **J Neurosci Methods** 1996 Jun;66(2):109–12

Symptoms, sweating and reactivity of infants who die of SIDS compared with community controls. New Zealand National Cot Death Study Group. Taylor BJ, et al. **J Paediatr Child Health** 1996 Aug;32(4):316–22

The effect of maternal smoking during pregnancy on sleep respiratory and arousal patterns in neonates. Tirosh E, et al. **J Perinatol** 1996 Nov–Dec;16(6):435–8

The role of stress and dopamine–GABA interactions in the vulnerability for schizophrenia. Benes FM. **J Psychiatr Res** 1997 Mar–Apr;31(2):257–75 (105 ref.)

Effects of ibotenic acid–induced loss of neurons in the medial prefrontal cortex of rats on behavioral vigilance: evidence for executive dysfunction. Miner LA, et al. **J Psychopharmacol (Oxf)** 1997;11(2):169–78

Psychological stress and myocardial perfusion in coronary disease patients and healthy controls. Benight CC, et al. **J Psychosom Res** 1997 Feb;42(2):137–44

Physiological stress reactivity and recovery: conceptual siblings separated at birth? Linden W, et al. **J Psychosom Res** 1997 Feb;42(2):117–35 (59 ref.)

Psychologic characteristics associated with acute stressor–induced leukocyte subset redistribution. Mills PJ, et al. **J Psychosom Res** 1996 Apr;40(4):417–23

Experimental stress and cardiac function [editorial] Tennant C. **J Psychosom Res** 1996 Jun;40(6):569–83 (125 ref.)

Delirium: the underlying pathophysiological mechanisms and the need for clinical research [editorial] van der Mast RC. **J Psychosom Res** 1996 Aug;41(2):109–13 (21 ref.)

Sympathetic skin response and R–R interval variability in multiple system atrophy and idiopathic Parkinson's disease. Bordet R, et al. **Mov Disord** 1996 May;11(3):268–72

Brainstem encephalopathy with stimulus–sensitive myoclonus leading to respiratory arrest, but with recovery: a description of two cases and review of the literature. Kullmann DM, et al. **Mov Disord** 1996 Nov;11(6):715–8 (22 ref.)

Arousal–induced modulation of memory storage processes in humans. Nielson KA, et al. **Neurobiol Learn Mem** 1996 Sep;66(2):133–42

Orienting of visual attention in Alzheimer's disease: its implication in favor of the interhemispheric balance. Caffarra P, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1997 Apr; 10(2):90–5

Nicotine affects the occipital theta rhythm after lesion of the pedunculopontine tegmental nucleus in rats. Bringmann A. **Neuropsychobiology** 1997;35(2):102–7

Repeated swim stress and peripheral–type benzodiazepine receptors. Burgin R, et al. **Neuropsychobiology** 1996; 33(1):28–31

Neuroendocrine responses to emotional arousal in normal women. Gerra G, et al. **Neuropsychobiology** 1996; 33(4):173–81

Living/non–living dissociation in a case of semantic dementia: a SPECT activation study. Cardebat D, et al. **Neuropsychologia** 1996 Dec;34(12):1175–9

Phasic arousal in response to auditory warnings after traumatic brain injury. Whyte J, et al. **Neuropsychologia** 1997 Mar;35(3):313–24

Relation of cerebral blood flow velocity and level of vigilance in humans. Schnittger C, et al. **Neuroreport** 1997 May 6;8(7):1637–9

Morning–type and evening–type individuals differ in the phase position of their endogenous circadian oscillator. Kerkhof GA, et al. **Neurosci Lett** 1996 Nov 8;218(3):153–6

Ambient temperature during torpor affects NREM sleep EEG during arousal episodes in hibernating European ground squirrels. Strijkstra AM, et al. **Neurosci Lett** 1997 Jan 17;221(2–3):177–80

Attack priming in female Syrian golden hamsters is associated with a c–fos–coupled process within the corticomedial amygdala. Potegal M, et al. **Neuroscience** 1996 Dec; 75(3):869–80

Generalized hypervigilance in fibromyalgia: evidence of perceptual amplification. McDermid AJ, et al. **Pain** 1996 Aug;66(2–3):133–44

Abnormal corticosterone regulation in an immature rat model of continuous chronic stress. Gilles EE, et al. **Pediatr Neurol** 1996 Sep;15(2):114–9

Test–retest reliability of a battery of sensory motor and physiological measures of aging. Anstey KJ, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):831–4

Modifications of electrogastrographic activity during the viewing of brief film sequences. Baldaro B, et al. **Percept Mot Skills** 1996 Jun;82(3 Pt 2):1243–50

Cortisol responses in adults who stutter: coping preferences and apprehension about communication. Blood GW, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):883–9

Effects on contingent negative variation of set created by anticipating variable foreperiods. Hiraku S, et al. **Percept Mot Skills** 1996 Dec;83(3 Pt 2):1163–9

Comparison of changes in autonomic and respiratory parameters of girls after yoga and games at a community home. Telles S, et al. **Percept Mot Skills** 1997 Feb; 84(1):251–7

An increase in cortical excitability with no change in spinal excitability during motor imagery. Yahagi S, et al. **Percept Mot Skills** 1996 Aug;83(1):288–90

EEG arousal, sympathetic activity, and brown adipose tissue thermogenesis after conditioned taste aversion. Amaro S, et al. **Physiol Behav** 1996 Jul;60(1):71–5

Effects of chronic stress on food acquisition, plasma hormones, and the estrous cycle of female rats. Anderson SM, et al. **Physiol Behav** 1996 Jul;60(1):325–9

Serotonergic stimulation and nonphotic phase–shifting in hamsters. Bobrzynska KJ, et al. **Physiol Behav** 1996 Feb; 59(2):221–30

Juvenile friends, behavior, and immune responses to separation in bonnet macaque infants. Boccia ML, et al. **Physiol Behav** 1997 Feb;61(2):191–8

Behavioral, cardiac and cortisol responses to brief peer separation and reunion in cattle. Boissy A, et al. **Physiol Behav** 1997 May;61(5):693–9

Isolation alters striatal met–enkephalin immunoreactivity in rat pups. Carden SE, et al. **Physiol Behav** 1996 Jul; 60(1):51–3

Beta–endorphin and cortisol levels in plasma and CSF following acute experimental spinal traumas. De Riu PL, et al. **Physiol Behav** 1997 Jul;62(1):1–5

Modulation of the baroreceptor reflex by stimulation of the hypothalamic defense and vigilance areas. Duan YF, et al. **Physiol Behav** 1996 Jun;59(6):1093–8

Cardiorespiratory components of defense reaction elicited from paraventricular nucleus. Duan YF, et al. **Physiol Behav** 1997 Feb;61(2):325–30

Functional relationship between the hypothalamic vigilance area and PAG vigilance area. Duan YF, et al. **Physiol Behav** 1997 Sep;62(3):675–9

Amsel's frustration effect: a pavlovian replication with control for frequency and distribution of rewards. Dudley RT, et al. **Physiol Behav** 1997 Apr;61(4):627–9

The effects of mixing on behavior and circadian parameters of salivary cortisol in pigs. Ekkel ED, et al. **Physiol Behav** 1997 Jul;62(1):181–4

Single and repeated environmental stress: effect on plasma oxytocin, corticosterone, catecholamines, and behavior. Hashiguchi H, et al. **Physiol Behav** 1997 May;61(5):731–6

Motoric responses to sucrose in postmature and term infants. Hayes MJ, et al. **Physiol Behav** 1997 Jan;61(1):101–6

Effect of environmental enrichment and housing density on immune system reactivity to acute exercise stress. Kingston SG, et al. **Physiol Behav** 1996 Jul;60(1):145–50

Effects of a 2–day abstinence from smoking on dietary, cognitive, subjective, and physiologic parameters among younger and older female smokers. Kos J, et al. **Physiol Behav** 1997 May;61(5):671–8

Acute and repeated activation of male sexual behavior by tail pinch: opioid and dopaminergic mechanisms. Leyton M, et al. **Physiol Behav** 1996 Jul;60(1):77–85

Forced swimming behavior is not related to the corticosterone levels achieved in the test: a study with four inbred rat strains. Marti J, et al. **Physiol Behav** 1996 Feb; 59(2):369–73

Sympathetic mediation of stress and aggressive competition: plasma catecholamines in free–living male tree lizards. Matt KS, et al. **Physiol Behav** 1997 May;61(5):639–47

Does tolerance develop to the anxiolytic effects of septal lesions? Menard J, et al. **Physiol Behav** 1996 Feb; 59(2):311–18

Involvement of the cholinergic system and periaqueductal gray matter in the modulation of tonic immobility in the guinea pig. Monassi CR, et al. **Physiol Behav** 1997 Jul; 62(1):53–9

Adult rat vigilance states discrimination by artificial neural networks using a single EEG channel. Robert C, et al. **Physiol Behav** 1996 Jun;59(6):1051–60

Is there a role for corticosterone in expression of abnormal behaviour in restricted–fed fowls? Savory CJ, et al. **Physiol Behav** 1997 Jul;62(1):7–13

The locus of origin of augmenting and reducing of visual evoked potentials in rat brain. Siegel J, et al. **Physiol Behav** 1996 Jul;60(1):287–91

Tail pinch induces fos immunoreactivity within several regions of the male rat brain: effects of age. Smith WJ, et al. **Physiol Behav** 1997 May;61(5):717–23

Social confrontation in male guinea pigs: behavior, experience, and complement activity [published erratum appears in Physiol Behav 1996 Nov;60(5):1391] Stefanski V, et al. **Physiol Behav** 1996 Jul;60(1):235–41

The mechanism by which exercise modifies brain function. Sutoo DE, et al. **Physiol Behav** 1996 Jul;60(1):177–81

Influences of fat and carbohydrate on postprandial sleepiness, mood, and hormones. Wells AS, et al. **Physiol Behav** 1997 May;61(5):679–86

Arousal and locomotion: from schizophrenia to narcolepsy. Garcia–Rill E, et al. **Prog Brain Res** 1996;107:417–34 (73 ref.)

Reliability of the task–related component (P3b) of P3 event–related potentials. Maeda H, et al. **Psychiatry Clin Neurosci** 1995 Dec;49(5–6):281–6

A method to determine activation thresholds in fMRI paradigms. Arndt S, et al. **Psychiatry Res** 1997 Aug 8; 75(1):15–22

Plasma vanillylmandelic acid level as an index of psychological stress response in normal subjects. Fukuda M, et al. **Psychiatry Res** 1996 Jun 26;63(1):7–16

Does muscle tension reflect arousal? Relationship between electromyographic and electroencephalographic recordings. Hoehn–Saric R, et al. **Psychiatry Res** 1997 Jun 16;71(1):49–55

Effects of P50 temporal variability on sensory gating in schizophrenia. Jin Y, et al. **Psychiatry Res** 1997 May 5; 70(2):71–81

Auditory event–related potentials to a two–tone discrimination paradigm in attention deficit hyperactivity disorder. Johnstone SJ, et al. **Psychiatry Res** 1996 Oct 16; 64(3):179–92

Activation of left posterior cingulate gyrus by the auditory presentation of threat–related words: an fMRI study. Maddock RJ, et al. **Psychiatry Res** 1997 Aug 8;75(1):1–14

Intracranial and extracranial blood flow during acute anxiety. Mathew RJ, et al. **Psychiatry Res** 1997 May 16;74(2):93–107

Delayed habituation of the skin–conductance orienting response correlates with impaired performance on the Wisconsin Card Sorting Task in schizophrenia. Schiffer RA, et al. **Psychiatry Res** 1996 Nov 15;65(2):107–12

Assessment of noradrenergic functioning in patients with non–combat–related posttraumatic stress disorder: a study with desmethylimipramine and orthostatic challenges. Yatham LN, et al. **Psychiatry Res** 1996 Jun 26;63(1):1–6

Power spectrum of the QRS complex in patients with panic disorder and normal controls. Yeragani VK, et al. **Psychiatry Res** 1997 Feb 7;66(2–3):167–74

Stressful events and salivary cortisol. Canals J, et al. **Psychol Rep** 1997 Feb;80(1):305–6

Cases of Sprague–Dawley rats which did not respond to an 'alarm substance' in the forced swimming test. Tachibana T, et al. **Psychol Rep** 1996 Dec;79(3 Pt 1):1007–18

Trait anxiety, coping with stress, and norharman. Verheij R, et al. **Psychol Rep** 1997 Feb;80(1):51–9

Multiple time scales in simple habituation. Staddon JE, et al. **Psychol Rev** 1996 Oct;103(4):720–33

Psychological disturbance alters thymic and adrenal hormone secretion in a parallel but independent manner. Coe CL, et al. **Psychoneuroendocrinology** 1996 Feb;21(2):237–47

Behavioral reactivity to novelty during youth as a predictive factor of stress–induced corticosterone secretion in the elderly––a life–span study in rats. Dellu F, et al. **Psychoneuroendocrinology** 1996 Jul;21(5):441–53

Corticotropin–releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. De Souza EB. **Psychoneuroendocrinology** 1995;20(8):789–819 (144 ref.)

Hormonal response to stress in brittle diabetes. Dutour A, et al. **Psychoneuroendocrinology** 1996 Aug;21(6):525–43

Sustained elevation of vasopressin plasma levels in healthy young men, but not in abstinent alcoholics, upon expectation of novelty. Ehrenreich H, et al. **Psychoneuroendocrinology** 1997 Jan;22(1):13–24

Context–dependent behavioral effects of interleukin–1 in the rhesus monkey (Macaca mulatta). Friedman EM, et al. **Psychoneuroendocrinology** 1996 Jul;21(5):455–68

Influence of the hippocampus/subiculum on antidiuretic hormone levels during stress. Goldman MB, et al. **Psychoneuroendocrinology** 1996 Oct;21(7):593–7

Neuroendocrine measures and lymphocyte subsets in depressive illness: influence of a clinical interview concerning life experiences. Griffiths J, et al. **Psychoneuroendocrinology** 1997 May;22(4):225–36

Long–term habituation of brain evoked potential responses and pituitary–adrenal secretion with repeated (placebo) testing. Hartmann A, et al. **Psychoneuroendocrinology** 1995; 20(8):865–77

Thyroid hormones correlate with symptoms of hyperactivity but not inattention in attention deficit hyperactivity disorder. Hauser P, et al. **Psychoneuroendocrinology** 1997 Feb;22(2):107–14

Multiple regulators of ultrasonic vocalization in the infant rat [published erratum appears in Psychoneuroendocrinology 1996 Jul;21(5):501] Hofer MA. **Psychoneuroendocrinology** 1996 Feb;21(2):203–17 (72 ref.)

Stress–induced regulation of the renal peripheral benzodiazepine receptor: possible role of the renin–angiotensin system. Holmes PV, et al. **Psychoneuroendocrinology** 1994;19(1):43–54

Severe hypoglycaemia unawareness is associated with an early decrease in vigilance during hypoglycaemia. Howorka K, et al. **Psychoneuroendocrinology** 1996 Apr; 21(3):295–312

Inhibition of GH in maternal separation may be mediated through altered serotonergic activity at 5–HT2A and 5–HT2C receptors. Katz LM, et al. **Psychoneuroendocrinology** 1996 Feb;21(2):219–35

Effects of the Transcendental Meditation program on adaptive mechanisms: changes in hormone levels and responses to stress after 4 months of practice. MacLean CR, et al. **Psychoneuroendocrinology** 1997 May; 22(4):277–95

Effects of the estrous cycle and ovarian hormones on

behavioral indices of anxiety in female rats. Mora S, et al. **Psychoneuroendocrinology** 1996 Oct;21(7):609–20

The premenstrual phase and reactions to aversive events: a study of hormonal influences on emotionality. Van Goozen SH, et al. **Psychoneuroendocrinology** 1996 Jul;21(5):479–97

Alterations of beta-endorphin-like immunoreactivity in CSF following behavioral training using a passive avoidance procedure. Wan RQ, et al. **Psychoneuroendocrinology** 1996 Aug;21(6):503–13

Probing picture perception: activation and emotion. Cuthbert BN, et al. **Psychophysiology** 1996 Mar;33(2):103–11

Respiratory psychophysiology and anxiety: cognitive intervention in the doxapram model of panic. Abelson JL, et al. **Psychosom Med** 1996 Jul–Aug;58(4):302–13

Multilevel statistical models for psychosomatic research [editorial; comment] Berry CC. **Psychosom Med** 1997 Jul–Aug;59(4):350–1. Comment on: Psychosom Med 1997 Jul–Aug;59(4):339–47.

Attenuated free cortisol response to psychosocial stress in children with atopic dermatitis. Buske-Kirschbaum A, et al. **Psychosom Med** 1997 Jul–Aug;59(4):419–26

Social support effects on cardiovascular reactivity: is a stranger as effective as a friend? Christenfeld N, et al. **Psychosom Med** 1997 Jul–Aug;59(4):388–98

Sociality and immunological health revisited [editorial; comment] Coe CL. **Psychosom Med** 1997 May–Jun; 59(3):222–3. Comment on: Psychosom Med 1997 May–Jun;59(3):213–21.

Psychophysiological assessment of respiratory function in panic disorder: evidence for a hyperventilation subtype. Hegel MT, et al. **Psychosom Med** 1997 May–Jun; 59(3):224–30

Marital conflict in older adults: endocrinological and immunological correlates [see comments] Kiecolt-Glaser JK, et al. **Psychosom Med** 1997 Jul–Aug;59(4):339–49. Comment in: Psychosom Med 1997 Jul–Aug;59(4):350–1.

Relationship of emotional behaviors induced by electrical stimulation of the hypothalamus to changes in EKG, heart, stomach, adrenal glands, and thymus. Kojima K, et al. **Psychosom Med** 1996 Jul–Aug;58(4):383–91

Heart rate variability in patients with coronary artery disease: differences in patients with higher and lower depression scores. Krittayaphong R, et al. **Psychosom Med** 1997 May–Jun;59(3):231–5

Life events, frontal electroencephalogram laterality, and functional immune status after acute psychological stressors in adolescents. Liang SW, et al. **Psychosom Med** 1997 Mar–Apr;59(2):178–86

Stress in employed women: a woman's work is never done if she's a working mom [editorial; comment] Light KC. **Psychosom Med** 1997 Jul–Aug;59(4):360–1. Comment on: Psychosom Med 1997 Jul–Aug;59(4):352–9.

Stress in employed women: impact of marital status and children at home on neurohormone output and home strain [see comments] Luecken LJ, et al. **Psychosom Med** 1997 Jul–Aug;59(4):352–9. Comment in: Psychosom Med 1997 Jul–Aug;59(4):360–1.

Plasma catecholamine and lymphocyte beta 2-adrenergic receptor alterations in elderly Alzheimer caregivers under stress. Mills PJ, et al. **Psychosom Med** 1997 May–Jun; 59(3):251–6

Psychobiologic reactivity to stress and childhood respiratory illness: results of two prospective studies [letter; comment] Ratliff-Crain J, et al. **Psychosom Med** 1996 Jul–Aug; 58(4):392–3. Comment on: Psychosom Med 1995 Sep–Oct;57(5):411–22. Comment on: Psychosom Med 1995 Sep–Oct;57(5):423–6.

Shaking up immunity: psychological and immunologic changes after a natural disaster [see comments] Solomon GF, et al. **Psychosom Med** 1997 Mar–Apr;59(2):114–27. Comment in: Psychosom Med 1997 Mar–Apr;59(2):142–3.

Differences in salivary habituation to palatable foods in bulimia nervosa patients and controls. Wisniewski L, et al. **Psychosom Med** 1997 Jul–Aug;59(4):427–33

Arousal responses of the newborn piglet to airways obstruction and rebreathing during normothermia and hyperthermia. Galland BC, et al. **Reprod Fertil Dev** 1996; 8(3):365–71

Physiological background of enuresis type I. A preliminary report. Watanabe H, et al. **Scand J Urol Nephrol Suppl** 1997;183:7–9; discussion 9–10

Behavioral and P3 amplitude enhancement in schizophrenia following feedback training. Fukuda M, et al. **Schizophr Res** 1997 Jun 20;25(3):231–42

What influences social skills in patients with schizophrenia? Preliminary study using the role play test, WAIS-R and event-related potential. Ikebuchi E, et al. **Schizophr Res** 1996 Nov 15;22(2):143–50

Negative symptoms and EEG alpha in schizophrenia: a replication. Merrin EL, et al. **Schizophr Res** 1996 May; 19(2–3):151–61

Cerebral blood flow activation and functional lesions in schizophrenia. Taylor SF. **Schizophr Res** 1996 May; 19(2–3):129–40 (42 ref.)

Differential pathophysiological mechanisms of reduced P300 amplitude in schizophrenia and depression: a single trial analysis. Wagner P, et al. **Schizophr Res** 1997 Jun 20; 25(3):221–9

Sudden arousals from slow wave sleep and panic disorder: successful treatment with anticonvulsants—a case report. Dantendorfer K, et al. **Sleep** 1996 Nov;19(9):744–6

Circadian characteristics of sleep propensity function in healthy elderly: a comparison with young adults. Haimov I, et al. **Sleep** 1997 Apr;20(4):294–300

The alerting effects of short and long naps in narcoleptic, sleep deprived, and alert individuals. Helmus T, et al. **Sleep** 1997 Apr;20(4):251–7

Sleep fragmentation in obstructive sleep apnea. Kimoff RJ. **Sleep** 1996 Nov;19(9 Suppl):S61–6 (65 ref.)

Infant sleep architecture during bedsharing and possible implications for SIDS. Mosko S, et al. **Sleep** 1996 Nov; 19(9):677–84

[Electrophysiologic studies] Bougerol T. **Encephale** 1996 Oct; 22 Spec No 3:13–7 (61 ref.) **(Fre)**

[The central nervous system, depression and cardiac death] Glassman AH. **Encephale** 1997 Jun;23 Spec No 3:55–8 (27 ref.) (Eng. Abstr.) **(Fre)**

[Transcranial Doppler ultrasound—robotics-controlled transducers for quantifying the effect of acupuncture] Litscher G, et al. **Biomed Tech (Berl)** 1997 May; 42(5):116–22 (Eng. Abstr.) **(Ger)**

[Chronopathology: from hypertension in general practice to manifest hypertension (interview)] Middeke M. **Fortschr Med** 1997 Apr 20;115(11):57–8 **(Ger)**

[Depression and electrodermal response measures in a habituation experiment. Results from over 400 depressed inpatients] Wolfersdorf M, et al. **Fortschr Neurol Psychiatr** 1996 Mar;64(3):105–9 (Eng. Abstr.) **(Ger)**

[Stress research between molecular and supra-molecular observations] Oehme P, et al. **Med Monatsschr Pharm** 1996 Sep;19(9):270–4 (7 ref.) **(Ger)**

[Event related brain potentials as indicators of neurochemical dysfunctions in psychiatric patients] Hegerl U, et al. **Nervenarzt** 1996 May;67(5):360–8 (67 ref.) (Eng. Abstr.) **(Ger)**

[Examination of psychological functions by functional imaging with positron emission tomography and magnetic resonance imaging] Schneider F, et al. **Nervenarzt** 1996 Sep;67(9):721–9 (60 ref.) (Eng. Abstr.) **(Ger)**

[Event-related potentials in semantic speech processing by schizophrenic patients] Spitzer M, et al. **Nervenarzt** 1997 Mar;68(3):212–25 (Eng. Abstr.) **(Ger)**

[Pupillography for objective vigilance assessment. Methodological problems and possible solutions] Wilhelm B, et al. **Ophthalmologe** 1996 Aug;93(4):446–50 (Eng. Abstr.) **(Ger)**

[Event related potentials and neuropsychological studies in sleep apnea patients] Kotterba S, et al. **Pneumologie** 1997 Aug;51 Suppl 3:712–5 (Eng. Abstr.) **(Ger)**

[The "cognitive pupillary oscillation hypothesis" in patients with neurotic disorders and organic psychosyndrome: reliability and validity of a new psychophysiologic method] Grünberger J, et al. **Wien Klin Wochenschr** 1996; 108(3):69–74 (Eng. Abstr.) **(Ger)**

[Restitutive effect of sleep on chronic performance stress] Becker-Carus C, et al. **Wien Med Wochenschr** 1996; 146(13–14):276–9 (Eng. Abstr.) **(Ger)**

[Sleep fragmentation as the cause of daytime sleepiness and reduced performance] Bonnet MH. **Wien Med Wochenschr** 1996;146(13–14):332–4 (14 ref.) (Eng. Abstr.) **(Ger)**

[nCPAP therapy and maxillary and mandibular osteotomy compared: attention during the day in obstructive sleep apnea] Conradt R, et al. **Wien Med Wochenschr** 1996; 146(13–14):372–4 (Eng. Abstr.) **(Ger)**

[Effect of adenotomy on mental performance of children with adenoid vegetations] Paditz E, et al. **Wien Med Wochenschr** 1996;146(13–14):327–8 (Eng. Abstr.) **(Ger)**

[Significance of oscillatory impedance in etiological determination of arousal in sleep related respiratory disorders] Schlenker E, et al. **Wien Med Wochenschr** 1996; 146(13–14):379–81 (Eng. Abstr.) **(Ger)**

[The role of neuropeptides in normal and disordered sleep regulation] Steiger A, et al. **Wien Med Wochenschr** 1996; 146(13–14):291–3 (Eng. Abstr.) **(Ger)**

[Pupillography as an objective attention test] Wilhelm B, et al. **Wien Med Wochenschr** 1996;146(13–14):387–9 (Eng. Abstr.) **(Ger)**

[Physical performance and sleep in athletes] Zimmermann E. **Wien Med Wochenschr** 1996;146(13–14):280–2 (Eng. Abstr.) **(Ger)**

[Are psychophysiologic changes in the "public speaking" paradigm an expression of emotional stress?] Erdmann G, et al. **Z Exp Psychol** 1996;43(2):224–55 (Eng. Abstr.) **(Ger)**

[Reliability of parameters of cognitive evoked P3 potentials] Minow F, et al. **Z Kinder Jugenpsychiatr** 1996 Dec; 24(4):265–71 (Eng. Abstr.) **(Ger)**

[A study on the quantitative evaluation method of human alertness and its application] Hagiwara H, et al. **Seishin Shinkeigaku Zasshi** 1997;99(1):23–34 (Eng. Abstr.) **(Jpn)**

[Non-apneic respiratory arousal in obstructive sleep apnea syndrome] Pareja JA, et al. **Neurologia** 1996 Aug–Sep; 11(7):244–7 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Effects of changes in arousal level by continuous light stimulus on contingent negative variation (CNV). Higuchi S, et al. **Appl Human Sci** 1997 Mar;16(2):55–60

ARRESTIN

A splice variant of arrestin from human retina. Smith WC. **Exp Eye Res** 1996 Jun;62(6):585–92

ANALYSIS

An immunocytochemical study of encephalic photoreceptors in three species of lamprey. García-Fernández JM, et al. **Cell Tissue Res** 1997 May;288(2):267–78

BIOSYNTHESIS

Retinoic aid increases arrestin mRNA levels in the mouse retina. Wagner E, et al. **FASEB J** 1997 Mar;11(4):271–5

CHEMISTRY

Immunological mimicry between retinal S-antigen and group A streptococcal M proteins. Lerner MP, et al. **Autoimmunity** 1995;22(2):95–106

Arrestin/clathrin interaction. Localization of the arrestin binding locus to the clathrin terminal domain. Goodman OB Jr, et al. **J Biol Chem** 1997 Jun 6;272(23):15017–22

GENETICS

Suppression of experimental autoimmune uveitis in Lewis rats by oral administration of recombinant Escherichia coli expressing retinal S-antigen. Singh VK, et al. **Cell Immunol** 1996 Sep 15;172(2):158–62

The 5' flanking regions of IRBP and arrestin have promoter activity in primary embryonic chicken retina cell cultures. Boatright JH, et al. **Exp Eye Res** 1997 Feb;64(2):269–77

Arrestins expressed in killifish photoreceptor cells. Hisatomi O, et al. **FEBS Lett** 1997 Jul 7;411(1):12–8

Oguchi disease: phenotypic characteristics of patients with the frequent 1147delA mutation in the arrestin gene. Nakazawa M, et al. **Retina** 1997;17(1):17–22

IMMUNOLOGY

Immunodetection of a protein related to mammalian arrestin in Euglena gracilis. Razaghi A, et al. **Biochem Biophys Res Commun** 1997 Apr 28;233(3):601–5

Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific. Laliotou B, et al. **Br J Ophthalmol** 1997 Jan;81(1):61–7

Immunomodulatory effects of linomide in animals immunized with immunopathogenic retinal antigens: dissociation between different immune functions. Shirkey BL, et al. **Clin Exp Immunol** 1997 Jun;108(3):539–44

Establishment of an E1A-immortalized retinal cell culture [letter] Seigel GM. **In Vitro Cell Dev Biol Anim** 1996 Feb; 32(2):66–8

Cellular immune response to retinal S-antigen & interphotoreceptor retinoid binding protein fragments in idiopathic human uveitis. Rajasingh J, et al. **Indian J Med Res** 1996 Apr;103:222–6

Permissive recognition of immunodominant determinants of the retinal S-antigen in different rat strains, primates and humans. Fukushima A, et al. **Int Immunol** 1997 Jan; 9(1):169–77

Differential APC requirements of self- and nonself-reactive T cells and T cell hybridomas specific for retinal S-antigen. Prasad SA, et al. **J Autoimmun** 1997 Feb;10(1):1–9

Studies on associations of antinuclear antibodies with antibodies to an uveitogenic peptide of retinal S antigen in children with uveitis. Rosenberg AM, et al. **J Rheumatol** 1996 Feb;23(2):370–3

[A case of paraneoplastic retinopathy with serum antibody against retinal soluble 70 kDa protein] Takahashi K, et al. **Nippon Ganka Gakkai Zasshi** 1997 Jan;101(1):92–6 (Eng. Abstr.) **(Jpn)**

[The clinico-immunological validation of a differentiated approach to the use of corticosteroids in treating S-dependent uveoretinitis] Slepova OS, et al. **Vestn Oftalmol** 1996 Apr–Jun;112(2):45–7 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

[Experiences with an isolation method for retinal S-antigen and interphotoreceptor retinoid-binding protein] Sych FJ, et al. **Ophthalmologe** 1996 Dec;93(6):732–8 (Eng. Abstr.) **(Ger)**

METABOLISM

Arrestin with a single amino acid substitution quenches light-activated rhodopsin in a phosphorylation-independent fashion. Gray-Keller MP, et al. **Biochemistry** 1997 Jun 10;36(23):7058–63

G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Ferguson SS, et al. **Can J Physiol Pharmacol** 1996 Oct; 74(10):1095–110 (137 ref.)

Anti-arrestin immunoreactivity in the human retina: difference between light- and dark-adaptation. Loeffler KU, et al. **Curr Eye Res** 1995 Dec;14(12):1165–8

Circadian aqueous flow mediated by beta-arrestin induced homologous desensitization. Wan XL, et al. **Exp Eye Res** 1997 Jun;64(6):1005–11

Arrestin/clathrin interaction. Localization of the arrestin binding locus to the clathrin terminal domain. Goodman

OB Jr, et al. **J Biol Chem** 1997 Jun 6;272(23):15017-22

Mechanism of quenching of phototransduction. Binding competition between arrestin and transducin for phosphorhodopsin. Krupnick JG, et al. **J Biol Chem** 1997 Jul 18;272(29):18125-31

Internalization of the m2 muscarinic acetylcholine receptor. Arrestin-independent and -dependent pathways. Pals-Rylaarsdam R, et al. **J Biol Chem** 1997 Sep 19; 272(38):23682-9

Rhodopsin phosphorylation sites and their role in arrestin binding. Zhang L, et al. **J Biol Chem** 1997 Jun 6; 272(23):14762-8

Calcium/calmodulin-dependent protein kinase II and arrestin phosphorylation in Limulus eyes. Calman BG, et al. **J Photochem Photobiol B** 1996 Aug;35(1-2):33-44

Mechanism of phosphorylation-recognition by visual arrestin and the transition of arrestin into a high affinity binding state. Gurevich VV, et al. **Mol Pharmacol** 1997 Jan; 51(1):161-9

PHARMACOLOGY

Immunotolerance induced by intratesticular antigen priming: expression of TGF-beta, Fas and Fas ligand. Li H, et al. **Ocul Immunol Inflamm** 1997 Jun;5(2):75-84

PHYSIOLOGY

Functional differences in the interaction of arrestin and its splice variant, p44, with rhodopsin. Pulvermüller A, et al. **Biochemistry** 1997 Jul 29;36(30):9253-60

Key elements involved in the negative regulation of the TSH receptor: G protein-coupled receptor kinases, arrestin and inducible cAMP early repressor. Kopp P. **Eur J Endocrinol** 1997 Mar;136(3):269-70

Prolonged photoresponses in transgenic mouse rods lacking arrestin. Xu J, et al. **Nature** 1997 Oct 2;389(6650):505-9

THERAPEUTIC USE

Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial [see comments] Nussenblatt RB, et al. **Am J Ophthalmol** 1997 May;123(5):583-92. Comment in: Am J Ophthalmol 1997 May;123(5):684-7.

Suppression of experimental autoimmune uveitis in Lewis rats by oral administration of recombinant Escherichia coli expressing retinal S-antigen. Singh VK, et al. **Cell Immunol** 1996 Sep 15;172(2):158-62

ARRESTINS

BIOSYNTHESIS

Beta-adrenergic receptor kinase-like activity and beta-arrestin are expressed in osteoblastic cells. Bliziotes M, et al. **J Bone Miner Res** 1996 Jun;11(6):820-6

CHEMISTRY

Arrestin/clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxy terminus. Krupnick JG, et al. **J Biol Chem** 1997 Jun 6; 272(23):15011-6

GENETICS

Studies of Rh1 metarhodopsin stabilization in wild-type Drosophila and in mutants lacking one or both arrestins. Kiselev A, et al. **Biochemistry** 1997 Feb 25;36(8):2188-96

Isolation of canine retinal arrestin cDNA and exclusion of three candidate genes for Swedish Briard retinal dystrophy. Veske A, et al. **Curr Eye Res** 1997 Mar;16(3):270-4

Splice variants of arrestins [letter] Palczewski K, et al. **Exp Eye Res** 1996 Nov;63(5):599-602

Expression and regulation of G protein-coupled receptor kinase 5 and beta-arrestin-1 in rat thyroid FRTL5 cells. Nagayama Y, et al. **Thyroid** 1996 Dec;6(6):627-31

METABOLISM

Arrestin/clathrin interaction. Localization of the clathrin binding domain of nonvisual arrestins to the carboxy terminus. Krupnick JG, et al. **J Biol Chem** 1997 Jun 6; 272(23):15011-6

Synergistic regulation of m2 muscarinic acetylcholine receptor desensitization and sequestration by G protein-coupled receptor kinase-2 and beta-arrestin-1. Schlador ML, et al. **J Biol Chem** 1997 Jul 25; 272(30):18882-90

Interaction of arrestins with intracellular domains of muscarinic and alpha2-adrenergic receptors. Wu G, et al. **J Biol Chem** 1997 Jul 11;272(28):17836-42

Calcium/calmodulin-dependent kinase II phosphorylates Drosophila visual arrestin. Kahn ES, et al. **J Neurochem** 1997 Jan;68(1):169-75

GRK2 and beta-arrestin 1 as negative regulators of thyrotropin receptor-stimulated response. Iacovelli L, et al. **Mol Endocrinol** 1996 Sep;10(9):1138-46

Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Goodman OB Jr, et al. **Nature** 1996 Oct 3;383(6599):447-50

PHYSIOLOGY

G-protein-coupled receptor kinases and arrestins: regulators of G-protein-coupled receptor sequestration. Ferguson SS, et al. **Biochem Soc Trans** 1996 Nov;24(4):953-9 (49 ref.)

Synergistic regulation of beta2-adrenergic receptor sequestration: intracellular complement of beta-adrenergic receptor kinase and beta-arrestin determine kinetics of internalization. Ménard L, et al. **Mol Pharmacol** 1997 May; 51(5):800-8

ARRHENOBLASTOMA see **ANDROBLASTOMA**

ARRHYTHMIA

see related
ANTI-ARRHYTHMIA AGENTS
ELECTRIC COUNTERSHOCK

Accelerated ventricular rhythm in the newborn. Kurotobi S, et al. **Acta Paediatr Jpn** 1995 Dec;37(6):701-2

Lessons from animal models of atrial arrhythmias. Frame LH. **Cardiol Clin** 1996 Nov;14(4):471-81 (48 ref.)

Bibliography of the current world literature. **Coron Artery Dis** 1996 Jan;7(1):83-93

Arrhythmias. **Curr Opin Cardiol** 1997 Jan;12(1):B1-25

The role of basic arrhythmia research. The continued need for experiments in the intact heart and organism. Allessie A, et al. **Eur Heart J** 1995 Nov;16(11):1469-75 (81 ref.)

Survival analysis and clinical medicine. An observational comparison of the implantable cardioverter defibrillator, amiodarone treatment, and heart transplantation. Ector H, et al. **Eur Heart J** 1996 Sep;17(9):1444-7

Intraventricular conduction disturbances. Kelkar PN, et al. **J Assoc Physicians India** 1996 Jun;44(6):402-6 (14 ref.)

Congestive heart failure and arrhythmias: therapeutic modalities. Singh SN. **J Cardiovasc Electrophysiol** 1997 Jan; 8(1):89-97 (61 ref.)

Incidence and significance of cardiac arrhythmia in geriatric oral surgery patients. Campbell JH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Jul;82(1):42-6

Europace '97. VIIIth Congress of the Working Groups on Cardiac Pacing and Cardiac Arrhythmias of the European Society of Cardiology. Athens, Greece, June 8-11, 1997. Abstracts. **Pacing Clin Electrophysiol** 1997 May;20(5 Pt 2):1383-601

Arrhythmias from Neonate to Adult. Symposium proceedings. The Netherlands, August 21-22, 1997. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2033-140

[14th improving course in rythmology. La Grande Motte, France, June 27-29, 1996 (editorial)] Slama R. **Arch Mal Coeur Vaiss** 1997 Apr;90 Spec No 1:9-10 **(Fre)**

[Right ventricular arrhythmogenic dysplasia] Loiselet P. **Presse Med** 1997 Feb 8;26(3):137-46 **(Fre)**

[Etiology and classification of cardiac arrhythmias] Atarashi H, et al. **Nippon Rinsho** 1996 Aug;54(8):2023-8 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Arrhythmias in ischemic heart disease] Ogawa S, et al. **Nippon Rinsho** 1996 Aug;54(8):2191-6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Arrhythmias with normal heart rate] Segawa K, et al. **Nippon Rinsho** 1996 Aug;54(8):2185-90 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Cardiac arrhythmias in cardiomyopathies] Yamaoki K, et al. **Nippon Rinsho** 1996 Aug;54(8):2197-201 (6 ref.) **(Jpn)**

[Arrhythmias in patients with metabolic disease] Yotsukura M, et al. **Nippon Rinsho** 1996 Aug;54(8):2202-6 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Escaped beat] Hata T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):517-8 (6 ref.) **(Jpn)**

[Drug refractory arrhythmia] Igawa O, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):535-7 (6 ref.) **(Jpn)**

[Arrhythmia] Nakano T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):475-8 (5 ref.) **(Jpn)**

[Atrial fibrillation--no malignant heart arrhythmia (letter; comment)] Stavem P. **Tidsskr Nor Laegeforen** 1997 Mar 20;117(8):1187-8. Comment on: Tidsskr Nor Laegeforen 1997 Feb 10;117(4):490-1. **(Nor)**

[Mechanisms involved in the antiarrhythmic and proarrhythmic effects of magnesium] Grin J, et al. **Medicina (B Aires)** 1996;56(3):231-40 (Eng. Abstr.) **(Spa)**

[Human and technical resources of arrhythmia units in Spain in 1995] Moro C, et al. **Rev Esp Cardiol** 1997 Apr; 50(4):225-32 (Eng. Abstr.) **(Spa)**

BLOOD

The influence of cardiopulmonary bypass on ionized magnesium in neonates, infants, and children undergoing repair of congenital heart lesions. Fox ML, et al. **Anesth Analg** 1997 Mar;84(3):497-500

Should C-section be applied to fetal arrhythmia? Amano K, et al. **Eur J Obstet Gynecol Reprod Biol** 1997 Mar;72 Suppl:S73-9

Hemodialysis using a constant potassium gradient: rationale of a multicenter study. Redaelli B, et al. **Int J Artif Organs** 1995 Nov;18(11):731-4

Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data. Lopez-Jimenez F, et al. **J Am Coll Cardiol** 1997 May;29(6):1241-5

Platelet activation during myocardial ischaemia: a contributory arrhythmogenic mechanism. Flores NA. **Pharmacol Ther** 1996;72(2):83-108 (237 ref.)

[Digoxin level as a limited drug toxicity indicator in the assessment of post-digitalis arrhythmia] Sinkiewicz W, et al. **Wiad Lek** 1994 Nov-Dec;47(21-24):808-12 (Eng. Abstr.) **(Pol)**

CHEMICALLY INDUCED

Caffeine and cardiac arrhythmias. An experimental study in dogs with review of literature. Mehta A, et al. **Acta Cardiol** 1997;52(3):273-83 (31 ref.)

Dobutamine-induced ST segment elevation and ventricular fibrillation with nonsignificant coronary artery disease. Shaheen J, et al. **Am Heart J** 1996 Nov;132(5):1058-60

Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death. Prystowsky EN. **Am J Cardiol** 1996 Oct 17; 78(8A):35-41 (87 ref.)

Attenuation of epinephrine-induced dysrhythmias by bradykinin: role of nitric oxide and prostaglandins. Rajani V, et al. **Am J Cardiol** 1997 Aug 4;80(3A):153A-157A

Erythromycin--a pro-kinetic and pro-arrhythmogenic agent [letter; comment] Kluger MT. **Anaesth Intensive Care** 1997 Jun;25(3):318-9. Comment on: Anaesth Intensive Care 1996 Dec;24(6):728.

Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide. Baguley WA, et al. **Anesth Analg** 1997 Jun;84(6):1380-1

The influence of chronic hypokalemia on myocardial adrenergic receptor densities: enhanced sensitivity to epinephrine-induced arrhythmias. Miletich DJ, et al. **Anesth Analg** 1997 Apr;84(4):734-9

Drug-induced QT interval prolongation [letter; comment] Thomas SH. **Br J Clin Pharmacol** 1996 Sep;42(3):399-400 . Comment on: Br J Clin Pharmacol 1996 Feb;41(2):77-81.

Pathophysiology and treatment of cocaine toxicity: implications for the heart and cardiovascular system. Williams RG, et al. **Can J Cardiol** 1996 Dec; 12(12):1295-301

Mechanism of epinephrine-induced dysrhythmias in rat involves local cholinergic activation. Igić R. **Can J Physiol Pharmacol** 1996 Jan;74(1):85-8

More about adenosine and arrhythmias [letter; comment] Tomcsányi J, et al. **Cardiovasc Res** 1997 Jun;34(3):603-5. Comment on: Cardiovasc Res 1996 Nov;32(5):797-813.

A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Girgis I, et al. **Chest** 1997 Sep; 112(3):646-53

Cardiac arrhythmias associated with coadministration of azole compounds and cisapride [letter; comment] Chan-Tompkins NH, et al. **Clin Infect Dis** 1997 Jun; 24(6):1285. Comment on: Clin Infect Dis 1996 Aug;23(2):305-13.

K+ channel opening: a new drug principle in cardiovascular medicine [letter; comment] Gussak I, et al. **Heart** 1997 May; 77(5):487. Comment on: Heart 1996 Aug;76(2):109-16.

Near fatal case of self-poisoning with thioridazine [letter] Annane D, et al. **Intensive Care Med** 1996 Dec; 22(12):1463-4

Cisapride in reducing postoperative gastrocaecal transit time after cardiac surgery in children [letter; comment] Jenkins IR. **Intensive Care Med** 1997 Apr;23(4):482-3. Comment on: Intensive Care Med 1996 Sep;22(9):977-80.

Comparison of proarrhythmogenic effects of two potassium channel openers, levcromakalim (BRL 38227) and nicorandil (RP 46417): a high-resolution mapping study on rabbit heart. Robert E, et al. **J Cardiovasc Pharmacol** 1997 Jan;29(1):109-18

Arrhythmogenic and antiarrhythmic actions of substances of abuse: effects on triggered activity. Gallardo-Carpentier A, et al. **J Electrocardiol** 1997 Apr;30(2):137-42

Cocaine-induced wide complex dysrhythmia. Kerns W 2nd, et al. **J Emerg Med** 1997 May-Jun;15(3):321-9

Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? Carlsson L, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):220-7

Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion. Heisler BE, et al. **J Pharmacol Exp Ther** 1996 Oct;279(1):317-24

Aberrant atrioventricular conduction triggered by antimalarial prophylaxis with mefloquine. Richter J, et al. **Lancet** 1997 Jan 11;349(9045):101-2

Fetal arrhythmia during treatment of pregnancy-associated acute promyelocytic leukemia with all-trans retinoic acid and favorable outcome [letter] Terada Y, et al. **Leukemia** 1997 Mar;11(3):454-5

Participation of central kappa-opioid receptor in arrhythmogenesis. Lishmanov YB, et al. **Life Sci** 1997; 61(3):PL33-8

Theophylline and sleep-disordered breathing in heart failure [letter; comment] Goggins M. **N Engl J Med** 1997 Jan 30; 336(5):379. Comment on: N Engl J Med 1996 Aug 22;335(8):562-7.

Mechanism of lethal proarrhythmia observed in the Cardiac Arrhythmia Suppression Trial: role of adrenergic modulation of drug binding. Packer DL, et al. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):455-67 (78 ref.)

Arrhythmias after astemizole overdose. Heidemann SM, et

al. **Pediatr Emerg Care** 1996 Apr;12(2):102–4 (17 ref.)

Pediatric ECMO for severe quinidine cardiotoxicity. Tecklenburg FW, et al. **Pediatr Emerg Care** 1997 Apr; 13(2):111–3

Arrhythmogenic action of endothelin peptides in isolated perfused whole hearts from guinea pigs and rats. Ercan ZS, et al. **Pharmacology** 1996 Oct;53(4):234–40

Adrenoceptor mechanism involved in thiopental–induced potentiation of halothane–epinephrine arrhythmias in dogs. Kamibayashi T, et al.
Res Commun Mol Pathol Pharmacol 1996 Aug;93(2):225–34

[Cardiac arrhythmia caused by massive resorption of glycine during hysteroscopy (letter; comment)] Chassard D, et al. **Ann Fr Anesth Reanim** 1996;15(2):227. Comment on: Ann Fr Anesth Reanim 1995;14(4):370–3. **(Fre)**

[Arrhythmia during the recovery phase in a child. Another ampoule story, a human error... (letter)] Paqueron X, et al. **Ann Fr Anesth Reanim** 1996;15(7):1134–5 **(Fre)**

[Cardiac side effects of anti–arrhythmia agents] Pfeiffer D, et al. **Internist (Berl)** 1996 Jan;37(1):53–9 (44 ref.) **(Ger)**

[Drug–induced arrhythmias] Inoue H. **Nippon Rinsho** 1996 Aug;54(8):2220–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Drug induced arrhythmias] Usuda K.
Ryoikibetsu Shokogun Shirizu 1996;(12):538–41 (12 ref.) **(Jpn)**

[Digoxin level as a limited drug toxicity indicator in the assessment of post–digitalis arrhythmia] Sinkiewicz W, et al. **Wiad Lek** 1994 Nov–Dec;47(21–24):808–12 (Eng. Abstr.) **(Pol)**

[New developments in predicting the arrhythmogenic effect of beta–adrenomimetics in chronic obstructive lung diseases] Andrianov VP, et al. **Voen Med Zh** 1996 Nov; 317(11):34–6 **(Rus)**

CLASSIFICATION

Correlation–based pattern recognition for implantable defibrillators. Wilkins J. **Proc AMIA Annu Fall Symp** 1996; :289–93

COMPLICATIONS

Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Shotan A, et al. **Am J Cardiol** 1997 Apr 15;79(8):1061–4

Type of arrhythmia at EMS arrival on scene in out–of–hospital cardiac arrest in relation to interval from collapse and whether a bystander initiated CPR. Herlitz J, et al. **Am J Emerg Med** 1996 Mar;14(2):119–23

Bartter's syndrome, supraventricular tachycardia, mitral valve prolapse, and asthma: a therapeutic challenge. Rodriguez DF, et al. **Am J Med Sci** 1997 Feb;313(2):114–6

Hospitalization for fainting: high stakes, low yield [editorial] [see comments] Gallagher EJ. **Ann Emerg Med** 1997 Apr; 29(4):540–2. Comment in: Ann Emerg Med 1997 Apr;29(4):459–66.

Driving issues related to arrhythmic syncope. Miles WM. **Cardiol Clin** 1997 May;15(2):327–39 (58 ref.)

Comparative study of mitral annular calcification (MAC) with cardiac arrhythmias in dialysis patients. Jeren–Strujić B, et al. **Coll Antropol** 1997 Jun;21(1):167–74

Incidence of ventricular arrhythmias during silent myocardial ischaemia in coronary artery disease. Parthenakis F, et al. **Int J Cardiol** 1996 Nov 15;57(1):61–7

Arrhythmias and sudden death in heart failure. Stevenson WG, et al. **Jpn Circ J** 1997 Sep;61(9):727–40 (115 ref.)

Ventricular arrhythmias and sudden cardiac death: an insight from recent multicenter randomized clinical trials. Akiyama T. **Keio J Med** 1996 Dec;45(4):313–7 (48 ref.)

Cardiac arrhythmias in chronic obstructive pulmonary disease. Górecka D. **Monaldi Arch Chest Dis** 1997 Jun; 52(3):278–81

Impact of autonomic neuropathy on circulatory instability during liver transplantation for familial amyloidotic polyneuropathy. Suhr OB, et al. **Transplantation** 1997 Mar 15;63(5):675–9

[Epilepsy and the heart] Jallon P. **Rev Neurol (Paris)** 1997 Apr;153(3):173–84 (172 ref.) (Eng. Abstr.) **(Fre)**

[Arrhythmia as risk factor] **Internist (Berl)** 1997 Feb;38(2 Suppl Risikofakt):1–8 **(Ger)**

[Syncope in elderly patients--which studies are sensible?] Cottier C. **Schweiz Rundsch Med Prax** 1996 Nov 12; 85(46):1482–9 (Eng. Abstr.) **(Ger)**

[Cerebral hypoperfusion symptoms in elderly subjects with hyperkinetic and/or hypokinetic arrhythmia. Study of institutionalized and non– institutionalized patients] Rossi MG, et al. **Minerva Med** 1997 Jan–Feb;88(1–2):9–14 (Eng. Abstr.) **(Ita)**

[Left ventricular lesions in arrhythmogenic right ventricular dysplasia and 12–lead electrocardiographic findings] Wada Y, et al. **J Cardiol** 1996 Dec;28(6):337–44 (Eng. Abstr.) **(Jpn)**

[Therapy of cardiogenic shock due to arrhythmia] Abe H, et al. **Nippon Naika Gakkai Zasshi** 1996 Jan 10;85(1):60–5 (6 ref.) **(Jpn)**

[Case of Emery–Dreifuss syndrome associated with atrial standstill] Sakuragawa K, et al.
Nippon Naika Gakkai Zasshi 1997 Feb 10;86(2):310–1 **(Jpn)**

[Fisher's syndrome with profound hypotension] Arai M, et al. **Rinsho Shinkeigaku** 1996 Jun;36(6):797–9 (Eng. Abstr.) **(Jpn)**

[A case of potassium–sensitive periodic paralysis with cardiac dysrhythmia] Nakamagoe K, et al. **Rinsho Shinkeigaku** 1997 Mar;37(3):239–42 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Complications associated with myocardial infarction] Horimoto M. **Ryoikibetsu Shokogun Shirizu** 1996;(12):704–8 (15 ref.) **(Jpn)**

[Arterial hypertension, diabetes and cardiac arrhythmias as risk factor in reversible and completed ischemic stroke] Jędrzejowska H, et al. **Neurol Neurochir Pol** 1996 Jul–Aug; 30(4):559–70 (Eng. Abstr.) **(Pol)**

[Relationship between mitral valve prolapse and arrhythmogenic right ventricular disease] Costa AM, et al. **Arq Bras Cardiol** 1996 Dec;67(6):379–83 (Eng. Abstr.) **(Por)**

[The heart and the brain. Aspects of their interrelations] Bartko D, et al. **Vnitr Lek** 1996 Jul;42(7):482–9 (Eng. Abstr.) **(Slo)**

CONGENITAL

[Congenital arrhythmia, atrial flutter, supraventricular tachycardia, ventricular tachycardia, congenital complete atrioventricular block] Ogawa K.
Ryoikibetsu Shokogun Shirizu 1996;(12):360–3 (14 ref.) **(Jpn)**

DIAGNOSIS

Impact of hemodialysis on comprehensive ventricular repolarization. Tuncer C, et al. **Acta Cardiol** 1997; 52(3):305–12

Automatic measurement of corrected QT interval in Holter recordings: comparison of its dynamic behavior in patients after myocardial infarction with and without life–threatening arrhythmias. Homs E, et al.
Am Heart J 1997 Aug;134(2 Pt 1):181–7

Utility and cost of event recorders in the diagnosis of palpitations, presyncope, and syncope. Fogel RI, et al.
Am J Cardiol 1997 Jan 15;79(2):207–8

Are monitored telemetry beds necessary for patients with nontraumatic chest pain and normal or nonspecific electrocardiograms? Hollander JE, et al. **Am J Cardiol** 1997 Apr 15;79(8):1110–1

Validation of the EINTHOVEN model–based computerized electrocardiogram rhythm analysis system with three classes of clinical arrhythmias. Widman LE, et al.
Am J Cardiol 1996 Oct 15;78(8):927–31

Utility of patient–activated cardiac event recorders in general clinical practice. Zimetbaum P, et al. **Am J Cardiol** 1997 Feb 1;79(3):371–2

Effect of dedicated monitor watchers on patients' outcomes. Funk M, et al. **Am J Crit Care** 1997 Jul;6(4):318–23

Accuracy of detection of clinically important dysrhythmias with and without a dedicated monitor watcher. Stukshis I, et al. **Am J Crit Care** 1997 Jul;6(4):312–7

Perioperative cardiac dysrhythmias: diagnosis and management. Atlee JL. **Anesthesiology** 1997 Jun; 86(6):1397–424 (290 ref.)

Ventricular dysrhythmia in the native heart after heterotopic heart transplantation: diagnosis with selective electrocardiography. Housmans PR, et al.
Anesthesiology 1996 Oct;85(4):936–9

Risk stratification of patients with syncope [comment] Martin TP, et al. **Ann Emerg Med** 1997 Apr;29(4):459–66. Comment on: Ann Emerg Med 1997 Apr;29(4):540–2.

Differential diagnosis of palpitations. Preliminary development of a screening instrument. Barsky AJ, et al. **Arch Fam Med** 1997 May–Jun;6(3):241–5

Illusions, arithmetic, and the bidirectional modulation of vagal control of the heart. Berntson GG, et al.
Biol Psychol 1996 Sep 27;44(1):1–17

Critique of arrhythmia detectors based on heuristic rules. Elghazzawi Z, et al. **Biomed Instrum Technol** 1997 May–Jun;31(3):263–71

Cardiac mapping. Zickler P. **Biomed Instrum Technol** 1997 Mar–Apr;31(2):173–5

Time domain signal–averaged electrocardiogram in predicting arrhythmic events after myocardial infarction: role of the duration of the filtered QRS complex. Bruna C, et al. **Cardiologia** 1996 Dec;41(12):1183–92

Retrograde atrio–His bundle dissociation as a sign indicative of retrograde accessory pathway conduction. Wang CH, et al. **Chang Keng I Hsueh** 1996 Mar;19(1):62–5

Predicting arrhythmic death: a plea for standardized reporting techniques and data based on continuous electrocardiographic monitoring [editorial; comment] Marchlinski FE. **Circulation** 1997 Sep 16;96(6):1713–6. Comment on: Circulation 1997 Sep 16;96(6):1888–92.

Automatic arrhythmia identification using analysis of the atrioventricular association. Application to a new generation of implantable defibrillators. Participating Centers of the Automatic Recognition of Arrhythmia Study Group. Nair M, et al. **Circulation** 1997 Feb 18; 95(4):967–73

QT dispersion ratio in patients with unstable angina pectoris (a new risk factor?). Cin VG, et al. **Clin Cardiol** 1997 Jun; 20(6):533–5

Myocardial contusion caused by a baseball [see comments] Morikawa M, et al. **Clin Cardiol** 1996 Oct;19(10):831–3 (19 ref.). Comment in: Clin Cardiol 1996 Dec;19(12):921.

Arrhythmogenic right ventricular disease, dysplasia and cardiomyopathy [editorial; comment] Fontaine G, et al. **Eur Heart J** 1996 Nov;17(11):1613–4. Comment on: Eur Heart J 1996 Nov;17(11):1717–22.

Progressive ECG changes in arrhythmogenic right ventricular disease. Evidence for an evolving disease [see comments] Jaoude SA, et al. **Eur Heart J** 1996 Nov; 17(11):1717–22. Comment in: Eur Heart J 1996 Nov;17(11):1613–4. Comment in: Eur Heart J 1997 Apr;18(4):703–4.

Measuring QT dispersion: man versus machine. Murray A, et al. **Heart** 1997 Jun;77(6):539–42

The time–sequenced adaptive filter for analysis of cardiac arrhythmias in intraventricular electrograms. Finelli CJ. **IEEE Trans Biomed Eng** 1996 Aug;43(8):811–9

Cerebral palsy and electronic fetal monitoring. Karthikeyna G. **Indian Pediatr** 1996 Oct;33(10):887–9

Arrhythmogenic right ventricular dysplasia. Chauhan A, et al. **Int J Cardiol** 1996 Oct 11;56(2):107–12 (48 ref.)

Maximal precordial ST–segment depression in leads V4–V6 in patients with inferior wall acute myocardial infarction indicates coronary artery disease involving the left anterior descending coronary artery system. Hasdai D, et al.
Int J Cardiol 1997 Feb;58(3):273–8

Cardiac arrhythmias as presenting symptoms in patients with limb–girdle muscular dystrophy. Ng W, et al.
Int J Cardiol 1997 Apr 18;59(2):157–60

Radiological case of the month. Arrhythmogenic right ventricular dysplasia. Nokes ST, et al. **J Ark Med Soc** 1996 Aug;93(3):151–2

Supervised exercise and electrocardiographic monitoring during cardiac rehabilitation. Impact on patient care. Vongvanich P, et al. **J Cardiopulm Rehabil** 1996 Jul–Aug; 16(4):233–8

An unusual electrocardiogram tracing. Kaplan S, et al.
J Cardiothorac Vasc Anesth 1996 Jun;10(4):557–8

Spectral turbulence versus time–domain analysis of signal–averaged ECG used for the prediction of different arrhythmic events in survivors of acute myocardial infarction. Copie X, et al. **J Cardiovasc Electrophysiol** 1996 Jul;7(7):583–93

A:V = 1:1 cardiac arrhythmia detection by VA interval analysis. Stevenson SA, et al. **J Electrocardiol** 1996;29 Suppl:198–201

Influence of ECG measurement accuracy on ECG diagnostic statements. Zywietz C, et al. **J Electrocardiol** 1996;29 Suppl:67–72

Subtle electrical alternans in a large pericardial effusion with tamponade. Slattery DE, et al. **J Emerg Med** 1997 May–Jun;15(3):371–2

ECG of the month: nomen dubium [letter] Martinez–Lopez JI. **J La State Med Soc** 1996 Feb;148(2):45–8

An evaluation of serum troponin T and signal–averaged electrocardiography in predicting electrocardiographic abnormalities after blunt chest trauma. Fulda GJ, et al.
J Trauma 1997 Aug;43(2):304–10; discussion 310–2

Management of fetal cardiac arrhythmias. Copel JA, et al.
Obstet Gynecol Clin North Am 1997 Mar;24(1):201–11 (34 ref.)

Dual level sensing significantly improves automatic threshold control for R wave sensing in implantable defibrillators. The Angeion Corporation. Brewer JE, et al.
Pacing Clin Electrophysiol 1996 Dec;19(12 Pt 1):2051–9

Augmented two–channel arrhythmia detection: an efficient diagnostic method for implantable devices. Chiang CM, et al. **Pacing Clin Electrophysiol** 1996 Oct;19(10):1493–501

Clinical significance of increased QT dispersion in the 12–lead standard ECG for arrhythmia risk prediction in dilated cardiomyopathy. Grimm W, et al.
Pacing Clin Electrophysiol 1996 Nov;19(11 Pt 2):1886–9

Maturation of the sensed electrogram amplitude over time in a new subcutaneous implantable loop recorder. Krahn AD, et al. **Pacing Clin Electrophysiol** 1997 Jun; 20(6):1686–90

Circulatory system in children with localized scleroderma. Rokicki W, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):213–7

EINTHOVEN and tolerance for human error: design issues in a decision support system for cardiac arrhythmia interpretation. Widman LE, et al.
Proc AMIA Annu Fall Symp 1996;:224–8

Current diagnosis and treatment of patients with cardiac arrhythmias – a guideline. South African Society of Cardiac Practitioners Annual Ses . Karos Indaba Hotel, Johannesburg, 20–23 July 1995. Mekele JM.
S Afr Med J 1997 Feb;87 Suppl 1:C29–C40

Occurrence of arrhythmias in general practice. Zwietering P, et al. **Scand J Prim Health Care** 1996 Dec;14(4):244–50

New bipolar leads for the study of atrial arrhythmias. Brenes–Pereira C. **Tex Heart Inst J** 1997;24(2):118–21

[Ventricular late potentials and sleep apnea syndromes] Maillier B, et al. **Ann Cardiol Angeiol (Paris)** 1996 Dec; 45(10):561–6 (Eng. Abstr.) **(Fre)**

[Esophageal approach in rythmology. Diagnostic and therapeutic applications] Moustaghfir A, et al.
Ann Cardiol Angeiol (Paris) 1996 Nov;45(9):539–44 (21 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic approach in coronary disease in developing countries] Broustet JP, et al. **Med Trop (Mars)** 1996; 56(3):219–22 (0 ref.) **(Fre)**

[Electrocardiography and case reports] Schoenfeld P, et al.
Rev Med Brux 1996 Sep;17(4):186–96 **(Fre)**

[Absolute arrhythmia and latent hyperthyroidism] Schlaghecke R. **Dtsch Med Wochenschr** 1997 Jan 17; 122(3):71 **(Ger)**

[What is your diagnosis? Thalamic pacemaker] Bolliger KP. **Schweiz Rundsch Med Prax** 1997 Jun 18;86(25–26):1057–9 **(Ger)**

[What is your diagnosis?] Brack M, et al. **Schweiz Rundsch Med Prax** 1997 Feb 25;86(9):335–6 **(Ger)**

[What is your diagnosis?] Popova N, et al. **Schweiz Rundsch Med Prax** 1996 Sep 24;85(39):1191–2 **(Ger)**

[Late arrhythmias after the Fontan operation] Nakanishi K, et al. **Kyobu Geka** 1996 Sep;49(10):804–8 (Eng. Abstr.) **(Jpn)**

[Simultaneous ambulatory electrocardiography and pulse oximetry] Nakamoto T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1997 Feb; 35(2):144–53 (Eng. Abstr.) **(Jpn)**

[Electrophysiological study] Enjoji Y, et al. **Nippon Rinsho** 1996 Aug;54(8):2099–103 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Advances in the diagnosis of arrhythmia Holter's ECG] Hayakawa H, et al. **Nippon Rinsho** 1996 Aug;54(8):2085–90 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Body surface mapping] Hayashi H. **Nippon Rinsho** 1996 Aug; 54(8):2091–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Standard 12 lead electrogram] Kondo M, et al. **Nippon Rinsho** 1996 Aug;54(8):2066–73 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Transesophageal pacing and recording] Takenaka S, et al. **Nippon Rinsho** 1996 Aug;54(8):2074–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Advancement of management of arrhythmias associated with exercise testing] Yoshida H, et al. **Nippon Rinsho** 1996 Aug;54(8):2080–4 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Studies on intraoperative cardiac mapping] Watanabe S, et al. **Rinsho Kyobu Geka** 1989 Jun;9(3):229–37 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Life threatening arrhythmia] Usuda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):384–7 (19 ref.) **(Jpn)**

[Dysrhythmias documented by 48–hour electrocardiographic monitoring in children with mitral valve prolapse] Bobkowski W, et al. **Pediatr Pol** 1996 Jun;71(6):493–7 (Eng. Abstr.) **(Pol)**

[Arrhythmia in patients with hypertrophic cardiomyopathy during an exercise test with 24–hour Holter monitoring] Nowalany–Kozielska E, et al. **Pol Merkuriusz Lek** 1996 Aug;1(2):82–4 (Eng. Abstr.) **(Pol)**

[Arrhythmogenic dysplasia of the right heart ventricle] Kalarus Z, et al. **Przegl Lek** 1997;54(1):43–5 (18 ref.) (Eng. Abstr.) **(Pol)**

[Fetal heart rhythm disorders. Detection and prenatal management] Zielinsky P. **Arq Bras Cardiol** 1996 Feb; 66(2):83–6 (25 ref.) **(Por)**

[The natural history of cardiac involvement in Portuguese–type familial amyloid polyneuropathy] Fonseca C, et al. **Rev Port Cardiol** 1997 Jan;16(1):101–5 **(Por)**

[The diagnosis and elimination of disorders in cardiac electrostimulation in patients with an artificial pacemaker] Iskenderov BG, et al. **Ter Arkh** 1997;69(4):37–40 (Eng. Abstr.) **(Rus)**

[The importance of clinical and instrumental indices in predicting cardiac rhythm disorders in hypertension] Ardashev VN, et al. **Voen Med Zh** 1996 Dec;317(12):23–6 **(Rus)**

[Noninvasive electrocardiographic monitoring and ventricular arrhythmias in patients after myocardial infarct] Gonsorčík J, et al. **Bratisl Lek Listy** 1996 Aug;97(8):457–62 (Eng. Abstr.) **(Slo)**

[Subarachnoid hemorrhage and electrocardiographic changes. Is it or is it not a sign of myocardial ischemia? (letter)] Hernández–Palazón J, et al. **Rev Esp Anestesiol Reanim** 1997 Feb;44(2):86 **(Spa)**

DRUG THERAPY

Derivatives of 2–mercaptobenzenesulphonamide. XVIII. Syntheses and cardiovascular effects of some S– and S,N–substituted 4–chloro–2–mercapto–5–methyl–N–(5–amino–1,2,4–triazol–3–yl) benzenesulphonamide derivatives. Brzozowski Z, et al. **Acta Pol Pharm** 1995 May–Jun; 52(3):223–30

Long–term results of electrophysiologically guided sotalol therapy for life–threatening ventricular arrhythmias. Lee RJ, et al. **Am Heart J** 1996 Nov;132(5):973–8

Adenosine as an antiarrhythmic agent. Wilbur SL, et al. **Am J Cardiol** 1997 Jun 19;79(12A):30–7 (69 ref.)

Amiodarone: a late comer. Futterman LG, et al. **Am J Crit Care** 1997 May;6(3):233–9 (23 ref.)

Magnesium sulfate therapy in certain emergency conditions. Frakes MA, et al. **Am J Emerg Med** 1997 Mar;15(2):182–7 (81 ref.)

Use of esmolol during intraoperative atrioventricular rhythm. James MF, et al. **Anaesth Intensive Care** 1996 Aug; 24(4):492–5

The rational use of intravenous amiodarone in the perioperative period. Balser JR. **Anesthesiology** 1997 Apr; 86(4):974–87 (83 ref.)

Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Chow MS. **Ann Pharmacother** 1996 Jun; 30(6):637–43 (38 ref.)

Effects of diltiazem versus digoxin on dysrhythmias and cardiac function after pneumonectomy. Amar D, et al. **Ann Thorac Surg** 1997 May;63(5):1374–81; discussion 1381–2

The role of ketoconazole in the QTc interval prolonging effects of H1–antihistamines in a guinea–pig model of arrhythmogenicity. Gras J, et al. **Br J Pharmacol** 1996 Sep; 119(2):187–8

Delayed protection against ischaemia–induced ventricular arrhythmias and infarct size limitation by the prior administration of Escherichia coli endotoxin. Song W, et al. **Br J Pharmacol** 1996 Aug;118(8):2157–63

Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential. Nair LA, et al. **Cardiovasc Drugs Ther** 1997 Apr;11(2):149–67 (140 ref.)

Effect of streptomycin on wall–stress–induced arrhythmias in the working rat heart. Salmon AH, et al. **Cardiovasc Res** 1997 Jun;34(3):493–503

Mexiletine in the treatment of resistant ventricular arrhythmias [letter; comment] Weissenburger J, et al. **Circulation** 1996 Dec 1;94(11):2986–7. Comment on: Circulation 1995 Dec 15;92(12):3381–6.

Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Singh BN. **Clin Cardiol** 1997 Jul;20(7):608–18 (33 ref.)

Magnolol reduces infarct size and suppresses ventricular arrhythmia in rats subjected to coronary ligation. Hong CY, et al. **Clin Exp Pharmacol Physiol** 1996 Aug; 23(8):660–4

Clinical trials of arrhythmia management: methods or madness. Camm AJ. **Control Clin Trials** 1996 Jun;17(3 Suppl):4S–16S

Masking drug treatments in the Cardiac Arrhythmia Pilot Study (CAPS). FASHP for the CAPS Investigators. Haakenson C, et al. **Control Clin Trials** 1996 Aug; 17(4):294–303

Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM): a critical appraisal. Prystowsky EN. **Control Clin Trials** 1996 Jun;17(3 Suppl):28S–36S

Magnesium and arrhythmias in acute myocardial infarction. Horner SM. **Coron Artery Dis** 1996 May;7(5):359–63 (66 ref.)

Congestive heart failure and disorders of the heart beat. Weaver T, et al. **Dent Clin North Am** 1996 Jul;40(3):543–61 (43 ref.)

Antiarrhythmic therapies for the prevention of sudden cardiac death. McAlister FA, et al. **Drugs** 1997 Aug; 54(2):235–52 (115 ref.)

Pharmacological management of arrhythmias in the elderly. Van Gelder IC, et al. **Drugs Aging** 1997 Aug;11(2):96–110 (65 ref.)

Antiarrhythmic effects of an aconitine–like compound, TJN–505, on canine arrhythmia models. Arita J, et al. **Eur J Pharmacol** 1996 Dec 30;318(2–3):333–40

Concerning the effect of the K+ channel blocking agent glibenclamide on ischaemic and reperfusion arrhythmias. Bernauer W. **Eur J Pharmacol** 1997 May 20; 326(2–3):147–56

L–canavanine and dexamethasone attenuate endotoxin–induced suppression of ischaemia–reperfusion arrhythmias. Iskit AB, et al. **Eur J Pharmacol** 1997 May 20;326(2–3):183–90

Nicorandil suppressed ventricular arrhythmias in a canine model of myocardial ischaemia. Vegh A, et al. **Eur J Pharmacol** 1996 Jun 3;305(1–3):163–8

ACE inhibitors and arrhythmias. Campbell RW. **Heart** 1996 Nov;76(3 Suppl 3):79–82 (36 ref.)

Amiodarone in high–risk post–infarction patients, Lessons from EMIAT and CAMIAT. European Myocardial Infarct Amiodarone Trial and Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Gambhir DS. **Indian Heart J** 1996 Jul–Aug;48(4):339–41 (14 ref.)

Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. Magnesium in Cardiac Arrhythmias (MAGICA) Investigators. Zehender M, et al. **J Am Coll Cardiol** 1997 Apr;29(5):1028–34

Adenosine in treating cardiac arrhythmias. Zehender M, et al. **J Auton Pharmacol** 1996 Dec;16(6):329–31

Antiarrhythmic drug therapy for ventricular arrhythmias: current perspectives. Link MS, et al. **J Cardiovasc Electrophysiol** 1996 Jul;7(7):653–70 (156 ref.)

Alteration of human placental vascular tone by antiarrhythmic medications in vitro. Omar HA, et al. **J Cardiovasc Electrophysiol** 1996 Dec;7(12):1197–203

Antiischemic and antiarrhythmic activities of some novel alinidine analogs in the rat heart. Challinor–Rogers JL, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):499–507

Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs. Chen J, et al. **J Cardiovasc Pharmacol** 1996 Oct;28(4):576–84

Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. Drexler AP, et al. **J Cardiovasc Pharmacol** 1996 Dec;28(6):848–55

Antiarrhythmic effects of optical isomers of disopyramide on canine ventricular arrhythmias. Nakamura M, et al. **J Cardiovasc Pharmacol** 1996 Mar;27(3):368–75

Comparative effects of idazoxan, prazosin, and yohimbine on coronary ligation–induced arrhythmias in spontaneously hypertensive rats. Roegel JC, et al. **J Cardiovasc Pharmacol** 1996 Feb;27(2):226–34

Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin–converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin? Shimada Y, et al. **J Cardiovasc Pharmacol** 1996 Mar; 27(3):428–38

The role of nitric oxide in modulating ischaemia–induced arrhythmias in rats. Sun W, et al. **J Cardiovasc Pharmacol** 1997 Apr;29(4):554–62

Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia. Iervasi G, et al. **J Clin Endocrinol Metab** 1997 Jan;82(1):275–80

Long–term cost–effectiveness of alternative management strategies for patients with life–threatening ventricular arrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) Investigators. Hlatky MA, et al. **J Clin Epidemiol** 1997 Feb;50(2):185–93

Effects of the new class I antiarrhythmic agent Ro 22–9194, (2R)–2–amino–N–(2,6–dimethylphenyl)–N–[3–(3–pyridyl) propyl]propionamide D–tartrate, on ischemia– and reperfusion–induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. Murakami M, et al. **J Pharmacol Exp Ther** 1996 Nov;279(2):877–83

The effects of class I drugs on the cycle length of sustained ventricular tachycardia and the signal–averaged electrocardiogram. Doi T, et al. **Jpn Circ J** 1997 Jun; 61(6):495–502

Effect of intravenous magnesium sulfate on cardiac arrhythmias in critically ill patients with low serum ionized magnesium. Kasaoka S, et al. **Jpn Circ J** 1996 Nov; 60(11):871–5

Inhibitory effect of CV4151, a thromboxane A2 synthetase inhibitor, on ventricular arrhythmias induced by coronary artery occlusion in rats. Umetani K, et al. **Jpn Circ J** 1996 Jun;60(6):349–54

Safety and efficacy of oral flecainide acetate in patients with cardiac arrhythmias. Nakazato Y, et al. **Jpn Heart J** 1997 May;38(3):379–85

Effects of antiarrhythmic agents and Mg2+ on aconitine–induced arrhythmias. Sawanobori T, et al. **Jpn Heart J** 1996 Sep;37(5):709–18 (26 ref.)

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators [published erratum appears in Lancet 1997 Jun 14;349(9067):1776] [see comments] Cairns JA, et al. **Lancet** 1997 Mar 8;349(9053):675–82. Comment in: Lancet 1997 Mar 8;349(9053):662–3. Comment in: Lancet 1997 Jun 14;349(9067):1767. Comment in: ACP J Club 1997 Sep–Oct;127(2):30–1.

KC8851, a tedisamil analogue with mixed channel blockade, exhibits antiarrhythmic properties against ischemia– and electrically–induced arrhythmias. Xu R, et al. **Life Sci** 1997; 61(3):237–48

Antiarrhythmic agents: current status and perspectives. Mátyus P, et al. **Med Res Rev** 1997 Sep;17(5):427–51 (165 ref.)

Arrhythmias and antiarrhythmic drugs. Hoffman BF. **Mt Sinai J Med** 1997 Mar;64(2):136–41 (22 ref.)

Digoxin in patients with heart failure [letter; comment] Böhm M. **N Engl J Med** 1997 Jul 10;337(2):129–30; discussion 130–1. Comment on: N Engl J Med 1997 Feb 20;336(8):525–33.

Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination. Grant AO. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):432–44 (65 ref.)

Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs. Matsuo K, et al. **Pacing Clin Electrophysiol** 1997 Apr;20(4 Pt 1):938–45

Thimerosal attenuates ischaemia–reperfusion arrhythmias in rats: no modification by anti–ischaemic agent trimetazidine or endothelin receptor antagonist bosentan. Iskit AB, et al. **Pharmacol Res** 1996 Jul–Aug;34(1–2):17–23

Targeting ischaemia—cell swelling and drug efficacy. Wright AR, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):224–8 (45 ref.)

Short– and intermediate–term efficacy of amiodarone in infants and children with cardiac arrhythmia. Celiker A, et al. **Turk J Pediatr** 1997 Apr–Jun;39(2):219–25

[Anti–arrhythmia therapy in general practice only for patients with healthy hearts (interview by Dr. rer. nat. Anita Scheiger)] Dotzer F. **Fortschr Med** 1997 Jan 20; 115(1–2):42, 44 **(Ger)**

[Successful treatment of cardiac arrhythmias. Current and future therapeutic possibilities] **Internist (Berl)** 1994 Nov; 35(11 Suppl):1–12 **(Ger)**

[Change in therapy of cardiac arrhythmias. Current studies—initial results] Meinertz T. **Med Klin** 1997 Apr 15; 92(4):211–4 (16 ref.) (Eng. Abstr.) **(Ger)**

[Propafenone and flecainide in the therapy of ventricular arrhythmias] Paperini L, et al. **Minerva Cardioangiol** 1995 Oct;43(10):449–57 (32 ref.) (Eng. Abstr.) **(Ita)**

[Class III antiarrhythmic drugs] Aiba T, et al. **Nippon Rinsho** 1996 Aug;54(8):2125–31 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Vaughan Williams class IV antiarrhythmic drugs] Horie M, et al. **Nippon Rinsho** 1996 Aug;54(8):2132–7 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical use of beta–blocker an as antiarrhythmic agent] Okazaki O, et al. **Nippon Rinsho** 1996 Aug;54(8):2117–24 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Imidazoline receptors and use of drug blocking receptors I1] Lada W. **Pol Merkuriusz Lek** 1996 Aug;1(2):124–5 (10 ref.) (Eng. Abstr.) **(Pol)**

[Antiarrhythmic effects of prajmaline (Neo–Gilurythmal) in stable angina pectoris in light of Holter

electrocardiographic monitoring] Janicki K, et al. **Przegl Lek** 1995;52(10):485–491 (Eng. Abstr.) **(Pol)**

[Brazilian multicenter study of sotalol effectiveness in ventricular arrhythmias] Maia IG, et al. **Arq Bras Cardiol** 1996 Mar;66(3):173–8 (Eng. Abstr.) **(Por)**

[Comparative anti-arrhythmia activity of befol, lidocaine, and bonnecor] Galenko-Iaroshevskiĭ PA, et al. **Biull Eksp Biol Med** 1996 Dec;122(12):665–8 **(Rus)**

[Effect of sufan, lidocaine and their combination on the course of early occlusive and reperfusion arrhythmias in cats] Galenko-Iaroshevskiĭ Pa, et al. **Biull Eksp Biol Med** 1997 May;123(5):545–7 **(Rus)**

[Comparative characteristic of sodium blocking properties of anti-arrhythmia agents on isolated rats cardiomyocytes] Khankoeva AI, et al. **Biull Eksp Biol Med** 1997 Jun; 123(6):666–8 **(Rus)**

[The mechanism of the anti-arrhythmia action of mu-opioid-receptor agonists in a model of CaCl2-induced arrhythmias: the role of the autonomic nervous system] Maslov LN, et al. **Eksp Klin Farmakol** 1997 Jan–Feb; 60(1):35–7 (Eng. Abstr.) **(Rus)**

[The effect of naloxone on rhythm disorders and on the conduction system of the heart] Shliakhto EV, et al. **Eksp Klin Farmakol** 1996 May–Jun;59(3):34–6 (Eng. Abstr.) **(Rus)**

[The efficacy of anti-arrhythmia therapy with bonnecor in middle-aged and elderly patients] Zaslavskaia RM, et al. **Klin Med (Mosk)** 1996;74(2):30–2 (Eng. Abstr.) **(Rus)**

[The cardioprotective action of the anticonvulsant preparation sodium valproate in disorders of cardiac contractile function caused by acute myocardial infarct in rats] Belkina LM, et al. **Patol Fiziol Eksp Ter** 1997 Apr–Jun; (2):18–21 (Eng. Abstr.) **(Rus)**

[Peptide correction of arrhythmias induced by stimulation of the vagal sympathetic trunk in cats] Osadchiĭ OE, et al. **Patol Fiziol Eksp Ter** 1997 Jul–Sep;(3):10–3 (Eng. Abstr.) **(Rus)**

[Possibilities of correcting adverse effects of anti-arrhythmia agents] Skibitskiĭ VV, et al. **Vestn Ross Akad Med Nauk** 1996;(5):9–12 (Eng. Abstr.) **(Rus)**

[The programmed therapy of rhythm and conduction disorders in ischemic heart disease] Ardashev VN, et al. **Voen Med Zh** 1997 Jul;318(7):32–8 **(Rus)**

[Plasma concentrations and amiodarone/desethylamiodarone relations in patients subjected to chronic treatment] Ortiz M, et al. **Rev Med Chil** 1996 Jan;124(1):77–82 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Rhythm disturbances after mitral valve surgery: comparison between left atrial and extended trans-septal approach. Tambeur L, et al. **Cardiovasc Surg** 1996 Dec;4(6):820–4

Effects of Ginkgo biloba extract and preconditioning on the diabetic rat myocardium. Tosaki A, et al. **Diabetologia** 1996 Nov;39(11):1255–62

Cardiac arrhythmias in the elderly. Shah CP, et al. **Indian Heart J** 1997 May–Jun;49(3):263–6 (18 ref.)

Prevalence of palpitations, cardiac arrhythmias and their associated risk factors in ambulant elderly. Lok NS, et al. **Int J Cardiol** 1996 Jun;54(3):231–6

Arrhythmia and mortality after the Mustard procedure: a 30-year single-center experience. Gelatt M, et al. **J Am Coll Cardiol** 1997 Jan;29(1):194–201

Prevalence of asymptomatic electrocardiographic abnormalities in a rural population. Gupta R, et al. **J Assoc Physicians India** 1996 Nov;44(11):775–7

[Arrhythmias and conduction block in the newborns of mothers who had received long-term tocolytic therapy] Wieczorek W. **Ginekol Pol** 1996 Aug;67(8):398–402 (Eng. Abstr.) **(Pol)**

[Usefulness of the preoperative electrocardiogram in elective surgery] Escolano F, et al. **Rev Esp Anestesiol Reanim** 1996 Nov;43(9):305–9 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Cardiac arrhythmias in patients on maintenance hemodialysis. Erem C, et al. **Acta Cardiol** 1997;52(1):25–36

Ventricular arrhythmia and possible myocardial ischemia in late stage Kawasaki disease: patient with a normal coronary arteriogram. Nakada T. **Acta Paediatr Jpn** 1996 Aug; 38(4):365–9

Effect of glimepiride and glibenclamide, inhibitors of ATP-dependent K(+)-channel, on ischaemia-reperfusion induced arrhythmias in rats. Bozdogan O, et al. **Acta Physiol Hung** 1996;84(3):265–6

Effect of almokalant a specific inhibitor of IKr on myocardial ischaemia-reperfusion induced arrhythmias in rabbits. Farkas A, et al. **Acta Physiol Hung** 1996;84(3):281–2

Pseudo-myocardial infarction in transurethral resection syndrome. Gustafson JG, et al. **Am Heart J** 1996 Nov; 132(5):1053–4

Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the Antiarrhythmics Vs Implantable Defibrillators (AVID) trial and nonrandomized registry patients. Kim SG, et al. **Am J Cardiol** 1997 Aug 15;80(4):454–7

Noninvasive risk modeling after myocardial infarction. Reinhardt L, et al. **Am J Cardiol** 1996 Sep 15;78(6):627–32

Amiodarone: a late comer. Futterman LG, et al. **Am J Crit Care** 1997 May;6(3):233–9 (23 ref.)

Autonomic neuropathy predisposing to arrhythmias in hemodialysis patients. Jassal SV, et al. **Am J Kidney Dis** 1997 Aug;30(2):219–23

Ventricular dysrhythmia in the native heart after heterotopic heart transplantation: diagnosis with selective electrocardiography. Housmans PR, et al. **Anesthesiology** 1996 Oct;85(4):936–9

Influence of bicaval anastomoses on late occurrence of atrial arrhythmia after heart transplantation. Brandt M, et al. **Ann Thorac Surg** 1997 Jul;64(1):70–2

Postoperative cardiac rhythms with superior-septal approach and lateral approach to the mitral valve. Masuda M, et al. **Ann Thorac Surg** 1996 Oct;62(4):1118–22

Conduction disturbances in acute myocardial infarction: incidence, site-wise relationship and the influence on in-hospital prognosis. Majumder AA, et al. **Bangladesh Med Res Counc Bull** 1996 Aug;22(2):74–80

Brief repetitive ischemia: effect on norepinephrine release, arrhythmias, and functional recovery in isolated perfused rat heart. Feng J, et al. **Can J Physiol Pharmacol** 1996 Dec; 74(12):1351–8

Arrhythmia and electrical heterogeneity during prolonged hypoxia in guinea pig papillary muscles. Hayashi H, et al. **Can J Physiol Pharmacol** 1997 Jan;75(1):44–51

Cardioprotection induced by ischemic preconditioning in the mammalian heart: effects on arrhythmogenesis. Lukas A, et al. **Can J Physiol Pharmacol** 1997 Apr;75(4):316–25 (102 ref.)

Wall stress-induced arrhythmias in the working rat heart as left ventricular hypertrophy regresses during captopril treatment. Dalton GR, et al. **Cardiovasc Res** 1997 Mar; 33(3):561–72

Age dependence of the development of ventricular arrhythmias in a canine model of sudden cardiac death. Moïse NS, et al. **Cardiovasc Res** 1997 Jun;34(3):483–92

Cardiac disease in myotonic dystrophy. Phillips MF, et al. **Cardiovasc Res** 1997 Jan;33(1):13–22 (61 ref.)

Arrhythmogenesis in experimental models of heart failure: the role of increased load. Pye MP, et al. **Cardiovasc Res** 1996 Aug;32(2):248–57

Cardiac hypertrophy, arrhythmogenicity and the new myocardial phenotype. II. The cellular adaptational process. Swynghedauw B, et al. **Cardiovasc Res** 1997 Jul; 35(1):6–12 (43 ref.)

Pathogenesis and prognostic significance of conduction abnormalities after coronary bypass surgery. Kirdar JA, et al. **Cardiovasc Surg** 1996 Dec;4(6):832–6

The early and late phases of ischemic preconditioning: a comparative analysis of their effects on infarct size, myocardial stunning, and arrhythmias in conscious pigs undergoing a 40-minute coronary occlusion. Qiu Y, et al. **Circ Res** 1997 May;80(5):730–42

Epitome of myocarditis [letter] Elson S. **Circulation** 1997 Sep 16;96(6):2082

Repolarization and the genesis of cardiac arrhythmias. Role of body surface mapping [editorial; comment] Fontaine G, et al. **Circulation** 1997 Jun 17;95(12):2600–2 (20 ref.). Comment on: Circulation 1997 Jun 17;95(12):2668–76.

Prospective study of the incidence and determinants of arrhythmia after total cavopulmonary connection. Gardiner HM, et al. **Circulation** 1996 Nov 1;94(9 Suppl):II17–21

Analysis of abnormal intra-QRS potentials. Improved predictive value for arrhythmic events with the signal-averaged electrocardiogram. Lander P, et al. **Circulation** 1997 Mar 18;95(6):1386–93

Body-surface QRST integral mapping. Arrhythmogenic righ ventricular dysplasia versus idiopathic right ventricular tachycardia [see comments] Peeters HA, et al. **Circulation** 1997 Jun 17;95(12):2668–76. Comment in: Circulation 1997 Jun 17;95(12):2600–2.

Usefulness of electron-beam computed tomography in arrhythmogenic right ventricular dysplasia. Relationship to electrophysiological abnormalities and left ventricular involvement. Tada H, et al. **Circulation** 1996 Aug 1; 94(3):437–44

Time course of lysophosphatidylcholine release from ischemic human myocardium parallels the time course of early ischemic ventricular arrhythmia. Sedlis SP, et al. **Coron Artery Dis** 1997 Jan;8(1):19–27

Alteration of cardiac function in patients with temporal lobe epilepsy: different roles of EEG-ECG monitoring and spectral analysis of RR variability. Massetani R, et al. **Epilepsia** 1997 Mar;38(3):363–9

Arrhythmogenic right ventricular disease, dysplasia and cardiomyopathy [editorial; comment] Fontaine G, et al. **Eur Heart J** 1996 Nov;17(11):1613–4. Comment on: Eur Heart J 1996 Nov;17(11):1717–22.

Protective effects of acidic fibroblast growth factor against cardiac arrhythmias induced by ischemia and reperfusion in rats. Cuevas P, et al. **Eur J Med Res** 1997 Jan;2(1):33–6

Arrhythmogenic right ventricular dysplasia: MR features. Midiri M, et al. **Eur Radiol** 1997;7(3):307–12

Cellular mechanisms of cardiac arrhythmias in the ischemic and reperfused heart. Bril A. **EXS** 1996;76:135–53 (78 ref.)

The roles of reactive oxygen species and endogenous opioid peptides in ischemia-induced arrhythmia of isolated rat hearts. Yang CS, et al. **Free Radic Biol Med** 1995 Mar; 18(3):593–8

Oral sodium phosphate versus sulfate-free polyethylene glycol electrolyte lavage solution in outpatient preparation for colonoscopy: a prospective comparison. Clarkston WK, et al. **Gastrointest Endosc** 1996 Jan;43(1):42–8

Association of ventricular arrhythmias with left ventricular remodelling after myocardial infarction. Popović AD, et al. **Heart** 1997 May;77(5):423–7

QT prolongation in end-stage liver disease: a result of altered sex hormone metabolism? [letter; comment] Lehmann MH. **Hepatology** 1997 Jul;26(1):244. Comment on: Hepatology 1996 May;23(5):1128–34.

Alcohol and rhythm disturbance: the holiday heart syndrome. Menz V, et al. **Herz** 1996 Aug;21(4):227–31 (33 ref.)

Digital rectal examination during early acute MI [editorial] Lee JR, et al. **Hosp Pract (Off Ed)** 1997 Sep 15;32(9):15–6 (11 ref.)

Role of noradrenaline uptake inhibition and alpha-adrenoceptors in reperfusion ventricular arrhythmias in vivo and in vitro. Shekher A, et al. **Indian J Exp Biol** 1996 Nov;34(11):1085–90

The production of ventricular arrhythmias following ligation of the right coronary artery in dogs [letter] Gautam CS, et al. **Indian J Physiol Pharmacol** 1996 Jul;40(3):277–8

Congestive cardiac failure and electrocardiographic abnormalities in acute glomerulonephritis. Banarurmath CR, et al. **Indian Pediatr** 1996 Jul;33(7):589–92

Blunt cardiac injury: a 10 year institutional review. van Wijngaarden MH, et al. **Injury** 1997 Jan;28(1):51–5

Electrocardiographic manifestations following electric injury. Arya KR, et al. **Int J Cardiol** 1996 Nov 15; 57(1):100–1

Abnormal QT dispersion in Behçet's disease. Göldeli O, et al. **Int J Cardiol** 1997 Aug 29;61(1):55–9

A peculiar form of pacemaker syndrome in DDD pacing. Simoncelli U, et al. **Int J Cardiol** 1996 Jan;53(1):90–3

Palpitations: what is the mechanism, and when should we treat them? Rosano GM, et al. **Int J Fertil Womens Med** 1997 Mar–Apr;42(2):94–100 (23 ref.)

Arrhythmias and ischemia-like ECG changes in Reye's syndrome. Sarti A, et al. **Intensive Care Med** 1996 Jan; 22(1):62–4

A family with adult type ceroid lipofuscinosis (Kufs' disease) and heart muscle disease: report of two autopsy cases. Sakajiri K, et al. **Intern Med** 1995 Dec;34(12):1158–63

Paroxysmal atrial fibrillation after insect sting. Ferrari S, et al. **J Allergy Clin Immunol** 1996 Oct;98(4):759–61

Predictive value for future arrhythmic events of fractal dimension, a measure of time clustering of ventricular premature complexes, after myocardial infarction. CAST Investigators. Cardia Arrhythmia Suppression Trial. Anderson JL, et al. **J Am Coll Cardiol** 1997 Jul;30(1):226–32

Repeated 15-minute coronary occlusions in pigs increase occlusion arrhythmias but decrease reperfusion arrhythmias that are associated with extracellular hypokalemia. Figueras J, et al. **J Am Coll Cardiol** 1996 Nov 15;28(6):1589–97

Cardiac arrhythmias during central venous catheter procedures in acute renal failure: a prospective study. Fiaccadori E, et al. **J Am Soc Nephrol** 1996 Jul;7(7):1079–84

"Orthoryhthmia" or postural cardiac dysrhythmia: clinical significance. Dogra R. **J Assoc Physicians India** 1996 May; 44(5):316–9

Complications of treadmill testing. Singh H, et al. **J Assoc Physicians India** 1996 May;44(5):313–5

An unusual electrocardiographic tracing [letter] Ceriana P, et al. **J Cardiothorac Vasc Anesth** 1996 Oct;10(6):834–6

Electrophysiological mechanisms for ventricular arrhythmias in patients with myocardial ischemia: anesthesiologic considerations, Pt II. Gallagher JD. **J Cardiothorac Vasc Anesth** 1997 Aug;11(5):641–56 (139 ref.)

Influence of anesthetics on the incidence of reperfusion-induced arrhythmias and sudden death in rats. Baczkó I, et al. **J Cardiovasc Pharmacol** 1997 Feb; 29(2):196–201

Quasiperiodicity and chaos in cardiac fibrillation [see comments] Garfinkel A, et al. **J Clin Invest** 1997 Jan 15; 99(2):305–14. Comment in: J Clin Invest 1997 Jan 15;99(2):156–7.

Complex oscillatory heart rhythm: a dance macabre [editorial; comment] Verrier RL, et al. **J Clin Invest** 1997 Jan 15;99(2):156–7. Comment on: J Clin Invest 1997 Jan 15;99(2):305–14.

Multiresolution decomposition of the signal-averaged ECG using the mallat approach for prediction of arrhythmic events after myocardial infarction. Sierra G, et al. **J Electrocardiol** 1996 Jul;29(3):223–34

Subtle electrical alternans in a large pericardial effusion with tamponade. Slattery DE, et al. **J Emerg Med** 1997 May–Jun;15(3):371–2

Reciprocal ST segment depression in acute myocardial infarction. Chatterjee S, et al. **J Indian Med Assoc** 1996 Jun;94(6):221–3

Cardiac rhythm abnormalities during intravenous immunoglobulin G infusion for treatment of thrombocytopenia. Savaşan S, et al. **J Pediatr Hematol Oncol** 1997 May–Jun;19(3):254–7

An evaluation of serum troponin T and signal-averaged electrocardiography in predicting electrocardiographic abnormalities after blunt chest trauma. Fulda GJ, et al. **J Trauma** 1997 Aug;43(2):304–10; discussion 310–2

Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Teragawa H, et al.

Jpn Heart J 1996 Nov;37(6):905–15

Ventricular arrhythmias in heart failure. Mitamura H. **Kelo J Med** 1996 Mar;45(1):1–8 (71 ref.)

Modeling triggered cardiac activity: an analysis of the interactions between potassium blockade, rhythm pauses, and cellular coupling. Gibb WJ, et al. **Math Biosci** 1996 Oct 15;137(2):101–33

Interference with cardiac pacemakers by cellular telephones [see comments] Hayes DL, et al. **N Engl J Med** 1997 May 22;336(21):1473–9. Comment in: N Engl J Med 1997 May 22;336(21):1518–9.

Resuscitation following arrhythmia in patients undergoing pharmacological/exercise stress for myocardial perfusion imaging [editorial] Prvulovich E. **Nucl Med Commun** 1996 Dec;17(12):1003–5 (11 ref.)

Pacemaker induced repetitive nonreentrant ventriculoatrial synchrony: initiation and termination by ventricular extrasystole. Barold SS. **Pacing Clin Electrophysiol** 1997 Apr;20(4 Pt 1):989–92

Atrial arrhythmia following a biatrial approach to mitral valve surgery. Bernstein NE, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1944–6

Cellular and pathophysiological mechanisms of ventricular arrhythmias in acute ischemia and infarction. Ehlert FA, et al. **Pacing Clin Electrophysiol** 1997 Apr;20(4 Pt 1):966–75 (77 ref.)

Role of Na(+)–H+ exchange on reperfusion related myocardial injury and arrhythmias in an open–chest swine model. Fukuta M, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):2027–33

Value of time– and frequency–domain analysis of signal–averaged electrocardiography for arrhythmia risk prediction in idiopathic dilated cardiomyopathy. Grimm W, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1923–7

Heart rate variability and major arrhythmic events in patients with idiopathic dilated cardiomyopathy. Hoffmann J, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1841–4

Mechanism of lethal proarrhythmia observed in the Cardiac Arrhythmia Suppression Trial: role of adrenergic modulation of drug binding. Packer DL, et al. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):455–67 (78 ref.)

Microfibrosis produces electrical load variations due to loss of side–to–side cell connections: a major mechanism of structural heart disease arrhythmias. Spach MS, et al. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):397–413 (60 ref.)

Ion channels, the QT interval, and arrhythmias. Wilde AA, et al. **Pacing Clin Electrophysiol** 1997 Aug;20(8 Pt 2):2048–51 (12 ref.)

Perioperative considerations in a newly described subtype of congenital long QT syndrome. Joseph–Reynolds AM, et al. **Paediatr Anaesth** 1997;7(3):237–41 (25 ref.)

Intraoperative cardiovascular collapse in an infant with Arnold–Chiari malformation. Tanaka M, et al. **Paediatr Anaesth** 1997;7(2):163–6

Comparison of sodium pentobarbitone and urethane anaesthesia in a rat model of coronary artery occlusion and reperfusion arrhythmias: interaction with L–NAME. Iskit AB, et al. **Pharmacol Res** 1996 Jan;33(1):13–8

Postoperative arrhythmias and myocardial electrolytes in patients undergoing coronary artery bypass grafting. Jensen BM, et al. **Scand J Thorac Cardiovasc Surg** 1996; 30(3–4):133–40

Conduction disturbances after different blood cardioplegia modes in coronary artery bypass grafting. Including comparison with an earlier patient series. Pehkonen EJ, et al. **Scand J Thorac Cardiovasc Surg** 1996;30(3–4):149–55

Is obstructive sleep apnea (OSA) a risk factor for myocardial infarction and cardiac arrhythmias in patients with coronary heart disease (CHD)? Koehler U, et al. **Sleep** 1996 May;19(4):283–6

Electrocardiographic monitoring in severe falciparum malaria. Bethell DB, et al. **Trans R Soc Trop Med Hyg** 1996 May–Jun;90(3):266–9

Targeting ischaemia—cell swelling and drug efficacy. Wright AR, et al. **Trends Pharmacol Sci** 1997 Jul;18(7):224–8 (45 ref.)

[An unusual cause of oxygen desaturation: isorhythmic atrioventricular dissociation] Mestre C, et al. **Ann Fr Anesth Reanim** 1996;15(5):673–6 (Eng. Abstr.) **(Fre)**

[Correlation between QT interval dispersion and ventricular arrhythmia in hypertension] Balanescu S, et al. **Arch Mal Coeur Vaiss** 1996 Aug;89(8):987–90 (Eng. Abstr.) **(Fre)**

[Right precordial leads and sudden death. Relation with arrhythmogenic right ventricular dysplasia] Fontaine G, et al. **Arch Mal Coeur Vaiss** 1996 Oct;89(10):1323–9 (Eng. Abstr.) **(Fre)**

[Amiodarone in arrhythmia] **Internist (Berl)** 1996 Nov;37(11 Suppl):1–4 **(Ger)**

[Arrhythmia and dyspnea. Moderately differentiated leiomyosarcoma] Kauczor HU, et al. **Radiologe** 1996 Feb; 36(2):169–71 **(Ger)**

[Role of spectral turbulence analysis of ECG in predicting risk of arrhythmia after myocardial infarction] Vado A, et al. **G Ital Cardiol** 1997 Jul;27(7):674–81 (25 ref.) (Eng. Abstr.) **(Ita)**

[Twenty cases of superior septal approach for mitral valve operation] Doi K, et al. **Kyobu Geka** 1997 Mar; 50(3):197–200 (Eng. Abstr.) **(Jpn)**

[Cardiac arrhythmias caused by electrolyte imbalance] Nishimura M, et al. **Nippon Rinsho** 1996 Aug;54(8):2207–12 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Dystrophin abnormality in a patient with polymyositis associated with primary biliary cirrhosis and myocardial injury] Tsai WC, et al. **Rinsho Shinkeigaku** 1996 Jul; 36(7):876–80 (Eng. Abstr.) **(Jpn)**

[Arrhythmias in patients with chronic pulmonary emphysema] Makino M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):436–9 (15 ref.) **(Jpn)**

[Cardiac arrhythmias in hemodialysis patients] Murakami S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):402–6 (8 ref.) **(Jpn)**

[Reperfusion arrhythmia] Nagao K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):277–81 (19 ref.) **(Jpn)**

[Pediatric arrhythmia] Ogawa K. **Ryoikibetsu Shokogun Shirizu** 1996;(12):304–7 (16 ref.) **(Jpn)**

[Postoperative cardiac arrhythmias] Yokoyama M. **Ryoikibetsu Shokogun Shirizu** 1996;(12):334–6 (5 ref.) **(Jpn)**

[The risk of surgical treatment in elderly patients] Swiątkowski J. **Pol Merkuriusz Lek** 1996 Oct;1(4):261–3 (Eng. Abstr.) **(Pol)**

[Arrhythmogenic potential of hypertensive cardiomyopathy. Prognostic value of Holter monitoring] Maia IG. **Arq Bras Cardiol** 1995 Dec;65(6):545–8 **(Por)**

[Disordered cardiac contractility after clinical death caused by acute blood loss] Dolgikh VT, et al. **Anesteziol Reanimatol** 1996 Sep–Oct;(5):42–5 (Eng. Abstr.) **(Rus)**

[Arrhythmogenic dysplasia of the right ventricle] Brugada J, et al. **Rev Esp Cardiol** 1997 Aug;50(8):541–7 (29 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

A proposed mutation, Val781Ile, associated with hyperkalemic periodic paralysis and cardiac dysrhythmia is a benign polymorphism. Green DS, et al. **Ann Neurol** 1997 Aug;42(2):253–6

Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice. Berul CI, et al. **J Clin Invest** 1997 Feb 15;99(4):570–6

A congenital heart defect in Drosophila caused by an action–potential mutation. Dowse H, et al. **J Neurogenet** 1995 Dec;10(3):153–68

Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Ptáček LJ. **Neuromuscul Disord** 1997 Jun;7(4):250–5 (56 ref.)

[Hereditary cardiac arrhythmia] Le Marec H, et al. **Arch Mal Coeur Vaiss** 1997 Apr;90 Spec No 1:57–66 (30 ref.) (Eng. Abstr.) **(Fre)**

HISTORY

[When the heart loses its rhythm... On the history of cardiac arrhythmias and their therapy with anti–arrhythmia substances] Lüderitz B. **Z Kardiol** 1996;85 Suppl 6:11–23 **(Ger)**

METABOLISM

Molecular and cellular aspects of re–entrant arrhythmias. Kleber AG, et al. **Basic Res Cardiol** 1997;92 Suppl 1:111–9 (31 ref.)

Free radicals in reperfusion–induced arrhythmias: study with EUK 8, a novel nonprotein catalytic antioxidant. Tanguy S, et al. **Free Radic Biol Med** 1996;21(7):945–54

The roles of reactive oxygen species and endogenous opioid peptides in ischemia–induced arrhythmia of isolated rat hearts. Yang CS, et al. **Free Radic Biol Med** 1995 Mar; 18(3):593–8

Arrhythmias caused by platelet activating factor. Hoffman BF, et al. **J Cardiovasc Electrophysiol** 1996 Feb;7(2):120–33

Role of intracellular sodium overload in the genesis of cardiac arrhythmias. Levi AJ, et al. **J Cardiovasc Electrophysiol** 1997 Jun;8(6):700–21 (209 ref.)

Ins(1,4,5)P3 during myocardial ischemia and its relationship to the development of arrhythmias. Woodcock EA, et al. **J Mol Cell Cardiol** 1996 Oct;28(10):2129–38

Donors of nitric oxide mimic effects of ischaemic preconditioning on reperfusion induced arrhythmias in isolated rat heart. Bilińska M, et al. **Mol Cell Biochem** 1996 Jul–Aug;160–161:265–71

[The defining role of calcium entering cells during ischemia as the mechanism for initiating reperfusion arrhythmias] Burashnikov AIu, et al. **Biofizika** 1997 Mar–Apr; 42(2):508–15 (Eng. Abstr.) **(Rus)**

[Central K1–opiate receptors and mechanisms of arrhythmogenesis] Ugdyzhekova DS, et al. **Biull Eksp Biol Med** 1997 Jun;123(6):656–8 **(Rus)**

MORTALITY

Mortality benefit of implantable cardioverter–defibrillator therapy in patients with persistent malignant ventricular arrhythmias despite amiodarone treatment. Barron HV, et al. **Am J Cardiol** 1997 May 1;79(9):1180–4

Mortality trials with implantable defibrillators [editorial] Nisam S, et al. **Am J Cardiol** 1997 Feb 15;79(4):468–71

Death in custody due to a colopericardial fistula. Huddleston DJ, et al. **Am J Forensic Med Pathol** 1997 Jun;18(2):194–8

Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST). Obias–Manno D, et al. **Ann Epidemiol** 1996 Mar;6(2):93–101

Influence of the implantable cardioverter–defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation [letter; comment] Sanmartin Fernández M, et al. **Circulation** 1997 Mar 18;95(6):1666. Comment on: Circulation 1995 Dec 1;92(11):3273–81.

Influence of implantable cardioverter–defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation [letter; comment] Stäblein A, et al. **Circulation** 1997 Mar 18;95(6):1666–7. Comment on: Circulation 1995 Dec 1;92(11):3273–81.

Contribution of heart rate variability to long–term risk stratification after myocardial infarction [editorial; comment] Fetsch T, et al. **Eur Heart J** 1997 May; 18(5):710–2. Comment on: Eur Heart J 1997 May;18(5):789–97.

Amiodarone after myocardial infarction: EMIAT and CAMIAT trials [letter; comment] Malik M, et al. **Lancet** 1997 Jun 14;349(9067):1767–8. Comment on: Lancet 1997 Mar 8;349(9053):662–3.

DIAMOND antiarrhythmic trials. Danish Investigations of Arrhythmia and Mortality on Dofetilide [letter; comment] Møller M. **Lancet** 1996 Dec 7;348(9041):1597–8. Comment on: Lancet 1996 Jul 6;348(9019):7–12.

Arrhythmogenic mortality in heart–transplant candidates. Fieguth HG, et al. **Transpl Int** 1996;9 Suppl 1:S219–20

[Analysis of maternal and fetal risk in 594 pregnancies with heart disease] Wada H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1996 Apr; 48(4):255–62 (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

[Ventricular arrhythmia in Chagas disease. Diagnostic, prognostic, and therapeutic features] Rassi Júnior A, et al. **Arq Bras Cardiol** 1995 Oct;65(4):377–87 **(Por)**

PATHOLOGY

Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Assayag P, et al. **Cardiovasc Res** 1997 Jun;34(3):439–44 (29 ref.)

Acute ischemic ventricular arrhythmias in pigs with healed myocardial infarction: comparative effects of ischemia at a distance and ischemia at the infarct zone. Cinca J, et al. **Circulation** 1997 Jul 15;96(2):653–8

Heterogeneous sympathetic innervation in German shepherd dogs with inherited ventricular arrhythmia and sudden cardiac death. Dae MW, et al. **Circulation** 1997 Aug 19; 96(4):1337–42

Cellular evidence for arrhythmogenic right ventricular dysplasia being an evolving disease [letter; comment] Cheng TO. **Eur Heart J** 1997 Apr;18(4):703–4. Comment on: Eur Heart J 1996 Nov;17(11):1717–22.

The syndrome of right bundle branch block, persistent ST segment elevation and sudden cardiac death. Which is the histological substrate? [letter] Morgera T, et al. **Eur Heart J** 1997 Jul;18(7):1190–1

[Arrhythmogenic dysplasia of the left ventricle and magnetic resonance: a happy union or a poor relationship? (editorial; comment)] Casolo GC. **G Ital Cardiol** 1996 May; 26(5):495–501. Comment on: G Ital Cardiol 1996 May;26(5):483–93. **(Ita)**

[Diagnostic contribution of magnetic resonance in clinically suspected arrhythmogenic dysplasia of the right ventricle (see comments)] Fattori R, et al. **G Ital Cardiol** 1996 May; 26(5):483–93 (Eng. Abstr.). Comment in: G Ital Cardiol 1996 May;26(5):495–501. **(Ita)**

PHYSIOPATHOLOGY

Prolongation of the QTc interval during alcohol withdrawal syndrome. Otero–Antón E, et al. **Acta Cardiol** 1997; 52(3):285–94

Are the inotropic and antiarrhythmic effects of bradykinin due to increases in coronary flow? Minshall RD, et al. **Am J Cardiol** 1997 Aug 4;80(3A):148A–152A

Attenuation of epinephrine–induced dysrhythmias by bradykinin: role of nitric oxide and prostaglandins. Rajani V, et al. **Am J Cardiol** 1997 Aug 4;80(3A):153A–157A

Evaluation of cardiac rhythm disturbances during extravehicular activity. Rossum AC, et al. **Am J Cardiol** 1997 Apr 15;79(8):1153–5

The effects on cardiac arrhythmias of antihypertensive therapy causing regression of left ventricular hypertrophy. Mayet J, et al. **Am J Hypertens** 1997 Jun;10(6):611–8

Effects of acidic reperfusion on arrhythmias and Na(+)–K(+)–ATPase activity in regionally ischemic rat hearts. Avkiran M, et al. **Am J Physiol** 1996 Mar;270(3 Pt 2):H957–64

Ins(1,4,5)P3 and arrhythmogenic responses during myocardial reperfusion: evidence for receptor specificity. Jacobsen AN, et al. **Am J Physiol** 1997 Sep;273(3 Pt 2):H1119–25

Relationships of the circadian rhythms of thrombotic, ischemic, hemorrhagic, and arrhythmic events to blood pressure rhythms. Manfredini R, et al. **Ann N Y Acad Sci** 1996 Aug 15;783:141–58 (183 ref.)

Molecular and cellular aspects of re–entrant arrhythmias.

Kleber AG, et al. **Basic Res Cardiol** 1997;92 Suppl 1:111–9 (31 ref.)

Pharmacokinetic–pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats. Ohtani H, et al. **Biol Pharm Bull** 1996 Sep; 19(9):1189–96

Heart rhythm in patients with neurofibromatosis type 1. Malmcrona R, et al. **Cardiology** 1996 Jul–Aug;87(4):300–2

Heart rate variability and its sympatho–vagal modulation. Lombardi F, et al. **Cardiovasc Res** 1996 Aug;32(2):208–16 (66 ref.)

Moratorium on mayhem lest there be a requiem. Weber KT. **Cardiovasc Res** 1997 Jul;35(1):4–5 (43 ref.)

Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias [see comments] Bubien RS, et al. **Circulation** 1996 Oct 1;94(7):1585–91. Comment in: Circulation 1996 Oct 1;94(7):1491–3.

Repolarization and the genesis of cardiac arrhythmias. Role of body surface mapping [editorial; comment] Fontaine G, et al. **Circulation** 1997 Jun 17;95(12):2600–2 (20 ref.). Comment on: Circulation 1997 Jun 17;95(12):2668–76.

Automatic external defibrillators for public access defibrillation: recommendations for specifying and reporting arrhythmia analysis algorithm performance, incorporating new waveforms, and enhancing safety. A statement for health professionals from the American Heart Association Task Force on Automatic External Defibrillation, Subcommittee on AED Safety and Efficacy. Kerber RE, et al. **Circulation** 1997 Mar 18;95(6):1677–82

Origin of respiratory sinus arrhythmia in conscious humans. An important role for arterial carotid baroreceptors. Piepoli M, et al. **Circulation** 1997 Apr 1;95(7):1813–21

Circadian variation in defibrillation energy requirements. Venditti FJ Jr, et al. **Circulation** 1996 Oct 1;94(7):1607–12

Heart rate variability in brain death. Freitas J, et al. **Clin Auton Res** 1996 Jun;6(3):141–6

Spectral characteristics of heart period variability during cold face stress and shock avoidance in normal subjects. Friedman BH, et al. **Clin Auton Res** 1996 Jun;6(3):147–52

Chronotropic incompetence—Part II: Clinical implications. Camm AJ, et al. **Clin Cardiol** 1996 Jun;19(6):503–8 (56 ref.)

Simulation of re-entry in a piece of myocardial tissue: strong sensitivity to spatial and temporal conditions. Wohlfart B, et al. **Clin Physiol** 1996 Jul;16(4):417–31

Exercise testing and training in patients with malignant arrhythmias. Pashkow FJ, et al. **Exerc Sport Sci Rev** 1997; 25:235–69 (128 ref.)

Prevalence of palpitations, cardiac arrhythmias and their associated risk factors in ambulant elderly. Lok NS, et al. **Int J Cardiol** 1996 Jun;54(3):231–6

Age related dilatation of the right ventricle in arrhythmogenic right ventricular dysplasia–cardiomyopathy. Peters S. **Int J Cardiol** 1996 Oct 11;56(2):163–7

Measuring cytosolic Ca2+ in cells with fluorescent probes: an aid to understanding cell pathophysiology. Hayes A, et al. **Int Rev Exp Pathol** 1996;36:197–212 (65 ref.)

Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart [see comments] Asano Y, et al. **J Am Coll Cardiol** 1997 Mar 15;29(4):831–42. Comment in: J Am Coll Cardiol 1997 Mar 15;29(4):843–5.

Electrophysiologic properties of the atrioventricular node in pediatric patients. Cohen MI, et al. **J Am Coll Cardiol** 1997 Feb;29(2):403–7

Electrocardiographic manifestations of dual atrioventricular node conduction during sinus rhythm. Fisch C, et al. **J Am Coll Cardiol** 1997 Apr;29(5):1015–22

Effect of high intensity drive train stimulation on dispersion of atrial refractoriness: role of autonomic nervous system. Yu WC, et al. **J Am Coll Cardiol** 1997 Apr;29(5):1000–6

The effects of hypokalemia on the heart. Dietz T, et al. **J Ark Med Soc** 1997 Jul;94(2):79–81

Heart rhythms, ventricular arrhythmias, and death in chronic heart failure [see comments] Ponikowski P, et al. **J Card Fail** 1996 Sep;2(3):177–83. Comment in: J Card Fail 1996 Sep;2(3):193–6.

Electrophysiological mechanisms for ventricular arrhythmias in patients with myocardial ischemia: anesthesiologic considerations, Part 1. Gallagher JD. **J Cardiothorac Vasc Anesth** 1997 Jun;11(4):495–505 (80 ref.)

Flecainide and the electrophysiologic matrix: the effects of flecainide acetate on the determinants of cardiac excitability in sheep Purkinje fibers. Arnsdorf MF, et al. **J Cardiovasc Electrophysiol** 1996 Dec;7(12):1172–82

Management of the patient with frequent discharges from implantable cardioverter defibrillator devices. Miller JM, et al. **J Cardiovasc Electrophysiol** 1996 Mar;7(3):278–85 (33 ref.)

An animal model of spontaneous arrhythmic death. Moïse NS, et al. **J Cardiovasc Electrophysiol** 1997 Jan;8(1):98–103

The signal-averaged electrocardiogram: update on clinical applications. Steinberg JS, et al. **J Cardiovasc Electrophysiol** 1996 Oct;7(10):972–88 (57 ref.)

Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice. Berul CI, et al. **J Clin Invest** 1997 Feb 15;99(4):570–6

Ambulatory patient-activated arrhythmia monitoring: comparison of a new wrist-applied monitor with a conventional precordial device. Kamalvand K, et al. **J Electrocardiol** 1997 Apr;30(2):127–31

Strategy for control of complex low-dimensional dynamics in cardiac tissue. Watanabe M, et al. **J Math Biol** 1996 Nov;35(1):73–87

Time course of the protection against ischaemia and reperfusion-induced ventricular arrhythmias resulting from brief periods of cardiac pacing. Kaszala K, et al. **J Mol Cell Cardiol** 1996 Oct;28(10):2085–95

Modulation of the electrophysiological effects of ischemia reperfusion by methylisobutyl amiloride. Ruiz Petrich E, et al. **J Mol Cell Cardiol** 1996 May;28(5):1129–41

Cardiac autonomic regulation during sleep in panic disorder [letter] Ferini-Strambi L, et al. **J Neurol Neurosurg Psychiatry** 1996 Oct;61(4):421–2

A model of myocardial ischemia for the simultaneous assessment of electrophysiological changes and arrhythmias in intact rabbits. Barrett TD, et al. **J Pharmacol Toxicol Methods** 1997 Feb;37(1):27–36

Tsutsugamushi myocarditis with congestive heart failure and persistent atrial standstill. Jeong MH, et al. **Jpn Circ J** 1996 Jun;60(6):382–8

Functions of cardiac ion channels under normal and pathological conditions. Hiraoka M, et al. **Jpn Heart J** 1996 Sep;37(5):693–707 (81 ref.)

Cardiac involvement in progressive muscular dystrophy of the Duchenne type. Ishikawa K. **Jpn Heart J** 1997 Mar; 38(2):163–80 (97 ref.)

Perpetual atrial arrhythmias causing a prolonged returning cycle as an expression of cardiac resonant oscillation. Izumi K, et al. **Mater Med Pol** 1996 Jan–Mar;28(1):20–8

Prostaglandins and the antiarrhythmic effect of preconditioning in the isolated rat heart. Arad M, et al. **Mol Cell Biochem** 1996 Jul–Aug;160–161:249–55

Cellular and pathophysiological mechanisms of ventricular arrhythmias in acute ischemia and infarction. Ehlert FA, et al. **Pacing Clin Electrophysiol** 1997 Apr;20(4 Pt 1):966–75 (77 ref.)

Value of heart rate variability parameters for prediction of serious arrhythmic events in patients with malignant ventricular arrhythmias. Filipecki A, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1852–6

Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination. Grant AO. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):432–44 (65 ref.)

Heart rate variability in myocardial infarction with and without malignant arrhythmias: comparison with heart transplant recipients and normal subjects. Rodrigues TR, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1857–62

Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: a major mechanism of structural heart disease arrhythmias. Spach MS, et al. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):397–413 (60 ref.)

The cardiac vulnerable period and reentrant arrhythmias: targets of anti- and proarrhythmic processes. Starmer CF. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):445–54 (43 ref.)

[Digoxin in chronic heart failure and sinus rhythm: is the end of the controversy in sight?] van Veldhuisen DJ, et al. **Ned Tijdschr Geneeskd** 1997 Mar 8;141(10):460–4 (39 ref.) (Eng. Abstr.) **(Dut)**

[Possible mechanisms of false positive results of averaged ECG] Brembilla-Perrot B, et al. **Ann Cardiol Angeiol (Paris)** 1997 Feb;46(2):69–75 (Eng. Abstr.) **(Fre)**

[Repolarization anomalies in postoperative ECG after aorto-coronary bypass] Rechtman D, et al. **Ann Cardiol Angeiol (Paris)** 1997 Feb;46(2):77–80 (Eng. Abstr.) **(Fre)**

[Physiology and pathophysiology of cardiac impulse conduction] Kléber AG, et al. **Z Kardiol** 1996;85 Suppl 6:25–33 (40 ref.) (Eng. Abstr.) **(Ger)**

[Cellular sequelae of myocardial ischemia] Richardt G, et al. **Z Kardiol** 1997;86 Suppl 1:23–32 (79 ref.) (Eng. Abstr.) **(Ger)**

[Thrombolysis & arrhythmias] Carù B, et al. **Cardiologia** 1995 Dec;40(12):921–6 (Eng. Abstr.) **(Ita)**

[The heart rate variability indices and the circadian rhythm of the hourly heart rate: 2 prognostic indicators of mortality and malignant ventricular arrhythmias in patients with a myocardial infarct] Curione M, et al. **Cardiologia** 1996 Dec; 41(12):1175–82 (Eng. Abstr.) **(Ita)**

[Relationship between late ventricular potentials and ventricular arrhythmias in patients in chronic dialysis treatment] Pomini G, et al. **Minerva Cardioangiol** 1997 Apr; 45(4):155–65 (Eng. Abstr.) **(Ita)**

[Cerebral hypoperfusion symptoms in elderly subjects with hyperkinetic and/or hypokinetic arrhythmia. Study of institutionalized and non- institutionalized patients] Rossi MG, et al. **Minerva Med** 1997 Jan–Feb;88(1–2):9–14 (Eng. Abstr.) **(Ita)**

[The treatment of the cardiac patient in dentistry and oromaxiliofacial surgery. I. The practical management of patients with arrhythmias] Chiarini L, et al. **Minerva Stomatol** 1997 Apr;46(4):175–82 (11 ref.) (Eng. Abstr.) **(Ita)**

[Atrial standstill] Hara M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):342–5 (15 ref.) **(Jpn)**

[Respiratory arrhythmia] Hayashi H. **Ryoikibetsu Shokogun Shirizu** 1996;(12):274–6 (20 ref.) **(Jpn)**

[Electric disturbance type of cardiomyopathy (ECM)] Inoue S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(14):203–5 (12 ref.) **(Jpn)**

[Arrhythmias in children with mitral valve prolapse syndrome] Nowak A, et al. **Pediatr Pol** 1996 Jun; 71(6):499–504 (Eng. Abstr.) **(Pol)**

[Opiatergic mechanisms of antiarrhythmic effect of adaptation] Lishmanov IuB, et al. **Biull Eksp Biol Med** 1996 Sep;122(9):276–8 **(Rus)**

[The role of cnetral and peripheral mu and delta opiate receptors in the realization of the anti-arrhythymic effect of adaptation] Lishmonov IuB, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):378–81 **(Rus)**

[The anti-arrhythmic effect of the mu-opiate receptor agonists in adrenal arrhythmia: the role of the autonomic nervous system] Maslov LN, et al. **Biull Eksp Biol Med** 1996 Jul;122(7):25–7 **(Rus)**

[The mechanism of the effect of laser irradiation on the development of ischemic heart arrhythmia during the stimulation of the sensorimotor cortex] Mikhaĭlova SD, et al. **Biull Eksp Biol Med** 1996 Oct;122(10):375–7 **(Rus)**

[The role of heart autonomic nerves in the mechanism of antiarrhythmic effect of beta-endorphin during experimental myocardial ischemia] Mikhaĭlova SD, et al. **Biull Eksp Biol Med** 1997 May;123(5):509–11 **(Rus)**

[The cardiohemodynamic characteristics of the action of obzidan in patients with an artificial pacemaker and ischemic heart disease with different types of blood circulation] Iskenderov BG, et al. **Eksp Klin Farmakol** 1996 Jul–Aug;59(4):21–4 (Eng. Abstr.) **(Rus)**

[The role of endogenous opioid peptides in the mechanisms of the antiarrhythmic effect of adaptation] Lishmanov IuB, et al. **Fiziol Zh Im I M Sechenova** 1996 May–Jun; 82(5–6):48–52 (Eng. Abstr.) **(Rus)**

[Immune and fibrinolytic system functions in the cardiac manifestations of atherosclerosis] Kamenev VF, et al. **Lik Sprava** 1997 Jan–Feb;(1):33–7 (Eng. Abstr.) **(Rus)**

[Late ventricular potentials, ventricular arrhythmias and sudden death in patients with acquired heart defects] Kubyshkin VF, et al. **Ter Arkh** 1996;68(4):45–7 (Eng. Abstr.) **(Rus)**

[Electrophysiologic and electrocardiographic aspects of the transplanted heart] Behulová R, et al. **Bratisl Lek Listy** 1997 May;98(5):248–52 (Eng. Abstr.) **(Slo)**

PREVENTION & CONTROL

The complications of thoracic surgery: prophylaxis and treatment of arrhythmias. Van Mieghem W. **Acta Cardiol** 1995;50(5):381–6 (11 ref.)

Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Wanless RS, et al. **Am Heart J** 1997 Apr;133(4):441–6

Chronobiology of acute myocardial infarction: cardiac arrhythmia suppression trial (CAST) experience. Peters RW, et al. **Am J Cardiol** 1996 Dec 1;78(11):1198–201

Dietary fish oil prevents reperfusion Ins(1,4,5)P3 release in rat heart: possible antiarrhythmic mechanism. Anderson KE, et al. **Am J Physiol** 1996 Oct;271(4 Pt 2):H1483–90

Beta blockade to prevent atrial dysrhythmias following coronary bypass surgery. Paull DL, et al. **Am J Surg** 1997 May;173(5):419–21

Antiarrhythmic action of rilmenidine on adrenaline-induced arrhythmia via central imidazoline receptors in halothane-anaesthetized dogs. Mammoto T, et al. **Br J Pharmacol** 1996 Apr;117(8):1744–8

Suppression of reperfusion-induced arrhythmias with combined administration of 5-HT2 and thromboxane A2 antagonists [published erratum appears in Br J Pharmacol 1997 Mar;120(6):1186] Shaw LA, et al. **Br J Pharmacol** 1996 Mar;117(5):817–22

Programmed ventricular stimulation after myocardial infarction does not help reduce the risk of ventricular events. Brembilla-Perrot B, et al. **Cardiovasc Drugs Ther** 1996 Nov;10(5):549–56

Prevention of ischemic rigor contracture during coronary occlusion by inhibition of Na(+)-H+ exchange. Garcia-Dorado D, et al. **Cardiovasc Res** 1997 Jul;35(1):80–9

The beneficial effects of atrial natriuretic peptide on arrhythmias and myocardial high-energy phosphates after reperfusion. Takata Y, et al. **Cardiovasc Res** 1996 Aug; 32(2):286–93

17 beta-Estradiol prevents dysfunction of canine coronary endothelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion. Kim YD, et al. **Circulation** 1996 Dec 1;94(11):2901–8

Dietary n-3 fatty acids in the prevention of lethal cardiac arrhythmias. Leaf A, et al. **Curr Opin Lipidol** 1997 Feb; 8(1):4–6 (20 ref.)

Protective effects of acidic fibroblast growth factor against cardiac arrhythmias induced by ischemia and reperfusion in rats. Cuevas P, et al. **Eur J Med Res** 1997 Jan;2(1):33–6

Protective effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes. Kang JX, et al. **Eur J Pharmacol** 1996 Feb 15;297(1–2):97–106

The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction. Papadopoulos CL, et al. **Int J Cardiol** 1996 Jul 26;55(2):137–42

Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty. Airaksinen KE, et al. **J Am Coll Cardiol** 1997 Apr;29(5):1035–8

Protection against reperfusion-induced arrhythmias by human thioredoxin. Aota M, et al. **J Cardiovasc Pharmacol** 1996 May;27(5):727–32

Prevention of reoxygenation-induced arrhythmias in guinea pig papillary muscles. Hayashi H, et al. **J Cardiovasc Pharmacol** 1996 Jun;27(6):816–23

Prevention of cardiac arrhythmia by dietary (n-3) polyunsaturated fatty acids and their mechanism of action. Nair SS, et al. **J Nutr** 1997 Mar;127(3):383–93 (93 ref.)

Extracellular Mg++ manipulation prevents the proarrhythmic activity of cromakalim in ischemic/reperfused diabetic hearts. Tosaki A, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):309–17

Adenosine mediates the antiarrhythmic effect of ischemic preconditioning in isolated rat hearts. Miyatake Y, et al. **Jpn Circ J** 1996 Jun;60(6):341–8

Effect of a new model of hemodialysis potassium removal on the control of ventricular arrhythmias. Redaelli B, et al. **Kidney Int** 1996 Aug;50(2):609–17

Magnesium: effects on reperfusion arrhythmias and membrane potential in isolated rat hearts. Ponce Zumino A, et al. **Mol Cell Biochem** 1997 Jun;171(1–2):85–93

Inhibition of centrally induced ventricular arrhythmias by rilmenidine and idazoxan in rabbits. Roegel JC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1996 Nov; 354(5):598–605

Evaluation of a new sensor-based algorithm to protect against atrial arrhythmias. Delay M, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1704–7

Clinical strategies for use of the implantable cardioverter defibrillator: the impact of current trials [editorial] Estes NA 3rd. **Pacing Clin Electrophysiol** 1996 Jul;19(7):1011–5 (33 ref.)

Ventricular protection against atrial arrhythmias in DDD pacing based on a statistical approach: clinical results. Gencel L, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1729–33

Effect of thoracic epidural anesthesia on spontaneous postinfarction ventricular dysrhythmia in awake dogs. Hogan QH, et al. **Reg Anesth** 1997 Jul–Aug;22(4):318–24

[Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study] Lardoux H, et al. **Ann Cardiol Angeiol (Paris)** 1996 Oct;45(8):469–79 (Eng. Abstr.) **(Fre)**

[Intravenous magnesium in acute myocardial infarct] Urek R, et al. **Lijec Vjesn** 1996 Nov–Dec;118(11–12):279–81 (Eng. Abstr.) **(Scr)**

[The effect of piperazine analogs of aryloxyaminopropanol (IIIq and IIIb) on the occurrence of reperfusion dysrhythmias in an in vivo experiment on rats] Jadroňová O, et al. **Ceska Slov Farm** 1996 Nov;45(6):292–5 (Eng. Abstr.) **(Slo)**

PSYCHOLOGY

Psychological factors and survival in the cardiac arrhythmia suppression trial (CAST): a reexamination. Thomas SA, et al. **Am J Crit Care** 1997 Mar;6(2):116–26

Mood disturbance in patients with recurrent ventricular dysrhythmia before insertion of implantable cardioverter defibrillator. Dunbar SB, et al. **Heart Lung** 1996 Jul–Aug; 25(4):253–61

RADIONUCLIDE IMAGING

Prediction of outcome of patients with life-threatening ventricular arrhythmias treated with automatic implantable cardioverter-defibrillators using SPECT perfusion imaging. Gioia G, et al. **Circulation** 1997 Jan 21;95(2):390–4

REHABILITATION

Exercise testing and training of patients with malignant ventricular arrhythmias. Kelly TM. **Med Sci Sports Exerc** 1996 Jan;28(1):53–61 (34 ref.)

[Central hemodynamic function and the correction of heart rhythm disorders at the rehabilitation stage in IHD patients] Sidorova LD, et al. **Ter Arkh** 1996;68(8):15–9 (Eng. Abstr.) **(Rus)**

SURGERY

Pretreatment with aspirin and ticlopidine confers lower thrombogenic potential of radiofrequency catheter ablation. Manolis AS, et al. **Am J Cardiol** 1997 Feb 15;79(4):494–7

Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias [see comments] Bubien RS, et al. **Circulation** 1996 Oct 1;94(7):1585–91. Comment in: Circulation 1996 Oct 1;94(7):1491–3.

Prediction of outcome of patients with life-threatening ventricular arrhythmias treated with automatic implantable cardioverter-defibrillators using SPECT perfusion imaging. Gioia G, et al. **Circulation** 1997 Jan 21;95(2):390–4

Arrhythmia surgery. Ferguson TB Jr, et al. **Coron Artery Dis** 1996 Jan;7(1):36–44 (30 ref.)

Use of troponin-T concentration and kinase isoforms for quantitation of myocardial injury induced by radiofrequency catheter ablation. Katritsis D, et al. **Eur Heart J** 1997 Jun;18(6):1007–13

Temperature monitoring during radiofrequency ablation. Dinerman JL, et al. **J Cardiovasc Electrophysiol** 1996 Feb; 7(2):163–73 (23 ref.)

Use of the His/RVA electrode catheter in children. Dick M 2nd, et al. **J Electrocardiol** 1996;29 Suppl:227–33

Radiofrequency ablation of cardiac arrhythmia: the first fifty cases experience in Siriraj Hospital. Bhuripanyo K, et al. **J Med Assoc Thai** 1996 Jul;79(7):448–53

Microwave catheter ablation of the atrioventricular junction in closed-chest dogs. Lin JC, et al. **Med Biol Eng Comput** 1996 Jul;34(4):295–8

Acute effects of radiofrequency ablation of atrial arrhythmias on implanted permanent pacing systems. Ellenbogen KA, et al. **Pacing Clin Electrophysiol** 1996 Sep;19(9):1287–95

Arrhythmia surgery: then and now. Lowe JE. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 2):585–99 (20 ref.)

A new contact probe for intraoperative laser ablation. Ohtake H, et al. **Pacing Clin Electrophysiol** 1996 Dec;19(12 Pt 1):2060–5

Initial and long-term evaluation of escape rhythm after radiofrequency ablation of the AV junction in 50 patients. Piot O, et al. **Pacing Clin Electrophysiol** 1996 Nov;19(11 Pt 2):1988–92

Incidence of femoral vein occlusion after catheter ablation in children: evaluation with magnetic resonance angiography. Miga DE, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):204–7

[Complications of radiofrequency ablation: A French experience. Le Groupe de Rythmologie de la Société Francaise de Cardiologie] **Arch Mal Coeur Vaiss** 1996 Dec; 89(12):1599–605 (30 ref.) (Eng. Abstr.) **(Fre)**

[Radiofrequency ablation of accessory atrioventricular pathways] Sebag C, et al. **Arch Mal Coeur Vaiss** 1997 Apr; 90 Spec No 1:11–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[The physical and chemical principles of radiofrequency catheter ablation in arrhythmias] Stabile G, et al. **Cardiologia** 1996 Nov;41(11):1053–9 (44 ref.) **(Ita)**

[Catheter ablation therapy for cardiac arrhythmias] Ino T. **Nippon Ika Daigaku Zasshi** 1997 Jun;64(3):268–71 **(Jpn)**

[Surgical treatment for arrhythmias] Kosakai Y. **Nippon Rinsho** 1996 Aug;54(8):2165–70 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Studies on intraoperative cardiac mapping] Watanabe S, et al. **Rinsho Kyobu Geka** 1989 Jun;9(3):229–37 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Nonpharmacologic treatment of heart arrhythmia--methods] Koźluk E, et al. **Pol Tyg Lek** 1996 Mar;51(10–13):163–5 (21 ref.) **(Pol)**

[Nonpharmacologic treatment for heart arrhythmia] Walczak F, et al. **Pol Tyg Lek** 1996 Mar;51(10–13):159–62 (23 ref.) (Eng. Abstr.) **(Pol)**

[Radiofrequency ablation of the sustained ventricular tachycardia in patients with structural heart disease] de Paola AA, et al. **Arq Bras Cardiol** 1996 Mar;66 Suppl 1:51–8 (52 ref.) **(Por)**

[One thousand consecutive radiofrequency ablation procedures. Indications, results, and complications] Brugada J, et al. **Rev Esp Cardiol** 1996 Nov;49(11):810–4 (Eng. Abstr.) **(Spa)**

THERAPY

The implantable defibrillator. From concept to clinical reality. Jordaens L. **Adv Cardiol** 1996;38:1–168 (398 ref.)

Are implantable cardioverter-defibrillators or drugs more effective in prolonging life? The Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial Executive Committee [editorial] [see comments] **Am J Cardiol** 1997 Mar 1;79(5):661–3. Comment in: Am J Cardiol 1997 Jul 15;80(2):194–7.

Mortality benefit of implantable cardioverter-defibrillator therapy in patients with persistent malignant ventricular arrhythmias despite amiodarone treatment. Barron HV, et al. **Am J Cardiol** 1997 May 1;79(9):1180–4

Influence of patient characteristics in the selection of patients for defibrillator implantation (the AVID Registry). Antiarrhythmics Versus Implantable Defibrillators. Curtis AB, et al. **Am J Cardiol** 1997 May 1;79(9):1185–9

Clinical and socioeconomic profile of patients with malignant ventricular arrhythmias in 1993 to 1995. AVID investigators. Antiarrhythmics Versus Implantable Defibrillator. Domanski MJ, et al. **Am J Cardiol** 1997 Aug 1;80(3):299–301

Clinical predictors of transvenous biphasic defibrillation thresholds. Gold MR, et al. **Am J Cardiol** 1997 Jun 15; 79(12):1623–7

Which device should "MADIT protocol" patients receive? Multicenter Automatic Defibrillator Implantation Trial. Higgins SL, et al. **Am J Cardiol** 1997 Mar 20;79(6A):31–5

The AVID trial: evidence based or randomized control trials--is the AVID study too late? Antiarrhythmics Versus Implantable Defibrillators [editorial; comment] Josephson ME, et al. **Am J Cardiol** 1997 Jul 15;80(2):194–7. Comment on: Am J Cardiol 1997 Mar 1;79(5):661–3.

Mortality trials with implantable defibrillators [editorial] Nisam S, et al. **Am J Cardiol** 1997 Feb 15;79(4):468–71

Do MADIT results apply only to "MADIT patients"? Multicenter Automatic Defibrillator Implantation Trial. Nisam S. **Am J Cardiol** 1997 Mar 20;79(6A):27–30

Myocardial injury after electrical therapy for cardiac arrhythmias assessed by troponin-T release. Runsiö M, et al. **Am J Cardiol** 1997 May 1;79(9):1241–5

Perioperative cardiac dysrhythmias: diagnosis and management. Atlee JL. **Anesthesiology** 1997 Jun; 86(6):1397–424 (290 ref.)

Automatic external defibrillators for public access defibrillation: recommendations for specifying and reporting arrhythmia analysis algorithm performance, incorporating new waveforms, and enhancing safety. A statement for health professionals from the American Heart Association Task Force on Automatic External Defibrillation, Subcommittee on AED and Efficacy. **Biomed Instrum Technol** 1997 May–Jun;31(3):238–44

Emergency arrhythmia management: an assessment of learning needs. Morris BA, et al. **Can J Cardiol** 1997 Mar; 13 Suppl A:7A–11A

NHLBI stops arrhythmia study: implantable cardiac defibrillators reduce deaths [news] **Circulation** 1997 Jun 3; 95(11):2465

Influence of the implantable cardioverter-defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation [letter; comment] Sanmartín Fernández M, et al. **Circulation** 1997 Mar 18;95(6):1666. Comment on: Circulation 1995 Dec 1;92(11):3273–81.

Influence of implantable cardioverter-defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation [letter; comment] Stäblein A, et al. **Circulation** 1997 Mar 18;95(6):1666–7. Comment on: Circulation 1995 Dec 1;92(11):3273–81.

Probability of successful defibrillation at multiples of the defibrillation energy requirement in patients with an implantable defibrillator. Strickberger SA, et al. **Circulation** 1997 Aug 19;96(4):1217–23

Cardiac electrophysiology: a cost-effective approach. DiMarco JP. **Clin Cardiol** 1996 Jul;19(7):575–8

Successful treatment of severe dysrhythmias in infants with respiratory syncytial virus infections: two cases and a literature review. Thomas JA, et al. **Crit Care Med** 1997 May;25(5):880–6 (44 ref.)

Health care reform: effects on electrophysiology and pacing. Naccarelli GV. **Curr Opin Cardiol** 1997 Jan;12(1):1–2

Initial experience with dual-sensor rate-responsive pacemakers in children [see comments] Celiker A, et al. **Eur Heart J** 1996 Aug;17(8):1251–5. Comment in: Eur Heart J 1996 Aug;17(8):1136–7.

Dual sensor pacing technology [editorial; comment] Sutton R. **Eur Heart J** 1996 Aug;17(8):1136–7. Comment on: Eur Heart J 1996 Aug;17(8):1251–5.

Combined use of non-thoracotomy cardioverter defibrillators and endocardial pacemakers. Noguera HH, et al. **Heart** 1997 Jul;78(1):50–5

High incidence of appropriate implantable cardioverter-defibrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias. Link MS, et al. **J Am Coll Cardiol** 1997 Feb;29(2):370–5

Efficacy of the implantable cardioverter-defibrillator in the elderly. Panotopoulos PT, et al. **J Am Coll Cardiol** 1997 Mar 1;29(3):556–60

Management of perioperative arrhythmias. Feeley TW. **J Cardiothorac Vasc Anesth** 1997 Apr;11(2 Suppl 1):10–5; discussion 24–5 (36 ref.)

Management of the patient with frequent discharges from implantable cardioverter defibrillator devices. Miller JM, et al. **J Cardiovasc Electrophysiol** 1996 Mar;7(3):278–85 (33 ref.)

Driving with an internal defibrillator: legal, ethical, and quality-of-life issues. Finch NJ, et al. **J Cardiovasc Nurs** 1997 Jan;11(2):58–67

Two biophysical mechanisms of defibrillation of cardiac tissue. Pumir A, et al. **J Theor Biol** 1997 Mar 21; 185(2):189–99

Referral of patients with myocardial infarction and low ejection fraction to arrhythmia specialists [letter; comment] Goff DC Jr. **JAMA** 1996 Nov 27;276(20):1634–5. Comment on: JAMA 1996 Aug 14;276(6):481–5.

Randomised trial of temporary cardiac pacing with semirigid and balloon-flotation electrode catheters [letter] Ferguson JD, et al. **Lancet** 1997 Jun 28;349(9069):1883

Overview of implantable cardioverter-defibrillator in reducing total mortality in the high-risk coronary patient. Mower MM. **Md Med J** 1997 Feb;46(2):75–8 (35 ref.)

Resuscitation following arrhythmia in patients undergoing pharmacological/exercise stress for myocardial perfusion imaging [editorial] Prvulovich E. **Nucl Med Commun** 1996 Dec;17(12):1003–5 (11 ref.)

Management of fetal cardiac arrhythmias. Copel JA, et al. **Obstet Gynecol Clin North Am** 1997 Mar;24(1):201–11 (34 ref.)

Transient entrainment: the evolution of a medical concept from description to prescription. Cooper MW. **Pacing Clin Electrophysiol** 1996 Aug;19(8):1162–76

Implantable cardioverter defibrillator (ICD) is becoming more accepted in the treatment of cardiac arrhythmias [letter] Pirzada FA. **Pacing Clin Electrophysiol** 1997 Jan; 20(1 Pt 1):140–1

Should unipolar pacemaker leads be banned? Lessons from pacemaker/implantable cardioverter defibrillator interactions [editorial] [see comments] Weiss DN, et al. **Pacing Clin Electrophysiol** 1997 Feb;20(2 Pt 1):237–9. Comment in: Pacing Clin Electrophysiol 1997 Jun;20(6):1744; discussion 1747–8. Comment in: Pacing Clin Electrophysiol 1997 Jun;20(6):1744–5; discussion 1747–8. Comment in: Pacing Clin Electrophysiol 1997 Jun;20(6):1745–7; discussion 1747–8.

Defibs: a GP guide to ICDs. Holdright DR. **Practitioner** 1996 Sep;240(1566):538–42 (5 ref.)

Presentation and explanation of medical decision models

using the World Wide Web. Sanders GD, et al. **Proc AMIA Annu Fall Symp** 1996;:60–4

[Management of arrhythmias: current trends] Schoenfeld P. **Rev Med Brux** 1996 Oct;17(5):331–6 (Eng. Abstr.) **(Fre)**

[Pacemaker cardiac stimulation (editorial)] Evéquoz D. **Schweiz Rundsch Med Prax** 1996 Oct 29;85(44):1392–3 **(Fre)**

[When–which pacemaker?] Fischer W. **Herz** 1996 Dec; 21(6):407–9 **(Ger)**

[Changes in therapy of cardiac arrhythmias (editorial)] Lüderitz B. **Med Klin** 1997 Apr 15;92(4):191 **(Ger)**

[Modification of the detection and stimulation behavior of active and passive fixed bipolar pacemaker electrodes by depot dexamethasone] Burkhardt D, et al. **Z Kardiol** 1997 Jul;86(7):530–7 (Eng. Abstr.) **(Ger)**

[The electrotherapy of the arrhythmias in 3 cases of myotonic dystrophy (Steinert's disease)] Gardini A, et al. **Cardiologia** 1996 Dec;41(12):1209–14 (24 ref.) (Eng. Abstr.) **(Ita)**

[What information is given by controlled clinical trials (pharmacological and nonpharmacological) for anti–arrhythmia therapy in the prevention of sudden death?] Naccarella F, et al. **G Ital Cardiol** 1996 Nov; 26(11):1345–64 (154 ref.) **(Ita)**

[Treatment of ventricular arrhythmia associated with heart failure] Kasakinu H. **Nippon Naika Gakkai Zasshi** 1994 Jan 10;83(1):80–7 (5 ref.) **(Jpn)**

[Implantable cardioverter defibrillator] Kasanuki H. **Nippon Rinsho** 1996 Aug;54(8):2150–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Management of permanent pacemaker implantation in elderly patients] Satani O, et al. **Nippon Ronen Igakkai Zasshi** 1997 Feb;34(2):110–3 (Eng. Abstr.) **(Jpn)**

[Treatment of arrhythmia in pregnant women (editorial)] Halawa B. **Pol Tyg Lek** 1996 Mar;51(10–13):131–4 **(Pol)**

[Arrhythmogenic dysplasia of the right heart ventricle] Kalarus Z, et al. **Przegl Lek** 1997;54(1):43–5 (18 ref.) (Eng. Abstr.) **(Pol)**

[Intermittent chronotropic incompetence: an indication for permanent pacemaker? Report of a clinical case] Dionísio P, et al. **Rev Port Cardiol** 1997 Mar;16(3):317–21 **(Por)**

[The diagnosis and elimination of disorders in cardiac electrostimulation in patients with an artificial pacemaker] Iskenderov BG, et al. **Ter Arkh** 1997;69(4):37–40 (Eng. Abstr.) **(Rus)**

[The effect of exposure to magnetics and lasers on the clinical status and the electrophysiological indices of the heart in patients with cardiac arrhythmias] Budnar' LN, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Mar–Apr;(2):5–8 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Sonographic assessment of fetal arrhythmias. Brown DL. **AJR Am J Roentgenol** 1997 Oct;169(4):1029–33

Outcome of fetuses with heart disease diagnosed in utero. Eronen M. **Arch Dis Child Fetal Neonatal Ed** 1997 Jul; 77(1):F41–6

QT interval in cardiac amyloidosis [see comments] Parthenakis FI, et al. **Clin Cardiol** 1996 Jan;19(1):51–4. Comment in: Clin Cardiol 1996 May;19(5):A22, 442.

The significance of echogenic foci in the fetal heart: a prospective study of 228 cases. Simpson JM, et al. **Ultrasound Obstet Gynecol** 1996 Oct;8(4):225–8

[Management of hemodynamically significant fetal arrhythmias] Hajdú J, et al. **Orv Hetil** 1997 Sep 14; 138(37):2335–8 (Eng. Abstr.) **(Hun)**

[Fetal arrhythmia] Hirose O. **Ryoikibetsu Shokogun Shirizu** 1996;(12):370–2 (16 ref.) **(Jpn)**

VETERINARY

The arrhythmogenic dose of epinephrine in halothane and isoflurane anesthetized dogs: an assessment of repeatability. Pettifer G, et al. **Can J Vet Res** 1997 Jul;61(3):221–6

An evaluation of the influence of medetomidine hydrochloride and atipamezole hydrochloride on the arrhythmogenic dose of epinephrine in dogs during halothane anesthesia. Pettifer GR, et al. **Can J Vet Res** 1996 Jan;60(1):1–6

Decreased density of Ito in left ventricular myocytes from German shepherd dogs with inherited arrhythmias [see comments] Freeman LC, et al. **J Cardiovasc Electrophysiol** 1997 Aug;8(8):872–83. Comment in: J Cardiovasc Electrophysiol 1997 Aug;8(8):884–6.

Cellular electrophysiology, heterogeneity, and arrhythmias [editorial; comment] Myerburg RJ, et al. **J Cardiovasc Electrophysiol** 1997 Aug;8(8):884–6. Comment on: J Cardiovasc Electrophysiol 1997 Aug;8(8):872–83.

Resolution of dysrhythmias and conduction abnormalities following treatment for bacterial endocarditis in a dog. Boswood A. **J Small Anim Pract** 1996 Jul;37(7):327–32

Electrocardiographic observation on spontaneously occurring arrhythmias in chickens. Mukai S, et al. **J Vet Med Sci** 1996 Oct;58(10):953–61

ARRHYTHMIA, SINUS

[Treatment and prognosis of tachyarrhythmia after atrial surgical repair of transposition of great vessels] Villain E, et al. **Arch Mal Coeur Vaiss** 1996 Jul;89(7):851–6 (Eng. Abstr.) **(Fre)**

[Sinus arrhythmia] Nishikado A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(12):399–401 (8 ref.) **(Jpn)**

CHEMICALLY INDUCED

Vegetative function diagnosis for early detection of lead intoxication. Pfister E, et al. **Int Arch Occup Environ Health** 1996;69(1):14–20

COMPLICATIONS

Respiratory sinus arrhythmia in patients with Prader–Willi syndrome. DiMario FJ Jr, et al. **J Child Neurol** 1996 Mar; 11(2):121–5

Tonic convulsion associated with sinus arrest due to hyperkalemia in a chronic hemodialysis patient [letter] Sakemi T, et al. **Nephron** 1996;73(2):370–1

[Predictive factors of thromboembolic complications in mitral stenosis in sinus rythm] Khatouri A, et al. **Ann Cardiol Angeiol (Paris)** 1996 Dec;45(10):573–6 (Eng. Abstr.) **(Fre)**

CONGENITAL

Association of fetal junctional rhythm and respiratory arrhythmia detected by magnetocardiography. Wakai RT, et al. **Pediatr Cardiol** 1997 May–Jun;18(3):201–3

DIAGNOSIS

Vegetative function diagnosis for early detection of lead intoxication. Pfister E, et al. **Int Arch Occup Environ Health** 1996;69(1):14–20

Prognostic value of Holter monitoring in asymptomatic elderly subjects with sinus rhythm. Gheno G, et al. **J Electrocardiol** 1996 Jan;29(1):39–44

DRUG THERAPY

[The effects of chronic beta–blocker administration on respiratory sinus arrhythmia] Pitzalis MV, et al. **Cardiologia** 1997 Feb;42(2):201–4 (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

[Incidence of atrial arrhythmia in patients with long term dual–chamber pacemakers. Contribution of the Holter function of pacemakers] Garrigue S, et al. **Arch Mal Coeur Vaiss** 1996 Jul;89(7):873–81 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Severe paroxysmal sinus bradycardia associated with high–frequency oscillatory ventilation. Mellema JD, et al. **Chest** 1997 Jul;112(1):181–5

GENETICS

Heritability of respiratory sinus arrhythmia: dependency on task and respiration rate. Snieder H, et al. **Psychophysiology** 1997 May;34(3):317–28

METABOLISM

Heart rate variability, respiratory sinus arrhythmia, and mathematical modeling of acetylcholine pharmacokinetics/pharmacodynamics in sinus node neuroeffector junctions [letter] Dexter F. **Anesth Analg** 1997 Jun;84(6):1393

PHYSIOPATHOLOGY

Cardiac rhythm effects of .125–Hz paced breathing through a resistive load: implications for paced breathing therapy and the polyvagal theory. Sargunaraj D, et al. **Biofeedback Self Regul** 1996 Jun;21(2):131–47

Vagal regulation of heart rate in the prediction of developmental outcome for very low birth weight preterm infants. Doussard–Roosevelt JA, et al. **Child Dev** 1997 Apr; 68(2):173–86

The effect of exposure to increased hydrostatic pressure up to 46 ATA on respiratory sinus arrhythmia in humans. Byrne DE, et al. **Exp Physiol** 1996 May;81(3):465–74

A between–subjects comparison of respiratory sinus arrhythmia and baroreceptor cardiac reflex sensitivity as non–invasive measures of tonic parasympathetic cardiac control. del Paso GA, et al. **Int J Psychophysiol** 1996 Jun–Jul;22(3):163–71

Cardiorespiratory interactions during fixed–pace resistive breathing. Blaber AP, et al. **J Appl Physiol** 1996 May; 80(5):1618–26

Irregular sinus parasystole due to intermittency and modulation of parasystolic activity. Satullo G, et al. **J Cardiovasc Electrophysiol** 1996 Mar;7(3):259–62

Respiratory sinus arrhythmia in children with severe cyanotic breath–holding spells. DiMario FJ Jr, et al. **J Child Neurol** 1997 Jun;12(4):260–2

Halothane and cardiac autonomic control in infants: assessment with quantitative respiratory sinus arrhythmia. Oberlander TF, et al. **Pediatr Res** 1996 Nov;40(5):710–7

Respiratory sinus arrhythmia in blood phobic subjects. Angrilli A, et al. **Percept Mot Skills** 1997 Apr;84(2):505–6

Baseline respiratory sinus arrhythmia and heart–rate responses during auditory stimulation of children with attention–deficit hyperactivity disorder. Shibagaki M, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):967–75

Inferential and descriptive influences on measures of respiratory sinus arrhythmia: sampling rate, R–wave trigger accuracy, and variance estimates. Riniolo T, et al. **Psychophysiology** 1997 Sep;34(5):613–21

[Determination of respiratory frequency from respiratory sinus arrhythmia] Bettermann H, et al. **Biomed Tech (Berl)** 1996 Nov;41(11):319–23 (Eng. Abstr.) **(Ger)**

[Sleep structure in relation to respiration and heart rate in children in puberty] Unbehaun A, et al. **Wien Med Wochenschr** 1996;146(13–14):329–31 (Eng. Abstr.) **(Ger)**

[The effect of neurotensin and adrenaline on sinus arrhythmia during firing stimulation of the vagus nerve] Osadchii OE, et al. **Biull Eksp Biol Med** 1997 May;123(5):494–7 **(Rus)**

THERAPY

Impact of continuous quality improvement on selection of pacing mode and rate of complications in permanent pacing. Møller JE, et al. **Heart** 1997 Apr;77(4):357–62

VDD pacing with single lead in a heart transplant recipient: case report. Sanmartin Fernández M, et al. **Pacing Clin Electrophysiol** 1996 Oct;19(10):1522–3

VETERINARY

ECG of the month. Sinus arrhythmia with occasional premature atrial complexes. Abbott JA. **J Am Vet Med Assoc** 1997 Apr 1;210(7):900–1

ARSENAMIDE

PHARMACOLOGY

Effect of arsenical drugs on in vitro vascular responses of pulmonary artery from heartworm–infected dogs. Maksimowich DS, et al. **Am J Vet Res** 1997 Apr; 58(4):389–93

Thiacetarsamide depresses relaxation of canine pulmonary artery in vitro. Maksimowich DS, et al. **Vet Parasitol** 1996 Sep 2;64(3):251–6

ARSENATES

CHEMISTRY

Endolymph volume changes during osmotic dehydration measured by two marker techniques. Salt AN, et al. **Hear Res** 1995 Oct;90(1–2):12–23

METABOLISM

Wood preservative leachates from docks in an estuarine environment. Wendt PH, et al. **Arch Environ Contam Toxicol** 1996 Jul;31(1):24–37

Chrysiogenes arsenatis gen. nov., sp. nov., a new arsenate–respiring bacterium isolated from gold mine wastewater. Macy JM, et al. **Int J Syst Bacteriol** 1996 Oct; 46(4):1153–7

PHARMACOKINETICS

Molecular evolution of an arsenate detoxification pathway by DNA shuffling [see comments] Crameri A, et al. **Nat Biotechnol** 1997 May;15(5):436–8. Comment in: Nat Biotechnol 1997 May;15(5):393.

PHARMACOLOGY

The mitochondrial membrane permeability transition induced by inorganic phosphate or inorganic arsenate. A comparative study. Bravo C, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1997 May; 117(1):93–9

Effect of arsenic (V) on the antioxidant defense system: in vitro oxidation of rat plasma lipoprotein. Schinella GR, et al. **Pharmacol Toxicol** 1996 Dec;79(6):293–6

Arsenate resistance as a possible marker in the differentiation of environmental and clinical isolates of Vibrio parahaemolyticus. Chauhan BS, et al. **Zentralbl Bakteriol** 1997 Apr;285(4):486–90

[Activation of endogenous nucleases as affected by sodium arsenate and cisplatin] Maksimovich MB, et al. **Antibiot Khimioter** 1996;41(7–8):18–21 (Eng. Abstr.) **(Rus)**

STANDARDS

Wormy wood? [news] **Environ Health Perspect** 1997 Jul; 105(7):692–3

TOXICITY

Wormy wood? [news] **Environ Health Perspect** 1997 Jul; 105(7):692–3

Basal metabolism of intraperitoneally injected carrier–free 74As–labeled arsenate in rabbits. Kimpe JD, et al. **Fundam Appl Toxicol** 1996 Dec;34(2):240–8

Involvement of calcium–dependent protein kinase C in arsenite–induced genotoxicity in Chinese hamster ovary cells. Liu YC, et al. **J Cell Biochem** 1997 Mar 1;64(3):423–33

Subchronic dispositional and toxicological effects of arsenate administered in drinking water to mice. Hughes MF, et

al. **J Toxicol Environ Health** 1996 Oct 11;49(2):177–96
Arsenate suppression of human keratinocyte programming. Kachinskas DJ, et al. **Mutat Res** 1997 Jun;386(3):253–61
Arsenic-induced neural tube defects in mice: alterations in cell cycle gene expression. Wlodarczyk BJ, et al. **Reprod Toxicol** 1996 Nov–Dec;10(6):447–54

URINE

Influence of dietary selenium on the disposition of arsenate in the female B6C3F1 mouse. Kenyon EM, et al. **J Toxicol Environ Health** 1997 Jun 27;51(3):279–99

ARSENIC

Arsenic: a paradoxical human carcinogen. Jager JW, et al. **Mutat Res** 1997 Jun;386(3):181–4 (0 ref.)

ADMINISTRATION & DOSAGE

Estimation of dietary intake of arsenic in the general population of the Republic of Croatia. Sapunar-Postružnik J, et al. **Sci Total Environ** 1996 Nov 18;191(1–2):119–23

ADVERSE EFFECTS

Lipid profile and peripheral vascular disease in arseniasis-hyperendemic villages in Taiwan. Tseng CH, et al. **Angiology** 1997 Apr;48(4):321–35
Clinicopathological features of bladder cancer associated with chronic exposure to arsenic. Chow NH, et al. **Br J Cancer** 1997;75(11):1708–10
Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Hsueh YM, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Aug;6(8):589–96
Hypersensitivity to mitomycin C-induced sister chromatid exchange as a biomarker of past exposure to arsenic. Liou SH, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Feb; 5(2):103–7
Micronuclei in exfoliated bladder cells among individuals chronically exposed to arsenic in drinking water. Moore LE, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Jan; 6(1):31–6
Bowen's disease and arsenism from tobacco smoke: an association? Person JR. **Cutis** 1996 Jul;58(1):65–6 (17 ref.)
Arsenic and bladder cancer mortality [letter; comment] Brown KG, et al. **Epidemiology** 1996 Sep;7(5):557–8. Comment on: Epidemiology 1996 Mar;7(2):117–24.
Arsenic in drinking water and incidence of urinary cancers. Guo HR, et al. **Epidemiology** 1997 Sep;8(5):545–50
p53 expression and proliferative activity in Bowen's disease with or without chronic arsenic exposure. Kuo TT, et al. **Hum Pathol** 1997 Jul;28(7):786–90
Carcinogenic risks of inorganic arsenic in perspective. Byrd DM, et al. **Int Arch Occup Environ Health** 1996; 68(6):484–94
The inhibitory effect of UVB irradiation on the expression of p53 and Ki-67 proteins in arsenic-induced Bowen's disease. Chai CY, et al. **J Cutan Pathol** 1997 Jan;24(1):8–13
Cancer risk in an arsenic-contaminated area of Chile. Rivara MI, et al. **Toxicol Ind Health** 1997 Mar–Jun;13(2–3):321–38
Health effects of ingesting arsenic-contaminated groundwater [see comments] Haupert TA, et al. **Wis Med J** 1996 Feb;95(2):100–4. Comment in: Wis Med J 1996 Feb;95(2):99.
[Bronchopulmonary cancer in workers exposed to arsenic: a case control study] Ferreccio C, et al. **Rev Med Chil** 1996 Jan;124(1):119–23 (Eng. Abstr.) **(Spa)**

ANALYSIS

Slurry sampling for hydride generation atomic absorption spectrometric determination of arsenic in cigarette tobaccos. Mierzwa J, et al. **Analyst** 1997 Jun;122(6):539–42
Rock-shells (Thais clavigera) as an indicator of As, Cu, and Zn contamination on the Putai Coast of the black-foot disease area in Taiwan. Han BC, et al. **Arch Environ Contam Toxicol** 1997 May;32(4):456–61
Arsenic residues in eggs from laying hens fed with a diet containing arsenic (III) oxide. Holcman A, et al. **Arch Environ Contam Toxicol** 1997 May;32(4):407–10
Arsenic content in hair of people exposed to natural arsenic polluted groundwater at Zimapán, México. Armienta MA, et al. **Bull Environ Contam Toxicol** 1997 Oct;59(4):583–9
Contamination of soil with copper, chromium, and arsenic under decks built from pressure treated wood. Stilwell DE, et al. **Bull Environ Contam Toxicol** 1997 Jan;58(1):22–9
Toenail samples as an indicator of drinking water arsenic exposure. Karagas MR, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Oct;5(10):849–52
Model of multiple exposure to contaminants in monitoring the environmental impact on population health. Kliment V. **Cent Eur J Public Health** 1996 Dec;4(4):246–9
Speciation of arsenic in serum, urine, and dialysate of patients on continuous ambulatory peritoneal dialysis. Zhang X, et al. **Clin Chem** 1997 Feb;43(2):406–8
Arsenic methylation patterns before and after changing from high to lower concentrations of arsenic in drinking water. Hopenhayn-Rich C, et al. **Environ Health Perspect** 1996 Nov;104(11):1200–7
Methylation study of a population environmentally exposed to arsenic in drinking water. Hopenhayn-Rich C, et al. **Environ Health Perspect** 1996 Jun;104(6):620–8
Inorganic arsenic species in groundwater: a case study from Purbasthali (Burdwan), India. Nag JK, et al. **J Trace Elem Med Biol** 1996 Apr;10(1):20–4
Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Chiou HY, et al. **Stroke** 1997 Sep;28(9):1717–23
Data on arsenic and cadmium contents of some common mushrooms. Vetter J. **Toxicon** 1994 Jan;32(1):11–5
[Annual daily intakes of Hg, PCB and arsenic from fish and shellfish and comparative survey of their residue levels in fish by body weight] Ikarashi A, et al. **Eisei Shikenjo Hokoku** 1996;(114):43–7 (Eng. Abstr.) **(Jpn)**
[Effects of salt-softener composition on the contents of toxic elements in processed cheeses] Zakharova NP, et al. **Vopr Pitan** 1997;(2):32–4 (Eng. Abstr.) **(Rus)**

HISTORY

Asthma among the famous. Thomas Fowler (1736–1801). Cohen SG. **Allergy Asthma Proc** 1996 May–Jun;17(3):163–5
[The use of arsenic in various respiratory diseases] Sauret Valet J. **Arch Bronconeumol** 1997 Apr;33(4):196–7 **(Spa)**

METABOLISM

Concentration of rare earth elements, As, and Th in human brain and brain tumors, determined by neutron activation analysis. Zhuang G, et al. **Biol Trace Elem Res** 1996 Summer;53(1–3):45–9
Regional variation in As, Cu, Hg, and Se and interaction between them. Raie RM. **Ecotoxicol Environ Saf** 1996 Dec; 35(3):248–52
Methylation study of a population environmentally exposed to arsenic in drinking water. Hopenhayn-Rich C, et al. **Environ Health Perspect** 1996 Jun;104(6):620–8
Allotropes versus polymorphisms. Fawell J. **Hum Exp Toxicol** 1996 Aug;15(8):698–9
Isolation and characterization of a new arsenic methylating bacterium from soil. Honschopp S, et al. **Microbiol Res** 1996 Mar;151(1):37–41
Enzymatic methylation of arsenic compounds: IV. In vitro and in vivo deficiency of the methylation of arsenite and monomethylarsonic acid in the guinea pig. Healy SM, et al. **Mutat Res** 1997 Jun;386(3):229–39
Arsenic-copper interaction in the kidney of the rat: influence of arsenic metabolites. Ademuyiwa O, et al. **Pharmacol Toxicol** 1996 Mar;78(3):154–60

PHARMACOKINETICS

Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. A pilot study. Del Razo LM, et al. **Arch Toxicol** 1997;71(4):211–7
Arsenic methylation patterns before and after changing from high to lower concentrations of arsenic in drinking water. Hopenhayn-Rich C, et al. **Environ Health Perspect** 1996 Nov;104(11):1200–7
Bioavailability of arsenic in soil and house dust impacted by smelter activities following oral administration in cynomolgus monkeys. Freeman GB, et al. **Fundam Appl Toxicol** 1995 Dec;28(2):215–22
A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. Mann S, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):471–86
[Human biomonitoring—studies of arsenic, lead and PCDD/F in inhabitants of a contaminated residential area] Ewers U, et al. **Gesundheitswesen** 1997 Jan;59(1):41–50 (Eng. Abstr.) **(Ger)**
[Blood and hair arsenic, lead and cadmium analysis of adults and correlation analysis with special reference to eating habits and other behavioral influences] Paulsen F, et al. **Gesundheitswesen** 1996 Aug–Sep;58(8–9):459–64 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Effects of arsenic (V)-chromium (III) interaction on plasma glucose and cholesterol levels in growing rats. Aguilar MV, et al. **Ann Nutr Metab** 1997;41(3):189–95
Bacterial heavy metal resistance: new surprises. Silver S, et al. **Annu Rev Microbiol** 1996;50:753–89 (132 ref.)
Transformation of Escherichia coli with a large plasmid of Acidiphilium multivorum AIU 301 encoding arsenic resistance. Suzuki K, et al. **Appl Environ Microbiol** 1997 May;63(5):2089–91
Virulence and arsenic resistance in Yersiniae. Neyt C, et al. **J Bacteriol** 1997 Feb;179(3):612–9
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Zhu J, et al. **Proc Natl Acad Sci U S A** 1997 Apr 15;94(8):3978–83

POISONING

Urinary porphyrins and heme biosynthetic enzyme activities measured by HPLC in arsenic toxicity. García-Vargas GG, et al. **Biomed Chromatogr** 1996 Nov–Dec;10(6):278–84 (40 ref.)
Delicious poison: arsenic trioxide for the treatment of leukemia [letter] Kwong YL, et al. **Blood** 1997 May 1; 89(9):3487–8
Arsenic in drinking water: how much is too much? [editorial; comment] Cantor KP. **Epidemiology** 1996 Mar;7(2):113–5 . Comment on: Epidemiology 1996 Mar;7(2):117–24.
Bladder cancer mortality associated with arsenic in drinking water in Argentina [see comments] [published erratum appears in Epidemiology 1997 May;8(3):334] Hopenhayn-Rich C, et al. **Epidemiology** 1996 Mar; 7(2):117–24. Comment in: Epidemiology 1996 Mar;7(2):113–5. Comment in: Epidemiology 1996 Sep;7(5):557–8.
Are we ready to replace dimercaprol (BAL) as an arsenic antidote? Mückter H, et al. **Hum Exp Toxicol** 1997 Aug; 16(8):460–5 (22 ref.)
Sister chromatid exchanges in human peripheral blood lymphocytes after ingestion of high doses of arsenicals. Hantson P, et al. **Int Arch Occup Environ Health** 1996; 68(5):342–4
Arsenic and the skin. Schwartz RA. **Int J Dermatol** 1997 Apr;36(4):241–50 (144 ref.)
Merkel cell carcinoma and multiple Bowen's disease: incidental association or possible relationship to inorganic arsenic exposure? Ohnishi Y, et al. **J Dermatol** 1997 May; 24(5):310–6
Increased hepatocytic mitotic activity as a diagnostic marker of acute arsenic intoxication. A report of two cases. Brenard R, et al. **J Hepatol** 1996 Aug;25(2):218–20
Treatment of chronic arsenic toxicity as observed in West Bengal [editorial] Mazumder DN. **J Indian Med Assoc** 1996 Feb;94(2):41–2
Acute demyelinating polyneuropathy with arsenic ingestion. Greenberg SA. **Muscle Nerve** 1996 Dec;19(12):1611–3
Further scientific evidence of the non-poisonous death of Napoleon. Corso PF, et al. **Sci Prog** 1996;79 (Pt 2):89–96
India's spreading health crisis draws global arsenic experts [news] [see comments] [published erratum appears in Science 1996 Nov 29;274(5292):1451] Bagla P, et al. **Science** 1996 Oct 11;274(5285):174–5. Comment in: Science 1996 Nov 22;274(5291):1287.
Arsenic poisoning in West Bengal [letter; comment] Saha DP. **Science** 1996 Nov 22;274(5291):1287. Comment on: Science 1996 Oct 11;274(5285):174–5.
Arsenic poisoning in West Bengal [letter] Subramanian KS. **Science** 1996 Nov 22;274(5291):1287–8
Acute arsenic toxicosis in five horses. Pace LW, et al. **Vet Pathol** 1997 Mar;34(2):160–4
Arsenic and an old "case" [editorial; comment] Schuster DS. **Wis Med J** 1996 Feb;95(2):99. Comment on: Wis Med J 1996 Feb;95(2):100–4.
[Blood and hair arsenic, lead and cadmium analysis of adults and correlation analysis with special reference to eating habits and other behavioral influences] Paulsen F, et al. **Gesundheitswesen** 1996 Aug–Sep;58(8–9):459–64 (Eng. Abstr.) **(Ger)**

TOXICITY

Interaction of carcinogenic metal compounds with deoxyribonucleic acid repair processes. Hartwig A, et al. **Ann Clin Lab Sci** 1996 Jan–Feb;26(1):31–8
Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Aposhian HV. **Annu Rev Pharmacol Toxicol** 1997;37:397–419 (76 ref.)
Comparative and environmental genotoxicity of antimony and arsenic. Gebel T, et al. **Anticancer Res** 1997 Jul–Aug; 17(4A):2603–7
Arsenic induces interleukin-8 expression in cultured keratinocytes [published erratum appears in Arch Dermatol Res 1997 Apr;289(5):306] Yen HT, et al. **Arch Dermatol Res** 1996 Oct;288(11):716–7
Fate and effects of soluble or sediment-bound arsenic in oysters (Crassostrea gigas Thun.). Ettajani H, et al. **Arch Environ Contam Toxicol** 1996 Jul;31(1):38–46
Assessment of exposure to inorganic arsenic, a human carcinogen, due to the consumption of seafood. Buchet JP, et al. **Arch Toxicol** 1996;70(11):773–8
Environmental aspects of arsenic toxicity. Peters GR, et al. **Crit Rev Clin Lab Sci** 1996 Dec;33(6):457–93 (176 ref.)
Arsenic-induced alterations in embryonic transcription factor gene expression: implications for abnormal neural development. Wlodraczyk B, et al. **Dev Genet** 1996; 18(4):306–15
Issues in arsenic cancer risk assessment [letter; comment] [see comments] Slayton TM, et al. **Environ Health Perspect** 1996 Oct;104(10):1012–8. Comment on: Environ Health Perspect 1995 Jul–Aug;103(7–8):684–9. Comment in: Environ Health Perspect 1997 Mar;105(3):266.
Toxic effects of arsenic (As3+) and other metal ions on acute promyelocytic leukemia cells. Kitamura K, et al. **Int J Hematol** 1997 Feb;65(2):179–85
Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Chiou HY, et al. **Mutat Res** 1997 Jun;386(3):197–207
Chromosomal aberrations in peripheral blood lymphocytes from native Andean women and children from northwestern Argentina exposed to arsenic in drinking water. Dulout FN, et al. **Mutat Res** 1996 Oct 1; 370(3–4):151–8
Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Germolec DR, et al. **Mutat Res** 1997 Jun;386(3):209–18
Cytogenetic effects in human exposure to arsenic. Gonsebatt ME, et al. **Mutat Res** 1997 Jun;386(3):219–28
Spontaneous and induced sister chromatid exchanges and delayed cell proliferation in peripheral lymphocytes of Bowen's disease patients and matched controls of arseniasis-hyperendemic villages in Taiwan. Hsu YH, et

ARSENIC

al. **Mutat Res** 1997 Jun;386(3):241–51

Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mass MJ, et al. **Mutat Res** 1997 Jun;386(3):263–77

Relative genotoxic potency of arsenic and its methylated metabolites. Moore MM, et al. **Mutat Res** 1997 Jun; 386(3):279–90

Variation in arsenic-induced sister chromatid exchange in human lymphocytes and lymphoblastoid cell lines. Rasmussen RE, et al. **Mutat Res** 1997 Jun;386(3):299–306

Human cells lack the inducible tolerance to arsenite seen in hamster cells. Rossman TG, et al. **Mutat Res** 1997 Jun; 386(3):307–14

Study of arsenic mutagenesis using the plasmid shuttle vector pZ189 propagated in DNA repair proficient human cells. Wiencke JK, et al. **Mutat Res** 1997 Jun;386(3):335–44

Arsenic–copper interaction in the kidney of the rat: influence of arsenic metabolites. Ademuyiwa O, et al. **Pharmacol Toxicol** 1996 Mar;78(3):154–60

Skin cancer and inorganic arsenic: uncertainty–status of risk. Brown KG, et al. **Risk Anal** 1997 Feb;17(1):37–42

A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. Mann S, et al. **Toxicol Appl Pharmacol** 1996 Oct;140(2):471–86

Sequence of exposure to cadmium and arsenic determines the extent of toxic effects in male Fischer rats. Hochadel JF, et al. **Toxicology** 1997 Jan 15;116(1–3):89–98

[Hygienic evaluation of the effects of vibration and arsenic in miners engaged in extraction of arsenic–containing ore] Remizov IuA, et al. **Med Tr Prom Ekol** 1996;(12):25–8 (Eng. Abstr.) **(Rus)**

[The response reaction of the body to exposure to arsenous carbonate water in an experiment] Antoniuk MV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jul–Aug;(4):24–6 (Eng. Abstr.) **(Rus)**

URINE

Attempt to correlate urine arsenic excretion with clinical course during melarsoprol therapy of patients with Rhodesian trypanosomiasis. Harrison SM, et al. **Am J Trop Med Hyg** 1997 Jun;56(6):632–6

The urinary excretion of arsenic metabolites after a single oral administration of dimethylarsinic acid to rats. Yoshida K, et al. **Arch Environ Contam Toxicol** 1997 May; 32(4):416–21

Urinary arsenic excretion as a biomarker of arsenic exposure in children. Hwang YH, et al. **Arch Environ Health** 1997 Mar–Apr;52(2):139–47

Intercomparison of analytical methods for arsenic speciation in human urine. Crecelius E, et al. **Environ Health Perspect** 1997 Jun;105(6):650–3

MMA:DMA ratios reversed [letter; comment] Slayton T. **Environ Health Perspect** 1997 Mar;105(3):266. Comment on: Environ Health Perspect 1996 Oct;104(10):1012–8.

Environmental arsenic exposure of children around a former copper smelter site. Hwang YH, et al. **Environ Res** 1997 Jan;72(1):72–81

Concentration of arsenic, selenium, zinc, iron and copper in the urine of blackfoot disease patients at different clinical stages. Wang CT. **Eur J Clin Chem Clin Biochem** 1996 Jun;34(6):493–7

Relationship of urinary arsenic to intake estimates and a biomarker of effect, bladder cell micronuclei. Biggs ML, et al. **Mutat Res** 1997 Jun;386(3):185–95

ARSENIC COMPOUNDS see **ARSENICALS**

ARSENICALS

ADMINISTRATION & DOSAGE

Arsenic residues in eggs from laying hens fed with a diet containing arsenic (III) oxide. Holcman A, et al. **Arch Environ Contam Toxicol** 1997 May;32(4):407–10

ADVERSE EFFECTS

[Possible etiologic role of occupational exposure to arsenic anhydride in a case of bladder carcinoma] La Paglia G, et al. **G Ital Med Lav Ergon** 1996 Jan–May;18(1–3):97–100 (Eng. Abstr.) **(Ita)**

ANALYSIS

Liberation and analysis of protein–bound arsenicals. Styblo M, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23; 677(1):161–6

CHEMICAL SYNTHESIS

Synthesis of catecholamide spiroarsoranes and their in vitro anthelmintic properties against Molinema dessetae and Nippostrongylus brasiliensis infective larvae. Loiseau PM, et al. **Arzneimittelforschung** 1996 Nov;46(11):1095–8

Synthesis of 3–arsonopyruvate and its interaction with phosphoenolpyruvate mutase. Chawla S, et al. **Biochem J** 1995 Jun 15;308 (Pt 3):931–5

CHEMISTRY

Speciation of arsenic oxides using laser desorption/ionization time–of–flight mass spectrometry. Allen TM, et al. **Anal Chem** 1996 Nov 15;68(22):4052–9

Liquid chromatography and mass spectrometry for the speciation of arsenic animal feed additives. Pergantis SA, et al. **J Chromatogr A** 1997 Mar 14;764(2):211–22

Quadrupolar nutation NMR on a compound semiconductor gallium–arsenide. Takeuchi J, et al. **Solid State Nucl Magn Reson** 1997 Apr;8(2):123–8

METABOLISM

Synthesis of 3–arsonopyruvate and its interaction with phosphoenolpyruvate mutase. Chawla S, et al. **Biochem J** 1995 Jun 15;308 (Pt 3):931–5

Resistance mechanisms to arsenicals and antimonials. Rosen BP. **J Basic Clin Physiol Pharmacol** 1995;6(3–4):251–63 (50 ref.)

Liberation and analysis of protein–bound arsenicals. Styblo M, et al. **J Chromatogr B Biomed Appl** 1996 Feb 23; 677(1):161–6

Enzymatic methylation of arsenic compounds: IV. In vitro and in vivo deficiency of the methylation of arsenite and monomethylarsonic acid in the guinea pig. Healy SM, et al. **Mutat Res** 1997 Jun;386(3):229–39

Enzymatic methylation of arsenic compounds. III. The marmoset and tamarin, but not the rhesus, monkeys are deficient in methyltransferases that methylate inorganic arsenic. Zakharyan RA, et al. **Toxicol Appl Pharmacol** 1996 Sep;140(1):77–84

PHARMACOKINETICS

Serum beta–carotene level, arsenic methylation capability, and incidence of skin cancer. Hsueh YM, et al. **Cancer Epidemiol Biomarkers Prev** 1997 Aug;6(8):589–96

PHARMACOLOGY

Effect of arsenical drugs on in vitro vascular responses of pulmonary artery from heartworm–infected dogs. Maksimowich DS, et al. **Am J Vet Res** 1997 Apr; 58(4):389–93

Regulation of the thyroid NADPH–dependent H2O2 generator by Ca2+: studies with phenylarsine oxide in thyroid plasma membrane. Gorin Y, et al. **Biochem J** 1997 Jan 15;321 (Pt 2):383–8

Redox regulation of signal transduction in smooth muscle cells: protein kinase C inhibition by thiol agents. Taher MM, et al. **Biochem Mol Biol Int** 1996 Sep;40(1):159–71

The anti–epileptic effect of 3–aminopropylarsonate on electrically–kindled and N–methyl–D–aspartate–kindled amygdala. Abdul–Ghani AS, et al. **Brain Res** 1996 Dec 2;742(1–2):305–12

New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Kitamura K, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S36–41

Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Styblo M, et al. **Chem Res Toxicol** 1997 Jan;10(1):27–33

Neutrophil–associated inflammatory responses in rats are inhibited by phenylarsine oxide. Roussin A, et al. **Eur J Pharmacol** 1997 Mar 12;322(1):91–6

Inhibition of ICE–related proteases (caspases) and nuclear apoptosis by phenylarsine oxide. Takahashi A, et al. **Exp Cell Res** 1997 Feb 25;231(1):123–31

Trypanosoma brucei: lack of cross–resistance to melarsoprol in vitro by cymelarsan–resistant parasites. Scott AG, et al. **Exp Parasitol** 1997 Jul;86(3):181–90

Phenylarsine oxide (PAO)–mediated activation of phospholipase D in rat basophilic leukemia (RBL–2H3) cells: possible involvement of calcium and protein kinase C. Kumada T, et al. **Immunobiology** 1996 Aug; 195(3):347–59

The phosphotyrosine phosphatase inhibitor–phenylarsine oxide restores defective phosphoinositide hydrolysis response in anergic C3H–gld/gld lymphocytes. Ling W, et al. **Immunol Cell Biol** 1996 Jun;74(3):231–8

Virulence and arsenic resistance in Yersiniae. Neyt C, et al. **J Bacteriol** 1997 Feb;179(3):612–9

Gallium arsenide selectively suppresses antigen processing by splenic macrophages for CD4+ T cell activation. Lewis TA, et al. **J Pharmacol Exp Ther** 1996 Sep;278(3):1244–51

Protein tyrosine phosphorylation modulates microvessel permeability in frog mesentery. Adamson RH. **Microcirculation** 1996 Jun;3(2):245–7 (13 ref.)

Induction of chromosomal aberrations in cultured human fibroblasts by inorganic and organic arsenic compounds and the different roles of glutathione in such induction. Oya–Ohta Y, et al. **Mutat Res** 1996 Oct 25;357(1–2):123–9

The effect of spiroarsoranes on Trypanosoma brucei brucei and T. b. rhodesiense. Loiseau PM, et al. **Parasitol Res** 1996;82(5):477–80

Alteration to one of three adenosine transporters is associated with resistance to cymelarsan in Trypanosoma evansi. Ross CA, et al. **Parasitol Res** 1996;82(2):183–8

The anterior central nervous system of male Onchocerca volvulus (Nematoda:Filarioidea) as a target for chemotherapy: results of an electron microscopy study. Strote G, et al. **Parasitol Res** 1997;83(6):549–57

Gallium arsenide augments antigen processing by peritoneal macrophages for CD4+ helper T cell stimulation. Hartmann CB, et al. **Toxicol Appl Pharmacol** 1996 Dec; 141(2):365–72

[Bacterial resistance to arsenic compounds] Cervantes C. **Rev Latinoam Microbiol** 1995 Oct–Dec;37(4):387–95 (62 ref.) (Eng. Abstr.) **(Spa)**

POISONING

Acute arsine intoxication as a consequence of metal burnishing operations. Romeo L, et al. **Am J Ind Med** 1997 Sep;32(3):211–6

THERAPEUTIC USE

Delicious poison: arsenic trioxide for the treatment of leukemia [letter] Kwong YL, et al. **Blood** 1997 May 1; 89(9):3487–8

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Shen ZX, et al. **Blood** 1997 May 1;89(9):3354–60

New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Kitamura K, et al. **Cancer Chemother Pharmacol** 1997;40 Suppl:S36–41

Arsenical pessaries in the treatment of metronidazole–resistant Trichomonas vaginalis [letter] Walker PP, et al. **Int J STD AIDS** 1997 Jul;8(7):473

Arsenical pessaries in the successful elimination of metronidazole–resistant Trichomonas vaginalis. Watson PG, et al. **Int J STD AIDS** 1996 Jul;7(4):296–7

TOXICITY

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose–dependent dual effects on APL cells. Chen GQ, et al. **Blood** 1997 May 1;89(9):3345–53

Comparative activity of melarsoprol and arsenic trioxide in chronic B–cell leukemia lines. König A, et al. **Blood** 1997 Jul 15;90(2):562–70

Testicular toxicity of gallium arsenide, indium arsenide, and arsenic oxide in rats by repetitive intratracheal instillation [published erratum appears in Fundam Appl Toxicol 1997 Jan;35(1):142] Omura M, et al. **Fundam Appl Toxicol** 1996 Jul;32(1):72–8

Sequence of toxic events in arsine–induced hemolysis in vitro: implications for the mechanism of toxicity in human erythrocytes. Winski SL, et al. **Fundam Appl Toxicol** 1997 Aug;38(2):123–8

Reactive oxygen species do not cause arsine–induced hemoglobin damage. Hatlelid KM, et al. **J Toxicol Environ Health** 1997 Apr 11;50(5):463–74

Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Mukhopadhyay R, et al. **Proc Natl Acad Sci U S A** 1996 Sep 17;93(19):10383–7

Testicular toxicity evaluation of arsenic–containing binary compound semiconductors, gallium arsenide and indium arsenide, in hamsters. Omura M, et al. **Toxicol Lett** 1996 Dec 16;89(2):123–9

The semiconductor elements arsenic and indium induce apoptosis in rat thymocytes. Bustamante J, et al. **Toxicology** 1997 Mar 28;118(2–3):129–36

Study of in vitro cytotoxicity of a water soluble organic arsenic compound, arsenosugar, in seaweed. Sakurai T, et al. **Toxicology** 1997 Oct 19;122(3):205–12

Isolation of three contiguous genes, ACR1, ACR2 and ACR3, involved in resistance to arsenic compounds in the yeast Saccharomyces cerevisiae. Bobrowicz P, et al. **Yeast** 1997 Jul;13(9):819–28

URINE

Methylation study of a population environmentally exposed to arsenic in drinking water. Hopenhayn–Rich C, et al. **Environ Health Perspect** 1996 Jun;104(6):620–8

DMPS–arsenic challenge test. I: Increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sulfonate. Aposhian HV, et al. **J Pharmacol Exp Ther** 1997 Jul;282(1):192–200

ARSENITES

ANALYSIS

Sensing antimonite and arsenite at the subattomole level with genetically engineered bioluminescent bacteria. Ramanathan S, et al. **Anal Chem** 1997 Aug 15;69(16):3380–4

Genetically engineered bacteria: electrochemical sensing systems for antimonite and arsenite. Scott DL, et al. **Anal Chem** 1997 Jan 1;69(1):16–20

DIAGNOSTIC USE

[Experience in the determination of iodine in the urine by the kinetic cerium arsenite method] Sepiatitskaia VG, et al. **Klin Lab Diagn** 1996 Sep–Oct;(5):22–4 (Eng. Abstr.) **(Rus)**

METABOLISM

Destabilization of the Ca2+–ATPase of sarcoplasmic reticulum by thiol–specific, heat shock inducers results in thermal denaturation at 37 degrees C. Senisterra GA, et al. **Biochemistry** 1997 Sep 9;36(36):11002–11

Enzymatic methylation of arsenic compounds: IV. In vitro and in vivo deficiency of the methylation of arsenite and monomethylarsonic acid in the guinea pig. Healy SM, et al. **Mutat Res** 1997 Jun;386(3):229–39

Arsenite efflux is inhibited by verapamil, cyclosporin A, and

GSH-depleting agents in arsenite-resistant Chinese hamster ovary cells. Huang RN, et al. **Toxicol Appl Pharmacol** 1996 Nov;141(1):17-22

PHARMACOLOGY

p70 S6 kinase is activated by sodium arsenite in adult rat cardiomyocytes: roles for phosphatidylinositol 3-kinase and p38 MAP kinase. Wang X, et al.
Biochem Biophys Res Commun 1997 Sep 8;238(1):207-12

Oxidative and chemical stress mimic insulin by selectively inhibiting the expression of phosphoenolpyruvate carboxykinase in hepatoma cells. Sutherland C, et al.
Diabetes 1997 Jan;46(1):17-22

The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. Cavigelli M, et al.
EMBO J 1996 Nov 15;15(22):6269-79

Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. Grondin K, et al.
EMBO J 1997 Jun 2;16(11):3057-65

Inositol phospholipid 3-kinase is activated by cellular stress but is not required for the stress-induced activation of glucose transport in L6 rat skeletal muscle cells. McDowell HE, et al. **Eur J Biochem** 1997 Jul 1;247(1):306-13

Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Barchowsky A, et al.
Free Radic Biol Med 1996;21(6):783-90

Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. Liu Y, et al.
Free Radic Biol Med 1996;21(6):771-81

Effect of arsenite on urea production by long-term cultures of adult rat hepatocytes. Sierra-Santoyo A, et al.
J Appl Toxicol 1996 Jul-Aug;16(4):281-7

Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. Wang TS, et al.
J Cell Physiol 1996 Nov;169(2):256-68

Mechanisms involved in sodium arsenite-induced apoptosis of human neutrophils. Watson RW, et al.
J Leukoc Biol 1996 Nov;60(5):625-32

Transkinetoplastidy in arsenite-resistant Leishmania major. Chiang SC, et al. **Mol Biochem Parasitol** 1996 Nov 12; 82(1):121-4

TOXICITY

Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts. Hartwig A, et al.
Carcinogenesis 1997 Feb;18(2):399-405

Inhibition of clastogenic effects of arsenic through continued oral administration of garlic extract in mice in vivo. Choudhury AR, et al. **Mutat Res** 1997 Aug 14; 392(3):237-42

Polymerase chain reaction-based deletion analysis of spontaneous and arsenite-enhanced gpt mutants in CHO-AS52 cells. Meng Z, et al. **Mutat Res** 1996 Sep 23; 356(2):255-9

Disruption of microtubule assembly and spindle formation as a mechanism for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide. Ramírez P, et al. **Mutat Res** 1997 Jun;386(3):291-8

Effect of hepatic methyl donor status on urinary excretion and DNA damage in B6C3F1 mice treated with sodium arsenite. Tice RR, et al. **Mutat Res** 1997 Jun;386(3):315-34

Inhibition of poly(ADP-ribose) polymerase by arsenite. Yager JW, et al. **Mutat Res** 1997 Jun;386(3):345-51

Influence of maternal stress on the effects of prenatal exposure to methylmercury and arsenic on postnatal development and behavior in mice: a preliminary evaluation. Colomina MT, et al. **Physiol Behav** 1997 Mar; 61(3):455-9

Arsenic induces overexpression of growth factors in human keratinocytes. Germolec DR, et al.
Toxicol Appl Pharmacol 1996 Nov;141(1):308-18

Expression of the 25-kDa heat-shock protein (HSP27) correlates with resistance to the toxicity of cadmium chloride, mercuric chloride, cis-platinum(II)-diammine dichloride, or sodium arsenite in mouse embryonic stem cells transfected with sense or antisense HSP27 cDNA. Wu W, et al. **Toxicol Appl Pharmacol** 1996 Nov; 141(1):330-9

Enhanced arsenite-induced hepatic morphological and biochemical changes in phenobarbital-pretreated rats. Albores A, et al. **Toxicol Pathol** 1996 Mar-Apr; 24(2):172-80

Effects of arsenite pretreatment on the acute toxicity of parathion. Siller FR, et al. **Toxicology** 1997 Jan 15; 116(1-3):59-65

Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Wang TS, et al. **Toxicology** 1997 Sep 5;121(3):229-37

ARSON see **FIRESETTING BEHAVIOR**

ARSPHENAMINE

HISTORY

The introduction of "606" in New Jersey. Wallhauser HT. **N J Med** 1997 Jul;94(7):43-6

[History of healing; early reception of the anti-syphilitic agent Salvarsan in The Netherlands (1910-1911)] Verhoef P. **Ned Tijdschr Geneeskd** 1996 Dec 14;140(50):2519-23 **(Dut)**

[First results of treatment with salvarsan in Krakow] Maciejasz B. **Przegl Lek** 1996;53(10):763-4 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

What's in a (compound) name? [letter; comment] Feuer AL. **N C Med J** 1997 Jan-Feb;58(1):7. Comment on: N C Med J 1996 Nov-Dec;57(6):342.

ART

see related
ANATOMY, ARTISTIC
MEDICAL ILLUSTRATION
MEDICINE IN ART

Art glassware and sinonasal cancer: report of three cases. Battista G, et al. **Am J Ind Med** 1996 Jul;30(1):31-5

Using the arts to enhance confluent learning. Peloquin SM.
Am J Occup Ther 1996 Feb;50(2):148-51

A transfer of technique: from induced song recall to the induced recall of paintings. Diaz de Chumaceiro CL.
Am J Psychoanal 1996 Sep;56(3):331-6

Skin problems in sugar artists. Bangha E, et al.
Br J Dermatol 1996 Nov;135(5):772-4

Human figure drawings by schooled and unschooled children in Papua New Guinea. Martlew M, et al. **Child Dev** 1996 Dec;67(6):2743-62

Exposing ourselves to art. Fields S.
Environ Health Perspect 1997 Mar;105(3):284-9

Safe use of art materials: who is responsible? [letter] Gottsegen M. **Environ Health Perspect** 1997 Jul; 105(7):687-8

Comments on "exposing ourselves to art" [letter] Weiss AL, et al. **Environ Health Perspect** 1997 Jul;105(7):686-7

Art and trauma. Laub D, et al. **Int J Psychoanal** 1995 Oct; 76 (Pt 5):991-1005

Reinstating the person in the professional: reflections on empathy and aesthetic experience. Smyth T.
J Adv Nurs 1996 Nov;24(5):932-7 (28 ref.)

To see the Thing Itself: the influence of early object loss on the life and art of Edward Weston. Hamilton JW.
J Am Acad Psychoanal 1995 Winter;23(4):671-91

Experimental evaluation of "The Images Within": an alcohol education and prevention program. Woodside M, et al.
J Drug Educ 1997;27(1):53-65

Why can't most people draw what they see? Cohen DJ, et al. **J Exp Psychol Hum Percept Perform** 1997 Jun; 23(3):609-21

Motor control differentiates children's from adults' drawings for child and adult judges. Cabe PA, et al.
J Genet Psychol 1997 Jun;158(2):189-99

Holes and grooves: the contribution of microscopy and taphonomy to the problem of art origins. D'Errico F, et al. **J Hum Evol** 1997 Jul;33(1):1-31

Medicine, the arts and imagination [letter] Evans M, et al.
J Med Ethics 1997 Aug;23(4):254

Implications of the people = male theory for the interpretation of the Draw-A-Person Test. Merritt RD, et al. **J Pers Assess** 1997 Feb;68(1):211-4

The Hammersmith. Baron JH. **J R Soc Med** 1997 Apr; 90(4):229

Addenbrooke's art and murals. Cannon WG.
J R Soc Med 1996 Dec;89(12):720

The Isle of Wight embroidery. Eades G. **J R Soc Med** 1996 Oct;89(10):592

Bert Irvin's Hollywood at Chelsea & Westminster Hospital. Loppert S. **J R Soc Med** 1996 Sep;89(9):519-20

The Bird Garden at the West Dorset Hospital. Pitt-Rivers V. **J R Soc Med** 1997 Feb;90(2):113

Some effects of sex, age, and household structure on family drawings of Barbadian children. Payne MA.
J Soc Psychol 1996 Oct;136(5):567-78

Suicide among artists. Stack S. **J Soc Psychol** 1997 Feb; 137(1):129-30

Medicine and the arts [editorial] Hutchens MP. **JAMA** 1997 Feb 5;277(5):432

Art in hospitals: why is it there and what is it for? Behrman P. **Lancet** 1997 Aug 23;350(9077):584-5

The art of visual neglect. Halligan PW, et al. **Lancet** 1997 Jul 12;350(9071):139-40

Enhanced artistic creativity with temporal lobe degeneration [letter] Miller BL, et al. **Lancet** 1996 Dec 21-28; 348(9043):1744-5

Communicating with children: could you use some help? McElveen KA. **MCN Am J Matern Child Nurs** 1997 Mar-Apr;22(2):108-11

The role of art within the medical setting. Corbat C.
Med Health R I 1997 Apr;80(4):112-4

The scope of medical informatics as art and science [editorial] Kulikowski CA. **Methods Inf Med** 1996 Sep;35(3):185-8

A celebration of health through art. Rigler M, et al.
Occas Pap R Coll Gen Pract 1994 Jan;(64):17-20

The inclination of artists to partition line sections in the golden ratio. Macrosson WD, et al. **Percept Mot Skills** 1997 Jun;84(3 Pt 1):707-13

Foreshortening in cube drawings by children and adults. Nicholls AL, et al. **Perception** 1995;24(12):1443-56

On creativity and medicine. Rodenhauser P. **Pharos** 1996 Fall;59(4):2-6

How the blind draw. Kennedy KM. **Sci Am** 1997 Jan; 276(1):76-81

Gender and suicide risk among artists: a multivariate analysis. Stack S. **Suicide Life Threat Behav** 1996 Winter;26(4):374-9

[Physicians for the National Theater (letter)] Hankiss J.
Orv Hetil 1996 Aug 11;137(32):1786 **(Hun)**

[The phenomenon of deja vu in psychopathology and literature] Farina B, et al. **Minerva Psichiatr** 1996 Jun; 37(2):99-106 (28 ref.) (Eng. Abstr.) **(Ita)**

HISTORY

The artist and defective sight (a book review and commentary). Tannebaum S. **J Am Optom Assoc** 1997 Apr; 68(4):261-4

The college suspended. Gibbs D.
J R Coll Physicians Lond 1997 May-Jun;31(3):332-5

Art in hospitals [editorial] Baron JH. **J R Soc Med** 1996 Sep; 89(9):482-3

Staffs as walking aids in ancient Egypt and Palestine. Loebl WY, et al. **J R Soc Med** 1997 Aug;90(8):450-4

[20-year anniversary of the Circle of Hungarian Medical Writers and Artists] Hankiss J. **Orv Hetil** 1996 Aug 11; 137(32):1765-9 **(Hun)**

ART THERAPY

Art: an occupation with promise for developing empathy. Peloquin SM. **Am J Occup Ther** 1996 Sep;50(8):655-61 (34 ref.)

Serial self-portrait: a technique to monitor changes in self-concept. Glaister JA. **Arch Psychiatr Nurs** 1996 Oct; 10(5):311-8

Differential aspects of sandplay with 10- and 11-year-old children. Zinni VR. **Child Abuse Negl** 1997 Jul;21(7):657-68

Indicators of abuse or neglect in preschool children's drawings. Carpenter M, et al.
J Psychosoc Nurs Ment Health Serv 1997 Apr;35(4):10-7

The Isle of Wight embroidery. Eades G. **J R Soc Med** 1996 Oct;89(10):592

Symbol, metaphor and story. The function of group art therapy in palliative care. Mayo S. **Palliat Med** 1996 Jul; 10(3):209-16

[Pictures by pregnant patients with premature labor. Initial experiences with art therapy] Herborn E, et al.
Z Geburtshilfe Neonatol 1996 Jul-Aug;200(4):151-4 (Eng. Abstr.) **(Ger)**

[Art therapy] Takaesu Y. **Seishin Shinkeigaku Zasshi** 1996; 98(10):694-700 **(Jpn)**

STANDARDS

Suicidal adolescent perceptions after an art future image intervention. Walsh SM, et al. **Appl Nurs Res** 1997 Feb; 10(1):19-26

ART-TRS GENE PROTEIN, HIV see **GENE PRODUCTS, REV**

ART-TRS GENES see **GENES, REV**

ARTEMIA

Accumulation of trimethoprim, sulfamethoxazole, and N-acetylsulfamethoxazole in fish and shrimp fed medicated Artemia franciscana. Chair M, et al.
Antimicrob Agents Chemother 1996 Jul;40(7):1649-52

Brine shrimp bioassay for biological activity of medicinal plants used in traditional medicines in Tanzania. Massele AY, et al. **East Afr Med J** 1995 Oct;72(10):661-3

CHEMISTRY

Determination of vitamin E in aquatic organisms by high-performance liquid chromatography with fluorescence detection. Huo JZ, et al. **Anal Biochem** 1996 Nov 1;242(1):123-8

Purification, structure and in vitro molecular-chaperone activity of Artemia p26, a small heat-shock/alpha-crystallin protein. Liang P, et al.
Eur J Biochem 1997 Jan 15;243(1-2):225-32

DRUG EFFECTS

Effect of endosulfan pesticide on the oxygen consumption rates of nauplii of different Spanish strains of Artemia. Varó I, et al. **J Environ Sci Health B** 1997 May;32(3):363-75

EMBRYOLOGY

Transcriptional regulation during the activation and development of Artemia franciscana encysted embryos. Martinez-Lamparero A, et al. **Int J Dev Biol** 1996;Suppl 1:91S-92S

Molecular characterization of a small heat shock/alpha-crystallin protein in encysted Artemia embryos. Liang P, et al. **J Biol Chem** 1997 Jul 25; 272(30):19051-8

Profiles of nuclear and mitochondrial encoded mRNAs in developing and quiescent embryos of Artemia franciscana. Hardewig I, et al. **Mol Cell Biochem** 1996 May 24; 158(2):139-47

ENZYMOLOGY

Protein kinases in mitochondria of the invertebrate Artemia franciscana. Vallejo CG, et al. **Arch Biochem Biophys** 1997

ISBN 0-16-049542-3